

NATIONAL INSTITUTES OF HEALTH

CUMULATED INDEX MEDICUS

1999

VOLUME 40 BOOK 18

BIBLIOGRAPHY OF MEDICAL REVIEWS

In-Z

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, MD 20894
NIH Publication Number: 00-259

ISSN: 0090-1423

Cumulated Index Medicus

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated index medicus.
Vol. 1 (Jan.-Dec. 1960)-
-- Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1960-
v. -- (1971-1979: DHEW publication ; no. (NIH) 72-259, etc.)

Annual.
As of Feb. 1998, citations published 1964-1965 also available online as: OLDMEDLINE, accessible through Internet Grateful Med.
Cumulation of the monthly publication: Index medicus.
Issues for 1967- include Bibliography of medical reviews.
HTTP- Citations published 1964-1965 also available online: http://igm.nlm.nih.gov/.
Continues: Quarterly cumulative index medicus.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.) III. Index medicus IV. Bibliography of medical reviews V. Title: OLDMEDLINE VI. Series: DHEW publication ; no. (NIH) 72-259, etc. VII. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated index medicus.
SUPT. OF DOCS. NO: HE 20.3612/3:

ZW 1 I384



This book is printed on acid-free paper for permanence.

The Secretary of Health and Human Services has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 2000.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328

CUMULATED INDEX MEDICUS 1999

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Headings viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xvi

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1519
Full Title Listing 1625

BOOK 2 Subject Index **A-At** 1709

BOOK 3 Subject Index **Au-Cg** 3556

BOOK 4 Subject Index **Ch-Do** 5371

BOOK 5 Subject Index **Dp-Gh** 7197

BOOK 6 Subject Index **Gi-Inr** 9029

BOOK 7 Subject Index **Ins-Mem** 10790

BOOK 8 Subject Index **Men-Os** 12631

BOOK 9 Subject Index **Ot-Pt** 14473

BOOK 10 Subject Index **Pu-Ss** 16294

BOOK 11 Subject Index **St-Z** 18087

Book 12 Author Index **A-De** 19943

BOOK 13 Author Index **Df-I** 21742

BOOK 14 Author Index **J-Mn** 23500

BOOK 15 Author Index **Mo-Se** 25314

BOOK 16 Author Index **Sf-Z** 27180

BOOK 17 Bibliography of Medical Reviews **A-Im** 29047

Book 18 Bibliography of Medical Reviews **In-Z** 30144

control disorders, and pathological aggression. Brady KT, et al. **Am J Addict** 1998 Summer;7(3):221–30 (82 ref.)

THERAPY

A review of behavioral and pharmacological treatments for habit disorders in individuals with mental retardation. Long ES, et al. **J Behav Ther Exp Psychiatry** 1998 Jun; 29(2):143–56 (100 ref.)

Sexual predators. Zonana HV, et al.
Psychiatr Clin North Am 1999 Mar;22(1):109–27, vii (68 ref.)

Prevalence, assessment, and treatment of pathological gambling: a review. Petry NM, et al. **Psychiatr Serv** 1999 Aug;50(8):1021–7 (70 ref.)

IMPULSE-RIDDEN PERSONALITY see **PERSONALITY DISORDERS**

IMPULSIVE BEHAVIOR

GENETICS

[Heredity and role of serotonin in aggressive impulsive behavior] Staner L, et al. **Encephale** 1998 Jul–Aug; 24(4):355–64 (90 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Attention deficit/hyperactivity disorder—from brain dysfunctions to behaviour [editorial] Sagvolden T, et al. **Behav Brain Res** 1998 Jul;94(1):1–10 (88 ref.)

PSYCHOLOGY

Impulsivity: a discussion of clinical and experimental findings. Evenden J. **J Psychopharmacol** 1999;13(2):180–92 (100 ref.)

[Compulsive buying: a new disorder?] de Lucas Taracena MT, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998 Jul–Aug;26(4):264–72 (47 ref.) (Eng. Abstr.) **(Spa)**

IN-HOSPITAL MORTALITY see **HOSPITAL MORTALITY**

IN SITU HYBRIDIZATION

Subcellular localization of mRNA in neuronal cells. Contributions of high-resolution in situ hybridization techniques. Martone ME, et al. **Mol Neurobiol** 1998 Dec; 18(3):227–46 (122 ref.)

METHODS

Ultrastructural in situ hybridization: a review of technical aspects. Le Guellec D. **Biol Cell** 1998 Jul;90(4):297–306 (51 ref.)

Automated in situ hybridization: diagnostic and research applications. Capodieci P, et al. **Diagn Mol Pathol** 1998 Apr;7(2):69–75 (43 ref.)

Flow cytometry in situ polymerase chain reaction as an innovative approach to HIV-1 proviral DNA detection. Gibellini D, et al. **Eur J Histochem** 1998;42(2):137–41 (16 ref.)

High performance Nanogold-silver in situ hybridisation. Hacker GW. **Eur J Histochem** 1998;42(2):111–20 (70 ref.)

In-situ polymerase chain reaction: foundation of the technology and today's options. Long AA.
Eur J Histochem 1998;42(2):101–9 (56 ref.)

The use of molecular technologies for the detection of enteroviral ribonucleic acid in myocarditis. Micevski V. **J Cardiovasc Nurs** 1999 Jul;13(4):78–90 (31 ref.)

Amplification methods to increase the sensitivity of in situ hybridization: play card(s). Speel EJ, et al.
J Histochem Cytochem 1999 Mar;47(3):281–8 (74 ref.)

Monitoring antisense oligodeoxynucleotide activity in hematopoietic cells. Sokol DL, et al. **Methods** 1999 Mar; 17(3):219–30 (112 ref.)

In situ hybridization with RNA probes. Breier G.
Methods Mol Biol 1999;96:107–17 (4 ref.)

In situ molecular hybridization techniques for ultrathin sections. Fournier JG, et al. **Methods Mol Biol** 1999; 117:167–81 (40 ref.)

In situ hybridization to human chromosomes of an alkaline phosphatase-labeled centromeric probe. Nardone RM.
Methods Mol Biol 1999;115:365–70 (4 ref.)

mRNA: detection by in Situ and northern hybridization. Parker RM, et al. **Methods Mol Biol** 1999;106:247–83 (30 ref.)

In situ RT-PCR and hybridization techniques. Thaker V. **Methods Mol Biol** 1999;115:379–402 (46 ref.)

In cell amplification. Uhlmann V, et al. **Mol Pathol** 1998 Jun;51(3):119–30 (60 ref.)

[Detection of receptor mRNAs using nonradioactive in situ hybridization] Shin M, et al. **Nippon Rinsho** 1998 Jul; 56(7):1667–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

IN SITU HYBRIDIZATION, FLUORESCENCE

DNA in situ hybridization as an adjunct in tumor diagnosis. Fletcher JA. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S11–8 (27 ref.)

Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer. Glassman AB.
Ann Clin Lab Sci 1998 Nov–Dec;28(6):324–30 (19 ref.)

The importance of cytogenetics and associated molecular techniques in the management of patients with leukaemia. Harrison CJ, et al. **Clin Oncol (R Coll Radiol)** 1998; 10(4):255–61 (54 ref.)

In situ methods for assessment of microorganisms and their activities. Amann R, et al. **Curr Opin Microbiol** 1998 Jun; 1(3):352–8 (66 ref.)

Prepregnancy genetic testing for age-related aneuploidies by polar body analysis. Verlinsky Y, et al. **Genet Test** 1997–98; 1(4):231–5 (13 ref.)

Genetics of childhood disorders: VI. FISH, FISH, and more FISH. Ward D, et al.
J Am Acad Child Adolesc Psychiatry 1999 Sep;38(9):1200–2 (5 ref.)

Fish analysis at diagnosis in acute lymphoblastic leukemia. Avet-Loiseau H. **Leuk Lymphoma** 1999 May;33(5–6):441–9 (43 ref.)

METHODS

The impact of the new fish technologies on the cytogenetics of haematological malignancies. Kearney L.
Br J Haematol 1999 Mar;104(4):648–58 (72 ref.)

Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Qian J, et al.
Eur Urol 1999;35(5–6):479–83 (35 ref.)

Emerging patterns of comparative genome organization in some mammalian species as revealed by Zoo-FISH. Chowdhary BP, et al. **Genome Res** 1998 Jun;8(6):577–89 (88 ref.)

Single and double FISH protocols for Drosophila. Hughes SC, et al. **Methods Mol Biol** 1999;122:93–101 (6 ref.)

Fluorescence in situ hybridization using whole chromosome library probes. Nardone RM. **Methods Mol Biol** 1999; 115:371–7 (9 ref.)

Overview of in situ hybridization. Nardone RM.
Methods Mol Biol 1999;115:357–63 (12 ref.)

IN SITU LABELING, PRIMED see **PRIMED IN SITU LABELING**

IN SITU NICK-END LABELING

see related
APOPTOSIS
DNA FRAGMENTATION

IN VIVO NMR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

INADEQUATE PERSONALITY see **PERSONALITY DISORDERS**

INAPPROPRIATE ADH SYNDROME

[Hypo-osmolar hyponatremic syndromes: physiopathology and clinical aspects] Garini G, et al. **Recenti Prog Med** 1999 Feb;90(2):100–8 (43 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

[The inappropriate antidiuretic hormone secretion syndrome and citalopram (letter)] Berrocal E, et al.
Med Clin (Barc) 1999 Jan 23;112(2):78 (9 ref.) **(Spa)**

DIAGNOSIS

Small cell lung cancer accompanied by lactic acidosis and syndrome of inappropriate secretion of antidiuretic hormone. Fujimura M, et al. **Lung Cancer** 1998 Dec; 22(3):251–4 (15 ref.)

NURSING

Syndrome of inappropriate secretion of antidiuretic hormone in malignancy. Keenan AM. **Semin Oncol Nurs** 1999 Aug; 15(3):160–7 (27 ref.)

INBORN ERRORS OF METABOLISM see **METABOLISM, INBORN ERRORS**

INBREEDING

see related
CONSANGUINITY

The major histocompatibility complex and mate choice: inbreeding avoidance and selection of good genes. Grob B, et al. **Exp Clin Immunogenet** 1998;15(3):119–29 (104 ref.)

INBREEDING, HUMAN see **CONSANGUINITY**

INCENTIVE PLANS, PHYSICIAN see **PHYSICIAN INCENTIVE PLANS**

INCENTIVE REIMBURSEMENT see **REIMBURSEMENT, INCENTIVE**

INCENTIVES see **MOTIVATION**

INCIDENCE

Critical appraisal of the health research literature: prevalence or incidence of a health problem. Loney PL, et al.
Chronic Dis Can 1998;19(4):170–6 (27 ref.)

INCIDENCE STUDIES see **COHORT STUDIES**

INCIDENT REPORTING, HOSPITAL see **RISK MANAGEMENT**

INCINERATION

[Genotoxicity of stack gas condensates of Bavarian waste incineration plants. IV. Overview and short comments on the results] Raabe F, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):531–40 (16 ref.) (Eng. Abstr.) **(Ger)**

INCIPIENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

INCISIVE PAPILLA see **PALATE**

INCISOR

PHYSIOPATHOLOGY

Mandibular lateral incisor–canine transposition, concomitant dental anomalies, and genetic control. Peck S, et al.
Angle Orthod 1998 Oct;68(5):455–66 (53 ref.)

INCLUSION BODIES

CHEMISTRY

Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. Kimber TE, et al.
J Neurol Sci 1998 Sep 18;160(1):33–40 (25 ref.)

GENETICS

Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? Rubinsztein DC, et al. **J Med Genet** 1999 Apr;36(4):265–70 (40 ref.)

PATHOLOGY

Corpora-amylacea and the family of polyglucosan diseases. Cavanagh JB. **Brain Res Brain Res Rev** 1999 Apr; 29(2–3):265–95 (235 ref.)

Filamentous nerve cell inclusions in neurodegenerative diseases. Goedert M, et al. **Curr Opin Neurobiol** 1998 Oct; 8(5):619–32 (92 ref.)

Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. Cooper AJ, et al. **J Neurochem** 1999 Mar;72(3):889–99 (98 ref.)

Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101–18 (148 ref.)

[Neuropathology of the motor neuron disease—Bunina body] Kusaka H. **Rinsho Shinkeigaku** 1999 Jan;39(1):65–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Sebastian platelet syndrome] Maeda M.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):320–1 (7 ref.) **(Jpn)**

[May-Hegglin anomaly] Shinjo K, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):56–8 (13 ref.) **(Jpn)**

PHYSIOLOGY

Ubiquitin, cellular inclusions and their role in neurodegeneration. Alves-Rodrigues A, et al.
Trends Neurosci 1998 Dec;21(12):516–20 (60 ref.)

ULTRASTRUCTURE

Sebastian syndrome: case report and review of the literature. Young G, et al. **Am J Hematol** 1999 May;61(1):62–5 (15 ref.)

Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout? Kim TW, et al.
Neuron 1998 Oct;21(4):657–9 (19 ref.)

[Döhle body] Kurokawa Y, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):96–7 (7 ref.) **(Jpn)**

[Fechtner syndrome] Ohata M.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):322–5 (15 ref.) **(Jpn)**

INCLUSION DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

INCOME

see related
SALARIES AND FRINGE BENEFITS

Income inequality and health: pathways and mechanisms. Kawachi I, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):215–27 (42 ref.)

Income inequality, social cohesion, and class relations: a critique of Wilkinson's neo-Durkheimian research program. Muntaner C, et al. **Int J Health Serv** 1999; 29(1):59–81 (127 ref.)

Hospital conversion revenue: a critical analysis of present law and future proposals to reform the manner in which

revenue generated from hospital conversions is employed. Standish JD. **J Contemp Health Law Policy** 1998 Fall; 15(1):131–82 (0 ref.)
Paid organ donation—the grey basket concept [editorial] Daar AS. **J Med Ethics** 1998 Dec;24(6):365–8 (24 ref.)
Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247–61 (81 ref.)
Individual Social Security accounts: issues of administrative feasibility and cost, 1998. Olsen KA, et al. **Soc Secur Bull** 1999;62(1):75–90 (103 ref.)
Noncitizens and the Supplemental Security Income program. Parrott TM, et al. **Soc Secur Bull** 1998;61(4):3–31 (0 ref.)

STATISTICS & NUMERICAL DATA

Rural women's economic realities [see comments] McLaughlin DK. **J Women Aging** 1998;10(4):41–65 (59 ref.) Comment in: J Women Aging 1998 ;10(4):81–90.
Retirement income security in the United Kingdom. Liu L. **Soc Secur Bull** 1999;62(1):23–46 (87 ref.)

INCOMPETENCY, MENTAL see **MENTAL COMPETENCY**

INCOMPLETE VIRUSES see **DEFECTIVE VIRUSES**

INCONTINENCE PADS

UTILIZATION

Pad testing in incontinent women: a review. Ryhammer AM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(2):111–5 (38 ref.)

INCONTINENTIA PIGMENTI ACHROMIANS see **PIGMENTATION DISORDERS**

INCREASED GRAVITY see **HYPERGRAVITY**

INCUBATORS

see related
ENVIRONMENT, CONTROLLED
LIFE SUPPORT SYSTEMS

INDANS

[Discovery and development of donepezil hydrochloride for the treatment of Alzheimer's disease] Sugimoto H, et al. **Yakugaku Zasshi** 1999 Feb;119(2):101–13 (27 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Is the placebo control obsolete in a world after donepezil and vitamin E? [see comments] Karlawish JH, et al. **Arch Neurol** 1998 Nov;55(11):1420–4 (35 ref.) Comment in: Arch Neurol 1998 Nov;55(11):1396–8.
Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Rogers SL. **Dement Geriatr Cogn Disord** 1998;9 Suppl 3:29–42 (67 ref.)
Donepezil update. **Drug Ther Bull** 1998 Aug;36(8):60–1 (9 ref.)
Clinical benefits of a new piperidine-class AChE inhibitor. Doody RS. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl 2:S69–77 (29 ref.)
Clinical profile of donepezil in the treatment of Alzheimer's disease. Doody RS. **Gerontology** 1999;45 Suppl 1:23–32 (62 ref.)
What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Shadlen MF, et al. **Postgrad Med** 1999 Jan;105(1):109–18 (25 ref.)
[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA Azanza JR, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):109–18 (43 ref.) **(Spa)**

INDENES

PHARMACOLOGY

Cannabimimetic indoles, pyrroles and indenes. Huffman JW. **Curr Med Chem** 1999 Aug;6(8):705–20 (49 ref.)

INDEPENDENT LIVING see **ACTIVITIES OF DAILY LIVING**

INDIAN CORN see **CORN**

INDIANS, NORTH AMERICAN

Native American medicine [published erratum appears in Altern Ther Health Med 1999 Jan;5(1):22] Cohen K. **Altern Ther Health Med** 1998 Nov;4(6):45–57 (97 ref.)
Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S–759S (37 ref.)
The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S–754S (78 ref.)
Cancer mortality among Native Americans [editorial; comment] Burhansstipanov L. **Cancer** 1998 Dec 1; 83(11):2247–50 (17 ref.) Comment on: Cancer 1998 Dec 1;83(11):2377–83.
Developing mental health services for Native American children. Barlow A, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):555–77, ix (45 ref.)
The public health epidemiology of type 2 diabetes in children and adolescents: a case study of American Indian adolescents in the Southwestern United States. Fagot-Campagna A, et al. **Clin Chim Acta** 1999 Aug; 286(1–2):81–95 (51 ref.)
Arthritis and HLA-B27 in native North American tribes. Walsh B, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):319–25 (46 ref.)
Implementing breast and cervical cancer prevention programs among the Houma Indians of southern Louisiana: cultural and ethical considerations. Coughlin SS. **J Health Care Poor Underserved** 1998 Feb;9(1):30–41 (44 ref.)
Type 2 diabetes among the Pima Indians of Arizona: an epidemic attributable to environmental change? Bennett PH. **Nutr Rev** 1999 May;57(5 Pt 2):S51–4 (15 ref.)
The Pima Indians in Sonora, Mexico. Valencia ME, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S55–7; discussion S57–8 (15 ref.)
Rheumatic diseases in North America's indigenous peoples. Peschken CA, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):368–91 (127 ref.)

GENETICS

Lessons from genetic studies in native Canadian populations. Hegele RA. **Nutr Rev** 1999 May;57(5 Pt 2):S43–9; discussion S49–50 (36 ref.)

PSYCHOLOGY

The American Indian Holocaust: healing historical unresolved grief. Brave Heart MY, et al. **Am Indian Alsk Native Ment Health Res** 1998;8(2):56–78 (90 ref.)
Addressing trauma in substance abuse treatment with American Indian adolescents. Gray N. **J Subst Abuse Treat** 1998 Sep-Oct;15(5):393–9 (42 ref.)
Traditional and western healing practices for alcoholism in American Indians and Alaska Natives. Abbott PJ. **Subst Use Misuse** 1998 Nov;33(13):2605–46 (95 ref.)

STATISTICS & NUMERICAL DATA

The health status of American Indians and Alaska Natives: 2. Lessons for cancer educators. Mahoney MC, et al. **J Cancer Educ** 1999 Spring;14(1):23–7 (34 ref.)

INDICATORS AND REAGENTS

see related
CHELATING AGENTS
DYES
REAGENT KITS, DIAGNOSTIC

The green fluorescent protein. Tsien RY. **Annu Rev Biochem** 1998;67:509–44 (114 ref.)
A FLASH of insight into cellular chemistry: genetically encoded labels for protein visualization in vivo. Luebke KJ. **Chem Biol** 1998 Dec;5(12):R317–22 (24 ref.)
The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Mitchell BS, et al. **Histol Histopathol** 1999 Jan;14(1):217–26 (70 ref.)
Solid-phase analytical derivatization: enhancement of sensitivity and selectivity of analysis. Rosenfeld JM. **J Chromatogr A** 1999 May 28;843(1–2):19–27 (36 ref.)
2-DE spot amino acid analysis with 9-fluorenylmethyl chloroformate. Wilkins MR, et al. **Methods Mol Biol** 1999; 112:445–60 (13 ref.)
[Caged compounds] Katayama Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1917–21 (15 ref.) **(Jpn)**
[Fluorescent probes for detecting active protein kinases in the living cells] Kudo Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1922–6 (4 ref.) **(Jpn)**
[Fluorescent calcium indicators] Kudo Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1912–6 (8 ref.) **(Jpn)**
[A revolution in Ca2+ imaging] Miyawaki A. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1931–8 (12 ref.) **(Jpn)**

CHEMISTRY

Parallel synthesis with fluorous reagents and reactants. Curran DP. **Med Res Rev** 1999 Sep;19(5):432–8 (15 ref.)
Phase-trafficking reagents and phase-switching strategies for parallel synthesis. Flynn DL. **Med Res Rev** 1999 Sep; 19(5):408–31 (69 ref.)

INDIGENCY see **POVERTY**

INDIGENCY, MEDICAL see **MEDICAL INDIGENCY**

INDIGENT CARE see **MEDICAL INDIGENCY**

INDINAVIR

ADVERSE EFFECTS

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Perazella MA, et al. **Clin Nephrol** 1998 Sep;50(3):194–6 (8 ref.)

METABOLISM

The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. Lin JH, et al. **Pharm Biotechnol** 1998; 11:233–55 (28 ref.)

INDIUM

see related
INDIUM RADIOISOTOPES

INDIUM RADIOISOTOPES

DIAGNOSTIC USE

Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L, et al. **Nucl Med Commun** 1999 Aug;20(8):689–96 (26 ref.)
Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)

INDIVIDUAL DIFFERENCES see **INDIVIDUALITY**

INDIVIDUALITY

Problems and prospects for the social support-reactivity hypothesis. Lepore SJ. **Ann Behav Med** 1998 Fall; 20(4):257–69 (93 ref.)
Expanding clinical applications of population pharmacodynamic modelling. Minto C, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):321–33 (90 ref.)
Individual variability and immunity. Cohen JJ. **Brain Behav Immun** 1999 Jun;13(2):76–9 (8 ref.)
Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21–33 (281 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.
The index of individuality is often a misinterpreted quantity characteristic. Petersen PH, et al. **Clin Chem Lab Med** 1999 Jun;37(6):655–61 (10 ref.)
Intraindividual variability in infant behavior. de Weerth C, et al. **Dev Psychol** 1999 Jul;35(4):1102–12 (55 ref.)
Soluble MHC antigens and olfactory recognition of genetic individuality: the mechanism. Pearse-Pratt R, et al. **Genetica** 1998–99;104(3):223–30 (13 ref.)
The present status of the 'carrier hypothesis' for chemosensory recognition of genetic individuality. Singh PB. **Genetica** 1998–99;104(3):231–3 (22 ref.)
Connectionist investigations of individual differences in Stroop performance. Phaf RH, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):899–914 (21 ref.)
Individual and social determinants of shiftwork tolerance. Nachreiner F. **Scand J Work Environ Health** 1998;24 Suppl 3:35–42 (50 ref.)

INDIVIDUATION

Theoretical and treatment issues of personality disorders in individualistic and collectivistic societies. Kim HA. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S242–5 (12 ref.)

INDO-PACIFIC BEAKED WHALE see **WHALES**

INDOCYANINE GREEN

DIAGNOSTIC USE

Fluorescein and indocyanine green angiography in vascular chorioretinal diseases. Brancato R, et al. **Semin Ophthalmol** 1998 Dec;13(4):189–98 (29 ref.)

INDOLEACETIC ACIDS

METABOLISM

Redundancy as a way of life - IAA metabolism. Normanly J, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):207–13 (62 ref.)

INDOLEAMINE 2,3-DIOXYGENASE see **TRYPTOPHAN OXYGENASE**

INDOLES

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)
Measurement of [Ca2+]i in cell suspensions using indo-1. Nelemans A. **Methods Mol Biol** 1999;114:41–7 (21 ref.)

INDOLES

ADVERSE EFFECTS

A review of the safety and tolerability of sertindole. Hale AS. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S65–70 (22 ref.)

CHEMICAL SYNTHESIS

Advances in indolo[2,3–a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Pindur U, et al. **Curr Med Chem** 1999 Jan;6(1):29–69 (79 ref.)

CHEMISTRY

Substituted indole–2–carboxylates as potent antagonists of the glycine binding site associated with the NMDA receptor. Micheli F, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):271–8 (36 ref.)

1 – 1. The chemistry and pharmacology of indole–3–carbinol (indole–3–methanol) and 3–(methoxymethyl)indole. [Part I]. Broadbent TA, et al. **Curr Med Chem** 1998 Oct; 5(5):337–52 (146 ref.)

1. The chemistry and pharmacology of indole–3–carbinol (indole–3–methanol) and 3–(methoxymethyl)indole. [Part II]. Broadbent TA, et al. **Curr Med Chem** 1998 Dec; 5(6):469–91 (177 ref.)

[Chemistry of indoles: new reactivities of indole nucleus and its synthetic application] Murakami Y. **Yakugaku Zasshi** 1999 Jan;119(1):35–60 (50 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

1. The chemistry and pharmacology of indole–3–carbinol (indole–3–methanol) and 3–(methoxymethyl)indole. [Part II]. Broadbent TA, et al. **Curr Med Chem** 1998 Dec; 5(6):469–91 (177 ref.)

1 – 1. The chemistry and pharmacology of indole–3–carbinol (indole–3–methanol) and 3–(methoxymethyl)indole. [Part I]. Broadbent TA, et al. **Curr Med Chem** 1998 Oct; 5(5):337–52 (146 ref.)

Cannabimimetic indoles, pyrroles and indenes. Huffman JW. **Curr Med Chem** 1999 Aug;6(8):705–20 (49 ref.)

Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Marek GJ, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):189–98 (80 ref.)

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Simoons ML, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J56–60 (44 ref.)

Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Moroni F. **Eur J Pharmacol** 1999 Jun 30;375(1–3):87–100 (183 ref.)

[Mechanisms of arbidole's immunomodulating action] Glushkov RG, et al. **Vestn Ross Akad Med Nauk** 1999; (3):36–40 (43 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Kuzel MD. **Am J Health Syst Pharm** 1999 Feb 1;56(3):217–24 (42 ref.)

Naratriptan: an alternative for migraine. Dulli DA. **Ann Pharmacother** 1999 Jun;33(6):704–11 (39 ref.)

Ropinirole and pramipexole, the new agonists. Hobson DE, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S27–33 (53 ref.)

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

Fluvastatin: a review of its use in lipid disorders. Langtry HD, et al. **Drugs** 1999 Apr;57(4):583–606 (107 ref.)

Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Peters DC, et al. **Drugs** 1998 Nov;56(5):871–93 (98 ref.)

Sertindole: a review of clinical efficacy. Kane JM. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S59–63; discussion S63–4 (8 ref.)

[Non–SU, insulin secretagogues] Kikuchi M. **Nippon Rinsho** 1999 Mar;57(3):702–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

INDOMETHACIN

ADVERSE EFFECTS

Molecular mechanisms involved in NSAID–induced gastropathy. Morise Z, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S87–90 (37 ref.)

[Psychiatric side effects of non–steroidal anti–inflammatory agents] Defromont L, et al. **Encephale** 1999 Jan–Feb; 25(1):11–5 (20 ref.) (Eng. Abstr.) **(Fre)**

INDOOR AIR POLLUTION see **AIR POLLUTION, INDOOR**

INDOOR AIR QUALITY see **AIR POLLUTION, INDOOR**

INDOPACETUS see **WHALES**

INDUCER CELLS see **T–LYMPHOCYTES, HELPER–INDUCER**

INDUS DOLPHIN see **DOLPHINS**

INDUSTRIAL ARTS see **TECHNOLOGY**

INDUSTRIAL HEALTH see **OCCUPATIONAL HEALTH**

INDUSTRIAL HYGIENE see **OCCUPATIONAL HEALTH**

INDUSTRIAL MEDICINE see **OCCUPATIONAL MEDICINE**

INDUSTRIAL MICROBIOLOGY

see related
GENETIC ENGINEERING

New perspectives on microbial dehalogenation of chlorinated solvents: insights from the field. Lee MD, et al. **Annu Rev Microbiol** 1998;52:423–52 (104 ref.)

Surface–active lipids in rhodococci. Lang S, et al. **Antonie Van Leeuwenhoek** 1998 Jul–Oct;74(1–3):59–70 (70 ref.)

Novel approaches for discovering industrial enzymes. Marrs B, et al. **Curr Opin Microbiol** 1999 Jun;2(3):241–5 (40 ref.)

Microbial enzymes: new industrial applications from traditional screening methods. Ogawa J, et al. **Trends Biotechnol** 1999 Jan;17(1):13–21 (63 ref.)

INDUSTRIAL WASTE

ADVERSE EFFECTS

Chemical wastes, children's health, and the Superfund Basic Research Program. Landrigan PJ, et al. **Environ Health Perspect** 1999 Jun;107(6):423–7 (44 ref.)

Trichloroethylene. I. Carcinogenicity of trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):211–4 (37 ref.)

INDUSTRIALIZATION see **INDUSTRY**

INDUSTRIALIZED COUNTRIES see **DEVELOPED COUNTRIES**

INDUSTRY

see related
COMMERCE
OCCUPATIONAL DISEASES
OCCUPATIONAL MEDICINE
WORKPLACE

Recent trends and controversies in industry–sponsored clinical trials. Reed CR, et al. **Acad Emerg Med** 1999 Aug; 6(8):833–9 (37 ref.)

The chemical control of biofouling in industrial water systems. Cloete TE, et al. **Biodegradation** 1998;9(1):23–37 (83 ref.)

Awareness of periodontal disease—the role of industry. Ishikawa I, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):261–7 (68 ref.)

The conflict–prone nature of occupational health research and practice. Nemery B. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):35–7 (12 ref.)

Climate forcings in the industrial era. Hansen JE, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12753–8 (47 ref.)

La roca magica: uses of natural zeolites in agriculture and industry. Mumpton FA. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3463–70 (106 ref.)

[Neurologic side effects of chemicals used in industry] Igisu H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):628–32 (16 ref.) **(Jpn)**

[The ecological epidemiological and immunological characteristics of infectious diseases in a large industrial region of the Don Basin (a review of the literature)] Frolov VM, et al. **Lik Sprava** 1999 Apr–May;(3):38–41 (32 ref.) **(Rus)**

[Occupational psychiatry: major stages and prospects of development (review of literature)] Beliaeva GG. **Med Tr Prom Ekol** 1999;(7):33–7 (37 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

The international electronics industry. LaDou J, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):1–18 (26 ref.)

The impact of lean production and related new systems of work organization on worker health. Landsbergis PA, et al. **J Occup Health Psychol** 1999 Apr;4(2):108–30 (132 ref.)

STANDARDS

Is health care ready for Six Sigma quality? Chassin MR. **Milbank Q** 1998;76(4):565–91, 510 (62 ref.)

INERT GAS NARCOSIS

[Medical aspects of diving—a sport for both women and men] Gustavsson LL, et al. **Lakartidningen** 1999 Feb 17; 96(7):749–53 (11 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

[Pneumologic aspects of diving medicine] Tetzlaff K, et al. **Pneumologie** 1998 Sep;52(9):489–500 (126 ref.) **(Ger)**

INFANT BEHAVIOR

Ultradian and circadian rhythms of sleep–wake and food–intake behavior during early infancy. Löhr B, et al. **Chronobiol Int** 1999 Mar;16(2):129–48 (54 ref.)

Intraindividual variability in infant behavior. de Weerth C, et al. **Dev Psychol** 1999 Jul;35(4):1102–12 (55 ref.)

The crying infant. Trocinski DR, et al. **Emerg Med Clin North Am** 1998 Nov;16(4):895–910, vii–viii (65 ref.)

Assessment of long–chain polyunsaturated fatty acid nutritional supplementation on infant neurobehavioral development and visual acuity. Jacobson SW. **Lipids** 1999 Feb;34(2):151–60 (65 ref.)

PHYSIOLOGY

Self–perception and action in infancy. Rochat P. **Exp Brain Res** 1998 Nov;123(1–2):102–9 (22 ref.)

From the big bang to the brain. Boliek CA, et al. **J Commun Disord** 1999 Jul–Aug;32(4):271–6 (12 ref.)

Precursors to speech in infancy: the prediction of speech and language disorders [see comments] Oller DK, et al. **J Commun Disord** 1999 Jul–Aug;32(4):223–45 (47 ref.) Comment in: J Commun Disord 1999 Jul–Aug;32(4):247–50.

The influence of neonatal nutrition on behavioral development: a critical appraisal. Wauben IP, et al. **Nutr Rev** 1999 Feb;57(2):35–44 (92 ref.)

PSYCHOLOGY

Influences on infant speech processing: toward a new synthesis. Werker JF, et al. **Annu Rev Psychol** 1999; 50:509–35 (126 ref.)

INFANT CARE

see related
CHILD CARE
INTENSIVE CARE, NEONATAL

METHODS

Kangaroo Mother Care [editorial] Simkiss DE. **J Trop Pediatr** 1999 Aug;45(4):192–4 (23 ref.)

The GP's role from birth to six months. Sawczenko A, et al. **Practitioner** 1998 Jul;242(1588):528, 532–4, 536 (0 ref.)

ORGANIZATION & ADMINISTRATION

Intensive intervention for maltreated infants and toddlers in foster care. Zeanah CH, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):357–71 (19 ref.)

TRENDS

[What is new in neonatology?] Simeoni U. **Arch Pediatr** 1999 Apr;6(4):447–56 (71 ref.) (Eng. Abstr.) **(Fre)**

INFANT DEVELOPMENT see **CHILD DEVELOPMENT**

INFANT FOOD

Soy protein for the prevention and treatment of children with cow–milk allergy. Businco L, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1447S–1452S (78 ref.)

Use of soy–protein formulas and soyfood for feeding infants and children in Asia. Quak SH, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1444S–1446S (16 ref.)

Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Høst A, et al. **Arch Dis Child** 1999 Jul;81(1):80–4 (39 ref.)

Principles for formulating parenteral nutrition for neonates [see comments] Ball P. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):261–4 (28 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):259–60.

Requirements for long–chain polyunsaturated fatty acids in the preterm infant. Uauy R, et al. **Curr Opin Pediatr** 1999 Apr;11(2):115–20 (53 ref.)

Special formulas in infant nutrition: a review. Maldonado J, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S23–32 (79 ref.)

Neonatal dietary gangliosides. Rueda R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S135–47 (60 ref.)

Fish oil: for use in infant formula? [editorial; comment] Udall JN Jr. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):244–5 (9 ref.) Comment on: J Pediatr Gastroenterol Nutr 1999 Mar;28(3):276–81.

The story of soy formula feeding in infants: a road paved with good intentions [letter] Zoppi G, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):541–3 (39 ref.)

Long–chain polyunsaturated fatty acids in diets for infants: choices for recommending and regulating bodies and for

manufacturers of dietary products. Koletzko B, et al. **Lipids** 1999 Feb;34(2):215–20 (34 ref.)
Complementary feeding: a global perspective. Michaelsen KF, et al. **Nutrition** 1998 Oct;14(10):763–6 (33 ref.)
Prematurity, immune function and infant feeding practices. Hampton SM. **Proc Nutr Soc** 1999 Feb;58(1):75–8 (16 ref.)
[After milk: what, when, how, why?] Turck D. **Arch Pediatr** 1998;5 Suppl 2:205s–209s (15 ref.) **(Fre)**
[Recommendations for prevention of iron deficiency. Delay cow's milk intake as a beverage to infants until 10–12 months of age!] Axelsson I, et al. **Lakartidningen** 1999 May 5;96(18):2206–8 (30 ref.) (Eng. Abstr.) **(Swe)**

ANALYSIS

Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Setchell KD, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1453S–1461S (86 ref.)
Breastmilk nucleotides [editorial] Ebrahim GJ. **J Trop Pediatr** 1998 Dec;44(6):318–9 (11 ref.)

STANDARDS

Assessment of nutrient requirements for infant formulas [published erratum appears in J Nutr 1999 May;129(5):1090] **J Nutr** 1998 Nov;128(11 Suppl):i–iv, 2059S–2293S (1034 ref.)

INFANT HEALTH see **INFANT WELFARE**

INFANT HEALTH SERVICES see **CHILD HEALTH SERVICES**

INFANT, LOW BIRTH WEIGHT

Low birth weight and cardiovascular disease: myth or reality? Jones SE, et al. **Curr Opin Lipidol** 1998 Aug; 9(4):309–12 (28 ref.)
Birth weight and the future development of diabetes. A review of the evidence. Phillips DI. **Diabetes Care** 1998 Aug;21 Suppl 2:B150–5 (41 ref.)
The risk of teen mothers having low birth weight babies: implications of recent medical research for school health personnel. Roth J, et al. **J Sch Health** 1998 Sep;68(7):271–5 (40 ref.)
Kangaroo Mother Care [editorial] Simkiss DE. **J Trop Pediatr** 1999 Aug;45(4):192–4 (23 ref.)
The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Hattersley AT, et al. **Lancet** 1999 May 22; 353(9166):1789–92 (43 ref.)
[Delivery methods for infants weighing less than 2500 grams. In cases of premature rupture of membranes, outside of labor] Batallan A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:292–4 (15 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. Which specific measures to consider for the newborn?] Bouillié J. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:314–7 (19 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. During labor, which delivery method should be chosen?] Boulot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:295–301 (22 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. Labor surveillance in cases of vaginal delivery] Carbonne B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:307–10 (14 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. In cases of in utero growth retardation, outside of labor] Fournié A. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:289–91 (7 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. Anesthesia methods in cesarean cases and vaginal deliveries] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:275–84 (55 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. In cases of cesareans, which particular techniques should be considered (excluding anesthetic techniques)?] Langer B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:302–6 (19 ref.) **(Fre)**
[Delivery methods for infants of birthweight less than 2500 grams. Description of practices in France. The Obstetricians Sentinel Network A.U.D.I.P.O.G.] Mamelle N. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:269–74 (7 ref.) **(Fre)**
[Delivery methods for infants weighing less than 2500 grams. Which particular preventative modalities should be proposed for natural delivery?] Verspyck E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:311–3 (13 ref.) **(Fre)**
[Neonatal care of premature infants] Ertl T. **Orv Hetil** 1999 Jul 18;140(29):1611–8 (5011 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

[Studying intestinal maturation in newborn infants by means of stable isotopes] Sáenz de Pipaón M, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):77–82 (59 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

[Delivery methods for infants weighing less than 2500 grams. Psychological implications] Molénat F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:285–8 (8 ref.) **(Fre)**

INFANT MORTALITY

see related
FETAL DEATH

Perinatal morbidity and mortality rates in twin pregnancies—a 15-year review study from Athens. Liapis AE, et al. **Acta Genet Med Gemellol (Roma)** 1997; 46(4):185–91 (25 ref.)
Socio-demographic risk factors for perinatal mortality. A study of perinatal mortality in the French district of Seine-Saint-Denis. Zeitlin J, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):826–35 (33 ref.)
Optimality of the birth population reduces learning and behaviour disorders and sudden infant death after the first month. Saugstad LF. **Acta Paediatr Suppl** 1999 May; 88(429):9–28 (171 ref.)
Neonatal risk scoring systems. Can they predict mortality and morbidity? Richardson DK, et al. **Clin Perinatol** 1998 Sep;25(3):591–611 (126 ref.)
Health trends in northern Finland. Näyhä S, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):94–103 (51 ref.)
Advances in perinatal medical care—from our experience. Sakamoto S, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S107–14 (9 ref.)
A phylogenetic analysis of the relationship between sub-adult mortality and mode of subsistence. Sellen DW, et al. **J Biosoc Sci** 1999 Jan;31(1):1–16 (59 ref.)
Fishing for trout in the milk [editorial] Berry PJ. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):99–101 (11 ref.)
Neonatal respiratory care and infant mortality in emerging countries [editorial; comment] Sola A, et al. **Pediatr Pulmonol** 1999 May;27(5):303–4 (8 ref.) Comment on: Pediatr Pulmonol 1999 May;27(5):305–11. Comment on: Pediatr Pulmonol 1999 May;27(5):312–7.
[Prenatal protection. Regulations. Perinatal mortality. Epidemiology] Kremp O. **Rev Prat** 1998 Jun 1; 48(11):1233–8 (0 ref.) **(Fre)**

TRENDS

The effects of infant mortality on fertility revisited: new evidence from Latin America. Palloni A, et al. **Demography** 1999 Feb;36(1):41–58 (56 ref.)
Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)

INFANT, NEWBORN

see related
ANIMALS, NEWBORN

The physicochemical environment of the neonatal intestine. Sanderson IR. **Am J Clin Nutr** 1999 May; 69(5):1028S–1034S (52 ref.)
Ethical issues surrounding resuscitation. Boyle RJ, et al. **Clin Perinatol** 1999 Sep;26(3):779–92 (73 ref.)
Medication use in neonatal resuscitation. Burchfield DJ. **Clin Perinatol** 1999 Sep;26(3):683–91 (57 ref.)
Delivery room resuscitation of the newborn. Wolkoff LI, et al. **Clin Perinatol** 1999 Sep;26(3):641–58 (45 ref.)
Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Eur J Pediatr** 1999 Apr;158(4):345–58 (85 ref.)
Bedside musical care: applications in pregnancy, childbirth, and neonatal care. Olson SL. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):569–75 (33 ref.)
An advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Pediatrics** 1999 Apr;103(4):e56 (85 ref.)
Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Resuscitation** 1999 Feb–Mar;40(2):71–88 (85 ref.)
Neonatal analgesia and anesthesia. Introduction. Anand KJ. **Semin Perinatol** 1998 Oct;22(5):347–9 (9 ref.)
Neuroblastoma in the neonate. Lukens JN. **Semin Perinatol** 1999 Aug;23(4):263–73 (64 ref.)

BLOOD

Hematopoietic growth factor levels in term and preterm infants. Rondini G, et al. **Curr Opin Hematol** 1999 May; 6(3):192–7 (59 ref.)

GROWTH & DEVELOPMENT

Developmental microbial ecology of the neonatal gastrointestinal tract. Mackie R, et al. **Am J Clin Nutr** 1999 May;69(5):1035S–1045S (135 ref.)
Ontogenetic constraints on neural and behavioral plasticity: evidence from imprinting and face processing. Johnson MH. **Can J Exp Psychol** 1999 Mar;53(1):77–91 (81 ref.)

IMMUNOLOGY

Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Collins MD, et al. **Am J Clin Nutr** 1999 May;69(5):1052S–1057S (66 ref.)
T-cell function in newborn mice and humans. Adkins B. **Immunol Today** 1999 Jul;20(7):330–5 (60 ref.)
Human neonatal natural killer cell cytotoxicity function. Kohl S. **Pediatr Infect Dis J** 1999 Jul;18(7):635–7 (43 ref.)
[Characteristics of immunoreactivity in neonates and young children. Review of the literature] Dekaris D. **Lijec Vjesn** 1998 Mar–Apr;120(3–4):65–72 (95 ref.) (Eng. Abstr.) **(Scr)**

METABOLISM

Alveolar fluid clearance in developing lungs and its role in neonatal transition. Jain L. **Clin Perinatol** 1999 Sep; 26(3):585–99 (88 ref.)
Metabolic response to neonatal surgery. Pierro A. **Curr Opin Pediatr** 1999 Jun;11(3):230–6 (65 ref.)
Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Makinde AO, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):49–56 (43 ref.)

PHYSIOLOGY

Concentrations of essential trace elements in maternal serum and the effect on birth weight and newborn body mass index in sub-arctic and arctic populations of Norway and Russia. Odland JO, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):605–14 (44 ref.)
The transition from fetus to neonate—an endocrine perspective. Gluckman PD, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):7–11 (34 ref.)
Perinatal effects of prenatal drug exposure. Neonatal aspects. Bauer CR. **Clin Perinatol** 1999 Mar;26(1):87–106 (181 ref.)
Physiologic reflexes and their impact on resuscitation of the newborn. Halbower AC, et al. **Clin Perinatol** 1999 Sep; 26(3):621–7, vi (33 ref.)
Pulmonary vascular biology during neonatal transition. Lakshminrusimha S, et al. **Clin Perinatol** 1999 Sep; 26(3):601–19 (120 ref.)
Role of corticosteroids in neonatal blood pressure homeostasis. Sasidharan P. **Clin Perinatol** 1998 Sep; 25(3):723–40, xi (160 ref.)
Effects of fetal and neonatal environment on sympathetic nervous system development. Young JB, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B156–60 (25 ref.)
Maternal nutritional factors: significance for the fetus and the neonate. Urgell MR, et al. **Early Hum Dev** 1998 Dec; 53 Suppl:S61–76 (20 ref.)
Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1–2):90–4 (43 ref.)
Perinatal characteristics and schizophrenia: electrodermal activity as a mediating link in a vulnerability-stress perspective. Hultman CM, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):307–16 (99 ref.)
Responses to maternal separation: mechanisms and mediators. Kuhn CM, et al. **Int J Dev Neurosci** 1998 Jun–Jul; 16(3–4):261–70 (57 ref.)
Neonatal skin: the ideal nursing interface. Lott JW, et al. **J Pediatr Nurs** 1998 Oct;13(5):302–6 (11 ref.)
Assessment of pain in the neonate. Abu-Saad HH, et al. **Semin Perinatol** 1998 Oct;22(5):402–16 (74 ref.)
Environmental and behavioral strategies to prevent and manage neonatal pain. Franck LS, et al. **Semin Perinatol** 1998 Oct;22(5):434–43 (85 ref.)
Anesthesia for neonatal surgical emergencies. Mellor DJ, et al. **Semin Perinatol** 1998 Oct;22(5):363–79 (74 ref.)
[Electroencephalography of the premature and term newborn. Maturational aspects and glossary] Lamblin MD, et al. **Neurophysiol Clin** 1999 Apr;29(2):123–219 (77 ref.) (Eng. Abstr.) **(Fre)**
[Pain in neonates (see comments)] Rønneberg M, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3610–3 (40 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1998 Nov 10;118(27):4270. **(Nor)**

PSYCHOLOGY

Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1–2):90–4 (43 ref.)
Neurobiology of mother-infant interactions: experience and central nervous system plasticity across development and generations. Fleming AS, et al. **Neurosci Biobehav Rev** 1999 May;23(5):673–85 (106 ref.)

INFANT, NEWBORN, DISEASES

see related
ABNORMALITIES

Hypercalcemia of the newborn: etiology, evaluation, and management. Rodd C, et al. **Pediatr Nephrol** 1999 Aug; 13(6):542–7 (35 ref.)
New clinical observations in hemangiomas. Blei F. **Semin Cutan Med Surg** 1999 Sep;18(3):187–94 (106 ref.)

CLASSIFICATION

Structure and performance of different DRG classification systems for neonatal medicine. Muldoon JH. **Pediatrics** 1999 Jan;103(1 Suppl E):302–18 (15 ref.)

INFANT, NEWBORN, DISEASES

DIAGNOSIS

Use of newer imaging modalities in the neonate: a rational approach. Chaudhari S. **Indian Pediatr** 1998 May; 35(5):437–45 (16 ref.)

Fishing for trout in the milk [editorial] Berry PJ. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):99–101 (11 ref.)

Computerized EEG monitoring. Rosenblatt B, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):120–7 (24 ref.)

New technologies in pediatric neurology. Near–infrared spectroscopy. Soul JS, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):101–10 (53 ref.)

[Vertical HIV–I–transmission. II. HIV–diagnosis in a child] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12; 142(50):2724–8 (33 ref.) (Eng. Abstr.) **(Dut)**

[Newborn infant bacterial infections. Diagnosis, treatment principles, prevention] Maingueneau C, et al. **Rev Prat** 1998 May 15;48(10):1129–35 (0 ref.) **(Fre)**

[Clinical and laboratory basis for the diagnosis and understanding of neonatal metabolic diseases] Bispo MA, et al. **Acta Med Port** 1998 Jul;11(7):675–81 (7 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Myeloid colony–stimulating factors: use in the newborn. Sreenan C, et al. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):984–8 (65 ref.)

Nitric oxide inhalation therapy for newborn infants. Skimming JW. **Curr Probl Pediatr** 1998 Sep;28(8):253–64 (110 ref.)

[Newborn infant bacterial infections. Diagnosis, treatment principles, prevention] Maingueneau C, et al. **Rev Prat** 1998 May 15;48(10):1129–35 (0 ref.) **(Fre)**

EPIDEMIOLOGY

Neonatology in developing countries: problems, practices and prospects. Dawodu A. **Ann Trop Paediatr** 1998 Sep; 18 Suppl:S73–9 (35 ref.)

Neonatal morbidities in gestational diabetes mellitus. Persson B, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B79–84 (45 ref.)

ETIOLOGY

Congenital diaphragmatic hernia. A cause of persistent pulmonary hypertension of the newborn which lacks an effective therapy. Thébaud B, et al. **Biol Neonate** 1998 Nov; 74(5):323–36 (106 ref.)

[Gestational diabetes: prognostic significance for the infant] Géronooz I, et al. **Rev Med Liege** 1999 Jun;54(6):517–21 (16 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The metabolic needs of critically ill children and neonates. Shew SB, et al. **Semin Pediatr Surg** 1999 Aug;8(3):131–9 (88 ref.)

MORTALITY

Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)

PHYSIOPATHOLOGY

Childhood systemic lupus erythematosus and neonatal lupus syndrome. Sandborg CI. **Curr Opin Rheumatol** 1998 Sep; 10(5):481–7 (78 ref.)

PREVENTION & CONTROL

[Newborn infant bacterial infections. Diagnosis, treatment principles, prevention] Maingueneau C, et al. **Rev Prat** 1998 May 15;48(10):1129–35 (0 ref.) **(Fre)**

Parasitic infections in pregnancy and congenital protozoan infections. Part I.: Protozoan infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):55–62 (44 ref.) (Eng. Abstr.) **(Ger)**

[Justification of a prevention policy of perinatal disease by group B streptococci (GBS). Recommendations] Andreu A, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):138–40 (8 ref.) **(Spa)**

SURGERY

Resuscitation of the surgical neonate. Chahine AA, et al. **Clin Perinatol** 1999 Sep;26(3):693–715 (38 ref.)

THERAPY

Use and misuse of albumin infusions in neonatal care. Greenough A. **Eur J Pediatr** 1998 Sep;157(9):699–702 (35 ref.)

Treating infants who may die [comment] Howe EG. **J Clin Ethics** 1998 Fall;9(3):215–24 (25 ref.) Comment on: J Clin Ethics 1998 Fall;9(3):314–22.

New practices in the transitional care center improve outcomes for babies and their families. Forsythe P. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S13–7 (4 ref.)

[Dehydration due to gastro–enteritis in children] Kist–van Holthe JE, et al. **Ned Tijdschr Geneeskd** 1999 Jan 23; 143(4):193–6 (19 ref.) (Eng. Abstr.) **(Dut)**

[What is new in neonatology?] Simeoni U. **Arch Pediatr** 1999 Apr;6(4):447–56 (71 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

[Neurological complications of HIV–1 infection in an infant born to a seropositive mother] Tardieu M. **Rev Neurol (Paris)** 1998 Dec;154(12):850–5 (24 ref.) **(Fre)**

INFANT, NEWBORN, INTENSIVE CARE see **INTENSIVE CARE, NEONATAL**

INFANT, NEWBORN, SCREENING see **NEONATAL SCREENING**

INFANT NUTRITION

see related
CHILD NUTRITION
MILK
MILK, HUMAN

The role of long chain polyunsaturated fatty acids (LCPUFA) in neonatal nutrition. Gibson RA, et al. **Acta Paediatr** 1998 Oct;87(10):1017–22 (45 ref.)

An updated view of the value of taurine in infant nutrition. Chesney RW, et al. **Adv Pediatr** 1998;45:179–200 (88 ref.)

Potential mechanisms of metabolic imprinting that lead to chronic disease. Waterland RA, et al. **Am J Clin Nutr** 1999 Feb;69(2):179–97 (13 ref.)

Nutrition in early life: somatic growth and serum lipids. Boulton TJ, et al. **Ann Med** 1999 Apr;31 Suppl 1:7–12 (46 ref.)

Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Høst A, et al. **Arch Dis Child** 1999 Jul;81(1):80–4 (39 ref.)

Nutritional and biochemical properties of human milk, Part I: General aspects, proteins, and carbohydrates. Kunz C, et al. **Clin Perinatol** 1999 Jun;26(2):307–33 (110 ref.)

Principles for formulating parenteral nutrition for neonates [see comments] Ball P. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):261–4 (28 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):259–60.

Some current controversies on nutritional requirements of full–term and pre–term newborn infants. Bayés R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S3–13 (37 ref.)

Special formulas in infant nutrition: a review. Maldonado J, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S23–32 (79 ref.)

Neonatal dietary gangliosides. Rueda R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S135–47 (60 ref.)

Assessment of nutrient requirements for infant formulas [published erratum appears in J Nutr 1999 May;129(5):1090] **J Nutr** 1998 Nov;128(11 Suppl):i–iv, 2059S–2293S (1034 ref.)

Statistical considerations in infant nutrition trials. Gore SM. **Lipids** 1999 Feb;34(2):185–97 (9 ref.)

The influence of neonatal nutrition on behavioral development: a critical appraisal. Wauben IP, et al. **Nutr Rev** 1999 Feb;57(2):35–44 (92 ref.)

Recent trends in infant nutrition. Lawson M. **Nutrition** 1998 Oct;14(10):755–7 (15 ref.)

Complementary feeding: a global perspective. Michaelsen KF, et al. **Nutrition** 1998 Oct;14(10):763–6 (33 ref.)

Nutrition and cognitive development. Morley R. **Nutrition** 1998 Oct;14(10):752–4 (24 ref.)

Nutritional issues for infants and toddlers. Aldous MB. **Pediatr Ann** 1999 Feb;28(2):101–5 (40 ref.)

The metabolic needs of critically ill children and neonates. Shew SB, et al. **Semin Pediatr Surg** 1999 Aug;8(3):131–9 (88 ref.)

Protective function of human milk: the milk fat globule. Hamosh M, et al. **Semin Perinatol** 1999 Jun;23(3):242–9 (65 ref.)

[Malnutrition at the beginning of life: long–term effects] Rolland–Cachera MF. **Arch Pediatr** 1998;5 Suppl 2:209s–211s (21 ref.) **(Fre)**

[After milk: what, when, how, why?] Turck D. **Arch Pediatr** 1998;5 Suppl 2:205s–209s (15 ref.) **(Fre)**

PHYSIOLOGY

Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates. Kurlak LO, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F148–54 (40 ref.)

The role of human milk fortification for premature infants. Schanler RJ. **Clin Perinatol** 1998 Sep;25(3):645–57, ix (69 ref.)

Oral feeding in infants. Lau C, et al. **Curr Probl Pediatr** 1999 Apr;29(4):105–24 (142 ref.)

INFANT NUTRITION DISORDERS

see related
CHILD NUTRITION DISORDERS

COMPLICATIONS

The Barker hypothesis. An analysis. Wilson J **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):1–7 (36 ref.)

INFANT, PREMATURE

Development of perception in action in healthy and at–risk children. van der Meer AL, et al. **Acta Paediatr Suppl** 1999 May;88(429):29–36 (36 ref.)

Continuous distending pressure. Morley C. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F152–6 (73 ref.)

Ethical challenges in the treatment of infants of drug–abusing mothers. Jain R, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):179–88 (37 ref.)

Fibrinolytic agents in the management of posthemorrhagic hydrocephalus in preterm infants: the evidence. Haines SJ, et al. **Childs Nerv Syst** 1999 May;15(5):226–34 (19 ref.)

Intervention programs for premature infants. How and do they affect development? Feldman R, et al. **Clin Perinatol** 1998 Sep;25(3):613–26, ix (74 ref.)

The use of human milk and breastfeeding in premature infants. Schanler RJ, et al. **Clin Perinatol** 1999 Jun; 26(2):379–98, vii (118 ref.)

Erythropoietin in the neonate. Juul SE. **Curr Probl Pediatr** 1999 May–Jun;29(5):129–49 (190 ref.)

Nutrition of the fetus and the premature infant. Battaglia FC, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B70–4 (42 ref.)

Some current controversies on nutritional requirements of full–term and pre–term newborn infants. Bayés R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S3–13 (37 ref.)

Mechanisms initiating lung injury in the preterm. Jobe AH, et al. **Early Hum Dev** 1998 Nov;53(1):81–94 (66 ref.)

White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Perlman JM. **Early Hum Dev** 1998 Dec;53(2):99–120 (134 ref.)

Protein demand in the premature neonate and in the small for gestational age full–term neonate. Robles R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S15–21 (30 ref.)

Ciprofloxacin in preterm neonates: case report and review of the literature. van den Oever HL, et al. **Eur J Pediatr** 1998 Oct;157(10):843–5 (8 ref.)

Role of periodontitis in systemic health: spontaneous preterm birth. Offenbacher S, et al. **J Dent Educ** 1998 Oct; 62(10):852–8 (20 ref.)

Nursing interventions to reduce stress in parents of hospitalized preterm infants. Griffin T, et al. **J Pediatr Nurs** 1998 Oct;13(5):290–5 (31 ref.)

A review of guidelines for the discharge of premature infants: opportunities for improving cost effectiveness. Merritt TA, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S27–37 (79 ref.)

Kangaroo Mother Care [editorial] Simkiss DE. **J Trop Pediatr** 1999 Aug;45(4):192–4 (23 ref.)

Is the pharmacological use of intravenous magnesium before preterm cerebroprotective or deleterious for premature infants? Possible importance of the use of magnesium sulphate [comment] Durlach J, et al. **Magnes Res** 1998 Dec; 11(4):323–5 (22 ref.) Comment on: Magnes Res 1996 Oct;9(3):217–9.

Bone mineralization in preterm infants. Ryan S. **Nutrition** 1998 Oct;14(10):745–7 (14 ref.)

A review of the pharmacokinetic and pharmacodynamic characteristics of beta–lactam/beta–lactamase inhibitor combination antibiotics in premature infants. Rubino CM, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1200–10 (69 ref.)

Pain in the very preterm baby: 'suffer little children?' McVey C. **Pediatr Rehabil** 1998 Apr–Jun;2(2):47–55 (106 ref.)

What's new in perinatology. Chescheir NC, et al. **Pediatr Rev** 1999 Feb;20(2):57–63 (11 ref.)

Prematurity, immune function and infant feeding practices. Hampton SM. **Proc Nutr Soc** 1999 Feb;58(1):75–8 (16 ref.)

Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Dammann O, et al. **Semin Pediatr Neurol** 1998 Sep;5(3):190–201 (116 ref.)

Antenatal glucocorticoid, magnesium exposure, and the prevention of brain injury of prematurity. Perlman JM. **Semin Pediatr Neurol** 1998 Sep;5(3):202–10 (89 ref.)

Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Volpe JJ. **Semin Pediatr Neurol** 1998 Sep;5(3):135–51 (138 ref.)

Anesthesia for the micropremie. Spaeth JP, et al. **Semin Perinatol** 1998 Oct;22(5):390–401 (50 ref.)

[Should premature infants be vaccinated? (editorial)] Floret D, et al. **Arch Pediatr** 1999 Jun;6(6):607–9 (17 ref.) **(Fre)**

[Prematurity and sudden infant death syndrome. Polysomnography in question] Lequien P, et al. **Arch Pediatr** 1999 Jun;6(6):683–5 (16 ref.) (Eng. Abstr.) **(Fre)**

[Iron supplementation in preterm infants treated with erythropoietin] Picaud JC, et al. **Arch Pediatr** 1999 Jun; 6(6):657–64 (57 ref.) (Eng. Abstr.) **(Fre)**

[Can we improve the neuro–intellectual and behavioral prognosis of premature infants by modifying their environment? (editorial)] Sizun J, et al. **Arch Pediatr** 1999 Jan;6(1):7–11 (37 ref.) **(Fre)**

[Neonatal care of premature infants] Ertl T. **Orv Hetil** 1999 Jul 18;140(29):1611–8 (5011 ref.) (Eng. Abstr.) **(Hun)**

[Neonatal viability and resuscitation in preterm newborns with an extremely low birth weight] García–Alix Pérez A, et al. **An Esp Pediatr** 1999 Jun;50(6):594–602 (64 ref.) **(Spa)**

[Preterm delivery: detection of risks and preventive

treatment] Althabe F, et al. **Rev Panam Salud Publica** 1999 Jun;5(6):373–85 (71 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Hematopoietic growth factor levels in term and preterm infants. Rondini G, et al. **Curr Opin Hematol** 1999 May; 6(3):192–7 (59 ref.)

Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)

GROWTH & DEVELOPMENT

Requirements for long-chain polyunsaturated fatty acids in the preterm infant. Uauy R, et al. **Curr Opin Pediatr** 1999 Apr;11(2):115–20 (53 ref.)

Environmental impact of the NICU on developmental outcomes. Blackburn S. **J Pediatr Nurs** 1998 Oct; 13(5):279–89 (60 ref.)

PHYSIOLOGY

Neonatal EEG: a powerful tool in the assessment of brain damage in preterm infants. Watanabe K, et al. **Brain Dev** 1999 Sep;21(6):361–72 (59 ref.)

Support of gas exchange in the delivery room and beyond: how do we avoid hurting the baby we seek to save? Clark RH. **Clin Perinatol** 1999 Sep;26(3):669–81, vii–viii (68 ref.)

The role of human milk fortification for premature infants. Schanler RJ. **Clin Perinatol** 1998 Sep;25(3):645–57, ix (69 ref.)

Thyroid function in the preterm infant. LaFranchi S. **Thyroid** 1999 Jan;9(1):71–8 (33 ref.)

[Implementation of an individualized program of sustained development in neonatal intensive care: why, how?] Sizun J, et al. **Arch Pediatr** 1999 Apr;6(4):434–9 (52 ref.) (Eng. Abstr.) **(Fre)**

[Electroencephalography of the premature and term newborn. Maturational aspects and glossary] Lamblin MD, et al. **Neurophysiol Clin** 1999 Apr;29(2):123–219 (77 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[Clinical significance of attachment research for the premature infant group: an overview of most recent research] Buchheim A, et al. **Z Kinder Jugendpsychiatr Psychother** 1999 May; 27(2):125–38 (105 ref.) **(Ger)**

INFANT, PREMATURE, DISEASES

CHEMICALLY INDUCED

Adverse effects of prenatal glucocorticoid treatment in the preterm infant. Rubaltelli FF, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:35–8 (25 ref.)

DIAGNOSIS

[Common anemias in neonatology] Humbert J, et al. **Schweiz Rundsch Med Prax** 1999 Jan 28;88(5):164–71 (15 ref.) (Eng. Abstr.) **(Ger)**

[Sepsis due to azole-resistant Candida albicans in a high-risk premature infant] Martínez Suárez V, et al. **An Esp Pediatr** 1999 Jan;50(1):77–8 (22 ref.) **(Spa)**

[Preterm delivery: detection of risks and preventive treatment] Althabe F, et al. **Rev Panam Salud Publica** 1999 Jun;5(6):373–85 (71 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Appraising the potential of pentoxifylline in septic premies [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):695–7 (32 ref.) Comment on: Crit Care Med 1999 Apr;27(4):807–14.

Ciprofloxacin in preterm neonates: case report and review of the literature. van den Oever HL, et al. **Eur J Pediatr** 1998 Oct;157(10):843–5 (8 ref.)

Thrombolysis of a neonatal brachial artery thrombosis with tissue plasminogen activator. Grieg A. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):460–2 (11 ref.)

Combined treatment with zidovudine, lamivudine, nelfinavir and ganciclovir in an infant with human immunodeficiency virus type 1 infection and cytomegalovirus encephalitis: case report and review of the literature. Rohrer T, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):382–6 (27 ref.)

Corticosteroids and chronic lung disease in extremely immature infants: a dilemma. Moriette G, et al. **Pediatr Pulmonol Suppl** 1999;18:209–11 (12 ref.)

ETIOLOGY

[Peritonitis in the neonatal period] Simão C, et al. **Acta Med Port** 1998 Dec;11(12):1127–9 (11 ref.) (Eng. Abstr.) **(Por)**

METABOLISM

Thyroid function in premature infants. The hypothyroxinemia of prematurity. Fisher DA. **Clin Perinatol** 1998 Dec;25(4):999–1014, viii (53 ref.)

PATHOLOGY

A case of panlobar nephroblastomatosis with bilateral Wilms' tumour. The concept of "nephroblastomatosis" and its clinical importance. Lancaster EJ, et al. **Cent Afr J Med** 1998 Jul;44(7):182–7 (15 ref.)

PREVENTION & CONTROL

Erythropoietin to prevent and treat the anemia of prematurity. Ohls RK. **Curr Opin Pediatr** 1999 Apr; 11(2):108–14 (52 ref.)

Brain damage in preterm newborns: might enhancement of developmentally regulated endogenous protection open a door for prevention? Dammann O, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):541–50 (187 ref.)

RADIOGRAPHY

Unusual site for oesophageal perforation in an extremely low birth weight infant. Cairns PA, et al. **Eur J Pediatr** 1999 Feb;158(2):152–3 (5 ref.)

SURGERY

[Duplication of the stomach as a rare cause of cystic epigastric tumor] Rudolph J, et al. **Zentralbl Chir** 1998; 123(7):850–4 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

High-frequency ventilation versus conventional ventilation: No winner–but no loser [editorial; comment] Truog WE. **J Pediatr** 1999 Jul;135(1):9–11 (10 ref.) Comment on: J Pediatr 1999 Jul;135(1):39–46.

Strategy for the prevention and treatment of chronic lung disease of the premature infant. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:212–5 (15 ref.)

INFANT PSYCHOLOGY see **CHILD PSYCHOLOGY**

INFANT, SMALL FOR GESTATIONAL AGE

Protein demand in the premature neonate and in the small for gestational age full-term neonate. Robles R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S15–21 (30 ref.)

Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Own observations and review of the literature. Van Erum R, et al. **Horm Res** 1998 Sep;50(3):141–6 (35 ref.)

BLOOD

Neonatal hypoglycemia: a little goes a long way [letter; comment] Cowett RM. **J Pediatr** 1999 Apr;134(4):389–91 (17 ref.) Comment on: J Pediatr 1999 Apr;134(4):492–8.

GROWTH & DEVELOPMENT

Small for gestational age is not a diagnosis [editorial] Soothill PW, et al. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):225–8 (27 ref.)

PHYSIOLOGY

Multiple hormone resistance in short children born with intrauterine growth retardation? Chatelain PG, et al. **Horm Res** 1998;49 Suppl 2:20–2 (26 ref.)

INFANT, VERY LOW BIRTH WEIGHT

Early nasal continuous positive airway pressure and minimal handling in the treatment of very-low-birth-weight infants. Kamper J. **Biol Neonate** 1999 Jun;76 Suppl 1:22–8 (34 ref.)

Neonatal viability in the 1990s: held hostage by technology. Muraskas J, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):160–70; discussion 170–2 (43 ref.)

Outcomes of children of extremely low birthweight and gestational age in the 1990's. Hack M, et al. **Early Hum Dev** 1999 Jan;53(3):193–218 (143 ref.)

Mechanisms initiating lung injury in the preterm. Jobe AH, et al. **Early Hum Dev** 1998 Nov;53(1):81–94 (66 ref.)

Unusual site for oesophageal perforation in an extremely low birth weight infant. Cairns PA, et al. **Eur J Pediatr** 1999 Feb;158(2):152–3 (5 ref.)

Subcapsular hemorrhage of the liver in a very-low-birth-weight neonate: survival after decompression laparotomy. Kosumi T, et al. **Pediatr Surg Int** 1999;15(3–4):270–1 (15 ref.)

The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)

Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)

Anesthesia for the micropremie. Spaeth JP, et al. **Semin Perinatol** 1998 Oct;22(5):390–401 (50 ref.)

[Neonatal viability and resuscitation in preterm newborns with an extremely low birth weight] García-Alix Pérez A, et al. **An Esp Pediatr** 1999 Jun;50(6):594–602 (64 ref.) **(Spa)**

BLOOD

Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)

PSYCHOLOGY

[Clinical significance of attachment research for the premature infant group: an overview of most recent research] Buchheim A, et al. **Z Kinder Jugendpsychiatr Psychother** 1999 May; 27(2):125–38 (105 ref.) **(Ger)**

INFANT WELFARE

Assessing the effects of welfare reform policies on reproductive and infant health [see comments] Wise P, et al. **Am J Public Health** 1999 Oct;89(10):1514–21 (79 ref.) Comment in: Am J Public Health 1999 Oct;89(10):1476–8. Comment in: Am J Public Health 1999 Oct;89(10):1479–82.

Appropriate technology: antenatal care. Lumbiganon P. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S91–5 (29 ref.)

[Maternal elimination diet during pregnancy and lactation, and the development of allergies in infants] Oldak E. **Pol Merkuriusz Lek** 1998 Dec;5(30):387–9 (29 ref.) (Eng. Abstr.) **(Pol)**

INFANTILE PAPULAR ACRODERMATITIS see **ACRODERMATITIS**

INFANTILE PARALYSIS see **POLIOMYELITIS**

INFANTILE REFSUM DISEASE see **PEROXISOMAL DISORDERS**

INFANTILE SPINAL MUSCULAR ATROPHY see **WERDNIG-HOFFMANN DISEASE**

INFANTILISM, GENITAL see **HYPOGONADISM**

INFANTILISM, SEXUAL see **HYPOGONADISM**

INFARCTION

see related
CEREBRAL INFARCTION
MYOCARDIAL INFARCTION
PULMONARY EMBOLISM
SPLENIC INFARCTION

[Small retinal, cochlear, and cerebral infarctions in the young patient, "SICRET" syndrome of Susac syndrome] Mala L, et al. **J Fr Ophtalmol** 1998 May;21(5):375–80 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Malignant fibrous histiocytoma associated with a bone infarct in a patient with hereditary bone dysplasia. Kenan S, et al. **Skeletal Radiol** 1998 Aug;27(8):463–7 (15 ref.)

DIAGNOSIS

Angiosarcomas associated with bone infarcts. Abdelwahab IF, et al. **Skeletal Radiol** 1998 Oct;27(10):546–51 (17 ref.)

[The role of imaging diagnosis in the study of intestinal infarct] Catalano O, et al. **Minerva Chir** 1998 Jun; 53(6):515–22 (43 ref.) (Eng. Abstr.) **(Ita)**

[Primary idiopathic segmental infarction of the greater omentum (letter)] Louredo Méndez A, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):150–1 (6 ref.) **(Spa)**

ETIOLOGY

Primary antiphospholipid syndrome presented by total infarction of right kidney with nephrotic syndrome. Sá H, et al. **Clin Nephrol** 1999 Jul;52(1):56–60 (21 ref.)

Transarterial chemoembolization and percutaneous ethanol injection therapy in patients with hepatocellular carcinoma [comment] Kirchhoff T, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):907–9 (57 ref.) Comment on: Eur J Gastroenterol Hepatol 1998 Nov;10(11):915–8.

[Bilateral diabetic infarction of the thigh adductor muscles in a diabetic female patient-- A case report and review of the literature] Satoh A, et al. **Rinsho Shinkeigaku** 1999 Feb–Mar;39(2–3):321–6 (27 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Kovacs KA, et al. **Medicine (Baltimore)** 1998 Nov;77(6):398–402 (26 ref.)

SURGERY

[Mesenteric infarct--when is the vascular surgeon needed?] Kniemeyer HW. **Zentralbl Chir** 1998;123(12):1411–7 (40 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of mesenteric infarct] Lagana S, et al. **Zentralbl Chir** 1998;123(12):1405–10 (23 ref.) (Eng. Abstr.) **(Ger)**

INFECTION

see related
ANTI-INFECTIVE AGENTS

[Infectiology] Ruf BR, et al. **Internist (Berl)** 1999 Apr; 40(4):369–80 (42 ref.) **(Ger)**

[Emerging and re-emerging infectious diseases] Iwamoto A. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):517–21 (0 ref.) **(Jpn)**

[Current trends in infections] Kimura T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1842–7 (10 ref.) **(Jpn)**

COMPLICATIONS

Infections and atherosclerosis: new clues from an old hypothesis? Nieto FJ. **Am J Epidemiol** 1998 Nov 15; 148(10):937–48 (137 ref.)

Lack of association of infectious agents with risk of future myocardial infarction and stroke: definitive evidence disproving the infection/coronary artery disease hypothesis? [editorial] Epstein SE, et al. **Circulation** 1999 Sep 28;100(13):1366–8 (14 ref.)

A review of selective infections in the adult diabetic. Gleckman RA, et al. **Compr Ther** 1999 Feb;25(2):109–13 (12 ref.)

Infectious diarrhea. Goodman L, et al. **Dis Mon** 1999 Jul; 45(7):268–99 (75 ref.)

Fever of unknown origin--past present and the future. Adhikari PM. **Indian J Med Sci** 1998 Aug;52(8):333–40 (20 ref.)

The role of infection in atopic dermatitis. Kanani AS, et al. **J Cutan Med Surg** 1999 Feb;3 Suppl 2:S2–29–S2–32 (39 ref.)

Burden of infection on growth failure. Stephensen CB. **J Nutr** 1999 Feb;129(2S Suppl):534S–538S (31 ref.)

[Infection and vascular purpura] Lévesque H, et al. **J Mal Vasc** 1999 Jun;24(3):177–82 (30 ref.) (Eng. Abstr.) **(Fre)**

[Diarrhea associated with systemic infection] Iwata S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):183–4 (2 ref.) **(Jpn)**

[Role of infections in arteriosclerotic vascular disease. The beginning of a long path] Ramos Rincón JM, et al. **Rev Clin Esp** 1999 Mar;199(3):153–60 (133 ref.) **(Spa)**

DIAGNOSIS

Prevention and management of overwhelming postsplenectomy infection--an update. Brigden ML, et al. **Crit Care Med** 1999 Apr;27(4):836–42 (46 ref.)

Mimickers of hand infections. Louis DS, et al. **Hand Clin** 1998 Nov;14(4):519–29, vii (52 ref.)

Fever in immunocompromised patients. Pizzo PA. **N Engl J Med** 1999 Sep 16;341(12):893–900 (32 ref.)

Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507–24, ix-x (6 ref.)

[Immunology in medical practice. XXI. Laboratory tests for immunologic diseases] Out TA, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1027–33 (30 ref.) (Eng. Abstr.) **(Dut)**

[Methods of investigation in pulmonary infections] Milosevic D, et al. **Presse Med** 1998 May 23–30;27(19):924–6 (19 ref.) **(Fre)**

Bacterial toxins and detection methods. Asari S. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):89–95 (6 ref.) (Eng. Abstr.) **(Jpn)**

The principle of diagnostic method and diagnostic imaging for infectious diseases. Niki Y. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):67–71 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic tests and items to be noted at the diagnostic laboratory] Ueno I, et al. **Rinsho Byori** 1999 Feb;Suppl 109:190–200 (10 ref.) **(Jpn)**

[Hemogram in differential diagnosis of infectious diseases] Bogomolov BP. **Klin Med (Mosk)** 1998;76(12):25–9 (0 ref.) **(Rus)**

DRUG THERAPY

Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics [editorial; comment] Conly J. **Can Fam Physician** 1998 Sep;44:1769–73, 1780–4 (30 ref.) Comment on: Can Fam Physician 1998 Sep;44 :1881–8. **(Eng, Fre)**

Controlling antimicrobial resistance. Health Canada proposes an integrated action plan for Canadians. Thomas RE. **Can Fam Physician** 1998 Sep;44:1901–5, 1907 (3 ref.) **(Eng, Fre)**

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov-Dec;44(6):427–35 (23 ref.)

Interventional antimicrobial therapy in febrile neutropenic patients. Maschmeyer G. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):205–12 (38 ref.)

How do the newer oral antimicrobials stack up against traditional agents? Gleckman R, et al. **Postgrad Med** 1998 Oct;104(4):119–22, 125–6 (22 ref.)

[Optimizing antibiotic therapy in a hospital setting] Guérin JM. **Presse Med** 1999 Jan 9;28(1):20–8 (57 ref.) (Eng. Abstr.) **(Fre)**

[Problems of updating antibacterial therapy] Alekseev GK. **Klin Med (Mosk)** 1999;77(3):4–8 (51 ref.) **(Rus)**

EPIDEMIOLOGY

Emerging and re-emerging infectious diseases. Banker DD. **Indian J Med Sci** 1998 Oct;52(10):458–61 (20 ref.)

IgG subclass deficiency and the day-care generation. Lawton AR. **Pediatr Infect Dis J** 1999 May;18(5):462–6 (32 ref.)

ETIOLOGY

Nitric oxide and infectious diseases. Burgner D, et al. **Arch Dis Child** 1999 Aug;81(2):185–8 (29 ref.)

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov-Dec;44(6):427–35 (23 ref.)

Complications of hemodynamic monitoring. Coulter TD, et al. **Clin Chest Med** 1999 Jun;20(2):249–67, vii (138 ref.)

Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Zügel U, et al. **Clin Microbiol Rev** 1999 Jan;12(1):19–39 (311 ref.)

Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Dybing E, et al. **Hum Exp Toxicol** 1999 Apr;18(4):202–5 (30 ref.)

NHLBI/FDA conference on thrombosis and infections with cardiovascular devices. **J Biomed Mater Res** 1998 Dec 5; 42(3):341–6 (0 ref.)

Protein toxins produced by pathogenic vibrios. Shinoda S. **J Nat Toxins** 1999 Jun;8(2):259–69 (78 ref.)

Iron and infection. Patruta SI, et al. **Kidney Int Suppl** 1999 Mar;69:S125–30 (75 ref.)

Emerging infectious diseases and risk to the traveler. Freedman DO, et al. **Med Clin North Am** 1999 Jul; 83(4):865–83, v (79 ref.)

Emerging marine diseases--climate links and anthropogenic factors. Harvell CD, et al. **Science** 1999 Sep 3; 285(5433):1505–10 (113 ref.)

[Risk of infection and locoregional anesthesia] Auboyer C. **Ann Fr Anesth Reanim** 1998;17(10):1257–60 (19 ref.) (Eng. Abstr.) **(Fre)**

[Infectious complications of long term intravenous devices: incidence, risk factors, diagnostic tools] Douard MC, et al. **Pathol Biol (Paris)** 1999 Mar;47(3):288–91 (18 ref.) (Eng. Abstr.) **(Fre)**

[Waterborne microbiological risk assessment: a state of the art and perspectives] Gofti L, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):61–73 (43 ref.) (Eng. Abstr.) **(Fre)**

[Infections and lupus] Le Moing V, et al. **Rev Prat** 1998 Mar 15;48(6):637–42 (26 ref.) (Eng. Abstr.) **(Fre)**

[IgG subclass deficiency and recurrent infections] Sakiyama Y. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Aug; 21(4):145–9 (16 ref.) **(Jpn)**

[Complications of hematopoietic stem cell transplantation: physiopathology and management. 1. Infections] Gondo H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1495–501 (11 ref.) **(Jpn)**

[Acute tonsillitis, peritonsillitis, and deep neck infection] Nonomura N. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):304–6 (7 ref.) **(Jpn)**

GENETICS

Proteomics in human disease: cancer, heart and infectious diseases. Jungblut PR, et al. **Electrophoresis** 1999 Jul; 20(10):2100–10 (66 ref.)

Genetic control of susceptibility to infections with intracellular pathogens. Skamene E. **Pathol Biol (Paris)** 1998 Nov;46(9):689–92 (0 ref.) **(Eng, Fre)**

Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Knight JC, et al. **Proc Assoc Am Physicians** 1999 Jul–Aug;111(4):290–8 (50 ref.)

IMMUNOLOGY

Do infections protect against atopic diseases? [comment] Bråbäck L. **Acta Paediatr** 1999 Jul;88(7):705–8 (27 ref.) Comment on: Acta Paediatr 1999 Jul;88(7):710–4.

Investigation of the immune system in recurrent infection. Gaspar HB, et al. **Br J Hosp Med** 1998 Nov 19–Dec 9; 58(10):517–20 (7 ref.)

Immunodeficiency syndromes and recurrent infection. Gaspar HB, et al. **Br J Hosp Med** 1998 Dec 10;58(11):565–8 (13 ref.)

Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589–97 (71 ref.)

Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Zügel U, et al. **Clin Microbiol Rev** 1999 Jan;12(1):19–39 (311 ref.)

The role of B cells in acute and chronic infections. Bachmann MF, et al. **Curr Opin Immunol** 1999 Jun;11(3):332–9 (71 ref.)

Infectious tolerance. Cobbold S, et al. **Curr Opin Immunol** 1998 Oct;10(5):518–24 (74 ref.)

Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Mosser DM, et al. **Curr Opin Immunol** 1999 Aug;11(4):406–11 (34 ref.)

The role of dendritic cells in the induction and regulation of immunity to microbial infection. Reis e Sousa C, et al. **Curr Opin Immunol** 1999 Aug;11(4):392–9 (76 ref.)

Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. Tlaskalová-Hogenová H, et al. **Folia Microbiol (Praha)** 1998;43(5):545–50 (50 ref.)

TCR specificity in infection induced granulomas. Hogan LH, et al. **Immunol Lett** 1999 May 3;68(1):115–20 (36 ref.)

Negative signaling in health and disease. Coggeshall KM. **Immunol Res** 1999;19(1):47–64 (165 ref.)

Atopic disorders: a default pathway in the absence of infection? Erb KJ. **Immunol Today** 1999 Jul;20(7):317–22 (54 ref.)

Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Casadevall A, et al. **Infect Immun** 1999 Aug;67(8):3703–13 (35 ref.)

Superantigens in human disease. Bernal A, et al. **J Clin Immunol** 1999 May;19(3):149–57 (83 ref.)

On the role of feedback in promoting conflicting goals of the adaptive immune system. Segel LA, et al. **J Immunol** 1999 Aug 1;163(3):1342–9 (24 ref.)

Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Würzner R. **Mol Immunol** 1999 Mar-Apr;36(4–5):249–60 (101 ref.)

The hygiene hypothesis in the development of atopy and asthma--still a matter of controversy? Hertzen LC. **QJM** 1998 Nov;91(11):767–71 (45 ref.)

Phylogenetic perspectives in innate immunity. Hoffmann JA, et al. **Science** 1999 May 21;284(5418):1313–8 (42 ref.)

The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Fraser IP, et al. **Semin Immunol** 1998 Oct;10(5):363–72 (94 ref.)

Innate immune recognition and control of adaptive immune responses. Medzhitov R, et al. **Semin Immunol** 1998 Oct; 10(5):351–3 (23 ref.)

[The mechanisms of the anti-infective protection of the female reproductive tract] Telesheva LF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug; (4):85–90 (41 ref.) **(Rus)**

METABOLISM

Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854–65 (80 ref.)

Inter-organ protein and carbohydrate metabolic relationships during sepsis: necessary evils or uncanny coincidences? Vary TC. **Curr Opin Clin Nutr Metab Care** 1999 May; 2(3):235–42 (64 ref.)

[Biosynthesis of nitric oxide in infection: should it be induced or avoided? (published erratum appears in Med Trop (Mars) 1999;59(1):8)] Millet P, et al. **Med Trop (Mars)** 1998; 58(4):331–5 (34 ref.) **(Fre)**

[Supranormal oxygen delivery] Katsuya H. **Masui** 1998 Dec; 47 Suppl:S81–7 (16 ref.) **(Jpn)**

MICROBIOLOGY

Clinical analyzers. Microbiology. Mouritsen CL, et al. **Anal Chem** 1999 Jun 15;71(12):366R–372R (79 ref.)

Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics [editorial; comment] Conly J. **Can Fam Physician** 1998 Sep;44:1769–73, 1780–4 (30 ref.) Comment on: Can Fam Physician 1998 Sep;44 :1881–8. **(Eng, Fre)**

Controlling antimicrobial resistance. Health Canada proposes an integrated action plan for Canadians. Thomas RE. **Can Fam Physician** 1998 Sep;44:1901–5, 1907 (3 ref.) **(Eng, Fre)**

Infections in the elderly--new developments. Crossley K, et al. **Curr Clin Top Infect Dis** 1998;18:75–100 (123 ref.)

Infectious agents and the etiology of chronic idiopathic diseases. Fredricks DN, et al. **Curr Clin Top Infect Dis** 1998;18:180–200 (90 ref.)

Procurement, interpretation, and value of postmortem cultures. Roberts FJ. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):821–7 (35 ref.)

Emerging infectious diseases and pathogens. Chou T. **Nurs Clin North Am** 1999 Jun;34(2):427–42 (47 ref.)

Population biology, evolution, and infectious disease: convergence and synthesis. Levin BR, et al. **Science** 1999 Feb 5;283(5403):806–9 (43 ref.)

[Collection of samples, their management and examination to identify the causative organisms] Yamaguchi K. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2223–7 (4 ref.) **(Jpn)**

The present state and problems of rapid diagnosis of infectious diseases in clinicocytological and histopathological examination. Obana Y. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):83–7 (8 ref.) **(Jpn)**

PATHOLOGY

Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Ginsburg I. **Med Hypotheses** 1998 Oct; 51(4):337–46 (68 ref.)

The present state and problems of rapid diagnosis of infectious diseases in clinicocytological and histopathological examination. Obana Y. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):83–7 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Friman G, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S172–82 (85 ref.)
[Nuclear transcription factor kappa B (NF-kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945–7 (13 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Nuclear medicine's role in infection and inflammation. Corstens FH, et al. **Lancet** 1999 Aug 28;354(9180):765–70 (37 ref.)
Radionuclide imaging of nonosseous infection. Palestro CJ, et al. **Q J Nucl Med** 1999 Mar;43(1):46–60 (69 ref.)
Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals. Weiner RE, et al. **Q J Nucl Med** 1999 Mar;43(1):2–8 (49 ref.)

THERAPY

Passive immunity against human pathogens using bovine antibodies. Weiner C, et al. **Clin Exp Immunol** 1999 May; 116(2):193–205 (100 ref.)
Prevention and management of overwhelming postsplenectomy infection—an update. Brigden ML, et al. **Crit Care Med** 1999 Apr;27(4):836–42 (46 ref.)
Perspectives on bifidobacteria as biotherapeutic agents in gastrointestinal health. Duffy LC, et al. **Dig Dis Sci** 1999 Aug;44(8):1499–505 (60 ref.)
Infections of the fingertip. Paronychias and felons. Jebson PJ. **Hand Clin** 1998 Nov;14(4):547–55, viii (31 ref.)
Deep subfascial space infections. Jebson PJ. **Hand Clin** 1998 Nov;14(4):557–66, viii (15 ref.)
The potential for monocyte-mediated immunotherapy during infection and malignancy—Part II: in vivo activation by exogenous cytokines and clinical applications. Williams MA, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):207–30 (123 ref.)
The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms. Williams MA, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):1–23 (123 ref.)
Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507–24, ix–x (6 ref.)
[Infections and aging] Cools HJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 10;142(41):2242–5 (43 ref.) (Eng. Abstr.) **(Dut)**
[Present-day concepts concerning immunoprophylaxis and immunotherapy of surgical infections] Pinegin BV, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):61–7 (35 ref.) **(Rus)**
[Indications for admission to the intensive care service of adult patients with severe infections] Alvarez Lerma F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):423–30 (70 ref.) **(Spa)**

TRANSMISSION

Infections acquired during cardiopulmonary resuscitation: estimating the risk and defining strategies for prevention. Mejicano GC, et al. **Ann Intern Med** 1998 Nov 15; 129(10):813–28 (212 ref.)
Granulomatous inflammation and transmission of infectious disease [letter] Di Perri G, et al. **Immunol Today** 1999 Jul; 20(7):337 (14 ref.)
[Imported infectious disease] Nagatake T. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):380–3 (7 ref.) **(Jpn)**

ULTRASONOGRAPHY

Infection: ultrasound-guided procedures. Craig JG. **Radiol Clin North Am** 1999 Jul;37(4):669–78 (55 ref.)

VETERINARY

Emerging marine diseases—climate links and anthropogenic factors. Harvell CD, et al. **Science** 1999 Sep 3; 285(5433):1505–10 (113 ref.)

INFECTION CONTROL

Infections acquired during cardiopulmonary resuscitation: estimating the risk and defining strategies for prevention. Mejicano GC, et al. **Ann Intern Med** 1998 Nov 15; 129(10):813–28 (212 ref.)
Infection control in the bronchoscopy suite. A review. Mehta AC, et al. **Clin Chest Med** 1999 Mar;20(1):19–32, ix (114 ref.)
Controversies on diagnosis and prevention of ventilator-associated pneumonia. Bonten MJ. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):199–204 (38 ref.)
A transphyletic anti-infectious control strategy based on the killer phenomenon. Conti S, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):151–61 (61 ref.)
Infection control and outpatient parenteral antibiotic therapy. Wade BH, et al. **Infect Dis Clin North Am** 1998 Dec; 12(4):979–94 (43 ref.)
Prevention of infections caused by central venous catheters—established and novel measures. Bach A. **Infection** 1999;27 Suppl 1:S11–5 (50 ref.)
MRSA in cystic fibrosis. London, 16 June 1997. **J Hosp Infect** 1998 Nov;40(3):179–91 (17 ref.)
Is infection control an academic study? Burnie JP. **J Hosp Infect** 1999 Jan;41(1):7–10 (30 ref.)
Glove powder: implications for infection control. Dave J, et al. **J Hosp Infect** 1999 Aug;42(4):283–5 (22 ref.)
Subcutaneous fluid administration—better than the intravenous approach? Jain S, et al. **J Hosp Infect** 1999 Apr;41(4):269–72 (13 ref.)
Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. Nelson RR. **J Hosp Infect** 1999 Aug;42(4):275–82 (70 ref.)
An outbreak of extended-spectrum, beta-lactamase-producing Salmonella senftenberg in a burns ward. Revathi G, et al. **J Hosp Infect** 1998 Dec; 40(4):295–302 (36 ref.)
Laboratory role in the management of hospital acquired infections. Wilson MP, et al. **J Hosp Infect** 1999 May; 42(1):1–6 (25 ref.)
Sterilization vs. disinfection vs. clean. Alvarado CJ. **Nurs Clin North Am** 1999 Jun;34(2):483–91 (34 ref.)
Emerging infectious diseases and pathogens. Chou T. **Nurs Clin North Am** 1999 Jun;34(2):427–42 (47 ref.)
The risk of occupational exposure and infection with infectious disease. Sharbaugh RJ. **Nurs Clin North Am** 1999 Jun;34(2):493–508 (29 ref.)
Issues related to human immunodeficiency virus transmission in schools, child care, medical settings, the home, and community. American Academy of Pediatrics. Committee of Pediatric AIDS and Committee on Infectious Diseases. **Pediatrics** 1999 Aug;104(2 Pt 1):318–24 (53 ref.)

LEGISLATION & JURISPRUDENCE

Legal and ethical issues in revising human immunodeficiency virus postexposure protocols. Barnes M. **Am J Med** 1997 May 19;102(5B):111–2; discussion 113–4 (05 ref.)
Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98–101 (10 ref.)
Postexposure chemoprophylaxis against HIV: what are the implications for people with AIDS and the organizations that serve them? Hodel D. **Am J Med** 1997 May 19; 102(5B):106–10 (10 ref.)
Rule-makers who establish infection control standards. Yost AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):527–33 (18 ref.)

METHODS

Prevention of infection in the immunocompromised host. Risi GF, et al. **Am J Infect Control** 1998 Dec;26(6):594–604; quiz 605–6 (76 ref.)
Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)
Risks of virus transmission associated with animal sera or substitutes and methods of control. Eloit M. **Dev Biol Stand** 1999;99:9–16 (10 ref.)
Issues in the management of resistant bacteria in long-term-care facilities. Bradley SF. **Infect Control Hosp Epidemiol** 1999 May;20(5):362–6 (47 ref.)
Infection control in gene therapy [see comments] Evans ME, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):568–76 (71 ref.) Comment in: Infect Control Hosp Epidemiol 1999 Aug;20(8):530–2.
Disinfection of endoscopes: review of new chemical sterilants used for high-level disinfection. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):69–76 (66 ref.)
Tuberculosis: what you don't know can hurt you [editorial; comment] Woeltje KF. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):626–8 (12 ref.) Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):629–34. Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):635–9.
A new technology of microdispersed silver in polyurethane induces antimicrobial activity in central venous catheters. Guggenbichler JP, et al. **Infection** 1999;27 Suppl 1:S16–23 (49 ref.)
Putting infection control principles into practice in home care. Friedman MM, et al. **Nurs Clin North Am** 1999 Jun; 34(2):463–82 (22 ref.)
Common infections acquired in the hospital: the nurse's role in prevention. Steed CJ. **Nurs Clin North Am** 1999 Jun; 34(2):443–61 (22 ref.)
Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr–Jun;14(2):247–84 (222 ref.)
Infection control practices and the pregnant health care worker. Mirza A, et al. **Pediatr Infect Dis J** 1999 Jan; 18(1):18–22 (51 ref.)
Successful interventions for gram-negative resistance to extended-spectrum beta-lactam antiobiotics. Rice LB. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):120S–128S; discussion 133S–137S (44 ref.)
Decreased antimicrobial resistance after changes in antibiotic use. Smith DW. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):129S–132S; discussion 133S–137S (26 ref.)
Legionella infection and control in occupational and environmental health [published erratum appears in Rev Environ Health 1999 Jan–Mar;14(1):following table of contents] Fujii J, et al. **Rev Environ Health** 1998 Oct–Dec; 13(4):179–203 (46 ref.)
[Ventilator-associated pneumonia; controversies with respect to diagnosis, pathogenesis, therapy and prevention] Bonten MJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):726–30 (24 ref.) (Eng. Abstr.) **(Dut)**

ORGANIZATION & ADMINISTRATION

Regionalization of infection prevention and control services in a publicly funded health care system. Wiens RM, et al. **Am J Infect Control** 1998 Aug;26(4):446–8 (5 ref.)
Emergency medical services. Arndt SD. **Am J Med** 1997 May 19;102(5B):104–5 (09 ref.)
Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)
The healthcare marketplace in the next millennium and nurses' roles in infection prevention and control. Jackson MM. **Nurs Clin North Am** 1999 Jun;34(2):411–26 (46 ref.)

STANDARDS

Issues complicating the implementation of postexposure prophylaxis. L'Ecuyer PB, et al. **Am J Med** 1997 May 19; 102(5B):90–4 (50 ref.)
Improving glove barrier effectiveness. Rabussay DP, et al. **AORN J** 1997 Dec;66(6):1043–6, 1049–54, 1057–60 passim (55 ref.)
Prion diseases—an evidence-based protocol for infection control. Steelman VM. **AORN J** 1999 May;69(5):946–54, 956–67 passim; quiz 968–76 (94 ref.)
Infection control during gastrointestinal endoscopy: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1999 Jun;49(6):836–41 (40 ref.)
Infection control—evidence into practice. Jenner EA, et al. **J Hosp Infect** 1999 Jun;42(2):91–104 (46 ref.)
Rule-makers who establish infection control standards. Yost AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):527–33 (18 ref.)
A review of infection control practices, risk reduction, and legislative regulations for blood-borne disease: applications for emergency medical services. Rinnert KJ. **Prehosp Emerg Care** 1998 Jan–Mar;2(1):70–5 (40 ref.)

INFECTION CONTROL, DENTAL

Water, water everywhere but not a drop to drink? Smith AJ, et al. **Br Dent J** 1999 Jan 9;186(1):12–4 (27 ref.)
Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Hall G, et al. **Clin Infect Dis** 1999 Jul; 29(1):1–8; quiz 9–10 (86 ref.)
Hepatitis viruses A, B, C, D, E and G: implications for dental personnel. Gillcrist JA. **J Am Dent Assoc** 1999 Apr; 130(4):509–20 (97 ref.)
Dental infection control at the year 2000: accomplishment recognized. Molinari JA. **J Am Dent Assoc** 1999 Sep; 130(9):1291–8 (35 ref.)

INFECTION CONTROL PRACTITIONERS

[Ebola virus: what the practitioner needs to know] Georges AJ, et al. **Med Trop (Mars)** 1998;58(2):177–86 (104 ref.) (Eng. Abstr.) **(Fre)**

INFECTIOUS ARTERITIS VIRUS, EQUINE see **ARTERITIS VIRUS, EQUINE**

INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFECTIOUS BRONCHITIS VIRUS, AVIAN

The early history of infectious bronchitis. Fabricant J. **Avian Dis** 1998 Oct–Dec;42(4):648–50 (24 ref.)

INFECTIOUS BURSAL AGENT see **INFECTIOUS BURSAL DISEASE VIRUS**

INFECTIOUS BURSAL DISEASE VIRUS

Poultry industry strategies for control of immunosuppressive diseases. Fussell LW. **Poult Sci** 1998 Aug;77(8):1193–6 (25 ref.)
Infectious bursal disease and hemorrhagic enteritis. Saif YM. **Poult Sci** 1998 Aug;77(8):1186–9 (29 ref.)

INFECTIOUS DISEASES see **COMMUNICABLE DISEASES**

INFECTIOUS HUMAN WART VIRUS see **PAPILLOMAVIRUS, HUMAN**

INFECTIOUS KERATOCONJUNCTIVITIS see **KERATOCONJUNCTIVITIS, INFECTIOUS**

INFECTIOUS MONONUCLEOSIS

[Infectious mononucleosis] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):145–7 (11 ref.) **(Jpn)**

INFECTIOUS MONONUCLEOSIS

[Epstein-Barr virus and rheumatic disease] Murakami K. **Ryumachi** 1998 Dec;38(6):849-59 (70 ref.) **(Jpn)**

COMPLICATIONS

Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Hudson LB, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):642-4 (4 ref.)

DIAGNOSIS

[Manganese superoxide dismutase-inhibiting autoantibodies in cholestatic Epstein-Barr viral hepatitis] Schaade L, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1478-82 (22 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

[Infectious mononucleosis caused by Epstein-Barr virus] Ueda T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):188-91 (8 ref.) **(Jpn)**

INFECTIOUS MONONUCLEOSIS-LIKE SYNDROME, CHRONIC see **FATIGUE SYNDROME, CHRONIC**

INFECTIOUS MONONUCLEOSIS VIRUS see **HERPESVIRUS 4, HUMAN**

INFECTIOUS PUSTULAR VULVOVAGINITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFERIOR VENA CAVA FILTERS see **VENA CAVA FILTERS**

INFERTILITY

CHEMICALLY INDUCED

Effects of occupational solvent exposure on fertility. Lindbohm ML. **Scand J Work Environ Health** 1999;25 Suppl 1:44-6 (10 ref.)

COMPLICATIONS

ABC of sexual health: sexual problems associated with infertility, pregnancy, and ageing. Read J. **BMJ** 1999 Feb 27;318(7183):587-9 (0 ref.)

DIAGNOSIS

Breaking bad news concerning fertility. Lalos A. **Hum Reprod** 1999 Mar;14(3):581-5 (25 ref.)

EPIDEMIOLOGY

The use of fecundability in epidemiological surveys. Spira A. **Hum Reprod** 1998 Jul;13(7):1753-6 (15 ref.)

Epidemiological approaches to infertility. Lumley J. **Reprod Fertil Dev** 1998;10(1):17-21 (29 ref.)

ETIOLOGY

Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272-4 (50 ref.)

Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218-28 (36 ref.)

Infertility and premature menopause in childhood cancer survivors. Byrne J. **Med Pediatr Oncol** 1999 Jul;33(1):24-8 (11 ref.)

General psychosocial and work-related stress and reduced fertility. Henriksen TB. **Scand J Work Environ Health** 1999; 25 Suppl 1:38-9 (11 ref.)

GENETICS

Menstrual disorders and infertility caused by inactivating mutations of the luteinizing hormone receptor gene. Arnhold IJ, et al. **Fertil Steril** 1999 Apr;71(4):597-601 (32 ref.)

Genetic issues in assisted reproductive technology. Ahrens M, et al. **Minn Med** 1998 Oct;81(10):43-7 (15 ref.)

IMMUNOLOGY

Antisperm antibodies: etiology, pathogenesis, diagnosis, and treatment. Mazumdar S, et al. **Fertil Steril** 1998 Nov; 70(5):799-810 (100 ref.)

PHYSIOPATHOLOGY

Human and clinical perspectives on leptin. Blum WF, et al. **Proc Nutr Soc** 1998 Aug;57(3):477-85 (78 ref.)

PREVENTION & CONTROL

Pharmacological protection of the gonads. Howell SJ, et al. **Med Pediatr Oncol** 1999 Jul;33(1):41-5 (48 ref.)

PSYCHOLOGY

Breaking bad news concerning fertility. Lalos A. **Hum Reprod** 1999 Mar;14(3):581-5 (25 ref.)

Does assisted reproduction make an impact on the identity and self-image of infertile couples? Daniels KR. **J Assist Reprod Genet** 1999 Feb;16(2):57-9 (12 ref.)

Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218-28 (36 ref.)

Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Schover LR. **Med Pediatr Oncol** 1999 Jul;33(1):53-9 (44 ref.)

[Adoption and/or reproductive medicine] Steck B. **Ther Umsch** 1999 May;56(5):251-9 (45 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Recombinant gonadotrophins. Hayden CJ, et al. **Br J Obstet Gynaecol** 1999 Mar;106(3):188-96 (51 ref.)

Cost-effective treatment of the infertile couple. Van Voorhis BJ, et al. **Fertil Steril** 1998 Dec;70(6):995-1005 (63 ref.)

Severe OHSS: patients should be allowed to weigh the morbidity of OHSS against the benefits of parenthood. Mathur RS, et al. **Hum Reprod** 1999 Sep;14(9):2183-5 (15 ref.)

Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Recombinant Human FSH Product Development Group. **Hum Reprod Update** 1998 Nov-Dec; 4(6):862-81 (53 ref.)

Infertility update: use of assisted reproductive technology. Yoshida TM. **J Am Pharm Assoc (Wash)** 1999 Jan-Feb; 39(1):65-72; quiz 103-4 (60 ref.)

Recent advances in infertility treatment. Session DR, et al. **Minn Med** 1998 Oct;81(10):27-32 (17 ref.)

Assisted reproductive techniques--promises and problems. Chew SC, et al. **Singapore Med J** 1999 Apr;40(4):303-9 (87 ref.)

INFERTILITY AGENTS see **FERTILITY AGENTS**

INFERTILITY AGENTS, FEMALE see **FERTILITY AGENTS, FEMALE**

INFERTILITY, FEMALE

Ovarian cancer in infertility patients. Burmeister L, et al. **Ann Med** 1998 Dec;30(6):525-8 (18 ref.)

Female infertility. Hull MG, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):851-76 (40 ref.)

The role of leukemia inhibitory factor and interleukin-6 in human reproduction. Smith SK, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:237-43; discussion 244-6 (46 ref.)

DIAGNOSIS

Transvaginal access heralds the end of standard diagnostic laparoscopy in infertility. Brosens I, et al. **Hum Reprod** 1998 Jul;13(7):1762-3 (19 ref.)

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177-88 (43 ref.)

[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700-4 (17 ref.) **(Fre)**

DRUG THERAPY

Recombinant follicle-stimulating hormone: new biotechnology for infertility. Prevost RR. **Pharmacotherapy** 1998 Sep-Oct;18(5):1001-10 (33 ref.)

EPIDEMIOLOGY

Trends and international comparisons in infertility in circumpolar areas. Raitio A, et al. **Int J Circumpolar Health** 1998 Jul;57(2-3):123-32 (38 ref.)

ETIOLOGY

Clinical presentation of uterine fibroids. Lumsden MA, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):177-95 (88 ref.)

The reproductive system after childhood cancer. Levitt GA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):946-53 (65 ref.)

Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Hensley ML, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):121-8 (55 ref.)

What effect does hydrosalpinx have on assisted reproduction? What is the preferred treatment for hydrosalpines? The ovary's perspective. Lass A. **Hum Reprod** 1999 Jul; 14(7):1674-7 (50 ref.)

The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Newton H. **Hum Reprod Update** 1998 May-Jun;4(3):237-47 (110 ref.)

Endometriosis and infertility: an integrated approach. Ledger WL. **Int J Gynaecol Obstet** 1999 Feb;64 Suppl 1:S33-40 (16 ref.)

What causes low rates of child-bearing in congenital adrenal hyperplasia? Meyer-Bahlburg HF. **J Clin Endocrinol Metab** 1999 Jun;84(6):1844-7 (58 ref.)

Subfertility associated with minimal to mild endometriosis. Main mechanisms. Panidis DK, et al. **J Reprod Med** 1998 Dec;43(12):1034-42 (45 ref.)

Antiphospholipid antibodies and infertility: fact or fallacy. Ware Branch D, et al. **Lupus** 1998;7 Suppl 2:S90-4 (19 ref.)

Obesity and reproductive disorders: a review. Norman RJ, et al. **Reprod Fertil Dev** 1998;10(1):55-63 (62 ref.)

Shift work and reproductive health. Nurminen T. **Scand J Work Environ Health** 1998;24 Suppl 3:28-34 (27 ref.)

[Hyperandrogenism and fertility] Deneux C, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):311-8 (26 ref.) **(Fre)**

[Evaluation of follicular reserve] Belaisch-Allart J. **Contracept Fertil Sex** 1999 Apr;27(4):259-62 (25 ref.) **(Fre)**

[Adenomyosis and fertility] Cosson M, et al. **Contracept Fertil Sex** 1998 Jul-Aug;26(7-8):605-7 (13 ref.) (Eng. Abstr.) **(Fre)**

[Fertility in women after cancer therapy] Marmor D. **Contracept Fertil Sex** 1999 Jun;27(6):417-22 (54 ref.) (Eng. Abstr.) **(Fre)**

[Polycystic ovaries: when to suspect the diagnosis?] Chardonnens D, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):459-61 (19 ref.) **(Fre)**

[Desire for children in tumor patients] Dällenbach RZ, et al. **Ther Umsch** 1999 May;56(5):276-81 (26 ref.) (Eng. Abstr.) **(Ger)**

[Polycystic ovary syndrome--only relevant in reproductive medicine?] Heim SC, et al. **Ther Umsch** 1999 May; 56(5):271-5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Endometriosis. Potential mechanism of sterility. Management of patients with endometriosis. Review and reflections] Gómez Arzapalo E, et al. **Ginecol Obstet Mex** 1999 Feb;67:58-63 (24 ref.) (Eng. Abstr.) **(Spa)**

[Determination of the tumor necrosis factor in the peritoneal fluid of gynecologic patients with intraperitoneal infections and endometriosis] Guerra-Infante FM, et al. **Ginecol Obstet Mex** 1999 May;67:221-6 (26 ref.) (Eng. Abstr.) **(Spa)**

[Catheterization of the tubal ostium using hysteroscopy under laparoscopic guidance] Salazar López-Ortiz C, et al. **Ginecol Obstet Mex** 1999 Feb;67:64-71 (44 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genetics, age, and infertility. Nasseri A, et al. **Maturitas** 1998 Oct 12;30(2):189-92 (21 ref.)

Fertility and infertility: genetic contributions from the hypothalamic-pituitary-gonadal axis. Achermann JC, et al. **Mol Endocrinol** 1999 Jun;13(6):812-8 (19 ref.)

Single-gene mutations resulting in reproductive dysfunction in women. Adashi EY, et al. **N Engl J Med** 1999 Mar 4; 340(9):709-18 (75 ref.)

[Physiopathology of gonadotropic control of gametogenesis] Deneux C, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):318-21 (16 ref.) **(Fre)**

[Is sterility a genetic burden?] Miny P, et al. **Ther Umsch** 1999 May;56(5):265-70 (9 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immunity to heat shock proteins and pregnancy outcome. Witkin SS. **Infect Dis Obstet Gynecol** 1999;7(1-2):35-8 (20 ref.)

Antisperm antibody: a monkey wrench in conception/magic bullet of contraception? Kamada M, et al. **J Med Invest** 1999 Feb;46(1-2):19-28 (51 ref.)

[Maternal anti-paternal reactivity--depends on etiology] Schütt C. **Zentralbl Gynakol** 1999;121(4):202-5 (10 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Fertility and infertility in aging women. Szamatowicz M, et al. **Gynecol Endocrinol** 1998 Dec;12(6):407-13 (31 ref.)

NURSING

Culture, conceptive technology, and nursing. Sandelowski M. **Int J Nurs Stud** 1999 Feb;36(1):13-20 (56 ref.)

PATHOLOGY

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):520-5 (37 ref.)

PHYSIOPATHOLOGY

Pathophysiology of endometriosis-associated infertility. Burns WN, et al. **Clin Obstet Gynecol** 1999 Sep; 42(3):586-610 (226 ref.)

Fertility in perimenopausal women. Cohen MA, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):958-65 (32 ref.)

Effects of epilepsy on women's reproductive health. Morrell MJ. **Epilepsia** 1998;39 Suppl 8:S32-7 (61 ref.)

Exercise and reproductive dysfunction. Chen EC, et al. **Fertil Steril** 1999 Jan;71(1):1-6 (68 ref.)

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36-46; discussion 47-51 (47 ref.)

Ovarian reserve tests in infertility practice and normal fertile women. Broekmans FJ, et al. **Maturitas** 1998 Oct 12; 30(2):205-14 (32 ref.)

Inactivating FSH receptor mutations and gonadal dysfunction. Tapanainen JS, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):129-35 (54 ref.)

[How to assess ovarian reserve in 1999?] Hédon B, et al. **Contracept Fertil Sex** 1999 Jun;27(6):412-6 (18 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Impact of lifestyle choices on female infertility. Silva PD, et al. **J Reprod Med** 1999 Mar;44(3):288–96 (121 ref.)

PSYCHOLOGY

Women and infertility. Rosenthal M.
Psychopharmacol Bull 1998;34(3):307–8 (10 ref.)

SURGERY

[Hysteroscopic surgery and fertility] Cravello L, et al. **Contracept Fertil Sex** 1998 Jul–Aug;26(7–8):589–92 (25 ref.) (Eng. Abstr.) **(Fre)**

[Myomectomy by laparoscopy and infertility: status of the controversy] Dubuisson JB, et al. **Contracept Fertil Sex** 1998 Oct;26(10):728–31 (42 ref.) (Eng. Abstr.) **(Fre)**

[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700–4 (17 ref.) **(Fre)**

THERAPY

Pregnancies in women with Turner's syndrome. Hovatta O. **Ann Med** 1999 Apr;31(2):106–10 (46 ref.)

Fertility in perimenopausal women. Cohen MA, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):958–65 (32 ref.)

Endometriosis and assisted reproductive technologies. Dokras A, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):687–98 (52 ref.)

Infertility in the older woman. Schmidt–Sarosi C.
Clin Obstet Gynecol 1998 Dec;41(4):940–50 (58 ref.)

Freezing of oocytes. Porcu E. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):297–300 (44 ref.)

Follicle stimulating hormone and its receptor: future perspectives. Chappel S, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:18–35; discussion 47–51 (77 ref.)

New approaches to ovarian stimulation. Diedrich K, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:1–13; discussion 14–7 (43 ref.)

New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127–36; discussion 145–7 (12 ref.)

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36–46; discussion 47–51 (47 ref.)

What effect does hydrosalpinx have on assisted reproduction? What is the preferred treatment for hydrosalpines? The ovary's perspective. Lass A. **Hum Reprod** 1999 Jul; 14(7):1674–7 (50 ref.)

The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Newton H. **Hum Reprod Update** 1998 May–Jun;4(3):237–47 (110 ref.)

Does assisted reproduction make an impact on the identity and self-esteem of infertile women during the transition to parenthood? McMahon CA. **J Assist Reprod Genet** 1999 Feb;16(2):59–62 (19 ref.)

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)

The impact of HIV on a fertility problems clinic. Hargreave TB, et al. **J Reprod Immunol** 1998 Dec;41(1–2):261–70 (21 ref.)

[Medical treatment of infertility: therapeutic guide. I. In women] Cohen J. **Contracept Fertil Sex** 1999 Jan; 27(1):23–34 (18 ref.) **(Fre)**

VETERINARY

[Postpartum anestrus in dairy cattle—a review] Opsomer G, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):30–5 (34 ref.) (Eng. Abstr.) **(Ger)**

INFERTILITY, MALE

Teratozoospermia and its effect on male fertility potential. Szczygiel M, et al. **Andrologia** 1999 Mar;31(2):63–75 (107 ref.)

Male fertility disorders. Hargreave T, et al.
Endocrinol Metab Clin North Am 1998 Dec;27(4):765–82, vii–viii (66 ref.)

Male infertility update. The ESHRE Capri Workshop Group. **Hum Reprod** 1998 Jul;13(7):2025–32 (93 ref.)

[Severe male infertility. Genetic investigation and counseling prior to intracytoplasmic sperm injection] Mikkelsen L. **Ugeskr Laeger** 1999 Apr 19;161(16):2348–51 (19 ref.) (Eng. Abstr.) **(Dan)**

[Assisted fertilization in male sterility is not without risks. Genetic aberrations can be transmitted to children and grandchildren] Bui TH, et al. **Lakartidningen** 1998 Nov 25;95(48):5430–2 (33 ref.) **(Swe)**

CHEMICALLY INDUCED

Occupational risk to male reproduction [editorial; comment] Bonde JP. **Int Arch Occup Environ Health** 1999 May; 72(3):133–4 (17 ref.) Comment on: Int Arch Occup Environ Health 1999 May;72(3):135–41.

Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al.
Scand J Work Environ Health 1999;25 Suppl 1:40–3 (8 ref.)

DIAGNOSIS

Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Seppälä M, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:262–91; discussion 270 (39 ref.)

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)

Male infertility. Evaluation and nonsurgical therapy. Chuang AT, et al. **Urol Clin North Am** 1998 Nov;25(4):703–13, x (40 ref.)

DRUG THERAPY

Therapy with growth hormone: major prospects for the treatment of male subfertility? Breier BH, et al.
Endocr J 1998 Apr;45 Suppl:S53–60 (31 ref.)

Is antioxidant therapy a promising strategy to improve human reproduction? Are anti-oxidants useful in the treatment of male infertility? Martin-Du Pan RC, et al. **Hum Reprod** 1998 Nov;13(11):2984–5 (25 ref.)

[Medical treatment of infertility: therapeutic guide. II. In males] Cohen J. **Contracept Fertil Sex** 1999 Feb; 27(2):107–13 (0 ref.) **(Fre)**

EPIDEMIOLOGY

Trends and international comparisons in infertility in circumpolar areas. Raitio A, et al.
Int J Circumpolar Health 1998 Jul;57(2–3):123–32 (38 ref.)

Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al.
Scand J Work Environ Health 1999;25 Suppl 1:40–3 (8 ref.)

[Analysis of decline in seminal fluid in the Italian population during the past 15 years] Bilotta P, et al.
Minerva Ginecol 1999 Jun;51(6):223–31 (53 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

The undescended testis: considerations and impact on fertility. Leissner J, et al. **BJU Int** 1999 May;83(8):885–91; quiz 891–2 (41 ref.)

The reproductive system after childhood cancer. Levitt GA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):946–53 (65 ref.)

Reproductive effects of nonteticular illness. Baker HW.
Endocrinol Metab Clin North Am 1998 Dec;27(4):831–50 (96 ref.)

Declining male fertility and environmental factors. Giwercman A, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):807–30, viii (122 ref.)

Occupational heat exposure and male fertility: a review. Thonneau P, et al. **Hum Reprod** 1998 Aug;13(8):2122–5 (34 ref.)

Cellular and molecular causes of male infertility in spinal cord injury. Rajasekaran M, et al. **J Androl** 1999 May–Jun; 20(3):326–30 (52 ref.)

The Amoroso Lecture. The human spermatozoon—a cell in crisis? Aitken RJ. **J Reprod Fertil** 1999 Jan;115(1):1–7 (49 ref.)

Cystic fibrosis and reproduction. Phillipson G.
Reprod Fertil Dev 1998;10(1):113–9 (44 ref.)

[Etiology and treatment of sterility due to azoospermia] Martin-du Pan RC, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):453–7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Desire for children in tumor patients] Dällenbach RZ, et al. **Ther Umsch** 1999 May;56(5):276–81 (26 ref.) (Eng. Abstr.) **(Ger)**

[Medical examination and therapy in infertility] Derouet H. **Urologe A** 1999 Jul;38(4):380–7 (17 ref.) **(Ger)**

GENETICS

Advances in Y chromosome mapping. Yen PH.
Curr Opin Obstet Gynecol 1999 Jun;11(3):275–81 (71 ref.)

The genetic basis of male infertility. Bhasin S, et al.
Endocrinol Metab Clin North Am 1998 Dec;27(4):783–805, viii (165 ref.)

Genetic abnormalities and male infertility. A comprehensive review. Thielemans BF, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Dec;81(2):217–25 (85 ref.)

Y chromosome and male infertility. Krausz C, et al.
Front Biosci 1999 Jan 15;4:E1–8 (62 ref.)

Genetic contribution to male infertility. Chandley AC.
Hum Reprod 1998 Jun;13 Suppl 3:76–83; discussion 84–8 (43 ref.)

Male infertility: analysis of the markers and genes on the human Y chromosome. Kostiner DR, et al.
Hum Reprod 1998 Nov;13(11):3032–8 (53 ref.)

Principles of sequence-tagged site selection in screening for Y deletions [comment] [see comments] Pryor JL, et al. **Hum Reprod** 1998 Jul;13(7):1768 (2 ref.) Comment on: Hum Reprod 1998 Jul;13(7):1764–8. Comment in: Hum Reprod 1999 Feb;14(2):572.

Current status of the molecular diagnosis of Y-chromosomal microdeletions in the work-up of male infertility. Initiative for international quality control [see comments] Simoni M, et al. **Hum Reprod** 1998 Jul;13(7):1764–8 (32 ref.) Comment in: Hum Reprod 1998 Jul;13(7):1768. Comment in: Hum Reprod 1999 Feb;14(2):572.

Developmental and genetic disorders in spermatogenesis. Diemer T, et al. **Hum Reprod Update** 1999 Mar–Apr; 5(2):120–40 (154 ref.)

Knockout mouse model and gametogenic failure. Grootegoed JA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):161–6 (45 ref.)

Genetics of male infertility. Hargreave TB, et al.
Mol Cell Endocrinol 1998 Oct 25;145(1–2):143–51 (67 ref.)

Fertility and infertility: genetic contributions from the hypothalamic–pituitary–gonadal axis. Achermann JC, et al. **Mol Endocrinol** 1999 Jun;13(6):812–8 (19 ref.)

Human chromosome deletions in Yq11, AZF candidate genes and male infertility: history and update. Vogt PH.
Mol Hum Reprod 1998 Aug;4(8):739–44 (51 ref.)

Genetic concerns for the subfertile male in the era of ICSI. Kim ED, et al. **Prenat Diagn** 1998 Dec;18(13):1349–65 (130 ref.)

The Y-chromosome and reproductive disorders.
McDonough PG. **Reprod Fertil Dev** 1998;10(1):1–16 (76 ref.)

Genetic disorders and spermatogenesis. McLachlan RI, et al. **Reprod Fertil Dev** 1998;10(1):97–104 (52 ref.)

Y chromosome and male infertility. Cooke HJ.
Rev Reprod 1999 Jan;4(1):5–10 (40 ref.)

Origin of DNA damage in ejaculated human spermatozoa. Sakkas D, et al. **Rev Reprod** 1999 Jan;4(1):31–7 (59 ref.)

[Physiopathology of gonadotropic control of gametogenesis] Deneux C, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):318–21 (16 ref.) **(Fre)**

[Genetic control of spermatogenesis: Y chromosome and male infertility] Krausz C, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):309–17 (50 ref.) **(Fre)**

[Genetic causes of male infertility] Seifer I, et al.
Ann Biol Clin (Paris) 1999 May;57(3):301–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Y chromosome microdeletions in male infertility] Siffroi JP, et al. **Contracept Fertil Sex** 1998 Dec;26(12):825–9 (34 ref.) **(Fre)**

[Is sterility a genetic burden?] Miny P, et al. **Ther Umsch** 1999 May;56(5):265–70 (9 ref.) (Eng. Abstr.) **(Ger)**

[Male infertility is often of genetic origin. Y chromosome deletions are discovered by the PCR technique] Arver S, et al. **Lakartidningen** 1998 Nov 25;95(48):5485–6 (9 ref.) **(Swe)**

METABOLISM

Reactive oxygen species in male infertility. Review of literature and personal observations. Conte G, et al.
Panminerva Med 1999 Mar;41(1):45–53 (58 ref.)

MICROBIOLOGY

Seminal tract infections: impact on male fertility and treatment options. Keck C, et al. **Hum Reprod Update** 1998 Nov–Dec;4(6):891–903 (132 ref.)

PATHOLOGY

What are the germ cell phenotypes from infertile men telling us about spermatogenesis? Escalier D.
Histol Histopathol 1999 Jul;14(3):959–71 (113 ref.)

PHYSIOPATHOLOGY

Cellular and molecular causes of male infertility in spinal cord injury. Rajasekaran M, et al. **J Androl** 1999 May–Jun; 20(3):326–30 (52 ref.)

PREVENTION & CONTROL

[A strategy for the prevention of male infertility] Comhaire FH, et al. **Verh K Acad Geneeskd Belg** 1999;61(3):441–52; discussion 453–5 (35 ref.) (Eng. Abstr.) **(Dut)**

PSYCHOLOGY

[Sexual dissatisfaction and somatic complaints in male infertility] Schilling G, et al.
Psychother Psychosom Med Psychol 1999 Aug;49(8):256–63 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Assisted reproduction for testicular failure: management of germ cell maturation arrest. Tesarik J, et al.
Curr Opin Obstet Gynecol 1999 Jun;11(3):283–8 (48 ref.)

Clinical application of new micromanipulative technologies to treat the male. Devroey P. **Hum Reprod** 1998 Jun;13 Suppl 3:112–22; discussion 123–6 (44 ref.)

New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127–36; discussion 145–7 (12 ref.)

Spermatid injection: reconsidering spermatid injection. Prapas Y, et al. **Hum Reprod** 1999 Sep;14(9):2186–8 (36 ref.)

Can we justify spermatid microinjection for severe male factor infertility? Aslam I, et al. **Hum Reprod Update** 1998 May–Jun;4(3):213–22 (93 ref.)

Semen retrieval by penile vibratory stimulation in men with spinal cord injury. Brackett NL. **Hum Reprod Update** 1999 May–Jun;5(3):216–22 (46 ref.)

Methods of semen collection not based on masturbation or surgical sperm retrieval. Gerris J. **Hum Reprod Update** 1999 May–Jun;5(3):211–5 (20 ref.)

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)

The impact of HIV on a fertility problems clinic. Hargreave

TB, et al. **J Reprod Immunol** 1998 Dec;41(1-2):261-70 (21 ref.)
The clinical management of male infertility. Razvi K, et al. **Singapore Med J** 1999 Apr;40(4):291-7 (61 ref.)
Treatment of infertility [clinical conference] Sønksen J, et al. **Spinal Cord** 1999 Feb;37(2):89-95 (46 ref.)
Male infertility. Evaluation and nonsurgical therapy. Chuang AT, et al. **Urol Clin North Am** 1998 Nov;25(4):703-13, x (40 ref.)

INFIBULATION see **CIRCUMCISION, FEMALE**

INFLAMMATION

see related
ACUTE-PHASE REACTION
ANTI-INFLAMMATORY AGENTS

Genes that regulate eosinophilic inflammation. Broide DH, et al. **Am J Hum Genet** 1999 Aug;65(2):302-7 (33 ref.)
Preeclampsia: an excessive maternal inflammatory response to pregnancy. Redman CW, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):499-506 (75 ref.)
Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Asimakopoulos G, et al. **Ann Thorac Surg** 1998 Dec;66(6):2135-44 (89 ref.)
Inflammation, antichymotrypsin, and lipid metabolism: autogenic etiology of Alzheimer's disease. Janciauskiene S, et al. **Bioessays** 1998 Dec;20(12):1039-46 (50 ref.)
IkappaB-NF-kappaB structures: at the interface of inflammation control [comment] Baeuerle PA. **Cell** 1998 Dec 11;95(6):729-31 (17 ref.) Comment on: Cell 1998 Dec 11;95(6):749-58. Comment on: Cell 1998 Dec 11;95(6):759-70.
Immune and inflammatory responses in sudden infant death syndrome. Forsyth KD. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):79-83 (27 ref.)
Inflammatory responses in sudden infant death syndrome — past and present views. Vege A, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):67-78 (135 ref.)
Possible role of ovarian epithelial inflammation in ovarian cancer. Ness RB, et al. **J Natl Cancer Inst** 1999 Sep 1; 91(17):1459-67 (144 ref.)
Neutrophil activation and mediators of inflammation in chronic venous insufficiency. Smith PD. **J Vasc Res** 1999; 36 Suppl 1:24-36 (48 ref.)
[Pathophysiology of inflammation and mechanisms of action of anti-inflammatory agents] Kawai S. **Nippon Rinsho** 1999 Feb;57(2):298-303 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Chemokines and inflammation] Inadera H, et al. **Nippon Ronen Igakkai Zasshi** 1999 Feb;36(2):82-9 (48 ref.) **(Jpn)**

BLOOD

Fibrinogen as a marker of inflammation: a clinical view. Andreotti F, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S3-4 (23 ref.)
Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. Ng T. **Br J Hosp Med** 1998 Nov 19-Dec 9;58(10):521-3 (17 ref.)
Low levels of plasma proteins: malnutrition or inflammation? Johnson AM. **Clin Chem Lab Med** 1999 Feb;37(2):91-6 (55 ref.)
Haemorheology and the inflammatory process. Rampling MW. **Clin Hemorheol Microcirc** 1998 Oct;19(2):129-32 (24 ref.)
Inflammation and outcome in unstable angina [editorial; comment] Curzen N, et al. **Eur Heart J** 1999 Apr; 20(8):554-5 (10 ref.) Comment on: Eur Heart J 1999 Apr;20(8):562-74.
[The eosinophilic leukocyte as a key cell of inflammation in atopic bronchial asthma] Fassakhov RS. **Patol Fiziol Eksp Ter** 1999 Jan-Mar;(1):22-4 (14 ref.) **(Rus)**

CHEMICALLY INDUCED

Proinflammatory cytokines lowering erythropoietin production. Jelkmann W. **J Interferon Cytokine Res** 1998 Aug;18(8):555-9 (61 ref.)

COMPLICATIONS

Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Ridker PM. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S9-12 (32 ref.)
The importance of inflammatory mechanisms for the development of Alzheimer's disease. Eikelenboom P, et al. **Exp Gerontol** 1999 Jun;34(3):453-61 (37 ref.)
Inflammation, sepsis, and coagulation. Esmon CT, et al. **Haematologica** 1999 Mar;84(3):254-9 (24 ref.)
Inflammation in asthma: the cornerstone of the disease and target of therapy. Busse WW. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 2):S17-22 (78 ref.)
Chronic inflammation and cancer: potential role of Bcl-2 gene family members as regulators of cellular antioxidant status. Frommel TO, et al. **Med Hypotheses** 1999 Jan; 52(1):27-30 (29 ref.)

DIAGNOSIS

Phospholipase A2: its usefulness in laboratory diagnostics. Kaiser E. **Crit Rev Clin Lab Sci** 1999 Apr;36(2):65-163 (700 ref.)
Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999 Apr 29;340(17):1376] Gabay C, et al. **N Engl J Med** 1999 Feb 11;340(6):448-54 (64 ref.)
Markers of allergy & inflammation. Warner JO, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):53-7 (33 ref.)
[Laboratory tests and clinical practice: from diagnosis of an inflammatory syndrome to colon cancer screening] Gulbis B. **Rev Med Brux** 1998 Sep;19(4):A248-51 (15 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Effect of plant flavonoids on immune and inflammatory cell function. Middleton E Jr. **Adv Exp Med Biol** 1998; 439:175-82 (27 ref.)
Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Tyrrell DJ, et al. **Adv Pharmacol** 1999;46:151-208 (349 ref.)
IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Haskó G, et al. **Br J Pharmacol** 1999 Jul;127(6):1295-304 (129 ref.)
CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Scherberich JE, et al. **Clin Chem Lab Med** 1999 Mar; 37(3):209-13 (18 ref.)
Therapeutic approaches to the treatment of neuroinflammatory diseases. Hays SJ. **Curr Pharm Des** 1998 Aug;4(4):335-48 (112 ref.)
Adenosine kinase inhibitors. Kowaluk EA, et al. **Curr Pharm Des** 1998 Oct;4(5):403-16 (178 ref.)
Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW, et al. **Curr Pharm Des** 1998 Oct; 4(5):367-79 (100 ref.)
Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381-96 (122 ref.)
Immunopharmacology: anti-inflammatory therapy targeting transcription factors. Pfeilschifter J, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):237-45 (103 ref.)
Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J, et al. **Inflamm Res** 1999 May;48(5):247-54 (97 ref.)
Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF. **Med Hypotheses** 1998 Jul;51(1):11-5 (63 ref.)
[Selective inhibition of cyclooxygense (COX-2)] Gömör B. **Orv Hetil** 1999 Feb 21;140(8):395-9 (37 ref.) (Eng. Abstr.) **(Hun)**
[Pharmacokinetic basis for the use of pefloxacin in severe forms of infectious-inflammatory diseases] Navashin PS, et al. **Antibiot Khimioter** 1998;43(12):30-8 (46 ref.) **(Rus)**

ENZYMOLOGY

Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation. Koehne P, et al. **Allergy** 1998 Nov;53(11):1023-42 (248 ref.)
Role and regulation of cyclooxygenase-2 during inflammation. Simon LS. **Am J Med** 1999 May 31; 106(5B):37S-42S (14 ref.)
Phospholipase A2: its usefulness in laboratory diagnostics. Kaiser E. **Crit Rev Clin Lab Sci** 1999 Apr;36(2):65-163 (700 ref.)
Modulation of drug metabolism in infectious and inflammatory diseases. Iber H, et al. **Drug Metab Rev** 1999 Feb;31(1):29-41 (41 ref.)
Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J, et al. **Inflamm Res** 1999 May;48(5):247-54 (97 ref.)
Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. Heinecke JW. **J Lab Clin Med** 1999 Apr;133(4):321-5 (32 ref.)
[Focalized matrix proteolysis and inflammation] Gaudin P, et al. **Ann Biol Clin (Paris)** 1998 Nov-Dec;56(6):661-9 (62 ref.) (Eng. Abstr.) **(Fre)**
[Granzyme B: an essential protease for the inflammatory response] Berthou C, et al. **Pathol Biol (Paris)** 1998 Oct; 46(8):617-24 (35 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Elenkov IJ, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:1-11; discussion 11-3 (59 ref.)
The nonspecific inflammatory response to injury. Mayers I, et al. **Can J Anaesth** 1998 Sep;45(9):871-9 (94 ref.)
The gut as a potential trigger of exercise-induced inflammatory responses. Marshall JC. **Can J Physiol Pharmacol** 1998 May;76(5):479-84 (54 ref.)
Radical species in inflammation and overtraining. Tiidus PM. **Can J Physiol Pharmacol** 1998 May;76(5):533-8 (77 ref.)
The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Finkelman FD, et al. **Curr Opin Immunol** 1999 Aug; 11(4):420-6 (84 ref.)
Mediators of inflammation and the inflammatory process. White M. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S378-81 (42 ref.)
[Overweight as a risk factor for cardiovascular diseases and its possible significance as a promotor of an increased inflammatory reaction] Halle M, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):905-9 (50 ref.) **(Ger)**
[Free radicals and their role in inflammation] Soteras F. **Arch Bronconeumol** 1999 May;35 Suppl 3:3-9 (50 ref.) **(Spa)**

GENETICS

The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Centola M, et al. **Hum Mol Genet** 1998;7(10):1581-8 (81 ref.)
Inflammatory disease in HLA-B27 transgenic rats. Taurog JD, et al. **Immunol Rev** 1999 Jun;169:209-23 (83 ref.)
The role of C/EBP isoforms in the control of inflammatory and native immunity functions. Poli V. **J Biol Chem** 1998 Nov 6;273(45):29279-82 (69 ref.)
Chronic inflammation and cancer: potential role of Bcl-2 gene family members as regulators of cellular antioxidant status. Frommel TO, et al. **Med Hypotheses** 1999 Jan; 52(1):27-30 (29 ref.)

IMMUNOLOGY

Major depression and activation of the inflammatory response system. Maes M. **Adv Exp Med Biol** 1999;461:25-46 (173 ref.)
Interleukin-12: a cytokine at the interface of inflammation and immunity. Trinchieri G. **Adv Immunol** 1998;70:83-243 (754 ref.)
Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Iwasaki A, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1074-8 (24 ref.)
The function of cell adhesion molecules in lung inflammation: more questions than answers. DeLisser HM, et al. **Am J Respir Cell Mol Biol** 1998 Oct;19(4):533-6 (53 ref.)
Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Locati M, et al. **Annu Rev Med** 1999;50:425-40 (78 ref.)
Onset and persistence of the allergic inflammation: a molecular explanation? Spinozzi F. **Arch Immunol Ther Exp (Warsz)** 1998;46(5):277-84 (44 ref.)
Neuropeptides: mediators of inflammation and tissue repair? Schäffer M, et al. **Arch Surg** 1998 Oct;133(10):1107-16 (170 ref.)
The acute inflammatory response and its regulation. Ward PA, et al. **Arch Surg** 1999 Jun;134(6):666-9 (23 ref.)
You can lead a macrophage to an inflammatory site but can you make it eat? Hart SP, et al. **Biochem Soc Trans** 1998 Nov;26(4):650-2 (18 ref.)
Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589-97 (71 ref.)
Immune responses to inflammation and trauma: a physical training model. Shephard RJ, et al. **Can J Physiol Pharmacol** 1998 May;76(5):469-72 (33 ref.)
Semantics, inflammation, cytokines and common sense. Kushner I. **Cytokine Growth Factor Rev** 1998 Sep-Dec; 9(3-4):191-6 (63 ref.)
Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Mukaida N, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):9-23 (148 ref.)
Mechanisms of cell signaling in immune-mediated inflammation. Bayón Y, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):275-86 (140 ref.)
Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. McKay LI, et al. **Endocr Rev** 1999 Aug;20(4):435-59 (271 ref.)
Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Eikelenboom P, et al. **Exp Neurol** 1998 Nov;154(1):89-98 (121 ref.)
Inflammatory disease in HLA-B27 transgenic rats. Taurog JD, et al. **Immunol Rev** 1999 Jun;169:209-23 (83 ref.)
Interleukin-15 and its role in chronic inflammatory diseases. Kirman I, et al. **Inflamm Res** 1998 Jul;47(7):285-9 (47 ref.)
Hemopoietic mechanisms in allergic airway inflammation. Denburg JA, et al. **Int Arch Allergy Immunol** 1998 Nov; 117(3):155-9 (55 ref.)
Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. Nel AE, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):539-54 (115 ref.)
Apoptosis of eosinophils and lymphocytes in allergic inflammation. Ohta K, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):14-21 (57 ref.)
Mobilizing dendritic cells for tolerance, priming, and chronic inflammation [comment] Sallusto F, et al. **J Exp Med** 1999 Feb 15;189(4):611-4 (33 ref.) Comment on: J Exp Med 1999 Feb 15;189(4):627-35.
Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Buku A. **Peptides** 1999; 20(3):415-20 (39 ref.)

New therapeutic targets for rheumatoid arthritis. Dinant HJ, et al. **Pharm World Sci** 1999 Apr;21(2):49–59 (109 ref.)
Role of inflammation in the pathogenesis of unstable coronary artery diseases. Biasucci LM, et al.
Scand J Clin Lab Invest Suppl 1999;230:12–22 (64 ref.)
The traffic of resting lymphocytes through delayed hypersensitivity and chronic inflammatory lesions: a dynamic equilibrium. Seabrook T, et al. **Semin Immunol** 1999 Apr;11(2):115–23 (41 ref.)
Immunobiology of dendritic cells in the respiratory tract: steady-state and inflammatory sentinels? McWilliam AS, et al. **Toxicol Lett** 1998 Dec 28;102–103:323–9 (19 ref.)
Endothelial cell adhesion molecules in inflammation and postischemic reperfusion injury. Beekhuizen H, et al.
Transplant Proc 1998 Dec;30(8):4251–6 (65 ref.)
The macrophage--a cell for all seasons. Morrissette N, et al. **Trends Cell Biol** 1999 May;9(5):199–201 (0 ref.)
[Inflammatory response of the body to surgery illustrated by pro-inflammatory and anti-inflammatory cytokines] Christensen VB, et al. **Ugeskr Laeger** 1998 Nov 23; 160(48):6951–3 (11 ref.) **(Dan)**
[Inflammatory cytokines and chemokines in acute inflammatory disease] Geiser T.
Schweiz Med Wochenschr 1999 Apr 10;129(14):540–6 (27 ref.) (Eng. Abstr.) **(Ger)**
[Inflammatory changes and immunological disturbances in stroke] Fiszer U, et al. **Neurol Neurochir Pol** 1998 Sep–Oct; 32(5):1219–27 (30 ref.) (Eng. Abstr.) **(Pol)**
[Inflammatory response in pneumonia] Montón C, et al.
Arch Bronconeumol 1998 Nov;34 Suppl 2:11–6 (35 ref.) **(Spa)**

METABOLISM

Flavonoids: inhibitors of cytokine induced gene expression. Gerritsen ME. **Adv Exp Med Biol** 1998;439:183–90 (29 ref.)
Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854–65 (80 ref.)
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Gelman L, et al.
Cell Mol Life Sci 1999 Jun;55(6–7):932–43 (141 ref.)
Activation and regulation of NFkappaB during acute inflammation. Lentsch AB, et al. **Clin Chem Lab Med** 1999 Mar;37(3):205–8 (28 ref.)
Soluble cytokine receptors: basic immunology and clinical applications. Fernandez-Botran R.
Crit Rev Clin Lab Sci 1999 Jun;36(3):165–224 (243 ref.)
Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151–9 (97 ref.)
The importance of inflammatory mechanisms in Alzheimer disease. McGeer EG, et al. **Exp Gerontol** 1998 Aug; 33(5):371–8 (22 ref.)
Experimental study of oxidative DNA damage. Loft S, et al. **Free Radic Res** 1998 Dec;29(6):525–39 (149 ref.)
Biology of basophils and their role in allergic inflammation. Chugh L. **Indian J Chest Dis Allied Sci** 1998 Oct–Dec; 40(4):257–67 (56 ref.)
Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. Matsukawa A, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S137–44 (61 ref.)
Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127–37 (163 ref.)

PATHOLOGY

New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Chen F, et al. **Clin Chem** 1999 Jan;45(1):7–17 (116 ref.)
The myofibroblast as an inflammatory cell in pulmonary fibrosis. Phan SH, et al. **Curr Top Pathol** 1999;93:173–82 (57 ref.)
Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Mukaida N, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):9–23 (148 ref.)
Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Goulding NJ, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S158–65 (68 ref.)
Effect of beta-agonists on inflammatory cells. Barnes PJ.
J Allergy Clin Immunol 1999 Aug;104(2 Pt 2):S10–7 (109 ref.)
Novel roles for chemokines and fibroblasts in interstitial fibrosis. Hogaboam CM, et al. **Kidney Int** 1998 Dec; 54(6):2152–9 (64 ref.)
Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Ginsburg I. **Med Hypotheses** 1998 Oct; 51(4):337–46 (68 ref.)
Endothelial gaps as sites for plasma leakage in inflammation. McDonald DM, et al. **Microcirculation** 1999 Mar;6(1):7–22 (50 ref.)
Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Gahtan E, et al.
Neurosci Biobehav Rev 1999 May;23(5):615–33 (197 ref.)
Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Mennicken F, et al. **Trends Pharmacol Sci** 1999 Feb;20(2):73–8 (83 ref.)
[The role of inflammation in the pathogenesis and prognosis of unstable angina] Miranda-Guardiola F, et al.
Rev Esp Cardiol 1999;52 Suppl 1:13–22 (58 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Inflammation and brain function under basal conditions and during long-term elevation of brain corticotropin-releasing hormone levels. Linthorst AC, et al.
Adv Exp Med Biol 1999;461:129–52 (83 ref.)
Dynamic regulation of proinflammatory cytokines. Watkins LR, et al. **Adv Exp Med Biol** 1999;461:153–78 (194 ref.)
Chemokines in inflammatory states. Conti P, et al.
Allergy Asthma Proc 1999 Jul-Aug;20(4):205–8 (31 ref.)
Nitric Oxide. III. A molecular prelude to intestinal inflammation. Miller MJ, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G795–9 (25 ref.)
Peptide modulation of fever and inflammation within the brain. Catania A, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:62–8 (54 ref.)
Heat shock proteins and the inflammatory response. Moseley PL. **Ann N Y Acad Sci** 1998 Sep 29;856:206–13 (45 ref.)
Proinflammatory cytokines and treatment of disease. van der Meer JW, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:243–51 (59 ref.)
Delineation of the proinflammatory cytokine cascade in fever induction. Zetterström M, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:48–52 (18 ref.)
Inflammatory mediators, cells and their products in acute host alloresponsiveness. Tilney NL, et al.
Ann Transplant 1996;1(3):5–13 (97 ref.)
Microglia as mediators of inflammatory and degenerative diseases. González-Scarano F, et al. **Annu Rev Neurosci** 1999;22:219–40 (134 ref.)
Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Baveye S, et al.
Clin Chem Lab Med 1999 Mar;37(3):281–6 (54 ref.)
How bacteria initiate inflammation: aspects of the emerging story. Hersh D, et al. **Curr Opin Microbiol** 1998 Feb; 1(1):43–8 (53 ref.)
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Heemskerk VH, et al. **Cytokine Growth Factor Rev** 1999 Mar;10(1):5–14 (109 ref.)
Cytokine regulation of cellular adhesion molecule expression in inflammation. Meager A.
Cytokine Growth Factor Rev 1999 Mar;10(1):27–39 (113 ref.)
Adhesion molecules in inflammatory diseases.
González-Amaro R, et al. **Drugs** 1998 Dec;56(6):977–88 (126 ref.)
Some aspects of the inflammatory process. Maślińska D, et al. **Folia Neuropathol** 1998;36(4):199–204 (36 ref.)
Inflammatory mediators and stroke: new opportunities for novel therapeutics. Barone FC, et al.
J Cereb Blood Flow Metab 1999 Aug;19(8):819–34 (203 ref.)
Activin A and follistatin: their role in the acute phase reaction and inflammation. de Kretser DM, et al. **J Endocrinol** 1999 May;161(2):195–8 (29 ref.)
A novel role of activin in inflammation and repair. Munz B, et al. **J Endocrinol** 1999 May;161(2):187–93 (34 ref.)
Inflammatory alterations in the myocardial microcirculation. Hansen PR. **J Mol Cell Cardiol** 1998 Dec;30(12):2555–9 (45 ref.)
Novel roles for chemokines and fibroblasts in interstitial fibrosis. Hogaboam CM, et al. **Kidney Int** 1998 Dec; 54(6):2152–9 (64 ref.)
Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF.
Med Hypotheses 1998 Jul;51(1):11–5 (63 ref.)
Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Sharief MK. **Mult Scler** 1998 Jun; 4(3):169–73 (35 ref.)
Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Gold MS. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7645–9 (69 ref.)
Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7723–30 (83 ref.)
Dietary lipids and the inflammatory response. Grimble RF.
Proc Nutr Soc 1998 Nov;57(4):535–42 (47 ref.)
Inflammation in the CNS: balance between immunological privilege and immune responses. Matyszak MK.
Prog Neurobiol 1998 Oct;56(1):19–35 (131 ref.)
[Adhesion receptors of the vascular endothelium and their role in acute inflammation] Bělohlávková S, et al.
Cesk Fysiol 1999 May;48(2):51–61 (47 ref.) (Eng. Abstr.) **(Cze)**
[Inflammatory mechanisms of renal fibrosis: glomerulonephritis] Baud L, et al. **Bull Acad Natl Med** 1999;183(1):23–31 (27 ref.) (Eng. Abstr.) **(Fre)**
[Nuclear transcription factor kappa B (NF-kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945–7 (13 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Kruzel ML, et al. **Adv Exp Med Biol** 1998;443:167–73 (38 ref.)
Use of postoperative steroids to reduce pain and inflammation. Fleischli JW, et al. **J Foot Ankle Surg** 1999 May-Jun;38(3):232–7 (31 ref.)
An anti-inflammatory role for glucocorticoids in the ovaries? Hillier SG, et al. **J Reprod Immunol** 1998 Aug;39(1–2):21–7 (36 ref.)

PSYCHOLOGY

Major depression and activation of the inflammatory response system. Maes M. **Adv Exp Med Biol** 1999;461:25–46 (173 ref.)

RADIONUCLIDE IMAGING

Nuclear medicine imaging in infection and inflammation. Peters AM. **J R Coll Physicians Lond** 1998 Nov–Dec; 32(6):512–9 (30 ref.)
Nuclear medicine's role in infection and inflammation. Corstens FH, et al. **Lancet** 1999 Aug 28;354(9180):765–70 (37 ref.)
Radionuclide imaging of nonosseous infection. Palestro CJ, et al. **Q J Nucl Med** 1999 Mar;43(1):46–60 (69 ref.)
Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals. Weiner RE, et al. **Q J Nucl Med** 1999 Mar;43(1):2–8 (49 ref.)

RADIOTHERAPY

Radiobiological mechanisms of anti-inflammatory radiotherapy. Trott KR, et al. **Radiother Oncol** 1999 Jun; 51(3):197–203 (44 ref.)

THERAPY

C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Kirschfink M, et al.
Mol Immunol 1999 Mar–Apr;36(4–5):225–32 (85 ref.)
Autologous stem cell therapy for treatment of severe inflammatory autoimmune diseases. van Bekkum DW.
Neth J Med 1998 Sep;53(3):130–3 (18 ref.)
Application of gene therapy to acute inflammatory diseases. Moldawer LL, et al. **Shock** 1999 Aug;12(2):83–101 (183 ref.)
[Free radical mechanisms of low-intensive laser radiation] Chichuk TV, et al. **Vestn Ross Akad Med Nauk** 1999; (2):27–32 (54 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Inflammatory diseases of the central nervous system in dogs. Thomas WB. **Clin Tech Small Anim Pract** 1998 Aug; 13(3):167–78 (86 ref.)

VIROLOGY

Cytomegalovirus infection. Regulation of inflammation. Hunninghake GW, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):150–2 (41 ref.)
Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma [comment] Mesri EA. **Blood** 1999 Jun 15;93(12):4031–3 (18 ref.) Comment on: Blood 1999 Jun 15;93(12):4034–43. Comment on: Blood 1999 Jun 15;93(12):4044–58.

INFLAMMATION MEDIATORS

Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Asimakopoulos G, et al.
Ann Thorac Surg 1998 Dec;66(6):2135–44 (89 ref.)

ANALYSIS

Can eosinophil-derived proteins be used to diagnose or to monitor childhood asthma? [editorial; comment] Hoekstra MO. **Clin Exp Allergy** 1999 Jul;29(7):873–4 (17 ref.) Comment on: Clin Exp Allergy 1999 Jul;29(7):926–32.
Expression of functional immunomodulatory and anti-inflammatory factors in human milk. Garofalo RP, et al. **Clin Perinatol** 1999 Jun;26(2):361–77 (115 ref.)

ANTAGONISTS & INHIBITORS

The taming of IL-12: suppressing the production of proinflammatory cytokines. Sutterwala FS, et al.
J Leukoc Biol 1999 May;65(5):543–51 (82 ref.)

BLOOD

Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Sacks FM, et al. **Herz** 1999 Feb; 24(1):51–6 (16 ref.)

IMMUNOLOGY

[The role of inflammation mediators in bronchial asthma and chronic obstructive pulmonary disease (editorial)] Chciałowski A, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):1–4 (34 ref.) (Eng. Abstr.) **(Pol)**

INFLAMMATION MEDIATORS

METABOLISM

Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. Ng T. **Br J Hosp Med** 1998 Nov 19-Dec 9;58(10):521-3 (17 ref.)

Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Nicoletti A, et al. **Cardiovasc Res** 1999 Mar;41(3):532-43 (123 ref.)

Regulation and metabolism of arachidonic acid. Seeds MC, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):5-26 (114 ref.)

Novel pathways for negative regulation of inflammatory cytokines centered on receptor expression. Mantovani A, et al. **Dev Biol Stand** 1999;97:97-104 (50 ref.)

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Artuc M, et al. **Exp Dermatol** 1999 Feb;8(1):1-16 (195 ref.)

The importance of inflammatory mechanisms in Alzheimer disease. McGeer EG, et al. **Exp Gerontol** 1998 Aug; 33(5):371-8 (22 ref.)

Clinical manifestations of the release of histamine and other inflammatory mediators. Naclerio R. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S382-5 (42 ref.)

Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Spokas EG, et al. **Methods Mol Biol** 1999;120:213-47 (145 ref.)

Inflammatory mediators of asthma: an update. Barnes PJ, et al. **Pharmacol Rev** 1998 Dec;50(4):515-96 (1481 ref.)

Complement, cytokines, and adhesion molecule expression in inflammatory reactions. Czermak BJ, et al. **Proc Assoc Am Physicians** 1998 Jul-Aug;110(4):306-12 (29 ref.)

Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. Fearon KC, et al. **World J Surg** 1999 Jun;23(6):584-8 (25 ref.)

[Histamine as a mediator of allergic inflammation (editorial)] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May; 6(35):232-5 (46 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Witko-Sarsat V, et al. **Adv Nephrol Necker Hosp** 1998; 28:321-41 (80 ref.)

Human eosinophil granule major basic protein and its novel homolog. Plager DA, et al. **Allergy** 1998;53(45 Suppl):33-40 (73 ref.)

Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. McGeer PL, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S1-6 (40 ref.)

Effects of inflammatory mediators on gut sensitivity. Bueno L, et al. **Can J Gastroenterol** 1999 Mar;13 Suppl A:42A-46A (25 ref.)

Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. Svanborg C, et al. **Curr Opin Microbiol** 1999 Feb;2(1):99-105 (59 ref.)

New developments in the role of cytokines and chemokines in inflammatory myopathies. Lundberg IE, et al. **Curr Opin Rheumatol** 1998 Nov;10(6):521-9 (53 ref.)

Interleukin-8: An autocrine inflammatory mediator. Atta-ur-Rahman, et al. **Curr Pharm Des** 1999 Apr; 5(4):241-53 (175 ref.)

Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381-96 (122 ref.)

Nerve injury and inflammatory cytokines modulate gap junctions in the peripheral nervous system. Chandross KJ. **Glia** 1998 Sep;24(1):21-31 (172 ref.)

Mediators of inflammation: production and implication in inflammatory bowel disease. Kolios G, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1601-9 (38 ref.)

Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators. Lügering N, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):338-44 (62 ref.)

Mediators of inflammation and the inflammatory process. White M. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S378-81 (42 ref.)

Mediators in polytrauma--pathophysiological significance and clinical relevance. Rose S, et al. **Langenbecks Arch Surg** 1998 Aug;383(3-4):199-208 (81 ref.)

The role of cytokines in bacterial pneumonia: an inflammatory balancing act. Moore TA, et al. **Proc Assoc Am Physicians** 1998 Jul-Aug;110(4):297-305 (81 ref.)

[Inflammatory mediator and organ dysfunction syndrome] Shimada H, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug; 99(8):490-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Problems and perspective approaches to correction of mediator response in sepsis] Mironov PI, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):54-9 (50 ref.) **(Rus)**

[The regulatory functions of pro-inflammatory cytokines and acute-phase proteins] Freidlin IS, et al. **Vestn Ross Akad Med Nauk** 1999;(5):28-32 (23 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Antimicrobial effects of antiinflammatory drugs, antiinflammatory effects of antimicrobial drugs. Bannwarth B. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):73S-76S (44 ref.)

INFLAMMATORY BOWEL DISEASES

Inflammatory bowel disease in the elderly. Lindner AE. **Clin Geriatr Med** 1999 Aug;15(3):487-97 (37 ref.)

Inflammatory bowel disease in pediatric and adolescent patients. Baldassano RN, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):445-58 (61 ref.)

Current theories on the causes of inflammatory bowel disease. Papadakis KA, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):283-96 (96 ref.)

Enteroscopy in small intestinal inflammatory diseases. Gay GJ, et al. **Gastrointest Endosc Clin N Am** 1999 Jan; 9(1):115-23 (38 ref.)

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. Irvine EJ. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S23-7 (14 ref.)

Impact of inflammatory bowel disease on educational achievements and work prospects. Mayberry JF. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S34-6 (9 ref.)

Inflammatory bowel disease. Griffiths AM. **Nutrition** 1998 Oct;14(10):788-91 (44 ref.)

BLOOD

[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations] Klotz U. **Med Klin** 1999 Feb 15; 94 Suppl 1:16-22 (53 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Idiopathic inflammatory bowel disease associated with colonic tattooing with india ink preparation--case report and review of literature. Gopal DV, et al. **Gastrointest Endosc** 1999 May;49(5):636-9 (19 ref.)

COMPLICATIONS

Thromboembolism in inflammatory bowel disease. Schapira M, et al. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):182-6 (55 ref.)

Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? [see comments] Barthet M, et al. **Am J Gastroenterol** 1999 Aug;94(8):2141-8 (42 ref.) Comment in: Am J Gastroenterol 1999 Aug;94(8):2001.

Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Valentine JF, et al. **Am J Gastroenterol** 1999 Apr;94(4):878-83 (40 ref.)

Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Das KM. **Dig Dis Sci** 1999 Jan;44(1):1-13 (118 ref.)

A strategy for osteoporosis in gastroenterology. Scott EM, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):689-96; discussion 696-8 (80 ref.)

Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423-43, ix (160 ref.)

Cancer risk in patients with inflammatory bowel disease. Lewis JD, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):459-77, x (101 ref.)

Hepatobiliary manifestations of inflammatory bowel disease. Raj V, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):491-513 (140 ref.)

Hepatobiliary complications of inflammatory bowel disease: overview of the issues. Balistreri WF. **Inflamm Bowel Dis** 1998 Aug;4(3):220-4 (37 ref.)

Bones and Crohn's: problems and solutions. Buchman AL. **Inflamm Bowel Dis** 1999 Aug;5(3):212-27 (214 ref.)

Risk factors and distinguishing features of cancer in IBD. Ekbom A. **Inflamm Bowel Dis** 1998 Aug;4(3):235-43 (86 ref.)

Malignancy and aneuploidy: prevention and early detection. Kirschner B. **Inflamm Bowel Dis** 1998 Aug;4(3):216-20 (25 ref.)

Inflammatory bowel disease and osteoporosis [editorial] Ljunghall S, et al. **Ital J Gastroenterol Hepatol** 1999 Mar; 31(2):103-9 (86 ref.)

Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate [see comments] Mouzas IA, et al. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):421-5 (44 ref.) Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):426-7.

Metabolic problems in inflammatory bowel disease. Allan RN. **Neth J Med** 1998 Dec;53(6):S9-12 (13 ref.)

Growth failure in inflammatory bowel disease [editorial] McCartney S, et al. **Nutrition** 1999 Feb;15(2):169-71 (24 ref.)

DIAGNOSIS

Review article: The management of inflammatory bowel disease during pregnancy. Subhani JM, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1039-53 (127 ref.)

Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Roozendaal C, et al. **Clin Exp Immunol** 1999 May; 116(2):206-13 (106 ref.)

Inflammatory bowel disease. Schölmerich J. **Endoscopy** 1999 Jan;31(1):66-73 (40 ref.)

Imaging modalities in inflammatory bowel disease. Scotiniotis I, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):391-421, ix (37 ref.)

The utility of ANCA and ASCA in inflammatory bowel disease. Targan SR. **Inflamm Bowel Dis** 1999 Feb;5(1):61-3; discussion 66-7 (7 ref.)

[Unconventional imaging techniques in inflammatory bowel diseases] Wasser MN, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2179-86 (31 ref.) (Eng. Abstr.) **(Dut)**

[Chronic inflammatory bowel diseases in the child: clinical aspects] Hugot JP, et al. **Arch Pediatr** 1998;5 Suppl 2:101s-104s (17 ref.) **(Fre)**

[Inflammatory bowel disease in children] Goulet O. **Rev Prat** 1998 Feb 15;48(4):403-9 (23 ref.) (Eng. Abstr.) **(Fre)**

[Interventional endoscopy in chronic inflammatory bowel disease] Rosenbaum A, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):967-71 (41 ref.) **(Ger)**

[Guidelines for the anatomopathological diagnosis of chronic idiopathic inflammatory bowel disease] Cornaggia M, et al. **Pathologica** 1999 Feb;91(1):42-8 (7 ref.) **(Ita)**

DIET THERAPY

Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423-43, ix (160 ref.)

Nutritional modulation of gut inflammation. Rowlands BJ, et al. **Proc Nutr Soc** 1998 Aug;57(3):395-401 (49 ref.)

DRUG THERAPY

Lipid treatment of inflammatory bowel disease. Endres S, et al. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):117-20 (21 ref.)

Medical therapy of inflammatory bowel disease for the 21st century. Robinson M. **Eur J Surg Suppl** 1998;(582):90-8 (64 ref.)

Medical therapy of specific clinical presentations. Michetti P, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):353-70, viii (146 ref.)

Medical therapy for inflammatory bowel disease. Stein RB, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):297-321 (252 ref.)

Novel treatments in inflammatory bowel disease. Pathmakanthan S, et al. **Hosp Med** 1999 Jan;60(1):19-23 (20 ref.)

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Modigliani R. **Inflamm Bowel Dis** 1998 Aug;4(3):244-7; discussion 253-4 (9 ref.)

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Schölmerich J. **Inflamm Bowel Dis** 1998 Aug;4(3):248-52; discussion 253-4 (21 ref.)

Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Day R, et al. **Lancet** 1999 Jul 3; 354(9172):62-5 (37 ref.)

["Targeted delivery" in the gastrointestinal tract] Leopold CS. **Med Klin** 1999 Feb 15;94 Suppl 1:6-11 (78 ref.) (Eng. Abstr.) **(Ger)**

[Methotrexate in therapy of gastrointestinal diseases] Schröder O, et al. **Z Gastroenterol** 1999 Jul;37(7):623-37 (103 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology and the natural course of inflammatory bowel disease. Andres PG, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):225-81, vii (125 ref.)

Bowel inflammation and the spondyloarthropathies. De Keyser F, et al. **Rheum Dis Clin North Am** 1998 Nov; 24(4):785-813, ix-x (146 ref.)

ETIOLOGY

Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Perner A, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):135-44 (92 ref.)

Genetics of inflammatory bowel disease. The candidate gene approach: susceptibility versus disease heterogeneity. Peña AS. **Dig Dis** 1998 Nov-Dec;16(6):356-63 (89 ref.)

Epidemiology and the natural course of inflammatory bowel disease. Andres PG, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):225-81, vii (125 ref.)

Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Bhan AK, et al. **Immunol Rev** 1999 Jun;169:195-207 (135 ref.)

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Kollias G, et al. **Immunol Rev** 1999 Jun;169:175-94 (198 ref.)

Etiopathogenesis of inflammatory bowel disease: a pediatric perspective. Seidman E. **Inflamm Bowel Dis** 1998 Aug; 4(3):204-9 (65 ref.)

Etiology of the inflammatory bowel diseases. Hugot JP, et al. **Int J Colorectal Dis** 1999 Feb;14(1):2-9 (52 ref.)

A role for transcription factor NF-kappa B in intestinal inflammation. Schottelius AJ, et al. **Int J Colorectal Dis** 1999 Feb;14(1):18-28 (132 ref.)

Toward a biobehavioral model of visceral hypersensitivity in irritable bowel syndrome [editorial] Naliboff BD, et al.

J Psychosom Res 1998 Dec;45(6):485–92 (48 ref.)
A nutritional component to inflammatory bowel disease: the contribution of meat to fecal sulfide excretion [editorial] Magee E. **Nutrition** 1999 Mar;15(3):244–6 (45 ref.)
[Pathogenesis: immunologic, infectious and genetic aspects] Colombel JF, et al. **Arch Pediatr** 1998;5 Suppl 2:97s–100s (38 ref.) **(Fre)**
[Progress in research of etiology and pathogenesis of chronic inflammatory bowel diseases] Dignass A, et al. **Internist (Berl)** 1998 Oct;39(10):1004–12 (56 ref.) **(Ger)**
[Cytokines and gut] Shimada T, et al. **Nippon Rinsho** 1998 Sep;56(9):2235–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Importance of CD44 variant isoforms in mouse models for inflammatory bowel disease. Günthert U. **Curr Top Microbiol Immunol** 1999;246:307–12; discussion 313 (25 ref.)
Genetic epidemiology in inflammatory bowel disease. Binder V. **Dig Dis** 1998 Nov–Dec;16(6):351–5 (27 ref.)
Genome-wide scanning in inflammatory bowel diseases. Hugot JP, et al. **Dig Dis** 1998 Nov–Dec;16(6):364–9 (31 ref.)
Genetics of inflammatory bowel disease. The candidate gene approach: susceptibility versus disease heterogeneity. Peña AS. **Dig Dis** 1998 Nov–Dec;16(6):356–63 (89 ref.)

IMMUNOLOGY

T cells in mouse models of gut inflammation. Simpson SJ, et al. **Chem Immunol** 1998;71:118–38 (82 ref.)
Importance of CD44 variant isoforms in mouse models for inflammatory bowel disease. Günthert U. **Curr Top Microbiol Immunol** 1999;246:307–12; discussion 313 (25 ref.)
An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D, et al. **Eur Cytokine Netw** 1999 Mar;10(1):7–15 (48 ref.)
Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review). Baumgart DC, et al. **Int J Mol Med** 1998 Feb;1(2):315–32 (268 ref.)
Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Amati L, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):313–25 (153 ref.)
Current concept of the role of monocytes/macrophages in inflammatory bowel disease—balance of proinflammatory and immunosuppressive mediators. Lügering N, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):338–44 (62 ref.)
Proinflammatory cytokines in IBD [editorial; comment] Asakura H. **J Gastroenterol** 1999 Feb;34(1):149–51 (13 ref.) Comment on: J Gastroenterol 1999 Feb;34(1):66–74.
Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Strober W, et al. **Scand J Immunol** 1998 Nov;48(5):453–8 (59 ref.)
The role of IL-10 in inflammatory bowel disease: "of mice and men". Leach MW, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):123–33 (137 ref.)
[The intestinal immune system in children and their disorders] Votava-Raić A, et al. **Lijec Vjesn** 1998 Mar–Apr; 120(3–4):72–9 (70 ref.) (Eng. Abstr.) **(Scr)**

METABOLISM

Nitric oxide and inflammatory bowel diseases. Guslandi M. **Eur J Clin Invest** 1998 Nov;28(11):904–7 (42 ref.)
Growth factors in inflammatory bowel disease. Beck PL, et al. **Inflamm Bowel Dis** 1999 Feb;5(1):44–60 (244 ref.)
A nutritional component to inflammatory bowel disease: the contribution of meat to fecal sulfide excretion [editorial] Magee E. **Nutrition** 1999 Mar;15(3):244–6 (45 ref.)

MICROBIOLOGY

Intestinal inflammation and the gut microflora. McKay DM. **Can J Gastroenterol** 1999 Jul–Aug;13(6):509–16 (110 ref.)

PHYSIOPATHOLOGY

Experimental models to study molecular mechanisms underlying intestinal inflammation. Elson CO, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:85–95 (46 ref.)
Nutrition in inflammatory bowel disease. Murch SH, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):719–38 (86 ref.)
Mediators of inflammation: production and implication in inflammatory bowel disease. Kolios G, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1601–9 (38 ref.)
Metabolic bone disease in adults with inflammatory bowel disease. Adachi JD, et al. **Inflamm Bowel Dis** 1999 Aug; 5(3):200–11 (137 ref.)
Bone mineral metabolism in pediatric inflammatory bowel disease. Issenman RM. **Inflamm Bowel Dis** 1999 Aug; 5(3):192–9 (86 ref.)
Quality of life in inflammatory bowel disease: background and definitions. Ferry GD. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S15–8 (28 ref.)
Local and systemic effects of macrophage cytokines in intestinal inflammation. Murch SH. **Nutrition** 1998 Oct; 14(10):780–3 (38 ref.)
[Nitric oxide and inflammatory bowel disease (see comments)] García-González MA, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):870–6 (61 ref.) (Eng. Abstr.) Comment in: Rev Esp Enferm Dig 1998 Dec;90(12):829–32. **(Spa)**

PSYCHOLOGY

Assessment of quality of life in the younger child: the use of an animated computer program. Büller H. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S53–5 (11 ref.)
Inflammatory bowel disease in children and adolescents: mental health and family functioning. Engstrom I. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S28–33 (21 ref.)
Potential uses for quality-of-life measures in childhood inflammatory bowel disease. Koot HM, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S56–61 (20 ref.)
Stress and mind-body impact on the course of inflammatory bowel diseases. Anton PA. **Semin Gastrointest Dis** 1999 Jan;10(1):14–9 (52 ref.)

RADIOGRAPHY

Polypoid and pseudopolypoid lesions of inflammatory bowel disease: diagnosis on double-contrast enema. De Backer AI, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):190–5 (24 ref.)

RADIONUCLIDE IMAGING

Clinical applications of radiolabeled blood elements in inflammatory bowel disease. Martin-Comin J, et al. **Q J Nucl Med** 1999 Mar;43(1):74–82 (74 ref.)

SURGERY

Colorectal surgery. Oliver GC. **J Am Coll Surg** 1999 Feb; 188(2):111–7 (48 ref.)
Laparoscopic-assisted bowel resections in inflammatory bowel disease: state of the art. Bemelman WA, et al. **Neth J Med** 1998 Dec;53(6):S39–46 (45 ref.)

THERAPY

Review article: The management of inflammatory bowel disease during pregnancy. Subhani JM, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1039–53 (127 ref.)
Inflammatory bowel disease: potential therapeutic strategies. Nielsen OH, et al. **Cytokines Cell Mol Ther** 1997 Dec; 3(4):267–81 (184 ref.)
An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D, et al. **Eur Cytokine Netw** 1999 Mar;10(1):7–15 (48 ref.)
Novel therapies for inflammatory bowel disease. Sands BE. **Gastroenterol Clin North Am** 1999 Jun;28(2):323–51 (220 ref.)
Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Less commonly used therapies for IBD or treatments on the fringe. Burakoff R. **Inflamm Bowel Dis** 1998 Nov;4(4):308–13; discussion 313–7 (34 ref.)
Complementary and alternative medicine: evaluating its effectiveness in inflammatory bowel disease. Hilsden RJ, et al. **Inflamm Bowel Dis** 1998 Nov;4(4):318–23 (32 ref.)
Initial maintenance therapy (relapse prevention) and therapy of steroid resistance and dependence. Winter H. **Inflamm Bowel Dis** 1998 Aug;4(3):209–13 (33 ref.)
Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Kirschner BS. **Neth J Med** 1998 Dec;53(6):S13–8 (13 ref.)
Experimental immunomodulatory therapy of inflammatory bowel disease. Schreiber S. **Neth J Med** 1998 Dec; 53(6):S24–31 (55 ref.)
Inflammatory bowel disease: current therapy and future options. Tandan M. **Trop Gastroenterol** 1998 Oct–Dec; 19(4):130–5 (45 ref.)
[Treatment of chronic inflammatory bowel diseases in the child] Goulet O, et al. **Arch Pediatr** 1998;5 Suppl 2:105s–108s (17 ref.) **(Fre)**
[Inflammatory bowel disease in children] Goulet O. **Rev Prat** 1998 Feb 15;48(4):403–9 (23 ref.) (Eng. Abstr.) **(Fre)**
[Interventional endoscopy in chronic inflammatory bowel disease] Rosenbaum A, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):967–71 (41 ref.) **(Ger)**

VETERINARY

Inflammatory bowel disease. Current perspectives. Jergens AE. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):501–21, vii (92 ref.)

INFLAMMATORY RESPONSE SYNDROME, SYSTEMIC see **SEPSIS SYNDROME**

INFLUENZA

First International Symposium on Influenza and Other Respiratory Viruses: summary and overview: Kapalua, Maui, Hawaii, December 4–6, 1998. Kaiser L, et al. **Antiviral Res** 1999 Jul;42(3):149–75 (94 ref.)
Hospitalizing influenza in adults. Kaiser L, et al. **Curr Clin Top Infect Dis** 1999;19:112–34 (103 ref.)
A rational strategy for influenza. Venkatesan P, et al. **Practitioner** 1997 Sep;241(1578):536–9 (18 ref.)
[Clinical features of the new influenza virus infection] Tanabe O. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):77–9 (8 ref.) **(Jpn)**
[Influenza virus pneumonia] Yamada M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):83–6 (15 ref.) **(Jpn)**

COMPLICATIONS

[Orthopnea: not always of cardiac origin (see comments)] Oranen BI, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):921–4 (32 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 3;143(27):1443–4. **(Dut)**
[Influenza and asthma] Murris-Espin M, et al. **Rev Mal Respir** 1999 Feb;16(1):9–15 (46 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The diagnosis and management of influenza. An update. Sintchenko V, et al. **Aust Fam Physician** 1999 Apr; 28(4):313–7 (13 ref.)

DRUG THERAPY

Approaches and strategies for the treatment of influenza virus infections. Colacino JM, et al. **Antivir Chem Chemother** 1999 Jul;10(4):155–85 (222 ref.)
The diagnosis and management of influenza. An update. Sintchenko V, et al. **Aust Fam Physician** 1999 Apr; 28(4):313–7 (13 ref.)
Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Dines GD, et al. **Drug Saf** 1998 Sep;19(3):233–41 (19 ref.)
New approaches to influenza chemotherapy. Neuraminidase inhibitors. Calfee DP, et al. **Drugs** 1998 Oct;56(4):537–53 (63 ref.)
Influenza viral infections: presentation, prevention, and treatment. Kennedy MM. **Nurse Pract** 1998 Sep;23(9):17, 21–2, 25–8 passim; quiz 38–9 (35 ref.)

EPIDEMIOLOGY

[Influenza A (H5N1) in Hong Kong: Forerunner of a pandemic or just a scientifically interesting phenomenon and a useful exercise in pandemiology?] de Jong JC, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1252–6 (14 ref.) (Eng. Abstr.) **(Dut)**

PREVENTION & CONTROL

An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1998–1999 season. **Can Commun Dis Rep** 1998 Jul 1;24:1–12 (45 ref.) **(Eng, Fre)**
Underused options for preventing and treating influenza. Mossad SB. **Cleve Clin J Med** 1999 Jan;66(1):19–23 (19 ref.)
Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Webster RG. **Clin Infect Dis** 1999 Feb;28(2):225–9 (26 ref.)
The next influenza pandemic: lessons from Hong Kong, 1997. Snacken R, et al. **Emerg Infect Dis** 1999 Mar–Apr; 5(2):195–203 (37 ref.)
Influenza viral infections: presentation, prevention, and treatment. Kennedy MM. **Nurse Pract** 1998 Sep;23(9):17, 21–2, 25–8 passim; quiz 38–9 (35 ref.)
Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Nguyen-Van-Tam JS, et al. **Semin Respir Infect** 1999 Jun;14(2):184–95 (116 ref.)
[Anticipating "flu mist"—soon a must] Gnehm HE. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2023–6 (8 ref.) **(Ger)**
[Why should all persons over age 65 years be vaccinated against influenza?] Linde A, et al. **Lakartidningen** 1998 Oct 21;95(43):4744–8 (20 ref.) **(Swe)**

VETERINARY

The equine influenza surveillance program. Mumford JA. **Adv Vet Med** 1999;41:379–87 (11 ref.)
The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Guthrie AJ, et al. **Rev Sci Tech** 1999 Apr;18(1):179–85 (6 ref.)

VIROLOGY

1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164–6 (31 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651–6.

INFLUENZA A VIRUS

The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Guthrie AJ, et al. **Rev Sci Tech** 1999 Apr;18(1):179–85 (6 ref.)

CHEMISTRY

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

DRUG EFFECTS

Zanamivir. A potent and selective inhibitor of influenza A

INFLUENZA A VIRUS

and B viruses. Aoki FY, et al. **Clin Pharmacokinet** 1999; 36 Suppl 1:v–ix (24 ref.)

IMMUNOLOGY

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

PATHOGENICITY

Cellular proteinases trigger the infectivity of the influenza A and Sendai viruses. Kido H, et al. **Mol Cells** 1999 Jun 30;9(3):235–44 (37 ref.)

[How can the carbohydrate moiety of influenza virus HA contribute to the initiation of viral infection?] Ohuchi M, et al. **Uirusu** 1998 Jun;48(1):1–8 (26 ref.) **(Jpn)**

INFLUENZA A VIRUS, AVIAN

[H 5 N1 avian influenza in Hong Kong] Tashiro M. **Uirusu** 1998 Dec;48(2):211–21 (21 ref.) **(Jpn)**

ISOLATION & PURIFICATION

[Influenza A (H5N1) in Hong Kong: Forerunner of a pandemic or just a scientifically interesting phenomenon and a useful exercise in pandemiology?] de Jong JC, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1252–6 (14 ref.) (Eng. Abstr.) **(Dut)**

INFLUENZA A VIRUS, HUMAN

[Clinical features of the new influenza virus infection] Tanabe O. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):77–9 (8 ref.) **(Jpn)**

GENETICS

1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164–6 (31 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651–6.

IMMUNOLOGY

Host responses to respiratory virus infection and immunization. Crowe JE Jr. **Curr Top Microbiol Immunol** 1999;236:191–214 (235 ref.)

INFLUENZA A VIRUS, PORCINE

GENETICS

1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164–6 (31 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651–6.

INFLUENZA B VIRUS

DRUG EFFECTS

Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Aoki FY, et al. **Clin Pharmacokinet** 1999; 36 Suppl 1:v–ix (24 ref.)

IMMUNOLOGY

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

INFLUENZA VACCINE

The equine influenza surveillance program. Mumford JA. **Adv Vet Med** 1999;41:379–87 (11 ref.)

An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1998–1999 season. **Can Commun Dis Rep** 1998 Jul 1;24:1–12 (45 ref.) **(Eng, Fre)**

ADMINISTRATION & DOSAGE

Underused options for preventing and treating influenza. Mossad SB. **Cleve Clin J Med** 1999 Jan;66(1):19–23 (19 ref.)

Influenza viral infections: presentation, prevention, and treatment. Kennedy MM. **Nurse Pract** 1998 Sep;23(9):17, 21–2, 25–8 passim; quiz 38–9 (35 ref.)

Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Nguyen-Van-Tam JS, et al. **Semin Respir Infect** 1999 Jun;14(2):184–95 (116 ref.)

[Anticipating "flu mist"—soon a must] Gnehm HE. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2023–6 (8 ref.) **(Ger)**

[Adverse effects associated with influenza vaccine in pediatrics] Martin Moreno V, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):319–29 (50 ref.) (Eng. Abstr.) **(Spa)**

[Why should all persons over age 65 years be vaccinated against influenza?] Linde A, et al. **Lakartidningen** 1998 Oct 21;95(43):4744–8 (20 ref.) **(Swe)**

IMMUNOLOGY

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Webster RG. **Clin Infect Dis** 1999 Feb;28(2):225–9 (26 ref.)

Influenza vaccination in elderly people. Remarque EJ. **Exp Gerontol** 1999 Jun;34(3):445–52 (43 ref.)

INFLUENZA VIRUS, AVIAN see **INFLUENZA A VIRUS, AVIAN**

INFLUENZA VIRUS, EQUINE see **INFLUENZA A VIRUS**

INFLUENZA VIRUS, PORCINE see **INFLUENZA A VIRUS, PORCINE**

INFLUENZA VIRUS TYPE A, HUMAN see **INFLUENZA A VIRUS, HUMAN**

INFLUENZA VIRUSES see **ORTHOMYXOVIRIDAE**

INFLUENZA VIRUSES TYPE A see **INFLUENZA A VIRUS**

INFLUENZA VIRUSES TYPE B see **INFLUENZA B VIRUS**

INFORMATION DISPLAY see **DATA DISPLAY**

INFORMATION DISSEMINATION see **INFORMATION SERVICES**

INFORMATION MANAGEMENT

MANPOWER

Preparing chief information officers for the clinical information systems environment. Valenta AL, et al. **Acad Med** 1999 May;74(5):511–5 (14 ref.)

METHODS

Data management in occupational medicine. Schumann SC, et al. **Occup Med** 1998 Oct–Dec;13(4):735–46, iv (8 ref.)

INFORMATION PROCESSING, AUTOMATIC see **AUTOMATIC DATA PROCESSING**

INFORMATION PROCESSING, HUMAN see **MENTAL PROCESSES**

INFORMATION RETRIEVAL see **INFORMATION STORAGE AND RETRIEVAL**

INFORMATION RETRIEVAL SYSTEMS see **INFORMATION SYSTEMS**

INFORMATION SCIENCE

Chemoinformatics—a new name for an old problem? Hann M, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):379–83 (35 ref.)

INFORMATION SERVICES

Medical information on the Internet. Rampil IJ. **Anesthesiology** 1998 Nov;89(5):1233–45 (13 ref.)

In pursuit of excellence for patients with cancer: the Scottish Cancer Therapy Network model. Stroner PL, et al. **Br J Cancer** 1999 Apr;79(11–12):1641–5 (25 ref.)

Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864–8 (2 ref.)

Epidemiology of contact dermatitis. The information network of departments of dermatology (IVDK) in Germany. Uter W, et al. **Eur J Dermatol** 1998 Jan–Feb; 8(1):36–40 (29 ref.)

Dermatology resources on the internet: a practical guide for dermatologists. Sitaru C. **Int J Dermatol** 1998 Sep; 37(9):641–7 (15 ref.)

What have new efforts to change professional practice achieved? Cochrane Effective Practice and Organization of Care Group. Grimshaw JM, et al. **J R Soc Med** 1998; 91 Suppl 35:20–5 (23 ref.)

Meeting information needs in health policy and public health: priorities for the National Library of Medicine and The National Network of Libraries of Medicine. Humphreys BL. **J Urban Health** 1998 Dec;75(4):878–83 (4 ref.)

Challenges to accessing useful information in health policy and public health: an introduction to a national forum held at the New York Academy of Medicine, March 23, 1998. Lasker RD. **J Urban Health** 1998 Dec;75(4):779–84 (0 ref.)

Information needs in public health and health policy: results of recent studies. O'Carroll PW, et al. **J Urban Health** 1998 Dec;75(4):785–93 (3 ref.)

Information resources for public health practice. Rambo N. **J Urban Health** 1998 Dec;75(4):807–25 (8 ref.)

Meeting information needs in health policy and public health: roles for the Centers for Disease Control and Prevention. Ross D. **J Urban Health** 1998 Dec;75(4):884–7 (2 ref.)

Prostate cancer research and the National Cancer Institute. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):235–40 (26 ref.)

[Significance of CD-ROM in medicine] Reiss M, et al. **Wien Med Wochenschr** 1999;149(1):1–3 (11 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Problem-solving for better health: literature as a resource. Akhigbe F. **Afr J Med Med Sci** 1997 Sep–Dec; 26(3–4):205–8 (21 ref.)

Expanding Internet access for health care consumers. Wilkins AS. **Health Care Manage Rev** 1999 Summer;24(3):30–41 (44 ref.)

Specific issues related to developing, disseminating, and implementing pediatric practice guidelines for physicians, patients, families, and other stakeholders. Bauchner H, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1161–77 (51 ref.)

AHCPR focuses on information for health care decision makers. Eisenberg JM. **Health Serv Res** 1998 Oct;33(4 Pt 1):767–81 (11 ref.)

The role of information dissemination in sustainability of international partnerships. Delclos GL, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):203–8 (14 ref.)

The uses of comparative information in perinatal care. Gagnon DE. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S6–9 (5 ref.)

A knowledge-based health service: how do the new initiatives work? Stevens A, et al. **J R Soc Med** 1998;91 Suppl 35:26–31 (26 ref.)

Strategies for addressing priority information problems in health policy and public health. Lasker RD. **J Urban Health** 1998 Dec;75(4):888–95 (0 ref.)

From research to policy: what have we learned? Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS291–305 (37 ref.)

[Internet for physicians: a tool for today and tomorrow] Boyer C, et al. **Rev Med Suisse Romande** 1999 Feb; 119(2):137–44 (14 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

A review of the quality of trauma protocols on the Internet. Branfoot T, et al. **Injury** 1999 Jan;30(1):1–7 (11 ref.)

Injury control strategies: extending the quality and quantity of data relating to road traffic accidents in children. Henson R, et al. **J Accid Emerg Med** 1999 Mar;16(2):87–90 (33 ref.)

Applied information quality: a framework for thinking about the quality of specific information. Bradley J. **J Urban Health** 1998 Dec;75(4):864–77 (8 ref.)

TRENDS

[New information sources] Steurer J. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2052–5 (4 ref.) **(Ger)**

[Quality assurance of scientific information and databanks] Schweim HG, et al. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):723–8 (34 ref.) (Eng. Abstr.) **(Ger)**

INFORMATION STORAGE AND RETRIEVAL

Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. McManus RJ, et al. **BMJ** 1998 Dec 5;317(7172):1562–3 (5 ref.)

The art and science of searching MEDLINE to answer clinical questions. Finding the right number of articles. Allison JJ, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):281–96 (59 ref.)

Web-based resources for retrieving health policy information: NLM and beyond. Cahn MA, et al. **J Urban Health** 1998 Dec;75(4):826–41 (26 ref.)

Sources used in health policy research and implications for information retrieval systems. Gray BH. **J Urban Health** 1998 Dec;75(4):842–52 (0 ref.)

The retrieval problem for health policy and public health: knowledge bases and search engines. Lynch C. **J Urban Health** 1998 Dec;75(4):794–806 (0 ref.)

How well do physicians use electronic information retrieval systems? A framework for investigation and systematic review [see comments] Hersh WR, et al. **JAMA** 1998 Oct 21;280(15):1347–52 (35 ref.) Comment in: JAMA 1998 Oct 21;280(15):1363. Comment in: JAMA 1999 Apr 14;281(14):1272–3.

Information retrieval at the millenium. Hersh W. **Proc AMIA Symp** 1998;:38–45 (39 ref.)

Kleisli: a new tool for data integration in biology. Chung SY, et al. **Trends Biotechnol** 1999 Sep;17(9):351–5 (29 ref.)

[The practice of systematic reviews. II. Searching and selection of studies] Assendelft WJ, et al. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):656–61 (30 ref.) (Eng. Abstr.) **(Dut)**

STANDARDS

Quality of public health information: lessons from the field. Bialek R. **J Urban Health** 1998 Dec;75(4):853–63 (9 ref.)

Strategies for addressing priority information problems in health policy and public health. Lasker RD. **J Urban Health** 1998 Dec;75(4):888–95 (0 ref.)

[Review of the literature, search of reports and critical reading of articles in cancerology] Bonichon F, et al.

Bull Cancer 1998 Oct;85(10):867–85 (109 ref.) (Eng. Abstr.) **(Fre)**

UTILIZATION

A global perspective on nurses' Internet access and information utilization. Uhlenhopp MB, et al. **Oncol Nurs Forum** 1998 Nov–Dec;25(10 Suppl):27–32 (16 ref.)

INFORMATION SYSTEMS

Information resources for public health practice. Rambo N. **J Urban Health** 1998 Dec;75(4):807–25 (8 ref.)

[Development of NIHS Information and Computing Infrastructure (NICI)] Nakata K, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):92–100 (7 ref.) (Eng. Abstr.) **(Jpn)**

[The use of computers and networking in the neurosurgical field] Oizumi T, et al. **Rinsho Byori** 1999 Feb;47(2):119–25 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Expert systems and automatic diagnostic systems in histopathology--a review] Tamai S. **Rinsho Byori** 1999 Feb;47(2):126–31 (22 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

Conceptual development of an information systems framework for improving continuity in epidemiological research. Linger H, et al. **Eur J Epidemiol** 1998 Sep; 14(6):587–93 (16 ref.)

Establishing a population data-based policy unit. Roos NP. **Med Care** 1999 Jun;37(6 Suppl):JS15–26 (29 ref.)

Managing health services: how the Population Health Information System (POPULIS) works for policymakers. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS27–41 (68 ref.)

Harnessing innovative technologies: what can you do with a shoe? Brennan PF. **Nurs Outlook** 1999 May–Jun; 47(3):128–32 (14 ref.)

INFORMED CONSENT

see related
HUMAN EXPERIMENTATION
TRUTH DISCLOSURE

Can acutely ill patients consent to research? Resolving an ethical dilemma with facts [editorial; comment] Fost N. **Acad Emerg Med** 1999 Aug;6(8):772–4 (11 ref.) Comment on: Acad Emerg Med 1999 Aug;6(8):776–80.

Theories of consent [see comments] Alderson P, et al. **BMJ** 1998 Nov 7;317(7168):1313–5 (18 ref.) Comment in: BMJ 1999 Mar 13;318(7185):735–6.

Can children and young people consent to be tested for adult onset genetic disorders? Dickenson DL. **BMJ** 1999 Apr 17;318(7190):1063–5 (27 ref.)

Promoting informed decision making: hormone replacement therapy. Bastian L, et al. **Cancer Treat Res** 1998;97:129–47 (98 ref.)

Bridging the knowledge gap and communicating uncertainties for informed consent in cervical cytology screening; we need unbiased information and a culture change. Anderson CM, et al. **Cytopathology** 1999 Aug; 10(4):221–8 (28 ref.)

The general psychiatrist's evaluation of competency. Miller MC. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):172–6 (18 ref.)

Research in developing countries: taking "benefit" seriously. Glantz LH, et al. **Hastings Cent Rep** 1998 Nov–Dec; 28(6):38–42 (18 ref.)

Making responsible decisions. An interpretive ethic for genetic decisionmaking. White MT. **Hastings Cent Rep** 1999 Jan–Feb;29(1):14–21 (7 ref.)

Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART). Quantification of risks as part of informed consent. Kemmann E. **Hum Reprod** 1998 Jul; 13(7):1777 (3 ref.)

ACOG committee opinion. Sterilization of women, including those with mental disabilities. Number 216, April 1999 (replaces number 63, September 1988, and number 73, September 1989). Committee on Ethics. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jun;65(3):317–20 (3 ref.)

Parental autonomy and consent to treatment. Taylor B. **J Adv Nurs** 1999 Mar;29(3):570–6 (33 ref.)

Phakic intraocular lenses and patient consent [editorial] Rosen ES. **J Cataract Refract Surg** 1999 Feb;25(2):153–5 (10 ref.)

Assessing competency without judging merit. May T. **J Clin Ethics** 1998 Fall;9(3):247–57 (23 ref.)

Organ donation: the family's right to make an informed choice. Beaulieu D. **J Neurosci Nurs** 1999 Feb;31(1):37–42 (25 ref.)

Informed consent in school health research: why, how, and making it easy. Ross JG, et al. **J Sch Health** 1999 May; 69(5):171–6 (14 ref.)

Managing the informed consent process in large multicenter projects. Mark BA, et al. **Nurs Res** 1999 Mar–Apr; 48(2):114–7 (10 ref.)

Holy Grail, sliding scale, and refusal as symptom: competency determinations for medical and psychiatric patients. Farr M. **Pharos** 1999 Spring;62(2):2–9 (15 ref.)

Consent (assent) for research with pediatric patients. Broome ME. **Semin Oncol Nurs** 1999 May;15(2):96–103 (23 ref.)

The ethical foundation of informed consent in clinical research. McCabe MS. **Semin Oncol Nurs** 1999 May; 15(2):76–80 (18 ref.)

Improving understanding of the informed consent process and document. Meade CD. **Semin Oncol Nurs** 1999 May; 15(2):124–37 (135 ref.)

National efforts to improve the informed consent process. Padberg RM, et al. **Semin Oncol Nurs** 1999 May; 15(2):138–44 (16 ref.)

Genetic testing and informed consent. Rieger PT, et al. **Semin Oncol Nurs** 1999 May;15(2):104–15 (48 ref.)

The nurse's role in the informed consent process. Rosse PA, et al. **Semin Oncol Nurs** 1999 May;15(2):116–23 (28 ref.)

Barriers to informed consent. Taylor HA. **Semin Oncol Nurs** 1999 May;15(2):89–95 (35 ref.)

Informed consent for clinical trials: in search of the "best" method. Edwards SJ, et al. **Soc Sci Med** 1998 Dec; 47(11):1825–40 (42 ref.)

Making decisions about life-sustaining medical treatment in patients with dementia. The problem of patient decision-making capacity. Derse AR. **Theor Med Bioeth** 1999 Jan;20(1):55–67 (42 ref.)

Whose consent is it anyway? A poststructuralist framing of the person in medical decision-making. Marta J. **Theor Med Bioeth** 1998 Aug;19(4):353–70 (33 ref.)

[Physician liability and patient information related to blood and plasma product safety] Bock RW. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):501–3 (0 ref.) **(Ger)**

[Informed consent in complementary explorations and invasive procedures] Pascual Torres D. **Gastroenterol Hepatol** 1998 Nov;21(9):464–8 (29 ref.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Waived consent for emergency research. Fost N. **Am J Law Med** 1998;24(2–3):163–83 (144 ref.)

Research with children. Glantz LH. **Am J Law Med** 1998; 24(2–3):213–44 (332 ref.)

Do the dead have interests? Policy issues for research after life. Nelkin D, et al. **Am J Law Med** 1998;24(2–3):261–91 (288 ref.)

Involuntary circumcision: the legal issues. Van Howe RS, et al. **BJU Int** 1999 Jan;83 Suppl 1:63–73 (148 ref.)

Forced cesareans. Ikemoto LC. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):465–8 (17 ref.)

Informed consent in the emergency department. Moskop JC. **Emerg Med Clin North Am** 1999 May;17(2):327–40, ix–x (19 ref.)

The law, adolescents, and the APOE epsilon 4 genotype: a view from Canada. Caulfield TA. **Genet Test** 1999; 3(1):107–13 (50 ref.)

The doctrine of informed consent: a tale of two cultures and two legal traditions. Walter P. **Issues Law Med** 1999 Spring; 14(4):357–73 (53 ref.)

Disclosure of operating practices by managed-care organizations to consumers of healthcare: obligations of informed consent. Khanna V, et al. **J Clin Ethics** 1998 Fall; 9(3):291–6 (27 ref.)

The emerging convergence of the doctrine of informed consent and judicial reinterpretation of the Employee Retirement Income Security Act. Blackmon W. **J Leg Med** 1998 Sep;19(3):377–95 (101 ref.)

'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369–75 (4 ref.) Comment in: J Med Ethics 1998 Dec;24(6):363–4.

Informed consent issues in assisted reproduction. Reame N. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):331–8 (31 ref.)

Research based on archived information and samples. Recommendations from the Royal College of Physicians Committee on Ethical Issues in Medicine. **J R Coll Physicians Lond** 1999 May–Jun;33(3):264–6 (15 ref.)

Documentation and informed consent. Weintraub MI. **Neurol Clin** 1999 May;17(2):371–81 (29 ref.)

[Informed well-considered consent ('informed consent'): an end or a means?] Schellings R, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1033–7 (35 ref.) (Eng. Abstr.) **(Dut)**

[Consent: between legality and legitimacy or between "formal" and "informed" consent] Lachaux B, et al. **Encephale** 1998 Nov–Dec;24(6):503–16 (55 ref.) (Eng. Abstr.) **(Fre)**

[Medical care as physical injury from the viewpoint of the law and jurisdiction] Gropp W. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):536–42 (34 ref.) (Eng. Abstr.) **(Ger)**

[Informed consent in cardiology. The Committee on Informed Consent of the Commission on Professional Matters of the Sociedad Española de Cardiologia] de los Reyes López M, et al. **Rev Esp Cardiol** 1998 Oct; 51(10):782–96 (39 ref.) (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Are efforts at expanding the donor pool misdirected? Rayburn BK, et al. **J Heart Lung Transplant** 1998 Oct; 17(10):998–1003 (40 ref.)

INFRARED RAYS

Radiation inducible DNA repair processes in eukaryotes. Eckardt-Schupp F, et al. **Biochimie** 1999 Jan–Feb; 81(1–2):161–71 (102 ref.)

Primary and secondary mechanisms of action of visible to near-IR radiation on cells. Karu T. **J Photochem Photobiol B** 1999 Mar;49(1):1–17 (151 ref.)

ADVERSE EFFECTS

Optical radiation hazards of welding arcs. Tenkate TD. **Rev Environ Health** 1998 Jul–Sep;13(3):131–46 (99 ref.)

DIAGNOSTIC USE

Functional imaging of the brain by infrared radiation (thermoencephaloscopy). Shevelev IA. **Prog Neurobiol** 1998 Oct;56(3):269–305 (198 ref.)

INFRARED SPECTROPHOTOMETRY see **SPECTROPHOTOMETRY, INFRARED**

INFUNDIBULAR NUCLEUS see **ARCUATE NUCLEUS**

INFUSION PUMPS

Intrathecal drug therapy. Nance P, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):385–401, viii–ix (100 ref.)

Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)

INFUSION PUMPS, EXTERNAL see **INFUSION PUMPS**

INFUSION PUMPS, IMPLANTABLE

see related
DRUG IMPLANTS

Therapeutic applications of implantable drug delivery systems. Dash AK, et al. **J Pharmacol Toxicol Methods** 1998 Jul;40(1):1–12 (57 ref.)

PSYCHOLOGY

[Psychological impact of presence of an implantable catheter in patients with serious illnesses] Zivkovic L. **Pathol Biol (Paris)** 1999 Mar;47(3):292–6 (8 ref.) (Eng. Abstr.) **(Fre)**

INFUSION THERAPY, HOME see **HOME INFUSION THERAPY**

INFUSIONS, INTRA-ARTERIAL

[The status of regional long-term chemotherapy in liver metastasis] Lorenz M, et al. **Chirurg** 1999 Feb;70(2):141–53 (74 ref.) (Eng. Abstr.) **(Ger)**

[Locoregional therapy methods] Kubicka S, et al. **Internist (Berl)** 1998 Nov;39(11):1139–47 (49 ref.) **(Ger)**

METHODS

Local delivery in coronary artery disease: an overview for the interventional cardiologist. Chandrasekar B, et al. **Indian Heart J** 1999 Jan–Feb;51(1):21–6 (57 ref.)

INFUSIONS, INTRAVENOUS

see related
IMMUNOGLOBULINS, INTRAVENOUS

ADVERSE EFFECTS

[Venous access in oncology] Lesimple T, et al. **Presse Med** 1998 Oct 31;27(33):1694–701 (30 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

The use of the Port-A-Cath in children with haemophilia--a review. Van Den Berg HM, et al. **Haemophilia** 1998 Jul; 4(4):418–20 (11 ref.)

METHODS

Intravenous infusion techniques: how to do it and why we should do it. Glass PS. **Minerva Anestesiol** 1999 May; 65(5):219–31 (35 ref.)

Intravenous access in infants and children. Stovroff M, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1373–93, viii (47 ref.)

INFUSIONS, PARENTERAL

see related
FLUID THERAPY
HOME INFUSION THERAPY

ADVERSE EFFECTS

[Drug injection method risky for transmission of blood-borne diseases: are we careful enough?] Bravo Portela MJ, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):289–301 (63 ref.) (Eng. Abstr.) **(Spa)**

INFUSIONS, PARENTERAL

METHODS

Subcutaneous infusion or hypodermoclysis: a practical approach. Ferry M, et al. **J Am Geriatr Soc** 1999 Jan; 47(1):93–5 (29 ref.)

INFUSIONS, REGIONAL ARTERIAL see **INFUSIONS, INTRA-ARTERIAL**

INFUSORS see **INFUSION PUMPS**

INGUINAL CANAL

ANATOMY & HISTOLOGY

Transverse subgluteal-ilioinguinal approach to the acetabulum. Amr S. **Microsurgery** 1998;18(7):432–41 (65 ref.)

INGUINAL HERNIA see **HERNIA, INGUINAL**

INHALATION ANESTHETICS see **ANESTHETICS, INHALATION**

INHALATION BURNS see **BURNS, INHALATION**

INHALATION DEVICES see **NEBULIZERS AND VAPORIZERS**

INHALATION DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

INHALATION EXPOSURE

Experimental approaches for studies of particulate matter: the case for stronger consideration of dosimetric and exposure issues [editorial] Everitt J. **Exp Lung Res** 1998 Nov–Dec;24(6):705–7 (4 ref.)

[Effects of iron-containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27–37 (123 ref.) **(Rus)**

ADVERSE EFFECTS

All but quiet on the particulate front [editorial; comment] Brunekreef B. **Am J Respir Crit Care Med** 1999 Feb; 159(2):354–6 (16 ref.) Comment on: Am J Respir Crit Care Med 1999 Feb;159(2):365–72. Comment on: Am J Respir Crit Care Med 1999 Feb;159(2):373–82.

Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. Andersen ME, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):161–71 (51 ref.)

[Occupational and environmental bronchial asthma] Baur X. **Internist (Berl)** 1999 Aug;40(8):844–8 (18 ref.) **(Ger)**

INHALATION INJURY, SMOKE see **SMOKE INHALATION INJURY**

INHALATION OF DRUGS see **ADMINISTRATION, INHALATION**

INHALATION PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

INHALATION THERAPY see **RESPIRATORY THERAPY**

INHALATORS see **NEBULIZERS AND VAPORIZERS**

INHALERS see **NEBULIZERS AND VAPORIZERS**

INHALING see **ASPIRATION**

INHIBIN

BIOSYNTHESIS

Advance in the study of inhibin, activin and follistatin production in pregnant women. Qu J, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):141–8 (88 ref.)

BLOOD

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837–57, vi (77 ref.)

Endocrine analytes in multiple-marker screening. Lambert-Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963–81, vii (95 ref.)

METABOLISM

Inhibins: paracrine and endocrine effects in female reproductive function. Petraglia F, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):241–7 (53 ref.)

Hope, hypothesis, and the inhibin receptor. Does specific inhibin binding suggest there is a specific inhibin receptor? [editorial; comment] Woodruff TK. **Endocrinology** 1999 Jan;140(1):3–5 (16 ref.) Comment on: Endocrinology 1999 Jan;140(1):6–12.

Inhibins, activins and follistatins: a review of complex regulators of the reproductive system. Renier MA, et al. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):129–35 (49 ref.)

Activin/follistatin and atherosclerosis--a review. Kozaki K, et al. **J Atheroscler Thromb** 1998;5(1):36–40 (41 ref.)

Inhibin and reproductive aging in women. Soules MR, et al. **Maturitas** 1998 Oct 12;30(2):193–204 (16 ref.)

PHYSIOLOGY

Cells' perception of position in a concentration gradient. Gurdon JB, et al. **Cell** 1998 Oct 16;95(2):159–62 (21 ref.)

Activin: a novel player in tissue repair processes. Hübner G, et al. **Histol Histopathol** 1999 Jan;14(1):295–304 (61 ref.)

Inhibins and activins in human ovulation, conception and pregnancy. Lockwood GM, et al. **Hum Reprod Update** 1998 May–Jun;4(3):284–95 (111 ref.)

Role of activin and other peptide growth factors in body patterning in the early amphibian embryo. Asashima M, et al. **Int Rev Cytol** 1999;191:1–52 (171 ref.)

Activin A and follistatin: their role in the acute phase reaction and inflammation. de Kretser DM, et al. **J Endocrinol** 1999 May;161(2):195–8 (29 ref.)

Novel cardiovascular actions of the activins. Molloy CJ, et al. **J Endocrinol** 1999 May;161(2):179–85 (52 ref.)

A novel role of activin in inflammation and repair. Munz B, et al. **J Endocrinol** 1999 May;161(2):187–93 (34 ref.)

Mechanisms of protein feedback on gonadotropin secretion. de Kretser DM, et al. **J Reprod Immunol** 1998 Aug; 39(1–2):1–12 (65 ref.)

Activin as a morphogen in Xenopus mesoderm induction. McDowell N, et al. **Semin Cell Dev Biol** 1999 Jun; 10(3):311–7 (39 ref.)

INHIBITION (PSYCHOLOGY)

Inhibitory motor control in stop paradigms: review and reinterpretation of neural mechanisms. Band GP, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):179–211 (104 ref.)

Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Knight RT, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):159–78 (115 ref.)

Varieties of inhibition: manifestations in cognition, event-related potentials and aging. Kok A. **Acta Psychol (Amst)** 1999 Apr;101(2–3):129–58 (138 ref.)

Alcohol and disinhibition. Källmén H, et al. **Eur Addict Res** 1998 Dec;4(4):150–62 (176 ref.)

The antisaccade: a review of basic research and clinical studies. Everling S, et al. **Neuropsychologia** 1998 Sep; 36(9):885–99 (133 ref.)

[Effects of antidepressants on symptoms, of inhibition] de Carvalho W. **Encephale** 1998 Sep–Oct;24(5):456–61 (7 ref.) **(Fre)**

INHIBITION, NEURAL see **NEURAL INHIBITION**

INHIBITORY CONCENTRATION 50

see related
MICROBIAL SENSITIVITY TESTS

INIA see **DOLPHINS**

INIIDAE see **DOLPHINS**

INJECTIONS

Is there a future for spermatid injections? Vanderzwalmen P, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:71–84 (48 ref.)

[Amnioinfusion or not during labor? Better documentation and more trials can answer the question] Wallin G. **Lakartidningen** 1999 Mar 3;96(9):1017–9 (30 ref.) (Eng. Abstr.) **(Swe)**

INJECTIONS, EPIDURAL

see related
ANESTHESIA, EPIDURAL

ADVERSE EFFECTS

Pneumocephalus following inadvertent intrathecal puncture during epidural anesthesia: a case report and review of the literature. Sherer DM, et al. **J Matern Fetal Med** 1999 May–Jun;8(3):138–40 (16 ref.)

Mycobacterium fortuitum meningitis associated with an epidural catheter: case report and a review of the literature. Madaras-Kelly KJ, et al. **Pharmacotherapy** 1999 May; 19(5):661–6 (26 ref.)

INJECTIONS, INTRAMUSCULAR

ADVERSE EFFECTS

[Intramuscular injections in Sub-saharan African children, apropos of a frequently misunderstood pathology: the complications related to intramuscular quinine injections] Barennes H. **Bull Soc Pathol Exot** 1999 Feb;92(1):33–7 (43 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Carruthers A, et al. **Dermatol Surg** 1998 Nov;24(11):1189–94 (11 ref.)

Electromyographic guidance in injecting botulinum toxin. Klein AW, et al. **Dermatol Surg** 1998 Nov;24(11):1184–6 (10 ref.)

INJECTIONS, INTRASPINAL see **INJECTIONS, SPINAL**

INJECTIONS, INTRATHECAL see **INJECTIONS, SPINAL**

INJECTIONS, INTRAVENOUS

ADVERSE EFFECTS

[Venous access in oncology] Lesimple T, et al. **Presse Med** 1998 Oct 31;27(33):1694–701 (30 ref.) (Eng. Abstr.) **(Fre)**

[Drug injection method risky for transmission of blood-borne diseases: are we careful enough?] Bravo Portela MJ, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):289–301 (63 ref.) (Eng. Abstr.) **(Spa)**

INJECTIONS, SPINAL

see related
ANESTHESIA, EPIDURAL
ANESTHESIA, SPINAL

The neurotoxicity of drugs given intrathecally (spinal). Hodgson PS, et al. **Anesth Analg** 1999 Apr;88(4):797–809 (83 ref.)

Practical issues when using neuraxial infusion. Krames ES. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):37–44 (28 ref.)

INSTRUMENTATION

Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)

INJECTIONS, SUBCUTANEOUS

METHODS

Subcutaneous infusion or hypodermoclysis: a practical approach. Ferry M, et al. **J Am Geriatr Soc** 1999 Jan; 47(1):93–5 (29 ref.)

INJURIES see **WOUNDS AND INJURIES**

INJURIES, MULTIPLE see **MULTIPLE TRAUMA**

INJURIES, NONPENETRATING see **WOUNDS, NONPENETRATING**

INJURY SEVERITY SCORE

Employment of trauma and injury severity score and a severity characterization of trauma in the outcome evaluation of trauma care and their research advances. Zhu P, et al. **Chin Med J (Engl)** 1998 Feb;111(2):169–73 (22 ref.)

Measures of injury severity in childhood: a critical overview. Beattie TF, et al. **Inj Prev** 1998 Sep;4(3):228–31 (26 ref.)

[How to describe and evaluate the clinical gravity of a head injury in order to define a therapeutic strategy at a given moment?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):27–35 (29 ref.) **(Fre)**

INLAYS

METHODS

The management of endodontically treated teeth using a Computer-Aided Design and Computer-Assisted Manufacturing/Computer-Aided Design and Computer-Integrated Manufacturing system. Foerster JG, et al. **Mil Med** 1999 Jan;164(1):37–40 (21 ref.)

INNATE BEHAVIOR see **INSTINCT**

INNOMINATE ARTERY see **BRACHIOCEPHALIC TRUNK**

INNOVATION DIFFUSION see **DIFFUSION OF INNOVATION**

INOCULATION LYMPHORETICULOSIS see **CAT-SCRATCH DISEASE**

INORGANIC CHEMICALS

[Methods for assay of antibacterial activity of inorganic antibacterial agents] Feng N, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):315–6 (16 ref.) **(Chi)**

CHEMISTRY

Pharmacological applications of inorganic complexes. Bakhtiar R, et al. **Gen Pharmacol** 1999 May;32(5):525–40 (93 ref.)

PHARMACOLOGY

Pharmacological applications of inorganic complexes. Bakhtiar R, et al. **Gen Pharmacol** 1999 May;32(5):525–40 (93 ref.)

INOSINE

GENETICS

Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion. Keller W, et al. **FEBS Lett** 1999 Jun 4;452(1-2):71-6 (44 ref.)

INOSINE PHOSPHORYLASE see **PURINE-NUCLEOSIDE PHOSPHORYLASE**

INOSINIC ACID DEHYDROGENASE see **IMP DEHYDROGENASE**

INOSITOL

ANALYSIS

[Synthesis of inositol-containing glycophospholipids] Stepanov AE, et al. **Bioorg Khim** 1998 Oct;24(10):731-46 (77 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34-49 (78 ref.)

The role of phosphatases in inositol signaling reactions. Majerus PW, et al. **J Biol Chem** 1999 Apr 16; 274(16):10669-72 (57 ref.)

INOSITOL PHOSPHATES

Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells. Wilcox RA, et al. **Methods Mol Biol** 1999;114:193-208 (26 ref.)

ANALYSIS

Measurement of inositol (poly)phosphate formation using [3H]inositol labeling protocols in permeabilized cells. Swigart P, et al. **Methods Mol Biol** 1999;114:165-73 (6 ref.)

METABOLISM

Bridging the GAP in inositol 1,3,4,5-tetrakisphosphate signalling. Cullen PJ. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):35-47 (85 ref.)

The versatility of inositol phosphates as cellular signals. Shears SB. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):49-67 (200 ref.)

Diphosphoinositol polyphosphates: the final frontier for inositide research? Safrany ST, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):945-51 (59 ref.)

Inositol 1,3,4,5-tetrakisphosphate as a second messenger--a special role in neurones? Irvine RF, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):49-57 (50 ref.)

Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Mikoshiba K, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):59-67 (46 ref.)

PHARMACOLOGY

D-myo inositol 1,2,6, triphosphate (alpha-trinositol, pp56): selective antagonist at neuropeptide Y (NPY) Y-receptors or selective inhibitor of phosphatidylinositol cell signaling? Bell D, et al. **Gen Pharmacol** 1998 Nov;31(5):689-96 (79 ref.)

PHYSIOLOGY

[Roles of inositol polyphosphates in the regulation of exocytosis] Ohara-Imaizumi M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1789-93 (17 ref.) **(Jpn)**

INOSITOL PHOSPHOGLYCERIDES see **PHOSPHATIDYLINOSITOLS**

INOSITOL 1,4,5-TRIPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

INOSITOL 1,4,5-TRISPHOSPHATE

Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells. Wilcox RA, et al. **Methods Mol Biol** 1999;114:193-208 (26 ref.)

ANALOGS & DERIVATIVES

New developments in the molecular pharmacology of the myo-inositol 1,4,5-trisphosphate receptor. Wilcox RA, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):467-75 (62 ref.)

ANALYSIS

Measurement of inositol(1,4,5)trisphosphate using a stereospecific radioreceptor mass assay. Smart D. **Methods Mol Biol** 1999;114:175-83 (11 ref.)

Inositol 1,4,5-trisphosphate mass assay. Zhang L. **Methods Mol Biol** 1998;105:77-87 (13 ref.)

METABOLISM

Ins(1,4,5)P3 and cardiac dysfunction. Woodcock EA, et al. **Cardiovasc Res** 1998 Nov;40(2):251-6 (68 ref.)

Type 1 inositol 1,4,5-trisphosphate receptor knock-out mice: their phenotypes and their meaning in neuroscience and clinical practice. Matsumoto M, et al. **J Mol Med** 1999 May;77(5):406-11 (36 ref.)

PHYSIOLOGY

Protein-protein interactions in intracellular Ca2+-release channel function. MacKrill JJ. **Biochem J** 1999 Feb 1;337 (Pt 3):345-61 (220 ref.)

Regulatory and spatial aspects of inositol trisphosphate-mediated calcium signals. Horne JH. **Cell Biochem Biophys** 1999;30(2):267-86 (64 ref.)

Protein kinase C and IP3 in photoresponses of functionally intact rod outer segments: constraints about their role. Jindrová H, et al. **Physiol Res** 1998;47(4):285-90 (39 ref.)

[Role of inositol triphosphate in the formation of the calcium signal in T-lymphocytes] Matyshevskaia OP. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):3-15 (69 ref.) (Eng. Abstr.) **(Rus)**

INOTROPIC AGENTS, POSITIVE CARDIAC see **CARDIOTONIC AGENTS**

INOTROPISM see **MUSCLE CONTRACTION**

INOTROPISM, CARDIAC see **MYOCARDIAL CONTRACTION**

INOVIRUS

CHEMISTRY

Analysis of X-ray diffraction from fibres of Pf1 Inovirus (filamentous bacteriophage) shows that the DNA in the virion is not highly ordered. Welsh LC, et al. **J Mol Biol** 1998 Dec 18;284(5):1265-71 (27 ref.)

INPATIENTS

Diagnosis of thyroid disease in hospitalized patients: a systematic review. Attia J, et al. **Arch Intern Med** 1999 Apr 12;159(7):658-65 (38 ref.)

Optimal management of the patient with an episode of atrial fibrillation in and out of the hospital: acute cardioversion or not? Knight BP, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):425-32 (53 ref.)

The case for inpatient initiation of antiarrhythmic therapy. Myerburg RJ, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):482-7 (23 ref.)

PSYCHOLOGY

Delirium in the hospitalized elderly: nursing assessment and management. Milisen K, et al. **Nurs Clin North Am** 1998 Sep;33(3):417-39 (86 ref.)

INR see **INTERNATIONAL NORMALIZED RATIO**

INSANITY DEFENSE

Empirical research on the insanity defense and attempted reforms: evidence toward informed policy. Borum R, et al. **Law Hum Behav** 1999 Feb;23(1):117-35 (69 ref.)

Empirical research on the insanity defense and attempted reforms: evidence toward informed policy. Borum R, et al. **Law Hum Behav** 1999 Jun;23(3):375-93 (71 ref.)

INSECT BITES AND STINGS

Can mosquitoes transmit AIDS? Bockarie MJ, et al. **P N G Med J** 1996 Sep;39(3):205-7 (6 ref.)

Mass envenomations by honey bees and wasps Vetter RS, et al. **West J Med** 1999 Apr;170(4):223-7 (59 ref.)

COMPLICATIONS

Acute renal failure following multiple wasp stings. Thiruventhiran T, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):214-7 (25 ref.)

[Round Table: Urticaria caused by arthropod bites and stings (excluding Hymenoptera)] Martínez-Molero MI. **Allergol Immunopathol (Madr)** 1999 Mar-Apr;27(2):96-104 (25 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Fire ant attacks on residents in health care facilities: a report of two cases. deShazo RD, et al. **Ann Intern Med** 1999 Sep 21;131(6):424-9 (27 ref.)

IMMUNOLOGY

Fleas, flea allergy, and flea control: a review. Sousa CA. **Dermatol Online J** 1997 Dec;3(2):7 (14 ref.)

INSECT CONTROL

see related
INSECTICIDE RESISTANCE
PEST CONTROL, BIOLOGICAL

Malaria: existing methods of vector control and molecular entomology. Curtis CF, et al. **Br Med Bull** 1998; 54(2):311-25 (61 ref.)

Onchocerciasis and Chagas' disease control: the evolution of control via applied research through changing development scenarios. Molyneux DH, et al. **Br Med Bull** 1998;54(2):327-39 (62 ref.)

The biology and control of phlebotomine sand flies. Killick-Kendrick R. **Clin Dermatol** 1999 May-Jun; 17(3):279-89 (156 ref.)

Insecticide resistance and vector control. Brogdon WG, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):605-13 (75 ref.)

METHODS

Fleas, flea allergy, and flea control: a review. Sousa CA. **Dermatol Online J** 1997 Dec;3(2):7 (14 ref.)

Can anything be done to maintain the effectiveness of pyrethroid-impregnated bednets against malaria vectors? Curtis CF, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29;353(1376):1769-75 (46 ref.)

Tsetse and trypanosomiasis control problems in south-east Uganda: past, present and alternative strategies. Okoth JO. **Schweiz Med Wochenschr** 1999 Aug 10;129(31-32):1091-8 (26 ref.)

INSECT GENES see **GENES, INSECT**

INSECT GROWTH REGULATORS see **JUVENILE HORMONES**

INSECT HORMONES

BIOSYNTHESIS

Control of ecdysteroidogenesis: activation and inhibition of prothoracic gland activity. Gilbert LI, et al. **Invert Neurosci** 1997 Sep-Dec;3(2-3):205-16 (83 ref.)

METABOLISM

Variability of metabolism and function of sterols in insects. Svoboda JA. **Crit Rev Biochem Mol Biol** 1999;34(1):49-57 (56 ref.)

Peptide hormones, steroid hormones, and puffs: mechanisms and models in insect development. Henrich VC, et al. **Vitam Horm** 1999;55:73-125 (178 ref.)

PHYSIOLOGY

New insights into adipokinetic hormone signaling. Vroemen SF, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):7-12 (40 ref.)

INSECT PARVOVIRUSES see **DENSOVIRUS**

INSECT PROTEINS

ANALYSIS

2-D protein extracts from Drosophila melanogaster. Ericsson C. **Methods Mol Biol** 1999;112:35-41 (12 ref.)

BIOSYNTHESIS

Biology of spider silk. Vollrath F. **Int J Biol Macromol** 1999 Mar-Apr;24(2-3):81-8 (33 ref.)

CHEMISTRY

Antimicrobial peptides in insects; structure and function. Bulet P, et al. **Dev Comp Immunol** 1999 Jun-Jul; 23(4-5):329-44 (61 ref.)

Peritrophic matrix proteins. Tellam RL, et al. **Insect Biochem Mol Biol** 1999 Feb;29(2):87-101 (82 ref.)

Biology of spider silk. Vollrath F. **Int J Biol Macromol** 1999 Mar-Apr;24(2-3):81-8 (33 ref.)

GENETICS

Activating inhibitors and inhibiting activators: a day in the life of a fly. Hardin PE. **Curr Opin Neurobiol** 1998 Oct; 8(5):642-7 (46 ref.)

Immune proteins and their gene expression in the silkworm, Bombyx mori. Yamakawa M, et al. **Dev Comp Immunol** 1999 Jun-Jul;23(4-5):281-9 (41 ref.)

Developmental anatomy of the Drosophila brain: neuroanatomy is gene expression. Meinertzhagen IA, et al. **J Comp Neurol** 1998 Dec 7;402(1):1-9 (76 ref.)

Polycomb silencing and the maintenance of stable chromatin states. Pirrotta V. **Results Probl Cell Differ** 1999;25:205-28 (110 ref.)

METABOLISM

Drosophila metamorphosis: the only way is USP? Buszczak M, et al. **Curr Biol** 1998 Dec 3;8(24):R879-82 (24 ref.)

Apoptosis: Ras to the rescue in the fly eye. McNeill H, et al. **Curr Biol** 1999 Mar 11;9(5):R176-9 (16 ref.)

Extracellular modulation of the Hedgehog, Wnt and TGF-beta signalling pathways during embryonic development. Capdevila J, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):427-33 (91 ref.)

Fringe, Notch, and making developmental boundaries. Irvine KD. **Curr Opin Genet Dev** 1999 Aug;9(4):434-41 (69 ref.)

New players and puzzles in the Hedgehog signaling pathway. Johnston RL, et al. **Curr Opin Genet Dev** 1998 Aug; 8(4):450-6 (77 ref.)

A ubiquitin ligase complex essential for the NF-kappaB,

INSECT PROTEINS

Wnt/Wingless, and Hedgehog signaling pathways. Maniatis T. **Genes Dev** 1999 Mar 1;13(5):505–10 (38 ref.)

Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse. Nagano T, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):869–75 (74 ref.)

Novel nitric oxide–liberating heme proteins from the saliva of bloodsucking insects. Walker FA, et al. **Met Ions Biol Syst** 1999;36:621–63 (189 ref.)

p75 neurotrophin receptor as a modulator of survival and death decisions. Casaccia-Bonnefil P, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):217–24 (80 ref.)

Molecular complexity at the synapse: new proteins and multiple isoforms detected in Drosophila. Buchner E. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):159–66 (58 ref.)

PHYSIOLOGY

Hedgehog and Spitz: making a match between photoreceptor axons and their targets. Salecker I, et al. **Cell** 1998 Nov 25;95(5):587–90 (18 ref.)

Multiple functions of the EGF receptor in Drosophila eye development. Domínguez M, et al. **Curr Biol** 1998 Sep 24; 8(19):1039–48 (46 ref.)

Ultrabithorax function in butterfly wings and the evolution of insect wing patterns. Weatherbee SD, et al. **Curr Biol** 1999 Feb 11;9(3):109–15 (32 ref.)

The roles of Sarcophaga defense molecules in immunity and metamorphosis. Natori S, et al. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):317–28 (69 ref.)

The armadillo family of structural proteins. Hatzfeld M. **Int Rev Cytol** 1999;186:179–224 (216 ref.)

Hedgehog and patched in neural development and disease. Goodrich LV, et al. **Neuron** 1998 Dec;21(6):1243–57 (212 ref.)

Cellular memory of transcriptional states by Polycomb-group proteins [see comments] Jacobs JJ, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):227–35 (90 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.

Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444–9 (48 ref.)

[Ca2+ influx mechanisms activated by receptors: capacitative Ca2+ entry and TRP proteins] Mori Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1567–76 (77 ref.) **(Jpn)**

INSECT VECTORS

Insecticide resistance and vector control. Brogdon WG, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):605–13 (75 ref.)

Emerging viral diseases: an Australian perspective. Mackenzie JS. **Emerg Infect Dis** 1999 Jan–Feb;5(1):1–8 (71 ref.)

[Imported Anopheles: in the luggage or from the airplane? A case of severe autochthonous malaria tropica near an airport] Praetorius F, et al. **Dtsch Med Wochenschr** 1999 Aug 27;124(34–35):998–1002 (10 ref.) (Eng. Abstr.) **(Ger)**

[The Phlebotominae (Diptera, Phlebotomidae) as vectors of parasitic and viral diseases from the aspect of biomedical research] MilčevićZ, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):190–5 (42 ref.) **(Scc)**

CLASSIFICATION

[The relationship of the susceptibility of mosquitoes to the causative agents of malaria to their taxonomic position and the geographical origin of the interacting organisms] Rasnitsyn SP. **Parazitologiia** 1998 Nov–Dec;32(6):495–500 (21 ref.) (Eng. Abstr.) **(Rus)**

PARASITOLOGY

The impact of Mectizan on the transmission of onchocerciasis. Boatin BA, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S46–60 (43 ref.)

The biology and control of phlebotomine sand flies. Killick-Kendrick R. **Clin Dermatol** 1999 May–Jun; 17(3):279–89 (156 ref.)

A historical review of the F-1 strain of Anopheles freeborni as a host and vector for studies of malaria. Collins WE, et al. **J Am Mosq Control Assoc** 1999 Jun;15(2):117–27 (165 ref.)

Periodic infectivity of Plasmodium gametocytes to the vector. A review. Gautret P, et al. **Parasite** 1999 Jun; 6(2):103–11 (69 ref.)

[The relationship of the susceptibility of mosquitoes to the causative agents of malaria to their taxonomic position and the geographical origin of the interacting organisms] Rasnitsyn SP. **Parazitologiia** 1998 Nov–Dec;32(6):495–500 (21 ref.) (Eng. Abstr.) **(Rus)**

INSECT VIRUSES

GENETICS

[Do viruses participate in the origin of group outbursts of gene mutations occurring in natural Drosophila populations?] Gershenzon SM. **Tsitol Genet** 1998 Sep–Oct; 32(5):94–102 (26 ref.) (Eng. Abstr.) **(Rus)**

INSECTICIDE RESISTANCE

Insect cytochromes P450: diversity, insecticide resistance and tolerance to plant toxins. Scott JG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):147–55 (74 ref.)

Insecticide resistance and vector control. Brogdon WG, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):605–13 (75 ref.)

Influence of permethrin, diazinon and ivermectin treatments on insecticide resistance in the horn fly (Diptera: Muscidae). Byford RL, et al. **Int J Parasitol** 1999 Jan; 29(1):125–35; discussion 137–8 (38 ref.)

Cytochrome P450 catalysed insecticide metaboiism: chemical and theoretical models. Keserü GM. **Sci Prog** 1998;81 (Pt 3):245–72 (43 ref.)

GENETICS

Cytochrome P450 monooxygenases and insecticide resistance in insects. Bergé JB, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1701–5 (45 ref.)

Why are there so few resistance-associated mutations in insecticide target genes? ffrench-Constant RH, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1685–93 (61 ref.)

The role of gene splicing, gene amplification and regulation in mosquito insecticide resistance. Hemingway J, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1695–9 (29 ref.)

Predicting insecticide resistance: mutagenesis, selection and response. McKenzie JA, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1729–34 (60 ref.)

PHYSIOLOGY

Cytochrome P450 monooxygenases and insecticide resistance in insects. Bergé JB, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1701–5 (45 ref.)

INSECTICIDES

see related
CHOLINESTERASE INHIBITORS

Evidence based case report: treatment for head lice [see comments] Dawes M, et al. **BMJ** 1999 Feb 6; 318(7180):385–6 (9 ref.) Comment in: BMJ 1999 May 22;318(7195):1422.

Factors influencing the larvicidal activity of bacterial toxin. Chowanadisai L. **Indian J Malariol** 1998 Jun;35(2):117–22 (31 ref.)

ADMINISTRATION & DOSAGE

A critical review of ultralow-volume aerosols of insecticide applied with vehicle-mounted generators for adult mosquito control. Mount GA. **J Am Mosq Control Assoc** 1998 Sep;14(3):305–34 (166 ref.)

ADVERSE EFFECTS

Immune parameters in biological monitoring of pesticide exposure: current knowledge and perspectives. Colosio C, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):285–95 (28 ref.)

PHARMACOKINETICS

Cytochrome P450 catalysed insecticide metabolism: chemical and theoretical models. Keserü GM. **Sci Prog** 1998;81 (Pt 3):245–72 (43 ref.)

PHARMACOLOGY

The insect voltage-gated sodium channel as target of insecticides. Zlotkin E. **Annu Rev Entomol** 1999;44:429–55 (73 ref.)

Influence of permethrin, diazinon and ivermectin treatments on insecticide resistance in the horn fly (Diptera: Muscidae). Byford RL, et al. **Int J Parasitol** 1999 Jan; 29(1):125–35; discussion 137–8 (38 ref.)

POISONING

[Exogenous lipoid pneumonia induced by inhalation of insecticide] Yokohori N, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):583–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Diagnosing and treating scabies. Burgess IF. **Practitioner** 1997 Dec;241(1581):739–43 (9 ref.)

A review of the use of a controlled-release formulation of ivermectin in the treatment and prophylaxis of Psoroptes ovis infestations in sheep. Forbes AB, et al. **Vet Parasitol** 1999 Jun 30;83(3–4):319–26 (21 ref.)

TOXICITY

Ion channels as targets for insecticides. Narahashi T, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):581–90 (34 ref.)

Neuroendocrine and reproductive effects of contemporary-use pesticides. Cooper RL, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):26–36 (44 ref.)

INSECTICIDES, BOTANICAL

ADVERSE EFFECTS

Urticaria due to airborne permethrin exposure. Fuortes L. **Vet Hum Toxicol** 1999 Apr;41(2):92–3 (16 ref.)

INSECTICIDES, CARBAMATE

STANDARDS

Regulating and assessing risks of cholinesterase-inhibiting pesticides: divergent approaches and interpretations. Carlock LL, et al. **J Toxicol Environ Health B Crit Rev** 1999 Apr–Jun; 2(2):105–60 (69 ref.)

TOXICITY

Neuroendocrine and reproductive effects of contemporary-use pesticides. Cooper RL, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):26–36 (44 ref.)

INSECTICIDES, ORGANOCHLORINE

ADVERSE EFFECTS

Contact pemphigus induced by dihydrodiphenyltrichlorethane. Tsankov N, et al. **Eur J Dermatol** 1998 Sep;3(6):442–3 (13 ref.)

Pesticide exposure: human cancers on the horizon. Jaga K, et al. **Rev Environ Health** 1999 Jan–Mar;14(1):39–50 (47 ref.)

[Effects of environmental chemicals transferred through human milk on the development of breast-feeding infants] Lu R, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):51–2 (10 ref.) **(Chi)**

[Neuropathy induced by insecticides] Konno N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):623–7 (15 ref.) **(Jpn)**

[Delayed effects of organochlorine pesticides in man] Nunes MV, et al. **Rev Saude Publica** 1998 Aug;32(4):372–82 (76 ref.) (Eng. Abstr.) **(Por)**

ANALYSIS

Measuring exposure of organochlorinated pesticides. Azevedo e Silva Mendonça G. **Cad Saude Publica** 1998; 14 Suppl 3:177–9 (13 ref.)

Organochlorine residues and elemental contaminants in U.S. freshwater fish, 1976–1986: National Contaminant Biomonitoring Program. Schmitt CJ, et al. **Rev Environ Contam Toxicol** 1999;162:43–104 (160 ref.)

ECONOMICS

Exporting DBCP and other banned pesticides: consideration of ethical issues. Lowry LK, et al. **Int J Occup Environ Health** 1999 Apr–Jun;5(2):135–41 (14 ref.)

TOXICITY

Breast Milk Monitoring Programs (BMMPs): world-wide early warning system for polyhalogenated POPs and for targeting studies in children's environmental health [comment] Hooper K. **Environ Health Perspect** 1999 Jun; 107(6):429–30 (14 ref.) Comment on: Environ Health Perspect 1999 Jun;107(6):447–57. Comment on: Environ Health Perspect 1999 Jun;107(6):459–62.

The toxicology of 1,2-dibromo-3-chloropropane (DBCP): a brief review. Teitelbaum DT. **Int J Occup Environ Health** 1999 Apr–Jun;5(2):122–6 (27 ref.)

Polychlorocycloalkane insecticide action on GABA-and glycine-dependent chloride flux. Suñol C, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):573–80 (54 ref.)

An evaluation of the carcinogenic hazard of 1,4-dichlorobenzene based on internationally recognized criteria. Barter JA, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):64–79 (78 ref.)

INSECTICIDES, ORGANOPHOSPHATE

see related
CHOLINESTERASE INHIBITORS

ADVERSE EFFECTS

[Neuropathy induced by insecticides] Konno N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):623–7 (15 ref.) **(Jpn)**

STANDARDS

Regulating and assessing risks of cholinesterase-inhibiting pesticides: divergent approaches and interpretations. Carlock LL, et al. **J Toxicol Environ Health B Crit Rev** 1999 Apr–Jun; 2(2):105–60 (69 ref.)

TOXICITY

Organophosphorus pesticides: do they all have the same mechanism of toxicity? Pope CN.

J Toxicol Environ Health B Crit Rev 1999 Apr-Jun; 2(2):161-81 (66 ref.)
Biochemical and molecular neurotoxicology: relevance to biomarker development, neurotoxicity testing and risk assessment. Costa LG. **Toxicol Lett** 1998 Dec 28; 102-103:417-21 (19 ref.)
Experimental and clinical toxicology of anticholinesterase agents. Moretto A. **Toxicol Lett** 1998 Dec 28; 102-103:509-13 (34 ref.)

INSECTICIDES, ORGANOPHOSPHATE, ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

INSECTICIDES, ORGANOTHIOPHOSPHATE

BLOOD

Human red blood cell acetylcholinesterase inhibition as the appropriate and conservative surrogate endpoint for establishing chlorpyrifos reference dose. Chen WL, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):15-22 (36 ref.)

POISONING

Hemorrhagic panesophagitis after acute organophosphorus poisoning. Koga H, et al. **Gastrointest Endosc** 1999 May; 49(5):642-3 (13 ref.)
Chlorpyrifos: a ten-year US poison center exposure experience. Kingston RL, et al. **Vet Hum Toxicol** 1999 Apr; 41(2):87-92 (16 ref.)
[Acute methyl parathion poisoning with extrapyramidal manifestations not previously reported] Montoya-Cabrera MA, et al. **Gac Med Mex** 1999 Jan-Feb;135(1):79-82 (27 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Determination of the reference dose for chlorpyrifos: proceedings of an expert panel. Clegg DJ, et al. **J Toxicol Environ Health B Crit Rev** 1999 Jul-Sep; 2(3):211-55 (64 ref.)
Expert panel report of human studies on chlorpyrifos and/or other organophosphate exposures. Clegg DJ, et al. **J Toxicol Environ Health B Crit Rev** 1999 Jul-Sep; 2(3):257-79 (66 ref.)
The legislation of toxicologic safety factors: the Food Quality Protection Act with chlorpyrifos as a test case. Schardein JL, et al. **Reprod Toxicol** 1999 Jan-Feb;13(1):1-14 (45 ref.)
How to determine if an additional 10x safety factor is needed for chemicals: a case study with chlorpyrifos. Gibson JE, et al. **Toxicol Sci** 1999 Mar;48(1):117-22 (42 ref.)

INSECTICIDES, ORGANOTHIOPHOSPHATE, ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

INSECTS

Insects as food: why the western attitude is important. DeFoliart GR. **Annu Rev Entomol** 1999;44:21-50 (134 ref.)
Insect pheromones--an overview of biosynthesis and endocrine regulation. Tillman JA, et al. **Insect Biochem Mol Biol** 1999 Jun;29(6):481-514 (372 ref.)

ANATOMY & HISTOLOGY

The ovaries of Mecoptera: basic similarities and one exception to the rule. Biliński SM, et al. **Folia Histochem Cytobiol** 1998;36(4):189-95 (33 ref.)
Ovaries, oogenesis and insect phylogeny. Introductory remarks. Biliński SM. **Folia Histochem Cytobiol** 1998; 36(4):143-5 (27 ref.)

CHEMISTRY

Peritrophic matrix proteins. Tellam RL, et al. **Insect Biochem Mol Biol** 1999 Feb;29(2):87-101 (82 ref.)
Histamine in the brain of insects: a review. Nässel DR. **Microsc Res Tech** 1999 Jan 15-Feb 1;44(2-3):121-36 (64 ref.)

DRUG EFFECTS

The insect voltage-gated sodium channel as target of insecticides. Zlotkin E. **Annu Rev Entomol** 1999;44:429-55 (73 ref.)

EMBRYOLOGY

Comparison of early nerve cord development in insects and vertebrates. Arendt D, et al. **Development** 1999 Jun; 126(11):2309-25 (266 ref.)

ENZYMOLOGY

Insect P450 enzymes. Feyereisen R. **Annu Rev Entomol** 1999; 44:507-33 (162 ref.)
Insect cytochromes P450: diversity, insecticide resistance and tolerance to plant toxins. Scott JG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):147-55 (74 ref.)
Cytochrome P450 monooxygenases and insecticide resistance in insects. Bergé JB, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1701-5 (45 ref.)

GENETICS

Cytochrome P450 monooxygenases and insecticide resistance in insects. Bergé JB, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1701-5 (45 ref.)
Imprinting and paternal genome elimination in insects. Herrick G, et al. **Results Probl Cell Differ** 1999;25:41-71 (150 ref.)

GROWTH & DEVELOPMENT

The developmental basis for allometry in insects. Stern DL, et al. **Development** 1999 Mar;126(6):1091-101 (130 ref.)

IMMUNOLOGY

Antimicrobial peptides in mammalian and insect host defence. Lehrer RI, et al. **Curr Opin Immunol** 1999 Feb;11(1):23-7 (54 ref.)
Antimicrobial peptides in insects; structure and function. Bulet P, et al. **Dev Comp Immunol** 1999 Jun-Jul; 23(4-5):329-44 (61 ref.)
Insect immunity: evolutionary roots of the mammalian innate immune system. Vilmos P, et al. **Immunol Lett** 1998 Jun; 62(2):59-66 (213 ref.)
[Insect lectins and defense mechanism] Natori S. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2435-41 (28 ref.) **(Jpn)**

METABOLISM

The insect voltage-gated sodium channel as target of insecticides. Zlotkin E. **Annu Rev Entomol** 1999;44:429-55 (73 ref.)
Variability of metabolism and function of sterols in insects. Svoboda JA. **Crit Rev Biochem Mol Biol** 1999;34(1):49-57 (56 ref.)
[Insects as a possible source of new antibiotics. Products produced by insects and their practical importance] Stavri N. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul-Sep; 43(3):117-21 (6 ref.) **(Rum)**

PHYSIOLOGY

Crustacean-insect relationships: the use of brain characters to derive phylogeny amongst segmented invertebrates. Strausfeld NJ. **Brain Behav Evol** 1998;52(4-5):186-206 (102 ref.)
Organization of the circadian system in insects. Helfrich-Förster C, et al. **Chronobiol Int** 1998 Nov; 15(6):567-94 (151 ref.)
Feeling the vibes: chordotonal mechanisms in insect hearing. Eberl DF. **Curr Opin Neurobiol** 1999 Aug;9(4):389-93 (40 ref.)
Discrimination of pheromonal cues in fish: emerging parallels with insects. Sorensen PW, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):458-67 (61 ref.)
Plant-insect interactions. Stotz HU, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):268-72 (50 ref.)
Ovaries, oogenesis and insect phylogeny. Introductory remarks. Biliński SM. **Folia Histochem Cytobiol** 1998; 36(4):143-5 (27 ref.)
Strength of synaptic transmission at neuromuscular junctions of crustaceans and insects in relation to calcium entry. Atwood HL, et al. **Invert Neurosci** 1997 Sep-Dec; 3(2-3):81-7 (39 ref.)
Control of ecdysteroidogenesis: activation and inhibition of prothoracic gland activity. Gilbert LI, et al. **Invert Neurosci** 1997 Sep-Dec;3(2-3):205-16 (83 ref.)
Elements of the olfactory signaling pathways in insect antennae. Krieger J, et al. **Invert Neurosci** 1997 Sep-Dec; 3(2-3):137-44 (50 ref.)
Insect circadian rhythms and photoperiodism. Saunders DS. **Invert Neurosci** 1997 Sep-Dec;3(2-3):155-64 (55 ref.)
Photoperiodic time measurement in insects: a review of clock models. Vaz Nunes M, et al. **J Biol Rhythms** 1999 Apr; 14(2):84-104 (144 ref.)
What do the mushroom bodies do for the insect brain? an introduction. Heisenberg M. **Learn Mem** 1998 May-Jun; 5(1-2):1-10 (101 ref.)
NO news from insect brains. Bicker G. **Trends Neurosci** 1998 Aug;21(8):349-55 (68 ref.)
Motion detection in insect orientation and navigation. Srinivasan MV, et al. **Vision Res** 1999 Aug;39(16):2749-66 (73 ref.)

VIROLOGY

[Genome organization of insect picorna-like viruses] Bando H, et al. **Uirusu** 1998 Jun;48(1):89-96 (41 ref.) **(Jpn)**
[The baculoviruses] Hashimoto Y, et al. **Uirusu** 1998 Jun; 48(1):51-7 (68 ref.) **(Jpn)**
[Present status and prospect of entomovirus research] Hukuhara T. **Uirusu** 1998 Jun;48(1):45-50 (21 ref.) **(Jpn)**
[Entomopoxviruses] Hukuhara T. **Uirusu** 1998 Jun; 48(1):59-65 (40 ref.) **(Jpn)**
[Densovirus] Kobayashi M, et al. **Uirusu** 1998 Jun;48(1):73-80 (65 ref.) **(Jpn)**
[Cytoplasmic polyhedrosis virus and polyhedrin] Mori H, et al. **Uirusu** 1998 Jun;48(1):81-8 (42 ref.) **(Jpn)**

INSEMINATION, ARTIFICIAL

see related
FERTILIZATION IN VITRO
SEMEN PRESERVATION

Recent advances in assisted reproductive technologies. Khamsi F, et al. **Endocrine** 1998 Aug;9(1):15-25 (76 ref.)
How useful is Leuven personalism in the world of bioethics? The test case of artificial insemination. de Wachter MA. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):227-33 (35 ref.)
Clinical application of new micromanipulative technologies to treat the male. Devroey P. **Hum Reprod** 1998 Jun;13 Suppl 3:112-22; discussion 123-6 (44 ref.)
New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127-36; discussion 145-7 (12 ref.)
The emergence of specialized procedures for the acquisition, processing, and cryopreservation of epididymal and testicular sperm in connection with intracytoplasmic sperm injection. Marmar JL. **J Androl** 1998 Sep-Oct;19(5):517-26 (106 ref.)
Secrecy, anonymity, and deception in donor insemination: a genetic, psycho-social and ethical critique. Landau R. **Soc Work Health Care** 1998;28(1):75-89 (19 ref.)
[Severe male infertility. Genetic investigation and counseling prior to intracytoplasmic sperm injection] Mikkelsen L. **Ugeskr Laeger** 1999 Apr 19;161(16):2348-51 (19 ref.) (Eng. Abstr.) **(Dan)**

VETERINARY

Deep uterine insemination of cattle: a fruitful way forward with smaller numbers of spermatozoa. Hunter RH, et al. **Acta Vet Scand** 1998;39(2):149-63 (64 ref.)

INSEMINATION, ARTIFICIAL, HOMOLOGOUS

METHODS

[Therapeutic strategies in azoospermia: management] Ohl J, et al. **Contracept Fertil Sex** 1998 Sep;26(9):656-62 (52 ref.) (Eng. Abstr.) **(Fre)**
[Etiology and treatment of sterility due to azoospermia] Martin-du Pan RC, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):453-7 (28 ref.) (Eng. Abstr.) **(Fre)**

INSEMINATION, ARTIFICIAL, HUSBAND see **INSEMINATION, ARTIFICIAL, HOMOLOGOUS**

INSERTION SEQUENCE ELEMENTS see **DNA TRANSPOSABLE ELEMENTS**

INSERTIONAL ACTIVATION see **MUTAGENESIS, INSERTIONAL**

INSERTIONAL MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

INSERVICE TRAINING

Staff education and training for ultrasound-assisted lipoplasty. Mustoe TA. **Clin Plast Surg** 1999 Apr; 26(2):295-8; ix (3 ref.)

METHODS

Training and supervision in effective cross-cultural mental health services. Bhui K, et al. **Hosp Med** 1998 Nov; 59(11):861-5 (20 ref.)
Mentorship in nursing: a literature review. Andrews M, et al. **J Adv Nurs** 1999 Jan;29(1):201-7 (52 ref.)

ORGANIZATION & ADMINISTRATION

A multidimensional evaluation of fire fighter training for hazardous materials response: first results from the IAFF Program. Cohen A. **Am J Ind Med** 1998 Oct;34(4):331-41 (12 ref.)
An interactive approach to training teams and developing programs. Corrigan PW, et al. **New Dir Ment Health Serv** 1998 Fall;(79):3-12 (34 ref.)
A systems approach to developing staff training. Giffort DW. **New Dir Ment Health Serv** 1998 Fall;(79):25-33 (23 ref.)
Training professionals for rehabilitation teams. Lefley HP. **New Dir Ment Health Serv** 1998 Fall;(79):13-23 (22 ref.)

TRENDS

[Problem orientation in social medicine--participation in social medicine] Rásky E, et al. **Gesundheitswesen** 1999 May;61(5):252-4 (7 ref.) (Eng. Abstr.) **(Ger)**

INSOMNIA

Insomnia. Eddy M, et al. **Am Fam Physician** 1999 Apr 1; 59(7):1911-6, 1918 (20 ref.)
[Insomnia] Vein AM, et al. **Klin Med (Mosk)** 1998;76(8):52-5 (15 ref.) **(Rus)**

DIAGNOSIS

Insomnia: assessment and management in primary care. National Heart, Lung, and Blood Institute Working Group

on Insomnia. **Am Fam Physician** 1999 Jun;59(11):3029–38 (36 ref.)
Evaluation and management of insomnia. Meyer TJ. **Hosp Pract (Off Ed)** 1998 Dec 15;33(12):75–8, 83–6 (11 ref.)
Diagnosis and treatment of insomnia. Bonnet MH, et al. **Respir Care Clin N Am** 1999 Sep;5(3):333–48, vii (49 ref.)
[Determinants of insomnia in relatively healthy elderly. A literature review] Beullens J. **Tijdschr Gerontol Geriatr** 1999 Feb;30(1):31–8 (29 ref.) (Eng. Abstr.) **(Dut)**
[Insomnia (editorial) (see comments)] Peraita Adrados MR. **Rev Clin Esp** 1998 Nov;198(11):717–8 (13 ref.) Comment in: Rev Clin Esp 1999 Jun;199(6):408–9. **(Spa)**

DRUG THERAPY

The use of melatonin for the treatment of insomnia. Zisapel N. **Biol Signals Recept** 1999 Jan–Apr;8(1–2):84–9 (51 ref.)
Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Waldhauser F, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):759–72 (72 ref.)
Antidepressant treatment of the depressed patient with insomnia. Thase ME. **J Clin Psychiatry** 1999;60 Suppl 17:28–31; discussion 46–8 (8 ref.)
[Changes in sedative therapy?] Shnädelbach S. **Med Monatsschr Pharm** 1998 Dec;21(12):391–2 (7 ref.) **(Ger)**

ETIOLOGY

[Determinants of insomnia in relatively healthy elderly. A literature review] Beullens J. **Tijdschr Gerontol Geriatr** 1999 Feb;30(1):31–8 (29 ref.) (Eng. Abstr.) **(Dut)**

NURSING

Sleep promotion in adults. Floyd JA. **Annu Rev Nurs Res** 1999;17:27–56 (100 ref.)

PHYSIOPATHOLOGY

[Familial fatal insomnia: a human prion disease which opens the door to a greater understanding of the thalamus] Barriga F, et al. **Rev Med Univ Navarra** 1997 Oct–Dec; 41(4):224–8 (24 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Insomnia: assessment and management in primary care. National Heart, Lung, and Blood Institute Working Group on Insomnia. **Am Fam Physician** 1999 Jun;59(11):3029–38 (36 ref.)
Insomnia in the elderly. Woodward M. **Aust Fam Physician** 1999 Jul;28(7):653–8 (55 ref.)
Evaluation and management of insomnia. Meyer TJ. **Hosp Pract (Off Ed)** 1998 Dec 15;33(12):75–8, 83–6 (11 ref.)
Nonpharmacological treatment of late-life insomnia. Morin CM, et al. **J Psychosom Res** 1999 Feb;46(2):103–16 (64 ref.)
An effective strategy for sleep. Williams A. **Practitioner** 1997 Oct;241(1579):606–10 (5 ref.)
Diagnosis and treatment of insomnia. Bonnet MH, et al. **Respir Care Clin N Am** 1999 Sep;5(3):333–48, vii (49 ref.)
[Treatment of insomnia] Peraita Adrados MR, et al. **Rev Clin Esp** 1999 Feb;199(2):109–13 (41 ref.) **(Spa)**

INSOMNIA, FATAL FAMILIAL see **PRION DISEASES**

1,4,5-INSP3 see **INOSITOL 1,4,5-TRISPHOSPHATE**

INSPIRATORY CAPACITY

Inspiratory flow rate: more may not be better [editorial; comment] Jubran A. **Crit Care Med** 1999 Apr;27(4):670–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):715–22.

INSPIRATORY POSITIVE-PRESSURE VENTILATION see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

INSTABILITY, JOINT see **JOINT INSTABILITY**

INSTINCT

see related
LIBIDO
Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1–2):90–4 (43 ref.)

INSTITUTES see **ACADEMIES AND INSTITUTES**

INSTITUTIONAL ADHERENCE see **GUIDELINE ADHERENCE**

INSTITUTIONAL ETHICS COMMITTEES see **ETHICS COMMITTEES**

INSTITUTIONAL LIABILITY see **LIABILITY, LEGAL**

INSTITUTIONAL MANAGEMENT TEAMS

Management training in critical care medicine. Kvetan V. **Ann Acad Med Singapore** 1998 May;27(3):444–7 (41 ref.)

INSTITUTIONAL PERSONNEL LICENSURE see **LICENSURE**

INSTITUTIONAL POLICY see **ORGANIZATIONAL POLICY**

INSTITUTIONAL PRACTICE

Organization of hospital-based acute pain management programs. Blau WS, et al. **South Med J** 1999 May; 92(5):465–71 (29 ref.)

INSTITUTIONAL REVIEW BOARD see **PROFESSIONAL STAFF COMMITTEES**

INSTITUTIONAL TAX see **TAXES**

INSTITUTIONALIZATION

see related
DEINSTITUTIONALIZATION
HOSPITALIZATION
Promoting oral health in institutionalised older adults: a nursing perspective. Holmes S. **J R Soc Health** 1998 Jun; 118(3):167–72 (64 ref.)
Patterns of burden in wives who care for husbands with dementia. Winslow BW, et al. **Nurs Clin North Am** 1999 Jun;34(2):275–87 (31 ref.)

INSTRUCTIONAL MODELS see **MODELS, EDUCATIONAL**

INSTRUMENTAL LEARNING see **CONDITIONING, OPERANT**

INSUFFLATION

[Review on the use of CO2 in laparoscopy surgery] Van Glabeke E, et al. **Prog Urol** 1998 Sep;8(4):586–9 (34 ref.) (Eng. Abstr.) **(Fre)**

METHODS

New tools in ventilatory support: high frequency ventilation, nitric oxide, tracheal gas insufflation, non-invasive ventilation. Biarent D. **Pediatr Pulmonol Suppl** 1999; 18:178–81 (25 ref.)

INSUFFLATION ANESTHESIA see **ANESTHESIA, INHALATION**

INSULA OF REIL see **CEREBRAL CORTEX**

INSULIN

see related
HYPERINSULINEMIA
HYPERINSULINISM
PROINSULIN
RECEPTORS, INSULIN
Insulin and polycystic ovary syndrome: a new look at an old subject. Ciampelli M, et al. **Gynecol Endocrinol** 1998 Aug;12(4):277–92 (127 ref.)

ADMINISTRATION & DOSAGE

Individualized insulin therapy in children and adolescents with type 1 diabetes. Becker D. **Acta Paediatr Suppl** 1998 Oct;425:20–4 (15 ref.)
Diabetic ketoacidosis. Brink SJ. **Acta Paediatr Suppl** 1999 Jan;88(427):14–24 (58 ref.)
Hypoglycaemia in children with type 1 diabetes mellitus. Chiarelli F, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):31–4 (17 ref.)
Practical aspects of managing preschool children with type 1 diabetes. Kiess W, et al. **Acta Paediatr Suppl** 1998 Oct; 425:67–71 (38 ref.)
Practical aspects of managing diabetes in adolescents. Mortensen HB. **Acta Paediatr Suppl** 1998 Oct;425:72–6 (27 ref.)
Insulin and type 2 diabetes. Last resort or rational management? Holmwood C, et al. **Aust Fam Physician** 1999 May;28(5):429–35 (13 ref.)
New insulin replacement technologies: overcoming barriers to tight glycemic control. Leslie CA. **Cleve Clin J Med** 1999 May;66(5):293–302 (50 ref.)
Novel methods of insulin delivery: an update. Chetty DJ, et al. **Crit Rev Ther Drug Carrier Syst** 1998;15(6):629–70 (140 ref.)
Recent approaches in insulin delivery. Trehan A, et al. **Drug Dev Ind Pharm** 1998 Jul;24(7):589–97 (83 ref.)
Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Ben-Chetrit E, et al. **J Intern Med** 1998 Aug;244(2):175–8 (11 ref.)
[Step-wise drug therapy in type 2 diabetes mellitus] König K, et al. **Z Arztl Fortbild Qualitatssich** 1998 Sep; 92(7):467–73 (33 ref.) (Eng. Abstr.) **(Ger)**
[Indication of intensive insulin therapy and its practice] Kishikawa H, et al. **Nippon Rinsho** 1999 Mar;57(3):681–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Epidemiology of adverse drug reactions in the elderly by drug class. Beyth RJ, et al. **Drugs Aging** 1999 Mar; 14(3):231–9 (76 ref.)
[Reevaluation of hypoglycemic risk in the course of intensive insulin therapy] Selam JL. **Journ Annu Diabetol Hotel Dieu** 1998;:257–80 (106 ref.) **(Fre)**
[Interaction between converting enzyme inhibitors and hypoglycemic sulfonamides or insulin] Girardin E, et al. **Presse Med** 1998 Nov 28;27(37):1914–23 (48 ref.) (Eng. Abstr.) **(Fre)**
[Insulin sensitivity in NIDDM patients with normo- and microalbuminuria] Trzepióra B, et al. **Wiad Lek** 1998; 51(9–10):435–40 (20 ref.) (Eng. Abstr.) **(Pol)**

ANALOGS & DERIVATIVES

Guidelines for using insulin lispro. Toth EL, et al. **Can Fam Physician** 1998 Nov;44:2444–9 (42 ref.)
Humalog—human kindling? [editorial] MacInnis BJ. **Can J Ophthalmol** 1998 Oct;33(6):303–5 (7 ref.) **(Eng, Fre)**
New insulin replacement technologies: overcoming barriers to tight glycemic control. Leslie CA. **Cleve Clin J Med** 1999 May;66(5):293–302 (50 ref.)
Long-acting insulin analogs. Rosskamp RH, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B109–13 (39 ref.)
Insulin aspart. Simpson KL, et al. **Drugs** 1999 May; 57(5):759–65; discussion 766–7 (18 ref.)
Hypoglycemia and insulin analogues: is there a reduction in the incidence? Heinemann L. **J Diabetes Complications** 1999 Mar–Apr;13(2):105–14 (53 ref.)
Insulin lispro—a review. Muzaffer Z, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):212–4 (13 ref.)
[Lispro-insulin analogs in therapy of diabetes (see comments)] Rosenberger JS, et al. **Wien Klin Wochenschr** 1997 Dec 12;109(23):910–8 (29 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1997 Dec 12;109(23):905–6. **(Ger)**
[Rapid-acting insulin analogues] Matsuda A, et al. **Nippon Rinsho** 1999 Mar;57(3):709–18 (20 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Insulin secretion: feed-forward control of insulin biosynthesis? Rutter GA. **Curr Biol** 1999 Jun 17; 9(12):R443–5 (25 ref.)
Prospects for insulin delivery by ex-vivo somatic cell gene therapy. Bailey CJ, et al. **J Mol Med** 1999 Jan;77(1):244–9 (37 ref.)

BLOOD

Epidemiology of insulin resistance and its relation to coronary artery disease. Haffner SM. **Am J Cardiol** 1999 Jul 8;84(1A):11J–14J (28 ref.)
Assays for insulin, proinsulin(s) and C-peptide. Clark PM. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):541–64 (161 ref.)
Nutritional factors adversely influencing the glucose/insulin system. Fields M. **J Am Coll Nutr** 1998 Aug;17(4):317–21 (72 ref.)

DEFICIENCY

Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Ferrannini E. **Endocr Rev** 1998 Aug;19(4):477–90 (160 ref.)

ECONOMICS

[Intensified insulin treatment is cost-effective] Reichard P, et al. **Lakartidningen** 1999 Jan 20;96(3):172–4 (11 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

(Pro)insulin and insulin-like growth factor I complementary expression and roles in early development. Alarcón C, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):13–7 (27 ref.)
Prospects for insulin delivery by ex-vivo somatic cell gene therapy. Bailey CJ, et al. **J Mol Med** 1999 Jan;77(1):244–9 (37 ref.)

HISTORY

Would R.D. Lawrence have been interested in the regulation of insulin secretion from pancreatic beta-cells? Jones PM. **Diabet Med** 1998 Aug;15(8):644–50 (34 ref.)

IMMUNOLOGY

Insulin autoimmune syndrome (IAS, Hirata disease). Uchigata Y, et al. **Ann Med Interne (Paris)** 1999 Apr; 150(3):245–53 (47 ref.)

METABOLISM

Differential regulation of signaling pathways for insulin and insulin-like growth factor I. Lopaczynski W. **Acta Biochim Pol** 1999;46(1):51–60 (52 ref.)
Insulin signaling and glucose transport in insulin resistant skeletal muscle. Special reference to GLUT4 transgenic and GLUT4 knockout mice. Galuska D, et al.

Adv Exp Med Biol 1998;441:73–85 (67 ref.)

Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Hunter SJ, et al. **Am J Med** 1998 Oct;105(4):331–45 (100 ref.)

Genetic engineering in mice: impact on insulin signalling and action. Lamothe B, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):193–204 (107 ref.)

The role of PI 3–kinase in insulin action. Alessi DR, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):151–64 (95 ref.)

GLUT4 trafficking in insulin–sensitive cells. A morphological review. Martin S, et al. **Cell Biochem Biophys** 1999;30(1):89–113 (126 ref.)

What does insulin do to Ras? Goalstone ML, et al. **Cell Signal** 1998 May;10(5):297–301 (43 ref.)

Insulin signalling: metabolic pathways and mechanisms for specificity. Nystrom FH, et al. **Cell Signal** 1999 Aug; 11(8):563–74 (162 ref.)

Insulin–family peptide–receptor interaction at the early stage of vertebrate evolution. Leibush BN, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):57–63 (25 ref.)

Some of my not so favorite things about insulin and insulin–like growth factors in fish. Plisetskaya EM. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):3–11 (78 ref.)

CaM kinase II: a protein kinase with extraordinary talents germane to insulin exocytosis. Easom RA. **Diabetes** 1999 Apr;48(4):675–84 (109 ref.)

Molecular basis of insulin action. Combettes–Souverain M, et al. **Diabetes Metab** 1998 Dec;24(6):477–89 (125 ref.)

Rosiglitazone. Balfour JA, et al. **Drugs** 1999 Jun;57(6):921–30; discussion 931–2 (66 ref.)

Growth factors in preimplantation development: role of insulin and insulin–like growth factors. Heyner S. **Early Pregnancy** 1997 Sep;3(3):153–63 (86 ref.)

Insulin degradation: progress and potential. Duckworth WC, et al. **Endocr Rev** 1998 Oct;19(5):608–24 (237 ref.)

Insulin exposure and unifying aging. Parr T. **Gerontology** 1999 May–Jun;45(3):121–35 (152 ref.)

Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. Virkamäki A, et al. **J Clin Invest** 1999 Apr;103(7):931–43 (186 ref.)

Genetically engineered mice in drug development. Livingston JN. **J Intern Med** 1999 Jun;245(6):627–35 (37 ref.)

Metabolic strategies to predict and improve intrahepatic islet graft function. Luzi L. **J Mol Med** 1999 Jan;77(1):49–56 (46 ref.)

Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Fantus IG, et al. **Mol Cell Biochem** 1998 May;182(1–2):109–19 (89 ref.)

Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus [comment] Shepherd PR, et al. **N Engl J Med** 1999 Jul 22;341(4):248–57 (103 ref.) Comment on: N Engl J Med 1999 Jul 22;341(4):240–6.

The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Cohen P. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1382):485–95 (83 ref.)

[The significance of leptin for the pathogenesis of diabetes mellitus type 2. Direct effects on endocrine pancreas] Seufert J. **Internist (Berl)** 1999 Aug;40(8):894–7 (00 ref.) **(Ger)**

[The role of the endosome in insulin signal transmission (published erratum appears in Postepy Biochem 1999;45(1):4)] Bobeszko M, et al. **Postepy Biochem** 1998; 44(3):263–5 (11 ref.) **(Pol)**

[Insulin–like effect of vanadium compounds] Kiersztan A. **Postepy Biochem** 1998;44(4):275–82 (103 ref.) **(Pol)**

PHARMACOLOGY

Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Cushman SW, et al. **Adv Exp Med Biol** 1998;441:63–71 (74 ref.)

Vascular reactivity. Baron AD. **Am J Cardiol** 1999 Jul 8; 84(1A):25J–27J (7 ref.)

Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin–stimulated glucose metabolism. Vestergaard H. **Dan Med Bull** 1999 Feb;46(1):13–34 (293 ref.)

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Gerich JE. **Endocr Rev** 1998 Aug;19(4):491–503 (161 ref.)

Insulin action in the normal and polycystic ovary. Franks S, et al. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):361–78 (46 ref.)

Molecular mechanisms of insulin action in normal and insulin–resistant states [see comments] Le Marchand–Brustel Y. **Exp Clin Endocrinol Diabetes** 1999; 107(2):126–32 (24 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111–2.

Mechanisms of insulin resistance in non–oxidative glucose metabolism: the role of glycogen synthase. Beck–Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):255–79 (39 ref.)

Central role of the adipocyte in insulin resistance. Bergman RN, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2–4):205–21 (38 ref.)

Insulin regulates expression of metabolic genes through divergent signaling pathways. Hall RK, et al. **J Basic Clin Physiol Pharmacol** 1999;10(2):119–33 (47 ref.)

The role of insulin and other hormones in the regulation of amino acid and protein metabolism in humans. Miers WR, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2–4):235–53 (86 ref.)

Recent progress in insulin signal transduction. Hei YJ. **J Pharmacol Toxicol Methods** 1998 Oct;40(3):123–35 (95 ref.)

Insulin inhibition of glucocorticoid–stimulated gene transcription: requirement for an insulin response element? Pierreux CE, et al. **Mol Cell Endocrinol** 1999 Jan 25; 147(1–2):1–5 (33 ref.)

Insulin action on skeletal muscle protein metabolism during catabolic states. Grizard J, et al. **Reprod Nutr Dev** 1999 Jan–Feb;39(1):61–74 (89 ref.)

[Hypertension and insulin] Kushiro T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):223–9 (18 ref.) **(Jpn)**

[Insulin–like effect of vanadium compounds] Kiersztan A. **Postepy Biochem** 1998;44(4):275–82 (103 ref.) **(Pol)**

PHYSIOLOGY

Vascular reactivity. Baron AD. **Am J Cardiol** 1999 Jul 8; 84(1A):25J–27J (7 ref.)

Insulin signaling in the arterial wall. Hsueh WA, et al. **Am J Cardiol** 1999 Jul 8;84(1A):21J–24J (35 ref.)

Insulin resistance. Whitelaw DC, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):567–83 (205 ref.)

Early steps in insulin action. Dorrestijn J, et al. **Arch Physiol Biochem** 1998 Oct;106(4):269–89 (207 ref.)

Interaction between insulin and AT1 receptor. Relevance for hypertension and arteriosclerosis. Nickenig G, et al. **Basic Res Cardiol** 1998;93 Suppl 2:135–9 (26 ref.)

Insulin, insulin–like growth factor–I (IGF–I) and glucagon: the evolution of their receptors. Navarro I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):137–53 (153 ref.)

From preadipocyte to adipocyte: differentiation–directed signals of insulin from the cell surface to the nucleus. Sorisky A. **Crit Rev Clin Lab Sci** 1999 Feb;36(1):1–34 (159 ref.)

Issues in management: the role of insulin in cardiovascular outcomes. Haffner SM. **Diabetes Metab Rev** 1998 Sep;14 Suppl 1:S51–6 (37 ref.)

PPARgamma, the ultimate thrifty gene. Auwerx J. **Diabetologia** 1999 Sep;42(9):1033–49 (190 ref.)

The direct and indirect effects of insulin on hepatic glucose production in vivo. Cherrington AD, et al. **Diabetologia** 1998 Sep;41(9):987–96 (24 ref.)

The insulin–related ovarian regulatory system in health and disease. Poretsky L, et al. **Endocr Rev** 1999 Aug; 20(4):535–82 (811 ref.)

Aspects of novel sites of regulation of the insulin stimulus–secretion coupling in normal and diabetic pancreatic islets. Sjöholm A. **Endocrine** 1998 Aug;9(1):1–13 (226 ref.)

Insulin action in the polycystic ovary syndrome. Dunaif A. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):341–59 (57 ref.)

Crosstalk between insulin and angiotensin II signalling systems [see comments] Folli F, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):133–9 (21 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111–2.

Insulin signal transduction: possible mechanisms for insulin resistance. Kellerer M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):97–106 (93 ref.)

Insulin–independent glucose transport regulates insulin sensitivity. Ebeling P, et al. **FEBS Lett** 1998 Oct 9; 436(3):301–3 (46 ref.)

Insulin in obstetrics: a main parameter in the management of pregnancy. Ciampelli M, et al. **Hum Reprod Update** 1998 Nov–Dec;4(6):904–14 (133 ref.)

Leptin, polycystic ovaries and polycystic ovary syndrome. Jacobs HS, et al. **Hum Reprod Update** 1999 Mar–Apr; 5(2):166–71 (70 ref.)

Insulin, cation metabolism and insulin resistance. Sowers JR, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):223–33 (65 ref.)

Molecular basis of insulin–stimulated GLUT4 vesicle trafficking. Location! Location! Location! Pessin JE, et al. **J Biol Chem** 1999 Jan 29;274(5):2593–6 (81 ref.)

The insulin signaling pathway. Taha C, et al. **J Membr Biol** 1999 May 1;169(1):1–12 (175 ref.)

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Hattersley AT, et al. **Lancet** 1999 May 22; 353(9166):1789–92 (43 ref.)

The role of brain insulin in the neurophysiology of serious mental disorders: review. Holden RJ. **Med Hypotheses** 1999 Mar;52(3):193–200 (64 ref.)

Insulin signal transduction through protein kinase cascades. Avruch J. **Mol Cell Biochem** 1998 May;182(1–2):31–48 (211 ref.)

Protein–tyrosine phosphatase–1B acts as a negative regulator of insulin signal transduction. Byon JC, et al. **Mol Cell Biochem** 1998 May;182(1–2):101–8 (51 ref.)

Insulin regulation of the Ras activation/inactivation cycle. Ceresa BP, et al. **Mol Cell Biochem** 1998 May;182(1–2):23–9 (79 ref.)

Insulin receptor–associated protein tyrosine phosphatase(s): role in insulin action. Drake PG, et al. **Mol Cell Biochem** 1998 May;182(1–2):79–89 (87 ref.)

Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Fantus IG, et al. **Mol Cell Biochem** 1998 May;182(1–2):109–19 (89 ref.)

Regulation of the insulin signalling pathway by cellular protein–tyrosine phosphatases. Goldstein BJ, et al. **Mol Cell Biochem** 1998 May;182(1–2):91–9 (74 ref.)

Spatial determinants of specificity in insulin action. Mastick CC, et al. **Mol Cell Biochem** 1998 May;182(1–2):65–71 (82 ref.)

Role of binding proteins to IRS–1 in insulin signalling. Ogawa W, et al. **Mol Cell Biochem** 1998 May;182(1–2):13–22 (108 ref.)

Protein phosphatase–1 and insulin action. Ragolia L, et al. **Mol Cell Biochem** 1998 May;182(1–2):49–58 (72 ref.)

Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Srivastava AK, et al. **Mol Cell Biochem** 1998 May;182(1–2):135–41 (65 ref.)

Regulation of the Na+/K+–ATPase by insulin: why and how? Sweeney G, et al. **Mol Cell Biochem** 1998 May; 182(1–2):121–33 (125 ref.)

The IRS–signalling system: a network of docking proteins that mediate insulin action. White MF. **Mol Cell Biochem** 1998 May;182(1–2):3–11 (81 ref.)

Insulin action in skeletal muscle from patients with NIDDM. Zierath JR, et al. **Mol Cell Biochem** 1998 May; 182(1–2):153–60 (65 ref.)

The IRS–signaling system: a network of docking proteins that mediate insulin and cytokine action. White MF. **Recent Prog Horm Res** 1998;53:119–38 (125 ref.)

[Insulin and insulin therapy] Sindelka G. **Cas Lek Cesk** 1999 Jan 18;138(2):35–9 (44 ref.) (Eng. Abstr.) **(Cze)**

SECRETION

Regulation of insulin secretion by nerves and neuropeptides. Ahrén B. **Ann Acad Med Singapore** 1999 Jan;28(1):99–104 (16 ref.)

Trioses and related substances: tools for the study of pancreatic beta–cell function. Best L, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):583–8 (53 ref.)

Glucagon–like peptide–1 (GLP–1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)

Role of mitochondria in metabolism–secretion coupling of insulin release in the pancreatic beta–cell. Maechler P, et al. **Biofactors** 1998;8(3–4):255–62 (48 ref.)

Insulin secretion: feed–forward control of insulin biosynthesis? Rutter GA. **Curr Biol** 1999 Jun 17; 9(12):R443–5 (25 ref.)

Would R.D. Lawrence have been interested in the regulation of insulin secretion from pancreatic beta–cells? Jones PM. **Diabet Med** 1998 Aug;15(8):644–50 (34 ref.)

Does leptin regulate insulin secretion? Poitout V, et al. **Diabetes Metab** 1998 Sep;24(4):321–6 (35 ref.)

Fatty acids, lipotoxicity and insulin secretion. McGarry JD, et al. **Diabetologia** 1999 Feb;42(2):128–38 (84 ref.)

Insulinotropic action of monosaccharide esters: therapeutic perspectives. Malaisse WJ. **Diabetologia** 1999 Mar; 42(3):286–91 (81 ref.)

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Gerich JE. **Endocr Rev** 1998 Aug;19(4):491–503 (161 ref.)

Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic beta–cells. Jones PM, et al. **Endocr Rev** 1998 Aug;19(4):429–61 (361 ref.)

Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Lang J. **Eur J Biochem** 1999 Jan;259(1–2):3–17 (224 ref.)

Repaglinide: a new short–acting insulinotropic agent for the treatment of type 2 diabetes. Owens DR. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:30–7 (39 ref.)

Clonidine–displacing substance and its putative role in control of insulin secretion: a minireview. Chan SL. **Gen Pharmacol** 1998 Oct;31(4):525–9 (53 ref.)

The structure and function of the ATP–sensitive K+ channel in insulin–secreting pancreatic beta–cells. Miki T, et al. **J Mol Endocrinol** 1999 Apr;22(2):113–23 (68 ref.)

Engineering cultured insulin–secreting pancreatic B–cell lines. McClenaghan NH, et al. **J Mol Med** 1999 Jan; 77(1):235–43 (67 ref.)

Ca2+ signaling and the insulin secretory cascade in the pancreatic beta–cell. Niki I. **Jpn J Pharmacol** 1999 Jul; 80(3):191–7 (41 ref.)

Glucose action 'beyond ionic events' in the pancreatic beta cell [published erratum appears in Trends Pharmacol Sci 1999 Mar;20(3):124] Aizawa T, et al. **Trends Pharmacol Sci** 1998 Dec;19(12):496–9 (48 ref.)

[Long–term effects of fatty acids on the secretion and biosynthesis of insulin: consequences for type 2 diabetes] Grill V, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:29–41 (39 ref.) **(Fre)**

[How and why to explore insulin secretion in the non–insulin–dependent diabetic] Vague P, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:193–203 (55 ref.) **(Fre)**

[Role of the NADH shuttle system in glucose–induced insulin secretion] Eto K, et al. **Nippon Rinsho** 1999 Mar; 57(3):503–14 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Paraventriculovagal path of carbohydrate homeostasis

INSULIN

regulation--a perspective biological model in studies on neuroimmunoendocrine interactions] Akmaev IG. **Biull Eksp Biol Med** 1999 Feb;127(2):124–8 (35 ref.) **(Rus)**

THERAPEUTIC USE

Modern insulin therapy in children and adolescents. Dahl-Jørgensen K. **Acta Paediatr Suppl** 1999 Jan; 88(427):25–30 (42 ref.)

Present and future perspectives on children with type 1 diabetes. Kordonouri O, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):43–6 (32 ref.)

Compartmental models for glycaemic prediction and decision-support in clinical diabetes care: promise and reality. Lehmann ED, et al. **Comput Methods Programs Biomed** 1998 May;56(2):193–204 (56 ref.)

Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Berger M, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C71–5 (40 ref.)

How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Bolli GB. **Diabetes Care** 1999 Mar;22 Suppl 2:B43–52 (44 ref.)

Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Boyne MS, et al. **Diabetes Care** 1999 Apr; 22 Suppl 3:C45–53 (95 ref.)

Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Buse JB. **Diabetes Care** 1999 Apr;22 Suppl 3:C65–70 (29 ref.)

Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus. Langer O. **Diabetes Care** 1998 Aug;21 Suppl 2:B91–8 (61 ref.)

Long-acting insulin analogs. Rosskamp RH, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B109–13 (39 ref.)

Treating obese patients with poorly controlled diabetes: confessions of an insulin therapist. Kerr D, et al. **Diabetes Metab Res Rev** 1999 May-Jun;15(3):219–25 (34 ref.)

Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Evans A, et al. **Drug Saf** 1999 Jul;21(1):7–22 (85 ref.)

Feasibility and outcomes of insulin therapy in elderly patients with diabetes mellitus. Saudek CD, et al. **Drugs Aging** 1999 May;14(5):375–85 (51 ref.)

Current therapeutic options in type 2 diabetes. Heine RJ. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:17–20 (43 ref.)

Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study? Lopez-Liuchi JV, et al. **Eur J Endocrinol** 1999 Jan;140(1):4–6 (11 ref.)

Diabetes mellitus and aging. Banerjee S, et al. **J Indian Med Assoc** 1998 May;96(5):147–8, 164 (9 ref.)

[Insulin and insulin therapy] Sindelka G. **Cas Lek Cesk** 1999 Jan 18;138(2):35–9 (44 ref.) (Eng. Abstr.) **(Cze)**

[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications (see comments)] Wolffenbuttel BH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1197–201 (20 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1188–91. **(Dut)**

[Economic impact of intensive insulin therapy in IDDM] Herman WH. **Journ Annu Diabetol Hotel Dieu** 1998;:241–8 (15 ref.) **(Fre)**

[Ultimate treatment of type 2 diabetes: intensive insulin therapy or bariatric surgery? Scheen AJ, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:81–97 (97 ref.) **(Fre)**

[Insulin in the treatment of type 2 diabetes] Meyer L, et al. **Rev Prat** 1999 Jan 1;49(1):51–5 (29 ref.) (Eng. Abstr.) **(Fre)**

INSULIN COMA THERAPY see **CONVULSIVE THERAPY**

INSULIN INFUSION SYSTEMS

Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps. Pinget M, et al. **Horm Metab Res** 1998 Aug;30(8):475–86 (75 ref.)

[Design and development strategy for wearable and implantable artificial endocrine pancreas] Shichiri M, et al. **Nippon Rinsho** 1999 Mar;57(3):719–25 (9 ref.) (Eng. Abstr.) **(Jpn)**

INSULIN-LIKE GROWTH FACTOR I

see related
RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I

ADMINISTRATION & DOSAGE

Can growth hormone counteract the effects of glucocorticoids on protein metabolism? Beaufrère B. **Acta Paediatr Suppl** 1999 Feb;88(428):97–9 (24 ref.)

ANALYSIS

Resistance to growth hormone in children with chronic liver disease. Bucuvalas JC, et al. **Pediatr Transplant** 1997 Aug; 1(1):73–9 (46 ref.)

DEFICIENCY

IGF-I deficiency due to GH receptor deficiency. Rosenbloom AL. **Horm Metab Res** 1999 Feb-Mar; 31(2-3):161–71 (72 ref.)

GENETICS

Human growth disorders: molecular genetics of the growth hormone-insulin-like growth factor I axis. Rotwein P. **Acta Paediatr Suppl** 1999 Feb;88(428):148–51; discussion 152 (32 ref.)

Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Woods KA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):158–62; discussion 163 (13 ref.)

(Pro)insulin and insulin-like growth factor I complementary expression and roles in early development. Alarcón C, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):13–7 (27 ref.)

Evolution of insulin-like growth factor-I (IGF-I) action: in vitro characterization of vertebrate IGF-I proteins. Upton Z, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep;121(1):35–41 (34 ref.)

Post-translational processing of insulin-like growth factors. Duguay SJ. **Horm Metab Res** 1999 Feb-Mar;31(2-3):43–9 (63 ref.)

The role of insulin-like growth factors in small intestinal cell growth and development. MacDonald RS. **Horm Metab Res** 1999 Feb-Mar;31(2-3):103–13 (72 ref.)

Differences between African American and white girls in the insulin-like growth factor-I and the binding proteins: importance of insulin resistance and hyperinsulinemia [editorial; comment] Caprio S. **J Pediatr** 1999 Sep; 135(3):270–1 (13 ref.) Comment on: J Pediatr 1999 Sep;135(3):296–300.

IMMUNOLOGY

Endocrine modulation of physiological responses to catabolic disease. Sartin JL, et al. **Domest Anim Endocrinol** 1998 Sep; 15(5):423–9 (38 ref.)

METABOLISM

Differential regulation of signaling pathways for insulin and insulin-like growth factor I. Lopaczynski W. **Acta Biochim Pol** 1999;46(1):51–60 (52 ref.)

Growth retardation in chronic diseases: possible mechanisms. Underwood LE. **Acta Paediatr Suppl** 1999 Feb; 88(428):93–6 (10 ref.)

Growth hormone and ovarian function. Franks S. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):331–40 (47 ref.)

Acquired growth hormone resistance in adults. Jenkins RC, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):315–29 (73 ref.)

The role of the IGF-I receptor in the growth and transformation of mammalian cells. Baserga R, et al. **Cell Prolif** 1994 Feb;27(2):63–71 (48 ref.)

Insulin-like growth factor-I resistance. Jain S, et al. **Endocr Rev** 1998 Oct;19(5):625–46 (206 ref.)

Insulin-like growth factors in endometrial function. Rutanen EM. **Gynecol Endocrinol** 1998 Dec;12(6):399–406 (45 ref.)

Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Bereket A, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):172–81 (76 ref.)

Cellular actions of insulin-like growth factor binding proteins. Ferry RJ Jr, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):192–202 (148 ref.)

Growth hormone and prostate cancer: guilty by association? Grimberg A, et al. **J Endocrinol Invest** 1999;22(5 Suppl):64–73 (71 ref.)

Determinants of circulating insulin-like growth factor-I. Hall K, et al. **J Endocrinol Invest** 1999;22(5 Suppl):48–57 (58 ref.)

Insulin-like growth factors and cancer. Yu H, et al. **J La State Med Soc** 1999 Apr;151(4):218–23 (53 ref.)

Blood-brain barrier for human growth hormone and insulin-like growth factor-I. Coculescu M. **J Pediatr Endocrinol Metab** 1999 Mar-Apr;12(2):113–24 (82 ref.)

Regulation of insulin-like growth factor-I in starvation and injury. Thissen JP, et al. **Nutr Rev** 1999 Jun;57(6):167–76 (53 ref.)

PHARMACOLOGY

Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. Schini-Kerth VB. **J Endocrinol Invest** 1999;22(5 Suppl):82–8 (38 ref.)

The haematopoietic effects of growth hormone and insulin-like growth factor-I. Merchav S. **J Pediatr Endocrinol Metab** 1998 Nov-Dec;11(6):677–85 (97 ref.)

Growth promotion by insulin-like growth factor I in hypophysectomized and diabetic rats. Zapf J. **Mol Cell Endocrinol** 1998 May 25;140(1-2):143–9 (25 ref.)

Absence of growth hormone-induced avian muscle growth in vivo. Vasilatos-Younken R. **Poult Sci** 1999 May; 78(5):759–68 (108 ref.)

PHYSIOLOGY

Growth factors and malnutrition in chronic renal failure. Fouque DP, et al. **Adv Nephrol Necker Hosp** 1998; 28:259–85 (88 ref.)

Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Lund PK. **Ann N Y Acad Sci** 1998 Nov 17;859:18–36 (87 ref.)

Growth hormone and a partial mediator of its biological action, insulin-like growth factor I. Pankov YA. **Biochemistry (Mosc)** 1999 Jan;64(1):1–7 (85 ref.)

The role of growth hormone and insulin-like growth factors in the immune system. van Buul-Offers SC, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1083–94 (160 ref.)

Insulin, insulin-like growth factor-I (IGF-I) and glucagon: the evolution of their receptors. Navarro I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):137–53 (153 ref.)

Evolution of insulin-like growth factor-I (IGF-I) action: in vitro characterization of vertebrate IGF-I proteins. Upton Z, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep;121(1):35–41 (34 ref.)

Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Heemskerk VH, et al. **Cytokine Growth Factor Rev** 1999 Mar;10(1):5–14 (109 ref.)

Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Clemmons DR, et al. **Endocr J** 1998 Apr;45 Suppl:S1–8 (35 ref.)

Insulin-like growth factor I--a prototypic peripheral-paracrine hormone? [editorial; comment] Melmed S. **Endocrinology** 1999 Sep;140(9):3879–80 (14 ref.) Comment on: Endocrinology 1999 Sep;140(9):3881–9.

Neuroendocrinology of the human growth hormone-insulin-like growth factor I axis during ageing. Arvat E, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:111–5 (55 ref.)

The role of growth hormone and insulin-like growth factor I in the regulation of apoptosis. Isgaard J, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:125–8 (43 ref.)

Insulin-like growth factor-I and central nervous system development. Anlar B, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):120–5 (61 ref.)

The role of the GH/IGF-I axis for cardiac function and structure. Isgaard J, et al. **Horm Metab Res** 1999 Feb-Mar; 31(2-3):50–4 (62 ref.)

Involvement of insulin-like growth factor-I in inner ear organogenesis and regeneration. León Y, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):126–32 (57 ref.)

Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Petley T, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):70–6 (51 ref.)

Insulin-like growth factors as mediators of functional plasticity in the adult brain. Torres-Aleman I. **Horm Metab Res** 1999 Feb-Mar;31(2-3):114–9 (66 ref.)

Insulin, cation metabolism and insulin resistance. Sowers JR, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):223–33 (65 ref.)

The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. Grothey A, et al. **J Cancer Res Clin Oncol** 1999;125(3-4):166–73 (77 ref.)

Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. Rosenbloom AL. **J Pediatr** 1999 Sep;135(3):280–9 (45 ref.)

The IGF family and folliculogenesis. Adashi EY. **J Reprod Immunol** 1998 Aug;39(1-2):13–9 (21 ref.)

Autocrine regulation of Leydig cell differentiated functions by insulin-like growth factor I and transforming growth factor beta. Le Roy C, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):379–84 (50 ref.)

The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-I. Burgess W, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):56–68 (133 ref.)

Growth factors in children with end-stage liver disease before and after liver transplantation: a review. Maes M, et al. **Pediatr Transplant** 1997 Nov;1(2):171–5 (34 ref.)

Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interaction with insulin-like growth factor-1. Loddick SA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9449–51 (33 ref.)

IGF-I physiology and breast cancer. Pollak M. **Recent Results Cancer Res** 1998;152:63–70 (53 ref.)

[The role of the GH/IGF-1 axis in cardiovascular physiopathology and therapy: the lessons from animal studies] Cittadini A, et al. **Cardiologia** 1998 Nov; 43(11):1185–92 (53 ref.) **(Ita)**

THERAPEUTIC USE

Potential role of insulinlike growth factors in fracture healing. Trippel SB. **Clin Orthop** 1998 Oct;(355 Suppl):S301–13 (88 ref.)

Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Zumkeller W, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):138–41 (57 ref.)

INSULIN-LIKE GROWTH FACTOR II

see related
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II

GENETICS

Mechanisms of in utero overgrowth. D'Ercole AJ. **Acta Paediatr Suppl** 1999 Feb;88(428):31-6 (33 ref.)
Transcriptional regulation and biological significance of the insulin like growth factor II gene. Engström W, et al. **Cell Prolif** 1998 Oct-Dec;31(5-6):173-89 (184 ref.)
Post-translational processing of insulin-like growth factors. Duguay SJ. **Horm Metab Res** 1999 Feb-Mar;31(2-3):43-9 (63 ref.)
The role of insulin-like growth factors in small intestinal cell growth and development. MacDonald RS. **Horm Metab Res** 1999 Feb-Mar;31(2-3):103-13 (72 ref.)
Involvement of IGF2 and H19 imprinting in choriocarcinoma development. Wake N, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S1-8 (21 ref.)
Imprinting of the mouse Igf2r gene depends on an intronic CpG island. Wutz A, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):9-14 (35 ref.)

METABOLISM

Insulin-like growth factor-I resistance. Jain S, et al. **Endocr Rev** 1998 Oct;19(5):625-46 (206 ref.)
Insulin-like growth factors in endometrial function. Rutanen EM. **Gynecol Endocrinol** 1998 Dec;12(6):399-406 (45 ref.)
Cellular actions of insulin-like growth factor binding proteins. Ferry RJ Jr, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):192-202 (148 ref.)
Insulin-like growth factors and cancer. Yu H, et al. **J La State Med Soc** 1999 Apr;151(4):218-23 (53 ref.)

PHYSIOLOGY

Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Clemmons DR, et al. **Endocr J** 1998 Apr;45 Suppl:S1-8 (35 ref.)

INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1

PHYSIOLOGY

Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. Giudice LC, et al. **J Reprod Immunol** 1998 Aug;39(1-2):133-48 (66 ref.)

INSULIN-LIKE-GROWTH-FACTOR-BINDING PROTEIN 6

GENETICS

Insulin-like growth factor binding protein-6: the "forgotten" binding protein? Bach LA. **Horm Metab Res** 1999 Feb-Mar;31(2-3):226-34 (71 ref.)

METABOLISM

Insulin-like growth factor binding protein-6: the "forgotten" binding protein? Bach LA. **Horm Metab Res** 1999 Feb-Mar;31(2-3):226-34 (71 ref.)

INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS

ANALYSIS

Insulin-like growth factors in human breast cancer. Ellis MJ, et al. **Breast Cancer Res Treat** 1998;52(1-3):175-84 (62 ref.)

DRUG EFFECTS

Partial growth hormone insensitivity--idiopathic short stature is not always idiopathic. Saenger P. **Acta Paediatr Suppl** 1999 Feb;88(428):194-8 (20 ref.)

GENETICS

Insulin-like growth factor binding proteins: a proposed superfamily. Hwa V, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):37-45 (58 ref.)
Differences between African American and white girls in the insulin-like growth factor-I and the binding proteins: importance of insulin resistance and hyperinsulinemia [editorial; comment] Caprio S. **J Pediatr** 1999 Sep; 135(3):270-1 (13 ref.) Comment on: J Pediatr 1999 Sep;135(3):296-300.

METABOLISM

Insulin-like growth factor binding proteins: a proposed superfamily. Hwa V, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):37-45 (58 ref.)
Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Maile LA, et al. **Growth Horm IGF Res** 1999 Apr; 9(2):85-95 (81 ref.)
Cellular actions of insulin-like growth factor binding proteins. Ferry RJ Jr, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):192-202 (148 ref.)
Insulin-like growth factors and cancer. Yu H, et al. **J La State Med Soc** 1999 Apr;151(4):218-23 (53 ref.)
Insulin-like growth factor-binding proteins: functional diversity or redundancy? Murphy LJ. **J Mol Endocrinol** 1998 Oct;21(2):97-107 (98 ref.)
Role of insulin-like growth factor binding proteins in controlling IGF actions. Clemmons DR. **Mol Cell Endocrinol** 1998 May 25;140(1-2):19-24 (32 ref.)

PHYSIOLOGY

Growth factors and malnutrition in chronic renal failure. Fouque DP, et al. **Adv Nephrol Necker Hosp** 1998; 28:259-85 (88 ref.)
Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Lund PK. **Ann N Y Acad Sci** 1998 Nov 17;859:18-36 (87 ref.)
Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Clemmons DR, et al. **Endocr J** 1998 Apr;45 Suppl:S1-8 (35 ref.)
Insulin-like growth factor binding proteins and their functions (minireview). Kostecka Y, et al. **Endocr Regul** 1999 Jun;33(2):90-4 (27 ref.)
The insulin-related ovarian regulatory system in health and disease. Poretsky L, et al. **Endocr Rev** 1999 Aug; 20(4):535-82 (811 ref.)
The insulin-like growth factor (IGF)-IGF-binding protein axis in critical illness. Baxter RC. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:67-9 (16 ref.)
Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Maile LA, et al. **Growth Horm IGF Res** 1999 Apr; 9(2):85-95 (81 ref.)
IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. Wang HS, et al. **J Endocrinol** 1999 Apr;161(1):1-13 (136 ref.)
Insulin-like growth factors and ovarian physiology. Yoshimura Y. **J Obstet Gynaecol Res** 1998 Oct;24(5):305-23 (117 ref.)
[The role of insulin-like growth-factor binding proteins in normal and polycystic ovaries] Vasiljević M, et al. **Srp Arh Celok Lek** 1998 Nov-Dec;126(11-12):488-94 (22 ref.) (Eng. Abstr.) **(Scc)**

INSULIN-LIKE GROWTH FACTORS see **SOMATOMEDINS**

INSULIN RECEPTOR KINASE see **INSULIN RECEPTOR PROTEIN-TYROSINE KINASE**

INSULIN RECEPTOR PROTEIN-TYROSINE KINASE

GENETICS

The insulin receptor--a critical link in glucose homeostasis and insulin action. Patti ME, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):89-109 (78 ref.)

PHYSIOLOGY

Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Kornberg LJ. **Head Neck** 1998 Dec;20(8):745-52 (52 ref.)
Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action. Drake PG, et al. **Mol Cell Biochem** 1998 May;182(1-2):79-89 (87 ref.)

INSULIN RECEPTORS see **RECEPTORS, INSULIN**

INSULIN RESISTANCE

Pregnancy-induced hypertension and insulin resistance: evidence for a connection. Innes KE, et al. **Acta Obstet Gynecol Scand** 1999 Apr;78(4):263-84 (359 ref.)
Insulin signaling and glucose transport in insulin resistant skeletal muscle. Special reference to GLUT4 transgenic and GLUT4 knockout mice. Galuska D, et al. **Adv Exp Med Biol** 1998;441:73-85 (67 ref.)
Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. Ruderman NB, et al. **Adv Exp Med Biol** 1998; 441:263-70 (31 ref.)
Vascular reactivity. Baron AD. **Am J Cardiol** 1999 Jul 8; 84(1A):25J-27J (7 ref.)
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Grundy SM. **Am J Cardiol** 1999 May 13; 83(9B):25F-29F (63 ref.)
Epidemiology of insulin resistance and its relation to coronary artery disease. Haffner SM. **Am J Cardiol** 1999 Jul 8;84(1A):11J-14J (28 ref.)
Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Hunter SJ, et al. **Am J Med** 1998 Oct;105(4):331-45 (100 ref.)
Insulin resistance. Whitelaw DC, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):567-83 (205 ref.)
Fibrinogen, obesity and insulin resistance. Juhan-Vague I, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S25-8 (36 ref.)
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Hansson L. **Blood Press** 1998;Suppl 3:20-2 (19 ref.)
Insulin resistance and diabetes in the context of treatment of hypertension. Lithell HO. **Blood Press** 1998;Suppl 3:28-31 (28 ref.)
Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Goyal RK. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):167-79 (44 ref.)
Insulin resistance: a marker of surgical stress. Thorell A, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):69-78 (68 ref.)
New therapeutic approaches to reversing insulin resistance. Sonnenberg GE, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):551-5 (51 ref.)
Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Wiernsperger NF. **Diabetes Metab** 1999 Jun;25(2):110-27 (174 ref.)
Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Ferrannini E. **Endocr Rev** 1998 Aug;19(4):477-90 (160 ref.)
The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Gerich JE. **Endocr Rev** 1998 Aug;19(4):491-503 (161 ref.)
Development of the multiple metabolic syndrome: an epidemiologic perspective. Liese AD, et al. **Epidemiol Rev** 1998;20(2):157-72 (209 ref.)
Western nutrition and the insulin resistance syndrome: a link to breast cancer. Stoll BA. **Eur J Clin Nutr** 1999 Feb; 53(2):83-7 (52 ref.)
Mechanisms of TNF-alpha-induced insulin resistance [see comments] Hotamisligil GS. **Exp Clin Endocrinol Diabetes** 1999;107(2):119-25 (48 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111-2.
Insulin signal transduction: possible mechanisms for insulin resistance. Kellerer M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):97-106 (93 ref.)
Multiple sites of insulin resistance: muscle, liver and adipose tissue [comment] Stumvoll M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):107-10 (32 ref.) Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):140-7.
Insulin resistance: solutions for a common problem. Lipsky MS, et al. **Hosp Pract (Off Ed)** 1999 May 15;34(5):120-1 (6 ref.)
Supplement. Obesity, hypertension, insulin resistance and lipid disorders: cross-sectional and longitudinal studies in Japanese adolescents and middle-aged men. Hirose H, et al. **Intern Med** 1999 Feb;38(2):198-200 (17 ref.)
Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. Virkamäki A, et al. **J Clin Invest** 1999 Apr;103(7):931-43 (186 ref.)
Growth hormone and the metabolic syndrome. Johannsson G, et al. **J Endocrinol Invest** 1999;22(5 Suppl):41-6 (42 ref.)
Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults. Johnston DG, et al. **J Endocrinol Invest** 1999;22(5 Suppl):37-40 (19 ref.)
How to measure insulin sensitivity. Ferrannini E, et al. **J Hypertens** 1998 Jul;16(7):895-906 (61 ref.)
The role of TNFalpha and TNF receptors in obesity and insulin resistance. Hotamisligil GS. **J Intern Med** 1999 Jun; 245(6):621-5 (37 ref.)
Intracellular starvation in the insulin resistance syndrome and type II diabetes mellitus. Fournier AM. **Med Hypotheses** 1998 Aug;51(2):95-9 (40 ref.)
Syndrome-AC: non-insulin-dependent diabetes mellitus and the anabolic/catabolic paradox. Provonsha S, et al. **Med Hypotheses** 1998 Nov;51(5):429-38 (14 ref.)
Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Legro RS. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):103-10 (54 ref.)
Nutrient-induced insulin resistance. Proietto J, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):143-9 (68 ref.)
The role of troglitazone in treating the insulin resistance syndrome. Granberry MC, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):973-87 (112 ref.)
Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Turner NC, et al. **Prog Drug Res** 1998;51:33-94 (370 ref.)
GLUT-4, tumor necrosis factor, essential fatty acids and daf-genes and their role in insulin resistance and non-insulin dependent diabetes mellitus. Das UN. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jan; 60(1):13-20 (43 ref.)
Insulin resistance syndrome: options for treatment. Granberry MC, et al. **South Med J** 1999 Jan;92(1):2-15 (123 ref.)
Evolutionary aspects of diet and insulin resistance. Brand-Miller JC, et al. **World Rev Nutr Diet** 1999; 84:74-105 (132 ref.)
[In vivo evaluation of insulin sensitivity and clinical applications] Raynaud E, et al. **Ann Biol Clin (Paris)** 1998 Jul-Aug;56(4):407-16 (48 ref.) (Eng. Abstr.) **(Fre)**
[Hexose transporters in humans: their role in insulin sensitivity of peripheral tissues] Bastard JP, et al. **Rev Med Interne** 1998 Feb;19(2):108-18 (67 ref.) (Eng. Abstr.) **(Fre)**

INSULIN RESISTANCE

[Syndromes of severe insulin resistance] Araki S. **Nippon Rinsho** 1999 Mar;57(3):617–21 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Syndrome X] Kotake H, et al. **Nippon Rinsho** 1999 Mar; 57(3):622–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus] Fábryová L, et al. **Bratisl Lek Listy** 1998 Mar–Apr;99(3–4):138–45 (80 ref.) (Eng. Abstr.) **(Slo)**

[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions] Galajda P, et al. **Vnitr Lek** 1998 Feb;44(2):111–4 (38 ref.) (Eng. Abstr.) **(Slo)**

[Insulin resistance in polycystic ovary syndrome] Aquino Carlos P, et al. **Ginecol Obstet Mex** 1998 Nov;66:446–51 (18 ref.) (Eng. Abstr.) **(Spa)**

[Endothelial dysfunction and metabolic syndrome] Martín Jadraque L, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:19–23 (21 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Insulin resistance in short children with intrauterine growth retardation. Chiarelli F, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):62–5 (37 ref.)

Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Müller–Wieland D, et al. **Basic Res Cardiol** 1998;93 Suppl 2:131–4 (16 ref.)

Molecular mechanisms of insulin action in normal and insulin-resistant states [see comments] Le Marchand-Brustel Y. **Exp Clin Endocrinol Diabetes** 1999; 107(2):126–32 (24 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111–2.

Genetics of insulin resistance [see comments] Pedersen O. **Exp Clin Endocrinol Diabetes** 1999;107(2):113–8 (37 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111–2.

Molecular mechanisms of insulin resistance. Introduction [comment] Taylor R, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):111–2 (18 ref.) Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):113–8. Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):119–25. Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):126–32. Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):133–9.

Insulin resistance syndrome: current perspective and its relevance in Indians [see comments] Misra A. **Indian Heart J** 1998 Jul–Aug;50(4):385–95 (134 ref.) Comment in: Indian Heart J 1998 Sep–Oct;50(5):573–4; discussion 575–7. Comment in: Indian Heart J 1998 Sep–Oct;50(5):574–7.

Syndromes associated with insulin resistance and acanthosis nigricans. Taylor SI, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):419–39 (76 ref.)

Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? Holte J. **J Endocrinol Invest** 1998 Oct;21(9):589–601 (101 ref.)

Differences between African American and white girls in the insulin-like growth factor-I and the binding proteins: importance of insulin resistance and hyperinsulinemia [editorial; comment] Caprio S. **J Pediatr** 1999 Sep; 135(3):270–1 (13 ref.) Comment on: J Pediatr 1999 Sep;135(3):296–300.

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Hattersley AT, et al. **Lancet** 1999 May 22; 353(9166):1789–92 (43 ref.)

[Genes and intra-uterine growth retardation] Jeanpierre M. **Arch Pediatr** 1998;5 Suppl 4:332S–337S (46 ref.) (Eng. Abstr.) **(Fre)**

[The heart and metabolic syndrome (published erratum appears in Z Kardiol 1999 May;88(5):380)] Tschoepe D, et al. **Z Kardiol** 1999 Mar;88(3):215–24 (131 ref.) (Eng. Abstr.) **(Ger)**

[Insulin receptor abnormality and its clinical aspect] Taira M, et al. **Nippon Rinsho** 1998 Jul;56(7):1866–70 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Insulin sensitivity, muscle fibre types, and membrane lipids. Helge JW, et al. **Adv Exp Med Biol** 1998;441:129–38 (56 ref.)

Insulin resistance and lipid metabolism. Howard BV. **Am J Cardiol** 1999 Jul 8;84(1A):28J–32J (25 ref.)

Insulin signaling in the arterial wall. Hsueh WA, et al. **Am J Cardiol** 1999 Jul 8;84(1A):21J–24J (35 ref.)

Insulin resistance and systemic hypertension. Osei K. **Am J Cardiol** 1999 Jul 8;84(1A):33J–36J (20 ref.)

Cellular mechanisms of insulin resistance in humans. Shulman GI. **Am J Cardiol** 1999 Jul 8;84(1A):3J–10J (28 ref.)

Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Jacob S, et al. **Am J Hypertens** 1998 Oct;11(10):1258–65 (44 ref.)

Malonyl-CoA, fuel sensing, and insulin resistance. Ruderman NB, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E1–E18 (152 ref.)

Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Müller–Wieland D, et al. **Basic Res Cardiol** 1998;93 Suppl 2:131–4 (16 ref.)

Programming of hepatic and peripheral tissue insulin sensitivity by maternal protein restriction. Ozanne SE. **Biochem Soc Trans** 1999 Feb;27(2):94–7 (27 ref.)

Insulin resistance and preeclampsia. Berkowitz KM. **Clin Perinatol** 1998 Dec;25(4):873–85 (51 ref.)

Glucocorticoids and insulin resistance: old hormones, new targets. Andrews RC, et al. **Clin Sci (Colch)** 1999 May; 96(5):513–23 (102 ref.)

Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy. Tchernof A, et al. **Coron Artery Dis** 1998;9(8):503–11 (65 ref.)

Amino acid-dependent signal transduction and insulin sensitivity. Meijer AJ, et al. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):207–11 (31 ref.)

Dyslipidemia of central obesity and insulin resistance. Brunzell JD, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C10–3 (69 ref.)

Insulin resistance and hyperglycemic associated risk factors: session summary. Després JP. **Diabetes Care** 1999 Apr;22 Suppl 3:C38–40 (24 ref.)

Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. King GL, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C31–7 (41 ref.)

Natural history of macrovascular disease in type 2 diabetes. Role of insulin resistance. Stern M. **Diabetes Care** 1999 Apr;22 Suppl 3:C2–5 (19 ref.)

Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Yudkin JS. **Diabetes Care** 1999 Apr;22 Suppl 3:C25–30 (65 ref.)

Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance. Göke B. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S15–20 (43 ref.)

Diabetic dyslipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul; 19 Suppl H:H27–40 (14 ref.)

Advancing age and insulin resistance: new facts about an ancient history. Paolisso G, et al. **Eur J Clin Invest** 1999 Sep;29(9):758–69 (95 ref.)

Mechanisms of insulin resistance in non-oxidative glucose metabolism: the role of glycogen synthase. Beck-Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):255–79 (39 ref.)

Central role of the adipocyte in insulin resistance. Bergman RN, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2–4):205–21 (38 ref.)

Insulin resistance: site of the primary defect or how the current and the emerging therapies work. Kolaczynski JW, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):281–94 (63 ref.)

The insulin receptor—a critical link in glucose homeostasis and insulin action. Patti ME, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):89–109 (78 ref.)

Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. Ruderman NB, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):295–308 (52 ref.)

Insulin, cation metabolism and insulin resistance. Sowers JR, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):223–33 (65 ref.)

From insulin receptor signalling to Glut 4 translocation abnormalities in obesity and insulin resistance. Le Marchand-Brustel Y, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):217–28 (41 ref.)

Complementary measures for promoting insulin sensitivity in skeletal muscle. McCarty MF. **Med Hypotheses** 1998 Dec;51(6):451–64 (193 ref.)

Membrane glycoprotein PC-1 and insulin resistance. Goldfine ID, et al. **Mol Cell Biochem** 1998 May; 182(1–2):177–84 (55 ref.)

TNF-alpha and insulin resistance: summary and future prospects. Peraldi P, et al. **Mol Cell Biochem** 1998 May; 182(1–2):169–75 (58 ref.)

Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Zemel MB. **Mol Cell Biochem** 1998 Nov; 188(1–2):129–36 (69 ref.)

Insulin resistance in obesity: metabolic mechanisms and measurement methods. Belfiore F, et al. **Mol Genet Metab** 1998 Oct;65(2):121–8 (32 ref.)

Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Boden G. **Proc Assoc Am Physicians** 1999 May–Jun;111(3):241–8 (71 ref.)

[Evolution of the concept of insulin resistance in the BigPRO studies. The BigPRO Group. Biguanides and Prevention of the Risk of Obesity] Isnard F. **Journ Annu Diabetol Hotel Dieu** 1998;:321–37 (38 ref.) **(Fre)**

[Evaluation of insulin sensitivity: the HOMA and CIGMA models] Levy JC. **Journ Annu Diabetol Hotel Dieu** 1998; :179–92 (35 ref.) **(Fre)**

[Fatty acids, insulin resistance and pancreatic beta cell function] McGarry JD, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:1–10 (24 ref.) **(Fre)**

[Role of fatty acids in hepatic and peripheral insulin resistance] Tappy L, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:11–6 (24 ref.) **(Fre)**

[Effect of fat distribution on risk] Toplak H. **Acta Med Austriaca** 1998;25(4–5):131–2 (4 ref.) (Eng. Abstr.) **(Ger)**

[Insulin resistance. Receptor and post-receptor abnormalities] Liguori M, et al. **Minerva Endocrinol** 1998 Jun;23(2):37–52 (81 ref.) (Eng. Abstr.) **(Ita)**

[Obesity and diseases. 3. Obesity and molecular structure of insulin resistance] Kadowaki T, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1797–801 (5 ref.) **(Jpn)**

[The effects of angiotensin II receptor antagonists on insulin resistance] Higashiura K, et al. **Nippon Rinsho** 1999 May; 57(5):1182–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of insulin resistance] Kobayashi M. **Nippon Rinsho** 1999 Mar;57(3):515–20 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanism and clinical impact of insulin resistance in type 2 diabetes mellitus] Maegawa H, et al. **Nippon Rinsho** 1999 Mar;57(3):539–44 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenesis of impaired insulin secretion in NIDDM] Yamada Y, et al. **Nippon Rinsho** 1999 Mar;57(3):534–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

INSULINASE see **INSULYSIN**

INSULINOMA

DIAGNOSIS

Insulinoma. Grant CS. **Surg Oncol Clin N Am** 1998 Oct; 7(4):819–44 (87 ref.)

[An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity] Wildbrett J, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):248–52 (24 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

[Development of insulinoma cells as therapy in insulin-dependent diabetes mellitus] Schnedl WJ. **Wien Klin Wochenschr** 1999 Jun 4;111(11):428–33 (47 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Intraoperative methods to stage and localize pancreatic and duodenal tumors. Norton JA. **Ann Oncol** 1999;10 Suppl 4:182–4 (15 ref.)

ULTRASONOGRAPHY

Endoscopic ultrasound localization of a pancreatic insulinoma: case report and review of the localization techniques. Hall RS, et al. **Mil Med** 1998 Dec;163(12):853–6 (34 ref.)

INSULOMA see **INSULINOMA**

INSULYSIN

METABOLISM

Insulin degradation: progress and potential. Duckworth WC, et al. **Endocr Rev** 1998 Oct;19(5):608–24 (237 ref.)

INSURANCE, ACCIDENT

LEGISLATION & JURISPRUDENCE

[Injury—damages—insurance: legal implications] Yvo V. **Rev Belge Med Dent** 1998;53(2):9–28 (14 ref.) (Eng. Abstr.) **(Fre)**

[Risk assessment expanded accident insurance for children (see comments)] Sittaro NA. **Versicherungsmedizin** 1998 Aug 1;50(4):131–40 (13 ref.) (Eng. Abstr.) Comment in: Versicherungsmedizin 1999 Mar 1;51(1):48–9. **(Ger)**

INSURANCE AUDIT see **INSURANCE CLAIM REVIEW**

INSURANCE BENEFITS

Choices in health care: what are they and what are they worth? Bernstein AB, et al. **Med Care Res Rev** 1999;56 Suppl 1:5–23 (22 ref.)

INSURANCE CARRIERS

Nonprofit to for-profit conversions by hospitals, health insurers, and health plans. Needleman J. **Public Health Rep** 1999 Mar–Apr;114(2):108–19 (41 ref.)

INSURANCE CASE MANAGEMENT see **MANAGED CARE PROGRAMS**

INSURANCE CLAIM REPORTING

ACC expert consensus document on ethical coding and billing practices for cardiovascular medicine specialists. American College of Cardiology. Blankenship JC, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):1076–86 (33 ref.)

[Analysis of claims for damage in the gynaecological sector during 1997 based on data taken from the Professional Association of Gynaecologists' third-party liability group insurance] von Harder Y. **Zentralbl Gynakol** 1998; 120(12):574–80 (32 ref.) (Eng. Abstr.) **(Ger)**

INSURANCE CLAIM REVIEW

Using state and federal claims data to evaluate the patterns and costs of cancer care. Desch CE, et al. **Cancer Treat Res** 1998;97:53–69 (48 ref.)

LEGISLATION & JURISPRUDENCE

Risk management lessons from a review of 168 cataract surgery claims. Brick DC. **Surv Ophthalmol** 1999 Jan–Feb; 43(4):356–60 (0 ref.)

STATISTICS & NUMERICAL DATA

When not to syringe an ear. Blake P, et al. **N Z Med J** 1998 Nov 13;111(1077):422–4 (6 ref.)

INSURANCE CLAIMS PROCESSING see **INSURANCE CLAIM REVIEW**

INSURANCE COVERAGE

Life insurance implications of mortality for up to 40 years after repair of congenital heart defects in childhood. Cumming GR. **J R Soc Med** 1999 Feb;92(2):73–8 (28 ref.)

Opportunities to improve health care for low-income adolescents. Collins KS, et al. **J Urban Health** 1998 Dec; 75(4):660–76 (14 ref.)

Children with chronic conditions in the 21st century. Stein RE. **J Urban Health** 1998 Dec;75(4):732–8 (7 ref.)

Health care coverage and access for children in an urban state: the New York perspective. Tallon JR Jr, et al. **J Urban Health** 1998 Dec;75(4):693–701 (8 ref.)

ECONOMICS

Improving prognosis of type 1 diabetes. Mortality, accidents, and impact on insurance. Borch-Johnsen K. **Diabetes Care** 1999 Mar;22 Suppl 2:B1–3 (19 ref.)

LEGISLATION & JURISPRUDENCE

Medicare+Choice appeal procedures: reconciling due process rights and cost containment. Gladieux JE. **Am J Law Med** 1999;25(1):61–116 (0 ref.)

INSURANCE, DISABILITY

LEGISLATION & JURISPRUDENCE

[Effects exercised by the new federal German social legislation SGB III on assessing the incapacity to work by the medical experts of German statutory sickness insurance bodies] Nüchtern E. **Gesundheitswesen** 1999 Jun; 61(6):299–302 (1 ref.) (Eng. Abstr.) **(Ger)**

INSURANCE, HEALTH

see related
PHYSICIAN'S PRACTICE PATTERNS

Choices in health care: what are they and what are they worth? Bernstein AB, et al. **Med Care Res Rev** 1999;56 Suppl 1:5–23 (22 ref.)

What do consumers want and need to know in making health care choices? Lubalin JS, et al. **Med Care Res Rev** 1999; 56 Suppl 1:67–102; discussion 103–12 (93 ref.)

Treating advanced ovarian cancer within the health maintenance organization: a Kaiser Permanente approach. Rarick M. **Semin Oncol** 1999 Feb;26(1 Suppl 1):52–8 (10 ref.)

Using social health insurance to meet policy goals. Normand C. **Soc Sci Med** 1999 Apr;48(7):865–9 (13 ref.)

["Self-inflicted injuries"—psychiatric, forensic and insurance aspects (II)] Möllhoff G, et al. **Versicherungsmedizin** 1999 Mar 1;51(1):30–5 (0 ref.) (Eng. Abstr.) **(Ger)**

[Health insurance as a means of supporting medical care for the population] Travkin AG, et al. **Vestn Oftalmol** 1999 May-Jun;115(3):30–3 (29 ref.) **(Rus)**

ECONOMICS

The role of government in health insurance markets with adverse selection. Feldman R, et al. **Health Econ** 1998 Dec; 7(8):659–70 (32 ref.)

The new child health insurance expansions: how will school-based health centers fit in? Koppelman J, et al. **J Sch Health** 1998 Dec;68(10):441–6 (8 ref.)

Increased competition and the quality of health care. Sisk JE. **Milbank Q** 1998;76(4):687–707, 512 (44 ref.)

Developing health insurance in transitional Asia. Ensor T. **Soc Sci Med** 1999 Apr;48(7):871–9 (25 ref.)

[Surgical aid for population in conditions of compulsory medical insurance] Gusev LI, et al. **Khirurgiia (Mosk)** 1999; (8):45–9 (33 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Genetic testing and insurance in the United Kingdom. Morrison PJ. **Clin Genet** 1998 Nov;54(5):375–9 (22 ref.)

["Self-inflicted injuries"—psychiatric, forensic and insurance aspects (I)] Möllhoff G, et al. **Versicherungsmedizin** 1998 Dec 1;50(6):226–31 (0 ref.) **(Ger)**

STANDARDS

Consumer Assessment of Health Plans Study (CAHPS). Foreword. Crofton C, et al. **Med Care** 1999 Mar;37(3 Suppl):MS1–9 (25 ref.)

INSURANCE, HEALTH, CATASTROPHIC see **INSURANCE, MAJOR MEDICAL**

INSURANCE, HEALTH, FOR AGED AND DISABLED see **MEDICARE**

INSURANCE, HEALTH, REIMBURSEMENT

Managed care organizations' assessment of reimbursement for new technology, procedures, and drugs. Zarkowsky H. **Arch Pathol Lab Med** 1999 Aug;123(8):677–9 (2 ref.)

Mental health assessment of young children in a managed care environment. Schaefer M. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):425–37 (11 ref.)

Billing third party payers for pharmaceutical care services. Poirier S, et al. **J Am Pharm Assoc (Wash)** 1999 Jan–Feb; 39(1):50–64; quiz 101–2 (22 ref.)

INSURANCE, LIABILITY

LEGISLATION & JURISPRUDENCE

No-fault vaccine insurance: lessons from the National Vaccine Injury Compensation Program. Ridgway D. **J Health Polit Policy Law** 1999 Feb;24(1):59–90 (47 ref.)

[Practice guidelines for medical treatment from the perspective of health law] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2480–4 (19 ref.) (Eng. Abstr.) **(Dut)**

INSURANCE, LIFE

Life insurance implications of mortality for up to 40 years after repair of congenital heart defects in childhood. Cumming GR. **J R Soc Med** 1999 Feb;92(2):73–8 (28 ref.)

INSURANCE, LONG-TERM CARE

Genetic testing, Alzheimer disease, and long-term care insurance. Fogarty M. **Genet Test** 1999;3(1):133–7 (22 ref.)

ECONOMICS

Financing long-term care for elderly persons: what are the options? Amaradio L. **J Health Care Finance** 1998 Winter; 25(2):75–84 (23 ref.)

INSURANCE, MAJOR MEDICAL

see related
CATASTROPHIC ILLNESS

[Analysis of claims for damage in the gynaecological sector during 1997 based on data taken from the Professional Association of Gynaecologists' third-party liability group insurance] von Harder Y. **Zentralbl Gynakol** 1998; 120(12):574–80 (32 ref.) (Eng. Abstr.) **(Ger)**

INSURANCE, PHARMACEUTICAL SERVICES

Pharmacy benefit management companies: dimensions of performance. Lipton HL, et al. **Annu Rev Public Health** 1999;20:361–401 (56 ref.)

INSURANCE POOLS

ORGANIZATION & ADMINISTRATION

Proposal for a mutual insurance pool for transplant organs. Schwindt R, et al. **J Health Polit Policy Law** 1998 Oct; 23(5):725–41 (44 ref.)

INSURANCE SELECTION BIAS

The role of government in health insurance markets with adverse selection. Feldman R, et al. **Health Econ** 1998 Dec; 7(8):659–70 (32 ref.)

INSURANCE STATUS see **INSURANCE COVERAGE**

INSURERS see **INSURANCE CARRIERS**

INTEGRAL MEMBRANE PROTEINS see **MEMBRANE PROTEINS**

INTEGRASE

Cre recombinase mediated alterations of the mouse genome using embryonic stem cells. Hadjantonakis AK, et al. **Methods Mol Biol** 1999;97:101–22 (42 ref.)

[Construction of HCV transgenic mice with Cre/loxP switching expression system] Wakita T. **Uirusu** 1998 Jun; 48(1):9–18 (32 ref.) **(Jpn)**

CHEMISTRY

Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity. Wlodawer A. **Adv Virus Res** 1999;52:335–50 (48 ref.)

GENETICS

In vivo analysis of retroviral integrase structure and function. Engelman A. **Adv Virus Res** 1999;52:411–26 (54 ref.)

The Cre/loxP system and gene targeting in the kidney. Stricklett PK, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F651–7 (47 ref.)

The Cre/loxP system—a versatile tool to study glucocorticoid signalling in mice. Reichardt HM, et al. **Biochem Soc Trans** 1999 Feb;27(2):78–83 (22 ref.)

Structure and mechanism in site-specific recombination. Gopaul DN, et al. **Curr Opin Struct Biol** 1999 Feb; 9(1):14–20 (43 ref.)

METABOLISM

Substrate recognition by retroviral integrases. Katzman M, et al. **Adv Virus Res** 1999;52:371–95 (125 ref.)

The Cre/loxP system—a versatile tool to study glucocorticoid signalling in mice. Reichardt HM, et al. **Biochem Soc Trans** 1999 Feb;27(2):78–83 (22 ref.)

Structure and mechanism in site-specific recombination. Gopaul DN, et al. **Curr Opin Struct Biol** 1999 Feb; 9(1):14–20 (43 ref.)

PHYSIOLOGY

In vivo analysis of retroviral integrase structure and function. Engelman A. **Adv Virus Res** 1999;52:411–26 (54 ref.)

INTEGRASE INHIBITORS, HIV see **HIV INTEGRASE INHIBITORS**

INTEGRATED DELIVERY SYSTEMS see **DELIVERY OF HEALTH CARE, INTEGRATED**

INTEGRATED HEALTH CARE SYSTEMS see **DELIVERY OF HEALTH CARE, INTEGRATED**

INTEGRATION, PROPHAGE see **LYSOGENY**

INTEGRATION, PROVIRUS see **VIRUS INTEGRATION**

INTEGRATION, VIRUS see **VIRUS INTEGRATION**

INTEGRIN ALPHA-IIB BETA-3 see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

INTEGRIN ALPHA-M BETA-2 see **MACROPHAGE-1 ANTIGEN**

INTEGRIN ALPHA-V BETA-3 see **RECEPTORS, VITRONECTIN**

INTEGRIN BETA 2 SUBUNIT see **ANTIGENS, CD18**

INTEGRINS

see related
ANTIGENS, CD18
CELL ADHESION MOLECULES

[Integrin story] Hayashi M, et al. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):130–5 (13 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Lin KC, et al. **Curr Opin Chem Biol** 1998 Aug; 2(4):453–7 (22 ref.)

[Anti-integrins—new platelet function inhibitors for therapy and prevention of acute coronary syndrome] Schrör K. **Wien Klin Wochenschr** 1999 Feb 12;111(3):90–7 (55 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Towards a structural model of an integrin. Humphries MJ. **Biochem Soc Symp** 1999;65:63–78 (34 ref.)

Invertebrate integrins: structure, function, and evolution. Burke RD. **Int Rev Cytol** 1999;191:257–84 (61 ref.)

GENETICS

Integrins: alternative splicing as a mechanism to regulate ligand binding and integrin signaling events. de Melker AA, et al. **Bioessays** 1999 Jun;21(6):499–509 (88 ref.)

Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Santoro SA. **Blood** 1999 Jun 1;93(11):3575–7 (32 ref.)

IMMUNOLOGY

Integrins in the immune system. Shimizu Y, et al. **Adv Immunol** 1999;72:325–80 (456 ref.)

Adhesion and signaling mediated by the cytoplasmic tails of leucocyte integrins. van Kooyk Y, et al. **Cell Adhes Commun** 1998;6(2–3):247–54 (72 ref.)

Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Wang J, et al. **Immunol Rev** 1998 Jun;163:197–215 (104 ref.)

METABOLISM

Extracellular matrix and integrin signalling: the shape of

INTEGRINS

things to come. Boudreau NJ, et al. **Biochem J** 1999 May 1;339 (Pt 3):481–8 (113 ref.)
Extracellular matrix–integrin interactions in osteoblast function and tissue remodeling. Damsky CH. **Bone** 1999 Jul;25(1):95–6 (14 ref.)
Extracellular matrix signaling: integration of form and function in normal and malignant cells. Boudreau N, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):640–6 (55 ref.)
The CCN family of angiogenic regulators: the integrin connection. Lau LF, et al. **Exp Cell Res** 1999 Apr 10; 248(1):44–57 (101 ref.)
Integrin–mediated signal transduction pathways. Cary LA, et al. **Histol Histopathol** 1999 Jul;14(3):1001–9 (144 ref.)
Integrin signal transduction in myeloid leukocytes. Lowell CA, et al. **J Leukoc Biol** 1999 Mar;65(3):313–20 (94 ref.)
Integrin–mediated stimulation of tyrosine phosphorylation in lymphoid cells. Gismondi A, et al. **Methods Mol Biol** 1999; 96:205–10 (8 ref.)
Regulation of integrin–mediated adhesion during cell migration. Cox EA, et al. **Microsc Res Tech** 1998 Dec 1; 43(5):412–9 (77 ref.)
Signaling by integrin receptors. Kumar CC. **Oncogene** 1998 Sep 17;17(11 Reviews):1365–73 (92 ref.)
NO/cGMP/VASP pathway is involved in integrin activation. Fässler R. **Postepy Hig Med Dosw** 1999; 53(2):223 (0 ref.)
Integrin signaling. Giancotti FG, et al. **Science** 1999 Aug 13;285(5430):1028–32 (65 ref.)
[Cell cycle–dependent change of the adhesive character of CD34+ progenitor cells and their VLA–4 expression] Yamaguchi M, et al. **Rinsho Byori** 1999 May;47(5):439–46 (30 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Fibronectin and its integrin receptors in cancer. Ruoslahti E. **Adv Cancer Res** 1999;76:1–20 (109 ref.)
The PS integrins are required for a regulatory event during Drosophila wing morphogenesis. Brabant MC, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:99–109 (32 ref.)
Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. Miyamoto S, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:119–29 (45 ref.)
Integrin–mediated cell adhesion: the cytoskeletal connection. Critchley DR, et al. **Biochem Soc Symp** 1999;65:79–99 (143 ref.)
Integrin signaling: cytoskeletal complexes, MAP kinase activation, and regulation of gene expression. Danen EH, et al. **Cell Adhes Commun** 1998;6(2–3):217–24 (46 ref.)
Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Friedl P, et al. **Cell Adhes Commun** 1998; 6(2–3):225–36 (67 ref.)
The alpha7beta1 integrin in muscle development and disease. Burkin DJ, et al. **Cell Tissue Res** 1999 Apr;296(1):183–90 (43 ref.)
Beta 7 integrins and their ligands in lymphocyte migration to the gut. Viney JL, et al. **Chem Immunol** 1998;71:64–76 (72 ref.)
Integrin associated proteins. Hemler ME. **Curr Opin Cell Biol** 1998 Oct;10(5):578–85 (87 ref.)
Bidirectional signaling between the cytoskeleton and integrins. Schoenwaelder SM, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):274–86 (156 ref.)
Integrins and signal transduction. Dedhar S. **Curr Opin Hematol** 1999 Jan;6(1):37–43 (60 ref.)
Integrins and the kidney: biology and pathobiology. Hamerski DA, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):9–14 (47 ref.)
Extracellular matrix, integrins and focal adhesions. Dogic D, et al. **Curr Top Pathol** 1999;93:75–85 (57 ref.)
Cytoskeleton and integrin–mediated adhesion signaling in human CD34+ hemopoietic progenitor cells. Lévesque JP, et al. **Exp Hematol** 1999 Apr;27(4):579–86 (60 ref.)
Use of adhesion molecules for gene delivery. Hart S. **Exp Nephrol** 1999 Mar–Apr;7(2):193–9 (52 ref.)
Arg–gly–Asp (RGD) peptides and peptidomimetics as therapeutics: relevance for renal diseases. Horton MA. **Exp Nephrol** 1999 Mar–Apr;7(2):178–84 (47 ref.)
Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Norman JT, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):167–77 (94 ref.)
Cell adhesion molecules in the kidney: from embryo to adult. Perantoni AO. **Exp Nephrol** 1999 Mar–Apr;7(2):80–102 (254 ref.)
Mesangial cells and their adhesive properties. Pröls F, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):137–46 (77 ref.)
Osteopontin function in pathology: lessons from osteopontin–deficient mice. Rittling SR, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):103–13 (91 ref.)
Leukocyte–endothelial cell interactions – lessons from knockout mice. Rosenkranz AR, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):125–36 (122 ref.)
Integrins and human intestinal cell functions. Beaulieu JF. **Front Biosci** 1999 Mar 15;4:D310–21 (134 ref.)
Focal adhesion kinase in integrin–mediated signaling. Cary LA, et al. **Front Biosci** 1999 Jan 15;4:D102–13 (142 ref.)
Sperm disintegrins, egg integrins, and other cell adhesion molecules of mammalian gamete plasma membrane interactions. Evans JP. **Front Biosci** 1999 Jan 15;4:D114–31 (147 ref.)
Integrins during muscle development and in muscular dystrophies. Gullberg D, et al. **Front Biosci** 1998 Oct 15; 3:D1039–50 (101 ref.)
The role of integrins in the malignant phenotype of gliomas. Uhm JH, et al. **Front Biosci** 1999 Feb 15;4:D188–99 (101 ref.)
Physiological roles of integrin alpha 6 beta 1 in ovarian functions. Fujiwara H, et al. **Horm Res** 1998;50 Suppl 2:25–9 (15 ref.)
Role of integrins during fertilization in mammals. Fénichel P, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:31–46 (77 ref.)
Endometrial integrins and the establishment of uterine receptivity. Lessey BA. **Hum Reprod** 1998 Jun;13 Suppl 3:247–58; discussion 259–61 (81 ref.)
The role of integrins in osteoclast function. Duong LT, et al. **J Bone Miner Metab** 1999;17(1):1–6 (42 ref.)
Integrin–mediated signaling in human neutrophil functioning [published erratum appears in J Leukoc Biol 1999 Jul;66(1):194] Williams MA, et al. **J Leukoc Biol** 1999 Jun; 65(6):725–36 (136 ref.)
Integrin signaling: tyrosine phosphorylation events in focal adhesions. Vuori K. **J Membr Biol** 1998 Oct 1;165(3):191–9 (125 ref.)
Modulation of integrin function inhibits HIV transmission to epithelial cells and fertilization. Davidson JB, et al. **J Reprod Immunol** 1998 Dec;41(1–2):271–90 (91 ref.)
Paracrine signaling in the endometrium: integrins and the establishment of uterine receptivity. Lessey BA, et al. **J Reprod Immunol** 1998 Aug;39(1–2):105–16 (40 ref.)
Integrins—the glue of life. Etzioni A. **Lancet** 1999 Jan 30; 353(9150):341–3 (14 ref.)
ECM–mediated glioma cell invasion. Goldbrunner RH, et al. **Microsc Res Tech** 1998 Nov 1;43(3):250–7 (80 ref.)
The role of alphav integrins during angiogenesis. Eliceiri BP, et al. **Mol Med** 1998 Dec;4(12):741–50 (82 ref.)
Integrins, endometrial maturation, & human embryo implantation. Coutifaris C, et al. **Semin Reprod Endocrinol** 1998;16(3):219–29 (87 ref.)
Integrins and T helper cell activation [see comments] van Seventer GA, et al. **Transplant Proc** 1998 Dec;30(8):4270–4 (60 ref.) Comment in: Transplant Proc 1998 Dec;30(8):4269.
Integrin–linked kinase (ILK): a regulator of integrin and growth–factor signalling. Dedhar S, et al. **Trends Cell Biol** 1999 Aug;9(8):319–23 (38 ref.)
Integrin affinity modulation. Hughes PE, et al. **Trends Cell Biol** 1998 Sep;8(9):359–64 (64 ref.)
Integrins take partners: cross–talk between integrins and other membrane receptors. Porter JC, et al. **Trends Cell Biol** 1998 Oct;8(10):390–6 (57 ref.)
The role of integrins in immune–mediated diseases of the nervous system. Archelos JJ, et al. **Trends Neurosci** 1999 Jan;22(1):30–8 (56 ref.)
[Adhesion receptors of the vascular endothelium and their role in acute inflammation] Bělohlávková S, et al. **Cesk Fysiol** 1999 May;48(2):51–61 (47 ref.) (Eng. Abstr.) **(Cze)**
[Integrins and metalloproteinases: an efficient collaboration in the invasive process] Rémy L, et al. **Bull Cancer** 1999 Feb;86(2):154–8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Cell adhesion molecules and pharmacologic applications. Round Table No 3 at Giens XIII] McGregor J, et al. **Therapie** 1998 Jul–Aug;53(4):371–9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Tumor metastasis and cell adhesion molecules] Murata J, et al. **Gan To Kagaku Ryoho** 1999 Apr;26(5):715–23 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of integrin function in the metastasis of colorectal cancer] Imai K, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):415–8 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Integrin signal transduction via FAK in osteoblasts—early differentiation triggered by osteopontin] Nemoto A, et al. **Seikagaku** 1999 Feb;71(2):140–5 (17 ref.) **(Jpn)**
[The role of integrin alpha 8 beta 1 in kidney morphogenesis] Denda S. **Tanpakushitsu Kakusan Koso** 1999 Feb; 44(2):136–42 (21 ref.) **(Jpn)**
[Integrins and integrin–associated molecules: targets for the development of antimetastatic therapies] Velasco–Velázquez MA, et al. **Rev Invest Clin** 1999 May–Jun;51(3):183–93 (87 ref.) (Eng. Abstr.) **(Spa)**

INTELLIGENCE

Differences in mental abilities. Deary IJ. **BMJ** 1998 Dec 19–26;317(7174):1701–3 (13 ref.)
The savant syndrome: intellectual impairment and exceptional skill. Miller LK. **Psychol Bull** 1999 Jan; 125(1):31–46 (155 ref.)
Intelligence and dyslexia: implications for diagnosis and intervention. Gustafson S, et al. **Scand J Psychol** 1999 Jun; 40(2):127–34 (52 ref.)
Thyroid hormone and intellectual development: a clinician's view. Lazarus JH. **Thyroid** 1999 Jul;9(7):659–60 (12 ref.)

GENETICS

Implications of the restricted range of family environments for estimates of heritability and nonshared environment in behavior–genetic adoption studies. Stoolmiller M. **Psychol Bull** 1999 Jul;125(4):392–409 (110 ref.)

INTELLIGENCE TESTS

Neuropsychologic and adaptive functioning in adolescents and young adults shunted for congenital hydrocephalus. Hommet C, et al. **J Child Neurol** 1999 Mar;14(3):144–50 (48 ref.)

INTENSIVE CARE

see related
CRITICAL CARE

Neuromuscular blockade in the intensive care unit. Lewis KS, et al. **Am J Health Syst Pharm** 1999 Jan 1;56(1):72–5 (51 ref.)
Bronchoscopy in the intensive care unit (ICU). Tai DY. **Ann Acad Med Singapore** 1998 Jul;27(4):552–9 (40 ref.)
ABC of intensive care. Cutting edge. Singer M, et al. **BMJ** 1999 Aug 21;319(7208):501–4 (0 ref.)
ABC of intensive care. Withdrawal of treatment. Winter B, et al. **BMJ** 1999 Jul 31;319(7205):306–8 (0 ref.)
Nutrition management in the ICU. Chan S, et al. **Chest** 1999 May;115(5 Suppl):145S–148S (23 ref.)
Cardiac management in the ICU. Ramsay JG. **Chest** 1999 May;115(5 Suppl):138S–144S (36 ref.)
Mechanisms and prevention of secondary brain damage during intensive care. Dearden NM. **Clin Neuropathol** 1998 Jul–Aug;17(4):221–8 (26 ref.)
Intensive care management of subarachnoid hemorrhage, ischemic stroke, and hemorrhagic stroke. Martin NA, et al. **Clin Neurosurg** 1999;45:101–12 (75 ref.)
Glutamine–containing TPN: a question of life and death for intensive care unit–patients? Wernerman J. **Clin Nutr** 1998 Feb;17(1):3–6 (31 ref.)
European life–support questionnaire [editorial; comment] Leonard C, et al. **Crit Care Med** 1999 Aug;27(8):1686–7 (9 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1626–33.
Autopsies in the ICU: we still need them! [editorial; comment] Pastores SM, et al. **Crit Care Med** 1999 Feb;27(2):235–6 (13 ref.) Comment on: Crit Care Med 1999 Feb;27(2):299–303.
Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review [see comments] Roberts I, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):729–33 (25 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):66.
Propofol–infusion syndrome in children [see comments] Hatch DJ. **Lancet** 1999 Apr 3;353(9159):1117–8 (12 ref.) Comment in: Lancet 1999 Jun 12;353(9169):2074–5.
Fluid replacement in ICU. Hillman K. **Minerva Anestesiol** 1999 May;65(5):284–5 (11 ref.)
Intensive care for patients with medical complications of haematological malignancy: is it worth it? Hinds CJ, et al. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1467–73 (20 ref.)
Quality of life after intensive care. Niskanen M. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1474–7 (23 ref.)
[Tracheostomy in intensive care] Westphal K, et al. **Anaesthesist** 1999 Mar;48(3):142–56 (70 ref.) (Eng. Abstr.) **(Ger)**
[Forced opioid detoxification under general anesthesia—a new challenge for anesthetists and intensive care physicians] [see comments] Hensel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 May; 34(5):261–8 (52 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1999 May;34(5):259–60. **(Ger)**
[ACE inhibitor–induced angioedema: remarkable new perspectives for intensive care/emergency medicine] Wernze H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Oct; 33(10):637–41 (38 ref.) (Eng. Abstr.) **(Ger)**
[Sleep–related respiration disorders: their relevance in intensive care medicine] Sanner BM, et al. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):296–8 (34 ref.) **(Ger)**
[Diagnostic imaging in intensive care. Techniques, indications, diagnostic signs—II] Bankier A, et al. **Internist (Berl)** 1999 Mar;40(3):W294–304 (18 ref.) **(Ger)**
[Diagnostic imaging in intensive care medicine. Techniques, indications, diagnostic signs—I] Bankier A, et al. **Internist (Berl)** 1999 Feb;40(2):W190–204 (18 ref.) **(Ger)**
[Ethical problems in the area of intensive care medicine] Schuster HP. **Internist (Berl)** 1999 Mar;40(3):260–9 (28 ref.) **(Ger)**
[Intensive care medicine in surgery. General principles and special surgical intensive care medicine (1)] Hartl WH, et al. **Zentralbl Chir** 1999;124(7):W63–74 (0 ref.) **(Ger)**
[Latest results of intensive care of sepsis, septic shock and multiple organ injuries] Incze F. **Orv Hetil** 1999 Mar 7; 140(10):515–20 (49 ref.) (Eng. Abstr.) **(Hun)**
[New advances and debated questions in intensive care in the 90–s] Incze F. **Orv Hetil** 1998 Dec 20;139(51):3059–64 (31 ref.) (Eng. Abstr.) **(Hun)**
[Antithrombin III in intensive therapy] Baudo F, et al. **Minerva Anestesiol** 1999 Jan–Feb;65(1–2 Suppl 1):71–6 (35 ref.) **(Ita)**
[Midazolam in sedation in intensive therapy] Braschi A, et al. **Minerva Anestesiol** 1998 Dec;64(12 Suppl 1):7–10 (7 ref.) **(Ita)**
[Therapeutic applications of hypothermia in intensive care] Faenza S, et al. **Minerva Anestesiol** 1999 Jun;65(6):367–71 (26 ref.) (Eng. Abstr.) **(Ita)**
[Strategy for intensive care in patients with subarachnoid

hemorrhage] Procaccio F. **Minerva Anestesiol** 1998 May; 64(5):207–8 (4 ref.) (Eng. Abstr.) **(Ita)**

[Logic of the development of intensive care in critical states] Riabov GA. **Anesteziol Reanimatol** 1999 Jan–Feb;(1):10–3 (13 ref.) **(Rus)**

[Variants of hyperosmolarity syndrome in diabetes mellitus patients in critical conditions] Ruiatkina LA, et al. **Klin Med (Mosk)** 1998;76(9):37–43 (24 ref.) (Eng. Abstr.) **(Rus)**

[Sedation and analgesia in intensive therapy] Pjević M, et al. **Med Pregl** 1998 Nov–Dec;51(11–12):509–17 (41 ref.) (Eng. Abstr.) **(Ser)**

[Indications for admission to the intensive care service of adult patients with severe infections] Alvarez Lerma F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):423–30 (70 ref.) **(Spa)**

[Intensive neurology. Past, present, and future] Tellería-Díaz A. **Rev Neurol** 1998 Nov;27(159):830–2 (17 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Severity of illness scoring systems and performance appraisal. Ridley S. **Anaesthesia** 1998 Dec;53(12):1185–94 (48 ref.)

ECONOMICS

To chest x-rays and beyond!! [editorial; comment] Helfaer M. **Crit Care Med** 1999 Aug;27(8):1676–7 (18 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1588–93.

Relationship between TISS and costs in intensive care [editorial; comment] Edbrooke D, et al. **Intensive Care Med** 1998 Oct;24(10):995–6 (13 ref.) Comment on: Intensive Care Med 1998 Oct;24(10):1009–17. Comment on: Intensive Care Med 1998 Oct;24(10):1062–9.

HISTORY

[The history of the development of intensive care medicine in Germany. Contemporary reflections. 4. Structural development of operative intensive care medicine in the former German Democratic Republic] Benad G, et al. **Anaesthesist** 1999 Apr;48(4):251–62 (35 ref.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[Privacy in intensive care] Buzzi F. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):37–41 (0 ref.) **(Ita)**

METHODS

Neurointensive care of aneurysmal SAH. Persson L, et al. **Acta Neurochir Suppl (Wien)** 1999;72:73–80 (30 ref.)

Risk reduction in the intensive care unit [see comments] Saint S, et al. **Am J Med** 1998 Dec;105(6):515–23 (117 ref.) Comment in: Am J Med 1998 Dec;105(6):551–3.

Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Bugg NC, et al. **Anaesthesia** 1998 Sep;53(9):895–902 (64 ref.)

Continuous renal replacement therapy: continuous blood purification in the intensive care unit. Bellomo R, et al. **Ann Acad Med Singapore** 1998 May;27(3):426–9 (28 ref.)

Contributions of respiratory care practitioners to intensive care: a review. Yu NC, et al. **Ann Acad Med Singapore** 1998 May;27(3):422–5 (21 ref.)

Current principles of treatment in acute pancreatitis. Puolakkainen P, et al. **Ann Chir Gynaecol** 1998;87(3):200–3 (27 ref.)

ABC of intensive care: other supportive care. Adam S, et al. **BMJ** 1999 Jul 17;319(7203):175–8 (0 ref.)

ABC of dysfunction: organ dysfunction. Evans TW, et al. **BMJ** 1999 Jun 12;318(7198):1606–9 (0 ref.)

ABC of intensive care: neurological support. Grant IS, et al. **BMJ** 1999 Jul 10;319(7202):110–3 (0 ref.)

ABC of intensive care: respiratory support. Shelly MP, et al. **BMJ** 1999 Jun 19;318(7199):1674–7 (0 ref.)

ABC of intensive care. Renal support. Short A, et al. **BMJ** 1999 Jul 3;319(7201):41–4 (0 ref.)

ABC of intensive care. Criteria for admission. Smith G, et al. **BMJ** 1999 Jun 5;318(7197):1544–7 (0 ref.)

ABC of intensive care. Transport of critically ill patients. Wallace PG, et al. **BMJ** 1999 Aug 7;319(7206):368–71 (0 ref.)

Does optimizing oxygen transport improve outcome in intensive care patients? Brazzi L, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:46–9 (28 ref.)

Pulmonary artery catheterization in anaesthesia and intensive care. Gómez CM, et al. **Br J Anaesth** 1998 Dec; 81(6):945–56 (192 ref.)

Reduced mortality from septic shock—lessons for the future [editorial; comment] Cohen NH. **Crit Care Med** 1998 Dec; 26(12):1956–8 (25 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2078–86.

Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650–1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429–36.

An intensivist's dilemma: support of the splanchnic circulation in critical illness [editorial; comment] Marshall JC. **Crit Care Med** 1998 Oct;26(10):1637–8 (20 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1749–58.

Charting the course of critical illness: prognostication and outcome description in the intensive care unit [editorial; comment] Marshall JC. **Crit Care Med** 1999 Apr; 27(4):676–8 (14 ref.) Comment on: Crit Care Med 1999 Apr;27(4):741.

Bispectral Index: better information for sedation in the intensive care unit? [editorial; comment] Shapiro BA. **Crit Care Med** 1999 Aug;27(8):1663–4 (20 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1499–1504.

Enteral nutrition: should we feed the stomach? [editorial; comment] Smith HG, et al. **Crit Care Med** 1999 Aug; 27(8):1652–3 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1447–53.

Therapy of sepsis: why have we made such little progress? [editorial; comment] Teplick R, et al. **Crit Care Med** 1999 Aug;27(8):1682–3 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1608–16.

Prone position in acute respiratory distress syndrome: turning over an old idea [editorial; comment] Trottier SJ. **Crit Care Med** 1998 Dec;26(12):1934–5 (20 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1977–85.

Stroke—a medical emergency. Berger C, et al. **Eur J Emerg Med** 1999 Mar;6(1):61–9 (47 ref.)

Monitoring the injured brain in intensive care: present and future. Gupta AK, et al. **Hosp Med** 1998 Sep;59(9):704–13 (27 ref.)

Immunonutrition in the critically ill. Jolliet P, et al. **Intensive Care Med** 1999 Jun;25(6):631–3 (3 ref.)

Sedation for the critically ill. Sydow M, et al. **Intensive Care Med** 1999 Jun;25(6):634–6 (4 ref.)

Management of the respiratory complications of neuromuscular diseases in the pediatric intensive care unit. Birnkrant DJ, et al. **J Child Neurol** 1999 Mar;14(3):139–43 (13 ref.)

Contribution of the neuro-intensivist in the choice of treatment of patients with aneurysm. Levati A, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):113–6 (21 ref.)

Efficacy and limitation of apheresis therapy in critical care. Hirasawa H, et al. **Ther Apher** 1997 Aug;1(3):228–32 (21 ref.)

[Treatment of intracranial hypertension in the case of severe craniocerebral injuries] Moeschler O, et al. **Ann Fr Anesth Reanim** 1997;16(4):453–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Intensive care for patients with multiple injuries] Waydhas C, et al. **Unfallchirurg** 1999 Jun;102(6):474–91 (82 ref.) **(Ger)**

[Intestinal ischemic reperfusion syndrome: pathophysiology, clinical significance, therapy] Schwarz B, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):539–48 (115 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Intensivists for the intensive care unit—do they make a difference? [editorial] Lew TW, et al. **Ann Acad Med Singapore** 1998 May;27(3):305–7 (20 ref.)

Recovery from intensive care. Griffiths RD, et al. **BMJ** 1999 Aug 14;319(7207):427–9 (0 ref.)

ABC of intensive care: circulatory support. Hinds CJ, et al. **BMJ** 1999 Jun 26;318(7200):1749–52 (0 ref.)

PSYCHOLOGY

Allegations of sexual abuse in an intensive care unit. Hansen-Flaschen J, et al. **Crit Care Med** 1999 Feb; 27(2):437–40 (32 ref.)

Possible allegations of sexual abuse in an intensive care unit: an editorial [editorial] Mohindra V, et al. **Crit Care Med** 1999 Feb;27(2):268–9 (10 ref.)

[Psychological problems and treatment possibilities in intensive care medicine exemplified by bone marrow transplantation] Schulz-Kindermann F, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):390–7 (55 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Intensive care in developed and developing countries: are comparisons of ICU performance meaningful? [editorial; comment] Armaganidis A. **Intensive Care Med** 1998 Nov; 24(11):1126–8 (27 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1144–51.

Enteral nutrition in intensive care patients: a practical approach. Working Group on Nutrition and Metabolism, ESICM. European Society of Intensive Care Medicine. Jolliet P, et al. **Intensive Care Med** 1998 Aug;24(8):848–59 (82 ref.)

[FRC measurement in intensive care patients. A definition of standards] Wauer HJ, et al. **Anaesthesist** 1998 Oct; 47(10):844–55 (125 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Has the mortality of septic shock changed with time [see comments] Friedman G, et al. **Crit Care Med** 1998 Dec; 26(12):2078–86 (144 ref.) Comment in: Crit Care Med 1998 Dec;26(12):1956–8.

[Point-of-care-testing—the intensive care laboratory] Müller MM, et al. **Anaesthesist** 1999 Jan;48(1):3–8 (14 ref.) (Eng. Abstr.) **(Ger)**

INTENSIVE CARE, NEONATAL

Neonatal viability in the 1990s: held hostage by technology. Muraskas J, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):160–70; discussion 170–2 (43 ref.)

Support of gas exchange in the delivery room and beyond: how do we avoid hurting the baby we seek to save? Clark RH. **Clin Perinatol** 1999 Sep;26(3):669–81, vii–viii (68 ref.)

Practical approach to analgesia and sedation in the neonatal intensive care unit. Menon G, et al. **Semin Perinatol** 1998 Oct;22(5):417–24 (73 ref.)

[Implementation of an individualized program of sustained development in neonatal intensive care: why, how?] Sizun J, et al. **Arch Pediatr** 1999 Apr;6(4):434–9 (52 ref.) (Eng. Abstr.) **(Fre)**

[Neonatal care of premature infants] Ertl T. **Orv Hetil** 1999 Jul 18;140(29):1611–8 (5011 ref.) (Eng. Abstr.) **(Hun)**

[Early discharge from maternity and neonatal care units—limitations and perspectives (see comments)] Hansen TW. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1893–6 (45 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 20;119(16):2391–2. **(Nor)**

[Neurologic development of children at age two who had been treated at a neonatal intensive care unit] Fernández Carrocera LA, et al. **Rev Panam Salud Publica** 1999 Jan; 5(1):29–35 (43 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Ethical and legal impediments to cost-efficient neonatal intensive care. Peabody JL. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S24–6 (29 ref.)

LEGISLATION & JURISPRUDENCE

Ethical and legal impediments to cost-efficient neonatal intensive care. Peabody JL. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S24–6 (29 ref.)

METHODS

Care of the surgical intensive care nursery graduate. The primary care pediatrician's perspective. Brown RL, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1327–52 (60 ref.)

ORGANIZATION & ADMINISTRATION

[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:94–103 (40 ref.) **(Fre)**

STANDARDS

Neonatal intensive care: satisfaction measured from a parent's perspective. Conner JM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):336–49 (67 ref.)

Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. Hack M. **Pediatrics** 1999 Jan;103(1 Suppl E):319–28 (110 ref.)

INTENSIVE CARE, SURGICAL see **INTENSIVE CARE**

INTENSIVE CARE UNITS

Nutrition management in the ICU. Chan S, et al. **Chest** 1999 May;115(5 Suppl):145S–148S (23 ref.)

Cardiac management in the ICU. Ramsay JG. **Chest** 1999 May;115(5 Suppl):138S–144S (36 ref.)

Who goes to the ICU postoperatively? Sirio CA, et al. **Chest** 1999 May;115(5 Suppl):125S–129S (29 ref.)

Clinical intervention trials: the ACE unit. Palmer RM, et al. **Clin Geriatr Med** 1998 Nov;14(4):831–49 (62 ref.)

Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Drusano GL. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S111–6 (32 ref.)

Regional anesthesia techniques for pain control in the intensive care unit. Burton AW, et al. **Crit Care Clin** 1999 Jan;15(1):77–88, vi (28 ref.)

Bird's-eye view of nosocomial infections in medical ICU: blue bugs, fungi, and device-days [editorial; comment] Bonten MJ, et al. **Crit Care Med** 1999 May;27(5):853–4 (15 ref.) Comment on: Crit Care Med 1999 May;27(5):887–92.

Hospital wards spreading vancomycin-resistant enterococci to intensive care units: returning coals to Newcastle [editorial; comment] Farr BM. **Crit Care Med** 1998 Dec; 26(12):1942–3 (14 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2001–4.

Continuous EEG monitoring in the neuroscience intensive care unit and emergency department. Jordan KG. **J Clin Neurophysiol** 1999 Jan;16(1):14–39 (92 ref.)

Management of pain in intensive care settings. Stevens DS, et al. **Surg Clin North Am** 1999 Apr;79(2):371–86 (76 ref.)

[The value of the CT scanner in intensive care] Berthezène Y, et al. **Rev Mal Respir** 1998 Sep;15(4):489–93 (16 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of nosocomial infections in the intensive care unit and the operating room] Gastmeier P, et al. **Anaesthesist** 1999 Aug;48(8):575–90 (30 ref.) **(Ger)**

[Stress ulceration related bleeding (SURB) in intensive care unit] Kitamura N, et al. **Nippon Rinsho** 1998 Sep; 56(9):2396–400 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Nosocomial pneumonia in intensive care units (review of the literature)] Gel'fand BR, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):38–46 (90 ref.) **(Rus)**

INTENSIVE CARE UNITS

ECONOMICS

How to use the results of an economic evaluation. Heyland DK, et al. **Crit Care Med** 1999 Jun;27(6):1195–202 (36 ref.)

MANPOWER

Intensivists for the intensive care unit--do they make a difference? [editorial] Lew TW, et al. **Ann Acad Med Singapore** 1998 May;27(3):305–7 (20 ref.)

A challenge for clinical nurses: a new nursing role [see comments] Balogh D, et al. **Heart Lung** 1998 Nov–Dec; 27(6):355–9 (11 ref.) Comment in: Heart Lung 1999 May–Jun;28(3):226.

ORGANIZATION & ADMINISTRATION

Critical care medicine in the Western Pacific region. Dobb GJ. **Ann Acad Med Singapore** 1998 May;27(3):381–6 (17 ref.)

Critical care--the worldwide perspective. Fisher M. **Ann Acad Med Singapore** 1998 May;27(3):376–80 (22 ref.)

ABC of intensive care: organisation of intensive care. Bennett D, et al. **BMJ** 1999 May 29;318(7196):1468–70 (0 ref.)

The clinical management database. Cowen JS, et al. **Crit Care Clin** 1999 Jul;15(3):481–97, v (28 ref.)

Electronic medical record in the intensive care unit. Sado AS. **Crit Care Clin** 1999 Jul;15(3):499–522 (76 ref.)

National intensive care unit datasets: lost at sea without a compass? [editorial; comment] Angus DC, et al. **Crit Care Med** 1999 Aug;27(8):1659–61 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1486–91.

STANDARDS

APACHE II, data accuracy and outcome prediction. Goldhill DR, et al. **Anaesthesia** 1998 Oct;53(10):937–43 (19 ref.)

Severity scoring systems in the modern intensive care unit. Clermont G, et al. **Ann Acad Med Singapore** 1998 May; 27(3):397–403 (44 ref.)

Improving outcomes in the ICU setting: are we effectively using all of the information that is potentially available to us? [editorial; comment] Kollef MH. **Chest** 1999 Jun; 115(6):1490–2 (17 ref.) Comment on: Chest 1999 Jun;115(6):1627–31.

Grappling with intensive care unit quality--does the readmission rate tell us anything? [editorial; comment] Angus DC. **Crit Care Med** 1998 Nov;26(11):1779–80 (12 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1834–41.

Incorporating palliative care into critical care education: principles, challenges, and opportunities [see comments] Danis M, et al. **Crit Care Med** 1999 Sep;27(9):2005–13 (59 ref.) Comment in: Crit Care Med 1999 Sep;27(9):2068–9.

Intensive care in developed and developing countries: are comparisons of ICU performance meaningful? [editorial; comment] Armaganidis A. **Intensive Care Med** 1998 Nov; 24(11):1126–8 (27 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1144–51.

Scoring systems in the measurement of performance of ICUs. Miranda DR. **Intensive Care Med** 1999 Apr;25(4):418–9 (4 ref.)

[New advances and debated questions in intensive care in the 90-s] Incze F. **Orv Hetil** 1998 Dec 20;139(51):3059–64 (31 ref.) (Eng. Abstr.) **(Hun)**

STATISTICS & NUMERICAL DATA

[Indications for admission to the intensive care service of adult patients with severe infections] Alvarez Lerma F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):423–30 (70 ref.) **(Spa)**

TRENDS

Bacteremia in the intensive care unit: a predicament propagated by progress [editorial; comment] Willy ME, et al. **Crit Care Med** 1999 Aug;27(8):1648–50 (12 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1421–8.

[Intensive care for patients with multiple injuries] Waydhas C, et al. **Unfallchirurg** 1999 Jun;102(6):474–91 (82 ref.) **(Ger)**

UTILIZATION

Women in the intensive care unit [editorial] Baggs JG. **Am J Crit Care** 1999 Jul;8(4):207–9 (24 ref.)

ABC of intensive care: outcome data and scoring systems. Gunning K, et al. **BMJ** 1999 Jul 24;319(7204):241–4 (0 ref.)

INTENSIVE CARE UNITS, NEONATAL

Early discharge from the NICU. Gamblian V, et al. **J Pediatr Nurs** 1998 Oct;13(5):296–301 (11 ref.)

The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)

[Early discharge from maternity and neonatal care units--limitations and perspectives (see comments)] Hansen TW. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1893–6 (45 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 20;119(16):2391–2. **(Nor)**

ECONOMICS

The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)

ORGANIZATION & ADMINISTRATION

Challenges in the NICU: questions or answers? Speer ME. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S1–5 (30 ref.)

STANDARDS

Environmental impact of the NICU on developmental outcomes. Blackburn S. **J Pediatr Nurs** 1998 Oct; 13(5):279–89 (60 ref.)

Risk adjustment for quality improvement. Richardson D, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):255–65 (76 ref.)

INTENSIVE CARE UNITS, PEDIATRIC

Pain management in the pediatric intensive care unit. Macfadyen AJ, et al. **Crit Care Clin** 1999 Jan;15(1):185–200, viii (67 ref.)

Pediatric intensive care. Macintire DK. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):971–88, vii–viii (13 ref.)

[Acute pain, analgesia and sedation in children (V): analgesia and sedation in pediatric intensive care] Valdivielso Serna A, et al. **An Esp Pediatr** 1998 Aug;49(2):193–208 (76 ref.) **(Spa)**

ECONOMICS

To chest x-rays and beyond!! [editorial; comment] Helfaer M. **Crit Care Med** 1999 Aug;27(8):1676–7 (18 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1588–93.

STANDARDS

Venous thromboembolic disease in the pediatric intensive care unit. Donnelly KM. **Curr Opin Pediatr** 1999 Jun; 11(3):213–7 (36 ref.)

INTERAGENCY RELATIONS see **INTERINSTITUTIONAL RELATIONS**

INTERCALATED NEURONS see **INTERNEURONS**

INTERCALATING AGENTS

CHEMISTRY

Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues. Bailly C, et al. **Bioconjug Chem** 1998 Sep–Oct;9(5):513–38 (299 ref.)

INTERCALATORS see **INTERCALATING AGENTS**

INTERCELLULAR ADHESION MOLECULE-1

BIOSYNTHESIS

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):95–100 (35 ref.)

BLOOD

Intercellular adhesion molecule--sICAM-1: an emerging cardiovascular risk factor. Drown DJ. **Prog Cardiovasc Nurs** 1998 Fall;13(4):30, 23 (4 ref.)

[New therapeutic strategy for autoimmune diseases. 2) Abnormality in expression of cell surface molecules in systemic erythematodes and its therapeutic application] Takasaki Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1741–4 (3 ref.) **(Jpn)**

DRUG EFFECTS

Probucol suppresses ICAM-1 expression in rat mesangial cells: possible role of IL-1. Sugiura T, et al. **Kidney Int Suppl** 1999 Jul;71:S167–70 (10 ref.)

GENETICS

Antisense oligodeoxynucleotides for organ transplantation. Stepkowski SM. **Clin Biochem** 1998 Jul;31(5):375–9 (29 ref.)

IMMUNOLOGY

[The role of cell adhesion molecules in certain neurological diseases] Niezgoda A, et al. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1485–96 (36 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Intercellular adhesion molecule-1 and hepatocyte growth factor in human endometriosis: original investigation and a review of literature. Fukaya T, et al. **Gynecol Obstet Invest** 1999;47 Suppl 1:11–6; discussion 16–7 (23 ref.)

ICAM-1 interactions in the renal interstitium: a novel activator of fibroblasts during nephritis. Clayton A, et al. **Histol Histopathol** 1999 Jul;14(3):861–70 (67 ref.)

Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Watanabe T, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S45–53; discussion S55 (57 ref.)

Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Roebuck KA. **Int J Mol Med** 1999 Sep;4(3):223–30 (102 ref.)

The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Takasaki Y, et al. **Intern Med** 1999 Feb;38(2):175–7 (8 ref.)

Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins [comment] Moss P. **Transplantation** 1999 Jan 15; 67(1):2–3 (14 ref.) Comment on: Transplantation 1999 Jan 15;67(1):137–44.

[The role of cell adhesion molecules in certain neurological diseases] Niezgoda A, et al. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1485–96 (36 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Diapedesis of leukocytes: antisense oligonucleotides for rescue. Dragun D, et al. **Exp Nephrol** 1999 Mar–Apr; 7(2):185–92 (68 ref.)

Dissemination of T cell lymphoma to target organs: a post-homing event implicating ICAM-1 and matrix metalloproteinases. St-Pierre Y, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):53–61 (55 ref.)

[The role of intercellular adhesion molecule-1 in respiratory disorders] Nagase T. **Nihon Kokyuki Gakkai Zasshi** 1998 Nov;36(11):923–7 (54 ref.) (Eng. Abstr.) **(Jpn)**

INTERCELLULAR ADHESION MOLECULES see **CELL ADHESION MOLECULES**

INTERCELLULAR JUNCTIONS

CHEMISTRY

Vinculin and alpha-catenin: shared and unique functions in adherens junctions. Rüdiger M. **Bioessays** 1998 Sep; 20(9):733–40 (79 ref.)

PHYSIOLOGY

Intercellular connections are developmentally controlled to help move molecules through the plant [comment] Pickard BG, et al. **Cell** 1999 Jul 9;98(1):5–8 (12 ref.) Comment on: Cell 1999 Jun 11;97(6):743–54.

Structure, function, regulation: experimental analysis in groups of non-excitable cells coupled via permeable junctions. Potapova TV, et al. **Membr Cell Biol** 1998; 11(6):817–29 (40 ref.)

[Endothelial intercellular junctions: relationship between vascular adhesion and morphogenesis] Huber P. **J Soc Biol** 1999;193(2):181–7 (64 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Structural and functional aspects of intercellular junctions in vascular endothelium. Schnittler HJ. **Basic Res Cardiol** 1998;93 Suppl 3:30–9 (86 ref.)

INTERCELLULAR SPACE see **EXTRACELLULAR SPACE**

INTERCOSTAL NERVES

INJURIES

Combined abdominal wall paresis and incisional hernia after laparoscopic cholecystectomy. Korenkov M, et al. **Surg Endosc** 1999 Mar;13(3):268–9 (5 ref.)

INTERCRINES see **CHEMOKINES**

INTERDENTAL PAPILLA see **GINGIVA**

INTERDIGITATING CELLS see **DENDRITIC CELLS**

INTERDISCIPLINARY HEALTH TEAM see **PATIENT CARE TEAM**

INTERFACE, USER COMPUTER see **USER-COMPUTER INTERFACE**

INTERFASCICULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

INTERFEROMETRY

METHODS

Three interferometric methods for measuring the thickness of layers of the tear film. King-Smith PE, et al. **Optom Vis Sci** 1999 Jan;76(1):19–32 (30 ref.)

INTERFEROMETRY, MICROSCOPIC see **MICROSCOPY, INTERFERENCE**

INTERFERON ALFA see **INTERFERON-ALPHA**

INTERFERON ALFA-2B

ADMINISTRATION & DOSAGE

[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature] Terheyden P, et al. **Hautarzt** 1998 Oct;49(10):770-3 (23 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Secondary hyperparathyroidism exacerbation: a rare side-effect of interferon-alpha? Calvino J, et al. **Clin Nephrol** 1999 Apr;51(4):248-51 (23 ref.)

Drug-induced hypertriglyceridemia with and without pancreatitis. Keung YK, et al. **South Med J** 1999 Sep; 92(9):912-4 (22 ref.)

THERAPEUTIC USE

Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Kirkwood JM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S12-7 (20 ref.)

Combination therapy for chronic hepatitis C: interferon and ribavirin. Christie JM, et al. **Hosp Med** 1999 May; 60(5):357-61 (24 ref.)

Two options for hepatitis C treatment. **Pa Med** 1999 Apr; 102(4):22-3 (9 ref.)

Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Davis GL. **Semin Liver Dis** 1999;19 Suppl 1:49-55 (46 ref.)

Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Dieterich DT, et al. **Semin Liver Dis** 1999;19 Suppl 1:87-94 (63 ref.)

Standards of treatment in chronic hepatitis C. Gish RG. **Semin Liver Dis** 1999;19 Suppl 1:35-47 (187 ref.)

The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Younossi ZM, et al. **Semin Liver Dis** 1999;19 Suppl 1:95-102 (32 ref.)

INTERFERON ALFA-2C see **INTERFERON ALFA, RECOMBINANT**

INTERFERON ALFA, RECOMBINANT

ADVERSE EFFECTS

Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Dumoulin FL, et al. **Biomed Pharmacother** 1999 Jun;53(5-6):242-54 (157 ref.)

THERAPEUTIC USE

Treatment of hepatitis C infection in patients with renal disease. Diego JM, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):557-62 (61 ref.)

Chronic myelogenous leukemia: update on biology and treatment. Faderl S, et al. **Oncology (Huntingt)** 1999 Feb; 13(2):169-80; discussion 181, 184 (75 ref.)

INTERFERON-ALPHA

ADMINISTRATION & DOSAGE

Adjuvant interferon treatment for melanoma. Agarwala SS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):823-33 (24 ref.)

Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. Kanda Y, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):193-7 (19 ref.)

Use of high-dose interferon in the treatment of chronic hepatitis C. Shiffman ML. **Semin Liver Dis** 1999;19 Suppl 1:25-33 (54 ref.)

[Chronic hepatitis C--therapeutic modalities for interferon failure] Hermann R. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1413-20 (82 ref.) (Eng. Abstr.) **(Ger)**

[Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature] Wedemeyer H, et al. **Z Gastroenterol** 1998 Sep;36(9):819-27 (35 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Mood and cognitive disorders in cancer patients receiving cytokine therapy. Meyers CA. **Adv Exp Med Biol** 1999; 461:75-81 (22 ref.)

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Re D, et al. **Bone Marrow Transplant** 1999 Feb;23(3):295-8 (23 ref.)

Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy [see comments] Shah M, et al. **Cancer** 1998 Nov 1;83(9):1938-46 (53 ref.) Comment in: Cancer 1999 Jun 15;85(12):2669-70.

[Side effects of interferon alfa] Berk L, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1461-4 (14 ref.) (Eng. Abstr.) **(Dut)**

[Autoimmune thyroid disease induced by interferon therapy] Murakami M, et al. **Nippon Rinsho** 1999 Aug;57(8):1779-83 (20 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Campbell IL, et al. **Brain Res** 1999 Jul 17;835(1):46-61 (81 ref.)

BLOOD

[New data on acid-labile alpha-interferon] Shcheglovitova ON. **Vopr Virusol** 1999 Mar-Apr;44(2):52-4 (23 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Human acid-labile interferon alpha. Piasecki E. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):89-98 (81 ref.)

IMMUNOLOGY

IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS. Bizzini B, et al. **Biomed Pharmacother** 1999 Mar;53(2):87-9 (21 ref.)

Neuroimmunomodulatory actions of hypothalamic interferon-alpha. Hori T, et al. **Neuroimmunomodulation** 1998 May-Aug;5(3-4):172-7 (63 ref.)

PHARMACOLOGY

Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Gale MJ Jr, et al. **Clin Diagn Virol** 1998 Jul 15;10(2-3):157-62 (30 ref.)

Hepatitis C virus infection: virus/host interactions. Pawlotsky JM. **J Viral Hepat** 1998 Sep;5 Suppl 1:3-8 (19 ref.)

PHYSIOLOGY

Human acid-labile interferon alpha. Piasecki E. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):89-98 (81 ref.)

Analysis of interferon-regulated proteins binding the interferon-alpha-stimulated response element. Levy DE. **Methods** 1998 Jul;15(3):167-74 (43 ref.)

Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Biron CA. **Semin Immunol** 1998 Oct; 10(5):383-90 (76 ref.)

[Anti-viral proteins: from interferon alpha to its receptor] Chieux V, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):283-90 (52 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Interferon alpha in the treatment of chronic myelogenous leukemia. Robak T. **Arch Immunol Ther Exp (Warsz)** 1998; 46(6):347-53 (42 ref.)

The management of Behçet's syndrome: how are we doing? [editorial] Yazici H, et al. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):145-7 (24 ref.)

Current therapy of cutaneous melanoma. Mays SR, et al. **Cutis** 1999 May;63(5):293-8 (52 ref.)

Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Guilhot F, et al. **Hematol Cell Ther** 1998 Oct;40(5):237-9 (12 ref.)

"Breakthrough" during interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible aetiology and recommendations for management. Colloredo G, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):333-7 (37 ref.)

Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. Ahmed A, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S12-8 (49 ref.)

Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children [see comments] Jara P, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):163-70 (19 ref.) Comment in: J Pediatr Gastroenterol Nutr 1999 Aug;29(2):125-6.

Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia? Pasternak G, et al. **Leukemia** 1999 Apr;13 Suppl 1:S55-64 (60 ref.)

Chronic myeloid leukemia. Sawyers CL. **N Engl J Med** 1999 Apr 29;340(17):1330-40 (98 ref.)

Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist [editorial] Fabrizi F, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2079-81 (10 ref.)

Riding on a carousel with IFN-alpha and TNF-alpha [editorial; comment] Zierhut M. **Ocul Immunol Inflamm** 1998 Dec;6(4):209-10 (15 ref.) Comment on: Ocul Immunol Inflamm 1998 Dec;6(4):215-26.

Role of interferon-alfa in NHL: still controversial? Haase-Statz S, et al. **Oncology (Huntingt)** 1999 Aug; 13(8):1147-59; discussion 1159-60, 1163 (64 ref.)

Two options for hepatitis C treatment. **Pa Med** 1999 Apr; 102(4):22-3 (9 ref.)

Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Faro A. **Springer Semin Immunopathol** 1998;20(3-4):425-36 (55 ref.)

[Interferon alpha in the treatment of non-Hodgkin's lymphomas of low malignancy] Monnereau A, et al. **Bull Cancer** 1998 Oct;85(10):855-65 (39 ref.) (Eng. Abstr.) **(Fre)**

[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C] Zeuzem S. **Dtsch Med Wochenschr** 1999 May 21;124(20):636-42 (42 ref.) **(Ger)**

[Therapy of chronic hepatitis B and C] Müllhaupt B, et al. **Schweiz Rundsch Med Prax** 1999 Apr 1;88(14):619-32 (119 ref.) (Eng. Abstr.) **(Ger)**

[Chemotherapy of advanced stage melanoma using cisplatin, epirubicin and alpha-interferon] Carpano S, et al. **Clin Ter** 1999 Mar-Apr;150(2):109-14 (39 ref.) (Eng. Abstr.) **(Ita)**

[Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation] Urabe A. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1381-6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Interferon-alpha treatment for chemotherapy-resistant primary macroglobulinemia with stomach and lung invasion] Kitamura N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):137-44 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Successful preoperative interferon-alpha therapy of renal cell carcinoma with tumor thrombus extending into the inferior vena cava--case report] Miki T, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):796-9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Chronic hepatitis C, autoimmunity and interferon alfa treatment (editorial; comment)] Garcia Buey L, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):165-7 (18 ref.) Comment on: Rev Esp Enferm Dig 1999 Mar;91(3):168-81. **(Spa)**

INTERFERON-BETA

ADVERSE EFFECTS

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Levesque MC, et al. **Arthritis Rheum** 1999 Mar;42(3):569-73 (32 ref.)

CHEMISTRY

The structure of human interferon-beta: implications for activity. Karpusas M, et al. **Cell Mol Life Sci** 1998 Nov; 54(11):1203-16 (72 ref.)

GENETICS

Structure and function of the interferon-beta enhanceosome. Maniatis T, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:609-20 (59 ref.)

IMMUNOLOGY

Development of antibodies to interferon beta in patients: technical and biological aspects. Antonelli G, et al. **Eur Cytokine Netw** 1999 Sep;10(3):413-22 (89 ref.)

PHARMACOKINETICS

[Comparison of pharmacokinetic and pharmacodynamic data of interferon-beta 1a preparations after intramuscular and subcutaneous administration] Gruber R. **Arzneimittelforschung** 1998 Oct;48(10):1043-6 (18 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

[Beta interferon in multiple sclerosis: pharmacological differences] Allain H, et al. **Rev Neurol (Paris)** 1999;155 Suppl 2:S24-30 (39 ref.) (Eng. Abstr.) **(Fre)**

[Comparison of pharmacokinetic and pharmacodynamic data of interferon-beta 1a preparations after intramuscular and subcutaneous administration] Gruber R. **Arzneimittelforschung** 1998 Oct;48(10):1043-6 (18 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Biron CA. **Semin Immunol** 1998 Oct; 10(5):383-90 (76 ref.)

THERAPEUTIC USE

Treatment of multiple sclerosis with interferon beta 1b. Dhib-Jalbut S, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):467-80 (80 ref.)

Interferon beta 1a. Pozzilli C, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):481-93 (34 ref.)

Interferon beta-1a in relapsing-remitting multiple sclerosis. Blumhardt L. **Hosp Med** 1999 Mar;60(3):192-5 (20 ref.)

Recent developments in drug therapy for multiple sclerosis. Smith PF, et al. **Mult Scler** 1999 Apr;5(2):110-20 (161 ref.)

Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Goodin DS. **Neuroepidemiology** 1999;18(2):53-63 (33 ref.)

[Beta interferon in multiple sclerosis: pharmacological differences] Allain H, et al. **Rev Neurol (Paris)** 1999;155 Suppl 2:S24-30 (39 ref.) (Eng. Abstr.) **(Fre)**

[Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis] Gusev EI, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(4):33-6 (18 ref.) **(Rus)**

INTERFERON, FIBROBLAST

INTERFERON, FIBROBLAST see **INTERFERON-BETA**

INTERFERON-GAMMA see **INTERFERON TYPE II**

INTERFERON-GAMMA-INDUCING FACTOR see **INTERLEUKIN-18**

INTERFERON, IMMUNE see **INTERFERON TYPE II**

INTERFERON INDUCERS

see related
ANTINEOPLASTIC AGENTS
ANTIVIRAL AGENTS

[Interferons and inductors of their synthesis (review)] Malashenkova IK, et al. **Ter Arkh** 1998;70(11):35–9 (0 ref.) **(Rus)**

[Interferon inducers: new generation of immunomodulators] Ershov FI, et al. **Vestn Ross Akad Med Nauk** 1999;(4):52–6 (7 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

[Mechanisms of arbidole's immunomodulating action] Glushkov RG, et al. **Vestn Ross Akad Med Nauk** 1999;(3):36–40 (43 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

[The antibacterial efficacy of preparations of interferon and its inducers] Spivak NIa, et al. **Mikrobiol Z** 1999 Jan–Feb;61(1):32–45 (55 ref.) (Eng. Abstr.) **(Rus)**

INTERFERON, LEUKOCYTE see **INTERFERON-ALPHA**

INTERFERON, LYMPHOBLAST see **INTERFERON-ALPHA**

INTERFERON RECEPTORS see **RECEPTORS, INTERFERON**

INTERFERON TYPE I

Interferon-delta: the first member of a novel type I interferon family. Lefèvre F, et al. **Biochimie** 1998 Aug–Sep;80(8–9):779–88 (55 ref.)

Trophoblast interferons. Roberts RM, et al. **Placenta** 1999 May;20(4):259–64 (60 ref.)

GENETICS

Type I interferon gene expression: differential expression of IFN-A genes induced by viruses and double-stranded RNA. Bragança J, et al. **Biochimie** 1998 Aug–Sep;80(8–9):673–87 (93 ref.)

Transcriptional repression of type I IFN genes. Lopez S, et al. **Biochimie** 1998 Aug–Sep;80(8–9):689–701 (139 ref.)

The evolution of the type I interferons [published erratum appears in J Interferon Cytokine Res 1999 Apr;19(4):427] Roberts RM, et al. **J Interferon Cytokine Res** 1998 Oct;18(10):805–16 (54 ref.)

PHARMACOLOGY

Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. Dickensheets HL, et al. **J Leukoc Biol** 1999 Mar;65(3):307–12 (45 ref.)

PHYSIOLOGY

IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Martal JL, et al. **Biochimie** 1998 Aug–Sep;80(8–9):755–77 (236 ref.)

Type I interferons: expression and signalization. Doly J, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1109–21 (136 ref.)

Type I interferons. De Maeyer E, et al. **Int Rev Immunol** 1998;17(1–4):53–73 (120 ref.)

INTERFERON TYPE I, RECOMBINANT see **INTERFERON ALFA, RECOMBINANT**

INTERFERON TYPE II

ADMINISTRATION & DOSAGE

Adjuvant interferon treatment for melanoma. Agarwala SS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):823–33 (24 ref.)

BIOSYNTHESIS

Regulating a regulator: IFNgamma production by the neonate [editorial; comment] Jones CA, et al. **Clin Exp Allergy** 1999 Jul;29(7):865–8 (37 ref.) Comment on: Clin Exp Allergy 1999 Jul;29(7):912–9.

Checkpoints for regulation of development and interferon gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):41–2 (10 ref.)

Checkpoints for regulation of development and IFN-gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Immunol Lett** 1999 Jan;65(1–2):41–4 (23 ref.)

Costimulation of human natural killer cells is required for interferon gamma production. Fehniger TA, et al. **Transplant Proc** 1999 May;31(3):1476–8 (38 ref.)

GENETICS

Inheritable defects in interleukin-12- and interferon-gamma-mediated immunity and the TH1/TH2 paradigm in man. Döffinger R, et al. **Allergy** 1999 May;54(5):409–12 (32 ref.)

The mouse interferon-gamma transgene chronic hepatitis model (Review). Okamoto T, et al. **Int J Mol Med** 1999 May;3(5):517–20 (31 ref.)

IMMUNOLOGY

IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Jouanguy E, et al. **Curr Opin Immunol** 1999 Jun;11(3):346–51 (45 ref.)

The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Tanaka K, et al. **Immunol Rev** 1998 Jun;163:161–76 (127 ref.)

Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Paludan SR. **Scand J Immunol** 1998 Nov;48(5):459–68 (99 ref.)

[Interferon gamma as a regulator of immune cell function] Szuster-Ciesielska A, et al. **Postepy Hig Med Dosw** 1999;53(1):23–41 (103 ref.) (Eng. Abstr.) **(Pol)**

[Immune protection against Mycobacterium tuberculosis. Role of interferon-gamma and T gamma-delta lymphocytes] Aspa Marco FJ, et al. **Arch Bronconeumol** 1998 Dec;34(11):547–53 (85 ref.) **(Spa)**

METABOLISM

Interferon-gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al. **Biochimie** 1998 Aug–Sep;80(8–9):729–37 (49 ref.)

Protein-DNA interactions in interferon-gamma signaling. Park C, et al. **Methods** 1998 Jul;15(3):175–88 (89 ref.)

PHARMACOLOGY

Antigen presentation by MHC class I and its regulation by interferon gamma. Früh K, et al. **Curr Opin Immunol** 1999 Feb;11(1):76–81 (52 ref.)

Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. Dickensheets HL, et al. **J Leukoc Biol** 1999 Mar;65(3):307–12 (45 ref.)

Interferon-gamma and human megakaryopoiesis. Tsuji K, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):107–13 (44 ref.)

PHYSIOLOGY

Immunomodulatory properties of interferon-gamma. An update. Billiau A, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:22–32 (50 ref.)

Similarities and differences of the immune response to exercise and trauma: the IFN-gamma concept. Northoff H, et al. **Can J Physiol Pharmacol** 1998 May;76(5):497–504 (53 ref.)

IFN-gamma expression in macrophages and its possible biological significance. Gessani S, et al. **Cytokine Growth Factor Rev** 1998 Jun;9(2):117–23 (65 ref.)

Signaling and signaling dysfunction through the interferon gamma receptor. Rodig S, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):49–53 (25 ref.)

Oligodendroglial response to the immune cytokine interferon gamma. Popko B, et al. **Neurochem Res** 1999 Feb;24(2):331–8 (97 ref.)

The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Muñoz-Fernández MA, et al. **Prog Neurobiol** 1998 Oct;56(3):307–40 (486 ref.)

INTERFERONS

see related
RECEPTORS, INTERFERON

Marketing medicines through randomised controlled trials: the case of interferon. Pieters T. **BMJ** 1998 Oct 31;317(7167):1231–3 (22 ref.)

Cytokine and interferon research in Israel. Kaempfer R. **Cytokine Growth Factor Rev** 1998 Jun;9(2):99–108 (110 ref.)

Trophoblast interferons. Roberts RM, et al. **Placenta** 1999 May;20(4):259–64 (60 ref.)

ADVERSE EFFECTS

[Neurologic side effects of interferon therapy] Kohira I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):610–3 (15 ref.) **(Jpn)**

BIOSYNTHESIS

Initial and innate responses to viral infections--pattern setting in immunity or disease. Biron CA. **Curr Opin Microbiol** 1999 Aug;2(4):374–81 (76 ref.)

[Interferons and inductors of their synthesis (review)] Malashenkova IK, et al. **Ter Arkh** 1998;70(11):35–9 (0 ref.) **(Rus)**

GENETICS

[In vitro and in vivo inhibition of HIV1 replication by retroviral transfer of interferon alpha, beta, or gamma genes: application to gene therapy of AIDS] Leissner P, et al. **Ann Biol Clin (Paris)** 1998 Mar–Apr;56(2):167–73 (31 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Interferon-inducible Mx proteins in fish. Leong JC, et al. **Immunol Rev** 1998 Dec;166:349–63 (103 ref.)

[Innate nonspecific antiviral immunity] Błach-Olszewska Z. **Postepy Hig Med Dosw** 1999;53(1):3–21 (67 ref.) (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

[Natural interferons: the methods of their isolation, the properties and characteristics of the preparations and their use in animal infections] Kishko IaH. **Mikrobiol Z** 1998 Sep–Oct;60(5):86–98 (55 ref.) (Eng. Abstr.) **(Ukr)**

METABOLISM

How cells respond to interferons. Stark GR, et al. **Annu Rev Biochem** 1998;67:227–64 (319 ref.)

Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Burke F. **Cytokines Cell Mol Ther** 1999 Mar;5(1):51–61 (182 ref.)

Mechanisms of interferon action. Leaman DW. **Prog Mol Subcell Biol** 1998;20:101–42 (227 ref.)

PHARMACOKINETICS

[Recombinant interferons: pharmacokinetics and therapeutic implications] Läer S. **Dtsch Med Wochenschr** 1998 Oct 30;123(44):1320–7 (43 ref.) **(Ger)**

PHARMACOLOGY

Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. Darnell JE Jr. **J Interferon Cytokine Res** 1998 Aug;18(8):549–54 (64 ref.)

The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. Rebouillat D, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):295–308 (108 ref.)

The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: a new face of death? Tan SL, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):543–54 (121 ref.)

Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167–74 (107 ref.)

[The interferons: generalities] Ben Rhomdhane N, et al. **Tunis Med** 1998 Nov;76(11):361–7 (54 ref.) **(Fre)**

PHYSIOLOGY

The role of interferon regulatory factors in the interferon system and cell growth control. Harada H, et al. **Biochimie** 1998 Aug–Sep;80(8–9):641–50 (72 ref.)

Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1. Taniguchi T, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):43–8 (48 ref.)

[Dysfunction of host defence systems caused by virus infection] Fujii N, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):8–18 (35 ref.) **(Jpn)**

[Disorders in the functioning of the interferon system in rheumatoid arthritis] Babynina LIa, et al. **Lik Sprava** 1999 Apr–May;(3):17–20 (35 ref.) **(Ukr)**

SECRETION

Triggering the interferon response: the role of IRF-3 transcription factor. Hiscott J, et al. **J Interferon Cytokine Res** 1999 Jan;19(1):1–13 (100 ref.)

THERAPEUTIC USE

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Poynard T, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):431–7 (53 ref.)

Up to date treatment of hepatitis C in adults. Schalm SW, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):397–9 (12 ref.)

Hepatitis C: Part II. Prevention counseling and medical evaluation [see comments] Moyer LA, et al. **Am Fam Physician** 1999 Jan 15;59(2):349–54, 357 (16 ref.) Comment in: Am Fam Physician 1999 Jan 15;59(2):273–4, 277.

Hepatitis C: natural history, diagnosis, and management. Lam NP. **Am J Health Syst Pharm** 1999 May 15;56(10):961–73; quiz 974–5 (87 ref.)

Pancreatic endocrine tumours, immunotherapy and gene therapy: chemotherapy and interferon therapy of endocrine tumours. Veenhof CH. **Ann Oncol** 1999;10 Suppl 4:185–7 (6 ref.)

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? [see comments] Rice G, et al. **Arch Neurol** 1998 Dec;55(12):1578–80 (12 ref.) Comment in: Arch Neurol 1998 Dec;55(12):1581–3.

Multiple sclerosis: therapeutic update. Tselis AC, et al. **Arch Neurol** 1999 Mar;56(3):277–80 (17 ref.)

Can we cure indolent lymphomas? Cabanillas F. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2655–9 (31 ref.)

Interferons in the management of viral hepatitis. Zein NN. **Cytokines Cell Mol Ther** 1998 Dec;4(4):229–41 (151 ref.)

Practical uses of the interferons in dermatology. Hurd DS, et al. **Int J Dermatol** 1998 Dec;37(12):881–96 (176 ref.)
Medications used in the treatment of multiple sclerosis. Schapiro RT. **Phys Med Rehabil Clin N Am** 1999 May; 10(2):437–46, ix (48 ref.)
[Cytokines and cancer: update in 1998] Négrier S. **Bull Cancer** 1999 Jan;86(1):37–9 (24 ref.) **(Fre)**
[Chemotherapy, interferon and growth factors in the selection of Philadelphia negative cells] Michallet M, et al. **Hematol Cell Ther** 1998 Oct;40(5):241–6 (47 ref.) **(Fre)**
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)] Delwaide J. **Rev Med Liege** 1998 Aug;53(8):467–9 (17 ref.) (Eng. Abstr.) **(Fre)**
[Interferons: Clinical applications in hematology] Ben Rhomdhane N, et al. **Tunis Med** 1998 Dec;76(12):427–36 (98 ref.) **(Fre)**
[Recombinant interferons: pharmacokinetics and therapeutic implications] Läer S. **Dtsch Med Wochenschr** 1998 Oct 30; 123(44):1320–7 (43 ref.) **(Ger)**
[Interferon therapy of chronic viral hepatitis in Hungary: 5-year experience. A multicenter study] Pár A, et al. **Orv Hetil** 1999 May 30;140(22):1227–33 (36 ref.) (Eng. Abstr.) **(Hun)**
[Metastasized carcinoid tumor treated with interferon and octreotide] Szilvás A, et al. **Orv Hetil** 1998 Oct 11; 139(41):2455–8 (41 ref.) (Eng. Abstr.) **(Hun)**
[New management of hepatitis B virus] Sata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):713–7 (14 ref.) **(Jpn)**
[The antibacterial efficacy of preparations of interferon and its inducers] Spivak NIa, et al. **Mikrobiol Z** 1999 Jan–Feb; 61(1):32–45 (55 ref.) (Eng. Abstr.) **(Rus)**
[Predictive value of diverse viral factors in the response to treatment with interferon in patients with chronic hepatitis C] Giménez-Barcons M, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):404–12 (69 ref.) **(Spa)**

INTERGENERATIONAL RELATIONS

The changing moral economy of ancestor worship in a Chinese emigrant district. Eng KK. **Cult Med Psychiatry** 1999 Mar;23(1):99–132 (61 ref.)
Continuities--a search for causal mechanisms: comment on the special section [comment] Patterson GR. **Dev Psychol** 1998 Nov;34(6):1263–8 (62 ref.) Comment on: Dev Psychol 1998 Nov;34(6):1162–74. Comment on: Dev Psychol 1998 Nov;34(6):1175–88. Comment on: Dev Psychol 1998 Nov;34(6):1189–201. Comment on: Dev Psychol 1998 Nov;34(6):1202–8. Comment on: Dev Psychol 1998 Nov;34(6):1209–19. Comment on: Dev Psychol 1998 Nov;34(6):1209–19. Comment on: Dev Psychol 1998 Nov;34(6):1220–32. Comment on: Dev Psychol 1998 Nov;34(6):1233–45. Comment on: Dev Psychol 1998 Nov;34(6):1246–62.
Understanding Generation X employees. Kupperschmidt BR. **J Nurs Adm** 1998 Dec;28(12):36–43 (14 ref.)
[Contribution of maternal sensitivity in transgenerational promotion of binding quality] Ziegenhain U. **Prax Kinderpsychol Kinderpsychiatr** 1999 Feb;48(2):86–100 (40 ref.) (Eng. Abstr.) **(Ger)**

INTERINSTITUTIONAL RELATIONS

Using case research to enhance linkages between academia and public health practice. Liang AP, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):12–3 (11 ref.)
Prevention research centers. The academic and community partnership. Riley PL, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):5–6 (4 ref.)
Organizing community research partnerships in the struggle against AIDS. Schensul JJ. **Health Educ Behav** 1999 Apr; 26(2):266–83 (47 ref.)
School-based health centers and school nurses: cementing the collaboration. Hacker K, et al. **J Sch Health** 1998 Dec; 68(10):409–14 (25 ref.)
Business and faith: key community partnerships for school-based health centers. Juszczak L, et al. **J Sch Health** 1998 Dec;68(10):429–33 (1 ref.)
Mutual accountability in partnerships: health agencies and community groups. Labonte R. **Promot Educ** 1999 Mar; 6(1):3–8, 36 (12 ref.)
Towards quality of care in child health programmes: a challenge for the partnership in health and social sciences. Kanani S. **Soc Sci Med** 1998 Nov;47(9):1223–30 (16 ref.)
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of decision-makers. An example currently in place: the prenatal network for child abuse prevention] Hermange MT. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:237–46 (15 ref.) **(Fre)**

INTERIOR DESIGN AND FURNISHINGS

Mismatch of classroom furniture and student body dimensions: empirical findings and health implications [see comments] Parcells C, et al. **J Adolesc Health** 1999 Apr; 24(4):265–73 (29 ref.) Comment in: J Adolesc Health 1999 Apr;24(4):229.
Animal facility design. Rahija R. **Occup Med** 1999 Apr–Jun; 14(2):407–22 (36 ref.)

STANDARDS

Ergonomic strategies for improving working conditions in some developing countries in Asia. Kawakami T, et al. **Ind Health** 1999 Apr;37(2):187–98 (33 ref.)

INTERIOR FURNISHINGS see **INTERIOR DESIGN AND FURNISHINGS**

INTERLEUKIN-1

see related
CASPASE 1
RECEPTORS, INTERLEUKIN-1

ANTAGONISTS & INHIBITORS

Treatment of rheumatoid arthritis with IL-1 inhibitors. Gabay C, et al. **Springer Semin Immunopathol** 1998; 20(1–2):229–46 (90 ref.)
[Treatment of rheumatoid arthritis with cytokine antagonists] Manger B. **Z Arztl Fortbild Qualitatssich** 1999 Mar; 93(2):101–4 (14 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Immunomodulating effects of methionine enkephalin. Li XY. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):3–6 (30 ref.)

GENETICS

Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Hurme M, et al. **Ann Med** 1998 Oct;30(5):469–73 (41 ref.)
Humoral regulation of physiological sleep: cytokines and GHRH. Krueger JM, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:53–9 (49 ref.)

IMMUNOLOGY

Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha [editorial] Rifas L. **Calcif Tissue Int** 1999 Jan;64(1):1–7 (106 ref.)
Biologic activities of IL-1 and its role in human disease. Rosenwasser LJ. **J Allergy Clin Immunol** 1998 Sep; 102(3):344–50 (47 ref.)
Humoral regulation of physiological sleep: cytokines and GHRH. Krueger JM, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:53–9 (49 ref.)

METABOLISM

Aspects of the involvement of interleukin-1 and nitric oxide in the pathogenesis of insulin-dependent diabetes mellitus. Sjöholm A. **Cell Death Differ** 1998 Jun;5(6):461–8 (67 ref.)
The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Graves DT. **Clin Infect Dis** 1999 Mar;28(3):482–90 (82 ref.)
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). Fantuzzi G, et al. **J Clin Immunol** 1999 Jan;19(1):1–11 (119 ref.)
[Interleukin-1 and nitric oxide involved in the pathogenesis of diabetes)] Sjöholm A. **Lakartidningen** 1999 May 12; 96(19):2338–41 (50 ref.) (Eng. Abstr.) **(Swe)**

PHARMACOLOGY

Individual variation in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Lenczowski MJ, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:139–47 (52 ref.)
Hematologic effects of interleukin-1 and interleukin-6. Ruscetti FW. **Curr Opin Hematol** 1994 May;1(3):210–5 (37 ref.)
Interleukin-1 and nociception in the rat. Bianchi M, et al. **J Neurosci Res** 1998 Sep 15;53(6):645–50 (67 ref.)
The Sixth John M. Kinney-Nestlé Clinical Nutrition Award for Enteral Nutrition. Recombinant human tumor necrosis factor and recombinant murine interleukin-1 alter the binding of Escherichia coli to intestine, mucin glycoprotein, and the HT29-C1 intestinal cell line: a context [see comments] Wanke CA. **Nutrition** 1999 Jun;15(6):427–9 (20 ref.) Comment in: Nutrition 1999 Jun;15(6):430.

PHYSIOLOGY

Stress, learned helplessness, and brain interleukin-1 beta. Maier SF, et al. **Adv Exp Med Biol** 1999;461:235–49 (63 ref.)
Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Miller AH, et al. **Adv Exp Med Biol** 1999; 461:107–16 (33 ref.)
Dynamic regulation of proinflammatory cytokines. Watkins LR, et al. **Adv Exp Med Biol** 1999;461:153–78 (194 ref.)
Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Dinarello CA. **Ann N Y Acad Sci** 1998 Sep 29;856:1–11 (84 ref.)
Sleep. A physiologic role for IL-1 beta and TNF-alpha. Krueger JM, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:148–59 (74 ref.)
Protein kinase cascades in intracellular signalling by interleukin-I and tumour necrosis factor. Saklatvala J, et al. **Biochem Soc Symp** 1999;64:63–77 (65 ref.)
The interleukin-1 and interleukin-1 converting enzyme families in the cardiovascular system. Loppnow H, et al. **Eur Cytokine Netw** 1998 Dec;9(4):675–80 (60 ref.)
The interleukin-1 family. Roux-Lombard P. **Eur Cytokine Netw** 1998 Dec;9(4):565–76 (159 ref.)
Actions of the pro-inflammatory cytokine IL-1 beta on central synaptic transmission. O'Connor JJ, et al. **Exp Physiol** 1999 Jul;84(4):601–14 (82 ref.)
Interleukin-1. Stylianou E, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1075–9 (13 ref.)
Identification of ceramide targets in interleukin-1 and tumor necrosis factor-alpha signaling in mesangial cells. Pfeilschifter J, et al. **Kidney Int Suppl** 1998 Sep;67:S34–9 (34 ref.)
Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Watkins LR, et al. **Life Sci** 1999;65(5):449–81 (290 ref.)
The potential role of interleukin-1 in the ovulatory process: an evolving hypothesis. Adashi EY. **Mol Cell Endocrinol** 1998 May 25;140(1–2):77–81 (50 ref.)
Age-related impairment in long-term potentiation in hippocampus: a role for the cytokine, interleukin-1 beta? Lynch MA. **Prog Neurobiol** 1998 Dec;56(5):571–89 (187 ref.)
Joint inflammation and cartilage destruction may occur uncoupled. van den Berg WB. **Springer Semin Immunopathol** 1998;20(1–2):149–64 (53 ref.)
Hypothalamic interleukin-1 in physiology and pathology. Tringali G, et al. **Toxicol Lett** 1998 Dec 28;102–103:295–9 (22 ref.)

THERAPEUTIC USE

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Bernsen MR, et al. **Cancer Treat Rev** 1999 Apr;25(2):73–82 (123 ref.)

INTERLEUKIN-1BETA see **INTERLEUKIN-1**

INTERLEUKIN-1BETA CONVERTING ENZYME see **CASPASE 1**

INTERLEUKIN-1 RECEPTORS see **RECEPTORS, INTERLEUKIN-1**

INTERLEUKIN-2

see related
RECEPTORS, INTERLEUKIN-2

ADMINISTRATION & DOSAGE

Regional IL-2-based immunochemotherapy of colorectal liver metastases. Okuno K, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1263–7 (8 ref.)
[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature] Terheyden P, et al. **Hautarzt** 1998 Oct;49(10):770–3 (23 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Lentsch AB, et al. **Cancer Immunol Immunother** 1999 Jan;47(5):243–8 (72 ref.)

ANALOGS & DERIVATIVES

Toxicity management in patients receiving low-dose aldesleukin therapy. Sundin DJ, et al. **Ann Pharmacother** 1998 Dec;32(12):1344–52 (34 ref.)

BIOSYNTHESIS

Immunomodulating effects of methionine enkephalin. Li XY. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):3–6 (30 ref.)
Antigen-specific CD4+ T cells that survive after the induction of peripheral tolerance possess an intrinsic lymphokine production defect. Pape KA, et al. **Novartis Found Symp** 1998;215:103–13; discussion 113–9, 186–90 (30 ref.)

GENETICS

Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols. Favrot MC, et al. **Adv Exp Med Biol** 1998;451:539–41 (13 ref.)

IMMUNOLOGY

Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Powell JD, et al. **Immunol Rev** 1998 Oct;165:287–300 (86 ref.)
Hypothesis: A recurrent, moderate activation fosters systemic autoimmunity--the apoptotic roles of TCR, IL-2 and Fas ligand. Matsui K, et al. **J Biomed Sci** 1999 Sep–Oct; 6(5):306–13 (57 ref.)
Recent advances in the understanding of interleukin-2 signal transduction. Gesbert F, et al. **J Clin Immunol** 1998 Sep; 18(5):307–20 (123 ref.)
Immune response of cattle infected with African trypanosomes. Taylor KA, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr;94(2):239–44 (62 ref.)
Immunosuppression through inhibition of

interleukin-2/interleukin-2 receptor interaction. Soulillou JP. **Transplant Proc** 1999 Feb-Mar;31(1-2A):49S-51S (23 ref.)

METABOLISM

Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Burke F. **Cytokines Cell Mol Ther** 1999 Mar;5(1):51-61 (182 ref.)

Signalling by cytokines interacting with the interleukin-2 receptor gamma chain. Demoulin JB, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):243-56 (133 ref.)

PHARMACOLOGY

Target cell-induced apoptosis in IL-2-activated human natural killer cells. Taga K, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):451-8 (49 ref.)

Down-modulation of IL-2-triggered JAK3-STAT5 signaling following CD4-ligand binding. Lowry RP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):820-1 (16 ref.)

PHYSIOLOGY

Biology of the interleukin-2 receptor. Nelson BH, et al. **Adv Immunol** 1998;70:1-81 (442 ref.)

Interleukin-2 signaling and inherited immunodeficiency. Cacalano NA, et al. **Am J Hum Genet** 1999 Aug; 65(2):287-93 (30 ref.)

The molecular basis for bidirectional communication between the immune and neuroendocrine systems. Jiang CL, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):363-9 (21 ref.)

Tyrosine kinase substrates in interleukin-2 signaling. Gesbert F, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):33-40 (70 ref.)

THERAPEUTIC USE

Immunotherapy with recombinant human interleukin 2 in patients with hematological malignancies after bone marrow or peripheral blood stem cell transplantation. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1999; 47(4):223-7 (40 ref.)

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cortes JE, et al. **Cancer** 1999 Apr 1;85(7):1506-13 (42 ref.)

Interleukin 2 in the treatment of acute leukemia. Blaise D, et al. **Leuk Res** 1998 Dec;22(12):1165-70 (29 ref.)

Interleukin-2 and leukemia. Goodman M, et al. **Leukemia** 1998 Nov;12(11):1671-5 (53 ref.)

[Cytokines and cancer: update in 1998] Négrier S. **Bull Cancer** 1999 Jan;86(1):37-9 (24 ref.) **(Fre)**

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237-9 (12 ref.) **(Fre)**

INTERLEUKIN-2 RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

INTERLEUKIN-3

see related
RECEPTORS, INTERLEUKIN-3

PHARMACOLOGY

Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. Anderson JE, et al. **Curr Opin Hematol** 1994 May;1(3):203-9 (43 ref.)

PHYSIOLOGY

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Blalock WL, et al. **Leukemia** 1999 Aug;13(8):1109-66 (871 ref.)

[Functional roles of signaling molecules in cytokine-induced cell growth] Matumura I. **Rinsho Ketsueki** 1999 Apr; 40(4):275-9 (9 ref.) **(Jpn)**

THERAPEUTIC USE

Thrombopoietic factors potentially useful in the treatment of acute leukemia. Archimbaud E, et al. **Leuk Res** 1998 Dec;22(12):1155-64 (141 ref.)

INTERLEUKIN-3 RECEPTORS see **RECEPTORS, INTERLEUKIN-3**

INTERLEUKIN-4

see related
HISTOCOMPATIBILITY ANTIGENS CLASS II

Early interleukin-4: its role in the switch towards a Th2 response and IgE-mediated allergy. Haas H, et al. **Int Arch Allergy Immunol** 1999 Jun;119(2):86-94 (92 ref.)

BIOSYNTHESIS

The development of CD4+ T effector cells during the type 2 immune response. Gause WC, et al. **Immunol Res** 1999; 20(1):55-65 (66 ref.)

GENETICS

Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. Dickensheets HL, et al. **J Leukoc Biol** 1999 Mar;65(3):307-12 (45 ref.)

IMMUNOLOGY

Interleukin-4 production in response to infection with intracellular bacteria. Collins H, et al. **Adv Exp Med Biol** 1998;452:75-83 (29 ref.)

IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Bruserud O. **Cytokines Cell Mol Ther** 1998 Sep;4(3):187-98 (137 ref.)

Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Paludan SR. **Scand J Immunol** 1998 Nov;48(5):459-68 (99 ref.)

PHARMACOLOGY

Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Puri RK. **Toxicol Pathol** 1999 Jan-Feb;27(1):53-7 (28 ref.)

PHYSIOLOGY

Interleukin-4 and interleukin-13: their similarities and discrepancies. Chomarat P, et al. **Int Rev Immunol** 1998; 17(1-4):1-52 (300 ref.)

Receptors and cytokines involved in allergic TH2 cell responses. de Vries JE, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S492-6 (31 ref.)

INTERLEUKIN-4 RECEPTORS see **RECEPTORS, INTERLEUKIN-4**

INTERLEUKIN-5

Biology of IL-5 in health and disease. Lalani T, et al. **Ann Allergy Asthma Immunol** 1999 Apr;82(4):317-32; quiz 332-3 (169 ref.)

ANTAGONISTS & INHIBITORS

IL-5 inhibition as a therapy for allergic disease. Garlisi CG. **Pulm Pharmacol Ther** 1999;12(2):81-5 (28 ref.)

BLOOD

Markedly high eosinophilia and an elevated serum IL-5 level in an infant with cow milk allergy. Matsumoto T, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):253-6 (11 ref.)

GENETICS

Interleukin-5: a proeosinophil cytokine mediator of inflammation in asthma and a target for antisense therapy. Weltman JK, et al. **Allergy Asthma Proc** 1998 Sep-Oct; 19(5):257-61 (42 ref.)

IMMUNOLOGY

Therapeutic effects of antibodies to interleukin-5. Cuss FM. **Allergy** 1998;53(45 Suppl):89-92 (46 ref.)

Nasal polyposis: eosinophils and interleukin-5. Kramer MF, et al. **Allergy** 1999 Jul;54(7):669-80 (127 ref.)

[Eosinophilia and interleukin-5: role in pulmonary atopic processes] Druilhe A, et al. **Med Trop (Mars)** 1998;58(4 Suppl):437-43 (66 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. de Groot RP, et al. **Cell Signal** 1998 Oct;10(9):619-28 (176 ref.)

PHYSIOLOGY

Interleukin-5: a proeosinophil cytokine mediator of inflammation in asthma and a target for antisense therapy. Weltman JK, et al. **Allergy Asthma Proc** 1998 Sep-Oct; 19(5):257-61 (42 ref.)

Interleukin-5 and the regulation of eosinophil production. Roboz GJ, et al. **Curr Opin Hematol** 1999 May;6(3):164-8 (44 ref.)

Interleukin 5 and B cell differentiation. Takatsu K. **Cytokine Growth Factor Rev** 1998 Mar;9(1):25-35 (86 ref.)

[Mechanisms of eosinophil development] Yamaguchi Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2161-71 (27 ref.) **(Jpn)**

INTERLEUKIN-6

see related
HYBRIDOMAS
PLASMACYTOMA

BIOSYNTHESIS

Individual variation in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Lenczowski MJ, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:139-47 (52 ref.)

Regulation and role of intrapituitary IL-6 production by folliculostellate cells. Renner U, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):353-62 (59 ref.)

BLOOD

Cytokine deregulation in hematological malignancies: clinical and biological implications. Kurzrock R. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2581-4 (31 ref.)

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837-57, vi (77 ref.)

IMMUNOLOGY

The relationship between interleukin-6 and herpes simplex virus type 1: implications for behavior and immunopathology. Baker M, et al. **Brain Behav Immun** 1999 Sep;13(3):201-11 (64 ref.)

Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha [editorial] Rifas L. **Calcif Tissue Int** 1999 Jan;64(1):1-7 (106 ref.)

Acute-phase responses and SIRS/MODS: the good, the bad, and the nebulous [editorial; comment] Deutschman CS. **Crit Care Med** 1998 Oct;26(10):1630-1 (22 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1683-9.

Anticytokine therapy in autoimmune diseases. Nishimoto N, et al. **Intern Med** 1999 Feb;38(2):178-82 (32 ref.)

Role of the brain in interleukin-6 modulation. Terreni L, et al. **Neuroimmunomodulation** 1998 May-Aug;5(3-4):214-9 (72 ref.)

METABOLISM

Interleukin-6 receptor shedding: a possible role for members of the ADAM family. Croucher PI, et al. **Biochem Soc Trans** 1999 Feb;27(2):224-8 (36 ref.)

IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Grötzinger J, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):803-13 (77 ref.)

PHARMACOLOGY

Interleukin-11. A gp130 cytokine. Trepicchio WL, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:12-21 (31 ref.)

Cross-talk between angiotensin II and interleukin-6-induced signaling through Stat3 transcription factor. Bhat GJ, et al. **Basic Res Cardiol** 1998;93 Suppl 3:26-9 (20 ref.)

Hematologic effects of interleukin-1 and interleukin-6. Ruscetti FW. **Curr Opin Hematol** 1994 May;1(3):210-5 (37 ref.)

Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis. Barkhudaryan N, et al. **Neurochem Res** 1999 Sep;24(9):1169-80 (183 ref.)

PHYSIOLOGY

Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Peters M, et al. **Blood** 1998 Nov 15;92(10):3495-504 (85 ref.)

Activation molecules on human myeloma cells. Klein B, et al. **Curr Top Microbiol Immunol** 1999;246:335-41 (30 ref.)

The role of leukemia inhibitory factor and interleukin-6 in human reproduction. Smith SK, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:237-43; discussion 244-6 (46 ref.)

The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Cross JT, et al. **Inflamm Res** 1999 May;48(5):255-61 (53 ref.)

Interleukin-10 and Gp130 cytokines in human multiple myeloma. Klein B, et al. **Leuk Lymphoma** 1999 Jun; 34(1-2):63-70 (66 ref.)

Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. McCarty MF. **Med Hypotheses** 1999 May;52(5):465-77 (229 ref.)

The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Muñoz-Fernández MA, et al. **Prog Neurobiol** 1998 Oct; 56(3):307-40 (486 ref.)

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Yoshizaki K, et al. **Springer Semin Immunopathol** 1998;20(1-2):247-59 (71 ref.)

Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127-37 (163 ref.)

[Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis] Mathurin P, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):311-9 (81 ref.) **(Fre)**

[New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition] Nishimoto N, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1745-50 (20 ref.) **(Jpn)**

[Advances in interleukin-6 therapy] Ogata A, et al. **Rinsho Byori** 1999 Apr;47(4):321-6 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Thrombopoietic factors potentially useful in the treatment of acute leukemia. Archimbaud E, et al. **Leuk Res** 1998 Dec;22(12):1155-64 (141 ref.)

URINE

[Urinary tract infection and biological markers: C-reactive protein, interleukins and procalcitonin] Gendrel D. **Arch Pediatr** 1998;5 Suppl 3:269S-273S (21 ref.) (Eng. Abstr.) **(Fre)**

INTERLEUKIN-6 RECEPTORS see **RECEPTORS, INTERLEUKIN-6**

INTERLEUKIN-7

IMMUNOLOGY

Reviewing the potential utility of interleukin-7 as a promoter of thymopoiesis and immune recovery. Or R, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):287-94 (71 ref.)

PHYSIOLOGY

Interleukin-7: physiological roles and mechanisms of action. Hofmeister R, et al. **Cytokine Growth Factor Rev** 1999 Mar; 10(1):41-60 (236 ref.)

Biological and clinical implications of interleukin-7 and lymphopoiesis. Appasamy PM. **Cytokines Cell Mol Ther** 1999 Mar;5(1):25-39 (202 ref.)

Role of interleukin-7 in T-cell development from hematopoietic stem cells. Akashi K, et al. **Immunol Rev** 1998 Oct;165:13-28 (137 ref.)

THERAPEUTIC USE

Biological and clinical implications of interleukin-7 and lymphopoiesis. Appasamy PM. **Cytokines Cell Mol Ther** 1999 Mar;5(1):25-39 (202 ref.)

INTERLEUKIN-7 RECEPTORS see **RECEPTORS, INTERLEUKIN-7**

INTERLEUKIN-8

see related
NEUTROPHIL ACTIVATION

BLOOD

Interleukin-8 and alcoholic liver disease. Huang YS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul;62(7):418-24 (43 ref.)

GENETICS

Regulation of interleukin-8 gene expression. Roebuck KA. **J Interferon Cytokine Res** 1999 May;19(5):429-38 (122 ref.)

[Molecular mechanism of interleukin-8 gene expression] Mukaida N, et al. **Rinsho Byori** 1998 Aug;46(8):821-8 (32 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Roebuck KA. **Int J Mol Med** 1999 Sep;4(3):223-30 (102 ref.)

Chemokine expression in Helicobacter pylori-infected gastric mucosa. Shimada T, et al. **J Gastroenterol** 1998 Oct; 33(5):613-7 (48 ref.)

PHARMACOLOGY

Biology of IL-8-induced stem cell mobilization. Fibbe WE, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:71-82 (39 ref.)

PHYSIOLOGY

Interleukin-8: An autocrine inflammatory mediator. Atta-ur-Rahman, et al. **Curr Pharm Des** 1999 Apr; 5(4):241-53 (175 ref.)

Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Mukaida N, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):9-23 (148 ref.)

Role of interleukin-8 in tumor growth and metastasis of human melanoma. Bar-Eli M. **Pathobiology** 1999;67(1):12-8 (66 ref.)

[Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis] Mathurin P, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):311-9 (81 ref.) **(Fre)**

[Tumor angiogenesis] Ono M, et al. **Seikagaku** 1998 Sep; 70(9):1159-70 (28 ref.) **(Jpn)**

INTERLEUKIN-10

BIOSYNTHESIS

Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Wilder RL, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:14-31 (152 ref.)

GENETICS

Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Hurme M, et al. **Ann Med** 1998 Oct;30(5):469-73 (41 ref.)

Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). Lu L, et al. **J Leukoc Biol** 1999 Aug; 66(2):293-6 (31 ref.)

IMMUNOLOGY

IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Bruserud O. **Cytokines Cell Mol Ther** 1998 Sep;4(3):187-98 (137 ref.)

Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Salazar-Onfray F. **Med Oncol** 1999 Jul;16(2):86-94 (97 ref.)

The role of IL-10 in inflammatory bowel disease: "of mice and men". Leach MW, et al. **Toxicol Pathol** 1999 Jan-Feb; 27(1):123-33 (137 ref.)

PHARMACOLOGY

IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. Akdis CA, et al. **FASEB J** 1999 Apr; 13(6):603-9 (74 ref.)

Therapeutic implications of interleukin-10 in surgical disease. Selzman CH, et al. **Shock** 1998 Nov;10(5):309-18 (156 ref.)

PHYSIOLOGY

Interleukin-10 and liver diseases. Le Moine O, et al. **Acta Gastroenterol Belg** 1999 Jan-Mar;62(1):1-8 (131 ref.)

Is interleukin-10 antifibrogenic in chronic liver injury? [editorial; comment] Tsukamoto H. **Hepatology** 1998 Dec; 28(6):1707-9 (29 ref.) Comment on: Hepatology 1998 Dec;28(6):1597-1606. Comment on: Hepatology 1998 Dec;28(6):1607-15.

The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Cross JT, et al. **Inflamm Res** 1999 May;48(5):255-61 (53 ref.)

The neutrophil: one of the cellular targets of interleukin-10. Cassatella MA. **Int J Clin Lab Res** 1998;28(3):148-61 (114 ref.)

The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. Donnelly RP, et al. **J Interferon Cytokine Res** 1999 Jun; 19(6):563-73 (82 ref.)

Interleukin-10 and Gp130 cytokines in human multiple myeloma. Klein B, et al. **Leuk Lymphoma** 1999 Jun; 34(1-2):63-70 (66 ref.)

Therapeutic implications of interleukin-10 in surgical disease. Selzman CH, et al. **Shock** 1998 Nov;10(5):309-18 (156 ref.)

[Interleukin 10: a key cytokine in disseminated lupus erythematosus (editorial)] Emilie D, et al. **Pathol Biol (Paris)** 1998 Oct;46(8):583-5 (4 ref.) **(Fre)**

[Interleukin-10 in dermatology] Asadullah K, et al. **Hautarzt** 1999 Jan;50(1):12-9 (88 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Opal SM, et al. **Clin Infect Dis** 1998 Dec;27(6):1497-507 (137 ref.)

INTERLEUKIN-11

CHEMISTRY

The interleukin-11/receptor complex: rational design of agonists/antagonists and immunoassays potentially useful in human therapy. Jacques Y, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):737-40 (13 ref.)

IMMUNOLOGY

The interleukin-11/receptor complex: rational design of agonists/antagonists and immunoassays potentially useful in human therapy. Jacques Y, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):737-40 (13 ref.)

PHARMACOLOGY

Interleukin-11. A gp130 cytokine. Trepicchio WL, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:12-21 (31 ref.)

Advances in understanding of biological effects of interleukin-11, leukemia inhibitory factor, and macrophage inflammatory protein 1 alpha. Broxmeyer HE. **Curr Opin Hematol** 1994 May;1(3):197-202 (58 ref.)

Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Schwertschlag US, et al. **Leukemia** 1999 Sep;13(9):1307-15 (98 ref.)

THERAPEUTIC USE

Thrombopoietic factors potentially useful in the treatment of acute leukemia. Archimbaud E, et al. **Leuk Res** 1998 Dec;22(12):1155-64 (141 ref.)

The biological basis for the attenuation of mucositis: the example of interleukin-11. Sonis S, et al. **Leukemia** 1999 Jun;13(6):831-4 (42 ref.)

Incorporating new modalities into practice guidelines: platelet growth factors. Rubenstein EB, et al. **Oncology (Huntingt)** 1998 Nov;12(11A):381-6 (15 ref.)

INTERLEUKIN-12

see related
IMMUNITY, CELLULAR

ANTAGONISTS & INHIBITORS

IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Haskó G, et al. **Br J Pharmacol** 1999 Jul;127(6):1295-304 (129 ref.)

The taming of IL-12: suppressing the production of proinflammatory cytokines. Sutterwala FS, et al. **J Leukoc Biol** 1999 May;65(5):543-51 (82 ref.)

BIOSYNTHESIS

Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Wilder RL, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:14-31 (152 ref.)

Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Mosser DM, et al. **Curr Opin Immunol** 1999 Aug;11(4):406-11 (34 ref.)

Positive and negative regulation of interleukin-12 gene expression. Ma X, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):54-64 (124 ref.)

Ignition of the type 1 response to intracellular infection by dendritic cell-derived interleukin-12. Sher A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):65-8 (18 ref.)

The taming of IL-12: suppressing the production of proinflammatory cytokines. Sutterwala FS, et al. **J Leukoc Biol** 1999 May;65(5):543-51 (82 ref.)

GENETICS

Inheritable defects in interleukin-12- and interferon-gamma-mediated immunity and the TH1/TH2 paradigm in man. Döffinger R, et al. **Allergy** 1999 May; 54(5):409-12 (32 ref.)

Positive and negative regulation of interleukin-12 gene expression. Ma X, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):54-64 (124 ref.)

IMMUNOLOGY

The role of dendritic cells in the initiation of host resistance to Toxoplasma gondii. Sher A, et al. **Adv Exp Med Biol** 1998;452:103-10 (23 ref.)

Interleukin-12: a cytokine at the interface of inflammation and immunity. Trinchieri G. **Adv Immunol** 1998;70:83-243 (754 ref.)

IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Jouanguy E, et al. **Curr Opin Immunol** 1999 Jun;11(3):346-51 (45 ref.)

IL-12 and viral infections. Komastu T, et al. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):277-85 (75 ref.)

Measles: immunosuppression, interleukin-12, and complement receptors. Karp CL. **Immunol Rev** 1999 Apr; 168:91-101 (109 ref.)

The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Yang YG, et al. **Leuk Lymphoma** 1999 May;33(5-6):409-20 (106 ref.)

Interleukin-12 and the host response to parasitic helminths; the paradoxical effect on protective immunity and immunopathology. Mountford AP, et al. **Parasite Immunol** 1998 Nov;20(11):509-17 (70 ref.)

METABOLISM

Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Burke F. **Cytokines Cell Mol Ther** 1999 Mar;5(1):51-61 (182 ref.)

PHYSIOLOGY

Interleukin-12: basic principles and clinical applications. Trinchieri G, et al. **Curr Top Microbiol Immunol** 1999; 238:57-78 (126 ref.)

IL-12 and viral infections. Komastu T, et al. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):277-85 (75 ref.)

Ignition of the type 1 response to intracellular infection by dendritic cell-derived interleukin-12. Sher A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):65-8 (18 ref.)

[Biological properties and clinical significance of interleukins 12 (IL-12)] Maranda E, et al. **Postepy Hig Med Dosw** 1998; 52(5):489-506 (105 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447-61 (60 ref.)

Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Golab J, et al. **Int J Mol Med** 1999 May;3(5):537-44 (83 ref.)

Neutralising IL-12 activity as a strategy for prolonging allograft survival and preventing graft-versus-host disease. Orr DJ, et al. **Scott Med J** 1998 Aug;43(4):109-11 (24 ref.)

TOXICITY

The toxicology of interleukin-12: a review. Car BD, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):58-63 (62 ref.)

INTERLEUKIN-13

INTERLEUKIN-13

IMMUNOLOGY

IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Bruserud O. **Cytokines Cell Mol Ther** 1998 Sep;4(3):187-98 (137 ref.)

PHYSIOLOGY

The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Finkelman FD, et al. **Curr Opin Immunol** 1999 Aug; 11(4):420-6 (84 ref.)

Interleukin-4 and interleukin-13: their similarities and discrepancies. Chomarat P, et al. **Int Rev Immunol** 1998; 17(1-4):1-52 (300 ref.)

Receptors and cytokines involved in allergic TH2 cell responses. de Vries JE, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S492-6 (31 ref.)

INTERLEUKIN-15

GENETICS

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Waldmann TA, et al. **Annu Rev Immunol** 1999;17:19-49 (142 ref.)

PHYSIOLOGY

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Waldmann TA, et al. **Annu Rev Immunol** 1999;17:19-49 (142 ref.)

Interleukin-15 and its role in chronic inflammatory diseases. Kirman I, et al. **Inflamm Res** 1998 Jul;47(7):285-9 (47 ref.)

INTERLEUKIN-16

PHYSIOLOGY

[Possible pathogenic role of IL-16 on SLE: with reference to HIV-1 infection] Lee S, et al. **Ryumachi** 1998 Oct; 38(5):747-51 (33 ref.) **(Jpn)**

INTERLEUKIN-18

Interleukin-18: perspectives on the newest interleukin. Gillespie MT, et al. **Cytokine Growth Factor Rev** 1998 Jun; 9(2):109-16 (48 ref.)

[IL-18 and IL-18 receptor] Kashiwamura S, et al. **Nippon Rinsho** 1998 Jul;56(7):1798-806 (36 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Okamura H, et al. **Adv Immunol** 1998;70:281-312 (112 ref.)

IMMUNOLOGY

Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Okamura H, et al. **Adv Immunol** 1998;70:281-312 (112 ref.)

METABOLISM

Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). Fantuzzi G, et al. **J Clin Immunol** 1999 Jan;19(1):1-11 (119 ref.)

PHYSIOLOGY

Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Dinarello CA. **Ann N Y Acad Sci** 1998 Sep 29;856:1-11 (84 ref.)

IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. Dinarello CA. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):11-24 (105 ref.)

INTERLEUKIN RECEPTORS see **RECEPTORS, INTERLEUKIN**

INTERLEUKINS

ANALYSIS

[Biochemical and endocrinological analysis of breast cyst fluid] Mizia-Stec K, et al. **Ginekol Pol** 1997 Sep;68(9):432-9 (48 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. He YW, et al. **Crit Rev Immunol** 1998; 18(6):503-24 (159 ref.)

[Biochemical and endocrinological analysis of breast cyst fluid] Mizia-Stec K, et al. **Ginekol Pol** 1997 Sep;68(9):432-9 (48 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

The cytokine response to strenuous exercise. Pedersen BK, et al. **Can J Physiol Pharmacol** 1998 May;76(5):505-11 (54 ref.)

PHYSIOLOGY

Interleukins in the control of osteoclast differentiation. Martin TJ, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):107-23 (143 ref.)

Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71-6 (55 ref.)

THERAPEUTIC USE

Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Mont MA, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S314-35 (236 ref.)

Immunologic approaches to the treatment of prostate cancer. Harris DT, et al. **Semin Oncol** 1999 Aug;26(4):439-47 (47 ref.)

INTERMEDIATE CARE FACILITIES

ECONOMICS

New practices in the transitional care center improve outcomes for babies and their families. Forsythe P. **J Perinatol** 1998 Nov-Dec;18(6 Pt 2 Su):S13-7 (4 ref.)

ORGANIZATION & ADMINISTRATION

Intermediate not indeterminate care. Bowman C, et al. **Hosp Med** 1998 Nov;59(11):877-9 (20 ref.)

New practices in the transitional care center improve outcomes for babies and their families. Forsythe P. **J Perinatol** 1998 Nov-Dec;18(6 Pt 2 Su):S13-7 (4 ref.)

INTERMEDIATE FILAMENT PROTEINS

GENETICS

The role of the peripherin/RDS gene in retinal dystrophies. Kohl S, et al. **Acta Anat (Basel)** 1998;162(2-3):75-84 (69 ref.)

Fish intermediate filament proteins in structure, evolution, and function. Markl J, et al. **Subcell Biochem** 1998;31:1-33 (113 ref.)

METABOLISM

Brains and brawn: plectin as regulator and reinforcer of the cytoskeleton. Allen PG, et al. **Bioessays** 1999 Jun; 21(6):451-4 (24 ref.)

Plectin: a cytolinker by design. Steinböck FA, et al. **Biol Chem** 1999 Feb;380(2):151-8 (56 ref.)

Expression, regulation, and function of the SPR family of proteins. A review. Tesfaigzi J, et al. **Cell Biochem Biophys** 1999;30(2):243-65 (47 ref.)

Measuring the assembly kinetics and binding properties of intermediate filament proteins. Hofmann I. **Subcell Biochem** 1998;31:363-80 (57 ref.)

Fish intermediate filament proteins in structure, evolution, and function. Markl J, et al. **Subcell Biochem** 1998;31:1-33 (113 ref.)

Possible regulation of intermediate filament proteins by Rho-binding kinases. Matsuzawa K, et al. **Subcell Biochem** 1998;31:423-35 (39 ref.)

Lens intermediate filament proteins. Sandilands A, et al. **Subcell Biochem** 1998;31:291-318 (80 ref.)

PHYSIOLOGY

Intermediate filament proteins during carcinogenesis and apoptosis (Review). Prasad S, et al. **Int J Oncol** 1999 Mar; 14(3):563-70 (77 ref.)

Role of plectin in cytoskeleton organization and dynamics. Wiche G. **J Cell Sci** 1998 Sep;111 (Pt 17):2477-86 (61 ref.)

INTERMEDIATE FILAMENTS

CHEMISTRY

Structure, assembly, and dynamics of intermediate filaments. Herrmann H, et al. **Subcell Biochem** 1998;31:319-62 (119 ref.)

Viscoelasticity of intermediate filament networks. Janmey PA, et al. **Subcell Biochem** 1998;31:381-97 (51 ref.)

Transient electric birefringence in the study of intermediate filament assembly. van Amerongen H, et al. **Subcell Biochem** 1998;31:399-421 (50 ref.)

METABOLISM

Cytoskeletal proteins connecting intermediate filaments to cytoplasmic and nuclear periphery. Djabali K. **Histol Histopathol** 1999 Apr;14(2):501-9 (86 ref.)

Neurofilaments in health and disease. Julien JP, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:1-23 (129 ref.)

Intermediate filament organization during oogenesis and early development in the clawed frog, Xenopus laevis. Gard DL, et al. **Subcell Biochem** 1998;31:35-70 (110 ref.)

Structure, assembly, and dynamics of intermediate filaments. Herrmann H, et al. **Subcell Biochem** 1998;31:319-62 (119 ref.)

The complexity of intermediate filaments in the nervous system. Leung CL, et al. **Subcell Biochem** 1998;31:497-526 (186 ref.)

Molecular dissection of desmosomal assembly and intermediate filament anchorage. Troyanovsky SM, et al. **Subcell Biochem** 1998;31:263-89 (127 ref.)

PHYSIOLOGY

Desmosomes: intercellular adhesive junctions specialized for attachment of intermediate filaments. Kowalczyk AP, et al. **Int Rev Cytol** 1999;185:237-302 (373 ref.)

Intermediate filaments in motion: observations of intermediate filaments in cells using green fluorescent protein-vimentin. Martys JL, et al. **Mol Biol Cell** 1999 May; 10(5):1289-95 (18 ref.)

Viscoelasticity of intermediate filament networks. Janmey PA, et al. **Subcell Biochem** 1998;31:381-97 (51 ref.)

ULTRASTRUCTURE

Neurofilaments in health and disease. Julien JP, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:1-23 (129 ref.)

INTERMEDINS see **MSH**

INTERMETATARSAL JOINT see **TARSAL JOINT**

INTERMITTENT CLAUDICATION

[Intermittent claudication--a major cardiovascular risk factor. Proposed guidelines for investigation and treatment (see comments)] Svensson P, et al. **Lakartidningen** 1999 Mar 31;96(13):1585-90 (45 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 May 19;96(20):2454, 2456. **(Swe)**

DIAGNOSIS

Estimation of walking distance in intermittent claudication: need for standardization. Duprez D, et al. **Eur Heart J** 1999 May;20(9):641-4 (20 ref.)

[Differential diagnosis of intermittent stress-related leg pain--not always an arterial problem] Canova CR, et al. **Ther Umsch** 1998 Oct;55(10):596-600 (6 ref.) (Eng. Abstr.) **(Ger)**

[A 56-year-old man with abdominal pain, intermittent claudication and a retroperitoneal mass] Medina Pérez M, et al. **Arch Esp Urol** 1998 Nov;51(9):935-7 (10 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Spontaneous popliteal artery dissection: a case report and review of the literature. Rabkin DG, et al. **J Vasc Surg** 1999 Apr;29(4):737-40 (10 ref.)

METABOLISM

Biochemical and inflammatory changes in the exercising claudicant. Tisi PV, et al. **Vasc Med** 1998;3(3):189-98 (104 ref.)

REHABILITATION

Exercise therapy for claudication. Nehler MR, et al. **Ann Vasc Surg** 1999 Jan;13(1):109-14 (34 ref.)

THERAPY

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Girolami B, et al. **Arch Intern Med** 1999 Feb 22;159(4):337-45 (116 ref.)

Intermittent claudication in older patients. Practical treatment guidelines. Boccalon H. **Drugs Aging** 1999 Apr; 14(4):247-59 (54 ref.)

Biochemical and inflammatory changes in the exercising claudicant. Tisi PV, et al. **Vasc Med** 1998;3(3):189-98 (104 ref.)

[Pain in chronic peripheral arterial occlusive disease. Pathogenesis and therapy] Rieger H, et al. **Internist (Berl)** 1999 Feb;40(2):133-9 (24 ref.) **(Ger)**

INTERMITTENT EXPLOSIVE DISORDER see **IMPULSE CONTROL DISORDERS**

INTERMITTENT POSITIVE-PRESSURE VENTILATION

High-frequency ventilation versus conventional ventilation: No winner-but no loser [editorial; comment] Truog WE. **J Pediatr** 1999 Jul;135(1):9-11 (10 ref.) Comment on: J Pediatr 1999 Jul;135(1):39-46.

Noninvasive positive pressure ventilation for chronic obstructive lung diseases. Wedzicha JA. **Monaldi Arch Chest Dis** 1999 Feb;54(1):79-82 (29 ref.)

Long-term ventilatory support. Wedzicha JA. **Monaldi Arch Chest Dis** 1998 Jun;53(3):317-20 (29 ref.)

[Mechanical ventilation for amyotrophic lateral sclerosis--Making a comparison between hospital and home care] Saito T. **Rinsho Shinkeigaku** 1999 Jan;

39(1):70–1 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Home mechanical ventilation as a treatment of the sequelae of tuberculosis surgery] Prats Soro E, et al. **An Med Interna** 1999 Jan;16(1):35–7 (12 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Noninvasive management of pediatric neuromuscular ventilatory failure: a viable alternative [editorial; comment] Barnes SD. **Crit Care Med** 1998 Dec;26(12):1952–3 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2061–5.
Nasal ventilation. Simonds AK. **Postgrad Med J** 1998 Jun; 74(872):343–6 (39 ref.)
[Noninvasive positive pressure ventilation (NIPPV) for the treatment of respiratory insufficiency] Oi M, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):77–81 (10 ref.) **(Jpn)**

INTERNAL CAROTID ARTERY DISEASES see **CAROTID ARTERY DISEASES**

INTERNAL-EXTERNAL CONTROL

The construct of control in mind–body medicine: implications for healthcare. Astin JA, et al. **Altern Ther Health Med** 1999 Mar;5(2):42–7 (72 ref.)
Autonomy, power, and control in palliative care. Scott PA. **Camb Q Healthc Ethics** 1999 Spring;8(2):139–47 (35 ref.)
Personal responsibility for health? A review of the arguments and the evidence at century's end. Minkler M. **Health Educ Behav** 1999 Feb;26(1):121–40 (118 ref.)
The primacy of primary control is a human universal: a reply to Gould's (1999) critique of the life-span theory of control. Heckhausen J, et al. **Psychol Rev** 1999 Jul;106(3):605–9 (36 ref.)
Executive cognitive functioning in alcohol use disorders. Giancola PR, et al. **Recent Dev Alcohol** 1998;14:227–51 (186 ref.)

INTERNAL FIXATORS

A concept of idiopathic scoliosis deformities as imperfect torsion(s). Asher MA, et al. **Clin Orthop** 1999 Jul; (364):11–25 (50 ref.)
[Dorsal stabilization of fractures of the thoracic and lumbar spine by external fixator—technique and outcome] Pizanis A, et al. **Zentralbl Chir** 1998;123(8):936–43 (20 ref.) (Eng. Abstr.) **(Ger)**

INTERNAL MAMMARY ARTERY see **MAMMARY ARTERIES**

INTERNAL MAMMARY ARTERY IMPLANTATION see **MYOCARDIAL REVASCULARIZATION**

INTERNAL MAMMARY-CORONARY ARTERY ANASTOMOSIS

Functional assessment of internal mammary artery bypass grafts: case reports and review of the literature. Seligman RW, et al. **Catheter Cardiovasc Interv** 1999 Feb; 46(2):218–22 (20 ref.)
[The functional study of the blood flow of internal mammary artery grafts via transthoracic Doppler echocardiography (editorial; comment)] Carreras F. **Rev Esp Cardiol** 1999 Apr;52(4):259–60 (11 ref.) Comment on: Rev Esp Cardiol 1999 Apr;52(4):253–8. **(Spa)**

NURSING

Minimally invasive direct coronary artery bypass surgery. Coulson AS, et al. **AORN J** 1997 Dec;66(6):1012–37; quiz 1039–42 (22 ref.)

INTERNAL MEDICINE

Update in General Internal Medicine. Altkorn D, et al. **Ann Intern Med** 1999 Aug 3;131(3):199–206 (15 ref.)
[Operative and anesthesiologic problems in hyperthyroidism from the viewpoint of the internist] Herrmann J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):39–43 (6 ref.) **(Ger)**
[Quality aspects in internal medicine—from anamnesis to meta-analysis] Battegay M, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24;87(51–52):1785–92 (22 ref.) (Eng. Abstr.) **(Ger)**
[Internal diseases and carbonyl stress] Miyata T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):347–54 (21 ref.) **(Jpn)**
[Methodology of meta analysis and internal diseases—therapy of hypertension complicated by diabetes as an example] Nago N, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):355–61 (15 ref.) **(Jpn)**
[Neuroses in present-day internal medicine] Krylov AA, et al. **Klin Med (Mosk)** 1998;76(9):60–3 (11 ref.) **(Rus)**

EDUCATION

A job-satisfaction measure for internal medicine residency program directors. Beasley BW, et al. **Acad Med** 1999 Mar; 74(3):263–70 (14 ref.)

STANDARDS

Defining educational priorities in managed care: a symposium overview. Kerr EA, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S1–5 (31 ref.)

TRENDS

[Hematology and internal medicine oncology] Engert A, et al. **Internist (Berl)** 1999 Apr;40(4):356–68 (51 ref.) **(Ger)**

INTERNAL THORACIC ARTERY see **MAMMARY ARTERIES**

INTERNATIONAL AGENCIES

The World Bank on world health: under fire. Abbasi K. **BMJ** 1999 Apr 10;318(7189):1003–6 (15 ref.)
The World Bank and world health: focus on South Asia–II: India and Pakistan. Abbasi K. **BMJ** 1999 Apr 24; 318(7191):1132–5 (12 ref.)
Towards achieving global haemophilia care--World Federation of Hemophilia programmes. Lee CA. **Haemophilia** 1998 Jul;4(4):463–73 (10 ref.)
The manipulation of international scientific organizations [editorial] Castleman BI, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):53–5 (17 ref.)
The duration of non-rodent toxicity studies for pharmaceuticals. DeGeorge JJ, et al. **Toxicol Sci** 1999 Jun; 49(2):143–55 (6 ref.)

ORGANIZATION & ADMINISTRATION

The World Bank and world health: changing sides [see comments] Abbasi K. **BMJ** 1999 Mar 27;318(7187):865–9 (9 ref.) Comment in: BMJ 1999 Mar 27;318(7187):822–3.

INTERNATIONAL COOPERATION

Practical lymphoma diagnosis: an approach to using the information organized in the REAL proposal. Revised European-American Lymphoid Neoplasm. Segal GH, et al. **Anat Pathol** 1998;3:147–68 (42 ref.)
Mectizan as a stimulus for development of novel partnerships: the international organization's perspective. Etya'alé DE. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S73–7 (7 ref.)
Science/industry: problematics of the European cooperative research in the biomaterials/biodevices area. Doddoli R. **Biomaterials** 1998 Aug;19(16):1433–9 (5 ref.)
An international work exchange: better than a midlife crisis. Bridge DT, et al. **BMJ** 1998 Dec 19–26;317(7174):1709–10 (6 ref.)
Food safety in the 21st century. Käferstein F, et al. **Bull World Health Organ** 1999;77(4):347–51 (15 ref.)
Reidentification of Canada's national cattle herd. Inch C. **Can Vet J** 1998 Sep;39(9):578–88 (3 ref.) **(Eng, Fre)**
The application of the UNSCOM experience to international biological arms control. United Nations Special Commission. Barton R. **Crit Rev Microbiol** 1998; 24(3):219–33 (3 ref.)
Verifying compliance to the biological and toxin weapons convention. Zilinskas RA. **Crit Rev Microbiol** 1998; 24(3):195–218 (124 ref.)
Normalising the crisis in Africa. Bradbury M. **Disasters** 1998 Dec;22(4):328–38 (21 ref.)
Military intervention and humanitarian action: trends and issues. Pugh M. **Disasters** 1998 Dec;22(4):339–51 (30 ref.)
International co-operation in world cardiology. The role of the World Heart Federation [see comments] Bayés de Luna A. **Eur Heart J** 1999 Apr;20(8):562–6 (21 ref.) Comment in: Eur Heart J 1999 Apr;20(8):554–5.
Towards achieving global haemophilia care--World Federation of Hemophilia programmes. Lee CA. **Haemophilia** 1998 Jul;4(4):463–73 (10 ref.)
The role of information dissemination in sustainability of international partnerships. Delclos GL, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):203–8 (14 ref.)
Systematic review of the effectiveness of interprofessional education: towards transatlantic collaboration. Barr H, et al. **J Allied Health** 1999 Summer;28(2):104–8 (26 ref.)
International cooperation in world cardiology: the role of the World Heart Federation [editorial] Bayés de Luna A. **J Am Coll Cardiol** 1999 Apr;33(5):1427–30 (20 ref.)
Warning: the imported food you are about to consume may (or may not) be harmful to your health. Burke JR. **J Contemp Health Law Policy** 1998 Fall;15(1):183–205 (0 ref.)
Cough up the money: a prescription for regulating Russian organized crime out of U.S. health care. Pilkerton CM. **J Contemp Health Law Policy** 1999 Spring;15(2):631–72 (273 ref.)
Abstracts of the International Myasthenia Gravis Workshop. November 8–10 (1998), Mysore, India. **J Neuroimmunol** 1998 Dec 1;92(1–2):1–7 (00 ref.)
First International Conference on familial Mediterranean fever, Jerusalem, Israel, September 7–11, 1997. Direskeneli H, et al. **J Rheumatol** 1998 Nov;25(11):2236–9 (46 ref.)
HIV and the returning expatriate. Jones ME. **J Travel Med** 1999 Jun;6(2):99–106 (47 ref.)
Venous ulcer reappraisal: insights from an international task force. Veines International Task Force. Clement DL. **J Vasc Res** 1999;36 Suppl 1:42–7 (23 ref.)
Nuclear weapons and the law. Murray RK. **Med Confl Surviv** 1999 Apr–Jun;15(2):126–37 (6 ref.)
AFM/MDA 1st International Myotonic Dystrophy Consortium Conference 30 June–1 July 1997, Paris, France. **Neuromuscul Disord** 1998 Aug;8(6):432–7 (0 ref.)
Across the water and down the ladder: occupational health in the global economy. Frumkin H. **Occup Med** 1999 Jul–Sep;14(3):637–63 (114 ref.)
A global perspective on nurses' Internet access and information utilization. Uhlenhopp MB, et al. **Oncol Nurs Forum** 1998 Nov–Dec;25(10 Suppl):27–32 (16 ref.)
Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). Trivedi MH, et al. **Psychopharmacol Bull** 1998;34(3):355–9 (7 ref.)
Management of animal health emergencies: general principles and legal and international obligations. Marabelli R, et al. **Rev Sci Tech** 1999 Apr;18(1):21–9 (6 ref.)
An international network for evaluating neuroprotective therapy after severe birth asphyxia. Levene MI, et al. **Semin Perinatol** 1999 Jun;23(3):226–33 (50 ref.)
National Institutes of Health (USA): role in tropical medicine research. Western KA. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):316–8 (0 ref.)
Banned drugs in sport. Does the International Olympic Committee (IOC) list need updating? Mottram DR. **Sports Med** 1999 Jan;27(1):1–10 (69 ref.)
Banning the anti-personnel mine: a treaty too far? Chaloner E. **Trop Doct** 1999 Apr;29(2):102–3 (8 ref.)
International harmonization issues. Thompson SR. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):181–95, x (7 ref.)
World trade: bringing health into the picture. Kinnon CM. **World Health Forum** 1998;19(4):397–406 (13 ref.)
Exporting hazards to developing countries. Menkes DB. **World Health Forum** 1998;19(4):412–6 (14 ref.)
[Classification of malignant lymphoma. WHO international proposal] Diebold J. **Ann Pathol** 1998 Oct;18(4):361–7 (31 ref.) **(Fre)**
[The requisite internationalization of the campaign against smoking] Dubois G. **Bull Acad Natl Med** 1998; 182(5):939–50; discussion 951–3 (61 ref.) (Eng. Abstr.) **(Fre)**
[Present-day global public health] Vartanian FE. **Vestn Ross Akad Med Nauk** 1999;(2):61–4 (9 ref.) **(Rus)**
[Strategies for minimizing nosocomial transmission of measles] Biellik RJ, et al. **Rev Panam Salud Publica** 1998 Nov;4(5):350–7 (62 ref.) (Eng. Abstr.) **(Spa)**

INTERNATIONAL COUNCIL OF NURSES

The ICNP's relevance in the US. Henry SB, et al. **Int Nurs Rev** 1998 Sep–Oct;45(5):153–9 (40 ref.)

INTERNATIONAL EDUCATIONAL EXCHANGE

The role of information dissemination in sustainability of international partnerships. Delclos GL, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):203–8 (14 ref.)

INTERNATIONAL HEALTH PROBLEMS see **WORLD HEALTH**

INTERNATIONAL NORMALIZED RATIO

see related
BLOOD COAGULATION

[Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time] Kagawa K, et al. **Rinsho Byori** 1999 May;47(5):431–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

INTERNET

Telemedicine and telepharmacy: current status and future implications. Angaran DM. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1405–26 (128 ref.)
Surgical Internet at a glance: volume IX. Allen J. **Am J Surg** 1999 Mar;177(3):183 (0 ref.)
Internet biomolecular resources. Cook JL. **Anal Biochem** 1999 Mar 15;268(2):165–72 (18 ref.)
Medical information on the Internet. Rampil IJ. **Anesthesiology** 1998 Nov;89(5):1233–45 (13 ref.)
The Internet: a practical guide for anesthesiologists [see comments] Ruskin KJ. **Anesthesiology** 1998 Oct; 89(4):1003–14 (20 ref.) Comment in: Anesthesiology 1998 Oct;89(4):817–9.
Web applications for total quality management. Golaz O, et al. **Clin Chem Lab Med** 1999 May;37(5):487–93 (11 ref.)
Preliminary experience with the Internet release of AIDA--an interactive educational diabetes simulator. Lehmann ED. **Comput Methods Programs Biomed** 1998 May;56(2):109–32 (42 ref.)
Critical care and the Internet. A clinician's perspective. Crippen D. **Crit Care Clin** 1999 Jul;15(3):605–14, vii (25

ref.)
Critical care and the World Wide Web. Varon J, et al. **Crit Care Clin** 1999 Jul;15(3):593–604, vii (19 ref.)
The role of computer networking in investigating unusual disease outbreaks and allegations of biological and toxin weapons use. Woodall J. **Crit Rev Microbiol** 1998; 24(3):255–72 (17 ref.)
The Internet and drug safety: what are the implications for pharmacovigilance? Cobert B, et al. **Drug Saf** 1999 Feb; 20(2):95–107 (21 ref.)
World Wide Web and Internet: applications for radiologists. Wunderbaldinger P, et al. **Eur Radiol** 1999;9(6):1170–82 (50 ref.)
WebWise: guide to the joint genome institute web site. Pruitt KD. **Genome Res** 1998 Sep;8(9):864–9 (1 ref.)
The Internet, intranets and reproductive medicine. Jenkins JM. **Hum Reprod** 1999 Mar;14(3):586–9 (9 ref.)
Dermatology resources on the internet: a practical guide for dermatologists. Sitaru C. **Int J Dermatol** 1998 Sep; 37(9):641–7 (15 ref.)
The Internet--approaching a ubiquitous tool for dental education. Johnson LA. **J Am Coll Dent** 1999 Summer; 66(2):16–28 (53 ref.)
Clinical decision-making and the Internet. Schleyer TK. **J Am Coll Dent** 1999 Summer;66(2):29–39 (92 ref.)
The basis for using the Internet to support the information needs of primary care. Westberg EE, et al. **J Am Med Inform Assoc** 1999 Jan–Feb;6(1):6–25 (365 ref.)
Digital images in dermatology and the Dermatology Online Atlas on the World Wide Web. Diepgen TL, et al. **J Dermatol** 1998 Dec;25(12):782–7 (20 ref.)
Promoting women's health via the World Wide Web. Hern MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):606–10 (6 ref.)
The Electron Microscopy Outreach Program: A Web-based resource for research and education. Sosinsky GE, et al. **J Struct Biol** 1999 Apr–May;125(2–3):246–52 (17 ref.)
Web-based resources for retrieving health policy information: NLM and beyond. Cahn MA, et al. **J Urban Health** 1998 Dec;75(4):826–41 (26 ref.)
The retrieval problem for health policy and public health: knowledge bases and search engines. Lynch C. **J Urban Health** 1998 Dec;75(4):794–806 (0 ref.)
Guiding parents' use of the Internet for newborn education. Lamp JM, et al. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):33–6 (8 ref.)
Nursing e-journals: are current models using the web's potential? Murray PJ, et al. **Medinfo** 1998;9 Pt 1:135–9 (9 ref.)
2-D databases on the World Wide Web. Appel RD, et al. **Methods Mol Biol** 1999;112:383–91 (11 ref.)
Constructing a 2-D database for the World Wide Web. Appel RD, et al. **Methods Mol Biol** 1999;112:411–6 (4 ref.)
Comparing 2-D electrophoretic gels across Internet databases. Lemkin PF. **Methods Mol Biol** 1999;112:393–410 (24 ref.)
An introduction to Internet resources for the molecular and genetic analysis of the lipases. Reue K. **Methods Mol Biol** 1999;109:309–28 (16 ref.)
Protein identification and analysis tools in the ExPASy server. Wilkins MR, et al. **Methods Mol Biol** 1999; 112:531–52 (16 ref.)
Keeping up with current drug approvals [see comments] Kupecz D. **Nurse Pract** 1999 Feb;24(2):44–8, 54, 56–7; quiz 58–9 (0 ref.) Comment in: Nurse Pract 1999 May;24(5):20.
Improving oncology nursing practice through understanding and exploring the Internet. Gomez EG, et al. **Oncol Nurs Forum** 1998 Nov–Dec;25(10 Suppl):4–10 (13 ref.)
A global perspective on nurses' Internet access and information utilization. Uhlenhopp MB, et al. **Oncol Nurs Forum** 1998 Nov–Dec;25(10 Suppl):27–32 (16 ref.)
Information retrieval at the millenium. Hersh W. **Proc AMIA Symp** 1998;:38–45 (39 ref.)
Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). Trivedi MH, et al. **Psychopharmacol Bull** 1998;34(3):355–9 (7 ref.)
An introduction to the World Wide Web. Smith MP, et al. **Reg Anesth Pain Med** 1999 Jul–Aug;24(4):369–74 (16 ref.)
How patients use the web for second opinions. Patrick K. **West J Med** 1999 Jun;170(6):332–3 (5 ref.)
Expanding yeast knowledge online. Dolinski K, et al. **Yeast** 1998 Dec;14(16):1453–69 (33 ref.)
[Communication on the Internet. Possibilities and risks of the Internet for psychiatry] Seemann O, et al. **Fortschr Neurol Psychiatr** 1998 Nov;66(11):483–6 (34 ref.) (Eng. Abstr.) **(Ger)**
[Development of NIHS Information and Computing Infrastructure (NICI)] Nakata K, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):92–100 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Status quo and the future of the electronic patient record system] Yoshiwara H. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):269–76 (16 ref.) **(Jpn)**
[Clinical computer applications in the radiology department] Ando Y. **Rinsho Byori** 1999 Feb;47(2):111–8 (15 ref.) (Eng. Abstr.) **(Jpn)**
[The state of the art of the computer applications in clinical laboratory medicine] Nishibori M, et al. **Rinsho Byori** 1999 Feb;47(2):132–45 (18 ref.) (Eng. Abstr.) **(Jpn)**
[The use of computers and networking in the neurosurgical field] Oizumi T, et al. **Rinsho Byori** 1999 Feb;47(2):119–25 (3 ref.) (Eng. Abstr.) **(Jpn)**
[The Internet for pneumologists and thoracic surgeons: an interactive fantasy (editorial)] Moreno Balsalobre R, et al. **Arch Bronconeumol** 1999 Jan;35(1):1–4 (19 ref.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Marketing health care products on the Internet: a proposal for updated federal regulations. Green K. **Am J Law Med** 1998;24(2–3):365–86 (145 ref.)
The copyright quagmire on the Internet. Goudreau KA. **Comput Nurs** 1999 Mar–Apr;17(2):82–5; quiz 86–8 (20 ref.)

ORGANIZATION & ADMINISTRATION

Synchronous communication technology tools in practice--future and current uses. Miller PA, et al. **Comput Nurs** 1998 Nov–Dec;16(6):303–6 (13 ref.)
Expanding Internet access for health care consumers. Wilkins AS. **Health Care Manage Rev** 1999 Summer;24(3):30–41 (44 ref.)
Electronic publishing and nursing research. Sparks SM. **Nurs Res** 1999 Jan–Feb;48(1):50–4 (3 ref.)
Broadsheet number 46: Internet for pathologists. Weinstein S. **Pathology** 1998 Nov;30(4):364–8 (9 ref.)
[Internet for physicians: a tool for today and tomorrow] Boyer C, et al. **Rev Med Suisse Romande** 1999 Feb; 119(2):137–44 (14 ref.) (Eng. Abstr.) **(Fre)**
[International foreign bibliographic databases Medline and Internet Grateful Med V2.6. Presentation and how to use] Bloch-Mouillet E. **Sante** 1998 Sep–Oct;8(5):379–86 (8 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

The quality of medical information on the Internet. A new public health concern [editorial] McLeod SD. **Arch Ophthalmol** 1998 Dec;116(12):1663–5 (19 ref.)
Towards quality management of medical information on the internet: evaluation, labelling, and filtering of information [see comments] Eysenbach G, et al. **BMJ** 1998 Nov 28; 317(7171):1496–1500 (30 ref.) Comment in: BMJ 1998 Nov 28;317(7171):1469–70. Comment in: BMJ 1999 Apr 24;318(7191):1144–5.
Published criteria for evaluating health related web sites: review. Kim P, et al. **BMJ** 1999 Mar 6;318(7184):647–9 (25 ref.)
A review of the quality of trauma protocols on the Internet. Branfoot T, et al. **Injury** 1999 Jan;30(1):1–7 (11 ref.)
Quality assurance guidelines for a biomedical information web system: the working experience of the BreakIT project. Sacile R, et al. **Med Inform Internet Med** 1999 Apr–Jun;24(2):109–20 (10 ref.)

TRENDS

Present technology and future applications. Bailes JE. **Clin Neurosurg** 1999;45:192–201 (16 ref.)
A survey of web resources for basic cancer genetics research. Bult CJ, et al. **Genome Res** 1999 May;9(5):397–408 (17 ref.)
WebWise: guide to the Washington University Center for Genetics in Medicine web site. Pruitt KD. **Genome Res** 1998 Jul;8(7):686–9 (0 ref.)
[Psychiatry and psychotherapy on the internet. Current overview] Seemann O, et al. **Nervenarzt** 1999 Jan; 70(1):76–80 (17 ref.) (Eng. Abstr.) **(Ger)**

INTERNEURONS

PHYSIOLOGY

Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Andrade R. **Ann N Y Acad Sci** 1998 Dec 15;861:190–203 (81 ref.)
GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Keverne EB. **Brain Res Bull** 1999 Mar 15;48(5):467–73 (71 ref.)
Interneurones are not so dormant in temporal lobe epilepsy: a critical reappraisal of the dormant basket cell hypothesis. Bernard C, et al. **Epilepsy Res** 1998 Sep;32(1–2):93–103 (61 ref.)
Mechanisms of spontaneous activity in developing spinal networks. O'Donovan MJ, et al. **J Neurobiol** 1998 Oct; 37(1):131–45 (73 ref.)
Role of interneurons in defensive withdrawal reflexes in Aplysia. Cleary LJ, et al. **Learn Mem** 1995 May–Aug; 2(3–4):133–51 (101 ref.)
Response properties of spinal interneurons in awake, behaving primates. Fetz EE. **Pain** 1999 Aug;Suppl 6:S55–60 (37 ref.)
Glutamatergic synapses onto hippocampal interneurons: precision timing without lasting plasticity. McBain CJ, et al. **Trends Neurosci** 1999 May;22(5):228–35 (61 ref.)
[Interneuronal signaling mediated by the trans-synaptic diffusion of neurotransmitters] Kopanitsia MV, et al. **Fiziol Zh** 1999;45(4):132–47 (95 ref.) (Eng. Abstr.) **(Ukr)**

INTERNSHIP AND RESIDENCY

A job-satisfaction measure for internal medicine residency program directors. Beasley BW, et al. **Acad Med** 1999 Mar; 74(3):263–70 (14 ref.)
Revisiting physical diagnosis during the medical residency: it is time for a logbook--and more. Mangione S, et al. **Acad Med** 1999 May;74(5):467–9 (8 ref.)
Developments and challenges in family practice nutrition education for residents and practicing physicians: an overview of the North American experience. Kolasa KM. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S89–96 (85 ref.)
Training residents in medical informatics. Jerant AF. **Fam Med** 1999 Jul–Aug;31(7):465–72 (48 ref.)
Introducing evidence-based medicine into a community family medicine residency. Kenney AF, et al. **J Miss State Med Assoc** 1998 Dec;39(12):441–3 (8 ref.)

ORGANIZATION & ADMINISTRATION

Restructuring residency training in obstetrics and gynecology. Bissonnette JM, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):516–8 (8 ref.)
Emergency medicine resident education: making a case for training residents to perform and interpret bedside sonographic examinations. Sankoff J, et al. **Ann Emerg Med** 1999 Jul;34(1):105–8 (28 ref.)
Changing policies in the Veterans Health Administration. Will they make a difference? [editorial] Jones DB. **Arch Ophthalmol** 1999 Jan;117(1):106–7 (3 ref.)
American medical residency programs: an analysis of New York's "Bell" regulations and the training of physicians. Tobias M. **Med Health R I** 1998 Sep;81(9):284–8 (19 ref.)

STANDARDS

Evaluating applicants to emergency medicine residency programs. Balentine J, et al. **J Emerg Med** 1999 Jan–Feb; 17(1):131–4 (32 ref.)

INTERNSHIP, DENTAL see **INTERNSHIP AND RESIDENCY**

INTERNUCLEOSOMAL DNA FRAGMENTATION see **DNA FRAGMENTATION**

INTEROBSERVER VARIATION see **OBSERVER VARIATION**

INTERPERSONAL RELATIONS

Assessing social integration in employment settings: current knowledge and future directions. Hughes C, et al. **Am J Ment Retard** 1998 Sep;103(2):173–85 (36 ref.)
Social relationships and the progression of human immunodeficiency virus infection: a review of evidence and possible underlying mechanisms. Miller GE, et al. **Ann Behav Med** 1998 Summer;20(3):181–9 (54 ref.)
Peer relationships and social competence during early and middle childhood. Ladd GW. **Annu Rev Psychol** 1999; 50:333–59 (131 ref.)
Interpersonal processes: the interplay of cognitive, motivational, and behavioral activities in social interaction. Snyder M, et al. **Annu Rev Psychol** 1999;50:273–303 (138 ref.)
Norman Cousins Memorial Lecture 1998. Stress, personal relationships, and immune function: health implications. Kiecolt-Glaser JK. **Brain Behav Immun** 1999 Mar; 13(1):61–72 (57 ref.)
Comprehending role conflicts in the coaching of children, adolescents, and young adults. Transference, countertransference, and achievement by proxy distortion paradigms. Ogilvie BC, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):879–90 (31 ref.)
Neuropsychologic impact of facial deformities in children. Neurodevelopmental role of the face in communication and bonding. Perry BD, et al. **Clin Plast Surg** 1998 Oct; 25(4):587–97, ix (47 ref.)
Violence in lesbian and gay relationships: theory, prevalence, and correlational factors. Burke LK, et al. **Clin Psychol Rev** 1999 Aug;19(5):487–512 (72 ref.)
Interpersonal and psychological correlates of marital dissatisfaction in late life: a review. Gagnon MD, et al. **Clin Psychol Rev** 1999 Apr;19(3):359–78 (102 ref.)
Psychosocial processes underlying the maintenance and persistence of depression: implications for understanding chronic depression. Lara ME, et al. **Clin Psychol Rev** 1999 Aug;19(5):553–70 (120 ref.)
Object relations theory and short-term dynamic psychotherapy: findings from the Quality of Object Relations Scale. Piper WE, et al. **Clin Psychol Rev** 1999 Sep;19(6):669–85 (69 ref.)
Prevention of marital dysfunction: behavioral approaches and beyond. Sayers SL, et al. **Clin Psychol Rev** 1998 Sep; 18(6):713–44 (121 ref.)
Considering the nature of intersubjectivity within professional nursing. Pierson W. **J Adv Nurs** 1999 Aug; 30(2):294–302 (46 ref.)
Social anxiety and social performance: why don't we see more catastrophes? Strahan EY, et al. **J Anxiety Disord** 1999 Jul–Aug;13(4):399–416 (52 ref.)
Extent of relational stigmatization of lesbians and their children by heterosexual college students. King BR, et al. **J Homosex** 1999;37(2):65–81 (62 ref.)
Interpersonal violence and the pregnant homeless woman. Robrecht LC, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):684–91 (32 ref.)
Date rape among adolescents and young adults. Rickert VI,

et al. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):167–75 (74 ref.)
Assertive, offensive, protective, and defensive styles of self-presentation: a taxonomy. Schütz A. **J Psychol** 1998 Nov;132(6):611–28 (80 ref.)
"You are a number, not a human being": Israeli breast cancer patients' experiences with the medical establishment. Sered S, et al. **Med Anthropol Q** 1999 Jun;13(2):223–52 (36 ref.)
Social interpersonal dimensions of the psychoses. Lindsay JS. **Med Hypotheses** 1999 Apr;52(4):335–47 (28 ref.)
Primate socioecology: new insights from males. Kappeler PM. **Naturwissenschaften** 1999 Jan;86(1):18–29 (147 ref.)
Oxytocin may mediate the benefits of positive social interaction and emotions. Uvnäs-Moberg K. **Psychoneuroendocrinology** 1998 Nov;23(8):819–35 (74 ref.)
Attachment and interpersonal communication in somatization. Stuart S, et al. **Psychosomatics** 1999 Jan–Feb; 40(1):34–43 (68 ref.)
Communication as social engagement: implications for interactions between deaf and hearing persons. Foster S. **Scand Audiol Suppl** 1998;49:116–24 (20 ref.)
Engendering stress in Australia: the embodiment of social relationships. Whittaker A, et al. **Women Health** 1998; 28(1):97–115 (31 ref.)

INTERPHASE

[Interphase cytogenetics in oncologic diagnosis] Pajor L. **Orv Hetil** 1998 Dec 6;139(49):2939–46 (60 ref.) (Eng. Abstr.) **(Hun)**
[Globular model of interphase chromosome and intrachromosomal exchange aberrations] Andreev SG, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):10–20 (44 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

[Chromosome association with the nuclear membrane and the orderliness of the spatial organization of the genetic material in the interphase nucleus] Glazkov MV. **Tsitol Genet** 1999 Mar–Apr;33(2):79–88 (60 ref.) (Eng. Abstr.) **(Rus)**

INTERPROFESSIONAL RELATIONS

An international work exchange: better than a midlife crisis. Bridge DT, et al. **BMJ** 1998 Dec 19–26;317(7174):1709–10 (6 ref.)
Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. McManus RJ, et al. **BMJ** 1998 Dec 5;317(7172):1562–3 (5 ref.)
Changing the response of professionals to child abuse. Munro E. **Br J Gen Pract** 1998 Sep;48(434):1609–11 (21 ref.)
Systems for collaboration. Integrating multiple perspectives. Briggs MH. **Child Adolesc Psychiatr Clin N Am** 1999 Apr; 8(2):365–77 (24 ref.)
Working with the primary care physician. Schowalter JE, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul; 7(3):599–613 (39 ref.)
Communication and conflict resolution in emergency medicine. O'Mara K. **Emerg Med Clin North Am** 1999 May; 17(2):451–9, xii (36 ref.)
Turf battles in radiology: how to avoid/how to fight/how to win. Schnyder P, et al. **Eur Radiol** 1999;9(4):741–8 (37 ref.)
Communicating effectively with regulatory agencies in the licensing process. Ryan MT. **Health Phys** 1999 Feb;76(2 Suppl):S41–6 (20 ref.)
Who cares? Who cures? The ongoing debate in the provision of health care. Baumann AO, et al. **J Adv Nurs** 1998 Nov; 28(5):1040–5 (24 ref.)
Systematic review of the effectiveness of interprofesional education: towards transatlantic collaboration. Barr H, et al. **J Allied Health** 1999 Summer;28(2):104–8 (26 ref.)
Building community: developing skills for interprofessional health professions education and relationship-centered care. NLN Appointed Interdisciplinary Health Education Panel. Walker PH, et al. **J Allied Health** 1998 Fall; 27(3):173–8 (14 ref.)
Nutrient Intake Report: a coordination of patient dietary assessment between physicians and registered dietitians. Olendzki BC, et al. **J Am Diet Assoc** 1998 Oct; 98(10):1159–62 (20 ref.)
Optometry and ophthalmology relations in managed care. Hettler DL. **J Am Optom Assoc** 1999 Feb;70(2):99–102 (28 ref.)
Principles of generalist-specialist relationships. Pearson SD. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S13–20 (30 ref.)
The interaction between family physicians and palliative care consultants in the delivery of palliative care: clinical and educational issues. Brenneis C, et al. **J Palliat Care** 1998 Autumn;14(3):58–61 (21 ref.)
Collaboration in improving care for patients: how can we find out what we haven't been able to figure out yet? Batalden PB, et al. **Jt Comm J Qual Improv** 1998 Oct; 24(10):609–18 (39 ref.)
Maintaining professional integrity in the midst of interdisciplinary collaboration. Lindeke LL, et al. **Nurs Outlook** 1998 Sep–Oct;46(5):213–8 (25 ref.)
Partnership in nursing education: a vision or a fantasy? Paterson B. **Nurs Outlook** 1998 Nov–Dec;46(6):284–9 (43 ref.)
How I address quality and teamwork issues in the occupational health department. Addley K. **Occup Med (Lond)** 1998 May;48(4):273–8 (6 ref.)
Three visual techniques to enhance interprofessional learning. Parsell G, et al. **Postgrad Med J** 1998 Jul;74(873):387–90 (17 ref.)
Models of collaboration. Lorenz AD, et al. **Prim Care** 1999 Jun;26(2):401–10 (14 ref.)
[Sedation by non-anesthesiologists should be centralized for considerations of safety (comment)] Lycklama à Nijeholt-Hamstra EW, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1077–9 (8 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1999 May 22;143(21):1098–102. **(Dut)**

INTERSEXUALITY see **HERMAPHRODITISM**

INTERSPERSED REPETITIVE ELEMENTS see **INTERSPERSED REPETITIVE SEQUENCES**

INTERSPERSED REPETITIVE SEQUENCES

see related
MUTAGENESIS, INSERTIONAL

SINEs of the perfect character [comment] Hillis DM. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9979–81 (34 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10261–6.

GENETICS

Mobile elements and disease. Kazazian HH Jr. **Curr Opin Genet Dev** 1998 Jun;8(3):343–50 (65 ref.)
[Gene instability induced by mobile genetic elements in Drosophila melanogaster] Shcherbata HR, et al. **Tsitol Genet** 1999 Jan–Feb;33(1):54–70 (120 ref.) (Eng. Abstr.) **(Ukr)**

INTERSTITIAL CELL-STIMULATING HORMONE see **LH**

INTERSTITIAL CELL TUMOR see **LEYDIG CELL TUMOR**

INTERSTITIAL CELLS, TESTICULAR see **LEYDIG CELLS**

INTERSTITIAL CYSTITIS see **CYSTITIS, INTERSTITIAL**

INTERSTITIAL FLUID see **EXTRACELLULAR SPACE**

INTERSTITIAL LUNG DISEASES see **LUNG DISEASES, INTERSTITIAL**

INTERSTITIAL NEPHRITIS see **NEPHRITIS, INTERSTITIAL**

INTERTARSAL JOINT see **TARSAL JOINT**

INTERTRIGO

DIAGNOSIS

[Amicrobial intertriginous pustulosis in autoimmune diseases--a new entity?] Hoch O, et al. **Hautarzt** 1998 Aug; 49(8):634–40 (26 ref.) (Eng. Abstr.) **(Ger)**

INTERTROCHANTERIC FRACTURES see **HIP FRACTURES**

INTERVENING SEQUENCES see **INTRONS**

INTERVENTION STUDIES

Clinical intervention trials: the ACE unit. Palmer RM, et al. **Clin Geriatr Med** 1998 Nov;14(4):831–49 (62 ref.)
Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Habicht JP, et al. **Int J Epidemiol** 1999 Feb;28(1):10–8 (20 ref.)
Confounding factors in observational and intervention studies. Feldman RA. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S248–53 (12 ref.)

INTERVERTEBRAL DISK

see related
DISKECTOMY

Degenerative conditions of the spine. Current diagnostic procedures and treatment modalities. Garfin SR. **Acta Orthop Scand Suppl** 1998 Jun;281:38–46 (134 ref.)
Alternatives to spinal fusion. Kostuik JP. **Orthop Clin North Am** 1998 Oct;29(4):701–15 (37 ref.)
[Calcification of the intervertebral disks in childhood as the cause of acute torticollis] Ferrer Ferrán J, et al. **An Esp Pediatr** 1999 Jun;50(6):607–9 (9 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Do intervertebral discs deserve their bad reputation? Buckwalter JA. **Iowa Orthop J** 1998;18:1–11 (33 ref.)

PATHOLOGY

MRI of the ageing and herniating intervertebral disc. Cassar-Pullicino VN. **Eur J Radiol** 1998 Jul;27(3):214–28 (67 ref.)
Degenerative disc disease and back pain. Modic MT. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):481–91, viii (67 ref.)
Spinal imaging and intervention: 1998. Mink JH, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):343–80, viii (116 ref.)

PHYSIOLOGY

Do intervertebral discs deserve their bad reputation? Buckwalter JA. **Iowa Orthop J** 1998;18:1–11 (33 ref.)
[Instrumental studies in laboratories dedicated to the examination of disk overload in health workers] Frigo C. **Med Lav** 1999 Mar–Apr;90(2):117–30 (21 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

A multi-center prospective study of the CD Spinal System in patients with degenerative disc disease. Michelsen C, et al. **J Spinal Disord** 1998 Dec;11(6):465–70; discussion 471 (10 ref.)
[Treatment of scoliosis in the adolescent by anterior release and vertebral arthrodesis under thoracoscopy. Preliminary results] Papin P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):231–8 (21 ref.) (Eng. Abstr.) **(Fre)**

INTERVERTEBRAL DISK CHEMOLYSIS

see related
CHYMOPAPAIN

[Chemonucleolysis. Development, experiences, prospects] Steffen R, et al. **Orthopade** 1999 Jul;28(7):609–14 (33 ref.) (Eng. Abstr.) **(Ger)**

INTERVERTEBRAL DISK DISPLACEMENT

see related
INTERVERTEBRAL DISK CHEMOLYSIS
SCIATICA

COMPLICATIONS

Voiding dysfunction in women with lumbar disc prolapse. Goldman HB, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):134–8 (18 ref.)
Low back pain and the lumbar intervertebral disk: clinical considerations for the doctor of chiropractic. Troyanovich SJ, et al. **J Manipulative Physiol Ther** 1999 Feb; 22(2):96–104 (58 ref.)
A review of basic science issues in low back pain Gordon SL, et al. **Phys Med Rehabil Clin N Am** 1998 May; 9(2):323–42, vii (172 ref.)

DIAGNOSIS

Clinical evaluation and treatment options for herniated lumbar disc. Humphreys SC, et al. **Am Fam Physician** 1999 Feb 1;59(3):575–82, 587–8 (24 ref.)
MRI of the ageing and herniating intervertebral disc. Cassar-Pullicino VN. **Eur J Radiol** 1998 Jul;27(3):214–28 (67 ref.)
Management of acute lumbar disk herniation initially presenting as mechanical low back pain. Crawford CM, et al. **J Manipulative Physiol Ther** 1999 May;22(4):235–44 (85 ref.)
Pitfalls of bungee jumping. Case report and review of the literature. Louw D, et al. **J Neurosurg** 1998 Dec; 89(6):1040–2 (08 ref.)
Spinal imaging and intervention: 1998. Mink JH, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):343–80, viii (116 ref.)
[Tingling in the hands] Geelen JA, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1593–7 (9 ref.) (Eng. Abstr.) **(Dut)**
[Physical diagnosis--signs of lumbosacral irritation (see comments) (published erratum appears in Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1400)] Oosterhuis HJ. **Ned Tijdschr Geneeskd** 1999 Mar 20;143(12):617–20 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1393–4. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394–5. **(Dut)**
[Cervical disc herniation] Hernesniemi J, et al. **Duodecim** 1995;111(21):2084–9 (15 ref.) **(Fin)**
[Diagnosis and treatment of vertebral disc herniation] Kotilainen E. **Duodecim** 1995;111(21):2078–83 (57 ref.) **(Fin)**
[The usefulness of neurological and radiological signs in lumbar discopathy] Sobolewski P. **Neurol Neurochir Pol** 1998 May–Jun;32(3):643–9 (28 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Progress in modern research on mechanism of Chinese herbal medicine in the treatment of lumbar intervertebral

disc prolapse] Li XS.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1997 Feb; 17(2):122–4 (24 ref.) **(Chi)**
[Chemonucleolysis. Development, experiences, prospects] Steffen R, et al. **Orthopade** 1999 Jul;28(7):609–14 (33 ref.) (Eng. Abstr.) **(Ger)**
[Pain in hernia has not only mechanical basis. Pharmacological treatment can open new possibilities] Udén A. **Lakartidningen** 1998 Dec 2;95(49):5590–1 (13 ref.) **(Swe)**

ETIOLOGY

The role of inflammation in disk herniation–associated radiculopathy. Goupille P, et al. **Semin Arthritis Rheum** 1998 Aug;28(1):60–71 (103 ref.)
The influence of occupation on lumbar degeneration. Videman T, et al. **Spine** 1999 Jun 1;24(11):1164–8 (31 ref.)

PHYSIOPATHOLOGY

[New information concerning pain caused by herniated disk and sciatica. Exposure to disk tissue sensitizes the nerve roots] Olmarker K, et al. **Lakartidningen** 1998 Dec 2; 95(49):5618–22 (46 ref.) (Eng. Abstr.) **(Swe)**

RADIOGRAPHY

The routine use of radiographic spinal displacement analysis: a dissent. Haas M, et al. **J Manipulative Physiol Ther** 1999 May;22(4):254–9 (43 ref.)

REHABILITATION

Management of acute lumbar disk herniation initially presenting as mechanical low back pain. Crawford CM, et al. **J Manipulative Physiol Ther** 1999 May;22(4):235–44 (85 ref.)

SURGERY

Modern alternatives and techniques for one–level discectomy and fusion. Whitecloud TS 3rd. **Clin Orthop** 1999 Feb; (359):67–76 (27 ref.)
Asymptomatic brain abscess as a complication of halo orthosis: report of a case and review of the literature. Kameyama O, et al. **J Orthop Sci** 1999;4(1):39–41 (13 ref.)
The anatomical basis of sciatica secondary to herniated lumbar disc: a review. Spencer DL. **Neurol Res** 1999;21 Suppl 1:S33–6 (41 ref.)
Management of degenerative disc disease above an L5–S1 segment requiring arthrodesis. Herkowitz HN, et al. **Spine** 1999 Jun 15;24(12):1268–70 (15 ref.)
[Cervical disc herniation] Hernesniemi J, et al. **Duodecim** 1995;111(21):2084–9 (15 ref.) **(Fin)**
[Surgical approach in lumbar intervertebral disk displacement. Topographical principles and characteristics] Grifka J, et al. **Orthopade** 1999 Jul;28(7):572–8 (17 ref.) (Eng. Abstr.) **(Ger)**
[Surgical treatment of lumbar intervertebral disk displacement. Indications and methods] Krämer J, et al. **Orthopade** 1999 Jul;28(7):579–84 (39 ref.) (Eng. Abstr.) **(Ger)**
[Microsurgical lumbar intervertebral disk operation. Technique and complications] Merk H, et al. **Orthopade** 1999 Jul;28(7):593–7 (21 ref.) (Eng. Abstr.) **(Ger)**
[Open lumbar intervertebral disk operation. Technique and results] Scholz R, et al. **Orthopade** 1999 Jul;28(7):585–92 (57 ref.) (Eng. Abstr.) **(Ger)**
[Percutaneous nucleotomy procedures in lumbar intervertebral disk displacement. Current status] Siebert W. **Orthopade** 1999 Jul;28(7):598–608 (89 ref.) (Eng. Abstr.) **(Ger)**
[Thoracic intervertebral disk herniation] Malawski S. **Chir Narzadow Ruchu Ortop Pol** 1999;64(2):147–57 (42 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Clinical evaluation and treatment options for herniated lumbar disc. Humphreys SC, et al. **Am Fam Physician** 1999 Feb 1;59(3):575–82, 587–8 (24 ref.)
Management of herniation of the lumbar disc. Postacchini F. **J Bone Joint Surg Br** 1999 Jul;81(4):567–76 (70 ref.)
Spinal imaging and intervention: 1998. Mink JH, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):343–80, viii (116 ref.)
[Diagnosis and treatment of vertebral disc herniation] Kotilainen E. **Duodecim** 1995;111(21):2078–83 (57 ref.) **(Fin)**

VETERINARY

[Hernia nucleus pulposus: the turning point when we realize what we do not know] Janssens LA.
Tijdschr Diergeneeskd 1998 Oct 15;123(20):606–9 (36 ref.) **(Dut)**

INTERVIEW, PSYCHOLOGICAL

METHODS

The psychiatric review of symptoms: a screening tool for family physicians. Carlat DJ. **Am Fam Physician** 1998 Nov 1;58(7):1617–24 (21 ref.)
The amobarbital interview revisited: a review of the literature since 1966. Kavirajan H. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):153–65 (63 ref.)

INTERVIEWER EFFECT see **EFFECT MODIFIERS (EPIDEMIOLOGY)**

INTERVIEWS

Evidence of self–report bias in assessing adherence to guidelines. Adams AS, et al. **Int J Qual Health Care** 1999 Jun;11(3):187–92 (28 ref.)
Interviewing children. Docherty S, et al.
Res Nurs Health 1999 Apr;22(2):177–85 (74 ref.)
[Medical research on patients' experiences—structured questionnaires result in worthless answers] Kirkengen AL. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3449–52 (20 ref.) (Eng. Abstr.) **(Nor)**

METHODS

Qualitative studies. Their role in medical research. Huston P, et al. **Can Fam Physician** 1998 Nov;44:2453–8 (19 ref.)
Learning to listen: serendipitous outcomes of a research training experience. Chambers–Evans J, et al.
J Adv Nurs 1999 Jun;29(6):1421–6 (12 ref.)
Donor selection procedures: is it possible to improve them? Kleinman S, et al. **Transfus Med Rev** 1998 Oct; 12(4):288–302 (68 ref.)

INTESTINAL ABSORPTION

see related
MALABSORPTION SYNDROMES
Molecular physiology of colonic epithelial sodium absorption. Clauss W. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):453–5 (57 ref.)
Recently identified molecular aspects of intestinal iron absorption. Wood RJ, et al. **J Nutr** 1998 Nov; 128(11):1841–4 (29 ref.)
Intestinal fructose absorption: clinical and molecular aspects. Corpe CP, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr; 28(4):364–74 (97 ref.)
The regulation of mineral absorption in the gastrointestinal tract. Powell JJ, et al. **Proc Nutr Soc** 1999 Feb;58(1):147–53 (41 ref.)
Intestinal absorption, blood transport and hepatic and muscle metabolism of fatty acids in preruminant and ruminant animals. Hocquette JF, et al. **Reprod Nutr Dev** 1999 Jan–Feb;39(1):27–48 (122 ref.)

DRUG EFFECTS

Nondigestibility characteristics of inulin and oligofructose in humans. Andersson HB, et al. **J Nutr** 1999 Jul;129(7 Suppl):1428S–30S (24 ref.)
Cutting fat absorption to halt weight gain. Lean M.
Practitioner 1998 Dec;242(1593):860–5 (5 ref.)

GENETICS

[Molecular mechanisms regulating intestinal epithelial cell turnover by nutrients] Ruemmele F, et al.
Gastroenterol Clin Biol 1999 Jan;23(1):47–55 (126 ref.) **(Fre)**

IMMUNOLOGY

Cytokine regulation of epithelial permeability and ion transport. McKay DM, et al. **Gut** 1999 Feb;44(2):283–9 (114 ref.)

PHYSIOLOGY

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Fleisher D, et al. **Clin Pharmacokinet** 1999 Mar; 36(3):233–54 (185 ref.)
Scaling of dimensions of small intestines in non–ruminant eutherian mammals and its significance for absorptive mechanisms. Pappenheimer JR.
Comp Biochem Physiol A Mol Integr Physiol 1998 Sep; 121(1):45–58 (111 ref.)
Intestinal cholesterol absorption. Dawson PA, et al.
Curr Opin Lipidol 1999 Aug;10(4):315–20 (48 ref.)
Gastrointestinal absorption of drugs: methods and studies. Barthe L, et al. **Fundam Clin Pharmacol** 1999;13(2):154–68 (89 ref.)
Role of nitric oxide in intestinal water and electrolyte transport. Mourad FH, et al. **Gut** 1999 Feb;44(2):143–7 (78 ref.)
New insights in the physiology and molecular basis of the intestinal bile acid absorption. Montagnani M, et al.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):435–40 (37 ref.)
Nutritional aspects of calcium absorption. Bronner F, et al.
J Nutr 1999 Jan;129(1):9–12 (49 ref.)
Modulation of intestinal functions by food substances. Shimizu M. **Nahrung** 1999 Jun;43(3):154–8 (35 ref.)
Is the role of the small intestine in first–pass metabolism overemphasized? Lin JH, et al. **Pharmacol Rev** 1999 Jun; 51(2):135–58 (149 ref.)
[Mechanisms of calcium absorption and absorption modifiers based in the elaboration of a low–cost diet for osteoporosis patients] Mota–Blancas E, et al. **Gac Med Mex** 1999 May–Jun;135(3):291–304 (88 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

[D–xylose test of resorption as a method to determine radiation side effects in the small intestine] Köst S, et al. **Strahlenther Onkol** 1998 Sep;174(9):462–7 (33 ref.) (Eng. Abstr.) **(Ger)**

INTESTINAL AMEBIASIS see **DYSENTERY, AMEBIC**

INTESTINAL ATRESIA

Congenital duodenal membrane: a ten–year review. Huang FC, et al.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1999 Mar–Apr;40(2):70–4 (16 ref.)

COMPLICATIONS

Colonic atresia associated with Hirschsprung's disease: it is not a diagnostic challenge. Akgür FM, et al.
Eur J Pediatr Surg 1998 Dec;8(6):378–9 (11 ref.)

EMBRYOLOGY

Embryogenesis of pancreaticobiliary maljunction inferred from development of duodenal atresia. Ando H, et al.
J Hepatobiliary Pancreat Surg 1999;6(1):50–4 (21 ref.)

INTESTINAL DISEASES

Small bowel review: Part I. Thomson AB, et al.
Can J Gastroenterol 1998 Oct;12(7):487–504 (226 ref.)
Small bowel review: Part II. Thomson AB, et al.
Can J Gastroenterol 1999 Jan–Feb;13(1):37–54 (265 ref.)
Small bowel diseases in the elderly. Nagar A, et al.
Clin Geriatr Med 1999 Aug;15(3):473–86 (104 ref.)
[Acute failure of the intestinal barrier—pathophysiology, diagnosis, prophylaxis and therapy] Hachenberg T, et al. **Anaesthesiol Reanim** 1999;24(1):4–12 (112 ref.) (Eng. Abstr.) **(Ger)**
[Actinomycosis of the intestine] Ito K.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):503–5 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Drug–induced disorders of the small bowel. Neitlich JD, et al. **Abdom Imaging** 1999 Jan–Feb;24(1):17–22 (45 ref.)
Nonsteroidal anti–inflammatory drug enteropathy. Morris AJ. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):125–33 (37 ref.)

COMPLICATIONS

Rheumatologic manifestations of gastrointestinal diseases. Katz JP, et al. **Gastroenterol Clin North Am** 1998 Sep; 27(3):533–62, v (188 ref.)
Ophthalmologic effects of bowel disease. Nakla ML, et al. **Gastroenterol Clin North Am** 1998 Sep;27(3):697–711, vii (71 ref.)
Characterization of intestinal disease associated with human immunodeficiency virus infection and response to antiretroviral therapy. Kotler DP. **J Infect Dis** 1999 May; 179 Suppl 3:S454–6 (15 ref.)
[A case of intestinal endometriosis with bilateral pneumothorax] Kirii H, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 Jan;96(1):38–44 (17 ref.) **(Jpn)**

DIAGNOSIS

Small–bowel endoscopy. Waye JD. **Endoscopy** 1999 Jan; 31(1):56–9 (15 ref.)
Endoscopic diagnosis of intestinal penicilliosis marneffei: report of three cases and review of the literature. Ko CI, et al. **Gastrointest Endosc** 1999 Jul;50(1):111–4 (19 ref.)
Intraoperative endoscopy. Delmotte JS, et al.
Gastrointest Endosc Clin N Am 1999 Jan;9(1):61–9 (40 ref.)
Radiology versus endoscopy of the small bowel. Lewis BS.
Gastrointest Endosc Clin N Am 1999 Jan;9(1):13–27 (56 ref.)
Push enteroscopy. MacKenzie JF.
Gastrointest Endosc Clin N Am 1999 Jan;9(1):29–36 (22 ref.)
The sonde exam. Seensalu R.
Gastrointest Endosc Clin N Am 1999 Jan;9(1):37–59 (34 ref.)
Vascular disorders of the small bowel. Sorbi D, et al.
Gastrointest Endosc Clin N Am 1999 Jan;9(1):71–92 (97 ref.)
Common anorectal symptomatology. Fathi DJ. **Prim Care** 1999 Mar;26(1):1–13 (7 ref.)
[Colonoscopy: indications, contraindications and complications] Nahas SC, et al.
Rev Hosp Clin Fac Med Sao Paulo 1998 Mar–Apr; 53(2):91–9 (72 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. De Ponti F, et al.
Pharmacol Ther 1998 Oct;80(1):49–88 (572 ref.)

ETIOLOGY

HIV/SIV enteropathy. Zeitz M, et al.
Ann N Y Acad Sci 1998 Nov 17;859:139–48 (48 ref.)
Motility disorders in childhood. Milla PJ.
Baillieres Clin Gastroenterol 1998 Dec;12(4):775–97 (70 ref.)
The cause and management of bladder, sexual and bowel

symptoms in multiple sclerosis. Fowler CJ.
Baillieres Clin Neurol 1997 Oct;6(3):447–66 (48 ref.)
Buerger's disease with intestinal involvement. Iwai T.
Int J Cardiol 1998 Oct 1;66 Suppl 1:S257–63; discussion S265 (25 ref.)
Visceral intestinal Buerger's disease. Lie JT.
Int J Cardiol 1998 Oct 1;66 Suppl 1:S249–56 (30 ref.)
Laparoscopic hernias: two case reports and a review of the literature. Bemporad JA, et al. **J Comput Assist Tomogr** 1999 Jan–Feb;23(1):86–9 (10 ref.)
Posttraumatic intestinal stenosis presenting as a perforation: report of a case. Konobu T, et al. **Surg Today** 1999; 29(6):564–7 (16 ref.)
[Adult renal polycystosis as the causal entity of an intercostal hernia containing an intestinal loop: an unusual clinical case] Serrano Pascual A, et al. **Arch Esp Urol** 1999 Jan–Feb; 52(1):80–3 (5 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Oral tolerance in disease. Garside P, et al. **Gut** 1999 Jan; 44(1):137–42 (112 ref.)
Role of NF-kappaB in immune and inflammatory responses in the gut. Neurath MF, et al. **Gut** 1998 Dec;43(6):856–60 (76 ref.)
[CREST or CREIST syndrome? (editorial)] Lévesque H, et al. **J Mal Vasc** 1999 Feb;24(1):7–9 (28 ref.) **(Fre)**

METABOLISM

The role of enterocytes in gut dysfunction. Kong SE, et al. **Pathol Res Pract** 1998;194(11):741–51 (121 ref.)

MICROBIOLOGY

Small intestine pathogens in AIDS: conventional and opportunistic. Koch J, et al.
Gastrointest Endosc Clin N Am 1998 Oct;8(4):869–88 (80 ref.)
Virulence factors of aeromonads--an emerging food borne pathogen problem. Agarwal RK, et al. **J Commun Dis** 1998 Jun;30(2):71–8 (70 ref.)

PATHOLOGY

Small-bowel necrosis associated with jejunal tube feeding. Lawlor DK, et al. **Can J Surg** 1998 Dec;41(6):459–62 (15 ref.)

PHYSIOPATHOLOGY

Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Lund PK.
Ann N Y Acad Sci 1998 Nov 17;859:18–36 (87 ref.)
Trefoil peptides. Wong WM, et al. **Gut** 1999 Jun;44(6):890–5 (88 ref.)
The patterns of small bowel motility: physiology and implications in organic disease and functional disorders. Husebye E. **Neurogastroenterol Motil** 1999 Jun; 11(3):141–61 (181 ref.)

PREVENTION & CONTROL

The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Kruzel ML, et al. **Adv Exp Med Biol** 1998;443:167–73 (38 ref.)

RADIOGRAPHY

CT enteroclysis: a superfluous diagnostic procedure or valuable when investigating small-bowel disease? Bender GN, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):373–8 (15 ref.)

REHABILITATION

[Principles of rehabilitation of patients with ileostomy] Palmeri R, et al. **Chir Ital** 1997;49(4–5):43–6 (13 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Vascular classification for small intestinal duplications: experience with 80 cases. Li L, et al. **J Pediatr Surg** 1998 Aug;33(8):1243–5 (16 ref.)
[Principles of rehabilitation of patients with ileostomy] Palmeri R, et al. **Chir Ital** 1997;49(4–5):43–6 (13 ref.) (Eng. Abstr.) **(Ita)**
[A case of internal hernia through a defect in the falciform ligament treated with laparoscopic surgery] Kobayashi S, et al. **Nippon Geka Gakkai Zasshi** 1999 Aug;100(8):513–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Nutritional management of enteropathy. Walker-Smith JA.
Nutrition 1998 Oct;14(10):775–9 (40 ref.)
[Colonoscopy: indications, contraindications and complications] Nahas SC, et al.
Rev Hosp Clin Fac Med Sao Paulo 1998 Mar–Apr; 53(2):91–9 (72 ref.) (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

[Intestinal ultrasound in rare small and large intestinal diseases] Dietrich CF, et al. **Z Gastroenterol** 1998 Nov; 36(11):955–70 (65 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Diet and large intestinal disease in dogs and cats. Simpson JW. **J Nutr** 1998 Dec;128(12 Suppl):2717S–2722S (55 ref.)
Intestinal protozoa important to poultry. McDougald LR.
Poult Sci 1998 Aug;77(8):1156–8 (5 ref.)
Clinical laboratory evaluation of small intestinal function. Hall EJ. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):441–69, vi (79 ref.)
Small intestinal bacterial overgrowth. Johnston KL.
Vet Clin North Am Small Anim Pract 1999 Mar; 29(2):523–50, vii (149 ref.)

INTESTINAL DISEASES, PARASITIC

Amoebiasis revisited: pathogenesis, diagnosis and management. Anand AC, et al. **Trop Gastroenterol** 1999 Jan–Mar;20(1):2–15 (82 ref.)
[Cryptosporidium, Cyclospora, Microsporidia] Ajisawa A.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):97–9 (6 ref.) **(Jpn)**
[Gnathostomiasis] Fujita K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):458–60 (7 ref.) **(Jpn)**
[Isosporiasis (Isospora belli)] Kamiya H.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):431–3 (8 ref.) **(Jpn)**
[Metagonimiasis yokogawai] Kawashima T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):493–5 (2 ref.) **(Jpn)**
[Pinworm infection (enterobiasis)] Kitada O.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):446–7 (4 ref.) **(Jpn)**
[Ascariasis] Kitada O. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):448–50 (7 ref.) **(Jpn)**
[Wakana disease] Kojima S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):437–8 (1 ref.) **(Jpn)**
[Tapeworm infections] Kojima S.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):500–3 (3 ref.) **(Jpn)**
[Schistosomiasis (intestinal, hepatic, urinary tract)] Ohnishi K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):481–4 (4 ref.) **(Jpn)**
[Trichostrongyliasis] Takeuchi T.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):472–3 (2 ref.) **(Jpn)**
[Trichinosis; trichinellosis] Takeuchi T.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):466–8 (6 ref.) **(Jpn)**
[Trichuriasis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):469–70 (5 ref.) **(Jpn)**
[Intestinal parasitic infections and leishmaniasis in patients with HIV infection] Moreno-Camacho A, et al.
Enferm Infecc Microbiol Clin 1998;16 Suppl 1:52–60 (139 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Radiological manifestations of liver and gastrointestinal parasitic infections. Sammak B, et al.
Hepatogastroenterology 1999 Mar–Apr;46(26):1016–22 (20 ref.)
[The first report in Cuba of human intestinal infection by Cyclospora cayetanensis, Ortega, 1993] Núñez Fernández FA, et al. **Rev Cubana Med Trop** 1995;47(3):211–4 (16 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Strongyloidiasis colitis: a case report and review of the literature. Al Samman M, et al. **J Clin Gastroenterol** 1999 Jan;28(1):77–80 (20 ref.)

IMMUNOLOGY

Th1 and Th2 cells and immunity to intestinal helminths. Bancroft AJ, et al. **Chem Immunol** 1998;71:192–208 (91 ref.)
Parasite immunology: pathways for expelling intestinal helminths. Maizels RM, et al. **Curr Biol** 1998 Oct 8; 8(20):R711–4 (25 ref.)
Intestinal nematode parasites, cytokines and effector mechanisms. Else KJ, et al. **Int J Parasitol** 1998 Aug; 28(8):1145–58 (104 ref.)
Immune responses to intestinal parasites: protection, pathology and prophylaxis. Wakelin D. **Parassitologia** 1997 Dec;39(4):269–74 (34 ref.)

PARASITOLOGY

Small intestine pathogens in AIDS: conventional and opportunistic. Koch J, et al.
Gastrointest Endosc Clin N Am 1998 Oct;8(4):869–88 (80 ref.)

PATHOLOGY

[Human microsporidiosis: emergence of a new opportunistic microorganism in patients infected with the human immunodeficiency virus (HIV)] Boldorini R, et al.
Pathologica 1998 Aug;90(4):412–3 (6 ref.) **(Ita)**

PREVENTION & CONTROL

Control strategies for human intestinal nematode infections. Albonico M, et al. **Adv Parasitol** 1999;42:277–341 (260 ref.)

VETERINARY

Genetic analysis of the essential components of the immunoprotective response to infection with Eimeria vermiformis. Smith AL, et al. **Int J Parasitol** 1998 Jul; 28(7):1061–9 (54 ref.)

INTESTINAL EPITHELIUM see **INTESTINAL MUCOSA**

INTESTINAL FISTULA

Biliary-enteric fistulas: report of five cases and review of the literature. Inal M, et al. **Eur Radiol** 1999;9(6):1145–51 (20 ref.)

DIAGNOSIS

Multiple parapapillary choledochoduodenal fistulas with ampullary carcinoma. Imaeda K, et al.
Hepatogastroenterology 1998 Nov–Dec;45(24):2097–100 (9 ref.)
[An appendiceal-vesical fistula in a patient with cystic fibrosis] Ziparo V, et al. **G Chir** 1998 Oct;19(10):387–9 (9 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Role of octreotide and somatostatin in the treatment of intestinal fistulae. Dorta G. **Digestion** 1999;60 Suppl 2:53–6 (23 ref.)
Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Management of fistula disease. Present DH. **Inflamm Bowel Dis** 1998 Nov;4(4):302–7 (21 ref.)

ETIOLOGY

Type IV thoraco-abdominal aortic aneurysm complicated by an aorto-enteric fistula due to previous infrarenal aortic graft. Karacagil S, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):268–70 (9 ref.)
Colocutaneous fistula after percutaneous endoscopic gastrostomy in a remnant stomach. Yamazaki T, et al.
Surg Endosc 1999 Mar;13(3):280–2 (15 ref.)
[Colovesical fistulae as a complication of diverticula: a report of 2 cases] Vitalone AM, et al. **G Chir** 1998 Oct; 19(10):395–8 (37 ref.) (Eng. Abstr.) **(Ita)**
[A colopleural fistula as the clinical presentation of colonic adenocarcinoma (letter)] Domingo-Morera JA, et al.
Arch Bronconeumol 1999 Jan;35(1):52–3 (6 ref.) **(Spa)**

SURGERY

A case of split notochord syndrome: presence of dorsal enteric diverticulum adjacent to the dorsal enteric fistula. Akgür FM, et al. **J Pediatr Surg** 1998 Aug;33(8):1317–9 (19 ref.)
[Treatment of colo-vesical fistulas in one-stage operation] Tiguert R, et al. **Prog Urol** 1998 Sep;8(4):507–10 (21 ref.) (Eng. Abstr.) **(Fre)**
[Duodeno-caval fistula: a rare cause of upper gastrointestinal hemorrhage] Runkel N, et al. **Chirurg** 1998 Aug;69(8):883–6 (22 ref.) (Eng. Abstr.) **(Ger)**
[A case of spontaneous pyeloduodenal fistula] Hamamoto Y, et al. **Hinyokika Kiyo** 1999 May;45(5):355–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Artificial nutritional support in patients with gastrointestinal fistulas. Dudrick SJ, et al. **World J Surg** 1999 Jun; 23(6):570–6 (29 ref.)

INTESTINAL HORMONES see **GASTROINTESTINAL HORMONES**

INTESTINAL MOTILITY see **GASTROINTESTINAL MOTILITY**

INTESTINAL MUCOSA

ANATOMY & HISTOLOGY

Lineage commitment and maturation of epithelial cells in the gut. Karam SM. **Front Biosci** 1999 Mar 15;4:D286–98 (82 ref.)

BLOOD SUPPLY

Management of ectopic varices. Norton ID, et al.
Hepatology 1998 Oct;28(4):1154–8 (35 ref.)
[Dieulafoy colonic ulcer. A rare cause of lower gastrointestinal hemorrhage] Maire F, et al.
Gastroenterol Clin Biol 1998 Nov;22(11):958–60 (25 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Suppression of gastric acid secretion: preventing excess gas [editorial; comment] Heard SO. **Intensive Care Med** 1998 Nov;24(11):1123–5 (26 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1139–43.

CYTOLOGY

Intestinal cell differentiation: cellular mechanisms and the search for the perfect model focus on "involvement of

p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation". Evers BM. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1243–4 (16 ref.)
Molecular mechanisms of enteroendocrine differentiation. Höcker M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:160–74 (88 ref.)
Mucosal T cell–epithelial cell interactions. Bland PW. **Chem Immunol** 1998;71:40–63 (127 ref.)
Phenotypes of T cells in the gut. Brandtzaeg P, et al. **Chem Immunol** 1998;71:1–26 (121 ref.)
Thymus-independent development of gut T cells. Klein JR. **Chem Immunol** 1998;71:88–102 (58 ref.)
Lamina propria T cells. MacDonald TT, et al. **Chem Immunol** 1998;71:103–17 (68 ref.)
Beta 7 integrins and their ligands in lymphocyte migration to the gut. Viney JL, et al. **Chem Immunol** 1998;71:64–76 (72 ref.)
Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650–1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429–36.
Notes from some crypt watchers: regulation of renewal in the mouse intestinal epithelium. Stappenbeck TS, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):702–9 (63 ref.)
Epithelial cells in antigen. Sampling and presentation in mucosal tissues. Kaiserlian D. **Curr Top Microbiol Immunol** 1999;236:55–78 (84 ref.)
Epithelial integrity, cell death and cell loss in mammalian small intestine. Mayhew TM, et al. **Histol Histopathol** 1999 Jan;14(1):257–67 (67 ref.)
The role of enterocytes in gut dysfunction. Kong SE, et al. **Pathol Res Pract** 1998;194(11):741–51 (121 ref.)
M cells at locations outside the gut. Gebert A, et al. **Semin Immunol** 1999 Jun;11(3):165–70 (74 ref.)
Plasticity of the gastrointestinal epithelium: the M cell paradigm and opportunism of pathogenic microorganisms. Kerneis S, et al. **Semin Immunol** 1999 Jun;11(3):205–15 (50 ref.)
Speculation on the lineage relationships among CD4(–)8(+) gut-derived T cells and their role(s). Poussier P, et al. **Semin Immunol** 1999 Aug;11(4):293–303 (43 ref.)
[Cytokines and gut] Shimada T, et al. **Nippon Rinsho** 1998 Sep;56(9):2235–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Role of endoscopy in nonsteroidal anti-inflammatory drug clinical trials. Kimmey MB. **Am J Med** 1998 Nov 2; 105(5A):28S–31S (14 ref.)
[Gastric and duodenal intramural hematoma: report of two cases] Dibuz M, et al. **Orv Hetil** 1998 Dec 6;139(49):2963 (39 ref.) (Eng. Abstr.) **(Hun)**

ENZYMOLOGY

Contributions of molecular motor enzymes to vesicle-based protein transport in gastrointestinal epithelial cells. McNiven MA, et al. **Gastroenterology** 1999 Feb; 116(2):438–51 (133 ref.)
Disaccharidase activities in children [editorial; comment] Baker R. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):242–3 (13 ref.) Comment on: J Pediatr Gastroenterol Nutr 1999 Mar;28(3):246–51.
Intestinal mucosa versus dietary carcinogens: the carcinogenic consequence of metabolic defense enzyme disruption [editorial] Patel HR. **Nutrition** 1999 Feb; 15(2):162–4 (28 ref.)

IMMUNOLOGY

Oral tolerance: mechanisms and therapeutic applications. Faria AM, et al. **Adv Immunol** 1999;73:153–264 (566 ref.)
Role of macrophage cytokines in mucosal adjuvanticity. Foss DL, et al. **Adv Vet Med** 1999;41:83–104 (67 ref.)
Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Iwasaki A, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1074–8 (24 ref.)
IV. Paneth cell antimicrobial peptides and the biology of the mucosal barrier. Ouellette AJ. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G257–61 (32 ref.)
Mucosal immunity and inflammation. III. The mucosal antigen barrier: cross talk with mucosal cytokines. Perdue MH. **Am J Physiol** 1999 Jul;277(1 Pt 1):G1–5 (25 ref.)
Microbial–host interactions at mucosal sites. Host response to pathogenic bacteria at mucosal sites. Phalipon A, et al. **Curr Top Microbiol Immunol** 1999;236:163–89 (154 ref.)
Cow's milk and type 1 diabetes: the real debate is about mucosal immune function. Harrison LC, et al. **Diabetes** 1999 Aug;48(8):1501–7 (81 ref.)
In vitro model of the pathogenesis of celiac disease. Oberhuber G, et al. **Dig Dis** 1998 Nov–Dec;16(6):341–4 (48 ref.)
Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. Tlaskalová-Hogenová H, et al. **Folia Microbiol (Praha)** 1998;43(5):545–50 (50 ref.)
Cytokine regulation of epithelial permeability and ion transport. McKay DM, et al. **Gut** 1999 Feb;44(2):283–9 (114 ref.)
Molecules controlling lymphocyte migration to the gut. Salmi M, et al. **Gut** 1999 Jul;45(1):148–53 (61 ref.)
Diversion colitis—new light through old windows. Edwards CM, et al. **Histopathology** 1999 Jan;34(1):1–5 (33 ref.)
Intestinal intraepithelial T lymphocytes. Our T cell horizons are expanding. Nanno M, et al. **Immunol Res** 1998 Aug; 18(1):41–53 (70 ref.)
A role for transcription factor NF-kappa B in intestinal inflammation. Schottelius AJ, et al. **Int J Colorectal Dis** 1999 Feb;14(1):18–28 (132 ref.)
Nitric oxide: a regulator of mucosal defense and injury. Elliott SN, et al. **J Gastroenterol** 1998 Dec;33(6):792–803 (103 ref.)
Modulation of intestinal immune system by dietary fat intake: relevance to Crohn's disease. Miura S, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1183–90 (57 ref.)
[The intestinal immune system] Reinking RR, et al. **Med Monatsschr Pharm** 1999 Jul;22(7):198–204 (23 ref.) **(Ger)**
[Neuroendocrine regulation of the mucosal immune system] Nagura H. **Arerugi** 1999 Apr;48(4):409–13 (24 ref.) **(Jpn)**
[Mucosal immune system of the intestine] Miura S, et al. **Nippon Rinsho** 1998 Sep;56(9):2228–34 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Dietary regulation of genes expressed in the developing intestinal epithelium. Sanderson IR. **Am J Clin Nutr** 1998 Nov;68(5):999–1005 (51 ref.)
I. Glucose galactose malabsorption. Wright EM. **Am J Physiol** 1998 Nov;275(5 Pt 1):G879–82 (24 ref.)
Water transport revisited. Powell DW. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):1 (6 ref.)
Sphingomyelin hydrolysis in the gut and clinical implications in colorectal tumorigenesis and other gastrointestinal diseases. Duan RD. **Scand J Gastroenterol** 1998 Jul; 33(7):673–83 (101 ref.)
Immunohistochemical findings in the jejunal mucosa of patients with coeliac disease. Arató A, et al. **Scand J Gastroenterol Suppl** 1998;228:3–10 (81 ref.)
[Tight junctional permeability of intestinal epithelium and its regulation by food factors] Shimizu M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):874–80 (35 ref.) **(Jpn)**

MICROBIOLOGY

Cellular microbiology: can we learn cell physiology from microorganisms? Fasano A. **Am J Physiol** 1999 Apr;276(4 Pt 1):C765–76 (95 ref.)
Interaction of microorganisms, epithelium, and lymphoid cells of the mucosa-associated lymphoid tissue. Hamzaoui N, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:65–74 (53 ref.)
Molecular bases of epithelial cell invasion by Shigella flexneri. Sansonetti PJ, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):191–7 (50 ref.)
Intestinal inflammation and the gut microflora. McKay DM. **Can J Gastroenterol** 1999 Jul–Aug;13(6):509–16 (110 ref.)
Enteropathogenic Escherichia coli: a pathogen that inserts its own receptor into host cells. DeVinney R, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):961–76 (122 ref.)
Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri. Sansonetti PJ, et al. **Clin Infect Dis** 1999 Mar;28(3):466–75 (71 ref.)
Molecular basis of the interaction of Salmonella with the intestinal mucosa. Darwin KH, et al. **Clin Microbiol Rev** 1999 Jul;12(3):405–28 (263 ref.)
Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. Tlaskalová-Hogenová H, et al. **Folia Microbiol (Praha)** 1998;43(5):545–50 (50 ref.)
Mycobacterium avium interaction with macrophages and intestinal epithelial cells. Sangari FJ, et al. **Front Biosci** 1999 Jul 15;4:D582–8 (64 ref.)
Bugs and guts: it's good to talk? Farthing MJ. **J R Coll Physicians Lond** 1999 May–Jun;33(3):267–75 (43 ref.)

PATHOLOGY

IV. Paneth cell antimicrobial peptides and the biology of the mucosal barrier. Ouellette AJ. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G257–61 (32 ref.)
Effect of critical illness and nutritional support on mucosal mass and function. Lara TM, et al. **Clin Nutr** 1998 Jun; 17(3):99–105 (61 ref.)
Staining in gastrointestinal endoscopy: clinical applications and limitations. Shim CS. **Endoscopy** 1999 Aug; 31(6):487–96 (72 ref.)
Endoscopic diagnosis of ileocecal mucosa-associated lymphoid tissue lymphoma. Hasegawa N, et al. **Gastrointest Endosc** 1999 Jul;50(1):115–7 (7 ref.)
Collagenous gastritis and collagenous colitis: a report with sequential histological and ultrastructural findings. Pulimood AB, et al. **Gut** 1999 Jun;44(6):881–5 (21 ref.)
Diversion colitis—new light through old windows. Edwards CM, et al. **Histopathology** 1999 Jan;34(1):1–5 (33 ref.)
Cell proliferation and its evaluation in the colorectal mucosa: effect of ethanol. Seitz HK, et al. **Z Gastroenterol** 1998 Aug;36(8):645–55 (82 ref.)
[The mechanisms of gastrointestinal mucosal injury and repair] Kobayashi K, et al. **Nippon Rinsho** 1998 Sep; 56(9):2215–22 (24 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Interaction of microorganisms, epithelium, and lymphoid cells of the mucosa-associated lymphoid tissue. Hamzaoui N, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:65–74 (53 ref.)
Molecular mechanisms of enteroendocrine differentiation. Höcker M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:160–74 (88 ref.)
From cytoskeleton to polarity and chemoreception in the gut epithelium. Höfer D, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:75–84 (36 ref.)
Intestinal epithelial–mesenchymal cell interactions. Kedinger M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:1–17 (72 ref.)
The laminins: role in intestinal morphogenesis and differentiation. Simon-Assmann P, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:46–64 (70 ref.)
Interactions between epithelial cells and immune cells in the intestine. Strober W. **Ann N Y Acad Sci** 1998 Nov 17; 859:37–45 (19 ref.)
Gamma delta T cells: bodyguards and/or sleepers in the gut. Takahashi I, et al. **Chem Immunol** 1998;71:77–87 (59 ref.)
Molecular physiology of colonic epithelial sodium absorption. Clauss W. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):453–5 (57 ref.)
Aging and cancer of the stomach and colon. Jaszewski R, et al. **Front Biosci** 1999 Mar 15;4:D322–8 (80 ref.)
Gastrointestinal mucosal regeneration: role of growth factors. Jones MK, et al. **Front Biosci** 1999 Mar 15;4:D303–9 (79 ref.)
The role of enterocytes in gut dysfunction. Kong SE, et al. **Pathol Res Pract** 1998;194(11):741–51 (121 ref.)
[The mechanisms of gastrointestinal mucosal injury and repair] Kobayashi K, et al. **Nippon Rinsho** 1998 Sep; 56(9):2215–22 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Factors involved in the regeneration of the gastrointestinal tract] Matsubara Y, et al. **Nippon Rinsho** 1998 Sep; 56(9):2253–7 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Trefoil peptides, cellular repair and progression (editorial)] Soriano A. **Gastroenterol Hepatol** 1999 Apr;22(4):188–90 (19 ref.) **(Spa)**

PHYSIOPATHOLOGY

Cellular microbiology: can we learn cell physiology from microorganisms? Fasano A. **Am J Physiol** 1999 Apr;276(4 Pt 1):C765–76 (95 ref.)
Nitric Oxide. III. A molecular prelude to intestinal inflammation. Miller MJ, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G795–9 (25 ref.)
Effect of critical illness and nutritional support on mucosal mass and function. Lara TM, et al. **Clin Nutr** 1998 Jun; 17(3):99–105 (61 ref.)
Correlation of intestinal structure and function in HIV infection. Reka S, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):841–56 (77 ref.)
The role of the gut in major surgical postoperative morbidity. Chieveley-Williams S, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):81–110 (133 ref.)
[Acute failure of the intestinal barrier—pathophysiology, diagnosis, prophylaxis and therapy] Hachenberg T, et al. **Anaesthesiol Reanim** 1999;24(1):4–12 (112 ref.) (Eng. Abstr.) **(Ger)**
[Nitric oxide and inflammatory bowel disease (see comments)] García-González MA, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):870–6 (61 ref.) (Eng. Abstr.) Comment in: Rev Esp Enferm Dig 1998 Dec;90(12):829–32. **(Spa)**

RADIATION EFFECTS

Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Henriksson R, et al. **Acta Oncol** 1999;38(2):159–64 (37 ref.)
Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Zimmermann FB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:85–9 (32 ref.)

SECRETION

Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Roman RM, et al. **Gastroenterology** 1999 Apr;116(4):964–79 (143 ref.)
Trefoil peptides. Wong WM, et al. **Gut** 1999 Jun;44(6):890–5 (88 ref.)
[Chloride secretion in the intestinal epithelium: channels, ions, and intracellular signaling] Mayol J, et al. **Rev Esp Enferm Dig** 1998 Oct;90(10):714–21 (56 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Endoscopic mucosal resection for esophageal and gastric mucosal cancers. Inoue H. **Can J Gastroenterol** 1998 Jul–Aug;12(5):355–9 (15 ref.)
Rapid growth of residual colonic tumor after incomplete mucosal resection. Matsuda K, et al. **J Gastroenterol** 1999 Apr;34(2):260–3 (5 ref.)

TRANSPLANTATION

Small-intestinal submucosa for bladder augmentation: a review of preclinical studies. Kropp BP. **World J Urol** 1998;

16(4):262–7 (38 ref.)

VIROLOGY

Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. Hocini H, et al. **J Infect Dis** 1999 May;179 Suppl 3:S448–53 (35 ref.)

Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. Kagnoff MF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S444–7 (11 ref.)

Characterization of intestinal disease associated with human immunodeficiency virus infection and response to antiretroviral therapy. Kotler DP. **J Infect Dis** 1999 May; 179 Suppl 3:S454–6 (15 ref.)

The effect of route of immunization on mucosal immunity and protection. Lehner T, et al. **J Infect Dis** 1999 May; 179 Suppl 3:S489–92 (19 ref.)

Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission. Neutra MR. **J Infect Dis** 1999 May;179 Suppl 3:S441–3 (16 ref.)

Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. Smith PD, et al. **J Infect Dis** 1999 May;179 Suppl 3:S436–40 (20 ref.)

INTESTINAL NEOPLASMS

Gastrointestinal polyposis syndromes. Guillem JG, et al. **Curr Probl Surg** 1999 Apr;36(4):217–323 (354 ref.)

Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. Wiedenmann B, et al. **J Mol Med** 1998 Aug;76(9):637–47 (103 ref.)

Psammocarcinoma with an aggressive course. Poggi SH, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):659–61 (8 ref.)

COMPLICATIONS

Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. Corpechot C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2586–8 (11 ref.)

Malignant fibrous histiocytoma metastases to the small intestine and colon presenting as an intussusception. Kanoh T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2594–5 (10 ref.)

DIAGNOSIS

Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Oberg K. **Ann Oncol** 1999;10 Suppl 2:S3–8 (30 ref.)

Adenosquamous carcinoma of the small intestine. Report of a case and review of the literature. Ngo N, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):739–42 (32 ref.)

Small bowel tumors and polyposis syndromes. Rossini FP, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):93–114 (133 ref.)

[Carcinoid tumors of the intestines: developments in the Netherlands for diagnosis and palliative treatment (published erratum appears in Ned Tijdschr Geneeskd 1999 Apr 3;143(14):768)] Taal BG, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):445–51 (24 ref.) (Eng. Abstr.) **(Dut)**

DIET THERAPY

[Medical aspect of food starch] Maksimov VI, et al. **Vopr Pitan** 1999;68(1):46–8 (49 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Matrilysin in early stage intestinal tumorigenesis. Fingleton BM, et al. **APMIS** 1999 Jan;107(1):102–10 (50 ref.)

EPIDEMIOLOGY

Acromegaly and intestinal neoplasms. Scialpi C, et al. **Panminerva Med** 1999 Jun;41(2):157–60 (34 ref.)

RADIOTHERAPY

[Carcinoid tumors of the intestines: developments in the Netherlands for diagnosis and palliative treatment (published erratum appears in Ned Tijdschr Geneeskd 1999 Apr 3;143(14):768)] Taal BG, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):445–51 (24 ref.) (Eng. Abstr.) **(Dut)**

SECONDARY

Malignant fibrous histiocytoma metastases to the small intestine and colon presenting as an intussusception. Kanoh T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2594–5 (10 ref.)

SURGERY

Prognostic factors in resected primary small bowel tumors. Brücher BL, et al. **Dig Surg** 1998;15(1):42–51 (52 ref.)

[Occlusive leiomyomas of the small intestine] Dumnici A, et al. **Chirurgia (Bucur)** 1998 Sep–Oct;93(5):349–52 (9 ref.) (Eng. Abstr.) **(Rum)**

THERAPY

Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Oberg K. **Ann Oncol** 1999;10 Suppl 2:S3–8 (30 ref.)

INTESTINAL OBSTRUCTION

CHEMICALLY INDUCED

Endoscopic balloon dilation of multiple NSAID-induced colonic strictures: case report and review of literature on NSAID-related colopathy. Gopal DV, et al. **Gastrointest Endosc** 1999 Jul;50(1):120–3 (45 ref.)

DIAGNOSIS

Splenic flexure volvulus in association with Chilaiditi syndrome: report of a case. Havenstrite KA, et al. **Am Surg** 1999 Sep;65(9):874–6 (5 ref.)

[Unconventional imaging techniques in inflammatory bowel diseases] Wasser MN, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2179–86 (31 ref.) (Eng. Abstr.) **(Dut)**

[Diagnosis of gallstone ileus] Aschoff AJ, et al. **Z Gastroenterol** 1998 Sep;36(9):853–8 (49 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature. Bungard TJ, et al. **Pharmacotherapy** 1999 Apr;19(4):416–23 (26 ref.)

ETIOLOGY

Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. Corpechot C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2586–8 (11 ref.)

Small-intestinal enteroliths—unusual cause of small-intestinal obstruction: report of three cases. Klingler PJ, et al. **Dis Colon Rectum** 1999 May;42(5):676–9 (22 ref.)

Preduodenal portal vein in the adult. Ooshima I, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):455–8 (21 ref.)

Bowel entrapment within pelvic fractures: a case report and review of the literature. Stubbart JR, et al. **J Orthop Trauma** 1999 Feb;13(2):145–8 (24 ref.)

Update on intestinal strictures. Littlewood JM. **J R Soc Med** 1999;92 Suppl 37:41–9 (65 ref.)

Bowel obstruction in the postoperative period of laparoscopic inguinal hernia repair (TAPP): review of the literature. Cueto J, et al. **J Soc Laparoendosc Surg** 1998 Jul–Sep; 2(3):277–80 (27 ref.)

[Cystic lymphangioma of the mesentery. A case of intestinal obstruction and a brief review of the literature] Fundarò S, et al. **Minerva Chir** 1998 Nov;53(11):939–42 (19 ref.) (Eng. Abstr.) **(Ita)**

[A strangulated perineal hernia. A rare case of intestinal obstruction] Sciacca P, et al. **Minerva Chir** 1998 Sep; 53(9):739–41 (5 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Small bowel volvulus: a review. Iwuagwu O, et al. **J R Coll Surg Edinb** 1999 Jun;44(3):150–5 (68 ref.)

PHYSIOPATHOLOGY

[Pathophysiology of ileus] Roscher R, et al. **Zentralbl Chir** 1998;123(12):1328–33 (39 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous endoscopic gastrostomy (PEG) in upper gastrointestinal tract occlusion in gynecologic oncology] Campagnutta E, et al. **Minerva Ginecol** 1998 Jul–Aug; 50(7–8):305–11 (28 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

[The concept of the clinical use of serotonin adipinate in treating surgical patients] Fedorov VD, et al. **Vestn Khir Im I I Grek** 1998;157(3):15–9 (24 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Computed tomography in abdominal cocoon [corrected and republished article originally printed in J Clin Gastroenterol 1998 Mar;26(2): 156–7] Wig JD, et al. **J Clin Gastroenterol** 1998 Oct;27(3):259–60 (11 ref.)

[The diagnostic contribution of computed tomography in a case of volvulus of the small intestine after an ileoanal anastomosis] Catalano O. **Minerva Chir** 1998 Sep; 53(9):747–50 (14 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Recurrent gallstone ileus: underestimated. Doogue MP, et al. **Aust N Z J Surg** 1998 Nov;68(11):755–6 (32 ref.)

Sclerosing encapsulating peritonitis: early and late results of surgical management in 32 cases. French Associations for Surgical Research. Célicout B, et al. **Dig Surg** 1998; 15(6):697–702 (35 ref.)

Small-intestinal enteroliths—unusual cause of small-intestinal obstruction: report of three cases. Klingler PJ, et al. **Dis Colon Rectum** 1999 May;42(5):676–9 (22 ref.)

Bowel entrapment within pelvic fractures: a case report and review of the literature. Stubbart JR, et al. **J Orthop Trauma** 1999 Feb;13(2):145–8 (24 ref.)

Volvulus of the transverse colon in children. Houshian S, et al. **J Pediatr Surg** 1998 Sep;33(9):1399–401 (23 ref.)

Acute small bowel obstruction due to ileal endometriosis: a case report and literature review. Wickramasekera D, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):59–60 (7 ref.)

[Laparoscopic treatment of small intestine obstruction] Slim K. **Chirurgie** 1999 Apr;124(2):177–81 (26 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative ileus—early, late or no surgery at all?] Decurtins M, et al. **Zentralbl Chir** 1998;123(12):1355–9 (32 ref.) (Eng. Abstr.) **(Ger)**

[Rectal carcinoma. Optimizing the procedures in an emergency] Hildebrandt U. **Zentralbl Chir** 1999; 124(5):446–50 (27 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of ileus of the large intestine] Maurer CA, et al. **Zentralbl Chir** 1998;123(12):1346–54 (108 ref.) (Eng. Abstr.) **(Ger)**

[What patient needs which stoma?] Säuberli H, et al. **Zentralbl Chir** 1998;123(12):1370–4 (9 ref.) (Eng. Abstr.) **(Ger)**

[Bochdalek hernia in Adulthood: case report and overview] Sterk P, et al. **Zentralbl Chir** 1998;123(10):1184–7 (11 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of ileus of the small intestine] Uhl W, et al. **Zentralbl Chir** 1998;123(12):1340–5 (33 ref.) (Eng. Abstr.) **(Ger)**

[Occlusive leiomyomas of the small intestine] Dumnici A, et al. **Chirurgia (Bucur)** 1998 Sep–Oct;93(5):349–52 (9 ref.) (Eng. Abstr.) **(Rum)**

[Lipid distress syndrome in surgery] Savel'ev VS, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):604–11 (24 ref.) **(Rus)**

THERAPY

Endoscopic balloon dilation of multiple NSAID-induced colonic strictures: case report and review of literature on NSAID-related colopathy. Gopal DV, et al. **Gastrointest Endosc** 1999 Jul;50(1):120–3 (45 ref.)

[Stent therapy] Schwacha H. **Schweiz Rundsch Med Prax** 1999 Jan 14;88(3):81–4 (17 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Emergency abdominal ultrasound in children: current concepts. Mendelson KL. **Med Health R I** 1999 Jun; 82(6):198–201 (22 ref.)

[Ultrasound ileus diagnosis] Seitz K, et al. **Ultraschall Med** 1998 Dec;19(6):242–9 (34 ref.) (Eng. Abstr.) **(Ger)**

INTESTINAL PERFORATION

COMPLICATIONS

[Psoas abscess with mediastinal extension secondary to rectal perforation (letter; comment)] Jiménez Almonacid P, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):149–50 (6 ref.) Comment on: Rev Esp Enferm Dig 1995 Nov;87(11):830–1. **(Spa)**

DIAGNOSIS

Laparoscopic bowel injury: incidence and clinical presentation. Bishoff JT, et al. **J Urol** 1999 Mar; 161(3):887–90 (31 ref.)

EPIDEMIOLOGY

Laparoscopic bowel injury: incidence and clinical presentation. Bishoff JT, et al. **J Urol** 1999 Mar; 161(3):887–90 (31 ref.)

ETIOLOGY

Ileal penetration by a Multiload-Cu 375 intrauterine contraceptive device. A case report with review of the literature [published erratum appears in Contraception 1998 Dec;58(6):following 389] Chen CP, et al. **Contraception** 1998 Nov;58(5):295–304 (36 ref.)

Perforation of the sigmoid colon with ischemic change due to polyarteritis nodosa. Okada M, et al. **J Gastroenterol** 1999 Jun;34(3):400–4 (12 ref.)

Poor outcome of gastrointestinal perforations associated with childhood abdominal non-Hodgkin's lymphoma. Yanchar NL, et al. **J Pediatr Surg** 1999 Jul;34(7):1169–74 (32 ref.)

Posttraumatic intestinal stenosis presenting as a perforation: report of a case. Konobu T, et al. **Surg Today** 1999; 29(6):564–7 (16 ref.)

Spontaneous perforation of the rectum with possible stercoral etiology: report of a case and review of the literature. Tokunaga Y, et al. **Surg Today** 1998;28(9):937–9 (11 ref.)

[A rare case of a perforated diverticulum of the cecum] Vitali V, et al. **Minerva Chir** 1998 Jun;53(6):531–4 (13 ref.) (Eng. Abstr.) **(Ita)**

[Crohn disease with recurrent free intestinal perforation (letter)] del Olmo Martínez ML, et al. **Gastroenterol Hepatol** 1999 May;22(5):258 (5 ref.) **(Spa)**

PATHOLOGY

[A case report of pancreatic mucinous cystadenocarcinoma with penetration to the stomach] Baek Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):685–90 (12 ref.) **(Jpn)**

SURGERY

[Traumatic lesions of the anorectum] Roche B, et al.

INTESTINAL PERFORATION

Swiss Surg 1998;(5):249–52 (26 ref.) (Eng. Abstr.) **(Fre)**
[Rectal carcinoma. Optimizing the procedures in an emergency] Hildebrandt U. **Zentralbl Chir** 1999; 124(5):446–50 (27 ref.) (Eng. Abstr.) **(Ger)**

INTESTINAL POLYPS

Gastrointestinal polyposis syndromes. Guillem JG, et al. **Curr Probl Surg** 1999 Apr;36(4):217–323 (354 ref.)
[Multiple lymphomatous polyposis] Tsujimura H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):341–3 (12 ref.) **(Jpn)**

PATHOLOGY

Juvenile polyp--a premalignant lesion? Cleary K. **Adv Anat Pathol** 1998 Mar;5(2):95–8 (1 ref.)
Inflammatory fibroid polyps of the large intestine. de la Plaza R, et al. **Dig Dis Sci** 1999 Sep;44(9):1810–6 (36 ref.)
Polyps as biomarkers for colorectal neoplasia. Tobi M. **Front Biosci** 1999 Mar 15;4:D329–38 (95 ref.)

INTESTINAL PSEUDO-OBSTRUCTION

CHEMICALLY INDUCED

[Severe flecainide acetate poisoning. Apropos of a case] Maury P, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):273–7 (10 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Family studies of infantile visceral myopathy: a congenital myopathic pseudo-obstruction syndrome. Guzé CD, et al. **Am J Med Genet** 1999 Jan 15;82(2):114–22 (51 ref.)

DIET THERAPY

Nutritional management of chronic intestinal pseudo-obstruction. Scolapio JS, et al. **J Clin Gastroenterol** 1999 Jun;28(4):306–12 (29 ref.)

ETIOLOGY

[Involvement of the small intestine in systemic scleroderma] Marie I, et al. **Rev Med Interne** 1999 Jun;20(6):504–13 (86 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Pseudo-obstruction: current approaches. Di Lorenzo C. **Gastroenterology** 1999 Apr;116(4):980–7 (27 ref.)

INTESTINAL SECRETIONS

see related
GASTROINTESTINAL HORMONES

INTESTINE, LARGE

Inflammatory fibroid polyps of the large intestine. de la Plaza R, et al. **Dig Dis Sci** 1999 Sep;44(9):1810–6 (36 ref.)
Diet and large intestinal disease in dogs and cats. Simpson JW. **J Nutr** 1998 Dec;128(12 Suppl):2717S–2722S (55 ref.)

ANATOMY & HISTOLOGY

Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Brinck U, et al. **Acta Anat (Basel)** 1998;161(1–4):219–33 (90 ref.)

CYTOLOGY

[The differentiation of the endocrinocytes of the large intestine in vertebrate animals and man] Ivanova OV, et al. **Morfologiia** 1998;114(4):107–11 (58 ref.) **(Rus)**

DRUG EFFECTS

Fiber, inulin and oligofructose: similarities and differences. Schneeman BO. **J Nutr** 1999 Jul;129(7 Suppl):1424S–7S (24 ref.)

INJURIES

Management of injuries to the urinary and gastrointestinal tract during cesarean section. Davis JD. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):469–80 (19 ref.)

MICROBIOLOGY

[Lactulose and the microecology of the large intestine] Maksimov VI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep–Oct; (5):101–7 (39 ref.) **(Rus)**

PHYSIOLOGY

The laminins: role in intestinal morphogenesis and differentiation. Simon-Assmann P, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:46–64 (70 ref.)
[A clinical significance of of methods of the colonic motor function investigation] Baltaitis IuV, et al. **Klin Khir** 1998; (8):42–6 (27 ref.) **(Rus)**

SURGERY

[Surgical therapy of ileus of the large intestine] Maurer CA, et al. **Zentralbl Chir** 1998;123(12):1346–54 (108 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Intestinal ultrasound in rare small and large intestinal diseases] Dietrich CF, et al. **Z Gastroenterol** 1998 Nov; 36(11):955–70 (65 ref.) (Eng. Abstr.) **(Ger)**

INTESTINE, SMALL

Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. Corpechot C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2586–8 (11 ref.)
Malignant fibrous histiocytoma metastases to the small intestine and colon presenting as an intussusception. Kanoh T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2594–5 (10 ref.)
Small bowel review: Part I. Thomson AB, et al. **Can J Gastroenterol** 1998 Oct;12(7):487–504 (226 ref.)
Small bowel review: Part II. Thomson AB, et al. **Can J Gastroenterol** 1999 Jan–Feb;13(1):37–54 (265 ref.)
Small bowel diseases in the elderly. Nagar A, et al. **Clin Geriatr Med** 1999 Aug;15(3):473–86 (104 ref.)
Technical advances and experimental devices for enteroscopy. Mosse CA, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):145–61 (57 ref.)

ABNORMALITIES

Vascular classification for small intestinal duplications: experience with 80 cases. Li L, et al. **J Pediatr Surg** 1998 Aug;33(8):1243–5 (16 ref.)

BLOOD SUPPLY

Histologic spectrum of arterial and arteriolar lesions in acute and chronic cocaine-induced mesenteric ischemia: report of three cases and literature review. Hoang MP, et al. **Am J Surg Pathol** 1998 Nov;22(11):1404–10 (25 ref.)
Schemes against ischemia; solutions for reperfusion (injury)? [editorial; comment] Barie PS. **Crit Care Med** 1999 Apr; 27(4):684–5 (11 ref.) Comment on: Crit Care Med 1999 Apr;27(4):764–70.
Vascular disorders of the small bowel. Sorbi D, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):71–92 (97 ref.)
Visceral intestinal Buerger's disease. Lie JT. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S249–56 (30 ref.)
Vascular classification for small intestinal duplications: experience with 80 cases. Li L, et al. **J Pediatr Surg** 1998 Aug;33(8):1243–5 (16 ref.)
The nature of ischemia/reperfusion injury. Massberg S, et al. **Transplant Proc** 1998 Dec;30(8):4217–23 (82 ref.)
[The role of imaging diagnosis in the study of intestinal infarct] Catalano O, et al. **Minerva Chir** 1998 Jun; 53(6):515–22 (43 ref.) (Eng. Abstr.) **(Ita)**

CYTOLOGY

Notes from some crypt watchers: regulation of renewal in the mouse intestinal epithelium. Stappenbeck TS, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):702–9 (63 ref.)
Epithelial integrity, cell death and cell loss in mammalian small intestine. Mayhew TM, et al. **Histol Histopathol** 1999 Jan;14(1):257–67 (67 ref.)
The nature and implication of intestinal endocrine cell changes in coeliac disease. el-Salhy M. **Histol Histopathol** 1998 Oct;13(4):1069–75 (59 ref.)
The role of insulin-like growth factors in small intestinal cell growth and development. MacDonald RS. **Horm Metab Res** 1999 Feb–Mar;31(2–3):103–13 (72 ref.)

DRUG EFFECTS

Small-bowel side-effects of non-steroidal anti-inflammatory drugs. Aabakken L. **Eur J Gastroenterol Hepatol** 1999 Apr; 11(4):383–8 (66 ref.)
Fiber, inulin and oligofructose: similarities and differences. Schneeman BO. **J Nutr** 1999 Jul;129(7 Suppl):1424S–7S (24 ref.)

ENZYMOLOGY

Solid-phase ELISA for tissue transglutaminase, an endomysial target for possible serological diagnosis of celiac disease. Freeman HJ. **Can J Gastroenterol** 1998 Jul–Aug;12(5):323–4 (0 ref.)

GROWTH & DEVELOPMENT

Ontogeny of the small intestine. Perin NM, et al. **Arq Gastroenterol** 1998 Jul–Sep;35(3):190–7 (74 ref.)

INJURIES

Perforation of acquired small bowel diverticulum. Schock J, et al. **J Am Osteopath Assoc** 1999 Feb;99(2):113–5 (9 ref.)
Management of injuries to the urinary and gastrointestinal tract during cesarean section. Davis JD. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):469–80 (19 ref.)

INNERVATION

["Interstitial cells of Cajal"] Nakamura K, et al. **Fukuoka Igaku Zasshi** 1998 Sep;89(9):255–60 (6 ref.) **(Jpn)**

METABOLISM

A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. Hegele RA. **Clin Biochem** 1998 Nov; 31(8):609–12 (26 ref.)
The role of glutaminase in the small intestine. McCauley R, et al. **Int J Biochem Cell Biol** 1999 Mar–Apr;31(3–4):405–13 (68 ref.)
Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. Wacher VJ, et al. **J Pharm Sci** 1998 Nov;87(11):1322–30 (83 ref.)
Is the role of the small intestine in first-pass metabolism overemphasized? Lin JH, et al. **Pharmacol Rev** 1999 Jun; 51(2):135–58 (149 ref.)
[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Small intestine pathogens in AIDS: conventional and opportunistic. Koch J, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):869–88 (80 ref.)
Small intestinal bacterial overgrowth. Johnston KL. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):523–50, vii (149 ref.)

PARASITOLOGY

Small intestine pathogens in AIDS: conventional and opportunistic. Koch J, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):869–88 (80 ref.)

PATHOLOGY

Small-bowel endoscopy. Waye JD. **Endoscopy** 1999 Jan; 31(1):56–9 (15 ref.)
Intraoperative endoscopy. Delmotte JS, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):61–9 (40 ref.)
Enteroscopy in small intestinal inflammatory diseases. Gay GJ, et al. **Gastrointest Endosc Clin N Am** 1999 Jan; 9(1):115–23 (38 ref.)
Radiology versus endoscopy of the small bowel. Lewis BS. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):13–27 (56 ref.)
Push enteroscopy. MacKenzie JF. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):29–36 (22 ref.)
Nonsteroidal anti-inflammatory drug enteropathy. Morris AJ. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):125–33 (37 ref.)
Small bowel tumors and polyposis syndromes. Rossini FP, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):93–114 (133 ref.)
The sonde exam. Seensalu R. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):37–59 (34 ref.)
Small bowel volvulus: a review. Iwuagwu O, et al. **J R Coll Surg Edinb** 1999 Jun;44(3):150–5 (68 ref.)
[Giant cell arteritis and necrosis of the small intestine. Report of a case] Tozzi N, et al. **J Mal Vasc** 1998 Oct;23(4):293–6 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The laminins: role in intestinal morphogenesis and differentiation. Simon-Assmann P, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:46–64 (70 ref.)
Scaling of dimensions of small intestines in non-ruminant eutherian mammals and its significance for absorptive mechanisms. Pappenheimer JR. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Sep; 121(1):45–58 (111 ref.)
The patterns of small bowel motility: physiology and implications in organic disease and functional disorders. Husebye E. **Neurogastroenterol Motil** 1999 Jun; 11(3):141–61 (181 ref.)
Clinical laboratory evaluation of small intestinal function. Hall EJ. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):441–69, vi (79 ref.)
Isolation of genes involved in intestinal remodeling during anuran metamorphosis. Amano T. **Wound Repair Regen** 1998 Jul–Aug;6(4):302–13 (80 ref.)

PHYSIOPATHOLOGY

The physiology of ileo-anal pouch function. Levitt MD, et al. **Am J Surg** 1998 Oct;176(4):384–9 (78 ref.)
[Involvement of the small intestine in systemic scleroderma] Marie I, et al. **Rev Med Interne** 1999 Jun;20(6):504–13 (86 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

[D-xylose test of resorption as a method to determine radiation side effects in the small intestine] Köst S, et al. **Strahlenther Onkol** 1998 Sep;174(9):462–7 (33 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

CT enteroclysis: a superfluous diagnostic procedure or valuable when investigating small-bowel disease? Bender GN, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):373–8 (15 ref.)

Radiology versus endoscopy of the small bowel. Lewis BS. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):13–27 (56 ref.)

Computed tomography in abdominal cocoon [corrected and republished article originally printed in J Clin Gastroenterol 1998 Mar;26(2): 156–7] Wig JD, et al. **J Clin Gastroenterol** 1998 Oct;27(3):259–60 (11 ref.)

[The diagnostic contribution of computed tomography in a case of volvulus of the small intestine after an ileoanal anastomosis] Catalano O. **Minerva Chir** 1998 Sep; 53(9):747–50 (14 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Prognostic factors in resected primary small bowel tumors. Brücher BL, et al. **Dig Surg** 1998;15(1):42–51 (52 ref.)

Small-intestinal enteroliths—unusual cause of small-intestinal obstruction: report of three cases. Klingler PJ, et al. **Dis Colon Rectum** 1999 May;42(5):676–9 (22 ref.)

[Laparoscopic treatment of small intestine obstruction] Slim K. **Chirurgie** 1999 Apr;124(2):177–81 (26 ref.) (Eng. Abstr.) **(Fre)**

[Surgical therapy of ileus of the small intestine] Uhl W, et al. **Zentralbl Chir** 1998;123(12):1340–5 (33 ref.) (Eng. Abstr.) **(Ger)**

[Occlusive leiomyomas of the small intestine] Dumnici A, et al. **Chirurgia (Bucur)** 1998 Sep–Oct;93(5):349–52 (9 ref.) (Eng. Abstr.) **(Rum)**

TRANSPLANTATION

Intestinal transplantation. Goulet O, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):234–8 (47 ref.)

Progress in experimental intestinal transplantation in small animal models. Timmermann W, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):216–20 (43 ref.)

The use of small intestine in bladder reconstruction. Kashif KM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998; 9(5):275–80 (29 ref.)

Quality of life issues: parenteral nutrition to small bowel transplantation—a review. Brook G. **Nutrition** 1998 Oct; 14(10):813–6 (24 ref.)

The nature of ischemia/reperfusion injury. Massberg S, et al. **Transplant Proc** 1998 Dec;30(8):4217–23 (82 ref.)

Small-intestinal submucosa for bladder augmentation: a review of preclinical studies. Kropp BP. **World J Urol** 1998; 16(4):262–7 (38 ref.)

ULTRASONOGRAPHY

[Intestinal ultrasound in rare small and large intestinal diseases] Dietrich CF, et al. **Z Gastroenterol** 1998 Nov; 36(11):955–70 (65 ref.) (Eng. Abstr.) **(Ger)**

INTESTINES

see related

ENTEROSTOMY

BLOOD SUPPLY

Intestinal (mesenteric) vasculopathy. I. Acute superior mesenteric arteriopathy and venopathy. Cappell MS. **Gastroenterol Clin North Am** 1998 Dec;27(4):783–825, vi (285 ref.)

Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Cappell MS. **Gastroenterol Clin North Am** 1998 Dec;27(4):827–60, vi (355 ref.)

The role of adhesion molecules and nitric oxide in intestinal and hepatic ischemia/reperfusion. Kubes P. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1458–63 (48 ref.)

Intestinal ischemia — the basics. Haglund U, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):233–8 (28 ref.)

Surgical strategies — anastomosis or stoma, a second look — when and why? Hanisch E, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):239–42 (31 ref.)

Integration of intestinal structure, function, and microvascular regulation. Bohlen HG. **Microcirculation** 1998;5(1):27–37 (30 ref.)

Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. Hansen MB, et al. **Physiol Res** 1998;47(5):307–27 (130 ref.)

[Intestinal ischemic reperfusion syndrome: pathophysiology, clinical significance, therapy] Schwarz B, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):539–48 (115 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

The physicochemical environment of the neonatal intestine. Sanderson IR. **Am J Clin Nutr** 1999 May; 69(5):1028S–1034S (52 ref.)

[Intestinal acidity as a protective factor in the host organism] Maksimov VI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug; (4):96–101 (50 ref.) **(Rus)**

CYTOLOGY

Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Powell DW, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):C183–201 (232 ref.)

[Molecular mechanisms regulating intestinal epithelial cell turnover by nutrients] Ruemmele F, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):47–55 (126 ref.) **(Fre)**

DRUG EFFECTS

Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle. Audolfsson G, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:39–47 (16 ref.)

EMBRYOLOGY

The Cdx-1 and Cdx-2 homeobox genes in the intestine. Freund JN, et al. **Biochem Cell Biol** 1998;76(6):957–69 (144 ref.)

Developmental competence of the gut endoderm: genetic potentiation by GATA and HNF3/fork head proteins. Zaret K. **Dev Biol** 1999 May 1;209(1):1–10 (114 ref.)

ENZYMOLOGY

The plasma membrane H+-V-ATPase from tobacco hornworm midgut. Wieczorek H, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):67–74 (60 ref.)

GROWTH & DEVELOPMENT

[Studying intestinal maturation in newborn infants by means of stable isotopes] Sáenz de Pipaón M, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):77–82 (59 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immune-epithelial interactions in host defense. Berin MC, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):16–25 (82 ref.)

Strategies for mucosal vaccine development. Boyaka PN, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):35–45 (117 ref.)

[The intestinal immune system in children and their disorders] Votava-Raić A, et al. **Lijec Vjesn** 1998 Mar–Apr; 120(3–4):72–9 (70 ref.) (Eng. Abstr.) **(Scr)**

INJURIES

Antidepressants for the virtually eviscerated patient: options instead of oral dosing. Koelle JS, et al. **Psychosom Med** 1998 Nov–Dec;60(6):723–5 (20 ref.)

INNERVATION

Lessons from genetically engineered animal models. II. Disorders of enteric neuronal development: insights from transgenic mice. Gershon MD. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G262–7 (35 ref.)

Intestinal peristalsis: a mammalian motor pattern controlled by enteric neural circuits. Costa M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:464–6 (12 ref.)

Effects of inflammatory mediators on gut sensitivity. Bueno L, et al. **Can J Gastroenterol** 1999 Mar;13 Suppl A:42A–46A (25 ref.)

Hirschsprung disease and other enteric dysganglionoses. Kapur RP. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):225–73 (307 ref.)

Connections between P2 purinoceptors and capsaicin-sensitive afferents in the intestine and other tissues. Barthó L, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):203–10 (103 ref.)

METABOLISM

Chylomicron synthesis by intestinal cells in vitro and in vivo. van Greevenbroek MM, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S9–16 (79 ref.)

Membrane traffic and the cellular uptake of cholera toxin. Lencer WI, et al. **Biochim Biophys Acta** 1999 Jul 8; 1450(3):177–90 (158 ref.)

Determinants of intestinal detoxication of lipid hydroperoxides. Aw TY. **Free Radic Res** 1998 Jun; 28(6):637–46 (52 ref.)

Enteral histaminosis: Clinical implications. Amon U, et al. **Inflamm Res** 1999 Jun;48(6):291–5 (31 ref.)

Cellular magnesium transport in the vertebrate intestine. Bijvelds MJ, et al. **Magnes Res** 1998 Dec;11(4):315–22 (80 ref.)

The pharmacological role of P-glycoprotein in the intestinal epithelium. Van Asperen J, et al. **Pharmacol Res** 1998 Jun; 37(6):429–35 (40 ref.)

Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Forte LR. **Regul Pept** 1999 May 31;81(1–3):25–39 (109 ref.)

Citrate transport by the kidney and intestine. Pajor AM. **Semin Nephrol** 1999 Mar;19(2):195–200 (55 ref.)

MICROBIOLOGY

The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Wold AE. **Allergy** 1998;53(46 Suppl):20–5 (73 ref.)

Influences of microbiota on intestinal immune system development. Cebra JJ. **Am J Clin Nutr** 1999 May; 69(5):1046S–1051S (50 ref.)

Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Collins MD, et al. **Am J Clin Nutr** 1999 May;69(5):1052S–1057S (66 ref.)

Healthy gut microflora and allergy: factors influencing development of the microbiota. Kirjavainen PV, et al. **Ann Med** 1999 Aug;31(4):288–92 (47 ref.)

Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? Macfarlane GT, et al. **BMJ** 1999 Apr 10;318(7189):999–1003 (48 ref.)

Dietary modulation of the human gut microflora using prebiotics. Gibson GR. **Br J Nutr** 1998 Oct;80(4):S209–12 (19 ref.)

Role of bacterial colonization in neonatal necrotizing enterocolitis and its prevention. Dai D, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov–Dec;39(6):357–65 (102 ref.)

Review of probiotics available to modify gastrointestinal flora. Gismondo MR, et al. **Int J Antimicrob Agents** 1999 Aug;12(4):287–92 (39 ref.)

Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. Gibson GR. **J Nutr** 1999 Jul;129(7 Suppl):1438S–41S (22 ref.)

Petfood applications of inulin and oligofructose. Hussein HS, et al. **J Nutr** 1999 Jul;129(7 Suppl):1454S–6S (28 ref.)

Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects. Rao AV. **J Nutr** 1999 Jul;129(7 Suppl):1442S–5S (15 ref.)

The locus of enterocyte effacement pathogenicity island of Shiga toxin-producing Escherichia coli O157:H7 and other attaching and effacing E. coli. Kaper JB. **Jpn J Med Sci Biol** 1998;51 Suppl:S101–7 (25 ref.)

Microbiology of the intestinal lymph follicle: a clue to elucidate causative microbial agent(s) in Crohn's disease. Chiba M, et al. **Med Hypotheses** 1998 Nov;51(5):421–7 (37 ref.)

Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Falk PG, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1157–70 (214 ref.)

Probiotics in the new millennium. Vaughan EE, et al. **Nahrung** 1999 Jun;43(3):148–53 (76 ref.)

The Sixth John M. Kinney-Nestlé Clinical Nutrition Award for Enteral Nutrition. Recombinant human tumor necrosis factor and recombinant murine interleukin-1 alter the binding of Escherichia coli to intestine, mucin glycoprotein, and the HT29-C1 intestinal cell line: a context [see comments] Wanke CA. **Nutrition** 1999 Jun;15(6):427–9 (20 ref.) Comment in: Nutrition 1999 Jun;15(6):430.

Evaluation of veterinary drug residues in food for their potential to affect human intestinal microflora. Cerniglia CE, et al. **Regul Toxicol Pharmacol** 1999 Jun;29(3):238–61 (130 ref.)

[Intestinal bacteria overgrowth in chronic hepatopathies] Casafont F, et al. **Rev Med Univ Navarra** 1998 Oct–Dec; 42(4):183–7 (28 ref.) (Eng. Abstr.) **(Spa)**

[Resistance of respiratory and enteral bacteria to antibiotics] Solórzano-Santos F, et al. **Salud Publica Mex** 1998 Nov–Dec;40(6):510–6 (44 ref.) **(Spa)**

PARASITOLOGY

Intestinal parasites in returned travelers. MacPherson DW. **Med Clin North Am** 1999 Jul;83(4):1053–75 (88 ref.)

[Intestinal anisakiasis] Uragami N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):464–5 (14 ref.) **(Jpn)**

PATHOLOGY

Intraduodenal hematoma complicating intestinal biopsy: case reports and review of the literature. Guzman C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2547–50 (29 ref.)

Determinants of intestinal detoxication of lipid hydroperoxides. Aw TY. **Free Radic Res** 1998 Jun; 28(6):637–46 (52 ref.)

[Interventional endoscopy in chronic inflammatory bowel disease] Rosenbaum A, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):967–71 (41 ref.) **(Ger)**

PHYSIOLOGY

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Gershon MD. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:15–30 (117 ref.)

Intestinal mucins in colonization and host defense against pathogens. Belley A, et al. **Am J Trop Med Hyg** 1999 Apr; 60(4 Suppl):10–5 (56 ref.)

Intestinal peristalsis: a mammalian motor pattern controlled by enteric neural circuits. Costa M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:464–6 (12 ref.)

T-cell receptor usage in the intestine. Probert CS, et al. **Chem Immunol** 1998;71:27–39 (43 ref.)

Nitric oxide and the gut: one more piece in the puzzle [editorial; comment] Fink MP. **Crit Care Med** 1999 Feb; 27(2):248–9 (23 ref.) Comment on: Crit Care Med 1999 Feb;27(2):356–64.

Nutrient regulation of intestinal gene expression [see comments] Kelly EJ, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):303–6 (20 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999

Jul;2(4):287–9.
Integrins and human intestinal cell functions. Beaulieu JF. **Front Biosci** 1999 Mar 15;4:D310–21 (134 ref.)
Nutrient regulation of intestinal growth and adaptation: role of glucagon-like peptide 2 and the enteroendocrine cell [editorial; comment] Rubin DC. **Gastroenterology** 1999 Jul; 117(1):261–3 (39 ref.) Comment on: Gastroenterology 1999 Jul;117(1):99–105.
Intestinal adaptation: molecular analyses of a complex process [editorial; comment] Rubin DC, et al. **Gastroenterology** 1998 Nov;115(5):1291–4 (28 ref.) Comment on: Gastroenterology 1998 Nov;115(5):1172–8.
The gut's role in metabolism, mucosal barrier function, and gut immunology. DeWitt RC, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):465–81, x (156 ref.)
Regulatory role of tachykinins on intestinal propulsive activity. Onori L, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):346–51 (62 ref.)
Integration of intestinal structure, function, and microvascular regulation. Bohlen HG. **Microcirculation** 1998;5(1):27–37 (30 ref.)
Modulation of intestinal functions by food substances. Shimizu M. **Nahrung** 1999 Jun;43(3):154–8 (35 ref.)

PHYSIOPATHOLOGY

Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine. Aw TY. **Am J Clin Nutr** 1999 Oct;70(4):557–65 (67 ref.)
Nitric Oxide. III. A molecular prelude to intestinal inflammation. Miller MJ, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G795–9 (25 ref.)
Dimensions of gut dysfunction in irritable bowel syndrome: altered sensory function. Azpiroz F. **Can J Gastroenterol** 1999 Mar;13 Suppl A:12A–14A (17 ref.)
Peripheral contributions to visceral hyperalgesia. Gebhart GF. **Can J Gastroenterol** 1999 Mar;13 Suppl A:37A–41A (16 ref.)
T-cell receptor usage in the intestine. Probert CS, et al. **Chem Immunol** 1998;71:27–39 (43 ref.)
Correlation of intestinal structure and function in HIV infection. Reka S, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):841–56 (77 ref.)
[Intestinal ischemic reperfusion syndrome: pathophysiology, clinical significance, therapy] Schwarz B, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):539–48 (115 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Metabolic consequences of urinary diversion with intestinal segments. Djavan B, et al. **Tech Urol** 1998 Dec;4(4):177–81 (48 ref.)
[Single-row intestinal sutures and and the current suture materials in colorectal surgery] Buianov VM, et al. **Vestn Khir Im I I Grek** 1999;158(2):77–82 (83 ref.) **(Rus)**

TRANSPLANTATION

Contribution of large animal models to the development of clinical intestinal transplantation. Pirenne J. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):221–5 (45 ref.)
Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Demetris AJ, et al. **Ann Transplant** 1997;2(2):27–44 (288 ref.)
Short bowel syndrome in patients studied at the National Institute of Pediatrics in Mexico. Care, cost and perspectives [published erratum appears in Arch Med Res 1999 Mar–Apr;30(2):159] Varela-Fascinetto G, et al. **Arch Med Res** 1998 Winter;29(4):337–40 (17 ref.)
Intestinal transplantation [see comments] Goulet O. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):315–21 (90 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.
Orthotopic bladder augmentation and substitution. Hohenfellner M, et al. **Curr Opin Urol** 1999 Jul;9(4):309–14 (46 ref.)
Pediatric transplantation. Reyes J, et al. **Surg Clin North Am** 1999 Feb;79(1):163–89 (94 ref.)
[Intestinal transplantation: a clinical reality in 1998] Pirenne J. **Bull Mem Acad R Med Belg** 1998;153(2):171–8; discussion 178–81 (7 ref.) (Eng. Abstr.) **(Fre)**

INTOXICATION see **POISONING**

INTOXICATION, ALCOHOLIC see **ALCOHOLIC INTOXICATION**

INTRA-ABDOMINAL INFUSIONS see **INFUSIONS, PARENTERAL**

INTRA-AORTIC BALLOON PUMPING

Rapid-staged strategy for concomitant critical carotid and left main coronary disease with left ventricular dysfunction: IABP use. Allie DE, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1230–5 (31 ref.)
30 years clinical intra-aortic balloon pumping: facts and figures. Mehlhorn U, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:298–303 (64 ref.)

INTRA-ARTERIAL LINES see **CATHETERS, INDWELLING**

INTRACELLULAR ADHESION MOLECULES see **CELL ADHESION MOLECULES**

INTRACELLULAR FLUID

METABOLISM

Calcium release and calcium-activated chloride channels in airway smooth muscle cells. Kotlikoff MI, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S109–14 (24 ref.)
Alteration of intracellular Ca2(+)-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats. Zolk O, et al. **Cardiovasc Res** 1998 Jul;39(1):242–56 (144 ref.)
The regulation of obese (ob) gene expression by intracellular fatty acid concentration in adipocytes. Kawakami Y, et al. **Intern Med** 1999 Feb;38(2):213–5 (6 ref.)
Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Zemel MB. **Mol Cell Biochem** 1998 Nov; 188(1–2):129–36 (69 ref.)
Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Londos C, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):51–8 (41 ref.)

PHYSIOLOGY

Nuclear import and export of proteins: the molecular basis for intracellular signaling. Sekimoto T, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):205–11 (61 ref.)
Endocytosis and intracellular transport of ricin: recent discoveries. Sandvig K, et al. **FEBS Lett** 1999 Jun 4; 452(1–2):67–70 (54 ref.)

INTRACELLULAR MEMBRANES

Mutants of Chlamydomonas: tools to study thylakoid membrane structure, function and biogenesis. de Vitry C, et al. **Biochimie** 1999 Jun;81(6):631–43 (77 ref.)

CHEMISTRY

Import of proteins into peroxisomes. Hettema EH, et al. **Biochim Biophys Acta** 1999 Aug 12;1451(1):17–34 (121 ref.)

DRUG EFFECTS

Pharmacological analysis of intracellular Ca2+ signalling: problems and pitfalls. Taylor CW, et al. **Trends Pharmacol Sci** 1998 Sep;19(9):370–5 (64 ref.)

METABOLISM

Focus on "multiple functional P2X and P2Y receptors in the luminal and basolateral membranes of pancreatic duct cells" [editorial; comment] Dubyak GR. **Am J Physiol** 1999 Aug; 277(2 Pt 1):C202–4 (21 ref.) Comment on: Am J Physiol 1999 Aug;277(2 Pt 1):C205–15.
Vesicle budding on Golgi membranes: regulation by G proteins and myosin motors. Stow JL, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):161–71 (98 ref.)
Localization and mobility of coenzyme Q in lipid bilayers and membranes. Lenaz G, et al. **Biofactors** 1999; 9(2–4):87–93 (21 ref.)
Regulation of intracellular membrane interactions: recent progress in the field of neurotransmitter release. Burger MM, et al. **J Cell Biochem Suppl** 1998;30–31:103–10 (35 ref.)
Intracellular calcium and magnesium: critical determinants of excitotoxicity? Reynolds IJ. **Prog Brain Res** 1998; 116:225–43 (162 ref.)
Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes. Moreno AJ, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II63–77 (100 ref.)
Lipid regulators of membrane traffic through the Golgi complex. Roth MG. **Trends Cell Biol** 1999 May;9(5):174–9 (64 ref.)
[ABC transporters in human cells] Bartosz G. **Postepy Biochem** 1998;44(2):136–51 (181 ref.) **(Pol)**
[Adaptation of thylakoid membranes to environmental light conditions] Romanowska E. **Postepy Biochem** 1999; 45(1):58–65 (75 ref.) **(Pol)**

PHYSIOLOGY

Regulation of membrane traffic in animal cells by COPI. Lowe M, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1–2):53–66 (107 ref.)
Do plastid envelope membranes play a role in the expression of the plastid genome? Sato N, et al. **Biochimie** 1999 Jun; 81(6):619–29 (72 ref.)
Stimulation of apoptosis by sulindac and piroxicam. Waddell WR. **Clin Sci (Colch)** 1998 Sep;95(3):385–8 (34 ref.)
Membrane transport: Take your fusion partners. Clague MJ. **Curr Biol** 1999 Apr 8;9(7):R258–60 (13 ref.)
Potential intracellular targets for anabolic/anti-catabolic therapies. Palmer RM, et al. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):213–8 (50 ref.)
Diverse roles of single membrane organelles: factors establishing the acid lumenal pH. Futai M, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):259–67 (109 ref.)
Ionic channels of the vacuolar membrane of higher plants. Tikhonova LI. **Membr Cell Biol** 1998;12(3):301–18 (117 ref.)
Lipids, lipid domains and lipid-protein interactions in endocytic membrane traffic. Kobayashi T, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):517–26 (133 ref.)
Protein and lipid sorting from the trans-Golgi network to secretory granules-recent developments. Thiele C, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):511–6 (57 ref.)
The composition and function of M cell apical membranes: implications for microbial pathogenesis. Neutra MR, et al. **Semin Immunol** 1999 Jun;11(3):171–81 (86 ref.)

ULTRASTRUCTURE

Structures of gram-negative cell walls and their derived membrane vesicles. Beveridge TJ. **J Bacteriol** 1999 Aug; 181(16):4725–33 (65 ref.)
[Chromosome association with the nuclear membrane and the orderliness of the spatial organization of the genetic material in the interphase nucleus] Glazkov MV. **Tsitol Genet** 1999 Mar–Apr;33(2):79–88 (60 ref.) (Eng. Abstr.) **(Rus)**

INTRACELLULAR SECOND MESSENGERS see **SECOND MESSENGER SYSTEMS**

INTRACEREBRAL PRESSURE see **INTRACRANIAL PRESSURE**

INTRACRANIAL ANEURYSM see **CEREBRAL ANEURYSM**

INTRACRANIAL ARTERIOVENOUS MALFORMATIONS see **CEREBRAL ARTERIOVENOUS MALFORMATIONS**

INTRACRANIAL HYPERTENSION

see related
HYDROCEPHALUS
PAPILLEDEMA
PSEUDOTUMOR CEREBRI

COMPLICATIONS

[Evaluation of ischemic repercussions of intracranial hypertension] Artru F. **Ann Fr Anesth Reanim** 1997; 16(4):410–4 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Outcomes analysis: intracranial pressure monitoring. Wilberger JE Jr. **Clin Neurosurg** 1997;44:439–48 (26 ref.)
Measurement inside the box [editorial; comment] Gibbons KJ. **Crit Care Med** 1999 May;27(5):869–70 (11 ref.) Comment on: Crit Care Med 1999 May;27(5):978–84.
Intracranial pressure monitoring by time domain analysis. Penson RP, et al. **J R Soc Health** 1998 Oct;118(5):289–94 (09 ref.)
[Indications for monitoring intracranial pressure] Melon E. **Ann Fr Anesth Reanim** 1997;16(4):415–9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Techniques for measuring intracranial hypertension] Pottecher T, et al. **Ann Fr Anesth Reanim** 1997;16(4):405–9 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Advances in the integrated traditional and Western medicine in the treatment of brain edema and intracranial hypertension in children] Yu PL. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun; 17(6):378–80 (15 ref.) **(Chi)**

EPIDEMIOLOGY

Benign intracranial hypertension. Pseudotumour cerebri: idiopathic intracranial hypertension. Sussman JD, et al. **Adv Tech Stand Neurosurg** 1998;24:261–305 (168 ref.)

ETIOLOGY

Measurement inside the box [editorial; comment] Gibbons KJ. **Crit Care Med** 1999 May;27(5):869–70 (11 ref.) Comment on: Crit Care Med 1999 May;27(5):978–84.
Diffuse calvarial meningioma. Case report and review of the literature. Anegawa S, et al. **J Neurosurg** 1999 May; 90(5):970–3 (21 ref.)
[When should you suspect a brain tumor?] Kallio M, et al. **Duodecim** 1995;111(21):2009–12 (5 ref.) **(Fin)**
[Post-traumatic intracranial hypertension and biochemical disorders: cases and consequences] Hans P. **Ann Fr Anesth Reanim** 1997;16(4):399–404 (46 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

[The internal environment and intracranial hypertension] Ichai C, et al. **Ann Fr Anesth Reanim** 1997;16(4):435–44 (73 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Cerebrovascular pressure transmission analysis as a guide to the pathophysiology of raised intracranial pressure. Lewis SB. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):947–50 (40 ref.)

[Biomechanics and intracranial hypertension] Bissonnette B, et al. **Ann Fr Anesth Reanim** 1997;16(4):389–93 (18 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral hemodynamics and intracranial hypertension] Bracco D, et al. **Ann Fr Anesth Reanim** 1997;16(4):429–34 (40 ref.) (Eng. Abstr.) **(Fre)**

[Slow pressure waves during intracranial hypertension] Lemaire JJ. **Ann Fr Anesth Reanim** 1997;16(4):394–8 (41 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Traumatic subdural pneumocephalus causing rise in intracranial pressure in the early phase of head trauma: report of two cases. Oge K, et al. **Acta Neurochir (Wien)** 1998;140(7):655–8 (13 ref.)

THERAPY

Treating elevated intracranial pressure: do we raise or lower the blood pressure? [editorial; comment] Schneck MJ. **Crit Care Med** 1998 Nov;26(11):1787–8 (19 ref.) Comment on: Crit Care Med 1997 Aug;25(8):1275–8. Comment on: Crit Care Med 1998 Feb;26(2):210–2. Comment on: Crit Care Med 1998 Nov;26(11):1881–6.

Management of increased intracranial pressure: a review for clinicians. Marik P, et al. **J Emerg Med** 1999 Jul–Aug; 17(4):711–9 (116 ref.)

[What are the indications and modalities of medical treatments for intracranial hypertension from severe head injuries?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):108–22 (45 ref.) **(Fre)**

[Treatment of intracranial hypertension in the case of severe craniocerebral injuries] Moeschler O, et al. **Ann Fr Anesth Reanim** 1997;16(4):453–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of increased intracranial pressure in space-occupying media infarcts] Schwab S, et al. **Z Arztl Fortbild Qualitatssich** 1999 May;93(3):203–8 (23 ref.) (Eng. Abstr.) **(Ger)**

INTRACRANIAL HYPERTENSION, BENIGN see **PSEUDOTUMOR CEREBRI**

INTRACRANIAL HYPOTENSION

COMPLICATIONS

[Prevention and treatment of headache due to intracranial hypotension] Arjona A. **Rev Neurol** 1998 Dec; 27(160):1027–33 (138 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Spontaneous intracranial hypotension: report of four cases and review of the literature. Christoforidis GA, et al. **Neuroradiology** 1998 Oct;40(10):636–43 (52 ref.)

[Intracranial hypotension] Bakouche P. **Presse Med** 1998 Sep 5;27(25):1296–301 (32 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Intracranial hypotension] Bakouche P. **Presse Med** 1998 Sep 5;27(25):1296–301 (32 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[A case of spontaneous intracranial hypotension successfully treated with an epidural blood patch] Ihara M, et al. **Rinsho Shinkeigaku** 1998 Sep;38(9):838–42 (21 ref.) (Eng. Abstr.) **(Jpn)**

INTRACRANIAL PRESSURE

Measurement inside the box [editorial; comment] Gibbons KJ. **Crit Care Med** 1999 May;27(5):869–70 (11 ref.) Comment on: Crit Care Med 1999 May;27(5):978–84.

Intracranial pressure monitoring by time domain analysis. Penson RP, et al. **J R Soc Health** 1998 Oct;118(5):289–94 (09 ref.)

Oncologic emergencies in the patient with lymphoma. Hogan DK, et al. **Semin Oncol Nurs** 1998 Nov;14(4):312–20 (38 ref.)

[Indications for monitoring intracranial pressure] Melon E. **Ann Fr Anesth Reanim** 1997;16(4):415–9 (28 ref.) (Eng. Abstr.) **(Fre)**

[Techniques for measuring intracranial hypertension] Pottecher T, et al. **Ann Fr Anesth Reanim** 1997;16(4):405–9 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

[Effects of anesthetic agents on intracranial pressure] Bazin JE. **Ann Fr Anesth Reanim** 1997;16(4):445–52 (87 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Outcomes analysis: intracranial pressure monitoring. Wilberger JE Jr. **Clin Neurosurg** 1997;44:439–48 (26 ref.)

[Therapy of increased intracranial pressure in space-occupying media infarcts] Schwab S, et al. **Z Arztl Fortbild Qualitatssich** 1999 May;93(3):203–8 (23 ref.) (Eng. Abstr.) **(Ger)**

[What kind of monitoring of intracranial pressure] Citerio G, et al. **Minerva Anestesiol** 1999 May;65(5):318–21 (24 ref.) (Eng. Abstr.) **(Ita)**

INTRACRANIAL TUBERCULOMA see **TUBERCULOMA, INTRACRANIAL**

INTRAMEDULLARY NAILING see **FRACTURE FIXATION, INTRAMEDULLARY**

INTRAMOLECULAR OXIDOREDUCTASES

[Prostanoid synthases] Shimonishi M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1097–103 (48 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. Zou M, et al. **Drug Metab Rev** 1999 May;31(2):343–9 (23 ref.)

INTRAMOLECULAR TRANSFERASES

ANTAGONISTS & INHIBITORS

Inhibitors of 2,3-oxidosqualene cyclase as tools for studying the mechanism and function of the enzyme. Cattel L, et al. **Crit Rev Biochem Mol Biol** 1998;33(5):353–73 (101 ref.)

Mechanism-based inhibitors and other active-site targeted inhibitors of oxidosqualene cyclase and squalene cyclase. Abe I, et al. **J Enzyme Inhib** 1998 Sep;13(6):385–98 (68 ref.)

METABOLISM

S-adenosylmethionine: a 'poor man's coenzyme B12' in the reaction of lysine 2,3-aminomutase. Frey PA, et al. **Biochem Soc Trans** 1998 Aug;26(3):304–10 (27 ref.)

INTRANETS see **COMPUTER COMMUNICATION NETWORKS**

INTRAOBSERVER VARIATION see **OBSERVER VARIATION**

INTRAOCULAR FLUID see **AQUEOUS HUMOR**

INTRAOCULAR PRESSURE

see related
GLAUCOMA
OCULAR HYPERTENSION
OCULAR HYPOTENSION
TONOMETRY

The Collaborative Normal-Tension Glaucoma Study and some of its lessons [editorial] Drance SM. **Can J Ophthalmol** 1999 Feb;34(1):1–6 (19 ref.) **(Eng, Fre)**

The tale of normal-tension glaucoma [editorial; comment] Van Buskirk EM. **J Glaucoma** 1998 Dec;7(6):363–5 (13 ref.) Comment on: J Glaucoma 1998 Dec;7(6):366–71.

Control of intraocular pressure after trabeculectomy. Haynes WL, et al. **Surv Ophthalmol** 1999 Jan–Feb;43(4):345–55 (82 ref.)

[Pathogenesis and treatment of low (normal) pressure glaucoma] Shmyreva VF, et al. **Vestn Oftalmol** 1998 Jul–Aug;114(4):47–8 (35 ref.) **(Rus)**

DRUG EFFECTS

The treatment of normal-tension glaucoma [editorial; comment] Caprioli J. **Am J Ophthalmol** 1998 Oct; 126(4):578–81 (21 ref.) Comment on: Am J Ophthalmol 1998 Oct;126(4):487–97. Comment on: Am J Ophthalmol 1998 Oct;126(4):498–505.

Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans [editorial; comment] Kaufman PF. **Arch Ophthalmol** 1999 May;117(5):673–4 (25 ref.) Comment on: Arch Ophthalmol 1999 May;117(5):586–91.

PHYSIOLOGY

[Endothelins and nitric oxide: their significance in the regulation of ocular blood flow and intraocular pressure and their role in the pathogenesis of primary glaucoma] Bakshinskii PP. **Vestn Oftalmol** 1999 May–Jun;115(3):33–7 (73 ref.) **(Rus)**

INTRAOPERATIVE CARE

Intraoperative considerations during minimal-access cardiac surgery. Krucylak PE. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):116–24 (71 ref.)

The current status of intraoperative radiotherapy in colorectal surgery. Nyam DC, et al. **Singapore Med J** 1998 Sep;39(9):422–5 (12 ref.)

Intraoperative and laparoscopic ultrasound. Machi J. **Surg Oncol Clin N Am** 1999 Jan;8(1):205–26 (47 ref.)

[Role of non-steroidal anti-inflammatory agents in the perioperative period. Usefulness and limitations] Derrier M, et al. **Ann Fr Anesth Reanim** 1997;16(5):498–520 (98 ref.) (Eng. Abstr.) **(Fre)**

[Intraoperative echography: the state of the art] Angelini L, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):223–30 (43 ref.) (Eng. Abstr.) **(Ita)**

[Intraoperative echography in biliopancreatic surgery] Marrano D, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):217–22 (24 ref.) (Eng. Abstr.) **(Ita)**

[Stress steroids] Inada E. **Masui** 1998 Dec;47 Suppl:S70–6 (31 ref.) **(Jpn)**

[Intraoperative radiotherapy with accelerated electrons for urinary bladder carcinoma: principles and results] Calvo FA, et al. **Arch Esp Urol** 1999 Jul–Aug;52(6):649–54 (19 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Intraoperative probes and imaging probes. Hoffman EJ, et al. **Eur J Nucl Med** 1999 Aug;26(8):913–35 (159 ref.)

METHODS

Intraoperative abdominal ultrasonography. Luck AJ, et al. **Br J Surg** 1999 Jan;86(1):5–16 (65 ref.)

Intraoperative fluid management—what and how much? Rosenthal MH. **Chest** 1999 May;115(5 Suppl):106S–112S (32 ref.)

Perioperative nutrition [editorial] Allison SP, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):55–9 (15 ref.)

Perioperative hyperglycemia, infection or risk? Khaodhiar L, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan; 2(1):79–82 (22 ref.)

Applications of image-guided surgery to intraoperative electrophysiology. Alonso-Vanegas MA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:140–56 (76 ref.)

Direct intraoperative recordings from the hippocampal formation: relation with quantitative volumetric MRI. Morrell F, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:112–22 (36 ref.)

Mild hypothermia: an alternative to deep hypothermia for achieving neuroprotection. Bell TE, et al. **J Cardiovasc Nurs** 1998 Oct;13(1):34–44 (35 ref.)

[Anesthesia and postoperative recovery for parathyroid gland surgery] Roland E. **Ann Chir** 1999;53(2):150–61 (48 ref.) (Eng. Abstr.) **(Fre)**

[Hypnosis and its application in surgery] Faymonville ME, et al. **Rev Med Liege** 1998 Jul;53(7):414–8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral protection in surgery on the aortic arch] Porqueddu M, et al. **Cardiologia** 1998 Nov;43(11):1153–8 (56 ref.) **(Ita)**

[Transesophageal echocardiography in the operating room] Almeida J. **Rev Port Cardiol** 1999 May;18(5):531–9 (23 ref.) (Eng. Abstr.) **(Por)**

INTRAOPERATIVE COMPLICATIONS

Flap complications of lamellar refractive surgery [editorial; comment] Gimbel HV. **Am J Ophthalmol** 1999 Feb; 127(2):202–4 (6 ref.) Comment on: Am J Ophthalmol 1999 Feb;127(2):129–36.

Iatrogenic cutaneous injuries in the neonate. Metzker A, et al. **Arch Dermatol** 1999 Jun;135(6):697–703 (26 ref.)

Complications of endoscopic sphincterotomy. Freeman ML. **Endoscopy** 1998 Nov;30(9):A216–20 (36 ref.)

Intraoperative transmission of blood-borne disease in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1998 Mar;4(2):75–8 (15 ref.)

Ischemic injury and its prevention. Riedel BJ. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):20–7; discussion 41–4 (73 ref.)

Long-term consequences from bladder perforation and/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature. Mydlo JH, et al. **J Urol** 1999 Apr;161(4):1128–32 (39 ref.)

Bladder entrapment during internal fixation of a pelvic fracture. Salomé F, et al. **J Urol** 1999 Jan;161(1):213–4 (2 ref.)

[Mild intraoperative hypothermia. Another risk factor for postoperative complications] Rosenberg J, et al. **Ugeskr Laeger** 1999 May 17;161(20):2935–8 (29 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSIS

Surgical monitoring of motor pathways [see comments] Burke D, et al. **J Clin Neurophysiol** 1998 May;15(3):194–205 (75 ref.) Comment in: J Clin Neurophysiol 1998 May;15(3):181–2.

Facial nerve electromyography and other cranial nerve monitoring [see comments] Harper CM, et al. **J Clin Neurophysiol** 1998 May;15(3):206–16 (18 ref.) Comment in: J Clin Neurophysiol 1998 May;15(3):181–2.

Spinal cord monitoring with somatosensory techniques. Nuwer MR. **J Clin Neurophysiol** 1998 May;15(3):183–93 (118 ref.)

Laparoscopic bowel injury: incidence and clinical presentation. Bishoff JT, et al. **J Urol** 1999 Mar; 161(3):887–90 (31 ref.)

INTRAOPERATIVE COMPLICATIONS

[Assessment of cardiovascular perioperative risk in non-cardiac surgery] Sirieix D, et al. **Ann Fr Anesth Reanim** 1998;17(10):1225-31 (38 ref.) (Eng. Abstr.) **(Fre)**

[Risk assessment of patients before lung surgery] Schulz C, et al. **Chirurg** 1999 Jun;70(6):664-73 (64 ref.) (Eng. Abstr.) **(Ger)**

[Complications at anesthesia in tonsillectomy] Protasevich GS. **Vestn Otorinolaringol** 1999;(3):57-60 (89 ref.) **(Rus)**

DRUG THERAPY

Epoetin alfa. A bloodless approach for the treatment of perioperative anemia. Faris PM, et al. **Clin Orthop** 1998 Dec;(357):60-7 (37 ref.)

[Heparin in anesthesia. Pharmacological and clinical aspects in the prophylaxis of venous thromboembolism] Verso M, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):35-9 (28 ref.) **(Ita)**

EPIDEMIOLOGY

Laparoscopic bowel injury: incidence and clinical presentation. Bishoff JT, et al. **J Urol** 1999 Mar; 161(3):887-90 (31 ref.)

[Morbidity and mortality in anesthesiology] Ravussin P, et al. **Rev Med Suisse Romande** 1999 Mar;119(3):161-6 (16 ref.) **(Fre)**

[Incidence and ranking of perioperative myocardial ischemias] Priebe HJ. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Mar; 34(3):177-81 (16 ref.) **(Ger)**

ETIOLOGY

Wisdom tooth removal and lingual nerve damage [editorial] McGurk M, et al. **Br J Oral Maxillofac Surg** 1999 Aug; 37(4):253-4 (22 ref.)

Perioperative cardiac risk assessment for noncardiac surgery. Mehta RH, et al. **Cardiologia** 1999 May;44(5):409-18 (75 ref.)

Obesity as a factor in penetrating keratoplasty. Johansen TR, et al. **Cornea** 1999 Jan;18(1):12-8 (10 ref.)

Intraoperative pacemaker dysfunction caused by the use of electrocautery during a total hip arthroplasty. Nercessian OA, et al. **J Arthroplasty** 1998 Aug;13(5):599-602 (33 ref.)

Laparoscopic surgery complications associated with trocar tip design: review of literature and own results. Leibl BJ, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr; 9(2):135-40 (33 ref.)

Disasters of endoscopic surgery and how to avoid them: error analysis. Troidl H. **World J Surg** 1999 Aug;23(8):846-55 (35 ref.)

[Eisenmenger syndrome in adults] Roos-Hesselink JW, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):501-5 (22 ref.) (Eng. Abstr.) **(Dut)**

[Trocar-induced complications in laparoscopy] Mosnier H, et al. **J Chir (Paris)** 1998 Nov;135(5):217-8, 231 (11 ref.) (Eng. Abstr.) **(Fre)**

[Morbidity and mortality in anesthesiology] Ravussin P, et al. **Rev Med Suisse Romande** 1999 Mar;119(3):161-6 (16 ref.) **(Fre)**

[Perioperative management of patients with arterial hypertension] Filipovic M, et al. **Ther Umsch** 1999 Jan; 56(1):37-42 (25 ref.) (Eng. Abstr.) **(Ger)**

[Complications in trauma surgery] Piltz S, et al. **Unfallchirurg** 1998 Nov;101(11):856-65 (18 ref.) **(Ger)**

[Vascular complications during laparoscopy. An analysis of a personal case] Esposito C, et al. **Minerva Chir** 1999 Mar; 54(3):163-5 (9 ref.) (Eng. Abstr.) **(Ita)**

[Accidental intraoperative whole-body hypothermia: the mechanisms of its occurrence and of self-warming] Romanov MA. **Anesteziol Reanimatol** 1998 Jul-Aug; (4):65-72 (145 ref.) **(Rus)**

NURSING

Management of hysteroscopic surgery complications. Morrison DM. **AORN J** 1999 Jan;69(1):194-7, 199-209; quiz 210, 213-5, 21 (35 ref.)

PATHOLOGY

Bone density measurements of the paranasal sinuses on plastinated whole-organ sections: anatomic data to prevent complications in endoscopic sinus surgery. Sprinzl GM, et al. **Laryngoscope** 1999 Mar;109(3):400-6 (33 ref.)

[Latex allergy. An not rare intraoperative event] Cantini Q, et al. **Minerva Anestesiol** 1999 Mar;65(3):101-7 (32 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Endothelial response to cardiopulmonary bypass surgery. Verrier ED, et al. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S17-9; discussion S25-8 (12 ref.)

Perioperative factors influencing surgical morbidity: what the anesthesiologist needs to know. Carli F. **Can J Anaesth** 1999 May;46(5 Pt 2):R70-9 (21 ref.) **(Eng, Fre)**

PREVENTION & CONTROL

What intraoperative monitoring makes sense? Brodsky JB. **Chest** 1999 May;115(5 Suppl):101S-105S (20 ref.)

Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. van Gorp EC, et al. **Drugs Aging** 1998 Aug;13(2):145-57 (94 ref.)

Brain protection for cerebral aneurysm surgery. Schievink WI, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):661-71 (118 ref.)

Temporary vascular occlusion during cerebral aneurysm surgery. Taylor CL, et al. **Neurosurg Clin N Am** 1998 Oct; 9(4):673-9 (46 ref.)

Should surgical patients be screened for thrombophilia? Wheeler HB. **Semin Thromb Hemost** 1998;24 Suppl 1:63-5 (10 ref.)

Prophylactic ureteral catheterization in gynecologic surgery. Kuno K, et al. **Urology** 1998 Dec;52(6):1004-8 (17 ref.)

Monitoring of oxygen delivery in cardiac and vascular surgery. Spahn DR. **Vox Sang** 1998;74 Suppl 2:395-7 (17 ref.)

[Using the electric scalpel in laparoscopy. Principles and prevention of complications] Mutter D. **Ann Chir** 1998; 52(1):53-60 (20 ref.) **(Fre)**

[Elective surgery and emergency surgery in patients undergoing oral anticoagulant therapy] Berrettini M. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):53-9 (19 ref.) **(Ita)**

[Consequences of perioperative hypothermia] Berti M, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):42-5 (25 ref.) **(Ita)**

[Prevention of hypertensive crisis by narcosis induction in vascular surgery] Loguercio G, et al. **Minerva Anestesiol** 1981 Jul;47(7):401-3 (16 ref.) **(Ita)**

RADIOGRAPHY

Imaging of pancreatic trauma. Patel SV, et al. **Br J Radiol** 1998 Sep;71(849):985-90 (9 ref.)

SURGERY

Left ventricular free wall rupture following mitral valve replacement. Yoshida K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):336-9 (12 ref.)

Inadvertent arterial injury during saphenous vein stripping: three cases and therapeutic strategies. Ramsheyi A, et al. **Arch Surg** 1998 Oct;133(10):1120-3 (6 ref.)

Intraoperative aneurysm rupture and complication avoidance. Chandler JP, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):861-8 (26 ref.)

Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567-83 (56 ref.)

THERAPY

LASIK: management of common complications. Laser in situ keratomileusis. Wilson SE. **Cornea** 1998 Sep;17(5):459-67 (14 ref.)

Stent-graft treatment of iatrogenic iliac artery perforations: report of three cases. Nyman U, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):259-63 (18 ref.)

INTRAOPERATIVE MONITORING see **MONITORING, INTRAOPERATIVE**

INTRAOSSEOUS GANGLION see **BONE CYSTS**

INTRAPERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

INTRASPINAL INJECTIONS see **INJECTIONS, SPINAL**

INTRATHECAL INJECTIONS see **INJECTIONS, SPINAL**

INTRAUTERINE CROSS-TRANSFUSION see **FETOFETAL TRANSFUSION**

INTRAUTERINE DEVICES

Appropriate use of the intrauterine device [see comments] Canavan TP. **Am Fam Physician** 1998 Dec;58(9):2077-84, 2087-8 (32 ref.) Comment in: Am Fam Physician 1998 Dec;58(9):1963-4.

Intrauterine devices: mechanisms of action, safety, and efficacy. Mishell DR Jr. **Contraception** 1998 Sep;58(3 Suppl):45S-53S; quiz 70S (46 ref.)

Intrauterine device practice guidelines: medical conditions. Nelson AL. **Contraception** 1998 Sep;58(3 Suppl):59S-63S; quiz 72S (22 ref.)

Intrauterine device practice guidelines: patient types. Sulak PJ. **Contraception** 1998 Sep;58(3 Suppl):55S-58S; quiz 71S (25 ref.)

Safety of emergency contraception. Glasier A. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):219-21 (21 ref.)

Emergency contraception: a global overview. Westley E. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):215-8, 237 (40 ref.)

Intrauterine devices. The optimal long-term contraceptive method? Fortney JA, et al. **J Reprod Med** 1999 Mar; 44(3):269-74 (19 ref.)

The intrauterine device: dispelling the myths. Kimble-Haas SL. **Nurse Pract** 1998 Nov;23(11):58, 63-9, 73 (28 ref.)

A request for coil removal after four abortions. Merriman H, et al. **Practitioner** 1998 Aug;242(1589):555-6, 559-60, 563 (0 ref.)

ADVERSE EFFECTS

The intrauterine contraceptive device: an often-forgotten and maligned method of contraception. Dardano KL, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):1-5 (25 ref.)

Ileal penetration by a Multiload-Cu 375 intrauterine contraceptive device. A case report with review of the literature [published erratum appears in Contraception 1998 Dec;58(6):following 389] Chen CP, et al. **Contraception** 1998 Nov;58(5):295-304 (36 ref.)

Sonographic images of a lost intrauterine device [letter] Zalel Y, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):376-7 (5 ref.)

[Etiology of ectopic pregnancy] Zhang H, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):476-8 (18 ref.) **(Chi)**

[Migration of an intrauterine device into the bladder. Report of a case] Nouri M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May;28(2):162-4 (7 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Contraception. Slow train gathers speed. Hampton N, et al. **Lancet** 1998 Dec 19-26;352 Suppl 4:SIV3 (5 ref.)

INTRAUTERINE DEVICES, COPPER

GyneFIX. The frameless intrauterine contraceptive implant--an update for interval, emergency and postabortal contraception. Wildemeersch D, et al. **Br J Fam Plann** 1999 Jan;24(4):149-59 (59 ref.)

INTRAUTERINE DIAGNOSIS see **PRENATAL DIAGNOSIS**

INTRAUTERINE GROWTH RETARDATION see **FETAL GROWTH RETARDATION**

INTRAVASCULAR AGGLUTINATION see **ERYTHROCYTE AGGREGATION, INTRAVASCULAR**

INTRAVENOUS ANESTHETICS see **ANESTHETICS, INTRAVENOUS**

INTRAVENOUS DRIP see **INFUSIONS, INTRAVENOUS**

INTRAVENOUS DRUG ABUSE see **SUBSTANCE ABUSE, INTRAVENOUS**

INTRAVENOUS DRUG DELIVERY SYSTEMS see **INFUSION PUMPS**

INTRAVENOUS FEEDING see **PARENTERAL NUTRITION**

INTRAVENOUS HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

INTRAVENOUS IMMUNOGLOBULINS see **IMMUNOGLOBULINS, INTRAVENOUS**

INTRAVENOUS INFUSIONS see **INFUSIONS, INTRAVENOUS**

INTRONS

Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Olivera BM, et al. **Ann N Y Acad Sci** 1999 May 18;870:223-37 (37 ref.)

Mass migration of a group I intron: promiscuity on a grand scale [comment] Gray MW. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14003-5 (20 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14244-9.

Why are human G-protein-coupled receptors predominantly intronless? [letter] Gentles AJ, et al. **Trends Genet** 1999 Feb;15(2):47-9 (12 ref.)

GENETICS

The recent origins of spliceosomal introns revisited. Logsdon JMJr. **Curr Opin Genet Dev** 1998 Dec;8(6):637-48 (92 ref.)

AT-AC pre-mRNA splicing mechanisms and conservation of minor introns in voltage-gated ion channel genes. Wu Q, et al. **Mol Cell Biol** 1999 May;19(5):3225-36 (130 ref.)

Imprinting of the mouse Igf2r gene depends on an intronic CpG island. Wutz A, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):9-14 (35 ref.)

[Anatomy of the eukaryotic gene] Acevedo S. **Sangre (Barc)** 1998 Oct;43(5):447-50 (19 ref.) **(Spa)**

INTUBATION

see related
CHEST TUBES

INTUBATION, ENDOTRACHEAL see **INTUBATION, INTRATRACHEAL**

INTUBATION, GASTROINTESTINAL

Intracranial insertion of a nasogastric tube in a case of homicidal head trauma. Gianelli Castiglione A, et al.

Am J Forensic Med Pathol 1998 Dec;19(4):329–34 (34 ref.)
Nasogastric tubes and dietary advancement after laparoscopic and open colorectal surgery. Sands DR, et al. **Nutrition** 1999 May;15(5):347–50 (34 ref.)
[Nasogastric tubes after elective abdominal surgery is not justified] Gouzi JL, et al. **J Chir (Paris)** 1998 Dec; 135(6):273–4 (11 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Strategies for reducing the pain and discomfort of nasogastric intubation [editorial; comment] Maglinte DD, et al. **Acad Emerg Med** 1999 Mar;6(3):166–9 (14 ref.) Comment on: Acad Emerg Med 1999 Mar;6(3):184–90.
Enteral nutrition: should we feed the stomach? [editorial; comment] Smith HG, et al. **Crit Care Med** 1999 Aug; 27(8):1652–3 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1447–53.

INSTRUMENTATION

Use of gastrostomy and combined gastrojejunostomy tubes for enteral feeding. Faries MB, et al. **World J Surg** 1999 Jun;23(6):603–7 (22 ref.)

METHODS

Enteral nutrition: should we feed the stomach? [editorial; comment] Smith HG, et al. **Crit Care Med** 1999 Aug; 27(8):1652–3 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1447–53.
Recent advances in the placement of tubes for enteral nutrition. Campos AC, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):265–9 (26 ref.)
Role of PEG/PEJ in enteral feeding. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):699–701 (33 ref.)

TRENDS

Recent advances in the placement of tubes for enteral nutrition. Campos AC, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):265–9 (26 ref.)

INTUBATION, INTRATRACHEAL

The unanticipated difficult airway with recommendations for management [see comments] Crosby ET, et al. **Can J Anaesth** 1998 Aug;45(8):757–76 (132 ref.) Comment in: Can J Anaesth 1999 Feb;46(2):198. Comment in: Can J Anaesth 1999 Mar;46(3):297–8; discussion 298–9. Comment in: Can J Anaesth 1999 Mar;46(3):298–9. Comment in: Can J Anaesth 1999 May;46(5 Pt 1):510–1. Comment in: Can J Anaesth 1999 May;46(5 Pt 1):511–2.
N-CPAP in the prevention of recurrent intubations and hospitalizations in a patient with refractory congestive heart failure. Parmar MS, et al. **Can J Cardiol** 1998 Nov; 14(11):1405–8 (22 ref.)
The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. [see comments] Pang D, et al. **Chest** 1998 Oct;114(4):1185–92 (23 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):58.
Does heliox decrease the need for intubation in acute bronchiolitis? [editorial; comment] Barnes SD. **Crit Care Med** 1998 Oct;26(10):1633–5 (18 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1731–6.
Impact of early tracheal extubation on hospital discharge. Cheng DC. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):35–40; discussion 41–4 (60 ref.)
The implications of hypothermia for early tracheal extubation following cardiac surgery. Leslie K, et al. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):30–4; discussion 41–4 (59 ref.)
Patient selection and anesthetic management for early extubation and hospital discharge: CABG. Royston D. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):11–9 (57 ref.)
[Endobronchial photodynamic therapy in France] Leroy M. **Presse Med** 1998 Jun 20;27(22):1121–3 (0 ref.) **(Fre)**
[COPA, LMA, tracheal intubation. What are the indications in pediatric anesthesia] Villani A, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):60–4 (36 ref.) **(Ita)**

ADVERSE EFFECTS

Nonsurgical treatment of a severe tracheal rupture after endotracheal intubation. Zettl R, et al. **Crit Care Med** 1999 Mar;27(3):661–3 (9 ref.)
Airway rupture from double-lumen tubes. Fitzmaurice BG, et al. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):322–9 (74 ref.)
Does postoperative ventilation have an effect on the integrity of the anastomosis in repaired oesophageal atresia? Beasley SW. **J Paediatr Child Health** 1999 Apr;35(2):120–2 (11 ref.)
An unusual complication of endotracheal intubation: ingestion of a laryngoscope bulb. Ince Z, et al. **Pediatr Emerg Care** 1998 Aug;14(4):275–6 (4 ref.)
Partial transsection of the neonatal trachea. Krause MF, et al. **Resuscitation** 1998 Jul;38(1):43–6 (17 ref.)
[Oro-dental injuries during intubation anesthesia] Folwaczny M, et al. **Anaesthesist** 1998 Sep;47(9):707–31 (204 ref.) (Eng. Abstr.) **(Ger)**
[Accidental esophageal intubation] Frova G. **Minerva Anestesiol** 1998 Nov;64(11):483–7 (10 ref.) **(Ita)**
[Anesthesia accidents: accidental esophageal intubation] Frova G, et al. **Minerva Anestesiol** 1999 Jun;65(6):362–6 (19 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

The 'dedicated airway': a review of the concept and an update of current practice. Charters P, et al. **Anaesthesia** 1999 Aug;54(8):778–86 (37 ref.)
Bronchial blocker placement through the lumen of an in situ tracheal tube. Ho AM. **J Trauma** 1999 Aug;47(2):423–5 (9 ref.)

METHODS

Normal saline instillation with endotracheal suctioning: primum non nocere (first do no harm). Blackwood B. **J Adv Nurs** 1999 Apr;29(4):928–34 (38 ref.)
The vocal athlete and endotracheal intubation: a management protocol. Loucks TM, et al. **J Voice** 1998 Sep;12(3):349–59 (35 ref.)
[Management of difficult intubation in the operating room] Boussofara M, et al. **Tunis Med** 1998 Feb;76(2):1033–40 (23 ref.) **(Fre)**

STANDARDS

Verification of endotracheal tube placement following intubation. National Association of EMS Physicians Standards and Clinical Practice Committee. O'Connor RE, et al. **Prehosp Emerg Care** 1999 Jul–Sep;3(3):248–50 (25 ref.)

INTUBATION, NASOGASTRIC see **INTUBATION, GASTROINTESTINAL**

INTUITION

[Intuitive dialogue--a way out of emotional blockages with defocusing imagination] Drees A. **Wien Med Wochenschr** 1998;148(6):166–70 (19 ref.) (Eng. Abstr.) **(Ger)**

INTUSSUSCEPTION

Intussusception in children: current concepts in diagnosis and enema reduction. del-Pozo G, et al. **Radiographics** 1999 Mar–Apr;19(2):299–319 (98 ref.)

COMPLICATIONS

Colo-colic intussusception in Henoch-Schönlein purpura. Choong CK, et al. **Pediatr Surg Int** 1998 Dec;14(3):173–4 (25 ref.)

DIAGNOSIS

Intra-abdominal manifestations of Henoch-Schönlein purpura. Choong CK, et al. **J Paediatr Child Health** 1998 Oct;34(5):405–9 (75 ref.)
Intussusception in children: current concepts in diagnosis and enema reduction. del-Pozo G, et al. **Radiographics** 1999 Mar–Apr;19(2):299–319 (98 ref.)
['Acute abdomen' in children] Festen C. **Ned Tijdschr Geneeskd** 1999 Jan 23;143(4):182–5 (2 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Malignant fibrous histiocytoma metastases to the small intestine and colon presenting as an intussusception. Kanoh T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2594–5 (10 ref.)
Intra-abdominal manifestations of Henoch-Schönlein purpura. Choong CK, et al. **J Paediatr Child Health** 1998 Oct;34(5):405–9 (75 ref.)
The Rapunzel syndrome (trichobezoar) causing atypical intussusception in a child: a case report. Dalshaug GB, et al. **J Pediatr Surg** 1999 Mar;34(3):479–80 (14 ref.)
The clinical implications of non-idiopathic intussusception. Blakelock RT, et al. **Pediatr Surg Int** 1998 Dec;14(3):163–7 (39 ref.)

PATHOLOGY

Inflammatory fibroid polyps of the large intestine. de la Plaza R, et al. **Dig Dis Sci** 1999 Sep;44(9):1810–6 (36 ref.)

SURGERY

Intussusception in adults: institutional review. Eisen LK, et al. **J Am Coll Surg** 1999 Apr;188(4):390–5 (14 ref.)

THERAPY

Intussusception: the paediatric radiologist's perspective [see comments] Littlewood Teele R, et al. **Pediatr Surg Int** 1998 Dec;14(3):158–62 (36 ref.) Comment in: Pediatr Surg Int 1998 Dec;14(3):157.

ULTRASONOGRAPHY

The pseudokidney sign. Anderson DR. **Radiology** 1999 May; 211(2):395–7 (17 ref.)

INUITS see **ESKIMOS**

INULIN

ADMINISTRATION & DOSAGE

Inulin and oligofructose: safe intakes and legal status. Coussement PA. **J Nutr** 1999 Jul;129(7 Suppl):1412S–7S (23 ref.)
Effects of dietary inulin on serum lipids. Davidson MH, et al. **J Nutr** 1999 Jul;129(7 Suppl):1474S–7S (13 ref.)
Petfood applications of inulin and oligofructose. Hussein HS, et al. **J Nutr** 1999 Jul;129(7 Suppl):1454S–6S (28 ref.)

ANALYSIS

Methods to determine food inulin and oligofructose. Prosky L, et al. **J Nutr** 1999 Jul;129(7 Suppl):1418S–23S (16 ref.)

METABOLISM

Caloric value of inulin and oligofructose. Roberfroid MB. **J Nutr** 1999 Jul;129(7 Suppl):1436S–7S (14 ref.)

PHARMACOLOGY

Nondigestibility characteristics of inulin and oligofructose in humans. Andersson HB, et al. **J Nutr** 1999 Jul;129(7 Suppl):1428S–30S (24 ref.)
Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. Gibson GR. **J Nutr** 1999 Jul;129(7 Suppl):1438S–41S (22 ref.)
Nondigestible carbohydrates and mineral bioavailability. Greger JL. **J Nutr** 1999 Jul;129(7 Suppl):1434S–5S (22 ref.)
Inulin, oligofructose and intestinal function. Jenkins DJ, et al. **J Nutr** 1999 Jul;129(7 Suppl):1431S–3S (26 ref.)
Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects. Rao AV. **J Nutr** 1999 Jul;129(7 Suppl):1442S–5S (15 ref.)
Fiber, inulin and oligofructose: similarities and differences. Schneeman BO. **J Nutr** 1999 Jul;129(7 Suppl):1424S–7S (24 ref.)

PHYSIOLOGY

The application of ecological principles and fermentable fibers to manage the gastrointestinal tract ecosystem. Buddington RK, et al. **J Nutr** 1999 Jul;129(7 Suppl):1446S–50S (62 ref.)
Inulin and oligofructose: what are they? Niness KR. **J Nutr** 1999 Jul;129(7 Suppl):1402S–6S (77 ref.)
Concepts in functional foods: the case of inulin and oligofructose. Roberfroid MB. **J Nutr** 1999 Jul;129(7 Suppl):1398S–401S (27 ref.)

THERAPEUTIC USE

Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. Reddy BS. **J Nutr** 1999 Jul;129(7 Suppl):1478S–82S (41 ref.)
Influence of inulin and oligofructose on breast cancer and tumor growth. Taper HS, et al. **J Nutr** 1999 Jul;129(7 Suppl):1488S–91S (25 ref.)
Effects of inulin on lipid parameters in humans. Williams CM. **J Nutr** 1999 Jul;129(7 Suppl):1471S–3S (14 ref.)

INVAGINATION, INTESTINAL see **INTUSSUSCEPTION**

INVASIVENESS, NEOPLASM see **NEOPLASM INVASIVENESS**

INVERSE PCR see **POLYMERASE CHAIN REACTION**

INVERSION (GENETICS)

Sperm chromosome analysis in a man heterozygous for a paracentric inversion of chromosome 14 (q24.1q32.1) [letter] Martin RH. **Am J Hum Genet** 1999 May; 64(5):1480–4 (27 ref.)
De novo inverted duplication 9p21pter involving telomeric repeated sequences. Sanlaville D, et al. **Am J Med Genet** 1999 Mar 12;83(2):125–31 (11 ref.)
Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis. Martinez-Climent JA, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):111–4 (9 ref.)
Population genetics of inversion polymorphism in Drosophila ananassae. Singh BN. **Indian J Exp Biol** 1998 Aug; 36(8):739–48 (112 ref.)
Acute myelomonoblastic leukemia carrying the PEBP2beta/MYH11 fusion gene. Asou N, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):81–91 (65 ref.)

INVERTEBRATE GANGLIA see **GANGLIA, INVERTEBRATE**

INVERTEBRATE HORMONES

CHEMISTRY

D-amino acids in crustacean hyperglycemic neurohormones. Huberman A, et al. **EXS** 1998;85:73–83 (37 ref.)

PHYSIOLOGY

Invertebrate neurohormones and their receptors.

INVERTEBRATE HORMONES

Grimmelikhuijzen CJ, et al. **Results Probl Cell Differ** 1999; 26:339–62 (70 ref.)

INVERTEBRATE PEPTIDE RECEPTORS see **RECEPTORS, INVERTEBRATE PEPTIDE**

INVERTEBRATE PHOTORECEPTORS see **PHOTORECEPTORS, INVERTEBRATE**

INVERTEBRATES

CHEMISTRY

Cysteine-rich antimicrobial peptides in invertebrates. Dimarcq JL, et al. **Biopolymers** 1998;47(6):465–77 (103 ref.)

Invertebrate compounds acting on the hemostatic mechanism [see comments] Arocha-Piñango CL, et al. **Blood Coagul Fibrinolysis** 1999 Mar;10(2):43–68 (229 ref.) Comment in: Blood Coagul Fibrinolysis 1999 Jun;10(4):213.

Tachykinin-related peptides in invertebrates: a review. Nässel DR. **Peptides** 1999;20(1):141–58 (113 ref.)

EMBRYOLOGY

Germline development in vertebrates and invertebrates. Saffman EE, et al. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1141–63 (230 ref.)

ENZYMOLOGY

Metazoan cytochrome P450 evolution. Nelson DR. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):15–22 (8 ref.)

GENETICS

Metazoan phylogenies: falling into place or falling to pieces? A palaeontological perspective. Morris SC. **Curr Opin Genet Dev** 1998 Dec;8(6):662–7 (53 ref.)

The notion of the Cambrian pananimalia genome and a genomic difference that separated vertebrates from invertebrates. Ohno S. **Prog Mol Subcell Biol** 1998; 21:97–117 (43 ref.)

The TBP-like factor: an alternative transcription factor in metazoa? Dantonel JC, et al. **Trends Biochem Sci** 1999 Sep; 24(9):335–9 (34 ref.)

IMMUNOLOGY

Allergens from mites: implications of cross-reactivity between invertebrate antigens. Aalberse RC. **Allergy** 1998; 53(48 Suppl):47–8 (13 ref.)

Cell adhesion molecules in invertebrate immunity. Johansson MW. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):303–15 (303 ref.)

Physiological aspects of the immunoglobulin superfamily in invertebrates. Mendoza HL, et al. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):359–74 (72 ref.)

A new theory on the common evolutionary origin of natural immunity, inflammation and stress response: the invertebrate phagocytic immunocyte as an eye-witness. Ottaviani E, et al. **Domest Anim Endocrinol** 1998 Sep; 15(5):291–6 (30 ref.)

Tropomyosin: an invertebrate pan-allergen. Reese G, et al. **Int Arch Allergy Immunol** 1999 Aug;119(4):247–58 (57 ref.)

METABOLISM

The fate of organic xenobiotics in aquatic ecosystems: quantitative and qualitative differences in biotransformation by invertebrates and fish. Livingstone DR. **Comp Biochem Physiol A Mol Integr Physiol** 1998 May; 120(1):43–9 (39 ref.)

[Current concepts on structure and catalytic properties of cholinesterase from vertebrates and invertebrates] Maralev SM, et al. **Zh Evol Biokhim Fiziol** 1999 Jan–Feb;35(1):3–14 (88 ref.) **(Rus)**

PHYSIOLOGY

Olfactory development in invertebrates. On the scent of central developmental issues. Tolbert LP. **Ann N Y Acad Sci** 1998 Nov 30;855:95–103 (52 ref.)

Crustacean–insect relationships: the use of brain characters to derive phylogeny amongst segmented invertebrates. Strausfeld NJ. **Brain Behav Evol** 1998;52(4–5):186–206 (102 ref.)

Intersegmental coordination in invertebrates and vertebrates. Skinner FK, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):725–32 (54 ref.)

Modulation of vertebrate and invertebrate neuromuscular junctions. Worden MK. **Curr Opin Neurobiol** 1998 Dec; 8(6):740–5 (47 ref.)

Invertebrate integrins: structure, function, and evolution. Burke RD. **Int Rev Cytol** 1999;191:257–84 (61 ref.)

Regulation of synaptic function by neurotrophic factors in vertebrates and invertebrates: implications for development and learning. McKay SE, et al. **Learn Mem** 1999 May–Jun; 6(3):193–215 (196 ref.)

Nitric oxide in invertebrates. Colasanti M, et al. **Mol Neurobiol** 1998 Winter;17(1–3):157–74 (105 ref.)

Homology and convergence in vertebrate and invertebrate nervous systems. Sandeman D. **Naturwissenschaften** 1999 Aug;86(8):378–87 (41 ref.)

Mechanisms and control of programmed cell death in invertebrates. Bergmann A, et al. **Oncogene** 1998 Dec 24; 17(25):3215–23 (130 ref.)

The genetics and molecular biology of the titin/connectin-like proteins of invertebrates. Benian GM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:235–68 (119 ref.)

INVERTED REPEAT SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

INVESTIGATIONAL NEW DRUG APPLICATION

Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example. Black LE, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):22–6 (6 ref.)

INVESTIGATIONAL NEW DRUGS see **DRUGS, INVESTIGATIONAL**

INVOLUNTARY COMMITMENT see **COMMITMENT OF MENTALLY ILL**

IO see **JUPITER**

IOBENGUANE see **3-IODOBENZYLGUANIDINE**

IODAMOEBIASIS see **AMEBIASIS**

IODIDE PEROXIDASE

Molecular evolution of thyroid peroxidase. Taurog A. **Biochimie** 1999 May;81(5):557–62 (45 ref.)

IMMUNOLOGY

[Anti-thyroid peroxidase antibody] Inukai T, et al. **Nippon Rinsho** 1999 Aug;57(8):1819–23 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Development effects of thyroid hormone: the role of deiodinases in regulatory control. St Germain DL. **Biochem Soc Trans** 1999 Feb;27(2):83–8 (57 ref.)

Local activation and inactivation of thyroid hormones: the deiodinase family. Köhrle J. **Mol Cell Endocrinol** 1999 May 25;151(1–2):103–19 (152 ref.)

IODIDES

METABOLISM

Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Pohlenz J, et al. **Biochimie** 1999 May; 81(5):469–76 (25 ref.)

Iodide channel of the thyroid: reconstitution of iodide conductance in proteoliposomes. Golstein PE, et al. **Methods Enzymol** 1999;294:304–19 (12 ref.)

IODINASE see **IODIDE PEROXIDASE**

IODINE

see related
IODINE ISOTOPES
IODINE RADIOISOTOPES

Functional indicators of iodine and selenium status. Arthur JR. **Proc Nutr Soc** 1999 May;58(2):507–12 (59 ref.)

[Iodine deficiency, iodine requirement and iodine excess of farm animals--experiments on growing pigs] Schöne F. **Berl Munch Tierarztl Wochenschr** 1999 Feb;112(2):64–70 (34 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Iodine intake and thyroid carcinoma--a potential risk factor. Franceschi S. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 3:S38–44 (56 ref.)

Impact evaluation of iron & iodine fortified salt. Nair KM, et al. **Indian J Med Res** 1998 Nov;108:203–11 (26 ref.)

Too much versus too little: the implications of current iodine intake in the United States. Lee K, et al. **Nutr Rev** 1999 Jun;57(6):177–81 (21 ref.)

Epidemiology of thyroid diseases in iodine sufficiency. Lind P, et al. **Thyroid** 1998 Dec;8(12):1179–83 (45 ref.)

[Development of preventive iodine administration in Austria] Eber O. **Wien Klin Wochenschr** 1998 Nov 13;110(21):733–7 (25 ref.) **(Ger)**

[Efficacy and safety of iodine prophylaxis] Vitti P, et al. **Ann Ist Super Sanita** 1998;34(3):357–61 (28 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. Lawrence JE, et al. **J Endocrinol Invest** 1999 May;22(5):405–7 (16 ref.)

BLOOD

Methods for measuring iodine in urine and serum. Rendl J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S34–41 (46 ref.)

CONTRAINDICATIONS

[Practical aspects of iodine-131 therapy of hyperthyroidism] Rogowski F, et al. **Pol Merkuriusz Lek** 1999 Jun; 6(36):347–51 (36 ref.) (Eng. Abstr.) **(Pol)**

DEFICIENCY

Genetic factors in iodine deficiency disorders: a general review. De Brackeleer M, et al. **Coll Antropol** 1998 Jun; 22(1):9–15 (83 ref.)

Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Derwahl M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S6–9 (41 ref.)

Screening for congenital hypothyroidism used as an indicator of the degree of iodine deficiency and of its control. Delange F. **Thyroid** 1998 Dec;8(12):1185–92 (43 ref.)

Thyroid hormone and intellectual development: a clinician's view. Lazarus JH. **Thyroid** 1999 Jul;9(7):659–60 (12 ref.)

[Development of preventive iodine administration in Austria] Eber O. **Wien Klin Wochenschr** 1998 Nov 13;110(21):733–7 (25 ref.) **(Ger)**

[Effects of the combined deficiency of selenium and iodine on thyroid function] Miniero R, et al. **Ann Ist Super Sanita** 1998;34(3):349–55 (39 ref.) (Eng. Abstr.) **(Ita)**

[Transient congenital hypothyroidism: physiopathology and clinica] Montanelli L, et al. **Ann Ist Super Sanita** 1998; 34(3):321–9 (25 ref.) (Eng. Abstr.) **(Ita)**

[Physiopathology of iodine deficiency] Pinchera A, et al. **Ann Ist Super Sanita** 1998;34(3):301–5 (26 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

[Autoantibody against Na+/I- symporter (NaIS)] Zeki K. **Nippon Rinsho** 1999 Aug;57(8):1824–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Maternal hypothyroidism: recognition and management. Brent GA. **Thyroid** 1999 Jul;9(7):661–5 (29 ref.)

What happens to the normal thyroid during pregnancy? Glinoer D. **Thyroid** 1999 Jul;9(7):631–5 (15 ref.)

[Prenatal diagnosis of fetal goiter revealing iodine utilization defect] Gire C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27(8):811–3 (8 ref.) (Eng. Abstr.) **(Fre)**

[The sodium-iodide-symporter (NIS): function, regulation and clinical importance] Köhrle J. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:17–22 (48 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

[The role of iodine in various thyroid disorders] Widala E, et al. **Przegl Lek** 1998;55(3):140–2 (21 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

The haemodynamic effects of iodinated water soluble radiographic contrast media: a review. Morcos SK, et al. **Eur J Radiol** 1998 Nov;29(1):31–46 (184 ref.)

POISONING

Kinetics of acute and chronic iodine excess. Saller B, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 3:S34–8 (29 ref.)

URINE

Simple methods for assessing urinary iodine, including preliminary description of a new rapid technique ("Fast B"). Dunn JT, et al. **Exp Clin Endocrinol Diabetes** 1998; 106 Suppl 3:S10–2 (7 ref.)

Methods for measuring iodine in urine and serum. Rendl J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S34–41 (46 ref.)

IODINE ISOTOPES

ANALYSIS

On the analysis of iodine-129 and iodine-127 in environmental materials by accelerator mass spectrometry and ion chromatography. Schmidt A, et al. **Sci Total Environ** 1998 Nov 10;223(2–3):131–56 (102 ref.)

IODINE RADIOISOTOPES

ADVERSE EFFECTS

Membranous glomerulonephritis associated with Graves' disease. Becker BA, et al. **Am J Kidney Dis** 1999 Feb; 33(2):369–73 (14 ref.)

Hypocalcemia as a complication of radioiodine therapy. Winslow CP, et al. **Am J Otolaryngol** 1998 Nov–Dec; 19(6):401–3 (15 ref.)

Radioactive iodine-associated cytomorphologic alterations

in thyroid follicular epithelium: is recognition possible in fine-needle aspiration specimens? Sturgis CD. **Diagn Cytopathol** 1999 Sep;21(3):207–10 (21 ref.)

Acute leukemias after treatment with radioiodine for thyroid cancer [letter] Roldán Schilling V, et al. **Haematologica** 1998 Aug;83(8):767–8 (6 ref.)

[Radioiodine therapy of Graves' disease—quality assurance and radiation protection] Reiners C. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:61–6 (40 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction. Franken PR, et al. **Int J Card Imaging** 1999 Feb;15(1):27–34 (28 ref.)

Myocardial imaging with 123I-BMIPP in patients with congestive heart failure. Ishida Y, et al. **Int J Card Imaging** 1999 Feb;15(1):71–7 (20 ref.)

BMIPP-design and development. Knapp FF Jr, et al. **Int J Card Imaging** 1999 Feb;15(1):1–9 (61 ref.)

Cardiac BMIPP imaging in acute myocardial infarction. Nakata T, et al. **Int J Card Imaging** 1999 Feb;15(1):21–6 (24 ref.)

BMIPP in angina pectoris. Nishimura S, et al. **Int J Card Imaging** 1999 Feb;15(1):35–9 (20 ref.)

beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Nishimura T. **Int J Card Imaging** 1999 Feb;15(1):41–8 (30 ref.)

BMIPP compared with thallium redistribution. Taki J, et al. **Int J Card Imaging** 1999 Feb;15(1):49–59 (58 ref.)

Future aspects of BMIPP. Tamaki N, et al. **Int J Card Imaging** 1999 Feb;15(1):79–89 (64 ref.)

Fatty acids for myocardial imaging. Corbett JR. **Semin Nucl Med** 1999 Jul;29(3):237–58 (89 ref.)

Detection of residual and recurrent thyroid cancer by radionuclide imaging. Maxon HR. **Thyroid** 1999 May; 9(5):443–6 (11 ref.)

[Nuclear oncology with monoclonal antibodies and peptides] Hosono M. **Kaku Igaku** 1998 Oct;35(8):681–7 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical significance of 123I-BMIPP myocardial SPECT] Yamazaki J. **Kaku Igaku** 1998 Jul;35(6):367–73 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Basic kinetics of 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in canine myocardium. Nohara R, et al. **Int J Card Imaging** 1999 Feb;15(1):11–20 (31 ref.)

Radioiodine and pregnancy. Gorman CA. **Thyroid** 1999 Jul; 9(7):721–6 (45 ref.)

THERAPEUTIC USE

Radioiodine treatment of Plummer's disease. Moser E. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S63–5 (29 ref.)

Milestones in the development of Lym-1 therapy. DeNardo GL, et al. **Hybridoma** 1999 Feb;18(1):1–11 (46 ref.)

Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Link EM. **Hybridoma** 1999 Feb;18(1):77–82 (34 ref.)

Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma—a critique. Roos DE, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):493–5 (12 ref.)

Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. Rivkees SA, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):3767–76 (160 ref.)

The use of radioactive iodine in patients with papillary and follicular thyroid cancer. Wartofsky L, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4195–203 (77 ref.)

Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? Marcocci C, et al. **J Endocrinol Invest** 1998 Jul-Aug; 21(7):468–71 (17 ref.)

Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? Weetman AP, et al. **J Endocrinol Invest** 1998 Jul-Aug; 21(7):472–5 (15 ref.)

Radioiodine treatment for nontoxic multinodular goiter. Maurer AH, et al. **J Nucl Med** 1999 Aug;40(8):1313–6 (64 ref.)

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Tepmongkol S, et al. **Med Pediatr Oncol** 1999 Jun;32(6):427–31; discussion 432 (63 ref.)

Ablation in differentiated thyroid carcinoma: how much surgery? How much iodine? [editorial] al-Nahhas AM. **Nucl Med Commun** 1999 Jul;20(7):595–7 (27 ref.)

Radioiodine therapy of thyrotoxicosis. Gross MD, et al. **Rays** 1999 Apr-Jun;24(2):334–47 (69 ref.) **(Eng, Ita)**

Guidelines for the use of radio-iodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Paloyan E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):665–80 (37 ref.)

[Radioactive iodine therapy in thyrotoxicoses] Ben Slimene MF, et al. **Tunis Med** 1999 Apr;77(4):191–4 (12 ref.) **(Fre)**

[The basis for radioiodine therapy in differentiated thyroid cancer] Haldemann AR. **Ther Umsch** 1999 Jul;56(7):403–7 (11 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism—advantages and disadvantages of pharmacologic, surgical, and radioactive iodine treatments] Meier CA. **Ther Umsch** 1999 Jul;56(7):364–8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Radioiodine therapy of Graves' disease—quality assurance and radiation protection] Reiners C. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:61–6 (40 ref.) (Eng. Abstr.) **(Ger)**

[Internal radiation therapy for malignant neoplasm] Yokoyama K, et al. **Gan To Kagaku Ryoho** 1999 May; 26(6):768–74 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Radioactive iodine (I-131) therapy] Kusakabe K, et al. **Nippon Rinsho** 1999 Aug;57(8):1855–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Consensus proposal on the use of 131I in the treatment of thyrotoxicosis and thyroid cancer] Michaud P. **Rev Med Chil** 1998 Jul;126(7):855–65 (58 ref.) (Eng. Abstr.) **(Spa)**

IODIZED OIL

DIAGNOSTIC USE

[Computerized tomography with lipiodol in hepatocarcinoma. Assessment of its diagnostic accuracy with anatomo-pathological control] Veltri A, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):81–6 (33 ref.) (Eng. Abstr.) **(Ita)**

IODOBENZENES

DIAGNOSTIC USE

BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction. Franken PR, et al. **Int J Card Imaging** 1999 Feb;15(1):27–34 (28 ref.)

Myocardial imaging with 123I-BMIPP in patients with congestive heart failure. Ishida Y, et al. **Int J Card Imaging** 1999 Feb;15(1):71–7 (20 ref.)

BMIPP-design and development. Knapp FF Jr, et al. **Int J Card Imaging** 1999 Feb;15(1):1–9 (61 ref.)

Cardiac BMIPP imaging in acute myocardial infarction. Nakata T, et al. **Int J Card Imaging** 1999 Feb;15(1):21–6 (24 ref.)

BMIPP in angina pectoris. Nishimura S, et al. **Int J Card Imaging** 1999 Feb;15(1):35–9 (20 ref.)

beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Nishimura T. **Int J Card Imaging** 1999 Feb;15(1):41–8 (30 ref.)

BMIPP compared with thallium redistribution. Taki J, et al. **Int J Card Imaging** 1999 Feb;15(1):49–59 (58 ref.)

Future aspects of BMIPP. Tamaki N, et al. **Int J Card Imaging** 1999 Feb;15(1):79–89 (64 ref.)

[Clinical significance of 123I-BMIPP myocardial SPECT] Yamazaki J. **Kaku Igaku** 1998 Jul;35(6):367–73 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Basic kinetics of 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in canine myocardium. Nohara R, et al. **Int J Card Imaging** 1999 Feb;15(1):11–20 (31 ref.)

3-IODOBENZYLGUANIDINE

THERAPEUTIC USE

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Tepmongkol S, et al. **Med Pediatr Oncol** 1999 Jun;32(6):427–31; discussion 432 (63 ref.)

[Internal radiation therapy for malignant neoplasm] Yokoyama K, et al. **Gan To Kagaku Ryoho** 1999 May; 26(6):768–74 (9 ref.) (Eng. Abstr.) **(Jpn)**

(3-IODO-(131I)BENZYL)GUANIDINE see **3-IODOBENZYLGUANIDINE**

IODOCHLORHYDROXYQUIN see **CLIOQUINOL**

IODOCHLOROXYQUINOLINE see **CLIOQUINOL**

19-IODOCHOLESTEROL

ANALOGS & DERIVATIVES

[Adrenal scintigraphy with 131I-6beta-iodomethyl-19-norcholesterol: good practice guideline] Bardet S, et al. **Ann Endocrinol (Paris)** 1998 Nov; 59(4):344–53 (53 ref.) (Eng. Abstr.) **(Fre)**

IODOPHORS

see related

ANTI-INFECTIVE AGENTS, LOCAL

IODOTHYRONINE DEIODINASE see **IODIDE PEROXIDASE**

IODOTHYRONINE 5'-DEIODINASE see **IODIDE PEROXIDASE**

IODOTYROSINE DEIODASE see **IODIDE PEROXIDASE**

ION CHANNEL GATING

The importance of voltage-dependent sodium channels in cerebral ischaemia. Carter AJ. **Amino Acids** 1998; 14(1-3):159–69 (91 ref.)

Receptor-activated Ca2+ inflow in animal cells: a variety of pathways tailored to meet different intracellular Ca2+ signalling requirements. Barritt GJ. **Biochem J** 1999 Jan 15;337 (Pt 2):153–69 (203 ref.)

Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Colquhoun D. **Br J Pharmacol** 1998 Nov;125(5):924–47 (111 ref.)

Calcium permeability of ligand-gated channels. Burnashev N. **Cell Calcium** 1998 Nov-Dec;24(5-6):325–32 (73 ref.)

Depolarization as a regulatory signal at voltage-gated calcium channels. Triggle DJ. **Chung Kuo Yao Li Hsueh Pao** 1996 May;17(3):193–6 (25 ref.)

Molecular elements of ion permeation and selectivity within calcium channels. Varadi G, et al. **Crit Rev Biochem Mol Biol** 1999;34(3):181–214 (161 ref.)

Pharmacology of voltage-gated and calcium-activated potassium channels. Kaczorowski GJ, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):448–58 (87 ref.)

Genetics and pathology of voltage-gated Ca2+ channels. Ophoff RA, et al. **Histol Histopathol** 1998 Jul;13(3):827–36 (97 ref.)

Molecular characterization of a novel family of low voltage-activated, T-type, calcium channels. Perez-Reyes E. **J Bioenerg Biomembr** 1998 Aug;30(4):313–8 (62 ref.)

Cyclic nucleotide-gated channels—mediators of NO:cGMP-regulated processes [see comments] Biel M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul; 358(1):140–4 (58 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111–2.

Regulation of neuronal voltage-gated calcium channels by ethanol. Walter HJ, et al. **Neurochem Int** 1999 Aug; 35(2):95–101 (71 ref.)

Molecular basis of the charge selectivity of nicotinic acetylcholine receptor and related ligand-gated ion channels. Corringer PJ, et al. **Novartis Found Symp** 1999; 225:215–24; discussion 224–30 (26 ref.)

Voltage-operated calcium channels: characteristics and their role in the mechanism of action of psychotropic drugs. Antkiewicz-Michaluk L. **Pol J Pharmacol** 1999 Mar-Apr; 51(2):179–86 (71 ref.)

The moving parts of voltage-gated ion channels. Yellen G. **Q Rev Biophys** 1998 Aug;31(3):239–95 (159 ref.)

Structure and function of cyclic nucleotide-gated channels. Biel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 135:151–71 (110 ref.)

Voltage-dependent calcium channels: from structure to function. Hofmann F, et al. **Rev Physiol Biochem Pharmacol** 1999;139:33–87 (279 ref.)

Channel gate! Tension, leak and disclosure. Batiza AF, et al. **Structure Fold Des** 1999 May;7(5):R99–103 (28 ref.)

DRUG EFFECTS

Alcohol action on membrane ion channels gated by extracellular ATP (P2X receptors). Weight FF, et al. **Neurochem Int** 1999 Aug;35(2):143–52 (64 ref.)

Alcohol effects on the 5-HT3 ligand-gated ion channel. Lovinger DM, et al. **Toxicol Lett** 1998 Nov 23; 100-101:239–46 (35 ref.)

Approaches to proving there are general anesthetic sites on ligand gated ion channels. Miller KW, et al. **Toxicol Lett** 1998 Nov 23;100-101:139–47 (30 ref.)

Conformational transitions of the nicotinic acetylcholine receptor as a model for anesthetic actions on ligand-gated ion channels: single and sequential mixing stopped-flow fluorescence studies. Raines DE. **Toxicol Lett** 1998 Nov 23;100-101:163–8 (19 ref.)

[Mechanism of action of general anesthetics. Effect on ion channel proteins or on membrane phospholipids?] Nuñez G, et al. **Rev Med Chil** 1998 Aug;126(8):993–1000 (46 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

AT-AC pre-mRNA splicing mechanisms and conservation of minor introns in voltage-gated ion channel genes. Wu Q, et al. **Mol Cell Biol** 1999 May;19(5):3225–36 (130 ref.)

PHYSIOLOGY

ATP hydrolysis cycles and the gating of CFTR Cl- channels. Gadsby DC, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:247–56 (54 ref.)

Diversity of mammalian voltage-gated sodium channels. Goldin AL. **Ann N Y Acad Sci** 1999 Apr 30;868:38–50 (110 ref.)

General anaesthetic actions on ligand-gated ion channels. Krasowski MD, et al. **Cell Mol Life Sci** 1999 Aug 15; 55(10):1278–303 (376 ref.)

The bacterial K+ channel structure and its implications for neuronal channels. Yellen G. **Curr Opin Neurobiol** 1999 Jun;9(3):267–73 (52 ref.)

ION CHANNEL GATING

Molecular biology of neuronal voltage-gated calcium channels. Chin H. **Exp Mol Med** 1998 Sep 30;30(3):123–30 (49 ref.)

Voltage-gated potassium channels: from hyperexcitability to excitement. Pongs O. **FEBS Lett** 1999 Jun 4;452(1–2):31–5 (40 ref.)

CFTR channel gating: incremental progress in irreversible steps [comment] Csanády L, et al. **J Gen Physiol** 1999 Jul; 114(1):49–53 (26 ref.) Comment on: J Gen Physiol 1999 Jul;114(1):55–70.

Tuning Ca2+ permeation in cyclic nucleotide-gated channels [comment] Frings S. **J Gen Physiol** 1999 Jun; 113(6):795–8 (23 ref.) Comment on: J Gen Physiol 1999 Jun;113(6):799–817.

Calcium channel permeation: A field in flux. McCleskey EW. **J Gen Physiol** 1999 Jun;113(6):765–72 (24 ref.)

Ionic hopping defended. Miller C. **J Gen Physiol** 1999 Jun; 113(6):783–7 (23 ref.)

Progress and prospects in permeation. Nonner W, et al. **J Gen Physiol** 1999 Jun;113(6):773–82 (49 ref.)

Shedding light on voltage-dependent gating. Perozo E. **J Gen Physiol** 1998 Oct;112(4):373–6 (21 ref.)

Structure and function of voltage-gated ion channels. Terlau H, et al. **Naturwissenschaften** 1998 Sep;85(9):437–44 (67 ref.)

Dynamic selectivity filters in ion channels. Khakh BS, et al. **Neuron** 1999 Aug;23(4):653–8 (43 ref.)

Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Gadsby DC, et al. **Physiol Rev** 1999 Jan;79(1 Suppl):S77–S107 (229 ref.)

Ion channels gated by heat. Cesare P, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7658–63 (32 ref.)

The dual role of calcium: pore blocker and modulator of gating [comment] Horn R. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3331–2 (26 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):4154–7.

Neuroprotective strategies: voltage-gated Na+-channel down-modulation versus presynaptic glutamate release inhibition. Obrenovitch TP. **Rev Neurosci** 1998 Jul–Dec; 9(3):203–11 (74 ref.)

Towards the three-dimensional structure of voltage-gated potassium channels. Choe S, et al. **Trends Biochem Sci** 1999 Sep;24(9):345–9 (54 ref.)

Low-voltage-activated (T-type) calcium-channel genes identified. Huguenard JR. **Trends Neurosci** 1998 Nov; 21(11):451–2 (36 ref.)

ION CHANNELS

see related
ION CHANNEL GATING
ION PUMPS

Ion channels in microbes. Saimi Y, et al. **Methods Enzymol** 1999;294:507–24 (83 ref.)

Correlations of structure, dynamics and function in the gramicidin channel by solid-state NMR spectroscopy. Cross TA, et al. **Novartis Found Symp** 1999;225:4–16; discussion 16–22 (33 ref.)

Can we use rate constants and state models to describe ion transport through gramicidin channels? Hladky SB. **Novartis Found Symp** 1999;225:93–107; discussion 107–12 (38 ref.)

Design and characterization of gramicidin channels with side chain or backbone mutations. Koeppe RE 2nd, et al. **Novartis Found Symp** 1999;225:44–55; discussion 55–61 (38 ref.)

The binding site of sodium in the gramicidin A channel. Roux B, et al. **Novartis Found Symp** 1999;225:113–24; discussion 124–7 (35 ref.)

The mechanism of channel formation by alamethicin as viewed by molecular dynamics simulations. Sansom MS, et al. **Novartis Found Symp** 1999;225:128–41; discussion 141–5 (35 ref.)

[Structures and functions of ion channels and pumps] Toyoshima C, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar; 44(4 Suppl):557–65 (21 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Commentary: A revised view of local anesthetic action: what channel state is really stabilized? Scheuer T. **J Gen Physiol** 1999 Jan;113(1):3–6 (19 ref.)

[Blockade of the ion channels of the skeletal muscle acetylcholine receptor] Danilov AF. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):73–5 (22 ref.) (Eng. Abstr.) **(Rus)**

[Ionic channel blocking as an approach to investigation of AMPA receptor subtypes] Magazanik LG. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):994–1005 (61 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Ion channel assembly: creating structures that function. Green WN. **J Gen Physiol** 1999 Feb;113(2):163–70 (55 ref.)

[How do annexins, soluble calcium-binding proteins, form membrane ion channels?] Bandorowicz-Pikula J, et al. **Postepy Biochem** 1998;44(3):237–44 (86 ref.) **(Pol)**

CHEMISTRY

Viral ion channels: molecular modeling and simulation. Sansom MS, et al. **Bioessays** 1998 Dec;20(12):992–1000 (71 ref.)

The behaviour of ions in narrow water-filled pores. Edmonds DT. **Biosci Rep** 1998 Dec;18(6):313–27 (29 ref.)

Bcl-2 family proteins as ion-channels. Schendel SL, et al. **Cell Death Differ** 1998 May;5(5):372–80 (59 ref.)

Designed membrane channels and pores. Bayley H. **Curr Opin Biotechnol** 1999 Feb;10(1):94–103 (72 ref.)

Modeling of ion channels. Levitt DG. **J Gen Physiol** 1999 Jun;113(6):789–94 (26 ref.)

Progress and prospects in permeation. Nonner W, et al. **J Gen Physiol** 1999 Jun;113(6):773–82 (49 ref.)

From structure to function in open ionic channels. Eisenberg RS. **J Membr Biol** 1999 Sep 1;171(1):1–24 (213 ref.)

Structure and function of voltage-gated ion channels. Terlau H, et al. **Naturwissenschaften** 1998 Sep;85(9):437–44 (67 ref.)

Channel gate! Tension, leak and disclosure. Batiza AF, et al. **Structure Fold Des** 1999 May;7(5):R99–103 (28 ref.)

DRUG EFFECTS

General anaesthetic actions on ligand-gated ion channels. Krasowski MD, et al. **Cell Mol Life Sci** 1999 Aug 15; 55(10):1278–303 (376 ref.)

Cognition enhancement strategies by ion channel modulation of neurotransmission. Eid CN Jr, et al. **Curr Pharm Des** 1999 May;5(5):345–61 (351 ref.)

Antiarrhythmic drugs and ion channels: have we made the connection? Carmeliet E. **J Cardiovasc Electrophysiol** 1999 May;10(5):755–9 (6 ref.)

Maitotoxin, a cationic channel activator. Escobar LI, et al. **Neurobiology (Bp)** 1998;6(1):59–74 (22 ref.)

Alcohol action on membrane ion channels gated by extracellular ATP (P2X receptors). Weight FF, et al. **Neurochem Int** 1999 Aug;35(2):143–52 (64 ref.)

Ion channels as targets for insecticides. Narahashi T, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):581–90 (34 ref.)

Interactions of general anesthetics within the pore of an ion channel. Barann M, et al. **Toxicol Lett** 1998 Nov 23; 100–101:155–61 (27 ref.)

Which molecular targets are most relevant to general anaesthesia? Franks NP, et al. **Toxicol Lett** 1998 Nov 23; 100–101:1–8 (41 ref.)

Approaches to proving there are general anesthetic sites on ligand gated ion channels. Miller KW, et al. **Toxicol Lett** 1998 Nov 23;100–101:139–47 (30 ref.)

Ion channel modulation as the basis for general anesthesia. Narahashi T, et al. **Toxicol Lett** 1998 Nov 23; 100–101:185–91 (23 ref.)

Ions in the fire: recent ion-channel research and approaches to pain therapy. Eglen RM, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):337–42 (45 ref.)

[Mechanism of action of general anesthetics. Effect on ion channel proteins or on membrane phospholipids?] Núñez G, et al. **Rev Med Chil** 1998 Aug;126(8):993–1000 (46 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels. Santoro B, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:741–64 (103 ref.)

Genetic regulation of glutamate receptor ion channels. Myers SJ, et al. **Annu Rev Pharmacol Toxicol** 1999;39:221–41 (119 ref.)

Amiloride-sensitive Na channels. Horisberger JD. **Curr Opin Cell Biol** 1998 Aug;10(4):443–9 (43 ref.)

Ion channel mutations affecting muscle and brain. Barchi RL. **Curr Opin Neurol** 1998 Oct;11(5):461–8 (52 ref.)

Genetics of the epilepsies. Berkovic SF, et al. **Curr Opin Neurol** 1999 Apr;12(2):177–82 (53 ref.)

Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Priori SG, et al. **Eur Heart J** 1999 Feb;20(3):174–95 (161 ref.)

Ion channels and neurological disease: DNA based diagnosis is now possible, and ion channels may be important in common paroxysmal disorders [editorial] Hanna MG, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):427–31 (66 ref.)

The molecular basis of long QT syndrome and prospects for therapy. Wang Q, et al. **Mol Med Today** 1998 Sep; 4(9):382–8 (43 ref.)

Ion channel defects in hereditary hearing loss. Holt JR, et al. **Neuron** 1999 Feb;22(2):217–9 (18 ref.)

Ion channel genes and human neurological disease: recent progress, prospects, and challenges. Cooper EC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4759–66 (102 ref.)

[Channelopathies: a genetic explanation of migraine and other paroxysmal neurologic disorders] Terwindt GM, et al. **Ned Tijdschr Geneeskd** 1998 May 2;142(18):1015–9 (20 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Antibodies to ion channels in paraneoplastic disorders. Vincent A. **Brain Pathol** 1999 Apr;9(2):285–91 (47 ref.)

ISOLATION & PURIFICATION

Iodide channel of the thyroid: reconstitution of iodide conductance in proteoliposomes. Golstein PE, et al. **Methods Enzymol** 1999;294:304–19 (12 ref.)

METABOLISM

Ion channel regulation. Introduction. Armstrong DL, et al. **Adv Second Messenger Phosphoprotein Res** 1999;33:ix–xx (84 ref.)

Cyclic nucleotide gated channels. Biel M, et al. **Adv Second Messenger Phosphoprotein Res** 1999;33:231–50 (146 ref.)

The company they keep: ion channels and their intracellular regulatory partners. Johnson BD. **Adv Second Messenger Phosphoprotein Res** 1999;33:203–28 (204 ref.)

Modulation of ion channels by protein phosphorylation. How the brain works. Levitan IB. **Adv Second Messenger Phosphoprotein Res** 1999;33:3–22 (89 ref.)

Ion channels as physiological effectors for growth factor receptor and Ras/ERK signaling pathways. Rane SG. **Adv Second Messenger Phosphoprotein Res** 1999;33:107–27 (126 ref.)

Regulation of ligand-gated ion channels by protein phosphorylation. Swope SL, et al. **Adv Second Messenger Phosphoprotein Res** 1999;33:49–78 (201 ref.)

Cyclic GMP and ion channel regulation. White RE. **Adv Second Messenger Phosphoprotein Res** 1999;33:251–77 (120 ref.)

Disorders of neuromuscular junction ion channels. Boonyapisit K, et al. **Am J Med** 1999 Jan;106(1):97–113 (180 ref.)

Cyclic nucleotide-gated channels. Molecular mechanisms of activation. Broillet MC, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:730–40 (54 ref.)

Functional and molecular diversity of purinergic ion channel receptors. MacKenzie AB, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:716–29 (97 ref.)

Neuronal ion channel signalling pathways: modulation by angiotensin II. Sumners C, et al. **Cell Signal** 1998 May; 10(5):303–11 (109 ref.)

Designed membrane channels and pores. Bayley H. **Curr Opin Biotechnol** 1999 Feb;10(1):94–103 (72 ref.)

Carriers and channels: current progress and future prospects. Bell TW. **Curr Opin Chem Biol** 1998 Dec;2(6):711–6 (38 ref.)

Managing hypoosmotic stress: aquaporins and mechanosensitive channels in Escherichia coli. Booth IR, et al. **Curr Opin Microbiol** 1999 Apr;2(2):166–9 (24 ref.)

Ion-channel-forming colicins. Stroud RM, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):525–33 (39 ref.)

The molecular and ionic specificity of antiarrhythmic drug actions. Nattel S. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):272–82 (75 ref.)

Intracellular calcium regulation of channel and receptor expression in the plasmalemma: potential sites of sensitivity along the pathways linking transcription, translation, and insertion. Barish ME. **J Neurobiol** 1998 Oct;37(1):146–57 (101 ref.)

Ion channel redistribution and function during development of the myelinated axon. Vabnick I, et al. **J Neurobiol** 1998 Oct;37(1):80–96 (90 ref.)

Ca2+ spark as a regulator of ion channel activity. Imaizumi Y, et al. **Jpn J Pharmacol** 1999 May;80(1):1–8 (42 ref.)

Mechanosensitive channels of bacteria. Blount P, et al. **Methods Enzymol** 1999;294:458–82 (48 ref.)

Reconstitution of native and cloned channels into planar bilayers. Favre I, et al. **Methods Enzymol** 1999;294:287–304 (82 ref.)

Engineering the NMDA receptor channel lining. Ferrer-Montiel AV, et al. **Methods Mol Biol** 1999; 128:167–78 (25 ref.)

Autoradiography of enzymes, second messenger systems, and ion channels. Walsh DA, et al. **Methods Mol Biol** 1999; 106:199–214 (36 ref.)

Regulation of ion channel expression in neural cells by hormones and growth factors. Chew LJ, et al. **Mol Neurobiol** 1998 Dec;18(3):175–225 (374 ref.)

Signal transduction and ion channels in guard cells. MacRobbie EA. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1475–88 (87 ref.)

Ion channels in presynaptic nerve terminals and control of transmitter release. Meir A, et al. **Physiol Rev** 1999 Jul; 79(3):1019–88 (1014 ref.)

CFTR is a conductance regulator as well as a chloride channel. Schwiebert EM, et al. **Physiol Rev** 1999 Jan;79(1 Suppl):S145–66 (135 ref.)

Neurotransmitter transport: models in flux [comment] Kavanaugh MP. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):12737–8 (17 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):13260–5.

Polyphosphate/poly-(R)-3-hydroxybutyrate) ion channels in cell membranes. Reusch RN. **Prog Mol Subcell Biol** 1999; 23:151–82 (101 ref.)

Structure and function of cyclic nucleotide-gated channels. Biel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 135:151–71 (110 ref.)

[Aquaporin--a cellular water channel as a therapeutic target?] Beitz E, et al. **Pharm Unserer Zeit** 1999 Mar; 28(2):67–73 (18 ref.) **(Ger)**

[Electric signals as universal mechanisms for fast information transfer between cells. Mechanisms of modulation in physiological and pathological conditions] Mozrzymas JW.

Postepy Hig Med Dosw 1999;53(2):247–61 (14 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Ionic conductances in gastrointestinal smooth muscles and interstitial cells of Cajal. Farrugia G. **Annu Rev Physiol** 1999;61:45–84 (130 ref.)

Ion channels of nociception. McCleskey EW, et al. **Annu Rev Physiol** 1999;61:835–56 (133 ref.)

Mechanosensitive ion channels and their mode of activation. Ghazi A, et al. **Biochimie** 1998 May–Jun;80(5–6):357–62 (45 ref.)

Neuromodulation, development and synaptic plasticity. Foehring RC, et al. **Can J Exp Psychol** 1999 Mar; 53(1):45–61 (125 ref.)

Ion channels, cell volume, and apoptotic cell death. Lang F, et al. **Cell Physiol Biochem** 1998;8(6):285–92 (80 ref.)

Sensors and signal transduction in the activation of cell volume regulatory ion transport systems. Hoffmann EK, et al. **Contrib Nephrol** 1998;123:50–78 (184 ref.)

Ion channels and ventricular arrhythmias: cellular and ionic mechanisms underlying the Brugada syndrome. Antzelevitch C. **Curr Opin Cardiol** 1999 May;14(3):274–9 (74 ref.)

The inhibitory glycine receptor: prospects for a therapeutic orphan? Breitinger HG, et al. **Curr Pharm Des** 1998 Aug; 4(4):315–34 (274 ref.)

Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptácek LJ. **Dig Dis Sci** 1999 Aug;44(8 Suppl):94S–96S (22 ref.)

The pharmacology of ion channels: with particular reference to voltage-gated Ca2+ channels. Triggle DJ. **Eur J Pharmacol** 1999 Jun 30;375(1–3):311–25 (82 ref.)

Mechanosensitive channels in bacteria as membrane tension reporters. Sukharev S. **FASEB J** 1999;13 Suppl:S55–61 (37 ref.)

Neuromuscular glutamatergic and GABAergic channels. Dudel J, et al. **Invert Neurosci** 1997 Sep–Dec;3(2–3):89–92 (26 ref.)

Organic osmolyte channels in cell volume regulation in vertebrates. Perlman DF, et al. **J Exp Zool** 1999 Jun 1; 283(7):725–33 (58 ref.)

Modeling of ion channels. Levitt DG. **J Gen Physiol** 1999 Jun;113(6):789–94 (26 ref.)

Progress and prospects in permeation. Nonner W, et al. **J Gen Physiol** 1999 Jun;113(6):773–82 (49 ref.)

Commentary: A revised view of local anesthetic action: what channel state is really stabilized? Scheuer T. **J Gen Physiol** 1999 Jan;113(1):3–6 (19 ref.)

From structure to function in open ionic channels. Eisenberg RS. **J Membr Biol** 1999 Sep 1;171(1):1–24 (213 ref.)

Ion channel defects in cardiac arrhythmia. Kirsch GE. **J Membr Biol** 1999 Aug 1;170(3):181–90 (98 ref.)

Endogenous ion channels in oocytes of xenopus laevis: recent developments. Weber WM. **J Membr Biol** 1999 Jul 1; 170(1):1–12 (153 ref.)

Control of spontaneous activity during development. Moody WJ. **J Neurobiol** 1998 Oct;37(1):97–109 (80 ref.)

Ionic channels of the vacuolar membrane of higher plants. Tikhonova LI. **Membr Cell Biol** 1998;12(3):301–18 (117 ref.)

Structure and function of voltage-gated ion channels. Terlau H, et al. **Naturwissenschaften** 1998 Sep;85(9):437–44 (67 ref.)

Role of aquaporins in renal water handling: physiology and pathophysiology. van Os CH, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1645–51 (66 ref.)

Touch channels sense blood pressure [comment] Franco-Obregón A, et al. **Neuron** 1998 Dec;21(6):1224–6 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1435–41.

Dynamic selectivity filters in ion channels. Khakh BS, et al. **Neuron** 1999 Aug;23(4):653–8 (43 ref.)

It is calmodulin after all! Mediator of the calcium modulation of multiple ion channels. Levitan IB. **Neuron** 1999 Apr; 22(4):645–8 (23 ref.)

Ionic interactions in multiply occupied channels. Dorman VL, et al. **Novartis Found Symp** 1999;225:153–67; discussion 167–9 (33 ref.)

The glutamate receptor ion channels. Dingledine R, et al. **Pharmacol Rev** 1999 Mar;51(1):7–61 (695 ref.)

Hypoxia and neuronal function under in vitro conditions. Nieber K. **Pharmacol Ther** 1999 Apr;82(1):71–86 (180 ref.)

Multitude of ion channels in the regulation of transmitter release. Rahamimoff R, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):281–8 (125 ref.)

Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Carmeliet E. **Physiol Rev** 1999 Jul; 79(3):917–1017 (1193 ref.)

Ion channels in sperm physiology. Darszon A, et al. **Physiol Rev** 1999 Apr;79(2):481–510 (327 ref.)

Microtubule-dependent vesicle transport: modulation of channel and transporter activity in liver and kidney. Hamm-Alvarez SF, et al. **Physiol Rev** 1998 Oct; 78(4):1109–29 (167 ref.)

Ion channels gated by heat. Cesare P, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7658–63 (32 ref.)

Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Carmeliet E, et al. **Prog Biophys Mol Biol** 1998; 70(1):1–72 (433 ref.)

Modulation of ions channels and membrane receptors activities by mechanical interventions in cardiomyocytes: possible mechanisms for mechanosensitivity. Cazorla O, et al. **Prog Biophys Mol Biol** 1999;71(1):29–58 (143 ref.)

Hormonal control of cardiac ion channels and transporters. Shimoni Y. **Prog Biophys Mol Biol** 1999;72(1):67–108 (409 ref.)

Molecular and pharmacological analysis of cyclic nucleotide-gated channel function in the central nervous system. Wei JY, et al. **Prog Neurobiol** 1998 Oct;56(1):37–64 (276 ref.)

Ion channels in the pulmonary vasculature. Reeve HL, et al. **Pulm Pharmacol Ther** 1997 Oct–Dec;10(5–6):243–52 (99 ref.)

The moving parts of voltage-gated ion channels. Yellen G. **Q Rev Biophys** 1998 Aug;31(3):239–95 (159 ref.)

Hyperpolarization-activated cation channels: a multi-gene family. Biel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 136:165–81 (60 ref.)

Excitable dendrites and spines: earlier theoretical insights elucidate recent direct observations. Segev I, et al. **Trends Neurosci** 1998 Nov;21(11):453–60 (93 ref.)

Novel tools for localizing ion channels in living cells. Lopatin AN, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):395–8 (29 ref.)

Signaltransduction in vascular endothelium: the role of intracellular calcium and ion channels. Nilius B. **Verh K Acad Geneeskd Belg** 1998;60(3):215–50 (51 ref.)

ION CHANNELS, CALCIUM see **CALCIUM CHANNELS**

ION CHANNELS, CHLORIDE see **CHLORIDE CHANNELS**

ION CHANNELS, POTASSIUM see **POTASSIUM CHANNELS**

ION CHANNELS, SODIUM see **SODIUM CHANNELS**

ION COTRANSPORT see **ION TRANSPORT**

ION EXCHANGE, INTRACELLULAR see **ION TRANSPORT**

ION EXCHANGE RESINS

see related
CHROMATOGRAPHY, ION EXCHANGE

ION PUMPS

[Structures and functions of ion channels and pumps] Toyoshima C, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar; 44(4 Suppl):557–65 (21 ref.) **(Jpn)**

CHEMISTRY

Fluctuation driven transport and models of molecular motors and pumps. Astumian RD, et al. **Eur Biophys J** 1998; 27(5):474–89 (71 ref.)

Bacterial rhodopsins: evolution of a mechanistic model for the ion pumps. Stoeckenius W. **Protein Sci** 1999 Feb; 8(2):447–59 (21 ref.)

METABOLISM

Serotonin, I(f) and human atrial arrhythmia [editorial; comment] Workman AJ, et al. **Cardiovasc Res** 1998 Dec; 40(3):436–7 (12 ref.) Comment on: Cardiovasc Res 1998 Dec;40(3):516–22.

Families of soft-metal-ion-transporting ATPases. Rensing C, et al. **J Bacteriol** 1999 Oct;181(19):5891–7 (63 ref.)

PHYSIOLOGY

Fluctuation driven transport and models of molecular motors and pumps. Astumian RD, et al. **Eur Biophys J** 1998; 27(5):474–89 (71 ref.)

ION TRANSPORT

see related
ANTIPORTERS
ION PUMPS

Ion transport and cystogenesis: the paradigm of autosomal dominant polycystic kidney disease. Devuyst O, et al. **Adv Nephrol Necker Hosp** 1998;28:439–78 (155 ref.)

Physiological significance of volume-regulatory transporters. O'Neill WC. **Am J Physiol** 1999 May;276(5 Pt 1):C995–C1011 (224 ref.)

Cell volume regulatory ion transport in cell migration. Ritter M. **Contrib Nephrol** 1998;123:135–57 (169 ref.)

Ion transport in chondrocytes: membrane transporters involved in intracellular ion homeostasis and the regulation of cell volume, free [Ca2+] and pH. Mobasheri A, et al. **Histol Histopathol** 1998 Jul;13(3):893–910 (105 ref.)

Can we use rate constants and state models to describe ion transport through gramicidin channels? Hladky SB. **Novartis Found Symp** 1999;225:93–107; discussion 107–12 (38 ref.)

Are ion-exchange processes central to understanding drug-resistance phenomena? Roepe PD, et al. **Trends Pharmacol Sci** 1999 Feb;20(2):62–5 (35 ref.)

DRUG EFFECTS

Modulation of intracellular Ca2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Valdivia HH. **Trends Pharmacol Sci** 1998 Dec; 19(12):479–82 (27 ref.)

GENETICS

The molecular biology of renal organic anion and organic cation transporters. Sweet DH, et al. **Cell Biochem Biophys** 1999;31(1):89–118 (77 ref.)

PHYSIOLOGY

Ion transport and signalling in human labial glands. Turner RJ, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S15–9 (35 ref.)

Serotonin, I(f) and human atrial arrhythmia [editorial; comment] Workman AJ, et al. **Cardiovasc Res** 1998 Dec; 40(3):436–7 (12 ref.) Comment on: Cardiovasc Res 1998 Dec;40(3):516–22.

Sensors and signal transduction in the activation of cell volume regulatory ion transport systems. Hoffmann EK, et al. **Contrib Nephrol** 1998;123:50–78 (184 ref.)

Volume regulation and 'cross-talk' in sodium-absorbing epithelial cells. Schultz SG, et al. **Contrib Nephrol** 1998; 123:205–19 (82 ref.)

CFTR, a regulator of channels. Kunzelmann K, et al. **J Membr Biol** 1999 Mar 1;168(1):1–8 (120 ref.)

Role of natriuretic peptides in ion transport mechanisms. Kourie JI, et al. **Med Res Rev** 1999 Jan;19(1):75–94 (120 ref.)

Conformational dynamics of vesicles [comment] Pincus P. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10550 (12 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10591–6.

RADIATION EFFECTS

Effects of electromagnetic fields on membrane ion transport of cultured cells. Ikehara T, et al. **J Med Invest** 1998 Aug; 45(1–4):47–56 (52 ref.)

IONIC STRENGTH see **OSMOLAR CONCENTRATION**

IONOPHORES

see related
CELL MEMBRANE PERMEABILITY

An analysis of the chronic oral toxicity of polyether ionophore antibiotics in animals. Oehme FW, et al. **Vet Hum Toxicol** 1999 Aug;41(4):251–7 (41 ref.)

IONS

Electrospray ionization mass spectrometry: a promising new technique in the study of protein/DNA noncovalent complexes. Veenstra TD. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):1–5 (21 ref.)

Quadrupolar metal ion NMR studies of metalloproteins. Aramini JM, et al. **Biochem Cell Biol** 1998;76(2–3):210–22 (80 ref.)

The behaviour of ions in narrow water-filled pores. Edmonds DT. **Biosci Rep** 1998 Dec;18(6):313–27 (29 ref.)

Ionization and charge-transfer: basic data for track structure calculations. Toburen LH. **Radiat Environ Biophys** 1998 Dec;37(4):221–33 (59 ref.)

IONS, HEAVY see **HEAVY IONS**

IONTOPHORESIS

Iontophoresis and electroporation: comparisons and contrasts. Banga AK, et al. **Int J Pharm** 1999 Mar 1; 179(1):1–19 (102 ref.)

Therapeutic modalities in hand surgery. Bissell JH. **J Hand Surg [Am]** 1999 May;24(3):435–48 (166 ref.)

INSTRUMENTATION

Transdermal iontophoresis. Part I: Basic principles and considerations. Nair V, et al. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):139–51 (90 ref.)

METHODS

An analysis of solute structure-human epidermal transport relationships in epidermal iontophoresis using the ionic mobility: pore model. Lai PM, et al. **J Controlled Release** 1999 Apr 19;58(3):323–33 (28 ref.)

Transdermal iontophoresis. Part II: Peptide and protein delivery. Pillai O, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr;21(3):229–40 (119 ref.)

[Augmentation of transdermal drug penetration] Préat MV. **Bull Mem Acad R Med Belg** 1998;153(5–6):295–300; discussion 301–2 (9 ref.) (Eng. Abstr.) **(Fre)**

IOPAMIDOL

PHARMACOLOGY

Protection of coronary angioplasty-induced oxidative stress

IOPAMIDOL

by Isovue used during angioplasty. Rajakumar AR, et al. **Can J Cardiol** 1999 Sep;15(9):989–98 (41 ref.) **(Eng, Fre)**

IPECAC

ADMINISTRATION & DOSAGE

Gastric decontamination—a view for the millennium. Bateman DN. **J Accid Emerg Med** 1999 Mar;16(2):84–6 (9 ref.)

THERAPEUTIC USE

Activated charcoal supercedes ipecac as gastric decontaminant. Fountain JS, et al. **N Z Med J** 1998 Oct 23;111(1076):402–4 (29 ref.)

The availability of activated charcoal and ipecac for home use. Nordt SP, et al. **Vet Hum Toxicol** 1999 Aug; 41(4):247–8 (10 ref.)

IPOMOEA see **SOLANACEAE**

IPPV see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

IPRATROPIUM

THERAPEUTIC USE

Nebulized ipratropium bromide in acute pediatric asthma: does it reduce hospital admissions among children presenting to the emergency department? Rowe BH, et al. **Ann Emerg Med** 1999 Jul;34(1):75–85 (34 ref.)

Can we justify ipratropium therapy as initial management of acute exacerbations of COPD? Demirkan K, et al. **Pharmacotherapy** 1999 Jul;19(7):838–43 (21 ref.)

IPROVERATRIL see **VERAPAMIL**

IPSID see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

IR GENES see **GENES, MHC CLASS II**

IRIDOCYCLITIS

ETIOLOGY

[The role of the sympathetic system in ocular pathology] Cernea P, et al. **Oftalmologia** 1998;44(3):5–12 (15 ref.) (Eng. Abstr.) **(Rum)**

IRIS

Iridology: A systematic review. Ernst E. **Forsch Komplementarmed** 1999 Feb;6(1):7–9 (15 ref.)

SURGERY

[Histopathological observations on bullous keratopathy after argon-laser iridotomy] Chen RJ, et al. **Nippon Ganka Gakkai Zasshi** 1999 Feb;103(2):129–36 (39 ref.) (Eng. Abstr.) **(Jpn)**

IRIS DISEASES

[Iris cysts] Moravská M, et al. **Cesk Slov Oftalmol** 1999 Jul; 55(4):246–50 (12 ref.) **(Cze)**

DIAGNOSIS

[Color and form changes in the iris] Wollensak J. **Klin Monatsbl Augenheilkd** 1999 May;214(5):266–9 (0 ref.) (Eng. Abstr.) **(Ger)**

[Cystic iris tumors] Koos MJ, et al. **Oftalmologia** 1998; 45(4):71–2 (7 ref.) (Eng. Abstr.) **(Rum)**

SURGERY

[Intraocular interventions in eyes with rubeosis iridis and neovascular glaucoma] Lucke K, et al. **Ophthalmologe** 1998 Jul;95(7):514–28 (10 ref.) **(Ger)**

IRIS NEOPLASMS

DIAGNOSIS

[Color and form changes in the iris] Wollensak J. **Klin Monatsbl Augenheilkd** 1999 May;214(5):266–9 (0 ref.) (Eng. Abstr.) **(Ger)**

IRITIS

DIAGNOSIS

Anterior uveitis: clinical and research perspectives. Rosenbaum JT, et al. **Springer Semin Immunopathol** 1999; 21(2):135–45 (81 ref.)

IRON

see related
FERRIC COMPOUNDS
FERRITIN
FERROUS COMPOUNDS
HEMOSIDEROSIS
SIDEROSIS
TRANSFERRIN

Iron and copper-associated cirrhosis in infants. Acquired metal toxicity or genetic disorder? Lockitch G. **Clin Lab Med** 1998 Dec;18(4):665–71, viii (38 ref.)

DNA damage mediated by metal ions with special reference to copper and iron. Sagripanti JL. **Met Ions Biol Syst** 1999; 36:179–209 (117 ref.)

Iron chelation therapy for malaria: a review. Mabeza GF, et al. **Pharmacol Ther** 1999 Jan;81(1):53–75 (170 ref.)

Defining optimal body iron. Cook JD. **Proc Nutr Soc** 1999 May;58(2):489–95 (54 ref.)

[Effects of iron-containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27–37 (123 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Therapy by taking away: the case of iron. Polla BS. **Biochem Pharmacol** 1999 Jun 15;57(12):1345–9 (42 ref.)

Impact evaluation of iron & iodine fortified salt. Nair KM, et al. **Indian J Med Res** 1998 Nov;108:203–11 (26 ref.)

Strategies for iron supplementation: oral versus intravenous. Macdougall IC. **Kidney Int Suppl** 1999 Mar;69:S61–6 (33 ref.)

Intravenous iron for the treatment of predialysis anemia. Silverberg DS, et al. **Kidney Int Suppl** 1999 Mar;69:S79–85 (81 ref.)

Iron status and iron supplementation in peritoneal dialysis patients. Vychytil A, et al. **Kidney Int Suppl** 1999 Mar; 69:S71–8 (91 ref.)

Parenteral iron: pharmacology and clinical use. Ifudu O. **Nephron** 1998 Nov;80(3):249–56 (75 ref.)

ADVERSE EFFECTS

Iron and infection. Patruta SI, et al. **Kidney Int Suppl** 1999 Mar;69:S125–30 (75 ref.)

Iron therapy and cardiovascular disease. Sullivan JL. **Kidney Int Suppl** 1999 Mar;69:S135–7 (24 ref.)

BLOOD

Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose. Siff JE, et al. **Ann Emerg Med** 1999 Jan;33(1):73–6 (21 ref.)

Iron, atherosclerosis, and ischemic heart disease. de Valk B, et al. **Arch Intern Med** 1999 Jul 26;159(14):1542–8 (121 ref.)

The molecular pathobiology of cell membrane iron: the sickle red cell as a model. Browne P, et al. **Free Radic Biol Med** 1998 Apr;24(6):1040–8 (69 ref.)

Non-transferrin-bound iron and cellular toxicity [editorial; comment] Anderson GJ. **J Gastroenterol Hepatol** 1999 Feb; 14(2):105–8 (26 ref.) Comment on: J Gastroenterol Hepatol 1999 Feb;14(2):126–32.

CHEMISTRY

Mineralization in ferritin: an efficient means of iron storage. Chasteen ND, et al. **J Struct Biol** 1999 Jun 30;126(3):182–94 (74 ref.)

Effects of nitric oxide on iron or hemoprotein-catalyzed oxidative reactions. Jourd'heuil D, et al. **Methods Enzymol** 1999;301:437–44 (20 ref.)

DEFICIENCY

Iron deficiency in pregnancy: effects on the newborn. Blot I, et al. **Curr Opin Hematol** 1999 Mar;6(2):65–70 (54 ref.)

Functional iron deficiency and inadequate dialysis: is there a connection? [editorial] Ifudu O. **Int J Artif Organs** 1999 Mar;22(3):128–30 (21 ref.)

Iron supplementation. Schümann K, et al. **J Trace Elem Med Biol** 1998 Nov;12(3):129–40 (109 ref.)

Iron deficiency in patients with renal failure. Nissenson AR, et al. **Kidney Int Suppl** 1999 Mar;69:S18–21 (39 ref.)

Intravenous iron for the treatment of predialysis anemia. Silverberg DS, et al. **Kidney Int Suppl** 1999 Mar;69:S79–85 (81 ref.)

Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Tarng DC, et al. **Kidney Int Suppl** 1999 Mar; 69:S107–18 (123 ref.)

Iron status and iron supplementation in peritoneal dialysis patients. Vychytil A, et al. **Kidney Int Suppl** 1999 Mar; 69:S71–8 (91 ref.)

Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Glaspy J, et al. **Oncology (Huntingt)** 1999 Apr;13(4):461–73; discussion 477–8, 483–8 (88 ref.)

[Epidemiology of iron deficiency and iron deficiency anemia in the French population] Hercberg S, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:49–52 (21 ref.) **(Fre)**

[Recommendations for prevention of iron deficiency. Delay cow's milk intake as a beverage to infants until 10–12 months of age!] Axelsson I, et al. **Lakartidningen** 1999 May 5;96(18):2206–8 (30 ref.) (Eng. Abstr.) **(Swe)**

DIAGNOSTIC USE

Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Reimer P, et al. **Eur Radiol** 1998; 8(7):1198–204 (38 ref.)

METABOLISM

The main systemic, highly effective, and quickly acting antimicrobial mechanisms generated by lactoferrin in mammals in vivo. Activity in health and disease. Zagulski T, et al. **Adv Exp Med Biol** 1998;443:247–50 (28 ref.)

Iron homeostasis and the assessment of iron status. Sherwood RA, et al. **Ann Clin Biochem** 1998 Nov;35 (Pt 6):693–708 (133 ref.)

Iron and LDL-oxidation in atherogenesis. Yuan XM, et al. **APMIS** 1998 Sep;106(9):825–42 (142 ref.)

Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. Vanin AF. **Biochemistry (Mosc)** 1998 Jul;63(7):782–93 (97 ref.)

Nitric oxide and iron proteins. Cooper CE. **Biochim Biophys Acta** 1999 May 5;1411(2–3):290–309 (136 ref.)

Immune response and iron metabolism. Weiss G, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:6–9 (35 ref.)

Acquisition, transport, and storage of iron by pathogenic fungi. Howard DH. **Clin Microbiol Rev** 1999 Jul; 12(3):394–404 (102 ref.)

Iron metabolism. Aisen P, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):200–6 (78 ref.)

Iron acquisition by plants. Mori S. **Curr Opin Plant Biol** 1999 Jun;2(3):250–3 (33 ref.)

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Jellinger KA. **Drugs Aging** 1999 Feb;14(2):115–40 (305 ref.)

Role of iron in anthracycline cardiotoxicity: new tunes for an old song? [published erratum appears in FASEB J 1999 Mar;13(3):594] Minotti G, et al. **FASEB J** 1999 Feb; 13(2):199–212 (106 ref.)

Iron and hepatitis viruses [editorial; comment] Deugnier Y, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):467–9 (30 ref.) Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):529–33.

Iron acquisition and metabolism by mycobacteria. De Voss JJ, et al. **J Bacteriol** 1999 Aug;181(15):4443–51 (85 ref.)

The role of iron in protozoan and fungal infectious diseases. Weinberg ED. **J Eukaryot Microbiol** 1999 May-Jun; 46(3):231–8 (100 ref.)

Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. Fletcher LM, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):202–14 (157 ref.)

Mammalian iron transport: an unexpected link between metal homeostasis and host defense. Fleming MD, et al. **J Lab Clin Med** 1998 Dec;132(6):464–8 (33 ref.)

Iron regulatory proteins, iron responsive elements and iron homeostasis. Eisenstein RS, et al. **J Nutr** 1998 Dec; 128(12):2295–8 (27 ref.)

Recently identified molecular aspects of intestinal iron absorption. Wood RJ, et al. **J Nutr** 1998 Nov; 128(11):1841–4 (29 ref.)

Mineralization in ferritin: an efficient means of iron storage. Chasteen ND, et al. **J Struct Biol** 1999 Jun 30;126(3):182–94 (74 ref.)

Inherited disorders of iron metabolism. Födinger M, et al. **Kidney Int Suppl** 1999 Mar;69:S22–34 (94 ref.)

Erythropoietin and iron. Kaltwasser JP, et al. **Kidney Int Suppl** 1999 Mar;69:S49–56 (58 ref.)

Cellular iron metabolism. Ponka P. **Kidney Int Suppl** 1999 Mar;69:S2–11 (62 ref.)

Iron and anemia of chronic disease. Weiss G. **Kidney Int Suppl** 1999 Mar;69:S12–7 (72 ref.)

Hereditary haemochromatosis: diagnosis and management in the gene era. Olynyk JK. **Liver** 1999 Apr;19(2):73–80 (81 ref.)

The case for iron repletion as a promoter in testicular cancer. Crawford RD. **Med Hypotheses** 1998 Aug;51(2):129–32 (35 ref.)

The mechanism of "Fenton-like" reactions and their importance for biological systems. A biologist's view. Liochev SI. **Met Ions Biol Syst** 1999;36:1–39 (169 ref.)

Reasons why 'Leptospirillum'-like species rather than Thiobacillus ferrooxidans are the dominant iron-oxidizing bacteria in many commercial processes for the biooxidation of pyrite and related ores. Rawlings DE, et al. **Microbiology** 1999 Jan;145 (Pt 1):5–13 (34 ref.)

Iron acquisition systems in the pathogenic Neisseria. Schryvers AB, et al. **Mol Microbiol** 1999 Jun;32(6):1117–23 (41 ref.)

Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356–8 (15 ref.)

Iron metabolism in the lower respiratory tract. Mateos F, et al. **Thorax** 1998 Jul;53(7):594–600 (67 ref.)

Bacterial solutions to the iron-supply problem. Braun V, et al. **Trends Biochem Sci** 1999 Mar;24(3):104–9 (33 ref.)

[Iron metabolism and its exploration in clinical biology] Brissot P, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:5–10 (31 ref.) **(Fre)**

[The transferrin receptor: its role in iron metabolism and its diagnosis utility] Vernet M. **Ann Biol Clin (Paris)** 1999 Jan-Feb;57(1):9–18 (49 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Molecular insights into mechanisms of iron transport. Andrews NC, et al. **Curr Opin Hematol** 1999 Mar;6(2):61–4 (27 ref.)

Iron transport across biologic membranes. Andrews NC, et al. **Nutr Rev** 1999 Apr;57(4):114–23 (97 ref.)
Interdependence of mycobacterial iron regulation, oxidative-stress response and isoniazid resistance. Dussurget O, et al. **Trends Microbiol** 1998 Sep;6(9):354–8 (34 ref.)

PHARMACOLOGY

Role of iron in 6-hydroxydopamine neurotoxicity. Double KL, et al. **Adv Neurol** 1999;80:287–96 (83 ref.)
Parenteral iron: pharmacology and clinical use. Ifudu O. **Nephron** 1998 Nov;80(3):249–56 (75 ref.)

PHYSIOLOGY

Iron, thermoregulation, and metabolic rate. Rosenzweig PH, et al. **Crit Rev Food Sci Nutr** 1999 Mar;39(2):131–48 (58 ref.)
New advances in iron metabolism, iron deficiency, and iron overload. Brittenham GM. **Curr Opin Hematol** 1994 Mar; 1(2):101–6 (45 ref.)
Iron transport across biologic membranes. Andrews NC, et al. **Nutr Rev** 1999 Apr;57(4):114–23 (97 ref.)
[Iron homeostasis and Parkinson's disease] Faucheux BA, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:23–30 (66 ref.) **(Fre)**

POISONING

Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose. Siff JE, et al. **Ann Emerg Med** 1999 Jan;33(1):73–6 (21 ref.)

THERAPEUTIC USE

The role of iron therapy in childhood plumbism. Wright RO. **Curr Opin Pediatr** 1999 Jun;11(3):255–8 (32 ref.)
Beneficial effects of iron therapy in renal failure patients on hemodialysis. Fishbane S, et al. **Kidney Int Suppl** 1999 Mar; 69:S67–70 (34 ref.)
Iron therapy and cardiovascular disease. Sullivan JL. **Kidney Int Suppl** 1999 Mar;69:S135–7 (24 ref.)
Iron therapy and cancer. Weinberg ED. **Kidney Int Suppl** 1999 Mar;69:S131–4 (29 ref.)
Anemia and cardiovascular complications: iron and EPO impact. Kurtzman NA, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):109–13 (25 ref.)

IRON CHELATES see **IRON CHELATING AGENTS**

IRON CHELATING AGENTS

THERAPEUTIC USE

Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Gordon RA, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1100–4 (32 ref.)
Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs [letter; comment] Richardson DR, et al. **J Lab Clin Med** 1998 Oct; 132(4):351–2 (8 ref.) Comment on: J Lab Clin Med 1998 Apr;131(4):290–1.
Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Richardson DR. **Leuk Lymphoma** 1998 Sep;31(1–2):47–60 (73 ref.)
[Iron chelation in 1998] de Montalembert M. **Transfus Clin Biol** 1998 Oct;5(5):353–6 (7 ref.) (Eng. Abstr.) **(Fre)**

IRON COMPOUNDS

CHEMISTRY

Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. Bonnemain B. **J Drug Target** 1998;6(3):167–74 (48 ref.)

IRON-DEFICIENCY ANEMIA see **ANEMIA, IRON-DEFICIENCY**

IRON-DEXTRAN COMPLEX

ADMINISTRATION & DOSAGE

Toxicity of parenteral iron dextran therapy. Burns DL, et al. **Kidney Int Suppl** 1999 Mar;69:S119–24 (34 ref.)

ADVERSE EFFECTS

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans [see comments] Faich G, et al. **Am J Kidney Dis** 1999 Mar;33(3):464–70 (20 ref.) Comment in: Am J Kidney Dis 1999 Mar;33(3):595.
Toxicity of parenteral iron dextran therapy. Burns DL, et al. **Kidney Int Suppl** 1999 Mar;69:S119–24 (34 ref.)

IRON, DIETARY

Iron supplementation in athletes. Current recommendations. Nielsen P, et al. **Sports Med** 1998 Oct;26(4):207–16 (45 ref.)

ADMINISTRATION & DOSAGE

Iron and infection in the tropics: paediatric clinical correlates. Oppenheimer SJ. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S81–7 (34 ref.)
Strategies for iron supplementation: oral versus intravenous. Macdougall IC. **Kidney Int Suppl** 1999 Mar;69:S61–6 (33 ref.)
Animal- and plant-food-based diets and iron status: benefits and costs. Hambraeus L. **Proc Nutr Soc** 1999 May; 58(2):235–42 (40 ref.)

ADVERSE EFFECTS

Non-transferrin-bound iron and cellular toxicity [editorial; comment] Anderson GJ. **J Gastroenterol Hepatol** 1999 Feb; 14(2):105–8 (26 ref.) Comment on: J Gastroenterol Hepatol 1999 Feb;14(2):126–32.

METABOLISM

High-dose vitamin C: a risk for persons with high iron stores? Gerster H. **Int J Vitam Nutr Res** 1999 Mar;69(2):67–82 (109 ref.)

PHARMACOKINETICS

The concept of iron bioavailability and its assessment. Wienk KJ, et al. **Eur J Nutr** 1999 Apr;38(2):51–75 (274 ref.)
[Dietary iron absorption. Role of vitamin A] García-Casal MN, et al. **Arch Latinoam Nutr** 1998 Sep;48(3):191–6 (65 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Iron supplementation. Schümann K, et al. **J Trace Elem Med Biol** 1998 Nov;12(3):129–40 (109 ref.)

IRON METABOLISM DISORDERS

[Iron metabolism and its exploration in clinical biology] Brissot P, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:5–10 (31 ref.) **(Fre)**
[Anemia in rheumatoid arthritis: iron metabolism and cytokines] Nishiya K. **Ryumachi** 1998 Dec;38(6):841–8 (75 ref.) **(Jpn)**

DIAGNOSIS

[Diagnosis of hyperferritinemia] Deugnier Y, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:41–3 (35 ref.) **(Fre)**

ETIOLOGY

Functional iron deficiency and inadequate dialysis: is there a connection? [editorial] Ifudu O. **Int J Artif Organs** 1999 Mar;22(3):128–30 (21 ref.)

IRON OVERLOAD

COMPLICATIONS

Iron overload in porphyria cutanea tarda. Sampietro M, et al. **Haematologica** 1999 Mar;84(3):248–53 (65 ref.)

DRUG THERAPY

Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs [letter; comment] Richardson DR, et al. **J Lab Clin Med** 1998 Oct; 132(4):351–2 (8 ref.) Comment on: J Lab Clin Med 1998 Apr;131(4):290–1.
[Iron chelation in 1998] de Montalembert M. **Transfus Clin Biol** 1998 Oct;5(5):353–6 (7 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

New advances in iron metabolism, iron deficiency, and iron overload. Brittenham GM. **Curr Opin Hematol** 1994 Mar; 1(2):101–6 (45 ref.)

ETIOLOGY

Non-transferrin-bound iron and cellular toxicity [editorial; comment] Anderson GJ. **J Gastroenterol Hepatol** 1999 Feb; 14(2):105–8 (26 ref.) Comment on: J Gastroenterol Hepatol 1999 Feb;14(2):126–32.
Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Eschbach JW, et al. **Kidney Int Suppl** 1999 Mar;69:S35–43 (70 ref.)
Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Tarng DC, et al. **Kidney Int Suppl** 1999 Mar; 69:S107–18 (123 ref.)
[Secondary iron overload] Galacteros F. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:44–8 (19 ref.) **(Fre)**

GENETICS

Iron overload: molecular clues to its cause. Kühn LC. **Trends Biochem Sci** 1999 May;24(5):164–6 (24 ref.)
[Iron overload and HFE gene] Deugnier Y, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):122–31 (103 ref.) **(Fre)**

METABOLISM

Mammalian iron transport: an unexpected link between metal homeostasis and host defense. Fleming MD, et al. **J Lab Clin Med** 1998 Dec;132(6):464–8 (33 ref.)
Iron-mediated cardiovascular injury. Horwitz LD, et al. **Vasc Med** 1999;4(2):93–9 (68 ref.)

THERAPY

Clinical management of iron overload. Tung BY, et al. **Gastroenterol Clin North Am** 1998 Sep;27(3):637–54 (86 ref.)

IRON PROTEINS, NON-HEME see **NONHEME IRON PROTEINS**

IRON-SULFUR PROTEINS

CHEMISTRY

The structure of iron-sulfur proteins. Sticht H, et al. **Prog Biophys Mol Biol** 1998;70(2):95–136 (296 ref.)

METABOLISM

Transcriptional regulation via redox-sensitive iron-sulphur centres in an oxidative stress response. Demple B, et al. **Biochem Soc Symp** 1999;64:119–28 (53 ref.)
S-adenosylmethionine: a 'poor man's coenzyme B12' in the reaction of lysine 2,3-aminomutase. Frey PA, et al. **Biochem Soc Trans** 1998 Aug;26(3):304–10 (27 ref.)
Proton translocation in the respiratory chain involving ubiquinone--a hypothetical semiquinone switch mechanism for complex I. Brandt U. **Biofactors** 1999;9(2–4):95–101 (30 ref.)
Nitrosative and oxidative modulation of iron regulatory proteins. Bouton C. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1043–53 (102 ref.)
Iron metabolism. Aisen P, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):200–6 (78 ref.)
Oxygen sensing by the global regulator, FNR: the role of the iron-sulfur cluster. Kiley PJ, et al. **FEMS Microbiol Rev** 1998 Dec;22(5):341–52 (45 ref.)
Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. Hanson ES, et al. **Gene Expr** 1999;7(4–6):367–76 (100 ref.)

PHYSIOLOGY

Glutamate synthase: a complex iron-sulfur flavoprotein. Vanoni MA, et al. **Cell Mol Life Sci** 1999 Apr;55(4):617–38 (67 ref.)
Fe-S proteins in sensing and regulatory functions. Beinert H, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):152–7 (59 ref.)
Iron regulatory proteins, iron responsive elements and iron homeostasis. Eisenstein RS, et al. **J Nutr** 1998 Dec; 128(12):2295–8 (27 ref.)

IRRAWADDY RIVER DOLPHIN see **DOLPHINS**

IRRIGATION

Surfactant lavage for the management of severe meconium aspiration syndrome. Lam BC. **Biol Neonate** 1999 Jun;76 Suppl 1:10–4 (37 ref.)
Clinical pharmacology and use of laxatives and lavage solutions. Schiller LR. **J Clin Gastroenterol** 1999 Jan; 28(1):11–8 (82 ref.)
[Uses of nasal lavage in occupational medicine and environmental medicine] Qu R, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):378–9 (16 ref.) **(Chi)**

METHODS

Encephalopathy after bladder irrigation with alum: case report and literature review. Phelps KR, et al. **Am J Med Sci** 1999 Sep;318(3):181–5 (37 ref.)

IRRIGATION, GASTRIC see **GASTRIC LAVAGE**

IRRIGATION, PERITONEAL see **PERITONEAL LAVAGE**

IRRITABLE BOWEL SYNDROME see **COLONIC DISEASES, FUNCTIONAL**

IRRITANT DERMATITIS see **DERMATITIS, IRRITANT**

IRRITANTS

ADVERSE EFFECTS

Skin susceptibility to dithranol: contact allergy or irritation? Loffler H, et al. **Eur J Dermatol** 1999 Jan–Feb;9(1):32–4 (23 ref.)

TOXICITY

Toxicologic evaluation of pepper spray as a possible weapon for the Dutch police force: risk assessment and efficacy. Busker RW, et al. **Am J Forensic Med Pathol** 1998 Dec; 19(4):309–16 (38 ref.)
A critical review of the assessment of eye irritation potential

using the Draize rabbit eye test. York M, et al. **J Appl Toxicol** 1998 Jul-Aug;18(4):233-40 (25 ref.)
Safety assessment of lactate esters. Clary JJ, et al. **Regul Toxicol Pharmacol** 1998 Apr;27(2):88-97 (67 ref.)
Cytokines and irritant contact dermatitis. Corsini E, et al. **Toxicol Lett** 1998 Dec 28;102-103:277-82 (34 ref.)
Use of in vivo confocal microscopy to understand the pathology of accidental ocular irritation. Maurer JK, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):44-7 (24 ref.)

IS ELEMENTS see **DNA TRANSPOSABLE ELEMENTS**

ISAACS' SYNDROME see **FASCICULATION**

ISATIN

METABOLISM

Stress and water balance: the roles of ANP, AVP and isatin. Bhattacharya SK, et al. **Indian J Exp Biol** 1998 Dec; 36(12):1195-200 (85 ref.)

ISCHEMIA

Mesenteric ischemia in the elderly. Ruotolo RA, et al. **Clin Geriatr Med** 1999 Aug;15(3):527-57 (93 ref.)
Molecular mechanisms of cell death and regeneration in acute ischemic renal injury. Padanilam BJ, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):15-9 (30 ref.)
Intestinal (mesenteric) vasculopathy. I. Acute superior mesenteric arteriopathy and venopathy. Cappell MS. **Gastroenterol Clin North Am** 1998 Dec;27(4):783-825, vi (285 ref.)
Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Cappell MS. **Gastroenterol Clin North Am** 1998 Dec;27(4):827-60, vi (355 ref.)
Decreasing the cold ischemia time. Abendroth D. **Transplant Proc** 1998 Dec;30(8):4288-90 (42 ref.)
What is a reasonably short cold ischemia time in kidney transplantation? Offermann G. **Transplant Proc** 1998 Dec; 30(8):4291-3 (8 ref.)

COMPLICATIONS

Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Yan SF, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2029-35 (41 ref.)
Ischemic necrotizing pancreatitis. Two case reports and review of the literature. Sakorafas GH, et al. **Int J Pancreatol** 1998 Oct;24(2):117-21 (45 ref.)
Esophagogastric anastomotic leaks: the importance of gastric ischemia and therapeutic applications of gastric conditioning. Urschel JD. **J Invest Surg** 1998 Jul-Aug; 11(4):245-50 (55 ref.)
Folding of secretory and membrane proteins. Kuznetsov G, et al. **N Engl J Med** 1998 Dec 3;339(23):1688-95 (69 ref.)
Vascular steal syndrome and ischaemic monomelic neuropathy: two variants of upper limb ischaemia after haemodialysis vascular access surgery [editorial] Miles AM. **Nephrol Dial Transplant** 1999 Feb;14(2):297-300 (26 ref.)
When to suspect ischemic colitis. Why is this condition so often missed or misdiagnosed? Alapati SV, et al. **Postgrad Med** 1999 Apr;105(4):177-80, 183-4, 187 (10 ref.)
Vascular contributions to pathogenesis of acute renal failure. Bankir L, et al. **Ren Fail** 1998 Sep;20(5):663-77 (143 ref.)
[Pathogenesis of non-traumatic femoral head osteonecrosis] Arlet J. **Acta Orthop Belg** 1999;65 Suppl 1:25-9 (25 ref.) **(Fre)**
[Splanchnic hypoperfusion and distant organ injury] Koike K, et al. **Nippon Geka Gakkai Zasshi** 1999 May; 100(5):357-60 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Chronic critical limb ischemia: diagnosis, treatment and prognosis. Santilli JD, et al. **Am Fam Physician** 1999 Apr 1;59(7):1899-908 (21 ref.)
Spinal cord monitoring with somatosensory techniques. Nuwer MR. **J Clin Neurophysiol** 1998 May;15(3):183-93 (118 ref.)
Ischemic nephropathy: diagnosis and treatment. Zuccalà A, et al. **J Nephrol** 1998 Nov-Dec;11(6):318-24 (69 ref.)
Intestinal ischemia — the basics. Haglund U, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):233-8 (28 ref.)
Diagnosis and treatment of chronic lower extremity ischemia. Sanchez LA, et al. **Vasc Med** 1998;3(4):291-9 (95 ref.)
[Differential diagnosis of intermittent stress-related leg pain—not always an arterial problem] Canova CR, et al. **Ther Umsch** 1998 Oct;55(10):596-600 (6 ref.) (Eng. Abstr.) **(Ger)**
[Ischemic disease of the intestine] Suzuki K, et al. **Nippon Rinsho** 1998 Sep;56(9):2365-8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Acute mesenteric ischemia--current diagnostic and therapeutic problems] Konturek A, et al. **Przegl Lek** 1999; 56(3):231-5 (31 ref.) (Eng. Abstr.) **(Pol)**
[The anterior segment ischemia syndrome] Cârstocea B, et al. **Oftalmologia** 1998;44(3):72-6 (16 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Schemes against ischemia; solutions for reperfusion (injury)? [editorial; comment] Barie PS. **Crit Care Med** 1999 Apr; 27(4):684-5 (11 ref.) Comment on: Crit Care Med 1999 Apr;27(4):764-70.
Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650-1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429-36.
Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Gonçalves LM. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II11-20 (103 ref.)
Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Osborne NN, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S102-28 (235 ref.)
[Clinical use of glycoprotein IIb/IIIa inhibitors] Simonetti I, et al. **Ann Ital Med Int** 1998 Jul-Sep;13(3):163-8 (20 ref.) (Eng. Abstr.) **(Ita)**
[Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency] Cappelli R, et al. **Minerva Cardioangiol** 1999 Mar;47(3):81-8 (30 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Tarcan T, et al. **Br J Urol** 1998 Dec; 82 Suppl 1:26-33 (65 ref.)
Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650-1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429-36.
Colonic ischemia. Greenwald DA, et al. **J Clin Gastroenterol** 1998 Sep;27(2):122-8 (37 ref.)
Kawasaki disease complicated by peripheral gangrene. Chang JS, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):139-42 (7 ref.)
Delayed presentation of traumatic arterial vasospasm. Davis GM, et al. **Pediatr Emerg Care** 1999 Feb;15(1):22-4 (12 ref.)
[Ischemic cholecystitis from cholesterol crystal embolism] Paraf F, et al. **Gastroenterol Clin Biol** 1999 May; 23(5):577-80 (28 ref.) (Eng. Abstr.) **(Fre)**
[Acute ischemia of the extremities] Eckstein HH. **Chirurg** 1998 Jul;69(7):786-800 (6 ref.) **(Ger)**
[Acute ischemia of the legs and rapidly progressing renal failure in a 39-year-old patient] Büchner N, et al. **Internist (Berl)** 1999 May;40(5):555-60 (20 ref.) **(Ger)**
[Ulcus cruris--vascular etiology and surgical treatment options] Kniemeyer HW, et al. **Ther Umsch** 1998 Oct; 55(10):643-9 (27 ref.) (Eng. Abstr.) **(Ger)**
[Ischemic necrosis of the spleen and gastric fundus. A rare complication of acute pancreatitis (letter)] Soria Aledo V, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):209 (8 ref.) **(Spa)**
[Neurological complications of aortic artery surgery] Carrascal Y, et al. **Rev Neurol** 1998 Nov;27(159):854-61 (89 ref.) (Eng. Abstr.) **(Spa)**
[Intestinal ischemia after abdominal aorta surgery. A dreaded complication surveyed by a combination of different methods] Björck M, et al. **Lakartidningen** 1999 Sep 1; 96(35):3659-62 (17 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGY

Upregulation of major histocompatibility complex-expression under ischemic conditions in experimental models. Shackleton CR. **Transplant Proc** 1998 Dec;30(8):4264-6 (6 ref.)

METABOLISM

The role of cell adhesion molecules in ischemic acute renal failure. Molitoris BA, et al. **Am J Med** 1999 May; 106(5):583-92 (79 ref.)

PATHOLOGY

Histologic spectrum of arterial and arteriolar lesions in acute and chronic cocaine-induced mesenteric ischemia: report of three cases and literature review. Hoang MP, et al. **Am J Surg Pathol** 1998 Nov;22(11):1404-10 (25 ref.)
Approaches to study of ischemia in bone. Winet H, et al. **J Biomed Mater Res** 1998 Winter;43(4):410-21 (66 ref.)
Mechanisms of reperfusion injury after warm ischemia of the liver. Jaeschke H. **J Hepatobiliary Pancreat Surg** 1998; 5(4):402-8 (84 ref.)
Mechanisms of cellular injury in ischemic acute renal failure. Sutton TA, et al. **Semin Nephrol** 1998 Sep;18(5):490-7 (32 ref.)

PHYSIOPATHOLOGY

alpha-Melanocyte-stimulating hormone and acute renal failure. Kohda Y, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):413-7 (32 ref.)
Skin wound healing and ischaemia. Studies on possible interventions. Quirinia A. **Dan Med Bull** 1999 Apr; 46(2):85-105 (178 ref.)
Bcl-2 genes and growth factors in the pathology of ischaemic acute renal failure. Gobé G, et al. **Immunol Cell Biol** 1999 Jun;77(3):279-86 (72 ref.)
Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. Korthuis RJ, et al. **J Vasc Res** 1999;36 Suppl 1:15-23 (31 ref.)
Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Hayreh SS. **Prog Retin Eye Res** 1999 Mar;18(2):191-221 (168 ref.)
Lessons learned from ischemic and cisplatin-induced nephrotoxicity in animals. Safirstein RL. **Ren Fail** 1999 May-Jul;21(3-4):359-64 (25 ref.)
Cell cycle events during renal injury. Safirstein RL. **Ren Fail** 1999 May-Jul;21(3-4):427-31 (24 ref.)
Mechanism and prevention of ischemia-reperfusion injury. Kurokawa T, et al. **Transplant Proc** 1999 Jun;31(4):1775-6 (5 ref.)
Predicting healing of arterial leg ulcers by means of segmental systolic pressure measurements. Wütschert R, et al. **Vasa** 1998 Nov;27(4):224-8 (13 ref.)
[Microcirculatory derangement and ischemia of the pancreas] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 May; 100(5):342-6 (16 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Mechanism and prevention of ischemia-reperfusion injury. Kurokawa T, et al. **Transplant Proc** 1999 Jun;31(4):1775-6 (5 ref.)
[Carotid surgery for prophylaxis of ischemic stroke] Eckstein HH, et al. **Chirurg** 1999 Apr;70(4):353-63 (70 ref.) (Eng. Abstr.) **(Ger)**
[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:72-7 (14 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Vascular disorders of the hand: therapist's commentary. Talley M. **J Hand Ther** 1999 Apr-Jun;12(2):160-3 (42 ref.)

SURGERY

Management of acute mesenteric ischemia. Mansour MA. **Arch Surg** 1999 Mar;134(3):328-30; discussion 331 (15 ref.)
Acute non-traumatic arm ischaemia. Eyers P, et al. **Br J Surg** 1998 Oct;85(10):1340-6 (86 ref.)
Adjuvant medical therapy in peripheral bypass surgery. Watson HR, et al. **Br J Surg** 1999 Aug;86(8):981-91 (58 ref.)
Lower limb oedema following distal arterial bypass grafting. Soong CV, et al. **Eur J Vasc Endovasc Surg** 1998 Dec; 16(6):465-71 (58 ref.)
The role of prophylactic fasciotomy and medical treatment in limb ischemia and revascularization. Hofmeister EP, et al. **Hand Clin** 1998 Aug;14(3):457-65, x (53 ref.)
Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. Hassan HA. **J Clin Gastroenterol** 1999 Jul;29(1):90-5 (54 ref.)
Surgical strategies — anastomosis or stoma, a second look — when and why? Hanisch E, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):239-42 (31 ref.)
[Traumatic peripheral vascular injuries] Markgraf E, et al. **Unfallchirurg** 1998 Jul;101(7):508-19 (64 ref.) (Eng. Abstr.) **(Ger)**
[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747-54 (754 ref.) (Eng. Abstr.) **(Spa)**
[Direct revascularization in chronic ischemia of the lower extremities] Sander SV. **Klin Khir** 1998;(7):47-50 (50 ref.) **(Ukr)**

THERAPY

Chronic critical limb ischemia: diagnosis, treatment and prognosis. Santilli JD, et al. **Am Fam Physician** 1999 Apr 1;59(7):1899-908 (21 ref.)
Role of enteral nutrition-induced splanchnic hyperemia in ameliorating splanchnic ischemia [editorial] Eleftheriadis E. **Nutrition** 1999 Mar;15(3):247-8 (13 ref.)
Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Baumgartner I, et al. **Vasa** 1998 Nov;27(4):201-6 (76 ref.)
Diagnosis and treatment of chronic lower extremity ischemia. Sanchez LA, et al. **Vasc Med** 1998;3(4):291-9 (95 ref.)
[Therapeutic influences on angiogenesis. "From bench to bedside"] Jaeger TM, et al. **Dtsch Med Wochenschr** 1999 Feb 5;124(5):121-3 (24 ref.) **(Ger)**
[Acute mesenteric ischemia--current diagnostic and therapeutic problems] Konturek A, et al. **Przegl Lek** 1999; 56(3):231-5 (31 ref.) (Eng. Abstr.) **(Pol)**

ISCHEMIA, MYOCARDIAL see **MYOCARDIAL ISCHEMIA**

ISCHEMIA-REPERFUSION INJURY see **REPERFUSION INJURY**

ISCHEMIC COLITIS see **COLITIS, ISCHEMIC**

ISCHEMIC HEART DISEASE see **MYOCARDIAL ISCHEMIA**

ISCHEMIC OPTIC NEUROPATHY see **OPTIC NEUROPATHY, ISCHEMIC**

ISCHEMIC PRECONDITIONING

Ischaemic preconditioning: mechanisms and potential clinical applications. Hawaleshka A, et al. **Can J Anaesth** 1998 Jul; 45(7):670–82 (89 ref.)

Mechanisms of ischemic preconditioning and clinical implications for multiorgan ischemic–reperfusion injury. Lee HT. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):78–91 (133 ref.)

If ischemic preconditioning is the gold standard, has a platinum standard of cardioprotection arrived? Comparison with NHE inhibition. Gumina RJ, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):39–44 (37 ref.)

Mechanisms of induced tolerance to cerebral ischemia. Welsh FA. **Nippon Ika Daigaku Zasshi** 1998 Dec;65(6):447–9 (3 ref.)

[Defense mechanism of the myocardium] Miura M, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1588–94 (16 ref.) **(Jpn)**

ISCHEMIC PRECONDITIONING, MYOCARDIAL

Ischemic preconditioning, myocardial stunning, and hibernation: basic aspects. Ferrari R, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):61–8 (65 ref.)

Oxygen free radical signaling in ischemic preconditioning. Das DK, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:49–65 (107 ref.)

New insights into cardioprotection by ischemic preconditioning and other forms of stress. de Zeeuw S, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:178–91 (70 ref.)

Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Liu Y, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:27–37 (30 ref.)

Alternatives for myocardial protection: adenosine-enhanced ischemic preconditioning. McCully JD, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:295–305 (60 ref.)

Cellular mechanisms of infarct size reduction with ischemic preconditioning. Role of calcium? Przyklenk K, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:192–210 (100 ref.)

Pharmacologic enhancement of tolerance to ischemic cardiac stress using monophosphoryl lipid A. A comparison with antecedent ischemia. Zhao L, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:222–35 (65 ref.)

The nitric oxide hypothesis of late preconditioning [editorial; see comments] Bolli R, et al. **Basic Res Cardiol** 1998 Oct; 93(5):325–38 (45 ref.) Comment in: Basic Res Cardiol 1998 Oct;93(5):422.

Angina: who needs it? Cardioprotection in the preconditioning era. Dana A, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):515–28 (142 ref.)

Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Simkhovich BZ, et al. **Cardiovasc Res** 1998 Oct;40(1):9–22 (115 ref.)

Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Gross GJ, et al. **Circ Res** 1999 May 14;84(9):973–9 (53 ref.)

Adenosine and preconditioning revisited. Miura T, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):92–9 (85 ref.)

New frontiers of cardioprotection. Terzic A. **Clin Pharmacol Ther** 1999 Aug;66(2):105–9 (41 ref.)

Clinical effects of ischemic preconditioning. Schwarz ER, et al. **Curr Opin Cardiol** 1999 Jul;14(4):340–8 (98 ref.)

The warm-up phenomenon and ischaemic preconditioning: an uncertain relationship [editorial; comment] Cohen MV, et al. **Eur Heart J** 1999 Feb;20(3):167–8 (9 ref.) Comment on: Eur Heart J 1999 Feb;20(3):196–202. Comment on: Eur Heart J 1999 Feb;20(3):203–10.

Myocardial adaptation to ischaemia—the preconditioning phenomenon. Carroll R, et al. **Int J Cardiol** 1999 Apr 10; 68 Suppl 1:S93–101 (108 ref.)

Myocardial preconditioning: mechanisms and man. Edwards RJ, et al. **Int J Clin Pract** 1998 Sep;52(6):395–401 (103 ref.)

Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. Baines CP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):741–54 (111 ref.)

Non-ischemic myocardial preconditioning. Domenech R, et al. **Mol Cell Biochem** 1998 Sep;186(1–2):201–3 (21 ref.)

Myocardial preconditioning: basic concepts and potential mechanisms. Okubo S, et al. **Mol Cell Biochem** 1999 Jun; 196(1–2):3–12 (140 ref.)

Molecular mechanisms of preconditioning: therapeutic implications. Bell RM, et al. **Rev Port Cardiol** 1998 Oct; 17 Suppl 2:II49–61 (143 ref.)

Pathophysiology of hibernation, stunning, and ischemic preconditioning. Dörge H, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:255–62; discussion 263 (57 ref.)

[Heat shock proteins and heart protection] Malyshev IIu, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):604–11 (37 ref.) **(Rus)**

[Autoinduced myocardial tolerance to ischemia: the role of stress proteins in the mechanisms of its occurrence] Shevchenko IuL, et al. **Fiziol Cheloveka** 1999 Jan–Feb; 25(1):134–9 (49 ref.) **(Rus)**

METHODS

Ischemic preconditioning in humans: models, mediators, and clinical relevance. Tomai F, et al. **Circulation** 1999 Aug 3;100(5):559–63 (44 ref.)

ISCHIUM

[Giant-cell tumor of bone] Calçada CP, et al. **Acta Med Port** 1998 Jun;11(6):563–8 (15 ref.) (Eng. Abstr.) **(Por)**

ISCOMS

see related
SAPONINS

ISCOM: a delivery system for neonates and for mucosal administration. Morein B, et al. **Adv Vet Med** 1999; 41:405–13 (20 ref.)

Functional aspects of iscoms. Morein F, et al. **Immunol Cell Biol** 1998 Aug;76(4):295–9 (29 ref.)

ADMINISTRATION & DOSAGE

Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses. Chin J, et al. **Immunol Cell Biol** 1998 Jun;76(3):245–55 (53 ref.)

IMMUNOLOGY

Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses. Chin J, et al. **Immunol Cell Biol** 1998 Jun;76(3):245–55 (53 ref.)

Immune stimulating complexes as mucosal vaccines. Smith RE, et al. **Immunol Cell Biol** 1998 Jun;76(3):263–9 (63 ref.)

ISCOMs: an adjuvant with multiple functions. Sjölander A, et al. **J Leukoc Biol** 1998 Dec;64(6):713–23 (152 ref.)

ISLAM

see related
ARABS

Caring for the Islamic patient. McKennis AT. **AORN J** 1999 Jun;69(6):1187–96; quiz 1199–206 (18 ref.)

PSYCHOLOGY

Asian-Islamic women and breast cancer screening: a socio-cultural analysis. Rajaram SS, et al. **Women Health** 1999;28(3):45–58 (45 ref.)

ISLAND FLAPS see **SURGICAL FLAPS**

ISLANDS OF LANGERHANS see **ISLETS OF LANGERHANS**

ISLET-ACTIVATING PROTEIN see **PERTUSSIS TOXINS**

ISLET CELL TUMOR see **ADENOMA, ISLET CELL**

ISLET CELL TUMOR, MALIGNANT see **CARCINOMA, ISLET CELL**

ISLET CELL TUMOR, ULCEROGENIC see **ZOLLINGER-ELLISON SYNDROME**

ISLET CELLS see **ISLETS OF LANGERHANS**

ISLETS OF LANGERHANS

Islet cryopreservation protocols. Rajotte RV. **Ann N Y Acad Sci** 1999 Jun 18;875:200–7 (39 ref.)

Processing, storage and experimental transplantation of human fetal pancreatic cells. Hayek A, et al. **Ann Transplant** 1997;2(3):46–54 (52 ref.)

Cryopreservation of human islets of Langerhans [comment] Warnock GL, et al. **Transplantation** 1999 Sep 15; 68(5):597–8 (4 ref.) Comment on: Transplantation 1999 Sep 15;68(5):655–62.

CYTOLOGY

Advantages of microencapsulation as an immunoprotection method in the transplantation of pancreatic islets. Sun AM. **Ann Transplant** 1997;2(3):55–62 (66 ref.)

Porcine neonatal pancreatic cell clusters (NPCCs): a potential source of tissue for islet transplantation. Weir GC, et al. **Ann Transplant** 1997;2(3):63–8 (55 ref.)

Beta cell proliferation and growth factors. Nielsen JH, et al. **J Mol Med** 1999 Jan;77(1):62–6 (49 ref.)

Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Bouwens L. **Microsc Res Tech** 1998 Nov 15;43(4):332–6 (40 ref.)

Morphogenesis and differentiation of the avian endocrine pancreas, with particular reference to experimental studies on the chick embryo. Rawdon BB. **Microsc Res Tech** 1998 Nov 15;43(4):292–305 (125 ref.)

Induction of islet cell neogenesis in the adult pancreas: the partial duct obstruction model. Rosenberg L. **Microsc Res Tech** 1998 Nov 15;43(4):337–46 (75 ref.)

DRUG EFFECTS

Trioses and related substances: tools for the study of pancreatic beta-cell function. Best L, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):583–8 (53 ref.)

Rosiglitazone. Balfour JA, et al. **Drugs** 1999 Jun;57(6):921–30; discussion 931–2 (66 ref.)

[Gluco-lipotoxicity and gene expression in the pancreatic beta cell] Prentki M, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:17–27 (50 ref.) **(Fre)**

EMBRYOLOGY

On the development of the islets of Langerhans. Larsson LI. **Microsc Res Tech** 1998 Nov 15;43(4):284–91 (60 ref.)

Expression of non-classical islet hormone-like peptides during the embryonic development of the pancreas. Mulder H, et al. **Microsc Res Tech** 1998 Nov 15;43(4):313–21 (70 ref.)

Morphogenesis and differentiation of the avian endocrine pancreas, with particular reference to experimental studies on the chick embryo. Rawdon BB. **Microsc Res Tech** 1998 Nov 15;43(4):292–305 (125 ref.)

ENZYMOLOGY

Inosine monophosphate dehydrogenase: A molecular switch integrating pleiotropic GTP-dependent beta-cell functions. Metz SA, et al. **Proc Assoc Am Physicians** 1999 Jul–Aug; 111(4):335–46 (86 ref.)

IMMUNOLOGY

Vesicular autoantigens of type 1 diabetes. Solimena M. **Diabetes Metab Rev** 1998 Sep;14(3):227–40 (91 ref.)

In vivo imaging of insulitis in autoimmune diabetes. Signore A, et al. **J Endocrinol Invest** 1999 Feb;22(2):151–8 (49 ref.)

Generation of nonimmune islet cells using genetic engineering. Brownlee M. **J Mol Med** 1999 Jan;77(1):230–4 (65 ref.)

Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. van Schilfgaarde R, et al. **J Mol Med** 1999 Jan; 77(1):199–205 (52 ref.)

Selective immunotherapy of IDDM: a discussion based on new findings from the RIP-LCMV model for autoimmune diabetes. von Herrath MG. **Transplant Proc** 1998 Dec; 30(8):4115–21 (122 ref.)

[Current concept of the pathogenesis of autoimmune type 1 diabetes mellitus] Satoh J, et al. **Nippon Rinsho** 1999 Mar; 57(3):528–33 (20 ref.) (Eng. Abstr.) **(Jpn)**

INNERVATION

Regulation of insulin secretion by nerves and neuropeptides. Ahrén B. **Ann Acad Med Singapore** 1999 Jan;28(1):99–104 (16 ref.)

The canine sympathetic neuropeptide galanin: a neurotransmitter in pancreas, a neuromodulator in liver. Taborsky GJ Jr, et al. **Horm Metab Res** 1999 May; 31(5):351–4 (24 ref.)

METABOLISM

Aspects of novel sites of regulation of the insulin stimulus-secretion coupling in normal and diabetic pancreatic islets. Sjöholm A. **Endocrine** 1998 Aug;9(1):1–13 (226 ref.)

Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Lang J. **Eur J Biochem** 1999 Jan;259(1–2):3–17 (224 ref.)

The role of 12-lipoxygenase in pancreatic -cells (Review). Bleich D, et al. **Int J Mol Med** 1998 Jan;1(1):265–72 (72 ref.)

The structure and function of the ATP-sensitive K + channel in insulin-secreting pancreatic beta-cells. Miki T, et al. **J Mol Endocrinol** 1999 Apr;22(2):113–23 (68 ref.)

Metabolic strategies to predict and improve intrahepatic islet graft function. Luzi L. **J Mol Med** 1999 Jan;77(1):49–56 (46 ref.)

Ca2+ signaling and the insulin secretory cascade in the pancreatic beta-cell. Niki I. **Jpn J Pharmacol** 1999 Jul; 80(3):191–7 (41 ref.)

Expression of non-classical islet hormone-like peptides during the embryonic development of the pancreas. Mulder H, et al. **Microsc Res Tech** 1998 Nov 15;43(4):313–21 (70 ref.)

PATHOLOGY

Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report. Pasieka JL, et al. **Can J Surg** 1999 Feb;42(1):55–8 (12 ref.)

The link between exocrine pancreatic cancer and the endocrine pancreas. Pour PM, et al. **Int J Pancreatol** 1999 Apr;25(2):77–87 (51 ref.)

Strategies of protection from nitric oxide toxicity in islet inflammation. Rothe H, et al. **J Mol Med** 1999 Jan; 77(1):40–4 (51 ref.)

PHYSIOLOGY

Stimulatory transducing systems in pancreatic islet cells. Emami S, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:118–31 (78 ref.)

The role of the target organ in cytokine-mediated beta-cell destruction. Possible relevance for the pathogenesis of insulin dependent diabetes mellitus. Andersen HU. **Dan Med Bull** 1999 Apr;46(2):127–64 (447 ref.)

ISLETS OF LANGERHANS

GH signalling in pancreatic beta-cells. Sekine N, et al. **Endocr J** 1998 Apr;45 Suppl:S33-40 (36 ref.)
Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit? Satin LS, et al. **Endocrine** 1998 Jun;8(3):213-23 (85 ref.)
Beta-cell ion channels: keys to endodermal excitability. Philipson LH. **Horm Metab Res** 1999 Aug;31(8):455-61 (90 ref.)
Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. van Schilfgaarde R, et al. **J Mol Med** 1999 Jan; 77(1):199-205 (52 ref.)
Intra- and intercellular Ca2+ signaling in paraneurons and other secretory cells. Kanno T. **Jpn J Physiol** 1998 Aug; 48(4):219-27 (73 ref.)
Parathyroid hormone-related protein in the pancreatic islet and the cardiovascular system. Vasavada RC, et al. **Recent Prog Horm Res** 1998;53:305-38; discussion 338-40 (68 ref.)
Glucose action 'beyond ionic events' in the pancreatic beta cell [published erratum appears in Trends Pharmacol Sci 1999 Mar;20(3):124] Aizawa T, et al. **Trends Pharmacol Sci** 1998 Dec;19(12):496-9 (48 ref.)
[Fatty acids, insulin resistance and pancreatic beta cell function] McGarry JD, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:1-10 (24 ref.) **(Fre)**
[Time for more active lipid-lowering treatment of patients with diabetes. Negative effect of hyperlipidemia on beta-cells is a neglected field] Sjöholm A. **Lakartidningen** 1998 Dec 9;95(50):5750-2 (38 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Kahn SE, et al. **Diabetes** 1999 Feb;48(2):241-53 (119 ref.)
Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance. Göke B. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S15-20 (43 ref.)
Aspects of novel sites of regulation of the insulin stimulus-secretion coupling in normal and diabetic pancreatic islets. Sjöholm A. **Endocrine** 1998 Aug;9(1):1-13 (226 ref.)

SECRETION

Genetically engineered pancreatic beta-cell lines for cell therapy of diabetes. Efrat S. **Ann N Y Acad Sci** 1999 Jun 18;875:286-93 (22 ref.)
Imidazolines and pancreatic hormone secretion. Morgan NG, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:217-28 (41 ref.)
Role of mitochondria in metabolism-secretion coupling of insulin release in the pancreatic beta-cell. Maechler P, et al. **Biofactors** 1998;8(3-4):255-62 (48 ref.)
Would R.D. Lawrence have been interested in the regulation of insulin secretion from pancreatic beta-cells? Jones PM. **Diabet Med** 1998 Aug;15(8):644-50 (34 ref.)
Does leptin regulate insulin secretion? Poitout V, et al. **Diabetes Metab** 1998 Sep;24(4):321-6 (35 ref.)
Actual perspectives in biohybrid artificial pancreas for the therapy of type 1, insulin-dependent diabetes mellitus. Calafiore R. **Diabetes Metab Rev** 1998 Dec;14(4):315-24 (29 ref.)
Insulinotropic action of monosaccharide esters: therapeutic perspectives. Malaisse WJ. **Diabetologia** 1999 Mar; 42(3):286-91 (81 ref.)
Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic beta-cells. Jones PM, et al. **Endocr Rev** 1998 Aug;19(4):429-61 (361 ref.)
Clonidine-displacing substance and its putative role in control of insulin secretion: a minireview. Chan SL. **Gen Pharmacol** 1998 Oct;31(4):525-9 (53 ref.)
The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. Miki T, et al. **J Mol Endocrinol** 1999 Apr;22(2):113-23 (68 ref.)
Engineering cultured insulin-secreting pancreatic B-cell lines. McClenaghan NH, et al. **J Mol Med** 1999 Jan; 77(1):235-43 (67 ref.)
Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? McCarty MF. **Med Hypotheses** 1999 May;52(5):397-400 (31 ref.)
[Paraventriculovagal path of carbohydrate homeostasis regulation--a perspective biological model in studies on neuroimmunoendocrine interactions] Akmaev IG. **Biull Eksp Biol Med** 1999 Feb;127(2):124-8 (35 ref.) **(Rus)**

ISLETS OF LANGERHANS TRANSPLANTATION

Genetically engineered pancreatic beta-cell lines for cell therapy of diabetes. Efrat S. **Ann N Y Acad Sci** 1999 Jun 18;875:286-93 (22 ref.)
Clinical islet transplantation: a review. Oberholzer J, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:189-99 (57 ref.)
Potential application of neonatal porcine islets as treatment for type 1 diabetes: a review. Rayat GR, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:175-88 (117 ref.)
Pancreas transplantation. Hakim NS. **Ann R Coll Surg Engl** 1998 Sep;80(5):313-5 (3 ref.)
Processing, storage and experimental transplantation of human fetal pancreatic cells. Hayek A, et al. **Ann Transplant** 1997;2(3):46-54 (52 ref.)
Porcine neonatal pancreatic cell clusters (NPCCs): a potential source of tissue for islet transplantation. Weir GC, et al. **Ann Transplant** 1997;2(3):63-8 (55 ref.)
Tilapia Brockmann Bodies: an inexpensive, simple model for discordant islet xenotransplantation. Wright JR Jr, et al. **Ann Transplant** 1997;2(3):72-5 (35 ref.)
Risks and benefits of kidney and pancreas transplantation for diabetic patients. Manske CL. **Diabetes Care** 1999 Mar;22 Suppl 2:B114-20 (97 ref.)
Clinical islet cell transplantation. Are we there yet? Rosenberg L. **Int J Pancreatol** 1998 Dec;24(3):145-68 (258 ref.)
Islet transplantation as a treatment for diabetes. Weir GC, et al. **J Am Optom Assoc** 1998 Nov;69(11):727-32 (33 ref.)
Indications for clinical islet transplantation today and in the forseeable future--the diabetologist's point of view. Federlin K, et al. **J Mol Med** 1999 Jan;77(1):148-52 (10 ref.)
Xenoislet transplantation: experimental and clinical aspects. Groth CG, et al. **J Mol Med** 1999 Jan;77(1):153-4 (9 ref.)
Fetal islet xenotransplantation in rodents and primates. Mandel TE. **J Mol Med** 1999 Jan;77(1):155-60 (43 ref.)
New approaches for control of anti-self reactivity in type 1 diabetes mellitus and transplantation of pancreatic islets. Slavin S, et al. **J Mol Med** 1999 Jan;77(1):223-5 (22 ref.)
Islet transplantation. Kovarik J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2A):45S-48S (55 ref.)
[Transplantation of islets of Langerhans: quo vadis? (editorial)] Triponez F, et al. **Chirurgie** 1999 Feb; 124(1):5-12 (46 ref.) **(Fre)**
[Development of insulinoma cells as therapy in insulin-dependent diabetes mellitus] Schnedl WJ. **Wien Klin Wochenschr** 1999 Jun 4;111(11):428-33 (47 ref.) (Eng. Abstr.) **(Ger)**
[Isolation of islands of Langerhans from human and porcine pancreas for transplantation to humans] Brandhorst D, et al. **Zentralbl Chir** 1998;123(7):814-22 (113 ref.) (Eng. Abstr.) **(Ger)**
[Transplantation of porcine Langerhans islets for therapy of type I diabetes. The way to clinical application] Ulrichs K, et al. **Zentralbl Chir** 1999;124(7):628-35 (37 ref.) (Eng. Abstr.) **(Ger)**
[Current status and future prospect of pancreas and islet transplantation] Nakagawa Y, et al. **Nippon Rinsho** 1999 Mar;57(3):726-35 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Antigen presentation pathways for immunity to islet transplants. Relevance to immunoisolation. Gill RG. **Ann N Y Acad Sci** 1999 Jun 18;875:255-60 (35 ref.)
Tolerance induction for islet transplantation. Exner BG, et al. **Ann Transplant** 1997;2(3):77-80 (68 ref.)
The role of adhesion molecules in allotransplanted islet cells rejection. Prolongation of islet cells allograft survival by antiadhesion treatment. Socha-Urbanek K, et al. **Ann Transplant** 1998;3(4):5-9 (36 ref.)
Advantages of microencapsulation as an immunoprotection method in the transplantation of pancreatic islets. Sun AM. **Ann Transplant** 1997;2(3):55-62 (66 ref.)
Islet transplantation: present and future perspectives. Kenyon NS, et al. **Diabetes Metab Rev** 1998 Dec;14(4):303-13 (100 ref.)
Immunosuppression in pancreas transplantation: progress, problems and perspective. Stratta RJ. **Transpl Immunol** 1998 Jun;6(2):69-77 (67 ref.)
Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody. Rossini AA, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):629-32 (15 ref.)
Xenogeneic islet transplantation. Simeonovic CJ. **Xenotransplantation** 1999 Feb;6(1):1-5 (35 ref.)
[Graft rejection in experimental xenogenic transplantation of isolated islands of Langerhans of the pig] Jahr H, et al. **Zentralbl Chir** 1998;123(7):823-9 (73 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammalians. Calafiore R, et al. **Ann N Y Acad Sci** 1999 Jun 18; 875:219-32 (17 ref.)
Advantages of microencapsulation as an immunoprotection method in the transplantation of pancreatic islets. Sun AM. **Ann Transplant** 1997;2(3):55-62 (66 ref.)
Human islet allotransplantation: world experience and current status. Cretin N, et al. **Dig Surg** 1998;15(6):656-62 (72 ref.)
Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. van Schilfgaarde R, et al. **J Mol Med** 1999 Jan; 77(1):199-205 (52 ref.)

PHYSIOLOGY

Metabolic strategies to predict and improve intrahepatic islet graft function. Luzi L. **J Mol Med** 1999 Jan;77(1):49-56 (46 ref.)

ISOANTIBODIES

see related
BLOOD GROUPS

Consensus Conference on Anti-D Prophylaxis. Edinburgh, United Kingdom, 8-9 April 1997. Papers and abstracts. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:iv, 1-44 (0 ref.)

BLOOD

Graft rejection in sensitized recipients. Kupiec-Węgliński JW. **Ann Transplant** 1996;1(1):34-40 (61 ref.)
Assays to predict the clinical significance of blood group antibodies. Zupańska B. **Curr Opin Hematol** 1998 Nov; 5(6):412-6 (43 ref.)
Immunologically high-risk recipient strategies. First MR. **Transplant Proc** 1999 Feb-Mar;31(1-2):243-6 (26 ref.)
Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing. Garratty G. **Vox Sang** 1998;74 Suppl 2:285-90 (43 ref.)
A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Hadley AG. **Vox Sang** 1998;74 Suppl 2:375-83 (79 ref.)
Evaluation of serological platelet antibody assays. Kaplan C. **Vox Sang** 1998;74 Suppl 2:355-8 (28 ref.)
Screening programmes for foetomaternal alloimmune thrombocytopenia. Williamson LM. **Vox Sang** 1998;74 Suppl 2:385-9 (32 ref.)
[Acquired inhibitor to coagulation factor V] Takahashi I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):506-8 (10 ref.) **(Jpn)**

IMMUNOLOGY

Transplantation immunology--the role of human leucocyte antigen in allorecognition. Vartdal F, et al. **Curr Top Pathol** 1999;92:1-18 (64 ref.)
Platelet refractoriness and alloimmunization. Slichter SJ. **Leukemia** 1998 Sep;12 Suppl 1:S51-3 (12 ref.)
Humoral transplantation antibodies. Milgrom F. **Transplant Proc** 1999 Feb-Mar;31(1-2):30-3 (33 ref.)
[The young hemophiliac, inhibitors and immune tolerance] Rothschild C. **Transfus Clin Biol** 1999 Jun;6(3):191-4 (11 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Immune thrombocytopenic purpura: why treat? [editorial; comment] Nugent DJ. **J Pediatr** 1999 Jan;134(1):3-4 (15 ref.) Comment on: J Pediatr 1999 Jan;134(1):21-6.

ISOANTIGENS

see related
BLOOD GROUPS

The influence of antiviral T-cell responses on the alloreactive repertoire. Burrows SR, et al. **Immunol Today** 1999 May; 20(5):203-7 (39 ref.)

IMMUNOLOGY

T cell immunobiology of alloimmune thrombocytopenias. Gorski J, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):269-75 (33 ref.)
The presentation of self and allogeneic MHC peptides to T lymphocytes. Benichou G, et al. **Hum Immunol** 1998 Sep; 59(9):540-8 (44 ref.)
Indirect recognition of allo MHC peptides--potential role in human transplantation [editorial] Watschinger B. **Nephrol Dial Transplant** 1999 Jan;14(1):8-11 (29 ref.)

ISOASPARTIC ACID see **ASPARTIC ACID**

ISOCHROMOSOMES

Parental origin of the isochromosome 12p in Pallister-Killian syndrome: molecular analysis of one patient and review of the reported cases. Struthers JL, et al. **Am J Med Genet** 1999 May 21;84(2):111-5 (23 ref.)
Formation of supernumerary euchromatic short arm isochromosomes: parent and cell stage of origin in new cases and review of the literature. Eggermann T, et al. **Ann Genet** 1999;42(2):75-80 (18 ref.)

ISOCITRATE DEHYDROGENASE

CHEMISTRY

Visualizing enzyme intermediates using fast diffraction and reaction trapping methods: isocitrate dehydrogenase. Stoddard BL. **Biochem Soc Trans** 1999 Feb;27(2):42-8 (33 ref.)

METABOLISM

Visualizing enzyme intermediates using fast diffraction and reaction trapping methods: isocitrate dehydrogenase. Stoddard BL. **Biochem Soc Trans** 1999 Feb;27(2):42-8 (33 ref.)

ISOCYANATES

ADVERSE EFFECTS

Current diagnostic methods for diisocyanate induced occupational asthma. Bernstein DI, et al. **Am J Ind Med** 1999 Oct;36(4):459–68 (35 ref.)

POISONING

Persistent respiratory effects in survivors of the Bhopal disaster. Beckett WS. **Thorax** 1998 Aug;53 Suppl 2:S43–6 (13 ref.)

TOXICITY

Toluene diisocyanates. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:865–79 (45 ref.)

New mechanistic model for organic diisocyanate-induced respiratory disease. Savolainen H. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):465–7 (31 ref.)

[Pathologic mechanisms of diseases caused by isocyanates—review of current knowledge] Raulf-Heimsoth M, et al. **Pneumologie** 1999 Mar; 53(3):143–9 (62 ref.) (Eng. Abstr.) **(Ger)**

ISOCYANIDES see **CYANIDES**

ISOELECTRIC FOCUSING

Theory and practice of isoelectric focusing of interacting systems. Cann JR. **Electrophoresis** 1998 Jul;19(10):1577–85 (42 ref.)

Isoelectric focusing in the vegetable seed industry. van den Berg BM. **Electrophoresis** 1998 Jul;19(10):1780–7 (63 ref.)

INSTRUMENTATION

Recycling isoelectric focusing and isotachophoresis. Bier M. **Electrophoresis** 1998 Jun;19(7):1057–63 (63 ref.)

METHODS

Recycling isoelectric focusing and isotachophoresis. Bier M. **Electrophoresis** 1998 Jun;19(7):1057–63 (63 ref.)

Recent developments in capillary isoelectric focusing with whole-column imaging detection. Fang X, et al. **Electrophoresis** 1998 Oct;19(13):2290–5 (23 ref.)

Gel electrofocusing method for studying protein S-nitrosylation. Ji Y, et al. **Methods Enzymol** 1999; 301:145–51 (15 ref.)

Advantages of carrier ampholyte IEF. Lopez MF. **Methods Mol Biol** 1999;112:109–10 (7 ref.)

2-D electrophoresis using carrier ampholytes in the first dimension (IEF). Lopez MF. **Methods Mol Biol** 1999; 112:111–27 (12 ref.)

Nonequilibrium pH gel electrophoresis (NEPHGE). Lopez MF. **Methods Mol Biol** 1999;112:129–31 (3 ref.)

Running preparative carrier ampholyte and immobilized pH gradient IEF gels for 2-D. Matsui NM, et al. **Methods Mol Biol** 1999;112:211–9 (14 ref.)

ISOENZYMES

Celecoxib, a COX-2-specific inhibitor: the clinical data. Fort J. **Am J Orthop** 1999 Mar;28(3 Suppl):13–8 (14 ref.)

Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. O'Banion MK. **Crit Rev Neurobiol** 1999; 13(1):45–82 (354 ref.)

Cyclooxygenase-2 as a therapeutic target. Mitchell JA, et al. **Inflamm Res** 1998 Oct;47 Suppl 2:S88–92 (22 ref.)

Cyclooxygenase-1 and -2 isoenzymes. Hla T, et al. **Int J Biochem Cell Biol** 1999 May;31(5):551–7 (43 ref.)

Multilocus enzyme electrophoresis: a valuable technique for providing answers to problems in parasite systematics. Andrews RH, et al. **Int J Parasitol** 1999 Feb;29(2):213–53 (189 ref.)

Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? Wallace JL, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S28–34 (37 ref.)

Examining the renin-angiotensin system one hundred years after its discovery. Bernstein KE. **Nephrologie** 1998; 19(7):391–5 (33 ref.)

[Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers] Ohara M, et al. **Masui** 1998 Nov;47(11):1325–32 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of COX-1 and COX-2 and gastrointestinal diseases] Tsujii M, et al. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2114–21 (15 ref.) **(Jpn)**

[Non-steroidal antiinflammatory drug—management of gastrointestinal complications and inhibition of $COX_{1,2}$] Tada Y, et al. **Nippon Rinsho** 1999 Feb;57(2):419–24 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress on the study of lipoxygenases—discovery of novel isozymes and molecular evolution] Takahashi Y, et al. **Seikagaku** 1998 Sep;70(9):1189–93 (14 ref.) **(Jpn)**

ANALYSIS

Triglyceride lipase assays based on a novel fluorogenic alkyldiacyl glycerol substrate. Hermetter A. **Methods Mol Biol** 1999;109:19–29 (19 ref.)

ANTAGONISTS & INHIBITORS

The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Spina D, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:24–34 (100 ref.)

Design of isoform-selective inhibitors of nitric oxide synthase. Babu BR, et al. **Curr Opin Chem Biol** 1998 Aug; 2(4):491–500 (87 ref.)

The inducible nitric oxide synthase in vascular and cardiac tissue. Stoclet JC, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1-3):139–55 (226 ref.)

Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Frye SV, et al. **Pharm Biotechnol** 1998;11:393–422 (85 ref.)

BIOSYNTHESIS

Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology. Gillam EM. **Clin Exp Pharmacol Physiol** 1998 Nov; 25(11):877–86 (74 ref.)

CHEMISTRY

Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Blanco G, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F633–50 (221 ref.)

The structure of phospholipase C isoforms and the regulation of phosphoinositide hydrolysis. James S. **Biochem Soc Trans** 1998 Aug;26(3):354–9 (24 ref.)

Families of phosphoinositide-specific phospholipase C: structure and function. Katan M. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):5–17 (98 ref.)

Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. Marnett LJ, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):482–90 (61 ref.)

Protein kinase C delta. Gschwendt M. **Eur J Biochem** 1999 Feb;259(3):555–64 (138 ref.)

Cyclooxygenase-1 and -2 isoenzymes. Hla T, et al. **Int J Biochem Cell Biol** 1999 May;31(5):551–7 (43 ref.)

Cyclooxygenase-2 inhibitors in tumorigenesis (part I). Taketo MM. **J Natl Cancer Inst** 1998 Oct 21;90(20):1529–36 (98 ref.)

Acetylcholinesterase: C-terminal domains, molecular forms and functional localization. Massoulié J, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):183–90 (59 ref.)

Determining lipase subunit structure by sucrose gradient centrifugation. Ben-Zeev O, et al. **Methods Mol Biol** 1999; 109:257–66 (32 ref.)

DRUG EFFECTS

COX-1 and COX-2 inhibition: current status and future perspective. Greyn J, et al. **Acta Anaesthesiol Belg** 1998; 49(3):175–83 (39 ref.)

The clinical potential of cyclooxygenase-2-specific inhibitors. Lipsky PE. **Am J Med** 1999 May 31; 106(5B):51S–57S (51 ref.)

The cyclooxygenase-2 inhibitors: safety and effectiveness. Kaplan-Machlis B, et al. **Ann Pharmacother** 1999 Sep; 33(9):979–88 (59 ref.)

COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs [editorial] Schachna L, et al. **Med J Aust** 1999 Aug 16;171(4):175–6 (20 ref.)

4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Talley JJ, et al. **Med Res Rev** 1999 May;19(3):199–208 (29 ref.)

Overview of nimesulide. Bennett A. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:1–3 (19 ref.)

Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Bjarnason I, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:24–32 (87 ref.)

Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rainsford KD. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:4–10 (22 ref.)

The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Shah AA, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:19–23 (47 ref.)

[New NSAIDS: COX-1, COX-2, what about them?] Peretz A. **Rev Med Brux** 1998 Sep;19(4):A399–402 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Regulation of pyruvate kinase M gene expression. Yamada K, et al. **Biochem Biophys Res Commun** 1999 Mar 16; 256(2):257–62 (63 ref.)

Hematologically important mutations: red cell pyruvate kinase (2nd update). Baronciani L, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):273–9 (41 ref.)

Insect cytochromes P450: diversity, insecticide resistance and tolerance to plant toxins. Scott JG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):147–55 (74 ref.)

Induced lipase mutations in the mouse. Semenkovich CF. **Methods Mol Biol** 1999;109:343–55 (21 ref.)

IMMUNOLOGY

Multiple roles for PI 3-kinase in the regulation of PLCgamma activity and Ca2+ mobilization in antigen-stimulated mast cells. Barker SA, et al. **J Leukoc Biol** 1999 Mar;65(3):321–9 (55 ref.)

Immunological characterization of digestive lipases. De Caro A, et al. **Methods Mol Biol** 1999;109:239–56 (29 ref.)

ISOLATION & PURIFICATION

Rainbow trout cytochrome P450s: purification, molecular aspects, metabolic activity, induction and role in environmental monitoring. Buhler DR, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):107–37 (209 ref.)

Determination of plasmalogen-selective phospholipase A2 activity by radiochemical and fluorometric assay procedures. Farooqui AA, et al. **Methods Mol Biol** 1999; 109:39–47 (15 ref.)

METABOLISM

Isozymes delta of phosphoinositide-specific phospholipase C. Pawełczyk T. **Acta Biochim Pol** 1999;46(1):91–8 (61 ref.)

Regulation of expression and function by subunits of oligomeric P-type ATPases. Béguin P, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:283–7 (11 ref.)

Conformational alterations resulting from mutations in cytoplasmic domains of the alpha subunit of the Na,K-ATPase. Blostein R, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:275–81 (26 ref.)

Subunit interactions coupling H+ transport and ATP synthesis in F1F0 ATP synthase. Fillingame RH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:163–8 (28 ref.)

The second stalk: the delta-b subunit connection in ECF1F0. Ogilvie I, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:169–75 (32 ref.)

Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Blanco G, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F633–50 (221 ref.)

The structure of phospholipase C isoforms and the regulation of phosphoinositide hydrolysis. James S. **Biochem Soc Trans** 1998 Aug;26(3):354–9 (24 ref.)

Cytochrome P450-dependent metabolism of arachidonic acid. Ivanov IV, et al. **Biochemistry (Mosc)** 1999 Jul; 64(7):725–37 (108 ref.)

Families of phosphoinositide-specific phospholipase C: structure and function. Katan M. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):5–17 (98 ref.)

The prevention of colorectal cancer by aspirin use. Giovannucci E. **Biomed Pharmacother** 1999 Aug; 53(7):303–8 (53 ref.)

Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Boucher JL, et al. **Cell Mol Life Sci** 1999 Jul;55(8-9):1015–28 (123 ref.)

Regulation of phospholipase C isozymes: activation of phospholipase C-gamma in the absence of tyrosine-phosphorylation. Sekiya F, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):3–11 (41 ref.)

The COX-1/COX-2 balance in asthma. Pang L, et al. **Clin Exp Allergy** 1998 Sep;28(9):1050–8 (75 ref.)

Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Katori M, et al. **Inflamm Res** 1998 Oct;47 Suppl 2:S107–11 (25 ref.)

Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Pairet M, et al. **Inflamm Res** 1998 Oct;47 Suppl 2:S93–101 (65 ref.)

Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J, et al. **Inflamm Res** 1999 May;48(5):247–54 (97 ref.)

Effects of obesity on the cytochrome P450 enzyme system. Kotlyar M, et al. **Int J Clin Pharmacol Ther** 1999 Jan; 37(1):8–19 (55 ref.)

Cyclo-oxygenase-2 in vascular smooth muscle. Bishop-Bailey D, et al. **Int J Mol Med** 1999 Jan;3(1):41–8 (70 ref.)

Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Chiarugi V, et al. **Int J Mol Med** 1998 Dec; 2(6):715–9 (35 ref.)

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. Marnett LJ, et al. **J Biol Chem** 1999 Aug 13;274(33):22903–6 (58 ref.)

The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. Rebouillat D, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):295–308 (108 ref.)

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). Taketo MM. **J Natl Cancer Inst** 1998 Nov 4;90(21):1609–20 (146 ref.)

Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS. **J Rheumatol** 1999 Apr;26 Suppl 56:31–6 (19 ref.)

Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? Lipsky PE. **J Rheumatol** 1999 Apr;26 Suppl 56:25–30 (88 ref.)

The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. Krozowski Z, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):391–401 (71 ref.)

Two 17beta-hydroxysteroid dehydrogenases (17HSDs) of estradiol biosynthesis: 17HSD type 1 and type 7. Peltoketo H, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):431–9 (46 ref.)

Androgen-activating enzymes in the central nervous system. Poletti A, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):117–22 (48 ref.)

Protein kinase C in normal and pathologic myocardial states.

Cain BS, et al. **J Surg Res** 1999 Feb;81(2):249–59 (166 ref.)
Subspecies-specific targeting mechanism of protein kinase C. Shirai Y, et al. **Jpn J Pharmacol** 1998 Dec;78(4):411–7 (30 ref.)
Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Dousa TP. **Kidney Int** 1999 Jan;55(1):29–62 (232 ref.)
Cox-2-selective inhibitors: the new super aspirins. DeWitt DL. **Mol Pharmacol** 1999 Apr;55(4):625–31 (35 ref.)
Ethanol interactions with other cytochrome P450 substrates including drugs, xenobiotics, and carcinogens. Djordjević D, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):760–70 (103 ref.)
Are GAD65 and GAD67 associated with specific pools of GABA in brain? Martin DL, et al. **Perspect Dev Neurobiol** 1998;5(2–3):119–29 (56 ref.)
Selective cyclooxygenase-2 inhibitors. Golden BD, et al. **Rheum Dis Clin North Am** 1999 May;25(2):359–78 (145 ref.)
COX-1, COX-2: so what? [editorial] Emery P. **Scand J Rheumatol** 1999;28(1):6–9 (16 ref.)
Selective COX-2 inhibitors: is the water becoming muddy? Wallace JL. **Trends Pharmacol Sci** 1999 Jan;20(1):4–6 (28 ref.)
[Non-steroidal anti-inflammatory agents (NSAID's) with lesser side effects by selective inhibition of cyclo-oxygenase-2] Bijlsma JW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1;142(31):1762–5 (20 ref.) (Eng. Abstr.) **(Dut)**
[COX-1 and COX-2: functions and pharmacological effects] Hinz B, et al. **Pharm Unserer Zeit** 1999 Jan;28(1):21–9 (80 ref.) **(Ger)**
[Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology] Ledro Cano D, et al. **Rev Esp Enferm Dig** 1999 Apr;91(4):305–9 (27 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

PKC-dependent signalling mechanisms in differentiated smooth muscle. Morgan KG, et al. **Acta Physiol Scand** 1998 Dec;164(4):495–505 (112 ref.)
Role of cyclooxygenase-1 and -2 in health and disease. Lipsky PE. **Am J Orthop** 1999 Mar;28(3 Suppl):8–12 (29 ref.)
Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Simkhovich BZ, et al. **Cardiovasc Res** 1998 Oct;40(1):9–22 (115 ref.)
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Leevers SJ, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):219–25 (54 ref.)
Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Amin AR, et al. **Curr Opin Rheumatol** 1999 May;11(3):202–9 (58 ref.)
Cytochrome-P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues. Juchau MR, et al. **Drug Metab Rev** 1998 Aug;30(3):541–68 (120 ref.)
Modeling the chemoprotective functions of glutathione S-transferases in cultured cell lines by heterologous expression. Townsend AJ, et al. **Drug Metab Rev** 1999 Feb; 31(1):43–69 (106 ref.)
Cyclooxygenase-1 and -2 isoenzymes. Hla T, et al. **Int J Biochem Cell Biol** 1999 May;31(5):551–7 (43 ref.)
Roles of COX-1 and COX-2 [letter; comment] McCormack K. **J Rheumatol** 1998 Nov;25(11):2279–81 (13 ref.) Comment on: J Rheumatol 1997 Feb;24(2):243–5. Comment on: J Rheumatol 1997 Feb;24(2):246–8.
Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects [see comments] Smolenski A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul; 358(1):134–9 (40 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111–2.
The advent of highly selective inhibitors of cyclooxygenase--a review. Cryer B, et al. **Prostaglandins Other Lipid Mediat** 1998 Aug; 56(5–6):341–61 (102 ref.)
Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS. **Scand J Rheumatol Suppl** 1999;109:31–7 (19 ref.)
COX-2: separating myth from reality. McKenna F. **Scand J Rheumatol Suppl** 1999;109:19–29 (57 ref.)
Expression of 11 beta-hydroxysteroid dehydrogenase in early pregnancy: implications in human trophoblast-endometrial interactions. Arcuri F, et al. **Semin Reprod Endocrinol** 1999; 17(1):53–61 (63 ref.)
[Pathogenetic significance of 5-alpha reductase isoenzymes for androgenetic alopecia] Hoffmann R, et al. **Hautarzt** 1999 Mar;50(3):165–73 (71 ref.) (Eng. Abstr.) **(Ger)**
[Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances] Hinz B, et al. **Wien Klin Wochenschr** 1999 Feb 12;111(3):103–12 (91 ref.) (Eng. Abstr.) **(Ger)**
[Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity] Dammann HG. **Z Gastroenterol** 1999 Jan; 37(1):45–58 (129 ref.) (Eng. Abstr.) **(Ger)**
[Physiological and adaptive value of Na+,K+-ATPase isoenzymes] Kaplia AA. **Ukr Biokhim Zh** 1998 May–Jun; 70(3):3–11 (76 ref.) (Eng. Abstr.) **(Rus)**

ISOETRETIN see **ACITRETIN**

ISOFLAVONES

Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Messina M, et al. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):707–28 (109 ref.)

ADMINISTRATION & DOSAGE

Legumes and soybeans: overview of their nutritional profiles and health effects. Messina MJ. **Am J Clin Nutr** 1999 Sep; 70(3 Suppl):439S–450S (188 ref.)
Dietary isoflavones: biological effects and relevance to human health. Setchell KD, et al. **J Nutr** 1999 Mar; 129(3):758S–767S (148 ref.)
Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy? Scheiber MD, et al. **Menopause** 1999 Fall;6(3):233–41 (61 ref.)

METABOLISM

Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Lu LJ, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1500S–1504S (35 ref.)
Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Setchell KD, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1453S–1461S (86 ref.)
Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Setchell KD. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1333S–1346S (226 ref.)

PHARMACOLOGY

Effects of isoflavones on alcohol pharmacokinetics and alcohol-drinking behavior in rats. Lin RC, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1512S–1515S (10 ref.)

THERAPEUTIC USE

Soy protein, isoflavones and cardiovascular disease risk. Lichtenstein AH. **J Nutr** 1998 Oct;128(10):1589–92 (56 ref.)

ISOFLURANE

ANALOGS & DERIVATIVES

Desflurane and sevoflurane. New volatile anesthetic agents. Clarke KW. **Vet Clin North Am Small Anim Pract** 1999 May;29(3):793–810, viii (95 ref.)

ISOFORMS see **PROTEIN ISOFORMS**

ISOFOSFAMIDE see **IFOSFAMIDE**

ISOGRAFT see **TRANSPLANTATION, ISOGENEIC**

ISOHEMAGGLUTININS see **HEMAGGLUTININS**

ISOIMMUNIZATION, RHESUS see **RH ISOIMMUNIZATION**

ISOLATION PERFUSION THERAPY see **PERFUSION, REGIONAL**

ISOLATION, SOCIAL see **SOCIAL ISOLATION**

ISOLEUCINE

ANALYSIS

Occurrence and function of D-amino acid-containing peptides and proteins: antimicrobial peptides. Mignogna G, et al. **EXS** 1998;85:29–36 (26 ref.)

PHYSIOLOGY

Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. Olde Damink SW, et al. **Med Hypotheses** 1999 Jun;52(6):515–9 (37 ref.)

3-ISOLEUCYL VASOPRESSIN see **VASOTOCIN**

ISOMETRIC CONTRACTION

PHYSIOLOGY

Tonic stretch reflexes in older able-bodied people. Yeo W, et al. **Electromyogr Clin Neurophysiol** 1998 Jul–Aug; 38(5):273–8 (26 ref.)

ISOMETRIC EXERCISE see **EXERCISE**

ISONIAZID

ADVERSE EFFECTS

[Isoniazid-induced pneumonitis] Hatakeyama S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):448–52 (12 ref.) (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs [letter; comment] Richardson DR, et al. **J Lab Clin Med** 1998 Oct; 132(4):351–2 (8 ref.) Comment on: J Lab Clin Med 1998 Apr;131(4):290–1.
Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Richardson DR. **Leuk Lymphoma** 1998 Sep;31(1–2):47–60 (73 ref.)

PHARMACOKINETICS

Isoniazid drug and food interactions. Self TH, et al. **Am J Med Sci** 1999 May;317(5):304–11 (76 ref.)

PHARMACOLOGY

Mechanisms for isoniazid action and resistance. Miesel L, et al. **Novartis Found Symp** 1998;217:209–20; discussion 220–1 (25 ref.)
Interdependence of mycobacterial iron regulation, oxidative-stress response and isoniazid resistance. Dussurget O, et al. **Trends Microbiol** 1998 Sep;6(9):354–8 (34 ref.)

THERAPEUTIC USE

[Chemotherapy for tuberculosis; yesterday, today, and tomorrow--basic and clinical studies] Aoyagi T. **Kekkaku** 1998 Jul;73(7):459–70 (114 ref.) (Eng. Abstr.) **(Jpn)**

ISONICOTINIC ACID HYDRAZIDE see **ISONIAZID**

ISONIPECAIN see **MEPERIDINE**

ISONIPECOTIC ACIDS

THERAPEUTIC USE

Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Herrstedt J. **Dan Med Bull** 1998 Sep;45(4):412–22 (168 ref.)

ISOPHOSPHAMIDE see **IFOSFAMIDE**

ISOPRENALINE see **ISOPROTERENOL**

ISOPRENOID PHOSPHATES see **POLYISOPRENYL PHOSPHATES**

ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

ISOPROPYLARTERENOL see **ISOPROTERENOL**

N-ISOPROPYLATROPINE see **IPRATROPIUM**

ISOPROTERENOL

ADVERSE EFFECTS

Epidemiologic studies of beta agonists and asthma deaths. Pearce N, et al. **Epidemiol Rev** 1998;20(2):173–86 (75 ref.)

ISOPTERA

MICROBIOLOGY

Molecular phylogenetic identification of the intestinal anaerobic microbial community in the hindgut of the termite, Reticulitermes speratus, without cultivation. Kudo T, et al. **Extremophiles** 1998 Aug;2(3):155–61 (26 ref.)

ISOQUINOLINES

[New muscle relaxants] Suzuki F. **Masui** 1998 Dec;47 Suppl:S113–7 (13 ref.) **(Jpn)**

PHARMACOLOGY

[Ecteinascidin 743] Lansiaux A, et al. **Bull Cancer** 1999 Feb; 86(2):139–41 (13 ref.) **(Fre)**

THERAPEUTIC USE

Effect of treatment on survival in an animal model of chronic heart failure. Bastien N, et al. **Am J Cardiol** 1998 Nov 19; 82(10A):50S–52S (11 ref.)
Rationale for ACE inhibition as an anti-ischaemic therapy. Pepine CJ. **Eur Heart J** 1998 Jul;19 Suppl G:G34–40 (50 ref.)

ISOSORBIDE DINITRATE

ADVERSE EFFECTS

The 'vasovagal effect' of nitrates: an under-recognised complication of nitrate use. Lydakis C, et al. **Int J Clin Pract** 1998 Sep;52(6):418–21 (40 ref.)

ANALOGS & DERIVATIVES

Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris. Gunasekara

NS, et al. **Drugs** 1999 Feb;57(2):261–77 (53 ref.)
Long-acting isosorbide mononitrate [published erratum appears in Drugs 1999 Mar;57(3):438] Prakash A, et al. **Drugs** 1999 Jan;57(1):93–9; discussion 100 (24 ref.)

THERAPEUTIC USE

[The treatment of chronic fissure in ano with nitrate ointment (see comments)] Stassen LP, et al.
Ned Tijdschr Geneeskd 1999 Jan 2;143(1):13–6 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Feb 13;143(7):381. **(Dut)**

ISOSPORA

[Laboratory diagnosis of protozoan and parasitic infections. 1. Protozoan infections. e. Isospora and Cyclospora infections] Kimata. **Rinsho Byori** 1998 Nov;Suppl 108:198–203I (5 ref.) **(Jpn)**
[Isosporiasis (Isospora belli)] Kamiya H.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):431–3 (8 ref.) **(Jpn)**

ULTRASTRUCTURE

The fine structure of reptilian Isospora species with intranuclear endogenous development. Paperna I, et al. **Parassitologia** 1998 Sep;40(3):283–96 (28 ref.)

ISOTACHOPHORESIS see **ELECTROPHORESIS**

ISOTHIOCYANATES

ADMINISTRATION & DOSAGE

Dietary isothiocyanates as confounding factors in the molecular epidemiology of colon cancer [editorial; comment] Ketterer B.
Cancer Epidemiol Biomarkers Prev 1998 Aug;7(8):645–6 (17 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Aug;7(8):647–52.

PHARMACOLOGY

Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. Hecht SS. **J Nutr** 1999 Mar; 129(3):768S–774S (54 ref.)
Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death. Kong AN, et al. **Pharm Res** 1999 Jun;16(6):790–8 (122 ref.)

THERAPEUTIC USE

Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. Hecht SS. **J Nutr** 1999 Mar; 129(3):768S–774S (54 ref.)

ISOTONIC SOLUTIONS

Fluid and electrolyte replacement in soccer. Kirkendall DT. **Clin Sports Med** 1998 Oct;17(4):729–38, vi (23 ref.)

ISOTOPE LABELING

Deuterium isotope effects on noncovalent interactions between molecules. Wade D. **Chem Biol Interact** 1999 Feb 12;117(3):191–217 (79 ref.)
Protein metabolism in critical illness: methodologies and their problems underlying in kinetic studies using isotope tracers in vivo. Sakurai Y. **Keio J Med** 1999 Jun;48(2):69–78 (100 ref.)
Measuring the radioactivity of 2-D protein extracts. Link AJ, et al. **Methods Mol Biol** 1999;112:105–7 (1 ref.)
[Efficient synthesis of nucleosides labeled with stable isotopes and their application to structural biology] Kawashima E, et al. **Yakugaku Zasshi** 1999 May;119(5):299–318 (50 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Protocol development for biological tracer studies. Dueker SR, et al. **Adv Exp Med Biol** 1998;445:363–78 (32 ref.)
New approaches to structure determination by NMR spectroscopy. Dötsch V, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):619–23 (37 ref.)
Eukaryotic cell labeling and preparation for 2-D. Bizios N. **Methods Mol Biol** 1999;112:49–52 (5 ref.)
Double-label analysis. Lee KH, et al. **Methods Mol Biol** 1999; 112:291–5 (3 ref.)
[Antibody radiolabeling with technetium-99m] Perera A, et al. **Rev Esp Med Nucl** 1998;17(4):302–9 (63 ref.) (Eng. Abstr.) **(Spa)**

ISOTOPES

see related
RADIOISOTOPES
Recent developments in solid-state nuclear magnetic resonance of quadrupolar nuclei and applications to biological systems. Wu G. **Biochem Cell Biol** 1998; 76(2–3):429–42 (119 ref.)
The use of stable isotope techniques for nutritional and metabolic research in paediatrics. Koletzko B, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S77–97 (39 ref.)
Mechanism from isotope effects. Cook PF. **Isotopes Environ Health Stud** 1998;34(1–2):3–17 (19 ref.)
1999 Jonathan E. Rhoads lecture. Isotopic metaprobes, nutrition, and the roads ahead. Young VR, et al. **JPEN J Parenter Enteral Nutr** 1999 Jul–Aug;23(4):175–94 (134 ref.)
Martian stable isotopes: volatile evolution, climate change and exobiological implications. Jakosky BM. **Orig Life Evol Biosph** 1999 Jan;29(1):47–57 (45 ref.)
The Rudolf Schoenheimer Centenary Lecture. Isotopes in nutrition research. Young VR, et al. **Proc Nutr Soc** 1999 Feb;58(1):15–32 (162 ref.)
[New aspects is stable-isotope-assisted NMR techniques: application to be structural analysis of larger complexes between proteins and nucleic acids] Ohki S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):574–81 (56 ref.) **(Jpn)**

ANALYSIS

Plasma source mass spectrometry in experimental nutrition. Barnes RM. **Adv Exp Med Biol** 1998;445:379–96 (108 ref.)
Protocol development for biological tracer studies. Dueker SR, et al. **Adv Exp Med Biol** 1998;445:363–78 (32 ref.)
[Applications of stable isotopes in biomedical sciences] González A, et al. **Rev Med Univ Navarra** 1998 Apr–Jun; 42(2):69–76 (57 ref.) (Eng. Abstr.) **(Spa)**

ISOTRETINOIN

ADVERSE EFFECTS

Side effects of acne therapy and their management. Miller RA. **J Cutan Med Surg** 1998 May;2 Suppl 3:14–8 (13 ref.)

THERAPEUTIC USE

Management of adult acne and acne variants. Cunliffe WJ. **J Cutan Med Surg** 1998 May;2 Suppl 3:7–13 (53 ref.)

ISOTYPE SWITCHING see **IMMUNOGLOBULIN CLASS SWITCHING**

ISOXAZOLES

PHARMACOLOGY

Zonisamide: a new antiepileptic drug. Oommen KJ, et al. **Clin Neuropharmacol** 1999 Jul–Aug;22(4):192–200 (57 ref.)

THERAPEUTIC USE

On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Wallace CA. **Clin Exp Rheumatol** 1999 Jul–Aug;17(4):499–504 (40 ref.)
Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo JE, et al. **Neurosurgery** 1998 Dec;43(6):1409–17; discussion 1417–8 (95 ref.)
Clinical pharmacology and therapeutic drug monitoring of zonisamide. Mimaki T. **Ther Drug Monit** 1998 Dec; 20(6):593–7 (30 ref.)
Treatment advances in rheumatoid arthritis. Arriola ER, et al. **West J Med** 1999 May;170(5):278–81 (16 ref.)
[Insulin-sensitizing agents] Kadowaki T. **Nippon Rinsho** 1999 Mar;57(3):688–94 (14 ref.) (Eng. Abstr.) **(Jpn)**

ISOZYMES see **ISOENZYMES**

ISRADIPINE

METABOLISM

Measurement of [3H]PN200-110 and [125I]omega-conotoxin MVIIA binding. Hirota K, et al. **Methods Mol Biol** 1999; 114:149–61 (20 ref.)

ISS SCORE see **INJURY SEVERITY SCORE**

ITAI-ITAI see **CADMIUM POISONING**

ITCHING see **PRURITUS**

ITO SYNDROME see **PIGMENTATION DISORDERS**

ITRACONAZOLE

CHEMISTRY

Itraconazole in cyclodextrin solution. Stevens DA. **Pharmacotherapy** 1999 May;19(5):603–11 (64 ref.)

PHARMACOLOGY

Drug interactions with itraconazole, fluconazole, and terbinafine and their management. Gupta AK, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):237–49 (225 ref.)

THERAPEUTIC USE

How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data [see comments] Epstein E. **Arch Dermatol** 1998 Dec; 134(12):1551–4 (28 ref.) Comment in: Arch Dermatol 1999 Jul;135(7):852–3.
Optimisation of itraconazole therapy using target drug concentrations. Poirier JM, et al. **Clin Pharmacokinet** 1998 Dec;35(6):461–73 (59 ref.)
Safety of itraconazole in diabetic patients. Verspeelt J, et al. **Dermatology** 1999;198(4):382–4 (21 ref.)
Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections. Del Rosso JQ, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):497–502 (25 ref.)
Triazole therapy for mucocutaneous candidiasis in HIV-infected patients. Thomas CJ. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(3):36–44 (46 ref.)
Onychomycosis in diabetes. Management considerations. Albreski DA, et al. **Postgrad Med** 1999 Jul;Spec No:26–30 (26 ref.)
Itraconazole and terbinafine in perspective. From petri dish to patient. De Doncker P, et al. **Postgrad Med** 1999 Jul; Spec No:6–11 (19 ref.)
Management of tinea capitis. A status report. Del Rosso JQ, et al. **Postgrad Med** 1999 Jul;Spec No:38–45 (40 ref.)
Oral itraconazole therapy for superficial, subcutaneous, and systemic infections. A panoramic view. De Rosso JQ, et al. **Postgrad Med** 1999 Jul;Spec No:46–52 (63 ref.)
Management of onychomycosis in children. Gupta AK, et al. **Postgrad Med** 1999 Jul;Spec No:31–7 (54 ref.)

IUGR see **FETAL GROWTH RETARDATION**

IVERMECTIN

ANALOGS & DERIVATIVES

Production-based control of parasitic nematodes of cattle. Rew RS. **Int J Parasitol** 1999 Jan;29(1):177–82; discussion 183–4 (12 ref.)

ECONOMICS

Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. Amazigo U, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S23–31 (27 ref.)

POISONING

An overview of ivermectin toxicosis. Roder JD, et al. **Vet Hum Toxicol** 1998 Dec;40(6):369–70 (8 ref.)

SUPPLY & DISTRIBUTION

Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. Amazigo U, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S23–31 (27 ref.)
The Mectizan Donation Programme--a 10-year report. Dull HB, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S69–71 (0 ref.)
Mectizan as a stimulus for development of novel partnerships: the international organization's perspective. Etya'ale DE. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S73–7 (7 ref.)

THERAPEUTIC USE

Onchocercal eye disease and the impact of Mectizan treatment. Abiose A. **Ann Trop Med Parasitol** 1998 Apr, 92 Suppl 1:S11–22 (49 ref.)
The impact of Mectizan on the transmission of onchocerciasis. Boatin BA, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S46–60 (43 ref.)
Changes in the use profile of Mectizan: 1987–1997. Brown KR. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S61–4 (10 ref.)
A review of the use of a controlled-release formulation of ivermectin in the treatment and prophylaxis of Psoroptes ovis infestations in sheep. Forbes AB, et al. **Vet Parasitol** 1999 Jun 30;83(3–4):319–26 (21 ref.)

IVIG see **IMMUNOGLOBULINS, INTRAVENOUS**

IVY METHOD see **BLEEDING TIME**

IXODES

Tick paralysis: development of a vaccine. Masina S, et al. **Int J Parasitol** 1999 Apr;29(4):535–41 (38 ref.)

MICROBIOLOGY

Lyme disease and related tick-borne illnesses. Edlow JA. **Ann Emerg Med** 1999 Jun;33(6):680–93 (102 ref.)
Lyme borreliosis and emerging tick-borne diseases in Europe [editorial] Stanek G, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):847–9 (29 ref.)

PARASITOLOGY

[A review of the types of parasite-host relations in ixodid ticks] Berdyev AB. **Parazitologiia** 1998 Nov-Dec; 32(6):481–8 (30 ref.) (Eng. Abstr.) **(Rus)**

IXODES DAMMINI see **IXODES**

IXODES PERSULCATUS see **IXODES**

IXODES RICINUS

IXODES RICINUS see **IXODES**

IXODES SCAPULARIS see **IXODES**

J-POUCH see **PROCTOCOLECTOMY, RESTORATIVE**

JACKALS see **CARNIVORA**

JACKKNIFE SEIZURES see **SPASMS, INFANTILE**

JACKSONIAN SEIZURE see **EPILEPSY, PARTIAL**

JACOBSON'S ORGAN see **VOMERONASAL ORGAN**

JAGUARS see **CARNIVORA**

JAKOB-CREUTZFELDT SYNDROME see **CREUTZFELDT-JAKOB SYNDROME**

JALAPENO PEPPER see **CAPSICUM**

JANSKY-BIELSCHOWSKY DISEASE see **NEURONAL CEROID-LIPOFUSCINOSIS**

JAPANESE AMERICANS see **ASIAN AMERICANS**

JAPANESE QUAIL see **COTURNIX**

JAUNDICE

[Jaundice] Iakhontova OI, et al. **Klin Med (Mosk)** 1998; 76(10):59–64 (6 ref.) **(Rus)**

CHEMICALLY INDUCED

An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Brown MC. **Chemotherapy** 1999 Sep–Oct;45(5):392–5 (6 ref.)

Postmarketing surveillance: strengths and limitations. The flucloxacillin–dicloxacillin story. McNeil JJ, et al. **Med J Aust** 1999 Mar 15;170(6):270–3 (20 ref.)

EPIDEMIOLOGY

Serological diagnosis of jaundice epidemics in India. Prakash C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):497–502 (21 ref.)

ETIOLOGY

[A case of intense cytolysis following the administration of a hepatitis B vaccine (letter)] Lasheras Carbajo MD, et al. **Rev Clin Esp** 1999 Jan;199(1):49–50 (11 ref.) **(Spa)**

THERAPY

Palliation of pain and jaundice: an overview. Russell RC. **Ann Oncol** 1999;10 Suppl 4:165–9 (28 ref.)

VIROLOGY

Serological diagnosis of jaundice epidemics in India. Prakash C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):497–502 (21 ref.)

JAUNDICE, CHOLESTATIC see **CHOLESTASIS**

JAUNDICE, CHOLESTATIC, EXTRAHEPATIC see **BILE DUCT OBSTRUCTION, EXTRAHEPATIC**

JAUNDICE, CHOLESTATIC, INTRAHEPATIC see **CHOLESTASIS, INTRAHEPATIC**

JAUNDICE, CHRONIC IDIOPATHIC

GENETICS

[Molecular biology analysis: hereditary hemochromatosis, Wilson disease, alpha 1-antitrypsin deficiency and Dubin-Johnson syndrome] Arnold C. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1390–6 (28 ref.) (Eng. Abstr.) **(Ger)**

JAUNDICE, HEMOLYTIC see **ANEMIA, HEMOLYTIC**

JAUNDICE, MECHANICAL see **CHOLESTASIS**

JAUNDICE, NEONATAL

Neonatal jaundice. An update for family physicians. Kumar RK. **Aust Fam Physician** 1999 Jul;28(7):679–82 (12 ref.)

DIAGNOSIS

Guidelines for management of the jaundiced term and near-term infant. Johnson L, et al. **Clin Perinatol** 1998 Sep; 25(3):555–74, viii (104 ref.)

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1998 Aug;10(4):453–8 (40 ref.)

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1999 Aug;11(4):367–73 (45 ref.)

EPIDEMIOLOGY

[Progresses in the study of pediatrics] Chen X, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):899–900 (0 ref.) **(Chi)**

ETIOLOGY

Jaundice in the breastfed infant. Gartner LM, et al. **Clin Perinatol** 1999 Jun;26(2):431–45, vii (73 ref.)

Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency. Kaplan M, et al. **Clin Perinatol** 1998 Sep;25(3):575–90, viii (65 ref.)

NURSING

Hyperbilirubinemia in the healthy term newborn. Augustine MC. **Nurse Pract** 1999 Apr;24(4):24–6, 29–32, 34–6 passim; quiz 42–3 (30 ref.)

PHYSIOPATHOLOGY

[Physiopathology of neonatal hyperbilirubinemia] Vert P. **Arch Pediatr** 1998 Sep;5(9):1028–30 (9 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Guidelines for management of the jaundiced term and near-term infant. Johnson L, et al. **Clin Perinatol** 1998 Sep; 25(3):555–74, viii (104 ref.)

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1998 Aug;10(4):453–8 (40 ref.)

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1999 Aug;11(4):367–73 (45 ref.)

[Management of hyperbilirubinemia of the term newborn in maternity wards] Di Maio M, et al. **Arch Pediatr** 1998 Oct; 5(10):1156–61 (11 ref.) (Eng. Abstr.) **(Fre)**

[Severe neonatal jaundice. Definition and management] Labrune P. **Arch Pediatr** 1998 Oct;5(10):1162–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Forward. An update on jaundice in the newborn] Simeoni U. **Arch Pediatr** 1998 Sep;5(9):1025–7 (15 ref.) **(Fre)**

JAUNDICE, OBSTRUCTIVE see **CHOLESTASIS**

JAUNDICE, OBSTRUCTIVE, EXTRAHEPATIC see **BILE DUCT OBSTRUCTION, EXTRAHEPATIC**

JAUNDICE, OBSTRUCTIVE, INTRAHEPATIC see **CHOLESTASIS, INTRAHEPATIC**

JAW

see related
DENTAL ARCH
TEMPOROMANDIBULAR JOINT

ANATOMY & HISTOLOGY

[The coronal approach in maxillofacial surgery. Notes on the surgical anatomy] Salgarelli A, et al. **Minerva Chir** 1998 Jun;53(6):567–73 (19 ref.) (Eng. Abstr.) **(Ita)**

EMBRYOLOGY

[Molecular aspects of craniofacial development and evolution: morphogenesis of the jaw apparatus and lamprey embryology] Kuratani S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):226–33 (30 ref.) **(Jpn)**

PATHOLOGY

Jaws: diversities of gnathological history and temporomandibular joint enterprise. Nelson DA, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):141–7 (80 ref.)

PHYSIOPATHOLOGY

Jaws: diversities of gnathological history and temporomandibular joint enterprise. Nelson DA, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):141–7 (80 ref.)

SURGERY

Factors affecting heat generation during implant site preparation: a review of biologic observations and future considerations. Tehemar SH. **Int J Oral Maxillofac Implants** 1999 Jan–Feb;14(1):127–36 (86 ref.)

JAW ABNORMALITIES

PREVENTION & CONTROL

Cheilognathopalatoschisis and its prophylaxis in animal experiments. Malek FA, et al. **Anat Anz** 1999 Jan; 181(1):107–10 (43 ref.)

JAW CYSTS

PATHOLOGY

Stafne cyst in an anterior location. Apruzzese D, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):333–8 (49 ref.)

RADIOGRAPHY

So-called simple bone cyst of the jaw: a family of pseudocysts of diverse nature and etiology. Shimoyama T, et al. **J Oral Sci** 1999 Jun;41(2):93–8 (122 ref.)

JAW DISEASES

ETIOLOGY

Intraosseous fibrous lesions of the jaws: a manifestation of tuberous sclerosis. Damm DD, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):334–40 (21 ref.)

PHYSIOPATHOLOGY

Tremulous jaw movements in rats: a model of parkinsonian tremor. Salamone JD, et al. **Prog Neurobiol** 1998 Dec; 56(6):591–611 (190 ref.)

VETERINARY

Maxillofacial surgery. Marretta SM. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1285–96, viii (29 ref.)

JAW, EDENTULOUS

REHABILITATION

The effect of prosthodontic treatment on alveolar bone loss: a review of the literature. Wyatt CC. **J Prosthet Dent** 1998 Sep;80(3):362–6 (82 ref.)

JAW, EDENTULOUS, PARTIALLY

SURGERY

The periodontist and the edentulous area—localised ridge augmentation. Cho JY. **Int Dent J** 1998 Jun;48(3 Suppl 1):326–9 (17 ref.)

JAW FRACTURES

VETERINARY

Maxillofacial surgery. Marretta SM. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1285–96, viii (29 ref.)

JAW NEOPLASMS

Anatomic classification of intraosseous ameloblastoma as a guide to surgical management. Arotiba DT, et al. **East Afr Med J** 1998 Jul;75(7):406–10 (37 ref.)

DIAGNOSIS

Unicystic ameloblastoma. A review of 193 cases from the literature. Philipsen HP, et al. **Oral Oncol** 1998 Sep; 34(5):317–25 (50 ref.)

[Odontogenic tumors and neoplastic-like changes of the jaw bone. Clinical study and evaluation of treatment results] Stypułkowska J. **Folia Med Cracov** 1998;39(1–2):35–141 (227 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Mesenchymal chondrosarcoma of the jaws. Report of four cases. Lockhart R, et al. **Int J Oral Maxillofac Surg** 1998 Oct;27(5):358–62 (13 ref.)

THERAPY

[Odontogenic tumors and neoplastic-like changes of the jaw bone. Clinical study and evaluation of treatment results] Stypułkowska J. **Folia Med Cracov** 1998;39(1–2):35–141 (227 ref.) (Eng. Abstr.) **(Pol)**

JAW RELATION RECORD

INSTRUMENTATION

Condylar axis position, as determined by the occlusion and measured by the CPI instrument, and signs and symptoms of temporomandibular dysfunction. Crawford SD. **Angle Orthod** 1999 Apr;69(2):103–15; discussion 115–6 (64 ref.)

JC VIRUS see **POLYOMAVIRUS HOMINIS 2**

JCAHO see **JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS**

JE PROTEIN see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

JEALOUSY

The dangerousness of persons with delusional jealousy. Silva AJ, et al. **J Am Acad Psychiatry Law** 1998;26(4):607–23 (66 ref.)

Jealousy and mutilation: nose-biting as retribution for adultery. Okimura JT, et al. **Lancet** 1998 Dec 19–26; 352(9145):2010–1 (21 ref.)

JEHOVAH'S WITNESSES see **CHRISTIANITY**

JEJUNAL DISEASES

Carcinoma in jejunal pancreatic heterotopia. Makhlouf HR, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):707–11 (30 ref.)

[Acquired jejunal and ileal diverticula (Meckel's excluded)] Huguenin A, et al. **Ann Chir** 1999;53(6):522–6 (28 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Medical and hormonal therapy in occult gastrointestinal bleeding. Lewis BS. **Semin Gastrointest Dis** 1999 Apr; 10(2):71–7 (49 ref.)

SURGERY

Type IV thoraco-abdominal aortic aneurysm complicated by an aorto-enteric fistula due to previous infrarenal aortic graft. Karacagil S, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):268–70 (9 ref.)

JEJUNAL NEOPLASMS

[Jejunal adenocarcinoma: case report and review of the literature] Tommasi GV, et al. **G Chir** 1999 Mar;20(3):94–6 (13 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Aggressive bowel lymphoma in a patient with intestinal lymphangiectasia and widespread viral warts [letter] Gumà J, et al. **Ann Oncol** 1998 Dec;9(12):1355–6 (6 ref.)

DIAGNOSIS

Abdominal pain in a patient with melanoma. Datner EM, et al. **Dermatol Surg** 1998 Oct;24(10):1100–2 (19 ref.)

[Primary jejunal carcinoma] Rosenbaum A, et al. **Dtsch Med Wochenschr** 1998 Nov 13;123(46):1385–8 (34 ref.) **(Ger)**

[Jejunal carcinoma: apropos 8 cases] Boselli AS, et al. **Acta Biomed Ateneo Parmense** 1996;67(5–6):165–71 (31 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[Metastasized carcinoid tumor treated with interferon and octreotide] Szilvás A, et al. **Orv Hetil** 1998 Oct 11; 139(41):2455–8 (41 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Carcinoma in jejunal pancreatic heterotopia. Makhlouf HR, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):707–11 (30 ref.)

Malignant hemangioendothelioma of the small intestine: report of a case. Yoshida R, et al. **Surg Today** 1999; 29(5):439–42 (15 ref.)

[A case of triple cancers with gastric, jejunal and colonic cancers] Nanba M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):953–8 (22 ref.) **(Jpn)**

SECONDARY

Abdominal pain in a patient with melanoma. Datner EM, et al. **Dermatol Surg** 1998 Oct;24(10):1100–2 (19 ref.)

JEJUNOSTOMY

Role of PEG/PEJ in enteral feeding. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):699–701 (33 ref.)

Jejunostomy: techniques, indications, and complications. Tapia J, et al. **World J Surg** 1999 Jun;23(6):596–602 (50 ref.)

INSTRUMENTATION

Use of gastrostomy and combined gastrojejunostomy tubes for enteral feeding. Faries MB, et al. **World J Surg** 1999 Jun;23(6):603–7 (22 ref.)

JEJUNUM

see related
JEJUNOSTOMY

Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. Corpechot C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2586–8 (11 ref.)

The Rapunzel syndrome (trichobezoar) causing atypical intussusception in a child: a case report. Dalshaug GB, et al. **J Pediatr Surg** 1999 Mar;34(3):479–80 (14 ref.)

BLOOD SUPPLY

Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. Hassan HA. **J Clin Gastroenterol** 1999 Jul;29(1):90–5 (54 ref.)

METABOLISM

Immunohistochemical findings in the jejunal mucosa of patients with coeliac disease. Arató A, et al. **Scand J Gastroenterol Suppl** 1998;228:3–10 (81 ref.)

PATHOLOGY

Small-bowel necrosis associated with jejunal tube feeding. Lawlor DK, et al. **Can J Surg** 1998 Dec;41(6):459–62 (15 ref.)

SURGERY

[Intestinal pouches: gastric reconstruction] Schuhmacher C, et al. **Chirurg** 1999 May;70(5):520–9 (47 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

[Stomach carcinoma. Optimizing therapy by stomach replacement or subtotal resection?] Meyer HJ, et al. **Zentralbl Chir** 1999;124(5):381–6 (25 ref.) (Eng. Abstr.) **(Ger)**

JELLYFISH

Dangers in the ocean: the traveler and marine envenomation. I. jellyfish. Fenner PJ. **J Travel Med** 1998 Sep;5(3):135–41 (18 ref.)

JERBOAS see **RODENTIA**

JERVELL-LANGE NIELSEN SYNDROME see **LONG QT SYNDROME**

JEWS

see related
JUDAISM

GENETICS

Clinical-genetic spectrum of primary dystonia. Bressman SB, et al. **Adv Neurol** 1998;78:79–91 (43 ref.)

Fanconi anemia: genetic testing in Ashkenazi Jews. Auerbach AD. **Genet Test** 1997;1(1):27–33 (38 ref.)

Establishing criteria for a carrier detection panel: lessons from the Ashkenazi Jewish model. Gilbert F. **Genet Test** 1998;2(4):301–4 (23 ref.)

Tay-Sachs disease carrier screening: a model for prevention of genetic disease. Kaplan F. **Genet Test** 1998;2(4):271–92 (192 ref.)

Cystic fibrosis in Jews: frequency and mutation distribution. Kerem B, et al. **Genet Test** 1997;1(1):35–9 (35 ref.)

JIMSONWEED see **STRAMONIUM**

JOB DESCRIPTION

Evolving competence in the practitioner role. Youngstrom MJ. **Am J Occup Ther** 1998 Oct;52(9):716–20 (10 ref.)

The psychiatric clinical nurse specialist/nurse practitioner: an example of a combined role [comment] Cukr PL, et al. **Arch Psychiatr Nurs** 1998 Dec;12(6):311–8 (34 ref.) Comment on: Arch Psychiatr Nurs 1997 Feb;11(1):2–12.

Psychiatric nurse practitioner versus clinical nurse specialist: moving from debate to action on the future of advanced psychiatric nursing. McCabe S, et al. **Arch Psychiatr Nurs** 1999 Jun;13(3):111–6 (9 ref.)

Linking public health education and practice: the Australian experience. Rotem A, et al. **Asia Pac J Public Health** 1998; 10(1):17–20 (10 ref.)

Developing successful performance appraisals through choosing appropriate words to effectively describe work. Timmreck TC. **Health Care Manage Rev** 1998 Summer; 23(3):48–57 (14 ref.)

Trends in community care and patient participation: implications for the roles of informal carers and community nurses in the United Kingdom. Kirk S, et al. **J Adv Nurs** 1998 Aug;28(2):370–81 (114 ref.)

Health promotion and health education: what role should the nurse adopt in practice? Norton L. **J Adv Nurs** 1998 Dec;28(6):1269–75 (32 ref.)

Career opportunities for neonatal nurses. Kenner C, et al. **J Pediatr Nurs** 1998 Oct;13(5):317–25 (30 ref.)

Optimizing the roles of school mental health professionals. Flaherty LT, et al. **J Sch Health** 1998 Dec;68(10):420–4 (34 ref.)

The school nurse's role in homeopathic interventions. Selekman J, et al. **J Sch Health** 1998 Oct;68(8):342–5 (7 ref.)

Community health nursing practice and the Roy Adaptation Model. Dixon EL. **Public Health Nurs** 1999 Aug; 16(4):290–300 (35 ref.)

JOB LADDERS see **CAREER MOBILITY**

JOB SATISFACTION

A job-satisfaction measure for internal medicine residency program directors. Beasley BW, et al. **Acad Med** 1999 Mar; 74(3):263–70 (14 ref.)

[Workload and stress in caring for the elderly: status of research and research agenda] Zimber A. **Z Gerontol Geriatr** 1998 Dec;31(6):417–25 (78 ref.) (Eng. Abstr.) **(Ger)**

JOB'S SYNDROME

[Hyperglobulinemia E syndrome with recurrent infections (Job's syndrome)] Moneret-Vautrin DA, et al. **Rev Med Interne** 1999 Feb;20(2):133–40 (67 ref.) (Eng. Abstr.) **(Fre)**

[Job's syndrome] Asano Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):76–8 (15 ref.) **(Jpn)**

[Job's syndrome (hyperimmunoglobulin E and recurrent infection syndrome)] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):261–3 (14 ref.) **(Jpn)**

IMMUNOLOGY

[Rare hyperimmunoglobulinemia E syndromes] Katchourine I, et al. **Rev Med Interne** 1998 Mar;19(3):185–91 (29 ref.) (Eng. Abstr.) **(Fre)**

JOHNE'S DISEASE see **PARATUBERCULOSIS**

JOINING REGION, IG see **IMMUNOGLOBULIN JOINING REGION**

JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS

Joint Commission on Accreditation of Healthcare Organizations' expectations for transfusion medicine in health care organizations. Belanger AC. **Arch Pathol Lab Med** 1999 Jun;123(6):472–4 (3 ref.)

JOINT COMMISSION ON ACCREDITATION OF HOSPITALS see **JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS**

JOINT DEFORMITIES, ACQUIRED

SURGERY

Total wrist arthroplasty. Carlson JR, et al. **J Am Acad Orthop Surg** 1998 Sep-Oct;6(5):308–15 (28 ref.)

JOINT DISEASES

The Bone and Joint Decade 2000–2010. Inaugural meeting 17 and 18 April 1998, Lund, Sweden. Björklund L. **Acta Orthop Scand Suppl** 1998 Jun;281:67–80 (0 ref.)

CLASSIFICATION

Patellofemoral disorders: a classification system and clinical guidelines for nonoperative rehabilitation. Wilk KE, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):307–22 (139 ref.)

COMPLICATIONS

Acute anterior uveitis and spondyloarthropathies. Feltkamp TE, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):314–8 (50 ref.)

DIAGNOSIS

The importance of arthroscopy in diagnosing synovial haemangioma of the knee joint. Farkas C, et al. **Acta Chir Hung** 1998;37(1–2):17–22 (22 ref.)

Monoarticular synovial lesions: radiologic pictorial essay with pathologic illustration. Wong K, et al. **Clin Radiol** 1999 May;54(5):273–84 (24 ref.)

Physical and arthroscopic examination techniques of the patellofemoral joint. Nissen CW, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):277–85 (46 ref.)

Physical examination of the elbow. Colman WW, et al. **Orthop Clin North Am** 1999 Jan;30(1):15–20 (5 ref.)

Imaging of elbow disorders. Miller TT. **Orthop Clin North Am** 1999 Jan;30(1):21–36 (78 ref.)

Elbow arthroscopy in trauma and reconstruction. Moskal MJ, et al. **Orthop Clin North Am** 1999 Jan;30(1):163–77 (69 ref.)

Psoriatic arthritis. Gladman DD. **Rheum Dis Clin North Am** 1998 Nov;24(4):829–44, x (81 ref.)

Disorders of the hallux sesamoid complex: MR features. Karasick D, et al. **Skeletal Radiol** 1998 Aug;27(8):411–8 (30 ref.)

[Shoulder complaints in family practice; a simple approach (see comments)] Winters JC, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1241–4 (16 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32:1832. Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32:1832–3. **(Dut)**

JOINT DISEASES

[Hip pain: diagnostic direction] Revel M, et al. **Rev Prat** 1998 Jun 1;48(11):1243–8 (0 ref.) **(Fre)**

[Overview of the current status of measurable parameters of cartilage metabolism in various body fluids] Ettrich U, et al. **Z Rheumatol** 1998 Dec;57(6):375–91 (139 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Parnham MJ. **Biochem Pharmacol** 1999 Jul 15;58(2):209–15 (61 ref.)

Topical NSAIDs for musculoskeletal conditions. A review of the literature. Vaile JH, et al. **Drugs** 1998 Nov; 56(5):783–99 (95 ref.)

[Pharma-clinics. The drug of the month. Aceclofenac (Biofenac)] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):62–4 (10 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Bowel inflammation and the spondyloarthropathies. De Keyser F, et al. **Rheum Dis Clin North Am** 1998 Nov; 24(4):785–813, ix–x (146 ref.)

ETIOLOGY

Common orthopaedic problems in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:53–60 (16 ref.)

Loss of extension after reconstruction of the anterior cruciate ligament. Petsche TS, et al. **J Am Acad Orthop Surg** 1999 Mar–Apr;7(2):119–27 (31 ref.)

Pathogenesis of joint damage in rheumatoid arthritis. Bresnihan B. **J Rheumatol** 1999 Mar;26(3):717–9 (24 ref.)

Limited joint mobility in diabetes. Aljahlan M, et al. **Postgrad Med** 1999 Feb;105(2):99–101, 105–6 (20 ref.)

[Bone and joint manifestations of sickle cell anemia] Hernigou P. **Acta Orthop Belg** 1999;65 Suppl 1:9–16 (28 ref.) **(Fre)**

[The articular damage of hemochromatosis. A little known aspect] Biasi D, et al. **Recenti Prog Med** 1999 Apr; 90(4):226–30 (22 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Synovial actinomycosis of the hip: case report and review. Dom K, et al. **Acta Orthop Belg** 1999 Jun;65(2):242–4 (5 ref.)

Bone and joint manifestations of systemic infectious diseases. Kosinski M, et al. **Clin Podiatr Med Surg** 1998 Oct; 15(4):673–86, vi (48 ref.)

PHYSIOPATHOLOGY

HLA-B27 and other predisposing factors in spondyloarthropathies. Khare SD, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):282–91 (73 ref.)

Common orthopaedic problems in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:53–60 (16 ref.)

The biomechanics of the patellofemoral joint. Grelsamer RP, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):286–98 (91 ref.)

RADIOGRAPHY

Radiologic diagnosis and pathology of the spondyloarthropathies. Braun J, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):697–735 (178 ref.)

Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors. Brien EW, et al. **Skeletal Radiol** 1999 Jan; 28(1):1–20 (32 ref.)

REHABILITATION

Proprioceptive training in haemophilia. Buzzard BM. **Haemophilia** 1998 Jul;4(4):528–31 (14 ref.)

Arthroplasty of the hand and wrist: therapist's commentary [comment] Michlovitz S. **J Hand Ther** 1999 Apr–Jun; 12(2):133–4 (8 ref.) Comment on: J Hand Ther 1999 Apr–Jun;12(2):123–32.

The biomechanics of the patellofemoral joint. Grelsamer RP, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):286–98 (91 ref.)

Rehabilitation of patellofemoral joint disorders: a critical review. Powers CM. **J Orthop Sports Phys Ther** 1998 Nov; 28(5):345–54 (67 ref.)

Patellofemoral disorders: a classification system and clinical guidelines for nonoperative rehabilitation. Wilk KE, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):307–22 (139 ref.)

[Apparatus and devices for local cryotherapy in joint diseases] Suzdal'nitskil DV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jul–Aug;(4):51–4 (70 ref.) **(Rus)**

SURGERY

Arthroscopy of the elbow. Baker CL Jr, et al. **Am J Sports Med** 1999 Mar–Apr;27(2):251–64 (77 ref.)

Operative arthroscopy into the next century. Miller GK. **Compr Ther** 1998 Aug;24(8):383–7 (7 ref.)

Arthroscopy of the great toe. Frey C, et al. **Instr Course Lect** 1999;48:343–6 (4 ref.)

Arthroscopic treatment of posterior elbow impingement. Moskal MJ, et al. **Instr Course Lect** 1999;48:399–404 (31 ref.)

Key developments in knee surgery. Isdale A, et al. **Practitioner** 1998 Nov;242(1592):777–80, 784 (10 ref.)

[Is panarthrodesis the gold standard in wrist joint surgery?] Nagy L, et al. **Handchir Mikrochir Plast Chir** 1998 Sep; 30(5):291–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Abrasion arthroplasty] Goymann V. **Orthopade** 1999 Jan; 28(1):11–8 (57 ref.) (Eng. Abstr.) **(Ger)**

[Autologous osteochondral transplantation on various joints] Imhoff AB, et al. **Orthopade** 1999 Jan;28(1):33–44 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Chiropractic intervention in the treatment of joint and soft tissue disorders. Crawford JP. **Can J Appl Physiol** 1999 Jun;24(3):279–89 (66 ref.)

From heel to toe. Stephens MM. **Ir J Med Sci** 1999 Apr–Jun; 168(2):127–32 (16 ref.)

Prognosis, course of disease, and treatment of the spondyloarthropathies. Leirisalo-Repo M. **Rheum Dis Clin North Am** 1998 Nov;24(4):737–51, viii (81 ref.)

ULTRASONOGRAPHY

Applications of musculoskeletal sonography. Hashimoto BE, et al. **J Clin Ultrasound** 1999 Jul–Aug;27(6):293–318 (153 ref.)

Ultrasound in inflammatory disease. Gibbon WW, et al. **Radiol Clin North Am** 1999 Jul;37(4):633–51 (72 ref.)

Joint sonography. Wang SC, et al. **Radiol Clin North Am** 1999 Jul;37(4):653–68 (75 ref.)

VETERINARY

The elbow. Reichle JK, et al. **Clin Tech Small Anim Pract** 1999 Aug;14(3):177–86 (37 ref.)

JOINT INSTABILITY

Shoulder instability in young athletes. Mahaffey BL, et al. **Am Fam Physician** 1999 May 15;59(10):2773–82, 2787 (24 ref.)

Chronic elbow instability. Lee ML, et al. **Orthop Clin North Am** 1999 Jan;30(1):81–9 (30 ref.)

CLASSIFICATION

Joint hypermobility and genetic collagen disorders: are they related? Grahame R. **Arch Dis Child** 1999 Feb;80(2):188–91 (29 ref.)

DIAGNOSIS

Glenohumeral instability: evaluation using MR arthrography of the shoulder. Shankman S, et al. **Skeletal Radiol** 1999 Jul;28(7):365–82 (35 ref.)

[Useful imaging data before intervention for an unstable shoulder] Dumontier C, et al. **Ann Radiol (Paris)** 1997; 40(3):153–65 (47 ref.) (Eng. Abstr.) **(Fre)**

[Lesions of the glenoid labrum] Setbon S, et al. **Ann Radiol (Paris)** 1997;40(3):166–75 (24 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pathogenesis of anterior knee pain syndrome and functional patellofemoral instability in the active young. Sanchis-Alfonso V, et al. **Am J Knee Surg** 1999 Winter; 12(1):29–40 (43 ref.)

Aneurysms and hypermobility in a 45-year-old woman. Santos-Ocampo AS, et al. **Cleve Clin J Med** 1999 Jul–Aug; 66(7):426–33 (38 ref.)

[Chronic recurrent ligament instability on the lateral ankle] Becker HP, et al. **Orthopade** 1999 Jun;28(6):483–92 (43 ref.) (Eng. Abstr.) **(Ger)**

[Management of old neglected posttraumatic acromioclavicular joint instability and arthrosis] Hedtmann A, et al. **Orthopade** 1998 Aug;27(8):556–66 (60 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

Open surgical treatment of anterior glenohumeral instability: an historical perspective and review of the literature. Part II. Rokito AS, et al. **Am J Orthop** 1998 Dec;27(12):784–90 (60 ref.)

Open surgical treatment of anterior glenohumeral instability: an historical perspective and review of the literature. Part I. Rokito AS, et al. **Am J Orthop** 1998 Nov;27(11):723–5 (0 ref.)

PHYSIOPATHOLOGY

The conflicting requirements of laxity and conformity in total knee replacement. Sathasivam S, et al. **J Biomech** 1999 Mar; 32(3):239–47 (24 ref.)

Dysafferentation: a novel term to describe the neuropathologic effects of joint complex dysfunction--a look at likely mechanisms of symptom generation [letter; comment] Knutson GA. **J Manipulative Physiol Ther** 1999 Jan;22(1):45–8 (21 ref.) Comment on: J Manipulative Physiol Ther 1998 May;21(4):267–80.

Biomechanics of the unstable ankle joint and clinical implications. Hintermann B. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S459–69 (115 ref.)

PREVENTION & CONTROL

The effect of ankle bracing on athletic performance. Bot SD, et al. **Sports Med** 1999 Mar;27(3):171–8 (54 ref.)

RADIOGRAPHY

Is stress radiography necessary in the diagnosis of acute or chronic ankle instability? Frost SC, et al. **Clin J Sport Med** 1999 Jan;9(1):40–5 (37 ref.)

REHABILITATION

Dysafferentation: a novel term to describe the neuropathologic effects of joint complex dysfunction--a look at likely mechanisms of symptom generation [letter; comment] Knutson GA. **J Manipulative Physiol Ther** 1999 Jan;22(1):45–8 (21 ref.) Comment on: J Manipulative Physiol Ther 1998 May;21(4):267–80.

SURGERY

Occipito-cervical fusion with the cervical Cotrel-Dubousset rod system. Heidecke V, et al. **Acta Neurochir (Wien)** 1998; 140(9):969–76 (31 ref.)

Medial collateral ligament instability and ulnar neuritis in the athlete's elbow. Ciccotti MG, et al. **Instr Course Lect** 1999;48:383–91 (36 ref.)

Medial epicondylar osteotomy: a technique used with primary and revision total knee arthroplasty to improve surgical exposure and correct varus deformity. Engh GA. **Instr Course Lect** 1999;48:153–6 (1 ref.)

Surgical treatment of the unstable ankle. Colville MR. **J Am Acad Orthop Surg** 1998 Nov–Dec;6(6):368–77 (26 ref.)

Revision anterior cruciate ligament reconstruction surgery. Getelman MH, et al. **J Am Acad Orthop Surg** 1999 May–Jun;7(3):189–98 (30 ref.)

The carpus: surgeon's perspective. Weiss AP. **J Hand Ther** 1999 Apr–Jun;12(2):103–7 (24 ref.)

Shoulder instability. Review of current trends in treatment. Norlin R, et al. **Scand J Med Sci Sports** 1998 Dec;8(6):394–7 (14 ref.)

[Injuries of the knee ligaments. II. Surgical therapy of anterior and posterior knee instability] Lobenhoffer P. **Chirurg** 1999 Mar;70(3):326–38 (0 ref.) **(Ger)**

[Instability of the distal radio-ulnar joint] Nagy L. **Handchir Mikrochir Plast Chir** 1998 Nov;30(6):361–9 (40 ref.) (Eng. Abstr.) **(Ger)**

[Effect of a crosslink or cerclage on the mechanical stability of an internal fixator] Bastian L, et al. **Orthopade** 1999 Aug; 28(8):714–22 (37 ref.) (Eng. Abstr.) **(Ger)**

[Results of posterior inferior capsular shift in posterior shoulder instability] Jerosch J, et al. **Unfallchirurg** 1998 Oct; 101(10):755–61 (39 ref.) (Eng. Abstr.) **(Ger)**

[The semitendinosus tendon as replacement for the anterior cruciate ligament] Hoffmann F, et al. **Zentralbl Chir** 1998; 123(9):994–1001 (48 ref.) (Eng. Abstr.) **(Ger)**

[Significance of combined anterior cruciate ligament and meniscus injury] Metak G, et al. **Zentralbl Chir** 1999; 124(7):646–52 (64 ref.) (Eng. Abstr.) **(Ger)**

[Anterior cruciate ligament-plasty and high valgus tibial osteotomy as a combined procedure in anterior instability and varus deviation] Roscher E, et al. **Zentralbl Chir** 1998; 123(9):1019–26 (42 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Arthroscopic shoulder stabilization. Differentiated treatment strategy with Suretac, Fastak, Holmium: YAG-laser and electrosurgery] Imhoff AB, et al. **Orthopade** 1998 Aug; 27(8):518–31 (114 ref.) (Eng. Abstr.) **(Ger)**

JOINT LOOSE BODIES

ULTRASONOGRAPHY

Detection of loose bodies in joints. Bianchi S, et al. **Radiol Clin North Am** 1999 Jul;37(4):679–90 (25 ref.)

JOINT PAIN see **ARTHRALGIA**

JOINT PROSTHESIS

see related
ARTHROPLASTY, REPLACEMENT

Titanium alloys in total joint replacement--a materials science perspective. Long M, et al. **Biomaterials** 1998 Sep; 19(18):1621–39 (146 ref.)

Total ankle arthroplasty: state of the art. Saltzman CL. **Instr Course Lect** 1999;48:263–8 (24 ref.)

Total wrist arthroplasty. Carlson JR, et al. **J Am Acad Orthop Surg** 1998 Sep–Oct;6(5):308–15 (28 ref.)

Reconstruction of the temporomandibular joint using calvarial bone after a failed Teflon-Proplast implant. Lee JJ, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):457–61 (14 ref.)

Posttraumatic elbow arthritis and arthroplasty. Lee DH. **Orthop Clin North Am** 1999 Jan;30(1):141–62 (115 ref.)

Which replacement joint should your patient have? Bulstrode C. **Practitioner** 1998 Nov;242(1592):752, 756, 761 passim

(4 ref.)
A review of metallic, ceramic and surface-treated metals used for bearing surfaces in human joint replacements. Dearnley PA. **Proc Inst Mech Eng [H]** 1999;213(2):107-35 (87 ref.)
[Materials for joint replacement and friction and wear] Wang C, et al.
Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih 1997 Mar; 14(1):64-7 (17 ref.) (Eng. Abstr.) **(Chi)**
[Prosthesis of the upper extremity] Rozing PM.
Ned Tijdschr Geneeskd 1998 May 30;142(22):1256-61 (12 ref.) (Eng. Abstr.) **(Dut)**

ADVERSE EFFECTS

[The artificial joint in the biological environment] Shchepëtkin IA, et al. **Usp Fiziol Nauk** 1998 Jul-Sep; 29(3):105-29 (100 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

[New materials improve joint prostheses. Metals, polymers, ceramics and composite materials extend the durability] Carlsson L, et al. **Lakartidningen** 1999 May 19; 96(20):2458-60, 2463-7 (20 ref.) (Eng. Abstr.) **(Swe)**

JOINT PROSTHESIS IMPLANTATION see **ARTHROPLASTY, REPLACEMENT**

JOINT TUBERCULOSIS see **TUBERCULOSIS, OSTEOARTICULAR**

JOINT VENTURES, HOSPITAL-PHYSICIAN see **HOSPITAL-PHYSICIAN JOINT VENTURES**

JOINTS

see related
ARTHROGRAPHY
ARTHROPLASTY
ARTHROSCOPY

ABNORMALITIES

Arthrogryposis multiplex congenita. Gordon N.
Brain Dev 1998 Oct;20(7):507-11 (37 ref.)

EMBRYOLOGY

BMP/GDF-signalling interactions during synovial joint development. Francis-West PH, et al. **Cell Tissue Res** 1999 Apr;296(1):111-9 (81 ref.)

INJURIES

Techniques for MR imaging of joints in sports medicine. Zlatkin MB. **Magn Reson Imaging Clin N Am** 1999 Feb; 7(1):1-21, vii (103 ref.)
Magnetic resonance imaging of chondral and osteochondral injuries. Rubin DA. **Top Magn Reson Imaging** 1998 Dec; 9(6):348-59 (88 ref.)

INNERVATION

The role of joint innervation in the pathogenesis of arthritis. Salo P. **Can J Surg** 1999 Apr;42(2):91-100 (82 ref.)

METABOLISM

The role of crystals in osteoarthritis. Ryan LM, et al.
Rheum Dis Clin North Am 1999 May;25(2):257-67 (55 ref.)

PATHOLOGY

The role of arthroscopy in early arthritis [editorial] Veale DJ. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):37-8 (14 ref.)
Pathogenesis of joint damage in rheumatoid arthritis. Bresnihan B. **J Rheumatol** 1999 Mar;26(3):717-9 (24 ref.)
Pathophysiology of osteoarthritis. Martel-Pelletier J.
Osteoarthritis Cartilage 1998 Nov;6(6):374-6 (16 ref.)

PHYSIOLOGY

Hyaluronan in joint cavitation. Ward AC, et al.
Biochem Soc Trans 1999 Feb;27(2):128-35 (48 ref.)
Age-related physiological alterations to muscles and joints and potential exercise interventions for their improvement. Bemben MG. **J Okla State Med Assoc** 1999 Jan;92(1):13-20 (57 ref.)

PHYSIOPATHOLOGY

Juvenile arthritis with oligoarticular onset. Pelkonen PM.
Baillieres Clin Rheumatol 1998 May;12(2):273-86 (47 ref.)
Can an anomalous lumbo-sacral or lumbo-iliac articulation cause low back pain? A retrospective study of 12 cases. Avimadje M, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):35-9 (6 ref.)

RADIONUCLIDE IMAGING

The clinical role of nuclear medicine in rheumatoid arthritis patients. A comparison with other diagnostic imaging modalities. Vos K, et al. **Q J Nucl Med** 1999 Mar; 43(1):38-45 (74 ref.)

SURGERY

Determining surgical priorities in rheumatoid arthritis. Alexiades MM. **Compr Ther** 1999 Feb;25(2):101-8 (36 ref.)

ULTRASONOGRAPHY

Joint sonography. Wang SC, et al. **Radiol Clin North Am** 1999 Jul;37(4):653-68 (75 ref.)

JOSAMYCIN

THERAPEUTIC USE

[Rokitamycin in the treatment of female genital Chlamydia and Mycoplasma infections. Comparative study vs josamycin] Colombo U, et al. **Minerva Ginecol** 1998 Nov; 50(11):491-7 (26 ref.) (Eng. Abstr.) **(Ita)**

JOSEPH AZOREAN DISEASE see **MACHADO-JOSEPH DISEASE**

JOSEPH DISEASE see **MACHADO-JOSEPH DISEASE**

JOURNALISM

Public trust and accountability for clinical performance: lessons from the national press reportage of the Bristol hearing [see comments] Davies HT, et al.
J Eval Clin Pract 1999 Aug;5(3):335-42 (28 ref.) Comment in: J Eval Clin Pract 1999 Aug;5(3):343-6.

JOURNALISM, MEDICAL

Managing/understanding chronic disease: a call for papers. Wilkes MS, et al. **West J Med** 1999 Jun;170(6):326-7 (6 ref.)

STANDARDS

Overviews of respiratory rehabilitation in chronic obstructive pulmonary disease. Lacasse Y, et al.
Monaldi Arch Chest Dis 1999 Apr;54(2):163-7 (33 ref.)
Your research: how to get it on paper and in print [see comments] Griscom NT. **Pediatr Radiol** 1999 Feb; 29(2):81-6 (12 ref.) Comment in: Pediatr Radiol 1999 Feb;29(2):79.

JOURNALS see **PERIODICALS**

JUDAISM

see related
JEWS

Childbirth customs in Orthodox Jewish traditions. Bodo K, et al. **Can Fam Physician** 1999 Mar;45:682-6 (11 ref.)
The doctrine of informed consent: a tale of two cultures and two legal traditions. Walter P. **Issues Law Med** 1999 Spring; 14(4):357-73 (53 ref.)
Relief of breast engorgement for the Sabbath-observant Jewish woman. Chertok I.
J Obstet Gynecol Neonatal Nurs 1999 Jul-Aug;28(4):365-9 (13 ref.)

JUDGMENT

Catching the wave: understanding the concept of critical thinking. Boychuk Duchscher JE. **J Adv Nurs** 1999 Mar; 29(3):577-83 (46 ref.)
Insight in severe mental illness: implications for treatment decisions. Husted JR. **J Am Acad Psychiatry Law** 1999; 27(1):33-49 (33 ref.)
Fuzzy-trace theory and children's false memories [see comments] Brainerd CJ, et al. **J Exp Child Psychol** 1998 Nov;71(2):81-129 (105 ref.) Comment in: J Exp Child Psychol 1998 Nov;71(2):130-43. Comment in: J Exp Child Psychol 1998 Nov;71(2):144-54. Comment in: J Exp Child Psychol 1998 Nov;71(2):155-64. Comment in: J Exp Child Psychol 1998 Nov;71(2):165-9. Comment in: J Exp Child Psychol 1998 Nov;71(2):170-7. Comment in: J Exp Child Psychol 1998 Nov;71(2):178-83. Comment in: J Exp Child Psychol 1998 Nov;71(2):184-93.
A broader look at medical futility. Shelton W.
Theor Med Bioeth 1998 Aug;19(4):383-400 (18 ref.)

PHYSIOLOGY

Facial expressions of emotions and schizophrenia: a review. Mandal MK, et al. **Schizophr Bull** 1998;24(3):399-412 (92 ref.)

JUDO see **MARTIAL ARTS**

JUGAL BONE see **ZYGOMA**

JUGULAR VEINS

Lemierre syndrome: a complication of acute pharyngitis. Williams A, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):51-7 (5 ref.)
Lemierre's syndrome (necrobacillosis). Golpe R, et al.
Postgrad Med J 1999 Mar;75(881):141-4 (31 ref.)
Internal jugular vein haemodialysis catheter-induced right atrium endocarditis--case report and review of the literature. Tarng DC, et al. **Scand J Urol Nephrol** 1998 Dec;32(6):411-4 (17 ref.)
[Measurement of central venous pressure at the jugular pulse wave] de Leeuw PW. **Ned Tijdschr Geneeskd** 1999 Aug 14;143(33):1692-6 (9 ref.) (Eng. Abstr.) **(Dut)**

ANATOMY & HISTOLOGY

[Relation between jugular bulb variation and middle and inner ear diseases] Chen J, et al.
Lin Chuang Erh Pi Yen Hou Ko Tsa Chih 1997 Oct; 11(10):484-5 (10 ref.) **(Chi)**

PHYSIOLOGY

[What will jugular bulb oxygen saturation monitoring tell?] Cormio M, et al. **Minerva Anestesiol** 1999 May;65(5):322-6 (25 ref.) (Eng. Abstr.) **(Ita)**

JUMPING GENES see **INTERSPERSED REPETITIVE SEQUENCES**

JUN B PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUN D PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUN GENES see **GENES, JUN**

JUN PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUNCTIONAL ECTOPIC TACHYCARDIA see **TACHYCARDIA, ECTOPIC JUNCTIONAL**

JUNCTIONAL EPIDERMOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

JUNCTIONAL EPITHELIUM see **EPITHELIAL ATTACHMENT**

JUNGIAN THEORY

[Archetypal aspects of aging: from Eros to Thanatos] Pérez Urdániz A, et al. **Actas Esp Psiquiatr** 1999 Mar-Apr; 27(2):127-32 (21 ref.) (Eng. Abstr.) **(Spa)**

JUPITER

The Galilean satellites. Showman AP, et al. **Science** 1999 Oct 1;286(5437):77-84 (121 ref.)

JURISPRUDENCE

see related
FORENSIC DENTISTRY
FORENSIC MEDICINE

The war against junk science: the use of expert panels in complex medical-legal scientific litigation. Price JM, et al.
Biomaterials 1998 Aug;19(16):1425-32 (28 ref.)
Posttraumatic polarization in psychiatry and law. Beahrs JO.
J Am Acad Psychiatry Law 1999;27(2):335-43 (60 ref.)
Tardive dyskinesia: tremors in law and medicine. Kaye NS, et al. **J Am Acad Psychiatry Law** 1999;27(2):315-33 (52 ref.)
Legal trends in bioethics. Forster HP. **J Clin Ethics** 1999 Spring;10(1):66-75 (28 ref.)
Legal and ethical considerations in the treatment of psychosis. Fitzgerald WL Jr. **J Clin Psychiatry** 1999;60 Suppl 19:59-65; discussion 66 (11 ref.)
The pregnant addict: treat or prosecute? Implications for midwifery management. Stephany TM.
J Nurse Midwifery 1999 Mar-Apr;44(2):154-6 (27 ref.)
Anxiety and depression among law students: current knowledge and future directions. Dammeyer MM, et al.
Law Hum Behav 1999 Feb;23(1):55-73 (43 ref.)
Nuclear weapons and the law. Murray RK.
Med Confl Surviv 1999 Apr-Jun;15(2):126-37 (6 ref.)
Jurisprudence for ratite practitioners. Shane SM.
Vet Clin North Am Food Anim Pract 1998 Nov; 14(3):525-31, vii (2 ref.)

HISTORY

The United States Supreme Court and psychiatry in the 1990s. Ciccone JR. **Psychiatr Clin North Am** 1999 Mar; 22(1):197-211 (24 ref.)

JURISPRUDENCE, PSYCHIATRIC see **FORENSIC PSYCHIATRY**

JUVENILE DELINQUENCY

CLASSIFICATION

Juvenile violence. Scott CL. **Psychiatr Clin North Am** 1999 Mar;22(1):71-83 (76 ref.)

LEGISLATION & JURISPRUDENCE

Juvenile justice, delinquency, and psychiatry. Steiner H, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):653-72 (83 ref.)

PREVENTION & CONTROL

Adolescents and violent crime. Cohall A, et al.
Curr Opin Pediatr 1998 Aug;10(4):356-62 (44 ref.)

JUVENILE DELINQUENCY

PSYCHOLOGY

Stress in children exposed to violence. Reenactment and rage. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):121–35, ix (50 ref.)

REHABILITATION

Juvenile justice, delinquency, and psychiatry. Steiner H, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):653–72 (83 ref.)

Multisystemic treatment of criminality and violence in adolescents. Borduin CM. **J Am Acad Child Adolesc Psychiatry** 1999 Mar;38(3):242–9 (36 ref.)

Self-regulating service delivery systems: a model for children and youth at risk. Junek W, et al. **J Behav Health Serv Res** 1999 Feb;26(1):64–79 (47 ref.)

STATISTICS & NUMERICAL DATA

Adolescents and violent crime. Cohall A, et al. **Curr Opin Pediatr** 1998 Aug;10(4):356–62 (44 ref.)

JUVENILE HORMONES

METABOLISM

Multifactorial control of the release of hormones from the locust retrocerebral complex. Vullings HG, et al. **Microsc Res Tech** 1999 May 1;45(3):142–53 (105 ref.)

JUXTAGLOMERULAR APPARATUS

see related
BARTTER'S DISEASE
RENIN

CHEMISTRY

Structural and molecular dissection of the juxtaglomerular apparatus: new aspects for the role of nitric oxide. Bachmann S, et al. **Kidney Int Suppl** 1998 Sep;67:S29–33 (32 ref.)

Ionic transport in macula densa cells. Lapointe JY, et al. **Kidney Int Suppl** 1998 Sep;67:S58–64 (29 ref.)

CYTOLOGY

Cellular control of renin secretion. Kurtz A, et al. **J Exp Biol** 1999 Feb;202 (Pt 3):219–25 (59 ref.)

ENZYMOLOGY

Structural and molecular dissection of the juxtaglomerular apparatus: new aspects for the role of nitric oxide. Bachmann S, et al. **Kidney Int Suppl** 1998 Sep;67:S29–33 (32 ref.)

Prostaglandins in macula densa function. Harris RC, et al. **Kidney Int Suppl** 1998 Sep;67:S49–52 (40 ref.)

METABOLISM

Regulation of renin secretion by angiotensin II–AT1 receptors. Kurtz A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S162–8 (77 ref.)

Ionic transport in macula densa cells. Lapointe JY, et al. **Kidney Int Suppl** 1998 Sep;67:S58–64 (29 ref.)

PHYSIOLOGY

Cellular control of renin secretion. Kurtz A, et al. **J Exp Biol** 1999 Feb;202 (Pt 3):219–25 (59 ref.)

Characteristics of isolated perfused juxtaglomerular apparatus. Ito S. **Kidney Int Suppl** 1998 Sep;67:S46–8 (12 ref.)

K CELLS see **KILLER CELLS**

KAHN TEST see **SYPHILIS SERODIAGNOSIS**

KAINATE RECEPTORS see **RECEPTORS, KAINIC ACID**

KAINIC ACID

see related
RECEPTORS, KAINIC ACID

ANALOGS & DERIVATIVES

The activation of glutamate receptors by kainic acid and domoic acid. Hampson DR, et al. **Nat Toxins** 1998; 6(3–4):153–8 (60 ref.)

PHARMACOLOGY

The activation of glutamate receptors by kainic acid and domoic acid. Hampson DR, et al. **Nat Toxins** 1998; 6(3–4):153–8 (60 ref.)

KAINIC ACID RECEPTORS see **RECEPTORS, KAINIC ACID**

KALA-AZAR see **LEISHMANIASIS, VISCERAL**

KALE see **BRASSICA**

KALLIKREIN

see related
COAGULANTS

CHEMISTRY

Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Margolius HS. **Clin Rev Allergy Immunol** 1998 Winter;16(4):337–49 (57 ref.)

GENETICS

Current perspectives on the molecular biology of the renal tissue kallikrein gene and the related tissue kallikrein gene family. Clements JA. **Biol Res** 1998;31(3):151–9 (88 ref.)

Effects of diuretics on renal kallikrein gene expression in rats. Penschow JD, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S86–90 (32 ref.)

[Experimental genetic modifications in the renin–angiotensin and kallikrein–kinin systems: significance for understanding cardiovascular regulation and study of genetic determinism of human diseases] Meneton P, et al. **Nephrologie** 1998; 19(7):385–9 (20 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The plasma kallikrein–kinin system in sepsis, inflammatory arthritis, and enterocolitis. Colman RW, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):365–84 (44 ref.)

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Rittenhouse HG, et al. **Crit Rev Clin Lab Sci** 1998 Aug;35(4):275–368 (457 ref.)

PHYSIOLOGY

Kallikreins, kinins and cardiovascular diseases: a short review. Margolius HS. **Biol Res** 1998;31(3):135–41 (32 ref.)

Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Margolius HS. **Clin Rev Allergy Immunol** 1998 Winter;16(4):337–49 (57 ref.)

KALLIKREIN HK3 see **PROSTATE-SPECIFIC ANTIGEN**

KALLIKREIN-KININ SYSTEM

Plasma contact activation: a revised hypothesis. Schmaier AH. **Biol Res** 1998;31(3):251–62 (55 ref.)

DRUG EFFECTS

Pharmacology and cardiovascular implications of the kinin–kallikrein system. Dendorfer A, et al. **Jpn J Pharmacol** 1999 Apr;79(4):403–26 (300 ref.)

The B1 receptors for kinins. Marceau F, et al. **Pharmacol Rev** 1998 Sep;50(3):357–86 (241 ref.)

PHYSIOLOGY

Crucial suppressive role of renal kallikrein–kinin system in development of salt-sensitive hypertension. Katori M, et al. **Biol Res** 1998;31(3):143–9 (22 ref.)

Kallikreins, kinins and cardiovascular diseases: a short review. Margolius HS. **Biol Res** 1998;31(3):135–41 (32 ref.)

The kallikrein–kinin system along the different stages of gestation: experimental and clinical findings. Valdés G, et al. **Biol Res** 1998;31(3):235–41 (49 ref.)

Cellular and functional aspects of the renal kallikrein system in health and disease. Vio CP, et al. **Biol Res** 1998; 31(3):305–22 (127 ref.)

Molecular biology of the kallikrein–kinin system: from structure to function. Pesquero JB, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1197–203 (40 ref.)

The plasma kallikrein–kinin system in sepsis, inflammatory arthritis, and enterocolitis. Colman RW, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):365–84 (44 ref.)

Bradykinin formation. Plasma and tissue pathways and cellular interactions. Kaplan AP, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):403–29 (181 ref.)

Pathophysiology of the kallikrein–kinin system in mammalian nervous tissue. Raidoo DM, et al. **Pharmacol Ther** 1998 Aug;79(2):105–27 (260 ref.)

Activation of the plasma kallikrein/kinin system on endothelial cells. Rojkjaer R, et al. **Proc Assoc Am Physicians** 1999 May–Jun;111(3):220–7 (48 ref.)

KALLIKREIN-TRYPSIN INACTIVATOR see **APROTININ**

KALLMANN SYNDROME

GENETICS

Molecular approach to the pathogenesis of renal anomalies in Kallmann's syndrome and in the branchio-oto-renal syndrome. Hardelin JP, et al. **Adv Nephrol Necker Hosp** 1998;28:419–28 (22 ref.)

Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Seminara SB, et al. **Endocr Rev** 1998 Oct; 19(5):521–39 (215 ref.)

KAMPO see **MEDICINE, CHINESE TRADITIONAL**

KANAMYCIN KINASE

Aminoglycoside phosphotransferases: proteins, structure, and mechanism. Wright GD, et al. **Front Biosci** 1999 Jan 1; 4:D9–21 (91 ref.)

METABOLISM

Developing a snapshot of the ATP binding domain(s) of aminoglycoside phosphotransferases. Perlin MH, et al. **Front Biosci** 1999 Jan 1;4:D63–71 (44 ref.)

KANDINSKY SYNDROME see **DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS**

KANGAROOS

PHYSIOLOGY

Energetics and biomechanics of locomotion by red kangaroos (Macropus rufus). Kram R, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):41–9 (48 ref.)

KANNER'S SYNDROME see **AUTISTIC DISORDER**

KANPO see **MEDICINE, CHINESE TRADITIONAL**

KAOLIN-CEPHALIN COAGULATION TIME see **PARTIAL THROMBOPLASTIN TIME**

KAPOSI DISEASE see **XERODERMA PIGMENTOSUM**

KAPOSI SARCOMA see **SARCOMA, KAPOSI**

KAPOSI SARCOMA-ASSOCIATED HERPESVIRUS see **HERPESVIRUS, KAPOSI SARCOMA-ASSOCIATED**

KAPOSI VARICELLIFORM ERUPTION

[Eczema herpeticum] Iwata S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):177–8 (4 ref.) **(Jpn)**

KAPPA B ENHANCER BINDING PROTEIN see **NF-KAPPA B**

KAPPA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, KAPPA-CHAIN**

KAPPA RECEPTORS see **RECEPTORS, OPIOID, KAPPA**

KARATE see **MARTIAL ARTS**

KARNOFSKY PERFORMANCE STATUS

see related
ACTIVITIES OF DAILY LIVING
QUALITY OF LIFE

KARTAGENER'S SYNDROME

[Epidural anesthesia and analgesia in the perioperative treatment of a patient with Kartagener syndrome] Errando CL, et al. **Rev Esp Anestesiol Reanim** 1998 Dec; 45(10):431–2 (8 ref.) (Eng. Abstr.) **(Spa)**

KARTAGENER'S TRIAD see **KARTAGENER'S SYNDROME**

KARWINSKIA see **RHAMNUS**

KARYOKINESIS see **MITOSIS**

KARYOTYPING

Karyotype studies in 18 ependymomas with literature review of 107 cases. Mazewski C, et al. **Cancer Genet Cytogenet** 1999 Aug;113(1):1–8 (56 ref.)

Safety of biological products prepared from mammalian cell culture. Karyology. **Dev Biol Stand** 1998;93:134–6 (0 ref.)

Karyology and tumorigenicity testing requirements: past, present and future. Petricciani JC, et al. **Dev Biol Stand** 1998;93:5–13 (20 ref.)

METHODS

Analysis of B-cell neoplasias by spectral karyotyping (SKY). Hilgenfeld E, et al. **Curr Top Microbiol Immunol** 1999; 246:169–74 (18 ref.)

Banded chromosomes and the zebrafish karyotype. Amores A, et al. **Methods Cell Biol** 1999;60:323–38 (52 ref.)

VETERINARY

Working with canine chromosomes: current

recommendations for karyotype description. Reimann N, et al. **J Hered** 1999 Jan–Feb;90(1):31–4 (25 ref.)

KASSEBAUM KENNEDY ACT see **HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT**

KATZ ADJUSTMENT SCALES see **PSYCHIATRIC STATUS RATING SCALES**

KAWASAKI DISEASE see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

KAZAL PANCREATIC TRYPSIN INHIBITOR see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

KEFIR see **MILK**

KELOID

see related
CICATRIX, HYPERTROPHIC

On the nature of hypertrophic scars and keloids: a review. Niessen FB, et al. **Plast Reconstr Surg** 1999 Oct; 104(5):1435–58 (363 ref.)

DRUG THERAPY

Hypopigmentation along subcutaneous veins following intrakeloid triamcinolone injection: a case report and review of literature. Kumar P, et al. **Burns** 1998 Aug; 24(5):487–8 (11 ref.)

PATHOLOGY

[Hypertrophic scar and keloid] Vähä-Kreula M, et al. **Duodecim** 1995;111(?9):1921–9 (52 ref.) **(Fin)**

PHYSIOPATHOLOGY

Keloids and hypertrophic scars: review and treatment strategies. Urioste SS, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):159–71 (141 ref.)

RADIOTHERAPY

The molecular and cellular biologic basis for the radiation treatment of benign proliferative diseases. Rubin P, et al. **Semin Radiat Oncol** 1999 Apr;9(2):203–14 (119 ref.)

THERAPY

Keloids and hypertrophic scars: review and treatment strategies. Urioste SS, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):159–71 (141 ref.)

KENNEDY KASSEBAUM ACT see **HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT**

KERATECTOMY, EXCIMER LASER see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

KERATECTOMY, EXCIMER LASER PHOTOREFRACTIVE see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER

Excimer laser refractive surgery in the pediatric population. Haw WW, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jul–Aug;36(4):173–7; quiz 206–7 (13 ref.)

Could apoptosis change the way we do PRK? [editorial; comment] Krueger RR. **J Refract Surg** 1998 Sep–Oct; 14(5):494–6 (10 ref.) Comment on: J Refract Surg 1998 Sep–Oct;14(5):526–33.

Excimer laser ophthalmic surgery: evaluation of a new technology. Infeld DA, et al. **Postgrad Med J** 1998 Sep; 74(875):524–8 (32 ref.)

[Refractive surgery and flight safety] Draeger J. **Ophthalmologe** 1998 Sep;95(9):639–44 (8 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Complications in photorefractive keratectomy for myopia correction] Quurke A, et al. **Ophthalmologe** 1998 Oct; 95(10):734–40 (7 ref.) **(Ger)**

INSTRUMENTATION

[Current status of infrared photoablation of the cornea] Jean B, et al. **Klin Monatsbl Augenheilkd** 1999 Apr; 214(4):195–202 (42 ref.) (Eng. Abstr.) **(Ger)**

METHODS

In perspective: eye tracking and autonomous laser radar [comment] Krueger RR. **J Refract Surg** 1999 Mar–Apr; 15(2):145–9 (4 ref.) Comment on: J Refract Surg 1999 Mar–Apr;15(2):137–44.

Surgical correction of moderate myopia: which method should you choose? III. Editorial. Dutton JJ. **Surv Ophthalmol** 1998 Sep–Oct;43(2):179–81 (9 ref.)

Surgical correction of moderate myopia: which method should you choose? II. PRK and LASIK are the treatments of choice. Steinert RF, et al. **Surv Ophthalmol** 1998 Sep–Oct;43(2):157–79 (248 ref.)

KERATIN

see related
KERATINOCYTES

BIOSYNTHESIS

Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Southgate J, et al. **Histol Histopathol** 1999 Apr;14(2):657–64 (56 ref.)

CHEMISTRY

Hard alpha-keratin intermediate filament chains: substructure of the N- and C-terminal domains and the predicted structure and function of the C-terminal domains of type I and type II chains. Parry DA, et al. **J Struct Biol** 1998; 122(1–2):67–75 (27 ref.)

GENETICS

Arginine in the beginning of the 1A rod domain of the keratin 10 gene is the hot spot for the mutation in epidermolytic hyperkeratosis. Yang JM, et al. **J Dermatol Sci** 1999 Feb; 19(2):126–33 (35 ref.)

A mutational hotspot in the 2B domain of human hair basic keratin 6 (hHb6) in monilethrix patients. Korge BP, et al. **J Invest Dermatol** 1998 Nov;111(5):896–9 (34 ref.)

Lessons from keratin transgenic and knockout mice. Magin TM. **Subcell Biochem** 1998;31:141–72 (122 ref.)

The complexity of gene families involved in epithelial differentiation. Keratin genes and the epidermal differentiation complex. Mischke D. **Subcell Biochem** 1998; 31:71–104 (159 ref.)

[Pachyonychia congenita. Keratin gene mutations with pleiotropic effect] Swensson O. **Hautarzt** 1999 Jul; 50(7):483–90 (48 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The wound repair-associated keratins 6, 16, and 17. Insights into the role of intermediate filaments in specifying keratinocyte cytoarchitecture. McGowan K, et al. **Subcell Biochem** 1998;31:173–204 (120 ref.)

Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Moll R. **Subcell Biochem** 1998; 31:205–62 (239 ref.)

Keratin modifications and solubility properties in epithelial cells and in vitro. Omary MB, et al. **Subcell Biochem** 1998; 31:105–40 (144 ref.)

PHYSIOLOGY

The viscoelasticity of alpha keratin fibres. Crewther WG. **Exp Dermatol** 1999 Aug;8(4):343–4 (9 ref.)

KERATINOCYTES

CYTOLOGY

Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. Piepkorn M, et al. **J Invest Dermatol** 1998 Nov; 111(5):715–21 (80 ref.)

Cultured keratinocytes in in vitro dermatotoxicological investigation: a review. Bernstein IA, et al. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar; 2(1):1–30 (91 ref.)

DRUG EFFECTS

Cultured keratinocytes in in vitro dermatotoxicological investigation: a review. Bernstein IA, et al. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar; 2(1):1–30 (91 ref.)

IMMUNOLOGY

Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus erythematosus. Furukawa F. **Histol Histopathol** 1999 Apr;14(2):627–33 (33 ref.)

METABOLISM

Bricks and mortar of the epidermal barrier. Nemes Z, et al. **Exp Mol Med** 1999 Mar 31;31(1):5–19 (220 ref.)

Distinct P-cadherin expression in cultured normal human keratinocytes and squamous cell carcinoma cell lines. Wakita H, et al. **Microsc Res Tech** 1998 Nov 1;43(3):218–23 (24 ref.)

Systemic replacement therapy from genetically modified epidermal keratinocytes. Taichman LB. **Proc Assoc Am Physicians** 1999 May–Jun;111(3):206–10 (37 ref.)

[Cutaneous gene therapy--perspectives of gene transfer in keratinocytes] Braun-Falco M, et al. **Hautarzt** 1998 Jul; 49(7):536–44 (55 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

The pathogenesis of psoriasis: immunological facts and speculations. Bos JD, et al. **Immunol Today** 1999 Jan; 20(1):40–6 (57 ref.)

The role of cellular senescence in skin aging. Campisi J. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):1–5 (51 ref.)

Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Fusenig NE, et al. **Mol Carcinog** 1998 Nov;23(3):144–58 (78 ref.)

PHYSIOLOGY

Keratinocyte growth factor: a unique player in epithelial repair processes. Werner S. **Cytokine Growth Factor Rev** 1998 Jun;9(2):153–65 (106 ref.)

Signal transduction in keratinocytes. Mitev V, et al. **Exp Dermatol** 1999 Apr;8(2):96–108 (83 ref.)

Contributions of the epidermal growth factor receptor to keratinocyte motility. Hudson LG, et al. **Microsc Res Tech** 1998 Dec 1;43(5):444–55 (140 ref.)

Keratocyte and fibroblast phenotypes in the repairing cornea. Fini ME. **Prog Retin Eye Res** 1999 Jul;18(4):529–51 (96 ref.)

RADIATION EFFECTS

Ultraviolet radiation-induced p53 responses in the epidermis are differentiation-dependent. Tron VA, et al. **J Cutan Med Surg** 1999 Jul;3(5):280–3 (43 ref.)

TRANSPLANTATION

Pre-confluent keratinocyte grafting: the future for cultured skin replacements? [editorial] Harris PA, et al. **Burns** 1998 Nov;24(7):591–3 (15 ref.)

Cultivation and transplantation of epidermal keratinocytes. Terskikh VV, et al. **Int Rev Cytol** 1999;188:41–72 (154 ref.)

Cultivation of human keratinocyte stem cells: current and future clinical applications. Pellegrini G, et al. **Med Biol Eng Comput** 1998 Nov;36(6):778–90 (190 ref.)

[Keratinocyte transplantation and tissue engineering. New approaches in treatment of chronic wounds] Tánczos E, et al. **Zentralbl Chir** 1999;124 Suppl 1:81–6 (23 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Role of human papillomaviruses in the malignant transformation of keratinocytes. Achim R. **Rom J Virol** 1997 Jan–Dec;48(1–4):71–83 (14 ref.)

KERATITIS

Fungal keratitis. Mabon M. **Int Ophthalmol Clin** 1998 Fall; 38(4):115–23 (53 ref.)

[KID syndrome (keratitis, ichthyosis and deafness)] André N, et al. **Arch Pediatr** 1999 Mar;6(3):302–6 (29 ref.) (Eng. Abstr.) **(Fre)**

[Fungal keratitis] Ogasawara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):326–8 (7 ref.) **(Jpn)**

DIAGNOSIS

Parasitic corneal infections. Silverstein BE. **Int Ophthalmol Clin** 1998 Fall;38(4):179–82 (12 ref.)

[Atypical Cogan syndrome: a case report and review of the literature] De Righetti F, et al. **Rev Med Suisse Romande** 1998 Oct;118(10):889–93 (50 ref.) **(Fre)**

ETIOLOGY

Indiscriminate use of corticosteroid-containing eyedrops. Baratz KH, et al. **Mayo Clin Proc** 1999 Apr;74(4):362–6 (35 ref.)

[Bacterial keratitis] Ikegami M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):319–21 (4 ref.) **(Jpn)**

MICROBIOLOGY

Surgical management of infectious and noninfectious keratitis. Diamant JI, et al. **Int Ophthalmol Clin** 1998 Fall; 38(4):197–217 (38 ref.)

Interstitial keratitis. Knox CM, et al. **Int Ophthalmol Clin** 1998 Fall;38(4):183–95 (34 ref.)

PARASITOLOGY

Pathogenesis of onchocercal keratitis (River blindness). Hall LR, et al. **Clin Microbiol Rev** 1999 Jul;12(3):445–53 (85 ref.)

PATHOLOGY

Cogan's syndrome. St Clair EW, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):47–52 (65 ref.)

REHABILITATION

A step-wise approach to ocular surface rehabilitation in patients with ocular inflammatory disease. Chan RY, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):83–108 (102 ref.)

KERATITIS

SURGERY

Surgical management of infectious and noninfectious keratitis. Diamant JI, et al. **Int Ophthalmol Clin** 1998 Fall; 38(4):197–217 (38 ref.)

KERATITIS, ACANTHAMOEBA see **ACANTHAMOEBA KERATITIS**

KERATITIS, HERPETIC

[Viral keratitis] Nouchi A, et al.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):322–5 (4 ref.) **(Jpn)**

CLASSIFICATION

Classification of herpes simplex virus keratitis. Holland EJ, et al. **Cornea** 1999 Mar;18(2):144–54 (30 ref.)
Classification of herpes simplex virus keratitis and anterior uveitis. Liesegang TJ. **Cornea** 1999 Mar;18(2):127–43 (110 ref.)

ETIOLOGY

Chemokines and ocular pathology caused by corneal infection with herpes simplex virus. Kumaraguru U, et al. **J Neurovirol** 1999 Feb;5(1):42–7 (39 ref.)

KERATITIS, ULCERATIVE see **CORNEAL ULCER**

KERATOACANTHOMA

PATHOLOGY

Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Beham A, et al. **Adv Anat Pathol** 1998 Sep;5(5):269–80 (91 ref.)
Distal digital keratoacanthoma: a report of 12 cases and a review of the literature. Baran R, et al. **Br J Dermatol** 1998 Sep;139(3):512–5 (16 ref.)

KERATOCONJUNCTIVITIS

DIAGNOSIS

[Ocular rosacea] Valanconny C, et al.
Ann Dermatol Venereol 1999 May;126(5):450–4 (31 ref.) **(Fre)**

IMMUNOLOGY

Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Bonini S, et al. **Curr Probl Dermatol** 1999; 28:88–94 (20 ref.)

KERATOCONJUNCTIVITIS, INFECTIOUS

Infectious bovine keratoconjunctivitis: a review. Brown MH, et al. **J Vet Intern Med** 1998 Jul–Aug;12(4):259–66 (103 ref.)

KERATOCONJUNCTIVITIS SICCA

ETIOLOGY

[Diagnostic criteria of Sjögren syndrome] Ceraulo S, et al.
Minerva Stomatol 1999 Mar;48(3):79–85 (27 ref.) (Eng. Abstr.) **(Ita)**

KERATOCONJUNCTIVITIS, VERNAL see **CONJUNCTIVITIS, ALLERGIC**

KERATOCONUS

DIAGNOSIS

Corneal topography in LASIK. Oshika T, et al.
Semin Ophthalmol 1998 Jun;13(2):64–70 (14 ref.)

SURGERY

Corneal topography in LASIK. Oshika T, et al.
Semin Ophthalmol 1998 Jun;13(2):64–70 (14 ref.)

KERATOCYSTS see **ODONTOGENIC CYSTS**

KERATODERMA BLENNORRHAGICUM see **KERATOSIS**

KERATODERMA, PALMOPLANTAR

COMPLICATIONS

Palmoplantar keratoderma associated with hypothyroidism [letter] Miller JJ, et al. **Br J Dermatol** 1998 Oct;139(4):741–2 (7 ref.)

GENETICS

The palmoplantar keratodermas: much more than palms and soles. Kelsell DP, et al. **Mol Med Today** 1999 Mar; 5(3):107–13 (49 ref.)

PATHOLOGY

The palmoplantar keratodermas: much more than palms and soles. Kelsell DP, et al. **Mol Med Today** 1999 Mar; 5(3):107–13 (49 ref.)

KERATOLYTIC AGENTS

ADMINISTRATION & DOSAGE

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. Koo J.
J Am Acad Dermatol 1999 Sep;41(3 Pt 2):S25–8 (21 ref.)
Acitretin: optimal dosing strategies. Ling MR.
J Am Acad Dermatol 1999 Sep;41(3 Pt 2):S13–7 (11 ref.)

ADVERSE EFFECTS

Tretinoin-induced sticky skin: a case report and review of the literature. Lockridge J, et al. **Cutis** 1999 Mar; 63(3):142–4 (7 ref.)
Potential risk of birth defects after acitretin discontinuation. Maradit H, et al. **Dermatology** 1999;198(1):3–4 (6 ref.)
Acitretin in psoriasis: an overview of adverse effects. Katz HI, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S7–S12 (28 ref.)
Pharmacokinetics and safety review of tazarotene. Marks R. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S134–8 (27 ref.)
Side effects of acne therapy and their management. Miller RA. **J Cutan Med Surg** 1998 May;2 Suppl 3:14–8 (13 ref.)

PHARMACOKINETICS

Pharmacokinetics and safety review of tazarotene. Marks R. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S134–8 (27 ref.)

PHARMACOLOGY

Rational design of receptor-selective retinoids. Chandraratna RA. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S124–8 (21 ref.)
The pathogenesis of psoriasis and the mechanism of action of tazarotene. Duvic M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S129–33 (27 ref.)
Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo. Fisher GJ, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):61–8 (48 ref.)
Topical agents used in association with cosmetic surgery. Draelos ZD. **Semin Cutan Med Surg** 1999 Jun;18(2):112–8 (33 ref.)

THERAPEUTIC USE

Topical retinoids in the treatment of acne vulgaris. Bershad S, et al. **Cutis** 1999 Aug;64(2 Suppl):8–20; quiz 21–3 (33 ref.)
Periorbital rejuvenation: a review of dermatologic treatments. Manaloto RM, et al. **Dermatol Surg** 1999 Jan; 25(1):1–9 (80 ref.)
Tazarotene in combination with phototherapy. Koo JY.
J Am Acad Dermatol 1998 Oct;39(4 Pt 2):S144–8 (29 ref.)
Tazarotene in combination with topical corticosteroids. Lebwohl M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S139–43 (15 ref.)
Acitretin in combination with UVB or PUVA. Lebwohl M.
J Am Acad Dermatol 1999 Sep;41(3 Pt 2):S22–4 (10 ref.)
Acitretin combination therapy. Roenigk HH Jr.
J Am Acad Dermatol 1999 Sep;41(3 Pt 2):S18–21 (14 ref.)
Management of adult acne and acne variants. Cunliffe WJ.
J Cutan Med Surg 1998 May;2 Suppl 3:7–13 (53 ref.)

KERATOMA see **KERATOSIS**

KERATOPLASTY see **CORNEAL TRANSPLANTATION**

KERATOPLASTY, LAMELLAR see **CORNEAL TRANSPLANTATION**

KERATOPLASTY, PENETRATING

Obesity as a factor in penetrating keratoplasty. Johansen TR, et al. **Cornea** 1999 Jan;18(1):12–8 (10 ref.)

KERATOSIS

COMPLICATIONS

Erythrokeratoderma variabilis: case report and review of the literature. Papadavid E, et al.
J Eur Acad Dermatol Venereol 1998 Sep;11(2):180–3 (14 ref.)

GENETICS

Inherited disorders of epidermal keratinization.
Ishida-Yamamoto A, et al. **J Dermatol Sci** 1998 Dec; 18(3):139–54 (111 ref.)

METABOLISM

Loricrin and human skin diseases: molecular basis of loricrin keratodermas. Ishida-Yamamoto A, et al.
Histol Histopathol 1998 Jul;13(3):819–26 (56 ref.)
Inherited disorders of epidermal keratinization.
Ishida-Yamamoto A, et al. **J Dermatol Sci** 1998 Dec; 18(3):139–54 (111 ref.)

PATHOLOGY

Keratosis pilaris. Lateef A, et al. **Cutis** 1999 Apr;63(4):205–7 (32 ref.)
Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. Tanuma H. **Mycoses** 1999 Apr;42(1–2):21–8 (49 ref.)

KERATOSIS BLENNORRHAGICA see **KERATOSIS**

KERATOSIS FOLLICULARIS

DRUG THERAPY

Management of Darier's disease. Burge S.
Clin Exp Dermatol 1999 Mar;24(2):53–6 (25 ref.)
Effective treatment of localized Darier's disease with adapalene 0.1% gel. English JC 3rd, et al. **Cutis** 1999 Apr; 63(4):227–30 (15 ref.)

KERATOSIS, ORAL see **LEUKOPLAKIA, ORAL**

KERATOSIS PALMARIS ET PLANTARIS see **KERATODERMA, PALMOPLANTAR**

KERATOSIS, PALMOPLANTAR see **KERATODERMA, PALMOPLANTAR**

KERATOTOMY, RADIAL

METHODS

Surgical correction of moderate myopia: which method should you choose? III. Editorial. Dutton JJ.
Surv Ophthalmol 1998 Sep–Oct;43(2):179–81 (9 ref.)
Surgical correction of moderate myopia: which method should you choose? I. Radial keratotomy will always have a place. Rowsey JJ, et al. **Surv Ophthalmol** 1998 Sep–Oct; 43(2):147–56 (86 ref.)

KEROSENE

POISONING

Kerosene-induced severe acute respiratory failure in near drowning: reports on four cases and review of the literature. Segev D, et al. **Crit Care Med** 1999 Aug; 27(8):1437–40 (14 ref.)

TOXICITY

Toxicity of middle distillates from dermal exposure. Koschier FJ. **Drug Chem Toxicol** 1999 Feb;22(1):155–64 (17 ref.)

KEROSINE see **KEROSENE**

KETAMINE

Ketamine: teaching an old drug new tricks. Kohrs R, et al.
Anesth Analg 1998 Nov;87(5):1186–93 (80 ref.)
[(S)-Ketamine--clinical utility and problems (editorial)] Adams HA.
Anasthesiol Intensivmed Notfallmed Schmerzther 1998 Dec; 33(12):761–3 (11 ref.) **(Ger)**
[The clinical use of S-(+)-ketamine--a determination of its place] Himmelseher S, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1998 Dec; 33(12):764–70 (43 ref.) (Eng. Abstr.) **(Ger)**
[Ketamine] Reboso Morales JA, et al.
Rev Esp Anestesiol Reanim 1999 Mar;46(3):111–22 (160 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Ketamine: teaching an old drug new tricks. Kohrs R, et al.
Anesth Analg 1998 Nov;87(5):1186–93 (80 ref.)
The NMDA antagonist model for schizophrenia: promise and pitfalls. Abi-Saab WM, et al. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:104–9 (50 ref.)

THERAPEUTIC USE

Intravenous analgesia. McArdle P. **Crit Care Clin** 1999 Jan; 15(1):89–104 (49 ref.)
Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Schmid RL, et al. **Pain** 1999 Aug; 82(2):111–25 (124 ref.)

KETANSERIN

PHARMACOLOGY

Influence of ketanserin on experimental loss of renal blood flow autoregulation. Verbeke M, et al.
Kidney Int Suppl 1998 Sep;67:S238–41 (25 ref.)

KETO ACIDS

METABOLISM

Keto-acid oxidoreductases in the anaerobic protozoa.

Upcroft JA, et al. **J Eukaryot Microbiol** 1999 Jul–Aug; 46(4):447–9 (20 ref.)

THERAPEUTIC USE

[Assignment of diet with various protein content in combination with keto-analogs of essential amino acids for management of chronic renal failure. State-of-the-art] Lifshits NL, et al. **Ter Arkh** 1999;71(1):74–7 (62 ref.) **(Rus)**

3-KETO-5-ALPHA-STEROID DELTA-4-DEHYDROGENASE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

KETOACID-LYASES see **OXO-ACID-LYASES**

KETOACIDOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

3-KETOACYL COA THIOLASE see **ACETYL-COA C-ACYLTRANSFERASE**

KETOCHOLESTEROLS

CHEMISTRY

7-Ketocholesterol. Lyons MA, et al. **Int J Biochem Cell Biol** 1999 Mar–Apr;31(3–4):369–75 (29 ref.)

KETOCONAZOLE

ADVERSE EFFECTS

The treatment of advanced prostate cancer with ketoconazole: safety issues. Bok RA, et al. **Drug Saf** 1999 May;20(5):451–8 (38 ref.)

THERAPEUTIC USE

Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Berwaerts J, et al. **Gynecol Endocrinol** 1999 Jun;13(3):175–82 (49 ref.)

African histoplasmosis: report of two patients treated with amphotericin B and ketoconazole. Akpuaka FC, et al. **Mycoses** 1998 Nov;41(9–10):363–4 (12 ref.)

KETOGLUTARATE GLUTAMINE AMIDOTRANSFERASE see **GLUTAMATE SYNTHASE**

KETOGLUTARIC ACIDS

THERAPEUTIC USE

The use of alpha-ketoglutarate salts in clinical nutrition and metabolic care. Cynober LA. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):33–7 (37 ref.)

KETONE BODIES

BIOSYNTHESIS

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Hegardt FG. **Biochem J** 1999 Mar 15;338 (Pt 3):569–82 (165 ref.)

Transcriptional regulation of mitochondrial HMG-CoA synthase in the control of ketogenesis. Hegardt FG. **Biochimie** 1998 Oct;80(10):803–6 (17 ref.)

Control of food intake by fatty acid oxidation and ketogenesis. Scharrer E. **Nutrition** 1999 Sep;15(9):704–14 (144 ref.)

KETONES

CHEMISTRY

Frontier orbitals in chemical and biological activity: quantitative relationships and mechanistic implications. Lewis DF. **Drug Metab Rev** 1999 Aug;31(3):755–816 (91 ref.)

KETOQUINOLINES see **QUINOLONES**

KETOSE-ALDOSE ISOMERASES see **ALDOSE-KETOSE ISOMERASES**

KETOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

3-KETOTHIOLASE see **ACETYL-COA C-ACYLTRANSFERASE**

KETOTIFEN

THERAPEUTIC USE

[Membrane stabilizers (chromones and ketotifen)] Mancel E, et al. **Allerg Immunol (Paris)** 1999 Apr;31(4):103–5 (9 ref.) (Eng. Abstr.) **(Fre)**

[Ketotifen (Zaditen and K-Asthmal): a drug with sales disproportionate to its demonstrated effectiveness] Pérez-Padilla JR. **Gac Med Mex** 1999 Mar–Apr; 135(2):165–70 (67 ref.) (Eng. Abstr.) **(Spa)**

KG-CAM see **ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE**

KI-67 ANTIGEN

METABOLISM

Utility of proliferation-associated marker MIB-1 in evaluating lesions of the uterine cervix. Mittal K. **Adv Anat Pathol** 1999 Jul;6(4):177–85 (22 ref.)

The proliferation-associated Ki-67 protein: definition in molecular terms. Duchrow M, et al. **Cell Prolif** 1994 May; 27(5):235–42 (35 ref.)

KI-1 ANTIGENS see **ANTIGENS, CD30**

KI-1 LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-1 LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-1-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-RAS GENES see **GENES, RAS**

KICKBACKS see **FRAUD**

KIDNAPPING see **CRIME**

KIDNEY

see related
DIURESIS
NEPHRECTOMY
RENAL CIRCULATION

Development of the renal interstitium. Alcorn D, et al. **Pediatr Nephrol** 1999 May;13(4):347–54 (35 ref.)

Kidney preservation in the next millenium. Stubenitsky BM, et al. **Transpl Int** 1999;12(2):83–91 (108 ref.)

Postischemic reperfusion injury and allograft dysfunction: is allograft rejection the result of a fateful confusion by the immune system of danger and benefit? Land W. **Transplant Proc** 1999 Feb–Mar;31(1–2):332–6 (20 ref.)

What is a reasonably short cold ischemia time in kidney transplantation? Offermann G. **Transplant Proc** 1998 Dec; 30(8):4291–3 (8 ref.)

ABNORMALITIES

Molecular approach to the pathogenesis of renal anomalies in Kallmann's syndrome and in the branchio-oto-renal syndrome. Hardelin JP, et al. **Adv Nephrol Necker Hosp** 1998;28:419–28 (22 ref.)

Prenatal diagnosis of crossed ectopic multicystic kidney. Maayan A, et al. **Am J Perinatol** 1998 Aug;15(8):499–502 (5 ref.)

Acro-renal-ocular syndrome: expansion of the phenotype. Guillén-Navarro E, et al. **Clin Dysmorphol** 1998 Oct; 7(4):243–8 (9 ref.)

A patient with three kidneys: a correlative imaging case report. Sy WM, et al. **Clin Nucl Med** 1999 Apr;24(4):264–6 (10 ref.)

Laparoscopic pyelolithotomy in a pelvic kidney: a case report and review of the literature. Hoenig DM, et al. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):163–5 (6 ref.)

Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. Yerkes E, et al. **Kidney Int Suppl** 1998 Sep;67:S75–7 (12 ref.)

Emerging roles of obstruction and mutations in renal malformations. Woolf AS. **Pediatr Nephrol** 1998 Oct; 12(8):690–4 (61 ref.)

Gartner's duct cyst with unilateral renal dysplasia presenting as an introital mass in a new born. Holmes M, et al. **Pediatr Surg Int** 1999;15(3–4):277–9 (12 ref.)

Increased incidence of renal anomalies in patients with chromosome 22q11 microdeletion. Stewart TL, et al. **Teratology** 1999 Jan;59(1):20–2 (6 ref.)

Surgical treatment of abdominal aortic aneurysm in association with horseshoe kidney. Three case reports and a review of technique. Canova G, et al. **Tex Heart Inst J** 1998;25(3):206–10 (26 ref.)

[Seminal vesicle cysts associated with ipsilateral renal agenesis. Diagnosis, and long-term clinical course] Uder M, et al. **Radiologe** 1998 Sep;38(9):766–73 (43 ref.) (Eng. Abstr.) **(Ger)**

[Seminal vesicle cysts (and ejaculatory duct cysts) with ipsilateral renal agenesis. Report of five cases and review of the literature] Gallmetzer J, et al. **Minerva Urol Nefrol** 1999 Mar;51(1):27–31 (17 ref.) (Eng. Abstr.) **(Ita)**

[A fibroepithelial myxoid polyp of the renal pelvis in a patient with horseshoe kidneys. Apropos a case] Camacho García C, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):609–12 (8 ref.) (Eng. Abstr.) **(Spa)**

[Primary cerebral hemiatrophy associated with other malformations. A case report] Marti Aromir G, et al. **An Esp Pediatr** 1998 Sep;49(3):305–7 (12 ref.) **(Spa)**

[Anomalies of Müllerian duct fusion. A report of 3 cases of uterus didelphys associated with a double vagina and ipsilateral renal agenesis] Ruibal Francisco JL, et al. **An Esp Pediatr** 1999 Jun;50(6):616–8 (14 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Anatomy and physiology of the kidney. Wallace MA. **AORN J** 1998 Nov;68(5):800, 803–16, 819–20; quiz 821–4 (33 ref.)

Stereologic methods and their application in kidney research [see comments] Nyengaard JR. **J Am Soc Nephrol** 1999 May;10(5):1100–23 (208 ref.) Comment in: J Am Soc Nephrol 1999 May;10(5):1124–5.

[Can man live with a pig kidney?] Valentin JF, et al. **Nephrologie** 1999;20(4):189–92 (33 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Primary antiphospholipid syndrome presented by total infarction of right kidney with nephrotic syndrome. Sá H, et al. **Clin Nephrol** 1999 Jul;52(1):56–60 (21 ref.)

Bcl-2 genes and growth factors in the pathology of ischaemic acute renal failure. Gobé G, et al. **Immunol Cell Biol** 1999 Jun;77(3):279–86 (72 ref.)

Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. Donnahoo KK, et al. **J Urol** 1999 Jul;162(1):196–203 (96 ref.)

Origins and formation of microvasculature in the developing kidney. Abrahamson DR, et al. **Kidney Int Suppl** 1998 Sep; 67:S7–11 (28 ref.)

Role of vascular endothelial growth factor in the response to vessel injury. Alvarez Arroyo MV, et al. **Kidney Int Suppl** 1998 Dec;68:S7–9 (8 ref.)

Shear stress and the endothelium. Ballermann BJ, et al. **Kidney Int Suppl** 1998 Sep;67:S100–8 (91 ref.)

Role of angiotensin in renal vascular development. Gomez RA. **Kidney Int Suppl** 1998 Sep;67:S12–6 (35 ref.)

Renal vascular disease in the elderly. Gómez Campderá FJ, et al. **Kidney Int Suppl** 1998 Dec;68:S73–7 (33 ref.)

Heterogeneous activation mechanisms in the renal microvasculature. Navar LG, et al. **Kidney Int Suppl** 1998 Sep;67:S17–21 (30 ref.)

Development and differentiation of endothelium. Risau W. **Kidney Int Suppl** 1998 Sep;67:S3–6 (30 ref.)

The heterogeneity of vascular findings in the kidneys of patients with benign essential hypertension. Tracy RE. **Nephrol Dial Transplant** 1999 Jul;14(7):1634–9 (18 ref.)

Vascular contributions to pathogenesis of acute renal failure. Bankir L, et al. **Ren Fail** 1998 Sep;20(5):663–77 (143 ref.)

Lessons learned from ischemic and cisplatin-induced nephrotoxicity in animals. Safirstein RL. **Ren Fail** 1999 May-Jul;21(3–4):359–64 (25 ref.)

Cell cycle events during renal injury. Safirstein RL. **Ren Fail** 1999 May-Jul;21(3–4):427–31 (24 ref.)

[Paracrine regulation of renal hemodynamics] Aki Y, et al. **Nippon Yakurigaku Zasshi** 1998 Nov;112(5):287–98 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747–54 (754 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Forssmann WG, et al. **Histochem Cell Biol** 1998 Oct;110(4):335–57 (258 ref.)

Hepatic and renal expression of senescence marker protein-30 and its biological significance. Fujita T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S124–31 (32 ref.)

Regulation of renal function by prostaglandin E receptors. Breyer MD, et al. **Kidney Int Suppl** 1998 Sep;67:S88–94 (74 ref.)

Physiological and pharmacological implications of AT1 versus AT2 receptors. Chung O, et al. **Kidney Int Suppl** 1998 Sep;67:S95–9 (59 ref.)

Role of calcium oxalate monohydrate crystal interactions with renal epithelial cells in the pathogenesis of nephrolithiasis: a review. Lieske JC, et al. **Scanning Microsc** 1996;10(2):519–33; discussion 533–4 (65 ref.)

[Kidney] Imanishi K, et al. **Nippon Rinsho** 1999 May; 57(5):1036–41 (27 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Gene therapy for renal fibroblasts [editorial] Clarke HC, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1615–7 (28 ref.)

Regulation of cell survival during renal development. Hammerman MR. **Pediatr Nephrol** 1998 Sep;12(7):596–602 (29 ref.)

Renal epithelial polarity in health and disease. Wagner MC, et al. **Pediatr Nephrol** 1999 Feb;13(2):163–70 (55 ref.)

Cell cycle events during renal injury. Safirstein RL. **Ren Fail** 1999 May-Jul;21(3–4):427–31 (24 ref.)

DRUG EFFECTS

Cardiovascular and renal benefits of dry bean and soybean intake. Anderson JW, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):464S–474S (154 ref.)

Renoprotective effects of antihypertensive drugs. Preston RA. **Am J Hypertens** 1999 Jan;12(1 Pt 2):19S–32S (107 ref.)

Crystal-induced acute renal failure. Perazella MA. **Am J Med** 1999 Apr;106(4):459–65 (53 ref.)

Nephrotoxicity of nonsteroidal anti-inflammatory drugs:

physiologic foundations and clinical implications. Whelton A. **Am J Med** 1999 May 31;106(5B):13S–24S (83 ref.)

Aminoglycosides: nephrotoxicity. Mingeot-Leclercq MP, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1003–12 (143 ref.)

Nephroprotection by antihypertensive therapy. Jacobi J, et al. **Basic Res Cardiol** 1998;93 Suppl 2:109–19 (98 ref.)

Renal functional effects of endothelins: dependency on cytochrome P450-derived arachidonate metabolites. Oyekan AO, et al. **Biol Res** 1998;31(3):209–15 (43 ref.)

Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients. Gurwith M, et al. **Chemotherapy** 1999 Jun;45 Suppl 1:39–47 (23 ref.)

Effects of diuretics on renal kallikrein gene expression in rats. Penschow JD, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S86–90 (32 ref.)

An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs. Hutchinson IV. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):665–71 (90 ref.)

Renal protection and antihypertensive drugs: current status. Salvetti A, et al. **Drugs** 1999 May;57(5):665–93 (273 ref.)

Chronic nitric oxide inhibition model six years on. Zatz R, et al. **Hypertension** 1998 Dec;32(6):958–64 (106 ref.)

Actions of angiotensin II on the renal microvasculature. Arendshorst WJ, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S149–61 (100 ref.)

Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. Hollenberg NK. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S239–42 (28 ref.)

Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. Morsing P. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S248–54 (69 ref.)

Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. Dekant W, et al. **J Cancer Res Clin Oncol** 1999;125(3–4):174–81 (93 ref.)

Renal protection by antihypertensive drugs: insights from microalbuminuria studies. Redon J. **J Hypertens** 1998 Dec; 16(12 Pt 2):2091–100 (79 ref.)

Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. Schrama YC, et al. **J Hypertens Suppl** 1998 Sep;16(4):S33–8 (89 ref.)

The renoprotective effect of antihypertensive drugs. Locatelli F, et al. **J Nephrol** 1998 Nov–Dec;11(6):330–6 (36 ref.)

Metallothionein transgenic and knock-out mouse models in the study of cadmium toxicity. Klaassen CD, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:97–102 (24 ref.)

Cardiovascular and renal risks of calcium-channel blockers--news from the HOT study [editorial] Ruilope LM. **Nephrol Dial Transplant** 1999 Feb;14(2):286–7 (14 ref.)

The acute renal effects of angiotensin II receptor blockers [editorial] Veelken R, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1928–9 (13 ref.)

Salt-sensitive hypertension: renal and cardiovascular implications. Campese VM. **Nutr Metab Cardiovasc Dis** 1999 Jun;9(3):143–56 (147 ref.)

Interactions between furosemide and the renal sympathetic nerves. Petersen JS. **Pharmacol Toxicol** 1999;84 Suppl 1:1–47 (390 ref.)

The nephrotoxicity of new and old immunosuppressive drugs. Bennett WM. **Ren Fail** 1998 Sep;20(5):687–90 (20 ref.)

Risk assessment of nephrotoxicity of cadmium. Fels LM. **Ren Fail** 1999 May-Jul;21(3–4):275–81 (45 ref.)

FK506 nephrotoxicity. Finn WF. **Ren Fail** 1999 May-Jul; 21(3–4):319–29 (48 ref.)

Biomedical testing of the kidney for persons exposed to hazardous substances in the environment. Lybarger JA, et al. **Ren Fail** 1999 May-Jul;21(3–4):263–74 (20 ref.)

An animal model of chronic cyclosporine nephrotoxicity. Porter GA, et al. **Ren Fail** 1999 May-Jul;21(3–4):365–8 (17 ref.)

Lessons learned from ischemic and cisplatin-induced nephrotoxicity in animals. Safirstein RL. **Ren Fail** 1999 May-Jul;21(3–4):359–64 (25 ref.)

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Capizzi RL. **Semin Oncol** 1999 Apr;26(2 Suppl 7):72–81 (68 ref.)

Recent advances in molecular mechanisms of nephrotoxicity. Endou H. **Toxicol Lett** 1998 Dec 28;102–103:29–33 (17 ref.)

Management of nephrotoxic drugs. Alsina J. **Transplant Proc** 1999 Feb-Mar;31(1–2):1117–9 (36 ref.)

[Renal-protective dose of dopamine: myth or reality?] de Werra P, et al. **Rev Med Suisse Romande** 1999 Mar; 119(3):203–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Kidney function in test subjects: published results and clinical relevance] Frink EJ. **Anaesthesist** 1998 Nov;47 Suppl 1:S33–6 (12 ref.) (Eng. Abstr.) **(Ger)**

[Renal effects of non-narcotic analgesics and non-steroidal anti-inflammatory drugs (editorial)] Tareeva IE, et al. **Ter Arkh** 1999;71(6):17–22 (28 ref.) **(Rus)**

[Nephrotoxicity of pesticides] Allazov S. **Urol Nefrol (Mosk)** 1998 Nov-Dec;(6):47–9 (79 ref.) **(Rus)**

[Cholinergic influence on the hemodynamics and excretory functions of the kidney] Fedorov VI. **Usp Fiziol Nauk** 1998 Oct-Dec;29(4):42–54 (125 ref.) (Eng. Abstr.) **(Rus)**

[Renal involvement in patients with chronic inflammatory intestinal disease treated with mesalazine. How to prevent its nephrotoxicity? (letter)] Bonet J, et al. **Med Clin (Barc)** 1999 Jul 10;113(5):199 (8 ref.) **(Spa)**

EMBRYOLOGY

RET proto-oncogene: role in kidney development and molecular pathology. Salomon R, et al. **Adv Nephrol Necker Hosp** 1998;28:401–17 (50 ref.)

Relevance of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Wallner EI, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F467–77 (128 ref.)

Cell lineages in the embryonic kidney: their inductive interactions and signalling molecules. Sariola H, et al. **Biochem Cell Biol** 1998;76(6):1009–16 (80 ref.)

The renin-angiotensin system and the development of the kidney and adrenal in sheep. Wintour EM, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S97–100 (39 ref.)

Role of retinoids in renal development: pathophysiological implication. Merlet-Bénichou C, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):39–43 (41 ref.)

Recent advances in renal development. Gomez RA, et al. **Curr Opin Pediatr** 1999 Apr;11(2):135–40 (34 ref.)

Molecular regulation of pronephric development. Carroll T, et al. **Curr Top Dev Biol** 1999;44:67–100 (158 ref.)

Architectural patterns in branching morphogenesis in the kidney. al-Awqati Q, et al. **Kidney Int** 1998 Dec; 54(6):1832–42 (65 ref.)

Origins and formation of microvasculature in the developing kidney. Abrahamson DR, et al. **Kidney Int Suppl** 1998 Sep; 67:S7–11 (28 ref.)

Role of angiotensin in renal vascular development. Gomez RA. **Kidney Int Suppl** 1998 Sep;67:S12–6 (35 ref.)

Functional development of the meso- and metanephros. Moritz KM, et al. **Pediatr Nephrol** 1999 Feb;13(2):171–8 (48 ref.)

The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pritchard-Jones K. **Pediatr Nephrol** 1999 Sep;13(7):620–5 (37 ref.)

The role of the polycystins in kidney development. van Adelsberg JS. **Pediatr Nephrol** 1999 Jun;13(5):454–9 (48 ref.)

The maturing kidney: development and susceptibility. Gomez RA, et al. **Ren Fail** 1999 May-Jul;21(3–4):283–91 (16 ref.)

Renin-angiotensin genes in renal development and the occurrence and progression of renal diseases. Hohenfellner K, et al. **Semin Nephrol** 1999 Mar;19(2):148–54 (50 ref.)

[Molecular basis of renal development] Lelongt B, et al. **Nephrologie** 1998;19(6):319–27 (62 ref.) (Eng. Abstr.) **(Fre)**

[The role of integrin alpha 8 beta 1 in kidney morphogenesis] Denda S. **Tanpakushitsu Kakusan Koso** 1999 Feb; 44(2):136–42 (21 ref.) **(Jpn)**

ENZYMOLOGY

Plasma membrane V-ATPases in proton-transporting cells of the mammalian kidney and osteoclast. Gluck SL, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:203–12 (84 ref.)

Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume. Braam B. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1551–61 (91 ref.)

Current perspectives on the molecular biology of the renal tissue kallikrein gene and the related tissue kallikrein gene family. Clements JA. **Biol Res** 1998;31(3):151–9 (88 ref.)

Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases. Costerousse O, et al. **Biol Res** 1998;31(3):161–7 (64 ref.)

Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Dousa TP. **Kidney Int** 1999 Jan;55(1):29–62 (232 ref.)

Kidney ectopeptidases. Structure, functions and clinical significance. Vlahović P, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):779–86 (80 ref.)

Cell signal transduction through the mitogen-activated protein kinase pathway. Schnaper HW. **Pediatr Nephrol** 1998 Nov;12(9):790–5 (9 ref.)

Proteases in renal cell death: calpains mediate cell death produced by diverse toxicants. Schnellmann RG, et al. **Ren Fail** 1998 Sep;20(5):679–86 (31 ref.)

Localization and regulation of nitric oxide synthase isoforms in the kidney. Kone BC. **Semin Nephrol** 1999 May; 19(3):230–41 (131 ref.)

[Enzymuria and urinary tract infection] Kiliś-Pstrusińska K, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):194–6 (39 ref.) (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

Kidney development branches out. Dressler GR. **Dev Genet** 1999;24(3–4):189–93 (39 ref.)

Thrombin: a novel renal growth factor. Grandaliano G, et al. **Exp Nephrol** 1999 Jan-Feb;7(1):20–5 (47 ref.)

Role of angiotensin in the development of the kidney and urinary tract. Pope JC 4th, et al. **Nephrologie** 1998; 19(7):433–6 (45 ref.)

Regulation of cell survival during renal development. Hammerman MR. **Pediatr Nephrol** 1998 Sep;12(7):596–602 (29 ref.)

The maturing kidney: development and susceptibility. Gomez RA, et al. **Ren Fail** 1999 May-Jul;21(3–4):283–91 (16 ref.)

IMMUNOLOGY

Renal immunology and pathology [editorial] Singh AK. **Curr Opin Nephrol Hypertens** 1999 May;8(3):277–9 (12 ref.)

ICAM-1 interactions in the renal interstitium: a novel activator of fibroblasts during nephritis. Clayton A, et al. **Histol Histopathol** 1999 Jul;14(3):861–70 (67 ref.)

Angiotensin-converting enzyme inhibitors in young patients with IgA nephropathy: effects against deterioration of renal function. A Biomedicine and Health Research Concerted Action. Coppo R. **Nephrol Dial Transplant** 1999 Apr; 14(4):840–1 (17 ref.)

INJURIES

Reconstructive surgery for trauma of the upper urinary tract. Brandes SB, et al. **Urol Clin North Am** 1999 Feb; 26(1):183–99, x (52 ref.)

Radiographic staging of renal injuries. Carpio F, et al. **World J Urol** 1999 Apr;17(2):66–70 (16 ref.)

Renal trauma: indications and techniques for surgical exploration. Meng MV, et al. **World J Urol** 1999 Apr; 17(2):71–7 (39 ref.)

[Conservative treatment of stage III kidney injuries] el Khader K, et al. **Acta Urol Belg** 1998 Dec;66(4):25–8 (25 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

The sympathetic nervous system and the kidney: its importance in renal diseases. Ritz E, et al. **Blood Press** 1998; Suppl 3:14–9 (35 ref.)

Neural control of kidney function. Veelken R. **Kidney Blood Press Res** 1998;21(2–4):249–52 (67 ref.)

Interactions between furosemide and the renal sympathetic nerves. Petersen JS. **Pharmacol Toxicol** 1999;84 Suppl 1:1–47 (390 ref.)

METABOLISM

Regulation of renal urate excretion: a critical review. Maesaka JK, et al. **Am J Kidney Dis** 1998 Dec;32(6):917–33 (176 ref.)

The role of cell adhesion molecules in ischemic acute renal failure. Molitoris BA, et al. **Am J Med** 1999 May; 106(5):583–92 (79 ref.)

Long-term regulation of aquaporins in the kidney. Marples D, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F331–9 (49 ref.)

Vasoactive peptide receptors in the rat kidney. Garcia R, et al. **Biol Res** 1998;31(3):217–25 (88 ref.)

Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension. Katori M, et al. **Biol Res** 1998;31(3):143–9 (22 ref.)

Cellular and functional aspects of the renal kallikrein system in health and disease. Vio CP, et al. **Biol Res** 1998; 31(3):305–22 (127 ref.)

The molecular biology of renal organic anion and organic cation transporters. Sweet DH, et al. **Cell Biochem Biophys** 1999;31(1):89–118 (77 ref.)

G protein-coupled receptor signalling in the kidney. Weiss RH. **Cell Signal** 1998 May;10(5):313–20 (82 ref.)

Rat renal alpha 1-adrenoceptor subtypes: characterization, function, and regulation. Buscher R, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul;17(4):289–92 (37 ref.)

The mammalian aquaporin water channel family: A promising new drug target. Beitz E, et al. **Curr Med Chem** 1999 Jun;6(6):457–67 (39 ref.)

Recent advances on renal inward rectifier K+ channels. Huang CL. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):503–8 (56 ref.)

Renal aquaporins: key roles in water balance and water balance disorders. Nielsen S, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):509–16 (53 ref.)

Molecular physiology of renal chloride channels. Steinmeyer K, et al. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):497–502 (91 ref.)

The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Thakker RV. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):385–8 (42 ref.)

Regulation of renal renin release. Wagner C, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):437–41 (59 ref.)

Nuclear magnetic resonance spectroscopy: a non-invasive probe of kidney metabolism and function. Foxall PJ, et al. **Exp Nephrol** 1998 Sep-Oct;6(5):409–14 (38 ref.)

Reversal of convention: from man to experimental animal in elucidating the function of the renal amiloride-sensitive sodium channel. Hummler E. **Exp Nephrol** 1998 Jul-Aug; 6(4):265–71 (56 ref.)

Regulation of the renal Na/K/2Cl cotransporter gene. Physiological modulation in health and abnormal function in disease. Nonoguchi H, et al. **Exp Nephrol** 1998 Jul-Aug; 6(4):272–6 (19 ref.)

Integrated function of urea transporters in the mammalian kidney. Trinh-Trang-Tan MM, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):471–9 (35 ref.)

Regulation of the ROMK potassium channel in the kidney. Wald H. **Exp Nephrol** 1999 May-Jun;7(3):201–6 (28 ref.)

Cystic fibrosis transmembrane conductance regulator in the kidney: clues to its role? Wilson PD. **Exp Nephrol** 1999 Jul-Aug;7(4):284–9 (43 ref.)

Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. Navar LG, et al. **J Am Soc Nephrol**

1999 Apr;10 Suppl 12:S266–72 (65 ref.)
Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. Dekant W, et al. **J Cancer Res Clin Oncol** 1999;125(3–4):174–81 (93 ref.)
Molecular pharmacology of organic cation transporters in kidney. Koepsell H, et al. **J Membr Biol** 1999 Jan 15; 167(2):103–17 (131 ref.)
Amino acid metabolism, substrate availability and the control of protein dynamics in the human kidney. Garibotto G, et al. **J Nephrol** 1999 Jul–Aug;12(4):203–11 (55 ref.)
Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review. Heiene R, et al. **J Vet Intern Med** 1998 Nov–Dec;12(6):401–14 (86 ref.)
Angiotensin II receptors in the kidney. Chung O, et al. **Kidney Blood Press Res** 1998;21(2–4):245–8 (29 ref.)
FGF-2: specific activity in kidney? [editorial; comment] Barasch J. **Kidney Int** 1999 Sep;56(3):1156–7 (13 ref.) Comment on: Kidney Int 1999 Sep;56(3):883–97.
Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Stumvoll M, et al. **Kidney Int** 1999 Mar;55(3):778–92 (218 ref.)
Angiotensin II, nitric oxide, and end-organ damage in hypertension. Batainch A, et al. **Kidney Int Suppl** 1998 Dec; 68:S14–9 (55 ref.)
Cellular iron metabolism. Ponka P. **Kidney Int Suppl** 1999 Mar;69:S2–11 (62 ref.)
Control of the renal renin system by local factors. Wagner C, et al. **Kidney Int Suppl** 1998 Sep;67:S78–83 (61 ref.)
Pathogenesis of renal sodium retention in congestive heart failure. Andreoli TE. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):11–20 (46 ref.)
Interaction of the renal amylin and renin–angiotensin systems in animal models of diabetes and hypertension. Wookey PJ, et al. **Miner Electrolyte Metab** 1998;24(6):389–99 (113 ref.)
Glucose production by the human kidney—its importance has been underestimated [editorial] Stumvoll M. **Nephrol Dial Transplant** 1998 Dec;13(12):2996–9 (18 ref.)
Relationship between urinary calcium and net acid excretion as determined by dietary protein and potassium: a review. Lemann J Jr. **Nephron** 1999;81 Suppl 1:18–25 (29 ref.)
Renal handling of calcium. Seldin DW. **Nephron** 1999;81 Suppl 1:2–7 (11 ref.)
The renal excretory mechanisms and the role of organic cations in modulating the renal handling of paraquat. Chan BS, et al. **Pharmacol Ther** 1998 Sep;79(3):193–203 (69 ref.)
Renal dopamine receptors in health and hypertension. Jose PA, et al. **Pharmacol Ther** 1998 Nov;80(2):149–82 (477 ref.)
Strategies to reduce renal radioactivity levels of antibody fragments. Arano Y. **Q J Nucl Med** 1998 Dec;42(4):262–70 (61 ref.)
Citrate transport by the kidney and intestine. Pajor AM. **Semin Nephrol** 1999 Mar;19(2):195–200 (55 ref.)
Regulation of potassium transport in the maturing kidney. Satlin LM. **Semin Nephrol** 1999 Mar;19(2):155–65 (63 ref.)
Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. Yamamoto K, et al. **Semin Thromb Hemost** 1998; 24(3):261–8 (56 ref.)
[Serum uric acid level and fractional excretion of urate in fluid and electrolyte disturbances] Shichiri M, et al. **Rinsho Byori** 1999 May;47(5):417–23 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Renal renin–angiotensin system in homeostatic water–electrolyte regulation] Lis GJ. **Przegl Lek** 1999; 56(2):164–8 (30 ref.) (Eng. Abstr.) **(Pol)**
[Paracellular ion transfer in kidney and tissues and its pharmacological regulation] Lebedev AA. **Vestn Ross Akad Med Nauk** 1999;(3):25–8 (12 ref.) (Eng. Abstr.) **(Rus)**
[Nitric oxide in health and kidney diseases] Peco-Antić A. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):183–9 (68 ref.) **(Scc)**
[Antioxidants of renal origin] Kozachok MM. **Lik Sprava** 1999 Jan–Feb;(1):6–11 (37 ref.) **(Ukr)**

PATHOLOGY

A case of panlobar nephroblastomatosis with bilateral Wilms' tumour. The concept of "nephroblastomatosis" and its clinical importance. Lancaster EJ, et al. **Cent Afr J Med** 1998 Jul;44(7):182–7 (15 ref.)
Mitogen-activated protein kinases and transcriptional responses in renal injury and repair. Bonventre JV, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):425–33 (89 ref.)
Integrins and the kidney: biology and pathobiology. Hamerski DA, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):9–14 (47 ref.)
Growth factors and apoptosis in acute renal injury. Hammerman MR. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):419–24 (43 ref.)
Renal immunology and pathology [editorial] Singh AK. **Curr Opin Nephrol Hypertens** 1999 May;8(3):277–9 (12 ref.)
Heat shock proteins in renal injury and recovery. Van Why SK, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):407–12 (49 ref.)
What makes cells grow larger and how do they do it? Renal hypertrophy revisited [editorial] Preisig P. **Exp Nephrol** 1999 Jul–Aug;7(4):273–83 (73 ref.)
Hypertension-induced end-organ damage : A new transgenic approach to an old problem. Luft FC, et al. **Hypertension** 1999 Jan;33(1 Pt 2):212–8 (76 ref.)
State-of-the-art magnetic resonance imaging of the kidneys and upper urinary tract. Dockery WD, et al. **J Endourol** 1999 Jul–Aug;13(6):417–23 (19 ref.)
New kids in the block: the role of FasL and Fas in kidney damage. Ortiz A, et al. **J Nephrol** 1999 May–Jun; 12(3):150–8 (78 ref.)
Chronic interstitial damage in proteinuria. Does complement mediate tubulointerstitial injury? Sheerin NS, et al. **Kidney Blood Press Res** 1999;22(1–2):47–52 (57 ref.)
Renal biopsy in lupus nephritis. Grande JP, et al. **Lupus** 1998; 7(9):611–7 (39 ref.)
Renal abnormalities in psoriatic patients: a review [editorial] Heuvels J, et al. **Nephron** 1999;82(1):1–6 (42 ref.)
Renal epithelial polarity in health and disease. Wagner MC, et al. **Pediatr Nephrol** 1999 Feb;13(2):163–70 (55 ref.)
Apoptosis in the kidney [see comments] Davis MA, et al. **Toxicol Pathol** 1998 Nov–Dec;26(6):810–25 (164 ref.) Comment in: Toxicol Pathol 1998 Nov–Dec;26(6):826–7.
Apoptosis in the kidney: a toxicologic pathologist's perspective [see comments] Short BG. **Toxicol Pathol** 1998 Nov–Dec;26(6):826–7 (11 ref.) Comment in: Toxicol Pathol 1998 Nov–Dec;26(6):810–25.
[Inflammatory mechanisms of renal fibrosis: glomerulonephritis] Baud L, et al. **Bull Acad Natl Med** 1999;183(1):23–31 (27 ref.) (Eng. Abstr.) **(Fre)**
[Genetics of kidney diseases and renal fibrosis] Grünfeld JP, et al. **Bull Acad Natl Med** 1999;183(1):57–63 (21 ref.) (Eng. Abstr.) **(Fre)**
[Metabolic mechanisms of renal fibrosis: diabetes] Marre M. **Bull Acad Natl Med** 1999;183(1):47–54; discussion 54–5 (26 ref.) (Eng. Abstr.) **(Fre)**
[Vascular mechanisms of renal fibrosis. Vasculonephropathies and arterial hypertension] Meyrier A. **Bull Acad Natl Med** 1999;183(1):33–45; discussion 45–6 (71 ref.) (Eng. Abstr.) **(Fre)**
[Tubulo–interstitial lesions in glomerular diseases] Uchida S. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1423–7 (8 ref.) **(Jpn)**
[The place of radionuclide methods in diagnostic imaging of renovascular hypertension] Pilecki S, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):220–3 (22 ref.) (Eng. Abstr.) **(Pol)**
[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul–Aug;(4):50–9 (101 ref.) **(Rus)**
[A bladder nephrogenic adenoma. A case report] Llanes González L, et al. **Arch Esp Urol** 1998 Nov;51(9):923–5 (11 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Biology and functions of renal receptors for angiotensin II and its active fragments. Ardaillou R, et al. **Adv Nephrol Necker Hosp** 1998;28:225–57 (123 ref.)
Recent insights into the coordinate regulation of body water and divalent mineral ion metabolism. Baum MA, et al. **Am J Med Sci** 1998 Nov;316(5):321–8 (79 ref.)
Role of aquaporin water channels in kidney and lung. Verkman AS. **Am J Med Sci** 1998 Nov;316(5):310–20 (80 ref.)
Gene transfer in the kidney. Kelley VR, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):F1–9 (72 ref.)
20-HETE and the kidney: resolution of old problems and new beginnings. McGiff JC, et al. **Am J Physiol** 1999 Sep; 277(3 Pt 2):R607–23 (118 ref.)
The Cre/loxP system and gene targeting in the kidney. Stricklett PK, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F651–7 (47 ref.)
Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Smyth DD, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:344–57 (72 ref.)
Anatomy and physiology of the kidney. Wallace MA. **AORN J** 1998 Nov;68(5):800, 803–16, 819–20; quiz 821–4 (33 ref.)
Blood pressure set point. Taquini AC. **Biol Res** 1998; 31(3):131–4 (17 ref.)
Serum cystatin C as an endogenous marker of the renal function—a review. Randers E, et al. **Clin Chem Lab Med** 1999 Apr;37(4):389–95 (74 ref.)
Chronic studies on the interaction between nitric oxide and endothelin in cardiovascular and renal function. Pollock DM. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):258–61 (27 ref.)
Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension. Wookey PJ, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):653–60 (70 ref.)
Molecular and cellular determinants of mineralocorticoid selectivity. Farman N. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):45–51 (64 ref.)
Role of retinoids in renal development: pathophysiological implication. Merlet-Bénichou C, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):39–43 (41 ref.)
Renographic indices for evaluation of changes in graft function. El-Maghraby TA, et al. **Eur J Nucl Med** 1998 Nov;25(11):1575–86 (79 ref.)
Functional imaging of the kidneys with fast MRI techniques. Prasad PV, et al. **Eur J Radiol** 1999 Feb;29(2):133–48 (54 ref.)
Imaging approaches to the correlation of structure and function in the kidney. Hare CM. **Exp Nephrol** 1998 Sep–Oct;6(5):382–90 (32 ref.)
Gene transfer into the adult kidney for unravelling disease processes. Kitamura M, et al. **Exp Nephrol** 1998 Sep–Oct; 6(5):429–37 (55 ref.)
Cell adhesion molecules in the kidney: from embryo to adult. Perantoni AO. **Exp Nephrol** 1999 Mar–Apr;7(2):80–102 (254 ref.)
Scintigraphic imaging of renal function. Peters AM. **Exp Nephrol** 1998 Sep–Oct;6(5):391–7 (39 ref.)
Osteopontin function in pathology: lessons from osteopontin-deficient mice. Rittling SR, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):103–13 (91 ref.)
Modifiable gene expression in mice: kidney-specific deletion of a target gene via the cre–loxP system. Stec DE, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):568–75 (41 ref.)
Blood pressure variability and kidney function. Holstein-Rathlou NH, et al. **Fundam Clin Pharmacol** 1998; 12 Suppl 1:29s–34s (20 ref.)
The aging kidney. Jassal SV, et al. **Geriatr Nephrol Urol** 1998; 8(3):141–7 (65 ref.)
Hepatocyte growth factor and the kidney: it is not just for the liver. Balkovetz DF, et al. **Int Rev Cytol** 1999; 186:225–60 (202 ref.)
What have we learned from gene targeting studies for the renin angiotensin system of the kidney? Nishimura H, et al. **Intern Med** 1999 Apr;38(4):315–23 (66 ref.)
Transmembrane proteins in the tight junction barrier. Fanning AS, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1337–45 (80 ref.)
Physiology and pathophysiology of renal aquaporins. Nielsen S, et al. **J Am Soc Nephrol** 1999 Mar;10(3):647–63 (119 ref.)
Lessons on renal physiology from transgenic mice lacking aquaporin water channels. Verkman AS. **J Am Soc Nephrol** 1999 May;10(5):1126–35 (48 ref.)
Integration of renal and gastrointestinal function. Braun EJ. **J Exp Zool** 1999 Mar–Apr 1;283(4–5):495–9 (8 ref.)
Osmoregulation in the mammalian kidney: the role of organic osmolytes. Grunewald RW, et al. **J Exp Zool** 1999 Jun 1;283(7):708–24 (153 ref.)
Transforming growth factor beta signal transduction in the kidney. Böttinger EP, et al. **Kidney Blood Press Res** 1998; 21(2–4):259–61 (19 ref.)
Epithelial sodium channel and its implication in the control of blood pressure. Hummler E. **Kidney Blood Press Res** 1998;21(2–4):253–5 (14 ref.)
Pregnancy-induced alterations in renal function. Schobel HP. **Kidney Blood Press Res** 1998;21(2–4):274–6 (15 ref.)
Neural control of kidney function. Veelken R. **Kidney Blood Press Res** 1998;21(2–4):249–52 (67 ref.)
The development of x-ray imaging to study renal function. Lerman LO, et al. **Kidney Int** 1999 Feb;55(2):400–16 (101 ref.)
Aquaporins in the kidney: emerging new aspects. Yamamoto T, et al. **Kidney Int** 1998 Oct;54(4):1041–51 (92 ref.)
Role of vascular endothelial growth factor in the response to vessel injury. Alvarez Arroyo MV, et al. **Kidney Int Suppl** 1998 Dec;68:S7–9 (8 ref.)
Regulation of renal function by prostaglandin E receptors. Breyer MD, et al. **Kidney Int Suppl** 1998 Sep;67:S88–94 (74 ref.)
Differential actions of angiotensin-(1–7) in the kidney. Chappell MC, et al. **Kidney Int Suppl** 1998 Dec;68:S3–6 (26 ref.)
Pathophysiology of renal fluid retention. Schrier RW, et al. **Kidney Int Suppl** 1998 Sep;67:S127–32 (62 ref.)
A genetic approach for studying the role of thromboxane A2 in the kidney. Thomas DW, et al. **Kidney Int Suppl** 1998 Sep;67:S84–7 (61 ref.)
Important role of the kidney in human carbohydrate metabolism. Stumvoll M, et al. **Med Hypotheses** 1999 May; 52(5):363–6 (51 ref.)
Control of renal function and blood pressure by angiotensin II: implications for diabetic glomerular injury. Brands MW, et al. **Miner Electrolyte Metab** 1998;24(6):371–80 (60 ref.)
The renal function of 25-hydroxyvitamin D3-1alpha-hydroxylase. Zehnder D, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):213–20 (60 ref.)
Circulation and the kidney. Basic physiological and pathophysiological concepts. Greger R. **Nephrol Dial Transplant** 1999;14 Suppl 4:35–7 (20 ref.)
The growth hormone–insulin–like growth factor axis in kidney re–revisited. Hammerman MR. **Nephrol Dial Transplant** 1999 Aug;14(8):1853–60 (54 ref.)
Cyclins and the cyclin–kinase system—their potential roles in nephrology [editorial] Terada Y, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1913–6 (15 ref.)
Role of aquaporins in renal water handling: physiology and pathophysiology. van Os CH, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1645–51 (66 ref.)
Renal disease in the elderly. Davison AM. **Nephron** 1998 Sep;80(1):6–16 (42 ref.)
Microtubule-dependent vesicle transport: modulation of channel and transporter activity in liver and kidney. Hamm-Alvarez SF, et al. **Physiol Rev** 1998 Oct; 78(4):1109–29 (167 ref.)
Size does matter: will knockout of p21(WAF1/CIP1) save the kidney by limiting compensatory renal growth? [comment] Al-Awqati Q, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10551–3 (17 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10830–5.
Role of nitric oxide in renal hemodynamics. Gabbai FB, et al. **Semin Nephrol** 1999 May;19(3):242–50 (98 ref.)

Obesity in dogs: effects on renal function, blood pressure, and renal disease. Joles JA. **Vet Q** 1998 Oct;20(4):117–20 (56 ref.)

[Kidney aging: cellular mechanisms of problems of hydration equilibrium] Teillet L, et al. **Therapie** 1999 Jan–Feb; 54(1):147–54 (43 ref.) (Eng. Abstr.) **(Fre)**

[Molecular physiology and pathophysiology of renal phosphate excretion] Murer H, et al. **Schweiz Med Wochenschr** 1998 Aug 22;128(34):1247–52 (32 ref.) (Eng. Abstr.) **(Ger)**

[Structures and functions of the renal tubules and interstitium] Inokuchi S, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1388–95 (6 ref.) **(Jpn)**

[Repair and regeneration of renal tissue] Nagata M, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):910–9 (19 ref.) **(Jpn)**

[Angiotensin II and the kidney] Kaname S, et al. **Nippon Rinsho** 1999 May;57(5):1103–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Adrenomedullin] Bełtowski J. **Postepy Hig Med Dosw** 1999; 53(1):99–123 (124 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Pathophysiology of aquaporin–2 in water balance disorders. Frøkiaer J, et al. **Am J Med Sci** 1998 Nov;316(5):291–9 (45 ref.)

Effect of high–dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189–91 (14 ref.)

Obstructive nephropathy in the pig. Aspects of renal hemodynamics and hormonal changes during acute unilateral ureteral obstruction. Frøkiaer J. **APMIS Suppl** 1998;82:7–48 (259 ref.)

Effect of ethanol ingestion on renal regulation of water and electrolytes. Rodrigo R, et al. **Arch Med Res** 1998 Autumn; 29(3):209–18 (96 ref.)

Diabetes––renal function––what are the special problems? Ritz E, et al. **Basic Res Cardiol** 1998;93 Suppl 2:125–30 (50 ref.)

Angiotensin II receptor blockade and renal protection. Sharma AM, et al. **Basic Res Cardiol** 1998;93 Suppl 2:120–4 (51 ref.)

Cardiorenal effects of behavioral inhibition of breathing. Anderson DE. **Biol Psychol** 1998 Sep;49(1–2):151–63 (42 ref.)

The kidney in chronic liver disease: circulatory abnormalities, renal sodium handling and role of natriuretic peptides. Valdivieso A. **Biol Res** 1998;31(3):291–304 (101 ref.)

Renal function in the elderly. Rodger RS. **Br J Urol** 1998 Dec;82 Suppl 1:65–70 (22 ref.)

Integrins and the kidney: biology and pathobiology. Hamerski DA, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):9–14 (47 ref.)

Regeneration processes in the kidney after acute injury: role of infiltrating cells. Ghielli M, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):502–7 (26 ref.)

Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Norman JT, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):167–77 (94 ref.)

Nephroprotective effect of antihypertensive drugs in essential hypertension. Susic D, et al. **J Hypertens** 1998 May; 16(5):555–67 (182 ref.)

Renal function in noninsulin–dependent diabetes mellitus patients treated with angiotensin–converting enzyme inhibitors and calcium channel blockers. Nosadini R, et al. **J Hypertens Suppl** 1998 Sep;16(4):S27–32 (30 ref.)

Pathogenesis of ascites and renal salt retention in cirrhosis. Palmer BF. **J Investig Med** 1999 May;47(5):183–202 (181 ref.)

Molecular pathophysiology of inborn renal Na+ transport defects. Greger R. **Kidney Blood Press Res** 1998; 21(2–4):222–5 (30 ref.)

Therapeutic implications and new perspectives for essential hypertension and renal damage. González–Albarrán O, et al. **Kidney Int Suppl** 1998 Dec;68:S46–50 (43 ref.)

Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. Yerkes E, et al. **Kidney Int Suppl** 1998 Sep;67:S75–7 (12 ref.)

The pulmonary–renal syndrome: a poorly understood clinicopathologic condition. Bosch X, et al. **Lupus** 1999; 8(4):258–62 (28 ref.)

Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Grande JP. **Lupus** 1998;7(9):604–10 (87 ref.)

Cardiovascular risk factors, smoking and kidney function. Baggio B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:2–5 (47 ref.)

Renal impairment in myeloma: time for a reappraisal? Mallick NP, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:30–2 (10 ref.)

Cytokine network and resident renal cells in glomerular diseases. Schena FP. **Nephrol Dial Transplant** 1999;14 Suppl 1:22–6 (46 ref.)

Cytokines and cellular activation in nephritis. Yokoyama H, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:39–41 (11 ref.)

Renal function and renal disease in males or females––vive la petite difference. Zeier M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2195–8 (63 ref.)

Mechanisms of renal repair and survival following acute injury. Safirstein R, et al. **Semin Nephrol** 1998 Sep; 18(5):519–22 (35 ref.)

Nitric oxide, sepsis, and the kidney. Schwartz D, et al. **Semin Nephrol** 1999 May;19(3):272–6 (28 ref.)

Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. Yamamoto K, et al. **Semin Thromb Hemost** 1998; 24(3):261–8 (56 ref.)

Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Palange P. **Thorax** 1998 Nov; 53(11):989–91 (41 ref.)

[Molecular physiology and pathophysiology of renal phosphate excretion] Murer H, et al. **Schweiz Med Wochenschr** 1998 Aug 22;128(34):1247–52 (32 ref.) (Eng. Abstr.) **(Ger)**

[Tobaccoism and albuminuria in hypertension and diabetes: is tobacco also harmful for the kidney? (editorial)] Martínez Ocaña JC, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):176–8 (61 ref.) **(Spa)**

RADIOGRAPHY

Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT. Yuh BI, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):747–55 (22 ref.)

Imaging approaches to the correlation of structure and function in the kidney. Hare CM. **Exp Nephrol** 1998 Sep–Oct;6(5):382–90 (32 ref.)

The development of x–ray imaging to study renal function. Lerman LO, et al. **Kidney Int** 1999 Feb;55(2):400–16 (101 ref.)

Radiographic staging of renal injuries. Carpio F, et al. **World J Urol** 1999 Apr;17(2):66–70 (16 ref.)

[The place of radionuclide methods in diagnostic imaging of renovascular hypertension] Pilecki S, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):220–3 (22 ref.) (Eng. Abstr.) **(Pol)**

[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul–Aug;(4):50–9 (101 ref.) **(Rus)**

RADIONUCLIDE IMAGING

Delayed gallium–67 uptake in renal atheroembolic disease. Peixoto AJ, et al. **Am J Kidney Dis** 1999 Jul;34(1):161–5 (30 ref.)

Scintigraphic imaging of renal function. Peters AM. **Exp Nephrol** 1998 Sep–Oct;6(5):391–7 (39 ref.)

Diagnostic imaging modalities for delayed renal graft function: a review. el–Maghraby TA, et al. **Nucl Med Commun** 1998 Oct;19(10):915–36 (156 ref.)

Report of the Radionuclides in Nephrourology Committee for evaluation of transplanted kidney (review of techniques). Dubovsky EV, et al. **Semin Nucl Med** 1999 Apr;29(2):175–88 (43 ref.)

Interventions in renal scintirenography. Fine EJ. **Semin Nucl Med** 1999 Apr;29(2):128–45 (78 ref.)

Technetium–99m–EC and other potential new agents in renal nuclear medicine. Moran JK. **Semin Nucl Med** 1999 Apr; 29(2):91–101 (38 ref.)

Consensus on renal cortical scintigraphy in children with urinary tract infection. Scientific Committee of Radionuclides in Nephrourology. Piepsz A, et al. **Semin Nucl Med** 1999 Apr;29(2):160–74 (125 ref.)

Radionuclide renography: a personal approach. Taylor A. **Semin Nucl Med** 1999 Apr;29(2):102–27 (104 ref.)

SURGERY

Percutaneous access techniques in renal surgery. Irby PB, et al. **Tech Urol** 1999 Mar;5(1):29–39 (52 ref.)

Reconstructive surgery for trauma of the upper urinary tract. Brandes SB, et al. **Urol Clin North Am** 1999 Feb; 26(1):183–99, x (52 ref.)

Complex renal reconstruction. Bretan PN Jr, et al. **Urol Clin North Am** 1999 Feb;26(1):201–17, x (33 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of crossed ectopic multicystic kidney. Maayan A, et al. **Am J Perinatol** 1998 Aug;15(8):499–502 (5 ref.)

[Ultrasonic methods in the diagnosis and treatment of pyelonephritis] Petrov DA, et al. **Urol Nefrol (Mosk)** 1998 Sep–Oct;(5):48–51 (98 ref.) **(Rus)**

ULTRASTRUCTURE

[Structures and functions of the renal tubules and interstitium] Inokuchi S, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1388–95 (6 ref.) **(Jpn)**

VIROLOGY

Renal manifestations of hepatitis C infection. Daghestani L, et al. **Am J Med** 1999 Mar;106(3):347–54 (103 ref.)

KIDNEY, ARTIFICIAL

The move from dead to living membranes: bioartificial organ support of failing systems. Kishore KK, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):324–32 (59 ref.)

HISTORY

The use of the artificial kidney in the treatment of uremia. 1952 [classical article] Merrill JP. **J Urban Health** 1998 Dec;75(4):911–8; discussion 919–21 (9 ref.)

KIDNEY–BRUSH–BORDER NEUTRAL PROTEINASE see **NEPRILYSIN**

KIDNEY CALCULI

[Renal calculosis in pediatrics] Khoory BJ, et al. **Pediatr Med Chir** 1998 Nov–Dec;20(6):367–76 (78 ref.) (Eng. Abstr.) **(Ita)**

[Pathogenesis, classification and treatment of coral–like nephrolithiasis] Driurak VS, et al. **Klin Khir** 1999;(1):48–50 (31 ref.) **(Ukr)**

CHEMICALLY INDUCED

[Drug induced lithiases] Daudon M, et al. **Presse Med** 1998 Apr 11;27(14):675–83 (60 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Renal stone analysis: is there any clinical value? Smith CL. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):703–9 (67 ref.)

Cell–crystal interactions and kidney stone formation. Lieske JC, et al. **Nephron** 1999;81 Suppl 1:8–17 (55 ref.)

COMPLICATIONS

[A case of transitional cell carcinoma and milk of calcium in a pyelocalyceal diverticulum] Yoshimura K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):649–52 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Role of electrohydraulic extracorporeal shockwave lithotripsy (Dornier HM 4) in the treatment of caliceal diverticulum lithiasis] Torrecilla Ortiz C, et al. **Actas Urol Esp** 1998 Oct;22(9):744–50 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Imaging the patient with acute abdominal pain: current concepts. Mayo–Smith WW. **Med Health R I** 1999 Jun; 82(6):202–6 (23 ref.)

[Functional evaluation in patients with kidney calculi] Stojimirović B. **Srp Arh Celok Lek** 1998 Sep–Oct; 126(9–10):394–8 (8 ref.) (Eng. Abstr.) **(Sec)**

EPIDEMIOLOGY

Renal stone disease in children. Santos–Victoriano M, et al. **Clin Pediatr (Phila)** 1998 Oct;37(10):583–99 (150 ref.)

ETIOLOGY

Renal calculi in children: imaging features that lead to diagnoses: a pictorial essay. Kraus SJ, et al. **Pediatr Radiol** 1999 Aug;29(8):624–30 (16 ref.)

Urinary tract infections and renal stone disease. Pupek–Musialik D. **Przegl Lek** 1998;55 Suppl 1:51–3 (12 ref.) **(Eng, Pol)**

Low calcium diet in hypercalciuric calcium nephrolithiasis: first do no harm. Hess B. **Scanning Microsc** 1996; 10(2):547–54; discussion 554–6 (62 ref.)

Role of calcium oxalate monohydrate crystal interactions with renal epithelial cells in the pathogenesis of nephrolithiasis: a review. Lieske JC, et al. **Scanning Microsc** 1996;10(2):519–33; discussion 533–4 (65 ref.)

[Idiopathic hypercalciuria in childhood] Reusz G. **Orv Hetil** 1998 Dec 6;139(49):2957–62 (50 ref.) (Eng. Abstr.) **(Hun)**

[2,8–dihydroxyadenine urolithiasis due to partial deficiency of adenine phosphoribosyltransferase: a case report] Ohne T, et al. **Hinyokika Kiyo** 1998 Oct;44(10):725–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Thakker RV. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):385–8 (42 ref.)

Nephrolithiasis. Scheinman SJ. **Semin Nephrol** 1999 Jul; 19(4):381–8 (66 ref.)

METABOLISM

Metabolic evaluation and medical therapy for stone formation [see comments] Krautschick AW. **Curr Opin Urol** 1999 Jul; 9(4):335–8 (32 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.

Idiopathic calcium nephrolithiasis. Marangella M, et al. **Nephron** 1999;81 Suppl 1:38–44 (33 ref.)

Struvite stones. Rodman JS. **Nephron** 1999;81 Suppl 1:50–9 (54 ref.)

[Update on the role of diet in recurrent nephrolithiasis] Riobó Serván P, et al. **Nutr Hosp** 1998 Jul–Aug;13(4):167–71 (28 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Renal stone analysis: is there any clinical value? Smith CL. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):703–9 (67 ref.)

PREVENTION & CONTROL

Urine volume: stone risk factor and preventive measure. Borghi L, et al. **Nephron** 1999;81 Suppl 1:31–7 (51 ref.)
Medical prevention of renal stone disease. Pak CY. **Nephron** 1999;81 Suppl 1:60–5 (20 ref.)

RADIOGRAPHY

Renal calculi in children: imaging features that lead to diagnoses: a pictorial essay. Kraus SJ, et al. **Pediatr Radiol** 1999 Aug;29(8):624–30 (16 ref.)

SURGERY

Laparoscopic pyelolithotomy in a pelvic kidney: a case report and review of the literature. Hoenig DM, et al. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):163–5 (6 ref.)
Percutaneous access techniques in renal surgery. Irby PB, et al. **Tech Urol** 1999 Mar;5(1):29–39 (52 ref.)

THERAPY

Metabolic evaluation and medical therapy for stone formation [see comments] Krautschick AW. **Curr Opin Urol** 1999 Jul; 9(4):335–8 (32 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.
Percutaneous nephrolithotripsy [see comments] Puppo P. **Curr Opin Urol** 1999 Jul;9(4):325–8 (14 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.
Treatment of renal stones by extracorporeal shock wave lithotripsy. Renner C, et al. **Nephron** 1999;81 Suppl 1:71–81 (81 ref.)
[Role of electrohydraulic extracorporeal shockwave lithotripsy (Dornier HM 4) in the treatment of caliceal diverticulum lithiasis] Torrecilla Ortiz C, et al. **Actas Urol Esp** 1998 Oct;22(9):744–50 (22 ref.) (Eng. Abstr.) **(Spa)**

URINE

Urine volume: stone risk factor and preventive measure. Borghi L, et al. **Nephron** 1999;81 Suppl 1:31–7 (51 ref.)

VETERINARY

Canine and feline nephrolithiasis. Epidemiology, detection, and management. Ross SJ, et al. **Vet Clin North Am Small Anim Pract** 1999 Jan; 29(1):231–50, xiii–xiv (15 ref.)

KIDNEY CALICES

Long-term outcome of caliceal diverticula following percutaneous endosurgical management. Shalhav AL, et al. **J Urol** 1998 Nov;160(5):1635–9 (25 ref.)
[Role of electrohydraulic extracorporeal shockwave lithotripsy (Dornier HM 4) in the treatment of caliceal diverticulum lithiasis] Torrecilla Ortiz C, et al. **Actas Urol Esp** 1998 Oct;22(9):744–50 (22 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Complete pyelo-calyceal avulsion as a result of blunt abdominal trauma. Pagano S, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):66–8 (8 ref.)

KIDNEY CIRCULATION see **RENAL CIRCULATION**

KIDNEY COLLECTING DUCTS see **KIDNEY TUBULES, COLLECTING**

KIDNEY CONCENTRATING ABILITY

PHYSIOLOGY

Regulation of thick ascending limb transport by vasopressin. Knepper MA, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):628–34 (75 ref.)
Regulation of renal urea transporters. Sands JM. **J Am Soc Nephrol** 1999 Mar;10(3):635–46 (137 ref.)

KIDNEY CORTEX

RADIONUCLIDE IMAGING

Consensus on renal cortical scintigraphy in children with urinary tract infection. Scientific Committee of Radionuclides in Nephrourology. Piepsz A, et al. **Semin Nucl Med** 1999 Apr;29(2):160–74 (125 ref.)

KIDNEY, CYSTIC

COMPLICATIONS

Prenatal diagnosis of crossed ectopic multicystic kidney. Maayan A, et al. **Am J Perinatol** 1998 Aug;15(8):499–502 (5 ref.)
Glomerulocystic kidney disease in an adult presenting as end-stage renal failure. Abderrahim E, et al. **Nephrol Dial Transplant** 1999 May;14(5):1276–8 (30 ref.)

DIAGNOSIS

Glomerulocystic kidney disease in an adult presenting as end-stage renal failure. Abderrahim E, et al. **Nephrol Dial Transplant** 1999 May;14(5):1276–8 (30 ref.)
[Cystic kidney disease] Sobral FT. **Acta Med Port** 1999 Jan–Mar;12(1–3):123–9 (22 ref.) (Eng. Abstr.) **(Por)**
[A simple kidney cyst in childhood] Morales Concepción J, et al. **Arch Esp Urol** 1998 Nov;51(9):897–900 (13 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Long-term management of dialysis patients. II. Beta 2-microglobulin associated amyloidosis and acquired cystic kidney disease] Floege J, et al. **Internist (Berl)** 1999 Jan; 40(1):64–9 (27 ref.) **(Ger)**
[Wunderlich's syndrome in a patient on hemodialysis with acquired cystic kidney disease. A report of a new case] Peña Porta JM, et al. **Actas Urol Esp** 1999 Jan;23(1):76–8 (11 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Renal cystic disease. Hildebrandt F. **Curr Opin Pediatr** 1999 Apr;11(2):141–51 (132 ref.)

PHYSIOPATHOLOGY

Renal cystic disease. Hildebrandt F. **Curr Opin Pediatr** 1999 Apr;11(2):141–51 (132 ref.)
Cystic diseases of the kidney: role of adhesion molecules in normal and abnormal tubulogenesis. Wilson PD, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):114–24 (107 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of crossed ectopic multicystic kidney. Maayan A, et al. **Am J Perinatol** 1998 Aug;15(8):499–502 (5 ref.)

KIDNEY DISEASES

Molecular mechanisms of cell death and regeneration in acute ischemic renal injury. Padanilam BJ, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):15–9 (30 ref.)
Current topics in renal nutrition. McQuiston B. **J Ren Nutr** 1999 Jul;9(3):172–4 (15 ref.)
Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. Yamamoto K, et al. **Semin Thromb Hemost** 1998; 24(3):261–8 (56 ref.)
[Tobacco, hypertension and kidney (editorial)] Muller S, et al. **Nephrologie** 1998;19(5):235–7 (27 ref.) **(Fre)**
[Renal abscess and perinephric abscess, perirenal abscess] Hayami H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):234–6 (12 ref.) **(Jpn)**

BLOOD

Optical measurement of hematocrit and other biological constituents in renal therapy. Steuer RR, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):217–24 (27 ref.)
Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Attman PO, et al. **Kidney Int Suppl** 1999 Jul;71:S14–7 (26 ref.)
Hyperuricemic nephropathies. Steele TH. **Nephron** 1999;81 Suppl 1:45–9 (42 ref.)

CHEMICALLY INDUCED

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Whelton A. **Am J Med** 1999 May 31;106(5B):13S–24S (83 ref.)
Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. Ader JL, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):539–45 (79 ref.)
Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use? Elseviers MM, et al. **Drug Saf** 1999 Jan;20(1):15–24 (48 ref.)
Antibacterial-induced nephrotoxicity in the newborn. Fanos V, et al. **Drug Saf** 1999 Mar;20(3):245–67 (205 ref.)
Lithium and the kidney: an updated review. Gitlin M. **Drug Saf** 1999 Mar;20(3):231–43 (77 ref.)
Drug-related renal dysfunction in the elderly. Bennett WM. **Geriatr Nephrol Urol** 1999;9(1):21–5 (10 ref.)
Renal effects of sevoflurane during conditions of possible increased risk [comment] Artru AA. **J Clin Anesth** 1998 Nov;10(7):531–8 (54 ref.) Comment on: J Clin Anesth 1998 Nov;10(7):539–45.
Nephrotoxicity in snake envenomation. Sitprija V, et al. **J Nat Toxins** 1999 Jun;8(2):271–7 (48 ref.)
Tubulotoxic mechanisms of ochratoxin A. Gekle M, et al. **Kidney Blood Press Res** 1998;21(2–4):277–9 (33 ref.)
The nephrotoxicity of new and old immunosuppressive drugs. Bennett WM. **Ren Fail** 1998 Sep;20(5):687–90 (20 ref.)
Risk assessment of nephrotoxicity of cadmium. Fels LM. **Ren Fail** 1999 May–Jul;21(3–4):275–81 (45 ref.)
FK506 nephrotoxicity. Finn WF. **Ren Fail** 1999 May–Jul; 21(3–4):319–29 (48 ref.)
Biomedical testing of the kidney for persons exposed to hazardous substances in the environment. Lybarger JA, et al. **Ren Fail** 1999 May–Jul;21(3–4):263–74 (20 ref.)
An animal model of chronic cyclosporine nephrotoxicity. Porter GA, et al. **Ren Fail** 1999 May–Jul;21(3–4):365–8 (17 ref.)
Renal toxicity of long-term cyclosporin [editorial] Zachariae H. **Scand J Rheumatol** 1999;28(2):65–8 (32 ref.)
Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney. Levin S, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):38–43 (0 ref.)
[Analgesic nephropathy] Pintér I, et al. **Orv Hetil** 1998 Nov 22;139(47):2839–43 (50 ref.) (Eng. Abstr.) **(Hun)**
[Drug-induced kidney diseases] Nishi S, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1247–53 (4 ref.) **(Jpn)**
[Kidney disorder caused by contrast media] Suzuki H. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2343–8 (16 ref.) **(Jpn)**
[Nephrotoxicity of pesticides] Allazov S. **Urol Nefrol (Mosk)** 1998 Nov–Dec;(6):47–9 (79 ref.) **(Rus)**

COMPLICATIONS

Non-parasitic chyluria: a case report and review of the literature. Cortvriend J, et al. **Acta Urol Belg** 1998 Oct; 66(3):11–5 (15 ref.)
Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. Mogensen CE. **Am J Cardiol** 1998 Nov 12;82(9B):4R–8R (60 ref.)
Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Sato K, et al. **Endocr J** 1998 Aug;45(4):431–9 (44 ref.)
Neurology and the kidney. Burn DJ, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):810–21 (49 ref.)
Does nutritional intervention in protein-energy malnutrition improve morbidity or mortality? Koretz RL. **J Ren Nutr** 1999 Jul;9(3):119–21 (17 ref.)
Management of hypertension in renal disease. Marcantoni C, et al. **Miner Electrolyte Metab** 1999 Jan–Apr; 25(1–2):80–3 (14 ref.)
Neuromuscular complications of kidney diseases. Galassi G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:41–7 (43 ref.)
Identification of non-diabetic glomerular disease in renal biopsies from diabetics--a dilemma. Olsen S. **Nephrol Dial Transplant** 1999 Aug;14(8):1846–9 (25 ref.)
Renal abnormalities in psoriatic patients: a review [editorial] Heuvels J, et al. **Nephron** 1999;82(1):1–6 (42 ref.)
Neurologic complications of pediatric cardiac, gastrointestinal, and renal diseases. Sanchez JL, et al. **Pediatr Ann** 1998 Oct;27(10):625–33 (58 ref.)
Renal dysplasia: the risks and consequences of leaving dysplastic tissue in situ. Husmann DA. **Urology** 1998 Oct; 52(4):533–6 (48 ref.)
[Lipid metabolism and atherosclerosis risk in renal diseases in pediatric age] Ferrara P, et al. **Minerva Pediatr** 1998 Dec;50(12):513–8 (35 ref.) (Eng. Abstr.) **(Ita)**
[A case of transitional cell carcinoma and milk of calcium in a pyelocalyceal diverticulum] Yoshimura K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):649–52 (15 ref.) (Eng. Abstr.) **(Jpn)**
[The eye and kidney diseases] Popa M, et al. **Oftalmologia** 1998;44(3):17–9 (16 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Genetic testing for renal diseases: medical and ethical considerations. Marsick R, et al. **Am J Kidney Dis** 1998 Dec;32(6):934–45 (64 ref.)
Renal granulomatous sarcoidosis in childhood: a report of 11 cases and a review of the literature. Coutant R, et al. **Eur J Pediatr** 1999 Feb;158(2):154–9 (35 ref.)
Beta-2 microglobulin in renal disease. Miyata T, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1723–35 (143 ref.)
Ischemic nephropathy: diagnosis and treatment. Zuccalà A, et al. **J Nephrol** 1998 Nov–Dec;11(6):318–24 (69 ref.)
Genetic testing for patients with renal disease: procedures, pitfalls, and ethical considerations. Korf BR. **Semin Nephrol** 1999 Jul;19(4):319–26 (40 ref.)
Primary renal mucormycosis. Lussier N, et al. **Urology** 1998 Nov;52(5):900–3 (22 ref.)
[Progressive systemic scleroderma--prognosis determining involvement of internal organ systems] Mittag M, et al. **Hautarzt** 1998 Jul;49(7):545–51 (40 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

From rats to man: a perspective on dietary L-arginine supplementation in human renal disease. Peters H, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1640–50 (99 ref.)

DRUG THERAPY

Renoprotective effects of antihypertensive drugs. Preston RA. **Am J Hypertens** 1999 Jan;12(1 Pt 2):19S–32S (107 ref.)
Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Perico N, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):571–8 (62 ref.)
Statins and the kidney. Wheeler DC. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):579–84 (58 ref.)
Arg-gly-Asp (RGD) peptides and peptidomimetics as therapeutics: relevance for renal diseases. Horton MA. **Exp Nephrol** 1999 Mar–Apr;7(2):178–84 (47 ref.)
Targets for endothelin in the diseased kidney: clues for therapeutic intervention [editorial] Rohmeiss P, et al. **Exp Nephrol** 1999 Jan–Feb;7(1):1–10 (130 ref.)

KIDNEY DISEASES

Angiotensin II antagonism in clinical practice: experience with valsartan. McInnes GT. **J Cardiovasc Pharmacol** 1999; 33 Suppl 1:S29–32; discussion S41–3 (14 ref.)

Valsartan and the kidney: present and future. Mann JF. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S37–40; discussion S41–3 (19 ref.)

The growing role for the cyclin kinase inhibitor p27Kip1 in renal disease [editorial; comment] Shankland SJ. **Kidney Int** 1998 Dec;54(6):2241–2 (14 ref.) Comment on: Kidney Int 1998 Dec;54(6):1923–33.

Recent advances in statins and the kidney. Oda H, et al. **Kidney Int Suppl** 1999 Jul;71:S2–5 (46 ref.)

Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease? [editorial] McLaughlin K, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):25–8 (30 ref.)

How good are nephrologists at controlling blood pressure in renal patients? [editorial] Maschio G. **Nephrol Dial Transplant** 1999 Sep;14(9):2075–7 (20 ref.)

Therapeutic uses of heparinoids in renal disease patients [editorial] Striker GE. **Nephrol Dial Transplant** 1999 Mar; 14(3):540–3 (23 ref.)

The clinical pharmacology of loop diuretics in the pediatric patient. Eades SK, et al. **Pediatr Nephrol** 1998 Sep; 12(7):603–16 (131 ref.)

Can L-arginine manipulation reduce renal disease? Klahr S. **Semin Nephrol** 1999 May;19(3):304–9 (37 ref.)

[Amyloidosis in adult Still's disease. Value of cyclophosphamide treatment] Kchir MM, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):527–9 (26 ref.) **(Fre)**

[Conversion enzyme inhibitors against the progression of renal and vascular diseases: yes but again] Vasmant D. **Nephrologie** 1998;19(7):457–62 (28 ref.) (Eng. Abstr.) **(Fre)**

[Potential role of angiotensin receptor antagonists in renal protection] Hayashi K, et al. **Nippon Rinsho** 1999 May; 57(5):1164–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pritchard-Jones K. **Pediatr Nephrol** 1999 Sep;13(7):620–5 (37 ref.)

EPIDEMIOLOGY

Study design and data analysis in clinical and environmental models of nephrotoxicity. Mueller PW. **Ren Fail** 1999 May–Jul;21(3–4):337–40 (6 ref.)

[Is it possible to reduce the incidence of aminoglycoside-induced nephrotoxicity?] Fillastre JP. **Bull Acad Natl Med** 1999;183(5):973–82; discussion 983 (24 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Renal and cardiac manifestations of B-cell dyscrasias with nonamyloidotic monoclonal light chain and light and heavy chain deposition diseases. Gallo GR, et al. **Adv Nephrol Necker Hosp** 1998;28:355–82 (51 ref.)

Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. He J, et al. **Am Heart J** 1999 Sep;138(3 Pt 2):211–9 (34 ref.)

The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Bakris GL. **Am J Hypertens** 1998 Oct; 11(10):158S–162S (23 ref.)

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease [editorial] Johnson RJ, et al. **Am J Kidney Dis** 1999 Feb;33(2):225–34 (82 ref.)

Neutral phosphate-induced renal tubular metabolic alkalosis. Abdullah S, et al. **Burns** 1999 Jun;25(4):364–5 (6 ref.)

Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Strobel ES, et al. **Clin Rheumatol** 1998;17(6):524–30 (43 ref.)

Chronic allograft nephropathy: the inevitable outcome of renal transplantation? Dodd SM. **Curr Top Pathol** 1999; 92:37–60 (149 ref.)

Ischemic nephropathy: an important cause of renal disease in the elderly. Buckalew VM Jr. **Geriatr Nephrol Urol** 1998; 8(3):155–9 (16 ref.)

Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. Aronson S, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):567–86 (189 ref.)

The kidney as part of the cardiovascular system. Ruilope LM. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S7–10; discussion S41–3 (50 ref.)

Does essential hypertension cause progressive renal disease? Fliser D, et al. **J Hypertens Suppl** 1998 Sep;16(4):S13–5 (41 ref.)

Simultaneous bilateral perirenal hematomas developing spontaneously in a patient with polyarteritis nodosa. Yonou H, et al. **J Urol** 1999 Aug;162(2):483 (3 ref.)

Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Strutz F, et al. **Kidney Blood Press Res** 1999;22(1–2):71–80 (91 ref.)

Therapeutic implications and new perspectives for essential hypertension and renal damage. González-Albarrán O, et al. **Kidney Int Suppl** 1998 Dec;68:S46–50 (43 ref.)

Nephrotoxicity of increased glomerular protein traffic. Abbate M, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):304–12 (78 ref.)

Genetic kidney diseases in the elderly. Grünfeld JP, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:48–50 (16 ref.)

New aspects concerning the role of catecholamines in the pathogenesis of glomerular disease [editorial] Pavenstädt H. **Nephrol Dial Transplant** 1998 Aug;13(8):1916–9 (22 ref.)

The molecular bases of plasma cell dyscrasia-related renal diseases. Ronco PM, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:4–8 (17 ref.)

Endothelins in hypertension and kidney diseases. Ivić MA, et al. **Pathol Biol (Paris)** 1998 Nov;46(9):723–30 (80 ref.)

Molecular and cellular pathophysiology of obstructive nephropathy. Chevalier RL. **Pediatr Nephrol** 1999 Sep; 13(7):612–9 (95 ref.)

Renal involvement in children with malignancies. Rossi R, et al. **Pediatr Nephrol** 1999 Feb;13(2):153–62 (153 ref.)

Viral hepatitis as a cause of renal disease. Krane NK, et al. **South Med J** 1999 Apr;92(4):354–60 (53 ref.)

[Eosinophilia and renal pathology] Giudicelli CP, et al. **Med Trop (Mars)** 1998;58(4 Suppl):477–81 (64 ref.) (Eng. Abstr.) **(Fre)**

[The nephropathies of reflux] **Prog Urol** 1998 Nov; 8(5):703–25 (114 ref.) **(Fre)**

[Puerperal thrombophlebitis of the ovarian vein revealed by renal colic] Sappey O, et al. **Prog Urol** 1999 Apr;9(2):313–8 (20 ref.) (Eng. Abstr.) **(Fre)**

[Rheumatoid arthritis and the kidney. Pinpointing an aspect of confusing contours] Biasi D, et al. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):403–6 (21 ref.) (Eng. Abstr.) **(Ita)**

[Spontaneous rupture of renal cell carcinoma: a case report] Tokiwa M, et al. **Hinyokika Kiyo** 1999 Apr;45(4):253–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Etiology and therapy of kidney disease due to hypertension] Ito S. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1292–7 (4 ref.) **(Jpn)**

[Kidney dysfunctions caused by collagen diseases] Makino H. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):522–6 (9 ref.) **(Jpn)**

[Renal disorders in patients with collagen vascular diseases] Nakano M. **Nippon Rinsho** 1999 Feb;57(2):400–3 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Oxidized lipoproteins and diseases] Itabe H. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1247–52 (27 ref.) **(Jpn)**

[Nonsteroidal anti-inflammatory drugs--nephrotoxic mechanism of action] Sułowicz W, et al. **Przegl Lek** 1999; 56(2):169–74 (60 ref.) (Eng. Abstr.) **(Pol)**

[The association between human toxocariasis and pyogenic abscesses] Rayes AA, et al. **Rev Soc Bras Med Trop** 1999 Jul–Aug;32(4):425–38 (110 ref.) (Eng. Abstr.) **(Por)**

[Spontaneous ruptures of the kidney and retroperitoneal hematomas in hemorrhagic fever with renal syndrome] Zagidullin IM, et al. **Urol Nefrol (Mosk)** 1998 Nov–Dec; (6):50–3 (56 ref.) **(Rus)**

GENETICS

Renal–coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Eccles MR, et al. **Clin Genet** 1999 Jul;56(1):1–9 (39 ref.)

Gene transfer into the adult kidney for unravelling disease processes. Kitamura M, et al. **Exp Nephrol** 1998 Sep–Oct; 6(5):429–37 (55 ref.)

Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. Staessen JA, et al. **J Cardiovasc Risk** 1997 Oct–Dec;4(5–6):401–22 (267 ref.)

Genetic disorders of renal electrolyte transport. Scheinman SJ, et al. **N Engl J Med** 1999 Apr 15;340(15):1177–87 (66 ref.)

Genetic kidney diseases in the elderly. Grünfeld JP, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:48–50 (16 ref.)

The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pritchard-Jones K. **Pediatr Nephrol** 1999 Sep;13(7):620–5 (37 ref.)

Review of the genetics of renal disease. Mueller PW. **Ren Fail** 1999 May–Jul;21(3–4):395–402 (49 ref.)

Overview: the genetics of renal disease. Guay-Woodford LM. **Semin Nephrol** 1999 Jul;19(4):312–8 (44 ref.)

Renin-angiotensin genes in renal development and the occurrence and progression of renal diseases. Hohenfellner K, et al. **Semin Nephrol** 1999 Mar;19(2):148–54 (50 ref.)

Glomerular disease. Kashtan CE. **Semin Nephrol** 1999 Jul; 19(4):353–63 (124 ref.)

Genetic testing for patients with renal disease: procedures, pitfalls, and ethical considerations. Korf BR. **Semin Nephrol** 1999 Jul;19(4):319–26 (40 ref.)

[The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease] Spiering W, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1445–50 (39 ref.) (Eng. Abstr.) **(Dut)**

[What's new in pediatric nephrology?] Broyer M. **Arch Pediatr** 1998 Oct;5(10):1132–6 (32 ref.) (Eng. Abstr.) **(Fre)**

[Genetics of kidney diseases and renal fibrosis] Grünfeld JP, et al. **Bull Acad Natl Med** 1999;183(1):57–63 (21 ref.) (Eng. Abstr.) **(Fre)**

[Genetically-induced kidney diseases] Zerres K, et al. **Internist (Berl)** 1999 May;40(5):534–42 (13 ref.) **(Ger)**

METABOLISM

The role of L-arginine in hypertension and nephrotoxicity. Klahr S. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):547–50 (25 ref.)

Transforming growth factor beta-angiotensin II interaction: implications for cardiac and renal disease. Luft FC. **J Mol Med** 1999 Jul;77(7):517–8 (15 ref.)

Arginine and nutrition in renal disease. Efron DT, et al. **J Ren Nutr** 1999 Jul;9(3):142–4 (23 ref.)

Cell cycle proteins in glomerular disease. Shankland SJ. **Kidney Blood Press Res** 1998;21(2–4):213–4 (8 ref.)

Chemokines, chemokine receptors and renal disease [editorial; comment] Egido J. **Kidney Int** 1999 Jul; 56(1):347–8 (10 ref.) Comment on: Kidney Int 1999 Jul;56(1):52–64.

The molecular bases of plasma cell dyscrasia-related renal diseases. Ronco PM, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:4–8 (17 ref.)

The complex role of osteopontin in renal disease [editorial] Wüthrich RP. **Nephrol Dial Transplant** 1998 Oct; 13(10):2448–50 (45 ref.)

Expression of bcl-2 and bax in glomerular disease. Yoshimura A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:55–7 (8 ref.)

[Cell adhesion, cytoskeleton, and kidney diseases--with special reference to cytoskeleton and adhesion control by a low molecular weight GTP-binding protein Rho] Fujimoto T, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):148–54 (14 ref.) **(Jpn)**

[Nitric oxide in health and kidney diseases] Peco-Antić A. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):183–9 (68 ref.) **(Sec)**

MICROBIOLOGY

Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy. Rey D, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):137–41 (9 ref.)

PARASITOLOGY

Tropical parasitic nephropathies. Barsoum RS. **Nephrol Dial Transplant** 1999;14 Suppl 3:79–91 (104 ref.)

[Hydatid cyst of the kidney. Report of 45 cases] Benchekroun A, et al. **Ann Urol (Paris)** 1999;33(1):19–24 (22 ref.) (Eng. Abstr.) **(Fre)**

[Important parasitic nephropathies: update from the recent literature] Duvic C, et al. **Nephrologie** 1999;20(2):65–74 (63 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Collagenofibrotic glomerulopathy: a systemic disease. Yasuda T, et al. **Am J Kidney Dis** 1999 Jan;33(1):123–7 (25 ref.)

Integrins and the kidney: biology and pathobiology. Hamerski DA, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):9–14 (47 ref.)

Reflux nephropathy. Dillon MJ, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2377–83 (91 ref.)

Molecular cell biology of renal diseases. Mené P. **J Nephrol** 1999 May–Jun;12(3):140–9 (95 ref.)

Injury mechanisms in vasculitis. Savage CO. **Kidney Blood Press Res** 1998;21(2–4):269–70 (11 ref.)

Role of mesangial cell damage in progressive renal disease. Shimizu F, et al. **Kidney Blood Press Res** 1999;22(1–2):5–12 (34 ref.)

Role of glomerular endothelial damage in progressive renal disease. Yamanaka N, et al. **Kidney Blood Press Res** 1999; 22(1–2):13–20 (60 ref.)

Progression of glomerular diseases: is the podocyte the culprit? Kriz W, et al. **Kidney Int** 1998 Sep;54(3):687–97 (133 ref.)

Atherosclerotic nephropathy. Scoble JE. **Kidney Int Suppl** 1999 Jul;71:S106–9 (27 ref.)

Clinical evaluation and monitoring of lupus kidney disease. Austin HA. **Lupus** 1998;7(9):618–21 (28 ref.)

Identification of non-diabetic glomerular disease in renal biopsies from diabetics--a dilemma. Olsen S. **Nephrol Dial Transplant** 1999 Aug;14(8):1846–9 (25 ref.)

Glomerular lesions other than amyloidosis in patients with familial Mediterranean fever [editorial] Yalçinkaya F, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):21–3 (17 ref.)

Chemokines, renal disease, and HIV infection. Wenzel UO, et al. **Nephron** 1999 Jan;81(1):5–16 (108 ref.)

Renal epithelial polarity in health and disease. Wagner MC, et al. **Pediatr Nephrol** 1999 Feb;13(2):163–70 (55 ref.)

Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney. Levin S, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):38–43 (0 ref.)

[Pathology of tubulo-interstitial nephropathies] Taguchi T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1402–9 (5 ref.) **(Jpn)**

[Tubulo-interstitial lesions in glomerular diseases] Uchida S. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1423–7 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Reducing hypertension-associated cardiorenal risk: the role of heart rate, left ventricular hypertrophy regression, and renoprotection. Materson BJ. **Am J Hypertens** 1999 Jan; 12(1 Pt 2):1S–2S (4 ref.)

Recoverability of renal function after relief of chronic partial upper urinary tract obstruction. Shokeir AA, et al. **BJU Int** 1999 Jan;83(1):11–7 (43 ref.)

The sympathetic nervous system and the kidney: its importance in renal diseases. Ritz E, et al. **Blood Press** 1998; Suppl 3:14–9 (35 ref.)
Renal function in the elderly. Rodger RS. **Br J Urol** 1998 Dec;82 Suppl 1:65–70 (22 ref.)
Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Matsubara H. **Circ Res** 1998 Dec 14–28;83(12):1182–91 (151 ref.)
The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Basile DP. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):21–30 (135 ref.)
Integrins and the kidney: biology and pathobiology. Hamerski DA, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):9–14 (47 ref.)
Diapedesis of leukocytes: antisense oligonucleotides for rescue. Dragun D, et al. **Exp Nephrol** 1999 Mar–Apr; 7(2):185–92 (68 ref.)
Arg–gly–Asp (RGD) peptides and peptidomimetics as therapeutics: relevance for renal diseases. Horton MA. **Exp Nephrol** 1999 Mar–Apr;7(2):178–84 (47 ref.)
Glomerular podocytes and adhesive interaction with glomerular basement membrane. Mundel P, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):160–6 (44 ref.)
Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Norman JT, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):167–77 (94 ref.)
Mesangial cells and their adhesive properties. Pröls F, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):137–46 (77 ref.)
Targets for endothelin in the diseased kidney: clues for therapeutic intervention [editorial] Rohmeiss P, et al. **Exp Nephrol** 1999 Jan–Feb;7(1):1–10 (130 ref.)
Cell cycle regulatory proteins in glomerular disease. Shankland SJ, et al. **Exp Nephrol** 1999 May–Jun;7(3):207–11 (22 ref.)
Glomerular disease in the elderly population. Glassock RJ. **Geriatr Nephrol Urol** 1998;8(3):149–54 (15 ref.)
How to assess glomerular function and damage in humans. Rahn KH, et al. **J Hypertens** 1999 Mar;17(3):309–17 (82 ref.)
Modern antihypertensive treatment and the progression of renal disease. Bauer JH. **J Hypertens Suppl** 1998 Oct; 16(5):S17–24 (66 ref.)
Mechanism of progression of renal disease: growth factors and related mechanisms. Benigni A, et al. **J Hypertens Suppl** 1998 Sep;16(4):S9–12 (50 ref.)
Does essential hypertension cause progressive renal disease? Fliser D, et al. **J Hypertens Suppl** 1998 Sep;16(4):S13–5 (41 ref.)
Mechanism of progression of renal disease: current hemodynamic concepts. Johnston CI, et al. **J Hypertens Suppl** 1998 Sep;16(4):S3–7 (20 ref.)
Renal perfusion and disease progression. Sensirivatana R, et al. **J Med Assoc Thai** 1999 May;82(5):496–505 (63 ref.)
Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Strutz F, et al. **Kidney Blood Press Res** 1999;22(1–2):71–80 (91 ref.)
Role of tubular cells in progressive renal disease. van Kooten C, et al. **Kidney Blood Press Res** 1999;22(1–2):53–61 (76 ref.)
Vasoactive factors and tubulointerstitial injury. Wolf G. **Kidney Blood Press Res** 1999;22(1–2):62–70 (89 ref.)
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Jandeleit–Dahm K, et al. **Kidney Int Suppl** 1999 Jul;71:S31–6 (27 ref.)
Endothelial function in proteinuric renal disease. Joles JA, et al. **Kidney Int Suppl** 1999 Jul;71:S57–61 (28 ref.)
Pathophysiology of progressive nephropathies. Remuzzi G, et al. **N Engl J Med** 1998 Nov 12;339(20):1448–56 (95 ref.)
Mechanisms for induction of apoptosis and glomerular disease. Kashihara N, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:52–4 (14 ref.)
The value of gene 'knock-out' for assessing the role of cell adhesion molecules in renal disease. McGinty A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:27–9 (19 ref.)
How good are nephrologists at controlling blood pressure in renal patients? [editorial] Maschio G. **Nephrol Dial Transplant** 1999 Sep;14(9):2075–7 (20 ref.)
Apoptosis: potential role in renal diseases. Menè P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1936–43 (68 ref.)
The Fas ligand/Fas system in renal injury [editorial] Ortiz A, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1831–4 (35 ref.)
Molecular studies of leptin: implications for renal disease. Stenvinkel P, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1103–12 (101 ref.)
Angiotensin II: a pivotal factor in the progression of renal diseases. Wolf G. **Nephrol Dial Transplant** 1999;14 Suppl 1:42–4 (17 ref.)
Renal function and renal disease in males or females--vive la petite difference. Zeier M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2195–8 (63 ref.)
Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms. Wolf G. **Nephrologie** 1998;19(7):451–6 (51 ref.)
Renal disease in the elderly. Davison AM. **Nephron** 1998 Sep;80(1):6–16 (42 ref.)
Molecular and cellular pathophysiology of obstructive nephropathy. Chevalier RL. **Pediatr Nephrol** 1999 Sep; 13(7):612–9 (95 ref.)
Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Forte LR. **Regul Pept** 1999 May 31;81(1–3):25–39 (109 ref.)
The maturing kidney: development and susceptibility. Gomez RA, et al. **Ren Fail** 1999 May–Jul;21(3–4):283–91 (16 ref.)
Pathophysiology of paraprotein production. Maniatis A. **Ren Fail** 1998 Nov;20(6):821–8 (35 ref.)
Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. Stevenson FT, et al. **Wien Klin Wochenschr** 1999 Apr 23;111(8):307–14 (94 ref.)
[Adhesion molecules in kidney diseases (part I)] Marković–Lipkovski J, et al. **Srp Arh Celok Lek** 1998 May–Jun;126(5–6):192–6 (12 ref.) (Eng. Abstr.) **(Scc)**
[Adhesion molecules in kidney diseases (part II)] Marković–Lipkovski J, et al. **Srp Arh Celok Lek** 1998 Jul–Aug;126(7–8):271–6 (46 ref.) (Eng. Abstr.) **(Scc)**
[Ambulatory monitoring of arterial pressure in a group of children with reflux nephropathy of different degrees] Jiménez–Hereza JM, et al. **An Esp Pediatr** 1998 Nov; 49(5):461–6 (34 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Renal protection and antihypertensive drugs: current status. Salvetti A, et al. **Drugs** 1999 May;57(5):665–93 (273 ref.)
Calcium antagonists and renal protection: emerging perspectives. Epstein M. **J Hypertens Suppl** 1998 Sep; 16(4):S17–25 (86 ref.)
Role of angiotensin–converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Velasquez MT, et al. **Metabolism** 1998 Dec;47(12 Suppl 1):7–11 (64 ref.)
Prevention of renal function loss after non–renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire? [editorial] Broekroelofs J, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1841–3 (13 ref.)
Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity. Roels HA, et al. **Ren Fail** 1999 May–Jul;21(3–4):251–62 (57 ref.)
[Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?] Deray G. **Arch Mal Coeur Vaiss** 1999 Jul;92(7):903–7 (26 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT. Yuh BI, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):747–55 (22 ref.)
Subservience of excretory urography to unenhanced CT in evaluating renal colic: a good idea?--benefits and consequences [letter] Lautin EM, et al. **Radiology** 1998 Oct; 209(1):286–7 (12 ref.)
[Renal malakoplakia: prognostic aspects] Vidal V, et al. **J Radiol** 1999 Mar;80(3):309–11 (9 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Technetium–99m–EC and other potential new agents in renal nuclear medicine. Moran JK. **Semin Nucl Med** 1999 Apr; 29(2):91–101 (38 ref.)
[Nuclear medicine in kidney diagnosis] Haufe S, et al. **Radiologe** 1999 May;39(5):386–97 (33 ref.) (Eng. Abstr.) **(Ger)**
[The significance of radioisotopic methods in internal diseases diagnosis] Rogulski B, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):44–6 (10 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Renal dysplasia: the risks and consequences of leaving dysplastic tissue in situ. Husmann DA. **Urology** 1998 Oct; 52(4):533–6 (48 ref.)

THERAPY

Optical measurement of hematocrit and other biological constituents in renal therapy. Steuer RR, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):217–24 (27 ref.)
Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. Mogensen CE. **Am J Cardiol** 1998 Nov 12;82(9B):4R–8R (60 ref.)
Hemodialysis morbidity and mortality: links to patient non–compliance. Bander SJ, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):649–53 (30 ref.)
Hemofiltration and double high flux dialysis: risks and benefits. Bosch JP, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):643–7 (16 ref.)
Treatment of hepatitis C infection in patients with renal disease. Diego JM, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):557–62 (61 ref.)
Diabetic nephropathy as a model of reversibility of established renal lesions. Fioretto P, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):489–94 (77 ref.)
Haemodialysis catheter bacteraemia: evolving strategies. O'Riordan E, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):639–42 (24 ref.)
The effects of nutritional supplements on the treatment of depression, diabetes, and hypercholesterolemia in the renal patient. Duncan MG. **J Ren Nutr** 1999 Apr;9(2):58–62 (16 ref.)
Toward an effective gene therapy in renal disease [editorial; comment] Basile DP. **Kidney Int** 1999 Feb;55(2):740–1 (11 ref.) Comment on: Kidney Int 1999 Feb;55(2):465–75.
Is complement a target for therapy in renal disease? Mathieson PW. **Kidney Int** 1998 Nov;54(5):1429–36 (70 ref.)
Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Yukawa S, et al. **Kidney Int Suppl** 1999 Jul;71:S141–3 (16 ref.)
The renal risks of high–dose intravenous immunoglobulin treatment [editorial] Stahl M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2182–5 (24 ref.)
Towards gene therapy for renal diseases. Imai E, et al. **Nephrologie** 1998;19(7):397–402 (40 ref.)
Therapeutic apheresis for renal diseases [editorial] Harada T, et al. **Ther Apher** 1998 Aug;2(3):193–8 (31 ref.)
Therapeutic apheresis for renal disorders. Kaplan AA. **Ther Apher** 1999 Feb;3(1):25–30 (83 ref.)
Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. Stevenson FT, et al. **Wien Klin Wochenschr** 1999 Apr 23;111(8):307–14 (94 ref.)

ULTRASONOGRAPHY

How sensitive is ultrasound in the detection of renal scars? Roebuck DJ, et al. **Br J Radiol** 1999 Apr;72(856):345–8 (26 ref.)
Imaging of subcapsular hepatic and renal hematomas in pregnancy complicated by preeclampsia and the HELLP syndrome. Chan AD, et al. **J Clin Ultrasound** 1999 Jan; 27(1):35–40 (28 ref.)
Tissue harmonic imaging: utility in abdominal and pelvic sonography. Desser TS, et al. **J Clin Ultrasound** 1999 Mar–Apr;27(3):135–42 (5 ref.)

URINE

A comparison of analytic procedures for measurement of fractional dextran clearances [see comments] Hemmelder MH, et al. **J Lab Clin Med** 1998 Nov;132(5):390–403 (57 ref.) Comment in: J Lab Clin Med 1998 Nov;132(5):360–2.
Assessment of glomerular size–selective function with fractional clearance of neutral dextran [editorial; comment] Remuzzi A, et al. **J Lab Clin Med** 1998 Nov;132(5):360–2 (27 ref.) Comment on: J Lab Clin Med 1998 Nov;132(5):390–403.
Urinary biomarkers: recommendations of the Joint European/United States Workshop for future research. Finn WF, et al. **Ren Fail** 1999 May–Jul;21(3–4):445–51 (18 ref.)
Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity. Roels HA, et al. **Ren Fail** 1999 May–Jul;21(3–4):251–62 (57 ref.)
Aquaporin–2 as a biomarker of distal renal tubular function using lithium as an experimental model. Sisson D, et al. **Ren Fail** 1999 May–Jul;21(3–4):331–6 (35 ref.)

VETERINARY

Interventional nutrition for renal disease. Brown SA, et al. **Clin Tech Small Anim Pract** 1998 Nov;13(4):217–23 (38 ref.)
Is there a role for dietary polyunsaturated fatty acid supplementation in canine renal disease? Brown SA, et al. **J Nutr** 1998 Dec;128(12 Suppl):2765S–2767S (25 ref.)
Obesity in dogs: effects on renal function, blood pressure, and renal disease. Joles JA. **Vet Q** 1998 Oct;20(4):117–20 (56 ref.)

KIDNEY FAILURE

Molecular aspects of endotoxins relevant to their biological functions. Haeffner–Cavaillon N, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):853–60 (47 ref.)

CHEMICALLY INDUCED

Aminoglycosides: nephrotoxicity. Mingeot–Leclercq MP, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1003–12 (143 ref.)
Drug–induced renal toxicity: diagnosis and prevention. Farrugia E. **Hosp Med** 1998 Feb;59(2):140–4 (11 ref.)
Induction of a critical elevation of povidone–iodine absorption in the treatment of a burn patient: report of a case. Aiba M, et al. **Surg Today** 1999;29(2):157–9 (10 ref.)
[Herbal remedies and nephrotoxicity] Nortier J, et al. **Rev Med Brux** 1999 Feb;20(1):9–14 (36 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Effect of high–dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189–91 (14 ref.)
Coexistent renal and heart failure: the importance of recognizing 'congestive cardio–renal failure'. Jones CH, et al. **Hosp Med** 1999 Jan;60(1):62–4 (24 ref.)
Cardiovascular disease and the kidney: an epidemiologic overview. Zanchetti A, et al. **J Cardiovasc Pharmacol** 1999; 33 Suppl 1:S1–6; discussion S41–3 (44 ref.)
Left ventricular hypertrophy in renal failure. Amann K, et al. **Kidney Int Suppl** 1998 Dec;68:S78–85 (43 ref.)
[Progressive sensorineural hearing loss: metabolic, hormonal and vascular etiology] Ravecca F, et al.

KIDNEY FAILURE

Acta Otorhinolaryngol Ital 1998 Aug;18(4 Suppl 59):42–50 (99 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. Esmail ZN, et al. **Ann Pharmacother** 1998 Oct;32(10):1096–8 (16 ref.)

ETIOLOGY

Recurrence of scleroderma in a renal allograft from an identical twin sister. Caplin NJ, et al. **Am J Kidney Dis** 1999 Apr;33(4):e7 (25 ref.)

Pregnancy performance and outcomes associated with diabetic nephropathy. Reece EA, et al. **Am J Perinatol** 1998 Jul;15(7):413–21 (26 ref.)

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Clark AD, et al. **Blood Rev** 1999 Jun;13(2):79–90 (116 ref.)

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire NH. **Contrib Nephrol** 1998; 124:76–93; discussion 93–102 (99 ref.)

Renal failure in liver disease. Eckardt KU. **Intensive Care Med** 1999 Jan;25(1):5–14 (80 ref.)

Antiviral therapy for HIV patients with renal insufficiency. Jayasekara D, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):384–95 (92 ref.)

Cardiovascular disease and the kidney: an epidemiologic overview. Zanchetti A, et al. **J Cardiovasc Pharmacol** 1999; 33 Suppl 1:S1–6; discussion S41–3 (44 ref.)

Renal function in treated and untreated hypertension. Rahn KH. **J Hum Hypertens** 1998 Sep;12(9):599–601 (12 ref.)

Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. Meldrum DR, et al. **J Surg Res** 1999 Aug; 85(2):185–99 (206 ref.)

Life-threatening situations in sarcoidosis. James DG. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):134–9 (13 ref.)

[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747–54 (754 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Cell localization and ontogeny of sodium transport pathways in the distal nephron: perspectives in function and failure. Bachmann S. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):31–8 (90 ref.)

Pharmacokinetic studies in volunteers with renal impairment. Keller F, et al. **Int J Clin Pharmacol Ther** 1998 Nov; 36(11):594–8 (12 ref.)

Pathogenesis of sodium and water retention in cardiac failure. Schrier RW, et al. **Ren Fail** 1998 Nov;20(6):773–81 (41 ref.)

PHYSIOPATHOLOGY

Neutrophils and renal failure. Heinzelmann M, et al. **Am J Kidney Dis** 1999 Aug;34(2):384–99 (121 ref.)

Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189–91 (14 ref.)

Mitogen-activated protein kinases and transcriptional responses in renal injury and repair. Bonventre JV, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):425–33 (89 ref.)

Heat shock proteins in renal injury and recovery. Van Why SK, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):407–12 (49 ref.)

Renal preservation in the perioperative period. Urzua J, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):111–23 (32 ref.)

Left ventricular hypertrophy in renal failure. Amann K, et al. **Kidney Int Suppl** 1998 Dec;68:S78–85 (43 ref.)

A role for endothelin in the pathogenesis of hypertension: fact or fiction? Pinto-Sietsma SJ, et al. **Kidney Int Suppl** 1998 Sep;67:S115–21 (94 ref.)

Progression of renal failure and hypertensive nephrosclerosis. Zucchelli P, et al. **Kidney Int Suppl** 1998 Dec;68:S55–9 (50 ref.)

Molecular mechanisms of vitamin D hyporesponsiveness in renal failure [editorial] Vanholder R, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):16–9 (23 ref.)

PREVENTION & CONTROL

Renal preservation in the perioperative period. Urzua J, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):111–23 (32 ref.)

SURGERY

Exercise after renal transplantation. Painter P. **Adv Ren Replace Ther** 1999 Apr;6(2):159–64 (31 ref.)

[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747–54 (754 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

On-line hemodiafiltration: technique and therapy. Ledebo I. **Adv Ren Replace Ther** 1999 Apr;6(2):195–208 (59 ref.)

ABC of intensive care. Renal support. Short A, et al. **BMJ** 1999 Jul 3;319(7201):41–4 (0 ref.)

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire NH. **Contrib Nephrol** 1998; 124:76–93; discussion 93–102 (99 ref.)

[Cardiovascular diseases in dialysis patients] Kooman JP, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1084–7 (21 ref.) (Eng. Abstr.) **(Dut)**

KIDNEY FAILURE, ACUTE

see related

HEMODIALYSIS

[Acute renal failure and electrolyte problems in the elderly] Okuda S. **Nippon Ronen Igakkai Zasshi** 1998 Aug; 35(8):615–8 (6 ref.) **(Jpn)**

[Acute renal failure: diagnosis, choice of treatment method, prognosis and outcomes] Milovanov IuS, et al. **Anesteziol Reanimatol** 1998 Nov–Dec;(6):65–8 (11 ref.) (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Crystal-induced acute renal failure. Perazella MA. **Am J Med** 1999 Apr;106(4):459–65 (53 ref.)

Contrast-induced nephropathy: review of incidence and pathophysiology. Quader MA, et al. **Ann Vasc Surg** 1998 Nov;12(6):612–20 (46 ref.)

Intravesicular formaldehyde instillation and renal complications. Sarnak MJ, et al. **Clin Nephrol** 1999 Feb; 51(2):122–5 (15 ref.)

Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Schaller S, et al. **Pediatr Emerg Care** 1998 Dec;14(6):416–8 (20 ref.)

Lessons learned from ischemic and cisplatin-induced nephrotoxicity in animals. Safirstein RL. **Ren Fail** 1999 May–Jul;21(3–4):359–64 (25 ref.)

Oxidant mechanisms in gentamicin nephrotoxicity. Walker PD, et al. **Ren Fail** 1999 May–Jul;21(3–4):433–42 (16 ref.)

Radiocontrast-induced nephropathy. Solomon R. **Semin Nephrol** 1998 Sep;18(5):551–7 (78 ref.)

[Severe cholestasis with kidney failure from anabolic steroids in a body builder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Sep 10;124(36):1029–32 (17 ref.) (Eng. Abstr.) **(Ger)**

[Contrast medium induced nephropathy: pathogenesis, clinical aspects, prevention] Haller C, et al. **Dtsch Med Wochenschr** 1999 Mar 19;124(11):332–6 (37 ref.) **(Ger)**

[Angiotensin-converting enzyme inhibitors and acute renal failure] Rozin A. **Harefuah** 1998 Sep;135(5–6):239–43 (52 ref.) **(Heb)**

[Renal effects of non-narcotic analgesics and non-steroidal anti-inflammatory drugs (editorial)] Tareeva IE, et al. **Ter Arkh** 1999;71(6):17–22 (28 ref.) **(Rus)**

COMPLICATIONS

Sjögren's syndrome with acute renal failure. Kwon YJ, et al. **J Korean Med Sci** 1998 Dec;13(6):665–9 (14 ref.)

[Intestinal complications of thrombotic microangiopathy in the adult. 4 cases and review of the literature] Klisnick A, et al. **Ann Med Interne (Paris)** 1999 Jan;150(1):4–9 (36 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Evaluation of urinary markers in acute renal failure. Rabb H. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):681–5 (24 ref.)

[Scleroderma renal crisis. 7 cases and review of the literature] Bonnet F, et al. **Ann Med Interne (Paris)** 1998 Sep; 149(5):243–50 (45 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and symptoms of kidney failure] Harada T, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1234–40 (6 ref.) **(Jpn)**

DIET THERAPY

[Nutrition in acute and chronic kidney replacement therapy] Hörl WH. **Internist (Berl)** 1999 Jan;40(1):49–54 (43 ref.) **(Ger)**

DRUG THERAPY

Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Power DA, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S23–8 (41 ref.)

[Renal-protective dose of dopamine: myth or reality?] de Werra P, et al. **Rev Med Suisse Romande** 1999 Mar; 119(3):203–8 (17 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Voluntary ingestion of Cortinarius mushrooms leading to chronic interstitial nephritis. Calviño J, et al. **Am J Nephrol** 1998;18(6):565–9 (19 ref.)

Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Power DA, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S23–8 (41 ref.)

Acute renal failure due to hypokalemic rhabdomyolysis in Gitelman's syndrome. Nishihara G, et al. **Clin Nephrol** 1998 Nov;50(5):330–2 (9 ref.)

Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43–55; discussion 55–63 (92 ref.)

The proximal tubule phenotype and its disruption in acute renal failure and polycystic kidney disease. Witzgall R. **Exp Nephrol** 1999 Jan–Feb;7(1):15–9 (36 ref.)

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099–104 (13 ref.)

Acute renal failure in rhabdomyolysis. Guglielminotti J, et al. **Minerva Anestesiol** 1999 May;65(5):250–5 (46 ref.)

Vasomotor nephropathy in the elderly. Andreucci VE, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:17–24 (63 ref.)

Another compartment syndrome for nephrologists? [editorial; comment] Doherty CC. **Nephrol Dial Transplant** 1998 Oct; 13(10):2468–70 (11 ref.) Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2651–3.

Renal failure and bone marrow transplantation [editorial] Noël C, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2464–6 (13 ref.)

The renal risks of high-dose intravenous immunoglobulin treatment [editorial] Stahl M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2182–5 (24 ref.)

Acute renal failure following multiple wasp stings. Thiruventhiran T, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):214–7 (25 ref.)

Vascular contributions to pathogenesis of acute renal failure. Bankir L, et al. **Ren Fail** 1998 Sep;20(5):663–77 (143 ref.)

Acute renal failure complicating muscle crush injury. Abassi ZA, et al. **Semin Nephrol** 1998 Sep;18(5):558–65 (61 ref.)

The role of neutrophils in acute renal failure. Lauriat S, et al. **Semin Nephrol** 1998 Sep;18(5):498–504 (37 ref.)

Acute renal failure: controversies, clinical trials, and future directions. Paller MS. **Semin Nephrol** 1998 Sep;18(5):482–9 (31 ref.)

Leukemia and kidney failure: case presentation and review of the literature. Reed AM, et al. **WMJ** 1998 Sep;97(8):56–7 (9 ref.)

[Association of acute pericarditis and acute renal insufficiency: causes and prognosis] Klisnick A, et al. **Presse Med** 1998 Oct 31;27(33):1668–73 (41 ref.) (Eng. Abstr.) **(Fre)**

[Acute ischemia of the legs and rapidly progressing renal failure in a 39-year-old patient] Büchner N, et al. **Internist (Berl)** 1999 May;40(5):555–60 (20 ref.) **(Ger)**

[Acute kidney failure of the aged] Okuda S. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):527–31 (5 ref.) **(Jpn)**

[Acute renal failure in rhabdomyolysis] Fernández-Fúnez A. **Rev Clin Esp** 1998 Nov;198(11):758–64 (118 ref.) **(Spa)**

METABOLISM

The role of cell adhesion molecules in ischemic acute renal failure. Molitoris BA, et al. **Am J Med** 1999 May; 106(5):583–92 (79 ref.)

MORTALITY

Acute renal failure in the intensive care unit. Therapy overview, patient risk stratification, complications of renal replacement, and special circumstances. Briglia A, et al. **Clin Chest Med** 1999 Jun;20(2):347–66, viii (143 ref.)

Outcomes in acute renal failure. Liaño F, et al. **Semin Nephrol** 1998 Sep;18(5):541–50 (124 ref.)

NURSING

Acute renal failure in pregnancy. Poole JH, et al. **MCN Am J Matern Child Nurs** 1999 Mar–Apr;24(2):66–72; quiz 73 (23 ref.)

PATHOLOGY

Acute nonoliguric renal failure after renal transplantation. de Fijter JW, et al. **Am J Kidney Dis** 1999 Jan;33(1):166–9 (13 ref.)

Sjögren's syndrome with acute renal failure. Kwon YJ, et al. **J Korean Med Sci** 1998 Dec;13(6):665–9 (14 ref.)

Necrosis and apoptosis in acute renal failure. Lieberthal W, et al. **Semin Nephrol** 1998 Sep;18(5):505–18 (103 ref.)

Mechanisms of cellular injury in ischemic acute renal failure. Sutton TA, et al. **Semin Nephrol** 1998 Sep;18(5):490–7 (32 ref.)

PHYSIOPATHOLOGY

Growth factors and apoptosis in acute renal injury. Hammerman MR. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):419–24 (43 ref.)

alpha-Melanocyte-stimulating hormone and acute renal failure. Kohda Y, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):413–7 (32 ref.)

A new model of renal microvascular injury. Nangaku M, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):457–62 (55 ref.)

Regeneration processes in the kidney after acute injury: role of infiltrating cells. Ghielli M, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):502–7 (26 ref.)

Bcl-2 genes and growth factors in the pathology of ischaemic acute renal failure. Gobé G, et al. **Immunol Cell Biol** 1999 Jun;77(3):279–86 (72 ref.)

Potential role of platelet activating factor in acute renal failure. López-Novoa JM. **Kidney Int** 1999 May; 55(5):1672–82 (105 ref.)

Polymorphonuclear neutrophils in acute renal failure: new insights [editorial] Caramelo C, et al.

Nephrol Dial Transplant 1998 Sep;13(9):2185–8 (29 ref.)
Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock [editorial] Khan RZ, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):814–8 (63 ref.)
Cell cycle events during renal injury. Safirstein RL. **Ren Fail** 1999 May–Jul;21(3–4):427–31 (24 ref.)
Oxidant mechanisms in gentamicin nephrotoxicity. Walker PD, et al. **Ren Fail** 1999 May–Jul;21(3–4):433–42 (16 ref.)
Duality of nitric oxide in acute renal injury. Goligorsky MS, et al. **Semin Nephrol** 1999 May;19(3):263–71 (58 ref.)
Mechanisms of renal repair and survival following acute injury. Safirstein R, et al. **Semin Nephrol** 1998 Sep; 18(5):519–22 (35 ref.)
[Severity and pathophysiology of kidney failure] Hishida A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1241–6 (3 ref.) **(Jpn)**

PREVENTION & CONTROL

Adolescent nephrourology: preventing progressive renal failure. Neild GH. **BJU Int** 1999 Apr;83 Suppl 3:13–22 (25 ref.)
Does hydration prevent radiocontrast-induced acute renal failure? [editorial] Erley CM. **Nephrol Dial Transplant** 1999 May;14(5):1064–6 (19 ref.)

RADIONUCLIDE IMAGING

Delayed gallium-67 uptake in renal atheroembolic disease. Peixoto AJ, et al. **Am J Kidney Dis** 1999 Jul;34(1):161–5 (30 ref.)

RADIOTHERAPY

Leukemia and kidney failure: case presentation and review of the literature. Reed AM, et al. **WMJ** 1998 Sep;97(8):56–7 (9 ref.)

THERAPY

The move from dead to living membranes: bioartificial organ support of failing systems. Kishore KK, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):324–32 (59 ref.)
Continuous renal replacement therapy: continuous blood purification in the intensive care unit. Bellomo R, et al. **Ann Acad Med Singapore** 1998 May;27(3):426–9 (28 ref.)
Acute renal failure in the intensive care unit. Therapy overview, patient risk stratification, complications of renal replacement, and special circumstances. Briglia A, et al. **Clin Chest Med** 1999 Jun;20(2):347–66, viii (143 ref.)
Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43–55; discussion 55–63 (92 ref.)
Biocompatibility of PMMA membranes in acute and chronic patients with renal failure. Manzoni C, et al. **Contrib Nephrol** 1999;125:65–75 (28 ref.)
Continuous renal replacement therapy or hemodialysis for acute renal failure? [editorial] Dillon JJ. **Int J Artif Organs** 1999 Mar;22(3):125–7 (12 ref.)
Treatment of acute renal failure. Star RA. **Kidney Int** 1998 Dec;54(6):1817–31 (112 ref.)
Renal replacement therapy quantification in acute renal failure. Clark WR, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:86–90 (43 ref.)
Contemporary points of view on treatment of acute renal failure (ARF). Książek A. **Przegl Lek** 1998;55 Suppl 1:37–9 (14 ref.) **(Eng, Pol)**
Acute renal failure--which treatment modality is the best? Papadimitriou M, et al. **Ren Fail** 1998 Sep;20(5):651–61 (36 ref.)
Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature. Schelling JR, et al. **Ren Fail** 1998 Jul;20(4):635–44 (32 ref.)
Dialysis and related therapies. Conger J. **Semin Nephrol** 1998 Sep;18(5):533–40 (65 ref.)
Acute renal failure: prevention and nondialytic therapy. Vijayan A, et al. **Semin Nephrol** 1998 Sep;18(5):523–32 (71 ref.)
[Adequate dialysis treatment in hemodialysis and peritoneal dialysis patients] Felten H, et al. **Internist (Berl)** 1999 Jan; 40(1):22–36 (80 ref.) **(Ger)**
[Indications for and selection of dialysis methods in acute and chronic renal failure including continuous methods] Samtleben W, et al. **Internist (Berl)** 1999 Jan;40(1):3–12 (28 ref.) **(Ger)**
[Nothing new in treatment of acute renal failure? (editorial; comment)] Druml W. **Wien Klin Wochenschr** 1999 Feb 26; 111(4):126–8 (19 ref.) Comment on: Wien Klin Wochenschr 1999 Feb 26;111(4):141–7. **(Ger)**
[Angiotensin-converting enzyme inhibitors and acute renal failure] Rozin A. **Harefuah** 1998 Sep;135(5–6):239–43 (52 ref.) **(Heb)**
[Acute blood purification] Hirasawa H, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1317–22 (5 ref.) **(Jpn)**

URINE

Evaluation of urinary markers in acute renal failure. Rabb H. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):681–5 (24 ref.)

VIROLOGY

Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. Vesely DL, et al. **Am J Med Sci** 1999 Jun; 317(6):419–24 (31 ref.)

KIDNEY FAILURE, CHRONIC

see related
HEMODIALYSIS
UREMIA

Pregnancy in chronic renal insufficiency and end-stage renal disease. Hou S. **Am J Kidney Dis** 1999 Feb;33(2):235–52 (83 ref.)
Hyperlipidemia in patients with chronic renal disease. Kasiske BL. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S142–56 (117 ref.)
Hypertension in patients with chronic renal disease. Mailloux LU, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S120–41 (229 ref.)
Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. Manske CL. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S157–71 (132 ref.)
Screening and treatment for cardiovascular disease in patients with chronic renal disease. Murphy SW, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S184–99 (141 ref.)
Selective review of key perioperative renal-electrolyte disturbances in chronic renal failure patients. Yee J, et al. **Chest** 1999 May;115(5 Suppl):149S–157S (40 ref.)
Estimates of body composition as intermediate outcome variables: are DEXA and BIA ready for prime time? Chertow GM. **J Ren Nutr** 1999 Jul;9(3):138–41 (25 ref.)
Principles of dialysis: special issues in women. Gipson D, et al. **Semin Nephrol** 1999 Mar;19(2):140–7 (78 ref.)
Osteoporosis in end-state renal disease. Lindberg JS, et al. **Semin Nephrol** 1999 Mar;19(2):115–22 (61 ref.)
[Progresses in the study of nephrology in China, 1997] Zhang Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):887–8 (0 ref.) **(Chi)**
[Chronic renal failure: etiology, physiopathology, diagnosis, principles of the treatment] Kessler M. **Rev Prat** 1998 Sep 1;48(13):1457–63 (0 ref.) **(Fre)**

BLOOD

The effect of blood draw methodology on selected nutritional parameters in chronic renal failure. Beto JA, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):85–92 (26 ref.)
Platelet and leucocyte behaviour during haemodialysis. Hoenich NA. **Contrib Nephrol** 1999;125:120–32 (36 ref.)
Biological basis of hypoalbuminemia in ESRD. Kaysen GA. **J Am Soc Nephrol** 1998 Dec;9(12):2368–76 (91 ref.)
Leptin in renal failure. Mantzoros CS. **J Ren Nutr** 1999 Jul; 9(3):122–5 (45 ref.)
Hyperphosphataemia--a silent killer of patients with renal failure? [editorial] Amann K, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2085–7 (22 ref.)
Normalization of haemoglobin: why not? Jacobs C. **Nephrol Dial Transplant** 1999;14 Suppl 2:75–9 (11 ref.)
Should anaemia in subtypes of CRF patients be managed differently? van Ypersele de Strihou C. **Nephrol Dial Transplant** 1999;14 Suppl 2:37–45 (74 ref.)
Hyperuricemic nephropathies. Steele TH. **Nephron** 1999;81 Suppl 1:45–9 (42 ref.)

CHEMICALLY INDUCED

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Perazella MA, et al. **Clin Nephrol** 1998 Sep;50(3):194–6 (8 ref.)
Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. McLaughlin JK, et al. **Kidney Int** 1998 Sep;54(3):679–86 (49 ref.)
A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine. Bach PH, et al. **Ren Fail** 1998 Nov;20(6):749–62 (113 ref.)
[Impaired kidney function in lithium therapy] Gabutti L, et al. **Ther Umsch** 1998 Sep;55(9):562–4 (7 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Growth factors and malnutrition in chronic renal failure. Fouque DP, et al. **Adv Nephrol Necker Hosp** 1998; 28:259–85 (88 ref.)
Malnutrition, cardiac disease, and mortality: an integrated point of view [editorial] Bergström J, et al. **Am J Kidney Dis** 1998 Nov;32(5):834–41 (87 ref.)
Hemodynamic stability during dialysis and cardiovascular disease in end-stage renal disease patients. Henrich WL. **Am J Kidney Dis** 1999 Jun;33(6):XLIX–LII (7 ref.)
Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Llach F, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S3–12 (72 ref.)
Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Mailloux LU, et al. **Am J Kidney Dis** 1998 Nov;32(5):705–19 (139 ref.)
Relative hypoparathyroidism and adynamic bone disease. Mucsi I, et al. **Am J Med Sci** 1999 Jun;317(6):405–9 (44 ref.)
Encephalopathy after bladder irrigation with alum: case report and literature review. Phelps KR, et al. **Am J Med Sci** 1999 Sep;318(3):181–5 (37 ref.)
Prevention of renal osteodystrophy in predialysis patients. Sanchez CP, et al. **Am J Med Sci** 1999 Jun;317(6):398–404 (59 ref.)
Aldosterone-producing adrenocortical adenoma complicated by chronic renal failure. Case report and review of the literature. Ito H, et al. **Am J Nephrol** 1998;18(6):541–6 (30 ref.)
An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy. Janzen L, et al. **Ann Pharmacother** 1999 Jan;33(1):86–92 (36 ref.)
Salt and hypertension in end-stage renal disease [editorial] Kooman JP, et al. **Blood Purif** 1998;16(6):301–11 (69 ref.)
Coagulase-negative staphylococcus endocarditis restricted to the normal pulmonic valve in a patient with end-stage renal disease: case report and review. Hussain KM, et al. **Clin Infect Dis** 1998 Dec;27(6):1550–2 (10 ref.)
Does early anemia correction prevent complications of chronic renal failure? Drüeke TB, et al. **Clin Nephrol** 1999 Jan;51(1):1–11 (121 ref.)
Approach to hyperkalemic end-stage renal disease patients in the emergency department. Perazella MA. **Conn Med** 1999 Mar;63(3):131–6 (34 ref.)
Coronary artery disease in dialysis patients. Wizemann V. **Contrib Nephrol** 1998;124:1–9; discussion 9–17 (52 ref.)
Gastrointestinal complications of renal failure. Etemad B. **Gastroenterol Clin North Am** 1998 Dec;27(4):875–92 (99 ref.)
Renal disease and the heart. Woolfson RG. **Hosp Med** 1999 Feb;60(2):85–9 (21 ref.)
Diffuse pulmonary calcinosis and multiple soft tissue calcification in renal failure patient with pathological femoral fracture. al-Homrany M, et al. **Indian J Chest Dis Allied Sci** 1998 Jul–Sep;40(3):205–11 (35 ref.)
Hyperhomocysteinemia in chronic renal disease. Bostom AG, et al. **J Am Soc Nephrol** 1999 Apr;10(4):891–900 (94 ref.)
The clinical epidemiology of cardiac disease in chronic renal failure. Parfrey PS, et al. **J Am Soc Nephrol** 1999 Jul; 10(7):1606–15 (53 ref.)
A structural approach to renal bone disease. Parfitt AM. **J Bone Miner Res** 1998 Aug;13(8):1213–20 (88 ref.)
GBV-C/HGV infection in end-stage renal disease. Fabrizi F, et al. **J Nephrol** 1999 May–Jun;12(3):131–9 (90 ref.)
Cardiovascular disease and mortality in ESRD. Foley RN, et al. **J Nephrol** 1998 Sep–Oct;11(5):239–45 (97 ref.)
Chronic renal failure causing brown tumors and myelopathy. Case report and review of pathophysiology and treatment. Fineman I, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):242–6 (18 ref.)
Pathophysiology of protein-energy wasting in chronic renal failure. Kopple JD. **J Nutr** 1999 Jan;129(1S Suppl):247S–251S (48 ref.)
Effectiveness of nutrition interventions in the management of malnourished patients treated with maintenance dialysis. Wolfson M. **J Ren Nutr** 1999 Jul;9(3):126–8 (15 ref.)
Causes of coronary heart disease in patients on renal replacement therapy. Wanner C, et al. **Kidney Blood Press Res** 1998;21(2–4):287–9 (16 ref.)
Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Eschbach JW, et al. **Kidney Int Suppl** 1999 Mar;69:S35–43 (70 ref.)
Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Lopez-Gomez JM, et al. **Kidney Int Suppl** 1998 Dec;68:S92–8 (74 ref.)
Hypertension in end-stage renal disease. Martínez-Maldonado M. **Kidney Int Suppl** 1998 Dec; 68:S67–72 (43 ref.)
Iron deficiency in patients with renal failure. Nissenson AR, et al. **Kidney Int Suppl** 1999 Mar;69:S18–21 (39 ref.)
Intravenous iron for the treatment of predialysis anemia. Silverberg DS, et al. **Kidney Int Suppl** 1999 Mar;69:S79–85 (81 ref.)
Anemia and cardiovascular complications: iron and EPO impact. Kurtzman NA, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):109–13 (25 ref.)
Cardiovascular consequences of renal anaemia and erythropoietin therapy. Eckardt KU. **Nephrol Dial Transplant** 1999 May;14(5):1317–23 (64 ref.)
Molecular pathogenesis of secondary hyperparathyroidism in renal failure: basic and clinical aspects. Fukagawa M, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:61–2 (19 ref.)
Anaemia in the patient with renal insufficiency: documenting the impact and reviewing treatment strategies [editorial] Levin A. **Nephrol Dial Transplant** 1999 Feb;14(2):292–5 (21 ref.)
Anorexia in patients with chronic renal failure--progress towards understanding the molecular basis [editorial] Mamoun AH. **Nephrol Dial Transplant** 1998 Oct; 13(10):2460–3 (18 ref.)
What are the short-term and long-term consequences of anaemia in CRF patients? Mann JF. **Nephrol Dial Transplant** 1999;14 Suppl 2:29–36 (35 ref.)
Angiodysplasia in the renal patient: how to diagnose and how to treat? [editorial] Poralla T. **Nephrol Dial Transplant** 1998 Sep;13(9):2188–91 (29 ref.)
Anemia during the predialysis period: A key to cardiac damage in renal failure. Silverberg D, et al. **Nephron** 1998 Sep;80(1):1–5 (72 ref.)
Erythropoietin treatment in children with renal failure. Van

Damme-Lombaerts R, et al. **Pediatr Nephrol** 1999 Feb; 13(2):148-52 (23 ref.)
Malnutrition, cardiac disease, and mortality. Bergström J, et al. **Perit Dial Int** 1999;19 Suppl 2:S309-14 (66 ref.)
Malnutrition: detection and intervention. McCann LM. **Perit Dial Int** 1999;19 Suppl 2:S527-32 (61 ref.)
Long-term experience with growth hormone treatment in children with chronic renal failure. Schaefer F, et al. **Perit Dial Int** 1999;19 Suppl 2:S467-72 (35 ref.)
[Renal anemia and the effect of long-term dialysis] Opatrná S, et al. **Cas Lek Cesk** 1999 Feb 22;138(4):107-10 (44 ref.) (Eng. Abstr.) **(Cze)**
[Severe flecainide acetate poisoning. Apropos of a case] Maury P, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):273-7 (10 ref.) (Eng. Abstr.) **(Fre)**
[Physiopathology of the somatotropin axis in chronic renal insufficiency] Cabrol S, et al. **Arch Pediatr** 1998;5 Suppl 4:348S-353S (44 ref.) (Eng. Abstr.) **(Fre)**
[Critical evaluation of growth hormone treatment in children with chronic renal insufficiency] Perfumo F, et al. **Arch Pediatr** 1998;5 Suppl 4:354S-359S (39 ref.) (Eng. Abstr.) **(Fre)**
[Management of malnutrition in chronic hemodialysis] Cano N, et al. **Nephrologie** 1998;19(6):353-7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Anomalies of phosphate and calcium metabolism in chronic renal insufficiency] Drüeke TB. **Rev Prat** 1998 Jun 1; 48(11):1207-12 (20 ref.) (Eng. Abstr.) **(Fre)**
[Morphine poisoning in chronic kidney failure. Morphine-6-glucuronide as a pharmacologically active morphine metabolite] Dubs A, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):896-8 (18 ref.) (Eng. Abstr.) **(Ger)**
[Causes and risks of hyperlipidemia during dialysis and after renal transplantation] Verzola A, et al. **Recenti Prog Med** 1998 Nov;89(11):590-7 (51 ref.) (Eng. Abstr.) **(Ita)**
[Bilateral renal cell carcinoma in a patient with chronic renal failure: a case report] Tsuchiya F, et al. **Hinyokika Kiyo** 1998 Nov;44(11):813-6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Gastric haemorrhagic mucosal lesion in uremic patients] Itoh K. **Nippon Rinsho** 1998 Sep;56(9):2391-5 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Neurological complications in patients with chronic renal failure] Ejma M, et al. **Pol Merkuriusz Lek** 1998 Sep; 5(27):173-7 (34 ref.) (Eng. Abstr.) **(Pol)**
[Advances of clinical diagnosis of osteodystrophy complicated by chronic renal failure] Nowak Z. **Pol Merkuriusz Lek** 1998 Nov;5(29):313-6 (30 ref.) (Eng. Abstr.) **(Pol)**
[Successful aorto-coronary bypass in the care of unstable heart ischemia in the course of irreversible renal failure treated by repeated hemodialyses] Wańkowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):292-4 (11 ref.) (Eng. Abstr.) **(Pol)**
[The treatment of ischemic heart disease in patients with chronic kidney failure] Diadyk AI, et al. **Lik Sprava** 1998 Jun;(4):42-5 (25 ref.) **(Rus)**
[Cardiovascular disorders in chronic renal failure] Bagrii AE. **Ter Arkh** 1998;70(11):80-3 (35 ref.) **(Rus)**
[Pro- and antiatherogenic mechanisms in chronic kidney failure] Kolesnyk MO, et al. **Lik Sprava** 1998 Dec;(8):18-23 (50 ref.) (Eng. Abstr.) **(Ukr)**

DIAGNOSIS

Screening for renal insufficiency: is it worth while? is it feasible? [editorial] Jungers P. **Nephrol Dial Transplant** 1999 Sep;14(9):2082-4 (12 ref.)
[Diagnosis and symptoms of kidney failure] Harada T, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1234-40 (6 ref.) **(Jpn)**
[Selenium and some antioxidants in blood of patients with chronic renal failure (published erratum appears in Pol Merkuriusz Lek 1998 Dec;5(30):356)] Trafikowska U, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):178-82 (61 ref.) (Eng. Abstr.) **(Pol)**

DIET THERAPY

Role of fermentable carbohydrate supplements with a low-protein diet in the course of chronic renal failure: experimental bases. Younes H, et al. **Am J Kidney Dis** 1999 Apr;33(4):633-46 (129 ref.)
Low protein diet in the management of patients with chronic renal failure: a controversial discussion. Kayser H, et al. **Artif Organs** 1998 Nov;22(11):948-51 (25 ref.)
Should protein intake be restricted in predialysis patients? Walser M, et al. **Kidney Int** 1999 Mar;55(3):771-7 (99 ref.)
Conservative treatment to slow deterioration of renal function: evidence-based recommendations. Burgess E. **Kidney Int Suppl** 1999 Jun;70:S17-25 (44 ref.)
Dietary treatment of diabetic nephropathy with chronic renal failure. Barsotti G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:49-52 (14 ref.)
[Nutrition in acute and chronic kidney replacement therapy] Hörl WH. **Internist (Berl)** 1999 Jan;40(1):49-54 (43 ref.) **(Ger)**
[Assignment of diet with various protein content in combination with keto-analogs of essential amino acids for management of chronic renal failure. State-of-the-art] Lifshits NL, et al. **Ter Arkh** 1999;71(1):74-7 (62 ref.) **(Rus)**

DRUG THERAPY

Androgen therapy in chronic renal failure. Handelsman DJ, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):485-500 (76 ref.)
Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. Mackenzie HS, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S283-6 (43 ref.)
Conservative treatment to slow deterioration of renal function: evidence-based recommendations. Burgess E. **Kidney Int Suppl** 1999 Jun;70:S17-25 (44 ref.)
Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Eschbach JW, et al. **Kidney Int Suppl** 1999 Mar;69:S35-43 (70 ref.)
Diuretics in renal failure. Andreucci M, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):32-8 (51 ref.)
[Chemotherapy of small cell bronchogenic carcinoma in a patient on hemodialysis for chronic renal failure. Apropos of a case] Guillou B, et al. **Rev Pneumol Clin** 1998 Sep; 54(4):215-8 (16 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Renal disease in the managed care setting: selection and monitoring of outcome criteria. Hannah R, et al. **Am J Kidney Dis** 1999 Apr;33(4 Suppl 1):S1-24 (55 ref.)
Chronic renal failure: an overview from a pediatric perspective. Saborio P, et al. **Nephron** 1998 Oct; 80(2):134-48 (191 ref.)

EPIDEMIOLOGY

Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Beto JA, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S172-83 (47 ref.)
Clinical epidemiology of cardiovascular disease in chronic renal disease. Foley RN, et al. **Am J Kidney Dis** 1998 Nov; 32(5 Suppl 3):S112-9 (40 ref.)
Renal disease in the elderly. Davison AM. **Contrib Nephrol** 1998;124:126-37; discussion 137-45 (42 ref.)
The epidemic of cardiovascular disease in end-stage renal disease. Brenner RM, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):365-9 (25 ref.)
Hypertension as cause of end-stage renal disease: lessons from international registries. Valderrábano F, et al. **Kidney Int Suppl** 1998 Dec;68:S60-6 (3 ref.)
The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Rychlik I, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:6-10 (23 ref.)
Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Nephron** 1998 Dec;80(4):380-400 (115 ref.)
[Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis (see comments)] Kacso I, et al. **Nephrologie** 1999;20(1):19-28 (46 ref.) (Eng. Abstr.) Comment in: Nephrologie 1999 ;20(1):3-7. **(Fre)**

ETIOLOGY

Heavy chain deposition disease: the disease spectrum. Kambham N, et al. **Am J Kidney Dis** 1999 May; 33(5):954-62 (26 ref.)
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Rabelink TJ, et al. **Cardiovasc Res** 1998 Sep;39(3):543-9 (102 ref.)
Sickle cell nephropathy. Saborio P, et al. **J Am Soc Nephrol** 1999 Jan;10(1):187-92 (41 ref.)
Renal failure in the recipients of nonrenal solid organ transplants. Wilkinson AH, et al. **J Am Soc Nephrol** 1999 May;10(5):1136-44 (70 ref.)
Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. Perna AF, et al. **J Nephrol** 1999 Jul-Aug;12(4):230-40 (121 ref.)
Hypertension as cause of end-stage renal disease: lessons from international registries. Valderrábano F, et al. **Kidney Int Suppl** 1998 Dec;68:S60-6 (3 ref.)
Pathophysiology of progressive nephropathies. Remuzzi G, et al. **N Engl J Med** 1998 Nov 12;339(20):1448-56 (95 ref.)
Glomerulocystic kidney disease in an adult presenting as end-stage renal failure. Abderrahim E, et al. **Nephrol Dial Transplant** 1999 May;14(5):1276-8 (30 ref.)
Familial aggregation of end-stage renal failure: aetiological implications [editorial] Freedman BI. **Nephrol Dial Transplant** 1999 Feb;14(2):295-7 (23 ref.)
Is renal failure caused by primary hypertension? Why does the controversy continue? [editorial; comment] Rostand SG. **Nephrol Dial Transplant** 1998 Dec;13(12):3007-10 (17 ref.) Comment on: Nephrol Dial Transplant 1998 Dec;13(12):3084-90.
The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Rychlik I, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:6-10 (23 ref.)
Normotensive scleroderma renal crisis: case report and review of the literature. Haviv YS, et al. **Ren Fail** 1998 Sep;20(5):733-6 (8 ref.)

GENETICS

Familial aggregation of end-stage renal failure: aetiological implications [editorial] Freedman BI. **Nephrol Dial Transplant** 1999 Feb;14(2):295-7 (23 ref.)

IMMUNOLOGY

[Cytokines in patients with chronic renal failure during non-invasive therapy (editorial)] Medyńska A, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):173-5 (37 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Homocysteine and chronic renal failure. Hannedouche TP, et al. **Adv Nephrol Necker Hosp** 1998;28:287-310 (64 ref.)
The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Slatopolsky E, et al. **Am J Med Sci** 1999 Jun;317(6):370-6 (40 ref.)
Oxidative stress in chronic renal failure. Hasselwander O, et al. **Free Radic Res** 1998 Jul;29(1):1-11 (118 ref.)
Effects of low-protein diet on carbohydrate metabolism and energy expenditure. Rigalleau V, et al. **J Ren Nutr** 1998 Oct;8(4):175-8 (37 ref.)
Iron deficiency in patients with renal failure. Nissenson AR, et al. **Kidney Int Suppl** 1999 Mar;69:S18-21 (39 ref.)
Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure. Garibotto G. **Nutrition** 1999 Feb;15(2):145-55 (82 ref.)
Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? [editorial] Bergström J, et al. **Perit Dial Int** 1998 Sep-Oct;18(5):467-73 (25 ref.)
Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Somerville AL, et al. **Pharmacotherapy** 1999 Jun;19(6):702-7 (28 ref.)

MORTALITY

Hyperphosphataemia--a silent killer of patients with renal failure? [editorial] Amann K, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2085-7 (22 ref.)

PATHOLOGY

Large artery structure and function in hypertension and end-stage renal disease. London GM, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1931-8 (84 ref.)
Parathyroid hyperplasia in chronic renal failure: role of calcium, phosphate, and calcitriol. Roussanne MC, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:68-9 (22 ref.)
[Factors of progression and chronic renal insufficiency and their prevention] Ronco P. **Bull Acad Natl Med** 1999; 183(1):65-77 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The effect of blood draw methodology on selected nutritional parameters in chronic renal failure. Beto JA, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):85-92 (26 ref.)
Physical functioning and exercise capacity in patients on dialysis. Johansen KL. **Adv Ren Replace Ther** 1999 Apr; 6(2):141-8 (42 ref.)
The physiological consequences of bed rest and inactivity. Krasnoff J, et al. **Adv Ren Replace Ther** 1999 Apr; 6(2):124-32 (47 ref.)
Physical functioning in end-stage renal disease. Introduction: a call to activity. Painter P, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):107-9 (21 ref.)
Physical functioning: definitions, measurement, and expectations. Painter P, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):110-23 (56 ref.)
Hemodynamic stability during dialysis and cardiovascular disease in end-stage renal disease patients. Henrich WL. **Am J Kidney Dis** 1999 Jun;33(6):XLIX-LII (7 ref.)
Calciotropic hormones and the skeleton in uraemia [comment] Lewin E, et al. **Eur J Clin Invest** 1999 Jun; 29(6):466-8 (13 ref.) Comment on: Eur J Clin Invest 1999 Jun;29(6):529-35.
Rethinking chronic allograft nephropathy: the concept of accelerated senescence. Halloran PF, et al. **J Am Soc Nephrol** 1999 Jan;10(1):167-81 (171 ref.)
Large artery structure and function in hypertension and end-stage renal disease. London GM, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1931-8 (84 ref.)
The peritoneal membrane in chronic peritoneal dialysis [clinical conference] Krediet RT. **Kidney Int** 1999 Jan; 55(1):341-56 (152 ref.)
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Rostand SG, et al. **Kidney Int** 1999 Aug;56(2):383-92 (124 ref.)
Hypertension in end-stage renal disease. Martinez-Maldonado M. **Kidney Int Suppl** 1998 Dec; 68:S67-72 (43 ref.)
Progression of renal failure in diabetic nephropathy. Marcantoni C, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:16-9 (34 ref.)
Pathophysiology of peritoneal fluid eosinophilia in peritoneal dialysis patients [editorial] Ejaz AA, et al. **Nephron** 1999 Feb;81(2):125-30 (43 ref.)
Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Ligtenberg G. **Neth J Med** 1999 Jul; 55(1):13-8 (36 ref.)
The pathogenesis of progressive renal failure. Vleming LJ, et al. **Neth J Med** 1999 Mar;54(3):114-28 (200 ref.)

Vitamin E may slow kidney failure owing to oxidative stress. Fryer MJ. **Redox Rep** 1997 Oct-Dec;3(5-6):259-61 (32 ref.)
[Vascular mechanisms of renal fibrosis. Vasculonephropathies and arterial hypertension] Meyrier A. **Bull Acad Natl Med** 1999;183(1):33-45; discussion 45-6 (71 ref.) (Eng. Abstr.) **(Fre)**
[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1338-48 (61 ref.) **(Fre)**
[Role of phosphate, vitamin D and acidosis in the secretion and synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1349-54 (59 ref.) **(Fre)**
[Physiopathology of parathyroid hyperplasia] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1355-61 (59 ref.) **(Fre)**
[Progression of chronic renal insufficiency] Ronco P, et al. **Rev Prat** 1998 Feb 1;48(3):241-7 (35 ref.) **(Fre)**
[Severity and pathophysiology of kidney failure] Hishida A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1241-6 (3 ref.) **(Jpn)**
[Chronic renal insufficiency: 1) adaptation of nephron function in chronic renal insufficiency and 2) progression of chronic renal insufficiency] Savin M. **Srp Arh Celok Lek** 1998 Jul-Aug;126(7-8):261-70 (83 ref.) (Eng. Abstr.) **(Scc)**

PREVENTION & CONTROL

Current strategies for management of hypertensive renal disease. Moore MA, et al. **Arch Intern Med** 1999 Jan 11; 159(1):23-8 (74 ref.)
Adolescent nephrourology: preventing progressive renal failure. Neild GH. **BJU Int** 1999 Apr;83 Suppl 3:13-22 (25 ref.)
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Rabelink TJ, et al. **Cardiovasc Res** 1998 Sep;39(3):543-9 (102 ref.)
Preventing end-stage renal disease. Mogensen CE. **Diabet Med** 1998;15 Suppl 4:S51-6 (55 ref.)
Nephropathy in patients with type 2 diabetes mellitus. Ritz E, et al. **N Engl J Med** 1999 Oct 7;341(15):1127-33 (65 ref.)
Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness [editorial] Marangella M. **Nephrol Dial Transplant** 1999 Feb; 14(2):301-3 (13 ref.)
Vitamin E may slow kidney failure owing to oxidative stress. Fryer MJ. **Redox Rep** 1997 Oct-Dec;3(5-6):259-61 (32 ref.)
[Can progression to terminal renal insufficiency be avoided in diabetic nephropathy? (editorial)] Luño J, et al. **An Med Interna** 1998 Nov;15(11):567-71 (64 ref.) **(Spa)**

PSYCHOLOGY

Health promotion for end-stage renal disease patients. Sadler JH. **Adv Ren Replace Ther** 1998 Oct;5(4):275-85 (58 ref.)
An AIDS patient's right to refuse life-sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161-4 (46 ref.)

RADIOGRAPHY

Selective angiography of the common carotid artery with gadopentetate dimeglumine in a patient with renal insufficiency. Kaufman JA, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1613-4 (8 ref.)

REHABILITATION

Staff responsibility to exercise. Carlson L, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):172-80 (6 ref.)
The risks of exercise. Copley JB, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):165-71 (46 ref.)
Self-reported functional status: an important predictor of health outcomes among end-stage renal disease patients. Curtin RB, et al. **Adv Ren Replace Ther** 1999 Apr; 6(2):133-40 (46 ref.)
Regular exercise: vitally important for the transplant recipient. O'Moore B. **Adv Ren Replace Ther** 1999 Apr; 6(2):187-8 (0 ref.)
The role of physical therapy in improving physical functioning of renal patients. Pianta TF. **Adv Ren Replace Ther** 1999 Apr;6(2):149-58 (17 ref.)
Exercise evaluation of children with end-stage renal disease. Sabath RJ. **Adv Ren Replace Ther** 1999 Apr;6(2):189-94 (46 ref.)
Exercise and a cycle of life: help us help ourselves. Stewart P. **Adv Ren Replace Ther** 1999 Apr;6(2):184-6 (0 ref.)

SURGERY

Renal transplantation. Wallace MA. **AORN J** 1998 Dec; 68(6):964-6, 969-72 passim; quiz 995-1002 (43 ref.)
Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness [editorial] Marangella M. **Nephrol Dial Transplant** 1999 Feb; 14(2):301-3 (13 ref.)
Pre-emptive kidney transplantation [editorial] Vanrenterghem Y, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2466-8 (8 ref.)
Pediatric renal transplantation: indications and special considerations. A position paper from the Pediatric Committee of the American Society of Transplant Physicians. Davis ID, et al. **Pediatr Transplant** 1998 May; 2(2):117-29 (99 ref.)
Renal transplantation for end-stage renal disease caused by systemic lupus erythematosus nephritis. Clark WF, et al. **Semin Nephrol** 1999 Jan;19(1):77-85 (109 ref.)
[Kidney transplantation for therapy of late-stage kidney failure] Sakai K, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1335-40 (5 ref.) **(Jpn)**

THERAPY

The future of end-stage renal disease care: nephrology enters a new millennium. Hoffart N, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):257-66 (34 ref.)
Daily hemodialysis: dialysis for the next century. Kjellstrand C, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):267-74 (34 ref.)
An AIDS patient's right to refuse life-sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161-4 (46 ref.)
III. Treatment modalities for ESRD patients. **Am J Kidney Dis** 1999 Aug;34(2 Suppl 1):S51-62 (48 ref.)
Modality-specific nutrition support in ESRD: weighing the evidence. Chertow GM. **Am J Kidney Dis** 1999 Jan; 33(1):193-7 (20 ref.)
Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Kopple JD. **Am J Kidney Dis** 1999 Jan;33(1):180-5 (53 ref.)
Optimal care of the pediatric end-stage renal disease patient on dialysis. Warady BA, et al. **Am J Kidney Dis** 1999 Mar; 33(3):567-83 (104 ref.)
Pathogenesis and management of dialysis-related amyloid bone disease. Nangaku M, et al. **Am J Med Sci** 1999 Jun; 317(6):410-5 (61 ref.)
Management of end-stage renal disease in children. Smith PS. **Ann Pharmacother** 1998 Sep;32(9):929-39 (71 ref.)
Dialysis or transplantation: fitting the treatment to the patient. Berkoben M, et al. **Annu Rev Med** 1999;50:193-205 (21 ref.)
Sex or body size? Selection of dialysis type revisited [editorial; comment] Levin A. **CMAJ** 1999 Mar 23; 160(6):828-9 (10 ref.) Comment on: CMAJ 1999 Mar 23;160(6):818-9.
Pyrogen transfer across PMMA membranes. Cappelli G, et al. **Contrib Nephrol** 1999;125:233-9 (41 ref.)
Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Contrib Nephrol** 1998;124:166-89; discussion 190-201 (115 ref.)
Biocompatibility of PMMA membranes in acute and chronic patients with renal failure. Manzoni C, et al. **Contrib Nephrol** 1999;125:65-75 (28 ref.)
Coronary artery disease in dialysis patients. Wizemann V. **Contrib Nephrol** 1998;124:1-9; discussion 9-17 (52 ref.)
How can we improve prognosis in diabetic patients with end-stage renal disease? Ritz E, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B80-3 (27 ref.)
Pregnancy in chronic dialysis: a review and analysis of the literature. Chan WS, et al. **Int J Artif Organs** 1998 May; 21(5):259-68 (82 ref.)
Functional iron deficiency and inadequate dialysis: is there a connection? [editorial] Ifudu O. **Int J Artif Organs** 1999 Mar;22(3):128-30 (21 ref.)
Adequacy in peritoneal dialysis: a true challenge [editorial] Locatelli A, et al. **Int J Artif Organs** 1999 Mar;22(3):123-4 (16 ref.)
Dialyzer reuse and the treatment of patients with end-stage renal disease by hemodialysis [editorial; comment] Kimmel PL, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2153-6 (32 ref.) Comment on: J Am Soc Nephrol 1998 Nov;9(11):2108-17.
Clinical practice guidelines in end-stage renal disease: a strategy for implementation. Kliger AS, et al. **J Am Soc Nephrol** 1999 Apr;10(4):872-7 (18 ref.)
End-stage renal disease (ESRD) and vascular access grafting: a critical review. Szycher M. **J Biomater Appl** 1999 Apr; 13(4):297-350 (125 ref.)
Epidemiologic cohort studies of critical nutritional issues in the care of the dialysis patient: report of the epidemiology work group. McClellan W, et al. **J Ren Nutr** 1999 Jul; 9(3):133-7 (49 ref.)
Prothrombotic risk factors and acute kidney transplant rejection. Heidenreich S, et al. **Kidney Blood Press Res** 1998;21(2-4):293-5 (13 ref.)
What is the place of peritoneal dialysis in the integrated treatment of renal failure? Coles GA, et al. **Kidney Int** 1998 Dec;54(6):2234-40 (64 ref.)
The peritoneal membrane in chronic peritoneal dialysis [clinical conference] Krediet RT. **Kidney Int** 1999 Jan; 55(1):341-56 (152 ref.)
Beneficial effects of iron therapy in renal failure patients on hemodialysis. Fishbane S, et al. **Kidney Int Suppl** 1999 Mar; 69:S67-70 (34 ref.)
Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Lopez-Gomez JM, et al. **Kidney Int Suppl** 1998 Dec;68:S92-8 (74 ref.)
Strategies for iron supplementation: oral versus intravenous. Macdougall IC. **Kidney Int Suppl** 1999 Mar;69:S61-6 (33 ref.)
Haemodialysis. Mallick NP, et al. **Lancet** 1999 Feb 27; 353(9154):737-42 (30 ref.)
Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Clark WF, et al. **Lupus** 1998; 7(9):649-53 (54 ref.)
End-stage renal disease in lupus: disease activity, dialysis, and the outcome of transplantation. Stone JH. **Lupus** 1998; 7(9):654-9 (38 ref.)
A practical approach to the management of patients with chronic renal failure [published erratum appears in Mayo Clin Proc 1999 May;74(5):538] McCarthy JT. **Mayo Clin Proc** 1999 Mar;74(3):269-73 (10 ref.)
Anemia and cardiovascular complications: iron and EPO impact. Kurtzman NA, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):109-13 (25 ref.)
Results from ethical international surveys on the management of the continuous renal replacement therapy. Zamperetti N, et al. **Minerva Anestesiol** 1999 Jun;65(6):437-9 (7 ref.)
Past, present and future of end-stage renal disease therapy in the United States. Uribarri J. **Mt Sinai J Med** 1999 Jan; 66(1):14-9 (39 ref.)
European best practice guidelines for the management of anaemia in patients with chronic renal failure. Cameron JS. **Nephrol Dial Transplant** 1999;14 Suppl 2:61-5 (7 ref.)
Ultrafiltration and convective-based dialysis modalities: new trends and applications for renal replacement therapy in ESRD patients. Canaud B, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:98-105 (57 ref.)
On-line haemodiafiltration: state of the art. Canaud B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:3-11 (55 ref.)
The treatment of diabetic end-stage renal disease with peritoneal dialysis. Feriani M, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:53-6 (30 ref.)
Pregnancy during dialysis: case report and management guidelines [see comments] Giatras I, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3266-72 (36 ref.) Comment in: Nephrol Dial Transplant 1998 Dec;13(12):3005-7.
Pregnancy and end-stage renal disease--past experience and new insights [editorial; comment] Levy DP, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3005-7 (11 ref.) Comment on: Nephrol Dial Transplant 1998 Dec;13(12):3266-72.
Integrated diet and dialysis programme. Locatelli F, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:132-8 (23 ref.)
What place diuretics in long-term CAPD? [editorial] Medcalf JF, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2193-4 (13 ref.)
Control of serum phosphate in patients with renal failure--new approaches [editorial] Mucsi I, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2457-60 (16 ref.)
Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Nephron** 1998 Dec;80(4):380-400 (115 ref.)
Impact of pretransplantation dialysis modality on patient outcome after renal transplantation: the role of peritoneal dialysis revisited [editorial] Van Biesen, et al. **Perit Dial Int** 1999 Mar-Apr;19(2):103-6 (33 ref.)
Dialysis therapy in the region of central and eastern Europe. Rutkowski B. **Przegl Lek** 1998;55 Suppl 1:32-4 (11 ref.) **(Eng, Pol)**
Natural history and treatment of lupus nephritis. Austin HA, et al. **Semin Nephrol** 1999 Jan;19(1):2-11 (85 ref.)
Current and future modalities for functional renal replacement. Amiel GE, et al. **Urol Clin North Am** 1999 Feb;26(1):235-46, xi (131 ref.)
[Indications for extra-renal dialysis in terminal chronic renal failure. National Agency for Medical Development and Evaluation. September 1996 (comment)] **Presse Med** 1998 Nov 21;27(36):1847-52 (0 ref.) Comment on: Presse Med 1998 Nov 21;27(36):1853-5. **(Fre)**
[Quality of life of patients treated for terminal chronic renal failure] Patte D. **Presse Med** 1998 Oct 3;27(29):1499-505 (58 ref.) **(Fre)**
[Adequate dialysis treatment in hemodialysis and peritoneal dialysis patients] Felten H, et al. **Internist (Berl)** 1999 Jan; 40(1):22-36 (80 ref.) **(Ger)**
[Long-term management of dialysis patients. II. Beta 2-microglobulin associated amyloidosis and acquired cystic kidney disease] Floege J, et al. **Internist (Berl)** 1999 Jan; 40(1):64-9 (27 ref.) **(Ger)**
[Indications for and selection of dialysis methods in acute and chronic renal failure including continuous methods] Samtleben W, et al. **Internist (Berl)** 1999 Jan;40(1):3-12 (28 ref.) **(Ger)**
[Long-term management of dialysis patients. I. Hypertension and anemia] Schäffer J, et al. **Internist (Berl)** 1999 Jan; 40(1):55-63 (49 ref.) **(Ger)**
[Treatment of anemia in chronic renal failure (predialysis)] Ruedin P. **Schweiz Rundsch Med Prax** 1999 Jan 28; 88(5):173-7 (35 ref.) (Eng. Abstr.) **(Ger)**
[Current therapy of chronic renal failure] Vaslaki L. **Orv Hetil** 1998 Dec 13;139(50):2995-9 (13 ref.) (Eng. Abstr.) **(Hun)**
[Long-term hemodialysis for advanced-stage chronic kidney failure and their complications] Maeda K. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1311-6 (5 ref.) **(Jpn)**
[Continuous ambulatory peritoneal dialysis for therapy of late-stage kidney failure] Nakayama M, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1329-34 (11 ref.) **(Jpn)**
[Home hemodialysis for therapy of late-stage kidney failure] Saito A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1323-8 (9 ref.) **(Jpn)**

KIDNEY FAILURE, CHRONIC

[Cytokines in patients with chronic renal failure during non-invasive therapy (editorial)] Medyńska A, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):173-5 (37 ref.) (Eng. Abstr.) **(Pol)**

[Alternative dialysis solutions in continuous ambulatory peritoneal dialysis] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):307-9 (30 ref.) (Eng. Abstr.) **(Pol)**

[Successful aorto-coronary bypass in the care of unstable heart ischemia in the course of irreversible renal failure treated by repeated hemodialyses] Wańkowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):292-4 (11 ref.) (Eng. Abstr.) **(Pol)**

[Late ventricular potential as a risk factor for sudden cardiac death in chronically hemodialysed patients] Wierzbicki P. **Pol Merkuriusz Lek** 1998 Nov;5(29):310-2 (25 ref.) (Eng. Abstr.) **(Pol)**

KIDNEY FUNCTION TESTS

How to assess glomerular function and damage in humans. Rahn KH, et al. **J Hypertens** 1999 Mar;17(3):309-17 (82 ref.)

METHODS

[Adequate dialysis treatment in hemodialysis and peritoneal dialysis patients] Felten H, et al. **Internist (Berl)** 1999 Jan; 40(1):22-36 (80 ref.) **(Ger)**

KIDNEY GLOMERULUS

see related
GLOMERULAR FILTRATION RATE
RENAL PLASMA FLOW, EFFECTIVE

Growth hormone and somatostatin in glomerular injury. Baud L, et al. **J Nephrol** 1999 Jan-Feb;12(1):18-23 (65 ref.)

Cell cycle proteins in glomerular disease. Shankland SJ. **Kidney Blood Press Res** 1998;21(2-4):213-4 (8 ref.)

Mechanisms for induction of apoptosis and glomerular disease. Kashihara N, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:52-4 (14 ref.)

New aspects concerning the role of catecholamines in the pathogenesis of glomerular disease [editorial] Pavenstädt H. **Nephrol Dial Transplant** 1998 Aug;13(8):1916-9 (22 ref.)

Expression of bcl-2 and bax in glomerular disease. Yoshimura A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:55-7 (8 ref.)

[Tubulo-interstitial lesions in glomerular diseases] Uchida S. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1423-7 (8 ref.) **(Jpn)**

BLOOD SUPPLY

A new model of renal microvascular injury. Nangaku M, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):457-62 (55 ref.)

CHEMISTRY

Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Groffen AJ, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2119-29 (115 ref.)

CYTOLOGY

Transfer of genetically engineered cells to the glomerulus. Kitamura M. **Exp Nephrol** 1999 May-Jun;7(3):259-66 (23 ref.)

Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Matsui K, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:9-11 (14 ref.)

DRUG EFFECTS

Lithium and the kidney: an updated review. Gitlin M. **Drug Saf** 1999 Mar;20(3):231-43 (77 ref.)

GROWTH & DEVELOPMENT

Role of laminin isoforms in glomerular structure. Hansen K, et al. **Pathobiology** 1999 Mar-Apr;67(2):84-91 (39 ref.)

IMMUNOLOGY

A 12-year-old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paueksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404-9 (13 ref.)

Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Berden JH, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):299-306 (57 ref.)

The concept of glomerular self-defense. Kitamura M, et al. **Kidney Int** 1999 May;55(5):1639-71 (413 ref.)

Adoptive transfer of genetically modified macrophages elucidated TGF-beta-mediated 'self-defence' of the glomerulus against local action of macrophages. Kitamura M. **Nephrol Dial Transplant** 1999;14 Suppl 1:35-8 (18 ref.)

Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis. Kaplan AA. **Ther Apher** 1997 Aug;1(3):255-9 (47 ref.)

INJURIES

Molecular basis of injury and progression in focal glomerulosclerosis [editorial] Harris RC. **Nephron** 1999; 82(4):289-99 (155 ref.)

METABOLISM

Carbonyl stress in the pathogenesis of diabetic nephropathy. Suzuki D, et al. **Intern Med** 1999 Apr;38(4):309-14 (60 ref.)

Determination of glomerular permselectivity: is it useful for diagnosis and clinical management of patients with glomerular disease? Mayer G. **Kidney Blood Press Res** 1998; 21(2-4):267-8 (11 ref.)

Pathophysiology of progressive nephropathies. Remuzzi G, et al. **N Engl J Med** 1998 Nov 12;339(20):1448-56 (95 ref.)

Nephrotoxicity of increased glomerular protein traffic. Abbate M, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):304-12 (78 ref.)

Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy [editorial] Wang SN, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2072-4 (12 ref.)

[Interaction between guanylate cyclases in the kidney glomerulus] Lewko B. **Postepy Hig Med Dosw** 1999; 53(2):225-31 (17 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Membranous glomerulonephritis associated with Graves' disease. Becker BA, et al. **Am J Kidney Dis** 1999 Feb; 33(2):369-73 (14 ref.)

Nephrotic range proteinuria and hematuria in a white bisexual male. Paueksakon P, et al. **Am J Kidney Dis** 1999 Mar;33(3):607-12 (27 ref.)

Collagenofibrotic glomerulopathy: a systemic disease. Yasuda T, et al. **Am J Kidney Dis** 1999 Jan;33(1):123-7 (25 ref.)

How does podocyte damage result in tubular damage? Kriz W, et al. **Kidney Blood Press Res** 1999;22(1-2):26-36 (33 ref.)

Progression of glomerular diseases: is the podocyte the culprit? Kriz W, et al. **Kidney Int** 1998 Sep;54(3):687-97 (133 ref.)

Molecular mechanisms of diabetic renal hypertrophy. Wolf G, et al. **Kidney Int** 1999 Aug;56(2):393-405 (153 ref.)

Thin basement membrane--do we have a window for understanding the molecular pathogenesis? [editorial] Netzer KO, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1060-1 (7 ref.)

Identification of non-diabetic glomerular disease in renal biopsies from diabetics--a dilemma. Olsen S. **Nephrol Dial Transplant** 1999 Aug;14(8):1846-9 (25 ref.)

Renal biopsy in lupus nephritis--what for, when and how often? [editorial] Ponticelli C, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2452-4 (10 ref.)

Cytokines and podocyte injury: the mechanism of fibroblast growth factor 2-induced podocyte injury. Sasaki T, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:33-4 (6 ref.)

Glomerular lesions of diabetes mellitus: preventable and reversible [editorial] Steffes MW. **Nephrol Dial Transplant** 1999 Jan;14(1):19-21 (17 ref.)

Glomerular lesions other than amyloidosis in patients with familial Mediterranean fever [editorial] Yalçinkaya F, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):21-3 (17 ref.)

Glomerular disease. Kashtan CE. **Semin Nephrol** 1999 Jul; 19(4):353-63 (124 ref.)

PHYSIOLOGY

Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice [see comments] Mukherjee AB, et al. **Am J Kidney Dis** 1998 Dec;32(6):1106-20 (151 ref.) Comment in: Am J Kidney Dis 1998 Dec;32(6):1084-5.

Role of macula densa NOS in tubuloglomerular feedback. Wilcox CS. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):443-9 (58 ref.)

Parathyroid hormone-related protein: roles in the glomerulus. Bosch RJ, et al. **Exp Nephrol** 1999 May-Jun; 7(3):212-6 (15 ref.)

Mesangial matrix modulation and glomerulosclerosis. Fogo AB. **Exp Nephrol** 1999 Mar-Apr;7(2):147-59 (107 ref.)

Transfer of genetically engineered cells to the glomerulus. Kitamura M. **Exp Nephrol** 1999 May-Jun;7(3):259-66 (23 ref.)

Glomerular podocytes and adhesive interaction with glomerular basement membrane. Mundel P, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):160-6 (44 ref.)

A comparison of analytic procedures for measurement of fractional dextran clearances [see comments] Hemmelder MH, et al. **J Lab Clin Med** 1998 Nov;132(5):390-403 (57 ref.) Comment in: J Lab Clin Med 1998 Nov;132(5):360-2.

Assessment of glomerular size-selective function with fractional clearance of neutral dextran [editorial; comment] Remuzzi A, et al. **J Lab Clin Med** 1998 Nov;132(5):360-2 (27 ref.) Comment on: J Lab Clin Med 1998 Nov;132(5):390-403.

Tubuloglomerular feedback: its physiological and pathophysiological significance. Kurokawa K. **Kidney Int Suppl** 1998 Sep;67:S71-4 (21 ref.)

Tubuloglomerular feedback: new concepts and developments. Schnermann J, et al. **Kidney Int Suppl** 1998 Sep;67:S40-5 (31 ref.)

Resetting protects efficiency of tubuloglomerular feedback. Thomson SC, et al. **Kidney Int Suppl** 1998 Sep;67:S65-70 (17 ref.)

Luminal signal in tubuloglomerular feedback: what about potassium? Vallon V, et al. **Kidney Int Suppl** 1998 Sep; 67:S177-9 (11 ref.)

Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Groffen AJ, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2119-29 (115 ref.)

Nitric oxide and tubuloglomerular feedback. Welch WJ, et al. **Semin Nephrol** 1999 May;19(3):251-62 (79 ref.)

PHYSIOPATHOLOGY

How to assess glomerular function and damage in humans. Rahn KH, et al. **J Hypertens** 1999 Mar;17(3):309-17 (82 ref.)

Macrophage activation and programming and its role for macrophage function in glomerular inflammation. Erwig LP, et al. **Kidney Blood Press Res** 1999;22(1-2):21-5 (46 ref.)

Glomerular filtration rate in normal and abnormal pregnancies. Baylis C. **Semin Nephrol** 1999 Mar;19(2):133-9 (55 ref.)

KIDNEY INSUFFICIENCY see **KIDNEY FAILURE**

KIDNEY INSUFFICIENCY, ACUTE see **KIDNEY FAILURE, ACUTE**

KIDNEY INSUFFICIENCY, CHRONIC see **KIDNEY FAILURE, CHRONIC**

KIDNEY MEDULLA

CHEMISTRY

Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Zhuo J, et al. **Kidney Int Suppl** 1998 Sep;67:S22-8 (29 ref.)

CYTOLOGY

Cellular response to osmotic stress in the renal medulla. Beck FX, et al. **Pflugers Arch** 1998 Nov;436(6):814-27 (153 ref.)

PHYSIOLOGY

Signalling and gene regulation by urea and NaCl in the renal medulla. Cohen DM. **Clin Exp Pharmacol Physiol** 1999 Jan; 26(1):69-73 (44 ref.)

Cellular osmoregulation in kidney medulla. Beck FX, et al. **Contrib Nephrol** 1998;123:169-84 (115 ref.)

Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Zhuo J, et al. **Kidney Int Suppl** 1998 Sep;67:S22-8 (29 ref.)

Cellular response to osmotic stress in the renal medulla. Beck FX, et al. **Pflugers Arch** 1998 Nov;436(6):814-27 (153 ref.)

[Role of renal interstitial pressure on chronic control of arterial blood pressure] Gamba G, et al. **Rev Invest Clin** 1998 Sep-Oct;50(5):441-9 (73 ref.) (Eng. Abstr.) **(Spa)**

KIDNEY NEOPLASMS

Renal cell carcinoma: a paradigm of lanthanic disease. Papac RJ, et al. **Am J Clin Oncol** 1999 Jun;22(3):223-31 (127 ref.)

Pediatric genitourinary tumors. Lee HH, et al. **Curr Opin Oncol** 1999 May;11(3):218-25 (57 ref.)

Extracellular matrix in renal cell carcinomas. Lohi J, et al. **Histol Histopathol** 1998 Jul;13(3):785-96 (158 ref.)

Renal cell carcinoma in children: experience at a single institution in Japan. Asanuma H, et al. **J Urol** 1999 Oct; 162(4):1402-5 (28 ref.)

Kidney cancer [see comments] Vogelzang NJ, et al. **Lancet** 1998 Nov 21;352(9141):1691-6 (79 ref.) Comment in: Lancet 1999 Feb 13;353(9152):594.

Wilms' tumor and related abnormalities in the fetus and newborn. Bove KE. **Semin Perinatol** 1999 Aug;23(4):310-8 (59 ref.)

[Cancer of the kidney in the adult] Delord JP, et al. **Bull Cancer** 1998 Sep;(1 Suppl):4-15 (115 ref.) (Eng. Abstr.) **(Fre)**

[Primary renal chondrosarcoma: apropos of a case] Colin J, et al. **Prog Urol** 1998 Sep;8(4):553-6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Myeloma kidney] Arai T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):476-9 (14 ref.) **(Jpn)**

BLOOD SUPPLY

Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Strohmeyer D. **Anticancer Res** 1999 Mar-Apr;19(2C):1557-61 (32 ref.)

CHEMICALLY INDUCED

Does diuretic therapy increase the risk of renal cell carcinoma? [editorial][see comments] Grossman E, et al. **Am J Cardiol** 1999 Apr 1;83(7):1090-3 (43 ref.) Comment in: Am J Cardiol 1999 Apr 1;83(7):1094.

Diuretic therapy for hypertension: a cancer risk? Lip GY, et al. **J Hum Hypertens** 1999 Jul;13(7):421-3 (23 ref.)

An evaluation of the carcinogenic hazard of 1,4-dichlorobenzene based on internationally recognized criteria. Barter JA, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):64-79 (78 ref.)

[Diuretic therapy and the risk of renal-cell carcinoma

(editorial)] Schmieder RE. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):410–1 (10 ref.) **(Ger)**

CHEMISTRY

Primary renal angiosarcoma: a case report with immunohistochemical, ultrastructural, and cytogenetic features and review of the literature. Cerilli LA, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):929–35 (8 ref.)

CLASSIFICATION

Renal tumours: the new order. Delahunt B, et al. **N Z Med J** 1998 Aug 28;111(1072):307–9 (29 ref.)

COMPLICATIONS

Epstein–Barr virus–associated renal smooth muscle neoplasm: report of a case with review of the literature. Creager AJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):277–81 (32 ref.)

Surgical treatment of renal cell carcinoma associated with Budd–Chiari syndrome: report of four cases and review of the literature. Kume H, et al. **Eur J Surg Oncol** 1999 Feb;25(1):71–5 (15 ref.)

Hypercalcemia associated with squamous cell carcinoma of the renal pelvis. Cadeddu JA, et al. **J Urol** 1998 Nov; 160(5):1798 (3 ref.)

Renal medullary carcinoma in an adolescent with sickle cell trait. Warren KE, et al. **Pediatrics** 1999 Feb;103(2):E22 (8 ref.)

[Paraneoplastic nephropathy associated with adult renal carcinoma (immunologic and clinicopathologic study)] Kiss B, et al. **Orv Hetil** 1999 Jan 10;140(2):75–80 (35 ref.) (Eng. Abstr.) **(Hun)**

[Spontaneous rupture of renal cell carcinoma: a case report] Tokiwa M, et al. **Hinyokika Kiyo** 1999 Apr;45(4):253–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A case of transitional cell carcinoma and milk of calcium in a pyelocalyceal diverticulum] Yoshimura K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):649–52 (15 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Classical congenital mesoblastic nephroma in an adult: a case report on an Ethiopian. Gemechu T, et al. **Ethiop Med J** 1997 Oct;35(4):257–62 (13 ref.)

DIAGNOSIS

Teratoid Wilms tumor arising as a botryoid growth within a supernumerary ectopic ureteropelvic structure. Pawel BR, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):925–8 (26 ref.)

Fine needle aspiration cytology of the kidney, renal pelvis, and adrenal. Nguyen GK, et al. **Clin Lab Med** 1998 Sep; 18(3):429–59, vi (65 ref.)

Renal cell carcinoma. Godley PA, et al. **Curr Opin Oncol** 1999 May;11(3):213–7 (31 ref.)

Renal cell carcinoma with hypercalcemia complicating a pregnancy: case report and review of the literature. Usta IM, et al. **Eur J Gynaecol Oncol** 1998;19(6):584–7 (27 ref.)

Von Hippel–Lindau disease: strategies in early detection (renal–, adrenal–, pancreatic masses). Hes FJ, et al. **Eur Radiol** 1999;9(4):598–610 (142 ref.)

Adult Wilms' tumour. A report of two cases and their treatment and prognosis. Akmansu M, et al. **Int Urol Nephrol** 1998;30(5):529–33 (15 ref.)

The incidental diagnosis. Silverberg LI. **J Am Osteopath Assoc** 1999 Apr;99(4):214–6 (18 ref.)

Renal fibrohistiocytic sarcoma. Three cases and a review of the literature. Haddad FS, et al. **J Med Liban** 1998 Nov–Dec;46(6):335–42 (50 ref.)

Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Neumann HP, et al. **Semin Pediatr Neurol** 1998 Dec;5(4):269–75 (49 ref.)

Pediatric renal tumors. Shamberger RC. **Semin Surg Oncol** 1999 Mar;16(2):105–20 (84 ref.)

Imaging of patients with Wilms' tumor. Goske MJ, et al. **Semin Urol Oncol** 1999 Feb;17(1):11–20 (23 ref.)

Second primary renal cell carcinomas following solid tumors. Four case reports and review of the literature. Koumarianou AA, et al. **Tumori** 1998 Sep–Oct;84(5):600–2 (14 ref.)

Subepithelial pelvic hematoma of the kidney clinically mimicking cancer: report of six cases and review of the literature. Iczkowski KA, et al. **Urology** 1999 Feb; 53(2):276–9 (12 ref.)

[Primary renal epithelioid angiosarcoma with transitional cell carcinoma in renal pelvis] Li N, et al. **Chung Hua Wai Ko Tsa Chih** 1997 May;35(5):294–5 (5 ref.) (Eng. Abstr.) **(Chi)**

[Primary osteosarcoma of the kidney] Wikström M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):166–8 (10 ref.) **(Ger)**

[Angiosarcoma of the kidney. Case report and review of the literature] Matter LE, et al. **Urologe A** 1999 Jan;38(1):65–8 (19 ref.) (Eng. Abstr.) **(Ger)**

[Renal oncocytoma: its differential diagnosis and the indications for surgical treatment] Terrinoni V, et al. **G Chir** 1999 May;20(5):225–8 (13 ref.) (Eng. Abstr.) **(Ita)**

[Bilateral renal oncocytoma. A clinical case and review of the literature] Cudazzo E, et al. **Minerva Chir** 1998 Sep; 53(9):769–74 (32 ref.) (Eng. Abstr.) **(Ita)**

[A case of synchronous triple primary cancers of prostate, kidney and bladder] Harima M, et al. **Hinyokika Kiyo** 1998 Sep;44(9):675–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A fibroepithelial myxoid polyp of the renal pelvis in a patient with horseshoe kidneys. Apropos a case] Camacho García C, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):609–12 (8 ref.) (Eng. Abstr.) **(Spa)**

[Tuberculosis and renal cancer] Conde Redondo C, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):617–20 (9 ref.) (Eng. Abstr.) **(Spa)**

[Renal oncocytoma: infrequent presentation form] Pinos Paul MA, et al. **Actas Urol Esp** 1999 Feb;23(2):160–3 (22 ref.) (Eng. Abstr.) **(Spa)**

[Fibroepithelial polyps of the upper urinary tract: their diagnostic evaluation and treatment in pediatrics] Mora Durbán MJ, et al. **Arch Esp Urol** 1999 Jan–Feb;52(1):61–7 (38 ref.) (Eng. Abstr.) **(Spa)**

[Renal leiomyosarcoma. Apropos a case] Rebassa Llull M, et al. **Arch Esp Urol** 1999 Jan–Feb;52(1):78–80 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Chemotherapy for renal cell carcinoma. Hartmann JT, et al. **Anticancer Res** 1999 Mar–Apr;19(2C):1541–3 (28 ref.)

Veno–occlusive disease of the liver in right–sided Wilms' tumours [see comments] Tornesello A, et al. **Eur J Cancer** 1998 Jul;34(8):1220–3 (21 ref.) Comment in: Eur J Cancer 1998 Jul;34(8):1145–7. Comment in: Eur J Cancer 1999 Mar;35(3):521–3.

Renal cell carcinoma and diuretics—should one restrict the use of diuretics? [editorial] Schmieder RE, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1621–3 (13 ref.)

ETIOLOGY

Radiation induced renal cell cancer: a report of 4 cases and review of the literature. Vogelzang NJ, et al. **J Urol** 1998 Dec;160(6 Pt 1):1987–90 (39 ref.)

Risk and prognosis in renal neoplasms. A pathologist's prospective. Bonsib SM. **Urol Clin North Am** 1999 Aug; 26(3):643–60, viii (172 ref.)

[Nephrogenic adenoma arising from an urethral diverticulum in a female. Report of a case and review of the literature] Greco A, et al. **Minerva Urol Nefrol** 1999 Mar;51(1):39–43 (30 ref.) (Eng. Abstr.) **(Ita)**

[A case of renal cell carcinoma associated with tuberous sclerosis] Kakimoto K, et al. **Hinyokika Kiyo** 1999 May; 45(5):335–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Primary adenocarcinoma of the renal pelvis in a young male: a case report] Megumi Y, et al. **Hinyokika Kiyo** 1998 Nov; 44(11):817–20 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Bilateral renal cell carcinoma in a patient with chronic renal failure: a case report] Tsuchiya F, et al. **Hinyokika Kiyo** 1998 Nov;44(11):813–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Glycolipid sulfotransferase and cancer] Honke K. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2373–7 (16 ref.) **(Jpn)**

GENETICS

Inherited carcinomas of the kidney. Zbar B, et al. **Adv Cancer Res** 1998;75:163–201 (181 ref.)

Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Beckwith JB. **Am J Med Genet** 1998 Oct 2;79(4):268–73 (25 ref.)

Wilms tumor genetics. Huff V. **Am J Med Genet** 1998 Oct 2;79(4):260–7 (86 ref.)

Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype. Désangles F, et al. **Cancer Genet Cytogenet** 1999 Sep;113(2):141–4 (22 ref.)

Advances in the molecular basis of renal neoplasia. Cohen HT. **Curr Opin Nephrol Hypertens** 1999 May;8(3):325–31 (91 ref.)

Genetics of kidney tumours. Fleming S. **Forum (Genova)** 1998 Apr–Jun;8(2):176–84 (33 ref.)

Syndrome of microcephaly, Dandy–Walker malformation, and Wilms tumor caused by mosaic variegated aneuploidy with premature centromere division (PCD): report of a new case and review of the literature. Kawame H, et al. **J Hum Genet** 1999;44(4):219–24 (16 ref.)

Inherited renal neoplasms. Torres VE, et al. **J Nephrol** 1998 Sep–Oct;11(5):229–38 (95 ref.)

Histopathology and molecular genetics of renal tumors toward unification of a classification system. Zambrano NR, et al. **J Urol** 1999 Oct;162(4):1246–58 (199 ref.)

Multitechnical pathological diagnosis in chromophobe renal cell carcinoma. Balzarini P, et al. **Oncol Rep** 1999 Mar–Apr; 6(2):295–9 (24 ref.)

Genetics of Wilms' tumor. Coppes MJ, et al. **Semin Urol Oncol** 1999 Feb;17(1):2–10 (85 ref.)

[Cytogenetic investigation of kidney tumors. A supplement to conventional diagnosis] Pedersen RK, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4376–9 (34 ref.) (Eng. Abstr.) **(Dan)**

[Genetically–induced kidney diseases] Zerres K, et al. **Internist (Berl)** 1999 May;40(5):534–42 (13 ref.) **(Ger)**

[Molecular genetic mechanism of hereditary human kidney cancer development] Shuin T. **Nippon Hinyokika Gakkai Zasshi** 1999 May;90(5):533–40 (28 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Matrix metalloproteinases and their inhibitors. Kugler A. **Anticancer Res** 1999 Mar–Apr;19(2C):1589–92 (21 ref.)

NURSING

Diagnosis and referral of Wilms' tumor. Pye S. **Nurse Pract** 1999 May;24(5):121–2, 127 (6 ref.)

PATHOLOGY

Benign tumors and tumor–like lesions of the adult kidney. Part I: Benign renal epithelial neoplasms. Ligato S, et al. **Adv Anat Pathol** 1999 Jan;6(1):1–11 (63 ref.)

Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Beckwith JB. **Am J Med Genet** 1998 Oct 2;79(4):268–73 (25 ref.)

Nuclear grooves in papillary (chromophil) renal cell carcinoma [letter; comment] Ng WK. **Am J Surg Pathol** 1998 Oct;22(10):1298–300 (5 ref.) Comment on: Am J Surg Pathol 1997 Jun;21(6):621–35.

Metanephric adenofibroma: report of a case and review of the literature. Shek TW, et al. **Am J Surg Pathol** 1999 Jun; 23(6):727–33 (10 ref.)

Collision tumor: a peripheral neuroepithelioma and a transitional–cell carcinoma occurring simultaneously in the renal pelvis. Phan ST, et al. **Ann Diagn Pathol** 1997 Dec; 1(2):91–8 (46 ref.)

The problematic nature of metastasized renal cell carcinoma. Bichler KH, et al. **Anticancer Res** 1999 Mar–Apr; 19(2C):1463–6 (55 ref.)

Cadherins in renal cell carcinoma. Heicappell R. **Anticancer Res** 1999 Mar–Apr;19(2C):1501–4 (42 ref.)

Contralateral solitary testis metastasis antedating renal cell carcinoma: a case–report and review. Lauro S, et al. **Anticancer Res** 1998 Nov–Dec;18(6B):4683–4 (7 ref.)

Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Strohmeyer D. **Anticancer Res** 1999 Mar–Apr;19(2C):1557–61 (32 ref.)

Benign fibroepithelial polyps of the renal pelvis. Nowak MA, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):850–2 (22 ref.)

Prognostic factors in renal cell and bladder cancer. Van Brussel JP, et al. **BJU Int** 1999 May;83(8):902–8; quiz 908–9 (75 ref.)

A case of panlobar nephroblastomatosis with bilateral Wilms' tumour. The concept of "nephroblastomatosis" and its clinical importance. Lancaster EJ, et al. **Cent Afr J Med** 1998 Jul;44(7):182–7 (15 ref.)

Mesoblastic nephroma in adulthood: a case report. Shiraishi K, et al. **Int J Urol** 1999 Aug;6(8):414–8 (23 ref.)

Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. Dechet CB, et al. **J Urol** 1999 Oct;162(4):1282–4; discussion 1284–5 (27 ref.)

Histopathology and molecular genetics of renal tumors toward unification of a classification system. Zambrano NR, et al. **J Urol** 1999 Oct;162(4):1246–58 (199 ref.)

Renal tumours: the new order. Delahunt B, et al. **N Z Med J** 1998 Aug 28;111(1072):307–9 (29 ref.)

Multitechnical pathological diagnosis in chromophobe renal cell carcinoma. Balzarini P, et al. **Oncol Rep** 1999 Mar–Apr; 6(2):295–9 (24 ref.)

A case of chromophobe renal cell carcinoma with sarcomatoid foci and a small daughter lesion. Kuroda N, et al. **Pathol Int** 1998 Oct;48(10):812–7 (30 ref.)

Wilms' tumor in the adult—report of a case and review of the literature. Tawil A, et al. **Pathol Res Pract** 1999; 195(2):105–11; discussion 113–4 (29 ref.)

Prognostic factors of epithelial tumours of the kidney. Algaba F. **Pathologica** 1999 Feb;91(1):51–3 (20 ref.)

National Wilms Tumor Study: an update for pathologists. Beckwith JB. **Pediatr Dev Pathol** 1998 Jan–Feb;1(1):79–84 (14 ref.)

Renal cell carcinoma metastasizing to the thyroid gland. Palazzo FF, et al. **Scand J Urol Nephrol** 1999 Jun; 33(3):202–4 (7 ref.)

Renal tumors exhibiting granular cytoplasm. Reuter VE. **Semin Diagn Pathol** 1999 May;16(2):135–45 (100 ref.)

Solitary choroid plexus metastasis from a renal cell carcinoma. Raila FA, et al. **South Med J** 1998 Dec; 91(12):1159–62 (24 ref.)

Risk and prognosis in renal neoplasms. A pathologist's prospective. Bonsib SM. **Urol Clin North Am** 1999 Aug; 26(3):643–60, viii (172 ref.)

Grading of renal cell carcinoma. Goldstein NS. **Urol Clin North Am** 1999 Aug;26(3):637–42, vii (32 ref.)

Epithelial tumours of the adult kidney. Montironi R, et al. **Virchows Arch** 1999 Apr;434(4):281–90 (63 ref.)

[Epithelioid angiomyolipoma of the kidney—a new tumor entity. Case report on a tumor with many multinucleated giant cells] Moch H, et al. **Pathologe** 1998 Nov;19(6):436–41 (30 ref.) (Eng. Abstr.) **(Ger)**

[Renal oncocytomatosis] Ulrich S, et al. **Pathologe** 1999 May; 20(3):189–94 (33 ref.) (Eng. Abstr.) **(Ger)**

[Recent progress of prognostic factors in renal cell carcinoma] Shimazui T. **Gan To Kagaku Ryoho** 1998 Nov; 25(13):2049–54 (46 ref.) (Eng. Abstr.) **(Jpn)**

[A case of renal pelvic carcinoma in a completely duplicated pelvis and ureter] Tamada H, et al. **Hinyokika Kiyo** 1998 Oct;44(10):733–5 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A case of renal oncocytoma with cystic formation] Amano E, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Jan; 90(1):49–52 (15 ref.) (Eng. Abstr.) **(Jpn)**

KIDNEY NEOPLASMS

PREVENTION & CONTROL

Chemoprevention of urological cancer. Kamat AM, et al. **J Urol** 1999 Jun;161(6):1748–60 (152 ref.)

RADIOGRAPHY

Is there still a place for angiography in the management of renal mass lesions? Roy C, et al. **Eur Radiol** 1999; 9(2):329–35 (23 ref.)

[Angiography and interventional radiology of the kidney] Hansmann J, et al. **Radiologe** 1999 May;39(5):361–72 (43 ref.) (Eng. Abstr.) **(Ger)**

[A spontaneously ruptured renal oncocytoma: fat inclusion simulating an angiomyolipoma] Miltner P. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Mar;170(3):325–6 (0 ref.) **(Ger)**

RADIONUCLIDE IMAGING

[Nuclear medicine in kidney diagnosis] Haufe S, et al. **Radiologe** 1999 May;39(5):386–97 (33 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Future strategies in external radiation therapy of renal cell carcinoma. Kortmann RD, et al. **Anticancer Res** 1999 Mar–Apr;19(2C):1601–3 (11 ref.)

SECONDARY

Osteosarcoma metastatic to the kidneys without lung involvement. Ogose A, et al. **Jpn J Clin Oncol** 1999 Aug; 29(8):395–8 (15 ref.)

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237–9 (12 ref.) **(Fre)**

[Metastatic renal tumor originating from esophageal carcinoma: a case report] Matsushita Y, et al. **Hinyokika Kiyo** 1998 Aug;44(8):591–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

The endourological management of upper urinary tract tumours. Borkowski A, et al. **BJU Int** 1999 Mar; 83(4):369–77 (64 ref.)

Nephron-sparing surgery for renal cell carcinoma. Novick AC. **Br J Urol** 1998 Sep;82(3):321–4 (19 ref.)

Surgical treatment of renal cell carcinoma associated with Budd–Chiari syndrome: report of four cases and review of the literature. Kume H, et al. **Eur J Surg Oncol** 1999 Feb;25(1):71–5 (15 ref.)

Risk-based management: current concepts of treating malignant solid tumors of childhood. Grosfeld JL. **J Am Coll Surg** 1999 Oct;189(4):407–25 (93 ref.)

A resected case of pancreatic metastasis from primary renal cell carcinoma. Eriguchi N, et al. **Kurume Med J** 1999; 46(2):119–22 (9 ref.)

Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma. Duque JL, et al. **Urology** 1998 Oct;52(4):584–90 (26 ref.)

Renal cryosurgery. Gill IS, et al. **Urology** 1999 Aug; 54(2):215–9 (21 ref.)

[Lymphatic metastases in renal cell carcinoma. What is the value of operation and adjuvant therapy?] Mickisch GH. **Urologe A** 1999 Jul;38(4):326–31 (29 ref.) (Eng. Abstr.) **(Ger)**

[Renal oncocytoma: its differential diagnosis and the indications for surgical treatment] Terrinoni V, et al. **G Chir** 1999 May;20(5):225–8 (13 ref.) (Eng. Abstr.) **(Ita)**

[The multifocality problem in elective partial nephrectomy for renal-cell carcinoma (editorial)] Cabezas CA, et al. **Actas Urol Esp** 1999 Jan;23(1):1–4 (18 ref.) **(Spa)**

[Synchronous bilateral renal adenocarcinoma. Our experience with conservative kidney surgery] Pérez Garcia FJ, et al. **Arch Esp Urol** 1999 Jun;52(5):471–7 (19 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The problematic nature of metastasized renal cell carcinoma. Bichler KH, et al. **Anticancer Res** 1999 Mar–Apr; 19(2C):1463–6 (55 ref.)

New treatment modalities--the urologist's view. Strohmaier WL. **Anticancer Res** 1999 Mar–Apr;19(2C):1605–9 (57 ref.)

Recent progress in cytokine therapy for renal cell cancer: a case for the European Organization for Research and Treatment of Cancer adjuvant cytokine trial in patients with poor-risk renal cell cancer after maximum debulking surgery. Ravi R, et al. **BJU Int** 1999 Feb;83(3):219–21 (23 ref.)

Renal cell carcinoma. Godley PA, et al. **Curr Opin Oncol** 1999 May;11(3):213–7 (31 ref.)

Wilms' tumour. Optimal treatment strategies. Suryanarayan K, et al. **Drugs** 1998 Oct;56(4):598–605 (28 ref.)

Adult Wilms' tumour. A report of two cases and their treatment and prognosis. Akmansu M, et al. **Int Urol Nephrol** 1998;30(5):529–33 (15 ref.)

Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: case report and review. Waldron PE, et al. **J Pediatr Hematol Oncol** 1999 Jan–Feb;21(1):53–7 (28 ref.)

Renal cell carcinoma: management of advanced disease. Figlin RA. **J Urol** 1999 Feb;161(2):381–6; discussion 386–7 (46 ref.)

Factors influencing prognosis in renal cell carcinoma. Ather MH, et al. **JPMA J Pak Med Assoc** 1998 May;48(5):145–7 (18 ref.)

Radiofrequency ablation: an outpatient percutaneous treatment. Dupuy DE. **Med Health R I** 1999 Jun; 82(6):213–6 (8 ref.)

Immunotherapy in renal cell carcinoma. Bukowski RM. **Oncology (Huntingt)** 1999 Jun;13(6):801–10; discussion 810, 813 (55 ref.)

Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours. Lümmen G, et al. **Pharmacol Res** 1998 Sep;38(3):151–64 (70 ref.)

Immunotherapy for renal cell cancer. Bower M, et al. **QJM** 1998 Sep;91(9):597–602 (57 ref.)

The role of arterial embolization in renal cell carcinoma. Kalman D, et al. **Scand J Urol Nephrol** 1999 Jun; 33(3):162–70 (64 ref.)

Pediatric renal tumors. Shamberger RC. **Semin Surg Oncol** 1999 Mar;16(2):105–20 (84 ref.)

Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Egeler RM, et al. **Semin Urol Oncol** 1999 Feb;17(1):55–61 (35 ref.)

Dendritic cell-based immunotherapy of renal cell carcinoma. Thurnher M, et al. **Urol Int** 1998;61(2):67–71 (18 ref.)

[Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology] van Herpen CM, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2613–8 (42 ref.) (Eng. Abstr.) **(Dut)**

[Cytokines and cancer: update in 1998] Négrier S. **Bull Cancer** 1999 Jan;86(1):37–9 (24 ref.) **(Fre)**

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237–9 (12 ref.) **(Fre)**

[Successful preoperative interferon-alpha therapy of renal cell carcinoma with tumor thrombus extending into the inferior vena cava--case report] Miki T, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):796–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The embolization of complicated renal angiomyolipoma] Nobre I, et al. **Acta Med Port** 1999 Apr–Jun;12(4–6):231–4 (13 ref.) (Eng. Abstr.) **(Por)**

[The immunological treatment of renal cancer] Tabernero Caturla J, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):340–8 (100 ref.) **(Spa)**

ULTRASTRUCTURE

Pigmented microcystic chromophobe cell carcinoma: a unique variant of renal cell carcinoma. Michal M, et al. **Ann Diagn Pathol** 1998 Jun;2(3):149–53 (27 ref.)

VETERINARY

Urinary tract neoplasia. Traub-Dargatz JL. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):495–504, vi (35 ref.)

KIDNEY PAPILLA see **KIDNEY MEDULLA**

KIDNEY PELVIS

Hypercalcemia associated with squamous cell carcinoma of the renal pelvis. Cadeddu JA, et al. **J Urol** 1998 Nov; 160(5):1798 (3 ref.)

Subepithelial pelvic hematoma of the kidney clinically mimicking cancer: report of six cases and review of the literature. Iczkowski KA, et al. **Urology** 1999 Feb; 53(2):276–9 (12 ref.)

[A case of spontaneous pyeloduodenal fistula] Hamamoto Y, et al. **Hinyokika Kiyo** 1999 May;45(5):355–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

[A case of renal pelvic carcinoma in a completely duplicated pelvis and ureter] Tamada H, et al. **Hinyokika Kiyo** 1998 Oct;44(10):733–5 (19 ref.) (Eng. Abstr.) **(Jpn)**

INJURIES

Complete pyelo-calyceal avulsion as a result of blunt abdominal trauma. Pagano S, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):66–8 (8 ref.)

PATHOLOGY

Non-parasitic chyluria: a case report and review of the literature. Cortvriend J, et al. **Acta Urol Belg** 1998 Oct; 66(3):11–5 (15 ref.)

Collision tumor: a peripheral neuroepithelioma and a transitional-cell carcinoma occurring simultaneously in the renal pelvis. Phan ST, et al. **Ann Diagn Pathol** 1997 Dec; 1(2):91–8 (46 ref.)

Benign fibroepithelial polyps of the renal pelvis. Nowak MA, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):850–2 (22 ref.)

Fine needle aspiration cytology of the kidney, renal pelvis, and adrenal. Nguyen GK, et al. **Clin Lab Med** 1998 Sep; 18(3):429–59, vi (65 ref.)

Extraosseous metaplasia of the renal pelvis in a child. Plata AL, et al. **J Urol** 1999 Apr;161(4):1295–6 (7 ref.)

SURGERY

Endopyelotomy review. Bernardo N, et al. **Arch Esp Urol** 1999 Jun;52(5):541–8 (45 ref.)

Ureteroscopic treatment of ureteropelvic junction obstruction. Tawfiek ER, et al. **J Urol** 1998 Nov; 160(5):1643–6; discussion 1646–7 (34 ref.)

KIDNEY, POLYCYSTIC

Unilateral renal cystic disease. Glassberg KI. **Urology** 1999 Jun;53(6):1227–8 (4 ref.)

[Etiology and therapy of polycystic kidney] Higashihara E. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1298–304 (14 ref.) **(Jpn)**

COMPLICATIONS

[Adult renal polycystosis as the causal entity of an intercostal hernia containing an intestinal loop: an unusual clinical case] Serrano Pascual A, et al. **Arch Esp Urol** 1999 Jan–Feb; 52(1):80–3 (5 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Nephronophthisis–medullary cystic disease: clinical and genetic aspects. Gusmano R, et al. **J Nephrol** 1998 Sep–Oct; 11(5):224–8 (53 ref.)

[Cystic kidney disease] Sobral FT. **Acta Med Port** 1999 Jan–Mar;12(1–3):123–9 (22 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

The proximal tubule phenotype and its disruption in acute renal failure and polycystic kidney disease. Witzgall R. **Exp Nephrol** 1999 Jan–Feb;7(1):15–9 (36 ref.)

[Current opinions on the etiology and pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). II. Factors other than genetic factors which have an influence on disease course and selected clinical problems] Jasik P, et al. **Przegl Lek** 1998;55(11):599–606 (108 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Nephronophthisis–medullary cystic disease: clinical and genetic aspects. Gusmano R, et al. **J Nephrol** 1998 Sep–Oct; 11(5):224–8 (53 ref.)

The molecular biology of polycystic kidney disease. Murcia NS, et al. **Pediatr Nephrol** 1998 Nov;12(9):721–6 (66 ref.)

[Current opinions about the etiology and pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). I. Selected genetic aspects and mechanisms of cyst formation] Jasik P, et al. **Przegl Lek** 1998;55(10):542–8 (89 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Unilateral renal cystic disease in adults. Hwang DY, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1999–2003 (23 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT

Pathophysiology and clinical management of polycystic kidney disease in women. Wilson PD, et al. **Semin Nephrol** 1999 Mar;19(2):123–32 (43 ref.)

COMPLICATIONS

Traumatic hematuria in patients with polycystic kidney disease. Klein AJ, et al. **Am Surg** 1999 May;65(5):464–6 (25 ref.)

DIAGNOSIS

Traumatic hematuria in patients with polycystic kidney disease. Klein AJ, et al. **Am Surg** 1999 May;65(5):464–6 (25 ref.)

[Renal polycystosis in pediatrics] Khoory BJ, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):269–73 (23 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Cyst formation in ADPKD: new insights from natural and targeted mutants [editorial] Ong AC. **Nephrol Dial Transplant** 1999 Mar;14(3):544–6 (20 ref.)

GENETICS

Phenotypic variability in PKD1: the family as a starting point [editorial; comment] Guay-Woodford LM. **Kidney Int** 1999 Jul;56(1):344–6 (19 ref.) Comment on: Kidney Int 1999 Jul;56(1):34–40.

New insights into the molecular pathophysiology of polycystic kidney disease. Murcia NS, et al. **Kidney Int** 1999 Apr;55(4):1187–97 (109 ref.)

The role of the polycystins in kidney development. van Adelsberg JS. **Pediatr Nephrol** 1999 Jun;13(5):454–9 (48 ref.)

The use of ultrasonography and linkage studies for early diagnosis of autosomal dominant polycystic kidney disease (ADPKD). Papadopoulou D, et al. **Ren Fail** 1999 Jan; 21(1):67–84 (67 ref.)

Autosomal dominant polycystic kidney disease associated with familial sensorineural deafness. Mora C, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):63–5 (18 ref.)

Molecular basis of autosomal dominant polycystic kidney disease. Watnick T, et al. **Semin Nephrol** 1999 Jul; 19(4):327–43 (80 ref.)

[Molecular biological mechanism for the development of cystic kidney] Horie S. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2335–42 (21 ref.) **(Jpn)**

METABOLISM

Ion transport and cystogenesis: the paradigm of autosomal dominant polycystic kidney disease. Devuyst O, et al. **Adv Nephrol Necker Hosp** 1998;28:439–78 (155 ref.)

PATHOLOGY

Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Zhou XJ, et al. **Diagn Mol Pathol** 1998 Apr;7(2):65–8 (20 ref.)

PHYSIOPATHOLOGY

PKD and CF: an interesting family provides insight into the molecular pathophysiology of polycystic kidney disease [editorial; comment] Cotton CU, et al. **Am J Kidney Dis** 1998 Dec;32(6):1081–3 (22 ref.) Comment on: Am J Kidney Dis 1998 Dec;32(6):976–83.

New insights into the molecular pathophysiology of polycystic kidney disease. Murcia NS, et al. **Kidney Int** 1999 Apr;55(4):1187–97 (109 ref.)

ULTRASONOGRAPHY

The use of ultrasonography and linkage studies for early diagnosis of autosomal dominant polycystic kidney disease (ADPKD). Papadopoulou D, et al. **Ren Fail** 1999 Jan; 21(1):67–84 (67 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE

DIAGNOSIS

[Renal polycystosis in pediatrics] Khoory BJ, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):269–73 (23 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Renal–retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus [see comments] Caridi G, et al. **Am J Kidney Dis** 1998 Dec;32(6):1059–62 (12 ref.) Comment in: Am J Kidney Dis 1998 Dec;32(6):1084–5.

New insights into the molecular pathophysiology of polycystic kidney disease. Murcia NS, et al. **Kidney Int** 1999 Apr;55(4):1187–97 (109 ref.)

METABOLISM

Epithelial transport in polycystic kidney disease. Sullivan LP, et al. **Physiol Rev** 1998 Oct;78(4):1165–91 (191 ref.)

PHYSIOPATHOLOGY

New insights into the molecular pathophysiology of polycystic kidney disease. Murcia NS, et al. **Kidney Int** 1999 Apr;55(4):1187–97 (109 ref.)

KIDNEY REPLACEMENT THERAPY see **RENAL REPLACEMENT THERAPY**

KIDNEY STONES see **KIDNEY CALCULI**

KIDNEY TRANSPLANTATION

Liver transplantation or liver and kidney transplantation? Samuel D, et al. **Adv Nephrol Necker Hosp** 1998;28:163–9 (22 ref.)

Exercise after renal transplantation. Painter P. **Adv Ren Replace Ther** 1999 Apr;6(2):159–64 (31 ref.)

Drug substitution in transplantation: a National Kidney Foundation White Paper. Sabatini S, et al. **Am J Kidney Dis** 1999 Feb;33(2):389–97 (32 ref.)

Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Weir MR, et al. **Am J Kidney Dis** 1999 Jul;34(1):1–13 (84 ref.)

Acute colonic pseudo–obstruction (Ogilvie's syndrome) after renal transplantation. O'Malley KJ, et al. **Am J Surg** 1999 Jun;177(6):492–6 (40 ref.)

Recurrence of IgA nephropathy after renal transplantation. van der Boog PJ, et al. **Ann Med Interne (Paris)** 1999 Feb; 150(2):137–42 (62 ref.)

Kaposi's sarcoma in renal transplant recipients. Shaheen FA, et al. **Ann Transplant** 1997;2(4):49–58 (218 ref.)

Ano–genital neoplasia in renal transplant patients. Sillman FH, et al. **Ann Transplant** 1997;2(4):59–66 (51 ref.)

Acute failure of the transplanted kidney––pathophysiology, diagnosis and prevention. Więcek A, et al. **Ann Transplant** 1996;1(4):5–9 (86 ref.)

Dialysis or transplantation: fitting the treatment to the patient. Berkoben M, et al. **Annu Rev Med** 1999;50:193–205 (21 ref.)

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Shaw LM, et al. **Clin Biochem** 1998 Jul; 31(5):317–22 (42 ref.)

Successful treatment of severe azathioprine–induced hepatic veno–occlusive disease in a kidney–transplanted patient with transjugular intrahepatic portosystemic shunt. Azoulay D, et al. **Clin Nephrol** 1998 Aug;50(2):118–22 (29 ref.)

Disseminated histoplasmosis 19 years after renal transplantation. Jha V, et al. **Clin Nephrol** 1999 Jun; 51(6):373–8 (38 ref.)

The role of tacrolimus in adult kidney transplantation: a review. Laskow DA, et al. **Clin Transplant** 1998 Dec; 12(6):489–503 (36 ref.)

Non–heartbeating kidney donors. Laskowski IA, et al. **Clin Transplant** 1999 Aug;13(4):281–6 (34 ref.)

Human parvovirus B19 infection in organ transplant recipients. Marchand S, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):17–24 (63 ref.)

An overview of combined heart and kidney transplantation. Castillo–Lugo JA, et al. **Curr Opin Cardiol** 1999 Mar; 14(2):121–5 (24 ref.)

Utilization of crossmatch techniques for renal transplantation. Harmer AW. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):687–90 (22 ref.)

Non–heartbeating donors: are they worth the effort? Jacobs RW, et al. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):655–8 (17 ref.)

Pathogenesis of chronic allograft nephropathy [editorial] Paul LC. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):635–7 (17 ref.)

Protocol biopsies in renal transplantation: research tool or clinically useful? Rush DN, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):691–4 (14 ref.)

Risks and benefits of kidney and pancreas transplantation for diabetic patients. Manske CL. **Diabetes Care** 1999 Mar;22 Suppl 2:B114–20 (97 ref.)

Rethinking chronic allograft nephropathy: the concept of accelerated senescence. Halloran PF, et al. **J Am Soc Nephrol** 1999 Jan;10(1):167–81 (171 ref.)

Living unrelated renal transplantation: progress and potential. Said MR, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2148–52 (38 ref.)

Successful surgical management of a ruptured abdominal aortic aneurysm in a renal transplant patient. A case report. Lachachi F, et al. **J Cardiovasc Surg (Torino)** 1998 Dec; 39(6):765–7 (13 ref.)

Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients? [editorial] Arlen DJ, et al. **J Nephrol** 1999 Jan–Feb; 12(1):5–8 (29 ref.)

Post–transplantation polyomavirus infections. Boubenider S, et al. **J Nephrol** 1999 Jan–Feb;12(1):24–9 (44 ref.)

Role of circulating lipid abnormalities in chronic renal allograft rejection. Kasiske BL. **Kidney Int Suppl** 1999 Jul; 71:S28–30 (19 ref.)

Erythropoietin and renal transplantation. Muirhead N. **Kidney Int Suppl** 1999 Mar;69:S86–92 (57 ref.)

Post transplant CD8+ gammadelta T–cell lymphoma associated with human herpes virus–6 infection. Lin WC, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):377–84 (40 ref.)

Recurrent IgA nephropathy after kidney transplantation: not a benign condition [editorial] Floege J, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1933–5 (14 ref.)

Concomitant parvovirus B19 and cytomegalovirus infections after living–related renal transplantation. Keung YK, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):469–71 (26 ref.)

Prophylaxis of cytomegalovirus infection in renal transplantation [editorial] Kuypers DR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3012–6 (12 ref.)

Can we improve the results and increase the number of renal transplants? Ponticelli C. **Nephrol Dial Transplant** 1999;14 Suppl 3:10–4 (39 ref.)

Laparoscopic live donor nephrectomy: the four year Johns Hopkins University experience. Ratner LE, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2090–3 (10 ref.)

Pre–emptive kidney transplantation [editorial] Vanrenterghem Y, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2466–8 (8 ref.)

Pediatric renal transplantation: indications and special considerations. A position paper from the Pediatric Committee of the American Society of Transplant Physicians. Davis ID, et al. **Pediatr Transplant** 1998 May; 2(2):117–29 (99 ref.)

Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF. **Pediatr Transplant** 1998 Feb;2(1):35–9 (24 ref.)

The potential role of rapamycin in pediatric transplantation as observed from adult studies. Kahan BD. **Pediatr Transplant** 1999 Aug;3(3):175–80 (32 ref.)

Recommended immunization practices for pediatric renal transplant recipients. Neu AM, et al. **Pediatr Transplant** 1998 Nov;2(4):263–9 (44 ref.)

Factors affecting growth and strategies for treatment in children after renal transplantation. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):176–82 (37 ref.)

Impact of pretransplantation dialysis modality on patient outcome after renal transplantation: the role of peritoneal dialysis revisited [editorial] Van Biesen, et al. **Perit Dial Int** 1999 Mar–Apr;19(2):103–6 (33 ref.)

Renal transplantation for end–stage renal disease caused by systemic lupus erythematosus nephritis. Clark WF, et al. **Semin Nephrol** 1999 Jan;19(1):77–85 (109 ref.)

Kidney preservation in the next millenium. Stubenitsky BM, et al. **Transpl Int** 1999;12(2):83–91 (108 ref.)

Living nonrelated kidney transplantation: time to be taken seriously. Daar AS. **Transplant Proc** 1999 Jun;31(4):1769–71 (18 ref.)

Lymphoproliferative disease in children. Harmon WE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1268–9 (22 ref.)

Hepatitis C virus infection and renal transplantation. Morales JM. **Transplant Proc** 1999 Sep;31(6):2221–4 (32 ref.)

The US multicenter double–blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design. Schroeder TJ, et al. **Transplant Proc** 1999 May;31(3B Suppl):1S–6S (42 ref.)

Patterns of malignancies following renal transplantation. Sheil AG. **Transplant Proc** 1999 Feb–Mar;31(1–2):1263–5 (30 ref.)

Effect of anti–lymphocyte antibody induction therapy on renal allograft survival. Szczech LA, et al. **Transplant Proc** 1999 May;31(3B Suppl):9S–11S (14 ref.)

Viral hepatitis in renal transplantation. Vathsala A. **Transplant Proc** 1999 Feb–Mar;31(1–2):337–9 (22 ref.)

Consensus conference on standardized listing criteria for renal transplant candidates. **Transplantation** 1998 Oct 15; 66(7):962–7 (0 ref.)

Simultaneous pancreas–kidney transplantation: an overview of indications, complications, and outcomes. Freise CE, et al. **West J Med** 1999 Jan;170(1):11–8 (36 ref.)

[Post–transplantation lymphomas and Epstein–Barr virus] Caillard S, et al. **Nephrologie** 1998;19(8):481–8 (100 ref.) (Eng. Abstr.) **(Fre)**

[Kidney transplantation and travel in the tropics] Receveur MC, et al. **Nephrologie** 1999;20(3):145–51 (32 ref.) (Eng. Abstr.) **(Fre)**

[Renal transplantation: success and uncertainties] Legendre C. **Pathol Biol (Paris)** 1998 Nov;46(9):667–8 (11 ref.) **(Fre)**

[Organ procurement from cardiac arrest donors: outcome of kidney grafts and recommendations] Benoit G, et al. **Presse Med** 1999 Jan 9;28(1):3–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Long–term stability of bone mineral density in patients with renal transplant treated with cyclosporine and low doses of corticoids. Protective role of cyclosporine?] Ezaitouni F, et al. **Presse Med** 1998 Apr 18;27(15):705–12 (41 ref.) (Eng. Abstr.) **(Fre)**

[Use of mycophenolate mofetil (MMF) in kidney transplantation: results of a single center trial] Pastural M, et al. **Prog Urol** 1999 Feb;9(1):19–25 (13 ref.) (Eng. Abstr.) **(Fre)**

[Radiodiagnosis following kidney transplantation] Schenk JP, et al. **Radiologe** 1999 May;39(5):404–14 (47 ref.) (Eng. Abstr.) **(Ger)**

[Human xenogenic kidney transplantation from the clinical viewpoint] Storck M, et al. **Zentralbl Chir** 1999; 124(7):616–20 (20 ref.) (Eng. Abstr.) **(Ger)**

[Causes and risks of hyperlipidemia during dialysis and after renal transplantation] Verzola A, et al. **Recenti Prog Med** 1998 Nov;89(11):590–7 (51 ref.) (Eng. Abstr.) **(Ita)**

[Kidney transplantation for therapy of late–stage kidney failure] Sakai K, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1335–40 (5 ref.) **(Jpn)**

[Myelodysplastic syndrome (RAEB in T) developed in a renal allograft recipient] Shiraishi J, et al. **Rinsho Ketsueki** 1998 Aug;39(8):600–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Platinum–based chemotherapy in renal transplant recipients with malignancies: a case report and review of literature] Wójcik J, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):145–6 (19 ref.) (Eng. Abstr.) **(Pol)**

[Pneumatosis intestinalis: an accidental finding in a patient after kidney transplantation (letter)] López A, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):318–9 (7 ref.) **(Spa)**

ADVERSE EFFECTS

Epidemiology of cancer in patients with renal transplants. Davison AM. **Adv Nephrol Necker Hosp** 1998;28:171–94 (100 ref.)

Tacrolimus in kidney transplantation. Kliem V, et al. **Contrib Nephrol** 1998;124:103–16; discussion 116–25 (73 ref.)

Bacterial infections after renal transplantation. Schmaldienst S, et al. **Contrib Nephrol** 1998;124:18–33; discussion 34–42 (101 ref.)

The use of mycophenolate mofetil (Cellcept) in renal transplantation. Vanrenterghem Y. **Contrib Nephrol** 1998; 124:64–9; discussion 69–75 (31 ref.)

Hypertension in the transplanted patient. Zeier M, et al. **Contrib Nephrol** 1998;124:146–57; discussion 158–65 (86 ref.)

The fate of bone after renal transplantation. Dissanayake IR, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):389–95 (83 ref.)

Chronic allograft nephropathy: the inevitable outcome of renal transplantation? Dodd SM. **Curr Top Pathol** 1999; 92:37–60 (149 ref.)

Lymphoproliferative disorders after renal transplantation: role of medical imaging. Claudon M, et al. **Eur Radiol** 1998; 8(9):1686–93 (38 ref.)

Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. Jassal SV, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1697–708 (87 ref.)

Viral hepatitis and kidney transplantation. Lai MK. **J Formos Med Assoc** 1998 Dec;97(12):801–11 (147 ref.)

Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process?

KIDNEY TRANSPLANTATION

Lu CY, et al. **Kidney Int** 1999 Jun;55(6):2157–68 (153 ref.)
Chronic allograft nephropathy: An update. Paul LC. **Kidney Int** 1999 Sep;56(3):783–93 (142 ref.)
Kaposi's sarcoma after renal transplantation [see comments] Francès C. **Nephrol Dial Transplant** 1998 Nov; 13(11):2768–73 (35 ref.) Comment in: Nephrol Dial Transplant 1999 May;14(5):1342–3. Comment in: Nephrol Dial Transplant 1999 May;14(5):1343.
Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation—is tacrolimus the answer? [editorial] Grupp C, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1629–31 (28 ref.)
Ischaemic heart disease after renal transplantation: how to assess and minimize the risk [editorial] Wheeler DC. **Nephrol Dial Transplant** 1999 May;14(5):1075–7 (10 ref.)
Posttransplant recurrent FSGS: molecular insights and future directions. Schachter AD, et al. **Nephron** 1999;82(4):300–5 (42 ref.)
Hypertension in the transplanted patient. Zeier M, et al. **Nephron** 1998 Nov;80(3):257–68 (86 ref.)
Early acute rejection and kidney allograft outcome in children [editorial; comment] Chavers B. **Pediatr Transplant** 1998 Nov;2(4):254–6 (13 ref.) Comment on: Pediatr Transplant 1998 Nov;2(4):294–8.
Mycophenolate mofetil—is it worth the cost? The in-favor opinion [see comments] Seikaly MG. **Pediatr Transplant** 1999 Feb;3(1):79–82 (19 ref.) Comment in: Pediatr Transplant 1999 Feb;3(1):5–9.
Risk issues in renal transplantation: cardiac aspects. Parfrey PS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):291–3 (20 ref.)
[Hepatitis C following kidney transplantation] Rostaing L, et al. **Presse Med** 1998 Apr 11;27(14):684–8 (55 ref.) (Eng. Abstr.) **(Fre)**
[Renal transplantation and urinary infection. Review] Burgos Revilla FJ, et al. **Actas Urol Esp** 1999 Feb;23(2):95–104 (47 ref.) (Eng. Abstr.) **(Spa)**
[Urologic neoplasms in patients with renal transplantation. Experience and review of the literature] Hermida Gutiérrez JF, et al. **Actas Urol Esp** 1998 Nov–Dec;22(10):818–27 (75 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Pharmacoeconomics of immunosuppressive agents in renal transplant recipients. Bennett WM, et al. **Transplant Proc** 1999 May;31(3A Suppl):6S (0 ref.)
The economics of immunosuppression in renal transplantation: a review of recent literature. Hutton J. **Transplant Proc** 1999 Feb–Mar;31(1–2):1328–32 (25 ref.)
[The cost of dialysis and kidney transplantation in the economically developed countries] Denisov VK. **Klin Khir** 1998;(9–10):74–6 (11 ref.) **(Rus)**

IMMUNOLOGY

The promise of xenografting. Hanaway MJ, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):299–308 (55 ref.)
Graft rejection in sensitized recipients. Kupiec-Węgliński JW. **Ann Transplant** 1996;1(1):34–40 (61 ref.)
Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Nicholls AJ. **Clin Biochem** 1998 Jul;31(5):329–33 (10 ref.)
Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN. **Clin Biochem** 1998 Jul;31(5):335–40 (69 ref.)
Current trends in transplant immunology. Hancock WW. **Curr Opin Nephrol Hypertens** 1999 May;8(3):317–24 (74 ref.)
Post-transplant acute myeloid leukemia (PT-AML). Thalhammer-Scherrer R, et al. **Leukemia** 1999 Mar; 13(3):321–6 (40 ref.)
Mycophenolate-update after it has come of age [editorial] Grinyó JM. **Nephrol Dial Transplant** 1999 Jan;14(1):31–4 (14 ref.)
The Th1–Th2 paradigm in 1998: law of nature or rule with exceptions [editorial] Kunzendorf U, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2445–8 (28 ref.)
Mycophenolate mofetil—is it worth the cost? The in-favor opinion [see comments] Seikaly MG. **Pediatr Transplant** 1999 Feb;3(1):79–82 (19 ref.) Comment in: Pediatr Transplant 1999 Feb;3(1):5–9.
Tacrolimus in pediatric renal transplantation: a review. Shapiro R. **Pediatr Transplant** 1998 Nov;2(4):270–6 (50 ref.)
The current status of mycophenolate mofetil in pediatric renal transplantation [editorial; comment] Tönshoff B. **Pediatr Transplant** 1999 Feb;3(1):5–9 (29 ref.) Comment on: Pediatr Transplant 1999 Feb;3(1):33–7. Comment on: Pediatr Transplant 1999 Feb;3(1):79–82.
Immunosuppressive therapy. Jain A, et al. **Surg Clin North Am** 1999 Feb;79(1):59–76 (160 ref.)
Management of nephrotoxic drugs. Alsina J. **Transplant Proc** 1999 Feb–Mar;31(1–2):1117–9 (36 ref.)
Immunologically high-risk recipient strategies. First MR. **Transplant Proc** 1999 Feb–Mar;31(1–2):243–6 (26 ref.)
The economics of immunosuppression in renal transplantation: a review of recent literature. Hutton J. **Transplant Proc** 1999 Feb–Mar;31(1–2):1328–32 (25 ref.)
Contemporary immunosuppression in renal transplant recipients: one size does not fit all. Lewis RM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):254–5 (21 ref.)
T-cell growth factors in allograft rejection and tolerance. Li XC, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):342–3 (19 ref.)
Optimal long-term immunotherapy protocols. Mathew TH. **Transplant Proc** 1999 Feb–Mar;31(1–2):1102–3 (5 ref.)
Use of steroids in renal transplantation. Ponticelli C, et al. **Transplant Proc** 1999 Sep;31(6):2210–1 (18 ref.)
Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):763–8 (44 ref.)
Ischemia reperfusion injury and chronic allograft rejection. Szabo A, et al. **Transplant Proc** 1998 Dec;30(8):4281–4 (59 ref.)
Incidence and cost of steroid side effects after renal transplantation. Veenstra DL, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):301–2 (10 ref.)
[Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants] van Gelder T, et al. **Ned Tijdschr Geneeskd** 1998 Jul 4;142(27):1550–4 (19 ref.) (Eng. Abstr.) **(Dut)**
[Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?] Haymann JP, et al. **Nephrologie** 1999; 20(3):139–43 (28 ref.) (Eng. Abstr.) **(Fre)**
[Cytomegalovirus infection, a risk factor for acute graft rejection in renal transplant recipients. A case-controlled study] Bouedjoro-Camus MC, et al. **Presse Med** 1999 Mar 27;28(12):619–24 (30 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Renal transplantation in adults. Breza J, et al. **BJU Int** 1999 Jul;84(2):216–23 (45 ref.)
Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness [editorial] Marangella M. **Nephrol Dial Transplant** 1999 Feb; 14(2):301–3 (13 ref.)

NURSING

Renal transplantation. Wallace MA. **AORN J** 1998 Dec; 68(6):964–6, 969–72 passim; quiz 995–1002 (43 ref.)

PATHOLOGY

Contrast-enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. Bagga H, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1509–11 (7 ref.)
Acute nonoliguric renal failure after renal transplantation. de Fijter JW, et al. **Am J Kidney Dis** 1999 Jan;33(1):166–9 (13 ref.)
Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Monaco AP, et al. **Am J Kidney Dis** 1999 Jan; 33(1):150–60 (47 ref.)
Allograft coronary disease: the role of antigen independent mechanisms in pathogenesis. Miller LW. **Ann Transplant** 1997;2(2):61–4 (53 ref.)
Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Cosyns JP, et al. **Clin Nephrol** 1998 Sep;50(3):144–53 (36 ref.)

PHYSIOLOGY

Regular exercise: vitally important for the transplant recipient. O'Moore B. **Adv Ren Replace Ther** 1999 Apr; 6(2):187–8 (0 ref.)
Function of endocrine organs in kidney transplant patients. Kokot F, et al. **Ann Transplant** 1996;1(1):23–8 (99 ref.)
Renographic indices for evaluation of changes in graft function. El-Maghraby TA, et al. **Eur J Nucl Med** 1998 Nov;25(11):1575–86 (79 ref.)
Diagnostic imaging modalities for delayed renal graft function: a review. el-Maghraby TA, et al. **Nucl Med Commun** 1998 Oct;19(10):915–36 (156 ref.)
Immunologic and nonimmunologic risk factors of chronic rejection. Fellström B, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1304–5 (20 ref.)
Postischemic reperfusion injury and allograft dysfunction: is allograft rejection the result of a fateful confusion by the immune system of danger and benefit? Land W. **Transplant Proc** 1999 Feb–Mar;31(1–2):332–6 (20 ref.)
What is a reasonably short cold ischemia time in kidney transplantation? Offermann G. **Transplant Proc** 1998 Dec; 30(8):4291–3 (8 ref.)
Surrogate end points in chronic kidney graft rejection studies. Paul LC, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1293–4 (17 ref.)
[Can man live with a pig kidney?] Valentin JF, et al. **Nephrologie** 1999;20(4):189–92 (33 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Non-compliance following renal transplantation in children and adolescents. Wolff G, et al. **Pediatr Nephrol** 1998 Nov; 12(9):703–8 (32 ref.)

RADIONUCLIDE IMAGING

Renographic indices for evaluation of changes in graft function. El-Maghraby TA, et al. **Eur J Nucl Med** 1998 Nov;25(11):1575–86 (79 ref.)
Quantitative scintigraphic parameters for the assessment of renal transplant patients. el Maghraby TA, et al. **Eur J Radiol** 1998 Oct;28(3):256–69 (74 ref.)
Report of the Radionuclides in Nephrourology Committee for evaluation of transplanted kidney (review of techniques). Dubovsky EV, et al. **Semin Nucl Med** 1999 Apr;29(2):175–88 (43 ref.)

STANDARDS

Can we improve the results and increase the number of renal transplants? Ponticelli C. **Nephrol Dial Transplant** 1999;14 Suppl 3:10–4 (39 ref.)

TRENDS

Distinguished Scientists Lecture Series. New developments in kidney development. Hammerman MR. **Nephron** 1999 Feb;81(2):131–5 (17 ref.)

UTILIZATION

Dialysis therapy in the region of central and eastern Europe. Rutkowski B. **Przegl Lek** 1998;55 Suppl 1:32–4 (11 ref.) **(Eng, Pol)**

KIDNEY TUBULAR NECROSIS, ACUTE

CHEMICALLY INDUCED

Cisplatin and hypomagnesemia. Lajer H, et al. **Cancer Treat Rev** 1999 Feb;25(1):47–58 (74 ref.)

DRUG THERAPY

Update on clinical trials with atrial natriuretic peptide in acute tubular necrosis. Allgren RL. **Ren Fail** 1998 Sep; 20(5):691–5 (2 ref.)

ETIOLOGY

Vasomotor nephropathy in the elderly. Andreucci VE, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:17–24 (63 ref.)

PATHOLOGY

Pathogenetic and regenerative mechanisms in acute tubular necrosis. Bonventre JV. **Kidney Blood Press Res** 1998; 21(2–4):226–9 (22 ref.)

KIDNEY TUBULAR TRANSPORT, INBORN ERRORS see **RENAL TUBULAR TRANSPORT, INBORN ERRORS**

KIDNEY TUBULES

DRUG EFFECTS

Lithium and the kidney: an updated review. Gitlin M. **Drug Saf** 1999 Mar;20(3):231–43 (77 ref.)
[Effect of angiotensin ii on Na+/H+ exchangers of the renal tubule] Poggioli J, et al. **Nephrologie** 1998;19(7):421–5 (56 ref.) (Eng. Abstr.) **(Fre)**
[Vasopressin: cellular and molecular aspects of its antidiuretic effect] Ivanova LN. **Vestn Ross Akad Med Nauk** 1999; (3):40–5 (74 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

[Enzymuria and urinary tract infection] Kiliś-Pstrusińska K, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):194–6 (39 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Role of tubule epithelial cells in the pathogenesis of tubulointerstitial fibrosis induced by glomerular disease [editorial] Healy E, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):525–30 (57 ref.)
Regulation of phosphate transport in the renal tubule through parathyroid hormone receptor: unexpected pathways. Silve C, et al. **Exp Nephrol** 1998 Jul–Aug;6(4):282–7 (16 ref.)
Genetic disorders of renal electrolyte transport. Scheinman SJ, et al. **N Engl J Med** 1999 Apr 15;340(15):1177–87 (66 ref.)
Mechanisms of tubular sodium chloride transport. Venkatesh S, et al. **Ren Fail** 1998 Nov;20(6):783–99 (128 ref.)
[Effect of angiotensin ii on Na+/H+ exchangers of the renal tubule] Poggioli J, et al. **Nephrologie** 1998;19(7):421–5 (56 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Neutral phosphate-induced renal tubular metabolic alkalosis. Abdullah S, et al. **Burns** 1999 Jun;25(4):364–5 (6 ref.)
Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Zhou XJ, et al. **Diagn Mol Pathol** 1998 Apr;7(2):65–8 (20 ref.)
Proteinuria as a mediator of tubulointerstitial injury. Abbate M, et al. **Kidney Blood Press Res** 1999;22(1–2):37–46 (101 ref.)
Tubulotoxic mechanisms of ochratoxin A. Gekle M, et al. **Kidney Blood Press Res** 1998;21(2–4):277–9 (33 ref.)
How does podocyte damage result in tubular damage? Kriz W, et al. **Kidney Blood Press Res** 1999;22(1–2):26–36 (33

ref.)
Chronic interstitial damage in proteinuria. Does complement mediate tubulointerstitial injury? Sheerin NS, et al. **Kidney Blood Press Res** 1999;22(1-2):47-52 (57 ref.)
Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Strutz F, et al. **Kidney Blood Press Res** 1999;22(1-2):71-80 (91 ref.)
Vasoactive factors and tubulointerstitial injury. Wolf G. **Kidney Blood Press Res** 1999;22(1-2):62-70 (89 ref.)
Mechanisms of interstitial fibrosis in obstructive nephropathy. Diamond JR, et al. **Semin Nephrol** 1998 Nov;18(6):594-602 (71 ref.)
The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Klahr S, et al. **Semin Nephrol** 1998 Nov;18(6):622-32 (89 ref.)
Transcription factor NF-kappaB regulation of renal fibrosis during ureteral obstruction. Morrissey J, et al. **Semin Nephrol** 1998 Nov;18(6):603-11 (79 ref.)
Cell apoptosis and proliferation in obstructive uropathy. Truong LD, et al. **Semin Nephrol** 1998 Nov;18(6):641-51 (66 ref.)
Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney. Levin S, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):38-43 (0 ref.)
[Pathology of tubulo-interstitial nephropathies] Taguchi T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1402-9 (5 ref.) **(Jpn)**
[Tubulo-interstitial lesions in glomerular diseases] Uchida S. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1423-7 (8 ref.) **(Jpn)**

PHYSIOLOGY

Transgenic models in renal tubular physiology. Jaisser F, et al. **Exp Nephrol** 1998 Sep-Oct;6(5):438-46 (51 ref.)
Combined in vivo and in vitro approaches to analysis of renal tubule function. Malnic G. **Exp Nephrol** 1998 Sep-Oct; 6(5):454-61 (72 ref.)
Tubule function in transgenic mice. Wang T, et al. **Exp Nephrol** 1998 Sep-Oct;6(5):447-53 (57 ref.)
Cystic diseases of the kidney: role of adhesion molecules in normal and abnormal tubulogenesis. Wilson PD, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):114-24 (107 ref.)
Tubuloglomerular feedback: its physiological and pathophysiological significance. Kurokawa K. **Kidney Int Suppl** 1998 Sep;67:S71-4 (21 ref.)
Tubuloglomerular feedback: new concepts and developments. Schnermann J, et al. **Kidney Int Suppl** 1998 Sep;67:S40-5 (31 ref.)
Luminal signal in tubuloglomerular feedback: what about potassium? Vallon V, et al. **Kidney Int Suppl** 1998 Sep; 67:S177-9 (11 ref.)
Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis. Zitnay C, et al. **Miner Electrolyte Metab** 1998;24(6):362-70 (93 ref.)
Nitric oxide and tubuloglomerular feedback. Welch WJ, et al. **Semin Nephrol** 1999 May;19(3):251-62 (79 ref.)
[Regulation of intracellular cAMP content in kidney tubules: role of adenylyl cyclases inhibitable by calcium] Chabardès D, et al. **Nephrologie** 1999;20(4):193-201 (56 ref.) (Eng. Abstr.) **(Fre)**
[Structures and functions of the renal tubules and interstitium] Inokuchi S, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1388-95 (6 ref.) **(Jpn)**
[The mechanisms of Na+, K(+)-ATPase in renal tubular epithelium] Beltowski J. **Postepy Biochem** 1998; 44(4):282-91 (159 ref.) **(Pol)**

PHYSIOPATHOLOGY

Role of tubular cells in progressive renal disease. van Kooten C, et al. **Kidney Blood Press Res** 1999;22(1-2):53-61 (76 ref.)
Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy [editorial] Wang SN, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2072-4 (12 ref.)
[Renal tubular dysfunctions and clinical symptoms of tubulo-interstitial nephropathies] Kato T. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1410-6 (1 ref.) **(Jpn)**

SECRETION

Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis. Woodland C, et al. **Med Hypotheses** 1998 Dec;51(6):489-91 (25 ref.)

ULTRASTRUCTURE

[Structures and functions of the renal tubules and interstitium] Inokuchi S, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1388-95 (6 ref.) **(Jpn)**

KIDNEY TUBULES, COLLECTING

ABNORMALITIES

Complete uterine septum with cervical duplication, longitudinal vaginal septum and duplication of a renal collecting system. A case report. Sharara FI. **J Reprod Med** 1998 Dec;43(12):1055-9 (5 ref.)

CYTOLOGY

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34-49 (78 ref.)

EMBRYOLOGY

Collecting duct morphogenesis. Davies JA, et al. **Pediatr Nephrol** 1999 Aug;13(6):535-41 (50 ref.)

GROWTH & DEVELOPMENT

Collecting duct morphogenesis. Davies JA, et al. **Pediatr Nephrol** 1999 Aug;13(6):535-41 (50 ref.)

METABOLISM

From vasopressin receptor to water channel: intracellular traffic, constraint and by-pass. Laycock JF, et al. **J Endocrinol** 1998 Dec;159(3):361-72 (77 ref.)

PHYSIOLOGY

Regulation of thick ascending limb transport by vasopressin. Knepper MA, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):628-34 (75 ref.)
Regulation of renal urea transporters. Sands JM. **J Am Soc Nephrol** 1999 Mar;10(3):635-46 (137 ref.)

PHYSIOPATHOLOGY

Nephrogenic diabetes insipidus. Knoers NV, et al. **Semin Nephrol** 1999 Jul;19(4):344-52 (62 ref.)

KIDNEY TUBULES, DISTAL

DRUG EFFECTS

Aquaporin-2 as a biomarker of distal renal tubular function using lithium as an experimental model. Sisson D, et al. **Ren Fail** 1999 May-Jul;21(3-4):331-6 (35 ref.)

ENZYMOLOGY

Role of macula densa NOS in tubuloglomerular feedback. Wilcox CS. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):443-9 (58 ref.)

METABOLISM

Cell localization and ontogeny of sodium transport pathways in the distal nephron: perspectives in function and failure. Bachmann S. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):31-8 (90 ref.)
Concentrations and actions of intraluminal angiotensin II. Navar LG, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S189-95 (55 ref.)

KIDNEY TUBULES, PROXIMAL

DRUG EFFECTS

Effect of lipid-lowering strategies on tubular cell biology. Vrtovsnik F, et al. **Kidney Int Suppl** 1999 Jul;71:S92-6 (27 ref.)

GROWTH & DEVELOPMENT

The proximal tubule phenotype and its disruption in acute renal failure and polycystic kidney disease. Witzgall R. **Exp Nephrol** 1999 Jan-Feb;7(1):15-9 (36 ref.)

IMMUNOLOGY

Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane. Tokumoto M, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2210-5 (28 ref.)

METABOLISM

Renal transport of organic anions. Roch-Ramel F. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):517-24 (71 ref.)
Concentrations and actions of intraluminal angiotensin II. Navar LG, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S189-95 (55 ref.)

PHYSIOLOGY

Renal dopamine receptor signaling mechanisms in spontaneously hypertensive and Fischer 344 old rats. Hussain T, et al. **Clin Exp Hypertens** 1999 Jan-Feb; 21(1-2):25-36 (51 ref.)
Molecular interactions between albumin and proximal tubular cells. Brunskill NJ. **Exp Nephrol** 1998 Nov-Dec;6(6):491-5 (23 ref.)
Insights from mathematical modeling of renal tubular function. Weinstein AM. **Exp Nephrol** 1998 Sep-Oct; 6(5):462-8 (46 ref.)
Is angiotensin II a key regulator of proximal tubular function? Some answers and new questions. Yanagawa N. **Exp Nephrol** 1998 Jul-Aug;6(4):277-81 (26 ref.)
Resetting protects efficiency of tubuloglomerular feedback. Thomson SC, et al. **Kidney Int Suppl** 1998 Sep;67:S65-70 (17 ref.)

ULTRASTRUCTURE

Lipiduria as seen by transmission electron microscopy. Blackburn V, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2682-4 (7 ref.)

KIENBOECK'S DISEASE see **OSTEOCHONDRITIS**

KIKUCHI DISEASE see **HISTIOCYTIC NECROTIZING LYMPHADENITIS**

KILLED VACCINES see **VACCINES, INACTIVATED**

KILLER CELLS

DRUG EFFECTS

[Additive effect of marihuana and retrovirus in the anergy of natural killer cells in mice] Ongrádi J, et al. **Orv Hetil** 1999 Jan 10;140(2):81-4 (32 ref.) (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

Cell biology and possible therapeutic applications of anti-CD3-activated killer-T cells (review). Hoskin DW, et al. **Int J Mol Med** 1998 May;1(5):893-902 (117 ref.)

KILLER CELLS, LYMPHOKINE-ACTIVATED

see related
IMMUNOTHERAPY, ADOPTIVE
INTERLEUKIN-2

KILLER CELLS, NATURAL

Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Whiteside TL, et al. **Am J Med** 1998 Sep 28;105(3A):27S-34S (44 ref.)

CHEMISTRY

DAP12: a key accessory protein for relaying signals by natural killer cell receptors. Campbell KS, et al. **Int J Biochem Cell Biol** 1999 Jun;31(6):631-6 (17 ref.)

CYTOLOGY

Lineage commitment and differentiation of T and natural killer lymphocytes in the fetal mouse. Carlyle JR, et al. **Immunol Rev** 1998 Oct;165:63-74 (84 ref.)
T-cell and natural killer cell development in thymectomized Xenopus. Horton JD, et al. **Immunol Rev** 1998 Dec; 166:245-58 (90 ref.)
Early stages in the development of human T, natural killer and thymic dendritic cells. Spits H, et al. **Immunol Rev** 1998 Oct;165:75-86 (79 ref.)
Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Williams NS, et al. **Immunol Rev** 1998 Oct;165:47-61 (131 ref.)
Developmental stages in the human thymus. Res P, et al. **Semin Immunol** 1999 Feb;11(1):39-46 (62 ref.)

IMMUNOLOGY

Activating and inhibitory NK cell receptors. Lanier LL. **Adv Exp Med Biol** 1998;452:13-8 (57 ref.)
Regulation of immune responses by inhibitory receptors. Long EO. **Adv Exp Med Biol** 1998;452:19-28 (56 ref.)
Development of self-recognition systems in natural killer cells. Sivakumar PV, et al. **Adv Exp Med Biol** 1998;452:1-12 (64 ref.)
Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. Vitaliano PP, et al. **Ann Behav Med** 1998 Summer;20(3):199-208 (91 ref.)
Natural killer cells in antiviral defense: function and regulation by innate cytokines. Biron CA, et al. **Annu Rev Immunol** 1999;17:189-220 (253 ref.)
The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Waldmann TA, et al. **Annu Rev Immunol** 1999;17:19-49 (142 ref.)
Human natural killer cells. Barão I, et al. **Arch Immunol Ther Exp (Warsz)** 1998;46(4):213-29 (234 ref.)
Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu-Lee L, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1067-75 (103 ref.)
Natural killer cell activation and inhibition by receptors for MHC class I. López-Botet M, et al. **Curr Opin Immunol** 1999 Jun;11(3):301-7 (75 ref.)
Initial and innate responses to viral infections--pattern setting in immunity or disease. Biron CA. **Curr Opin Microbiol** 1999 Aug;2(4):374-81 (76 ref.)
Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Braud VM, et al. **Curr Top Microbiol Immunol** 1999;244:85-95 (30 ref.)
HLA-specific and non-HLA-specific human NK receptors. Moretta A, et al. **Curr Top Microbiol Immunol** 1999; 244:69-84 (84 ref.)
Inhibitory role of murine Ly49 lectin-like receptors on natural killer cells. Salcedo M. **Curr Top Microbiol Immunol** 1999;244:97-105 (45 ref.)
gp49: an Ig-like receptor with inhibitory properties on mast cells and natural killer cells. Wagtmann N. **Curr Top Microbiol Immunol** 1999;244:107-13 (40 ref.)

KILLER CELLS, NATURAL

The human natural killer lymphocyte receptors for MHC class I molecules. Bensussan A. **Eur Cytokine Netw** 1998 Dec;9(4):577–83 (73 ref.)
Natural killer cells in healthy aging. Solana R, et al. **Exp Gerontol** 1999 Jun;34(3):435–43 (47 ref.)
Human uterine lymphocytes. King A, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):480–5 (49 ref.)
Endometriosis and unexplained recurrent spontaneous abortion: pathological states resulting from aberrant modulation of natural killer cell function? Somigliana E, et al. **Hum Reprod Update** 1999 Jan–Feb;5(1):40–51 (12 ref.)
NK cells and apoptosis. Warren HS, et al. **Immunol Cell Biol** 1999 Feb;77(1):64–75 (167 ref.)
Natural killer and T cells of innate and adaptive immunity: lymphoid compartments with different requirements for common gamma chain–dependent cytokines. Di Santo JP, et al. **Immunol Rev** 1998 Oct;165:29–38 (85 ref.)
Cytomegalovirus evasion of natural killer cell responses. Farrell HE, et al. **Immunol Rev** 1999 Apr;168:187–97 (68 ref.)
HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. Posch PE, et al. **J Biomed Sci** 1998 Sep–Oct; 5(5):321–31 (102 ref.)
Target cell–induced apoptosis in IL-2–activated human natural killer cells. Taga K, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):451–8 (49 ref.)
Natural killer cell reactivity: activation and cytolysis mechanism models, involving heat shock protein, haemopoietic histocompatibility, major histocompatibility complex and complement molecules. Manzo G. **Med Hypotheses** 1998 Jul;51(1):5–9 (30 ref.)
Human neonatal natural killer cell cytotoxicity function. Kohl S. **Pediatr Infect Dis J** 1999 Jul;18(7):635–7 (43 ref.)
Natural killer cell–mediated recognition of human trophoblast. Biassoni R, et al. **Semin Cancer Biol** 1999 Feb; 9(1):13–8 (38 ref.)
How do NK cells sense the expression of HLA-G class Ib molecules? López-Botet M, et al. **Semin Cancer Biol** 1999 Feb;9(1):19–26 (70 ref.)
Costimulation of human natural killer cells is required for interferon gamma production. Fehniger TA, et al. **Transplant Proc** 1999 May;31(3):1476–8 (38 ref.)
[T-cell lymphomas and "natural killer". Histopathologic, immunologic and molecular aspects] Kanavaros P, et al. **Ann Pathol** 1998 Oct;18(4):299–314 (102 ref.) **(Fre)**
[Regulatory mechanisms of NK cell functions] Toyama-Sorimachi N, et al. **Nippon Rinsho** 1999 Feb; 57(2):304–9 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Natural killer cells and endogenous biological relay] Cheknev SB. **Biull Eksp Biol Med** 1998 Aug;126(8):124–35 (117 ref.) **(Rus)**
[Natural cytotoxicity in complex of cell interactions] Cheknev SB. **Vestn Ross Akad Med Nauk** 1999;(4):30–4 (52 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Intracellular signalling pathways induced by chemokines in natural killer cells. Maghazachi AA. **Cell Signal** 1999 Jun; 11(6):385–90 (63 ref.)
Cytokine-induced expression of killer inhibitory receptors in human T lymphocytes. Ponte M, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):69–72 (23 ref.)
Structure of a human natural killer cell inhibitory receptor. Fan QR, et al. **Transplant Proc** 1999 Jun;31(4):1871–2 (13 ref.)

PATHOLOGY

The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms. Kinney MC. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S104–18 (135 ref.)
Natural killer cell neoplasms. Chan JK. **Anat Pathol** 1998; 3:77–145 (256 ref.)
Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia [see comments] Suzuki R, et al. **Leuk Res** 1999 Jul;23(7):615–24 (50 ref.) Comment in: Leuk Res 1999 Jul;23(7):675–6.
Peripheral T-cell and NK-cell neoplasms: an integrated approach to diagnosis. Chan JK. **Mod Pathol** 1999 Feb; 12(2):177–99 (94 ref.)
[NK-cell lymphoma] Kaneko T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):309–14 (20 ref.) **(Jpn)**
[Natural killer cell leukemia] Kawa K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):142–4 (16 ref.) **(Jpn)**

PHYSIOLOGY

Natural killer cells and their role in graft rejection. Manilay JO, et al. **Curr Opin Immunol** 1998 Oct;10(5):532–8 (77 ref.)
Development and tolerance of natural killer cells. Raulet DH. **Curr Opin Immunol** 1999 Apr;11(2):129–34 (51 ref.)

KILLER PHENOTYPE see **PHENOTYPE**

KILLER WHALE see **DOLPHINS**

KIMURA DISEASE see **ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA**

KINASES see **PHOSPHOTRANSFERASES**

KINDLING (NEUROLOGY)

Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Weiss SR, et al. **Neuropsychobiology** 1998 Oct;38(3):167–80 (87 ref.)

PHYSIOLOGY

Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. Ghaemi SN, et al. **Biol Psychiatry** 1999 Jan 15;45(2):137–44 (50 ref.)
Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders: the role of serotonergic mechanisms in illness progression. Post RM, et al. **Biol Psychiatry** 1998 Aug 1;44(3):193–206 (125 ref.)
On some neurochemical aspects of kindling. Lasoń W. **Pol J Pharmacol** 1999 Jan–Feb;51(1):95–8 (51 ref.)

KINESICS

[Motor signs of depression] Lemke MR. **Nervenarzt** 1999 Jul; 70(7):600–12 (145 ref.) (Eng. Abstr.) **(Ger)**

KINESIN

BIOSYNTHESIS

Kinesin-like microtubule motors in early development. Chen MC, et al. **Methods Cell Biol** 1999;59:227–50 (45 ref.)

CHEMISTRY

Structures of kinesin and kinesin-microtubule interactions. Mandelkow E, et al. **Curr Opin Cell Biol** 1999 Feb; 11(1):34–44 (90 ref.)

METABOLISM

Universal and unique features of kinesin motors: insights from a comparison of fungal and animal conventional kinesins. Kirchner J, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):915–21 (50 ref.)
Motor proteins of the kinesin family. Structures, variations, and nucleotide binding sites. Sack S, et al. **Eur J Biochem** 1999 May;262(1):1–11 (52 ref.)

PHYSIOLOGY

Microtubule motors in spindle and chromosome motility. Endow SA. **Eur J Biochem** 1999 May;262(1):12–8 (94 ref.)
Motor and cargo interactions. Sheetz MP. **Eur J Biochem** 1999 May;262(1):19–25 (97 ref.)
Microtubule-dependent vesicle transport: modulation of channel and transporter activity in liver and kidney. Hamm-Alvarez SF, et al. **Physiol Rev** 1998 Oct; 78(4):1109–29 (167 ref.)
The structural and mechanochemical cycle of kinesin. Mandelkow E, et al. **Trends Biochem Sci** 1998 Nov; 23(11):429–33 (42 ref.)
[Protein motors: structure and generation of mechanical force] Zima VL. **Ukr Biokhim Zh** 1998 May–Jun; 70(3):23–38 (60 ref.) (Eng. Abstr.) **(Rus)**

KINESTHESIS

PHYSIOLOGY

Illusory self-motion and motion sickness: a model for brain-gut interactions and nausea. Koch KL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):53S–57S (25 ref.)

KINETICS, DRUG see **PHARMACOKINETICS**

KINETOCHORES

METABOLISM

In vitro assays for studying Saccharomyces cerevisiae kinetochore activity. Severin F, et al. **Methods Cell Biol** 1999;61:145–53 (13 ref.)
Methods for in situ localization of proteins and DNA in the centromere-kinetochore complex. Van Hooser A, et al. **Methods Cell Biol** 1999;61:57–80 (54 ref.)

PHYSIOLOGY

Kinetochores and the checkpoint mechanism that monitors for defects in the chromosome segregation machinery. Skibbens RV, et al. **Annu Rev Genet** 1998;32:307–37 (189 ref.)
"Dumb" versus "smart" kinetochore models for chromosome congression during mitosis in vertebrate somatic cells. Khodjakov A, et al. **Cell Motil Cytoskeleton** 1999; 43(3):179–85 (28 ref.)
The kinetochore of higher eucaryotes: a molecular view. Maney T, et al. **Int Rev Cytol** 2000;194:67–131 (261 ref.)
The vertebrate cell kinetochore and its roles during mitosis. Rieder CL, et al. **Trends Cell Biol** 1998 Aug;8(8):310–8 (65 ref.)

KINETOPLAST DNA see **DNA, KINETOPLAST**

KINETOPLAST DNA MAXICIRCLES see **DNA, KINETOPLAST**

KINETOPLAST DNA MINICIRCLES see **DNA, KINETOPLAST**

KININASE I see **LYSINE CARBOXYPEPTIDASE**

KININASE II see **PEPTIDYL-DIPEPTIDASE A**

KININASE II INHIBITORS see **ANGIOTENSIN-CONVERTING ENZYME INHIBITORS**

KININOGEN, HIGH-MOLECULAR-WEIGHT

DEFICIENCY

[High molecular weight kininogen deficiency] Ishimaru F, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):434–6 (13 ref.) **(Jpn)**

KININOGENASE see **KALLIKREIN**

KININOGENS

Croxatto's fifty-year pursuit: from pepsanurin to the discovery of a new kininogen-derived peptide (PU-D1). Boric MP, et al. **Biol Res** 1998;31(3):117–29 (95 ref.)

DEFICIENCY

[Secretion defect of kininogens and bulk flow] Hayashi I. **Seikagaku** 1998 Jul;70(7):553–7 (15 ref.) **(Jpn)**

GENETICS

The kininogen gene family in obstructive uropathy. El-Dahr SS. **Semin Nephrol** 1998 Nov;18(6):633–40 (75 ref.)

METABOLISM

Plasma contact activation: a revised hypothesis. Schmaier AH. **Biol Res** 1998;31(3):251–62 (55 ref.)

KININS

BLOOD

The plasma kallikrein–kinin system in sepsis, inflammatory arthritis, and enterocolitis. Colman RW, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):365–84 (44 ref.)

GENETICS

[Experimental genetic modifications in the renin–angiotensin and kallikrein–kinin systems: significance for understanding cardiovascular regulation and study of genetic determinism of human diseases] Meneton P, et al. **Nephrologie** 1998; 19(7):385–9 (20 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Autoradiographic and immunological techniques to analyse kinin receptor distribution in rat and human tissues. Figueroa CD, et al. **Biol Res** 1998;31(3):175–87 (51 ref.)
The kinin system in rhinitis and asthma. Proud D. **Clin Rev Allergy Immunol** 1998 Winter;16(4):351–64 (83 ref.)

PHYSIOLOGY

Kallikreins, kinins and cardiovascular diseases: a short review. Margolius HS. **Biol Res** 1998;31(3):135–41 (32 ref.)
Kinin receptors. Marceau F, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):385–401 (94 ref.)
Renin–angiotensin–aldosterone–kinin system influences on diabetic vascular disease and cardiomyopathy. Flack JM, et al. **Miner Electrolyte Metab** 1998;24(6):412–22 (106 ref.)
Nonpeptide antagonists for kinin receptors. Altamura M, et al. **Regul Pept** 1999 Mar 17;80(1–2):13–26 (94 ref.)

KINKY HAIR SYNDROME

Animal models of Menkes disease. Mercer JF, et al. **Adv Exp Med Biol** 1999;448:97–108 (40 ref.)
The cell biology of the Menkes disease protein. Petris MJ, et al. **Adv Exp Med Biol** 1999;448:53–66 (50 ref.)

DIAGNOSIS

Menkes disease: underlying genetic defect and new diagnostic possibilities. Tümer Z, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):604–12 (42 ref.)
Clinical manifestations and treatment of Menkes disease and its variants. Kodama H, et al. **Pediatr Int** 1999 Aug; 41(4):423–9 (50 ref.)

ENZYMOLOGY

Multiple forms of the Menkes Cu-ATPase. Harris ED, et al. **Adv Exp Med Biol** 1999;448:39–51 (28 ref.)
Mutation spectrum of ATP7A, the gene defective in Menkes disease. Tümer Z, et al. **Adv Exp Med Biol** 1999;448:83–95 (67 ref.)

GENETICS

Mutation spectrum of ATP7A, the gene defective in Menkes disease. Tümer Z, et al. **Adv Exp Med Biol** 1999;448:83–95 (67 ref.)
Menkes disease: underlying genetic defect and new diagnostic possibilities. Tümer Z, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):604–12 (42 ref.)
Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Kaler SG. **Pediatr Dev Pathol** 1998 Jan–Feb;1(1):85–98 (168 ref.)

METABOLISM

Genetic disorders of membrane transport. IV. Wilson's disease and Menkes disease. Schaefer M, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G311–4 (24 ref.)
Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. Menkes JH. **Europ J Paediatr Neurol** 1999;3(4):147–58 (112 ref.)
Molecular mechanisms of copper metabolism and the role of the Menkes disease protein. Harrison MD, et al. **J Biochem Mol Toxicol** 1999;13(2):93–106 (110 ref.)
Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Kaler SG. **Pediatr Dev Pathol** 1998 Jan–Feb;1(1):85–98 (168 ref.)
Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Suzuki M, et al. **Pediatr Int** 1999 Aug;41(4):436–42 (26 ref.)

PHYSIOPATHOLOGY

Molecular genetics and pathophysiology of Menkes disease. Kodama H, et al. **Pediatr Int** 1999 Aug;41(4):430–5 (47 ref.)

KIRSCHNER WIRES see **BONE WIRES**

KIT PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-KIT**

KIWIS see **RATITES**

KLATSKIN'S TUMOR

DIAGNOSIS

[Diagnosis of hilar bile duct carcinoma (Klatskin tumor)] Lammert F, et al. **Dtsch Med Wochenschr** 1998 Sep 25; 123(39):1145–8 (16 ref.) **(Ger)**
[An update in the diagnosis and treatment of tumors of the hepatic portal] Vadalà G, et al. **Minerva Chir** 1998 Sep; 53(9):701–7 (17 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Klatskin tumor. A study of 15 resected cases] Santoro E, et al. **Chirurgie** 1999 Apr;124(2):132–9; discussion 139–40 (28 ref.) (Eng. Abstr.) **(Fre)**
[An update in the diagnosis and treatment of tumors of the hepatic portal] Vadalà G, et al. **Minerva Chir** 1998 Sep; 53(9):701–7 (17 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

[Therapeutic strategies in hilar bile duct carcinoma (Klatskin's tumor)] Lammert F, et al. **Dtsch Med Wochenschr** 1998 Oct 2;123(40):1179–82 (17 ref.) **(Ger)**

KLEBSIELLA AEROGENES see **KLEBSIELLA PNEUMONIAE**

KLEBSIELLA INFECTIONS

Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Podschun R, et al. **Clin Microbiol Rev** 1998 Oct; 11(4):589–603 (261 ref.)
[Klebsiella sepsis] Koga H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):262–5 (11 ref.) **(Jpn)**
[Klebsiella pneumoniae pneumonia] Sugiyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):366–8 (11 ref.) **(Jpn)**

DRUG THERAPY

Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Segal-Maurer S, et al. **Clin Infect Dis** 1999 May; 28(5):1134–8 (36 ref.)

KLEBSIELLA PNEUMONIAE

[Klebsiella sepsis] Koga H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):262–5 (11 ref.) **(Jpn)**
[Klebsiella pneumoniae pneumonia] Sugiyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):366–8 (11 ref.) **(Jpn)**

KLEIN-WAARDENBURG SYNDROME see **WAARDENBURG'S SYNDROME**

KLEPTOMANIA see **IMPULSE CONTROL DISORDERS**

KLINEFELTER'S SYNDROME

COMPLICATIONS

Seizures in Klinefelter's syndrome. Tatum WO 4th, et al. **Pediatr Neurol** 1998 Oct;19(4):275–8 (29 ref.)
[Syngeneic peripheral blood stem cell transplantation for chronic myelogenous leukemia associated with Klinefelter's syndrome] Fujii H, et al. **Rinsho Ketsueki** 1999 Mar; 40(3):218–23 (15 ref.) (Eng. Abstr.) **(Jpn)**

KLIPPEL-FEIL SYNDROME

COMPLICATIONS

[Progressive paraparesis due to cervical spondyloptosis in a child with the Klippel-Feil syndrome] Martinez Campos M, et al. **An Esp Pediatr** 1998 Sep;49(3):302–4 (11 ref.) **(Spa)**

DIAGNOSIS

[Wildervanck or cervico-oculo-acoustic syndrome] Wang Y, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Nov; 11(11):499–501 (7 ref.) (Eng. Abstr.) **(Chi)**

KLIPPEL-TRENAUNAY DISEASE see **KLIPPEL-TRENAUNAY-WEBER SYNDROME**

KLIPPEL-TRENAUNAY-WEBER SYNDROME

PATHOLOGY

Klippel-Trenaunay syndrome. Berry SA, et al. **Am J Med Genet** 1998 Oct 2;79(4):319–26 (21 ref.)

THERAPY

Klippel-Trenaunay syndrome. Berry SA, et al. **Am J Med Genet** 1998 Oct 2;79(4):319–26 (21 ref.)

ULTRASONOGRAPHY

Klippel-Trenaunay syndrome. Berry SA, et al. **Am J Med Genet** 1998 Oct 2;79(4):319–26 (21 ref.)

KLORAMFENIKOL see **CHLORAMPHENICOL**

KLUYVEROMYCES

METABOLISM

Production of bioingredients from Kluyveromyces marxianus grown on whey: an alternative. Belem MA, et al. **Crit Rev Food Sci Nutr** 1998 Oct;38(7):565–98 (110 ref.)

KNEE

Modern prosthetic knee mechanisms. Michael JW. **Clin Orthop** 1999 Apr;(361):39–47 (32 ref.)
Physical and arthroscopic examination techniques of the patellofemoral joint. Nissen CW, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):277–85 (46 ref.)
Rehabilitation of patellofemoral joint disorders: a critical review. Powers CM. **J Orthop Sports Phys Ther** 1998 Nov; 28(5):345–54 (67 ref.)
Patellofemoral disorders: a classification system and clinical guidelines for nonoperative rehabilitation. Wilk KE, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):307–22 (139 ref.)

KNEE INJURIES

Knee pain in competitive swimming. Rodeo SA. **Clin Sports Med** 1999 Apr;18(2):379–87, viii (9 ref.)
Jumper's knee. Review of the literature. Fredberg U, et al. **Scand J Med Sci Sports** 1999 Apr;9(2):66–73 (98 ref.)
[Common overuse knee-to-toes injuries in recreational exercise. Most cases are treatable in primary health care] Pålsson L, et al. **Lakartidningen** 1998 Sep 30; 95(40):4369–70, 4374–5 (13 ref.) (Eng. Abstr.) **(Swe)**

COMPLICATIONS

Are there long-term sequelae from soccer? Roos H. **Clin Sports Med** 1998 Oct;17(4):819–31, viii (88 ref.)
Delayed presentation of traumatic arterial vasospasm. Davis GM, et al. **Pediatr Emerg Care** 1999 Feb;15(1):22–4 (12 ref.)

DIAGNOSIS

Pathogenesis of anterior knee pain syndrome and functional patellofemoral instability in the active young. Sanchis-Alfonso V, et al. **Am J Knee Surg** 1999 Winter; 12(1):29–40 (43 ref.)
Musculoskeletal rehabilitation and sports medicine. 3. Knee and lower extremity injuries. Ellen MI, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S59–67 (100 ref.)
Sports injuries of the knee. Fadale PD, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):144–50 (35 ref.)
The posterior cruciate ligament injured knee: principles of evaluation and treatment. Miller MD, et al. **Instr Course Lect** 1999;48:199–207 (58 ref.)
Knee dislocations. Schenck RC Jr, et al. **Instr Course Lect** 1999;48:515–22 (26 ref.)
"Bone bruises" of the knee: a review. Mathis CE, et al. **Iowa Orthop J** 1998;18:112–7 (16 ref.)
MR imaging of knee anterior cruciate ligament and associated injuries in skiers. Ho CP, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):117–30 (29 ref.)
Recommendations for the diagnosis of traumatic meniscal injuries in athletes. Muellner T, et al. **Sports Med** 1999 May; 27(5):337–45 (61 ref.)

ETIOLOGY

Knee disorders and injuries in adolescents. Roach JW. **Adolesc Med** 1998 Oct;9(3):589–97, vii (32 ref.)
Periprosthetic fractures following total knee arthroplasty: the good, bad, & ugly. Dennis DA. **Orthopedics** 1998 Sep; 21(9):1048–50 (36 ref.)
[Current advances in sports-related cartilage research. Meniscus and ligament injuries are associated with increased risk of knee joint arthrosis] Messner K. **Lakartidningen** 1998 Oct 14;95(42):4611–2, 4615 (20 ref.) (Eng. Abstr.) **(Swe)**
[Increased risk of knee and hip arthrosis among elite athletes. Lower level exercise and sports seem to be "harmless"] Roos H. **Lakartidningen** 1998 Oct 14;95(42):4606–10 (56 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

Sports injuries of the knee. Fadale PD, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):144–50 (35 ref.)

REHABILITATION

Factors contributing to function of the knee joint after injury or reconstruction of the anterior cruciate ligament. Dye SF, et al. **Instr Course Lect** 1999;48:185–98 (81 ref.)
Rehabilitation following surgical procedures to address articular cartilage lesions in the knee. Irrgang JJ, et al. **J Orthop Sports Phys Ther** 1998 Oct;28(4):232–40 (46 ref.)
[Plea for accelerated rehabilitation after ligament plasty of the knee by a bone-patellar tendon-bone graft] Boileau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):475–90 (97 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Osteochondral mosaicplasty for the treatment of focal chondral and osteochondral lesions of the knee and talus in the athlete. Rationale, indications, techniques, and results. Kish G, et al. **Clin Sports Med** 1999 Jan;18(1):45–66, vi (53 ref.)
The role of cartilage repair techniques, including chondrocyte transplantation, in focal chondral knee damage. Minas T. **Instr Course Lect** 1999;48:629–43 (60 ref.)
Knee dislocations. Schenck RC Jr, et al. **Instr Course Lect** 1999;48:515–22 (26 ref.)
Use of allografts in knee reconstruction: II. Surgical considerations. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):169–75 (29 ref.)
Use of allografts in knee reconstruction: I. Basic science aspects and current status. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):165–8 (15 ref.)
Rehabilitation following surgical procedures to address articular cartilage lesions in the knee. Irrgang JJ, et al. **J Orthop Sports Phys Ther** 1998 Oct;28(4):232–40 (46 ref.)
Meniscus transplantation--consensus declaration [editorial] **Scand J Med Sci Sports** 1999 Jun;9(3):131–3 (0 ref.)
[Plea for accelerated rehabilitation after ligament plasty of the knee by a bone-patellar tendon-bone graft] Boileau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):475–90 (97 ref.) (Eng. Abstr.) **(Fre)**
[Injuries of the knee ligaments. II. Surgical therapy of anterior and posterior knee instability] Lobenhoffer P. **Chirurg** 1999 Mar;70(3):326–38 (0 ref.) **(Ger)**
[Knee ligament injuries. Anatomy, biomechanics, diagnosis, indications] Lobenhoffer P. **Chirurg** 1999 Feb;70(2):219–30 (14 ref.) **(Ger)**
[Treatment of cartilage defects] Meenen NM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:568–76 (21 ref.) (Eng. Abstr.) **(Ger)**
[Transfer of the posterior femoral condyle. First experience with a salvage operation] Imhoff AB, et al. **Orthopade** 1999 Jan;28(1):45–51 (45 ref.) (Eng. Abstr.) **(Ger)**
[To brace of not to brace? How effective are knee braces in rehabilitation?] Martinek V, et al. **Orthopade** 1999 Jun; 28(6):565–70 (66 ref.) (Eng. Abstr.) **(Ger)**
[Cartilage replacement operation using pre-cultured cells] Messner K. **Orthopade** 1999 Jan;28(1):61–7 (30 ref.) (Eng. Abstr.) **(Ger)**
[Treatment concept in complex fractures of the head of the tibia] Ballmer FT, et al. **Swiss Surg** 1998;(6):288–95 (33 ref.) (Eng. Abstr.) **(Ger)**
[Complex knee trauma--cartilage injuries] Jakob RP, et al. **Swiss Surg** 1998;(6):296–310 (30 ref.) (Eng. Abstr.) **(Ger)**
[Knee dislocation] Oswald AS, et al. **Swiss Surg** 1998; (6):279–87 (26 ref.) (Eng. Abstr.) **(Ger)**
[The semitendinosus tendon as replacement for the anterior cruciate ligament] Hoffmann F, et al. **Zentralbl Chir** 1998; 123(9):994–1001 (48 ref.) (Eng. Abstr.) **(Ger)**

KNEE INJURIES

[Augmentation techniques: are they out?] Kiefer H, et al. **Zentralbl Chir** 1998;123(9):1002–13 (86 ref.) (Eng. Abstr.) **(Ger)**

[Golden standard: patellar tendon-plasty--technique and management of postoperative complications] Lobenhoffer P. **Zentralbl Chir** 1998;123(9):981–93 (61 ref.) (Eng. Abstr.) **(Ger)**

[Combined anterior cruciate ligament and posterior cruciate ligament injury--technique and results of simultaneous arthroscopic reconstruction] Martinek V, et al. **Zentralbl Chir** 1998;123(9):1027–32 (21 ref.) (Eng. Abstr.) **(Ger)**

[Significance of combined anterior cruciate ligament and meniscus injury] Metak G, et al. **Zentralbl Chir** 1999; 124(7):646–52 (64 ref.) (Eng. Abstr.) **(Ger)**

[Revision surgery in failed anterior cruciate ligament-plasty] Oettl GM, et al. **Zentralbl Chir** 1998;123(9):1033–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Anterior cruciate ligament-plasty and high valgus tibial osteotomy as a combined procedure in anterior instability and varus deviation] Roscher E, et al. **Zentralbl Chir** 1998; 123(9):1019–26 (42 ref.) (Eng. Abstr.) **(Ger)**

[Management of the anterior cruciate ligament rupture: indications, choice of procedure, timing, concomitant and after-care] Wentzensen A, et al. **Zentralbl Chir** 1998; 123(9):970–80 (50 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The multiple ligament injured knee. Cole BJ, et al. **Clin Sports Med** 1999 Jan;18(1):241–62 (46 ref.)

The posterior cruciate ligament injured knee: principles of evaluation and treatment. Miller MD, et al. **Instr Course Lect** 1999;48:199–207 (58 ref.)

Psychobiology and the athlete with anterior cruciate ligament (ACL) injury. Doyle J, et al. **Sports Med** 1998 Dec; 26(6):379–93 (59 ref.)

ULTRASONOGRAPHY

Ultrasound in acute and chronic knee injury. Ptasznik R. **Radiol Clin North Am** 1999 Jul;37(4):797–830, x (49 ref.)

KNEE JOINT

Malignant tumors about the knee. Frink SJ, et al. **Am J Knee Surg** 1998 Fall;11(4):257–66 (33 ref.)

Osteochondritis dissecans of the knee. Williams JS Jr, et al. **Am J Knee Surg** 1998 Fall;11(4):221–32 (126 ref.)

Benign bone and soft-tissue tumors about the knee. Wurtz LD, et al. **Am J Knee Surg** 1998 Fall;11(4):246–56 (21 ref.)

Kinematic CT and MR imaging of the patellofemoral joint. Muhle C, et al. **Eur Radiol** 1999;9(3):508–18 (47 ref.)

Treatment of hip and knee problems in myelomeningocele. Greene WB. **Instr Course Lect** 1999;48:563–74 (49 ref.)

Nonoperative treatment for patellofemoral pain. Brody LT, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):336–44 (71 ref.)

Physical and arthroscopic examination techniques of the patellofemoral joint. Nissen CW, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):277–85 (46 ref.)

Rehabilitation of patellofemoral joint disorders: a critical review. Powers CM. **J Orthop Sports Phys Ther** 1998 Nov; 28(5):345–54 (67 ref.)

Patellofemoral disorders: a classification system and clinical guidelines for nonoperative rehabilitation. Wilk KE, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):307–22 (139 ref.)

Treatment of limited motion after anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Knee Surg Sports Traumatol Arthrosc** 1999;7(2):85–92 (35 ref.)

[Role of arthroscopy in knee joint osteonecrosis] Baillon M, et al. **Acta Orthop Belg** 1999;65 Suppl 1:127–8 (8 ref.) **(Fre)**

[Use of needle biopsy in femoral condyle osteonecrosis] Ficat C. **Acta Orthop Belg** 1999;65 Suppl 1:123–6 (18 ref.) **(Fre)**

[Development of arthrosis: methods of objective evaluation using medical imaging and arthroscopy. Application to medial femoro-tibial gonarthrosis] Ayral X, et al. **Presse Med** 1998 Oct 3;27(29):1491–8 (56 ref.) **(Fre)**

[Villonodular synovitis of the knee. Analysis of a series of 17 cases and review of the literature] Le Tiec T, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(7):607–16 (57 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Knee disorders and injuries in adolescents. Roach JW. **Adolesc Med** 1998 Oct;9(3):589–97, vii (32 ref.)

ANATOMY & HISTOLOGY

Clinical magnetic resonance imaging of articular cartilage. Disler DG, et al. **Top Magn Reson Imaging** 1998 Dec; 9(6):360–76 (73 ref.)

PATHOLOGY

The importance of arthroscopy in diagnosing synovial haemangioma of the knee joint. Farkas C, et al. **Acta Chir Hung** 1998;37(1–2):17–22 (22 ref.)

Pathogenesis of anterior knee pain syndrome and functional patellofemoral instability in the active young. Sanchis-Alfonso V, et al. **Am J Knee Surg** 1999 Winter; 12(1):29–40 (43 ref.)

Evaluation and management of tumors about the knee. Yaw KM. **Am J Knee Surg** 1998 Fall;11(4):241–5 (3 ref.)

Articular cartilage lesions of the knee. Mandelbaum BR, et al. **Am J Sports Med** 1998 Nov–Dec;26(6):853–61 (53 ref.)

Anterior knee pain syndrome. A review of current concepts and controversies. Hull JB, et al. **J R Army Med Corps** 1999 Jun;145(2):89–94 (19 ref.)

Lipoma arborescens of the knee. Narváez J, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):351–3 (17 ref.)

Magnetic resonance imaging of osteoarthritis. Waldschmidt JG, et al. **Rheum Dis Clin North Am** 1999 May;25(2):451–65 (25 ref.)

Magnetic resonance imaging of knee cartilage repair. Gold GE, et al. **Top Magn Reson Imaging** 1998 Dec;9(6):377–92 (46 ref.)

PHYSIOLOGY

Biomechanics of knee ligaments. Woo SL, et al. **Am J Sports Med** 1999 Jul–Aug;27(4):533–43 (70 ref.)

The conflicting requirements of laxity and conformity in total knee replacement. Sathasivam S, et al. **J Biomech** 1999 Mar; 32(3):239–47 (24 ref.)

The biomechanics of the patellofemoral joint. Grelsamer RP, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):286–98 (91 ref.)

Knee joint motion: description and measurement. Bull AM, et al. **Proc Inst Mech Eng [H]** 1998;212(5):357–72 (122 ref.)

PHYSIOPATHOLOGY

The influence of clinical and biomechanical factors on the results of valgus high tibial osteotomy. Catani F, et al. **Chir Organi Mov** 1998 Jul–Sep;83(3):249–62 (37 ref.) **(Eng, Ita)**

The anterior cruciate ligament and arthritis. Clatworthy M, et al. **Clin Sports Med** 1999 Jan;18(1):173–98, vii (84 ref.)

Overview of treatment options for arthritis in the active patient. Vangsness CT Jr. **Clin Sports Med** 1999 Jan; 18(1):1–11, v (75 ref.)

Effect of knee pain on joint loading in patients with osteoarthritis. Hurwitz DE, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):422–6 (40 ref.)

Loss of extension after reconstruction of the anterior cruciate ligament. Petsche TS, et al. **J Am Acad Orthop Surg** 1999 Mar–Apr;7(2):119–27 (31 ref.)

The aging knee joint--an insight. Muhury S. **J Indian Med Assoc** 1998 May;96(5):159–64 (9 ref.)

Proprioceptive impairment in knee osteoarthritis. Sharma L. **Rheum Dis Clin North Am** 1999 May;25(2):299–314, vi (59 ref.)

SURGERY

Meniscal allograft transplantation. Johnson DL, et al. **Clin Sports Med** 1999 Jan;18(1):93–108 (72 ref.)

Options in meniscal repair. Rispoli DM, et al. **Clin Sports Med** 1999 Jan;18(1):77–91, vi (94 ref.)

Arthroscopic management for degenerative arthritis of the knee. Stuart MJ. **Instr Course Lect** 1999;48:135–41 (29 ref.)

Surgical management of inflammatory arthritis of the adult hip and knee. Stuchin SA, et al. **Instr Course Lect** 1999; 48:93–109 (113 ref.)

Revision anterior cruciate ligament reconstruction surgery. Getelman MH, et al. **J Am Acad Orthop Surg** 1999 May–Jun;7(3):189–98 (30 ref.)

Use of allografts in knee reconstruction: I. Basic science aspects and current status. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):165–8 (15 ref.)

Use of allografts in knee reconstruction: II. Surgical considerations. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):169–75 (29 ref.)

Treatment of articular cartilage defects of the knee with autologous chondrocyte implantation. Gillogly SD, et al. **J Orthop Sports Phys Ther** 1998 Oct;28(4):241–51 (64 ref.)

Key developments in knee surgery. Isdale A, et al. **Practitioner** 1998 Nov;242(1592):777–80, 784 (10 ref.)

Knee replacement surgery for osteoarthritis: effectiveness, practice variations, indications and possible determinants of utilization. Dieppe P, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):73–83 (90 ref.)

Magnetic resonance imaging of knee cartilage repair. Gold GE, et al. **Top Magn Reson Imaging** 1998 Dec;9(6):377–92 (46 ref.)

[Possibilities of surgical treatment of knee joint in rheumatoid arthritis patients] Gaździk T. **Wiad Lek** 1998; 51(11–12):518–24 (18 ref.) (Eng. Abstr.) **(Pol)**

KNEE PROSTHESIS

see related
ARTHROPLASTY, REPLACEMENT, KNEE

Current concepts review: symmetry versus asymmetry in the design of total knee femoral components--an unresolved controversy. Bindelglass DF, et al. **J Arthroplasty** 1998 Dec;13(8):939–44 (35 ref.)

The conflicting requirements of laxity and conformity in total knee replacement. Sathasivam S, et al. **J Biomech** 1999 Mar; 32(3):239–47 (24 ref.)

Wear in total hip and knee replacements. Schmalzried TP, et al. **J Bone Joint Surg Am** 1999 Jan;81(1):115–36 (256 ref.)

[In vivo determination of patello-femoral separation and linear impulse forces] Komistek RD, et al. **Orthopade** 1998 Sep;27(9):612–8 (0 ref.) (Eng. Abstr.) **(Ger)**

[Patellar resurfacing in total knee arthroplasty, current state of the controversy] Schroeder-Boersch H. **Orthopade** 1998 Sep;27(9):600–11 (140 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Hanssen AD, et al. **Instr Course Lect** 1999;48:111–22 (141 ref.)

[The causes of failure for hip and knee arthroplasties] Huiskes R. **Ned Tijdschr Geneeskd** 1998 Sep 12;142(37):2035–40 (9 ref.) (Eng. Abstr.) **(Dut)**

KNEE REPLACEMENT, TOTAL see **ARTHROPLASTY, REPLACEMENT, KNEE**

KNOCKOUT MICE see **MICE, KNOCKOUT**

KNOWLEDGE

Combining stories and numbers: a methodologic approach for a critical nursing science. Berman H, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):1–15 (51 ref.)

An emancipatory impulse: a feminist postmodern integrated turning point in nursing research. Glass N, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):43–52 (45 ref.)

The nature of ethical expertise. Yoder SD. **Hastings Cent Rep** 1998 Nov–Dec;28(6):11–9 (35 ref.)

The theory of the organism-environment system: III. Role of efferent influences on receptors in the formation of knowledge. Jarvilehto T. **Integr Physiol Behav Sci** 1999 Apr–Jun;34(2):90–100 (28 ref.)

Writing poetry: a way of knowing nursing. Holmes V, et al. **J Adv Nurs** 1998 Dec;28(6):1191–4 (11 ref.)

The nature of philosophy of science, theory and knowledge relating to nursing and professionalism. Rutty JE. **J Adv Nurs** 1998 Aug;28(2):243–50 (63 ref.)

Clinical jazz: harmonizing clinical experience and evidence-based medicine [see comments] Shaughnessy AF, et al. **J Fam Pract** 1998 Dec;47(6):425–8 (16 ref.) Comment in: J Fam Pract 1999 Apr;48(4):306.

ReVisions in knowledge development: a passion for substance. Meleis AI. **Sch Inq Nurs Pract** 1998 Spring; 12(1):65–77; discussion 79–94 (26 ref.)

A theoretical analysis of Carper's ways of knowing using a model of social cognition. Stein KF, et al. **Sch Inq Nurs Pract** 1998 Spring;12(1):43–60; discussion 61–4 (58 ref.)

Assignments of meaning in epidemiology. Little M. **Soc Sci Med** 1998 Nov;47(9):1135–45 (31 ref.)

The tacit-explicit connection: Polanyian integrative philosophy and a Neo-Polanyian medical epistemology. Jha SR. **Theor Med Bioeth** 1998 Dec;19(6):547–68 (24 ref.)

[Medical research on patients' experiences--structured questionnaires result in worthless answers] Kirkengen AL. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3449–52 (20 ref.) (Eng. Abstr.) **(Nor)**

[Wisdom--knowledge, the patient and the physician] Vestbø E. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1146–8 (17 ref.) (Eng. Abstr.) **(Nor)**

[Quality registries are a gold-mine of information that should be better used. Knowledge of improvement is acquired by means of special projects] Sachs MA, et al. **Lakartidningen** 1999 May 19;96(20):2438–40 (16 ref.) **(Swe)**

KNOWLEDGE ACQUISITION (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KNOWLEDGE, ATTITUDES, PRACTICE

Toward creating physician-healers: fostering medical students' self-awareness, personal growth, and well-being. Novack DH, et al. **Acad Med** 1999 May;74(5):516–20 (51 ref.)

Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. Hecht FM, et al. **Ann Intern Med** 1999 Jul 20;131(2):136–43 (63 ref.)

Are physicians aware of what patients know about what physicians know? [editorial] Sabbioni ME, et al. **Ann Oncol** 1999 Jan;10(1):11–2 (8 ref.)

Herbal remedies. How much do you know? Myerscough M. **Aust Fam Physician** 1998 Nov;27(11):1037–40 (33 ref.)

Screening for cervical cancer: a review of women's attitudes, knowledge, and behaviour [see comments] Fylan F. **Br J Gen Pract** 1998 Aug;48(433):1509–14 (83 ref.) Comment in: Br J Gen Pract 1998 Oct;48(435):1704.

Oral contraception: current use and attitudes. Jones KP. **Contraception** 1999 Jan;59(1 Suppl):17S–20S (12 ref.)

Strength training and nutritional supplement use in adolescents. Metzl JD. **Curr Opin Pediatr** 1999 Aug; 11(4):292–6 (35 ref.)

Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Lévy S, et al. **Eur Heart J** 1998 Sep;19(9):1294–320 (213 ref.)

Dietary advice in British General Practice. Gray DP. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S3–8 (54 ref.)

Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Thomas PK. **Eur Neurol** 1999;41 Suppl 1:35–43 (62 ref.)
Public understanding of genetics and Alzheimer disease. Stockdale A. **Genet Test** 1999;3(1):139–45 (25 ref.)
Adolescent abstinence and condom use: are we sure we are really teaching what is safe? Haignere CS, et al. **Health Educ Behav** 1999 Feb;26(1):43–54 (65 ref.)
Effective presentation of radiation safety training--risk communication: an important function of radiation safety training. Johnson RH Jr. **Health Phys** 1999 Feb;76(2 Suppl):S10–5 (7 ref.)
Swan-Ganz catheter: misconceptions, pitfalls, and incomplete user knowledge--an identified trilogy in need of correction. Brandstetter RD, et al. **Heart Lung** 1998 Jul–Aug;27(4):218–22 (40 ref.)
A relational approach to group therapy for women with bulimia nervosa: moving from understanding to action. Tantillo M. **Int J Group Psychother** 1998 Oct;48(4):477–98 (61 ref.)
Contraceptive use: the US perspective. Burnhill MS. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S17–23 (7 ref.)
Gender violence and reproductive health. Diniz SG, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S33–42 (44 ref.)
HIV: mother to child transmission, current knowledge and on-going studies. Giaquinto C, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S161–5 (22 ref.)
Barriers to uptake and use of modern methods of contraception in developing countries. Konje JC, et al. **Int J Gynaecol Obstet** 1999 Jun;65(3):287–94 (25 ref.)
Contraceptives: regional perspectives, issues, and unmet needs--the European perspective. Newton J. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S25–30 (13 ref.)
The dietitians' philosophy and practice in multidisciplinary weight management. Dalton S. **J Am Diet Assoc** 1998 Oct; 98(10 Suppl 2):S49–54 (49 ref.)
Clinical practice guidelines in end-stage renal disease: a strategy for implementation. Kliger AS, et al. **J Am Soc Nephrol** 1999 Apr;10(4):872–7 (18 ref.)
Surgical progress is not the answer to intersexuality. Chase C. **J Clin Ethics** 1998 Winter;9(4):385–92 (40 ref.)
Management of intersex: a shifting paradigm. Wilson BE, et al. **J Clin Ethics** 1998 Winter;9(4):360–9 (32 ref.)
Differences in clinical communication by gender. Elderkin-Thompson V, et al. **J Gen Intern Med** 1999 Feb; 14(2):112–21 (116 ref.)
Knowledge, patterns of care, and outcomes of care for generalists and specialists [see comments] Harrold LR, et al. **J Gen Intern Med** 1999 Aug;14(8):499–511 (92 ref.) Comment in: J Gen Intern Med 1999 Aug;14(8):514–5.
Defining educational priorities in managed care: a symposium overview. Kerr EA, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S1–5 (31 ref.)
Integrating Buddhism and HIV prevention in U.S. southeast Asian communities. Loue S, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):100–21 (107 ref.)
Extent of relational stigmatization of lesbians and their children by heterosexual college students. King BR, et al. **J Homosex** 1999;37(2):65–81 (62 ref.)
Who will challenge evidence-based medicine? Goodman NW. **J R Coll Physicians Lond** 1999 May–Jun;33(3):249–51 (31 ref.)
Clergy perspectives and practices regarding intimate violence: a rural view. Strickland GA, et al. **J Rural Health** 1998 Fall;14(4):305–11 (29 ref.)
Using picture identification for research with preschool children. Wiley DC, et al. **J Sch Health** 1998 Aug; 68(6):227–30 (26 ref.)
Collaboration in improving care for patients: how can we find out what we haven't been able to figure out yet? Batalden PB, et al. **Jt Comm J Qual Improv** 1998 Oct; 24(10):609–18 (39 ref.)
One size does not fit all: questions to answer before intervening to change physician behavior. Poses RM. **Jt Comm J Qual Improv** 1999 Sep;25(9):486–95 (78 ref.)
Prevention: are we really reaching today's teens? Muscari ME. **MCN Am J Matern Child Nurs** 1999 Mar–Apr; 24(2):87–91 (7 ref.)
A theoretical model for the study of active and passive smoking in military women: an at-risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475–80 (56 ref.)
Is it over yet? Hope or hype: status of the HIV/AIDS pandemic. Miramontes HM, et al. **Nurs Outlook** 1998 Jul–Aug;46(4):155–6 (22 ref.)
Sex education to grade seven students in Papua New Guinea, yes or no? Bouten M. **P N G Med J** 1996 Sep;39(3):225–7 (0 ref.)
AIDS and the community. Farmer E. **P N G Med J** 1996 Sep;39(3):214–7 (6 ref.)
AIDS: what should nurses know? Richards T. **P N G Med J** 1996 Sep;39(3):228–9 (2 ref.)
Prevention and intervention strategies with children of alcoholics. Emshoff JG, et al. **Pediatrics** 1999 May;103(5 Pt 2):1112–21 (76 ref.)
The social ecology of addiction: race, risk, and resilience. Wallace JM Jr. **Pediatrics** 1999 May;103(5 Pt 2):1122–7 (41 ref.)
The placebo effect: mocking or mirroring medicine? Biller N. **Perspect Biol Med** 1999 Spring;42(3):398–401 (11 ref.)
Reproductive health. New perspectives on men's participation. Drennan M. **Popul Rep J** 1998 Oct;(46):1–35 (299 ref.)
Patients with alcohol problems in primary care: understanding their resistance and motivating change. Botelho RJ, et al. **Prim Care** 1999 Jun;26(2):279–98 (50 ref.)
Compliance of patients with arterial hypertension to therapeutic recommendations. Więcek A. **Przegl Lek** 1998; 55 Suppl 1:65–6 (8 ref.) **(Eng, Pol)**
Raising questions about antidepressants. Antonuccio DO, et al. **Psychother Psychosom** 1999;68(1):3–14 (162 ref.)
Is imposing risk awareness cultural imperialism? Førde OH. **Soc Sci Med** 1998 Nov;47(9):1155–9 (25 ref.)
Probabilities and health risks: a qualitative approach. Heyman B, et al. **Soc Sci Med** 1998 Nov;47(9):1295–306 (48 ref.)
Can we stop children and adolescents from smoking? [comment] Yach D, et al. **Soc Sci Med** 1999 Mar; 48(6):757–8 (15 ref.) Comment on: Soc Sci Med 1999 Mar;48(6):759–75.
Recent developments in medical care of Jehovah's Witnesses. Muramoto O. **West J Med** 1999 May;170(5):297–301 (22 ref.)
Community perceptions of health, illness and care: identifying issues for indigenous communities. Kelaher M, et al. **Women Health** 1998;28(1):41–61 (36 ref.)
Engendering stress in Australia: the embodiment of social relationships. Whittaker A, et al. **Women Health** 1998; 28(1):97–115 (31 ref.)
[Predictive factors of smoking cessation after myocardial infarction. Review of the literature (see comments)] Aboyans V, et al. **Ann Cardiol Angeiol (Paris)** 1998 Mar; 47(3):177–82 (37 ref.) (Eng. Abstr.) Comment in: Ann Cardiol Angeiol (Paris) 1998 Mar;47(3):183–4. **(Fre)**
[Questions about sexual ethics related to AIDS] Colpin H. **Contracept Fertil Sex** 1998 Nov;26(11):812–8 (29 ref.) (Eng. Abstr.) **(Fre)**
[How do we utilize our knowledge of psychiatry?] Magnussen F, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30; 118(23):3659–62 (5 ref.) **(Nor)**
[Folate and health--new knowledge and new recommendation (see comments)] Tell GS, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3155–60 (60 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1998 Oct 10;118(24):3832. **(Nor)**
[Health education and prevention of AIDS] Cucić V, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):196–201 (46 ref.) **(Scc)**
[Risk of food-borne infections is both reduced and increased. Expertise is greater, but so is the risk of exposure] Lindberg A. **Lakartidningen** 1999 Jun 23;96(25):3064–6 (13 ref.) (Eng. Abstr.) **(Swe)**

KNOWLEDGE BASES (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KNOWLEDGE REPRESENTATION (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KO-1173 see **MEXILETINE**

KOCK POUCH see **PROCTOCOLECTOMY, RESTORATIVE**

KOEHLER'S DISEASE see **OSTEOCHONDRITIS**

KOGIA see **WHALES**

KOJEWNIKOW'S SYNDROME see **EPILEPSIA PARTIALIS CONTINUA**

KOLMOGOROV-SMIRNOV TEST see **STATISTICS, NONPARAMETRIC**

KOZHEVNIKOV'S SYNDROME see **EPILEPSIA PARTIALIS CONTINUA**

KRABBE DISEASE see **LEUKODYSTROPHY, GLOBOID CELL**

KRAUROSIS PENIS see **BALANITIS**

KRAUSE'S END BULBS see **MECHANORECEPTORS**

KREBS CYCLE see **CITRIC ACID CYCLE**

KRILL see **CRUSTACEA**

KRUPIN VALVES see **GLAUCOMA DRAINAGE IMPLANTS**

KRUSKAL-WALLIS H STATISTIC see **STATISTICS, NONPARAMETRIC**

KRYPTOSTEROL see **LANOSTEROL**

KSHV see **HERPESVIRUS, KAPOSI SARCOMA-ASSOCIATED**

KUFS DISEASE see **NEURONAL CEROID-LIPOFUSCINOSIS**

KUNG FU see **MARTIAL ARTS**

KUNITZ PANCREATIC TRYPSIN INHIBITOR see **APROTININ**

KUPFFER CELLS

IMMUNOLOGY

Leukocytes as modulators of stellate cell activation. Maher JJ. **Alcohol Clin Exp Res** 1999 May;23(5):917–21 (29 ref.)
Role of transcriptional factors in stellate cell activation. Rippe RA. **Alcohol Clin Exp Res** 1999 May;23(5):926–9 (33 ref.)
Cytokine regulation of hepatic stellate cells in liver fibrosis. Tsukamoto H. **Alcohol Clin Exp Res** 1999 May;23(5):911–6 (61 ref.)

METABOLISM

Glutathione defense in non-parenchymal cells. DeLeve LD. **Semin Liver Dis** 1998;18(4):403–13 (95 ref.)

PATHOLOGY

II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Thurman RG. **Am J Physiol** 1998 Oct;275(4 Pt 1):G605–11 (55 ref.)

PHYSIOLOGY

Intracellular signaling pathways in stellate cell activation. Britton RS, et al. **Alcohol Clin Exp Res** 1999 May; 23(5):922–5 (30 ref.)
Stellate cell activation in alcoholic fibrosis--an overview. Friedman SL. **Alcohol Clin Exp Res** 1999 May;23(5):904–10 (76 ref.)
Acetaldehyde-mediated collagen regulation in hepatic stellate cells. Greenwel P. **Alcohol Clin Exp Res** 1999 May; 23(5):930–3 (36 ref.)
Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. Rose ML, et al. **Drug Metab Rev** 1999 Feb;31(1):87–116 (81 ref.)
Pathobiology of hepatic stellate cells. Burt AD. **J Gastroenterol** 1999 Jun;34(3):299–304 (63 ref.)
The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. Thurman RG, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S39–50 (88 ref.)
Mechanisms of reperfusion injury after warm ischemia of the liver. Jaeschke H. **J Hepatobiliary Pancreat Surg** 1998; 5(4):402–8 (84 ref.)
Kupffer cell-dependent reperfusion injury in liver transplantation: new clinically relevant use of glycine. Thurman RG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:185–90 (31 ref.)
Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1055–8 (18 ref.)

KURU

[Kuru] Mori S. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):222–5 (14 ref.) **(Jpn)**

TRANSMISSION

[Acquired forms of Creutzfeldt-Jakob disease] Mikol J. **Clin Exp Pathol** 1999;47(3–4):145–51 (47 ref.) (Eng. Abstr.) **(Fre)**

KVEIM TEST

Kveim antigen: what does it tell us about causation of sarcoidosis? Teirstein AS. **Semin Respir Infect** 1998 Sep; 13(3):206–11 (57 ref.)

KWASHIORKOR

ETIOLOGY

Oedematous malnutrition. Golden MH. **Br Med Bull** 1998; 54(2):433–44 (71 ref.)

KYNURENINE

PHARMACOLOGY

Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Moroni F. **Eur J Pharmacol** 1999 Jun 30;375(1–3):87–100 (183 ref.)

KYPHOSIS

ETIOLOGY

Postlaminectomy kyphosis. Albert TJ, et al. **Spine** 1998 Dec 15;23(24):2738–45 (45 ref.)
Severe kyphosis secondary to glucocorticoid-induced osteoporosis in a young adult with Cushing's disease. A

KYPHOSIS

case report and literature review. Freehill AK, et al. **Spine** 1999 Jan 15;24(2):189–93 (14 ref.)

PHYSIOPATHOLOGY

The importance of an intact abdominal musculature mechanism in maintaining spinal sagittal balance. Case illustration in prune-belly syndrome. Lam KS, et al. **Spine** 1999 Apr 1;24(7):719–22 (16 ref.)

SURGERY

Kyphosis deformity in myelomeningocele. Sarwark JF. **Orthop Clin North Am** 1999 Jul;30(3):451–5, viii–ix (29 ref.)

L3T4 ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

L CELLS (INTESTINE) see **ENDOCRINE CELLS OF GUT**

L-MYC GENES see **GENES, MYC**

L-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

L SELECTIN see **L-SELECTIN**

LA CROSSE VIRUS

see related
ENCEPHALITIS, CALIFORNIA

LA PLATA DOLPHIN see **DOLPHINS**

LABELING, DRUG see **DRUG LABELING**

LABELING, FOOD see **FOOD LABELING**

LABETALOL

THERAPEUTIC USE

How low can you go? Blood pressure control after intracranial hemorrhage [editorial; comment] Kochanek PM, et al. **Crit Care Med** 1999 May;27(5):867–9 (11 ref.) Comment on: Crit Care Med 1999 May;27(5):965–71.

LABOR

see related
FETAL MONITORING
NATURAL CHILDBIRTH
OXYTOCICS
TRIAL OF LABOR

Epidural analgesia during labor [see comments] Vincent RD Jr, et al. **Am Fam Physician** 1998 Nov 15;58(8):1785–92 (26 ref.) Comment in: Am Fam Physician 1998 Nov 15;58(8):1743–4, 1746.

Epidural analgesia in association with duration of labor and mode of delivery: a quantitative review. Zhang J, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):970–7 (22 ref.)

ABC of labour care: place of birth. Zander L, et al. **BMJ** 1999 Mar 13;318(7185):721–3 (0 ref.)

Psychosocial support or active management of labour or both to improve the outcome of labour. Arulkumaran S, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):617–9 (17 ref.)

Evidence-based intrapartum care: evidence from the Cochrane library. Neilson JP. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S97–102 (18 ref.)

The changing role of receiving hospitals under the Emergency Medical Treatment and Active Labor Act. Kuettel AC. **J Leg Med** 1998 Sep;19(3):351–76 (79 ref.)

No free lunch on labor day. The risks and benefits of epidural analgesia during labor [see comments] Lieberman E. **J Nurse Midwifery** 1999 Jul–Aug;44(4):394–8 (20 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

Evidence-based practice and its application to childbirth care for low-risk women [see comments] Rooks JP. **J Nurse Midwifery** 1999 Jul–Aug;44(4):355–69 (122 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

The midwifery model of care [see comments] Rooks JP. **J Nurse Midwifery** 1999 Jul–Aug;44(4):370–4 (38 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

Theory and practice for teaching the childbearing couple. Farrell M, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):613–8 (22 ref.)

Working with childhood sexual abuse survivors during pregnancy, labor, and birth. Heritage C. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):671–7 (17 ref.)

Bedside musical care: applications in pregnancy, childbirth, and neonatal care. Olson SL. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):569–75 (33 ref.)

Instrumentation for the diagnosis of term and preterm labour. Garfield RE, et al. **J Perinat Med** 1998;26(6):413–36 (128 ref.)

Active management of labor. Socol ML, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):287–94 (31 ref.)

Dead mothers and injured wives: the social context of maternal morbidity and mortality among the Hausa of northern Nigeria. Wall LL. **Stud Fam Plann** 1998 Dec; 29(4):341–59 (128 ref.)

[Should pethidine still be administered to women in labor? (see comments)] Matheson I, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):234–6 (33 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1999 Mar 20;119(8):1194. **(Nor)**

BLOOD

Role of lactate measurements during labor. Westgren M, et al. **Obstet Gynecol Surv** 1999 Jan;54(1):43–8 (40 ref.)

GENETICS

What knockout mice can tell us about parturition. Kimura T, et al. **Rev Reprod** 1999 May;4(2):73–80 (71 ref.)

METABOLISM

New peptides, hormones and parturition. Di Iorio R, et al. **Gynecol Endocrinol** 1998 Dec;12(6):429–34 (28 ref.)

Key enzymes of prostaglandin biosynthesis and metabolism. Coordinate regulation of expression by cytokines in gestational tissues: a review. Hansen WR, et al. **Prostaglandins Other Lipid Mediat** 1999 Jun;57(4):243–57 (128 ref.)

PHYSIOLOGY

A role for estriol in human labor, term and preterm. Goodwin TM. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S208–13 (35 ref.)

A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Majzoub JA, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S232–41 (71 ref.)

The relationship between hormones and human parturition. Chaim W, et al. **Arch Gynecol Obstet** 1998;262(1–2):43–51 (46 ref.)

The effect of vaginal delivery on anal function. Rieger N, et al. **Aust N Z J Surg** 1999 Mar;69(3):172–7 (68 ref.)

The effects of epidural analgesia on the course and outcome of labour. Finster M, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):473–83 (59 ref.)

ABC of labour care: physiology and management of normal labour. Steer P, et al. **BMJ** 1999 Mar 20;318(7186):793–6 (0 ref.)

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

Regulation of parturition update. Endocrine and paracrine effectors of term and preterm labor. Kniss DA, et al. **Clin Perinatol** 1998 Dec;25(4):819–36, v (128 ref.)

Control and assessment of the uterus and cervix during pregnancy and labour. Garfield RE, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):673–95 (87 ref.)

The problematic symmetry between brain birth and brain death. Jones DG. **J Med Ethics** 1998 Aug;24(4):237–42 (37 ref.)

Mechanisms of full-term and preterm labor: factors influencing uterine activity. Ruiz RJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):652–60 (47 ref.)

Changes in the cervical extracellular matrix during pregnancy and parturition. Winkler M, et al. **J Perinat Med** 1999;27(1):45–60 (56 ref.)

Putative role of placental corticotropin-releasing factor in the mechanisms of human parturition. Reis FM, et al. **J Soc Gynecol Investig** 1999 May–Jun;6(3):109–19 (106 ref.)

The control of labor. Norwitz ER, et al. **N Engl J Med** 1999 Aug 26;341(9):660–6 (70 ref.)

[The monitoring of fetal status during birth. The current possibilities, problems and directions for improvement] Nikolov A. **Akush Ginekol (Sofiia)** 1998;37(3):48–51 (35 ref.) **(Bul)**

[Eutocic delivery] Darbois Y. **Rev Prat** 1999 Jan 15; 49(2):133–8 (1 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Childbirth customs in Orthodox Jewish traditions. Bodo K, et al. **Can Fam Physician** 1999 Mar;45:682–6 (11 ref.)

Childbirth customs in Vietnamese traditions. Bodo K, et al. **Can Fam Physician** 1999 Mar;45:690–2, 695–7 (14 ref.)

Comfort in labor and midwifery art. Schuiling KD, et al. **Image J Nurs Sch** 1999;31(1):77–81 (40 ref.)

LABOR COMPLICATIONS

Ethical aspects of decision-making at the limit of viability [comment] Finnström O, et al. **Acta Paediatr** 1999 Jul; 88(7):708–9 (9 ref.) Comment on: Acta Paediatr 1999 Jul;88(7):789–90.

Peripartum hemorrhage. Alamia V Jr, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):385–98 (63 ref.)

Management of fetal distress. Penning S, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):259–74 (55 ref.)

CHEMICALLY INDUCED

A mechanistic-based approach for assessing chemical hazards to parturition. Loch-Caruso R. **J Womens Health** 1999 Mar;8(2):235–48 (96 ref.)

DIAGNOSIS

Common peripartum emergencies [see comments] Morrison EH. **Am Fam Physician** 1998 Nov 1;58(7):1593–604 (39 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2984, 2989; discussion 2990. Comment in: Am Fam Physician 1999 Jun;59(11):2989–90.

Intrapartum fetal hypoxia and biochemical markers: a review. Nordström L, et al. **Obstet Gynecol Surv** 1998 Oct; 53(10):645–57 (152 ref.)

[The course of pregnancy, labor and the postpartum period in a woman with a myomatous node of the uterus who gave birth to twins] Istatkov M, et al. **Akush Ginekol (Sofiia)** 1998;37(4):56–8 (6 ref.) **(Bul)**

[Delivery methods for infants weighing less than 2500 grams. Labor surveillance in cases of vaginal delivery] Carbonne B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:307–10 (14 ref.) **(Fre)**

[Are there indications for abortion or cesarean section and contraindications for spontaneous delivery in ophthalmologic diseases? Case report and overview] Kuba GB, et al. **Zentralbl Gynakol** 1998;120(8):406–12 (68 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Maternal satisfaction with labour analgesia. Ross A. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):499–512 (88 ref.)

Neuraxial opioids in labour. Wilson DJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):363–76 (67 ref.)

EPIDEMIOLOGY

Birth trauma and the pelvic floor: lessons from the developing world. Wall LL. **J Womens Health** 1999 Mar;8(2):149–55 (36 ref.)

Anal sphincter tears at vaginal delivery: risk factors and clinical outcome of primary repair. Zetterström J, et al. **Obstet Gynecol** 1999 Jul;94(1):21–8 (38 ref.)

Dead mothers and injured wives: the social context of maternal morbidity and mortality among the Hausa of northern Nigeria. Wall LL. **Stud Fam Plann** 1998 Dec; 29(4):341–59 (128 ref.)

ETIOLOGY

Ballet dancers--pregnancy outcomes. Barry S. **J R Soc Health** 1998 Dec;118(6):360–2 (10 ref.)

NURSING

Comfort in labor and midwifery art. Schuiling KD, et al. **Image J Nurs Sch** 1999;31(1):77–81 (40 ref.)

PHYSIOPATHOLOGY

Physiology of pain in labour. Rowlands S, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):347–62 (86 ref.)

Maternal and obstetric effects of prenatal drug exposure. Bishai R, et al. **Clin Perinatol** 1999 Mar;26(1):75–86, vii (65 ref.)

[Effect of delivery on the anal sphincter] Bourguignon J, et al. **Presse Med** 1998 Oct 31;27(33):1702–6 (32 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

The substance-abusing parturient: implications for analgesia and anaesthesia management. Birnbach DJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):443–60 (120 ref.)

The long-term effects of analgesia in labour. Durbridge J, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):485–98 (55 ref.)

The effects of pain and its management on mother and fetus. May AE, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):423–41 (64 ref.)

Promising non-narcotic analgesic techniques for labour. Mercier FJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):397–407 (58 ref.)

Traditional analgesic agents: are parenteral narcotics passé and do inhalational agents still have a place in labour? Olofsson C, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):409–21 (72 ref.)

New epidural techniques for labour analgesia: patient-controlled epidural analgesia and combined spinal-epidural analgesia. Paech M. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):377–95 (112 ref.)

ABC of labour care. Relief of pain. Findley I, et al. **BMJ** 1999 Apr 3;318(7188):927–30 (0 ref.)

Evidence-based intrapartum care: evidence from the Cochrane library. Neilson JP. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S97–102 (18 ref.)

Birth trauma and the pelvic floor: lessons from the developing world. Wall LL. **J Womens Health** 1999 Mar;8(2):149–55 (36 ref.)

Active management of labor. Socol ML, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):287–94 (31 ref.)

[Delivery methods for infants weighing less than 2500 grams. Which particular preventative modalities should be proposed for natural delivery?] Verspyck E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:311–3 (13 ref.) **(Fre)**

[Review of the literature on advantages and disadvantages: episiotomy: only limited protection against ruptures—time for a revision?] Haadem K. **Lakartidningen** 1998 Sep 30; 95(40):4354–8 (29 ref.) (Eng. Abstr.) **(Swe)**

SURGERY

ABC of labour care: operative delivery. Chamberlain G, et al. **BMJ** 1999 May 8;318(7193):1260–4 (10 ref.)

Anal sphincter tears at vaginal delivery: risk factors and clinical outcome of primary repair. Zetterström J, et al. **Obstet Gynecol** 1999 Jul;94(1):21–8 (38 ref.)

THERAPY

Common peripartum emergencies [see comments] Morrison EH. **Am Fam Physician** 1998 Nov 1;58(7):1593–604 (39 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2984, 2989; discussion 2990. Comment in: Am Fam Physician 1999 Jun;59(11):2989–90.

ABC of labour care: obstetric emergencies. Chamberlain G, et al. **BMJ** 1999 May 15;318(7194):1342–5 (5 ref.)

ABC of labour care: labour in special circumstances. Chamberlain G, et al. **BMJ** 1999 Apr 24;318(7191):1124–7 (0 ref.)

Uterine emergencies. Atony, inversion, and rupture. Ripley DL. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):419–34, vii (41 ref.)

[Amnio-infusion during labor: experience and review of the literature] Hourdequin P, et al. **Contracept Fertil Sex** 1999 Mar;27(3):222–30 (60 ref.) (Eng. Abstr.) **(Fre)**

[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:94–103 (40 ref.) **(Fre)**

[Severe maternal and fetal situations during delivery] Chauvet MP, et al. **Rev Prat** 1999 Jan 15;49(2):151–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Amnioinfusion or not during labor? Better documentation and more trials can answer the question] Wallin G. **Lakartidningen** 1999 Mar 3;96(9):1017–9 (30 ref.) (Eng. Abstr.) **(Swe)**

LABOR, INDUCED

see related
OXYTOCICS

Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Plaut MM, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1535–42 (27 ref.)

Labor induction with misoprostol. Wing DA. **Am J Obstet Gynecol** 1999 Aug;181(2):339–45 (36 ref.)

Epidemiology of cesarean sections: prolonged pregnancy. Scollo P. **Clin Exp Obstet Gynecol** 1999;26(1):22–6 (25 ref.)

A risk-benefit assessment of oxytocics in obstetric practice. Winkler M, et al. **Drug Saf** 1999 Apr;20(4):323–45 (125 ref.)

METHODS

Current trends in cervical ripening and labor induction. Harman JH Jr, et al. **Am Fam Physician** 1999 Aug; 60(2):477–84 (27 ref.)

ABC of labour care: induction. Chamberlain G, et al. **BMJ** 1999 Apr 10;318(7189):995–8 (0 ref.)

Evidence based case report: use of prostaglandins to induce labour in women with a caesarean section scar. Vause S, et al. **BMJ** 1999 Apr 17;318(7190):1056–8 (37 ref.)

Sweeping of the membranes to prevent post-term pregnancy and to induce labour: a systematic review. Boulvain M, et al. **Br J Obstet Gynaecol** 1999 May;106(5):481–5 (21 ref.)

Misoprostol for induction of labour: a systematic review. Hofmeyr GJ, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):798–803 (34 ref.)

Premature rupture of the membranes in term patients: induction of labor versus expectant management. Duff P. **Clin Obstet Gynecol** 1998 Dec;41(4):883–91 (35 ref.)

Induction of labour: new horizons. Brennand J, et al. **Hosp Med** 1998 Nov;59(11):856–60 (37 ref.)

Cervical ripening. Riskin-Mashiah S, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):243–57 (86 ref.)

[Delivery methods for infants weighing less than 2500 grams. In cases of in utero growth retardation, outside of labor] Fournié A. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:289–91 (7 ref.) **(Fre)**

[Stripping membranes at term. Review of randomized trials] Schmitz T, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27(8):749–54 (12 ref.) (Eng. Abstr.) **(Fre)**

[Cervical ripening and labor induction] Tardif D, et al. **Rev Prat** 1999 Jan 15;49(2):146–50 (16 ref.) (Eng. Abstr.) **(Fre)**

LABOR MIGRATION see **TRANSIENTS AND MIGRANTS**

LABOR ONSET

PHYSIOLOGY

Prostaglandin dehydrogenase and the initiation of labor. Challis JR, et al. **J Perinat Med** 1999;27(1):26–34 (34 ref.)

LABOR, PREMATURE

see related
INFANT, PREMATURE
TOCOLYTIC AGENTS

Preterm labor. Weismiller DG. **Am Fam Physician** 1999 Feb 1;59(3):593–602 (41 ref.)

A role for estriol in human labor, term and preterm. Goodwin TM. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S208–13 (35 ref.)

ABC of labour care: preterm labour and premature rupture of membranes. Steer P, et al. **BMJ** 1999 Apr 17; 318(7190):1059–62 (0 ref.)

The control of labor. Norwitz ER, et al. **N Engl J Med** 1999 Aug 26;341(9):660–6 (70 ref.)

Delayed interval delivery in multiple gestations. Platt JS, et al. **Obstet Gynecol Surv** 1999 May;54(5):343–8 (40 ref.)

[Preterm delivery: detection of risks and preventive treatment] Althabe F, et al. **Rev Panam Salud Publica** 1999 Jun;5(6):373–85 (71 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Antibiotic treatment in preterm labor with intact membranes] Chaim W, et al. **Harefuah** 1998 Aug; 135(3–4):130–4 (31 ref.) **(Heb)**

DIAGNOSIS

Prediction of preterm labour in multiple pregnancies. Chuileannáin FN, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):53–66 (78 ref.)

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837–57, vi (77 ref.)

Monitoring women at risk for preterm labor. Chern-Hughes B. **J Nurse Midwifery** 1998 Sep–Oct;43(5):393–4 (0 ref.)

Instrumentation for the diagnosis of term and preterm labour. Garfield RE, et al. **J Perinat Med** 1998;26(6):413–36 (128 ref.)

Markers of risk for preterm delivery. Lockwood CJ, et al. **J Perinat Med** 1999;27(1):5–20 (163 ref.)

Prenatal screening with evaluated high risk scores. Papiernik E, et al. **J Perinat Med** 1999;27(1):21–5 (6 ref.)

DRUG THERAPY

A review of the role of trials of the use of antibiotics in women with preterm labor and intact membranes. Chaim W, et al. **Arch Gynecol Obstet** 1998;261(4):167–72 (21 ref.)

Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Bossmar T. **J Perinat Med** 1998;26(6):458–65 (67 ref.)

Antibiotics: treatment of preterm labor. Reimer T, et al. **J Perinat Med** 1999;27(1):35–40 (14 ref.)

Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Lam F, et al. **Obstet Gynecol Surv** 1998 Nov;53(11 Suppl):S85–95 (99 ref.)

ETIOLOGY

Stress-associated preterm delivery: the role of corticotropin-releasing hormone. Lockwood CJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S264–6 (18 ref.)

Molecular aspects of preterm labor. Challis JR. **Bull Mem Acad R Med Belg** 1998;153(5–6):263–70; discussion 270–3 (6 ref.)

Tocolytic therapy in preterm PROM. Allen SR. **Clin Obstet Gynecol** 1998 Dec;41(4):842–8 (16 ref.)

Antenatal corticosteroids in preterm premature rupture of membranes. Chen B, et al. **Clin Obstet Gynecol** 1998 Dec; 41(4):832–41 (40 ref.)

Antibiotic therapy in preterm premature rupture of membranes. Locksmith GJ. **Clin Obstet Gynecol** 1998 Dec; 41(4):864–9 (28 ref.)

Management of preterm premature rupture of the membranes. Mercer BM. **Clin Obstet Gynecol** 1998 Dec; 41(4):870–82 (81 ref.)

Regulation of parturition update. Endocrine and paracrine effectors of term and preterm labor. Kniss DA, et al. **Clin Perinatol** 1998 Dec;25(4):819–36, v (128 ref.)

The role of antibiotic therapy in the prevention of prematurity. Mazor M, et al. **Clin Perinatol** 1998 Sep; 25(3):659–85, x (147 ref.)

IMMUNOLOGY

Cytokines in preterm parturition. Mazor M, et al. **Gynecol Endocrinol** 1998 Dec;12(6):421–7 (43 ref.)

METABOLISM

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837–57, vi (77 ref.)

Corticotropin-releasing hormone signals adversity in both the placenta and the brain: regulation by glucocorticoids and allostatic overload. Schulkin J. **J Endocrinol** 1999 Jun; 161(3):349–56 (108 ref.)

Biochemical markers for preterm labor and birth: what is their role in the care of pregnant women? Moore ML. **MCN Am J Matern Child Nurs** 1999 Mar–Apr;24(2):80–6 (25 ref.)

MICROBIOLOGY

The diagnosis of intrauterine infection in women with preterm premature rupture of the membranes (PPROM). Greig PC. **Clin Obstet Gynecol** 1998 Dec;41(4):849–63 (48 ref.)

PHYSIOPATHOLOGY

Immunoendocrinology of preterm labor: the link between corticotropin-releasing hormone and inflammation. Dudley DJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S251–6 (62 ref.)

Stress-associated preterm delivery: the role of corticotropin-releasing hormone. Lockwood CJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S264–6 (18 ref.)

A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Majzoub JA, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S232–41 (71 ref.)

Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272–4 (50 ref.)

Molecular aspects of preterm labor. Challis JR. **Bull Mem Acad R Med Belg** 1998;153(5–6):263–70; discussion 270–3 (6 ref.)

Regulation of parturition update. Endocrine and paracrine effectors of term and preterm labor. Kniss DA, et al. **Clin Perinatol** 1998 Dec;25(4):819–36, v (128 ref.)

Mechanisms of full-term and preterm labor: factors influencing uterine activity. Ruiz RJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):652–60 (47 ref.)

The importance of extracellular matrix in the induction of preterm delivery. Rath W, et al. **J Perinat Med** 1998; 26(6):437–41 (23 ref.)

PREVENTION & CONTROL

Prevention of preterm birth in multiple pregnancy. Crowther CA. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):67–75 (50 ref.)

We need to know more. Preterm Birth Prevention Consensus Conference. Finestone DL. **Can Fam Physician** 1998 Nov; 44:2482–3 (0 ref.)

The home management of preterm premature ruptured membranes. Bartfield MC, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):503–14 (38 ref.)

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

Recent advances in the therapeutic management of preterm labour. Sawdy RJ, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):131–9 (117 ref.)

A risk-benefit assessment of therapies for premature labour. Higby K, et al. **Drug Saf** 1999 Jul;21(1):35–56 (242 ref.)

Should multifetal pregnancy reduction be used for prevention of preterm deliveries in triplet or higher order multiple pregnancies? Papiernik E, et al. **J Perinat Med** 1998; 26(5):365–70 (22 ref.)

Basic aspects of prematurity prevention and results achieved by a suitable, simple program. Saling E. **J Perinat Med** 1998;26(6):466–8 (8 ref.)

Obstetrics. Preterm birth and pre-eclampsia—bad news and good news. Roberts JM, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV22 (5 ref.)

What's new in perinatology. Chescheir NC, et al. **Pediatr Rev** 1999 Feb;20(2):57–63 (11 ref.)

[The threat of premature labor: new aspects for management] Wertz JP, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1998;135(1):51–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[Tocolytic agents] Thoulon JM. **Contracept Fertil Sex** 1998 Sep;26(9):627–33 (53 ref.) **(Fre)**

[Arguments in favor of a relation between the organization of perinatal care and the optimal management of prematurity and multiple pregnancies] Truffert P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:85–93 (37 ref.) **(Fre)**

[Intravaginal ultrasonography of the uterine cervix: hope in the campaign against premature births] Rozenberg P. **J Radiol** 1999 May;80(5):421–9 (48 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacology of ritodrine] Mangrella M, et al. **Minerva Ginecol** 1999 Jun;51(6):233–44 (52 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Ambulatory management of preterm labor. Shellhaas CS, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):491–502 (28 ref.)

Recent advances in the therapeutic management of preterm labour. Sawdy RJ, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):131–9 (117 ref.)

Role of nitric oxide in the uterus and cervix: implications for the management of labor. Chwalisz K, et al. **J Perinat Med** 1998;26(6):448–57 (51 ref.)

ULTRASONOGRAPHY

[Value of cervical echography in the prediction of premature delivery: literature review] Dupuis O, et al. **Contracept Fertil Sex** 1999 Feb;27(2):147–54 (51 ref.) (Eng.

Abstr.) (Fre)

LABOR PRESENTATION

see related
DELIVERY
VERSION, FETAL

Shoulder dystocia. Owen P, et al. **Hosp Med** 1998 Sep; 59(9):698–703 (43 ref.)

The Zavanelli maneuver: 12 years of recorded experience [see comments] Sandberg EC. **Obstet Gynecol** 1999 Feb; 93(2):312–7 (35 ref.) Comment in: Obstet Gynecol 1999 Jul;94(1):159.

Poor perinatal outcome associated with vasa previa: is it preventable? A report of three cases and review of the literature [see comments] Fung TY, et al. **Ultrasound Obstet Gynecol** 1998 Dec;12(6):430–3 (43 ref.) Comment in: Ultrasound Obstet Gynecol 1998 Dec;12(6):377–9.

[Eutocic delivery] Darbois Y. **Rev Prat** 1999 Jan 15; 49(2):133–8 (1 ref.) (Eng. Abstr.) (Fre)

LABOR PRESENTATION, BREECH see **BREECH PRESENTATION**

LABOR, SECOND STAGE see **LABOR STAGE, SECOND**

LABOR STAGE, SECOND

PHYSIOLOGY

Maternal fatigue: implications of second stage labor nursing care. Mayberry LJ, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Mar–Apr; 28(2):175–81 (42 ref.)

LABOR UNIONS

The missing millions: organized labor, business, and the defeat of Clinton's Health Security Act. Gottschalk M. **J Health Polit Policy Law** 1999 Jun;24(3):489–529 (176 ref.)

LEGISLATION & JURISPRUDENCE

Navigating between a rock and a hard place: an employer's obligation to reasonably accommodate the disabled in the unionized workplace. Hankinson KD. **J Contemp Health Law Policy** 1998 Fall;15(1):245–74 (0 ref.)

ORGANIZATION & ADMINISTRATION

Physician unionization. The impact on the medical profession. Phan C. **J Leg Med** 1999 Mar;20(1):115–40 (203 ref.)

Organizing marginalized workers. Taylor AK. **Occup Med** 1999 Jul–Sep;14(3):687–95 (24 ref.)

LABORATORIES

see related
TECHNOLOGY, MEDICAL LABORATORY

Bisphosphonates: from the laboratory to the clinic and back again. Russell RG, et al. **Bone** 1999 Jul;25(1):97–106 (106 ref.)

Testing environment for single-gene disorders in U.S. reference laboratories. Amos J, et al. **Hum Mutat** 1998; 12(5):293–300 (13 ref.)

The origin, effects and control of air pollution in laboratories used for human embryo culture. Hall J, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:146–55 (12 ref.)

Internal quality control and external quality assurance in the IVF laboratory. Matson PL. **Hum Reprod** 1998 Dec;13 Suppl 4:156–65 (50 ref.)

Perspective on the clinical laboratory: new uses for informatics. McPherson RA. **J Clin Lab Anal** 1999; 13(2):53–8 (14 ref.)

In situ transmission electron microscopy employed for studies of effects of ion and electron irradiation on materials. Allen CW, et al. **Microsc Res Tech** 1998 Aug 15;42(4):255–9 (16 ref.)

[Surveillance of multiresistant bacteria: justification, role of the laboratory, indicators, and recent French data] Marty L, et al. **Pathol Biol (Paris)** 1998 Apr;46(4):217–26 (20 ref.) (Eng. Abstr.) (Fre)

["The consultation lab"—training clinical communication] Larsen JH, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10; 119(1):52–5 (18 ref.) (Eng. Abstr.) (Nor)

[The management and information technology applicable to clinical microbiology laboratories] Brezmes Valdivieso MF, et al. **Enferm Infecc Microbiol Clin** 1999 May; 17(5):231–41 (65 ref.) (Spa)

LEGISLATION & JURISPRUDENCE

Juries and crime labs: correcting the weak links in the DNA chain. McDonald R. **Am J Law Med** 1998;24(2–3):345–63 (178 ref.)

Health Care Financing Administration/clinical laboratory improvement amendments of 1988. Wanamaker V. **Arch Pathol Lab Med** 1999 Jun;123(6):478–81 (8 ref.)

ORGANIZATION & ADMINISTRATION

Laboratory medicine: the need for a broader view the "multiple bundle" model of clinical laboratory function. Dominiczak MH. **Clin Chem Lab Med** 1999 Feb; 37(2):97–100 (15 ref.)

Animal facility design. Rahija R. **Occup Med** 1999 Apr–Jun; 14(2):407–22 (36 ref.)

STANDARDS

Are we failing in molecular genetic testing? [editorial; comment] Robinson RA. **Am J Clin Pathol** 1999 Jul; 112(1):11–3 (7 ref.) Comment on: Am J Clin Pathol 1999 Jul;112(1):14–21.

Clinical microbiology quality assurance program: a Taiwan experience. Tsai WC, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 May;28(2):95–108 (31 ref.)

Progress in methodology and standards in European molecular genetics laboratories. Carracedo A, et al. **Clin Chim Acta** 1998 Dec;278(2):163–9 (4 ref.)

Protection of personnel and environment against Creutzfeldt–Jakob disease in pathology laboratories. Richard M, et al. **Clin Exp Pathol** 1999;47(3–4):192–200 (23 ref.)

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Wahl RA, et al. **Curr Opin Pediatr** 1998 Dec;10(6):641–50 (78 ref.)

Biosafety considerations in handling medically important fungi. Padhye AA, et al. **Med Mycol** 1998;36 Suppl 1:258–65 (28 ref.)

A general guide for conducting in-process inspections. Massari C. **Qual Assur** 1998 Apr–Jun;6(2):97–105 (2 ref.)

[Determination of the international normalized ratio (INR)] Sousa SR. **Acta Med Port** 1998 Aug–Sep;11(8–9):773–7 (29 ref.) (Eng. Abstr.) (Por)

[Accreditation and certification of clinical laboratories] Panadero MT. **Sangre (Barc)** 1999 Jun;44(3):231–5 (23 ref.) (Spa)

TRENDS

The molecular pathology laboratory of the 21st century. Kiechle FL, et al. **Ann Clin Lab Sci** 1999 Jan–Mar; 29(1):59–77 (134 ref.)

Technology that will initiate future revolutionary changes in healthcare and the clinical laboratory. Nakamura RM. **J Clin Lab Anal** 1999;13(2):49–52 (23 ref.)

LABORATORIES, HOSPITAL

Laboratory role in the management of hospital acquired infections. Wilson MP, et al. **J Hosp Infect** 1999 May; 42(1):1–6 (25 ref.)

STANDARDS

Differential diagnosis of monoclonal gammopathies. Alexanian R, et al. **Arch Pathol Lab Med** 1999 Feb; 123(2):108–13 (16 ref.)

Introduction to the report of the consensus conference on monoclonal gammopathies. Goeken JA, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):104–5 (4 ref.)

Evaluation of cryoglobulins. Kallemuchikkal U, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):119–25 (45 ref.)

Procedures for the evaluation of monoclonal immunoglobulins. Keren DF. **Arch Pathol Lab Med** 1999 Feb;123(2):126–32 (18 ref.)

Sequence of testing for monoclonal gammopathies. Kyle RA. **Arch Pathol Lab Med** 1999 Feb;123(2):114–8 (17 ref.)

The pathologic obsession with turnaround time in gynecologic cytology: is it warranted? [editorial] Yu GH, et al. **Diagn Cytopathol** 1998 Nov;19(5):321–2 (5 ref.)

Improving the utilization of clinical laboratory tests. Wu AH. **J Eval Clin Pract** 1998 Aug;4(3):171–81 (43 ref.)

LABORATORY ANIMAL TECHNOLOGISTS see **ANIMAL TECHNICIANS**

LABORATORY ANIMALS see **ANIMALS, LABORATORY**

LABORATORY DIAGNOSIS see **LABORATORY TECHNIQUES AND PROCEDURES**

LABORATORY INFECTION

PREVENTION & CONTROL

Biosafety considerations in handling medically important fungi. Padhye AA, et al. **Med Mycol** 1998;36 Suppl 1:258–65 (28 ref.)

Mycobacteria. General culture methodology and safety considerations. Allen BW. **Methods Mol Biol** 1998; 101:15–30 (48 ref.)

[Safety measures for handling laboratory specimen and patients with Creutzfeldt-Jakob disease] Van Everbroeck B, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1511–4 (24 ref.) (Eng. Abstr.) (Dut)

TRANSMISSION

Nosocomial and laboratory-acquired infection with Escherichia coli O157. Coia JE. **J Hosp Infect** 1998 Oct; 40(2):107–13 (39 ref.)

LABORATORY INFORMATION SYSTEMS see **CLINICAL LABORATORY INFORMATION SYSTEMS**

LABORATORY MARKERS see **BIOLOGICAL MARKERS**

LABORATORY PERSONNEL

Protection of personnel and environment against Creutzfeldt–Jakob disease in pathology laboratories. Richard M, et al. **Clin Exp Pathol** 1999;47(3–4):192–200 (23 ref.)

Tuberculosis acquired in laboratories and necropsy rooms. Collins CH, et al. **Commun Dis Public Health** 1999 Sep; 2(3):161–7 (100 ref.)

[Role of the laboratory scientist in the diagnosis and treatment of acute lymphoblastic leukemia in children] Fournier M, et al. **Ann Biol Clin (Paris)** 1998 May–Jun; 56(3):343–7 (17 ref.) (Fre)

LABORATORY TECHNICIANS see **LABORATORY PERSONNEL**

LABORATORY TECHNIQUES AND PROCEDURES

see related
TECHNOLOGY, MEDICAL LABORATORY

Fundamentals and applications of pharmacogenetics for the clinical laboratory. Linder MW, et al. **Ann Clin Lab Sci** 1999 Apr–Jun;29(2):140–9 (24 ref.)

Clastogenic factors: biomarkers of oxidative stress of potential utility in the clinical chemistry laboratory. Liu TZ, et al. **Ann Clin Lab Sci** 1999 Apr–Jun;29(2):134–9 (42 ref.)

The integration of molecular diagnostic methods into the clinical laboratory. Mulcahy GM. **Ann Clin Lab Sci** 1999 Jan–Mar;29(1):43–54 (84 ref.)

Evaluating serum alpha–tocopherol (vitamin E) in terms of a lipid ratio. Winbauer AN, et al. **Ann Clin Lab Sci** 1999 Jul–Sep;29(3):185–91 (16 ref.)

Acute phase proteins: clinical and laboratory diagnosis. A review. Pedrazzi AH. **Ann Pharm Fr** 1998;56(3):108–14 (22 ref.)

Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Jayasena SD. **Clin Chem** 1999 Sep;45(9):1628–50 (181 ref.)

Maximizing efficacy of endocrine tests: importance of decision-focused testing strategies and appropriate patient preparation. Klee GG. **Clin Chem** 1999 Aug;45(8 Pt 2):1323–30 (42 ref.)

Physiopathology of proteinuria and laboratory diagnostic strategy based on single protein analysis. Guder WG, et al. **Clin Chem Lab Med** 1998 Dec;36(12):935–9 (25 ref.)

Improved laboratory test selection and enhanced perception of test results as tools for cost–effective medicine. Mayer M, et al. **Clin Chem Lab Med** 1998 Sep;36(9):683–90 (40 ref.)

Laboratory diagnosis of visceral leishmaniasis. Shahi SK, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):361–72 (73 ref.)

Pseudohypoparathyroidism: from bedside to bench and back. Levine MA. **J Bone Miner Res** 1999 Aug;14(8):1255–60 (70 ref.)

Overview of ligand–receptor binding techniques. Qume M. **Methods Mol Biol** 1999;106:3–23 (20 ref.)

Methodological issues relating to the measurement of food, energy and nutrient intake in human laboratory-based studies. Stubbs RJ, et al. **Proc Nutr Soc** 1998 Aug; 57(3):357–72 (115 ref.)

Laboratory diagnosis of the thrombophilic state in cancer patients. Gouin-Thibault I, et al. **Semin Thromb Hemost** 1999;25(2):167–72 (47 ref.)

Laboratory diagnosis of hereditary thrombophilia. Michiels JJ, et al. **Semin Thromb Hemost** 1998;24(4):309–20 (65 ref.)

Laboratory support for the poisoned patient. Watson ID. **Ther Drug Monit** 1998 Oct;20(5):490–7 (27 ref.)

[Value of laboratory findings in the diagnosis of hypereosinophilia] Magnaval JF. **Med Trop (Mars)** 1998; 58(4 Suppl):493–8 (63 ref.) (Eng. Abstr.) (Fre)

[Laboratory tests and clinical practice: from diagnosis of an inflammatory syndrome to colon cancer screening] Gulbis B. **Rev Med Brux** 1998 Sep;19(4):A248–51 (15 ref.) (Eng. Abstr.) (Fre)

[Appropriate use of clinical tests in health-insurance managed medical care] Mori M. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1985–92 (4 ref.) (Jpn)

[Laboratory diagnosis as part of the clinical support system] Shimetani N. **Rinsho Byori** 1999 Feb;Suppl 109:81–90 (8 ref.) (Jpn)

[Blood culture: gold standard for definitive diagnosis of bacterial and fungal infections—from the laboratory aspect] Yamane N. **Rinsho Byori** 1998 Sep;46(9):887–92 (7 ref.) (Eng. Abstr.) (Jpn)

STANDARDS

Quality requirements and control: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul–Aug;19(4A):2791–4 (12 ref.)

Tumour markers in germ cell cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul–Aug;19(4A):2795–8 (18 ref.)

Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.

Anticancer Res 1999 Jul-Aug;19(4A):2799-801 (40 ref.)
Tumour markers in breast cancer--EGTM recommendations. European Group on Tumor Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2803-5 (41 ref.)
Tumour markers in gynaecological cancers--EGTM recommendations. European Group on Tumor Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2807-10 (27 ref.)
Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2811-5 (39 ref.)
Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2817-9 (24 ref.)
Compostable packaging materials--test methods and limit values for biodegradation. Pagga U. **Appl Microbiol Biotechnol** 1999 Feb;51(2):125-33 (35 ref.)
Selection of protocols for value assignment. Johnson AM. **Clin Biochem** 1998 Aug;31(6):447-8 (4 ref.)
The role of laboratory investigations in identifying body fluids. Murphy M. **Hosp Med** 1999 Apr;60(4):281-4 (15 ref.)
[Concept of quality assurance and its practice] Hosogaya S, et al. **Rinsho Byori** 1999 Feb;Suppl 109:72-80 (21 ref.) **(Jpn)**
[Data interpretation for clinical support] Matsuo S. **Rinsho Byori** 1999 Feb;Suppl 109:91-102 (11 ref.) **(Jpn)**

TRENDS

The new millennium in laboratory automation. Gochman N, et al. **Ann Clin Lab Sci** 1999 Apr-Jun;29(2):104-5 (4 ref.)
Tuberculosis in the 1990's: From bedside to bench and back. Jamieson FB, et al. **Can Respir J** 1999 Jul-Aug;6(4):341-4 (15 ref.)
Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Ostrea EM Jr. **Curr Probl Pediatr** 1999 Feb;29(2):37-56 (86 ref.)
[Point-of-care-testing--the intensive care laboratory] Müller MM, et al. **Anaesthesist** 1999 Jan;48(1):3-8 (14 ref.) (Eng. Abstr.) **(Ger)**
[Clinical chemistry in laboratory medicine in Europe. The past, present, and future] Guder W, et al. **Klin Lab Diagn** 1998 Oct;(10):35-40 (21 ref.) **(Rus)**

UTILIZATION

Improving the utilization of clinical laboratory tests. Wu AH. **J Eval Clin Pract** 1998 Aug;4(3):171-81 (43 ref.)

VETERINARY

Standardization of diagnostic assays for animal acute phase proteins. Eckersall PD, et al. **Adv Vet Med** 1999;41:643-55 (41 ref.)

LABYRINTH

see related
ENDOLYMPH

ABNORMALITIES

Single gene influences on radiologically-detectable malformations of the inner ear. Smith SD, et al. **J Commun Disord** 1998 Sep-Oct;31(5):391-408; quiz 409-10 (60 ref.)
[A report of two familial cases of Michel syndrome (bilateral agenesis of the inner ear)] Ghazli K, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Feb;115(1):29-34 (11 ref.) (Eng. Abstr.) **(Fre)**
[MRI in progressive sensorineural hearing loss] Ferrara P, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):80-6 (26 ref.) (Eng. Abstr.) **(Ita)**

ANATOMY & HISTOLOGY

Comparative review of the human bony labyrinth. Spoor F, et al. **Am J Phys Anthropol** 1998;Suppl 27:211-51 (128 ref.)
Tympanoplasty: prudent considerations of silent otitis media and interactions of middle ear and inner ear. Vambutas A, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):505-12 (29 ref.)

DRUG EFFECTS

[Chemical labyrinthectomy: results and applications] Mondain M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115(4):234-42 (40 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The mammalian aquaporin water channel family: A promising new drug target. Beitz E, et al. **Curr Med Chem** 1999 Jun;6(6):457-67 (39 ref.)
Vestibular and hearing loss in genetic and metabolic disorders. Gasparini P, et al. **Curr Opin Neurol** 1999 Feb; 12(1):35-9 (32 ref.)
Gap junctions and connexin expression in the inner ear. Forge A, et al. **Novartis Found Symp** 1999;219:134-50; discussion 151-6 (46 ref.)

PATHOLOGY

[Bone neogenesis in a rare space-occupying lesion of the inner ear canal] Relic A, et al. **HNO** 1999 Jun;47(6):563-8 (39 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Gap junctions and connexin expression in the inner ear. Forge A, et al. **Novartis Found Symp** 1999;219:134-50; discussion 151-6 (46 ref.)
[Recent experimental and clinical findings retarding an interlabyrinthine connection] Schreiner L. **Laryngorhinootologie** 1999 Jul;78(7):387-93 (47 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Molecular mechanisms of vestibular compensation in the central vestibular system--review. Kitahara T, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:19-27 (59 ref.)

LABYRINTH DISEASES

Lipomas of the internal auditory canal and cerebellopontine angle. Bigelow DC, et al. **Laryngoscope** 1998 Oct; 108(10):1459-69 (52 ref.)

DIAGNOSIS

A critical appraisal of spontaneous perilymphatic fistulas of the inner ear. Friedland DR, et al. **Am J Otol** 1999 Mar; 20(2):261-76; discussion 276-9 (135 ref.)
Slow-growing labyrinthine masses: contribution of MRI to diagnosis, follow-up and treatment. Deux JF, et al. **Neuroradiology** 1998 Oct;40(10):684-9 (21 ref.)
[Benign paroxysmal positional vertigo (see comments)] van der Plas JP, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5; 142(49):2669-74 (25 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 30;143(5):276. **(Dut)**
[Osteoma of the internal auditory canal. Presentation of a case and review of the bibliography] Torres-Valenzuela A. **Gac Med Mex** 1998 May-Jun;134(3):355-7 (9 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

What you need to know--hearing loss and inner ear diseases--can they be cured? Ruan RS, et al. **Singapore Med J** 1999 Jan;40(1):60-1 (5 ref.)

ETIOLOGY

Labyrinthine involvement in Langerhans' cell histiocytosis. Nanduri VR, et al. **Int J Pediatr Otorhinolaryngol** 1998 Nov 15;46(1-2):109-15 (18 ref.)

PHYSIOPATHOLOGY

The interaction of otolith and proprioceptive information in the perception of verticality. The effects of labyrinthine and CNS disease. Bronstein AM. **Ann N Y Acad Sci** 1999 May 28;871:324-33 (25 ref.)

THERAPY

[Benign paroxysmal positional vertigo (see comments)] van der Plas JP, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5; 142(49):2669-74 (25 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 30;143(5):276. **(Dut)**

LAC GENE see **LAC OPERON**

LAC OPERON

The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Krüger A, et al. **Cancer Metastasis Rev** 1998-99;17(3):285-94 (35 ref.)
Visualization of large-scale chromatin structure and dynamics using the lac operator/lac repressor reporter system. Belmont AS, et al. **Methods Cell Biol** 1999; 58:203-22 (29 ref.)

LAC REPRESSORS see **REPRESSOR PROTEINS**

LACHESIS see **VIPERIDAE**

LACRIMAL APPARATUS

see related
DACRYOCYSTORHINOSTOMY
TEARS
[Lacrimal gland ectopia--a clinical case] Cătălin C, et al. **Oftalmologia** 1998;42(2):68-70 (10 ref.) (Eng. Abstr.) **(Rum)**

ABNORMALITIES

Computed tomography of the lacrimal drainage system: retrospective study of 107 cases of dacryostenosis. Francis IC, et al. **Ophthal Plast Reconstr Surg** 1999 May; 15(3):217-26 (68 ref.)

METABOLISM

Fas (APO-1/CD95)-assisted suicide in NOD exocrine glands [editorial; comment] Elkon KB. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):659-61 (23 ref.) Comment on: Clin Exp Rheumatol 1998 Nov-Dec;16(6):659-61.

PATHOLOGY

The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Stern ME, et al. **Cornea** 1998 Nov;17(6):584-9 (49 ref.)

RADIOGRAPHY

Computed tomography of the lacrimal drainage system: retrospective study of 107 cases of dacryostenosis. Francis IC, et al. **Ophthal Plast Reconstr Surg** 1999 May; 15(3):217-26 (68 ref.)

SURGERY

Punctal occlusion [editorial] Cohen EJ. **Arch Ophthalmol** 1999 Mar;117(3):389-90 (9 ref.)

LACRIMAL APPARATUS DISEASES

DIAGNOSIS

Lacrimal gland tumors and simulating lesions. Clinicopathologic and MR imaging features. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):219-39, xii (58 ref.)

ETIOLOGY

Ethmoid sinus osteoma presenting as epiphora and orbital cellulitis: case report and literature review. Mansour AM, et al. **Surv Ophthalmol** 1999 Mar-Apr;43(5):413-26 (128 ref.)

PATHOLOGY

Hemangiopericytoma of the lacrimal sac. Charles NC, et al. **Arch Ophthalmol** 1998 Dec;116(12):1677-80 (17 ref.)
Oncocytic adenomatous hyperplasia of the lacrimal sac: a case report and review of the literature. Chen LJ, et al. **Ophthal Plast Reconstr Surg** 1998 Nov;14(6):436-40 (28 ref.)
Kimura disease of the orbit and ocular adnexa. Buggage RR, et al. **Surv Ophthalmol** 1999 Jul-Aug;44(1):79-91 (41 ref.)
Squamous cell carcinoma of the lacrimal drainage system: case report and literature review. De Stefani A, et al. **Tumori** 1998 Jul-Aug;84(4):506-10 (19 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of dacryocystocele: a possible marker for syndromes. Sharony R, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):71-3 (14 ref.)

LACRIMAL DUCT OBSTRUCTION

CHEMICALLY INDUCED

Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Lee V, et al. **Eye** 1998;12 (Pt 3a):343-9 (23 ref.)

RADIOGRAPHY

Computed tomography of the lacrimal drainage system: retrospective study of 107 cases of dacryostenosis. Francis IC, et al. **Ophthal Plast Reconstr Surg** 1999 May; 15(3):217-26 (68 ref.)

SURGERY

There is no use crying over spilt tears: the surgical management of primary acquired nasolacrimal duct obstruction. Rosser PM. **Aust N Z J Ophthalmol** 1999 Apr; 27(2):95-100 (39 ref.)
Endocanalicular Nd: YAG laser dacryocystorhinostomy. Fay AM, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):177-84 (18 ref.)
[Value of external dacryocystorhinostomy (editorial)] Struck HG. **Klin Monatsbl Augenheilkd** 1999 Jul;215(1):1-3 (31 ref.) (Eng. Abstr.) **(Ger)**

LACRIMAL GLAND see **LACRIMAL APPARATUS**

LACROSSE see **RACQUET SPORTS**

LACTALBUMIN

CHEMISTRY

Chimeras of human lysozyme and alpha-lactalbumin: an interesting tool for studying partially folded states during protein folding. Van Dael H. **Cell Mol Life Sci** 1998 Nov; 54(11):1217-30 (104 ref.)

METABOLISM

Influence of feeding alkaline/heat processed proteins on growth and protein and mineral status of rats. Sarwar G, et al. **Adv Exp Med Biol** 1999;459:161-77 (29 ref.)

LACTAMS

ADVERSE EFFECTS

Beta-lactam crossreactivity. Adkinson NF Jr. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:37-40 (20 ref.)
New aspects in betalactam recognition. Torres MJ, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:25-8 (44 ref.)

LACTAMS

CHEMICAL SYNTHESIS

Synthetic strategies and medicinal properties of beta-lactams. Kidwai M, et al. **Curr Med Chem** 1999 Mar;6(3):195-215 (130 ref.)

CHEMISTRY

From beta-lactams to alpha- and beta-amino acid derived peptides. Palomo C, et al. **Amino Acids** 1999;16(3-4):321-43 (94 ref.)

'In vivo' models of hapten generation. Bolzacchini E, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:83-6 (11 ref.)

IMMUNOLOGY

Beta-lactam crossreactivity. Adkinson NF Jr. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:37-40 (20 ref.)

LACTASES see **BETA-GALACTOSIDASE**

LACTATE see **LACTIC ACID**

LACTATE DEHYDROGENASE

BLOOD

Cardiac biomarkers: past, present, and future [see comments] Adams JE 3rd, et al. **Am J Crit Care** 1998 Nov;7(6):418-23; quiz 424-5 (11 ref.) Comment in: Am J Crit Care 1999 May;8(3):204.

Antioxidant status in patients with acute respiratory distress syndrome [editorial; comment] Koch T. **Intensive Care Med** 1999 Feb;25(2):134-6 (18 ref.) Comment on: Intensive Care Med 1999 Feb;25(2):180-5.

DEFICIENCY

[Analysis of hereditary enzyme abnormalities] Sudo K, et al. **Rinsho Byori** 1999 Feb;Suppl 109:168-78 (13 ref.) **(Jpn)**

LACTATE DEHYDROGENASE ISOENZYMES

BLOOD

[Analysis of abnormal enzyme activities--with special reference to LD] Fujita K. **Rinsho Byori** 1999 Feb;Suppl 109:140-9 (21 ref.) **(Jpn)**

DEFICIENCY

A novel in-frame deletion mutation in a case of lactate dehydrogenase (LD) H subunit deficiency showing an atypical LD isoenzyme pattern in serum and erythrocytes. Sudo K, et al. **Clin Biochem** 1999 Mar;32(2):137-41 (8 ref.)

GENETICS

A novel in-frame deletion mutation in a case of lactate dehydrogenase (LD) H subunit deficiency showing an atypical LD isoenzyme pattern in serum and erythrocytes. Sudo K, et al. **Clin Biochem** 1999 Mar;32(2):137-41 (8 ref.)

LACTATE DEHYDROGENASE ISOZYMES see **LACTATE DEHYDROGENASE ISOENZYMES**

LACTATES

METABOLISM

Lactate transport in skeletal muscle - role and regulation of the monocarboxylate transporter. Juel C, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):633-42 (65 ref.)

[Lactate metabolism and lactic acidosis] Kawanishi K, et al. **Rinsho Byori** 1998 Aug;46(8):804-12 (16 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Safety assessment of lactate esters. Clary JJ, et al. **Regul Toxicol Pharmacol** 1998 Apr;27(2):88-97 (67 ref.)

LACTATION

see related
BREAST FEEDING
MILK
MILK, HUMAN

Treatment for lactation suppression: little progress in one hundred years. Spitz AM, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1485-90 (26 ref.)

An evaluation of postabsorptive protein and amino acid metabolism in the lactating dairy cow. Hanigan MD, et al. **J Dairy Sci** 1998 Dec;81(12):3385-401 (84 ref.)

Clostridium difficile-associated disease. Implications for midwifery practice. Alef K. **J Nurse Midwifery** 1999 Jan-Feb;44(1):19-29 (132 ref.)

Herbs and the childbearing woman. Guidelines for midwives. Belew C. **J Nurse Midwifery** 1999 May-Jun;44(3):231-52 (103 ref.)

Homeopathy. A theoretical framework and clinical application. Castro M. **J Nurse Midwifery** 1999 May-Jun; 44(3):280-90 (24 ref.)

METABOLISM

Essential fatty acid requirements of vegetarians in pregnancy, lactation, and infancy. Sanders TA. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):555S-559S (28 ref.)

PHYSIOLOGY

Physiology of lactation. Neville MC. **Clin Perinatol** 1999 Jun; 26(2):251-79, v (116 ref.)

Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options? Broussard CN, et al. **Drug Saf** 1998 Oct;19(4):325-37 (70 ref.)

Pregnancy and lactation in relation to range of acceptable carbohydrate and fat intake. Catalano PM. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S124-31; discussion S131-5 (45 ref.)

Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. Bequette BJ, et al. **J Dairy Sci** 1998 Sep;81(9):2540-59 (116 ref.)

Variability in delivery of nutrients to lactating dairy cows. Kertz AF. **J Dairy Sci** 1998 Nov;81(11):3075-84 (47 ref.)

Mammary involution in dairy animals. Capuco AV, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):137-44 (38 ref.)

Transcription factor activities and gene expression during mouse mammary gland involution. Marti A, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):145-52 (53 ref.)

Control of milk secretion and apoptosis during mammary involution. Wilde CJ, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):129-36 (53 ref.)

Factorial calculation of nutrient requirements in lactating queens. Kienzle E. **J Nutr** 1998 Dec;128(12 Suppl):2609S-2614S (32 ref.)

Relationship between overfeeding and overconditioning in the dry period and the problems of high producing dairy cows during the postparturient period. Rukkwamsuk T, et al. **Vet Q** 1999 Jun;21(3):71-7 (125 ref.)

[Maternal elimination diet during pregnancy and lactation, and the development of allergies in infants] Oldak E. **Pol Merkuriusz Lek** 1998 Dec;5(30):387-9 (29 ref.) (Eng. Abstr.) **(Pol)**

LACTATION DISORDERS

Slow weight gain and low milk supply in the breastfeeding dyad. Powers NG. **Clin Perinatol** 1999 Jun;26(2):399-430 (76 ref.)

ETHNOLOGY

Relief of breast engorgement for the Sabbath-observant Jewish woman. Chertok I. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):365-9 (13 ref.)

NURSING

Relief of breast engorgement for the Sabbath-observant Jewish woman. Chertok I. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):365-9 (13 ref.)

VETERINARY

Loss in milk yield and related composition changes resulting from clinical mastitis in dairy cows. Hortet P, et al. **Prev Vet Med** 1998 Dec 1;37(1-4):1-20 (66 ref.)

LACTATION, PROLONGED see **LACTATION**

LACTIC ACID

Orthopaedic applications for PLA-PGA biodegradable polymers. Athanasiou KA, et al. **Arthroscopy** 1998 Oct; 14(7):726-37 (95 ref.)

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Lima KM, et al. **Braz J Med Biol Res** 1999 Feb;32(2):171-80 (63 ref.)

Something new in the field of PLA/GA bioresorbable polymers? Vert M, et al. **J Controlled Release** 1998 Apr 30;53(1-3):85-92 (16 ref.)

[Current status and trends of guided tissue regeneration materials] Zhang Q, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):365-8 (28 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov-Dec; 15(6):699-713 (28 ref.)

BIOSYNTHESIS

Brain anaerobic lactate production: a suicide note or a survival kit? Schurr A, et al. **Dev Neurosci** 1998; 20(4-5):348-57 (64 ref.)

BLOOD

Lactate in sepsis and trauma--hindrance or help? Sladen RN. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):237-8 (14 ref.)

Lactate and pHi: our continued search for markers of tissue distress [editorial; comment] Kellum JA. **Crit Care Med** 1998 Nov;26(11):1783-4 (19 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1850-6.

Unmeasured anions: déjà vu all over again? [editorial] [comment] Zaritsky A. **Crit Care Med** 1999 Aug; 27(8):1672-3 (8 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1577-81.

Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. James JH, et al. **Lancet** 1999 Aug 7; 354(9177):505-8 (47 ref.)

Role of lactate measurements during labor. Westgren M, et al. **Obstet Gynecol Surv** 1999 Jan;54(1):43-8 (40 ref.)

Interpretation of lactate levels in critical illness. Pinder M, et al. **S Afr J Surg** 1998 Aug;36(3):93-6 (34 ref.)

[Lactate for assessing physical performance, load capacity and monitoring of training] Jeschke D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):234-6 (6 ref.) **(Ger)**

[Clinical evaluation and methodological aspects of serum lactate] Mertzlufft F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):226-33 (31 ref.) **(Ger)**

CHEMISTRY

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov-Dec; 15(6):699-713 (28 ref.)

METABOLISM

Energy metabolism in critically ill patients: lactate is a major oxidizable substrate. Leverve XM. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):165-9 (63 ref.)

[Lactate as an indicator of ischemic-traumatic brain injury] Metz C. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):239-43 (25 ref.) **(Ger)**

PHARMACOLOGY

Integrating microbial decontamination with organic acids in HACCP programmes for muscle foods: prospects and controversies. Smulders FJ, et al. **Int J Food Microbiol** 1998 Nov 10;44(3):149-69 (133 ref.)

LACTIC ACIDOSIS see **ACIDOSIS, LACTIC**

LACTIC CYTOCHROME REDUCTASE see **LACTATE DEHYDROGENASE**

LACTOBACILLACEAE

PHYSIOLOGY

Lactic acid bacteria and the human gastrointestinal tract. Hove H, et al. **Eur J Clin Nutr** 1999 May;53(5):339-50 (120 ref.)

LACTOBACILLUS

DRUG EFFECTS

Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. Gibson GR. **J Nutr** 1999 Jul;129(7 Suppl):1438S-41S (22 ref.)

ENZYMOLOGY

The function of adenosylcobalamin in the mechanism of ribonucleoside triphosphate reductase from Lactobacillus leichmannii. Lawrence CC, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):650-5 (33 ref.)

GENETICS

Gene expression systems for lactic acid bacteria. de Vos WM. **Curr Opin Microbiol** 1999 Jun;2(3):289-95 (68 ref.)

IMMUNOLOGY

[Immunostimulating action of lactobacteria used as the basis of probiotic preparations] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):107-12 (57 ref.) **(Rus)**

METABOLISM

Heteropolysaccharides from lactic acid bacteria. De Vuyst L, et al. **FEMS Microbiol Rev** 1999 Apr;23(2):153-77 (145 ref.)

PATHOGENICITY

Safety of industrial lactic acid bacteria. Adams MR. **J Biotechnol** 1999 Feb 19;68(2-3):171-8 (25 ref.)

PHYSIOLOGY

Probiotic spectra of lactic acid bacteria (LAB). Naidu AS, et al. **Crit Rev Food Sci Nutr** 1999 Jan;39(1):13-126 (490 ref.)

LACTOBACILLUS ACIDOPHILUS

IMMUNOLOGY

[The role of Lactobacillus acidophilus in the prevention and adjuvant therapy of certain infectious diseases] Halmy C, et al. **Orv Hetil** 1998 Sep 27;139(39):2313-8 (43 ref.) (Eng. Abstr.) **(Hun)**

LACTOCOCCUS

PATHOGENICITY

Safety of industrial lactic acid bacteria. Adams MR. **J Biotechnol** 1999 Feb 19;68(2-3):171-8 (25 ref.)

LACTOCOCCUS LACTIS

METABOLISM

Heterologous protein secretion in Lactococcus lactis: a novel antigen delivery system. Langella P, et al. **Braz J Med Biol Res** 1999 Feb;32(2):191-8 (24 ref.)

LACTOFERRIN

Structures of buffalo and mare lactoferrins. Similarities, differences, and flexibility. Sharma AK, et al. **Adv Exp Med Biol** 1998;443:15-21 (8 ref.)

ADMINISTRATION & DOSAGE

Host defensive effects of orally administered bovine lactoferrin. Tomita M, et al. **Adv Exp Med Biol** 1998; 443:189-97 (54 ref.)

CHEMISTRY

Three-dimensional structure of lactoferrin. Implications for function, including comparisons with transferrin. Baker EN, et al. **Adv Exp Med Biol** 1998;443:1-14 (32 ref.)

DEFICIENCY

[Neutrophil lactoferrin deficiency] Shinozaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):70-2 (12 ref.) **(Jpn)**

GENETICS

Cloning of human genomic lactoferrin sequence and expression in the mammary glands of transgenic animals. Kim SJ, et al. **Adv Exp Med Biol** 1998;443:79-83 (23 ref.)

Regulation of lactoferrin gene expression by estrogen and epidermal growth factor: molecular mechanism. Teng CT. **Cell Biochem Biophys** 1999;31(1):49-64 (66 ref.)

METABOLISM

Three-dimensional structure of lactoferrin. Implications for function, including comparisons with transferrin. Baker EN, et al. **Adv Exp Med Biol** 1998;443:1-14 (32 ref.)

The LDL-receptor family. Lactoferrin and lipid metabolism. Huettinger M, et al. **Adv Exp Med Biol** 1998;443:107-11 (20 ref.)

Glycation ligand binding motif in lactoferrin. Implications in diabetic infection. Li YM. **Adv Exp Med Biol** 1998; 443:57-63 (25 ref.)

Lactoferrin secretion into mouse milk. Development of secretory activity, the localization of lactoferrin in the secretory pathway, and interactions of lactoferrin with milk iron. Neville MC, et al. **Adv Exp Med Biol** 1998;443:141-53 (39 ref.)

The antibacterial activity of lactoferrin and neonatal E. coli infections. A selective and critical review. Reiter B, et al. **Adv Exp Med Biol** 1998;443:175-88 (49 ref.)

Bacterial lactoferrin receptors. Schryvers AB, et al. **Adv Exp Med Biol** 1998;443:123-33 (31 ref.)

Immunohistochemical demonstration of lactoferrin in human neoplastic tissues. Tuccari G, et al. **Adv Exp Med Biol** 1998; 443:337-40 (22 ref.)

The main systemic, highly effective, and quickly acting antimicrobial mechanisms generated by lactoferrin in mammals in vivo. Activity in health and disease. Zagulski T, et al. **Adv Exp Med Biol** 1998;443:247-50 (28 ref.)

PHARMACOLOGY

Antiviral activity of lactoferrin. Valenti P, et al. **Adv Exp Med Biol** 1998;443:199-203 (31 ref.)

PHYSIOLOGY

Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Baveye S, et al. **Clin Chem Lab Med** 1999 Mar;37(3):281-6 (54 ref.)

SECRETION

Lactoferrin secretion into mouse milk. Development of secretory activity, the localization of lactoferrin in the secretory pathway, and interactions of lactoferrin with milk iron. Neville MC, et al. **Adv Exp Med Biol** 1998;443:141-53 (39 ref.)

THERAPEUTIC USE

The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Kruzel ML, et al. **Adv Exp Med Biol** 1998;443:167-73 (38 ref.)

Antiviral activity of lactoferrin. Valenti P, et al. **Adv Exp Med Biol** 1998;443:199-203 (31 ref.)

LACTOGEN HORMONE, PLACENTAL see **PLACENTAL LACTOGEN**

LACTOGENIC HORMONE, PITUITARY see **PROLACTIN**

LACTONES

CHEMICAL SYNTHESIS

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Wender PA, et al. **Med Res Rev** 1999 Sep;19(5):388-407 (80 ref.)

CHEMISTRY

Chemistry and pharmacology of Monimiaceae: a special focus on Siparuna and Mollinedia. Leitão GG, et al. **J Ethnopharmacol** 1999 May;65(2):87-102 (61 ref.)

PHARMACOLOGY

Annonaceous acetogenins: recent progress. Alali FQ, et al. **J Nat Prod** 1999 Mar;62(3):504-40 (138 ref.)

THERAPEUTIC USE

Review article: malnutrition and maltreatment--a comment on orlistat for the treatment of obesity. Cahill A, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):997-1002 (27 ref.)

The war against obesity: attacking a new front [editorial; comment] [see comments] Klein S. **Am J Clin Nutr** 1999 Jun;69(6):1061-3 (13 ref.) Comment on: Am J Clin Nutr 1999 Jun;69(6):1108-16. Comment in: Am J Clin Nutr 1999 Jun;69(6):1059-60.

Orlistat. McNeely W, et al. **Drugs** 1998 Aug;56(2):241-9; discussion 250 (35 ref.)

Modern medical management of obesity: the role of pharmaceutical intervention. Aronne LJ. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S23-6 (14 ref.)

Cutting fat absorption to halt weight gain. Lean M. **Practitioner** 1998 Dec;242(1593):860-5 (5 ref.)

Key developments in endocrinology. Weston PJ. **Practitioner** 1999 Feb;243(1595):83-4, 89-96 (7 ref.)

[Orlistat (Xenical)] Crenier L, et al. **Rev Med Brux** 1999 Jun; 20(3):159-63 (17 ref.) (Eng. Abstr.) **(Fre)**

[Is orlistat medically essential for the treatment of obesity?] Fritze J. **Versicherungsmedizin** 1999 Mar 1;51(1):36-7 (15 ref.) (Eng. Abstr.) **(Ger)**

LACTOSE

ADMINISTRATION & DOSAGE

[Lactose in human nutrition] de Vrese M, et al. **Schweiz Med Wochenschr** 1998 Sep 19;128(38):1393-400 (46 ref.) (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES

Thermal analysis of hydroxypropylmethylcellulose and methylcellulose: powders, gels and matrix tablets. Ford JL. **Int J Pharm** 1999 Mar 15;179(2):209-28 (67 ref.)

GENETICS

Design of gene circuitry by natural selection: analysis of the lactose catabolic system in Escherichia coli. Savageau MA. **Biochem Soc Trans** 1999 Feb;27(2):264-70 (24 ref.)

METABOLISM

Design of gene circuitry by natural selection: analysis of the lactose catabolic system in Escherichia coli. Savageau MA. **Biochem Soc Trans** 1999 Feb;27(2):264-70 (24 ref.)

LACTOSE INTOLERANCE

Overview of lactose maldigestion (lactase nonpersistence). Inman-Felton AE. **J Am Diet Assoc** 1999 Apr;99(4):481-9 (20 ref.)

DIAGNOSIS

Lactose intolerance: problems in diagnosis and treatment. Shaw AD, et al. **J Clin Gastroenterol** 1999 Apr;28(3):208-16 (80 ref.)

[Lactose intolerance in children. An analysis of hydrogen gas in exhaled air simplifies and improves diagnosis] Sarnblad S, et al. **Lakartidningen** 1999 Mar 10;96(10):1180-3 (12 ref.) **(Swe)**

EPIDEMIOLOGY

Racial bias in federal nutrition policy, Part I: The public health implications of variations in lactase persistence. Bertron P, et al. **J Natl Med Assoc** 1999 Mar;91(3):151-7 (52 ref.)

Lactose intolerance and irritable bowel syndrome. Mascolo R, et al. **Nutr Rev** 1998 Oc:;56(10):306-8 (15 ref.)

ETIOLOGY

Lactose intolerance and irritable bowel syndrome. Mascolo R, et al. **Nutr Rev** 1998 Oct;56(10):306-8 (15 ref.)

[Lactose in human nutrition] de Vrese M, et al. **Schweiz Med Wochenschr** 1998 Sep 19;128(38):1393-400 (46 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Review of probiotics available to modify gastrointestinal flora. Gismondo MR, et al. **Int J Antimicrob Agents** 1999 Aug;12(4):287-92 (39 ref.)

Lactose intolerance: problems in diagnosis and treatment. Shaw AD, et al. **J Clin Gastroenterol** 1999 Apr;28(3):208-16 (80 ref.)

LACTOSE MALABSORPTION see **LACTOSE INTOLERANCE**

LACTOYL GLUTATHIONE LYASE see **LACTOYLGLUTATHIONE LYASE**

LACTOYLGLUTATHIONE LYASE

GENETICS

[Mechanism of stress response and gene expression of glyoxalase I in yeast] Inoue Y. **Seikagaku** 1998 Oct; 70(10):1278-83 (18 ref.) **(Jpn)**

METABOLISM

A possible evolutionary role of formaldehyde. Kalapos MP. **Exp Mol Med** 1999 Mar 31;31(1):1-4 (25 ref.)

[Participation of glyoxalases and methylglyoxal in diabetic complication development] Piskorska D, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):342-4 (20 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

On the promine/retine theory of cell division: now and then. Kalapos MP. **Biochim Biophys Acta** 1999 Jan 4;1426(1):1-16 (149 ref.)

LACTULOSE

THERAPEUTIC USE

[Lactulose and the microecology of the large intestine] Maksimov VI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):101-7 (39 ref.) **(Rus)**

LACZ GENES see **LAC OPERON**

LAFORA DISEASE see **EPILEPSY, MYOCLONIC**

LAGENODELPHIS see **DOLPHINS**

LAGENORHYNCHUS see **DOLPHINS**

LAGOTHRIX see **CEBIDAE**

LAKI-LORAND FACTOR see **FACTOR XIII**

LAMBDA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, LAMBDA-CHAIN**

LAMBDA PHAGE see **BACTERIOPHAGE LAMBDA**

LAMBERT-EATON MYASTHENIC SYNDROME

COMPLICATIONS

A malignancy work-up in patients with cancer-associated (paraneoplastic) autoimmune diseases: pemphigus and myasthenic syndromes as cases in point (review). Sherer Y, et al. **Oncol Rep** 1999 May-Jun;6(3):665-8 (48 ref.)

DIAGNOSIS

[Myasthenia gravis with electrophysiological features of Lambert-Eaton myasthenic syndrome: usefulness of serum autoantibodies assay and neuromuscular junction biopsy] Matsumoto R, et al. **Rinsho Shinkeigaku** 1999 May; 39(5):531-7 (25 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome. Takamori M. **Intern Med** 1999 Feb;38(2):86-96 (53 ref.)

IMMUNOLOGY

[Lambert-Eaton myasthenic syndrome] Takamori M. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1903-11 (30 ref.) **(Jpn)**

THERAPY

[Treatment of the paraneoplastic Lambert-Eaton syndrome] Courau E, et al. **Rev Pneumol Clin** 1998 May;54(2):65-70 (36 ref.) (Eng. Abstr.) **(Fre)**

LAMBLIA

LAMBLIA see **GIARDIA**

LAMBLIA INTESTINALIS see **GIARDIA LAMBLIA**

LAMBLIASIS see **GIARDIASIS**

LAMIACEAE

see related
HERBS

METABOLISM

Genetic engineering of essential oil production in mint [see comments] Lange BM, et al. **Curr Opin Plant Biol** 1999 Apr;2(2):139–44 (43 ref.) Comment in: Curr Opin Plant Biol 1999 Apr;2(2):121–2.

LAMINA BASALIS CHOROIDEAE see **BRUCH MEMBRANE**

LAMINAR AIR-FLOW AREAS see **ENVIRONMENT, CONTROLLED**

LAMINECTOMY

Multisegmental cervical spondylotic myelopathy and radiculopathy treated by multilevel oblique corpectomies without fusion. George B, et al. **Neurosurgery** 1999 Jan; 44(1):81–90 (117 ref.)

ADVERSE EFFECTS

Postlaminectomy kyphosis. Albert TJ, et al. **Spine** 1998 Dec 15;23(24):2738–45 (45 ref.)

METHODS

Expansive laminoplasty for myelopathy in ossification of the longitudinal ligament. Hirabayashi K, et al. **Clin Orthop** 1999 Feb;(359):35–48 (100 ref.)

[Acute symptom transverse laminectomy for a benign osteoclastoma of thethoracic spine—case report and review of the literature] Gruber AW, et al. **Zentralbl Neurochir** 1999;60(2):93–9 (18 ref.) (Eng. Abstr.) **(Ger)**

LAMININ

see related
RECEPTORS, LAMININ

CHEMISTRY

Structural and genetic analysis of laminin–nidogen interaction. Mayer U, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:130–42 (21 ref.)

Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579–84 (57 ref.)

Laminin–11. Miner JH, et al. **Int J Biochem Cell Biol** 1999 Aug;31(8):811–6 (20 ref.)

DEFICIENCY

[Muscular dystrophies due to alterations at extracellular space level: congenital muscular dystrophy caused by merosin deficiency] Smeyers P. **Rev Neurol** 1999 Jan 16–31; 28(2):141–9 (88 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Structural and genetic analysis of laminin–nidogen interaction. Mayer U, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:130–42 (21 ref.)

METABOLISM

Velcro in the nuclear envelope: LBR and LAPs. Chu A, et al. **FEBS Lett** 1998 Dec 18;441(2):165–9 (43 ref.)

Laminins of the dermo–epidermal junction. Aumailley M, et al. **Matrix Biol** 1999 Feb;18(1):19–28 (96 ref.)

PHYSIOLOGY

Laminin isoforms and epithelial development. Ekblom M, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:194–211 (68 ref.)

The laminins: role in intestinal morphogenesis and differentiation. Simon–Assmann P, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:46–64 (70 ref.)

The role of laminins in basement membrane function. Aumailley M, et al. **J Anat** 1998 Jul;193 (Pt 1):1–21 (198 ref.)

Role of laminin isoforms in glomerular structure. Hansen K, et al. **Pathobiology** 1999 Mar–Apr;67(2):84–91 (39 ref.)

[Collagen and laminin: which messages for which cells?] Rousselle P, et al. **Pathol Biol (Paris)** 1998 Sep;46(7):543–54 (106 ref.) (Eng. Abstr.) **(Fre)**

[Identification of biologically active sites in laminin an extracellular matrix protein] Nomizu M. **Yakugaku Zasshi** 1998 Dec;118(12):566–80 (57 ref.) (Eng. Abstr.) **(Jpn)**

LAMININ RECEPTORS see **RECEPTORS, LAMININ**

LAMIVUDINE

PHARMACOKINETICS

Clinical pharmacokinetics of lamivudine. Johnson MA, et al. **Clin Pharmacokinet** 1999 Jan;36(1):41–66 (70 ref.)

THERAPEUTIC USE

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Al-Taie OH, et al. **Ann Hematol** 1999 May;78(5):247–9 (18 ref.)

Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Jarvis B, et al. **Drugs** 1999 Jul;58(1):101–41 (279 ref.)

[New management of hepatitis B virus] Sata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):713–7 (14 ref.) **(Jpn)**

LAMPREYS

ANATOMY & HISTOLOGY

The chemoarchitecture of the forebrain of lampreys: evolutionary implications by comparisons with gnathostomes. Weigle C, et al. **Eur J Morphol** 1999 Apr; 37(2–3):122–5 (17 ref.)

EMBRYOLOGY

[Molecular aspects of craniofacial development and evolution: morphogenesis of the jaw apparatus and lamprey embryology] Kuratani S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):226–33 (30 ref.) **(Jpn)**

METABOLISM

Parathyroid hormone-related protein in lower vertebrates. Danks JA, et al. **Clin Exp Pharmacol Physiol** 1998 Sep; 25(9):750–2 (17 ref.)

The chemoarchitecture of the forebrain of lampreys: evolutionary implications by comparisons with gnathostomes. Weigle C, et al. **Eur J Morphol** 1999 Apr; 37(2–3):122–5 (17 ref.)

LANGERHANS-CELL GRANULOMATOSIS see **HISTIOCYTOSIS, LANGERHANS-CELL**

LANGERHANS CELLS

CHEMISTRY

CD44 variant isoforms are essential for the function of epidermal Langerhans cells and dendritic cells. Weiss JM, et al. **Cell Adhes Commun** 1998;6(2–3):157–60 (22 ref.)

DRUG EFFECTS

The effect of neuropeptides/hormones on Langerhans cells. Torii H, et al. **J Dermatol Sci** 1998 May;20(1):21–8 (47 ref.)

IMMUNOLOGY

Immune functions of the human skin. Models of in vitro studies using Langerhans cells. Schmitt D. **Cell Biol Toxicol** 1999 Feb;15(1):41–5 (23 ref.)

Langerhans cells and chemical allergy. Kimber I, et al. **Curr Opin Immunol** 1998 Dec;10(6):614–9 (55 ref.)

Roles of Langerhans cells in genetic immunization. Morita A, et al. **J Dermatol Sci** 1998 May;20(1):39–52 (145 ref.)

METABOLISM

Accessory and adhesion molecules expressed on murine epidermal Langerhans cells and the modulation by cytokines. Nakamura K, et al. **J Dermatol Sci** 1998 May; 20(1):14–20 (50 ref.)

PHYSIOLOGY

Role of cytokines in epidermal Langerhans cell migration. Wang B, et al. **J Leukoc Biol** 1999 Jul;66(1):33–9 (86 ref.)

RADIATION EFFECTS

Langerhans cell responses to ultraviolet B radiation. Kitajima T, et al. **J Dermatol Sci** 1999 Apr;19(3):153–60 (58 ref.)

LANGUAGE

see related
MULTILINGUALISM
SIGN LANGUAGE

Language contrivance on consciousness (and vice versa). Lecours AR. **Adv Neurol** 1998;77:167–79; discussion 179–80 (58 ref.)

A common structure for concepts of individuals, stuffs, and real kinds: more Mama, more milk, and more mouse. Millikan RG. **Behav Brain Sci** 1998 Feb;21(1):55–65; discussion 65–100 (203 ref.)

Can independence be observed in a dependent system? The case of tip-of-the-tongue states. Vinson DP, et al. **Brain Lang** 1999 Jun 1–15;68(1–2):118–26 (10 ref.)

Rethinking eliminative connectionism. Marcus GF. **Cognit Psychol** 1998 Dec;37(3):243–82 (95 ref.)

Is grammar special? Bloom P. **Curr Biol** 1999 Feb 25; 9(4):R127–8 (12 ref.)

Cognition, language and behaviour in motor neurone disease: evidence of frontotemporal dysfunction. Bak TH, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:29–32 (37 ref.)

The relationship between oral and written language [see comments] de Montfort Supple M. **Folia Phoniatr Logop** 1998;50(5):243–55 (86 ref.) Comment in: Folia Phoniatr Logop 1998 ;50(5):239–42.

Neuroimaging studies of brain activation for language, with an emphasis on functional magnetic resonance imaging: a review. Kent RD. **Folia Phoniatr Logop** 1998 Nov–Dec; 50(6):291–304 (77 ref.)

Transcranial magnetic stimulation: language function. Epstein CM. **J Clin Neurophysiol** 1998 Jul;15(4):325–32 (32 ref.)

Improving the health and health care of non-English-speaking patients [editorial; comment] Taira DA. **J Gen Intern Med** 1999 May;14(5):322–3 (13 ref.) Comment on: J Gen Intern Med 1999 May;14(5):303–9.

Why do we speak with the left hemisphere? Capozzoli NJ. **Med Hypotheses** 1999 Jun;52(6):497–503 (18 ref.)

The language of breathlessness. Elliott MW. **Monaldi Arch Chest Dis** 1998 Dec;53(6):664–8 (7 ref.)

On the similarity of odor and language perception. Lorig TS. **Neurosci Biobehav Rev** 1999;23(3):391–8 (60 ref.)

Cognitive integration of language and memory in bilinguals: semantic representation. Francis WS. **Psychol Bull** 1999 Mar;125(2):193–222 (165 ref.)

Understanding the continuum of discrete-trial traditional behavioral to social-pragmatic developmental approaches in communication enhancement for young children with autism/PDD. Prizant BM, et al. **Semin Speech Lang** 1998; 19(4):329–52; quiz 353; 424 (98 ref.)

LANGUAGE ARTS

On the matter of rules. Past-tense formation and its significance for cognitive neuroscience. Pulvermüller F. **Network** 1998 Aug;9(3):R1–52 (94 ref.)

LANGUAGE COMPREHENSION TESTS see **LANGUAGE TESTS**

LANGUAGE DELAY see **LANGUAGE DEVELOPMENT DISORDERS**

LANGUAGE DEVELOPMENT

see related
SPEECH

Influences on infant speech processing: toward a new synthesis. Werker JF, et al. **Annu Rev Psychol** 1999; 50:509–35 (126 ref.)

The frame/content theory of evolution of speech production. MacNeilage PF. **Behav Brain Sci** 1998 Aug;21(4):499–511; discussion 511–46 (456 ref.)

Patterns of acquisition in the emerging mental lexicon: the case of to and for in English. Rice S. **Brain Lang** 1999 Jun 1–15;68(1–2):268–76 (21 ref.)

Linguistic complexity: locality of syntactic dependencies. Gibson E. **Cognition** 1998 Aug;68(1):1–76 (180 ref.)

The study of child language in South Africa [see comments] Penn C. **Folia Phoniatr Logop** 1998;50(5):256–70 (87 ref.) Comment in: Folia Phoniatr Logop 1998 ;50(5):239–42.

Implications of developmental plasticity for the language acquisition of deaf children with cochlear implants. Robinson K. **Int J Pediatr Otorhinolaryngol** 1998 Nov 15; 46(1–2):71–80 (49 ref.)

Rethinking innateness [see comments] Rispoli M. **J Child Lang** 1999 Feb;26(1):217–25 (13 ref.) Comment in: J Child Lang 1999 Feb;26(1):242–5. Comment in: J Child Lang 1999 Feb;26(1):248–53. Comment in: J Child Lang 1999 Feb;26(1):253–60.

Language and the infant brain. Bates E. **J Commun Disord** 1999 Jul–Aug;32(4):195–205 (28 ref.)

From the big bang to the brain. Boliek CA, et al. **J Commun Disord** 1999 Jul–Aug;32(4):271–6 (12 ref.)

Narrowing the distance to language: one step at a time [see comments] Jusczyk PW. **J Commun Disord** 1999 Jul–Aug; 32(4):207–22 (60 ref.) Comment in: J Commun Disord 1999 Jul–Aug;32(4):247–50.

Origins of theory of mind, cognition and communication. Meltzoff AN. **J Commun Disord** 1999 Jul–Aug;32(4):251–69 (78 ref.)

Precursors to speech in infancy: the prediction of speech and language disorders [see comments] Oller DK, et al. **J Commun Disord** 1999 Jul–Aug;32(4):223–45 (47 ref.) Comment in: J Commun Disord 1999 Jul–Aug;32(4):247–50.

What children contribute to language-learning. Goldin-Meadow S. **Sci Prog** 1999;82 (Pt 1):89–102 (24 ref.)

LANGUAGE DEVELOPMENT DISORDERS

Specific developmental disorders. The language-learning continuum. Swank LK. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):89–112, vi (95 ref.)

Understanding childhood language disorders. Rapin I. **Curr Opin Pediatr** 1998 Dec;10(6):561–6 (52 ref.)
Severe developmental disorders and bilingualism. Toppelberg CO, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Sep; 38(9):1197–9 (17 ref.)

DIAGNOSIS

Assessing speech, language and communication. **Paul R**, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr; 8(2):297–322, vii (44 ref.)
Screening for speech and language delay: a systematic review of the literature. Law J, et al. **Health Technol Assess** 1998; 2(9):1–184 (598 ref.)
Screening for primary speech and language delay: a systematic review of the literature. Law J, et al. **Int J Lang Commun Disord** 1998;33 Suppl:21–3 (3 ref.)
Practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. AACAP. **J Am Acad Child Adolesc Psychiatry** 1998 Oct;37(10 Suppl):46S–62S (119 ref.)
Summary of the practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. American Academy of Child and Adolescent Psychiatry] **J Am Acad Child Adolesc Psychiatry** 1998 Oct; 37(10):1117–9 (1 ref.)
Belief term development in children with autism, Asperger syndrome, specific language impairment, and normal development: links to theory of mind development. Ziatas K, et al. **J Child Psychol Psychiatry** 1998 Jul;39(5):755–63 (60 ref.)
Phonological representations in deaf children: the importance of early linguistic experience. Leybaert J. **Scand J Psychol** 1998 Sep;39(3):169–73 (42 ref.)
Interactions of language and memory in deaf children and adults. Marschark M, et al. **Scand J Psychol** 1998 Sep; 39(3):145–8 (26 ref.)

ETIOLOGY

Language problems in neonatal at risk children: towards an understanding of developmental mechanisms. Wolke D. **Acta Paediatr** 1999 May;88(5):488–90 (20 ref.)

THERAPY

Practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. AACAP. **J Am Acad Child Adolesc Psychiatry** 1998 Oct;37(10 Suppl):46S–62S (119 ref.)

LANGUAGE DISORDERS

see related
SPEECH DISORDERS

COMPLICATIONS

Specific language impairments and behavioural problems. Coster FW, et al. **Folia Phoniatr Logop** 1999;51(3):99–107 (28 ref.)

DIAGNOSIS

Specific language impairments and behavioural problems. Coster FW, et al. **Folia Phoniatr Logop** 1999;51(3):99–107 (28 ref.)
Auditory gap detection, perceptual channels, and temporal resolution in speech perception. Phillips DP. **J Am Acad Audiol** 1999 Jun;10(6):343–54 (72 ref.)
Language, social cognitive processing, and behavioral characteristics of psychiatrically disturbed children with previously identified and unsuspected language impairments. Cohen NJ, et al. **J Child Psychol Psychiatry** 1998 Sep;39(6):853–64 (117 ref.)
Language, achievement, and cognitive processing in psychiatrically disturbed children with previously identified and unsuspected language impairments. Cohen NJ, et al. **J Child Psychol Psychiatry** 1998 Sep;39(6):865–77 (104 ref.)
Precursors to speech in infancy: the prediction of speech and language disorders [see comments] Oller DK, et al. **J Commun Disord** 1999 Jul–Aug;32(4):223–45 (47 ref.) Comment in: J Commun Disord 1999 Jul–Aug;32(4):247–50.

ETIOLOGY

Memory and language in neurodegenerative diseases. Dalla Barba G, et al. **Curr Opin Neurol** 1998 Oct;11(5):429–33 (32 ref.)
Language, speech, and educational outcomes of otitis media. Gravel JS, et al. **J Otolaryngol** 1998;27 Suppl 2:17–25 (74 ref.)
The picture exchange communication system. Bondy AS, et al. **Semin Speech Lang** 1998;19(4):373–88; quiz 389; 424 (42 ref.)
Environmental supports to enhance social–communication. Quill KA. **Semin Speech Lang** 1998;19(4):407–22; quiz 422–3; 424 (77 ref.)

PHYSIOPATHOLOGY

Language learning impairments: integrating basic science, technology, and remediation. Tallal P, et al. **Exp Brain Res** 1998 Nov;123(1–2):210–9 (86 ref.)

PSYCHOLOGY

Semantic dysfunction in frontotemporal lobar degeneration. Snowden JS. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:33–6 (8 ref.)

REHABILITATION

Issues in augmentative and alternative communication in child psychiatry. Sevcik RA, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):77–87 (29 ref.)

THERAPY

Issues to consider in the evaluation of speech and language therapy for preschool children. Roulstone S, et al. **Child Care Health Dev** 1999 Mar;25(2):141–55 (31 ref.)
Speechreading: advances in understanding its cortical bases and implications for deafness and speech rehabilitation. Campbell R. **Scand Audiol Suppl** 1998;49:80–6 (31 ref.)
Pivotal responses and the natural language teaching paradigm. Koegel LK, et al. **Semin Speech Lang** 1998; 19(4):355–71; quiz 372; 424 (102 ref.)
Environmental supports to enhance social–communication. Quill KA. **Semin Speech Lang** 1998;19(4):407–22; quiz 422–3; 424 (77 ref.)

LANGUAGE PATHOLOGY see **SPEECH–LANGUAGE PATHOLOGY**

LANGUAGE TESTS

Assessing communication in children with psychiatric and communication disorders. Kennedy MD. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):113–35, vii (90 ref.)

LANGUAGE THERAPY

Treatment for aphasia following stroke: evidence for effectiveness. Greener J, et al. **Int J Lang Commun Disord** 1998;33 Suppl:158–61 (13 ref.)
[Indications for orthophony therapy in written language disorders in children. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Pouymayou C, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115 Suppl 1:S75–88 (246 ref.) **(Fre)**

STANDARDS

Issues to consider in the evaluation of speech and language therapy for preschool children. Roulstone S, et al. **Child Care Health Dev** 1999 Mar;25(2):141–55 (31 ref.)

LANGUAGE TRAINING see **LANGUAGE THERAPY**

LANGURS see **CERCOPITHECIDAE**

LANOLIN

ADVERSE EFFECTS

The myth of lanolin allergy. Kligman AM. **Contact Dermatitis** 1998 Sep;39(3):103–7 (29 ref.)

LANOSTEROL

ANALOGS & DERIVATIVES

Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Frye LL, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):123–40 (52 ref.)

PHARMACOLOGY

Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Frye LL, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):123–40 (52 ref.)

LANSING VIRUS see **POLIOVIRUSES, HUMAN 1–3**

LANUGO see **HAIR**

LAPAROSCOPES see **ENDOSCOPES**

LAPAROSCOPIC CHOLECYSTECTOMY see **CHOLECYSTECTOMY, LAPAROSCOPIC**

LAPAROSCOPIC SURGICAL PROCEDURES see **SURGICAL PROCEDURES, LAPAROSCOPIC**

LAPAROSCOPY

Staging laparoscopy: a peek may save a cut [editorial; comment] Saeian K, et al. **Endoscopy** 1999 Jun;31(5):389–91 (31 ref.) Comment on: Endoscopy 1999 Jun;31(5):342–7.
Diagnostic laparoscopy: an update. Saeian K, et al. **Endoscopy** 1999 Jan;31(1):103–9 (42 ref.)
Laparoscopic ultrasonography for abdominal tumor staging. van Delden OM, et al. **Eur Radiol** 1998;8(8):1405–8 (29 ref.)
Laparoscopy in AIDS. Endres JC, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):975–90 (104 ref.)
Potential decreased morbidity of interstitial brachytherapy for gynecologic malignancies using laparoscopy: A pilot study. Choi JC, et al. **Gynecol Oncol** 1999 May;73(2):210–5 (19 ref.)
Laparoscopy and retroperitoneoscopy--novel techniques of which clinical nephrologists should be aware. Rassweiler J, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):313–7 (7 ref.)
Laparoscopy and hysteroscopy. Schenk LM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):1–22, v (61 ref.)
Laparoscopy in gynecologic malignancies. Chi DS. **Oncology (Huntingt)** 1999 Jun;13(6):773–82; discussion 782–5 passim (49 ref.)
Microlaparoscopy. O'Donovan PJ, et al. **Semin Laparosc Surg** 1999 Jun;6(2):51–7 (29 ref.)
Laparoscopic anatomy of the pelvis. Scott-Conner CE, et al. **Semin Laparosc Surg** 1999 Jun;6(2):43–50 (16 ref.)
Diagnostic laparoscopy for contralateral patent processus vaginalis and nonpalpable testes. Holcomb GW 3rd. **Semin Pediatr Surg** 1998 Nov;7(4):232–8 (32 ref.)
Laparoscopic evaluation of lymphoma. Johna S, et al. **Semin Surg Oncol** 1998 Oct–Nov;15(3):176–82 (31 ref.)
Laparoscopic evaluation in pancreatic cancer. Merchant NB, et al. **Semin Surg Oncol** 1998 Oct–Nov;15(3):155–65 (53 ref.)
Intraoperative and laparoscopic ultrasound. Machi J. **Surg Oncol Clin N Am** 1999 Jan;8(1):205–26 (47 ref.)
[The role of laparoscopy in gynecologic oncology] Holub Z. **Ceska Gynekol** 1999 Jan;64(1):63–8 (34 ref.) **(Cze)**
[Laparoscopy with a diagnostic aim in abdominal emergencies] Vons C. **Chirurgie** 1999 Apr;124(2):182–6 (27 ref.) (Eng. Abstr.) **(Fre)**
[Laparoscopy in acute abdomen as diagnostic and surgical aid] Montgomery A, et al. **Lakartidningen** 1999 Feb 10; 96(6):593–6 (20 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Is the port site really at risk? Biology, mechanisms and prevention: a critical view. Allardyce RA. **Aust N Z J Surg** 1999 Jul;69(7):479–85 (83 ref.)
The pathogenesis of port-site recurrences. Reymond MA, et al. **J Gastrointest Surg** 1998 Sep–Oct;2(5):406–14 (88 ref.)
Complications of laparoscopy. Strategies for prevention and cure. Lin P, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):23–38, v (37 ref.)
[Complications of laparoscopy in gynecology] Abboud J, et al. **Contracept Fertil Sex** 1999 May;27(5):383–7 (41 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

[Trocar-induced complications in laparoscopy] Mosnier H, et al. **J Chir (Paris)** 1998 Nov;135(5):217–8, 231 (11 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Diagnostic laparoscopy. Alaish SM, et al. **Curr Opin Pediatr** 1998 Jun;10(3):323–7 (19 ref.)
Laparoscopically assisted total enteroscopy: a new approach to small intestinal diseases. Ingrosso M, et al. **Gastrointest Endosc** 1999 May;49(5):651–3 (16 ref.)
Laparoscopic staging of malignant disease. Payne JH Jr. **Hawaii Med J** 1998 Nov;57(11):705–9 (27 ref.)
Transvaginal access heralds the end of standard diagnostic laparoscopy in infertility. Brosens I, et al. **Hum Reprod** 1998 Jul;13(7):1762–3 (19 ref.)
Role of laparoscopy in the staging of gastrointestinal cancer. Jerby BL, et al. **Oncology (Huntingt)** 1998 Sep; 12(9):1353–60 (36 ref.)
Laparoscopy for diagnosis and staging of malignancy. Ramshaw BJ, et al. **Semin Surg Oncol** 1999 Jun; 16(4):279–83 (59 ref.)
Role of laparoscopy for Hodgkin's and non-Hodgkin's lymphoma. Walsh RM, et al. **Semin Surg Oncol** 1999 Jun; 16(4):284–92 (34 ref.)
[The application of laparocentesis and peritoneal lavage and the analysis of hemo-peritoneal volume in the diagnosis of closed abdominal wound] Tishchenko VV. **Klin Khir** 1999;(1):11–2 (2 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

[The healing process following gynecologic laparoscopy: data on the significance of psychological factors] Szeverényi P, et al. **Orv Hetil** 1999 May 9;140(19):1043–8 (30 ref.) (Eng. Abstr.) **(Hun)**

TRENDS

Analysis of laparoscopy in trauma. Villavicencio RT, et al. **J Am Coll Surg** 1999 Jul;189(1):11–20 (62 ref.)
Robotics and the future of laparoscopy. Semm K. **JSLS** 1999 Jan–Mar;3(1):87–8 (0 ref.)

LAPAROTOMY

Comparison of adhesion formation in open and laparoscopic surgery. Schäfer M, et al. **Dig Surg** 1998;15(2):148–52 (48 ref.)

Prophylactic ureteral catheterization in gynecologic surgery. Kuno K, et al. **Urology** 1998 Dec;52(6):1004–8 (17 ref.)

[Complications of tubal sterilization by minilaparotomy under local anesthesia] Cisse CT, et al. **Dakar Med** 1997; 42(2):96–8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Inguinal hernia treatment] Boudet MJ, et al. **J Chir (Paris)** 1998 May;135(2):57–64 (89 ref.) (Eng. Abstr.) **(Fre)**

[Nasogastric tubes after elective abdominal surgery is not justified] Gouzi JL, et al. **J Chir (Paris)** 1998 Dec; 135(6):273–4 (11 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Open vs. laparoscopic repair of perforated peptic ulcer [letter; comment] Bergamaschi R. **Surg Laparosc Endosc** 1998 Dec; 8(6):479–80 (8 ref.) Comment on: Surg Laparosc Endosc 1998 Apr;8(2):153–6.

[A surgical technic for cesarean section and gynecological laparotomy without suturing of the parietal and visceral peritoneum and the single-layer suturing of the uterus during the section (a review of the literature and initial experience)] Katsulov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):40–6 (25 ref.) **(Bul)**

[Abdominosacral resection for locoregional recurrence rectal cancer] Meneu JC, et al. **Rev Esp Enferm Dig** 1999 May; 91(5):374–9 (30 ref.) (Eng. Abstr.) **(Spa)**

LARVA

[The BMW (biosurgical mechanical wound treatment) in diabetic foot] Moch D, et al. **Zentralbl Chir** 1999;124 Suppl 1:69–72 (10 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Differential response of the tail and body epidermis of Rana catesbeiana tadpoles in vitro to the anticancer drug, cisplatin [letter] Menon J, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan;35(1):8–11 (12 ref.)

LARVA MIGRANS

[Creeping eruption] Kojima S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):439–41 (15 ref.) **(Jpn)**

PATHOLOGY

Larva migrans within scalp sebaceous gland. Guimarães LC, et al. **Rev Soc Bras Med Trop** 1999 Mar–Apr;32(2):187–9 (8 ref.)

LARVA MIGRANS, CUTANEOUS see **LARVA MIGRANS**

LARVA MIGRANS, OCULAR see **LARVA MIGRANS**

LARVA MIGRANS, VISCERAL

COMPLICATIONS

[The association between human toxocariasis and pyogenic abscesses] Rayes AA, et al. **Rev Soc Bras Med Trop** 1999 Jul–Aug;32(4):425–38 (110 ref.) (Eng. Abstr.) **(Por)**

LARYNGEAL DISEASES

Vallecular cysts in newborns and young infants. Gutiérrez JP, et al. **Pediatr Pulmonol** 1999 Apr;27(4):282–5 (19 ref.)

COMPLICATIONS

Laryngeal pathology in the acquired immunodeficiency syndrome: diagnostic and therapeutic dilemmas. Tami TA, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):214–20 (41 ref.)

CONGENITAL

[Genetic aspects of congenital pathology of the larynx and trachea] Maslova IV, et al. **Vestn Otorinolaringol** 1999; (2):30–3 (17 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Intralaryngotracheal thyroid--ectopic thyroid or invasive carcinoma? See AC, et al. **J Laryngol Otol** 1998 Jul; 112(7):673–6 (26 ref.)

Epidermolysis bullosa of the head and neck: a case report of laryngotracheal involvement and 10-year review of cases at the Hospital for Sick Children. Liu RM, et al. **J Otolaryngol** 1999 Apr;28(2):76–82 (17 ref.)

Investigation and treatment of chronic stridor in infancy. Landau LI. **Monaldi Arch Chest Dis** 1999 Feb;54(1):18–21 (10 ref.)

Flexible nasolaryngoscopy. A low-risk, high-yield procedure. Hayes JT, et al. **Postgrad Med** 1999 Sep; 106(3):107–10, 114 (7 ref.)

ETIOLOGY

Transglottic scleroma. Keschner D, et al. **Am J Otolaryngol** 1998 Nov–Dec;19(6):407–11 (11 ref.)

GENETICS

[Genetic aspects of congenital pathology of the larynx and trachea] Maslova IV, et al. **Vestn Otorinolaringol** 1999; (2):30–3 (17 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Pharyngo-laryngeal histoplasmosis: one case in an immunocompetent child. Coiffier T, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 2;45(2):177–81 (18 ref.)

SURGERY

Epidermolysis bullosa of the head and neck: a case report of laryngotracheal involvement and 10-year review of cases at the Hospital for Sick Children. Liu RM, et al. **J Otolaryngol** 1999 Apr;28(2):76–82 (17 ref.)

THERAPY

Investigation and treatment of chronic stridor in infancy. Landau LI. **Monaldi Arch Chest Dis** 1999 Feb;54(1):18–21 (10 ref.)

VIROLOGY

Neonatal stridor in association with herpes simplex infection of the larynx. Sharp HR, et al. **J Laryngol Otol** 1998 Dec; 112(12):1192–3 (7 ref.)

LARYNGEAL EDEMA

COMPLICATIONS

Severe postoperative laryngeal oedema causing total airway obstruction immediately on extubation. Dark A, et al. **Br J Anaesth** 1999 Apr;82(4):644–6 (14 ref.)

LARYNGEAL MASK AIRWAY see **LARYNGEAL MASKS**

LARYNGEAL MASKS

The unanticipated difficult airway with recommendations for management [see comments] Crosby ET, et al. **Can J Anaesth** 1998 Aug;45(8):757–76 (132 ref.) Comment in: Can J Anaesth 1999 Feb;46(2):198. Comment in: Can J Anaesth 1999 Mar;46(3):297–8; discussion 298–9. Comment in: Can J Anaesth 1999 Mar;46(3):298–9. Comment in: Can J Anaesth 1999 May;46(5 Pt 1):510–1. Comment in: Can J Anaesth 1999 May;46(5 Pt 1):511–2.

Noninvasive management of pediatric neuromuscular ventilatory failure: a viable alternative [editorial; comment] Barnes SD. **Crit Care Med** 1998 Dec;26(12):1952–3 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2061–5.

[Mask induction and one-lung ventilation with sevoflurane] Janshon GP, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S52–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[COPA, LMA, tracheal intubation. What are the indications in pediatric anesthesia] Villani A, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):60–4 (36 ref.) **(Ita)**

ADVERSE EFFECTS

Recurrent laryngeal nerve injury caused by a laryngeal mask airway. Lowinger D, et al. **Anaesth Intensive Care** 1999 Apr;27(2):202–5 (26 ref.)

[Risks and complications in the use of the laryngeal mask] Hempel V. **Anaesthesist** 1999 Jun;48(6):399–402 (46 ref.) **(Ger)**

LARYNGEAL NEOPLASMS

Leiomyosarcoma of the larynx. Review of the literature and report of two cases. Paczona R, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):677–82 (46 ref.)

A review of neuroendocrine neoplasms of the larynx: update on diagnosis and treatment. Ferlito A, et al. **J Laryngol Otol** 1998 Sep;112(9):827–34 (91 ref.)

Treatment of the patient with upper airway obstruction caused by cancer of the larynx. Bradley PJ. **Otolaryngol Head Neck Surg** 1999 May;120(5):737–41 (25 ref.)

CHEMISTRY

[Hormonal receptors of laryngeal cancer] Kruk-Zagajewska A, et al. **Otolaryngol Pol** 1999;53(1):41–6 (25 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Laryngeal pathology in the acquired immunodeficiency syndrome: diagnostic and therapeutic dilemmas. Tami TA, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):214–20 (41 ref.)

[Hypothyroidism in patients treated for laryngeal cancer: preliminary results] Romero A, et al. **Acta Otorrinolaringol Esp** 1999 Apr;50(3):205–10 (34 ref.) (Eng. Abstr.) **(Spa)**

[Laryngeal cancer and the leukemoid reaction (letter)] De Vega Santos T, et al. **An Med Interna** 1999 Jul;16(7):382–3 (5 ref.) **(Spa)**

DIAGNOSIS

Giant lipoma of the larynx: a case report and literature review. Yoskovitch A, et al. **Ear Nose Throat J** 1999 Feb; 78(2):122–5; quiz 126–8 (18 ref.)

Imaging of laryngeal cancer. Castelijns JA, et al. **Semin Ultrasound CT MR** 1998 Dec;19(6):492–504 (42 ref.)

[Adenoid cystic carcinoma of the larynx. A case report and review of the literature] Shin YJ, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(2):105–8 (14 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Chemotherapy combined with conservation surgery in the treatment of early larynx cancer. Laccourreye O, et al. **Curr Opin Oncol** 1999 May;11(3):200–3 (17 ref.)

MORTALITY

Impact of phenotype on treatment and prognosis of laryngeal malignancies. Ferlito A, et al. **J Laryngol Otol** 1998 Aug; 112(8):710–4 (47 ref.)

PATHOLOGY

Laryngeal rhabdomyosarcoma in adults. Ruske DR, et al. **J Laryngol Otol** 1998 Jul;112(7):670–2 (17 ref.)

Fibrous histiocytoma of the larynx. Saleem M, et al. **J Laryngol Otol** 1998 Dec;112(12):1205–7 (12 ref.)

Upper aerodigestive tract liposarcoma: report on four cases and literature review. Mandell DL, et al. **Laryngoscope** 1999 Aug;109(8):1245–52 (28 ref.)

Case study of well-differentiated carcinoid tumor of the larynx and review of laryngeal neuroendocrine tumors. McBride LC, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):536–9 (14 ref.)

Juvenile-onset recurrent respiratory papillomatosis involving the lung: A case report and review of the literature. Magid MS, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):157–63 (29 ref.)

Non-squamous cell neoplasms of the larynx: radiologic-pathologic correlation. Becker M, et al. **Radiographics** 1998 Sep–Oct;18(5):1189–209 (45 ref.)

[Adenoid cystic carcinoma of the larynx. Case report and literature review] Damborenea Tajada J, et al. **An Otorrinolaringol Ibero Am** 1999;26(3):257–63 (13 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Computed tomography of laryngeal carcinoma: technique, imaging findings and implications for radiation therapy. Hermans R, et al. **J Belge Radiol** 1998 Aug;81(4):190–8 (25 ref.)

Non-squamous cell neoplasms of the larynx: radiologic-pathologic correlation. Becker M, et al. **Radiographics** 1998 Sep–Oct;18(5):1189–209 (45 ref.)

RADIOTHERAPY

Computed tomography of laryngeal carcinoma: technique, imaging findings and implications for radiation therapy. Hermans R, et al. **J Belge Radiol** 1998 Aug;81(4):190–8 (25 ref.)

T3–4 squamous cell carcinoma of the larynx treated with radiation therapy alone. Mendenhall WM. **Semin Radiat Oncol** 1998 Oct;8(4):262–9 (43 ref.)

[Liposarcoma of the larynx. Review of the literature apropos of a case] Acharki A, et al. **Cancer Radiother** 1999 May–Jun;3(3):245–8 (21 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Laryngeal metastasis from a signet ring cell carcinoma of the colon. A case report and review of the literature. Giacomini PG, et al. **An Otorrinolaringol Ibero Am** 1998; 25(5):463–70 (11 ref.)

SURGERY

Leiomyosarcoma of the larynx. Case report. Thomas S, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):794–6 (10 ref.)

Chemotherapy combined with conservation surgery in the treatment of early larynx cancer. Laccourreye O, et al. **Curr Opin Oncol** 1999 May;11(3):200–3 (17 ref.)

Selective lateral neck dissection for laryngeal cancer in the clinically negative neck: is it justified? Ferlito A, et al. **J Laryngol Otol** 1998 Oct;112(10):921–4 (24 ref.)

Selective lateral neck dissection for laryngeal cancer with limited metastatic disease: is it indicated? Ferlito A, et al. **J Laryngol Otol** 1998 Nov;112(11):1031–3 (19 ref.)

[Liposarcoma of the larynx. Review of the literature apropos of a case] Acharki A, et al. **Cancer Radiother** 1999 May–Jun;3(3):245–8 (21 ref.) (Eng. Abstr.) **(Fre)**

[On fronto-anterior reconstructive laryngectomy] Samson-Zakrzewski J, et al. **Otolaryngol Pol** 1998; 52(3):265–9 (15 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Squamous cell carcinoma of the glottic larynx: a review emphasizing the University of Florida philosophy. Mendenhall WM, et al. **South Med J** 1999 Apr;92(4):385–93

(69 ref.)
[Organ preservation in ORL oncology: myth or reality. The case for laryngeal preservation] Eschwège F, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):437-45 (44 ref.) (Eng. Abstr.) **(Fre)**
[Hypothyroidism in patients treated for laryngeal cancer: preliminary results] Romero A, et al. **Acta Otorrinolaringol Esp** 1999 Apr;50(3):205-10 (34 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

[Virologic aspects of juvenile laryngeal papillomatosis] Major T, et al. **Orv Hetil** 1999 Feb 21;140(8):405-9 (33 ref.) (Eng. Abstr.) **(Hun)**

LARYNGEAL NERVE, INFERIOR see **RECURRENT LARYNGEAL NERVE**

LARYNGEAL PARALYSIS see **VOCAL CORD PARALYSIS**

LARYNGEAL PERICHONDRITIS see **LARYNGEAL DISEASES**

LARYNGEAL PROSTHESIS see **LARYNX, ARTIFICIAL**

LARYNGEAL STENOSIS see **LARYNGOSTENOSIS**

LARYNGECTOMY

see related
LARYNX, ARTIFICIAL
SPEECH, ALARYNGEAL

Leiomyosarcoma of the larynx. Review of the literature and report of two cases. Paczona R, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):677-82 (46 ref.)
The treatment of hypertonicity of the pharyngo-oesophageal segment after laryngectomy. Brok HA, et al. **Clin Otolaryngol** 1998 Aug;23(4):302-7 (51 ref.)
[Bacterial and fungal colonization in indwelling total laryngectomy phonatory prostheses: identification of microbial agents, treatment protocol and prevention] Nazionale G, et al. **Acta Otorhinolaryngol Ital** 1998 Apr; 18(2):107-10 (21 ref.) (Eng. Abstr.) **(Ita)**
[Voice restoration and clinical outcome in patients undergoing laryngectomy with voice prostheses] Kumazawa H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Nov;101(11):1303-10 (31 ref.) (Eng. Abstr.) **(Jpn)**
[On fronto-anterior reconstructive laryngectomy] Samson-Zakrzewski J, et al. **Otolaryngol Pol** 1998; 52(3):265-9 (15 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

[Organ preservation in ORL oncology: myth or reality. The case for laryngeal preservation] Eschwège F, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):437-45 (44 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Organ preservation in ORL oncology: myth or reality. The case for laryngeal preservation] Eschwège F, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):437-45 (44 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Restoration of voice after laryngectomy. Jassar P, et al. **J R Soc Med** 1999 Jun;92(6):299-302 (25 ref.)
[Surgical voice restoration following laryngectomy] Herrmann IF. **Laryngorhinootologie** 1999 Jun; 78(6):OP57-68 (0 ref.) **(Ger)**

LARYNGISMUS

DRUG THERAPY

Severe laryngospasm without intravenous access--a case report and literature review of the non-intravenous routes of administration of suxamethonium. Seah TG, et al. **Singapore Med J** 1998 Jul;39(7):328-30 (21 ref.)

LARYNGITIS

DIAGNOSIS

[Acute respiratory insufficiency in children] Duiverman EJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 23;143(4):197-201 (17 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

[Corticotherapy in ENT. Subglottic laryngitis in children, acute sinusitis, naso-sinusal polyposis, sero-mucous otitis] De Corbiere S, et al. **Ann Med Interne (Paris)** 1998 Dec; 149(8):508-11 (16 ref.) (Eng. Abstr.) **(Fre)**
[Cromones in the therapy of food-induced allergic rhinitis, pharyngitis and laryngitis] Buczyłko K. **Pol Merkuriusz Lek** 1998 Dec;5(30):357-9 (18 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

[Cromones in the therapy of food-induced allergic rhinitis, pharyngitis and laryngitis] Buczyłko K. **Pol Merkuriusz Lek** 1998 Dec;5(30):357-9 (18 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

[Recent advances in the treatment of laryngitis (editorial)] Benito Fernández J. **An Esp Pediatr** 1998 Nov;49(5):444-7 (32 ref.) **(Spa)**

LARYNGOPHARYNX see **HYPOPHARYNX**

LARYNGOSCOPY

The unanticipated difficult airway with recommendations for management [see comments] Crosby ET, et al. **Can J Anaesth** 1998 Aug;45(8):757-76 (132 ref.) Comment in: Can J Anaesth 1999 Feb;46(2):198. Comment in: Can J Anaesth 1999 Mar;46(3):297-8; discussion 298-9. Comment in: Can J Anaesth 1999 Mar;46(3):298-9. Comment in: Can J Anaesth 1999 May;46(5 Pt 1):510-1. Comment in: Can J Anaesth 1999 May;46(5 Pt 1):511-2.
Values and limitations of pharyngolaryngoscopy (transnasal, transoral) in patients with dysphagia. Schröter-Morasch H, et al. **Folia Phoniatr Logop** 1999 Jul-Oct;51(4-5):172-82 (43 ref.)
[Video-laryngostroboscopy in phonation] Haddad AC, et al. **J Med Liban** 1998 May-Jun;46(3):140-5 (26 ref.) **(Fre)**

ADVERSE EFFECTS

An unusual complication of endotracheal intubation: ingestion of a laryngoscope bulb. Ince Z, et al. **Pediatr Emerg Care** 1998 Aug;14(4):275-6 (4 ref.)

INSTRUMENTATION

[Flexible endoscopy in the ENT area] Hörmann K, et al. **HNO** 1998 Jul;46(7):654-9 (35 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Analysis of the forces and position required for direct laryngoscopic exposure of the anterior vocal folds. Hochman II, et al. **Ann Otol Rhinol Laryngol** 1999 Aug; 108(8):715-24 (38 ref.)
Flexible nasolaryngoscopy. A low-risk, high-yield procedure. Hayes JT, et al. **Postgrad Med** 1999 Sep; 106(3):107-10, 114 (7 ref.)
[High-resolution virtual laryngoscopy based on spiral CT data] Aschoff AJ, et al. **Radiologe** 1998 Oct;38(10):810-5 (47 ref.) (Eng. Abstr.) **(Ger)**

LARYNGOSPASM see **LARYNGISMUS**

LARYNGOSTENOSIS

ETIOLOGY

Subglottic stenosis: evaluation and management. Brodner DC, et al. **J La State Med Soc** 1999 Apr;151(4):159-64 (11 ref.)

SURGERY

Subglottic stenosis: evaluation and management. Brodner DC, et al. **J La State Med Soc** 1999 Apr;151(4):159-64 (11 ref.)

LARYNX

see related
LARYNGECTOMY
LARYNGOSCOPY

[Tracheotomy in the child with a foreign body in the lower respiratory passages] Diop EM, et al. **Dakar Med** 1997; 42(2):165-8 (10 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Adult presentation of a tracheoesophageal fistula with co-existing laryngeal cleft. Lancaster JL, et al. **J Laryngol Otol** 1999 May;113(5):469-72 (17 ref.)
Congenital laryngotracheoesophageal cleft. Carr MM, et al. **J Otolaryngol** 1999 Apr;28(2):112-7 (45 ref.)
Long-term survival in a patient with congenital laryngeal atresia and multiple malformations. Okada T, et al. **Pediatr Surg Int** 1998 Sep;13(7):521-3 (13 ref.)

PATHOLOGY

Non-squamous cell neoplasms of the larynx: radiologic-pathologic correlation. Becker M, et al. **Radiographics** 1998 Sep-Oct;18(5):1189-209 (45 ref.)

PHYSIOLOGY

Upper airway function and dysfunction in respiration. Pierce RJ, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):1-10 (102 ref.)

PHYSIOPATHOLOGY

Larynx and neonatal apneas. Praud JP. **Pediatr Pulmonol Suppl** 1999;18:190-3 (17 ref.)

SURGERY

[Expert phoniatric assessment of voice adaptation in male to female transsexualism] Rosanowski F, et al. **HNO** 1999 Jun;47(6):556-62 (36 ref.) (Eng. Abstr.) **(Ger)**

LARYNX, ARTIFICIAL

see related
SPEECH, ALARYNGEAL

Restoration of voice after laryngectomy. Jassar P, et al. **J R Soc Med** 1999 Jun;92(6):299-302 (25 ref.)
[Voice restoration and clinical outcome in patients undergoing laryngectomy with voice prostheses] Kumazawa H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Nov;101(11):1303-10 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Torpid pneumonia secondary to the aspiration of a phonation prosthesis (letter)] Garcia Gasalla M, et al. **Rev Clin Esp** 1999 Jul;199(7):481-2 (10 ref.) **(Spa)**

MICROBIOLOGY

[Bacterial and fungal colonization in indwelling total laryngectomy phonatory prostheses: identification of microbial agents, treatment protocol and prevention] Nazionale G, et al. **Acta Otorhinolaryngol Ital** 1998 Apr; 18(2):107-10 (21 ref.) (Eng. Abstr.) **(Ita)**

LASER ANGIOPLASTY see **ANGIOPLASTY, LASER**

LASER COAGULATION

Reaffirming the role of the laser in glaucoma management [editorial] Higginbotham EJ. **Arch Ophthalmol** 1999 Aug; 117(8):1075-6 (13 ref.)
Determining the clinical significance of randomized clinical trials: a review of the efficacy of laser photocoagulation. Sharma S. **Can J Ophthalmol** 1999 Feb;34(1):46-9 (13 ref.)
Ablation therapy for Barrett's esophagus: is it time to choose our weapons? [editorial; comment] Lightdale CJ. **Gastrointest Endosc** 1999 Jan;49(1):122-5 (22 ref.) Comment on: Gastrointest Endosc 1999 Jan;49(1):1-7. Comment on: Gastrointest Endosc 1999 Jan;49(1):8-12. Comment on: Gastrointest Endosc 1999 Jan;49(1):97-101.
Laser tissue welding: a urological surgeon's perspective. Poppas DP, et al. **Haemophilia** 1998 Jul;4(4):456-62 (33 ref.)
Diode laser transscleral cyclophotocoagulation. Chen TC, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):169-76 (32 ref.)
Can laser photocoagulation of eyes with high-risk drusen prevent vision loss from age-related macular degeneration? [editorial; comment] Folk JC, et al. **Ophthalmology** 1999 Jul;106(7):1241-2 (19 ref.) Comment on: Ophthalmology 1999 Jul;106(7):1367-73; discussion 1374.
Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Abdelsalam A, et al. **Surv Ophthalmol** 1999 Jul-Aug;44(1):1-29 (148 ref.)
[Intraocular interventions in eyes with rubeosis iridis and neovascular glaucoma] Lucke K, et al. **Ophthalmologe** 1998 Jul;95(7):514-28 (10 ref.) **(Ger)**

METHODS

Interstitial laser coagulation for hepatic tumours. Heisterkamp J, et al. **Br J Surg** 1999 Mar;86(3):293-304 (112 ref.)
Technology for in situ ablation by laparoscopic and image-guided interstitial laser hyperthermia. Germer CT, et al. **Semin Laparosc Surg** 1998 Sep;5(3):195-203 (65 ref.)

LASER DESORPTION-IONIZATION MASS SPECTROMETRY, MATRIX-ASSISTED see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

LASER-DOPPLER FLOWMETRY

Intrapartum umbilical artery Doppler velocimetry as a predictor of adverse perinatal outcome: a systematic review. Farrell T, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):783-92 (58 ref.)
Objective non-invasive assessment of patch tests with the laser Doppler perfusion scanning technique. Bjarnason B, et al. **Contact Dermatitis** 1999 May;40(5):251-60 (35 ref.)
Abnormal Doppler velocities in the umbilical artery [editorial] Karsdorp VH. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):129-31 (11 ref.)
Laser Doppler flowmetry of the optic nerve head in glaucoma. Piltz-Seymour JR. **Surv Ophthalmol** 1999 Jun; 43 Suppl 1:S191-8 (56 ref.)

METHODS

Principles and practice of the laser-Doppler perfusion technique. Leahy MJ, et al. **Technol Health Care** 1999; 7(2-3):143-62 (52 ref.)

STANDARDS

Bioengineering and the skin: from standard error to standard operating procedure. Serup J. **Acta Derm Venereol Suppl (Stockh)** 1994;185:5-8 (15 ref.)

LASER-DOPPLER VELOCIMETRY

LASER-DOPPLER VELOCIMETRY see **LASER-DOPPLER FLOWMETRY**

LASER-INDUCED SHOCKWAVE LITHOTRIPSY see **LITHOTRIPSY, LASER**

LASER KNIFE see **LASER SURGERY**

LASER LITHOTRIPSY see **LITHOTRIPSY, LASER**

LASER MICROSCOPY see **MICROSCOPY, CONFOCAL**

LASER SCALPEL see **LASER SURGERY**

LASER SCANNING CONFOCAL MICROSCOPY see **MICROSCOPY, CONFOCAL**

LASER SCANNING MICROSCOPY see **MICROSCOPY, CONFOCAL**

LASER SURGERY

Leiomyosarcoma of the larynx. Review of the literature and report of two cases. Paczona R, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):677–82 (46 ref.)

Why does carbon dioxide resurfacing work? A review. Ross EV, et al. **Arch Dermatol** 1999 Apr;135(4):444–54 (98 ref.)

Current status of transmyocardial laser revascularization: review of the literature. Abramov D, et al. **Can J Cardiol** 1999 Mar;15(3):303–10 (39 ref.)

Percutaneous transmyocardial laser revascularization: an overview [see comments] Kornowski R, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):354–9 (48 ref.) Comment in: Catheter Cardiovasc Interv 1999 Jul;47(3):360.

Hair removal using a long-pulsed alexandrite laser. Ash K, et al. **Dermatol Clin** 1999 Apr;17(2):387–99, ix (42 ref.)

A clinical overview of hair removal using lasers and light sources. Dierickx C, et al. **Dermatol Clin** 1999 Apr; 17(2):357–66, ix (25 ref.)

Hair removal using an Nd:YAG laser system. Littler CM. **Dermatol Clin** 1999 Apr;17(2):401–30, x (67 ref.)

Theoretical considerations in laser hair removal. Ross EV, et al. **Dermatol Clin** 1999 Apr;17(2):333–55, viii (78 ref.)

Hair removal using a pulsed-intense light source. Tse Y. **Dermatol Clin** 1999 Apr;17(2):373–85, ix (25 ref.)

Technology status evaluation: developments in laser technology: November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):711–6 (63 ref.)

Current status of percutaneous transmyocardial revascularisation. Bhargava B, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:130–7 (41 ref.)

Surgical advances in retinopathy of prematurity. Andrews AP, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):275–90 (41 ref.)

Endocanalicular Nd: YAG laser dacryocystorhinostomy. Fay AM, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):177–84 (18 ref.)

Laser in situ keratomileusis for the treatment of myopia. Yoo SH, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):37–44 (24 ref.)

Cutaneous laser resurfacing. Ratner D, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):365–89; quiz 390–2 (314 ref.)

Energy systems for operative laparoscopy. Brill AI. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):333–45; quiz 347–9 (58 ref.)

Monovision and LASIK. Hom MM. **J Am Optom Assoc** 1999 Feb;70(2):117–22 (35 ref.)

Contact lenses after LASIK. Szczotka LB, et al. **J Am Optom Assoc** 1998 Dec;69(12):775–84 (27 ref.)

Laser therapy in the management of rosacea. Laughlin SA, et al. **J Cutan Med Surg** 1998 Jun;2 Suppl 4:S4–24–9 (22 ref.)

Aural papillomatosis--treatment with the carbon dioxide laser. Blair RL, et al. **J Laryngol Otol** 1998 Jun;112(6):565–6 (6 ref.)

Management of cervical intraepithelial neoplasia [see comments] Cox JT. **Lancet** 1999 Mar 13;353(9156):857–9 (17 ref.) Comment in: Lancet 1999 Jun 5;353(9168):1973.

New frontiers in the management of obstructive sleep apnoea syndrome. Krieger J. **Monaldi Arch Chest Dis** 1998 Oct; 53(5):515–9 (29 ref.)

Carbon dioxide laser skin resurfacing. Biesman BS. **Semin Ophthalmol** 1998 Sep;13(3):123–35 (53 ref.)

Preoperative and postoperative skin care with laser resurfacing. Hrabovsky SL. **Semin Ophthalmol** 1998 Sep; 13(3):115–22 (32 ref.)

Erbium: YAG laser--an improved periorbital resurfacing device. Kopelman J. **Semin Ophthalmol** 1998 Sep; 13(3):136–41 (16 ref.)

Laser blepharoplasty. Lessner AM, et al. **Semin Ophthalmol** 1998 Sep;13(3):90–102 (10 ref.)

Corneal topography in LASIK. Oshika T, et al. **Semin Ophthalmol** 1998 Jun;13(2):64–70 (14 ref.)

The krypton yellow-green laser for the treatment of facial vascular and pigmented lesions. Patel BC. **Semin Ophthalmol** 1998 Sep;13(3):158–70 (7 ref.)

Transmyocardial laser revascularization and angiogenesis: the potential for therapeutic benefit. Lee LY, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):29–35 (86 ref.)

Combination TMR and gene therapy. Sayeed-Shah U, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):36–9 (34 ref.)

Surgical correction of moderate myopia: which method should you choose? III. Editorial. Dutton JJ. **Surv Ophthalmol** 1998 Sep–Oct;43(2):179–81 (9 ref.)

Surgical correction of moderate myopia: which method should you choose? II. PRK and LASIK are the treatments of choice. Steinert RF, et al. **Surv Ophthalmol** 1998 Sep–Oct;43(2):157–79 (248 ref.)

[CO2 laser skin resurfacing. Critical analysis of recent literature] Dubois R, et al. **Ann Chir Plast Esthet** 1998 Dec; 43(6):659–63 (22 ref.) (Eng. Abstr.) **(Fre)**

[Value of external dacryocystorhinostomy (editorial)] Struck HG. **Klin Monatsbl Augenheilkd** 1999 Jul;215(1):1–3 (31 ref.) (Eng. Abstr.) **(Ger)**

[Laser therapy in dermatology] St Lautenschlager. **Ther Umsch** 1998 Aug;55(8):522–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Lasers in medicine] Fuchs B, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):259–66 (18 ref.) (Eng. Abstr.) **(Ger)**

[Laser surgery in the conservative management of vaginal intraepithelial neoplasms] Sopracordevole F, et al. **Minerva Ginecol** 1998 Dec;50(12):507–12 (38 ref.) (Eng. Abstr.) **(Ita)**

[Transmyocardial laser revascularization] Tominaga R. **Fukuoka Igaku Zasshi** 1998 Dec;89(12):329–32 (7 ref.) **(Jpn)**

[Laser surgery for patients with nasal mucosal lesions] Suzaki H. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Jan;102(1):84–7 (3 ref.) **(Jpn)**

[Laser surgery in otolaryngology] Kubiczkowa J. **Otolaryngol Pol** 1997;51 Suppl 25:95–104 (50 ref.) (Eng. Abstr.) **(Pol)**

[Efficacy and indications for YAG laser optico-reconstructive surgery on the anterior eye segment in children] Arestova NN, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):25–9 (9 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Possible hazards of cryogen use with pulsed dye laser. A case report and summary. White JM, et al. **Dermatol Surg** 1999 Mar;25(3):250–2; discussion 252–3 (1 ref.)

Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. Ross EV, et al. **J Am Acad Dermatol** 1998 Dec;39(6):975–81 (33 ref.)

Diagnosis and treatment of postoperative complications after skin resurfacing. Demas PN, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):837–41 (27 ref.)

[Histopathological observations on bullous keratopathy after argon-laser iridotomy] Chen RJ, et al. **Nippon Ganka Gakkai Zasshi** 1999 Feb;103(2):129–36 (39 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Q-switched ruby laser treatment of tattoos and benign pigmented skin lesions: a critical review. Raulin C, et al. **Ann Plast Surg** 1998 Nov;41(5):555–65 (66 ref.)

Laser tweezers and optical microsurgery in cellular and molecular biology. Working principles and selected applications. Greulich KO, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):701–10 (25 ref.)

Hair removal using the long-pulsed ruby laser. Williams RM, et al. **Dermatol Clin** 1999 Apr;17(2):367–72 (10 ref.)

A practical review of laser-assisted hair removal using the Q-switched Nd:YAG, long-pulsed ruby, and long-pulsed alexandrite lasers. Nanni CA, et al. **Dermatol Surg** 1998 Dec;24(12):1399–405; discussion 1405 (15 ref.)

Optical hair removal. Ort RJ, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):149–58 (42 ref.)

[Current status of laser therapy in dermatology] Hellwig S, et al. **Hautarzt** 1998 Sep;49(9):690–704 (154 ref.) (Eng. Abstr.) **(Ger)**

[Progress in molecular medicine: "laser capture microdissection" (see comments)] Bornstein SR, et al. **Med Klin** 1998 Dec 15;93(12):739–43 (29 ref.) (Eng. Abstr.) Comment in: Med Klin 1998 Dec 15;93(12):738. **(Ger)**

[Laser surgery in esthetic surgery. Review] Mang WL, et al. **Mund Kiefer Gesichtschir** 1999 May;3 Suppl 1:S162–7 (13 ref.) (Eng. Abstr.) **(Ger)**

[Therapeutic use of lasers in dermatology] Hohenleutner U, et al. **Ther Umsch** 1999 Apr;56(4):170–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[The new-generation laser surgical apparatus Doktor in the combined treatment of stomatological disease in an outpatient setting] Prokhonchukov AA, et al. **Stomatologiia (Mosk)** 1998;77(5):44–9 (14 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Transmyocardial laser revascularization. Horvath KA. **Adv Card Surg** 1998;10:141–54 (30 ref.)

Laser tweezers and optical microsurgery in cellular and molecular biology. Working principles and selected applications. Greulich KO, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):701–10 (25 ref.)

Endobronchial laser therapy. Turner JF Jr, et al. **Clin Chest Med** 1999 Mar;20(1):107–22 (82 ref.)

Ocular disease in the diabetic elderly. Kincaid MC. **Clin Geriatr Med** 1999 May;15(2):279–92 (62 ref.)

LASIK: management of common complications. Laser in situ keratomileusis. Wilson SE. **Cornea** 1998 Sep;17(5):459–67 (14 ref.)

Laser therapy and dermatologic surgery. Cunningham BB. **Curr Opin Pediatr** 1998 Aug;10(4):405–10 (40 ref.)

Lasers in the military for cutaneous disease and wound healing. Ross EV, et al. **Dermatol Clin** 1999 Jan; 17(1):135–50, ix (67 ref.)

Side-firing Neodymium:YAG laser prostatectomy. Costello AJ, et al. **Eur Urol** 1999 Feb;35(2):138–46 (68 ref.)

Holmium laser resection of the prostate. Le Duc A, et al. **Eur Urol** 1999 Feb;35(2):155–60 (32 ref.)

Interstitial laser therapy of benign prostatic hyperplasia. Muschter R, et al. **Eur Urol** 1999 Feb;35(2):147–54 (62 ref.)

Surgery for voice. Davies DG. **Hosp Med** 1999 Mar; 60(3):196–201 (11 ref.)

Lasers in surgery: a return to reason [editorial] Kavic MS. **J Soc Laparoendosc Surg** 1997 Jul–Sep;1(3):209–11 (12 ref.)

Management of coronary artery disease including transmyocardial laser revascularization. Gupta S, et al. **Md Med J** 1998 Nov;47(5):241–6 (17 ref.)

Advances in refractive surgery. New options expand the scope of corrective procedures. Chaudhry IM, et al. **Postgrad Med** 1999 Sep;106(3):129–31, 135–7 (10 ref.)

[Laser CO2 and ocular plastic surgery] Ameline-Audelan V, et al. **J Fr Ophtalmol** 1998 Mar;21(3):234–40 (42 ref.) **(Fre)**

[The use of CO2 laser in otolaryngology] Budziński R. **Otolaryngol Pol** 1999;53(3):343–6 (11 ref.) (Eng. Abstr.) **(Pol)**

[The use of intravascular laser therapy in ischemic disorders of cerebral circulation] Skupchenko VV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(4):37–42 (34 ref.) (Eng. Abstr.) **(Rus)**

LASER THERMOCOAGULATION see **LASER COAGULATION**

LASERS

Laser micromanipulation systems as universal tools in cellular and molecular biology and in medicine. Schütze K, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):735–46 (33 ref.)

Laser-scanning cytometry: A new instrumentation with many applications. Darzynkiewicz Z, et al. **Exp Cell Res** 1999 May 25;249(1):1–12 (52 ref.)

Technology status evaluation: developments in laser technology: November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):711–6 (63 ref.)

Overview of laser microbeam applications as related to antibody targeting. Pine PS. **Methods Mol Biol** 1999; 115:159–74 (29 ref.)

[Nanometer/piconewton manipulation of single membrane protein molecules by laser tweezers] Kusumi A. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):906–11 (21 ref.) **(Jpn)**

[Characteristics of laser light] Takač S, et al. **Med Pregl** 1999 Jan–Feb;52(1–2):29–34 (17 ref.) (Eng. Abstr.) **(Ser)**

ADVERSE EFFECTS

Laser injuries of the eye. Thach AB. **Int Ophthalmol Clin** 1999 Spring;39(2):13–27 (93 ref.)

Laser pointers: toys, nuisances, or significant eye hazards? Yolton RL, et al. **J Am Optom Assoc** 1999 May;70(5):285–9 (15 ref.)

[The laser pointer: no demonstrated danger to the eyes] van Norren D, et al. **Ned Tijdschr Geneeskd** 1998 Sep 5; 142(36):1979–82 (7 ref.) (Eng. Abstr.) **(Dut)**

DIAGNOSTIC USE

Optic nerve assessment: a clinical endpoint of optic neuropathy. Antón López A. **Eur J Ophthalmol** 1999 Jan–Mar;9 Suppl 1:S37–9 (11 ref.)

[Lasers in medicine] Fuchs B, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):259–66 (18 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Optical hair removal. Ort RJ, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):149–58 (42 ref.)

[Safety of laser use] Mierczyk Z, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):211–7 (14 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Lasers in urology. Floratos DL, et al. **BJU Int** 1999 Jul; 84(2):204–11 (59 ref.)

A systematic review of the clinical efficacy and effectiveness of the holmium:YAG laser in urology. Larizgoitia I, et al. **BJU Int** 1999 Jul;84(1):1–9 (85 ref.)

Port-wine stains unresponsive to pulsed dye laser: explanations and solutions. Lanigan SW. **Br J Dermatol**

1998 Aug;139(2):173–7 (39 ref.)
Review of modern techniques in detecting port-wine stain response to laser therapy. Le KV, et al. **Dermatol Surg** 1999 Feb;25(2):127–32 (34 ref.)
Therapeutic modalities in hand surgery. Bissell JH. **J Hand Surg [Am]** 1999 May;24(3):435–48 (166 ref.)
Clinical efficacy of low power laser therapy in osteoarthritis. Marks R, et al. **Physiother Res Int** 1999;4(2):141–57 (31 ref.)
Laser treatment of pigmented lesions in children. Carpo BG, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):233–43 (59 ref.)
[Pulsed laser in scar treatment] Hellwig S, et al. **Hautarzt** 1999 Jul;50(7):465–9 (31 ref.) (Eng. Abstr.) **(Ger)**
[Current status of laser therapy in dermatology] Hellwig S, et al. **Hautarzt** 1998 Sep;49(9):690–704 (154 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic use of lasers in dermatology] Hohenleutner U, et al. **Ther Umsch** 1999 Apr;56(4):170–5 (28 ref.) (Eng. Abstr.) **(Ger)**
[Laser therapy in dermatology] St Lautenschlager. **Ther Umsch** 1998 Aug;55(8):522–8 (22 ref.) (Eng. Abstr.) **(Ger)**
[Lasers in medicine] Fuchs B, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):259–66 (18 ref.) (Eng. Abstr.) **(Ger)**
[Transmyocardial laser revascularization] Lutter G, et al. **Zentralbl Chir** 1999;124(3):171–5 (50 ref.) (Eng. Abstr.) **(Ger)**
[Safety of laser use] Mierczyk Z, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):211–7 (14 ref.) (Eng. Abstr.) **(Pol)**
[Laser therapy and its application in gastroenterology] Rapoport SI, et al. **Klin Med (Mosk)** 1999;77(1):34–9 (28 ref.) **(Rus)**
[Free radical mechanisms of low-intensive laser radiation] Chichuk TV, et al. **Vestn Ross Akad Med Nauk** 1999; (2):27–32 (54 ref.) (Eng. Abstr.) **(Rus)**
[The clinical effect of low-intensity laser radiation as a result of the development of body adaptation] Vasil'ev AP, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jul-Aug; (4):49–51 (41 ref.) **(Rus)**
[Treatment of malignant choroidal melanoma with transpupillary thermotherapy using the diode laser] Strmeň P, et al. **Cesk Slov Oftalmol** 1999 May;55(3):176–80 (27 ref.) **(Slo)**

UTILIZATION

Cell ablation studies in plant development. Berger F. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):711–9 (24 ref.)
Laser tweezers and optical microsurgery in cellular and molecular biology. Working principles and selected applications. Greulich KO, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):701–10 (25 ref.)

LASSA FEVER

[Lassa fever: its virological and clinical aspects] Hirabayashi Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):80–4 (23 ref.) **(Jpn)**

DIAGNOSIS

[Laboratory diagnosis of viral infections. 8. Viral hemorrhagic fever] Morikawa S. **Rinsho Byori** 1998 Nov; Suppl 108:105–10 (9 ref.) **(Jpn)**

IMMUNOLOGY

Lassa fever: implications of T-cell immunity for vaccine development. ter Meulen J. **J Biotechnol** 1999 Aug 20; 73(2–3):207–12 (21 ref.)

PREVENTION & CONTROL

Lassa fever: implications of T-cell immunity for vaccine development. ter Meulen J. **J Biotechnol** 1999 Aug 20; 73(2–3):207–12 (21 ref.)

LASSITUDE see **FATIGUE**

LATE GENE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

LATE PROMOTERS see **PROMOTER REGIONS (GENETICS)**

LATENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

LATERAL CYST see **PERIODONTAL CYST**

LATERAL GENICULATE BODY see **GENICULATE BODIES**

LATERAL LIGAMENT, ANKLE

INJURIES

[Chronic recurrent ligament instability on the lateral ankle] Becker HP, et al. **Orthopade** 1999 Jun;28(6):483–92 (43 ref.) (Eng. Abstr.) **(Ger)**

LATERAL MENISCI see **MENISCI, TIBIAL**

LATERAL SCLEROSIS see **AMYOTROPHIC LATERAL SCLEROSIS**

LATERALITY

On the nature of left hemisphere specialization for signed language. Corina DP. **Brain Lang** 1999 Sep;69(2):230–40 (34 ref.)
Dyslexia, gender, and brain imaging. Lambe EK. **Neuropsychologia** 1999 May;37(5):521–36 (137 ref.)
[Hemicerebral atrophy and epilepsy in an adult] Viala K, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):45–50 (10 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The genetics of hand-clasping--a review and a familial study. Reiss M. **Ann Hum Biol** 1999 Jan–Feb;26(1):39–48 (47 ref.)
Left-handedness as a function of sex, maternal versus paternal inheritance, and report bias. Annett M. **Behav Genet** 1999 Mar;29(2):103–14 (50 ref.)
[Hand clasping--an overview] Reiss M. **Anthropol Anz** 1999 Jun;57(2):165–84 (115 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Major review: ocular sighting dominance: a review and a study of athletic proficiency and eye-hand dominance in a collegiate baseball team [see comments] Portal JM, et al. **Binocul Vis Strabismus Q** 1998 Summer-Winter;13(2 2nd Qtr):125–32 (12 ref.) Comment in: Binocul Vis Strabismus Q 1998 Fall;13(3 3rd Qtr):165–6.
Cerebral hemispheric mechanisms linking ambiguous word meaning retrieval and creativity. Atchley RA, et al. **Brain Cogn** 1999 Aug;40(3):479–99 (79 ref.)
Child age and planum temporale asymmetry. Preis S, et al. **Brain Cogn** 1999 Aug;40(3):441–52 (36 ref.)
ECoG findings in hemispherectomy. Wennberg R, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:132–9 (33 ref.)
Handedness and cerebral dominance: the right shift theory. Annett M. **J Neuropsychiatry Clin Neurosci** 1998 Fall; 10(4):459–69 (96 ref.)
Why do we speak with the left hemisphere? Capozzoli NJ. **Med Hypotheses** 1999 Jun;52(6):497–503 (18 ref.)
Functional anatomy of dominance for speech comprehension in left handers vs right handers. Tzourio N, et al. **Neuroimage** 1998 Jul;8(1):1–16 (100 ref.)
Background gamma-oscillations in neuronal networks with interhemisphere connections. Sil'kis IG, et al. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):645–59 (48 ref.)
Neuronal cell death during sexual differentiation and lateralisation of vocal communication. Holman SD. **Neurosci Biobehav Rev** 1998 Oct;22(6):725–34 (94 ref.)
Sexually-dimorphic patterns of cortical asymmetry, and the role for sex steroid hormones in determining cortical patterns of lateralization. Wisniewski AB. **Psychoneuroendocrinology** 1998 Jul;23(5):519–47 (130 ref.)
Laterality in animals: relevance to schizophrenia. Cowell PE, et al. **Schizophr Bull** 1999;25(1):41–62 (255 ref.)
Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation. Gruzelier JH. **Schizophr Bull** 1999;25(1):91–120 (235 ref.)
Laterality in functional brain imaging studies of schizophrenia. Gur RE, et al. **Schizophr Bull** 1999; 25(1):141–56 (87 ref.)
Structural asymmetries of the human brain and their disturbance in schizophrenia. Petty RG. **Schizophr Bull** 1999;25(1):121–39 (224 ref.)
Atypical handedness in schizophrenia: some methodological and theoretical issues. Satz P, et al. **Schizophr Bull** 1999; 25(1):63–78 (110 ref.)
Molecular mechanisms of vertebrate left-right development. Ramsdell AF, et al. **Trends Genet** 1998 Nov;14(11):459–65 (49 ref.)
Does the right side know what the left is doing? Koltzenburg M, et al. **Trends Neurosci** 1999 Mar;22(3):122–7 (91 ref.)
[Bilateral intracranial subdural hematoma following lumbar puncture: report of a case] Lavie F, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):703–5 (12 ref.) (Eng. Abstr.) **(Fre)**
[Anatomical and surgical note: functional hemispherectomy] Yoshimine T, et al. **No Shinkei Geka** 1998 Nov; 26(11):956–68 (45 ref.) **(Jpn)**
[Role of the right and left cerebral hemispheres in space perception. I. Object perception and reflection in the frontal plane] Nikolaenko NN, et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):54–64 (38 ref.) **(Rus)**
[The role of the right and left cerebral hemispheres in space perception. II. Depth perception as an interhemispheric phenomenon] Nikolaenko NN, et al. **Fiziol Cheloveka** 1998 Nov-Dec;24(6):21–31 (32 ref.) **(Rus)**

LATEX

ADVERSE EFFECTS

Allergy to natural rubber latex. Yunginger JW. **Minn Med** 1998 Sep;81(9):27–30 (33 ref.)

IMMUNOLOGY

Latex antigens: identification and use in clinical and experimental studies, including crossreactivity with food and pollen allergens. Nel A, et al. **Ann Allergy Asthma Immunol** 1998 Nov;81(5 Pt 1):388–96; quiz 397–8 (60 ref.)

LATEX ALLERGY

see related
DERMATITIS, ALLERGIC CONTACT
HYPERSENSITIVITY, IMMEDIATE

Update in allergy and immunology. O'Hollaren MT. **Ann Intern Med** 1998 Dec 15;129(12):1036–43 (5 ref.)
Natural rubber latex allergy. Wakelin SH, et al. **Clin Exp Dermatol** 1999 Jul;24(4):245–8 (30 ref.)
Review of latex allergy. Cheng L, et al. **J Am Board Fam Pract** 1999 Jul-Aug;12(4):285–92 (39 ref.)
The dental team and latex hypersensitivity. ADA Council on Scientific Affairs. **J Am Dent Assoc** 1999 Feb; 130(2):257–64 (50 ref.)
Latex sensitivity: a public health care challenge. Bartlett J. **J Community Health Nurs** 1998;15(4):193–204 (37 ref.)
Latex allergy: a review of considerations for the oral and maxillofacial surgeon. Mehra P, et al. **J Oral Maxillofac Surg** 1998 Dec;56(12):1426–30 (9 ref.)
Latex allergy: a review for the dental professional. Spina AM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):5–11 (47 ref.)
[Latex: a complex allergy] Ferreira MB, et al. **Allerg Immunol (Paris)** 1999 Jan;31(1):18–21 (34 ref.) (Eng. Abstr.) **(Fre)**
[Latex allergy] Jeannet-Peter N. **Rev Med Suisse Romande** 1999 Mar;119(3):227–9 (5 ref.) **(Fre)**
[Latex allergy: a current medical problem] Gromova VV, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):27–33 (45 ref.) **(Rus)**

COMPLICATIONS

Latex hypersensitivity/glove component reaction as a contributing factor to osteomyelitis of the hand: a case report and review of the literature. Duplechain MT, et al. **J La State Med Soc** 1998 Nov;150(11):527–32 (22 ref.)
Work-related asthma and latex allergy. Sorting out the types, causes, and consequences. Avila PC, et al. **Postgrad Med** 1999 Jun;105(7):39–46 (19 ref.)

DIAGNOSIS

How do you diagnose latex allergy? Apter A, et al. **Am J Contact Dermat** 1999 Sep;10(3):177–9 (6 ref.)
Latex allergy: a patient and health care system emergency. Kelly KJ, et al. **Ann Emerg Med** 1998 Dec;32(6):723–9 (42 ref.)
Latex allergy [see comments] Kelso JM. **Pediatr Ann** 1998 Nov;27(11):736–9 (10 ref.) Comment in: Pediatr Ann 1998 Nov;27(11):708.

DRUG THERAPY

Latex allergy: a patient and health care system emergency. Kelly KJ, et al. **Ann Emerg Med** 1998 Dec;32(6):723–9 (42 ref.)

EPIDEMIOLOGY

Latex allergy in neurosurgical practice. Mazagri R, et al. **Childs Nerv Syst** 1999 Aug;15(8):404–7 (45 ref.)
Latex allergy in children. Cantani A. **J Investig Allergol Clin Immunol** 1999 Jan–Feb;9(1):14–20 (57 ref.)
A review of current literature on epidemiology of immediate glove irritation and latex allergy. Kujala V. **Occup Med (Lond)** 1999 Jan;49(1):3–9 (73 ref.)
Rubber contact dermatitis in patients attended at Walter Cantidio Hospital, Federal University of Ceará, Brasil. Diógenes MJ, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar-Apr;40(2):101–3 (10 ref.)

ETIOLOGY

Allergy to natural rubber latex. Yunginger JW. **Minn Med** 1998 Sep;81(9):27–30 (33 ref.)

IMMUNOLOGY

Latex antigens: identification and use in clinical and experimental studies, including crossreactivity with food and pollen allergens. Nel A, et al. **Ann Allergy Asthma Immunol** 1998 Nov;81(5 Pt 1):388–96; quiz 397–8 (60 ref.)
[Urologic surgery and allergy to natural latex] Chartier-Kastler E, et al. **Presse Med** 1998 Apr 25; 27(16):771–8 (48 ref.) **(Fre)**
[Plant defense-related proteins as latex allergens] Yagami T. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):46–62 (121 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Latex allergy. An not rare intraoperative event] Cantini O, et al. **Minerva Anestesiol** 1999 Mar;65(3):101–7 (32 ref.) (Eng. Abstr.) **(Ita)**

LATEX ALLERGY

PREVENTION & CONTROL

A review of current literature on epidemiology of immediate glove irritation and latex allergy. Kujala V. **Occup Med (Lond)** 1999 Jan;49(1):3–9 (73 ref.)

[Prevention of work-related latex allergy] Mehlum IS. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3287–92 (38 ref.) (Eng. Abstr.) **(Nor)**

LATEX BEADS see **MICROSPHERES**

LATEX HYPERSENSITIVITY see **LATEX ALLERGY**

LATEX PARTICLES see **MICROSPHERES**

LATEX SPHERES see **MICROSPHERES**

LATHYRUS see **LEGUMES**

LATINOS see **HISPANIC AMERICANS**

LATRODECTUS MACTANS see **BLACK WIDOW SPIDER**

LATS see **LONG-ACTING THYROID STIMULATOR**

LATS RECEPTORS see **RECEPTORS, THYROID HORMONE**

LAUDACON see **HYDROMORPHONE**

LAUNDRY SERVICE, HOSPITAL

see related
BEDDING AND LINENS

LAURACEAE

CHEMISTRY

Chemistry and pharmacology of Monimiaceae: a special focus on Siparuna and Mollinedia. Leitão GG, et al. **J Ethnopharmacol** 1999 May;65(2):87–102 (61 ref.)

LAURALES see **LAURACEAE**

LAURENCE-MOON-BIEDL SYNDROME

Otolaryngologic features of Laurence-Moon-Bardet-Biedl syndrome. Urben SL, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):571–4 (16 ref.)

LAV-2 see **HIV-2**

LAV ANTIBODIES see **HIV ANTIBODIES**

LAV ANTIGENS see **HIV ANTIGENS**

LAV-HTLV-III see **HIV**

LAVAGE see **IRRIGATION**

LAVAGE, GASTRIC see **GASTRIC LAVAGE**

LAVAGE, PERITONEAL see **PERITONEAL LAVAGE**

LAVENDER see **LAMIACEAE**

LAW ENFORCEMENT OFFICERS see **POLICE**

LAXATIVES see **CATHARTICS**

LAXITY, JOINT see **JOINT INSTABILITY**

LAYING-ON-OF-HANDS see **THERAPEUTIC TOUCH**

LCF FACTOR see **INTERLEUKIN-16**

LCK KINASE see **LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK)**

LCM VIRUSES see **LYMPHOCYTIC CHORIOMENINGITIS VIRUS**

LDL CHOLESTEROL see **LIPOPROTEINS, LDL CHOLESTEROL**

LDL RECEPTORS see **RECEPTORS, LDL**

LE CELLS see **NEUTROPHILS**

LEAD

see related
LEAD RADIOISOTOPES

ADVERSE EFFECTS

Selective vulnerability of the developing brain to lead. Johnston MV, et al. **Curr Opin Neurol** 1998 Dec; 11(6):689–93 (36 ref.)

Lead contamination in Uruguay. Mañay N, et al. **Rev Environ Contam Toxicol** 1999;159:25–39 (21 ref.)

Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:40–3 (8 ref.)

ANALYSIS

Elevated lead exposure in American woodcock (Scolopax minor) in Eastern Canada. Scheuhammer AM, et al. **Arch Environ Contam Toxicol** 1999 Apr;36(3):334–40 (56 ref.)

Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Hu H, et al. **Environ Health Perspect** 1998 Jan;106(1):1–8 (94 ref.)

Predicting blood lead concentrations from lead in environmental media. Mahaffey KR. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1485–93 (64 ref.)

Origin of cadmium and lead in clear softwater lakes of high-altitude and high-latitude, and their bioavailability and toxicity to fish. Köck G, et al. **EXS** 1998;86:225–57 (206 ref.)

Relationship of lead in drinking water to bone lead levels twenty years later in Boston men: the Normative Aging Study. Potula V, et al. **J Occup Environ Med** 1999 May; 41(5):349–55 (32 ref.)

Heavy metal concentrations in adult acanthocephalans and cestodes compared to their fish hosts and to established free-living bioindicators. Sures B, et al. **Parassitologia** 1997 Sep;39(3):213–8 (20 ref.)

BLOOD

Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Gordon RA, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1100–4 (32 ref.)

Measurement error, biases, and the validation of complex models for blood lead levels in children. Carroll RJ, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1535–9 (4 ref.)

Predicting blood lead concentrations from lead in environmental media. Mahaffey KR. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1485–93 (64 ref.)

The integrated exposure uptake biokinetic model for lead in children: independent validation and verification. Zaragoza L, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1551–6 (40 ref.)

HISTORY

Historical perspective on lead biokinetic models. Rabinowitz M. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1461–5 (56 ref.)

METABOLISM

Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Hu H, et al. **Environ Health Perspect** 1998 Jan;106(1):1–8 (94 ref.)

[Accumulation of lead in bone and its effects on health] Sanín LH, et al. **Salud Publica Mex** 1998 Jul–Aug;40(4):359–68 (91 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Roles of lead-binding proteins in mediating lead bioavailability. Fowler BA. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1585–7 (28 ref.)

Structure, use, and validation of the IEUBK model. Mickle MH. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1531–4 (13 ref.)

A physiologically based kinetic model for lead in children and adults. O'Flaherty EJ. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1495–503 (51 ref.)

The ICRP age-specific biokinetic model for lead: validations, empirical comparisons, and explorations. Pounds JG, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1505–11 (29 ref.)

The conceptual structure of the integrated exposure uptake biokinetic model for lead in children. White PD, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1513–30 (99 ref.)

PHARMACOLOGY

Molecular mechanisms of lead neurotoxicity. Bressler J, et al. **Neurochem Res** 1999 Apr;24(4):595–600 (64 ref.)

Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Savolainen KM, et al. **Neurotoxicology** 1998 Aug–Oct; 19(4–5):669–74 (51 ref.)

TOXICITY

Structure, use, and validation of the IEUBK model. Mickle MH. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1531–4 (13 ref.)

Uses and limits of empirical data in measuring and modeling human lead exposure. Mushak P. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1467–84 (111 ref.)

The ICRP age-specific biokinetic model for lead: validations, empirical comparisons, and explorations. Pounds JG, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1505–11 (29 ref.)

Historical perspective on lead biokinetic models. Rabinowitz M. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1461–5 (56 ref.)

The conceptual structure of the integrated exposure uptake biokinetic model for lead in children. White PD, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1513–30 (99 ref.)

Interactions of excitatory neurotransmitters and xenobiotics in excitotoxicity and oxidative stress: glutamate and lead. Savolainen KM, et al. **Toxicol Lett** 1998 Dec 28; 102–103:363–7 (25 ref.)

LEAD POISONING

COMPLICATIONS

Lead--the toxic metal to stay with human. Srianujata S. **J Toxicol Sci** 1998 Jul;23 Suppl 2:237–40 (13 ref.)

DRUG THERAPY

The role of iron therapy in childhood plumbism. Wright RO. **Curr Opin Pediatr** 1999 Jun;11(3):255–8 (32 ref.)

EPIDEMIOLOGY

Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Hu H, et al. **Environ Health Perspect** 1998 Jan;106(1):1–8 (94 ref.)

[Chronic lead poisoning in children today. A pathology of poverty and social exclusion] Sinnaeve O, et al. **Arch Pediatr** 1999 Jul;6(7):762–7 (37 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Hu H, et al. **Environ Health Perspect** 1998 Jan;106(1):1–8 (94 ref.)

PHYSIOPATHOLOGY

Selective vulnerability of the developing brain to lead. Johnston MV, et al. **Curr Opin Neurol** 1998 Dec; 11(6):689–93 (36 ref.)

[Metal poisoning] Inoue N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):618–22 (12 ref.) **(Jpn)**

PREVENTION & CONTROL

Childhood lead poisoning: the promise and abandonment of primary prevention [see comments] Needleman HL. **Am J Public Health** 1998 Dec;88(12):1871–7 (38 ref.) Comment in: Am J Public Health 1998 Dec;88(12):1759–60. Comment in: Am J Public Health 1999 Jul;89(7):1126–31.

Protecting children from lead poisoning and building healthy communities [editorial] Ryan D, et al. **Am J Public Health** 1999 Jun;89(6):822–4 (25 ref.)

THERAPY

Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Gordon RA, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1100–4 (32 ref.)

LEAD RADIOISOTOPES

ANALYSIS

Dating human skeletal remains: investigating the viability of measuring the equilibrium between 210Po and 210Pb as a means of estimating the post-mortem interval. Swift B. **Forensic Sci Int** 1998 Nov 30;98(1–2):119–26 (29 ref.)

LEADER MRNA SEQUENCES see **5' UNTRANSLATED REGIONS**

LEADER SEQUENCES, MRNA see **5' UNTRANSLATED REGIONS**

LEADER SIGNAL PEPTIDES see **SIGNAL PEPTIDES**

LEADERSHIP

[Quality assurance of department administration] Lichtenberg SM, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):983–6 (10 ref.) **(Nor)**

LEAFHOPPERS see **HEMIPTERA**

LEARNED HELPLESSNESS see **HELPLESSNESS, LEARNED**

LEARNING

Teaching and learning communication in medicine: a rhetorical approach. Lingard L, et al. **Acad Med** 1999 May; 74(5):507–10 (10 ref.)

Learning in preschool children with neurological disability. Stanley O, et al. **Arch Dis Child** 1999 May;80(5):481–4 (30 ref.)

Issues in teaching and learning time-limited psychodynamic psychotherapy. Binder JL. **Clin Psychol Rev** 1999 Sep; 19(6):705–19 (67 ref.)

Theory and practice for teaching the childbearing couple. Farrell M, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec;27(6):613-8 (22 ref.)
Cholinergic facilitation of trace eyeblink conditioning in aging rabbits. Disterhoft JF, et al. **Life Sci** 1999; 64(6-7):541-8 (66 ref.)
Considerations in the education of children with hearing loss. Matkin ND, et al. **Pediatr Clin North Am** 1999 Feb; 46(1):143-52 (19 ref.)
Stress-axis, coping and dementia: gene-manipulation studies. Heinrichs SC. **Trends Pharmacol Sci** 1999 Aug;20(8):311-5 (51 ref.)

CLASSIFICATION

Images of medial temporal lobe functions in human learning and memory. Gabrieli JD, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):275-83 (51 ref.)

DRUG EFFECTS

Posttraining estrogen and memory modulation. Packard MG. **Horm Behav** 1998 Oct;34(2):126-39 (135 ref.)
The behavioral functions of the cholinergic basal forebrain: lessons from 192 IgG-saporin. Wrenn CC, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):595-602 (69 ref.)
Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models. Hiramatsu M, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):595-9 (34 ref.)
Piracetam: novelty in a unique mode of action. Müller WE, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:2-9 (59 ref.)
[The effect of NC-1900: its ameliorating effects on impairments of learning and memory in the CA1 neurons and its intracellular signal transduction pathways] Akaike N, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:44P-47P (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Bench to bedside in medical education. Turnbull J. **Acad Med** 1999 Jun;74(6):664-6 (12 ref.)
The role of cortico-striatal circuits in learning sequential information. Brown RG. **Adv Neurol** 1999;80:31-9 (60 ref.)
Involvement of the pallidal-thalamocortical circuit in adaptive behavior. Kalivas PW, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:64-70 (23 ref.)
Modulation of acetylcholine and serotonin transmission by galanin. Relationship to spatial and aversive learning. Ogren SO, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:342-63 (77 ref.)
Neuroethology of spatial learning: the birds and the bees. Capaldi EA, et al. **Annu Rev Psychol** 1999;50:651-82 (216 ref.)
The cerebellum and postural sensorimotor learning in mice and rats. Caston J, et al. **Behav Brain Res** 1998 Sep; 95(1):17-22 (45 ref.)
The neurochemical basis of learning and neurocomputation: the redox theory. Smythies J. **Behav Brain Res** 1999 Feb 15;99(1):1-6 (57 ref.)
Learning by imitation: a hierarchical approach. Byrne RW, et al. **Behav Brain Sci** 1998 Oct;21(5):667-84; discussion 684-721 (240 ref.)
The development of features in object concepts. Schyns PG, et al. **Behav Brain Sci** 1998 Feb;21(1):1-17; discussion 17-54 (298 ref.)
Long-term potentiation: what's learning got to do with it? Shors TJ, et al. **Behav Brain Sci** 1997 Dec;20(4):597-614; discussion 614-55 (575 ref.)
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Berridge KC, et al. **Brain Res Brain Res Rev** 1998 Dec;28(3):309-69 (531 ref.)
Modeling memory: what do we learn from attractor neural networks? Brunel N, et al. **C R Acad Sci III** 1998 Feb-Mar; 321(2-3):249-52 (19 ref.)
A molecular biological approach to synaptic plasticity and learning. Davis S, et al. **C R Acad Sci III** 1998 Feb-Mar; 321(2-3):97-107 (109 ref.)
Memory, learning and metacognition. Jacob P. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):253-9 (32 ref.)
The first panic attack: a neurobiological theory. Jacobs WJ, et al. **Can J Exp Psychol** 1999 Mar;53(1):92-107 (148 ref.)
The link between brain learning, attention, and consciousness. Grossberg S. **Conscious Cogn** 1999 Mar;8(1):1-44 (116 ref.)
Cortical function: jump-starting the brain. O'Breathnach U, et al. **Curr Biol** 1999 Mar 11;9(5):R184-5 (12 ref.)
Molecular mechanisms of synaptic plasticity and memory. Elgersma Y, et al. **Curr Opin Neurobiol** 1999 Apr; 9(2):209-13 (43 ref.)
Sensitive periods and circuits for learned birdsong. Mooney R. **Curr Opin Neurobiol** 1999 Feb;9(1):121-7 (66 ref.)
Learning in the oculomotor system: from molecules to behavior. Raymond JL. **Curr Opin Neurobiol** 1998 Dec; 8(6):770-6 (77 ref.)
Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1-2):90-4 (43 ref.)
Automatic activation of the medial temporal lobe during encoding: lateralized influences of meaning and novelty. Martin A. **Hippocampus** 1999;9(1):62-70 (57 ref.)
Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Schacter DL, et al. **Hippocampus** 1999;9(1):7-24 (86 ref.)
Recent progress in the neurology of learning: memory molecules in the developing brain. Johnston MV, et al. **J Dev Behav Pediatr** 1999 Feb;20(1):50-6 (50 ref.)
Role of interneurons in defensive withdrawal reflexes in Aplysia. Cleary LJ, et al. **Learn Mem** 1995 May-Aug; 2(3-4):133-51 (101 ref.)
Prediction and preparation, fundamental functions of the cerebellum. Courchesne E, et al. **Learn Mem** 1997 May-Jun;4(1):1-35 (101 ref.)
Learning from LTP: a comment on recent attempts to identify cellular and molecular mechanisms of memory. Eichenbaum H. **Learn Mem** 1996 Sep-Oct;3(2-3):61-73 (68 ref.)
Behavioral development in the honey bee: toward the study of learning under natural conditions. Fahrbach SE, et al. **Learn Mem** 1995 Sep-Oct;2(5):199-224 (141 ref.)
Late-training amnesic deficits in probabilistic category learning: a neurocomputational analysis. Gluck MA, et al. **Learn Mem** 1996 Nov-Dec;3(4):326-40 (68 ref.)
Regulation of synaptic function by neurotrophic factors in vertebrates and invertebrates: implications for development and learning. McKay SE, et al. **Learn Mem** 1999 May-Jun; 6(3):193-215 (196 ref.)
The predictive brain: temporal coincidence and temporal order in synaptic learning mechanisms. Montague PR, et al. **Learn Mem** 1994 May-Jun;1(1):1-33 (165 ref.)
A cerebellar model of timing and prediction in the control of reaching. Barto AG, et al. **Neural Comput** 1999 Apr 1;11(3):565-94 (90 ref.)
Recurrent sampling models for the Helmholtz machine. Dayan P. **Neural Comput** 1999 Apr 1;11(3):653-78 (44 ref.)
Parameter convergence and learning curves for neural networks. Fine TL, et al. **Neural Comput** 1999 Apr 1; 11(3):747-70 (22 ref.)
Synaptic plasticity and learning and memory: 15 years of progress. Baudry M. **Neurobiol Learn Mem** 1998 Jul-Sep; 70(1-2):113-8 (19 ref.)
Images of medial temporal lobe functions in human learning and memory. Gabrieli JD, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):275-83 (51 ref.)
The basal ganglia and chunking of action repertoires. Graybiel AM. **Neurobiol Learn Mem** 1998 Jul-Sep; 70(1-2):119-36 (97 ref.)
Differential roles of the frontal cortex, basal ganglia, and cerebellum in visuomotor sequence learning. Hikosaka O, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):137-49 (18 ref.)
A comparative perspective on motor learning. Striedter GF. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):189-96 (35 ref.)
A role for the cerebellum in learning movement coordination. Thach WT. **Neurobiol Learn Mem** 1998 Jul-Sep; 70(1-2):177-88 (59 ref.)
The nature of reinforcement in cerebellar learning. Thompson RF, et al. **Neurobiol Learn Mem** 1998 Jul-Sep; 70(1-2):150-76 (110 ref.)
Learning something ORIGINal at the Drosophila neuromuscular junction [comment] DiAntonio A. **Neuron** 1999 May;23(1):1-2 (10 ref.) Comment on: Neuron 1999 May;23(1):45-54.
Working memory contributions to human learning and remembering. Wagner AD. **Neuron** 1999 Jan;22(1):19-22 (20 ref.)
Transcranial magnetic stimulation can measure and modulate learning and memory. Grafman J, et al. **Neuropsychologia** 1999 Feb;37(2):159-67 (51 ref.)
Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Hölscher C, et al. **Neurosci Biobehav Rev** 1999;23(3):399-410 (125 ref.)
Is learning blocked by saturation of synaptic weights in the hippocampus? Moser EI, et al. **Neurosci Biobehav Rev** 1999 May;23(5):661-72 (110 ref.)
Combination, complementarity and automatic control: a role for the cerebellum in learning movement coordination. Thach WT. **Novartis Found Symp** 1998;218:219-28; discussion 228-32 (30 ref.)
Taste aversion learning: a contemporary perspective. Bernstein IL. **Nutrition** 1999 Mar;15(3):229-34 (67 ref.)
The neural correlates of consciousness: an analysis of cognitive skill learning. Raichle ME. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1889-901 (75 ref.)
Learning-induced physiological plasticity in the thalamo-cortical sensory systems: a critical evaluation of receptive field plasticity, map changes and their potential mechanisms. Edeline JM. **Prog Neurobiol** 1999 Feb; 57(2):165-224 (369 ref.)
How does the cerebral cortex work? Learning, attention, and grouping by the laminar circuits of visual cortex. Grossberg S. **Spat Vis** 1999;12(2):163-85 (105 ref.)
Imprinting, learning and development: from behaviour to brain and back. Bolhuis JJ, et al. **Trends Neurosci** 1998 Jul;21(7):306-11 (51 ref.)
[Olfactory training: memory systems in the rats] Chaillan FA, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):157-61 (16 ref.) **(Fre)**
[The use of dissociated learning in the study of the mechanisms of memory] Azarashvili AA. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 May-Jun; 49(3):371-84 (25 ref.) (Eng. Abstr.) **(Rus)**

LEARNING DISORDERS

see related
DYSLEXIA

Learning disabilities, dyslexia, and vision: a subject review. Committee on Children with Disabilities, American Academy of Pediatrics (AAP) and American Academy of Ophthalmology (AAO), American Association for Pediatric Ophthalmology and Strabismus (AAPOS). **Pediatrics** 1998 Nov;102(5):1217-9 (24 ref.)
[Why should LD be discussed now?] Futakami S. **No To Hattatsu** 1999 May;31(3):226-8 (6 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

School problems and the family physician. Phillips DM, et al. **Am Fam Physician** 1999 May 15;59(10):2816-24 (12 ref.)
Practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. AACAP. **J Am Acad Child Adolesc Psychiatry** 1998 Oct;37(10 Suppl):46S-62S (119 ref.)
Summary of the practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. American Academy of Child and Adolescent Psychiatry] **J Am Acad Child Adolesc Psychiatry** 1998 Oct; 37(10):1117-9 (1 ref.)

DRUG THERAPY

Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Meneses A. **Rev Neurosci** 1998;9(4):275-89 (89 ref.)

EPIDEMIOLOGY

Optimality of the birth population reduces learning and behaviour disorders and sudden infant death after the first month. Saugstad LF. **Acta Paediatr Suppl** 1999 May; 88(429):9-28 (171 ref.)

ETIOLOGY

Drug addiction as dopamine-dependent associative learning disorder. Di Chiara G. **Eur J Pharmacol** 1999 Jun 30; 375(1-3):13-30 (140 ref.)
Multiple chemical sensitivity as a conditional response. Siegel S. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):323-30 (71 ref.)

PHYSIOPATHOLOGY

Language learning impairments: integrating basic science, technology, and remediation. Tallal P, et al. **Exp Brain Res** 1998 Nov;123(1-2):210-9 (86 ref.)
Emotional and cognitive aspects in adolescence-onset school difficulties. Masi G, et al. **Panminerva Med** 1999 Mar; 41(1):54-8 (21 ref.)

PSYCHOLOGY

The misunderstood child: the child with a nonverbal learning disorder. Little L. **J Soc Pediatr Nurs** 1999 Jul-Sep; 4(3):113-21; quiz 123-4 (26 ref.)

THERAPY

Practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. AACAP. **J Am Acad Child Adolesc Psychiatry** 1998 Oct;37(10 Suppl):46S-62S (119 ref.)
A patient with learning disability and menorrhagia. Wishart K, et al. **Practitioner** 1998 Jan;242(1582):9, 15 (0 ref.)

LEBER HEREDITARY OPTIC ATROPHY see **OPTIC ATROPHY, HEREDITARY**

LECAM-1 see **L-SELECTIN**

LECAM-2 see **E-SELECTIN**

LECAM-3 see **P-SELECTIN**

LECITHIN ACYLTRANSFERASE see **PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE**

LECITHIN CHOLESTEROL ACYLTRANSFERASE see **PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE**

LECITHINASE A1 see **PHOSPHOLIPASES A**

LECITHINASE A2 see **PHOSPHOLIPASES A**

LECITHINASE B see **LYSOPHOSPHOLIPASE**

LECITHINASE C see **PHOSPHOLIPASE C**

LECITHINASE D see **PHOSPHOLIPASE D**

LECITHINASES see **PHOSPHOLIPASES**

LECITHINS

LECITHINS see **PHOSPHATIDYLCHOLINES**

LECTIN, CASTOR BEAN see **RICIN**

LECTIN RECEPTORS see **RECEPTORS, MITOGEN**

LECTIN, RICINUS see **RICIN**

LECTINS

see related
RECEPTORS, MITOGEN

Plant lectins - more than just tools for glycoscientists: occurrence, structure, and possible functions of plant lectins. Rüdiger H. **Acta Anat (Basel)** 1998;161(1-4):130-52 (381 ref.)

Multimodal application of lectin affinity electrophoresis of alpha-fetoprotein. Taketa K. **Electrophoresis** 1998 Jul; 19(10):1774-9 (28 ref.)

Characterization of sugar chain structures of human alpha-fetoprotein by lectin affinity electrophoresis. ibarahp@oka.urban.ne.jp. Taketa K. **Electrophoresis** 1998 Nov;19(15):2595-602 (36 ref.)

The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Mitchell BS, et al. **Histol Histopathol** 1999 Jan;14(1):217-26 (70 ref.)

Histochemistry and cytochemistry of endogenous animal lectins. Akimoto Y, et al. **Prog Histochem Cytochem** 1998; 33(1):1-90 (322 ref.)

[Preparation of glyco-replica peptides which mimic functional roles of carbohydrates by using phage-displayed peptide library] Ishikawa D, et al.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2611-7 (30 ref.) **(Jpn)**

ANALYSIS

Glycobiology of the olfactory system. Plendl J, et al.
Acta Anat (Basel) 1998;161(1-4):234-53 (188 ref.)

The Griffonia simplicifolia I-B4 isolectin. A probe for alpha-D-galactosyl end groups. Goldstein IJ, et al.
Subcell Biochem 1999;32:127-41 (67 ref.)

CHEMISTRY

Lectin ligands: new insights into their conformations and their dynamic behavior and the discovery of conformer selection by lectins. von der Lieth C, et al.
Acta Anat (Basel) 1998;161(1-4):91-109 (113 ref.)

Structure and functions of lectins in the central and peripheral nervous system. Zanetta JP. **Acta Anat (Basel)** 1998; 161(1-4):180-95 (116 ref.)

The C-type lectin superfamily in the immune system. Weis WI, et al. **Immunol Rev** 1998 Jun;163:19-34 (73 ref.)

[A novel plant lectin group has homologous structure to ribosome-inactivating protein, ricin] Kaku H. **Seikagaku** 1999 Feb;71(2):124-8 (15 ref.) **(Jpn)**

CLASSIFICATION

[Animal lectins--structure and function] Matejuk A, et al.
Postepy Hig Med Dosw 1998;52(5):445-70 (145 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSTIC USE

Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Brinck U, et al.
Acta Anat (Basel) 1998;161(1-4):219-33 (90 ref.)

Applications of lectins and neoglycoconjugates in histology and pathology. Danguy A, et al. **Acta Anat (Basel)** 1998; 161(1-4):206-18 (106 ref.)

IMMUNOLOGY

Structure, biologic properties, and expression of surfactant protein D (SP-D). Crouch EC. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):278-89 (72 ref.)

Role of lectins in the innate immunity of horseshoe crab. Kawabata S, et al. **Dev Comp Immunol** 1999 Jun-Jul; 23(4-5):391-400 (28 ref.)

Complement systems in invertebrates. The ancient alternative and lectin pathways. Smith LC, et al.
Immunopharmacology 1999 May;42(1-3):107-20 (64 ref.)

ISOLATION & PURIFICATION

The Griffonia simplicifolia I-B4 isolectin. A probe for alpha-D-galactosyl end groups. Goldstein IJ, et al.
Subcell Biochem 1999;32:127-41 (67 ref.)

METABOLISM

Animal lectins as cell adhesion molecules. Kaltner H, et al.
Acta Anat (Basel) 1998;161(1-4):162-79 (135 ref.)

Beyond plant lectin histochemistry: preparation and application of markers to visualize the cellular capacity for protein-carbohydrate recognition. Gabius HJ, et al.
Biotech Histochem 1998 Sep;73(5):263-77 (79 ref.)

How to extinguish lymphocyte activation, immunotyrosine-based inhibition motif (ITIM)-bearing molecules a solution? Blery M, et al.
Clin Chem Lab Med 1999 Mar;37(3):187-91 (54 ref.)

Lectins as chaperones in glycoprotein folding. Trombetta ES, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):587-92 (48 ref.)

Location of the binding site of the mannose-specific lectin comitin on F-actin. Fulgenzi G, et al. **J Mol Biol** 1998 Dec 18;284(5):1255-63 (38 ref.)

I-type lectins in the nervous system. Probstmeier R, et al.
Prog Neurobiol 1999 Jun;58(2):163-84 (253 ref.)

[Tumor metastases and adhesion molecules carbohydrates and lectins] Nemoto Y, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):849-56 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Olfactory epithelium of the rat. Lectin-mediated histochemical studies] Melgarejo Moreno P, et al.
An Otorrinolaringol Ibero Am 1998;25(5):471-80 (43 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Mechanisms and assessment of lectin-mediated mitogenesis. Kilpatrick DC. **Mol Biotechnol** 1999 Feb;11(1):55-65 (86 ref.)

[Antitumor activity of natural substances: lectins and saffron] Abdullaev FI, et al. **Arch Latinoam Nutr** 1997 Sep; 47(3):195-202 (62 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Glycocoding as an information management system in embryonic development. Mann PL, et al.
Acta Anat (Basel) 1998;161(1-4):153-61 (40 ref.)

Structure and functions of lectins in the central and peripheral nervous system. Zanetta JP. **Acta Anat (Basel)** 1998; 161(1-4):180-95 (116 ref.)

Role of lectins (and rhizobial exopolysaccharides) in legume nodulation. Hirsch AM. **Curr Opin Plant Biol** 1999 Aug; 2(4):320-6 (53 ref.)

Inhibitory role of murine Ly49 lectin-like receptors on natural killer cells. Salcedo M.
Curr Top Microbiol Immunol 1999;244:97-105 (45 ref.)

Immunological aspects of the potential role of dietary carbohydrates and lectins in human health. Kilpatrick DC. **Eur J Nutr** 1999 Jun;38(3):107-17 (99 ref.)

Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis. Zhang Y, et al.
Immunopharmacology 1999 May;42(1-3):81-90 (22 ref.)

[Cellular recognition through glyco-chain signals involved in differentiation and pathogenesis] Irimura T.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2540-1 (0 ref.) **(Jpn)**

[Insect lectins and defense mechanism] Natori S.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2435-41 (28 ref.) **(Jpn)**

[Animal lectins--structure and function] Matejuk A, et al.
Postepy Hig Med Dosw 1998;52(5):445-70 (145 ref.) (Eng. Abstr.) **(Pol)**

LEECHES

EMBRYOLOGY

The other side of the embryo: an appreciation of the non-D quadrants in leech embryos. Weisblat DA, et al.
Curr Top Dev Biol 1999;46:105-32 (53 ref.)

Formation and localization of cytoplasmic domains in leech and ascidian zygotes. Fernández J, et al.
Int J Dev Biol 1998 Nov;42(8):1075-84 (86 ref.)

GROWTH & DEVELOPMENT

Axial patterning in the leech: developmental mechanisms and evolutionary implications. Shankland M, et al. **Biol Bull** 1998 Dec;195(3):370-2 (11 ref.)

LEFT HEART BYPASS see **HEART BYPASS, LEFT**

LEFT HEART SYNDROME, HYPOPLASTIC see **HYPOPLASTIC LEFT HEART SYNDROME**

LEFT VENTRICULAR DYSFUNCTION see **VENTRICULAR DYSFUNCTION, LEFT**

LEFT VENTRICULAR FUNCTION see **VENTRICULAR FUNCTION, LEFT**

LEFT VENTRICULAR HYPERTROPHY see **HYPERTROPHY, LEFT VENTRICULAR**

LEFT VENTRICULAR REMODELING see **VENTRICULAR REMODELING**

LEG

see related
HINDLIMB
LEG BONES

Calcaneal osteotomy for the treatment of posterior tibial tendon dysfunction. LaFontaine J, et al.
Clin Podiatr Med Surg 1999 Jul;16(3):491-9 (21 ref.)

The limping child. Lawrence LL.
Emerg Med Clin North Am 1998 Nov;16(4):911-29, viii (31 ref.)

Amputation surgery in peripheral vascular disease. Pinzur MS, et al. **Instr Course Lect** 1999;48:687-91 (33 ref.)

A primer on lower extremity outcome measurement instruments. Saltzman CL, et al. **Iowa Orthop J** 1998; 18:101-11 (35 ref.)

Should people with nocturnal leg cramps drink tonic water and bitter lemon? Brasić JR. **Psychol Rep** 1999 Apr; 84(2):355-67 (69 ref.)

Lower leg pain. Diagnosis and treatment of compartment syndromes and other pain syndromes of the leg. Touliopolous S, et al. **Sports Med** 1999 Mar;27(3):193-204 (73 ref.)

Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May-Jun;85(3):199-204 (41 ref.)

[Drug treatment strategies for peripheral obliterative arteriopathy] Bounameaux H, et al. **Drugs** 1998;56 Suppl 3:17-23 (22 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic and therapeutic stragegies in peripheral obliterative arteriopathy: non-drug treatment] Fiessinger JN. **Drugs** 1998;56 Suppl 3:11-6 (24 ref.) (Eng. Abstr.) **(Fre)**

[Lower limb spasticity in adults. Clinical evaluation with motor block] Filipetti P, et al. **Neurochirurgie** 1998 Sep; 44(3):167-74 (18 ref.) (Eng. Abstr.) **(Fre)**

[Unilateral swelling of the leg] Aschwanden M, et al.
Ther Umsch 1998 Oct;55(10):628-31 (9 ref.) (Eng. Abstr.) **(Ger)**

[Differential diagnosis of intermittent stress-related leg pain--not always an arterial problem] Canova CR, et al.
Ther Umsch 1998 Oct;55(10):596-600 (6 ref.) (Eng. Abstr.) **(Ger)**

[Leg pain from the orthopedic viewpoint] Fellmann J, et al. **Ther Umsch** 1998 Oct;55(10):613-7 (5 ref.) (Eng. Abstr.) **(Ger)**

[Leg edema] Reinhart WH. **Ther Umsch** 1998 Oct; 55(10):624-7 (12 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Rehabilitation and orthotic management of congenital and acquired meromelia in the lower limbs of children. Wenz W, et al. **Pediatr Rehabil** 1998 Jul-Sep;2(3):123-8 (12 ref.)

Accessory limbs associated with spina bifida - a second look. Krishna A, et al. **Pediatr Surg Int** 1999;15(3-4):248-50 (16 ref.)

BLOOD SUPPLY

Chronic critical limb ischemia: diagnosis, treatment and prognosis. Santilli JD, et al. **Am Fam Physician** 1999 Apr 1;59(7):1899-908 (21 ref.)

Animal models for the study of lower extremity chronic venous disease: lessons learned and future needs. Dalsing MC, et al. **Ann Vasc Surg** 1998 Sep;12(5):487-94 (47 ref.)

The clinical diagnosis of deep venous thrombosis: integrating incidence, risk factors, and symptoms and signs [see comments] Kahn SR. **Arch Intern Med** 1998 Nov 23; 158(21):2315-23 (57 ref.) Comment in: Arch Intern Med 1999 May 24;159(10):1144.

Adjuvant medical therapy in peripheral bypass surgery. Watson HR, et al. **Br J Surg** 1999 Aug;86(8):981-91 (58 ref.)

Lower limb oedema following distal arterial bypass grafting. Soong CV, et al. **Eur J Vasc Endovasc Surg** 1998 Dec; 16(6):465-71 (58 ref.)

The role of prophylactic fasciotomy and medical treatment in limb ischemia and revascularization. Hofmeister EP, et al. **Hand Clin** 1998 Aug;14(3):457-65, x (53 ref.)

Deep-vein thrombosis [see comments] Lensing AW, et al. **Lancet** 1999 Feb 6;353(9151):479-85 (44 ref.) Comment in: Lancet 1999 May 15;353(9165):1708.

Delayed presentation of traumatic arterial vasospasm. Davis GM, et al. **Pediatr Emerg Care** 1999 Feb;15(1):22-4 (12 ref.)

Deep venous thrombosis: recent advances and optimal investigation with US. Fraser JD, et al. **Radiology** 1999 Apr;211(1):9-24 (118 ref.)

Review of the assessment of single level and multilevel arterial occlusive disease in lower limbs by duplex ultrasound. Allard L, et al. **Ultrasound Med Biol** 1999 May; 25(4):495-502 (57 ref.)

Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Baumgartner I, et al. **Vasa** 1998 Nov;27(4):201-6 (76 ref.)

Predicting healing of arterial leg ulcers by means of segmental systolic pressure measurements. Wütschert R, et al. **Vasa** 1998 Nov;27(4):224-8 (13 ref.)

Diagnosis and treatment of chronic lower extremity ischemia. Sanchez LA, et al. **Vasc Med** 1998;3(4):291-9 (95 ref.)

[Leg perforating veins] Perrin M. **J Mal Vasc** 1999 Feb; 24(1):19-24 (39 ref.) (Eng. Abstr.) **(Fre)**

[Arteriopathy of the lower limbs: toward a global medical care (editorial)] Priollet P. **Rev Med Interne** 1999 Jun; 20(6):473-5 (19 ref.) **(Fre)**

[Post-thrombotic syndrome of the legs: complementary examinations and therapeutic options] Buchheim G.
Rev Med Suisse Romande 1998 Oct;118(10):859-65 (13 ref.) **(Fre)**

[Thrombosis of the deep leg and pelvic veins in congenital agenesis of the vena cava inferior] Klessen C, et al.
Dtsch Med Wochenschr 1999 Apr 30;124(17):523-6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Acute ischemia of the legs and rapidly progressing renal failure in a 39-year-old patient] Büchner N, et al.
Internist (Berl) 1999 May;40(5):555-60 (20 ref.) **(Ger)**

[Management of abdominal aortic and peripheral aneurysm

using stent grafts] Dorffner R, et al. **Radiologe** 1999 Feb; 39(2):110–7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Ulcus cruris--vascular etiology and surgical treatment options] Kniemeyer HW, et al. **Ther Umsch** 1998 Oct; 55(10):643–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Perforating veins and venous insufficiency] Clerici T, et al. **Zentralbl Chir** 1999;124(6):525–9 (10 ref.) (Eng. Abstr.) **(Ger)**

[Hypolipemic therapy in peripheral arterial diseases: reasons of its clinical use] Balbarini A, et al. **Cardiologia** 1999 Feb; 44(2):137–45 (65 ref.) **(Ita)**

[Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency] Cappelli R, et al. **Minerva Cardioangiol** 1999 Mar;47(3):81–8 (30 ref.) (Eng. Abstr.) **(Ita)**

[Methods of concealed exclusion of lower extremities perforated and varicose veins in chronic venous insufficiency] Gervaziev VB. **Khirurgiia (Mosk)** 1999; (4):52–5 (6 ref.) (Eng. Abstr.) **(Rus)**

[Treatment of lower limbs varicose veins in outpatient clinic] Kutin AA, et al. **Khirurgiia (Mosk)** 1999;(3):66–71 (135 ref.) **(Rus)**

[Thromboembolic complications, venous hemodynamics and lower extremities in laparoscopic operations] Starkov IuG, et al. **Khirurgiia (Mosk)** 1999;(8):63–7 (68 ref.) **(Rus)**

[Ticlid: clinical effectiveness and significance in combined conservative treatment of chronic obliterating diseases of lower limb arteries] Koskin VM, et al. **Ter Arkh** 1998; 70(9):89–91 (22 ref.) **(Rus)**

[Direct revascularization in chronic ischemia of the lower extremities] Sander SV. **Klin Khir** 1998;(7):47–50 (50 ref.) **(Ukr)**

GROWTH & DEVELOPMENT

Are growing pains a myth? [see comments] Manners P. **Aust Fam Physician** 1999 Feb;28(2):124–7 (4 ref.) Comment in: Aust Fam Physician 1999 May;28(5):427–8. Comment in: Aust Fam Physician 1999 May;28(5):428.

INNERVATION

Proximal sensory neuropathies of the Leg. Reid V, et al. **Neurol Clin** 1999 Aug;17(3):655–67, viii (45 ref.)

Lower extremity sensory nerve conduction studies. Blando AV. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):853–70, vii (83 ref.)

[Leg pain--the contribution of the neurologist] Beer S, et al. **Ther Umsch** 1998 Oct;55(10):618–23 (31 ref.) (Eng. Abstr.) **(Ger)**

[Radicular and pseudo-radicular pain syndrome] Knutti O, et al. **Ther Umsch** 1998 Oct;55(10):601–12 (29 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Cutaneous ciliated cyst of the right lower leg. Yokozaki H, et al. **Pathol Int** 1999 Apr;49(4):354–7 (24 ref.)

PHYSIOLOGY

The biomechanics of kicking in soccer. Barfield WR. **Clin Sports Med** 1998 Oct;17(4):711–28, vi (52 ref.)

RADIOGRAPHY

[Computerized tomography of 150 cases of lymphedema of the leg] Marotel M, et al. **J Radiol** 1998 Nov;79(11):1373–8 (9 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Daily functioning of patients with an amputated lower extremity. Pandian G, et al. **Clin Orthop** 1999 Apr; (361):91–7 (16 ref.)

Lower-limb deficiencies and amputations in children. Krajbich JI. **J Am Acad Orthop Surg** 1998 Nov-Dec; 6(6):358–67 (32 ref.)

Efficacy of microsurgical free-tissue transfer in chronic osteomyelitis of the leg and foot: review of 22 cases. Musharafieh R, et al. **J Reconstr Microsurg** 1999 May; 15(4):239–44 (59 ref.)

Preventing amputations in the diabetic population. Spollett GR. **Nurs Clin North Am** 1998 Dec;33(4):629–41 (44 ref.)

[Direct revascularization in chronic ischemia of the lower extremities] Sander SV. **Klin Khir** 1998;(7):47–50 (50 ref.) **(Ukr)**

LEG, ARTIFICIAL see **ARTIFICIAL LIMBS**

LEG BONES

SURGERY

The Ilizarov method. Orthopedic and soft tissue applications. Gugenheim JJ Jr. **Clin Plast Surg** 1998 Oct;25(4):567–78 (68 ref.)

Amputation surgery in peripheral vascular disease. Pinzur MS, et al. **Instr Course Lect** 1999;48:687–91 (33 ref.)

LEG DERMATOSES

Cutaneous polyarteritis nodosa: a case report and literature review. Khoo BP, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):868–72 (33 ref.)

LEG INJURIES

COMPLICATIONS

Extremity fractures in the patient with a traumatic brain injury. Kushwaha VP, et al. **J Am Acad Orthop Surg** 1998 Sep-Oct;6(5):298–307 (48 ref.)

Necrotizing fasciitis due to Vibrio alginolyticus following an injury inflicted by a stingray. Ho PL, et al. **Scand J Infect Dis** 1998;30(2):192–3 (13 ref.)

[Acute compartment syndrome in the post-traumatic leg (see comments)] Ménétrey J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):272–80 (58 ref.) (Eng. Abstr.) Comment in: Rev Chir Orthop Reparatrice Appar Mot 1998 Nov;84(8):762. **(Fre)**

DIAGNOSIS

Musculoskeletal rehabilitation and sports medicine. 3. Knee and lower extremity injuries. Ellen MI, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S59–67 (100 ref.)

Exercise-related chronic lower leg pain. Locke S. **Aust Fam Physician** 1999 Jun;28(6):569–73 (9 ref.)

MR imaging of musculoskeletal trauma to the pelvis and the lower limb. Brossmann J, et al. **Eur Radiol** 1999;9(2):183–91 (78 ref.)

[Analysis of leg geometry--standard techniques and normal values] Keppler P, et al. **Chirurg** 1998 Nov;69(11):1141–52 (33 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Intrinsic risk factors for exercise-related lower limb injuries. Neely FG. **Sports Med** 1998 Oct;26(4):253–63 (48 ref.)

ETIOLOGY

The downside of snowboarding. Common injuries in novices and those seeking 'hospital air'. Bindner SR, et al. **Postgrad Med** 1999 Jan;105(1):83–8 (13 ref.)

Injuries in cross-country skiing. Trail markers for diagnosis and treatment. Morris PJ, et al. **Postgrad Med** 1999 Jan; 105(1):89–91, 95–8, 101 (12 ref.)

PHYSIOPATHOLOGY

Biomechanical risk factors for exercise-related lower limb injuries. Neely FG. **Sports Med** 1998 Dec;26(6):395–413 (109 ref.)

RADIOGRAPHY

Pitfalls in radiological diagnosis of lower limb injuries. Cooper JR, et al. **Br J Hosp Med** 1998 Nov 19–Dec 9; 58(10):524–9 (9 ref.)

SURGERY

[Analysis of leg geometry] Strecker W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:581–6 (15 ref.) (Eng. Abstr.) **(Ger)**

[Corrective osteotomies of the lower extremities following posttraumatic deformities] Siebert CH, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan-Feb;137(1):43–7 (28 ref.) (Eng. Abstr.) **(Ger)**

LEG LENGTH INEQUALITY

DIAGNOSIS

[Analysis of leg geometry--standard techniques and normal values] Keppler P, et al. **Chirurg** 1998 Nov;69(11):1141–52 (33 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Limb shortening for the management of leg length discrepancy. Coppola C, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):46–54 (107 ref.)

[Analysis of leg geometry] Strecker W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:581–6 (15 ref.) (Eng. Abstr.) **(Ger)**

LEG PROSTHESIS see **ARTIFICIAL LIMBS**

LEG ULCER

Atrophie blanche. Maessen-Visch MB, et al. **Int J Dermatol** 1999 Mar;38(3):161–72 (136 ref.)

CHEMICALLY INDUCED

Skin ulceration from tibial cement extrusion: case report and literature review. Ward WG, et al. **J Arthroplasty** 1998 Oct;13(7):826–9 (9 ref.)

Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. Kato N, et al. **J Dermatol** 1999 Jan;26(1):56–62 (35 ref.)

DIAGNOSIS

Successful methods of treating leg ulcers. The tried and true, plus the novel and new. Phillips TJ. **Postgrad Med** 1999 May 1;105(5):159–61, 165–6, 173–4 passim (6 ref.)

DRUG THERAPY

Does oral zinc aid the healing of chronic leg ulcers? A systematic literature review. Wilkinson EA, et al. **Arch Dermatol** 1998 Dec;134(12):1556–60 (16 ref.)

ETIOLOGY

Common causes of leg ulceration. Bull R. **Hosp Med** 1998 Nov;59(11):845–9 (10 ref.)

[Allergy test batteries for leg ulcers] Truchetet F. **Ann Dermatol Venereol** 1999 Apr;126(4):364–8 (28 ref.) **(Fre)**

[Differential ulcus cruris diagnosis] Hafner J. **Ther Umsch** 1998 Oct;55(10):632–42 (7 ref.) (Eng. Abstr.) **(Ger)**

[Ulcus cruris--vascular etiology and surgical treatment options] Kniemeyer HW, et al. **Ther Umsch** 1998 Oct; 55(10):643–9 (27 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Predicting healing of arterial leg ulcers by means of segmental systolic pressure measurements. Wütschert R, et al. **Vasa** 1998 Nov;27(4):224–8 (13 ref.)

THERAPY

Management of leg ulcers. Ryan TJ. **Hosp Med** 1998 Nov; 59(11):838–40 (14 ref.)

Successful methods of treating leg ulcers. The tried and true, plus the novel and new. Phillips TJ. **Postgrad Med** 1999 May 1;105(5):159–61, 165–6, 173–4 passim (6 ref.)

LEGAL GUARDIANS

Research with children. Glantz LH. **Am J Law Med** 1998; 24(2-3):213–44 (332 ref.)

Parental autonomy and consent to treatment. Taylor B. **J Adv Nurs** 1999 Mar;29(3):570–6 (33 ref.)

LEGISLATION & JURISPRUDENCE

Grandparents' visitation rights and custody. Stanton AM. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):409–22 (21 ref.)

Normativity, guardianship, and the elderly. Some lessons from Canadian legislation. Landry LY. **Theor Med Bioeth** 1999 Jan;20(1):69–84 (47 ref.)

[Legal representatives of the child with respect to the Act on Consent to Medical Treatment (WGBO): more representatives possible the under the new family law] Hulst EH. **Ned Tijdschr Geneeskd** 1999 Jun 12; 143(24):1268–71 (10 ref.) (Eng. Abstr.) **(Dut)**

LEGAL MEDICINE see **FORENSIC MEDICINE**

LEGG-PERTHES DISEASE

ETIOLOGY

Significance of synovitis in Legg-Calvé-Perthes disease. Wingstrand H. **J Pediatr Orthop B** 1999 Jul;8(3):156–60 (56 ref.)

RADIOGRAPHY

Legg-Calvé-Perthes' disease [see comments] Wall EJ. **Curr Opin Pediatr** 1999 Feb;11(1):76–9 (16 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):65–6.

Trichorhinophalangeal syndrome type I in monozygotic twins discordant for hip pathology. Report on the morphological evolution of cone-shaped epiphyses and the unusual pattern of skeletal maturation. Naselli A, et al. **Pediatr Radiol** 1998 Nov;28(11):851–5 (9 ref.)

LEGIONELLA PNEUMOPHILA

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. File TM Jr, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):569–92, vii (127 ref.)

GROWTH & DEVELOPMENT

[Human parasites and amoeba: lower warm-water temperature is favourable to Legionella bacteria] Bernander S, et al. **Lakartidningen** 1998 Sep 30;95(40):4340–4 (43 ref.) (Eng. Abstr.) **(Swe)**

METABOLISM

Surface-associated heat shock proteins of Legionella pneumophila and Helicobacter pylori: roles in pathogenesis and immunity. Hoffman PS, et al. **Infect Dis Obstet Gynecol** 1999;7(1-2):58–63 (23 ref.)

PHYSIOLOGY

Invasion of protozoa by Legionella pneumophila and its role in bacterial ecology and pathogenesis. Abu Kwaik Y, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3127–33 (49 ref.)

Cell biology of Legionella pneumophila. Vogel JP, et al. **Curr Opin Microbiol** 1999 Feb;2(1):30–4 (52 ref.)

Fatal attraction of mammalian cells to Legionella pneumophila. Kwaik YA. **Mol Microbiol** 1998 Nov; 30(4):689–95 (25 ref.)

LEGIONELLA PNEUMOPHILA INFECTIONS see **LEGIONNAIRES' DISEASE**

LEGIONELLOSIS

[Legionellosis (Legionnaires' disease, Pontiac fever)] Tateyama M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):11–4 (13 ref.) **(Jpn)**

DIAGNOSIS

[Diagnosis of infections with difficulty in isolation and identification of the causative agent. 1) Legionellosis] Saito A. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2191–6 (11 ref.) **(Jpn)**

PREVENTION & CONTROL

Legionella infection and control in occupational and environmental health [published erratum appears in Rev Environ Health 1999 Jan–Mar;14(1):following table of contents] Fujii J, et al. **Rev Environ Health** 1998 Oct–Dec; 13(4):179–203 (46 ref.)

LEGIONNAIRES' DISEASE

[Acute pericarditis of unusual etiology] Larive S, et al. **Rev Pneumol Clin** 1998 Jul;54(3):152–5 (21 ref.) (Eng. Abstr.) **(Fre)**

[Legionella pneumonia--epidemiology, clinical characteristics and development of diagnosis] Yamaguchi K, et al. **Nippon Rinsho** 1998 Oct;56(10):2707–17 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Legionnaires' disease and hepatitis (letter)] Gavilán JC, et al. **Rev Clin Esp** 1998 Nov;198(11):781 (5 ref.) **(Spa)**

DRUG THERAPY

The treatment of Legionnaires' disease. Dedicoat M, et al. **J Antimicrob Chemother** 1999 Jun;43(6):747–52 (44 ref.)

EPIDEMIOLOGY

Legionella pneumonia in neonates: a literature review. Levy I, et al. **J Perinatol** 1998 Jul–Aug;18(4):287–90 (21 ref.)

[Legionella epidemic in the Netherlands] Hoepelman IM. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1192–6 (19 ref.) (Eng. Abstr.) **(Dut)**

MICROBIOLOGY

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. File TM Jr, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):569–92, vii (127 ref.)

Surface-associated heat shock proteins of Legionella pneumophila and Helicobacter pylori: roles in pathogenesis and immunity. Hoffman PS, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):58–63 (23 ref.)

PARASITOLOGY

[Human parasites and amoeba: lower warm-water temperature is favourable to Legionella bacteria] Bernander S, et al. **Lakartidningen** 1998 Sep 30;95(40):4340–4 (43 ref.) (Eng. Abstr.) **(Swe)**

PREVENTION & CONTROL

[Legionella epidemic in the Netherlands] Hoepelman IM. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1192–6 (19 ref.) (Eng. Abstr.) **(Dut)**

TRANSMISSION

Legionellosis associated with ships: 1977 to 1997. Rowbotham TJ. **Commun Dis Public Health** 1998 Sep; 1(3):146–51 (32 ref.)

LEGISLATION

see related
LICENSURE

How legislation and health systems can promote adolescent health. Klerman LV. **Adolesc Med** 1999 Feb;10(1):23–40, v (28 ref.)

TRENDS

Dilemmas facing regulatory and advisory bodies dealing with conflicting results. Barlow SM. **Chemosphere** 1999 Oct; 39(8):1287–92 (25 ref.)

LEGISLATION, DENTAL

[The new law concerning public health services in North Rhine- Westphalia--essentials and perspectives in dentistry] Wolf M, et al. **Gesundheitswesen** 1999 May; 61(5):260–2 (6 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION, DRUG

European Union directives on medicinal products found to be seriously defective [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1999 Mar;18(1):3–4 (2 ref.)

Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment [see comments] Lewis DC. **J Addict Dis** 1999; 18(2):5–21 (82 ref.) Comment in: J Addict Dis 1999 ;18(2):1–4.

Drugs prohibited from extralabel use in food animals. Payne MA, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):28–32 (49 ref.)

Primer on estimating withdrawal times after extralabel drug use. Riviere JE, et al. **J Am Vet Med Assoc** 1998 Oct 1; 213(7):966–8 (2 ref.)

Problems and opportunities in regulation of benzodiazepines. Woods JH. **J Clin Pharmacol** 1998 Sep;38(9):773–82 (42 ref.)

Generic immunosuppressants: the European perspective. Christians U. **Transplant Proc** 1999 May;31(3A Suppl):19S–22S (21 ref.)

A review of the safety of generic drugs. Dighe SV. **Transplant Proc** 1999 May;31(3A Suppl):23S–24S (5 ref.)

United States food and drug laws and ratites as emerging food animals. Spenser EL. **Vet Clin North Am Food Anim Pract** 1998 Nov;14(3):533–40 (26 ref.)

[Survey of 50 years of veterinary remedy provision in the Netherlands] van den Bos T. **Tijdschr Diergeneeskd** 1998 Dec 15;123(24):743–8 (31 ref.) (Eng. Abstr.) **(Dut)**

[Excipients: regulatory aspects] Artiges A. **Therapie** 1999 Jan–Feb;54(1):15–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Sildenafil (Viagra). Hormonal properties, indications and legal problems] Ullrich T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):233–45 (84 ref.) **(Ger)**

[Ban on antimicrobial growth promoters: a safety advantage for consumers?] Althaus FR. **Schweiz Arch Tierheilkd** 1999; 141(3):103–7 (0 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

The US Food and Drug Administration Modernization Act of 1997: impact on consumers. Golodner LF. **Clin Ther** 1998;20 Suppl C:C20–5 (5 ref.)

Prescription to over-the-counter switch: a regulatory perspective. Juhl RP. **Clin Ther** 1998;20 Suppl C:C111–7 (1 ref.)

LEGISLATION, FOOD

Effective regulatory approval process for food ingredient technologies. Kirschman JC. **Crit Rev Food Sci Nutr** 1998 Aug;38(6):465–510 (108 ref.)

A critical review of the quality and safety of BADGE-based epoxy coatings for cans: implications for legislation on epoxy coatings for food contact. Simal-Gándara J, et al. **Crit Rev Food Sci Nutr** 1998 Nov;38(8):675–88 (70 ref.)

Regulation of foods derived from genetically engineered crops. Mitten DH, et al. **Curr Opin Biotechnol** 1999 Jun; 10(3):298–302 (15 ref.)

Aggregate exposures under the Food Quality Protection Act: An approach using chlorpyrifos. Shurdut BA, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):165–77 (65 ref.)

The legislation of toxicologic safety factors: the Food Quality Protection Act with chlorpyrifos as a test case. Schardein JL, et al. **Reprod Toxicol** 1999 Jan–Feb;13(1):1–14 (45 ref.)

The 1996 Food Quality Protection Act--an evolution or a revolution for toxicology and risk assessment? McCarthy JF. **Toxicol Pathol** 1998 Nov–Dec;26(6):828–9 (11 ref.)

United States food and drug laws and ratites as emerging food animals. Spenser EL. **Vet Clin North Am Food Anim Pract** 1998 Nov;14(3):533–40 (26 ref.)

LEGISLATION, MEDICAL

Human rights and abortion laws. Cook RJ, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):81–7 (50 ref.)

Legal trends in bioethics. Davis DS, et al. **J Clin Ethics** 1998 Fall;9(3):323–32 (29 ref.)

Elective surgery and the HIV-positive patient: medical, legal, and ethical issues. Clarke SR, et al. **J La State Med Soc** 1999 May;151(5):245–9 (17 ref.)

[Legal grounds for patient information in orthopedics] Bergmann KO. **Orthopade** 1998 Oct;27(10):705–12 (69 ref.) **(Ger)**

[Problems in the legislative regulation of folk and nontraditional medicines] Pokanevych VV. **Lik Sprava** 1999 Jan–Feb;(1):134–9 (19 ref.) **(Ukr)**

LEGISLATION, PHARMACY

Pharmacists' liability into the year 2000. Lynn NJ, et al. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec;38(6):747–52; quiz 753–4 (10 ref.)

LEGISLATION, VETERINARY

Drugs prohibited from extralabel use in food animals. Payne MA, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):28–32 (49 ref.)

Primer on estimating withdrawal times after extralabel drug use. Riviere JE, et al. **J Am Vet Med Assoc** 1998 Oct 1; 213(7):966–8 (2 ref.)

United States food and drug laws and ratites as emerging food animals. Spenser EL. **Vet Clin North Am Food Anim Pract** 1998 Nov;14(3):533–40 (26 ref.)

[Survey of 50 years of veterinary remedy provision in the Netherlands] van den Bos T. **Tijdschr Diergeneeskd** 1998 Dec 15;123(24):743–8 (31 ref.) (Eng. Abstr.) **(Dut)**

[Ban on antimicrobial growth promoters: a safety advantage for consumers?] Althaus FR. **Schweiz Arch Tierheilkd** 1999; 141(3):103–7 (0 ref.) (Eng. Abstr.) **(Ger)**

LEGUMES

see related
PLANTS, EDIBLE

Locoweeds: effects on reproduction in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):53–62 (49 ref.)

CHEMISTRY

[Nutritional importance of oligosaccharides] Amarowicz R. **Rocz Panstw Zakl Hig** 1999;50(1):89–95 (37 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

CuI-semiquinone radical species in plant copper-amine oxidases. Medda R, et al. **FEBS Lett** 1999 Jun 18; 453(1–2):1–5 (32 ref.)

IMMUNOLOGY

Legumes, eggs, and milk. Sampson HA. **Allergy** 1998;53(46 Suppl):38–43 (60 ref.)

MICROBIOLOGY

Regulation of symbiotic root nodule development. Schultze M, et al. **Annu Rev Genet** 1998;32:33–57 (176 ref.)

Recent advances in the study of nod factor perception and signal transduction. Niebel A, et al. **Biochimie** 1999 Jun; 81(6):669–74 (50 ref.)

Genes and signal molecules involved in the rhizobia-leguminoseae symbiosis. Bladergroen MR, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):353–9 (61 ref.)

Genealogy of legume-Rhizobium symbioses. Broughton WJ, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):305–11 (50 ref.)

Development of the arbuscular mycorrhizal symbiosis. Harrison MJ. **Curr Opin Plant Biol** 1998 Aug;1(4):360–5 (46 ref.)

Legume nodulation and mycorrhizae formation; two extremes in host specificity meet. Albrecht C, et al. **EMBO J** 1999 Jan 15;18(2):281–8 (66 ref.)

PHYSIOLOGY

Carbohydrate determinants of Rhizobium-legume symbioses. Price NP. **Carbohydr Res** 1999 Apr 30;317(1–4):1–9 (89 ref.)

Role of lectins (and rhizobial exopolysaccharides) in legume nodulation. Hirsch AM. **Curr Opin Plant Biol** 1999 Aug; 2(4):320–6 (53 ref.)

Mass spectrometric analysis of lipo-chitin oligosaccharides--signal molecules mediating the host-specific legume-rhizobium symbiosis. van der Drift KM, et al. **Mass Spectrom Rev** 1998 Mar–Apr;17(2):75–95 (102 ref.)

THERAPEUTIC USE

Cardiovascular and renal benefits of dry bean and soybean intake. Anderson JW, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):464S–474S (154 ref.)

Cereals, legumes, and chronic disease risk reduction: evidence from epidemiologic studies. Kushi LH, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):451S–458S (94 ref.)

Legumes and soybeans: overview of their nutritional profiles and health effects. Messina MJ. **Am J Clin Nutr** 1999 Sep; 70(3 Suppl):439S–450S (188 ref.)

TOXICITY

Locoweed grazing. Ralphs MH, et al. **J Nat Toxins** 1999 Feb;8(1):47–51 (42 ref.)

LEIGH DISEASE

DIAGNOSIS

Is Alexander's disease a nosologic entity or a common pathologic pattern of diverse etiology? [editorial] Herndon RM. **J Child Neurol** 1999 May;14(5):275–6 (15 ref.)

[Genetic counseling and prenatal diagnosis in mitochondrial diseases] Klopstock T, et al. **Nervenarzt** 1999 Jun; 70(6):504–8 (21 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Adult Leigh syndrome with mitochondrial DNA mutation at 8993. Nagashima T, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):416–22 (30 ref.)

Getting to the nucleus of mitochondrial disorders: identification of respiratory chain-enzyme genes causing

Leigh syndrome [editorial; comment] Dahl HH. **Am J Hum Genet** 1998 Dec;63(6):1594–7 (19 ref.) Comment on: Am J Hum Genet 1998 Dec;63(6):1598–1608. Comment on: Am J Hum Genet 1998 Dec;63(6):1609–21.
[Genetic counseling and prenatal diagnosis in mitochondrial diseases] Klopstock T, et al. **Nervenarzt** 1999 Jun; 70(6):504–8 (21 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Adult Leigh syndrome with mitochondrial DNA mutation at 8993. Nagashima T, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):416–22 (30 ref.)

LEIOMYOBLASTOMA see **LEIOMYOMA, EPITHELIOID**

LEIOMYOMA

Introduction: the epidemiology of uterine leiomyomas. Vollenhoven B. **Baillieres Clin Obstet Gynaecol** 1998 Jun; 12(2):169–76 (35 ref.)
Current fibroid management. Chappatte O. **Practitioner** 1999 Jun;243(1599):474–6, 479, 481–3 (9 ref.)

BLOOD

Hydropic degenerating leiomyoma presenting as pseudo-Meigs syndrome with elevated CA 125. Dunn JS Jr, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):648–9 (9 ref.)

COMPLICATIONS

Clinical presentation of uterine fibroids. Lumsden MA, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):177–95 (88 ref.)
Deep vein thrombosis in patients with large uterine myomata. Chong YS, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):707 (4 ref.)
Aborted leiomyosarcoma after treatment with leuprolide acetate. Mesia AF, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):664–6 (7 ref.)
[Three cases of urinary retention caused by uterine leiomyoma] Kuroda K, et al. **Hinyokika Kiyo** 1999 Feb; 45(2):115–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Imaging techniques for fibroid detection. Hurley V. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):213–24 (28 ref.)
Adrenal leiomyoma: a case report and review of the literature. Jacobs IA, et al. **J Surg Oncol** 1998 Oct; 69(2):111–2 (09 ref.)
Hydropic degenerating leiomyoma presenting as pseudo-Meigs syndrome with elevated CA 125. Dunn JS Jr, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):648–9 (9 ref.)
[The course of pregnancy, labor and the postpartum period in a woman with a myomatous node of the uterus who gave birth to twins] Istatkov M, et al. **Akush Ginekol (Sofiia)** 1998;37(4):56–8 (6 ref.) **(Bul)**
[Leiomyoma of the bladder: report of two cases] Naganuma T, et al. **Hinyokika Kiyo** 1998 Nov;44(11):833–7 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Bladder leiomyoma: review of the literature and report of 3 clinical cases] Abengózar García-Moreno A, et al. **Actas Urol Esp** 1998 Sep;22(8):702–6 (20 ref.) (Eng. Abstr.) **(Spa)**
[Bladder leiomyoma during pregnancy] Núñez Mora C, et al. **Arch Esp Urol** 1999 Jun;52(5):510–3 (14 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effects of leuprolide acetate on treatment of leiomyomata--clues to mechanisms of action. Demopoulos RI, et al. **Adv Anat Pathol** 1998 Mar;5(2):129–36 (38 ref.)
Other medical management of uterine fibroids. Eldar-Geva T, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun; 12(2):269–88 (76 ref.)
Gonadotrophin hormone-releasing hormone analogue treatment of fibroids. Shaw RW. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):245–68 (67 ref.)
Aborted leiomyosarcoma after treatment with leuprolide acetate. Mesia AF, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):664–6 (7 ref.)
[Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(1):55–7 (20 ref.) **(Bul)**

GENETICS

Warner-Lambert/Parke-Davis Award lecture. Many tumors and many genes: genetics of uterine leiomyomata. Morton CC. **Am J Pathol** 1998 Oct;153(4):1015–20 (41 ref.)
Genetic basis of uterine leiomyoma: involvement of high mobility group protein genes. Van de Ven WJ. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):289–93 (22 ref.)

NURSING

Uterine myomas: treatment options. Grabo TN, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan-Feb;28(1):23–31 (44 ref.)

PATHOLOGY

Factors in fibroid growth. Andersen J. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):225–43 (100 ref.)
Pathology of uterine fibroids. Crow J. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):197–211 (21 ref.)
Solitary adult myofibroma of the pinna. Balakrishnan R, et al. **J Laryngol Otol** 1999 Feb;113(2):155–7 (16 ref.)
Solitary mucosal "infantile" myofibroma in a 21-year-old man. Uğar DA, et al. **J Oral Maxillofac Surg** 1999 Apr; 57(4):448–51 (13 ref.)
Monoclonal antibody confirmation of a primary leiomyoma of the testis. Gonzalez CM, et al. **J Urol** 1999 Jun; 161(6):1908 (4 ref.)
Intraosseous leiomyoma of the mandible. Loyola AM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):78–82 (22 ref.)
[Leiomyoma of the female urethra (case report and review of the literature) Saidi R, et al. **Tunis Med** 1999 Jan; 77(1):54–6 (13 ref.) **(Fre)**
[Multiple lungs tumors found 17 years after hysterectomy--a case of benign metastasizing leiomyoma] Mikami I, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Jul;46(7):634–8 (27 ref.) (Eng. Abstr.) **(Jpn)**
[A rare case of ovarian leiomyoma. A case report with review of literature] Gut R, et al. **Ginekol Pol** 1997 Nov; 68(11):567–71 (13 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):520–5 (37 ref.)

RADIOGRAPHY

[Leiomyoma of the bladder. Report of a case and review of the literature] Greco A, et al. **Minerva Urol Nefrol** 1999 Mar;51(1):33–8 (25 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Thoracoscopic resection of a giant leiomyoma of the esophagus with a mediastinal outgrowth. Tamura K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):351–3 (11 ref.)
Hysterectomy and myomectomy by laparotomy. West CP. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):317–35 (41 ref.)
Endoscopic treatment of uterine fibroids. Wood C, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):289–316 (67 ref.)
Endoscopic myomectomy. Laparoscopy and hysteroscopy. Tulandi T, et al. **Obstet Gynecol Clin North Am** 1999 Mar; 26(1):135–48, viii (65 ref.)
Laparoscopic myomectomy. Miskry T, et al. **Semin Laparosc Surg** 1999 Jun;6(2):73–9 (40 ref.)
[Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(1):55–7 (20 ref.) **(Bul)**
[Gastrointestinal stroma tumor: a surgical oncology problem child?] Irani S, et al. **Chirurg** 1999 Mar;70(3):259–64 (25 ref.) (Eng. Abstr.) **(Ger)**
[Laparoscopic myomectomy] Dicker D, et al. **Harefuah** 1998 Oct;135(7-8):310–2 (8 ref.) **(Heb)**
[Bilateral simultaneous epididymal leiomyoma: a case report] Kimura T, et al. **Hinyokika Kiyo** 1998 Dec;44(12):901–3 (4 ref.) (Eng. Abstr.) **(Jpn)**
[A rare case of ovarian leiomyoma. A case report with review of literature] Gut R, et al. **Ginekol Pol** 1997 Nov; 68(11):567–71 (13 ref.) (Eng. Abstr.) **(Pol)**
[Occlusive leiomyomas of the small intestine] Dumnici A, et al. **Chirurgia (Bucur)** 1998 Sep-Oct;93(5):349–52 (9 ref.) (Eng. Abstr.) **(Rum)**

THERAPY

Uterine artery embolization for fibroid disease. Reidy JF, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct; 21(5):357–60 (17 ref.)
Ambulatory management of uterine leiomyomata. Barbieri RL. **Clin Obstet Gynecol** 1999 Jun;42(2):196–205 (27 ref.)
Uterine artery embolization for the treatment of uterine fibroids. Goodwin SC, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):315–20 (13 ref.)
Uterine myomas: treatment options. Grabo TN, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan-Feb;28(1):23–31 (44 ref.)

ULTRASTRUCTURE

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):520–5 (37 ref.)

VETERINARY

Equine sarcoids. Goodrich L, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):607–23, vii (86 ref.)

LEIOMYOMA, EPITHELIOID

DIAGNOSIS

Uterine malignant leiomyoblastoma (epithelioid leiomyosarcoma) during pregnancy. Bekkers RL, et al. **Gynecol Oncol** 1999 Mar;72(3):433–6 (14 ref.)
[Gastric leiomyoblastoma. (Review of the literature in the light of a case)] Simeth C, et al. **Ann Ital Chir** 1999 Jan-Feb; 70(1):57–60 (15 ref.) (Eng. Abstr.) **(Ita)**

LEIOMYOMATOSIS

DIAGNOSIS

Leiomyomatosis peritonealis disseminata complicated by sarcomatous transformation and ovarian torsion: presentation of two cases and review of the literature. Fulcher AS, et al. **Abdom Imaging** 1998 Nov-Dec; 23(6):640–4 (18 ref.)
[Leiomyomatous neoplasms of the esophagus (editorial)] Fersini M. **G Chir** 1999 Jun-Jul;20(6-7):265–75 (26 ref.) **(Ita)**

EPIDEMIOLOGY

Esophageal leiomyomatosis in children: report of a case and review of the literature. Federici S, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):358–63 (23 ref.)

LEIOMYOSARCOMA

Leiomyosarcoma of the larynx. Review of the literature and report of two cases. Paczona R, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):677–82 (46 ref.)
Primary malignant tumors of the venous system in the lower extremities. Reix T, et al. **Ann Vasc Surg** 1998 Nov; 12(6):589–96 (49 ref.)
Leiomyosarcoma of the thoracic aorta. Iorgulescu DG, et al. **Aust N Z J Surg** 1999 Jul;69(7):537–40 (41 ref.)

COMPLICATIONS

Leiomyosarcoma of the esophagus in a patient with chagasic megaesophagus: case report and literature review. Adad SJ, et al. **Am J Trop Med Hyg** 1999 May;60(5):879–81 (17 ref.)
Aborted leiomyosarcoma after treatment with leuprolide acetate. Mesia AF, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):664–6 (7 ref.)

DIAGNOSIS

Leiomyomatosis peritonealis disseminata complicated by sarcomatous transformation and ovarian torsion: presentation of two cases and review of the literature. Fulcher AS, et al. **Abdom Imaging** 1998 Nov-Dec; 23(6):640–4 (18 ref.)
Epithelioid and spindle-celled leiomyosarcoma of the heart. Report of 2 cases and review of the literature. Pins MR, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):782–8 (23 ref.)
Pedunculated exogastric leiomyosarcoma: case report and brief literature review. Shimoji H, et al. **Clin Imaging** 1999 Mar-Apr;23(2):94–8 (15 ref.)
Uterine malignant leiomyoblastoma (epithelioid leiomyosarcoma) during pregnancy. Bekkers RL, et al. **Gynecol Oncol** 1999 Mar;72(3):433–6 (14 ref.)
[Clinical experience with uterine sarcoma] Melilli GA, et al. **Minerva Ginecol** 1998 Jul-Aug;50(7-8):291–5 (25 ref.) (Eng. Abstr.) **(Ita)**
[Leiomyosarcoma of the prostate: report of two cases] Iida K, et al. **Hinyokika Kiyo** 1998 Oct;44(10):739–42 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Renal leiomyosarcoma. Apropos a case] Rebassa Llull M, et al. **Arch Esp Urol** 1999 Jan-Feb;52(1):78–80 (12 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Bernardis V, et al. **Digestion** 1999 Jan-Feb;60(1):82–5 (16 ref.)

METABOLISM

Progesterone receptors in gastric leiomyosarcoma [letter] Munoz E. **Eur J Surg** 1998 Oct;164(10):796 (5 ref.)

PATHOLOGY

Pedunculated esophageal leiomyosarcoma: a case report. Aiko S, et al. **Dis Esophagus** 1998 Oct;11(4):263–7 (26 ref.)
Leiomyosarcoma of the parotid gland: a case report and review of the literature. Kang J, et al. **Head Neck** 1999 Mar;21(2):168–71 (7 ref.)
A case of superficial leiomyosarcoma, and a review of Japanese cases. Wakasugi S, et al. **J Dermatol** 1998 Sep; 25(9):606–11 (16 ref.)
Primary leiomyosarcoma of the mandible in a 7-year-old girl: report of a case and review of the literature. Carter LC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):477–84 (37 ref.)
Retroperitoneal leiomyosarcoma of a male centenarian. Yokoo H, et al. **Pathol Int** 1998 Dec;48(12):985–8 (15 ref.)

LEIOMYOSARCOMA

Primary epithelioid leiomyosarcoma of bone. Case report and literature review. Lopez-Barea F, et al. **Virchows Arch** 1999 Apr;434(4):367-71 (41 ref.)
[Leiomyosarcoma of the gingiva. Apropos of a case. Review of the literature] Moussaoui O, et al. **Rev Stomatol Chir Maxillofac** 1998 Oct;99(3):132-7 (29 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Primary leiomyosarcoma of the greater omentum. Ishida J, et al. **J Clin Gastroenterol** 1999 Mar;28(2):167-70 (13 ref.)

SURGERY

Leiomyosarcoma of the larynx. Case report. Thomas S, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):794-6 (10 ref.)
Gastrointestinal leiomyosarcomas: experience of 14 cases and review of published reports. Papagrigoriadis S, et al. **Eur J Surg** 1998 Sep;164(9):693-6 (12 ref.)
Stromal sarcoma of the stomach--a report of 20 surgically treated patients. Peiper M, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):442-6 (24 ref.)
[Leiomyosarcoma of the heart and great vessels] Babatasi G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jul-Sep; 47(7):451-8 (43 ref.) (Eng. Abstr.) **(Fre)**
[A case of leiomyosarcoma of the testis] Nagae H, et al. **Hinyokika Kiyo** 1998 Dec;44(12):905-6 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Primary leiomyosarcoma of the heart, report of a case and review of the literature] Myojin K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1339-44 (16 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Management of uterine leiomyosarcoma in Australia. Gard GB, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):93-8 (17 ref.)

ULTRASONOGRAPHY

Left atrial leiomyosarcoma: double occurrence and double recurrence--report of one case. Minardi G, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1171-6 (38 ref.)

LEIOMYOSARCOMA, EPITHELIOID see **LEIOMYOSARCOMA**

LEIOMYOSARCOMA, MYXOID see **LEIOMYOSARCOMA**

LEISHMANIA

CLASSIFICATION

Cutaneous leishmaniasis. The parasite. Dedet JP, et al. **Clin Dermatol** 1999 May-Jun;17(3):261-8 (52 ref.)

DRUG EFFECTS

Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Barrett MP, et al. **Trends Microbiol** 1999 Feb;7(2):82-8 (40 ref.)

GENETICS

Genetic exchange in the trypanosomatidae. Gibson W, et al. **Adv Parasitol** 1999;43:1-46 (150 ref.)
Leishmania virulence and genetic heterogeneity. Chang KP, et al. **Clin Dermatol** 1999 May-Jun;17(3):269-73 (17 ref.)

IMMUNOLOGY

Immune response to Leishmania infection in human skin. Ghersetich I, et al. **Clin Dermatol** 1999 May-Jun; 17(3):333-8 (39 ref.)
Recent trends in vaccine development and immunization. Jaffe CL. **Clin Dermatol** 1999 May-Jun;17(3):339-44 (54 ref.)
Host susceptibility factors to cutaneous leishmaniasis. Jones DE, et al. **Front Biosci** 1998 Nov 15;3:D1171-80 (125 ref.)
The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Antoine JC, et al. **Trends Microbiol** 1998 Oct;6(10):392-401 (46 ref.)
[Immunopathology of American tegumentary leishmaniasis] Castés M, et al. **Acta Cient Venez** 1998;49(1):42-56 (104 ref.) (Eng. Abstr.) **(Spa)**

PATHOGENICITY

Leishmania virulence and genetic heterogeneity. Chang KP, et al. **Clin Dermatol** 1999 May-Jun;17(3):269-73 (17 ref.)
Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Mottram JC, et al. **Curr Opin Microbiol** 1998 Aug;1(4):455-60 (47 ref.)

PHYSIOLOGY

The biology and control of phlebotomine sand flies. Killick-Kendrick R. **Clin Dermatol** 1999 May-Jun; 17(3):279-89 (156 ref.)
Reservoir hosts of cutaneous leishmaniasis. Saliba EK, et al. **Clin Dermatol** 1999 May-Jun;17(3):275-7 (22 ref.)
Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses. McDowell MA, et al. **Curr Opin Microbiol** 1999 Aug;2(4):438-43 (67 ref.)
[Leishmaniasis: principles of the immune response and function of nitric oxide] Bogdan C. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):409-14 (54 ref.) (Eng. Abstr.) **(Ger)**

LEISHMANIA DONOVANI

IMMUNOLOGY

Survival strategies of Leishmania donovani in mammalian host macrophages. Desjardins M, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):689-92 (34 ref.)

LEISHMANIA DONOVANI CHAGASI see **LEISHMANIA INFANTUM**

LEISHMANIA DONOVANI INFANTUM see **LEISHMANIA INFANTUM**

LEISHMANIA INFANTUM

[Mediterranean visceral leishmaniasis: physiopathology] Minodier P, et al. **Presse Med** 1999 Jan 9;28(1):33-9 (56 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cutaneous leishmaniasis: strategies for prevention. Ashford RW. **Clin Dermatol** 1999 May-Jun;17(3):327-32 (9 ref.)

LEISHMANIA (LEISHMANIA) see **LEISHMANIA**

LEISHMANIA (LEISHMANIA) DONOVANI see **LEISHMANIA DONOVANI**

LEISHMANIA (LEISHMANIA) INFANTUM see **LEISHMANIA INFANTUM**

LEISHMANIA (LEISHMANIA) MAJOR see **LEISHMANIA MAJOR**

LEISHMANIA (LEISHMANIA) TROPICA see **LEISHMANIA TROPICA**

LEISHMANIA MAJOR

IMMUNOLOGY

Genetic control of the T cell response to Leishmania major infection. Coffman RL, et al. **Adv Exp Med Biol** 1998; 452:61-6 (14 ref.)
Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Louis JA, et al. **Adv Exp Med Biol** 1998;452:53-60 (35 ref.)
Leishmania major infection of inbred mice: unmasking genetic determinants of infectious diseases. Fowell DJ, et al. **Bioessays** 1999 Jun;21(6):510-8 (76 ref.)
Regulation of protective immunity against Leishmania major in mice. Louis J, et al. **Curr Opin Immunol** 1998 Aug; 10(4):459-64 (67 ref.)
Disease susceptibility and development of the cytokine repertoire in the murine Leishmania major model. Fowell DJ, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):102-6 (32 ref.)
Immune effector mechanism in parasitic infections. Liew FY, et al. **Immunol Lett** 1999 Jan;65(1-2):101-4 (39 ref.)

PATHOGENICITY

Some of the early events underlying Th2 cell maturation and susceptibility to Leishmania major infection in BALB/c mice. Himmelrich H, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):909-14 (31 ref.)
Susceptibility to infectious diseases: Leishmania as a paradigm. Locksley RM, et al. **J Infect Dis** 1999 Mar;179 Suppl 2:S305-8 (19 ref.)

PHYSIOLOGY

Cutaneous leishmaniasis: strategies for prevention. Ashford RW. **Clin Dermatol** 1999 May-Jun;17(3):327-32 (9 ref.)

LEISHMANIA TROPICA

PHYSIOLOGY

Cutaneous leishmaniasis: strategies for prevention. Ashford RW. **Clin Dermatol** 1999 May-Jun;17(3):327-32 (9 ref.)

LEISHMANIA TROPICA MAJOR see **LEISHMANIA MAJOR**

LEISHMANIA TROPICA MINOR see **LEISHMANIA TROPICA**

LEISHMANIA (VIANNIA) see **LEISHMANIA**

LEISHMANIASIS

Leishmaniasis: a re-emerging zoonosis. Marsella R, et al. **Int J Dermatol** 1998 Nov;37(11):801-14 (45 ref.)
[Pulmonary parasitoses. General aspects] L'Her P, et al. **Rev Pneumol Clin** 1998 Dec;54(6):321-8 (36 ref.) (Eng. Abstr.) **(Fre)**
[Leishmaniasis] Katakura K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):159-63 (4 ref.) **(Jpn)**
[Intestinal parasitic infections and leishmaniasis in patients with HIV infection] Moreno-Camacho A, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:52-60 (139 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Leishmaniasis. Basic principles, clinical aspects, diagnosis and therapy] Burbach G, et al. **Dtsch Med Wochenschr** 1999 Jan 29;124(4):88-93 (30 ref.) **(Ger)**

DRUG THERAPY

Practical guide for the treatment of leishmaniasis. Davidson RN. **Drugs** 1998 Dec;56(6):1009-18 (37 ref.)
Recent advances in the fight against leishmaniasis with natural products. Akendengue B, et al. **Parasite** 1999 Mar; 6(1):3-8 (26 ref.)
[Chemotherapy of leishmaniasis and human trypanosomiasis: status and new developments] Kayser O, et al. **Pharm Unserer Zeit** 1999 Jul;28(4):177-85 (31 ref.) **(Ger)**

EPIDEMIOLOGY

Leishmaniasis in the United States military. Martin S, et al. **Mil Med** 1998 Dec;163(12):801-7 (85 ref.)

IMMUNOLOGY

Some of the early events underlying Th2 cell maturation and susceptibility to Leishmania major infection in BALB/c mice. Himmelrich H, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):909-14 (31 ref.)
Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses. McDowell MA, et al. **Curr Opin Microbiol** 1999 Aug;2(4):438-43 (67 ref.)
Macrophage NRAMP1 and its role in resistance to microbial infections. Govoni G, et al. **Inflamm Res** 1998 Jul; 47(7):277-84 (65 ref.)
alpha-Galactosyl-bearing epitopes as potent immunogens in Chagas' disease and leishmaniasis. Avila JL. **Subcell Biochem** 1999;32:173-213 (100 ref.)
[Leishmaniasis: principles of the immune response and function of nitric oxide] Bogdan C. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):409-14 (54 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Antoine JC, et al. **Trends Microbiol** 1998 Oct;6(10):392-401 (46 ref.)

PREVENTION & CONTROL

Leishmania transmission-blocking vaccines: a review. Tonui WK. **East Afr Med J** 1999 Feb;76(2):93-6 (30 ref.)

TRANSMISSION

[The Phlebotominae (Diptera, Phlebotomidae) as vectors of parasitic and viral diseases from the aspect of biomedical research] MiščevićZ, et al. **Srp Arh Celok Lek** 1999 May-Jun;127(5-6):190-5 (42 ref.) **(Scc)**

VETERINARY

[Leishmaniasis: principles of the immune response and function of nitric oxide] Bogdan C. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):409-14 (54 ref.) (Eng. Abstr.) **(Ger)**

LEISHMANIASIS, AMERICAN see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, CUTANEOUS

The United States military and leishmaniasis. Kenner JR, et al. **Dermatol Clin** 1999 Jan;17(1):77-92, viii (77 ref.)

DIAGNOSIS

Cutaneous leishmaniasis: clinical features and diagnosis. Salman SM, et al. **Clin Dermatol** 1999 May-Jun;17(3):291-6 (44 ref.)

DRUG THERAPY

Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Moskowitz PF, et al. **Clin Dermatol** 1999 May-Jun;17(3):305-15 (111 ref.)

EPIDEMIOLOGY

Global control and Leishmania HIV co-infection. Desjeux P. **Clin Dermatol** 1999 May-Jun;17(3):317-25 (13 ref.)
Epidemiology of cutaneous leishmaniasis. Klaus SN, et al. **Clin Dermatol** 1999 May-Jun;17(3):257-60 (28 ref.)

GENETICS

Leishmania major infection of inbred mice: unmasking genetic determinants of infectious diseases. Fowell DJ, et al. **Bioessays** 1999 Jun;21(6):510–8 (76 ref.)

IMMUNOLOGY

Genetic control of the T cell response to Leishmania major infection. Coffman RL, et al. **Adv Exp Med Biol** 1998; 452:61–6 (14 ref.)

Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Louis JA, et al. **Adv Exp Med Biol** 1998;452:53–60 (35 ref.)

Leishmania major infection of inbred mice: unmasking genetic determinants of infectious diseases. Fowell DJ, et al. **Bioessays** 1999 Jun;21(6):510–8 (76 ref.)

Immune response to Leishmania infection in human skin. Ghersetich I, et al. **Clin Dermatol** 1999 May–Jun; 17(3):333–8 (39 ref.)

Regulation of protective immunity against Leishmania major in mice. Louis J, et al. **Curr Opin Immunol** 1998 Aug; 10(4):459–64 (67 ref.)

Disease susceptibility and development of the cytokine repertoire in the murine Leishmania major model. Fowell DJ, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):102–6 (32 ref.)

Host susceptibility factors to cutaneous leishmaniasis. Jones DE, et al. **Front Biosci** 1998 Nov 15;3:D1171–80 (125 ref.)

T-cell response in human leishmaniasis. Kharazmi A, et al. **Immunol Lett** 1999 Jan;65(1–2):105–8 (19 ref.)

Immune effector mechanism in parasitic infections. Liew FY, et al. **Immunol Lett** 1999 Jan;65(1–2):101–4 (39 ref.)

Cytokines in parasitic diseases: the example of cutaneous leishmaniasis. Launois P, et al. **Int Rev Immunol** 1998; 17(1–4):157–80 (94 ref.)

[Immunopathology of American tegumentary leishmaniasis] Castés M, et al. **Acta Cient Venez** 1998;49(1):42–56 (104 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Leishmania virulence and genetic heterogeneity. Chang KP, et al. **Clin Dermatol** 1999 May–Jun;17(3):269–73 (17 ref.)

Cutaneous leishmaniasis. The parasite. Dedet JP, et al. **Clin Dermatol** 1999 May–Jun;17(3):261–8 (52 ref.)

[Progresses in the study of tropical diseases and parasitology in China, 1997] Zheng J. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):902–3 (0 ref.) **(Chi)**

PATHOLOGY

Histologic diagnosis of cutaneous leishmaniasis. Mehregan DR, et al. **Clin Dermatol** 1999 May–Jun;17(3):297–304 (57 ref.)

PREVENTION & CONTROL

Cutaneous leishmaniasis: strategies for prevention. Ashford RW. **Clin Dermatol** 1999 May–Jun;17(3):327–32 (9 ref.)

Recent trends in vaccine development and immunization. Jaffe CL. **Clin Dermatol** 1999 May–Jun;17(3):339–44 (54 ref.)

The biology and control of phlebotomine sand flies. Killick-Kendrick R. **Clin Dermatol** 1999 May–Jun; 17(3):279–89 (156 ref.)

SURGERY

Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Moskowitz PF, et al. **Clin Dermatol** 1999 May–Jun;17(3):305–15 (111 ref.)

TRANSMISSION

The biology and control of phlebotomine sand flies. Killick-Kendrick R. **Clin Dermatol** 1999 May–Jun; 17(3):279–89 (156 ref.)

Reservoir hosts of cutaneous leishmaniasis. Saliba EK, et al. **Clin Dermatol** 1999 May–Jun;17(3):275–7 (22 ref.)

LEISHMANIASIS, NEW WORLD see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, OLD WORLD see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, VISCERAL

COMPLICATIONS

[Visceral leishmaniasis and HIV infection in differential diagnosis of fever conditions] Rugol' LV, et al. **Klin Med (Mosk)** 1998;76(9):68–9 (5 ref.) **(Rus)**

DIAGNOSIS

Laboratory diagnosis of visceral leishmaniasis. Shahi SK, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):361–72 (73 ref.)

DRUG THERAPY

Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion. Berman J, et al. **Chemotherapy** 1999 Jun;45 Suppl 1:54–66 (29 ref.)

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis [see comments] Meyerhoff A. **Clin Infect Dis** 1999 Jan;28(1):42–8; discussion 49–51 (24 ref.) Comment in: Clin Infect Dis 1999 Jan;28(1):49–51.

Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Brogden RN, et al. **Drugs** 1998 Sep; 56(3):365–83 (76 ref.)

[Treatment of infantile visceral leishmaniasis] Minodier P, et al. **Arch Pediatr** 1999 Jan;6(1):59–66 (86 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Global control and Leishmania HIV co-infection. Desjeux P. **Clin Dermatol** 1999 May–Jun;17(3):317–25 (13 ref.)

Epidemiology of visceral leishmaniasis in India. Bora D. **Natl Med J India** 1999 Mar–Apr;12(2):62–8 (81 ref.)

TRANSMISSION

[Mediterranean visceral leishmaniasis: physiopathology] Minodier P, et al. **Presse Med** 1999 Jan 9;28(1):33–9 (56 ref.) (Eng. Abstr.) **(Fre)**

LEISURE ACTIVITIES

[Hearing loss caused by leisure noise] Zenner HP, et al. **HNO** 1999 Apr;47(4):236–48 (69 ref.) (Eng. Abstr.) **(Ger)**

LEMMINGS see **MICROTINAE**

LEMMUS see **MICROTINAE**

LENGTH OF LIFE see **LONGEVITY**

LENGTH OF STAY

Early postpartum discharge. Brumfield CG. **Clin Obstet Gynecol** 1998 Sep;41(3):611–25 (57 ref.)

Early discharge from the NICU. Gamblian V, et al. **J Pediatr Nurs** 1998 Oct;13(5):296–301 (11 ref.)

Fast tracking in cardiac surgery: implications for practice. Chen CA. **Prog Cardiovasc Nurs** 1998 Summer;13(3):31–8, 47 (24 ref.)

[Mechanical ventilation for amyotrophic lateral sclerosis--Making a comparison between hospital and home care] Saito T. **Rinsho Shinkeigaku** 1999 Jan; 39(1):70–1 (3 ref.) (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Systematic review of the effectiveness of planned short hospital stays for mental health care. Johnstone P, et al. **BMJ** 1999 May 22;318(7195):1387–90 (27 ref.)

TRENDS

Early discharge. Risks, benefits, and who decides. Kiely M, et al. **Clin Perinatol** 1998 Sep;25(3):539–53, vii–viii (62 ref.)

LENS CAPSULE, CRYSTALLINE

Endocapsular hematoma: report of a case following glaucoma surgery in a pseudophakic eye. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):389–93 (22 ref.)

PATHOLOGY

Posterior capsule opacification. Part 1: Experimental investigations. Nishi O. **J Cataract Refract Surg** 1999 Jan; 25(1):106–17 (71 ref.)

LENS CORTEX, CRYSTALLINE

PATHOLOGY

Connexins in the lens: are they to blame in diabetic cataractogenesis? Kistler J, et al. **Novartis Found Symp** 1999;219:97–108; discussion 108–12 (32 ref.)

LENS, CRYSTALLINE

Phakomatous choristoma may be located in the eyelid or orbit or both. Seregard S. **Acta Ophthalmol Scand** 1999 Jun;77(3):343–6 (15 ref.)

Phakic intraocular lenses and patient consent [editorial] Rosen ES. **J Cataract Refract Surg** 1999 Feb;25(2):153–5 (10 ref.)

BLOOD SUPPLY

Ultrasonographic diagnosis of persistent hyperplastic tunica vasculosa lentis/persistent hyperplastic primary vitreous in two dogs. Boroffka SA, et al. **Vet Radiol Ultrasound** 1998 Sep–Oct;39(5):440–4 (13 ref.)

CYTOLOGY

Analysis of nuclear degradation during lens cell differentiation. Counis MF, et al. **Cell Death Differ** 1998 Apr;5(4):251–61 (87 ref.)

Lens fibre cell differentiation - A link with apoptosis? Dahm R. **Ophthalmic Res** 1999;31(3):163–83 (149 ref.)

EMBRYOLOGY

Cataract mutations and lens development. Graw J. **Prog Retin Eye Res** 1999 Mar;18(2):235–67 (169 ref.)

GROWTH & DEVELOPMENT

Lens biology: development and human cataractogenesis. Francis PJ, et al. **Trends Genet** 1999 May;15(5):191–6 (51 ref.)

INJURIES

Electric cataract: a case report and review of the literature. Reddy SC. **Eur J Ophthalmol** 1999 Apr–Jun;9(2):134–8 (23 ref.)

METABOLISM

The mechanisms of simultaneous stereoinversion, racemization, and isomerization at specific aspartyl residues of aged lens proteins. Fujii N, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):347–58 (22 ref.)

[The role of crystalline lens lipids in the pathogenesis of age-related cataract] Iatsenko OV. **Lik Sprava** 1998 Jun; (4):50–3 (35 ref.) **(Rus)**

PATHOLOGY

The relationship between cataract, cell swelling and volume regulation. Jacob TJ. **Prog Retin Eye Res** 1999 Mar; 18(2):223–33 (105 ref.)

PHYSIOLOGY

Lens fibre cell differentiation - A link with apoptosis? Dahm R. **Ophthalmic Res** 1999;31(3):163–83 (149 ref.)

The eyes of deep-sea fish. I: Lens pigmentation, tapeta and visual pigments. Douglas RH, et al. **Prog Retin Eye Res** 1998 Oct;17(4):597–636 (178 ref.)

PHYSIOPATHOLOGY

Observations on the optical effects of a cataract. Campbell C. **J Cataract Refract Surg** 1999 Jul;25(7):995–1003 (3 ref.)

[Aging of the crystalline lens and presbyopia] Beers AP, et al. **Tijdschr Gerontol Geriatr** 1998 Aug;29(4):185–8 (22 ref.) (Eng. Abstr.) **(Dut)**

LENS DISLOCATION see **LENS SUBLUXATION**

LENS IMPLANTATION, INTRAOCULAR

see related
PSEUDOPHAKIA

[Triple procedure] Subbotina IN. **Vestn Oftalmol** 1998 Nov–Dec;114(6):49–51 (49 ref.) **(Rus)**

METHODS

Phakic intraocular lenses for correction of high myopia. Garrana RM, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):45–57 (51 ref.)

LENS OPACITIES see **CATARACT**

LENS PROTEINS see **CRYSTALLINS**

LENS SUBLUXATION

SURGERY

Surgical approaches for the removal of posteriorly dislocated crystalline lenses. You TT, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):249–59 (26 ref.)

Management of retained intravitreal lens fragments after cataract surgery. Monshizadeh R, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):397–404 (54 ref.)

LENSES, CONTACT see **CONTACT LENSES**

LENSES, INTRAOCULAR

Phakic intraocular lenses for correction of high myopia. Garrana RM, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):45–57 (51 ref.)

Phakic intraocular lenses and patient consent [editorial] Rosen ES. **J Cataract Refract Surg** 1999 Feb;25(2):153–5 (10 ref.)

New perspectives in cataract surgery. Bahr RL. **Med Health R I** 1999 Feb;82(2):41–5 (5 ref.)

[Materials for intraocular lenses. II. Silicone intraocular lenses (published erratum appears in J Fr Ophtalmol 1999 May;22(5):613)] Werner LP, et al. **J Fr Ophtalmol** 1999 May;22(4):492–501 (84 ref.) **(Fre)**

[Materials for intraocular implants. I. Polymethylmethacrylate intraocular implants and surface modifications] Werner LP, et al. **J Fr Ophtalmol** 1998 Aug–Sep;21(7):515–24 (75 ref.) **(Fre)**

LENTICULAR NUCLEUS see **CORPUS STRIATUM**

LENTIFORM NUCLEUS see **CORPUS STRIATUM**

LENTIGINOSIS see **LENTIGO**

LENTIGINOSIS, PERIORAL

LENTIGINOSIS, PERIORAL see **PEUTZ-JEGHERS SYNDROME**

LENTIGO

PATHOLOGY

Naevi spili, Café-au-lait spots and melanocytic naevi aggregated alongside Blaschko's lines, with a review of segmental melanocytic lesions. Langenbach N, et al. **Acta Derm Venereol** 1998 Sep;78(5):378–80 (22 ref.)

LENTIGO, MALIGNANT see **HUTCHINSON'S MELANOTIC FRECKLE**

LENTILS see **LEGUMES**

LENTIVIRINAE see **LENTIVIRUS**

LENTIVIRUS

GENETICS

Lentiviruses as gene transfer agents for delivery to non-dividing cells. Naldini L. **Curr Opin Biotechnol** 1998 Oct;9(5):457–63 (71 ref.)

METABOLISM

The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Piguet V, et al. **Immunol Rev** 1999 Apr;168:51–63 (112 ref.)

PATHOGENICITY

The comparative pathology of the lentiviruses. Campbell RS, et al. **J Comp Pathol** 1998 Nov;119(4):333–95 (309 ref.)

PHYSIOLOGY

Lentiviral vectors and gene therapy. Klimatcheva E, et al. **Front Biosci** 1999 Jun 1;4:D481–96 (149 ref.)

LENTIVIRUS INFECTIONS

IMMUNOLOGY

Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. Montelaro RC, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S255–9 (22 ref.)

PATHOLOGY

The comparative pathology of the lentiviruses. Campbell RS, et al. **J Comp Pathol** 1998 Nov;119(4):333–95 (309 ref.)

PHYSIOPATHOLOGY

The Nef protein of primate lentiviruses. Piguet V, et al. **Rev Med Virol** 1999 Apr-Jun;9(2):111–20 (93 ref.)

PREVENTION & CONTROL

Animal studies of prophylaxis. Black RJ. **Am J Med** 1997 May 19;102(5B):39–44 (19 ref.)

LENTIVIRUSES, PRIMATE

PHYSIOLOGY

The Nef protein of primate lentiviruses. Piguet V, et al. **Rev Med Virol** 1999 Apr-Jun;9(2):111–20 (93 ref.)

LENTIVIRUSES, SIMIAN see **SIV**

LEON VIRUS see **POLIOVIRUSES, HUMAN 1–3**

LEONTIASIS OSSIUM see **HYPEROSTOSIS FRONTALIS INTERNA**

LEOPARDS see **CARNIVORA**

LEOPARDS BANE see **ARNICA**

LEPIDOPTERA

PATHOGENICITY

Dermatitis causada por Hylesia metabus (Lepidoptera: Hemileucidae) en la región costera del Estado del Delta del Amacuro, Venezuela [Dermatitis caused by Hylesia metabus (Lepidoptera: Hemileucidae) in the costal region of the state of Delta Amacuro, Venezuela] Rodriguez-Acosta A, et al. **Rev Cubana Med Trop** 1998; 50(3):215–7 (11 ref.)

LEPROSTATIC AGENTS

ADMINISTRATION & DOSAGE

[Chemotherapy of Hansen's disease in Japan--present status] Goto M, et al. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul; 67(2):305–11 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Experiences in implementing WHO/MDT in the south west of Bangladesh] Ishida Y, et al. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):329–43 (3 ref.) **(Jpn)**

[Implementing WHO/multi drug treatment for leprosy] Obara A. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul; 67(2):345–51 (4 ref.) **(Jpn)**

[Chemotherapy of leprosy in Japan--its problems to be solved] Ozaki M. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):297–303 (10 ref.) **(Jpn)**

ADVERSE EFFECTS

The return of thalidomide: can birth defects be prevented? Lary JM, et al. **Drug Saf** 1999 Sep;21(3):161–9 (24 ref.)

THERAPEUTIC USE

The return of thalidomide: can birth defects be prevented? Lary JM, et al. **Drug Saf** 1999 Sep;21(3):161–9 (24 ref.)

LEPROSY

see related
LEPROSTATIC AGENTS

Leprosy--new perspectives on an old disease. Whitty CJ, et al. **J Infect** 1999 Jan;38(1):2–5 (30 ref.)

Leprosy. Jacobson RR, et al. **Lancet** 1999 Feb 20; 353(9153):655–60 (67 ref.)

[Hansen's disease, leprosy] Nakajima H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):221–5 (5 ref.) **(Jpn)**

COMPLICATIONS

Management of ocular problems in leprosy. Thompson K, et al. **Indian J Lepr** 1998 Jul-Sep;70(3):295–315 (23 ref.)

Surgery of common paralytic conditions. Duerkson F. **Lepr Rev** 1998 Dec;69(4):390–6 (0 ref.)

Ulcer surgery for non-specialist surgeons. Kazen RO. **Lepr Rev** 1999 Jun;70(2):204–11 (0 ref.)

Management of plantar ulcers in leprosy. Kazen RO. **Lepr Rev** 1999 Mar;70(1):63–9 (0 ref.)

DRUG THERAPY

[Chemotherapy of Hansen's disease in Japan--present status] Goto M, et al. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul; 67(2):305–11 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Experiences in implementing WHO/MDT in the south west of Bangladesh] Ishida Y, et al. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):329–43 (3 ref.) **(Jpn)**

[Implementing WHO/multi drug treatment for leprosy] Obara A. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul; 67(2):345–51 (4 ref.) **(Jpn)**

[Chemotherapy of leprosy in Japan--its problems to be solved] Ozaki M. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):297–303 (10 ref.) **(Jpn)**

EPIDEMIOLOGY

Leprosy in India. Bhattacharya SN, et al. **Clin Dermatol** 1999 Mar-Apr;17(2):159–70; discussion 105–6 (108 ref.)

ETIOLOGY

Dystroglycan in development and disease. Durbeej M, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):594–601 (71 ref.)

Leprosy: pathogenesis updated. Abulafia J, et al. **Int J Dermatol** 1999 May;38(5):321–34 (104 ref.)

IMMUNOLOGY

Pregnancy and leprosy: a comprehensive literature review. Lockwood DN, et al. **Int J Lepr Other Mycobact Dis** 1999 Mar;67(1):6–12 (21 ref.)

The management of leprosy reversal reactions. Britton WJ. **Lepr Rev** 1998 Sep;69(3):225–34 (51 ref.)

Immunoregulation of cytokines in infectious diseases (leprosy), future strategies. Singh RP. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):263–8 (34 ref.)

Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reactions. Rook GA, et al. **Trop Med Int Health** 1999 Jul;4(7):493–8 (45 ref.)

METABOLISM

Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reactions. Rook GA, et al. **Trop Med Int Health** 1999 Jul;4(7):493–8 (45 ref.)

MICROBIOLOGY

Conjunctival biopsy in patients with leprosy. Campos WB, et al. **Indian J Lepr** 1998 Jul-Sep;70(3):291–4 (14 ref.)

SURGERY

Indications for surgery in leprosy. Virmond M. **Lepr Rev** 1998 Sep;69(3):297–304 (0 ref.)

THERAPY

Mycobacterium w immunotherapy in leprosy [editorial] Whitty C. **Lepr Rev** 1998 Sep;69(3):222–4 (10 ref.)

LEPROSY, CUTANEOUS see **LEPROSY, LEPROMATOUS**

LEPROSY, LEPROMATOUS

PSYCHOLOGY

Dimensions and process of stigmatization in leprosy. Bainson KA, et al. **Lepr Rev** 1998 Dec;69(4):341–50 (15 ref.)

LEPROSY, NODULAR see **LEPROSY, LEPROMATOUS**

LEPTOMENINGEAL CYSTS see **ARACHNOID CYSTS**

LEPTOMONAS see **TRYPANOSOMATINA**

LEPTOSPIRA

ISOLATION & PURIFICATION

Leptospirosis in an urban setting: case report and review of an emerging infectious disease. Binder WD, et al. **J Emerg Med** 1998 Nov-Dec;16(6):851–6 (29 ref.)

PATHOGENICITY

Leptospirosis. Bradley KK. **J Okla State Med Assoc** 1999 Mar;92(3):114–5 (4 ref.)

LEPTOSPIROSIS

Leptospirosis. Bradley KK. **J Okla State Med Assoc** 1999 Mar;92(3):114–5 (4 ref.)

[Respiratory manifestations of leptospirosis. A retrospective study of 91 cases (1978–1984)] Courtin JP, et al. **Rev Pneumol Clin** 1998 Dec;54(6):382–92 (98 ref.) (Eng. Abstr.) **(Fre)**

[Leptospirosis (Weil's disease)] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):298–9 (1 ref.) **(Jpn)**

DIAGNOSIS

Leptospirosis in an urban setting: case report and review of an emerging infectious disease. Binder WD, et al. **J Emerg Med** 1998 Nov-Dec;16(6):851–6 (29 ref.)

Leptospirosis. Rathinam SR, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):109–18 (46 ref.)

DRUG THERAPY

Leptospirosis in an urban setting: case report and review of an emerging infectious disease. Binder WD, et al. **J Emerg Med** 1998 Nov-Dec;16(6):851–6 (29 ref.)

THERAPY

Leptospirosis. Rathinam SR, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):109–18 (46 ref.)

LEPTOTHRIX see **GRAM-NEGATIVE AEROBIC BACTERIA**

LESBIANISM see **HOMOSEXUALITY, FEMALE**

LESCH-NYHAN SYNDROME

GENETICS

Transition mutations at CpG dinucleotides are the most frequent in vivo spontaneous single-based substitution mutation in the human HPRT gene. O'Neill JP, et al. **Environ Mol Mutagen** 1998;32(2):188–91 (15 ref.)

THERAPY

Gene therapy for inherited neurological disorders: towards therapeutic intervention in the Lesch-Nyhan syndrome. Lowenstein PR, et al. **Prog Brain Res** 1998;117:485–501 (113 ref.)

LESS-DEVELOPED COUNTRIES see **DEVELOPING COUNTRIES**

LETHAL JUNCTIONAL EPIDERMOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

LETHAL MIDLINE GRANULOMA see **GRANULOMA, LETHAL MIDLINE**

LETHARGY see **SLEEP STAGES**

LETS PROTEINS see **FIBRONECTINS**

LETTERER-SIWE DISEASE

[Letterer-Siwe disease] Shimazaki C, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):380–2 (16 ref.) **(Jpn)**

LEU ANTIGENS see **ANTIGENS, DIFFERENTIATION**

LEU ANTIGENS, B-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

LEU ANTIGENS, T-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

LEU-2 ANTIGENS see **ANTIGENS, CD8**

LEUCINE

The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. Iozzo RV. **J Biol Chem** 1999 Jul 2;274(27):18843-6 (52 ref.)

ANALYSIS

Occurrence and function of D-amino acid-containing peptides and proteins: antimicrobial peptides. Mignogna G, et al. **EXS** 1998;85:29-36 (26 ref.)

DIAGNOSTIC USE

[Studying intestinal maturation in newborn infants by means of stable isotopes] Sáenz de Pipaón M, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):77-82 (59 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

MRI and MRS in HMG-CoA lyase deficiency. Yalçinkaya C, et al. **Pediatr Neurol** 1999 May;20(5):375-80 (13 ref.)

PHARMACOLOGY

Leucine supplementation and intensive training. Mero A. **Sports Med** 1999 Jun;27(6):347-58 (56 ref.)

PHYSIOLOGY

A possible role of di-leucine-based motifs in targeting and sorting of the syntaxin family of proteins. Tang BL, et al. **FEBS Lett** 1999 Mar 12;446(2-3):211-2 (29 ref.)

THERAPEUTIC USE

Leucine supplementation and intensive training. Mero A. **Sports Med** 1999 Jun;27(6):347-58 (56 ref.)

LEUCINE-SPECIFIC TRNA see **RNA, TRANSFER, LEU**

LEUCINE ZIPPERS

ATF3 and stress responses. Hai T, et al. **Gene Expr** 1999; 7(4-6):321-35 (144 ref.)

The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Lüscher B, et al. **Oncogene** 1999 May 13;18(19):2955-66 (110 ref.)

PHYSIOLOGY

Multiple ATM-dependent pathways: an explanation for pleiotropy [editorial] Brown KD, et al. **Am J Hum Genet** 1999 Jan;64(1):46-50 (35 ref.)

LEUCOHARMINE see **HARMINE**

LEUCONOSTOC

PATHOGENICITY

Safety of industrial lactic acid bacteria. Adams MR. **J Biotechnol** 1999 Feb 19;68(2-3):171-8 (25 ref.)

LEUCOTOMY see **PSYCHOSURGERY**

LEUCOVORIN

THERAPEUTIC USE

Successful treatment of intrathecal methotrexate overdose with folinic acid rescue: a case report. Riva L, et al. **Acta Paediatr** 1999 Jul;88(7):780-2 (14 ref.)

UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM, et al. **Anticancer Drugs** 1998 Jul;9(6):479-90 (90 ref.)

Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Goldberg RM, et al. **Oncology (Huntingt)** 1998 Aug;12(8 Suppl 6):59-63 (31 ref.)

European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Khayat D, et al. **Oncology (Huntingt)** 1998 Aug;12(8 Suppl 6):64-7 (12 ref.)

Introduction. Beyond 5-fluorouracil. Pazdur R. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):15-6 (0 ref.)

Clinical implications of 5-FU modulation. Rustum YM. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):22-5 (12 ref.)

Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer. Smith IE. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):82-5 (12 ref.)

Induction therapy for rectal carcinoma. Busse PM, et al. **Semin Surg Oncol** 1998 Sep;15(2):120-5 (37 ref.)

[Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer] Wiboltt K, et al. **Ugeskr Laeger** 1999 Jun 21;161(25):3827-32 (36 ref.) (Eng. Abstr.) **(Dan)**

LEUKAPHERESIS

INSTRUMENTATION

Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter [editorial] Suemitsu J, et al. **Ther Apher** 1998 Feb;2(1):31-6 (12 ref.)

Present status of apheresis technologies: part 4. Leukocyte filter. Sueoka A. **Ther Apher** 1998 Feb;2(1):78-86 (12 ref.)

METHODS

Peripheral blood stem cell collection from G-CSF-stimulated unrelated donors for second transplant. Dini G, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S41-5 (33 ref.)

Collection of peripheral blood stem cells in pediatric patients: a concise review on technical aspects. Marson P, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S7-11 (28 ref.)

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application [published erratum appears in J Immunol Methods 1999 Apr 22;224(1-2):211] Thurner B, et al. **J Immunol Methods** 1999 Feb 1;223(1):1-15 (33 ref.)

[Leukocyte adsorption and removal for the treatment of ulcerative colitis] Shimoyama T, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):724-30 (7 ref.) **(Jpn)**

LEUKEMIA

see related **LEUKEMIC INFILTRATION**

Hematopathology: integration of morphologic features and biologic markers for diagnosis. Jaffe ES. **Mod Pathol** 1999 Feb;12(2):109-15 (36 ref.)

Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. Willman CL. **Mod Pathol** 1999 Feb;12(2):218-28 (48 ref.)

[Leukemias and malignant lymphomas in children] Schmiegelow K. **Ugeskr Laeger** 1999 Apr 12; 161(15):2191-5 (15 ref.) **(Dan)**

[Natural killer cell leukemia] Kawa K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):142-4 (16 ref.) **(Jpn)**

[Mixed lineage leukemia/hybrid leukemia/biphenotypic leukemia] Ogawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):139-41 (14 ref.) **(Jpn)**

[Risk factors for the acute leukemias in children] Ferris i Tortajada J, et al. **An Esp Pediatr** 1999 May;50(5):439-46 (73 ref.) **(Spa)**

BLOOD

Plasminogen activation in human leukemia and in normal hematopoietic cells. Mustjoki S, et al. **APMIS** 1999 Jan; 107(1):144-9 (59 ref.)

CLASSIFICATION

The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Frizzera G, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S13-39 (490 ref.)

COMPLICATIONS

Hepatosplenic candidiasis in patients with acute leukemia: increasingly encountered complication. Sallah S. **Anticancer Res** 1999 Jan-Feb;19(1B):757-60 (14 ref.)

Invasive yeast infections other than Candida spp. in acute leukaemia. Krcmery V, et al. **J Hosp Infect** 1999 Mar; 41(3):181-94 (101 ref.)

CONGENITAL

Congenital and neonatal leukemia. Sande JE, et al. **Semin Perinatol** 1999 Aug;23(4):274-85 (106 ref.)

DIAGNOSIS

Practical applications of immunohistochemistry in hematolymphoid neoplasms. Chu PG, et al. **Ann Diagn Pathol** 1999 Apr;3(2):104-33 (287 ref.)

Uncommon patterns of presentation of leukemia. Vidal C, et al. **Hematol Oncol** 1999 Mar;17(1):11-29 (73 ref.)

[Immunology in medical practice. XXI. Laboratory tests for immunologic diseases] Out TA, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1027-33 (30 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

The evolution of antibiotic therapy for neutropenic patients. Bodey GP. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2660-5 (32 ref.)

The scientific basis of clinical trials: statistical aspects. Gehan EA. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2587-90 (22 ref.)

Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. McCulloch EA. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2676-81 (81 ref.)

Multidrug resistance in leukemia. Leith C. **Curr Opin Hematol** 1998 Jul;5(4):287-91 (51 ref.)

Antisense strategy in hematological malignancies. Warzocha K. **Cytokines Cell Mol Ther** 1999 Mar;5(1):15-23 (90 ref.)

Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. James SY, et al. **Gen Pharmacol** 1999 Jan;32(1):143-54 (174 ref.)

Differentiation therapy of leukemia: achievements, limitations and future prospects. Hozumi M. **Int J Hematol** 1998 Aug; 68(2):107-29 (176 ref.)

Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Den Boer ML, et al. **Leukemia** 1998 Nov; 12(11):1657-70 (183 ref.)

Induction of apoptosis by topotecan: implications for the treatment of leukemia. Seiter K. **Semin Hematol** 1998 Jul; 35(3 Suppl 4):22-5 (24 ref.)

Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. List AF. **Semin Oncol** 1999 Apr;26(2 Suppl 7):61-5 (30 ref.)

[Treatment strategies for childhood acute leukemia and their effectiveness: message to internists from a pediatrician] Hujimoto T. **Rinsho Ketsueki** 1999 Apr;40(4):255-61 (14 ref.) **(Jpn)**

[New approaches of differentiation-inducing therapy for leukemia] Kosugi H, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):480-3 (14 ref.) **(Jpn)**

[Development of anti-leukemic drugs and clinical studies in Japan] Ohno R. **Rinsho Ketsueki** 1999 Mar;40(3):168-71 (5 ref.) **(Jpn)**

ENZYMOLOGY

Role of histone deacetylases in acute leukemia. Fenrick R, et al. **J Cell Biochem Suppl** 1998;30-31:194-202 (35 ref.)

Alkaline phosphatase, defensin gene expression and effect of myeloid cell growth factors in normal and leukemic cells. Tsuruta T, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):237-47 (115 ref.)

Myeloperoxidase gene expression and regulation by myeloid cell growth factors in normal and leukemic cells. Tsuruta T, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):257-67 (107 ref.)

EPIDEMIOLOGY

Epidemiology of leukemia and lymphoma. Bhatia S, et al. **Curr Opin Hematol** 1999 Jul;6(4):201-4 (26 ref.)

Recent advances in the study of the hereditary and environmental basis of childhood leukemia. Mizutani S. **Int J Hematol** 1998 Aug;68(2):131-43 (66 ref.)

Lymphatic and hematopoietic cancer in teachers. Baker P, et al. **Scand J Work Environ Health** 1999 Feb;25(1):5-17 (38 ref.)

[Is there an increased risk of leukemia, brain tumors or breast cancer after exposure to high-frequency radiation? Review of methods and results of epidemiologic studies] Blettner M, et al. **Med Klin** 1999 Mar 15;94(3):150-8 (41 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Zipursky A, et al. **Clin Lab Med** 1999 Mar;19(1):157-67, vii (28 ref.)

The causes of acute leukemia. Severson RK, et al. **Curr Opin Oncol** 1999 Jan;11(1):20-4 (40 ref.)

Hemopoietic growth factor receptor abnormalities in leukemia. Alexander WS, et al. **Leuk Res** 1998 Dec; 22(12):1097-111 (134 ref.)

[Leukemias--diseases of haemopoietic organs stroma (hypothesis)] Morozova VT. **Klin Lab Diagn** 1999 Jun; (6):3-13 (29 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The critical role of chromosome translocations in human leukemias. Rowley JD. **Annu Rev Genet** 1998;32:495-519 (94 ref.)

The SCL gene: from case report to critical hematopoietic regulator. Begley CG, et al. **Blood** 1999 May 1; 93(9):2760-70 (141 ref.)

Chromatin remodeling and leukemia: new therapeutic paradigms. Redner RL, et al. **Blood** 1999 Jul 15; 94(2):417-28 (149 ref.)

Trisomy 14 and leukemia. Reddy KS. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):144-51 (30 ref.)

Oncogenes and tumor suppressor genes: therapeutic implications. Stass SA, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 2):2687-95 (58 ref.)

Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Meyn MS. **Clin Genet** 1999 May;55(5):289-304 (181 ref.)

The importance of cytogenetics and associated molecular techniques in the management of patients with leukaemia. Harrison CJ, et al. **Clin Oncol (R Coll Radiol)** 1998; 10(4):255-61 (54 ref.)

Molecular basis of leukemogenesis. Rubnitz JE, et al. **Curr Opin Hematol** 1998 Jul;5(4):264-70 (60 ref.)

Molecular diagnostics in the treatment of leukemia. Rubnitz JE, et al. **Curr Opin Hematol** 1999 Jul;6(4):229-35 (73 ref.)

Homeobox genes in normal hematopoiesis and leukemogenesis. Chiba S. **Int J Hematol** 1998 Dec; 68(4):343-53 (82 ref.)

Recent advances in the study of the hereditary and environmental basis of childhood leukemia. Mizutani S. **Int J Hematol** 1998 Aug;68(2):131-43 (66 ref.)

Molecular abnormalities in leukemia: the 11q23 story so far. Gregorini A, et al. **J Biol Regul Homeost Agents** 1998 Oct-Dec;12(4):95-105 (127 ref.)

Translocations, fusion genes, and acute leukemia. Saha V, et al. **J Cell Biochem Suppl** 1998;30-31:264-76 (64 ref.)

RAS and leukemia: from basic mechanisms to gene-directed therapy. Beaupre DM, et al. **J Clin Oncol** 1999 Mar;

17(3):1071-9 (116 ref.)
Molecular genetics of human leukemia. Gilliland DG. **Leukemia** 1998 Sep;12 Suppl 1:S7-12 (61 ref.)
The role of TEL fusion genes in pediatric leukemias. Rubnitz JE, et al. **Leukemia** 1999 Jan;13(1):6-13 (85 ref.)
[Molecular cytogenetics of cancer in children: clinical applications] Martínez Climent JA, et al. **Med Clin (Barc)** 1998 Oct 3;111(10):389-97 (165 ref.) (Eng. Abstr.) **(Spa)**
[Importance of the study of chromosomal alterations in acute leukemias] González Sarmiento R. **Sangre (Barc)** 1998 Oct; 43(5):343-4 (7 ref.) **(Spa)**

IMMUNOLOGY

Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. Spaner D. **Cancer Metastasis Rev** 1998 Jun; 17(2):249-57 (62 ref.)
CD44 isoforms in normal and leukemic hematopoiesis. Ghaffari S, et al. **Exp Hematol** 1999 Jun;27(6):978-93 (184 ref.)
Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. Kim TJ, et al. **J Korean Med Sci** 1998 Oct;13(5):455-8 (14 ref.)
The clinical significance of Fas expression in leukemia: questions and controversies. Findley HW, et al. **Leukemia** 1999 Feb;13(2):147-9 (25 ref.)

METABOLISM

Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Gametchu B, et al. **Steroids** 1999 Jan-Feb;64(1-2):107-19 (47 ref.)

PATHOLOGY

Molecular pathology of leukemia and lymphoma. Bagg A, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S76-92 (115 ref.)
The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Frizzera G, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S13-39 (490 ref.)
Natural killer cell neoplasms. Chan JK. **Anat Pathol** 1998; 3:77-145 (256 ref.)
Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. McCulloch EA. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2676-81 (81 ref.)
Differentiation therapy of leukemia: achievements, limitations and future prospects. Hozumi M. **Int J Hematol** 1998 Aug; 68(2):107-29 (176 ref.)
CD44 and adhesion of normal and leukemic CD34+ cells to bone marrow stroma. Bendall LJ, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):427-39 (99 ref.)
History and classification of human leukemia-lymphoma cell lines. Drexler HG, et al. **Leuk Lymphoma** 1998 Oct; 31(3-4):305-16 (128 ref.)
Induction of apoptosis by topotecan: implications for the treatment of leukemia. Seiter K. **Semin Hematol** 1998 Jul; 35(3 Suppl 4):22-5 (24 ref.)
[Leukemias--diseases of haemopoietic organs stroma (hypothesis)] Morozova VT. **Klin Lab Diagn** 1999 Jun; (6):3-13 (29 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. Stunnenberg HG, et al. **Biochim Biophys Acta** 1999 Jan 29;1423(1):F15-33 (159 ref.)
Core-binding factor: a central player in hematopoiesis and leukemia. Speck NA, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1789s-1793s (47 ref.)
A role for growth hormone and prolactin in leukaemia and lymphoma? Hooghe R, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1095-101 (85 ref.)

RADIOTHERAPY

Radioimmunotherapy of hematological cancer: problems and progress. Jurcic JG, et al. **Clin Cancer Res** 1995 Dec; 1(12):1439-46 (69 ref.)
[Radioimmunotherapy of lymphomas and leukemias] Rain JD, et al. **Pathol Biol (Paris)** 1998 May;46(5):341-5 (14 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Prospective comparative study of different amino acid and lipid solutions in parenteral nutrition of patients undergoing bone marrow transplantation] Jiménez Jiménez FJ, et al. **Nutr Hosp** 1999 Mar-Apr;14(2):57-66 (47 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Reisner Y, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:336-48; discussion 348-50 (37 ref.)
The graft-versus-leukemia effects of allogeneic cell therapy. Porter DL, et al. **Annu Rev Med** 1999;50:369-86 (80 ref.)
Umbilical cord blood transplantation. Will AM. **Arch Dis Child** 1999 Jan;80(1):3-6 (26 ref.)
Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. Spaner D. **Cancer Metastasis Rev** 1998 Jun; 17(2):249-57 (62 ref.)
Advances in therapy of multiple myeloma: lessons from acute leukemia. Barlogie B. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2605-13 (81 ref.)
Hematopoietic supportive care. Hester J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2666-70 (27 ref.)
Oncogenes and tumor suppressor genes: therapeutic implications. Stass SA, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 2):2687-95 (58 ref.)
Molecular diagnostics in the treatment of leukemia. Rubnitz JE, et al. **Curr Opin Hematol** 1999 Jul;6(4):229-35 (73 ref.)
Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Reisner Y, et al. **Immunol Today** 1999 Aug;20(8):343-7 (50 ref.)
Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. Kim TJ, et al. **J Korean Med Sci** 1998 Oct;13(5):455-8 (14 ref.)
Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. Singhal S, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):287-94 (37 ref.)
The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Yang YG, et al. **Leuk Lymphoma** 1999 May;33(5-6):409-20 (106 ref.)
Thrombopoietic factors potentially useful in the treatment of acute leukemia. Archimbaud E, et al. **Leuk Res** 1998 Dec;22(12):1155-64 (141 ref.)
Interleukin 2 in the treatment of acute leukemia. Blaise D, et al. **Leuk Res** 1998 Dec;22(12):1165-70 (29 ref.)
Interleukin-2 and leukemia. Goodman M, et al. **Leukemia** 1998 Nov;12(11):1671-5 (53 ref.)
Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Kolb HJ. **Vox Sang** 1998;74 Suppl 2:321-9 (71 ref.)
[Leukemias in children and adolescents] Bürger BJ, et al. **Med Monatsschr Pharm** 1999 Jun;22(6):175-83 (8 ref.) **(Ger)**
[Management of hematologic systemic diseases and rare tumor entities with manifestations in the oromaxillofacial area] Petrasch S. **Mund Kiefer Gesichtschir** 1998 Jul; 2(4):172-80 (74 ref.) (Eng. Abstr.) **(Ger)**
[Malignant tumors in childhood] Fujimoto T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:191-8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Gene therapy for hematological malignancies] Tani K. **Rinsho Byori** 1998 Aug;46(8):797-803 (9 ref.) **(Jpn)**
[Therapeutic application for leukemia with ribozyme] Matsushita H, et al. **Rinsho Ketsueki** 1998 Aug;39(8):553-64 (63 ref.) **(Jpn)**

LEUKEMIA, ADULT T-CELL see **LEUKEMIA, T-CELL**

LEUKEMIA, ALEUKEMIC see **LEUKEMIA, SUBLEUKEMIC**

LEUKEMIA, B-CELL

IMMUNOLOGY

CD5 B cells and B-cell malignancies. Lydyard PM, et al. **Curr Opin Hematol** 1999 Jan;6(1):30-6 (107 ref.)

THERAPY

Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Schultze JL, et al. **Curr Opin Oncol** 1998 Nov;10(6):542-7 (31 ref.)

LEUKEMIA, B-CELL, ACUTE

[B lineage acute lymphoblastic leukemia] Ino T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):85-90 (18 ref.) **(Jpn)**
[Myeloid antigen positive B-ALL] Kitayama H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):170-2 (11 ref.) **(Jpn)**

DIAGNOSIS

[Burkitt's leukemia-lymphoma] Jantunen E, et al. **Duodecim** 1995;111(22):2115-21 (33 ref.) **(Fin)**

GENETICS

Analysis of B-cell neoplasias by spectral karyotyping (SKY). Hilgenfeld E, et al. **Curr Top Microbiol Immunol** 1999; 246:169-74 (18 ref.)

THERAPY

[Burkitt's leukemia-lymphoma] Jantunen E, et al. **Duodecim** 1995;111(22):2115-21 (33 ref.) **(Fin)**

LEUKEMIA, B-CELL, CHRONIC

B-cell chronic lymphocytic leukemia: a bird of a different feather. Caligaris-Cappio F, et al. **J Clin Oncol** 1999 Jan; 17(1):399-408 (125 ref.)
B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Pangalis GA, et al. **Semin Hematol** 1999 Apr;36(2):104-14 (139 ref.)

DIAGNOSIS

Is it time for a reassessment of prognostic features in B-cell chronic lymphocytic leukemia? Molica S. **Hematol Cell Ther** 1999 Jun;41(3):87-93 (70 ref.)

GENETICS

Alternative splicing of CD79a (Ig alpha) and CD79b (Ig beta) transcripts in human B-CLL cells. Alfarano A, et al. **Curr Top Microbiol Immunol** 1999;246:241-6; discussion 247-8 (28 ref.)
Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. Döhner H, et al. **J Mol Med** 1999 Feb;77(2):266-81 (123 ref.)

IMMUNOLOGY

Alternative splicing of CD79a (Ig alpha) and CD79b (Ig beta) transcripts in human B-CLL cells. Alfarano A, et al. **Curr Top Microbiol Immunol** 1999;246:241-6; discussion 247-8 (28 ref.)

METABOLISM

TGF-beta activity and expression of its receptors in B-cell chronic lymphocytic leukemia. Lagneaux L, et al. **Leuk Lymphoma** 1998 Sep;31(1-2):99-106 (25 ref.)
Growth and survival of B-chronic lymphocytic leukaemia cells. Söderberg O. **Med Oncol** 1998 Jul;15(2):73-8 (75 ref.)

PATHOLOGY

Apoptosis in B-chronic lymphocytic leukaemia. Osorio LM, et al. **Med Oncol** 1998 Dec;15(4):234-40 (83 ref.)
[Discordant lymphoma: a report of 2 new cases and a review of the literature] Azaceta Reinares G, et al. **Rev Clin Esp** 1998 Nov;198(11):749-51 (11 ref.) (Eng. Abstr.) **(Spa)**

LEUKEMIA, BASOPHILIC, ACUTE

[Basophilic leukemia] Moriyama Y. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):153-6 (14 ref.) **(Jpn)**

DIAGNOSIS

Diagnosis of acute basophilic leukemia. Duchayne E, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):269-78 (53 ref.)

PATHOLOGY

Diagnosis of acute basophilic leukemia. Duchayne E, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):269-78 (53 ref.)

LEUKEMIA, EOSINOPHILIC see **HYPEREOSINOPHILIC SYNDROME**

LEUKEMIA, ERYTHROBLASTIC, ACUTE

[M6, erythroleukemia] Hino K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):77-80 (9 ref.) **(Jpn)**

LEUKEMIA, EXPERIMENTAL

Advantages of the CBA mouse in leukemogenesis research. Rithidech KN, et al. **Blood Cells Mol Dis** 1999 Feb; 25(1):38-45 (69 ref.)

DRUG THERAPY

Leukemia: A model for drug development. Keating MJ. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2598-604 (43 ref.)

GENETICS

Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Westervelt P, et al. **Blood** 1999 Apr 1;93(7):2143-8 (26 ref.)
Molecular basis of leukemogenesis. Rubnitz JE, et al. **Curr Opin Hematol** 1998 Jul;5(4):264-70 (60 ref.)
Cycling, stressed-out and nervous: cellular functions of c-Abl. Van Etten RA. **Trends Cell Biol** 1999 May; 9(5):179-86 (62 ref.)
[Generation and analysis of mouse models for leukemia] Honda H. **Rinsho Ketsueki** 1999 Apr;40(4):284-9 (13 ref.) **(Jpn)**

METABOLISM

The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Valk PJ, et al. **Leuk Lymphoma** 1998 Dec; 32(1-2):29-43 (108 ref.)

PHYSIOPATHOLOGY

Cycling, stressed-out and nervous: cellular functions of c-Abl. Van Etten RA. **Trends Cell Biol** 1999 May; 9(5):179-86 (62 ref.)

LEUKEMIA, GRANULOCYTIC see **LEUKEMIA, MYELOID**

LEUKEMIA, GRANULOCYTIC, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, HAIRY CELL

Hairy-cell leukaemia: biology and management. Pettitt AR, et al. **Br J Haematol** 1999 Jul;106(1):2–8 (71 ref.)

Hairy cell leukemia. What is new forty years after the first description? Troussard X, et al. **Hematol Cell Ther** 1998 Aug;40(4):139–48 (80 ref.)

[Hairy cell leukemia: authors' own experience (1977–1998)] Telek B, et al. **Orv Hetil** 1999 May 2;140(18):987–91 (38 ref.) (Eng. Abstr.) **(Hun)**

[Hairy cell leukemia] Asou N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):126–9 (15 ref.) **(Jpn)**

BLOOD

Hairy cell leukemia with an associated lupus-type anticoagulant [see comments] Kirkpatrick J, et al. **J Am Osteopath Assoc** 1999 Feb;99(2):109–12, 116 (24 ref.) Comment in: J Am Osteopath Assoc 1999 Aug;99(8):394–5.

DRUG THERAPY

Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: case report and review of the literature. Al-Fiar F, et al. **Leuk Res** 1999 Aug;23(8):719–21 (24 ref.)

Treatment of hairy-cell leukemia: current views. Tallman MS, et al. **Semin Hematol** 1999 Apr;36(2):155–63 (109 ref.)

[Hairy cell leukemia—a potentially curable malignancy. Selected aspects of purine analog therapy] Rucińska M, et al. **Przegl Lek** 1998;55(7–8):400–6 (38 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Familial hairy cell leukemia: a HLA-linked disease or farmers-linked disease? [letter] Casado LF, et al. **Haematologica** 1998 Aug;83(8):751–2 (11 ref.)

LEUKEMIA L5178

METABOLISM

Failure to adequately use positive control data leads to poor quality mouse lymphoma data assessments. Moore MM, et al. **Mutagenesis** 1999 May;14(3):261–3 (19 ref.)

LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOBLASTIC see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOBLASTIC, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, PHILADELPHIA-POSITIVE see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, BURKITT-TYPE see **LEUKEMIA, B-CELL, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

LEUKEMIA, LYMPHOCYTIC

Chronic lymphoid leukemias and lymphoproliferative disorders. Foucar K. **Mod Pathol** 1999 Feb;12(2):141–50 (44 ref.)

[Large granular lymphocyte leukemia] Hanada S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):110–3 (13 ref.) **(Jpn)**

COMPLICATIONS

Two cases of disseminated mucormycosis in patients with hematological malignancies and literature review. Cuvelier I, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec; 17(12):859–63 (15 ref.)

DRUG THERAPY

[Large granular lymphocytic leukemia] Wyszecka-Polk I, et al. **Wiad Lek** 1998;51(7–8):368–72 (17 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

[Large granular lymphocytic leukemia] Wyszecka-Polk I, et al. **Wiad Lek** 1998;51(7–8):368–72 (17 ref.) (Eng. Abstr.) **(Pol)**

LEUKEMIA, LYMPHOCYTIC, ACUTE

[Central nervous system leukemia] Asou N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):130–4 (15 ref.) **(Jpn)**

[Acute leukemias] Díaz Mediavilla J. **Rev Clin Esp** 1999 Apr; 199 Suppl 1:22–7 (17 ref.) **(Spa)**

COMPLICATIONS

Central nervous system infections due to Stomatococcus mucilaginosus in immunocompromised hosts. Goldman M, et al. **Clin Infect Dis** 1998 Nov;27(5):1241–6 (13 ref.)

Childhood leukaemia: a model of pre-obesity. Ventham JC, et al. **Proc Nutr Soc** 1999 May;58(2):277–81 (45 ref.)

DIAGNOSIS

Biology and clinical significance of the TEL/AML1 rearrangement [see comments] Borkhardt A, et al. **Curr Opin Pediatr** 1999 Feb;11(1):33–8 (39 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):31–2.

Detection of minimal residual disease in acute leukemia by flow cytometry. Campana D, et al. **Cytometry** 1999 Aug 15;38(4):139–52 (100 ref.)

Fish analysis at diagnosis in acute lymphoblastic leukemia. Avet-Loiseau H. **Leuk Lymphoma** 1999 May;33(5–6):441–9 (43 ref.)

[Current diagnosis of acute leukemia (lecture)] Frenkel' MA. **Klin Lab Diagn** 1999 Jan;(1):25–32 (15 ref.) **(Rus)**

DRUG THERAPY

Successful treatment of intrathecal methotrexate overdose with folinic acid rescue: a case report. Riva L, et al. **Acta Paediatr** 1999 Jul;88(7):780–2 (14 ref.)

Use of L-asparaginase in childhood ALL. Müller HJ, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):97–113 (174 ref.)

Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. Gómez-Almaguer D, et al. **Int J Cancer Suppl** 1998;11:52–5 (17 ref.)

Intrathecal vincristine: an analysis of reasons for recurrent fatal chemotherapeutic error with recommendations for prevention. Fernandez CV, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):587–90 (13 ref.)

ETIOLOGY

Acute lymphoid leukemia following polycythemia vera. Camós M, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):395–8 (20 ref.)

GENETICS

Role of TCL1 and ALL1 in human leukemias and development. Croce CM. **Cancer Res** 1999 Apr 1;59(7 Suppl):1778s–1783s (46 ref.)

Unusual immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemias. Szczepański T, et al. **Curr Top Microbiol Immunol** 1999; 246:205–13; discussion 214–5 (30 ref.)

Seminars from the University of Minnesota. Chromosome translocations: dangerous liaisons. Rowley JD. **J Lab Clin Med** 1998 Oct;132(4):244–50 (29 ref.)

Monosomy X as the sole cytogenetic abnormality in acute lymphoblastic leukemia: a report of two new patients. Bueno JL, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):381–4 (14 ref.)

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia [editorial] Drexler HG, et al. **Leuk Res** 1999 Mar;23(3):207–15 (84 ref.)

Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature. Solves P, et al. **Leuk Res** 1999 Sep;23(9):851–4 (17 ref.)

Leukemia in infants. Felix CA, et al. **Oncologist** 1999; 4(3):225–40 (221 ref.)

[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases] Beltinger C, et al. **Klin Padiatr** 1998 Jul-Aug;210(4):153–8 (37 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Unusual immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemias. Szczepański T, et al. **Curr Top Microbiol Immunol** 1999; 246:205–13; discussion 214–5 (30 ref.)

METABOLISM

Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Gati WP, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):45–54 (44 ref.)

PHYSIOPATHOLOGY

Childhood leukaemia: a model of pre-obesity. Ventham JC, et al. **Proc Nutr Soc** 1999 May;58(2):277–81 (45 ref.)

THERAPY

Transplantation with peripheral blood stem cells, manipulated or unmanipulated, for the treatment of high-risk childhood leukemia. Takaue Y, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S1–6 (15 ref.)

Recent advances in the biology and management of acute lymphoblastic leukemia in adults. O'Connor OA, et al. **Cancer Treat Res** 1999;99:307–33 (133 ref.)

Hematopoietic growth factors and acute leukemia. Rowe JM, et al. **Cancer Treat Res** 1999;99:195–226 (129 ref.)

Relapse of acute lymphoblastic leukemia in pregnancy: survival following chemoirradiation and autologous transfer of interleukin-2-activated stem cells. Tewari K, et al. **Gynecol Oncol** 1999 Jul;74(1):143–6 (20 ref.)

Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Ohno R. **Leuk Res** 1998 Dec;22(12):1143–54 (62 ref.)

Growth factors in the treatment of acute lymphoblastic leukemia. Ottmann OG, et al. **Leuk Res** 1998 Dec; 22(12):1171–8 (30 ref.)

Infertility and premature menopause in childhood cancer survivors. Byrne J. **Med Pediatr Oncol** 1999 Jul;33(1):24–8 (11 ref.)

[Hematopoietic stem cell transplantation for treatment of acute leukemia] Harada M. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1387–95 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment for a high-risk group for childhood acute lymphoblastic leukemia] Koizumi S. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1042–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. I. Acute leukemia] Ikeda K, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1464–9 (6 ref.) **(Jpn)**

[Acute lymphoblastic leukemia: its clinical cure and molecular cure (editorial; comment)] Colomer Pujol D. **Med Clin (Barc)** 1999 Apr 17;112(13):495–6 (20 ref.) Comment on: Med Clin (Barc) 1999 Apr 17;112(13):481–4. **(Spa)**

LEUKEMIA, LYMPHOCYTIC, ACUTE, B-CELL see **LEUKEMIA, B-CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, ACUTE, L1

Acute lymphoblastic leukemia. Melnick SJ. **Clin Lab Med** 1999 Mar;19(1):169–86, vii (66 ref.)

Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Pui CH. **Curr Opin Hematol** 1998 Jul;5(4):292–301 (125 ref.)

DIAGNOSIS

Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Foroni L, et al. **Br J Haematol** 1999 Apr;105(1):7–24 (174 ref.)

The clinical significance of detection of residual disease in childhood ALL. Faderl S, et al. **Crit Rev Oncol Hematol** 1998 Jun;28(1):31–55 (197 ref.)

Detection of residual disease in acute lymphoblastic leukemia of childhood. Estrov Z, et al. **Leuk Lymphoma** 1999 Mar; 33(1–2):47–52 (35 ref.)

[Role of the laboratory scientist in the diagnosis and treatment of acute lymphoblastic leukemia in children] Fournier M, et al. **Ann Biol Clin (Paris)** 1998 May-Jun; 56(3):343–7 (17 ref.) **(Fre)**

DRUG THERAPY

Maintenance chemotherapy of acute lymphoblastic leukemia in children. Schmiegelow K. **Dan Med Bull** 1998 Nov; 45(5):510–32 (291 ref.)

Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia. Lilleyman JS. **Leuk Lymphoma** 1998 Nov;31(5–6):501–6 (25 ref.)

Pharmacodynamic monitoring of cancer chemotherapy: childhood acute lymphoblastic leukemia as a model. Yates CR, et al. **Ther Drug Monit** 1998 Oct;20(5):453–8 (42 ref.)

[Role of the laboratory scientist in the diagnosis and treatment of acute lymphoblastic leukemia in children] Fournier M, et al. **Ann Biol Clin (Paris)** 1998 May-Jun; 56(3):343–7 (17 ref.) **(Fre)**

EPIDEMIOLOGY

Clustering of childhood acute leukaemia: The EUROCLUS Project. Alexander F. **Radiat Environ Biophys** 1998 Jul; 37(2):71–4 (19 ref.)

ETIOLOGY

Acute lymphoblastic leukemia occurring as a second malignancy: report of a case and review of literature. Geetha N, et al. **Pediatr Hematol Oncol** 1999 May-Jun; 16(3):267–70 (10 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE, L1

GENETICS

Genes and cancer. Birch JM. **Arch Dis Child** 1999 Jan; 80(1):1–3 (25 ref.)

Molecular genetics, natural history and the demise of childhood leukaemia. Greaves M. **Eur J Cancer** 1999 Feb; 35(2):173–85 (87 ref.)

Childhood acute lymphoblastic leukemia: is there a tumor suppressor gene in chromosome 12p12.3? Aïssani B, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):231–9 (70 ref.)

THERAPY

[Hematopoietic stem cell transplantation in childhood leukemias] Kawano Y, et al. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1415–23 (34 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, LYMPHOCYTIC, ACUTE, L2

DIAGNOSIS

Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Foroni L, et al. **Br J Haematol** 1999 Apr;105(1):7–24 (174 ref.)

DRUG THERAPY

Dose-intensive therapy for adult acute lymphoblastic leukemia. Finiewicz KJ, et al. **Semin Oncol** 1999 Feb; 26(1):6–20 (68 ref.)

SURGERY

Dose-intensive therapy for adult acute lymphoblastic leukemia. Finiewicz KJ, et al. **Semin Oncol** 1999 Feb; 26(1):6–20 (68 ref.)

THERAPY

[Treatment of adult acute lymphoblastic leukemia] Gökbuget N, et al. **Schweiz Rundsch Med Prax** 1999 Mar 4; 88(10):407–20 (73 ref.) (Eng. Abstr.) **(Ger)**

[Differences in therapeutic strategies for adult leukemia and lymphoma between Japan and western countries] Sakamaki H. **Gan To Kagaku Ryoho** 1999 Jan;26(1):41–8 (37 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, LYMPHOCYTIC, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, B-CELL see **LEUKEMIA, B-CELL**

LEUKEMIA, LYMPHOCYTIC, CHRONIC

Chronic lymphocytic leukaemia. Oscier D. **Br J Haematol** 1999 Apr;105 Suppl 1:1–3 (9 ref.)

Chronic lymphocytic leukemia. Kipps TJ. **Curr Opin Hematol** 1998 Jul;5(4):244–53 (124 ref.)

[Chronic lymphocytic leukemia (CLL)] Ito S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):95–8 (12 ref.) **(Jpn)**

CLASSIFICATION

The concept of typical and atypical chronic lymphocytic leukaemia. Criel A, et al. **Leuk Lymphoma** 1999 Mar; 33(1–2):33–45 (80 ref.)

COMPLICATIONS

Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Lai R, et al. **Am J Clin Pathol** 1999 Mar;111(3):373–8 (21 ref.)

Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. Nousari HC, et al. **J Am Acad Dermatol** 1999 May; 40(5 Pt 1):750–4 (24 ref.)

[An unusual effect of cyclosporine A in a patient with chronic lympholeukemia complicated by autoimmune hemolysis and thrombocytolysis] Vinogradova OA, et al. **Ter Arkh** 1998;70(7):75–7 (12 ref.) **(Rus)**

DIAGNOSIS

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Schultze JL, et al. **J Mol Med** 1999 Feb;77(2):259–65 (34 ref.)

DRUG THERAPY

Uracil mustard revisited. Kennedy BJ, et al. **Cancer** 1999 May 15;85(10):2265–72 (51 ref.)

[Advances in the treatment of chronic lymphocytic leukemia (CLL)] Lechner K, et al. **Wien Klin Wochenschr** 1998 Oct 30;110(20):701–8 (69 ref.) (Eng. Abstr.) **(Ger)**

[An unusual effect of cyclosporine A in a patient with chronic lympholeukemia complicated by autoimmune hemolysis and thrombocytolysis] Vinogradova OA, et al. **Ter Arkh** 1998;70(7):75–7 (12 ref.) **(Rus)**

EPIDEMIOLOGY

Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Mauro FR, et al. **Blood** 1999 Jul 15; 94(2):448–54 (41 ref.)

GENETICS

Chronic lymphocytic leukemia. Wierda WG, et al. **Curr Opin Hematol** 1999 Jul;6(4):253–61 (111 ref.)

Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. Merup M. **Med Oncol** 1998 Jul;15(2):79–88 (87 ref.)

Genetics of small lymphocyte disorders. Panayiotidis P, et al. **Semin Hematol** 1999 Apr;36(2):171–7 (77 ref.)

METABOLISM

Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. Meinhardt G, et al. **J Mol Med** 1999 Feb; 77(2):282–93 (155 ref.)

PATHOLOGY

Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. Meinhardt G, et al. **J Mol Med** 1999 Feb; 77(2):282–93 (155 ref.)

The concept of typical and atypical chronic lymphocytic leukaemia. Criel A, et al. **Leuk Lymphoma** 1999 Mar; 33(1–2):33–45 (80 ref.)

Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia. McConkey DJ, et al. **Leuk Lymphoma** 1999 May;33(5–6):421–31 (60 ref.)

RADIOTHERAPY

Milestones in the development of Lym-1 therapy. DeNardo GL, et al. **Hybridoma** 1999 Feb;18(1):1–11 (46 ref.)

SURGERY

Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived. Waselenko JK, et al. **Semin Oncol** 1999 Feb;26(1):48–61 (105 ref.)

THERAPY

Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy. Wendtner CM, et al. **Ann Oncol** 1999 May; 10(5):505–9 (16 ref.)

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Khouri IF, et al. **Curr Opin Hematol** 1998 Nov;5(6):454–9 (29 ref.)

Chronic lymphocytic leukemia. Wierda WG, et al. **Curr Opin Hematol** 1999 Jul;6(4):253–61 (111 ref.)

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Schultze JL, et al. **J Mol Med** 1999 Feb;77(2):259–65 (34 ref.)

Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Boussiotis VA, et al. **Semin Hematol** 1999 Apr;36(2):209–16 (49 ref.)

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL see **LEUKEMIA, B-CELL, CHRONIC**

LEUKEMIA, LYMPHOCYTIC, CHRONIC, T-CELL see **LEUKEMIA, T-CELL, CHRONIC**

LEUKEMIA, LYMPHOCYTIC, L3 see **LEUKEMIA, B-CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, LARGE GRANULAR see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOCYTIC, T-CELL see **LEUKEMIA, T-CELL**

LEUKEMIA, LYMPHOID see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA-LYMPHOMA, ADULT T-CELL see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED

[A case of adult T cell leukemia (lymphoma type) involving the pancreas] Ohnishi Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):64–9 (30 ref.) **(Jpn)**

[Adult T-cell leukemia/lymphoma] Matsuoka M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):114–8 (11 ref.) **(Jpn)**

LEUKEMIA, MEGAKARYOBLASTIC, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MEGAKARYOCYTIC see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MEGAKARYOCYTIC, ACUTE

[M7, acute leukemia of megakaryocyte lineage] Nakamaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):81–4 (15 ref.) **(Jpn)**

GENETICS

Are cells with trisomy 10 always malignant in hematopoietic disorders? Berger R, et al. **Ann Genet** 1999;42(1):5–10 (20 ref.)

LEUKEMIA, MONOBLASTIC, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MONOCYTIC, ACUTE

[M5, acute monocytic leukemia] Nakamaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):72–6 (12 ref.) **(Jpn)**

CONGENITAL

Congenital leukemia: successful treatment of a newborn with t(5;11)(q31;q23). Fernandez MC, et al. **J Pediatr Hematol Oncol** 1999 Mar–Apr;21(2):152–7 (47 ref.)

DRUG THERAPY

Effective treatment of thymic carcinoma with operation and combination chemotherapy against acute monocyte leukemia: case report and review of the literature. Kitami A, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):555–8 (28 ref.)

GENETICS

Jumping translocations involving chromosome 1q in a patient with Crohn disease and acute monocytic leukemia: a review of the literature on jumping translocations in hematological malignancies and Crohn disease. Reddy KS, et al. **Cancer Genet Cytogenet** 1999 Mar;109(2):144–9 (40 ref.)

SURGERY

Effective treatment of thymic carcinoma with operation and combination chemotherapy against acute monocyte leukemia: case report and review of the literature. Kitami A, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):555–8 (28 ref.)

LEUKEMIA, MYELOBLASTIC, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOCYTIC see **LEUKEMIA, MYELOID**

LEUKEMIA, MYELOCYTIC, ACUTE

[Acute myelogenous leukemia in elderly] Mori M. **Rinsho Ketsueki** 1999 Feb;40(2):77–80 (21 ref.) **(Jpn)**

[M1, acute myeloid leukemia without maturation] Hino K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):58–61 (11 ref.) **(Jpn)**

[M2, acute myeloid leukemia with maturation] Hino K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):62–4 (9 ref.) **(Jpn)**

[Trilineage myelodysplasia] Kuriyama K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):209–12 (14 ref.) **(Jpn)**

[Acute myeloid leukemia expressing lymphoid associated antigens] Kuriyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):166–9 (16 ref.) **(Jpn)**

[Secondary leukemia] Nakamura H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):177–9 (10 ref.) **(Jpn)**

[Hypocellular acute leukemia] Sawada A, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):145–8 (21 ref.) **(Jpn)**

[M0, minimally differentiated acute myeloid leukemia] Tsuruoka N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):55–7 (7 ref.) **(Jpn)**

COMPLICATIONS

Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Lai R, et al. **Am J Clin Pathol** 1999 Mar;111(3):373–8 (21 ref.)

Two cases of disseminated mucormycosis in patients with hematological malignancies and literature review. Cuvelier I, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec; 17(12):859–63 (15 ref.)

[Acute myelocytic leukemia in immunodeficiency virus infection] Pulik M, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):475–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Necrotizing fasciitis of the neck in a patient with acute myeloid leukemia: clinical features, therapeutic strategy and review of the literature] Ferri E, et al. **Acta Otorhinolaryngol Ital** 1998 Apr;18(2):116–22 (75 ref.) (Eng. Abstr.) **(Ita)**

[Respiratory distress syndrome due to hyperleukocytic leukemias] Valdovinos Mahave MC, et al. **An Med Interna** 1999 Jul;16(7):359–60 (8 ref.) (Eng. Abstr.)

(Spa)

DIAGNOSIS

Detection of minimal residual disease in acute leukemia by flow cytometry. Campana D, et al. **Cytometry** 1999 Aug 15;38(4):139–52 (100 ref.)

DRUG THERAPY

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cortes JE, et al. **Cancer** 1999 Apr 1;85(7):1506–13 (42 ref.)

Leukemia: A model for drug development. Keating MJ. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2598–604 (43 ref.)

Granulocyte colony-stimulating factor in combination with intensive chemotherapy in the treatment of acute myeloid leukemia. Dombret H. **Leuk Res** 1998 Dec;22(12):1137–42 (29 ref.)

New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids. Estey EH. **Leukemia** 1998 Sep;12 Suppl 1:S13–5 (1 ref.)

What is the best induction regimen for acute myelogenous leukemia? Rowe JM. **Leukemia** 1998 Sep;12 Suppl 1:S16–9 (31 ref.)

Treatment of resistant disease. Schiller GJ. **Leukemia** 1998 Sep;12 Suppl 1:S20–4 (36 ref.)

[Hematologic tumors] Ogawa M. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:165–72 (35 ref.) (Eng. Abstr.) (Jpn)

[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs] Machaczka M, et al. **Przegl Lek** 1998; 55(7–8):407–13 (53 ref.) (Eng. Abstr.) (Pol)

ETIOLOGY

Acute leukemias after treatment with radioiodine for thyroid cancer [letter] Roldán Schilling V, et al. **Haematologica** 1998 Aug;83(8):767–8 (6 ref.)

Leukemia arising out of paroxysmal nocturnal hemoglobinuria. Harris JW, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):401–26 (189 ref.)

GENETICS

Duplication of band 12q24 in acute myeloblastic leukemia. Bonomi R, et al. **Cancer Genet Cytogenet** 1999 Jan 1; 108(1):75–8 (36 ref.)

Late appearance of t(5;12)(q31;p12) in acute myeloid leukemia associated with eosinophilia. Yahata N, et al. **Cancer Genet Cytogenet** 1998 Dec;107(2):147–50 (17 ref.)

Seminars from the University of Minnesota. Chromosome translocations: dangerous liaisons. Rowley JD. **J Lab Clin Med** 1998 Oct;132(4):244–50 (29 ref.)

Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR. Tobal K, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):115–20 (39 ref.)

[t(3;5) (q21;q31) chromosomal abnormality in a patient with acute myelogenous leukemia with trilineage myelodysplasia] Sasai Y, et al. **Rinsho Ketsueki** 1998 Sep; 39(9):658–64 (22 ref.) (Eng. Abstr.) (Jpn)

IMMUNOLOGY

IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Bruserud O. **Cytokines Cell Mol Ther** 1998 Sep;4(3):187–98 (137 ref.)

Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Bruserud O. **Leukemia** 1999 Aug; 13(8):1175–87 (177 ref.)

METABOLISM

Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Gati WP, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):45–54 (44 ref.)

Thrombopoietin receptor in acute myeloid leukemia. Wetzler M, et al. **Leuk Res** 1999 Feb;23(2):191–4 (33 ref.)

PATHOLOGY

Acute myeloid leukemia in the elderly. Harousseau JL. **Blood Rev** 1998 Sep;12(3):145–53 (39 ref.)

Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Koc Y, et al. **Cancer** 1999 Feb 1; 85(3):608–15 (27 ref.)

Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Bruserud O. **Leukemia** 1999 Aug; 13(8):1175–87 (177 ref.)

Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Edenfield WJ, et al. **Semin Oncol** 1999 Feb;26(1):21–34 (112 ref.)

[Acute myeloid leukemia (AML)] Büchner T. **Schweiz Rundsch Med Prax** 1999 Mar 4;88(10):421–30 (79 ref.) (Eng. Abstr.) (Ger)

[Extramedullary lesions in acute myeloblastic leukemia] Bialik TE, et al. **Ter Arkh** 1998;70(7):79–82 (33 ref.) (Rus)

PREVENTION & CONTROL

Treatment of resistant disease. Schiller GJ. **Leukemia** 1998 Sep;12 Suppl 1:S20–4 (36 ref.)

THERAPY

Hematopoietic growth factors and acute leukemia. Rowe JM, et al. **Cancer Treat Res** 1999;99:195–226 (129 ref.)

Acute myeloblastic leukaemia in the elderly: biology, prognostic factors and treatment. Manoharan A. **Int J Hematol** 1998 Oct;68(3):235–43 (48 ref.)

Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Ohno R. **Leuk Res** 1998 Dec;22(12):1143–54 (62 ref.)

Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Matthews DC. **Leukemia** 1998 Sep;12 Suppl 1:S33–6 (12 ref.)

Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Edenfield WJ, et al. **Semin Oncol** 1999 Feb;26(1):21–34 (112 ref.)

[Therapeutic approach to acute myeloid leukemia] Ferrant A. **Bull Mem Acad R Med Belg** 1998;153(2):161–8; discussion 168–9 (9 ref.) (Eng. Abstr.) (Fre)

[Hematopoietic stem cell transplantation for treatment of acute leukemia] Harada M. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1387–95 (27 ref.) (Eng. Abstr.) (Jpn)

[Indication and results of hematopoietic stem cell transplantation. 1. Acute leukemia] Ikeda K, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1464–9 (6 ref.) (Jpn)

[Clinical use of hematopoietic growth factors in the treatment of acute myeloblastic leukemia] Tóthová E. **Vnitr Lek** 1998 Jun;44(6):373–7 (36 ref.) (Eng. Abstr.) (Slo)

LEUKEMIA, MYELOCYTIC, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, MYELOGENOUS see **LEUKEMIA, MYELOID**

LEUKEMIA, MYELOGENOUS, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOGENOUS, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, MYELOGENOUS, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

LEUKEMIA, MYELOGENOUS, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

LEUKEMIA, MYELOID

Advantages of the CBA mouse in leukemogenesis research. Rithidech KN, et al. **Blood Cells Mol Dis** 1999 Feb; 25(1):38–45 (69 ref.)

Acute myeloid leukaemias. Ritter J. **Eur J Cancer** 1998 May; 34(6):862–72; discussion 871–2 (116 ref.)

Acute myeloid leukemia in the elderly: 'per aspera ad astra'? Latagliata R, et al. **Leuk Res** 1999 Jul;23(7):603–13 (84 ref.)

[Myeloblastoma (chloroma)] Uchida T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):180–2 (7 ref.) (Jpn)

[Acute leukemias] Diaz Mediavilla J. **Rev Clin Esp** 1999 Apr; 199 Suppl 1:22–7 (17 ref.) (Spa)

CHEMICALLY INDUCED

Secondary leukemias induced by topoisomerase-targeted drugs. Felix CA. **Biochim Biophys Acta** 1998 Oct 1; 1400(1–3):233–55 (276 ref.)

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. Kushner BH, et al. **J Clin Oncol** 1998 Dec;16(12):3880–9 (105 ref.)

Acute leukemia following treatment of malignant glioma. Perry JR, et al. **J Neurooncol** 1998 Oct;40(1):39–46 (56 ref.)

Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: case report and review of the literature. Al-Fiar F, et al. **Leuk Res** 1999 Aug;23(8):719–21 (24 ref.)

COMPLICATIONS

Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. Corpechot C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2586–8 (11 ref.)

DIAGNOSIS

Diagnosis of childhood acute myeloid leukemia. Behm FG. **Clin Lab Med** 1999 Mar;19(1):187–237, vii (281 ref.)

Primary myeloid leukemia presenting concomitantly with primary multiple myeloma: two cases and an update of the literature. Anderson CM, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):385–90 (23 ref.)

Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia. Okabe-Kado J, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):19–28 (40 ref.)

DRUG THERAPY

Reversal of multidrug resistance in hematological malignancies. Vossebeld PJ, et al. **Blood Rev** 1999 Jun; 13(2):67–78 (129 ref.)

Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach. Mandelli F, et al. **Haematologica** 1998 Nov;83(11):1015–23 (64 ref.)

[Acyclovir and ganciclovir in the treatment of malignant hematological diseases] Zhou X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May;36(5):349–51 (19 ref.) (Chi)

[The therapy of acute myeloid leukemia in patients of advanced age] Kern W, et al. **Dtsch Med Wochenschr** 1999 Aug 27;124(34–35):1005–14 (60 ref.) (Ger)

[Large granular lymphocytic leukemia] Wyszecka-Polk I, et al. **Wiad Lek** 1998;51(7–8):368–72 (17 ref.) (Eng. Abstr.) (Pol)

ETIOLOGY

Post-transplant acute myeloid leukemia (PT-AML). Thalhammer-Scherrer R, et al. **Leukemia** 1999 Mar; 13(3):321–6 (40 ref.)

[Large granular lymphocytic leukemia] Wyszecka-Polk I, et al. **Wiad Lek** 1998;51(7–8):368–72 (17 ref.) (Eng. Abstr.) (Pol)

GENETICS

Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Strout MP, et al. **Ann Hematol** 1999 Jun;78(6):251–64 (123 ref.)

The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Downing JR. **Br J Haematol** 1999 Aug;106(2):296–308 (134 ref.)

The involvement of Bcr in leukemias with the Philadelphia chromosome. Arlinghaus RB. **Crit Rev Oncog** 1998; 9(1):1–18 (97 ref.)

Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. Martinez-Climent JA, et al. **J Pediatr Hematol Oncol** 1999 Mar-Apr;21(2):91–102 (182 ref.)

Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Sawyers CL. **Leuk Res** 1998 Dec;22(12):1113–22 (88 ref.)

Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Behre G, et al. **Methods** 1999 Mar;17(3):231–7 (61 ref.)

Myeloid leukemia: disease genes and mouse models. Copeland NG, et al. **Prog Exp Tumor Res** 1999;35:53–63 (35 ref.)

IMMUNOLOGY

Retinoid-mediated signaling pathways in CD38 antigen expression in myeloid leukemia cells. Mehta K, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):441–9 (65 ref.)

CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Tien HF, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):93–8 (43 ref.)

METABOLISM

Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Drexler HG, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):83–91 (44 ref.)

Retinoid-mediated signaling pathways in CD38 antigen expression in myeloid leukemia cells. Mehta K, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):441–9 (65 ref.)

Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia. Okabe-Kado J, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):19–28 (40 ref.)

Role of MRP1 in multidrug resistance in acute myeloid leukemia. Legrand O, et al. **Leukemia** 1999 Apr; 13(4):578–84 (76 ref.)

Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Behre G, et al. **Methods** 1999 Mar;17(3):231–7 (61 ref.)

PATHOLOGY

AML-M0: a review of laboratory features and proposal of new diagnostic criteria. Stasi R, et al. **Blood Cells Mol Dis** 1999 Apr;25(2):120–9 (39 ref.)

Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia [see comments] Suzuki R, et al. **Leuk Res** 1999 Jul;23(7):615–24 (50 ref.) Comment in: Leuk Res 1999 Jul;23(7):675–6.

PHYSIOPATHOLOGY

Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria. Tooze JA, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):231–41 (104 ref.)

[The role of cytokines in the pathology of acute myeloid leukemia] Kandefer-Szerszeń M, et al. **Postepy Hig Med Dosw** 1998;52(4):325–45 (103 ref.) (Eng. Abstr.) (Pol)

SURGERY

Isolated recurrence of granulocytic sarcoma of the brain: successful treatment with surgical resection, intrathecal injection, irradiation and prophylactic systemic chemotherapy. Yamamoto K, et al. **Jpn J Clin Oncol** 1999 Apr;29(4):214–8 (20 ref.)

LEUKEMIA, MYELOID

THERAPY

Novel biologic approaches to hematologic malignancies. Dutcher JP, et al. **Cancer Treat Res** 1999;99:275–306 (210 ref.)
Tailoring the treatment of acute myeloid leukemia. Burnett AK. **Curr Opin Hematol** 1999 Jul;6(4):247–52 (29 ref.)
Tailoring the treatment of acute myeloid leukemia. Burnett AK. **Curr Opin Oncol** 1999 Jan;11(1):14–9 (29 ref.)
Adult acute myeloid leukaemia: update on treatment. Bishop JF. **Med J Aust** 1999 Jan 4;170(1):39–43 (36 ref.)

LEUKEMIA, MYELOID, ACUTE, M1 see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M2 see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M3 see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M4 see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M5 see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M6 see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M7 see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MYELOID, CHRONIC

Chronic myeloid leukemia. Deininger MW, et al. **Curr Opin Hematol** 1998 Jul;5(4):302–8 (72 ref.)
Chronic myelogenous leukemia: molecular and cellular aspects. Pasternak G, et al. **J Cancer Res Clin Oncol** 1998; 124(12):643–60 (148 ref.)
Chronic myelogenous leukemia: update on biology and treatment. Faderl S, et al. **Oncology (Huntingt)** 1999 Feb; 13(2):169–80; discussion 181, 184 (75 ref.)
[Progress in laboratory medicine in chronic myeloid leukemia] Miura A. **Rinsho Byori** 1998 Dec;46(12):1226–31 (5 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Eaves C, et al. **Leuk Res** 1998 Dec; 22(12):1085–96 (86 ref.)

COMPLICATIONS

Tumor lysis syndrome. Ezzone SA. **Semin Oncol Nurs** 1999 Aug;15(3):202–8 (15 ref.)

DIAGNOSIS

Long-lasting haematological remission despite persistence of the Philadelphia-positive clone in an untreated chronic myeloid leukaemia patient. Hilbe W, et al. **Acta Haematol** 1998;100(2):101–3 (12 ref.)
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Faderl S, et al. **Blood** 1999 May 1;93(9):2755–9 (42 ref.)
Molecular approaches to the detection and monitoring of chronic myeloid leukemia: theory and practice. Yee K, et al. **Blood Rev** 1999 Jun;13(2):105–26 (355 ref.)
Chronic myelogenous leukemia. Curable with early diagnosis and treatment. Hill JM, et al. **Postgrad Med** 1999 Sep; 106(3):149–52, 157–9 (20 ref.)

DRUG THERAPY

Interferon alpha in the treatment of chronic myelogenous leukemia. Robak T. **Arch Immunol Ther Exp (Warsz)** 1998; 46(6):347–53 (42 ref.)
Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Villeneuve L. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):1–17 (294 ref.)
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Aguayo A, et al. **Cancer** 1999 Jan 1;85(1):58–64 (40 ref.)
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy [see comments] Shah M, et al. **Cancer** 1998 Nov 1;83(9):1938–46 (53 ref.) Comment in: Cancer 1999 Jun 15;85(12):2669–70.
Tyrosine kinase inhibitors in chronic myeloid leukemia. Sawyers CL, et al. **Cancer J Sci Am** 1999 Mar–Apr; 5(2):63–9 (66 ref.)
Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Guilhot F, et al. **Hematol Cell Ther** 1998 Oct;40(5):237–9 (12 ref.)
Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. Kato N, et al. **J Dermatol** 1999 Jan;26(1):56–62 (35 ref.)
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. Kanda Y, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):193–7 (19 ref.)

ENZYMOLOGY

Tyrosine kinase inhibitors in chronic myeloid leukemia. Sawyers CL, et al. **Cancer J Sci Am** 1999 Mar–Apr; 5(2):63–9 (66 ref.)

ETIOLOGY

Treatment-related chronic myelogenous leukemia. Waller CF, et al. **Ann Hematol** 1999 Aug;78(8):341–54 (125 ref.)
Fitness landscapes and the myeloid leukemias. Preisler HD. **Leuk Res** 1999 Feb;23(2):167–76 (32 ref.)

GENETICS

Unusual clinical course and acquisition of del(11)(q23) in second lymphatic blastic phase of a Ph-positive chronic myeloid leukemia. Dierlamm J, et al. **Cancer Genet Cytogenet** 1999 Aug;113(1):85–9 (16 ref.)
Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature. Solves P, et al. **Leuk Res** 1999 Sep;23(9):851–4 (17 ref.)
Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Ghaffari S, et al. **Leukemia** 1999 Aug;13(8):1200–6 (66 ref.)
The biology of chronic myeloid leukemia. Faderl S, et al. **N Engl J Med** 1999 Jul 15;341(3):164–72 (72 ref.)

METABOLISM

Cobalamin metabolism in chronic myelogenous leukemia. Gimsing P. **Dan Med Bull** 1998 Nov;45(5):459–79 (289 ref.)

PATHOLOGY

Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Koc Y, et al. **Cancer** 1999 Feb 1; 85(3):608–15 (27 ref.)
Chronic myelogenous leukemia. Osarogiagbon UR, et al. **Curr Opin Hematol** 1999 Jul;6(4):241–6 (66 ref.)

PHYSIOPATHOLOGY

Chronic myelogenous leukemia: biology and therapy. Faderl S, et al. **Ann Intern Med** 1999 Aug 3;131(3):207–19 (144 ref.)
Molecular pathophysiology of chronic myelogenous leukemia. Turhan AG, et al. **Hematol Cell Ther** 1998 Oct; 40(5):217–21 (41 ref.)
Chronic myelogenous leukemia: from pathogenesis to therapy. Verfaillie CM. **J Hematother** 1999 Feb;8(1):3–13 (153 ref.)

SURGERY

Patients with morbid obesity don't get life-saving bone marrow transplants. Clarke B, et al. **Obes Surg** 1999 Feb; 9(1):77–9 (13 ref.)
Progenitor cell transplantation for chronic myelogenous leukemia. Szatrowski TP. **Semin Oncol** 1999 Feb;26(1):62–6 (27 ref.)

THERAPY

Chronic myelogenous leukemia: biology and therapy. Faderl S, et al. **Ann Intern Med** 1999 Aug 3;131(3):207–19 (144 ref.)
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Faderl S, et al. **Blood** 1999 May 1;93(9):2755–9 (42 ref.)
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology [see comments] Silver RT, et al. **Blood** 1999 Sep 1;94(5):1517–36 (108 ref.) Comment in: Blood 1999 Sep 1;94(5):1515–6.
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Kantarjian HM, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2723–33 (101 ref.)
Hematopoietic stem cell transplantation in chronic myeloid leukemia. Apperley JF. **Curr Opin Hematol** 1998 Nov; 5(6):445–53 (67 ref.)
Chronic myelogenous leukemia. Osarogiagbon UR, et al. **Curr Opin Hematol** 1999 Jul;6(4):241–6 (66 ref.)
Immunotherapy for chronic myeloid leukaemia. Apperley JF, et al. **Hematol Cell Ther** 1998 Oct;40(5):229–32 (23 ref.)
Minimal residual disease in chronic myeloid leukaemia. Cross NC. **Hematol Cell Ther** 1998 Oct;40(5):224–8 (22 ref.)
Chronic myelogenous leukemia: from pathogenesis to therapy. Verfaillie CM. **J Hematother** 1999 Feb;8(1):3–13 (153 ref.)
Interleukin-2 and leukemia. Goodman M, et al. **Leukemia** 1998 Nov;12(11):1671–5 (53 ref.)
Gene therapy for chronic myelogenous leukemia. Verfaillie CM, et al. **Mol Med Today** 1999 Aug;5(8):359–66 (56 ref.)
Chronic myeloid leukemia. Sawyers CL. **N Engl J Med** 1999 Apr 29;340(17):1330–40 (98 ref.)
Chronic myelogenous leukemia. Curable with early diagnosis and treatment. Hill JM, et al. **Postgrad Med** 1999 Sep; 106(3):149–52, 157–9 (20 ref.)
[Chronic myeloid leukemia: application of cellular and gene therapy to the clinic] Reiffers J. **Hematol Cell Ther** 1998 Oct;40(5):247–50 (13 ref.) **(Fre)**
[Chronic myelogenous leukemia and blood stem cell transplantation] Masaoka T. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1396–400 (2 ref.) (Eng. Abstr.) **(Jpn)**
[Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation] Urabe A. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1381–6 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Indication and results of hematopoietic stem cell transplantation. 2. Chronic myelogenous leukemia] Takahashi S. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1470–6 (13 ref.) **(Jpn)**
[Syngeneic peripheral blood stem cell transplantation for chronic myelogenous leukemia associated with Klinefelter's syndrome] Fujii H, et al. **Rinsho Ketsueki** 1999 Mar; 40(3):218–23 (15 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, MYELOID, NAEGELI-TYPE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

LEUKEMIA, MYELOID, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE

see related
PHILADELPHIA CHROMOSOME

DRUG THERAPY

[Chemotherapy, interferon and growth factors in the selection of Philadelphia negative cells] Michallet M, et al. **Hematol Cell Ther** 1998 Oct;40(5):241–6 (47 ref.) **(Fre)**

LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE

see related
PHILADELPHIA CHROMOSOME

DIAGNOSIS

Long-lasting haematological remission despite persistence of the Philadelphia-positive clone in an untreated chronic myeloid leukaemia patient. Hilbe W, et al. **Acta Haematol** 1998;100(2):101–3 (12 ref.)
Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection? Anguita E, et al. **Haematologica** 1998 Aug;83(8):744–7 (16 ref.)

DRUG THERAPY

Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Aguayo A, et al. **Cancer** 1999 Jan 1;85(1):58–64 (40 ref.)
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. Kanda Y, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):193–7 (19 ref.)

GENETICS

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Warmuth M, et al. **Ann Hematol** 1999 Feb;78(2):49–64 (186 ref.)
Unusual clinical course and acquisition of del(11)(q23) in second lymphatic blastic phase of a Ph-positive chronic myeloid leukemia. Dierlamm J, et al. **Cancer Genet Cytogenet** 1999 Aug;113(1):85–9 (16 ref.)

PATHOLOGY

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia [editorial] Drexler HG, et al. **Leuk Res** 1999 Mar;23(3):207–15 (84 ref.)
Cell biology of CML cells. Gordon MY, et al. **Leukemia** 1999 Apr;13 Suppl 1:S65–71 (45 ref.)
[The hypereosinophilic variant of Ph'-positive chronic myeloleukemia] Khoroshko ND, et al. **Ter Arkh** 1998; 70(7):29–37 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia? Pasternak G, et al. **Leukemia** 1999 Apr;13 Suppl 1:S55–64 (60 ref.)

LEUKEMIA, MYELOID, SCHILLING-TYPE see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MYELOMONOCYTIC, ACUTE

Acute myeloid leukemia. Löwenberg B, et al. **N Engl J Med** 1999 Sep 30;341(14):1051–62 (117 ref.)

[M4, acute myelomonocytic leukemia] Nakamaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):68–71 (14 ref.) **(Jpn)**

DRUG THERAPY

Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia. Niitsu N, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):261–71 (67 ref.)

GENETICS

Are cells with trisomy 10 always malignant in hematopoietic disorders? Berger R, et al. **Ann Genet** 1999;42(1):5–10 (20 ref.)

Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis. Martinez-Climent JA, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):111–4 (9 ref.)

Acute myelomonoblastic leukemia carrying the PEBP2beta/MYH11 fusion gene. Asou N, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):81–91 (65 ref.)

Leukemia in infants. Felix CA, et al. **Oncologist** 1999; 4(3):225–40 (221 ref.)

THERAPY

Transfusion-related acute lung injury (TRALI) following autologous stem cell transplant for relapsed acute myeloid leukaemia: a case report and review of the literature [see comments] Leach M, et al. **Transfus Med** 1998 Dec; 8(4):333–7 (26 ref.) Comment in: Transfus Med 1999 Jun;9(2):175.

LEUKEMIA, MYELOMONOCYTIC, CHRONIC

[Chronic myelomonocytic leukemia] Furusawa S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):201–5 (15 ref.) **(Jpn)**

PATHOLOGY

Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Kraus MD, et al. **Am J Surg Pathol** 1998 Oct;22(10):1255–66 (35 ref.)

LEUKEMIA, NEUTROPHILIC, CHRONIC

DIAGNOSIS

Transition of polycythemia vera to chronic neutrophilic leukemia. Higuchi T, et al. **Leuk Lymphoma** 1999 Mar; 33(1–2):203–6 (21 ref.)

LEUKEMIA, NONLYMPHOBLASTIC, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

LEUKEMIA, NONLYMPHOCYTIC, ACUTE

Acute myeloid leukemia. Löwenberg B, et al. **N Engl J Med** 1999 Sep 30;341(14):1051–62 (117 ref.)

COMPLICATIONS

[Acute abdomen in a young woman with acute nonlymphoblastic leukemia] Rodriguez-Calvillo M, et al. **Rev Clin Esp** 1999 Jul;199(7):469–70 (7 ref.) **(Spa)**

DIAGNOSIS

[Current diagnosis of acute leukemia (lecture)] Frenkel' MA. **Klin Lab Diagn** 1999 Jan;(1):25–32 (15 ref.) **(Rus)**

DRUG THERAPY

[Progress in the treatment of acute leukemia with traditional Chinese medicine] Li HY. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jan; 17(1):58–60 (33 ref.) **(Chi)**

ETIOLOGY

Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis [see comments] Kager L, et al. **Pediatr Hematol Oncol** 1999 May-Jun;16(3):251–6 (19 ref.) Comment in: Pediatr Hematol Oncol 1999 May-Jun;16(3):183–5.

LEUKEMIA, PLASMA CELL see **LEUKEMIA, PLASMACYTIC**

LEUKEMIA, PLASMACYTIC

[Leukemic macroglobulinemia] Kimura N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):453–6 (23 ref.) **(Jpn)**

[Plasma cell leukemia] Moriyama Y. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):157–61 (15 ref.) **(Jpn)**

LEUKEMIA, PROGRANULOCYTIC see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

LEUKEMIA, PROLYMPHOCYTIC

[T-cell prolymphocytic leukemia] Uchida T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):102–5 (10 ref.) **(Jpn)**

[B-cell prolymphocytic leukemia] Uchida T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):99–101 (6 ref.) **(Jpn)**

PATHOLOGY

T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. Ascani S, et al. **Ann Oncol** 1999 Jun;10(6):649–53 (33 ref.)

LEUKEMIA, PROMYELOCYTIC, ACUTE

Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Lo Coco F, et al. **Blood** 1999 Jul 1;94(1):12–22 (119 ref.)

The thrombophilic state in acute promyelocytic leukemia. Tallman MS. **Semin Thromb Hemost** 1999;25(2):209–15 (72 ref.)

[M3, promyelocytic leukemia] Tsuruoka N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):65–7 (12 ref.) **(Jpn)**

[Acute leukemias] Díaz Mediavilla J. **Rev Clin Esp** 1999 Apr; 199 Suppl 1:22–7 (17 ref.) **(Spa)**

BLOOD

The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia. Federici AB, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):491–9 (41 ref.)

COMPLICATIONS

Central nervous system involvement in acute promyelocytic leukemia. A description of two cases and review of the literature [letter] Rives S, et al. **Haematologica** 1999 May; 84(5):473–4 (10 ref.)

[DIC associated with acute promyelocyte leukemia] Sakata Y. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):517–20 (10 ref.) **(Jpn)**

DIAGNOSIS

Acute promyelocytic leukemia. New methods in diagnosis and treatment. Varghese L, et al. **J Ky Med Assoc** 1999 Feb;97(2):61–5 (11 ref.)

Diagnostic approaches to acute promyelocytic leukaemia. O'Connor SJ, et al. **Leuk Lymphoma** 1999 Mar; 33(1–2):53–63 (57 ref.)

DRUG THERAPY

Current approaches to acute promyelocytic leukemia. Frankel SR, et al. **Cancer Treat Res** 1999;99:125–53 (172 ref.)

Extramedullary disease in acute promyelocytic leukemia. Evans GD, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):219–29 (86 ref.)

All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Miyauchi J. **Leuk Lymphoma** 1999 Apr;33(3–4):267–80 (138 ref.)

Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Takeuchi M, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):441–51 (53 ref.)

Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167–74 (107 ref.)

Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Tallman MS. **Leukemia** 1998 Sep;12 Suppl 1:S37–40 (24 ref.)

In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. He LZ, et al. **Oncogene** 1999 Sep 20; 18(38):5278–92 (119 ref.)

Acute promyelocytic leukemia: from treatment to genetics and back. Kogan SC, et al. **Oncogene** 1999 Sep 20; 18(38):5261–7 (78 ref.)

[Progresses in the study of hematology in China, 1997] Zhang Z. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):890–1 (0 ref.) **(Chi)**

[Progress in the treatment of acute leukemia with traditional Chinese medicine] Li HY. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jan; 17(1):58–60 (33 ref.) **(Chi)**

[Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?] de Thé H. **C R Seances Soc Biol Fil** 1998;192(2):273–81 (40 ref.) (Eng. Abstr.) **(Fre)**

[The biological characteristics and treatment of acute promyelocytic leukemia (editorial)] Savchenko VG, et al. **Ter Arkh** 1998;70(7):5–11 (20 ref.) **(Rus)**

ETIOLOGY

The biology and treatment of acute progranulocytic leukemia. Slack JL. **Curr Opin Oncol** 1999 Jan;11(1):9–13 (25 ref.)

Acute leukemias after treatment with radioiodine for thyroid cancer [letter] Roldán Schilling V, et al. **Haematologica** 1998 Aug;83(8):767–8 (6 ref.)

GENETICS

Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Hodges M, et al. **Am J Hum Genet** 1998 Aug;63(2):297–304 (68 ref.)

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167–215 (605 ref.)

Complex variant 15;17 translocations in acute promyelocytic leukemia. A case report and review of three-way translocations. Wan TS, et al. **Cancer Genet Cytogenet** 1999 Jun;111(2):139–43 (16 ref.)

Terminal deletion of the long arm of chromosome 9 in acute promyelocytic leukemia with a cryptic PML/RAR alpha rearrangement. Yamamoto K, et al. **Cancer Genet Cytogenet** 1999 Sep;113(2):120–5 (3 ref.)

The molecular biology of acute promyelocytic leukemia. Slack JL, et al. **Cancer Treat Res** 1999;99:75–124 (215 ref.)

In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. He LZ, et al. **Oncogene** 1999 Sep 20; 18(38):5278–92 (119 ref.)

Acute promyelocytic leukemia: from treatment to genetics and back. Kogan SC, et al. **Oncogene** 1999 Sep 20; 18(38):5261–7 (78 ref.)

Molecular genetics of acute promyelocytic leukemia. Lin RJ, et al. **Trends Genet** 1999 May;15(5):179–84 (69 ref.)

[Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?] de Thé H. **C R Seances Soc Biol Fil** 1998;192(2):273–81 (40 ref.) (Eng. Abstr.) **(Fre)**

[The biological characteristics and treatment of acute promyelocytic leukemia (editorial)] Savchenko VG, et al. **Ter Arkh** 1998;70(7):5–11 (20 ref.) **(Rus)**

METABOLISM

Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167–74 (107 ref.)

PATHOLOGY

Biology and treatment of acute progranulocytic leukemia. Slack JL. **Curr Opin Hematol** 1999 Jul;6(4):236–40 (25 ref.)

All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Miyauchi J. **Leuk Lymphoma** 1999 Apr;33(3–4):267–80 (138 ref.)

[Extramedullary relapse in the external auditory canal in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and autologous peripheral blood stem cell transplantation] Yagita M, et al. **Rinsho Ketsueki** 1998 Sep;39(9):709–15 (14 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167–215 (605 ref.)

Extramedullary disease in acute promyelocytic leukemia. Evans GD, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):219–29 (86 ref.)

THERAPY

Biology and treatment of acute progranulocytic leukemia. Slack JL. **Curr Opin Hematol** 1999 Jul;6(4):236–40 (25 ref.)

The biology and treatment of acute progranulocytic leukemia. Slack JL. **Curr Opin Oncol** 1999 Jan;11(1):9–13 (25 ref.)

LEUKEMIA, RADIATION-INDUCED

see related

NEOPLASMS, SECOND PRIMARY

Effects of small doses of ionising radiation [see comments] Doll R. **J Radiol Prot** 1998 Sep;18(3):163–74 (70 ref.) Comment in: J Radiol Prot 1999 Mar;19(1):63–5.

ETIOLOGY

Acute leukemias after treatment with radioiodine for thyroid cancer [letter] Roldán Schilling V, et al. **Haematologica** 1998 Aug;83(8):767–8 (6 ref.)

Transgenerational susceptibility to leukaemia induction resulting from preconception, paternal irradiation. Lord BI. **Int J Radiat Biol** 1999 Jul;75(7):801–10 (89 ref.)

Childhood and adult cancer after intrauterine exposure to ionizing radiation. Boice JD Jr, et al. **Teratology** 1999 Apr; 59(4):227–33 (60 ref.)

LEUKEMIA, RADIATION-INDUCED

GENETICS

Genetic instability in radiation-induced leukaemias: mouse models. Plumb M, et al. **Int J Radiat Biol** 1998 Dec; 74(6):711-20 (69 ref.)

LEUKEMIA, SMOULDERING see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

LEUKEMIA, SUBLEUKEMIC

[Aleukemic leukemia] Asou N.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):135-8 (15 ref.) **(Jpn)**

LEUKEMIA, T-CELL

T-small lymphocyte disorders. Bartlett NL, et al. **Semin Hematol** 1999 Apr;36(2):164-70 (61 ref.)

[Adult T-cell leukemia not associated with human T-lymphotropic virus type I] Hiruma K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):119-21 (7 ref.) **(Jpn)**

[Adult T-cell leukemia] Taguchi H.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):38-41 (7 ref.) **(Jpn)**

DRUG THERAPY

Involvement of granulocyte colony-stimulating factor in proliferation of adult T-cell leukemia cells. Matsushita K, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):295-304 (94 ref.)

ETIOLOGY

[Pathogenesis of adult T-cell leukemia] Uchiyama T. **Rinsho Ketsueki** 1999 Jun;40(6):437-40 (9 ref.) **(Jpn)**

GENETICS

Role of TCL1 and ALL1 in human leukemias and development. Croce CM. **Cancer Res** 1999 Apr 1;59(7 Suppl):1778s-1783s (46 ref.)

IMMUNOLOGY

ATM in lymphoid development and tumorigenesis. Xu Y. **Adv Immunol** 1999;72:179-89 (58 ref.)

PATHOLOGY

Involvement of granulocyte colony-stimulating factor in proliferation of adult T-cell leukemia cells. Matsushita K, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):295-304 (94 ref.)

VIROLOGY

Epstein-Barr virus involvement in T-cell malignancy: significance in adult T-cell leukemia. Ohtsubo H, et al. **Leuk Lymphoma** 1999 May;33(5-6):451-8 (71 ref.)

LEUKEMIA, T-CELL, ACUTE

[T lineage acute lymphoblastic leukemia] Ino T, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):91-4 (16 ref.) **(Jpn)**

[Myeloid antigen positive T-ALL] Mizuki M, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):173-6 (9 ref.) **(Jpn)**

COMPLICATIONS

Leukemia and kidney failure: case presentation and review of the literature. Reed AM, et al. **WMJ** 1998 Sep;97(8):56-7 (9 ref.)

DIAGNOSIS

Detection of minimal residual disease: methods and relationship to outcome in T-lineage acute lymphoblastic leukemia. Dibenedetto SP, et al. **Leuk Lymphoma** 1998 Dec; 32(1-2):65-75 (73 ref.)

GENETICS

Notch signalling pathway and human diseases. Joutel A, et al. **Semin Cell Dev Biol** 1998 Dec;9(6):619-25 (50 ref.)

LEUKEMIA, T-CELL, CHRONIC

[Chronic T-lymphocytic leukemia] Ishida Y, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):106-9 (12 ref.) **(Jpn)**

PATHOLOGY

T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. Ascani S, et al. **Ann Oncol** 1999 Jun;10(6):649-53 (33 ref.)

LEUKEMIA VIRUS I, HUMAN T-CELL see **HTLV-I**

LEUKEMIA VIRUS II, HUMAN T-CELL see **HTLV-II**

LEUKEMIA VIRUSES, MURINE

PHYSIOLOGY

Xenotropism: the elusive viral receptor finally uncovered [comment] Levy JA. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):802-4 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 2;96(3):927-32.

LEUKEMIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, LEUKEMIC**

LEUKEMIC INFILTRATION

PATHOLOGY

Specific cutaneous lesions of the scalp in myelodysplastic syndrome with deletion of 20q. Namba Y, et al. **J Dermatol** 1999 Apr;26(4):220-4 (15 ref.)

[Extramedullary lesions in acute myeloblastic leukemia] Bialik TE, et al. **Ter Arkh** 1998;70(7):79-82 (33 ref.) **(Rus)**

LEUKEMIC RETICULOENDOTHELIOSIS see **LEUKEMIA, HAIRY CELL**

LEUKEMOGENIC VIRUSES see **RETROVIRIDAE**

LEUKEMOID REACTION

[Lymphocytic leukemoid reaction] Miwa A.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):169-75 (14 ref.) **(Jpn)**

[Monocytic leukemoid reaction] Motoyoshi K.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):146-8 (8 ref.) **(Jpn)**

[Megakaryoblastic leukemoid reaction] Sakamoto S.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):12-4 (9 ref.) **(Jpn)**

ETIOLOGY

[Leukemoid reaction] Sakamoto S.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):5-11 (19 ref.) **(Jpn)**

[Laryngeal cancer and the leukemoid reaction (letter)] De Vega Santos T, et al. **An Med Interna** 1999 Jul;16(7):382-3 (5 ref.) **(Spa)**

LEUKOCIDINS

PHARMACOLOGY

[Pore-forming leukotoxins from Staphylococcus aureus: variability of the target cells and 2 pharmacological processes] Prévost G, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):435-41 (40 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Leukocidal toxins of staphylococci. Szmigielski S, et al. **Zentralbl Bakteriol** 1999 Apr;289(2):185-201 (40 ref.)

LEUKOCYTAPHERESIS see **LEUKAPHERESIS**

LEUKOCYTE ADHESION INHIBITOR see **INTERLEUKIN-8**

LEUKOCYTE ADHESION MOLECULES see **CELL ADHESION MOLECULES**

LEUKOCYTE ANTIGENS see **HLA ANTIGENS**

LEUKOCYTE COMMON ANTIGENS see **ANTIGENS, CD45**

LEUKOCYTE COUNT

Accuracy of leukocyte count in the diagnosis of acute appendicitis [comment] Snyder BK, et al. **Ann Emerg Med** 1999 May;33(5):565-74 (11 ref.) Comment on: Ann Emerg Med 1999 May;33(5):575-80.

Benefits of leukocyte-reduced blood transfusions in surgical patients. Jensen LS. **Curr Opin Hematol** 1998 Nov; 5(6):376-80 (31 ref.)

Leukocyte-reduced blood products. Kadar JG. **Curr Opin Hematol** 1998 Nov;5(6):381-5 (42 ref.)

METHODS

[Elastic light scattering of blood cell counting and classification] Yang Y, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Jun; 14(2):170-5 (12 ref.) (Eng. Abstr.) **(Chi)**

[Methods and criteria for studying polynuclear eosinophil activation] Couissinier-Paris P. **Med Trop (Mars)** 1998;58(4 Suppl):503-7 (41 ref.) (Eng. Abstr.) **(Fre)**

LEUKOCYTE COUNT, DIFFERENTIAL see **LEUKOCYTE COUNT**

LEUKOCYTE DIFFERENTIATION ANTIGENS, HUMAN see **ANTIGENS, CD**

LEUKOCYTE DISORDERS

[Acquired neutrophil dysfunction] Higuchi T, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):88-90 (14 ref.) **(Jpn)**

[Döhle body] Kurokawa Y, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):96-7 (7 ref.) **(Jpn)**

[Monocytosis] Motoyoshi K.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):143-5 (8 ref.) **(Jpn)**

[Basophilia] Nishimura J, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):138-40 (15 ref.) **(Jpn)**

[Basophilopenia] Nishimura J, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):141-2 (8 ref.) **(Jpn)**

[Myeloperoxidase deficiency] Okamura T, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):64-6 (14 ref.) **(Jpn)**

[Neutrophil ATP depletion] Yasui K, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):91-3 (5 ref.) **(Jpn)**

GENETICS

[Hereditary giant neutrophil leucocytes] Fuse I, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):84-5 (5 ref.) **(Jpn)**

LEUKOCYTE ELASTASE

ANTAGONISTS & INHIBITORS

Succinimide and saccharin-based enzyme-activated inhibitors of serine proteases. Martyn DC, et al. **Curr Pharm Des** 1999 Jun;5(6):405-15 (49 ref.)

METABOLISM

[Inflammatory mediators in the acute pancreatitis] Markert R, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):100-3 (32 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

The protease-antiprotease battle in the cystic fibrosis lung. Balfour-Lynn IM. **J R Soc Med** 1999;92 Suppl 37:23-30 (65 ref.)

LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1 see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

LEUKOCYTE NUMBER see **LEUKOCYTE COUNT**

LEUKOCYTE TRANSFUSION

The graft-versus-leukemia effects of allogeneic cell therapy. Porter DL, et al. **Annu Rev Med** 1999;50:369-86 (80 ref.)

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Kolb HJ. **Vox Sang** 1998;74 Suppl 2:321-9 (71 ref.)

LEUKOCYTES

see related
PHAGOCYTOSIS

Leukoreduction of the blood supply in Rhode Island. Sweeney JD. **Med Health R I** 1998 Dec;81(12):386-91 (12 ref.)

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Corash L. **Transfus Med Rev** 1999 Jan;13(1):18-30 (92 ref.)

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates. Corash L. **Vox Sang** 1998;74 Suppl 2:173-6 (45 ref.)

CHEMISTRY

Adhesion and signaling mediated by the cytoplasmic tails of leucocyte integrins. van Kooyk Y, et al. **Cell Adhes Commun** 1998;6(2-3):247-54 (72 ref.)

Presence and functional regulation of cannabinoid receptors in immune cells. Parolaro D. **Life Sci** 1999;65(6-7):637-44 (63 ref.)

Mechanisms that regulate the function of the selectins and their ligands. Vestweber D, et al. **Physiol Rev** 1999 Jan; 79(1):181-213 (386 ref.)

CYTOLOGY

Interpreting blood smears (or what blood smears are trying to tell you!). Mills JN. **Aust Vet J** 1998 Sep;76(9):596-600 (7 ref.)

Do adhesion molecules importantly regulate leukocyte kinetics within intraacinar microvessels of the lung? Yamaguchi K, et al. **Histol Histopathol** 1998 Oct; 13(4):1089-102 (70 ref.)

Is Wiskott--Aldrich syndrome a cell trafficking disorder? Thrasher AJ, et al. **Immunol Today** 1998 Dec;19(12):537-9 (27 ref.)

Regulation of leukocyte adherence and migration by glycosylphosphatidyl-inositol-anchored proteins. Sendo F,

et al. **J Leukoc Biol** 1999 Sep;66(3):369–74 (58 ref.)
The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Yang J, et al. **Thromb Haemost** 1999 Jan;81(1):1–7 (76 ref.)

DRUG EFFECTS

Corticosteroid effects on cytokines and chemokines. Frieri M. **Allergy Asthma Proc** 1999 May–Jun;20(3):147–59 (98 ref.)
Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Parnham MJ. **Biochem Pharmacol** 1999 Jul 15;58(2):209–15 (61 ref.)
Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Lentsch AB, et al. **Cancer Immunol Immunother** 1999 Jan;47(5):243–8 (72 ref.)
H1-receptor antagonists: effects on leukocytes, myth or reality? De Vos C. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:60–3 (21 ref.)
Diapedesis of leukocytes: antisense oligonucleotides for rescue. Dragun D, et al. **Exp Nephrol** 1999 Mar–Apr; 7(2):185–92 (68 ref.)
Lipocortin 1 and chemokine modulation of granulocyte and monocyte accumulation in experimental inflammation. Perretti M. **Gen Pharmacol** 1998 Oct;31(4):545–52 (72 ref.)
Potential drug targets: small GTPases that regulate leukocyte function. Benard V, et al. **Trends Pharmacol Sci** 1999 Sep; 20(9):365–70 (98 ref.)

ENZYMOLOGY

NADPH oxidase: an update. Babior BM. **Blood** 1999 Mar 1;93(5):1464–76 (117 ref.)
Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Bird PI. **Immunol Cell Biol** 1999 Feb;77(1):47–57 (96 ref.)
The cell biology of leukocyte-mediated proteolysis. Owen CA, et al. **J Leukoc Biol** 1999 Feb;65(2):137–50 (164 ref.)

IMMUNOLOGY

The function of small GTPases in signaling by immune recognition and other leukocyte receptors. Altman A, et al. **Adv Immunol** 1999;72:1–101 (561 ref.)
Effects of stress on leukocyte trafficking and immune responses: implications for vaccination. Kehrli ME, et al. **Adv Vet Med** 1999;41:61–81 (108 ref.)
Leukocytes as modulators of stellate cell activation. Maher JJ. **Alcohol Clin Exp Res** 1999 May;23(5):917–21 (29 ref.)
Leucocyte activation markers in clinical practice. Viedma Contreras JA. **Clin Chem Lab Med** 1999 Jun;37(6):607–22 (226 ref.)
LAIR-1, a widely distributed human ITIM-bearing receptor on hematopoietic cells. Meyaard L. **Curr Top Microbiol Immunol** 1999;244:151–7 (37 ref.)
Leukocyte polarization in cell migration and immune interactions. Sánchez-Madrid F, et al. **EMBO J** 1999 Feb 1;18(3):501–11 (126 ref.)
Chemokine receptors and their role in leukocyte activation. Wells TN, et al. **Immunol Lett** 1999 Jan;65(1–2):35–40 (46 ref.)
Functional and molecular characterization of teleost leukocytes. Miller N, et al. **Immunol Rev** 1998 Dec; 166:187–97 (65 ref.)
Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Shearer GM, et al. **Immunol Today** 1999 Feb;20(2):66–71 (49 ref.)
The role of the formed elements of the blood in host defense. Royston D. **Int Anesthesiol Clin** 1999 Spring;37(2):1–37 (123 ref.)
Chemoattractant receptor cross-desensitization. Ali H, et al. **J Biol Chem** 1999 Mar 5;274(10):6027–30 (52 ref.)
A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **J Leukoc Biol** 1999 Sep; 66(3):375–81 (61 ref.)
Cell adhesion and the immune system: a case study using earthworms. Cooper EL, et al. **Microsc Res Tech** 1999 Feb 15;44(4):237–53 (175 ref.)
Polyphenolic antioxidant (–)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Katiyar SK, et al. **Photochem Photobiol** 1999 Feb;69(2):148–53 (34 ref.)
Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions. Bowen MA, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):795–6 (26 ref.)

METABOLISM

Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Kevil CG, et al. **Am J Med** 1999 Jun;106(6):677–87 (92 ref.)
CD100 is a leukocyte semaphorin. Delaire S, et al. **Cell Mol Life Sci** 1998 Nov;54(11):1265–76 (69 ref.)
Leucocyte activation markers in clinical practice. Viedma Contreras JA. **Clin Chem Lab Med** 1999 Jun;37(6):607–22 (226 ref.)
Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Ebnet K, et al. **Histochem Cell Biol** 1999 Jul;112(1):1–23 (247 ref.)
The modular architecture of leukocyte cell-surface receptors. Campbell ID. **Immunol Rev** 1998 Jun;163:11–8 (53 ref.)
The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis (Review). Weeks BS. **Int J Mol Med** 1998 Feb;1(2):361–6 (54 ref.)
Leukocyte-endothelium adhesion molecules in atherosclerosis. Dong ZM, et al. **J Lab Clin Med** 1998 Nov; 132(5):369–75 (61 ref.)
Integrin signal transduction in myeloid leukocytes. Lowell CA, et al. **J Leukoc Biol** 1999 Mar;65(3):313–20 (94 ref.)
The significance of zinc for leukocyte biology. Wellinghausen N, et al. **J Leukoc Biol** 1998 Nov;64(5):571–7 (110 ref.)
Assay for chemoattractant binding. Harvath L, et al. **Methods Mol Biol** 1999;115:299–308 (12 ref.)
Leukocyte-endothelial monolayer adhesion assay (static conditions). Kiely JM, et al. **Methods Mol Biol** 1999; 96:131–6 (8 ref.)
Mechanisms that regulate the function of the selectins and their ligands. Vestweber D, et al. **Physiol Rev** 1999 Jan; 79(1):181–213 (386 ref.)
[Angiogenesis and the regulation of antitumor defense] Pappas NP, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1555–9 (22 ref.) (Eng. Abstr.) **(Dut)**

PARASITOLOGY

Review: Theileria schizonts induce fundamental alterations in their host cells. Ahmed JS, et al. **Parasitol Res** 1999 Jul;85(7):527–38 (90 ref.)

PATHOLOGY

Dynamic interactions between lung fibroblasts and leukocytes: implications for fibrotic lung disease. Hogaboam CM, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):313–20 (57 ref.)
[Adhesion of leukocytes to endothelial cells in atherosclerosis] Masuda M, et al. **Rinsho Byori** 1998 Nov; 46(11):1149–55 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Interactions between platelets and leukocytes during hemodialysis. Bonomini M, et al. **Artif Organs** 1999 Jan; 23(1):23–8 (52 ref.)
Osteoclast precursors as leukocytes: importance of the area code. Parfitt AM. **Bone** 1998 Dec;23(6):491–4 (43 ref.)
Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Panés J, et al. **Br J Pharmacol** 1999 Feb; 126(3):537–50 (103 ref.)
Molecular basis of localized responses during chemotaxis in amoebae and leukocytes. van Es S, et al. **Cell Mol Life Sci** 1999 Aug 15;55(10):1341–51 (69 ref.)
Detection of active oxygen species in biological systems. Nakano M. **Cell Mol Neurobiol** 1998 Dec;18(6):565–79 (19 ref.)
Leukocyte adhesion molecules in atherogenesis. Cybulsky MI, et al. **Clin Chim Acta** 1999 Aug;286(1–2):207–18 (51 ref.)
Nitric oxide in atherosclerosis: vascular protector or villain? Dusting GJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S34–41 (65 ref.)
Platelet and leucocyte behaviour during haemodialysis. Hoenich NA. **Contrib Nephrol** 1999;125:120–32 (36 ref.)
Tumor necrosis factor receptor expression on inflammatory cells in sepsis [editorial; comment] Opal SM. **Crit Care Med** 1999 Feb;27(2):240–1 (10 ref.) Comment on: Crit Care Med 1999 Feb;27(2):319–24.
Adhesion molecules in clinical medicine. Cavenagh JD, et al. **Crit Rev Clin Lab Sci** 1998 Sep;35(5):415–59 (237 ref.)
Leukocyte polarization in cell migration and immune interactions. Sánchez-Madrid F, et al. **EMBO J** 1999 Feb 1;18(3):501–11 (126 ref.)
Diapedesis of leukocytes: antisense oligonucleotides for rescue. Dragun D, et al. **Exp Nephrol** 1999 Mar–Apr; 7(2):185–92 (68 ref.)
Leukocyte-endothelial cell interactions – lessons from knockout mice. Rosenkranz AR, et al. **Exp Nephrol** 1999 Mar–Apr;7(2):125–36 (122 ref.)
Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Grisham MB, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):404–33 (208 ref.)
Phenotypic and functional studies of leukocytes in human endometrium and endometriosis. Jones RK, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):702–9 (55 ref.)
Signal transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an aspect of immunoreceptor function? Horejsi V, et al. **Immunol Lett** 1998 Sep; 63(2):63–73 (185 ref.)
Modulation of leukocyte transendothelial migration by integrin-associated glycosyl phosphatidyl inositol (GPI)-anchored proteins. Sendo F, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S133–6 (30 ref.)
Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. Korthuis RJ, et al. **J Vasc Res** 1999;36 Suppl 1:15–23 (31 ref.)
Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Fryer AD, et al. **Life Sci** 1999;64(6–7):449–55 (49 ref.)
The multiple sclerosis lesion: initiated by a localized hypoperfusion in a central nervous system where mechanisms allowing leukocyte infiltration are readily upregulated? Juurlink BH. **Med Hypotheses** 1998 Oct; 51(4):299–303 (41 ref.)
Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF. **Med Hypotheses** 1998 Jul;51(1):11–5 (63 ref.)
Leukocyte transmigration through vascular endothelium. An in vitro method. Allavena P, et al. **Methods Mol Biol** 1999; 96:171–6 (14 ref.)
Is extravasation a Fas-regulated process? Walsh K, et al. **Mol Med Today** 1999 Feb;5(2):61–7 (63 ref.)
Leukotrienes and lipoxins: lipoxygenase-derived modulators of leukocyte recruitment and vascular tone in glomerulonephritis. Clarkson MR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3043–51 (92 ref.)
Leukocyte traffic in the central nervous system: the participants and their roles. Hickey WF. **Semin Immunol** 1999 Apr;11(2):125–37 (106 ref.)
The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Yang J, et al. **Thromb Haemost** 1999 Jan;81(1):1–7 (76 ref.)
Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Feldman M, et al. **Transplant Proc** 1998 Dec;30(8):4126–7 (9 ref.)
[Role of leukocytes in the pathogenesis of trophic venous disorders] Carpentier PH. **J Mal Vasc** 1998 Oct;23(4):274–6 (23 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Quarmby S, et al. **Int J Cancer** 1999 Jul 30;82(3):385–95 (101 ref.)

ULTRASTRUCTURE

Sebastian syndrome: case report and review of the literature. Young G, et al. **Am J Hematol** 1999 May;61(1):62–5 (15 ref.)

VIROLOGY

Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. Jensen PN, et al. **J Leukoc Biol** 1999 Apr;65(4):428–38 (99 ref.)

LEUKOCYTES, MONONUCLEAR

IMMUNOLOGY

Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. Cotter RL, et al. **J Leukoc Biol** 1999 Apr;65(4):416–27 (136 ref.)

METABOLISM

Restoration of cytokine imbalance by immunotherapy [editorial; comment] Mavroleon G. **Clin Exp Allergy** 1998 Aug;28(8):917–20 (31 ref.) Comment on: Clin Exp Allergy 1998 Aug;28(8):943–9.
Regulation of chemokine receptors in mononuclear phagocytes versus dendritic cells and in the amplification of Th1 versus Th2 responses. Mantovani A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):76–80 (28 ref.)
Analysis of the cytokine production by cord and adult blood. Cohen SB, et al. **Hum Immunol** 1999 Apr;60(4):331–6 (32 ref.)

LEUKOCYTES, POLYMORPHONUCLEAR see **NEUTROPHILS**

LEUKOCYTOPENIA see **LEUKOPENIA**

LEUKOCYTOSIS

[Chronic idiopathic leukocytosis] Suzuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):17–8 (2 ref.) **(Jpn)**
[Pseudoneutrophilia] Suzuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):19–20 (4 ref.) **(Jpn)**

CHEMICALLY INDUCED

Carbamazepine-induced thrombocytopenia defined by a challenge test. Ishikita T, et al. **Am J Hematol** 1999 Sep; 62(1):52–5 (20 ref.)

COMPLICATIONS

[Respiratory distress syndrome due to hyperleukocytic leukemias] Valdovinos Mahave MC, et al. **An Med Interna** 1999 Jul;16(7):359–60 (8 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884–90 (37 ref.)
[Adrenocorticosteroid-induced neutrophilia] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):21–2 (6 ref.) **(Jpn)**

LEUKOCYTOSIS

[Leukocytosis in pregnancy] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):23–4 (5 ref.) **(Jpn)**

GENETICS

[Hereditary neutrophilia] Hato F, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):15–6 (3 ref.) **(Jpn)**

LEUKODYSTROPHY, GLOBOID CELL

[Galactosylceramide synthase (CGT) knockout mouse] Suzuki K. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2318–24 (26 ref.) **(Jpn)**

DIAGNOSIS

Globoid cell leukodystrophy: distinguishing early-onset from late-onset disease using a brain MR imaging scoring method. Loes DJ, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):316–23 (23 ref.)

LEUKODYSTROPHY, METACHROMATIC

GENETICS

Metachromatic leukodystrophy: molecular genetics and an animal model. Gieselmann V, et al. **J Inherit Metab Dis** 1998 Aug;21(5):564–74 (49 ref.)

LEUKODYSTROPHY, SPONGIFORM see **CANAVAN DISEASE**

LEUKOENCEPHALITIS, ACUTE HEMORRHAGIC

ETIOLOGY

[Radiation necrosis] Yamada T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):434–7 (12 ref.) **(Jpn)**

LEUKOENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL

[Progressive multifocal leukoencephalopathy] Ochi H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):427–30 (13 ref.) **(Jpn)**

[Progressive multifocal leukoencephalopathy] Ochi H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):65–8 (12 ref.) **(Jpn)**

DIAGNOSIS

Opportunistic infections of the central nervous system during HIV-1 infection (emphasis on cytomegalovirus disease). Roullet E. **J Neurol** 1999 Apr;246(4):237–43 (55 ref.)

[Progressive multifocal leukoencephalopathy] Wasmuth JC, et al. **Med Klin** 1999 May 15;94(5):264–73 (139 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Re D, et al. **Bone Marrow Transplant** 1999 Feb;23(3):295–8 (23 ref.)

GENETICS

CADASIL: hereditary disease of arteries causing brain infarcts and dementia. Kalimo H, et al. **Neuropathol Appl Neurobiol** 1999 Aug;25(4):257–65 (33 ref.)

[Young-adult-onset hereditary subcortical vascular dementia: cerebral autosomal recessive arteriosclerosis with subcortical infarcts and leukoencephalopathy (CARASIL)] Fukutake T. **Rinsho Shinkeigaku** 1999 Jan;39(1):50–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

CADASIL: hereditary disease of arteries causing brain infarcts and dementia. Kalimo H, et al. **Neuropathol Appl Neurobiol** 1999 Aug;25(4):257–65 (33 ref.)

[Vascular leukoencephalopathies and dementia] Chabriat H. **Rev Neurol (Paris)** 1998;154 Suppl 2:S85–90 (46 ref.) **(Fre)**

PHYSIOPATHOLOGY

CADASIL and white matter syndromes [editorial] Mohr JP. **Ann Neurol** 1998 Nov;44(5):715–6 (14 ref.)

VIROLOGY

The human polyomavirus, JCV, and neurological diseases (review). Gordon J, et al. **Int J Mol Med** 1998 Apr; 1(4):647–55 (75 ref.)

LEUKOMA see **CORNEAL OPACITY**

LEUKOMALACIA, PERIVENTRICULAR

COMPLICATIONS

White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Perlman JM. **Early Hum Dev** 1998 Dec;53(2):99–120 (134 ref.)

PATHOLOGY

Human oligodendroglial development: relationship to periventricular leukomalacia. Kinney HC, et al. **Semin Pediatr Neurol** 1998 Sep;5(3):180–9 (62 ref.)

LEUKOPENIA

THERAPY

A clinical study on acupuncture for prevention and treatment of toxic side-effects during radiotherapy and chemotherapy. Zhou J, et al. **J Tradit Chin Med** 1999 Mar; 19(1):16–21 (19 ref.)

[Use of G-CSF (Neupogen) in multimodal treatment in radiotherapy] Bartzsch O, et al. **Strahlenther Onkol** 1998 Nov;174(11):551–5 (19 ref.) (Eng. Abstr.) **(Ger)**

LEUKOPHERESIS see **LEUKAPHERESIS**

LEUKOPLAKIA

PREVENTION & CONTROL

Chemoprevention of head and neck and lung (pre)cancer. de Vries N, et al. **Recent Results Cancer Res** 1999;151:13–25 (47 ref.)

LEUKOPLAKIA, HAIRY

DIAGNOSIS

Oral hairy leukoplakia: an ultrastructural study and review of the literature. Guccion JG, et al. **Ultrastruct Pathol** 1999 May-Jun;23(3):181–7 (39 ref.)

PATHOLOGY

Oral hairy leukoplakia: an ultrastructural study and review of the literature. Guccion JG, et al. **Ultrastruct Pathol** 1999 May-Jun;23(3):181–7 (39 ref.)

LEUKOPLAKIA, ORAL

Leukoplakia: still a gallimaufry or is progress being made?--A review. Suarez P, et al. **Adv Anat Pathol** 1998 May;5(3):137–55 (54 ref.)

LEUKOPOIESIS

A historical perspective and cellular regulation of megakaryocytopoiesis. Baatout S. **Haematologia (Budap)** 1998;29(2):67–79 (68 ref.)

Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: "miniallografts" are no small matter [editorial] Martino R, et al. **Haematologica** 1998 Oct;83(10):865–7 (13 ref.)

The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. McAdam AJ, et al. **Immunol Rev** 1998 Oct;165:231–47 (96 ref.)

GENETICS

Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Behre G, et al. **Methods** 1999 Mar;17(3):231–7 (61 ref.)

PHYSIOLOGY

Lymphopoiesis and matrix glycoprotein SC1/ECM2. Oritani K, et al. **Leuk Lymphoma** 1998 Dec;32(1-2):1–7 (42 ref.)

LEUKOSIS, AVIAN see **AVIAN LEUKOSIS**

LEUKOTAXIS see **CHEMOTAXIS, LEUKOCYTE**

LEUKOTOMY see **PSYCHOSURGERY**

LEUKOTRIENE ANTAGONISTS

ADVERSE EFFECTS

Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety. Dubé LM, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):213–21 (36 ref.)

Pharmacology and safety of the leukotriene antagonists. Smith LJ. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):195–212 (72 ref.)

PHARMACOKINETICS

Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety. Dubé LM, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):213–21 (36 ref.)

PHARMACOLOGY

Antileukotrienes and laboratory models of asthma. Lazarus SC. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):223–33 (83 ref.)

The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Simon RA. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):271–5 (29 ref.)

Pharmacology and safety of the leukotriene antagonists. Smith LJ. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):195–212 (72 ref.)

5-Lipoxygenase: a target for antiinflammatory drugs revisited. Steinhilber D. **Curr Med Chem** 1999 Jan; 6(1):71–85 (154 ref.)

Therapeutic advances: leukotriene antagonists for the treatment of asthma. Misson J, et al. **J Clin Pharm Ther** 1999 Feb;24(1):17–22 (17 ref.)

Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. Claesson HE, et al. **J Intern Med** 1999 Mar;245(3):205–27 (257 ref.)

Pharmacodynamic properties of leukotriene receptor antagonists. Nicosia S. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):242–6 (41 ref.)

Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Devillier P, et al. **Pharmacol Res** 1999 Jul;40(1):3–13 (117 ref.)

[The anti-leukotrienes: a new class of drugs to integrate into the therapeutic strategy of asthma] Fellrath JM, et al. **Rev Med Suisse Romande** 1999 Mar;119(3):217–26 (52 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Inhaled corticosteroids versus anti-leukotrienes: a literature review on the clinical effects. Ind PW. **Allergy** 1999;54 Suppl 50:43–6 (20 ref.)

Current synthetic notions on aspirin induced asthma. Sonneville A. **Biomed Pharmacother** 1999 Aug;53(7):312–4 (16 ref.)

Leukotriene receptor antagonists and related compounds. Wenzel SE. **Can Respir J** 1999 Mar-Apr;6(2):189–93 (35 ref.)

Antileukotrienes and asthma: alternative or adjunct to inhaled steroids? Kavuru MS, et al. **Cleve Clin J Med** 1998 Nov-Dec;65(10):519–26 (25 ref.)

Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Busse WW, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:110–5 (27 ref.)

Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma. Dahlén SE. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:141–6; discussion 171–3 (43 ref.)

Leukotriene modifiers as novel therapeutics in asthma. Leff JA. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:147–53; discussion 171–3 (43 ref.)

The prospects for long-term intervention in asthma with antileukotrienes. Smith LJ. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:154–63; discussion 171–3 (81 ref.)

Pulmonary diseases other than asthma as potential targets for antileukotriene therapy. Peters-Golden M. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):247–60 (48 ref.)

Efficacy of anti-LT agents in the treatment of chronic asthma. Spector SL. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):235–46 (31 ref.)

Antileukotrienes, asthma pathogenesis and the pharmaceutical industry [editorial; comment] O'Byrne PM. **CMAJ** 1999 Jan 26;160(2):209–10 (9 ref.) Comment on: CMAJ 1999 Jan 26;160(2):217–23.

Antileukotriene agents in asthma: the dart that kills the elephant? [see comments] Renzi PM. **CMAJ** 1999 Jan 26; 160(2):217–23 (60 ref.) Comment in: CMAJ 1999 Jan 26;160(2):209–10.

Newer therapeutic agents for asthma. Deykin A, et al. **Dis Mon** 1999 Apr;45(4):117–44 (98 ref.)

A risk-benefit assessment of antileukotrienes in asthma. Smith LJ. **Drug Saf** 1998 Sep;19(3):205–18 (87 ref.)

Leukotriene modifiers in the management of asthma. Elnabtity MH, et al. **J Am Osteopath Assoc** 1999 Jul;99(7 Suppl):S1–6 (34 ref.)

Leukotriene receptor antagonist treatment of asthma: are we there yet? [editorial; comment] Kercsmar CM. **J Pediatr** 1999 Mar;134(3):256–9 (21 ref.) Comment on: J Pediatr 1999 Mar;134(3):273–9.

Leukotriene-receptor antagonists. Lipworth BJ. **Lancet** 1999 Jan 2;353(9146):57–62 (49 ref.)

Asthma controller therapy: role of antileukotrienes, a new therapeutic class. Allegra L, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):136–45 (98 ref.)

Treatment of asthma with drugs modifying the leukotriene pathway [published erratum appears in N Engl J Med 1999 Feb 25;340(8):663] Drazen JM, et al. **N Engl J Med** 1999 Jan 21;340(3):197–206 (110 ref.)

Anti-leukotriene therapy in asthma. Diamant Z, et al. **Neth J Med** 1998 Oct;53(4):176–89 (103 ref.)

Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and

leukotriene synthesis inhibitors in asthma. Devillier P, et al. **Pharmacol Res** 1999 Jul;40(1):15-29 (143 ref.)
Anti-leukotrienes: a new treatment for asthma. Barnes PJ. **Practitioner** 1998 May;242(1586):395-9 (19 ref.)
Role of leukotrienes and leukotriene receptor antagonists in asthma. Jones TR, et al. **Pulm Pharmacol Ther** 1999; 12(2):107-10 (30 ref.)
[Leukotriene antagonists] Mallet JP.
Allerg Immunol (Paris) 1999 Apr;31(4):113-6 (20 ref.) (Eng. Abstr.) **(Fre)**
[Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class] Santais MC, et al.
Rev Med Interne 1998 Feb;19(2):98-107 (74 ref.) (Eng. Abstr.) **(Fre)**
[The anti-leukotrienes: a new class of drugs to integrate into the therapeutic strategy of asthma] Fellrath JM, et al.
Rev Med Suisse Romande 1999 Mar;119(3):217-26 (52 ref.) (Eng. Abstr.) **(Fre)**
[Antileukotrienes in the therapy of bronchial asthma (editorial)] Rossi G. **Recenti Prog Med** 1998 Dec; 89(12):654-6 (30 ref.) **(Ita)**
[The role of anti-leukotriene drugs in the management of chronic asthma] Adachi M, et al. **Arerugi** 1999 Jul; 48(7):683-5 (7 ref.) **(Jpn)**
[The use of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in bronchial asthma treatment (editorial)] Kuziemski K, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):317-20 (39 ref.) (Eng. Abstr.) **(Pol)**
[The therapeutic potentials of antileukotriene preparations in bronchial asthma patients] Fedoseev GB, et al.
Ter Arkh 1998;70(8):81-4 (52 ref.) **(Rus)**

LEUKOTRIENE B4

BIOSYNTHESIS

Adenosine. An endogenous inhibitor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Krump E, et al. **Adv Exp Med Biol** 1999;447:107-15 (65 ref.)
Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis. Haeggström JZ.
Clin Rev Allergy Immunol 1999 Spring-Summer; 17(1-2):111-31 (87 ref.)

METABOLISM

Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions. Weber C, et al. **Clin Chem Lab Med** 1999 Mar;37(3):243-51 (88 ref.)

LEUKOTRIENE D4

ANTAGONISTS & INHIBITORS

Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Busse WW, et al.
Clin Exp Allergy 1999 Jun;29 Suppl 2:110-5 (27 ref.)
Leukotriene antagonism in asthma and rhinitis. Lane SJ.
Respir Med 1998 Jun;92(6):795-809 (150 ref.)

LEUKOTRIENE RECEPTOR ANTAGONISTS see **LEUKOTRIENE ANTAGONISTS**

LEUKOTRIENE RECEPTORS see **RECEPTORS, LEUKOTRIENE**

LEUKOTRIENES

see related
RECEPTORS, LEUKOTRIENE

ADVERSE EFFECTS

Leukotriene antagonists. Costello JF.
Pulm Pharmacol Ther 1998 Oct-Dec;11(5-6):393-5 (28 ref.)

ANALYSIS

Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. Tsikas D. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9;717(1-2):201-45 (304 ref.)
Extraction and measurements of prostanoids and leukotrienes by radioimmunoassays. Battistini B, et al.
Methods Mol Biol 1998;105:187-99 (10 ref.)
Measurements of prostanoids, leukotrienes, and isoprostanes by enzyme immunoassays. Battistini B, et al.
Methods Mol Biol 1998;105:201-7 (5 ref.)

BIOSYNTHESIS

Asthma treatment: antileukotriene drugs. O'Byrne PM.
Can Respir J 1998 Jul-Aug;5 Suppl A:64A-70A (42 ref.)
Molecular mechanisms of leukotriene synthesis: the changing paradigm. Peters-Golden M. **Clin Exp Allergy** 1998 Sep; 28(9):1059-65 (42 ref.)
Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Sanak M, et al. **Clin Exp Allergy** 1999 Mar; 29(3):306-13 (42 ref.)
5-Lipoxygenase: a target for antiinflammatory drugs revisited. Steinhilber D. **Curr Med Chem** 1999 Jan; 6(1):71-85 (154 ref.)
Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Spokas EG, et al. **Methods Mol Biol** 1999;120:213-47 (145 ref.)
Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Devillier P, et al. **Pharmacol Res** 1999 Jul;40(1):3-13 (117 ref.)
Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma. Devillier P, et al. **Pharmacol Res** 1999 Jul;40(1):15-29 (143 ref.)

CHEMISTRY

Biochemistry and physiology of the leukotrienes. Barnes NC, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):27-42 (61 ref.)

IMMUNOLOGY

Antileukotrienes, asthma pathogenesis and the pharmaceutical industry [editorial; comment] O'Byrne PM. **CMAJ** 1999 Jan 26;160(2):209-10 (9 ref.) Comment on: CMAJ 1999 Jan 26;160(2):217-23.
Role of leukotrienes in antimicrobial defense of the lung. Peters-Golden M, et al. **J Lab Clin Med** 1998 Oct; 132(4):251-7 (42 ref.)

ISOLATION & PURIFICATION

The measurement of leukotrienes in human fluids. Westcott JY. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):153-77 (156 ref.)

METABOLISM

Leukotrienes as mediators of airway obstruction. Drazen JM. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S193-200 (139 ref.)
Pharmacogenetics of the 5-lipoxygenase pathway in asthma. Silverman E, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:164-70; discussion 171-3 (35 ref.)
Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. Claesson HE, et al. **J Intern Med** 1999 Mar;245(3):205-27 (257 ref.)

PHYSIOLOGY

Biological relevance of the 12-lipoxygenase pathway for platelet and lymphocyte functions. Lagarde M, et al.
Adv Exp Med Biol 1999;447:87-93 (53 ref.)
Biochemistry and physiology of the leukotrienes. Barnes NC, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):27-42 (61 ref.)
Role of leukotrienes in antimicrobial host defense of the lung. Peters-Golden M, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):261-9 (34 ref.)
The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Simon RA. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):271-5 (29 ref.)
Treatment of asthma with drugs modifying the leukotriene pathway [published erratum appears in N Engl J Med 1999 Feb 25;340(8):663] Drazen JM, et al. **N Engl J Med** 1999 Jan 21;340(3):197-206 (110 ref.)
Leukotrienes and lipoxins: lipoxygenase-derived modulators of leukocyte recruitment and vascular tone in glomerulonephritis. Clarkson MR, et al.
Nephrol Dial Transplant 1998 Dec;13(12):3043-51 (92 ref.)
[Leukotrienes in allergic inflammatory reactions] Bogić M, et al. **Srp Arh Celok Lek** 1998 Sep-Oct;126(9-10):382-7 (40 ref.) (Eng. Abstr.) **(Scc)**
[Leukotrienes in asthma] Ruiz Fernández M, et al.
Rev Alerg Mex 1999 Jul-Aug;46(4):97-103 (65 ref.) (Eng. Abstr.) **(Spa)**

LEUKOVIRUS PROTEINS see **RETROVIRIDAE PROTEINS**

LEUKOVIRUSES see **RETROVIRIDAE**

LEUPROLIDE

THERAPEUTIC USE

Effects of leuprolide acetate on treatment of leiomyomata--clues to mechanisms of action. Demopoulos RI, et al. **Adv Anat Pathol** 1998 Mar;5(2):129-36 (38 ref.)
Aborted leiomyosarcoma after treatment with leuprolide acetate. Mesia AF, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):664-6 (7 ref.)

LEUPRORELIN see **LEUPROLIDE**

LEUROCRISTINE see **VINCRISTINE**

LEVAMETHADYL see **METHADYL ACETATE**

LEVANS see **FRUCTANS**

LEVARTERENOL see **NOREPINEPHRINE**

LEVEL OF HEALTH see **HEALTH STATUS**

LEVOAMPHETAMINE see **AMPHETAMINE**

LEVODOPA

ADMINISTRATION & DOSAGE

Molecular and biochemical aspects of hereditary progressive and dopa-responsive dystonia. Furukawa Y, et al.
Adv Neurol 1998;78:267-82 (104 ref.)

ADVERSE EFFECTS

Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. Brotchie JM.
Adv Neurol 1999;80:71-85 (84 ref.)
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Henry B, et al. **Adv Neurol** 1998;78:53-61 (36 ref.)
Surgical treatment of levodopa-induced dyskinesias. Jankovic J, et al. **Adv Neurol** 1999;80:603-9 (59 ref.)
Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients. Rascol O, et al. **Adv Neurol** 1999; 80:485-90 (36 ref.)
Parkinson's disease--levodopa complications. King DB.
Can J Neurol Sci 1999 Aug;26 Suppl 2:S13-20 (45 ref.)
Treating and preventing levodopa-induced dyskinesias: current and future strategies. Durif F. **Drugs Aging** 1999 May;14(5):337-45 (49 ref.)
Does levodopa accelerate Parkinson's disease? Simuni T, et al. **Drugs Aging** 1999 Jun;14(6):399-408 (98 ref.)
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. Melamed E, et al. **J Neural Transm Suppl** 1999; 56:173-83 (40 ref.)
[Understanding and treating levodopa-induced dyskinesias] Hadj Tahar A, et al. **Tunis Med** 1998 Dec;76(12):437-47 (96 ref.) **(Fre)**
[Toxic and adverse neurological effects of anti-parkinsonian drugs] Sunohara N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):527-31 (15 ref.) **(Jpn)**
[Long-term complications of treatment with levodopa] Castro Garcia A, et al. **Neurologia** 1998;13 Suppl 1:41-8 (79 ref.) **(Spa)**
[Motor complications of treatment with levodopa in Parkinson's disease] Garcia-Escrig M, et al. **Rev Neurol** 1999 Apr 16-30;28(8):799-809 (198 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Mandel RJ, et al. **Exp Neurol** 1999 Sep;159(1):47-64 (161 ref.)

PHARMACOKINETICS

Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Guay DR.
Pharmacotherapy 1999 Jan;19(1):6-20 (59 ref.)

THERAPEUTIC USE

An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy. Janzen L, et al. **Ann Pharmacother** 1999 Jan;33(1):86-92 (36 ref.)
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA [see comments] Fahn S. **Arch Neurol** 1999 May;56(5):529-35 (108 ref.) Comment in: Arch Neurol 1999 May;56(5):524.
Apomorphine and levodopa challenge in patients with a focal midbrain lesion. Moro E, et al. **Mov Disord** 1999 Mar; 14(2):269-75 (22 ref.)
Levodopa effective parkinsonism associated with aqueductal stenosis: a case report and review of the literature. Asamoto S, et al. **No Shinkei Geka** 1998 Dec;26(12):1089-92 (6 ref.)
[Drug therapy in Parkinson's disease] van Hilten JJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30;143(5):234-40 (27 ref.) (Eng. Abstr.) **(Dut)**
[Arguments in favor of the early treatment of Parkinson's disease with L-Dopa (see comments)] Broussolle E.
Rev Neurol (Paris) 1999 Jan;155(1):27-33 (82 ref.) Comment in: Rev Neurol (Paris) 1999 Jan;155(1):43-5. **(Fre)**
[Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists? (comment)] Defer GL. **Rev Neurol (Paris)** 1999 Jan; 155(1):43-5 (12 ref.) Comment on: Rev Neurol (Paris) 1999 Jan;155(1):27-33. Comment on: Rev Neurol (Paris) 1999 Jan;155(1):35-42. **(Fre)**
[New dopaminergic agonists] de Mattos JP, et al.
Arq Neuropsiquiatr 1999 Jun;57(2A):329-32 (16 ref.) (Eng. Abstr.) **(Por)**
[Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function] Horga de la Parte JF. **Rev Neurol** 1999 Mar 1-15; 28(5):499-504 (31 ref.) (Eng. Abstr.) **(Spa)**

LEVOFLOXACIN see **OFLOXACIN**

LEVOMYCETIN

LEVOMYCETIN see **CHLORAMPHENICOL**

LEVONOREPINEPHRINE see **NOREPINEPHRINE**

LEVONORGESTREL

Research, introduction, and use: advancing from Norplant. Harrison PF, et al. **Contraception** 1998 Dec;58(6):323–34 (15 ref.)

Research on mifepristone and levonorgestrel in comparison with the Yuzpe regimen. von Hertzen H. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):222–4, 232 (20 ref.)

Intrauterine devices. The optimal long-term contraceptive method? Fortney JA, et al. **J Reprod Med** 1999 Mar; 44(3):269–74 (19 ref.)

ADVERSE EFFECTS

Long-acting hormonal contraception: assessing impact on bone density, weight, and mood. Kaunitz AM. **Int J Fertil Womens Med** 1999 Mar–Apr;44(2):110–7 (27 ref.)

PHARMACOLOGY

Effects of hormonal contraceptives on bone mineral density. Cromer BA. **Drug Saf** 1999 Mar;20(3):213–22 (33 ref.)

STANDARDS

Contraceptive introduction reconsidered: a new methodology for policy and program development. Simmons R, et al. **J Womens Health** 1999 Mar;8(2):163–73 (12 ref.)

THERAPEUTIC USE

The use of long-acting contraceptives in adolescents. Harel Z, et al. **Pediatr Clin North Am** 1999 Aug;46(4):719–32 (77 ref.)

LEVOPROPOXYPHENE see **PROPOXYPHENE**

LEVOTHYROXINE

ADVERSE EFFECTS

Pseudogout attack associated with chronic thyroiditis and Sjögren's syndrome. Hama Y, et al. **Intern Med** 1999 Jan; 38(1):59–62 (18 ref.)

THERAPEUTIC USE

Substitution therapy after surgery for autonomous adenomas. Feldkamp J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S85–7 (33 ref.)

[Administration of levothyroxine in the treatment of Basedow disease] Hörmann R. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:47–52 (24 ref.) (Eng. Abstr.) **(Ger)**

LEVOTHYROXINE SODIUM see **LEVOTHYROXINE**

LEVULOSE see **FRUCTOSE**

LEWIS BLOOD-GROUP SYSTEM

IMMUNOLOGY

[Human fucosyltransferases: tissue distribution of blood group antigens, cancer-associated antigens and fucosyltransferases] Narimatsu H. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2394–403 (18 ref.) **(Jpn)**

PHYSIOLOGY

Role for cell surface oligosaccharide in cell–cell recognition during implantation. Zhu ZM, et al. **Mol Hum Reprod** 1998 Aug;4(8):735–8 (30 ref.)

LEWIS SYSTEM see **LEWIS BLOOD-GROUP SYSTEM**

LEWY BODIES

PATHOLOGY

Alzheimer's disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Horoupian DS, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):317–22 (23 ref.)

Pathobiology of the Lewy body. Galvin JE, et al. **Adv Neurol** 1999;80:313–24 (114 ref.)

Recent advances in research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutations: neuronal Lewy body–like hyaline inclusions and astrocytic hyaline inclusions. Kato S, et al. **Histol Histopathol** 1999 Jul;14(3):973–89 (113 ref.)

Dementia with Lewy bodies. Gómez-Tortosa E, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1449–58 (154 ref.)

Dementia with Lewy bodies: review and pharmacotherapeutic implications. Rojas-Fernandez CH, et al. **Pharmacotherapy** 1999 Jul;19(7):795–803 (58 ref.)

PHYSIOLOGY

Pathobiology of the Lewy body. Galvin JE, et al. **Adv Neurol** 1999;80:313–24 (114 ref.)

LEWY BODY DISEASE see **PARKINSON DISEASE**

LEYDIG CELL TUMOR

[Malignant Leydig cell tumor. Report of a case and review of the literature] Jiménez López-Lucendo N, et al. **Arch Esp Urol** 1999 Mar;52(2):174–7 (15 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Hormonal profile of patients with Leydig cell tumors: a urologic cause of gynecomastia. Xciarra A, et al. **Minerva Urol Nefrol** 1998 Dec;50(4):225–31 (108 ref.)

COMPLICATIONS

Hormonal profile of patients with Leydig cell tumors: a urologic cause of gynecomastia. Xciarra A, et al. **Minerva Urol Nefrol** 1998 Dec;50(4):225–31 (108 ref.)

DIAGNOSIS

[The Leydig-cell testicular tumor. A case report with magnetic resonance images] Tamayo Ruiz JC, et al. **Arch Esp Urol** 1998 Nov;51(9):928–31 (10 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Cook JC, et al. **Crit Rev Toxicol** 1999 Mar; 29(2):169–261 (550 ref.)

PATHOLOGY

Stromal Leydig cell tumor of the ovary. Case report and literature review. Takeuchi S, et al. **Int J Gynecol Pathol** 1999 Apr;18(2):178–82 (9 ref.)

[An occult Leydig-cell tumor in a cryptorchid testis] Medina Pérez M, et al. **Arch Esp Urol** 1999 Jan–Feb;52(1):76–8 (7 ref.) (Eng. Abstr.) **(Spa)**

LEYDIG CELLS

DRUG EFFECTS

In vitro models for the investigation of reproductive toxicology in the testis. Cooke BA. **Adv Exp Med Biol** 1998;444:95–102; discussion 102–3 (33 ref.)

METABOLISM

Interactions between testicular macrophages and Leydig cells. Hutson JC. **J Androl** 1998 Jul–Aug;19(4):394–8 (55 ref.)

Autocrine regulation of Leydig cell differentiated functions by insulin-like growth factor I and transforming growth factor beta. Le Roy C, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):379–84 (50 ref.)

LFA-1 see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

LH

see related
RECEPTORS, LH

GENETICS

Alterations in gonadal steroidogenesis in individuals expressing a common genetic variant of luteinizing hormone. Huhtaniemi IT, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):281–5 (26 ref.)

Transcriptional regulation of pituitary gonadotrophin subunit genes. Brown P, et al. **Rev Reprod** 1999 May;4(2):117–24 (62 ref.)

METABOLISM

Control of luteinizing hormone and prolactin secretion in birds. Sharp PJ, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):275–82 (88 ref.)

Molecular mysteries of polycystic ovary syndrome. Strauss JF 3rd, et al. **Mol Endocrinol** 1999 Jun;13(6):800–5 (46 ref.)

PHYSIOLOGY

The role of luteinizing hormone in folliculogenesis and ovulation induction. Filicori M. **Fertil Steril** 1999 Mar; 71(3):405–14 (88 ref.)

Molecular mechanisms of ovulation and luteinization. Richards JS, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):47–54 (73 ref.)

[Physiopathology of gonadotropic control of gametogenesis] Deneux C, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):318–21 (16 ref.) **(Fre)**

SECRETION

Medical therapy for gonadotroph and thyrotroph tumors. Shomali ME, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):223–40, viii (103 ref.)

Inhibitory effect of melatonin on GnRH-induced LH release. Vanecek J. **Rev Reprod** 1999 May;4(2):67–72 (53 ref.)

LH-FSH RELEASING HORMONE see **GONADORELIN**

LH-HCG RECEPTORS see **RECEPTORS, LH**

LH RECEPTORS see **RECEPTORS, LH**

LH-RELEASING HORMONE see **GONADORELIN**

LHFSHRH RECEPTORS see **RECEPTORS, LHRH**

LHRH see **GONADORELIN**

LHRH RECEPTORS see **RECEPTORS, LHRH**

LI-FRAUMENI SYNDROME

see related
GENES, P53

GENETICS

[Germline mutations of the p53 gene] Frebourg T. **Pathol Biol (Paris)** 1997 Dec;45(10):845–51 (80 ref.) (Eng. Abstr.) **(Fre)**

LIABILITY, LEGAL

see related
MALPRACTICE

The Omnibus Reconciliation Act of 1990: redefining pharmacists' legal responsibilities. Huang SW. **Am J Law Med** 1998;24(4):417–42 (0 ref.)

Liability in prescribing choice: the example of the antidepressants [see comments] Beerworth EE, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):560–6 (66 ref.) Comment in: Aust N Z J Psychiatry 1999 Apr;33(2):281–2.

Neurobiologic correlates of violence: relevance to criminal responsibility. Berman ME, et al. **Behav Sci Law** 1998 Summer;16(3):303–18 (55 ref.)

Medicolegal issues and fine needle aspiration of the breast. What you can do to decrease your risk of being sued. DeMay RM. **Clin Lab Med** 1998 Sep;18(3):599–605, vii (18 ref.)

Intoxication, the law and criminal responsibility--a sparkling cocktail at times: the case studies of Canada and Germany. Fischer B, et al. **Eur Addict Res** 1998 Sep;4(3):89–101 (53 ref.)

Psychiatric criteria of legal responsibility after the consumption of alcohol: the German situation. Kröber HL. **Eur Addict Res** 1998 Sep;4(3):107–12 (19 ref.)

Pharmacists' liability into the year 2000. Lynn NJ, et al. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec;38(6):747–52; quiz 753–4 (10 ref.)

The saga of tobacco products liability litigation: a look back and a proposal for the future. Nusbaum NJ. **J Community Health** 1998 Oct;23(5):325–35 (43 ref.)

Product liability and prescription diet drug cocktail, Fen–Phen: a hard combination to swallow. Crisanti CA. **J Contemp Health Law Policy** 1998 Fall;15(1):207–44 (0 ref.)

Preventive law by corporate professional team players: liability and responsibility in the work of company doctors. Draper E. **J Contemp Health Law Policy** 1999 Spring; 15(2):525–607 (99 ref.)

Practice guidelines and tort reform: the legal system confronts the technocratic wish. Matthews JR. **J Health Polit Policy Law** 1999 Apr;24(2):275–304 (40 ref.)

Suing health care providers for saving lives. Liability for providing unwanted life-sustaining treatment. Rodriguez KF. **J Leg Med** 1999 Mar;20(1):1–66 (331 ref.)

'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369–75 (4 ref.) Comment in: J Med Ethics 1998 Dec;24(6):363–4.

Professional accountability and legal liability for the team leader and charge nurse. Mahlmeister L. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):300–9 (23 ref.)

The legal and ethical aspects of telemedicine. 4: Product liability and jurisdictional problems. Stanberry B. **J Telemed Telecare** 1998;4(3):132–9 (39 ref.)

Potential liabilities of medical directors for actions of EMTs. Hall SA. **Prehosp Emerg Care** 1998 Jan–Mar;2(1):76–80 (43 ref.)

From courtroom to couch. Working with repressed memory and avoiding lawsuits. Scheflin AW, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):847–67, vii (136 ref.)

Ethics and law for the radiologic technologist. Lynn SD. **Radiol Technol** 1999 Jan–Feb;70(3):257–66; quiz 267–9 (22 ref.)

[Principles of medical liability and practice in medical imaging] Thibierge M, et al. **J Radiol** 1999 Jul;80(7):701–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Physician liability and patient information related to blood and plasma product safety] Bock RW. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):501–3 (0 ref.) **(Ger)**

[Quality assurance based on civil and penal law] Bock RW. **Zentralbl Gynakol** 1998;120(12):584–7 (13 ref.) (Eng. Abstr.) **(Ger)**

LIBIDO

Psychosexual effects of menopause: role of androgens. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):319–24 (29 ref.)

ABC of sexual health: female sexual problems I: loss of desire–what about the fun? Butcher J. **BMJ** 1999 Jan 2; 318(7175):41–3 (0 ref.)

Sex and the mature woman. Pariser SF, et al. **J Womens Health** 1998 Sep;7(7):849–59 (38 ref.)

[Archetypal aspects of aging: from Eros to Thanatos] Pérez Urdániz A, et al. **Actas Esp Psiquiatr** 1999 Mar–Apr; 27(2):127–32 (21 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

[Inhibition of sexual desire associated with menopause] Mouchamps E, et al. **Rev Med Liege** 1999 May;54(5):489–94 (45 ref.) (Eng. Abstr.) **(Fre)**

LIBMAN–SACKS DISEASE see **LUPUS ERYTHEMATOSUS, SYSTEMIC**

LIBRARIES, HEALTH SCIENCE see **LIBRARIES, MEDICAL**

LIBRARIES, MEDICAL

Meeting information needs in health policy and public health: priorities for the National Library of Medicine and The National Network of Libraries of Medicine. Humphreys BL. **J Urban Health** 1998 Dec;75(4):878–83 (4 ref.)

ECONOMICS

Publish or perish--and bankrupt the medical library while we're at it. Halperin EC. **Acad Med** 1999 May;74(5):470–2 (19 ref.)

LICE

see related
LICE INFESTATIONS

LICE INFESTATIONS

The saga of ectoparasitoses: scabies and pediculosis. Parish LC, et al. **Int J Dermatol** 1999 Jun;38(6):432–3 (11 ref.)

THERAPY

Evidence based case report: treatment for head lice [see comments] Dawes M, et al. **BMJ** 1999 Feb 6; 318(7180):385–6 (9 ref.) Comment in: BMJ 1999 May 22;318(7195):1422.

LICENSES see **LICENSURE**

LICENSURE

see related
ACCREDITATION
CERTIFICATION

Current licensure for acupuncture in the United States. Leake R, et al. **Altern Ther Health Med** 1999 Jul;5(4):94–6 (2 ref.)

Effects of high school driver education on motor vehicle crashes, violations, and licensure. Vernick JS, et al. **Am J Prev Med** 1999 Jan;16(1 Suppl):40–6 (36 ref.)

Communicating effectively with regulatory agencies in the licensing process. Ryan MT. **Health Phys** 1999 Feb;76(2 Suppl):S41–6 (20 ref.)

Franchise issues--exclusivity of territory. Allen JF. **Inquiry** 1999 Spring;36(1):8–11 (13 ref.)

Statistical shortcomings in licensing applications. Lewis JA, et al. **Stat Med** 1998 Aug 15–30;17(15–16):1663–73 (24 ref.)

Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT. **Stat Med** 1998 Aug 15–30;17(15–16):1851–8; discussion 1859–62 (6 ref.)

LEGISLATION & JURISPRUDENCE

The ramifications of regulatory reform. Moyers PA. **Am J Occup Ther** 1998 Oct;52(9):702–8 (28 ref.)

Graduated licensing comes to the United States. Williams AF. **Inj Prev** 1999 Jun;5(2):133–5 (34 ref.)

[Rules for granting a driver's license as of May 6, 1999] Gramberg-Danielsen B. **Klin Monatsbl Augenheilkd** 1999 Jun;214(6):aA10–1 (5 ref.) **(Ger)**

LICENSURE, INSTITUTIONAL, PERSONNEL see **LICENSURE**

LICENSURE, MEDICAL

Conducting forensic examinations on the road: are you practicing your profession without a license? Simon RI, et al. **J Am Acad Psychiatry Law** 1999;27(1):75–82 (20 ref.)

The performance of doctors: the new professionalism [see comments] Irvine D. **Lancet** 1999 Apr 3;353(9159):1174–7 (30 ref.) Comment in: Lancet 1999 Jul 10;354(9173):165.

LICENSURE, NURSING

Evolution and current status of direct-entry midwifery education, regulation, and practice in the United States, with examples from Washington State [see comments] Myers-Ciecko JA. **J Nurse Midwifery** 1999 Jul–Aug; 44(4):384–93 (58 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

LICHEN NITIDUS

DIAGNOSIS

Generalized lichen nitidus: case report and literature review. Soroush V, et al. **Cutis** 1999 Aug;64(2):135–6 (22 ref.)

LICHEN PLANUS

COMPLICATIONS

Lichen sclerosus and lichen planus: a spectrum of disease? Report of two cases and review of the literature. Holmes SC, et al. **Clin Exp Dermatol** 1998 May;23(3):129–31 (20 ref.)

DIAGNOSIS

Esophageal lichen planus. Bobadilla J, et al. **Gastrointest Endosc** 1999 Aug;50(2):268–71 (23 ref.)

[Lichenoid eruptions in the child] Michel JL, et al. **Arch Pediatr** 1998 Aug;5(8):909–15 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Lichen planus as a side effect of HBV vaccination [editorial] [published erratum appears in Dermatology 1999;198(2):222] Rebora A, et al. **Dermatology** 1999; 198(1):1–2 (16 ref.)

THERAPY

Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Cribier B, et al. **Arch Dermatol** 1998 Dec;134(12):1521–30 (153 ref.)

LICHEN PLANUS, ORAL

COMPLICATIONS

Squamous cell carcinoma of the tongue arising in lichen planus: a case report and review of the literature. Camisa C, et al. **Cutis** 1998 Oct;62(4):175–8 (13 ref.)

The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Lo Muzio L, et al. **Oral Oncol** 1998 Jul;34(4):239–46 (90 ref.)

PATHOLOGY

A review of the recent literature regarding malignant transformation of oral lichen planus. van der Meij EH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):307–10 (35 ref.)

LICHEN RUBER PLANUS see **LICHEN PLANUS**

LICHEN SCLEROSUS see **LICHEN SCLEROSUS ET ATROPHICUS**

LICHEN SCLEROSUS ET ATROPHICUS

Lichen sclerosus. Powell JJ, et al. **Lancet** 1999 May 22; 353(9166):1777–83 (61 ref.)

COMPLICATIONS

Lichen sclerosus and lichen planus: a spectrum of disease? Report of two cases and review of the literature. Holmes SC, et al. **Clin Exp Dermatol** 1998 May;23(3):129–31 (20 ref.)

LICHENIFORM ERUPTIONS see **LICHENOID ERUPTIONS**

LICHENOID ERUPTIONS

COMPLICATIONS

Lichen amyloidosis in an HIV-infected Patient. A case report and review of the literature [letter] Vaghjimal A, et al. **Acta Derm Venereol** 1998 Sep;78(5):399 (6 ref.)

ETIOLOGY

[Lichenoid eruptions in the child] Michel JL, et al. **Arch Pediatr** 1998 Aug;5(8):909–15 (23 ref.) (Eng. Abstr.) **(Fre)**

LICHENS

The research of lichenized fungi in Hungary. Farkas E, et al. **Acta Microbiol Immunol Hung** 1999;46(2–3):199–203 (20 ref.)

LIDOCAINE

Epinephrine in digital blocks: revisited. Wilhelmi BJ, et al. **Ann Plast Surg** 1998 Oct;41(4):410–4 (62 ref.)

Use of topical lidocaine in pediatric laceration repair: a review of topical anesthetics. Stewart GM, et al. **Pediatr Emerg Care** 1998 Dec;14(6):419–23 (39 ref.)

ADMINISTRATION & DOSAGE

[Pharma clinics. How I treat...or preventing pain with "patches"] Piérard GE. **Rev Med Liege** 1998 Oct; 53(10):586–7 (19 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature [see comments] Weightman W, et al. **Contact Dermatitis** 1998 Nov;39(5):265–6 (22 ref.) Comment in: Contact Dermatitis 1999 May;40(5):292–3.

[Toxic and adverse effects of local anesthetics/neuromuscular blocker: lidocaine, succinylcholine] Takagi A. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):542–4 (4 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). Kodama I, et al. **Jpn Circ J** 1999 Jan;63(1):1–12 (126 ref.)

[Importance of determination of monoethylglycinexylidide (MEGX)--as a liver function test in hepatology and liver transplantation] Kupčová V. **Bratisl Lek Listy** 1999 Jan; 100(1):49–53 (46 ref.) (Eng. Abstr.) **(Slo)**

DIAGNOSTIC USE

[Importance of determination of monoethylglycinexylidide (MEGX)--as a liver function test in hepatology and liver transplantation] Kupčová V. **Bratisl Lek Listy** 1999 Jan; 100(1):49–53 (46 ref.) (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era [editorial; comment] Tan HL, et al. **Am Heart J** 1999 May;137(5):770–3 (27 ref.) Comment on: Am Heart J 1999 May;137(5):792–8. Comment on: Am Heart J 1999 May;137(5):799–805.

LIFE

Evolutionary body building: adaptive physical designs for robots. Funes P, et al. **Artif Life** 1998 Fall;4(4):337–57 (40 ref.)

Life without neuropeptide Y. Palmiter RD, et al. **Recent Prog Horm Res** 1998;53:163–99 (115 ref.)

[Hope] Kaasa S, et al. **Tidsskr Nor Laegeforen** 1999 Apr 10; 119(9):1313–5 (13 ref.) (Eng. Abstr.) **(Nor)**

LIFE CARE CENTERS, RETIREMENT see **HOUSING FOR THE ELDERLY**

LIFE CHANGE EVENTS

Functional associations among trauma, PTSD, and substance-related disorders. Stewart SH, et al. **Addict Behav** 1998 Nov–Dec;23(6):797–812 (90 ref.)

Depressogenic cognitive styles: predictive validity, information processing and personality characteristics, and developmental origins. Alloy LB, et al. **Behav Res Ther** 1999 Jun;37(6):503–31 (120 ref.)

Does stress damage the brain? Bremner JD. **Biol Psychiatry** 1999 Apr 1;45(7):797–805 (93 ref.)

Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21–33 (281 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.

Biological factors associated with susceptibility to posttraumatic stress disorder [see comments] Yehuda R. **Can J Psychiatry** 1999 Feb;44(1):34–9 (46 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.

Dealing with stress and trauma in families. Kiser LJ, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):87–103, viii–ix (55 ref.)

Stress in children exposed to violence. Reenactment and rage. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):121–35, ix (50 ref.)

Recovered memories of trauma: phenomenology and cognitive mechanisms. Brewin CR, et al. **Clin Psychol Rev** 1998 Dec;18(8):949–70 (98 ref.)

Psychosocial processes underlying the maintenance and persistence of depression: implications for understanding chronic depression. Lara ME, et al. **Clin Psychol Rev** 1999 Aug;19(5):553–70 (120 ref.)

Treatment for traumatic memories: review and recommendations. Leskin GA, et al. **Clin Psychol Rev** 1998 Dec;18(8):983–1001 (106 ref.)

LIFE CHANGE EVENTS

Creating a life story: the task of reconciliation. Coleman PG. **Gerontologist** 1999 Apr;39(2):133–9 (35 ref.)
Events in the life of the therapist: the effect on transference and countertransference. Gold JH. **Harv Rev Psychiatry** 1999 Jan–Feb;6(5):263–9 (51 ref.)
Negative life events and adolescent suicidal behavior: a critical analysis from the stress process perspective. Sandin B, et al. **J Adolesc** 1998 Aug;21(4):415–26 (52 ref.)
'Coming out' as a life transition: homosexual identity formation and its implications for health care practice. Taylor B. **J Adv Nurs** 1999 Aug;30(2):520–5 (52 ref.)
Menopause and beyond. The wise woman way. Weed SS. **J Nurse Midwifery** 1999 May–Jun;44(3):267–79 (76 ref.)
The structure of autobiographical memory and the event history calendar: potential improvements in the quality of retrospective reports in surveys. Belli RF. **Memory** 1998 Jul;6(4):383–406 (52 ref.)
Disaster mental health: current status and future directions. Young BH, et al. **New Dir Ment Health Serv** 1999 Summer; (82):53–64 (94 ref.)
Behavioral medicine. Vogel ME, et al. **Prim Care** 1999 Jun; 26(2):385–400 (9 ref.)
Stressful life events and adolescent substance use and depression: conditional and gender differentiated effects. Hoffmann JP, et al. **Subst Use Misuse** 1998 Sep; 33(11):2219–62 (120 ref.)
Suicide across the life span: pathways to prevention. King CA. **Suicide Life Threat Behav** 1998 Winter;28(4):328–37 (31 ref.)
[How to prevent post-traumatic stress disorder before traumatization occurs?] Melançon G, et al. **Can J Psychiatry** 1999 Apr;44(3):253–8 (50 ref.) (Eng. Abstr.) **(Fre)**
[Measure of negative life events before onset of cancer] Saltel P, et al. **Encephale** 1998 Dec;24 Spec No 2:42–9 (19 ref.) **(Fre)**
[Personal biography in the aging process and attitude to personal biography in social work with the elderly] Schweppe C. **Z Gerontol Geriatr** 1998 Oct;31(5):325–30 (35 ref.) (Eng. Abstr.) **(Ger)**
[On love in medicine] Getz L. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1316–8 (0 ref.) (Eng. Abstr.) **(Nor)**

LIFE CYCLE see **LIFE CYCLE STAGES**

LIFE CYCLE STAGES

Advances in the life cycle of Toxoplasma gondii. Dubey JP. **Int J Parasitol** 1998 Jul;28(7):1019–24 (38 ref.)

PHYSIOLOGY

Reproduction and love: strategies of the organism's cellular defense system? De Loof A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):167–76 (33 ref.)

LIFE EXPECTANCY

see related
LONGEVITY

Aging: phenomena and theories. Harman D. **Ann N Y Acad Sci** 1998 Nov 20;854:1–7 (28 ref.)
The universality of bioenergetic disease. Age-associated cellular bioenergetic degradation and amelioration therapy. Linnane AW, et al. **Ann N Y Acad Sci** 1998 Nov 20; 854:202–13 (60 ref.)
The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Viganò A, et al. **Cancer** 1999 Jul 1;86(1):170–6 (29 ref.)
Long-term oxygen therapy in COPD patients with moderate hypoxaemia: does it add years to life? [editorial; comment] Zieliński J. **Eur Respir J** 1998 Oct;12(4):756–8 (32 ref.) Comment on: Eur Respir J 1998 Oct;12(4):780–4.
Primary pulmonary hypertension and its life prognosis [editorial; comment] Kunieda T. **Intern Med** 1999 Jan; 38(1):1–2 (18 ref.) Comment on: Intern Med 1999 Jan;38(1):12–6.
Revisiting the role of fat mass in the life extension induced by caloric restriction. Barzilai N, et al. **J Gerontol A Biol Sci Med Sci** 1999 Mar;54(3):B89–96; discussion B97–8 (110 ref.)
The effects of poverty and ageing on the increase in tuberculosis. Davies PD. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):168–71 (12 ref.)
[Extended life expectancy with physical activity] Heitkamp HC. **Wien Med Wochenschr** 1999;149(7):149–56 (47 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Premature deaths and long-term mortality effects of air pollution [letter] Quénel P, et al. **Int J Epidemiol** 1999 Apr; 28(2):362 (7 ref.)
Human longevity: nature vs. nurture--fact or fiction. Carnes BA, et al. **Perspect Biol Med** 1999 Spring;42(3):422–41 (83 ref.)

LIFE EXPERIENCES see **LIFE CHANGE EVENTS**

LIFE SCIENCES see **BIOLOGICAL SCIENCES**

LIFE STRESS see **STRESS, PSYCHOLOGICAL**

LIFE STYLE

see related
HEALTH BEHAVIOR
QUALITY OF LIFE

Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project. Ornish D. **Am J Cardiol** 1998 Nov 26;82(10B):72T–76T (20 ref.)
Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Beto JA, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S172–83 (47 ref.)
Diet and lifestyle in the prevention of colorectal cancer: an overview. Shike M. **Am J Med** 1999 Jan 25; 106(1A):11S–15S; discussion 50S–51S (50 ref.)
Lifestyle physical activity interventions. History, short- and long-term effects, and recommendations. Dunn AL, et al. **Am J Prev Med** 1998 Nov;15(4):398–412 (77 ref.)
Coronary heart disease. At the interface of molecular genetics and preventive medicine. Ellsworth DL, et al. **Am J Prev Med** 1999 Feb;16(2):122–33 (87 ref.)
A world behaving badly: the global challenge for behavioral surveillance [editorial] McQueen DV. **Am J Public Health** 1999 Sep;89(9):1312–4 (26 ref.)
Excess catecholamine syndrome. Pathophysiology and therapy. Rupp H. **Ann N Y Acad Sci** 1999 Jun 21; 881:430–44 (98 ref.)
Rheumatic disease and the Australian aborigine. Roberts-Thomson RA, et al. **Ann Rheum Dis** 1999 May; 58(5):266–70 (33 ref.)
Retiring at 55: is it a media-created myth? Lee G. **Can J Gastroenterol** 1999 Jun;13(5):382–4 (2 ref.)
Nonpharmacologic therapies that reduce blood pressure: a fresh perspective. Appel LJ. **Clin Cardiol** 1999 Jul;22(7 Suppl):III1–5 (41 ref.)
Dietary Approaches to Stop Hypertension (DASH) in clinical practice: a primary care experience. Kolasa KM. **Clin Cardiol** 1999 Jul;22(7 Suppl):III16–22 (15 ref.)
Effects of lifestyle and body composition on the ovary. Yen SS. **Endocrinol Metab Clin North Am** 1998 Dec; 27(4):915–26, ix (82 ref.)
Implications of the hyperinsulinaemia–diabetes–cancer link for preventive efforts. Moore MA, et al. **Eur J Cancer Prev** 1998 Apr;7(2):89–107 (243 ref.)
The epidemiology of gallbladder cancer: lifestyle related risk factors and limited surgical possibilities for prevention. Moerman CJ, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):1533–9 (39 ref.)
The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. Foreyt JP, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S5–11 (64 ref.)
Obesity as a chronic disease: modern medical and lifestyle management. Rippe JM, et al. **J Am Diet Assoc** 1998 Oct; 98(10 Suppl 2):S9–15 (67 ref.)
A phylogenetic analysis of the relationship between sub-adult mortality and mode of subsistence. Sellen DW, et al. **J Biosoc Sci** 1999 Jan;31(1):1–16 (59 ref.)
Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? Holte J. **J Endocrinol Invest** 1998 Oct;21(9):589–601 (101 ref.)
Colorectal cancer: molecules and populations. Potter JD. **J Natl Cancer Inst** 1999 Jun 2;91(11):916–32 (238 ref.)
Impact of lifestyle choices on female infertility. Silva PD, et al. **J Reprod Med** 1999 Mar;44(3):288–96 (121 ref.)
Lifestyle change in women with coronary heart disease: what do we know? Toobert DJ, et al. **J Womens Health** 1998 Aug;7(6):685–99 (77 ref.)
Managing the lifestyle of the child with epilepsy. Parker C. **Pediatr Ann** 1999 Apr;28(4):254–9 (10 ref.)
Status of the year 2000 health goals for physical activity and fitness. Francis KT. **Phys Ther** 1999 Apr;79(4):405–14 (70 ref.)
Nonpharmacologic therapy in hypertension: from single components to overall dietary management. McCarron DA, et al. **Prog Cardiovasc Dis** 1999 May–Jun;41(6):451–60 (89 ref.)
[What role do physical activity and sedentary life style play in development and maintenance of excess pounds in the child? (editorial)] Maffeis C, et al. **Arch Pediatr** 1998 Nov; 5(11):1191–6 (66 ref.) **(Fre)**
[Treatment of gastroesophageal reflux: life style–dietetic rules and topical agents] Ducrotté P. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S70–7 (83 ref.) **(Fre)**
[A society on the move and allergy] Spertini F. **Rev Med Suisse Romande** 1999 Aug;119(8):613–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[Changes in life style as a causal therapeutic approach in coronary heart disease] Gleichmann U, et al. **Z Kardiol** 1998;87 Suppl 2:125–35 (86 ref.) (Eng. Abstr.) **(Ger)**
[Life style modification for the treatment of hypertension] Matsuura H. **Nippon Naika Gakkai Zasshi** 1999 Feb 10; 88(2):255–61 (5 ref.) **(Jpn)**
[Diabetes mellitus as a life-style related disease--importance of environmental factors on pathogenesis and progress of type-2 diabetes] Matsuoka K. **Nippon Rinsho** 1999 Mar; 57(3):521–7 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Life style changes in hypertension patients. Members of the Working Group on Arterial Hypertension of the Societat Catalana de Medicina de Família i Comunitària] Coll de Tuero G, et al. **Aten Primaria** 1998 Nov 30;22(9):596–8, 600–2, 604–6 (50 ref.) **(Spa)**
[Prescribed exercise can help the patient to change his habits] Hellénius ML, et al. **Lakartidningen** 1999 Jul 28; 96(30–31):3343–6 (34 ref.) **(Swe)**

ETHNOLOGY

Is imposing risk awareness cultural imperialism? Førde OH. **Soc Sci Med** 1998 Nov;47(9):1155–9 (25 ref.)

LIFE SUPPORT CARE

see related
RESUSCITATION ORDERS

European life-support questionnaire [editorial; comment] Leonard C, et al. **Crit Care Med** 1999 Aug;27(8):1686–7 (9 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1626–33.
Supportive care in hematological malignancies: hematopoietic growth factors, infections, transfusion therapy. Fetscher S, et al. **Curr Opin Hematol** 1999 Jul; 6(4):262–73 (80 ref.)
Treating infants who may die [comment] Howe EG. **J Clin Ethics** 1998 Fall;9(3):215–24 (25 ref.) Comment on: J Clin Ethics 1998 Fall;9(3):314–22.
End-of-life ethical issues. Heffner JE. **Respir Care Clin N Am** 1998 Sep;4(3):541–59, x (92 ref.)
Making decisions about life-sustaining medical treatment in patients with dementia. The problem of patient decision-making capacity. Derse AR. **Theor Med Bioeth** 1999 Jan;20(1):55–67 (42 ref.)

LEGISLATION & JURISPRUDENCE

Suing health care providers for saving lives. Liability for providing unwanted life-sustaining treatment. Rodriguez KF. **J Leg Med** 1999 Mar;20(1):1–66 (331 ref.)

METHODS

Cardiopulmonary cerebral resuscitation--present and future perspectives. Rubertsson S. **Acta Anaesthesiol Scand** 1999 May;43(5):526–35 (122 ref.)
Foregoing life support in medically futile patients. Tai DY, et al. **Ann Acad Med Singapore** 1998 May;27(3):430–6 (28 ref.)
Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Eur J Pediatr** 1999 Apr;158(4):345–58 (85 ref.)
[Guidelines for basic cardiopulmonary resuscitation of adult patients. European Resuscitation Council] **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):814–7 (21 ref.) (Eng. Abstr.) **(Nor)**

ORGANIZATION & ADMINISTRATION

Teaching adult resuscitation in the United States--time for a rethink. Kaye W, et al. **Resuscitation** 1998 Jun; 37(3):177–87 (110 ref.)

STANDARDS

Precedent autonomy: life-sustaining intervention and the demented patient. Newton MJ. **Camb Q Healthc Ethics** 1999 Spring;8(2):189–99 (63 ref.)

LIFE SUPPORT SYSTEMS

[Hybrid biophysical-chemical life support systems for human] Shepelev Ela, et al. **Aviakosm Ekolog Med** 1998; 32(6):27–30 (8 ref.) (Eng. Abstr.) **(Rus)**
[Biological life support systems: investigations on board of orbital complex "Mir"] Sychev VN, et al. **Aviakosm Ekolog Med** 1999;33(1):10–6 (17 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

[The history of the development of life support systems under the conditions of the vacuum of space] Cherniakov IN. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):90–6 (31 ref.) **(Rus)**

LIFE SUPPORT SYSTEMS, REGENERATIVE see **ECOLOGICAL SYSTEMS, CLOSED**

LIFTING

The psychophysical approach to manual materials handling task design. Ayoub MM, et al. **Ergonomics** 1999 Jan; 42(1):17–31 (55 ref.)
Is there a rational basis for post-surgical lifting restrictions? 1. Current understanding. Magnusson ML, et al. **Eur Spine J** 1999;8(3):170–8 (93 ref.)
Is there a rational basis for post-surgical lifting restrictions? 2. Possible scientific approach. Pope MH, et al. **Eur Spine J** 1999;8(3):179–86 (75 ref.)

ADVERSE EFFECTS

[The epidemiology of musculoskeletal changes due to biomechanical overload of the spine in the manual lifting of patients] Bordini L, et al. **Med Lav** 1999 Mar–Apr; 90(2):103–16 (47 ref.) (Eng. Abstr.) **(Ita)**

LIGAMENTA FLAVA see **LIGAMENTUM FLAVUM**

LIGAMENTS

[An arterial compression syndrome due to the ligamentum arcuatum mediale of the diaphragm] Rietzler B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):76–8 (8 ref.) **(Ger)**

INJURIES

Scar formation and ligament healing. Hildebrand KA, et al. **Can J Surg** 1998 Dec;41(6):425–9 (16 ref.)

Cytokines and the role they play in the healing of ligaments and tendons. Evans CH. **Sports Med** 1999 Aug;28(2):71–6 (43 ref.)

PATHOLOGY

An unusual presentation of congenital infantile myofibromatosis arising from the interspinous ligament. Kubota A, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):138–9 (14 ref.)

[A case of internal hernia through a defect in the falciform ligament treated with laparoscopic surgery] Kobayashi S, et al. **Nippon Geka Gakkai Zasshi** 1999 Aug;100(8):513–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Fibrocartilage in tendons and ligaments--an adaptation to compressive load. Benjamin M, et al. **J Anat** 1998 Nov;193 (Pt 4):481–94 (100 ref.)

TRANSPLANTATION

Use of allografts in knee reconstruction: II. Surgical considerations. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):169–75 (29 ref.)

Use of allografts in knee reconstruction: I. Basic science aspects and current status. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):165–8 (15 ref.)

ULTRASONOGRAPHY

Spinal ligament pathology. Gillis C. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):97–101 (20 ref.)

LIGAMENTS, ARTICULAR

INJURIES

The multiple ligament injured knee. Cole BJ, et al. **Clin Sports Med** 1999 Jan;18(1):241–62 (46 ref.)

The ankle joint: imaging strategies in the evaluation of ligamentous injuries. Long D, et al. **Crit Rev Diagn Imaging** 1998 Dec;39(6):393–445 (65 ref.)

Molecular biology and biomechanics of normal and healing ligaments--a review. Frank CB, et al. **Osteoarthritis Cartilage** 1999 Jan;7(1):130–40 (65 ref.)

Magnetic resonance imaging in the evaluation of ligament injuries. Farooki S, et al. **Skeletal Radiol** 1999 Feb; 28(2):61–74 (107 ref.)

Treatment of acute lateral ankle ligament rupture in the athlete. Conservative versus surgical treatment. Lynch SA, et al. **Sports Med** 1999 Jan;27(1):61–71 (98 ref.)

Intra-articular ligaments: degradation is predictable but healing is not [editorial; comment] McIlwraith CW. **Vet J** 1999 Jan;157(1):1–3 (15 ref.) Comment on: Vet J 1999 Jan;157(1):23–9.

[Knee ligament injuries. Anatomy, biomechanics, diagnosis, indications] Lobenhoffer P. **Chirurg** 1999 Feb;70(2):219–30 (14 ref.) **(Ger)**

[Diagnosis and therapy of ligament injuries of the ankle joint] Weigel B, et al. **Chirurg** 1998 Sep;69(9):994–1010 (16 ref.) **(Ger)**

[13-MHc high frequency ultrasound of the lateral ligaments of the ankle joint and the anterior tibia-fibular ligament. Comparison and results of MRI in 64 patients] Milz P, et al. **Radiologe** 1999 Jan;39(1):34–40 (25 ref.) (Eng. Abstr.) **(Ger)**

[Ligament injuries of the ankle--what happens later? Non-surgical treatment is effective in 80–90 per cent of cases] Karlsson J. **Lakartidningen** 1998 Sep 30; 95(40):4376–8 (20 ref.) (Eng. Abstr.) **(Swe)**

PATHOLOGY

Magnetic resonance imaging in the evaluation of ligament injuries. Farooki S, et al. **Skeletal Radiol** 1999 Feb; 28(2):61–74 (107 ref.)

PHYSIOLOGY

Biomechanics of knee ligaments. Woo SL, et al. **Am J Sports Med** 1999 Jul–Aug;27(4):533–43 (70 ref.)

RADIOGRAPHY

Acute neck pain and fever as the first manifestation of chondrocalcinosis with calcification of the transverse ligament of the atlas. Five case-reports with a literature review. Constantin A, et al. **Rev Rhum Engl Ed** 1998 Oct; 65(10):583–5 (16 ref.)

SURGERY

Ossification of transverse ligament of the atlas associated with atlanto-axial dislocation--case report. Hayashi T, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):425–8 (18 ref.)

Treatment of acute lateral ankle ligament rupture in the athlete. Conservative versus surgical treatment. Lynch SA, et al. **Sports Med** 1999 Jan;27(1):61–71 (98 ref.)

LIGAMENTUM FLAVUM

Spinal cord compression caused by unusual location and extension of ossified ligamenta flava in a Caucasian male. A case report and literature review. van Oostenbrugge RJ, et al. **Spine** 1999 Mar 1;24(5):486–8 (21 ref.)

PATHOLOGY

Pathology of ossification of the posterior longitudinal ligament and ligamentum flavum. Ono K, et al. **Clin Orthop** 1999 Feb;(359):18–26 (27 ref.)

LIGAMENTUM LATERALE ARTICULATIONIS TALOCRURALIS see **LATERAL LIGAMENT, ANKLE**

LIGAMENTUM LONGITUDINALE see **LONGITUDINAL LIGAMENTS**

LIGAMENTUM PATELLAE see **PATELLAR LIGAMENT**

LIGANDINS see **GLUTATHIONE TRANSFERASE**

LIGANDS

see related
RADIOLIGAND ASSAY
RECEPTORS, CELL SURFACE

Dietary lipids: ancestral ligands and regulators of cell signaling pathways [editorial; comment] Zaloga GP. **Crit Care Med** 1999 Aug;27(8):1646–8 (10 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1409–20.

DR (MHC class II) ligands: an approach to rheumatoid arthritis therapeutics. Hanson GJ. **Curr Pharm Des** 1998 Oct;4(5):397–402 (57 ref.)

Allogeneic hepatocyte transplantation: contribution of Fas-Fas ligand interaction to allogeneic hepatocyte rejection. Kawahara T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S119–23 (55 ref.)

Overview of ligand-receptor binding techniques. Qume M. **Methods Mol Biol** 1999;106:3–23 (20 ref.)

The use of ligand binding in assays of NMDA receptor function. Reynolds IJ, et al. **Methods Mol Biol** 1999; 128:93–102 (25 ref.)

Borrowing to make ends meet [comment] Clardy J. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1826–7 (11 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1953–8.

[Structure and function of a novel ErbB ligand, NTAK] Ishiguro H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):137–42 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The ways of designing new-generation medicinal and biochemical agents by using ligand-receptor interactions for active membrane transport] Iurkevich AM, et al. **Vestn Ross Akad Med Nauk** 1999;(3):3–7 (14 ref.) (Eng. Abstr.) **(Rus)**

LIGASES

The ligation systems for ubiquitin and ubiquitin-like proteins. Tanaka K, et al. **Mol Cells** 1998 Oct 31;8(5):503–12 (65 ref.)

CHEMISTRY

Cyclases of the 3'-terminal phosphate in RNA: a new family of RNA processing enzymes conserved in eucarya, bacteria and archaea. Filipowicz W, et al. **Acta Biochim Pol** 1998; 45(4):895–906 (30 ref.)

Swinging arms in multifunctional enzymes and the specificity of post-translational modification. Perham RN, et al. **Biochem Soc Trans** 1998 Aug;26(3):299–303 (47 ref.)

METABOLISM

Cyclases of the 3'-terminal phosphate in RNA: a new family of RNA processing enzymes conserved in eucarya, bacteria and archaea. Filipowicz W, et al. **Acta Biochim Pol** 1998; 45(4):895–906 (30 ref.)

Swinging arms in multifunctional enzymes and the specificity of post-translational modification. Perham RN, et al. **Biochem Soc Trans** 1998 Aug;26(3):299–303 (47 ref.)

SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. Peters JM. **Curr Opin Cell Biol** 1998 Dec; 10(6):759–68 (97 ref.)

Subunits and substrates of the anaphase-promoting complex. Peters JM. **Exp Cell Res** 1999 May 1;248(2):339–49 (102 ref.)

A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Maniatis T. **Genes Dev** 1999 Mar 1;13(5):505–10 (38 ref.)

Ubiquitin system: selectivity and timing of protein destruction. Yamao F. **J Biochem (Tokyo)** 1999 Feb; 125(2):223–9 (48 ref.)

Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions. Harvey KF, et al. **Trends Cell Biol** 1999 May;9(5):166–9 (34 ref.)

[New classes of ribozymes isolated by in vitro selection. RNA ligases] Zhenodarova SM, et al. **Mol Biol (Mosk)** 1998 Nov-Dec;32(6):948–54 (23 ref.) **(Rus)**

PHYSIOLOGY

Cyclases of the 3'-terminal phosphate in RNA: a new family of RNA processing enzymes conserved in eucarya, bacteria and archaea. Filipowicz W, et al. **Acta Biochim Pol** 1998; 45(4):895–906 (30 ref.)

Whose end is destruction: cell division and the anaphase-promoting complex. Zachariae W, et al. **Genes Dev** 1999 Aug 15;13(16):2039–58 (165 ref.)

LIGATION, TUBAL see **STERILIZATION, TUBAL**

LIGHT

see related
LIGHTING
LUMINESCENCE
PHOTIC STIMULATION
PHOTOBIOLOGY
PHOTOCHEMISTRY
PHOTOCHEMOTHERAPY
PHOTOSENSITIVITY DISORDERS
PHOTOSYNTHESIS
PHOTOTHERAPY
SUNLIGHT
ULTRAVIOLET THERAPY

The photodynamic and non-photodynamic actions of porphyrins. Afonso SG, et al. **Braz J Med Biol Res** 1999 Mar;32(3):255–66 (56 ref.)

Generation and entrainment of circadian rhythms. Kennaway DJ. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):862–5 (32 ref.)

Light-activated proteins. Curley K, et al. **Curr Opin Chem Biol** 1999 Feb;3(1):84–8 (19 ref.)

Primary and secondary mechanisms of action of visible to near-IR radiation on cells. Karu T. **J Photochem Photobiol B** 1999 Mar;49(1):1–17 (151 ref.)

The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature. Brainard GC, et al. **J Pineal Res** 1999 Mar;26(2):65–100 (210 ref.)

Protein kinase C and IP3 in photoresponses of functionally intact rod outer segments: constraints about their role. Jindrová H, et al. **Physiol Res** 1998;47(4):285–90 (39 ref.)

Signalling in light-controlled development [see comments] Deng XW, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):121–9 (71 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.

[Photo-activatable caged peptides and proteins] Tatsu Y, et al. **Seikagaku** 1999 Mar;71(3):197–201 (15 ref.) **(Jpn)**

[Role of calcium ions in photoreceptor light-adaptation] Kawamura S. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1806–13 (53 ref.) **(Jpn)**

[Adaptation of thylakoid membranes to environmental light conditions] Romanowska E. **Postepy Biochem** 1999; 45(1):58–65 (75 ref.) **(Pol)**

ADVERSE EFFECTS

Light exposure is not associated with retinopathy of prematurity. Mills MD. **Arch Ophthalmol** 1998 Nov; 116(11):1517–8 (18 ref.)

Retinal phototoxicity. Solley WA, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):1–12 (55 ref.)

Effects of premature exposure to light: a credibility struggle. Silverman WA. **Paediatr Perinat Epidemiol** 1999 Apr; 13(2):128–30 (12 ref.)

DIAGNOSTIC USE

Is light-induced fluorescence better than the endoscopist's eye? Marcon NE. **Can J Gastroenterol** 1999 Jun; 13(5):417–21 (14 ref.)

LIGHT ADAPTATION see **ADAPTATION, OCULAR**

LIGHT COAGULATION

Treatment of diabetic retinopathy. Ferris FL 3rd, et al. **N Engl J Med** 1999 Aug 26;341(9):667–78 (128 ref.)

LIGHT, LUMINESCENT see **LUMINESCENCE**

LIGHT METALS see **METALS, LIGHT**

LIGHT SIGNAL TRANSDUCTION see **PHOTOTRANSDUCTION**

LIGHT, VISIBLE see **LIGHT**

LIGHTING

ADVERSE EFFECTS

[The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythematosus] Aharon-Maor A, et al. **Harefuah** 1998 Oct;135(7–8):295–9 (38 ref.) **(Heb)**

LIGHTING

METHODS

Reduce risk of inducing spatial disorientation using physiologically compatible ground lighting. Schmidt RT. **Aviat Space Environ Med** 1999 Jun;70(6):598–603 (22 ref.)

LIGHTNING INJURIES

[ELectro-trauma by lightning through the telephone (letter)] Santonja JM, et al. **Rev Neurol** 1998 Dec;27(160):1073 (11 ref.) **(Spa)**

LIGHTNING STROKE see **LIGHTNING INJURIES**

LIGNAC-FANCONI SYNDROME see **FANCONI SYNDROME**

LIGNANS

PHARMACOLOGY

Antiviral activity of lignans. Charlton JL. **J Nat Prod** 1998 Nov;61(11):1447–51 (27 ref.)

THERAPEUTIC USE

Experimental studies on lignans and cancer. Thompson LU. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):691–705 (64 ref.)

LIGNIN

BIOSYNTHESIS

A 20(th) century roller coaster ride: a short account of lignification. Lewis NG. **Curr Opin Plant Biol** 1999 Apr; 2(2):153–62 (55 ref.)

Unexpected variation in lignin. Sederoff RR, et al. **Curr Opin Plant Biol** 1999 Apr;2(2):145–52 (75 ref.)

LIGNOCAINE see **LIDOCAINE**

LIKELIHOOD FUNCTIONS

Stature estimation and calibration: Bayesian and maximum likelihood perspectives in physical anthropology. Konigsberg LW, et al. **Am J Phys Anthropol** 1998;Suppl 27:65–92 (95 ref.)

Review of inference procedures for the interclass correlation coefficient with emphasis on applications to family studies. Donner A, et al. **Genet Epidemiol** 1998;15(6):627–46 (47 ref.)

Maximum likelihood analysis of generalized linear models with missing covariates. Horton NJ, et al. **Stat Methods Med Res** 1999 Mar;8(1):37–50 (41 ref.)

LILIACEAE

[Antitumor activity of natural substances: lectins and saffron] Abdullaev FI, et al. **Arch Latinoam Nutr** 1997 Sep; 47(3):195–202 (62 ref.) (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Micropropagation of flower bulbs. Lily and narcissus. Langens-Gerrits MM, et al. **Methods Mol Biol** 1999; 111:141–7 (17 ref.)

LILY see **LILIACEAE**

LIMB BUD

CYTOLOGY

Pattern formation in dissociated limb bud mesenchyme in vitro and in vivo. Ide H, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):398–402 (12 ref.)

EMBRYOLOGY

Shaping limbs by apoptosis. Chen Y, et al. **J Exp Zool** 1998 Dec 15;282(6):691–702 (119 ref.)

The molecular ZPA. Pearse RV 2nd, et al. **J Exp Zool** 1998 Dec 15;282(6):677–90 (117 ref.)

Morphogen gradients in vertebrate limb development. Tickle C. **Semin Cell Dev Biol** 1999 Jun;10(3):345–51 (46 ref.)

[Signaling molecules involved in induction and early patterning of limb buds] Kawakami Y, et al. **Kaibogaku Zasshi** 1998 Dec;73(6):655–66 (97 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Dorsoventral patterning of the vertebrate limb: a process governed by multiple events. Chen H, et al. **Cell Tissue Res** 1999 Apr;296(1):67–73 (49 ref.)

The recombinant limb as a model for the study of limb patterning, and its application to muscle development. Fernandez-Teran M, et al. **Cell Tissue Res** 1999 Apr; 296(1):121–9 (58 ref.)

TRANSPLANTATION

Grafting of apical ridge and polarizing region. Tickle C. **Methods Mol Biol** 1999;97:281–91 (33 ref.)

LIMB DEFORMITIES, CONGENITAL

Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Xu X, et al. **Cell Tissue Res** 1999 Apr;296(1):33–43 (102 ref.)

CHEMICALLY INDUCED

Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Genest DR, et al. **Clin Dysmorphol** 1999 Jan;8(1):53–8 (24 ref.)

GENETICS

Acromelic frontonasal dysostosis. Slaney SF, et al. **Am J Med Genet** 1999 Mar 12;83(2):109–16 (30 ref.)

Formin defines a large family of morphoregulatory genes and functions in establishment of the polarising region. Zeller R, et al. **Cell Tissue Res** 1999 Apr;296(1):85–93 (56 ref.)

Reconstructing the history of human limb development: lessons from birth defects. Bamshad M, et al. **Pediatr Res** 1999 Mar;45(3):291–9 (79 ref.)

PATHOLOGY

Bilaterally cleft lip, limb defects, and haematological manifestations: Roberts syndrome versus TAR syndrome. Urban M, et al. **Am J Med Genet** 1998 Sep 23;79(3):155–60 (30 ref.)

PHYSIOPATHOLOGY

Mandibular malformations: growth characteristics and management in hemifacial microsomia and Nager syndrome. Vargervik K. **Acta Odontol Scand** 1998 Dec; 56(6):331–8 (42 ref.)

Fibroblast-growth-factor-induced additional limbs in the study of initiation of limb formation, limb identity, myogenesis, and innervation. Ohuchi H, et al. **Cell Tissue Res** 1999 Apr;296(1):45–56 (79 ref.)

From head to toe: conservation of molecular signals regulating limb and craniofacial morphogenesis. Schneider RA, et al. **Cell Tissue Res** 1999 Apr;296(1):103–9 (36 ref.)

LIMB PROSTHESIS see **ARTIFICIAL LIMBS**

LIMBIC SYSTEM

Psychoneuroendocrine aspects of temporolimbic epilepsy. Part I. Brain, reproductive steroids, and emotions. Herzog AG. **Psychosomatics** 1999 Mar–Apr;40(2):95–101 (82 ref.)

DRUG EFFECTS

Neuropsychological effects of vasopressin in healthy humans. Born J, et al. **Prog Brain Res** 1998;119:619–43 (126 ref.)

METABOLISM

Sensitivity to ageing of the limbic dopaminergic system: a review. Barili P, et al. **Mech Ageing Dev** 1998 Dec 1; 106(1–2):57–92 (248 ref.)

PHYSIOLOGY

Mesolimbic neuronal activity across behavioral states. Woodward DJ, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:91–112 (58 ref.)

Temporal characterization of subcortical nuclei in mnemonic processes: results of tetrodotoxin reversible inactivation studies in the rat. Ambrogi Lorenzini CG, et al. **Arch Ital Biol** 1998 Nov;136(4):279–96 (82 ref.)

Efferent connections of the anteromedial nucleus of the thalamus of the rat. van Groen T, et al. **Brain Res Brain Res Rev** 1999 Jul;30(1):1–26 (200 ref.)

Role of the mesolimbic dopamine system in cardiovascular homeostasis. Stimulation of the ventral tegmental area modulates the effect of vasopressin on blood pressure in conscious rats. van den Buuse M. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):661–8 (74 ref.)

Gonadal steroid-dependent neuronal circuitries in avian limbic and preoptic regions. Panzica GC, et al. **Eur J Morphol** 1999 Apr;37(2–3):112–6 (21 ref.)

The role of TRH and related peptides in the mechanism of action of ECT. Sattin A. **J ECT** 1999 Mar;15(1):76–92 (103 ref.)

Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Millan MJ, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):61S–67S (37 ref.)

Neuropsychological effects of vasopressin in healthy humans. Born J, et al. **Prog Brain Res** 1998;119:619–43 (126 ref.)

A peptidergic basis for sexual behavior in mammals. Smock T, et al. **Prog Brain Res** 1998;119:467–81 (113 ref.)

Electrophysiological effects of oxytocin within the bed nuclei of the stria terminalis: influence of reproductive stage and ovarian steroids. Wakerley JB, et al. **Prog Brain Res** 1998; 119:321–34 (57 ref.)

Stress and the developing limbic-hypothalamic-pituitary-adrenal axis. Vázquez DM. **Psychoneuroendocrinology** 1998 Oct;23(7):663–700 (110 ref.)

Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation. Ebert D, et al. **Psychopharmacology (Berl)** 1998 Nov;140(1):1–10 (98 ref.)

[The functional asymmetry of the limbic structures of the brain] Simonov PV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan–Feb; 49(1):22–7 (34 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Role of the limbic system in dependence on drugs. Rodríguez de Fonseca F, et al. **Ann Med** 1998 Aug;30(4):397–405 (87 ref.)

Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies. Epstein J, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:562–74 (97 ref.)

Environmental influences on neural plasticity, the limbic system, emotional development and attachment: a review. Joseph R. **Child Psychiatry Hum Dev** 1999 Spring; 29(3):189–208 (97 ref.)

Chronic epileptogenic cellular alterations in the limbic system after status epilepticus. Coulter DA. **Epilepsia** 1999;40 Suppl 1:S23–33; discussion S40–1 (82 ref.)

Human memory, cerebral hemispheres, and the limbic system: a new approach. Rotenberg VS, et al. **Genet Soc Gen Psychol Monogr** 1999 Feb;125(1):45–70 (100 ref.)

Negative symptoms in schizophrenia: neurobiological models and treatment response. Goff DC, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):59–77 (208 ref.)

Multiple chemical sensitivity: a test of the olfactory-limbic model. Brown-DeGagne AM, et al. **J Occup Environ Med** 1999 May;41(5):366–77 (71 ref.)

Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Moberg PJ, et al. **Neuropsychopharmacology** 1999 Sep;21(3):325–40 (90 ref.)

Interictal-ictal interactions and limbic seizure generation. Avoli M, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):468–71 (17 ref.)

Neuropeptide Y and limbic seizures. Baraban SC. **Rev Neurosci** 1998;9(2):117–28 (94 ref.)

[Limbic ictus as a condition for anxiety attacks] Gallinat J, et al. **Nervenarzt** 1999 Mar;70(3):206–15 (83 ref.) (Eng. Abstr.) **(Ger)**

LIMBS see **EXTREMITIES**

LIMBS, ARTIFICIAL see **ARTIFICIAL LIMBS**

LIMBUS CORNEAE

Keratolimbal allograft: recommendations for tissue procurement and preparation by eye banks, and standard surgical technique. Croasdale CR, et al. **Cornea** 1999 Jan; 18(1):52–8 (9 ref.)

CYTOLOGY

Limbal stem-cell transplantation. Akpek EK, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):71–82 (67 ref.)

LIMITATION OF ACTIVITY, CHRONIC see **ACTIVITIES OF DAILY LIVING**

LIMULUS see **HORSESHOE CRABS**

LINAC RADIOSURGERY see **RADIOSURGERY**

LINEAR ACCELERATOR RADIOSURGERY see **RADIOSURGERY**

LINEAR ACCELERATORS see **PARTICLE ACCELERATORS**

LINEAR MODELS

Usefulness and limitations of linear approximations to the understanding of Ca++ signals [published erratum appears in Cell Calcium 1999 Mar;25(3):275] Neher E. **Cell Calcium** 1998 Nov-Dec;24(5–6):345–57 (76 ref.)

Misuse of correlation and regression in three medical journals. Porter AM. **J R Soc Med** 1999 Mar;92(3):123–8 (39 ref.)

The mechanistic basis of the linear-quadratic formalism [letter] Sachs RK, et al. **Med Phys** 1998 Oct;25(10):2071–3 (30 ref.)

Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Koch GG, et al. **Stat Med** 1998 Aug 15–30;17(15–16):1863–92 (46 ref.)

Counts and times to events. Lindsey JK. **Stat Med** 1998 Aug 15–30;17(15–16):1745–51 (7 ref.)

Tutorial in biostatistics. An introduction to hierarchical linear modelling. Sullivan LM, et al. **Stat Med** 1999 Apr 15; 18(7):855–88 (16 ref.)

Maximum likelihood analysis of generalized linear models with missing covariates. Horton NJ, et al. **Stat Methods Med Res** 1999 Mar;8(1):37–50 (41 ref.)

LINEAR REGRESSION see **LINEAR MODELS**

LINENS see **BEDDING AND LINENS**

LINGUAL BONE see **HYOID BONE**

LINGUAL NERVE

INJURIES

Wisdom tooth removal and lingual nerve damage [editorial] McGurk M, et al. **Br J Oral Maxillofac Surg** 1999 Aug; 37(4):253–4 (22 ref.)

Anesthesia of the inferior alveolar and lingual nerves as a complication of a fractured condylar process. Griffiths H, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):77–9 (22 ref.)

LINGUISTICS

Evolution of linguistic diversity in a simple communication system. Arita T, et al. **Artif Life** 1998 Winter;4(1):109–24 (18 ref.)

Linguistic complexity: locality of syntactic dependencies. Gibson E. **Cognition** 1998 Aug;68(1):1–76 (180 ref.)

Is grammar special? Bloom P. **Curr Biol** 1999 Feb 25; 9(4):R127–8 (12 ref.)

LINITIS PLASTICA

SECONDARY

EUS and EUS-guided fine-needle aspiration for the diagnosis of rectal linitis plastica secondary to prostate carcinoma. Bhutani MS. **Gastrointest Endosc** 1999 Jul; 50(1):117–9 (13 ref.)

LINKAGE (GENETICS)

Clinical-genetic spectrum of primary dystonia. Bressman SB, et al. **Adv Neurol** 1998;78:79–91 (43 ref.)

Dopamine cell death by a single genetic mechanism: phenotypic analysis and linkage study of autosomal recessive juvenile parkinsonism. Matsumine H, et al. **Adv Neurol** 1999;80:187–94 (25 ref.)

Lethal multiple pterygium syndrome in four male fetuses in a family: evidence for an X-linked recessive subtype? [letter] Meyer-Cohen J, et al. **Am J Med Genet** 1999 Jan 1;82(1):97–9 (11 ref.)

Genetic linkage analysis. Pulst SM. **Arch Neurol** 1999 Jun; 56(6):667–72 (16 ref.)

New insights into the pathogenesis of inherited phosphate wasting disorders. Econs MJ. **Bone** 1999 Jul;25(1):131–5 (59 ref.)

The molecular genetics of X-linked lymphoproliferative (Duncan's) disease. Sumegi J, et al. **Cancer J Sci Am** 1999 Mar-Apr;5(2):57–62 (33 ref.)

Chromosome 3-linked frontotemporal dementia. Brown J. **Cell Mol Life Sci** 1998 Sep;54(9):925–7 (11 ref.)

Chromosome 17-linked dementias. Wilhelmsen KC. **Cell Mol Life Sci** 1998 Sep;54(9):920–4 (22 ref.)

New genetic concepts and stroke prevention. Auburger G. **Cerebrovasc Dis** 1998;8 Suppl 5:28–32 (50 ref.)

Genetics of complex human diseases: genome screening, association studies and fine mapping. Xu J, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:1–5; discussion 26–8 (20 ref.)

Sequence variation: looking for effects of genetic linkage. Charlesworth D, et al. **Curr Biol** 1998 Sep 10;8(18):R658–61 (15 ref.)

The abnormal gene in X-linked lymphoproliferative syndrome. Sullivan JL. **Curr Opin Immunol** 1999 Aug; 11(4):431–4 (16 ref.)

Genetic recombination in plants. Schnable PS, et al. **Curr Opin Plant Biol** 1998 Apr;1(2):123–9 (69 ref.)

Modifier genes in humans: strategies for identification. Houlston RS, et al. **Eur J Hum Genet** 1998 Jan;6(1):80–8 (42 ref.)

Advances in carrier detection in haemophilia. Goodeve AC. **Haemophilia** 1998 Jul;4(4):358–64 (44 ref.)

Affected sib-pair methods for detecting linkage to dichotomous traits: review of the methodology. Holmans P. **Hum Biol** 1998 Dec;70(6):1025–40 (75 ref.)

Recent advances in the diagnosis of X-linked agammaglobulinemia [editorial; comment] Nonoyama S. **Intern Med** 1999 Sep;38(9):687–8 (6 ref.) Comment on: Intern Med 1999 Sep;38(9):722–5.

Progress and pitfalls: bipolar molecular linkage studies. Berrettini W. **J Affect Disord** 1998 Sep;50(2–3):287–97 (102 ref.)

Genetics of childhood disorders: IV. Linkage analysis. Pauls D. **J Am Acad Child Adolesc Psychiatry** 1999 Jul; 38(7):932–4 (6 ref.)

A comparative approach to physical and linkage mapping of genes on canine chromosomes using gene-associated simple sequence repeat polymorphisms illustrated by studies of dog chromosome 9. Werner P, et al. **J Hered** 1999 Jan-Feb;90(1):39–42 (21 ref.)

On the front of X-linked adrenoleukodystrophy. Aubourg P. **Neurochem Res** 1999 Apr;24(4):515–20 (46 ref.)

X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Smith KD, et al. **Neurochem Res** 1999 Apr; 24(4):521–35 (76 ref.)

Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Funakoshi M, et al. **Neuromuscul Disord** 1999 Mar;9(2):108–14 (55 ref.)

The use of ultrasonography and linkage studies for early diagnosis of autosomal dominant polycystic kidney disease (ADPKD). Papadopoulou D, et al. **Ren Fail** 1999 Jan; 21(1):67–84 (67 ref.)

DNA chips: promising toys have become powerful tools. Gerhold D, et al. **Trends Biochem Sci** 1999 May; 24(5):168–73 (28 ref.)

The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Dubois-Dalcq M, et al. **Trends Neurosci** 1999 Jan;22(1):4–12 (73 ref.)

A gene hunting we will go! [editorial] Gingrich JR, et al. **Urol Res** 1998;26(6):361–9 (31 ref.)

[X-linked recessive myotubular myopathy with a splice-site mutation in the myotubularin gene] Watanabe T, et al. **No To Hattatsu** 1998 Nov;30(6):523–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Amyloid goiter as the beginning symptom of amyloidosis in a patient with sex-linked agammaglobulinemia (letter)] López J, et al. **Rev Clin Esp** 1999 Jul;199(7):481 (4 ref.) **(Spa)**

GENETICS

Candidate-gene association studies of schizophrenia. O'Donovan MC, et al. **Am J Hum Genet** 1999 Sep; 65(3):587–92 (37 ref.)

Genetic studies of alcoholism and substance dependence. Reich T, et al. **Am J Hum Genet** 1999 Sep;65(3):599–605 (45 ref.)

Linkage and association. Elston RC. **Genet Epidemiol** 1998; 15(6):565–76 (66 ref.)

Central deafness in a young child with Moyamoya disease: paternal linkage in a Caucasian family: two case reports and a review of the literature. Setzen G, et al. **Int J Pediatr Otorhinolaryngol** 1999 Apr 25;48(1):53–76 (115 ref.)

X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)-MIM 302060 [editorial; comment] Barth PG, et al. **J Pediatr** 1999 Sep;135(3):273–6 (19 ref.) Comment on: J Pediatr 1999 Sep;135(3):311–5.

X-linked recessive spondyloepiphyseal dysplasia tarda. Clinical and radiographic evolution in a 6-generation kindred and review of the literature. Whyte MP, et al. **Medicine (Baltimore)** 1999 Jan;78(1):9–25 (60 ref.)

X-linked hypophosphataemia: a homologous disorder in humans and mice. Tenenhouse HS. **Nephrol Dial Transplant** 1999 Feb;14(2):333–41 (88 ref.)

LINKAGE DISEQUILIBRIUM

Linkage disequilibrium mapping of complex disease: fantasy or reality? Terwilliger JD, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):578–94 (156 ref.)

Genetic susceptibility factors in type 1 diabetes: linkage, disequilibrium and functional analyses. She JX, et al. **Curr Opin Immunol** 1998 Dec;10(6):682–9 (64 ref.)

[Linkage disequilibrium between the Machado-Joseph disease and intragenic polymorphisms] Ichikawa Y. **Nippon Rinsho** 1999 Apr;57(4):832–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases I. DNA pooling. Risch N, et al. **Genome Res** 1998 Dec;8(12):1273–88 (23 ref.)

Mapping genes through the use of linkage disequilibrium generated by genetic drift: 'drift mapping' in small populations with no demographic expansion. Terwilliger JD, et al. **Hum Hered** 1998 May-Jun;48(3):138–54 (62 ref.)

LINKAGE MAPPING see **CHROMOSOME MAPPING**

LINKER-INSERTION MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

LINOLEATE see **LINOLEIC ACID**

LINOLEIC ACID

Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. Parodi PW. **J Dairy Sci** 1999 Jun; 82(6):1339–49 (98 ref.)

METABOLISM

Linoleic acid peroxidation--the dominant lipid peroxidation process in low density lipoprotein--and its relationship to chronic diseases. Spiteller G. **Chem Phys Lipids** 1998 Oct; 95(2):105–62 (518 ref.)

The role of linoleic acid in endothelial cell gene expression. Relationship to atherosclerosis. Toborek M, et al. **Subcell Biochem** 1998;30:415–36 (93 ref.)

LINOLEIC ACIDS

ADVERSE EFFECTS

Leukotoxins and the lung. Ishizaki T, et al. **Pulm Pharmacol Ther** 1999;12(3):145–55 (49 ref.)

PHYSIOLOGY

Biogenesis and biological function of marine algal oxylipins. Gerwick WH, et al. **Adv Exp Med Biol** 1999;447:211–8 (20 ref.)

Phytooxylipins and plant defense reactions. Blée E. **Prog Lipid Res** 1998 May;37(1):33–72 (361 ref.)

LIOTHYRONINE see **TRIIODOTHYRONINE**

LIP

Anatomy of the platysma and lip depressor muscles. A simplified mnemonic approach. Hoefflin SM. **Dermatol Surg** 1998 Nov;24(11):1225–31 (17 ref.)

ANATOMY & HISTOLOGY

The flow rate and composition of human labial gland saliva. Ferguson DB. **Arch Oral Biol** 1999 May;44 Suppl 1:S11–4 (30 ref.)

Ion transport and signalling in human labial glands. Turner RJ, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S15–9 (35 ref.)

INNERVATION

Transcranial cortical magnetic stimulation of lower-lip mimetic muscles: effect of coil position on motor evoked potentials. Rödel R, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 May-Jun; 61(3):119–25 (26 ref.)

PHYSIOLOGY

The cerebellum, LTD, and memory: alternative views. Llinás R, et al. **Learn Mem** 1997 Mar-Apr;3(6):445–55 (41 ref.)

SURGERY

[Increasing the length of the columella. Concepts and techniques] Schauss F. **HNO** 1999 Jul;47(7):663–73 (23 ref.) **(Ger)**

LIP DISEASES

PATHOLOGY

[Hyperpigmented spots on the lips, oral mucosa, fingers and nails] Paricio Rubio JF, et al. **Rev Clin Esp** 1998 Nov; 198(11):769–70 (13 ref.) **(Spa)**

LIP NEOPLASMS

DIAGNOSIS

Trichofolliculoma of the upper lip: report of a case. Mizutani H, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):135–6 (10 ref.)

PATHOLOGY

Primary adenoid squamous cell carcinoma of the upper lip associated with a locoregional metastasis: a case report and review of the literature. Blackburn TK, et al. **J Oral Maxillofac Surg** 1999 May;57(5):612–6 (12 ref.)

Infiltrating angiolipoma of the mucolabial fold: a case report and review of the literature. Sugiura J, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):446–8 (9 ref.)

Multiple canalicular adenomas: a case report and review of the literature. Rousseau A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):346–50 (26 ref.)

LIPASE

ADMINISTRATION & DOSAGE

[Pancreatic lipase drug delivery with glyceride-containing prodrugs] Scriba GK. **Pharm Unserer Zeit** 1999 Mar; 28(2):87–94 (23 ref.) **(Ger)**

ANALYSIS

Detection and measurement of microbial lipase activity: a review. Thomson CA, et al. **Crit Rev Food Sci Nutr** 1999 Mar;39(2):165–87 (96 ref.)

Determining lipoprotein lipase and hepatic lipase activity using radiolabeled substrates. Briquet-Laugier V, et al. **Methods Mol Biol** 1999;109:81–94 (17 ref.)

Triglyceride lipase assays based on a novel fluorogenic alkyldiacyl glycerol substrate. Hermetter A. **Methods Mol Biol** 1999;109:19–29 (19 ref.)

Assays for pancreatic triglyceride lipase and colipase. Lowe ME. **Methods Mol Biol** 1999;109:59–70 (31 ref.)

In vitro measurement of lipoprotein and hepatic lipases. Vilella E, et al. **Methods Mol Biol** 1998;110:243–51 (11 ref.)

ANTAGONISTS & INHIBITORS

New aspects in the management of obesity: operation and the impact of lipase inhibitors. Uusitupa M. **Curr Opin Lipidol** 1999 Feb;10(1):3–7 (25 ref.)

BIOSYNTHESIS

Modulation of the expression level of human acidic lipases by various signal peptides. Canaan S, et al. **Methods Mol Biol** 1999;109:203–13 (17 ref.)

BLOOD

Amylase normal, lipase elevated: is it pancreatitis? A case

LIPASE

series and review of the literature. Frank B, et al. **Am J Gastroenterol** 1999 Feb;94(2):463–9 (27 ref.)
[The patient with isolated pancreatic enzyme elevation] Spangenberg HC. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1575–8 (13 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Structural basis for the substrate selectivity of pancreatic lipases and some related proteins. Carrière F, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):417–32 (47 ref.)
Determining lipase subunit structure by sucrose gradient centrifugation. Ben-Zeev O, et al. **Methods Mol Biol** 1999; 109:257–66 (32 ref.)

DEFICIENCY

Hepatic lipase deficiency. Connelly PW, et al. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):547–72 (62 ref.)

GENETICS

Hepatic lipase deficiency. Connelly PW, et al. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):547–72 (62 ref.)
Hepatic lipase. Fan J, et al. **J Atheroscler Thromb** 1998; 5(1):41–5 (29 ref.)
An introduction to Internet resources for the molecular and genetic analysis of the lipases. Reue K. **Methods Mol Biol** 1999;109:309–28 (16 ref.)
Induced lipase mutations in the mouse. Semenkovich CF. **Methods Mol Biol** 1999;109:343–55 (21 ref.)

IMMUNOLOGY

Immunological characterization of digestive lipases. De Caro A, et al. **Methods Mol Biol** 1999;109:239–56 (29 ref.)

ISOLATION & PURIFICATION

Purification of rat hepatic lipase essentially free of apolipoprotein E and apolipoprotein B. Bensadoun A, et al. **Methods Mol Biol** 1999;109:151–6 (17 ref.)
One-step purification and biochemical characterization of recombinant pancreatic lipases expressed in insect cells. Bezzine S, et al. **Methods Mol Biol** 1999;109:187–202 (27 ref.)
Purification of lipases and phospholipases by heparin-sepharose chromatography. Farooqui AA, et al. **Methods Mol Biol** 1999;109:133–43 (40 ref.)
High-level expression and purification of human hepatic lipase from mammalian cells. Hill JS. **Methods Mol Biol** 1999;109:157–63 (20 ref.)

METABOLISM

A toolbox of recombinant lipases for industrial applications. Schmidt-Dannert C, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:14–22 (27 ref.)
The realm of microbial lipases in biotechnology. Pandey A, et al. **Biotechnol Appl Biochem** 1999 Apr;29 (Pt 2):119–31 (212 ref.)
The role of hepatic lipase in lipoprotein metabolism. Connelly PW. **Clin Chim Acta** 1999 Aug;286(1–2):243–55 (27 ref.)
Hepatic lipase: new insights from genetic and metabolic studies. Cohen JC, et al. **Curr Opin Lipidol** 1999 Jun; 10(3):259–67 (63 ref.)
Hepatic lipase. Fan J, et al. **J Atheroscler Thromb** 1998; 5(1):41–5 (29 ref.)
Monolayer techniques for studying lipase kinetics. Ransac S, et al. **Methods Mol Biol** 1999;109:279–302 (69 ref.)
"Mixed" triglyceride breath test: methodological problems and clinical applications. Perri F, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):99–103 (15 ref.)
Candida rugosa lipases: molecular biology and versatility in biotechnology. Benjamin S, et al. **Yeast** 1998 Sep 15; 14(12):1069–87 (147 ref.)

SECRETION

Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. Layer P, et al. **J Clin Gastroenterol** 1999 Jan;28(1):3–10 (80 ref.)

LIPECTOMY

Wetting solutions in ultrasound-assisted lipoplasty. Fodor PB, et al. **Clin Plast Surg** 1999 Apr;26(2):289–93; ix (27 ref.)
Analysis and introduction of a technology: Ultrasound-assisted Lipoplasty Task Force. Fredricks S. **Clin Plast Surg** 1999 Apr;26(2):187–204; vii (5 ref.)
Comparing ultrasound-assisted lipoplasty with suction-assisted lipoplasty. Gingrass MK, et al. **Clin Plast Surg** 1999 Apr;26(2):283–8; ix (2 ref.)
Patient selection, planning, and marking in ultrasound-assisted lipoplasty. Hughes CE 3rd. **Clin Plast Surg** 1999 Apr;26(2):279–82; ix (0 ref.)
Ultrasound-assisted lipoplasty. Basic science and clinical research. Kenkel JM, et al. **Clin Plast Surg** 1999 Apr; 26(2):221–34; vii (35 ref.)
Staff education and training for ultrasound-assisted lipoplasty. Mustoe TA. **Clin Plast Surg** 1999 Apr; 26(2):295–8; ix (3 ref.)
Positioning for ultrasound-assisted lipoplasty. Nahai F. **Clin Plast Surg** 1999 Apr;26(2):235–43 (2 ref.)
Patient evaluation and indications for ultrasound-assisted lipoplasty. Rohrich RJ, et al. **Clin Plast Surg** 1999 Apr; 26(2):269–78; viii (11 ref.)
Operative principles for optimizing results in circumferential body contouring with ultrasound-assisted lipoplasty. Rohrich RJ, et al. **Clin Plast Surg** 1999 Apr;26(2):305–16; x (12 ref.)
Basic physics for ultrasound-assisted lipoplasty. Zocchi ML. **Clin Plast Surg** 1999 Apr;26(2):209–20; vii (0 ref.)

INSTRUMENTATION

A comparison of various ultrasound technologies. Chang CC, et al. **Clin Plast Surg** 1999 Apr;26(2):261–8; viii (5 ref.)
The solid-probe technique in ultrasound-assisted lipoplasty. Grotting JC, et al. **Clin Plast Surg** 1999 Apr;26(2):245–54; viii (9 ref.)
Use of hollow cannula technology in ultrasound-assisted lipoplasty. Maxwell GP. **Clin Plast Surg** 1999 Apr; 26(2):255–60; viii (7 ref.)
Equipment and instrumentation for ultrasound-assisted lipoplasty. Thornton LK, et al. **Clin Plast Surg** 1999 Apr; 26(2):299–304; x (7 ref.)
[Body contouring by removal of skin and fatty tissue] Erni D, et al. **Ther Umsch** 1999 Apr;56(4):206–11 (3 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Liposculpture with ultrasound: biomedical considerations. Bruno G, et al. **Aesthetic Plast Surg** 1998 Nov-Dec; 22(6):401–3 (20 ref.)
Ultrasonic assisted liposuction. Kanter WR, et al. **Md Med J** 1999 Jul-Aug;48(4):165–8 (18 ref.)
Advanced techniques in liposuction. Johnson DS, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):139–48 (26 ref.)
[Liposuction] Bloemenkamp DG, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1946–50 (26 ref.) (Eng. Abstr.) **(Dut)**

STANDARDS

Safety issues in ultrasound-assisted large-volume lipoplasty. Gilliland MD, et al. **Clin Plast Surg** 1999 Apr;26(2):317–35; x (86 ref.)

LIPEMIA-CLEARING FACTOR see **LIPOPROTEIN LIPASE**

LIPID A

Lipid A diversity and the innate host response to bacterial infection. Darveau RP. **Curr Opin Microbiol** 1998 Feb; 1(1):36–42 (63 ref.)

ANALOGS & DERIVATIVES

Pharmacologic enhancement of tolerance to ischemic cardiac stress using monophosphoryl lipid A. A comparison with antecedent ischemia. Zhao L, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:222–35 (65 ref.)

LIPID BILAYERS

see related
LIPOSOMES

Reconstitution of native and cloned channels into planar bilayers. Favre I, et al. **Methods Enzymol** 1999;294:287–304 (82 ref.)
Use of planar lipid bilayer membranes for rapid screening of membrane active compounds. Mirzabekov TA, et al. **Methods Enzymol** 1999;294:661–74 (22 ref.)
Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Hooper NM. **Mol Membr Biol** 1999 Apr-Jun;16(2):145–56 (115 ref.)
Peptide-lipid interactions and mechanisms of antimicrobial peptides. Huang HW. **Novartis Found Symp** 1999; 225:188–200; discussion 200–6 (32 ref.)

CHEMISTRY

Polyelectrolyte-induced domains in lipid bilayer membranes: the deuterium NMR perspective. Macdonald PM, et al. **Biochem Cell Biol** 1998;76(2–3):452–64 (56 ref.)
MARCKS, membranes, and calmodulin: kinetics of their interaction. Arbuzova A, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):369–79 (81 ref.)
Hydrophobic interactions of peptides with membrane interfaces. White SH, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):339–52 (75 ref.)
Hydrophobically driven attachments of synthetic polymers onto surfaces of biological interest: lipid bilayers and globular proteins. Tribet C. **Biochimie** 1998 May-Jun; 80(5–6):461–73 (65 ref.)
Localization and mobility of coenzyme Q in lipid bilayers and membranes. Lenaz G, et al. **Biofactors** 1999; 9(2–4):87–93 (21 ref.)
Investigation of phase transitions in bilayer membranes. Mason JT. **Methods Enzymol** 1998;295:468–94 (21 ref.)
A new look at lipid-membrane structure in relation to drug research. Mouritsen OG, et al. **Pharm Res** 1998 Oct; 15(10):1507–19 (131 ref.)

METABOLISM

Lipid translocation across the plasma membrane of mammalian cells. Bevers EM, et al. **Biochim Biophys Acta** 1999 Aug 18;1439(3):317–30 (113 ref.)
Interactions of alpha-helices with lipid bilayers: a review of simulation studies. Biggin PC, et al. **Biophys Chem** 1999 Feb 22;76(3):161–83 (152 ref.)
Fluorescence measurement of lipid-binding affinity and interbilayer transfer of bimane-labeled lipidated peptides. Silvius JR. **Methods Mol Biol** 1999;116:177–86 (13 ref.)
Determination of the kinetics of intervesicle transfer and transbilayer diffusion of bimane-labeled lipidated peptides. Silvius JR. **Methods Mol Biol** 1999;116:187–91 (2 ref.)
Measurement of Ca2+ flux through Ins(1,4,5)P3 receptor-Ca2+ channels in lipid bilayers ("dip-tip" and "Schindler" methodology). Thrower EC. **Methods Mol Biol** 1999;114:221–33 (19 ref.)

LIPID EMULSIONS, INTRAVENOUS see **FAT EMULSIONS, INTRAVENOUS**

LIPID METABOLISM, INBORN ERRORS

Clinical and biochemical features of fatty acid oxidation disorders. Rinaldo P, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):615–21 (48 ref.)
[Jordans' anomaly] Asano Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):86–7 (10 ref.) **(Jpn)**

COMPLICATIONS

[Lipid disorders in children with insulin-dependent diabetes mellitus] Bogalho P. **Acta Med Port** 1998 Jul;11(7):683–90 (28 ref.) (Eng. Abstr.) **(Por)**
[Lipidic myopathies] Muñoz-Blanco JL. **Rev Neurol** 1998 Apr;26 Suppl 1:S72–80 (91 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Sudden and unexpected neonatal death: a protocol for the postmortem diagnosis of fatty acid oxidation disorders. Rinaldo P, et al. **Semin Perinatol** 1999 Apr;23(2):204–10 (52 ref.)

ENZYMOLOGY

Disorders of mitochondrial fatty acyl-CoA beta-oxidation. Wanders RJ, et al. **J Inherit Metab Dis** 1999 Jun; 22(4):442–87 (176 ref.)

EPIDEMIOLOGY

Neonatal onset in fatty acid oxidation disorders: how can we minimize morbidity and mortality? Riudor E. **J Inherit Metab Dis** 1998 Aug;21(6):619–23 (19 ref.)

ETIOLOGY

Signaling molecules derived from the cholesterol biosynthetic pathway: mechanisms of action and possible roles in human disease [published erratum appears in Curr Opin Lipidol 1999 Feb;10(1):following 83] Edwards PA, et al. **Curr Opin Lipidol** 1998 Oct;9(5):433–40 (85 ref.)

GENETICS

[Lipidic myopathies] Muñoz-Blanco JL. **Rev Neurol** 1998 Apr;26 Suppl 1:S72–80 (91 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Inherited disorders of fatty alcohol metabolism. Rizzo WB. **Mol Genet Metab** 1998 Oct;65(2):63–73 (99 ref.)

MORTALITY

Neonatal onset in fatty acid oxidation disorders: how can we minimize morbidity and mortality? Riudor E. **J Inherit Metab Dis** 1998 Aug;21(6):619–23 (19 ref.)

PHYSIOPATHOLOGY

Recognition and management of fatty acid oxidation defects: a series of 107 patients. Saudubray JM, et al. **J Inherit Metab Dis** 1999 Jun;22(4):488–502 (59 ref.)

THERAPY

Recognition and management of fatty acid oxidation defects: a series of 107 patients. Saudubray JM, et al. **J Inherit Metab Dis** 1999 Jun;22(4):488–502 (59 ref.)

LIPID PEROXIDATION

Iron, atherosclerosis, and ischemic heart disease. de Valk B, et al. **Arch Intern Med** 1999 Jul 26;159(14):1542–8 (121 ref.)
Nitric oxide and lipid peroxidation. Hogg N, et al. **Biochim Biophys Acta** 1999 May 5;1411(2–3):378–84 (48 ref.)
Linoleic acid peroxidation--the dominant lipid peroxidation process in low density lipoprotein--and its relationship to chronic diseases. Spiteller G. **Chem Phys Lipids** 1998 Oct; 95(2):105–62 (518 ref.)
Nitric oxide and its role in lipid peroxidation. Violi F, et al. **Diabetes Metab Res Rev** 1999 Jul-Aug;15(4):283–8 (30 ref.)
The isoprostanes: unique prostaglandin-like products of

free-radical-initiated lipid peroxidation. Morrow JD, et al. **Drug Metab Rev** 1999 Feb;31(1):117-39 (67 ref.)
Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Upston JM, et al. **FASEB J** 1999 Jun; 13(9):977-94 (151 ref.)
Determinants of intestinal detoxication of lipid hydroperoxides. Aw TY. **Free Radic Res** 1998 Jun; 28(6):637-46 (52 ref.)
Lipid peroxidation and biogenic aldehydes: from the identification of 4-hydroxynonenal to further achievements in biopathology. Comporti M. **Free Radic Res** 1998 Jun; 28(6):623-35 (68 ref.)
4-Hydroxynonenal and cell signalling. Dianzani MU. **Free Radic Res** 1998 Jun;28(6):553-60 (53 ref.)
Glutathione S-transferases and prevention of cellular free radical damage. Ketterer B. **Free Radic Res** 1998 Jun; 28(6):647-58 (70 ref.)
Measurement of lipid peroxidation. Moore K, et al. **Free Radic Res** 1998 Jun;28(6):659-71 (671 ref.)
Lipid peroxidation in the reperfusion injury of the liver. Poli G, et al. **Free Radic Res** 1998 Jun;28(6):547-51 (15 ref.)
Lipid peroxidation and tissue damage. Mylonas C, et al. **In Vivo** 1999 May-Jun;13(3):295-309 (56 ref.)
Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. Lawson JA, et al. **J Biol Chem** 1999 Aug 27;274(35):24441-4 (69 ref.)
Biologically active oxidized phospholipids. McIntyre TM, et al. **J Biol Chem** 1999 Sep 3;274(36):25189-92 (86 ref.)
The isoprostanes: unique bioactive products of lipid peroxidation. An overview. Liu TZ, et al. **J Biomed Sci** 1998 Nov-Dec;5(6):415-20 (27 ref.)
Lipid peroxidation and atherosclerosis in type II diabetes. Oranje WA, et al. **J Lab Clin Med** 1999 Jul;134(1):19-32 (183 ref.)
The role of tocopherols in biomembrane lipid peroxidation. Burlakova EB, et al. **Membr Cell Biol** 1998;12(2):173-211 (204 ref.)
Free-radical and cyclooxygenase-catalyzed lipid peroxidation in membranes of blood cells under UV irradiation. Roshchupkin DI, et al. **Membr Cell Biol** 1998; 12(2):279-86 (14 ref.)
Involvement of metal ions in lipid peroxidation: biological implications. Sergent O, et al. **Met Ions Biol Syst** 1999; 36:251-87 (188 ref.)
Lipid peroxidation-DNA damage by malondialdehyde. Marnett LJ. **Mutat Res** 1999 Mar 8;424(1-2):83-95 (48 ref.)
Etheno DNA-base adducts from endogenous reactive species. Nair J, et al. **Mutat Res** 1999 Mar 8;424(1-2):59-69 (57 ref.)
Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Halliwell B. **Nutr Rev** 1999 Apr;57(4):104-13 (90 ref.)
The role of carotenoids in modulating DNA stability and lipid peroxidation. Importance for human health. Duthie SJ, et al. **Subcell Biochem** 1998;30:181-207 (87 ref.)
[Evaluation of lipid peroxidation by measuring thiobarbituric acid reactive substances] Lefèvre G, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):305-19 (90 ref.) (Eng. Abstr.) **(Fre)**
[Lipid peroxidation induced by hemoproteins in terms of forensic medicine] Iwase H. **Nippon Hoigaku Zasshi** 1998 Oct;52(5):306-10 (34 ref.) **(Jpn)**
[Oxidized lipoproteins and diseases] Itabe H. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1247-52 (27 ref.) **(Jpn)**
[Importance of free radicals during the reproduction cycle] Durán Reyes G, et al. **Ginecol Obstet Mex** 1998 Sep; 66:371-6 (26 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation. Goss SP, et al. **Methods Enzymol** 1999;301:444-53 (27 ref.)
Alcohol, free radicals and antioxidants. Puddey IB, et al. **Novartis Found Symp** 1998;216:51-62; discussion 63-7, 152-8 (56 ref.)
Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes. Moreno AJ, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II63-77 (100 ref.)
The molecular action of alpha-tocopherol in lipoprotein lipid peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions. Witting PK, et al. **Subcell Biochem** 1998;30:345-90 (145 ref.)
[The drug correction of functional disorders of blood coagulation and lipid peroxidation in patients with infectious myocarditis] Doroshenko BH. **Lik Sprava** 1998 Dec;(8):3-6 (44 ref.) (Eng. Abstr.) **(Ukr)**

GENETICS

Genotoxic lipid peroxidation products: their DNA damaging properties and role in formation of endogenous DNA adducts. Burcham PC. **Mutagenesis** 1998 May; 13(3):287-305 (215 ref.)
[Replicative senescence as a model of aging: the role of oxidative stress and telomere shortening--an overview] Saretzki G, et al. **Z Gerontol Geriatr** 1999 Apr;32(2):69-75 (84 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Oxidative injury in the nervous system. Delanty N, et al. **Acta Neurol Scand** 1998 Sep;98(3):145-53 (90 ref.)
The lag phase. Cadenas E, et al. **Free Radic Res** 1998 Jun; 28(6):601-9 (42 ref.)
Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Keller JN, et al. **Rev Neurosci** 1998;9(2):105-16 (100 ref.)
Oxygen radicals, antioxidants, and lipid peroxidation. Santanam N, et al. **Semin Reprod Endocrinol** 1998; 16(4):275-80 (51 ref.)
[Serum antioxidative activity] Klebanov GI, et al. **Vestn Ross Akad Med Nauk** 1999;(2):15-22 (46 ref.) (Eng. Abstr.) **(Rus)**
[Physical activity and arteriosclerosis. The effects of physical activity on lipid oxidation, hemostasis and endothelial function] Codina O, et al. **Med Clin (Barc)** 1999 Apr 17; 112(13):508-15 (133 ref.) **(Spa)**

LIPID PEROXIDES

[Recent progress of oxidized lipid] Nakagawa Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1234-5 (6 ref.) **(Jpn)**

ANALYSIS

Usual and unusual methods for detection of lipid peroxides as indicators of tissue injury in cerebral ischemia: what is appropriate and useful? Watson BD. **Cell Mol Neurobiol** 1998 Dec;18(6):581-98 (68 ref.)

BIOSYNTHESIS

Lipid hydroperoxide generation, turnover, and effector action in biological systems. Girotti AW. **J Lipid Res** 1998 Aug;39(8):1529-42 (127 ref.)
[Mechanism for the production of lipid peroxides] Yamamoto Y, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1253-8 (14 ref.) **(Jpn)**

BLOOD

Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Ursini F, et al. **Free Radic Biol Med** 1998 Jul 15;25(2):250-2 (15 ref.)

METABOLISM

Lipid peroxides in the free radical pathophysiology of brain diseases. Farooqui AA, et al. **Cell Mol Neurobiol** 1998 Dec; 18(6):599-608 (68 ref.)
[Lipid peroxide and antioxidants in the elderly] Tokunaga K, et al. **Rinsho Byori** 1998 Aug;46(8):783-9 (35 ref.) (Eng. Abstr.) **(Jpn)**

LIPIDOSIS see **LIPOIDOSIS**

LIPIDS

see related

FATS

[Atherosclerosis and lipids: overview] Yamada N. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1259-60 (0 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Prospective comparative study of different amino acid and lipid solutions in parenteral nutrition of patients undergoing bone marrow transplantation] Jiménez Jiménez FJ, et al. **Nutr Hosp** 1999 Mar-Apr;14(2):57-66 (47 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the carotid artery. Grønholdt ML. **Arterioscler Thromb Vasc Biol** 1999 Jan;19(1):2-13 (145 ref.)
Nutritional and biochemical properties of human milk: II. Lipids, micronutrients, and bioactive factors. Rodriguez-Palmero M, et al. **Clin Perinatol** 1999 Jun; 26(2):335-59 (132 ref.)
Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. Parodi PW. **J Dairy Sci** 1999 Jun; 82(6):1339-49 (98 ref.)
Analysis of lipids in caveolae. Liu J, et al. **Methods Mol Biol** 1999;116:61-72 (35 ref.)
Analysis of the lipid moiety of GPI anchor in the yeast Saccharomyces cerevisiae. Reggiori F, et al. **Methods Mol Biol** 1999;116:91-105 (22 ref.)

BIOSYNTHESIS

De novo lipogenesis in humans: metabolic and regulatory aspects. Hellerstein MK. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S53-65 (83 ref.)
Eukaryotic lipid-biosynthetic enzymes: the same but not the same. Vance JE. **Trends Biochem Sci** 1998 Nov; 23(11):423-8 (39 ref.)
Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Daum G, et al. **Yeast** 1998 Dec;14(16):1471-510 (310 ref.)

BLOOD

Lipid metabolism, physical activity, and postmenopausal hormone therapy. Wenger NK. **Am J Kidney Dis** 1998 Nov; 32(5 Suppl 3):S80-8 (28 ref.)
Evaluating serum alpha-tocopherol (vitamin E) in terms of a lipid ratio. Winbauer AN, et al. **Ann Clin Lab Sci** 1999 Jul-Sep;29(3):185-91 (16 ref.)
Nutrition in early life: somatic growth and serum lipids. Boulton TJ, et al. **Ann Med** 1999 Apr;31 Suppl 1:7-12 (46 ref.)
Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Krause BR, et al. **Atherosclerosis** 1998 Sep;140(1):15-24 (108 ref.)
Effects of probiotics and prebiotics on blood lipids. Taylor GR, et al. **Br J Nutr** 1998 Oct;80(4):S225-30 (35 ref.)
Lipids and vascular disease: what we do and do not know. Sniderman AD, et al. **Clin Chim Acta** 1999 Aug; 286(1-2):7-22 (65 ref.)
Effect of beta-glucan from oats and yeast on serum lipids. Bell S, et al. **Crit Rev Food Sci Nutr** 1999 Mar;39(2):189-202 (33 ref.)
Metabolic risk factors for coronary heart disease: current and future prospects. Wilson PW. **Curr Opin Cardiol** 1999 Mar; 14(2):176-85 (124 ref.)
Genes, variation of cholesterol and fat intake and serum lipids. Ordovas JM, et al. **Curr Opin Lipidol** 1999 Feb; 10(1):15-22 (33 ref.)
Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities. Steiner G. **Diabetes Care** 1999 Apr;22 Suppl 3:C6-9 (46 ref.)
Physical activity, obesity and blood lipids. Hardman AE. **Int J Obes Relat Metab Disord** 1999 Apr;23 Suppl 3:S64-71 (84 ref.)
Lipid-lowering therapy for the primary prevention of coronary heart disease. Gotto AM Jr. **J Am Coll Cardiol** 1999 Jun;33(7):2078-82 (33 ref.)
Role of circulating lipid abnormalities in chronic renal allograft rejection. Kasiske BL. **Kidney Int Suppl** 1999 Jul; 71:S28-30 (19 ref.)
The role of lipids in transplant vascular disease. McDonald PC, et al. **Lab Invest** 1998 Oct;78(10):1187-201 (125 ref.)
Tibolone and the serum lipid/lipoprotein profile: does this have a role in cardiovascular protection in postmenopausal women? [editorial; comment] Ginsburg J, et al. **Menopause** 1999 Summer;6(2):87-9 (34 ref.) Comment on: Menopause 1999 Summer;6(2):92-97. Comment on: Menopause 1999 Summer;6(2):98-104.
The importance of timing and accurate interpretation of the benefits of weight reduction on plasma lipids [editorial; comment] Eckel RH. **Obes Res** 1999 Mar;7(2):227-8 (19 ref.) Comment on: Obes Res 1999 Mar;7(2):170-8.
Exercise and lipid abnormalities. Daniels SR. **Pediatr Cardiol** 1999 Jan-Feb;20(1):71-7; discussion 78 (49 ref.)
The genetics of serum lipid responsiveness to dietary interventions. Ordovas JM. **Proc Nutr Soc** 1999 Feb; 58(1):171-87 (186 ref.)
Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. Rubenfire M, et al. **Prog Cardiovasc Dis** 1998 Sep-Oct; 41(2):95-116 (145 ref.)
Alcohol and lipids. Baraona E, et al. **Recent Dev Alcohol** 1998;14:97-134 (339 ref.)
Serum lipid physiology and the influence of glaucoma medications. Stewart WC, et al. **Surv Ophthalmol** 1998 Nov-Dec;43(3):233-44 (134 ref.)
[Lipid metabolic disorders in obesity: their epidemiology, physiopathology and clinico-therapeutic implications] Campanini M, et al. **Ann Ital Med Int** 1997 Oct-Dec; 12(4):223-9 (42 ref.) (Eng. Abstr.) **(Ita)**
[Lipid metabolism and atherosclerosis risk in renal diseases in pediatric age] Ferrara P, et al. **Minerva Pediatr** 1998 Dec;50(12):513-8 (35 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Food processing and lipid oxidation. German JB. **Adv Exp Med Biol** 1999;459:23-50 (58 ref.)
Relevance of the protein-lipid interaction on the functioning of the bacterial reaction center. Agostiano A, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:215-9 (10 ref.)
Surface-active lipids in rhodococci. Lang S, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):59-70 (70 ref.)
Liposomes in gene therapy. Structural polymorphism of lipids and effectiveness of gene delivery. Tarahovsky YS, et al. **Biochemistry (Mosc)** 1998 Jun;63(6):607-18 (124 ref.)
Self-evolving microstructured systems upon enzymatic catalysis [published erratum appears in Biochimie 1998 Jul;80(7):634] Chopineau J, et al. **Biochimie** 1998 May-Jun; 80(5-6):421-35 (106 ref.)
Lipid modification strategies in the production of nutritionally functional fats and oils. Willis WM, et al. **Crit Rev Food Sci Nutr** 1998 Nov;38(8):639-74 (142 ref.)
Application of lipids and plasmid design for gene delivery to mammalian cells. Scherman D, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):480-5 (59 ref.)
Protein crystallization on lipid layers and structure determination of the RNA polymerase II transcription initiation complex. Asturias FJ, et al. **J Biol Chem** 1999 Mar 12;274(11):6813-6 (29 ref.)

LIPIDS

Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. Marjukka Suhonen T, et al. **J Controlled Release** 1999 May 20; 59(2):149–61 (106 ref.)

Looking at lipid rafts? [see comments] Jacobson K, et al. **Trends Cell Biol** 1999 Mar;9(3):87–91 (34 ref.) Comment in: Trends Cell Biol 1999 Jun;9(6):212–3.

GENETICS

Genetic engineering of plant lipids. Broun P, et al. **Annu Rev Nutr** 1999;19:197–216 (105 ref.)

[The genetic contribution to coronary disease. The genetic factors related to lipid metabolism] da Silva PM. **Rev Port Cardiol** 1999 Jul–Aug;18(7–8):735–47 (64 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Porcelli SA, et al. **Annu Rev Immunol** 1999;17:297–329 (160 ref.)

Mechanisms of lipid antigen presentation by CD1. Jackman RM, et al. **Crit Rev Immunol** 1999;19(1):49–63 (66 ref.)

Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Hong S, et al. **Immunol Rev** 1999 Jun;169:31–44 (122 ref.)

Presentation of bacterial lipid antigens by CD1 molecules. Prigozy TI, et al. **Trends Microbiol** 1998 Nov;6(11):454–9 (25 ref.)

METABOLISM

Bioactive lipids and gene expression in neuronal plasticity. Bazan NG. **Adv Exp Med Biol** 1998;446:37–49 (70 ref.)

Insulin sensitivity, muscle fibre types, and membrane lipids. Helge JW, et al. **Adv Exp Med Biol** 1998;441:129–38 (56 ref.)

The LDL-receptor family. Lactoferrin and lipid metabolism. Huettinger M, et al. **Adv Exp Med Biol** 1998;443:107–11 (20 ref.)

Training induced changes in the fatty acid composition of skeletal muscle lipids. Functional aspects. Vessby B, et al. **Adv Exp Med Biol** 1998;441:139–45 (29 ref.)

Cardioprotective effects of postmenopausal hormone treatment. Espeland MA. **Am J Cardiol** 1998 Nov 19; 82(10A):37S–39S (13 ref.)

Insulin resistance and lipid metabolism. Howard BV. **Am J Cardiol** 1999 Jul 8;84(1A):28J–32J (25 ref.)

Abnormalities of membrane function and lipid metabolism in hypertension: a review. Zicha J, et al. **Am J Hypertens** 1999 Mar;12(3):315–31 (217 ref.)

Amyloid and lipids in the pathology of Alzheimer disease. Roher AE, et al. **Amyloid** 1999 Jun;6(2):136–45 (130 ref.)

Role of lipoprotein lipases in postprandial lipid metabolism. Jansen H, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S31–4 (40 ref.)

Postprandial lipid metabolism in diabetes. Mero N, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S53–5 (22 ref.)

Postprandial lipaemia and haemostatic factors. Miller GJ. **Atherosclerosis** 1998 Dec;141 Suppl 1:S47–51 (30 ref.)

Estrogens and postprandial lipid metabolism. Westerveld HE. **Atherosclerosis** 1998 Dec;141 Suppl 1:S105–7 (25 ref.)

Dietary interventions affecting chylomicron and chylomicron remnant clearance. Williams CM. **Atherosclerosis** 1998 Dec; 141 Suppl 1:S87–92 (42 ref.)

Nutritional support of infants and children: supply and metabolism of lipids. Koletzko B, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):671–96 (93 ref.)

CTP:phosphocholine cytidylyltransferase: insights into regulatory mechanisms and novel functions. Clement JM, et al. **Biochem Biophys Res Commun** 1999 Apr 21; 257(3):643–50 (100 ref.)

Mechanisms and functional features of polarized membrane traffic in epithelial and hepatic cells. Zegers MMP, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):257–69 (179 ref.)

Modelling lipid metabolism in plants: a slippery problem? Harwood JL, et al. **Biochem Soc Trans** 1999 Feb; 27(2):285–9 (20 ref.)

Lipid translocation across the plasma membrane of mammalian cells. Bevers EM, et al. **Biochim Biophys Acta** 1999 Aug 18;1439(3):317–30 (113 ref.)

The contribution of lipids and lipid metabolism to cellular functions of the Golgi complex. Fang M, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):85–100 (97 ref.)

Self-evolving microstructured systems upon enzymatic catalysis [published erratum appears in Biochimie 1998 Jul;80(7):634] Chopineau J, et al. **Biochimie** 1998 May–Jun; 80(5–6):421–35 (106 ref.)

Inflammation, antichymotrypsin, and lipid metabolism: autogenic etiology of Alzheimer's disease. Janciauskiene S, et al. **Bioessays** 1998 Dec;20(12):1039–46 (50 ref.)

Mechanism of action of fibrates on lipid and lipoprotein metabolism. Staels B, et al. **Circulation** 1998 Nov 10; 98(19):2088–93 (78 ref.)

Vesicle transport: klarsicht clears up the matter. Jäckle H, et al. **Curr Biol** 1998 Jul 16;8(15):R542–4 (14 ref.)

Lipid/vascular wall interaction. Allen S. **Curr Opin Cardiol** 1998 Nov;13(6):439–46 (71 ref.)

Hepatocellular transport and secretion of biliary lipids. Cohen DE. **Curr Opin Lipidol** 1999 Aug;10(4):295–302 (73 ref.)

New insights into plaque stabilisation by lipid lowering. Libby P, et al. **Drugs** 1998;56 Suppl 1:9–13; discussion 33 (32 ref.)

Lipids: regulatory functions in membrane traffic and cell development. Kfar Blum Kibbutz Guest House, Galilee, Israel, May 10–15, 1998. Futerman AH, et al. **EMBO J** 1998 Dec 1;17(23):6772–5 (15 ref.)

De novo lipogenesis in humans: metabolic and regulatory aspects. Hellerstein MK. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S53–65 (83 ref.)

Adaptation of maternal lipid flux to pregnancy: research needs. Neville MC. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S120–3 (16 ref.)

Lipid signaling and cell responses at the nuclear level. Neri LM, et al. **Histol Histopathol** 1999 Jan;14(1):321–35 (157 ref.)

Fat metabolism during exercise: a review--part III: effects of nutritional interventions. Jeukendrup AE, et al. **Int J Sports Med** 1998 Aug;19(6):371–9 (97 ref.)

Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? Crook MA, et al. **Int J STD AIDS** 1999 Jun;10(6):353–6 (32 ref.)

The isoprostanes: unique bioactive products of lipid peroxidation. An overview. Liu TZ, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):415–20 (27 ref.)

Peroxisomes in lipid metabolism. Seedorf U. **J Cell Biochem Suppl** 1998;30–31:158–67 (65 ref.)

The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism [see comments] Willnow TE. **J Mol Med** 1999 Mar;77(3):306–15 (75 ref.) Comment in: J Mol Med 1999 Mar;77(3):303–4.

Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation. Rustaeus S, et al. **J Nutr** 1999 Feb;129(2S Suppl):463S–466S (22 ref.)

New insights into lipid metabolism in the nephrotic syndrome. Kaysen GA, et al. **Kidney Int Suppl** 1999 Jul; 71:S18–21 (27 ref.)

Metabolic labeling of protein-derived lipid thioesters in palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:213–9 (10 ref.)

Fatty acid analysis of protein-derived lipid thioesters isolated from palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:221–8 (4 ref.)

Determination of the kinetics of intervesicle transfer and transbilayer diffusion of bimane-labeled lipidated peptides. Silvius JR. **Methods Mol Biol** 1999;116:187–91 (2 ref.)

Fluorescence measurement of lipid-binding affinity and interbilayer transfer of bimane-labeled lipidated peptides. Silvius JR. **Methods Mol Biol** 1999;116:177–86 (13 ref.)

Lipid metabolism in peroxisomes in relation to human disease. Wanders RJ, et al. **Mol Aspects Med** 1998 Apr;19(2):69–154 (305 ref.)

Lipid-based systems for the intracellular delivery of genetic drugs. Maurer N, et al. **Mol Membr Biol** 1999 Jan–Mar; 16(1):129–40 (112 ref.)

Saposins and their interaction with lipids. Vaccaro AM, et al. **Neurochem Res** 1999 Feb;24(2):307–14 (55 ref.)

Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Vanier MT. **Neurochem Res** 1999 Apr;24(4):481–9 (59 ref.)

Alcohol intake, lipids and risks of myocardial infarction. Gaziano JM, et al. **Novartis Found Symp** 1998;216:86–95; discussion 95–110 (65 ref.)

Metabolic complications of HIV disease. Swindells S. **Nurse Pract** 1999 Feb;24(2):125–6, 129 (13 ref.)

Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Reiter RJ, et al. **Proc West Pharmacol Soc** 1998;41:229–36 (156 ref.)

Lipid trafficking in plant cells. Moreau P, et al. **Prog Lipid Res** 1998 Dec;37(6):371–91 (171 ref.)

Transport and transformations of yolk lipids during development of the avian embryo. Speake BK, et al. **Prog Lipid Res** 1998 May;37(1):1–32 (161 ref.)

Lipid metabolism during plant senescence. Thompson JE, et al. **Prog Lipid Res** 1998 Jul–Aug;37(2–3):119–41 (183 ref.)

Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Londos C, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):51–8 (41 ref.)

Inflammation, lipids, and free radicals: lessons learned from the atherogenic process. Rosenfeld ME. **Semin Reprod Endocrinol** 1998;16(4):249–61 (173 ref.)

Lipid metabolism during exercise. Ranallo RF, et al. **Sports Med** 1998 Jul;26(1):29–42 (36 ref.)

Progesterone induces meiotic division in the amphibian oocyte by releasing lipid second messengers from the plasma membrane. Morrill GA, et al. **Steroids** 1999 Jan–Feb;64(1–2):157–67 (45 ref.)

Antioxidant activity of vitamin A within lipid environments. Livrea MA, et al. **Subcell Biochem** 1998;30:113–43 (112 ref.)

Lipidic signaling and peroxisomal function. Masters C. **Subcell Biochem** 1998;30:437–52 (35 ref.)

Vimentin and lipid metabolism. Schweitzer SC, et al. **Subcell Biochem** 1998;31:437–62 (72 ref.)

Mechanisms of lipid-body formation. Murphy DJ, et al. **Trends Biochem Sci** 1999 Mar;24(3):109–15 (41 ref.)

Lipid regulators of membrane traffic through the Golgi complex. Roth MG. **Trends Cell Biol** 1999 May;9(5):174–9 (64 ref.)

[Genetic predisposition in multiple metabolic syndrome. Part 3. Metabolism of lipids, lipoproteins and apolipoproteins] Sobra J, et al. **Cas Lek Cesk** 1999 Mar 1;138(5):136–41 (37 ref.) (Eng. Abstr.) **(Cze)**

[Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes] Scheen AJ, et al. **Rev Med Liege** 1999 Jun;54(6):535–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[The effects of angiotensin II receptor antagonists on glucose, lipid, and uric acid metabolism in essential hypertensives] Takizawa H, et al. **Nippon Rinsho** 1999 May;57(5):1137–40 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Cell biological studies on intracellular trafficking of lipids] Nishijima M. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1157–8 (0 ref.) **(Jpn)**

[Peroxisomes and peroxisome proliferators. Specific environmental poisons and therapeutic agents affecting lipid metabolism and hormone release] Hammer TA, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3603–8 (66 ref.) (Eng. Abstr.) **(Nor)**

[Disturbances of lipid metabolism and fatty liver] Mach T. **Przegl Lek** 1999;56(3):205–10 (42 ref.) (Eng. Abstr.) **(Pol)**

[The role of estrogens in hormonal regulation of lipid metabolism in women] Szafran H, et al. **Przegl Lek** 1998; 55(5):266–70 (31 ref.) (Eng. Abstr.) **(Pol)**

[Changes in lipid metabolism with the use of alcohol deterrent preparations] Selevich MI, et al. **Eksp Klin Farmakol** 1999 Jan–Feb;62(1):70–4 (51 ref.) (Eng. Abstr.) **(Rus)**

[The role of crystalline lens lipids in the pathogenesis of age-related cataract] Iatsenko OV. **Lik Sprava** 1998 Jun; (4):50–3 (35 ref.) **(Rus)**

[Arterial hypertension and lipid metabolism] Cía Gómez P, et al. **An Med Interna** 1999 Jun;16(6):315–20 (61 ref.) (Eng. Abstr.) **(Spa)**

[Lipid metabolism and lipogenesis: application of stable isotopes] Martinez JA, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):91–8 (34 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Dietary lipids: more than just a source of calories [editorial] Calder PC, et al. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):105–7 (18 ref.)

Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Boger DL, et al. **Curr Pharm Des** 1998 Aug; 4(4):303–14 (81 ref.)

Bioactive lipids naturally occurring in bovine milk. Molkentin J. **Nahrung** 1999 Jun;43(3):185–9 (95 ref.)

[Gluco-lipotoxicity and gene expression in the pancreatic beta cell] Prentki M, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:17–27 (50 ref.) **(Fre)**

PHYSIOLOGY

Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function. Ohanian J, et al. **Acta Physiol Scand** 1998 Dec; 164(4):533–48 (138 ref.)

Effects of lipids and lipoproteins on thrombosis and rheology. Rosenson RS, et al. **Atherosclerosis** 1998 Oct;140(2):271–80 (135 ref.)

The contribution of lipids and lipid metabolism to cellular functions of the Golgi complex. Fang M, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):85–100 (97 ref.)

The role of lipids in pulmonary surfactant. Veldhuizen R, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):90–108 (80 ref.)

Lipid signaling in CD95-mediated apoptosis. Malisan F, et al. **FEBS Lett** 1999 Jun 4;452(1–2):100–3 (42 ref.)

Lipids in vascular function. Sellmayer A, et al. **Lipids** 1999; 34 Suppl:S13–8 (48 ref.)

Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. Dudler T, et al. **Methods Mol Biol** 1999;116:161–76 (19 ref.)

[Regulation of protein function by lipid modifications] Fukada Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1319–20 (0 ref.) **(Jpn)**

SECRETION

Hepatocellular transport and secretion of biliary lipids. Cohen DE. **Curr Opin Lipidol** 1999 Aug;10(4):295–302 (73 ref.)

The mechanism of biliary lipid secretion and its defects. Elferink RP, et al. **Gastroenterol Clin North Am** 1999 Mar; 28(1):59–74, vi (56 ref.)

Protein and lipid sorting from the trans-Golgi network to secretory granules-recent developments. Thiele C, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):511–6 (57 ref.)

THERAPEUTIC USE

Clinical use of lipid emulsions. Dupont IE, et al. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):139–45 (66 ref.)

Lipids in enteral nutrition. Redgrave TG. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):147–52 (56 ref.)

URINE

Lipiduria as seen by transmission electron microscopy. Blackburn V, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2682–4 (7 ref.)

LIPOCHONDRODYSTROPHY see **MUCOPOLYSACCHARIDOSIS I**

LIPOCORTIN I see **ANNEXIN I**

LIPOCORTIN II see **ANNEXIN II**

LIPOCORTIN V see **ANNEXIN V**

LIPOCORTINS see **ANNEXINS**

LIPODYSTROPHY

CHEMICALLY INDUCED

[Lipodystrophy--an adverse effect of protease inhibitors used against HIV infection? Concern about negative delayed effects of this break-through] Morfeldt L, et al. **Lakartidningen** 1998 Oct 14;95(42):4616-7 (16 ref.) **(Swe)**

DIAGNOSIS

Patient evaluation and indications for ultrasound-assisted lipoplasty. Rohrich RJ, et al. **Clin Plast Surg** 1999 Apr; 26(2):269-78; viii (11 ref.)

ETIOLOGY

Lipoatrophia semicircularis--a traumatic panniculitis: report of seven cases and review of the literature. Nagore E, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):879-81 (18 ref.)

IMMUNOLOGY

Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Levy Y, et al. **Immunol Res** 1998 Aug; 18(1):55-60 (45 ref.)

MICROBIOLOGY

[Tropheryma whippelii, an emerging intracellular pathogen causing Whipple disease] Drancourt M. **Presse Med** 1999 Feb 27;28(8):435-9, 433 (30 ref.) (Eng. Abstr.) **(Fre)**

LIPODYSTROPHY, INTESTINAL see **WHIPPLE'S DISEASE**

LIPOFUSCINOSIS, NEURONAL CEROID see **NEURONAL CEROID-LIPOFUSCINOSIS**

LIPOIC ACID see **THIOCTIC ACID**

LIPOIDOSIS

DIAGNOSIS

Erdheim-Chester disease: a case report and literature overview. Kenn W, et al. **Eur Radiol** 1999;9(1):153-8 (42 ref.)

LIPOIDPROTEINOSIS

DIAGNOSIS

Lipoid proteinosis of the oral mucosa: case report and review of the literature. Aroni K, et al. **Pathol Res Pract** 1998; 194(12):855-9 (15 ref.)

RADIOGRAPHY

[Urbach-Wiethe disease/lipoidproteinosis] Maia R, et al. **Acta Med Port** 1998 Dec;11(12):1113-5 (8 ref.) (Eng. Abstr.) **(Por)**

LIPOLYSIS

Mechanisms regulating adipocyte lipolysis. Carey GB. **Adv Exp Med Biol** 1998;441:157-70 (98 ref.)

Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Large V, et al. **Diabetes Metab** 1998 Nov;24(5):409-18 (91 ref.)

Catecholamine-induced lipolysis in obesity. Arner P. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:10-3 (18 ref.)

Monolayer techniques for studying lipase kinetics. Ransac S, et al. **Methods Mol Biol** 1999;109:279-302 (69 ref.)

DRUG EFFECTS

On the presence of a putative fourth beta-adrenoceptor in human adipose tissue [letter; comment] Galitzky J, et al. **Trends Pharmacol Sci** 1998 May;19(5):164-6 (16 ref.) Comment on: Trends Pharmacol Sci 1996 Oct;17(10):373-81.

GENETICS

Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul;19 Suppl H:H23-6 (13 ref.)

PHYSIOLOGY

Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Patsch J. **Eur Heart J** 1998 Jul;19 Suppl H:H2-6 (15 ref.)

LIPOLYSIS, SUCTION see **LIPECTOMY**

LIPOMA

Lipomas of the internal auditory canal and cerebellopontine angle. Bigelow DC, et al. **Laryngoscope** 1998 Oct; 108(10):1459-69 (52 ref.)

A case of Pai syndrome. Mishima K, et al. **Plast Reconstr Surg** 1999 Jan;103(1):166-70 (27 ref.)

DIAGNOSIS

Giant lipoma of the larynx: a case report and literature review. Yoskovitch A, et al. **Ear Nose Throat J** 1999 Feb; 78(2):122-5; quiz 126-8 (18 ref.)

Lipoma arborescens of the knee. Narváez J, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):351-3 (17 ref.)

[An intraosseous lipoma of the calcaneus] Schulz T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Mar;170(3):324-5 (0 ref.) **(Ger)**

[Lipoma of the adrenal gland. Case report and review of the literature] Guerreiro S, et al. **Urologe A** 1998 Sep; 37(5):526-9 (79 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Infiltrating lipoma of the head and neck: a report of one pediatric case. Lerosey Y, et al. **Int J Pediatr Otorhinolaryngol** 1999 Jan 25;47(1):91-5 (27 ref.)

[Lumbosacral intraspinal lipomas associated or not with a tethered cord syndrome (series of 8 cases)] Sakho Y, et al. **Dakar Med** 1998;43(1):13-20 (18 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The cytogenetic and molecular characterization of benign and malignant soft tissue tumors. Sreekantaiah C. **Cytogenet Cell Genet** 1998;82(1-2):13-29 (277 ref.)

PATHOLOGY

Lipoblastoma and liposarcoma in children: an analysis of 9 cases and a review of the literature. Miller GG, et al. **Can J Surg** 1998 Dec;41(6):455-8 (16 ref.)

Chondrolipoma of the breast: a case report and review of the literature. Greer J, et al. **Conn Med** 1999 Jun; 63(6):327-9 (6 ref.)

Aspiration cytology of a pleomorphic lipoma--a cautionary note. Verghese A, et al. **Cytopathology** 1999 Aug; 10(4):280-2 (4 ref.)

Spindle cell lipoma of the scalp: a case report and review. Haas AF, et al. **Dermatol Surg** 1999 Jan;25(1):68-71 (30 ref.)

Benign chondrolipomatous tumour of the breast. Güler G, et al. **Eur J Surg** 1999 Feb;165(2):164-6 (12 ref.)

Infiltrating angiolipoma of the mucolabial fold: a case report and review of the literature. Sugiura J, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):446-8 (9 ref.)

Congenital intraspinal lipomas: histological analysis of 234 cases and review of the literature. Lellouch-Tubiana A, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):346-52 (25 ref.)

[Visceral pleura lipoma: a previously undescribed localization and review of the literature on pleural lipomas] Naccarato AG, et al. **Pathologica** 1998 Jun;90(3):298-301 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Spindle cell lipoma of the scalp: a case report and review. Haas AF, et al. **Dermatol Surg** 1999 Jan;25(1):68-71 (30 ref.)

[A case of cardiac lipoma in the ventricular septum] Kato Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):1057-60 (13 ref.) (Eng. Abstr.) **(Jpn)**

LIPOMA, PLEOMORPHIC see **LIPOMA**

LIPOMATOSIS

[Pelvic lipomatosis] Prisco RM, et al. **Actas Urol Esp** 1998 Sep;22(8):717-20 (17 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Corticosteroid-induced epidural lipomatosis. Efficacy of medical treatment] Lemaire M, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):459-63 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Pelvic lipomatosis associated with proliferative cystitis: case report and review of the Japanese literature. Masumori N, et al. **Int J Urol** 1999 Jan;6(1):44-9 (23 ref.)

DIAGNOSIS

Diffuse lipomatosis of thyroid gland. Arslan A, et al. **Auris Nasus Larynx** 1999 Apr;26(2):213-5 (20 ref.)

Lipomatosis of the minor salivary glands. Saleh HA, et al. **J Laryngol Otol** 1998 Sep;112(9):895-7 (19 ref.)

[Lipomatous hypertrophy of the interatrial septum: its assessment with TEE, CT and MRI] Iacovoni A, et al. **G Ital Cardiol** 1998 Nov;28(11):1273-7 (18 ref.) (Eng. Abstr.) **(Ita)**

["Giant" gastric lipomas in asymptomatic adolescent] Gheza G, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):123-5 (8 ref.) **(Ita)**

PATHOLOGY

Symmetric lipomatosis of the tongue: report of a case and review of the literature. Calvo-García N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 May;87(5):610-2 (9 ref.)

RADIOGRAPHY

Mediastinal lipomatosis. Nguyên KQ, et al. **South Med J** 1998 Dec;91(12):1169-72 (31 ref.)

SURGERY

[Liposuction] Bloemenkamp DG, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1946-50 (26 ref.) (Eng. Abstr.) **(Dut)**

THERAPY

[Corticosteroid-induced epidural lipomatosis. Efficacy of medical treatment] Lemaire M, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):459-63 (20 ref.) (Eng. Abstr.) **(Fre)**

LIPOMATOSIS, MULTIPLE SYMMETRICAL

[Madelung's disease. Clinical case and review of the literature] Amicucci G, et al. **Minerva Chir** 1998 Jul-Aug; 53(7-8):655-7 (4 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Multiple symmetrical lipomatosis (MSL): a clinical case and a review of the literature] Lomartire N, et al. **Ann Ital Chir** 1999 Mar-Apr;70(2):259-62; discussion 262-3 (19 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Liposuction] Bloemenkamp DG, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1946-50 (26 ref.) (Eng. Abstr.) **(Dut)**

LIPOMATOSIS, NODULAR CIRCUMSCRIBED see **LIPOMATOSIS, MULTIPLE SYMMETRICAL**

LIPOPOLYSACCHARIDE RECEPTORS see **ANTIGENS, CD14**

LIPOPOLYSACCHARIDES

BIOSYNTHESIS

Carbohydrate determinants of Rhizobium-legume symbioses. Price NP. **Carbohydr Res** 1999 Apr 30;317(1-4):1-9 (89 ref.)

BLOOD

The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Beamer LJ, et al. **Biochem Pharmacol** 1999 Feb 1; 57(3):225-9 (34 ref.)

CHEMISTRY

Microbial glycoconjugates. Mengeling BJ, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):572-7 (45 ref.)

Helicobacter pylori LPS: molecular mimicry with the host and role in autoimmunity. Vandenbroucke-Grauls CM, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S259-60 (15 ref.)

Mass spectrometric analysis of lipo-chitin oligosaccharides--signal molecules mediating the host-specific legume-rhizobium symbiosis. van der Drift KM, et al. **Mass Spectrom Rev** 1998 Mar-Apr;17(2):75-95 (102 ref.)

Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Heinrichs DE, et al. **Mol Microbiol** 1998 Oct;30(2):221-32 (33 ref.)

METABOLISM

Recent advances in the study of nod factor perception and signal transduction. Niebel A, et al. **Biochimie** 1999 Jun; 81(6):669-74 (50 ref.)

The dual role of lipopolysaccharide as effector and target molecule. Wiese A, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):767-84 (181 ref.)

A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Schumann RR, et al. **Clin Chem Lab Med** 1999 Mar;37(3):271-4 (41 ref.)

Endotoxin interactions with lipopolysaccharide-responsive cells. Tobias PS, et al. **Clin Infect Dis** 1999 Mar; 28(3):476-81 (59 ref.)

Microbial glycoconjugates. Mengeling BJ, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):572-7 (45 ref.)

Therapeutic implications of microglia activation by

LIPOPOLYSACCHARIDES

lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. Mayer AM. **Medicina (B Aires)** 1998;58(4):377–85 (137 ref.)

Host resistance to infection: genetic control of lipopolysaccharide responsiveness by TOLL-like receptor genes. Qureshi ST, et al. **Trends Genet** 1999 Aug; 15(8):291–4 (24 ref.)

TOXICITY

Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis. Zhang Y, et al. **Immunopharmacology** 1999 May;42(1–3):81–90 (22 ref.)

Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Ingalls RR, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):341–53, vii (99 ref.)

Molecular aspects of endotoxins relevant to their biological functions. Haeffner-Cavaillon N, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):853–60 (47 ref.)

[The mechanisms of the synergistic lethal action of enterobacterial lipopolysaccharide and staphylococcal enterotoxin type A] Riabichenko EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):80–5 (50 ref.) **(Rus)**

LIPOPROTEIN(A)

[Lipoprotein (a): biochemical aspects and physiopathological variations] Ben Ammar S, et al. **Tunis Med** 1998 Jun–Jul; 76(6–7):155–9 (30 ref.) **(Fre)**

BLOOD

Lipoprotein(a) as a risk factor for coronary artery disease. Marcovina SM, et al. **Am J Cardiol** 1998 Dec 17; 82(12A):57U–66U; discussion 86U (104 ref.)

Biochemical risk factors and patient's outcome: the case of lipoprotein(a). Lippi G, et al. **Clin Chim Acta** 1999 Feb; 280(1–2):59–71 (95 ref.)

Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors. Seman LJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):186–91 (84 ref.)

Lipoprotein(a): intrigues and insights. Hobbs HH, et al. **Curr Opin Lipidol** 1999 Jun;10(3):225–36 (152 ref.)

Dietary and genetic interactions in the regulation of plasma lipoprotein(a). Puckey L, et al. **Curr Opin Lipidol** 1999 Feb; 10(1):35–40 (54 ref.)

Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? Christ G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):277–85 (95 ref.)

Effects of exercise on lipoprotein(a). Mackinnon LT, et al. **Sports Med** 1999 Jul;28(1):11–24 (73 ref.)

[Lipoprotein(a): risk factor for atherosclerotic vascular disease important to take into account in practice] Couderc R, et al. **Ann Biol Clin (Paris)** 1999 Mar–Apr;57(2):157–67 (84 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

[Oxidative modification of lipoprotein (a): physical chemical aspects and biologic implications] Beaudeux JL. **Ann Pharm Fr** 1999 May;57(3):266–75 (48 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetic architecture and evolution of the lipoprotein(a) trait. Utermann G. **Curr Opin Lipidol** 1999 Apr;10(2):133–41 (51 ref.)

Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). Dieplinger H, et al. **Wien Klin Wochenschr** 1999 Jan 15;111(1):5–20 (170 ref.)

Genetics and metabolism of lipoprotein(a) and clinical implications (2)] Dieplinger H, et al. **Wien Klin Wochenschr** 1999 Jan 29;111(2):46–55 (275 ref.)

ISOLATION & PURIFICATION

Isolation and purification of serum lipoprotein (a) using lectin affinity. Seman LJ, et al. **Methods Mol Biol** 1998;110:131–6 (11 ref.)

METABOLISM

Atherothrombogenicity of lipoprotein(a): the debate. Scanu AM. **Am J Cardiol** 1998 Nov 5;82(9A):26Q–33Q (91 ref.)

Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Nielsen LB. **Atherosclerosis** 1999 Apr;143(2):229–43 (112 ref.)

The seventh myth of lipoprotein(a): where and how is it assembled? Dieplinger H, et al. **Curr Opin Lipidol** 1999 Jun;10(3):275–83 (82 ref.)

Proteolytic modifications of lipoprotein(a): potential relevance to its postulated atherothrombogenic role. Scanu AM. **J Investig Med** 1998 Oct;46(8):359–63 (38 ref.)

PHYSIOLOGY

[Oxidative modification of lipoprotein (a): physical chemical aspects and biologic implications] Beaudeux JL. **Ann Pharm Fr** 1999 May;57(3):266–75 (48 ref.) (Eng. Abstr.) **(Fre)**

LIPOPROTEIN DEFICIENCY, HDL, FAMILIAL see **TANGIER DISEASE**

LIPOPROTEIN LDL RECEPTORS see **RECEPTORS, LDL**

LIPOPROTEIN LIPASE

ANALYSIS

Determining lipoprotein lipase and hepatic lipase activity using radiolabeled substrates. Briquet-Laugier V, et al. **Methods Mol Biol** 1999;109:81–94 (17 ref.)

Immunodetection of lipoprotein lipase: antibody production, immunoprecipitation, and western blotting techniques. Doolittle MH, et al. **Methods Mol Biol** 1999;109:215–37 (16 ref.)

In vitro measurement of lipoprotein and hepatic lipases. Vilella E, et al. **Methods Mol Biol** 1998;110:243–51 (11 ref.)

DRUG EFFECTS

Effect of growth hormone on adipose tissue and skeletal muscle lipoprotein lipase activity in humans. Richelsen B. **J Endocrinol Invest** 1999;22(5 Suppl):10–5 (31 ref.)

GENETICS

Techniques for the measurement of lipoprotein lipase messenger RNA. Ranganathan G, et al. **Methods Mol Biol** 1999;109:329–35 (7 ref.)

In vitro transcription and translation of lipoprotein lipase. Ranganathan G, et al. **Methods Mol Biol** 1999;109:337–41 (16 ref.)

ISOLATION & PURIFICATION

Large-scale lipoprotein lipase purification from adipose tissue. Bensadoun A, et al. **Methods Mol Biol** 1999; 109:145–50 (6 ref.)

METABOLISM

Role of lipoprotein lipases in postprandial lipid metabolism. Jansen H, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S31–4 (40 ref.)

Detecting ligands interacting with lipoprotein lipase. Pillarisetti S. **Methods Mol Biol** 1999;109:267–78 (34 ref.)

[Lipoprotein lipase (LPL) in the pathogenesis of atherosclerosis] Skoczyńska A. **Postepy Hig Med Dosw** 1998;52(4):347–65 (80 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Lipoprotein lipase and the disposition of dietary fatty acids. Fielding BA, et al. **Br J Nutr** 1998 Dec;80(6):495–502 (61 ref.)

[Lipoprotein lipase and atherosclerosis] Gotoda T. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1294–301 (26 ref.) **(Jpn)**

LIPOPROTEIN RECEPTORS see **RECEPTORS, LIPOPROTEIN**

LIPOPROTEINOSIS see **LIPOIDPROTEINOSIS**

LIPOPROTEINS

see related
APOLIPOPROTEINS
HYPERLIPOPROTEINEMIA
HYPOLIPOPROTEINEMIA
LIPOIDPROTEINOSIS
PROTEOLIPIDS
RECEPTORS, LIPOPROTEIN

Lipoproteins and atherogenesis. Hoeg JM. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):569–84, viii (113 ref.)

[Lipoproteins in clinical laboratory medicine] Kuriyama M. **Rinsho Byori** 1998 Dec;46(12):1219–25 (17 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Implications of lag time concept in the oxidation of LDL. Parthasarathy S, et al. **Free Radic Res** 1998 Jun; 28(6):583–91 (39 ref.)

Measurement of lipoprotein particles. Fievet C, et al. **Methods Mol Biol** 1998;110:153–66 (36 ref.)

BLOOD

Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Brewer HB Jr. **Am J Cardiol** 1999 May 13;83(9B):3F–12F (116 ref.)

Nuts and their bioactive constituents: effects on serum lipids and other factors that affect disease risk. Kris-Etherton PM, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):504S–511S (44 ref.)

High-performance liquid chromatography in clinical analysis. Anderson DJ. **Anal Chem** 1999 Jun 15; 71(12):314R–327R (379 ref.)

Nonoxidative modifications of lipoproteins in atherogenesis. Tabas I. **Annu Rev Nutr** 1999;19:123–39 (117 ref.)

Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Krause BR, et al. **Atherosclerosis** 1998 Sep;140(1):15–24 (108 ref.)

Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis [editorial; comment] Hodis HN. **Circulation** 1999 Jun 8;99(22):2852–4 (20 ref.) Comment on: Circulation 1999 Jun 8;99(22):2858–60.

A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. Hegele RA. **Clin Biochem** 1998 Nov; 31(8):609–12 (26 ref.)

Kinetic study of apo B100 containing lipoprotein metabolism using amino acids labeled with stable isotopes: methodological aspects. Maugeais C, et al. **Clin Chem Lab Med** 1998 Oct;36(10):739–45 (51 ref.)

Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function. Blum A, et al. **Curr Opin Lipidol** 1998 Dec;9(6):575–86 (97 ref.)

Intermediate-density lipoproteins, diabetes and coronary artery disease. Steiner G. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S29–33 (37 ref.)

Analysis of apolipoproteins and lipoproteins by capillary electrophoresis. Stocks J, et al. **Electrophoresis** 1999 Jul; 20(10):2118–23 (15 ref.)

Diet, lipoproteins, and coronary heart disease. Schaefer EJ, et al. **Endocrinol Metab Clin North Am** 1998 Sep; 27(3):711–32, xi (121 ref.)

Diabetic dyslipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul; 19 Suppl H:H27–40 (14 ref.)

Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Thompson GR. **Eur Heart J** 1998 Jul;19 Suppl H:H31–6 (16 ref.)

Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Sacks FM, et al. **Herz** 1999 Feb; 24(1):51–6 (16 ref.)

Diet, plasma lipoproteins and experimental atherosclerosis in baboons (Papio sp.). Kushwaha RS, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):420–9 (78 ref.)

Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Attman PO, et al. **Kidney Int Suppl** 1999 Jul;71:S14–7 (26 ref.)

Lipoprotein abnormalities in diabetic nephropathy. Hirano T. **Kidney Int Suppl** 1999 Jul;71:S22–4 (10 ref.)

Tibolone and the serum lipid/lipoprotein profile: does this have a role in cardiovascular protection in postmenopausal women? [editorial; comment] Ginsburg J, et al. **Menopause** 1999 Summer;6(2):87–9 (34 ref.) Comment on: Menopause 1999 Summer;6(2):92–97. Comment on: Menopause 1999 Summer;6(2):98–104.

[Estrogens and lipid metabolism] Berthezène F. **Therapie** 1999 May–Jun;54(3):393–5 (22 ref.) (Eng. Abstr.) **(Fre)**

[Theories and problems related to direct determination of lipoprotein cholesterol] Sugiuchi H. **Rinsho Byori** 1999 Feb; Suppl 109:126–39 (15 ref.) **(Jpn)**

[Fatty acid transport in the blood by lipoproteins as macromolecules: facts and a hypothesis] Titov VN. **Usp Fiziol Nauk** 1999 Jul–Sep;30(3):23–37 (69 ref.) (Eng. Abstr.) **(Rus)**

[Specific features of cardiovascular diseases in patients with mono- and polygenic types of dyslipoproteinemia] Ol'binskaia LI, et al. **Vestn Ross Akad Med Nauk** 1998; (10):56–60 (26 ref.) (Eng. Abstr.) **(Rus)**

[The alterations of lipid spectrum in patients with migraine] Shestakov VV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(5):8–10 (23 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Infrared studies of protein-induced perturbation of lipids in lipoproteins and membranes. Arrondo JL, et al. **Chem Phys Lipids** 1998 Nov;96(1–2):53–68 (59 ref.)

Methodological approaches for assessing lipid and protein oxidation and modification in plasma and isolated lipoproteins. Sattler W, et al. **Methods Mol Biol** 1998; 110:167–91 (65 ref.)

CLASSIFICATION

Lipoprotein classes and coronary disease regression. Zambon A, et al. **Curr Opin Lipidol** 1998 Aug;9(4):329–36 (52 ref.)

GENETICS

Tissue factor pathway inhibitor gene disruption. Broze GJ Jr. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S89–92 (18 ref.)

PCR methodology applied to genetic studies of lipoprotein metabolism and atherosclerosis. Cole SA, et al. **Methods Mol Biol** 1998;110:1–34 (70 ref.)

ISOLATION & PURIFICATION

Preparative isolation of plasma lipoproteins using fast protein liquid chromatography (FPLC). Ordovas JM, et al. **Methods Mol Biol** 1998;110:105–11 (7 ref.)

Fast ultracentrifugation methods for the separation of plasma lipoproteins. Ordovas JM. **Methods Mol Biol** 1998; 110:93–103 (7 ref.)

METABOLISM

Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Jong

MC, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar; 19(3):472–84 (180 ref.)
Metabolic modes of action of the statins in the hyperlipoproteinemias. Aguilar-Salinas CA, et al. **Atherosclerosis** 1998 Dec;141(2):203–7 (48 ref.)
Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Camejo G, et al. **Atherosclerosis** 1998 Aug;139(2):205–22 (131 ref.)
Triglycerides are more important in atherosclerosis than epidemiology has suggested. Durrington PN. **Atherosclerosis** 1998 Dec;141 Suppl 1:S57–62 (36 ref.)
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Staels B, et al. **Circulation** 1998 Nov 10; 98(19):2088–93 (78 ref.)
Postprandial triglyceride metabolism in diabetes mellitus. Georgopoulos A. **Clin Cardiol** 1999 Jun;22(6 Suppl):II28–33 (14 ref.)
The role of hepatic lipase in lipoprotein metabolism. Connelly PW. **Clin Chim Acta** 1999 Aug;286(1–2):243–55 (27 ref.)
Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era? Angelin B, et al. **Curr Opin Lipidol** 1999 Jun;10(3):269–74 (51 ref.)
Contribution of cholesterol 7alpha-hydroxylase to the regulation of lipoprotein metabolism. Cohen JC. **Curr Opin Lipidol** 1999 Aug;10(4):303–7 (21 ref.)
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Fruchart JC, et al. **Curr Opin Lipidol** 1999 Jun;10(3):245–57 (99 ref.)
Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Linton MF, et al. **Curr Opin Lipidol** 1999 Apr;10(2):97–105 (51 ref.)
The response-to-retention hypothesis of atherogenesis reinforced. Williams KJ, et al. **Curr Opin Lipidol** 1998 Oct; 9(5):471–4 (40 ref.)
Lipid oxidation products and vascular function. Bruckdorfer KR. **Free Radic Res** 1998 Jun;28(6):573–81 (74 ref.)
The lag phase. Cadenas E, et al. **Free Radic Res** 1998 Jun; 28(6):601–9 (42 ref.)
Cellular thiol production and oxidation of low-density lipoprotein. Graham A. **Free Radic Res** 1998 Jun; 28(6):611–21 (105 ref.)
Implications of lag time concept in the oxidation of LDL. Parthasarathy S, et al. **Free Radic Res** 1998 Jun; 28(6):583–91 (39 ref.)
Role of the enterohepatic circulation of bile salts in lipoprotein metabolism. Cooper AD. **Gastroenterol Clin North Am** 1999 Mar;28(1):211–29, viii (112 ref.)
Dynamics of lipoprotein metabolism in adult growth hormone deficiency. Christ ER, et al. **J Endocrinol Invest** 1999;22(5 Suppl):16–21 (23 ref.)
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. Mahley RW, et al. **J Lipid Res** 1999 Jan; 40(1):1–16 (126 ref.)
Measurements of proteoglycan-lipoprotein interaction by gel mobility shift assay. Hurt-Camejo E, et al. **Methods Mol Biol** 1998;110:267–79 (23 ref.)
Receptor-mediated mechanisms of lipoprotein remnant catabolism. Chappell DA, et al. **Prog Lipid Res** 1998 Dec; 37(6):393–422 (262 ref.)
Lipoprotein and cholesterol metabolism in diet-induced coronary artery atherosclerosis in primates. Role of cholesterol and fatty acids. Rudel LL, et al. **Prog Lipid Res** 1998 Dec;37(6):353–70 (101 ref.)
The molecular action of alpha-tocopherol in lipoprotein lipid peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions. Witting PK, et al. **Subcell Biochem** 1998;30:345–90 (145 ref.)
[Genetic predisposition in multiple metabolic syndrome. Part 3. Metabolism of lipids, lipoproteins and apolipoproteins] Sobra J, et al. **Cas Lek Cesk** 1999 Mar 1;138(5):136–41 (37 ref.) (Eng. Abstr.) **(Cze)**
[Gene polymorphisms in atherosclerotic diseases and lipoprotein metabolism disorders] Yokode M. **Nippon Ronen Igakkai Zasshi** 1999 Apr;36(4):238–41 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Imaging of endosome traffic in cells] Yamada M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1227–33 (10 ref.) **(Jpn)**

PHYSIOLOGY

Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Byrne CD. **Atherosclerosis** 1999 Jul;145(1):1–15 (115 ref.)
Lipoprotein physiology. Ginsberg HN. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):503–19 (40 ref.)
Tissue factor pathway inhibitor. Camici M, et al. **Minerva Med** 1999 Jan-Feb;90(1–2):25–32 (73 ref.)

LIPOPROTEINS, HDL

BLOOD

Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. Brunzell JD, et al. **Am J Med** 1999 Aug 23;107(2A):16S–18S (25 ref.)
Atheroprotective mechanisms of HDL. Stein O, et al. **Atherosclerosis** 1999 Jun;144(2):285–301 (208 ref.)
High density lipoprotein: are elevated levels desirable and achievable? Bisgaier CL, et al. **Curr Pharm Des** 1998 Feb; 4(1):53–70 (361 ref.)
Factors affecting high-density lipoproteins. Gordon DJ. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):699–709, xi (40 ref.)
Plasma triglyceride-rich lipoprotein and high density lipoproteins disorders associated with atherosclerosis. Genest J Jr, et al. **J Investig Med** 1998 Oct;46(8):351–8 (73 ref.)

CLASSIFICATION

High-density lipoprotein subclasses and apolipoprotein A-I. Duriez P, et al. **Clin Chim Acta** 1999 Aug;286(1–2):97–114 (68 ref.)

DRUG EFFECTS

Mechanistic studies of high-density lipoproteins. Kashyap ML. **Am J Cardiol** 1998 Dec 17;82(12A):42U–48U; discussion 85U–86U (26 ref.)

ISOLATION & PURIFICATION

Electrophoretic separation of LDL and HDL subclasses. Rainwater DL. **Methods Mol Biol** 1998;110:137–51 (23 ref.)

METABOLISM

Remodelling of high density lipoproteins by plasma factors. Rye KA, et al. **Atherosclerosis** 1999 Aug;145(2):227–38 (140 ref.)
Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Otvos J. **Clin Cardiol** 1999 Jun;22(6 Suppl):II21–7 (8 ref.)
Metabolism of high density lipoprotein subfractions. Colvin PL, et al. **Curr Opin Lipidol** 1999 Aug;10(4):309–14 (33 ref.)
High density associated enzymes: their role in vascular biology. Navab M, et al. **Curr Opin Lipidol** 1998 Oct; 9(5):449–56 (69 ref.)
Unraveling the mysteries of high density lipoprotein metabolism [editorial] Rudel LL, et al. **Curr Opin Lipidol** 1999 Aug;10(4):293–4 (7 ref.)
High-density lipoprotein: multipotent effects on cells of the vasculature. Cockerill GW, et al. **Int Rev Cytol** 1999; 188:257–97 (179 ref.)
High density lipoproteins in health and in disease. Genest J Jr, et al. **J Investig Med** 1999 Jan;47(1):31–42 (129 ref.)
[Lipid metabolism in Tangier disease] Yokoyama S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1277–81 (19 ref.) **(Jpn)**

PHYSIOLOGY

Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis. Francis GA, et al. **Clin Chim Acta** 1999 Aug;286(1–2):219–30 (54 ref.)
High density lipoprotein: are elevated levels desirable and achievable? Bisgaier CL, et al. **Curr Pharm Des** 1998 Feb; 4(1):53–70 (361 ref.)

RADIATION EFFECTS

[Oxidation of lipoproteins and mechanism of action of antioxidants : contribution of gamma radiolysis] Bonnefont-Rousselot D. **Ann Biol Clin (Paris)** 1999 Jul-Aug;57(4):409–16 (48 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Therapeutic strategies for coronary artery disease beyond low density lipoprotein (LDL)--lowering. Arad Y, et al. **Curr Pharm Des** 1999 Jan;5(1):1–10 (170 ref.)

LIPOPROTEINS, HDL CHOLESTEROL

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

ADVERSE EFFECTS

Wine and polyphenols related to platelet aggregation and atherothrombosis. Ruf JC. **Drugs Exp Clin Res** 1999; 25(2–3):125–31 (49 ref.)

BLOOD

Pathophysiology and management of low high-density lipoprotein cholesterol. Rader DJ. **Am J Cardiol** 1999 May 13;83(9B):22F–24F (15 ref.)
New perspectives on the management of low levels of high-density lipoprotein cholesterol [see comments] Harper CR, et al. **Arch Intern Med** 1999 May 24;159(10):1049–57 (64 ref.) Comment in: Arch Intern Med 1999 May 24;159(10):1038–40.
HDL metabolism in hypertriglyceridemic states: an overview. Lamarche B, et al. **Clin Chim Acta** 1999 Aug; 286(1–2):145–61 (74 ref.)
Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Patsch J. **Eur Heart J** 1998 Jul;19 Suppl H:H2–6 (15 ref.)
Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Dobiásová M, et al. **Physiol Res** 1998; 47(6):387–97 (74 ref.)
Aggressive lipid therapy in the statin era. Farmer JA. **Prog Cardiovasc Dis** 1998 Sep-Oct;41(2):71–94 (67 ref.)
[Theories and problems related to direct determination of lipoprotein cholesterol] Sugiuchi H. **Rinsho Byori** 1999 Feb; Suppl 109:126–39 (15 ref.) **(Jpn)**

DEFICIENCY

Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Belalcazar LM, et al. **Prog Cardiovasc Dis** 1998 Sep-Oct;41(2):151–74 (186 ref.)

METABOLISM

Alcohol intake, lipids and risks of myocardial infarction. Gaziano JM, et al. **Novartis Found Symp** 1998;216:86–95; discussion 95–110 (65 ref.)

PHYSIOLOGY

The antiatherogenic role of high-density lipoprotein cholesterol. Kwiterovich PO Jr. **Am J Cardiol** 1998 Nov 5;82(9A):13Q–21Q (60 ref.)
[Cellular cholesterol efflux and HDL] Yokoyama S. **Seikagaku** 1998 Nov;70(11):1354–9 (22 ref.) **(Jpn)**

LIPOPROTEINS, LDL

see related
RECEPTORS, LDL

Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column [editorial] Kojima S, et al. **Ther Apher** 1997 Nov;1(4):309–13 (16 ref.)
[LDL-apheresis therapy, methods and indications] Assogba U, et al. **Presse Med** 1999 May 15;28(18):985–91 (60 ref.) (Eng. Abstr.) **(Fre)**
[Oxidized lipoproteins and diseases] Itabe H. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1247–52 (27 ref.) **(Jpn)**

BLOOD

Heparin-mediated extracorporeal LDL/fibrinogen precipitation--H.E.L.P.--in coronary and cerebral ischemia. Jaeger BR, et al. **Acta Neurochir Suppl (Wien)** 1999;73:81–4 (28 ref.)
Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. Brunzell JD, et al. **Am J Med** 1999 Aug 23;107(2A):16S–18S (25 ref.)
Clinical trials of reducing low-density lipoprotein concentrations. Rifkind BM. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):585–95, viii–ix (33 ref.)
In vivo studies of VLDL metabolism and LDL heterogeneity. Demant T, et al. **Eur Heart J** 1998 Jul;19 Suppl H:H7–10 (13 ref.)
Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Yukawa S, et al. **Kidney Int Suppl** 1999 Jul;71:S141–3 (16 ref.)
Lipoprotein atherogenicity: an overview of current mechanisms. Griffin BA. **Proc Nutr Soc** 1999 Feb; 58(1):163–9 (36 ref.)
Clinical experience and future directions for low-density lipoprotein apheresis in the United States. Gordon BR, et al. **Ther Apher** 1997 Aug;1(3):249–52 (21 ref.)
Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns. Koga N. **Ther Apher** 1999 May;3(2):155–60 (26 ref.)
Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits [editorial] Yamamoto T, et al. **Ther Apher** 1998 Feb; 2(1):25–30 (42 ref.)
[Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus] Fábryová L, et al. **Bratisl Lek Listy** 1998 Mar-Apr;99(3–4):138–45 (80 ref.) (Eng. Abstr.) **(Slo)**

CHEMISTRY

LDL particle size: an important drug target? Rajman I, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):125–33 (84 ref.)
Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. Heinecke JW. **FASEB J** 1999 Jul;13(10):1113–20 (79 ref.)

DRUG EFFECTS

Pharmacologic management of triglycerides. Hunninghake DB. **Clin Cardiol** 1999 Jun;22(6 Suppl):II44–8 (10 ref.)
Lowering cholesterol in old age. Oliver MF. **J R Coll Physicians Lond** 1999 May-Jun;33(3):252–3 (15 ref.)

GENETICS

The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Lamarche B, et al. **Diabetes Metab** 1999 Sep;25(3):199–211 (116 ref.)

LIPOPROTEINS, LDL

IMMUNOLOGY

Antiphospholipid antibodies and myocardial infarction. Vaarala O. **Lupus** 1998;7 Suppl 2:S132–4 (20 ref.)

ISOLATION & PURIFICATION

Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL–apheresis. Stefanutti C, et al. **Clin Ter** 1998 May–Jun;149(3):231–3 (20 ref.)

Electrophoretic separation of LDL and HDL subclasses. Rainwater DL. **Methods Mol Biol** 1998;110:137–51 (23 ref.)

The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia [editorial] Thompson GR, et al. **Ther Apher** 1997 Feb;1(1):13–6 (18 ref.)

METABOLISM

Oxidative modification of low–density lipoproteins in atherothrombosis. Holvoet P. **Acta Cardiol** 1998; 53(5):253–60 (62 ref.)

Iron and LDL–oxidation in atherogenesis. Yuan XM, et al. **APMIS** 1998 Sep;106(9):825–42 (142 ref.)

Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Nielsen LB. **Atherosclerosis** 1999 Apr;143(2):229–43 (112 ref.)

Linoleic acid peroxidation—the dominant lipid peroxidation process in low density lipoprotein—and its relationship to chronic diseases. Spiteller G. **Chem Phys Lipids** 1998 Oct; 95(2):105–62 (518 ref.)

Pathophysiology of triglyceride–rich lipoproteins in atherothrombosis: clinical aspects. Hodis HN, et al. **Clin Cardiol** 1999 Jun;22(6 Suppl):II15–20 (15 ref.)

Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions. Weber C, et al. **Clin Chem Lab Med** 1999 Mar;37(3):243–51 (88 ref.)

Scavenger receptors and oxidized low density lipoproteins. Dhaliwal BS, et al. **Clin Chim Acta** 1999 Aug; 286(1–2):191–205 (91 ref.)

Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. Greaves DR, et al. **Curr Opin Lipidol** 1998 Oct;9(5):425–32 (63 ref.)

Is oxidized low–density lipoprotein present in vivo? Ylä–Herttuala S. **Curr Opin Lipidol** 1998 Aug;9(4):337–44 (101 ref.)

Tocopherol–mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Upston JM, et al. **FASEB J** 1999 Jun; 13(9):977–94 (151 ref.)

Oxidative stress in chronic renal failure. Hasselwander O, et al. **Free Radic Res** 1998 Jul;29(1):1–11 (118 ref.)

Nitric oxide and low–density lipoprotein oxidation. Hogg N, et al. **Free Radic Res** 1998 Jun;28(6):593–600 (57 ref.)

Dynamics of vitamin E action against LDL oxidation. Noguchi N, et al. **Free Radic Res** 1998 Jun;28(6):561–72 (77 ref.)

Molecular mechanisms of the copper dependent oxidation of low–density lipoprotein. Patel RP, et al. **Free Radic Res** 1999 Jan;30(1):1–9 (58 ref.)

The oxidation of lipoproteins by monocytes–macrophages. Biochemical and biological mechanisms. Chisolm GM 3rd, et al. **J Biol Chem** 1999 Sep 10;274(37):25959–62 (119 ref.)

Antioxidant effects of nitric oxide and nitric oxide donor compounds on low–density lipoprotein oxidation. Goss SP, et al. **Methods Enzymol** 1999;301:444–53 (27 ref.)

LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Aviram M, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):149–59 (76 ref.)

Oxidized low–density lipoprotein enhances intimal thickening and alters vascular reactivity. Herman A, et al. **Verh K Acad Geneeskd Belg** 1999;61(1):19–36; discussion 36–8 (63 ref.)

PHARMACOLOGY

Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kamanna VS, et al. **Kidney Int Suppl** 1999 Jul;71:S70–5 (23 ref.)

The role of oxidized low–density lipoprotein in the activation of peroxisome proliferator–activated receptor gamma: implications for atherosclerosis. Wolf G. **Nutr Rev** 1999 Mar;57(3):88–91 (11 ref.)

PHYSIOLOGY

Oxidized LDL and atherogenesis. Ylä–Herttuala S. **Ann N Y Acad Sci** 1999 Jun 30;874:134–7 (15 ref.)

Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Heinecke JW. **Atherosclerosis** 1998 Nov;141(1):1–15 (158 ref.)

RADIATION EFFECTS

[Oxidation of lipoproteins and mechanism of action of antioxidants : contribution of gamma radiolysis] Bonnefont–Rousselot D. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):409–16 (48 ref.) (Eng. Abstr.) **(Fre)**

LIPOPROTEINS, LDL CHOLESTEROL

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis. Schettler V, et al. **Ther Apher** 1999 Aug;3(3):219–26 (67 ref.)

BLOOD

Low–density lipoproteins and risk for coronary artery disease. Ballantyne CM. **Am J Cardiol** 1998 Nov 5; 82(9A):3Q–12Q (59 ref.)

Is aggressive cholesterol control justified? Review of the post–coronary artery bypass graft trial. Hunninghake DB. **Am J Cardiol** 1998 Nov 26;82(10B):45T–48T (20 ref.)

Why cholesterol as a central theme in coronary artery disease? Sacks FM. **Am J Cardiol** 1998 Nov 26; 82(10B):14T–17T (41 ref.)

Combined hyperlipidemia as a risk factor for premature atherosclerotic disease. East C. **Am J Med** 1999 Aug 23; 107(2A):46S–47S (17 ref.)

Inhibition of cholesterol absorption by plant sterols for mass intervention. Ikeda I, et al. **Curr Opin Lipidol** 1998 Dec; 9(6):527–31 (42 ref.)

Safety and effectiveness of long–term LDL–apheresis in patients at high risk. Thiery J, et al. **Curr Opin Lipidol** 1998 Dec;9(6):521–6 (45 ref.)

Cholesterol lowering and coronary artery disease: mechanisms of risk reduction. Archbold RA, et al. **Heart** 1998 Dec;80(6):543–7 (58 ref.)

Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Dobiásová M, et al. **Physiol Res** 1998; 47(6):387–97 (74 ref.)

Aggressive lipid therapy in the statin era. Farmer JA. **Prog Cardiovasc Dis** 1998 Sep–Oct;41(2):71–94 (67 ref.)

The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low–density lipoprotein apheresis in patients with familial hypercholesterolemia. Koga N. **Ther Apher** 1997 Aug; 1(3):260–70 (33 ref.)

[Apolipoprotein B and LDL cholesterol: which parameter(s) should be included in the assessment of cardiovascular risk?] Bloch S, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct; 56(5):539–44 (30 ref.) (Eng. Abstr.) **(Fre)**

[Plaque stabilization by LDL apheresis?] Schuff–Werner P, et al. **Herz** 1999 Feb;24(1):57–61 (20 ref.) (Eng. Abstr.) **(Ger)**

[How far should one lower LDL cholesterol] Wasielewski S. **Med Monatsschr Pharm** 1998 Dec;21(12):387–90 (4 ref.) **(Ger)**

[Pharmacology of HMG CoA reductase inhibitors (statins)] Kostner GM. **Wien Med Wochenschr** 1999;149(5–6):120–4 (13 ref.) (Eng. Abstr.) **(Ger)**

[Theories and problems related to direct determination of lipoprotein cholesterol] Sugiuchi H. **Rinsho Byori** 1999 Feb; Suppl 109:126–39 (15 ref.) **(Jpn)**

[The new debate on cholesterol: is the lowest level the best?] Olsson AG. **Lakartidningen** 1999 Feb 10;96(6):648–52 (16 ref.) **(Swe)**

METABOLISM

Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Alving CR, et al. **Immunol Today** 1999 Aug;20(8):362–6 (31 ref.)

PHARMACOLOGY

Management of lipid disorders. Friedrich CA, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):507–20 (53 ref.)

LIPOPROTEINS, VLDL

BIOSYNTHESIS

The role of factors that regulate the synthesis and secretion of very–low–density lipoprotein by hepatocytes. Mason TM. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):461–87 (74 ref.)

The assembly and secretion of apolipoprotein B–containing lipoproteins. Olofsson SO, et al. **Curr Opin Lipidol** 1999 Aug;10(4):341–6 (56 ref.)

Assembly of very low density lipoprotein: a two–step process of apolipoprotein B core lipidation. Rustaeus S, et al. **J Nutr** 1999 Feb;129(2S Suppl):463S–466S (22 ref.)

Apolipoprotein B in the rough endoplasmic reticulum: translation, translocation and the initiation of lipoprotein assembly. Shelness GS, et al. **J Nutr** 1999 Feb;129(2S Suppl):456S–462S (78 ref.)

Estrogen induction of VLDLy assembly in egg–laying hens. Walzem RL, et al. **J Nutr** 1999 Feb;129(2S Suppl):467S–472S (43 ref.)

BLOOD

In vivo studies of VLDL metabolism and LDL heterogeneity. Demant T, et al. **Eur Heart J** 1998 Jul;19 Suppl H:H7–10 (13 ref.)

CHEMISTRY

The VLDL receptor: an LDL receptor relative with eight ligand binding repeats, LR8. Nimpf J, et al. **Atherosclerosis** 1998 Dec;141(2):191–202 (103 ref.)

[Lipid metabolism and lipogenesis: application of stable isotopes] Martinez JA, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):91–8 (34 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Kinetics of triglyceride rich lipoproteins: chylomicrons and very low density lipoproteins. Hugh P, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S35–40 (33 ref.)

Regulation of the assembly and secretion of very low density lipoproteins by the liver. Kendrick JS, et al. **Biol Chem** 1998 Aug–Sep;379(8–9):1033–40 (51 ref.)

The assembly of triacylglycerol–rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein. White DA, et al. **Br J Nutr** 1998 Sep;80(3):219–29 (67 ref.)

PHYSIOLOGY

The VLDL receptor: an LDL receptor relative with eight ligand binding repeats, LR8. Nimpf J, et al. **Atherosclerosis** 1998 Dec;141(2):191–202 (103 ref.)

SECRETION

The role of factors that regulate the synthesis and secretion of very–low–density lipoprotein by hepatocytes. Mason TM. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):461–87 (74 ref.)

The assembly and secretion of apolipoprotein B–containing lipoproteins. Olofsson SO, et al. **Curr Opin Lipidol** 1999 Aug;10(4):341–6 (56 ref.)

LIPOSARCOMA

Liposarcoma: a review of current diagnosis and management. Wong CK, et al. **Br J Hosp Med** 1998 Dec 10;58(11):589–91 (19 ref.)

Recurrent primary well–differentiated intrascrotal liposarcoma: case report and review of the literature. Kochman A, et al. **Tumori** 1999 Mar–Apr;85(2):135–6 (11 ref.)

CLASSIFICATION

Liposarcoma: an update. Weiss SW. **Verh Dtsch Ges Pathol** 1998;82:67–74 (19 ref.)

DIAGNOSIS

Primary omental liposarcoma presenting with torsion: a case report. Tsutsumi H, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):2110–2 (10 ref.)

Well–differentiated liposarcoma of the hypopharynx. Fahmy FF, et al. **J Laryngol Otol** 1998 Sep;112(9):880–2 (7 ref.)

[Recent data in the diagnosis of liposarcoma] Guillou L. **Ann Pathol** 1998;18(5 Suppl):59–63 (12 ref.) **(Fre)**

[Liposarcoma of the spermatic cord: a report of a new case and a review of the literature] Soler Soler JL, et al. **Actas Urol Esp** 1999 May;23(5):447–54 (38 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

A mesenteric liposarcoma with production of granulocyte colony–stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884–90 (37 ref.)

PATHOLOGY

Massive localized lymphedema in the morbidly obese: a histologically distinct reactive lesion simulating liposarcoma. Farshid G, et al. **Am J Surg Pathol** 1998 Oct; 22(10):1277–83 (4 ref.)

Lipoblastoma and liposarcoma in children: an analysis of 9 cases and a review of the literature. Miller GG, et al. **Can J Surg** 1998 Dec;41(6):455–8 (16 ref.)

Upper aerodigestive tract liposarcoma: report on four cases and literature review. Mandell DL, et al. **Laryngoscope** 1999 Aug;109(8):1245–52 (28 ref.)

Liposarcoma: an update. Weiss SW. **Verh Dtsch Ges Pathol** 1998;82:67–74 (19 ref.)

[Malignant phyllodes tumor with liposarcomatous differentiation. Description of a clinical case] Scala M, et al. **Minerva Chir** 1999 May;54(5):355–8 (25 ref.) (Eng. Abstr.) **(Ita)**

[Primary round–cell liposarcoma of the bladder] Veiga González M, et al. **Arch Esp Urol** 1998 Nov;51(9):925–8 (8 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

[Liposarcoma of the larynx. Review of the literature apropos of a case] Acharki A, et al. **Cancer Radiother** 1999 May–Jun;3(3):245–8 (21 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Liposarcoma of the larynx. Review of the literature apropos of a case] Acharki A, et al. **Cancer Radiother** 1999 May–Jun;3(3):245–8 (21 ref.) (Eng. Abstr.) **(Fre)**

LIPOSARCOMA, DEDIFFERENTIATED see **LIPOSARCOMA**

LIPOSARCOMA, MYXOID

PATHOLOGY

A parapharyngeal myxoid liposarcoma. Fagan JJ, et al. **J Laryngol Otol** 1999 Feb;113(2):179–82 (14 ref.)

LIPOSARCOMA, PLEOMORPHIC see **LIPOSARCOMA**

LIPOSOMES

Liposomes in gene therapy. Structural polymorphism of lipids and effectiveness of gene delivery. Tarahovsky YS, et al. **Biochemistry (Mosc)** 1998 Jun;63(6):607–18 (124 ref.)

Liposomes: from biophysics to the design of peptide vaccines. Frézard F. **Braz J Med Biol Res** 1999 Feb;32(2):181–9 (37 ref.)

Liposomes as a gene delivery system. Ropert C. **Braz J Med Biol Res** 1999 Feb;32(2):163–9 (50 ref.)

Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Mayer LD. **Cancer Metastasis Rev** 1998 Jun;17(2):211–8 (32 ref.)

The potential of liposomes in oral drug delivery. Rogers JA, et al. **Crit Rev Ther Drug Carrier Syst** 1998;15(5):421–80 (254 ref.)

Chromatographic approaches to liposomes, proteoliposomes and biomembrane vesicles. Lundahl P, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1–2):103–20 (147 ref.)

Lipoplexes and tumours. A review. Dass CR, et al. **J Pharm Pharmacol** 1999 Jul;51(7):755–70 (198 ref.)

Gene delivery systems using the Sendai virus. Nakanishi M, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):123–7 (22 ref.)

Impact of liposomes as delivery systems in veterinary medicine. Sallovitz JM, et al. **Vet Res** 1998 Sep–Oct; 29(5):409–30 (115 ref.)

[Preparation of unilamellar fusogenic liposomes using the Sendai virus] Nakanishi M, et al. **Nippon Yakurigaku Zasshi** 1998 Nov;112(5):299–305 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Liposomes and other nanoparticles as drug delivery systems] Kaplun AP, et al. **Vopr Med Khim** 1999 Jan–Feb;45(1):3–12 (50 ref.) (Eng. Abstr.) **(Rus)**

[From single dose to lipid forms] López JB, et al. **Rev Esp Quimioter** 1998 Sep;11(3):189–95 (86 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Liposomal drug formulations. Rationale for development and what we can expect for the future. Allen TM. **Drugs** 1998 Nov;56(5):747–56 (76 ref.)

Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. Désormeaux A, et al. **J Drug Target** 1998;6(1):1–15 (105 ref.)

Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Düzgüneş N, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):111–8 (72 ref.)

CHEMISTRY

Fluorometric phospholipase assays based on polymerized liposome substrates. Cho W, et al. **Methods Mol Biol** 1999; 109:7–17 (14 ref.)

DIAGNOSTIC USE

Liposomes for scintigraphic imaging: optimization of in vivo behavior. Boerman OC, et al. **Q J Nucl Med** 1998 Dec; 42(4):271–9 (70 ref.)

METABOLISM

New directions in liposome gene delivery. Templeton NS, et al. **Mol Biotechnol** 1999 Apr;11(2):175–80 (23 ref.)

[Liposome gene delivery system] Langner M. **Postepy Biochem** 1998;44(4):299–305 (88 ref.) **(Pol)**

THERAPEUTIC USE

Targeting of therapeutics to the liver: liposomes and viral vectors. Di Campli C, et al. **Alcohol Clin Exp Res** 1999 May;23(5):950–4 (36 ref.)

NF-kappa B, liposomes and pathogenesis of hepatic injury and fibrosis. Wu J, et al. **Front Biosci** 1999 Jun 15;4:D520–7 (67 ref.)

LIPOSUCTION see **LIPECTOMY**

LIPOTES see **DOLPHINS**

LIPOTIDAE see **DOLPHINS**

LIPOTROPIN 61–91 see **BETA-ENDORPHIN**

LIPOXIDASE see **LIPOXYGENASE**

LIPOXYGENASE

[Recent progress on the study of lipoxygenases--discovery of novel isozymes and molecular evolution] Takahashi Y, et al. **Seikagaku** 1998 Sep;70(9):1189–93 (14 ref.) **(Jpn)**

[Lipoxygenases] Yamamoto S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1132–8 (38 ref.) **(Jpn)**

GENETICS

Lipoxygenase gene disruption studies. Status and applications. Johnson EN, et al. **Adv Exp Med Biol** 1999; 447:63–73 (42 ref.)

METABOLISM

The release of polyunsaturated fatty acids and their lipoxygenation in the brain. Kim HY, et al. **Adv Exp Med Biol** 1999;447:75–85 (34 ref.)

Measurements of arachidonic acid metabolites derived from the lipoxygenase pathways by high-pressure liquid chromatography. Borgeat P, et al. **Methods Mol Biol** 1998; 105:209–16 (2 ref.)

Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Spokas EG, et al. **Methods Mol Biol** 1999;120:213–47 (145 ref.)

Recent developments in biochemistry of the plant lipoxygenase pathway. Grechkin A. **Prog Lipid Res** 1998 Nov;37(5):317–52 (277 ref.)

PHYSIOLOGY

The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. Kuhn H, et al. **FEBS Lett** 1999 Apr 16;449(1):7–11 (49 ref.)

Role of lipoxygenases in breast cancer. Natarajan R, et al. **Front Biosci** 1998 Jun 8;3:E81–8 (64 ref.)

Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. Brash AR. **J Biol Chem** 1999 Aug 20;274(34):23679–82 (59 ref.)

Leukotrienes and lipoxins: lipoxygenase-derived modulators of leukocyte recruitment and vascular tone in glomerulonephritis. Clarkson MR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3043–51 (92 ref.)

5-LIPOXYGENASE see **ARACHIDONATE 5-LIPOXYGENASE**

12-LIPOXYGENASE see **ARACHIDONATE 12-LIPOXYGENASE**

15-LIPOXYGENASE see **ARACHIDONATE 15-LIPOXYGENASE**

LIPOXYGENASE INHIBITORS

METABOLISM

Lipoxygenase inhibitors as potential cancer chemopreventives. Steele VE, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May;8(5):467–83 (244 ref.)

PHARMACOLOGY

Lipoxygenase inhibition in prostate cancer. Myers CE, et al. **Eur Urol** 1999;35(5–6):395–8 (3 ref.)

Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism. Christie MJ, et al. **Inflamm Res** 1999 Jan;48(1):1–4 (27 ref.)

THERAPEUTIC USE

Lipoxygenase inhibitors as potential cancer chemopreventives. Steele VE, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May;8(5):467–83 (244 ref.)

Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Busse WW, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:110–5 (27 ref.)

Leukotriene antagonism in asthma and rhinitis. Lane SJ. **Respir Med** 1998 Jun;92(6):795–809 (150 ref.)

[Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class] Santais MC, et al. **Rev Med Interne** 1998 Feb;19(2):98–107 (74 ref.) (Eng. Abstr.) **(Fre)**

[The use of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in bronchial asthma treatment (editorial)] Kuziemski K, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):317–20 (39 ref.) (Eng. Abstr.) **(Pol)**

LIPREADING

Speechreading: advances in understanding its cortical bases and implications for deafness and speech rehabilitation. Campbell R. **Scand Audiol Suppl** 1998;49:80–6 (31 ref.)

Everyday speechreading: understanding seen speech action. Campbell R. **Scand J Psychol** 1998 Sep;39(3):163–7 (40 ref.)

LISINOPRIL

ADVERSE EFFECTS

Drug-induced pancreatitis (lisinopril). Miller LG, et al. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):150–3 (17 ref.)

LISSODELPHIS see **DOLPHINS**

LISTERIA

PHYSIOLOGY

Spatial control of actin filament assembly: lessons from Listeria. Beckerle MC. **Cell** 1998 Dec 11;95(6):741–8 (46 ref.)

LISTERIA INFECTIONS

Listeria infection after liver transplantation: report of a case and review of the literature. Limaye AP, et al. **Am J Gastroenterol** 1998 Oct;93(10):1942–4 (23 ref.)

Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Mylonakis E, et al. **Medicine (Baltimore)** 1998 Sep;77(5):313–36 (309 ref.)

Listeriosis during pregnancy. Silver HM. **Obstet Gynecol Surv** 1998 Dec;53(12):737–40 (26 ref.)

[Listeriosis] Inamura Y. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):354–6 (9 ref.) **(Jpn)**

[Hepatic listeriosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):446–8 (20 ref.) **(Jpn)**

[Listeria monocytogenes--the perfect parasite?] Wyller VB, et al. **Tidsskr Nor Laegeforen** 1999 Jan 30;119(3):375–9 (65 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

[Infectious aneurysm due to Listeria monocytogenes: a new case and review of the literature] Paccalin M, et al. **Rev Med Interne** 1998 Sep;19(9):661–5 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Listeriosis: recognizing it, treating it, preventing it. Taege AJ. **Cleve Clin J Med** 1999 Jun;66(6):375–80 (39 ref.)

Listeria monocytogenes causing solitary liver abscess. Case report and review of the literature. Brönnimann S, et al. **Dig Surg** 1998;15(4):364–8 (30 ref.)

ETIOLOGY

Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Roesler J, et al. **Exp Hematol** 1999 Sep;27(9):1368–74 (23 ref.)

THERAPY

Listeriosis: recognizing it, treating it, preventing it. Taege AJ. **Cleve Clin J Med** 1999 Jun;66(6):375–80 (39 ref.)

LISTERIA MONOCYTOGENES

[Listeria monocytogenes--the perfect parasite?] Wyller VB, et al. **Tidsskr Nor Laegeforen** 1999 Jan 30;119(3):375–9 (65 ref.) (Eng. Abstr.) **(Nor)**

ENZYMOLOGY

Bacterial phospholipases and intracellular growth: the two distinct phospholipases C of Listeria monocytogenes. Goldfine H, et al. **Soc Appl Bacteriol Symp Ser** 1998; 27:7S–14S (53 ref.)

IMMUNOLOGY

Listeria monocytogenes as a probe to study cell-mediated immunity. Shen H, et al. **Curr Opin Immunol** 1998 Aug; 10(4):450–8 (65 ref.)

ISOLATION & PURIFICATION

Listeria monocytogenes causing solitary liver abscess. Case report and review of the literature. Brönnimann S, et al. **Dig Surg** 1998;15(4):364–8 (30 ref.)

[Infectious aneurysm due to Listeria monocytogenes: a new case and review of the literature] Paccalin M, et al. **Rev Med Interne** 1998 Sep;19(9):661–5 (20 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

The relationship between acid stress responses and virulence in Salmonella typhimurium and Listeria monocytogenes. Gahan CG, et al. **Int J Food Microbiol** 1999 Sep 15; 50(1–2):93–100 (38 ref.)

PHYSIOLOGY

The relationship between acid stress responses and virulence in Salmonella typhimurium and Listeria monocytogenes. Gahan CG, et al. **Int J Food Microbiol** 1999 Sep 15; 50(1–2):93–100 (38 ref.)

LITERACY PROGRAMS see **EDUCATION**

LITERATURE

see related
MEDICINE IN LITERATURE

LITHIASIS

LITHIASIS

see related
CALCULI

COMPLICATIONS

Rhinolithiasis associated with septal perforation. A case report. Kharoubi S. **Acta Otorhinolaryngol Belg** 1998; 52(3):241–5 (22 ref.)

ETIOLOGY

[Testicular microlithiasis] Said M, et al. **Ann Urol (Paris)** 1998;32(5):321–4 (24 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Idiopathic calcium nephrolithiasis. Marangella M, et al. **Nephron** 1999;81 Suppl 1:38–44 (33 ref.)

RADIOGRAPHY

[The cauda equina syndrome and a sacral lithic mass] Zambrana Garcia JL, et al. **Rev Clin Esp** 1999 Jul; 199(7):471–2 (7 ref.) **(Spa)**

ULTRASONOGRAPHY

Testicular microlithiasis: US findings in six pediatric cases and literature review. Dell'Acqua A, et al. **Eur Radiol** 1999; 9(5):940–4 (40 ref.)

[Testicular microlithiasis] Said M, et al. **Ann Urol (Paris)** 1998;32(5):321–4 (24 ref.) (Eng. Abstr.) **(Fre)**

LITHIUM

ADVERSE EFFECTS

Lithium and the kidney: an updated review. Gitlin M. **Drug Saf** 1999 Mar;20(3):231–43 (77 ref.)

Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini RJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:77–84; discussion 111–6 (58 ref.)

Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. Kleiner J, et al. **J Clin Psychiatry** 1999 Apr;60(4):249–55 (96 ref.)

Is thyroxine during lithium therapy necessary? [comment] Bartalena L, et al. **J Endocrinol Invest** 1999 Mar;22(3):220–2 (12 ref.) Comment on: J Endocrinol Invest 1998 Dec;21(11):784–6.

Is thyroxine during lithium therapy necessary? [see comments] Lazarus JH. **J Endocrinol Invest** 1998 Dec; 21(11):784–6 (15 ref.) Comment in: J Endocrinol Invest 1999 Mar;22(3):220–2.

Aquaporin-2 as a biomarker of distal renal tubular function using lithium as an experimental model. Sisson D, et al. **Ren Fail** 1999 May-Jul;21(3–4):331–6 (35 ref.)

The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Lazarus JH. **Thyroid** 1998 Oct;8(10):909–13 (52 ref.)

METABOLISM

Effect of metabolic acidosis on renal tubular sodium handling in rats as determined by lithium clearance. Menegon LF, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1269–73 (26 ref.)

PHARMACOLOGY

Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Ikonomov OC, et al. **Am J Psychiatry** 1999 Oct; 156(10):1506–14 (70 ref.)

The legacy of lithium effects on development. Kao KR, et al. **Biol Cell** 1998 Nov;90(8):585–9 (74 ref.)

Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji HK, et al. **J Clin Psychiatry** 1999;60 Suppl 2:27–39; discussion 40–1, 113–6 (138 ref.)

POISONING

Lithium intoxication. Timmer RT, et al. **J Am Soc Nephrol** 1999 Mar;10(3):666–74 (34 ref.)

THERAPEUTIC USE

Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Ikonomov OC, et al. **Am J Psychiatry** 1999 Oct; 156(10):1506–14 (70 ref.)

Family history of affective disorders and the significance for prophylactic effect of lithium treatment [letter] Nylander PO, et al. **Biol Psychiatry** 1999 Apr 15;45(8):1079–81 (23 ref.)

The prophylactic efficacy of lithium--transient or persistent? Kleindienst N, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249(3):144–9 (41 ref.)

The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. Schou M. **J Affect Disord** 1998 Sep;50(2–3):253–9 (33 ref.)

Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini RJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:77–84; discussion 111–6 (58 ref.)

Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Calabrese JR, et al. **J Clin Psychiatry** 1999;60 Suppl 5:5–13; discussion 14–5 (42 ref.)

An overview of the treatment of schizoaffective disorder. McElroy SL, et al. **J Clin Psychiatry** 1999;60 Suppl 5:16–21; discussion 22 (68 ref.)

Mood-stabilizing drugs in depression. Shelton RC. **J Clin Psychiatry** 1999;60 Suppl 5:37–40; discussion 41–2 (44 ref.)

Pharmacogenetics of lithium response in bipolar disorder [see comments] Alda M. **J Psychiatry Neurosci** 1999 Mar; 24(2):154–8 (36 ref.) Comment in: J Psychiatry Neurosci 1999 Mar;24(2):139–40.

A bimodal model of the mechanism of action of lithium. Jope RS. **Mol Psychiatry** 1999 Jan;4(1):21–5 (35 ref.)

Anti-bipolar therapy: mechanism of action of lithium. Jope RS. **Mol Psychiatry** 1999 Mar;4(2):117–28 (150 ref.)

The social and economic effects of manic depressive illness and of its treatment in lithium clinics. Armond AD. **Occup Med (Lond)** 1998 Nov;48(8):505–9 (17 ref.)

[Current trends in the therapeutic use of thymic regulators] Dardennes R, et al. **Presse Med** 1998 Dec 19;27(40):2157–63 (74 ref.) (Eng. Abstr.) **(Fre)**

[Lithium in the treatment of acute depression (see comments)] Adli M, et al. **Fortschr Neurol Psychiatr** 1998 Oct; 66(10):435–41 (49 ref.) (Eng. Abstr.) Comment in: Fortschr Neurol Psychiatr 1999 Aug;67(8):384–6. **(Ger)**

LITHIUM CARBONATE

ADVERSE EFFECTS

[Impaired kidney function in lithium therapy] Gabutti L, et al. **Ther Umsch** 1998 Sep;55(9):562–4 (7 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

[Pharmacotherapy in bipolar disorder] Nolen WA. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1299–305 (23 ref.) (Eng. Abstr.) **(Dut)**

[Lithium salts in child and adolescent psychiatry] Moll GH, et al. **Nervenarzt** 1998 Nov;69(11):935–43 (20 ref.) (Eng. Abstr.) **(Ger)**

LITHIUM CHLORIDE

ADVERSE EFFECTS

Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Schou M. **Pharmacopsychiatry** 1998 Nov;31(6):210–5 (45 ref.)

THERAPEUTIC USE

Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Schou M. **Pharmacopsychiatry** 1998 Nov;31(6):210–5 (45 ref.)

LITHOLAPAXY see **LITHOTRIPSY**

LITHOTRIPSY

see related
HIGH-ENERGY SHOCK WAVES

Current advances in shock wave lithotripsy [see comments] Tolley DA, et al. **Curr Opin Urol** 1999 Jul;9(4):319–23 (21 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.

Treatment of renal stones by extracorporeal shock wave lithotripsy. Renner C, et al. **Nephron** 1999;81 Suppl 1:71–81 (81 ref.)

[Extracorporeal shockwave therapy (ESWT) in orthopedic indications: a selective review] Fritze J. **Versicherungsmedizin** 1998 Oct 1;50(5):180–5 (51 ref.) (Eng. Abstr.) **(Ger)**

[Role of electrohydraulic extracorporeal shockwave lithotripsy (Dornier HM 4) in the treatment of caliceal diverticulum lithiasis] Torrecilla Ortiz C, et al. **Actas Urol Esp** 1998 Oct;22(9):744–50 (22 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Anti-glomerular basement membrane glomerulonephritis after extracorporeal shock wave lithotripsy. Xenocostas A, et al. **Am J Kidney Dis** 1999 Jan;33(1):128–32 (20 ref.)

Venous thrombosis after extracorporeal shock-wave lithotripsy in a patient with heterozygous APC-resistance [letter] Brodmann M, et al. **Thromb Haemost** 1998 Nov; 80(5):861 (4 ref.)

METHODS

Percutaneous nephrolithotripsy [see comments] Puppo P. **Curr Opin Urol** 1999 Jul;9(4):325–8 (14 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.

[The mechanical effects of shock waves in extracorporeal shock wave treatment of calcific tendinitis--an in vitro model] Perlick L, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan-Feb;137(1):10–6 (27 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Electrohydraulic and extracorporeal shock-wave lithotripsy. Adams LG, et al. **Vet Clin North Am Small Anim Pract** 1999 Jan; 29(1):293–302, xv (27 ref.)

LITHOTRIPSY, LASER

METHODS

Ureteroscopic lithotripsy [see comments] Grasso M 3rd. **Curr Opin Urol** 1999 Jul;9(4):329–33 (40 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.

LITIGATION see **JURISPRUDENCE**

LITOMOSOIDES see **FILARIOIDEA**

LITTLE'S DISEASE see **CEREBRAL PALSY**

LIVEDO RETICULARIS see **SKIN DISEASES, VASCULAR**

LIVER

see related
HEPATECTOMY

Ischaemia-reperfusion injury of the liver: treatment in theory and in practice. Tredger JM. **Biofactors** 1998;8(1–2):161–4 (25 ref.)

Survival and function of isolated hepatocytes after cryopreservation. Guillouzo A, et al. **Chem Biol Interact** 1999 Jun 1;121(1):7–16 (32 ref.)

Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Li AP, et al. **Chem Biol Interact** 1999 Jun 1;121(1):117–23 (15 ref.)

A systems approach in hepatology. Molino G, et al. **Forum (Genova)** 1999 Apr-Jun;9(2):94–110 (52 ref.)

Hepatic gene therapy for haemophilia B. Kay MA. **Haemophilia** 1998 Jul;4(4):389–92 (20 ref.)

Successful treatment of a hepatic abscess that formed secondary to fish bone penetration by percutaneous transhepatic removal of the foreign body: report of a case. Horii K, et al. **Surg Today** 1999;29(9):922–6 (16 ref.)

ANATOMY & HISTOLOGY

Architectural pattern, tissue and cellular morphology in livers of fishes: relationship to experimentally-induced neoplastic responses. Hinton DE, et al. **EXS** 1998;86:141–64 (83 ref.)

The Glissonian approach of the hilum. Launois B, et al. **Swiss Surg** 1999;5(3):143–6 (11 ref.)

BLOOD SUPPLY

Transarterial chemoembolization and percutaneous ethanol injection therapy in patients with hepatocellular carcinoma [comment] Kirchhoff T, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):907–9 (57 ref.) Comment on: Eur J Gastroenterol Hepatol 1998 Nov;10(11):915–8.

'Nonportal' splanchnic venous supply to the liver: abnormal findings on CT, US and MRI. Itai Y, et al. **Eur Radiol** 1999;9(2):237–43 (35 ref.)

The role of adhesion molecules and nitric oxide in intestinal and hepatic ischemia/reperfusion. Kubes P. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1458–63 (48 ref.)

Role of microcirculation in hepatic ischemia/reperfusion injury. Menger MD, et al. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1452–7 (78 ref.)

Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Okuda K, et al. **Hepatology** 1998 Nov;28(5):1191–8 (105 ref.)

Focally spared area of fatty liver that receives blood passing through the sinusoids of a hypervascular hepatocellular carcinoma. Murakami T, et al. **J Comput Assist Tomogr** 1999 Mar-Apr;23(2):320–2 (6 ref.)

Pseudolesion in segments II and III of the liver on CT during arterial portography caused by aberrant right gastric venous drainage. Yoon KH, et al. **J Comput Assist Tomogr** 1999 Mar-Apr;23(2):306–9 (12 ref.)

Mechanisms of reperfusion injury after warm ischemia of the liver. Jaeschke H. **J Hepatobiliary Pancreat Surg** 1998; 5(4):402–8 (84 ref.)

Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. Konno H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):1–6 (30 ref.)

Total vascular exclusion for liver resections: pros and cons. Zografos GN, et al. **J Surg Oncol** 1999 Sep;72(1):50–5; discussion 55–6 (76 ref.)

Kupffer cell-dependent reperfusion injury in liver transplantation: new clinically relevant use of glycine. Thurman RG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:185–90 (31 ref.)

Glutathione defense in non-parenchymal cells. DeLeve LD. **Semin Liver Dis** 1998;18(4):403–13 (95 ref.)

Role of cytokines and cytokine-producing cells in reperfusion injury to the liver. Lichtman SN, et al.

Semin Liver Dis 1999;19(2):171–87 (244 ref.)

Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor–delta in reperfusion injury of liver transplantation–mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1055–8 (18 ref.)

[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:72–7 (14 ref.) (Eng. Abstr.) **(Ger)**

[Duplex ultrasound of the liver and portal vein system] Mohr HH, et al. **Med Klin** 1998 Nov 15;93(11):669–77 (72 ref.) (Eng. Abstr.) **(Ger)**

[Usefulness and problems of total hepatic vascular exclusion in liver surgery] Shimahara Y, et al. **Nippon Geka Gakkai Zasshi** 1999 May;100(5):335–41 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Role of cytokines in hepatic ischemia and reperfusion injury] Suzuki S, et al. **Nippon Geka Gakkai Zasshi** 1999 May; 100(5):325–30 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Ischemia–reperfusion liver injury] Turecký L. **Bratisl Lek Listy** 1999 Jan;100(1):36–40 (31 ref.) (Eng. Abstr.) **(Slo)**

CHEMISTRY

Hepatic and renal expression of senescence marker protein–30 and its biological significance. Fujita T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S124–31 (32 ref.)

CYTOLOGY

Cytokine regulation of hepatic stellate cells in liver fibrosis. Tsukamoto H. **Alcohol Clin Exp Res** 1999 May;23(5):911–6 (61 ref.)

Mechanisms and functional features of polarized membrane traffic in epithelial and hepatic cells. Zegers MMP, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):257–69 (179 ref.)

Fas–mediated apoptosis of hepatic cells. Feldmann G, et al. **Biomed Pharmacother** 1998;52(9):378–85 (71 ref.)

An update on high–yield hepatocyte isolation methods and on the potential clinical use of isolated liver cells. Puviani AC, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Oct;121(2):99–109 (68 ref.)

Liver stem cells: a two compartment system. Alison M. **Curr Opin Cell Biol** 1998 Dec;10(6):710–5 (43 ref.)

Role of Kupffer cells in peroxisome proliferator–induced hepatocyte proliferation. Rose ML, et al. **Drug Metab Rev** 1999 Feb;31(1):87–116 (81 ref.)

The current status of primary hepatocyte culture. Mitaka T. **Int J Exp Pathol** 1998 Dec;79(6):393–409 (180 ref.)

Tumour necrosis factor alpha––mediator of apoptosis and cell proliferation of hepatocytes. Plümpe J, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):235–43 (96 ref.)

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. Arthur MJ, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S33–8 (59 ref.)

Growth and maturation of small hepatocytes. Mitaka T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S70–7 (44 ref.)

Dose–dependent biphasic effects of phenobarbital on growth and differentiation of primary culture rat hepatocytes. Miyazaki M, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S78–82 (31 ref.)

Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. Riordan SM, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):757–70 (163 ref.)

Molecular mechanisms in the reversible regulation of morphology, proliferation and collagen metabolism in hepatic stellate cells by the three–dimensional structure of the extracellular matrix. Senoo H, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S19–32 (51 ref.)

Growth and differentiation of adult rat hepatocytes regulated by the interaction between parenchymal and non–parenchymal liver cells. Tateno C, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S83–92 (24 ref.)

Hepatic stem cells. Alison M, et al. **J Hepatol** 1998 Oct; 29(4):676–82 (67 ref.)

Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. Gupta S, et al. **J Hepatol** 1999 Jan; 30(1):162–70 (59 ref.)

Ceramide–mediated apoptosis of hepatocytes in vivo: a matter of the nucleus? [editorial; comment] Hoekstra D. **J Hepatol** 1999 Jul;31(1):161–4 (25 ref.) Comment on: J Hepatol 1999 Jul;31(1):8–17.

Foreword: prospects of liver cell transplantation and liver–directed gene therapy. Chowdhury JR. **Semin Liver Dis** 1999;19(1):1–6 (28 ref.)

Principles of therapeutic liver repopulation. Grompe M, et al. **Semin Liver Dis** 1999;19(1):7–14 (41 ref.)

Hepatocyte transplantation for the treatment of human disease. Strom SC, et al. **Semin Liver Dis** 1999;19(1):39–48 (80 ref.)

[Glutamine and the liver cell: metabolism, properties and the concept of metabolic regulation by cell swelling] Lavoinne A, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct;56(5):557–62 (31 ref.) (Eng. Abstr.) **(Fre)**

[Polarity of epithelial cells of the liver. Cellular and molecular mechanisms, and pathologic changes] Maurice M, et al. **Gastroenterol Clin Biol** 1998 May;22(5):530–40 (100 ref.) **(Fre)**

[Hepatocellular transplantation––from the beginning to clinical application] Markus PM, et al. **Chirurg** 1999 Feb; 70(2):162–8 (79 ref.) (Eng. Abstr.) **(Ger)**

[A pivotal role of activated hepatic macrophage in the progression of alcoholic liver disease] Yamada S. **Sangyo Ika Daigaku Zasshi** 1999 Mar 1;21(1):37–45 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of cell growth by N–acetylglucosaminyltransferases] Miyoshi E, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2275–80 (12 ref.) **(Jpn)**

[Phenomenon of karyolysis in cytophotomorphometric examinations] Parafiniuk M. **Ann Acad Med Stetin** 1998; Suppl 43:1–87 (108 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Jones AL, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):129–33 (56 ref.)

Alcohol, vitamin A, and beta–carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Leo MA, et al. **Am J Clin Nutr** 1999 Jun;69(6):1071–85 (208 ref.)

Nonsteroidal anti–inflammatory drug–associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Bjorkman D. **Am J Med** 1998 Nov 2;105(5A):17S–21S (51 ref.)

Hepatotoxicity due to ticlopidine [letter] Martínez Pérez–Balsa A, et al. **Ann Pharmacother** 1998 Nov; 32(11):1250–1 (17 ref.)

Chemopreventive effects of 2–(allylthio)pyrazine. Kim ND, et al. **Arch Pharm Res** 1999 Apr;22(2):99–107 (65 ref.)

Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Romagnuolo J, et al. **Can J Gastroenterol** 1998 Oct; 12(7):479–83 (24 ref.)

Immunological investigation in hepatic drug reactions. Maria VA, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:71–7 (40 ref.)

Acarbose–associated hepatotoxicity [letter] Andrade RJ, et al. **Diabetes Care** 1998 Nov;21(11):2029–30 (11 ref.)

Phenobarbital–mediated changes in gene expression in the liver. Meyer UA, et al. **Drug Metab Rev** 1999 May; 31(2):365–73 (32 ref.)

Multiple sites of insulin resistance: muscle, liver and adipose tissue [comment] Stumvoll M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):107–10 (32 ref.) Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):140–7.

Chronic ethanol, oxygen tension and hepatocyte energy metabolism. Cunningham CC, et al. **Front Biosci** 1999 Jul 1;4:D551–6 (26 ref.)

Mechanisms of alcohol–induced hepatotoxicity: studies in rats. Thurman RG, et al. **Front Biosci** 1999 Jul 15;4:e42–6 (29 ref.)

Mechanism of hepatoprotective action of bile salts in liver disease. Stiehl A, et al. **Gastroenterol Clin North Am** 1999 Mar;28(1):195–209, viii (108 ref.)

Hepatotoxicity of psychotropic drugs. Selim K, et al. **Hepatology** 1999 May;29(5):1347–51 (69 ref.)

Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes. Tanaka E. **J Clin Pharm Ther** 1998 Dec;23(6):403–16 (148 ref.)

Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. Kristensen T, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):314–7 (26 ref.)

Metallothionein transgenic and knock–out mouse models in the study of cadmium toxicity. Klaassen CD, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:97–102 (24 ref.)

Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Amacher DE. **Regul Toxicol Pharmacol** 1998 Apr;27(2):119–30 (107 ref.)

Characteristics and significance of D–tagatose–induced liver enlargement in rats: An interpretative review. Bär A. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S83–93 (122 ref.)

Peroxisome proliferator–activated receptor (PPAR) alpha activation and its consequences in humans. Hertz R, et al. **Toxicol Lett** 1998 Dec 28;102–103:85–90 (40 ref.)

Marriage of a medium–term liver model to surrogate markers––a practical approach for risk and benefit assessment. Moore MA, et al. **Toxicol Pathol** 1999 Mar–Apr;27(2):237–42 (37 ref.)

[Natural antioxidants as hepatoprotectors] Buniatian ND, et al. **Eksp Klin Farmakol** 1999 Mar–Apr;62(2):64–7 (14 ref.) **(Rus)**

[The effect of glucocorticoid preparations on liver metabolism] Vengerovskiĭ AI, et al. **Eksp Klin Farmakol** 1999 Jan–Feb;62(1):75–80 (90 ref.) (Eng. Abstr.) **(Rus)**

[The hepatotoxicity of flutamide] Pogromov AP, et al. **Klin Med (Mosk)** 1998;76(7):56–8 (18 ref.) **(Rus)**

EMBRYOLOGY

Early liver differentiation: genetic potentiation and multilevel growth control. Zaret K. **Curr Opin Genet Dev** 1998 Oct; 8(5):526–31 (58 ref.)

Fetal liver organ cultures as a tool to study selection processes during B cell development. Ceredig R, et al. **Curr Top Microbiol Immunol** 1999;246:11–7; discussion 18–9 (19 ref.)

Liver development: a paradigm for hepatobiliary disease in later life. Bezerra JA. **Semin Liver Dis** 1998;18(3):203–16 (84 ref.)

ENZYMOLOGY

Inducible nitric oxide synthase in the liver: regulation and function. Taylor BS, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):766–81 (138 ref.)

The insulin receptor substrate 1 associates with phosphotyrosine phosphatase SHPTP2 in liver and muscle of rats. Lima MH, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1409–13 (17 ref.)

The role of hepatic lipase in lipoprotein metabolism. Connelly PW. **Clin Chim Acta** 1999 Aug;286(1–2):243–55 (27 ref.)

Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids. Knights KM. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):776–82 (75 ref.)

Dopamine sulphate: an enigma resolved. Eisenhofer G, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S41–53 (117 ref.)

An update on high–yield hepatocyte isolation methods and on the potential clinical use of isolated liver cells. Puviani AC, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Oct;121(2):99–109 (68 ref.)

Hepatic lipase deficiency. Connelly PW, et al. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):547–72 (62 ref.)

Hepatic lipase: new insights from genetic and metabolic studies. Cohen JC, et al. **Curr Opin Lipidol** 1999 Jun; 10(3):259–67 (63 ref.)

Application of cryopreserved precision–cut liver slices in pharmacotoxicology––principles, literature data and own investigations with special reference to CYP1A1–mRNA induction. Glöckner R, et al. **Exp Toxicol Pathol** 1998 Sep; 50(4–6):440–9 (35 ref.)

Hepatic lipase. Fan J, et al. **J Atheroscler Thromb** 1998; 5(1):41–5 (29 ref.)

Extrahepatic drug metabolizing enzymes. Kapitulnik J, et al. **J Biochem Mol Toxicol** 1999;13(5):227–30 (17 ref.)

C/EBP and the control of phosphoenolpyruvate carboxykinase gene transcription in the liver. Croniger C, et al. **J Biol Chem** 1998 Nov 27;273(48):31629–32 (52 ref.)

Purification of rat hepatic lipase essentially free of apolipoprotein E and apolipoprotein B. Bensadoun A, et al. **Methods Mol Biol** 1999;109:151–6 (17 ref.)

Determining lipoprotein lipase and hepatic lipase activity using radiolabeled substrates. Briquet–Laugier V, et al. **Methods Mol Biol** 1999;109:81–94 (17 ref.)

Lysosomal acid lipase. Assay and purification. Merkel M, et al. **Methods Mol Biol** 1999;109:95–107 (23 ref.)

In vitro measurement of lipoprotein and hepatic lipases. Vilella E, et al. **Methods Mol Biol** 1998;110:243–51 (11 ref.)

[Significance of hepatic cytochrome P450 enzymes for psychopharmacology] Normann C, et al. **Nervenarzt** 1998 Nov;69(11):944–55 (146 ref.) (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

Nucleoside transporters and liver cell growth. Pastor–Anglada M, et al. **Biochem Cell Biol** 1998; 76(5):771–7 (39 ref.)

IMMUNOLOGY

Cytokine regulation of hepatic stellate cells in liver fibrosis. Tsukamoto H. **Alcohol Clin Exp Res** 1999 May;23(5):911–6 (61 ref.)

Hepatic dendritic cells: immunobiology and role in liver transplantation. Thomson AW, et al. **J Leukoc Biol** 1999 Aug;66(2):322–30 (68 ref.)

INJURIES

The management of blunt liver injuries. Strong RW. **Aust N Z J Surg** 1999 Aug;69(8):609–16 (42 ref.)

Inferior vena caval thrombosis after traumatic liver injury. Kimoto T, et al. **HPB Surg** 1998;11(2):111–6 (22 ref.)

Immunopharmacologic agents in the amelioration of hepatic injuries. Farghali H, et al. **Int J Immunopharmacol** 1998 Apr–May;20(4–5):125–39 (103 ref.)

Traumatic thoracobiliary fistula: report of a case successfully managed conservatively, with an overview of current diagnostic and therapeutic options. Sheik–Gafoor MH, et al. **J Trauma** 1998 Oct;45(4):819–21 (16 ref.)

[Blunt injuries of the liver. Reliable approaches to treatment] Létoublon C, et al. **Ann Chir** 1998;52(2):166–71 (9 ref.) **(Fre)**

[Hepatic trauma: pediatric features] Moog R, et al. **Ann Chir** 1998;52(10):1022–7 (33 ref.) (Eng. Abstr.) **(Fre)**

[Surgical management of liver rupture] Safi F, et al. **Chirurg** 1999 Mar;70(3):253–8 (33 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Role of hepatic, intrahepatic and hepatoenteral nerves in the regulation of carbohydrate metabolism and hemodynamics of the liver and intestine. Jungermann K, et al. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1414–7 (13 ref.)

The canine sympathetic neuropeptide galanin: a

neurotransmitter in pancreas, a neuromodulator in liver. Taborsky GJ Jr, et al. **Horm Metab Res** 1999 May; 31(5):351–4 (24 ref.)

A non-essential role of liver innervation in controlling feeding behavior [editorial] Bellinger LL. **Nutrition** 1999 Jun;15(6):506 (10 ref.)

METABOLISM

Cu metabolism in the liver. McArdle HJ, et al. **Adv Exp Med Biol** 1999;448:29–37 (42 ref.)

Cellular mechanisms of insulin resistance in humans. Shulman GI. **Am J Cardiol** 1999 Jul 8;84(1A):3J–10J (28 ref.)

Regulation of glucose production by the liver. Nordlie RC, et al. **Annu Rev Nutr** 1999;19:379–406 (117 ref.)

Role of lipoprotein lipases in postprandial lipid metabolism. Jansen H, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S31–4 (40 ref.)

Glycogen storage diseases and the liver. Burchell A. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):337–54 (78 ref.)

Other hereditary diseases and the liver. Poley JR, et al. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):369–407 (154 ref.)

Specific features of glycogen metabolism in the liver. Bollen M, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):19–31 (180 ref.)

Anionic phospholipids and the regulation of cell functions. Wilton DC. **Biochem Soc Trans** 1998 Aug;26(3):378–83 (38 ref.)

Interactions between nitric oxide and cytochrome P-450 in the liver. Khatsenko O. **Biochemistry (Mosc)** 1998 Jul; 63(7):833–9 (49 ref.)

Glutamine and regulation of gene expression in rat hepatocytes: the role of cell swelling. Lavoinne A, et al. **Biochimie** 1998 Oct;80(10):807–11 (31 ref.)

Regulation of the assembly and secretion of very low density lipoproteins by the liver. Kendrick JS, et al. **Biol Chem** 1998 Aug–Sep;379(8–9):1033–40 (51 ref.)

An important drug interaction. Williams CN. **Can J Gastroenterol** 1998 Nov–Dec;12(8):535 (9 ref.)

Nuclear orphan receptors control cholesterol catabolism. Russell DW. **Cell** 1999 May 28;97(5):539–42 (17 ref.)

Cathepsins as effector proteases in hepatocyte apoptosis. Roberts LR, et al. **Cell Biochem Biophys** 1999;30(1):71–88 (43 ref.)

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro–in vivo correlations. Lavé T, et al. **Clin Pharmacokinet** 1999 Mar;36(3):211–31 (63 ref.)

Inhibition and induction of cytochrome P450 and the clinical implications. Lin JH, et al. **Clin Pharmacokinet** 1998 Nov; 35(5):361–90 (192 ref.)

Pharmacokinetics of opioids in liver disease. Tegeder I, et al. **Clin Pharmacokinet** 1999 Jul;37(1):17–40 (257 ref.)

The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes. Mason TM. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):461–87 (74 ref.)

Past and present scenario of hepatoprotectants. Ram VJ, et al. **Curr Med Chem** 1999 Mar;6(3):217–54 (302 ref.)

Bile acid and xenobiotic transporters in liver. Stieger B, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):462–7 (55 ref.)

Inter-organ protein and carbohydrate metabolic relationships during sepsis: necessary evils or uncanny coincidences? Vary TC. **Curr Opin Clin Nutr Metab Care** 1999 May; 2(3):235–42 (64 ref.)

Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Björkhem I, et al. **Curr Opin Lipidol** 1999 Apr;10(2):161–5 (20 ref.)

Hepatocellular transport and secretion of biliary lipids. Cohen DE. **Curr Opin Lipidol** 1999 Aug;10(4):295–302 (73 ref.)

Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Cherrington AD. **Diabetes** 1999 May; 48(5):1198–214 (57 ref.)

Regulation of hepatic glutathione synthesis: current concepts and controversies. Lu SC. **FASEB J** 1999 Jul; 13(10):1169–83 (124 ref.)

Alpha-lipoic acid in liver metabolism and disease. Bustamante J, et al. **Free Radic Biol Med** 1998 Apr; 24(6):1023–39 (141 ref.)

Chronic ethanol, oxygen tension and hepatocyte energy metabolism. Cunningham CC, et al. **Front Biosci** 1999 Jul 1;4:D551–6 (26 ref.)

Aldehyde-protein adducts in the liver as a result of ethanol-induced oxidative stress. Niemelä O. **Front Biosci** 1999 Jun 1;4:D506–13 (90 ref.)

Role of the enterohepatic circulation of bile salts in lipoprotein metabolism. Cooper AD. **Gastroenterol Clin North Am** 1999 Mar;28(1):211–29, viii (112 ref.)

Regulation of bile acid biosynthesis. Vlahcevic ZR, et al. **Gastroenterol Clin North Am** 1999 Mar;28(1):1–25, v (142 ref.)

Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Bouscarel B, et al. **Gastroenterology** 1999 Aug; 117(2):433–52 (217 ref.)

Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Rudling M, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:1–7 (41 ref.)

Role of hepatic, intrahepatic and hepatoenteral nerves in the regulation of carbohydrate metabolism and hemodynamics of the liver and intestine. Jungermann K, et al. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1414–7 (13 ref.)

Dietary fat and alcoholic liver disease. Mezey E. **Hepatology** 1998 Oct;28(4):901–5 (42 ref.)

Advances in hepatic transport: molecular mechanisms, genetic disorders, and treatment. A summary of the 1998 AASLD single topic conference. Wolkoff AW, et al. **Hepatology** 1998 Dec;28(6):1713–9 (100 ref.)

Liver-directed gene transfer vectors. Ferry N, et al. **Hum Gene Ther** 1998 Sep 20;9(14):1975–81 (96 ref.)

ATP7B (WND) protein. Terada K, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1063–7 (17 ref.)

Splanchnic tissue energy use in ruminants that consume forage-based diets ad libitum. Goetsch AL. **J Anim Sci** 1998 Oct;76(10):2737–46 (92 ref.)

Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. Kamisako T, et al. **J Gastroenterol Hepatol** 1999 May;14(5):405–12 (75 ref.)

Molecular regulation of hepatocellular transport systems in cholestasis. Trauner M, et al. **J Hepatol** 1999 Jul; 31(1):165–78 (145 ref.)

Dietary polyunsaturated fatty acids and hepatic gene expression. Jump DB, et al. **Lipids** 1999;34 Suppl:S209–12 (25 ref.)

Importance of metabolism in pharmacological studies: possible in vitro predictability. Delaforge M. **Nucl Med Biol** 1998 Nov;25(8):705–9 (15 ref.)

Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Ito K, et al. **Pharmacol Rev** 1998 Sep;50(3):387–412 (93 ref.)

Receptor-mediated mechanisms of lipoprotein remnant catabolism. Chappell DA, et al. **Prog Lipid Res** 1998 Dec; 37(6):393–422 (262 ref.)

Fatty acid ethyl esters: ethanol metabolites which mediate ethanol-induced organ damage and serve as markers of ethanol intake. Laposata M. **Prog Lipid Res** 1998 Nov; 37(5):307–16 (65 ref.)

Intestinal absorption, blood transport and hepatic and muscle metabolism of fatty acids in preruminant and ruminant animals. Hocquette JF, et al. **Reprod Nutr Dev** 1999 Jan–Feb;39(1):27–48 (122 ref.)

Oxidative stress in the liver and biliary tract diseases. Fehér J, et al. **Scand J Gastroenterol Suppl** 1998;228:38–46 (51 ref.)

Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Ballatori N, et al. **Semin Liver Dis** 1998; 18(4):377–87 (125 ref.)

Glutathione defense in non-parenchymal cells. DeLeve LD. **Semin Liver Dis** 1998;18(4):403–13 (95 ref.)

Retroviral vectors for liver-directed gene therapy. Kalpana GV. **Semin Liver Dis** 1999;19(1):27–37 (40 ref.)

Regulation of hepatic glutathione synthesis. Lu SC. **Semin Liver Dis** 1998;18(4):331–43 (127 ref.)

Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Ookhtens M, et al. **Semin Liver Dis** 1998; 18(4):313–29 (125 ref.)

Cytokines and the hepatic acute-phase response. Ramadori G, et al. **Semin Liver Dis** 1999;19(2):141–55 (173 ref.)

Hepatocyte-directed gene delivery by receptor-mediated endocytosis. Smith RM, et al. **Semin Liver Dis** 1999; 19(1):83–92 (107 ref.)

Gene delivery to the liver using simian virus 40-derived vectors. Strayer DS, et al. **Semin Liver Dis** 1999;19(1):71–81 (51 ref.)

The clearance of thrombin-antithrombin and related serpin-enzyme complexes from the circulation: role of various hepatocyte receptors. Wells MJ, et al. **Thromb Haemost** 1999 Mar;81(3):325–37 (179 ref.)

[Glutamine and the liver cell: metabolism, properties and the concept of metabolic regulation by cell swelling] Lavoinne A, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct;56(5):557–62 (31 ref.) (Eng. Abstr.) **(Fre)**

[Progressive familial intrahepatic cholestasis and hereditary anomalies if hepatocellular metabolism of bile acids] Jacquemin E. **Arch Pediatr** 1998 Jan;5(1):45–53 (53 ref.) (Eng. Abstr.) **(Fre)**

[From the glycogenic function of the liver to gene regulation by glucose] Kahn A. **C R Seances Soc Biol Fil** 1998; 192(5):813–27 (39 ref.) (Eng. Abstr.) **(Fre)**

[Perfusion and metabolism of liver and splanchnic nerve area under sevoflurane anesthesia] Schindler E, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S19–23 (60 ref.) (Eng. Abstr.) **(Ger)**

[The role of estrogens in hormonal regulation of lipid metabolism in women] Szafran H, et al. **Przegl Lek** 1998; 55(5):266–70 (31 ref.) (Eng. Abstr.) **(Pol)**

[Atherogenesis and the acute-phase reaction of the liver] Nagornev VA, et al. **Arkh Patol** 1998 Nov–Dec;60(6):62–8 (51 ref.) (Eng. Abstr.) **(Rus)**

[Some aspects of biliation] Ivanchenkova RA. **Klin Med (Mosk)** 1999;77(7):18–22 (38 ref.) **(Rus)**

PATHOLOGY

Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities. Dodd GD 3rd, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1031–6 (8 ref.)

III. Intracellular signaling in response to toxic liver injury. Jones BE, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G874–8 (40 ref.)

V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Lemasters JJ. **Am J Physiol** 1999 Jan;276(1 Pt 1):G1–6 (40 ref.)

A case of late onset primary hyperoxaluria type I (PH-I) presented with black liver. Kazama-Saegusa S, et al. **Clin Nephrol** 1998 Sep;50(3):184–7 (14 ref.)

Role of tissue repair in toxicologic interactions among hepatotoxic organics. Soni MG, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1307–17 (79 ref.)

Fast magnetic resonance imaging of liver. Ichikawa T, et al. **Eur J Radiol** 1999 Mar;29(3):186–210 (79 ref.)

Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Reimer P, et al. **Eur Radiol** 1998; 8(7):1198–204 (38 ref.)

Scoring procedures in clinical hepatology. Torchio M, et al. **Forum (Genova)** 1999 Apr–Jun;9(2):141–55 (59 ref.)

Mechanisms of alcohol-induced hepatotoxicity: studies in rats. Thurman RG, et al. **Front Biosci** 1999 Jul 15;4:e42–6 (29 ref.)

HIV-Related hepatic disease: when and why to biopsy. Poles MA. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):939–62 (98 ref.)

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Cerny A, et al. **Hepatology** 1999 Sep;30(3):595–601 (99 ref.)

Death receptors in liver biology and pathobiology. Faubion WA, et al. **Hepatology** 1999 Jan;29(1):1–4 (48 ref.)

Gene regulation in hepatic stellate cell. Lang A, et al. **Ital J Gastroenterol Hepatol** 1999 Mar;31(2):173–9 (86 ref.)

Liver and apoptosis. Valente M, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):73–7 (46 ref.)

Thorotrast associated nodular regenerative hyperplasia of the liver. Beer TW, et al. **J Clin Pathol** 1998 Dec;51(12):941–2 (12 ref.)

Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. Li D, et al. **J Gastroenterol Hepatol** 1999 Jul;14(7):618–33 (220 ref.)

The detection of occult liver metastases of colorectal carcinoma. Leen E. **J Hepatobiliary Pancreat Surg** 1999; 6(1):7–15 (30 ref.)

Angiomyolipoma of the liver: case report and collective review of cases diagnosed from fine needle aspiration biopsy specimens. Sawai H, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):333–8 (18 ref.)

Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. Mathieu D, et al. **J Magn Reson Imaging** 1999 Aug;10(2):193–5 (15 ref.)

Pyrrolizidine alkaloid plants, metabolism and toxicity. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):95–116 (155 ref.)

Hepatitis C virus infection: virus/host interactions. Pawlotsky JM. **J Viral Hepat** 1998 Sep;5 Suppl 1:3–8 (19 ref.)

Acute and chronic hepatic allograft rejection: pathology and classification. Batts KP. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S21–9 (27 ref.)

Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health (review). Chevalier S, et al. **Oncol Rep** 1998 Nov–Dec;5(6):1319–27 (117 ref.)

Broadsheet number 47: Chronic hepatitis: an update with guidelines for histopathological assessment of liver biopsies. Board of Education of The Royal College of Pathologists of Australasia. Hall PD. **Pathology** 1998 Nov;30(4):369–80 (68 ref.)

Histopathologic approach to metabolic liver disease: Part 1. Jevon GP, et al. **Pediatr Dev Pathol** 1998 May–Jun; 1(3):179–99 (121 ref.)

Hepatic neoplasms in childhood – a clinicopathologic study. Bhattacharya S, et al. **Pediatr Surg Int** 1998 Nov; 14(1–2):51–4 (22 ref.)

Recommendations for handling of pediatric liver biopsy specimens. Finn LS, et al. **Semin Diagn Pathol** 1998 Nov; 15(4):300–5 (18 ref.)

Differential diagnosis of hepatocellular nodular lesions. Hytiroglou P, et al. **Semin Diagn Pathol** 1998 Nov; 15(4):285–99 (26 ref.)

Interpretation of biopsy findings in the transplant liver. Jones KD, et al. **Semin Diagn Pathol** 1998 Nov;15(4):306–17 (39 ref.)

Management of focal nodular hyperplasia and hepatocellular adenoma. Mentha G, et al. **Swiss Surg** 1999;5(3):122–5 (13 ref.)

[Apoptosis in normal and diseased liver] Guettier C, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):381–93 (128 ref.) (Eng. Abstr.) **(Fre)**

[Hepatocyte dysplasia: pre- or peri-neoplastic lesion?] Scoazec JY. **Gastroenterol Clin Biol** 1999 Apr;23(4):433–7 (39 ref.) **(Fre)**

[Value of liver histology in diagnosis of chronic hepatopathies] Schmid M. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1397–401 (20 ref.) (Eng. Abstr.) **(Ger)**

[Histological findings of TTV-positive non-B non-C chronic hepatitis patients] Hasebe C, et al. **Nippon Rinsho** 1999 Jun; 57(6):1350–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Fatal liver necrosis due to allopurinol] Pereira S, et al. **Acta Med Port** 1998 Dec;11(12):1141–4 (15 ref.) (Eng. Abstr.) **(Por)**

[Sinusoidal portal hypertension secondary to nodular regenerative hyperplasia of the liver] Gento Peña E, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):183–5 (18 ref.)

(Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Hepatic glucose production during exercise. Kjaer M. **Adv Exp Med Biol** 1998;441:117–27 (67 ref.)

V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Lemasters JJ. **Am J Physiol** 1999 Jan;276(1 Pt 1):G1–6 (40 ref.)

Programming of hepatic and peripheral tissue insulin sensitivity by maternal protein restriction. Ozanne SE. **Biochem Soc Trans** 1999 Feb;27(2):94–7 (27 ref.)

Mast cells in the liver [editorial; comments] Benyon RC. **Clin Exp Allergy** 1999 Feb;29(2):155–8 (40 ref.)

Osmoregulation of liver cell function: signalling, osmolytes and cell heterogeneity. Häussinger D. **Contrib Nephrol** 1998;123:185–204 (100 ref.)

The direct and indirect effects of insulin on hepatic glucose production in vivo. Cherrington AD, et al. **Diabetologia** 1998 Sep;41(9):987–96 (24 ref.)

Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Roman RM, et al. **Gastroenterology** 1999 Apr;116(4):964–79 (143 ref.)

Nitric oxide in liver injury. Clemens MG. **Hepatology** 1999 Jul;30(1):1–5 (84 ref.)

Homeostatic control of angiogenesis: A newly identified function of the liver? Clément B, et al. **Hepatology** 1999 Mar;29(3):621–3 (27 ref.)

Death receptors in liver biology and pathobiology. Faubion WA, et al. **Hepatology** 1999 Jan;29(1):1–4 (48 ref.)

The C/EBP family of transcription factors in the liver and other organs. Takiguchi M. **Int J Exp Pathol** 1998 Dec; 79(6):369–91 (232 ref.)

Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes–treated rats. Toshima K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S51–4 (19 ref.)

Ceramide–mediated apoptosis of hepatocytes in vivo: a matter of the nucleus? [editorial; comment] Hoekstra D. **J Hepatol** 1999 Jul;31(1):161–4 (25 ref.) Comment on: J Hepatol 1999 Jul;31(1):8–17.

Predicting outcome after liver transplantation [editorial; comment] Wall WJ. **Liver Transpl Surg** 1999 Sep;5(5):458–9 (13 ref.) Comment on: Liver Transpl Surg 1999 Sep;5(5):357–61.

Hepatobiliary transport: molecular mechanisms of development and cholestasis. Arrese M, et al. **Pediatr Res** 1998 Aug;44(2):141–7 (82 ref.)

Microtubule–dependent vesicle transport: modulation of channel and transporter activity in liver and kidney. Hamm–Alvarez SF, et al. **Physiol Rev** 1998 Oct; 78(4):1109–29 (167 ref.)

Cytokines: overview. Maher JJ. **Semin Liver Dis** 1999; 19(2):109–15 (57 ref.)

Thyroid hormone induces a reprogramming of gene expression in the liver of premetamorphic Rana catesbeiana tadpoles. Atkinson BG, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):323–37 (56 ref.)

[Apoptosis in normal and diseased liver] Guettier C, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):381–93 (128 ref.) (Eng. Abstr.) **(Fre)**

[Fibrinolysis and liver regeneration] Seki T, et al. **Seikagaku** 1999 May;71(5):350–3 (17 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Stellate cell activation in alcoholic fibrosis--an overview. Friedman SL. **Alcohol Clin Exp Res** 1999 May;23(5):904–10 (76 ref.)

III. Intracellular signaling in response to toxic liver injury. Jones BE, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G874–8 (40 ref.)

Mechanisms of hepatic toxicity. IV. Pathogenetic mechanisms involved in hepatitis C virus–inducedliver diseases. Lau JYN. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1217–20 (30 ref.)

Hepatic hemodynamics and cell functions in human and experimental sepsis. Pastor CM, et al. **Anesth Analg** 1999 Aug;89(2):344–52 (94 ref.)

Nitric oxide in liver injury. Clemens MG. **Hepatology** 1999 Jul;30(1):1–5 (84 ref.)

Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation. Gupta S, et al. **Semin Liver Dis** 1999;19(1):15–26 (62 ref.)

Assessment of liver function prior to hepatic resection. Lauterburg BH. **Swiss Surg** 1999;5(3):92–6 (16 ref.)

[Pathophysiologically advisable operations on the biliary–hepatic–pancreatic system] Daskalov M. **Khirurgiia (Sofiia)** 1998;51(4):8–11 (0 ref.) (Eng. Abstr.) **(Bul)**

[Role of fatty acids in hepatic and peripheral insulin resistance] Tappy L, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:11–6 (24 ref.) **(Fre)**

[Liver changes in HIV/AIDS] Telegdy L, et al. **Orv Hetil** 1999 Apr 11;140(15):811–4 (36 ref.) (Eng. Abstr.) **(Hun)**

RADIOGRAPHY

Pseudolesion in segments II and III of the liver on CT during arterial portography caused by aberrant right gastric venous drainage. Yoon KH, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):306–9 (12 ref.)

Nodular lesions of the liver revealing multiple myeloma. Chemlal K, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):389–92 (15 ref.)

SECRETION

Cell and molecular biology of the assembly and secretion of apolipoprotein B–containing lipoproteins by the liver. Davis RA. **Biochim Biophys Acta** 1999 Aug 25;1440(1):1–31 (304 ref.)

Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Burnett JR, et al. **Clin Chim Acta** 1999 Aug;286(1–2):231–42 (51 ref.)

SURGERY

Arterioportal fistula with portal hypertension after liver trauma and resection: a case report and review of the literature. Wolf S, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):821–6 (24 ref.)

Potential applications of N–terminal recombinant fragments of bactericidal/permeability–increasing protein in liver surgery. Wiezer MJ, et al. **Liver Transpl Surg** 1999 Mar; 5(2):126–35 (107 ref.)

The Glissonian approach of the hilum. Launois B, et al. **Swiss Surg** 1999;5(3):143–6 (11 ref.)

Assessment of liver function prior to hepatic resection. Lauterburg BH. **Swiss Surg** 1999;5(3):92–6 (16 ref.)

[Pathophysiologically advisable operations on the biliary–hepatic–pancreatic system] Daskalov M. **Khirurgiia (Sofiia)** 1998;51(4):8–11 (0 ref.) (Eng. Abstr.) **(Bul)**

[Methods of gallbladder intrahepatic bed treatment after cholecystectomy (literature review)] Kasum'ian SA, et al. **Khirurgiia (Mosk)** 1999;(5):67–9 (84 ref.) **(Rus)**

[Liver transplantation from a living donor is now possible. The first cases in Sweden completed with good results] Olausson M, et al. **Lakartidningen** 1999 Feb 3;96(5):452–5 (8 ref.) (Eng. Abstr.) **(Swe)**

ULTRASONOGRAPHY

Color Doppler applications in hepatic imaging. Shapiro RS, et al. **Clin Imaging** 1998 Jul–Aug;22(4):272–9 (23 ref.)

VIROLOGY

Will transplantation of an hepatitis C–infected graft improve the outcome of liver transplantation in HCV patients? [editorial; comment] Féray C, et al. **Gastroenterology** 1999 Jul;117(1):263–5 (14 ref.) Comment on: Gastroenterology 1999 Jul;117(1):149–53.

LIVER ABSCESS

[Liver abscess] Arakawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):442–5 (10 ref.) **(Jpn)**

COMPLICATIONS

Schistosomiasis and associated infections. Lambertucci JR, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:135–9 (49 ref.)

DIAGNOSIS

[A tuberculous liver abscess in HIV (letter)] Fernández Muinelo M, et al. **An Med Interna** 1999 Feb;16(2):105–6 (10 ref.) **(Spa)**

ETIOLOGY

Crohn's disease presenting as pyogenic liver abscess with review of previous case reports. Narayanan S, et al. **Am J Gastroenterol** 1998 Dec;93(12):2607–9 (9 ref.)

Successful treatment of a hepatic abscess that formed secondary to fish bone penetration by percutaneous transhepatic removal of the foreign body: report of a case. Horii K, et al. **Surg Today** 1999;29(9):922–6 (16 ref.)

Pyogenic liver abscess: aetiology, clinical manifestations and management. Kar P, et al. **Trop Gastroenterol** 1998 Oct–Dec;19(4):136–40 (44 ref.)

[The association between human toxocariasis and pyogenic abscesses] Rayes AA, et al. **Rev Soc Bras Med Trop** 1999 Jul–Aug;32(4):425–38 (110 ref.) (Eng. Abstr.) **(Por)**

MICROBIOLOGY

Listeria monocytogenes causing solitary liver abscess. Case report and review of the literature. Brönnimann S, et al. **Dig Surg** 1998;15(4):364–8 (30 ref.)

RADIOGRAPHY

[The spontaneous rupture of a pyogenic liver abscess. A clinical case] Rumi A, et al. **G Chir** 1999 May;20(5):219–21 (10 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Pyogenic liver abscess: aetiology, clinical manifestations and management. Kar P, et al. **Trop Gastroenterol** 1998 Oct–Dec;19(4):136–40 (44 ref.)

[The percutaneous drainage with a pigtail catheter of multiple pyogenic liver abscesses in a 7–year–old girl (letter)] Méndez R, et al. **Gastroenterol Hepatol** 1999 May; 22(5):260–1 (11 ref.) **(Spa)**

LIVER ABSCESS, AMEBIC

[Liver abscess] Arakawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):442–5 (10 ref.) **(Jpn)**

[Amoebic liver abscess] Mizuno Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):419–22 (9 ref.) **(Jpn)**

COMPLICATIONS

[Amebic liver abscesses with bacterial superinfection in a nonendemic area] Ciriza C, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):286–9 (16 ref.) (Eng. Abstr.) **(Spa)**

LIVER, ARTIFICIAL

Bioreactors for hybrid liver support: historical aspects and novel designs. Busse B, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:326–39 (102 ref.)

Overview of extracorporeal liver support systems and clinical results. McLaughlin BE, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:310–25 (61 ref.)

Liver assist systems: state of the art. Arkadopoulos N, et al. **Int J Artif Organs** 1998 Dec;21(12):781–7 (60 ref.)

Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. Riordan SM, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):757–70 (163 ref.)

Artificial liver: review and Cedars–Sinai experience. Kamohara Y, et al. **J Hepatobiliary Pancreat Surg** 1998; 5(3):273–85 (73 ref.)

[Liver and artificial liver] Chamuleau RA. **Ned Tijdschr Geneeskd** 1998 Jun 6;142(23):1300–5 (32 ref.) (Eng. Abstr.) **(Dut)**

[Extracorporeal liver assist devices in acute liver failure] Horn N, et al. **Anaesthesist** 1999 Jun;48(6):387–94 (32 ref.) (Eng. Abstr.) **(Ger)**

[The artificial liver--an interim report] Koebe HG, et al. **Wien Klin Wochenschr** 1998 Sep 4;110(16):551–63 (51 ref.) (Eng. Abstr.) **(Ger)**

LIVER CELL ADHESION MOLECULES see **CADHERINS**

LIVER CIRCULATION

see related
ENTEROHEPATIC CIRCULATION
PORTAL SYSTEM

Hepatic abnormalities related to blood flow: evaluation with dual–phase helical CT. Choi BI, et al. **Abdom Imaging** 1999 Jul–Aug;24(4):340–56 (88 ref.)

Liver circulation in the development of portal hypertension. Clemens MG. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1429–33 (61 ref.)

Hepatic and splanchnic microvascular responses to inflammation and shock. McCuskey RS. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1464–7 (49 ref.)

Complications of cirrhosis: is endothelium guilty? [editorial; comment] Laffi G, et al. **J Hepatol** 1999 Mar;30(3):532–5 (35 ref.) Comment on: J Hepatol 1999 Mar;30(3):451–5. Comment on: J Hepatol 1999 Mar;30(3):456–60.

Mechanism and prevention of ischemia–reperfusion injury. Kurokawa T, et al. **Transplant Proc** 1999 Jun;31(4):1775–6 (5 ref.)

Hepatic venous outflow obstruction. Pande GK, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):82–95 (137 ref.)

DRUG EFFECTS

[Perfusion and metabolism of liver and splanchnic nerve area under sevoflurane anesthesia] Schindler E, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S19–23 (60 ref.) (Eng. Abstr.) **(Ger)**

[Ethanol–induced hepatic microcirculatory disturbance] Takei Y, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1999 Apr; 34(2):107–16 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Recent developments in hepatic circulatory physiology. Sucmatsu M. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1406–8 (23 ref.)

LIVER CIRRHOSIS

Molecular regulation of hepatic fibrogenesis. Olaso E, et al. **J Hepatol** 1998 Nov;29(5):836–47 (134 ref.)

Cytokines and fibrogenesis. Friedman SL. **Semin Liver Dis** 1999;19(2):129–40 (156 ref.)

Cirrhosis of liver. Anand BS. **West J Med** 1999 Aug; 171(2):110–5 (28 ref.)

BLOOD

Resistance to growth hormone in children with chronic liver disease. Bucuvalas JC, et al. **Pediatr Transplant** 1997 Aug; 1(1):73–9 (46 ref.)

LIVER CIRRHOSIS

CHEMICALLY INDUCED

Wine: risk factors for liver disease and antifibrotic compounds. Svegliati-Baroni G, et al. **Drugs Exp Clin Res** 1999;25(2-3):143-5 (13 ref.)

Copper associated liver diseases in children. Introduction. Hadorn HB. **Eur J Med Res** 1999 Jun 28;4(6):212-3 (13 ref.)

COMPLICATIONS

Hepatic hydrothorax: pathogenesis, diagnosis, and management. Lazaridis KN, et al. **Am J Med** 1999 Sep; 107(3):262-7 (39 ref.)

Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Bottelli R, et al. **Clin Radiol** 1998 Oct;53(10):713-6 (34 ref.)

Longer treatment with vasoactive drugs to prevent early variceal rebleeding in cirrhosis. de Franchis R. **Eur J Gastroenterol Hepatol** 1998 Dec;10(12):1041-4 (32 ref.)

Further experiments are necessary to determine whether transjugular intrahepatic portosystemic shunt is the definitive treatment for refractory hepatic hydrothorax [editorial; comment] Mitamura K. **J Gastroenterol** 1999 Feb;34(1):154-6 (18 ref.) Comment on: J Gastroenterol 1999 Feb;34(1):128-31.

Posttraumatic intra-gallbladder hemorrhage in a patient with liver cirrhosis. Nishiwaki M, et al. **J Gastroenterol** 1999 Apr;34(2):282-5 (21 ref.)

Ileal varices associated with recurrent bleeding in a patient with liver cirrhosis. Ohtani T, et al. **J Gastroenterol** 1999 Apr;34(2):264-8 (12 ref.)

Cardiopulmonary dysfunction in cirrhosis. Liu H, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):600-8 (87 ref.)

[Management of patients with cirrhosis and ascites] Moreau R, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):379-87 (47 ref.) **(Fre)**

[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172-4 (0 ref.) **(Ger)**

[Zinc deficiency in liver cirrhosis: a curiosity or a problem?] Marchetti P, et al. **Ann Ital Med Int** 1998 Jul-Sep; 13(3):157-62 (64 ref.) (Eng. Abstr.) **(Ita)**

[Gastrointestinal lesions in liver cirrhosis] Fujiwara Y, et al. **Nippon Rinsho** 1998 Sep;56(9):2387-90 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Definitions and diagnostic criteria of digestive hemorrhage and its causes in cirrhosis] Sanz E, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):191-9 (91 ref.) **(Spa)**

DIAGNOSIS

Liver cell dysplasia and other atypical lesions: new insights and applications. Schwartz MR. **Adv Anat Pathol** 1998 Mar; 5(2):99-105 (27 ref.)

[Management of asymptomatic elevated serum aminotransferase levels, particularly in nonalcoholic steatohepatitis] Oldenburg B, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):506-9 (14 ref.) (Eng. Abstr.) **(Dut)**

[Non-invasive and early diagnosis of liver cirrhosis] Pilette C, et al. **Gastroenterol Clin Biol** 1999 May;23(5):557-65 (76 ref.) **(Fre)**

[The natural course of hepatitis B and hepatitis C virus infection] Schwabe RF, et al. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1403-7 (56 ref.) (Eng. Abstr.) **(Ger)**

[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971-5 (18 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

Feeding long-chain PUFA to advanced cirrhotics: is it worthwhile? [editorial] Cabré E, et al. **Nutrition** 1999 Apr; 15(4):322-4 (42 ref.)

DRUG THERAPY

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Poynard T, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):431-7 (53 ref.)

Phase I studies in patients with liver cirrhosis. Wensing G. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):599-603 (42 ref.)

Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? [editorial; comment] Ginès P, et al. **J Hepatol** 1998 Sep;29(3):490-4 (40 ref.) Comment on: J Hepatol 1998 Sep;29(3):430-6. Comment on: J Hepatol 1998 Sep;29(3):437-42.

ETIOLOGY

Iron and copper-associated cirrhosis in infants. Acquired metal toxicity or genetic disorder? Lockitch G. **Clin Lab Med** 1998 Dec;18(4):665-71, viii (38 ref.)

Erythropoietic protoporphyria with fatal liver failure. Ishibashi A, et al. **J Gastroenterol** 1999 Jun;34(3):405-9 (17 ref.)

Non-transferrin-bound iron and cellular toxicity [editorial; comment] Anderson GJ. **J Gastroenterol Hepatol** 1999 Feb; 14(2):105-8 (26 ref.) Comment on: J Gastroenterol Hepatol 1999 Feb;14(2):126-32.

The natural course of chronic hepatitis C: implications for clinical practice. Dusheiko GM. **J Viral Hepat** 1998 Sep; 5 Suppl 1:9-12 (15 ref.)

Experimental and human liver fibrogenesis. Kovalszky I, et al. **Scand J Gastroenterol Suppl** 1998;228:51-5 (25 ref.)

GENETICS

Indian childhood cirrhosis and Tyrolean childhood cirrhosis. Disorders of a copper transport gene? Tanner MS. **Adv Exp Med Biol** 1999;448:127-37 (37 ref.)

Iron and copper-associated cirrhosis in infants. Acquired metal toxicity or genetic disorder? Lockitch G. **Clin Lab Med** 1998 Dec;18(4):665-71, viii (38 ref.)

Non-Indian childhood cirrhosis. Müller T, et al. **Eur J Med Res** 1999 Jul 28;4(7):293-7 (39 ref.)

Gene regulation in hepatic stellate cell. Lang A, et al. **Ital J Gastroenterol Hepatol** 1999 Mar;31(2):173-9 (86 ref.)

IMMUNOLOGY

Cytokine regulation of hepatic stellate cells in liver fibrosis. Tsukamoto H. **Alcohol Clin Exp Res** 1999 May;23(5):911-6 (61 ref.)

Markedly elevated CA125 in hepatic cirrhosis: two case illustrations and review of the literature. DiBaise JK, et al. **J Clin Gastroenterol** 1999 Mar;28(2):159-61 (16 ref.)

METABOLISM

Effect of cirrhosis on energy expenditure [editorial] McCullough AJ, et al. **Am J Clin Nutr** 1999 Jun; 69(6):1066-8 (34 ref.)

Abnormalities in branched-chain amino acid metabolism in cirrhosis: influence of hormonal and nutritional factors and directions for future research. Blonde-Cynober F, et al. **Clin Nutr** 1999 Feb;18(1):5-13 (76 ref.)

Phase I studies in patients with liver cirrhosis. Wensing G. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):599-603 (42 ref.)

Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Verbeeck RK, et al. **Pharm World Sci** 1998 Oct; 20(5):183-92 (104 ref.)

Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy. Schrier RW, et al. **Proc Assoc Am Physicians** 1998 Sep-Oct; 110(5):407-11 (46 ref.)

[Dynamics of ascitic fluid in decompensated cirrhosis] Milani A, et al. **Recenti Prog Med** 1999 Feb;90(2):94-9 (29 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities. Dodd GD 3rd, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1031-6 (8 ref.)

Gene regulation in hepatic stellate cell. Lang A, et al. **Ital J Gastroenterol Hepatol** 1999 Mar;31(2):173-9 (86 ref.)

Pathobiology of hepatic stellate cells. Burt AD. **J Gastroenterol** 1999 Jun;34(3):299-304 (63 ref.)

Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. Li D, et al. **J Gastroenterol Hepatol** 1999 Jul;14(7):618-33 (220 ref.)

[Should small nodules in cirrhotic liver be biopsied?] Labadie H, et al. **Gastroenterol Clin Biol** 1999 May;23(5):540-3 (42 ref.) **(Fre)**

[Cirrhosis of the liver as a precancerous condition] Maier KP. **Schweiz Rundsch Med Prax** 1998 Oct 28;87(44):1462-5 (11 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Arthur MJ, et al. **Alcohol Clin Exp Res** 1999 May;23(5):940-3 (28 ref.)

Role of metalloproteinases in liver fibrosis. Rojkind M. **Alcohol Clin Exp Res** 1999 May;23(5):934-9 (50 ref.)

Restoration of nitric oxide function in human hyperlipidaemia, congestive heart failure and liver cirrhosis. Chin-Dusting JP, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):645-52 (101 ref.)

Interplay of matrix and myofibroblasts during hepatic fibrogenesis. Schuppan D, et al. **Curr Top Pathol** 1999; 93:205-18 (68 ref.)

Pathobiology of hepatic stellate cells. Burt AD. **J Gastroenterol** 1999 Jun;34(3):299-304 (63 ref.)

Complications of cirrhosis: is endothelium guilty? [editorial; comment] Laffi G, et al. **J Hepatol** 1999 Mar;30(3):532-5 (35 ref.) Comment on: J Hepatol 1999 Mar;30(3):451-5. Comment on: J Hepatol 1999 Mar;30(3):456-60.

Pathogenesis of ascites and renal salt retention in cirrhosis. Palmer BF. **J Investig Med** 1999 May;47(5):183-202 (181 ref.)

[Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis] Petrides AS. **Z Gastroenterol** 1999 Jun;Suppl 1:15-21 (13 ref.) (Eng. Abstr.) **(Ger)**

[Biochemical markers of fibrogenesis in liver diseases] Szántová M, et al. **Bratisl Lek Listy** 1999 Jan;100(1):28-35 (49 ref.) (Eng. Abstr.) **(Slo)**

[Hemodynamic changes in liver cirrhosis] Szántová M, et al. **Bratisl Lek Listy** 1999 Jan;100(1):41-8 (33 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Prevention and treatment of liver fibrosis based on pathogenesis. Lieber CS. **Alcohol Clin Exp Res** 1999 May; 23(5):944-9 (59 ref.)

[Prevention of cirrhosis is the best measure against hepatocellular cancer] Kaczynski J. **Lakartidningen** 1999 Jan 27;96(4):338-41 (107 ref.) (Eng. Abstr.) **(Swe)**

RADIOGRAPHY

[Helical CT of the liver. Principles and applications] Blum A, et al. **Gastroenterol Clin Biol** 1998 Jun-Jul; 22(6-7):576-89 (55 ref.) **(Fre)**

SURGERY

Shunt versus transplantation. Langnas AN. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S105-7 (12 ref.)

Helical CT angiography of transjugular intrahepatic portosystemic shunts. Chopra S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):25-35 (21 ref.)

[Portal hypertension and variceal bleeding: shunt in concomitant or general prehepatic block] Hirner A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:443-50 (25 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Prevention and treatment of liver fibrosis based on pathogenesis. Lieber CS. **Alcohol Clin Exp Res** 1999 May; 23(5):944-9 (59 ref.)

Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond. Lochs H, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):345-9 (22 ref.)

Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. Riordan SM, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):757-70 (163 ref.)

[Management of patients with cirrhosis and ascites] Moreau R, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):379-87 (47 ref.) **(Fre)**

[The therapy of the hepatorenal syndrome in liver cirrhosis] Biecker E, et al. **Dtsch Med Wochenschr** 1999 Sep 10; 124(36):1039-42 (26 ref.) **(Ger)**

[Hepatic hydrothorax. Recommendations for a rational therapy] Rössle M, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1485-9 (39 ref.) **(Ger)**

[Pathogenetic basis for treatment of liver fibrosis] Flisiak R. **Pol Arch Med Wewn** 1998 May;99(5):423-9 (38 ref.) **(Pol)**

VIROLOGY

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Poynard T, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):431-7 (53 ref.)

LIVER CIRRHOSIS, ALCOHOLIC

COMPLICATIONS

Dermatological manifestations of alcoholic cirrhosis. Ruocco V, et al. **Clin Dermatol** 1999 Jul-Aug;17(4):463-8 (70 ref.)

[Recurrent spontaneous bacterial peritonitis due to encapsulated microorganisms (Haemophilus influenzae and Streptococcus pneumoniae) in a patient with liver cirrhosis (letter)] Salavert M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):30-1 (10 ref.) **(Spa)**

METABOLISM

Chronic alcohol intake interferes with retinoid metabolism and signaling. Wang XD. **Nutr Rev** 1999 Feb;57(2):51-9 (68 ref.)

PATHOLOGY

Interrelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma. Yoshihara H, et al. **Recent Dev Alcohol** 1998;14:457-69 (58 ref.)

PHYSIOPATHOLOGY

Stellate cell activation in alcoholic fibrosis--an overview. Friedman SL. **Alcohol Clin Exp Res** 1999 May;23(5):904-10 (76 ref.)

SURGERY

One center's experience with liver transplantation: alcohol use relapse over the long-term. Campbell DA Jr, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S58-64 (18 ref.)

Transplantation for alcoholic liver disease: a perspective from Europe. Neuberger J. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S51-7 (28 ref.)

[Alcoholic cirrhosis and liver transplantation: which criteria for indication? Work Group for Indication Criteria for Transplantation for Alcoholic Cirrhosis] Borie DC, et al. **Gastroenterol Clin Biol** 1999 Feb;23(2):171-7 (50 ref.) **(Fre)**

LIVER CIRRHOSIS, BILIARY

Autoimmune liver diseases. Recurrence after liver transplantation. Balan V, et al. **Surg Clin North Am** 1999 Feb;79(1):147–52 (28 ref.)

[Physiopathology and treatment of autoimmune liver diseases] Nishioka M. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):456–60 (10 ref.) **(Jpn)**

BLOOD

Eosinophils and primary biliary cirrhosis–stoking the fire? [editorial; comment] Neuberger J. **Hepatology** 1999 Jul; 30(1):335–7 (44 ref.) Comment on: Hepatology 1999 Jul;30(1):71–8.

COMPLICATIONS

The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Jones EA, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):623–31 (32 ref.)

Prevention and treatment of osteoporosis in primary biliary cirrhosis. Vleggaar FP, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):617–21 (50 ref.)

Case report: a rare association of primary biliary cirrhosis and systemic lupus erythematosus and review of the literature. Islam S, et al. **J Gastroenterol Hepatol** 1999 May; 14(5):431–5 (28 ref.)

DIAGNOSIS

First report of association of chronic pancreatitis, primary biliary cirrhosis, and systemic sclerosis. Hastier P, et al. **Dig Dis Sci** 1998 Nov;43(11):2426–8 (17 ref.)

Liver transplantation for cholestatic liver disease: screening and assessment of risk factors. Crippin JS. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S2–8 (19 ref.)

[Primary biliary cirrhosis: diagnostic standards and the reference for its severity] Nishioka M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):609–14 (4 ref.) **(Jpn)**

[Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis] Romero Gómez M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):11–3 (24 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Evidence-based therapy of primary biliary cirrhosis. Heathcote EJ. **Eur J Gastroenterol Hepatol** 1999 Jun; 11(6):607–15 (57 ref.)

Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Hay JE. **Liver Transpl Surg** 1998 Sep; 4(5 Suppl 1):S9–17 (52 ref.)

[Methotrexate in therapy of gastrointestinal diseases] Schröder O, et al. **Z Gastroenterol** 1999 Jul;37(7):623–37 (103 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Parikh-Patel A, et al. **Clin Immunol** 1999 May; 91(2):206–18 (136 ref.)

Hepatocellular carcinoma in primary biliary cirrhosis: a case report and review of the Japanese literature. Shimizu A, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2352–5 (22 ref.)

[Primary biliary cirrhosis: epidemiological analysis] Inoue K, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10; 88(4):597–602 (3 ref.) **(Jpn)**

[Association of extrahepatic autoimmune diseases in primary biliary cirrhosis—clinical statistics and analyses of Japanese and non-Japanese cases] Ueno Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2687–98 (48 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

[Association of extrahepatic autoimmune diseases in primary biliary cirrhosis—clinical statistics and analyses of Japanese and non-Japanese cases] Ueno Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2687–98 (48 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[New molecular aspects of cholestatic liver diseases] Trauner M, et al. **Z Gastroenterol** 1999 Jul;37(7):639–47 (52 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Genetic susceptibility to primary biliary cirrhosis. Agarwal K, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):603–6 (45 ref.)

Immunopathology of primary biliary cirrhosis. Joplin RE, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):587–93 (42 ref.)

Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Strassburg CP, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):595–601 (41 ref.)

PBC and AMA—what is the connection? Neuberger J, et al. **Hepatology** 1999 Jan;29(1):271–6 (66 ref.)

Antigen peptide analog: induction of T cell anergy in primary biliary cirrhosis. Ishibashi H, et al. **Intern Med** 1999 Feb; 38(2):173–5 (12 ref.)

[Primary biliary cirrhosis] Cecere A, et al. **Clin Ter** 1998 Mar-Apr;149(2):143–50 (49 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Myofibroblastic differentiation and extracellular matrix deposition in early stages of cholestatic fibrosis in rat liver. Tuchweber B, et al. **Curr Top Pathol** 1999;93:103–9 (30 ref.)

[Primary biliary cirrhosis: a study on developmental pathology and physiopathology] Onji M. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):603–8 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Primary biliary cirrhosis: a study on developmental pathology and physiopathology] Onji M. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):603–8 (5 ref.) **(Jpn)**

PREVENTION & CONTROL

Primary biliary cirrhosis. Is (and how much of) the pathology preventible? Bar-Dayan Y, et al. **Immunol Res** 1998; 18(2):117–23 (52 ref.)

PSYCHOLOGY

The experience of women with primary biliary cirrhosis: a literature review. Fahey S. **J Adv Nurs** 1999 Aug; 30(2):506–12 (43 ref.)

SURGERY

Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation. Haagsma EB. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):639–42 (14 ref.)

Liver transplantation for cholestatic liver disease: screening and assessment of risk factors. Crippin JS. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S2–8 (19 ref.)

Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Hay JE. **Liver Transpl Surg** 1998 Sep; 4(5 Suppl 1):S9–17 (52 ref.)

[Primary biliary cirrhosis: liver transplantation] Hirata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):620–5 (11 ref.) **(Jpn)**

THERAPY

[New therapeutic strategy for autoimmune diseases. 1) An antigenic peptide analog] Ishibashi H, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1735–40 (9 ref.) **(Jpn)**

[Primary biliary cirrhosis: progress in its therapy] Kuroki T, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10; 88(4):615–9 (9 ref.) **(Jpn)**

LIVER CIRRHOSIS, EXPERIMENTAL

ETIOLOGY

Experimental models of hepatic fibrosis in the rat. Wasser S, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):109–11 (10 ref.)

NF-kappa B, liposomes and pathogenesis of hepatic injury and fibrosis. Wu J, et al. **Front Biosci** 1999 Jun 15;4:D520–7 (67 ref.)

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. Arthur MJ, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S33–8 (59 ref.)

Experimental and human liver fibrogenesis. Kovalszky I, et al. **Scand J Gastroenterol Suppl** 1998;228:51–5 (25 ref.)

PREVENTION & CONTROL

Is interleukin-10 antifibrogenic in chronic liver injury? [editorial; comment] Tsukamoto H. **Hepatology** 1998 Dec; 28(6):1707–9 (29 ref.) Comment on: Hepatology 1998 Dec;28(6):1597–1606. Comment on: Hepatology 1998 Dec;28(6):1607–15.

LIVER CIRRHOSIS, OBSTRUCTIVE see **LIVER CIRRHOSIS, BILIARY**

LIVER DISEASES

Update in hepatology. Schiff ER. **Ann Intern Med** 1999 Jan 5;130(1):52–7 (0 ref.)

Liver diseases. Varanasi RV, et al. **Clin Geriatr Med** 1999 Aug;15(3):559–70 (51 ref.)

Assessment and treatment of liver disease in Japanese haemophilia patients. Fukuda Y, et al. **Haemophilia** 1998 Jul;4(4):595–600 (45 ref.)

Nutritional aspects of liver disease in children. Shetty AK, et al. **Nutrition** 1999 Sep;15(9):727–9 (23 ref.)

Oxidative stress in the liver and biliary tract diseases. Fehér J, et al. **Scand J Gastroenterol Suppl** 1998;228:38–46 (51 ref.)

[Hepatobiliary diseases in the elderly] Weik C, et al. **Dtsch Med Wochenschr** 1999 Apr 16;124(15):466–71 (50 ref.) **(Ger)**

[Hepatic aspergillosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):323–4 (5 ref.) **(Jpn)**

[Hepatic actinomycosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):449–50 (11 ref.) **(Jpn)**

[Hepatic candidiasis] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):339–41 (12 ref.) **(Jpn)**

[Hepatic cryptococcosis] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):361–3 (9 ref.) **(Jpn)**

BLOOD

Special considerations in interpreting liver function tests. Johnston DE. **Am Fam Physician** 1999 Apr 15; 59(8):2223–30 (32 ref.)

CHEMICALLY INDUCED

Hydroxyethyl radicals in ethanol hepatotoxicity. Albano E, et al. **Front Biosci** 1999 Jun 15;4:D533–40 (73 ref.)

COMPLICATIONS

Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation. Ng TM, et al. **Ann Pharmacother** 1999 Feb;33(2):233–5 (24 ref.)

Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Terra SG, et al. **Ann Pharmacother** 1998 Nov;32(11):1228–30 (29 ref.)

Hepatosplenic candidiasis in patients with acute leukemia: increasingly encountered complication. Sallah S. **Anticancer Res** 1999 Jan-Feb;19(1B):757–60 (14 ref.)

Management of bleeding with uremia and liver disease. DeLoughery TG. **Curr Opin Hematol** 1999 Sep;6(5):329–33 (32 ref.)

Polycystic liver disease: an unusual cause of bleeding varices. Srinivasan R. **Dig Dis Sci** 1999 Feb;44(2):389–92 (20 ref.)

The risk of surgery in patients with liver disease. Friedman LS. **Hepatology** 1999 Jun;29(6):1617–23 (124 ref.)

Portal hemodynamics in chronic liver disease. Nagral A, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):78–83 (73 ref.)

Renal failure in liver disease. Eckardt KU. **Intensive Care Med** 1999 Jan;25(1):5–14 (80 ref.)

Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: four cases and a review. Sheikh RA, et al. **J Clin Gastroenterol** 1999 Jun;28(4):323–8 (37 ref.)

Surgery in the patient with liver disease. Patel T. **Mayo Clin Proc** 1999 Jun;74(6):593–9 (21 ref.)

Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Hunt J, et al. **Mod Pathol** 1999 Mar;12(3):325–8 (12 ref.)

Conditionally essential fatty acid deficiencies in end-stage liver disease. Burke PA, et al. **Nutrition** 1999 Apr; 15(4):302–4 (15 ref.)

Inflammatory pseudotumor of the liver in Kostmann's disease. Hsiao CC, et al. **Pediatr Surg Int** 1999; 15(3-4):266–9 (23 ref.)

Neuropathy as an extrahepatic manifestation of chronic liver diseases. Szalay F, et al. **Scand J Gastroenterol Suppl** 1998; 228:130–2 (20 ref.)

Obstructive jaundice caused by a huge liver cyst riding on the hilum: report of a case. Kanai T, et al. **Surg Today** 1999;29(8):791–4 (15 ref.)

Portopulmonary hypertension and the liver transplant candidate. Kuo PC, et al. **Transplantation** 1999 Apr 27; 67(8):1087–93 (41 ref.)

[Diagnosis and treatment of pulmonary tuberculosis complicated with chronic liver disease] Harada H, et al. **Nippon Rinsho** 1998 Dec;56(12):3212–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Thyroid disease in autoimmune liver diseases] Zeniya M. **Nippon Rinsho** 1999 Aug;57(8):1882–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

[An autopsy case of intravascular malignant lymphomatosis with hemophagocytic syndrome, mental confusion and liver dysfunction] Onishi Y, et al. **Rinsho Ketsueki** 1998 Aug;39(8):586–92 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Jaundice] Iakhontova OI, et al. **Klin Med (Mosk)** 1998; 76(10):59–64 (6 ref.) **(Rus)**

[Hepatobiliary disease in cystic fibrosis] Pérez-Aguilar F, et al. **Med Clin (Barc)** 1998 Sep 19;111(8):302–6 (55 ref.) **(Spa)**

CONGENITAL

Other hereditary diseases and the liver. Poley JR, et al. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):369–407 (154 ref.)

DIAGNOSIS

Post-transplantation lymphoproliferative disorder versus acute liver rejection: do we need a scoring system? Dietze O. **Adv Anat Pathol** 1998 Jan;5(1):30–5 (10 ref.)

Liver disease in pregnancy. Hunt CM, et al. **Am Fam Physician** 1999 Feb 15;59(4):829–36 (37 ref.)

Special considerations in interpreting liver function tests. Johnston DE. **Am Fam Physician** 1999 Apr 15; 59(8):2223–30 (32 ref.)

Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Reimer P, et al. **Eur Radiol** 1998; 8(7):1198–204 (38 ref.)

Non-invasive diagnosis and management of chronic liver

diseases. van Hoek B. **Forum (Genova)** 1999 Apr-Jun; 9(2):113-36 (189 ref.)
HIV-Related hepatic disease: when and why to biopsy. Poles MA. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):939-62 (98 ref.)
Isolated hepatic splenosis: first reported case. D'Angelica M, et al. **HPB Surg** 1998;11(1):39-42 (5 ref.)
Chianciano Consensus Conference on Prognostic Studies in Hepatology. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):580-3 (0 ref.)
Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: four cases and a review. Sheikh RA, et al. **J Clin Gastroenterol** 1999 Jun;28(4):323-8 (37 ref.)
Advances in imaging techniques for the diagnosis of focal hepatic lesions. Li KC, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S22-7 (26 ref.)
Cerebral magnetic resonance imaging in patients with chronic liver disease. Morgan MY. **Metab Brain Dis** 1998 Dec; 13(4):273-90 (55 ref.)
Ductular reaction and its diagnostic significance. Roskams T, et al. **Semin Diagn Pathol** 1998 Nov;15(4):259-69 (79 ref.)
Evaluation and interpretation of iron in the liver. Turlin B, et al. **Semin Diagn Pathol** 1998 Nov;15(4):237-45 (63 ref.)
[Duodenal ulcer with penetration into the liver. Endoscopic-biopsy diagnosis] Mall K. **Med Klin** 1999 Feb 15;94(2):101-4 (17 ref.) (Eng. Abstr.) **(Ger)**
[Diagnostic imaging in hepatosplenic candidiasis] Müller D, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jun;170(6):587-90 (24 ref.) (Eng. Abstr.) **(Ger)**
[Value of liver histology in diagnosis of chronic hepatopathies] Schmid M. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1397-401 (20 ref.) (Eng. Abstr.) **(Ger)**
[Liver and endocrine system. Part II: pituitary-gonadal axis and adrenal gland activity disturbances] Marek B, et al. **Wiad Lek** 1998;51(7-8):352-9 (23 ref.) (Eng. Abstr.) **(Pol)**
[Importance of determination of monoethylglycinexylidide (MEGX)--as a liver function test in hepatology and liver transplantation] Kupčová V. **Bratisl Lek Listy** 1999 Jan; 100(1):49-53 (46 ref.) (Eng. Abstr.) **(Slo)**

DIET THERAPY

[Guidelines of GASL for nutrition in liver diseases and liver transplantation] Plauth M, et al. **Z Gastroenterol** 1999 Apr; 37(4):301-12 (154 ref.) **(Ger)**

DRUG THERAPY

Targeting of therapeutics to the liver: liposomes and viral vectors. Di Campli C, et al. **Alcohol Clin Exp Res** 1999 May;23(5):950-4 (36 ref.)
Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Trauner M, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):979-96 (188 ref.)
Immunopharmacologic agents in the amelioration of hepatic injuries. Farghali H, et al. **Int J Immunopharmacol** 1998 Apr-May;20(4-5):125-39 (103 ref.)
[Hepatic inflammatory pseudotumor: apropos a case with a response to steroid treatment] Fernández de la Puebla Giménez RA, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):14-7 (20 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

NF-kappa B, liposomes and pathogenesis of hepatic injury and fibrosis. Wu J, et al. **Front Biosci** 1999 Jun 15;4:D520-7 (67 ref.)
The effects of vasculitis on the gastrointestinal tract and liver. Bailey M, et al. **Gastroenterol Clin North Am** 1998 Dec; 27(4):747-82, v-vi (173 ref.)
Hepatobiliary manifestations of inflammatory bowel disease. Raj V, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):491-513 (140 ref.)
Hepatobiliary complications of inflammatory bowel disease: overview of the issues. Balistreri WF.
Inflamm Bowel Dis 1998 Aug;4(3):220-4 (37 ref.)
Haemochromatosis and the liver. Niederau C, et al.
J Hepatol 1999;30 Suppl 1:6-11 (22 ref.)
Mitochondria and childhood liver diseases. Sokol RJ, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):4-16 (59 ref.)
The liver and metabolic diseases of childhood. McDiarmid SV. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S34-50 (140 ref.)
Liver development: a paradigm for hepatobiliary disease in later life. Bezerra JA. **Semin Liver Dis** 1998;18(3):203-16 (84 ref.)
Liver and biliary problems in cystic fibrosis. Colombo C, et al. **Semin Liver Dis** 1998;18(3):227-35 (84 ref.)
Alpha-1-antitrypsin deficiency. Perlmutter DH.
Semin Liver Dis 1998;18(3):217-25 (64 ref.)
Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Strauss AW, et al. **Semin Perinatol** 1999 Apr;23(2):100-12 (55 ref.)

GENETICS

Liver disease and compensatory growth: unexpected lessons from genetically altered mice. Braun KM, et al.
Int J Dev Biol 1998;42(7 Spec No):935-42 (21 ref.)
The haemochromatosis gene: a co-factor for chronic liver diseases? George DK, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):745-9 (50 ref.)
Genetics of tumour necrosis factor (TNF) in autoimmune liver diseases: red hot or red herring? [editorial; comment] Wilson AG. **J Hepatol** 1999 Feb;30(2):331-3 (26 ref.) Comment on: J Hepatol 1999 Feb;30(2):232-6. Comment on: J Hepatol 1999 Feb;30(2):237-41.

IMMUNOLOGY

Nodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature. Morlà RM, et al. **Lupus** 1999;8(2):160-3 (20 ref.)
Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Hunt J, et al. **Mod Pathol** 1999 Mar;12(3):325-8 (12 ref.)
Immunological liver diseases in children. Mieli-Vergani G, et al. **Semin Liver Dis** 1998;18(3):271-9 (49 ref.)
[Liver and endocrine system. Part I: pituitary-thyroid axis activity disorders] Marek B, et al. **Wiad Lek** 1998; 51(5-6):271-6 (23 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Pharmacokinetics of opioids in liver disease. Tegeder I, et al. **Clin Pharmacokinet** 1999 Jul;37(1):17-40 (257 ref.)
Past and present scenario of hepatoprotectants. Ram VJ, et al. **Curr Med Chem** 1999 Mar;6(3):217-54 (302 ref.)
Amino acid metabolism in liver disease. Holm E, et al.
Curr Opin Clin Nutr Metab Care 1999 Jan;2(1):47-53 (80 ref.)
Alpha-lipoic acid in liver metabolism and disease. Bustamante J, et al. **Free Radic Biol Med** 1998 Apr; 24(6):1023-39 (141 ref.)
Impact of diseases on detoxication. Blouin RA, et al.
J Biochem Mol Toxicol 1999;13(3-4):215-8 (27 ref.)
Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants -- an update. Tanaka E, et al.
J Clin Pharm Ther 1998 Oct;23(5):331-6 (38 ref.)
Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. Tanaka E.
J Clin Pharm Ther 1998 Jun;23(3):161-70 (117 ref.)
Surgery in the patient with liver disease. Patel T.
Mayo Clin Proc 1999 Jun;74(6):593-9 (21 ref.)
Liver transplantation, body composition, and substrate utilization: does organ transplantation normalize the metabolic situation of the patient? [editorial] [see comments] Roske AE, et al. **Nutrition** 1999 Jun;15(6):504-5 (14 ref.) Comment in: Nutrition 1999 Jun;15(6):507-8.
Cytokines: overview. Maher JJ. **Semin Liver Dis** 1999; 19(2):109-15 (57 ref.)

MICROBIOLOGY

Gastrointestinal and hepatic manifestations of human ehrlichiosis: 8 cases and a review of the literature. Nutt AK, et al. **Dig Dis** 1999;17(1):37-43 (10 ref.)
[Hepatic brucelloma: 2 cases and a review of the literature] Halimi C, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):513-7 (23 ref.) (Eng. Abstr.) **(Fre)**
[The liver and brucellosis (editorial)] Janbon F.
Gastroenterol Clin Biol 1999 Apr;23(4):431-2 (4 ref.) **(Fre)**
[Intestinal bacteria overgrowth in chronic hepatopathies] Casafont F, et al. **Rev Med Univ Navarra** 1998 Oct-Dec; 42(4):183-7 (28 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Ciliated hepatic foregut cyst: a study of six cases and review of the literature. Vick DJ, et al. **Am J Surg Pathol** 1999 Jun;23(6):671-7 (47 ref.)
Scoring procedures in clinical hepatology. Torchio M, et al. **Forum (Genova)** 1999 Apr-Jun;9(2):141-55 (59 ref.)
Liver regeneration after portal vein embolization [editorial; comment] Manabe T. **J Gastroenterol** 1999 Feb;34(1):152-3 (10 ref.) Comment on: J Gastroenterol 1999 Feb;34(1):100-4.
Apoptosis and the liver: relevance for the hepato-biliary-pancreatic surgeon. Miyoshi H, et al.
J Hepatobiliary Pancreat Surg 1998;5(4):409-15 (63 ref.)
Hepatic granulomas. Lefkowitch JH. **J Hepatol** 1999;30 Suppl 1:40-5 (33 ref.)
Nodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature. Morlà RM, et al. **Lupus** 1999;8(2):160-3 (20 ref.)
Histopathologic approach to metabolic liver disease: Part 1. Jevon GP, et al. **Pediatr Dev Pathol** 1998 May-Jun; 1(3):179-99 (121 ref.)
Histopathologic approach to metabolic liver disease: Part 2. Jevon GP, et al. **Pediatr Dev Pathol** 1998 Jul-Aug; 1(4):261-9 (37 ref.)
Recommendations for handling of pediatric liver biopsy specimens. Finn LS, et al. **Semin Diagn Pathol** 1998 Nov; 15(4):300-5 (18 ref.)
Differential diagnosis of hepatocellular nodular lesions. Hytiroglou P, et al. **Semin Diagn Pathol** 1998 Nov; 15(4):285-99 (26 ref.)
Interpretation of biopsy findings in the transplant liver. Jones KD, et al. **Semin Diagn Pathol** 1998 Nov;15(4):306-17 (39 ref.)
Striking cholestatic liver disease: a distinct manifestation of advanced primary amyloidosis. Rockey DC.
South Med J 1999 Feb;92(2):236-41 (58 ref.)
[Apoptosis and liver diseases] Joulin V.
C R Seances Soc Biol Fil 1998;192(6):1077-94 (66 ref.) (Eng. Abstr.) **(Fre)**
[Recommendations for clinicopathologic quality standards in gastroenterology and hepatology. Consensus report of the Austrian Society of Gastroenterology ahd Hepatology and the Austrian Society of Pathology] Wrba F, et al.
Z Gastroenterol 1998 Oct;36(10):917-23 (5 ref.) **(Ger)**

PHYSIOPATHOLOGY

Interleukin-10 and liver diseases. Le Moine O, et al.
Acta Gastroenterol Belg 1999 Jan-Mar;62(1):1-8 (131 ref.)
The kidney in chronic liver disease: circulatory abnormalities, renal sodium handling and role of natriuretic peptides. Valdivieso A. **Biol Res** 1998;31(3):291-304 (101 ref.)
Haemodynamics and fluid retention in liver disease. Henriksen JH, et al. **Ital J Gastroenterol Hepatol** 1998 Jun; 30(3):320-32 (147 ref.)
Abnormalities of circadian rhythmicity in liver disease. Blei AT, et al. **J Hepatol** 1998 Nov;29(5):832-5 (31 ref.)
Amyloidosis and the liver. Gillmore JD, et al. **J Hepatol** 1999;30 Suppl 1:17-33 (95 ref.)
The sympathetic nervous system in liver disease. Henriksen JH, et al. **J Hepatol** 1998 Aug;29(2):328-41 (169 ref.)
Growth factors in children with end-stage liver disease before and after liver transplantation: a review. Maes M, et al. **Pediatr Transplant** 1997 Nov;1(2):171-5 (34 ref.)
Neurohumoral fluid regulation in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):361-72 (107 ref.)
Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation. Gupta S, et al.
Semin Liver Dis 1999;19(1):15-26 (62 ref.)
Disorders of the mitochondria. Treem WR, et al.
Semin Liver Dis 1998;18(3):237-53 (68 ref.)
Assessment of liver function prior to hepatic resection. Lauterburg BH. **Swiss Surg** 1999;5(3):92-6 (16 ref.)

PREVENTION & CONTROL

Mechanism of hepatoprotective action of bile salts in liver disease. Stiehl A, et al. **Gastroenterol Clin North Am** 1999 Mar;28(1):195-209, viii (108 ref.)
Present status of hepatoprotectants. Ram VJ, et al.
Prog Drug Res 1999;52:53-101 (131 ref.)

RADIOGRAPHY

Hepatic abnormalities related to blood flow: evaluation with dual-phase helical CT. Choi BI, et al. **Abdom Imaging** 1999 Jul-Aug;24(4):340-56 (88 ref.)
Spiral CT of the abdomen: increased diagnostic potential. El Sherif A, et al. **Eur J Radiol** 1999 Jul;31(1):43-52 (46 ref.)
Pseudolesion in segments II and III of the liver on CT during arterial portography caused by aberrant right gastric venous drainage. Yoon KH, et al.
J Comput Assist Tomogr 1999 Mar-Apr;23(2):306-9 (12 ref.)

RADIONUCLIDE IMAGING

[The significance of radioisotopic methods in internal diseases diagnosis] Rogulski B, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):44-6 (10 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Pediatric liver transplantation. Dhawan A, et al.
Acta Paediatr Jpn 1998 Dec;40(6):525-9 (31 ref.)
Who needs a liver transplant? (new disease specific indications). Baker A, et al. **Arch Dis Child** 1998 Nov; 79(5):460-4 (39 ref.)
Intraoperative abdominal ultrasonography. Luck AJ, et al.
Br J Surg 1999 Jan;86(1):5-16 (65 ref.)
Liver transplantation: who to refer and when. Van Thiel DH, et al. **Forum (Genova)** 1999 Apr-Jun;9(2):157-63 (22 ref.)
Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. Gupta S, et al. **J Hepatol** 1999 Jan; 30(1):162-70 (59 ref.)
Current results and evolving indications for liver transplantation in children. Kelly DA.
J Pediatr Gastroenterol Nutr 1998 Aug;27(2):214-21 (98 ref.)
The liver and metabolic diseases of childhood. McDiarmid SV. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S34-50 (140 ref.)
Liver transplantation, body composition, and substrate utilization: does organ transplantation normalize the metabolic situation of the patient? [editorial] [see comments] Roske AE, et al. **Nutrition** 1999 Jun;15(6):504-5 (14 ref.) Comment in: Nutrition 1999 Jun;15(6):507-8.
Liver transplant pathology in pediatric metabolic disorders. Jaffe R. **Pediatr Dev Pathol** 1998 Mar-Apr;1(2):102-17 (93 ref.)
Subcapsular hemorrhage of the liver in a very-low-birth-weight neonate: survival after

decompression laparotomy. Kosumi T, et al. **Pediatr Surg Int** 1999;15(3-4):270-1 (15 ref.)
Indications for pediatric liver transplantation. McDiarmid SV, et al. **Pediatr Transplant** 1998 May;2(2):106-16 (81 ref.)
Principles of therapeutic liver repopulation. Grompe M, et al. **Semin Liver Dis** 1999;19(1):7-14 (41 ref.)
Hepatocyte transplantation for the treatment of human disease. Strom SC, et al. **Semin Liver Dis** 1999;19(1):39-48 (80 ref.)
Autoimmune liver diseases. Recurrence after liver transplantation. Balan V, et al. **Surg Clin North Am** 1999 Feb;79(1):147-52 (28 ref.)
Liver transplantation for metabolic liver diseases. Khanna A, et al. **Surg Clin North Am** 1999 Feb;79(1):153-62, ix (61 ref.)
Early complications after orthotopic liver transplantation. Mazariegos GV, et al. **Surg Clin North Am** 1999 Feb; 79(1):109-29 (103 ref.)
Pediatric transplantation. Reyes J, et al. **Surg Clin North Am** 1999 Feb;79(1):163-89 (94 ref.)
Assessment of liver function prior to hepatic resection. Lauterburg BH. **Swiss Surg** 1999;5(3):92-6 (16 ref.)
Portopulmonary hypertension and the liver transplant candidate. Kuo PC, et al. **Transplantation** 1999 Apr 27; 67(8):1087-93 (41 ref.)
[Biliary cysts and hepatic polycystosis] Farges O. **Ann Chir** 1998;52(1):68-70 (10 ref.) **(Fre)**
[Liver transplantation in the adult: who and when to transplant?] Le Treut YP, et al. **Rev Med Interne** 1998 Dec; 19(12):892-903 (91 ref.) (Eng. Abstr.) **(Fre)**
[Hepatobiliary surgery in 2009] Gal'perin EI. **Khirurgiia (Mosk)** 1999;(8):56-9 (0 ref.) **(Rus)**

THERAPY

Recent advances: hepatology. McCarthy M, et al. **BMJ** 1999 May 8;318(7193):1256-9 (21 ref.)
Recent advances in gene therapy of GI and liver diseases. Wu GY. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Sep-Oct;39(5):297-300 (25 ref.)
Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. Restrepo A, et al. **Crit Rev Oncog** 1999;10(3):239-45 (37 ref.)
Gene therapy for human liver diseases. Di Campli C, et al. **Eur J Gastroenterol Hepatol** 1999 Apr;11(4):421-9 (58 ref.)
Non-invasive diagnosis and management of chronic liver diseases. van Hoek B. **Forum (Genova)** 1999 Apr-Jun; 9(2):113-36 (189 ref.)
NF-kappa B, liposomes and pathogenesis of hepatic injury and fibrosis. Wu J, et al. **Front Biosci** 1999 Jun 15;4:D520-7 (67 ref.)
Herbal products for liver diseases: a therapeutic challenge for the new millennium. Schuppan D, et al. **Hepatology** 1999 Oct;30(4):1099-104 (78 ref.)
Hepatocyte growth factor for liver disease [editorial; comment] Tsubouchi H. **Hepatology** 1999 Jul;30(1):333-4 (22 ref.) Comment on: Hepatology 1999 Jul;30(1):151-9.
Amyloidosis and the liver. Gillmore JD, et al. **J Hepatol** 1999;30 Suppl 1:17-33 (95 ref.)
Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. Sokol RJ, et al. **J Pediatr Gastroenterol Nutr** 1999;28 Suppl 1:S1-13 (87 ref.)
Strategy of liver-directed gene therapy: present status and future prospects. Shiratori Y, et al. **Liver** 1999 Aug; 19(4):265-74 (83 ref.)
Feeding the child with chronic liver disease. Protheroe SM. **Nutrition** 1998 Oct;14(10):796-800 (31 ref.)
Interventional radiology of the liver and pancreas. Newman J. **Radiol Technol** 1999 Jul-Aug;70(6):513-30; quiz 531-3 (25 ref.)
Nontransplant alternatives for the treatment of patients with metabolic disease. Hesham A-Kader H, et al. **Semin Liver Dis** 1998;18(3):255-61 (38 ref.)
Adenovirus-mediated gene therapy of liver diseases. Ilan Y, et al. **Semin Liver Dis** 1999;19(1):49-59 (86 ref.)
Retroviral vectors for liver-directed gene therapy. Kalpana GV. **Semin Liver Dis** 1999;19(1):27-37 (40 ref.)
Hepatic gene therapy using adeno-associated virus vectors. Patijn GA, et al. **Semin Liver Dis** 1999;19(1):61-9 (106 ref.)
[Indications for immunosuppressive therapy in hepatology] Husa P, et al. **Vnitr Lek** 1998 Nov;44(11):665-70 (26 ref.) (Eng. Abstr.) **(Cze)**

ULTRASONOGRAPHY

Imaging of subcapsular hepatic and renal hematomas in pregnancy complicated by preeclampsia and the HELLP syndrome. Chan AD, et al. **J Clin Ultrasound** 1999 Jan; 27(1):35-40 (28 ref.)
Tissue harmonic imaging: utility in abdominal and pelvic sonography. Desser TS, et al. **J Clin Ultrasound** 1999 Mar-Apr;27(3):135-42 (5 ref.)

VETERINARY

Nutritional support for dogs and cats with hepatobiliary disease. Center SA. **J Nutr** 1998 Dec;128(12 Suppl):2733S-2746S (24 ref.)
Chronic liver disease: current concepts of disease mechanisms. Center SA. **J Small Anim Pract** 1999 Mar; 40(3):106-14 (41 ref.)

VIROLOGY

Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Antonaci S, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):455-72 (62 ref.)
[The association of TTV genetic variant with liver disease] Kurihara C, et al. **Nippon Rinsho** 1999 Jun;57(6):1256-61 (15 ref.) (Eng. Abstr.) **(Jpn)**

LIVER DISEASES, ALCOHOLIC

BLOOD

Interleukin-8 and alcoholic liver disease. Huang YS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul;62(7):418-24 (43 ref.)

ETIOLOGY

Endotoxin and alcoholic liver disease: tolerance and susceptibility [editorial; comment] Hoek JB. **Hepatology** 1999 May;29(5):1602-4 (26 ref.) Comment on: Hepatology 1999 May;29(5):1503-10.
Metabolism of ethanol and some associated adverse effects on the liver and the stomach. Lieber CS, et al. **Recent Dev Alcohol** 1998;14:7-40 (245 ref.)
[A pivotal role of activated hepatic macrophage in the progression of alcoholic liver disease] Yamada S. **Sangyo Ika Daigaku Zasshi** 1999 Mar 1;21(1):37-45 (26 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The inheritance of alcoholic liver disease. Bassendine MF, et al. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):317-35 (98 ref.)

IMMUNOLOGY

Cytokines in alcoholic liver disease. McClain CJ, et al. **Semin Liver Dis** 1999;19(2):205-19 (150 ref.)

METABOLISM

Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. Fletcher LM, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):202-14 (157 ref.)
The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. Thurman RG, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S39-50 (88 ref.)
Nutritional and metabolic effects of alcoholism: their relationship with alcoholic liver disease. Bunout D. **Nutrition** 1999 Jul-Aug;15(7-8):583-9 (133 ref.)

PATHOLOGY

II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Thurman RG. **Am J Physiol** 1998 Oct;275(4 Pt 1):G605-11 (55 ref.)

PHYSIOPATHOLOGY

II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Thurman RG. **Am J Physiol** 1998 Oct;275(4 Pt 1):G605-11 (55 ref.)
Dietary fat and alcoholic liver disease. Mezey E. **Hepatology** 1998 Oct;28(4):901-5 (42 ref.)

LIVER DISEASES, PARASITIC

[Clonorchiasis] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):490-2 (5 ref.) **(Jpn)**
[Schistosomiasis (intestinal, hepatic, urinary tract)] Ohnishi K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):481-4 (4 ref.) **(Jpn)**

DIAGNOSIS

Radiological manifestations of liver and gastrointestinal parasitic infections. Sammak B, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1016-22 (20 ref.)

LIVER FAILURE

Cholestasis and end-stage liver disease. Protheroe SM, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):823-41 (58 ref.)

CHEMICALLY INDUCED

[Recommendations for blood studies and clinical monitoring in early detection of valproate-associated liver failure. Results of a consensus conferences 9 May - 11 May 1997 in Berlin] König SA, et al. **Nervenarzt** 1998 Oct; 69(10):835-40 (32 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Erythropoietic protoporphyria with fatal liver failure. Ishibashi A, et al. **J Gastroenterol** 1999 Jun;34(3):405-9 (17 ref.)
Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus. Yoshikawa M, et al. **J Gastroenterol** 1998 Dec;33(6):880-5 (33 ref.)
Life-threatening situations in sarcoidosis. James DG. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):134-9 (13 ref.)

PHYSIOPATHOLOGY

Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Jones EA, et al. **Metab Brain Dis** 1998 Dec;13(4):351-60 (49 ref.)

PREVENTION & CONTROL

Hepatectomy: preoperative analysis of hepatic function and postoperative liver failure [see comments] Zimmermann H, et al. **Dig Surg** 1998;15(1):1-11 (103 ref.) Comment in: Dig Surg 1998;15(3):191-2.

SURGERY

Xenotransplantation: A potential solution to the critical organ donor shortage. Sim KH, et al. **Can J Gastroenterol** 1999 May;13(4):311-8 (77 ref.)
[Liver transplantation] Berg T, et al. **Internist (Berl)** 1998 Dec;39(12):1237-45 (54 ref.) **(Ger)**

THERAPY

Artificial liver: review and Cedars-Sinai experience. Kamohara Y, et al. **J Hepatobiliary Pancreat Surg** 1998; 5(3):273-85 (73 ref.)
Bilirubin adsorbent column for plasma perfusion. Takenaka Y. **Ther Apher** 1998 May;2(2):129-33 (25 ref.)
[Liver and artificial liver] Chamuleau RA. **Ned Tijdschr Geneeskd** 1998 Jun 6;142(23):1300-5 (32 ref.) (Eng. Abstr.) **(Dut)**
[The artificial liver--an interim report] Koebe HG, et al. **Wien Klin Wochenschr** 1998 Sep 4;110(16):551-63 (51 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. Vesely DL, et al. **Am J Med Sci** 1999 Jun; 317(6):419-24 (31 ref.)

LIVER FAILURE, ACUTE

SURGERY

Pediatric liver transplantation. Kelly DA. **Curr Opin Pediatr** 1998 Oct;10(5):493-8 (43 ref.)
[Liver transplantation in acute liver failure: who? When? How? (editorial)] Pauletzki J, et al. **Wien Klin Wochenschr** 1998 Sep 4;110(16):547-50 (29 ref.) **(Ger)**
[Severe liver failure in erythropoietic protoporphyria. A report of a case treated by liver transplantation] Jiménez-Sáenz M, et al. **Med Clin (Barc)** 1999 Jul 10; 113(5):176-9 (20 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Overview of extracorporeal liver support systems and clinical results. McLaughlin BE, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:310-25 (61 ref.)
Management of acute liver failure. Herrera JL. **Dig Dis** 1998 Sep-Oct;16(5):274-83 (90 ref.)
Liver assist systems: state of the art. Arkadopoulos N, et al. **Int J Artif Organs** 1998 Dec;21(12):781-7 (60 ref.)
Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. Riordan SM, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):757-70 (163 ref.)
Current concepts in pediatric liver transplant. Alonso MH, et al. **Semin Liver Dis** 1998;18(3):295-307 (70 ref.)
[Extracorporeal liver assist devices in acute liver failure] Horn N, et al. **Anaesthesist** 1999 Jun;48(6):387-94 (32 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of liver failure. New frontiers (editorial)] Muraca M. **Recenti Prog Med** 1998 Nov;89(11):579-86 (34 ref.) **(Ita)**

LIVER FAILURE, FULMINANT see **HEPATIC ENCEPHALOPATHY**

LIVER FIBROSIS see **LIVER CIRRHOSIS**

LIVER FUNCTION TESTS

Special considerations in interpreting liver function tests. Johnston DE. **Am Fam Physician** 1999 Apr 15; 59(8):2223-30 (32 ref.)
Hepatectomy: preoperative analysis of hepatic function and postoperative liver failure [see comments] Zimmermann H, et al. **Dig Surg** 1998;15(1):1-11 (103 ref.) Comment in: Dig Surg 1998;15(3):191-2.
Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. Tanaka E. **J Clin Pharm Ther** 1998 Jun;23(3):161-70 (117 ref.)
[Importance of determination of monoethylglycinexylidide (MEGX)--as a liver function test in hepatology and liver transplantation] Kupčová V. **Bratisl Lek Listy** 1999 Jan;

100(1):49–53 (46 ref.) (Eng. Abstr.) **(Slo)**

LIVER MICROSOMES see **MICROSOMES, LIVER**

LIVER MITOCHONDRIA see **MITOCHONDRIA, LIVER**

LIVER NEOPLASMS

Hepatocellular carcinoma. Akriviadis EA, et al. **Br J Surg** 1998 Oct;85(10):1319–31 (127 ref.)

Hepatocellular carcinoma in children. Chang MH. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov–Dec;39(6):366–70 (21 ref.)

Hepatocellular carcinoma [see comments] Schafer DF, et al. **Lancet** 1999 Apr 10;353(9160):1253–7 (57 ref.) Comment in: Lancet 1999 Jul 17;354(9174):253. Comment in: Lancet 1999 Jul 17;354(9174):253–4.

Human and experimental hepatocarcinogenesis. Schaff Z, et al. **Scand J Gastroenterol Suppl** 1998;228:90–7 (67 ref.)

Primary and metastatic liver cancer. Groen KA. **Semin Oncol Nurs** 1999 Feb;15(1):48–57 (55 ref.)

Hepatobiliary malignancies. Primary hepatic malignant neoplasms. Molmenti EP, et al. **Surg Clin North Am** 1999 Feb;79(1):43–57, viii (32 ref.)

Molecular aspects of hepatocellular carcinoma. Abou-Shady M, et al. **Swiss Surg** 1999;5(3):102–6 (53 ref.)

[Study on small hepatocellular carcinoma: a review of 20 years experience] Tang Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Oct; 19(5):395–400 (67 ref.) **(Chi)**

BLOOD SUPPLY

Focally spared area of fatty liver that receives blood passing through the sinusoids of a hypervascular hepatocellular carcinoma. Murakami T, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):320–2 (6 ref.)

[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma] Konno H, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):441–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review. Law CH, et al. **Can J Surg** 1999 Jun;42(3):211–4 (20 ref.)

Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. Kristensen T, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):314–7 (26 ref.)

Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health (review). Chevalier S, et al. **Oncol Rep** 1998 Nov–Dec;5(6):1319–27 (117 ref.)

Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. James NH, et al. **Toxicol Lett** 1998 Dec 28;102–103:91–6 (40 ref.)

COMPLICATIONS

Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature. Te HS, et al. **Am J Gastroenterol** 1999 Jan;94(1):262–6 (40 ref.)

Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature. Huang WS, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar; 22(1):111–6 (20 ref.)

Endoscopic management of major bile leaks complicating hepatic resections for hepatocellular carcinoma. Lau JY, et al. **Gastrointest Endosc** 1999 Jul;50(1):99–101 (10 ref.)

Calcification in mucinous cholangiocellular carcinoma. Nagakura S, et al. **Hepatogastroenterology** 1999 Jan–Feb; 46(25):465–6 (11 ref.)

Fatal tumor lysis syndrome and gastric hemorrhage associated with metastatic small-cell lung carcinoma. Marinella MA. **Med Pediatr Oncol** 1999 Jun;32(6):464–5 (10 ref.)

Primary dissection of the hepatic artery: report of a case. Nakamura S, et al. **Surg Today** 1998;28(10):1065–8 (14 ref.)

DIAGNOSIS

Angiomyolipoma of the liver: significance of CT and MR dynamic study. Ahmadi T, et al. **Abdom Imaging** 1998 Sep–Oct;23(5):520–6 (41 ref.)

Liver cell dysplasia and other atypical lesions: new insights and applications. Schwartz MR. **Adv Anat Pathol** 1998 Mar; 5(2):99–105 (27 ref.)

Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Palma LD. **Br J Radiol** 1998 Aug;71(848):808–18 (73 ref.)

Fine needle aspiration biopsy of the liver. Principal diagnostic challenges. Pitman MB. **Clin Lab Med** 1998 Sep; 18(3):483–506, vi (64 ref.)

Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Lonardo A, et al. **Dig Dis Sci** 1998 Nov;43(11):2489–92 (46 ref.)

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Nguyen HN, et al. **Dig Dis Sci** 1999 Jun;44(6):1148–55 (37 ref.)

Primary liver adenomatosis. Report of two cases and literature review. Cristaldi M, et al. **Dig Surg** 1998; 15(1):75–8 (13 ref.)

Fast magnetic resonance imaging of liver. Ichikawa T, et al. **Eur J Radiol** 1999 Mar;29(3):186–210 (79 ref.)

Tumor diagnosis in the adult liver transplant candidate. Mahfouz A, et al. **Eur Radiol** 1999;9(5):841–52 (66 ref.)

Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Reimer P, et al. **Eur Radiol** 1998; 8(7):1198–204 (38 ref.)

Hepatic angiomyolipoma: report of changing size and internal composition on follow-up examination in two cases. Irie H, et al. **J Comput Assist Tomogr** 1999 Mar–Apr; 23(2):310–3 (13 ref.)

Spontaneous regression of hepatocellular carcinoma. Misawa K, et al. **J Gastroenterol** 1999 Jun;34(3):410–4 (15 ref.)

Imaging of hepatocellular carcinoma. Frazer C. **J Gastroenterol Hepatol** 1999 Aug;14(8):750–6 (46 ref.)

Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. Johnson PJ. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S32–6 (33 ref.)

The detection of occult liver metastases of colorectal carcinoma. Leen E. **J Hepatobiliary Pancreat Surg** 1999; 6(1):7–15 (30 ref.)

Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. Mathieu D, et al. **J Magn Reson Imaging** 1999 Aug;10(2):193–5 (15 ref.)

Angiomyolipoma of the liver--a case report and review of 48 cases reported in Japan. Sajima S, et al. **Kurume Med J** 1999;46(2):127–31 (24 ref.)

Hepatocellular carcinoma: risk factors and natural history. Martin P. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S87–91 (21 ref.)

Hepatic lymphangiomatosis mimicking polycystic liver disease. O'Sullivan DA, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1188–92 (24 ref.)

A primary hepatic carcinoid tumor: evaluation by computed tomography and magnetic resonance imaging. Fujino K, et al. **Radiat Med** 1998 Sep–Oct;16(5):371–3 (15 ref.)

CT and MR imaging of benign hepatic and biliary tumors. Horton KM, et al. **Radiographics** 1999 Mar–Apr; 19(2):431–51 (30 ref.)

Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. McLarney JK, et al. **Radiographics** 1999 Mar–Apr;19(2):453–71 (54 ref.)

Pediatric liver tumors. Reynolds M. **Semin Surg Oncol** 1999 Mar;16(2):159–72 (42 ref.)

Imaging of hepatobiliary neoplasms. DeMatteo RP, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):59–89 (62 ref.)

Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Picciocchi A, et al. **Surg Today** 1998;28(12):1257–60 (18 ref.)

[Liver tumors: radio-pathologic correlations and practical approach for the pathologist in 1998] Le Bail B, et al. **Ann Pathol** 1998;18(5 Suppl):47–58 (9 ref.) **(Fre)**

[Benign liver tumors: diagnosis and therapy--a review] Nufer M, et al. **Schweiz Med Wochenschr** 1999 Sep 4; 129(35):1257–64 (16 ref.) (Eng. Abstr.) **(Ger)**

[Value of liver histology in diagnosis of chronic hepatopathies] Schmid M. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1397–401 (20 ref.) (Eng. Abstr.) **(Ger)**

[The natural course of hepatitis B and hepatitis C virus infection] Schwabe RF, et al. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1403–7 (56 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of hepatic cancer] Toda G. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1848–55 (10 ref.) **(Jpn)**

[Recent progress in liver tumor imaging] Itai Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1085–93 (41 ref.) **(Jpn)**

[Diagnosis of small hepatocellular carcinoma and its prognosis] Okita K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Mar;96(3):251–8 (12 ref.) **(Jpn)**

[Hepatic biliary cystadenoma. Report of 3 cases and review of the literature] Herman P, et al. **Arq Gastroenterol** 1998 Jul–Sep;35(3):186–9 (19 ref.) (Eng. Abstr.) **(Por)**

[A fibrolamellar variety of hepatocarcinoma in a young woman 17 years old] Téllez-Zenteno JF, et al. **Gac Med Mex** 1999 Jan–Feb;135(1):83–7 (17 ref.) (Eng. Abstr.) **(Spa)**

[A young oligosymptomatic woman] Poza A, et al. **Rev Clin Esp** 1999 Apr;199(4):251–2 (12 ref.) **(Spa)**

DRUG THERAPY

TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Eggermont AM. **Anticancer Res** 1998 Sep–Oct;18(5D):3899–905 (80 ref.)

Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C. Link KH, et al. **Gan To Kagaku Ryoho** 1999 Feb;26(3):269–81 (37 ref.)

Chemotherapy in hepatocellular carcinoma. Okada S. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1259–63 (20 ref.)

Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. Kemeny N, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):39–49 (82 ref.)

Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. Konno H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):1–6 (30 ref.)

Selective modification of sterol composition of hepatomas: new opportunities for chemotherapy. Feigin AM. **Med Hypotheses** 1999 May;52(5):383–8 (46 ref.)

Therapy for advanced colorectal cancer. Benson AB 3rd. **Semin Oncol** 1998 Oct;25(5 Suppl 11):2–11 (31 ref.)

Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? Goldberg RM. **Semin Oncol** 1998 Oct;25(5 Suppl 11):21–8 (40 ref.)

Nonsurgical therapies for hepatocellular and cholangiocellular carcinoma. Schmassmann A. **Swiss Surg** 1999;5(3):116–21 (45 ref.)

[Local, non-surgical treatment of hepatocellular carcinoma] Roche A. **Ann Chir** 1998;52(1):75–8 (10 ref.) **(Fre)**

EPIDEMIOLOGY

Primary malignancies of the hepato-biliary-pancreatic system in organ allograft recipients. Penn I. **J Hepatobiliary Pancreat Surg** 1998;5(2):157–64 (42 ref.)

Hepatocellular carcinoma: risk factors and natural history. Martin P. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S87–91 (21 ref.)

ETHNOLOGY

Hepatitis B and hepatocellular carcinoma in Eskimo/Inuit population. McMahon BJ, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:414–9 (40 ref.)

ETIOLOGY

Primary hepatic lymphoma in hepatitis C: case report and review of the literature. Chowla A, et al. **Am Surg** 1999 Sep;65(9):881–3 (6 ref.)

Hepatocellular carcinoma. Falkson G, et al. **Cancer Treat Res** 1998;98:83–109 (167 ref.)

The role of hepatitis C virus in hepatocellular carcinoma. Colombo M. **Recent Results Cancer Res** 1998;154:337–44 (50 ref.)

The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Hildt E, et al. **Recent Results Cancer Res** 1998;154:315–29 (50 ref.)

Hepatitis viruses and hepatocellular carcinoma. Kew MC. **Res Virol** 1998 Sep–Oct;149(5):257–62 (55 ref.)

[Co-infection of HBV with HCV and a possible role of HBV DNA in hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1999 Jan;57(1):213–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Westra WH, et al. **Am J Surg Pathol** 1998 Oct;22(10):1247–54 (33 ref.)

Gene expression in hepatomas. Kokura K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S132–41 (59 ref.)

Repair of DNA lesion O6-methylguanine in hepatocellular carcinogenesis. Major GN, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):355–66 (123 ref.)

Liver enriched transcription factors and differentiation of hepatocellular carcinoma. Hayashi Y, et al. **Mol Pathol** 1999 Feb;52(1):19–24 (86 ref.)

TP53 and hepatocellular carcinoma. Puisieux A, et al. **Pathol Biol (Paris)** 1997 Dec;45(10):864–70 (63 ref.)

Genetic dissection of murine susceptibilities to liver and lung tumors based on the two-stage concept of carcinogenesis. Lee GH. **Pathol Int** 1998 Dec;48(12):925–33 (60 ref.)

IMMUNOLOGY

CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Krammer PH, et al. **Adv Cancer Res** 1998;75:251–73 (114 ref.)

METABOLISM

Several new targets of antitumor agents. Wang XW, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jul;18(4):289–92 (32 ref.)

Prognostic significance of pathological and biological factors in hepatocellular carcinoma. Ng IO. **J Gastroenterol Hepatol** 1998 Jun;13(6):666–70 (44 ref.)

Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia. Guglielmi A, et al. **J Hepatobiliary Pancreat Surg** 1998;5(2):212–6 (17 ref.)

Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. Gonzalez FJ, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1702–9 (77 ref.)

Selective modification of sterol composition of hepatomas: new opportunities for chemotherapy. Feigin AM. **Med Hypotheses** 1999 May;52(5):383–8 (46 ref.)

Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. Bell JD, et al. **NMR Biomed** 1998 Nov;11(7):354–9 (41 ref.)

NMR studies of phospholipid metabolism in hepatic lymphoma. Dixon RM. **NMR Biomed** 1998 Nov; 11(7):370–9 (49 ref.)

Cellular aspects of alpha-fetoprotein reexpression in tumors. Abelev GI, et al. **Semin Cancer Biol** 1999 Apr;9(2):95–107 (99 ref.)

MORTALITY

Survival and distribution pattern of childhood liver cancer in Taiwan. Lee CL, et al. **Eur J Cancer** 1998 Dec; 34(13):2064–7 (2 ref.)

PATHOLOGY

Primary non-Hodgkin's lymphoma of the liver. Memeo L, et al. **Acta Oncol** 1999;38(5):655–8 (31 ref.)

Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Chang KL, et al. **Adv Anat Pathol** 1998 Jan;5(1):21–9 (22 ref.)

Primary hepatic neuroendocrine tumor: successful hepatectomy in two cases and review of the literature. Rückert RI, et al. **Digestion** 1999 Mar–Apr;60(2):110–6 (36 ref.)

Theoretical evaluation of measurements used to assess the growth of colorectal hepatic metastases. Purkiss SF. **Eur J Surg** 1998 Nov;164(11):803–9 (34 ref.)

Architectural pattern, tissue and cellular morphology in livers of fishes: relationship to experimentally-induced neoplastic responses. Hinton DE, et al. **EXS** 1998;86:141–64 (83 ref.)

Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors. Lauwers GY, et al. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1197–202 (34 ref.)

Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver disease. Nakanuma Y, et al. **Histol Histopathol** 1998 Oct;13(4):1077–87 (37 ref.)

Secretory breast carcinoma in a 66 year old man. Kuwabara H, et al. **J Clin Pathol** 1998 Jul;51(7):545–7 (12 ref.)

Primary yolk sac tumour of the liver in adulthood. Wong NA, et al. **J Clin Pathol** 1998 Dec;51(12):939–40 (9 ref.)

Primary hepatic carcinoid tumor. Asakawa T, et al. **J Gastroenterol** 1999 Feb;34(1):123–7 (22 ref.)

Liver regeneration, liver cancers and cyclins. Kitamura T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S96–9 (16 ref.)

Prognostic significance of pathological and biological factors in hepatocellular carcinoma. Ng IO. **J Gastroenterol Hepatol** 1998 Jun;13(6):666–70 (44 ref.)

Hepatocellular carcinoma with chondrosarcomatous variation: case report with immunohistochemical findings, and review of the literature. Ikebe T, et al. **J Hepatobiliary Pancreat Surg** 1998;5(2):217–20 (6 ref.)

Cell adhesion molecules in the formation of liver metastasis. Jiang WG. **J Hepatobiliary Pancreat Surg** 1998;5(4):375–82 (49 ref.)

Angiomyolipoma of the liver: case report and collective review of cases diagnosed from fine needle aspiration biopsy specimens. Sawai H, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):333–8 (18 ref.)

Spontaneous regression of hepatocellular carcinoma confirmed by surgical specimen: report of two cases and review of the literature. Stoelben E, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):447–52 (51 ref.)

Nodular lesions of the liver revealing multiple myeloma. Chemlal K, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):389–92 (15 ref.)

Initial presentation of hepatocellular carcinoma as a mandibular mass: case report and review of the literature. Chin A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Oct;86(4):457–60 (58 ref.)

Schwannoma of the liver: report of two surgical cases. Wada Y, et al. **Pathol Int** 1998 Aug;48(8):611–7 (17 ref.)

Primary hepatic osteosarcoma: case report and literature review. Govender D, et al. **Pathology** 1998 Aug;30(3):323–5 (13 ref.)

Hepatic neoplasms in childhood - a clinicopathologic study. Bhattacharya S, et al. **Pediatr Surg Int** 1998 Nov; 14(1–2):51–4 (22 ref.)

Interrelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma. Yoshihara H, et al. **Recent Dev Alcohol** 1998;14:457–69 (58 ref.)

Oncocytic and oncocytoid tumors of the exocrine pancreas, liver, and gastrointestinal tract. Papotti M, et al. **Semin Diagn Pathol** 1999 May;16(2):126–34 (71 ref.)

Successful surgical treatment for implanted intraperitoneal metastases of ruptured small hepatocellular carcinoma: report of a case. Kosaka A, et al. **Surg Today** 1999; 29(5):453–7 (16 ref.)

[Hepatocellular carcinoma in the non-cirrhotic liver: renewed interest] Bernard PH, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):371–4 (60 ref.) **(Fre)**

[Should small nodules in cirrhotic liver be biopsied?] Labadie H, et al. **Gastroenterol Clin Biol** 1999 May;23(5):540–3 (42 ref.) **(Fre)**

[Hepatocyte dysplasia: pre- or peri-neoplastic lesion?] Scoazec JY. **Gastroenterol Clin Biol** 1999 Apr;23(4):433–7 (39 ref.) **(Fre)**

[Radiologic staging of liver and pancreatic malignancies] Schima W, et al. **Radiologe** 1999 Jul;39(7):568–77 (53 ref.) (Eng. Abstr.) **(Ger)**

[Recommendations for clinicopathologic quality standards in gastroenterology and hepatology. Consensus report of the Austrian Society of Gastroenterology and Hepatology and the Austrian Society of Pathology] Wrba F, et al. **Z Gastroenterol** 1998 Oct;36(10):917–23 (5 ref.) **(Ger)**

[Recurrence of hepatocellular carcinoma after liver resection] Ikai I, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):191–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Cell cycle regulators and human hepatocarcinogenesis. Hui AM, et al. **Hepatogastroenterology** 1998 Sep–Oct; 45(23):1635–42 (90 ref.)

The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Andrisani OM, et al. **Int J Oncol** 1999 Aug;15(2):373–9 (93 ref.)

[Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma] Clavière C, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):73–86 (166 ref.) **(Fre)**

PREVENTION & CONTROL

Hepatitis C: implications for the general physician. Fallon HJ. **Compr Ther** 1999 May;25(5):253–7 (8 ref.)

Towards global control of liver cancer? Stuver SO. **Semin Cancer Biol** 1998 Aug;8(4):299–306 (115 ref.)

[Prevention of hepatic carcinogenesis by retinoids] Moriwaki H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1548–53 (11 ref.) **(Jpn)**

[Prevention of cirrhosis is the best measure against hepatocellular cancer] Kaczynski J. **Lakartidningen** 1999 Jan 27;96(4):338–41 (107 ref.) (Eng. Abstr.) **(Swe)**

RADIOGRAPHY

Multiple hepatic angiolipomas: a case report and review of literature. Strotzer M, et al. **Eur Radiol** 1999;9(2):259–61 (32 ref.)

Nodular lesions of the liver revealing multiple myeloma. Chemlal K, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):389–92 (15 ref.)

[Helical CT of the liver. Principles and applications] Blum A, et al. **Gastroenterol Clin Biol** 1998 Jun–Jul; 22(6–7):576–89 (55 ref.) **(Fre)**

[Computerized tomography with lipiodol in hepatocarcinoma. Assessment of its diagnostic accuracy with anatomo-pathological control] Veltri A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):81–6 (33 ref.) (Eng. Abstr.) **(Ita)**

[Interventional radiology for recurrent cancer] Uchida H, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):220–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Hemoperitoneum as the form of presentation of hepatocellular carcinoma. The contribution of computed tomography to the diagnosis] da Fonseca CR, et al. **Acta Med Port** 1999 Apr–Jun;12(4–6):223–6 (15 ref.) (Eng. Abstr.) **(Por)**

RADIOTHERAPY

Conformal irradiation for hepatobiliary malignancies. Gunderson LL, et al. **Ann Oncol** 1999;10 Suppl 4:221–5 (31 ref.)

Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Ho S, et al. **Cancer** 1998 Nov 1;83(9):1894–907 (98 ref.)

SECONDARY

Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature. Te HS, et al. **Am J Gastroenterol** 1999 Jan;94(1):262–6 (40 ref.)

Colorectal cancer liver metastasis: local treatment for a systemic disease? Köhne CH, et al. **Ann Oncol** 1998 Sep; 9(9):967–71 (54 ref.)

Colorectal cancer in adolescents. Shankar A, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):100–4 (52 ref.)

Liver transplantation for primary and metastatic liver cancers. Testa G, et al. **Ann Transplant** 1997;2(4):19–21 (21 ref.)

Extracranial metastatic meningioma. Figueroa BE, et al. **Br J Radiol** 1999 May;72(857):513–6 (48 ref.)

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Nguyen HN, et al. **Dig Dis Sci** 1999 Jun;44(6):1148–55 (37 ref.)

Theoretical evaluation of measurements used to assess the growth of colorectal hepatic metastases. Purkiss SF. **Eur J Surg** 1998 Nov;164(11):803–9 (34 ref.)

Liver metastases: interventional therapeutic techniques and results, state of the art. Vogl TJ, et al. **Eur Radiol** 1999; 9(4):675–84 (43 ref.)

Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C. Link KH, et al. **Gan To Kagaku Ryoho** 1999 Feb;26(3):269–81 (37 ref.)

Surgical management of liver metastases from colorectal cancer. Huang J, et al. **Hosp Med** 1998 Aug;59(8):608–11 (10 ref.)

Treatment of metastatic glucagonoma to the liver: case report and literature review. Casadei R, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):308–12 (34 ref.)

Gastric enterochromaffin-like-cell tumor with liver and splenic metastases. Eriguchi N, et al. **J Gastroenterol** 1999 Jun;34(3):383–6 (10 ref.)

Treatment strategy for multiple hepatic metastases of colorectal carcinoma. Imamura H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):23–9 (43 ref.)

Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. Kemeny N, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):39–49 (82 ref.)

Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. Konno H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):1–6 (30 ref.)

The detection of occult liver metastases of colorectal carcinoma. Leen E. **J Hepatobiliary Pancreat Surg** 1999; 6(1):7–15 (30 ref.)

Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. Mathieu D, et al. **J Magn Reson Imaging** 1999 Aug;10(2):193–5 (15 ref.)

A long-term survival patient with advanced gallbladder cancer massively metastasizing to the liver. Eriguchi N, et al. **Kurume Med J** 1999;46(1):83–6 (17 ref.)

Management of hepatic metastases. Choti MA, et al. **Liver Transpl Surg** 1999 Jan;5(1):65–80 (148 ref.)

Surgical treatment and other regional treatments for colorectal cancer liver metastases. Yoon SS, et al. **Oncologist** 1999;4(3):197–208 (102 ref.)

Hepatic colorectal metastasis: current status of surgical therapy. Fong Y, et al. **Oncology (Huntingt)** 1998 Oct; 12(10):1489–98; discussion 1498–500, 1503 (90 ref.)

Extraneural metastasizing ependymoma of the spinal cord. Graf M, et al. **Pathol Oncol Res** 1999;5(1):56–60 (36 ref.)

Congenital mediastinal dumbbell neuroblastoma with spontaneous regression of liver metastases. Komuro H, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):86–8 (19 ref.)

Technology for in situ ablation by laparoscopic and image-guided interstitial laser hyperthermia. Germer CT, et al. **Semin Laparosc Surg** 1998 Sep;5(3):195–203 (65 ref.)

Therapy for advanced colorectal cancer. Benson AB 3rd. **Semin Oncol** 1998 Oct;25(5 Suppl 11):2–11 (31 ref.)

Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? Goldberg RM. **Semin Oncol** 1998 Oct;25(5 Suppl 11):21–8 (40 ref.)

Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. Henderson CA. **Semin Oncol** 1998 Oct;25(5 Suppl 11):29–38 (46 ref.)

Laparoscopic cryoablation of hepatic metastases. Heniford BT, et al. **Semin Surg Oncol** 1998 Oct–Nov;15(3):194–201 (51 ref.)

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Lehnert T. **Transplantation** 1998 Nov 27;66(10):1307–12 (37 ref.)

[A role for cryosurgery in the treatment of non-resectable liver metastases of colorectal neoplasms] Ruers TJ, et al. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2448–52 (26 ref.) (Eng. Abstr.) **(Dut)**

[Surgery of liver metastases of colorectal carcinoma] Adam R. **Ann Chir** 1998;52(1):85–7 (10 ref.) **(Fre)**

[Liver imaging for metastases] Kunstlinger F. **Ann Chir** 1998; 52(1):82–4 (5 ref.) **(Fre)**

[Surgery of liver metastases of non-colorectal origin] Le Treut YP, et al. **Ann Chir** 1998;52(1):88–91 (12 ref.) **(Fre)**

[Treatment of liver metastases of colorectal cancers: how far should we go? (editorial; comment)] Penna C, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1046–7 (9 ref.) Comment on: Gastroenterol Clin Biol 1998 Dec;22(12):1048–55. **(Fre)**

[Gene therapy and liver metastases] Martinet O, et al. **Schweiz Med Wochenschr** 1999 Aug 28;129(34):1187–95 (43 ref.) (Eng. Abstr.) **(Fre)**

[Cryosurgery--renaissance or real progress?] Feifel G, et al. **Chirurg** 1999 Feb;70(2):154–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and staging of liver metastases with imaging methods] Helmberger T, et al. **Chirurg** 1999 Feb; 70(2):114–22 (47 ref.) (Eng. Abstr.) **(Ger)**

[The status of regional long-term chemotherapy in liver metastasis] Lorenz M, et al. **Chirurg** 1999 Feb;70(2):141–53 (74 ref.) (Eng. Abstr.) **(Ger)**

[Principles of curative resection of liver metastases] Schlag PM, et al. **Chirurg** 1999 Feb;70(2):123–32 (69 ref.) (Eng. Abstr.) **(Ger)**

[Therapeutic options in non-resectable liver metastases. Percutaneous radiological interventions] Vogl TJ, et al. **Chirurg** 1999 Feb;70(2):133–40 (29 ref.) (Eng. Abstr.) **(Ger)**

[Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide] Rischke HC, et al. **Dtsch Med Wochenschr** 1999 Feb 19;124(7):182–6 (21 ref.) (Eng. Abstr.) **(Ger)**

[Surgical procedure in primary and metastatic breast carcinoma] Hampl M, et al. **Zentralbl Chir** 1998;123 Suppl 5:81–6 (37 ref.) (Eng. Abstr.) **(Ger)**

[Interstitial percutaneous therapies in primary and secondary liver tumors] Torzilli G, et al. **Ann Ital Chir** 1999 Mar–Apr; 70(2):185–94 (62 ref.) (Eng. Abstr.) **(Ita)**

[Intra-arterial chemotherapy in the treatment of liver metastases of colorectal cancer] Lupo F, et al. **Minerva Chir** 1999 May;54(5):325–30 (40 ref.) (Eng. Abstr.) **(Ita)**

[Implication of VEGF and MMPs in hepatic metastasis of human colon cancer] Arii S, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):436–40 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma] Konno H, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):441–5 (17

ref.) (Eng. Abstr.) **(Jpn)**

[Multidisciplinary treatment for colorectal liver metastases] Okuno K, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul; 99(7):430–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):200–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Interventional radiology for recurrent cancer] Uchida H, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):220–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of variant CD44 in colorectal cancer and its relationship to liver metastasis] Yamaguchi A. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):409–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

[A case of adenosquamous pancreatic cancer with high serum level of parathyroid related protein in which both primary and liver metastatic lesions showed remarkable cystic changes] Hyodo N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):181–8 (13 ref.) **(Jpn)**

SURGERY

Current surgical management of primary hepatocellular carcinoma. Hemming AW, et al. **Adv Surg** 1999;32:169–92 (97 ref.)

Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature. Pergolizzi JV Jr, et al. **Am Surg** 1999 May;65(5):402–5 (13 ref.)

Liver transplantation for primary and metastatic liver cancers. Testa G, et al. **Ann Transplant** 1997;2(4):19–21 (21 ref.)

Interstitial laser coagulation for hepatic tumours. Heisterkamp J, et al. **Br J Surg** 1999 Mar;86(3):293–304 (112 ref.)

Primary hepatic neuroendocrine tumor: successful hepatectomy in two cases and review of the literature. Rückert RI, et al. **Digestion** 1999 Mar–Apr;60(2):110–6 (36 ref.)

Liver transplantation for hepatocellular carcinoma? Van Thiel DH, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):1944–9 (19 ref.)

Surgical management of liver metastases from colorectal cancer. Huang J, et al. **Hosp Med** 1998 Aug;59(8):608–11 (10 ref.)

Radiofrequency thermal ablation of liver tumors. Rhim H, et al. **J Clin Ultrasound** 1999 Jun;27(5):221–9 (37 ref.)

Resection versus transplantation for hepatocellular carcinoma. Esquivel CO, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S37–41 (29 ref.)

Treatment strategy for multiple hepatic metastases of colorectal carcinoma. Imamura H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):23–9 (43 ref.)

Total vascular exclusion for liver resections: pros and cons. Zografos GN, et al. **J Surg Oncol** 1999 Sep;72(1):50–5; discussion 55–6 (76 ref.)

Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Houben KW, et al. **Liver Transpl Surg** 1999 Mar;5(2):91–5 (28 ref.)

Surgical options for hepatocellular carcinoma: resection and transplantation. Olthoff KM. **Liver Transpl Surg** 1998 Sep; 4(5 Suppl 1):S98–104 (32 ref.)

Hepatic colorectal metastasis: current status of surgical therapy. Fong Y, et al. **Oncology (Huntingt)** 1998 Oct; 12(10):1489–98; discussion 1498–500, 1503 (90 ref.)

Technology for in situ ablation by laparoscopic and image-guided interstitial laser hyperthermia. Germer CT, et al. **Semin Laparosc Surg** 1998 Sep;5(3):195–203 (65 ref.)

Laparoscopic cryoablation of hepatic metastases. Heniford BT, et al. **Semin Surg Oncol** 1998 Oct–Nov;15(3):194–201 (51 ref.)

Successful surgical treatment for implanted intraperitoneal metastases of ruptured small hepatocellular carcinoma: report of a case. Kosaka A, et al. **Surg Today** 1999; 29(5):453–7 (16 ref.)

Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Picciocchi A, et al. **Surg Today** 1998;28(12):1257–60 (18 ref.)

Liver transplantation for hepatocellular carcinoma. Neuhaus P, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):469–71 (13 ref.)

[A role for cryosurgery in the treatment of non-resectable liver metastases of colorectal neoplasms] Ruers TJ, et al. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2448–52 (26 ref.) (Eng. Abstr.) **(Dut)**

[Surgical treatment of hepatocellular carcinoma] Cherqui D. **Ann Chir** 1998;52(1):79–81 (16 ref.) **(Fre)**

[Benign tumors of the liver: primum non nocere] Chiche L. **Ann Chir** 1998;52(1):64–7 (10 ref.) **(Fre)**

[Cryosurgery--renaissance or real progress?] Feifel G, et al. **Chirurg** 1999 Feb;70(2):154–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Hepatocellular carcinoma: surgical treatment] Gundlach M, et al. **Schweiz Rundsch Med Prax** 1998 Oct 28;87(44):1471–4 (11 ref.) (Eng. Abstr.) **(Ger)**

[Recurrence of hepatocellular carcinoma after liver resection] Ikai I, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):191–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[The development of microwave coagulation therapy for hepatocellular carcinoma] Tabuse K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May;96(5):493–501 (31 ref.) **(Jpn)**

[Adenoma of the liver in a young woman] Sukharev VF, et al. **Vestn Khir Im I I Grek** 1998;157(3):90–1 (7 ref.) **(Rus)**

[Therapeutic alternative in metastasizing neuroendocrine tumors. In carefully selected cases liver transplantation is possible] Oberg K. **Lakartidningen** 1999 Sep 8; 96(36):3745–7 (16 ref.) **(Swe)**

THERAPY

Colorectal cancer liver metastasis: local treatment for a systemic disease? Köhne CH, et al. **Ann Oncol** 1998 Sep; 9(9):967–71 (54 ref.)

Treatment of colorectal liver metastases. Geoghegan JG, et al. **Br J Surg** 1999 Feb;86(2):158–69 (94 ref.)

Local-regional therapy for metastatic liver tumors. Talamonti MS, et al. **Cancer Treat Res** 1998;98:172–99 (137 ref.)

Transarterial chemoembolization and percutaneous ethanol injection therapy in patients with hepatocellular carcinoma [comment] Kirchhoff T, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):907–9 (57 ref.) Comment on: Eur J Gastroenterol Hepatol 1998 Nov;10(11):915–8.

Liver metastases: interventional therapeutic techniques and results, state of the art. Vogl TJ, et al. **Eur Radiol** 1999; 9(4):675–84 (43 ref.)

Regional IL-2-based immunochemotherapy of colorectal liver metastases. Okuno K, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1263–7 (8 ref.)

Intra-arterial chemoembolization in patients with hepatocellular carcinoma. Trinchet JC, et al. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1242–7 (25 ref.)

Clinical trials of HCC in Taiwan. Whang-Peng J, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):1937–43 (16 ref.)

Treatment of metastatic glucagonoma to the liver: case report and literature review. Casadei R, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):308–12 (34 ref.)

Management of hepatic metastases. Choti MA, et al. **Liver Transpl Surg** 1999 Jan;5(1):65–80 (148 ref.)

Treatment of hepatocellular carcinoma: medical options. Fried MW. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S92–7 (36 ref.)

Radiofrequency ablation: an outpatient percutaneous treatment. Dupuy DE. **Med Health R I** 1999 Jun; 82(6):213–6 (8 ref.)

Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Gates J, et al. **Radiographics** 1999 Mar–Apr;19(2):399–414 (7 ref.)

Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. Henderson CA. **Semin Oncol** 1998 Oct;25(5 Suppl 11):29–38 (46 ref.)

Pediatric liver tumors. Reynolds M. **Semin Surg Oncol** 1999 Mar;16(2):159–72 (42 ref.)

Management of focal nodular hyperplasia and hepatocellular adenoma. Mentha G, et al. **Swiss Surg** 1999;5(3):122–5 (13 ref.)

[Survey and progress in the research of Chinese medicinal herbs intervention therapy in treating primary liver carcinoma] Cheng JH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Mar; 17(3):187–90 (30 ref.) **(Chi)**

[Nonsurgical treatment of hepatocellular carcinoma] Raoul JL, et al. **Bull Cancer** 1999 Jun;86(6):537–43 (40 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of liver metastases of colorectal cancers: how far should we go? (editorial; comment)] Penna C, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1046–7 (9 ref.) Comment on: Gastroenterol Clin Biol 1998 Dec;22(12):1048–55. **(Fre)**

[Gene therapy and liver metastases] Martinet O, et al. **Schweiz Med Wochenschr** 1999 Aug 28;129(34):1187–95 (43 ref.) (Eng. Abstr.) **(Fre)**

[Primary liver and bile duct tumors: approach to conservative therapy] Henne-Bruns D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:343–7 (23 ref.) (Eng. Abstr.) **(Ger)**

[Hepatocellular carcinoma: npn-surgical treatment] Allgaier HP, et al. **Schweiz Rundsch Med Prax** 1998 Oct 28; 87(44):1466–70 (33 ref.) (Eng. Abstr.) **(Ger)**

[Hepatocellular carcinoma: interdisciplinary treatment concept] Stadler BM, et al. **Schweiz Rundsch Med Prax** 1998 Oct 28;87(44):1475–7 (9 ref.) (Eng. Abstr.) **(Ger)**

[Interstitial percutaneous therapies in primary and secondary liver tumors] Torzilli G, et al. **Ann Ital Chir** 1999 Mar–Apr; 70(2):185–94 (62 ref.) (Eng. Abstr.) **(Ita)**

[Cancer of the liver, pancreas, gallbladder, and bile duct] Furue H. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:139–44 (48 ref.) (Eng. Abstr.) **(Jpn)**

[Advanced hepatocellular carcinoma: therapeutic results in 110 patients and therapeutic strategy] Inoue Y, et al. **Gan To Kagaku Ryoho** 1998 Oct;25(12):1857–64 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Multidisciplinary treatment for colorectal liver metastases] Okuno K, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul; 99(7):430–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of hepatic cancer] Toda G. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1848–55 (10 ref.) **(Jpn)**

ULTRASONOGRAPHY

Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature. Pergolizzi JV Jr, et al. **Am Surg** 1999 May;65(5):402–5 (13 ref.)

Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Bottelli R, et al. **Clin Radiol** 1998 Oct;53(10):713–6 (34 ref.)

Portohepatic vascular pathology and liver disease: diagnosis and monitoring. Bolondi L, et al. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S41–52 (41 ref.)

Focal liver lesions: Doppler ultrasound. Hosten N, et al. **Eur Radiol** 1999;9(3):428–35 (34 ref.)

Role of laparoscopic ultrasound in cancer management. Thompson DM, et al. **Semin Surg Oncol** 1998 Oct–Nov; 15(3):166–75 (34 ref.)

VIROLOGY

Molecular mechanisms of hepatitis B and C viruses related to liver carcinogenesis. Brechot C. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1189–96 (46 ref.)

Proceedings of the single theme consensus conference on Hepatitis B and C: Carrier to Cancer, Asian Perspectives. New Delhi, India, December 5–6, 1998. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S1–42 (0 ref.)

Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. Feitelson MA. **J Hepatobiliary Pancreat Surg** 1998;5(4):367–74 (111 ref.)

Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. Idilman R, et al. **J Viral Hepat** 1998 Sep; 5(5):285–99 (86 ref.)

[Prospect of the study on the relation between hepatitis C virus and hepatocellular carcinoma] Wang W. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct;26(5):315–6 (10 ref.) **(Chi)**

[Hepatitis virus and hepatocellular carcinoma] Rosmorduc O, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):363–75 (126 ref.) **(Fre)**

[Detection of TTV DNA in hepatocellular carcinoma] Ueda K, et al. **Nippon Rinsho** 1999 Jun;57(6):1375–80 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Prevalence of TT virus infection and viral integration in human hepatocellular carcinoma] Yamamoto T, et al. **Nippon Rinsho** 1999 Jun;57(6):1370–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

LIVER NEOPLASMS, EXPERIMENTAL

Human and experimental hepatocarcinogenesis. Schaff Z, et al. **Scand J Gastroenterol Suppl** 1998;228:90–7 (67 ref.)

CHEMICALLY INDUCED

Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay. Enzmann H, et al. **Food Chem Toxicol** 1998 Nov;36(11):979–95 (184 ref.)

Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin [see comments] Andersen ME, et al. **Hum Exp Toxicol** 1998 Dec;17(12):683–90; discussion 701–4, 708–18 (36 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705–7; discussion 701–4, 716–8.

An evaluation of the carcinogenic hazard of 1,4-dichlorobenzene based on internationally recognized criteria. Barter JA, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):64–79 (78 ref.)

DRUG THERAPY

New actions of melatonin on tumor metabolism and growth. Blask DE, et al. **Biol Signals Recept** 1999 Jan–Apr; 8(1–2):49–55 (20 ref.)

ETIOLOGY

Genetic and hormonal regulation of murine hepatocarcinogenesis. Chiaverotti T, et al. **Prog Exp Tumor Res** 1999;35:131–42 (52 ref.)

GENETICS

Genetic and hormonal regulation of murine hepatocarcinogenesis. Chiaverotti T, et al. **Prog Exp Tumor Res** 1999;35:131–42 (52 ref.)

PHYSIOPATHOLOGY

Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. Holden PR, et al. **J Mol Endocrinol** 1999 Feb;22(1):1–8 (70 ref.)

LIVER REGENERATION

Roles of CCAAT/enhancer-binding proteins in regulation of liver regenerative growth. Diehl AM. **J Biol Chem** 1998 Nov 20;273(47):30843–6 (65 ref.)

Liver regeneration after portal vein embolization [editorial; comment] Manabe T. **J Gastroenterol** 1999 Feb;34(1):152–3 (10 ref.) Comment on: J Gastroenterol 1999 Feb;34(1):100–4.

Transcriptional regulatory signals define cytokine-dependent

and -independent pathways in liver regeneration. Taub R, et al. **Semin Liver Dis** 1999;19(2):117-27 (86 ref.)
[Liver regeneration. The Prometheus myth in the light of molecular biology] Tygstrup N, et al. **Ugeskr Laeger** 1998 Dec 21;160(52):7612-5 (10 ref.) **(Dan)**
[Fibrinolysis and liver regeneration] Seki T, et al. **Seikagaku** 1999 May;71(5):350-3 (17 ref.) **(Jpn)**
[Sinusoidal portal hypertension secondary to nodular regenerative hyperplasia of the liver] Gento Peña E, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):183-5 (18 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Role of tissue repair in toxicologic interactions among hepatotoxic organics. Soni MG, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1307-17 (79 ref.)
Tumour necrosis factor alpha--mediator of apoptosis and cell proliferation of hepatocytes. Plümpe J, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):235-43 (96 ref.)
Signal transduction during liver regeneration. Brenner DA. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S93-5 (11 ref.)
Liver regeneration, liver cancers and cyclins. Kitamura T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S96-9 (16 ref.)
Regulation of G1 cyclin-dependent kinases in liver regeneration. Menjo M, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S100-5 (65 ref.)
Role of calcium-binding protein regucalcin in regenerating rat liver. Yamaguchi M. **J Gastroenterol Hepatol** 1998 Sep; 13 Suppl:S106-12 (73 ref.)
Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. Gupta S, et al. **J Hepatol** 1999 Jan; 30(1):162-70 (59 ref.)
Role of shear stress and immune responses in liver regeneration after a partial hepatectomy. Sato Y, et al. **Surg Today** 1999;29(1):1-9 (70 ref.)

LIVER TRANSPLANTATION

Pediatric liver transplantation. Dhawan A, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):525-9 (31 ref.)
Liver transplantation or liver and kidney transplantation? Samuel D, et al. **Adv Nephrol Necker Hosp** 1998;28:163-9 (22 ref.)
Listeria infection after liver transplantation: report of a case and review of the literature. Limaye AP, et al. **Am J Gastroenterol** 1998 Oct;93(10):1942-4 (23 ref.)
Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation. Ng TM, et al. **Ann Pharmacother** 1999 Feb;33(2):233-5 (24 ref.)
Liver transplantation for primary and metastatic liver cancers. Testa G, et al. **Ann Transplant** 1997;2(4):19-21 (21 ref.)
Who needs a liver transplant? (new disease specific indications). Baker A, et al. **Arch Dis Child** 1998 Nov; 79(5):460-4 (39 ref.)
Update in liver transplantation. Wong WW, et al. **Can Fam Physician** 1999 May;45:1241-9 (33 ref.)
Pediatric liver transplantation. Kelly DA. **Curr Opin Pediatr** 1998 Oct;10(5):493-8 (43 ref.)
Advances in liver transplantation: overview and status. Kaur S, et al. **Dis Mon** 1999 May;45(5):150-83 (148 ref.)
Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation. Haagsma EB. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):639-42 (14 ref.)
Tumor diagnosis in the adult liver transplant candidate. Mahfouz A, et al. **Eur Radiol** 1999;9(5):841-52 (66 ref.)
Liver transplantation: who to refer and when. Van Thiel DH, et al. **Forum (Genova)** 1999 Apr-Jun;9(2):157-63 (22 ref.)
Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? [editorial; comment] Féray C, et al. **Gastroenterology** 1999 Jul;117(1):263-5 (14 ref.) Comment on: Gastroenterology 1999 Jul;117(1):149-53.
Hepatitis C and liver transplantation. Berenguer M, et al. **Gut** 1999 Aug;45(2):159-63 (52 ref.)
Hepatitis C virus recurrence after liver transplantation. Bizollon T, et al. **Gut** 1999 Apr;44(4):575-8 (57 ref.)
Liver transplantation: problems and perspectives. Fevery J. **Hepatogastroenterology** 1998 Jul-Aug;45(22):1039-44 (31 ref.)
Liver transplantation and rejection: an overview. Henderson JM. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1482-4 (24 ref.)
Liver transplantation for hepatocellular carcinoma? Van Thiel DH, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):1944-9 (19 ref.)
Viral hepatitis and liver transplantation. Bzowej NH, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S53-60 (19 ref.)
Resection versus transplantation for hepatocellular carcinoma. Esquivel CO, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S37-41 (29 ref.)
The long- and short-term outcome of living-donor liver transplantation [editorial; comment] Bucuvalas JC, et al. **J Pediatr** 1999 Mar;134(3):259-61 (17 ref.) Comment on: J Pediatr 1999 Mar;134(3):280-6.
Current results and evolving indications for liver transplantation in children. Kelly DA. **J Pediatr Gastroenterol Nutr** 1998 Aug;27(2):214-21 (98 ref.)
One center's experience with liver transplantation: alcohol use relapse over the long-term. Campbell DA Jr, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S58-64 (18 ref.)
The immunoreactive propensity of autoimmune hepatitis: is It corticosteroid-dependent after liver transplantation? [editorial; comment] Czaja AJ. **Liver Transpl Surg** 1999 Sep;5(5):460-3 (29 ref.) Comment on: Liver Transpl Surg 1999 Sep;5(5):375-80.
Cholestatic liver disease: an overview. Dickson ER. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S1 (2 ref.)
Early steroid withdrawal in liver transplantation is safe and beneficial. Everson GT, et al. **Liver Transpl Surg** 1999 Jul; 5(4 Suppl 1):S48-57 (23 ref.)
Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Feranchak AP, et al. **Liver Transpl Surg** 1998 Nov;4(6):469-76 (39 ref.)
Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Houben KW, et al. **Liver Transpl Surg** 1999 Mar;5(2):91-5 (28 ref.)
Shunt versus transplantation. Langnas AN. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S105-7 (12 ref.)
Use of antilymphocyte induction therapy in liver transplantation: A European perspective. Langrehr JM, et al. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S71-84 (118 ref.)
The liver and metabolic diseases of childhood. McDiarmid SV. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S34-50 (140 ref.)
Surgical options for hepatocellular carcinoma: resection and transplantation. Olthoff KM. **Liver Transpl Surg** 1998 Sep; 4(5 Suppl 1):S98-104 (32 ref.)
Reducing the shortage of donor livers: what would It take to reliably split livers for transplantation into two adult recipients? Strasberg SM, et al. **Liver Transpl Surg** 1999 Sep;5(5):437-50 (47 ref.)
Predicting outcome after liver transplantation [editorial; comment] Wall WJ. **Liver Transpl Surg** 1999 Sep;5(5):458-9 (13 ref.) Comment on: Liver Transpl Surg 1999 Sep;5(5):357-61.
Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Wiesner RH, et al. **Liver Transpl Surg** 1999 Sep;5(5):388-400 (70 ref.)
Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Hunt J, et al. **Mod Pathol** 1999 Mar;12(3):325-8 (12 ref.)
Liver transplantation, body composition, and substrate utilization: does organ transplantation normalize the metabolic situation of the patient? [editorial] [see comments] Roske AE, et al. **Nutrition** 1999 Jun;15(6):504-5 (14 ref.) Comment in: Nutrition 1999 Jun;15(6):507-8.
Dental management of children undergoing liver transplantation. Sheehy EC, et al. **Pediatr Dent** 1999 Jul-Aug;21(4):272-80 (64 ref.)
Orthotopic liver transplantation in patients with biliary atresia and situs inversus. Mattei P, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):104-10 (14 ref.)
Resistance to growth hormone in children with chronic liver disease. Bucuvalas JC, et al. **Pediatr Transplant** 1997 Aug; 1(1):73-9 (46 ref.)
Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF. **Pediatr Transplant** 1998 Feb;2(1):35-9 (24 ref.)
Indications for pediatric liver transplantation. McDiarmid SV, et al. **Pediatr Transplant** 1998 May;2(2):106-16 (81 ref.)
Growth factors in children with end-stage liver disease before and after liver transplantation: a review. Maes M, et al. **Pediatr Transplant** 1997 Nov;1(2):171-5 (34 ref.)
Current concepts in pediatric liver transplant. Alonso MH, et al. **Semin Liver Dis** 1998;18(3):295-307 (70 ref.)
Immunological liver diseases in children. Mieli-Vergani G, et al. **Semin Liver Dis** 1998;18(3):271-9 (49 ref.)
Autoimmune liver diseases. Recurrence after liver transplantation. Balan V, et al. **Surg Clin North Am** 1999 Feb;79(1):147-52 (28 ref.)
Liver transplantation for chronic viral hepatitis. Dodson SF, et al. **Surg Clin North Am** 1999 Feb;79(1):131-45 (93 ref.)
Liver transplantation for metabolic liver diseases. Khanna A, et al. **Surg Clin North Am** 1999 Feb;79(1):153-62, ix (61 ref.)
Early complications after orthotopic liver transplantation. Mazariegos GV, et al. **Surg Clin North Am** 1999 Feb; 79(1):109-29 (103 ref.)
Pediatric transplantation. Reyes J, et al. **Surg Clin North Am** 1999 Feb;79(1):163-89 (94 ref.)
Mechanism and prevention of ischemia-reperfusion injury. Kurokawa T, et al. **Transplant Proc** 1999 Jun;31(4):1775-6 (5 ref.)
Present and future challenges in living related liver transplantation. Malagó M, et al. **Transplant Proc** 1999 Jun; 31(4):1777-81 (33 ref.)
Liver transplantation for hepatocellular carcinoma. Neuhaus P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):469-71 (13 ref.)
Portopulmonary hypertension and the liver transplant candidate. Kuo PC, et al. **Transplantation** 1999 Apr 27; 67(8):1087-93 (41 ref.)
Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Lehnert T. **Transplantation** 1998 Nov 27;66(10):1307-12 (37 ref.)
Understanding "marginal" liver grafts [comment] Melendez HV, et al. **Transplantation** 1999 Aug 27;68(4):469-71 (16 ref.) Comment on: Transplantation 1999 Aug 27;68(4):572-5.
[Advances in partial liver transplantation from living donors] Guan W, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jun; 35(6):377-80 (23 ref.) **(Chi)**
[Liver transplantation from a living donor] Boillot O. **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6-7):703-6 (36 ref.) **(Fre)**
[Alcoholic cirrhosis and liver transplantation: which criteria for indication? Work Group for Indication Criteria for Transplantation for Alcoholic Cirrhosis] Borie DC, et al. **Gastroenterol Clin Biol** 1999 Feb;23(2):171-7 (50 ref.) **(Fre)**
[Primary sclerosing cholangitis--an ulcerative colitis-associated illness with surgical consequences] Heuschen G, et al. **Chirurg** 1998 Oct;69(10):1028-34 (67 ref.) (Eng. Abstr.) **(Ger)**
[Liver transplantation] Berg T, et al. **Internist (Berl)** 1998 Dec;39(12):1237-45 (54 ref.) **(Ger)**
[Guidelines of GASL for nutrition in liver diseases and liver transplantation] Plauth M, et al. **Z Gastroenterol** 1999 Apr; 37(4):301-12 (154 ref.) **(Ger)**
[Quality of life following liver transplantation in childhood] Roll C, et al. **Zentralbl Chir** 1999;124(2):79-83 (14 ref.) (Eng. Abstr.) **(Ger)**
[Xenotransplantation of the liver] Winkler M, et al. **Zentralbl Chir** 1999;124(7):621-7 (62 ref.) (Eng. Abstr.) **(Ger)**
[Primary biliary cirrhosis] Cecere A, et al. **Clin Ter** 1998 Mar-Apr;149(2):143-50 (49 ref.) (Eng. Abstr.) **(Ita)**
[Primary biliary cirrhosis: liver transplantation] Hirata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):620-5 (11 ref.) **(Jpn)**
[Fulminant hepatitis: liver transplantation] Tanaka K, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):653-8 (5 ref.) **(Jpn)**
[A young female case of primary sclerosing cholangitis received liver transplantation] Kojima K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):53-8 (20 ref.) **(Jpn)**
[Indication and results of liver transplantation in adults] Leonardi LS, et al. **Arq Gastroenterol** 1998 Jul-Sep; 35(3):198-206 (55 ref.) (Eng. Abstr.) **(Por)**
[Importance of determination of monoethylglycinexylidide (MEGX)--as a liver function test in hepatology and liver transplantation] Kupčová V. **Bratisl Lek Listy** 1999 Jan; 100(1):49-53 (46 ref.) (Eng. Abstr.) **(Slo)**
[Hepatitis C virus in liver transplantation] Sanchez Fueyo A, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):139-46 (66 ref.) **(Spa)**
[Severe liver failure in erythropoietic protoporphyria. A report of a case treated by liver transplantation] Jiménez-Sáenz M, et al. **Med Clin (Barc)** 1999 Jul 10; 113(5):176-9 (20 ref.) (Eng. Abstr.) **(Spa)**
[Mixed cryoglobulinemia due to hepatitis C viral infection in a post-liver transplant patient (letter)] López Hidalgo JL, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):117-8 (10 ref.) **(Spa)**
[Liver transplantation (clinical conference)] Rimola A. **Med Clin (Barc)** 1999 Feb 27;112(7):270-6 (66 ref.) **(Spa)**
[Liver transplantation in patients infected with the human immunodeficiency virus: the difficult challenge of a new stage (editorial)] Torre-Cisneros J, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):215-8 (33 ref.) **(Spa)**
[Therapeutic alternative in metastasizing neuroendocrine tumors. In carefully selected cases liver transplantation is possible] Oberg K. **Lakartidningen** 1999 Sep 8; 96(36):3745-7 (16 ref.) **(Swe)**

ADVERSE EFFECTS

Post-transplantation lymphoproliferative disorder versus acute liver rejection: do we need a scoring system? Dietze O. **Adv Anat Pathol** 1998 Jan;5(1):30-5 (10 ref.)
Disseminated toxoplasmosis after liver transplantation: case report and review. Lappalainen M, et al. **Clin Infect Dis** 1998 Nov;27(5):1327-8 (5 ref.)
Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. Restrepo A, et al. **Crit Rev Oncog** 1999;10(3):239-45 (37 ref.)
Splenic peliosis: a rare complication following liver transplantation. Raghavan R, et al. **Dig Dis Sci** 1999 Jun; 44(6):1128-31 (24 ref.)
The bile duct anastomosis in liver transplantation. Seiler CA. **Dig Surg** 1999;16(2):102-6 (11 ref.)
In situ hybridization evidence of the donor origin of a post-transplant lymphoproliferative disorder [letter] Kerim S, et al. **Eur J Haematol** 1999 Jul;63(1):61-3 (17 ref.)
Lipid peroxidation in the reperfusion injury of the liver. Poli G, et al. **Free Radic Res** 1998 Jun;28(6):547-51 (15 ref.)
Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. Tung BY, et al. **Gastrointest Endosc** 1999 May;49(5):647-51 (18 ref.)
Hepatitis B and C: an overview. Bodenheimer HC Jr. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S65-7 (26 ref.)
Management of posttransplantation viral hepatitis--hepatitis B. Dickson RC. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S73-8 (40 ref.)

LIVER TRANSPLANTATION

Complications of liver transplantation: a perioperative perspective. Merritt WT. **Liver Transpl Surg** 1999 Jul; 5(4):342–4 (11 ref.)
Management of posttransplantation viral hepatitis C. Shiffman ML. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S79–86 (43 ref.)
Hepatitis after transplantation. Ye MQ, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S68–72 (15 ref.)
From malnutrition to obesity: changes in nutritional status associated with liver transplantation [editorial; comment] Hasse J. **Nutrition** 1999 Jun;15(6):507–8 (6 ref.) Comment on: Nutrition 1999 Jun;15(6):504–5.

CONTRAINDICATIONS

[Liver transplantation in acute liver failure: who? When? How? (editorial)] Pauletzki J, et al. **Wien Klin Wochenschr** 1998 Sep 4;110(16):547–50 (29 ref.) **(Ger)**

IMMUNOLOGY

Are dendritic cells the key to liver transplant tolerance? Thomson AW, et al. **Immunol Today** 1999 Jan;20(1):27–32 (82 ref.)
Allogeneic hepatocyte transplantation: contribution of Fas–Fas ligand interaction to allogeneic hepatocyte rejection. Kawahara T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S119–23 (55 ref.)
Hepatic dendritic cells: immunobiology and role in liver transplantation. Thomson AW, et al. **J Leukoc Biol** 1999 Aug;66(2):322–30 (68 ref.)
Post-transplant acute myeloid leukemia (PT-AML). Thalhammer-Scherrer R, et al. **Leukemia** 1999 Mar; 13(3):321–6 (40 ref.)
Acute and chronic hepatic allograft rejection: pathology and classification. Batts KP. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S21–9 (27 ref.)
Toward tolerance: lessons learned from liver transplantation. Fung JJ. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S90–7 (45 ref.)
Neoral/cyclosporine-based immunosuppression. Levy GA. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S37–47 (59 ref.)
Changing perspectives on the role of corticosteroids after liver transplantation. Lucey MR. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S58–63 (26 ref.)
Mycophenolate mofetil as induction therapy after liver transplantation. McDiarmid SV. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S85–9 (19 ref.)
Treatment of liver allograft rejection. Millis JM. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S98–S106 (22 ref.)
Incidence, timing, and risk factors for acute and chronic rejection. Neuberger J. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S30–6 (34 ref.)
Immunology of acute and chronic hepatic allograft rejection. Vierling JM. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S1–S20 (215 ref.)
Use of antilymphocyte induction therapy in liver transplantation. Wall WJ. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S64–70 (45 ref.)
Immunosuppressive therapy. Jain A, et al. **Surg Clin North Am** 1999 Feb;79(1):59–76 (160 ref.)
[The rejection of a hepatic graft] Pandrea I, et al. **Chirurgia (Bucur)** 1998 Nov-Dec;93(6):375–86 (80 ref.) (Eng. Abstr.) **(Rum)**

METHODS

Split liver transplantation. Busuttil RW, et al. **Ann Surg** 1999 Mar;229(3):313–21 (38 ref.)
Technical aspects of orthotopic liver transplantation. Nyckowski P, et al. **Ann Transplant** 1996;1(4):10–21 (38 ref.)
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis [see comments] Papatheodoridis GV, et al. **Gut** 1998 Nov; 43(5):639–44 (40 ref.) Comment in: Gut 1998 Nov;43(5):595–6.
Surgical techniques of orthotopic rat liver transplantation. Spiegel HU, et al. **J Invest Surg** 1998 Mar-Apr;11(2):83–96 (70 ref.)
Liver transplantation for cholestatic liver disease: screening and assessment of risk factors. Crippin JS. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S2–8 (19 ref.)
Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Hay JE. **Liver Transpl Surg** 1998 Sep; 4(5 Suppl 1):S9–17 (52 ref.)
[Liver and artificial liver] Chamuleau RA. **Ned Tijdschr Geneeskd** 1998 Jun 6;142(23):1300–5 (32 ref.) (Eng. Abstr.) **(Dut)**
[Liver transplantation in the adult: who and when to transplant?] Le Treut YP, et al. **Rev Med Interne** 1998 Dec; 19(12):892–903 (91 ref.) (Eng. Abstr.) **(Fre)**
[Liver transplantation from a living donor is now possible. The first cases in Sweden completed with good results] Olausson M, et al. **Lakartidningen** 1999 Feb 3;96(5):452–5 (8 ref.) (Eng. Abstr.) **(Swe)**

PATHOLOGY

Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Demetris AJ, et al. **Ann Transplant** 1997;2(2):27–44 (288 ref.)
Pathology of the liver allograft. Portmann B, et al. **Curr Top Pathol** 1999;92:61–105 (134 ref.)
An approach to the rational use of steatotic donor livers in liver transplantation. Urena MA, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1164–73 (89 ref.)
Liver transplant pathology in pediatric metabolic disorders. Jaffe R. **Pediatr Dev Pathol** 1998 Mar-Apr;1(2):102–17 (93 ref.)
Interpretation of biopsy findings in the transplant liver. Jones KD, et al. **Semin Diagn Pathol** 1998 Nov;15(4):306–17 (39 ref.)

PHYSIOLOGY

The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? Papatheodoridis GV, et al. **J Hepatol** 1999 Apr;30(4):731–8 (87 ref.)
Kupffer cell-dependent reperfusion injury in liver transplantation: new clinically relevant use of glycine. Thurman RG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:185–90 (31 ref.)
Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1055–8 (18 ref.)
[Hemostasis and coagulation during major liver surgery and during orthotopic liver transplant] De Gasperi A. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):77–91 (43 ref.) **(Ita)**

STANDARDS

Summary of guidelines on organ allocation and patient listing for liver transplantation. Keeffe EB. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S108–14 (20 ref.)

STATISTICS & NUMERICAL DATA

Transplantation for alcoholic liver disease: a perspective from Europe. Neuberger J. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S51–7 (28 ref.)

TRENDS

Liver transplantation: past accomplishments and future challenges. Wall WJ. **Can J Gastroenterol** 1999 Apr; 13(3):257–63 (70 ref.)
[Hepatocellular transplantation--from the beginning to clinical application] Markus PM, et al. **Chirurg** 1999 Feb; 70(2):162–8 (79 ref.) (Eng. Abstr.) **(Ger)**
[Prospect of liver transplantation in Japan] Fujiwara K. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct; 95(10):1094–100 (6 ref.) **(Jpn)**

LIVESTOCK see **ANIMALS, DOMESTIC**

LIVING DONORS

Living unrelated renal transplantation: progress and potential. Said MR, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2148–52 (38 ref.)
The long- and short-term outcome of living-donor liver transplantation [editorial; comment] Bucuvalas JC, et al. **J Pediatr** 1999 Mar;134(3):259–61 (17 ref.) Comment on: J Pediatr 1999 Mar;134(3):280–6.
The ethics of organ transplantation reconsidered: paid organ donation and the use of executed prisoners as donors [see comments] Cameron JS, et al. **Kidney Int** 1999 Feb; 55(2):724–32 (45 ref.) Comment in: Kidney Int 1999 Feb;55(2):733.
Concomitant parvovirus B19 and cytomegalovirus infections after living-related renal transplantation. Keung YK, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):469–71 (26 ref.)
Laparoscopic live donor nephrectomy: the four year Johns Hopkins University experience. Ratner LE, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2090–3 (10 ref.)
Living nonrelated kidney transplantation: time to be taken seriously. Daar AS. **Transplant Proc** 1999 Jun;31(4):1769–71 (18 ref.)
Present and future challenges in living related liver transplantation. Malagó M, et al. **Transplant Proc** 1999 Jun; 31(4):1777–81 (33 ref.)
Laparoscopic live donor nephrectomy: con [editorial; comment] Novick AC. **Urology** 1999 Apr;53(4):668–70 (18 ref.) Comment on: Urology 1999 Apr;53(4):665–7.
[Advances in partial liver transplantation from living donors] Guan W, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jun; 35(6):377–80 (23 ref.) **(Chi)**
[Liver transplantation from a living donor] Boillot O. **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6-7):703–6 (36 ref.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Legal developments in transplantation. Dickens BM. **Ann Transplant** 1998;3(3):30–7 (39 ref.)
Paid organ donation--the grey basket concept [editorial] Daar AS. **J Med Ethics** 1998 Dec;24(6):365–8 (24 ref.)

LIVING WILLS

see related
RIGHT TO DIE

LIVOR MORTIS see **POSTMORTEM CHANGES**

LIZARDS

ANATOMY & HISTOLOGY

Species-specific differences in the corticohypothalamic connections of lizards. Hoogland PV, et al. **Eur J Morphol** 1999 Apr;37(2-3):85–8 (13 ref.)
Structure, function, and evolution of the oviducts of squamate reptiles, with special reference to viviparity and placentation. Blackburn DG. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):560–617 (314 ref.)

PHYSIOLOGY

Developmental effects on intersexual and intrasexual variation in growth and reproduction in a lizard with temperature-dependent sex determination. Crews D, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):229–41 (83 ref.)

LLAMAS see **CAMELIDS, NEW WORLD**

LMWH see **HEPARIN, LOW-MOLECULAR-WEIGHT**

LOAD-BEARING see **WEIGHT-BEARING**

LOBAR PNEUMONIA see **PNEUMONIA, PNEUMOCOCCAL**

LOBBYING

Lobbying and advocacy for the public's health: what are the limits for nonprofit organizations? Vernick JS. **Am J Public Health** 1999 Sep;89(9):1425–9 (31 ref.)
Motivation, mobilization, and monitoring: the role of groups in health policy [editorial] Peterson MA. **J Health Polit Policy Law** 1999 Jun;24(3):415–20 (17 ref.)
Regulating managed care: interest group competition for control and behavioral health care. Ross EC. **J Health Polit Policy Law** 1999 Jun;24(3):599–625 (58 ref.)

LOBOTOMY see **PSYCHOSURGERY**

LOBSTEIN'S DISEASE see **OSTEOGENESIS IMPERFECTA**

LOBSTERS

ENZYMOLOGY

Structure and functions of arthropod proteasomes. Mykles DL. **Mol Biol Rep** 1999 Apr;26(1-2):103–11 (54 ref.)

PHYSIOLOGY

Basic principles for generating motor output in the stomatogastric ganglion. Selverston A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:35–50 (29 ref.)

LOCKED-IN SYNDROME see **QUADRIPLEGIA**

LOCOMOTION

see related
GAIT

Branching out in locomotion: the mechanics of perch use in birds and primates. Bonser RH. **J Exp Biol** 1999 Jun; 202 (Pt 11):1459–63 (35 ref.)
[Ergonomic aspects in the prevention of occupational cumulative trauma disorders of the locomotor system] Swat K. **Med Pr** 1998;49(6):589–602 (37 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

GABAergic control of spinal locomotor networks in the neonatal rat. Cazalets JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:168–80 (58 ref.)
Recovery of locomotion following transplantation of monoaminergic neurons in the spinal cord of paraplegic rats. Gimenez y Ribotta M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:393–411 (73 ref.)
How do we approach the locomotor network in the mammalian spinal cord? Hultborn H, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:70–82 (36 ref.)
Initiation of locomotion in mammals. Jordan LM. **Ann N Y Acad Sci** 1998 Nov 16;860:83–93 (37 ref.)
Reorganization of locomotor activity during development in the prenatal rat. Kudo N, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:306–17 (36 ref.)
Neuronal basis of afferent-evoked enhancement of locomotor activity. McCrea DA. **Ann N Y Acad Sci** 1998 Nov 16; 860:216–25 (38 ref.)
Cerebellar-induced locomotion: reticulospinal control of spinal rhythm generating mechanism in cats. Mori S, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:94–105 (40 ref.)
Mechanisms of spontaneous activity in the developing spinal

cord and their relevance to locomotion. O'Donovan MJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:130–41 (33 ref.)
Enhancement and resetting of locomotor activity by muscle afferents. Pearson KG, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:203–15 (36 ref.)
Analysis and modeling of the locomotor central pattern generator as a network of coupled oscillators. Sigvardt KA, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:250–65 (63 ref.)
Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Reschke MF, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):102–17 (189 ref.)
Studies of evolutionary temperature adaptation: muscle function and locomotor performance in Antarctic fish. Franklin CE. **Clin Exp Pharmacol Physiol** 1998 Sep; 25(9):753–6 (30 ref.)
Muscle–tendon stresses and elastic energy storage during locomotion in the horse. Biewener AA. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):73–87 (44 ref.)
Energetics and biomechanics of locomotion by red kangaroos (Macropus rufus). Kram R, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):41–9 (48 ref.)
The mechanics of quadrupedal locomotion. 'How is the body propelled by muscles?'. Schamhardt HC. **Eur J Morphol** 1998 Dec;36(4–5):272–9 (14 ref.)
Understanding quadrupedal locomotion. Weijs WA. **Eur J Morphol** 1998 Dec;36(4–5):270–1 (5 ref.)
What functions do reflexes serve during human locomotion? Zehr EP, et al. **Prog Neurobiol** 1999 Jun;58(2):185–205 (124 ref.)
Gait after spinal cord injury and the central pattern generator for locomotion. Pinter MM, et al. **Spinal Cord** 1999 Aug; 37(8):531–7 (40 ref.)

LOCOMOTION, CELL see **CELL MOVEMENT**

LOCOMOTOR ACTIVITY see **MOTOR ACTIVITY**

LOCOMOTOR ATAXIA see **TABES DORSALIS**

LOCUS COERULEUS

METABOLISM

Morphological substrates underlying opioid, epinephrine and gamma-aminobutyric acid inhibitory actions in the rat locus coeruleus. Van Bockstaele EJ. **Brain Res Bull** 1998 Sep 1;47(1):1–15 (145 ref.)
Release of neurotransmitters in the locus coeruleus. Singewald N, et al. **Prog Neurobiol** 1998 Oct;56(2):237–67 (328 ref.)

PATHOLOGY

The functional anatomy of noradrenergic neurons in Parkinson's disease. Soldani P, et al. **Funct Neurol** 1999 Apr–Jun;14(2):97–109 (53 ref.)

PHYSIOLOGY

Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus. Lehnert H, et al. **Neurochem Res** 1998 Aug;23(8):1039–52 (178 ref.)
Vasopressin in the locus coeruleus and dorsal pontine tegmentum affects posture and vestibulospinal reflexes. Pompeiano O. **Prog Brain Res** 1998;119:537–54 (65 ref.)

PHYSIOPATHOLOGY

The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Gold PW, et al. **Proc Assoc Am Physicians** 1999 Jan–Feb; 111(1):22–34 (90 ref.)

LOCUS CONTROL REGION

Activation by locus control regions? Grosveld F. **Curr Opin Genet Dev** 1999 Apr;9(2):152–7 (45 ref.)

PHYSIOLOGY

Do LCRs open chromatin domains? Higgs DR. **Cell** 1998 Oct 30;95(3):299–302 (18 ref.)

LOCUS OF CONTROL see **INTERNAL–EXTERNAL CONTROL**

LOCUSTS see **GRASSHOPPERS**

LOEFFLER SYNDROME see **PULMONARY EOSINOPHILIA**

LOEFFLER'S ENDOCARDITIS see **HYPEREOSINOPHILIC SYNDROME**

LOG-LINEAR MODELS see **LINEAR MODELS**

LOGIC

Certainty, leaps of faith, and tradition: rethinking clinical interventions [see comments] Dzurec LC. **ANS Adv Nurs Sci** 1998 Dec;21(2):52–61 (36 ref.) Comment in: ANS Adv Nurs Sci 1999 Jun;21(4):vii.
Induction versus Popper: substance versus semantics [letter] Wildner M. **Int J Epidemiol** 1999 Apr;28(2):361–2 (2 ref.)
Casuistry and principlism: the convergence of method in biomedical ethics. Kuczewski M. **Theor Med Bioeth** 1998 Dec;19(6):509–24 (40 ref.)

LOGIC, FUZZY see **FUZZY LOGIC**

LOGISTIC MODELS

Logistic regression models in obstetrics and gynecology literature. Khan KS, et al. **Obstet Gynecol** 1999 Jun; 93(6):1014–20 (21 ref.)
Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Koch GG, et al. **Stat Med** 1998 Aug 15–30;17(15–16):1863–92 (46 ref.)
Counts and times to events. Lindsey JK. **Stat Med** 1998 Aug 15–30;17(15–16):1745–51 (7 ref.)

LOGISTIC REGRESSION see **LOGISTIC MODELS**

LOGIT MODELS see **LOGISTIC MODELS**

LOH see **LOSS OF HETEROZYGOSITY**

LOLIUM

GROWTH & DEVELOPMENT

Isolation, culture, and plant regeneration of suspension-derived protoplasts of Lolium. Folling M, et al. **Methods Mol Biol** 1999;111:183–93 (16 ref.)

LONG-ACTING THYROID STIMULATOR

see related
RECEPTORS, THYROID HORMONE

BLOOD

Thyroid stimulating immunoglobulin (TSI) in Graves' disease. Ochi Y, et al. **Endocr J** 1998 Dec;45(6):701–8 (35 ref.)

LONG-CHAIN ACYL COA see **ACYL COENZYME A**

LONG QT SYNDROME

[The long QT syndromes] Castro A, et al. **G Ital Cardiol** 1998 Aug;28(8):920–33 (131 ref.) **(Ita)**

CHEMICALLY INDUCED

Exploring the hidden danger of noncardiac drugs [editorial; comment] Priori SG. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1114–6 (12 ref.) Comment on: J Cardiovasc Electrophysiol 1998 Oct;9(10):1109–13.
[The side effects of anti-arrhythmia medications] Eränen J. **Duodecim** 1995;111(24):2406–12 (29 ref.) **(Fin)**

COMPLICATIONS

The long QT syndrome and seizures in childhood. Davis AM, et al. **J Paediatr Child Health** 1998 Oct;34(5):410–1 (15 ref.)

CONGENITAL

[Congenital long QT syndrome] Lupoglazoff JM, et al. **Presse Med** 1998 Jun 13;27(21):1029–34 (31 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of sudden death in congenital long-QT syndrome] Oliveira M, et al. **Rev Port Cardiol** 1999 Jun; 18(6):627–33 (32 ref.) (Eng. Abstr.) **(Por)**
[The congenital long QT syndrome and its management with a permanent pacemaker] Espinosa Caleti B, et al. **Arch Inst Cardiol Mex** 1998 Mar–Apr;68(2):124–9 (18 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases:hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association] Maron BJ, et al. **Circulation** 1998 Oct 6;98(14):1460–71 (143 ref.)
Molecular genetics of long-QT syndrome. Wattanasirichaigoon D, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):628–34 (58 ref.)
[Clinical aspects and molecular genetics of the long QT-syndrome] Haverkamp W, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):972–9 (42 ref.) **(Ger)**
[QT-dispersion--analysis and prognostic implications] Schneider CA, et al. **Dtsch Med Wochenschr** 1999 Apr 1; 124(13):396–402 (44 ref.) **(Ger)**
[QT syndrome: new diagnostic possibilities] Lewalter T, et al. **Z Kardiol** 1998 Jul;87(7):517–21 (24 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Tale of two (or three or more) cities [editorial; comment] Gettes LS. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):165–7 (15 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Feb;10(2):154–64.

GENETICS

Molecular genetics of long-QT syndrome. Wattanasirichaigoon D, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):628–34 (58 ref.)
Molecular genetics of inherited long QT syndromes. Geelen JL, et al. **Eur Heart J** 1998 Oct;19(10):1427–33 (52 ref.)
The genetic basis for cardiac dysrhythmias and the long QT syndrome. Vizgirda VM. **J Cardiovasc Nurs** 1999 Jul; 13(4):34–45 (53 ref.)
Impact of molecular genetics on clinical cardiology. Mayosi BM, et al. **J R Coll Physicians Lond** 1999 Mar–Apr; 33(2):124–31 (27 ref.)
The molecular basis of long QT syndrome and prospects for therapy. Wang Q, et al. **Mol Med Today** 1998 Sep; 4(9):382–8 (43 ref.)
The LQT syndromes--current status of molecular mechanisms. Schulze-Bahr E, et al. **Z Kardiol** 1999 Apr; 88(4):245–54 (71 ref.)
[Clinical aspects and molecular genetics of the long QT-syndrome] Haverkamp W, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):972–9 (42 ref.) **(Ger)**

PHYSIOPATHOLOGY

Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective. Bonate PL, et al. **J Clin Pharmacol** 1999 Apr;39(4):349–58 (37 ref.)
The long QT syndrome and torsade de pointes. el-Sherif N, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 1):91–110 (75 ref.)
The IKs channel: coassembly of IsK (minK) and KvLQT1 proteins. Suessbrich H, et al. **Rev Physiol Biochem Pharmacol** 1999;137:191–226 (147 ref.)
[Dispersion of the QT interval: and index that deserves more widespread clinical use?] Ciolli A, et al. **G Ital Cardiol** 1998 Sep;28(9):1032–7 (46 ref.) **(Ita)**

THERAPY

The molecular basis of long QT syndrome and prospects for therapy. Wang Q, et al. **Mol Med Today** 1998 Sep; 4(9):382–8 (43 ref.)
Gene specific therapy for cardiac disease: the case of long QT syndrome. Priori SG. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III27–38 (41 ref.)
[The congenital long QT syndrome and its management with a permanent pacemaker] Espinosa Caleti B, et al. **Arch Inst Cardiol Mex** 1998 Mar–Apr;68(2):124–9 (18 ref.) (Eng. Abstr.) **(Spa)**

LONG-TERM CARE

see related
INSURANCE, LONG-TERM CARE

The use of antidepressants in long-term care and the geriatric patient: geriatric psychiatry issues. Carroll BJ. **Geriatrics** 1998 Dec;53 Suppl 4:S4–11 (26 ref.)
Infected pressure ulcers in the long-term-care facility. Smith PW, et al. **Infect Control Hosp Epidemiol** 1999 May; 20(5):358–61 (35 ref.)
Outpatient antibiotic therapy in long-term care facilities. Petrak RM. **Infect Dis Clin North Am** 1998 Dec; 12(4):995–1008 (33 ref.)
Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. Salzman C. **J Clin Psychiatry** 1999;60 Suppl 20:30–3 (32 ref.)

ECONOMICS

Genetic testing, Alzheimer disease, and long-term care insurance. Fogarty M. **Genet Test** 1999;3(1):133–7 (22 ref.)

METHODS

Provision of long-term mechanical ventilation. Scheinhorn DJ, et al. **Crit Care Clin** 1998 Oct;14(4):819–32, viii (68 ref.)
Management and long-term complications of pediatric cancer. Grossi M. **Pediatr Clin North Am** 1998 Dec; 45(6):1637–58 (213 ref.)
[Gastroesophageal reflux in the adult: long-term strategy] Bigard MA. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S187–93 (41 ref.) **(Fre)**
[Gastroesophageal reflux: long-term therapeutic strategy] Guillemot F, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S307–12 (38 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Long stay care and the NHS: discontinuities between policy and practice [see comments] Turrell AR, et al. **BMJ** 1998 Oct 3;317(7163):942–4 (21 ref.) Comment in: BMJ 1999 Mar 6;318(7184):668.
Incorporating education on palliative care into the long-term care setting. National Consensus Conference on Medical Education for Care Near the End of Life. Steel K, et al. **J Am Geriatr Soc** 1999 Jul;47(7):904–7 (15 ref.)

LONG-TERM CARE

TRENDS

Long-term therapy for pulmonary hypertension in children. Dent CL, et al. **Curr Opin Pediatr** 1999 Jun;11(3):218–22 (27 ref.)

LONG-TERM CARE INSURANCE see **INSURANCE, LONG-TERM CARE**

LONG-TERM POTENTIATION

The return of the spike: postsynaptic action potentials and the induction of LTP and LTD. Linden DJ. **Neuron** 1999 Apr;22(4):661–6 (54 ref.)

Silencing the controversy in LTP? [comment] Malinow R. **Neuron** 1998 Dec;21(6):1226–7 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1443–51.

DRUG EFFECTS

Memory and the brain: unexpected chemistries and a new pharmacology. Lynch G. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):82–100 (94 ref.)

PHYSIOLOGY

Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Nicoll RA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:515–25 (44 ref.)

To fear or not to fear: what was the question? A potential role for Ras-GRF in memory. Finkbeiner S, et al. **Bioessays** 1998 Sep;20(9):691–5 (27 ref.)

Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Bortolotto ZA, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):299–304 (64 ref.)

Morphological changes associated with long-term potentiation. Agnihotri N, et al. **Histol Histopathol** 1998 Oct;13(4):1155–62 (93 ref.)

Current studies on a working model of CaM kinase II in hippocampal long-term potentiation and memory. Fukunaga K, et al. **Jpn J Pharmacol** 1999 Jan;79(1):7–15 (39 ref.)

Learning from LTP: a comment on recent attempts to identify cellular and molecular mechanisms of memory. Eichenbaum H. **Learn Mem** 1996 Sep–Oct;3(2–3):61–73 (68 ref.)

Long-lasting forms of synaptic potentiation in the mammalian hippocampus. Huang YY, et al. **Learn Mem** 1996 Sep–Oct;3(2–3):74–85 (56 ref.)

A biochemist's view of long-term potentiation. Roberson ED, et al. **Learn Mem** 1996 Jul–Aug;3(1):1–24 (168 ref.)

Can molecules explain long-term potentiation? Sanes JR, et al. **Nat Neurosci** 1999 Jul;2(7):597–604 (122 ref.)

Memory and the brain: unexpected chemistries and a new pharmacology. Lynch G. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):82–100 (94 ref.)

Two different forms of long-term potentiation in the hippocampus. López-García JC. **Neurobiology (Bp)** 1998; 6(1):75–98 (112 ref.)

Nomadic AMPA receptors and LTP [comment] Morales M, et al. **Neuron** 1999 Jul;23(3):431–4 (20 ref.) Comment on: Neuron 1998 Aug;21(2):267–70.

Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Hölscher C, et al. **Neurosci Biobehav Rev** 1999;23(3):399–410 (125 ref.)

Is learning blocked by saturation of synaptic weights in the hippocampus? Moser EI, et al. **Neurosci Biobehav Rev** 1999 May;23(5):661–72 (110 ref.)

Homosynaptic long-term depression: a mechanism for memory? Bear MF. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9457–8 (24 ref.)

Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Hawkins RD, et al. **Prog Brain Res** 1998;118:155–72 (137 ref.)

Modulation of LTP induction by NMDA receptor activation and nitric oxide release. Zorumski CF, et al. **Prog Brain Res** 1998;118:173–82 (58 ref.)

Age-related impairment in long-term potentiation in hippocampus: a role for the cytokine, interleukin-1 beta? Lynch MA. **Prog Neurobiol** 1998 Dec;56(5):571–89 (187 ref.)

Analysis of the mechanisms underlying the age-related impairment in long-term potentiation in the rat. Lynch MA. **Rev Neurosci** 1998 Jul–Dec;9(3):169–201 (336 ref.)

Long-term potentiation—a decade of progress? Malenka RC, et al. **Science** 1999 Sep 17;285(5435):1870–4 (62 ref.)

Cellular mechanisms of cerebellar LTD. Daniel H, et al. **Trends Neurosci** 1998 Sep;21(9):401–7 (63 ref.)

[Long-term potentiation in mammalian visual cortex] Sha Q, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct; 27(4):371–3 (9 ref.) **(Chi)**

[Long-term potentiation of synaptic transmission] Manabe T. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1841–8 (23 ref.) **(Jpn)**

[Long-term potentiation of the NMDA-dependent component of the EPSP in the hippocampus] Kleshchevnikov AM. **Usp Fiziol Nauk** 1998 Oct–Dec; 29(4):6–23 (97 ref.) (Eng. Abstr.) **(Rus)**

[The peptide-dependent mechanisms of long-term posttetanic potentiation (the facts and a hypothesis)] Mokrushin AA, et al. **Usp Fiziol Nauk** 1999 Jan–Mar; 30(1):3–28 (294 ref.) (Eng. Abstr.) **(Rus)**

LONG-TERM SURVIVORS see **SURVIVORS**

LONG-TERM SURVIVORS, HIV see **HIV LONG-TERM SURVIVORS**

LONG TERMINAL REPEAT, HIV see **HIV LONG TERMINAL REPEAT**

LONGEVITY

see related
AGED
AGED, 80 AND OVER
LIFE EXPECTANCY

Height, body size and longevity. Samaras TT, et al. **Acta Med Okayama** 1999 Aug;53(4):149–69 (134 ref.)

Thinness and weight loss: beneficial or detrimental to longevity? Gaesser GA. **Med Sci Sports Exerc** 1999 Aug; 31(8):1118–28 (157 ref.)

[Beneficial effects of caloric restriction] Zhang Q. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar; 32(2):118–9 (19 ref.) **(Chi)**

DRUG EFFECTS

Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Kitani K, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:291–306 (36 ref.)

GENETICS

Genetics of longevity. Jazwinski SM. **Exp Gerontol** 1998 Nov–Dec;33(7–8):773–83 (69 ref.)

The evolutionary genetics of ageing and longevity. Zwaan BJ. **Heredity** 1999 Jun;82 (Pt 6):589–97 (87 ref.)

Genetics, aging, and the heart. Thurmon TF. **J La State Med Soc** 1998 Aug;150(8):356–66 (12 ref.)

Human longevity: nature vs. nurture—fact or fiction. Carnes BA, et al. **Perspect Biol Med** 1999 Spring;42(3):422–41 (83 ref.)

PHYSIOLOGY

A review of the effects of microgravity and of hypergravity on aging and longevity. Le Bourg E. **Exp Gerontol** 1999 Jun;34(3):319–36 (50 ref.)

Calorie restriction in primates: will it work and how will we know? Roth GS, et al. **J Am Geriatr Soc** 1999 Jul; 47(7):896–903 (40 ref.)

LONGITUDINAL LIGAMENTS

see related
OSSIFICATION OF POSTERIOR LONGITUDINAL LIGAMENT

PATHOLOGY

Pathology of ossification of the posterior longitudinal ligament and ligamentum flavum. Ono K, et al. **Clin Orthop** 1999 Feb;(359):18–26 (27 ref.)

LONGITUDINAL STUDIES

Quality assurance and quality control in longitudinal studies. Whitney CW, et al. **Epidemiol Rev** 1998;20(1):71–80 (40 ref.)

Longitudinal and observational studies module. Lassere MN. **J Rheumatol** 1999 Feb;26(2):459–68 (119 ref.)

Longitudinal data analysis (repeated measures) in clinical trials. Albert PS. **Stat Med** 1999 Jul 15;18(13):1707–32 (130 ref.)

Parametric models for incomplete continuous and categorical longitudinal data. Kenward MG, et al. **Stat Methods Med Res** 1999 Mar;8(1):51–83 (67 ref.)

LOOP ILEOSTOMY see **ILEOSTOMY**

LOOP OF HENLE

CYTOLOGY

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34–49 (78 ref.)

ENZYMOLOGY

Prostaglandins in macula densa function. Harris RC, et al. **Kidney Int Suppl** 1998 Sep;67:S49–52 (40 ref.)

PHYSIOLOGY

Regulation of thick ascending limb transport by vasopressin. Knepper MA, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):628–34 (75 ref.)

LOOSE BODIES, JOINT see **JOINT LOOSE BODIES**

LORATADINE

ADVERSE EFFECTS

Cardiovascular profile of loratadine. Hey JA, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:197–9 (16 ref.)

Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Kay GG, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:147–50 (19 ref.)

LORDOSIS

SURGERY

[Surgical management of severe thoracic lordosis in myelomeningocele—a case report with review of the literature] Niemeyer T, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct;136(5):463–6 (17 ref.) (Eng. Abstr.) **(Ger)**

LORR'S INPATIENT MULTIDIMENSIONAL PSYCHIATRIC RATING SCALE see **PSYCHIATRIC STATUS RATING SCALES**

LOSARTAN

[Pathophysiological function of angiotensin II AT1 and AT2 receptors and clinical application of AT1 antagonists] Matsubara H, et al. **Nippon Rinsho** 1998 Jul;56(7):1912–8 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Losartan] Quetglas EG, et al. **Rev Med Univ Navarra** 1997 Jul–Sep;41(3):193–7 (19 ref.) **(Spa)**

ADVERSE EFFECTS

[Drug-interactions and adverse effects of losartan potassium, an angiotensin II receptor antagonist] Yoshinaga K. **Nippon Rinsho** 1999 May;57(5):1194–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

[Pharmacological properties and its significance in clinical practice] Nishikibe M, et al. **Nippon Rinsho** 1999 May; 57(5):1124–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Losartan: angiotensin II type 1 receptor antagonist] Piątkowska H, et al. **Wiad Lek** 1999;52(1–2):49–55 (20 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. Esmail ZN, et al. **Ann Pharmacother** 1998 Oct;32(10):1096–8 (16 ref.)

Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. Birkenhäger WH, et al. **J Hypertens** 1999 Jul;17(7):873–81 (85 ref.)

[Losartan—a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure] Berezin AE, et al. **Klin Med (Mosk)** 1998;76(7):12–5 (43 ref.) **(Rus)**

LOSS OF HETEROZYGOSITY

Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. Brown MR, et al. **Gynecol Oncol** 1999 Jul;74(1):98–102 (26 ref.)

Loss of heterozygosity in human skin. Happle R. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):143–64 (265 ref.)

GENETICS

Genetic instability in osteoblastic tumors of the skeletal system. Radig K, et al. **Pathol Res Pract** 1998; 194(10):669–77 (71 ref.)

LOU GEHRIG'S DISEASE see **AMYOTROPHIC LATERAL SCLEROSIS**

LOUDNESS PERCEPTION

PHYSIOLOGY

Cochlear mechanisms of frequency and intensity coding. II. Dynamic range and the code for loudness. Chatterjee M, et al. **Hear Res** 1998 Oct;124(1–2):170–81 (50 ref.)

Disturbances of loudness perception. Phillips DP, et al. **J Am Acad Audiol** 1998 Oct;9(5):371–9; quiz 399 (76 ref.)

LOUDNESS RECRUITMENT see **RECRUITMENT, LOUDNESS**

LOUIS-BAR SYNDROME see **ATAXIA TELANGIECTASIA**

LOVASTATIN

ADMINISTRATION & DOSAGE

[Further studies are required: in spite of positive effects of statins many patients still develop myocardial infarction] Werkö L. **Lakartidningen** 1998 Dec 2;95(49):5654–5 (8 ref.) **(Swe)**

THERAPEUTIC USE

Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial. Hunninghake DB. **Am J Cardiol** 1998 Nov 26;82(10B):45T–48T (20 ref.)

The role of diet and exercise in the statin era. LaRosa JC. **Prog Cardiovasc Dis** 1998 Sep–Oct;41(2):137–50 (94 ref.)

[Are there differences in various statins?] Otto C, et al. **Internist (Berl)** 1998 Sep;39(9):987–93 (42 ref.) **(Ger)**

[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke] Marta-Moreno J, et al. **Rev Neurol** 1998 Nov;

27(159):827–30 (28 ref.) (Eng. Abstr.) **(Spa)**

LOVE

Preoccupations and behaviors associated with romantic and parental love. Perspectives on the origin of obsessive–compulsive disorder. Leckman JF, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jul;8(3):635–65 (152 ref.)

Decoding the language of the heart: developing a physiology of inclusion. Lynch JJ. **Integr Physiol Behav Sci** 1998 Apr–Jun;33(2):130–6 (38 ref.)

Erotomania after aneurysmal subarachnoid hemorrhage: case report and literature review. Anderson CA, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer;10(3):330–7 (57 ref.)

Neuroendocrine perspectives on social attachment and love. Carter CS. **Psychoneuroendocrinology** 1998 Nov; 23(8):779–818 (205 ref.)

The evolutionary antecedents to love. Crews D. **Psychoneuroendocrinology** 1998 Nov;23(8):751–64 (20 ref.)

Love as sensory stimulation: physiological consequences of its deprivation and expression. Komisaruk BR, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):927–44 (58 ref.)

Love: an emergent property of the mammalian autonomic nervous system. Porges SW. **Psychoneuroendocrinology** 1998 Nov;23(8):837–61 (60 ref.)

[On love in medicine] Getz L. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1316–8 (0 ref.) (Eng. Abstr.) **(Nor)**

LOW BACK PAIN

see related

SCIATICA

Evaluating back pain in older patients. Mazanec DJ. **Cleve Clin J Med** 1999 Feb;66(2):89–91, 95–99 (19 ref.)

Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Borenstein DG. **Curr Opin Rheumatol** 1999 Mar;11(2):151–7 (39 ref.)

Biomedical and feminist perspectives on low back pain during pregnancy. DeJoseph JF, et al. **Nurs Clin North Am** 1998 Dec;33(4):713–24 (31 ref.)

[Clinical management of low back pain in primary health care] Lie H. **Tidsskr Nor Laegeforen** 1999 Jun 10; 119(15):2215–8 (17 ref.) (Eng. Abstr.) **(Nor)**

DIAGNOSIS

Management of acute lumbar disk herniation initially presenting as mechanical low back pain. Crawford CM, et al. **J Manipulative Physiol Ther** 1999 May;22(4):235–44 (85 ref.)

Low back pain and the lumbar intervertebral disk: clinical considerations for the doctor of chiropractic. Troyanovich SJ, et al. **J Manipulative Physiol Ther** 1999 Feb; 22(2):96–104 (58 ref.)

Disability: how successful are we in determining disability? Carey TS. **Neurol Clin** 1999 Feb;17(1):167–78 (27 ref.)

Management of low back pain. Current assessment and formulation of a blueprint for the health care delivery system of the future. Boden SD, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):419–33, ix (21 ref.)

The sacroiliac joint. Nothing is sacred. Swezey RL. **Phys Med Rehabil Clin N Am** 1998 May;9(2):515–9, x (31 ref.)

Imaging studies for acute low back pain. When and when not to order them. Staiger TO, et al. **Postgrad Med** 1999 Apr;105(4):161–2, 165–6, 171–2 (14 ref.)

[Low back pain: diagnosis and conservative therapy from the orthopedic viewpoint] Tilscher H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):795–8 (5 ref.) **(Ger)**

[Prognosis in back pain] Ursin H. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1909–12 (35 ref.) (Eng. Abstr.) **(Nor)**

DRUG THERAPY

Pharmacologic therapies. Von Feldt JM, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):473–87, ix (46 ref.)

Glucocorticoid therapy in common lumbar spinal disorders. Rozenberg S. **Rev Rhum Engl Ed** 1998 Nov;65(11):649–55 (77 ref.)

Efficacy of epidural steroids in low back pain and sciatica. A critical appraisal by a French Task Force of randomized trials. Critical Analysis Group of the French Society for Rheumatology. Rozenberg S, et al. **Rev Rhum Engl Ed** 1999 Feb;66(2):79–85 (23 ref.)

[Epidural corticosteroid infections in patients with low back pain (editorial)] Elkayam O, et al. **Harefuah** 1998 Oct; 135(7–8):282–4 (36 ref.) **(Heb)**

EPIDEMIOLOGY

Epidemiological features of chronic low-back pain. Andersson GB. **Lancet** 1999 Aug 14;354(9178):581–5 (46 ref.)

The prevalence of low back pain in adults: a methodological review of the literature. Loney PL, et al. **Phys Ther** 1999 Apr;79(4):384–96 (43 ref.)

[Prevalence of low back pain in the population] Schochat T, et al. **Rehabilitation (Stuttg)** 1998 Nov;37(4):216–23 (85 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Varicosities of the paravertebral plexus of veins associated with nocturnal spinal pain as imaged by magnetic resonance venography: a brief report. LaBan MM, et al. **Am J Phys Med Rehabil** 1999 Jan–Feb;78(1):72–6 (23 ref.)

Clinical evaluation of low back pain. Goldsmith ME, et al. **Compr Ther** 1998 Aug;24(8):370–7 (5 ref.)

Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)

Low back pain. Evaluation and management in the primary care setting. Rosomoff HL, et al. **Med Clin North Am** 1999 May;83(3):643–62 (24 ref.)

Clinical neurophysiologic studies: which test is useful and when? Lomen-Hoerth C, et al. **Neurol Clin** 1999 Feb; 17(1):65–74 (27 ref.)

Differential diagnosis: a reasonable clinical approach. Swenson R. **Neurol Clin** 1999 Feb;17(1):43–63 (81 ref.)

A review of basic science issues in low back pain. Gordon SL, et al. **Phys Med Rehabil Clin N Am** 1998 May; 9(2):323–42, vii (172 ref.)

The sacroiliac joint. Nothing is sacred. Swezey RL. **Phys Med Rehabil Clin N Am** 1998 May;9(2):515–9, x (31 ref.)

Imaging studies for acute low back pain. When and when not to order them. Staiger TO, et al. **Postgrad Med** 1999 Apr;105(4):161–2, 165–6, 171–2 (14 ref.)

Evaluation of lower back pain with bone scintigraphy and SPECT. De Maeseneer M, et al. **Radiographics** 1999 Jul–Aug;19(4):901–12; discussion 912–4 (25 ref.)

Can an anomalous lumbo-sacral or lumbo-iliac articulation cause low back pain? A retrospective study of 12 cases. Avimadje M, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):35–9 (6 ref.)

Smoking and low back pain. A systematic literature review of 41 journal articles reporting 47 epidemiologic studies. Lebocuf-Yde C. **Spine** 1999 Jul 15;24(14):1463–70 (53 ref.)

[Lumbago. Diagnostic indications] Revel M, et al. **Rev Prat** 1998 Mar 15;48(6):689–93 (4 ref.) **(Fre)**

[Diagnostic assessment in lumbar back pain. I. Anamnesis and clinical examination] Boos N, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):305–13 (13 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic assessment in lumbar back pain. II. Imaging and image-guided infiltrations] Pfirrmann CW, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):315–21 (19 ref.) (Eng. Abstr.) **(Ger)**

[The Maffucci syndrome with axial bone lesions. A rare cause of low back pain] Ribeiro C, et al. **Acta Med Port** 1998 Jun;11(6):559–62 (10 ref.) (Eng. Abstr.) **(Por)**

NURSING

Chronic low back pain: early interventions. Faucett J. **Annu Rev Nurs Res** 1999;17:155–82 (102 ref.)

Identification and management of pregnancy-related low back pain. Perkins J, et al. **J Nurse Midwifery** 1998 Sep–Oct;43(5):331–40 (39 ref.)

Metastatic epidural spinal cord compression. Bucholtz JD. **Semin Oncol Nurs** 1999 Aug;15(3):150–9 (27 ref.)

PHYSIOPATHOLOGY

Applying the results of self-report measures to individual patients: an example using the Roland-Morris Questionnaire. Stratford PW, et al. **J Orthop Sports Phys Ther** 1999 Apr;29(4):232–9 (34 ref.)

Low back pain: current physiologic concepts. Haldeman S. **Neurol Clin** 1999 Feb;17(1):1–15 (21 ref.)

The clinical relevance of biomechanics. Pope MH, et al. **Neurol Clin** 1999 Feb;17(1):17–41 (161 ref.)

[Low back pain from the neurologic viewpoint] Wessely P. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):791–5 (15 ref.) **(Ger)**

PREVENTION & CONTROL

Do workplace interventions prevent low-back disorders? If so, why?: a methodologic commentary. Volinn E. **Ergonomics** 1999 Jan;42(1):258–72 (65 ref.)

Work-related low-back problems in nursing. Lagerström M, et al. **Scand J Work Environ Health** 1998 Dec;24(6):449–64 (86 ref.)

PSYCHOLOGY

Psychosocial issues: their importance in predicting disability, response to treatment, and search for compensation. Gatchel RJ, et al. **Neurol Clin** 1999 Feb;17(1):149–66 (73 ref.)

[Psychosomatic aspects of chronic low back pain] Bach M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):802–6 (10 ref.) **(Ger)**

[Psychosomatic aspects of failed back syndrome: why low back pain becomes a chronic disorder] Heger S. **Nervenarzt** 1999 Mar;70(3):225–32 (65 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

The routine use of radiographic spinal displacement analysis: a dissent. Haas M, et al. **J Manipulative Physiol Ther** 1999 May;22(4):254–9 (43 ref.)

[Radiological imaging in lumbago and sciatica] Dullerud R. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1778–81 (14 ref.) (Eng. Abstr.) **(Nor)**

REHABILITATION

Management of acute lumbar disk herniation initially presenting as mechanical low back pain. Crawford CM, et al. **J Manipulative Physiol Ther** 1999 May;22(4):235–44 (85 ref.)

Is there a role for transversus abdominis in lumbo-pelvic stability? Hodges PW. **Man Ther** 1999 May;4(2):74–86 (82 ref.)

Perils, pitfalls, and accomplishments of guidelines for treatment of back problems. Bigos SJ. **Neurol Clin** 1999 Feb;17(1):179–92 (5 ref.)

Spinal manipulation: current state of research and its indications. Bronfort G. **Neurol Clin** 1999 Feb;17(1):91–111 (107 ref.)

Rehabilitation: what do we do with the chronic patient? Mayer TG. **Neurol Clin** 1999 Feb;17(1):131–47 (84 ref.)

Physical therapy: exercises and the modalities: when, what, and Why? Nordin M, et al. **Neurol Clin** 1999 Feb; 17(1):75–89 (46 ref.)

A report from the Second International Forum for Primary Care Research on Low Back Pain. Reexamining priorities. Borkan JM, et al. **Spine** 1998 Sep 15;23(18):1992–6 (8 ref.)

Outcome measures for low back pain research. A proposal for standardized use [published erratum appears in Spine 1999 Feb 15;24(4):418] Deyo RA, et al. **Spine** 1998 Sep 15;23(18):2003–13 (17 ref.)

[Chronic backache—do guidelines/standards exist?] Lucius H. **Versicherungsmedizin** 1998 Aug 1;50(4):145–8 (0 ref.) (Eng. Abstr.) **(Ger)**

[Effectiveness of back-school programs in controlled trials. A review of the literature] Lühmann D, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jul;93(5):341–8 (22 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Lumbar arthrodesis for the treatment of back pain. Hanley EN Jr, et al. **J Bone Joint Surg Am** 1999 May;81(5):716–30 (228 ref.)

A multi-center prospective study of the CD Spinal System in patients with degenerative disc disease. Michelsen C, et al. **J Spinal Disord** 1998 Dec;11(6):465–70; discussion 471 (10 ref.)

MR imaging of the postoperative lumbar spine. Ross JS. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):513–24, viii (50 ref.)

Surgery: indications and options. Hall H. **Neurol Clin** 1999 Feb;17(1):113–30 (49 ref.)

Epidural fibrosis and the failed back surgery syndrome: history and physical findings. Samy Abdou M, et al. **Neurol Res** 1999;21 Suppl 1:S5–8 (27 ref.)

The surgical treatment of low back pain. Dawson E, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):489–95, x (16 ref.)

[Low back pain: the neurosurgical viewpoint] Lanner G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec;33(12):798–800 (6 ref.) **(Ger)**

[Surgical treatment of low back pain] Magnaes B. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1773–7 (30 ref.) (Eng. Abstr.) **(Nor)**

THERAPY

Low back pain: opportunities and problems of management. Stanton-Hicks M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):806–9 (4 ref.)

Chronic low back pain. What are the treatment options? Broadhurst NA. **Aust Fam Physician** 1999 Jan;28(1):25–30 (15 ref.)

Low back pain: which is the best way forward? Samanta A, et al. **BMJ** 1999 Apr 24;318(7191):1122–3 (15 ref.)

Low back pain: an algorithmic approach to diagnosis and management. Rose-Innes AP, et al. **Geriatrics** 1998 Oct; 53(10):26–8, 33–6, 39–40 passim (16 ref.)

Low back pain and the lumbar intervertebral disk: clinical considerations for the doctor of chiropractic. Troyanovich SJ, et al. **J Manipulative Physiol Ther** 1999 Feb; 22(2):96–104 (58 ref.)

Identification and management of pregnancy-related low back pain. Perkins J, et al. **J Nurse Midwifery** 1998 Sep–Oct;43(5):331–40 (39 ref.)

Clinical practices in the management of new-onset, uncomplicated, low back workers' compensation disability claims. Tacci JA, et al. **J Occup Environ Med** 1999 May; 41(5):397–404 (37 ref.)

Massage therapy for low back pain: a systematic review. Ernst E. **J Pain Symptom Manage** 1999 Jan;17(1):65–9 (26 ref.)

Low back pain. Evaluation and management in the primary care setting. Rosomoff HL, et al. **Med Clin North Am** 1999 May;83(3):643–62 (24 ref.)

Issues in the use of complementary/alternative medical therapies for low back pain. Berman BM, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):497–513, x (84 ref.)

Management of low back pain. Current assessment and formulation of a blueprint for the health care delivery

LOW BACK PAIN

system of the future. Boden SD, et al.
Phys Med Rehabil Clin N Am 1998 May;9(2):419–33, ix (21 ref.)
Conservative management of low back pain. Rosen NB, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):435–72, ix (110 ref.)
[Physical therapy and rehabilitation of unspecified vertebral pain] Fialka-Moser V.
Anasthesiol Intensivmed Notfallmed Schmerzther 1998 Dec; 33(12):800–2 (9 ref.) **(Ger)**
[Low back pain: diagnosis and conservative therapy from the orthopedic viewpoint] Tilscher H.
Anasthesiol Intensivmed Notfallmed Schmerzther 1998 Dec; 33(12):795–8 (5 ref.) **(Ger)**
[Is exercise therapy and manipulation effective in low back pain?] Brox JI, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2042–50 (75 ref.) (Eng. Abstr.) **(Nor)**
[A simple therapeutic regime for subacute back pain (see comments)] Indahl A. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1906–8 (39 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 20;119(16):2391. **(Nor)**
[Chiropractic in general and in low back pain] Myhrvold K. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2054–8 (44 ref.) (Eng. Abstr.) **(Nor)**

LOW CARDIAC OUTPUT see **CARDIAC OUTPUT, LOW**

LOW CARDIAC OUTPUT SYNDROME see **CARDIAC OUTPUT, LOW**

LOW-DENSITY LIPOPROTEINS see **LIPOPROTEINS, LDL**

LOW GRAVITY see **HYPOGRAVITY**

LOW-INCOME POPULATION see **POVERTY**

LOW-MOLECULAR-WEIGHT HEPARIN see **HEPARIN, LOW-MOLECULAR-WEIGHT**

LOW MOLECULAR WEIGHT NUCLEAR RNA see **RNA, SMALL NUCLEAR**

LOW-PROTEIN DIET see **DIET, PROTEIN-RESTRICTED**

LOW T3 AND T4 SYNDROME see **EUTHYROID SICK SYNDROMES**

LOW T3 SYNDROME see **EUTHYROID SICK SYNDROMES**

LOWER EXTREMITY see **LEG**

LOWER NEPHRON NEPHROSIS see **KIDNEY TUBULAR NECROSIS, ACUTE**

LOXAPINE

THERAPEUTIC USE

Does loxapine have "atypical" properties? Clinical evidence. Glazer WM. **J Clin Psychiatry** 1999;60 Suppl 10:42–6 (38 ref.)

LOXAPINSUCCINATE see **LOXAPINE**

LP(A) see **LIPOPROTEIN(A)**

LSD see **LYSERGIC ACID DIETHYLAMIDE**

LTB4 see **LEUKOTRIENE B4**

LTD4 see **LEUKOTRIENE D4**

LUBRICATION

[Diagnostic criteria of Sjögren syndrome] Ceraulo S, et al. **Minerva Stomatol** 1999 Mar;48(3):79–85 (27 ref.) (Eng. Abstr.) **(Ita)**

LUCERNE see **ALFALFA**

LUCIFERASE

METABOLISM

Bioluminescence. Wilson T, et al.
Annu Rev Cell Dev Biol 1998;14:197–230 (163 ref.)

LUCIFERINS

METABOLISM

Bioluminescence. Wilson T, et al.
Annu Rev Cell Dev Biol 1998;14:197–230 (163 ref.)

LUDWIG'S ANGINA

DIAGNOSIS

Ludwig's angina in children. Hartmann RW Jr.
Am Fam Physician 1999 Jul;60(1):109–12 (15 ref.)

THERAPY

Ludwig angina: a review of current airway management [see comments] Marple BF.
Arch Otolaryngol Head Neck Surg 1999 May;125(5):596–9 (9 ref.) Comment in: Arch Otolaryngol Head Neck Surg 1999 May;125(5):599. Comment in: Arch Otolaryngol Head Neck Surg 1999 May;125(5):600.

LULIBERIN see **GONADORELIN**

LULIBERIN RECEPTORS see **RECEPTORS, LHRH**

LUMBAGO see **LOW BACK PAIN**

LUMBAR MANIPULATION see **MANIPULATION, SPINAL**

LUMBAR PLEXUS see **LUMBOSACRAL PLEXUS**

LUMBAR PUNCTURE see **SPINAL PUNCTURE**

LUMBAR REGION see **LUMBOSACRAL REGION**

LUMBAR VERTEBRAE

Aspiration of intraspinal synovial cyst: recurrence after temporal improvement. Imai K, et al.
Arch Orthop Trauma Surg 1998;118(1–2):103–5 (10 ref.)
Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)
Voiding dysfunction in women with lumbar disc prolapse. Goldman HB, et al.
Int Urogynecol J Pelvic Floor Dysfunct 1999;10(2):134–8 (18 ref.)
Management of herniation of the lumbar disc. Postacchini F. **J Bone Joint Surg Br** 1999 Jul;81(4):567–76 (70 ref.)
Management of acute lumbar disk herniation initially presenting as mechanical low back pain. Crawford CM, et al. **J Manipulative Physiol Ther** 1999 May;22(4):235–44 (85 ref.)
Low back pain and the lumbar intervertebral disk: clinical considerations for the doctor of chiropractic. Troyanovich SJ, et al. **J Manipulative Physiol Ther** 1999 Feb; 22(2):96–104 (58 ref.)
Differential diagnosis: a reasonable clinical approach. Swenson R. **Neurol Clin** 1999 Feb;17(1):43–63 (81 ref.)
A physiological approach to the evaluation of lumbosacral spinal stenosis. Kraft GH.
Phys Med Rehabil Clin N Am 1998 May;9(2):381–9, viii (19 ref.)
Spinal imaging and intervention: 1998. Mink JH, et al.
Phys Med Rehabil Clin N Am 1998 May;9(2):343–80, viii (116 ref.)
The influence of occupation on lumbar degeneration. Videman T, et al. **Spine** 1999 Jun 1;24(11):1164–8 (31 ref.)
[Physical diagnosis--signs of lumbosacral irritation (see comments) (published erratum appears in Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1400)] Oosterhuis HJ.
Ned Tijdschr Geneeskd 1999 Mar 20;143(12):617–20 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1393–4. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394–5. **(Dut)**
[Diagnosis and treatment of vertebral disc herniation] Kotilainen E. **Duodecim** 1995;111(21):2078–83 (57 ref.) **(Fin)**
[Endocarditis manifesting as a spondylodiscitis and psoas abscess] Berger A, et al. **Rev Med Suisse Romande** 1999 Jan;119(1):55–7 (12 ref.) (Eng. Abstr.) **(Fre)**
[Chemonucleolysis. Development, experiences, prospects] Steffen R, et al. **Orthopade** 1999 Jul;28(7):609–14 (33 ref.) (Eng. Abstr.) **(Ger)**
[Candida spondylitis. Case report and review of the literature] Andermahr J, et al. **Unfallchirurg** 1998 Dec;101(12):955–9 (27 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

MR imaging of congenital anomalies of the pediatric spine. Egelhoff JC. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):459–79 (97 ref.)

ANATOMY & HISTOLOGY

Pulse sequences in lumbar spine imaging. Ruggieri PM.
Magn Reson Imaging Clin N Am 1999 Aug;7(3):425–37, vii (67 ref.)
Anatomic and technical considerations in needle electromyography of the lumbar spine. Frank LW, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):795–814, vi–vii (76 ref.)
Physical measurements of the lumbar spine. Mooney V.
Phys Med Rehabil Clin N Am 1998 May;9(2):391–410, viii (72 ref.)
[Anatomical and functional aspects of the thoracic and lumbar spine] Graichen H, et al. **Orthopade** 1999 May; 28(5):424–31 (43 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Vascular anatomy and disorders of the lumbar spine and spinal cord. Bowen BC, et al.
Magn Reson Imaging Clin N Am 1999 Aug;7(3):555–71 (54 ref.)

INJURIES

Lesson of the week: fractures of the thoracolumbar spine in major trauma patients [see comments] Meek S. **BMJ** 1998 Nov 21;317(7170):1442–3 (11 ref.) Comment in: BMJ 1999 May 8;318(7193):1287–8. Comment in: BMJ 1999 May 8;318(7193):1288.
Nonsurgical treatment of thoracic and lumbar fractures. Rechtine GR. **Instr Course Lect** 1999;48:413–6 (20 ref.)
MR imaging of the traumatized lumbar spine. Young PC, et al. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):589–602 (58 ref.)
Lateral extracavitary approach for thoracic and thoracolumbar spine trauma: operative complications. Resnick DK, et al. **Neurosurgery** 1998 Oct;43(4):796–802; discussion 802–3 (22 ref.)
Thoracic and lumbar trauma: rationale for selecting the appropriate fusion technnique. McCullen G, et al.
Orthop Clin North Am 1998 Oct;29(4):813–28 (87 ref.)
Traumatic L1–L2 dislocation without fracture in a 6-year-old girl. Incomplete neurologic deficit and total recovery. Yazici M, et al. **Spine** 1999 Jul 15;24(14):1483–6 (18 ref.)
[Management of injuries of the thoracic and lumbar vertebrae in children] Kathrein A, et al. **Orthopade** 1999 May; 28(5):441–50 (60 ref.) (Eng. Abstr.) **(Ger)**
[Transpedicular fusion of the thoraco-lumbar junction. Clinical, radiographic and CT results] Knop C, et al.
Orthopade 1999 Aug;28(8):703–13 (35 ref.) (Eng. Abstr.) **(Ger)**
[Combined surgery for fractures of the thoraco-lumbar junction using the inlay-span method] Kossmann T, et al.
Orthopade 1999 May;28(5):432–40 (47 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the thoracic and lumbar spine] Eggers C, et al.
Unfallchirurg 1998 Oct;101(10):779–90 (11 ref.) **(Ger)**
[Dorsal stabilization of fractures of the thoracic and lumbar spine by external fixator--technique and outcome] Pizanis A, et al. **Zentralbl Chir** 1998;123(8):936–43 (20 ref.) (Eng. Abstr.) **(Ger)**
[Thoraco-lumbar spinal injuries--surgical indications and timing] Weckback A, et al. **Zentralbl Chir** 1998; 123(8):930–5 (6 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Blastomycosis of the lumbar spine: case report and review of the literature, with emphasis on diagnostic laboratory tools and management. Hadjipavlou AG, et al.
Eur Spine J 1998;7(5):416–21 (34 ref.)
MR imaging of spinal infections. Dagirmanjian A, et al.
Magn Reson Imaging Clin N Am 1999 Aug;7(3):525–38 (52 ref.)

PATHOLOGY

Bilateral ganglion cysts: case report and review of the literature. Diamantopoulos J, et al.
Acta Neurochir (Wien) 1999;141(7):783–4 (5 ref.)
MR imaging changes of lumbar vertebral sarcoidosis. Fisher AJ, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):354–6 (8 ref.)
Imaging the bad back: increasing reliance on MRI. Dixon AK. **Hosp Med** 1998 Jun;59(6):496–8 (17 ref.)
Classification of thoracolumbar fractures and posterior instrumentation for treatment of thoracolumbar fractures. Capen DA. **Instr Course Lect** 1999;48:437–41 (24 ref.)
Thoracolumbar trauma imaging overview. Flanders AE.
Instr Course Lect 1999;48:429–31 (16 ref.)
Lumbar intraspinal synovial cysts of different etiologies: diagnosis by CT and MR imaging. Farrokh D.
J Belge Radiol 1998 Dec;81(6):275–8 (20 ref.)
MR evaluation of stenosis involving the neural foramina, lateral recesses, and central canal of the lumbosacral spine. Jinkins JR. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):493–511, viii (43 ref.)
Degenerative disc disease and back pain. Modic MT.
Magn Reson Imaging Clin N Am 1999 Aug;7(3):481–91, viii (67 ref.)
MR imaging of neoplasms of the lumbar spine. Sevick RJ, et al. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):539–53, ix (64 ref.)

PHYSIOLOGY

The coordinated movement of the lumbo-pelvic-hip complex during running: a literature review. Schache AG, et al. **Gait Posture** 1999 Sep;10(1):30–47 (138 ref.)
Physical measurements of the lumbar spine. Mooney V.
Phys Med Rehabil Clin N Am 1998 May;9(2):391–410, viii (72 ref.)

PHYSIOPATHOLOGY

Is there a role for transversus abdominis in lumbo-pelvic stability? Hodges PW. **Man Ther** 1999 May;4(2):74–86 (82 ref.)
[Physical therapy and rehabilitation of unspecified vertebral pain] Fialka-Moser V.
Anasthesiol Intensivmed Notfallmed Schmerzther 1998 Dec; 33(12):800–2 (9 ref.) **(Ger)**

RADIOGRAPHY

The radiological investigation of lumbar spondylolysis. Harvey CJ, et al. **Clin Radiol** 1998 Oct;53(10):723–8 (39 ref.)
Plain CT of the degenerative lumbar spine. Tallroth K. **Eur J Radiol** 1998 Jul;27(3):206–13 (29 ref.)

SURGERY

Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Van Royen BJ, et al. **Ann Rheum Dis** 1999 Jul;58(7):399–406 (65 ref.)
Outcome analysis in lumbar spine: instabilities/degenerative disease. Fessler RG. **Clin Neurosurg** 1997;44:297–303 (12 ref.)
Degenerative lumbar spinal instability: technical aspects of operative treatment. Karahalios DG, et al. **Clin Neurosurg** 1997;44:109–35 (38 ref.)
Selection criteria for degenerative lumbar spine instability. McCormick PC. **Clin Neurosurg** 1997;44:29–39 (39 ref.)
Combined anterior and posterior surgery for fractures of the thoracolumbar spine. Vaccaro AR. **Instr Course Lect** 1999; 48:443–9 (9 ref.)
L4–L5 degenerative spondylolisthesis: indications and technique for operative management. O'Rourke MR, et al. **Iowa Orthop J** 1998;18:76–86 (42 ref.)
Degenerative lumbar stenosis: diagnosis and management. Hilibrand AS, et al. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):239–49 (41 ref.)
Lumbar arthrodesis for the treatment of back pain. Hanley EN Jr, et al. **J Bone Joint Surg Am** 1999 May;81(5):716–30 (228 ref.)
Interbody fusion cages in reconstructive operations on the spine. McAfee PC. **J Bone Joint Surg Am** 1999 Jun; 81(6):859–80 (110 ref.)
MR imaging of the postoperative lumbar spine. Ross JS. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):513–24, viii (50 ref.)
Indications for thoracic and lumbar spine fusion and trends in use. Abraham DJ, et al. **Orthop Clin North Am** 1998 Oct;29(4):803 (70 ref.)
The biology of posterolateral lumbar spinal fusion. Boden SD. **Orthop Clin North Am** 1998 Oct;29(4):603–19 (127 ref.)
Clinical outcome after fusion of the thoracic or lumbar spine in the adult patient. Hellman EW, et al. **Orthop Clin North Am** 1998 Oct;29(4):859–69 (84 ref.)
Minimally invasive posterolateral lumbar arthrodesis. Moskovitz PA. **Orthop Clin North Am** 1998 Oct;29(4):665–7 (10 ref.)
Laparoscopic bone dowel fusions of the lumbar spine. Silcox DH 3rd. **Orthop Clin North Am** 1998 Oct;29(4):655–63 (22 ref.)
Management of degenerative disc disease above an L5–S1 segment requiring arthrodesis. Herkowitz HN, et al. **Spine** 1999 Jun 15;24(12):1268–70 (15 ref.)
Intraoperative electromyography during thoracolumbar spinal surgery. Holland NR. **Spine** 1998 Sep 1; 23(17):1915–22 (35 ref.)
Surgical management of lumbar spinal stenosis. Postacchini F. **Spine** 1999 May 15;24(10):1043–7 (21 ref.)
Surgical management for instability and paraplegia caused by spinal sarcoidosis. A case report. Tzagarakis GP, et al. **Spine** 1998 Aug 1;23(15):1711–4 (24 ref.)
[Retroperitoneoscopic anterior approach to the L2, L3, L4 vertebral bodies] De Peretti F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 May; 85(2):183–8 (10 ref.) (Eng. Abstr.) **(Fre)**
[Surgical approach in lumbar intervertebral disk displacement. Topographical principles and characteristics] Grifka J, et al. **Orthopade** 1999 Jul;28(7):572–8 (17 ref.) (Eng. Abstr.) **(Ger)**
[Surgical treatment of lumbar intervertebral disk displacement. Indications and methods] Krämer J, et al. **Orthopade** 1999 Jul;28(7):579–84 (39 ref.) (Eng. Abstr.) **(Ger)**
[Open lumbar intervertebral disk operation. Technique and results] Scholz R, et al. **Orthopade** 1999 Jul;28(7):585–92 (57 ref.) (Eng. Abstr.) **(Ger)**
[Percutaneous nucleotomy procedures in lumbar intervertebral disk displacement. Current status] Siebert W. **Orthopade** 1999 Jul;28(7):598–608 (89 ref.) (Eng. Abstr.) **(Ger)**
[Lumbar interbody fusion. Biomechanical significance for the spine] Maciejczak A, et al. **Neurol Neurochir Pol** 1998 Sep–Oct;32(5):1247–59 (20 ref.) (Eng. Abstr.) **(Pol)**

LUMBOSACRAL PLEXUS

ANATOMY & HISTOLOGY

Anatomy and evaluation of the lumbosacral plexus. Fann AV. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):815–29 (65 ref.)

INJURIES

Transverse subgluteal–ilioinguinal approach to the acetabulum. Amr S. **Microsurgery** 1998;18(7):432–41 (65 ref.)

SURGERY

Transverse subgluteal–ilioinguinal approach to the acetabulum. Amr S. **Microsurgery** 1998;18(7):432–41 (65 ref.)

LUMBOSACRAL REGION

see related
LOW BACK PAIN

PHYSIOLOGY

EMG assessment of back muscle function during cyclical lifting. Roy SH, et al. **J Electromyogr Kinesiol** 1998 Aug; 8(4):233–45 (33 ref.)

PHYSIOPATHOLOGY

Can an anomalous lumbo–sacral or lumbo–iliac articulation cause low back pain? A retrospective study of 12 cases. Avimadje M, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):35–9 (6 ref.)

LUMBRICUS see **OLIGOCHAETA**

LUMBRICUS TERRESTRIS see **OLIGOCHAETA**

LUMINESCENCE

see related
CHEMILUMINESCENCE
Bioluminescence. Wilson T, et al. **Annu Rev Cell Dev Biol** 1998;14:197–230 (163 ref.)
Spontaneous ultraweak bioluminescence in plants: origin, mechanisms and properties. Radotić K, et al. **Gen Physiol Biophys** 1998 Dec;17(4):289–308 (105 ref.)

LUMINESCENT PROTEINS

The green fluorescent protein. Tsien RY. **Annu Rev Biochem** 1998;67:509–44 (114 ref.)
Membrane trafficking in higher plant cells: GFP and antibodies, partners for probing the secretory pathway. Satiat–Jeunemaitre B, et al. **Biochimie** 1999 Jun; 81(6):597–605 (40 ref.)
A FLASH of insight into cellular chemistry: genetically encoded labels for protein visualization in vivo. Luebke KJ. **Chem Biol** 1998 Dec;5(12):R317–22 (24 ref.)
Green fluorescent protein (GFP) as a vital marker in mammals. Ikawa M, et al. **Curr Top Dev Biol** 1999;44:1–20 (76 ref.)
Visualization of large–scale chromatin structure and dynamics using the lac operator/lac repressor reporter system. Belmont AS, et al. **Methods Cell Biol** 1999; 58:203–22 (29 ref.)
Using green fluorescent protein fusion proteins to quantitate microtubule and spindle dynamics in budding yeast. Bloom KS, et al. **Methods Cell Biol** 1999;61:369–83 (38 ref.)
GFP as a cell and developmental marker in the Drosophila nervous system. Brand A. **Methods Cell Biol** 1999; 58:165–81 (40 ref.)
Cytoskeletal dynamics in yeast. Carminati JL, et al. **Methods Cell Biol** 1999;58:87–105 (33 ref.)
GFP fusions to a microtubule motor protein to visualize meiotic and mitotic spindle dynamics in Drosophila. Endow SA. **Methods Cell Biol** 1999;58:153–63 (21 ref.)
Flow cytometric analysis and FACS sorting of cells based on GFP accumulation. Galbraith DW, et al. **Methods Cell Biol** 1999;58:315–41 (63 ref.)
GFP biofluorescence: imaging gene expression and protein dynamics in living cells. Design considerations for a fluorescence imaging laboratory. Goodwin PC. **Methods Cell Biol** 1999;58:343–67 (33 ref.)
GFP variants for multispectral imaging of living cells. Haseloff J. **Methods Cell Biol** 1999;58:139–51 (31 ref.)
Visualizing protein interactions in living cells using digitized GFP imaging and FRET microscopy. Periasamy A, et al. **Methods Cell Biol** 1999;58:293–314 (98 ref.)
Synchronous real–time reporting of multiple cellular events. Plautz JD, et al. **Methods Cell Biol** 1999;58:283–91 (19 ref.)
GFP fusion proteins as probes for cytology in fission yeast. Sawin KE. **Methods Cell Biol** 1999;58:123–38 (35 ref.)
Using time–lapse confocal microscopy for analysis of centromere dynamics in human cells. Sullivan KF, et al. **Methods Cell Biol** 1999;58:183–202 (26 ref.)
Centrosome dynamics in living cells. Young A, et al. **Methods Cell Biol** 1999;58:223–38 (13 ref.)
Live imaging with green fluorescent protein. Haseloff J, et al. **Methods Mol Biol** 1999;122:241–59 (57 ref.)
Dual–colour imaging with GFP variants. Ellenberg J, et al. **Trends Cell Biol** 1999 Feb;9(2):52–6 (31 ref.)
Using GFP in FRET–based applications. Pollok BA, et al. **Trends Cell Biol** 1999 Feb;9(2):57–60 (14 ref.)
Photobleaching GFP reveals protein dynamics inside live cells. White J, et al. **Trends Cell Biol** 1999 Feb;9(2):61–5 (29 ref.)
[A revolution in Ca2+ imaging] Miyawaki A. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1931–8 (12 ref.) **(Jpn)**

ANALYSIS

Single–molecule fluorescence detection of green fluorescence protein and application to single–protein dynamics. Pierce DW, et al. **Methods Cell Biol** 1999;58:49–73 (33 ref.)
Quantitative imaging of the green fluorescent protein (GFP). Piston DW, et al. **Methods Cell Biol** 1999;58:31–48 (23 ref.)
Intermediate filaments in motion: observations of intermediate filaments in cells using green fluorescent protein–vimentin. Martys JL, et al. **Mol Biol Cell** 1999 May; 10(5):1289–95 (18 ref.)
Visualizing protein–protein interactions in the nucleus of the living cell. Day RN, et al. **Mol Endocrinol** 1999 Apr; 13(4):517–26 (63 ref.)

CHEMISTRY

Understanding structure–function relationships in the Aequorea victoria green fluorescent protein. Cubitt AB, et al. **Methods Cell Biol** 1999;58:19–30 (37 ref.)
Biophysics of the green fluorescent protein. Prendergast FG. **Methods Cell Biol** 1999;58:1–18 (39 ref.)

GENETICS

Green fluorescent protein as a reporter of transcription and protein localization in fungi. Cormack B. **Curr Opin Microbiol** 1998 Aug;1(4):406–10 (42 ref.)
Applications of the green fluorescent protein as a molecular marker in environmental microorganisms. Errampalli D, et al. **J Microbiol Methods** 1999 Apr;35(3):187–99 (60 ref.)
Enlightening mitosis: construction and expression of green fluorescent fusion proteins. Sullivan KF. **Methods Cell Biol** 1999;61:113–35 (33 ref.)

METABOLISM

Using green fluorescent protein to understand the mechanisms of G–protein–coupled receptor regulation. Ferguson SS. **Braz J Med Biol Res** 1998 Nov;31(11):1471–7 (50 ref.)
Applications of the green fluorescent protein as a molecular marker in environmental microorganisms. Errampalli D, et al. **J Microbiol Methods** 1999 Apr;35(3):187–99 (60 ref.)
Transfections of primary muscle cell cultures with plasmids coding for GFP linked to full–length and truncated muscle proteins. Dabiri GA, et al. **Methods Cell Biol** 1999; 58:239–60 (44 ref.)
Targeting GFP to organelles. De Giorgi F, et al. **Methods Cell Biol** 1999;58:75–85 (16 ref.)
Monitoring the dynamics and mobility of membrane proteins tagged with green fluorescent protein. Lippincott–Schwartz J, et al. **Methods Cell Biol** 1999; 58:261–81 (26 ref.)

PHYSIOLOGY

Understanding structure–function relationships in the Aequorea victoria green fluorescent protein. Cubitt AB, et al. **Methods Cell Biol** 1999;58:19–30 (37 ref.)

LUMPECTOMY see **MASTECTOMY, SEGMENTAL**

LUNAR CYCLE see **MOON**

LUNAR PHASES see **MOON**

LUNDBORG–UNVERRICHT SYNDROME see **EPILEPSY, MYOCLONIC**

LUNG

see related
PNEUMONECTOMY
PULMONARY CIRCULATION
RESPIRATION
Peripherally inserted central venous catheter fracture and embolization to the lung. Kossoff EH, et al. **Pediatr Emerg Care** 1998 Dec;14(6):403–5 (11 ref.)
Tension pneumothorax secondary to grass head aspiration. Newson TP, et al. **Pediatr Emerg Care** 1998 Aug; 14(4):287–9 (12 ref.)

ABNORMALITIES

Esophageal lung with multiple congenital anomalies: conundrums in diagnosis and management. Saydam TC, et al. **J Pediatr Surg** 1999 Apr;34(4):615–8 (21 ref.)
Variation in major pulmonary fissures: incidence in fetal postmortem examinations and a review of significant extrapulmonary structural abnormalities in sixty cases. Bates AW. **Pediatr Dev Pathol** 1998 Jul–Aug;1(4):289–94 (45 ref.)
[Congenital diaphragmatic hernia. I. Simple defect of the diaphragm or anomaly of the pulmonary mesenchyme?] Thébaud B, et al. **Arch Pediatr** 1998 Sep;5(9):1009–19 (86 ref.) (Eng. Abstr.) **(Fre)**
[Congenital diaphragmatic hernia. II. Is pulmonary hypoplasia an indefinable obstacle?] Thébaud B, et al. **Arch Pediatr** 1999 Feb;6(2):186–98 (120 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Fast magnetic resonance imaging of the lung. Hatabu H, et al. **Eur J Radiol** 1999 Feb;29(2):114–32 (84 ref.)
Ventilation–perfusion MR imaging of the lung. Hatabu H, et al. **Magn Reson Imaging Clin N Am** 1999 May;

7(2):379–92, x (47 ref.)

BLOOD SUPPLY

Anomalous systemic arterial supply to normal basal segments of the left lower lobe. Yamanaka A, et al. **Ann Thorac Surg** 1999 Aug;68(2):332–8 (20 ref.)

Partitioning lung and plasma proteins: circulating surfactant proteins as biomarkers of alveolocapillary permeability. Doyle IR, et al. **Clin Exp Pharmacol Physiol** 1999 Mar; 26(3):185–97 (110 ref.)

Pulmonary vascular biology during neonatal transition. Lakshminrusimha S, et al. **Clin Perinatol** 1999 Sep; 26(3):601–19 (120 ref.)

Magnetic resonance pulmonary angiography. Wielopolski PA. **Coron Artery Dis** 1999 May;10(3):157–75 (108 ref.)

Pulmonary involvement in Behçet disease. Erkan F. **Curr Opin Pulm Med** 1999 Sep;5(5):314–8 (40 ref.)

Regulation of vasodilator synthesis during lung development. Shaul PW. **Early Hum Dev** 1999 Apr;54(3):271–94 (87 ref.)

Do adhesion molecules importantly regulate leukocyte kinetics within intraacinar microvessels of the lung? Yamaguchi K, et al. **Histol Histopathol** 1998 Oct; 13(4):1089–102 (70 ref.)

Contrast-enhanced magnetic resonance angiography of the pulmonary vasculature. A review. Kauczor HU. **Invest Radiol** 1998 Sep;33(9):606–17 (65 ref.)

Pulmonary MR angiography. Meaney JF, et al. **Magn Reson Imaging Clin N Am** 1999 May;7(2):393–409, x (39 ref.)

Stress-induced injury of pulmonary capillaries. West JB, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec;110(6):506–12 (46 ref.)

Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Voelkel NF, et al. **Pulm Pharmacol Ther** 1997 Oct–Dec;10(5–6):231–41 (104 ref.)

Spiral CT angiography of the pulmonary circulation. Remy-Jardin M, et al. **Radiology** 1999 Sep;212(3):615–36 (132 ref.)

[Mechanical extracorporeal circulation. Artificial heart. Percutaneous cardiopulmonary circulation. Part II] Ostrowska G. **Pol Merkuriusz Lek** 1999 Mar;6(33):146–51 (53 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

The function of cell adhesion molecules in lung inflammation: more questions than answers. DeLisser HM, et al. **Am J Respir Cell Mol Biol** 1998 Oct;19(4):533–6 (53 ref.)

[Angiotensin receptor in the lung] Noda K. **Nippon Rinsho** 1999 May;57(5):1049–53 (22 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Investigating stem cells in the lung. Magdaleno SM, et al. **Adv Pediatr** 1998;45:363–96 (125 ref.)

Lung epithelium-specific proteins: characteristics and potential applications as markers. Hermans C, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):646–78 (469 ref.)

Modulation of myofibroblast and smooth-muscle phenotypes in the lung. Low RB. **Curr Top Pathol** 1999;93:19–26 (29 ref.)

Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium [see comments] Hiemstra PS, et al. **Eur Respir J** 1998 Nov;12(5):1200–8 (103 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250–1.

DRUG EFFECTS

Antenatal hormone therapy for fetal lung maturation. Merrill JD, et al. **Clin Perinatol** 1998 Dec;25(4):983–97 (86 ref.)

Improved delivery of inhaled steroids to the large and small airways. Leach CL. **Respir Med** 1998 Jun;92 Suppl A:3–8 (25 ref.)

Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Seale JP, et al. **Respir Med** 1998 Jun;92 Suppl A:9–15 (9 ref.)

Perspective article: transforming growth factor-beta: crossroad of glucocorticoid and bleomycin regulation of collagen synthesis in lung fibroblasts. Shukla A, et al. **Wound Repair Regen** 1999 May-Jun;7(3):133–40 (73 ref.)

[Alcohol and the lungs] Giorcelli L. **Arch Bronconeumol** 1998 Dec;34(11):554–60 (133 ref.) **(Spa)**

EMBRYOLOGY

Assessment of fetal lung maturity. Practice parameter. Dubin SB. **Am J Clin Pathol** 1998 Dec;110(6):723–32 (47 ref.)

Molecular embryology of the lung: then, now, and in the future. Warburton D, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L697–704 (57 ref.)

Commitment and differentiation of lung cell lineages. Warburton D, et al. **Biochem Cell Biol** 1998;76(6):971–95 (212 ref.)

Molecular mechanisms controlling lung morphogenesis. Perl AK, et al. **Clin Genet** 1999 Jul;56(1):14–27 (139 ref.)

Alveolar fluid clearance in developing lungs and its role in neonatal transition. Jain L. **Clin Perinatol** 1999 Sep; 26(3):585–99 (88 ref.)

Antenatal hormone therapy for fetal lung maturation. Merrill JD, et al. **Clin Perinatol** 1998 Dec;25(4):983–97 (86 ref.)

Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Pepicelli CV, et al. **Curr Biol** 1998 Sep 24;8(19):1083–6 (18 ref.)

Epithelial/mesenchymal interactions and branching morphogenesis of the lung. Hogan BL, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):481–6 (46 ref.)

Current concepts on lung development. Warburton D, et al. **Curr Opin Pediatr** 1999 Jun;11(3):188–92 (23 ref.)

Regulation of vasodilator synthesis during lung development. Shaul PW. **Early Hum Dev** 1999 Apr;54(3):271–94 (87 ref.)

Amniotic fluid lamellar body count: cost-effective screening for fetal lung maturity. Lewis PS, et al. **Obstet Gynecol** 1999 Mar;93(3):387–91 (17 ref.)

Genetic control of branching morphogenesis. Metzger RJ, et al. **Science** 1999 Jun 4;284(5420):1635–9 (39 ref.)

Molecular approaches to understanding organogenesis. Crisera CA, et al. **Semin Pediatr Surg** 1999 Aug;8(3):109–18 (61 ref.)

ENZYMOLOGY

Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Raunio H, et al. **Exp Toxicol Pathol** 1999 Jul;51(4–5):412–7 (49 ref.)

[Cathepsin cysteine proteinases in the lung] Bühling F, et al. **Pneumologie** 1999 Aug;53(8):400–7 (77 ref.) (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

Maturation of the mammalian respiratory system. Hilaire G, et al. **Physiol Rev** 1999 Apr;79(2):325–60 (500 ref.)

IMMUNOLOGY

Cysteinyl-leukotrienes and the human lung. Gorenne I, et al. **Adv Exp Med Biol** 1999;447:171–9 (42 ref.)

Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness--a murine model. Hamelmann E, et al. **Allergy** 1999 Apr; 54(4):297–305 (51 ref.)

The function of cell adhesion molecules in lung inflammation: more questions than answers. DeLisser HM, et al. **Am J Respir Cell Mol Biol** 1998 Oct;19(4):533–6 (53 ref.)

The macroimportance of the pulmonary immune microenvironment. Lee NA, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):298–302 (47 ref.)

Interactions of surfactant protein A with pathogens. Haagsman HP. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):264–77 (73 ref.)

Surfactant protein A (SP-A) gene targeted mice. Korfhagen TR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):296–302 (46 ref.)

Role of leukotrienes in antimicrobial host defense of the lung. Peters-Golden M, et al. **Clin Rev Allergy Immunol** 1999 Spring–Summer;17(1–2):261–9 (34 ref.)

Cytokines and pulmonary inflammatory and immune diseases. Xing Z, et al. **Histol Histopathol** 1999 Jan;14(1):185–201 (49 ref.)

Airway epithelial cells as regulators of airway inflammation (Review). Takizawa H. **Int J Mol Med** 1998 Feb; 1(2):367–78 (107 ref.)

Role of leukotrienes in antimicrobial defense of the lung. Peters-Golden M, et al. **J Lab Clin Med** 1998 Oct; 132(4):251–7 (42 ref.)

Pulmonary host defenses. Twigg HL 3rd. **J Thorac Imaging** 1998 Oct;13(4):221–33 (88 ref.)

The role of cytokines in bacterial pneumonia: an inflammatory balancing act. Moore TA, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):297–305 (81 ref.)

The lung in the immunocompromised patient. Infectious complications Part 1. Baughman RP. **Respiration** 1999; 66(2):95–109 (179 ref.)

Immunobiology of dendritic cells in the respiratory tract: steady-state and inflammatory sentinels? McWilliam AS, et al. **Toxicol Lett** 1998 Dec 28;102–103:323–9 (19 ref.)

INJURIES

Lung injury caused by mechanical ventilation. Slutsky AS. **Chest** 1999 Jul;116(1 Suppl):9S–15S (42 ref.)

Ventilator-associated lung injury. Kacmarek RM. **Int Anesthesiol Clin** 1999 Summer;37(3):47–64 (67 ref.)

Invited editorial on "tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs". Al-Mehdi AB, et al. **J Appl Physiol** 1998 Dec;85(6):2003–4 (16 ref.)

Prone positioning in acute lung injury. Dries DJ. **J Trauma** 1998 Oct;45(4):849–52 (23 ref.)

Mechanical ventilation in acute respiratory distress syndrome: evolving concepts. Mehta S, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):647–53 (58 ref.)

Protective ventilatory strategy for ARDS: physiological evaluation of the clinical trials. Ranieri VM, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):644–6 (35 ref.)

Mechanisms of ventilation-induced lung injury: physiological rationale to prevent it. Verbrugge SJ, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):22–37 (158 ref.)

Surfactant and acute lung injury. Jobe AH, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec;110(6):489–95 (53 ref.)

Ventilator-induced injury: from barotrauma to biotrauma. Tremblay LN, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec;110(6):482–8 (56 ref.)

Pulmonary contusion in children: diagnosis and management. Allen GS, et al. **South Med J** 1998 Dec;91(12):1099–106 (67 ref.)

Diving and the risk of barotrauma. Russi EW. **Thorax** 1998 Aug;53 Suppl 2:S20–4 (31 ref.)

[Lung damage due to mechanical ventilation] Plötz FB, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):133–6 (33 ref.) (Eng. Abstr.) **(Dut)**

[Pneumologic aspects of diving medicine] Tetzlaff K, et al. **Pneumologie** 1998 Sep;52(9):489–500 (126 ref.) **(Ger)**

INNERVATION

The pulmonary neuroendocrine system: the past decade. Van Lommel A, et al. **Arch Histol Cytol** 1999 Mar;62(1):1–16 (111 ref.)

Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Fryer AD, et al. **Life Sci** 1999;64(6–7):449–55 (49 ref.)

Neuroepithelial bodies as airway oxygen sensors. Cutz E, et al. **Respir Physiol** 1999 Apr 1;115(2):201–14 (57 ref.)

[Pathogenetic substantiation of lung denervation in bronchial asthma and it's indications] Smakov GM. **Khirurgiia (Mosk)** 1999;(2):67–9 (48 ref.) **(Rus)**

METABOLISM

Ca2+-activated Cl- channels: focus on "molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland". Cuppoletti J, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1259–60 (19 ref.)

Nucleosides and nucleotides in the lung: role in asthma. Fedan JS. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):7–9 (26 ref.)

Lung epithelium-specific proteins: characteristics and potential applications as markers. Hermans C, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):646–78 (469 ref.)

Structure, strength, failure, and remodeling of the pulmonary blood-gas barrier. West JB, et al. **Annu Rev Physiol** 1999; 61:543–72 (91 ref.)

Regulatory mechanisms of surfactant secretion. Mason RJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):226–40 (99 ref.)

Lung cytokines and ARDS: Roger S. Mitchell Lecture. Martin TR. **Chest** 1999 Jul;116(1 Suppl):2S–8S (73 ref.)

Partitioning lung and plasma proteins: circulating surfactant proteins as biomarkers of alveolocapillary permeability. Doyle IR, et al. **Clin Exp Pharmacol Physiol** 1999 Mar; 26(3):185–97 (110 ref.)

Kinetic aspects of drug disposition in the lungs. Upton RN, et al. **Clin Exp Pharmacol Physiol** 1999 May–Jun; 26(5–6):381–91 (80 ref.)

Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Gauldie J, et al. **Curr Top Pathol** 1999;93:35–45 (38 ref.)

Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Jiang Q, et al. **Eur J Hum Genet** 1998 Jan;6(1):12–31 (157 ref.)

Glucose transporter expression in developing fetal lungs and lung neoplasms. Ito T, et al. **Histol Histopathol** 1999 Jul; 14(3):895–904 (67 ref.)

Intrapulmonary concentrations of antimicrobial agents. Nix DE. **Infect Dis Clin North Am** 1998 Sep;12(3):631–46, viii (46 ref.)

Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Keller M. **Int J Pharm** 1999 Sep 10;186(1):81–90 (36 ref.)

Invited editorial on "tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs". Al-Mehdi AB, et al. **J Appl Physiol** 1998 Dec;85(6):2003–4 (16 ref.)

Alveolar epithelial fluid transport: basic mechanisms and clinical relevance. Matthay MA, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec;110(6):496–505 (65 ref.)

Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Snell NJ, et al. **Respir Med** 1999 Feb;93(2):123–33 (56 ref.)

Neuroepithelial bodies as airway oxygen sensors. Cutz E, et al. **Respir Physiol** 1999 Apr 1;115(2):201–14 (57 ref.)

Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity. Costello RW, et al. **Thorax** 1998 Jul;53(7):613–6 (78 ref.)

MICROBIOLOGY

Role of leukotrienes in antimicrobial host defense of the lung. Peters-Golden M, et al. **Clin Rev Allergy Immunol** 1999 Spring–Summer;17(1–2):261–9 (34 ref.)

PATHOLOGY

Micronodular pneumocyte hyperplasia: the versatile type 2 pneumocyte all dressed up in yet another brand new suit! Myers JL. **Adv Anat Pathol** 1999 Jan;6(1):49–55 (38 ref.)

Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma [see comments] Kitamura H, et al. **Am J Clin Pathol** 1999 May;111(5):610–22 (125 ref.) Comment in: Am J Clin Pathol 1999 May;111(5):587–9.

Pulmonary atypical adenomatous hyperplasia. A histologic lesion in search of usable criteria and clinical significance [editorial; comment] Ritter JH. **Am J Clin Pathol** 1999 May; 111(5):587–9 (15 ref.) Comment on: Am J Clin Pathol 1999 May;111(5):610–22.

Adhesion molecules and cellular biomechanical changes in acute lung injury: Giles F. Filley Lecture. Doerschuk CM, et al. **Chest** 1999 Jul;116(1 Suppl):37S–43S (51 ref.)

Pathways to cell death in hyperoxia. Horowitz S. **Chest** 1999 Jul;116(1 Suppl):64S–67S (33 ref.)

Cellular alterations in fibroproliferative lung disease. Toews GB. **Chest** 1999 Jul;116(1 Suppl):112S–116S (32 ref.)

Thoracoscopic lung biopsy or open lung biopsy for interstitial lung disease. Ferson PF, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):749–62 (24 ref.)

Video-assisted thoracic surgery for diagnosis of the solitary lung nodule. Hazelrigg SR, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):763–74, vii (31 ref.)

Pulmonary pathology in patients with systemic autoimmune diseases. Colby TV. **Clin Chest Med** 1998 Dec; 19(4):587–612, vii (63 ref.)

Early diagnosis of lung cancer. Lam S, et al. **Clin Chest Med** 1999 Mar;20(1):53–61, x (110 ref.)

Proteinase–antiproteinase imbalance in the pathogenesis of emphysema: the role of metalloproteinases in lung damage. Pardo A, et al. **Histol Histopathol** 1999 Jan;14(1):227–33 (76 ref.)

Ozone-induced lung inflammation and mucosal barrier disruption: toxicology, mechanisms, and implications. Bhalla DK. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar;2(1):31–86 (103 ref.)

Cervical spine dysraphism with teratoma exhibiting pulmonary differentiation: case report and review of the literature. Ramdial PK, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):528–33 (22 ref.)

Dynamic interactions between lung fibroblasts and leukocytes: implications for fibrotic lung disease. Hogaboam CM, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):313–20 (57 ref.)

The role of cytokines in bacterial pneumonia: an inflammatory balancing act. Moore TA, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):297–305 (81 ref.)

Acute respiratory distress syndrome. Cellular biology and pathology. Parsley EL. **Respir Care Clin N Am** 1998 Dec; 4(4):583–609, vii (142 ref.)

Strategy and cost in investigating solitary pulmonary nodules. Gould MK, et al. **Thorax** 1998 Aug;53 Suppl 2:S32–7 (26 ref.)

Transfusion-related acute lung injury (TRALI) following autologous stem cell transplant for relapsed acute myeloid leukaemia: a case report and review of the literature [see comments] Leach M, et al. **Transfus Med** 1998 Dec; 8(4):333–7 (26 ref.) Comment in: Transfus Med 1999 Jun;9(2):175.

[Interferon-alpha treatment for chemotherapy-resistant primary macroglobulinemia with stomach and lung invasion] Kitamura N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):137–44 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Role of aquaporin water channels in kidney and lung. Verkman AS. **Am J Med Sci** 1998 Nov;316(5):310–20 (80 ref.)

Neuroendocrine differentiation, neuropeptides, and neprilysin. Cohen AJ, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):1–3 (20 ref.)

Mouse models of airway responsiveness: physiological basis of observed outcomes and analysis of selected examples using these outcome indicators. Drazen JM, et al. **Annu Rev Physiol** 1999;61:593–625 (25 ref.)

Evolution of the vertebrate cardio-pulmonary system. Farmer CG. **Annu Rev Physiol** 1999;61:573–92 (95 ref.)

The pulmonary neuroendocrine system: the past decade. Van Lommel A, et al. **Arch Histol Cytol** 1999 Mar;62(1):1–16 (111 ref.)

Commitment and differentiation of lung cell lineages. Warburton D, et al. **Biochem Cell Biol** 1998;76(6):971–95 (212 ref.)

The role of lipids in pulmonary surfactant. Veldhuizen R, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):90–108 (80 ref.)

Modeling the nuclear magnetic resonance behavior of lung: from electrical engineering to critical care medicine. Cutillo AG, et al. **Bioelectromagnetics** 1999;Suppl 4:110–9 (29 ref.)

Regulation of lung water. Charan NB. **Cardiologia** 1998 Dec; 43(12):1305–14 (76 ref.)

Peptidases: structure, function and modulation of peptide-mediated effects in the human lung. van der Velden VH, et al. **Clin Exp Allergy** 1999 Apr;29(4):445–56 (50 ref.)

Molecular insights into the physiology of the 'thin film' of airway surface liquid. Boucher RC. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):631–8 (26 ref.)

Cardiopulmonary limitations to exercise in restrictive lung disease. Hsia CC. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S28–32 (15 ref.)

One lung ventilation: prospective from an interested observer. Cohen E. **Minerva Anestesiol** 1999 May; 65(5):275–83 (22 ref.)

Clinical perspectives of "the open lung concept". Suárez-Sipmann F, et al. **Minerva Anestesiol** 1999 May; 65(5):310–2 (17 ref.)

Methods of testing lung function in early childhood. Beardsmore CS. **Pediatr Allergy Immunol** 1998;9(11 Suppl):30–6 (56 ref.)

Lung function testing in preschool children. Marchal F, et al. **Pediatr Pulmonol Suppl** 1999;18:21–3 (15 ref.)

Lung function testing in infants. Stocks J. **Pediatr Pulmonol Suppl** 1999;18:14–20 (10 ref.)

Maturation of the mammalian respiratory system. Hilaire G, et al. **Physiol Rev** 1999 Apr;79(2):325–60 (500 ref.)

Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Battistini B, et al. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):79–88 (105 ref.)

Endothelin receptor subtypes: distribution and function in the lung. Goldie RG. **Pulm Pharmacol Ther** 1998 Apr–Jun; 11(2–3):89–95 (103 ref.)

The evaluation of lung function with PET. Schuster DP. **Semin Nucl Med** 1998 Oct;28(4):341–51 (75 ref.)

[Respiration and aging] Guenard H. **Rev Mal Respir** 1998 Dec;15(6):713–21 (86 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide and its importance in the regulation of pulmonary function] Motavkin PA, et al. **Morfologiia** 1998; 114(5):99–111 (132 ref.) **(Rus)**

[Mast cells and their significance in lung physiology and diseases] Zuga MV, et al. **Ter Arkh** 1999;71(3):76–80 (88 ref.) **(Rus)**

[Alcohol and the lungs] Giorcelli L. **Arch Bronconeumol** 1998 Dec;34(11):554–60 (133 ref.) **(Spa)**

PHYSIOPATHOLOGY

Invited commentary on "early and late weight gain following smoking cessation in the Lung Health Study" [comment] Thun MJ, et al. **Am J Epidemiol** 1998 Nov 1;148(9):831–2 (21 ref.) Comment on: Am J Epidemiol 1998 Nov 1;148(9):821–30.

Pulmonary function after cardiac and thoracic surgery. Weissman C. **Anesth Analg** 1999 Jun;88(6):1272–9 (66 ref.)

Physiologic consequences of pneumonectomy. Long-term consequences of pneumonectomy done in children. Lezama-del Valle Valle P, et al. **Chest Surg Clin N Am** 1999 May;9(2):485–95, xiii (36 ref.)

Nutrition and lung function in the critically ill patient. Radrizzani D, et al. **Clin Nutr** 1998 Feb;17(1):7–10 (67 ref.)

Outcome of asthma: longitudinal changes in lung function. Ulrik CS. **Eur Respir J** 1999 Apr;13(4):904–18 (123 ref.)

Normal chest radiograph and lung function do not necessarily mean normal lungs [editorial; comment] Shimura S. **Intern Med** 1998 Nov;37(11):901–2 (10 ref.) Comment on: Intern Med 1998 Nov;37(11):922–6.

Effect of pneumonia in childhood on adult lung function. Johnston ID. **J Pediatr** 1999 Aug;135(2 Pt 2):33–7 (48 ref.)

Advantages of comprehensive lung function techniques in cystic fibrosis. van der Ent CK, et al. **J R Soc Med** 1999; 92 Suppl 37:13–8 (35 ref.)

Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Fryer AD, et al. **Life Sci** 1999;64(6–7):449–55 (49 ref.)

The pulmonary-renal syndrome: a poorly understood clinicopathologic condition. Bosch X, et al. **Lupus** 1999; 8(4):258–62 (28 ref.)

The lungs in congenital diaphragmatic hernia: do we understand? IJsselstijn H, et al. **Pediatr Pulmonol** 1998 Sep; 26(3):204–18 (187 ref.)

Role of CFTR in airway disease. Pilewski JM, et al. **Physiol Rev** 1999 Jan;79(1 Suppl):S215–55 (342 ref.)

Can 'old' lungs be restored? Strategies for preserving lung health and preventing and treating COPD. Petty TL. **Postgrad Med** 1998 Oct;104(4):173–8, 181–2 (20 ref.)

A role for natriuretic peptides as well as endothelins in the hypoxic lungs of patients with chronic obstructive pulmonary disease [editorial; comment] Dorrington KL. **Respiration** 1999;66(3):208–9 (12 ref.) Comment on: Respiration 1999 ;66(3):212–9.

The pathophysiology of high altitude pulmonary edema. Grissom CK, et al. **Wilderness Environ Med** 1999 Summer; 10(2):88–92 (32 ref.)

[Genesis of airway inflammation and hyperreactivity: insight into the asthma mouse model] Hamelmann E. **Pneumologie** 1999 Jun;53(6):307–12 (40 ref.) **(Ger)**

[Assessment of pulmonary epithelial permeability in interstitial lung diseases] Ishizaka A. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):515–25 (79 ref.) (Eng. Abstr.) **(Jpn)**

[Pathophysiology of respiratory insufficiency based on the lung function] Kanazawa M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):11–7 (4 ref.) **(Jpn)**

[Pulmonary hyperinflation. The functional and clinico-radiological criteria, mechanisms and surgery to reduce lung volume in severe emphysema] Spânu V, et al. **Pneumoftiziologia** 1998 Jan–Mar;47(1):29–35 (5 ref.) **(Rum)**

RADIOGRAPHY

Enhancement of subtle density differences of the lung parenchyma on CT. Yang GZ, et al. **Br J Radiol** 1998 Jun;71(846):686–90 (6 ref.)

Recent advances in pediatric pulmonary imaging. Harty MP, et al. **Curr Opin Pediatr** 1998 Jun;10(3):227–35 (45 ref.)

Normal chest radiograph and lung function do not necessarily mean normal lungs [editorial; comment] Shimura S. **Intern Med** 1998 Nov;37(11):901–2 (10 ref.) Comment on: Intern Med 1998 Nov;37(11):922–6.

Two cases of intrapulmonary lymph node presenting as a peripheral nodular shadow: diagnostic differentiation from lung cancer. Fujimoto N, et al. **Lung Cancer** 1998 Jun; 20(3):203–9 (35 ref.)

Pulmonary adenomatoid malformation presenting as unilobar cysts in an adult. Hellmuth D, et al. **Respir Med** 1998 Dec; 92(12):1364–7 (26 ref.)

[Pulmonary actinomycosis with "balls-in-a hole" appearance diagnosed by examination of bronchial lavage fluid] Morikawa T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Sep; 36(9):813–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Lung thallium imaging in coronary transplant arteriopathy: "Ce n'est pas un pipe" [editorial; comment] Miller DD. **Am Heart J** 1999 May;137(5):782–5 (25 ref.) Comment on: Am Heart J 1999 May;137(5):942–8.

The evaluation of lung function with PET. Schuster DP. **Semin Nucl Med** 1998 Oct;28(4):341–51 (75 ref.)

SURGERY

[Surgery for lung volume reduction] Licker M, et al. **Ann Fr Anesth Reanim** 1999 Feb;18(2):196–210 (98 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Transthoracic sonography in the diagnosis of pulmonary embolism] Mathis G. **Acta Med Austriaca** 1999;26(2):52–6 (36 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Amniotic fluid lamellar body count: cost-effective screening for fetal lung maturity. Lewis PS, et al. **Obstet Gynecol** 1999 Mar;93(3):387–91 (17 ref.)

LUNG ABSCESS

[Pulmonary abscesses and bronchiectasis] Ris HB, et al. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):547–55 (21 ref.) (Eng. Abstr.) **(Ger)**

[Lung abscess] Isonuma H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):431–3 (9 ref.) **(Jpn)**

MICROBIOLOGY

Lung abscess: pathogenesis, diagnosis and treatment. Davis B, et al. **Curr Clin Top Infect Dis** 1998;18:252–73 (85 ref.)

LUNG CAPACITIES see **LUNG VOLUME MEASUREMENTS**

LUNG COMPLIANCE

Chest wall elastance and acute respiratory failure [editorial; comment] Jardin F. **Crit Care Med** 1999 Aug;27(8):1653–4 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1454–60.

LUNG DISEASES

see related

PULMONARY HEART DISEASE

Update in pulmonary diseases. Karnik AM. **Ann Intern Med** 1999 Oct 19;131(8):596–604 (5 ref.)

Update in pulmonary medicine [published erratum appears in Ann Intern Med 1999 Jul 6;131(1):74] King TE Jr. **Ann Intern Med** 1998 Nov 15;129(10):806–12 (7 ref.)

Geriatric respiratory medicine. Chan ED, et al. **Chest** 1998 Dec;114(6):1704–33 (376 ref.)

Pulmonary vasculitis. Sullivan EJ, et al. **Clin Chest Med** 1998 Dec;19(4):759–76, ix (138 ref.)

Understanding airway disease in infants. Finder JD. **Curr Probl Pediatr** 1999 Mar;29(3):65–81 (46 ref.)

Host responses to respiratory virus infection and immunization. Crowe JE Jr. **Curr Top Microbiol Immunol** 1999;236:191–214 (235 ref.)

Advising the traveller with lung disease. Sullivan P, et al. **Practitioner** 1998 May;242(1586):379–83 (0 ref.)

The pulmonary cachexia syndrome: aspects of energy balance. Congleton J. **Proc Nutr Soc** 1999 May;58(2):321–8 (57 ref.)

Nutrition and lung health. Sridhar MK. **Proc Nutr Soc** 1999 May;58(2):303–8 (52 ref.)

Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Milman N, et al. **Respir Med** 1998 Jul;92(7):902–7 (50 ref.)

[Solitary nodular pulmonary amyloidosis] Fujii H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):499–502 (15 ref.) **(Jpn)**

[Pulmonary actinomycosis, pulmonary nocardiosis] Toyoda T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):396–9 (6 ref.) **(Jpn)**

CHEMICALLY INDUCED

Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Rait JL. **Aust N Z J Ophthalmol** 1999 Feb; 27(1):57–64 (60 ref.)

Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Libby D, et al. **Clin Chest Med** 1998 Dec;19(4):809–21, x (95 ref.)

Diesel exhaust in the occupational setting. Current understanding of pulmonary health effects. Comstock ML. **Clin Lab Med** 1998 Dec;18(4):767–79 (45 ref.)

Experimental approaches for studies of particulate matter: the case for stronger consideration of dosimetric and exposure issues [editorial] Everitt J. **Exp Lung Res** 1998 Nov–Dec;24(6):705–7 (4 ref.)

New mechanistic model for organic diisocyanate–induced respiratory disease. Savolainen H. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):465–7 (31 ref.)

[Acute toxic pneumopathies] Garnier R. **Rev Prat** 1998 Jun 15;48(12):1319–23 (20 ref.) (Eng. Abstr.) **(Fre)**

[Synthetic mineral fibers] Boillat MA. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):468–74 (30 ref.) (Eng. Abstr.) **(Fre)**

[Pathologic mechanisms of diseases caused by isocyanates—review of current knowledge] Raulf–Heimsoth M, et al. **Pneumologie** 1999 Mar; 53(3):143–9 (62 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Techniques of pneumonectomy. Pneumonectomy through an empyema. Odell JA, et al. **Chest Surg Clin N Am** 1999 May;9(2):369–78, x–xi (16 ref.)

[Non–infectious pulmonary complications in cystic fibrosis in the adult] Martínez Martínez MT. **Arch Bronconeumol** 1998 Sep;34(8):400–4 (43 ref.) **(Spa)**

DIAGNOSIS

Surfactant proteins A and D: disease markers. Kuroki Y, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):334–45 (47 ref.)

The initial pulmonary evaluation of the immunocompromised patient. Walsh FW, et al. **Chest Surg Clin N Am** 1999 Feb; 9(1):19–38 (95 ref.)

Transbronchial needle aspiration. An underused diagnostic technique. Dasgupta A, et al. **Clin Chest Med** 1999 Mar; 20(1):39–51 (1001 ref.)

Role of bronchoscopy in AIDS. Raoof S, et al. **Clin Chest Med** 1999 Mar;20(1):63–76 (111 ref.)

Magnetic resonance pulmonary angiography. Wielopolski PA. **Coron Artery Dis** 1999 May;10(3):157–75 (108 ref.)

Recent advances in pediatric pulmonary imaging. Harty MP, et al. **Curr Opin Pediatr** 1998 Jun;10(3):227–35 (45 ref.)

Diffuse pulmonary calcinosis and multiple soft tissue calcification in renal failure patient with pathological femoral fracture. al–Homrany M, et al. **Indian J Chest Dis Allied Sci** 1998 Jul–Sep;40(3):205–11 (35 ref.)

Lemierre syndrome: a complication of acute pharyngitis. Williams A, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):51–7 (5 ref.)

Unusual and infrequent indications for thoracoscopy. Dieter RA Jr, et al. **Int Surg** 1998 Jan–Mar;83(1):15–20 (25 ref.)

Normal chest radiograph and lung function do not necessarily mean normal lungs [editorial; comment] Shimura S. **Intern Med** 1998 Nov;37(11):901–2 (10 ref.) Comment on: Intern Med 1998 Nov;37(11):922–6.

Takayasu's arteritis involving proximal pulmonary arteries and mimicking thromboembolic disease. Haque U, et al. **J Rheumatol** 1999 Feb;26(2):450–3 (15 ref.)

The recent evolution of pulmonary imaging in the fetus and neonate. Daneman A. **Pediatr Pulmonol Suppl** 1999;18:61–3 (5 ref.)

Diagnostic imaging of bullous pulmonary disease. A review. Zompatori M, et al. **Radiol Med (Torino)** 1998 Sep; 96(3):161–7 (44 ref.)

[What is new in pediatric pneumology?] Sayegh N, et al. **Arch Pediatr** 1998 Nov;5(11):1256–68 (69 ref.) (Eng. Abstr.) **(Fre)**

[Methods of investigation in pulmonary infections] Milosevic D, et al. **Presse Med** 1998 May 23–30;27(19):924–6 (19 ref.) **(Fre)**

[The value of the CT scanner in intensive care] Berthezène Y, et al. **Rev Mal Respir** 1998 Sep;15(4):489–93 (16 ref.) (Eng. Abstr.) **(Fre)**

[Progressive systemic scleroderma--prognosis determining involvement of internal organ systems] Mittag M, et al. **Hautarzt** 1998 Jul;49(7):545–51 (40 ref.) (Eng. Abstr.) **(Ger)**

[Spontaneous porto–pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172–4 (0 ref.) **(Ger)**

[New frontiers in imaging diagnosis in pneumology] Domingo ML, et al. **Arch Bronconeumol** 1999 May; 35(5):233–41 (22 ref.) **(Spa)**

[Sarcoidosis 10 years later (editorial)] Mañá J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):54–5 (21 ref.) **(Spa)**

[Telethermography in pulmonology] Voloshyn HH. **Lik Sprava** 1999 Apr–May;(3):24–9 (46 ref.) **(Ukr)**

DRUG THERAPY

Pulmonary diseases other than asthma as potential targets for antileukotriene therapy. Peters–Golden M. **Clin Rev Allergy Immunol** 1999 Spring–Summer; 17(1–2):247–60 (48 ref.)

Vasodilators in mechanical ventilation. Zimmerman JL, et al. **Crit Care Clin** 1998 Oct;14(4):611–27 (89 ref.)

Antibiotic treatment of adults with chest infection in general practice. **Drug Ther Bull** 1998 Sep;36(9):68–72 (34 ref.)

Report of eight cases of pulmonary actinomycosis and their treatment with imipenem–cilastatin. Yew WW, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):126–9 (15 ref.)

Corticosteroids and chronic lung disease in extremely immature infants: a dilemma. Moriette G, et al. **Pediatr Pulmonol Suppl** 1999;18:209–11 (12 ref.)

When to prescribe in lower respiratory tract infection? Macfarlane J, et al. **Practitioner** 1997 Dec;241(1581):732–4, 737–8 (11 ref.)

[Therapeutic use of N–acetylcysteine in acute lung diseases] Domenighetti G, et al. **Rev Mal Respir** 1999 Feb; 16(1):29–37 (42 ref.) (Eng. Abstr.) **(Fre)**

[Role of corticosteroid therapy in non–malignant diseases] Vignes S, et al. **Rev Med Interne** 1998 Nov;19(11):799–810 (87 ref.) (Eng. Abstr.) **(Fre)**

[Aerosols: a re–emerging treatment] Diot P, et al. **Rev Pneumol Clin** 1998 Jul;54(3):125–34 (49 ref.) (Eng. Abstr.) **(Fre)**

[Physiopathology and treatment of acute lung injury] Kitamura S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1658–66 (14 ref.) **(Jpn)**

EPIDEMIOLOGY

Antioxidants, infections and environmental factors in health and disease in northern Finland. Luoma P. **Int J Circumpolar Health** 1998 Jul;57(2–3):109–13 (40 ref.)

Preoperative pulmonary evaluation. Smetana GW. **N Engl J Med** 1999 Mar 25;340(12):937–44 (69 ref.)

ETIOLOGY

A 12–year–old girl with pulmonary hemorrhage, skin lesions, and hematuria. Pauleksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)

Mechanisms of lung injury after bone marrow transplantation. Folz RJ. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1097–9 (20 ref.)

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. **Am J Respir Crit Care Med** 1999 Aug; 160(2):736–55 (331 ref.)

Mechanisms and mediators in coal dust induced toxicity: a review. Schins RP, et al. **Ann Occup Hyg** 1999 Jan; 43(1):7–33 (256 ref.)

Genetics of the hydrophilic surfactant proteins A and D. Floros J, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):312–22 (53 ref.)

Tick–borne pulmonary disease: update on diagnosis and management. Faul JL, et al. **Chest** 1999 Jul;116(1):222–30 (95 ref.)

Pulmonary manifestations of ankylosing spondylitis and relapsing polychondritis. Lee–Chiong TL Jr. **Clin Chest Med** 1998 Dec;19(4):747–57, ix (89 ref.)

Respiratory complications in mixed connective tissue disease. Prakash UB. **Clin Chest Med** 1998 Dec;19(4):733–46, ix (75 ref.)

Pulmonary complications of mechanical ventilation. Sandur S, et al. **Clin Chest Med** 1999 Jun;20(2):223–47 (128 ref.)

The lung in polymyositis. Schwarz MI. **Clin Chest Med** 1998 Dec;19(4):701–12, viii (88 ref.)

Health effects of cigarette smoking. Skurnik Y, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):545–56 (106 ref.)

Pulmonary malacoplakia associated with Rhodococcus equi infection in patients with AIDS: case report and review. Guerrero MF, et al. **Clin Infect Dis** 1999 Jun;28(6):1334–6 (15 ref.)

Pulmonary complications of cancer therapy. Wesselius LJ. **Compr Ther** 1999 May;25(5):272–7 (20 ref.)

Altitude–related pulmonary disorders. Krieger BP, et al. **Crit Care Clin** 1999 Apr;15(2):265–80, viii (54 ref.)

Pulmonary involvement in Behçet disease. Erkan F. **Curr Opin Pulm Med** 1999 Sep;5(5):314–8 (40 ref.)

Systemic lupus erythematosus and related disorders of childhood. Arkachaisri T, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):384–92 (63 ref.)

Human health effects of air pollution from mobile sources in Europe. Viegi G, et al. **Int J Tuberc Lung Dis** 1998 Nov;2(11):947–67 (132 ref.)

Noninfectious lung disease in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1999 Jan;14(1):9–24 (94 ref.)

Pulmonary disease in the immunocompromised child. Pennington DJ, et al. **J Thorac Imaging** 1999 Jan; 14(1):37–50 (72 ref.)

Surviving the cancer, surviving the treatment: acute cardiac and pulmonary toxicity. Camp–Sorrell D. **Oncol Nurs Forum** 1999 Jul;26(6):983–90 (34 ref.)

Henoch–Schönlein purpura and pulmonary hemorrhage: a report and literature review. Vats KR, et al. **Pediatr Nephrol** 1999 Aug;13(6):530–4 (23 ref.)

The lung in sickle cell disease. Knight J, et al. **Pediatr Pulmonol** 1999 Sep;28(3):205–16 (87 ref.)

Functional pulmonary surfactant deficiency and neonatal respiratory disorders. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:175–7 (8 ref.)

Leukotoxins and the lung. Ishizaki T, et al. **Pulm Pharmacol Ther** 1999;12(3):145–55 (49 ref.)

Pulmonary parenchymal manifestations of mitral valve disease. Woolley K, et al. **Radiographics** 1999 Jul–Aug; 19(4):965–72 (8 ref.)

The lung in the immunocompromised patient. Infectious complications part 2. Tamm M. **Respiration** 1999; 66(3):199–207 (77 ref.)

Epithelioid cell granulomatosis of the lung: new insights and concepts. Popper HH. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):32–46 (62 ref.)

[Pulmonary infections other than AIDS] Perdu D, et al. **Presse Med** 1998 May 23–30;27(19):934–40 (39 ref.) **(Fre)**

[Lung diseases in HIV–infected children] Nadal D. **Schweiz Med Wochenschr** 1998 Sep 12;128(37):1375–84 (74 ref.) (Eng. Abstr.) **(Ger)**

[Role of oxygen free radicals in the pathogenesis of lung diseases] Włodarczyk R, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):41–3 (24 ref.) (Eng. Abstr.) **(Pol)**

[The characteristics of the onset and course of bronchopulmonary pathology in persons who abuse alcohol] Tkachishin VS. **Klin Med (Mosk)** 1998;76(7):43–5 (51 ref.) **(Rus)**

[Polymorphism of protein systems and individual predisposition to broncho–pulmonary occupational diseases (literature review)] Kuz'mina LP. **Med Tr Prom Ekol** 1999; (5):28–31 (25 ref.) **(Rus)**

[Effects of iron–containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27–37 (123 ref.) **(Rus)**

[Pulmonary complications related to cocaine consumption] Nistal de Paz F, et al. **An Med Interna** 1999 Jul;16(7):371–9 (158 ref.) **(Spa)**

GENETICS

Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Saltini C, et al. **Eur Respir J** 1998 Dec;12(6):1463–75 (123 ref.)

[Polymorphism of protein systems and individual predisposition to broncho–pulmonary occupational diseases (literature review)] Kuz'mina LP. **Med Tr Prom Ekol** 1999; (5):28–31 (25 ref.) **(Rus)**

IMMUNOLOGY

Pulmonary manifestations of Sjögren's syndrome. Cain HC, et al. **Clin Chest Med** 1998 Dec;19(4):687–99, viii (80 ref.)

Pulmonary manifestations of systemic lupus erythematosus. Murin S, et al. **Clin Chest Med** 1998 Dec;19(4):641–65, viii (209 ref.)

Radiologic manifestations of the systemic autoimmune diseases. Primack SL, et al. **Clin Chest Med** 1998 Dec; 19(4):573–86, vii (68 ref.)

Pulmonary manifestations of rheumatoid arthritis. Tanoue LT. **Clin Chest Med** 1998 Dec;19(4):667–85, viii (150 ref.)

Cytokines and pulmonary inflammatory and immune diseases. Xing Z, et al. **Histol Histopathol** 1999 Jan;14(1):185–201 (49 ref.)

Innate immunity, cytokines, and pulmonary host defense. Nelson S, et al. **Infect Dis Clin North Am** 1998 Sep; 12(3):555–67, vii (59 ref.)

Pulmonary infections in immunocompromised patients who do not have acquired immunodeficiency syndrome: a systematic approach. Conces DJ Jr. **J Thorac Imaging** 1998 Oct;13(4):234–46 (106 ref.)

Cells and cytokines involved in the pathogenesis of sarcoidosis. Moller DR. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):24–31 (59 ref.)

[ANCA–associated lung hemorrhage] Díaz Alcázar F, et al. **Rev Clin Esp** 1999 Mar;199(3):147–9 (14 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

[Inflammatory cytokines and chemokines in acute inflammatory disease] Geiser T. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):540–6 (27 ref.) (Eng. Abstr.) **(Ger)**

[Role of oxygen free radicals in the pathogenesis of lung diseases] Włodarczyk R, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):41–3 (24 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life [see comments] Groll AH, et al. **Clin Infect Dis** 1998 Sep;27(3):437–52 (106 ref.) Comment in: Clin Infect Dis 1998 Sep;27(3):453–7.

Mycobacteria as pathogens of respiratory infection. Griffith DE. **Infect Dis Clin North Am** 1998 Sep;12(3):593–611 (68 ref.)

Mixed viral–bacterial pulmonary infections in children. Korppi M. **Pediatr Pulmonol Suppl** 1999;18:110–2 (14 ref.)

[Pleuropulmonary manifestations of salmonellosis] Hovette P, et al. **Med Trop (Mars)** 1998;58(4):403–7 (67 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary infections during AIDS] Deslée G, et al. **Presse Med** 1998 May 23–30;27(19):927–33 (40 ref.) **(Fre)**

[Pulmonary actinomycosis with "balls-in-a hole" appearance diagnosed by examination of bronchial lavage fluid] Morikawa T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Sep; 36(9):813-7 (15 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pulmonary pathology in patients with systemic autoimmune diseases. Colby TV. **Clin Chest Med** 1998 Dec; 19(4):587-612, vii (63 ref.)

[The roles of apoptosis in lung injury and fibrosis] Kuwano K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Sep; 36(9):739-44 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumonia caused by granulomatous Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome] Tanaka Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug; 36(8):690-5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Radiologic-pathologic correlation of respiratory tract diseases --with special reference to HRCT] Ito H. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):498-506 (3 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? van der Vliet A, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):1-9 (78 ref.)

Nitric oxide in adult lung disease. Hart CM. **Chest** 1999 May; 115(5):1407-17 (94 ref.)

Physiologic consequences of pneumonectomy. Consequences on the pulmonary function. Tronc F, et al. **Chest Surg Clin N Am** 1999 May;9(2):459-73, xii-xiii (70 ref.)

Peroxynitrite in airway diseases. Sadeghi-Hashjin G, et al. **Clin Exp Allergy** 1998 Dec;28(12):1464-73 (97 ref.)

Pain management and pulmonary dysfunction. Desai PM. **Crit Care Clin** 1999 Jan;15(1):151-66, vii (48 ref.)

Pathophysiology of changes in absolute lung volumes. Bancalari E, et al. **Eur Respir J** 1998 Jul;12(1):248-58 (141 ref.)

Pulmonary surfactant in health and human lung diseases: state of the art. Griese M. **Eur Respir J** 1999 Jun;13(6):1455-76 (216 ref.)

Regulation of mucociliary clearance in health and disease [see comments] Houtmeyers E, et al. **Eur Respir J** 1999 May;13(5):1177-88 (98 ref.) Comment in: Eur Respir J 1999 May;13(5):949-50.

Mechanical ventilatory constraints in aging, lung disease, and obesity: perspectives and brief review. Babb TG. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S12-22 (44 ref.)

Cardiopulmonary limitations to exercise in restrictive lung disease. Hsia CC. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S28-32 (15 ref.)

Endothelin-1: an interesting peptide or an important mediator in pulmonary diseases? Hay DW. **Pulm Pharmacol Ther** 1998 Apr-Jun;11(2-3):141-6 (75 ref.)

New mechanistic model for organic diisocyanate-induced respiratory disease. Savolainen H. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):465-7 (31 ref.)

[Work capacity in the cae of pulmonary diseases] Thorens B, et al. **Schweiz Med Wochenschr** 1999 Mar 27; 129(12):459-64 (13 ref.) (Eng. Abstr.) **(Fre)**

[Physiology and physiopathology of the pulmonary circulation] Olschewski H, et al. **Internist (Berl)** 1999 Jul; 40(7):696-709 (30 ref.) **(Ger)**

[Assessment of pulmonary epithelial permeability in interstitial lung diseases] Ishizaka A. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):515-25 (79 ref.) (Eng. Abstr.) **(Jpn)**

[Physiopathology and treatment of acute lung injury] Kitamura S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1658-66 (14 ref.) **(Jpn)**

PREVENTION & CONTROL

Clinical trials of postnatal corticosteroids: inhaled and systemic. Halliday HL. **Biol Neonate** 1999 Jun;76 Suppl 1:29-40 (55 ref.)

Assessing and modifying the risk of postoperative pulmonary complications. Doyle RL. **Chest** 1999 May;115(5 Suppl):77S-81S (43 ref.)

Preoperative assessment of pulmonary risk. Ferguson MK. **Chest** 1999 May;115(5 Suppl):58S-63S (59 ref.)

RADIOGRAPHY

Enhancement of subtle density differences of the lung parenchyma on CT. Yang GZ, et al. **Br J Radiol** 1998 Jun;71(846):686-90 (6 ref.)

Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment. Connolly JE Jr, et al. **Clin Radiol** 1999 Aug;54(8):487-94 (17 ref.)

The radiology of the thoracic manifestations of AIDS. Oldham SA, et al. **Crit Rev Diagn Imaging** 1998 Aug; 39(4):259-338 (174 ref.)

Imaging pulmonary disease in AIDS: state of the art. Kuhlman JE. **Eur Radiol** 1999;9(3):395-408 (206 ref.)

Pulmonary infections in immunocompromised patients who do not have acquired immunodeficiency syndrome: a systematic approach. Conces DJ Jr. **J Thorac Imaging** 1998 Oct;13(4):234-46 (106 ref.)

Approach to the diagnosis of pulmonary disease in patients infected with the human immunodeficiency virus. Haramati LB, et al. **J Thorac Imaging** 1998 Oct;13(4):247-60 (70 ref.)

Pulmonary parenchymal manifestations of mitral valve disease. Woolley K, et al. **Radiographics** 1999 Jul-Aug; 19(4):965-72 (8 ref.)

Spiral CT angiography of the pulmonary circulation. Remy-Jardin M, et al. **Radiology** 1999 Sep;212(3):615-36 (132 ref.)

Computed tomography in the assessment of diffuse lung disease. Grenier P, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):47-56 (81 ref.)

[Idiopathic pulmonary ossification] Friedrich T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):267-73 (29 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary actinomycosis with "balls-in-a hole" appearance diagnosed by examination of bronchial lavage fluid] Morikawa T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Sep; 36(9):813-7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[CT diagnosis of solitary pulmonary nodule] Adachi S. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 May; 59(6):231-8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Radiologic-pathologic correlation of respiratory tract diseases --with special reference to HRCT] Ito H. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):498-506 (3 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

The radiology of the thoracic manifestations of AIDS. Oldham SA, et al. **Crit Rev Diagn Imaging** 1998 Aug; 39(4):259-338 (174 ref.)

REHABILITATION

Pulmonary rehabilitation-1999. American Thoracic Society. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1666-82 (208 ref.)

Who needs chest physiotherapy? Moving from anecdote to evidence. Wallis C, et al. **Arch Dis Child** 1999 Apr; 80(4):393-7 (49 ref.)

[Work capacity in the cae of pulmonary diseases] Thorens B, et al. **Schweiz Med Wochenschr** 1999 Mar 27; 129(12):459-64 (13 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonological rehabilitation. An integral therapeutic concept for the improvement of management capability and quality of life] Petro W, et al. **Internist (Berl)** 1999 Jul;40(7):772-8 (7 ref.) **(Ger)**

SURGERY

Preparation of high-risk patients for major thoracic surgery. Bisson A, et al. **Chest Surg Clin N Am** 1998 Aug; 8(3):541-55, viii (58 ref.)

Indications for pneumonectomy. Pneumonectomy for benign disease. Conlan AA, et al. **Chest Surg Clin N Am** 1999 May;9(2):311-26 (53 ref.)

Physiologic consequences of pneumonectomy. Consequences on the pulmonary function. Tronc F, et al. **Chest Surg Clin N Am** 1999 May;9(2):459-73, xii-xiii (70 ref.)

Techniques of pneumonectomy. Completion pneumonectomy. Tronc F, et al. **Chest Surg Clin N Am** 1999 May;9(2):393-405, xi (23 ref.)

Update on lung transplantation in children. Gaynor JW, et al. **Curr Opin Pediatr** 1998 Jun;10(3):256-61 (15 ref.)

New developments in fetal lung surgery. Kitano Y, et al. **Curr Opin Pediatr** 1999 Jun;11(3):193-9 (37 ref.)

THERAPY

Engineering viral vectors to subvert the airway defense response. Look DC, et al. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1103-6 (48 ref.)

Ventilation in the patient with unilateral lung disease. Thomas AR, et al. **Crit Care Clin** 1998 Oct;14(4):743-73 (115 ref.)

Vasodilators in mechanical ventilation. Zimmerman JL, et al. **Crit Care Clin** 1998 Oct;14(4):611-27 (89 ref.)

Inhaled nitric oxide therapy for pulmonary disease in pediatrics. Abman SH, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):236-42 (33 ref.)

Unusual and infrequent indications for thoracoscopy. Dieter RA Jr, et al. **Int Surg** 1998 Jan-Mar;83(1):15-20 (25 ref.)

When do infants need additional inspired oxygen? A review of the current literature. Poets CF. **Pediatr Pulmonol** 1998 Dec;26(6):424-8 (36 ref.)

Strategy for the prevention and treatment of chronic lung disease of the premature infant. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:212-5 (15 ref.)

Respiratory illness: a complementary perspective. Lewith GT. **Thorax** 1998 Oct;53(10):898-904 (96 ref.)

Gene therapy for lung disease. Ennist DL. **Trends Pharmacol Sci** 1999 Jun;20(6):260-6 (131 ref.)

[Pneumology] Uldry C, et al. **Schweiz Med Wochenschr** 1998 Dec 26;128(51-52):2011-4 (4 ref.) **(Fre)**

[Pulmonological rehabilitation. An integral therapeutic concept for the improvement of management capability and quality of life] Petro W, et al. **Internist (Berl)** 1999 Jul;40(7):772-8 (7 ref.) **(Ger)**

ULTRASONOGRAPHY

Fetal lung abnormalities--what do they mean? Pilling D. **Clin Radiol** 1998 Nov;53(11):789-95 (35 ref.)

[Diagnosis of parenchymal lung diseases. Possibilities and limits of transthoracic sonography] Kroegel C, et al. **Dtsch Med Wochenschr** 1999 Jun 18;124(24):765-72 (22 ref.) **(Ger)**

VETERINARY

Review of furosemide in horse racing: its effects and regulation. Soma LR, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):228-40 (103 ref.)

VIROLOGY

Detection of SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases. Galateau-Salle F, et al. **Dev Biol Stand** 1998;94:147-52 (28 ref.)

An attractive relation of human herpesvirus-8 with multicentric Castleman's disease [editorial; comment] Katano H, et al. **Intern Med** 1999 Mar;38(3):221-2 (10 ref.) Comment on: Intern Med 1999 Mar;38(3):279-82.

LUNG DISEASES, FUNGAL

Pulmonary mucormycosis: the last 30 years. Lee FY, et al. **Arch Intern Med** 1999 Jun 28;159(12):1301-9 (98 ref.)

Aspergillus and other fungi. Robinson LA. **Chest Surg Clin N Am** 1999 Feb;9(1):193-225, x (86 ref.)

[Exotic pulmonary mycoses] Dupont B. **Rev Pneumol Clin** 1998 Dec;54(6):301-8 (24 ref.) (Eng. Abstr.) **(Fre)**

[American pulmonary histoplasmosis caused by Histoplasma capsulatum] Guigay J, et al. **Rev Pneumol Clin** 1998 Dec; 54(6):311-20 (56 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary cryptococcosis] Kitamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):358-60 (5 ref.) **(Jpn)**

[Pulmonary aspergilloma] Matsushima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):308-11 (4 ref.) **(Jpn)**

[Invasive pulmonary aspergillosis] Niki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):312-5 (9 ref.) **(Jpn)**

[Non-invasive pulmonary aspergillosis] Niki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):316-8 (8 ref.) **(Jpn)**

[Pulmonary histoplasmosis] Suzaki A, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):372-4 (14 ref.) **(Jpn)**

[Pulmonary candidiasis] Yamamoto K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):335-8 (12 ref.) **(Jpn)**

COMPLICATIONS

[Primary pulmonary cryptococcosis with pleural effusion] Matsunaga K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug;36(8):708-12 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Intralobar pulmonary sequestration presenting increased serum CEA, CA 19-9, and CA 125, and associated with asymptomatic pulmonary aspergillosis] Sekiya M, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 May;37(5):433-7 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Left vocal cord paralysis as a primary manifestation of invasive pulmonary aspergillosis in a nonimmunocompromised host. Nakahira M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):691-3 (6 ref.)

Paracoccidioidomycosis. Bethlem EP, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):319-25 (57 ref.)

Many faces of pulmonary aspergillosis. Sharma OP, et al. **Eur Respir J** 1998 Sep;12(3):705-15 (86 ref.)

Endemic fungal pneumonia in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1999 Jan;14(1):1-8 (52 ref.)

Opportunistic fungal pneumonia. Connolly JE Jr, et al. **J Thorac Imaging** 1999 Jan;14(1):51-62 (60 ref.)

Pulmonary scedosporiosis. Severo LC, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):241-3 (19 ref.)

ETIOLOGY

[Meningoencephalomyelitis due to Angiostrongylus cantonensis with lung involvement] Siles Cadillá J, et al. **An Esp Pediatr** 1998 Sep;49(3):308-10 (12 ref.) **(Spa)**

IMMUNOLOGY

Protective immunity in coccidioidomycosis. Cox RA, et al. **Res Immunol** 1998 May-Jun;149(4-5):417-28; discussion 506-7 (70 ref.)

Cells and cytokines in pulmonary cryptococcosis. Huffnagle GB, et al. **Res Immunol** 1998 May-Jun;149(4-5):387-96; discussion 512-4 (80 ref.)

Pulmonary host defences against Aspergillus fumigatus. Roilides E, et al. **Res Immunol** 1998 May-Jun; 149(4-5):454-65; discussion 523-4 (110 ref.)

MICROBIOLOGY

Arthroconidia in coccidioidoma: case report and literature review. Nosanchuk JD, et al. **Int J Infect Dis** 1998 Jul-Sep;

LUNG DISEASES, FUNGAL

3(1):32–5 (38 ref.)
Pulmonary scedosporiosis. Severo LC, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul–Aug;40(4):241–3 (19 ref.)

PREVENTION & CONTROL

Protective immunity in coccidioidomycosis. Cox RA, et al. **Res Immunol** 1998 May–Jun;149(4–5):417–28; discussion 506–7 (70 ref.)

RADIOGRAPHY

Radiologic findings: pulmonary infections after bone marrow transplantation. Choi YH, et al. **J Thorac Imaging** 1999 Jul;14(3):201–6 (9 ref.)

LUNG DISEASES, INTERSTITIAL

Current concepts on interstitial lung disease in children. Howenstine MS, et al. **Curr Opin Pediatr** 1999 Jun; 11(3):200–4 (25 ref.)
Interstitial lung disease in children: an overview. Chernick V. **Pediatr Pulmonol Suppl** 1999;18:30 (7 ref.)
[Giant cell interstitial pneumonia] Barzó P, et al. **Orv Hetil** 1998 Dec 20;139(51):3079–83 (43 ref.) (Eng. Abstr.) **(Hun)**

BLOOD

[Respiratory tract diseases and tumor markers] kono N. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):141–7 (12 ref.) **(Jpn)**

CHEMICALLY INDUCED

Nylon flock–associated interstitial lung disease. Eschenbacher WL, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):2003–8 (9 ref.)
[Drug–induced interstitial pulmonary disease] Aouina H, et al. **Tunis Med** 1999 May;77(5):247–54 (47 ref.) **(Fre)**
[A case of ulcerative colitis associated with interstitial pneumonitis during administration of 5–aminosalicylic acid] Ogino H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):164–9 (14 ref.) **(Jpn)**

COMPLICATIONS

[Recurrent pneumomediastinum in the course of interstitial pneumonia associated with dermatomyositis] Satomi K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Nov;36(11):984–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Etiology and physiopathology of diseases responsible for the development of respiratory insufficiency] Suga M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):37–44 (5 ref.) **(Jpn)**

DIAGNOSIS

The role of thoracic surgery in diagnosing interstitial lung disease. Rizzato G. **Curr Opin Pulm Med** 1999 Sep; 5(5):284–6 (27 ref.)
Parvovirus B19–associated interstitial lung disease, hepatitis, and myositis. Bousvaros A, et al. **Pediatr Pulmonol** 1998 Nov;26(5):365–9 (24 ref.)
[Acute interstitial pneumonia: report of a case] Wang J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):744–7 (10 ref.) (Eng. Abstr.) **(Chi)**
[Bronchoalveolar lavage in the diagnosis of diffuse interstitial lung disease (see comments)] Drent M, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2661–5 (17 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Mar 6;143(10):540; discussion 540–1. **(Dut)**
[How to investigate ... diffuse interstitial lung disease] Bury T. **Rev Med Liege** 1999 Jan;54(1):54–7 (9 ref.) (Eng. Abstr.) **(Fre)**
[Drug–induced interstitial pulmonary disease] Aouina H, et al. **Tunis Med** 1999 May;77(5):247–54 (47 ref.) **(Fre)**
[Transbronchial biopsy in diffuse infiltrative lung diseases] Zsiray M, et al. **Orv Hetil** 1999 May 30;140(22):1239–43 (39 ref.) (Eng. Abstr.) **(Hun)**
[Differential diagnosis in pulmonary infiltrates] Saperov VN. **Klin Med (Mosk)** 1999;77(4):46–8 (0 ref.) **(Rus)**

DRUG THERAPY

Treatment issues in interstitial lung disease in tropical countries. Jindal SK, et al. **Curr Opin Pulm Med** 1999 Sep; 5(5):287–92 (44 ref.)
[Current status of the prevention and treatment of intersititial lung diseases by traditional Chinese medicine] Tao K, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Sep; 17(9):574–6 (22 ref.) **(Chi)**

ETIOLOGY

Manifestations of scleroderma pulmonary disease. Minai OA, et al. **Clin Chest Med** 1998 Dec;19(4):713–31, viii–ix (168 ref.)
Pulmonary involvement in adult–onset Still's disease. Cheema GS, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):305–9 (36 ref.)
Pulmonary associations in familial Mediterranean fever. Livneh A, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):326–31 (66 ref.)
[How to investigate ... diffuse interstitial lung disease] Bury T. **Rev Med Liege** 1999 Jan;54(1):54–7 (9 ref.) (Eng. Abstr.) **(Fre)**
[Pulmonary lesion associated with collagen vascular diseases: interstitial pneumonia] Nagai S. **Nippon Rinsho** 1999 Feb; 57(2):393–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Thoracoscopic lung biopsy or open lung biopsy for interstitial lung disease. Ferson PF, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):749–62 (24 ref.)
Idiopathic interstitial pneumonias: clinical findings, pathogenesis, pathology and radiologic findings. Lee KS, et al. **J Korean Med Sci** 1999 Apr;14(2):113–27 (95 ref.)
Perilobular pulmonary opacities: high–resolution CT findings and pathologic correlation. Johkoh T, et al. **J Thorac Imaging** 1999 Jul;14(3):172–7 (10 ref.)
[Pathology of diseases responsible for the development of respiratory insufficiency] Nagai A. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):45–50 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Coagulation and fibrinolysis in interstitial lung diseases] Talałaj J, et al. **Pneumonol Alergol Pol** 1999;67(3–4):146–50 (20 ref.) **(Pol)**

RADIOGRAPHY

Perilobular pulmonary opacities: high–resolution CT findings and pathologic correlation. Johkoh T, et al. **J Thorac Imaging** 1999 Jul;14(3):172–7 (10 ref.)
A case of acute interstitial pneumonia indistinguishable from bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia: high–resolution CT findings and pathologic correlation. Ichikado K, et al. **Radiat Med** 1998 Sep–Oct;16(5):367–70 (12 ref.)

SURGERY

Technical aspects of adult lung transplantation. Meyers BF, et al. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):213–20 (14 ref.)

LUNG DISEASES, OBSTRUCTIVE

see related
AIRWAY OBSTRUCTION

Bronchiectasis: the 'other' obstructive lung disease. Mysliwiec V, et al. **Postgrad Med** 1999 Jul;106(1):123–6, 128–31 (14 ref.)
A GP guide to the COPD guidelines. Pearson M. **Practitioner** 1998 Jan;242(1582):57–60 (2 ref.)
End–of–life ethical issues. Heffner JE. **Respir Care Clin N Am** 1998 Sep;4(3):541–59, x (92 ref.)

BLOOD

Nonconventional indications for LTOT: isolated nocturnal oxygen therapy in chronic lung disease. Fletcher EC. **Monaldi Arch Chest Dis** 1999 Feb;54(1):67–71 (32 ref.)

CHEMICALLY INDUCED

Persistent respiratory effects in survivors of the Bhopal disaster. Beckett WS. **Thorax** 1998 Aug;53 Suppl 2:S43–6 (13 ref.)

COMPLICATIONS

Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. **Chest** 1999 Aug;116(2):521–34 (63 ref.)
Vertebral Aspergillus osteomyelitis and acute diskitis in patients with chronic obstructive pulmonary disease. Martinez M, et al. **Mayo Clin Proc** 1999 Jun;74(6):579–83 (31 ref.)
Dyspnoea in chronic obstructive pulmonary disease. Mahler DA. **Monaldi Arch Chest Dis** 1998 Dec;53(6):669–71 (12 ref.)
Is early noninvasive mechanical ventilation of first choice in stable COPD patients with chronic respiratory failure? Patessio A. **Monaldi Arch Chest Dis** 1999 Feb;54(1):83–6 (48 ref.)
Is early noninvasive mechanical ventilation of first choice in stable restrictive patients with chronic respiratory failure? Raphaël JC, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):90–7 (95 ref.)
Sleep–related disorders and chronic obstructive pulmonary disease. Brown LK. **Respir Care Clin N Am** 1998 Sep; 4(3):493–512 (97 ref.)
Asthma and chronic obstructive airway diseases are associated with osteoporosis and fractures: a literature review. Smith BJ, et al. **Respirology** 1999 Jun;4(2):101–9 (76 ref.)
[Methods of nutritional assessment in chronic obstructive lung diseases] Doré MF, et al. **Rev Pneumol Clin** 1999 Jun; 55(3):155–67 (58 ref.) (Eng. Abstr.) **(Fre)**
[Etiology and physiopathology of diseases responsible for the development of respiratory insufficiency] Suga M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):37–44 (5 ref.) **(Jpn)**
[Respiratory sleep disorders in COPD] Masa Jiménez JF. **Arch Bronconeumol** 1999 May;35 Suppl 3:28–33 (64 ref.) **(Spa)**
[Infection and chronic obstructive pulmonary disease] Zalacain R. **Arch Bronconeumol** 1998 Oct;34(9):453–62 (118 ref.) **(Spa)**

DIAGNOSIS

Chronic obstructive pulmonary disease and '150 years of blowing'. Miller MR. **Hosp Med** 1998 Sep;59(9):719–22 (25 ref.)
Diagnosis and treatment of chronic obstructive pulmonary disease: evidence–based medicine. Siafakas NM, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):704–8 (11 ref.)
Diagnosing and monitoring the clinical course of chronic obstructive pulmonary disease. Phillips YY, et al. **Respir Care Clin N Am** 1998 Sep;4(3):371–89 (71 ref.)
[Functional capacity (dyspnea) and quality of life in patients with chronic obstructive lung disease (COPD): instruments of assessment and methodological aspects] Hütter BO, et al. **Pneumologie** 1999 Mar;53(3):133–42 (81 ref.) (Eng. Abstr.) **(Ger)**
[The role of inflammation mediators in bronchial asthma and chronic obstructive pulmonary disease (editorial)] Chciałowski A, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):1–4 (34 ref.) (Eng. Abstr.) **(Pol)**
[The therapeutic considerations in the "overlap syndrome"] Mihăiţan F, et al. **Pneumoftiziologia** 1998 Jan–Mar; 47(1):41–4 (12 ref.) (Eng. Abstr.) **(Rum)**

DIET THERAPY

Nutritional and metabolic support strategies. Schols AM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):577–81 (32 ref.)

DRUG THERAPY

Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Busse WW, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:110–5 (27 ref.)
Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen–presenting dendritic cell: influence of treatment with fluticasone propionate. Hoogsteden HC, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:116–24 (77 ref.)
Therapeutic activities of theophylline in chronic obstructive pulmonary disease. Peleman RA, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:53–6 (36 ref.)
Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Schmidt D, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:99–109 (109 ref.)
Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol. Costello J. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 2):S61–8 (42 ref.)
Pharmacotherapy of chronic obstructive pulmonary disease. Borron W, et al. **J La State Med Soc** 1998 Dec; 150(12):596–600 (26 ref.)
Tiotropium bromide (Ba 679 BR), a novel long–acting muscarinic antagonist for the treatment of obstructive airways disease. Barnes PJ, et al. **Life Sci** 1995; 56(11–12):853–9 (47 ref.)
Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Disse B, et al. **Life Sci** 1999;64(6–7):457–64 (20 ref.)
Mucoactive drugs in the management of chronic obstructive pulmonary disease. Del Donno M, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):714–9 (50 ref.)
Prevention and medical treatment. Estopà i Miró R. **Monaldi Arch Chest Dis** 1998 Jun;53(3):312–6 (17 ref.)
Pharmacology of chronic obstructive pulmonary disease: antibiotics. Woodhead M. **Monaldi Arch Chest Dis** 1999 Jun;54(3):247–9 (11 ref.)
Can we justify ipratropium therapy as initial management of acute exacerbations of COPD? Demirkan K, et al. **Pharmacotherapy** 1999 Jul;19(7):838–43 (21 ref.)
Strategies for novel COPD therapies. Barnes PJ. **Pulm Pharmacol Ther** 1999;12(2):67–71 (15 ref.)
Open questions on guidelines for treatment of asthma and COPD. Paggiaro PL, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):401–5 (24 ref.)
Are anti–oxidant and anti–inflammatory treatments effective in different subgroups of COPD? A hypothesis. van Schayck CP, et al. **Respir Med** 1998 Nov;92(11):1259–64 (45 ref.)
Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease. Cazzola M, et al. **Thorax** 1999 Aug;54(8):730–6 (85 ref.)
Chronic obstructive pulmonary disease: new opportunities for drug development. Barnes PJ. **Trends Pharmacol Sci** 1998 Oct;19(10):415–23 (78 ref.)
[Inhaler therapy for adults with obstructive lung diseases: powder or aerosol?] Dekhuijzen PN. **Ned Tijdschr Geneeskd** 1998 Jun 13;142(24):1369–74 (15 ref.) (Eng. Abstr.) **(Dut)**
[The place of long–acting beta 2 adrenergic agonists in the treatment of asthma and chronic obstructive lung disease (COPD) (see comments)] van Schayck CP, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):137–40 (30 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Apr 3;143(14):764. **(Dut)**
[Treatment with inhalation corticosteroids: useful or useless in chronic obstructive pulmonary disease (COPD)?] van Schayck CP. **Ned Tijdschr Geneeskd** 1999 Apr 10;

143(15):778–80 (6 ref.) (Eng. Abstr.) **(Dut)**

[Bronchodilator nebulization in bronchial obstructions] Muir JF, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S41–3 (23 ref.) **(Fre)**

[Use of delayed-action beta-2 mimetics in the management of chronic obstructive bronchial diseases--for] Muir JF, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S75–6 (10 ref.) **(Fre)**

[Aerosol therapy] Wildhaber JH. **Schweiz Med Wochenschr** 1998 Aug 15;128(33):1223–8 (44 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of respiratory insufficiency. Drug therapy] Ishihara K. **Nippon Naika Gakkai Zasshi** 1999 Jan 10; 88(1):63–9 (4 ref.) **(Jpn)**

ECONOMICS

[Economic aspects. Cost-effectiveness, cost-benefit analysis] Durieux P. **Rev Mal Respir** 1998 Sep;15 Suppl 2:S37–41 (20 ref.) **(Fre)**

EPIDEMIOLOGY

Dietary influences on chronic obstructive lung disease and asthma: a review of the epidemiological evidence. Smit HA, et al. **Proc Nutr Soc** 1999 May;58(2):309–19 (57 ref.)

Socioeconomic status and chronic obstructive pulmonary disease. Prescott E, et al. **Thorax** 1999 Aug;54(8):737–41 (95 ref.)

Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. van Ede L, et al. **Thorax** 1999 Aug;54(8):688–92 (38 ref.)

[Chronic obstructive pulmonary disease and lung cancer] Radzikowska E. **Pneumonol Alergol Pol** 1998; 66(9–10):480–6 (31 ref.) (Eng. Abstr.) **(Pol)**

[Identification of emergencies for asthma and chronic obstructive pulmonary disease in the emergency rooms of a hospital. A reliability study] Merelles Tormo A, et al. **Gac Sanit** 1999 Jan–Feb;13(1):30–7 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The pathogenesis of chronic obstructive pulmonary disease. Markewitz BA, et al. **Am J Med Sci** 1999 Aug;318(2):74–8 (54 ref.)

The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group. O'byrne PM, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 2):S41–63 (310 ref.)

Role of respiratory infection in onset of asthma and chronic obstructive pulmonary disease. Martinez FD. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:53–8 (42 ref.)

Effect of pneumonia in childhood on adult lung function. Johnston ID. **J Pediatr** 1999 Aug;135(2 Pt 2):33–7 (48 ref.)

Causes and pathophysiology of chronic obstructive pulmonary disease exacerbations. Delafosse C, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):305–11 (40 ref.)

Definitions, causes, course, and prognosis of chronic obstructive pulmonary disease. Petty TL. **Respir Care Clin N Am** 1998 Sep;4(3):345–58, vii (52 ref.)

Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. Koyama H, et al. **Thorax** 1998 Aug;53 Suppl 2:S10–4 (51 ref.)

Update on the "Dutch hypothesis" for chronic respiratory disease. Vestbo J, et al. **Thorax** 1998 Aug;53 Suppl 2:S15–9 (45 ref.)

Effects of air pollution and smoking on chronic obstructive pulmonary disease and bronchial asthma. Sasaki H, et al. **Tohoku J Exp Med** 1998 Nov;186(3):151–67 (73 ref.)

Chronic airway disease: the infection connection. Greenberg SB, et al. **Trans Am Clin Climatol Assoc** 1999;110:38–48; discussion 49–50 (67 ref.)

[Etiology and therapy of obstructive respiratory tract diseases in infancy and early childhood] Frey U. **Schweiz Med Wochenschr** 1998 Sep 12;128(37):1356–65 (34 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysiological and pathomorphological aspects of pulmonology] Uglov FG. **Vestn Ross Akad Med Nauk** 1998;(10):36–8 (2 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Genetics of chronic obstructive pulmonary disease and disseminated bronchiectasis. Luisetti M, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):614–6 (17 ref.)

Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Barnes PJ. **Thorax** 1999 Mar;54(3):245–52 (110 ref.)

Genetics and pulmonary medicine.10: Genetic epidemiology of pulmonary function. Chen Y. **Thorax** 1999 Sep; 54(9):818–24 (69 ref.)

[Progresses in the study of respiratory diseases in China, 1997] Zhang Z. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):885–7 (0 ref.) **(Chi)**

[Alpha 1-antiproteinase deficiency] Ritscher D, et al. **Ther Umsch** 1999 Mar;56(3):142–6 (10 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[The role of inflammation mediators in bronchial asthma and chronic obstructive pulmonary disease (editorial)] Chciałowski A, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):1–4 (34 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Metabolic and nutritional consequences of chronic hypoxia. Leverve X. **Clin Nutr** 1998 Dec;17(6):241–51 (94 ref.)

Energy balance and intermediate metabolism in chronic lung disease. Muers MF, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):564–73 (51 ref.)

Role of transcription factors in inflammatory lung diseases. Rahman I, et al. **Thorax** 1998 Jul;53(7):601–12 (119 ref.)

MORTALITY

Mortality in and prevalence of chronic obstructive pulmonary disease in different parts of Europe. Gulsvik A. **Monaldi Arch Chest Dis** 1999 Apr;54(2):160–2 (18 ref.)

Circumstances of death in chronic obstructive pulmonary disease. Zieliński J. **Monaldi Arch Chest Dis** 1998 Jun; 53(3):324–30 (89 ref.)

PATHOLOGY

Differences and similarities between chronic obstructive pulmonary disease and asthma. Jeffery PK. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:14–26 (104 ref.)

[Current studies on airway inflammation in chronic obstructive pulmonary disease] Fang Q, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Aug; 20(4):244–6 (17 ref.) **(Chi)**

[Pathology of diseases responsible for the development of respiratory insufficiency] Nagai A. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):45–50 (5 ref.) **(Jpn)**

[Pathophysiological and pathomorphological aspects of pulmonology] Uglov FG. **Vestn Ross Akad Med Nauk** 1998;(10):36–8 (2 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Course and prognosis of chronic obstructive pulmonary disease. George RB. **Am J Med Sci** 1999 Aug;318(2):103–6 (23 ref.)

Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 2):S1–40 (577 ref.)

Asthma versus chronic obstructive pulmonary disease--exploring why 'reversibility versus irreversibility' is no longer an appropriate approach. Dow L. **Clin Exp Allergy** 1999 Jun;29(6):739–43 (32 ref.)

Are chronic obstructive pulmonary disease (COPD) and asthma different diseases? Magnussen H, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:187–94; discussion 203–5 (89 ref.)

The Link Between Asthma and COPD. Foreword, summary and conclusions. Postma DS, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:2–7 (1 ref.)

Metabolic and nutritional consequences of chronic hypoxia. Leverve X. **Clin Nutr** 1998 Dec;17(6):241–51 (94 ref.)

Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium [see comments] Hiemstra PS, et al. **Eur Respir J** 1998 Nov;12(5):1200–8 (103 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250–1.

Assessing the effect of deep inhalation on airway calibre: a novel approach to lung function in bronchial asthma and COPD. Pellegrino R, et al. **Eur Respir J** 1998 Nov; 12(5):1219–27 (87 ref.)

Respiratory muscle function in patients with neuromuscular disorders and cardiopulmonary diseases. Syabbalo N. **Int J Clin Pract** 1998 Jul–Aug;52(5):319–29 (129 ref.)

Anabolic therapies in chronic obstructive pulmonary disease. Casaburi R. **Monaldi Arch Chest Dis** 1998 Aug;53(4):454–9 (94 ref.)

Pulmonary rehabilitation and lung volume reduction surgery in the treatment of patients with chronic obstructive pulmonary disease. Celli BR. **Monaldi Arch Chest Dis** 1998 Aug;53(4):471–9 (78 ref.)

Measures of functional status and quality of life in chronic obstructive pulmonary disease. Cullen DL. **Monaldi Arch Chest Dis** 1999 Apr;54(2):183–5 (16 ref.)

Causes and pathophysiology of chronic obstructive pulmonary disease exacerbations. Delafosse C, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):305–11 (40 ref.)

Body composition, skeletal muscle function, and exercise performance in chronic respiratory disease. Fitting JW. **Monaldi Arch Chest Dis** 1998 Oct;53(5):574–6 (20 ref.)

Peripheral skeletal muscles and exercise performance in patients with chronic obstructive pulmonary disease. Gosselink R, et al. **Monaldi Arch Chest Dis** 1998 Aug; 53(4):419–23 (39 ref.)

Pathophysiology of chronic obstructive pulmonary disease. Celli BR. **Respir Care Clin N Am** 1998 Sep;4(3):359–70, vii (39 ref.)

Methods and clinical significance of studying chemical drives. De Backer WA. **Respir Physiol** 1998 Oct; 114(1):75–81 (41 ref.)

A role for natriuretic peptides as well as endothelins in the hypoxic lungs of patients with chronic obstructive pulmonary disease [editorial; comment] Dorrington KL. **Respiration** 1999;66(3):208–9 (12 ref.) Comment on: Respiration 1999 ;66(3):212–9.

Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Fabbri L, et al. **Thorax** 1998 Sep;53(9):803–8 (96 ref.)

Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Palange P. **Thorax** 1998 Nov; 53(11):989–91 (41 ref.)

[The autonomic nervous system] Advenier C. **Rev Mal Respir** 1998 Sep;15 Suppl 2:S11–6 (25 ref.) **(Fre)**

[Clinico-functional correlations] Huchon G. **Rev Mal Respir** 1998 Sep;15 Suppl 2:S33–6 (25 ref.) **(Fre)**

[Bronchial asthma and chronic obstructive lung disease (COPD). Differences and similarities] Ullmer E, et al. **Internist (Berl)** 1999 Aug;40(8):837–43 (26 ref.) **(Ger)**

[Functional capacity (dyspnea) and quality of life in patients with chronic obstructive lung disease (COPD): instruments of assessment and methodological aspects] Hütter BO, et al. **Pneumologie** 1999 Mar;53(3):133–42 (81 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary hyperinflation. The functional and clinico-radiological criteria, mechanisms and surgery to reduce lung volume in severe emphysema] Spânu V, et al. **Pneumoftiziologia** 1998 Jan–Mar;47(1):29–35 (5 ref.) **(Rum)**

[Assessing exertion capacity in COPD. A critical review of walking tests] Montemayor T, et al. **Arch Bronconeumol** 1999 May;35 Suppl 3:34–9 (41 ref.) **(Spa)**

PREVENTION & CONTROL

Prevention and medical treatment. Estopà i Miró R. **Monaldi Arch Chest Dis** 1998 Jun;53(3):312–6 (17 ref.)

Can 'old' lungs be restored? Strategies for preserving lung health and preventing and treating COPD. Petty TL. **Postgrad Med** 1998 Oct;104(4):173–8, 181–2 (20 ref.)

RADIOGRAPHY

Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography. King GG, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):992–1004 (37 ref.)

Imaging the 'dirty lung'--has high resolution computed tomography cleared the smoke? Gückel C, et al. **Clin Radiol** 1998 Oct;53(10):717–22 (43 ref.)

REHABILITATION

Pulmonary rehabilitation for the patient with severe chronic obstructive pulmonary disease. San Pedro GS. **Am J Med Sci** 1999 Aug;318(2):99–102 (15 ref.)

Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Casaburi R. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):407–18 (89 ref.)

Training in the rehabilitation of pulmonary patients with chronic obstructive pulmonary disease. Celli BR. **Monaldi Arch Chest Dis** 1998 Aug;53(4):438–49 (81 ref.)

Overviews of respiratory rehabilitation in chronic obstructive pulmonary disease. Lacasse Y, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):163–7 (33 ref.)

Selection criteria and outcome assessment in pulmonary rehabilitation. ZuWallack RL. **Monaldi Arch Chest Dis** 1998 Aug;53(4):429–37 (35 ref.)

Maximizing functional capacity. Pulmonary rehabilitation and adjunctive measures. Resnikoff PM, et al. **Respir Care Clin N Am** 1998 Sep;4(3):475–92 (91 ref.)

The prediction of benefit from pulmonary rehabilitation: setting, training intensity and the effect of selection by disability. Morgan MD. **Thorax** 1999 Aug;54 Suppl 2:S3–7 (26 ref.)

[Difficult weaning from mechanical ventilation: a graduated approach and teamwork] Van Der Werf TS, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2390–5 (38 ref.) (Eng. Abstr.) **(Dut)**

[Rehabilitation of severely hypoxemic patients with chronic obstructive lung disease] Pison C. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S139–40 (23 ref.) **(Fre)**

[Ambulatory community pneumologic prevention and rehabilitation of chronic obstructive respiratory tract diseases--status, prospects and need for research] Szczepanski R, et al. **Pneumologie** 1998 Aug;52(8):475–82 (83 ref.) **(Ger)**

[Illness specific data collection on quality of life of patients with asthma and chronic obstructive bronchitis] Mühlig S, et al. **Rehabilitation (Stuttg)** 1998 Aug; 37(3):XXV–XXXVIII (140 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Ther Umsch** 1999 Mar;56(3):147–50 (8 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation in COPD] Villiger B. **Ther Umsch** 1999 Mar; 56(3):131–5 (31 ref.) (Eng. Abstr.) **(Ger)**

[Inspiratory muscle training in patients with chronic obstructive pulmonary disease] Lisboa C, et al. **Rev Med Chil** 1998 May;126(5):563–8 (29 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Surgical treatment of chronic obstructive pulmonary disease. Payne DK, et al. **Am J Med Sci** 1999 Aug;318(2):89–95 (53 ref.)

Technical aspects of adult lung transplantation. Meyers BF, et al. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):213–20 (14 ref.)

LUNG DISEASES, OBSTRUCTIVE

Lung transplantation for chronic obstructive pulmonary disease. Waddell TK, et al. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):191–201 (39 ref.)

Lung transplantation for chronic obstructive pulmonary disease: an exercise in quality rather than quantity? Corris PA. **Thorax** 1999 Aug;54 Suppl 2:S24–7 (31 ref.)

Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema. Young J, et al. **Thorax** 1999 Sep; 54(9):779–89 (54 ref.)

[Evaluation of surgical risk in patients with COPD] Stucki A, et al. **Ther Umsch** 1999 Mar;56(3):151–6 (17 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Outpatient management of chronic obstructive pulmonary disease. Owens MW, et al. **Am J Med Sci** 1999 Aug; 318(2):79–83 (37 ref.)

Stable chronic obstructive pulmonary disease. Kerstjens HA. **BMJ** 1999 Aug 21;319(7208):495–500 (41 ref.)

Recent changes: pulmonary medicine. Roche N. **BMJ** 1999 Jan 16;318(7177):171–6 (48 ref.)

Ventilation of patients with asthma and obstructive lung disease. Jain S, et al. **Crit Care Clin** 1998 Oct;14(4):685–705 (85 ref.)

Being more positive about negative ventilation? [editorial; comment] Wysocki M. **Eur Respir J** 1998 Sep;12(3):515–6 (19 ref.) Comment on: Eur Respir J 1998 Sep;12(3):519–25.

Long-term oxygen therapy in COPD patients with moderate hypoxaemia: does it add years to life? [editorial; comment] Zieliński J. **Eur Respir J** 1998 Oct;12(4):756–8 (32 ref.) Comment on: Eur Respir J 1998 Oct;12(4):780–4.

Mechanical ventilation of the patient with severe chronic obstructive pulmonary disease. Gladwin MT, et al. **Intensive Care Med** 1998 Sep;24(9):898–910 (108 ref.)

Therapeutic strategies in weaning failure. Appendini L, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):372–6 (36 ref.)

Compliance as a critical issue in long-term oxygen therapy. Avdeev SN, et al. **Monaldi Arch Chest Dis** 1999 Feb; 54(1):61–6 (56 ref.)

Anabolic therapies in chronic obstructive pulmonary disease. Casaburi R. **Monaldi Arch Chest Dis** 1998 Aug;53(4):454–9 (94 ref.)

Pulmonary rehabilitation and lung volume reduction surgery in the treatment of patients with chronic obstructive pulmonary disease. Celli BR. **Monaldi Arch Chest Dis** 1998 Aug;53(4):471–9 (78 ref.)

If and when to close tracheostomy. Clini E, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):377–80 (31 ref.)

Nonconventional indications of long-term oxygen therapy: oxygen therapy during exercise. Crockett AJ, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):72–4 (28 ref.)

Noninvasive ventilation in acute exacerbations of chronic obstructive pulmonary disease. Elliott MW. **Monaldi Arch Chest Dis** 1998 Jun;53(3):343–7 (22 ref.)

Nonconventional indications for LTOT: isolated nocturnal oxygen therapy in chronic lung disease. Fletcher EC. **Monaldi Arch Chest Dis** 1999 Feb;54(1):67–71 (32 ref.)

Conventional indications for long-term oxygen therapy and mechanical ventilation. Howard P. **Monaldi Arch Chest Dis** 1999 Feb;54(1):55–7 (2 ref.)

Long-term oxygen therapy: advances and perspectives in technical devices. Keller RR. **Monaldi Arch Chest Dis** 1999 Feb;54(1):75–8 (30 ref.)

Weaning from artificial ventilation. Mancebo J. **Monaldi Arch Chest Dis** 1998 Jun;53(3):350–4 (42 ref.)

Controversial indications for long-term respiratory care: long-term oxygen therapy. Petty TL. **Monaldi Arch Chest Dis** 1999 Feb;54(1):58–60 (12 ref.)

Invasive mechanical ventilation in exacerbations of chronic obstructive pulmonary disease. Pingleton SK. **Monaldi Arch Chest Dis** 1998 Jun;53(3):337–42 (44 ref.)

Diagnosis and treatment of chronic obstructive pulmonary disease: evidence-based medicine. Siafakas NM, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):704–8 (11 ref.)

Patient-ventilator interactions. Stroetz RW, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):331–6 (22 ref.)

Long-term ventilatory support. Wedzicha JA. **Monaldi Arch Chest Dis** 1998 Jun;53(3):317–20 (29 ref.)

Noninvasive positive pressure ventilation for chronic obstructive lung diseases. Wedzicha JA. **Monaldi Arch Chest Dis** 1999 Feb;54(1):79–82 (29 ref.)

Indications for long-term oxygen therapy: a reappraisal. Zieliński J. **Monaldi Arch Chest Dis** 1999 Apr;54(2):178–82 (31 ref.)

Can 'old' lungs be restored? Strategies for preserving lung health and preventing and treating COPD. Petty TL. **Postgrad Med** 1998 Oct;104(4)•173–8, 181–2 (20 ref.)

Outpatient management. Donado JR, et al. **Respir Care Clin N Am** 1998 Sep;4(3):391–423 (118 ref.)

Mechanical ventilation of the patient with chronic obstructive pulmonary disease. Hess DR, et al. **Respir Care Clin N Am** 1998 Sep;4(3):439–73 (146 ref.)

Inpatient management of chronic obstructive pulmonary disease. Stoller JK, et al. **Respir Care Clin N Am** 1998 Sep; 4(3):425–38 (25 ref.)

Management of dyspnea in advanced cancer patients [see comments] Ripamonti C. **Support Care Cancer** 1999 Jul; 7(4):233–43 (122 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):215–6.

Home treatment of COPD exacerbations. Postma DS, et al. **Thorax** 1999 Aug;54 Suppl 2:S8–13 (39 ref.)

[Bronchial asthma and chronic obstructive lung disease (COPD). Differences and similarities] Ullmer E, et al. **Internist (Berl)** 1999 Aug;40(8):837–43 (26 ref.) **(Ger)**

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Schweiz Med Wochenschr** 1999 Jul 13; 129(27–28):1013–24 (45 ref.) (Eng. Abstr.) **(Ger)**

[Etiology, diagnosis and therapy of COPD] Ullmer E, et al. **Ther Umsch** 1999 Mar;56(3):125–30 (15 ref.) (Eng. Abstr.) **(Ger)**

[Nutritional care of patients with respiratory insufficiency] Yoneda T, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):94–9 (10 ref.) **(Jpn)**

[What is new in the treatment of COPD? (editorial)] Sobradillo Peña V. **Arch Bronconeumol** 1999 Feb;35(2):57–9 (43 ref.) **(Spa)**

[Chronic obstructive airways disease and perceived health (editorial)] Alonso J, et al. **Med Clin (Barc)** 1998 Nov 7; 111(15):580–2 (58 ref.) **(Spa)**

[Ambulatory management of chronic obstructive pulmonary disease (COPD): a consensus report] Moreno R, et al. **Rev Med Chil** 1999 Feb;127(2):229–34 (1 ref.) (Eng. Abstr.) **(Spa)**

LUNG DISEASES, PARASITIC

Opportunistic thoracic infections. Bacteria, viruses, and protozoa. Talbot EA, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):167–92, ix–x (91 ref.)

Human pulmonary dirofilariasis: review of the literature. Shah MK. **South Med J** 1999 Mar;92(3):276–9 (37 ref.)

[Pulmonary parasitoses. General aspects] L'Her P, et al. **Rev Pneumol Clin** 1998 Dec;54(6):321–8 (36 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary strongyloidiasis] Yamamoto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):442–5 (15 ref.) **(Jpn)**

[Paragonimiasis westermani] Yoshimatsu T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):485–7 (13 ref.) **(Jpn)**

[Paragonimiasis miyazakii] Yoshimatsu T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):488–9 (11 ref.) **(Jpn)**

[Parasites in pneumology] Cremades Romero MJ. **Arch Bronconeumol** 1998 Nov;34(10):500–8 (65 ref.) **(Spa)**

ETIOLOGY

[Pulmonary infections other than AIDS] Perdu D, et al. **Presse Med** 1998 May 23–30;27(19):934–40 (39 ref.) **(Fre)**

PARASITOLOGY

[Pulmonary infections during AIDS] Deslée G, et al. **Presse Med** 1998 May 23–30;27(19):927–33 (40 ref.) **(Fre)**

LUNG FUNCTION TESTS see **RESPIRATORY FUNCTION TESTS**

LUNG INJURY, ACUTE see **RESPIRATORY DISTRESS SYNDROME, ADULT**

LUNG LAVAGE see **BRONCHOALVEOLAR LAVAGE**

LUNG LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

LUNG NEOPLASMS

see related
CARCINOMA, NON-SMALL-CELL LUNG
CARCINOMA, SMALL CELL

NHLBI Workshop Summary. Report of workshop on lymphangioleiomyomatosis.National Heart, Lung, and Blood Institute. **Am J Respir Crit Care Med** 1999 Feb; 159(2):679–83 (30 ref.)

Lymphangioleiomyomatosis: a review. Sullivan EJ. **Chest** 1998 Dec;114(6):1689–703 (124 ref.)

Recent developments in the diagnosis and treatment of lung cancer. Gilligan D. **Int J Clin Pract** 1998 Jul–Aug; 52(5):330–4 (27 ref.)

Current guidelines for the management of small cell lung cancer. Adjei AA, et al. **Mayo Clin Proc** 1999 Aug; 74(8):809–16 (70 ref.)

The Carney Triad: a lesson in observation, creativity, and perseverance [editorial; comment] Appelman HD. **Mayo Clin Proc** 1999 Jun;74(6):638–40 (15 ref.) Comment on: Mayo Clin Proc 1999 Jun;74(6):543–52.

Vitamins and lung cancer. Virtamo J. **Proc Nutr Soc** 1999 May;58(2):329–33 (41 ref.)

Primary pulmonary lymphoma. Habermann TM, et al. **Semin Oncol** 1999 Jun;26(3):307–15 (87 ref.)

Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Johnson S. **Thorax** 1999 Mar;54(3):254–64 (105 ref.)

[New prognostic factors in bronchogenic cancer (see comments)] Navío Martín P, et al. **Rev Clin Esp** 1998 Sep; 198(9):604–9 (47 ref.) Comment in: Rev Clin Esp 1999 Apr;199(4):255. **(Spa)**

BLOOD

[Bibliographic analysis of the use of laboratory blood parameters for the prognosis of primary lung cancer] Watine J, et al. **Ann Biol Clin (Paris)** 1999 Jan–Feb; 57(1):57–68 (123 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory tract diseases and tumor markers] kono N. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):141–7 (12 ref.) **(Jpn)**

BLOOD SUPPLY

Spiral CT angiography of the pulmonary circulation. Remy-Jardin M, et al. **Radiology** 1999 Sep;212(3):615–36 (132 ref.)

CHEMICALLY INDUCED

Maintenance work and asbestos-related cancers in the refinery and petrochemical sector. Finkelstein MM. **Am J Ind Med** 1999 Feb;35(2):201–5 (18 ref.)

Mechanistic model predicts a U-shaped relation of radon exposure to lung cancer risk reflected in combined occupational and US residential data [see comments] Bogen KT. **Hum Exp Toxicol** 1998 Dec;17(12):691–6; discussion 701–4, 708–18 (31 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705–7; discussion 716–8.

Salud ocupacional [letter] Castleman B, et al. **Int J Occup Med Environ Health** 1998;11(2):195–7 (10 ref.)

[Survey of the effects of smoking in an occupational cohort study. Value and limits of a new method] Moulin JJ, et al. **Rev Epidemiol Sante Publique** 1998 Sep;46(4):289–97 (31 ref.) (Eng. Abstr.) **(Fre)**

[Synthetic mineral fibers] Boillat MA. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):468–74 (30 ref.) (Eng. Abstr.) **(Fre)**

[Information on a new occupational disease: "Lung cancer caused by polycyclic aromatic hydrocarbons with evidence of the effect of a cumulative dose of at least 100 benzo(a)pyrene years ([microgram/m3] * years)] Praml G, et al. **Pneumologie** 1998 Dec;52(12):684–6 (20 ref.) **(Ger)**

COMPLICATIONS

Pulmonary capillary haemangiomatosis coexistence with sinus venosus ASD: morphometric analysis and literature review. Slovis BS, et al. **Eur Respir J** 1998 Jul;12(1):240–4 (23 ref.)

An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome. Takamori M. **Intern Med** 1999 Feb;38(2):86–96 (53 ref.)

Fatal tumor lysis syndrome and gastric hemorrhage associated with metastatic small-cell lung carcinoma. Marinella MA. **Med Pediatr Oncol** 1999 Jun;32(6):464–5 (10 ref.)

Stents in the management of malignant airway obstruction. Stöhr S, et al. **Monaldi Arch Chest Dis** 1999 Jun;54(3):264–8 (24 ref.)

[Association of acute pericarditis and acute renal insufficiency: causes and prognosis] Klisnick A, et al. **Presse Med** 1998 Oct 31;27(33):1668–73 (41 ref.) (Eng. Abstr.) **(Fre)**

[The infectious complications of bronchial cancer] Klastersky J. **Rev Mal Respir** 1998 Sep;15(4):451–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Acute respiratory insufficiency in patients with bronchopulmonary cancer] Mayaud C, et al. **Rev Pneumol Clin** 1998 Sep;54(4):171–9 (56 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic Cushing's syndrome and small cell bronchial carcinoma] Mennecier B, et al. **Rev Pneumol Clin** 1999 Apr; 55(2):77–80 (8 ref.) (Eng. Abstr.) **(Fre)**

[The coexistence of pulmonary tuberculosis and lung cancer] Kurasawa T. **Nippon Rinsho** 1998 Dec;56(12):3167–70 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of cachexia in the course of lung cancer] Radzikowska E. **Pneumonol Alergol Pol** 1999;67(1–2):70–5 (25 ref.) **(Pol)**

DIAGNOSIS

Mucinous cystadenoma of the lung. Divisi D, et al. **Acta Biomed Ateneo Parmense** 1997;68(5–6):115–8 (8 ref.)

"Carcinoid tumorlets". Case report and review of the literature. Fabbri N, et al. **Ann Ital Chir** 1998 Jul–Aug; 69(4):509–11 (10 ref.)

Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul–Aug;19(4A):2817–9 (24 ref.)

Diagnosis of primary fibrosarcoma of the lung by fine-needle aspiration and core biopsy. Logrono R, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):731–5 (18 ref.)

Pleuropulmonary blastoma in an adult: an initial case report. Hill DA, et al. **Cancer** 1999 Jun 1;85(11):2368–74 (33 ref.)

Follow-up of patients with completely resected lung cancer [editorial; comment] Downey RJ. **Chest** 1999 Jun; 115(6):1487–8 (9 ref.) Comment on: Chest 1999 Jun;115(6):1494–9.

Role of bronchoscopy in lung cancer research. Baughman RP, et al. **Clin Chest Med** 1999 Mar;20(1):191–9 (97 ref.)

Early diagnosis of lung cancer. Lam S, et al. **Clin Chest Med** 1999 Mar;20(1):53–61, x (110 ref.)

Answers to 5 key questions on lung cancer. Margolis ML, et al. **Compr Ther** 1998 Oct;24(10):503–10 (16 ref.)

Neoplasms of the lung [editorial] Lillington GA.

Curr Opin Pulm Med 1999 Jul;5(4):185–8 (28 ref.)

CA 125 in biological fluids. Molina R, et al. **Int J Biol Markers** 1998 Oct–Dec;13(4):224–30 (29 ref.)

Small cell lung cancer accompanied by lactic acidosis and syndrome of inappropriate secretion of antidiuretic hormone. Fujimura M, et al. **Lung Cancer** 1998 Dec; 22(3):251–4 (15 ref.)

Primary pulmonary melanoma: case report and literature review. Ost D, et al. **Mayo Clin Proc** 1999 Jan;74(1):62–6 (39 ref.)

Consensus statement on prevention and early diagnosis of lung cancer. Varese, Italy, December, 1998. **Oncology (Huntingt)** 1999 Mar;13(3):298 (0 ref.)

Pulmonary fibrosarcoma in childhood: fiber–optic bronchoscopic diagnosis and review of the literature. Picard E, et al. **Pediatr Pulmonol** 1999 May;27(5):347–50 (12 ref.)

Fluorescence bronchoscopy for the early detection of lung cancer. George PJ. **Thorax** 1999 Feb;54(2):180–3 (34 ref.)

Pulmonary lymphangioleiomyomatosis in Korea. Oh YM, et al. **Thorax** 1999 Jul;54(7):618–21 (25 ref.)

[Evaluation of preoperative functional status in patients with lung cancer] Riedel M, et al. **Cas Lek Cesk** 1999 May 10; 138(10):301–9 (78 ref.) (Eng. Abstr.) **(Cze)**

[Endobronchial tuberculosis presenting as an obstructive tumor in an HIV–1–positive patient. Apropos of a case and review of the literature] Saadoun R, et al. **Rev Med Interne** 1998 May;19(5):344–7 (9 ref.) (Eng. Abstr.) **(Fre)**

[Malignant small–cell thoracic pulmonary tumor (Askin tumor)] Kabiri H, et al. **Rev Pneumol Clin** 1999 Mar; 55(1):21–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Early diagnosis of bronchial carcinoma. Technical endoscopic progress––a step toward new screening concepts?] Häussinger K, et al. **Pneumologie** 1999 Feb; 53(2):77–82 (35 ref.) (Eng. Abstr.) **(Ger)**

[The relative importance of humoral tumor markers in the diagnosis and therapy of primary bronchial carcinoma and pulmonary metastasis] Heckmayr M. **Pneumologie** 1999 May;53(5):276–82 (86 ref.) **(Ger)**

[Recurrent spontaneous pneumothorax as the earliest indication of the pulmonary metastasis of a synovial sarcoma?] Bode F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):318–20 (10 ref.) **(Ger)**

[Transbronchial biopsy in diffuse infiltrative lung diseases] Zsiray M, et al. **Orv Hetil** 1999 May 30;140(22):1239–43 (39 ref.) (Eng. Abstr.) **(Hun)**

[Bronchiolo–alveolar carcinoma. The clinico–diagnostic and therapeutic considerations and the results of a retrospective study in our experience] Calabrese L, et al. **Acta Biomed Ateneo Parmense** 1997;68(5–6):87–105 (49 ref.) (Eng. Abstr.) **(Ita)**

[Telomerase and telomeres in lung neoplasms––biological and clinical significance] Kuchta G, et al. **Pneumonol Alergol Pol** 1998;66(11–12):568–73 (25 ref.) **(Pol)**

[Differential diagnosis in pulmonary infiltrates] Saperov VN. **Klin Med (Mosk)** 1999;77(4):46–8 (0 ref.) **(Rus)**

[Pulmonary involvement in IgA multiple myeloma. A case report and review of the literature (letter)] Conesa Bernal C, et al. **Arch Bronconeumol** 1999 Jan;35(1):54–5 (6 ref.) **(Spa)**

[A young oligosymptomatic woman] Poza A, et al. **Rev Clin Esp** 1999 Apr;199(4):251–2 (12 ref.) **(Spa)**

DRUG THERAPY

Chemotherapy for brain metastases of lung cancer: a review. Postmus PE, et al. **Ann Oncol** 1999 Jul;10(7):753–9 (84 ref.)

Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Cersosimo RJ. **Ann Pharmacother** 1998 Dec;32(12):1324–33 (64 ref.)

Role of taxanes in lung–cancer chemotherapy. Schiller JH. **Cancer Invest** 1998;16(7):471–7 (48 ref.)

Gemcitabine: a pharmacologic and clinical overview. Barton–Burke M. **Cancer Nurs** 1999 Apr;22(2):176–83 (46 ref.)

Second–line chemotherapy and its evaluation in small cell lung cancer. Huisman C, et al. **Cancer Treat Rev** 1999 Aug; 25(4):199–206 (42 ref.)

Drug resistance in lung cancer. Nishio K, et al. **Curr Opin Oncol** 1999 Mar;11(2):109–15 (92 ref.)

Combined–modality therapy in the nonsurgical management of unresectable stage III non–small cell lung cancer. Hensing TA, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):194–200 (35 ref.)

Are platinum compounds mandatory in the treatment of metastatic non–small cell lung cancer? Ruckdeschel JC, et al. **Eur J Cancer** 1998 Dec;34(13):1993–9 (74 ref.)

The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Schwartz GN, et al. **Eur J Cancer** 1998 Sep;34(10):1543–8 (39 ref.)

Should maintenance chemotherapy be used to treat small cell lung cancer? Sculier JP, et al. **Eur J Cancer** 1998 Jul; 34(8):1148–55 (38 ref.)

Vitamin D3 derivatives (deltanoids) in the treatment of tumor cell invasion [editorial; comment] Keski–Oja J. **J Lab Clin Med** 1999 Feb;133(2):95–7 (11 ref.) Comment on: J Lab Clin Med 1999 Feb;133(2):120–8.

Gemcitabine: single–agent and combination therapy in non–small cell lung cancer [see comments] Sandler A, et al. **Oncologist** 1999;4(3):241–51 (61 ref.) Comment in: Oncologist 1999;4(3):252–5.

Irinotecan plus cisplatin in patients with advanced non–small–cell lung cancer. Devore R 3rd, et al. **Oncology (Huntingt)** 1998 Aug;12(8 Suppl 6):79–83 (20 ref.)

Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies. Gordon GS, et al. **Oncology (Huntingt)** 1999 Aug;13(8):1075–88; discussion 1088, 1091–4 (83 ref.)

Adjuvant treatment of early stage non–small–cell lung cancer. Wada H. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):102–5 (17 ref.)

Non–surgical therapy for patients with advanced non–small cell lung cancer. Clarke SJ, et al. **Respirology** 1998 Sep; 3(3):175–82 (31 ref.)

Non–surgical treatment of advanced non–small cell lung cancer in Japan. Kunitoh H. **Respirology** 1998 Sep; 3(3):167–74 (46 ref.)

Chemotherapy for advanced (stage IIIB and stage IV) non–small cell lung cancer: the Hong Kong perspective. Lam WK, et al. **Respirology** 1998 Sep;3(3):145–9 (49 ref.)

Non–surgical therapy for the patients with advanced non–small cell lung cancer. Lee CT. **Respirology** 1998 Sep; 3(3):159–66 (55 ref.)

Non–surgical therapy for patients with advanced non–small cell lung cancer. Liao M. **Respirology** 1998 Sep;3(3):151–7 (27 ref.)

Docetaxel (Taxotere) in combination with platinum–based regimens in non–small cell lung cancer: results and future developments. Belani CP. **Semin Oncol** 1999 Jun;26(3 Suppl 10):15–8 (31 ref.)

Incorporation of paclitaxel and carboplatin in combined–modality therapy for locally advanced non–small cell lung cancer. Belani CP. **Semin Oncol** 1999 Feb;26(1 Suppl 2):44–54 (43 ref.)

Review of paclitaxel/carboplatin in advanced non–small cell lung cancer. Bonomi P. **Semin Oncol** 1999 Feb;26(1 Suppl 2):55–9 (27 ref.)

Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non–small cell lung cancer. Bunn PA Jr. **Semin Oncol** 1999 Feb;26(1 Suppl 4):25–30 (26 ref.)

Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non–small cell lung cancer. Choy H, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):36–43 (31 ref.)

Overview of docetaxel (Taxotere) in the treatment of non–small cell lung cancer. Fossella FV. **Semin Oncol** 1999 Jun;26(3 Suppl 11):4–8 (34 ref.)

Emerging role of docetaxel (Taxotere) in advanced non–small cell lung cancer. Gandara DR, et al. **Semin Oncol** 1999 Jun;26(3 Suppl 10):3–7 (27 ref.)

Gemcitabine plus taxane combinations in non–small cell lung cancer. Giaccone G. **Semin Oncol** 1999 Feb;26(1 Suppl 4):19–24 (21 ref.)

The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Hainsworth JD, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):60–6 (21 ref.)

Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non–small cell lung cancer. Langer CJ, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 4):12–8 (24 ref.)

Docetaxel (Taxotere) in non–small cell lung cancer: ongoing studies in Heidelberg and future plans. Manegold C. **Semin Oncol** 1999 Jun;26(3 Suppl 11):23–7 (17 ref.)

Docetaxel (Taxotere) and neoadjuvant chemotherapy for non–small cell lung cancer. Mattson K. **Semin Oncol** 1999 Jun;26(3 Suppl 10):25–8 (27 ref.)

Overview of MTA in the treatment of non–small cell lung cancer. Postmus PE, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 4):31–6 (35 ref.)

Docetaxel (Taxotere) and gemcitabine in combination therapy. Rizvi NA. **Semin Oncol** 1999 Jun;26(3 Suppl 11):19–22 (21 ref.)

New approaches in the adjuvant and neoadjuvant therapy of non–small cell lung cancer, including docetaxel (Taxotere) combinations. Rosell R. **Semin Oncol** 1999 Jun; 26(3 Suppl 11):32–7 (29 ref.)

Future directions in non–small cell lung cancer. Schiller JH. **Semin Oncol** 1999 Apr;26(2 Suppl 7):120–4 (38 ref.)

Carboplatin and paclitaxel in non–small cell lung cancer: the role of amifostine. Selvaggi G, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):51–60 (85 ref.)

Chemotherapy for non–small cell lung cancer: have we reached a new plateau? Shepherd FA. **Semin Oncol** 1999 Feb;26(1 Suppl 4):3–11 (33 ref.)

Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies. van Oosterom AT. **Semin Oncol** 1999 Jun;26(3 Suppl 10):8–11 (20 ref.)

Concurrent paclitaxel–containing regimens and thoracic radiation therapy for limited–disease small cell lung cancer. Ettinger DS. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):148–50 (20 ref.)

[Radiochemotherapy and radiosensitization for locally advanced non–small–cell bronchial cancer] Quoix E, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):590–9 (58 ref.) (Eng. Abstr.) **(Fre)**

[Which chemotherapy for diffuse forms of small–cell cancers?] Pujol JL, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S149–55 (51 ref.) **(Fre)**

[New cytotoxics in the treatment of bronchial cancers] Quantin X, et al. **Rev Mal Respir** 1998 Oct;15(5):597–612 (96 ref.) (Eng. Abstr.) **(Fre)**

[Management of non–small–cell bronchial cancers. Which chemotherapy for a stage IV?] Quoix E. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S122–5 (42 ref.) **(Fre)**

[Medical–economic evaluation of lung cancers. Theoretical approaches and practical applications] Vergnenegre A, et al. **Rev Mal Respir** 1998 Sep;15(4):469–78 (47 ref.) (Eng. Abstr.) **(Fre)**

[Maintenance chemotherapy in the treatment of small cell lung cancer: the advocate's view] Berghmans T, et al. **Rev Pneumol Clin** 1998 Jul;54(3):119–22 (17 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy of small cell bronchogenic carcinoma in a patient on hemodialysis for chronic renal failure. Apropos of a case] Guillou B, et al. **Rev Pneumol Clin** 1998 Sep; 54(4):215–8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Docetaxel (taxotere): current status of clinical development in non–small–cell bronchial carcinoma (NSCLC)] Manegold C. **Med Klin** 1998 Sep 15;93 Suppl 3:16–21 (55 ref.) (Eng. Abstr.) **(Ger)**

[Epoietin alfa in lung cancer] Ardizzoni A, et al. **Tumori** 1998 Nov–Dec;84(6 Suppl 1):S20–6 (35 ref.) (Eng. Abstr.) **(Ita)**

[Short history of the clinical developments in lung cancer treatment] Niitani H. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:110–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Gemcitabine hydrochloride is a new anti–cancer agent which will be available in the patients with non–small cell lung cancer (NSCLC) in Japan] Yokoyama A. **Gan To Kagaku Ryoho** 1999 Jun;26(7):908–15 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Small cell lung cancer associated with nephrotic syndrome: remission after chemotherapy] Tomoda K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jun;36(6):541–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical application of the new action of macrolide preparations to respiratory diseases] Mikasa K, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1533–40 (17 ref.) **(Jpn)**

[Consensus on the treatment of lung cancer] Shimokata K. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):494–7 (13 ref.) **(Jpn)**

[Chemotherapy of advanced non–small cell carcinoma of the lung] Radosavljević D, et al. **Srp Arh Celok Lek** 1999 Mar–Apr;127(3–4):142–8 (30 ref.) **(Scc)**

ECONOMICS

Economic issues in lung cancer: a review. Goodwin PJ, et al. **J Clin Oncol** 1998 Dec;16(12):3900–12 (66 ref.)

[Medical–economic evaluation of lung cancers. Theoretical approaches and practical applications] Vergnenegre A, et al. **Rev Mal Respir** 1998 Sep;15(4):469–78 (47 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation. Jørgensen LG. **Dan Med Bull** 1999 Feb;46(1):1–12 (200 ref.)

Matrix–metalloproteinases in bronchopulmonary carcinomas. Martinella–Catusse C, et al. **Histol Histopathol** 1999 Jul; 14(3):839–43 (27 ref.)

[Enzymatic polymorphisms and pulmonary cancer] Ladero JM, et al. **Med Clin (Barc)** 1998 Oct 17;111(12):465–70 (89 ref.) **(Spa)**

EPIDEMIOLOGY

Lung carcinoma in patients age younger than 30 years. Mizushima Y, et al. **Cancer** 1999 Apr 15;85(8):1730–3 (18 ref.)

Asbestosis: a marker for the increased risk of lung cancer among workers exposed to asbestos [see comments] [published erratum appears in Chest 1999 May;115(5):1485] Weiss W. **Chest** 1999 Feb;115(2):536–49 (79 ref.) Comment in: Chest 1999 Feb;115(2):320–2.

Environmental tobacco smoke and lung cancer incidence. Leonard CT, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):189–93 (24 ref.)

Asbestos and cancer: An overview of current trends in Europe. Albin M, et al. **Environ Health Perspect** 1999 May; 107 Suppl 2:289–98 (73 ref.)

Epidemiology and prevention of lung cancer in nonsmokers. Brownson RC, et al. **Epidemiol Rev** 1998;20(2):218–36 (165 ref.)

Global perspective of tobacco habits and lung cancer: a lesson for third world countries. Pandey M, et al. **Eur J Cancer Prev** 1999 Aug;8(4):271–9 (58 ref.)

Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer. Bennett WP, et al. **J Pathol** 1999 Jan;187(1):8–18 (126 ref.)

Risk of developing lung cancer in relation to exposure to fumes from Chinese–style cooking. Zhong L, et al. **Scand J Work Environ Health** 1999 Aug;25(4):309–16 (35 ref.)

[Exploration of etiology of lung cancer and good epidemiological practices] Du YS, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec; 18(6):367–71 (16 ref.) **(Chi)**

[Some unsolved problems in epidemiological study of risk factors of female lung cancer in China] Koo LC. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec;

18(6):372–4 (0 ref.) **(Chi)**

[The task and the methods of exploration of the etiology of lung cancer in female: from the view point of the changing of disease pattern in recent years] Xu ZY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec; 18(6):377–8 (7 ref.) **(Chi)**

[Study on the individual sensitivity to some tumors and their related biological markers in residents in Guangdong Province] Zhang Q, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec; 18(6):379–80 (7 ref.) **(Chi)**

[Biology of bronchial cancer. Molecular epidemiology] Urban T. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S13–4 (10 ref.) **(Fre)**

[Chronic obstructive pulmonary disease and lung cancer] Radzikowska E. **Pneumonol Alergol Pol** 1998; 66(9–10):480–6 (31 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Consensus on synergism between cigarette smoke and other environmental carcinogens in the causation of lung cancer. Reif AE, et al. **Adv Cancer Res** 1999;76:161–86 (147 ref.)

Influence of characteristics of inhaled fibres on development of tumours in the rat lung. Miller BG, et al. **Ann Occup Hyg** 1999 Apr;43(3):167–79 (39 ref.)

Asbestos and cancer: An overview of current trends in Europe. Albin M, et al. **Environ Health Perspect** 1999 May; 107 Suppl 2:289–98 (73 ref.)

The hazards of chrysotile asbestos: a critical review. Landrigan PJ, et al. **Ind Health** 1999 Jul;37(3):271–80 (21 ref.)

Tobacco smoke carcinogens and lung cancer. Hecht SS. **J Natl Cancer Inst** 1999 Jul 21;91(14):1194–210 (249 ref.)

[Cancer in patients infected with the human immunodeficiency virus. The unusual aspects] Peyrade F, et al. **Presse Med** 1999 Apr 17;28(15):809–14 (39 ref.) (Eng. Abstr.) **(Fre)**

[Asbestos exposure and pleuropulmonary cancer] Begin R. **Rev Mal Respir** 1998 Dec;15(6):723–30 (41 ref.) (Eng. Abstr.) **(Fre)**

[Asbestos-related diseases] Paris C, et al. **Rev Prat** 1998 Jun 15;48(12):1292–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Lung diseases in HIV-infected children] Nadal D. **Schweiz Med Wochenschr** 1998 Sep 12;128(37):1375–84 (74 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Walch AK, et al. **Am J Pathol** 1998 Oct;153(4):1089–98 (54 ref.)

Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung. Schreiber G, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):1109–15 (43 ref.)

Clinical implications of molecular abnormalities in lung cancer. Dziadziuszko R, et al. **Cancer Treat Rev** 1998 Oct; 24(5):317–30 (154 ref.)

How many tumor suppressor genes are involved in human lung carcinogenesis? Kohno T, et al. **Carcinogenesis** 1999 Aug;20(8):1403–10 (123 ref.)

Hot spots for molecular genetic alterations in lung cancer. Pitterle DM, et al. **In Vivo** 1998 Nov–Dec;12(6):643–58 (119 ref.)

Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer. Bennett WP, et al. **J Pathol** 1999 Jan;187(1):8–18 (126 ref.)

Molecular genetic characteristics of lung cancer--useful as real' tumor markers? Fleischhacker M, et al. **Lung Cancer** 1999 Jul;25(1):7–24 (117 ref.)

p53 mutations, benzo[a]pyrene and lung cancer [see comments] Krawczak M, et al. **Mutagenesis** 1998 Jul; 13(4):319–20 (7 ref.) Comment in: Mutagenesis 1998 Nov;13(6):537–8.

Modeling human lung cancer in mice: similarities and shortcomings. Tuveson DA, et al. **Oncogene** 1999 Sep 20; 18(38):5318–24 (109 ref.)

Clinical significance of p53 in non-small-cell lung cancer. Komiya T, et al. **Oncol Rep** 1999 Jan–Feb;6(1):19–28 (119 ref.)

p53 and lung cancer. Brambilla E, et al. **Pathol Biol (Paris)** 1997 Dec;45(10):852–63 (115 ref.)

Genetic dissection of murine susceptibilities to liver and lung tumors based on the two-stage concept of carcinogenesis. Lee GH. **Pathol Int** 1998 Dec;48(12):925–33 (60 ref.)

Inheritance of pulmonary adenoma susceptibility in mice. Malkinson AM. **Prog Exp Tumor Res** 1999;35:78–94 (95 ref.)

Is there a genetic basis for lung cancer susceptibility? Amos CI, et al. **Recent Results Cancer Res** 1999;151:3–12 (40 ref.)

Genetic mapping of cancer susceptibility/resistance loci in the mouse. Manenti G, et al. **Recent Results Cancer Res** 1998;154:292–7 (29 ref.)

Multi-step evolution of lung cancer. Braithwaite KL, et al. **Semin Cancer Biol** 1999 Aug;9(4):255–65 (80 ref.)

Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer. Roland M, et al. **Thorax** 1998 Nov;53(11):979–83 (52 ref.)

Tumor suppressor genes in rodent lung carcinogenesis-mutation of p53 does not appear to be an early lesion in lung tumor pathogenesis. Miller MS. **Toxicol Appl Pharmacol** 1999 Apr 1;156(1):70–7 (104 ref.)

A child with a t(11;19)(q14–21;p12) in a pulmonary mucoepidermoid carcinoma. Stenman G, et al. **Virchows Arch** 1998 Dec;433(6):579–81 (13 ref.)

[Progresses in the study of respiratory diseases in China, 1997] Zhang Z. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):885–7 (0 ref.) **(Chi)**

[Cell cycle, tumor suppressor genes and lung cancers] Bréchot JM. **Rev Mal Respir** 1998 Sep;15(4):461–6 (43 ref.) (Eng. Abstr.) **(Fre)**

[Biology of bronchial cancer. Molecular epidemiology] Urban T. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S13–4 (10 ref.) **(Fre)**

[From dysplasia to cancer: cytologic, histopathologic and molecular aspects] Vignaud JM. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S107–11 (18 ref.) **(Fre)**

[Role of metabolic polymorphisms in lung carcinogenesis] Kiyohara C, et al. **Nippon Koshu Eisei Zasshi** 1999 Apr; 46(4):241–9 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Telomerase and telomeres in lung neoplasms--biological and clinical significance] Kuchta G, et al. **Pneumonol Alergol Pol** 1998;66(11–12):568–73 (25 ref.) **(Pol)**

[Enzymatic polymorphisms and pulmonary cancer] Ladero JM, et al. **Med Clin (Barc)** 1998 Oct 17;111(12):465–70 (89 ref.) **(Spa)**

IMMUNOLOGY

Pulmonary malignancies in the immunocompromised patient. Cadranel J, et al. **Respiration** 1999;66(4):289–309 (231 ref.)

METABOLISM

Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Rozengurt E. **Curr Opin Oncol** 1999 Mar;11(2):116–22 (80 ref.)

Glucose transporter expression in developing fetal lungs and lung neoplasms. Ito T, et al. **Histol Histopathol** 1999 Jul; 14(3):895–904 (67 ref.)

The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Cox G, et al. **Thorax** 1999 Feb; 54(2):169–79 (208 ref.)

MORTALITY

Cohen's paradox [letter] Field RW, et al. **Health Phys** 1999 Sep;77(3):328–9 (21 ref.)

Pleuropulmonary blastoma: long-term survival and literature review. Romeo C, et al. **Med Pediatr Oncol** 1999 Oct; 33(4):372–6 (34 ref.)

Linear extrapolation models of lung cancer risk associated with exposure to environmental tobacco smoke. Rosenbaum WL, et al. **Regul Toxicol Pharmacol** 1998 Oct; 28(2):106–14 (30 ref.)

NURSING

Pulmonary metastasis. Smith EL. **Semin Oncol Nurs** 1998 Aug;14(3):178–86 (75 ref.)

PATHOLOGY

Role of video-assisted thoracic surgery (VATS) in staging, diagnosis and treatment of lung cancer. Van Schil P. **Acta Chir Belg** 1999 May–Jun;99(3):103–8 (39 ref.)

Precursors to pulmonary neoplasia. Colby TV, et al. **Adv Anat Pathol** 1998 Jul;5(4):205–15 (72 ref.)

Micronodular pneumocyte hyperplasia: the versatile type 2 pneumocyte all dressed up in yet another brand new suit! Myers JL. **Adv Anat Pathol** 1999 Jan;6(1):49–55 (38 ref.)

Lung carcinoma presenting as metastasis to intracranial meningioma: case report and review of the literature. Bhargava P, et al. **Am J Clin Oncol** 1999 Apr;22(2):199–202 (29 ref.)

Pulmonary atypical adenomatous hyperplasia. A histologic lesion in search of usable criteria and clinical significance [editorial; comment] Ritter JH. **Am J Clin Pathol** 1999 May; 111(5):587–9 (15 ref.) Comment on: Am J Clin Pathol 1999 May;111(5):610–22.

Pulmonary plasmacytomas: a clinicopathologic and immunohistochemical study of five cases. Koss MN, et al. **Ann Diagn Pathol** 1998 Feb;2(1):1–11 (37 ref.)

Multiple chondromatous hamartomas of the lung: a case report and review of the literature with special reference to Carney syndrome. Kiryu T, et al. **Cancer** 1999 Jun 15; 85(12):2557–61 (30 ref.)

The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Leong SS, et al. **Chest** 1999 Jan;115(1):242–8 (36 ref.)

Acinic cell carcinoma of the lung with metastasis to lymph nodes. Ukoha OO, et al. **Chest** 1999 Feb;115(2):591–5 (19 ref.)

The surgical treatment of lung metastases: an update. Robert JH, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):91–6 (52 ref.)

Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Kitaichi M, et al. **Eur Respir J** 1998 Jul;12(1):89–96 (33 ref.)

Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging. Cote RJ, et al. **J Surg Oncol** 1998 Dec;69(4):265–74 (54 ref.)

Metastasis to the appendix: sonographic appearance and review of the literature. Wolf C, et al. **J Ultrasound Med** 1999 Jan;18(1):23–5 (14 ref.)

Carcinoma en cuirasse of the scrotum: an unusual presentation of lung carcinoma metastatic to the scrotum. Ferguson MA, et al. **J Urol** 1998 Dec;160(6 Pt 1):2154–5 (3 ref.)

Myoepithelioma of the lung: report of two cases and review of the literature. Higashiyama M, et al. **Lung Cancer** 1998 Apr;20(1):47–56 (16 ref.)

Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment. Hiraki A, et al. **Oncol Rep** 1999 Jan–Feb; 6(1):75–80 (13 ref.)

A tumorous type of pulmonary rhabdomyomatous dysplasia [see comments] Ramaswamy A, et al. **Pathol Res Pract** 1998;194(9):639–42 (15 ref.) Comment in: Pathol Res Pract 1999;195(3):199–200.

Multi-step evolution of lung cancer. Braithwaite KL, et al. **Semin Cancer Biol** 1999 Aug;9(4):255–65 (80 ref.)

Syndrome of inappropriate secretion of antidiuretic hormone in malignancy. Keenan AM. **Semin Oncol Nurs** 1999 Aug; 15(3):160–7 (27 ref.)

Staging and surgery for non-small cell lung cancer (NSCLC). Alpard SK, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):25–43 (103 ref.)

The new lung cancer staging system: what does it mean? Burnett RJ, et al. **Surg Oncol Clin N Am** 1999 Apr; 8(2):231–44 (24 ref.)

Surgical strategies for metastatic lung cancer. Olak J. **Surg Oncol Clin N Am** 1999 Apr;8(2):245–57 (64 ref.)

Strategy and cost in investigating solitary pulmonary nodules. Gould MK, et al. **Thorax** 1998 Aug;53 Suppl 2:S32–7 (26 ref.)

[Value and limits of surgery in stage IIIB non-small-cell bronchial cancers] Grunenwald D. **Cancer Radiother** 1998 Sep–Oct;2(5):568–73 (30 ref.) (Eng. Abstr.) **(Fre)**

[From dysplasia to cancer: cytologic, histopathologic and molecular aspects] Vignaud JM. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S107–11 (18 ref.) **(Fre)**

[Staging of bronchial carcinoma] Wunderbaldinger P, et al. **Radiologe** 1999 Jul;39(7):525–37 (39 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node dissection during surgery for lung cancer. Solely staging or therapy?] Hoffmann H, et al. **Zentralbl Chir** 1999;124(2):115–9 (25 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Clinical implications of molecular abnormalities in lung cancer. Dziadziuszko R, et al. **Cancer Treat Rev** 1998 Oct; 24(5):317–30 (154 ref.)

Physiologic consequences of pneumonectomy. Long-term consequences of pneumonectomy done in children. Lezama-del Valle Valle P, et al. **Chest Surg Clin N Am** 1999 May;9(2):485–95, xiii (36 ref.)

[Assessment of functional surgical treatment of patients with bronchial carcinoma] Schulz C, et al. **Pneumologie** 1999 Jul;53(7):337–47 (78 ref.) **(Ger)**

PREVENTION & CONTROL

Beta-carotene and lung cancer: a case study. Albanes D. **Am J Clin Nutr** 1999 Jun;69(6):1345S–1350S (37 ref.)

Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Ki Hong W, et al. **Clin Cancer Res** 1995 Jul;1(7):677–86 (64 ref.)

Epidemiology and prevention of lung cancer in nonsmokers. Brownson RC, et al. **Epidemiol Rev** 1998;20(2):218–36 (165 ref.)

Prevention of lung cancer by long-term use of alternative nicotine delivery systems? Kunze U, et al. **Eur J Cancer** 1999 Feb;35(2):195–6 (19 ref.)

Retinoids in chemoprevention. Whelan P. **Eur Urol** 1999; 35(5–6):424–8 (47 ref.)

Preclinical and clinical models of lung cancer chemoprevention. You M, et al. **Hematol Oncol Clin North Am** 1998 Oct;12(5):1037–53 (107 ref.)

Dietary carotenoids and lung cancer: a review of recent research. Cooper DA, et al. **Nutr Rev** 1999 May;57(5 Pt 1):133–45 (114 ref.)

Consensus statement on prevention and early diagnosis of lung cancer. Varese, Italy, December, 1998. **Oncology (Huntingt)** 1999 Mar;13(3):298 (0 ref.)

The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Chung FL. **Proc Soc Exp Biol Med** 1999 Apr;220(4):244–8 (28 ref.)

Chemoprevention of head and neck and lung (pre)cancer. de Vries N, et al. **Recent Results Cancer Res** 1999;151:13–25 (47 ref.)

Lung cancer screening and the surgical oncologist: the controversy. Strauss GM, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):371–87 (43 ref.)

RADIOGRAPHY

Approach to the diagnosis of pulmonary disease in patients infected with the human immunodeficiency virus. Haramati LB, et al. **J Thorac Imaging** 1998 Oct;13(4):247–60 (70 ref.)

Two cases of intrapulmonary lymph node presenting as a peripheral nodular shadow: diagnostic differentiation from lung cancer. Fujimoto N, et al. **Lung Cancer** 1998 Jun; 20(3):203–9 (35 ref.)

CT bronchoscopy. Hopper KD.
Semin Ultrasound CT MR 1999 Feb;20(1):10–5 (22 ref.)
[Computed tomography in metastatic lung lesions (a review of the literature and the author's own data). I. Pathogenesis and the CT semeiotics] Tiurin IE.
Vestn Rentgenol Radiol 1998 Mar–Apr;(2):38–44 (28 ref.) **(Rus)**
[Computed tomography in metastatic lung lesions (a review of the literature and the author's own data). II. Detection and differential diagnosis] Tiurin IE.
Vestn Rentgenol Radiol 1998 Mar–Apr;(2):45–50 (25 ref.) **(Rus)**
[Pulmonary nodules in a patient with von Recklinghausen's disease] Díaz Pollán B, et al. **Rev Clin Esp** 1999 Jul; 199(7):465–6 (9 ref.) **(Spa)**
[A 47–year–old man with epigastric discomfort] San Román Montero JM, et al. **Rev Clin Esp** 1998 Nov;198(11):771–2 (6 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Usefulness of positron emission tomography imaging in the management of lung cancer. Sarinas PS, et al.
Curr Opin Pulm Med 1999 Jul;5(4):201–7 (58 ref.)
Nuclear medicine procedures in lung cancer. Chiti A, et al.
Eur J Nucl Med 1999 May;26(5):533–55 (194 ref.)
PET in lung cancer. Coleman RE. **J Nucl Med** 1999 May; 40(5):814–20 (65 ref.)
Applications of PET in lung cancer. Al–Sugair A, et al.
Semin Nucl Med 1998 Oct;28(4):303–19 (63 ref.)
Current role of positron emission tomography in thoracic oncology. Lowe VJ, et al. **Thorax** 1998 Aug;53(8):703–12 (76 ref.)
[Diagnostic techniques for bronchial cancer. New scintigraphic techniques (immunoscintigraphy and positron–emission tomography)] Vaylet F, et al.
Rev Mal Respir 1999 Jan;16 Suppl 3:S78–82 (24 ref.) **(Fre)**
[Fluorodeoxyglucose and bronchopulmonary cancer. Initial French results with positron emission tomography] Vaylet F, et al. **Rev Pneumol Clin** 1998 Sep;54(4):187–95 (43 ref.) (Eng. Abstr.) **(Fre)**
[Progress of nuclear oncology] Endo K.
Gan To Kagaku Ryoho 1999 Aug;26(9):1261–8 (3 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

What is the role of radiation therapy in locally advanced non–small–cell lung cancer? [editorial; comment] Livingston RB. **Ann Oncol** 1999 Mar;10(3):259–60 (10 ref.) Comment on: Ann Oncol 1999 Mar;10(3):295–303.
Chylothorax from radiation–induced mediastinal fibrosis [letter] Lee YC, et al. **Aust N Z J Med** 1998 Oct;28(5):667–8 (7 ref.)
Target volume definition for three–dimensional conformal radiation therapy of lung cancer. Armstrong JG.
Br J Radiol 1998 Jun;71(846):587–94 (24 ref.)
Combined–modality therapy in the nonsurgical management of unresectable stage III non–small cell lung cancer. Hensing TA, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):194–200 (35 ref.)
Brachytherapy in the treatment of thoracic tumors. Lung and esophageal. Speiser BL.
Hematol Oncol Clin North Am 1999 Jun;13(3):609–34 (68 ref.)
Contemporary brachytherapy approaches in non–small–cell lung cancer. Hilaris BS, et al. **J Surg Oncol** 1998 Dec; 69(4):258–64 (25 ref.)
Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies. Gordon GS, et al. **Oncology (Huntingt)** 1999 Aug;13(8):1075–88; discussion 1088, 1091–4 (83 ref.)
Radiotherapy, local control and survival in lung cancer. Trodella L, et al. **Rays** 1998 Jul–Sep;23(3):572–9 (35 ref.) **(Eng, Ita)**
Non–surgical therapy for patients with advanced non–small cell lung cancer. Clarke SJ, et al. **Respirology** 1998 Sep; 3(3):175–82 (31 ref.)
Non–surgical therapy for the patients with advanced non–small cell lung cancer. Lee CT. **Respirology** 1998 Sep; 3(3):159–66 (55 ref.)
Non–surgical therapy for patients with advanced non–small cell lung cancer. Liao M. **Respirology** 1998 Sep;3(3):151–7 (27 ref.)
Future directions in non–small cell lung cancer. Schiller JH.
Semin Oncol 1999 Apr;26(2 Suppl 7):120–4 (38 ref.)
Concurrent paclitaxel–containing regimens and thoracic radiation therapy for limited–disease small cell lung cancer. Ettinger DS. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):148–50 (20 ref.)
Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. King TC, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):4–11 (58 ref.)
[Guideline 'Radiotherapy in non–small–cell lung carcinoma. Working Group, National Organization for Quality Assurance in Hospitals, Netherlands (see comments)] Festen J. **Ned Tijdschr Geneeskd** 1998 Oct 10; 142(41):2248–51 (32 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Dec 19;142(15):2809–10. **(Dut)**
[Radiotherapy for non–small–cell bronchial cancers: definitions of volumes, patient selection. Recommendations of the International Association for the Study of Lung Cancer (IASLC)] Mornex F, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):579–89 (33 ref.) (Eng. Abstr.) **(Fre)**
[Radiochemotherapy and radiosensitization for locally advanced non–small–cell bronchial cancer] Quoix E, et al.
Cancer Radiother 1998 Sep–Oct;2(5):590–9 (58 ref.) (Eng. Abstr.) **(Fre)**
[Which fractionation and radiation dose for non–small–cell bronchial cancers?] Van Houtte P, et al.
Cancer Radiother 1998 Sep–Oct;2(5):574–8 (25 ref.) (Eng. Abstr.) **(Fre)**
[Current approaches to the use of radiotherapy in patients with non–small–cell lung cancer] Goldobenko GV, et al.
Vopr Onkol 1998;44(5):623–8 (18 ref.) **(Rus)**

SECONDARY

Primary meningeal malignant fibrous histiocytoma with cerebrospinal dissemination and pulmonary metastasis. Akimoto J, et al. **Acta Neurochir (Wien)** 1998; 140(11):1191–6 (20 ref.)
Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung. Schreiber G, et al.
Anticancer Res 1999 Mar–Apr;19(2A):1109–15 (43 ref.)
Extracranial metastatic meningioma. Figueroa BE, et al.
Br J Radiol 1999 May;72(857):513–6 (48 ref.)
Pulmonary cysts as the sole metastatic manifestation of soft tissue sarcoma: case report and consideration of the pathogenesis. Hasegawa S, et al. **Chest** 1999 Jul; 116(1):263–5 (12 ref.)
Thoracic involvement with pheochromocytoma: a review. Sandur S, et al. **Chest** 1999 Feb;115(2):511–21 (93 ref.)
Metastatic basal cell carcinoma to the lung. Berti JJ, et al.
Cutis 1999 Mar;63(3):165–6 (12 ref.)
Pilomatrix carcinoma with multiple metastases: report of a case and review of the literature. Bremnes RM, et al.
Eur J Cancer 1999 Mar;35(3):433–7 (44 ref.)
Metastatic trophoblastic disease following partial hydatidiform mole: case report and literature review. Menczer J, et al. **Gynecol Oncol** 1999 Aug;74(2):304–7 (17 ref.)
Tagged tumor cells reveal regulatory steps during earliest stages of tumor progression and micrometastasis. Culp LA, et al. **Histol Histopathol** 1999 Jul;14(3):879–86 (31 ref.)
Pulmonary metastasis of ameloblastoma: case report and review of the literature. Henderson JM, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Aug;88(2):170–6 (19 ref.)
Extraneural metastasizing ependymoma of the spinal cord. Graf M, et al. **Pathol Oncol Res** 1999;5(1):56–60 (36 ref.)
Wilms' tumor in the adult––report of a case and review of the literature. Tawil A, et al. **Pathol Res Pract** 1999; 195(2):105–11; discussion 113–4 (29 ref.)
Primary intraosseous malignant peripheral nerve sheath tumor: a case report and review of the literature. Khan RJ, et al. **Pathology** 1998 Aug;30(3):237–41 (72 ref.)
Pulmonary metastasis. Smith EL. **Semin Oncol Nurs** 1998 Aug;14(3):178–86 (75 ref.)
Isolated lung perfusion for the treatment of pulmonary metastases. Hendriks JM, et al. **Surg Oncol** 1998 Jul–Aug; 7(1–2):59–63 (33 ref.)
Surgical treatment of pulmonary metastases. Downey RJ. **Surg Oncol Clin N Am** 1999 Apr;8(2):341 (72 ref.)
Multiple pulmonary metastasis of prostatic carcinoma with little or no bone or lymph node metastasis. Report of two cases and review of the literature. Kume H, et al.
Urol Int 1999;62(1):44–7 (9 ref.)
[Surgical treatment of pulmonary metastasis of colorectal cancer. Prognostic survival factors] Baron O, et al.
Presse Med 1998 May 16;27(18):885–8 (38 ref.) (Eng. Abstr.) **(Fre)**
[The relative importance of humoral tumor markers in the diagnosis and therapy of primary bronchial carcinoma and pulmonary metastasis] Heckmayr M. **Pneumologie** 1999 May;53(5):276–82 (86 ref.) **(Ger)**
[Recurrent spontaneous pneumothorax as the earliest indication of the pulmonary metastasis of a synovial sarcoma?] Bode F, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1998 Sep;169(3):318–20 (10 ref.) **(Ger)**
[Surgical procedure in primary and metastatic breast carcinoma] Hampl M, et al. **Zentralbl Chir** 1998;123 Suppl 5:81–6 (37 ref.) (Eng. Abstr.) **(Ger)**
[The surgery of lung metastases of melanoma] Morone G, et al. **Ann Ital Chir** 1998 Jul–Aug;69(4):461–4 (32 ref.) (Eng. Abstr.) **(Ita)**
[Multiple lungs tumors found 17 years after hysterectomy––a case of benign metastasizing leiomyoma] Mikami I, et al.
Jpn J Thorac Cardiovasc Surg 1998 Jul;46(7):634–8 (27 ref.) (Eng. Abstr.) **(Jpn)**
[A case of surgical resection of metastatic multiple lung pheochromocytoma with long–term survival] Kido T, et al. **Kyobu Geka** 1999 Jun;52(6):458–62 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Mediastinal and hilar lymph node of cancer unknown origin: 3 case reports] Sakuraba M, et al.
Nihon Kokyuki Gakkai Zasshi 1999 Jan;37(1):72–7 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical management of pulmonary metastases] Hara S, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):855–60 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical treatment of pulmonary metastases from digestive organs and management of malignant pleural effusions] Ogawa J. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):216–9 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Case of malignant ameloblastoma of multiple lung metastasis following surgical removal of the primary site 13 years earlier] Tada K, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1376–8 (7 ref.) **(Jpn)**
[Computed tomography in metastatic lung lesions (a review of the literature and the author's own data). II. Detection and differential diagnosis] Tiurin IE.
Vestn Rentgenol Radiol 1998 Mar–Apr;(2):45–50 (25 ref.) **(Rus)**
[Computed tomography in metastatic lung lesions (a review of the literature and the author's own data). I. Pathogenesis and the CT semeiotics] Tiurin IE.
Vestn Rentgenol Radiol 1998 Mar–Apr;(2):38–44 (28 ref.) **(Rus)**

SURGERY

Role of video–assisted thoracic surgery (VATS) in staging, diagnosis and treatment of lung cancer. Van Schil P.
Acta Chir Belg 1999 May–Jun;99(3):103–8 (39 ref.)
Surgery in limited stage small cell lung cancer. Lassen U, et al. **Cancer Treat Rev** 1999 Apr;25(2):67–72 (57 ref.)
Indications for pneumonectomy. Pneumonectomy for malignant disease. James TW, et al.
Chest Surg Clin N Am 1999 May;9(2):291–309, ix (61 ref.)
The surgical treatment of lung metastases: an update. Robert JH, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):91–6 (52 ref.)
Staging and surgery for non–small cell lung cancer (NSCLC). Alpard SK, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):25–43 (103 ref.)
Surgical treatment of pulmonary metastases. Downey RJ.
Surg Oncol Clin N Am 1999 Apr;8(2):341 (72 ref.)
Surgical strategies for metastatic lung cancer. Olak J.
Surg Oncol Clin N Am 1999 Apr;8(2):245–57 (64 ref.)
[Supraventricular arrhythmia after pneumonectomy. Apropos of 100 cases and review of the literature] Douchet MP, et al. **Ann Cardiol Angeiol (Paris)** 1998 May; 47(5):323–7 (30 ref.) (Eng. Abstr.) **(Fre)**
[Value and limits of surgery in stage IIIB non–small–cell bronchial cancers] Grunenwald D. **Cancer Radiother** 1998 Sep–Oct;2(5):568–73 (30 ref.) (Eng. Abstr.) **(Fre)**
[Bronchial cancer. Consensual attitudes, twilight zones and practical difficulties. International Association for Study on Lung Cancer] Depierre A. **Presse Med** 1999 Jan 16; 28(2):79–81 (8 ref.) **(Fre)**
[Extended surgery of lung cancer] Grunenwald D.
Rev Mal Respir 1999 Jan;16 Suppl 3:S174–5 (16 ref.) **(Fre)**
[Risk assessment of patients before lung surgery] Schulz C, et al. **Chirurg** 1999 Jun;70(6):664–73 (64 ref.) (Eng. Abstr.) **(Ger)**
[Assessment of functional surgical treatment of patients with bronchial carcinoma] Schulz C, et al. **Pneumologie** 1999 Jul;53(7):337–47 (78 ref.) **(Ger)**
[Lymph node dissection during surgery for lung cancer. Solely staging or therapy?] Hoffmann H, et al.
Zentralbl Chir 1999;124(2):115–9 (25 ref.) (Eng. Abstr.) **(Ger)**
[VATS (video–assisted thoracoscopic surgery): possibilities and limits of surgical therapy of malignant lung diseases] Stoelben E, et al. **Zentralbl Chir** 1998;123(10):1129–33 (36 ref.) (Eng. Abstr.) **(Ger)**
[The surgery of lung metastases of melanoma] Morone G, et al. **Ann Ital Chir** 1998 Jul–Aug;69(4):461–4 (32 ref.) (Eng. Abstr.) **(Ita)**
[A case of surgical resection of metastatic multiple lung pheochromocytoma with long–term survival] Kido T, et al. **Kyobu Geka** 1999 Jun;52(6):458–62 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Results of surgical treatment of T3 lung carcinoma according to the combined resection of involved organs] Shirakusa T, et al. **Kyobu Geka** 1998 Oct;51(11):949–53 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical management of pulmonary metastases] Hara S, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):855–60 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical treatment of pulmonary metastases from digestive organs and management of malignant pleural effusions] Ogawa J. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):216–9 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Classification of surgical procedures in lung cancer] Bisenkov LN, et al. **Khirurgiia (Mosk)** 1999;(4):47–9 (5 ref.) (Eng. Abstr.) **(Rus)**
[Surgery in the multidisciplinary treatment of small–cell lung carcinoma] Maestu Maiques I, et al. **Rev Clin Esp** 1998 Nov;198(11):752–7 (61 ref.) **(Spa)**

THERAPY

Immune therapy for lung cancer: are we getting closer? Bunn PA Jr. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):10–2 (28 ref.)
Complications from induction regimens for thoracic malignancies. Perioperative considerations. Liptay MJ, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):79–95 (36 ref.)
Combined modality therapy of lung cancer. Livingston RB.
Clin Cancer Res 1997 Dec;3(12 Pt 2):2638–47 (94 ref.)
Role of bronchoscopy in lung cancer research. Baughman RP, et al. **Clin Chest Med** 1999 Mar;20(1):191–9 (97 ref.)
New perspectives for the pharmacological and biological

LUNG NEOPLASMS

therapy of small cell lung cancer. Ardizzoni A, et al. **Crit Rev Oncol Hematol** 1999 Jul;31(2):135-45 (113 ref.)
Neoplasms of the lung [editorial] Lillington GA. **Curr Opin Pulm Med** 1999 Jul;5(4):185-8 (28 ref.)
Gene therapy for lung cancer. Frederiksen KS, et al. **Lung Cancer** 1999 Mar;23(3):191-207 (99 ref.)
Follow-up of patients with thoracic malignancies. Virgo KS, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):355-69 (72 ref.)
Is there a role for adjuvant therapy for resected non-small cell lung cancer? Jett JR. **Thorax** 1999 Aug;54 Suppl 2:S37-41 (12 ref.)
[Treatment of non-small-cell bronchial cancers] Ayoub A, et al. **Tunis Med** 1998 Mar;76(3):1-8 (49 ref.) **(Fre)**
[Gene therapy in cancers of the lung and pleura] Wiewrodt R, et al. **Pneumologie** 1999 Mar;53(3):176-84 (64 ref.) **(Ger)**
[Lung cancer] Goya T, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(1):49-53 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Trends in adjuvant therapy after surgery of lung cancer] Ayabe K. **Kyobu Geka** 1999 Jul;52(8 Suppl):707-13 (46 ref.) **(Jpn)**
[Forefront of lung cancer therapy] Hara N, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1946-50 (13 ref.) **(Jpn)**

LUNG PURPURA WITH NEPHRITIS see **GOODPASTURE SYNDROME**

LUNG TRANSPLANTATION

see related
HEART-LUNG TRANSPLANTATION

Surgical treatment of chronic obstructive pulmonary disease. Payne DK, et al. **Am J Med Sci** 1999 Aug;318(2):89-95 (53 ref.)
Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Veness MJ, et al. **Cancer** 1999 Apr 15;85(8):1758-64 (21 ref.)
Late-stage emphysema: when medical therapy fails. Dasgupta A, et al. **Cleve Clin J Med** 1999 Jul-Aug; 66(7):415-7, 421-5 (41 ref.)
Flexible bronchoscopy in lung transplantation. Trulock EP. **Clin Chest Med** 1999 Mar;20(1):77-87 (74 ref.)
Lung transplantation for cystic fibrosis. Zuckerman JB, et al. **Clin Chest Med** 1998 Sep;19(3):535-54, vii (95 ref.)
Airway responsiveness to inhaled albuterol in patients with pulmonary hypertension. O'Hagan AR, et al. **Clin Pediatr (Phila)** 1999 Jan;38(1):27-33 (41 ref.)
Bronchoalveolar lavage in lung transplantation. State of the art. Tiroke AH, et al. **Clin Transplant** 1999 Apr; 13(2):131-57 (210 ref.)
Update on lung transplantation in children. Gaynor JW, et al. **Curr Opin Pediatr** 1998 Jun;10(3):256-61 (15 ref.)
Pneumatosis intestinalis with Clostridium difficile colitis as a cause of acute abdomen after lung transplantation. Schenk P, et al. **Dig Dis Sci** 1998 Nov;43(11):2455-8 (17 ref.)
Advances in lung transplantation. Kesten S. **Dis Mon** 1999 Mar;45(3):101-14 (41 ref.)
Hypertension in thoracic transplant recipients. Jenkins GH, et al. **J Hum Hypertens** 1998 Dec;12(12):813-23 (124 ref.)
Lung transplantation. Arcasoy SM, et al. **N Engl J Med** 1999 Apr 8;340(14):1081-91 (100 ref.)
Surgical approaches to advanced emphysema. Edelman JD, et al. **Respir Care Clin N Am** 1998 Sep;4(3):513-39, x (98 ref.)
Extracorporeal photochemotherapy: a treatment for organ graft rejection [editorial] Heshmati F, et al. **Ther Apher** 1997 May;1(2):121-5 (25 ref.)
Lung transplantation for chronic obstructive pulmonary disease: an exercise in quality rather than quantity? Corris PA. **Thorax** 1999 Aug;54 Suppl 2:S24-7 (31 ref.)
Role of infections, pathogenesis, and management in lung transplantation. Frost AE. **Transplant Proc** 1999 Feb-Mar; 31(1-2):175-7 (17 ref.)
[Experimental xenogenic lung transplantation] Fraund S, et al. **Zentralbl Chir** 1999;124(7):609-15 (41 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Bronchiolitis obliterans after lung transplantation: a review. Boehler A, et al. **Chest** 1998 Nov;114(5):1411-26 (192 ref.)
Non-invasive diagnosis of acute heart- or lung-transplant rejection using radiolabeled annexin V. Blankenberg FG, et al. **Pediatr Radiol** 1999 May;29(5):299-305 (53 ref.)
Bronchiolitis obliterans. Sundaresan S. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):221-6 (25 ref.)

CONTRAINDICATIONS

Assessment for lung transplantation in cystic fibrosis. Aurora P, et al. **J R Soc Med** 1999;92 Suppl 37:31-4 (15 ref.)

IMMUNOLOGY

Post-transplant acute myeloid leukemia (PT-AML). Thalhammer-Scherrer R, et al. **Leukemia** 1999 Mar; 13(3):321-6 (40 ref.)

METHODS

Review of significant microvascular surgical breakthroughs involving the heart and lungs in rats. Chung WS, et al. **Microsurgery** 1999;19(2):71-7 (66 ref.)
Technical aspects of adult lung transplantation. Meyers BF, et al. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):213-20 (14 ref.)
Lung transplantation for chronic obstructive pulmonary disease. Waddell TK, et al. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):191-201 (39 ref.)
[Lung transplantation in advanced pulmonary emphysema] Speich R, et al. **Ther Umsch** 1999 Mar;56(3):161-5 (4 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pathology of pulmonary transplantation. Alvarez-Fernández E. **Curr Top Pathol** 1999;92:167-80 (36 ref.)

STATISTICS & NUMERICAL DATA

Thoracic transplantation in 1998. Conte JV Jr. **Md Med J** 1998 Nov;47(5):235-40 (8 ref.)

LUNG VOLUME MEASUREMENTS

Pathophysiology of changes in absolute lung volumes. Bancalari E, et al. **Eur Respir J** 1998 Jul;12(1):248-58 (141 ref.)

LUNG VOLUME REDUCTION see **PNEUMONECTOMY**

LUNG WATER, EXTRAVASCULAR see **EXTRAVASCULAR LUNG WATER**

LUPUS

IMMUNOLOGY

Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Shen GQ, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):321-34 (93 ref.)

LUPUS ANTICOAGULANT see **LUPUS COAGULATION INHIBITOR**

LUPUS COAGULATION INHIBITOR

see related
ANTIPHOSPHOLIPID SYNDROME

Hairy cell leukemia with an associated lupus-type anticoagulant [see comments] Kirkpatrick J, et al. **J Am Osteopath Assoc** 1999 Feb;99(2):109-12, 116 (24 ref.)
Comment in: J Am Osteopath Assoc 1999 Aug;99(8):394-5.

BLOOD

Lupus anticoagulants and antiphospholipid antibodies. Thiagarajan P, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1167-92, v (194 ref.)
Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Erkan D, et al. **Lupus** 1999; 8(7):560-4 (31 ref.)
[The association between cocaine consumption and lupus anticoagulant as the probable cause of ischemic stroke (letter)] Cuervo Pinna MA, et al. **Rev Clin Esp** 1999 May; 199(5):329-30 (9 ref.) **(Spa)**

IMMUNOLOGY

Lupus anticoagulants, thrombosis and the protein C system. Esmon NL, et al. **Haematologica** 1999 May;84(5):446-51 (32 ref.)
Mechanism of action of beta2-glycoprotein I-dependent lupus anticoagulants. Arnout J, et al. **Lupus** 1998;7 Suppl 2:S23-8 (64 ref.)
Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. de Groot PG, et al. **Lupus** 1998;7 Suppl 2:S32-6 (36 ref.)
Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Rauch J. **Lupus** 1998;7 Suppl 2:S29-31 (20 ref.)
Many faces of lupus anticoagulants. Triplett DA. **Lupus** 1998; 7 Suppl 2:S18-22 (30 ref.)

LUPUS ERYTHEMATOSUS, CHRONIC CUTANEOUS see **LUPUS ERYTHEMATOSUS, DISCOID**

LUPUS ERYTHEMATOSUS, CUTANEOUS

[Dermatologic manifestations of lupus] Francès C. **Rev Prat** 1998 Mar 15;48(6):615-9 (13 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Dermatological aspects of SLE, especially regarding the ARA (ARC) criteria. Baart de la Faille H. **Neth J Med** 1998 Sep;53(3):141-2 (5 ref.)

IMMUNOLOGY

Rowell's syndrome. Child FJ, et al. **Clin Exp Dermatol** 1999 Mar;24(2):74-7 (9 ref.)
Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus erythematosus. Furukawa F. **Histol Histopathol** 1999 Apr;14(2):627-33 (33 ref.)

PATHOLOGY

Linear cutaneous lupus erythematosus in an adult. Bouzit N, et al. **Dermatology** 1999;199(1):60-2 (8 ref.)

LUPUS ERYTHEMATOSUS, CUTANEOUS, CHRONIC see **LUPUS ERYTHEMATOSUS, DISCOID**

LUPUS ERYTHEMATOSUS, CUTANEOUS, SUBACUTE see **LUPUS ERYTHEMATOSUS, CUTANEOUS**

LUPUS ERYTHEMATOSUS, DISCOID

DIAGNOSIS

Linear childhood discoid lupus erythematosus following the lines of Blaschko: a case report with review of the linear manifestations of lupus erythematosus. Green JJ, et al. **Pediatr Dermatol** 1999 Mar-Apr;16(2):128-33 (48 ref.)

LUPUS ERYTHEMATOSUS DISSEMINATUS see **LUPUS ERYTHEMATOSUS, SYSTEMIC**

LUPUS ERYTHEMATOSUS, SUBACUTE CUTANEOUS see **LUPUS ERYTHEMATOSUS, CUTANEOUS**

LUPUS ERYTHEMATOSUS, SYSTEMIC

see related
ANTIPHOSPHOLIPID SYNDROME
LUPUS COAGULATION INHIBITOR

Pulmonary manifestations of systemic lupus erythematosus. Murin S, et al. **Clin Chest Med** 1998 Dec;19(4):641-65, viii (209 ref.)
[Animal models of collagen disease] Tada Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2469-75 (5 ref.) **(Jpn)**
[Advances in systemic lupus erythematosus] Kubota T. **Nippon Rinsho** 1999 Feb;57(2):329-32 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Mixed connective tissue disease and overlap syndrome] Nishimaki T. **Nippon Rinsho** 1999 Feb;57(2):355-9 (8 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus [editorial] Kutsuki H, et al. **Ther Apher** 1998 Feb;2(1):18-24 (23 ref.)

CHEMICALLY INDUCED

Etiology and mechanisms of drug-induced lupus. Rubin RL. **Curr Opin Rheumatol** 1999 Sep;11(5):357-63 (58 ref.)
Hydralazine-induced lupus and vocal fold paralysis. Hari CK, et al. **J Laryngol Otol** 1998 Sep;112(9):875-7 (31 ref.)
Drug-induced lupus. Le Goff P, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):40-5 (57 ref.)
Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Angulo JM, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):187-92 (41 ref.)

CLASSIFICATION

[Definition, diagnosis, and classification of lupus] Meyer O. **Rev Prat** 1998 Mar 15;48(6):609-14 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Antiphospholipid syndrome in SLE. Amigo MC, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):477-93 (60 ref.)
Pregnancy in SLE. Petri M. **Baillieres Clin Rheumatol** 1998 Aug;12(3):449-76 (105 ref.)
Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Grimbacher B, et al. **Br J Rheumatol** 1998 Sep; 37(9):1023-8 (13 ref.)
Kikuchi disease in systemic lupus erythematosus: clinical features and literature review. Chen YH, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1998 Sep;31(3):187-92 (28 ref.)
Neuropsychiatric syndromes in systemic lupus erythematosus: a new look [editorial] Khoshbin S, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):395-8 (64 ref.)
Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Giorgi D, et al. **Clin Rheumatol** 1999;18(2):124-31 (21 ref.)
Systemic lupus erythematosus and related disorders of childhood. Arkachaisri T, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):384-92 (63 ref.)
Clinical development in the management of lupus in the neonate, child, and adolescent. Szer IS. **Curr Opin Rheumatol** 1998 Sep;10(5):431-4 (9 ref.)
The heart in systemic lupus erythematosus. Roberts WC, et al. **Curr Probl Cardiol** 1999 Jan;24(1):1-56 (117 ref.)
Systemic lupus erythematosus, eosinophilia and Löffler's

endocarditis. An unusual association. Thomeer M, et al. **Eur Respir J** 1999 Apr;13(4):930–3 (21 ref.)

Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy. Giorgi D, et al. **Hum Immunol** 1999 Aug;60(8):688–96 (49 ref.)

Systemic lupus erythematosus demonstrating serum anti-GM1 antibody, with sudden onset of drop foot as the initial presentation [see comments] Matsuki Y, et al. **Intern Med** 1999 Sep;38(9):729–32 (25 ref.) Comment in: Intern Med 1999 Sep;38(9):689–90.

Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist? Shteyngarts AR, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):773–7 (32 ref.)

Systemic lupus erythematosus: a review of the cardiac manifestations. Holmes D, et al. **J Ark Med Soc** 1999 Jan; 95(8):355–7 (11 ref.)

Case report: a rare association of primary biliary cirrhosis and systemic lupus erythematosus and review of the literature. Islam S, et al. **J Gastroenterol Hepatol** 1999 May; 14(5):431–5 (28 ref.)

Dystonia and chorea in acquired systemic disorders. Janavs JL, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct; 65(4):436–45 (139 ref.)

Association of aortic aneurysm in patients with systemic lupus erythematosus: a series of case reports and a review of the literature. Khan AS, et al. **J Rheumatol** 1998 Oct; 25(10):2019–21 (10 ref.)

Acute sympathetic hyperfunction in overlapping syndromes of systemic lupus erythematosus and polymyositis. Nakajima A, et al. **J Rheumatol** 1998 Aug;25(8):1638–41 (12 ref.)

Pseudotumor cerebri and leukoencephalopathy in childhood lupus. Chaves-Carballo E, et al. **Lupus** 1999;8(1):81–4 (26 ref.)

Lupus anticoagulant–hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Erkan D, et al. **Lupus** 1999; 8(7):560–4 (31 ref.)

Acute acalculous cholecystitis in systemic lupus erythematosus: a case report and review of the literature. Kamimura T, et al. **Lupus** 1998;7(5):361–3 (15 ref.)

Cardiac involvement in systemic lupus erythematosus. Moder KG, et al. **Mayo Clin Proc** 1999 Mar;74(3):275–84 (100 ref.)

Hepatic aneurysm and portal vein thrombosis in a patient with lupus erythematosus on dialysis. Huang JW, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):753–6 (12 ref.)

Catastrophic antiphospholipid syndromes in systemic lupus erythematosus. Stratta P, et al. **Ren Fail** 1999 Jan; 21(1):49–61 (53 ref.)

1998 update on pregnancy in lupus patients. New horizons, new hopes. Wechsler B, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):619–24 (66 ref.)

Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Angulo JM, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):187–92 (41 ref.)

Internuclear ophthalmoplegia in systemic lupus erythematosus. Galindo M, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):179–86 (52 ref.)

[Exudative enteropathy in disseminated lupus erythematosus. Report of 3 cases and review of the literature] Viallard JF, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):485–91 (24 ref.) (Eng. Abstr.) **(Fre)**

[Association of acute pericarditis and acute renal insufficiency: causes and prognosis] Klisnick A, et al. **Presse Med** 1998 Oct 31;27(33):1668–73 (41 ref.) (Eng. Abstr.) **(Fre)**

[Dermatologic manifestations of lupus] Frances C. **Rev Prat** 1998 Mar 15;48(6):615–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Severe visceral involvement of lupus] Hatron PY. **Rev Prat** 1998 Mar 15;48(6):620–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Infections and lupus] Le Moing V, et al. **Rev Prat** 1998 Mar 15;48(6):637–42 (26 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy and acute disseminated lupus erythematosus] Wechsler B, et al. **Rev Prat** 1998 Mar 15;48(6):632–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Two cases of coronary artery bypass grafting associated with antiphospholipid syndrome in systemic lupus erythematosus] Jinno T, et al. **Kyobu Geka** 1999 Aug; 52(9):774–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Central nervous system involvement in rheumatic diseases] Hirohata S. **Nippon Rinsho** 1999 Feb;57(2):409–12 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Acute lupus hemophagocytic syndrome] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):352–4 (13 ref.) **(Jpn)**

[A case of systemic lupus erythematosus overlapping with progressive systemic sclerosis accompanied by deposition of AA amyloid in the stomach] Obata T, et al. **Ryumachi** 1998 Dec;38(6):810–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Lupus cystitis and peritonitis successfully treated with intravenous cyclophosphamide pulse therapy: a case report] Tsutsumino M, et al. **Ryumachi** 1998 Aug;38(4):611–7 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Acute transverse myelitis in systemic lupus erythematosus] Romero Ganuza FJ, et al. **Rev Clin Esp** 1999 Apr; 199(4):218–21 (37 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. **Arthritis Rheum** 1999 Apr;42(4):599–608 (123 ref.)

Current role of renal biopsy in patients with SLE. Esdaile JM. **Baillieres Clin Rheumatol** 1998 Aug;12(3):433–48 (52 ref.)

Measures of disease activity and damage in SLE. Urowitz MB, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):405–13 (32 ref.)

Spinal cord involvement in pediatric systemic lupus erythematosus: case report and literature review. al-Mayouf SM, et al. **Clin Exp Rheumatol** 1999 Jul–Aug; 17(4):505–8 (20 ref.)

Cutaneous Mycobacterium kansasii infection in a patient with systemic lupus erythematosus: case report and review. Czelusta A, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):359–63 (34 ref.)

Systemic lupus erythematosus and pregnancy. Zarcone R, et al. **Panminerva Med** 1998 Dec;40(4):319–28 (71 ref.)

Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Musio F, et al. **Semin Arthritis Rheum** 1998 Aug;28(1):1–19 (71 ref.)

Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Trapani S, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):319–25 (27 ref.)

[Definition, diagnosis, and classification of lupus] Meyer O. **Rev Prat** 1998 Mar 15;48(6):609–14 (17 ref.) (Eng. Abstr.) **(Fre)**

[Severe pulmonary hypertension in systemic lupus erythematosus. The successful therapy of an unusual manifestation] Beckh S, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):618–23 (13 ref.) (Eng. Abstr.) **(Ger)**

[Progress in clinical tests and the pathophysiological tests of collagen diseases--complement] Horiuchi T, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2427–33 (5 ref.) **(Jpn)**

[Ventricular extrasystoles as a form of presentation of neonatal lupus (letter)] Bringué Espuny X, et al. **An Esp Pediatr** 1998 Dec;49(6):644–5 (16 ref.) **(Spa)**

DIET THERAPY

The dietary treatment of inflammatory arthritis: case reports and review of the literature. Danao-Camara TC, et al. **Hawaii Med J** 1999 May;58(5):126–31 (48 ref.)

DRUG THERAPY

Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Ginzler EM, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):495–510 (102 ref.)

Indications for, and use of, cytotoxic agents in SLE. Klippel JH. **Baillieres Clin Rheumatol** 1998 Aug;12(3):511–27 (54 ref.)

Dehydroepiandrosterone (DHEA) for serious disease, a possibility? [editorial; comment] Lahita RG. **Lupus** 1999; 8(3):169–70 (11 ref.) Comment on: Lupus 1999 ;8(3):181–7.

[Treatment of systemic lupus erythematosus systemic] Piette JC. **Rev Prat** 1998 Mar 15;48(6):643–7 (23 ref.) (Eng. Abstr.) **(Fre)**

[The use of Vasaprostan in patients with systemic lupus erythematosus and the antiphospholipid syndrome] Reshetniak TM, et al. **Ter Arkh** 1999;71(5):40–7 (52 ref.) **(Rus)**

EPIDEMIOLOGY

The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis" [see comments] Bae SC, et al. **Arthritis Rheum** 1998 Dec;41(12):2091–9 (102 ref.) Comment in: Arthritis Rheum 1999 Jul;42(7):1560–1.

The pathophysiology of lupus erythematosus. Vanholder R, et al. **Eur J Dermatol** 1998 Jan–Feb;8(1):4–7 (37 ref.)

ETHNOLOGY

The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis" [see comments] Bae SC, et al. **Arthritis Rheum** 1998 Dec;41(12):2091–9 (102 ref.) Comment in: Arthritis Rheum 1999 Jul;42(7):1560–1.

ETIOLOGY

The key role of nucleosomes in lupus. Amoura Z, et al. **Arthritis Rheum** 1999 May;42(5):833–43 (124 ref.)

Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Cooper GS, et al. **Arthritis Rheum** 1998 Oct;41(10):1714–24 (99 ref.)

Immunopathogenesis of SLE. Mason LJ, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):385–403 (51 ref.)

The pathophysiology of lupus erythematosus. Vanholder R, et al. **Eur J Dermatol** 1998 Jan–Feb;8(1):4–7 (37 ref.)

Human T-cell lymphotropic virus type I and systemic lupus erythematosus [editorial; comment] Ijichi S, et al. **Intern Med** 1999 Jun;38(6):459–60 (24 ref.) Comment on: Intern Med 1999 Jun;38(6):512–5.

GENETICS

The genetics of human systemic lupus erythematosus. Harley JB, et al. **Curr Opin Immunol** 1998 Dec;10(6):690–6 (63 ref.)

Complement deficiency and autoimmunity. Sullivan KE. **Curr Opin Pediatr** 1998 Dec;10(6):600–6 (48 ref.)

The genetics of lupus. Tan FK, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):399–408 (86 ref.)

MHC-linked control of murine SLE. Ibnou-Zekri N, et al. **Curr Top Microbiol Immunol** 1999;246:275–80; discussion 281 (28 ref.)

Effector and predisposing genes in murine lupus. Theofilopoulos AN. **Lupus** 1998;7(9):575–84 (118 ref.)

The role of in vitro expression systems in the investigation of antibodies to DNA. Rahman A, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):130–9 (45 ref.)

The regulation of heat shock proteins and their role in systemic lupus erythematosus. Stephanou A, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):155–62 (54 ref.)

[Progresses in the study of rheumatology in China, 1997] Wu D. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):891–3 (0 ref.) **(Chi)**

[Immunogenetic bases of systemic lupus erythematosus in humans] Michel M, et al. **Rev Med Interne** 1998 Oct; 19(10):726–30 (27 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antiphospholipid syndrome in SLE. Amigo MC, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):477–93 (60 ref.)

Immunopathogenesis of SLE. Mason LJ, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):385–403 (51 ref.)

Pregnancy in SLE. Petri M. **Baillieres Clin Rheumatol** 1998 Aug;12(3):449–76 (105 ref.)

Mechanisms of lupus: the role of estrogens [editorial] Yung RL. **Clin Exp Rheumatol** 1999 May–Jun;17(3):271–5 (89 ref.)

New pieces to the SLE cytokine puzzle [editorial] Kirou KA, et al. **Clin Immunol** 1999 Apr;91(1):1–5 (53 ref.)

Emerging concepts of the molecular basis for estrogen effects on T lymphocytes in systemic lupus erythematosus [editorial; comment] Kammer GM, et al. **Clin Immunol Immunopathol** 1998 Dec;89(3):192–5 (45 ref.) Comment on: Clin Immunol Immunopathol 1998 Nov;89(2):171–80.

Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Shen GQ, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):321–34 (93 ref.)

Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment? Spronk PE, et al. **Clin Rev Allergy Immunol** 1998 Fall;16(3):211–8 (39 ref.)

Initiation of systemic autoimmunity and sequence specific anti-DNA autoantibodies. Radic MZ, et al. **Crit Rev Immunol** 1999;19(2):117–26 (76 ref.)

Autoantibodies in systemic lupus erythematosus. Cabral AR, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):409–16 (52 ref.)

The role of sex hormones in systemic lupus erythematosus. Lahita RG. **Curr Opin Rheumatol** 1999 Sep;11(5):352–6 (29 ref.)

Pregnancy in lupus. Meng C, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):348–51 (19 ref.)

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):417–25 (70 ref.)

MHC-linked control of murine SLE. Ibnou-Zekri N, et al. **Curr Top Microbiol Immunol** 1999;246:275–80; discussion 281 (28 ref.)

C1q and systemic lupus erythematosus. Walport MJ, et al. **Immunobiology** 1998 Aug;199(2):265–85 (93 ref.)

Immune cell signaling aberrations in human lupus. Liossis SN, et al. **Immunol Res** 1998 Aug;18(1):27–39 (69 ref.)

The central and multiple roles of B cells in lupus pathogenesis. Chan OT, et al. **Immunol Rev** 1999 Jun; 169:107–21 (188 ref.)

Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Singh RR, et al. **Immunol Rev** 1998 Aug; 164:201–8 (57 ref.)

Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Navratil JS, et al. **Immunopharmacology** 1999 May;42(1–3):47–52 (34 ref.)

The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Cross JT, et al. **Inflamm Res** 1999 May;48(5):255–61 (53 ref.)

Peripheral neuropathies in lupus patients with anti-GM1 antibodies [editorial; comment] Hashimoto H. **Intern Med** 1999 Sep;38(9):689–90 (8 ref.) Comment on: Intern Med 1999 Sep;38(9):729–32.

Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells. Datta SK. **Lupus** 1998; 7(9):591–6 (48 ref.)

Immunisation of patients with systemic lupus erythematosus: the current state of play. Ioannou Y, et al. **Lupus** 1999; 8(7):497–501 (51 ref.)

Advances in autoantibodies in SLE [see comments] von Mühlen CA, et al. **Lupus** 1998;7(8):507–14 (81 ref.) Comment in: Lupus 1999;8(4):332.

Significance of IgA antiphospholipid antibodies. Wilson WA, et al. **Lupus** 1998;7 Suppl 2:S110–3 (34 ref.)

Signaling in human lupus T lymphocytes [editorial] Zouali M. **Lupus** 1998;7(8):499–502 (37 ref.)

Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. Rahman A, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):141–54 (76 ref.)

The role of in vitro expression systems in the investigation of antibodies to DNA. Rahman A, et al.

Semin Arthritis Rheum 1998 Oct;28(2):130–9 (45 ref.)
The regulation of heat shock proteins and their role in systemic lupus erythematosus. Stephanou A, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):155–62 (54 ref.)
The role of apoptosis in autoimmunity: immunogen, antigen, and accelerant. Levine JS, et al. **Semin Nephrol** 1999 Jan; 19(1):34–47 (100 ref.)
Breakdown of self-tolerance and the pathogenesis of autoimmunity. Ring GH, et al. **Semin Nephrol** 1999 Jan; 19(1):25–33 (88 ref.)
[Interleukin 10: a key cytokine in disseminated lupus erythematosus (editorial)] Emilie D, et al. **Pathol Biol (Paris)** 1998 Oct;46(8):583–5 (4 ref.) **(Fre)**
[Biopathology of disseminated lupus erythematosus] Youinou P, et al. **Rev Prat** 1998 Mar 15;48(6):603–8 (21 ref.) (Eng. Abstr.) **(Fre)**
[New therapeutic strategy for autoimmune diseases. 2) Abnormality in expression of cell surface molecules in systemic erythematodes and its therapeutic application] Takasaki Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1741–4 (3 ref.) **(Jpn)**
[Physiopathological and therapeutic therapy of collagen diseases based on results of clinical tests--disorders of lymphocyte signal transduction] Takeuchi T. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2446–52 (23 ref.) **(Jpn)**
[Possible pathogenic role of IL-16 on SLE: with reference to HIV-1 infection] Lee S, et al. **Ryumachi** 1998 Oct; 38(5):747–51 (33 ref.) **(Jpn)**

METABOLISM

The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Takasaki Y, et al. **Intern Med** 1999 Feb;38(2):175–7 (8 ref.)
Defective signal transduction via TCR-CD3 complex in patients with systemic lupus erythematosus. Takeuchi T, et al. **Intern Med** 1999 Feb;38(2):169 (6 ref.)
Cytokines in the pathogenesis of systemic lupus erythematosus. Kelley VR, et al. **Semin Nephrol** 1999 Jan; 19(1):57–66 (91 ref.)

MICROBIOLOGY

Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature. Hansen KE, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):193–9 (22 ref.)

NURSING

Systemic lupus erythematosus: perinatal and neonatal implications. Classen SR, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct; 27(5):493–500 (20 ref.)

PATHOLOGY

Current role of renal biopsy in patients with SLE. Esdaile JM. **Baillieres Clin Rheumatol** 1998 Aug;12(3):433–48 (52 ref.)
Spinal cord involvement in pediatric systemic lupus erythematosus: case report and literature review. al-Mayouf SM, et al. **Clin Exp Rheumatol** 1999 Jul–Aug; 17(4):505–8 (20 ref.)
Clinical evaluation and monitoring of lupus kidney disease. Austin HA. **Lupus** 1998;7(9):618–21 (28 ref.)

PHYSIOPATHOLOGY

Neuroendocrine immune features of pediatric inflammatory rheumatic diseases. Chikanza IC. **Ann N Y Acad Sci** 1999 Jun 22;876:71–80; discussion 80–2 (47 ref.)
Emerging concepts for sexual predilection in the disease systemic lupus erythematosus. Lahita RG. **Ann N Y Acad Sci** 1999 Jun 22;876:64–9; discussion 69–70 (45 ref.)
Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ostensen M. **Ann N Y Acad Sci** 1999 Jun 22;876:131–43; discussion 144 (95 ref.)
Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Cutolo M, et al. **Ann Rheum Dis** 1998 Oct;57(10):573–7 (67 ref.)
Measures of disease activity and damage in SLE. Urowitz MB, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):405–13 (32 ref.)
Mechanisms of lupus: the role of estrogens [editorial] Yung RL. **Clin Exp Rheumatol** 1999 May–Jun;17(3):271–5 (89 ref.)
Cognitive and physical measures in rehabilitation of patients with lupus. Bleiberg J, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):442–5 (17 ref.)
Childhood systemic lupus erythematosus and neonatal lupus syndrome. Sandborg CI. **Curr Opin Rheumatol** 1998 Sep; 10(5):481–7 (78 ref.)
Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):417–25 (70 ref.)
Immune cell signaling aberrations in human lupus. Liossis SN, et al. **Immunol Res** 1998 Aug;18(1):27–39 (69 ref.)
The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Cross JT, et al. **Inflamm Res** 1999 May;48(5):255–61 (53 ref.)
What is the relationship between complement and systemic lupus erythematosus? [editorial; comment] Podrebarac TA, et al. **J Rheumatol** 1998 Nov;25(11):2062–4 (18 ref.) Comment on: J Rheumatol 1998 Nov;25(11):2118–25.
[The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythematosus] Aharon-Maor A, et al. **Harefuah** 1998 Oct;135(7–8):295–9 (38 ref.) **(Heb)**

PSYCHOLOGY

Neuropsychiatric systemic lupus erythematosus. Sibbitt WL Jr, et al. **Compr Ther** 1999 Apr;25(4):198–208 (32 ref.)
Cognitive and physical measures in rehabilitation of patients with lupus. Bleiberg J, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):442–5 (17 ref.)
Using single-subject methodology to investigate psychiatric treatments in systemic lupus erythematosus. Iverson GL, et al. **Lupus** 1998;7(5):295–300 (31 ref.)

RADIOGRAPHY

Evaluation of patients with CNS involvement in SLE. Hanly JG. **Baillieres Clin Rheumatol** 1998 Aug;12(3):415–31 (57 ref.)

RADIONUCLIDE IMAGING

Evaluation of patients with CNS involvement in SLE. Hanly JG. **Baillieres Clin Rheumatol** 1998 Aug;12(3):415–31 (57 ref.)

THERAPY

Opportunities for future biological therapy in SLE. Wofsy D, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):529–41 (51 ref.)
Evaluation of recent clinical trials in lupus. Brooks EB, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):341–7 (61 ref.)
Therapeutic advances in systemic lupus erythematosus. Godfrey T, et al. **Curr Opin Rheumatol** 1998 Sep; 10(5):435–41 (81 ref.)
Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. Strand V. **Curr Opin Rheumatol** 1999 Sep;11(5):330–40 (105 ref.)
Clinical development in the management of lupus in the neonate, child, and adolescent. Szer IS. **Curr Opin Rheumatol** 1998 Sep;10(5):431–4 (9 ref.)
It's not the same old lupus or Sjögren's any more: one hundred new insights, approaches, and options since 1990. Wallace DJ, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):321–9 (40 ref.)
Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Gordon C, et al. **Lupus** 1998; 7(7):429–33 (52 ref.)
Using single-subject methodology to investigate psychiatric treatments in systemic lupus erythematosus. Iverson GL, et al. **Lupus** 1998;7(5):295–300 (31 ref.)
End-stage renal disease in lupus: disease activity, dialysis, and the outcome of transplantation. Stone JH. **Lupus** 1998; 7(9):654–9 (38 ref.)
Apheresis for lupus erythematosus. Wallace DJ. **Lupus** 1999; 8(3):174–80 (83 ref.)
Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus [editorial] Kutsuki H, et al. **Ther Apher** 1998 Feb;2(1):18–24 (23 ref.)

LUPUS GLOMERULONEPHRITIS see **LUPUS NEPHRITIS**

LUPUS NEPHRITIS

Lupus nephritis: update on pathogenesis and disease mechanisms. Foster MH, et al. **Semin Nephrol** 1999 Mar; 19(2):173–81 (51 ref.)

COMPLICATIONS

Renal transplantation for end-stage renal disease caused by systemic lupus erythematosus nephritis. Clark WF, et al. **Semin Nephrol** 1999 Jan;19(1):77–85 (109 ref.)

DIAGNOSIS

Current role of renal biopsy in patients with SLE. Esdaile JM. **Baillieres Clin Rheumatol** 1998 Aug;12(3):433–48 (52 ref.)

DRUG THERAPY

Natural history and treatment of lupus nephritis. Austin HA, et al. **Semin Nephrol** 1999 Jan;19(1):2–11 (85 ref.)
Lupus nephritis: novel immunosuppressive modalities and future directions. Tumlin JA. **Semin Nephrol** 1999 Jan; 19(1):67–76 (44 ref.)

ETIOLOGY

Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Kuroiwa T, et al. **Lupus** 1998;7(9):597–603 (73 ref.)

GENETICS

Susceptibility to lupus nephritis in the NZB/W model system. Morel L, et al. **Curr Opin Immunol** 1998 Dec;10(6):718–25 (65 ref.)
Genetic susceptibility to lupus nephritis. Tsao BP. **Lupus** 1998;7(9):585–90 (33 ref.)
Relevance of systemic lupus erythematosus nephritis animal models to human disease. Foster MH. **Semin Nephrol** 1999 Jan;19(1):12–24 (84 ref.)

IMMUNOLOGY

Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Berden JH, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):299–306 (57 ref.)
Pathogenesis of lupus nephritis: a review. McLigeyo SO. **East Afr Med J** 1998 Nov;75(11):628–31 (45 ref.)
Relevance of systemic lupus erythematosus nephritis animal models to human disease. Foster MH. **Semin Nephrol** 1999 Jan;19(1):12–24 (84 ref.)
The role of autoantibodies in the pathogenesis of lupus nephritis. Madaio MP. **Semin Nephrol** 1999 Jan;19(1):48–56 (69 ref.)
Lupus nephritis: novel immunosuppressive modalities and future directions. Tumlin JA. **Semin Nephrol** 1999 Jan; 19(1):67–76 (44 ref.)

PATHOLOGY

Current role of renal biopsy in patients with SLE. Esdaile JM. **Baillieres Clin Rheumatol** 1998 Aug;12(3):433–48 (52 ref.)
Lupus nephritis in children. Gloor JM. **Lupus** 1998; 7(9):639–43 (38 ref.)
Renal biopsy in lupus nephritis. Grande JP, et al. **Lupus** 1998; 7(9):611–7 (39 ref.)
Renal biopsy in lupus nephritis--what for, when and how often? [editorial] Ponticelli C, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2452–4 (10 ref.)
The value of electron microscopy in the diagnosis and clinical management of lupus nephritis. Herrera GA. **Ultrastruct Pathol** 1999 Mar–Apr;23(2):63–77 (73 ref.)

PHYSIOPATHOLOGY

Lupus nephritis. Cameron JS. **J Am Soc Nephrol** 1999 Feb; 10(2):413–24 (38 ref.)
Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Grande JP. **Lupus** 1998;7(9):604–10 (87 ref.)
Natural history and treatment of lupus nephritis. Austin HA, et al. **Semin Nephrol** 1999 Jan;19(1):2–11 (85 ref.)

PREVENTION & CONTROL

Flares in lupus nephritis: incidence, impact on renal survival and management. Ponticelli C, et al. **Lupus** 1998;7(9):635–8 (18 ref.)

THERAPY

Treatment options in lupus nephritis. McLigeyo SO. **East Afr Med J** 1998 Oct;75(10):609–13 (44 ref.)
Lupus nephritis. Cameron JS. **J Am Soc Nephrol** 1999 Feb; 10(2):413–24 (38 ref.)
Outcome criteria for lupus nephritis trials: a critical overview. Boumpas DT, et al. **Lupus** 1998;7(9):622–9 (37 ref.)
Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Clark WF, et al. **Lupus** 1998; 7(9):649–53 (54 ref.)
The interdisciplinary team's approach to lupus nephritis. Crane M, et al. **Lupus** 1998;7(9):660–5 (19 ref.)
Immunosuppressive therapy of lupus nephritis. Dooley MA, et al. **Lupus** 1998;7(9):630–4 (50 ref.)
Novel approaches in the treatment of lupus nephritis. Illei GG, et al. **Lupus** 1998;7(9):644–8 (59 ref.)

LUPUS VULGARIS see **LUPUS**

LURCHER MICE see **MICE, NEUROLOGIC MUTANTS**

LUTEAL PHASE

PHYSIOLOGY

Changes in basement membrane thickness in the human endometrium during the luteal phase of the menstrual cycle. Dockery P, et al. **Hum Reprod Update** 1998 Sep–Oct; 4(5):486–95 (56 ref.)

LUTEINIZING HORMONE see **LH**

LUTEINIZING HORMONE RECEPTORS see **RECEPTORS, LH**

LUTEINIZING HORMONE-RELEASING HORMONE see **GONADORELIN**

LUTEOTROPIN see **PROLACTIN**

LUTROPIN see **LH**

LUTROPIN RECEPTORS see **RECEPTORS, LH**

LUTZOMYIA see **PSYCHODIDAE**

LY ANTIGENS see **ANTIGENS, LY**

17,20-LYASE see **STEROID 17 ALPHA-MONOOXYGENASE**

LYASES

ANTAGONISTS & INHIBITORS

Mechanism-based inhibitors and other active-site targeted inhibitors of oxidosqualene cyclase and squalene cyclase. Abe I, et al. **J Enzyme Inhib** 1998 Sep;13(6):385-98 (68 ref.)

METABOLISM

Dehalogenases applied to industrial-scale biocatalysis. Swanson PE. **Curr Opin Biotechnol** 1999 Aug;10(4):365-9 (38 ref.)

LYCINE see **BETAINE**

LYCOPERSICON ESCULENTUM see **TOMATOES**

LYELL'S SYNDROME see **EPIDERMAL NECROLYSIS, TOXIC**

LYING see **DECEPTION**

LYME BORRELIOSIS see **LYME DISEASE**

LYME DISEASE

Lyme disease. Evans J. **Curr Opin Rheumatol** 1998 Jul; 10(4):339-46 (78 ref.)

Lyme disease. Evans J. **Curr Opin Rheumatol** 1999 Jul; 11(4):281-8 (62 ref.)

[Lyme borreliosis] Mrázek V, et al. **Cas Lek Cesk** 1999 May 24;138(11):329-32 (40 ref.) (Eng. Abstr.) **(Cze)**

[Lyme disease] Kawabata M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):100-3 (10 ref.) **(Jpn)**

COMPLICATIONS

Lyme disease in a child presenting with bilateral facial nerve palsy: MRI findings and review of the literature. Vanzieleghem B, et al. **Neuroradiology** 1998 Nov; 40(11):739-42 (22 ref.)

DIAGNOSIS

Lyme disease and related tick-borne illnesses. Edlow JA. **Ann Emerg Med** 1999 Jun;33(6):680-93 (102 ref.)

Overdiagnosis and overtreatment of Lyme disease leads to inappropriate health service use. Sigal LH. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):41 (3 ref.)

Management of Lyme arthritis. Sigal LH. **Compr Ther** 1999 Apr;25(4):228-38 (90 ref.)

Emergency department presentations of Lyme disease in children. Bachman DT, et al. **Pediatr Emerg Care** 1998 Oct;14(5):356-61 (44 ref.)

The underdiagnosis of neuropsychiatric Lyme disease in children and adults. Fallon BA, et al. **Psychiatr Clin North Am** 1998 Sep;21(3):693-703, viii (21 ref.)

Borrelia burgdorferi in Lyme arthritis and undifferentiated arthritis. Jaulhac B, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):20S-22S (27 ref.)

[Lyme neuroborreliosis with acute meningitis as the presenting manifestation: report of a case] Sheng R, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(1):21-4 (10 ref.) (Eng. Abstr.) **(Chi)**

[Interpretation of borreliosis serology. Step-wise diagnosis--introduction to case examples] Hassler D, et al. **Fortschr Med** 1998 Oct 20;116(29):20-2, 24 (16 ref.) **(Ger)**

[Lyme borreliosis: current status of diagnosis and therapy] Landgraf S, et al. **Med Klin** 1999 Feb 15;94(2):105-8 (0 ref.) **(Ger)**

[Mechanisms of inflammation and immunity regulation in the pathogenesis of Lyme disease] Fedorov ES, et al. **Klin Med (Mosk)** 1999;77(6):14-9 (66 ref.) **(Rus)**

[Laboratory diagnosis of Lyme borreliosis] Gutiérrez J, et al. **Rev Med Chil** 1998 Jun;126(6):702-14 (88 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Overdiagnosis and overtreatment of Lyme disease leads to inappropriate health service use. Sigal LH. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):41 (3 ref.)

Management of Lyme arthritis. Sigal LH. **Compr Ther** 1999 Apr;25(4):228-38 (90 ref.)

Systematic review of the treatment of early Lyme disease. Loewen PS, et al. **Drugs** 1999 Feb;57(2):157-73 (63 ref.)

[Lyme borreliosis: therapeutic aspects] Dhôte R, et al. **Presse Med** 1998 Dec 12;27(39):2043-7 (61 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Fall and rise of Lyme disease and other Ixodes tick-borne infections in North America and Europe. Barbour AG. **Br Med Bull** 1998;54(3):647-58 (60 ref.)

Lyme disease in Italy, 1983-1996. Ciceroni L, et al. **New Microbiol** 1998 Oct;21(4):407-18 (42 ref.)

Molecular epidemiology of the aetiological agents of Lyme borreliosis. Baranton G, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):850-5 (38 ref.)

IMMUNOLOGY

[Mechanisms of inflammation and immunity regulation in the pathogenesis of Lyme disease] Fedorov ES, et al. **Klin Med (Mosk)** 1999;77(6):14-9 (66 ref.) **(Rus)**

MICROBIOLOGY

Molecular epidemiology of the aetiological agents of Lyme borreliosis. Baranton G, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):850-5 (38 ref.)

Pathogenesis of neuroborreliosis--lessons from a monkey model. Pachner AR, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):870-3 (17 ref.)

Lyme borreliosis and emerging tick-borne diseases in Europe [editorial] Stanek G, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):847-9 (29 ref.)

[Borrelia burgdorferi, taxonomy, pathogenicity and spread] Baranton G, et al. **Ann Med Interne (Paris)** 1998 Nov; 149(7):455-8 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Lyme disease prevention and vaccine prophylaxis. Hayney MS, et al. **Ann Pharmacother** 1999 Jun;33(6):723-9 (55 ref.)

Vaccination as a modality to prevent Lyme disease. A status report. Wormser GP. **Infect Dis Clin North Am** 1999 Mar; 13(1):135-48, vii (65 ref.)

THERAPY

Lyme disease and related tick-borne illnesses. Edlow JA. **Ann Emerg Med** 1999 Jun;33(6):680-93 (102 ref.)

TRANSMISSION

[Borrelia burgdorferi, taxonomy, pathogenicity and spread] Baranton G, et al. **Ann Med Interne (Paris)** 1998 Nov; 149(7):455-8 (30 ref.) (Eng. Abstr.) **(Fre)**

LYMNAEA

PARASITOLOGY

Ecology of host parasite relationships in the Baltic Sea. Zander CD. **Naturwissenschaften** 1998 Sep;85(9):426-36 (38 ref.)

LYMPH

IMMUNOLOGY

Local immune responses in afferent and efferent lymph. Haig DM, et al. **Immunology** 1999 Feb;96(2):155-63 (70 ref.)

LYMPH NODE DISSECTION see **LYMPH NODE EXCISION**

LYMPH NODE EXCISION

Mesorectal excision for rectal carcinoma: the new standard? Beart RW Jr. **Adv Surg** 1999;32:193-203 (50 ref.)

Therapeutic node dissections in malignant melanoma. Karakousis CP. **Ann Surg Oncol** 1998 Sep;5(6):473-82 (63 ref.)

Sentinel lymphadenectomy in breast cancer: identification of sentinel lymph node and detection of metastases. Noguchi M, et al. **Breast Cancer Res Treat** 1999 Jan;53(2):97-104 (50 ref.)

Infiltrating breast carcinoma smaller than 0.5 centimeters: is lymph node dissection necessary? Saiz E, et al. **Cancer** 1999 May 15;85(10):2206-11 (30 ref.)

The roles of multimodality treatment and lymphadenectomy in the management of esophageal cancer. Law S, et al. **Chin Med J (Engl)** 1997 Nov;110(11):819-25 (59 ref.)

Colorectal carcinoma: is lymphadenectomy useful? Curti G, et al. **Dig Surg** 1998;15(3):193-208 (167 ref.)

Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? Morton DL, et al. **J Am Coll Surg** 1999 Aug; 189(2):214-23 (93 ref.)

The role of elective lymph node dissection in malignant melanoma: who should undergo this nodal staging procedure? Reintgen D. **J Am Coll Surg** 1999 Aug; 189(2):224-32 (22 ref.)

Mesorectal lymph node dissection: is it beneficial? Hohenberger W, et al. **Langenbecks Arch Surg** 1998 Dec; 383(6):402-8 (54 ref.)

Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits? Mann B, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):355-8 (24 ref.)

Histologic evaluation of neck dissection specimens. Gillies EM, et al. **Otolaryngol Clin North Am** 1998 Oct; 31(5):759-71 (54 ref.)

Neck dissection in the treatment of cancer of major salivary glands. Medina JE. **Otolaryngol Clin North Am** 1998 Oct; 31(5):815-22 (21 ref.)

Surgical management of chylous fistula after retroperitoneal lymph node dissection. Haukaas SA, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):71-2 (6 ref.)

Lymph node dissection for gastric cancer. Meyer HJ, et al. **Semin Surg Oncol** 1999 Sep;17(2):117-24 (51 ref.)

Papillary thyroid carcinoma: justification for total thyroidectomy and management of lymph node metastases. Chen H, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):645-63 (64 ref.)

Radioguided surgery for melanoma. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):413-26, vii (29 ref.)

Historical perspectives and future applications. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):391-400, vii (47 ref.)

[Sentinel node--malignant melanoma and primary breast cancer. The significance of sentinel node in the treatment of malignant melanoma and primary breast cancer] Axelsson CK, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2343-7 (40 ref.) (Eng. Abstr.) **(Dan)**

[Lymph node excision in cancer of the stomach] Msika S. **J Chir (Paris)** 1998 Oct;135(4):155-61 (52 ref.) (Eng. Abstr.) **(Fre)**

[Breast cancer: axillary dissection--or an unnecessary procedure?] Schäfer P. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1667-74 (45 ref.) (Eng. Abstr.) **(Fre)**

[Differentiated thyroid gland carcinoma p-T2/T3--extent of lymphadenectomy] Wahl RA, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:203-11 (35 ref.) (Eng. Abstr.) **(Ger)**

[Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated?] Böhler FK, et al. **Strahlenther Onkol** 1998 Dec;174(12):605-12 (125 ref.) (Eng. Abstr.) **(Ger)**

[Lymphatic metastases in renal cell carcinoma. What is the value of operation and adjuvant therapy?] Mickisch GH. **Urologe A** 1999 Jul;38(4):326-31 (29 ref.) (Eng. Abstr.) **(Ger)**

[Lymphatic metastases in bladder carcinoma. Is radical cystectomy indicated?] Otto T, et al. **Urologe A** 1999 Jul; 38(4):323-5 (8 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node metastases in penis carcinoma. Therapeutic options and outcome] Wilbert DM. **Urologe A** 1999 Jul; 38(4):332-6 (21 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node dissection during surgery for lung cancer. Solely staging or therapy?] Hoffmann H, et al. **Zentralbl Chir** 1999;124(2):115-9 (25 ref.) (Eng. Abstr.) **(Ger)**

[Current therapeutic orientation toward testicular germ cell tumors] Catani M, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):113-7 (24 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

American Cancer Society Lymphedema Workshop. Workgroup I: Treatment of the axilla with surgery and radiation--preoperative and postoperative risk assessment. Leitch AM, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2877-9 (8 ref.)

Surgical treatment and lymphedema. Pressman PI. **Cancer** 1998 Dec 15;83(12 Suppl American):2782-7 (38 ref.)

American Cancer Society Lymphedema Workshop. Workgroup II: Patient education--pre-and posttreatment. Runowicz CD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2880-1 (0 ref.)

Transvaginal evisceration of small bowel after radical hysterectomy and pelvic lymphadenectomy. Dawlatly B, et al. **Gynecol Oncol** 1999 Apr;73(1):165-6 (5 ref.)

METHODS

The role of intraoperative lymphatic mapping and sentinel lymphadenectomy in the management of patients with breast cancer. Ollila DW, et al. **Adv Surg** 1999;32:349-64 (40 ref.)

Minimal access surgery for staging regional lymph nodes: the sentinel-node concept. Krag DN. **Curr Probl Surg** 1998 Nov;35(11):951-1016 (156 ref.)

Sentinel lymphadenectomy in the management of primary cutaneous malignant melanoma. An update. White WL, et al. **Dermatol Clin** 1999 Jul;17(3):645-55, ix-x (33 ref.)

Laparoscopic para-aortic and pelvic lymphadenectomy: experience with 150 patients and review of the literature. Possover M, et al. **Gynecol Oncol** 1998 Oct;71(1):19-28 (50 ref.)

Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. Glass FL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):603-10 (64 ref.)

Selective lateral neck dissection for laryngeal cancer in the clinically negative neck: is it justified? Ferlito A, et al. **J Laryngol Otol** 1998 Oct;112(10):921-4 (24 ref.)

Lymph-node dissection in pancreatic cancer -- what are the facts? Birk D, et al. **Langenbecks Arch Surg** 1999 Apr; 384(2):158-66 (64 ref.)

Actual standards and controversies on operative technique and lymph-node dissection in colorectal cancer. Bruch HP, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):167-75 (89 ref.)

Conservative neck surgery in squamous cell carcinoma. England RJ, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):91-4 (25 ref.)

D2 dissection for gastric cancer. Lee JS, et al. **Surg Oncol** 1997 Dec;6(4):215-25 (55 ref.)

[Axillary lymph node surgery in 1998] Nos C, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):475-81 (43 ref.) (Eng. Abstr.) **(Fre)**

LYMPH NODE EXCISION

[Sentinel lymphadenectomy in malignant melanoma] Büchels HK, et al. **Chirurg** 1998 Jul;69(7):701–7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Sentinel node detection in breast carcinoma] Hohenberger P, et al. **Chirurg** 1998 Jul;69(7):708–16 (39 ref.) (Eng. Abstr.) **(Ger)**

[Lymphadenectomy in colorectal carcinoma] Nieroda CA, et al. **Chirurg** 1998 Jul;69(7):717–24 (33 ref.) (Eng. Abstr.) **(Ger)**

[Complications and results of peri-aortocoval lymphadenectomy in gynecology] Schlicht E, et al. **Zentralbl Gynakol** 1998;120(9):425–36 (51 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Reflections and proposals for the worldwide standardization of lymphadenectomy for gastric carcinoma [letter] Elias D. **J Surg Oncol** 1999 Jun;71(2):120–2 (20 ref.)

[The sentinel node procedure: standard intervention for surgical treatment of breast cancer (see comments)] Meijer S, et al. **Ned Tijdschr Geneeskd** 1998 Oct 10;142(41):2235–7 (14 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 10;142(41):2240–2. Comment in: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2754–5. **(Dut)**

LYMPH NODE HYPERPLASIA, GIANT see **GIANT LYMPH NODE HYPERPLASIA**

LYMPH NODE SYNDROME, MUCOCUTANEOUS see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

LYMPH NODES

see related
LYMPH NODE EXCISION
RADICAL NECK DISSECTION

CYTOLOGY

Benign mesothelial cells in lymph node. Colby TV. **Adv Anat Pathol** 1999 Jan;6(1):41–8 (19 ref.)

In situ analysis of lymphocyte migration to lymph nodes. von Andrian UH, et al. **Cell Adhes Commun** 1998; 6(2–3):85–96 (49 ref.)

The physiology of lymphocyte migration through the single lymph node in vivo. Young AJ. **Semin Immunol** 1999 Apr; 11(2):73–83 (83 ref.)

GROWTH & DEVELOPMENT

MAdCAM-1 dependent colonization of developing lymph nodes involves a unique subset of CD4+CD3- hematolymphoid cells. Mebius RE, et al. **Cell Adhes Commun** 1998;6(2–3):97–103 (50 ref.)

Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Kong YY, et al. **Immunol Cell Biol** 1999 Apr; 77(2):188–93 (45 ref.)

IMMUNOLOGY

Pathways of antigen traffic from skin allotransplant to recipient lymph nodes--an evolutionarily developed route for initiation of rejection of foreign antigens. Olszewski WL, et al. **Ann Transplant** 1998;3(4):15–20 (38 ref.)

Local immune responses in afferent and efferent lymph. Haig DM, et al. **Immunology** 1999 Feb;96(2):155–63 (70 ref.)

Lymph nodes and human tumors (review). Lores B, et al. **Int J Mol Med** 1998 Apr;1(4):729–33 (51 ref.)

MICROBIOLOGY

Microbiology of the intestinal lymph follicle: a clue to elucidate causative microbial agent(s) in Crohn's disease. Chiba M, et al. **Med Hypotheses** 1998 Nov;51(5):421–7 (37 ref.)

PATHOLOGY

Fever of unknown origin due to inflammatory pseudotumour of lymph nodes. Knockaert DC, et al. **Acta Clin Belg** 1998 Dec;53(6):367–70 (10 ref.)

Molecular diagnosis of cancer and micrometastases. Hruban RH, et al. **Adv Anat Pathol** 1998 May;5(3):175–8 (21 ref.)

Primary cutaneous adenoid cystic carcinoma with lymph node metastasis [see comments] Kato N, et al. **Am J Dermatopathol** 1998 Dec;20(6):571–7 (43 ref.) Comment in: Am J Dermatopathol 1999 Aug;21(4):400.

Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'. Logani S, et al. **Am J Surg Pathol** 1999 Jun;23(6):656–61 (11 ref.)

Occult breast carcinoma presenting as an axillary mass. Scoggins CR, et al. **Am Surg** 1999 Jan;65(1):1–5 (8 ref.)

Disseminated tumor cells versus micrometastasis: definitions and problems. Hermanek P. **Anticancer Res** 1999 Jul–Aug; 19(4A):2771–4 (47 ref.)

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Lymphatic mapping and sentinel node biopsy in breast cancer. McIntosh SA, et al. **Br J Surg** 1998 Oct; 85(10):1347–56 (126 ref.)

Infiltrating breast carcinoma smaller than 0.5 centimeters: is lymph node dissection necessary? Saiz E, et al. **Cancer** 1999 May 15;85(10):2206–11 (30 ref.)

Fine needle aspiration cytopathology of malignant lymphoma. Wakely PE Jr. **Clin Lab Med** 1998 Sep; 18(3):541–59, vi–vii (17 ref.)

Minimal access surgery for staging regional lymph nodes: the sentinel-node concept. Krag DN. **Curr Probl Surg** 1998 Nov;35(11):951–1016 (156 ref.)

Sentinel lymphadenectomy in the management of primary cutaneous malignant melanoma. An update. White WL, et al. **Dermatol Clin** 1999 Jul;17(3):645–55, ix–x (33 ref.)

Sentinel lymph node detection and imaging. Keshtgar MRS, et al. **Eur J Nucl Med** 1999 Jan;26(1):57–67 (28 ref.)

Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Nieweg OE, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S11–6 (39 ref.)

The sentinel node procedure in cutaneous melanoma: an overview of 6 years' experience. Statius Muller MG, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S20–5 (52 ref.)

Pathological investigation of sentinel lymph nodes. van Diest PJ, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S43–9 (62 ref.)

Diagnostic approach to lymph node enlargement. Ghirardelli ML, et al. **Haematologica** 1999 Mar;84(3):242–7 (7 ref.)

Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Reintgen DS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):807–21, vii (41 ref.)

The challenge of sentinel lymph node biopsy. Anderson TJ. **Histopathology** 1999 Jul;35(1):82–4 (21 ref.)

A pseudo-tumoral form of Kikuchi's disease in children: a case report and review of the literature. Lerosey Y, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):1–6 (41 ref.)

Sentinel lymphatic mapping in breast cancer. Hill AD, et al. **J Am Coll Surg** 1999 May;188(5):545–9 (41 ref.)

Sentinel node biopsy in breast cancer. Hsueh EC, et al. **J Am Coll Surg** 1999 Aug;189(2):207–13 (65 ref.)

The role of elective lymph node dissection in malignant melanoma: who should undergo this nodal staging procedure? Reintgen D. **J Am Coll Surg** 1999 Aug; 189(2):224–32 (22 ref.)

Fine needle aspiration of lymph nodes. Buley ID. **J Clin Pathol** 1998 Dec;51(12):881–5 (20 ref.)

Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging. Cote RJ, et al. **J Surg Oncol** 1998 Dec;69(4):265–74 (54 ref.)

What can we learn from the phenomenon of preferential lymph node metastasis in carcinoma? Gendreau KM, et al. **J Surg Oncol** 1999 Mar;70(3):199–204 (60 ref.)

Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. Meyer JS. **J Surg Oncol** 1998 Dec;69(4):212–8 (33 ref.)

External beam radiotherapy for pelvic node recurrence after curative resection of colon cancer: report of a case. Masaki T, et al. **Jpn J Clin Oncol** 1999 Apr;29(4):229–33 (24 ref.)

Small B-cell lymphomas of the lymph nodes and spleen: practical insights to diagnosis and pathogenesis. Swerdlow SH. **Mod Pathol** 1999 Feb;12(2):125–40 (193 ref.)

Sentinel lymph node mapping in breast cancer. Cody HS 3rd. **Oncology (Huntingt)** 1999 Jan;13(1):25–34; discussion 35–6, 39, 43 (43 ref.)

Histologic evaluation of neck dissection specimens. Gillies EM, et al. **Otolaryngol Clin North Am** 1998 Oct; 31(5):759–71 (54 ref.)

Interdigitating reticulum cell tumor of lymph node: a case report and literature review. Liu SM, et al. **Pathol Int** 1998 Dec;48(12):974–80 (36 ref.)

Epithelial inclusion in axillary lymph node associated with a breast carcinoma: report of a case with a review of the literature. Fraggetta F, et al. **Pathol Res Pract** 1999; 195(4):263–6 (17 ref.)

Localised primary amyloidosis of inguinal lymph node with superimposed bone metaplasia. Spitale LS, et al. **Pathology** 1998 Aug;30(3):321–2 (14 ref.)

Congenital thyroid teratoma: a case with persistent neuroglial involvement of cervical lymph nodes. Keen CE, et al. **Pediatr Dev Pathol** 1998 Jul–Aug;1(4):322–7 (11 ref.)

Current techniques in sentinel node mapping. Kamm BL. **Radiol Technol** 1999 Mar–Apr;70(4):323–33; quiz 334–7 (46 ref.)

Lymphatic mapping and sentinel lymph node biopsy for nonmelanoma skin cancers. Pu LL, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):527–39, x (25 ref.)

The significance of breast cancer lymph node micrometastases. Yeatman TJ, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):481–96, ix (40 ref.)

Multiple pulmonary metastasis of prostatic carcinoma with little or no bone or lymph node metastasis. Report of two cases and review of the literature. Kume H, et al. **Urol Int** 1999;62(1):44–7 (9 ref.)

[Sentinel node--malignant melanoma and primary breast cancer. The significance of sentinel node in the treatment of malignant melanoma and primary breast cancer] Axelsson CK, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2343–7 (40 ref.) (Eng. Abstr.) **(Dan)**

[The sentinel node procedure: standard intervention for surgical treatment of breast cancer (see comments)] Meijer S, et al. **Ned Tijdschr Geneeskd** 1998 Oct 10;142(41):2235–7 (14 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 10;142(41):2240–2. Comment in: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2754–5. **(Dut)**

[Littoral-cell angioma--a rare differential diagnosis on splenic tumors] Sauer J, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):624–8 (9 ref.) (Eng. Abstr.) **(Ger)**

[The lymph node staging of malignant testicular germ-cell tumors] Krug B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):87–94 (66 ref.) (Eng. Abstr.) **(Ger)**

[Immunocytochemical and molecular proof of disseminated tumor cells in bone marrow, peritoneal lavage, blood and regional lymph nodes. A review of the literature and own results] Broll R, et al. **Zentralbl Chir** 1999;124(4):286–91 (43 ref.) (Eng. Abstr.) **(Ger)**

[Refractory multiple myeloma preceded by extramedullary plasmacytoma of lymph node--a case report and review of the literature] Ise M, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):505–10 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Abdominal lymphoma: lymph node and visceral involvemnet] Sánchez del Peral Otero G, et al. **Sangre (Barc)** 1998 Dec;43(6):483–92 (42 ref.) **(Spa)**

[A new method can result in more accurate staging of breast cancer. Sentinel node biopsy is a possible way to reduce axillary intervention] Bergkvist L. **Lakartidningen** 1999 Apr 7;96(14):1670–2 (19 ref.) **(Swe)**

RADIATION EFFECTS

Elective irradiation of the N0 neck in squamous cell carcinoma of the upper aerodigestive tract. Shasha D, et al. **Otolaryngol Clin North Am** 1998 Oct;31(5):803–13 (48 ref.)

RADIOGRAPHY

Two cases of intrapulmonary lymph node presenting as a peripheral nodular shadow: diagnostic differentiation from lung cancer. Fujimoto N, et al. **Lung Cancer** 1998 Jun; 20(3):203–9 (35 ref.)

RADIONUCLIDE IMAGING

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Radiopharmaceuticals in sentinel lymph-node detection - an overview. Wilhelm AJ, et al. **Eur J Nucl Med** 1999 Apr; 26(4 Suppl):S36–42 (50 ref.)

Use of sentinel node lymphoscintigraphy in malignant melanoma. Yudd AP, et al. **Radiographics** 1999 Mar–Apr; 19(2):343–53; discussion 354–6 (21 ref.)

Sentinel node localization in breast cancer. Glass EC, et al. **Semin Nucl Med** 1999 Jan;29(1):57–68 (75 ref.)

Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Edwards MJ, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):51–7 (26 ref.)

Lymphoscintigraphy in malignant melanoma and breast cancer. Berman CG, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):401–12, vii (22 ref.)

[Contribution of nuclear medicine to lymphatic mapping and sentinel node identification in oncology] Valdés Olmos RA, et al. **Rev Esp Med Nucl** 1999;18(2):111–21 (48 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Sentinel lymphadenectomy in the management of primary cutaneous malignant melanoma. An update. White WL, et al. **Dermatol Clin** 1999 Jul;17(3):645–55, ix–x (33 ref.)

Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Reintgen DS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):807–21, vii (41 ref.)

[Intrapulmonary lymph node detected as a small coin lesion: a case report and a review of the Japanese literature] Kamiyoshihara M, et al. **Kyobu Geka** 1999 Apr;52(4):341–3 (4 ref.) (Eng. Abstr.) **(Jpn)**

[The central nervous system and the lymphatic system. Lymphatic drainage of the cerebrospinal fluid] Kiwic G, et al. **Neurol Neurochir Pol** 1998 May–Jun;32(3):633–41 (20 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

[Ultrasound of the lymph nodes and the subcutis in dermatology. Part 1] Blum A, et al. **Hautarzt** 1998 Dec; 49(12):942–9 (34 ref.) **(Ger)**

LYMPHADENECTOMY see **LYMPH NODE EXCISION**

LYMPHADENITIS

Periodic fever syndrome. Thomas KT, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):68–9 (11 ref.)

[Cervical lymphadenitis] Suzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):617–20 (13 ref.) **(Jpn)**

DIAGNOSIS

Diagnostic approach to lymph node enlargement. Ghirardelli ML, et al. **Haematologica** 1999 Mar;84(3):242–7 (7 ref.)

A pseudo-tumoral form of Kikuchi's disease in children: a case report and review of the literature. Lerosey Y, et al.

Int J Pediatr Otorhinolaryngol 1998 Sep 15;45(1):1–6 (41 ref.)

Benign superior vena cava syndrome due to suppurative mediastinal lymphadenitis: anterior mediastinoscopic management. Roy D, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1185–7 (17 ref.)

MICROBIOLOGY

Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Hazra R, et al. **Clin Infect Dis** 1999 Jan;28(1):123–9 (19 ref.)

PARASITOLOGY

[Toxoplasmic lymphadenitis] Kobayashi H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):335–7 (16 ref.) **(Jpn)**

PATHOLOGY

Atypical mycobacterial lymphadenitis in childhood--a clinicopathological study of 17 cases. Evans MJ, et al. **J Clin Pathol** 1998 Dec;51(12):925–7 (10 ref.)

THERAPY

Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Hazra R, et al. **Clin Infect Dis** 1999 Jan;28(1):123–9 (19 ref.)

Benign superior vena cava syndrome due to suppurative mediastinal lymphadenitis: anterior mediastinoscopic management. Roy D, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1185–7 (17 ref.)

LYMPHADENITIS, HISTIOCYTIC NECROTIZING see **HISTIOCYTIC NECROTIZING LYMPHADENITIS**

LYMPHADENITIS, TUBERCULOUS see **TUBERCULOSIS, LYMPH NODE**

LYMPHADENOPATHY see **LYMPHATIC DISEASES**

LYMPHADENOPATHY-ASSOCIATED ANTIBODIES see **HIV ANTIBODIES**

LYMPHADENOPATHY-ASSOCIATED ANTIGENS see **HIV ANTIGENS**

LYMPHADENOPATHY-ASSOCIATED VIRUS see **HIV**

LYMPHADENOPATHY, IMMUNOBLASTIC see **IMMUNOBLASTIC LYMPHADENOPATHY**

LYMPHANGIECTASIS, INTESTINAL

COMPLICATIONS

Aggressive bowel lymphoma in a patient with intestinal lymphangiectasia and widespread viral warts [letter] Gumà J, et al. **Ann Oncol** 1998 Dec;9(12):1355–6 (6 ref.)

LYMPHANGIOENDOTHELIOMA see **LYMPHANGIOMA**

LYMPHANGIOENDOTHELIOMA, MALIGNANT see **LYMPHANGIOSARCOMA**

LYMPHANGIOMA

Vascular anomalies of the mediastinum. Fishman SJ. **Semin Pediatr Surg** 1999 May;8(2):92–8 (21 ref.)

DIAGNOSIS

Hepatic lymphangiomatosis mimicking polycystic liver disease. O'Sullivan DA, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1188–92 (24 ref.)

PATHOLOGY

Acquired vulvar lymphangioma mimicking genital warts. A case report and review of the literature. Mu XC, et al. **J Cutan Pathol** 1999 Mar;26(3):150–4 (62 ref.)

[Cervical lymphangioma in adults. Description of 2 cases] Muñoz Herrera A, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Nov;115(5):299–302 (21 ref.) (Eng. Abstr.) **(Fre)**

LYMPHANGIOMA, CAVERNOUS see **LYMPHANGIOMA**

LYMPHANGIOMA, CYSTIC

Cystic hygroma in the fetus and newborn. Gallagher PG, et al. **Semin Perinatol** 1999 Aug;23(4):341–56 (113 ref.)

COMPLICATIONS

[Cystic lymphangioma of the mesentery. A case of intestinal obstruction and a brief review of the literature] Fundarò S, et al. **Minerva Chir** 1998 Nov;53(11):939–42 (19 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

[Cystic lymphangioma of the neck and mediastinum: are there acquired forms? Report of 37 cases] Riquet M, et al. **Rev Mal Respir** 1999 Feb;16(1):71–9 (89 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Disseminated cystic lymphangiomatosis presenting with acute abdomen: report of a case and review of the literature. Yang CS, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):196–8 (11 ref.)

Bilateral adrenal cystic lymphangiomas in nevoid basal cell carcinoma (Gorlin–Goltz) syndrome: US, CT, and MR findings. Mortelé KJ, et al. **J Comput Assist Tomogr** 1999 Jul–Aug;23(4):562–4 (7 ref.)

[Cystic lymphangioma of the mediastinum. Apropos of 3 cases, review of the literature] Icard P, et al. **Ann Chir** 1998;52(7):629–34 (25 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Excision of cervical cystic lymphangioma using injection of hydrocolloid dental impression material. A technical case report. Katsuno S, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):295–6 (7 ref.)

LYMPHANGIOMYOMATOSIS

NHLBI Workshop Summary. Report of workshop on lymphangioleiomyomatosis.National Heart, Lung, and Blood Institute. **Am J Respir Crit Care Med** 1999 Feb; 159(2):679–83 (30 ref.)

Lymphangioleiomyomatosis: a review. Sullivan EJ. **Chest** 1998 Dec;114(6):1689–703 (124 ref.)

Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Johnson S. **Thorax** 1999 Mar;54(3):254–64 (105 ref.)

DIAGNOSIS

Pulmonary lymphangioleiomyomatosis in Korea. Oh YM, et al. **Thorax** 1999 Jul;54(7):618–21 (25 ref.)

LYMPHANGIOSARCOMA

ETIOLOGY

Lymphangiosarcoma of the pubic region: a rare complication arising in congenital non-hereditary lymphedema. Cerri A, et al. **Eur J Dermatol** 1998 Oct–Nov;8(7):511–4 (26 ref.)

LYMPHANGITIS

[Acute superficial lymphangitis] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):597–8 (0 ref.) **(Jpn)**

DIAGNOSIS

Lymphocutaneous syndrome. A review of non-sporothrix causes. Smego RA Jr, et al. **Medicine (Baltimore)** 1999 Jan; 78(1):38–63 (261 ref.)

MICROBIOLOGY

Lymphocutaneous syndrome. A review of non-sporothrix causes. Smego RA Jr, et al. **Medicine (Baltimore)** 1999 Jan; 78(1):38–63 (261 ref.)

PATHOLOGY

[Carcinomatous lymphangitis] Hominal S, et al. **Presse Med** 1999 May 15;28(18):979–84 (39 ref.) (Eng. Abstr.) **(Fre)**

LYMPHAPHERESIS see **LEUKAPHERESIS**

LYMPHATIC CAPILLARIES see **LYMPHATIC SYSTEM**

LYMPHATIC DISEASES

see related
CHYLOTHORAX
LEUKEMIA, LYMPHOCYTIC
LYMPHOMA

Managing lumps in the neck. Mady SM. **Practitioner** 1998 Jun;242(1587):472–5 (4 ref.)

COMPLICATIONS

Fever of unknown origin due to inflammatory pseudotumour of lymph nodes. Knockaert DC, et al. **Acta Clin Belg** 1998 Dec;53(6):367–70 (10 ref.)

Non-parasitic chyluria: a case report and review of the literature. Cortvriend J, et al. **Acta Urol Belg** 1998 Oct; 66(3):11–5 (15 ref.)

DIAGNOSIS

Lymphadenopathy: differential diagnosis and evaluation [see comments] Ferrer R. **Am Fam Physician** 1998 Oct 15; 58(6):1313–20 (12 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2984.

Diagnostic and interventional imaging of lymphatic disorders. Witte CL, et al. **Int Angiol** 1999 Mar;18(1):25–30 (23 ref.)

Clear cell (glycogen-rich) rhabdomyosarcoma presenting as cervical lymphadenopathy. Govender D, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb; 61(1):52–4 (9 ref.)

[Left supraclavicular adenopathy with a neuroendocrine pattern of unknown cause: prostatic carcinoma metastasis] Fernández Borrell A, et al. **Actas Urol Esp** 1999 Jul–Aug; 23(7):603–8 (22 ref.) (Eng. Abstr.) **(Spa)**

[Ulcers and regional adenopathies in a butcher] Maradona Hidalgo JA, et al. **Rev Clin Esp** 1998 Nov;198(11):773–4 (4 ref.) **(Spa)**

ETIOLOGY

Lymphadenopathy: differential diagnosis and evaluation [see comments] Ferrer R. **Am Fam Physician** 1998 Oct 15; 58(6):1313–20 (12 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2984.

Primary amyloidosis presenting as massive cervical lymphadenopathy with severe dyspnea: a case report and review of the literature. Leach DB, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):560–4 (21 ref.)

PATHOLOGY

Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'. Logani S, et al. **Am J Surg Pathol** 1999 Jun;23(6):656–61 (11 ref.)

Fine needle aspiration of lymph nodes. Buley ID. **J Clin Pathol** 1998 Dec;51(12):881–5 (20 ref.)

Localised primary amyloidosis of inguinal lymph node with superimposed bone metaplasia. Spitale LS, et al. **Pathology** 1998 Aug;30(3):321–2 (14 ref.)

PHYSIOPATHOLOGY

The skin and its response to movement. Ryan TJ. **Lymphology** 1998 Sep;31(3):128–9 (4 ref.)

LYMPHATIC FILARIASIS see **ELEPHANTIASIS, FILARIAL**

LYMPHATIC IRRADIATION

[Lymph node positive prostate carcinoma. A case for radiotherapy] Steiner U, et al. **Urologe A** 1999 Jul; 38(4):349–52 (26 ref.) (Eng. Abstr.) **(Ger)**

LYMPHATIC METASTASIS

Neck abscess: an unusual presentation of a thoracic malignancy. Thorp MA, et al. **J Laryngol Otol** 1998 Sep; 112(9):891–2 (11 ref.)

Papillary thyroid carcinoma: justification for total thyroidectomy and management of lymph node metastases. Chen H, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):645–63 (64 ref.)

Lymphatic mapping in gynecologic malignancies. Grendys EC Jr, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):541–53, x (40 ref.)

The significance of breast cancer lymph node micrometastases. Yeatman TJ, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):481–96, ix (40 ref.)

[Cervical lymphadenopathy revealing differentiated thyroid cancer. Review of the literature and therapeutic approach] Rodier JF, et al. **Ann Chir** 1998;52(9):922–6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Current results of the treatment of cervical metastatic lymph nodes by concurrent hyperfractionation of carboplatin and irradiation] de Serdio JL, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):554–60 (49 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. Ross MI, et al. **Eur J Cancer** 1998 Jul;34 Suppl 3:S7–11 (15 ref.)

Sentinel lymph node detection and imaging. Keshtgar MRS, et al. **Eur J Nucl Med** 1999 Jan;26(1):57–67 (28 ref.)

Diagnostic approach to lymph node enlargement. Ghirardelli ML, et al. **Haematologica** 1999 Mar;84(3):242–7 (7 ref.)

The challenge of sentinel lymph node biopsy. Anderson TJ. **Histopathology** 1999 Jul;35(1):82–4 (21 ref.)

Clear cell (glycogen-rich) rhabdomyosarcoma presenting as cervical lymphadenopathy. Govender D, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb; 61(1):52–4 (9 ref.)

Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Boiselle PM, et al. **Radiographics** 1998 Sep–Oct; 18(5):1061–9 (17 ref.)

PATHOLOGY

Benign mesothelial cells in lymph node. Colby TV. **Adv Anat Pathol** 1999 Jan;6(1):41–8 (19 ref.)

Small mucosal carcinoma of the stomach with para-aortic lymph node metastasis: a case report and review of the literature. Miyaji M, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):343–6 (15 ref.)

The sentinel node procedure in cutaneous melanoma: an overview of 6 years' experience. Statius Muller MG, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S20–5 (52 ref.)

Pathological investigation of sentinel lymph nodes. van Diest PJ, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S43–9 (62

ref.)
Fine needle aspiration of lymph nodes. Buley ID. **J Clin Pathol** 1998 Dec;51(12):881–5 (20 ref.)
Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging. Cote RJ, et al. **J Surg Oncol** 1998 Dec;69(4):265–74 (54 ref.)
What can we learn from the phenomenon of preferential lymph node metastasis in carcinoma? Gendreau KM, et al. **J Surg Oncol** 1999 Mar;70(3):199–204 (60 ref.)
Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. Meyer JS. **J Surg Oncol** 1998 Dec;69(4):212–8 (33 ref.)
Management of the neck in nasopharyngeal carcinoma (NPC). Brown JJ, et al. **Otolaryngol Clin North Am** 1998 Oct;31(5):785–802 (54 ref.)
Management of the neck in nonmelanocytic cutaneous carcinomas. Brown RO, et al. **Otolaryngol Clin North Am** 1998 Oct;31(5):841–56 (32 ref.)
Management of the neck in thyroid cancer. Shaha AR. **Otolaryngol Clin North Am** 1998 Oct;31(5):823–31 (25 ref.)
Lymphatic mapping and sentinel lymph node biopsy for nonmelanoma skin cancers. Pu LL, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):527–39, x (25 ref.)
Molecular staging for melanoma and breast cancer. Shivers SC, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):515–26 (41 ref.)
[Carcinomatous lymphangitis] Hominal S, et al. **Presse Med** 1999 May 15;28(18):979–84 (39 ref.) (Eng. Abstr.) **(Fre)**
[Experimental model for cancer metastasis] Takahashi Y. **Gan To Kagaku Ryoho** 1999 Feb;26(3):401–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Selective lateral neck dissection for laryngeal cancer with limited metastatic disease: is it indicated? Ferlito A, et al. **J Laryngol Otol** 1998 Nov;112(11):1031–3 (19 ref.)

RADIOGRAPHY

Lymphatic mapping in breast cancer. Dauway EL, et al. **Hematol Oncol Clin North Am** 1999 Apr;13(2):349–71, vi (32 ref.)

RADIONUCLIDE IMAGING

Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Nieweg OE, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S11–6 (39 ref.)
Lymphoscintigraphy in oncology: a rediscovered challenge. Valdés Olmos RA, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S2–S10 (56 ref.)
Radiopharmaceuticals in sentinel lymph-node detection – an overview. Wilhelm AJ, et al. **Eur J Nucl Med** 1999 Apr; 26(4 Suppl):S36–42 (50 ref.)
Sentinel node localisation: A new prospective in the treatment of nodal melanoma metastases. Gennari R, et al. **Int J Oncol** 1999 Jul;15(1):25–32 (36 ref.)
Nuclear medicine and the surgeon. Krag D, et al. **Lancet** 1999 Sep 18;354(9183):1019–22 (33 ref.)
Radiopharmaceuticals for sentinel node detection. Frier M. **Nucl Med Commun** 1999 Apr;20(4):306–8 (12 ref.)
Sentinel node lymphoscintigraphy in malignant melanoma. O'Doherty M, et al. **Nucl Med Commun** 1999 Apr; 20(4):305–6 (7 ref.)
Specification and performance of intra-operative gamma probes for sentinel node detection. Perkins AC, et al. **Nucl Med Commun** 1999 Apr;20(4):309–15 (36 ref.)
Sentinel node localization in breast cancer. Glass EC, et al. **Semin Nucl Med** 1999 Jan;29(1):57–68 (75 ref.)
Lymphoscintigraphy in malignant melanoma and breast cancer. Berman CG, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):401–12, vii (22 ref.)
Techniques for lymphatic mapping in breast carcinoma. Cox CE, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):447–68, viii (25 ref.)
Radioguided surgery for melanoma. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):413–26, vii (29 ref.)
[Contribution of nuclear medicine to lymphatic mapping and sentinel node identification in oncology] Valdés Olmos RA, et al. **Rev Esp Med Nucl** 1999;18(2):111–21 (48 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Does pelvic irradiation play a role in the management of prostate cancer? Stock RG, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1467–72; discussion 1472, 1475–6 (47 ref.)

LYMPHATIC RADIATION THERAPY see **LYMPHATIC IRRADIATION**

LYMPHATIC SARCOMA see **LYMPHOMA, DIFFUSE**

LYMPHATIC SYSTEM

ANATOMY & HISTOLOGY

The brain and the lymphatic system revisited. Földi M. **Lymphology** 1999 Jun;32(2):40–4 (13 ref.)

EMBRYOLOGY

Embryonic lymphangiogenesis. Wilting J, et al. **Cell Tissue Res** 1999 Jul;297(1):1–11 (86 ref.)

GROWTH & DEVELOPMENT

Analysing the developing lymphocyte system of neonates and infants. de Vries E, et al. **Eur J Pediatr** 1999 Aug; 158(8):611–7 (50 ref.)

IMMUNOLOGY

Prion diseases and the immune system [editorial] Aucouturier P, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):75–8 (26 ref.)
The lymphoid system and its role in maintaining immunocompetence. Workman ML. **Semin Oncol Nurs** 1998 Nov;14(4):248–55 (22 ref.)

PHYSIOLOGY

The skin and its response to movement. Ryan TJ. **Lymphology** 1998 Sep;31(3):128–9 (4 ref.)
[Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C] Mandriota SJ, et al. **J Soc Biol** 1999;193(2):159–63 (31 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The pathophysiology of lymphedema. Mortimer PS. **Cancer** 1998 Dec 15;83(12 Suppl American):2798–802 (24 ref.)

RADIONUCLIDE IMAGING

Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Nieweg OE, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S11–6 (39 ref.)
Lymphoscintigraphy in oncology: a rediscovered challenge. Valdés Olmos RA, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S2–S10 (56 ref.)

LYMPHATIC VENULES see **LYMPHATIC SYSTEM**

LYMPHATISM see **LYMPHATIC DISEASES**

LYMPHEDEMA

American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Rockson SG, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2882–5 (8 ref.)
Lymphedema following breast cancer treatment. Davis S. **Radiol Technol** 1998 Sep–Oct;70(1):42–56; quiz 57–60 (47 ref.)

CLASSIFICATION

Lymphedema: classification, diagnosis and therapy. Szuba A, et al. **Vasc Med** 1998;3(2):145–56 (158 ref.)

COMPLICATIONS

Lymphangiosarcoma of the pubic region: a rare complication arising in congenital non-hereditary lymphedema. Cerri A, et al. **Eur J Dermatol** 1998 Oct–Nov;8(7):511–4 (26 ref.)

DIAGNOSIS

Lymphedema-distichiasis syndrome: report of a case and review [letter] Johnson SM, et al. **Arch Dermatol** 1999 Mar; 135(3):347–8 (5 ref.)
Imaging techniques in the management and prevention of posttherapeutic upper limb edemas. Bourgeois P, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2805–13 (75 ref.)
A review of measures of lymphedema. Gerber LH. **Cancer** 1998 Dec 15;83(12 Suppl American):2803–4 (12 ref.)
ISL Consensus Document revisited: suggested modifications (summarized from discussions at the 16th ICL, Madrid, Spain, September 1997 and the Interim ISL Executive Committee meeting). Witte MH, et al. **Lymphology** 1998 Sep;31(3):138–40 (0 ref.)
[Post-therapeutic lymphedema of the arm--possibilities and limits of diagnosis and therapy] Döller W. **Wien Med Wochenschr** 1999;149(2–4):101–4 (33 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Benzo-pyrones in the treatment of lymphoedema. Casley-Smith JR. **Int Angiol** 1999 Mar;18(1):31–41 (41 ref.)

ETIOLOGY

Massive localized lymphedema in the morbidly obese: a histologically distinct reactive lesion simulating liposarcoma. Farshid G, et al. **Am J Surg Pathol** 1998 Oct; 22(10):1277–83 (4 ref.)
Imaging techniques in the management and prevention of posttherapeutic upper limb edemas. Bourgeois P, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2805–13 (75 ref.)
Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Brennan MJ, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2821–7 (51 ref.)
American Cancer Society Lymphedema Workshop: Workgroup V: Collaboration and advocacy. Candeira M, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2888–90 (0 ref.)
The treatment of lymphedema. Földi E. **Cancer** 1998 Dec 15;83(12 Suppl American):2833–4 (0 ref.)
A review of measures of lymphedema. Gerber LH. **Cancer** 1998 Dec 15;83(12 Suppl American):2803–4 (12 ref.)
The Vodder School: the Vodder method. Kasseroller RG. **Cancer** 1998 Dec 15;83(12 Suppl American):2840–2 (8 ref.)
American Cancer Society Lymphedema Workshop. Workgroup I: Treatment of the axilla with surgery and radiation--preoperative and postoperative risk assessment. Leitch AM, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2877–9 (8 ref.)
Complete decongestive physiotherapy and the Lerner Lymphedema Services Academy of Lymphatic Studies (the Lerner School). Lerner R. **Cancer** 1998 Dec 15;83(12 Suppl American):2861–3 (13 ref.)
Breast radiotherapy and lymphedema. Meek AG. **Cancer** 1998 Dec 15;83(12 Suppl American):2788–97 (68 ref.)
The pathophysiology of lymphedema. Mortimer PS. **Cancer** 1998 Dec 15;83(12 Suppl American):2798–802 (24 ref.)
Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Passik SD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2817–20 (12 ref.)
Incidence of breast carcinoma-related lymphedema. Petrek JA, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2776–81 (22 ref.)
Surgical treatment and lymphedema. Pressman PI. **Cancer** 1998 Dec 15;83(12 Suppl American):2782–7 (38 ref.)
Conservative approaches to lymphedema treatment. Rinehart-Ayres ME. **Cancer** 1998 Dec 15;83(12 Suppl American):2828–32 (26 ref.)
Precipitating factors in lymphedema: myths and realities. Rockson SG. **Cancer** 1998 Dec 15;83(12 Suppl American):2814–6 (9 ref.)
Lymphedema: patient and provider education: current status and future trends. Runowicz CD. **Cancer** 1998 Dec 15;83(12 Suppl American):2874–6 (5 ref.)
American Cancer Society Lymphedema Workshop. Workgroup II: Patient education--pre-and posttreatment. Runowicz CD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2880–1 (0 ref.)
Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864–8 (2 ref.)
American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources--professional education and availability of patient services. Walley DR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2886–7 (0 ref.)
Metastatic basal cell carcinoma presenting as unilateral lymphedema. Christian MM, et al. **Dermatol Surg** 1998 Oct; 24(10):1151–3 (10 ref.)
[Seromas (lymphorrhea) after surgical treatment of breast cancer] Bulynskii BT, et al. **Vopr Onkol** 1999;45(3):219–22 (42 ref.) **(Rus)**

PHYSIOPATHOLOGY

The pathophysiology of lymphedema. Mortimer PS. **Cancer** 1998 Dec 15;83(12 Suppl American):2798–802 (24 ref.)

PREVENTION & CONTROL

American Cancer Society Lymphedema Workshop. Workgroup I: Treatment of the axilla with surgery and radiation--preoperative and postoperative risk assessment. Leitch AM, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2877–9 (8 ref.)
American Cancer Society Lymphedema Workshop. Workgroup II: Patient education--pre-and posttreatment. Runowicz CD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2880–1 (0 ref.)
[Seromas (lymphorrhea) after surgical treatment of breast cancer] Bulynskii BT, et al. **Vopr Onkol** 1999;45(3):219–22 (42 ref.) **(Rus)**

PSYCHOLOGY

Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Passik SD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2817–20 (12 ref.)

RADIOGRAPHY

[Computerized tomography of 150 cases of lymphedema of the leg] Marotel M, et al. **J Radiol** 1998 Nov;79(11):1373–8 (9 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Treatment for lymphedema of the arm--the Casley-Smith method: a noninvasive method produces continued reduction. Casley-Smith JR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2843–60 (55 ref.)
The Vodder School: the Vodder method. Kasseroller RG. **Cancer** 1998 Dec 15;83(12 Suppl American):2840–2 (8 ref.)
Complete decongestive physiotherapy and the Lerner Lymphedema Services Academy of Lymphatic Studies (the Lerner School). Lerner R. **Cancer** 1998 Dec 15;83(12 Suppl

American):2861-3 (13 ref.)

THERAPY

Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Brennan MJ, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2821-7 (51 ref.)

American Cancer Society Lymphedema Workshop: Workgroup V: Collaboration and advocacy. Candeira M, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2888-90 (0 ref.)

The treatment of lymphedema. Földi E. **Cancer** 1998 Dec 15;83(12 Suppl American):2833-4 (0 ref.)

Conservative approaches to lymphedema treatment. Rinehart-Ayres ME. **Cancer** 1998 Dec 15;83(12 Suppl American):2828-32 (26 ref.)

Lymphedema: patient and provider education: current status and future trends. Runowicz CD. **Cancer** 1998 Dec 15;83(12 Suppl American):2874-6 (5 ref.)

Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864-8 (2 ref.)

American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources--professional education and availability of patient services. Walley DR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2886-7 (0 ref.)

ISL Consensus Document revisited: suggested modifications (summarized from discussions at the 16th ICL, Madrid, Spain, September 1997 and the Interim ISL Executive Committee meeting). Witte MH, et al. **Lymphology** 1998 Sep;31(3):138-40 (0 ref.)

Physical therapist management of lymphedema following treatment for breast cancer: a critical review of its effectiveness. Megens A, et al. **Phys Ther** 1998 Dec; 78(12):1302-11 (39 ref.)

Lymphedema of the limb. An overview of treatment options. Tunkel RS, et al. **Postgrad Med** 1998 Oct;104(4):131-4, 137-8, 141 passim (30 ref.)

LYMPHOBLAST TRANSFORMATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOBLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOBLASTIC LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

LYMPHOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

LYMPHOBLASTIC LEUKEMIA, ACUTE, ADULT see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOBLASTIC LEUKEMIA, ACUTE, CHILDHOOD see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOBLASTIC LEUKEMIA, ACUTE, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOBLASTIC LEUKEMIA, ACUTE, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOBLASTIC LEUKEMIA, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOBLASTIC LEUKEMIA, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

LYMPHOBLASTIC LYMPHOMA see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOBLASTIC LYMPHOSARCOMA, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOCYTAPHERESIS see **LEUKAPHERESIS**

LYMPHOCYTE-ACTIVATING FACTOR see **INTERLEUKIN-1**

LYMPHOCYTE ACTIVATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOCYTE CHEMOATTRACTANT FACTOR see **INTERLEUKIN-16**

LYMPHOCYTE COUNT

[Flow cytometry in the diagnosis of the primary immunodeficiencies] Garcia Rodriguez MC, et al. **Sangre (Barc)** 1999 Apr;44(2):127-33 (27 ref.) **(Spa)**

LYMPHOCYTE COUNT, CD4 see **CD4 LYMPHOCYTE COUNT**

T4 LYMPHOCYTE COUNT see **CD4 LYMPHOCYTE COUNT**

LYMPHOCYTE DEPLETION

[Leukocyte depletion] Bégué S. **Transfus Clin Biol** 1998 Dec; 5(6):411-4 (6 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates. Corash L. **Vox Sang** 1998;74 Suppl 2:173-6 (45 ref.)

B-LYMPHOCYTE DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

T-LYMPHOCYTE DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

B-LYMPHOCYTE EPITOPES see **EPITOPES, B-LYMPHOCYTE**

T-LYMPHOCYTE EPITOPES see **EPITOPES, T-LYMPHOCYTE**

LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1

BLOOD

[New therapeutic strategy for autoimmune diseases. 2) Abnormality in expression of cell surface molecules in systemic erythematodes and its therapeutic application] Takasaki Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1741-4 (3 ref.) **(Jpn)**

IMMUNOLOGY

Making a little affinity go a long way: a topological view of LFA-1 regulation. Dustin ML. **Cell Adhes Commun** 1998;6(2-3):255-62 (36 ref.)

METABOLISM

Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Watanabe T, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S45-53; discussion S55 (57 ref.)

The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Takasaki Y, et al. **Intern Med** 1999 Feb;38(2):175-7 (8 ref.)

B-LYMPHOCYTE GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE**

T-LYMPHOCYTE GENE REARRANGEMENT see **GENE REARRANGEMENT, T-LYMPHOCYTE**

B-LYMPHOCYTE HEAVY CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

LYMPHOCYTE HOMING RECEPTORS see **RECEPTORS, LYMPHOCYTE HOMING**

LYMPHOCYTE IMMUNOPHENOTYPING see **IMMUNOPHENOTYPING**

LYMPHOCYTE MEDIATORS see **LYMPHOKINES**

LYMPHOCYTE MITOGENIC FACTOR see **INTERLEUKIN-2**

B-LYMPHOCYTE MU CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK)

PHYSIOLOGY

Molecular requirements for lineage commitment in the thymus--antibody-mediated receptor engagements reveal a central role for lck in lineage decisions. Basson MA, et al. **Immunol Rev** 1998 Oct;165:181-94 (94 ref.)

LYMPHOCYTE STIMULATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOCYTE SUBPOPULATIONS see **LYMPHOCYTE SUBSETS**

LYMPHOCYTE SUBSETS

see related
IMMUNOPHENOTYPING

[Flow cytometry in the diagnosis of the primary immunodeficiencies] Garcia Rodriguez MC, et al. **Sangre (Barc)** 1999 Apr;44(2):127-33 (27 ref.) **(Spa)**

CYTOLOGY

Dealing from the evolutionary pawnshop: how lymphocytes make decisions. Reiner SL, et al. **Immunity** 1999 Jul; 11(1):1-10 (100 ref.)

Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells. Paloczi K. **Leukemia** 1999 Apr;13 Suppl 1:S87-9 (36 ref.)

IMMUNOLOGY

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674-5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733-40.

Dealing from the evolutionary pawnshop: how lymphocytes make decisions. Reiner SL, et al. **Immunity** 1999 Jul; 11(1):1-10 (100 ref.)

[Natural cytotoxicity in complex of cell interactions] Cheknev SB. **Vestn Ross Akad Med Nauk** 1999;(4):30-4 (52 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Novel CD4 and CD8 T-cell subsets. Thomas MJ, et al. **Allergy** 1998 Dec;53(12):1122-32 (121 ref.)

B-LYMPHOCYTE SUBSETS

IMMUNOLOGY

Peritoneal B-1 cells switch in vivo to IgA and these IgA antibodies can bind to bacteria of the normal intestinal microflora. Kroese FG, et al. **Curr Top Microbiol Immunol** 1999;246:343-9; discussion 350 (25 ref.)

CD21high IgMhigh splenic B cells enriched in the marginal zone: distinct phenotypes and functions. Martin F, et al. **Curr Top Microbiol Immunol** 1999;246:45-50; discussion 51-2 (9 ref.)

CD5 expression in human B-cell populations. Youinou P, et al. **Immunol Today** 1999 Jul;20(7):312-6 (60 ref.)

T-LYMPHOCYTE SUBSETS

CHEMISTRY

Selective differences in the expression of the homing receptors of helper lymphocyte subsets. Burastero SE, et al. **Clin Immunol Immunopathol** 1998 Nov;89(2):110-6 (54 ref.)

CYTOLOGY

Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Maino VC, et al. **Cytometry** 1998 Oct 15;34(5):207-15 (61 ref.)

The role of vitamin E in T-cell differentiation and the decrease of cellular immunity with aging. Moriguchi S, et al. **J Med Invest** 1998 Aug;45(1-4):1-8 (35 ref.)

Signals involved in gamma/delta T cell versus alpha/beta T cell lineage commitment. Hayday AC, et al. **Semin Immunol** 1999 Aug;11(4):239-49 (79 ref.)

IMMUNOLOGY

Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. Biron CA, et al. **Adv Exp Med Biol** 1998;452:143-9 (32 ref.)

Interleukin-4 production in response to infection with intracellular bacteria. Collins H, et al. **Adv Exp Med Biol** 1998;452:75-83 (29 ref.)

The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1999 Jul; 42(1):44-8 (47 ref.)

Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model. Toyoda H, et al. **Bioessays** 1998 Sep;20(9):750-7 (66 ref.)

T-cell subsets: chemokine receptors guide the way. O'Garra A, et al. **Curr Biol** 1998 Sep 10;8(18):R646-9 (29 ref.)

The new numerology of immunity mediated by virus-specific CD8(+) T cells. Doherty PC. **Curr Opin Microbiol** 1998 Aug;1(4):419-22 (37 ref.)

T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Weyand CM, et al. **Curr Opin Rheumatol** 1999 May;11(3):210-7 (47 ref.)

The role of chemokine receptors in directing traffic of naive, type 1 and type 2 T cells. Sallusto F, et al. **Curr Top Microbiol Immunol** 1999;246:123-8; discussion 129 (21 ref.)

Human CD4+ T cell differentiation and effector function: implications for autoimmunity. Davis LS, et al. **Immunol Res** 1999;19(1):25-34 (60 ref.)

T-cell clonality in immune responses. Maini MK, et al. **Immunol Today** 1999 Jun;20(6):262-6 (66 ref.)

Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71-6 (55 ref.)

Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Akdis CA, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):140-4 (23 ref.)

Characterization of porcine T lymphocytes and their immune

response against viral antigens. Saalmüller A, et al. **J Biotechnol** 1999 Aug 20;73(2–3):223–33 (70 ref.)

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Greil R, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):477–90 (69 ref.)

Immunoregulation of cytokines in infectious diseases (leprosy), future strategies. Singh RP. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):263–8 (34 ref.)

Cytokine- and T-helper-dependent immunity in murine aspergillosis. Cenci E, et al. **Res Immunol** 1998 May-Jun; 149(4–5):445–54; discussion 504–5 (60 ref.)

[Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives] Gaugler B, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):771–8 (64 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of the contact sensitivity reaction by suppression of T gamma delta lymphocytes] Szczepanik M. **Folia Med Cracov** 1998;39(1–2):5–33 (68 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Maino VC, et al. **Cytometry** 1998 Oct 15;34(5):207–15 (61 ref.)

TCR specificity in infection induced granulomas. Hogan LH, et al. **Immunol Lett** 1999 May 3;68(1):115–20 (36 ref.)

T cell receptors in health and disease. Introduction. Grunewald J, et al. **Springer Semin Immunopathol** 1999; 21(1):1–4 (6 ref.)

gamma delta T cells, their T cell receptor usage and role in human diseases. Kabelitz D, et al. **Springer Semin Immunopathol** 1999;21(1):55–75 (196 ref.)

PATHOLOGY

Clinical and preclinical immunology of type 1 diabetes. de Vries RR, et al. **Neth J Med** 1998 Sep;53(3):127–9 (7 ref.)

T cell receptors in health and disease. Introduction. Grunewald J, et al. **Springer Semin Immunopathol** 1999; 21(1):1–4 (6 ref.)

PHYSIOLOGY

Immunoregulatory functions of gamma delta T cells. Born W, et al. **Adv Immunol** 1999;71:77–144 (357 ref.)

Alpha beta/gamma delta lineage commitment in the thymus of normal and genetically manipulated mice. Fehling HJ, et al. **Adv Immunol** 1999;71:1–76 (236 ref.)

The importance of lymphocyte trafficking in regulating blood lymphocyte levels during HIV and SIV infections. Rosenberg YJ, et al. **Semin Immunol** 1999 Apr;11(2):139–54 (113 ref.)

LYMPHOCYTE SUBTYPING see **IMMUNOPHENOTYPING**

LYMPHOCYTE TRANSFORMATION

Mechanisms of cell transformation by Herpesvirus saimiri. Tsygankov AY, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):973–83 (120 ref.)

Effector pathways regulating T cell activation. Favero J, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1539–47 (137 ref.)

How to extinguish lymphocyte activation, immunotyrosine-based inhibition motif (ITIM)-bearing molecules a solution? Blery M, et al. **Clin Chem Lab Med** 1999 Mar;37(3):187–91 (54 ref.)

Leucocyte activation markers in clinical practice. Viedma Contreras JA. **Clin Chem Lab Med** 1999 Jun;37(6):607–22 (226 ref.)

FcR-mediated inhibition of cell activation and other forms of coinhibition. Anderson CC, et al. **Crit Rev Immunol** 1998; 18(6):525–44 (131 ref.)

CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells. Frasca L, et al. **Crit Rev Immunol** 1998; 18(6):569–94 (221 ref.)

CD28/B7 costimulation: a review. Greenfield EA, et al. **Crit Rev Immunol** 1998;18(5):389–418 (229 ref.)

Costimulatory regulation of T cell function. Chambers CA, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):203–10 (81 ref.)

Lymphocyte activation: the coming of the protein tyrosine phosphatases. Mustelin T, et al. **Front Biosci** 1998 Nov 1; 3:D1060–96 (473 ref.)

Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15 (161 ref.)

LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Klein E, et al. **Immunol Lett** 1999 May 3;68(1):147–54 (33 ref.)

The influence of base sequence on the immunostimulatory properties of DNA. Pisetsky DS. **Immunol Res** 1999; 19(1):35–46 (60 ref.)

Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor. Scheipers P, et al. **Immunol Res** 1998;18(2):103–15 (93 ref.)

Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Lehmann PV, et al. **Immunol Rev** 1998 Aug;164:53–61 (59 ref.)

The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. McAdam AJ, et al. **Immunol Rev** 1998 Oct;165:231–47 (96 ref.)

Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification. Nishimura Y, et al. **Intern Med** 1998 Oct;37(10):804–17 (96 ref.)

HIV infection and signal transduction. Bovolenta C, et al. **J Biol Regul Homeost Agents** 1998 Jul-Sep;12(3):63–6 (56 ref.)

Recent developments in lymphocyte activation: linking kinases to downstream signaling events. Clements JL, et al. **J Clin Invest** 1999 Apr;103(7):925–9 (43 ref.)

Target cell-induced apoptosis in IL-2-activated human natural killer cells. Taga K, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):451–8 (49 ref.)

Differential signalling by variant ligands of the T cell receptor and the kinetic model of T cell activation. Madrenas J. **Life Sci** 1999;64(9):717–31 (118 ref.)

Natural killer cell reactivity: activation and cytolysis mechanism models, involving heat shock protein, haemopoietic histocompatibility, major histocompatibility complex and complement molecules. Manzo G. **Med Hypotheses** 1998 Jul;51(1):5–9 (30 ref.)

Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Zimmermann AG, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:181–209 (179 ref.)

Pathogenesis and treatment of central nervous system demyelinating disease. Zamvil SS, et al. **Rev Neurol (Paris)** 1998 Sep;154(8–9):573–5 (8 ref.)

Role of 4-1BB in immune responses. Vinay DS, et al. **Semin Immunol** 1998 Dec;10(6):481–9 (43 ref.)

Apoptosis of activated peripheral T cells. Genestier L, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2A):33S–38S (87 ref.)

T-cell activation pathways: a transplantation perspective. Halloran PF. **Transplant Proc** 1999 Feb-Mar; 31(1–2):769–71 (10 ref.)

Integrins and T helper cell activation [see comments] van Seventer GA, et al. **Transplant Proc** 1998 Dec;30(8):4270–4 (60 ref.) Comment in: Transplant Proc 1998 Dec;30(8):4269.

Mutated Ras peptides as vaccines in immunotherapy of cancer. Gjertsen MK, et al. **Vox Sang** 1998;74 Suppl 2:489–95 (49 ref.)

[Early nuclear modifications related to cellular activation: from histology to molecular cytopathology (1967–1997)] Pompidou A. **Bull Acad Natl Med** 1999;183(1):143–55; discussion 156–8 (68 ref.) (Eng. Abstr.) **(Fre)**

[How the membrane gangliosides modulate T cell activation?] Nohara K. **Seikagaku** 1999 May;71(5):337–41 (15 ref.) **(Jpn)**

IMMUNOLOGY

Inhibitory pathways triggered by ITIM-containing receptors. Bolland S, et al. **Adv Immunol** 1999;72:149–77 (180 ref.)

Current views in intracellular transport: insights from studies in immunology. Hsu VW, et al. **Adv Immunol** 1998; 70:369–415 (259 ref.)

Giant cell arteritis—a molecular approach to the multiple facets of the syndrome. Weyand CM, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):420–4 (24 ref.)

T-cell activation and the dynamic world of rafts. Viola A, et al. **APMIS** 1999 Jul;107(7):615–23 (70 ref.)

From TCR engagement to T cell activation: a kinetic view of T cell behavior. Lanzavecchia A, et al. **Cell** 1999 Jan 8;96(1):1–4 (29 ref.)

The actin cytoskeleton and lymphocyte activation. Penninger JM, et al. **Cell** 1999 Jan 8;96(1):9–12 (20 ref.)

Probing the activation requirements for naive CD8+ T cells with Drosophila cell transfectants as antigen presenting cells. Cai Z, et al. **Immunol Rev** 1998 Oct;165:249–65 (65 ref.)

T-cell survival. Marrack P, et al. **Immunol Rev** 1998 Oct; 165:279–85 (26 ref.)

T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. de Rosbo NK, et al. **J Autoimmun** 1998 Aug;11(4):287–99 (120 ref.)

TCR peptide-reactive T cells and peripheral tolerance to myelin basic protein. Kumar V. **Res Immunol** 1998 Nov-Dec;149(9):827–34; discussion 852–4, 855–60 (66 ref.)

T-cell design: optimizing the therapeutic potential of autoreactive T cells by genetic modification. Tuohy VK, et al. **Res Immunol** 1998 Nov-Dec;149(9):834–42; discussion 854–60 (54 ref.)

[Regulation of T-cell activation by CD28 and CTLA-4] Nagel T, et al. **Med Klin** 1998 Oct 15;93(10):592–7 (41 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The structural basis of T cell activation by superantigens. Li H, et al. **Annu Rev Immunol** 1999;17:435–66 (183 ref.)

Adhesion and lymphocyte costimulatory molecules in systemic rheumatic diseases. Sfikakis PP, et al. **Clin Rheumatol** 1999;18(4):317–27 (129 ref.)

Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Höllsberg P. **Microbiol Mol Biol Rev** 1999 Jun;63(2):308–33 (325 ref.)

Cytoskeletal rearrangement during migration and activation of T lymphocytes. Serrador JM, et al. **Trends Cell Biol** 1999 Jun;9(6):228–33 (49 ref.)

[CD45, antigen with phosphatase activity, structure; function and role in T lymphocyte activation] Bohr I, et al. **Postepy Biochem** 1998;44(3):208–15 (79 ref.) **(Pol)**

[Antigen peptide/MHC complex as an initiator of a signal for lymphocyte T activation] Kuśnierczyk P. **Postepy Hig Med Dosw** 1999;53(2):331–41 (24 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

The treatment of blood components with ultraviolet-B irradiation. Pamphilon DH. **Vox Sang** 1998;74 Suppl 2:15–9 (9 ref.)

LYMPHOCYTES

see related

ANTILYMPHOCYTE SERUM

Histologically proven lymphocytic hypophysitis: spontaneous resolution and subsequent pregnancy. Gagneja H, et al. **Mayo Clin Proc** 1999 Feb;74(2):150–4 (29 ref.)

[Collagenous and lymphocytic colitis] Mühlhöfer A, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):435–40 (48 ref.) **(Ger)**

[Lymphocytic leukemoid reaction] Miwa A. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):169–75 (14 ref.) **(Jpn)**

[Collagenous colitis and lymphocytic colitis: not such an infrequent diagnosis (editorial)] Fernández-Bañares F. **Rev Esp Enferm Dig** 1999 Feb;91(2):91–2 (12 ref.) **(Spa)**

CHEMISTRY

Making a little affinity go a long way: a topological view of LFA-1 regulation. Dustin ML. **Cell Adhes Commun** 1998;6(2–3):255–62 (36 ref.)

The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. Ferrero E, et al. **J Leukoc Biol** 1999 Feb;65(2):151–61 (77 ref.)

CYTOLOGY

Lymphohematopoietic stem cell engraftment. Quesenberry PJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:40–5; discussion 45–7 (19 ref.)

Cell death induced in lymphocytes expressing the elastin-laminin receptor by excess agonists: necrosis and apoptosis. Péterszegi G, et al. **Biomed Pharmacother** 1998; 52(9):369–77 (33 ref.)

The two poles of the lymphocyte: specialized cell compartments for migration and recruitment. del Pozo MA, et al. **Cell Adhes Commun** 1998;6(2–3):125–33 (50 ref.)

Making a little affinity go a long way: a topological view of LFA-1 regulation. Dustin ML. **Cell Adhes Commun** 1998;6(2–3):255–62 (36 ref.)

Vascular and non-vascular ligands for L-selectin. Kawashima H, et al. **Cell Adhes Commun** 1998;6(2–3):135–9 (26 ref.)

Discrete domains within the hyaluronan receptor CD44 regulate membrane localization and cell migration. Sheikh H, et al. **Cell Adhes Commun** 1998;6(2–3):149–56 (44 ref.)

In situ analysis of lymphocyte migration to lymph nodes. von Andrian UH, et al. **Cell Adhes Commun** 1998; 6(2–3):85–96 (49 ref.)

Apoptosis signaling in lymphocytes. Scaffidi C, et al. **Curr Opin Immunol** 1999 Jun;11(3):277–85 (113 ref.)

Lymphocyte development in fish and amphibians. Hansen JD, et al. **Immunol Rev** 1998 Dec;166:199–220 (159 ref.)

Genetic models of abnormal apoptosis in lymphocytes. Refaeli Y, et al. **Immunol Rev** 1999 Jun;169:273–82 (48 ref.)

Apoptosis: mechanisms of life and death in the immune system [see comments] Cohen JJ. **J Allergy Clin Immunol** 1999 Apr;103(4):548–54 (47 ref.) Comment in: J Allergy Clin Immunol 1999 Apr;103(4):555–8.

Apoptosis of eosinophils and lymphocytes in allergic inflammation. Ohta K, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):14–21 (57 ref.)

DRUG EFFECTS

Uncaria tomentosa (Willd.) DC.—ethnomedicinal use and new pharmacological, toxicological and botanical results. Keplinger K, et al. **J Ethnopharmacol** 1999 Jan;64(1):23–34 (60 ref.)

ENZYMOLOGY

Drug metabolizing enzymes in lymphocytes. Raucy JL, et al. **J Biochem Mol Toxicol** 1999;13(3–4):223–6 (22 ref.)

Phospholipase A2 (EC 3.1.1.4) and D (EC 3.1.4.4) signalling in lymphocytes. Wakelam MJ, et al. **Proc Nutr Soc** 1998 Nov;57(4):551–4 (22 ref.)

IMMUNOLOGY

Lymphocyte trafficking and regional immunity. Butcher EC, et al. **Adv Immunol** 1999;72:209–53 (178 ref.)

Biology of the interleukin-2 receptor. Nelson BH, et al. **Adv Immunol** 1998;70:1–81 (442 ref.)

Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Franklin J, et al. **Ann Oncol** 1998;9 Suppl 5:S39–44 (30 ref.)

Lymphocyte recirculation, exercise, and immune responses. **Hay JB**, et al. **Can J Physiol Pharmacol** 1998 May; 76(5):490–6 (38 ref.)
The recirculation of naive and memory lymphocytes. Watson SR, et al. **Cell Adhes Commun** 1998;6(2–3):105–10 (51 ref.)
How do lymphocytes kill tumor cells? Graubert TA, et al. **Clin Cancer Res** 1996 May;2(5):785–9 (52 ref.)
Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Kwon B, et al. **Curr Opin Immunol** 1999 Jun;11(3):340–5 (33 ref.)
Apoptosis signaling in lymphocytes. Scaffidi C, et al. **Curr Opin Immunol** 1999 Jun;11(3):277–85 (113 ref.)
Interactions of LIRs, a family of immunoreceptors expressed in myeloid and lymphoid cells, with viral and cellular MHC class I antigens. Borges L, et al. **Curr Top Microbiol Immunol** 1999;244:123–36 (49 ref.)
A novel family of inhibitory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **Curr Top Microbiol Immunol** 1999; 244:115–22 (39 ref.)
Adrenergic/cholinergic immunomodulation in the rat model--in vivo veritas? Rinner I, et al. **Dev Immunol** 1998; 6(3–4):245–52 (35 ref.)
Molecules controlling lymphocyte migration to the gut. Salmi M, et al. **Gut** 1999 Jul;45(1):148–53 (61 ref.)
Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15 (161 ref.)
Genetic models of abnormal apoptosis in lymphocytes. Refaeli Y, et al. **Immunol Rev** 1999 Jun;169:273–82 (48 ref.)
Local immune responses in afferent and efferent lymph. Haig DM, et al. **Immunology** 1999 Feb;96(2):155–63 (70 ref.)
Dietary fatty acids and the immune system. Calder PC. **Lipids** 1999;34 Suppl:S137–40 (59 ref.)
Immunologic tolerance: self-nonself discrimination versus costimulatory factors and second signals. Simon Z, et al. **Med Hypotheses** 1998 Jul;51(1):1–3 (11 ref.)
Molecular genetic studies in lymphocyte apoptosis and human autoimmunity. Martin DA, et al. **Novartis Found Symp** 1998;215:73–82; discussion 82–91 (20 ref.)
Dietary fatty acids and lymphocyte functions. Calder PC. **Proc Nutr Soc** 1998 Nov;57(4):487–502 (100 ref.)
Human chemokines: role in lymphocyte trafficking. Moser B. **Sci Prog** 1998;81 (Pt 4):299–313 (25 ref.)
Innate immune recognition and control of adaptive immune responses. Medzhitov R, et al. **Semin Immunol** 1998 Oct; 10(5):351–3 (23 ref.)
[New therapeutic strategy for autoimmune diseases. 2) Abnormality in expression of cell surface molecules in systemic erythematodes and its therapeutic application] Takasaki Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1741–4 (3 ref.) **(Jpn)**
[Mucosal immune system of the intestine] Miura S, et al. **Nippon Rinsho** 1998 Sep;56(9):2228–34 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Immunological aspects of human growth hormone and prolactin. Hattori N, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):371–5 (11 ref.)
Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15 (161 ref.)
Small GTPases in lymphocyte biology: Rho proteins take center stage. Henning S, et al. **Immunol Res** 1999; 20(1):29–42 (59 ref.)
Endogenous relatives of ADP-ribosylating bacterial toxins in mice and men: potential regulators of immune cell function. Haag F, et al. **J Biol Regul Homeost Agents** 1998 Jul–Sep;12(3):53–62 (87 ref.)
Induction of Ca2+ flux by adhesion molecules in lymphocytes. De Maria R, et al. **Methods Mol Biol** 1999; 96:199–204 (14 ref.)
Integrin-mediated stimulation of tyrosine phosphorylation in lymphoid cells. Gismondi A, et al. **Methods Mol Biol** 1999; 96:205–10 (8 ref.)
Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. Christ M, et al. **Steroids** 1999 Jan–Feb;64(1–2):35–41 (48 ref.)
[Synthesis and release of neuropeptides in immune system] Xing YT, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):261–4 (10 ref.) **(Chi)**

PATHOLOGY

An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Straus SE, et al. **Ann Intern Med** 1999 Apr 6;130(7):591–601 (68 ref.)
Lymphocytic gastritis: a study of its frequency and review of the literature. Ribeiro VL, et al. **Arq Gastroenterol** 1998 Jan–Mar;35(1):26–31 (40 ref.)
Diabetic mastopathy, complication of type 1 diabetes mellitus: report of two cases and a review of the literature. Boullu S, et al. **Diabetes Metab** 1998 Nov;24(5):448–54 (19 ref.)
The atypical colitides. Giardiello FM, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):479–90, x (53 ref.)
Lymphocytic gastritis, Helicobacter pylori, and gastric cancer: is vitamin C the common link? [editorial] Hayat M, et al. **Nutrition** 1999 May;15(5):402–3 (20 ref.)
[Collagen and lymphocytic colitis] Schwab D, et al. **Dtsch Med Wochenschr** 1998 Oct 23;123(43):1285–91 (51 ref.) **(Ger)**

PHYSIOLOGY

Biological relevance of the 12-lipoxygenase pathway for platelet and lymphocyte functions. Lagarde M, et al. **Adv Exp Med Biol** 1999;447:87–93 (53 ref.)
Soluble cytokine receptors: basic immunology and clinical applications. Fernandez-Botran R. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):165–224 (243 ref.)
The role of cytokine receptor signaling in lymphocyte development. Baird AM, et al. **Curr Opin Immunol** 1999 Apr;11(2):157–66 (111 ref.)
Control of lymphocyte development by the Ikaros gene family. Cortes M, et al. **Curr Opin Immunol** 1999 Apr; 11(2):167–71 (23 ref.)
Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):417–25 (70 ref.)
Interleukin-7: physiological roles and mechanisms of action. Hofmeister R, et al. **Cytokine Growth Factor Rev** 1999 Mar; 10(1):41–60 (236 ref.)
Lymphocyte traffic and homing in autoimmune thyroid disorders. Marazuela M. **Eur J Endocrinol** 1999 Apr; 140(4):287–90 (12 ref.)
Analysing the developing lymphocyte system of neonates and infants. de Vries E, et al. **Eur J Pediatr** 1999 Aug; 158(8):611–7 (50 ref.)
Lymphocyte activation: the coming of the protein tyrosine phosphatases. Mustelin T, et al. **Front Biosci** 1998 Nov 1; 3:D1060–96 (473 ref.)
Regulation of lymphocyte traffic by adhesion molecules. Fabbri M, et al. **Inflamm Res** 1999 May;48(5):239–46 (89 ref.)
Probing lymphocyte biology by genomic-scale gene expression analysis. Alizadeh A, et al. **J Clin Immunol** 1998 Nov;18(6):373–9 (31 ref.)
The traffic of resting lymphocytes through delayed hypersensitivity and chronic inflammatory lesions: a dynamic equilibrium. Seabrook T, et al. **Semin Immunol** 1999 Apr;11(2):115–23 (41 ref.)
The physiology of lymphocyte migration through the single lymph node in vivo. Young AJ. **Semin Immunol** 1999 Apr; 11(2):73–83 (83 ref.)
[Induction of apoptosis in lymphocytes by glucocorticoids: between physiology and pharmacology] Pallardy M, et al. **C R Seances Soc Biol Fil** 1998;192(6):1051–63 (37 ref.) (Eng. Abstr.) **(Fre)**

B-LYMPHOCYTES

see related

GERMINAL CENTER

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Gross TG, et al. **Bone Marrow Transplant** 1999 Feb;23(3):251–8 (42 ref.)
[B-cell prolymphocytic leukemia] Uchida T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):99–101 (6 ref.) **(Jpn)**

CHEMISTRY

Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells [comment] Müller-Hermelink HK, et al. **Am J Pathol** 1998 Nov;153(5):1341–6 (59 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1609–14.

CYTOLOGY

Signal transduction pathways that regulate the fate of B lymphocytes. Craxton A, et al. **Adv Immunol** 1999; 73:79–152 (506 ref.)
Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. Küppers R, et al. **Ann Oncol** 1998;9 Suppl 5:S17–20 (36 ref.)
Cell interaction molecules utilized in bone marrow. Kincade PW, et al. **Cell Adhes Commun** 1998;6(2–3):211–5 (34 ref.)
Regulation of adhesion and migration in the germinal center microenvironment. Pals ST, et al. **Cell Adhes Commun** 1998; 6(2–3):111–6 (67 ref.)
Transcriptional regulation in B cell differentiation. Liberg D, et al. **Crit Rev Immunol** 1999;19(2):127–53 (287 ref.)
Genetic basis of abnormal B cell development. Conley ME, et al. **Curr Opin Immunol** 1998 Aug;10(4):399–406 (76 ref.)
Fetal liver organ cultures as a tool to study selection processes during B cell development. Ceredig R, et al. **Curr Top Microbiol Immunol** 1999;246:11–7; discussion 18–9 (19 ref.)
The transition from immature to mature B cells. Rolink AG, et al. **Curr Top Microbiol Immunol** 1999;246:39–43; discussion 44 (21 ref.)
Galt versus bone marrow models of B cell ontogeny. Weill JC, et al. **Dev Comp Immunol** 1998 May–Jun;22(3):379–85 (21 ref.)
The chosen few? Positive selection and the generation of naive B lymphocytes. Pillai S. **Immunity** 1999 May; 10(5):493–502 (113 ref.)
B cell development in the mouse from early progenitors to mature B cells. Rolink AG, et al. **Immunol Lett** 1999 May 3;68(1):89–93 (19 ref.)
B-cell development: a comparison between mouse and man. Ghia P, et al. **Immunol Today** 1998 Oct;19(10):480–5 (58 ref.)
Dendritic cells directly modulate B cell growth and differentiation. Dubois B, et al. **J Leukoc Biol** 1999 Aug; 66(2):224–30 (67 ref.)
Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Tosato G, et al. **Springer Semin Immunopathol** 1998;20(3–4):405–23 (176 ref.)
Blood cell precursors in context. Composition of the bone marrow microenvironment that supports B lymphopoiesis. Kincade PW, et al. **Vox Sang** 1998;74 Suppl 2:265–8 (19 ref.)
[Regulation of B cell differentiation] Kikutani H. **Nippon Rinsho** 1999 Feb;57(2):262–6 (13 ref.) **(Jpn)**

ENZYMOLOGY

Bruton's tyrosine kinase controls a sustained calcium signal essential for B lineage development and function. Rawlings DJ. **Clin Immunol** 1999 Jun;91(3):243–53 (116 ref.)
Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation. Siminovitch KA, et al. **Curr Top Microbiol Immunol** 1999;246:291–7; discussion 298 (39 ref.)
Functions of Bruton's tyrosine kinase in mast and B cells. Kawakami Y, et al. **J Leukoc Biol** 1999 Mar;65(3):286–90 (46 ref.)

IMMUNOLOGY

Non-structural determinants of immunogenicity and the B cell co-receptors, CD19, CD21, and CD22. Fearon DT. **Adv Exp Med Biol** 1998;452:181–4 (44 ref.)
Inhibitory pathways triggered by ITIM-containing receptors. Bolland S, et al. **Adv Immunol** 1999;72:149–77 (180 ref.)
Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Nara PL. **Adv Vet Med** 1999;41:115–34 (69 ref.)
Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Ichinohasama R, et al. **Am J Surg Pathol** 1998 Dec; 22(12):1528–37 (45 ref.)
The many faces of Hodgkin's disease around the world: what have we learned from its pathology? Harris NL. **Ann Oncol** 1998;9 Suppl 5:S45–56 (112 ref.)
Genetic analysis of B cell antigen receptor signaling. Kurosaki T. **Annu Rev Immunol** 1999;17:555–92 (182 ref.)
Assembly and secretion of antibodies during B cell development. Maggioni C, et al. **Bratisl Lek Listy** 1998 Aug–Sep;99(8–9):419–25 (83 ref.)
Immune receptor editing: revise and select. Nussenzweig MC. **Cell** 1998 Dec 23;95(7):875–8 (21 ref.)
Regulation of adhesion and migration in the germinal center microenvironment. Pals ST, et al. **Cell Adhes Commun** 1998; 6(2–3):111–6 (67 ref.)
Receptor editing: genetic reprogramming of autoreactive lymphocytes. Retter MW, et al. **Cell Biochem Biophys** 1999; 31(1):81–8 (66 ref.)
Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu-Lee L, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1067–75 (103 ref.)
Bruton's tyrosine kinase controls a sustained calcium signal essential for B lineage development and function. Rawlings DJ. **Clin Immunol** 1999 Jun;91(3):243–53 (116 ref.)
Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Atassi MZ, et al. **Crit Rev Immunol** 1999;19(3):219–60 (27 ref.)
Germinal centers: getting there is half the fun. Tarlinton D. **Curr Biol** 1998 Oct 22;8(21):R753–6 (17 ref.)
CD5 B cells and B-cell malignancies. Lydyard PM, et al. **Curr Opin Hematol** 1999 Jan;6(1):30–6 (107 ref.)
The role of B cells in acute and chronic infections. Bachmann MF, et al. **Curr Opin Immunol** 1999 Jun;11(3):332–9 (71 ref.)
Signal transduction from the B cell antigen-receptor. Campbell KS. **Curr Opin Immunol** 1999 Jun;11(3):256–64 (74 ref.)
T-cell-independent antiviral antibody responses. Szomolanyi-Tsuda E, et al. **Curr Opin Immunol** 1998 Aug; 10(4):431–5 (42 ref.)
Co-receptors on B lymphocytes. Tsubata T. **Curr Opin Immunol** 1999 Jun;11(3):249–55 (58 ref.)
Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Schultze JL, et al. **Curr Opin Oncol** 1998 Nov;10(6):542–7 (31 ref.)
Role of complement receptors CD21/CD35 in B lymphocyte activation and survival. Carroll M. **Curr Top Microbiol Immunol** 1999;246:63–8; discussion 69 (27 ref.)
Negative selection of self-reactive B lymphocytes involves complement. Carroll M. **Curr Top Microbiol Immunol** 1999; 246:21–7; discussion 28–9 (21 ref.)
Antibody-mediated protection of mucosal surfaces. Corthesy B, et al. **Curr Top Microbiol Immunol** 1999;236:93–111 (130

ref.)
Chemokines and B-cell homing to follicles. Cyster JG, et al. **Curr Top Microbiol Immunol** 1999;246:87-92; discussion 93 (15 ref.)
Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. Klein G. **Curr Top Microbiol Immunol** 1999;246:161-7 (17 ref.)
Negative regulation of hematopoietic cell activation and proliferation by Fc gamma RIIB. Malbec O, et al. **Curr Top Microbiol Immunol** 1999;244:13-27 (84 ref.)
Regulation of expression of chemokine receptor BLR1/CXCR5 during B cell maturation. Pevzner V, et al. **Curr Top Microbiol Immunol** 1999;246:79-84; discussion 85 (18 ref.)
The transition from immature to mature B cells. Rolink AG, et al. **Curr Top Microbiol Immunol** 1999;246:39-43; discussion 44 (21 ref.)
A novel CC chemokine ABCD-1, produced by dendritic cells and activated B cells, exclusively attracts activated T lymphocytes. Schaniel C, et al. **Curr Top Microbiol Immunol** 1999;246:95-101 (12 ref.)
Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation. Siminovitch KA, et al. **Curr Top Microbiol Immunol** 1999;246:291-7; discussion 298 (39 ref.)
Cross-talk between CD44 and c-Met in B cells. Taher TE, et al. **Curr Top Microbiol Immunol** 1999;246:31-7; discussion 38 (26 ref.)
The formation and selection of cells expressing preB cell receptors and B cell receptors. ten Boekel E, et al. **Curr Top Microbiol Immunol** 1999;246:3-9; discussion 9-10 (38 ref.)
The adaptor protein SLP-65/BLNK controls the calcium response in activated B cells. Wollscheid B, et al. **Curr Top Microbiol Immunol** 1999;246:283-8; discussion 288-9 (25 ref.)
Insights into the mechanisms of antibody-affinity maturation and the generation of the memory B-cell compartment using genetically altered mice. Vora KA, et al. **Dev Immunol** 1998;6(3-4):305-16 (70 ref.)
Immunopathology of primary biliary cirrhosis. Joplin RE, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):587-93 (42 ref.)
A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Agren L, et al. **Immunol Cell Biol** 1998 Jun; 76(3):280-7 (47 ref.)
LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Klein E, et al. **Immunol Lett** 1999 May 3;68(1):147-54 (33 ref.)
Negative signaling in health and disease. Coggeshall KM. **Immunol Res** 1999;19(1):47-64 (165 ref.)
Developmental regulation of immunoglobulin mRNA processing and the IgA response: establishing a paradigm. Lebman DA, et al. **Immunol Res** 1999;20(1):43-53 (55 ref.)
The influence of base sequence on the immunostimulatory properties of DNA. Pisetsky DS. **Immunol Res** 1999; 19(1):35-46 (60 ref.)
The central and multiple roles of B cells in lupus pathogenesis. Chan OT, et al. **Immunol Rev** 1999 Jun; 169:107-21 (188 ref.)
B-cell epitope spreading in autoimmunity. James JA, et al. **Immunol Rev** 1998 Aug;164:185-200 (81 ref.)
Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Mamula MJ. **Immunol Rev** 1998 Aug;164:231-9 (57 ref.)
Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Singh RR, et al. **Immunol Rev** 1998 Aug; 164:201-8 (57 ref.)
Regional specialization in the mucosal immune system: what happens in the microcompartments? Brandtzaeg P, et al. **Immunol Today** 1999 Mar;20(3):141-51 (84 ref.)
Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Brandtzaeg P, et al. **Immunol Today** 1999 Jun;20(6):267-77 (111 ref.)
Growing up on the streets: why B-cell development differs from T-cell development. Townsend SE, et al. **Immunol Today** 1999 May;20(5):217-20 (44 ref.)
Analysis of B-cell epitopes of the Ro/SS-A autoantigen. Wahren-Herlenius M, et al. **Immunol Today** 1999 May; 20(5):234-40 (57 ref.)
Malaria immunity: an overview on B cell responses and assays for detection of humoral immune responses. Kabilan L. **Indian J Med Sci** 1998 Sep;52(9):399-402 (19 ref.)
The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Cross JT, et al. **Inflamm Res** 1999 May;48(5):255-61 (53 ref.)
Regulation of B cell apoptosis by Bcl-2 and Bcl-XL and its role in the development of autoimmune diseases (Review). López-Hoyos M, et al. **Int J Mol Med** 1998 Feb;1(2):475-83 (116 ref.)
B cell maturation in relation to multiple myeloma. Stevenson FK, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):89-97 (65 ref.)
Regulation of antigen receptor function by protein tyrosine kinases. Bubeck-Wardenburg J, et al. **Prog Biophys Mol Biol** 1999;71(3-4):373-92 (126 ref.)
Genetic B-cell variation based on immunoglobulin heavy G-chain (Gm) genes. Oxelius VA. **Scand J Immunol** 1999 Apr;49(4):345-6 (10 ref.)
Control of lymphocyte function through CD27-CD70 interactions. Lens SM, et al. **Semin Immunol** 1998 Dec; 10(6):491-9 (89 ref.)
Reflections on tolerance, self-tolerance and Felix Milgrom. Rose NR. **Transplant Proc** 1999 May;31(3):1460-3 (34 ref.)
[At the crossroads between B lymphoproliferative syndromes to autoimmune diseases are CD5-positive B-lymphocytes: a new hypothesis] Youinou P. **Bull Acad Natl Med** 1999; 183(1):159-69; discussion 170 (30 ref.) (Eng. Abstr.) **(Fre)**
[B-cell, T-cell surface phenotypes and epitopes in autoimmune thyroid diseases] Nishiya K, et al. **Nippon Rinsho** 1999 Aug;57(8):1743-8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Immunological aspects of diabetic angiopathies pathogenesis] Galenok VA, et al. **Ter Arkh** 1998; 70(10):5-10 (51 ref.) **(Rus)**
[Clinical and immunological studies in borderline mental disorders: problems and solutions] Aleksandrovskii IuA, et al. **Vestn Ross Akad Med Nauk** 1999;(7):12-5 (7 ref.) (Eng. Abstr.) **(Rus)**
[Cell interaction in immune response] Iarilin AA. **Vestn Ross Akad Med Nauk** 1999;(4):25-9 (23 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Signal transduction pathways that regulate the fate of B lymphocytes. Craxton A, et al. **Adv Immunol** 1999; 73:79-152 (506 ref.)
Transcriptional regulation in B cell differentiation. Liberg D, et al. **Crit Rev Immunol** 1999;19(2):127-53 (287 ref.)
Lymphocyte signalling: a coordinating role for Vav? Cantrell D. **Curr Biol** 1998 Jul 16;8(15):R535-8 (15 ref.)
Lymphocyte signaling: adapting new adaptors. Rudd CE. **Curr Biol** 1998 Nov 5;8(22):R805-8 (18 ref.)
Transgenic shuttle vector assays for assessing oxidative B-cell mutagenesis in vivo. Felix K, et al. **Curr Top Microbiol Immunol** 1999;246:369-75; discussion 376-7 (19 ref.)
Cross-talk between CD44 and c-Met in B cells. Taher TE, et al. **Curr Top Microbiol Immunol** 1999;246:31-7; discussion 38 (26 ref.)
The adaptor protein SLP-65/BLNK controls the calcium response in activated B cells. Wollscheid B, et al. **Curr Top Microbiol Immunol** 1999;246:283-8; discussion 288-9 (25 ref.)
Genetic B-cell variation based on immunoglobulin heavy G-chain (Gm) genes. Oxelius VA. **Scand J Immunol** 1999 Apr;49(4):345-6 (10 ref.)

PATHOLOGY

Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture. Dammacco F, et al. **Leuk Lymphoma** 1998 Nov; 31(5-6):463-76 (89 ref.)
Adhesion molecules in B-chronic lymphoproliferative disorders. Angelopoulou MK, et al. **Semin Hematol** 1999 Apr;36(2):178-97 (156 ref.)
[Persistent polyclonal B-cell lymphocytosis. A Western pattern versus and Oriental model?] Sánchez Fayos J, et al. **Sangre (Barc)** 1998 Jun;43(3):174-7 (36 ref.) **(Spa)**

PHYSIOLOGY

Regulation of B and T cell development by anterior pituitary hormones. Foster M, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1076-82 (55 ref.)
EBV genes and B cell proliferation. Manet E, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):129-37 (59 ref.)
B cell development: signal transduction by antigen receptors and their surrogates. Benschop RJ, et al. **Curr Opin Immunol** 1999 Apr;11(2):143-51 (87 ref.)
B cell memory and the long-lived plasma cell. McHeyzer-Williams MG, et al. **Curr Opin Immunol** 1999 Apr;11(2):172-9 (75 ref.)
Interleukin 5 and B cell differentiation. Takatsu K. **Cytokine Growth Factor Rev** 1998 Mar;9(1):25-35 (86 ref.)
Biological and clinical implications of interleukin-7 and lymphopoiesis. Appasamy PM. **Cytokines Cell Mol Ther** 1999 Mar;5(1):25-39 (202 ref.)
The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Cross JT, et al. **Inflamm Res** 1999 May;48(5):255-61 (53 ref.)
Chemokines: signal lamps for trafficking of T and B cells for development and effector function. Kim CH, et al. **J Leukoc Biol** 1999 Jan;65(1):6-15 (111 ref.)
Apoptosis in B-chronic lymphocytic leukaemia. Osorio LM, et al. **Med Oncol** 1998 Dec;15(4):234-40 (83 ref.)
Homing behaviour of the malignant cell clone in multiple myeloma. Van Riet I, et al. **Med Oncol** 1998 Sep; 15(3):154-64 (78 ref.)

VIROLOGY

Epstein-Barr virus in Hodgkin's disease. Chapman AL, et al. **Ann Oncol** 1998;9 Suppl 5:S5-16 (118 ref.)
EBNA2 and c-myc in B cell immortalization by Epstein-Barr virus and in the pathogenesis of Burkitt's lymphoma. Zimber-Strobl U, et al. **Curr Top Microbiol Immunol** 1999; 246:315-20; discussion 321 (23 ref.)
Epstein-Barr virus immortalization and latency. Rowe DT. **Front Biosci** 1999 Mar 15;4:D346-71 (263 ref.)
The control of lytic replication of Epstein-Barr virus in B lymphocytes (Review). Schwarzmann F, et al. **Int J Mol Med** 1998 Jan;1(1):137-42 (44 ref.)

T-LYMPHOCYTES

see related
IMMUNITY, CELLULAR

Immune response to human immu- deficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Pinto LA, et al. **Am J Med** 1997 May 19;102(5B):21-4 (31 ref.)
[T-cell prolymphocytic leukemia] Uchida T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):102-5 (10 ref.) **(Jpn)**

CYTOLOGY

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Lenardo M, et al. **Annu Rev Immunol** 1999;17:221-53 (347 ref.)
Cells' perception of position in a concentration gradient. Gurdon JB, et al. **Cell** 1998 Oct 16;95(2):159-62 (21 ref.)
Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Friedl P, et al. **Cell Adhes Commun** 1998; 6(2-3):225-36 (67 ref.)
Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors [see comments] Szondy Z, et al. **Cell Death Differ** 1998 Jan; 5(1):4-10 (78 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1-3.
Mucosal T cell-epithelial cell interactions. Bland PW. **Chem Immunol** 1998;71:40-63 (127 ref.)
Phenotypes of T cells in the gut. Brandtzaeg P, et al. **Chem Immunol** 1998;71:1-26 (121 ref.)
Thymus-independent development of gut T cells. Klein JR. **Chem Immunol** 1998;71:88-102 (58 ref.)
Lamina propria T cells. MacDonald TT, et al. **Chem Immunol** 1998;71:103-17 (68 ref.)
T-cell development: What does Notch do for T cells? von Boehmer H. **Curr Biol** 1999 Mar 11;9(5):R186-8 (10 ref.)
Development of T-cells during fish embryogenesis. Trede NS, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):253-63 (89 ref.)
Role of interleukin-7 in T-cell development from hematopoietic stem cells. Akashi K, et al. **Immunol Rev** 1998 Oct;165:13-28 (137 ref.)
Lineage commitment and differentiation of T and natural killer lymphocytes in the fetal mouse. Carlyle JR, et al. **Immunol Rev** 1998 Oct;165:63-74 (84 ref.)
The Syk family of protein tyrosine kinases in T-cell activation and development. Chu DH, et al. **Immunol Rev** 1998 Oct;165:167-80 (79 ref.)
T-cell fate. Hedrick SM, et al. **Immunol Rev** 1998 Oct; 165:95-110 (119 ref.)
T-cell and natural killer cell development in thymectomized Xenopus. Horton JD, et al. **Immunol Rev** 1998 Dec; 166:245-58 (90 ref.)
Developmental regulation of V(D)J recombination at the TCR alpha/delta locus. Krangel MS, et al. **Immunol Rev** 1998 Oct;165:131-47 (181 ref.)
The role of the T-cell receptor (TCR) in alpha beta/gamma delta lineage commitment: clues from intracellular TCR staining. MacDonald HR, et al. **Immunol Rev** 1998 Oct; 165:87-94 (42 ref.)
T-cell survival. Marrack P, et al. **Immunol Rev** 1998 Oct; 165:279-85 (26 ref.)
The linkage between T-cell and dendritic cell development in the mouse thymus. Shortman K, et al. **Immunol Rev** 1998 Oct;165:39-46 (42 ref.)
Accessibility control of variable region gene assembly during T-cell development. Sleckman BP, et al. **Immunol Rev** 1998 Oct;165:121-30 (59 ref.)
Early stages in the development of human T, natural killer and thymic dendritic cells. Spits H, et al. **Immunol Rev** 1998 Oct;165:75-86 (79 ref.)
Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. von Boehmer H, et al. **Immunol Rev** 1998 Oct;165:111-9 (56 ref.)
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Sallusto F, et al. **Immunol Today** 1998 Dec;19(12):568-74 (89 ref.)
The organization of mature T-cell pools. Tanchot C, et al. **Immunol Today** 1998 Dec;19(12):575-9 (36 ref.)
CD95 mediated T cell apoptosis and its relevance to immune deviation. Varadhachary AS, et al. **Oncogene** 1998 Dec 24;17(25):3271-6 (99 ref.)
Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Haks MC, et al. **Semin Immunol** 1999 Feb;11(1):23-37 (143 ref.)
In vitro models of T cell development. Hare KJ, et al. **Semin Immunol** 1999 Feb;11(1):3-12 (66 ref.)
Signals involved in gamma/delta T cell versus alpha/beta T cell lineage commitment. Hayday AC, et al. **Semin Immunol** 1999 Aug;11(4):239-49 (79 ref.)
Using thymus anatomy to dissect T cell repertoire selection. Laufer TM, et al. **Semin Immunol** 1999 Feb;11(1):65-70 (49 ref.)
Regulation of naive T cell differentiation by varying the

potency of TCR signal transduction. Leitenberg D, et al. **Semin Immunol** 1999 Aug;11(4):283–92 (51 ref.)
Signals involved in thymocyte positive and negative selection. Mariathasan S, et al. **Semin Immunol** 1999 Aug; 11(4):263–72 (104 ref.)
Developmental stages in the human thymus. Res P, et al. **Semin Immunol** 1999 Feb;11(1):39–46 (62 ref.)
Thymic microenvironments, 3–D versus 2–D? van Ewijk W, et al. **Semin Immunol** 1999 Feb;11(1):57–64 (29 ref.)
Cytoskeletal rearrangement during migration and activation of T lymphocytes. Serrador JM, et al. **Trends Cell Biol** 1999 Jun;9(6):228–33 (49 ref.)
[The molecular mechanisms governing T cell development in the thymus] Kimura M, et al. **Nippon Rinsho** 1999 Feb; 57(2):267–72 (35 ref.) (Eng. Abstr.) **(Jpn)**
[Roles of the cell surface purinergic receptors for extracellular adenosine and ATP in T–cell development and effector functions] Koshiba M.
Tanpakushitsu Kakusan Koso 1999 Mar;44(3):263–9 (29 ref.) **(Jpn)**

DRUG EFFECTS

Alcoholic hepatitis as a T–cell mediated disorder: an hypothesis. Batey RG, et al. **Alcohol Clin Exp Res** 1999 Jul;23(7):1207–9 (32 ref.)
Emerging concepts of the molecular basis for estrogen effects on T lymphocytes in systemic lupus erythematosus [editorial; comment] Kammer GM, et al.
Clin Immunol Immunopathol 1998 Dec;89(3):192–5 (45 ref.)
Comment on: Clin Immunol Immunopathol 1998 Nov;89(2):171–80.
New therapeutic targets for rheumatoid arthritis. Dinant HJ, et al. **Pharm World Sci** 1999 Apr;21(2):49–59 (109 ref.)
[Pore–forming leukotoxins from Staphylococcus aureus: variability of the target cells and 2 pharmacological processes] Prévost G, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):435–41 (40 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

The role of caspases in T cell development and the control of immune responses. Denis F, et al. **Cell Mol Life Sci** 1998 Sep;54(9):1005–19 (201 ref.)
Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Kahne T, et al.
Int J Mol Med 1999 Jul;4(1):3–15 (101 ref.)
Role of alanyl aminopeptidase in growth and function of human T cells (review). Lendeckel U, et al.
Int J Mol Med 1999 Jul;4(1):17–27 (88 ref.)
Recent developments in lymphocyte activation: linking kinases to downstream signaling events. Clements JL, et al. **J Clin Invest** 1999 Apr;103(7):925–9 (43 ref.)
Inosine–5'–monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Zimmermann AG, et al.
Prog Nucleic Acid Res Mol Biol 1998;61:181–209 (179 ref.)

IMMUNOLOGY

Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting. Stinissen P, et al.
Acta Neurol Belg 1999 Mar;99(1):65–9 (29 ref.)
Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP). Hedlund–Treutiger I, et al.
Acta Paediatr Suppl 1998 Jun;424:46–50 (35 ref.)
The labyrinthine ways of cancer immunotherapy––T cell, tumor cell encounter: "how do I lose thee? Let me count the ways". Ellem KA, et al. **Adv Cancer Res** 1998;75:203–49 (247 ref.)
Genetic control of the T cell response to Leishmania major infection. Coffman RL, et al. **Adv Exp Med Biol** 1998; 452:61–6 (14 ref.)
Innate functions of epithelial gamma delta T cells. Havran WL, et al. **Adv Exp Med Biol** 1998;452:29–35 (42 ref.)
Interleukin–4 receptor signalling mechanisms and their biological significance. Nelms K, et al.
Adv Exp Med Biol 1998;452:37–43 (19 ref.)
Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Schirrmacher V, et al.
Adv Exp Med Biol 1998;451:251–7 (43 ref.)
Inhibitory pathways triggered by ITIM–containing receptors. Bolland S, et al. **Adv Immunol** 1999;72:149–77 (180 ref.)
T cell dynamics in HIV–1 infection. Clark DR, et al.
Adv Immunol 1999;73:301–27 (97 ref.)
Current views in intracellular transport: insights from studies in immunology. Hsu VW, et al. **Adv Immunol** 1998; 70:369–415 (259 ref.)
Function of the CD3 subunits of the pre–TCR and TCR complexes during T cell development. Malissen B, et al.
Adv Immunol 1999;72:103–48 (198 ref.)
Confrontation between intracellular bacteria and the immune system. Schaible UE, et al. **Adv Immunol** 1999;71:267–377 (719 ref.)
T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Stockinger B. **Adv Immunol** 1999; 71:229–65 (255 ref.)
T–cell responses and the influence of dendritic cells in cattle. Howard CJ, et al. **Adv Vet Med** 1999;41:275–88 (47 ref.)
Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Nara PL.
Adv Vet Med 1999;41:115–34 (69 ref.)
The role of allergen–specific T cells in the allergic immune response: relevance to allergy vaccination. van Neerven RJ. **Allergy** 1999 Jun;54(6):552–61 (134 ref.)
Essential role of T lymphocytes in the development of allergen–driven airway hyperresponsiveness. Gelfand EW. **Allergy Asthma Proc** 1998 Nov–Dec;19(6):365–9 (28 ref.)
Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Iwasaki A, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1074–8 (24 ref.)
Giant cell arteritis––a molecular approach to the multiple facets of the syndrome. Weyand CM, et al.
Ann Med Interne (Paris) 1998 Nov;149(7):420–4 (24 ref.)
Molecular mimicry and multiple sclerosis: degenerate T–cell recognition and the induction of autoimmunity. Gran B, et al. **Ann Neurol** 1999 May;45(5):559–67 (93 ref.)
Immune escape mechanisms in Hodgkin's disease. Poppema S, et al. **Ann Oncol** 1998;9 Suppl 5:S21–4 (44 ref.)
Chronic rejection from bedside to bench: role of T cells. Knoflach A, et al. **Ann Transplant** 1997;2(2):53–60 (139 ref.)
The regulation of CD4 and CD8 coreceptor gene expression during T cell development. Ellmeier W, et al.
Annu Rev Immunol 1999;17:523–54 (144 ref.)
Structural basis of T cell recognition. Garcia KC, et al.
Annu Rev Immunol 1999;17:369–97 (143 ref.)
The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Germain RN, et al. **Annu Rev Immunol** 1999;17:467–522 (271 ref.)
Transcriptional regulation of T lymphocyte development and function. Kuo CT, et al. **Annu Rev Immunol** 1999;17:149–87 (222 ref.)
Mature T lymphocyte apoptosis––immune regulation in a dynamic and unpredictable antigenic environment. Lenardo M, et al. **Annu Rev Immunol** 1999;17:221–53 (347 ref.)
The structural basis of T cell activation by superantigens. Li H, et al. **Annu Rev Immunol** 1999;17:435–66 (183 ref.)
The CD1 system: antigen–presenting molecules for T cell recognition of lipids and glycolipids. Porcelli SA, et al.
Annu Rev Immunol 1999;17:297–329 (160 ref.)
Regulation of T cell fate by Notch. Robey E.
Annu Rev Immunol 1999;17:283–95 (66 ref.)
Selection of the T cell repertoire. Sebzda E, et al.
Annu Rev Immunol 1999;17:829–74 (291 ref.)
Immunodominance in major histocompatibility complex class I–restricted T lymphocyte responses. Yewdell JW, et al.
Annu Rev Immunol 1999;17:51–88 (116 ref.)
T–cell activation and the dynamic world of rafts. Viola A, et al. **APMIS** 1999 Jul;107(7):615–23 (70 ref.)
T cell immunobiology of alloimmune thrombocytopenias. Gorski J, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):269–75 (33 ref.)
Onset and persistence of the allergic inflammation: a molecular explanation? Spinozzi F.
Arch Immunol Ther Exp (Warsz) 1998;46(5):277–84 (44 ref.)
Expression and function of CD30 on T lymphocytes. Tarkowski M. **Arch Immunol Ther Exp (Warsz)** 1999; 47(4):217–21 (40 ref.)
Effector pathways regulating T cell activation. Favero J, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1539–47 (137 ref.)
From the decidual cell internet: trophoblast–recognizing T cells. Arck P, et al. **Biol Reprod** 1999 Feb;60(2):227–33 (98 ref.)
An accessory peptide binding site with allosteric effect on the formation of peptide–MHC–II complexes? Gerlier D, et al. **C R Acad Sci III** 1998 Jan;321(1):19–24 (23 ref.)
Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. Spaner D. **Cancer Metastasis Rev** 1998 Jun; 17(2):249–57 (62 ref.)
Mechanisms of resistance against B–cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T–cell immunity. Sternas LA, et al.
Cancer Treat Res 1999;99:267–73 (25 ref.)
From TCR engagement to T cell activation: a kinetic view of T cell behavior. Lanzavecchia A, et al. **Cell** 1999 Jan 8;96(1):1–4 (29 ref.)
Immune receptor editing: revise and select. Nussenzweig MC. **Cell** 1998 Dec 23;95(7):875–8 (21 ref.)
Adaptors and molecular scaffolds in immune cell signaling. Rudd CE. **Cell** 1999 Jan 8;96(1):5–8 (28 ref.)
The role of caspases in T cell development and the control of immune responses. Denis F, et al. **Cell Mol Life Sci** 1998 Sep;54(9):1005–19 (201 ref.)
Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu–Lee L, et al.
Cell Mol Life Sci 1998 Oct;54(10):1067–75 (103 ref.)
Signalling into the T–cell nucleus: NFAT regulation. Masuda ES, et al. **Cell Signal** 1998 Oct;10(9):599–611 (132 ref.)
Role of T cells in asthma. Kay AB. **Chem Immunol** 1998; 71:178–91 (53 ref.)
T–cell response to orally administered antigens and its role in the treatment of autoimmune diseases. Liu LM, et al.
Chem Immunol 1998;71:139–60 (143 ref.)
T cell and cytokine regulation of the IgA response. Lycke N. **Chem Immunol** 1998;71:209–34 (130 ref.)
T–cell response to inhaled antigen. Palliser D, et al.
Chem Immunol 1998;71:161–77 (80 ref.)
T cells in mouse models of gut inflammation. Simpson SJ, et al. **Chem Immunol** 1998;71:118–38 (82 ref.)
The role of the facilitating cell in the establishment of donor chimerism and transplantation tolerance. Davenport C, et al. **Clin Biochem** 1998 Jul;31(5):359–67 (99 ref.)
Participation of T lymphocytes in cutaneous allergic reactions to drugs. González FJ, et al.
Clin Exp Allergy 1998 Sep;28 Suppl 4:3–6 (26 ref.)
Regulating a regulator: IFNgamma production by the neonate [editorial; comment] Jones CA, et al.
Clin Exp Allergy 1999 Jul;29(7):865–8 (37 ref.) Comment on: Clin Exp Allergy 1999 Jul;29(7):912–9.
Immunological investigation in hepatic drug reactions. Maria VA, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:71–7 (40 ref.)
Metabolites and allergic drug reactions. Merk HF, et al.
Clin Exp Allergy 1998 Sep;28 Suppl 4:21–4 (23 ref.)
T–cell response in penicillin allergy. Padovan E.
Clin Exp Allergy 1998 Sep;28 Suppl 4:33–6 (12 ref.)
Presentation of non–peptide antigens, in particular drugs, to specific T cells. von Greyerz S, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:7–11 (20 ref.)
Emerging concepts of the molecular basis for estrogen effects on T lymphocytes in systemic lupus erythematosus [editorial; comment] Kammer GM, et al.
Clin Immunol Immunopathol 1998 Dec;89(3):192–5 (45 ref.)
Comment on: Clin Immunol Immunopathol 1998 Nov;89(2):171–80.
Regulation and function of T–cell–mediated immunity during Toxoplasma gondii infection. Denkers EY, et al.
Clin Microbiol Rev 1998 Oct;11(4):569–88 (239 ref.)
Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Atassi MZ, et al.
Crit Rev Immunol 1999;19(3):219–60 (27 ref.)
T cell precursors in man and mice. Blom B, et al.
Crit Rev Immunol 1998;18(4):371–88 (155 ref.)
CD28/B7 costimulation: a review. Greenfield EA, et al.
Crit Rev Immunol 1998;18(5):389–418 (229 ref.)
The structure and function of gamma c–dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. He YW, et al. **Crit Rev Immunol** 1998; 18(6):503–24 (159 ref.)
Mechanisms of lipid antigen presentation by CD1. Jackman RM, et al. **Crit Rev Immunol** 1999;19(1):49–63 (66 ref.)
Linkage of immune self–tolerance with the positive selection of T cells. Rubin RL, et al. **Crit Rev Immunol** 1999; 19(3):199–218 (141 ref.)
Role of gamma delta T lymphocytes in immune response in humans and mice. Salerno A, et al.
Crit Rev Immunol 1998;18(4):327–57 (194 ref.)
Immunologic nonresponsiveness to tumors. Antonia SJ, et al. **Crit Rev Oncog** 1998;9(1):35–41 (62 ref.)
Germinal centers: getting there is half the fun. Tarlinton D.
Curr Biol 1998 Oct 22;8(21):R753–6 (17 ref.)
Costimulatory regulation of T cell function. Chambers CA, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):203–10 (81 ref.)
Minor histocompatibility antigens as targets for T–cell therapy after bone marrow transplantation. Warren EH, et al. **Curr Opin Hematol** 1998 Nov;5(6):429–33 (38 ref.)
T lymphocyte responses in HIV–1 infection: implications for vaccine development. Brander C, et al.
Curr Opin Immunol 1999 Aug;11(4):451–9 (106 ref.)
Convergent peptide libraries, or mixotopes, to elicit or to identify specific immune responses. Gras–Masse H, et al.
Curr Opin Immunol 1999 Apr;11(2):223–8 (48 ref.)
The role of antigen–presenting cells in the regulation of allergen–specific T cell responses. Kapsenberg ML, et al.
Curr Opin Immunol 1998 Dec;10(6):607–13 (60 ref.)
T cell responses to bacterial infection. Kerksiek KM, et al.
Curr Opin Immunol 1999 Aug;11(4):400–5 (77 ref.)
T cell immunity to oral allergens. MacDonald TT.
Curr Opin Immunol 1998 Dec;10(6):620–7 (64 ref.)
Control of immune pathology by regulatory T cells. Mason D, et al. **Curr Opin Immunol** 1998 Dec;10(6):649–55 (71 ref.)
CTLA–4 and T cell activation. Oosterwegel MA, et al.
Curr Opin Immunol 1999 Jun;11(3):294–300 (52 ref.)
Immunotherapy of allergy: anergy, deletion, and immune deviation. Rolland J, et al. **Curr Opin Immunol** 1998 Dec; 10(6):640–5 (53 ref.)
T–cell–independent antiviral antibody responses.
Szomolanyi–Tsuda E, et al. **Curr Opin Immunol** 1998 Aug; 10(4):431–5 (42 ref.)
T cell co–stimulatory molecules other than CD28. Watts TH, et al. **Curr Opin Immunol** 1999 Jun;11(3):286–93 (63 ref.)
HIV–2 and T cell recognition. Whittle HC, et al.
Curr Opin Immunol 1998 Aug;10(4):382–7 (66 ref.)
Immune deficiency, immune silencing, and clonal exhaustion of T cell responses during viral infections. Welsh RM, et al. **Curr Opin Microbiol** 1999 Aug;2(4):382–7 (48 ref.)
Costimulatory approaches to adoptive immunotherapy. Liebowitz DN, et al. **Curr Opin Oncol** 1998 Nov; 10(6):533–41 (85 ref.)
Tumor–specific adoptive T–cell therapy for CD40+ B–cell malignancies. Schultze JL, et al. **Curr Opin Oncol** 1998 Nov;10(6):542–7 (31 ref.)
Cellular camouflage: fooling the immune system with polymers. Scott MD, et al. **Curr Pharm Des** 1998 Dec; 4(6):423–38 (59 ref.)
Effector and regulatory lymphoid cells and cytokines in mucosal sites. MacDonald TT.
Curr Top Microbiol Immunol 1999;236:113–35 (133 ref.)
Negative regulation of hematopoietic cell activation and proliferation by Fc gamma RIIB. Malbec O, et al.
Curr Top Microbiol Immunol 1999;244:13–27 (84 ref.)

Immunological issues in vaccine trials: T-cell responses. Kourilsky P, et al. **Dev Biol Stand** 1998;95:117-24 (33 ref.)
Role of prolactin and growth hormone on thymus physiology. De Mello-Coelho V, et al. **Dev Immunol** 1998; 6(3-4):317-23 (45 ref.)
Positive and negative selection in the thymus and the thymic paradox. Reza JN, et al. **Dev Immunol** 1998;5(3):161-8 (90 ref.)
MHC restriction to T-cell autoaggression: an emerging understanding of IDDM pathogenesis. Choudhuri K, et al. **Diabetes Metab Rev** 1998 Dec;14(4):285-301 (108 ref.)
Autoimmune premature ovarian failure--endocrine aspects of a T cell disease [editorial; comment] Melner MH, et al. **Endocrinology** 1999 Aug;140(8):3401-3 (15 ref.) Comment on: Endocrinology 1999 Aug;140(8):3720-6.
Immunopathology of primary biliary cirrhosis. Joplin RE, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):587-93 (42 ref.)
T cell immunosenescence in vitro and in vivo. Pawelec G, et al. **Exp Gerontol** 1999 Jun;34(3):419-29 (56 ref.)
IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. Akdis CA, et al. **FASEB J** 1999 Apr; 13(6):603-9 (74 ref.)
T cells and aging (update february 1999). Pawelec G, et al. **Front Biosci** 1999 Mar 1;4:D216-69 (657 ref.)
Do T cells "see" the hepatitis B core and e antigens differently? [editorial; comment] Milich DR. **Gastroenterology** 1999 Mar;116(3):765-8 (25 ref.) Comment on: Gastroenterology 1999 Mar;116(3):650-7.
Psoriasis as a T cell-mediated autoimmune disease. Barker JN. **Hosp Med** 1998 Jul;59(7):530-3 (25 ref.)
Thymic function, aging, and AIDS. Haynes BF, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):59-60, 63-5, 69-70, passim (12 ref.)
The presentation of self and allogeneic MHC peptides to T lymphocytes. Benichou G, et al. **Hum Immunol** 1998 Sep; 59(9):540-8 (44 ref.)
Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases. Hombach A, et al. **Hybridoma** 1999 Feb;18(1):57-61 (10 ref.)
The role of B7 costimulation in T-cell immunity. Harris NL, et al. **Immunol Cell Biol** 1999 Aug;77(4):304-11 (98 ref.)
The role of CTLA-4 in the regulation of T cell immune responses. McCoy KD, et al. **Immunol Cell Biol** 1999 Feb; 77(1):1-10 (92 ref.)
Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Pender MP. **Immunol Cell Biol** 1999 Jun;77(3):216-23 (82 ref.)
Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development. Kaufmann SH, et al. **Immunol Lett** 1999 Jan; 65(1-2):81-4 (17 ref.)
T-cell response in human leishmaniasis. Kharazmi A, et al. **Immunol Lett** 1999 Jan;65(1-2):105-8 (19 ref.)
Common features of T cell reactivity in persistent helminth infections: lymphatic filariasis and schistosomiasis. Yazdanbakhsh M. **Immunol Lett** 1999 Jan;65(1-2):109-15 (35 ref.)
The human thymus. A chimeric organ comprised of central and peripheral lymphoid components [corrected and republished in Immunol Res 1998;18(3):175-92] Haynes BF, et al. **Immunol Res** 1998;18(2):61-78 (70 ref.)
Immunological self/nonself discrimination: integration of self vs nonself during cognate T cell interactions with antigen-presenting cells. Mannie MD. **Immunol Res** 1999; 19(1):65-87 (154 ref.)
Intestinal intraepithelial T lymphocytes. Our T cell horizons are expanding. Nanno M, et al. **Immunol Res** 1998 Aug; 18(1):41-53 (70 ref.)
Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor. Scheipers P, et al. **Immunol Res** 1998;18(2):103-15 (93 ref.)
CD28/CTLA-4 and CD80/CD86 families: signaling and function. Slavik JM, et al. **Immunol Res** 1999;19(1):1-24 (198 ref.)
Peripheral T-cell tolerance: the contribution of permissive T-cell migration into parenchymal tissues of the neonate. Alferink J, et al. **Immunol Rev** 1999 Jun;169:255-61 (43 ref.)
Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis. Anderton S, et al. **Immunol Rev** 1999 Jun;169:123-37 (78 ref.)
The Syk family of protein tyrosine kinases in T-cell activation and development. Chu DH, et al. **Immunol Rev** 1998 Oct;165:167-80 (79 ref.)
Natural killer and T cells of innate and adaptive immunity: lymphoid compartments with different requirements for common gamma chain-dependent cytokines. Di Santo JP, et al. **Immunol Rev** 1998 Oct;165:29-38 (85 ref.)
Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Ganss R, et al. **Immunol Rev** 1999 Jun;169:263-72 (62 ref.)
CD30 prevents T-cell responses to non-lymphoid tissues. Heath WR, et al. **Immunol Rev** 1999 Jun;169:23-9 (23 ref.)
Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems. Ji H, et al. **Immunol Rev** 1999 Jun;169:139-46 (55 ref.)
Determinant spreading during experimental autoimmune encephalomyelitis: is it potentiating, protecting or participating in the disease? Kumar V. **Immunol Rev** 1998 Aug;164:73-80 (42 ref.)
Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Lehmann PV, et al. **Immunol Rev** 1998 Aug;164:53-61 (59 ref.)
T-cell survival. Marrack P, et al. **Immunol Rev** 1998 Oct; 165:279-85 (26 ref.)
Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Ramachandra L, et al. **Immunol Rev** 1999 Apr;168:217-39 (188 ref.)
Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Singh RR, et al. **Immunol Rev** 1998 Aug; 164:201-8 (57 ref.)
Heat-shock protein T-cell epitopes trigger a spreading regulatory control in a diversified arthritogenic T-cell response. van Eden W, et al. **Immunol Rev** 1998 Aug; 164:169-74 (22 ref.)
Toward a predictive understanding of molecular recognition. Weng Z, et al. **Immunol Rev** 1998 Jun;163:251-66 (109 ref.)
General and specific immunosuppression caused by antiviral T-cell responses. Zinkernagel RM, et al. **Immunol Rev** 1999 Apr;168:305-15 (78 ref.)
T-cell function in newborn mice and humans. Adkins B. **Immunol Today** 1999 Jul;20(7):330-5 (60 ref.)
The pathogenesis of psoriasis: immunological facts and speculations. Bos JD, et al. **Immunol Today** 1999 Jan; 20(1):40-6 (57 ref.)
Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Brandtzaeg P, et al. **Immunol Today** 1999 Jun;20(6):267-77 (111 ref.)
The influence of antiviral T-cell responses on the alloreactive repertoire. Burrows SR, et al. **Immunol Today** 1999 May; 20(5):203-7 (39 ref.)
Is T-cell priming required for initiation of pathology in malaria infections? Riley EM. **Immunol Today** 1999 May; 20(5):228-33 (53 ref.)
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Sallusto F, et al. **Immunol Today** 1998 Dec;19(12):568-74 (89 ref.)
The organization of mature T-cell pools. Tanchot C, et al. **Immunol Today** 1998 Dec;19(12):575-9 (36 ref.)
Growing up on the streets: why B-cell development differs from T-cell development. Townsend SE, et al. **Immunol Today** 1999 May;20(5):217-20 (44 ref.)
Distribution of activated T cells migrating through the body: a matter of life and death. Westermann J, et al. **Immunol Today** 1999 Jul;20(7):302-6 (61 ref.)
Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy. Engberg J, et al. **Immunotechnology** 1999 Mar;4(3-4):273-8 (40 ref.)
T-Cell function in atopic children. Jenmalm MC. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):395-8 (57 ref.)
Molecular basis of drug recognition by specific T-cell receptors. von Greyerz S, et al. **Int Arch Allergy Immunol** 1999 Jul;119(3):173-80 (49 ref.)
Therapeutic strategy for post-transfusion graft-vs.-host disease. Saigo K, et al. **Int J Hematol** 1999 Apr;69(3):147-51 (29 ref.)
Cell biology and possible therapeutic applications of anti-CD3-activated killer-T cells (review). Hoskin DW, et al. **Int J Mol Med** 1998 May;1(5):893-902 (117 ref.)
Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Kahne T, et al. **Int J Mol Med** 1999 Jul;4(1):3-15 (101 ref.)
Role of alanyl aminopeptidase in growth and function of human T cells (review). Lendeckel U, et al. **Int J Mol Med** 1999 Jul;4(1):17-27 (88 ref.)
Lymph nodes and human tumors (review). Lores B, et al. **Int J Mol Med** 1998 Apr;1(4):729-33 (51 ref.)
Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review). Poccia F, et al. **Int J Mol Med** 1998 Feb;1(2):409-13 (62 ref.)
Bovine T cell responses to Cryptosporidium parvum infection. Abrahamsen MS. **Int J Parasitol** 1998 Jul; 28(7):1083-8 (38 ref.)
Role of T lymphocytes and cytokines in coccidiosis. Lillehoj HS. **Int J Parasitol** 1998 Jul;28(7):1071-81 (90 ref.)
Antigen peptide analog: induction of T cell anergy in primary biliary cirrhosis. Ishibashi H, et al. **Intern Med** 1999 Feb; 38(2):173-5 (12 ref.)
T cell costimulatory blockade: new therapies for transplant rejection. Gudmundsdottir H, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1356-65 (72 ref.)
T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. de Rosbo NK, et al. **J Autoimmun** 1998 Aug;11(4):287-99 (120 ref.)
Lassa fever: implications of T-cell immunity for vaccine development. ter Meulen J. **J Biotechnol** 1999 Aug 20; 73(2-3):207-12 (21 ref.)
Treatment of an autoimmune disease with "classical" T cell veto: a proposal. Staerz UD, et al. **J Clin Immunol** 1999 Jul;19(4):195-202 (97 ref.)
Cancer vaccines. Greten TF, et al. **J Clin Oncol** 1999 Mar; 17(3):1047-60 (148 ref.)
The use of human leucocyte antigen class I transgenic mice to investigate human immune function. Faulkner L, et al. **J Immunol Methods** 1998 Dec 1;221(1-2):1-16 (83 ref.)
Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. Seo N, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):555-61 (66 ref.)
The molecular mechanisms of veto mediated regulation of alloresponsiveness. George JF, et al. **J Mol Med** 1999 Jul; 77(7):519-26 (100 ref.)
Molecular mimicry and multiple sclerosis--a possible role for degenerate T cell recognition in the induction of autoimmune responses. Gran B, et al. **J Neural Transm Suppl** 1999;55:19-31 (43 ref.)
The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. Hemmer B, et al. **J Pept Res** 1998 Nov;52(5):338-45 (42 ref.)
Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses? Schultze JL. **Leuk Lymphoma** 1999 Jan;32(3-4):223-36 (99 ref.)
Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Bruserud O. **Leukemia** 1999 Aug; 13(8):1175-87 (177 ref.)
Differential signalling by variant ligands of the T cell receptor and the kinetic model of T cell activation. Madrenas J. **Life Sci** 1999;64(9):717-31 (118 ref.)
DNA damage and mutation: contributors to the age-related alterations in T cell-mediated immune responses? Barnett YA, et al. **Mech Ageing Dev** 1998 May 15;102(2-3):165-75 (49 ref.)
Aging and T-cell-mediated immunity. Chakravarti B, et al. **Mech Ageing Dev** 1999 May 17;108(3):183-206 (168 ref.)
Zinc, T-cell pathways, aging: role of metallothioneins. Mocchegiani E, et al. **Mech Ageing Dev** 1998 Dec 1; 106(1-2):183-204 (117 ref.)
Immune response of cattle infected with African trypanosomes. Taylor KA, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr;94(2):239-44 (62 ref.)
Immunotherapy using T cell defined tumor antigens for melanoma. Kawakami Y. **Microbiol Immunol** 1998; 42(12):801-13 (61 ref.)
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Hicklin DJ, et al. **Mol Med Today** 1999 Apr;5(4):178-86 (50 ref.)
Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis. Stinissen P, et al. **Mult Scler** 1998 Jun; 4(3):203-11 (70 ref.)
The thymic repertoire of neuroendocrine-related self antigens: biological role in T-cell selection and pharmacological implications. Geenen V, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):115-25 (107 ref.)
A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Allison JP, et al. **Novartis Found Symp** 1998;215:92-8; discussion 98-102, 186-90 (28 ref.)
Mechanisms of peripheral T cell tolerance. van Parijs L, et al. **Novartis Found Symp** 1998;215:5-14; discussion 14-20, 33-40 (23 ref.)
CD95 mediated T cell apoptosis and its relevance to immune deviation. Varadhachary AS, et al. **Oncogene** 1998 Dec 24;17(25):3271-6 (99 ref.)
T cell-mediated terminal maturation of dendritic cells, a critical transition into fully potent antigen presenting cells. Takashima A, et al. **Pathol Biol (Paris)** 1998 Jan;46(1):53-60 (62 ref.)
T cell receptor antagonism in vivo, at last [comment] Jameson SC. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14001-2 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14332-6.
Regulation of antigen receptor function by protein tyrosine kinases. Bubeck-Wardenburg J, et al. **Prog Biophys Mol Biol** 1999;71(3-4):373-92 (126 ref.)
Adaptor proteins and T-cell antigen receptor signaling. Samelson LE. **Prog Biophys Mol Biol** 1999;71(3-4):393-403 (53 ref.)
The small heat shock protein alpha B-crystallin as key autoantigen in multiple sclerosis. Van Noort JM, et al. **Prog Brain Res** 1998;117:435-52 (73 ref.)
Is gliadin mispresented to the immune system in coeliac disease? A hypothesis. Biagi F, et al. **QJM** 1999 Feb; 92(2):119-22 (34 ref.)
Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. Ferrari C, et al. **Recent Results Cancer Res** 1998;154:330-6 (30 ref.)
Modulatory proteins and processes in alliance with immune cells, mediators, and extracellular proteins in renal interstitial fibrosis. Wardle EN. **Ren Fail** 1999 Mar; 21(2):121-33 (110 ref.)
Chemokine regulation of CNS T-cell infiltration in experimental autoimmune encephalomyelitis. Hoffman LM, et al. **Res Immunol** 1998 Nov-Dec;149(9):790-4; discussion 846-7, 855-60 (44 ref.)
T-cell design: optimizing the therapeutic potential of autoreactive T cells by genetic modification. Tuohy VK, et al. **Res Immunol** 1998 Nov-Dec;149(9):834-42; discussion 854-60 (54 ref.)
Pathogenesis and treatment of central nervous system demyelinating disease. Zamvil SS, et al. **Rev Neurol (Paris)** 1998 Sep;154(8-9):573-5 (8 ref.)
Effect of age on thymic development, T cell immunity, and

helper T cell function. Shen SS, et al. **Rev Physiol Biochem Pharmacol** 1999;139:123–39 (52 ref.)

The standard model of T-cell receptor function: a critical reassessment. Langman RE, et al. **Scand J Immunol** 1999 Jun;49(6):570–7 (24 ref.)

Deficient cellular immunity--finding and fixing the defects. Greenberg PD, et al. **Science** 1999 Jul 23;285(5427):546–51 (58 ref.)

Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Haks MC, et al. **Semin Immunol** 1999 Feb;11(1):23–37 (143 ref.)

In vitro models of T cell development. Hare KJ, et al. **Semin Immunol** 1999 Feb;11(1):3–12 (66 ref.)

Using thymus anatomy to dissect T cell repertoire selection. Laufer TM, et al. **Semin Immunol** 1999 Feb;11(1):65–70 (49 ref.)

Control of lymphocyte function through CD27–CD70 interactions. Lens SM, et al. **Semin Immunol** 1998 Dec; 10(6):491–9 (89 ref.)

The human thymic microenvironment: new approaches to functional analysis. Ritter MA, et al. **Semin Immunol** 1999 Feb;11(1):13–21 (62 ref.)

Signals involved in CD4/CD8 lineage commitment: current concepts and potential mechanisms. Singer A, et al. **Semin Immunol** 1999 Aug;11(4):273–81 (62 ref.)

T cell receptor-mediated signs and signals governing T cell development. van Oers NS. **Semin Immunol** 1999 Aug; 11(4):227–37 (82 ref.)

Role of 4–1BB in immune responses. Vinay DS, et al. **Semin Immunol** 1998 Dec;10(6):481–9 (43 ref.)

Control of early thymocyte development by the pre-T cell receptor complex: A receptor without a ligand? Wiest DL, et al. **Semin Immunol** 1999 Aug;11(4):251–62 (111 ref.)

Involvement of T cells and alterations in T cell receptors in sarcoidosis. Moller DR. **Semin Respir Infect** 1998 Sep; 13(3):174–83 (80 ref.)

The effects of injury on the adaptive immune response. Lederer JA, et al. **Shock** 1999 Mar;11(3):153–9 (75 ref.)

Molecular mechanism of immune response, synovial proliferation and apoptosis in rheumatoid arthritis. Hasunuma T, et al. **Springer Semin Immunopathol** 1998; 20(1–2):41–52 (94 ref.)

Apoptosis of activated peripheral T cells. Genestier L, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2A):33S–38S (87 ref.)

T-cell activation pathways: a transplantation perspective. Halloran PF. **Transplant Proc** 1999 Feb-Mar; 31(1–2):769–71 (10 ref.)

On costimulatory signals and T cell tolerance: relevance for transplantation immunity. Holländer GA, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2A):25S–31S (78 ref.)

T-cell growth factors in allograft rejection and tolerance. Li XC, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):342–3 (19 ref.)

Positive and negative signaling pathways. Pratt JC, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):772–4 (23 ref.)

Reflections on tolerance, self-tolerance and Felix Milgrom. Rose NR. **Transplant Proc** 1999 May;31(3):1460–3 (34 ref.)

The visualization of T cell responses. Barbara JA, et al. **Transplantation** 1999 Jun 27;67(12):1508–14 (56 ref.)

T cell-mediated xenograft rejection: specific tolerance is probably required for long term xenograft survival. Dorling A, et al. **Xenotransplantation** 1998 Nov;5(4):234–45 (119 ref.)

[Can T-cell immunity in an adult be regenerated?] Plum J. **Verh K Acad Geneeskd Belg** 1999;61(3):457–64; discussion 464–5 (14 ref.) (Eng. Abstr.) **(Dut)**

[Immunologic basis of bronchial asthma] Simon HU, et al. **Internist (Berl)** 1999 Aug;40(8):849–54 (34 ref.) **(Ger)**

[Regulation of T-cell activation by CD28 and CTLA-4] Nagel T, et al. **Med Klin** 1998 Oct 15;93(10):592–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Phenotypic and functional characterization of porcine T-lymphocytes] Saalmüller A, et al. **Zentralbl Chir** 1998; 123(7):798–802 (43 ref.) (Eng. Abstr.) **(Ger)**

[New therapeutic strategy for autoimmune diseases. 1) An antigenic peptide analog] Ishibashi H, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1735–40 (9 ref.) **(Jpn)**

[New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes] Kawakami Y. **Nippon Naika Gakkai Zasshi** 1998 Dec 10; 87(12):2536–44 (12 ref.) **(Jpn)**

[Clonality of infiltrative T cells in tubular dysfunction caused by Sjogren's syndrome] Murata H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1486–91 (5 ref.) **(Jpn)**

[Physiopathological and therapeutic therapy of collagen diseases based on results of clinical tests--disorders of lymphocyte signal transduction] Takeuchi T. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2446–52 (23 ref.) **(Jpn)**

[T cell receptor and its related molecules in signal transduction] Kobata T, et al. **Nippon Rinsho** 1999 Feb; 57(2):273–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

[B-cell, T-cell surface phenotypes and epitopes in autoimmune thyroid diseases] Nishiya K, et al. **Nippon Rinsho** 1999 Aug;57(8):1743–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Role of antigen-specific T cells in the pathogenesis of aplastic anemia] Nakao S. **Rinsho Ketsueki** 1999 Mar; 40(3):159–63 (15 ref.) **(Jpn)**

[How the membrane gangliosides modulate T cell activation?] Nohara K. **Seikagaku** 1999 May;71(5):337–41 (15 ref.) **(Jpn)**

[Antigen peptide/MHC complex as an initiator of a signal for lymphocyte T activation] Kuśnierczyk P. **Postepy Hig Med Dosw** 1999;53(2):331–41 (24 ref.) (Eng. Abstr.) **(Pol)**

[Impaired signal transduction in T-lymphocytes of the aged] Witkowski JM. **Postepy Hig Med Dosw** 1999;53(2):365–82 (85 ref.) (Eng. Abstr.) **(Pol)**

[Mechanisms of inflammation and immunity regulation in the pathogenesis of Lyme disease] Fedorov ES, et al. **Klin Med (Mosk)** 1999;77(6):14–9 (66 ref.) **(Rus)**

[Immunological aspects of diabetic angiopathies pathogenesis] Galenok VA, et al. **Ter Arkh** 1998; 70(10):5–10 (51 ref.) **(Rus)**

[Clinical and immunological studies in borderline mental disorders: problems and solutions] Aleksandrovskii IuA, et al. **Vestn Ross Akad Med Nauk** 1999;(7):12–5 (7 ref.) (Eng. Abstr.) **(Rus)**

[Cell interaction in immune response] Iarilin AA. **Vestn Ross Akad Med Nauk** 1999;(4):25–9 (23 ref.) (Eng. Abstr.) **(Rus)**

[T lymphocytes in allergic inflammation] Tomić-Spirić V, et al. **Srp Arh Celok Lek** 1998 Jul-Aug;126(7–8):309–15 (42 ref.) (Eng. Abstr.) **(Scc)**

[Immune protection against Mycobacterium tuberculosis. Role of interferon-gamma and T gamma-delta lymphocytes] Aspa Marco FJ, et al. **Arch Bronconeumol** 1998 Dec;34(11):547–53 (85 ref.) **(Spa)**

METABOLISM

Expression and function of CD30 on T lymphocytes. Tarkowski M. **Arch Immunol Ther Exp (Warsz)** 1999; 47(4):217–21 (40 ref.)

Signalling into the T-cell nucleus: NFAT regulation. Masuda ES, et al. **Cell Signal** 1998 Oct;10(9):599–611 (132 ref.)

Ca2+ signaling in T-lymphocytes. Guse AH. **Crit Rev Immunol** 1998;18(5):419–48 (214 ref.)

Lymphocyte signalling: a coordinating role for Vav? Cantrell D. **Curr Biol** 1998 Jul 16;8(15):R535–8 (15 ref.)

Lymphocyte signaling: adapting new adaptors. Rudd CE. **Curr Biol** 1998 Nov 5;8(22):R805–8 (18 ref.)

Cytokine-induced expression of killer inhibitory receptors in human T lymphocytes. Ponte M, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):69–72 (23 ref.)

Fyn, a Src family tyrosine kinase. Resh MD. **Int J Biochem Cell Biol** 1998 Nov;30(11):1159–62 (15 ref.)

Fc epsilon RI on dendritic cells: a receptor, which links IgE mediated allergic reaction and T cell mediated cellular response. Shibaki A. **J Dermatol Sci** 1998 May;20(1):29–38 (90 ref.)

T cell mediated immunotherapy for B cell lymphoma. Schultze JL, et al. **J Mol Med** 1999 Mar;77(3):322–31 (134 ref.)

The effects of injury on the adaptive immune response. Lederer JA, et al. **Shock** 1999 Mar;11(3):153–9 (75 ref.)

[CD45, antigen with phosphatase activity, structure; function and role in T lymphocyte activation] Bohr I, et al. **Postepy Biochem** 1998;44(3):208–15 (79 ref.) **(Pol)**

[The function of voltage-gated potassium canals in T-lymphocytes under physiological and pathologic conditions] Teisseyre A. **Postepy Hig Med Dosw** 1999; 53(2):383–97 (42 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

ATM in lymphoid development and tumorigenesis. Xu Y. **Adv Immunol** 1999;72:179–89 (58 ref.)

Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Rüdiger T, et al. **Am J Surg Pathol** 1998 Oct;22(10):1184–91 (31 ref.)

Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Aguayo A, et al. **Cancer** 1999 Jan 1;85(1):58–64 (40 ref.)

Novel mechanism for the impairment of cell proliferation in HIV-1 infection. Bofill M, et al. **Immunol Today** 1999 Jun;20(6):258–61 (29 ref.)

T cell rich B cell lymphoma (TCRBCL): study of sixteen cases with review of literature. Muzaffar S, et al. **Indian J Pathol Microbiol** 1999 Jan;42(1):15–23 (34 ref.)

T cell apoptosis in HIV infection: mechanisms and relevance for AIDS pathogenesis. Gougeon ML, et al. **Results Probl Cell Differ** 1998;24:233–48 (81 ref.)

[Synergistic function of TAL1 and LMO in hematopoietic differentiation and T cell tumorigenesis] Ono Y. **Seikagaku** 1999 Apr;71(4):269–73 (18 ref.) **(Jpn)**

PHYSIOLOGY

Analysis of transmembrane signalling and T cell defects associated with idiopathic thrombocytopenic purpura (ITP). Lazarus AH, et al. **Acta Paediatr Suppl** 1998 Jun; 424:21–5 (29 ref.)

Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model. De Winter H, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1317–21 (26 ref.)

Mechanisms of cell transformation by Herpesvirus saimiri. Tsygankov AY, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):973–83 (120 ref.)

Regulation of B and T cell development by anterior pituitary hormones. Foster M, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1076–82 (55 ref.)

T-cell signal transduction and the role of protein kinase C. Wilkinson SE, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1122–44 (168 ref.)

Gamma delta T cells: bodyguards and/or sleepers in the gut. Takahashi I, et al. **Chem Immunol** 1998;71:77–87 (59 ref.)

Which T cells cause psoriasis? Prinz JC. **Clin Exp Dermatol** 1999 Jul;24(4):291–5 (34 ref.)

Signal transduction in T lymphocytes. Peterson EJ, et al. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):107–14 (111 ref.)

T-cell development: a role for self-peptides in positive selection. Janeway CA Jr. **Curr Biol** 1999 May 6; 9(9):R342–5 (24 ref.)

Interactions between T lymphocytes and endothelial cells in allograft rejection. Briscoe DM, et al. **Curr Opin Immunol** 1998 Oct;10(5):525–31 (88 ref.)

Peripheral T cell survival. Freitas AA, et al. **Curr Opin Immunol** 1999 Apr;11(2):152–6 (52 ref.)

Biological and clinical implications of interleukin-7 and lymphopoiesis. Appasamy PM. **Cytokines Cell Mol Ther** 1999 Mar;5(1):25–39 (202 ref.)

Age-related changes of signal transduction in T cells. Hirokawa K. **Exp Gerontol** 1999 Jan;34(1):7–18 (68 ref.)

T cell signaling: effect of age. Pahlavani MA. **Front Biosci** 1998 Nov 1;3:D1120–33 (144 ref.)

T cell signaling: a decision of life and death. Medema JP, et al. **Hum Immunol** 1999 May;60(5):403–11 (97 ref.)

Distribution of activated T cells migrating through the body: a matter of life and death. Westermann J, et al. **Immunol Today** 1999 Jul;20(7):302–6 (61 ref.)

Chemokines: signal lamps for trafficking of T and B cells for development and effector function. Kim CH, et al. **J Leukoc Biol** 1999 Jan;65(1):6–15 (111 ref.)

Thymic expression of neuroendocrine self-peptide precursors: role in T cell survival and self-tolerance. Geenen V, et al. **J Neuroendocrinol** 1998 Nov;10(11):811–22 (137 ref.)

The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? Harlan DM, et al. **JAMA** 1999 Sep 15;282(11):1076–82 (68 ref.)

Signaling in human lupus T lymphocytes [editorial] Zouali M. **Lupus** 1998;7(8):499–502 (37 ref.)

Role of T cells in murine IgA nephropathy. Nagasawa R, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:12–3 (3 ref.)

Cells and cytokines involved in the pathogenesis of sarcoidosis. Moller DR. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):24–31 (59 ref.)

ZAP-70 and defects of T-cell receptor signaling. Elder ME. **Semin Hematol** 1998 Oct;35(4):310–20 (62 ref.)

The ontogeny of T cell recirculation during foetal life. Cahill RN, et al. **Semin Immunol** 1999 Apr;11(2):105–14 (44 ref.)

Rodent models of lymphocyte migration. Kulidjian AA, et al. **Semin Immunol** 1999 Apr;11(2):85–93 (83 ref.)

Down-modulation of IL-2-triggered JAK3-STAT5 signaling following CD4-ligand binding. Lowry RP, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):820–1 (16 ref.)

[Functional role of nur77 family in T-cell apoptosis and stress response] Okabe T, et al. **Nippon Rinsho** 1998 Jul; 56(7):1734–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Role of chemokine receptors in T lymphocytes] Utsunomiya I. **Seikagaku** 1998 Oct;70(10):1266–70 (15 ref.) **(Jpn)**

[Selectin and homing of lymphocytes] Kannagi R, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2549–58 (34 ref.) **(Jpn)**

[Role of inositol triphosphate in the formation of the calcium signal in T-lymphocytes] Matyshevskaia OP. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):3–15 (69 ref.) (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

Adoptive T-cell therapy. Lokhorst HM, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):26–9 (6 ref.)

VIROLOGY

Epstein-Barr virus in Hodgkin's disease. Chapman AL, et al. **Ann Oncol** 1998;9 Suppl 5:S5–16 (118 ref.)

Interference with the signaling capacity of CC chemokine receptor 5 can compromise its role as an HIV-1 entry coreceptor in primary T lymphocytes [comment] Wang JM, et al. **J Exp Med** 1999 Sep 6;190(5):591–5 (40 ref.) Comment on: J Exp Med 1999 Sep 6;190(5):597–605.

Herpesvirus saimiri strategies for T cell stimulation and transformation. Bröker BM, et al. **Med Microbiol Immunol (Berl)** 1999 Mar;187(3):127–36 (128 ref.)

T-cell transformation by Marek's disease virus. Ross NL. **Trends Microbiol** 1999 Jan;7(1):22–9 (62 ref.)

T-LYMPHOCYTES, CYTOTOXIC

IMMUNOLOGY

Antitumor immunity at work in a melanoma patient. Coulie PG, et al. **Adv Cancer Res** 1999;76:213–42 (69 ref.)

Cytotoxic T lymphocytes in resistance to tuberculosis.

Mazzaccaro RJ, et al. **Adv Exp Med Biol** 1998;452:85–101 (73 ref.)
Immune control of HIV-1 replication. Walker BD, et al. **Adv Exp Med Biol** 1998;452:159–67 (32 ref.)
Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Schirmbeck R, et al. **Biol Chem** 1999 Mar; 380(3):285–91 (90 ref.)
Targeting human tumours with antigen-specific cytotoxic T-cells. Rickinson AB. **Br J Cancer** 1999 Jul;80 Suppl 1:51–6 (64 ref.)
The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes. Zeuthen J, et al. **Bratisl Lek Listy** 1998 Aug–Sep;99(8–9):426–34 (68 ref.)
Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance? McKenna HJ. **Cancer Immunol Immunother** 1999 Sep; 48(6):281–6 (69 ref.)
Cell-mediated immunity: dealing a direct blow to pathogens. Kaufmann SH. **Curr Biol** 1999 Feb 11;9(3):R97–9 (10 ref.)
Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Chen L. **Curr Opin Immunol** 1999 Apr; 11(2):219–22 (33 ref.)
Cross-clade T cell recognition of HIV.1. Gotch F. **Curr Opin Immunol** 1998 Aug;10(4):388–92 (34 ref.)
Cytotoxic T lymphocyte activation by cross-priming. Heath WR, et al. **Curr Opin Immunol** 1999 Jun;11(3):314–8 (56 ref.)
Stress proteins and immunity mediated by cytotoxic T lymphocytes. Schild H, et al. **Curr Opin Immunol** 1999 Feb; 11(1):109–13 (55 ref.)
How do cytotoxic lymphocytes kill their targets? Shresta S, et al. **Curr Opin Immunol** 1998 Oct;10(5):581–7 (55 ref.)
Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. Bitton N, et al. **Front Biosci** 1999 Apr 1;4:D386–93 (95 ref.)
Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Leibson PJ. **Immunity** 1998 Sep;9(3):289–94 (50 ref.)
Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction [published erratum appears in Immunol Cell Biol 1999 Jun;77(3):287] Edwards KM, et al. **Immunol Cell Biol** 1999 Feb;77(1):76–89 (180 ref.)
Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo? Borrow P, et al. **Immunol Rev** 1998 Aug;164:37–51 (115 ref.)
HIV's evasion of the cellular immune response. Collins KL, et al. **Immunol Rev** 1999 Apr;168:65–74 (68 ref.)
Hierarchies of antigen-specific cytotoxic T-cell responses. Gallimore A, et al. **Immunol Rev** 1998 Aug;164:29–36 (48 ref.)
Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape. Green WR. **Immunol Rev** 1999 Apr;168:271–86 (93 ref.)
Non-traditionally derived CTL epitopes: exceptions that prove the rules? Mayrand SM, et al. **Immunol Today** 1998 Dec;19(12):551–6 (37 ref.)
Cytotoxic T lymphocytes, chemokines and antiviral immunity. Price DA, et al. **Immunol Today** 1999 May; 20(5):212–6 (60 ref.)
Granulysin: a lethal weapon of cytolytic T cells. Stenger S, et al. **Immunol Today** 1999 Sep;20(9):390–4 (42 ref.)
CTL granules: evolution of vesicles essential for combating virus infections. Trapani JA, et al. **Immunol Today** 1999 Aug;20(8):351–6 (71 ref.)
The dynamics of HTLV-I and the CTL response. Wodarz D, et al. **Immunol Today** 1999 May;20(5):220–7 (28 ref.)
Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Antonaci S, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):455–72 (62 ref.)
The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses [comment] Kalams SA, et al. **J Exp Med** 1998 Dec 21;188(12):2199–204 (51 ref.) Comment on: J Exp Med 1998 Dec 21;188(12):2205–13.
The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. Price DA, et al. **J Mol Med** 1998 Sep;76(10):699–708 (91 ref.)
Effects of TGF-beta on the immune system: implications for cancer immunotherapy. de Visser KE, et al. **Leukemia** 1999 Aug;13(8):1188–99 (152 ref.)
Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Romero P, et al. **Mol Med Today** 1998 Jul;4(7):305–12 (48 ref.)
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3–15 (84 ref.)
Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Bangham CR, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):691–700 (76 ref.)
Granule-mediated cytotoxicity. Darmon AJ, et al. **Results Probl Cell Differ** 1999;23:103–25 (173 ref.)
Lymphocyte-mediated cytolysis: dual apoptotic mechanisms with overlapping cytoplasmic and nuclear signalling pathways. Trapani JA, et al. **Results Probl Cell Differ** 1999; 23:78–102 (147 ref.)
CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Toes REM, et al. **Semin Immunol** 1998 Dec;10(6):443–8 (44 ref.)
Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review). Menéndez-Arias L, et al. **Viral Immunol** 1998;11(4):167–81 (81 ref.)
Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341–3 (7 ref.)
CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection. Fowler DH, et al. **Vox Sang** 1998;74 Suppl 2:331–40 (60 ref.)
Mutated Ras peptides as vaccines in immunotherapy of cancer. Gjertsen MK, et al. **Vox Sang** 1998;74 Suppl 2:489–95 (49 ref.)
EBV specific CTL: a model for immune therapy. Rooney CM, et al. **Vox Sang** 1998;74 Suppl 2:497–8 (6 ref.)
Targeted superantigens for immunotherapy of haematopoietic tumours. Tötterman TH, et al. **Vox Sang** 1998;74 Suppl 2:483–7 (36 ref.)

TRANSPLANTATION

[Clinical application of cytotoxic T-cell clones] Yasukawa M. **Rinsho Ketsueki** 1999 Jun;40(6):469–71 (6 ref.) **(Jpn)**

T-LYMPHOCYTES, HELPER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-LYMPHOCYTES, HELPER-INDUCER

see related
INTERLEUKIN-2

CHEMISTRY

Selective differences in the expression of the homing receptors of helper lymphocyte subsets. Burastero SE, et al. **Clin Immunol Immunopathol** 1998 Nov;89(2):110–6 (54 ref.)

CYTOLOGY

Molecular mechanisms of T helper cell differentiation and tissue-specific migration. D'Ambrosio D, et al. **Curr Top Microbiol Immunol** 1999;246:117–22 (30 ref.)
Dealing from the evolutionary pawnshop: how lymphocytes make decisions. Reiner SL, et al. **Immunity** 1999 Jul; 11(1):1–10 (100 ref.)

IMMUNOLOGY

Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Semple JW. **Acta Paediatr Suppl** 1998 Jun;424:41–5 (48 ref.)
T cells and the immune response: down-regulation via mucosal exposure. Bienenstock J. **Can Respir J** 1998 Jul–Aug;5 Suppl A:27A–30A (25 ref.)
Molecular mechanisms of T helper cell differentiation and tissue-specific migration. D'Ambrosio D, et al. **Curr Top Microbiol Immunol** 1999;246:117–22 (30 ref.)
Manipulation of Th responses by oral tolerance. Garcia G, et al. **Curr Top Microbiol Immunol** 1999;238:123–45 (126 ref.)
T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Murphy KM, et al. **Curr Top Microbiol Immunol** 1999;238:13–26 (72 ref.)
Dealing from the evolutionary pawnshop: how lymphocytes make decisions. Reiner SL, et al. **Immunity** 1999 Jul; 11(1):1–10 (100 ref.)
The optimization of helper T lymphocyte (HTL) function in vaccine development. Alexander J, et al. **Immunol Res** 1998;18(2):79–92 (145 ref.)
The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses [comment] Kalams SA, et al. **J Exp Med** 1998 Dec 21;188(12):2199–204 (51 ref.) Comment on: J Exp Med 1998 Dec 21;188(12):2205–13.
Effect of age on thymic development, T cell immunity, and helper T cell function. Shen SS, et al. **Rev Physiol Biochem Pharmacol** 1999;139:123–39 (52 ref.)
Integrins and T helper cell activation [see comments] van Seventer GA, et al. **Transplant Proc** 1998 Dec;30(8):4270–4 (60 ref.) Comment in: Transplant Proc 1998 Dec;30(8):4269.

PHYSIOLOGY

Helper T cell differentiation. Swain SL. **Curr Opin Immunol** 1999 Apr;11(2):180–5 (49 ref.)
Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. Almawi WY, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1497–502 (104 ref.)

T-LYMPHOCYTES, INDUCER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-LYMPHOCYTES, REGULATORY see **T-LYMPHOCYTES**

T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR

IMMUNOLOGY

The comeback of the elusive "suppressor" cell: an update on the regulatory network in EAE. Segal BM. **Res Immunol** 1998 Nov–Dec;149(9):811–20; discussion 850–1, 855–60 (54 ref.)

PHYSIOLOGY

Suppressor T-cells [editorial] Mathé G. **Biomed Pharmacother** 1999 Jun;53(5–6):213–7 (28 ref.)

T4 LYMPHOCYTES see **CD4-POSITIVE T-LYMPHOCYTES**

T8 LYMPHOCYTES see **CD8-POSITIVE T-LYMPHOCYTES**

LYMPHOCYTES, TUMOR-INFILTRATING

see related
IMMUNOTHERAPY, ADOPTIVE

IMMUNOLOGY

Oligoclonal T cells in human cancer. Halapi E. **Med Oncol** 1998 Dec;15(4):203–11 (104 ref.)
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3–15 (84 ref.)

LYMPHOCYTIC CHORIOMENINGITIS

[Lymphocytic choriomeningitis] Shoji H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):11–2 (5 ref.) **(Jpn)**

IMMUNOLOGY

Dynamics of the CD8+ T cell response during acute LCMV infection. Butz E, et al. **Adv Exp Med Biol** 1998;452:111–22 (37 ref.)
Immune deficiency, immune silencing, and clonal exhaustion of T cell responses during viral infections. Welsh RM, et al. **Curr Opin Microbiol** 1999 Aug;2(4):382–7 (48 ref.)
General and specific immunosuppression caused by antiviral T-cell responses. Zinkernagel RM, et al. **Immunol Rev** 1999 Apr;168:305–15 (78 ref.)

LYMPHOCYTIC CHORIOMENINGITIS VIRUS

IMMUNOLOGY

Dynamics of the CD8+ T cell response during acute LCMV infection. Butz E, et al. **Adv Exp Med Biol** 1998;452:111–22 (37 ref.)
Immune deficiency, immune silencing, and clonal exhaustion of T cell responses during viral infections. Welsh RM, et al. **Curr Opin Microbiol** 1999 Aug;2(4):382–7 (48 ref.)
General and specific immunosuppression caused by antiviral T-cell responses. Zinkernagel RM, et al. **Immunol Rev** 1999 Apr;168:305–15 (78 ref.)

LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

B-LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, B-CELL**

T-LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, T-CELL**

LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

B-LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, B-CELL, ACUTE**

T-LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, B-CELL see **LEUKEMIA, B-CELL**

LYMPHOCYTIC LEUKEMIA, B-CELL, ACUTE see **LEUKEMIA, B-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

B-LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, B-CELL, CHRONIC**

T-LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, T-CELL, CHRONIC**

LYMPHOCYTIC LEUKEMIA, CHRONIC, B-CELL see **LEUKEMIA, B-CELL, CHRONIC**

LYMPHOCYTIC LEUKEMIA, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOCYTIC LEUKEMIA, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOCYTIC LEUKEMIA, L3 see **LEUKEMIA, B-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, T-CELL see **LEUKEMIA, T-CELL**

LYMPHOCYTIC LEUKEMIA, T-CELL, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, T-CELL, CHRONIC see **LEUKEMIA, T-CELL, CHRONIC**

LYMPHOCYTIC LYMPHOMA see **LYMPHOMA, SMALL-CELL**

LYMPHOCYTIC LYMPHOMA, DIFFUSE, POORLY-DIFFERENTIATED see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOCYTIC LYMPHOMA, DIFFUSE, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTIC LYMPHOMA, NODULAR, POORLY-DIFFERENTIATED see **LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR**

LYMPHOCYTIC LYMPHOMA, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTOMA see **PSEUDOLYMPHOMA**

LYMPHOCYTOPENIA see **LYMPHOPENIA**

T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE

[Idiopathic CD4+ T-lymphocytopenia] Hayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):185-7 (14 ref.) **(Jpn)**

DIAGNOSIS

[Idiopathic CD4+ T-lymphocyte deficiency: the clinical evolution of a case (see comments)] Galiè M, et al. **Ann Ital Med Int** 1997 Oct-Dec;12(4):233-7 (36 ref.) (Eng. Abstr.) Comment in: Ann Ital Med Int 1997 Oct-Dec;12(4):197-8. **(Ita)**

LYMPHOCYTOSIS

Large granular lymphocytosis. Zambello R, et al. **Haematologica** 1998 Oct;83(10):936-42 (52 ref.)

[Richter's syndrome: analysis of literature data and original observations] Osmanov DSh, et al. **Ter Arkh** 1999; 71(7):47-58 (136 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Persistent polyclonal B-cell lymphocytosis. A Western pattern versus and Oriental model?] Sánchez Fayos J, et al. **Sangre (Barc)** 1998 Jun;43(3):174-7 (36 ref.) **(Spa)**

PATHOLOGY

[Relevance of lymphocytic (microscopic) and collagenous colitis] Pohl C, et al. **Internist (Berl)** 1998 Oct; 39(10):1048-54 (40 ref.) **(Ger)**

LYMPHOCYTOTOXIC ANTIBODIES see **ANTILYMPHOCYTE SERUM**

LYMPHOGRANULOMA INGUINALE see **LYMPHOGRANULOMA VENEREUM**

LYMPHOGRANULOMA, MALIGNANT see **HODGKIN DISEASE**

LYMPHOGRANULOMA VENEREUM

[Lymphogranuloma inguinale] Ishihara S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):36-7 (10 ref.) **(Jpn)**

LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

LYMPHOID CELLS see **LYMPHOCYTES**

LYMPHOID HYPERPLASIA, REACTIVE see **PSEUDOLYMPHOMA**

LYMPHOID IRRADIATION see **LYMPHATIC IRRADIATION**

LYMPHOID LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

LYMPHOID TISSUE

ANATOMY & HISTOLOGY

Organization of mucosal lymphoid tissue. Hein WR. **Curr Top Microbiol Immunol** 1999;236:1-15 (28 ref.)

CYTOLOGY

Galt versus bone marrow models of B cell ontogeny. Weill JC, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):379-85 (21 ref.)

Lymphoid development from hematopoietic stem cells. Akashi K, et al. **Int J Hematol** 1999 Jun;69(4):217-26 (90 ref.)

Development of Peyer's patches, follicle-associated epithelium and M cell: lessons from immunodeficient and knockout mice. Debard N, et al. **Semin Immunol** 1999 Jun; 11(3):183-91 (61 ref.)

M cells at locations outside the gut. Gebert A, et al. **Semin Immunol** 1999 Jun;11(3):165-70 (74 ref.)

Plasticity of the gastrointestinal epithelium: the M cell paradigm and opportunism of pathogenic microorganisms. Kernéis S, et al. **Semin Immunol** 1999 Jun;11(3):205-15 (50 ref.)

The composition and function of M cell apical membranes: implications for microbial pathogenesis. Neutra MR, et al. **Semin Immunol** 1999 Jun;11(3):171-81 (86 ref.)

GROWTH & DEVELOPMENT

Development and maturation of secondary lymphoid tissues. Fu YX, et al. **Annu Rev Immunol** 1999;17:399-433 (119 ref.)

IMMUNOLOGY

Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Haase AT. **Annu Rev Immunol** 1999;17:625-56 (158 ref.)

Chemokine receptors in lymphoid organ homeostasis. Jung S, et al. **Curr Opin Immunol** 1999 Jun;11(3):319-25 (53 ref.)

A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. Gräler MH, et al. **Curr Top Microbiol Immunol** 1999;246:131-6; discussion 137 (31 ref.)

A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **J Leukoc Biol** 1999 Sep; 66(3):375-81 (61 ref.)

Gastrointestinal immunity in health and disease. Elwood CM, et al. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):471-500, vi-vii (135 ref.)

METABOLISM

A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. Gräler MH, et al. **Curr Top Microbiol Immunol** 1999;246:131-6; discussion 137 (31 ref.)

MICROBIOLOGY

Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria. Lugton I. **Immunol Cell Biol** 1999 Aug;77(4):364-72 (102 ref.)

Plasticity of the gastrointestinal epithelium: the M cell paradigm and opportunism of pathogenic microorganisms. Kernéis S, et al. **Semin Immunol** 1999 Jun;11(3):205-15 (50 ref.)

PATHOLOGY

ATM in lymphoid development and tumorigenesis. Xu Y. **Adv Immunol** 1999;72:179-89 (58 ref.)

Lymphoid complement of the human salivary glands: function and pathology. Ciccone E, et al. **Eur J Morphol** 1998 Aug;36 Suppl:252-6 (13 ref.)

PHYSIOLOGY

Lymphoid complement of the human salivary glands: function and pathology. Ciccone E, et al. **Eur J Morphol** 1998 Aug;36 Suppl:252-6 (13 ref.)

RADIATION EFFECTS

A new concept of skin-associated lymphoid tissue (SALT): UVB light impaired cutaneous immunity reveals a prominent role for cutaneous nerves. Streilein JW, et al. **Keio J Med** 1999 Mar;48(1):22-7 (33 ref.)

VIROLOGY

HIV type 1 infection in lymphoid tissue: natural history and model systems. Kitchen SG, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S235-9 (54 ref.)

Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Haase AT. **Annu Rev Immunol** 1999;17:625-56 (158 ref.)

[AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment] Notermans DW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1909-12 (48 ref.) (Eng. Abstr.) **(Dut)**

LYMPHOKINES

see related
IMMUNITY, CELLULAR

Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Eriksson U, et al. **Curr Top Microbiol Immunol** 1999;237:41-57 (52 ref.)

ANALYSIS

[Angiogenic factor of brain tumor] Sawada T. **No To Shinkei** 1999 May;51(5):404-10 (34 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now? Leenders WP. **Int J Exp Pathol** 1998 Dec;79(6):339-46 (67 ref.)

BIOSYNTHESIS

[Advances in the study of the role of vascular endothelial growth factor and its receptor in tumor angiogenesis and its relation with anti-angiogenesis effect] Bian X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug;26(4):248-50 (15 ref.) **(Chi)**

CHEMISTRY

Molecular and biological properties of vascular endothelial growth factor. Ferrara N. **J Mol Med** 1999 Jul;77(7):527-43 (230 ref.)

GENETICS

Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Nathan CA, et al. **Laryngoscope** 1999 Aug;109(8):1253-8 (18 ref.)

IMMUNOLOGY

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Ryan AM, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):78-86 (75 ref.)

[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma] Konno H, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):441-5 (17 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The possible role of vascular endothelial growth factor (VEGF) in gastric ulcer healing: effect of sofalcone on VEGF release in vitro. Takahashi M, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S178-82 (33 ref.)

A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Williams B. **Miner Electrolyte Metab** 1998;24(6):400-5 (45 ref.)

Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Hyder SM, et al. **Mol Endocrinol** 1999 Jun;13(6):806-11 (60 ref.)

Surgical implications of therapeutic angiogenesis. Zimmerman MA, et al. **Surgery** 1999 Mar;125(3):243-9 (58 ref.)

[Hair follicles and vascular endothelial growth factor] Lachgar S, et al. **Ann Dermatol Venereol** 1998 Apr; 125(4):271-4 (32 ref.) **(Fre)**

PHARMACOLOGY

Advances in understanding of biological effects of interleukin-11, leukemia inhibitory factor, and macrophage inflammatory protein 1 alpha. Broxmeyer HE. **Curr Opin Hematol** 1994 May;1(3):197-202 (58 ref.)

Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Feng D, et al. **Microcirculation** 1999 Mar;6(1):23-44 (50 ref.)

PHYSIOLOGY

Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. Ortéga N, et al. **Biol Cell** 1998 Sep;90(5):381-90 (102 ref.)

Vascular endothelial growth factor: environmental controls and effects in angiogenesis. Hlatky L, et al. **Br J Cancer Suppl** 1996 Jul;27:S151-6 (50 ref.)

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Siemeister G, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):241-8 (70 ref.)

Vascular endothelial growth factor in reproductive biology. Lebovic DI, et al. **Curr Opin Obstet Gynecol** 1999 Jun; 11(3):255-60 (54 ref.)

Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Carmeliet P, et al. **Curr Top Microbiol Immunol** 1999;237:133-58 (133 ref.)

Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Dvorak HF, et al. **Curr Top Microbiol Immunol** 1999;237:97-132 (171 ref.)

Vascular endothelial growth factor: molecular and biological

aspects. Ferrara N. **Curr Top Microbiol Immunol** 1999; 237:1–30 (205 ref.)
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Duh E, et al. **Diabetes** 1999 Oct; 48(10):1899–906 (101 ref.)
Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Crew JP. **Eur Urol** 1999 Jan; 35(1):2–8 (87 ref.)
Vascular endothelial growth factor: how it transmits its signal. Zachary I. **Exp Nephrol** 1998 Nov–Dec;6(6):480–7 (62 ref.)
Vascular endothelial growth factor (VEGF) and its receptors. Neufeld G, et al. **FASEB J** 1999 Jan;13(1):9–22 (182 ref.)
Signal relays in the VEGF system. Ortega N, et al. **Front Biosci** 1999 Feb 1;4:D141–52 (130 ref.)
The role of leukemia inhibitory factor and interleukin-6 in human reproduction. Smith SK, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:237–43; discussion 244–6 (46 ref.)
Angiogenesis, vascular endothelial growth factor and the endometrium. Smith SK. **Hum Reprod Update** 1998 Sep–Oct;4(5):509–19 (130 ref.)
Vascular endothelial growth factor. Zachary I. **Int J Biochem Cell Biol** 1998 Nov;30(11):1169–74 (22 ref.)
The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Achen MG, et al. **Int J Exp Pathol** 1998 Oct;79(5):255–65 (89 ref.)
Review: The role of leukaemia inhibitory factor in the establishment of pregnancy. Vogiagis D, et al. **J Endocrinol** 1999 Feb;160(2):181–90 (82 ref.)
Molecular and biological properties of vascular endothelial growth factor. Ferrara N. **J Mol Med** 1999 Jul;77(7):527–43 (230 ref.)
Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. Hayman R, et al. **J Soc Gynecol Investig** 1999 Jan–Feb;6(1):3–10 (70 ref.)
Role of vascular endothelial growth factor in the regulation of angiogenesis. Ferrara N. **Kidney Int** 1999 Sep; 56(3):794–814 (285 ref.)
Role of vascular endothelial growth factor in the response to vessel injury. Alvarez Arroyo MV, et al. **Kidney Int Suppl** 1998 Dec;68:S7–9 (8 ref.)
Vascular endothelial growth factor and microvascular permeability. Bates DO, et al. **Microcirculation** 1999 Jun; 6(2):83–96 (116 ref.)
VEGFs, receptors and angiogenesis. Veikkola T, et al. **Semin Cancer Biol** 1999 Jun;9(3):211–20 (99 ref.)
Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Tosato G, et al. **Springer Semin Immunopathol** 1998;20(3–4):405–23 (176 ref.)
Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127–37 (163 ref.)
[The function and application of vascular endothelial growth factor] Zhang M, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):255–7 (10 ref.) **(Chi)**
[Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C] Mandriota SJ, et al. **J Soc Biol** 1999;193(2):159–63 (31 ref.) (Eng. Abstr.) **(Fre)**
[VEGF in therapeutic coronary and peripheral artery angiogenesis] Elbaz M, et al. **Pathol Biol (Paris)** 1999 Apr; 47(4):380–4 (27 ref.) (Eng. Abstr.) **(Fre)**
[Vascular endothelial growth factor. From basic research to clinical application] Smirne C, et al. **Minerva Med** 1999 Jan–Feb;90(1–2):15–23 (100 ref.) (Eng. Abstr.) **(Ita)**
[Tumor progression and angiogenesis] Maru Y. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1509–19 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Implication of VEGF and MMPs in hepatic metastasis of human colon cancer] Arii S, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):436–40 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Functions and the regulation of cytokines and growth factors in the thrombotic event of arteries and veins] Harada H, et al. **Nippon Rinsho** 1999 Jul;57(7):1497–501 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor angiogenesis] Ono M, et al. **Seikagaku** 1998 Sep; 70(9):1159–70 (28 ref.) **(Jpn)**

THERAPEUTIC USE

Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis. Isner JM. **Am J Cardiol** 1998 Nov 19;82(10A):63S–64S (5 ref.)
Manipulating angiogenesis against vascular disease. Isner JM. **Hosp Pract (Off Ed)** 1999 Jun 15;34(6):69–74, 76, 79–80 passim (8 ref.)
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. Isner JM, et al. **J Clin Invest** 1999 May;103(9):1231–6 (28 ref.)
LIF (AM424), a promising growth factor for the treatment of ALS. Kurek JB, et al. **J Neurol Sci** 1998 Oct;160 Suppl 1:S106–13 (64 ref.)
Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Baumgartner I, et al. **Vasa** 1998 Nov;27(4):201–6 (76 ref.)
[VEGF in therapeutic coronary and peripheral artery angiogenesis] Elbaz M, et al. **Pathol Biol (Paris)** 1999 Apr; 47(4):380–4 (27 ref.) (Eng. Abstr.) **(Fre)**
[Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease] Kalka C, et al. **Med Klin** 1999 Apr 15;94(4):193–201 (98 ref.) (Eng. Abstr.) **(Ger)**
[Angiogenic gene therapy for ischemic heart disease] Ueno H. **Nippon Rinsho** 1998 Oct;56(10):2645–52 (32 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA

Hematopathology: integration of morphologic features and biologic markers for diagnosis. Jaffe ES. **Mod Pathol** 1999 Feb;12(2):109–15 (36 ref.)
Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. Coiffier B, et al. **Semin Hematol** 1999 Apr; 36(2):198–208 (47 ref.)
Primary cutaneous lymphomas other than mycosis fungoides. Gilliam AC, et al. **Semin Oncol** 1999 Jun;26(3):290–306 (107 ref.)
[Leukemias and malignant lymphomas in children] Schmiegelow K. **Ugeskr Laeger** 1999 Apr 12; 161(15):2191–5 (15 ref.) **(Dan)**
[Treatment of malignant lymphoma with extranodal lesions--indications and timing for local therapies] Kinoshita T, et al. **Rinsho Ketsueki** 1999 Mar;40(3):192–5 (11 ref.) **(Jpn)**
[Clinical features of extranodal malignant lymphoma--staging classification and treatment strategies] Takagi T. **Rinsho Ketsueki** 1999 Mar;40(3):188–91 (7 ref.) **(Jpn)**

CHEMICALLY INDUCED

Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Georgescu L, et al. **Drug Saf** 1999 Jun;20(6):475–87 (105 ref.)

CLASSIFICATION

The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Frizzera G, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S13–39 (490 ref.)
Classification of cutaneous lymphoma: a critical appraisal of recent proposals. Norton AJ. **Am J Dermatopathol** 1999 Jun;21(3):279–87 (54 ref.)
Epidemiology of the Revised European-American Lymphoma Classification subtypes. Herrinton LJ. **Epidemiol Rev** 1998;20(2):187–203 (134 ref.)
[Classification of malignant lymphoma. WHO international proposal] Diebold J. **Ann Pathol** 1998 Oct;18(4):361–7 (31 ref.) **(Fre)**
[Clinical evaluation of classifications of malignant lymphoma from the viewpoint of history] Tobinai K. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2157–66 (18 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. Kraus MD, et al. **Am J Med** 1999 Aug; 107(2):169–76 (31 ref.)
Successful treatment of cytomegalovirus retinitis in a patient with malignant lymphoma: a case report and review of the literature. Kawai Y, et al. **Int J Hematol** 1999 Jun; 69(4):256–9 (15 ref.)

DIAGNOSIS

Diagnosis of lymphoma in the new millennium. Morse EE. **Ann Clin Lab Sci** 1998 Nov–Dec;28(6):370–9 (22 ref.)
Practical applications of immunohistochemistry in hematolymphoid neoplasms. Chu PG, et al. **Ann Diagn Pathol** 1999 Apr;3(2):104–33 (287 ref.)
Fine needle aspiration cytopathology of malignant lymphoma. Wakely PE Jr. **Clin Lab Med** 1998 Sep; 18(3):541–59, vi–vii (17 ref.)
Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Cerroni L, et al. **Semin Cutan Med Surg** 1999 Mar;18(1):64–70 (37 ref.)
Cerebellopontine angle lymphoma: a case report and review of the literature. Nishimura T, et al. **Surg Neurol** 1998 Nov; 50(5):480–5; discussion 485–6 (23 ref.)
[Immunology in medical practice. XXI. Laboratory tests for immunologic diseases] Out TA, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1027–33 (30 ref.) (Eng. Abstr.) **(Dut)**
[Molecular genetic diagnostics and prognostic factors in lymphoma] Nakamine H, et al. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2193–201 (46 ref.) (Eng. Abstr.) **(Jpn)**
[Endocrine surgery. Diagnosis and therapy for thyroid malignant lymphoma] Akasu H, et al. **Nippon Ika Daigaku Zasshi** 1998 Aug;65(4):320–3 (9 ref.) **(Jpn)**
[Differential diagnosis of Hashimoto's thyroiditis from thyroidal neoplastic diseases] Aozasa K, et al. **Nippon Rinsho** 1999 Aug;57(8):1894–8 (11 ref.) (Eng. Abstr.) **(Jpn)**
[A new case of multifocal bone lymphoma (letter)] Marcos Sánchez F, et al. **An Med Interna** 1999 Jul;16(7):384–5 (7 ref.) **(Spa)**
[Central nervous system lymphoma] Cristóbal CB. **Sangre (Barc)** 1998 Dec;43(6):527–33 (13 ref.) **(Spa)**
[Lymphoma of the gastrointestinal tract] Moreno Casado MJ, et al. **Sangre (Barc)** 1998 Dec;43(6):493–8 (15 ref.) **(Spa)**
[Lymphoma of the urogenital system] Parlorio de Andrés E, et al. **Sangre (Barc)** 1998 Dec;43(6):499–505 (34 ref.) **(Spa)**
[Lymphomas of the head and neck] Saiz Ayala A, et al. **Sangre (Barc)** 1998 Dec;43(6):507–14 (27 ref.) **(Spa)**
[Abdominal lymphoma: lymph node and visceral involvemnet] Sánchez del Peral Otero G, et al. **Sangre (Barc)** 1998 Dec;43(6):483–92 (42 ref.) **(Spa)**

DRUG THERAPY

Leukemia: A model for drug development. Keating MJ. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2598–604 (43 ref.)
Antisense strategy in hematological malignancies. Warzocha K. **Cytokines Cell Mol Ther** 1999 Mar;5(1):15–23 (90 ref.)
Successful treatment of cytomegalovirus retinitis in a patient with malignant lymphoma: a case report and review of the literature. Kawai Y, et al. **Int J Hematol** 1999 Jun; 69(4):256–9 (15 ref.)
Paclitaxel-based treatment of lymphoma. Younes A. **Semin Oncol** 1999 Feb;26(1 Suppl 2):123–8 (22 ref.)
[Lymphogenesis: from phenotype to treatment] Reyes F. **Rev Med Interne** 1998;19 Suppl 1:12S–13S (6 ref.) **(Fre)**
[Hematologic tumors] Ogawa M. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:165–72 (35 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Epidemiology of leukemia and lymphoma. Bhatia S, et al. **Curr Opin Hematol** 1999 Jul;6(4):201–4 (26 ref.)
Epidemiology of the Revised European-American Lymphoma Classification subtypes. Herrinton LJ. **Epidemiol Rev** 1998;20(2):187–203 (134 ref.)
Lymphatic and hematopoietic cancer in teachers. Baker P, et al. **Scand J Work Environ Health** 1999 Feb;25(1):5–17 (38 ref.)

ETIOLOGY

Idiopathic thrombocytopenic purpura preceding malignant lymphoma: report of one case. Lin WC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 Jan–Feb;40(1):39–42 (17 ref.)
Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Dotti G, et al. **Leukemia** 1999 May;13(5):664–70 (35 ref.)
The role of immunosuppression in lymphoma formation. Penn I. **Springer Semin Immunopathol** 1998;20(3–4):343–55 (54 ref.)
[Post-transplantation lymphomas and Epstein-Barr virus] Caillard S, et al. **Nephrologie** 1998;19(8):481–8 (100 ref.) (Eng. Abstr.) **(Fre)**
[Lymphogenesis: from phenotype to treatment] Reyes F. **Rev Med Interne** 1998;19 Suppl 1:12S–13S (6 ref.) **(Fre)**
[Primary lymphoma of the central nervous system. Review of etiological factors] Garcia-Pravos A, et al. **Rev Neurol** 1998 Oct;27(158):577–81 (42 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Ichinohasama R, et al. **Am J Surg Pathol** 1998 Dec; 22(12):1528–37 (45 ref.)
Genes and cancer. Birch JM. **Arch Dis Child** 1999 Jan; 80(1):1–3 (25 ref.)
ATM and lymphoid malignancies; use of oriented peptide libraries to identify novel substrates of ATM critical in downstream signaling pathways. Rathbun GA, et al. **Curr Top Microbiol Immunol** 1999;246:267–73; discussion 274 (25 ref.)
Cytogenetic changes in the progression of lymphoma. Knutsen T. **Leuk Lymphoma** 1998 Sep;31(1–2):1–19 (126 ref.)
The mouse lymphoma assay in the wake of ICH4--where are we now? Cole J, et al. **Mutagenesis** 1999 May; 14(3):265–70 (47 ref.)
Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Adams JM, et al. **Oncogene** 1999 Sep 20;18(38):5268–77 (127 ref.)
Genetics of small lymphocyte disorders. Panayiotidis P, et al. **Semin Hematol** 1999 Apr;36(2):171–7 (77 ref.)
[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases] Beltinger C, et al. **Klin Padiatr** 1998 Jul–Aug;210(4):153–8 (37 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Murine models of thymic lymphomas: premalignant scenarios amenable to prophylactic therapy. Yefenof E. **Adv Immunol** 1999;73:511–39 (172 ref.)

METABOLISM

Issues for conducting the microtiter version of the mouse lymphoma thymidine kinase (tk) assay and a critical review of data generated in a collaborative trial using the microtiter method. Moore MM, et al. **Mutagenesis** 1999 May;14(3):271–81 (16 ref.)
NMR studies of phospholipid metabolism in hepatic lymphoma. Dixon RM. **NMR Biomed** 1998 Nov;

11(7):370–9 (49 ref.)
Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Gametchu B, et al. **Steroids** 1999 Jan–Feb;64(1–2):107–19 (47 ref.)
Gallium-67 as a tumor-seeking agent in lymphomas--a review. Draisma A, et al. **Tumori** 1998 Jul–Aug; 84(4):434–41 (86 ref.)

NURSING

Lymphoma at the extremes of age. Boyle DA, et al. **Semin Oncol Nurs** 1998 Nov;14(4):302–11 (70 ref.)
Lymphomas: long-term sequelae and survivorship issues. Fernsler J, et al. **Semin Oncol Nurs** 1998 Nov;14(4):321–8 (82 ref.)
Oncologic emergencies in the patient with lymphoma. Hogan DK, et al. **Semin Oncol Nurs** 1998 Nov;14(4):312–20 (38 ref.)

PATHOLOGY

Primary malignant lymphoma of the appendix (a case report and review of the literature). Uncu H, et al. **Acta Chir Hung** 1998;37(1–2):11–6 (12 ref.)
Advances in immunohistochemical techniques: toward making things simpler, cheaper, more sensitive, and more reproducible [published erratum appears in Adv Anat Pathol 1998 Nov;5(6):399] Chan JK. **Adv Anat Pathol** 1998 Sep;5(5):314–25 (55 ref.)
Molecular pathology of leukemia and lymphoma. Bagg A, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S76–92 (115 ref.)
The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Frizzera G, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S13–39 (490 ref.)
Natural killer cell neoplasms. Chan JK. **Anat Pathol** 1998; 3:77–145 (256 ref.)
Practical lymphoma diagnosis: an approach to using the information organized in the REAL proposal. Revised European-American Lymphoid Neoplasm. Segal GH, et al. **Anat Pathol** 1998;3:147–68 (42 ref.)
Lymphomas and reactive lymphoid lesions in HIV infection. Bain BJ. **Blood Rev** 1998 Sep;12(3):154–62 (77 ref.)
The lymphomas in 1998: from cell biology to therapy [editorial] D'Onofrio G, et al. **Eur Rev Med Pharmacol Sci** 1998 Mar–Apr;2(2):49–52 (11 ref.)
History and classification of human leukemia–lymphoma cell lines. Drexler HG, et al. **Leuk Lymphoma** 1998 Oct; 31(3–4):305–16 (128 ref.)
Microscopic mimicry of lymphomas: diagnostic pitfalls. Banks PM. **Mod Pathol** 1999 Feb;12(2):116–24 (19 ref.)
Anaplastic cancer, lymphoma, and metastases of the thyroid gland. Pasieka JL. **Surg Oncol Clin N Am** 1998 Oct; 7(4):707–20 (61 ref.)
[Lymphoid hyperplasia associated with human immunodeficiency virus and Epstein-Barr virus; relationship with lymphomatous pathology] Raphaël M, et al. **Ann Pathol** 1998 Oct;18(4):325–30 (61 ref.) **(Fre)**
[Thyroid biopsy in the auto-immune thyroid diseases] Fukuuchi A. **Nippon Rinsho** 1999 Aug;57(8):1841–5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Clinicopathologic features of extranodal lesions of malignant lymphomas] Yoshino T, et al. **Rinsho Ketsueki** 1999 Mar; 40(3):182–4 (7 ref.) **(Jpn)**

PHYSIOPATHOLOGY

A role for growth hormone and prolactin in leukaemia and lymphoma? Hooghe R, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1095–101 (85 ref.)
The molecular biology of lymphoma. Engstrom CA, et al. **Semin Oncol Nurs** 1998 Nov;14(4):256–61 (34 ref.)
[Disturbance of signalling pathways for apoptosis in thymic lymphomas from TCR transgenic mice] Strządała L. **Postepy Hig Med Dosw** 1999;53(2):345–50 (15 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

[Bone lymphoma] Merino Menéndez S, et al. **Sangre (Barc)** 1998 Dec;43(6):521–5 (17 ref.) **(Spa)**
[Thoracic lymphoma] Vidal Carreira JJ, et al. **Sangre (Barc)** 1998 Dec;43(6):515–20 (16 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. Delbeke D. **J Nucl Med** 1999 Apr;40(4):591–603 (81 ref.)
Gallium-67 as a tumor-seeking agent in lymphomas--a review. Draisma A, et al. **Tumori** 1998 Jul–Aug; 84(4):434–41 (86 ref.)
Somatostatin receptor scintigraphy of malignant lymphoma--current status. Serafini AN. **Yale J Biol Med** 1997 Sep–Dec;70(5–6):555–9 (20 ref.)

RADIOTHERAPY

[Radiotherapy in primary cerebral lymphoma] Legros L, et al. **Cancer Radiother** 1999 Mar–Apr;3(2):149–53 (24 ref.) (Eng. Abstr.) **(Fre)**
[Radioimmunotherapy of lymphomas and leukemias] Rain JD, et al. **Pathol Biol (Paris)** 1998 May;46(5):341–5 (14 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Lymphomas: long-term sequelae and survivorship issues. Fernsler J, et al. **Semin Oncol Nurs** 1998 Nov;14(4):321–8 (82 ref.)

SURGERY

[Prospective comparative study of different amino acid and lipid solutions in parenteral nutrition of patients undergoing bone marrow transplantation] Jiménez Jiménez FJ, et al. **Nutr Hosp** 1999 Mar–Apr;14(2):57–66 (47 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Stem cell mobilisation in lymphoproliferative diseases. Russell NH, et al. **Bone Marrow Transplant** 1998 Nov; 22(10):935–40 (41 ref.)
Therapy of diffuse aggressive lymphomas. Koc Y, et al. **Cancer Treat Res** 1999;99:47–73 (163 ref.)
The development of bone marrow transplantation as a treatment for patients with lymphoma--twentieth Richard and Hinda Rosenthal Foundation Award Lecture. Armitage JO. **Clin Cancer Res** 1997 Jun;3(6):829–36 (84 ref.)
Can we cure indolent lymphomas? Cabanillas F. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2655–9 (31 ref.)
The lymphomas in 1998: from cell biology to therapy [editorial] D'Onofrio G, et al. **Eur Rev Med Pharmacol Sci** 1998 Mar–Apr;2(2):49–52 (11 ref.)
Parotid cancer. Stafford ND, et al. **Surg Oncol** 1997 Dec; 6(4):209–13 (36 ref.)
[Treatment of aggressive lymphoma in adults] Milpied N. **Rev Med Interne** 1998;19 Suppl 1:21S–22S (9 ref.) **(Fre)**
[Monoclonal antibodies in therapy of malignant lymphomas] Buske C, et al. **Internist (Berl)** 1998 Dec;39(12):1205–14 (61 ref.) **(Ger)**
[Management of hematologic systemic diseases and rare tumor entities with manifestations in the oromaxillofacial area] Petrasch S. **Mund Kiefer Gesichtschir** 1998 Jul; 2(4):172–80 (74 ref.) (Eng. Abstr.) **(Ger)**
[Malignant tumors in childhood] Fujimoto T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:191–8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Endocrine surgery. Diagnosis and therapy for thyroid malignant lymphoma] Akasu H, et al. **Nippon Ika Daigaku Zasshi** 1998 Aug;65(4):320–3 (9 ref.) **(Jpn)**
[Indication and results of hematopoietic stem cell transplantation. 4. Malignant lymphoma and multiple myeloma] Tanosaki R. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1483–7 (4 ref.) **(Jpn)**
[Gene therapy for hematological malignancies] Tani K. **Rinsho Byori** 1998 Aug;46(8):797–803 (9 ref.) **(Jpn)**

VIROLOGY

Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy. Berneman ZN, et al. **Ann Hematol** 1998 Dec;77(6):275–8 (59 ref.)
Lymphomas and reactive lymphoid lesions in HIV infection. Bain BJ. **Blood Rev** 1998 Sep;12(3):154–62 (77 ref.)
Epstein-Barr virus and lymphoma. Ambinder RF, et al. **Cancer Treat Res** 1999;99:27–45 (130 ref.)
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Drexler HG, et al. **Leukemia** 1998 Oct; 12(10):1507–17 (46 ref.)
The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Cesarman E, et al. **Semin Cancer Biol** 1999 Jun;9(3):165–74 (92 ref.)

LYMPHOMA, AIDS-RELATED

AIDS-related malignancies. Smith C, et al. **Ann Med** 1998 Aug;30(4):323–44 (212 ref.)
Acquired immunodeficiency syndrome-related lymphoma. Roth EL. **Semin Oncol Nurs** 1998 Nov;14(4):284–92 (43 ref.)
[HIV-associated lymphoma] Omine M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):301–4 (9 ref.) **(Jpn)**

COMPLICATIONS

Rare cause of blindness in a patient with acquired immunodeficiency syndrome. Cook MA, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):711–4 (16 ref.)
[Hodgkin's disease in patients infected with the human immunodeficiency virus] Costello R, et al. **Rev Med Interne** 1998 Aug;19(8):558–64 (69 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Non-Hodgkin lymphoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyon. Jan NA, et al. **Am J Clin Oncol** 1999 Feb;22(1):82–3 (12 ref.)
Rare cause of blindness in a patient with acquired immunodeficiency syndrome. Cook MA, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):711–4 (16 ref.)
Acquired immunodeficiency syndrome-related primary cerebral lymphoma. Khoo VS, et al. **Clin Oncol (R Coll Radiol)** 1999;11(1):6–14 (82 ref.)
Oral lymphoma in human immunodeficiency virus infection: a report of six cases and review of the literature. Jordan RC, et al. **Otolaryngol Head Neck Surg** 1998 Dec; 119(6):672–7 (43 ref.)
Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Picciocchi A, et al. **Surg Today** 1998;28(12):1257–60 (18 ref.)
[Primary cerebral lymphoma associated with AIDS: clinical profile, diagnostic criteria and therapeutic development] Rubio Rodríguez MC, et al. **Rev Clin Esp** 1999 Mar; 199(3):161–6 (74 ref.) **(Spa)**

EPIDEMIOLOGY

Nasopharyngeal mucosa-associated lymphoid tissue lymphoma in patients infected with the human immunodeficiency virus. Sundaram K, et al. **Am J Otolaryngol** 1999 Jan–Feb;20(1):56–8 (6 ref.)
AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. Grulich AE. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S27–30 (22 ref.)
Overview of the epidemiology of malignancy in immune deficiency. Mueller N. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S5–10 (23 ref.)

ETIOLOGY

Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment. Mitsuyasu R. **Clin Infect Dis** 1999 Jul;29(1):35–43 (77 ref.)

GENETICS

Susceptibility genes for AIDS and AIDS-related lymphoma. Rabkin CS, et al. **Curr Top Microbiol Immunol** 1999; 246:111–4; discussion 115 (13 ref.)
BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. Gaidano G, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):39–46 (50 ref.)

PATHOLOGY

Cerebral lymphomas in AIDS. Neuropathological study. Zelman IB, et al. **Folia Neuropathol** 1998;36(2):65–79 (41 ref.)
Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Dhodapkar MV, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):35–43 (53 ref.)
[The pathology spectrum of AIDS-related non-Hodgkin's lymphoma] Carbone A, et al. **Pathologica** 1998 Dec; 90(6):763–70 (43 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Picciocchi A, et al. **Surg Today** 1998;28(12):1257–60 (18 ref.)

THERAPY

AIDS-associated lymphoma. Volm MD, et al. **Cancer Treat Res** 1999;99:241–66 (93 ref.)
Acquired immunodeficiency syndrome-related primary cerebral lymphoma. Khoo VS, et al. **Clin Oncol (R Coll Radiol)** 1999;11(1):6–14 (82 ref.)
[Primary cerebral lymphoma associated with AIDS: clinical profile, diagnostic criteria and therapeutic development] Rubio Rodríguez MC, et al. **Rev Clin Esp** 1999 Mar; 199(3):161–6 (74 ref.) **(Spa)**

LYMPHOMA, ATYPICAL DIFFUSE SMALL LYMPHOID see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, B-CELL

An Asian variant of intravascular lymphomatosis: an updated review of malignant histiocytosis-like B-cell lymphoma [published erratum appears in Leuk Lymphoma 1999 Jun;34(1–2):following 206] Murase T, et al. **Leuk Lymphoma** 1999 May;33(5–6):459–73 (98 ref.)
Gastrointestinal lymphomas of T- and B-cell types. Isaacson PG. **Mod Pathol** 1999 Feb;12(2):151–8 (50 ref.)
Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Catovsky D, et al. **Semin Hematol** 1999 Apr;36(2):148–54 (31 ref.)
Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma). Nathwani BN, et al. **Semin Hematol** 1999 Apr;36(2):128–38 (66 ref.)
[From Hashimoto thyroiditis to B-cell lymphoma of the thyroid gland] Fehr-Merhof A, et al. **Schweiz Med Wochenschr** 1999 Jun 12;129(23):883–9 (32 ref.) (Eng. Abstr.) **(Ger)**
[Composite lymphoma, discordant lymphoma] Isobe Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):268–71 (18 ref.) **(Jpn)**
[Signet ring cell lymphoma] Kawakami M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):291–3 (5 ref.)

LYMPHOMA, B-CELL

(Jpn)

CLASSIFICATION

Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Russell-Jones R. **Br J Dermatol** 1998 Dec;139(6):945–9 (25 ref.)

Cutaneous lymphoma. Understanding the new classification schemes. Duncan LM. **Dermatol Clin** 1999 Jul;17(3):569–92 (125 ref.)

COMPLICATIONS

Adrenal insufficiency caused by primary aggressive non-Hodgkin's lymphoma of bilateral adrenal glands: report of a case and literature review. Hsu CW, et al. **Ann Hematol** 1999 Mar;78(3):151–4 (29 ref.)

Fine-needle aspiration of large cell lymphoma in a patient with agnogenic myeloid metaplasia: a case report and review of the literature. Liu K, et al. **Diagn Cytopathol** 1998 Sep;19(3):205–9 (25 ref.)

Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus. Yoshikawa M, et al. **J Gastroenterol** 1998 Dec;33(6):880–5 (33 ref.)

[A case of primary central nervous system lymphoma with the onset of impotence] Hori T, et al. **Rinsho Shinkeigaku** 1999 Feb-Mar;39(2-3):333–9 (20 ref.) (Eng. Abstr.) (Jpn)

DIAGNOSIS

Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma [editorial; comment] Chadburn A, et al. **Am J Clin Pathol** 1999 Aug;112(2):155–8 (40 ref.) Comment on: Am J Clin Pathol 1999 Aug;112(2):241–7.

Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Rüdiger T, et al. **Am J Surg Pathol** 1998 Oct;22(10):1184–91 (31 ref.)

Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Rüdiger T, et al. **Ann Oncol** 1998; 9 Suppl 5:S31–8 (27 ref.)

Early detection of cutaneous lymphoma. Abd-el-Baki J, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1521–30; discussion 1532–4 (62 ref.)

[Primary non-Hodgkin lymphoma of the mandible—a case report] Schimming R, et al. **Schweiz Monatsschr Zahnmed** 1999;109(8):837–43 (28 ref.) (Ger, Fre)

DRUG THERAPY

Use of rituximab, the new FDA-approved antibody. Leget GA, et al. **Curr Opin Oncol** 1998 Nov;10(6):548–51 (29 ref.)

ENZYMOLOGY

Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma. Hsueh RC, et al. **Curr Top Microbiol Immunol** 1999; 246:299–304; discussion 305 (14 ref.)

EPIDEMIOLOGY

Clinicopathologic features of posttransplant lymphoproliferative disorders. Nalesnik MA. **Ann Transplant** 1997;2(4):33–40 (113 ref.)

Epidemiology of B-cell lymphomas. Rabkin CS. **Curr Top Microbiol Immunol** 1999;246:235–9; discussion 240 (10 ref.)

ETIOLOGY

Primary hepatic lymphoma in hepatitis C: case report and review of the literature. Chowla A, et al. **Am Surg** 1999 Sep;65(9):881–3 (6 ref.)

Do germinal centers have a role in the generation of lymphomas? Yang K, et al. **Curr Top Microbiol Immunol** 1999;246:53–60; discussion 61–2 (15 ref.)

In situ hybridization evidence of the donor origin of a post-transplant lymphoproliferative disorder [letter] Kerim S, et al. **Eur J Haematol** 1999 Jul;63(1):61–3 (17 ref.)

Identifying the precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease: role of the germinal center in B-cell lymphomagenesis. Küppers R. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S74–9 (47 ref.)

Mechanism for the development of pyothorax-associated lymphoma. Kanno H, et al. **Pathol Int** 1998 Sep; 48(9):653–64 (87 ref.)

GENETICS

Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells [comment] Müller-Hermelink HK, et al. **Am J Pathol** 1998 Nov;153(5):1341–6 (59 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1609–14.

Analysis of B-cell neoplasias by spectral karyotyping (SKY). Hilgenfeld E, et al. **Curr Top Microbiol Immunol** 1999; 246:169–74 (18 ref.)

Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. Mushinski JF, et al. **Curr Top Microbiol Immunol** 1999;246:183–9; discussion 190–2 (24 ref.)

t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma. Amakawa R, et al. **Int J Hematol** 1999 Feb;69(2):65–9 (37 ref.)

Somatic hypermutation and B-cell malignancies. Spencer JO, et al. **J Pathol** 1999 Jan;187(2):158–63 (54 ref.)

Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Iida S, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):25–33 (51 ref.)

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64–77 (32 ref.)

[Primary splenic lymphoma with t(3;14)(q27;q32) chromosomal abnormality and rearrangement of BCL-6 gene] Yata K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):587–92 (14 ref.) (Eng. Abstr.) (Jpn)

IMMUNOLOGY

Strategies to elicit anti-idiotypic immune response in B-lymphoma patients. Peptide and genetic immunization. Rinaldi M, et al. **Adv Exp Med Biol** 1998;451:323–30 (37 ref.)

Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity. Sternas LA, et al. **Cancer Treat Res** 1999;99:267–73 (25 ref.)

CD5 B cells and B-cell malignancies. Lydyard PM, et al. **Curr Opin Hematol** 1999 Jan;6(1):30–6 (107 ref.)

Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma. Hsueh RC, et al. **Curr Top Microbiol Immunol** 1999; 246:299–304; discussion 305 (14 ref.)

Monoclonal antibodies in the treatment of human B-cell malignancies. Link BK, et al. **Leuk Lymphoma** 1998 Oct; 31(3-4):237–49 (89 ref.)

Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses? Schultze JL. **Leuk Lymphoma** 1999 Jan;32(3-4):223–36 (99 ref.)

METABOLISM

BCL2 overexpression in diffuse large B-cell lymphoma. Monni O, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):45–52 (60 ref.)

PATHOLOGY

Are there site-specific differences among extranodal aggressive B-cell neoplasms? Mann RB. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S144–50 (32 ref.)

Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease. Hancock JC, et al. **Ann Diagn Pathol** 1999 Feb;3(1):23–34 (51 ref.)

Sinonasal malignant lymphomas: a distinct clinicopathological category. Vidal RW, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):411–9 (40 ref.)

Morphologic spectrum of cutaneous B-cell lymphomas. Sander CA, et al. **Dermatol Clin** 1999 Jul;17(3):593–9, ix (46 ref.)

T cell rich B cell lymphoma (TCRBCL): study of sixteen cases with review of literature. Muzaffar S, et al. **Indian J Pathol Microbiol** 1999 Jan;42(1):15–23 (34 ref.)

Molecular markers of B-cell lymphoma. Stevenson GT, et al. **Semin Cancer Biol** 1999 Apr;9(2):139–47 (38 ref.)

[Morphological aspects of low-grade B-cell lymphoma] Berger F, et al. **Ann Pathol** 1998 Oct;18(4):261–75 (30 ref.) (Fre)

[An autopsy case of intravascular malignant lymphomatosis with hemophagocytic syndrome, mental confusion and liver dysfunction] Onishi Y, et al. **Rinsho Ketsueki** 1998 Aug;39(8):586–92 (18 ref.) (Eng. Abstr.) (Jpn)

THERAPY

Strategies to elicit anti-idiotypic immune response in B-lymphoma patients. Peptide and genetic immunization. Rinaldi M, et al. **Adv Exp Med Biol** 1998;451:323–30 (37 ref.)

Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Schultze JL, et al. **Curr Opin Oncol** 1998 Nov;10(6):542–7 (31 ref.)

Management of rare forms of lymphoma. Zucca E, et al. **Curr Opin Oncol** 1998 Sep;10(5):377–84 (76 ref.)

Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy. Buske C, et al. **Eur J Cancer** 1999 Apr; 35(4):549–57 (99 ref.)

T cell mediated immunotherapy for B cell lymphoma. Schultze JL, et al. **J Mol Med** 1999 Mar;77(3):322–31 (134 ref.)

Monoclonal antibodies in the treatment of human B-cell malignancies. Link BK, et al. **Leuk Lymphoma** 1998 Oct; 31(3-4):237–49 (89 ref.)

Clinical status and optimal use of rituximab for B-cell lymphomas. McLaughlin P, et al. **Oncology (Huntingt)** 1998 Dec;12(12):1763–9; discussion 1769–70, 1775–7, (16 ref.)

VIROLOGY

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64–77 (32 ref.)

LYMPHOMA, BURKITT see **BURKITT LYMPHOMA**

LYMPHOMA, CENTROCYTIC SMALL-CELL see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, CONVOLUTED T-CELL see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, DIFFUSE

PATHOLOGY

T cell rich B cell lymphoma (TCRBCL): study of sixteen cases with review of literature. Muzaffar S, et al. **Indian J Pathol Microbiol** 1999 Jan;42(1):15–23 (34 ref.)

LYMPHOMA, DIFFUSE, LARGE FOLLICULAR CENTER-CELL see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, DIFFUSE, MIXED LYMPHOCYTIC-HISTIOCYTIC see **LYMPHOMA, MIXED-CELL, DIFFUSE**

LYMPHOMA, FOLLICULAR

DIAGNOSIS

[Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes] al Saati T, et al. **Bull Cancer** 1998 Oct;85(10):847–54 (64 ref.) (Eng. Abstr.) (Fre)

PATHOLOGY

Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Chan WC. **Semin Hematol** 1999 Jul;36(3):242–52 (83 ref.)

THERAPY

High-dose therapy and stem cell transplantation in follicular lymphoma. Friedberg JW, et al. **Ann Hematol** 1999 May; 78(5):203–11 (62 ref.)

Treatment of follicular lymphoma. Connors JM, et al. **Curr Opin Oncol** 1998 Sep;10(5):392–5 (18 ref.)

Allogeneic peripheral blood stem cell transplantation as an alternative to allogeneic bone marrow transplantation [editorial; comment] Harada M. **Intern Med** 1998 Dec; 37(12):1001–2 (9 ref.) Comment on: Intern Med 1998 Dec;37(12):1050–4.

Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. Tezcan H, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):273–85 (32 ref.)

[Treatment of malignant low-grade lymphoma. Follicular Lymphoma Study Group] Solal-Celigny P. **Rev Med Interne** 1998;19 Suppl 1:18S–20S (4 ref.) (Fre)

LYMPHOMA, FOLLICULAR, MIXED LYMPHOCYTIC-HISTIOCYTIC see **LYMPHOMA, MIXED-CELL, FOLLICULAR**

LYMPHOMA, FOLLICULAR, MIXED SMALL AND LARGE LYMPHOID see **LYMPHOMA, MIXED-CELL, FOLLICULAR**

LYMPHOMA, FOLLICULAR, SMALL AND LARGE CLEAVED-CELL see **LYMPHOMA, MIXED-CELL, FOLLICULAR**

LYMPHOMA, GIANT FOLLICULAR see **LYMPHOMA, FOLLICULAR**

LYMPHOMA, HIGH-GRADE

DIAGNOSIS

Primary breast lymphoma. Vianello F, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):188–95 (24 ref.)

THERAPY

Management of high-grade lymphomas. Magrath IT. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):40–8 (55 ref.)

LYMPHOMA, HISTIOCYTIC see **LYMPHOMA, LARGE-CELL**

LYMPHOMA, HISTIOCYTIC, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, HISTIOCYTIC, NODULAR see **LYMPHOMA, LARGE-CELL, FOLLICULAR**

LYMPHOMA, HIV-RELATED see **LYMPHOMA, AIDS-RELATED**

LYMPHOMA, IMMUNOBLASTIC, LARGE-CELL see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

LYMPHOMA, INTERMEDIATE-GRADE

DRUG THERAPY

Management of intermediate-grade lymphomas. Miller TP. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):35-9 (29 ref.)

LYMPHOMA, KI-1 see **LYMPHOMA, LARGE-CELL, KI-1**

LYMPHOMA L5178 see **LEUKEMIA L5178**

LYMPHOMA, LARGE-CELL

An Asian variant of intravascular lymphomatosis: an updated review of malignant histiocytosis-like B-cell lymphoma [published erratum appears in Leuk Lymphoma 1999 Jun;34(1-2):following 206] Murase T, et al. **Leuk Lymphoma** 1999 May;33(5-6):459-73 (98 ref.)

Primary large cell lymphoma of the mediastinum. Aisenberg AC. **Semin Oncol** 1999 Jun;26(3):251-8 (72 ref.)

COMPLICATIONS

Fine-needle aspiration of large cell lymphoma in a patient with agnogenic myeloid metaplasia: a case report and review of the literature. Liu K, et al. **Diagn Cytopathol** 1998 Sep;19(3):205-9 (25 ref.)

Hyperthyroidism due to lymphoma involving the thyroid gland in a patient with acquired immunodeficiency syndrome: case report and review of the literature. Samuels MH, et al. **Thyroid** 1998 Aug;8(8):673-7 (41 ref.)

DIAGNOSIS

Intrameatal tumours presenting as a hearing disturbance: case reports of meningioma and lymphoma. Kawamura S, et al. **Acta Neurochir (Wien)** 1998;140(7):675-9 (16 ref.)

Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma [editorial; comment] Chadburn A, et al. **Am J Clin Pathol** 1999 Aug;112(2):155-8 (40 ref.) Comment on: Am J Clin Pathol 1999 Aug;112(2):241-7.

Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Rüdiger T, et al. **Ann Oncol** 1998; 9 Suppl 5:S31-8 (27 ref.)

[Lymphomas presenting as Tietze's syndrome: a report of 4 clinical cases] Cocco R, et al. **Ann Ital Med Int** 1999 Apr-Jun;14(2):118-23 (20 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Non-Hodgkin's lymphoma associated with Gaucher's disease. Perales M, et al. **Leuk Lymphoma** 1998 Nov; 31(5-6):609-12 (24 ref.)

PATHOLOGY

Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset [published erratum appears in Adv Anat Pathol 1998 Nov;5(6):399] Chan JK. **Adv Anat Pathol** 1998 Sep;5(5):281-313 (83 ref.)

Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Fonseca R, et al. **Am J Hematol** 1998 Oct;59(2):161-7 (32 ref.)

Interdigitating reticulum cell tumor of lymph node: a case report and literature review. Liu SM, et al. **Pathol Int** 1998 Dec;48(12):974-80 (36 ref.)

Primary large-cell lymphomas of the mediastinum. Suster S. **Semin Diagn Pathol** 1999 Feb;16(1):51-64 (53 ref.)

LYMPHOMA, LARGE-CELL, DIFFUSE

[Diffuse lymphoma, large cell type] Dobashi N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):252-5 (15 ref.) **(Jpn)**

[Composite lymphoma, discordant lymphoma] Isobe Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):268-71 (18 ref.) **(Jpn)**

COMPLICATIONS

Aggressive bowel lymphoma in a patient with intestinal lymphangiectasia and widespread viral warts [letter] Gumà J, et al. **Ann Oncol** 1998 Dec;9(12):1355-6 (6 ref.)

DIAGNOSIS

[Waldenström's macroglobulinemia and primary cerebral diffuse large-cell lymphoma (letter)] Domingo JM, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):800-1 (7 ref.) **(Spa)**

DRUG THERAPY

[Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease] Uno S, et al. **Rinsho Ketsueki** 1999 May;40(5):414-9 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

BCL2 overexpression in diffuse large B-cell lymphoma. Monni O, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):45-52 (60 ref.)

PATHOLOGY

Primary large-cell lymphomas of the mediastinum. Suster S. **Semin Diagn Pathol** 1999 Feb;16(1):51-64 (53 ref.)

THERAPY

Treatment of grey zone lymphomas. Fisher RI. **Ann Oncol** 1998;9 Suppl 5:S121-3 (12 ref.)

LYMPHOMA, LARGE-CELL, DIFFUSE, UNDIFFERENTIATED see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, LARGE-CELL, FOLLICULAR

[Follicular lymphoma, large cell type] Dobashi N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):240-3 (13 ref.) **(Jpn)**

LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC

see related
LYMPHOMA, T-CELL, PERIPHERAL

Perianal lymphoma in a heterosexual and nonimmunocompromised patient: report of a case and review of the literature. Smith DL 2nd, et al. **Dis Colon Rectum** 1999 Jul;42(7):952-4 (13 ref.)

[Immunoblastic lymphoma] Tani Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):256-8 (15 ref.) **(Jpn)**

LYMPHOMA, LARGE-CELL, KI-1

see related
ANTIGENS, CD30

Primary Ki-1-positive T-cell lymphoma of the brain in a child. Buxton N, et al. **Pediatr Neurosurg** 1998 Nov; 29(5):250-2 (9 ref.)

[Null-cell lymphoma] Hayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):315-8 (22 ref.) **(Jpn)**

[Anaplastic large cell lymphoma] Suzukawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):298-300 (15 ref.) **(Jpn)**

GENETICS

Rarity of genomic instability in pathogenesis of systemic anaplastic large cell lymphoma (ALCL) in immunocompetent patients. Hodges KB, et al. **Hum Pathol** 1999 Feb;30(2):173-7 (42 ref.)

PATHOLOGY

The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Kinney MC, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S56-67 (79 ref.)

Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. Tomaszewski MM, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):857-61 (21 ref.)

[Hodgkin's disease and anaplastic large cell lymphoma in 1998] Delsol G, et al. **Ann Pathol** 1998 Oct;18(4):331-42 (40 ref.) **(Fre)**

PHYSIOPATHOLOGY

Anaplastic large-cell lymphoma of null-cell type with multiple bone involvement. Suzukawa K, et al. **Ann Hematol** 1998 Dec;77(6):287-90 (20 ref.)

THERAPY

Treatment of grey zone lymphomas. Fisher RI. **Ann Oncol** 1998;9 Suppl 5:S121-3 (12 ref.)

LYMPHOMA, LARGE LYMPHOID, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, LARGE LYMPHOID, NODULAR see **LYMPHOMA, LARGE-CELL, FOLLICULAR**

LYMPHOMA, LOW-GRADE

Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Catovsky D, et al. **Semin Hematol** 1999 Apr;36(2):148-54 (31 ref.)

DRUG THERAPY

[Interferon alpha in the treatment of non-Hodgkin's lymphomas of low malignancy] Monnereau A, et al. **Bull Cancer** 1998 Oct;85(10):855-65 (39 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Morphological aspects of low-grade B-cell lymphoma] Berger F, et al. **Ann Pathol** 1998 Oct;18(4):261-75 (30 ref.) **(Fre)**

[Primary MALT-type lymphoma of the breast] Rafel M, et al. **Sangre (Barc)** 1998 Jun;43(3):244-7 (22 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Current approaches to therapy for indolent non-Hodgkin's lymphoma. Cheson BD. **Oncology (Huntingt)** 1998 Oct; 12(10 Suppl 8):25-34 (122 ref.)

Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Boussiotis VA, et al. **Semin Hematol** 1999 Apr;36(2):209-16 (49 ref.)

[Treatment of malignant low-grade lymphoma. Follicular Lymphoma Study Group] Solal-Celigny P. **Rev Med Interne** 1998;19 Suppl 1:18S-20S (4 ref.) **(Fre)**

VIROLOGY

HCV infection, cryoglobulinaemia, membranoproliferative glomerulonephritis and low grade non-Hodgkin lymphoma [comment] Lunel F, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):54-5 (18 ref.) Comment on: Ital J Gastroenterol Hepatol 1999 Jan-Feb;31(1):45-53.

LYMPHOMA, LYMPHOBLASTIC

see related
LEUKEMIA, T-CELL, ACUTE

[Lymphoblastic lymphoma] Tani Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):259-61 (10 ref.) **(Jpn)**

LYMPHOMA, LYMPHOBLASTIC, CONVOLUTED see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, LARGE-CELL see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, NONCONVOLUTED see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOCYTIC see **LYMPHOMA, SMALL-CELL**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, INTERMEDIATE DIFFERENTIATION see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, POORLY-DIFFERENTIATED see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, LYMPHOCYTIC, NODULAR, POORLY-DIFFERENTIATED see **LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR**

LYMPHOMA, LYMPHOCYTIC, PLASMACYTOID see **LYMPHOMA, SMALL-CELL**

LYMPHOMA, LYMPHOCYTIC, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, LYMPHOPLASMACYTOID, CLL see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, MALIGNANT see **LYMPHOMA**

LYMPHOMA, MEDITERRANEAN see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

LYMPHOMA, MIXED see **LYMPHOMA, MIXED-CELL**

LYMPHOMA, MIXED-CELL

PATHOLOGY

Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease. Hancock JC, et al. **Ann Diagn Pathol** 1999 Feb;3(1):23-34 (51 ref.)

LYMPHOMA, MIXED-CELL, DIFFUSE

[Diffuse lymphoma, mixed type] Dobashi N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):248-51 (14 ref.) **(Jpn)**

ETIOLOGY

[Malignant lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease)] Itoh T, et al. **Rinsho Ketsueki** 1998 Sep;39(9):698-702 (5 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA, MIXED-CELL, FOLLICULAR

[Follicular lymphoma, medium-sized cell type and mixed type] Ohno T, et al. **Ryoikibetsu Shokogun Shirizu** 1998; (22 Pt 3):235-9 (19 ref.) **(Jpn)**

DIAGNOSIS

[Extranodal lymphomas. A rare clinical entity or a protean disease? A case report] Scarti L, et al. **Recenti Prog Med** 1999 Jan;90(1):17-9 (9 ref.) (Eng. Abstr.) **(Ita)**

LYMPHOMA, MIXED LYMPHOCYTIC-HISTIOCYTIC see **LYMPHOMA, MIXED-CELL**

LYMPHOMA, MIXED SMALL AND LARGE CELL, DIFFUSE see **LYMPHOMA, MIXED-CELL, DIFFUSE**

LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE

Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission. Shimizu K, et al. **Int J Hematol** 1999 Feb;69(2):96-100 (22 ref.)

Acquired gastric mucosa-associated lymphoid tissue (MALT): a review with special emphasis on association with extragastric diseases and management problems of gastric MALT [see comments] Tursi A, et al. **J Clin Gastroenterol** 1999 Sep;29(2):133-7 (34 ref.) Comment in: J Clin Gastroenterol 1999 Sep;29(2):116-7.

Primary lymphoma of the epididymis. Kausch I, et al. **J Urol** 1998 Nov;160(5):1801-2 (9 ref.)

Mucosa-associated lymphoid tissue lymphoma. Isaacson PG. **Semin Hematol** 1999 Apr;36(2):139-47 (58 ref.)

[Pathogenesis and clinical pathology of mucosa-associated lymphoid tissue (MALT) lymphoma] Akagi T. **Rinsho Ketsueki** 1999 Mar;40(3):177-81 (16 ref.) **(Jpn)**

[MALT lymphoma] Kim EH, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):287-90 (14 ref.) **(Jpn)**

CLASSIFICATION

MALT lymphomas in 1997. Where do we stand? Banks PM, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S75-83 (25 ref.)

COMPLICATIONS

[Conjunctival adnexal lymphoid tissue lymphoma, a suspect in chronic conjunctivitis (see comments)] Creuzot-Garcher C, et al. **J Fr Ophtalmol** 1999 May;22(5):581-3 (14 ref.) Comment in: J Fr Ophtalmol 1999 May;22(5):521. **(Fre)**

EPIDEMIOLOGY

Nasopharyngeal mucosa-associated lymphoid tissue lymphoma in patients infected with the human immunodeficiency virus. Sundaram K, et al. **Am J Otolaryngol** 1999 Jan-Feb;20(1):56-8 (6 ref.)

ETIOLOGY

Helicobacter pylori and gastric malignancies. Melange M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):305-6 (9 ref.)

Recent advances in our understanding of the biology and pathogenesis of gastric mucosa-associated lymphoid tissue (malt) lymphoma. Du MQ, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):162-73 (121 ref.)

[MALT lymphoma of the parotid gland associated with Sjögren syndrome. A case report and review of literature] Damborenea Tajada J, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):595-8 (23 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Role of Helicobacter pylori in the pathogenesis of gastric carcinoma and progression of lymphoid nodules to lymphoma. Guindi M. **Can J Gastroenterol** 1999 Apr; 13(3):224-7 (39 ref.)

Gastric cancer and lymphoma. Mukhopadhyay P. **Curr Top Microbiol Immunol** 1999;241:57-69 (91 ref.)

Helicobacter pylori and lymphoproliferative disorders. Fischbach W. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S299-303 (39 ref.)

PATHOLOGY

MALT lymphomas in 1997. Where do we stand? Banks PM, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S75-83 (25 ref.)

Are there site-specific differences among the MALT lymphomas--morphologic, clinical? Burke JS. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S133-43 (83 ref.)

Recent advances in our understanding of the biology and pathogenesis of gastric mucosa-associated lymphoid tissue (malt) lymphoma. Du MQ, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):162-73 (121 ref.)

Endoscopic diagnosis of ileocecal mucosa-associated lymphoid tissue lymphoma. Hasegawa N, et al. **Gastrointest Endosc** 1999 Jul;50(1):115-7 (7 ref.)

Gastric low-grade mucosa-associated lymphoid tissue lymphomas: their histogenesis and high-grade transformation. Yoshino T, et al. **Pathol Int** 1998 May; 48(5):323-31 (104 ref.)

[Gastric mucosa-associated lymphoid tissue lymphomas (MALT) and their treatment] Ruskoné-Fourmestraux A. **Ann Chir** 1999;53(2):143-9 (50 ref.) **(Fre)**

[Extranodal lymphoma] de Mascarel A, et al. **Ann Pathol** 1998 Oct;18(4):277-97 (111 ref.) **(Fre)**

[MALT gastric lymphoma: update] Doglioni C, et al. **Pathologica** 1998 Jun;90(3):313-7 (27 ref.) **(Ita)**

[Primary non-Hodgkin's lymphoma of the esophagus following Hodgkin's disease (letter)] Fernández-Llamazares J, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):356-7 (10 ref.) **(Spa)**

[Primary MALT-type lymphoma of the breast] Rafel M, et al. **Sangre (Barc)** 1998 Jun;43(3):244-7 (22 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Gastric MALT lymphoma: from concept to cure. Isaacson PG. **Ann Oncol** 1999 Jun;10(6):637-45 (96 ref.)

SURGERY

Sinonasal mucosa-associated lymphoid tissue lymphoma. Babb MJ, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):585-8 (19 ref.)

THERAPY

[Gastric mucosa-associated lymphoid tissue lymphomas (MALT) and their treatment] Ruskoné-Fourmestraux A. **Ann Chir** 1999;53(2):143-9 (50 ref.) **(Fre)**

LYMPHOMA, NODULAR see **LYMPHOMA, FOLLICULAR**

LYMPHOMA, NODULAR, LARGE FOLLICULAR CENTER-CELL see **LYMPHOMA, LARGE-CELL, FOLLICULAR**

LYMPHOMA, NODULAR, MIXED LYMPHOCYTIC-HISTIOCYTIC see **LYMPHOMA, MIXED-CELL, FOLLICULAR**

LYMPHOMA, NODULAR, MIXED SMALL AND LARGE CELL see **LYMPHOMA, MIXED-CELL, FOLLICULAR**

LYMPHOMA, NON-HODGKIN

Primary bilateral adrenal lymphoma. Salvatore JR, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):111-7 (63 ref.)

Primary thyroid lymphoma. Ansell SM, et al. **Semin Oncol** 1999 Jun;26(3):316-23 (55 ref.)

Primary non-Hodgkin's lymphoma of bone. Baar J, et al. **Semin Oncol** 1999 Jun;26(3):270-5 (37 ref.)

Lymphomas of the breast: pathology and clinical behavior. Brogi E, et al. **Semin Oncol** 1999 Jun;26(3):357-64 (47 ref.)

Lymphoma of the gastrointestinal tract. Crump M, et al. **Semin Oncol** 1999 Jun;26(3):324-37 (111 ref.)

Primary pulmonary lymphoma. Habermann TM, et al. **Semin Oncol** 1999 Jun;26(3):307-15 (87 ref.)

Primary CNS lymphoma. Maher EA, et al. **Semin Oncol** 1999 Jun;26(3):346-56 (56 ref.)

Testicular lymphoma. Shahab N, et al. **Semin Oncol** 1999 Jun;26(3):259-69 (119 ref.)

Lymphomas of the head and neck. Yuen A, et al. **Semin Oncol** 1999 Jun;26(3):338-45 (52 ref.)

Non-Hodgkin's lymphoma. Bilodeau BA, et al. **Semin Oncol Nurs** 1998 Nov;14(4):273-83 (59 ref.)

Acquired immunodeficiency syndrome-related lymphoma. Roth EL. **Semin Oncol Nurs** 1998 Nov;14(4):284-92 (43 ref.)

Lymphomas of the anterior mediastinum. Glick RD, et al. **Semin Pediatr Surg** 1999 May;8(2):69-77 (60 ref.)

[Biological characteristics of malignant lymphoma with extranodal involvement] Masumoto A, et al. **Rinsho Ketsueki** 1999 Mar;40(3):185-7 (5 ref.) **(Jpn)**

[Intravascular lymphoma (IVL)] Hori M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):294-7 (19 ref.) **(Jpn)**

[Sarcoidosis-lymphoma syndrome] Nitta M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):323-5 (11 ref.) **(Jpn)**

[Non-Hodgkin's lymphoma: biologic classification, diagnosis and treatment] Jiménez-Zepeda VH, et al. **Gac Med Mex** 1998 Jul-Aug;134(4):443-63 (113 ref.) (Eng. Abstr.) **(Spa)**

[Hodgkin's disease and non-Hodgkin lymphomas] Ojeda Gutiérrez E. **Rev Clin Esp** 1999 Apr;199 Suppl 1:44-51 (40 ref.) **(Spa)**

CHEMICALLY INDUCED

Non-Hodgkin's lymphoma risk derived from exposure to organic solvents: a review of epidemiologic studies. Rêgo MA. **Cad Saude Publica** 1998;14 Suppl 3:41-66 (98 ref.)

CHEMISTRY

The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas. Howard OM, et al. **Curr Opin Oncol** 1998 Sep;10(5):385-91 (46 ref.)

CLASSIFICATION

World Health Organization Classification of lymphomas: a work in progress. Jaffe ES, et al. **Ann Oncol** 1998;9 Suppl 5:S25-30 (31 ref.)

New classifications for non-Hodgkin's lymphoma. Finn WG, et al. **Cancer Treat Res** 1999;99:1-26 (110 ref.)

COMPLICATIONS

Poor outcome of gastrointestinal perforations associated with childhood abdominal non-Hodgkin's lymphoma. Yanchar NL, et al. **J Pediatr Surg** 1999 Jul;34(7):1169-74 (32 ref.)

Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis. Mariette X. **Leuk Lymphoma** 1999 Mar;33(1-2):93-9 (49 ref.)

Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma. San Miguel JF, et al. **Med Oncol** 1998 Aug;15 Suppl 1:S29-34 (39 ref.)

[Chylothorax resulting from malignant non Hodgkin's lymphoma] Ohyama S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):473-7 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Non-Hodgkin lymphoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyon. Jan NA, et al. **Am J Clin Oncol** 1999 Feb;22(1):82-3 (12 ref.)

Evaluation and management of the "new" lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. Porcu P, et al. **Curr Probl Cancer** 1998 Sep-Oct;22(5):283-368 (200 ref.)

Primary breast lymphoma. Vianello F, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):188-95 (24 ref.)

Clinical and biological applications of image analysis in non-Hodgkin's lymphomas. Canzonieri V, et al. **Hematol Oncol** 1998 Mar;16(1):15-28 (50 ref.)

Dumbbell lymphoma of the cervical spine in a child. Case report. Gezen F, et al. **J Neurosurg Sci** 1998 Dec; 42(4):239-44 (27 ref.)

Establishing the diagnosis of lymphoma: from initial biopsy to clinical staging. Gascoyne RD. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):11-6 (43 ref.)

Overview of prognostic factors in non-Hodgkin's lymphoma. Moore DF Jr, et al. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):17-24 (65 ref.)

Laparoscopic evaluation of lymphoma. Johna S, et al. **Semin Surg Oncol** 1998 Oct-Nov;15(3):176-82 (31 ref.)

Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Picciocchi A, et al. **Surg Today** 1998;28(12):1257-60 (18 ref.)

[Malignant pancreatic non-hodgkin's lymphoma manifesting as severe acute pancreatitis] Mofredj A, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):528-31 (21 ref.) (Eng. Abstr.) **(Fre)**

[Diabetes insipidus revealing primary malignant non-Hodgkin's lymphoma of bone] Liozon E, et al. **Rev Med Interne** 1998 Nov;19(11):830-4 (24 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Villeneuve L. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):1-17 (294 ref.)

Reversal of multidrug resistance in hematological malignancies. Vossebeld PJ, et al. **Blood Rev** 1999 Jun; 13(2):67-78 (129 ref.)

Uracil mustard revisited. Kennedy BJ, et al. **Cancer** 1999 May 15;85(10):2265-72 (51 ref.)

Advances and future challenges in non-Hodgkin's lymphoma. Kliencke B, et al. **Curr Opin Oncol** 1998 Sep; 10(5):422-7 (37 ref.)

Rituximab. Onrust SV, et al. **Drugs** 1999 Jul;58(1):79-88; discussion 89-90 (50 ref.)

Non-Hodgkin's lymphoma in the elderly: a guide to drug treatment. Niitsu N. **Drugs Aging** 1999 Jun;14(6):447-57 (78 ref.)

Role of interferon-alfa in NHL: still controversial? Haase-Statz S, et al. **Oncology (Huntingt)** 1999 Aug; 13(8):1147-59; discussion 1159-60, 1163 (64 ref.)

Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Couderc LJ, et al. **Respir Med** 1999 Jan;93(1):65-8 (16 ref.)

High-dose therapy and transplantation in non-Hodgkin's lymphoma. Morrison VA, et al. **Semin Oncol** 1999 Feb; 26(1):84-98 (120 ref.)

[Chemotherapy for non-Hodgkin's lymphoma] Kuraishi Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2210-6 (33 ref.) (Eng. Abstr.) **(Jpn)**

[New antitumor drugs for non-Hodgkin's lymphoma] Ohnishi K, et al. **Gan To Kagaku Ryoho** 1998 Dec; 25(14):2223-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of malignant lymphoma with extranodal lesions--current trends and new strategies in chemotherapy] Okumura H. **Rinsho Ketsueki** 1999 Mar; 40(3):196-8 (2 ref.) **(Jpn)**

EPIDEMIOLOGY

AIDS-associated non-Hodgkin's lymphoma in the era of

highly active antiretroviral therapy. Grulich AE. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S27–30 (22 ref.)

Intermediate and high grade non Hodgkin's lymphoma in the elderly. Peters FP, et al. **Leuk Lymphoma** 1999 Apr; 33(3–4):243–52 (115 ref.)

[Epidemiology of malignant non-Hodgkin's lymphoma: current data] Chassagne-Clément C, et al. **Rev Med Interne** 1998;19 Suppl 1:9S–11S (23 ref.) **(Fre)**

[Unexplained increase of non-Hodgkin lymphoma cases. Immunodeficiency and infections are possible causes] Glimelius B. **Lakartidningen** 1998 Dec 16;95(51–52):5854–6 (20 ref.) **(Swe)**

ETIOLOGY

Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. Restrepo A, et al. **Crit Rev Oncog** 1999;10(3):239–45 (37 ref.)

Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture. Dammacco F, et al. **Leuk Lymphoma** 1998 Nov; 31(5–6):463–76 (89 ref.)

Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis. Mariette X. **Leuk Lymphoma** 1999 Mar;33(1–2):93–9 (49 ref.)

GENETICS

The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas. Howard OM, et al. **Curr Opin Oncol** 1998 Sep;10(5):385–91 (46 ref.)

High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression. Matolcsy A. **Leuk Lymphoma** 1999 Jul;34(3–4):251–9 (88 ref.)

Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. Merup M. **Med Oncol** 1998 Jul;15(2):79–88 (87 ref.)

IMMUNOLOGY

Cytokine deregulation in hematological malignancies: clinical and biological implications. Kurzrock R. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2581–4 (31 ref.)

Serum CD44 in non-Hodgkin's lymphoma. Ristamäki R, et al. **Leuk Lymphoma** 1999 May;33(5–6):433–40 (53 ref.)

MORTALITY

Poor outcome of gastrointestinal perforations associated with childhood abdominal non-Hodgkin's lymphoma. Yanchar NL, et al. **J Pediatr Surg** 1999 Jul;34(7):1169–74 (32 ref.)

PATHOLOGY

Primary non-Hodgkin's lymphoma of the liver. Memeo L, et al. **Acta Oncol** 1999;38(5):655–8 (31 ref.)

Breast carcinoma metastatic to a lymphoma: report of a case with review of literature [letter] [published erratum appears in Histopathology 1999 May;34(5):477] Ambrosiani L, et al. **Histopathology** 1999 Jan;34(1):87–9 (8 ref.)

Role of laparoscopy for Hodgkin's and non-Hodgkin's lymphoma. Walsh RM, et al. **Semin Surg Oncol** 1999 Jun; 16(4):284–92 (34 ref.)

[Non-Hodgkin's lymphoma. Aspects of clinical pathology] Gaulard P. **Rev Med Interne** 1998;19 Suppl 1:14S–17S (15 ref.) **(Fre)**

[Malignant lymphoproliferative lesions of the trachea] Kharchenko VP, et al. **Arkh Patol** 1998 Nov–Dec; 60(6):52–6 (31 ref.) (Eng. Abstr.) **(Rus)**

[Discordant lymphoma: a report of 2 new cases and a review of the literature] Azaceta Reinares G, et al. **Rev Clin Esp** 1998 Nov;198(11):749–51 (11 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Primary effusional lymphoma: A new non-Hodgkin s lymphoma entity. Matolcsy A. **Pathol Oncol Res** 1999; 5(2):87–9 (18 ref.)

RADIOTHERAPY

Radioimmunotherapy of hematological cancer: problems and progress. Jurcic JG, et al. **Clin Cancer Res** 1995 Dec; 1(12):1439–46 (69 ref.)

Milestones in the development of Lym-1 therapy. DeNardo GL, et al. **Hybridoma** 1999 Feb;18(1):1–11 (46 ref.)

SURGERY

High-dose therapy and transplantation in non-Hodgkin's lymphoma. Morrison VA, et al. **Semin Oncol** 1999 Feb; 26(1):84–98 (120 ref.)

Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Picciocchi A, et al. **Surg Today** 1998;28(12):1257–60 (18 ref.)

THERAPY

International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Shipp MA, et al. **Ann Oncol** 1999 Jan;10(1):13–9 (33 ref.)

Treatment of non-Hodgkin's lymphoma. Dranitsaris G. **Anticancer Drugs** 1998 Nov;9(10):879–88 (94 ref.)

Bone marrow transplant for lymphoma: where is the field going? Gribben JG. **Biochim Biophys Acta** 1999 May 31; 1423(3):C31–45 (57 ref.)

Second-line treatment for primary central nervous system lymphoma. Reni M, et al. **Br J Cancer** 1999 Feb; 79(3–4):530–4 (44 ref.)

Novel biologic approaches to hematologic malignancies. Dutcher JP, et al. **Cancer Treat Res** 1999;99:275–306 (210 ref.)

Hodgkin's disease and non-Hodgkin's lymphoma. Bociek RG, et al. **Curr Opin Hematol** 1999 Jul;6(4):205–15 (126 ref.)

Advances in the management of Hodgkin's and non-Hodgkin's lymphoma. Davis TA, et al. **Curr Opin Hematol** 1998 Jul;5(4):259–63 (18 ref.)

Evaluation and management of the "new" lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. Porcu P, et al. **Curr Probl Cancer** 1998 Sep–Oct;22(5):283–368 (200 ref.)

Treatment of non-Hodgkin's lymphoma in the elderly: an update. Tirelli U, et al. **Hematol Oncol** 1998 Mar;16(1):1–13 (46 ref.)

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. Shipp MA, et al. **J Clin Oncol** 1999 Jan;17(1):423–9 (32 ref.)

Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. Tezcan H, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):273–85 (32 ref.)

Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Maloney DG, et al. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):63–76 (89 ref.)

Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma. Stiff PJ. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):56–62 (43 ref.)

Management of non-Hodgkin's lymphomas. Mounter PJ, et al. **Postgrad Med J** 1999 Jan;75(879):2–6 (42 ref.)

[Intensive therapy in non-Hodgkins lymphoma. Indications and modalities] Albin N, et al. **Presse Med** 1998 Jun 6; 27(20):977–85 (71 ref.) (Eng. Abstr.) **(Fre)**

[New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies] Buske C, et al. **Dtsch Med Wochenschr** 1999 Jul 9;124(27):842–7 (42 ref.) **(Ger)**

[Hematopoietic stem cell transplantation for malignant lymphoma] Morishima Y. **Gan To Kagaku Ryoho** 1999 Sep; 26(10):1401–6 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous peripheral blood stem cell transplantation for malignant lymphoma] Morishima Y. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2217–22 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Differences in therapeutic strategies for adult leukemia and lymphoma between Japan and western countries] Sakamaki H. **Gan To Kagaku Ryoho** 1999 Jan;26(1):41–8 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Non-Hodgkin's lymphoma: treatment and outcome of children with advanced disease] Tsurusawa M. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1050–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Hepatitis C virus, mixed cryoglobulinaemia and non-Hodgkin's lymphoma. Mazzaro C, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):428–34 (49 ref.)

LYMPHOMA, SMALL AND LARGE CLEAVED-CELL, DIFFUSE see **LYMPHOMA, MIXED-CELL, DIFFUSE**

LYMPHOMA, SMALL-CELL

Small B-cell lymphomas of the lymph nodes and spleen: practical insights to diagnosis and pathogenesis. Swerdlow SH. **Mod Pathol** 1999 Feb;12(2):125–40 (193 ref.)

PATHOLOGY

How do you distinguish benign from malignant extranodal small B-cell proliferations? Kurtin PJ. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S119–25 (66 ref.)

Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease. Hancock JC, et al. **Ann Diagn Pathol** 1999 Feb;3(1):23–34 (51 ref.)

Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia [see comments] Suzuki R, et al. **Leuk Res** 1999 Jul;23(7):615–24 (50 ref.) Comment in: Leuk Res 1999 Jul;23(7):675–6.

LYMPHOMA, SMALL-CELL, CENTROCYTIC see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE

Central nervous system involvement in patients with mantle cell lymphoma. Oinonen R, et al. **Ann Hematol** 1999 Mar; 78(3):145–9 (39 ref.)

Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission. Shimizu K, et al. **Int J Hematol** 1999 Feb;69(2):96–100 (22 ref.)

Mantle-cell lymphoma. Campo E, et al. **Semin Hematol** 1999 Apr;36(2):115–27 (123 ref.)

[Diffuse lymphoma, medium sized cell type] Dobashi N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):244–7 (14 ref.) **(Jpn)**

[Mantle cell lymphoma] Ohno T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):305–8 (15 ref.) **(Jpn)**

[Multiple lymphomatous polyposis] Tsujimura H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):341–3 (12 ref.) **(Jpn)**

COMPLICATIONS

Third degree atrio-ventricular-block caused by malignant non-Hodgkin's lymphoma: an unusual indication for epicardial pacing. Aleksic I, et al. **Cardiovasc Surg** 1999 Apr;7(3):378–80 (12 ref.)

PATHOLOGY

Mantle cell lymphoma. Kurtin PJ. **Adv Anat Pathol** 1998 Nov;5(6):376–98 (137 ref.)

The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Ott G, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):55–63 (52 ref.)

THERAPY

Management of mantle cell lymphoma. Armitage JO. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):49–55 (49 ref.)

LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR

[Composite lymphoma, discordant lymphoma] Isobe Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):268–71 (18 ref.) **(Jpn)**

THERAPY

[Autoimmune thrombocytopenia following syngeneic peripheral blood stem cell transplantation] Nishio M, et al. **Rinsho Ketsueki** 1998 Aug;39(8):580–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA, SMALL FOLLICULAR CENTER-CELL see **LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR**

LYMPHOMA, SMALL LYMPHOCYTIC

see related
LEUKEMIA, LYMPHOCYTIC, CHRONIC

B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Pangalis GA, et al. **Semin Hematol** 1999 Apr;36(2):104–14 (139 ref.)

[Diffuse small lymphocytic lymphoma] Ohno T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):231–4 (4 ref.) **(Jpn)**

GENETICS

Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Iida S, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):25–33 (51 ref.)

IMMUNOLOGY

Plural immunoglobulin synthesis in a single cell: an ultrastructural study of two cases with three M-proteins. Saito N, et al. **Ultrastruct Pathol** 1998 Nov–Dec; 22(6):421–9 (26 ref.)

LYMPHOMA, SMALL LYMPHOCYTIC, PLASMACYTOID see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, SMALL LYMPHOID, FOLLICULAR see **LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR**

LYMPHOMA, SMALL NONCLEAVED-CELL

[Small noncleaved cell lymphoma, non-Burkitt's type] Mizuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):265–7 (10 ref.) **(Jpn)**

LYMPHOMA, T-CELL

Gastrointestinal lymphomas of T- and B-cell types. Isaacson PG. **Mod Pathol** 1999 Feb;12(2):151–8 (50 ref.)

[Composite lymphoma, discordant lymphoma] Isobe Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):268–71 (18 ref.) **(Jpn)**

[Lennert's lymphoma] Kaneko T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):279–82 (15 ref.) **(Jpn)**

[T-zone lymphoma] Kaneko T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):283–6 (11 ref.) **(Jpn)**

LYMPHOMA, T-CELL

[NK-cell lymphoma] Kaneko T.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):309-14 (20 ref.) **(Jpn)**
[Peripheral gamma delta T-cell lymphoma] Kato R, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):319-22 (15 ref.) **(Jpn)**
[Signet ring cell lymphoma] Kawakami M, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):291-3 (5 ref.) **(Jpn)**

CLASSIFICATION

Extranodal peripheral T-cell and NK-cell neoplasms. Jaffe ES, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S46-55 (82 ref.)
The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms. Kinney MC. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S104-18 (135 ref.)

COMPLICATIONS

Pleomorphic T-cell lymphoma with chondropathia tuberosa: a case report and review. Krohn-Grimberghe B, et al. **Anticancer Res** 1999 May-Jun;19(3B):2221-8 (29 ref.)
Peripheral T-cell lymphoma presenting as ascites: a case report and review of the literature. Vakar-López F, et al. **Diagn Cytopathol** 1999 Jun;20(6):382-4 (5 ref.)
Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and H. pylori infection. Itatsu T, et al. **Dig Dis Sci** 1999 Sep;44(9):1823-36 (67 ref.)
Myositis and malignancy: is there a true association? Brown H, et al. **Hosp Med** 1999 Jan;60(1):51-3 (10 ref.)

DIAGNOSIS

Primary central nervous system T-cell lymphoma. Case report. Takeshita M, et al. **Neurol Med Chir (Tokyo)** 1999 Jun;39(6):452-8 (50 ref.)

DRUG THERAPY

Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Pautier P, et al. **Leuk Lymphoma** 1999 Feb; 32(5-6):545-52 (28 ref.)

ETIOLOGY

[Malignant lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease)] Itoh T, et al. **Rinsho Ketsueki** 1998 Sep;39(9):698-702 (5 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64-77 (32 ref.)

IMMUNOLOGY

Enteropathy-associated T-cell lymphoma and its immunocarcinogenic correlates: case report and review of the literature. Palacio A, et al. **Crit Rev Oncog** 1998; 9(1):63-81 (341 ref.)
Cytokines and cutaneous T-cell lymphomas. Asadullah K, et al. **Exp Dermatol** 1998 Dec;7(6):314-20 (64 ref.)
Post transplant CD8+ gammadelta T-cell lymphoma associated with human herpes virus-6 infection. Lin WC, et al. **Leuk Lymphoma** 1999 Apr;33(3-4):377-84 (40 ref.)

PATHOLOGY

Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Chang KL, et al. **Adv Anat Pathol** 1998 Jan;5(1):21-9 (22 ref.)
Extranodal peripheral T-cell and NK-cell neoplasms. Jaffe ES, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S46-55 (82 ref.)
The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms. Kinney MC. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S104-18 (135 ref.)
Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease. Hancock JC, et al. **Ann Diagn Pathol** 1999 Feb;3(1):23-34 (51 ref.)
Sinonasal malignant lymphomas: a distinct clinicopathological category. Vidal RW, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):411-9 (40 ref.)
Primary gastric T-cell lymphomas: report of two cases and a review of the literature. Horie R, et al. **Jpn J Clin Oncol** 1999 Mar;29(3):171-8 (58 ref.)
Dissemination of T cell lymphoma to target organs: a post-homing event implicating ICAM-1 and matrix metalloproteinases. St-Pierre Y, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):53-61 (55 ref.)
[T-cell lymphomas and "natural killer". Histopathologic, immunologic and molecular aspects] Kanavaros P, et al. **Ann Pathol** 1998 Oct;18(4):299-314 (102 ref.) **(Fre)**

THERAPY

Management of rare forms of lymphoma. Zucca E, et al. **Curr Opin Oncol** 1998 Sep;10(5):377-84 (76 ref.)

VIROLOGY

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64-77 (32 ref.)

LYMPHOMA, T-CELL, CUTANEOUS

Cutaneous T-cell lymphomas. Samuelson E. **Semin Oncol Nurs** 1998 Nov;14(4):293-301 (55 ref.)

CLASSIFICATION

Cutaneous lymphoma. Understanding the new classification schemes. Duncan LM. **Dermatol Clin** 1999 Jul;17(3):569-92 (125 ref.)
[Importance of the new classification of primary cutaneous lymphomas elaborated by the EORTC (European Organization for Research and Treatment of Cancer) group] Wechsler J. **Ann Pathol** 1998 Oct;18(4):315-23 (45 ref.) **(Fre)**

COMPLICATIONS

Syringolymphoid hyperplasia and follicular mucinosis in a patient with cutaneous T-cell lymphoma. Tannous Z, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):303-8 (8 ref.)

DIAGNOSIS

Cutaneous T-cell lymphoma presenting as benign dermatoses. Elmer KB, et al. **Am Fam Physician** 1999 May 15;59(10):2809-13 (09 ref.)
Early detection of cutaneous lymphoma. Abd-el-Baki J, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1521-30; discussion 1532-4 (62 ref.)
Cutaneous T cell lymphoma in children. Garzon MC. **Semin Cutan Med Surg** 1999 Sep;18(3):226-32 (47 ref.)

PATHOLOGY

Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria. Glusac EJ, et al. **Dermatol Clin** 1999 Jul;17(3):601-14, ix (71 ref.)
Use of the polymerase chain reaction in the evaluation of cutaneous T-cell infiltrates. Kohler S, et al. **Dermatol Clin** 1999 Jul;17(3):657-66, x (33 ref.)

THERAPY

Management of cutaneous lymphomas using a multidisciplinary approach. Parry EJ, et al. **Arch Dermatol** 1999 Aug;135(8):907-11 (37 ref.)
Novel treatment approaches for cutaneous T-cell lymphoma. Foss FM, et al. **Cancer Treat Res** 1999;99:227-40 (51 ref.)
Cutaneous T cell lymphoma in children. Garzon MC. **Semin Cutan Med Surg** 1999 Sep;18(3):226-32 (47 ref.)

VIROLOGY

Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Wagner M, et al. **Clin Infect Dis** 1998 Nov;27(5):1299-308 (112 ref.)

LYMPHOMA, T-CELL, PERIPHERAL

Peripheral T cell lymphoma in a patient with common variable immunodeficiency disease: case report and literature review. Gottesman SR, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):589-95 (35 ref.)
Peripheral T-cell and NK-cell neoplasms: an integrated approach to diagnosis. Chan JK. **Mod Pathol** 1999 Feb; 12(2):177-99 (94 ref.)

PATHOLOGY

Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. López-Guillermo A, et al. **Ann Oncol** 1998 Aug;9(8):849-55 (38 ref.)

LYMPHOMA, UNDIFFERENTIATED, DIFFUSE see **LYMPHOMA, SMALL NONCLEAVED-CELL**

LYMPHOMATOID GRANULOMATOSIS

[Lymphomatoid granulomatosis] Wakatsuki S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):344-6 (13 ref.) **(Jpn)**

COMPLICATIONS

[Pulmonary lymphomatoid granulomatosis associated with AIDS. Report of a case and review of the literature] Pastrana Delgado J, et al. **An Med Interna** 1998 Sep; 15(9):487-9 (25 ref.) (Eng. Abstr.) **(Spa)**

LYMPHOPENIA

see related
LYMPHOCYTE DEPLETION

Two cases of idiopathic CD4+ T-lymphocytopenia in elderly patients. Matsuyama W, et al. **Intern Med** 1998 Oct; 37(10):891-5 (28 ref.)

CHEMICALLY INDUCED

Drug-induced lymphopenia: focus on CD4+ and CD8+ cells. Gergely P. **Drug Saf** 1999 Aug;21(2):91-100 (77 ref.)

CONGENITAL

[Congenital lymphopenia] Naishiro Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):176-9 (11 ref.) **(Jpn)**

ETIOLOGY

[Acquired lymphocytopenia] Adachi M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):180-4 (10 ref.) **(Jpn)**

IMMUNOLOGY

Thymic function, aging, and AIDS. Haynes BF, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):59-60, 63-5, 69-70, passim (12 ref.)

LYMPHOPLASMACYTOID LYMPHOMA, CLL see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOPOIETIN-1 see **INTERLEUKIN-7**

LYMPHOPROLIFERATIVE DISORDERS

Large granular lymphocytosis. Zambello R, et al. **Haematologica** 1998 Oct;83(10):936-42 (52 ref.)
Chronic lymphoid leukemias and lymphoproliferative disorders. Foucar K. **Mod Pathol** 1999 Feb;12(2):141-50 (44 ref.)
Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Nalesnik MA. **Springer Semin Immunopathol** 1998;20(3-4):325-42 (111 ref.)
[Post-transplant lymphoproliferative disorders] Kita K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):159-62 (12 ref.) **(Jpn)**
[X-linked lymphoproliferative disorder] Kobayashi Y. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):165-8 (8 ref.) **(Jpn)**
[Idiopathic lymphoproliferative disease of granular lymphocyte] Masuda M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):163-4 (6 ref.) **(Jpn)**
[X-linked lymphoproliferative (XLP) syndrome (Duncan disease)] Nakamura Y. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):158-60 (9 ref.) **(Jpn)**
[Chronic lymphoproliferative syndromes with leukemic expression] Krsnik Castelló I. **Rev Clin Esp** 1999 Apr;199 Suppl 1:37-43 (29 ref.) **(Spa)**

DIAGNOSIS

Post-transplantation lymphoproliferative disorder versus acute liver rejection: do we need a scoring system? Dietze O. **Adv Anat Pathol** 1998 Jan;5(1):30-5 (10 ref.)
Diagnostic approach to lymph node enlargement. Ghirardelli ML, et al. **Haematologica** 1999 Mar;84(3):242-7 (7 ref.)
Endoscopic diagnosis of lymphoproliferative disease after solid organ transplantation [editorial; comment] Kocoshis SA. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):375-6 (6 ref.) Comment on: J Pediatr Gastroenterol Nutr 1999 Apr;28(4):380-5.
Imaging of orbital lymphoproliferative disorders. Valvassori GE, et al. **Radiol Clin North Am** 1999 Jan;37(1):135-50, x-xi (48 ref.)
Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Cerroni L, et al. **Semin Cutan Med Surg** 1999 Mar;18(1):64-70 (37 ref.)

EPIDEMIOLOGY

Clinicopathologic features of posttransplant lymphoproliferative disorders. Nalesnik MA. **Ann Transplant** 1997;2(4):33-40 (113 ref.)
Lymphoproliferative disease in children. Harmon WE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1268-9 (22 ref.)

ETIOLOGY

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Gross TG, et al. **Bone Marrow Transplant** 1999 Feb;23(3):251-8 (42 ref.)
Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Aguilar LK, et al. **Curr Opin Oncol** 1999 Mar;11(2):96-101 (57 ref.)
Lymphoproliferative disorders after renal transplantation: role of medical imaging. Claudon M, et al. **Eur Radiol** 1998; 8(9):1686-93 (38 ref.)
Cancers in children infected with the human immunodeficiency virus. Mueller BU. **Oncologist** 1999; 4(4):309-17 (100 ref.)
Cancers after stem cell transplantation in children: a cost of cure? Ship AM, et al. **Pediatr Transplant** 1997 Nov; 1(2):104-10 (38 ref.)
[Post-transplantation lymphomas and Epstein-Barr virus] Caillard S, et al. **Nephrologie** 1998;19(8):481-8 (100 ref.) (Eng. Abstr.) **(Fre)**
[Gougerot-Sjögren syndrome and malignant

lymphoproliferative syndromes] Grosbois B, et al. **Rev Med Interne** 1998 May;19(5):319–24 (52 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The molecular genetics of X-linked lymphoproliferative (Duncan's) disease. Sumegi J, et al. **Cancer J Sci Am** 1999 Mar–Apr;5(2):57–62 (33 ref.)

The abnormal gene in X-linked lymphoproliferative syndrome. Sullivan JL. **Curr Opin Immunol** 1999 Aug; 11(4):431–4 (16 ref.)

Molecular genetic studies in lymphocyte apoptosis and human autoimmunity. Martin DA, et al. **Novartis Found Symp** 1998;215:73–82; discussion 82–91 (20 ref.)

The molecular genetics of post-transplantation lymphoproliferative disorders. Knowles DM. **Springer Semin Immunopathol** 1998;20(3–4):357–73 (69 ref.)

[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases] Beltinger C, et al. **Klin Padiatr** 1998 Jul–Aug;210(4):153–8 (37 ref.) (Eng. Abstr.) **(Ger)**

[Genetic origin of malignant hematopoiesis well defined] Bernell P, et al. **Lakartidningen** 1998 Nov 25;95(48):5493–4, 5497–8 (15 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGY

Immunodeficiency-associated lymphoproliferative disorders. Knowles DM. **Mod Pathol** 1999 Feb;12(2):200–17 (92 ref.)

Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Tosato G, et al. **Springer Semin Immunopathol** 1998;20(3–4):405–23 (176 ref.)

[At the crossroads between B lymphoproliferative syndromes to autoimmune diseases are CD5-positive B-lymphocytes: a new hypothesis] Youinou P. **Bull Acad Natl Med** 1999; 183(1):159–69; discussion 170 (30 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Adhesion molecules in B-chronic lymphoproliferative disorders. Angelopoulou MK, et al. **Semin Hematol** 1999 Apr;36(2):178–97 (156 ref.)

PATHOLOGY

Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Vergier B, et al. **Am J Surg Pathol** 1998 Oct;22(10):1192–202 (47 ref.)

An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Straus SE, et al. **Ann Intern Med** 1999 Apr 6;130(7):591–601 (68 ref.)

Atypical cutaneous lymphoproliferative disorder in patients with HIV infection. Friedler S, et al. **Int J Dermatol** 1999 Feb;38(2):111–8 (24 ref.)

X-linked lymphoproliferative disease: pathology and diagnosis. Maia DM, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):72–7 (18 ref.)

[Richter's syndrome: analysis of literature data and original observations] Osmanov DSh, et al. **Ter Arkh** 1999; 71(7):47–58 (136 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Haque T, et al. **Br J Haematol** 1999 Aug; 106(2):309–16 (68 ref.)

The antiviral prophylaxis of post-transplant lymphoproliferative disorder. Davis CL. **Springer Semin Immunopathol** 1998;20(3–4):437–53 (169 ref.)

EBV specific CTL: a model for immune therapy. Rooney CM, et al. **Vox Sang** 1998;74 Suppl 2:497–8 (6 ref.)

PSYCHOLOGY

[Examining the quality of life in patients with proliferative diseases of the hemopoietic system] Wichary R, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):513–8 (32 ref.) **(Pol)**

THERAPY

Treatment and prognosis of post-transplant lymphoproliferative disease. Mamzer-Bruneel MF, et al. **Ann Transplant** 1997;2(4):42–8 (72 ref.)

Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Faro A. **Springer Semin Immunopathol** 1998;20(3–4):425–36 (55 ref.)

Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. O'Reilly RJ, et al. **Springer Semin Immunopathol** 1998;20(3–4):455–91 (228 ref.)

[Antineoplastic agents and biologic response modifiers in oncologic hematology] Cabrera Marin JR, et al. **Rev Clin Esp** 1999 Apr;199 Suppl 1:3–13 (17 ref.) **(Spa)**

VETERINARY

Lymphoproliferative and myeloproliferative disorders. Savage CJ. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):563–78, vii (52 ref.)

VIROLOGY

Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy. Berneman ZN, et al. **Ann Hematol** 1998 Dec;77(6):275–8 (59 ref.)

Epstein-Barr virus and lymphoproliferative disease. Mosier DE. **Curr Opin Hematol** 1999 Jan;6(1):25–9 (59 ref.)

Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Aguilar LK, et al. **Curr Opin Oncol** 1999 Mar;11(2):96–101 (57 ref.)

Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders. Haque T, et al. **Springer Semin Immunopathol** 1998;20(3–4):375–87 (58 ref.)

LYMPHOPROLIFERATIVE VIRUSES see **GAMMAHERPESVIRINAE**

LYMPHOSARCOMA see **LYMPHOMA, DIFFUSE**

LYMPHOSARCOMA, LYMPHOBLASTIC, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOTOXIN

IMMUNOLOGY

Tumour necrosis factor-alpha and lymphotoxin-alpha in the pathology of experimental autoimmune encephalomyelitis: is either one responsible or is there another ligand-mediating disease? Willenborg DO, et al. **Res Immunol** 1998 Nov–Dec;149(9):804–10; discussion 849–50, 855–60 (41 ref.)

T-LYMPHOTROPIC VIRUS, TYPE I, SIMIAN see **STLV**

T-LYMPHOTROPIC VIRUS TYPE III ANTIBODIES, HUMAN see **HIV ANTIBODIES**

T-LYMPHOTROPIC VIRUS TYPE III ANTIGENS, HUMAN see **HIV ANTIGENS**

T-LYMPHOTROPIC VIRUS TYPE III INFECTIONS, HUMAN see **HIV INFECTIONS**

T-LYMPHOTROPIC VIRUS, TYPE III, SIMIAN see **SIV**

LYNCH SYNDROME see **COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS**

LYNX see **CARNIVORA**

LYOPHILIZATION see **FREEZE DRYING**

LYPRESSIN

ANALOGS & DERIVATIVES

Longer treatment with vasoactive drugs to prevent early variceal rebleeding in cirrhosis. de Franchis R. **Eur J Gastroenterol Hepatol** 1998 Dec;10(12):1041–4 (32 ref.)

[Terlipressin in the treatment of portal hypertension (see comments)] Escorsell A, et al. **Gastroenterol Hepatol** 1998 Nov;21(9):452–8 (57 ref.) Comment in: Gastroenterol Hepatol 1999 May;22(5):258–60. **(Spa)**

LYSERGIC ACID DIETHYLAMIDE

ADVERSE EFFECTS

Do hallucinogens cause residual neuropsychological toxicity? Halpern JH, et al. **Drug Alcohol Depend** 1999 Feb 1; 53(3):247–56 (103 ref.)

PHARMACOLOGY

Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Backstrom JR, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):77S–81S (25 ref.)

LYSERGIDE see **LYSERGIC ACID DIETHYLAMIDE**

LYSINE

BIOSYNTHESIS

Microbial production of L-lysine: a review. Chatterjee M, et al. **Hindustan Antibiot Bull** 1997 Feb–Nov;39(1–4):20–49 (251 ref.)

CHEMISTRY

[Basic (cleaving arginine and lysine residues) metallocarboxypeptidase of mammalian tissue: structure, properties and function] Vernigora AN, et al. **Ukr Biokhim Zh** 1998 Jul–Aug;70(4):16–24 (79 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Strategies to reduce renal radioactivity levels of antibody fragments. Arano Y. **Q J Nucl Med** 1998 Dec;42(4):262–70 (61 ref.)

LYSINE CARBOXYPEPTIDASE

CHEMISTRY

[Basic (cleaving arginine and lysine residues) metallocarboxypeptidase of mammalian tissue: structure, properties and function] Vernigora AN, et al. **Ukr Biokhim Zh** 1998 Jul–Aug;70(4):16–24 (79 ref.) (Eng. Abstr.) **(Rus)**

LYSINE VASOPRESSIN see **LYPRESSIN**

LYSINOALANINE

CHEMISTRY

Lysinoalanine in food and in antimicrobial proteins. Friedman M. **Adv Exp Med Biol** 1999;459:145–59 (71 ref.)

METABOLISM

Influence of feeding alkaline/heat processed proteins on growth and protein and mineral status of rats. Sarwar G, et al. **Adv Exp Med Biol** 1999;459:161–77 (29 ref.)

LYSOGENY

Bacteriophages in the evolution of pathogen-host interactions. Miao EA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9452–4 (31 ref.)

LYSOLECITHINASE see **LYSOPHOSPHOLIPASE**

LYSOPHOSPHATIDIC ACIDS see **LYSOPHOSPHOLIPIDS**

LYSOPHOSPHOLIPASE

[Phospholipase B/lipase belonging to a new lipase family] Tojo H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1032–7 (26 ref.) **(Jpn)**

CHEMISTRY

[Structure and function of animal lysophospholipase] Yamashita S, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun; 44(8 Suppl):1043–51 (48 ref.) **(Jpn)**

METABOLISM

Mammalian lysophospholipases. Wang A, et al. **Biochim Biophys Acta** 1999 Jul 9;1439(1):1–16 (195 ref.)

PHYSIOLOGY

[Structure and function of animal lysophospholipase] Yamashita S, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun; 44(8 Suppl):1043–51 (48 ref.) **(Jpn)**

LYSOPHOSPHOLIPIDS

[Occurrence, metabolism and bioactions of lysophosphatidic acid and cyclic phosphatidic acid as lysophospholipid mediators] Kobayashi T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1118–25 (32 ref.) **(Jpn)**

[Cell biology of lysobisphosphatidic acid] Kobayashi T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1181–6 (42 ref.) **(Jpn)**

GENETICS

A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). Chun J, et al. **Cell Biochem Biophys** 1999;30(2):213–42 (75 ref.)

METABOLISM

A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). Chun J, et al. **Cell Biochem Biophys** 1999;30(2):213–42 (75 ref.)

Lysophosphatidic acid and mesangial cells: implications for renal diseases. Inoue CN, et al. **Clin Sci (Colch)** 1999 Apr; 96(4):431–6 (40 ref.)

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. Goetzl EJ, et al. **FASEB J** 1998 Dec;12(15):1589–98 (52 ref.)

PHYSIOLOGY

[Induction of tumor invasion by lysophosphatidic acid and inhibition of tumor invasion by cyclic phosphatidic acid] Mukai M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1126–31 (16 ref.) **(Jpn)**

LYSOSOMAL ALPHA-GLUCOSIDASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

LYSOSOMAL ELASTASE see **LEUKOCYTE ELASTASE**

LYSOSOMAL ENZYME DISORDERS

LYSOSOMAL ENZYME DISORDERS see **LYSOSOMAL STORAGE DISEASES**

LYSOSOMAL STORAGE DISEASES

[Sialidosis type 1] Suzuki Y.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):166–8 (7 ref.) **(Jpn)**

[Sialidosis type 2] Suzuki Y.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):169–70 (3 ref.) **(Jpn)**

DIAGNOSIS

Clinical spectrum of infantile free sialic acid storage disease. Lemyre E, et al. **Am J Med Genet** 1999 Feb 19;82(5):385–91 (31 ref.)

GENETICS

Animal models of lysosomal disease: an overview. Suzuki K, et al. **J Inherit Metab Dis** 1998 Aug;21(5):540–7 (34 ref.)

METABOLISM

Processing of sphingolipid activator proteins and the topology of lysosomal digestion. Sandhoff K, et al.
Acta Biochim Pol 1998;45(2):373–84 (52 ref.)

The glycosphingolipidoses–from disease to basic principles of metabolism. Schuette CG, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):759–66 (28 ref.)

PHYSIOPATHOLOGY

Abnormalities of developing white matter in lysosomal storage diseases. Folkerth RD.
J Neuropathol Exp Neurol 1999 Sep;58(9):887–902 (99 ref.)

THERAPY

Gene transfer approaches to the lysosomal storage disorders. Barranger JA, et al. **Neurochem Res** 1999 Apr;24(4):601–15 (129 ref.)

LYSOSOMES

ENZYMOLOGY

The lysosomal cysteine proteases. McGrath ME.
Annu Rev Biophys Biomol Struct 1999;28:181–204 (112 ref.)

Insights into myeloperoxidase biosynthesis from its inherited deficiency. Nauseef WM. **J Mol Med** 1998 Sep;76(10):661–8 (107 ref.)

Lysosomal acid lipase. Assay and purification. Merkel M, et al. **Methods Mol Biol** 1999;109:95–107 (23 ref.)

METABOLISM

Processing of sphingolipid activator proteins and the topology of lysosomal digestion. Sandhoff K, et al.
Acta Biochim Pol 1998;45(2):373–84 (52 ref.)

Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. Wurmser AE, et al. **J Biol Chem** 1999 Apr 2; 274(14):9129–32 (71 ref.)

Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease. Oyama F, et al.
Neurosci Res 1998 May;31(1):1–8 (70 ref.)

Tripeptidyl peptidases: enzymes that count. Tomkinson B.
Trends Biochem Sci 1999 Sep;24(9):355–9 (31 ref.)

[Neutrophil adherence-inhibiting factor, AIF, is released from lysosomes of activated platelets] Iwabuchi K, et al.
Seikagaku 1999 May;71(5):353–8 (19 ref.) **(Jpn)**

PHYSIOLOGY

Novel pathways, membrane coats and PI kinase regulation in yeast lysosomal trafficking. Burd CG, et al.
Semin Cell Dev Biol 1998 Oct;9(5):527–33 (77 ref.)

HLA-DM – an endosomal and lysosomal chaperone for the immune system. Vogt AB, et al. **Trends Biochem Sci** 1999 Apr;24(4):150–4 (48 ref.)

[Phenomenon of karyolysis in cytophotomorphometric examinations] Parafiniuk M. **Ann Acad Med Stetin** 1998; Suppl 43:1–87 (108 ref.) (Eng. Abstr.) **(Pol)**

LYSOZYME see **MURAMIDASE**

LYT 1 ANTIGEN see **ANTIGENS, LY**

M13 PHAGE see **BACTERIOPHAGE M13**

M-CSF see **MACROPHAGE COLONY-STIMULATING FACTOR**

M PHASE see **MITOSIS**

M PHASE-PROMOTING FACTOR see **MATURATION-PROMOTING FACTOR**

MAC-1 ANTIGEN see **MACROPHAGE-1 ANTIGEN**

MACACA MULATTA

Nuclear transfer in the rhesus monkey: practical and basic implications. Wolf DP, et al. **Biol Reprod** 1999 Feb; 60(2):199–204 (29 ref.)

Review of exertional rhabdomyolysis and a case in a rhesus monkey (Macaca mulatta). Reuter JD, et al.
J Med Primatol 1998 Dec;27(6):303–9 (29 ref.)

Nonhuman primates as models for aging and Alzheimer's disease. Voytko ML. **Lab Anim Sci** 1998 Dec;48(6):611–7 (66 ref.)

GROWTH & DEVELOPMENT

Development and organization of the hypophysiotropic hypothalamus driving the pituitary-gonadal axis in the rhesus monkey. Plant TM, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):60–6 (43 ref.)

PHYSIOLOGY

Primate models to understand human aggression. Kalin NH.
J Clin Psychiatry 1999;60 Suppl 15:29–32 (14 ref.)

VIROLOGY

The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. Rausch DM, et al. **J Leukoc Biol** 1999 Apr;65(4):466–74 (74 ref.)

MACACA NEMESTRINA

PHYSIOLOGY

14C-deoxyglucose mapping of the monkey brain during reaching to visual targets. Savaki HE, et al.
Prog Neurobiol 1999 Aug;58(6):473–540 (600 ref.)

MACHADO-JOSEPH DISEASE

[Machado-Joseph disease] Sakai T.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):270–4 (16 ref.) **(Jpn)**

GENETICS

[Linkage disequilibrium between the Machado-Joseph disease and intragenic polymorphisms] Ichikawa Y.
Nippon Rinsho 1999 Apr;57(4):832–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical and molecular genetic studies of Machado-Joseph disease] Nishizawa M. **Nippon Rinsho** 1999 Apr; 57(4):826–31 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of expanded CAG trinucleotide repeat in the neural and nonneural tissues of Machado-Joseph disease (MJD)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr; 57(4):838–42 (15 ref.) (Eng. Abstr.) **(Jpn)**

MACHIAVELLIANISM

The general approach to the difficult patient. Adams J, et al. **Emerg Med Clin North Am** 1998 Nov;16(4):689–700, v (23 ref.)

The manipulation of international scientific organizations [editorial] Castleman BI, et al.
Int J Occup Environ Health 1998 Jan–Mar;4(1):53–5 (17 ref.)

MACHINE INTELLIGENCE see **ARTIFICIAL INTELLIGENCE**

MACHINE LEARNING see **ARTIFICIAL INTELLIGENCE**

MACROGLOBULINEMIA see **WALDENSTROM MACROGLOBULINEMIA**

MACROGLOSSIA

see related
BECKWITH-WIEDEMANN SYNDROME

ETIOLOGY

Traumatic macroglossia: a new approach [editorial; comment] Lebovics RS. **Crit Care Med** 1999 Aug; 27(8):1689–90 (11 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634–45.

SURGERY

Surgical management of macroglossia due to primary amyloidosis. Mardinger O, et al.
Int J Oral Maxillofac Surg 1999 Apr;28(2):129–31 (10 ref.)

THERAPY

Traumatic macroglossia: a new approach [editorial; comment] Lebovics RS. **Crit Care Med** 1999 Aug; 27(8):1689–90 (11 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634–45.

MACROGOLS see **POLYETHYLENE GLYCOLS**

MACROLIDE ANTIBIOTICS see **ANTIBIOTICS, MACROLIDE**

MACROLIDES

ISOLATION & PURIFICATION

Marine spongean cytotoxins. Kobayashi M, et al.
J Nat Toxins 1999 Jun;8(2):249–58 (31 ref.)

THERAPEUTIC USE

Macrolide immunosuppressants. Mrowietz U.
Eur J Dermatol 1999 Jul–Aug;9(5):346–51 (52 ref.)

Microbiological aspects of antibiotic resistant Helicobacter pylori strains. Monteiro L, et al.
Ital J Gastroenterol Hepatol 1998 Oct;30 Suppl 3:S329–33 (24 ref.)

MACROMOLECULAR SYSTEMS

see related
POLYMERS

Recent developments for the efficient crystallographic refinement of macromolecular structures. Brünger AT, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):606–11 (40 ref.)

MACROPHAGE ACTIVATION

Leucocyte activation markers in clinical practice. Viedma Contreras JA. **Clin Chem Lab Med** 1999 Jun;37(6):607–22 (226 ref.)

Macrophage-restricted molecules: role in differentiation and activation. Gordon S. **Immunol Lett** 1999 Jan;65(1–2):5–8 (19 ref.)

DRUG EFFECTS

The Nramp1 protein and its role in resistance to infection and macrophage function. Canonne-Hergaux F, et al.
Proc Assoc Am Physicians 1999 Jul–Aug;111(4):283–9 (56 ref.)

IMMUNOLOGY

Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Schubert P, et al.
Alzheimer Dis Assoc Disord 1998;12 Suppl 2:S21–8 (45 ref.)

PHYSIOLOGY

MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. Fairlie WD, et al.
J Leukoc Biol 1999 Jan;65(1):2–5 (12 ref.)

[Microglia: mechanisms of activation and significance in pathogenesis of neuropsychiatric illnesses] Gebicke-Haerter PJ, et al. **Nervenarzt** 1998 Sep; 69(9):752–62 (126 ref.) (Eng. Abstr.) **(Ger)**

MACROPHAGE COLONY-STIMULATING FACTOR

see related
RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR

PHYSIOLOGY

The role of CSF-1 in normal and neoplastic breast physiology. Sapi E, et al. **Proc Soc Exp Biol Med** 1999 Jan;220(1):1–8 (79 ref.)

THERAPEUTIC USE

Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Ohno R. **Leuk Res** 1998 Dec;22(12):1143–54 (62 ref.)

MACROPHAGE-GRANULOCYTE INDUCER see **COLONY-STIMULATING FACTORS**

MACROPHAGE INFLAMMATORY PROTEIN-1

PHARMACOLOGY

Advances in understanding of biological effects of interleukin-11, leukemia inhibitory factor, and macrophage inflammatory protein 1 alpha. Broxmeyer HE.
Curr Opin Hematol 1994 May;1(3):197–202 (58 ref.)

MACROPHAGE MIGRATION-INHIBITORY FACTORS

PHYSIOLOGY

Novel pathophysiological aspects of macrophage migration inhibitory factor (review). Nishihira J. **Int J Mol Med** 1998 Jul;2(1):17–28 (81 ref.)

Macrophage migration inhibitory factor: cytokine, hormone, or enzyme? Swope MD, et al.
Rev Physiol Biochem Pharmacol 1999;139:1–32 (94 ref.)

MACROPHAGE-1 ANTIGEN

DRUG EFFECTS

Potential non-glycoprotein IIb/IIIa effects of abciximab. Coller BS. **Am Heart J** 1999 Jul;138(1 Pt 2):S1-5 (50 ref.)

MACROPHAGES

see related
PHAGOCYTOSIS

CYTOLOGY

The Rho GTPases in macrophage motility and chemotaxis. Jones GE, et al. **Cell Adhes Commun** 1998;6(2-3):237-45 (40 ref.)

Myb-transformed hematopoietic cells as a model for monocyte differentiation into dendritic cells and macrophages. Banyer JL, et al. **J Leukoc Biol** 1999 Aug; 66(2):217-23 (82 ref.)

DRUG EFFECTS

Effects of muramyl peptides on macrophages, monokines, and sleep. Pabst MJ, et al. **Neuroimmunomodulation** 1999 Jul-Aug;6(4):261-83 (177 ref.)

ENZYMOLOGY

Synthesis of cholesterol esterase by monocyte-derived macrophages: a potential role in the biodegradation of poly(urethane)s. Labow RS, et al. **J Biomater Appl** 1999 Jan;13(3):187-205 (75 ref.)

IMMUNOLOGY

Role of macrophage cytokines in mucosal adjuvanticity. Foss DL, et al. **Adv Vet Med** 1999;41:83-104 (67 ref.)

Giant cell arteritis--a molecular approach to the multiple facets of the syndrome. Weyand CM, et al.
Ann Med Interne (Paris) 1998 Nov;149(7):420-4 (24 ref.)

Mechanisms of phagocytosis in macrophages. Aderem A, et al. **Annu Rev Immunol** 1999;17:593-623 (151 ref.)

Roles of ICAM-3 and CD14 in the recognition and phagocytosis of apoptotic cells by macrophages. Gregory CD, et al. **Biochem Soc Trans** 1998 Nov;26(4):644-9 (45 ref.)

You can lead a macrophage to an inflammatory site but can you make it eat? Hart SP, et al. **Biochem Soc Trans** 1998 Nov;26(4):650-2 (18 ref.)

Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu-Lee L, et al.
Cell Mol Life Sci 1998 Oct;54(10):1067-75 (103 ref.)

Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Mosser DM, et al. **Curr Opin Immunol** 1999 Aug;11(4):406-11 (34 ref.)

IFN-gamma expression in macrophages and its possible biological significance. Gessani S, et al.
Cytokine Growth Factor Rev 1998 Jun;9(2):117-23 (65 ref.)

The role of macrophages in antitumor defense of patients with ovarian cancer. Zavadova E, et al.
Hematol Oncol Clin North Am 1999 Feb;13(1):135-44, ix (48 ref.)

Macrophage-restricted molecules: role in differentiation and activation. Gordon S. **Immunol Lett** 1999 Jan;65(1-2):5-8 (19 ref.)

Class A scavenger receptors and the phagocytosis of apoptotic cells. Platt N, et al. **Immunol Lett** 1999 Jan; 65(1-2):15-9 (27 ref.)

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. Andreesen R, et al. **J Leukoc Biol** 1998 Oct;64(4):419-26 (82 ref.)

A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **J Leukoc Biol** 1999 Sep; 66(3):375-81 (61 ref.)

Immune response of cattle infected with African trypanosomes. Taylor KA, et al.
Mem Inst Oswaldo Cruz 1999 Mar-Apr;94(2):239-44 (62 ref.)

Adoptive transfer of genetically modified macrophages elucidated TGF-beta-mediated 'self-defence' of the glomerulus against local action of macrophages. Kitamura M. **Nephrol Dial Transplant** 1999;14 Suppl 1:35-8 (18 ref.)

Macrophages and heat shock proteins. Bachelet M, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):727-32 (40 ref.)

An endogenous human immunostimulant acting on mononuclear phagocytes: a study in laboratory mice. Briend E, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):703-9 (40 ref.)

Modulation of phagosome processing as a key strategy for Mycobacterium avium survival within macrophages. de Chastellier C, et al. **Res Immunol** 1998 Sep-Oct; 149(7-8):699-702 (19 ref.)

Survival strategies of Leishmania donovani in mammalian host macrophages. Desjardins M, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):689-92 (34 ref.)

The role of the macrophage in immune regulation. Gordon S. **Res Immunol** 1998 Sep-Oct;149(7-8):685-8 (23 ref.)

Macrophage-targeted killing and vaccines. Guyre CA, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):655-60 (17 ref.)

Autologous human macrophages and anti-tumour cell therapy. Lesimple T, et al. **Res Immunol** 1998 Sep-Oct; 149(7-8):663-71 (70 ref.)

Endometriosis: a disease of oxidative stress? Murphy AA, et al. **Semin Reprod Endocrinol** 1998;16(4):263-73 (81 ref.)

The macrophage--a cell for all seasons. Morrissette N, et al. **Trends Cell Biol** 1999 May;9(5):199-201 (0 ref.)

Macrophages in host defense against Histoplasma capsulatum. Newman SL. **Trends Microbiol** 1999 Feb;7(2):67-71 (44 ref.)

How important is Nramp1 in tuberculosis? North RJ, et al. **Trends Microbiol** 1998 Nov;6(11):441-3 (20 ref.)

METABOLISM

Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. Fadok VA, et al. **Biochem Soc Trans** 1998 Nov;26(4):653-6 (10 ref.)

Tissue factor expression by monocytes: regulation and pathophysiological roles. Osterud B.
Blood Coagul Fibrinolysis 1998 Mar;9 Suppl 1:S9-14 (36 ref.)

Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Linton MF, et al. **Curr Opin Lipidol** 1999 Apr;10(2):97-105 (51 ref.)

Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses. McDowell MA, et al. **Curr Opin Microbiol** 1999 Aug;2(4):438-43 (67 ref.)

The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. Chisolm GM 3rd, et al. **J Biol Chem** 1999 Sep 10;274(37):25959-62 (119 ref.)

LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Aviram M, et al.
Mol Cell Biochem 1998 Nov;188(1-2):149-59 (76 ref.)

Local and systemic effects of macrophage cytokines in intestinal inflammation. Murch SH. **Nutrition** 1998 Oct; 14(10):780-3 (38 ref.)

MICROBIOLOGY

The role of macrophage cell death in tuberculosis. Kornfeld H, et al. **Cell Death Differ** 1999 Jan;6(1):71-8 (69 ref.)

Mycobacterium avium interaction with macrophages and intestinal epithelial cells. Sangari FJ, et al. **Front Biosci** 1999 Jul 15;4:D582-8 (64 ref.)

Modulation of phagosome processing as a key strategy for Mycobacterium avium survival within macrophages. de Chastellier C, et al. **Res Immunol** 1998 Sep-Oct; 149(7-8):699-702 (19 ref.)

PARASITOLOGY

Survival strategies of Leishmania donovani in mammalian host macrophages. Desjardins M, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):689-92 (34 ref.)

The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Antoine JC, et al. **Trends Microbiol** 1998 Oct;6(10):392-401 (46 ref.)

PATHOLOGY

Biological implications of macrophage infiltration in human tumor angiogenesis. Ono M, et al.
Cancer Chemother Pharmacol 1999;43 Suppl:S69-71 (19 ref.)

Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes. Ferrario F, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1627-31 (37 ref.)

PHYSIOLOGY

Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic diseases. Cutolo M. **Ann N Y Acad Sci** 1999 Jun 22;876:32-41; discussion 41-2 (53 ref.)

Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Wilder RL, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:14-31 (152 ref.)

Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Schnittler HJ, et al.
Curr Top Microbiol Immunol 1999;235:175-204 (163 ref.)

Monocytes/macrophages in atherosclerosis. Plenz G, et al. **Eur Cytokine Netw** 1998 Dec;9(4):701-3 (6 ref.)

The role of macrophages in antitumor defense of patients with ovarian cancer. Zavadova E, et al.
Hematol Oncol Clin North Am 1999 Feb;13(1):135-44, ix (48 ref.)

Macrophage NRAMP1 and its role in resistance to microbial infections. Govoni G, et al. **Inflamm Res** 1998 Jul; 47(7):277-84 (65 ref.)

Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators. Lügering N, et al.
Ital J Gastroenterol Hepatol 1998 Jun;30(3):338-44 (62 ref.)

Interactions between testicular macrophages and Leydig cells. Hutson JC. **J Androl** 1998 Jul-Aug;19(4):394-8 (55 ref.)

Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes-treated rats. Toshima K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S51-4 (19 ref.)

Macrophage activation and programming and its role for macrophage function in glomerular inflammation. Erwig LP, et al. **Kidney Blood Press Res** 1999;22(1-2):21-5 (46 ref.)

Cytokines and cellular activation in nephritis. Yokoyama H, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:39-41 (11 ref.)

The role of microglia and macrophages in the pathophysiology of the CNS. Stoll G, et al.
Prog Neurobiol 1999 Jun;58(3):233-47 (187 ref.)

Cells and cytokines involved in the pathogenesis of sarcoidosis. Moller DR.
Sarcoidosis Vasc Diffuse Lung Dis 1999 Mar;16(1):24-31 (59 ref.)

The role of macrophages and reactive oxygen species in experimental hydronephrosis. Ricardo SD, et al.
Semin Nephrol 1998 Nov;18(6):612-21 (80 ref.)

[A pivotal role of activated hepatic macrophage in the progression of alcoholic liver disease] Yamada S.
Sangyo Ika Daigaku Zasshi 1999 Mar 1;21(1):37-45 (26 ref.) (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Adoptive transfer of genetically modified macrophages elucidated TGF-beta-mediated 'self-defence' of the glomerulus against local action of macrophages. Kitamura M. **Nephrol Dial Transplant** 1999;14 Suppl 1:35-8 (18 ref.)

Potential repair of rat spinal cord injuries using stimulated homologous macrophages. Schwartz M, et al.
Neurosurgery 1999 May;44(5):1041-5; discussion 1045-6 (41 ref.)

VIROLOGY

Co-infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages. Wahl SM, et al. **J Infect Dis** 1999 May;179 Suppl 3:S457-60 (18 ref.)

MACROPHAGES, ALVEOLAR

DRUG EFFECTS

The potential mechanism of induction of inducible nitric oxide synthase mRNA in alveolar macrophages by lipopolysaccharide and its suppression by ethanol, in vivo. Greenberg SS, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):260S-265S (80 ref.)

IMMUNOLOGY

Innate immunity, cytokines, and pulmonary host defense. Nelson S, et al. **Infect Dis Clin North Am** 1998 Sep; 12(3):555-67, vii (59 ref.)

Role of leukotrienes in antimicrobial defense of the lung. Peters-Golden M, et al. **J Lab Clin Med** 1998 Oct; 132(4):251-7 (42 ref.)

Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Limper AH. **Semin Respir Infect** 1998 Dec;13(4):339-47 (77 ref.)

METABOLISM

Peroxynitrite in airway diseases. Sadeghi-Hashjin G, et al. **Clin Exp Allergy** 1998 Dec;28(12):1464-73 (97 ref.)

PHYSIOLOGY

Cryopreserved normal macrophages as a control for assays of macrophage function [letter] Lamb LS Jr, et al.
In Vitro Cell Dev Biol Anim 1999 Feb;35(2):64-6 (25 ref.)

Alveolar macrophage interactions with Pneumocystis carinii. Vassallo R, et al. **J Lab Clin Med** 1999 Jun;133(6):535-40 (35 ref.)

MACROPHAGES, PERITONEAL

DRUG EFFECTS

Downregulation of class II antigen expression by FGF-heparin complexes is due primarily to heparin effect. Hackshaw KV, et al.
Res Commun Mol Pathol Pharmacol 1998 Aug; 101(2):99-114 (45 ref.)

IMMUNOLOGY

The peritoneal immune system and continuous ambulatory peritoneal dialysis [editorial] Rapoport J, et al. **Nephron** 1999;81(4):373-80 (32 ref.)

PHYSIOLOGY

Effect of peritoneal dialysis on peritoneal macrophages. Li FK. **Perit Dial Int** 1999;19 Suppl 2:S343-7 (49 ref.)

MACROPHAGES, PULMONARY see **MACROPHAGES, ALVEOLAR**

MACROSOMIA, FETAL see **FETAL MACROSOMIA**

MACULA LUTEA

Diabetic macular edema [editorial] Cunha-Vaz J.
Eur J Ophthalmol 1998 Jul-Sep;8(3):127-30 (9 ref.)

DRUG EFFECTS

Detection and prevention of maculopathy associated with antimalarial agents. Easterbrook M. **Int Ophthalmol Clin** 1999 Spring;39(2):49-57 (33 ref.)

PATHOLOGY

Recent advances in the molecular genetics of hereditary retinal dystrophies with primary involvement of the macula. Weber BH. **Acta Anat (Basel)** 1998;162(2-3):65-74 (93 ref.)

PHYSIOLOGY

Focal macular electroretinography. Miyake Y.
Nagoya J Med Sci 1998 Oct;61(3-4):79-84 (35 ref.)

PHYSIOPATHOLOGY

Electrophysiological evaluation of the macular cone system: focal electroretinography and visual evoked potentials after photostress. Parisi V, et al. **Semin Ophthalmol** 1998 Dec; 13(4):178-88 (76 ref.)

MACULAR DEGENERATION

Alternative therapies in exudative age related macular degeneration. Chong NH, et al. **Br J Ophthalmol** 1998 Dec; 82(12):1441-3 (46 ref.)

[Age-related macular degeneration] Garcia Layana A.
Rev Med Univ Navarra 1998 Jan-Mar;42(1):42-8 (44 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy] Glacet-Bernard A, et al. **Contracept Fertil Sex** 1999 Apr;27(4):285-90 (29 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Can laser photocoagulation of eyes with high-risk drusen prevent vision loss from age-related macular degeneration? [editorial; comment] Folk JC, et al. **Ophthalmology** 1999 Jul;106(7):1241-2 (19 ref.) Comment on: Ophthalmology 1999 Jul;106(7):1367-73; discussion 1374.

Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Abdelsalam A, et al. **Surv Ophthalmol** 1999 Jul-Aug;44(1):1-29 (148 ref.)

DIAGNOSIS

Common causes of vision loss in elderly patients. Quillen DA. **Am Fam Physician** 1999 Jul;60(1):99-108 (28 ref.)

A protocol for the evaluation and treatment of atrophic age-related macular degeneration. Richer S.
J Am Optom Assoc 1999 Jan;70(1):13-23 (77 ref.)

[Fluorescein angiography in age-related macular degeneration] Dobberstein H, et al. **Ophthalmologe** 1998 Aug;95(8):581-96 (37 ref.) **(Ger)**

DIET THERAPY

Dietary prevention of age-related macular degeneration. Pratt S. **J Am Optom Assoc** 1999 Jan;70(1):39-47 (70 ref.)

EPIDEMIOLOGY

Dietary carotenoids and certain cancers, heart disease, and age-related macular degeneration: a review of recent research. Cooper DA, et al. **Nutr Rev** 1999 Jul;57(7):201-14 (120 ref.)

The prevalence of age-related maculopathy by geographic region and ethnicity. Klein R, et al.
Prog Retin Eye Res 1999 May;18(3):371-89 (103 ref.)

ETHNOLOGY

The prevalence of age-related maculopathy by geographic region and ethnicity. Klein R, et al.
Prog Retin Eye Res 1999 May;18(3):371-89 (103 ref.)

ETIOLOGY

Age-related macular degeneration: review of pathogenesis. Zarbin MA. **Eur J Ophthalmol** 1998 Oct-Dec;8(4):199-206 (65 ref.)

Do age-related macular degeneration and cardiovascular disease share common antecedents? Snow KK, et al.
Ophthalmic Epidemiol 1999 Jun;6(2):125-43 (158 ref.)

GENETICS

The best excitement in age-related macular degeneration [published erratum appears in Arch Ophthalmol 1999 Jun;117(6):841] Dryja TP. **Arch Ophthalmol** 1999 Jan; 117(1):108-9 (10 ref.)

The rod photoreceptor ATP-binding cassette transporter gene, ABCR, and retinal disease: from monogenic to multifactorial. Shroyer NF, et al. **Vision Res** 1999 Jul; 39(15):2537-44 (52 ref.)

[Recent advances in the study of blindness] Salamanca-Gómez F. **Gac Med Mex** 1998 Sep-Oct; 134(5):619-20 (7 ref.) **(Spa)**

PHYSIOPATHOLOGY

Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Harris A, et al. **Prog Retin Eye Res** 1999 Sep;18(5):669-87 (122 ref.)

[Pathogenesis of age-related macular degeneration and possibilities of its treatment] Potocký M, et al.
Cesk Slov Oftalmol 1998;54(5):343-6 (17 ref.) **(Slo)**

PREVENTION & CONTROL

The potential preventive effects of vitamins for cataract and age-related macular degeneration. Jacques PF.
Int J Vitam Nutr Res 1999 May;69(3):198-205 (50 ref.)

Antioxidant vitamins and age-related eye disease. Christen WG. **Proc Assoc Am Physicians** 1999 Jan-Feb;111(1):16-21 (53 ref.)

[Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy] Glacet-Bernard A, et al. **Contracept Fertil Sex** 1999 Apr;27(4):285-90 (29 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Radiotherapy and the treatment of age-related macular degeneration. External beam radiation therapy is effective in the treatment of age-related macular degeneration. Finger PT, et al. **Arch Ophthalmol** 1998 Nov; 116(11):1507-11 (29 ref.)

Radiotherapy for age-related macular degeneration. Gibbs SJ, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):356-60 (36 ref.)

Radiation therapy for age-related macular degeneration. Berson AM, et al. **Semin Radiat Oncol** 1999 Apr; 9(2):155-62 (56 ref.)

SURGERY

Stereotactic radiosurgery--the role of charged particles. Levy RP, et al. **Acta Oncol** 1999;38(2):165-9 (21 ref.)

Neural retinal cell transplantation: ideal versus reality [editorial] Berson EL, et al. **Ophthalmology** 1999 Mar; 106(3):445-6 (13 ref.)

THERAPY

A protocol for the evaluation and treatment of atrophic age-related macular degeneration. Richer S.
J Am Optom Assoc 1999 Jan;70(1):13-23 (77 ref.)

Age-related macular degeneration: a review of experimental treatments. Ciulla TA, et al. **Surv Ophthalmol** 1998 Sep-Oct;43(2):134-46 (183 ref.)

MACULAR DYSTROPHY, CORNEAL see **CORNEAL DYSTROPHIES, HEREDITARY**

MACULAR EDEMA, CYSTOID

DIAGNOSIS

[Macular edema: from symptom to diagnosis] Bischoff P.
Klin Monatsbl Augenheilkd 1999 May;214(5):311-6 (27 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Flach AJ.
Trans Am Ophthalmol Soc 1998;96:557-634 (379 ref.)

THERAPY

The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Flach AJ.
Trans Am Ophthalmol Soc 1998;96:557-634 (379 ref.)

MACULAR HOLES see **RETINAL PERFORATIONS**

MACULOPATHY, AGE-RELATED see **MACULAR DEGENERATION**

MAD COW DISEASE see **ENCEPHALOPATHY, BOVINE SPONGIFORM**

MADELUNG'S NECK see **LIPOMATOSIS, MULTIPLE SYMMETRICAL**

MADURA FOOT see **MADUROMYCOSIS**

MADUROMYCOSIS

Nocardia, nocardiosis and mycetoma. Boiron P, et al.
Med Mycol 1998;36 Suppl 1:26-37 (93 ref.)

[Allescheriasis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):384-6 (14 ref.) **(Jpn)**

[Mycetoma pedis (nocardiosis)] Yamamoto Y.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):247-8 (5 ref.) **(Jpn)**

DIAGNOSIS

[Osteoarticular involvement in parasitic diseases: bone mycetoma] Gueguen GE, et al. **J Radiol** 1998 Nov; 79(11):1359-62 (26 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Scapulo-thoracic mycetoma. A rare localization, a particular form] Sy MH, et al.
Rev Chir Orthop Reparatrice Appar Mot 1998 Jul; 84(4):368-72 (17 ref.) (Eng. Abstr.) **(Fre)**

MAFFUCCI SYNDROME see **ENCHONDROMATOSIS**

MAG PROTEIN see **MYELIN-ASSOCIATED GLYCOPROTEIN**

MAGENTAS see **ROSANILINE DYES**

MAGGOT INFESTATIONS see **MYIASIS**

MAGGOTS see **LARVA**

MAGNAPORTHE

GROWTH & DEVELOPMENT

Infection-related development in the rice blast fungus Magnaporthe grisea. Hamer JE, et al.
Curr Opin Microbiol 1998 Dec;1(6):693-7 (39 ref.)

MAGNESIUM

Optimal nutrition: calcium, magnesium and phosphorus. Cashman KD, et al. **Proc Nutr Soc** 1999 May;58(2):477-87 (96 ref.)

ADMINISTRATION & DOSAGE

The effects of potassium, magnesium, calcium, and fiber on risk of stroke. Suter PM. **Nutr Rev** 1999 Mar;57(3):84-8 (35 ref.)

[Migraine and prevention of migraine: the value of magnesium] Schuck P, et al. **Schweiz Med Wochenschr** 1999 Jan 23;129(3):63-70 (74 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Is the pharmacological use of intravenous magnesium before preterm cerebroprotective or deleterious for premature infants? Possible importance of the use of magnesium sulphate [comment] Durlach J, et al. **Magnes Res** 1998 Dec; 11(4):323-5 (22 ref.) Comment on: Magnes Res 1996 Oct;9(3):217-9.

BLOOD

Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: case report and review of literature. Al-Tweigeri T, et al. **Gynecol Oncol** 1999 Jan; 72(1):120-2 (35 ref.)

[Disorders of magnesium balance] Kisters K.
Internist (Berl) 1998 Aug;39(8):815-9 (13 ref.) **(Ger)**

[Magnesium: its significance in cardiology] Mysiak A.
Pol Merkuriusz Lek 1999 Mar;6(33):161-3 (37 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Mg-ATP binding: its modification by spermine, the relevance to cytosolic Mg2+ buffering, changes in the intracellular ionized Mg2+ concentration and the estimation of Mg2+ by 31P-NMR. Lüthi D, et al. **Exp Physiol** 1999 Mar; 84(2):231-52 (57 ref.)

Dietary calcium and mineral/vitamin supplementation: a controversial problem. Celotti F, et al. **J Int Med Res** 1999 Jan-Feb;27(1):1-14 (79 ref.)

Cytoplasmic free concentrations of Ca2+ and Mg2+ in skeletal muscle fibers at rest and during contraction. Konishi M. **Jpn J Physiol** 1998 Dec;48(6):421-38 (114 ref.)

Cellular magnesium transport in the vertebrate intestine. Bijvelds MJ, et al. **Magnes Res** 1998 Dec;11(4):315-22 (80 ref.)

Do forestomach epithelia exhibit a Mg2+/2H(+)-exchanger? Leonhard-Marek S.
Magnes Res 1999 Jun;12(2):99-108 (89 ref.)

The cellular ionic basis of hypertension and allied clinical conditions. Resnick L. **Prog Cardiovasc Dis** 1999 Jul-Aug; 42(1):1-22 (132 ref.)

[Magnesium (Mg) status in patients with cardiovascular diseases] Sasaki S, et al. **Rinsho Byori** 1999 May; 47(5):396-401 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Magnesium supplementation and bone turnover. Martini LA.
Nutr Rev 1999 Jul;57(7):227-9 (20 ref.)

PHYSIOLOGY

On the role of magnesium ions in RNA stability. Misra VK, et al. **Biopolymers** 1998;48(2-3):113-35 (142 ref.)

Magnesium in cell proliferation and differentiation. Wolf FI, et al. **Front Biosci** 1999 Aug 1;4:D607-17 (74 ref.)

Magnesium in health and disease. Ahsan SK.
JPMA J Pak Med Assoc 1998 Aug;48(8):246-50 (43 ref.)

Cardiovasoprotective foods and nutrients: possible importance of magnesium intake. Durlach J, et al.

Magnes Res 1999 Mar;12(1):57–61 (48 ref.)
Magnesium supplementation and bone turnover. Martini LA. **Nutr Rev** 1999 Jul;57(7):227–9 (20 ref.)
Intracellular calcium and magnesium: critical determinants of excitotoxicity? Reynolds IJ. **Prog Brain Res** 1998; 116:225–43 (162 ref.)
[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1338–48 (61 ref.) **(Fre)**
[The biochemistry and physiology of Mg2+ in the heart and other organs] Rodriguez-Zavala JS.
Arch Inst Cardiol Mex 1998 May–Jun;68(3):262–72 (55 ref.) **(Spa)**

THERAPEUTIC USE

Magnesium treatment in acute myocardial infarction: an unresolved consensus [editorial; comment] Oto A.
Eur Heart J 1999 Jan;20(2):86–8 (10 ref.) Comment on: Eur Heart J 1999 Jan;20(2):111–20.
Magnesium the forgotten cation [editorial] Khalil SI.
Int J Cardiol 1999 Feb 28;68(2):133–5 (24 ref.)
Magnesium in the management of asthma: critical review of acute and chronic treatments, and Deutsches Medizinisches Zentrum's (DMZ's) clinical experience at the Dead Sea. Harari M, et al. **J Asthma** 1998;35(7):525–36 (43 ref.)
[Magnesium: its significance in cardiology] Mysiak A.
Pol Merkuriusz Lek 1999 Mar;6(33):161–3 (37 ref.) (Eng. Abstr.) **(Pol)**

MAGNESIUM ADP see **ADENOSINE DIPHOSPHATE**

MAGNESIUM ATP see **ADENOSINE TRIPHOSPHATE**

MAGNESIUM COMPOUNDS

METABOLISM

Historical perspectives and current advancements in the bacteriology and medical therapy of struvite urinary stone disease. Schwartz BF. **Curr Pharm Des** 1999 Jul;5(7):503–13 (93 ref.)
Struvite stones. Rodman JS. **Nephron** 1999;81 Suppl 1:50–9 (54 ref.)

MAGNESIUM DEFICIENCY

COMPLICATIONS

Magnesium in diabetes mellitus. de Valk HW.
Neth J Med 1999 Apr;54(4):139–46 (70 ref.)

DIAGNOSIS

Hypomagnesemia. Agus ZS. **J Am Soc Nephrol** 1999 Jul; 10(7):1616–22 (57 ref.)

ETIOLOGY

Cisplatin and hypomagnesemia. Lajer H, et al.
Cancer Treat Rev 1999 Feb;25(1):47–58 (74 ref.)
[Disorders of magnesium balance] Kisters K.
Internist (Berl) 1998 Aug;39(8):815–9 (13 ref.) **(Ger)**

MAGNESIUM SULFATE

ADMINISTRATION & DOSAGE

Intravenous magnesium sulfate treatment in a child with status asthmaticus. Dib JG, et al.
Am J Health Syst Pharm 1999 May 15;56(10):997–1000 (24 ref.)
Is the pharmacological use of intravenous magnesium before preterm cerebroprotective or deleterious for premature infants? Possible importance of the use of magnesium sulphate [comment] Durlach J, et al. **Magnes Res** 1998 Dec; 11(4):323–5 (22 ref.) Comment on: Magnes Res 1996 Oct;9(3):217–9.
[Magnesium sulfate is recommended against eclampsia] Hjertberg R. **Lakartidningen** 1999 Jan 27;96(4):356–7 (25 ref.) (Eng. Abstr.) **(Swe)**

PHARMACOLOGY

Antenatal glucocorticoid, magnesium exposure, and the prevention of brain injury of prematurity. Perlman JM. **Semin Pediatr Neurol** 1998 Sep;5(3):202–10 (89 ref.)

THERAPEUTIC USE

Prevention and treatment of eclamptic convulsions. Witlin AG. **Clin Obstet Gynecol** 1999 Sep;42(3):507–18 (53 ref.)
Divalent cations and bronchodilation in asthma [editorial; comment] Alberts WM. **Crit Care Med** 1999 Jun; 27(6):1056–7 (15 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1159–63.
Magnesium sulfate therapy in preeclampsia and eclampsia. Witlin AG, et al. **Obstet Gynecol** 1998 Nov;92(5):883–9 (42 ref.)
Neurologic issues in eclampsia. Kaplan PW.
Rev Neurol (Paris) 1999 May;155(5):335–41 (63 ref.)

MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

MAGNETIC RESONANCE ANGIOGRAPHY

Contrast-enhanced MR angiography. Maki JH, et al.
Abdom Imaging 1998 Sep–Oct;23(5):469–84 (89 ref.)
MR arteriography of intracranial circulation. Barboriak DP, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1469–78 (73 ref.)
Absence of the infrarenal inferior vena cava with preservation of the suprarenal segment as revealed by CT and MR venography. Bass JE, et al.
AJR Am J Roentgenol 1999 Jun;172(6):1610–2 (8 ref.)
The emerging role of magnetic resonance angiography in the management of patients with third cranial nerve palsy. Jacobson DM, et al. **Am J Ophthalmol** 1999 Jul;128(1):94–6 (28 ref.)
Magnetic resonance angiography in nutcracker phenomenon [letter] Kaneko K, et al. **Clin Nephrol** 1999 Apr; 51(4):259–60 (6 ref.)
Magnetic resonance angiography of renal arterial stenosis. Grist TM. **Coron Artery Dis** 1999 May;10(3):151–6 (46 ref.)
Magnetic resonance imaging of the aorta and branch vessels. Ho VB, et al. **Coron Artery Dis** 1999 May;10(3):141–9 (45 ref.)
Physical principles of magnetic resonance angiography. Li D. **Coron Artery Dis** 1999 May;10(3):129–34 (37 ref.)
Magnetic resonance imaging of the coronary arteries: anatomy of the coronary arteries and veins in three-dimensional imaging. van Geuns RJ, et al.
Coron Artery Dis 1999 Jun;10(4):261–7 (17 ref.)
Magnetic resonance pulmonary angiography. Wielopolski PA. **Coron Artery Dis** 1999 May;10(3):157–75 (108 ref.)
MR of the thoracic aorta: a pulse sequence approach to discrete feature analysis. Czum JM, et al.
Crit Rev Diagn Imaging 1999 Apr;40(1):23–61 (69 ref.)
Magnetic resonance angiography. Biederman RW, et al.
Curr Opin Cardiol 1998 Nov;13(6):430–7 (38 ref.)
Fast magnetic resonance imaging of liver. Ichikawa T, et al. **Eur J Radiol** 1999 Mar;29(3):186–210 (79 ref.)
Update on diagnostic strategies of pulmonary embolism. Kauczor HU, et al. **Eur Radiol** 1999;9(2):262–75 (109 ref.)
Non-invasive imaging of the great vessels of the chest. Marchal G, et al. **Eur Radiol** 1998;8(7):1099–105 (56 ref.)
MRI of non-ischemic vascular disease: aneurysms and vascular malformations. Wilms G, et al. **Eur Radiol** 1999; 9(6):1055–60 (23 ref.)
Contrast-enhanced magnetic resonance angiography of peripheral vessels. Different contrast agent applications and sequence strategies: a review. Boos M, et al.
Invest Radiol 1998 Sep;33(9):538–46 (27 ref.)
Technology assessment of magnetic resonance angiography. Why pretty pictures are not enough: an overview. Flamm CR. **Invest Radiol** 1998 Sep;33(9):547–52 (19 ref.)
Magnetic resonance angiography of mesenteric arteries. A review. Heiss SG, et al. **Invest Radiol** 1998 Sep;33(9):670–81 (58 ref.)
Optimization of gadolinium-enhanced magnetic resonance angiography using an automated bolus-detection algorithm (MR SmartPrep). Original investigation. Ho VB, et al.
Invest Radiol 1998 Sep;33(9):515–23 (25 ref.)
Contrast-enhanced magnetic resonance angiography of the pulmonary vasculature. A review. Kauczor HU.
Invest Radiol 1998 Sep;33(9):606–17 (65 ref.)
Gadolinium-enhanced three-dimensional magnetic resonance angiography of the thoracic aorta and arch vessels. A review. Krinsky G. **Invest Radiol** 1998 Sep; 33(9):587–605 (82 ref.)
Magnetic resonance angiography of the hand. A review. Lee VS, et al. **Invest Radiol** 1998 Sep;33(9):687–98 (36 ref.)
Contrast-enhanced magnetic resonance imaging of the coronary arteries. A review. Li D, et al. **Invest Radiol** 1998 Sep;33(9):578–86 (54 ref.)
Determinants of image appearance in contrast-enhanced magnetic resonance angiography. A review. Saloner D.
Invest Radiol 1998 Sep;33(9):488–95 (15 ref.)
Contrast-enhanced magnetic resonance angiography. Potential applications and pitfalls in magnetic resonance angiography-guided therapy: a review. Schild HH, et al.
Invest Radiol 1998 Sep;33(9):524–7 (12 ref.)
Portal venous magnetic resonance angiography. A review. Stafford-Johnson DB, et al. **Invest Radiol** 1998 Sep; 33(9):628–36 (42 ref.)
Gadolinium-enhanced magnetic resonance angiography of the aorta. A review. Yamada CY, et al. **Invest Radiol** 1998 Sep;33(9):618–27 (17 ref.)
Intravascular radiographic contrast media: issues for family physicians. Hash RB. **J Am Board Fam Pract** 1999 Jan–Feb; 12(1):32–42 (76 ref.)
Bilateral thrombosis of the internal carotid arteries after a closed trauma. Advantages of magnetic resonance imaging and review of the literature. Gouny P, et al.
J Cardiovasc Surg (Torino) 1998 Aug;39(4):417–24 (23 ref.)
Current clinical relevance of cardiovascular magnetic resonance and its relationship to nuclear cardiology [editorial] van der Wall EE, et al. **J Nucl Cardiol** 1999 Jul–Aug;6(4):462–9 (59 ref.)
Magnetic resonance angiography--the procedure of choice to diagnose renal artery stenosis? [editorial] Olbricht CJ, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1620–2 (30 ref.)
Association of an intracranial arteriovenous malformation and a meningioma. Castillo M, et al. **Neuroradiology** 1998 Sep;40(9):574–6 (30 ref.)
Moyamoya disease and pregnancy: case report and review of the literature. Komiyama M, et al. **Neurosurgery** 1998 Aug;43(2):360–8; discussion 368–9 (64 ref.)
Coronary MR angiography. Duerinckx AJ.
Radiol Clin North Am 1999 Mar;37(2):273–318, v (190 ref.)
Spiral computed tomographic scanning and magnetic resonance angiography for the diagnosis of pulmonary embolism. Grenier PA, et al. **Thorax** 1998 Aug;53 Suppl 2:S25–31 (43 ref.)
[Magnetic resonance angiography of the carotid artery: artifacts, anatomy, diseases] Bousson V, et al. **J Radiol** 1998 Aug;79(8):723–41 (42 ref.) (Eng. Abstr.) **(Fre)**
[Contrast-enhanced 3D MR-angiography of the thorax, abdomen and lower extremities] Rühm SG, et al.
Radiologe 1999 Feb;39(2):100–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul–Aug;(4):50–9 (101 ref.) **(Rus)**

HISTORY

X-ray digital subtraction angiography to magnetic resonance-digital subtraction angiography using three-dimensional TRICKS. Historical perspective and computer simulations: a review. Mistretta CA, et al.
Invest Radiol 1998 Sep;33(9):496–505 (43 ref.)

INSTRUMENTATION

[Vascular imaging with magnetic resonance angiography (MRA)] Goyen M, et al. **Z Arztl Fortbild Qualitatssich** 1998 Sep;92(7):491–3 (9 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Contrast-enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. Bagga H, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1509–11 (7 ref.)
The combination of magnetic resonance angiography and computational fluid dynamics: a critical review. Long Q, et al. **Crit Rev Biomed Eng** 1998;26(4):227–74 (125 ref.)
Breathhold cardiac MRI and MRA. Hartnell GG.
Int J Card Imaging 1999 Apr;15(2):139–50 (32 ref.)
Magnetic resonance angiography of primary varicella vasculitis: report of two cases. Kramer LA, et al.
J Magn Reson Imaging 1999 Mar;9(3):491–6 (15 ref.)
MR-perfusion measurements: basic methodology and current status. Hiller KH, et al. **MAGMA** 1998 Sep;6(2–3):98–9 (7 ref.)
MR coronary angiography--basic methodology and current status. Sandstede J. **MAGMA** 1998 Sep;6(2–3):94–5 (8 ref.)
Coronary artery and bypass flow measurement--basic methodology and current status. Voigtländer T.
MAGMA 1998 Sep;6(2–3):96–7 (2 ref.)
Advances in abdominal, aortic, and peripheral contrast-enhanced MR angiography. Fenlon HM, et al.
Magn Reson Imaging Clin N Am 1999 May;7(2):319–36 (59 ref.)
Black-blood MR angiography. Techniques, and clinical applications. Jara H, et al.
Magn Reson Imaging Clin N Am 1999 May;7(2):303–17 (36 ref.)
Pulmonary MR angiography. Meaney JF, et al.
Magn Reson Imaging Clin N Am 1999 May;7(2):393–409, x (39 ref.)
Coronary MR angiography. Woodard PK, et al.
Magn Reson Imaging Clin N Am 1999 May;7(2):365–78 (62 ref.)
Effect of age on cerebral blood flow: measurement with ungated two-dimensional phase-contrast MR angiography in 250 adults. Buijs PC, et al. **Radiology** 1998 Dec; 209(3):667–74 (59 ref.)
Gadolinium-enhanced MR angiography of the carotid arteries: a small step, a giant leap? [editorial; comment] Rofsky NM, et al. **Radiology** 1998 Oct;209(1):31–4 (40 ref.) Comment on: Radiology 1998 Oct;209(1):95–102.
[Contrast-enhanced magnetic resonance angiography] Leiner T, et al. **Ned Tijdschr Geneeskd** 1999 May 22; 143(21):1087–93 (27 ref.) (Eng. Abstr.) **(Dut)**
[Radiological investigations of arterial vascular disease: techniques and indications] Didier D, et al.
Rev Med Suisse Romande 1998 Oct;118(10):871–9 (10 ref.) **(Fre)**
[CT and MRI diagnosis] Takasu J, et al. **Nippon Rinsho** 1999 Jul;57(7):1543–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Current developments in and future direction of coronary magnetic resonance angiography. Woodard PK, et al.
Coron Artery Dis 1999 May;10(3):135–40 (49 ref.)
The future of contrast-enhanced magnetic resonance angiography. Are blood pool agents needed? [editorial] [published erratum appears in Invest Radiol 1999 Jan;34(1):82] Mühler A. **Invest Radiol** 1998 Sep; 33(9):709–14 (16 ref.)

MAGNETIC RESONANCE IMAGING

see related
NUCLEAR MAGNETIC RESONANCE

Angiomyolipoma of the liver: significance of CT and MR dynamic study. Ahmadi T, et al. **Abdom Imaging** 1998 Sep–Oct;23(5):520–6 (41 ref.)

MR quantification of flow in abdominal vessels. Debatin JF. **Abdom Imaging** 1998 Sep–Oct;23(5):485–95 (39 ref.)

Intrameatal tumours presenting as a hearing disturbance: case reports of meningioma and lymphoma. Kawamura S, et al. **Acta Neurochir (Wien)** 1998;140(7):675–9 (16 ref.)

MR imaging of invasive carcinoma of the uterine cervix. Lien HH. **Acta Radiol** 1999 May;40(3):236–45 (51 ref.)

MR imaging investigations in a non-human primate model of multiple sclerosis [editorial; comment] Genain CP. **AJNR Am J Neuroradiol** 1999 Jun–Jul;20(6):955–7 (20 ref.)
Comment on: AJNR Am J Neuroradiol 1999 Jun–Jul;20(6):965–76.

Globoid cell leukodystrophy: distinguishing early-onset from late-onset disease using a brain MR imaging scoring method. Loes DJ, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):316–23 (23 ref.)

Radiologic and pathologic findings of intracerebral schwannoma. Zagardo MT, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1290–3 (38 ref.)

Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities. Dodd GD 3rd, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1031–6 (8 ref.)

MR imaging changes of lumbar vertebral sarcoidosis. Fisher AJ, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):354–6 (8 ref.)

Imaging evaluation and classification of developmental anomalies of the female reproductive system with an emphasis on MR imaging. O'Neill MJ, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):407–16 (38 ref.)

Computational neuroimaging of human visual cortex. Wandell BA. **Annu Rev Neurosci** 1999;22:145–73 (86 ref.)

Brain imaging technologies: how, what, when and why? Gordon E. **Aust N Z J Psychiatry** 1999 Apr;33(2):187–96 (53 ref.)

Magnetic resonance imaging of regenerating and dystrophic mouse muscle. McIntosh LM, et al. **Biochem Cell Biol** 1998; 76(2–3):532–41 (61 ref.)

Spatial and temporal resolution of functional magnetic resonance imaging. Menon RS, et al. **Biochem Cell Biol** 1998;76(2–3):560–71 (101 ref.)

An fMRI study of Stroop word-color interference: evidence for cingulate subregions subserving multiple distributed attentional systems. Peterson BS, et al. **Biol Psychiatry** 1999 May 15;45(10):1237–58 (100 ref.)

MR imaging of synovial tumours and tumour-like lesions. Ritchie DA. **Br J Radiol** 1999 Feb;72(854):212–8 (8 ref.)

Magnetic resonance imaging of the painful wrist. Seymour R, et al. **Br J Radiol** 1998 Dec;71(852):1323–30 (9 ref.)

Differential diagnosis of gynaecological "stained glass" tumours on MRI. Tanaka YO, et al. **Br J Radiol** 1999 Apr; 72(856):414–20 (8 ref.)

MRI-based brain volumetrics: emergence of a developmental brain science. Caviness VS Jr, et al. **Brain Dev** 1999 Jul; 21(5):289–95 (69 ref.)

Magnetic resonance imaging. Application to family practice. Goh RH, et al. **Can Fam Physician** 1999 Sep;45:2118–28, 2131–2 (45 ref.)

Interventional magnetic resonance: realistic prospect or wishful thinking? Günther RW, et al. **Cardiovasc Intervent Radiol** 1999 May–Jun;22(3):187–95 (61 ref.)

Functional imaging of recovery from stroke: A review of personal experience. Frackowiak R. **Cerebrovasc Dis** 1999; 9 Suppl 5:23–8 (15 ref.)

Diffuse bilateral thalamic astrocytomas as examined serially by MRI. Yoshida M, et al. **Childs Nerv Syst** 1998 Aug; 14(8):384–8 (14 ref.)

Volumetric neuroimaging in children with neurodevelopmental disorders—mapping the brain and behavior. Chang YC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Sep–Oct;39(5):285–92 (74 ref.)

MR of the thoracic aorta: a pulse sequence approach to discrete feature analysis. Czum JM, et al. **Crit Rev Diagn Imaging** 1999 Apr;40(1):23–61 (69 ref.)

Imaging of abdominal manifestations of melanoma. Kamel IR, et al. **Crit Rev Diagn Imaging** 1998 Dec;39(6):447–86 (24 ref.)

Magnetic resonance imaging of the wrist. Anderson MW, et al. **Curr Probl Diagn Radiol** 1998 Nov–Dec;27(6):187–229 (136 ref.)

Magnetic resonance imaging of musculoskeletal tumors: skeletal and soft tissue masses. Ma LD. **Curr Probl Diagn Radiol** 1999 Mar–Apr;28(2):29–62 (32 ref.)

Applications of image-guided surgery to intraoperative electrophysiology. Alonso-Vanegas MA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:140–56 (76 ref.)

Virtual colonoscopy in 1999: computed tomography or magnetic resonance imaging? Debatin JF, et al. **Endoscopy** 1999 Feb;31(2):174–9 (20 ref.)

New developments in non-invasive cardiac imaging: critical assessment of the clinical role of cardiac magnetic resonance imaging. Nagel E, et al. **Eur Heart J** 1998 Sep; 19(9):1286–93 (62 ref.)

Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging. Callicott JH, et al. **Eur J Radiol** 1999 May;30(2):95–104 (104 ref.)

MRI of the ageing and herniating intervertebral disc. Cassar-Pullicino VN. **Eur J Radiol** 1998 Jul;27(3):214–28 (67 ref.)

Intracranial meningiomas: correlations between MR imaging and histology. Maiuri F, et al. **Eur J Radiol** 1999 Jul; 31(1):69–75 (22 ref.)

Organization of the human motor system as studied by functional magnetic resonance imaging. Mattay VS, et al. **Eur J Radiol** 1999 May;30(2):105–14 (98 ref.)

Acute swelling of the limbs: magnetic resonance pictorial review of fascial and muscle signal changes. Révelon G, et al. **Eur J Radiol** 1999 Apr;30(1):11–21 (14 ref.)

Imaging breasts with silicone implants. Azavedo E, et al. **Eur Radiol** 1999;9(2):349–55 (60 ref.)

MR imaging of musculoskeletal trauma to the pelvis and the lower limb. Brossmann J, et al. **Eur Radiol** 1999;9(2):183–91 (78 ref.)

MR imaging of the brain: metabolic and toxic white matter diseases. Forsting M. **Eur Radiol** 1999;9(6):1061–5 (23 ref.)

MR imaging and CT of the female pelvis: radiologic-pathologic correlation. Hamm B, et al. **Eur Radiol** 1999;9(1):3–15 (49 ref.)

K-space sampling strategies. Hennig J. **Eur Radiol** 1999; 9(6):1020–31 (28 ref.)

'Nonportal' splanchnic venous supply to the liver: abnormal findings on CT, US and MRI. Itai Y, et al. **Eur Radiol** 1999;9(2):237–43 (35 ref.)

Erdheim-Chester disease: a case report and literature overview. Kenn W, et al. **Eur Radiol** 1999;9(1):153–8 (42 ref.)

CT and MRI of the male genital tract: radiologic-pathologic correlation. Kubik-Huch RA, et al. **Eur Radiol** 1999; 9(1):16–28 (85 ref.)

Non-invasive imaging of the great vessels of the chest. Marchal G, et al. **Eur Radiol** 1998;8(7):1099–105 (56 ref.)

CT and MRI appearances of a thoracic chordoma. Murphy JM, et al. **Eur Radiol** 1998;8(9):1677–9 (13 ref.)

Cryptorchidism: strategies in detection. Nguyen HT, et al. **Eur Radiol** 1999;9(2):336–43 (37 ref.)

MR imaging: acronyms and clinical applications. Nitz WR. **Eur Radiol** 1999;9(5):979–97 (178 ref.)

MR imaging of the brain: tumors. Sartor K. **Eur Radiol** 1999; 9(6):1047–54 (25 ref.)

Magnetic resonance imaging of normal bone marrow. Vande Berg BC, et al. **Eur Radiol** 1998;8(8):1327–34 (69 ref.)

Magnetic resonance imaging of the bone marrow in hematological malignancies. Vande Berg BC, et al. **Eur Radiol** 1998;8(8):1335–44 (94 ref.)

Subcutaneous granuloma annulare: MR imaging and literature review. Vandevenne JE, et al. **Eur Radiol** 1998; 8(8):1363–5 (9 ref.)

MRI of bone metastases. Vanel D, et al. **Eur Radiol** 1998; 8(8):1345–51 (23 ref.)

MRI of non-ischemic vascular disease: aneurysms and vascular malformations. Wilms G, et al. **Eur Radiol** 1999; 9(6):1055–60 (23 ref.)

Functional magnetic resonance imaging of the human brain: data acquisition and analysis. Turner R, et al. **Exp Brain Res** 1998 Nov;123(1–2):5–12 (33 ref.)

Neuroimaging studies of brain activation for language, with an emphasis on functional magnetic resonance imaging: a review. Kent RD. **Folia Phoniatr Logop** 1998 Nov–Dec; 50(6):291–304 (77 ref.)

The impact of magnetic resonance cholangiopancreatography on ERCP. Devière J, et al. **Gastrointest Endosc** 1999 Jul;50(1):136–40; discussion 140–3 (23 ref.)

Imaging the bad back: increasing reliance on MRI. Dixon AK. **Hosp Med** 1998 Jun;59(6):496–8 (17 ref.)

New developments in cardiac magnetic resonance imaging. Hartnell GG. **Hosp Med** 1998 Jul;59(7):567–73 (20 ref.)

Neurofibromatosis types I and II: radiological appearance. Romanowski CA, et al. **Hosp Med** 1998 Feb;59(2):134–9 (13 ref.)

Neuro-functional imaging and profound deafness. Truy E. **Int J Pediatr Otorhinolaryngol** 1999 Feb 15;47(2):131–6 (27 ref.)

"Bone bruises" of the knee: a review. Mathis CE, et al. **Iowa Orthop J** 1998;18:112–7 (16 ref.)

Use of magnetic resonance imaging in spinal trauma: indications, techniques, and utility. Slucky AV, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):134–45 (22 ref.)

Lumbar intraspinal synovial cysts of different etiologies: diagnosis by CT and MR imaging. Farrokh D. **J Belge Radiol** 1998 Dec;81(6):275–8 (20 ref.)

Measuring cerebral blood flow using magnetic resonance imaging techniques. Calamante F, et al. **J Cereb Blood Flow Metab** 1999 Jul;19(7):701–35 (221 ref.)

Spatiotemporal EEG analysis and distributed source estimation in presurgical epilepsy evaluation. Michel CM, et al. **J Clin Neurophysiol** 1999 May;16(3):239–66 (67 ref.)

Intrafibular varix: MR diagnosis. Díaz-Candamio MJ, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):328–30 (4 ref.)

Inflammatory pseudotumor of the bladder: MR findings. Fujiwara T, et al. **J Comput Assist Tomogr** 1999 Jul–Aug; 23(4):558–61 (14 ref.)

Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. Bonnemain B. **J Drug Target** 1998;6(3):167–74 (48 ref.)

State-of-the-art magnetic resonance imaging of the kidneys and upper urinary tract. Dockery WD, et al. **J Endourol** 1999 Jul–Aug;13(6):417–23 (19 ref.)

Complete agenesis of the dorsal pancreas. Fukuoka K, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):94–7 (20 ref.)

Biliary imaging: magnetic resonance cholangiography versus endoscopic retrograde cholangiography. Sackmann M, et al. **J Hepatol** 1999 Feb;30(2):334–8 (82 ref.)

Functional magnetic resonance imaging: clinical applications and potential. Matthews PM, et al. **J Inherit Metab Dis** 1999 Jun;22(4):337–52 (68 ref.)

Magnetic resonance cholangiopancreatography. Coakley FV, et al. **J Magn Reson Imaging** 1999 Feb;9(2):157–62 (25 ref.)

Clinical and magnetic resonance imaging heterogeneity in multiple sclerosis [editorial; comment] Miller DH. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):139 (5 ref.)
Comment on: J Neurol Neurosurg Psychiatry 1999 Aug;67(2):153–7.

Functional magnetic resonance imaging in the visual system. McFadzean RM, et al. **J Neuroophthalmol** 1999 Sep; 19(3):186–200 (138 ref.)

The relationship between magnetic resonance imaging findings and clinical manifestations of hypothalamic hamartoma. Arita K, et al. **J Neurosurg** 1999 Aug; 91(2):212–20 (63 ref.)

Growing blood clot mimicking an aneurysm on postoperative computerized tomography and magnetic resonance imaging studies. Case report and review of the literature. Bertalanffy A, et al. **J Neurosurg** 1999 Oct;91(4):679–81 (20 ref.)

Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. Fouladi M, et al. **J Neurosurg** 1999 Sep;91(3):499–502 (17 ref.)

Greater superficial petrosal nerve neurinoma. Case report. Kumon Y, et al. **J Neurosurg** 1999 Oct;91(4):691–6 (22 ref.)

Rosai-Dorfman disease presenting multiple intracranial lesions with unique findings on magnetic resonance imaging. Case report. Udono H, et al. **J Neurosurg** 1999 Aug;91(2):335–9 (29 ref.)

Dumbbell lymphoma of the cervical spine in a child. Case report. Gezen F, et al. **J Neurosurg Sci** 1998 Dec; 42(4):239–44 (27 ref.)

Current clinical relevance of cardiovascular magnetic resonance and its relationship to nuclear cardiology [editorial] van der Wall EE, et al. **J Nucl Cardiol** 1999 Jul–Aug;6(4):462–9 (59 ref.)

Magnetic resonance imaging in oncology: an overview. Wallis F, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):117–25 (48 ref.)

Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. Kindrick AV, et al. **J Urol** 1998 Dec;160(6 Pt 1):2102–6 (15 ref.)

Unusual MRI finding of multiple adenomas in the pituitary gland: a case report and review of the literature. Cannavò S, et al. **Magn Reson Imaging** 1999 May;17(4):633–6 (13 ref.)

MR imaging in sports injuries of the foot and ankle. Bencardino J, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):131–49, ix (73 ref.)

MR imaging of stress reactions, muscle injuries, and other overuse injuries in runners. Bergman AG, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):151–74, ix (114 ref.)

Vascular anatomy and disorders of the lumbar spine and spinal cord. Bowen BC, et al. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):555–71 (54 ref.)

MR imaging of spinal infections. Dagirmanjian A, et al. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):525–38 (52 ref.)

New MR imaging contrast agents. Earls JP, et al. **Magn Reson Imaging Clin N Am** 1999 May;7(2):255–73 (91 ref.)

MR imaging of congenital anomalies of the pediatric spine. Egelhoff JC. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):459–79 (97 ref.)

MR imaging of sports injuries of the elbow. Fritz RC. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):51–72, viii (137 ref.)

MR imaging of the spine in sports injuries. Gundry CR, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):85–103 (48 ref.)

MR imaging of rotator interval, long biceps, and associated injuries in the overhead-throwing athlete. Ho CP. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):23–37 (18 ref.)

MR imaging of knee anterior cruciate ligament and associated injuries in skiers. Ho CP, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):117–30 (29 ref.)

MR evaluation of stenosis involving the neural foramina, lateral recesses, and central canal of the lumbosacral spine. Jinkins JR. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):493–511, viii (43 ref.)

MR imaging of sports injuries of the hip. Kneeland JB. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):105–15, viii (16 ref.)

MR imaging of cerebrospinal fluid flow and spinal cord motion in neurologic disorders of the spine. Levy LM.

Magn Reson Imaging Clin N Am 1999 Aug;7(3):573–87 (60 ref.)

MR–guided therapy. Applications in the abdomen. Lu DS, et al. **Magn Reson Imaging Clin N Am** 1999 May; 7(2):337–48 (59 ref.)

Degenerative disc disease and back pain. Modic MT. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):481–91, viii (67 ref.)

MR imaging of the postoperative lumbar spine. Ross JS. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):513–24, viii (50 ref.)

Pulse sequences in lumbar spine imaging. Ruggieri PM. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):425–37, vii (67 ref.)

Role of MR imaging in the management of injuries in professional football players. Schlegel TF, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):175–90, ix (16 ref.)

MR imaging of neoplasms of the lumbar spine. Sevick RJ, et al. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):539–53, ix (64 ref.)

MR imaging of the traumatized lumbar spine. Young PC, et al. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):589–602 (58 ref.)

Polar sampling in k–space: reconstruction effects. Lauzon ML, et al. **Magn Reson Med** 1998 Nov;40(5):769–82 (21 ref.)

Imaging of the foot and ankle in the injured athlete. Lazarus ML. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S412–20 (28 ref.)

Cerebral magnetic resonance imaging in patients with chronic liver disease. Morgan MY. **Metab Brain Dis** 1998 Dec; 13(4):273–90 (55 ref.)

MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Barkhof F. **Mult Scler** 1999 Aug;5(4):283–6 (35 ref.)

Normal–appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Filippi M, et al. **Mult Scler** 1999 Aug;5(4):273–82 (86 ref.)

Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Stevenson VL, et al. **Mult Scler** 1999 Aug;5(4):268–72 (49 ref.)

Myelin basic protein–like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes. Whitaker JN. **Mult Scler** 1998 Jun;4(3):243–6 (51 ref.)

Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Jueptner M, et al. **Neuroimage** 1995 Jun;2(2):148–56 (60 ref.)

Reopening the mental imagery debate: lessons from functional anatomy. Mellet E, et al. **Neuroimage** 1998 Aug; 8(2):129–39 (90 ref.)

Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Davis PC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):93–114 (80 ref.)

Diffusion imaging in pediatric hypoxic ischemia injury. Phillips MD, et al. **Neuroimaging Clin N Am** 1999 Feb; 9(1):41–52 (57 ref.)

Prospective analysis of complications of catheter cerebral angiography in the digital subtraction angiography and magnetic resonance era. Komiyama M, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38(9):534–9; discussion 539–40 (24 ref.)

Magnetization transfer contrast: its utility as a technique and its application to central nervous system pathology. Bagley LJ, et al. **Neurology** 1999;53(5 Suppl 3):S49–51 (30 ref.)

Pathological correlates of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis. Brochet B, et al. **Neurology** 1999;53(5 Suppl 3):S12–7 (17 ref.)

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Fazekas F, et al. **Neurology** 1999 Aug 11;53(3):448–56 (72 ref.)

Magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions. Filippi M. **Neurology** 1999;53(5 Suppl 3):S18–22 (56 ref.)

Application of magnetization transfer imaging to multiple sclerosis. Grossman RI. **Neurology** 1999;53(5 Suppl 3):S8–11 (34 ref.)

The physical basis of magnetization transfer imaging. McGowan JC. **Neurology** 1999;53(5 Suppl 3):S3–7 (32 ref.)

Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. Richert ND, et al. **Neurology** 1999;53(5 Suppl 3):S29–32 (38 ref.)

Correlations between magnetization transfer metrics and other magnetic resonance abnormalities in multiple sclerosis. Rovaris M, et al. **Neurology** 1999;53(5 Suppl 3):S40–5 (46 ref.)

Standardization of magnetization transfer imaging for multicenter studies. Silver NC, et al. **Neurology** 1999;53(5 Suppl 3):S33–9 (48 ref.)

Magnetization transfer histogram methodology: its clinical and neuropsychological correlates. van Buchem MA, et al. **Neurology** 1999;53(5 Suppl 3):S23–8 (43 ref.)

Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. van Waesberghe JH, et al. **Neurology** 1999;53(5 Suppl 3):S46–8 (11 ref.)

MRI of the spinal cord in myelopathy complicating vitamin B12 deficiency: two additional cases and a review of the literature. Bassi SS, et al. **Neuroradiology** 1999 Apr; 41(4):271–4 (17 ref.)

MRI in primary intraspinal extradural hydatid disease: case report. Berk C, et al. **Neuroradiology** 1998 Jun;40(6):390–2 (12 ref.)

Slow–growing labyrinthine masses: contribution of MRI to diagnosis, follow–up and treatment. Deux JF, et al. **Neuroradiology** 1998 Oct;40(10):684–9 (21 ref.)

Cerebellar involvement in metabolic disorders: a pattern–recognition approach. Steinlin M, et al. **Neuroradiology** 1998 Jun;40(6):347–54 (41 ref.)

Spinal disease in neurologically symptomatic HIV–positive patients. Taber KH, et al. **Neuroradiology** 1999 May; 41(5):360–8 (53 ref.)

MRI description of vertebral osteomyelitis, neoplasm, and compression fracture. Vaccaro AR, et al. **Orthopedics** 1999 Jan;22(1):67–73; quiz 74–5 (18 ref.)

MRI and MRS in HMG–CoA lyase deficiency. Yalçinkaya C, et al. **Pediatr Neurol** 1999 May;20(5):375–80 (13 ref.)

Does the tuberous sclerosis complex include intracranial aneurysms? A case report with a review of the literature. Beltramello A, et al. **Pediatr Radiol** 1999 Mar;29(3):206–11 (40 ref.)

US and MRI in a case of persistent Müllerian duct syndrome. Di Cesare E, et al. **Pediatr Radiol** 1998 Nov;28(11):865–7 (4 ref.)

Fracture dislocation of the sacro–coccygeal joint: MRI evaluation [letter] Raissaki MT, et al. **Pediatr Radiol** 1999 Aug;29(8):642–3 (6 ref.)

MR findings in Shone's complex of left heart obstructive lesions. Roche KJ, et al. **Pediatr Radiol** 1998 Nov; 28(11):841–5 (6 ref.)

Correlating MR lesions and functional deficits in multiple sclerosis patients. Anatomical atlas registration. Gardner JC, et al. **Phys Med Rehabil Clin N Am** 1998 Aug; 9(3):569–86, vi (68 ref.)

Correlations of evoked potentials with MR imaging and MR spectroscopy in multiple sclerosis. Kraft GH, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):561–7, vi (57 ref.)

Central nervous system imaging. When is CT more appropriate than MRI? Laughlin S, et al. **Postgrad Med** 1998 Nov;104(5):73–6, 81–4, 87–8 (30 ref.)

Morphological brain imaging studies on major psychoses. Okazaki Y. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S215–8 (23 ref.)

Magnetic resonance imaging study of the brain in autism. Saitoh O, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S219–22 (27 ref.)

A primary hepatic carcinoid tumor: evaluation by computed tomography and magnetic resonance imaging. Fujino K, et al. **Radiat Med** 1998 Sep–Oct;16(5):371–3 (15 ref.)

MR diffusion imaging in stroke: review and controversies. Beauchamp NJ Jr, et al. **Radiographics** 1998 Sep–Oct; 18(5):1269–83; discussion 1283–5 (36 ref.)

Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Boiselle PM, et al. **Radiographics** 1998 Sep–Oct; 18(5):1061–9 (17 ref.)

Cardiac MR imaging: a guide for the beginner. Boxt LM. **Radiographics** 1999 Jul–Aug;19(4):1009–25; discussion 1026–8 (25 ref.)

MR imaging of the adrenal gland: radiologic–pathologic correlation. Krebs TL, et al. **Radiographics** 1998 Nov–Dec; 18(6):1425–40 (47 ref.)

MR imaging of benign soft–tissue masses of the foot and ankle. Llauger J, et al. **Radiographics** 1998 Nov–Dec; 18(6):1481–98 (27 ref.)

Contrast–enhanced three–dimensional MR portography. Okumura A, et al. **Radiographics** 1999 Jul–Aug; 19(4):973–87 (24 ref.)

Pitfalls and artifacts encountered in clinical MR imaging of the spine. Taber KH, et al. **Radiographics** 1998 Nov–Dec; 18(6):1499–521 (62 ref.)

Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119–31, x (64 ref.)

Emergency MR imaging of orthopedic trauma. Current and future directions. Eustace S, et al. **Radiol Clin North Am** 1999 Sep;37(5):975–94, vi (113 ref.)

MR imaging and CT of orbital infections and complications in acute rhinosinusitis. Eustis HS, et al. **Radiol Clin North Am** 1998 Nov;36(6):1165–83, xi (56 ref.)

Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Hidayat AA, et al. **Radiol Clin North Am** 1998 Nov;36(6):1229–40, xii (68 ref.)

Musculoskeletal sonography and MR imaging. A role for both imaging methods. Jacobson JA. **Radiol Clin North Am** 1999 Jul;37(4):713–35 (45 ref.)

Retinoblastoma and simulating lesions. Role of CT, MR imaging and use of Gd–DTPA contrast enhancement. Kaufman LM, et al. **Radiol Clin North Am** 1998 Nov; 36(6):1101–17 (63 ref.)

Uveal melanoma, choroidal hemangioma, and simulating lesions. Role of MR imaging. Mafee MF. **Radiol Clin North Am** 1998 Nov;36(6):1083–99, x (67 ref.)

Sarcoidosis of the eye, orbit, and central nervous system. Role of MR imaging. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):73–87, x (53 ref.)

Lacrimal gland tumors and simulating lesions. Clinicopathologic and MR imaging features. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):219–39, xii (58 ref.)

Optic nerve sheath meningiomas. Role of MR imaging. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):37–58, ix (84 ref.)

MR imaging anatomy of the optic pathways. Tamraz JC, et al. **Radiol Clin North Am** 1999 Jan;37(1):1–36, ix (65 ref.)

Fibro–osseous, osseous, and cartilaginous lesions of the orbit and paraorbital region. Correlative clinicopathologic and radiographic features, including the diagnostic role of CT and MR imaging. Wenig BM, et al. **Radiol Clin North Am** 1998 Nov;36(6):1241–59, xii (67 ref.)

MR imaging of adult patients with congenital heart disease. Wimpfheimer O, et al. **Radiol Clin North Am** 1999 Mar; 37(2):421–38, vii (79 ref.)

Imaging of acute cerebral ischemia. Beauchamp NJ Jr, et al. **Radiology** 1999 Aug;212(2):307–24 (177 ref.)

Subcutaneous granuloma annulare: MR imaging features in six children and literature review. Chung S, et al. **Radiology** 1999 Mar;210(3):845–9 (15 ref.)

Obstetric MR imaging. Levine D, et al. **Radiology** 1999 Jun; 211(3):609–17 (73 ref.)

MR imaging of articular cartilage. McCauley TR, et al. **Radiology** 1998 Dec;209(3):629–40 (90 ref.)

Intraoperative MR imaging guidance for intracranial neurosurgery: experience with the first 200 cases. Schwartz RB, et al. **Radiology** 1999 May;211(2):477–88 (32 ref.)

Tissue characterization in the female pelvis by means of MR imaging. Siegelman ES, et al. **Radiology** 1999 Jul; 212(1):5–18 (140 ref.)

MRI assessment of myocardial viability: comparison with other imaging techniques. Baer FM, et al. **Rays** 1999 Jan–Mar;24(1):96–108 (31 ref.) **(Eng, Ita)**

Value of magnetic resonance imaging in synovitis. Laredo JD, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):630–3 (15 ref.)

Lipoma arborescens of the knee. Narváez J, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):351–3 (17 ref.)

The contribution of functional imaging techniques to our understanding of rheumatic pain. Jones AK. **Rheum Dis Clin North Am** 1999 Feb;25(1):123–52 (123 ref.)

Magnetic resonance imaging of osteoarthritis. Waldschmidt JG, et al. **Rheum Dis Clin North Am** 1999 May;25(2):451–65 (25 ref.)

Magnetic resonance imaging of the fetal brain. Bilaniuk LT. **Semin Roentgenol** 1999 Jan;34(1):48–61 (32 ref.)

MRI and echocardiography: how do they compare in adults? Hartnell GG, et al. **Semin Roentgenol** 1998 Jul;33(3):252–61 (47 ref.)

Preoperative and postoperative MRI of congenital heart disease. Hubbard AM, et al. **Semin Roentgenol** 1998 Jul; 33(3):218–27 (57 ref.)

Prenatal magnetic resonance imaging of fetal anomalies. Hubbard AM, et al. **Semin Roentgenol** 1999 Jan;34(1):41–7 (42 ref.)

Imaging features of posterior fossa neoplasms in children and adults. Loevner LA. **Semin Roentgenol** 1999 Apr; 34(2):84–101 (34 ref.)

Cerebral neoplasms in adults. Maldjian JA, et al. **Semin Roentgenol** 1999 Apr;34(2):102–22 (57 ref.)

MRI and echocardiography in children: how do they compare? Marx GR, et al. **Semin Roentgenol** 1998 Jul; 33(3):281–92 (36 ref.)

MRI of the female pelvis. Kennedy AM, et al. **Semin Ultrasound CT MR** 1999 Aug;20(4):214–30 (35 ref.)

MR assessment of the extremity veins. Polak JF, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):36–46 (27 ref.)

Magnetic resonance imaging in the evaluation of ligament injuries. Farooki S, et al. **Skeletal Radiol** 1999 Feb; 28(2):61–74 (107 ref.)

Disorders of the hallux sesamoid complex: MR features. Karasick D, et al. **Skeletal Radiol** 1998 Aug;27(8):411–8 (30 ref.)

Rheumatoid nodule of the foot: MRI appearances mimicking an indeterminate soft tissue mass. Sanders TG, et al. **Skeletal Radiol** 1998 Aug;27(8):457–60 (14 ref.)

Glenohumeral instability: evaluation using MR arthrography of the shoulder. Shankman S, et al. **Skeletal Radiol** 1999 Jul;28(7):365–82 (35 ref.)

Classification and detection of bone marrow lesions with magnetic resonance imaging. Vande Berg BC, et al. **Skeletal Radiol** 1998 Oct;27(10):529–45 (97 ref.)

Magnetic resonance imaging of the normal bone marrow. Vande Berg BC, et al. **Skeletal Radiol** 1998 Sep; 27(9):471–83 (79 ref.)

Imaging of the cervical spine. Kaiser JA, et al. **Spine** 1998 Dec 15;23(24):2701–12 (70 ref.)

Clinical magnetic resonance imaging of articular cartilage. Disler DG, et al. **Top Magn Reson Imaging** 1998 Dec; 9(6):360–76 (73 ref.)

Magnetic resonance imaging of knee cartilage repair. Gold GE, et al. **Top Magn Reson Imaging** 1998 Dec;9(6):377–92 (46 ref.)

High–resolution magnetic resonance imaging of articular cartilage: correlation with histology and pathology. Goodwin DW, et al. **Top Magn Reson Imaging** 1998 Dec; 9(6):337–47 (59 ref.)

Magnetic resonance imaging arthrography of the ankle. Helgason JW, et al. **Top Magn Reson Imaging** 1998 Oct; 9(5):286–94 (40 ref.)

Magnetic resonance imaging of the peroneal tendons. Mota J, et al. **Top Magn Reson Imaging** 1998 Oct;9(5):273–85

(51 ref.)
Magnetic resonance imaging of articular cartilage: an overview. Recht MP, et al. **Top Magn Reson Imaging** 1998 Dec;9(6):328–36 (69 ref.)
Magnetic resonance imaging of chondral and osteochondral injuries. Rubin DA. **Top Magn Reson Imaging** 1998 Dec; 9(6):348–59 (88 ref.)
Painful syndromes around the ankle and foot: magnetic resonance imaging evaluation. Steinbach LS. **Top Magn Reson Imaging** 1998 Oct;9(5):311–26 (40 ref.)
Diabetic foot and neuroarthropathy: magnetic resonance imaging evaluation. Yu JS. **Top Magn Reson Imaging** 1998 Oct;9(5):295–310 (96 ref.)
Tracking neural pathways with MRI. Rye DB. **Trends Neurosci** 1999 Sep;22(9):373–4 (31 ref.)
Neuronal migration disorders. Part II: Magnetic resonance imaging. Saatçi I, et al. **Turk J Pediatr** 1998 Oct–Dec; 40(4):481–90 (17 ref.)
Current concepts in imaging of adrenal masses. Teeger S, et al. **World J Urol** 1999 Feb;17(1):3–8 (18 ref.)
[Non-invasive imaging of atherosclerosis by MRI and ultrasonography] Toussaint JF, et al. **Arch Mal Coeur Vaiss** 1999 Mar;92(3):349–54 (32 ref.) (Eng. Abstr.) **(Fre)**
[Nuclear magnetic resonance brain imaging in the prenatal period] Girard N, et al. **Arch Pediatr** 1998;5 Suppl 2:171s–174s (27 ref.) **(Fre)**
[MRI cholangiopancreatography] Asselah T, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):320–7 (24 ref.) **(Fre)**
[Which investigations should be selected for the preoperative assessment before the decision for treatment of abdominal aortic aneurysm by endoprosthesis: arteriography, tomodensitometry or magnetic resonance imaging?] Kobeiter H. **J Mal Vasc** 1998 Dec;23(5):387–9 (10 ref.) (Eng. Abstr.) **(Fre)**
[MRI aspects of spinal cord abscesses. Report of 5 cases and review of the literature] Condette-Auliac S, et al. **J Neuroradiol** 1998 Oct;25(3):189–200 (36 ref.) (Eng. Abstr.) **(Fre)**
[MRI evaluation of placenta accreta treated by embolization. Apropos of a case. Review of the literature] Lemercier E, et al. **J Radiol** 1999 Apr;80(4):383–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Magnetic resonance imaging of multiple myeloma (editorial)] Rahmouni A. **J Radiol** 1998 Apr;79(4):299–300 (19 ref.) **(Fre)**
[Diagnostic and prognostic value of magnetic resonance imaging in multiple myeloma: the clinician's point of view (editorial)] Sibilia J, et al. **J Radiol** 1998 Apr;79(4):303–4 (16 ref.) **(Fre)**
[Gorham disease of the rib with osteolysis followed by bone remodeling. Study with magnetic resonance imaging] Sans N, et al. **Rev Mal Respir** 1999 Feb;16(1):98–101 (14 ref.) (Eng. Abstr.) **(Fre)**
[Clinical imaging of osteo-condensed metastases] Buthiau D, et al. **Rev Med Interne** 1999 Apr;20(4):353–64 (62 ref.) (Eng. Abstr.) **(Fre)**
[What can be expected from MRI of the central nervous system in systemic diseases?] Dumas JL, et al. **Rev Med Interne** 1998;19 Suppl 1:47S–48S (3 ref.) **(Fre)**
[Dementia and memory: morphologic imagery with MRI] Lehéricy S, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S115–21 (38 ref.) (Eng. Abstr.) **(Fre)**
[Value of magnetic resonance cholangiopancreatography in diagnosis of biliopancreatic diseases] Albert J, et al. **Dtsch Med Wochenschr** 1998 Sep 25;123(39):1149–55 (59 ref.) **(Ger)**
[Progress in diagnostic imaging of the thorax (CT, MRI, intervention)--significance and value for the surgeon] Schildberg FW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:255–60 (0 ref.) (Eng. Abstr.) **(Ger)**
[MRI arthrography in labrum lesions of the hip joint. Method and diagnostic value] Urban M, et al. **Orthopade** 1998 Oct; 27(10):691–8 (33 ref.) (Eng. Abstr.) **(Ger)**
[2D and 3D parameter i.nages for the analysis of contrast medium distribution in dynamic CT and MRI] Beier J, et al. **Radiologe** 1998 Oct;38(10):832–40 (27 ref.) (Eng. Abstr.) **(Ger)**
[13-MHc high frequency ultrasound of the lateral ligaments of the ankle joint and the anterior tibia-fibular ligament. Comparison and results of MRI in 64 patients] Milz P, et al. **Radiologe** 1999 Jan;39(1):34–40 (25 ref.) (Eng. Abstr.) **(Ger)**
[The magnetic resonance tomography of complex congenital heart diseases in adults] Bremerich J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Apr;170(4):397–403 (30 ref.) (Eng. Abstr.) **(Ger)**
[The value of MRT in the diagnosis of benign and malignant tumors of the uterus] Hamm B. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Apr;170(4):327–37 (42 ref.) (Eng. Abstr.) **(Ger)**
[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172–4 (0 ref.) **(Ger)**
[Partial priapism. Case report and review of the literature of diagnostic and therapeutic measures] Schneede P, et al. **Urologe A** 1999 Mar;38(2):179–83 (8 ref.) (Eng. Abstr.) **(Ger)**
[Neuroradiologic diagnosis in acute stroke] Brückmann H, et al. **Z Arztl Fortbild Qualitatssich** 1999 May;93(3):191–6 (10 ref.) (Eng. Abstr.) **(Ger)**
[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971–5 (18 ref.) (Eng. Abstr.) **(Ger)**
[How early and how specifically can hypoxic-ischemic brain lesions be detected with diagnostic imaging?] Krägeloh-Mann I, et al. **Z Geburtshilfe Neonatol** 1998 Sep; 202(5):182–6 (35 ref.) (Eng. Abstr.) **(Ger)**
[Imaging diagnosis in suspected inflammatory rheumatoid axial skeleton diseases (sacroilitis)] Bollow M, et al. **Z Rheumatol** 1999 Apr;58(2):61–70 (40 ref.) (Eng. Abstr.) **(Ger)**
[Cervix carcinoma: staging, therapy, after-care. Experiences with magnetic resonance tomography of cervix carcinoma based on recent literature 1993 to 1997] Oellinger JJ, et al. **Zentralbl Gynakol** 1998;120(8):373–85 (47 ref.) (Eng. Abstr.) **(Ger)**
[The role of TC and MRI in the identification, characterization and staging of tumors of the spinal vertebrae] Gualdi GF, et al. **Clin Ter** 1999 Jan–Feb; 150(1):51–65 (51 ref.) (Eng. Abstr.) **(Ita)**
[Lipomatous hypertrophy of the interatrial septum: its assessment with TEE, CT and MRI] Iacovoni A, et al. **G Ital Cardiol** 1998 Nov;28(11):1273–7 (18 ref.) (Eng. Abstr.) **(Ita)**
[Magnetic resonance of the breast] Del Maschio A, et al. **Radiol Med (Torino)** 1998 Sep;96(3):154–60 (41 ref.) **(Ita)**
[Magnetic resonance in congenital cardiopathy. Part I] Midiri M, et al. **Radiol Med (Torino)** 1998 Oct;96(4):289–99 (26 ref.) **(Ita)**
[Magnetic resonance in congenital cardiopathy. Part II] Midiri M, et al. **Radiol Med (Torino)** 1998 Nov;96(5):425–33 (25 ref.) **(Ita)**
[Magnetic resonance findings in a case of herpes zoster myelitis] Pierallini A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):107–8 (15 ref.) **(Ita)**
[MR imaging of pancreatic neoplasms] Pavone P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S6–10 (22 ref.) (Eng. Abstr.) **(Ita)**
[Differential diagnosis of astrocytic tumors] Korogi Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 Apr; 59(5):170–5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical role of magnetic resonance imaging (MRI) of prostatic cancer] Nasu Y, et al. **Nippon Rinsho** 1998 Aug; 56(8):2042–5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Basic principles and historical consideration of MR cholangiopancreatography] Ohgi K, et al. **Nippon Rinsho** 1998 Nov;56(11):2755–9 (14 ref.) (Eng. Abstr.) **(Jpn)**
[MR images of mycobacterial infection] Ohno Y, et al. **Nippon Rinsho** 1998 Dec;56(12):3067–72 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical evaluation of MRCP] Sai J, et al. **Nippon Rinsho** 1998 Nov;56(11):2768–72 (20 ref.) (Eng. Abstr.) **(Jpn)**
[MR analysis of brain function] Nakada T. **No To Hattatsu** 1999 May;31(3):212–6 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Magnetic resonance imaging in multiple sclerosis] Saida T. **Rinsho Shinkeigaku** 1999 Jan;39(1):114–5 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Cholangiopancreatography with magnetic resonance: a new approach for assessing the bile and pancreatic ducts] Rocha MS, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):226–8 (13 ref.) **(Por)**
[Potentialities of magnetic-resonance tomography in morphologic research] Kosourov AK, et al. **Morfologiia** 1999;115(2):59–64 (66 ref.) **(Rus)**
[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul–Aug;(4):50–9 (101 ref.) **(Rus)**
[A magnetic resonance (MR) follow-up of central nervous system (CNS) tumors in children: recurrence or radionecrosis?] Bernácer Borja M, et al. **An Esp Pediatr** 1998 Dec;49(6):638–40 (14 ref.) **(Spa)**
[The Leydig-cell testicular tumor. A case report with magnetic resonance images] Tamayo Ruiz JC, et al. **Arch Esp Urol** 1998 Nov;51(9):928–31 (10 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Safety aspects of switched gradient fields. Schaefer DJ. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):731–48 (51 ref.)
Safety aspects of radiofrequency power deposition in magnetic resonance. Schaefer DJ. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):775–89 (47 ref.)
MR safety at high magnetic fields. Schenck JF. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):715–30 (128 ref.)

INSTRUMENTATION

Cardiac MR imaging. Smith HJ. **Acta Radiol** 1999 Jan; 40(1):1–22 (99 ref.)
Functional magnetic resonance imaging: the basics of blood-oxygen-level dependent (BOLD) imaging. Forster BB, et al. **Can Assoc Radiol J** 1998 Oct;49(5):320–9 (43 ref.)
High-resolution magnetic resonance imaging of the anal sphincter using a dedicated endoanal receiver coil. deSouza NM, et al. **Eur Radiol** 1999;9(3):436–43 (26 ref.)
CT and MR colography (virtual colonoscopy): status report. Rex DK. **J Clin Gastroenterol** 1998 Oct;27(3):199–203 (37 ref.)
Detection of MRI brain contour using isotropic and anisotropic diffusion filter. A comparative study. Zingale R, et al. **J Neurosurg Sci** 1998 Jun;42(2):111–4 (15 ref.)
MRI for physiology and function: technical advances in MRI of congenital heart disease. Haselgrove JC, et al. **Semin Roentgenol** 1998 Jul;33(3):293–301 (20 ref.)
Very-high-field magnetic resonance imaging: instrumentation and safety issues. Kelley DA, et al. **Top Magn Reson Imaging** 1999 Feb;10(1):79–89 (28 ref.)
[Diffusion-weighted imaging in acute stroke] Jakob PM, et al. **Nervenarzt** 1998 Aug;69(8):683–93 (63 ref.) (Eng. Abstr.) **(Ger)**
[MRI follow-up in multiple sclerosis. A guideline for quality assurance] Gass A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):581–6 (51 ref.) (Eng. Abstr.) **(Ger)**
[Breath-hold MR cholangiopancreatography with 2D and 3D-FASE sequence at 0.5 tesla: evaluation based on measurements of signal intensity ratio and contrast-to-noise ratio] Ichikawa T, et al. **Nippon Rinsho** 1998 Nov; 56(11):2817–24 (16 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Magnetic resonance imaging and temporal lobe epilepsy. King D, et al. **Acta Neurol Scand** 1998 Oct;98(4):217–23 (70 ref.)
The roles of diffusion and perfusion MR imaging in acute stroke management [editorial; comment] Latchaw RE. **AJNR Am J Neuroradiol** 1999 Jun–Jul;20(6):957–9 (15 ref.) Comment on: AJNR Am J Neuroradiol 1999 Jun–Jul;20(6):983–9.
Interventional MR imaging: concepts, systems, and applications in neuroradiology. Lewin JS. **AJNR Am J Neuroradiol** 1999 May;20(5):735–48 (63 ref.)
Newer sequences for spinal MR imaging: smorgasbord or succotash of acronyms? Ross JS. **AJNR Am J Neuroradiol** 1999 Mar;20(3):361–73 (82 ref.)
Image-guided surgical navigation in otology and neurotology. Selesnick SH, et al. **Am J Otol** 1999 Sep; 20(5):688–93; discussion 693–7 (21 ref.)
Functional magnetic resonance imaging of brain reward circuitry in the human. Breiter HC, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:523–47 (76 ref.)
Magnetic resonance imaging in urology. Probert JL, et al. **BJU Int** 1999 Feb;83(3):201–14 (88 ref.)
Monitoring cancer by magnetic resonance. Stubbs M, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:86–94 (58 ref.)
Magnetic resonance cholangiopancreatography in the evaluation of pancreatic duct pathology. Larena JA, et al. **Br J Radiol** 1998 Oct;71(850):1100–4 (6 ref.)
Dynamic contrast-enhanced MRI studies in human tumours. Padhani AR. **Br J Radiol** 1999 May;72(857):427–31 (37 ref.)
Visual attention: spotlight on the primary visual cortex. Sengpiel F, et al. **Curr Biol** 1999 May 6;9(9):R318–21 (16 ref.)
Magnetic resonance imaging in multiple sclerosis. Clanet M, et al. **Curr Opin Neurol** 1998 Aug;11(4):299–303 (44 ref.)
Direct intraoperative recordings from the hippocampal formation: relation with quantitative volumetric MRI. Morrell F, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:112–22 (36 ref.)
Fast magnetic resonance imaging techniques. Chen Q, et al. **Eur J Radiol** 1999 Feb;29(2):90–100 (40 ref.)
Exploring brain function with magnetic resonance imaging. Di Salle F, et al. **Eur J Radiol** 1999 May;30(2):84–94 (126 ref.)
Fast magnetic resonance imaging of the lung. Hatabu H, et al. **Eur J Radiol** 1999 Feb;29(2):114–32 (84 ref.)
Fast magnetic resonance imaging of liver. Ichikawa T, et al. **Eur J Radiol** 1999 Mar;29(3):186–210 (79 ref.)
Ultrafast MR imaging of the pelvis. Outwater EK. **Eur J Radiol** 1999 Mar;29(3):233–44 (54 ref.)
Functional imaging of the kidneys with fast MRI techniques. Prasad PV, et al. **Eur J Radiol** 1999 Feb;29(2):133–48 (54 ref.)
Fast magnetic resonance imaging of the heart. Sakuma H, et al. **Eur J Radiol** 1999 Feb;29(2):101–13 (68 ref.)
Fast MR imaging for evaluating the pancreaticobiliary system. Takehara Y. **Eur J Radiol** 1999 Mar;29(3):211–32 (58 ref.)
MR contribution in surgery of epilepsy. Meiners LC, et al. **Eur Radiol** 1999;9(3):493–507 (57 ref.)
Contrast mechanisms in MR imaging. Nitz WR, et al. **Eur Radiol** 1999;9(6):1032–46 (35 ref.)
Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Reimer P, et al. **Eur Radiol** 1998; 8(7):1198–204 (38 ref.)
Magnetic resonance imaging and ischaemic stroke. Tress BM. **Hosp Med** 1999 May;60(5):343–7 (20 ref.)
Automated extraction and variability analysis of sulcal neuroanatomy. Le Goualher G, et al.

IEEE Trans Med Imaging 1999 Mar;18(3):206–17 (47 ref.)
Mathematical analysis of lead field expansions. Taylor JG, et al. **IEEE Trans Med Imaging** 1999 Feb;18(2):151–63 (27 ref.)
Breathhold cardiac MRI and MRA. Hartnell GG. **Int J Card Imaging** 1999 Apr;15(2):139–50 (32 ref.)
Linear and nonlinear current density reconstructions. Fuchs M, et al. **J Clin Neurophysiol** 1999 May;16(3):267–95 (45 ref.)
Ultrafast fetal MR images of intracranial teratoma. Peng SS, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):318–9 (8 ref.)
Electroanatomic imaging using magnetic catheter tracking in the diagnosis and treatment of atrial arrhythmias. Wilber DJ, et al. **J Electrocardiol** 1998;31 Suppl:92–100 (25 ref.)
Unexpected MR–T1 enhancement of endocrine liver metastases with mangafodipir. Mathieu D, et al. **J Magn Reson Imaging** 1999 Aug;10(2):193–5 (15 ref.)
The role of magnetic resonance imaging studies in multiple sclerosis. Cerreta E. **J Neurosci Nurs** 1998 Oct; 30(5):290–301 (91 ref.)
Detection of MRI brain contour using isotropic and anisotropic diffusion filter. A comparative study. Zingale R, et al. **J Neurosurg Sci** 1998 Jun;42(2):111–4 (15 ref.)
Human cardiac spectroscopy. Bottomley PA, et al. **MAGMA** 1998 Sep;6(2–3):157–60 (13 ref.)
1H MR spectroscopy in patients with mesial temporal epilepsy. Hájek M, et al. **MAGMA** 1998 Dec;7(2):95–114 (135 ref.)
Basic pulse sequences for fast cardiac MR imaging. Jakob PM, et al. **MAGMA** 1998 Sep;6(2–3):84–7 (12 ref.)
Myocardial tagging for the analysis left ventricular function. Nagel E, et al. **MAGMA** 1998 Sep;6(2–3):91–3 (0 ref.)
Motion artifact control in body MR imaging. Barish MA, et al. **Magn Reson Imaging Clin N Am** 1999 May; 7(2):289–301 (12 ref.)
Whole-body MR imaging. Practical issues, clinical applications, and future directions. Eustace SJ, et al. **Magn Reson Imaging Clin N Am** 1999 May;7(2):209–36 (57 ref.)
Ventilation–perfusion MR imaging of the lung. Hatabu H, et al. **Magn Reson Imaging Clin N Am** 1999 May; 7(2):379–92, x (47 ref.)
Vascularity assessment of breast lesions with gadolinium–enhanced MR imaging. Hylton NM. **Magn Reson Imaging Clin N Am** 1999 May;7(2):411–20, x (37 ref.)
Clinical applications of half–Fourier (HASTE) MR sequences in abdominal imaging. Regan F. **Magn Reson Imaging Clin N Am** 1999 May;7(2):275–88 (37 ref.)
SMASH imaging. Sodickson DK, et al. **Magn Reson Imaging Clin N Am** 1999 May;7(2):237–54, vii–viii (33 ref.)
Virtual endoscopy in abdominal MR imaging. Wildermuth S, et al. **Magn Reson Imaging Clin N Am** 1999 May; 7(2):349–64 (28 ref.)
Techniques for MR imaging of joints in sports medicine. Zlatkin MB. **Magn Reson Imaging Clin N Am** 1999 Feb; 7(1):1–21, vii (103 ref.)
Innovations in neuroimaging and neurointerventional radiology. Tung GA, et al. **Med Health R I** 1999 Jun; 82(6):207–12 (23 ref.)
Review and evaluation of MRI nonuniformity corrections for brain tumor response measurements. Velthuizen RP, et al. **Med Phys** 1998 Sep;25(9):1655–66 (63 ref.)
Newer magnetic resonance techniques and disease activity in multiple sclerosis: new concepts and new concerns. Filippi M, et al. **Mult Scler** 1998 Dec;4(6):469–70 (16 ref.)
Clinical applications of intracranial perfusion MR imaging. Lev MH, et al. **Neuroimaging Clin N Am** 1999 May; 9(2):309–31 (105 ref.)
Diffusion MR imaging. Theory and applications. Rowley HA, et al. **Neuroimaging Clin N Am** 1999 May;9(2):343–61 (94 ref.)
Do acute lesions of Wernicke's encephalopathy show contrast enhancement? Report of three cases and review of the literature. Mascalchi M, et al. **Neuroradiology** 1999 Apr;41(4):249–54 (20 ref.)
Brain biopsy using high–field strength interventional magnetic resonance imaging. Hall WA, et al. **Neurosurgery** 1999 Apr;44(4):807–13; discussion 813–4 (11 ref.)
Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. Nelson SJ, et al. **NMR Biomed** 1999 May;12(3):123–38 (119 ref.)
In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. Rudin M, et al. **NMR Biomed** 1999 Apr;12(2):69–97 (357 ref.)
Functional magnetic resonance imaging: imaging techniques and contrast mechanisms. Howseman AM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1179–94 (128 ref.)
Event–related functional magnetic resonance imaging: modelling, inference and optimization. Josephs O, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1215–28 (44 ref.)
Functional mapping in the human brain using high magnetic fields. Uğurbil K, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1195–213 (112 ref.)
Fat suppression in MR imaging: techniques and pitfalls [published erratum appears in Radiographics 1999 Jul–Aug;19(4):1092] Delfaut EM, et al. **Radiographics** 1999 Mar–Apr;19(2):373–82 (28 ref.)
Chemical shift: the artifact and clinical tool revisited. Hood MN, et al. **Radiographics** 1999 Mar–Apr;19(2):357–71 (44 ref.)
CT and MR imaging of benign hepatic and biliary tumors. Horton KM, et al. **Radiographics** 1999 Mar–Apr; 19(2):431–51 (30 ref.)
Detection of lipid in abdominal tissues with opposed–phase gradient–echo images at 1.5 T: techniques and diagnostic importance. Outwater EK, et al. **Radiographics** 1998 Nov–Dec;18(6):1465–80 (31 ref.)
Endoluminal MR imaging of the rectum and anus: technique, applications, and pitfalls. Stoker J, et al. **Radiographics** 1999 Mar–Apr;19(2):383–98 (20 ref.)
Diagnostic pitfalls of MR cholangiopancreatography in the evaluation of the biliary tract and gallbladder. Watanabe Y, et al. **Radiographics** 1999 Mar–Apr;19(2):415–29 (25 ref.)
Diffusion–weighted magnetic resonance imaging: theory and potential applications to child neurology. Beaulieu C, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):87–100 (41 ref.)
Functional magnetic resonance imaging in children. Logan WJ. **Semin Pediatr Neurol** 1999 Jun;6(2):78–86 (55 ref.)
MRI for physiology and function in congenital heart disease: functional assessment of the heart preoperatively and postoperatively. Fogel MA, et al. **Semin Roentgenol** 1998 Jul;33(3):239–51 (71 ref.)
Congenital heart disease: measuring physiology with MRI. Reddy GP, et al. **Semin Roentgenol** 1998 Jul;33(3):228–38 (39 ref.)
CT and MR assessment of osteoporosis. Grampp S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):2–9 (66 ref.)
Endoluminal MR imaging of diseases of the anus and rectum. Stoker J, et al. **Semin Ultrasound CT MR** 1999 Feb; 20(1):47–55 (36 ref.)
Beyond anatomy: MR imaging as a molecular diagnostic tool. Calvo BF, et al. **Surg Oncol Clin N Am** 1999 Jan; 8(1):171–83 (43 ref.)
A review of magnetic resonance (MR) imaging of trabecular bone micro–architecture: contribution to the prediction of biomechanical properties and fracture prevalence. Majumdar S. **Technol Health Care** 1998 Dec;6(5–6):321–7 (31 ref.)
New architectural parameters derived from micro–MRI for the prediction of trabecular bone strength. Wehrli FW, et al. **Technol Health Care** 1998 Dec;6(5–6):307–20 (47 ref.)
High spatial resolution functional magnetic resonance imaging at very–high–magnetic field. Chen W, et al. **Top Magn Reson Imaging** 1999 Feb;10(1):63–78 (111 ref.)
Very–high–field magnetic resonance imaging: instrumentation and safety issues. Kelley DA, et al. **Top Magn Reson Imaging** 1999 Feb;10(1):79–89 (28 ref.)
Cognitive functional magnetic resonance imaging at very–high–field: eye movement control. Luna B, et al. **Top Magn Reson Imaging** 1999 Feb;10(1):3–15 (68 ref.)
Looking deeper into vertebrate development. Jacobs RE, et al. **Trends Cell Biol** 1999 Feb;9(2):73–6 (18 ref.)
[What to expect from MRi in the investigation of the central nervous system?] Le Bihan D. **Bull Acad Natl Med** 1999; 183(3):487–505; discussion 505–7 (47 ref.) (Eng. Abstr.) **(Fre)**
[Brain plasticity during development: physiological bases and functional MRI approach] Hertz–Pannier L. **J Neuroradiol** 1999 Mar;26(1):S66–74 (62 ref.) (Eng. Abstr.) **(Fre)**
[Practical aspects of realization of a functional MRI] Le Bihan D, et al. **J Neuroradiol** 1999 Mar;26(1):S54–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Functional MRI: brain plasticity, brain disease and functional recovery] Lehéricy S, et al. **J Neuroradiol** 1999 Mar; 26(1):S75–81 (36 ref.) (Eng. Abstr.) **(Fre)**
[What is bright on T1 MRI scans?] de Kerviler E, et al. **J Radiol** 1998 Feb;79(2):117–26 (51 ref.) (Eng. Abstr.) **(Fre)**
[MRI visualization of multiple sclerosis lesions] Berry I, et al. **Rev Neurol (Paris)** 1998 Sep;154(8–9):607–17 (61 ref.) (Eng. Abstr.) **(Fre)**
[Magnetic resonance tomography with inhalation of polarized noble gases: new perspectives in functional imaging diagnosis of emphysema] Kauczor HU, et al. **Pneumologie** 1998 Oct;52(10):563–7 (22 ref.) (Eng. Abstr.) **(Ger)**
[Magnetic resonance tomography in stroke—its methodological bases and clinical use] Heiland S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):3–14 (51 ref.) (Eng. Abstr.) **(Ger)**
[Current techniques in MR imaging of cerebral infarction] Aoki S. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 Apr; 59(5):163–9 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Optimization of pulse sequences for MR cholangiopancreatography with FASE] Akiyama H, et al. **Nippon Rinsho** 1998 Nov;56(11):2813–6 (6 ref.) (Eng. Abstr.) **(Jpn)**
[MR cholangiopancreatography of Mirizzi syndrome and Lemmel syndrome] Doai K, et al. **Nippon Rinsho** 1998 Nov; 56(11):2933–8 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical usefulness of fat suppression technique for MR cholangiopancreatography (MRCP)] Dohke M, et al. **Nippon Rinsho** 1998 Nov;56(11):2870–3 (8 ref.) (Eng. Abstr.) **(Jpn)**
[The utilities and outlooks of MR cholangiography (MRCP) as a non contrast and noninvasive technique] Hachiya J, et al. **Nippon Rinsho** 1998 Nov;56(11):2747–54 (8 ref.) (Eng. Abstr.) **(Jpn)**
[FASE (fast advanced spin echo)] Higashi M. **Nippon Rinsho** 1998 Nov;56(11):2783–91 (20 ref.) (Eng. Abstr.) **(Jpn)**
[HASTE: features and clinical applications] Imura C. **Nippon Rinsho** 1998 Nov;56(11):2778–82 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Cystic lesions of the pancreas] Irimoto M, et al. **Nippon Rinsho** 1998 Nov;56(11):2902–6 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Maximum intensity projection (MIP) and multiplanar reformation (MPR) for post–processing cholangiopancreatographic data set—clinical application and pitfalls] Isogai S, et al. **Nippon Rinsho** 1998 Nov; 56(11):2760–7 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Usefulness of T2–weighted images using single shot fast spin echo (SSFSE) pulse sequence for the evaluation of pancreatobiliary diseases: comparison with MRCP using SSFSE] Kadoya M, et al. **Nippon Rinsho** 1998 Nov; 56(11):2836–41 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Efficacy of multidirection MRCP] Koike S, et al. **Nippon Rinsho** 1998 Nov;56(11):2808–12 (0 ref.) (Eng. Abstr.) **(Jpn)**
[PSIF/CE–FAST (fast gradient echo) and TSE (turbo spin echo)] Miyazaki T, et al. **Nippon Rinsho** 1998 Nov; 56(11):2773–7 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Characteristics and detectability of RARE technique] Murata K, et al. **Nippon Rinsho** 1998 Nov;56(11):2799–802 (2 ref.) (Eng. Abstr.) **(Jpn)**
[Ultrafast CT, MRI] Nakanishi T, et al. **Nippon Rinsho** 1998 Oct;56(10):2544–9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Optimal scan parameters of MRCP using HASTE] Nishio H, et al. **Nippon Rinsho** 1998 Nov;56(11):2803–7 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Single shot fast spin echo (SSFSE)] Nozaki A. **Nippon Rinsho** 1998 Nov;56(11):2792–7 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Elimination of artifacts in MRCP: technical consideration] Ohgi K, et al. **Nippon Rinsho** 1998 Nov;56(11):2854–8 (10 ref.) (Eng. Abstr.) **(Jpn)**
[MR cholangiography of congenital biliary malformations in infancy] Osada H, et al. **Nippon Rinsho** 1998 Nov; 56(11):2946–51 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Common bile ductal carcinoma, hilar cholangiocarcinoma: evaluation with MR cholangiography] Sato K, et al. **Nippon Rinsho** 1998 Nov;56(11):2928–32 (12 ref.) (Eng. Abstr.) **(Jpn)**
[MR cholangiopancreatography with single–shot fast–spin–echo sequences] Shiratori Y, et al. **Nippon Rinsho** 1998 Nov;56(11):2842–8 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical efficacy of suppression and visualization of the duodenal fluid in MR cholangiopancreatography using ferric ammonium citrate] Takahara T, et al. **Nippon Rinsho** 1998 Nov;56(11):2865–9 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Anatomic variants of the cystic duct and cysticohepatic junction: diagnosis with MR cholangiography] Tsunoda M, et al. **Nippon Rinsho** 1998 Nov;56(11):2918–22 (20 ref.) (Eng. Abstr.) **(Jpn)**
[MRCP in the diagnosis of pancreaticobiliary diseases—its progression and limitation] Sai J, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Mar;96(3):259–65 (23 ref.) **(Jpn)**
[Endodermal cyst of the cerebellopontine angle cistern: case report] Nakagawa S, et al. **No Shinkei Geka** 1999 May; 27(5):475–80 (21 ref.) (Eng. Abstr.) **(Jpn)**
[MR axonography: application of MRI] Nakada T. **No To Shinkei** 1998 Aug;50(8):712–8 (6 ref.) **(Jpn)**
[BOLD functional MRI: practical pitfalls] Nakada T. **Rinsho Shinkeigaku** 1999 Jan;39(1):39–41 (2 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Technology status evaluation: magnetic resonance cholangiopancreatography: November 1998. From the ASGE. American Society for Gastrointestinal Endoscopy. Carr–Locke DL, et al. **Gastrointest Endosc** 1999 Jun; 49(6):858–61 (22 ref.)

TRENDS

Recent advances in pediatric pulmonary imaging. Harty MP, et al. **Curr Opin Pediatr** 1998 Jun;10(3):227–35 (45 ref.)
Advances in abdominal MR imaging. Ferrucci JT. **Radiographics** 1998 Nov–Dec;18(6):1569–86 (86 ref.)

VETERINARY

Advanced imaging concepts: a pictorial glossary of CT and MRI technology. Tidwell AS, et al. **Clin Tech Small Anim Pract** 1999 May;14(2):65–111 (67 ref.)

MAGNETIC RESONANCE IMAGING, CINE

METHODS

Kinematic CT and MR imaging of the patellofemoral joint.

MAGNETIC RESONANCE IMAGING, CINE

Muhle C, et al. **Eur Radiol** 1999;9(3):508–18 (47 ref.)
Cardiac anatomy, mass and function--great vessels. Kenn W. **MAGMA** 1998 Sep;6(2–3):88–90 (10 ref.)
MRI for physiology and function in congenital heart disease: functional assessment of the heart preoperatively and postoperatively. Fogel MA, et al. **Semin Roentgenol** 1998 Jul;33(3):239–51 (71 ref.)

MAGNETIC RESONANCE IMAGING, ECHO-PLANAR see **ECHO-PLANAR IMAGING**

MAGNETIC RESONANCE IMAGING, FUNCTIONAL see **MAGNETIC RESONANCE IMAGING**

MAGNETIC RESONANCE SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

MAGNETICS

Transcranial magnetic stimulation during PET: reaching and verifying the target site. Paus T, et al.
Hum Brain Mapp 1998;6(5–6):399–402 (23 ref.)
Repetitive transcranial magnetic stimulation as a neuropsychiatric tool: present status and future potential. Post RM, et al. **J ECT** 1999 Mar;15(1):39–59 (88 ref.)
[Assay of protein phosphatase activities with phosphopeptide-magnetic bead conjugates] Kameshita I, et al. **Seikagaku** 1998 Nov;70(11):1360–3 (6 ref.) **(Jpn)**

DIAGNOSTIC USE

Transcranial magnetic stimulation: studying the brain–behaviour relationship by induction of 'virtual lesions'. Pascual-Leone A, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jul 29; 354(1387):1229–38 (88 ref.)

INSTRUMENTATION

Rare earth magnets in orthodontics: an overview. Noar JH, et al. **Br J Orthod** 1999 Mar;26(1):29–37 (51 ref.)
Transcranial cortical magnetic stimulation of lower-lip mimetic muscles: effect of coil position on motor evoked potentials. Rödel R, et al.
ORL J Otorhinolaryngol Relat Spec 1999 May–Jun; 61(3):119–25 (26 ref.)

THERAPEUTIC USE

Transcranial magnetic stimulation: applications in neuropsychiatry [comment] George MS, et al.
Arch Gen Psychiatry 1999 Apr;56(4):300–11 (148 ref.)
Comment on: Arch Gen Psychiatry 1999 Apr;56(4):315–20.
Transcranial magnetic stimulation in depression [editorial] Reid PD, et al. **Br J Psychiatry** 1998 Dec;173:449–52 (34 ref.)
Magnetoreception attributed to the efficacy of light therapy. Partonen T. **Med Hypotheses** 1998 Nov;51(5):447–8 (4 ref.)

MAGNETIZATION TRANSFER CONTRAST IMAGING see **MAGNETIC RESONANCE IMAGING**

MAGNETOENCEPHALOGRAPHY

Spatiotemporal EEG analysis and distributed source estimation in presurgical epilepsy evaluation. Michel CM, et al. **J Clin Neurophysiol** 1999 May;16(3):239–66 (67 ref.)
'Human see, human do' cortex. Salenius S.
Mol Psychiatry 1999 Jul;4(4):307–9 (14 ref.)
[Fluid-attenuated-inversion-recovery (FLAIR) imaging in the diagnosis of cerebral gliomas and metastases] Essig M, et al. **Radiologe** 1999 Feb;39(2):151–60 (32 ref.) (Eng. Abstr.) **(Ger)**
[Functional localization of the somatomotor area by magnetoencephalography] Nagamine T.
Rinsho Shinkeigaku 1999 Jan;39(1):42–3 (4 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Cerebral function revealed by transcranial magnetic stimulation. Cracco RQ, et al. **J Neurosci Methods** 1999 Jan;86(2):209–19 (80 ref.)
Oscillations of the human sensorimotor system as revealed by magnetoencephalography. Volkmann J. **Mov Disord** 1998;13 Suppl 3:73–6 (17 ref.)
Magnetoencephalography in the study of human somatosensory cortical processing. Hari R, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jul 29; 354(1387):1145–54 (99 ref.)

MAGNETOMETRY see **MAGNETICS**

MAGNOLIOPHYTA see **ANGIOSPERMS**

MAHAIM-TYPE PRE-EXCITATION see **PRE-EXCITATION, MAHAIM-TYPE**

MAIC see **MYCOBACTERIUM AVIUM COMPLEX**

MAIDENHAIR TREE see **GINKGO BILOBA**

MAILLARD REACTION

The naturally occurring furanones: formation and function from pheromone to food. Colin Slaughter J.
Biol Rev Camb Philos Soc 1999 Aug;74(3):259–76 (110 ref.)
[Maillard reaction products and chronic diabetic complications] Trivin F, et al. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):445–54 (53 ref.) **(Fre)**

MAINTENANCE

Maintenance work and asbestos-related cancers in the refinery and petrochemical sector. Finkelstein MM.
Am J Ind Med 1999 Feb;35(2):201–5 (18 ref.)

MAIZE see **CORN**

MAJOR CORE PROTEIN see **VIRAL CORE PROTEINS**

MAJOR CORE PROTEINS, VIRAL see **VIRAL CORE PROTEINS**

MAJOR DEPRESSIVE DISORDER see **DEPRESSION, INVOLUTIONAL**

MAJOR HISTOCOMPATIBILITY COMPLEX

see related
GENES, MHC CLASS I

Natural selection at major histocompatibility complex loci of vertebrates. Hughes AL, et al. **Annu Rev Genet** 1998; 32:415–35 (59 ref.)
Description and prediction of peptide–MHC binding: the 'human MHC project'. Buus S. **Curr Opin Immunol** 1999 Apr;11(2):209–13 (47 ref.)
MHC-linked control of murine SLE. Ibnou-Zekri N, et al. **Curr Top Microbiol Immunol** 1999;246:275–80; discussion 281 (28 ref.)
Molecular genetics of the human MHC complement gene cluster. Yu CY. **Exp Clin Immunogenet** 1998;15(4):213–30 (105 ref.)
New perspectives on mate choice and the MHC. Jordan WC, et al. **Heredity** 1998 Sep;81 (Pt 3):239–45 (57 ref.)
New perspectives on mate choice and the MHC. Jordan WC, et al. **Heredity** 1998 Aug;81 (Pt 2):127–33 (55 ref.)
What sharks can tell us about the evolution of MHC genes. Bartl S. **Immunol Rev** 1998 Dec;166:317–31 (99 ref.)
Human pathogen subversion of antigen presentation. Brodsky FM, et al. **Immunol Rev** 1999 Apr;168:199–215 (215 ref.)
The major histocompatibility complex in swine. Chardon P, et al. **Immunol Rev** 1999 Feb;167:179–92 (66 ref.)
Cattle MHC: evolution in action? Ellis SA, et al.
Immunol Rev 1999 Feb;167:159–68 (72 ref.)
Major histocompatibility genes in cyprinid fishes: theory and practice. Stet RJ, et al. **Immunol Rev** 1998 Dec;166:301–16 (97 ref.)
Intramolecular and intermolecular spreading during the course of organ allograft rejection. Suciu-Foca N, et al. **Immunol Rev** 1998 Aug;164:241–6 (42 ref.)
Modulation by epitope-specific antibodies of class II MHC-restricted presentation of the tetanus toxin antigen. Watts C, et al. **Immunol Rev** 1998 Aug;164:11–6 (22 ref.)
Natural killer cell reactivity: activation and cytolysis mechanism models, involving heat shock protein, haemopoietic histocompatibility, major histocompatibility complex and complement molecules. Manzo G.
Med Hypotheses 1998 Jul;51(1):5–9 (30 ref.)
Indirect recognition of allo MHC peptides--potential role in human transplantation [editorial] Watschinger B.
Nephrol Dial Transplant 1999 Jan;14(1):8–11 (29 ref.)
Impact of genetics on disease resistance. Lamont SJ.
Poult Sci 1998 Aug;77(8):1111–8 (96 ref.)
Upregulation of major histocompatibility complex-expression under ischemic conditions in experimental models. Shackleton CR. **Transplant Proc** 1998 Dec;30(8):4264–6 (6 ref.)
MHC structure and function. Thorsby E. **Transplant Proc** 1999 Feb–Mar;31(1–2):713–6 (28 ref.)
[Primary immunodeficiencies and the major histocompatibility system] Gómez de la Concha E, et al. **Sangre (Barc)** 1999 Apr;44(2):123–6 (27 ref.) **(Spa)**

GENETICS

Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models. Ruuls SR, et al. **Am J Hum Genet** 1999 Aug;65(2):294–301 (38 ref.)
The new heterozygosity theory of mate choice and the MHC. Brown JL. **Genetica** 1998–99;104(3):215–21 (87 ref.)
Balancing selection and MHC. Hedrick PW. **Genetica** 1998–99;104(3):207–14 (66 ref.)
The MHC big bang. Abi Rached L, et al. **Immunol Rev** 1999 Feb;167:33–44 (55 ref.)
The mouse major histocompatibility complex: some assembly required. Amadou C, et al. **Immunol Rev** 1999 Feb; 167:211–21 (106 ref.)
Recombination within the human MHC. Carrington M.
Immunol Rev 1999 Feb;167:245–56 (106 ref.)
Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease. Dawkins R, et al. **Immunol Rev** 1999 Feb;167:275–304 (167 ref.)
Toward an evolutionary genomics of the avian Mhc. Edwards SV, et al. **Immunol Rev** 1999 Feb;167:119–32 (85 ref.)
Insight into the primordial MHC from studies in ectothermic vertebrates. Flajnik MF, et al. **Immunol Rev** 1999 Feb; 167:59–67 (77 ref.)
Gene conversion can create new MHC alleles. Högstrand K, et al. **Immunol Rev** 1999 Feb;167:305–17 (69 ref.)
The chromosomal duplication model of the major histocompatibility complex. Kasahara M. **Immunol Rev** 1999 Feb;167:17–32 (121 ref.)
Gene organisation determines evolution of function in the chicken MHC. Kaufman J, et al. **Immunol Rev** 1999 Feb; 167:101–17 (81 ref.)
Comparative organization and function of the major histocompatibility complex of domesticated cattle. Lewin HA, et al. **Immunol Rev** 1999 Feb;167:145–58 (90 ref.)
Monomorphism and polymorphism at Mhc DRB loci in domestic and wild ruminants. Mikko S, et al.
Immunol Rev 1999 Feb;167:169–78 (60 ref.)
Comparative genome organization of the major histocompatibility complex: lessons from the Felidae. O'Brien SJ, et al. **Immunol Rev** 1999 Feb;167:133–44 (99 ref.)
Effect of gene conversion on polymorphic patterns at major histocompatibility complex loci. Ohta T. **Immunol Rev** 1999 Feb;167:319–25 (25 ref.)
Virtual reality in the MHC. Parham P. **Immunol Rev** 1999 Feb;167:5–15 (21 ref.)
Evolution of the mammalian MHC: natural selection, recombination, and convergent evolution. Yeager M, et al. **Immunol Rev** 1999 Feb;167:45–58 (77 ref.)
Organization of the canine major histocompatibility complex: current perspectives. Wagner JL, et al. **J Hered** 1999 Jan–Feb;90(1):35–8 (29 ref.)
Potential of gene transfer for the induction of specific unresponsiveness to alloantigens in vivo. Wood KJ.
Transplant Proc 1999 Feb–Mar;31(1–2A):19S–20S (16 ref.)
[Functional analysis of non-HLA genes within MHC region with knockout-mouse technology] Matsumoto M.
Seikagaku 1999 May;71(5):323–32 (55 ref.) **(Jpn)**
[Participation of major histocompatibility system alleles in the susceptibility to rheumatic fever] Vargas-Alarcón G, et al. **Arch Inst Cardiol Mex** 1999 Jan–Feb;69(1):72–9 (54 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cytotoxic T lymphocytes in resistance to tuberculosis. Mazzaccaro RJ, et al. **Adv Exp Med Biol** 1998;452:85–101 (73 ref.)
MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Cunha-Neto E. **Braz J Med Biol Res** 1999 Feb; 32(2):199–205 (45 ref.)
Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Warren EH, et al. **Curr Opin Hematol** 1998 Nov;5(6):429–33 (38 ref.)
MHC restriction to T-cell autoaggression: an emerging understanding of IDDM pathogenesis. Choudhuri K, et al. **Diabetes Metab Rev** 1998 Dec;14(4):285–301 (108 ref.)
Balancing selection and MHC. Hedrick PW. **Genetica** 1998–99;104(3):207–14 (66 ref.)
Origin, functions and chemistry of H-2 regulated odorants. Yamazaki K, et al. **Genetica** 1998–99;104(3):235–40 (59 ref.)
The major histocompatibility complex: an important factor in every stage of pregnancy from preimplantation to birth? Part I. Christiansen OB. **Hum Reprod Update** 1999 Mar–Apr;5(2):91–3 (8 ref.)
Placental HLA-G protein expression in vivo: where and what for? Le Bouteiller P, et al. **Hum Reprod Update** 1999 May–Jun;5(3):223–33 (101 ref.)
Toward an evolutionary genomics of the avian Mhc. Edwards SV, et al. **Immunol Rev** 1999 Feb;167:119–32 (85 ref.)
Gene conversion can create new MHC alleles. Högstrand K, et al. **Immunol Rev** 1999 Feb;167:305–17 (69 ref.)
Gene organisation determines evolution of function in the chicken MHC. Kaufman J, et al. **Immunol Rev** 1999 Feb; 167:101–17 (81 ref.)
Effect of gene conversion on polymorphic patterns at major histocompatibility complex loci. Ohta T. **Immunol Rev** 1999 Feb;167:319–25 (25 ref.)
Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy. Engberg J, et al. **Immunotechnology** 1999 Mar;4(3–4):273–8 (40 ref.)
Specific tolerance induction and organ transplantation. de Vries-van der Zwan A, et al. **Leuk Lymphoma** 1998 Sep; 31(1–2):131–42 (56 ref.)
Isolating the molecular suspect: HLA transgenic mice in the study of human autoimmune disease. Hall FC, et al.
Rheumatology (Oxford) 1999 Aug;38(8):697–704 (72 ref.)
[HLA-peptide complex and immunity-related diseases] Matsushita S. **Rinsho Byori** 1999 Jun;47(6):511–8 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Antigen peptide/MHC complex as an initiator of a signal for lymphocyte T activation] Kuśnierczyk P.
Postepy Hig Med Dosw 1999;53(2):331–41 (24 ref.) (Eng. Abstr.) **(Pol)**
[Dendritic cells and their role in pathology] Coronato S, et al. **Medicina (B Aires)** 1998;58(2):209–18 (69 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The major histocompatibility complex and mate choice: inbreeding avoidance and selection of good genes. Grob B, et al. **Exp Clin Immunogenet** 1998;15(3):119–29 (104 ref.)
Olfactory cues associated with the major histocompatibility complex. Eggert F, et al. **Genetica** 1998–99;104(3):191–7 (35 ref.)
Developmental aspects of kin recognition. Hepper PG, et al. **Genetica** 1998–99;104(3):199–205 (41 ref.)
A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and feto–maternal interactions. Fernandez N, et al. **Hum Reprod Update** 1999 May–Jun;5(3):234–48 (154 ref.)
Comparative organization and function of the major histocompatibility complex of domesticated cattle. Lewin HA, et al. **Immunol Rev** 1999 Feb;167:145–58 (90 ref.)

MALABSORPTION SYNDROMES

DIAGNOSIS

D-xylose testing. Craig RM, et al. **J Clin Gastroenterol** 1999 Sep;29(2):143–50 (112 ref.)

ETIOLOGY

The mechanisms of fat malabsorption in cystic fibrosis patients [editorial] Kalivianakis M, et al. **Nutrition** 1999 Feb;15(2):167–9 (23 ref.)
[Involvement of the small intestine in systemic scleroderma] Marie I, et al. **Rev Med Interne** 1999 Jun;20(6):504–13 (86 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

I. Glucose galactose malabsorption. Wright EM. **Am J Physiol** 1998 Nov;275(5 Pt 1):G879–82 (24 ref.)

PREVENTION & CONTROL

Practitioners' guide to meeting the vitamin B-12 recommended dietary allowance for people aged 51 years and older. Ho C, et al. **J Am Diet Assoc** 1999 Jun; 99(6):725–7 (24 ref.)

MALACOPLAKIA

ETIOLOGY

Pulmonary malacoplakia associated with Rhodococcus equi infection in patients with AIDS: case report and review. Guerrero MF, et al. **Clin Infect Dis** 1999 Jun;28(6):1334–6 (15 ref.)

RADIOGRAPHY

[Renal malakoplakia: prognostic aspects] Vidal V, et al. **J Radiol** 1999 Mar;80(3):309–11 (9 ref.) (Eng. Abstr.) **(Fre)**

MALAR BONE see **ZYGOMA**

MALARIA

see related

ANTIMALARIALS

A historical review of the F-1 strain of Anopheles freeborni as a host and vector for studies of malaria. Collins WE, et al. **J Am Mosq Control Assoc** 1999 Jun;15(2):117–27 (165 ref.)
Viewpoint: management of malaria--working with the private sector. Brugha R, et al. **Trop Med Int Health** 1999 May;4(5):402–6 (40 ref.)
[Pregnancy and malaria. Study of 143 cases in French Guyana] Carles G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27(8):798–805 (34 ref.) (Eng. Abstr.) **(Fre)**
[Malaria. Epidemiology, etiology, physiopathology, diagnosis, disease progression, treatment and principles of individual prevention] Simon F, et al. **Rev Prat** 1999 Jan 1;49(1):81–7 (2 ref.) **(Fre)**
[Drug resistant malaria] Kano S. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):205–8 (7 ref.) **(Jpn)**
[Malaria] Ohtomo H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):152–5 (8 ref.) **(Jpn)**

BLOOD

Protein trafficking in malaria-infected erythrocytes. Foley M, et al. **Int J Parasitol** 1998 Nov;28(11):1671–80 (69 ref.)

COMPLICATIONS

Guillain-Barre syndrome following malaria. Kanjalkar M, et al. **J Infect** 1999 Jan;38(1):48–50 (14 ref.)

DIAGNOSIS

[Simple malaria attack] Touze JE, et al. **Rev Prat** 1998 Feb 1;48(3):268–72 (12 ref.) (Eng. Abstr.) **(Fre)**
[Laboratory diagnosis of protozoan and parasitic infections. 1. Protozoan infections. a. Malaria] Karino S. **Rinsho Byori** 1998 Nov;Suppl 108:175–81 (10 ref.) **(Jpn)**

DRUG THERAPY

Making malaria-treatment policy in the face of drug resistance. Bloland PB, et al. **Ann Trop Med Parasitol** 1999 Jan;93(1):5–23 (54 ref.)
Malaria: new developments in treatment and prevention. Newton P, et al. **Annu Rev Med** 1999;50:179–92 (55 ref.)
Drug resistance in malaria. White NJ. **Br Med Bull** 1998; 54(3):703–15 (56 ref.)
Bisquinoline antimalarials: their role in malaria chemotherapy. Raynes K. **Int J Parasitol** 1999 Mar; 29(3):367–79 (90 ref.)
The role of the qinghaosu derivatives in the treatment of severe malaria. Boele van Hensbroek M. **Med Trop (Mars)** 1998;58(3 Suppl):59–60 (10 ref.)
What role can public health institutions play in drug development for the poor? A case study of artesunate. Gomes M, et al. **Med Trop (Mars)** 1998;58(3 Suppl):97–100 (10 ref.)
Intrarectal artemisinin derivatives. Nosten F, et al. **Med Trop (Mars)** 1998;58(3 Suppl):63–4 (10 ref.)
Qinghaosu in combinations. White NJ. **Med Trop (Mars)** 1998;58(3 Suppl):85–8 (19 ref.)
Artemisinin and derivatives in the treatment of uncomplicated malaria. White NJ, et al. **Med Trop (Mars)** 1998;58(3 Suppl):54–6 (28 ref.)
Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. van Agtmael MA, et al. **Trends Pharmacol Sci** 1999 May;20(5):199–205 (110 ref.)
[Malaria prophylaxis] Bouchaud O, et al. **Rev Prat** 1998 Feb 1;48(3):279–86 (28 ref.) (Eng. Abstr.) **(Fre)**
[Simple malaria attack] Touze JE, et al. **Rev Prat** 1998 Feb 1;48(3):268–72 (12 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The return of swamp fever: malaria in Canadians [editorial; comment] MacLean JD, et al. **CMAJ** 1999 Jan 26; 160(2):211–2 (12 ref.) Comment on: CMAJ 1999 Jan 26;160(2):195–200.
How does molecular epidemiology help to understand malaria? [editorial] Beck HP. **Trop Med Int Health** 1999 Jan;4(1):1–3 (27 ref.)
[Epidemiological stratification of malaria in the Comoro archipelago] Blanchy S, et al. **Bull Soc Pathol Exot** 1999 Jul;92(3):177–84 (37 ref.) (Eng. Abstr.) **(Fre)**
[Malaria, a worldwide scourge] Danis M, et al. **Rev Prat** 1998 Feb 1;48(3):254–7 (11 ref.) (Eng. Abstr.) **(Fre)**
[Evolutionary ecology and epidemiology of interactions between Anopheles mosquitoes and malaria] Koella JC. **Schweiz Med Wochenschr** 1999 Aug 10;129(31–32):1106–10 (13 ref.) (Eng. Abstr.) **(Ger)**
[Clinico-epidemiological analysis of imported malaria in Donetsk region (1979–1997)] Tulnov VA, et al. **Ter Arkh** 1998;70(11):43–5 (8 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Pediatric imported malaria in New York: delayed diagnosis. Viani RM, et al. **Clin Pediatr (Phila)** 1999 Jun;38(6):333–7 (33 ref.)

IMMUNOLOGY

Immune effector mechanisms in malaria. Good MF, et al. **Curr Opin Immunol** 1999 Aug;11(4):412–9 (74 ref.)
Malaria immunity: an overview on B cell responses and assays for detection of humoral immune responses. Kabilan L. **Indian J Med Sci** 1998 Sep;52(9):399–402 (19 ref.)

MORTALITY

Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Coleman PG, et al. **Trop Med Int Health** 1999 Mar; 4(3):175–86 (48 ref.)

PARASITOLOGY

Adhesive proteins of the malaria parasite. Coppel RL, et al. **Curr Opin Microbiol** 1998 Aug;1(4):472–81 (84 ref.)
Multispecies Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1999 Feb;85(1):12–8 (76 ref.)
How does molecular epidemiology help to understand malaria? [editorial] Beck HP. **Trop Med Int Health** 1999 Jan;4(1):1–3 (27 ref.)
[Human transmission and plasmodium resistance] Le Bras J, et al. **Rev Prat** 1998 Feb 1;48(3):258–63 (15 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Malaria prevention in travelers. Juckett G. **Am Fam Physician** 1999 May 1;59(9):2523–30, 2535–6 (13 ref.)
Malaria. The latest in advice for travellers. Pellegrini M, et al. **Aust Fam Physician** 1999 Jul;28(7):683–8 (8 ref.)
Malaria: existing methods of vector control and molecular entomology. Curtis CF, et al. **Br Med Bull** 1998; 54(2):311–25 (61 ref.)
The return of swamp fever: malaria in Canadians [editorial; comment] MacLean JD, et al. **CMAJ** 1999 Jan 26; 160(2):211–2 (12 ref.) Comment on: CMAJ 1999 Jan 26;160(2):195–200.
Evaluation of WHO's antimalaria programme during the past 50 years and prospects for the future. Farid MA. **East Mediterr Health J** 1998;4 Suppl:S111–24 (21 ref.)
Prevention of malaria in travelers. Baird JK, et al. **Med Clin North Am** 1999 Jul;83(4):923–44, vi (77 ref.)
Can anything be done to maintain the effectiveness of pyrethroid-impregnated bednets against malaria vectors? Curtis CF, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29;353(1376):1769–75 (46 ref.)
Challenges in the development of antimalarial drugs with causal prophylactic activity. Chulay JD. **Trans R Soc Trop Med Hyg** 1998 Nov–Dec;92(6):577–9 (25 ref.)
Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Coleman PG, et al. **Trop Med Int Health** 1999 Mar; 4(3):175–86 (48 ref.)
[Progresses in the study of tropical diseases and parasitology in China, 1997] Zheng J. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):902–3 (0 ref.) **(Chi)**
[Malaria prophylaxis] Bouchaud O, et al. **Rev Prat** 1998 Feb 1;48(3):279–86 (28 ref.) (Eng. Abstr.) **(Fre)**
[Malaria, a worldwide scourge] Danis M, et al. **Rev Prat** 1998 Feb 1;48(3):254–7 (11 ref.) (Eng. Abstr.) **(Fre)**
[Antimalarial vaccination: advances and controversies] Le Bras M, et al. **Rev Prat** 1998 Feb 1;48(3):291–5 (25 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

Odor-mediated behavior of Afrotropical malaria mosquitoes. Takken W, et al. **Annu Rev Entomol** 1999;44:131–57 (195 ref.)
Periodic infectivity of Plasmodium gametocytes to the vector. A review. Gautret P, et al. **Parasite** 1999 Jun; 6(2):103–11 (69 ref.)
The evolution of multiple drug resistance in malaria parasites. Mackinnon MJ, et al. **Trans R Soc Trop Med Hyg** 1998 Mar–Apr;92(2):188–95 (33 ref.)
[Human transmission and plasmodium resistance] Le Bras J, et al. **Rev Prat** 1998 Feb 1;48(3):258–63 (15 ref.) (Eng. Abstr.) **(Fre)**
[Evolutionary ecology and epidemiology of interactions between Anopheles mosquitoes and malaria] Koella JC. **Schweiz Med Wochenschr** 1999 Aug 10;129(31–32):1106–10 (13 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Periodic infectivity of Plasmodium gametocytes to the vector. A review. Gautret P, et al. **Parasite** 1999 Jun; 6(2):103–11 (69 ref.)

MALARIA, FALCIPARUM

[Tropical malaria] Popov AF, et al. **Klin Med (Mosk)** 1998; 76(10):11–4 (53 ref.) **(Rus)**

COMPLICATIONS

Haematuria. Mukherjee B. **J Indian Med Assoc** 1998 Apr; 96(4):121–2 (0 ref.)
Neurological manifestations of malaria : an update. Garg RK, et al. **Neurol India** 1999 Jun;47(2):85–91 (62 ref.)
[Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?] Mariéthoz S, et al. **Ann Chir Plast Esthet** 1999 Feb;44(1):81–8 (77 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Travel outside our frontiers: parasitic diseases not to be missed] Pelloux H. **Rev Med Suisse Romande** 1999 Feb; 119(2):93–7 (24 ref.) **(Fre)**
[Severe malaria] Gachot B, et al. **Rev Prat** 1998 Feb 1; 48(3):273–8 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Looareesuwan S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):533–41 (22 ref.)
Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Price R, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):547–55 (25 ref.)
Pharmacokinetics and pharmacodynamics of qinghaosu derivatives: how do they impact on the choice of drug and the dosage regimens? Kyle DE, et al. **Med Trop (Mars)** 1998;58(3 Suppl):38–44 (32 ref.)
How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Li Y, et al. **Med Trop (Mars)** 1998;58(3 Suppl):9–12 (26 ref.)
The rational use of qinghaosu and its derivatives: what is the future of new compounds? Looareesuwan S, et al. **Med Trop (Mars)** 1998;58(3 Suppl):89–92 (10 ref.)
Treatment of uncomplicated malaria with artemisinin derivatives. A systematic review of randomised controlled trials. McIntosh HM, et al. **Med Trop (Mars)** 1998;58(3 Suppl):57–8 (1 ref.)
Artemisinin antimalarials: mechanisms of action and resistance. Meshnick SR. **Med Trop (Mars)** 1998;58(3 Suppl):13–7 (56 ref.)
Use of artemisinin derivatives for the control of malaria

[published erratum appears in Med Trop (Mars) 1998;58(4):368] Nosten F, et al. **Med Trop (Mars)** 1998;58(3 Suppl):45–9 (13 ref.)

Positioning, labelling, and medical information control of co-artemether tablets (CPG 56697): a fixed novel combination of artemether and benflumetol. Novartis Co-Artemether International Development Team. Skelton-Stroud P, et al. **Med Trop (Mars)** 1998;58(3 Suppl):77–81 (4 ref.)

Research on new antimalarial drugs and the use of drugs in combination at the Bangkok Hospital for Tropical Diseases. Looareesuwan S, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):344–54 (82 ref.)

Consensus recommendation on the treatment of malaria in Southeast Asia. Looareesuwan S, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):355–60 (54 ref.)

The treatment of chloroquine-resistant malaria. van Vugt M, et al. **Trop Doct** 1999 Jul;29(3):176–9 (23 ref.)

[Severe malaria] Gachot B, et al. **Rev Prat** 1998 Feb 1; 48(3):273–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[1998 malaria therapy] Markwalder K, et al. **Schweiz Med Wochenschr** 1998 Sep 5;128(36):1313–27 (142 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

New insights into the epidemiology of malaria relevant for disease control. Snow RW, et al. **Br Med Bull** 1998; 54(2):293–309 (50 ref.)

Malaria miscellany. Isaäcson M. **J Travel Med** 1999 Jun; 6(2):155–7 (9 ref.)

Genetic structure and dynamics of Plasmodium falciparum infections in the Kilombero region of Tanzania. Babiker HA, et al. **Trans R Soc Trop Med Hyg** 1999 Feb;93 Suppl 1:11–4 (29 ref.)

GENETICS

Thalassemia and malaria: new insights into an old problem. Clegg JB, et al. **Proc Assoc Am Physicians** 1999 Jul–Aug; 111(4):278–82 (35 ref.)

The immunogenetics of resistance to malaria. Hill AV. **Proc Assoc Am Physicians** 1999 Jul–Aug;111(4):272–7 (35 ref.)

IMMUNOLOGY

Vaccines against the blood stages of falciparum malaria. Miller LH, et al. **Adv Exp Med Biol** 1998;452:193–205 (45 ref.)

Antigenic variation in Plasmodium falciparum: mechanisms and consequences. Newbold CI. **Curr Opin Microbiol** 1999 Aug;2(4):420–5 (67 ref.)

IgE and tumor necrosis factor in malaria infection. Perlmann P, et al. **Immunol Lett** 1999 Jan;65(1–2):29–33 (43 ref.)

Is T-cell priming required for initiation of pathology in malaria infections? Riley EM. **Immunol Today** 1999 May; 20(5):228–33 (53 ref.)

Malaria vaccines [comment] Holder AA. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1167–9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1615–20.

Selected problems of malaria blood stage immunity. Perlmann P, et al. **Tokai J Exp Clin Med** 1998 Apr; 23(2):55–62 (71 ref.)

Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections. Smith T, et al. **Trans R Soc Trop Med Hyg** 1999 Feb;93 Suppl 1:59–64 (56 ref.)

PHYSIOPATHOLOGY

Molecular mechanisms of cytoadherence in malaria. Ho M, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1231–42 (101 ref.)

[Molecular analysis of Plasmodium falciparum infections in man] Mercereau-Puijalon O. **Transfus Clin Biol** 1999 Feb; 6(1):44–56 (35 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Malaria miscellany. Isaäcson M. **J Travel Med** 1999 Jun; 6(2):155–7 (9 ref.)

Mefloquine for malaria chemoprophylaxis 1992–1998: a review. Schlagenhauf P. **J Travel Med** 1999 Jun;6(2):122–33 (96 ref.)

[Malaria in airports and their neighborhoods] Giacomini T. **Rev Prat** 1998 Feb 1;48(3):264–7 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Iron chelation therapy for malaria: a review. Mabeza GF, et al. **Pharmacol Ther** 1999 Jan;81(1):53–75 (170 ref.)

[Treatment of infections of the current interest. 3) Malignant malaria] Otomo H. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2274–9 (4 ref.) **(Jpn)**

TRANSMISSION

[Malaria in airports and their neighborhoods] Giacomini T. **Rev Prat** 1998 Feb 1;48(3):264–7 (25 ref.) (Eng. Abstr.) **(Fre)**

[Imported Anopheles: in the luggage or from the airplane? A case of severe autochthonous malaria tropica near an airport] Praetorius F, et al. **Dtsch Med Wochenschr** 1999 Aug 27;124(34–35):998–1002 (10 ref.) (Eng. Abstr.) **(Ger)**

MALARIA VACCINES

Malaria vaccines [comment] Holder AA. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1167–9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1615–20.

[Antimalarial vaccination: advances and controversies] Le Bras M, et al. **Rev Prat** 1998 Feb 1;48(3):291–5 (25 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

From genomics to vaccines: malaria as a model system [comment] Hoffman SL, et al. **Nat Med** 1998 Dec; 4(12):1351–3 (12 ref.) Comment on: Nat Med 1998 Dec;4(12):1360–2.

IMMUNOLOGY

Vaccines against the blood stages of falciparum malaria. Miller LH, et al. **Adv Exp Med Biol** 1998;452:193–205 (45 ref.)

MALARIA, VIVAX

DIAGNOSIS

[Diagnostic and therapeutic difficulties with tertian malaria] Blum J, et al. **Schweiz Rundsch Med Prax** 1999 May 27; 88(22):985–91 (28 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Use of artemisinin derivatives for the control of malaria [published erratum appears in Med Trop (Mars) 1998;58(4):368] Nosten F, et al. **Med Trop (Mars)** 1998;58(3 Suppl):45–9 (13 ref.)

Consensus recommendation on the treatment of malaria in Southeast Asia. Looareesuwan S, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):355–60 (54 ref.)

[Diagnostic and therapeutic difficulties with tertian malaria] Blum J, et al. **Schweiz Rundsch Med Prax** 1999 May 27; 88(22):985–91 (28 ref.) (Eng. Abstr.) **(Ger)**

MALASSEZIA

[Pityriasis versicolor and Malassezia folliculitis] Katoh T, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(2):69–71 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Skin diseases associated with Malassezia furfur] Yamada T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):252–5 (15 ref.) **(Jpn)**

CLASSIFICATION

The role of Malassezia species in the ecology of human skin and as pathogens. Guého E, et al. **Med Mycol** 1998;36 Suppl 1:220–9 (83 ref.)

[Taxonomy of genus Malassezia: progress and problems] Makimura K, et al. **Nippon Ishinkin Gakkai Zasshi** 1999; 40(2):59–62 (23 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Pityrosporum species as a cause of allergy and infection. Faergemann J. **Allergy** 1999 May;54(5):413–9 (59 ref.)

The role of Malassezia species in the ecology of human skin and as pathogens. Guého E, et al. **Med Mycol** 1998;36 Suppl 1:220–9 (83 ref.)

[Fungi and atopic dermatitis] Hiruma M, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(2):79–83 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Cutaneous immune and inflammatory reactions to Malassezia furfur] Terui T, et al. **Nippon Ishinkin Gakkai Zasshi** 1999; 40(2):63–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

[Seborrhoeic dermatitis] Sei Y, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(2):73–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

PATHOGENICITY

Pityrosporum species as a cause of allergy and infection. Faergemann J. **Allergy** 1999 May;54(5):413–9 (59 ref.)

MALATE DEHYDROGENASE

CHEMISTRY

Malate dehydrogenase: distribution, function and properties. Musrati RA, et al. **Gen Physiol Biophys** 1998 Sep; 17(3):193–210 (83 ref.)

METABOLISM

Malate dehydrogenase: distribution, function and properties. Musrati RA, et al. **Gen Physiol Biophys** 1998 Sep; 17(3):193–210 (83 ref.)

MALATHION

POISONING

Hemorrhagic panesophagitis after acute organophosphorus poisoning. Koga H, et al. **Gastrointest Endosc** 1999 May; 49(5):642–3 (13 ref.)

MALD-MS see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MALE BREAST NEOPLASMS see **BREAST NEOPLASMS, MALE**

MALE PATTERN BALDNESS see **ALOPECIA**

MALIGNANCIES, POST-TRAUMATIC see **NEOPLASMS, POST-TRAUMATIC**

MALIGNANT CARCINOID SYNDROME

DIAGNOSIS

[Carcinoid syndrome: advances in diagnosis and treatment] Ortiz V, et al. **Rev Esp Enferm Dig** 1999 Jan;91(1):61–9 (74 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

[Carcinoid syndrome: advances in diagnosis and treatment] Ortiz V, et al. **Rev Esp Enferm Dig** 1999 Jan;91(1):61–9 (74 ref.) (Eng. Abstr.) **(Spa)**

MALIGNANT HYPERPYREXIA see **MALIGNANT HYPERTHERMIA**

MALIGNANT HYPERTHERMIA

Malignant hyperthermia [see comments] Denborough M. **Lancet** 1998 Oct 3;352(9134):1131–6 (57 ref.) Comment in: Lancet 1998 Nov 28;352(9142):1785. Comment in: Lancet 1998 Nov 28;352(9142):1785–6.

DIAGNOSIS

[Malignant anesthesia hyperthermia] Adnet P, et al. **Presse Med** 1998 Mar 7;27(9):427–33 (57 ref.) (Eng. Abstr.) **(Fre)**

[Malignant hyperthermia] Chastonay P, et al. **Rev Med Suisse Romande** 1999 Mar;119(3):191–202 (49 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Malignant anesthesia hyperthermia] Adnet P, et al. **Presse Med** 1998 Mar 7;27(9):427–33 (57 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Malignant hyperthermia] Otsu K. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1898–902 (26 ref.) **(Jpn)**

GENETICS

The anesthetic myopathies and malignant hyperthermias. Hogan K. **Curr Opin Neurol** 1998 Oct;11(5):469–76 (34 ref.)

PHYSIOPATHOLOGY

Control of calcium in skeletal muscle excitation-contraction coupling: implications for malignant hyperthermia. Wingertzahn MA, et al. **Mol Genet Metab** 1998 Oct; 65(2):113–20 (69 ref.)

[Sevoflurane in pediatric anesthesia. Malignant hyperthermia] Scholz J. **Anaesthesist** 1998 Nov;47 Suppl 1:S43–8 (53 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Malignant hyperthermia] Chastonay P, et al. **Rev Med Suisse Romande** 1999 Mar;119(3):191–202 (49 ref.) (Eng. Abstr.) **(Fre)**

MALIGNANT MELANOMA see **MELANOMA**

MALINGERING

DIAGNOSIS

Malingering assessment in behavioral toxicology: what, why, and how. Ben-Avi I, et al. **Am J Ind Med** 1998 Oct; 34(4):325–30 (32 ref.)

Current issues in the diagnosis and management of malingering. LoPiccolo CJ, et al. **Ann Med** 1999 Jun; 31(3):166–74 (22 ref.)

The detection of malingered psychosis. Resnick PJ. **Psychiatr Clin North Am** 1999 Mar;22(1):159–72 (62 ref.)

MALLEUS

INJURIES

Malleus-handle fracture: historical review and three new cases. Iurato S, et al. **Am J Otol** 1999 Jan;20(1):19–25 (51 ref.)

MALLORY-WEISS SYNDROME

[Mallory-Weiss syndrome] Tanabe S, et al. **Nippon Rinsho** 1998 Sep;56(9):2332–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

MALNUTRITION see **NUTRITION DISORDERS**

MALOCCLUSION

see related
MANDIBULAR ADVANCEMENT
ORTHODONTICS, CORRECTIVE
PROGNATHISM

COMPLICATIONS

Condylar axis position, as determined by the occlusion and measured by the CPI instrument, and signs and symptoms of temporomandibular dysfunction. Crawford SD. **Angle Orthod** 1999 Apr;69(2):103–15; discussion 115–6 (64 ref.)

Tooth position and speech—is there a relationship? Johnson NC, et al. **Angle Orthod** 1999 Aug;69(4):306–10 (42 ref.)

GENETICS

The heritability of malocclusion: Part 1—Genetics, principles and terminology. Mossey PA. **Br J Orthod** 1999 Jun; 26(2):103–13 (61 ref.)

PSYCHOLOGY

Psychological assessment of patients requesting orthognathic surgery and the relevance of body dysmorphic disorder. Cunningham SJ, et al. **Br J Orthod** 1998 Nov;25(4):293–8 (22 ref.)

THERAPY

Patients' anticipation of pain and pain-related side effects, and their perception of pain as a result of orthodontic treatment with fixed appliances. Firestone AR, et al. **Eur J Orthod** 1999 Aug;21(4):387–96 (38 ref.)

Management of space problems in the primary and mixed dentitions. Ngan P, et al. **J Am Dent Assoc** 1999 Sep; 130(9):1330–9 (52 ref.)

Common pediatric dental problems. Creighton PR. **Pediatr Clin North Am** 1998 Dec;45(6):1579–60 (21 ref.)

MALOCCLUSION, ANGLE CLASS II

DIAGNOSIS

Crossing the midline: a long-term case report. McCollum AG. **Am J Orthod Dentofacial Orthop** 1999 May; 115(5):559–62 (10 ref.)

ETIOLOGY

Early developmental traits in class II malocclusion. Varrela J. **Acta Odontol Scand** 1998 Dec;56(6):375–7 (21 ref.)

THERAPY

Temporomandibular disorders and mandibular function in relation to Class II malocclusion and orthodontic treatment. A controlled, prospective and longitudinal study. Henrikson T. **Swed Dent J Suppl** 1999;134:1–144 (131 ref.)

MALOCCLUSION, ANGLE CLASS III

see related
PROGNATHISM

MALONALDEHYDE see **MALONDIALDEHYDE**

MALONDIALDEHYDE

Lipid peroxidation-DNA damage by malondialdehyde. Marnett LJ. **Mutat Res** 1999 Mar 8;424(1-2):83–95 (48 ref.)

IMMUNOLOGY

Immune reactivity to proteins biotransformed by alcohol metabolites. Klassen LW, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):204S–207S (15 ref.)

MALONYL COA see **MALONYL COENZYME A**

MALONYL COENZYME A

METABOLISM

Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. Ruderman NB, et al. **Adv Exp Med Biol** 1998; 441:263–70 (31 ref.)

Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. Ruderman NB, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):295–308 (52 ref.)

PHYSIOLOGY

Malonyl-CoA, fuel sensing, and insulin resistance. Ruderman NB, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E1–E18 (152 ref.)

MALPRACTICE

see related
INSURANCE, LIABILITY

Strategic risk management: reducing malpractice claims through more effective patient-doctor communication. Virshup BB, et al. **Am J Med Qual** 1999 Jul-Aug; 14(4):153–9 (26 ref.)

The misplace of litigation in medical practice. Wood C. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):365–76 (20 ref.)

Medical malpractice: defending yourself. Yablon IG. **Instr Course Lect** 1999;48:699–703 (14 ref.)

Potential liabilities of medical directors for actions of EMTs. Hall SA. **Prehosp Emerg Care** 1998 Jan-Mar;2(1):76–80 (43 ref.)

Necrotizing fasciitis and malpractice claims. Fink S, et al. **South Med J** 1999 Aug;92(8):770–4 (30 ref.)

Act first and look up the law afterward?: medical malpractice and the ethics of defensive medicine. De Ville K. **Theor Med Bioeth** 1998 Dec;19(6):569–89 (96 ref.)

[A computerized system for regional management of incidents is now tested. A complement to the Lex Maria system, indicates unobserved risks (see comments)] Westerling R, et al. **Lakartidningen** 1999 Feb 3;96(5):486–8 (7 ref.) Comment in: Lakartidningen 1999 Feb 10;96(6):580. **(Swe)**

LEGISLATION & JURISPRUDENCE

Burden of proof: judging science and protecting public health in (and out of) the courtroom [see comments] Annas GJ. **Am J Public Health** 1999 Apr;89(4):490–3 (32 ref.) Comment in: Am J Public Health 1999 Apr;89(4):487–9.

Ethics, epidemiology, and law: the case of silicone breast implants [comment] Macklin R. **Am J Public Health** 1999 Apr;89(4):487–9 (10 ref.) Comment on: Am J Public Health 1999 Apr;89(4):484–7. Comment on: Am J Public Health 1999 Apr;89(4):490–3.

Product liability and prescription diet drug cocktail, Fen-Phen: a hard combination to swallow. Crisanti CA. **J Contemp Health Law Policy** 1998 Fall;15(1):207–44 (0 ref.)

Public trust and accountability for clinical performance: lessons from the national press reportage of the Bristol hearing [see comments] Davies HT, et al. **J Eval Clin Pract** 1999 Aug;5(3):335–42 (28 ref.) Comment in: J Eval Clin Pract 1999 Aug;5(3):343–6.

Practice guidelines and tort reform: the legal system confronts the technocratic wish. Matthews JR. **J Health Polit Policy Law** 1999 Apr;24(2):275–304 (40 ref.)

'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369–75 (4 ref.) Comment in: J Med Ethics 1998 Dec;24(6):363–4.

Legal issues in neonatal nursing: considerations for staff nurses and advanced practice nurses. Enzman Hagedorn MI, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May-Jun; 28(3):320–30 (29 ref.)

Strategies for reducing the risk of malpractice litigation in perinatal nursing. Koniak-Griffin D. **J Obstet Gynecol Neonatal Nurs** 1999 May-Jun;28(3):291–9 (33 ref.)

Fetal surveillance and monitoring legal issues revisited. McRae MJ. **J Obstet Gynecol Neonatal Nurs** 1999 May-Jun;28(3):310–9 (28 ref.)

Clinical practice guidelines before the law: sword or shield? [see comments] Pelly JE, et al. **Med J Aust** 1998 Sep 21; 169(6):330–3 (9 ref.) Comment in: Med J Aust 1998 Sep 21;169(6):292–3.

Introduction to notification, deposition, and court testimony: A primer for the defendant physician. Bounds JA. **Neurol Clin** 1999 May;17(2):335–43 (6 ref.)

Neurologic malpractice: the perspective of a patient's lawyer. Mackauf SH. **Neurol Clin** 1999 May;17(2):345–53 (4 ref.)

The neurologically impaired child and alleged malpractice at birth. Nelson KB. **Neurol Clin** 1999 May;17(2):283–93 (56 ref.)

Managed care liability: what is the proper remedy? Porter KD. **Neurol Clin** 1999 May;17(2):315–9 (9 ref.)

Medicolegal issues: headache. Saper JR. **Neurol Clin** 1999 May;17(2):197–214 (63 ref.)

Expert witness testimony: A trial judge's perspective. Weinstein JB. **Neurol Clin** 1999 May;17(2):355–62 (34 ref.)

Expert witness testimony: An update. Weintraub MI. **Neurol Clin** 1999 May;17(2):363–9 (27 ref.)

Documentation and informed consent. Weintraub MI. **Neurol Clin** 1999 May;17(2):371–81 (29 ref.)

Malpractice in psychotherapy. An overview. Slovenko R. **Psychiatr Clin North Am** 1999 Mar;22(1):1–15, v (63 ref.)

Managed care, liability, and ERISA. Stone AA. **Psychiatr Clin North Am** 1999 Mar;22(1):17–29 (40 ref.)

Risk management lessons from a review of 168 cataract surgery claims. Brick DC. **Surv Ophthalmol** 1999 Jan-Feb; 43(4):356–60 (0 ref.)

[Principles of medical liability and practice in medical imaging] Thibierge M, et al. **J Radiol** 1999 Jul;80(7):701–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Rights and responsibilities of the radiologist in determining indications and applying radiologic procedures] Schunk K. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):7–15 (29 ref.) (Eng. Abstr.) **(Ger)**

[Medical care as physical injury from the viewpoint of the law and jurisdiction] Gropp W. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):536–42 (34 ref.) (Eng. Abstr.) **(Ger)**

[Legal questions with regard to laparoscopic cholecystectomy] Laum HD. **Zentralbl Chir** 1999; 124(6):542–8 (27 ref.) (Eng. Abstr.) **(Ger)**

[Documentation in law and general practice] Röhlig HW. **Zentralbl Chir** 1999;124 Suppl 1:49–51 (4 ref.) (Eng. Abstr.) **(Ger)**

MALT see **CEREALS**

MALT LYMPHOMA see **LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE**

MALTA FEVER see **BRUCELLOSIS**

MALTASES see **ALPHA-GLUCOSIDASES**

MALTHUSIANISM see **POPULATION DYNAMICS**

MALTOSE

CHEMISTRY

On the molecular characteristics, compositional properties, and structural-functional mechanisms of maltodextrins: a review. Chronakis IS. **Crit Rev Food Sci Nutr** 1998 Oct; 38(7):599–637 (136 ref.)

METABOLISM

The ABC maltose transporter. Ehrmann M, et al. **Mol Microbiol** 1998 Aug;29(3):685–94 (93 ref.)

MAMMAE

CYTOLOGY

Mammary involution in dairy animals. Capuco AV, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):137–44 (38 ref.)

NF-kappaB and apoptosis in mammary epithelial cells. Clarkson RW, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):165–75 (76 ref.)

Clearance: the last and often forgotten stage of apoptosis. Fadok VA. **J Mammary Gland Biol Neoplasia** 1999 Apr; 4(2):203–11 (86 ref.)

Programmed cell death in the terminal endbud. Humphreys RC. **J Mammary Gland Biol Neoplasia** 1999 Apr; 4(2):213–20 (46 ref.)

Growth factors, apoptosis, and survival of mammary epithelial cells. Rosfjord EC, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):229–37 (89 ref.)

Adhesion-mediated signaling in the regulation of mammary epithelial cell survival. Streuli CH, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):183–91 (60 ref.)

Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells. Weaver VM, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):193–201 (57 ref.)

Control of milk secretion and apoptosis during mammary involution. Wilde CJ, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):129–36 (53 ref.)

DRUG EFFECTS

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. Labrie F, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):51–84 (224 ref.)

EMBRYOLOGY

Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison. Hovey RC, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan; 4(1):53–68 (98 ref.)

HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models. Kamalati T, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):69–77 (55 ref.)

Progesterone signaling and mammary gland morphogenesis. Shyamala G. **J Mammary Gland Biol Neoplasia** 1999 Jan; 4(1):89–104 (72 ref.)

ENZYMOLOGY

Matrix metalloproteinases and their expression in mammary gland. Uria JA, et al. **Cell Res** 1998 Sep;8(3):187–94 (20 ref.)

MAMMAE

GROWTH & DEVELOPMENT

Stem cells in breast epithelia. Li P, et al. **Int J Exp Pathol** 1998 Aug;79(4):193–206 (79 ref.)

The mammary gland: a model for development. Daniel CW, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):3–8 (29 ref.)

Parathyroid hormone–related protein: a developmental regulatory molecule necessary for mammary gland development. Dunbar ME, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):21–34 (69 ref.)

Regulation of mammary gland development by tissue interaction. Robinson GW, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):9–19 (32 ref.)

METABOLISM

Cloning of human genomic lactoferrin sequence and expression in the mammary glands of transgenic animals. Kim SJ, et al. **Adv Exp Med Biol** 1998;443:79–83 (23 ref.)

Lactoferrin secretion into mouse milk. Development of secretory activity, the localization of lactoferrin in the secretory pathway, and interactions of lactoferrin with milk iron. Neville MC, et al. **Adv Exp Med Biol** 1998;443:141–53 (39 ref.)

Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. Bequette BJ, et al. **J Dairy Sci** 1998 Sep;81(9):2540–59 (116 ref.)

PATHOLOGY

The comparative pathology of human and mouse mammary glands. Cardiff RD, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):105–22 (76 ref.)

PHYSIOLOGY

Cripto: a novel epidermal growth factor (EGF)–related peptide in mammary gland development and neoplasia. Salomon DS, et al. **Bioessays** 1999 Jan;21(1):61–70 (71 ref.)

Mammary involution in dairy animals. Capuco AV, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):137–44 (38 ref.)

NF-kappaB and apoptosis in mammary epithelial cells. Clarkson RW, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):165–75 (76 ref.)

Prolactin and mammary gland development. Horseman ND. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):79–88 (63 ref.)

Programmed cell death in the terminal endbud. Humphreys RC. **J Mammary Gland Biol Neoplasia** 1999 Apr; 4(2):213–20 (46 ref.)

Regulation of p53 and its targets during involution of the mammary gland. Jerry DJ, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):177–81 (44 ref.)

Transcription factor activities and gene expression during mouse mammary gland involution. Marti A, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):145–52 (53 ref.)

Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. Schorr K, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):153–64 (92 ref.)

Control of milk secretion and apoptosis during mammary involution. Wilde CJ, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):129–36 (53 ref.)

The role of CSF-1 in normal and neoplastic breast physiology. Sapi E, et al. **Proc Soc Exp Biol Med** 1999 Jan;220(1):1–8 (79 ref.)

RADIATION EFFECTS

Radiation-induced instability and its relation to radiation carcinogenesis. Ullrich RL, et al. **Int J Radiat Biol** 1998 Dec;74(6):747–54 (12 ref.)

VIROLOGY

SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Furth PA. **Dev Biol Stand** 1998; 94:281–7 (15 ref.)

MAMMALIAN ADENOVIRUSES see **MASTADENOVIRUS**

MAMMALS

Thermoregulatory competence and behavioral expression in the young of altricial species--revisited. Blumberg MS, et al. **Dev Psychobiol** 1998 Sep;33(2):107–23 (109 ref.)

Potential of assisted breeding techniques for the conservation of endangered mammalian species in captivity: a review. Bainbridge DR, et al. **Vet Rec** 1998 Aug 8;143(6):159–68 (137 ref.)

ANATOMY & HISTOLOGY

The neural substrate for 'learned' and 'nonlearned' activities in birds: a discussion of the organization of bulbar reticular premotor systems with side-lights on the mammalian situation. Dubbeldam JL. **Acta Anat (Basel)** 1998; 163(3):157–72 (84 ref.)

Synaptic-like microvesicles in mammalian pinealocytes. Redecker P. **Int Rev Cytol** 1999;191:201–55 (285 ref.)

Why do almost all mammals have seven cervical vertebrae? Developmental constraints, Hox genes, and cancer. Galis F. **J Exp Zool** 1999 Apr 15;285(1):19–26 (55 ref.)

Structure and diversity in mammalian accessory olfactory bulb. Meisami E, et al. **Microsc Res Tech** 1998 Dec 15; 43(6):476–99 (134 ref.)

CLASSIFICATION

SINEs of the perfect character [comment] Hillis DM. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9979–81 (34 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10261–6.

EMBRYOLOGY

Polarity in early mammalian development. Gardner RL. **Curr Opin Genet Dev** 1999 Aug;9(4):417–21 (50 ref.)

Mammalian sex determination: a molecular drama. Swain A, et al. **Genes Dev** 1999 Apr 1;13(7):755–67 (87 ref.)

A systematic molecular genetic approach to study mammalian germline development. Abe K, et al. **Int J Dev Biol** 1998;42(7 Spec No):1051–65 (134 ref.)

Cell differentiation in the embryonic mammalian spinal cord. Mayer-Pröschel M. **J Neural Transm Suppl** 1999;55:1–8 (40 ref.)

Genes, cells and organs: recent developments in the molecular genetics of mammalian sex determination. Greenfield A. **Mamm Genome** 1998 Sep;9(9):683–7 (47 ref.)

GENETICS

Foreign DNA in mammalian systems. Doerfler W, et al. **APMIS Suppl** 1998;84:62–8 (23 ref.)

Sry and Sox9: mammalian testis-determining genes. Koopman P. **Cell Mol Life Sci** 1999 Jun;55(6–7):839–56 (187 ref.)

The regional integration of retroviral sequences into the mosaic genomes of mammals. Rynditch AV, et al. **Gene** 1998 Nov 5;222(1):1–16 (160 ref.)

Hypoxia-mediated regulation of gene expression in mammalian cells. Shih SC, et al. **Int J Exp Pathol** 1998 Dec;79(6):347–57 (86 ref.)

Control of genes by mammalian retroposons. Tomilin NV. **Int Rev Cytol** 1999;186:1–48 (277 ref.)

Nuclear transfer in mammals: recent developments and future perspectives. Wolf E, et al. **J Biotechnol** 1998 Oct 27; 65(2–3):99–110 (100 ref.)

Genes, cells and organs: recent developments in the molecular genetics of mammalian sex determination. Greenfield A. **Mamm Genome** 1998 Sep;9(9):683–7 (47 ref.)

SINEs of the perfect character [comment] Hillis DM. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9979–81 (34 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10261–6.

Mitochondrial DNA in mammalian reproduction. Cummins J. **Rev Reprod** 1998 Sep;3(3):172–82 (111 ref.)

[Sex determination in mammals: state of the art] Berta P, et al. **Contracept Fertil Sex** 1999 Jun;27(6):423–33 (78 ref.) (Eng. Abstr.) **(Fre)**

[Family of hsp70 stress genes in mammals] Lisowska K, et al. **Postepy Biochem** 1998;44(3):179–92 (197 ref.) **(Pol)**

GROWTH & DEVELOPMENT

Neural development in metatherian and eutherian mammals: variation and constraint. Darlington RB, et al. **J Comp Neurol** 1999 Aug 30;411(3):359–68 (21 ref.)

[The mechanisms of onto- and gerontogenesis in representatives of the class of mammals] Arshavskiĭ IA. **Usp Fiziol Nauk** 1998 Oct-Dec;29(4):93–107 (49 ref.) **(Rus)**

IMMUNOLOGY

Antimicrobial peptides in mammalian and insect host defence. Lehrer RI, et al. **Curr Opin Immunol** 1999 Feb;11(1):23–7 (54 ref.)

Insect immunity: evolutionary roots of the mammalian innate immune system. Vilmos P, et al. **Immunol Lett** 1998 Jun; 62(2):59–66 (213 ref.)

METABOLISM

Energetics of free-ranging mammals, reptiles, and birds. Nagy KA, et al. **Annu Rev Nutr** 1999;19:247–77 (173 ref.)

Appropriate mammalian expression systems for biopharmaceuticals. Werner RG, et al. **Arzneimittelforschung** 1998 Aug;48(8):870–80 (28 ref.)

Mammalian phospholipase D structure and regulation. Frohman MA, et al. **Biochim Biophys Acta** 1999 Jul 30; 1439(2):175–86 (83 ref.)

Mammalian nitric oxide synthases. Stuehr DJ. **Biochim Biophys Acta** 1999 May 5;1411(2–3):217–30 (135 ref.)

Mammalian lysophospholipases. Wang A, et al. **Biochim Biophys Acta** 1999 Jul 9;1439(1):1–16 (195 ref.)

Purification and assay of mammalian group I and group IIa secretory phospholipase A2. Cho W, et al. **Methods Mol Biol** 1999;109:31–8 (16 ref.)

Nitrinergic neurons in the developing and adult human telencephalon: transient and permanent patterns of expression in comparison to other mammals. Judas M, et al. **Microsc Res Tech** 1999 Jun 15;45(6):401–19 (178 ref.)

Why adult mammalian intrafusal and extrafusal fibers contain different myosin heavy-chain isoforms. Walro JM, et al. **Trends Neurosci** 1999 Apr;22(4):180–4 (49 ref.)

[Calcitonin and stanniocalcin. Particular aspects of the endocrine regulation of phospho-calcium metabolism in mammals and fish] Barlet JP, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):281–90 (130 ref.) (Eng. Abstr.) **(Fre)**

[Male germ cells. A new source of estrogens in the mammalian testis] Carreau S, et al. **Ann Endocrinol (Paris)** 1998 Jul;59(2):79–92 (142 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Evolution of host adaptation in Salmonella enterica. Bäumler AJ, et al. **Infect Immun** 1998 Oct;66(10):4579–87 (123 ref.)

PHYSIOLOGY

Control of cross-bridge cycling by myosin light chain phosphorylation in mammalian smooth muscle. Butler TM, et al. **Acta Physiol Scand** 1998 Dec;164(4):389–400 (56 ref.)

The medial extended amygdala in male reproductive behavior. A node in the mammalian social behavior network. Newman SW. **Ann N Y Acad Sci** 1999 Jun 29; 877:242–57 (103 ref.)

Mammalian sex determination: joining pieces of the genetic puzzle. Jiménez R, et al. **Bioessays** 1998 Sep;20(9):696–9 (24 ref.)

Entrainment of the circadian system of mammals by nonphotic cues. Hastings MH, et al. **Chronobiol Int** 1998 Sep;15(5):425–45 (112 ref.)

Evolution of daily torpor and hibernation in birds and mammals: importance of body size. Geiser F. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):736–9 (37 ref.)

Scaling of dimensions of small intestines in non-ruminant eutherian mammals and its significance for absorptive mechanisms. Pappenheimer JR. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Sep; 121(1):45–58 (111 ref.)

Evidence for diverse pathways of hypophysiotropic hormone transport in mammals. Anthony EL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):365–74 (34 ref.)

Regulation of appetite and body weight in seasonal mammals. Mercer JG. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):295–303 (64 ref.)

The specification of olfactory neurons. Ebrahimi FA, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):453–7 (36 ref.)

Factors controlling hair-cell regeneration/repair in the inner ear. Staecker H, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):480–7 (52 ref.)

In vitro studies of cochlear excitation. Ulfendahl M, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):475–9 (30 ref.)

The mechanics of quadrupedal locomotion. 'How is the body propelled by muscles?'. Schamhardt HC. **Eur J Morphol** 1998 Dec;36(4–5):272–9 (14 ref.)

Understanding quadrupedal locomotion. Weijs WA. **Eur J Morphol** 1998 Dec;36(4–5):270–1 (5 ref.)

Molecular aspects of mammalian ovulation. Tsafriri A, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):1–11 (140 ref.)

Voltage dependent calcium channels in mammalian spermatozoa. Benoff S. **Front Biosci** 1998 Dec 1; 3:D1220–40 (254 ref.)

Role of fertilization promoting peptide (FPP) in modulating mammalian sperm function. Fraser LR. **Front Biosci** 1998 Dec 1;3:D1187–91 (34 ref.)

Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Rubin E, et al. **Front Biosci** 1998 Dec 1;3:D1209–19 (90 ref.)

The role of carbohydrates in mammalian sperm-egg interactions: how important are carbohydrate epitopes? Zara J, et al. **Front Biosci** 1998 Oct 15;3:D1028–38 (96 ref.)

Arginine vasopressin as a neurotransmitter in brain. Reghunandanan V, et al. **Indian J Exp Biol** 1998 Jul; 36(7):635–43 (103 ref.)

Evoked otoacoustic emissions arise by two fundamentally different mechanisms: a taxonomy for mammalian OAEs. Shera CA, et al. **J Acoust Soc Am** 1999 Feb;105(2 Pt 1):782–98 (118 ref.)

Cellular distribution of the calcium-binding proteins parvalbumin, calbindin, and calretinin in the neocortex of mammals: phylogenetic and developmental patterns. Hof PR, et al. **J Chem Neuroanat** 1999 Feb;16(2):77–116 (198 ref.)

Review: The role of leukaemia inhibitory factor in the establishment of pregnancy. Vogiagis D, et al. **J Endocrinol** 1999 Feb;160(2):181–90 (82 ref.)

Osmoregulation in the mammalian kidney: the role of organic osmolytes. Grunewald RW, et al. **J Exp Zool** 1999 Jun 1;283(7):708–24 (153 ref.)

Glutathione and signal transduction in the mammalian CNS. Janáky R, et al. **J Neurochem** 1999 Sep;73(3):889–902 (99 ref.)

The Parkes Lecture. Heat and the testis. Setchell BP. **J Reprod Fertil** 1998 Nov;114(2):179–94 (258 ref.)

Neuronal control of mammalian vocalization, with special reference to the squirrel monkey. Jürgens U. **Naturwissenschaften** 1998 Aug;85(8):376–88 (53 ref.)

Love: an emergent property of the mammalian autonomic nervous system. Porges SW. **Psychoneuroendocrinology** 1998 Nov;23(8):837–61 (60 ref.)
Volatile anesthetics significantly suppress central and peripheral mammalian sodium channels. Duch DS, et al. **Toxicol Lett** 1998 Nov 23;100–101:255–63 (47 ref.)
[Physiological and sensorial determinism of maternal behavior in mammals] Lévy F. **Contracept Fertil Sex** 1998 Oct;26(10):718–27 (78 ref.) (Eng. Abstr.) **(Fre)**
[The biological clock in mammals: structure and function] Lewandowski MH. **Postepy Hig Med Dosw** 1999; 53(3):405–22 (40 ref.) (Eng. Abstr.) **(Pol)**
[Can the nervous system functions of mammals be restored during deep cooling without warming? New facts and the evolution of views] Ivanov KP. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):73–89 (68 ref.) (Eng. Abstr.) **(Rus)**
[FMRFa and FMRFamide-like peptides (FaRPs) in the pathogenesis of shock] Tiniakov RL, et al. **Usp Fiziol Nauk** 1998 Jul–Sep;29(3):56–65 (62 ref.) (Eng. Abstr.) **(Rus)**
[The role of the striatum in the evolution of the mammalian forebrain] Tolkunov BF. **Zh Evol Biokhim Fiziol** 1998 Jul–Aug;34(4):392–400 (43 ref.) **(Rus)**

MAMMAPLASTY

see related
BREAST IMPLANTS

METHODS

[Mammoplasty for symmetry of the contralateral breast and its oncologic value] Lanfrey E, et al. **Ann Chir Plast Esthet** 1997 Apr;42(2):160–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[Breast reconstruction] Brewaeys P, et al. **Rev Med Liege** 1998 Aug;53(8):483–9 (27 ref.) (Eng. Abstr.) **(Fre)**
[Breast reconstruction after mastectomy for cancer] Chavoin JP, et al. **Rev Prat** 1998 Jan 1;48(1):67–70 (15 ref.) (Eng. Abstr.) **(Fre)**
[Esthetic breast surgery] Nievergelt JK. **Ther Umsch** 1999 Apr;56(4):176–81 (4 ref.) (Eng. Abstr.) **(Ger)**

MAMMARY ARTERIES

Does a LIMA side branch ever need occlusion? (Why I don't think so) [editorial; comment] Kern MJ. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):307–9 (20 ref.) Comment on: Cathet Cardiovasc Diagn 1998 Nov;45(3):301–6.

ULTRASONOGRAPHY

[The functional study of the blood flow of internal mammary artery grafts via transthoracic Doppler echocardiography (editorial; comment)] Carreras F. **Rev Esp Cardiol** 1999 Apr;52(4):259–60 (11 ref.) Comment on: Rev Esp Cardiol 1999 Apr;52(4):253–8. **(Spa)**

MAMMARY CANCER VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

MAMMARY DYSPLASIA see **FIBROCYSTIC DISEASE OF BREAST**

MAMMARY GLANDS see **BREAST**

MAMMARY GLANDS, ANIMAL see **MAMMAE**

MAMMARY NEOPLASMS

CHEMICALLY INDUCED

Active cell death (apoptosis) and cellular proliferation as indicators of exposure to carcinogens. Schulte-Hermann R, et al. **IARC Sci Publ** 1999;(146):273–85 (57 ref.)

DRUG THERAPY

Inhibition of mammary cancer by citrus flavonoids. Guthrie N, et al. **Adv Exp Med Biol** 1998;439:227–36 (42 ref.)
Influence of inulin and oligofructose on breast cancer and tumor growth. Taper HS, et al. **J Nutr** 1999 Jul;129(7 Suppl):1488S–91S (25 ref.)

METABOLISM

Cripto: a novel epidermal growth factor (EGF)–related peptide in mammary gland development and neoplasia. Salomon DS, et al. **Bioessays** 1999 Jan;21(1):61–70 (71 ref.)

PHYSIOPATHOLOGY

The role of CSF-1 in normal and neoplastic breast physiology. Sapi E, et al. **Proc Soc Exp Biol Med** 1999 Jan;220(1):1–8 (79 ref.)

PREVENTION & CONTROL

Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Lamartiniere CA, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1400S–1405S (40 ref.)

MAMMARY NEOPLASMS, EXPERIMENTAL

DRUG THERAPY

Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl) ethylenediamine] platinum(II). Gust R, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):261–70 (31 ref.)
[Bisphosphonates in the adjuvant therapy of breast cancer--pathophysiology, animal models, and clinical experiences] Diel IJ. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):64–71 (47 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Mammary gland carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats: possible mechanisms. Snyderwine EG. **Cancer Lett** 1999 Sep 1;143(2):211–5 (22 ref.)
Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity. Hilakivi-Clarke L, et al. **Mol Cell Biochem** 1998 Nov; 188(1–2):5–12 (82 ref.)

GENETICS

The genetic components of susceptibility to breast cancer in the rat. Shepel LA, et al. **Prog Exp Tumor Res** 1999; 35:158–69 (23 ref.)

MAMMARY TUMOR VIRUSES, MOUSE

IMMUNOLOGY

Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Acha-Orbea H, et al. **Immunol Rev** 1999 Apr;168:287–303 (130 ref.)

MAMMOGRAPHY

Breast dosimetry. Dance DR, et al. **Appl Radiat Isot** 1999 Jan;50(1):185–203 (77 ref.)
Mammographic densities and breast cancer risk. Boyd NF, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec; 7(12):1133–44 (135 ref.)
Imaging breasts with silicone implants. Azavedo E, et al. **Eur Radiol** 1999;9(2):349–55 (60 ref.)
Benefits and risks of screening mammography for women in their forties: a statistical appraisal [see comments] Berry DA. **J Natl Cancer Inst** 1998 Oct 7;90(19):1431–9 (43 ref.) Comment in: J Natl Cancer Inst 1999 Feb 17;91(4):382–4.
Ten-year risk of false positive screening mammograms and clinical breast examinations. Rosenberg K. **J Nurse Midwifery** 1998 Sep–Oct;43(5):394–5 (1 ref.)
The false-negative mammogram. Huynh PT, et al. **Radiographics** 1998 Sep–Oct;18(5):1137–54; quiz 1243–4 (27 ref.)
Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging. Feig SA. **Semin Nucl Med** 1999 Jan;29(1):3–15 (50 ref.)
Breast cancer imaging. Hurd TC, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):1–15 (50 ref.)
[Ductal carcinoma in situ of the breast: role of imaging] Netter E, et al. **J Radiol** 1998 Jul;79(7):651–8 (62 ref.) (Eng. Abstr.) **(Fre)**
[Mammography screening for breast cancer] Drożdż W, et al. **Przegl Lek** 1998;55(12):663–8 (27 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

[Mammography and radiation risk (see comments)] Jung H. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):336–43 (20 ref.) (Eng. Abstr.) Comment in: Rofo Fortschr Geb Rontgenstr Neuen Bildge 1998 Oct;169(4):335. **(Ger)**

INSTRUMENTATION

Imaging-guided core biopsies in the breast. Soo MS. **South Med J** 1998 Nov;91(11):994–1000 (21 ref.)

METHODS

Silicone breast implants: a review. Hadden WE. **Australas Radiol** 1998 Nov;42(4):296–302 (26 ref.)
Advances in breast imaging. Reynolds HE. **Hematol Oncol Clin North Am** 1999 Apr;13(2):333–48, v (59 ref.)
Analysis of mammographic density and breast cancer risk from digitized mammograms. Byng JW, et al. **Radiographics** 1998 Nov–Dec;18(6):1587–98 (44 ref.)
[Mammography or ultrasound in the breast cancer diagnosis] Iwaszkiewicz K, et al. **Pol Merkuriusz Lek** 1998 Sep; 5(27):185–6 (11 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Current issues in mammographic breast cancer screening. Rickard MT. **Hosp Med** 1999 May;60(5):325–8 (25 ref.)
Quality assurance in mammography: artifact analysis. Hogge JP, et al. **Radiographics** 1999 Mar–Apr;19(2):503–22 (15 ref.)
Quality control and artifacts in mammography. Newman J. **Radiol Technol** 1998 Sep–Oct;70(1):61–76; quiz 77–80 (27 ref.)

TRENDS

[Mammographic screening starting in the fifth or sixth decade of life] Saeger HD, et al. **Chirurg** 1999 Apr;70(4):380–3 (23 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

Managed care organizations and mammography: opportunities to serve underserved women. Reid WM, et al. **Women Health** 1999;28(4):13–28 (76 ref.)
Breast screening practices among Russian immigrant women in Israel. Remennick LI. **Women Health** 1999;28(4):29–51 (36 ref.)

MAMMOGRAPHY, ULTRASONIC see **ULTRASONOGRAPHY, MAMMARY**

MAMMOTROPIC HORMONE, PITUITARY see **PROLACTIN**

MAMMOTROPIC HORMONE, PLACENTAL see **PLACENTAL LACTOGEN**

MAMMOTROPIN see **PROLACTIN**

MAN (TAXONOMY) see **HOMINIDAE**

MANAGED CARE PROGRAMS

Renal disease in the managed care setting: selection and monitoring of outcome criteria. Hannah R, et al. **Am J Kidney Dis** 1999 Apr;33(4 Suppl 1):S1–24 (55 ref.)
Promises and perils of managed care for older patients with cardiac disease. Friesinger GC, et al. **Cardiol Clin** 1999 Feb; 17(1):67–77, viii (83 ref.)
Mental health assessment of young children in a managed care environment. Schaefer M. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):425–37 (11 ref.)
Simple, sensible preventive measures for managed care settings. Waltzer KB. **Geriatrics** 1998 Oct;53(10):65–8, 75–7, 81; quiz 82 (29 ref.)
Making Medicaid managed care research relevant. Gold M. **Health Serv Res** 1999 Feb;33(6):1639–50 (13 ref.)
Improving physicians' relationships with patients. Clark W, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S45–50 (46 ref.)
Nursing work redesign in response to managed care. Hoover KW. **J Nurs Adm** 1998 Nov;28(11):9–18 (54 ref.)
Preserving midwifery practice in a managed care environment [see comments] Williams DR. **J Nurse Midwifery** 1999 Jul–Aug;44(4):375–83 (54 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.
A strategic approach to occupational injuries. Comstock ML. **Occup Med** 1998 Oct–Dec;13(4):823–40, v (23 ref.)
Asthma in managed care. Lozano P, et al. **Pediatr Ann** 1999 Jan;28(1):74–80 (41 ref.)
Problems with managed mental health care for multicultural populations. Dana RH. **Psychol Rep** 1998 Aug;83(1):283–94 (43 ref.)
Implementation of disease management guidelines in patients with advanced ovarian cancer. Hensley ML, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 1):46–51 (22 ref.)
Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Schink JC. **Semin Oncol** 1999 Feb;26(1 Suppl 1):2–7 (31 ref.)
Diabetes in the managed care setting: a prospective plan. Grundel BL, et al. **South Med J** 1999 May;92(5):459–64 (24 ref.)
[Appropriate use of clinical tests in health-insurance managed medical care] Mori M. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1985–92 (4 ref.) **(Jpn)**

ECONOMICS

Commercial managed care. Reynolds S. **Cancer Invest** 1999; 17(6):434–40 (10 ref.)
Escalating health care costs: managed care organizations. Wehrmacher WH, et al. **Compr Ther** 1998 Nov–Dec; 24(11–12):596–600 (6 ref.)
Getting the incentives right for children. Glied S. **Health Serv Res** 1998 Oct;33(4 Pt 2):1143–60 (35 ref.)
Financial incentives: current realities and challenges for physicians. Gold M. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S6–S12 (17 ref.)
RBRVS (Medicare Resource-Based Relative Value Scale) revisited. Harris-Shapiro J. **J Health Care Finance** 1998 Winter;25(2):49–54 (0 ref.)
Cost analysis in the Department of Veterans Affairs: consensus and future directions. Swindle R, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS3–8 (13 ref.)
The era of managed care: the struggle of cost containment and compassionate, effective care of persons with HIV/AIDS. Gallagher DM. **Nurs Clin North Am** 1999 Mar;34(1):227–35 (8 ref.)
24-hour programs: great idea or unrealistic? Igoe JA, et al. **Occup Med** 1998 Oct–Dec;13(4):727–33, iv (16 ref.)
The market for occupational medicine managed care. Leone

FH, et al. **Occup Med** 1998 Oct-Dec;13(4):869-79, v (4 ref.)
[Managed care in Germany: legal and economic aspects of its transferability] König HH, et al. **Gesundheitswesen** 1999 Jun;61(6):274-9 (18 ref.) (Eng. Abstr.) **(Ger)**
[Managed care--a model also for ambulatory medical care in Germany?] Schucht C, et al.
Z Arztl Fortbild Qualitatssich 1998 Dec;92(10):685-9 (32 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Medicare+Choice appeal procedures: reconciling due process rights and cost containment. Gladieux JE.
Am J Law Med 1999;25(1):61-116 (0 ref.)
State regulation of managed care: the impact on children. Anderson GF. **Future Child** 1998 Summer-Fall;8(2):76-92 (70 ref.)
The spread of state any willing provider laws. Ohsfeldt RL, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1537-62 (26 ref.)
Disclosure of operating practices by managed-care organizations to consumers of healthcare: obligations of informed consent. Khanna V, et al. **J Clin Ethics** 1998 Fall; 9(3):291-6 (27 ref.)
Standards of care and standard form contracts: distinguishing patient rights and consumer rights in managed care. Mariner WK. **J Contemp Health Law Policy** 1998 Fall; 15(1):1-55 (0 ref.)
Error in medicine: legal impediments to U.S. reform. Liang BA. **J Health Polit Policy Law** 1999 Feb;24(1):27-58 (101 ref.)
Is utilization review the practice of medicine? Implications for managed care administrators. Andresen JS.
J Leg Med 1998 Sep;19(3):431-54 (158 ref.)
The emerging convergence of the doctrine of informed consent and judicial reinterpretation of the Employee Retirement Income Security Act. Blackmon W.
J Leg Med 1998 Sep;19(3):377-95 (101 ref.)
Managed care liability: what is the proper remedy? Porter KD. **Neurol Clin** 1999 May;17(2):315-9 (9 ref.)
Regulatory trends in workers' compensation managed care. Eccleston SM, et al. **Occup Med** 1998 Oct-Dec; 13(4):787-98, iv (15 ref.)
Managed care, liability, and ERISA. Stone AA.
Psychiatr Clin North Am 1999 Mar;22(1):17-29 (40 ref.)
What factors affect women's experiences with Medicaid managed care? Bernstein AB. **Womens Health Issues** 1998 Nov-Dec;8(6):325-38; discussion 350-8 (38 ref.)
[Managed care in Germany: legal and economic aspects of its transferability] König HH, et al. **Gesundheitswesen** 1999 Jun;61(6):274-9 (18 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The impact of managed care on psychiatry. Domino ME, et al. **Adm Policy Ment Health** 1998 Nov;26(2):149-57 (34 ref.)
Managed care and people with disabilities: framing the issues. Sutton JP, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1312-6 (47 ref.)
Americanization of our health care [editorial] Mulligan PK. **Can Fam Physician** 1998 Nov;44:2351-3, 2363-5 (11 ref.) **(Eng, Fre)**
Managed health care: outcomes and update. Wenzel RP.
Curr Clin Top Infect Dis 1999;19:216-25 (29 ref.)
Molecular pathology and managed care: challenges and opportunities. Ross JS. **Diagn Mol Pathol** 1998 Aug; 7(4):189-91 (0 ref.)
Palliative care in managed Medicare: reasons for hope--and for concern. Rousseau P. **Geriatrics** 1998 Nov;53(11):59-60, 63-5; quiz 66 (20 ref.)
What is left of professionalism after managed care? Sullivan WM. **Hastings Cent Rep** 1999 Mar-Apr;29(2):7-13 (12 ref.)
A broader vision for managed care, Part 2: A typology of community benefits. Schlesinger M, et al.
Health Aff (Millwood) 1998 Sep-Oct;17(5):26-49 (62 ref.)
The managerial revolution in the U.S. health care sector: lessons from the U.S. economy. Herzlinger RE.
Health Care Manage Rev 1998 Summer;23(3):19-29 (86 ref.)
Academic health centers in turbulent times: strategies for survival. Topping S, et al. **Health Care Manage Rev** 1999 Spring;24(2):7-18 (52 ref.)
Homeopathy and managed care: manageable or unmanageable [see comments] Ullman D.
J Altern Complement Med 1999 Feb;5(1):65-73 (40 ref.) Comment in: J Altern Complement Med 1999 Feb;5(1):1-2.
Optometry and ophthalmology relations in managed care. Hettler DL. **J Am Optom Assoc** 1999 Feb;70(2):99-102 (28 ref.)
The Patients' Bill of Rights: managed care under siege. Misocky M. **J Contemp Health Law Policy** 1998 Fall; 15(1):57-100 (0 ref.)
The doctor-patient relationship: challenges, opportunities, and strategies. Dorr Goold S, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S26-33 (51 ref.)
Challenges in medical education: training physicians to work collaboratively. Ramsbottom-Lucier M, et al.
J Gen Intern Med 1999 Jan;14 Suppl 1:S21-5 (13 ref.)
Rationale, principles, and educational approaches of organizational transformation. Suchman AL, et al.
J Gen Intern Med 1999 Jan;14 Suppl 1:S51-7 (18 ref.)
Managed care: rationing without justice, but not unjustly [see comments] Buchanan A. **J Health Polit Policy Law** 1998 Aug;23(4):617-34 (16 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687-95.
Protecting patient welfare in managed care: six safeguards [see comments] Emanuel EJ, et al.
J Health Polit Policy Law 1998 Aug;23(4):635-59 (71 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687-95.
Oregon's bold experiment: whatever happened to rationing? Leichter HM. **J Health Polit Policy Law** 1999 Feb; 24(1):147-60 (17 ref.)
The functions and limitations of trust in the provision of medical care [see comments] Mechanic D.
J Health Polit Policy Law 1998 Aug;23(4):661-86 (53 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687-95.
Regulating managed care: interest group competition for control and behavioral health care. Ross EC.
J Health Polit Policy Law 1999 Jun;24(3):599-625 (58 ref.)
Potential effects of managed care organizations in rural communities: a framework. Christianson J.
J Rural Health 1998 Summer;14(3):169-79 (2 ref.)
Research on managed care organizations in rural communities. Krein S, et al. **J Rural Health** 1998 Summer; 14(3):180-99 (84 ref.)
Managed care, school health programs, and adolescent health services: opportunities for health promotion. Santelli J, et al. **J Sch Health** 1998 Dec;68(10):434-40 (46 ref.)
Mental health carve-outs: effects and implications. Grazier KL, et al. **Med Care Res Rev** 1999;56 Suppl 2:37-59 (40 ref.)
Academic medical centers: a prescription for success in an era of managed care and capitation. Huntsinger CR Jr, et al. **Mil Med** 1999 Aug;164(8):585-9 (11 ref.)
Physician role change in managed care: a frontline report. Christian JH. **Occup Med** 1998 Oct-Dec;13(4):851-68, v (0 ref.)
Evaluating the impact of managed health care in workers' compensation. Dembe AE. **Occup Med** 1998 Oct-Dec; 13(4):799-821, v (32 ref.)
Managed occupational health. Harris JS. **Occup Med** 1998 Oct-Dec;13(4):625-43, iii (67 ref.)
Networks in workers' compensation medical delivery. Miller LA. **Occup Med** 1998 Oct-Dec;13(4):717-25, iv (1 ref.)
Demonstrating oncology provider value: data, guidelines, and the law. Gosfield AG. **Oncology (Huntingt)** 1998 Nov; 12(11A):157-61 (14 ref.)
Ten dimensions of public-sector managed care [see comments] Hoge MA, et al. **Psychiatr Serv** 1999 Jan; 50(1):51-5 (27 ref.) Comment in: Psychiatr Serv 1999 Jan;50(1):7.
Nonprofit to for-profit conversions by hospitals, health insurers, and health plans. Needleman J.
Public Health Rep 1999 Mar-Apr;114(2):108-19 (41 ref.)
Medicaid managed care and public health data. Rutherford GW, et al. **Public Health Rep** 1999 May-Jun;114(3):225-30 (25 ref.)
Managed care organizations and mammography: opportunities to serve underserved women. Reid WM, et al. **Women Health** 1999;28(4):13-28 (76 ref.)
Women's health, chronic disease, and disease management: new words and old music? Bierman AS, et al.
Womens Health Issues 1999 Jan-Feb;9(1):2-17; discussion 30-41 (66 ref.)
Health plans and purchasers: managing women's primary care. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):15S-25S (36 ref.)
Confronting STDs: a challenge for managed care. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):36S-46S (25 ref.)
Women's primary care in managed care: clinical and provider issues. Gonen JS. **Womens Health Issues** 1999 Mar-Apr; 9(2 Suppl):5S-14S (46 ref.)
Medicaid managed care: the challenge of providing care to low-income women. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):57S-67S (32 ref.)
Neither prevention nor cure: managed care for women with chronic conditions. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):68S-78S (23 ref.)

STANDARDS

Pharmacy benefit management companies: dimensions of performance. Lipton HL, et al.
Annu Rev Public Health 1999;20:361-401 (56 ref.)
Ethics and managed care. Perkel RL. **Clin Plast Surg** 1999 Jan;26(1):163-73 (23 ref.)
Ethical issues of managed care. Larkin GL.
Emerg Med Clin North Am 1999 May;17(2):397-415 (88 ref.)
The University HealthSystems Consortium: a bureaucracy designed to smother academic excellence [editorial] Edlich RF, et al. **J Emerg Med** 1998 Nov-Dec;16(6):893-4 (5 ref.)
Concluding thoughts--looking forward. Clancy CM, et al.
J Gen Intern Med 1999 Jan;14 Suppl 1:S63-4 (14 ref.)
The role of bioethics and business ethics. Eiser AR, et al.
J Gen Intern Med 1999 Jan;14 Suppl 1:S58-62 (29 ref.)
Defining educational priorities in managed care: a symposium overview. Kerr EA, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S1-5 (31 ref.)
Managed care and quality of care [editorial; comment] Krumholz HM. **J Gen Intern Med** 1999 Feb;14(2):136-7 (5 ref.) Comment on: J Gen Intern Med 1999 Feb;14(2):73-81.
The patient-provider relationship: opportunities as well as problems. Lo B. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S41-4 (5 ref.)
The role of regulation in quality improvement [see comments] Brennan TA. **Milbank Q** 1998;76(4):709-31, 512 (49 ref.) Comment in: Milbank Q 1998 ;76(4):745-7.
Occupational medicine practice guidelines. Bruckman RZ, et al. **Occup Med** 1998 Oct-Dec;13(4):679-91 (19 ref.)
Employer-provider partnerships in advanced managed care: human assets risk management. Comstock ML.
Occup Med 1998 Oct-Dec;13(4):645-61, iii (28 ref.)
The role of prevention in workers' compensation managed care arrangements. Dembe AE, et al. **Occup Med** 1998 Oct-Dec;13(4):663-77, iii (48 ref.)
Performance measurement in workers' compensation managed care organizations. Greenberg EL, et al.
Occup Med 1998 Oct-Dec;13(4):755-72, iv (28 ref.)
State of the art case management. Hall JC. **Occup Med** 1998 Oct-Dec;13(4):705-15, iv (11 ref.)
Managed care workers' compensation outcome measurements: how can a clinic compete? Mueller KL.
Occup Med 1998 Oct-Dec;13(4):773-86, iv (35 ref.)
Performance measures in occupational medicine: a tool to manage quality. Rudolph L. **Occup Med** 1998 Oct-Dec; 13(4):747-53, iv (28 ref.)
Quality in women's health: taking the measure of managed care. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):79S-88S (16 ref.)
Managed care and women's mental health: a focus on depression. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):47S-56S (41 ref.)
Managed care and unintended pregnancy: testing the limits of prevention. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):26S-35S (24 ref.)

STATISTICS & NUMERICAL DATA

An overview of tobacco measures. Davis RM.
Tob Control 1998 Winter;7 Suppl:S36-40; discussion S47-9 (14 ref.)

TRENDS

The role of departments of ophthalmology in the changing health care environment: resist or lead the change? [editorial] Clarkson JG. **Am J Ophthalmol** 1998 Nov; 126(5):713-6 (2 ref.)
Managed care and the quality of children's health services. Bergman DA, et al. **Future Child** 1998 Summer-Fall; 8(2):60-75 (62 ref.)
Children and managed health care: analysis and recommendations. Deal LW, et al. **Future Child** 1998 Summer-Fall;8(2):4-24 (60 ref.)
Medicaid managed care and children: an overview. Deal LW, et al. **Future Child** 1998 Summer-Fall;8(2):93-104 (21 ref.)
Improving state Medicaid contracts and plan practices for children with special needs. Fox HB, et al.
Future Child 1998 Summer-Fall;8(2):105-18 (10 ref.)
Managed care and children: an overview. Hughes DC, et al. **Future Child** 1998 Summer-Fall;8(2):25-38 (21 ref.)
The impact of managed care on mental health services for children and their families. Stroul BA, et al.
Future Child 1998 Summer-Fall;8(2):119-33 (25 ref.)
Managed care for older people: a primer for the geriatrician. Reed RL, et al. **J Am Geriatr Soc** 1999 Feb;47(2):241-9 (43 ref.)
The future of gastroenterology in the era of managed care. Ganz RA. **J Clin Gastroenterol** 1999 Mar;28(2):117-24 (34 ref.)
Hand care in the new millennium: surgeon's perspective. McAuliffe JA. **J Hand Ther** 1999 Apr-Jun;12(2):178-81 (12 ref.)
Quality of health care for people with developmental disabilities: the challenge of managed care. Walsh KK, et al. **Ment Retard** 1999 Feb;37(1):1-15 (60 ref.)
Chronic disease, women's health, and "disease management": the latest trend? Gevirtz F, et al.
Womens Health Issues 1999 Jan-Feb;9(1):18-29; discussion 30-41 (23 ref.)
[Do we really want managed care?] Geraedts M.
Gesundheitswesen 1998 Aug-Sep;60(8-9):473-81 (46 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

A framework for evaluating underutilization of health care services. Fetterolf DE. **Am J Med Qual** 1999 Mar-Apr; 14(2):89-97 (40 ref.)
Managed care for children: effect on access to care and utilization of health services. Szilagyi PG. **Future Child** 1998 Summer-Fall;8(2):39-59 (68 ref.)

MANAGED COMPETITION

Choice and representation in health care [see comments] Emanuel EJ. **Med Care Res Rev** 1999;56 Suppl 1:113-40 (14 ref.) Comment in: Med Care Res Rev 1999 ;56 Suppl 1:141-4.

MANAGED HEALTH CARE INSURANCE PLANS see **MANAGED CARE PROGRAMS**

MANAGEMENT INFORMATION SYSTEMS

Preparing chief information officers for the clinical information systems environment. Valenta AL, et al. **Acad Med** 1999 May;74(5):511–5 (14 ref.)
The clinical management database. Cowen JS, et al. **Crit Care Clin** 1999 Jul;15(3):481–97, v (28 ref.)
[A computerized system for regional management of incidents is now tested. A complement to the Lex Maria system, indicates unobserved risks (see comments)] Westerling R, et al. **Lakartidningen** 1999 Feb 3;96(5):486–8 (7 ref.) Comment in: Lakartidningen 1999 Feb 10;96(6):580. **(Swe)**

MANAGEMENT QUALITY CIRCLES

[From quality circles to evidence-based clinical practice--a status article on quality development. I. Concepts, methods and strategies] Kjaergaard J, et al. **Ugeskr Laeger** 1998 Nov 9;160(46):6638–43 (31 ref.) (Eng. Abstr.) **(Dan)**
[From quality circles to evidence-based clinical practice--a status article on quality development. III. Responsibility and tasks] Knudsen JL, et al. **Ugeskr Laeger** 1998 Nov 23;160(48):6945–50 (34 ref.) **(Dan)**

MANAGEMENT SERVICE ORGANIZATIONS see **HOSPITAL-PHYSICIAN JOINT VENTURES**

MANAGEMENT TEAMS, INSTITUTIONAL see **INSTITUTIONAL MANAGEMENT TEAMS**

MANATEE, CARIBBEAN see **TRICHECHUS MANATUS**

MANATEE, FLORIDA see **TRICHECHUS MANATUS**

MANATEE, WEST INDIAN see **TRICHECHUS MANATUS**

MANDATORY REPORTING

Elder abuse and neglect: the emergency medicine perspective. Allison EJ, et al. **Eur J Emerg Med** 1998 Sep; 5(3):355–63 (32 ref.)
Domestic violence: a primer for the primary care physician. Konchak PS. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S11–4 (12 ref.)
Mandatory reporting of intimate partner violence by health care professionals: a policy review. Glass N, et al. **Nurs Outlook** 1998 Nov-Dec;46(6):279–83 (35 ref.)

MANDATORY TESTING

see related
SUBSTANCE ABUSE DETECTION

MANDELIC ACIDS

THERAPEUTIC USE

An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Goldenberg MM. **Clin Ther** 1999 Apr;21(4):634–42 (27 ref.)

MANDIBLE

see related
CHIN
TEMPOROMANDIBULAR JOINT

Retrieval of a broken needle in the pterygomandibular space. Bedrock RD, et al. **J Am Dent Assoc** 1999 May; 130(5):685–7 (12 ref.)
Cherubism: clinicopathologic features. Yamaguchi T, et al. **Skeletal Radiol** 1999 Jun;28(6):350–3 (19 ref.)

ABNORMALITIES

Mandibular malformations: growth characteristics and management in hemifacial microsomia and Nager syndrome. Vargervik K. **Acta Odontol Scand** 1998 Dec; 56(6):331–8 (42 ref.)
Prenatal ultrasonographic diagnosis of the cerebro-costo-mandibular syndrome: case report and review of the literature. Megier P, et al. **Prenat Diagn** 1998 Dec;18(12):1294–9 (30 ref.)
Familial inheritance of mandibular arch malformations affecting three individuals in one family. Rust OA, et al. **South Med J** 1999 May;92(5):505–9 (25 ref.)
[Maxillo-mandibular + + disharmonies] Raphaël B, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):481–514 (53 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Arteriovenous malformations of the dental arcades. The place of endovascular therapy: results in 12 cases are presented. Rodesch G, et al. **J Craniomaxillofac Surg** 1998 Oct; 26(5):306–13 (17 ref.)
Anomalous relationship of the facial nerve and the retromandibular vein: a case report. Bhattacharyya N, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):75–6 (3 ref.)

EMBRYOLOGY

Extracellular matrix remodeling during morphogenesis. Werb Z, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:110–8 (33 ref.)

PATHOLOGY

Muscular reconstruction to improve the deterioration of facial appearance and speech caused by mandibular atrophy: technique and case reports. Bosker H, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):277–84 (11 ref.)

PHYSIOLOGY

Mandibular corpus strain in primates: further evidence for a functional link between symphyseal fusion and jaw-adductor muscle force. Hylander WL, et al. **Am J Phys Anthropol** 1998 Nov;107(3):257–71 (36 ref.)

RADIOGRAPHY

[Dental CT: image quality and radiation exposure in relation to scan parameters] Schorn C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):137–44 (24 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Distraction osteogenesis--a review. Davies J, et al. **Br Dent J** 1998 Nov 14;185(9):462–7 (31 ref.)
Zygomatico-coronoid ankylosis: a case report. Vanhove F, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):258–9 (10 ref.)
Distraction osteogenesis of a fibula free flap used for mandibular reconstruction: preliminary report. Siciliano S, et al. **J Craniomaxillofac Surg** 1998 Dec;26(6):386–90 (20 ref.)
Stress fracture of the tibia: an unusual complication of reconstructive surgery of the mandible. Westesson PL, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):70–4 (21 ref.)
Functional criteria for mandibular implant placement post resection and reconstruction for cancer. Marunick MT, et al. **J Prosthet Dent** 1999 Jul;82(1):107–13 (50 ref.)
Primary leiomyosarcoma of the mandible in a 7-year-old girl: report of a case and review of the literature. Carter LC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):477–84 (37 ref.)
[Experimental and clinical study of distraction osteogenesis of the mandible] Yang P, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1997 May;13(3):208–11 (22 ref.) (Eng. Abstr.) **(Chi)**
[Maxillo-mandibular + + disharmonies] Raphaël B, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):481–514 (53 ref.) (Eng. Abstr.) **(Fre)**

MANDIBULAR ADVANCEMENT

Oral appliances for the management of snoring and obstructive sleep apnoea. Bennett LS, et al. **Thorax** 1998 Aug;53 Suppl 2:S58–64 (47 ref.)

METHODS

Distraction osteogenesis--a review. Davies J, et al. **Br Dent J** 1998 Nov 14;185(9):462–7 (31 ref.)

MANDIBULAR CONDYLE

see related
TEMPOROMANDIBULAR JOINT

ABNORMALITIES

[Bilateral bifid mandibular condyle. Report of a case and review of the literature] Preda L, et al. **Radiol Med (Torino)** 1999 May;97(5):411–4 (26 ref.) **(Ita)**

INJURIES

Mandibular condyle fractures: a consensus [editorial] Bos RR, et al. **Br J Oral Maxillofac Surg** 1999 Apr;37(2):87–9 (14 ref.)
Anesthesia of the inferior alveolar and lingual nerves as a complication of a fractured condylar process. Griffiths H, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):77–9 (22 ref.)
[Fractures of the mandibular condyle. Therapeutic controversies] Martins JS, et al. **Acta Med Port** 1999 Apr-Jun;12(4–6):209–15 (45 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

A case of a new entity named unilateral dysplasia of the mandibular condyle [letter; comment] Martin-Granizo R, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):486–7 (4 ref.) Comment on: J Oral Maxillofac Surg 1998 Jun;56(6):765–9.

PHYSIOPATHOLOGY

Condylar axis position, as determined by the occlusion and measured by the CPI instrument, and signs and symptoms of temporomandibular dysfunction. Crawford SD. **Angle Orthod** 1999 Apr;69(2):103–15; discussion 115–6 (64 ref.)

RADIOGRAPHY

[Bilateral bifid mandibular condyle. Report of a case and review of the literature] Preda L, et al. **Radiol Med (Torino)** 1999 May;97(5):411–4 (26 ref.) **(Ita)**

MANDIBULAR DISEASES

[Osteomyelitis of the jaw] Kaneko A. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):357–9 (0 ref.) **(Jpn)**

DIAGNOSIS

Combined central odontogenic fibroma and giant cell granuloma-like lesion of the mandible: report of a case and review of the literature. Mosqueda Taylor A, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1258–62 (24 ref.)
Chronic recurrent multifocal osteomyelitis involving the mandible in a 4-year-old girl: a case report and a review of the literature. Otsuka K, et al. **J Oral Maxillofac Surg** 1999 Aug;57(8):1013–6 (15 ref.)

PATHOLOGY

Stafne cyst in an anterior location. Apruzzese D, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):333–8 (49 ref.)
Bilateral central giant cell granulomas in a patient with neurofibromatosis: report of a case and review of the literature. Ardekian L, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):869–72 (24 ref.)
A case of a new entity named unilateral dysplasia of the mandibular condyle [letter; comment] Martin-Granizo R, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):486–7 (4 ref.) Comment on: J Oral Maxillofac Surg 1998 Jun;56(6):765–9.
Glandular odontogenic cyst (sialo-odontogenic cyst): report of two cases and literature review of 45 previously reported cases. Koppang HS, et al. **J Oral Pathol Med** 1998 Oct; 27(9):455–62 (33 ref.)

RADIOGRAPHY

Bilateral dentigerous cysts--report of an unusual case and review of the literature. Ko KS, et al. **J Can Dent Assoc** 1999 Jan;65(1):49–51 (17 ref.)
Glandular odontogenic cyst of the mandible. Chavez JA, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):461–4 (14 ref.)
So-called simple bone cyst of the jaw: a family of pseudocysts of diverse nature and etiology. Shimoyama T, et al. **J Oral Sci** 1999 Jun;41(2):93–8 (122 ref.)

MANDIBULAR FRACTURES

COMPLICATIONS

Anesthesia of the inferior alveolar and lingual nerves as a complication of a fractured condylar process. Griffiths H, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):77–9 (22 ref.)

DRUG THERAPY

[Pathological fracture of the mandible: a report of a clinical case treated with clodronate] Califano L, et al. **G Chir** 1999 Jun-Jul;20(6–7):307–9 (12 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Treatment methods for fractures of the mandibular angle. Ellis E 3rd. **Int J Oral Maxillofac Surg** 1999 Aug; 28(4):243–52 (74 ref.)
[Fractures of the mandibular condyle. Therapeutic controversies] Martins JS, et al. **Acta Med Port** 1999 Apr-Jun;12(4–6):209–15 (45 ref.) (Eng. Abstr.) **(Por)**

THERAPY

Mandibular condyle fractures: a consensus [editorial] Bos RR, et al. **Br J Oral Maxillofac Surg** 1999 Apr;37(2):87–9 (14 ref.)

MANDIBULAR INJURIES

SURGERY

Z-plasty closure of the donor defect of the radial forearm free flap. Hui KC, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):19–21 (10 ref.)

MANDIBULAR NEOPLASMS

Fibromatosis of the mandible: case report and review of previous publications. De Santis D. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):384–8 (35 ref.)

DIAGNOSIS

Combined central odontogenic fibroma and giant cell granuloma-like lesion of the mandible: report of a case and review of the literature. Mosqueda Taylor A, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1258–62 (24 ref.)
[Primary non-Hodgkin lymphoma of the mandible--a case report] Schimming R, et al. **Schweiz Monatsschr Zahnmed** 1999;109(8):837–43 (28 ref.) **(Ger, Fre)**
[A nonpigmented melanoblastoma of the mandibular alveolar process] Shmurun RI. **Stomatologiia (Mosk)** 1999;78(3):35–6

MANDIBULAR NEOPLASMS

(9 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Granular cell ameloblastoma of jaw. A report of rare case and brief review of literature. Vyas MC, et al. **Indian J Cancer** 1998 Sep;35(3):115–8 (11 ref.)

Central acinic cell carcinoma of the mandible. Report of a case. Nakazawa M, et al. **Int J Oral Maxillofac Surg** 1998 Dec;27(6):448–50 (12 ref.)

Central granular cell odontogenic tumor: case report and review of literature. Ardekian L, et al. **J Oral Maxillofac Surg** 1998 Nov;56(11):1343–5 (12 ref.)

Multiple odontomas of the mandible: a case report. Iwamoto O, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):338–41 (5 ref.)

Solitary mucosal "infantile" myofibroma in a 21-year-old man. Ugar DA, et al. **J Oral Maxillofac Surg** 1999 Apr; 57(4):448–51 (13 ref.)

Odontogenic ghost cell carcinoma: report of four new cases and review of the literature. Lu Y, et al. **J Oral Pathol Med** 1999 Aug;28(7):323–9 (34 ref.)

Primary leiomyosarcoma of the mandible in a 7-year-old girl: report of a case and review of the literature. Carter LC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):477–84 (37 ref.)

Pulmonary metastasis of ameloblastoma: case report and review of the literature. Henderson JM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):170–6 (19 ref.)

A unique case of desmoplastic ameloblastoma of the mandible: report of a case and brief review of the English language literature. Kawai T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):258–63 (15 ref.)

Intraosseous leiomyoma of the mandible. Loyola AM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):78–82 (22 ref.)

[Epithelioma cuniculatum. Apropos of a case in the anterior gingiva with involvement of the mandibular symphyseal bone and reconstruction using a fibular osteocutaneous flap and integrated implants] Huault M, et al. **Rev Stomatol Chir Maxillofac** 1998 Oct;99(3):143–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Clear cell odontogenic carcinoma in connection with squamous epithelial carcinoma. Case report and review of the literature] Vesper M, et al. **Mund Kiefer Gesichtschir** 1998 Sep;2(5):270–4 (22 ref.) (Eng. Abstr.) **(Ger)**

[Case of malignant ameloblastoma of multiple lung metastasis following surgical removal of the primary site 13 years earlier] Tada K, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1376–8 (7 ref.) **(Jpn)**

REHABILITATION

Functional criteria for mandibular implant placement post resection and reconstruction for cancer. Marunick MT, et al. **J Prosthet Dent** 1999 Jul;82(1):107–13 (50 ref.)

SECONDARY

Simultaneous metastatic ameloblastoma and thyroid carcinoma in the cervical region: report of a case. Sugiyama M, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1255–8 (18 ref.)

Initial presentation of hepatocellular carcinoma as a mandibular mass: case report and review of the literature. Chin A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Oct;86(4):457–60 (58 ref.)

SURGERY

Primary leiomyosarcoma of the mandible in a 7-year-old girl: report of a case and review of the literature. Carter LC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):477–84 (37 ref.)

MANDIBULAR NERVE

INJURIES

Anesthesia of the inferior alveolar and lingual nerves as a complication of a fractured condylar process. Griffiths H, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):77–9 (22 ref.)

PATHOLOGY

Localized hypertrophic neuropathy involving the inferior alveolar nerve. Ethunandan M, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):84–9 (23 ref.)

MANDIBULAR REST POSITION see **VERTICAL DIMENSION**

MANDIBULAR RIDGE AUGMENTATION see **ALVEOLAR RIDGE AUGMENTATION**

MANDIBULOFACIAL DYSOSTOSIS

GENETICS

Treacher Collins syndrome: from linkage to prenatal testing. Dixon MJ. **J Laryngol Otol** 1998 Aug;112(8):705–9 (35 ref.)

PATHOLOGY

Mandibulofacial dysostosis Bauru type syndrome: A new case [letter] Zechi-Ceide RM, et al. **Am J Med Genet** 1999 Sep 10;86(2):199–201 (8 ref.)

PHYSIOPATHOLOGY

Mandibular malformations: growth characteristics and management in hemifacial microsomia and Nager syndrome. Vargervik K. **Acta Odontol Scand** 1998 Dec; 56(6):331–8 (42 ref.)

SURGERY

[Experimental and clinical study of distraction osteogenesis of the mandible] Yang P, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1997 May;13(3):208–11 (22 ref.) (Eng. Abstr.) **(Chi)**

MANDRAGORA see **PLANTS, TOXIC**

MANDRAKE, EUROPEAN see **PLANTS, TOXIC**

MANDRILL see **PAPIO**

MANDUCA

ENZYMOLOGY

The plasma membrane H+-V-ATPase from tobacco hornworm midgut. Wieczorek H, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):67–74 (60 ref.)

GROWTH & DEVELOPMENT

Peptide hormones, steroid hormones, and puffs: mechanisms and models in insect development. Henrich VC, et al. **Vitam Horm** 1999;55:73–125 (178 ref.)

PHYSIOLOGY

Control of ecdysteroidogenesis: activation and inhibition of prothoracic gland activity. Gilbert LI, et al. **Invert Neurosci** 1997 Sep-Dec;3(2–3):205–16 (83 ref.)

MANDUCA SEXTA see **MANDUCA**

MANGANESE

Considerations for determining 'optimal nutrition' for copper, zinc, manganese and molybdenum. Failla ML. **Proc Nutr Soc** 1999 May;58(2):497–505 (74 ref.)

ADVERSE EFFECTS

Neurotoxic effects of low level exposure to manganese in human populations. Mergler D. **Environ Res** 1999 Feb;80(2 Pt 1):99–102 (17 ref.)

DEFICIENCY

Manganese deficiency and toxicity: are high or low dietary amounts of manganese cause for concern? Finley JW, et al. **Biofactors** 1999;10(1):15–24 (100 ref.)

Nutrition versus toxicology of manganese in humans: evaluation of potential biomarkers. Greger JL. **Neurotoxicology** 1999 Apr-Jun;20(2-3):205–12 (74 ref.)

Nutritional aspects of manganese from experimental studies. Keen CL, et al. **Neurotoxicology** 1999 Apr-Jun; 20(2-3):213–23 (67 ref.)

DIAGNOSTIC USE

Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. Mathieu D, et al. **J Magn Reson Imaging** 1999 Aug;10(2):193–5 (15 ref.)

METABOLISM

Recent advances in the understanding of the biological chemistry of manganese. Yocum CF, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):182–7 (57 ref.)

PHARMACOKINETICS

Manganese homeostasis in the CNS. Aschner M. **Environ Res** 1999 Feb;80(2 Pt 1):105–9 (33 ref.)

Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. Andersen ME, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):161–71 (51 ref.)

Manganese uptake and distribution in the central nervous system (CNS). Aschner M, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):173–80 (62 ref.)

Distribution of manganese in development. Fechter LD. **Neurotoxicology** 1999 Apr-Jun;20(2-3):197–201 (12 ref.)

Manganese and calcium transport in mitochondria: implications for manganese toxicity. Gavin CE, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):445–53 (69 ref.)

PHYSIOLOGY

Role of manganese in the pathogenesis of portal-systemic encephalopathy. Layrargues GP, et al. **Metab Brain Dis** 1998 Dec;13(4):311–7 (35 ref.)

POISONING

[Manganism and parkinsonism] Kondo T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):41–4 (24 ref.) **(Jpn)**

TOXICITY

Manganese deficiency and toxicity: are high or low dietary amounts of manganese cause for concern? Finley JW, et al. **Biofactors** 1999;10(1):15–24 (100 ref.)

Manganese. Barceloux DG. **J Toxicol Clin Toxicol** 1999; 37(2):293–307 (115 ref.)

Inhalation health risks of manganese: an EPA perspective. Davis JM. **Neurotoxicology** 1999 Apr-Jun;20(2-3):511–8 (40 ref.)

Manganese and calcium transport in mitochondria: implications for manganese toxicity. Gavin CE, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):445–53 (69 ref.)

Nutrition versus toxicology of manganese in humans: evaluation of potential biomarkers. Greger JL. **Neurotoxicology** 1999 Apr-Jun;20(2-3):205–12 (74 ref.)

Effects from environmental Mn exposures: a review of the evidence from non-occupational exposure studies. Hudnell HK. **Neurotoxicology** 1999 Apr-Jun;20(2-3):379–97 (130 ref.)

Manganese neurotoxicity in industrial exposures: proof of effects, critical exposure level, and sensitive tests. Iregren A. **Neurotoxicology** 1999 Apr-Jun;20(2-3):315–23 (27 ref.)

Nutritional aspects of manganese from experimental studies. Keen CL, et al. **Neurotoxicology** 1999 Apr-Jun; 20(2-3):213–23 (67 ref.)

Environmental effects and exposures to manganese from use of methylcyclopentadienyl manganese tricarbonyl (MMT) in gasoline. Lynam DR, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):145–50 (40 ref.)

A brief history of the neurobehavioral toxicity of manganese: some unanswered questions. McMillan DE. **Neurotoxicology** 1999 Apr-Jun;20(2-3):499–507 (40 ref.)

Animal models of manganese's neurotoxicity. Newland MC. **Neurotoxicology** 1999 Apr-Jun;20(2-3):415–32 (87 ref.)

Manganese neurotoxicity: a review of clinical features, imaging and pathology. Pal PK, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):227–38 (139 ref.)

Peripheral biomarkers and exposure to manganese. Smargiassi A, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):401–6 (37 ref.)

Manganese neurotoxicity: a mechanistic hypothesis. Verity MA. **Neurotoxicology** 1999 Apr-Jun;20(2-3):489–97 (41 ref.)

Manganese in the context of an integrated risk and decision process. Weiss B. **Neurotoxicology** 1999 Apr-Jun; 20(2-3):519–25 (17 ref.)

MANGANESE COMPOUNDS

METABOLISM

Electrochemical concepts and techniques in the study of stainless steel ennoblement. Dickinson WH, et al. **Biodegradation** 1998;9(1):11–21 (43 ref.)

PHARMACOLOGY

The 2.2 A structure of a permanganate-sensitive DNA site bound by the Epstein-Barr virus origin binding protein, EBNA1. Bochkarev A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1273–8 (24 ref.)

MANGE see **MITE INFESTATIONS**

MANGE, SARCOPTIC see **SCABIES**

MANIC-DEPRESSIVE PSYCHOSIS see **BIPOLAR DISORDER**

MANIC DISORDER see **BIPOLAR DISORDER**

MANIHOT see **CASSAVA**

MANIKINS

The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353–6 (15 ref.)

MANIOC see **CASSAVA**

MANIPULATION, CHIROPRACTIC see **MANIPULATION, SPINAL**

MANIPULATION, ORTHOPEDIC

see related
CHIROPRACTIC

[Physiotherapy as manual therapy] Torstensen TA, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2059–63 (57 ref.) (Eng. Abstr.) **(Nor)**

METHODS

An osteopathic approach to asthma [see comments] Rowane WA, et al. **J Am Osteopath Assoc** 1999 May;99(5):259–64 (61 ref.) Comment in: J Am Osteopath Assoc 1999 May;99(5):251.

Commentary: torque misuse revisited [letter; comment] Herzog W. **J Manipulative Physiol Ther** 1999 Jun; 22(5):347–8 (3 ref.) Comment on: J Manipulative Physiol Ther 1998 Nov–Dec;21(9):649–55.

MANIPULATION, PSYCHOLOGICAL see **MACHIAVELLIANISM**

MANIPULATION, SPINAL

Music therapy and chiropractic: an integrative model of tonal and rhythmic spinal adjustment. Miller EB, et al. **Altern Ther Health Med** 1999 Mar;5(2):102–4 (8 ref.)

Management of acute lumbar disk herniation initially presenting as mechanical low back pain. Crawford CM, et al. **J Manipulative Physiol Ther** 1999 May;22(4):235–44 (85 ref.)

Rationale for assessing the effects of manipulative therapy on autonomic tone by analysis of heart rate variability. Eingorn AM, et al. **J Manipulative Physiol Ther** 1999 Mar–Apr;22(3):161–5 (51 ref.)

Dysafferentation: a novel term to describe the neuropathologic effects of joint complex dysfunction--a look at likely mechanisms of symptom generation [letter; comment] Knutson GA. **J Manipulative Physiol Ther** 1999 Jan;22(1):45–8 (21 ref.) Comment on: J Manipulative Physiol Ther 1998 May;21(4):267–80.

Spinal manipulation: current state of research and its indications. Bronfort G. **Neurol Clin** 1999 Feb;17(1):91–111 (107 ref.)

[Is exercise therapy and manipulation effective in low back pain?] Brox JI, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2042–50 (75 ref.) (Eng. Abstr.) **(Nor)**

[Chiropractic in general and in low back pain] Myhrvold K. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2054–8 (44 ref.) (Eng. Abstr.) **(Nor)**

[Physiotherapy as manual therapy] Torstensen TA, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2059–63 (57 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Manipulation of the cervical spine: risks and benefits [see comments] Di Fabio RP. **Phys Ther** 1999 Jan;79(1):50–65 (201 ref.) Comment in: Phys Ther 1999 May;79(5):514, 516.

Risk factors and precipitating neck movements causing vertebrobasilar artery dissection after cervical trauma and spinal manipulation. Haldeman S, et al. **Spine** 1999 Apr 15;24(8):785–94 (211 ref.)

MANIPULATION THERAPY see **MANIPULATION, ORTHOPEDIC**

MANN-WHITNEY U TEST see **STATISTICS, NONPARAMETRIC**

MANNANS

CHEMISTRY

The Candida albicans phosphomannan complex in Candida–host interactions. Cutler JE. **Res Immunol** 1998 May–Jun;149(4–5):299–308; discussion 507–9 (75 ref.)

IMMUNOLOGY

Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis. Zhang Y, et al. **Immunopharmacology** 1999 May;42(1–3):81–90 (22 ref.)

METABOLISM

Mannosylphosphate transfer to yeast mannan. Jigami Y, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):335–45 (52 ref.)

MANNEQUINS see **MANIKINS**

MANNITOL

ADMINISTRATION & DOSAGE

Mannitol and cardiac surgery. Poullis M. **Thorac Cardiovasc Surg** 1999 Feb;47(1):58–62 (57 ref.)

THERAPEUTIC USE

Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review [see comments] Roberts I, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):729–33 (25 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):66.

MANNOSE

METABOLISM

Location of the binding site of the mannose-specific lectin comitin on F-actin. Fulgenzi G, et al. **J Mol Biol** 1998 Dec 18;284(5):1255–63 (38 ref.)

[VIP36 recognizes high-mannose type glycans in relation to apical membrane traffic] Yamashita K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2455–63 (41 ref.) **(Jpn)**

[The role of the minor sugars in the vital activities of the human body] Chepurnoi IP. **Vopr Pitan** 1999;68(3):42–6 (49 ref.) **(Rus)**

MANNOSE-6-PHOSPHATE RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

MANNOSEPHOSPHATES

METABOLISM

Mannosylphosphate transfer to yeast mannan. Jigami Y, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):335–45 (52 ref.)

MANNOSIDASES

ANTAGONISTS & INHIBITORS

The pathogenesis and toxicokinetics of locoweed (Astragalus and Oxytropis spp.) poisoning in livestock. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):35–45 (81 ref.)

MANNOSIDOSIS

VETERINARY

The pathogenesis and toxicokinetics of locoweed (Astragalus and Oxytropis spp.) poisoning in livestock. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):35–45 (81 ref.)

MANNOSYL-GLYCOPROTEIN ENDO-BETA-N-ACETYLGLUCOSAMINIDASE

METABOLISM

Endo-N-acetyl-beta-D-glucosaminidases and their potential substrates: structure/function relationships. Karamanos Y. **Res Microbiol** 1997 Nov;148(8):661–71 (68 ref.)

MANNOSYLTRANSFERASES

GENETICS

The KTR and MNN1 mannosyltransferase families of Saccharomyces cerevisiae. Lussier M, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):323–34 (40 ref.)

METABOLISM

Asparagine-linked glycosylation in the yeast Golgi. Dean N. **Biochim Biophys Acta** 1999 Jan 6;1426(2):309–22 (98 ref.)

Protein O-mannosylation. Strahl-Bolsinger S, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):297–307 (98 ref.)

MANOMETRY

[Indications for monitoring intracranial pressure] Melon E. **Ann Fr Anesth Reanim** 1997;16(4):415–9 (28 ref.) (Eng. Abstr.) **(Fre)**

[Recommendations for the practice of esophageal manometry in adults. Work group for recommendations for the practice of esophageal manometry] Boulant J, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1081–94 (121 ref.) **(Fre)**

INSTRUMENTATION

How to use articles about diagnostic technology: gastric tonometry. Keenan SP, et al. **Crit Care Med** 1999 Sep; 27(9):1726–31 (38 ref.)

Gastrointestinal manometry studies in children. Kaul A, et al. **J Clin Gastroenterol** 1998 Oct;27(3):187–91 (7 ref.)

METHODS

Increased stability of airflow following botulinum toxin injection. Finnegan EM, et al. **Laryngoscope** 1999 Aug; 109(8):1300–6 (22 ref.)

What you need to know--objective assessment of nasal patency--why it is important. Wang DY, et al. **Singapore Med J** 1999 Mar;40(3):186–7 (4 ref.)

[The use of anorectal manometry in the postoperative assessment of continence in congenital anorectal malformations in childhood] Mladenov A. **Khirurgiia (Sofiia)** 1998;51(1):51–9 (15 ref.) (Eng. Abstr.) **(Bul)**

[Value of the functional investigation of the bone: intramedullary pressure measurement, trans-osseus phlebography and needle biopsy] Ficat C. **Acta Orthop Belg** 1999;65 Suppl 1:35–44 (31 ref.) **(Fre)**

[Techniques for measuring intracranial hypertension] Pottecher T, et al. **Ann Fr Anesth Reanim** 1997;16(4):405–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Rhinomanometry: a method of objective study of nasal patency] Wojdas A, et al. **Otolaryngol Pol** 1997;51 Suppl 25:199–202 (10 ref.) (Eng. Abstr.) **(Pol)**

MANUALS

Manualized treatment for substance abusers with personality disorders: dual focus schema therapy. Ball SA. **Addict Behav** 1998 Nov–Dec;23(6):883–91 (30 ref.)

STANDARDS

Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21–33 (281 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.

MANURE

Environmental concerns about animal manure. Jongbloed AW, et al. **J Anim Sci** 1998 Oct;76(10):2641–8 (32 ref.)

Potential for reduction of odorous compounds in swine manure through diet modification. Sutton AL, et al. **J Anim Sci** 1999 Feb;77(2):430–9 (59 ref.)

Health, safety, and environmental concerns of farm animal waste. Cole DJ, et al. **Occup Med** 1999 Apr–Jun; 14(2):423–48 (177 ref.)

Safe handling and disposal of laboratory animal waste. Hill D. **Occup Med** 1999 Apr–Jun;14(2):449–68 (41 ref.)

Management and utilization of poultry wastes. Williams CM, et al. **Rev Environ Contam Toxicol** 1999;162:105–57 (338 ref.)

MANUSCRIPTS, MEDICAL

[Preparing a manuscript for publication in a scientific journal] Claes L, et al. **Unfallchirurg** 1999 May;102(5):377–83 (6 ref.) (Eng. Abstr.) **(Ger)**

MANY-TOOTHED BLACKFISH see **DOLPHINS**

MAO see **MONOAMINE OXIDASE**

MAO INHIBITORS see **MONOAMINE OXIDASE INHIBITORS**

MAP KINASES see **CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE**

MARASMUS see **PROTEIN-ENERGY MALNUTRITION**

MARBLE BONE DISEASE see **OSTEOPETROSIS**

MARBURG VIRUS

[Ebola hemorrhagic fever and Marburg virus disease: their virological and clinical aspects] Hirabayashi Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):85–9 (28 ref.) **(Jpn)**

METABOLISM

Co- and posttranslational modifications and functions of Marburg virus proteins. Becker S, et al. **Curr Top Microbiol Immunol** 1999;235:23–34 (53 ref.)

PATHOGENICITY

The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Feldmann H, et al. **Arch Virol Suppl** 1999;15:159–69 (53 ref.)

PHYSIOLOGY

Characteristics of Filoviridae: Marburg and Ebola viruses. Beer B, et al. **Naturwissenschaften** 1999 Jan;86(1):8–17 (88 ref.)

MARBURG VIRUS DISEASE

[Ebola hemorrhagic fever and Marburg virus disease: their virological and clinical aspects] Hirabayashi Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):85–9 (28 ref.) **(Jpn)**

EPIDEMIOLOGY

The Marburg virus outbreak of 1967 and subsequent episodes. Slenczka WG. **Curr Top Microbiol Immunol** 1999;235:49–75 (105 ref.)

Characteristics of Filoviridae: Marburg and Ebola viruses. Beer B, et al. **Naturwissenschaften** 1999 Jan;86(1):8–17 (88 ref.)

MARCHIAFAVA-MICHELI SYNDROME see **HEMOGLOBINURIA, PAROXYSMAL**

MAREK'S DISEASE

IMMUNOLOGY

In ovo vaccination technology. Ricks CA, et al. **Adv Vet Med** 1999;41:495–515 (51 ref.)

MAREK'S DISEASE

Chicken industry strategies for control of tumor virus infections. Kreager KS. **Poult Sci** 1998 Aug;77(8):1213–6 (6 ref.)
Control strategies for Marek's disease: a perspective for the future. Witter RL. **Poult Sci** 1998 Aug;77(8):1197–203 (37 ref.)

PREVENTION & CONTROL

Control strategies for Marek's disease: a perspective for the future. Witter RL. **Poult Sci** 1998 Aug;77(8):1197–203 (37 ref.)

VIROLOGY

T-cell transformation by Marek's disease virus. Ross NL. **Trends Microbiol** 1999 Jan;7(1):22–9 (62 ref.)

MAREK'S DISEASE HERPESVIRUS 1 see **HERPESVIRUS 2, GALLID**

MARFAN SYNDROME

COMPLICATIONS

Massive aortic regurgitation by spontaneous rupture of a fibrous strand in a fenestrated aortic valve. Akiyama K, et al. **J Heart Valve Dis** 1998 Sep;7(5):521–3 (15 ref.)
Petit mal seizure in a child with Marfan's syndrome. Goenka S, et al. **Tenn Med** 1999 Feb;92(2):53–4 (10 ref.)

DIAGNOSIS

Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases:hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association] Maron BJ, et al. **Circulation** 1998 Oct 6;98(14):1460–71 (143 ref.)
[Marfan's syndrome: diagnosis and treatment] Gielerak G, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):98–100 (28 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Marfan syndrome: new clues to genotype-phenotype correlations. Ramirez F, et al. **Ann Med** 1999 Jun; 31(3):202–7 (30 ref.)
Impact of molecular genetics on clinical cardiology. Mayosi BM, et al. **J R Coll Physicians Lond** 1999 Mar–Apr; 33(2):124–31 (27 ref.)

PHYSIOPATHOLOGY

Exercise and the Marfan syndrome. Braverman AC. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S387–95 (37 ref.)

RADIOGRAPHY

Musculoskeletal manifestations of the Antley-Bixler syndrome. Rumball KM, et al. **J Pediatr Orthop B** 1999 Apr;8(2):139–43 (17 ref.)

THERAPY

Towards an RNA-based therapy for Marfan syndrome. Kilpatrick MW, et al. **Mol Med Today** 1998 Sep;4(9):376–81 (30 ref.)
[Marfan's syndrome: diagnosis and treatment] Gielerak G, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):98–100 (28 ref.) (Eng. Abstr.) **(Pol)**

MARGARINE

[Is the Finnish "healthy margarine" food or medicine? Addition of plant sterols can lower cholesterol levels] Wikström AC. **Lakartidningen** 1998 Nov 11;95(46):5146–8 (18 ref.) (Eng. Abstr.) **(Swe)**

MARGINAL ULCER see **PEPTIC ULCER**

MARIE-BAMBERGER DISEASE see **OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC**

MARIE-STRUEMPELL DISEASE see **SPONDYLITIS, ANKYLOSING**

MARIJUANA see **CANNABIS**

MARIJUANA ABUSE

The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems. Ambrosio E, et al. **Life Sci** 1999;65(6–7):687–94 (52 ref.)
Marijuana: still a "signal of misunderstanding". Ungerleider JT. **Proc Assoc Am Physicians** 1999 Mar–Apr;111(2):173–81 (47 ref.)

EPIDEMIOLOGY

Sex differences in marijuana use in the United States. Greenfield SF, et al. **Harv Rev Psychiatry** 1999 Mar–Apr; 6(6):297–303 (62 ref.)

PREVENTION & CONTROL

American Academy of Pediatrics. Committee on Substance Abuse. Marijuana: A continuing concern for pediatricians. Heyman RB, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):982–5 (58 ref.)

MARIJUANA DEPENDENCE see **MARIJUANA ABUSE**

MARIJUANA SMOKING

Marijuana smoking vs cannabinoids for glaucoma therapy [see comments] Green K. **Arch Ophthalmol** 1998 Nov; 116(11):1433–7 (82 ref.) Comment in: Arch Ophthalmol 1998 Nov;116(11):1512–3.

ADVERSE EFFECTS

Adverse effects of cannabis [see comments] Hall W, et al. **Lancet** 1998 Nov 14;352(9140):1611–6 (50 ref.) Comment in: Lancet 1998 Nov 14;352(9140):1565.

PHYSIOPATHOLOGY

Cannabis and endogenous cannabinoid systems. Childers SR, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):173–87 (165 ref.)

MARINE BIOLOGY

see related
PLANKTON

Bioactive agents from natural sources: trends in discovery and application. Grabley S, et al. **Adv Biochem Eng Biotechnol** 1999;64:101–54 (360 ref.)
Pyrroloquinoline and pyridoacridine alkaloids from marine sources. Ding Q, et al. **Curr Med Chem** 1999 Jan;6(1):1–27 (53 ref.)
Dangers in the ocean: the traveler and marine envenomation. II. Marine vertebrates. Fenner PJ. **J Travel Med** 1998 Dec; 5(4):213–6 (11 ref.)
The impact of parasites on marine mammals: a review. Raga JA, et al. **Parassitologia** 1997 Dec;39(4):293–6 (36 ref.)
Trace element trophic transfer in aquatic organisms: a critique of the kinetic model approach. Reinfelder JR, et al. **Sci Total Environ** 1998 Aug 28;219(2–3):117–35 (124 ref.)
Emerging marine diseases--climate links and anthropogenic factors. Harvell CD, et al. **Science** 1999 Sep 3; 285(5433):1505–10 (113 ref.)

MARINE TOXINS

Phycotoxins. Quilliam MA. **J AOAC Int** 1999 May–Jun; 82(3):773–81 (100 ref.)

CHEMISTRY

Marine spongean cytotoxins. Kobayashi M, et al. **J Nat Toxins** 1999 Jun;8(2):249–58 (31 ref.)
Toxins from sea cucumbers (holothuroids): chemical structures, properties, taxonomic distribution, biosynthesis and evolution. Stonik VA, et al. **J Nat Toxins** 1999 Jun; 8(2):235–48 (71 ref.)

PHARMACOLOGY

Molecular mechanisms underlying inhibition of protein phosphatases by marine toxins. Dawson JF, et al. **Front Biosci** 1999 Oct 1;4:D646–58 (0 ref.)
Maitotoxin, a cationic channel activator. Escobar LI, et al. **Neurobiology (Bp)** 1998;6(1):59–74 (22 ref.)

TOXICITY

Cyanobacterial toxins in Portugal: effects on aquatic animals and risk for human health. Vasconcelos VM. **Braz J Med Biol Res** 1999 Mar;32(3):249–54 (40 ref.)

MARINES see **MILITARY PERSONNEL**

MARINESCO-SJOGREN SYNDROME see **SPINOCEREBELLAR DEGENERATION**

MARITAL RELATIONSHIP see **MARRIAGE**

MARITAL STATUS

The doctor's troubled marriage. Harari E. **Aust Fam Physician** 1998 Nov;27(11):999–1004 (16 ref.)
[Violence between couples] Moreno Martin F. **Rev Panam Salud Publica** 1999 Apr–May;5(4–5):245–58 (61 ref.) (Eng. Abstr.) **(Spa)**

MARITAL THERAPY

see related
COUPLES THERAPY

Marital therapy in the treatment of depression: toward a third generation of therapy and research. Beach SR, et al. **Clin Psychol Rev** 1998 Sep;18(6):635–61 (125 ref.)
Not just a time-out: change dynamics of prayer for religious couples in conflict situations. Butler MH, et al. **Fam Process** 1998 Winter;37(4):451–78 (70 ref.)
Understanding betrayals in marriage: a synthesized model of forgiveness. Gordon KC, et al. **Fam Process** 1998 Winter; 37(4):425–49 (49 ref.)

METHODS

Interventions for couples. Christensen A, et al. **Annu Rev Psychol** 1999;50:165–90 (107 ref.)
Individual psychopathology and marital distress. Analyzing the association and implications for therapy. Halford WK, et al. **Behav Modif** 1999 Feb;23(2):179–216 (155 ref.)

MARKER ANTIGENS see **ANTIGENS, DIFFERENTIATION**

MARKERS, BIOCHEMICAL see **BIOLOGICAL MARKERS**

MARKERS, BIOLOGICAL see **BIOLOGICAL MARKERS**

MARKERS, CLINICAL see **BIOLOGICAL MARKERS**

MARKERS, DNA see **GENETIC MARKERS**

MARKERS, GENETIC see **GENETIC MARKERS**

MARKERS, IMMUNOLOGIC see **BIOLOGICAL MARKERS**

MARKERS, LABORATORY see **BIOLOGICAL MARKERS**

MARKERS, SERUM see **BIOLOGICAL MARKERS**

MARKERS, SURROGATE see **BIOLOGICAL MARKERS**

MARKERS, TUMOR see **TUMOR MARKERS, BIOLOGICAL**

MARKERS, VIRAL see **BIOLOGICAL MARKERS**

MARKETING OF HEALTH SERVICES

Marketing medicines through randomised controlled trials: the case of interferon. Pieters T. **BMJ** 1998 Oct 31; 317(7167):1231–3 (22 ref.)
Turf battles in radiology: how to avoid/how to fight/how to win. Schnyder P, et al. **Eur Radiol** 1999;9(4):741–8 (37 ref.)
Fund-holding and contracting for community nursing services: a selective review of the literature. Livesey H. **J Adv Nurs** 1998 Sep;28(3):483–90 (112 ref.)

LEGISLATION & JURISPRUDENCE

Marketing health care products on the Internet: a proposal for updated federal regulations. Green K. **Am J Law Med** 1998;24(2–3):365–86 (145 ref.)

METHODS

Medication challenges in the assisted living facility. Crutchfield DB. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr; 39(2):222–5; quiz 293–4 (5 ref.)
Population-based recruitment for quit-smoking programs: an analytic review of communication variables. McDonald PW. **Prev Med** 1999 Jun;28(6):545–57 (86 ref.)

ORGANIZATION & ADMINISTRATION

The once and future application of cost-effectiveness analysis. Berger ML. **Jt Comm J Qual Improv** 1999 Sep; 25(9):455–61 (15 ref.)
Developing health insurance in transitional Asia. Ensor T. **Soc Sci Med** 1999 Apr;48(7):871–9 (25 ref.)

TRENDS

The healthcare marketplace in the next millennium and nurses' roles in infection prevention and control. Jackson MM. **Nurs Clin North Am** 1999 Jun;34(2):411–26 (46 ref.)

MARKOV CHAINS

Profile hidden Markov models. Eddy SR. **Bioinformatics** 1998;14(9):755–63 (73 ref.)

MARKOV PROCESS see **MARKOV CHAINS**

MARMOSET, COMMON see **CALLITHRIX**

MARMOSET, SHORT-TUSKED see **CALLITHRIX**

MARMOSET VIRUS see **SIMPLEXVIRUS**

MARMOSETS see **CALLITHRIX**

MAROTEAUX-LAMY SYNDROME see **MUCOPOLYSACCHARIDOSIS VI**

MARRIAGE

see related
SPOUSES

Sampling biases in a marital study on severe major depression.

Marin A, et al. **Psychopathology** 1999 Jan-Feb;32(1):12-22 (61 ref.)

PSYCHOLOGY

Individual psychopathology and marital distress. Analyzing the association and implications for therapy. Halford WK, et al. **Behav Modif** 1999 Feb;23(2):179-216 (155 ref.)

Interpersonal and psychological correlates of marital dissatisfaction in late life: a review. Gagnon MD, et al. **Clin Psychol Rev** 1999 Apr;19(3):359-78 (102 ref.)

Prevention of marital dysfunction: behavioral approaches and beyond. Sayers SL, et al. **Clin Psychol Rev** 1998 Sep; 18(6):713-44 (121 ref.)

Not just a time-out: change dynamics of prayer for religious couples in conflict situations. Butler MH, et al. **Fam Process** 1998 Winter;37(4):451-78 (70 ref.)

Improving practice in marriage preparation. Silliman B, et al. **J Sex Marital Ther** 1999 Jan-Mar;25(1):23-43 (95 ref.)

Alcohol and the marriage effect. Leonard KE, et al. **J Stud Alcohol Suppl** 1999 Mar;13:139-46 (30 ref.)

The psychological effects of work experiences and disagreements about gender role beliefs in dual-earner couples: a longitudinal study. James JB, et al. **Womens Health** 1998 Winter;4(4):341-68 (50 ref.)

Does child care involvement increase or decrease distress among dual-earner couples? Ozer EM, et al. **Womens Health** 1998 Winter;4(4):285-311 (71 ref.)

MARRIAGE THERAPY see **MARITAL THERAPY**

MARRIED PERSONS see **SPOUSES**

MARROW see **BONE MARROW**

MARS

Medical issues for a mission to Mars. Davis JR. **Aviat Space Environ Med** 1999 Feb;70(2):162-8 (18 ref.)

Life on Mars: chemical arguments and clues from Martian meteorites. Brack A, et al. **Extremophiles** 1998 Aug; 2(3):313-9 (44 ref.)

Martian stable isotopes: volatile evolution, climate change and exobiological implications. Jakosky BM. **Orig Life Evol Biosph** 1999 Jan;29(1):47-57 (45 ref.)

Peroxide-modified titanium dioxide: a chemical analog of putative Martian soil oxidants. Quinn RC, et al. **Orig Life Evol Biosph** 1999 Jan;29(1):59-72 (27 ref.)

MARSUPIALIA

Killer kangaroos and other murderous marsupials. Wroe S. **Sci Am** 1999 May;280(5):68-74 (3 ref.)

ANATOMY & HISTOLOGY

Retinal structure and visual acuity in a polyprotodont marsupial, the fat-tailed dunnart (Sminthopsis crassicaudata). Arrese C, et al. **Brain Behav Evol** 1999; 53(3):111-26 (154 ref.)

PHYSIOLOGY

Manipulation of the fertility of marsupials for conservation of endangered species and control of over-abundant populations. Mate KE, et al. **Anim Reprod Sci** 1998 Oct; 53(1-4):65-76 (57 ref.)

Retinal structure and visual acuity in a polyprotodont marsupial, the fat-tailed dunnart (Sminthopsis crassicaudata). Arrese C, et al. **Brain Behav Evol** 1999; 53(3):111-26 (154 ref.)

Sex chromosomes and sex-determining genes: insights from marsupials and monotremes. Pask A, et al. **Cell Mol Life Sci** 1999 Jun;55(6-7):864-75 (76 ref.)

MARTENS see **CARNIVORA**

MARTES see **CARNIVORA**

MARTIAL ARTS

see related
WRESTLING

INJURIES

Martial arts. Buschbacher RM, et al. **Phys Med Rehabil Clin N Am** 1999 Feb;10(1):35-47, vi (36 ref.)

MASKING, PERCEPTUAL see **PERCEPTUAL MASKING**

MASKS

Surgical face masks: are they mandatory for interventional endovascular procedures? Taylor PR, et al. **Cardiovasc Intervent Radiol** 1998 Nov-Dec;21(6):448-9 (22 ref.)

Noninvasive positive pressure ventilation in acute respiratory failure. Mehta S. **Intensive Care Med** 1998 Oct; 24(10):1113-4 (4 ref.)

The art of interface. Tools for administering noninvasive ventilation. Leger SS, et al. **Med Klin** 1999 Apr;94(1 Spec No):35-9 (30 ref.)

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Ther Umsch** 1999 Mar;56(3):147-50 (8 ref.) (Eng. Abstr.) **(Ger)**

MASS BEHAVIOR

see related
CIVIL DISORDERS

MASS FRAGMENTOGRAPHY

Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Vogel JS, et al. **Adv Exp Med Biol** 1998;445:397-410 (41 ref.)

Clinical applications of gas chromatography and gas chromatography-mass spectrometry of steroids. Wolthers BG, et al. **J Chromatogr A** 1999 May 28;843(1-2):247-74 (134 ref.)

[Lipid metabolism and lipogenesis: application of stable isotopes] Martinez JA, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):91-8 (34 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Plasma source mass spectrometry in experimental nutrition. Barnes RM. **Adv Exp Med Biol** 1998;445:379-96 (108 ref.)

Protocol development for biological tracer studies. Dueker SR, et al. **Adv Exp Med Biol** 1998;445:363-78 (32 ref.)

Two-dimensional mass spectrometry of biomolecules at the subfemtomole level. McLafferty FW, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):571-8 (51 ref.)

METHODS

The role of gas chromatography/mass spectrometry. Instrumental techniques in forensic urine drug testing. Lehrer M. **Clin Lab Med** 1998 Dec;18(4):631-49 (18 ref.)

Facts about the artifacts in the measurement of oxidative DNA base damage by gas chromatography-mass spectrometry. Dizdaroglu M. **Free Radic Res** 1998 Dec; 29(6):551-63 (61 ref.)

DNA adducts in mammalian cells as indicators of exposure to carcinogens. Shuker DE. **IARC Sci Publ** 1999; (146):287-308 (157 ref.)

Carbohydrate profiling of bacteria by gas chromatography-mass spectrometry and their trace detection in complex matrices by gas chromatography-tandem mass spectrometry. Fox A. **J Chromatogr A** 1999 May 28;843(1-2):287-300 (40 ref.)

Applied gas chromatography coupled to isotope ratio mass spectrometry. Meier-Augenstein W. **J Chromatogr A** 1999 May 21;842(1-2):351-71 (166 ref.)

Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. Tsikas D. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9;717(1-2):201-45 (304 ref.)

Urinary nucleosides. Schram KH. **Mass Spectrom Rev** 1998 May-Jun;17(3):131-251 (112 ref.)

MASS MEDIA

Physical activity interventions using mass media, print media, and information technology. Marcus BH, et al. **Am J Prev Med** 1998 Nov;15(4):362-78 (68 ref.)

Rethinking anti-smoking media campaigns: two generations of research and issues for the next. Logan RA, et al. **J Health Care Finance** 1999 Summer;25(4):77-90 (59 ref.)

Is it over yet? Hope or hype: status of the HIV/AIDS pandemic. Miramontes HM, et al. **Nurs Outlook** 1998 Jul-Aug;46(4):155-6 (22 ref.)

Children, adolescents, and the media: issues and solutions. Strasburger VC, et al. **Pediatrics** 1999 Jan;103(1):129-39 (156 ref.)

Interactions between science, government and media on selection and testing of donors. Sazama K. **Vox Sang** 1998; 74 Suppl 2:503-6 (24 ref.)

[Tumor angiogenesis inhibitors: media and scientific aspects] Raymond E. **Presse Med** 1998 Jul 4-11;27(24):1221-4 (12 ref.) (Eng. Abstr.) **(Fre)**

[Impact of mass media on the use of health services. A systematic review of the literature] Grilli R, et al. **Epidemiol Prev** 1998 Apr-Jun;22(2):103-10 (35 ref.) (Eng. Abstr.) **(Ita)**

MASS SCREENING

see related
SENSITIVITY AND SPECIFICITY

Helicobacter pylori--screening prospect. Scaillon M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):367-75 (86 ref.)

Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening and HPV testing. Sigurdsson K. **Acta Obstet Gynecol Scand** 1999 Jul; 78(6):467-77 (126 ref.)

Screening for prostate cancer--more questions than answers [see comments] Rietbergen JB, et al. **Acta Oncol** 1998; 37(6):515-32 (179 ref.) Comment in: Acta Oncol 1998 ;37(6):513-4.

The rationale for early diagnosis of cancer--the example of breast cancer. Tubiana M, et al. **Acta Oncol** 1999; 38(3):295-303 (48 ref.)

European Consensus Statement on Neonatal Hearing Screening. Finalized at the European Consensus Development Conference on Neonatal Hearing Screening. Milan, 15-16 May 1998. **Acta Paediatr** 1999 Jan;88(1):107-8 (0 ref.)

Flexible sigmoidoscopy: screening for colorectal cancer [see comments] [corrected and republished in Am Fam Physician 1999 Mar 15;59(6):1537-46] Johnson BA. **Am Fam Physician** 1999 Jan 15;59(2):313-24, 327-8 (21 ref.) Comment in: Am Fam Physician 1999 Jan 15;59(2):270, 273.

Health screening in older women [see comments] Mouton CP, et al. **Am Fam Physician** 1999 Apr 1;59(7):1835-42 (54 ref.) Comment in: Am Fam Physician 1999 Apr 1;59(7):1747-8, 1750.

Breast cancer screening. Jatoi I. **Am J Surg** 1999 Jun; 177(6):518-24 (48 ref.)

Screening for ovarian cancer. MacDonald ND, et al. **Ann Acad Med Singapore** 1998 Sep;27(5):676-82 (33 ref.)

Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Cogswell ME, et al. **Ann Intern Med** 1998 Dec 1;129(11):971-9 (80 ref.)

Screening for hemochromatosis in primary care settings. McDonnell SM, et al. **Ann Intern Med** 1998 Dec 1; 129(11):962-70 (48 ref.)

Public health surveillance for hereditary hemochromatosis. Wetterhall SF, et al. **Ann Intern Med** 1998 Dec 1; 129(11):980-6 (58 ref.)

PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases [see comments] Barry MJ. **Ann Oncol** 1998 Dec;9(12):1279-82 (20 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

PSA screening for prostate cancer: the current controversy [see comments] de Koning HJ, et al. **Ann Oncol** 1998 Dec; 9(12):1293-6 (19 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

Screening for prostate cancer [see comments] Neal DE, et al. **Ann Oncol** 1998 Dec;9(12):1289-92 (30 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

PSA screening--current controversy [see comments] Svetec D, et al. **Ann Oncol** 1998 Dec;9(12):1283-8 (42 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. Woolf SH, et al. **Annu Rev Med** 1999;50:207-21 (61 ref.)

Screening for breast cancer. Gilbert FJ. **Br J Hosp Med** 1998 Dec 10;58(11):595-8 (14 ref.)

Should diabetic patients be screened for glaucoma? DARTS/MEMO Collaboration. Ellis JD, et al. **Br J Ophthalmol** 1999 Mar;83(3):369-72 (46 ref.)

Screening for prostate cancer: the current position. Moss SM, et al. **Br Med Bull** 1998;54(4):791-805 (54 ref.)

Screening for genital chlamydial infection. Stephenson JM. **Br Med Bull** 1998;54(4):891-902 (46 ref.)

Is screening for osteoporosis worthwhile? Walker-Bone K, et al. **Br Med Bull** 1998;54(4):915-27 (50 ref.)

Barrett's esophagus: is it all that bad? Tytgat GN. **Can J Gastroenterol** 1999 Jun;13(5):385-8 (54 ref.)

Harvard Report on Cancer Prevention. Volume 3: prevention of colon cancer in the United States. Tomeo CA, et al. **Cancer Causes Control** 1999 Jun;10(3):167-80 (103 ref.)

Prostate cancer screening: promise and peril--a review. Godley PA. **Cancer Detect Prev** 1999;23(4):316-24 (97 ref.)

Screening for neuroblastoma: progress and pitfalls. Ross JA, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Feb; 8(2):189-94 (82 ref.)

Is routine antenatal toxoplasmosis screening justified in the United States? Statistical considerations in the application of medical screening tests. Mittendorf R, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):163-73; quiz 174-5 (16 ref.)

Office screening for gynecologic cancer. Zweizig SL. **Clin Obstet Gynecol** 1999 Jun;42(2):267-75 (15 ref.)

Cancer in developing countries: Part II--Cancer control: strategies and priorities. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(5):283-7 (36 ref.)

Prostate cancer: 4. Screening. Meyer F, et al. **CMAJ** 1998 Oct 20;159(8):968-72 (22 ref.)

Colorectal cancer screening. Houlston RS. **Crit Rev Oncol Hematol** 1999 May;30(3):183-7 (33 ref.)

Screening for colorectal cancer and other GI cancers. Scotiniotis I, et al. **Curr Opin Oncol** 1999 Jul;11(4):305-11 (41 ref.)

The role of screening in the management of skin cancer. Wolfe JT. **Curr Opin Oncol** 1999 Mar;11(2):123-8 (64 ref.)

Cervical cytology and colposcopy in young patients attending genitourinary medicine clinics: invalid intrusion or preventive opportunity and definitive audit? Moss TR. **Cytopathology** 1999 Feb;10(1):2-7 (21 ref.)

Translating clinical research to community-based practice: lessons from colorectal cancer screening and diagnosis. Ness RM, et al. **Endoscopy** 1999 Feb;31(2):170-3 (48 ref.)

Screening methods for thyroid hormone disruptors. DeVito M, et al. **Environ Health Perspect** 1999 May;107(5):407-15 (108 ref.)

Cancer screening: an educational challenge? Moore MA, et al. **Eur J Cancer Prev** 1999 Feb;8(1):7-16 (113 ref.)

Is there a place for screening in ovarian cancer? MacDonald ND, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb; 82(2):155-7 (16 ref.)

Screening for colorectal cancer: present, past and future. Anwar S, et al. **Eur J Surg Oncol** 1998 Dec;24(6):477-86

(126 ref.)
Cancer screening in the elderly. van Dongen JA. **Eur J Surg Oncol** 1998 Oct;24(5):367–9 (15 ref.)
Colorectal surveillance for neoplasia: an overview. Bond JH. **Gastrointest Endosc** 1999 Mar;49(3 Pt 2):S35–40 (28 ref.)
Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. Falk GW. **Gastrointest Endosc** 1999 Mar;49(3 Pt 2):S29–34 (45 ref.)
Practical periodontal screening and diagnosis. Corbet EF. **Int Dent J** 1998 Jun;48(3 Suppl 1):268–74 (75 ref.)
Steps towards the prevention of obesity and associated complications. Falkenberg M. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S20–2 (16 ref.)
How do we assess the value of surveillance techniques in ulcerative colitis? Bernstein CN. **J Gastrointest Surg** 1998 Jul–Aug;2(4):318–21 (22 ref.)
Antenatal screening for HIV in the UK: what is to be done? [editorial] [see comments] Nicoll A. **J Med Screen** 1998; 5(4):170–1 (31 ref.) Comment in: J Med Screen 1999;6(2):111–2.
Assessment of women for partner abuse. Fishwick NJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):661–70 (15 ref.)
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. Rietbergen JB, et al. **J Urol** 1999 Apr;161(4):1192–8 (23 ref.)
Rapid assessment, injecting drug use, and public health. Rhodes T, et al. **Lancet** 1999 Jul 3;354(9172):65–8 (32 ref.)
Report of the 1998 Consensus Conference on Neuroblastoma Screening [see comments] **Med Pediatr Oncol** 1999 Oct; 33(4):357–9 (0 ref.) Comment in: Med Pediatr Oncol 1999 Oct;33(4):355–6. Comment in: Med Pediatr Oncol 1999 Oct;33(4):360–1.
Does preseason screening for cardiac disease really work?: the British perspective. MacAuley D. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S345–50 (45 ref.)
Screening for renal insufficiency: is it worth while? is it feasible? [editorial] Jungers P. **Nephrol Dial Transplant** 1999 Sep;14(9):2082–4 (12 ref.)
Consensus statement on prevention and early diagnosis of lung cancer. Varese, Italy, December, 1998. **Oncology (Huntingt)** 1999 Mar;13(3):298 (0 ref.)
The role of the pediatrician in hearing loss. From detection to connection. Finitzo T, et al. **Pediatr Clin North Am** 1999 Feb;46(1):15–34, ix–x (25 ref.)
Tuberculosis screening: a review and a potential role for prehospital care providers. Cannon GM Jr, et al. **Prehosp Emerg Care** 1999 Jan–Mar;3(1):47–53 (75 ref.)
Experience with the alcohol use disorders identification test (AUDIT) in Mexico. Medina-Mora E, et al. **Recent Dev Alcohol** 1998;14:383–96 (32 ref.)
Race and serum prostate-specific antigen levels: current status and future directions. Abdalla I, et al. **Semin Urol Oncol** 1998 Nov;16(4):207–13 (55 ref.)
The epidemiology of prostate cancer part I: descriptive epidemiology. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov;16(4):187–92 (46 ref.)
Prostate cancer and black men. Brawley OW. **Semin Urol Oncol** 1998 Nov;16(4):184–6 (25 ref.)
The social impact of HIV testing: a comparative analysis of Britain and Sweden. Danziger R. **Soc Sci Med** 1999 Feb; 48(3):293–300 (40 ref.)
Colorectal cancer screening: an overview of available methods and current recommendations. Early DS. **South Med J** 1999 Mar;92(3):258–65 (34 ref.)
Lung cancer screening and the surgical oncologist: the controversy. Strauss GM, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):371–87 (43 ref.)
Emerging viruses in blood transfusion. Allain JP. **Vox Sang** 1998;74 Suppl 2:125–9 (24 ref.)
Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Busch MP. **Vox Sang** 1998; 74 Suppl 2:147–54 (79 ref.)
HTLV testing in blood transfusion. Couroucé AM, et al. **Vox Sang** 1998;74 Suppl 2:165–9 (25 ref.)
An estimate of prostate cancer prevalence for a demographically similar workforce population. Westra CS, et al. **W V Med J** 1999 May–Jun;95(3):116–22 (14 ref.)
Cervical cancer: developments in screening and evaluation of the abnormal Pap smear. Walsh JM. **West J Med** 1998 Nov;169(5):304–10 (60 ref.)
[The screening and diagnosis of ovarian cancer] Zlatkov V, et al. **Akush Ginekol (Sofiia)** 1998;37(3):54–6 (16 ref.) (Eng. Abstr.) **(Bul)**
[Laboratory diagnosis in preventive cardiology] Soufi M, et al. **Herz** 1999 Feb;24(1):13–25 (47 ref.) (Eng. Abstr.) **(Ger)**
[Colorectal carcinoma. Prevention and early detection] Seidensticker F, et al. **Urologe A** 1998 Jul;37(4):W431–9 (60 ref.) **(Ger)**
[Colorectal cancer: prevention and screening] Taricciotti G, et al. **Ann Ital Med Int** 1998 Oct–Dec;13(4):217–26 (64 ref.) (Eng. Abstr.) **(Ita)**
[The significance and limitation of prostate specific antigen in the mass screening for prostate cancer] Imai K, et al. **Nippon Rinsho** 1998 Aug;56(8):1994–7 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Screening for cancer] Bjørge T, et al. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1129–36 (66 ref.) (Eng. Abstr.) **(Nor)**
[Screening for adult celiac disease] Hovdenak N. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1885–7 (62 ref.) (Eng. Abstr.) **(Nor)**
[Screening for type 2 diabetes is justified] Andersson DK, et al. **Lakartidningen** 1998 Nov 11;95(46):5167–70, 5175 (9 ref.) (Eng. Abstr.) **(Swe)**
[Screening in primary health care. How do the new criteria affect the incidence of diabetes?] Andersson DK, et al. **Lakartidningen** 1998 Nov 11;95(46):5171–5 (7 ref.) (Eng. Abstr.) **(Swe)**
[A new method for detecting congenital hearing disorders. Infants are screened by measuring otoacoustic emissions (see comments)] Hergils L. **Lakartidningen** 1999 Mar 10; 96(10):1166–8 (15 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Jun 9;96(23):2835–6. **(Swe)**

ADVERSE EFFECTS

Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations. Malm HM. **Hastings Cent Rep** 1999 Jan–Feb;29(1):26–37 (55 ref.)

ECONOMICS

Sexuality and health: the hidden costs of screening for Chlamydia trachomatis. Duncan B, et al. **BMJ** 1999 Apr 3;318(7188):931–3 (18 ref.)
The economic perspective. Brown J, et al. **Br Med Bull** 1998; 54(4):993–1009 (62 ref.)
The cost–effectiveness of cervical screening [see comments] Smith WJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):83–5 (23 ref.) Comment in: Curr Opin Obstet Gynecol 1999 Feb;11(1):81.
The use of CT scanning in dementia. A systematic review. Foster GR, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):406–23 (66 ref.)
Health and cost-benefits of chlamydia screening in young women. Mangione-Smith R, et al. **Sex Transm Dis** 1999 Jul;26(6):309–16 (83 ref.)

INSTRUMENTATION

[Early diagnosis of bronchial carcinoma. Technical endoscopic progress—a step toward new screening concepts?] Häussinger K, et al. **Pneumologie** 1999 Feb; 53(2):77–82 (35 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Legal considerations in screening pregnant women for human immunodeficiency virus. Grimes RM, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):259–64 (24 ref.)

METHODS

Cardiovascular evaluation of the young athlete. Luckstead EF. **Adolesc Med** 1998 Oct;9(3):441–55, v (25 ref.)
Practical issues in cognitive screening of elderly illiterate populations in developing countries. The Indo-US Cross-National Dementia Epidemiology Study. Chandra V, et al. **Aging (Milano)** 1998 Oct;10(5):349–57 (16 ref.)
The psychiatric review of symptoms: a screening tool for family physicians. Carlat DJ. **Am Fam Physician** 1998 Nov 1;58(7):1617–24 (21 ref.)
Screening for developmental dysplasia of the hip. French LM, et al. **Am Fam Physician** 1999 Jul;60(1):177–84, 187–8 (57 ref.)
Colorectal cancer: risk factors and recommendations for early detection [see comments] Read TE, et al. **Am Fam Physician** 1999 Jun;59(11):3083–92 (46 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2979–80.
Screening guidelines for colorectal cancer. Bond JH. **Am J Med** 1999 Jan 25;106(1A):7S–10S (18 ref.)
Surveillance and prevention of hepatitis B virus transmission [comment] Smith N, et al. **Am J Public Health** 1999 Jan; 89(1):11–3 (23 ref.) Comment on: Am J Public Health 1999 Jan;89(1):14–8. Comment on: Am J Public Health 1999 Jan;89(1):19–24.
Surveillance for endometrial cancer in women receiving tamoxifen. Suh-Burgmann EJ, et al. **Ann Intern Med** 1999 Jul 20;131(2):127–35 (87 ref.)
Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al. **Ann Occup Hyg** 1999 Jul;43(5):367–76 (15 ref.)
Prostate cancer and PSA screening. Mameghan H. **Aust Fam Physician** 1999 Aug;28(8):777–81 (11 ref.)
Review. Guidelines for the urological screening and initial management of lower urinary tract dysfunction in children with anorectal malformations—the ARGUS protocol. Boemers TM, et al. **BJU Int** 1999 Apr;83(6):662–71 (24 ref.)
Screening for diabetes: what are we really doing? Goyder E, et al. **BMJ** 1998 Dec 12;317(7173):1644–6 (33 ref.)
Allogeneic bone marrow transplantation: implications of herpesvirus screening and diagnosis. Barber S. **Br J Biomed Sci** 1998 Dec;55(4):281–6 (27 ref.)
Screening in child health. Hall DM, et al. **Br Med Bull** 1998; 54(4):929–43 (30 ref.)
Screening for abdominal aortic aneurysms. Law M. **Br Med Bull** 1998;54(4):903–13 (36 ref.)
Screening for breast and ovarian cancer: the relevance of family history. Pharoah PD, et al. **Br Med Bull** 1998; 54(4):823–38 (40 ref.)
Should we be screening for colorectal cancer? Robinson MH, et al. **Br Med Bull** 1998;54(4):807–21 (46 ref.)
Breast and cervical cancer screening interventions: an assessment of the literature. Meissner HI, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):951–61 (89 ref.)
Colorectal cancer screening: making sense of the different guidelines. Burke CA, et al. **Cleve Clin J Med** 1999 May; 66(5):303–11 (45 ref.)
Enthusiasm for ultrasound for osteoporosis screening is premature [editorial; comment] Richmond BJ. **Cleve Clin J Med** 1998 Sep;65(8):403–4 (9 ref.) Comment on: Cleve Clin J Med 1998 Sep;65(8):398–401.
Ultrasound and alendronate: new tools for osteoporosis screening and treatment [see comments] Tonino RP. **Cleve Clin J Med** 1998 Sep;65(8):398–401 (15 ref.) Comment in: Cleve Clin J Med 1998 Sep;65(8):403.
Hepatitis C update: implications of the blood transfusion "lookback". Younossi ZM, et al. **Cleve Clin J Med** 1998 Sep;65(8):412–5, 418–22 (22 ref.)
Risk factors: assessment and preventive measures. Wild RA. **Clin Obstet Gynecol** 1998 Dec;41(4):966–75 (12 ref.)
Endocrine analytes in multiple-marker screening. Lambert-Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963–81, vii (95 ref.)
Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Bottelli R, et al. **Clin Radiol** 1998 Oct;53(10):713–6 (34 ref.)
Osteoporosis and bone densitometry: does the emperor have clothes? [editorial; comment] [see comments] Lentle BC. **CMAJ** 1998 Nov 17;159(10):1261–4 (27 ref.) Comment on: CMAJ 1998 Nov 17;159(10):1253–7. Comment in: CMAJ 1999 Jun 29;160(13):1822–3.
Automated Papanicolaou smear analysis as a screening tool for female lower genital tract malignancies. Ku NN. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):41–3 (6 ref.)
Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Ostrea EM Jr. **Curr Probl Pediatr** 1999 Feb;29(2):37–56 (86 ref.)
Human papillomavirus (HPV) typing as an adjunct to cervical cancer screening. Syrjänen KJ, et al. **Cytopathology** 1999 Feb;10(1):8–15 (49 ref.)
Should there be mass screening using faecal occult blood tests for colorectal cancer? [see comments] Faivre J, et al. **Eur J Cancer** 1998 May;34(6):773–80 (22 ref.) Comment in: Eur J Cancer 1999 Feb;35(2):326.
The role of high- and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency. Oelkers W. **Eur J Endocrinol** 1998 Dec;139(6):567–70 (22 ref.)
Breast cancer imaging—what are the optimal modalities? Douek M, et al. **Eur J Surg Oncol** 1998 Dec;24(6):573–82 (70 ref.)
Variability of adjustments to indices in determining patient risk in biochemical screening. Brooks K, et al. **Fetal Diagn Ther** 1999 Jan–Feb;14(1):41–6 (45 ref.)
Malignancy and aneuploidy: prevention and early detection. Kirschner B. **Inflamm Bowel Dis** 1998 Aug;4(3):216–20 (25 ref.)
The role of CA 125 in screening for ovarian cancer. Rosenthal AN, et al. **Int J Biol Markers** 1998 Oct–Dec; 13(4):216–20 (16 ref.)
Screening for primary speech and language delay: a systematic review of the literature. Law J, et al. **Int J Lang Commun Disord** 1998;33 Suppl:21–3 (3 ref.)
Genetic and molecular markers for vascular disease. Overview. Ballantyne CM. **J Cardiovasc Risk** 1997 Oct–Dec;4(5–6):321–3 (9 ref.)
Using parents' concerns to detect and address developmental and behavioral problems. Glascoe FP. **J Soc Pediatr Nurs** 1999 Jan–Mar;4(1):24–35 (23 ref.)
Liver transplantation for cholestatic liver disease: screening and assessment of risk factors. Crippin JS. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S2–8 (19 ref.)
Presymptomatic testing for Huntington's disease: the role of genetic counseling. Walsh A. **Med Health R I** 1999 May; 82(5):168–70 (12 ref.)
Identifying diabetic patients at high risk for amputation. Umeh L, et al. **Nurse Pract** 1999 Aug;24(8):56, 60, 63–6, 70 (29 ref.)
Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications. Gerard MJ, et al. **Oncol Nurs Forum** 1998 Oct;25(9):1561–9 (63 ref.)
Cancer risk assessment: conceptual considerations for clinical practice. Mahon SM. **Oncol Nurs Forum** 1998 Oct; 25(9):1535–47 (34 ref.)
Mass screening for neuroblastoma by HPLC and by non-HPLC: a review. Nishi M, et al. **Oncol Rep** 1998 Nov–Dec;5(6):1399–1402 (15 ref.)
Oral cancer in the UK: to screen or not to screen. Rodrigues VC, et al. **Oral Oncol** 1998 Nov;34(6):454–65 (142 ref.)
State programs for universal newborn hearing screening. Hayes D. **Pediatr Clin North Am** 1999 Feb;46(1):89–94 (13 ref.)
A stepwise approach to the diagnosis and treatment of hereditary hearing loss. Tomaski SM, et al. **Pediatr Clin North Am** 1999 Feb;46(1):35–48 (25 ref.)
Is endocrinological assessment and follow-up of children after bone marrow transplantation necessary? How, and for how long? [editorial; comment] Cohen A. **Pediatr Transplant** 1999 Feb;3(1):1–4 (23 ref.) Comment

on: Pediatr Transplant 1999 Feb;3(1):38–44. Comment on: Pediatr Transplant 1999 Feb;3(1):60–6.
Nitroaromatic munition compounds: environmental effects and screening values. Talmage SS, et al. **Rev Environ Contam Toxicol** 1999;161:1–156 (278 ref.)
Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why? de Moerloose P, et al. **Semin Thromb Hemost** 1998;24(4):321–7 (57 ref.)
Factor V:Q506 mutation–resistance to activated protein C (APC): clinical implications with respect to family screening. Middeldorp S, et al. **Semin Thromb Hemost** 1998; 24(4):363–6 (30 ref.)
Hepatitis C: universal or selective screening? Brettle RP. **Sex Transm Infect** 1998 Oct;74(5):374–5 (6 ref.)
Genomic screening for blood–borne viruses in transfusion settings. Lee HH, et al. **Vox Sang** 1998;74 Suppl 2:119–23 (22 ref.)
[Prevention of cutaneous melanoma] van der Rhee HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1356–9 (24 ref.) (Eng. Abstr.) **(Dut)**
[Is ultrasound screening for ovarian cancer possible in 1998?] Descamps P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):476–81 (44 ref.) (Eng. Abstr.) **(Fre)**
[Echo–doppler surveillance of revascularization of the legs in asymptomatic postoperative patients. Why? With what rhythm? How much time? How?] Mellière D, et al. **J Mal Vasc** 1999 Jun;24(3):233–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Topicality of serologic screening of human immunodeficiency virus infections in adults] Dubrous P, et al. **Pathol Biol (Paris)** 1998 Jan;46(1):61–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Cervical–vaginal smears: an unpopular test!] Gompel C. **Presse Med** 1998 Jun 6;27(20):971–3 (33 ref.) (Eng. Abstr.) **(Fre)**
[Screening, prediction and prevention of type I diabetes. Role of the Belgian Diabetes Registry] Dorchy H. **Rev Med Brux** 1999 Feb;20(1):15–20 (17 ref.) (Eng. Abstr.) **(Fre)**
[Laboratory tests and clinical practice: from diagnosis of an inflammatory syndrome to colon cancer screening] Gulbis B. **Rev Med Brux** 1998 Sep;19(4):A248–51 (15 ref.) (Eng. Abstr.) **(Fre)**
[Routine screening of asymptomatic patients at risk, without warning signs: a necessity] Sternon J. **Rev Med Brux** 1998 Sep;19(4):A263–9 (16 ref.) (Eng. Abstr.) **(Fre)**
[The use of screening tools in psychiatry of the elderly person] Copeland JR, et al. **Rev Med Suisse Romande** 1999 Apr;119(4):323–8 (39 ref.) **(Fre)**
[Autistic disorders: screening and early intervention] Rodrigues–Dagaeff C, et al. **Rev Med Suisse Romande** 1999 Feb;119(2):111–5 (13 ref.) **(Fre)**
[Detection and diagnosis of alcoholism] Gache P. **Rev Prat** 1999 Feb 15;49(4):375–8 (21 ref.) (Eng. Abstr.) **(Fre)**
[Breast cancer: epidemiology, risk factors, screening] Gairard B, et al. **Rev Prat** 1998 Jan 1;48(1):21–7 (32 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of skin cancers] Grob JJ, et al. **Rev Prat** 1999 Apr 15;49(8):838–42 (17 ref.) (Eng. Abstr.) **(Fre)**
[Prostatic mass screening program and its technology] Watanabe H, et al. **Nippon Rinsho** 1998 Aug;56(8):1974–7 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Mammography screening for breast cancer] Drożdż W, et al. **Przegl Lek** 1998;55(12):663–8 (27 ref.) (Eng. Abstr.) **(Pol)**

ORGANIZATION & ADMINISTRATION

Issues underlying the evaluation of screening programmes. Peckham CS, et al. **Br Med Bull** 1998;54(4):767–78 (41 ref.)
Screening in general practice and primary care. Robson J. **Br Med Bull** 1998;54(4):961–82 (95 ref.)
Evaluation and management of nonmelanoma skin cancer. The military perspective. Welch ML, et al. **Dermatol Clin** 1999 Jan;17(1):19–28, vii (36 ref.)
Mass screening programs in Japan: what can we learn in the West? [editorial; comment] Lambert R. **Endoscopy** 1998 Oct;30(8):721–3 (14 ref.) Comment on: Endoscopy 1998 Oct;30(8):669–74.
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. **Eur J Cancer** 1999 Feb;35(2):262–71 (12 ref.)
Breast cancer screening in Rhode Island: modest improvement, significant challenge. Maxim R. **Med Health R I** 1999 Jun;82(6):219–20 (2 ref.)
Screening, early identification, and office–based intervention with children and youth living in substance–abusing families. Werner MJ, et al. **Pediatrics** 1999 May;103(5 Pt 2):1099–112 (53 ref.)

PSYCHOLOGY

Screening for cervical cancer: a review of women's attitudes, knowledge, and behaviour [see comments] Fylan F. **Br J Gen Pract** 1998 Aug;48(433):1509–14 (83 ref.) Comment in: Br J Gen Pract 1998 Oct;48(435):1704.
Asian–Islamic women and breast cancer screening: a socio–cultural analysis. Rajaram SS, et al. **Women Health** 1999;28(3):45–58 (45 ref.)

STANDARDS

Screening for early detection of cancer––ethical aspects. Törnberg SA. **Acta Oncol** 1999;38(1):77–81 (17 ref.)
Screening guidelines for colorectal cancer. Bond JH. **Am J Med** 1999 Jan 25;106(1A):7S–10S (18 ref.)
The performance of screening tests for ovarian cancer: results of a systematic review. Bell R, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1136–47 (50 ref.)
Quality assurance in screening programmes. Gray JA, et al. **Br Med Bull** 1998;54(4):983–92 (5 ref.)
Ethical and legal issues. Markham IS. **Br Med Bull** 1998; 54(4):1011–21 (15 ref.)
Colorectal cancer screening: A guide to the guidelines. Rex DK. **Can J Gastroenterol** 1999 Jun;13(5):397–402 (61 ref.)
A summary of cancer screening guidelines. Lipskie TL. **Chronic Dis Can** 1998;19(3):112–30 (62 ref.)
Prostate cancer screening: waiting for Godot [editorial; comment] Iscoe NA. **CMAJ** 1998 Dec 1;159(11):1375–7 (18 ref.) Comment on: CMAJ 1998 Dec 1;159(11):1368–72.
Bridging the knowledge gap and communicating uncertainties for informed consent in cervical cytology screening; we need unbiased information and a culture change. Anderson CM, et al. **Cytopathology** 1999 Aug; 10(4):221–8 (28 ref.)
Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations. Malm HM. **Hastings Cent Rep** 1999 Jan–Feb;29(1):26–37 (55 ref.)
Current issues in mammographic breast cancer screening. Rickard MT. **Hosp Med** 1999 May;60(5):325–8 (25 ref.)
Nongynecologic healthcare screening in women. Krueger PM. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S15–9 (24 ref.)
Benefits and risks of screening mammography for women in their forties: a statistical appraisal [see comments] Berry DA. **J Natl Cancer Inst** 1998 Oct 7;90(19):1431–9 (43 ref.) Comment in: J Natl Cancer Inst 1999 Feb 17;91(4):382–4.
Who should decide how effective cervical cancer screening will be? [editorial] Austin RM. **J Reprod Med** 1999 Apr; 44(4):317–20 (11 ref.)
Factors influencing the efficacy of universal newborn hearing screening. Stein LK. **Pediatr Clin North Am** 1999 Feb; 46(1):95–105 (32 ref.)
Screening for cancer in the patient with rheumatic disease. Bowles KE, et al. **Rheum Dis Clin North Am** 1999 Aug; 25(3):719–44, x (137 ref.)
[The potentials for optimizing cervical screening] Zlatkov V, et al. **Akush Ginekol (Sofiia)** 1998;37(2):45–9 (8 ref.) **(Bul)**
[The periodic health examination: a useless test?] Roland M, et al. **Rev Med Brux** 1998 Sep;19(4):A255–62 (26 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Screening for aneuploidy. Evans MI, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):115–8 (34 ref.)
Screening for cancer: future potential. Cuzick J. **Eur J Cancer** 1999 May;35(5):685–92 (53 ref.)
[Mammographic screening starting in the fifth or sixth decade of life] Saeger HD, et al. **Chirurg** 1999 Apr;70(4):380–3 (23 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

Think HIV: why physicians should lower their threshold for HIV testing. Freedberg KA, et al. **Arch Intern Med** 1999 Sep 27;159(17):1994–2000 (69 ref.)

MASS SPECTROMETRY see **SPECTRUM ANALYSIS, MASS**

MASS SPECTROMETRY, MATRIX–ASSISTED LASER DESORPTION–IONIZATION see **SPECTROMETRY, MASS, MATRIX–ASSISTED LASER DESORPTION–IONIZATION**

MASS SPECTROSCOPY see **SPECTRUM ANALYSIS, MASS**

MASS SPECTROSCOPY, MATRIX–ASSISTED LASER DESORPTION–IONIZATION see **SPECTROMETRY, MASS, MATRIX–ASSISTED LASER DESORPTION–IONIZATION**

MASS STORAGE DEVICES see **COMPUTER STORAGE DEVICES**

MASSAGE

Massage and ultrasound as therapeutic modalities in exercise–induced muscle damage. Tiidus PM. **Can J Appl Physiol** 1999 Jun;24(3):267–78 (50 ref.)
Aquatic sports massage therapy. Bell GW. **Clin Sports Med** 1999 Apr;18(2):427–35, ix (17 ref.)
Abdominal massage therapy for chronic constipation: A systematic review of controlled clinical trials. Ernst E. **Forsch Komplementarmed** 1999 Jun;6(3):149–51 (13 ref.)
Massage therapy for low back pain: a systematic review. Ernst E. **J Pain Symptom Manage** 1999 Jan;17(1):65–9 (26 ref.)
Prostatitis unplugged? Prostatic massage revisited. Nickel JC, et al. **Tech Urol** 1999 Mar;5(1):1–7 (19 ref.)

ADVERSE EFFECTS

[Supplementary history and occupational dermatologic evaluation of medical bath workers, masseurs, and physical therapists] Wessbecher R, et al. **Hautarzt** 1998 Dec; 49(12):912–9 (64 ref.) (Eng. Abstr.) **(Ger)**

MASSETER MUSCLE

PATHOLOGY

Hypertrophic branchial myopathy with uniform type 2 fibers: a case report. Kitagawa Y, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):465–71; discussion 471–2 (17 ref.)
Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. Mandel L, et al. **J Oral Maxillofac Surg** 1999 Aug;57(8):1017–9 (15 ref.)

MAST–CELL COLONY–STIMULATING FACTOR see **INTERLEUKIN–3**

MAST–CELL DISEASE see **MASTOCYTOSIS**

MAST CELL GROWTH FACTOR see **STEM CELL FACTOR**

MAST CELL GROWTH FACTOR–2 see **INTERLEUKIN–4**

MAST CELLS

DRUG EFFECTS

Beyond the histamine receptor: effect of antihistamines on mast cells. Cuss FM. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:54–9 (40 ref.)

ENZYMOLOGY

Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Jones D, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):229–44 (131 ref.)
Inhibitors of tryptase for the treatment of mast cell–mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381–96 (122 ref.)
Functions of Bruton's tyrosine kinase in mast and B cells. Kawakami Y, et al. **J Leukoc Biol** 1999 Mar;65(3):286–90 (46 ref.)
[Mastocyte proteinase] Olejnik AK, et al. **Postepy Hig Med Dosw** 1998;52(4):381–99 (86 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

On the role of PGD2 metabolites as markers of mast cell activation in asthma. O'Sullivan S. **Acta Physiol Scand Suppl** 1999 Apr;644:1–74 (375 ref.)
Basophils and mast cells in airway inflammation and asthma. Denburg JA. **Can Respir J** 1998 Jul–Aug;5 Suppl A:41A–4A (51 ref.)
Asthma, adenosine, mast cells and theophylline. Coward WR, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:42–6 (28 ref.)
Immunopathology and human mast cell cytokines. Bradding P, et al. **Crit Rev Oncol Hematol** 1999 Jul;31(2):119–33 (137 ref.)
Mast cells as sentinels of innate immunity. Galli SJ, et al. **Curr Opin Immunol** 1999 Feb;11(1):53–9 (71 ref.)
Negative regulation of hematopoietic cell activation and proliferation by Fc gamma RIIB. Malbec O, et al. **Curr Top Microbiol Immunol** 1999;244:13–27 (84 ref.)
gp49: an Ig–like receptor with inhibitory properties on mast cells and natural killer cells. Wagtmann N. **Curr Top Microbiol Immunol** 1999;244:107–13 (40 ref.)
The mast cell function–associated antigen, a new member of the ITIM family. Xu R, et al. **Curr Top Microbiol Immunol** 1999;244:159–68 (22 ref.)
Immunoreceptor tyrosine–based inhibition motif–bearing receptors regulate the immunoreceptor tyrosine–based activation motif–induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15 (161 ref.)
Multiple roles for PI 3–kinase in the regulation of PLCgamma activity and Ca2+ mobilization in antigen–stimulated mast cells. Barker SA, et al. **J Leukoc Biol** 1999 Mar;65(3):321–9 (55 ref.)
Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Buku A. **Peptides** 1999; 20(3):415–20 (39 ref.)

METABOLISM

Mast cells and their mediators in cutaneous wound healing––active participants or innocent bystanders? Artuc M, et al. **Exp Dermatol** 1999 Feb;8(1):1–16 (195 ref.)
Immunoreceptor tyrosine–based inhibition motif–bearing receptors regulate the immunoreceptor tyrosine–based activation motif–induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15 (161 ref.)

MICROBIOLOGY

Clinical implications of mast cell–bacteria interaction. Malaviya R, et al. **J Mol Med** 1998 Aug;76(9):617–23 (61

MAST CELLS

ref.)

PATHOLOGY

Immunopathology and human mast cell cytokines. Bradding P, et al. **Crit Rev Oncol Hematol** 1999 Jul;31(2):119–33 (137 ref.)

PHYSIOLOGY

Mast-cell growth and differentiation. Li L, et al. **Allergy** 1999 Apr;54(4):306–12 (76 ref.)

Mast cells in the liver [editorial; comments] Benyon RC. **Clin Exp Allergy** 1999 Feb;29(2):155–8 (40 ref.)

Mast cell cultures: bench to bedside [see comments] Rossi GL, et al. **Clin Exp Allergy** 1998 Oct;28(10):1182–90 (79 ref.) Comment in: Clin Exp Allergy 1998 Oct;28(10):1167–70.

Regulation of human mast cell and basophil function by cAMP. Weston MC, et al. **Gen Pharmacol** 1998 Nov; 31(5):715–9 (70 ref.)

Deciphering the early-response transcription factor networks in mast cells. Nechushtan H, et al. **Immunol Today** 1998 Oct;19(10):441–4 (30 ref.)

Adenosine, mast cells and asthma. Forsythe P, et al. **Inflamm Res** 1999 Jun;48(6):301–7 (73 ref.)

Mast cells: a possible link between psychological stress, enteric infection, food allergy and gut hypersensitivity in the irritable bowel syndrome. Gui XY. **J Gastroenterol Hepatol** 1998 Oct;13(10):980–9 (149 ref.)

Histamine content and secretion in basophils and mast cells. Dvorak AM. **Prog Histochem Cytochem** 1998; 33(3–4):III–IX, 169–320 (355 ref.)

Mast cells and basophils in innate immunity. Abraham SN, et al. **Semin Immunol** 1998 Oct;10(5):373–81 (46 ref.)

The mast cell–nerve axis in wound healing: a hypothesis. Gottwald T, et al. **Wound Repair Regen** 1998 Jan–Feb; 6(1):8–20 (160 ref.)

[Mast cells and their significance in lung physiology and diseases] Zuga MV, et al. **Ter Arkh** 1999;71(3):76–80 (88 ref.) **(Rus)**

SECRETION

[Secretory mechanisms and secretory products of mast cells] Bykov VL. **Morfologiia** 1999;115(2):64–72 (111 ref.) **(Rus)**

MASTADENOVIRUS

[The patterns in the molecular biology of the adenoviruses (the results of a 20-year study at the Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine)] Diachenko NS. **Mikrobiol Z** 1999 Jan–Feb;61(1):3–31 (132 ref.) (Eng. Abstr.) **(Rus)**

MASTECTOMY

Postmastectomy radiotherapy: toxicities and techniques to reduce them. Hardenbergh PH, et al. **Semin Radiat Oncol** 1999 Jul;9(3):259–68 (42 ref.)

Is the use of radiation therapy after mastectomy cost-effective? Hayman JA, et al. **Semin Radiat Oncol** 1999 Jul;9(3):287–91 (11 ref.)

Postmastectomy radiation therapy: A surgical perspective. Morrow M. **Semin Radiat Oncol** 1999 Jul;9(3):269–74 (52 ref.)

Postmastectomy radiotherapy: future directions. Pierce LJ. **Semin Radiat Oncol** 1999 Jul;9(3):300–4 (19 ref.)

Role of postmastectomy radiotherapy: A medical oncology perspective. Robert NJ. **Semin Radiat Oncol** 1999 Jul; 9(3):241–6 (26 ref.)

Radiation therapy as an adjunct to primary surgery in early stage breast cancer: biological and clinical rationale. Rutqvist LE. **Semin Radiat Oncol** 1999 Jul;9(3):217–22 (24 ref.)

[Radiation and concomitant chemotherapy after surgery for breast cancer: Arcosein study] Calais G. **Cancer Radiother** 1998 Sep–Oct;2(5):469–74 (31 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of breast cancer by prophylactic mastectomy] Lefranc JP, et al. **Chirurgie** 1998 Sep;123(4):410–4 (24 ref.) **(Fre)**

[Breast reconstruction after mastectomy for cancer] Chavoin JP, et al. **Rev Prat** 1998 Jan 1;48(1):67–70 (15 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Breast surgery] Fahlke J, et al. **Zentralbl Chir** 1999; 124(2):W7–17 (9 ref.) **(Ger)**

[Management of breast cancer in geriatric age; observations on 164 cases] Roseano M, et al. **Ann Ital Chir** 1998 Sep–Oct; 69(5):587–94 (43 ref.) (Eng. Abstr.) **(Ita)**

[Seromas (lymphorrhea) after surgical treatment of breast cancer] Bulynskii BT, et al. **Vopr Onkol** 1999;45(3):219–22 (42 ref.) **(Rus)**

[Comparative evaluation and psychoemotional rehabilitation of patients with breast cancer after radical treatment depending on the extent of surgery] Ivanov LN, et al. **Vopr Onkol** 1998;44(4):447–9 (10 ref.) **(Rus)**

MASTECTOMY, MODIFIED RADICAL

Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Bijker N, et al. **Cancer** 1999 Apr 15; 85(8):1773–81 (42 ref.)

Postmastectomy irradiation: rationale for treatment field selection. Strom EA, et al. **Semin Radiat Oncol** 1999 Jul; 9(3):247–53 (40 ref.)

MASTECTOMY, RADICAL

[Post-therapeutic lymphedema of the arm--possibilities and limits of diagnosis and therapy] Döller W. **Wien Med Wochenschr** 1999;149(2–4):101–4 (33 ref.) (Eng. Abstr.) **(Ger)**

MASTECTOMY, SEGMENTAL

Breast cellulitis complicating breast conservation therapy. Baddour LM. **J Intern Med** 1999 Jan;245(1):5–9 (17 ref.)

[Indications and contraindications for breast preservation in patients with breast cancer] Jakesz R, et al. **Chirurg** 1999 Apr;70(4):394–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Breast saving mastectomy in benign and malignant diseases] Lippert H, et al. **Chirurg** 1999 May;70(5):W15–26 (11 ref.) **(Ger)**

[Possibilities and limits of diagnostic frozen section in breast carcinoma] Guski H, et al. **Zentralbl Chir** 1998;123 Suppl 5:19–22 (12 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Surgery for subclinical breast lesions] Le Bouedec G, et al. **J Chir (Paris)** 1998 Dec;135(6):267–72 (35 ref.) (Eng. Abstr.) **(Fre)**

MASTECTOMY, SIMPLE

Recurrent ductal carcinoma in situ after total mastectomy. Clark L, et al. **J Surg Oncol** 1999 Jul;71(3):182–5 (17 ref.)

[Do indications remain for total mastectomy for cancer?] Weber B, et al. **Bull Cancer** 1998 Sep;85(9):755–62 (97 ref.) (Eng. Abstr.) **(Fre)**

[Malignant phyllodes tumor with liposarcomatous differentiation. Description of a clinical case] Scala M, et al. **Minerva Chir** 1999 May;54(5):355–8 (25 ref.) (Eng. Abstr.) **(Ita)**

MASTECTOMY, SUBCUTANEOUS

[Indications and contraindications for breast preservation in patients with breast cancer] Jakesz R, et al. **Chirurg** 1999 Apr;70(4):394–9 (27 ref.) (Eng. Abstr.) **(Ger)**

MASTICATION

Mandibular corpus strain in primates: further evidence for a functional link between symphyseal fusion and jaw-adductor muscle force. Hylander WL, et al. **Am J Phys Anthropol** 1998 Nov;107(3):257–71 (36 ref.)

PHYSIOLOGY

Masticatory function and its effects on general health. Nakata M. **Int Dent J** 1998 Dec;48(6):540–8 (78 ref.)

Attrition, eruption, and the periodontium. Newman HN. **J Dent Res** 1999 Mar;78(3):730–4 (56 ref.)

Jaws: diversities of gnathological history and temporomandibular joint enterprise. Nelson DA, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):141–7 (80 ref.)

Does chewing performance depend upon a specific masticatory pattern? Yamashita S, et al. **J Oral Rehabil** 1999 Jul;26(7):547–53 (21 ref.)

Engineering approaches to chewing and digestion. Alexander RM. **Sci Prog** 1999;82 (Pt 2):171–84 (20 ref.)

MASTICATORY MUSCLES

Anatomic study of complex anomalies of the digastric muscle and review of the literature. Sargon MF, et al. **Okajimas Folia Anat Jpn** 1999 Mar;75(6):305–13 (23 ref.)

PHYSIOLOGY

[The effect of the use of chewing gum on the biomechanics of the masticatory system and periodontal tissue] Loginova NK, et al. **Stomatologiia (Mosk)** 1998;77(5):63–8 (102 ref.) **(Rus)**

MASTICATORY SYSTEM see **STOMATOGNATHIC SYSTEM**

MASTIGOPHORA

GENETICS

Group I twintrons: genetic elements in myxomycete and schizopyrenid amoeboflagellate ribosomal DNAs. Einvik C, et al. **J Biotechnol** 1998 Sep 17;64(1):63–74 (36 ref.)

PHYSIOLOGY

Graviresponses of certain ciliates and flagellates. Hemmersbach R, et al. **FASEB J** 1999;13 Suppl:S69–75 (62 ref.)

MASTIGOPHORA INFECTIONS

VETERINARY

Immunization and diagnosis in bovine reproductive tract infections. Corbeil LB. **Adv Vet Med** 1999;41:217–39 (108 ref.)

MASTITIS

[Mastitis puerperalis] Kano T. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):185–7 (7 ref.) **(Jpn)**

ETIOLOGY

Diabetic mastopathy, complication of type 1 diabetes mellitus: report of two cases and a review of the literature. Boullu S, et al. **Diabetes Metab** 1998 Nov;24(5):448–54 (19 ref.)

PARASITOLOGY

Breast infection due to Dirofilaria repens: report of two new Italian cases and revision of the literature. Pampiglione S, et al. **Parassitologia** 1998 Sep;40(3):269–73 (31 ref.)

PHYSIOPATHOLOGY

Breast-feeding, mastitis, and HIV transmission: nutritional implications. Semba RD, et al. **Nutr Rev** 1999 May;57(5 Pt 1):146–53 (100 ref.)

THERAPY

Homeopathy. A theoretical framework and clinical application. Castro M. **J Nurse Midwifery** 1999 May–Jun; 44(3):280–90 (24 ref.)

MASTITIS, BOVINE

DIAGNOSIS

Vaccines and diagnostic methods for bovine mastitis: fact and fiction. Yancey RJ Jr. **Adv Vet Med** 1999;41:257–73 (68 ref.)

DRUG THERAPY

[Pharmacokinetic aspects of mastitis therapy] Ehinger AM, et al. **Berl Munch Tierarztl Wochenschr** 1998 Sep; 111(9):337–43 (50 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Vaccines and diagnostic methods for bovine mastitis: fact and fiction. Yancey RJ Jr. **Adv Vet Med** 1999;41:257–73 (68 ref.)

METABOLISM

Loss in milk yield and related composition changes resulting from clinical mastitis in dairy cows. Hortet P, et al. **Prev Vet Med** 1998 Dec 1;37(1–4):1–20 (66 ref.)

PREVENTION & CONTROL

Streptococcus uberis: a permanent barrier to the control of bovine mastitis? Leigh JA. **Vet J** 1999 May;157(3):225–38 (97 ref.)

TRANSMISSION

[Feeding of milk from cows with diseased udders to calves from the viewpoint of public health] Hässig M. **Schweiz Arch Tierheilkd** 1999;141(3):125–9 (0 ref.) (Eng. Abstr.) **(Ger)**

MASTITIS, CYSTIC see **FIBROCYSTIC DISEASE OF BREAST**

MASTOCYTOMA, BENIGN see **MASTOCYTOSIS**

MASTOCYTOSIS

Cutaneous and systemic manifestations of mastocytosis. Alto WA, et al. **Am Fam Physician** 1999 Jun;59(11):3047–54, 3059–60 (21 ref.)

[Systemic mastocytosis] Terada H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):152–5 (16 ref.) **(Jpn)**

DIAGNOSIS

Strategies in childhood and adult mastocytosis. Kissling S, et al. **Dermatology** 1999;198(4):426–30 (36 ref.)

[Systemic mastocytosis. A review of current diagnostic and therapeutic approaches] Pari F, et al. **Recenti Prog Med** 1999 Mar;90(3):169–72 (50 ref.) (Eng. Abstr.) **(Ita)**

[Systemic mastocytosis and fever of unknown origin (letter)] Luaces Rodrigo J, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):319 (7 ref.) **(Spa)**

DRUG THERAPY

[Systemic mastocytosis. A review of current diagnostic and therapeutic approaches] Pari F, et al. **Recenti Prog Med** 1999 Mar;90(3):169–72 (50 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Systemic mastocytosis and other mast cell neoplasms. Bain BJ. **Br J Haematol** 1999 Jul;106(1):9-17 (61 ref.)

THERAPY

Strategies in childhood and adult mastocytosis. Kissling S, et al. **Dermatology** 1999;198(4):426-30 (36 ref.)

MASTOCYTOSIS, BULLOUS see **URTICARIA PIGMENTOSA**

MASTOCYTOSIS, DIFFUSE CUTANEOUS see **URTICARIA PIGMENTOSA**

MASTOID

SURGERY

Mastoid and tympanomastoid procedures in otitis media: classic mastoidectomy (simple, modified, and radical) and current adaptations; open-cavity, closed-cavity, and intact-bridge tympanomastoidectomy. Goycoolea MV. **Otolaryngol Clin North Am** 1999 Jun;32(3):513-23 (4 ref.)

Closed tympanomastoidectomy. Graham MD, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):547-54 (35 ref.)

Flexible approach to tympanomastoidectomy. Kimberley BP, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):585-95 (3 ref.)

Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567-83 (56 ref.)

Open-cavity tympanomastoidectomy. Roland PS, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):525-46 (17 ref.)

A one-stage, versatile procedure: intact-bridge mastoidectomy. Sajjadi H. **Otolaryngol Clin North Am** 1999 Jun;32(3):555-65 (12 ref.)

[The retro-auricular, transmastoid, infralabyrinth approach. A simple route for excision of tumors of the jugular foramen] Fournier HD, et al. **Neurochirurgie** 1998 Apr; 44(2):111-6 (18 ref.) (Eng. Abstr.) **(Fre)**

MASTOIDITIS

Mastoiditis: a case-based review. Wang NE, et al. **Pediatr Emerg Care** 1998 Aug;14(4):290-2 (26 ref.)

[Acute mastoiditis] Miwa T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):307-9 (10 ref.) **(Jpn)**

DIAGNOSIS

Aspergillus mastoiditis in acquired immunodeficiency syndrome. Chen D, et al. **Am J Otol** 1999 Sep;20(5):561-7 (16 ref.)

SURGERY

[Current possibilities in microsurgery of the external and middle ear, and the mastoid] Mudry A. **Rev Med Suisse Romande** 1998 Oct;118(10):881-7 (39 ref.) **(Fre)**

THERAPY

Aspergillus mastoiditis in acquired immunodeficiency syndrome. Chen D, et al. **Am J Otol** 1999 Sep;20(5):561-7 (16 ref.)

MASTOMYS see **MURIDAE**

MATCHED CASE-CONTROL STUDIES see **CASE-CONTROL STUDIES**

MATERIA MEDICA

see related
MEDICINE, TRADITIONAL

MATERIALS MANAGEMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

Hospital supply channel management. Frazier D. **J Soc Health Syst** 1998;5(4):63-8 (0 ref.)

MATERIALS TESTING

A review of nondestructive test methods and their application to measure the stability and osseointegration of bone anchored endosseous implants. Meredith N. **Crit Rev Biomed Eng** 1998;26(4):275-91 (35 ref.)

The effects of the surface topography of micromachined titanium substrata on cell behavior in vitro and in vivo. Brunette DM, et al. **J Biomech Eng** 1999 Feb;121(1):49-57 (56 ref.)

Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. Denstedt JD, et al. **J Endourol** 1998 Dec;12(6):493-500 (75 ref.)

Use of quantitative convergent-beam electron diffraction in materials science. Holmestad R, et al. **Microsc Res Tech** 1999 Jul 15;46(2):130-45 (75 ref.)

A review of metallic, ceramic and surface-treated metals used for bearing surfaces in human joint replacements. Dearnley PA. **Proc Inst Mech Eng [H]** 1999;213(2):107-35 (87 ref.)

[Materials for intraocular implants. I. Polymethylmethacrylate intraocular implants and surface modifications] Werner LP, et al. **J Fr Ophtalmol** 1998 Aug-Sep;21(7):515-24 (75 ref.) **(Fre)**

[Biocompatibility of renal replacement therapy] Schiffl H, et al. **Internist (Berl)** 1999 Jan;40(1):37-48 (98 ref.) **(Ger)**

METHODS

The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353-6 (15 ref.)

Surface characterization of polymers for medical devices. Werner C, et al. **Int J Artif Organs** 1999 Mar;22(3):160-76 (104 ref.)

Thermal cycling procedures for laboratory testing of dental restorations. Gale MS, et al. **J Dent** 1999 Feb;27(2):89-99 (177 ref.)

Clinically relevant approach to failure testing of all-ceramic restorations. Kelly JR. **J Prosthet Dent** 1999 Jun; 81(6):652-61 (62 ref.)

STANDARDS

Regulatory perspective on characterization and testing of orthopedic bone cements. Demian HW, et al. **Biomaterials** 1998 Sep;19(17):1607-18 (82 ref.)

MATERNAL AGE

Prepregnancy genetic testing for age-related aneuploidies by polar body analysis. Verlinsky Y, et al. **Genet Test** 1997-98; 1(4):231-5 (13 ref.)

Long-term effects of delayed parenthood. Tarín JJ, et al. **Hum Reprod** 1998 Sep;13(9):2371-6 (106 ref.)

MATERNAL AGE 35 AND OVER

see related
PREGNANCY, HIGH-RISK

Fertility in perimenopausal women. Cohen MA, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):958-65 (32 ref.)

Infertility in the older woman. Schmidt-Sarosi C. **Clin Obstet Gynecol** 1998 Dec;41(4):940-50 (58 ref.)

Contraception at age 35 years and older. Westhoff C. **Clin Obstet Gynecol** 1998 Dec;41(4):951-7 (26 ref.)

Achieving and maintaining pregnancy after age 40. Corson SL. **Int J Fertil Womens Med** 1998 Sep-Oct;43(5):249-56 (15 ref.)

The impact of age on reproductive potential: lessons learned from oocyte donation. Sauer MV. **Maturitas** 1998 Oct 12; 30(2):221-5 (23 ref.)

MATERNAL BEHAVIOR

PHYSIOLOGY

Commentary: is maternal stimulation the mediator of the handling effect in infancy? Denenberg VH. **Dev Psychobiol** 1999 Jan;34(1):1-3 (15 ref.)

Neurobiology of mother-infant interactions: experience and central nervous system plasticity across development and generations. Fleming AS, et al. **Neurosci Biobehav Rev** 1999 May;23(5):673-85 (106 ref.)

Role of the vomeronasal input in maternal behavior. Del Cerro MC. **Psychoneuroendocrinology** 1998 Nov; 23(8):905-26 (93 ref.)

[Physiological and sensorial determinism of maternal behavior in mammals] Lévy F. **Contracept Fertil Sex** 1998 Oct;26(10):718-27 (78 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Maternal care and the development of stress responses. Francis DD, et al. **Curr Opin Neurobiol** 1999 Feb; 9(1):128-34 (49 ref.)

MATERNAL-CHILD NURSING

A concept analysis of parent-infant attachment. Goulet C, et al. **J Adv Nurs** 1998 Nov;28(5):1071-81 (84 ref.)

Selecting pumps for breastfeeding mothers. Biancuzzo M. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):417-26 (20 ref.)

Relief of breast engorgement for the Sabbath-observant Jewish woman. Chertok I. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):365-9 (13 ref.)

Systemic lupus erythematosus: perinatal and neonatal implications. Classen SR, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct; 27(5):493-500 (20 ref.)

Bedside musical care: applications in pregnancy, childbirth, and neonatal care. Olson SL. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):569-75 (33 ref.)

Guiding parents' use of the Internet for newborn education. Lamp JM, et al. **MCN Am J Matern Child Nurs** 1999 Jan-Feb;24(1):33-6 (8 ref.)

MATERNAL DEPRIVATION

Responses to maternal separation: mechanisms and mediators. Kuhn CM, et al. **Int J Dev Neurosci** 1998 Jun-Jul; 16(3-4):261-70 (57 ref.)

Stress and the developing limbic-hypothalamic-pituitary-adrenal axis. Vázquez DM. **Psychoneuroendocrinology** 1998 Oct;23(7):663-700 (110 ref.)

MATERNAL EXPOSURE

see related
MATERNAL-FETAL EXCHANGE
PATERNAL EXPOSURE
PRENATAL EXPOSURE DELAYED EFFECTS

Three cases of a hitherto unrecognized pituitary tumour: it is caused by maternal exposure to unidentified factor(s) during pregnancy? [letter] Horvath E, et al. **Clin Endocrinol (Oxf)** 1998 Oct;49(4):547-8 (4 ref.)

[Biological capabilities of the thymus of human fetus during normal development and during constant exposure to small doses of radiation after the accident at the Chernobyl power plant] Khlystova ZS, et al. **Arkh Patol** 1998 Sep-Oct;60(5):74-9 (41 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Child health and environmental pollution in the Aral Sea region in Kazakhstan. Zetterström R. **Acta Paediatr Suppl** 1999 May;88(429):49-54 (23 ref.)

Disentangling the separate effects of prenatal and postnatal smoking on the risk of SIDS [comment] Spiers PS. **Am J Epidemiol** 1999 Apr 1;149(7):603-6; discussion 607 (33 ref.) Comment on: Am J Epidemiol 1999 Apr 1;149(7):593-602.

Physiologic programming of the fetus. Seckl JR. **Clin Perinatol** 1998 Dec;25(4):939-62, vii (171 ref.)

A mechanistic-based approach for assessing chemical hazards to parturition. Loch-Caruso R. **J Womens Health** 1999 Mar;8(2):235-48 (96 ref.)

[The effect of unfavorable environmental factors on the mother-fetus system] Serova LV. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):62-72 (58 ref.) (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Methodological issues in the study of rare exposures and rare outcomes in perinatal epidemiology. Bracken MB. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S354-5 (7 ref.)

MATERNAL-FETAL EXCHANGE

see related
ABNORMALITIES, DRUG-INDUCED

Fetal cells in the maternal circulation: feasibility for prenatal diagnosis. Bianchi DW. **Br J Haematol** 1999 Jun; 105(3):574-83 (126 ref.)

Controlling drug delivery across the placenta. Audus KL. **Eur J Pharm Sci** 1999 Jul;8(3):161-5 (38 ref.)

Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Dybing E, et al. **Hum Exp Toxicol** 1999 Apr;18(4):202-5 (30 ref.)

From in utero and childhood exposure to parental smoking to childhood cancer: a possible link and the need for action. Sasco AJ, et al. **Hum Exp Toxicol** 1999 Apr;18(4):192-201 (115 ref.)

Mechanisms of drug transfer across the human placenta. van der Aa EM, et al. **Pharm World Sci** 1998 Aug;20(4):139-48 (139 ref.)

Central integrative role of oestrogen in modulating the communication between the placenta and fetus that results in primate fecal-placental development. Albrecht ED, et al. **Placenta** 1999 Mar-Apr;20(2-3):129-39 (128 ref.)

Maternal cocaine use and cigarette smoking in pregnancy in relation to amino acid transport and fetal growth. Pastrakuljic A, et al. **Placenta** 1999 Sep;20(7):499-512 (136 ref.)

Dynamics of immunoglobulins at the feto-maternal interface. Saji F, et al. **Rev Reprod** 1999 May;4(2):81-9 (85 ref.)

Effects of maternal anesthesia in the neonate. D'Alessio JG, et al. **Semin Perinatol** 1998 Oct;22(5):350-62 (95 ref.)

Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Strauss AW, et al. **Semin Perinatol** 1999 Apr;23(2):100-12 (55 ref.)

Radioiodine and pregnancy. Gorman CA. **Thyroid** 1999 Jul; 9(7):721-6 (45 ref.)

Transplacental transfer of radionuclides. A review. von Zallinger C, et al. **Zentralbl Veterinarmed A** 1998 Dec; 45(10):581-90 (45 ref.)

[Smoking cessation and pregnancy] Møller AM, et al. **Ugeskr Laeger** 1999 Sep 6;161(36):4985-6 (10 ref.) (Eng. Abstr.) **(Dan)**

[Fetal cells in the maternal blood: a step towards non-invasive prenatal diagnosis? Review of the literature] Houfflin-Debarge V, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):483-93 (83 ref.) (Eng. Abstr.) **(Fre)**

[The effect of unfavorable environmental factors on the mother-fetus system] Serova LV. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):62-72 (58 ref.) (Eng. Abstr.) **(Rus)**

MATERNAL-FETAL EXCHANGE

DRUG EFFECTS

Maternal-Fetal Medicine Units (MFMU) studies of inhaled corticosteroids during pregnancy. Dombrowski M, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S356-9 (2 ref.)

[Pharmacological principles in pregnancy] Villanueva LA, et al. **Gac Med Mex** 1998 Sep-Oct;134(5):575-82 (32 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and feto-maternal interactions. Fernandez N, et al. **Hum Reprod Update** 1999 May-Jun;5(3):234-48 (154 ref.)

Autoimmune disease and the long-term persistence of fetal and maternal microchimerism [editorial] Nelson JL. **Lupus** 1999;8(7):493-6 (36 ref.)

Fetomaternal HLA differences and the onset and course of rheumatoid arthritis. Hazes JM. **Rev Rhum Engl Ed** 1998 Nov;65(11):611-3 (27 ref.)

HLA-G expression: immune privilege for tumour cells? Cabestre FA, et al. **Semin Cancer Biol** 1999 Feb;9(1):27-36 (49 ref.)

HLA-G and HLA-C at the feto-maternal interface: lessons learned from pathogenic viruses. Schust DJ, et al. **Semin Cancer Biol** 1999 Feb;9(1):37-46 (71 ref.)

[The immunological aspects of maternal-fetal interrelationships] Pal'tsev MA, et al. **Vestn Ross Akad Med Nauk** 1999;(5):32-6 (46 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Programming of hepatic and peripheral tissue insulin sensitivity by maternal protein restriction. Ozanne SE. **Biochem Soc Trans** 1999 Feb;27(2):94-7 (27 ref.)

Maternal nutrition and endocrine programming of fetal adipose tissue development. Symonds ME, et al. **Biochem Soc Trans** 1999 Feb;27(2):97-103 (46 ref.)

Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Miller WL. **Clin Perinatol** 1998 Dec;25(4):799-817, v (104 ref.)

Nutrition of the fetus and the premature infant. Battaglia FC, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B70-4 (42 ref.)

Effect of maternal metabolism on fetal growth and body composition. Catalano PM, et al. **Diabetes Care** 1998 Aug; 21 Suppl 2:B85-90 (35 ref.)

Novel insights into human endometrial paracrinology and embryo-maternal communication by intrauterine microdialysis. Licht P, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):532-8 (30 ref.)

Current knowledge about fetal blood cells in the maternal circulation. Bianchi DW. **J Perinat Med** 1998;26(3):175-85 (83 ref.)

First trimester utero-placental circulation: maternal-fetal interaction. Jaffe R. **J Perinat Med** 1998;26(3):168-74 (49 ref.)

Physiological roles of placental proteases in feto-placental homeostasis. Mizutani S. **Nagoya J Med Sci** 1998 Oct; 61(3-4):85-95 (73 ref.)

MATERNAL HEALTH see **MATERNAL WELFARE**

MATERNAL HEALTH SERVICES

ORGANIZATION & ADMINISTRATION

Organizing delivery care: what works for safe motherhood? Koblinsky MA, et al. **Bull World Health Organ** 1999; 77(5):399-406 (17 ref.)

Early discharge. Risks, benefits, and who decides. Kiely M, et al. **Clin Perinatol** 1998 Sep;25(3):539-53, vii-viii (62 ref.)

IAMANEH and the new concept of reproductive health. International Association for Maternal and Neonatal Health. Pinotti JA, et al. **Int J Gynaecol Obstet** 1998 Dec; 63 Suppl 1:S3-12 (14 ref.)

"Changing childbirth" in the United Kingdom: lessons for U.S. health policy. Declercq E. **J Health Polit Policy Law** 1998 Oct;23(5):833-59 (90 ref.)

A review of recent findings on substance abuse treatment for pregnant women. Howell EM, et al. **J Subst Abuse Treat** 1999 Apr;16(3):195-219 (128 ref.)

[Networks and channels in perinatology. Definitions, typology and enterprises] Naiditch M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:52-61 (25 ref.) **(Fre)**

[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:94-103 (40 ref.) **(Fre)**

[Pregnancy and delivery in western Africa. Towards a lower risk motherhood?] Prual A. **Sante Publique** 1999 Jun; 11(2):167-91 (126 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

The Safe Motherhood Initiative: why has it stalled? Maine D, et al. **Am J Public Health** 1999 Apr;89(4):480-2 (18 ref.)

A systematic review comparing continuity of midwifery care with standard maternity services. Waldenström U, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1160-70 (32 ref.)

MATERNAL MORTALITY

Maternal mortality in Nigeria: the real issues. Harrison KA. **Afr J Reprod Health** 1997 Mar;1(1):7-13 (8 ref.)

Abortion and maternal health. Bernstein PS, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S115-22 (32 ref.)

Advances in perinatal medical care--from our experience. Sakamoto S, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S107-14 (9 ref.)

Short birth intervals don't kill women: evidence from Matlab, Bangladesh. Ronsmans C, et al. **Stud Fam Plann** 1998 Sep; 29(3):282-90 (34 ref.)

Dead mothers and injured wives: the social context of maternal morbidity and mortality among the Hausa of northern Nigeria. Wall LL. **Stud Fam Plann** 1998 Dec; 29(4):341-59 (128 ref.)

[Safe motherhood: is the initiative an orphan?] Weil O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jun; 28(3):205-10 (21 ref.) (Eng. Abstr.) **(Fre)**

[Maternal morbidity and mortality related to delivery] Magnin G. **Rev Prat** 1999 Jan 15;49(2):172-7 (7 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy and delivery in western Africa. High risk motherhood] Prual A. **Sante Publique** 1999 Jun; 11(2):155-65 (126 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

The Safe Motherhood Initiative: why has it stalled? Maine D, et al. **Am J Public Health** 1999 Apr;89(4):480-2 (18 ref.)

The influence of abortion legislation on maternal mortality. Singh K, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S123-9 (12 ref.)

Maternal mortality in the developing world: many unanswered questions. Rizvi JH, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):149-51 (24 ref.)

MATERNAL PATTERNS OF CARE see **MATERNAL BEHAVIOR**

MATERNAL WELFARE

see related
MATERNAL HEALTH SERVICES

Assessing the effects of welfare reform policies on reproductive and infant health [see comments] Wise P, et al. **Am J Public Health** 1999 Oct;89(10):1514-21 (79 ref.) Comment in: Am J Public Health 1999 Oct;89(10):1476-8. Comment in: Am J Public Health 1999 Oct;89(10):1479-82.

Physical abuse during pregnancy: a significant threat to maternal and child health [editorial; comment] MacMillan HL. **CMAJ** 1999 Apr 6;160(7):1022-3 (11 ref.) Comment on: CMAJ 1999 Apr 6;160(7):1007-11.

Abortion and maternal health. Bernstein PS, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S115-22 (32 ref.)

The traditional birth attendant: a reality and a challenge. Kamal IT. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S43-52 (11 ref.)

[Safe motherhood: is the initiative an orphan?] Weil O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jun; 28(3):205-10 (21 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Birth trauma and the pelvic floor: lessons from the developing world. Wall LL. **J Womens Health** 1999 Mar;8(2):149-55 (36 ref.)

TRENDS

The Safe Motherhood Initiative: why has it stalled? Maine D, et al. **Am J Public Health** 1999 Apr;89(4):480-2 (18 ref.)

IAMANEH and the new concept of reproductive health. International Association for Maternal and Neonatal Health. Pinotti JA, et al. **Int J Gynaecol Obstet** 1998 Dec; 63 Suppl 1:S3-12 (14 ref.)

MATERNALLY-ACQUIRED IMMUNITY see **IMMUNITY, MATERNALLY-ACQUIRED**

MATERNITY LEAVE see **PARENTAL LEAVE**

MATERNITY NURSING see **MATERNAL-CHILD NURSING**

MATHEMATICAL COMPUTING

Calculation of standard transformed formation properties of biochemical reactants and standard apparent reduction potentials of half reactions. Alberty RA. **Arch Biochem Biophys** 1998 Oct 1;358(1):25-39 (50 ref.)

Recent developments towards a unified theory for separation science (minireview). Bowser MT, et al. **Electrophoresis** 1998 Jul;19(10):1586-9 (34 ref.)

Application of mathematical methods in dynamic nuclear medicine studies. Lawson RS. **Phys Med Biol** 1999 Apr; 44(4):R57-98 (120 ref.)

The complexities of DNA computation. Cox JC, et al. **Trends Biotechnol** 1999 Apr;17(4):151-4 (29 ref.)

MATHEMATICS

Is integer arithmetic fundamental to mental processing?: the mind's secret arithmetic. Snyder AW, et al. **Proc R Soc Lond B Biol Sci** 1999 Mar 22;266(1419):587-92 (49 ref.)

[Significance of philosophy, bio-mathematics, biometry and model theory for medicine] Gerok W. **Med Klin** 1998 Aug 15;93(8):501-6 (6 ref.) **(Ger)**

MATING BEHAVIOR, ANIMAL see **SEX BEHAVIOR, ANIMAL**

MATING-TYPE GENES see **GENES, FUNGAL**

MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MATRIX, EXTRACELLULAR see **EXTRACELLULAR MATRIX**

MATRIX METALLOPROTEINASE 3 see **STROMELYSIN 1**

MATTRESSES see **BEDS**

MATURATION-PROMOTING FACTOR

see related
CYCLINS

METABOLISM

Maturation promoting factor activation in early amphibian embryos: temporal and spatial control. Beckhelling C, et al. **Biol Cell** 1998 Oct;90(6-7):467-76 (122 ref.)

Nuclear responses to MPF activation and inactivation in Xenopus oocytes and early embryos. Lohka MJ. **Biol Cell** 1998 Nov;90(8):591-9 (98 ref.)

PHYSIOLOGY

Regulating the onset of mitosis. Ohi R, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):267-73 (65 ref.)

The molecular mechanisms of oocyte maturation and early embryonic development are unveiling new insights into reproductive medicine. Heikinheimo O, et al. **Mol Hum Reprod** 1998 Aug;4(8):745-56 (137 ref.)

MATURITY-ONSET DIABETES MELLITUS see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

MAXILLA

see related
MAXILLOFACIAL DEVELOPMENT

Cherubism: clinicopathologic features. Yamaguchi T, et al. **Skeletal Radiol** 1999 Jun;28(6):350-3 (19 ref.)

ABNORMALITIES

Cheilognathopalatoschisis and its prophylaxis in animal experiments. Malek FA, et al. **Anat Anz** 1999 Jan; 181(1):107-10 (43 ref.)

State of the art in oral and maxillofacial surgery: treatment of maxillary hypoplasia and anterior palatal and alveolar clefts. Steinberg B, et al. **Cleft Palate Craniofac J** 1999 Jul;36(4):283-91 (44 ref.)

[Maxillo-mandibular ++disharmonies] Raphaël B, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):481-514 (53 ref.) (Eng. Abstr.) **(Fre)**

[Cheilognathopalatoschisis: its embryology, epidemiology, etiology, clinical picture and therapy. The experience of a division of pediatrics] Tarallo D, et al. **Pediatr Med Chir** 1998 Jul-Aug;20(4):281-4 (27 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[The effects of tooth loss on the anatomy of the maxilla] Solar P, et al. **Schweiz Monatsschr Zahnmed** 1998; 108(9):871-8 (22 ref.) **(Ger, Fre)**

PHYSIOLOGY

Toward an understanding of implant occlusion and strain adaptive bone modeling and remodeling. Stanford CM, et al. **J Prosthet Dent** 1999 May;81(5):553-61 (111 ref.)

RADIOGRAPHY

[Dental CT: image quality and radiation exposure in relation to scan parameters] Schorn C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):137-44 (24 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Bimaxillary surgery using an intermediate splint to position the maxilla [see comments] Ellis E 3rd.

J Oral Maxillofac Surg 1999 Jan;57(1):53–6 (52 ref.) Comment in: J Oral Maxillofac Surg 1999 Jan;57(1):57–60.
[Maxillo–mandibular ++disharmonies] Raphaël B, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):481–514 (53 ref.) (Eng. Abstr.) **(Fre)**

MAXILLARY ANTRUM see **MAXILLARY SINUS**

MAXILLARY ARTERY

ABNORMALITIES

Arteriovenous malformations of the dental arcades. The place of endovascular therapy: results in 12 cases are presented. Rodesch G, et al. **J Craniomaxillofac Surg** 1998 Oct; 26(5):306–13 (17 ref.)

MAXILLARY DISEASES

CHEMICALLY INDUCED

Oral and systemic effects of prolonged minocycline therapy. Patel K, et al. **Br Dent J** 1998 Dec 12–26;185(11–12):560–2 (19 ref.)

DIAGNOSIS

Herpes zoster infection of the maxilla: case report. Owotade FJ, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1249–51 (21 ref.)
[Giant–cell reparative granuloma (GCRG). A review of the literature, the present state of knowledge and therapeutic suggestions] Fancello A, et al. **Minerva Stomatol** 1998 Sep; 47(9):399–407 (47 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Midfacial complications of prolonged cocaine snorting. Villa PD. **J Can Dent Assoc** 1999 Apr;65(4):218–23 (28 ref.)

PATHOLOGY

Glandular odontogenic cyst (sialo–odontogenic cyst): report of two cases and literature review of 45 previously reported cases. Koppang HS, et al. **J Oral Pathol Med** 1998 Oct; 27(9):455–62 (33 ref.)

SURGERY

Gigantiform Torus palatinus: review of the literature and report of a case. MacInnis EL, et al. **Int Dent J** 1998 Feb; 48(1):40–3 (21 ref.)

MAXILLARY EXPANSION see **PALATAL EXPANSION TECHNIQUE**

MAXILLARY NEOPLASMS

DIAGNOSIS

Presentation and diagnosis of unilateral maxillary swelling in children. Koch BL, et al. **Am J Otolaryngol** 1999 Mar–Apr;20(2):106–29 (92 ref.)

ETIOLOGY

Odontogenic ghost cell carcinoma: report of a case. Kamijo R, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1266–70 (11 ref.)

PATHOLOGY

Ameloblastoma of the maxilla. Case report. Iordanidis S, et al. **Aust Dent J** 1999 Mar;44(1):51–5 (26 ref.)
Mesenchymal chondrosarcoma of the maxilla: report of a case. Ariyoshi Y, et al. **J Oral Maxillofac Surg** 1999 Jun; 57(6):733–7 (13 ref.)
Odontogenic ghost cell carcinoma: report of four new cases and review of the literature. Lu Y, et al. **J Oral Pathol Med** 1999 Aug;28(7):323–9 (34 ref.)
Bizarre parosteal osteochondromatous proliferation in the anterior maxilla: report of a case. Shankly PE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):351–6 (26 ref.)

RADIOGRAPHY

An unusual case of maxillary ameloblastoma. Schutyser K, et al. **J Belge Radiol** 1998 Aug;81(4):178–80 (8 ref.)

MAXILLARY PROSTHESIS see **MAXILLOFACIAL PROSTHESIS**

MAXILLARY RIDGE AUGMENTATION see **ALVEOLAR RIDGE AUGMENTATION**

MAXILLARY SINUS

INJURIES

A classification system for sinus membrane perforations during augmentation procedures with options for repair. Vlassis JM, et al. **J Periodontol** 1999 Jun;70(6):692–9 (28 ref.)

MICROBIOLOGY

Evaluation of the microbiology of chronic maxillary sinusitis. Biel MA, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):942–5 (19 ref.)

PATHOLOGY

Myospherulosis of maxillary sinus—a case report with review of literature. Sarkar S, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):491–3 (10 ref.)
Cavernous haemangioma in the infraorbital nerve canal—an unusual expansion in the maxillary sinus. Walch C, et al. **J Laryngol Otol** 1998 Sep;112(9):872–4 (10 ref.)

SURGERY

A classification system for sinus membrane perforations during augmentation procedures with options for repair. Vlassis JM, et al. **J Periodontol** 1999 Jun;70(6):692–9 (28 ref.)
[Maxillary sinusotomy] Lambrecht JT. **Schweiz Monatsschr Zahnmed** 1998;108(12):1201–20 (61 ref.) **(Ger, Fre)**

MAXILLARY SINUS NEOPLASMS

Verrucous carcinoma of the maxillary antrum [letter; comment] Indudharan R. **J Laryngol Otol** 1998 Dec; 112(12):1218 (3 ref.) Comment on: J Laryngol Otol 1998 Apr;112(4):399–402.

COMPLICATIONS

Rare cause of blindness in a patient with acquired immunodeficiency syndrome. Cook MA, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):711–4 (16 ref.)

DIAGNOSIS

Rare cause of blindness in a patient with acquired immunodeficiency syndrome. Cook MA, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):711–4 (16 ref.)
Acinic cell carcinoma of maxillary sinus. Fujii M, et al. **Auris Nasus Larynx** 1998 Dec;25(4):451–7 (23 ref.)
Plexiform ameloblastoma involving the maxillary antrum. A case report [see comments] Guariglia J, et al. **N Y State Dent J** 1998 Nov;64(9):34–6 (25 ref.) Comment in: N Y State Dent J 1999 Feb;65(2):9.
[Maxillary ameloblastoma. Illustration apropos of a clinical case] Gruyer X, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(5):329–32 (11 ref.) (Eng. Abstr.) **(Fre)**
[Atypical localization of a small cell carcinoma in the paranasal sinus area—case report] Heib C, et al. **Laryngorhinootologie** 1998 Jul;77(7):394–7 (23 ref.) (Eng. Abstr.) **(Ger)**
[Multiple brown tumors of the paranasal sinuses in tertiary hyperparathyroidism] Pöckler–Schöniger C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):72–5 (10 ref.) **(Ger)**

MAXILLARY SINUSITIS

[Maxillary sinusitis] Takayama M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):295–7 (1 ref.) **(Jpn)**

ETIOLOGY

Recirculation of mucus as a cause of persistent sinusitis. Kane KJ. **Am J Rhinol** 1997 Sep–Oct;11(5):361–9 (9 ref.)
Artificial ventilation–acquired sinopathy in the critically ill – the maxillary sinuses revisited. Westergren V. **Clin Exp Allergy** 1999 Mar;29(3):298–305 (52 ref.)
Midfacial complications of prolonged cocaine snorting. Villa PD. **J Can Dent Assoc** 1999 Apr;65(4):218–23 (28 ref.)

SURGERY

Recirculation of mucus as a cause of persistent sinusitis. Kane KJ. **Am J Rhinol** 1997 Sep–Oct;11(5):361–9 (9 ref.)

MAXILLOFACIAL ABNORMALITIES

PREVENTION & CONTROL

The role of folic acid in oral clefting. Hartridge T, et al. **Br J Orthod** 1999 Jun;26(2):115–20 (42 ref.)

MAXILLOFACIAL DEVELOPMENT

see related
CEPHALOMETRY
VERTICAL DIMENSION

Craniofacial growth in children treated for malignant diseases. Dahllöf G. **Acta Odontol Scand** 1998 Dec; 56(6):378–82 (40 ref.)
Craniofacial growth in juvenile chronic arthritis. Kjellberg H. **Acta Odontol Scand** 1998 Dec;56(6):360–5 (58 ref.)
Facial growth after different methods of surgical intervention in patients with cleft lip and palate. Semb G, et al. **Acta Odontol Scand** 1998 Dec;56(6):352–5 (24 ref.)
The spheno–occipital synchondrosis: the missing link between the profession's concept of craniofacial growth and orthodontic treatment. Coben SE. **Am J Orthod Dentofacial Orthop** 1998 Dec;114(6):709–12; discussion 713–4 (31 ref.)
Basic science and clinical experimental primate studies in craniofaciodental biology: a personal historical review. Sarnat BG. **J Oral Maxillofac Surg** 1999 Jun;57(6):714–24 (30 ref.)

GENETICS

The genetic basis of normal and abnormal craniofacial development. Thesleff I. **Acta Odontol Scand** 1998 Dec; 56(6):321–5 (39 ref.)

PHYSIOLOGY

Postural disorders and dentofacial morphology. Huggare J. **Acta Odontol Scand** 1998 Dec;56(6):383–6 (39 ref.)
Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Own observations and review of the literature. Van Erum R, et al. **Horm Res** 1998 Sep;50(3):141–6 (35 ref.)

MAXILLOFACIAL INJURIES

CLASSIFICATION

A classification system for sinus membrane perforations during augmentation procedures with options for repair. Vlassis JM, et al. **J Periodontol** 1999 Jun;70(6):692–9 (28 ref.)

DIAGNOSIS

[Controversies and current status of therapy of optic nerve damage in craniofacial traumatology and surgery] Gellrich NC. **Mund Kiefer Gesichtschir** 1999 Jul;3(4):176–94 (208 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Unusual maxillofacial injury caused by a model airplane. Aldegheri A, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):1009–12 (8 ref.)
[Oro–dental injuries during intubation anesthesia] Folwaczny M, et al. **Anaesthesist** 1998 Sep;47(9):707–31 (204 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Selecting the appropriate setting for management of maxillofacial trauma. Haug RH. **J Oral Maxillofac Surg** 1999 Aug;57(8):983–9 (19 ref.)
[Fixed rotatory subluxation of the atlanto–axial joint in polytrauma patients] Weisskopf M, et al. **Chirurg** 1999 Jul; 70(7):818–22 (25 ref.) (Eng. Abstr.) **(Ger)**
[Absorbable and bioconvertible osteosynthesis materials in maxillofacial surgery] Obwegeser JA. **Mund Kiefer Gesichtschir** 1998 Nov;2(6):288–308 (221 ref.) (Eng. Abstr.) **(Ger)**
[Athletic injuries in mouth, jaw and facial surgery] Mischkowski RA, et al. **Sportverletz Sportschaden** 1998 Dec;12(4):152–61 (15 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Critical systemic and psychosocial considerations in management of trauma in the elderly. Marciani RD. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):272–80 (58 ref.)

MAXILLOFACIAL PROCEDURES see **ORAL SURGICAL PROCEDURES**

MAXILLOFACIAL PROSTHESIS

[Uses of artificial implants in the repair and reconstruction of craniomaxillofacial area] Zou L, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jul;11(4):193–5 (20 ref.) **(Chi)**

ADVERSE EFFECTS

Selection of materials for orbital floor reconstruction [see comments] Chowdhury K, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1398–401 (16 ref.) Comment in: Arch Otolaryngol Head Neck Surg 1998 Dec;124(12):1402. Comment in: Arch Otolaryngol Head Neck Surg 1998 Dec;124(12):1402–3.

MAXILLOFACIAL PROSTHESIS IMPLANTATION

see related
MAXILLOFACIAL PROSTHESIS

MAXIMUM ALLOWABLE CONCENTRATION see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

MAXIMUM LIKELIHOOD ESTIMATES see **LIKELIHOOD FUNCTIONS**

MAXIMUM PERMISSIBLE EXPOSURE LEVEL

Molecular biology, epidemiology, and the demise of the linear no-threshold (LNT) hypothesis. Pollycove M, et al. **C R Acad Sci III** 1999 Feb-Mar;322(2-3):197-204 (36 ref.)

Maximum workplace concentration values and carcinogenicity classification for mixtures. Bartsch R, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1291-3 (18 ref.)

Proposal for the assessment of quantitative dermal exposure limits in occupational environments: Part 1. Development of a concept to derive a quantitative dermal occupational exposure limit. Bos PM, et al. **Occup Environ Med** 1998 Dec;55(12):795-804 (48 ref.)

MAZE LEARNING

Age-associated memory impairment. Assessing the role of nitric oxide. Meyer RC, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:307-17 (62 ref.)

PHYSIOLOGY

A working memory "theory of relativity": elasticity in temporal, spatial, and modality dimensions conserves item capacity in radial maze, verbal tasks, and other cognition. Glassman RB. **Brain Res Bull** 1999 Mar 15;48(5):475-89 (187 ref.)

The cerebellum in the spatial problem solving: a co-star or a guest star? Petrosini L, et al. **Prog Neurobiol** 1998 Oct; 56(2):191-210 (117 ref.)

MCCUNE-ALBRIGHT SYNDROME see **FIBROUS DYSPLASIA, POLYOSTOTIC**

MCGILL PAIN QUESTIONNAIRE see **PAIN MEASUREMENT**

MCLS see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

MCNAUGHTON RULE see **INSANITY DEFENSE**

MCP-1 see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

MDA see **3,4-METHYLENEDIOXYAMPHETAMINE**

MDG1 RETROTRANSPOSONS see **RETROELEMENTS**

MDMA see **N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE**

MDR GENES see **GENES, MDR**

MDR1 GENE see **GENES, MDR**

MDR1 PROTEIN see **P-GLYCOPROTEIN**

MEALS ON WHEELS see **FOOD SERVICES**

MEALWORM see **TENEBRIO**

MEASLES

Cotton rats (Sigmodon hispidus): an animal model to study the pathogenesis of measles virus infection. Niewiesk S. **Immunol Lett** 1999 Jan;65(1-2):47-50 (31 ref.)

Rubella and rubeola. Rosa C. **Semin Perinatol** 1998 Aug; 22(4):318-22 (14 ref.)

[Rubella and measles] Kurashige T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):169-72 (15 ref.) **(Jpn)**

[Immunosuppressive measles encephalitis] Nihei K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):63-4 (5 ref.) **(Jpn)**

[Measles pneumonia] Seki M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):99-101 (15 ref.) **(Jpn)**

COMPLICATIONS

Measles, mycobacterium paratuberculosis and Crohn's disease. Rhodes J, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):255-7 (8 ref.)

Crohn's disease: the case for measles virus. Wakefield AJ, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):247-54 (75 ref.)

EPIDEMIOLOGY

[Eradication of measles in Cuba (published erratum appears in Rev Panam Salud Publica 1998 Nov;4(5):345)] Galindo MA, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):171-7 (23 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[A case of measles encephaloneuropathy in a pregnant women] Haraguchi T, et al. **No To Shinkei** 1998 Aug; 50(8):761-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Measles: immunosuppression, interleukin-12, and complement receptors. Karp CL. **Immunol Rev** 1999 Apr; 168:91-101 (109 ref.)

Virus interactions with dendritic cells. Klagge IM, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):823-33 (101 ref.)

PREVENTION & CONTROL

Measles vaccines: a review of adverse events. Duclos P, et al. **Drug Saf** 1998 Dec;19(6):435-54 (135 ref.)

Measles in adults in Canada and the United States: implications for measles elimination and eradication. Duclos P, et al. **Int J Epidemiol** 1999 Feb;28(1):141-6 (22 ref.)

[Factors affecting acceptance rate of measles vaccine] Isomura S. **Uirusu** 1998 Dec;48(2):183-8 (8 ref.) **(Jpn)**

TRANSMISSION

[Strategies for minimizing nosocomial transmission of measles] Biellik RJ, et al. **Rev Panam Salud Publica** 1998 Nov;4(5):350-7 (62 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Pathogenic aspects of measles virus infections. Schneider-Schaulies S, et al. **Arch Virol Suppl** 1999; 15:139-58 (79 ref.)

MEASLES, GERMAN see **RUBELLA**

MEASLES VACCINE

Immunisation and type 1 diabetes mellitus: is there a link? Hiltunen M, et al. **Drug Saf** 1999 Mar;20(3):207-12 (36 ref.)

[Factors affecting acceptance rate of measles vaccine] Isomura S. **Uirusu** 1998 Dec;48(2):183-8 (8 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Dry powder inhalation as a potential delivery method for vaccines. LiCalsi C, et al. **Vaccine** 1999 Mar 26; 17(13-14):1796-803 (33 ref.)

[Eradication of measles in Cuba (published erratum appears in Rev Panam Salud Publica 1998 Nov;4(5):345)] Galindo MA, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):171-7 (23 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Measles vaccines: a review of adverse events. Duclos P, et al. **Drug Saf** 1998 Dec;19(6):435-54 (135 ref.)

IMMUNOLOGY

Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Poland GA. **Vaccine** 1999 Mar 26;17(13-14):1719-25 (52 ref.)

Measles vaccines, new developments and immunization strategies. Wild TF. **Vaccine** 1999 Mar 26;17(13-14):1726-9 (29 ref.)

MEASLES VIRUS

ISOLATION & PURIFICATION

Subacute sclerosing panencephalitis. Garg RK, et al. **Indian Pediatr** 1998 Apr;35(4):337-44 (41 ref.)

Crohn's disease: the case for measles virus. Wakefield AJ, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):247-54 (75 ref.)

Case report and molecular analysis of subacute sclerosing panencephalitis in a South African Child. Vardas E, et al. **J Clin Microbiol** 1999 Mar;37(3):775-7 (15 ref.)

PATHOGENICITY

Pathogenic aspects of measles virus infections. Schneider-Schaulies S, et al. **Arch Virol Suppl** 1999; 15:139-58 (79 ref.)

MEAT

Meat, metabolic genotypes and risk for colorectal cancer. Roberts-Thomson IC, et al. **Eur J Cancer Prev** 1999 Jul; 8(3):207-11 (19 ref.)

What are the livestock industries doing, and what do they need from us? Meeker DL. **J Anim Sci** 1999 Feb; 77(2):361-6 (5 ref.)

Centralized packaging of retail meat cuts: a review. Tewari G, et al. **J Food Prot** 1999 Apr;62(4):418-25 (64 ref.)

China: the soyabean-pork dilemma. Geissler C. **Proc Nutr Soc** 1999 May;58(2):345-53 (54 ref.)

Meat production in developing countries. Gill M. **Proc Nutr Soc** 1999 May;58(2):371-6 (20 ref.)

Animal- and plant-food-based diets and iron status: benefits and costs. Hambraeus L. **Proc Nutr Soc** 1999 May; 58(2):235-42 (40 ref.)

Animal v. plant foods in human diets and health: is the historical record unequivocal? Nestle M. **Proc Nutr Soc** 1999 May;58(2):211-8 (87 ref.)

Alternative futures for world cereal and meat consumption. Rosegrant MW, et al. **Proc Nutr Soc** 1999 May;58(2):219-34 (10 ref.)

Development of farmed fish: a nutritionally necessary alternative to meat. Sargent JR, et al. **Proc Nutr Soc** 1999 May;58(2):377-83 (26 ref.)

Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. Dashwood RH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):239-43 (28 ref.)

Center for Veterinary Medicine's perspective on the beef hormone case. Leighton JK. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):167-80, x (9 ref.)

ADVERSE EFFECTS

Australian trends in colorectal cancer incidence and Australian guidelines for prevention. Young GP. **Eur J Cancer Prev** 1999 Jul;8(3):179-81 (4 ref.)

High-meat diets and cancer risk. Bingham SA. **Proc Nutr Soc** 1999 May;58(2):243-8 (52 ref.)

Meat and colo-rectal cancer. Hill MJ. **Proc Nutr Soc** 1999 May;58(2):261-4 (25 ref.)

ANALYSIS

Manipulating meat quality and composition. Wood JD, et al. **Proc Nutr Soc** 1999 May;58(2):363-70 (42 ref.)

[Residues of antibiotics and chemotherapeutics in meat] Jemmi T, et al. **Schweiz Arch Tierheilkd** 1999;141(3):109-13 (0 ref.) (Eng. Abstr.) **(Ger)**

[Heterocyclic amines in cooked meat] Vikse R, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):45-9 (38 ref.) (Eng. Abstr.) **(Nor)**

ECONOMICS

[Consumer demands concerning meat between price and ethics] Branscheid W. **DTW Dtsch Tierarztl Wochenschr** 1998 Aug;105(8):289-92 (9 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Wegener HC, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):329-35 (50 ref.)

Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistant bacteria among food animals. Aarestrup FM. **Int J Antimicrob Agents** 1999 Aug;12(4):279-85 (73 ref.)

Integrating microbial decontamination with organic acids in HACCP programmes for muscle foods: prospects and controversies. Smulders FJ, et al. **Int J Food Microbiol** 1998 Nov 10;44(3):149-69 (133 ref.)

Nonacid meat decontamination technologies: model studies and commercial applications. Sofos JN, et al. **Int J Food Microbiol** 1998 Nov 10;44(3):171-88 (92 ref.)

STANDARDS

Reidentification of Canada's national cattle herd. Inch C. **Can Vet J** 1998 Sep;39(9):578-88 (3 ref.) **(Eng, Fre)**

Hazard Analysis and Critical Control Point systems as a preventive tool. Dreesen DW. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1741-4 (7 ref.)

Extracellular modifications to muscle collagen: implications for meat quality. McCormick RJ. **Poult Sci** 1999 May; 78(5):785-91 (30 ref.)

Contribution of muscle proteinases to meat tenderization. Jiang ST. **Proc Natl Sci Counc Repub China B** 1998 Jul; 22(3):97-107 (102 ref.)

Producer quality assurance programs. Kla J, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):197-208 (5 ref.)

[Consumer demands concerning meat between price and ethics] Branscheid W. **DTW Dtsch Tierarztl Wochenschr** 1998 Aug;105(8):289-92 (9 ref.) (Eng. Abstr.) **(Ger)**

[Bovine spongiform encephalopathy in ruminants and the new variant of Creutzfeldt-Jakob disease in humans] Groschup MH. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):329-31 (22 ref.) (Eng. Abstr.) **(Ger)**

MEAT-PACKING INDUSTRY

Health hazards in the meatpacking industry. Campbell DS. **Occup Med** 1999 Apr-Jun;14(2):351-72 (211 ref.)

MEAT PRODUCTS

Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Knize MG, et al. **Adv Exp Med Biol** 1999;459:179-93 (60 ref.)

Changes in the components of dry-fermented sausages during ripening. Ordóñez JA, et al. **Crit Rev Food Sci Nutr** 1999 Jul;39(4):329-67 (276 ref.)

China: the soyabean-pork dilemma. Geissler C. **Proc Nutr Soc** 1999 May;58(2):345-53 (54 ref.)

MEBENDAZOLE

THERAPEUTIC USE

Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. Ammann RW, et al. **J Hepatol** 1998 Dec;29(6):994-8 (18 ref.)

MEBUBARBITAL see **PENTOBARBITAL**

MEBUMAL see **PENTOBARBITAL**

MECC see **CHROMATOGRAPHY, MICELLAR ELECTROKINETIC CAPILLARY**

MECHANICAL VENTILATOR WEANING see **VENTILATOR WEANING**

MECHANORECEPTORS

see related
PROPRIOCEPTION

ANATOMY & HISTOLOGY

The Chievitz juxtaparotid organ. D'Andrea V, et al. **G Chir** 1999 May;20(5):213-7 (37 ref.)

PHYSIOLOGY

The transduction of very small hydrostatic pressures. Macdonald AG, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Jan; 122(1):13-36 (153 ref.)

Feeling the vibes: chordotonal mechanisms in insect hearing. Eberl DF. **Curr Opin Neurobiol** 1999 Aug;9(4):389-93 (40 ref.)

A comparison of hair bundle mechanoreceptors in sea anemones and vertebrate systems. Watson GM, et al. **Curr Top Dev Biol** 1999;43:51-84 (75 ref.)

Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. Burnstock G. **J Anat** 1999 Apr;194 (Pt 3):335-42 (103 ref.)

Dysafferentation: a novel term to describe the neuropathologic effects of joint complex dysfunction--a look at likely mechanisms of symptom generation [letter; comment] Knutson GA. **J Manipulative Physiol Ther** 1999 Jan;22(1):45-8 (21 ref.) Comment on: J Manipulative Physiol Ther 1998 May;21(4):267-80.

Touch channels sense blood pressure [comment] Franco-Obregón A, et al. **Neuron** 1998 Dec;21(6):1224-6 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1435-41.

The spike trains of inhibited pacemaker neurons seen through the magnifying glass of nonlinear analyses. Segundo JP, et al. **Neuroscience** 1998 Dec;87(4):741-66 (73 ref.)

The sensory world of the platypus. Pettigrew JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1199-210 (38 ref.)

The role of calcium in the response of cardiac muscle to stretch. Calaghan SC, et al. **Prog Biophys Mol Biol** 1999; 71(1):59-90 (156 ref.)

Modulation of ions channels and membrane receptors activities by mechanical interventions in cardiomyocytes: possible mechanisms for mechanosensitivity. Cazorla O, et al. **Prog Biophys Mol Biol** 1999;71(1):29-58 (143 ref.)

Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models. Kohl P, et al. **Prog Biophys Mol Biol** 1999;71(1):91-138 (282 ref.)

Mechanosensitivity as an integrative system in heart: an audit. Lab MJ. **Prog Biophys Mol Biol** 1999;71(1):7-27 (144 ref.)

Cardiac mechano-electric feedback in man: clinical relevance. Taggart P, et al. **Prog Biophys Mol Biol** 1999; 71(1):139-54 (58 ref.)

MECKEL'S DIVERTICULUM

SURGERY

Acute Meckel's diverticulum in a senior patient. Campione O, et al. **Minerva Chir** 1998 Sep;53(9):743-5 (19 ref.)

MECONIUM

Meconium masquerading as a scrotal mass. Han K, et al. **Br J Urol** 1998 Nov;82(5):765-7 (5 ref.)

Management of meconium-stained amniotic fluid. Wiswell TE, et al. **Clin Perinatol** 1999 Sep;26(3):659-68 (65 ref.)

CHEMISTRY

Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Ostrea EM Jr. **Curr Probl Pediatr** 1999 Feb;29(2):37-56 (86 ref.)

PHYSIOLOGY

Fetal defaecation: is it a normal physiological process? Kimble RM, et al. **J Paediatr Child Health** 1999 Apr; 35(2):116-9 (49 ref.)

MECONIUM ASPIRATION

ETIOLOGY

The meconium aspiration syndrome: the saga continues [editorial] Wiswell TE, et al. **Indian Pediatr** 1998 Nov; 35(11):1059-62 (19 ref.)

Functional pulmonary surfactant deficiency and neonatal respiratory disorders. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:175-7 (8 ref.)

PREVENTION & CONTROL

Management of meconium-stained amniotic fluid. Wiswell TE, et al. **Clin Perinatol** 1999 Sep;26(3):659-68 (65 ref.)

THERAPY

Surfactant lavage for the management of severe meconium aspiration syndrome. Lam BC. **Biol Neonate** 1999 Jun;76 Suppl 1:10-4 (37 ref.)

Meconium aspiration syndrome: current concepts and management. Srinivasan HB, et al. **Compr Ther** 1999 Feb; 25(2):82-9 (62 ref.)

The meconium aspiration syndrome: the saga continues [editorial] Wiswell TE, et al. **Indian Pediatr** 1998 Nov; 35(11):1059-62 (19 ref.)

MEDAKA see **ORYZIAS**

MEDEX see **PHYSICIAN ASSISTANTS**

MEDIAL GENICULATE BODY see **GENICULATE BODIES**

MEDIAL MENISCI see **MENISCI, TIBIAL**

MEDIAN NERVE

see related
CARPAL TUNNEL SYNDROME

Uncommon nerve compression syndromes of the upper extremity. Lubahn JD, et al. **J Am Acad Orthop Surg** 1998 Nov-Dec;6(6):378-86 (38 ref.)

Proximal median neuropathies. Gross PT, et al. **Neurol Clin** 1999 Aug;17(3):425-45, v (53 ref.)

Distal median neuropathies. Preston DC. **Neurol Clin** 1999 Aug;17(3):407-24, v (24 ref.)

INJURIES

Traumatic forearm amputation with avulsions of the ulnar and median nerves from the brachial plexus. Kaleli T, et al. **Arch Orthop Trauma Surg** 1998;118(1-2):119-20 (9 ref.)

PHYSIOLOGY

Premotor potentials. Mandel JD. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):765-76, vi (21 ref.)

Median and ulnar nerves in the hand. Sable AW. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):737-53 (74 ref.)

SURGERY

Carpal tunnel decompression: open vs endoscopic. Tennent TD, et al. **Br J Hosp Med** 1998 Dec 10;58(11):551-4 (35 ref.)

MEDIASTINAL CYST

Thoracic duct cyst: a case report and review of 29 cases. Mattila PS, et al. **Ann Otol Rhinol Laryngol** 1999 May; 108(5):505-8 (30 ref.)

Mediastinal thoracic duct cyst. Chen F, et al. **Chest** 1999 Feb;115(2):584-5 (6 ref.)

MICROBIOLOGY

Chest-wall abscess due to cat-scratch disease (CSD) in an adult with antibodies to Bartonella clarridgeiae: case report and review of the thoracopulmonary manifestations of CSD. Margileth AM, et al. **Clin Infect Dis** 1998 Aug; 27(2):353-7 (26 ref.)

SURGERY

Mediastinal parathyroid cysts revisited. Shields TW, et al. **Ann Thorac Surg** 1999 Feb;67(2):581-90 (75 ref.)

MEDIASTINAL DISEASES

COMPLICATIONS

Combined idiopathic retroperitoneal and mediastinal fibrosis with pericardial involvement. Klisnick A, et al. **Clin Nephrol** 1999 Jul;52(1):51-5 (31 ref.)

DIAGNOSIS

Mediastinal masses: diagnostic approach. Laurent F, et al. **Eur Radiol** 1998;8(7):1148-59 (84 ref.)

Diagnosis of mediastinal masses and principles of surgical tactics and technique for their treatment. Esposito G. **Semin Pediatr Surg** 1999 May;8(2):54-60 (30 ref.)

[Plasma-cell granuloma of the mediastinum] Tazzioli G, et al. **Minerva Chir** 1998 Jun;53(6):549-51 (8 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Late complications. Postpneumonectomy syndrome. Mehran RJ, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):655-73, x (32 ref.)

[Psoas abscess with mediastinal extension secondary to rectal perforation (letter; comment)] Jiménez Almonacid P, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):149-50 (6 ref.) Comment on: Rev Esp Enferm Dig 1995 Nov;87(11):830-1. **(Spa)**

RADIOGRAPHY

CT evaluation of mediastinal masses in children: spectrum of disease with pathologic correlation. Buckley JA, et al. **Crit Rev Diagn Imaging** 1998 Sep;39(5):365-92 (8 ref.)

Mediastinal lipomatosis. Nguyên KQ, et al. **South Med J** 1998 Dec;91(12):1169-72 (31 ref.)

SURGERY

[Operations of the chest wall and thorax. Chest wall operations including thoracotomy. 2] Dienemann H. **Zentralbl Chir** 1998;123(11):1317-21 (6 ref.) **(Ger)**

MEDIASTINAL EMPHYSEMA

COMPLICATIONS

Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. Jansen TL, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):733-5 (21 ref.)

ETIOLOGY

Bilateral cervicofacial, axillary, and anterior mediastinal emphysema: a rare complication of third molar extraction. Capes JO, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):996-9 (12 ref.)

[Recurrent pneumomediastinum in the course of interstitial pneumonia associated with dermatomyositis] Satomi K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Nov;36(11):984-8 (20 ref.) (Eng. Abstr.) **(Jpn)**

MEDIASTINAL NEOPLASMS

Primary large cell lymphoma of the mediastinum. Aisenberg AC. **Semin Oncol** 1999 Jun;26(3):251-8 (72 ref.)

Germ cell, mesenchymal, and thymic tumors of the mediastinum. Billmire DF. **Semin Pediatr Surg** 1999 May; 8(2):85-91 (49 ref.)

Vascular anomalies of the mediastinum. Fishman SJ. **Semin Pediatr Surg** 1999 May;8(2):92-8 (21 ref.)

Lymphomas of the anterior mediastinum. Glick RD, et al. **Semin Pediatr Surg** 1999 May;8(2):69-77 (60 ref.)

Posterior mediastinal neurogenic tumors in infants and children. Saenz NC. **Semin Pediatr Surg** 1999 May; 8(2):78-84 (36 ref.)

COMPLICATIONS

Anterior mediastinal masses: an anaesthetic challenge. Goh MH, et al. **Anaesthesia** 1999 Jul;54(7):670-4 (14 ref.)

CONGENITAL

Congenital mediastinal dumbbell neuroblastoma with spontaneous regression of liver metastases. Komuro H, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):86-8 (19 ref.)

[Cystic lymphangioma of the neck and mediastinum: are there acquired forms? Report of 37 cases] Riquet M, et al. **Rev Mal Respir** 1999 Feb;16(1):71-9 (89 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma [editorial; comment] Chadburn A, et al. **Am J Clin Pathol** 1999 Aug;112(2):155-8 (40 ref.) Comment on: Am J Clin Pathol 1999 Aug;112(2):241-7.

Neurogenic tumors of the mediastinum in children. Inci I, et al. **Childs Nerv Syst** 1999 Aug;15(8):372-6 (47 ref.)

Mediastinal masses: diagnostic approach. Laurent F, et al. **Eur Radiol** 1998;8(7):1148-59 (84 ref.)

Schwannoma of posterior mediastinum: a case report and concise review. Khanlou H, et al. **Heart Lung** 1998 Sep-Oct;27(5):344-7 (14 ref.)

[Cystic lymphangioma of the mediastinum. Apropos of 3 cases, review of the literature] Icard P, et al. **Ann Chir** 1998;52(7):629-34 (25 ref.) (Eng. Abstr.) **(Fre)**

[The rare differential diagnosis of a mediastinal space-occupying lesion] Bohle W, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):245-7 (9 ref.) (Eng. Abstr.) **(Ger)**

[A tumor of the cerebellopontile angle and a large posterior mediastinal mass] Barón Saura JM, et al. **Rev Clin Esp** 1998 Nov;198(11):777-8 (4 ref.) **(Spa)**

PATHOLOGY

Germ-cell tumors of the mediastinum. Moran CA, et al. **Adv Anat Pathol** 1998 Jan;5(1):1-15 (99 ref.)

Primary ependymoma of the mediastinum: a clinicopathologic study of three cases. Wilson RW, et al. **Ann Diagn Pathol** 1998 Oct;2(5):293-300 (33 ref.)

Mediastinal tumors of peripheral nervous system origin. Marchevsky AM. **Semin Diagn Pathol** 1999 Feb;16(1):65-78 (107 ref.)

Primary large-cell lymphomas of the mediastinum. Suster S. **Semin Diagn Pathol** 1999 Feb;16(1):51-64 (53 ref.)

Germ-cell tumors of the mediastinum. Weidner N. **Semin Diagn Pathol** 1999 Feb;16(1):42-50 (47 ref.)

MEDIASTINAL NEOPLASMS

RADIOTHERAPY

Radiotherapy for the treatment of metastatic granulosa cell tumor in the mediastinum: a case report. Lee IW, et al. **Gynecol Oncol** 1999 Jun;73(3):455–60 (12 ref.)

SECONDARY

Thoracoscopic resection of a giant leiomyoma of the esophagus with a mediastinal outgrowth. Tamura K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):351–3 (11 ref.)

Radiotherapy for the treatment of metastatic granulosa cell tumor in the mediastinum: a case report. Lee IW, et al. **Gynecol Oncol** 1999 Jun;73(3):455–60 (12 ref.)

[Mediastinal and hilar lymph node of cancer unknown origin: 3 case reports] Sakuraba M, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):72–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Thoracoscopic resection of a giant leiomyoma of the esophagus with a mediastinal outgrowth. Tamura K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):351–3 (11 ref.)

Neurogenic tumors of the mediastinum in children. Inci I, et al. **Childs Nerv Syst** 1999 Aug;15(8):372–6 (47 ref.)

Preanesthetic evaluation of children with anterior mediastinal masses. Shamberger RC. **Semin Pediatr Surg** 1999 May; 8(2):61–8 (31 ref.)

Thoracoscopic resection of intrathoracic vagus neurofibroma. Yamagishi T, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):122–4 (8 ref.)

[Operations of the chest wall and thorax. Chest wall operations including thoracotomy. 2] Dienemann H. **Zentralbl Chir** 1998;123(11):1317–21 (6 ref.) **(Ger)**

[Anesthetic problems in the mediastinal masses] Zadra N, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):74–7 (7 ref.) **(Ita)**

[Dumbbell type schwannoma of the posterior mediastinum: a report of two cases with different surgical approaches] Hattori Y, et al. **Kyobu Geka** 1999 Aug;52(9):728–32 (11 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Follow-up of patients with thoracic malignancies. Virgo KS, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):355–69 (72 ref.)

MEDIASTINOSCOPY

Benign superior vena cava syndrome due to suppurative mediastinal lymphadenitis: anterior mediastinoscopic management. Roy D, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1185–7 (17 ref.)

MEDIASTINUM

see related
MEDIASTINOSCOPY

Left mediastinal central line malposition--a case report. Moskal TL, et al. **Angiology** 1999 Apr;50(4):349–53 (21 ref.)

PATHOLOGY

Chylothorax from radiation-induced mediastinal fibrosis [letter] Lee YC, et al. **Aust N Z J Med** 1998 Oct;28(5):667–8 (7 ref.)

MEDIATING see **NEGOTIATING**

MEDIATORS OF INFLAMMATION see **INFLAMMATION MEDIATORS**

MEDICAGO see **ALFALFA**

MEDICAID

Making Medicaid managed care research relevant. Gold M. **Health Serv Res** 1999 Feb;33(6):1639–50 (13 ref.)

ECONOMICS

Medicaid reimbursement and timeliness of payment. Weber RD. **Mich Med** 1999 Jan;98(1):8–9 (0 ref.)

LEGISLATION & JURISPRUDENCE

What factors affect women's experiences with Medicaid managed care? Bernstein AB. **Womens Health Issues** 1998 Nov-Dec;8(6):325–38; discussion 350–8 (38 ref.)

ORGANIZATION & ADMINISTRATION

The key to the door: Medicaid's role in improving health care for women and children. Rowland D, et al. **Annu Rev Public Health** 1999;20:403–26 (106 ref.)

Methods of reducing the financial risk of physicians under capitation. Anderson GF, et al. **Arch Fam Med** 1999 Mar-Apr;8(2):149–55 (33 ref.)

The Oregon Health Plan and the political paradox of rationing: what advocates and critics have claimed and what Oregon did. Jacobs L, et al. **J Health Polit Policy Law** 1999 Feb;24(1):161–80 (19 ref.)

Oregon's bold experiment: whatever happened to rationing? Leichter HM. **J Health Polit Policy Law** 1999 Feb; 24(1):147–60 (17 ref.)

Medicaid managed care and public health data. Rutherford GW, et al. **Public Health Rep** 1999 May-Jun;114(3):225–30 (25 ref.)

Medicaid managed care: the challenge of providing care to low-income women. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):57S–67S (32 ref.)

TRENDS

Medicaid managed care and children: an overview. Deal LW, et al. **Future Child** 1998 Summer-Fall;8(2):93–104 (21 ref.)

Making Medicaid viable for the 21st century. May D. **Mich Med** 1999 Jan;98(1):14–5 (0 ref.)

UTILIZATION

Medicaid's impact on access to and utilization of health care services among racial and ethnic minority children. Hall AG. **J Urban Health** 1998 Dec;75(4):677–92 (25 ref.)

Women, welfare, and work: one view of the debate. Schroeder C, et al. **Nurs Outlook** 1998 Sep-Oct; 46(5):226–32 (34 ref.)

MEDICAL ASSISTANCE, TITLE 19 see **MEDICAID**

MEDICAL AUDIT

In pursuit of excellence for patients with cancer: the Scottish Cancer Therapy Network model. Stroner PL, et al. **Br J Cancer** 1999 Apr;79(11–12):1641–5 (25 ref.)

Errors in histopathology reporting: detection and avoidance. Ramsay AD. **Histopathology** 1999 Jun;34(6):481–90 (94 ref.)

The role of audit in making do not resuscitate decisions. Hayes S, et al. **J Eval Clin Pract** 1999 Aug;5(3):305–12 (30 ref.)

An analysis of Australian adverse drug events. Malpass A, et al. **J Qual Clin Pract** 1999 Mar;19(1):27–30 (7 ref.)

Audit of patient outcomes after herniorrhaphy. O'Riordan DC, et al. **Surg Clin North Am** 1998 Dec;78(6):1129–39, viii–ix (22 ref.)

[The quality audit in a blood transfusion center] Hergon E. **Transfus Clin Biol** 1998 Dec;5(6):422–30 (12 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Auditing the management of hypertension in British general practice: a critical literature review. Cranney M, et al. **Br J Gen Pract** 1998 Jul;48(432):1424–8 (35 ref.)

The lack of integration of clinical audit and the maintenance of medical dominance within British hospital trusts. McErlain-Burns TL, et al. **J Eval Clin Pract** 1999 Aug; 5(3):323–33 (36 ref.)

ORGANIZATION & ADMINISTRATION

Maintaining good medical practice. Clinical governance and self regulation for physicians. A report of the Royal College of Physicians. **J R Coll Physicians Lond** 1999 May-Jun; 33(3):241–5 (6 ref.)

STANDARDS

APACHE II, data accuracy and outcome prediction. Goldhill DR, et al. **Anaesthesia** 1998 Oct;53(10):937–43 (19 ref.)

MEDICAL CARE COSTS see **HEALTH CARE COSTS**

MEDICAL CARE RESEARCH see **HEALTH SERVICES RESEARCH**

MEDICAL CARE TEAM see **PATIENT CARE TEAM**

MEDICAL CENTERS, ACADEMIC see **ACADEMIC MEDICAL CENTERS**

MEDICAL CENTERS, UNIVERSITY see **ACADEMIC MEDICAL CENTERS**

MEDICAL COMPUTER SCIENCE see **MEDICAL INFORMATICS**

MEDICAL DECISION MAKING, COMPUTER-ASSISTED see **DECISION MAKING, COMPUTER-ASSISTED**

MEDICAL DEVICE DESIGN see **EQUIPMENT DESIGN**

MEDICAL DEVICE SAFETY see **EQUIPMENT SAFETY**

MEDICAL DEVICES see **EQUIPMENT AND SUPPLIES**

MEDICAL DIRECTORS see **PHYSICIAN EXECUTIVES**

MEDICAL ECONOMICS see **ECONOMICS, MEDICAL**

MEDICAL EDUCATION see **EDUCATION, MEDICAL**

MEDICAL EDUCATION, CONTINUING see **EDUCATION, MEDICAL, CONTINUING**

MEDICAL EDUCATION, GRADUATE see **EDUCATION, MEDICAL, GRADUATE**

MEDICAL EDUCATION, UNDERGRADUATE see **EDUCATION, MEDICAL, UNDERGRADUATE**

MEDICAL ERRORS

see related
IATROGENIC DISEASE
MALPRACTICE

Problems with evidence-based medicine. Lalwani SI, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):237–40 (9 ref.)

Errors in dialysis--the lessons to learn [comment] Bommer J. **Nephrol Dial Transplant** 1998 Oct;13(10):2483–4 (0 ref.) Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2480–1. Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2481–3.

Disasters of endoscopic surgery and how to avoid them: error analysis. Troidl H. **World J Surg** 1999 Aug;23(8):846–55 (35 ref.)

[Health care safety should be focused on prevention. Lessons to be learned from aviation, nuclear power plants and offshore industries] Odegård S. **Lakartidningen** 1999 Jun 23;96(25):3068–73 (19 ref.) (Eng. Abstr.) **(Swe)**

[A computerized system for regional management of incidents is now tested. A complement to the Lex Maria system, indicates unobserved risks (see comments)] Westerling R, et al. **Lakartidningen** 1999 Feb 3;96(5):486–8 (7 ref.) Comment in: Lakartidningen 1999 Feb 10;96(6):580. **(Swe)**

CLASSIFICATION

[The nosology of medical errors] Viniegra-Velázquez L. **Rev Invest Clin** 1998 Nov-Dec;50(6):505–16 (15 ref.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Error in medicine: legal impediments to U.S. reform. Liang BA. **J Health Polit Policy Law** 1999 Feb;24(1):27–58 (101 ref.)

PREVENTION & CONTROL

The potential for improved teamwork to reduce medical errors in the emergency department. The MedTeams Research Consortium [see comments] Risser DT, et al. **Ann Emerg Med** 1999 Sep;34(3):373–83 (25 ref.) Comment in: Ann Emerg Med 1999 Sep;34(3):370–2.

Human error in emergency medicine [editorial; comment] Wears R, et al. **Ann Emerg Med** 1999 Sep;34(3):370–2 (14 ref.) Comment on: Ann Emerg Med 1999 Sep;34(3):373–83.

Error in medicine: legal impediments to U.S. reform. Liang BA. **J Health Polit Policy Law** 1999 Feb;24(1):27–58 (101 ref.)

PSYCHOLOGY

The psychology of human error [see comments] Green R. **Eur J Anaesthesiol** 1999 Mar;16(3):148–55 (59 ref.) Comment in: Eur J Anaesthesiol 1999 Mar;16(3):147.

STATISTICS & NUMERICAL DATA

Human error in emergency medicine [editorial; comment] Wears R, et al. **Ann Emerg Med** 1999 Sep;34(3):370–2 (14 ref.) Comment on: Ann Emerg Med 1999 Sep;34(3):373–83.

MEDICAL FUTILITY

see related
RESUSCITATION ORDERS

Foregoing life support in medically futile patients. Tai DY, et al. **Ann Acad Med Singapore** 1998 May;27(3):430–6 (28 ref.)

Bioethics for clinicians: 16. Dealing with demands for inappropriate treatment [see comments] Weijer C, et al. **CMAJ** 1998 Oct 6;159(7):817–21 (39 ref.) Comment in: CMAJ 1999 Feb 9;160(3):309–10.

The scope for rehabilitation in severely disabled stroke patients. Gladman JR, et al. **Disabil Rehabil** 1998 Oct; 20(10):391–4 (30 ref.)

Intensive care for patients with medical complications of haematological malignancy: is it worth it? Hinds CJ, et al. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1467–73 (20 ref.)

A broader look at medical futility. Shelton W. **Theor Med Bioeth** 1998 Aug;19(4):383–400 (18 ref.)

Respect for patients should dominate health care decisions [comment] Alpers A. **West J Med** 1999 May;170(5):291–2 (11 ref.) Comment on: West J Med 1999 May;170(5):287–90.

Medical futility [editorial] Weijer C. **West J Med** 1999 May; 170(5):254 (6 ref.)

["Meaningless treatment" in terminal care. Importance of declaring do-not-resuscitate orders] Löfmark R, et al. **Lakartidningen** 1998 Oct 21;95(43):4759–61 (20 ref.) (Eng. Abstr.) **(Swe)**

MEDICAL GEOGRAPHY see **GEOGRAPHY**

MEDICAL HISTORY TAKING

see related
DATA COLLECTION

Narrative based medicine: stories we hear and stories we tell: analysing talk in clinical practice. Elwyn G, et al.

BMJ 1999 Jan 16;318(7177):186–8 (31 ref.)
The family history component of cancer genetic risk counseling. Loescher LJ. **Cancer Nurs** 1999 Feb; 22(1):96–102 (30 ref.)
Obtaining and formulating a developmental history. Cox CE. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):271–9, vi–vii (6 ref.)
Initial assessment: the history in women with pelvic floor problems. Brubaker L. **Clin Obstet Gynecol** 1998 Sep; 41(3):657–62 (0 ref.)
The management of embarrassment and sexuality in health care. Meerabeau L. **J Adv Nurs** 1999 Jun;29(6):1507–13 (55 ref.)
Salvaging the history, physical examination and doctor–patient relationship in a technological cardiology environment. Clement DL, et al. **J Am Coll Cardiol** 1999 Mar;33(3):892–3 (0 ref.)
[Evaluation of symptoms of gastroesophageal reflux and their impact on quality of life] Amouretti M. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S45–9 (33 ref.) **(Fre)**
[Quality aspects in internal medicine—from anamnesis to meta-analysis] Battegay M, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24;87(51–52):1785–92 (22 ref.) (Eng. Abstr.) **(Ger)**
[Diagnostic assessment in lumbar back pain. I. Anamnesis and clinical examination] Boos N, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):305–13 (13 ref.) (Eng. Abstr.) **(Ger)**
[A tool for nutritional anamnesis of elderly patients] Lauque S, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:145–54 (37 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The psychiatric review of symptoms: a screening tool for family physicians. Carlat DJ. **Am Fam Physician** 1998 Nov 1;58(7):1617–24 (21 ref.)
Shedding light on the sexual history. Warner PH, et al. **Am J Nurs** 1999 Jun;99(6):34–40; quiz 41 (11 ref.)
ABC of sexual health: taking a sexual history [see comments] Tomlinson J. **BMJ** 1998 Dec 5;317(7172):1573–6 (0 ref.) Comment in: BMJ 1999 May 8;318(7193):1289.
Comparison of family history measures used to identify high risk of coronary heart disease. Silberberg J, et al. **Genet Epidemiol** 1999;16(4):344–55 (21 ref.)
Improving physicians' relationships with patients. Clark W, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S45–50 (46 ref.)
Cancer risk assessment: conceptual considerations for clinical practice. Mahon SM. **Oncol Nurs Forum** 1998 Oct; 25(9):1535–47 (34 ref.)
[Detection and diagnosis of alcoholism] Gache P. **Rev Prat** 1999 Feb 15;49(4):375–8 (21 ref.) (Eng. Abstr.) **(Fre)**
[Methodology of psychiatric case histories] Scherbaum N, et al. **Fortschr Neurol Psychiatr** 1999 May;67(5):229–36 (44 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Alcohol intake assessment: the sober facts. Feunekes GI, et al. **Am J Epidemiol** 1999 Jul 1;150(1):105–12 (41 ref.)
Effects of misclassification on estimates of relative risk in family history studies. Szatmari P, et al. **Genet Epidemiol** 1999;16(4):368–81 (32 ref.)

MEDICAL ILLUSTRATION

Anatomy atlases. Rosse C. **Clin Anat** 1999;12(4):293–9 (22 ref.)
Digital images in dermatology and the Dermatology Online Atlas on the World Wide Web. Diepgen TL, et al. **J Dermatol** 1998 Dec;25(12):782–7 (20 ref.)
Atlas of brain proton magnetic resonance spectra. Part I: General and methodological considerations. Vion-Dury J, et al. **J Neuroradiol** 1998 Oct;25(3):207–12 (19 ref.)
Correlating MR lesions and functional deficits in multiple sclerosis patients. Anatomical atlas registration. Gardner JC, et al. **Phys Med Rehabil Clin N Am** 1998 Aug; 9(3):569–86, vi (68 ref.)

MEDICAL IMAGING see **DIAGNOSTIC IMAGING**

MEDICAL INDIGENCY

Medical care of children who are homeless or in foster care. Simms MD. **Curr Opin Pediatr** 1998 Oct;10(5):486–90 (35 ref.)

MEDICAL INFORMATICS

A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Kenny T, et al. **Fam Pract** 1998 Oct;15(5):471–9 (96 ref.)
Promoting women's health via the World Wide Web. Hern MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):606–10 (6 ref.)
An evidence-based approach to interactive health communication: a challenge to medicine in the information age. Science Panel on Interactive Communication and Health. Robinson TN, et al. **JAMA** 1998 Oct 14; 280(14):1264–9 (82 ref.)
[Trends in genome informatics] Takagi T. **Nippon Rinsho** 1998 Nov;56(11):2963–72 (16 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Preparing chief information officers for the clinical information systems environment. Valenta AL, et al. **Acad Med** 1999 May;74(5):511–5 (14 ref.)

STANDARDS

The quality of medical information on the Internet. A new public health concern [editorial] McLeod SD. **Arch Ophthalmol** 1998 Dec;116(12):1663–5 (19 ref.)
Towards quality management of medical information on the internet: evaluation, labelling, and filtering of information [see comments] Eysenbach G, et al. **BMJ** 1998 Nov 28; 317(7171):1496–1500 (30 ref.) Comment in: BMJ 1998 Nov 28;317(7171):1469–70. Comment in: BMJ 1999 Apr 24;318(7191):1144–5.
Published criteria for evaluating health related web sites: review. Kim P, et al. **BMJ** 1999 Mar 6;318(7184):647–9 (25 ref.)
Quality assurance guidelines for a biomedical information web system: the working experience of the BreakIT project. Sacile R, et al. **Med Inform Internet Med** 1999 Apr–Jun;24(2):109–20 (10 ref.)

TRENDS

Terminology and concept representation languages: where are we? Rector AL. **Artif Intell Med** 1999 Jan;15(1):1–4 (24 ref.)
Trends in assessment of IT-based solutions in healthcare and recommendations for the future. Brender J. **Int J Med Inf** 1998 Oct–Dec;52(1–3):217–27 (74 ref.)
The Human Brain Project: neuroinformatics tools for integrating, searching and modeling multidisciplinary neuroscience data. Shepherd GM, et al. **Trends Neurosci** 1998 Nov;21(11):460–8 (27 ref.)

MEDICAL INFORMATICS APPLICATIONS

Desiderata for controlled medical vocabularies in the twenty-first century. Cimino JJ. **Methods Inf Med** 1998 Nov;37(4–5):394–403 (85 ref.)
[The management and information technology applicable to clinical microbiology laboratories] Brezmes Valdivieso MF, et al. **Enferm Infecc Microbiol Clin** 1999 May; 17(5):231–41 (65 ref.) **(Spa)**

MEDICAL INFORMATICS COMPUTING

The Emerging Importance of Genetics in Epidemiologic Research III. Bioinformatics and statistical genetic methods. Ellsworth DL, et al. **Ann Epidemiol** 1999 May; 9(4):207–24 (78 ref.)
Computerized physiologic monitoring. Booth FV. **Crit Care Clin** 1999 Jul;15(3):547–62, vi (40 ref.)
Training residents in medical informatics. Jerant AF. **Fam Med** 1999 Jul–Aug;31(7):465–72 (48 ref.)
Desiderata for controlled medical vocabularies in the twenty-first century. Cimino JJ. **Methods Inf Med** 1998 Nov;37(4–5):394–403 (85 ref.)
Conceptual graph grammar—a simple formalism for sublanguage. Johnson SB. **Methods Inf Med** 1998 Nov; 37(4–5):345–52 (35 ref.)
The nature of lexical knowledge. McCray AT. **Methods Inf Med** 1998 Nov;37(4–5):353–60 (35 ref.)
Modeling concepts in medicine for medical language understanding. Rassinoux AM, et al. **Methods Inf Med** 1998 Nov;37(4–5):361–72 (0 ref.)
Cooperative knowledge evolution: a construction-integration approach to knowledge discovery in medicine. Schmalhofer FJ, et al. **Methods Inf Med** 1998 Nov; 37(4–5):491–500 (33 ref.)

TRENDS

Nursing informatics. Issues for critical care medicine. Jastremski CA. **Crit Care Clin** 1999 Jul;15(3):563–76 (34 ref.)
Concepts, knowledge and language in healthcare information systems: follow-up 30 months later. Scherrer JR. **Methods Inf Med** 1998 Nov;37(4–5):312–4 (23 ref.)

MEDICAL INFORMATION SCIENCE see **MEDICAL INFORMATICS**

MEDICAL JOURNALISM see **JOURNALISM, MEDICAL**

MEDICAL JURISPRUDENCE see **JURISPRUDENCE**

MEDICAL LABORATORY TECHNOLOGY see **TECHNOLOGY, MEDICAL LABORATORY**

MEDICAL MISSIONS, OFFICIAL

ORGANIZATION & ADMINISTRATION

The dermatologist's Baedeker. Preparation for medical assistance missions. Norton SA. **Dermatol Clin** 1999 Jan; 17(1):187–208, ix–x (41 ref.)
Physicians bring GI diagnosis, procedures to rural Mexico. Doctors Veldman and Wiedemer on a medical mission. Brusstar G. **Mich Med** 1999 Jan;98(1):36–9 (0 ref.)
The medical department in military operations other than war. Part I. Planning for deployment. Baker MS, et al. **Mil Med** 1999 Aug;164(8):572–9 (22 ref.)

MEDICAL MISTAKES see **MEDICAL ERRORS**

MEDICAL ONCOLOGY

see related
NEOPLASMS

Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. Foy R, et al. **BMJ** 1999 Feb 13;318(7181):456–9 (25 ref.)
The development of bone marrow transplantation as a treatment for patients with lymphoma—twentieth Richard and Hinda Rosenthal Foundation Award Lecture. Armitage JO. **Clin Cancer Res** 1997 Jun;3(6):829–36 (84 ref.)
Cancer in developing countries: Part I—Cancer burden, resources, epidemiology, aetiology and clinical practice. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(4):219–25 (45 ref.)
Expectations about alternative therapies and women with gynecological cancer. Granai CO. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):3–10 (89 ref.)
Meeting impossible psychosocial demands in pediatric oncology: creative solutions to universal challenges [see comments] Whitsett SF, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):289–91 (0 ref.) Comment in: Med Pediatr Oncol 1999 Apr;32(4):292–3.
[Review of the literature, search of reports and critical reading of articles in cancerology] Bonichon F, et al. **Bull Cancer** 1998 Oct;85(10):867–85 (109 ref.) (Eng. Abstr.) **(Fre)**
[Phase III trials in oncology] Imadalou K, et al. **Bull Cancer** 1999 Feb;86(2):143–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Oncologic principles associated with colon carcinoma. Diagnosis, therapy and follow-up] Lehnert T, et al. **Chirurg** 1999 Apr;70(4):499–510 (4 ref.) **(Ger)**

HISTORY

Chronic myelogenous leukemia—progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Kantarjian HM, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2723–33 (101 ref.)

METHODS

Using evaluations of diagnostic tests: understanding their limitations and making the most of available evidence. Deeks JJ. **Ann Oncol** 1999 Jul;10(7):761–8 (37 ref.)
Selecting computer-based evidence sources. Wyatt JC, et al. **Ann Oncol** 1999 Mar;10(3):267–73 (22 ref.)
Positron emission tomography as a diagnostic tool in oncology. Schiepers C, et al. **Eur Radiol** 1998;8(8):1481–94 (160 ref.)

ORGANIZATION & ADMINISTRATION

Demonstrating oncology provider value: data, guidelines, and the law. Gosfield AG. **Oncology (Huntingt)** 1998 Nov; 12(11A):157–61 (14 ref.)
[Current issues and perspectives in Japan Clinical Oncology Group] Fukuda H, et al. **Gan To Kagaku Ryoho** 1999 Jan; 26(2 Suppl):204–11 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Need to establish academic research organization for cancer clinical trial and clinical research system having clinical investigators and study coordinators, with special reference to promotion of medical and life science research policy] Shimoyama M. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):235–46 (6 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Access to quality cancer care: consensus statement of the American Federation of Clinical Oncologic Societies. Edwards MJ. **Ann Surg Oncol** 1998 Oct–Nov;5(7):657–9 (0 ref.)

TRENDS

Neuro-oncology: an overview. Levin VA. **Arch Neurol** 1999 Apr;56(4):401–4 (11 ref.)
Recent advances: oncology. Tattersall MH, et al. **BMJ** 1999 Feb 13;318(7181):445–8 (33 ref.)
Medical oncology: its origin, evolution, current status, and future. Kennedy BJ. **Cancer** 1999 Jan 1;85(1):1–8 (84 ref.)
The future of clinical cancer research in the next millennium. Freireich EJ. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2563–70 (23 ref.)
Foundations of clinical cancer research: perspective for the 21st century. Hersh EM. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2551–3 (30 ref.)
Surgical oncology. Sondak VK. **J Am Coll Surg** 1999 Feb; 188(2):178–83 (39 ref.)
Historical perspectives and future applications. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):391–400, vii (47 ref.)

MEDICAL ONCOLOGY

[Hematology and internal medicine oncology] Engert A, et al. **Internist (Berl)** 1999 Apr;40(4):356–68 (51 ref.) **(Ger)**

[Present situation and future subjects of N.SAS study--based on experience of managing data center] Adachi T, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):212–6 (1 ref.) (Eng. Abstr.) **(Jpn)**

[Advances in cancer research. Cancer research and clinical oncology in the 21st century] Kanamaru R. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:3–7 (2 ref.) (Eng. Abstr.) **(Jpn)**

MEDICAL POWER OF ATTORNEY see **ADVANCE DIRECTIVES**

MEDICAL RECORD LINKAGE

Use of computerized record linkage in cohort studies. Howe GR. **Epidemiol Rev** 1998;20(1):112–21 (24 ref.)

Integration and communication for the continuity of cardiac care (I4C). van Bemmel JH, et al. **J Electrocardiol** 1998; 31 Suppl:60–8 (18 ref.)

MEDICAL RECORDS

see related
FORMS AND RECORDS CONTROL
MEDICAL HISTORY TAKING

Case studies, single-subject research, and N of 1 randomized trials: comparisons and contrasts. Backman CL, et al. **Am J Phys Med Rehabil** 1999 Mar–Apr;78(2):170–6 (22 ref.)

Record-linkage for pharmacovigilance in Scotland. Evans JM, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):105–10 (38 ref.)

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):951–4 (12 ref.)

LEGISLATION & JURISPRUDENCE

Protecting genetic privacy by permitting employer access only to job-related employee medical information: analysis of a unique Minnesota law. Rothstein MA, et al. **Am J Law Med** 1998;24(4):399–416 (0 ref.)

Confidentiality in crisis: Part II—Confidentiality of treatment records. Glancy GD, et al. **Can J Psychiatry** 1998 Dec; 43(10):1006–11 (26 ref.)

Medical records confidentiality. Rutberg MP. **Neurol Clin** 1999 May;17(2):307–13 (44 ref.)

Documentation and informed consent. Weintraub MI. **Neurol Clin** 1999 May;17(2):371–81 (29 ref.)

STANDARDS

Temperature charts: a time for change? Zeal JD. **Hosp Med** 1998 Oct;59(10):766–8 (13 ref.)

Research based on archived information and samples. Recommendations from the Royal College of Physicians Committee on Ethical Issues in Medicine. **J R Coll Physicians Lond** 1999 May–Jun;33(3):264–6 (15 ref.)

STATISTICS & NUMERICAL DATA

Geographically masking health data to preserve confidentiality. Armstrong MP, et al. **Stat Med** 1999 Mar 15;18(5):497–525 (61 ref.)

MEDICAL RECORDS SYSTEMS, COMPUTERIZED

Clinical coding in sports medicine--it's good to talk. Kemp S. **Br J Sports Med** 1999 Feb;33(1):4–5 (11 ref.)

Electronic medical record in the intensive care unit. Sado AS. **Crit Care Clin** 1999 Jul;15(3):499–522 (76 ref.)

Use of computerized record linkage in cohort studies. Howe GR. **Epidemiol Rev** 1998;20(1):112–21 (24 ref.)

The ICNP's relevance in the US. Henry SB, et al. **Int Nurs Rev** 1998 Sep–Oct;45(5):153–9 (40 ref.)

Evaluating natural language processors in the clinical domain. Friedman C, et al. **Methods Inf Med** 1998 Nov; 37(4–5):334–44 (39 ref.)

Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing. Beatty WW. **Mult Scler** 1999 Aug;5(4):239–43 (51 ref.)

Databases in MS research: pitfalls and promises. Weinshenker BG. **Mult Scler** 1999 Aug;5(4):206–11 (18 ref.)

American Academy of Pediatrics. Pediatric Practice Action Group and Task Force on Medical Informatics. Privacy protection and health information: patient rights and pediatrician responsibilities. Chilton L, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):973–7 (27 ref.)

Perinatal information systems for quality improvement: visions for today. Slagle TA. **Pediatrics** 1999 Jan;103(1 Suppl E):266–77 (64 ref.)

The benefits and challenges of an electronic medical record: much more than a "word-processed" patient chart. Sujansky WV. **West J Med** 1998 Sep;169(3):176–83 (48 ref.)

[Evaluation of standardized routine documentation with implementation of the requirements of multicenter studies. Presentation on the example of a knee endoprosthesis] Bernsmann K, et al. **Orthopade** 1999 Mar;28(3):292–8 (30 ref.) (Eng. Abstr.) **(Ger)**

[Status quo and the future of the electronic patient record system] Yoshiwara H. **Nihon Hansenbyo Gakkai Zasshi** 1998 Jul;67(2):269–76 (16 ref.) **(Jpn)**

[Do computerized reminders to the patients affect the preventive work in general practice?] Steen M, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):42–4 (35 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

The U.S. health data privacy debate. Will there be comprehension before closure? Freeman P, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):316–31 (22 ref.)

ORGANIZATION & ADMINISTRATION

Electronic medical record systems at academic health centers: advantages and implementation issues. Retchin SM, et al. **Acad Med** 1999 May;74(5):493–8 (22 ref.)

Integration and communication for the continuity of cardiac care (I4C). van Bemmel JH, et al. **J Electrocardiol** 1998; 31 Suppl:60–8 (18 ref.)

Clinical documentation: the handheld computer as a survival tool. Wofford MM, et al. **MD Comput** 1998 Nov–Dec; 15(6):352–4, 356, 358 (30 ref.)

STANDARDS

Record-linkage for pharmacovigilance in Scotland. Evans JM, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):105–10 (38 ref.)

Medical records. Enhancing privacy, preserving the common good. Etzioni A. **Hastings Cent Rep** 1999 Mar–Apr; 29(2):14–23 (53 ref.)

TRENDS

Multimedia electronic medical record systems. Lowe HJ. **Acad Med** 1999 Feb;74(2):146–52 (56 ref.)

MEDICAL RESEARCH see **RESEARCH**

MEDICAL SCHOOLS see **SCHOOLS, MEDICAL**

MEDICAL SOCIOLOGY see **SOCIOLOGY, MEDICAL**

MEDICAL STAFF

PSYCHOLOGY

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of an epidemiologist] Bréart G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:189–90 (11 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning . Analysis and point-of-view of private clinic pediatricians] Buisson G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:165–75 (18 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic obstetricians] Crézé B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:117–20 (3 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of Maternal-Infant Care physicians] Delour M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:137–46 (33 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic anesthetists] Fillette D. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:186–8 (8 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of public health physicians] Lombrail P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:191–6 (29 ref.) **(Fre)**

STANDARDS

Professional self respect: rights and responsibilities in the new NHS [see comments] Richards P. **BMJ** 1998 Oct 24; 317(7166):1146–8 (20 ref.) Comment in: BMJ 1999 Mar 13;318(7185):734. Comment in: BMJ 1999 Mar 13;318(7185):734–5.

MEDICAL STAFF, HOSPITAL

Identifying appropriate tasks for the preregistration year: modified Delphi technique. Stewart J, et al. **BMJ** 1999 Jul 24;319(7204):224–9 (19 ref.)

[Work shifts, sleep and biological rhythms] Gaspar S, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):239–45 (13 ref.) **(Por)**

[The standardization of the criteria for the prevention of occupational postexposure to the human immunodeficiency virus] Haro Pérez AM, et al. **Rev Clin Esp** 1999 Apr; 199(4):233–8 (89 ref.) **(Spa)**

EDUCATION

American medical residency programs: an analysis of New York's "Bell" regulations and the training of physicians. Tobias M. **Med Health R I** 1998 Sep;81(9):284–8 (19 ref.)

LEGISLATION & JURISPRUDENCE

Public trust and accountability for clinical performance: lessons from the national press reportage of the Bristol hearing [see comments] Davies HT, et al. **J Eval Clin Pract** 1999 Aug;5(3):335–42 (28 ref.) Comment in: J Eval Clin Pract 1999 Aug;5(3):343–6.

ORGANIZATION & ADMINISTRATION

Staff responsibility to exercise. Carlson L, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):172–80 (6 ref.)

PSYCHOLOGY

[Analysis and point-of-view of mobile emergency service pediatricians] Chabernaud JL. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:176–81 (17 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of obstetricians of general hospital centers] Dauptain G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:110–6 (13 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center obstetricians] Lévy G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:104–9 (9 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of public hospital anesthetists] Palot M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:182–5 (8 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center pediatricians] Rozé JC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:153–61 (61 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of central general hospital pediatricians] Zaoui C. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:162–4 (21 ref.) **(Fre)**

MEDICAL STAFF PRIVILEGES

STANDARDS

Reviewing credentials and granting privileges. Peterson JL. **Tex Med** 1998 Nov;94(11):91–9 (13 ref.)

MEDICAL STAFF PRIVILEGES, NONPHYSICIAN see **MEDICAL STAFF PRIVILEGES**

MEDICAL TECHNOLOGY see **TECHNOLOGY, MEDICAL**

MEDICAL TOPOGRAPHY see **TOPOGRAPHY, MEDICAL**

MEDICAL TRANSCRIPTION see **MEDICAL RECORDS**

MEDICAL WASTE

see related
BLOOD-BORNE PATHOGENS

Microbiological aspects of clinical waste. Phillips G. **J Hosp Infect** 1999 Jan;41(1):1–6 (41 ref.)

MEDICAL WASTE DISPOSAL

METHODS

Microbiological aspects of clinical waste. Phillips G. **J Hosp Infect** 1999 Jan;41(1):1–6 (41 ref.)

MEDICALLY ASSISTED SUICIDE see **SUICIDE, ASSISTED**

MEDICALLY UNDERSERVED AREA

see related
HEALTH SERVICES ACCESSIBILITY

Cultural humility versus cultural competence: a critical distinction in defining physician training outcomes in multicultural education [editorial] Tervalon M, et al. **J Health Care Poor Underserved** 1998 May;9(2):117–25 (32 ref.)

Do targeted efforts for the rural underserved help kill comprehensive reform? Taylor DH Jr. **J Rural Health** 1999 Winter;15(1):55–60 (27 ref.)

Access denied: taking action for medically underserved children. Redlener I. **J Urban Health** 1998 Dec; 75(4):724–31 (2 ref.)

Community health centers: promise and performance. Dievler A, et al. **Med Care Res Rev** 1998 Dec;55(4):405–31 (54 ref.)

Cross-country truck drivers: a vulnerable population. Renner

DA. **Nurs Outlook** 1998 Jul-Aug;46(4):164-8 (32 ref.)
Skin grafting in difficult situations. James J. **Trop Doct** 1999 Jan;29(1):41-2 (2 ref.)

MEDICARE

LEGISLATION & JURISPRUDENCE

The Health Insurance Portability and Accountability Act of 1996: understanding the anti-kickback laws. Tomes JP. **J Health Care Finance** 1998 Winter;25(2):55-62 (9 ref.)

ORGANIZATION & ADMINISTRATION

Home health care [see comments] Montauk SL. **Am Fam Physician** 1998 Nov 1;58(7):1608-14 (9 ref.) Comment in: Am Fam Physician 1999 Jul;60(1):53-4.
Palliative care in managed Medicare: reasons for hope--and for concern. Rousseau P. **Geriatrics** 1998 Nov;53(11):59-60, 63-5; quiz 66 (20 ref.)

STANDARDS

A tale of two walls [editorial; comment] Day H, et al. **J Gen Intern Med** 1998 Oct;13(10):718-9 (15 ref.) Comment on: J Gen Intern Med 1998 Oct;13(10):705-9.
Eligibility for home care certification: what clinicians should know [see comments] Wachtel TJ, et al. **J Gen Intern Med** 1998 Oct;13(10):705-9 (24 ref.) Comment in: J Gen Intern Med 1998 Oct;13(10):718-9.

STATISTICS & NUMERICAL DATA

Gastrostomy placement and mortality among hospitalized Medicare beneficiaries. Kobayashi K, et al. **Gastrointest Endosc** 1999 Jun;49(6):810-1 (8 ref.)

MEDICARE CHOICE see **MEDICARE PART C**

MEDICARE PART B

RBRVS (Medicare Resource-Based Relative Value Scale) revisited. Harris-Shapiro J. **J Health Care Finance** 1998 Winter;25(2):49-54 (0 ref.)

MEDICARE PART C

LEGISLATION & JURISPRUDENCE

Medicare+Choice appeal procedures: reconciling due process rights and cost containment. Gladieux JE. **Am J Law Med** 1999;25(1):61-116 (0 ref.)

MEDICARE PLUS CHOICE see **MEDICARE PART C**

MEDICARE SUPPLEMENTARY MEDICAL INSURANCE PROGRAM see **MEDICARE PART B**

MEDICATION ERRORS

Intrathecal vincristine: an analysis of reasons for recurrent fatal chemotherapeutic error with recommendations for prevention. Fernandez CV, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):587-90 (13 ref.)
[A computerized system for regional management of incidents is now tested. A complement to the Lex Maria system, indicates unobserved risks (see comments)] Westerling R, et al. **Lakartidningen** 1999 Feb 3;96(5):486-8 (7 ref.) Comment in: Lakartidningen 1999 Feb 10;96(6):580. **(Swe)**

ADVERSE EFFECTS

First-degree atrioventricular block in alprazolam overdose reversed by flumazenil. Mullins ME. **J Pharm Pharmacol** 1999 Mar;51(3):367-70 (17 ref.)

LEGISLATION & JURISPRUDENCE

Liability in prescribing choice: the example of the antidepressants [see comments] Beerworth EE, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):560-6 (66 ref.) Comment in: Aust N Z J Psychiatry 1999 Apr;33(2):281-2.

MEDICINAL HERBS see **PLANTS, MEDICINAL**

MEDICINE

see related
ECONOMICS, MEDICAL
EDUCATION, MEDICAL
LEGISLATION, MEDICAL

Academic health centers can bridge the gulf between medicine and public health. Williams JF, et al. **Acad Med** 1999 May;74(5):484-7 (4 ref.)
On writing medical history. Joy RJ, et al. **Ann Diagn Pathol** 1997 Dec;1(2):130-7 (67 ref.)
Representation of change in controlled medical terminologies. Oliver DE, et al. **Artif Intell Med** 1999 Jan; 15(1):53-76 (45 ref.)
Narrative based medicine: why study narrative? Greenhalgh T, et al. **BMJ** 1999 Jan 2;318(7175):48-50 (18 ref.)
A broad view of medical science [editorial] Wolf S. **Integr Physiol Behav Sci** 1998 Jul-Sep;33(3):221-6 (8 ref.)
Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990-1996. Chang WY, et al. **Nurs Res** 1999 Mar-Apr;48(2):94-104 (110 ref.)
The role of science in medicine. Nordin I. **Theor Med Bioeth** 1999 Jun;20(3):229-44 (18 ref.)
[2 medicines] Vecchio C. **G Ital Cardiol** 1999 May; 29(5):583-5 (15 ref.) **(Ita)**
[From P.K.Anokhin's teaching on functional systems to modern integrative ecology and medicine] Agadzhanian NA, et al. **Vestn Ross Akad Med Nauk** 1999;(6):15-20 (16 ref.) **(Rus)**
[Immunogenetic achievements for medicine] Khaitov RM, et al. **Vestn Ross Akad Med Nauk** 1999;(4):35-9 (22 ref.) (Eng. Abstr.) **(Rus)**
[General human pathology and methodology of medicine] Tsaregorodtsev GI. **Vestn Ross Akad Med Nauk** 1998; (10):41-5 (0 ref.) (Eng. Abstr.) **(Rus)**

MEDICINE, AFRICAN TRADITIONAL

Indigenous patterns of conserving biodiversity: pharmacologic implications. Etkin NL. **J Ethnopharmacol** 1998 Dec;63(3):233-45 (48 ref.)
The toxicology of African herbal remedies. Stewart MJ, et al. **Ther Drug Monit** 1998 Oct;20(5):510-6 (117 ref.)

MEDICINE, ALTERNATIVE see **ALTERNATIVE MEDICINE**

MEDICINE, ARABIC

HISTORY

Avicenna: a bright star from the east. Qayumi AK. **J Invest Surg** 1998 Jul-Aug;11(4):243-4 (0 ref.)

MEDICINE, AYURVEDIC

Prevention of diseases an Ayurvedic approach. Upadyay RL. **Indian J Med Sci** 1998 Mar;52(3):119-24 (0 ref.)
Dementia in Ayurveda. Manyam BV. **J Altern Complement Med** 1999 Feb;5(1):81-8 (30 ref.)
Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Rege NN, et al. **Phytother Res** 1999 Jun;13(4):275-91 (90 ref.)

MEDICINE, CHINESE TRADITIONAL

see related
DRUGS, CHINESE HERBAL
YIN DEFICIENCY

Seeing to the distant mountain: diagnosis in Tibetan medicine. Tokar E. **Altern Ther Health Med** 1999 Mar;5(2):50-8 (21 ref.)
The basic clinical diagnostic framework synergized. Yu EC. **Chin Med J (Engl)** 1998 May;111(5):460-5 (9 ref.)
How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Li Y, et al. **Med Trop (Mars)** 1998;58(3 Suppl):9-12 (26 ref.)
Use of herbal medicine for treating psychiatric disorders in Japan. Kanba S, et al. **Psychiatry Clin Neurosci** 1998 Dec; 52 Suppl:S331-3 (4 ref.)
Traditional Chinese medicine, acupuncture, and other alternative medicines for prostate cancer: an introduction and the need for more research. Moyad MA, et al. **Semin Urol Oncol** 1999 May;17(2):103-10 (72 ref.)
Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Gong X, et al. **Trends Pharmacol Sci** 1999 May;20(5):191-6 (38 ref.)
[Current status of and progress in the research on syndrome differentiation in unstable angina] Lei Y, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Nov; 17(11):701-4 (17 ref.) **(Chi)**
[Progress in the pathogenic studies of Alzheimer's disease and its therapeutic approach] Shen ZY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov; 16(11):698-700 (22 ref.) **(Chi)**
[Present status and prospects of researches on type A behavior] Zhang SY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Apr; 17(4):251-3 (18 ref.) **(Chi)**
[Adjustment function of life message apparatus type SMS-03] Zheng XW. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov; 16(11):701-2 (13 ref.) **(Chi)**

MEDICINE, COMPLEMENTARY see **ALTERNATIVE MEDICINE**

MEDICINE, EMPORIATRIC see **TRAVEL**

MEDICINE, EVIDENCE-BASED see **EVIDENCE-BASED MEDICINE**

MEDICINE, FOLK see **MEDICINE, TRADITIONAL**

MEDICINE, HERBAL

see related
DRUGS, CHINESE HERBAL
PLANTS, MEDICINAL

Health-promoting properties of common herbs. Craig WJ. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):491S-499S (115 ref.)
Black cohosh: Cimicifuga racemosa. Pepping J. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1400-2 (21 ref.)
Herbal remedies in psychiatric practice. Wong AH, et al. **Arch Gen Psychiatry** 1998 Nov;55(11):1033-44 (303 ref.)
Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Mashour NH, et al. **Arch Intern Med** 1998 Nov 9;158(20):2225-34 (125 ref.)
Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions [see comments] Miller LG. **Arch Intern Med** 1998 Nov 9; 158(20):2200-11 (171 ref.) Comment in: Arch Intern Med 1999 May 24;159(10):1142-3.
Herbs as medicines. Winslow LC, et al. **Arch Intern Med** 1998 Nov 9;158(20):2192-9 (70 ref.)
The DINs and don'ts of herbal/natural preparations. Mishkin S. **Can J Gastroenterol** 1999 May;13(4):335-7 (14 ref.)
Management of perimenopause: focus on alternative therapies. Thacker HL, et al. **Cleve Clin J Med** 1999 Apr; 66(4):213-8 (9 ref.)
Herbal products for liver diseases: a therapeutic challenge for the new millennium. Schuppan D, et al. **Hepatology** 1999 Oct;30(4):1099-104 (78 ref.)
Herbal medicine for periodontal diseases. Cao CF, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):316-22 (19 ref.)
Dementia in Ayurveda. Manyam BV. **J Altern Complement Med** 1999 Feb;5(1):81-8 (30 ref.)
Herbal interventions in asthma and allergy. Bielory L, et al. **J Asthma** 1999;36(1):1-65 (235 ref.)
Herbs and the childbearing woman. Guidelines for midwives. Belew C. **J Nurse Midwifery** 1999 May-Jun;44(3):231-52 (103 ref.)
Homeopathic remedies in prenatal care. Brennan P. **J Nurse Midwifery** 1999 May-Jun;44(3):291-9 (20 ref.)
Homeopathy. A theoretical framework and clinical application. Castro M. **J Nurse Midwifery** 1999 May-Jun; 44(3):280-90 (24 ref.)
Introducing herbal medicine into conventional health care settings. Lee L. **J Nurse Midwifery** 1999 May-Jun; 44(3):253-66 (66 ref.)
Herbalism in Minnesota. What should physicians know? Plotnikoff GA, et al. **Minn Med** 1999 May;82(5):12-26 (0 ref.)
Review, critique, and guidelines for the use of herbs and homeopathy. Glisson J, et al. **Nurse Pract** 1999 Apr; 24(4):44-6, 53, 60 passim; quiz 68-9 (73 ref.)
Recent advances in the fight against leishmaniasis with natural products. Akendengue B, et al. **Parasite** 1999 Mar; 6(1):3-8 (26 ref.)
Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Rege NN, et al. **Phytother Res** 1999 Jun;13(4):275-91 (90 ref.)
Nontraditional treatments for localized prostate cancer: ten rules to know before talking to my patients. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):64-9 (52 ref.)
Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Lowe FC, et al. **Urology** 1999 Apr; 53(4):671-8 (55 ref.)
[Phytotherapy in chronic dermatoses and wounds: what is the evidence?] Grimme H, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:5-8 (36 ref.) (Eng. Abstr.) **(Ger)**
[A method for the diagnosis and phytotherapy of the mycosis caused by the fungus Alternaria alternata (Fr.) Keissler] Trikoz GA. **Lik Sprava** 1999 Mar;(2):128-30 (12 ref.) **(Rus)**
[The modern concepts of phyto-aromatherapy] Dashina TA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Mar-Apr; (2):47-53 (37 ref.) **(Rus)**

HISTORY

Historical data as an aid in pharmaceutical prospecting and drug safety determination. Riddle JM. **J Altern Complement Med** 1999 Apr;5(2):195-201 (47 ref.)

MEDICINE, HINDU see **MEDICINE, AYURVEDIC**

MEDICINE IN ART

Art and Parkinson's disease. Lakke JP. **Adv Neurol** 1999; 80:471-9 (10 ref.)
Traditional pharmacology and medicine in Africa. Ethnopharmacological themes in sub-Saharan art objects and utensils. De Smet PA. **J Ethnopharmacol** 1998 Nov; 63(1-2):1-175 (600 ref.)
[Psychosis, language and literature] Maier T. **Nervenarzt** 1999 May;70(5):438-43 (35 ref.) (Eng. Abstr.) **(Ger)**

MEDICINE IN LITERATURE

[Psychosis, language and literature] Maier T. **Nervenarzt** 1999 May;70(5):438-43 (35 ref.) (Eng. Abstr.) **(Ger)**

MEDICINE, INDIGENOUS see **MEDICINE, TRADITIONAL**

MEDICINE, ORIENTAL TRADITIONAL

Nursing in Thailand: western concepts vs Thai tradition.

MEDICINE, ORIENTAL TRADITIONAL

Ekintumas D. **Int Nurs Rev** 1999 Mar-Apr;46(2):55-7 (19 ref.)
Deer velvet antler: some unanswered questions on toxicology. Dalefield RR, et al. **Vet Hum Toxicol** 1999 Feb; 41(1):39-41 (25 ref.)

MEDICINE, PRIMITIVE see **MEDICINE, TRADITIONAL**

MEDICINE, TRADITIONAL

see related
HEALTH SERVICES, INDIGENOUS
SHAMANISM

Traditional and complementary therapies in Parkinson's disease. Manyam BV, et al. **Adv Neurol** 1999;80:565-74 (29 ref.)
Intriguing gastrointestinal properties of bismuth: a folk remedy brought into the realm of clinical and investigative medicine. Mishkin S. **Can J Gastroenterol** 1998 Nov-Dec; 12(8):569-70 (12 ref.)
Ethnopharmacology and some traditional medical practices--Part I. Ansari KV, et al. **Indian J Med Sci** 1998 Apr;52(4):151-4 (14 ref.)
Dhat syndrome--culture bound sex neurosis. Bhatia MS, et al. **Indian J Med Sci** 1998 Jan;52(1):30-5 (25 ref.)
Uncaria tomentosa (Willd.) DC.--ethnomedicinal use and new pharmacological, toxicological and botanical results. Keplinger K, et al. **J Ethnopharmacol** 1999 Jan;64(1):23-34 (60 ref.)
Scientific aspects of traditional usage of bioresources. Thebtaranonth Y. **J Nat Toxins** 1999 Jun;8(2):279-84 (21 ref.)
Menopause and beyond. The wise woman way. Weed SS. **J Nurse Midwifery** 1999 May-Jun;44(3):267-79 (76 ref.)
The use of Japanese herbal medicine in the treatment of medically unexplained physical symptoms [editorial] Mizushima H, et al. **J Psychosom Res** 1999 Jun;46(6):531-5 (11 ref.)
Ethnopharmacology and ethnobotany along the US-Mexican border: potential problems with cross-cultural "borrowings". Huxtable RJ. **Proc West Pharmacol Soc** 1998; 41:259-64 (60 ref.)
Traditional and western healing practices for alcoholism in American Indians and Alaska Natives. Abbott PJ. **Subst Use Misuse** 1998 Nov;33(13):2605-46 (95 ref.)
Cultural interpretations of contagion [see comments] Caprara A. **Trop Med Int Health** 1998 Dec;3(12):996-1001 (39 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):993-5.
Women's choice between indigenous and Western contraception in urban Mozambique. Agadjanian V. **Women Health** 1998;28(2):1-17 (25 ref.)
[Problems in the legislative regulation of folk and nontraditional medicines] Pokanevych VV. **Lik Sprava** 1999 Jan-Feb;(1):134-9 (19 ref.) **(Ukr)**

HISTORY

Traditional pharmacology and medicine in Africa. Ethnopharmacological themes in sub-Saharan art objects and utensils. De Smet PA. **J Ethnopharmacol** 1998 Nov; 63(1-2):1-175 (600 ref.)
[Menstruation still full of myths] Bergqvist A. **Lakartidningen** 1999 Apr 14;96(15):1860-7 (28 ref.) **(Swe)**

MEDICINE, VETERINARY see **VETERINARY MEDICINE**

MEDITATION

see related
YOGA

Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Coker KH. **Semin Urol Oncol** 1999 May;17(2):111-8 (30 ref.)

METHODS

Meditation for prevention of disease. Subramanian P. **Indian J Med Sci** 1998 Mar;52(3):114-8 (0 ref.)

MEDITERRANEAN FEVER, FAMILIAL see **PERIODIC DISEASE**

MEDITERRANEAN FRUIT FLY see **DIPTERA**

MEDITERRANEAN SPOTTED FEVER see **BOUTONNEUSE FEVER**

MEDLINE

Religious and spiritual case reports on MEDLINE: a systematic analysis of records from 1980 to 1996. Lukoff D, et al. **Altern Ther Health Med** 1999 Jan;5(1):64-70 (68 ref.)
Making the most of MEDLINE. Brazier H, et al. **Hosp Med** 1998 Oct;59(10):756-8, 760-1 (12 ref.)

ORGANIZATION & ADMINISTRATION

The art and science of searching MEDLINE to answer clinical questions. Finding the right number of articles. Allison JJ, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):281-96 (59 ref.)
[International foreign bibliographic databases Medline and Internet Grateful Med V2.6. Presentation and how to use] Bloch-Mouillet E. **Sante** 1998 Sep-Oct;8(5):379-86 (8 ref.) (Eng. Abstr.) **(Fre)**

MEDPHALAN see **MELPHALAN**

MEDROXYPROGESTERONE

THERAPEUTIC USE

The heart and estrogen/progestin replacement study (HERS). Speroff L. **Maturitas** 1998 Nov 30;31(1):9-14 (38 ref.)

MEDROXYPROGESTERONE 17-ACETATE

New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera. Hall PE. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S43-56 (36 ref.)
Depo-Provera: an ideal contraceptive for adolescents? Boroditsky RS. **J Pediatr Adolesc Gynecol** 1999 May; 12(2):95-9 (26 ref.)

ADMINISTRATION & DOSAGE

Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A, et al. **Br J Fam Plann** 1999 Jul;25(2):69-76 (69 ref.)

ADVERSE EFFECTS

Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A, et al. **Br J Fam Plann** 1999 Jul;25(2):69-76 (69 ref.)
Long-acting hormonal contraception: assessing impact on bone density, weight, and mood. Kaunitz AM. **Int J Fertil Womens Med** 1999 Mar-Apr;44(2):110-7 (27 ref.)

PHARMACOLOGY

Effects of hormonal contraceptives on bone mineral density. Cromer BA. **Drug Saf** 1999 Mar;20(3):213-22 (33 ref.)

THERAPEUTIC USE

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Mantovani G, et al. **Crit Rev Oncog** 1998; 9(2):99-106 (36 ref.)
Endocrine therapy in pancreatic carcinoma. Yamashita J, et al. **Oncology** 1998 Dec;55 Suppl 1:17-22 (52 ref.)
The use of long-acting contraceptives in adolescents. Harel Z, et al. **Pediatr Clin North Am** 1999 Aug;46(4):719-32 (77 ref.)

MEDULLA OBLONGATA

Thoracic intramedullary schwannoma. Lee DY, et al. **J Spinal Disord** 1999 Apr;12(2):174-6 (22 ref.)
Intramedullary spinal teratoma presenting with urinary retention: case report and review of the literature. Poeze M, et al. **Neurosurgery** 1999 Aug;45(2):379-85 (62 ref.)
Intramedullary cavernous angioma. Resection by oblique corpectomy. Fontaine D, et al. **Surg Neurol** 1999 Apr; 51(4):435-41; discussion 441-2 (33 ref.)
[X-chromosomal recessive spinobulbar muscular atrophy (Kennedy type). Description of a family, clinical aspects, molecular genetics, differential diagnosis and therapy] Kuhlenbäumer G, et al. **Nervenarzt** 1998 Aug;69(8):660-5 (19 ref.) (Eng. Abstr.) **(Ger)**
[Spinal cord compression secondary to epidural extramedullary hematopoiesis in thalassemia: a clinical case and review of literature] Martinez-Rodrigo MA, et al. **Rev Neurol** 1998 Dec;27(160):998-1004 (61 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Ventrolateral medullary control of cardiovascular activity during muscle contraction. Ally A. **Neurosci Biobehav Rev** 1998;23(1):65-86 (206 ref.)
[Medial medullary infarct] Seiser A, et al. **Wien Klin Wochenschr** 1998 Sep 18;110(17):616-20 (24 ref.) (Eng. Abstr.) **(Ger)**
[Disturbance of deep sensation in medial medullary syndrome. Topographical localization of medial lemniscus in the medulla oblongata] Koyano S, et al. **Rinsho Shinkeigaku** 1998 Aug;38(8):739-44 (30 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pediatric intramedullary spinal cord tumors. Critical review of the literature. Nadkarni TD, et al. **Childs Nerv Syst** 1999 Jan;15(1):17-28 (75 ref.)
Hematoma in a low-grade medullary astrocytoma: report of an unusual case and literature review. van Ouwerkerk WJ, et al. **Childs Nerv Syst** 1998 Dec;14(12):742-6 (64 ref.)
[Intramedullary tuberculoma: a case report] Vukusic S, et al. **Rev Neurol (Paris)** 1998 Jul;154(6-7):535-8 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Ventrolateral medullary control of cardiovascular activity during muscle contraction. Ally A. **Neurosci Biobehav Rev** 1998;23(1):65-86 (206 ref.)
The neurophysiology of sleep and waking: intracerebral connections, functioning and ascending influences of the medulla oblongata. Gottesmann C. **Prog Neurobiol** 1999 Sep;59(1):1-54 (267 ref.)

SURGERY

Intramedullary hemangioblastoma of the medulla oblongata--two case reports and review of the literature. Fukushima T, et al. **Neurol Med Chir (Tokyo)** 1998 Aug; 38(8):489-98 (31 ref.)

MEDULLOBLASTOMA

CHEMISTRY

Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line. Miller TR, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):179-85 (27 ref.)

COMPLICATIONS

Turcot's syndrome presenting with medulloblastoma and familiar adenomatous polyposis: a case report and review of the literature. Hamada H, et al. **Acta Neurochir (Wien)** 1998;140(6):631-2 (5 ref.)

DIAGNOSIS

Childhood medulloblastoma: progress and future challenges. Packer RJ. **Brain Dev** 1999 Mar;21(2):75-81 (31 ref.)
Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. Fouladi M, et al. **J Neurosurg** 1999 Sep;91(3):499-502 (17 ref.)
[A tumor of the cerebellopontile angle and a large posterior mediastinal mass] Barón Saura JM, et al. **Rev Clin Esp** 1998 Nov;198(11):777-8 (4 ref.) **(Spa)**

DRUG THERAPY

Perspectives: Chemotherapy of medulloblastoma. Mastrangelo S, et al. **Med Pediatr Oncol** 1999 Aug; 33(2):116-9 (20 ref.)

MORTALITY

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Saran FH, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):959-67 (62 ref.)

RADIOTHERAPY

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Saran FH, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):959-67 (62 ref.)

SURGERY

Prognostic factors in medulloblastoma. Giordana MT, et al. **Childs Nerv Syst** 1998 Jun;14(6):256-62 (61 ref.)
Medulloblastoma. Rutka JT. **Clin Neurosurg** 1997;44:571-85 (19 ref.)

THERAPY

Childhood medulloblastoma: progress and future challenges. Packer RJ. **Brain Dev** 1999 Mar;21(2):75-81 (31 ref.)
Medulloblastoma in adults: clinical characteristics and treatment. Brandes AA, et al. **Cancer Treat Rev** 1999 Feb; 25(1):3-12 (76 ref.)

MEDULLOMYOBLASTOMA see **MEDULLOBLASTOMA**

MEDUSA see **JELLYFISH**

MEFLOQUINE

THERAPEUTIC USE

Mefloquine for malaria chemoprophylaxis 1992-1998: a review. Schlagenhauf P. **J Travel Med** 1999 Jun;6(2):122-33 (96 ref.)
Use of artemisinin derivatives for the control of malaria [published erratum appears in Med Trop (Mars) 1998;58(4):368] Nosten F, et al. **Med Trop (Mars)** 1998;58(3 Suppl):45-9 (13 ref.)

MEGACOLON

VETERINARY

Pathogenesis, diagnosis, and therapy of feline idiopathic megacolon. Washabau RJ, et al. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):589-603 (47 ref.)

MEGACOLON, CONGENITAL see **HIRSCHSPRUNG DISEASE**

MEGACOLON, TOXIC

COMPLICATIONS

A patient who survived total colonic type ulcerative colitis complicated by toxic megacolon, disseminated intravascular coagulation, methicillin-resistant Staphylococcus aureus infection and bilateral femoral phlebothrombosis. Arai H, et al. **J Gastroenterol** 1999 Jun; 34(3):395–9 (8 ref.)

DIAGNOSIS

[Toxic megacolon as a complication of Campylobacter jejuni enterocolitis] Kummer AF, et al. **Schweiz Med Wochenschr** 1998 Oct 10;128(41):1553–8 (23 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Toxic megacolon: surgical timing important!] Aeberhard P. **Zentralbl Chir** 1998;123(12):1365–9 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Therapy of Crohn disease in internal medicine: short bowel syndrome and toxic megacolon] Forssmann K, et al. **Schweiz Rundsch Med Prax** 1998 Nov 26;87(48):1652–6 (14 ref.) (Eng. Abstr.) **(Ger)**

MEGAESOPHAGUS see **ESOPHAGEAL ACHALASIA**

MEGAKARYOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR see **THROMBOPOIETIN**

MEGAKARYOCYTES

CYTOLOGY

The enigmatic megakaryocyte gradually reveals its secrets. Kaushansky K. **Bioessays** 1999 Apr;21(4):353–60 (63 ref.)
Megakaryocyte structure and function. Cramer EM. **Curr Opin Hematol** 1999 Sep;6(5):354–61 (40 ref.)
Extracellular matrix receptors and the differentiation of human megakaryocytes in vitro. Molla A, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):15–23 (46 ref.)
[Thrombopoietin and megakaryocyte differentiation] Vainchenker W, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1575–81 (36 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Interferon-gamma and human megakaryopoiesis. Tsuji K, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):107–13 (44 ref.)
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14–8 (23 ref.)
Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Apr;13 Suppl 1:S14–8 (23 ref.)
Platelet growth factors: potential impact on transfusion medicine. Kuter DJ, et al. **Transfusion** 1999 Mar; 39(3):321–32 (60 ref.)

METABOLISM

Thrombopoietin signal transduction: studies from cell lines and primary cells. Drachman JG, et al. **Methods** 1999 Mar; 17(3):238–49 (80 ref.)

PATHOLOGY

[Amegakaryocytic thrombocytopenia] Nagasawa T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):342–6 (18 ref.) **(Jpn)**

PHYSIOLOGY

The Mpl ligand and platelet homeostasis. Nichol JL. **Acta Paediatr Suppl** 1998 Jun;424:7–15 (49 ref.)
Megakaryocyte structure and function. Cramer EM. **Curr Opin Hematol** 1999 Sep;6(5):354–61 (40 ref.)
Thrombopoietin and its receptor. Wendling F, et al. **Eur Cytokine Netw** 1998 Sep;9(3):221–31 (139 ref.)
A historical perspective and cellular regulation of megakaryocytopoiesis. Baatout S. **Haematologia (Budap)** 1998;29(2):67–79 (68 ref.)
Potassium-current oscillation of rat megakaryocytes: As a model system for drug evaluation (Review). Uneyama C, et al. **Int J Mol Med** 1999 Aug;4(2):163–9 (36 ref.)
Regulation of megakaryocytopoiesis and platelet production by tyrosine kinases and tyrosine phosphatases. Avraham H, et al. **Methods** 1999 Mar;17(3):250–64 (131 ref.)

MEGAKARYOCYTIC LEUKEMIA see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAKARYOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAPTERA see **WHALES**

MEGAVOLT RADIOTHERAPY see **RADIOTHERAPY, HIGH-ENERGY**

MEGESTROL ACETATE

THERAPEUTIC USE

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Mantovani G, et al. **Crit Rev Oncog** 1998; 9(2):99–106 (36 ref.)
Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. Stockheim JA, et al. **J Pediatr** 1999 Mar;134(3):368–70 (8 ref.)

MEGLUMINE

ANALOGS & DERIVATIVES

Gadobenate dimeglumine (Gd-BOPTA). An overview. Kirchin MA, et al. **Invest Radiol** 1998 Nov;33(11):798–809 (76 ref.)

MEGLUMINE DIATRIZOATE see **DIATRIZOATE MEGLUMINE**

MEIBOMIAN GLANDS

PATHOLOGY

The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Stern ME, et al. **Cornea** 1998 Nov;17(6):584–9 (49 ref.)

MEIGE SYNDROME

[Meige's syndrome] Hirose K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):128–31 (15 ref.) **(Jpn)**

MEIGS' SYNDROME

BLOOD

Hydropic degenerating leiomyoma presenting as pseudo-Meigs syndrome with elevated CA 125. Dunn JS Jr, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):648–9 (9 ref.)

DIAGNOSIS

Meigs' syndrome with elevated CA125: case report and review of the literature. Abad A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):97–9 (19 ref.)
[Deimons-Meigs syndrome and elevated CA-125: diagnosis of ovarian cancer and therapeutic implications] Plaisant N, et al. **Contracept Fertil Sex** 1999 Jan;27(1):47–50 (28 ref.) (Eng. Abstr.) **(Fre)**
[Meigs' syndrome: is it possible to make a preoperative diagnosis?] Rouzier R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):517–22 (38 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Hydropic degenerating leiomyoma presenting as pseudo-Meigs syndrome with elevated CA 125. Dunn JS Jr, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):648–9 (9 ref.)

MEIOSIS

see related
MATURATION-PROMOTING FACTOR

Meiosis: vive la difference! Shaw P, et al. **Curr Opin Plant Biol** 1998 Dec;1(6):458–62 (37 ref.)
Prepregnancy genetic testing for age-related aneuploidies by polar body analysis. Verlinsky Y, et al. **Genet Test** 1997–98; 1(4):231–5 (13 ref.)
Comparative aspects of meiotic cell cycle control in mammals. Albertini DF, et al. **J Mol Med** 1998 Nov-Dec; 76(12):795–9 (26 ref.)
Role of cyclic nucleotide phosphodiesterases in resumption of meiosis. Conti M, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):9–14 (36 ref.)
Progesterone induces meiotic division in the amphibian oocyte by releasing lipid second messengers from the plasma membrane. Morrill GA, et al. **Steroids** 1999 Jan-Feb;64(1–2):157–67 (45 ref.)

GENETICS

Formation of supernumerary euchromatic short arm isochromosomes: parent and cell stage of origin in new cases and review of the literature. Eggermann T, et al. **Ann Genet** 1999;42(2):75–80 (18 ref.)
The leptotene-zygotene transition of meiosis. Zickler D, et al. **Annu Rev Genet** 1998;32:619–97 (315 ref.)
What makes homologous chromosomes find each other in meiosis? A review and an hypothesis. Sybenga J. **Chromosoma** 1999 Aug;108(4):209–19 (100 ref.)
Meiosis: MeiRNA hits the spot. Ohno M, et al. **Curr Biol** 1999 Jan 28;9(2):R66–9 (12 ref.)
Telomeres and telomerase: broad effects on cell growth. Price CM. **Curr Opin Genet Dev** 1999 Apr;9(2):218–24 (53 ref.)
Human minisatellites, repeat DNA instability and meiotic recombination. Jeffreys AJ, et al. **Electrophoresis** 1999 Jun; 20(8):1665–75 (38 ref.)
Alzheimer's disease and down syndrome: from meiosis to dementia. Petronis A. **Exp Neurol** 1999 Aug;158(2):403–13 (113 ref.)
Meiotic telomeres: a matchmaker for homologous chromosomes. Hiraoka Y. **Genes Cells** 1998 Jul;3(7):405–13 (55 ref.)

PHYSIOLOGY

Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. Duesbery NS, et al. **Biol Cell** 1998 Oct;90(6–7):461–6 (72 ref.)
Roles of the DNA mismatch repair and nucleotide excision repair proteins during meiosis. Kirkpatrick DT. **Cell Mol Life Sci** 1999 Mar;55(3):437–49 (112 ref.)
Meiosis: Avoiding inappropriate relationships. Haber JE. **Curr Biol** 1998 Nov 19;8(23):R832–5 (23 ref.)
Gonadotropin-induced resumption of oocyte meiosis and meiosis-activating sterols. Andersen CY, et al. **Curr Top Dev Biol** 1999;41:163–85 (120 ref.)
Meiosis-activating sterols: background, discovery, and possible use. Byskov AG, et al. **J Mol Med** 1998 Nov-Dec; 76(12):818–23 (30 ref.)
GFP fusions to a microtubule motor protein to visualize meiotic and mitotic spindle dynamics in Drosophila. Endow SA. **Methods Cell Biol** 1999;58:153–63 (21 ref.)
The molecular mechanisms of oocyte maturation and early embryonic development are unveiling new insights into reproductive medicine. Heikinheimo O, et al. **Mol Hum Reprod** 1998 Aug;4(8):745–56 (137 ref.)
Dynamics of meiotic prophase I during spermatogenesis: from pairing to division [see comments] Cobb J, et al. **Semin Cell Dev Biol** 1998 Aug;9(4):445–50 (31 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379–91.
Meiotic maturation in mollusc oocytes [see comments] Colas P, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):539–48 (90 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Cell cycle arrest and release in starfish oocytes and eggs [see comments] Kishimoto T. **Semin Cell Dev Biol** 1998 Oct; 9(5):549–57 (50 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Ins and outs of meiosis in ascidians [see comments] Russo GL, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):559–67 (82 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–72.
Molecular mechanisms of meiotic maturation and arrest in fish and amphibian oocytes [see comments] Yamashita M. **Semin Cell Dev Biol** 1998 Oct;9(5):569–79 (84 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.

MEISSNER'S CORPUSCLE see **MECHANORECEPTORS**

MEKC see **CHROMATOGRAPHY, MICELLAR ELECTROKINETIC CAPILLARY**

MELANCHOLIA see **DEPRESSIVE DISORDER**

MELANCHOLIA, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

MELANINS

ADVERSE EFFECTS

Binding of drugs to eye melanin is not predictive of ocular toxicity. Leblanc B, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):124–32 (120 ref.)

BIOSYNTHESIS

Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Slominski A, et al. **Anticancer Res** 1998 Sep-Oct;18(5B):3709–15 (84 ref.)
Human pigmentation genetics: the difference is only skin deep. Sturm RA, et al. **Bioessays** 1998 Sep;20(9):712–21 (84 ref.)
Human pigmentation genes and their response to solar UV radiation. Sturm RA. **Mutat Res** 1998 Nov 9;422(1):69–76 (42 ref.)

METABOLISM

Binding of drugs to eye melanin is not predictive of ocular toxicity. Leblanc B, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):124–32 (120 ref.)
[Development of concepts on the biochemistry and pharmacology of melanin pigments] Borshchevskaia MI, et al. **Vopr Med Khim** 1999 Jan-Feb;45(1):13–23 (53 ref.) (Eng. Abstr.) **(Rus)**

MELANINS

PHARMACOLOGY

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Jellinger KA. **Drugs Aging** 1999 Feb;14(2):115–40 (305 ref.)

[Development of concepts on the biochemistry and pharmacology of melanin pigments] Borshchevskaia MI, et al. **Vopr Med Khim** 1999 Jan–Feb;45(1):13–23 (53 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Nitric oxide and its implications in skin homeostasis and disease – a review. Bruch-Gerharz D, et al. **Arch Dermatol Res** 1998 Dec;290(12):643–51 (79 ref.)

RADIATION EFFECTS

Human pigmentation genes and their response to solar UV radiation. Sturm RA. **Mutat Res** 1998 Nov 9;422(1):69–76 (42 ref.)

MELANISM see **MELANOSIS**

MELANOAMELOBLASTOMA see **NEUROECTODERMAL TUMOR, MELANOTIC**

MELANOCYTE-STIMULATING HORMONES see **MSH**

MELANOCYTES

Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium. Beermann F, et al. **Pigment Cell Res** 1999 Apr;12(2):71–80 (71 ref.)

CYTOLOGY

Melan–A, a new melanocytic differentiation marker. Busam KJ, et al. **Adv Anat Pathol** 1999 Jan;6(1):12–8 (27 ref.)

The melanocyte differentiation pathway in spitz nevi. Cramer SF. **Am J Dermatopathol** 1998 Dec;20(6):555–70 (218 ref.)

Melanocyte biology and its implications for the clinician. Vancoillie G, et al. **Eur J Dermatol** 1999 Apr–May; 9(3):241–51 (88 ref.)

Pigmented human skin equivalent--as a model of the mechanisms of control of cell-cell and cell-matrix interactions. Nakazawa K, et al. **Med Biol Eng Comput** 1998 Nov;36(6):813–20 (88 ref.)

DRUG EFFECTS

Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Slominski A, et al. **Anticancer Res** 1998 Sep–Oct;18(5B):3709–15 (84 ref.)

PATHOLOGY

Unusual clinical presentation of a meningeal melanocytoma with seizures: case report and review of the literature. Leonardi MA, et al. **Acta Neurochir (Wien)** 1998; 140(6):621–8 (56 ref.)

Recent developments in the pathology of melanocytic neoplasia. Shea CR, et al. **Dermatol Clin** 1999 Jul; 17(3):615–30, ix (81 ref.)

Aging in epidermal melanocytes: cell cycle genes and melanins. Haddad MM, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):36–40 (58 ref.)

Pagetoid melanocytosis: tease or tocsin? Stern JB, et al. **Semin Diagn Pathol** 1998 Aug;15(3):225–9 (16 ref.)

PHYSIOLOGY

Melanocyte biology and its implications for the clinician. Vancoillie G, et al. **Eur J Dermatol** 1999 Apr–May; 9(3):241–51 (88 ref.)

Genetic and epigenetic control of the proliferation and differentiation of mouse epidermal melanocytes in culture. Hirobe T, et al. **Pigment Cell Res** 1999 Jun;12(3):147–63 (117 ref.)

MELANOMA

Malignant melanoma: a clinical review. Brown TJ, et al. **Cutis** 1999 May;63(5):275–8, 281–4 (66 ref.)

Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Byers HR, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):717–35 (65 ref.)

Public health interventions for melanoma. Prevention, early detection, and education. Koh HK, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):903–28 (126 ref.)

Prognosis in malignant melanoma. Stadelmann WK, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):767–96, vi (92 ref.)

Melanomas, from the cell cycle point of view (Review). Halaban R, et al. **Int J Mol Med** 1998 Feb;1(2):419–25 (86 ref.)

Clinical implications of the new biology in the development of melanoma vaccines. Hemmila MR, et al. **J Surg Oncol** 1999 Apr;70(4):263–74 (98 ref.)

Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium. Beermann F, et al. **Pigment Cell Res** 1999 Apr;12(2):71–80 (71 ref.)

[Melanoma] Dréno B. **Rev Prat** 1999 Apr 15;49(8):833–7 (9 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression [letter] [see comment] Kos J, et al. **Clin Chem** 1998 Dec;44(12):2556–7 (7 ref.) Comment in: Clin Chem 1999 May;45(5):718–9.

[S–100 beta protein in serum, a tumor marker in malignant melanoma— current state of knowledge and clinical experience] Jäckel A, et al. **Hautarzt** 1999 Apr;50(4):250–6 (35 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? [comment] Bissell MJ. **Am J Pathol** 1999 Sep;155(3):675–9 (50 ref.) Comment on: Am J Pathol 1999 Sep;155(3):739–52.

CHEMICALLY INDUCED

Environmental selenium and cancer: risk or protection? [editorial; comment] Clark LC, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):847–8; discussion 851–2 (14 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.

False presumptions and continued surprises: how much do we really know about nutritional supplements and cancer risk? [editorial; comment] Kristal AR, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):849–50; discussion 851–2 (12 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.

Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? Lindelöf B. **Drug Saf** 1999 Apr;20(4):289–97 (115 ref.)

Malignant melanoma in patients treated for psoriasis with PUVA. Stern RS. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):37–8 (6 ref.)

CHEMISTRY

Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Friedl P, et al. **Cell Adhes Commun** 1998; 6(2–3):225–36 (67 ref.)

Malignant melanoma of the oesophagus: clinicopathological features, lack of p53 expression and steroid receptors and a review of the literature. Lam KY, et al. **Eur J Surg Oncol** 1999 Apr;25(2):168–72 (28 ref.)

CLASSIFICATION

Classification and staging of melanoma. Gershenwald JE, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):737–65 (114 ref.)

[Pigmented tumors of the caruncle. Review of the literature] Kodjikian L, et al. **J Fr Ophtalmol** 1999 Jun–Jul; 22(6):688–99 (83 ref.) **(Fre)**

DIAGNOSIS

Malignant melanoma of the ovary and exposure to clomiphene citrate: a case report and review of the literature. Fuller PN. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1499–503 (15 ref.)

The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Merimsky O, et al. **Clin Rev Allergy Immunol** 1998 Fall;16(3):227–36 (30 ref.)

Imaging of abdominal manifestations of melanoma. Kamel IR, et al. **Crit Rev Diagn Imaging** 1998 Dec;39(6):447–86 (24 ref.)

Moles and melanoma. Chamlin SL, et al. **Curr Opin Pediatr** 1998 Aug;10(4):398–404 (80 ref.)

Ocular melanoma. Cather JC, et al. **Cutis** 1999 May; 63(5):285–92 (43 ref.)

Melanoma precursors in children. Lefkowitz A, et al. **Cutis** 1999 Jun;63(6):321–4 (41 ref.)

Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Reed JA, et al. **Dermatol Clin** 1999 Jul;17(3):631–43 (108 ref.)

Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. Ross MI, et al. **Eur J Cancer** 1998 Jul;34 Suppl 3:S7–11 (15 ref.)

Clinical recognition of melanoma and its precursors. Langley RG, et al. **Hematol Oncol Clin North Am** 1998 Aug; 12(4):699–715, v (62 ref.)

The misdiagnosis of malignant melanoma. Grant-Kels JM, et al. **J Am Acad Dermatol** 1999 Apr;40(4):539–48 (73 ref.)

Primary pulmonary melanoma: case report and literature review. Ost D, et al. **Mayo Clin Proc** 1999 Jan;74(1):62–6 (39 ref.)

Malignant melanoma. Lang PG Jr. **Med Clin North Am** 1998 Nov;82(6):1325–58 (83 ref.)

Uveal melanoma, choroidal hemangioma, and simulating lesions. Role of MR imaging. Mafee MF. **Radiol Clin North Am** 1998 Nov;36(6):1083–99, x (67 ref.)

[S–100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience] Jäckel A, et al. **Hautarzt** 1999 Apr;50(4):250–6 (35 ref.) (Eng. Abstr.) **(Ger)**

[Spitz nevus and Reed nevus: simulating melanoma in adults] Paredes B, et al. **Pathologe** 1998 Nov;19(6):403–11 (39 ref.) (Eng. Abstr.) **(Ger)**

[A clinical case of primary malignant melanoma of the oral cavity] Colella G, et al. **Minerva Stomatol** 1998 Oct; 47(10):535–40 (25 ref.) (Eng. Abstr.) **(Ita)**

[A nonpigmented melanoblastoma of the mandibular alveolar process] Shmurun RI. **Stomatologiia (Mosk)** 1999;78(3):35–6 (9 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Slominski A, et al. **Anticancer Res** 1998 Sep–Oct;18(5B):3709–15 (84 ref.)

Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Castro MP, et al. **Cancer** 1999 Mar 1;85(5):1055–9 (40 ref.)

Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. MacKie RM. **Curr Opin Oncol** 1999 Mar;11(2):129–31 (15 ref.)

Current therapy of cutaneous melanoma. Mays SR, et al. **Cutis** 1999 May;63(5):293–8 (52 ref.)

The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Rusthoven JJ. **Eur J Cancer** 1998 Jul;34 Suppl 3:S31–6 (47 ref.)

Adjuvant interferon treatment for melanoma. Agarwala SS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):823–33 (24 ref.)

Systemic treatment of metastatic melanoma with chemotherapy. Green RJ, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):863–75, viii (51 ref.)

Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review). Toma S, et al. **Int J Oncol** 1999 Aug;15(2):321–37 (87 ref.)

The chemoresistance of human malignant melanoma: an update. Serrone L, et al. **Melanoma Res** 1999 Feb;9(1):51–8 (67 ref.)

ENZYMOLOGY

Proteases in cutaneous melanoma. Ferrier CM, et al. **Ann Med** 1998 Oct;30(5):431–42 (86 ref.)

Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Frade R. **Immunopharmacology** 1999 May;42(1–3):39–45 (37 ref.)

EPIDEMIOLOGY

Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Veness MJ, et al. **Cancer** 1999 Apr 15;85(8):1758–64 (21 ref.)

Incidence, risk factors and prevention of melanoma. MacKie RM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S3–6 (14 ref.)

Issues in the epidemiology of melanoma. Weinstock MA. **Hematol Oncol Clin North Am** 1998 Aug;12(4):681–98 (115 ref.)

Multiple primary melanomas: analysis of 49 cases. Savoia P, et al. **Melanoma Res** 1998 Aug;8(4):361–6 (24 ref.)

[Melanoma in pregnancy (see comments)] de Wit AC, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19;142(38):2087–90 (29 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2073–5. **(Dut)**

[Prevention of cutaneous melanoma] van der Rhee HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1356–9 (24 ref.) (Eng. Abstr.) **(Dut)**

[Melanoma of human skin: its epidemiology, etiology and pathogenesis] Korovin SI. **Lik Sprava** 1998 Jun;(4):46–50 (38 ref.) **(Rus)**

ETHNOLOGY

Conjunctival melanoma in the black population. Singh AD, et al. **Surv Ophthalmol** 1998 Sep–Oct;43(2):127–33 (43 ref.)

ETIOLOGY

Cigarette smoking and skin cancer. Merimsky O, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):585–8 (32 ref.)

Melanoma and sun exposure: where are we now? Whiteman DC, et al. **Int J Dermatol** 1999 Jul;38(7):481–9 (99 ref.)

Molecular biology of human melanoma development and progression. Sauter ER, et al. **Mol Carcinog** 1998 Nov; 23(3):132–43 (151 ref.)

The pathogenesis of melanoma induced by ultraviolet radiation. Gilchrest BA, et al. **N Engl J Med** 1999 Apr 29;340(17):1341–8 (94 ref.)

The relationship of pregnancy, hormones, and melanoma. Grin CM, et al. **Semin Cutan Med Surg** 1998 Sep; 17(3):167–71 (44 ref.)

[Skin cancers and environmental factors] Autier P. **Rev Med Brux** 1998 Sep;19(4):A346–50 (20 ref.) (Eng. Abstr.) **(Fre)**

[UV–induced immunosuppression and skin cancers] Meunier L, et al. **Rev Med Interne** 1998 Apr;19(4):247–54 (72 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenesis of malignant melanoma. Molecular biology aspect] Waldmann V, et al. **Hautarzt** 1999 Jun; 50(6):398–405 (62 ref.) (Eng. Abstr.) **(Ger)**

[Risk factors for the development of malignant melanomas]

Itin PH. **Ther Umsch** 1999 Jun;56(6):298–301 (18 ref.) (Eng. Abstr.) **(Ger)**

[Sun and skin] Gelmetti C. **Minerva Pediatr** 1998 Jun; 50(6):283–7 (37 ref.) **(Ita)**

[Melanoma of human skin: its epidemiology, etiology and pathogenesis] Korovin SI. **Lik Sprava** 1998 Jun;(4):46–50 (38 ref.) **(Rus)**

GENETICS

Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma. Bullock GJ, et al. **Am J Surg** 1999 Jan;177(1):15–8 (39 ref.)

The genetics of melanoma: the UK experience. Newton Bishop JA, et al. **Clin Exp Dermatol** 1998 Jul;23(4):158–61 (23 ref.)

Genetic predisposition to ocular melanoma. Houlston RS, et al. **Eye** 1999;13 (Pt 1):43–6 (58 ref.)

Malignant melanoma: modern black plague and genetic black box. Chin L, et al. **Genes Dev** 1998 Nov 15;12(22):3467–81 (169 ref.)

Molecular changes in human melanoma metastasis. Luca MR, et al. **Histol Histopathol** 1998 Oct;13(4):1225–31 (50 ref.)

Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. Graadt van Roggen JF, et al. **J Pathol** 1998 Sep;186(1):3–7 (43 ref.)

Modeling malignant melanoma in mice: pathogenesis and maintenance. Chin L. **Oncogene** 1999 Sep 20;18(38):5304–10 (65 ref.)

Molecular staging for melanoma and breast cancer. Shivers SC, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):515–26 (41 ref.)

[MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma] Bosserhoff AK, et al. **Hautarzt** 1998 Oct;49(10):762–9 (17 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis of malignant melanoma. Molecular biology aspect] Waldmann V, et al. **Hautarzt** 1999 Jun; 50(6):398–405 (62 ref.) (Eng. Abstr.) **(Ger)**

[Cytogenetic aspects of malignant melanoma] Böni R, et al. **Ther Umsch** 1999 Jun;56(6):309–11 (14 ref.) (Eng. Abstr.) **(Ger)**

[Genetics of cutaneous melanoma] Bonin S, et al. **Pathologica** 1998 Oct;90(5):474–5 (18 ref.) **(Ita)**

[Genetic basis of malignant melanoma] Drewa G, et al. **Postepy Hig Med Dosw** 1998;52(4):367–80 (78 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Antitumor immunity at work in a melanoma patient. Coulie PG, et al. **Adv Cancer Res** 1999;76:213–42 (69 ref.)

The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes. Zeuthen J, et al. **Bratisl Lek Listy** 1998 Aug–Sep;99(8–9):426–34 (68 ref.)

Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB. **Hematol Oncol Clin North Am** 1998 Aug;12(4):877–902, viii (149 ref.)

Immune escape mechanisms in malignant melanoma. Geertsen R, et al. **Int J Mol Med** 1999 Jan;3(1):49–57 (109 ref.)

Immunotherapy using T cell defined tumor antigens for melanoma. Kawakami Y. **Microbiol Immunol** 1998; 42(12):801–13 (61 ref.)

HLA-G expression: immune privilege for tumour cells? Cabestre FA, et al. **Semin Cancer Biol** 1999 Feb;9(1):27–36 (49 ref.)

Immunological factors which influence response to immunotherapy in malignant melanoma. Morton D, et al. **Surgery** 1970 Jul;68(1):158–63; discussion 163–4 (32 ref.)

METABOLISM

Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. Kramer DL, et al. **Biochem Soc Trans** 1998 Nov; 26(4):609–14 (25 ref.)

MORTALITY

Cause-specific versus all-cause survival [editorial; comment] McLean IW, et al. **Ophthalmology** 1998 Nov; 105(11):1989–90 (3 ref.) Comment on: Ophthalmology 1998 Nov;105(11):2035–45.

PATHOLOGY

Tumor progression, early diagnosis and prognosis of melanoma. Elder D. **Acta Oncol** 1999;38(5):535–47 (124 ref.)

Melan-A, a new melanocytic differentiation marker. Busam KJ, et al. **Adv Anat Pathol** 1999 Jan;6(1):12–8 (27 ref.)

Molecular pathology of malignant melanoma. Slominski A, et al. **Am J Clin Pathol** 1998 Dec;110(6):788–94 (136 ref.)

Subungual malignant melanoma with cartilaginous differentiation. Cachia AR, et al. **Am J Dermatopathol** 1999 Apr;21(2):165–9 (15 ref.)

Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression [comment] Seftor RE. **Am J Pathol** 1998 Nov;153(5):1347–51 (78 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1435–42.

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Primary melanocytoma arising from the thoracic leptomeninges case. Shimoda H, et al. **Clin Neuropathol** 1999 Mar–Apr;18(2):80–3 (10 ref.)

Metastatic melanoma of the nasal cavity in a patient with oculocutaneous albinism. Malaguarnera M, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):404–6 (34 ref.)

Recent developments in the pathology of melanocytic neoplasia. Shea CR, et al. **Dermatol Clin** 1999 Jul; 17(3):615–30, ix (81 ref.)

Sentinel lymphadenectomy in the management of primary cutaneous malignant melanoma. An update. White WL, et al. **Dermatol Clin** 1999 Jul;17(3):645–55, ix-x (33 ref.)

Simulators of malignant melanoma of the skin. Cerroni L, et al. **Eur J Dermatol** 1998 Sep;8(6):388–96 (67 ref.)

Malignant melanoma of the oesophagus: clinicopathological features, lack of p53 expression and steroid receptors and a review of the literature. Lam KY, et al. **Eur J Surg Oncol** 1999 Apr;25(2):168–72 (28 ref.)

Classification and staging of melanoma. Gershenwald JE, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):737–65 (114 ref.)

Systemic treatment of metastatic melanoma with chemotherapy. Green RJ, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):863–75, viii (51 ref.)

Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Reintgen DS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):807–21, vii (41 ref.)

Cutaneous melanoma: diagnosis and at risk patients. Hall PN, et al. **Hosp Med** 1998 Nov;59(11):866–71 (21 ref.)

Dimensionalities: borderline and intermediate melanocytic neoplasia. Reed RJ. **Hum Pathol** 1999 May;30(5):521–4 (16 ref.)

Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Frade R. **Immunopharmacology** 1999 May;42(1–3):39–45 (37 ref.)

Role of the transcription factor AP-1 in melanoma differentiation (review). Kang DC, et al. **Int J Oncol** 1998 Dec;13(6):1117–26 (104 ref.)

Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. Glass FL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):603–10 (64 ref.)

Molecular biology of human melanoma development and progression. Sauter ER, et al. **Mol Carcinog** 1998 Nov; 23(3):132–43 (151 ref.)

Melanoma in childhood: review and perspectives. Spatz A, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):463–74 (122 ref.)

'Is this mole all right'? Jackson A. **Practitioner** 1998 Apr; 242(1585):254–6, 260–2, 264 passim (7 ref.)

Current techniques in sentinel node mapping. Kamm BL. **Radiol Technol** 1999 Mar–Apr;70(4):323–33; quiz 334–7 (46 ref.)

Childhood melanoma. Barnhill RL. **Semin Diagn Pathol** 1998 Aug;15(3):189–94 (8 ref.)

Malicious masquerade: myxoid melanoma. Hitchcock MG, et al. **Semin Diagn Pathol** 1998 Aug;15(3):195–202 (56 ref.)

Pagetoid melanocytosis: tease or tocsin? Stern JB, et al. **Semin Diagn Pathol** 1998 Aug;15(3):225–9 (16 ref.)

Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Edwards MJ, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):51–7 (26 ref.)

[Desmoplastic malignant melanoma of the ear. A case report] Dumortier R, et al. **Ann Chir Plast Esthet** 1997 Aug; 42(4):329–32 (22 ref.) (Eng. Abstr.) **(Fre)**

[Malignant melanoma. Epidemiology, screening, diagnosis, evolution, prognostic clinical and histopathologic criteria] Roudier-Pujol C, et al. **Rev Prat** 1998 Oct 1;48(15):1729–35 (3 ref.) **(Fre)**

PHYSIOPATHOLOGY

Cell–cell interactions during transendothelial migration of tumor cells. Voura EB, et al. **Microsc Res Tech** 1998 Nov 1;43(3):265–75 (110 ref.)

PREVENTION & CONTROL

Clinical implications of the new biology in the development of melanoma vaccines. Hemmila MR, et al. **J Surg Oncol** 1999 Apr;70(4):263–74 (98 ref.)

Melanoma vaccines as a therapeutic option. McGee JM, et al. **South Med J** 1999 Jul;92(7):698–704 (54 ref.)

[Prevention of cutaneous melanoma] van der Rhee HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1356–9 (24 ref.) (Eng. Abstr.) **(Dut)**

[Prevention of malignant melanoma] Blum A, et al. **Hautarzt** 1998 Nov;49(11):826–34 (54 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Melanoma patients: psychosocial stress, coping with illness and social support. A systematic review] Söllner W, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):338–48 (62 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Primary malignant melanoma of the esophagus: radiographic findings in seven patients. Yoo CC, et al. **Radiology** 1998 Nov;209(2):455–9 (18 ref.)

RADIONUCLIDE IMAGING

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Role of nuclear medicine in melanoma. Hoefnagel CA. **Eur J Nucl Med** 1998 Nov;25(11):1567–74 (47 ref.)

Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. Delbeke D. **J Nucl Med** 1999 Apr;40(4):591–603 (81 ref.)

Sentinel node lymphoscintigraphy in malignant melanoma. O'Doherty M, et al. **Nucl Med Commun** 1999 Apr; 20(4):305–6 (7 ref.)

Use of sentinel node lymphoscintigraphy in malignant melanoma. Yudd AP, et al. **Radiographics** 1999 Mar–Apr; 19(2):343–53; discussion 354–6 (21 ref.)

Lymphoscintigraphy in malignant melanoma and breast cancer. Berman CG, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):401–12, vii (22 ref.)

[Contribution of nuclear medicine to lymphatic mapping and sentinel node identification in oncology] Valdés Olmos RA, et al. **Rev Esp Med Nucl** 1999;18(2):111–21 (48 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

The evolution of the role of radiation therapy in the management of mucocutaneous malignant melanoma. Cooper JS. **Hematol Oncol Clin North Am** 1998 Aug; 12(4):849–62, vii (58 ref.)

Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Link EM. **Hybridoma** 1999 Feb;18(1):77–82 (34 ref.)

Choroidal melanoma: a review and case report. Cymbor MJ, et al. **J Am Optom Assoc** 1998 Oct;69(10):656–65 (50 ref.)

Primary sinonasal mucosal melanoma: three different therapeutic approaches to inoperable local disease or recurrence and a review of the literature. De Meerleer GO, et al. **Melanoma Res** 1998 Oct;8(5):449–57 (52 ref.)

SECONDARY

Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature. Te HS, et al. **Am J Gastroenterol** 1999 Jan;94(1):262–6 (40 ref.)

Pancreaticoduodenectomy for melanoma metastatic to the duodenum: a case report and review of the literature. Meyers MO, et al. **Am Surg** 1998 Dec;64(12):1174–6 (15 ref.)

An update of tumor metastasis to the breast data [letter; comment] Alva S, et al. **Arch Surg** 1999 Apr;134(4):450 (2 ref.) Comment on: Arch Surg 1998 Oct;133(10):1117–9.

Cardiac metastases from malignant melanoma. Gibbs P, et al. **Cancer** 1999 Jan 1;85(1):78–84 (38 ref.)

Imaging of abdominal manifestations of melanoma. Kamel IR, et al. **Crit Rev Diagn Imaging** 1998 Dec;39(6):447–86 (24 ref.)

Abdominal pain in a patient with melanoma. Datner EM, et al. **Dermatol Surg** 1998 Oct;24(10):1100–2 (19 ref.)

New prognostic factors in melanoma: mRNA tumour markers. Keilholz U. **Eur J Cancer** 1998 Jul;34 Suppl 3:S37–41 (37 ref.)

Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. Ross MI, et al. **Eur J Cancer** 1998 Jul;34 Suppl 3:S7–11 (15 ref.)

The sentinel node procedure in cutaneous melanoma: an overview of 6 years' experience. Statius Muller MG, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S20–5 (52 ref.)

Intraocular metastases of cutaneous malignant melanoma: a case report and review of the literature. Ramaesh K, et al. **Eye** 1999 Apr;13 (Pt 2):247–50 (24 ref.)

Molecular changes in human melanoma metastasis. Luca MR, et al. **Histol Histopathol** 1998 Oct;13(4):1225–31 (50 ref.)

Sentinel node localisation: A new prospective in the treatment of nodal melanoma metastases. Gennari R, et al. **Int J Oncol** 1999 Jul;15(1):25–32 (36 ref.)

Indications for surgical resection of metastatic ocular melanoma. A case report and review of the literature. Cunningham JD, et al. **Int J Pancreatol** 1998 Aug; 24(1):49–53 (17 ref.)

Sentinel node lymphoscintigraphy in malignant melanoma. O'Doherty M, et al. **Nucl Med Commun** 1999 Apr; 20(4):305–6 (7 ref.)

Role of interleukin-8 in tumor growth and metastasis of human melanoma. Bar-Eli M. **Pathobiology** 1999;67(1):12–8 (66 ref.)

Dying dogma: the pathological diagnosis of epidermotropic metastatic malignant melanoma. White WL, et al. **Semin Diagn Pathol** 1998 Aug;15(3):176–88 (72 ref.)

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237–9 (12 ref.) **(Fre)**

[Systemic therapy of metastatic melanoma] Dummer R, et al. **Ther Umsch** 1999 Jun;56(6):330–3 (8 ref.) (Eng. Abstr.) **(Ger)**

[The surgery of lung metastases of melanoma] Morone G, et al. **Ann Ital Chir** 1998 Jul–Aug;69(4):461–4 (32 ref.) (Eng. Abstr.) **(Ita)**

MELANOMA

[Chemotherapy of advanced stage melanoma using cisplatin, epirubicin and alpha-interferon] Carpano S, et al. **Clin Ter** 1999 Mar-Apr;150(2):109-14 (39 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Pancreaticoduodenectomy for melanoma metastatic to the duodenum: a case report and review of the literature. Meyers MO, et al. **Am Surg** 1998 Dec;64(12):1174-6 (15 ref.)

Therapeutic node dissections in malignant melanoma. Karakousis CP. **Ann Surg Oncol** 1998 Sep;5(6):473-82 (63 ref.)

Cardiac metastases from malignant melanoma. Gibbs P, et al. **Cancer** 1999 Jan 1;85(1):78-84 (38 ref.)

Current therapy of cutaneous melanoma. Mays SR, et al. **Cutis** 1999 May;63(5):293-8 (52 ref.)

Comments on Management of cutaneous melanoma M0: state of the art and trends, Rossi et al., Eur J Cancer 1997, 33, 2302-2312 [letter; comment] Bartoli C, et al. **Eur J Cancer** 1998 Aug;34(9):1467-8 (5 ref.) Comment on: Eur J Cancer 1997 Dec;33(14):2302-12.

The surgical treatment of primary melanoma. McCarthy WH, et al. **Hematol Oncol Clin North Am** 1998 Aug; 12(4):797-805, vi (20 ref.)

Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Reintgen DS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):807-21, vii (41 ref.)

Surgical treatment for recurrent tumors of primary malignant melanoma of the esophagus: a case report and review of the literature. Mukaiya M, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):295-8 (22 ref.)

Indications for surgical resection of metastatic ocular melanoma. A case report and review of the literature. Cunningham JD, et al. **Int J Pancreatol** 1998 Aug; 24(1):49-53 (17 ref.)

Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. Glass FL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):603-10 (64 ref.)

Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? Morton DL, et al. **J Am Coll Surg** 1999 Aug; 189(2):214-23 (93 ref.)

The role of elective lymph node dissection in malignant melanoma: who should undergo this nodal staging procedure? Reintgen D. **J Am Coll Surg** 1999 Aug; 189(2):224-32 (22 ref.)

Melanoma during pregnancy: a case report and review of the literature. Teplitzky S, et al. **J La State Med Soc** 1998 Nov;150(11):539-43 (19 ref.)

Primary sinonasal mucosal melanoma: three different therapeutic approaches to inoperable local disease or recurrence and a review of the literature. De Meerleer GO, et al. **Melanoma Res** 1998 Oct;8(5):449-57 (52 ref.)

Melanoma resection margin recommendations, unconventionally based on available facts. Piepkorn M. **Semin Diagn Pathol** 1998 Aug;15(3):230-4 (50 ref.)

Historical perspectives and future applications. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):391-400, vii (47 ref.)

Radioguided surgery for melanoma. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):413-26, vii (29 ref.)

[Sentinel node--malignant melanoma and primary breast cancer. The significance of sentinel node in the treatment of malignant melanoma and primary breast cancer] Axelsson CK, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2343-7 (40 ref.) (Eng. Abstr.) **(Dan)**

[Sentinel lymphadenectomy in malignant melanoma] Büchels HK, et al. **Chirurg** 1998 Jul;69(7):701-7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Surgical treatment of malignant melanoma] Bösch U, et al. **Ther Umsch** 1999 Jun;56(6):318-23 (28 ref.) (Eng. Abstr.) **(Ger)**

[The surgery of lung metastases of melanoma] Morone G, et al. **Ann Ital Chir** 1998 Jul-Aug;69(4):461-4 (32 ref.) (Eng. Abstr.) **(Ita)**

[Prospective comparative study of different amino acid and lipid solutions in parenteral nutrition of patients undergoing bone marrow transplantation] Jiménez Jiménez FJ, et al. **Nutr Hosp** 1999 Mar-Apr;14(2):57-66 (47 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine. Horvath JC, et al. **Acta Microbiol Immunol Hung** 1999;46(1):1-20 (113 ref.)

Treatment of malignant melanoma. Durán García E, et al. **Ann Pharmacother** 1999 Jun;33(6):730-8 (44 ref.)

Developing recombinant and synthetic vaccines for the treatment of melanoma. Restifo NP, et al. **Curr Opin Oncol** 1999 Jan;11(1):50-7 (81 ref.)

Moles and melanoma. Chamlin SL, et al. **Curr Opin Pediatr** 1998 Aug;10(4):398-404 (80 ref.)

Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eggermont AM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S22-6 (47 ref.)

Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Kirkwood JM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S12-7 (20 ref.)

Future perspectives in specific immunotherapy of melanoma. Parmiani G. **Eur J Cancer** 1998 Jul;34 Suppl 3:S42-7 (35 ref.)

The treatment of metastatic uveal melanoma. Pyrhönen S. **Eur J Cancer** 1998 Jul;34 Suppl 3:S27-30 (29 ref.)

Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB. **Hematol Oncol Clin North Am** 1998 Aug;12(4):877-902, viii (149 ref.)

Vaccines and other adjuvant therapies for melanoma. Wolchok JD, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):835-48, vii (67 ref.)

Therapeutic trends in cutaneous melanoma. Hall PN, et al. **Hosp Med** 1999 Jan;60(1):39-43 (22 ref.)

Immune and gene therapy for melanoma, and the immunobiology of melanoma. Smith KJ, et al. **Int J Dermatol** 1999 Jul;38(7):490-508 (123 ref.)

Immunotherapy using T cell defined tumor antigens for melanoma. Kawakami Y. **Microbiol Immunol** 1998; 42(12):801-13 (61 ref.)

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3-15 (84 ref.)

Immunocytokines: a promising approach to cancer immunotherapy. Lode HN, et al. **Pharmacol Ther** 1998 Dec; 80(3):277-92 (101 ref.)

Autologous, hapten-modified vaccine as a treatment for human cancers. Berd D, et al. **Semin Oncol** 1998 Dec; 25(6):646-53 (25 ref.)

Active immunotherapy with allogeneic tumor cell vaccines: present status. Chan AD, et al. **Semin Oncol** 1998 Dec; 25(6):611-22 (73 ref.)

Ganglioside vaccines with emphasis on GM2. Livingston P. **Semin Oncol** 1998 Dec;25(6):636-45 (63 ref.)

Perspective on allogeneic melanoma lysates in active specific immunotherapy. Mitchell MS. **Semin Oncol** 1998 Dec; 25(6):623-35 (29 ref.)

[Melanoma update] Lejeune FJ. **Bull Cancer** 1999 Jan; 86(1):47-51 (45 ref.) **(Fre)**

[Cytokines and cancer: update in 1998] Négrier S. **Bull Cancer** 1999 Jan;86(1):37-9 (24 ref.) **(Fre)**

[Managing cutaneous melanoma] Thomas L, et al. **Cancer Radiother** 1998 Dec;2(6):732-46 (256 ref.) (Eng. Abstr.) **(Fre)**

[Uveal melanomas and their treatment] Zografos L. **Rev Med Suisse Romande** 1998 Nov;118(11):915-26 (59 ref.) **(Fre)**

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237-9 (12 ref.) **(Fre)**

[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature] Terheyden P, et al. **Hautarzt** 1998 Oct;49(10):770-3 (23 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of cutaneous melanoma] Dummer R, et al. **Ther Umsch** 1998 Aug;55(8):509-14 (13 ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant therapy of malignant melanoma] Hauschild A, et al. **Ther Umsch** 1999 Jun;56(6):324-9 (26 ref.) (Eng. Abstr.) **(Ger)**

[Skin cancer melanoma] Ishihara K. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:173-84 (23 ref.) (Eng. Abstr.) **(Jpn)**

[The treatment of malignant melanoblastoma of the skin] Korovin SI. **Lik Sprava** 1998 Jul-Aug;(5):41-6 (43 ref.) **(Rus)**

[Treatment of malignant choroidal melanoma with transpupillary thermotherapy using the diode laser] Strmeň P, et al. **Cesk Slov Oftalmol** 1999 May;55(3):176-80 (27 ref.) **(Slo)**

ULTRASTRUCTURE

Cell-cell interactions during transendothelial migration of tumor cells. Voura EB, et al. **Microsc Res Tech** 1998 Nov 1;43(3):265-75 (110 ref.)

Meningeal melanocytoma: a case report and literature review. Alameda F, et al. **Ultrastruct Pathol** 1998 Jul-Aug; 22(4):349-56 (17 ref.)

VETERINARY

The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Modiano JF, et al. **J Vet Intern Med** 1999 May-Jun;13(3):163-74 (138 ref.)

MELANOMA, AMELANOTIC

PATHOLOGY

Amelanotic lentigo maligna melanoma: report of a case and review of the literature. Rocamora V, et al. **Cutis** 1999 Jul;64(1):53-6 (33 ref.)

MELANOMA, B16 see **MELANOMA, EXPERIMENTAL**

MELANOMA, CLOUDMAN S91 see **MELANOMA, EXPERIMENTAL**

MELANOMA, EXPERIMENTAL

DRUG THERAPY

Vitamin D3 derivatives (deltanoids) in the treatment of tumor cell invasion [editorial; comment] Keski-Oja J. **J Lab Clin Med** 1999 Feb;133(2):95-7 (11 ref.) Comment on: J Lab Clin Med 1999 Feb;133(2):120-8.

MELANOMA, HARDING-PASSEY see **MELANOMA, EXPERIMENTAL**

MELANOMA, MALIGNANT, OF SOFT PARTS see **SARCOMA, CLEAR CELL**

MELANOSIS

DIAGNOSIS

Differential diagnosis of the conjunctival melanoses. McLean IW. **Ann Diagn Pathol** 1998 Aug;2(4):264-70 (14 ref.)

PATHOLOGY

Pigmented squamous cell carcinoma of the skin: report of two cases and review of the literature [published erratum appears in Am J Dermatopathol 1999 Jun;21(3):310] Jurado I, et al. **Am J Dermatopathol** 1998 Dec;20(6):578-81 (11 ref.)

Melanosis of the uterine cervix: a report of two cases and discussion of pigmented cervical lesions. Yilmaz AG, et al. **Int J Gynecol Pathol** 1999 Jan;18(1):73-6 (15 ref.)

Necrotizing esophagitis presenting as a black esophagus. Obermeyer R, et al. **Surg Endosc** 1998 Dec;12(12):1430-3 (11 ref.)

Melanosis thyroidi. Veinot JP, et al. **Ultrastruct Pathol** 1998 Sep-Oct;22(5):401-6 (25 ref.)

[Linear and whorled nevoid hypermelanosis: report of two cases] Claudel P, et al. **Arch Pediatr** 1998 Oct; 5(10):1098-102 (22 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Chemical peels. Godin DA, et al. **J La State Med Soc** 1998 Nov;150(11):513-20 (14 ref.)

THERAPY

Treatment of melasma: a review with personal experience. Piamphongsant T. **Int J Dermatol** 1998 Dec;37(12):897-903 (35 ref.)

MELANOTIC FRECKLE see **HUTCHINSON'S MELANOTIC FRECKLE**

MELANOTROPIN see **MSH**

MELAS SYNDROME

[MELAS] Nonaka I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):191-3 (9 ref.) **(Jpn)**

DIAGNOSIS

Skin manifestations of a patient with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS syndrome). Kubota Y, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):469-73 (8 ref.)

MELASMA see **MELANOSIS**

MELATONIN

Melatonin: a chemical photoperiodic signal with clinical significance in humans. Pang SF, et al. **Chin Med J (Engl)** 1998 Mar;111(3):197-203 (69 ref.)

ADMINISTRATION & DOSAGE

Melatonin. Pineal gland hormone--a brief review. Patel JC. **Indian J Med Sci** 1998 Dec;52(12):567-8 (0 ref.)

ADVERSE EFFECTS

Melatonin: aeromedical, toxicopharmacological, and analytical aspects. Sanders DC, et al. **J Anal Toxicol** 1999 May-Jun;23(3):159-67 (100 ref.)

AGONISTS

Indole melatonin agonists and antagonists derived by shifting the melatonin side chain from the C-3 to the N-1 or to the C-2 indole position. Tarzia G, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):24-31 (29 ref.)

ANALOGS & DERIVATIVES

Structure-affinity relationships of indole-based melatonin analogs. Spadoni G, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):15-23 (36 ref.)

[Development of animal models for the chronobiotics of melatonin analogs] Guardiola-Lemaitre B. **Therapie** 1998 Sep-Oct;53(5):439-44 (30 ref.) (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Indole melatonin agonists and antagonists derived by shifting the melatonin side chain from the C-3 to the N-1 or to

the C-2 indole position. Tarzia G, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):24-31 (29 ref.)

BIOSYNTHESIS

The pineal gland and melatonin: molecular and pharmacologic regulation. Borjigin J, et al. **Annu Rev Pharmacol Toxicol** 1999;39:53-65 (79 ref.)

Extrapineal melatonin and exogenous serotonin in seasonal affective disorder. Partonen T. **Med Hypotheses** 1998 Nov; 51(5):441-2 (5 ref.)

Melatonin synthesis pathway: circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Bernard M, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):325-34 (44 ref.)

BLOOD

The dim light melatonin onset, melatonin assays and biological rhythm research in humans. Lewy AJ. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):79-83 (27 ref.)

Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Waldhauser F, et al. **Exp Gerontol** 1998 Nov-Dec;33(7-8):759-72 (72 ref.)

DEFICIENCY

Melatonin. Pineal gland hormone--a brief review. Patel JC. **Indian J Med Sci** 1998 Dec;52(12):567-8 (0 ref.)

IMMUNOLOGY

Melatonin as a time-meaningful signal in circadian organization of immune response. Cardinali DP, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):41-8 (22 ref.)

METABOLISM

The oxidant/antioxidant network: role of melatonin. Reiter RJ, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):56-63 (64 ref.)

Molecular rhythms in the pineal gland. Li X, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):648-51 (24 ref.)

Can high maternal melatonin concentrations be responsible for inducing fetal pathologies, and can melatonin participate in immunohormonal homeostasis by determining prohormone convertase activity?--Hypothesis and facts. Ciesla W. **Med Hypotheses** 1998 Oct;51(4):269-80 (100 ref.)

[Signaling by melatonin receptors] Petit L, et al. **Therapie** 1998 Sep-Oct;53(5):421-8 (55 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin and its role the circadian function] Nowak JZ, et al. **Postepy Hig Med Dosw** 1999;53(3):445-71 (98 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

New actions of melatonin on tumor metabolism and growth. Blask DE, et al. **Biol Signals Recept** 1999 Jan-Apr; 8(1-2):49-55 (20 ref.)

Melatonin. Mor M, et al. **Curr Med Chem** 1999 Jun; 6(6):501-18 (142 ref.)

Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. Muñoz-Hoyos A, et al. **J Child Neurol** 1998 Oct;13(10):501-9 (112 ref.)

Melatonin: from biochemistry to therapeutic applications. Zawilska JB, et al. **Pol J Pharmacol** 1999 Jan-Feb; 51(1):3-23 (222 ref.)

Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Reiter RJ, et al. **Proc West Pharmacol Soc** 1998;41:229-36 (156 ref.)

[Melatonin and reproduction in domestic farm animals] Chemineau P, et al. **Therapie** 1998 Sep-Oct;53(5):445-52 (52 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Melatonin: the dark force. Bergstrom WH, et al. **Adv Pediatr** 1998;45:91-106 (64 ref.)

Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Reiter RJ, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:410-24 (77 ref.)

Antioxidant properties of melatonin--an emerging mystery. Beyer CE, et al. **Biochem Pharmacol** 1998 Nov 15; 56(10):1265-72 (59 ref.)

Melatonin as a time-meaningful signal in circadian organization of immune response. Cardinali DP, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):41-8 (22 ref.)

Cross-talk between the pineal gland and immune system. Poon AM, et al. **Chin Med J (Engl)** 1998 Jan;111(1):7-11 (70 ref.)

Melatonin's role in vertebrate circadian rhythms. Cassone VM. **Chronobiol Int** 1998 Sep;15(5):457-73 (86 ref.)

Melatonin. Mor M, et al. **Curr Med Chem** 1999 Jun; 6(6):501-18 (142 ref.)

Extrapineal melatonin: location and role within diffuse neuroendocrine system. Kvetnoy IM. **Histochem J** 1999 Jan;31(1):1-12 (70 ref.)

Melatonin, biological rhythm disorders and phototherapy. Srinivasan V. **Indian J Physiol Pharmacol** 1997 Oct; 41(4):309-28 (105 ref.)

The role of melatonin in the human fetus (review). Thomas L, et al. **Int J Mol Med** 1998 Mar;1(3):539-43 (53 ref.)

Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. Reiter RJ, et al. **J Mol Med** 1999 Jan; 77(1):36-9 (43 ref.)

The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature. Brainard GC, et al. **J Pineal Res** 1999 Mar;26(2):65-100 (210 ref.)

Does the impairment of the hypothalamic-pituitary-gonadal axis in anorexia nervosa depend on increased sensitivity to endogenous melatonin? Pawlikowski M, et al. **Med Hypotheses** 1999 Feb;52(2):111-3 (15 ref.)

Cytoprotective properties of melatonin: presumed association with oxidative damage and aging [see comments] Reiter RJ. **Nutrition** 1998 Sep;14(9):691-6 (80 ref.) Comment in: Nutrition 1998 Sep;14(9):712-3.

Melatonin and 5-methoxytryptamine in non-metazoans. Hardeland R. **Reprod Nutr Dev** 1999 May-Jun; 39(3):399-408 (43 ref.)

Melatonin and the seasonal control of reproduction. Malpaux B, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):355-66 (75 ref.)

Melatonin mediates seasonal adjustments in immune function. Nelson RJ, et al. **Reprod Nutr Dev** 1999 May-Jun; 39(3):383-98 (148 ref.)

Inhibitory effect of melatonin on GnRH-induced LH release. Vanecek J. **Rev Reprod** 1999 May;4(2):67-72 (53 ref.)

Complex effects of melatonin. Arendt J. **Therapie** 1998 Sep-Oct;53(5):479-88 (52 ref.)

Putative roles of melatonin in glucose regulation. Van Cauter E. **Therapie** 1998 Sep-Oct;53(5):467-72 (36 ref.)

[Melatonin and reproduction in domestic animals] Chemineau P, et al. **C R Seances Soc Biol Fil** 1998;192(4):669-82 (52 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin: hormone and medication] Touitou Y. **C R Seances Soc Biol Fil** 1998;192(4):643-57 (52 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin and biological rhythms] Pevet P. **Therapie** 1998 Sep-Oct;53(5):411-20 (65 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin and regulation of the cardiovascular system] Scalbert E, et al. **Therapie** 1998 Sep-Oct;53(5):459-65 (52 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin and aging] Touitou Y, et al. **Therapie** 1998 Sep-Oct;53(5):473-8 (51 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin in dermatology. Experimental and clinical aspects] Fischer T, et al. **Hautarzt** 1999 Jan;50(1):5-11 (48 ref.) (Eng. Abstr.) **(Ger)**

[Sleep-promoting substances] Fujitani Y, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):811-6 (53 ref.) **(Jpn)**

[Extrapineal melatonin: its place and role in the neuroendocrine regulation of homeostasis] Kvetnoi IM, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):364-70 (60 ref.) **(Rus)**

[Role of melatonin in human body] Malinovskaia NK. **Klin Med (Mosk)** 1998;76(10):15-22 (143 ref.) **(Rus)**

[Melatonin and its wide-spectrum effects: use of melatonin in the treatment of tumors] Solár P. **Cesk Fysiol** 1999 Feb; 48(1):27-40 (149 ref.) (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Prospects of the clinical utilization of melatonin. Bubenik GA, et al. **Biol Signals Recept** 1998 Jul-Aug;7(4):195-219 (227 ref.)

Melatonin in circadian sleep disorders in the blind. Skene DJ, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):90-5 (37 ref.)

The use of melatonin for the treatment of insomnia. Zisapel N. **Biol Signals Recept** 1999 Jan-Apr;8(1-2):84-9 (51 ref.)

Melatonin treatment of non-epileptic myoclonus in children. Jan JE, et al. **Dev Med Child Neurol** 1999 Apr;41(4):255-9 (48 ref.)

Melatonin treatment of sleep-wake cycle disorders in children and adolescents. Jan JE, et al. **Dev Med Child Neurol** 1999 Jul;41(7):491-500 (191 ref.)

Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Waldhauser F, et al. **Exp Gerontol** 1998 Nov-Dec;33(7-8):759-72 (72 ref.)

Melatonin: aeromedical, toxicopharmacological, and analytical aspects. Sanders DC, et al. **J Anal Toxicol** 1999 May-Jun;23(3):159-67 (100 ref.)

Melatonin and clinical application. Wetterberg L. **Reprod Nutr Dev** 1999 May-Jun;39(3):367-82 (70 ref.)

[Melatonin: hormone and medication] Touitou Y. **C R Seances Soc Biol Fil** 1998;192(4):643-57 (52 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin and its wide-spectrum effects: use of melatonin in the treatment of tumors] Solár P. **Cesk Fysiol** 1999 Feb; 48(1):27-40 (149 ref.) (Eng. Abstr.) **(Slo)**

MELEDA DISEASE see **KERATODERMA, PALMOPLANTAR**

MELIOIDOSIS

[Pulmonary melioidosis] Perret JL, et al. **Rev Pneumol Clin** 1998 Dec;54(6):365-72 (65 ref.) (Eng. Abstr.) **(Fre)**

[Melioidosis] Watanabe K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):255-7 (12 ref.) **(Jpn)**

DRUG THERAPY

Burkholderia pseudomallei: the unbeatable foe? Leelarasamee A. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):410-5 (26 ref.)

MICROBIOLOGY

Neonatal meningitis and septicaemia caused by Burkholderia pseudomallei. Halder D, et al. **Ann Trop Paediatr** 1998 Jun; 18(2):161-4 (9 ref.)

MORTALITY

Burkholderia pseudomallei: the unbeatable foe? Leelarasamee A. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):410-5 (26 ref.)

MELITTEN

PHARMACOLOGY

Effect of melittin on ion transport across cell membranes. Yang S, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan; 18(1):3-5 (31 ref.)

MELITTIN see **MELITTEN**

MELKERSSON-ROSENTHAL SYNDROME

[Melkersson-Rosenthal syndrome] Cousin F, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):495-501 (31 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Melkersson-Rosenthal syndrome in a diabetic boy. Ruza Paz-Curbera E, et al. **Allergol Immunopathol (Madr)** 1998 Nov-Dec;26(6):291-3 (15 ref.)

MELLITIN see **MELITTEN**

MELNICK-NEEDLES SYNDROME see **OSTEOCHONDRODYSPLASIAS**

MELON-HEADED WHALE see **DOLPHINS**

MELORHEOSTOSIS

DIAGNOSIS

Sclerotome distribution of melorheostosis and multicentric fibromatosis. Rhys R, et al. **Skeletal Radiol** 1998 Nov; 27(11):633-6 (16 ref.)

MELPHALAN

ADMINISTRATION & DOSAGE

Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189-91 (14 ref.)

Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Schraffordt Koops H, et al. **Radiother Oncol** 1998 Jul; 48(1):1-4 (19 ref.)

MEMANTINE

ADVERSE EFFECTS

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Parsons CG, et al. **Neuropharmacology** 1999 Jun;38(6):735-67 (379 ref.)

MEMBRANE ALANYL AMINOPEPTIDASE see **ANTIGENS, CD13**

MEMBRANE ATTACK COMPLEX see **COMPLEMENT MEMBRANE ATTACK COMPLEX**

MEMBRANE CHANNELS see **ION CHANNELS**

MEMBRANE FLUIDITY

DRUG EFFECTS

Piracetam: novelty in a unique mode of action. Müller WE, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:2-9 (59 ref.)

MEMBRANE FUSION

Annexins and ATP in membrane traffic: a comparison with membrane fusion machinery. Bandorowicz-Pikula J, et al. **Acta Biochim Pol** 1998;45(3):721-33 (81 ref.)

SNAREs and membrane fusion in the Golgi apparatus. Nichols BJ, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1-2):9-31 (149 ref.)

Coiled coils in both intracellular vesicle and viral membrane fusion. Skehel JJ, et al. **Cell** 1998 Dec 23;95(7):871-4 (19 ref.)

Membrane fusion: structure snared at last. Hughson FM.

MEMBRANE FUSION

Curr Biol 1999 Jan 28;9(2):R49–52 (18 ref.)
Regulation of endosome fusion. Mills IG, et al.
Mol Membr Biol 1999 Jan–Mar;16(1):73–9 (54 ref.)
Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Nir S, et al.
Mol Membr Biol 1999 Jan–Mar;16(1):95–101 (36 ref.)
Springs and zippers: coiled coils in SNARE-mediated membrane fusion. Harbury PA. **Structure** 1998 Dec 15; 6(12):1487–91 (16 ref.)
Pictures in cell biology. Structures of fusion-machinery components. **Trends Cell Biol** 1998 Dec;8(12):502 (12 ref.)

PHYSIOLOGY

Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Cammack N.
Antivir Chem Chemother 1999 Mar;10(2):53–62 (94 ref.)
SNAREs and SNARE regulators in membrane fusion and exocytosis. Gerst JE. **Cell Mol Life Sci** 1999 May; 55(5):707–34 (351 ref.)
Electrostatic attraction at the core of membrane fusion. Montal M. **FEBS Lett** 1999 Mar 26;447(2–3):129–30 (21 ref.)
Peptides and membrane fusion: towards an understanding of the molecular mechanism of protein-induced fusion. Pécheur EI, et al. **J Membr Biol** 1999 Jan 1;167(1):1–17 (120 ref.)
Structural basis for membrane fusion by enveloped viruses. Weissenhorn W, et al. **Mol Membr Biol** 1999 Jan–Mar; 16(1):3–9 (78 ref.)
Glycoprotein K of herpes simplex virus: a transmembrane protein encoded by the UL53 gene which regulates membrane fusion. Rajčáni J, et al. **Virus Genes** 1999; 18(1):81–90 (63 ref.)
[Monitoring exocytosis using patch-clamp capacitance measurement] Maruyama Y, et al.
Tanpakushitsu Kakusan Koso 1998 Sep;43(12 Suppl):1770–6 (15 ref.) **(Jpn)**

MEMBRANE GLYCOPROTEINS

Dystroglycan in development and disease. Durbeej M, et al.
Curr Opin Cell Biol 1998 Oct;10(5):594–601 (71 ref.)
The toll of innate immunity on microbial pathogens. Modlin RL, et al. **N Engl J Med** 1999 Jun 10;340(23):1834–5 (5 ref.)
[Costimulatory molecules, CD 80 and CD 86] Takasaki Y.
Ryumachi 1998 Aug;38(4):623–30 (45 ref.) **(Jpn)**

ANALYSIS

Is sperm galactosyltransferase a signaling subunit of a multimeric gamete receptor? Shur BD.
Biochem Biophys Res Commun 1998 Sep 29;250(3):537–43 (79 ref.)
Surfactants in membrane solubilisation. Jones MN.
Int J Pharm 1999 Jan 25;177(2):137–59 (115 ref.)
Antigenic characterization of Pneumocystis carinii. Gigliotti F, et al. **Semin Respir Infect** 1998 Dec;13(4):313–22 (52 ref.)

ANTAGONISTS & INHIBITORS

[Antagonists of glycoprotein IIb/IIIa as new antiplatelet agents] Petrusewicz J. **Przegl Lek** 1998;55(2):64–7 (27 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? [comment] Laurén J, et al. **Am J Pathol** 1998 Nov;153(5):1333–9 (79 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1459–66.
The Gas1 glycoprotein, a putative wall polymer cross-linker. Popolo L, et al. **Biochim Biophys Acta** 1999 Jan 6; 1426(2):385–400 (77 ref.)

CHEMISTRY

Structure and function of the Na+/glucose cotransporter. Wright EM, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:257–64 (25 ref.)
Structural and genetic analysis of laminin–nidogen interaction. Mayer U, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:130–42 (21 ref.)
The contribution of cell wall proteins to the organization of the yeast cell wall. Kapteyn JC, et al.
Biochim Biophys Acta 1999 Jan 6;1426(2):373–83 (81 ref.)
CD100 is a leukocyte semaphorin. Delaire S, et al.
Cell Mol Life Sci 1998 Nov;54(11):1265–76 (69 ref.)
Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Mikoshiba K, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):59–67 (46 ref.)
CD46 (membrane cofactor protein of complement, measles virus receptor): structural and functional divergence among species (review). Seya T, et al. **Int J Mol Med** 1998 May; 1(5):809–16 (72 ref.)
Structure and activation of the large latent transforming growth factor-Beta complex. Nunes I, et al.
J Am Optom Assoc 1998 Oct;69(10):643–8 (45 ref.)
The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)
[Structural and functional analysis of gp64, a membrane protein of the cellular slime mold Polysphondylium pallidum] Saito T, et al. **Seikagaku** 1998 Jul;70(7):537–42 (16 ref.) **(Jpn)**

DRUG EFFECTS

The serotonin transporter: a primary target for antidepressant drugs. Schloss P, et al. **J Psychopharmacol** 1998; 12(2):115–21 (65 ref.)

GENETICS

The role of the peripherin/RDS gene in retinal dystrophies. Kohl S, et al. **Acta Anat (Basel)** 1998;162(2–3):75–84 (69 ref.)
Structural and genetic analysis of laminin–nidogen interaction. Mayer U, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:130–42 (21 ref.)
The KTR and MNN1 mannosyltransferase families of Saccharomyces cerevisiae. Lussier M, et al.
Biochim Biophys Acta 1999 Jan 6;1426(2):323–34 (40 ref.)
Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Lesch KP, et al.
Biol Psychiatry 1998 Aug 1;44(3):179–92 (75 ref.)
The sarcoglycan complex in limb–girdle muscular dystrophy. Lim LE, et al. **Curr Opin Neurol** 1998 Oct;11(5):443–52 (103 ref.)
Comparison of ZP3 protein sequences among vertebrate species: to obtain a consensus sequence for immunocontraception. Zhu X, et al. **Front Biosci** 1999 Mar 1;4:D212–5 (29 ref.)
Genetic analysis of functions for cell surface proteoglycans [see comments] Selleck S. **Matrix Biol** 1998 Nov; 17(7):473–6 (30 ref.) Comment in: Matrix Biol 1998 Nov;17(7):461–3.
The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)
Role of L1 in neural development: what the knockouts tell us. Kamiguchi H, et al. **Mol Cell Neurosci** 1998 Sep; 12(1–2):48–55 (54 ref.)
Hallucinations: psychopathology meets functional genomics [editorial] Lesch KP. **Mol Psychiatry** 1998 Jul;3(4):278–81 (20 ref.)
Transcriptional regulation of Syndecan-1 expression by growth factors. Jaakkola P, et al.
Prog Nucleic Acid Res Mol Biol 1999;63:109–38 (130 ref.)
Negative regulation of inflammation by Fas ligand expression on the vascular endothelium. Walsh K, et al.
Trends Cardiovasc Med 1999 Jan–Feb;9(1–2):34–41 (58 ref.)
Host resistance to infection: genetic control of lipopolysaccharide responsiveness by TOLL-like receptor genes. Qureshi ST, et al. **Trends Genet** 1999 Aug; 15(8):291–4 (24 ref.)

IMMUNOLOGY

Childhood membranous nephropathy, circulating antibodies to the 58-kD TIN antigen, and anti-tubular basement membrane nephritis: an 11-year follow-up. Iványi B, et al. **Am J Kidney Dis** 1998 Dec;32(6):1068–74 (38 ref.)
Anticardiolipin and anti-beta 2glycoprotein I immunoassays in the diagnosis of antiphospholipid syndrome. Tincani A, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):396–402 (103 ref.)
Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Braud VM, et al.
Curr Top Microbiol Immunol 1999;244:85–95 (30 ref.)
L1 makes immunological progress by expanding its relations. Kadmon G, et al. **Dev Immunol** 1998;6(3–4):205–13 (40 ref.)
Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. O'Connell J, et al. **Dis Esophagus** 1999; 12(2):83–9 (51 ref.)
CD28/CTLA-4 and CD80/CD86 families: signaling and function. Slavik JM, et al. **Immunol Res** 1999;19(1):1–24 (198 ref.)
Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Antonaci S, et al.
Immunopharmacol Immunotoxicol 1998 Nov;20(4):455–72 (62 ref.)
HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. Posch PE, et al. **J Biomed Sci** 1998 Sep–Oct; 5(5):321–31 (102 ref.)
The clinical significance of Fas expression in leukemia: questions and controversies. Findley HW, et al.
Leukemia 1999 Feb;13(2):147–9 (25 ref.)
Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Denton MD, et al.
Pediatr Transplant 1998 Feb;2(1):6–15 (81 ref.)
Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody. Rossini AA, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):629–32 (15 ref.)
[Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis] Romero Gómez M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):11–3 (24 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Structure and function of the Na+/glucose cotransporter. Wright EM, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:257–64 (25 ref.)
Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Mikoshiba K, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):59–67 (46 ref.)
Cystinuria calls for heteromultimeric amino acid transporters. Palacín M, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):455–61 (53 ref.)
Molecular interactions of the syndecan core proteins. Rapraeger AC, et al. **Curr Opin Cell Biol** 1998 Oct; 10(5):620–8 (63 ref.)
Processing of the Ebola virus glycoprotein. Volchkov VE.
Curr Top Microbiol Immunol 1999;235:35–47 (76 ref.)
CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Laman JD, et al. **Dev Immunol** 1998; 6(3–4):215–22 (50 ref.)
The syndecans, tuners of transmembrane signaling. Zimmermann P, et al. **FASEB J** 1999;13 Suppl:S91–S100 (79 ref.)
Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Sim RB, et al. **Immunobiology** 1998 Aug; 199(2):208–24 (77 ref.)
The role of B7 costimulation in T-cell immunity. Harris NL, et al. **Immunol Cell Biol** 1999 Aug;77(4):304–11 (98 ref.)
Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Kong YY, et al. **Immunol Cell Biol** 1999 Apr; 77(2):188–93 (45 ref.)
The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Takasaki Y, et al. **Intern Med** 1999 Feb;38(2):175–7 (8 ref.)
Structure and activation of the large latent transforming growth factor-Beta complex. Nunes I, et al.
J Am Optom Assoc 1998 Oct;69(10):643–8 (45 ref.)
Regulation of renal urea transporters. Sands JM.
J Am Soc Nephrol 1999 Mar;10(3):635–46 (137 ref.)
Hypothesis: A recurrent, moderate activation fosters systemic autoimmunity--the apoptotic roles of TCR, IL-2 and Fas ligand. Matsui K, et al. **J Biomed Sci** 1999 Sep–Oct; 6(5):306–13 (57 ref.)
Is extravasation a Fas-regulated process? Walsh K, et al.
Mol Med Today 1999 Feb;5(2):61–7 (63 ref.)
Modulatory proteins and processes in alliance with immune cells, mediators, and extracellular proteins in renal interstitial fibrosis. Wardle EN. **Ren Fail** 1999 Mar; 21(2):121–33 (110 ref.)
CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Toes REM, et al. **Semin Immunol** 1998 Dec;10(6):443–8 (44 ref.)
Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Liu Y, et al.
Trends Cell Biol 1999 Sep;9(9):356–63 (73 ref.)
Ontogeny of ECL cells in the rat. Sundler F.
Yale J Biol Med 1998 May–Aug;71(3–4):155–61 (24 ref.)
[Studies on the receptor for Clostridium botulinum neurotoxin] Kozaki S. **Nippon Saikingaku Zasshi** 1999 Apr; 54(2):401–14 (56 ref.) **(Jpn)**
[The mechanisms of endoplasmic reticulum protein localization by vesicle recycling] Sato K, et al.
Seikagaku 1998 Dec;70(12):1387–400 (91 ref.) **(Jpn)**

PHARMACOLOGY

TRAIL induces apoptosis and activation of NFkappaB. Jeremias I, et al. **Eur Cytokine Netw** 1998 Dec;9(4):687–8 (14 ref.)

PHYSIOLOGY

Urea excretion revisited: physiology and transporters. Bankir L, et al. **Adv Nephrol Necker Hosp** 1998;28:83–135 (200 ref.)
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Takahashi N, et al.
Biochem Biophys Res Commun 1999 Mar 24;256(3):449–55 (55 ref.)
Mammalian sperm–egg recognition: does fertilin beta have a major role to play? Frayne J, et al. **Bioessays** 1999 Mar; 21(3):183–7 (20 ref.)
Neural cell adhesion molecule L1: relating disease to function. Kenwrick S, et al. **Bioessays** 1998 Aug; 20(8):668–75 (57 ref.)
Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Blakely RD, et al. **Biol Psychiatry** 1998 Aug 1;44(3):169–78 (65 ref.)
Fas-mediated apoptosis of hepatic cells. Feldmann G, et al. **Biomed Pharmacother** 1998;52(9):378–85 (71 ref.)
Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Peters M, et al. **Blood** 1998 Nov 15;92(10):3495–504 (85 ref.)
Dystroglycan versatility. Hemler ME. **Cell** 1999 May 28; 97(5):543–6 (18 ref.)
Apoptosis control by death and decoy receptors. Ashkenazi A, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):255–60 (66 ref.)
TRAIL: a molecule with multiple receptors and control mechanisms. Griffith TS, et al. **Curr Opin Immunol** 1998

Oct;10(5):559–63 (25 ref.)
The Toll-receptor family and control of innate immunity. Kopp EB, et al. **Curr Opin Immunol** 1999 Feb;11(1):13–8 (48 ref.)
Shared resources between the neural and immune systems: semaphorins join the ranks. Spriggs MK. **Curr Opin Immunol** 1999 Aug;11(4):387–91 (58 ref.)
Tumor expression of Fas ligand (CD95L) and the consequences. Walker PR, et al. **Curr Opin Immunol** 1998 Oct;10(5):564–72 (73 ref.)
The angiopoietins: Yin and Yang in angiogenesis. Davis S, et al. **Curr Top Microbiol Immunol** 1999;237:173–85 (42 ref.)
Inhibitory role of murine Ly49 lectin-like receptors on natural killer cells. Salcedo M. **Curr Top Microbiol Immunol** 1999;244:97–105 (45 ref.)
gp49: an Ig-like receptor with inhibitory properties on mast cells and natural killer cells. Wagtmann N. **Curr Top Microbiol Immunol** 1999;244:107–13 (40 ref.)
The mast cell function-associated antigen, a new member of the ITIM family. Xu R, et al. **Curr Top Microbiol Immunol** 1999;244:159–68 (22 ref.)
Integrated function of urea transporters in the mammalian kidney. Trinh-Trang-Tan MM, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):471–9 (35 ref.)
Chloroplast precursor protein translocon. May T, et al. **FEBS Lett** 1999 Jun 4;452(1–2):52–6 (53 ref.)
The Pneumocystis carinii major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. Benfield TL, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):129–34 (48 ref.)
The major surface antigen of Pneumocystis carinii. Nakamura Y. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):67–74 (69 ref.)
Perforin-dependent nuclear targeting of granzymes: A central role in the nuclear events of granule-exocytosis-mediated apoptosis? Blink EJ, et al. **Immunol Cell Biol** 1999 Jun;77(3):206–15 (101 ref.)
Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Waring P, et al. **Immunol Cell Biol** 1999 Aug;77(4):312–7 (88 ref.)
The Fas counterattack: cancer as a site of immune privilege. O'Connell J, et al. **Immunol Today** 1999 Jan;20(1):46–52 (118 ref.)
Cytokine pleiotropy and redundancy--gp130 cytokines in human implantation. Sánchez-Cuenca J, et al. **Immunol Today** 1999 Feb;20(2):57–9 (32 ref.)
CD40-CD154 interaction in experimental and human disease (review). Biancone L, et al. **Int J Mol Med** 1999 Apr; 3(4):343–53 (112 ref.)
CD46 (membrane cofactor protein of complement, measles virus receptor): structural and functional divergence among species (review). Seya T, et al. **Int J Mol Med** 1998 May; 1(5):809–16 (72 ref.)
Allogeneic hepatocyte transplantation: contribution of Fas-Fas ligand interaction to allogeneic hepatocyte rejection. Kawahara T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S119–23 (55 ref.)
TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. Wong BR, et al. **J Leukoc Biol** 1999 Jun;65(6):715–24 (75 ref.)
New kids in the block: the role of FasL and Fas in kidney damage. Ortiz A, et al. **J Nephrol** 1999 May-Jun; 12(3):150–8 (78 ref.)
Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Dhodapkar MV, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):35–43 (53 ref.)
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Greil R, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):477–90 (69 ref.)
Interleukin-10 and Gp130 cytokines in human multiple myeloma. Klein B, et al. **Leuk Lymphoma** 1999 Jun; 34(1–2):63–70 (66 ref.)
The emerging roles of cell surface heparan sulfate proteoglycans [comment] David G, et al. **Matrix Biol** 1998 Nov;17(7):461–3 (12 ref.) Comment on: Matrix Biol 1998 Nov;17(7):473–6. Comment on: Matrix Biol 1998 Nov;17(7):477–84. Comment on: Matrix Biol 1998 Nov;17(7):485–94.
Syndecan proteoglycans and cell adhesion [see comments] Woods A, et al. **Matrix Biol** 1998 Nov;17(7):477–83 (49 ref.) Comment in: Matrix Biol 1998 Nov;17(7):461–3.
Syndecan-3 in limb skeletal development. Kosher RA. **Microsc Res Tech** 1998 Oct 15;43(2):123–30 (97 ref.)
Membrane glycoprotein PC-1 and insulin resistance. Goldfine ID, et al. **Mol Cell Biochem** 1998 May; 182(1–2):177–84 (55 ref.)
Apoptosis and heart failure. Williams RS. **N Engl J Med** 1999 Sep 2;341(10):759–60 (1 ref.)
Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Matsui K, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:9–11 (14 ref.)
The Fas ligand/Fas system in renal injury [editorial] Ortiz A, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1831–4 (35 ref.)
CD95 mediated T cell apoptosis and its relevance to immune deviation. Varadhachary AS, et al. **Oncogene** 1998 Dec 24;17(25):3271–6 (99 ref.)
The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces. Guller S, et al. **Semin Reprod Endocrinol** 1999;17(1):39–44 (53 ref.)
Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127–37 (163 ref.)
The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Yang J, et al. **Thromb Haemost** 1999 Jan;81(1):1–7 (76 ref.)
The CD95(APO-1/Fas)/CD95L system. Krammer PH. **Toxicol Lett** 1998 Dec 28;102–103:131–7 (43 ref.)
Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444–9 (48 ref.)
[A presynaptic Ca(2+)-binding protein--synaptotagmin] Qiang M, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):268–70 (10 ref.) **(Chi)**
[Roles of C2 domains of synaptotagmin in the regulation of exocytosis] Ohara-Imaizumi M. **Seikagaku** 1998 Oct; 70(10):1283–8 (19 ref.) **(Jpn)**
[Role of osteoclast differentiation factor, the new member of the TNF ligand family, in osteoclast differentiation and function] Takahashi N, et al. **Seikagaku** 1999 Apr; 71(4):241–53 (66 ref.) **(Jpn)**
[Role of inositol polyphosphates: implications for cellular function] Fukuda M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1784–8 (26 ref.) **(Jpn)**
[Molecular biological approach to functions of telencephalin, a cell adhesion molecule and HNK-1 carbohydrate epitope, which is commonly expressed on cell adhesion molecules in the nervous system] Oka S. **Yakugaku Zasshi** 1998 Oct; 118(10):431–46 (34 ref.) (Eng. Abstr.) **(Jpn)**

MEMBRANE LIPIDS

[Recent progress of oxidized lipid] Nakagawa Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1234–5 (6 ref.) **(Jpn)**
[Membrane lipid signaling system participating in intracellular signal transduction--General concept] Nozawa Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):947–8 (12 ref.) **(Jpn)**

ANALYSIS

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Brown MS, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11041–8 (60 ref.)

BLOOD

Are lipid phase transitions responsible for chilling damage in human platelets? Crowe JH, et al. **Cryobiology** 1999 May; 38(3):180–91 (60 ref.)

CHEMISTRY

Genetic analysis of lipid-protein interactions in Escherichia coli membranes. Dowhan W. **Biochim Biophys Acta** 1998 Nov 10;1376(3):455–66 (80 ref.)
Lipid polymorphism and protein-lipid interactions. Epand RM. **Biochim Biophys Acta** 1998 Nov 10;1376(3):353–68 (107 ref.)
Theoretical analysis of protein organization in lipid membranes. Gil T, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):245–66 (130 ref.)
Attenuated total reflection infrared spectroscopy of proteins and lipids in biological membranes. Goormaghtigh E, et al. **Biochim Biophys Acta** 1999 Jul 6;1422(2):105–85 (397 ref.)
Emerging techniques for investigating molecular interactions at lipid membranes. Heyse S, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):319–38 (138 ref.)
Hydrophobic mismatch between proteins and lipids in membranes. Killian JA. **Biochim Biophys Acta** 1998 Nov 10;1376(3):401–15 (99 ref.)
How lipids interact with an intrinsic membrane protein: the case of the calcium pump. Lee AG. **Biochim Biophys Acta** 1998 Nov 10;1376(3):381–90 (48 ref.)
Structure, dynamics and composition of the lipid-protein interface. Perspectives from spin-labelling. Marsh D, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):267–96 (114 ref.)
The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Rietveld A, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):467–79 (143 ref.)
Lateral organisation of membrane lipids. The superlattice view. Somerharju P, et al. **Biochim Biophys Acta** 1999 Aug 25;1440(1):32–48 (131 ref.)
Solid-state NMR approaches for studying the interaction of peptides and proteins with membranes. Watts A. **Biochim Biophys Acta** 1998 Nov 10;1376(3):297–318 (111 ref.)
Lipid-protein interactions in blood coagulation. Zwaal RF, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):433–53 (151 ref.)
Solid-state NMR for the study of membrane systems: the use of anisotropic interactions. Warschawski DE, et al. **Biochimie** 1998 May-Jun;80(5–6):437–50 (91 ref.)
Structural diversity of membrane lipids in members of Halobacteriaceae. Kamekura M, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):969–72 (39 ref.)
Infrared studies of protein-induced perturbation of lipids in lipoproteins and membranes. Arrondo JL, et al. **Chem Phys Lipids** 1998 Nov;96(1–2):53–68 (59 ref.)
Structure and origin of ordered lipid domains in biological membranes. Brown DA, et al. **J Membr Biol** 1998 Jul 15; 164(2):103–14 (105 ref.)
Structure and functional properties of diacylglycerols in membranes. Goñi FM, et al. **Prog Lipid Res** 1999 Jan; 38(1):1–48 (180 ref.)
Does the membrane's physical state control the expression of heat shock and other genes? Vigh L, et al. **Trends Biochem Sci** 1998 Oct;23(10):369–74 (61 ref.)

IMMUNOLOGY

[Antiphospholipid-protein antibodies. Effects on the endothelium-platelet interaction] Forastiero RR, et al. **Sangre (Barc)** 1999 Jun;44(3):223–30 (85 ref.) **(Spa)**

METABOLISM

How cytidylyltransferase uses an amphipathic helix to sense membrane phospholipid composition. Cornell RB. **Biochem Soc Trans** 1998 Aug;26(3):539–44 (38 ref.)
Cytochrome b5 and tocopherol provide functions of lipid-radical cycles and energy conversion in membranes. Dmitriev LF. **Biochemistry (Mosc)** 1998 Oct;63(10):1233–6 (22 ref.)
Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Newton AC, et al. **Biochim Biophys Acta** 1998 Aug 21; 1376(2):155–72 (131 ref.)
Transmembrane phospholipid distribution in blood cells: control mechanisms and pathophysiological significance. Bevers EM, et al. **Biol Chem** 1998 Aug-Sep; 379(8–9):973–86 (173 ref.)
Signalling properties of glycosylphosphatidylinositols and their regulated release from membranes in the turnover of glycosylphosphatidylinositol-anchored proteins. Brodbeck U. **Biol Chem** 1998 Aug-Sep;379(8–9):1041–4 (31 ref.)
Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Gianturco SH, et al. **Clin Cardiol** 1999 Jun;22(6 Suppl):II7–14 (55 ref.)
Lipid signalling. Downes CP, et al. **Curr Biol** 1998 Dec 3; 8(24):R865–7 (6 ref.)
Bricks and mortar of the epidermal barrier. Nemes Z, et al. **Exp Mol Med** 1999 Mar 31;31(1):5–19 (220 ref.)
The essence of being extremophilic: the role of the unique archaeal membrane lipids. van de Vossenberg JL, et al. **Extremophiles** 1998 Aug;2(3):163–70 (90 ref.)
Lipophilic compounds in biotechnology--interactions with cells and technological problems. Angelova B, et al. **J Biotechnol** 1999 Jan 8;67(1):13–32 (178 ref.)
Membrane transport of long-chain fatty acids: evidence for a facilitated process. Abumrad N, et al. **J Lipid Res** 1998 Dec;39(12):2309–18 (103 ref.)
Regulatory mechanisms of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling. Bevers EM, et al. **Lupus** 1998; 7 Suppl 2:S126–31 (77 ref.)
Protein and lipid sorting from the trans-Golgi network to the plasma membrane in polarized cells. Ikonen E, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):503–9 (73 ref.)
Protein and lipid sorting between the endoplasmic reticulum and the Golgi complex. Nickel W, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):493–501 (76 ref.)
Does the membrane's physical state control the expression of heat shock and other genes? Vigh L, et al. **Trends Biochem Sci** 1998 Oct;23(10):369–74 (61 ref.)
[Membrane phospholipid metabolism] Banno Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1800–5 (34 ref.) **(Jpn)**
[Role of membrane phospholipid dynamics in cell division] Emoto K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1173–80 (26 ref.) **(Jpn)**

PHYSIOLOGY

Functions of lipid rafts in biological membranes. Brown DA, et al. **Annu Rev Cell Dev Biol** 1998;14:111–36 (127 ref.)
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Leevers SJ, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):219–25 (54 ref.)
Lipids, lipid domains and lipid-protein interactions in endocytic membrane traffic. Kobayashi T, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):517–26 (133 ref.)
[Role of membrane phospholipid dynamics in cytoskeletal organization] Emoto K, et al. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):1973–80 (26 ref.) **(Jpn)**

MEMBRANE METALLO-ENDOPEPTIDASE see **NEPRILYSIN**

MEMBRANE POTENTIALS

DRUG EFFECTS

Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line. Miller TR, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):179–85 (27 ref.)

MEMBRANE POTENTIALS

PHYSIOLOGY

Potassium-current oscillation of rat megakaryocytes: As a model system for drug evaluation (Review). Uneyama C, et al. **Int J Mol Med** 1999 Aug;4(2):163–9 (36 ref.)

Hypoxia and neuronal function under in vitro conditions. Nieber K. **Pharmacol Ther** 1999 Apr;82(1):71–86 (180 ref.)

MEMBRANE PROTEINS

Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Lorenzo HK, et al. **Cell Death Differ** 1999 Jun;6(6):516–24 (77 ref.)

Loricrin and human skin diseases: molecular basis of loricrin keratodermas. Ishida-Yamamoto A, et al. **Histol Histopathol** 1998 Jul;13(3):819–26 (56 ref.)

The patched signaling pathway in tumorigenesis and development: lessons from animal models. Hahn H, et al. **J Mol Med** 1999 Jun;77(6):459–68 (102 ref.)

[Analysis of a novel delta gene during the formation of cortical layers] Nakayama K. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):143–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Adrenomedullin receptors] Murabe H, et al. **Nippon Rinsho** 1998 Jul;56(7):1919–24 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Nucleotide-sugar transporters: cDNA cloning, structures and expression] Ishida N, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2325–34 (32 ref.) **(Jpn)**

[Membrane protein: bacteriorhodopsin] Kimura Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):546–56 (21 ref.) **(Jpn)**

[Nanometer/piconewton manipulation of single membrane protein molecules by laser tweezers] Kusumi A. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):906–11 (21 ref.) **(Jpn)**

ANALYSIS

Surfactants in membrane solubilisation. Jones MN. **Int J Pharm** 1999 Jan 25;177(2):137–59 (115 ref.)

Immunological and biochemical characterization of membrane proteins. Duffy MF, et al. **Methods Mol Biol** 1998;104:279–98 (34 ref.)

Imaging fluorescence resonance energy transfer as probe of membrane organization and molecular associations of GPI-anchored proteins. Kenworthy AK, et al. **Methods Mol Biol** 1999;116:37–49 (23 ref.)

BIOSYNTHESIS

Biogenesis of transport intermediates in the endocytic pathway. Gu F, et al. **FEBS Lett** 1999 Jun 4;452(1–2):61–6 (100 ref.)

Expression of the oestrogen responsive protein pS2 in human breast cancer. Balleine RL, et al. **Histol Histopathol** 1999 Apr;14(2):571–8 (63 ref.)

Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Gati WP, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):45–54 (44 ref.)

Modulation of cell surface protein expression by infection with HIV-1. Speth C, et al. **Leukemia** 1999 Apr;13 Suppl 1:S99–105 (85 ref.)

BLOOD

[The erythroblast antigen: a membrane protein bound to the erythroid form of the transferrin receptor?] Fuxon VI, et al. **Ontogenez** 1999 May-Jun;30(3):165–75 (85 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Crystal structural studies of a membrane protein complex, cytochrome c oxidase from bovine heart. Tsukihara T, et al. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):895–904 (60 ref.)

Structural aspects of transmembrane alpha-helices. von Heijne G. **Acta Physiol Scand Suppl** 1998 Aug;643:17–9 (6 ref.)

The structural study of membrane proteins by electron crystallography. Fujiyoshi Y. **Adv Biophys** 1998;35:25–80 (42 ref.)

Function and dysfunction of the presenilins. Sisodia SS, et al. **Am J Hum Genet** 1999 Jul;65(1):7–12 (42 ref.)

Membrane protein folding and stability: physical principles. White SH, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:319–65 (188 ref.)

A new concept in polytopic membrane proteins following from the study of band 3 protein. Hamasaki N, et al. **Biochem Cell Biol** 1998;76(5):729–33 (18 ref.)

Helical structure and dynamics in membrane polypeptides. Dempsey CE, et al. **Biochem Soc Trans** 1998 Aug; 26(3):444–50 (37 ref.)

Towards structural genomics for transmembrane proteins. Jones DT, et al. **Biochem Soc Trans** 1998 Aug;26(3):429–38 (35 ref.)

Molecular dynamics simulations of membranes with embedded proteins and peptides: porin, alamethicin and influenza virus M2. Sansom MS, et al. **Biochem Soc Trans** 1998 Aug;26(3):438–43 (27 ref.)

Modelling the packing of transmembrane helices: application to aquaporin-1. Sansom MS, et al. **Biochem Soc Trans** 1998 Aug;26(3):509–15 (30 ref.)

Structure of the G-protein-coupled receptor, rhodopsin: a domain approach. Yeagle PL, et al. **Biochem Soc Trans** 1998 Aug;26(3):520–31 (70 ref.)

Genetic analysis of lipid-protein interactions in Escherichia coli membranes. Dowhan W. **Biochim Biophys Acta** 1998 Nov 10;1376(3):455–66 (80 ref.)

Lipid polymorphism and protein-lipid interactions. Epand RM. **Biochim Biophys Acta** 1998 Nov 10;1376(3):353–68 (107 ref.)

Theoretical analysis of protein organization in lipid membranes. Gil T, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):245–66 (130 ref.)

Attenuated total reflection infrared spectroscopy of proteins and lipids in biological membranes. Goormaghtigh E, et al. **Biochim Biophys Acta** 1999 Jul 6;1422(2):105–85 (397 ref.)

Hydrophobic mismatch between proteins and lipids in membranes. Killian JA. **Biochim Biophys Acta** 1998 Nov 10;1376(3):401–15 (99 ref.)

How lipids interact with an intrinsic membrane protein: the case of the calcium pump. Lee AG. **Biochim Biophys Acta** 1998 Nov 10;1376(3):381–90 (48 ref.)

Structure, dynamics and composition of the lipid-protein interface. Perspectives from spin-labelling. Marsh D, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):267–96 (114 ref.)

Solid-state NMR approaches for studying the interaction of peptides and proteins with membranes. Watts A. **Biochim Biophys Acta** 1998 Nov 10;1376(3):297–318 (111 ref.)

Hydrophobic interactions of peptides with membrane interfaces. White SH, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):339–52 (75 ref.)

The structure and function of the brown fat uncoupling protein UCP1: current status. Rial E, et al. **Biofactors** 1998; 8(3–4):209–19 (87 ref.)

Coiled coils in both intracellular vesicle and viral membrane fusion. Skehel JJ, et al. **Cell** 1998 Dec 23;95(7):871–4 (19 ref.)

pHi regulatory ion transporters: an update on structure, regulation and cell function. Pucéat M. **Cell Mol Life Sci** 1999 Aug 15;55(10):1216–29 (159 ref.)

Infrared studies of protein-induced perturbation of lipids in lipoproteins and membranes. Arrondo JL, et al. **Chem Phys Lipids** 1998 Nov;96(1–2):53–68 (59 ref.)

Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579–84 (57 ref.)

Membrane protein folding. Booth PJ, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):115–21 (64 ref.)

NMR structural studies of membrane proteins. Marassi FM, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):640–8 (52 ref.)

Structures of membrane proteins determined at atomic resolution. Sakai H, et al. **J Biochem (Tokyo)** 1998 Dec 1;124(6):1051–9 (43 ref.)

Protein interactions implicated in neurotransmitter release. el Far O, et al. **J Physiol Paris** 1998 Apr;92(2):129–33 (26 ref.)

Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Girault JA, et al. **Mol Med** 1998 Dec;4(12):751–69 (137 ref.)

Membrane protein structure determination by solid state NMR. Watts A, et al. **Nat Prod Rep** 1999 Aug;16(4):419–23 (39 ref.)

Peptide-lipid interactions and mechanisms of antimicrobial peptides. Huang HW. **Novartis Found Symp** 1999; 225:188–200; discussion 200–6 (32 ref.)

Wrapping the package [comment] Ungewickell E. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8809–10 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):8907–12.

Insights into the structure and function of membrane polypeptides carrying blood group antigens. Cartron JP, et al. **Vox Sang** 1998;74 Suppl 2:29–64 (300 ref.)

CLASSIFICATION

The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane [letter] Chishti AH, et al. **Trends Biochem Sci** 1998 Aug;23(8):281–2 (38 ref.)

GENETICS

Paroxysmal nocturnal hemoglobinuria: analysis of the effects of mutant PIG-A on gene expression. Kanai N, et al. **Am J Hematol** 1999 Aug;61(4):221–31 (40 ref.)

Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Engelman JA, et al. **Am J Hum Genet** 1998 Dec;63(6):1578–87 (49 ref.)

Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Hummler E, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G567–71 (34 ref.)

The tight junction: morphology to molecules. Stevenson BR, et al. **Annu Rev Cell Dev Biol** 1998;14:89–109 (125 ref.)

Towards structural genomics for transmembrane proteins. Jones DT, et al. **Biochem Soc Trans** 1998 Aug;26(3):429–38 (35 ref.)

Transgenic mouse models of Alzheimer's disease. Sirinathsinghji DJ. **Biochem Soc Trans** 1998 Aug; 26(3):504–8 (20 ref.)

Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Pohlenz J, et al. **Biochimie** 1999 May; 81(5):469–76 (25 ref.)

How do yeast cells sense glucose? Kruckeberg AL, et al. **Bioessays** 1998 Dec;20(12):972–6 (36 ref.)

Metastasis-related genes in prostate cancer: the role of caveolin-1. Thompson TC. **Cancer Metastasis Rev** 1998–99; 17(4):439–42 (18 ref.)

Monogenic determinants of familial Alzheimer's disease: presenilin-1 mutations. Kovacs DM, et al. **Cell Mol Life Sci** 1998 Sep;54(9):902–9 (86 ref.)

Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations. Renbaum P, et al. **Cell Mol Life Sci** 1998 Sep;54(9):910–9 (74 ref.)

Presenilins in their infancy. Schweisguth F. **Chem Biol** 1999 Jul;6(7):R187–90 (30 ref.)

Molecular pathology of the cutaneous basement membrane zone. Mellerio JE. **Clin Exp Dermatol** 1999 Jan;24(1):25–32 (45 ref.)

Biology of presenilins as causative molecules for Alzheimer disease. Nishimura M, et al. **Clin Genet** 1999 Apr; 55(4):219–25 (52 ref.)

Alzheimer's disease: clues from flies and worms. Anderton BH. **Curr Biol** 1999 Feb 11;9(3):R106–9 (10 ref.)

Reflexions on a newly discovered diabetogenic gene, wolframin (WFS1). Gerbitz KD. **Diabetologia** 1999 May; 42(5):627–30 (25 ref.)

Implications of the molecular characterization of the sodium-iodide symporter (NIS). Schmutzler C, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 3:S1–10 (61 ref.)

Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. Frillingos S, et al. **FASEB J** 1998 Oct;12(13):1281–99 (117 ref.)

Hydropathy profile alignment: a tool to search for structural homologues of membrane proteins. Lolkema JS, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):305–22 (39 ref.)

FtsH--a single-chain charonin? Schumann W. **FEMS Microbiol Rev** 1999 Jan;23(1):1–11 (50 ref.)

Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5. Mole SE, et al. **Hum Mutat** 1999;14(3):199–215 (81 ref.)

Mitochondria uncoupling proteins and obesity: molecular and genetic aspects of UCP1. Kozak LP, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S33–7 (29 ref.)

Thyroid hormone and other regulators of uncoupling proteins. Reitman ML, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S56–9 (36 ref.)

Molecular and genetic aspects of the UCPs: view from the chair. Stock MJ. **Int J Obes Relat Metab Disord** 1999 Jun; 23 Suppl 6:S51–2 (6 ref.)

Genetics of uncoupling proteins in humans. Warden C. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S46–8 (14 ref.)

The molecular basis of disorders of the red cell membrane. McMullin MF. **J Clin Pathol** 1999 Apr;52(4):245–8 (21 ref.)

Patching together the genetics of Gorlin syndrome. Bale SJ, et al. **J Cutan Med Surg** 1998 Jul;3(1):31–4 (14 ref.)

Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. Yamashita T, et al. **J Endocrinol** 1998 Oct;159(1):1–8 (13 ref.)

Sequence analyses and phylogenetic characterization of the ZIP family of metal ion transport proteins. Eng BH, et al. **J Membr Biol** 1998 Nov 1;166(1):1–7 (24 ref.)

What do we learn from a few familial Alzheimer's disease cases? Haass C, et al. **J Neural Transm Suppl** 1998;54:137–45 (34 ref.)

Early diagnosis and the clinical genetics of Alzheimer's disease. Lovestone S. **J Neurol** 1999 Feb;246(2):69–72 (24 ref.)

Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Funakoshi M, et al. **Neuromuscul Disord** 1999 Mar;9(2):108–14 (55 ref.)

Molecular mechanisms and putative signalling events controlling utrophin expression in mammalian skeletal muscle fibres. Gramolini AO, et al. **Neuromuscul Disord** 1998 Aug;8(6):351–61 (144 ref.)

Genetic control of susceptibility to infections with intracellular pathogens. Skamene E. **Pathol Biol (Paris)** 1998 Nov;46(9):689–92 (0 ref.) **(Eng, Fre)**

The role of alternative pre-mRNA splicing in regulating the structure and function of skeletal protein 4.1. Conboy J. **Proc Soc Exp Biol Med** 1999 Feb;220(2):73–8 (44 ref.)

[Presenilins as a marker of Alzheimer's disease] Scheper W, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1247–52 (40 ref.) (Eng. Abstr.) **(Dut)**

[The protective role of Klotho gene on vascular endothelium] Saito Y, et al. **Nippon Rinsho** 1999 Jul;57(7):1514–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Recent advances in presenilin research] Okuizumi K, et al. **No To Shinkei** 1998 Sep;50(9):797–806 (50 ref.) **(Jpn)**

[Genetic factors in the pathogenesis of Alzheimer's disease: roles of beta-amyloid and presenilins] Iwatsubo T, et al. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):1963–72 (68 ref.) **(Jpn)**

IMMUNOLOGY

Regulation of T cell fate by Notch. Robey E. **Annu Rev Immunol** 1999;17:283–95 (66 ref.)

Discrete domains within the hyaluronan receptor CD44 regulate membrane localization and cell migration. Sheikh H, et al. **Cell Adhes Commun** 1998;6(2–3):149–56 (44 ref.)

Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Leslie RD, et al. **Diabetologia** 1999 Jan;42(1):3–14 (105 ref.)

How important is Nramp1 in tuberculosis? North RJ, et al. **Trends Microbiol** 1998 Nov;6(11):441–3 (20 ref.)

[Autoantibody against Na+/I– symporter (NaIS)] Zeki K. **Nippon Rinsho** 1999 Aug;57(8):1824–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Tight junction proteins. Citi S, et al. **Biochim Biophys Acta** 1998 Nov 19;1448(1):1–11 (113 ref.)

Synthetic neoglycolipids for biological applications: correlation between their structures and their interactions with membrane proteins. Rico-Lattes I, et al. **Biochimie** 1998 May–Jun;80(5–6):483–7 (18 ref.)

Purification of caveolae-derived membrane microdomains containing lipid-anchored signaling molecules, such as GPI-anchored proteins, H-Ras, Src-family tyrosine kinases, eNOS, and G-protein alpha-, beta-, and gamma-subunits. Lisanti MP, et al. **Methods Mol Biol** 1999; 116:51–60 (40 ref.)

METABOLISM

Protein–carbohydrate interactions during fertilization. Sinowatz F, et al. **Acta Anat (Basel)** 1998;161(1–4):196–205 (92 ref.)

GABA and human spermatozoa: characterization and regulation of GABA transport proteins. Aanesen A. **Acta Physiol Scand Suppl** 1998 Nov;642:1–61 (243 ref.)

Surface protein phosphorylation by ecto-protein kinases. Role in neuronal development and synaptic plasticity. Ehrlich YH, et al. **Adv Exp Med Biol** 1998;446:51–71 (85 ref.)

Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Hummler E, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G567–71 (34 ref.)

Interactions of presynaptic Ca2+ channels and snare proteins in neurotransmitter release. Catterall WA. **Ann N Y Acad Sci** 1999 Apr 30;868:144–59 (84 ref.)

Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Killar L, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:442–52 (69 ref.)

Membrane protein folding and stability: physical principles. White SH, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:319–65 (188 ref.)

Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Bonifacino JS, et al. **Annu Rev Cell Dev Biol** 1998;14:19–57 (164 ref.)

Anion exchangers in the red cell and beyond. Casey JR, et al. **Biochem Cell Biol** 1998;76(5):709–13 (33 ref.)

Mechanisms controlling the shedding of transmembrane molecules. Merlos-Suárez A, et al. **Biochem Soc Trans** 1999 Feb;27(2):243–6 (14 ref.)

Role for ADAM-family proteinases as membrane protein secretases. Turner AJ, et al. **Biochem Soc Trans** 1999 Feb; 27(2):255–9 (34 ref.)

Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Wolfe MS, et al. **Biochemistry** 1999 Aug 31; 38(35):11223–30 (81 ref.)

COPII and selective export from the endoplasmic reticulum. Barlowe C. **Biochim Biophys Acta** 1998 Aug 14; 1404(1–2):67–76 (57 ref.)

Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Buday L. **Biochim Biophys Acta** 1999 Jul 6;1422(2):187–204 (246 ref.)

Structure and function of the uncoupling protein from brown adipose tissue. Klingenberg M, et al. **Biochim Biophys Acta** 1999 Jan 8;1415(2):271–96 (152 ref.)

Protein transport from the secretory to the endocytic pathway in mammalian cells. Le Borgne R, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):195–209 (136 ref.)

Membrane proteins involved in pollen-pistil interactions. Giranton JL, et al. **Biochimie** 1999 Jun;81(6):675–80 (46 ref.)

Protein retention and localization in the endoplasmic reticulum and the golgi apparatus. Gomord V, et al. **Biochimie** 1999 Jun;81(6):607–18 (109 ref.)

Involvement of plasma membrane proteins in plant defense responses. Analysis of the cryptogein signal transduction in tobacco. Lebrun-Garcia A, et al. **Biochimie** 1999 Jun; 81(6):663–8 (52 ref.)

Interactions of alpha-helices with lipid bilayers: a review of simulation studies. Biggin PC, et al. **Biophys Chem** 1999 Feb 22;76(3):161–83 (152 ref.)

Twin peaks: Spitz and Argos star in patterning of the Drosophila egg [comment] Stevens L. **Cell** 1998 Oct 30; 95(3):291–4 (16 ref.) Comment on: Cell 1998 Oct 30;95(3):355–64.

pHi regulatory ion transporters: an update on structure, regulation and cell function. Pucéat M. **Cell Mol Life Sci** 1999 Aug 15;55(10):1216–29 (159 ref.)

The enzymology and pharmacology of 5-lipoxygenase and 5-lipoxygenase activating protein. Bell RL, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1–2):91–109 (111 ref.)

Eye development: Notch lends a handedness. Blair SS. **Curr Biol** 1999 May 20;9(10):R356–60 (17 ref.)

NMR of drugs and ligands bound to membrane receptors. Watts A. **Curr Opin Biotechnol** 1999 Feb;10(1):48–53 (46 ref.)

ADAMs: focus on the protease domain. Black RA, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):654–9 (41 ref.)

Regulation of cortical structure by the ezrin–radixin–moesin protein family. Bretscher A. **Curr Opin Cell Biol** 1999 Feb; 11(1):109–16 (56 ref.)

Nonpeptidic ligands for peptide and protein receptors. Freidinger RM. **Curr Opin Chem Biol** 1999 Aug; 3(4):395–406 (51 ref.)

Fringe, Notch, and making developmental boundaries. Irvine KD. **Curr Opin Genet Dev** 1999 Aug;9(4):434–41 (69 ref.)

Notch signaling: direct or what? Weinmaster G. **Curr Opin Genet Dev** 1998 Aug;8(4):436–42 (67 ref.)

Peroxisome biogenesis: from yeast to man. Kunau WH. **Curr Opin Microbiol** 1998 Apr;1(2):232–7 (61 ref.)

Secretion of proteins and assembly of bacterial surface organelles: shared pathways of extracellular protein targeting. Lory S. **Curr Opin Microbiol** 1998 Feb;1(1):27–35 (71 ref.)

Clinical and biochemical features of fatty acid oxidation disorders. Rinaldo P, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):615–21 (48 ref.)

Four cholesterol-sensing proteins. Lange Y, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):435–9 (55 ref.)

Molecules associated with human Th1 or Th2 cells. Annunziato F, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):12–6 (30 ref.)

Bricks and mortar of the epidermal barrier. Nemes Z, et al. **Exp Mol Med** 1999 Mar 31;31(1):5–19 (220 ref.)

The mechanism of proton transport mediated by mitochondrial uncoupling proteins. Garlid KD, et al. **FEBS Lett** 1998 Oct 30;438(1–2):10–4 (34 ref.)

Modular PH and C2 domains in membrane attachment and other functions. Katan M, et al. **FEBS Lett** 1999 Jun 4; 452(1–2):36–40 (61 ref.)

The Tol proteins of Escherichia coli and their involvement in the uptake of biomolecules and outer membrane stability. Lazzaroni JC, et al. **FEMS Microbiol Lett** 1999 Aug 15; 177(2):191–7 (33 ref.)

FtsH--a single-chain charonin? Schumann W. **FEMS Microbiol Rev** 1999 Jan;23(1):1–11 (50 ref.)

Familial Alzheimer's disease: oxidative stress, beta-amyloid, presenilins, and cell death. Velez-Pardo C, et al. **Gen Pharmacol** 1998 Nov;31(5):675–81 (108 ref.)

Cell surface galactosyltransferase: current issues. Shur BD, et al. **Glycoconj J** 1998 Jun;15(6):537–48 (96 ref.)

Mammalian mitochondrial uncoupling proteins. Ježek P, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1163–8 (21 ref.)

Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Culligan KG, et al. **Int J Mol Med** 1998 Dec;2(6):639–48 (120 ref.)

Excitation–contraction–relaxation cycle: role of Ca2+-regulatory membrane proteins in normal, stimulated and pathological skeletal muscle (review). Murray BE, et al. **Int J Mol Med** 1998 Apr;1(4):677–87 (109 ref.)

Emerging roles for proteinases in cancer. Noël A, et al. **Invasion Metastasis** 1997;17(5):221–39 (103 ref.)

Transmembrane proteins in the tight junction barrier. Fanning AS, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1337–45 (80 ref.)

Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse. Nagano T, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):869–75 (74 ref.)

Communication between the cell membrane and the nucleus: role of protein compartmentalization. Lelièvre SA, et al. **J Cell Biochem Suppl** 1998;30–31:250–63 (140 ref.)

Nuclear magnetic resonance chromatography: applications of pulse field gradient diffusion NMR to mixture analysis and ligand-receptor interactions. Gounarides JS, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 2;725(1):79–90 (51 ref.)

PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. Fanning AS, et al. **J Clin Invest** 1999 Mar;103(6):767–72 (29 ref.)

Biophysical approaches to G protein-coupled receptors: structure, function and dynamics. Chollet A, et al. **J Comput Aided Mol Des** 1999 May;13(3):209–19 (31 ref.)

Contributions of studies on uncoupling proteins to research on metabolic diseases. Ricquier D, et al. **J Intern Med** 1999 Jun;245(6):637–42 (27 ref.)

Mammalian iron transport: an unexpected link between metal homeostasis and host defense. Fleming MD, et al. **J Lab Clin Med** 1998 Dec;132(6):464–8 (33 ref.)

Molecular pharmacology of organic cation transporters in kidney. Koepsell H, et al. **J Membr Biol** 1999 Jan 15; 167(2):103–17 (131 ref.)

Presenilins and Alzheimer's disease: the role of A beta 42. Eckman CB. **J Neural Transm Suppl** 1998;53:181–4 (18 ref.)

Muscarinic cholinergic signaling in cardiac myocytes: dynamic targeting of M2AChR to sarcolemmal caveolae and eNOS activation. Feron O, et al. **Life Sci** 1999; 64(6–7):471–7 (24 ref.)

Evidence for age-related deamidation reactions in erythrocyte p55 and glycophorins C and D: implications for signal transduction involving tumour-suppressor proteins in higher eukaryotes. Lofthouse JT. **Med Hypotheses** 1998 Oct;51(4):321–4 (14 ref.)

Monitoring the dynamics and mobility of membrane proteins tagged with green fluorescent protein. Lippincott-Schwartz J, et al. **Methods Cell Biol** 1999; 58:261–81 (26 ref.)

Analysis of the cell-surface distribution of GPI-anchored proteins. Mayor S. **Methods Mol Biol** 1999;116:23–36 (22 ref.)

Protein targeting to the endoplasmic reticulum in yeast. 1997 Fleming Lecture. Stirling CJ. **Microbiology** 1999 May;145 (Pt 5):991–8 (65 ref.)

Nucleoside transporters: molecular biology and implications for therapeutic development. Baldwin SA, et al. **Mol Med Today** 1999 May;5(5):216–24 (48 ref.)

Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Nir S, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):95–101 (36 ref.)

Folding of secretory and membrane proteins. Kuznetsov G, et al. **N Engl J Med** 1998 Dec 3;339(23):1688–95 (69 ref.)

Molecular mechanisms and putative signalling events controlling utrophin expression in mammalian skeletal muscle fibres. Gramolini AO, et al. **Neuromuscul Disord** 1998 Aug;8(6):351–61 (144 ref.)

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Lebowitz PF, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1439–45 (76 ref.)

The specificity of vesicle trafficking: coat proteins and SNAREs. Sanderfoot AA, et al. **Plant Cell** 1999 Apr; 11(4):629–42 (108 ref.)

Neurotransmitter transport: models in flux [comment] Kavanaugh MP. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):12737–8 (17 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):13260–5.

Wrapping the package [comment] Ungewickell E. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8809–10 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):8907–12.

Effects of leptin on mitochondrial 'proton leak' and uncoupling proteins: implications for mammalian energy metabolism. Porter RK, et al. **Proc Nutr Soc** 1998 Aug; 57(3):455–60 (86 ref.)

The role of alternative pre-mRNA splicing in regulating the structure and function of skeletal protein 4.1. Conboy J. **Proc Soc Exp Biol Med** 1999 Feb;220(2):73–8 (44 ref.)

Structural conservation of Notch receptors and ligands. Fleming RJ. **Semin Cell Dev Biol** 1998 Dec;9(6):599–607 (65 ref.)

Protein and lipid sorting from the trans-Golgi network to the plasma membrane in polarized cells. Ikonen E, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):503–9 (73 ref.)

Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Londos C, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):51–8 (41 ref.)

Protein and lipid sorting between the endoplasmic reticulum and the Golgi complex. Nickel W, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):493–501 (76 ref.)

Control of lymphocyte function through CD27–CD70 interactions. Lens SM, et al. **Semin Immunol** 1998 Dec; 10(6):491–9 (89 ref.)

Possible regulation of intermediate filament proteins by Rho-binding kinases. Matsuzawa K, et al. **Subcell Biochem** 1998;31:423–35 (39 ref.)

The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane [letter] Chishti AH, et al. **Trends Biochem Sci** 1998 Aug;23(8):281–2 (38 ref.)

Pictures in cell biology. Structures of fusion-machinery components. **Trends Cell Biol** 1998 Dec;8(12):502 (12 ref.)

AKAPs: from structure to function. Colledge M, et al. **Trends Cell Biol** 1999 Jun;9(6):216–21 (57 ref.)

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Selkoe DJ. **Trends Cell Biol** 1998 Nov;8(11):447–53 (75 ref.)

Throwing the switch in bacterial chemotaxis. Silversmith RE, et al. **Trends Microbiol** 1999 Jan;7(1):16–22 (26 ref.)

RAMPs: accessory proteins for seven transmembrane domain receptors. Foord SM, et al. **Trends Pharmacol Sci** 1999 May;20(5):184–7 (32 ref.)

[Thermoregulation mechanisms of brown adipose tissue] Wang ZK, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct; 27(4):353–5 (8 ref.) **(Chi)**

[Cooperation of membrane proteins and cytosolic proteins in metabolic regulation--involvement of binding of hexokinase to mitochondria in regulation of glucose metabolism and association and complex formation between membrane proteins and cytosolic proteins in regulation of active oxygen production] Ishibashi S. **Yakugaku Zasshi** 1999 Jan;119(1):16–34 (49 ref.) (Eng. Abstr.) **(Jpn)**

[Adaptation of thylakoid membranes to environmental light conditions] Romanowska E. **Postepy Biochem** 1999; 45(1):58–65 (75 ref.) **(Pol)**

PHARMACOLOGY

Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance? McKenna HJ. **Cancer Immunol Immunother** 1999 Sep; 48(6):281–6 (69 ref.)

Effects of FLT3 ligand on proliferation and survival of

myeloid leukemia cells. Drexler HG, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):83-91 (44 ref.)

PHYSIOLOGY

Function and dysfunction of the presenilins. Sisodia SS, et al. **Am J Hum Genet** 1999 Jul;65(1):7-12 (42 ref.)

Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Liu Y, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:27-37 (30 ref.)

Presenilins--in search of functionality. Karran EH, et al. **Biochem Soc Trans** 1998 Aug;26(3):491-6 (48 ref.)

COPI in ER/Golgi and intra-Golgi transport: do yeast COPI mutants point the way? Gaynor EC, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):33-51 (124 ref.)

Clathrin and adaptors. Hirst J, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):173-93 (186 ref.)

Regulation of membrane traffic in animal cells by COPI. Lowe M, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1-2):53-66 (107 ref.)

SNAREs and membrane fusion in the Golgi apparatus. Nichols BJ, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1-2):9-31 (149 ref.)

Recent advances on proteins of plant terminal membranes. Grignon C. **Biochimie** 1999 Jun;81(6):577-96 (170 ref.)

The structure and function of the brown fat uncoupling protein UCP1: current status. Rial E, et al. **Biofactors** 1998; 8(3-4):209-19 (87 ref.)

Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Milner LA, et al. **Blood** 1999 Apr 15;93(8):2431-48 (189 ref.)

Signal transduction pathways regulated by the Rho family of small GTPases. Hall A. **Br J Cancer** 1999 Jul;80 Suppl 1:25-7 (17 ref.)

Metastasis-related genes in prostate cancer: the role of caveolin-1. Thompson TC. **Cancer Metastasis Rev** 1998-99; 17(4):439-42 (18 ref.)

Hedgehog and Spitz: making a match between photoreceptor axons and their targets. Salecker I, et al. **Cell** 1998 Nov 25;95(5):587-90 (18 ref.)

SNAREs and SNARE regulators in membrane fusion and exocytosis. Gerst JE. **Cell Mol Life Sci** 1999 May; 55(5):707-34 (351 ref.)

Crowded little caves: structure and function of caveolae. Schlegel A, et al. **Cell Signal** 1998 Jul;10(7):457-63 (62 ref.)

Recruitment of proteins to modulate protein-protein interactions. Liu JO. **Chem Biol** 1999 Aug;6(8):R213-5 (18 ref.)

Membrane fusion: structure snared at last. Hughson FM. **Curr Biol** 1999 Jan 28;9(2):R49-52 (18 ref.)

Vertebrate segmentation: the clock is linked to Notch signalling. Jiang YJ, et al. **Curr Biol** 1998 Dec 3; 8(24):R868-71 (23 ref.)

T-cell development: What does Notch do for T cells? von Boehmer H. **Curr Biol** 1999 Mar 11;9(5):R186-8 (10 ref.)

Eph receptors and ephrins in neural development. O'Leary DD, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):65-73 (74 ref.)

FLT3: receptor and ligand. Biology and potential clinical application. Shurin MR, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):37-48 (104 ref.)

Snare proteins essential for cyclic AMP-regulated exocytosis in salivary glands. Fujita-Yoshigaki J, et al. **Eur J Morphol** 1998 Aug;36 Suppl:46-9 (24 ref.)

SNAREs and the secretory pathway-lessons from yeast. Pelham HR. **Exp Cell Res** 1999 Feb 25;247(1):1-8 (26 ref.)

Mitochondrial assembly in yeast. Grivell LA, et al. **FEBS Lett** 1999 Jun 4;452(1-2):57-60 (40 ref.)

A possible role of di-leucine-based motifs in targeting and sorting of the syntaxin family of proteins. Tang BL, et al. **FEBS Lett** 1999 Mar 12;446(2-3):211-2 (29 ref.)

DNA strand exchange proteins: a biochemical and physical comparison. Bianco PR, et al. **Front Biosci** 1998 Jun 17; 3:D570-603 (307 ref.)

Overcoming barriers in the study of tight junction functions: from occludin to claudin. Tsukita S, et al. **Genes Cells** 1998 Sep;3(9):569-73 (40 ref.)

Macrophage NRAMP1 and its role in resistance to microbial infections. Govoni G, et al. **Inflamm Res** 1998 Jul; 47(7):277-84 (65 ref.)

UCP1, UCP2 and UCP3: are they true uncouplers of respiration? Bouillaud F. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S19-23 (30 ref.)

Biochemical aspects of the uncoupling proteins: view from the chair. Himms-Hagen J, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S30-2 (7 ref.)

Structure-function relationship in UCP1. Klingenberg M, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S24-9 (18 ref.)

Mitochondria uncoupling proteins and obesity: molecular and genetic aspects of UCP1. Kozak LP, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S33-7 (29 ref.)

The physiological role of the novel uncoupling proteins: view from the chair. Silva JE. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S72-4 (14 ref.)

Occludin and the functions of tight junctions. Matter K, et al. **Int Rev Cytol** 1999;186:117-46 (108 ref.)

Photoreceptor membrane proteins, phototransduction, and retinal degenerative diseases. The Friedenwald Lecture. Molday RS. **Invest Ophthalmol Vis Sci** 1998 Dec; 39(13):2491-513 (183 ref.)

Role of SNARE's in the GLUT4 translocation response to insulin in adipose cells and muscle. St-Denis JF, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):153-65 (42 ref.)

Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431-5 (33 ref.)

Septins: a highly conserved family of membrane-associated GTPases with functions in cell division and beyond. Trimble WS. **J Membr Biol** 1999 May 15;169(2):75-81 (43 ref.)

Protein interactions implicated in neurotransmitter release. el Far O, et al. **J Physiol Paris** 1998 Apr;92(2):129-33 (26 ref.)

Hemidesmosomes and their unique transmembrane protein BP180. Hirako Y, et al. **Microsc Res Tech** 1998 Nov 1; 43(3):207-17 (130 ref.)

Modulation of ion channels: a "current" view of AKAPs. Fraser ID, et al. **Neuron** 1999 Jul;23(3):423-6 (20 ref.)

Hedgehog and patched in neural development and disease. Goodrich LV, et al. **Neuron** 1998 Dec;21(6):1243-57 (212 ref.)

Semaphorin signaling: a little less per-plexin. Yu HH, et al. **Neuron** 1999 Jan;22(1):11-4 (20 ref.)

The role of the polycystins in kidney development. van Adelsberg JS. **Pediatr Nephrol** 1999 Jun;13(5):454-9 (48 ref.)

The Nramp1 protein and its role in resistance to infection and macrophage function. Canonne-Hergaux F, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):283-9 (56 ref.)

Notch signaling: cell fate control and signal integration in development. Artavanis-Tsakonas S, et al. **Science** 1999 Apr 30;284(5415):770-6 (92 ref.)

Notch signalling in Drosophila: three ways to use a pathway. Bray S. **Semin Cell Dev Biol** 1998 Dec;9(6):591-7 (60 ref.)

Novel pathways, membrane coats and PI kinase regulation in yeast lysosomal trafficking. Burd CG, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):527-33 (77 ref.)

Notch signalling pathway and human diseases. Joutel A, et al. **Semin Cell Dev Biol** 1998 Dec;9(6):619-25 (50 ref.)

Lipids, lipid domains and lipid-protein interactions in endocytic membrane traffic. Kobayashi T, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):517-26 (133 ref.)

Notch signalling and the control of cell fate choices in vertebrates. Lewis J. **Semin Cell Dev Biol** 1998 Dec; 9(6):583-9 (61 ref.)

Protein and lipid sorting between the endoplasmic reticulum and the Golgi complex. Nickel W, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):493-501 (76 ref.)

Modulators of Notch signaling. Panin VM, et al. **Semin Cell Dev Biol** 1998 Dec;9(6):609-17 (83 ref.)

Introduction: Notch signalling and choice of cell fates in development. Simpson P. **Semin Cell Dev Biol** 1998 Dec; 9(6):581-2 (11 ref.)

Springs and zippers: coiled coils in SNARE-mediated membrane fusion. Harbury PA. **Structure** 1998 Dec 15; 6(12):1487-91 (16 ref.)

Notch/LIN-12 signaling: transduction by regulated protein slicing. Kimble J, et al. **Trends Biochem Sci** 1998 Sep; 23(9):353-7 (48 ref.)

AKAPs: from structure to function. Colledge M, et al. **Trends Cell Biol** 1999 Jun;9(6):216-21 (57 ref.)

ERM proteins in cell adhesion and membrane dynamics. Mangeat P, et al. **Trends Cell Biol** 1999 May;9(5):187-92 (59 ref.)

Occludin and claudins in tight-junction strands: leading or supporting players? Tsukita S, et al. **Trends Cell Biol** 1999 Jul;9(7):268-73 (45 ref.)

Frizzled signaling and the developmental control of cell polarity. Shulman JM, et al. **Trends Genet** 1998 Nov; 14(11):452-8 (56 ref.)

Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444-9 (48 ref.)

[The sodium-iodide-symporter (NIS): function, regulation and clinical importance] Köhrle J. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:17-22 (48 ref.) (Eng. Abstr.) **(Ger)**

[Cell adhesion, cytoskeleton, and kidney diseases--with special reference to cytoskeleton and adhesion control by a low molecular weight GTP-binding protein Rho] Fujimoto T, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):148-54 (14 ref.) **(Jpn)**

[Cellular signal transduction via the neurofibromatosis type 2 tumor suppressor gene product; merlin] Araki N, et al. **Seikagaku** 1999 Feb;71(2):128-34 (18 ref.) **(Jpn)**

[Molecular mechanisms and developmental functions of notch signaling] Matsuno K. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):19-31 (58 ref.) **(Jpn)**

[Mechanism of COPI and COPII vesicle formation: coat assembly direct formation of coated vesicles] Matsuoka K. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):676-82 (29 ref.) **(Jpn)**

[VIP36 recognizes high-mannose type glycans in relation to apical membrane traffic] Yamashita K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2455-63 (41 ref.) **(Jpn)**

ULTRASTRUCTURE

The structural study of membrane proteins by electron crystallography. Fujiyoshi Y. **Adv Biophys** 1998;35:25-80 (42 ref.)

MEMBRANE PROTEINS, VIRAL see **VIRAL MATRIX PROTEINS**

MEMBRANES

see related
CELL MEMBRANE
CELL WALL
INTRACELLULAR MEMBRANES
MEMBRANE LIPIDS
MEMBRANE PROTEINS
NUCLEAR MEMBRANE
SYNOVIAL MEMBRANE

CHEMISTRY

Chemistry and physics of giant vesicles as biomembrane models. Menger FM, et al. **Curr Opin Chem Biol** 1998 Dec; 2(6):726-32 (22 ref.)

METABOLISM

Origin of the resting potential. Sabah NH. **IEEE Eng Med Biol Mag** 1999 Sep-Oct;18(5):100-5 (8 ref.)

Use of immobilized artificial membrane chromatography for drug transport applications. Stewart BH, et al. **J Pharm Sci** 1998 Dec;87(12):1471-8 (53 ref.)

The role of tocopherols in biomembrane lipid peroxidation. Burlakova EB, et al. **Membr Cell Biol** 1998;12(2):173-211 (204 ref.)

PHYSIOLOGY

Vitamin E as a universal antioxidant and stabilizer of biological membranes. Evstigneeva RP, et al. **Membr Cell Biol** 1998;12(2):151-72 (150 ref.)

MEMBRANES, ARTIFICIAL

Biocompatibility of dialysis membrane. Kes P. **Acta Med Croatica** 1999;53(1):29-40 (60 ref.)

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Burcelin R, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:277-85 (42 ref.)

Polymorphonuclear granulocyte stimulation by cellulose-based hemodialysis membranes. Körmöczi GF, et al. **Clin Chem Lab Med** 1999 Mar;37(3):351-5 (60 ref.)

Nitric oxide production with PMMA membrane. Amore A, et al. **Contrib Nephrol** 1999;125:182-96 (72 ref.)

Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes. Campistol JM, et al. **Contrib Nephrol** 1999;125:76-85 (42 ref.)

Pyrogen transfer across PMMA membranes. Cappelli G, et al. **Contrib Nephrol** 1999;125:233-9 (41 ref.)

Effects of PMMA membrane on hepatocyte growth factor release. Dal Canton A. **Contrib Nephrol** 1999;125:197-204 (21 ref.)

Structural and functional characteristics of currently available PMMA dialyzers. Ghezzi PM, et al. **Contrib Nephrol** 1999;125:25-40 (18 ref.)

Biocompatibility of PMMA membranes in acute and chronic patients with renal failure. Manzoni C, et al. **Contrib Nephrol** 1999;125:65-75 (28 ref.)

Continuous hemodialfiltration using PMMA membrane: clinical efficacy and its mechanisms. Moriyama K, et al. **Contrib Nephrol** 1999;125:222-32 (21 ref.)

Polymethylmethacrylate: from polymer to dialyzer. Sugaya H, et al. **Contrib Nephrol** 1999;125:1-8 (8 ref.)

Polymethylmethacrylate: one biomaterial for a series of membrane. Takeyama T, et al. **Contrib Nephrol** 1999; 125:9-24 (27 ref.)

Chromatographic approaches to liposomes, proteoliposomes and biomembrane vesicles. Lundahl P, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1-2):103-20 (147 ref.)

Gel fiberglass membranes for affinity chromatography columns and their application to cancer detection. Zusman I. **J Chromatogr B Biomed Sci Appl** 1998 Sep 11; 715(1):297-306 (92 ref.)

An analysis of solute structure-human epidermal transport relationships in epidermal iontophoresis using the ionic mobility: pore model. Lai PM, et al. **J Controlled Release** 1999 Apr 19;58(3):323-33 (28 ref.)

Successful implant restoration without the use of membrane barriers. Clarizio LF. **J Oral Maxillofac Surg** 1999 Sep; 57(9):1117-21 (38 ref.)

Successful implant restoration with the use of barrier membranes. Malmquist JP. **J Oral Maxillofac Surg** 1999 Sep;57(9):1114-6 (22 ref.)

Hemodialysis membrane biocompatibility--does it matter? Jacobson SH. **Scand J Urol Nephrol** 1999 Apr;33(2):83-8 (26 ref.)

Membrane apheresis technology: historical perspective and new trends toward bioincompatible systems [editorial] Nosé Y, et al. **Ther Apher** 1997 Feb;1(1):5-12 (11 ref.)

Present status of apheresis technologies: Part 1. Membrane plasma separator [editorial] Sueoka A. **Ther Apher** 1997

Feb;1(1):42–8 (26 ref.)
Applications of membrane technologies for therapeutic apheresis. Sueoka A. **Ther Apher** 1998 Nov;2(4):252–6 (11 ref.)
[Dialysate and biocompatibility in hemodialysis] Berland Y. **Nephrologie** 1998;19(6):329–34 (27 ref.) (Eng. Abstr.) **(Fre)**

MEMBRANES, INTRACELLULAR see **INTRACELLULAR MEMBRANES**

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MEMBRANOUS GLOMERULOPATHY see **GLOMERULONEPHRITIS, MEMBRANOUS**

MEMORY

Diet and rat strain as factors in nervous system function and influence of confounders. Kacew S, et al. **Biomed Environ Sci** 1998 Sep;11(3):203–17 (84 ref.)
Memories of childhood sexual abuse: a survey of young adults. Epstein MA, et al. **Child Abuse Negl** 1998 Dec; 22(12):1217–38 (109 ref.)
Errors in autobiographical memory. Hyman IE Jr, et al. **Clin Psychol Rev** 1998 Dec;18(8):933–47 (42 ref.)
Treatment for traumatic memories: review and recommendations. Leskin GA, et al. **Clin Psychol Rev** 1998 Dec;18(8):983–1001 (106 ref.)
What is remembered about early childhood events? Pillemer DB. **Clin Psychol Rev** 1998 Dec;18(8):895–913 (76 ref.)
Cognitive impact of traumatic events. Bower GH, et al. **Dev Psychopathol** 1998 Fall;10(4):625–53 (182 ref.)
The fate of traumatic memories in childhood and adulthood. Christianson SA, et al. **Dev Psychopathol** 1998 Fall; 10(4):761–80 (109 ref.)
Trauma, memory, and suggestibility in children. Eisen ML, et al. **Dev Psychopathol** 1998 Fall;10(4):717–38 (155 ref.)
Children's recollections of traumatic and nontraumatic events. Fivush R. **Dev Psychopathol** 1998 Fall; 10(4):699–716 (105 ref.)
Individual differences in factors that modulate storage and retrieval of traumatic memories. Howe ML. **Dev Psychopathol** 1998 Fall;10(4):681–98 (118 ref.)
Repression: a mistaken impression? Loftus E, et al. **Dev Psychopathol** 1998 Fall;10(4):781–92 (61 ref.)
Stress, memory, and emotion: developmental considerations from the study of child maltreatment. Pollak S, et al. **Dev Psychopathol** 1998 Fall;10(4):811–28 (98 ref.)
Creating a life story: the task of reconciliation. Coleman PG. **Gerontologist** 1999 Apr;39(2):133–9 (33 ref.)
Implantable brain chips? Time for debate. Maguire GQ Jr, et al. **Hastings Cent Rep** 1999 Jan–Feb;29(1):7–13 (35 ref.)
Some neurobiological aspects of psychotherapy. A review. Liggan DY, et al. **J Psychother Pract Res** 1999 Spring; 8(2):103–14 (137 ref.)
Biological aspects of near-death experiences. Greyson B. **Perspect Biol Med** 1998 Autumn;42(1):14–32 (82 ref.)
From objects to names: a cognitive neuroscience approach. Humphreys GW, et al. **Psychol Res** 1999;62(2–3):118–30 (56 ref.)
[Prospective memory and its theoretical considerations] Umeda S, et al. **Shinrigaku Kenkyu** 1998 Oct;69(4):317–33 (124 ref.) (Eng. Abstr.) **(Jpn)**
[Organization and substrate of memory] Andersen P. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4729–35 (30 ref.) (Eng. Abstr.) **(Nor)**

CLASSIFICATION

Process, not representation: reply to Radvansky (1999). Anderson JR, et al. **J Exp Psychol Gen** 1999 Jun; 128(2):207–10 (12 ref.)
The fan effect: a tale of two theories. Radvansky GA. **J Exp Psychol Gen** 1999 Jun;128(2):198–206 (45 ref.)
Distributed memory for both short and long term. Fuster JM. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):268–74 (17 ref.)
The neurophysiology of reminiscence. McNaughton BL. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):252–67 (31 ref.)
On the relations among priming, conscious recollection, and intentional retrieval: evidence from neuroimaging research. Schacter DL, et al. **Neurobiol Learn Mem** 1998 Jul–Sep; 70(1–2):284–303 (85 ref.)

DRUG EFFECTS

Temporal characterization of subcortical nuclei in mnemonic processes: results of tetrodotoxin reversible inactivation studies in the rat. Ambrogi Lorenzini CG, et al. **Arch Ital Biol** 1998 Nov;136(4):279–96 (82 ref.)
5-HT4 receptors: long-term blockade of K+ channels and effects on olfactory memory. Bockaert J, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):217–21 (33 ref.)
The pharmacology of memory. Iversen SD. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):209–15 (27 ref.)
Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Simard M, et al. **Drugs Aging** 1999 Mar;14(3):197–230 (180 ref.)
Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Tredici G, et al. **Drugs Exp Clin Res** 1999;25(2–3):99–103 (21 ref.)
Posttraining estrogen and memory modulation. Packard MG. **Horm Behav** 1998 Oct;34(2):126–39 (135 ref.)
Cannabinoids, hippocampal function and memory. Hampson RE, et al. **Life Sci** 1999;65(6–7):715–23 (71 ref.)
Schizophrenia – A disturbance of signal interaction between the entorhinal cortex and the dentate gyrus? The contribution of experimental dibenamine psychosis to the pathogenesis of schizophrenia: A hypothesis. Arnold OH. **Neuropsychobiology** 1999;40(1):21–32 (54 ref.)
Neuropsychological effects of vasopressin in healthy humans. Born J, et al. **Prog Brain Res** 1998;119:619–43 (126 ref.)
Role of hippocampus in alcohol-induced memory impairment: implications from behavioral and immediate early gene studies. Ryabinin AE. **Psychopharmacology (Berl)** 1998 Sep;139(1–2):34–43 (111 ref.)
[The effect of NC-1900: its ameliorating effects on impairments of learning and memory in the CA1 neurons and its intracellular signal transduction pathways] Akaike N, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:44P–47P (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Bench to bedside in medical education. Turnbull J. **Acad Med** 1999 Jun;74(6):664–6 (12 ref.)
The neuronal basis of visual memory and imagery in the primate: a neurophysiological approach. Nakahara K, et al. **Adv Biophys** 1998;35:103–19 (43 ref.)
Molecular specificity of synaptic changes responsible for associative memory. Alkon DL. **Adv Exp Med Biol** 1998; 446:1–15 (49 ref.)
The septal region and memory. von Cramon DY, et al. **Adv Tech Stand Neurosurg** 1998;24:3–40 (162 ref.)
The seven sins of memory. Insights from psychology and cognitive neuroscience. Schacter DL. **Am Psychol** 1999 Mar;54(3):182–203 (224 ref.)
5-HT4 receptors: gene, transduction and effects on olfactory memory. Bockaert J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:1–15 (61 ref.)
Using olfaction to study memory. Eichenbaum H. **Ann N Y Acad Sci** 1998 Nov 30;855:657–69 (24 ref.)
Galanin inhibits performance on rodent memory tasks. McDonald MP, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:305–22 (59 ref.)
Age-associated memory impairment. Assessing the role of nitric oxide. Meyer RC, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:307–17 (62 ref.)
Regulation of galanin in memory pathways. Miller MA. **Ann N Y Acad Sci** 1998 Dec 21;863:323–41 (89 ref.)
Odor memory in normal aging and Alzheimer's disease. Nordin S, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:686–93 (33 ref.)
The suggestibility of children's memory. Bruck M, et al. **Annu Rev Psychol** 1999;50:419–39 (56 ref.)
Separate mechanisms for short- and long-term memory. Izquierdo I, et al. **Behav Brain Res** 1999 Aug;103(1):1–11 (68 ref.)
To fear or not to fear: what was the question? A potential role for Ras-GRF in memory. Finkbeiner S, et al. **Bioessays** 1998 Sep;20(9):691–5 (27 ref.)
EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Klimesch W. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):169–95 (169 ref.)
The effect of gravity on human recognition of disoriented objects. Leone G. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):203–14 (113 ref.)
A working memory "theory of relativity": elasticity in temporal, spatial, and modality dimensions conserves item capacity in radial maze, verbal tasks, and other cognition. Glassman RB. **Brain Res Bull** 1999 Mar 15;48(5):475–89 (187 ref.)
Modeling memory: what do we learn from attractor neural networks? Brunel N, et al. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):249–52 (19 ref.)
Memory, learning and metacognition. Jacob P. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):253–9 (32 ref.)
Brain imaging and memory systems in humans: the contribution of PET methods. Perani D. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):199–205 (37 ref.)
A genetic switch for long-term memory. Pittenger C, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):91–6 (36 ref.)
Memory systems. Squire LR. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):153–6 (24 ref.)
The relationships between working memory and long-term memory. van der Linden M. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):175–7 (13 ref.)
CREB: a message to remember. Lamprecht R. **Cell Mol Life Sci** 1999 Apr;55(4):554–63 (73 ref.)
Protein kinases: which one is the memory molecule? Micheau J, et al. **Cell Mol Life Sci** 1999 Apr;55(4):534–48 (128 ref.)
The role of Ca2+/calmodulin-stimulable adenylyl cyclases as molecular coincidence detectors in memory formation. Mons N, et al. **Cell Mol Life Sci** 1999 Apr;55(4):525–33 (71 ref.)
Making more synapses: a way to store information? Moser MB. **Cell Mol Life Sci** 1999 Apr;55(4):593–600 (68 ref.)
Introduction: molecular mechanisms of memory formation—from receptor activation to synaptic changes. Riedel G, et al. **Cell Mol Life Sci** 1999 Apr;55(4):521–4 (18 ref.)
If phosphatases go up, memory goes down. Riedel G. **Cell Mol Life Sci** 1999 Apr;55(4):549–53 (34 ref.)
Memory formation and the regulation of gene expression. Stork O, et al. **Cell Mol Life Sci** 1999 Apr;55(4):575–92 (219 ref.)
Activation of immediate early genes and memory formation. Tischmeyer W, et al. **Cell Mol Life Sci** 1999 Apr; 55(4):564–74 (132 ref.)
Biochemical dysfunction and memory loss: the case of Alzheimer's dementia. von Linstow Roloff E, et al. **Cell Mol Life Sci** 1999 Apr;55(4):601–16 (157 ref.)
Olfactory memory: the long and short of it. White TL. **Chem Senses** 1998 Aug;23(4):433–41 (93 ref.)
Sex steroid control of mood, mental state and memory. Fink G, et al. **Clin Exp Pharmacol Physiol** 1998 Oct; 25(10):764–75 (163 ref.)
Memory, amnesia, and the issue of recovered memory: neurobiological aspects. Zola SM. **Clin Psychol Rev** 1998 Dec;18(8):915–32 (77 ref.)
Linguistic complexity: locality of syntactic dependencies. Gibson E. **Cognition** 1998 Aug;68(1):1–76 (180 ref.)
Flashbulb memories and other repetitive images: a psychiatric perspective. Sierra M, et al. **Compr Psychiatry** 1999 Mar–Apr;40(2):115–25 (91 ref.)
Memory mechanisms: the nociceptin connection. Goda Y, et al. **Curr Biol** 1998 Dec 3;8(24):R889–91 (15 ref.)
Memory: dissociating multiple memory processes. Owen AM. **Curr Biol** 1998 Nov 19;8(23):R850–2 (11 ref.)
Molecular mechanisms of synaptic plasticity and memory. Elgersma Y, et al. **Curr Opin Neurobiol** 1999 Apr; 9(2):209–13 (43 ref.)
Neural models of memory. Hasselmo ME, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):184–8 (54 ref.)
The effects of stress on memory and the hippocampus throughout the life cycle: implications for childhood development and aging. Bremner JD, et al. **Dev Psychopathol** 1998 Fall;10(4):871–85 (98 ref.)
Models of human memory and their implications for research on aging and psychopathology. Estes WK. **Dev Psychopathol** 1998 Fall;10(4):607–24 (82 ref.)
The effects of stress and trauma on brain and memory: a view from developmental cognitive neuroscience. Nelson CA, et al. **Dev Psychopathol** 1998 Fall;10(4):793–809 (87 ref.)
Neural plasticity and emotional memory. Post RM, et al. **Dev Psychopathol** 1998 Fall;10(4):829–55 (112 ref.)
Remembering, forgetting, and the effects of trauma on memory: a developmental psychopathology perspective [editorial] Toth SL, et al. **Dev Psychopathol** 1998 Fall; 10(4):589–605 (110 ref.)
N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Adriani W, et al. **Exp Brain Res** 1998 Nov; 123(1–2):52–9 (55 ref.)
Idiothetic input into object-place configuration as the contribution to memory of the monkey and human hippocampus: a review. Gaffan D. **Exp Brain Res** 1998 Nov;123(1–2):201–9 (64 ref.)
Are glutamate receptors specifically implicated in some forms of memory processes? Ungerer A, et al. **Exp Brain Res** 1998 Nov;123(1–2):45–51 (31 ref.)
Human memory, cerebral hemispheres, and the limbic system: a new approach. Rotenberg VS, et al. **Genet Soc Gen Psychol Monogr** 1999 Feb;125(1):45–70 (100 ref.)
Hippocampal system and declarative (relational) memory: summarizing the data from functional neuroimaging studies. Cohen NJ, et al. **Hippocampus** 1999;9(1):83–98 (52 ref.)
Automatic activation of the medial temporal lobe during encoding: lateralized influences of meaning and novelty. Martin A. **Hippocampus** 1999;9(1):62–70 (57 ref.)
Functional differentiation in the hippocampus. Moser MB, et al. **Hippocampus** 1998;8(6):608–19 (126 ref.)
Reconciling Barnes et al. (1997) and Tanila et al. (1997a,b) [comment] Redish AD, et al. **Hippocampus** 1998; 8(5):438–43 (37 ref.) Comment on: Hippocampus 1998 ;8(5):432–5.
Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Schacter DL, et al. **Hippocampus** 1999;9(1):7–24 (86 ref.)
Positron emission tomography correlations in and beyond medial temporal lobes. Tulving E, et al. **Hippocampus** 1999; 9(1):71–82 (75 ref.)
Convergent approaches to electrophysiological and hemodynamic investigations of memory. Rugg MD. **Hum Brain Mapp** 1998;6(5–6):394–8 (10 ref.)
Explicit memory in anxiety disorders. Becker ES, et al. **J Abnorm Psychol** 1999 Feb;108(1):153–63 (67 ref.)
Time and memory: towards a pacemaker-free theory of interval timing [see comments] Staddon JE, et al. **J Exp Anal Behav** 1999 Mar;71(2):215–51 (143 ref.) Comment in: J Exp Anal Behav 1999 Mar;71(2):253–6; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):257–63; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):264–71; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):272–5; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):275–80; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):281–4. Comment in: J Exp Anal Behav 1999 Mar;71(2):284–88. Comment in: J Exp Anal Behav 1999 Mar;71(2):288–91.
Fuzzy-trace theory and children's false memories [see

comments] Brainerd CJ, et al. **J Exp Child Psychol** 1998 Nov;71(2):81–129 (105 ref.) Comment in: J Exp Child Psychol 1998 Nov;71(2):130–43. Comment in: J Exp Child Psychol 1998 Nov;71(2):144–54. Comment in: J Exp Child Psychol 1998 Nov;71(2):155–64. Comment in: J Exp Child Psychol 1998 Nov;71(2):165–9. Comment in: J Exp Child Psychol 1998 Nov;71(2):170–7. Comment in: J Exp Child Psychol 1998 Nov;71(2):178–83. Comment in: J Exp Child Psychol 1998 Nov;71(2):184–93.

Fuzzy-trace theory and false memory: new frontiers. Reyna VF, et al. **J Exp Child Psychol** 1998 Nov;71(2):194–209 (104 ref.)

The distinctions of false and fuzzy memories [comment] Schooler JW. **J Exp Child Psychol** 1998 Nov;71(2):130–43 (40 ref.) Comment on: J Exp Child Psychol 1998 Nov;71(2):81–129.

Current studies on a working model of CaM kinase II in hippocampal long-term potentiation and memory. Fukunaga K, et al. **Jpn J Pharmacol** 1999 Jan;79(1):7–15 (39 ref.)

Remembering and forgetting as context discrimination. Capaldi EJ, et al. **Learn Mem** 1995 May–Aug;2(3–4):107–32 (82 ref.)

How big is human memory, or on being just useful enough. Dudai Y. **Learn Mem** 1997 Jan–Feb;3(5):341–65 (115 ref.)

Learning from LTP: a comment on recent attempts to identify cellular and molecular mechanisms of memory. Eichenbaum H. **Learn Mem** 1996 Sep–Oct;3(2–3):61–73 (68 ref.)

Drosophila conditioned courtship: two ways of testing memory. Kamyshev NG, et al. **Learn Mem** 1999 Jan–Feb; 6(1):1–20 (50 ref.)

The cerebellum, LTD, and memory: alternative views. Llinás R, et al. **Learn Mem** 1997 Mar–Apr;3(6):445–55 (41 ref.)

Physiological illnesses and their potential for influencing testimony. Norfolk GA. **Med Sci Law** 1999 Apr; 39(2):105–12 (31 ref.)

The structure of autobiographical memory and the event history calendar: potential improvements in the quality of retrospective reports in surveys. Belli RF. **Memory** 1998 Jul;6(4):383–406 (52 ref.)

Frontal cortex contributes to human memory formation. Buckner RL, et al. **Nat Neurosci** 1999 Apr;2(4):311–4 (55 ref.)

A model of cortical associative memory based on a horizontal network of connected columns. Fransén E, et al. **Network** 1998 May;9(2):235–64 (81 ref.)

The role and mechanisms of action of glucocorticoid involvement in memory storage. Sandi C. **Neural Plast** 1998 Jul–Sep;6(3):41–52 (58 ref.)

Role of cannabinoid receptors in memory storage. Hampson RE, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):474–82 (72 ref.)

Neural topography and chronology of memory consolidation: a review of functional inactivation findings. Ambrogi Lorenzini CG, et al. **Neurobiol Learn Mem** 1999 Jan; 71(1):1–18 (70 ref.)

Distributed memory for both short and long term. Fuster JM. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):268–74 (17 ref.)

Immediate-early genes and synaptic function. Lanahan A, et al. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):37–43 (34 ref.)

Memory and the brain: unexpected chemistries and a new pharmacology. Lynch G. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):82–100 (94 ref.)

The neurophysiology of reminiscence. McNaughton BL. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):252–67 (31 ref.)

Contributions of cell adhesion molecules to altered synaptic weightings during memory consolidation. Murphy KJ, et al. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):73–81 (35 ref.)

On the relations among priming, conscious recollection, and intentional retrieval: evidence from neuroimaging research. Schacter DL, et al. **Neurobiol Learn Mem** 1998 Jul–Sep; 70(1–2):284–303 (85 ref.)

Molecular, cellular, and neuroanatomical substrates of place learning. Silva AJ, et al. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):44–61 (84 ref.)

Physiological memory in primary auditory cortex: characteristics and mechanisms. Weinberger NM. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):226–51 (81 ref.)

CREB can get you depressed [comment] Siegelbaum SA. **Neuron** 1999 Jul;23(3):414–5 (8 ref.) Comment on: Neuron 1999 Jul;23(3):559–68.

Working memory contributions to human learning and remembering. Wagner AD. **Neuron** 1999 Jan;22(1):19–22 (20 ref.)

Memory and the hippocampus in food-storing birds: a comparative approach. Clayton NS. **Neuropharmacology** 1998 Apr–May;37(4–5):441–52 (93 ref.)

Transcranial magnetic stimulation can measure and modulate learning and memory. Grafman J, et al. **Neuropsychologia** 1999 Feb;37(2):159–67 (51 ref.)

Adaptations and pathologies linked to dynamic stabilization of neural circuitry. Kavanau JL. **Neurosci Biobehav Rev** 1999 May;23(5):635–48 (133 ref.)

Errors made by animals in memory paradigms are not always due to failure of memory. Wilkie DM, et al. **Neurosci Biobehav Rev** 1999;23(3):451–5 (20 ref.)

Prion proteins as memory molecules: an hypothesis. Tompa P, et al. **Neuroscience** 1998 Oct;86(4):1037–43 (58 ref.)

The role of prefrontal cortex in working memory: examining the contents of consciousness. Courtney SM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1819–28 (59 ref.)

Memory, consciousness and neuroimaging. Schacter DL, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1861–78 (142 ref.)

When encoding yields remembering: insights from event-related neuroimaging. Wagner AD, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1307–24 (101 ref.)

Homosynaptic long-term depression: a mechanism for memory? Bear MF. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9457–8 (24 ref.)

Role of vasopressin in learning and memory in the hippocampus. Alescio-Lautier B, et al. **Prog Brain Res** 1998;119:501–21 (106 ref.)

Vasopressin in the mammalian brain: the neurobiology of a mnemonic peptide. Diaz Brinton R. **Prog Brain Res** 1998; 119:177–99 (103 ref.)

Interaction of nitric oxide and external calcium fluctuations: a possible substrate for rapid information retrieval. Egelman DM, et al. **Prog Brain Res** 1998;118:199–211 (29 ref.)

Vasopressin metabolites: a link between vasopressin and memory? Reijmers LG, et al. **Prog Brain Res** 1998; 119:523–35 (63 ref.)

Repressed memories. When are they real? How are they false? Loftus EF, et al. **Psychiatr Clin North Am** 1999 Mar; 22(1):61–70 (29 ref.)

Stimulus generalization, context change, and forgetting [see comments] Bouton ME, et al. **Psychol Bull** 1999 Mar; 125(2):171–86 (88 ref.) Comment in: Psychol Bull 1999 Mar;125(2):187–9.

Cognitive integration of language and memory in bilinguals: semantic representation. Francis WS. **Psychol Bull** 1999 Mar;125(2):193–222 (165 ref.)

Storage and executive processes in the frontal lobes. Smith EE, et al. **Science** 1999 Mar 12;283(5408):1657–61 (41 ref.)

Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Alkon DL, et al. **Trends Neurosci** 1998 Dec;21(12):529–37 (97 ref.)

Mechanisms of emotional arousal and lasting declarative memory. Cahill L, et al. **Trends Neurosci** 1998 Jul; 21(7):294–9 (83 ref.)

Vectors, routes and maps: new discoveries about navigation in insects. Giurfa M, et al. **Trends Neurosci** 1999 Jun; 22(6):237–42 (44 ref.)

Visual imprinting and the neural mechanisms of recognition memory. Horn G. **Trends Neurosci** 1998 Jul;21(7):300–5 (79 ref.)

On brain lesions, the milkman and Sigmunda [see comments] Izquierdo I, et al. **Trends Neurosci** 1998 Oct;21(10):423–6 (46 ref.) Comment in: Trends Neurosci 1999 Feb;22(2):61.

Is the Ras–MAPK signalling pathway necessary for long-term memory formation? Orban PC, et al. **Trends Neurosci** 1999 Jan;22(1):38–44 (90 ref.)

A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Paulsen O, et al. **Trends Neurosci** 1998 Jul;21(7):273–8 (61 ref.)

[Olfactory training: memory systems in the rats] Chaillan FA, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):157–61 (16 ref.) **(Fre)**

[For a "neurocognitive" approach to memory: value of neuropsychology] Dubois B. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):235–9 (11 ref.) (Eng. Abstr.) **(Fre)**

[Memory consolidation and the hippocampal system] Jaffard R, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):163–6 (18 ref.) **(Fre)**

[New methods for evaluation of memory in temporal lobe epilepsy: a functional imaging approach] Dupont S, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):509–14 (39 ref.) (Eng. Abstr.) **(Fre)**

[Memory: clinico-pathologic data] Duyckaerts C, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S8–17 (84 ref.) (Eng. Abstr.) **(Fre)**

[Memory and dementia] Laurent B, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S33–49 (104 ref.) (Eng. Abstr.) **(Fre)**

[Expression af early genes in memory mechanisms] Anokhin KV. **Vestn Ross Akad Med Nauk** 1998;(12):58–61 (33 ref.) **(Rus)**

[The retrieval of attention-dependent long-term memory traces] Arkhipov VI. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Sep–Oct; 48(5):836–45 (50 ref.) (Eng. Abstr.) **(Rus)**

[The use of dissociated learning in the study of the mechanisms of memory] Azarashvili AA. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 May–Jun; 49(3):371–84 (25 ref.) (Eng. Abstr.) **(Rus)**

MEMORY DISORDERS

Age-associated memory impairment. Assessing the role of nitric oxide. Meyer RC, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:307–17 (62 ref.)

CHEMICALLY INDUCED

Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models. Hiramatsu M, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):595–9 (34 ref.)

DIAGNOSIS

Neuropsychological evaluation of everyday memory. Perez Garcia M, et al. **Neuropsychol Rev** 1998 Dec;8(4):203–27 (105 ref.)

DRUG THERAPY

Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Meneses A. **Rev Neurosci** 1998;9(4):275–89 (89 ref.)

ETIOLOGY

Memory and language in neurodegenerative diseases. Dalla Barba G, et al. **Curr Opin Neurol** 1998 Oct;11(5):429–33 (32 ref.)

Models of human memory and their implications for research on aging and psychopathology. Estes WK. **Dev Psychopathol** 1998 Fall;10(4):607–24 (82 ref.)

Neuroendocrine activity and memory-related impairments in posttraumatic stress disorder. Golier J, et al. **Dev Psychopathol** 1998 Fall;10(4):857–69 (63 ref.)

Remembering, forgetting, and the effects of trauma on memory: a developmental psychopathology perspective [editorial] Toth SL, et al. **Dev Psychopathol** 1998 Fall; 10(4):589–605 (110 ref.)

Toward understanding age-related memory loss in late adulthood. Luszcz MA, et al. **Gerontology** 1999 Jan–Feb; 45(1):2–9 (76 ref.)

[Dementias and memory impairment of degenerative origin] Baron JC. **Rev Neurol (Paris)** 1998;154 Suppl 2:S122–30 (57 ref.) (Eng. Abstr.) **(Fre)**

[New methods for evaluation of memory in temporal lobe epilepsy: a functional imaging approach] Dupont S, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):509–14 (39 ref.) (Eng. Abstr.) **(Fre)**

[Cerebrovascular disorder with memory disturbance, drowsiness, and a lack of drive as major symptoms] Tagawa K. **Fukuoka Igaku Zasshi** 1998 Nov;89(11):303–11 (16 ref.) **(Jpn)**

[Memory in multiple sclerosis: review of performance and relationship with clinical variables and neuroimaging] Porcel J, et al. **Rev Neurol** 1998 Dec;27(160):1034–42 (81 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part III: animal model. Chen M. **Front Biosci** 1998 Jun 17;3:A47–51 (42 ref.)

NURSING

Cognitive interventions among older adults. McDougall GJ Jr. **Annu Rev Nurs Res** 1999;17:219–40 (107 ref.)

PATHOLOGY

[Dementia and memory: morphologic imagery with MRI] Lehéricy S, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S115–21 (38 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Arciniegas D, et al. **Brain Inj** 1999 Jan;13(1):1–13 (89 ref.)

The deterioration of semantic memory in Alzheimer's disease. Salmon DP, et al. **Can J Exp Psychol** 1999 Mar; 53(1):108–17 (56 ref.)

Long-term memory in Alzheimer's disease. Fleischman DA, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):240–4 (50 ref.)

Episodic memory: new insights from the study of semantic dementia. Graham KS, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):245–50 (73 ref.)

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part II: therapeutic rationale. Chen M. **Front Biosci** 1998 Jun 8;3:A32–7 (37 ref.)

Age-related impairment in long-term potentiation in hippocampus: a role for the cytokine, interleukin-1 beta? Lynch MA. **Prog Neurobiol** 1998 Dec;56(5):571–89 (187 ref.)

On brain lesions, the milkman and Sigmunda [see comments] Izquierdo I, et al. **Trends Neurosci** 1998 Oct;21(10):423–6 (46 ref.) Comment in: Trends Neurosci 1999 Feb;22(2):61.

[Memory disorders: from lesional deficit to functional disorders] Widlöcher D. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):229–33 (18 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Integrated medicine and the prevention and reversal of memory loss. Khalsa DS. **Altern Ther Health Med** 1998 Nov;4(6):38–43 (121 ref.)

PSYCHOLOGY

[Clinical evaluation of memory] Eustache F, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S18–32 (61 ref.) (Eng. Abstr.) **(Fre)**

[Memory and dementia] Laurent B, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S33–49 (104 ref.) (Eng. Abstr.) **(Fre)**

[Memory complaints: what should be done? From consultation to the memory center] Pasquier F, et al.

Rev Neurol (Paris) 1998;154 Suppl 2:S106–14 (29 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Current trends in cognitive rehabilitation for memory disorders. Kashima H, et al. **Keio J Med** 1999 Jun; 48(2):79–86 (55 ref.)

THERAPY

Integrated medicine and the prevention and reversal of memory loss. Khalsa DS. **Altern Ther Health Med** 1998 Nov;4(6):38–43 (121 ref.)

Chronic electrical stimulation of the left ventrointermediate (Vim) thalamic nucleus for the treatment of pharmacotherapy-resistant Parkinson's disease: a differential impact on access to semantic and episodic memory? Tröster AI, et al. **Brain Cogn** 1998 Nov; 38(2):125–49 (120 ref.)

Memory and therapeutic action [editorial] Fonagy P. **Int J Psychoanal** 1999 Apr;80 (Pt 2):215–23 (70 ref.)

MEMORY FOR DESIGNS TEST see **NEUROPSYCHOLOGICAL TESTS**

MEMORY, IMMEDIATE see **MEMORY, SHORT-TERM**

MEMORY, PHOTOGRAPHIC see **EIDETIC IMAGERY**

MEMORY, SHORT-TERM

PHYSIOLOGY

Separate mechanisms for short- and long-term memory. Izquierdo I, et al. **Behav Brain Res** 1999 Aug;103(1):1–11 (68 ref.)

Working memory. Baddeley A. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):167–73 (40 ref.)

The relationships between working memory and long-term memory. van der Linden M. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):175–7 (13 ref.)

The psychophysics of perceptual memory. Magnussen S, et al. **Psychol Res** 1999;62(2–3):81–92 (74 ref.)

Visual-spatial working memory, attention, and scene representation: a neuro-cognitive theory. Schneider WX. **Psychol Res** 1999;62(2–3):220–36 (106 ref.)

Storage and executive processes in the frontal lobes. Smith EE, et al. **Science** 1999 Mar 12;283(5408):1657–61 (41 ref.)

Mechanisms of emotional arousal and lasting declarative memory. Cahill L, et al. **Trends Neurosci** 1998 Jul; 21(7):294–9 (83 ref.)

MEN

Men's health [editorial] Connell RW, et al. **Med J Aust** 1998 Sep 21;169(6):295–6 (12 ref.)

Gender matters: an integrated model for understanding men's and women's health. Bird CE, et al. **Soc Sci Med** 1999 Mar;48(6):745–55 (51 ref.)

PSYCHOLOGY

Strategies for dealing with men in general practice. Burkitt G. **Aust Fam Physician** 1999 Aug;28(8):773–4 (4 ref.)

Calling for the absent male. Edgar D. **Aust Fam Physician** 1999 Aug;28(8):797–9 (5 ref.)

Psychoanalytic contributions to the study of gender issues. Barbieri NB. **Can J Psychiatry** 1999 Feb;44(1):72–6 (53 ref.)

Why physician gender matters in shaping the physician–patient relationship. Roter DL, et al. **J Womens Health** 1998 Nov;7(9):1093–7 (24 ref.)

Reproductive health. New perspectives on men's participation. Drennan M. **Popul Rep J** 1998 Oct;(46):1–35 (299 ref.)

MEN 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

MEN 2 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

MEN 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

MEN 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

MEN 3 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

MENADIONE see **VITAMIN K**

MENADIONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

MENAQUINONE see **VITAMIN K**

MENIERE'S DISEASE

see related
ENDOLYMPHATIC HYDROPS

Menière's disease. Hamann K, et al. **Adv Otorhinolaryngol** 1999;55:137–68 (117 ref.)

Diagnosing and treating Menière's disease. Bottrill I. **Practitioner** 1998 Jun;242(1587):482–4 (7 ref.)

COMPLICATIONS

[Chemical labyrinthectomy: results and applications] Mondain M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115(4):234–42 (40 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunologic aspects of Meniere's disease. Ruckenstein MJ. **Am J Otolaryngol** 1999 May–Jun;20(3):161–5 (45 ref.)

PATHOLOGY

[Relation between jugular bulb variation and middle and inner ear diseases] Chen J, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Oct; 11(10):484–5 (10 ref.) **(Chi)**

SURGERY

Vestibular surgery for Ménière's disease in the elderly: a review of techniques and indications. Rosenberg SI. **Ear Nose Throat J** 1999 Jun;78(6):443–6 (9 ref.)

MENIERE'S SYNDROME see **MENIERE'S DISEASE**

MENINGEAL ARTERIES

Intracerebral hemorrhage caused by the rupture of a nontraumatic middle meningeal artery aneurysm. Case report and review of the literature. Sandin JA 3rd, et al. **J Neurosurg** 1999 May;90(5):951–4 (14 ref.)

MENINGEAL NEOPLASMS

Meningeal chondrosarcomas, a review of 31 patients. Forbes RB, et al. **Br J Neurosurg** 1998 Oct;12(5):461–4 (30 ref.)

Extracranial metastatic meningioma. Figueroa BE, et al. **Br J Radiol** 1999 May;72(857):513–6 (48 ref.)

Intraparenchymal clear cell meningioma of the brainstem in a 2-year-old child. Case report and literature review. Teo JG, et al. **Pediatr Neurosurg** 1998 Jan;28(1):27–30 (19 ref.)

COMPLICATIONS

Unusual clinical presentation of a meningeal melanocytoma with seizures: case report and review of the literature. Leonardi MA, et al. **Acta Neurochir (Wien)** 1998; 140(6):621–8 (56 ref.)

Referred facial pain from intracranial tumors: a diagnostic dilemma. Bhaya MH, et al. **Am J Otolaryngol** 1998 Nov–Dec;19(6):383–6 (11 ref.)

Meningioma with meningioangiomatosis: a condition mimicking invasive meningiomas in children and young adults: report of two cases and review of the literature. Giangaspero F, et al. **Am J Surg Pathol** 1999 Aug; 23(8):872–5 (16 ref.)

[Meningioma with a peritumoral abscess] Onopchenko EV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar; (1):28–30 (16 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Meningioma of the infratemporal fossa: report of a case. Galant C, et al. **Acta Clin Belg** 1998 Aug;53(4):282–4 (9 ref.)

Primary meningeal malignant fibrous histiocytoma with cerebrospinal dissemination and pulmonary metastasis. Akimoto J, et al. **Acta Neurochir (Wien)** 1998; 140(11):1191–6 (20 ref.)

Intrameatal tumours presenting as a hearing disturbance: case reports of meningioma and lymphoma. Kawamura S, et al. **Acta Neurochir (Wien)** 1998;140(7):675–9 (16 ref.)

Meningioma with meningioangiomatosis: a condition mimicking invasive meningiomas in children and young adults: report of two cases and review of the literature. Giangaspero F, et al. **Am J Surg Pathol** 1999 Aug; 23(8):872–5 (16 ref.)

Leptomeningeal carcinomatosis. Grossman SA, et al. **Cancer Treat Rev** 1999 Apr;25(2):103–19 (121 ref.)

Intracranial meningiomas: correlations between MR imaging and histology. Maiuri F, et al. **Eur J Radiol** 1999 Jul; 31(1):69–75 (22 ref.)

Sarcoidosis of the cauda equina mimicking leptomeningeal malignancy. Abrey LE, et al. **J Neurooncol** 1998 Sep; 39(3):261–5 (11 ref.)

Primary meningeal fibrosarcoma: a particular neuroradiological presentation. Donnet A, et al. **J Neurooncol** 1999 Mar;42(1):79–83 (10 ref.)

Intracerebral cystic meningioma--case report. Shimizu K, et al. **Neurol Med Chir (Tokyo)** 1999 Jul;39(7):530–3 (19 ref.)

Association of an intracranial arteriovenous malformation and a meningioma. Castillo M, et al. **Neuroradiology** 1998 Sep;40(9):574–6 (30 ref.)

Foreign body granuloma mimicking intracranial meningioma: case report and review of the literature. Feldman RP, et al. **Neurosurgery** 1999 Apr;44(4):855–8 (21 ref.)

[A combination of a meningioma of the base of the skull and an arteriovenous micromalformation of the brain stem] Konovalov AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr–Jun; (2):21–4 (23 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

[Radiation-induced meningioma 20 years after operation and high-dose irradiation of an ependymoma] Daentzer D, et al. **Zentralbl Neurochir** 1999;60(1):27–32 (26 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

[Prognosis of brain tumors: epidemiology, survival time and clinical course] Steiner HH, et al. **Versicherungsmedizin** 1998 Oct 1;50(5):173–9 (32 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Unusual clinical presentation of a meningeal melanocytoma with seizures: case report and review of the literature. Leonardi MA, et al. **Acta Neurochir (Wien)** 1998; 140(6):621–8 (56 ref.)

Parasagittal solitary fibrous tumor of the meninges. Case report and review of the literature. Nikas DC, et al. **Acta Neurochir (Wien)** 1999;141(3):307–13 (57 ref.)

Primary melanocytoma arising from the thoracic leptomeninges case. Shimoda H, et al. **Clin Neuropathol** 1999 Mar–Apr;18(2):80–3 (10 ref.)

Atypical and malignant meningiomas: an outcome report of seventeen cases. Coke CC, et al. **J Neurooncol** 1998 Aug; 39(1):65–70 (15 ref.)

Meningiomas presenting in the temporal bone: the pathways of spread from an intracranial site of origin. Chang CY, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):658–64 (31 ref.)

Diffuse leptomeningeal gliomatosis with oligodendroglioma. Ng HK, et al. **Pathology** 1999 Feb;31(1):59–63 (33 ref.)

Solitary fibrous tumor of the meninges: two new cases and review of the literature. Brunori A, et al. **Surg Neurol** 1999 Jun;51(6):636–40 (34 ref.)

[Intracranial location of a case of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease) mimicking meningioma] Losi L, et al. **Pathologica** 1998 Aug;90(4):403–7 (16 ref.) (Eng. Abstr.) **(Ita)**

[Lymphoplasmacyte-rich meningioma: a report of three cases and a review of the literature] Yoneyama T, et al. **No Shinkei Geka** 1999 Apr;27(4):383–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Role of radiation therapy in parameningeal rhabdomyosarcoma. Paulino AC. **Cancer Invest** 1999; 17(3):223–30 (40 ref.)

SECONDARY

Lung carcinoma presenting as metastasis to intracranial meningioma: case report and review of the literature. Bhargava P, et al. **Am J Clin Oncol** 1999 Apr;22(2):199–202 (29 ref.)

Meningeal carcinomatosis from transitional cell carcinoma of the bladder: report of two cases and review of the literature. Cozzarini C, et al. **Cancer Invest** 1999;17(6):402–7 (29 ref.)

Acute subdural hematoma and pachymeningitis carcinomatosa: case report. Caputi F, et al. **Rev Neurol (Paris)** 1999 May;155(5):383–5 (10 ref.)

SURGERY

Meningioma surgery in the elderly: a case-control study assessing morbidity and mortality. Black P, et al. **Acta Neurochir (Wien)** 1998;140(10):1013–6; discussion 1016–7 (12 ref.)

Foramen magnum meningiomas. David CA, et al. **Clin Neurosurg** 1997;44:467–89 (26 ref.)

Management of meningiomas of the cavernous sinus: conservative surgery and adjuvant therapy. Friedlander RM, et al. **Clin Neurosurg** 1999;45:279–82 (16 ref.)

Tentorial meningiomas. Harrison MJ, et al. **Clin Neurosurg** 1997;44:451–66 (39 ref.)

Benign tumors of the cavernous sinus. Rosseau G. **Clin Neurosurg** 1999;45:260–2 (20 ref.)

The case for aggressive resection. Sekhar LN, et al. **Clin Neurosurg** 1999;45:263–78 (18 ref.)

Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314–7 (21 ref.)

Stereotactic radiosurgery for meningiomas. Kondziolka D, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):317–25 (21 ref.)

[Neurosurgical management of extracerebral tumors] Antoniadis G, et al. **Rontgenpraxis** 1998;51(8–9):304–10 (26 ref.) **(Ger)**

ULTRASTRUCTURE

Meningeal melanocytoma: a case report and literature review. Alameda F, et al. **Ultrastruct Pathol** 1998 Jul–Aug; 22(4):349–56 (17 ref.)

MENINGEAL PLAGUE see **PLAGUE**

MENINGES

BLOOD SUPPLY

[Glioblastoma fed by meningeal branches of the external

MENINGES

carotid artery: a case report] Okuyama T, et al. **No Shinkei Geka** 1999 May;27(5):447-52 (11 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Meningioma with meningioangiomatosis: a condition mimicking invasive meningiomas in children and young adults: report of two cases and review of the literature. Giangaspero F, et al. **Am J Surg Pathol** 1999 Aug; 23(8):872-5 (16 ref.)

Meningioangiomatosis. A comprehensive analysis of clinical and laboratory features. Wiebe S, et al. **Brain** 1999 Apr; 122 (Pt 4):709-26 (43 ref.)

[Intramedullary spinal cord metastasis and leptomeningeal involvement in Hodgkin's disease. Case report and review of the literature] Jardin F, et al. **Rev Med Interne** 1999 Mar;20(3):267-71 (30 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Isolated leptomeningeal Castleman's disease with viral particles in the follicular dendritic cells. Gulati P, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):1026-9 (18 ref.)

MENINGIOMA

Intraparenchymal clear cell meningioma of the brainstem in a 2-year-old child. Case report and literature review. Teo JG, et al. **Pediatr Neurosurg** 1998 Jan;28(1):27-30 (19 ref.)

CLASSIFICATION

[Classification and grading of gliomas and meningiomas] Niedermayer I, et al. **Radiologe** 1998 Nov;38(11):888-97 (63 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Referred facial pain from intracranial tumors: a diagnostic dilemma. Bhaya MH, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):383-6 (11 ref.)

Meningioma with meningioangiomatosis: a condition mimicking invasive meningiomas in children and young adults: report of two cases and review of the literature. Giangaspero F, et al. **Am J Surg Pathol** 1999 Aug; 23(8):872-5 (16 ref.)

[Meningioma with a peritumoral abscess] Onopchenko EV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan-Mar; (1):28-30 (16 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Meningioma of the infratemporal fossa: report of a case. Galant C, et al. **Acta Clin Belg** 1998 Aug;53(4):282-4 (9 ref.)

Intrameatal tumours presenting as a hearing disturbance: case reports of meningioma and lymphoma. Kawamura S, et al. **Acta Neurochir (Wien)** 1998;140(7):675-9 (16 ref.)

Meningioma with meningioangiomatosis: a condition mimicking invasive meningiomas in children and young adults: report of two cases and review of the literature. Giangaspero F, et al. **Am J Surg Pathol** 1999 Aug; 23(8):872-5 (16 ref.)

Meningioma of the cavernous sinus in a child. Erşahin Y, et al. **Childs Nerv Syst** 1999 Jan;15(1):8-10 (16 ref.)

Intracranial meningiomas: correlations between MR imaging and histology. Maiuri F, et al. **Eur J Radiol** 1999 Jul; 31(1):69-75 (22 ref.)

Diffuse calvarial meningioma. Case report and review of the literature. Anegawa S, et al. **J Neurosurg** 1999 May; 90(5):970-3 (21 ref.)

Intracerebral cystic meningioma--case report. Shimizu K, et al. **Neurol Med Chir (Tokyo)** 1999 Jul;39(7):530-3 (19 ref.)

Association of an intracranial arteriovenous malformation and a meningioma. Castillo M, et al. **Neuroradiology** 1998 Sep;40(9):574-6 (30 ref.)

Foreign body granuloma mimicking intracranial meningioma: case report and review of the literature. Feldman RP, et al. **Neurosurgery** 1999 Apr;44(4):855-8 (21 ref.)

Juxtaorbital en plaque meningiomas. Report of four cases and review of literature. Charbel FT, et al. **Radiol Clin North Am** 1999 Jan;37(1):89-100, x (59 ref.)

Optic nerve sheath meningiomas. Role of MR imaging. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):37-58, ix (84 ref.)

[A combination of a meningioma of the base of the skull and an arteriovenous micromalformation of the brain stem] Konovalov AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):21-4 (23 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Intracranial meningiomas. The Dakar experience apropos of 79 cases] Badiane SB, et al. **Neurochirurgie** 1999 May; 45(2):134-8 (13 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Radiation-induced meningioma 20 years after operation and high-dose irradiation of an ependymoma] Daentzer D, et al. **Zentralbl Neurochir** 1999;60(1):27-32 (26 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

[Prognosis of brain tumors: epidemiology, survival time and clinical course] Steiner HH, et al. **Versicherungsmedizin** 1998 Oct 1;50(5):173-9 (32 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Atypical and malignant meningiomas: an outcome report of seventeen cases. Coke CC, et al. **J Neurooncol** 1998 Aug; 39(1):65-70 (15 ref.)

Meningiomas presenting in the temporal bone: the pathways of spread from an intracranial site of origin. Chang CY, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):658-64 (31 ref.)

Solitary fibrous tumor of the meninges: two new cases and review of the literature. Brunori A, et al. **Surg Neurol** 1999 Jun;51(6):636-40 (34 ref.)

[Intracranial location of a case of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) mimicking meningioma] Losi L, et al. **Pathologica** 1998 Aug;90(4):403-7 (16 ref.) (Eng. Abstr.) **(Ita)**

[Lymphoplasmacyte-rich meningioma: a report of three cases and a review of the literature] Yoneyama T, et al. **No Shinkei Geka** 1999 Apr;27(4):383-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

[[Assessment of quality of life of patients with brain tumors] Tucha O, et al. **Zentralbl Neurochir** 1998;59(4):263-8 (32 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Lung carcinoma presenting as metastasis to intracranial meningioma: case report and review of the literature. Bhargava P, et al. **Am J Clin Oncol** 1999 Apr;22(2):199-202 (29 ref.)

Extracranial metastatic meningioma. Figueroa BE, et al. **Br J Radiol** 1999 May;72(857):513-6 (48 ref.)

SURGERY

Meningioma surgery in the elderly: a case-control study assessing morbidity and mortality. Black P, et al. **Acta Neurochir (Wien)** 1998;140(10):1013-6; discussion 1016-7 (12 ref.)

Foramen magnum meningiomas. David CA, et al. **Clin Neurosurg** 1997;44:467-89 (26 ref.)

Management of meningiomas of the cavernous sinus: conservative surgery and adjuvant therapy. Friedlander RM, et al. **Clin Neurosurg** 1999;45:279-82 (16 ref.)

Tentorial meningiomas. Harrison MJ, et al. **Clin Neurosurg** 1997;44:451-66 (39 ref.)

Benign tumors of the cavernous sinus. Rosseau G. **Clin Neurosurg** 1999;45:260-2 (20 ref.)

The case for aggressive resection. Sekhar LN, et al. **Clin Neurosurg** 1999;45:263-78 (18 ref.)

Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314-7 (21 ref.)

Stereotactic radiosurgery for meningiomas. Kondziolka D, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):317-25 (21 ref.)

[Neurosurgical management of extracerebral tumors] Antoniadis G, et al. **Rontgenpraxis** 1998;51(8-9):304-10 (26 ref.) **(Ger)**

MENINGIOMAS, MULTIPLE see **MENINGIOMA**

MENINGIOMATOSIS see **MENINGIOMA**

MENINGITIS

DIAGNOSIS

Imaging of central nervous system infections. Wong J, et al. **Semin Roentgenol** 1999 Apr;34(2):123-43 (84 ref.)

[Cranial pachymeningitis] Fain O, et al. **Rev Med Interne** 1999 Mar;20(3):234-46 (77 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Eosinophilic meningitis/angiostrongyliasis from eating aquaculture-raised snails: a case report. Marsh CM. **Hawaii Med J** 1998 Oct;57(10):652-4 (10 ref.)

Imaging of central nervous system infections. Wong J, et al. **Semin Roentgenol** 1999 Apr;34(2):123-43 (84 ref.)

IMMUNOLOGY

Cytokines and chemokines in meningeal inflammation: biology and clinical implications. Täuber MG, et al. **Clin Infect Dis** 1999 Jan;28(1):1-11; quiz 12 (109 ref.)

METABOLISM

Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Andes DR, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):595-618 (134 ref.)

MICROBIOLOGY

Sporothrix meningitis. Wescott BL, et al. **Nurse Pract** 1999 Feb;24(2):90, 93-4, 97-8 passim (19 ref.)

Mycobacterium fortuitum meningitis associated with an epidural catheter: case report and a review of the literature. Madaras-Kelly KJ, et al. **Pharmacotherapy** 1999 May; 19(5):661-6 (26 ref.)

PARASITOLOGY

Parasitic meningitis [editorial; comment] Prociv P. **Med J Aust** 1999 Jun 7;170(11):517-8 (14 ref.) Comment on: Med J Aust 1999 Jun 7;170(11):541-3.

Acanthamoebiasis in Korea: two new cases with clinical cases review. Im K, et al. **Yonsei Med J** 1998 Oct;39(5):478-84 (15 ref.)

[Eosinophilic meningitis due to Angiostrongylus cantonensis] Legrand G, et al. **Rev Neurol (Paris)** 1998 Apr; 154(3):236-42 (58 ref.) (Eng. Abstr.) **(Fre)**

MENINGITIS, ASEPTIC

Aseptic meningitis in the newborn and young infant. Norris CM, et al. **Am Fam Physician** 1999 May 15;59(10):2761-70 (22 ref.)

[Mollaret's meningitis] Kanda T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):13-6 (20 ref.) **(Jpn)**

CHEMICALLY INDUCED

The challenge of drug-induced aseptic meningitis. Moris G, et al. **Arch Intern Med** 1999 Jun 14;159(11):1185-94 (160 ref.)

COMPLICATIONS

Histiocytic necrotizing lymphadenitis (Kikuchi's disease) with aseptic meningitis. Sato Y, et al. **J Neurol Sci** 1999 Mar 1;163(2):187-91 (13 ref.)

MENINGITIS, BACTERIAL

[Suppurative meningitis. Epidemiology, etiology, diagnosis, evolution, treatment, prevention] Stahl JP. **Rev Prat** 1998 Oct 1;48(15):1681-8 (00 ref.) **(Fre)**

[Acute purulent meningitis: a clinical and therapeutic update] Manfredi R. **Recenti Prog Med** 1999 May;90(5):280-5 (44 ref.) (Eng. Abstr.) **(Ita)**

[Campylobacter meningitis] Endo K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):304-7 (15 ref.) **(Jpn)**

[Staphylococcus meningitis] Nakamura I. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):293-6 (8 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Antibiotic pharmacodynamics in cerebrospinal fluid. Lutsar I, et al. **Clin Infect Dis** 1998 Nov;27(5):1117-27, quiz 1128-9 (105 ref.)

[Normocellular bacterial meningitis] Lindberg JA. **Ugeskr Laeger** 1998 Nov 30;160(49):7105-8 (40 ref.) (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Molecular mechanisms of brain damage in bacterial meningitis. Braun JS, et al. **Adv Pediatr Infect Dis** 1999; 14:49-71 (140 ref.)

Supportive management in bacterial meningitis. Rauf SJ, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):647-59, viii (40 ref.)

Salmonella meningitis and its complications in infants. Lee WS, et al. **J Paediatr Child Health** 1999 Aug;35(4):379-82 (23 ref.)

Meningitis and meningococcal septicaemia [see comments] Pollard AJ, et al. **J R Coll Physicians Lond** 1998 Jul-Aug; 32(4):319-28 (55 ref.) Comment in: J R Coll Physicians Lond 1998 Nov-Dec;32(6):589.

Spontaneous disappearance of a middle cranial fossa arachnoid cyst after suppurative meningitis [see comments] Yoshioka H, et al. **Surg Neurol** 1998 Nov;50(5):487-91 (26 ref.) Comment in: Surg Neurol 1999 Jun;51(6):687-8.

DIAGNOSIS

Clinical presentations, diagnosis, and prognostic factors of bacterial meningitis. Kaplan SL. **Infect Dis Clin North Am** 1999 Sep;13(3):579-94, vi-vii (63 ref.)

Paediatric neurobrucellosis: case report and literature review. Habeeb YK, et al. **J Infect** 1998 Jul;37(1):59-62 (33 ref.)

Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. Fouladi M, et al. **J Neurosurg** 1999 Sep;91(3):499-502 (17 ref.)

[Lyme neuroborreliosis with acute meningitis as the presenting manifestation: report of a case] Sheng R, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(1):21-4 (10 ref.) (Eng. Abstr.) **(Chi)**

[Streptococcus bovis sepsis, purulent meningitis and colonic diverticulosis (letter)] Fresco Benito FJ, et al. **An Med Interna** 1999 Jul;16(7):383-4 (10 ref.) **(Spa)**

DRUG THERAPY

Treatment of bacterial meningitis. Hasbun R, et al. **Compr Ther** 1999 Feb;25(2):73-81 (62 ref.)

Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Sáez-Llorens X, et al.

Infect Dis Clin North Am 1999 Sep;13(3):619–36, vii (83 ref.)

[Community-acquired purulent meningitis. Short text of the 9th consensus conference on anti-infectious therapy] **Presse Med** 1998 Jun 27;27(23):1145–50 (0 ref.) **(Fre)**

[Childhood bacterial meningitis. Role of corticosteroids] Aigrain EJ. **Presse Med** 1998 Jun 27;27(23):1187–94 (46 ref.) (Eng. Abstr.) **(Fre)**

[Childhood bacterial meningitis. Bacterial epidemiology and antibiotic resistance] Doit C, et al. **Presse Med** 1998 Jun 27;27(23):1177–82 (35 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels. Hauck W, et al. **Semin Perinatol** 1999 Jun;23(3):250–60 (92 ref.)

EPIDEMIOLOGY

Epidemiology of bacterial meningitis. Gold R. **Infect Dis Clin North Am** 1999 Sep;13(3):515–25, v (114 ref.)

Meningitis and meningococcal septicaemia [see comments] Pollard AJ, et al. **J R Coll Physicians Lond** 1998 Jul–Aug; 32(4):319–28 (55 ref.) Comment in: J R Coll Physicians Lond 1998 Nov–Dec;32(6):589.

[Childhood bacterial meningitis. Bacterial epidemiology and antibiotic resistance] Doit C, et al. **Presse Med** 1998 Jun 27;27(23):1177–82 (35 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

[Nosocomial meningitis in the adult] Pottecher T, et al. **Ann Fr Anesth Reanim** 1999 May;18(5):558–66 (51 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Oxidative stress in bacterial meningitis. Koedel U, et al. **Brain Pathol** 1999 Jan;9(1):57–67 (116 ref.)

MICROBIOLOGY

Neonatal meningitis and septicaemia caused by Burkholderia pseudomallei. Halder D, et al. **Ann Trop Paediatr** 1998 Jun; 18(2):161–4 (9 ref.)

Meningitis in adults due to Campylobacter fetus subspecies fetus. Dronda F, et al. **Clin Infect Dis** 1998 Oct;27(4):906–7 (10 ref.)

Emergence of drug resistance. Impact on bacterial meningitis. Klugman KP, et al. **Infect Dis Clin North Am** 1999 Sep; 13(3):637–46, vii (82 ref.)

Models of experimental bacterial meningitis. Role and limitations. Koedel U, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):549–77, vi (183 ref.)

Pathogenesis of bacterial meningitis. Leib SL, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):527–48, v–vi (96 ref.)

Bacterial meningitis and the newborn infant. Pong A, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):711–33, viii (103 ref.)

Neonatal meningitis due to a vertical transmission of Pasteurella multocida. Zaramella P, et al. **Pediatr Int** 1999 Jun;41(3):307–10 (23 ref.)

[Meningitis caused by Streptococcus mitis in a cocaine addict (letter)] Echeverria MJ, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):441–2 (9 ref.) **(Spa)**

[Salmonella enteritidis meningitis in adults. Report of 2 cases and review of the literature (letter)] Asensi JM, et al. **Rev Clin Esp** 1998 Sep;198(9):633–4 (10 ref.) **(Spa)**

[Bacteremia, endocarditis and meningitis caused by Pseudomonas aeruginosa] Cisneros Herreros JM, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:25–9 (49 ref.) **(Spa)**

MORTALITY

Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Harvey D, et al. **Semin Perinatol** 1999 Jun;23(3):218–25 (26 ref.)

PATHOLOGY

Models of experimental bacterial meningitis. Role and limitations. Koedel U, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):549–77, vi (183 ref.)

PHYSIOPATHOLOGY

[Childhood meningitis. Current data on physiopathology] Nassif X. **Presse Med** 1998 Jun 27;27(23):1171–6 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prophylaxis of bacterial meningitis. Peltola H. **Infect Dis Clin North Am** 1999 Sep;13(3):685–710, viii (138 ref.)

Recent developments in bacterial conjugate vaccines. Goldblatt D. **J Med Microbiol** 1998 Jul;47(7):563–7 (41 ref.)

THERAPY

Fluid management of bacterial meningitis in developing countries. Duke T. **Arch Dis Child** 1998 Aug;79(2):181–5 (30 ref.)

Supportive management in bacterial meningitis. Rauf SJ, et al. **Infect Dis Clin North Am** 1999 Sep;13(3):647–59, viii (40 ref.)

[Hydration and meningitis] Floret D. **Arch Pediatr** 1999 Feb; 6(2):199–202 (26 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

Neonatal meningitis due to a vertical transmission of Pasteurella multocida. Zaramella P, et al. **Pediatr Int** 1999 Jun;41(3):307–10 (23 ref.)

MENINGITIS, CRYPTOCOCCAL

[Central nervous system cryptococcosis] Yamaguchi H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):353–7 (22 ref.) **(Jpn)**

DRUG THERAPY

[The efficacy of sequential treatment with amphotericin B–fluorocytosine and fluconazole in cryptococcal meningitis not associated with AIDS (letter)] Pintado García V, et al. **Rev Clin Esp** 1999 Jul;199(7):480 (10 ref.) **(Spa)**

MENINGITIS, FUNGAL

[Candidal meningitis] Yamaguchi H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):329–31 (19 ref.) **(Jpn)**

COMPLICATIONS

Visual loss due to cryptococcal meningitis in AIDS patients [letter] Torres OH, et al. **AIDS** 1999 Mar 11;13(4):530–2 (16 ref.)

DIAGNOSIS

[Coccidioides immitis: primary infection of the central nervous system. Case report and literature review] Niño Oberto S, et al. **Rev Invest Clin** 1999 Jan–Feb;51(1):43–8 (12 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Clinical significance of Candida species isolated from cerebrospinal fluid following neurosurgery. Geers TA, et al. **Clin Infect Dis** 1999 May;28(5):1139–47 (27 ref.)

Invasive infections due to Clavispora lusitaniae. Krcmery V Jr, et al. **FEMS Immunol Med Microbiol** 1999 Jan; 23(1):75–8 (6 ref.)

MENINGITIS, HAEMOPHILUS

[Haemophilus influenzae meningitis] Endo K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):301–3 (12 ref.) **(Jpn)**

DRUG THERAPY

[Childhood bacterial meningitis. Role of corticosteroids] Aigrain EJ. **Presse Med** 1998 Jun 27;27(23):1187–94 (46 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Chemoprophylaxis in meningitis] Otero MC, et al. **Rev Esp Quimioter** 1998 Jun;11(2):118–27 (50 ref.) **(Spa)**

MENINGITIS, LISTERIA

[Listeria meningitis] Nakamura I. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):297–300 (10 ref.) **(Jpn)**

MENINGITIS, MENINGOCOCCAL

Neisseria meningitidis endogenous endophthalmitis: case report and literature review. Wong JS, et al. **J Pediatr Ophthalmol Strabismus** 1999 May–Jun; 36(3):145–52 (40 ref.)

[Neisseria meningitidis and meningitis] Nicolas P, et al. **Med Trop (Mars)** 1999;59(1):68–78 (87 ref.) (Eng. Abstr.) **(Fre)**

[Meningococcal meningitis] Haruta T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):286–8 (9 ref.) **(Jpn)**

DIAGNOSIS

[Late neonatal sepsis with meningitis due to meningococcus serogroup C (letter)] Falero Gallego MP, et al. **An Esp Pediatr** 1999 Jun;50(6):639–40 (10 ref.) **(Spa)**

DRUG THERAPY

[Childhood bacterial meningitis. Antibiotic strategies] Bourrillon A, et al. **Presse Med** 1998 Jun 27;27(23):1183–6 (22 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The epidemiology and control of invasive meningococcal disease. Diaz PS. **Pediatr Infect Dis J** 1999 Jul;18(7):633–4 (9 ref.)

[Meningococcal disease: epidemiology and control of secondary cases] Barroso DE, et al. **Rev Saude Publica** 1998 Feb;32(1):89–97 (59 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

[Anti-meningococcal vaccine: myth and reality] Nassif X. **Arch Pediatr** 1999;6 Suppl 3:647s–649s (13 ref.) **(Fre)**

PREVENTION & CONTROL

[Meningococcal disease: epidemiology and control of secondary cases] Barroso DE, et al. **Rev Saude Publica** 1998 Feb;32(1):89–97 (59 ref.) (Eng. Abstr.) **(Por)**

[Chemoprophylaxis in meningitis] Otero MC, et al. **Rev Esp Quimioter** 1998 Jun;11(2):118–27 (50 ref.) **(Spa)**

MENINGITIS, PNEUMOCOCCAL

[Pneumococcal meningitis] Haruta T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):289–92 (7 ref.) **(Jpn)**

COMPLICATIONS

Purpura fulminans associated with Streptococcus pneumoniae infection in a child. Cnota JF, et al. **Pediatr Emerg Care** 1999 Jun;15(3):187–8 (17 ref.)

DRUG THERAPY

[Childhood bacterial meningitis. Antibiotic strategies] Bourrillon A, et al. **Presse Med** 1998 Jun 27;27(23):1183–6 (22 ref.) (Eng. Abstr.) **(Fre)**

[A survival case of fulminant pneumococcal meningitis as overwhelming postsplenectomy infection (OPSI) syndrome] Yamashita S, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1054–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

[Chemoprophylaxis in meningitis] Otero MC, et al. **Rev Esp Quimioter** 1998 Jun;11(2):118–27 (50 ref.) **(Spa)**

MENINGITIS, TUBERCULOUS see **TUBERCULOSIS, MENINGEAL**

MENINGITIS, VIRAL

[Enteroviral meningitis] Kaji M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):7–10 (9 ref.) **(Jpn)**

COMPLICATIONS

[A case of Ramsay Hunt syndrome associated with local meningitis, multiple cranial neuropathy, and the second cervical nerve involvement] Nagano K, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):475–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Viral meningitis—or encephalitis? Dedicoat M, et al. **Practitioner** 1998 Jun;242(1587):489–92 (10 ref.)

[Acute severe headache: a subarachnoidal hemorrhage?] Linn FH, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):545–50 (17 ref.) (Eng. Abstr.) **(Dut)**

[Laboratory diagnosis of viral infections. 2. Nervous system infections] Ueda S. **Rinsho Byori** 1998 Nov;Suppl 108:59–64 (1 ref.) **(Jpn)**

MENINGOCELE

COMPLICATIONS

Anterior sacral meningocele associated with a rectal fistula. Case report and review of the literature. Fitzpatrick MO, et al. **J Neurosurg** 1999 Jul;91(1 Suppl):124–7 (26 ref.)

MENINGOCOCCAL INFECTIONS

Meningococcal disease: recognition, treatment, and prevention. Herf C, et al. **Nurse Pract** 1998 Aug;23(8):30, 33–6, 39–40 passim (16 ref.)

[Current perspective of meningococcal pericariditis in children and adults] Finkelstein Y, et al. **Harefuah** 1998 Sep;135(5–6):226–9 (50 ref.) **(Heb)**

COMPLICATIONS

[Meningococcal sepsis and septic shock: efficient measures and controversial treatments] Casado Flores J, et al. **An Esp Pediatr** 1999 Apr;50(4):346–52 (74 ref.) **(Spa)**

DIAGNOSIS

A ring hypopyon in a patient with meningococcal endophthalmitis: a case report and review of the literature. Gonzalez GA, et al. **J Pediatr Ophthalmol Strabismus** 1998 Nov–Dec;35(6):329–33 (15 ref.)

Life-threatening rashes: dermatologic signs of four infectious diseases. Drage LA. **Mayo Clin Proc** 1999 Jan;74(1):68–72

MENINGOCOCCAL INFECTIONS

(10 ref.)
[Meningococcal sepsis in 3 young men] Diet F, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):424–8 (10 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Early management of meningococcal disease. Cartwright KA. **Infect Dis Clin North Am** 1999 Sep;13(3):661–84, viii (79 ref.)

EPIDEMIOLOGY

The epidemiology and control of invasive meningococcal disease. Diaz PS. **Pediatr Infect Dis J** 1999 Jul;18(7):633–4 (9 ref.)
Addressing emerging infections. The partnership between public health and primary care physicians. Danila RN, et al. **Postgrad Med** 1999 Aug;106(2):90–2, 97–8, 103–5 (15 ref.)

IMMUNOLOGY

[Human resistance to generalized bacterial infections (exemplified by meningococcal infection)] Platonov AE. **Vestn Ross Akad Med Nauk** 1999;(5):40–5 (31 ref.) (Eng. Abstr.) **(Rus)**
[Meningococcal infection. Immunologic aspects (editorial)] Blanco Quirós A, et al. **An Esp Pediatr** 1999 Apr; 50(4):325–32 (82 ref.) **(Spa)**

MICROBIOLOGY

Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Kahler CM, et al. **Crit Rev Microbiol** 1998;24(4):281–334 (250 ref.)

PHYSIOPATHOLOGY

Pathophysiology of meningococcal sepsis in children. de Kleijn ED, et al. **Eur J Pediatr** 1998 Nov;157(11):869–80 (143 ref.)

PREVENTION & CONTROL

Vaccination against meningococcus in complement-deficient individuals [comment] Morgan BP, et al. **Clin Exp Immunol** 1998 Dec;114(3):327–9 (28 ref.) Comment on: Clin Exp Immunol 1998 Dec;114(3):362–9.
[Meningococcal infection. Immunologic aspects (editorial)] Blanco Quirós A, et al. **An Esp Pediatr** 1999 Apr; 50(4):325–32 (82 ref.) **(Spa)**

THERAPY

[Meningococcal sepsis and septic shock: efficient measures and controversial treatments] Casado Flores J, et al. **An Esp Pediatr** 1999 Apr;50(4):346–52 (74 ref.) **(Spa)**

MENINGOCOCCUS see **NEISSERIA MENINGITIDIS**

MENINGOENCEPHALITIS

Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Mylonakis E, et al. **Medicine (Baltimore)** 1998 Sep;77(5):313–36 (309 ref.)
[Primary amebic meningoencephalitis (Naegleria)] Hashimoto R, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):412–4 (6 ref.) **(Jpn)**

ETIOLOGY

[Meningoencephalomyelitis due to Angiostrongylus cantonensis with lung involvement] Siles Cadillá J, et al. **An Esp Pediatr** 1998 Sep;49(3):308–10 (12 ref.) **(Spa)**

PARASITOLOGY

Trypanosoma cruzi meningoencephalitis in HIV-infected patients. Silva N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):342–9 (27 ref.)

PATHOLOGY

The morphological picture of developing meningo-encephalitis in central nervous system. Dąmbska M, et al. **Folia Neuropathol** 1998;36(4):205–10 (25 ref.)

VIROLOGY

Meningoencephalitis caused by human herpesvirus-6 in an immunocompetent adult patient: case report and review of the literature. Torre D, et al. **Infection** 1998 Nov-Dec; 26(6):402–4 (28 ref.)

MENINGOMYELOCELE

COMPLICATIONS

Current concepts in myelomeningocele. Drennan JC. **Instr Course Lect** 1999;48:543–50 (20 ref.)
Treatment of hip and knee problems in myelomeningocele. Greene WB. **Instr Course Lect** 1999;48:563–74 (49 ref.)
Kyphosis deformity in myelomeningocele. Sarwark JF. **Orthop Clin North Am** 1999 Jul;30(3):451–5, viii–ix (29 ref.)
[The significance of associated malformations of the central nervous system in myelomeningocele] Christensen B, et al. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4232–4 (38 ref.) (Eng. Abstr.) **(Nor)**

DIAGNOSIS

Transdural spinal cord herniation: imaging and clinical spectra [see comments] Watters MR, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1337–44 (20 ref.) Comment in: AJNR Am J Neuroradiol 1998 Aug;19(7):1185.

SURGERY

[Surgical management of severe thoracic lordosis in myelomeningocele--a case report with review of the literature] Niemeyer T, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep-Oct;136(5):463–6 (17 ref.) (Eng. Abstr.) **(Ger)**

MENISCI, LATERAL see **MENISCI, TIBIAL**

MENISCI, MEDIAL see **MENISCI, TIBIAL**

MENISCI, TIBIAL

ABNORMALITIES

A ring-shaped lateral meniscus. Choi NH. **Am J Knee Surg** 1999 Spring;12(2):109–10 (8 ref.)
Discoid lateral meniscus. Fleissner PR, et al. **Am J Knee Surg** 1999 Spring;12(2):125–31 (41 ref.)

ANATOMY & HISTOLOGY

The menisci of the knee joint. Anatomical and functional characteristics, and a rationale for clinical treatment. Messner K, et al. **J Anat** 1998 Aug;193 (Pt 2):161–78 (156 ref.)
Neural and vascular anatomy of the menisci of the human knee. Gray JC. **J Orthop Sports Phys Ther** 1999 Jan; 29(1):23–30 (55 ref.)

INJURIES

"Bone bruises" of the knee: a review. Mathis CE, et al. **Iowa Orthop J** 1998;18:112–7 (16 ref.)
Meniscus transplantation--consensus declaration [editorial] **Scand J Med Sci Sports** 1999 Jun;9(3):131–3 (0 ref.)
Meniscal substitutes--human experience. Goble EM, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):146–57 (55 ref.)
Meniscal substitutes--animal experience. Kohn D, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):141–5 (42 ref.)
Recommendations for the diagnosis of traumatic meniscal injuries in athletes. Muellner T, et al. **Sports Med** 1999 May; 27(5):337–45 (61 ref.)
[Significance of combined anterior cruciate ligament and meniscus injury] Metak G, et al. **Zentralbl Chir** 1999; 124(7):646–52 (64 ref.) (Eng. Abstr.) **(Ger)**
[Current advances in sports-related cartilage research. Meniscus and ligament injuries are associated with increased risk of knee joint arthrosis] Messner K. **Lakartidningen** 1998 Oct 14;95(42):4611–2, 4615 (20 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOLOGY

Function of the normal meniscus and consequences of meniscal resection. Aagaard H, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):134–40 (68 ref.)
Meniscal regeneration or meniscal transplantation? Messner K. **Scand J Med Sci Sports** 1999 Jun;9(3):162–7 (47 ref.)

SURGERY

Meniscal reconstruction. Part II: Outcome, potential complications, and future directions. Maitra RS, et al. **Am J Orthop** 1999 May;28(5):280–6 (85 ref.)
Meniscal reconstruction. Part I: indications, techniques, and graft considerations. Maitra RS, et al. **Am J Orthop** 1999 Apr;28(4):213–8 contd (0 ref.)
Meniscus repair. DeHaven KE. **Am J Sports Med** 1999 Mar-Apr;27(2):242–50 (66 ref.)
Options in meniscal repair. Rispoli DM, et al. **Clin Sports Med** 1999 Jan;18(1):77–91, vi (94 ref.)
Function of the normal meniscus and consequences of meniscal resection. Aagaard H, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):134–40 (68 ref.)
Meniscal substitutes--animal experience. Kohn D, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):141–5 (42 ref.)

TRANSPLANTATION

Meniscal allograft transplantation. Johnson DL, et al. **Clin Sports Med** 1999 Jan;18(1):93–108 (72 ref.)
Meniscus transplantation--consensus declaration [editorial] **Scand J Med Sci Sports** 1999 Jun;9(3):131–3 (0 ref.)
Meniscal substitutes--human experience. Goble EM, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):146–57 (55 ref.)
Meniscal regeneration or meniscal transplantation? Messner K. **Scand J Med Sci Sports** 1999 Jun;9(3):162–7 (47 ref.)

MENKES SYNDROME see **KINKY HAIR SYNDROME**

MENOPAUSE

see related
ESTROGEN REPLACEMENT THERAPY
HOT FLASHES
OSTEOPOROSIS, POSTMENOPAUSAL
POSTMENOPAUSE
PREMENOPAUSE

Selective estrogen receptor modulators and postmenopausal women's health: the promise for the next millennium [editorial] Agnusdei D. **Aging (Milano)** 1998 Aug; 10(4):269–72 (26 ref.)
Black cohosh: Cimicifuga racemosa. Pepping J. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1400–2 (21 ref.)
Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Beto JA, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S172–83 (47 ref.)
Phytoestrogens and the menopause. Eden J. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):581–7 (13 ref.)
Obstetric and gynecologic care of women with epilepsy. El-Sayed YY. **Epilepsia** 1998;39 Suppl 8:S17–25 (87 ref.)
Managing the climacteric. Rozenberg S, et al. **Int J Fertil Womens Med** 1999 Jan-Feb;44(1):12–8 (32 ref.)
Menopause and beyond. The wise woman way. Weed SS. **J Nurse Midwifery** 1999 May-Jun;44(3):267–79 (76 ref.)
Progestins in the menopause. Sitruk-Ware R. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1–6):185–93 (61 ref.)
Sex and the mature woman. Pariser SF, et al. **J Womens Health** 1998 Sep;7(7):849–59 (38 ref.)
Menopause: when hormone replacement therapy is not an option. Part II. Waldman TN. **J Womens Health** 1998 Aug; 7(6):673–83 (41 ref.)
The menopause. Greendale GA, et al. **Lancet** 1999 Feb 13; 353(9152):571–80 (52 ref.)
Ovarian ageing and the general biology of senescence. Kirkwood TB. **Maturitas** 1998 Oct 12;30(2):105–11 (41 ref.)
Models of intervention in menopause: proposal of a holistic or integral model. Olazábal Ulacia JC, et al. **Menopause** 1999 Fall;6(3):264–72 (50 ref.)
An historical perspective of natural and surgical menopause. Utian WH. **Menopause** 1999 Summer;6(2):83–6 (26 ref.)
Natural options for menopause. Norling S. **Minn Med** 1999 May;82(5):42–4 (6 ref.)
Micronized progesterone: a new option for women's health care. Wetzel W. **Nurse Pract** 1999 May;24(5):62–6, 71, 75–6 (29 ref.)
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms. **Oncology (Huntingt)** 1999 Apr;13(4):551–4, 557–60, 563 passim (36 ref.)
[Critical review of current indications in hormone replacement therapy for menopause] Burger H. **Contracept Fertil Sex** 1999 Mar;27(3):171–4 (11 ref.) **(Fre)**
[Present status concerning hormone replacement therapy in menopause and the risk of breast cancer] Lopes P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27 Suppl 1:12–6 (30 ref.) **(Fre)**
[Update about substitution hormonotherapy in menopause: equine estrogens] van den Brûle F. **Rev Med Liege** 1998 Sep;53(9):579–81 (13 ref.) **(Fre)**
[Modifications of the hemostatic balance during estrogen treatments: menopause and its treatment] Conard J. **Therapie** 1999 May-Jun;54(3):363–7 (35 ref.) (Eng. Abstr.) **(Fre)**
[Cardiovascular risk and hormone replacement therapy in menopause] Plu-Bureau G. **Therapie** 1999 May-Jun; 54(3):375–80 (23 ref.) (Eng. Abstr.) **(Fre)**
[Why has menopause become a public health problem?] Rozenbaum H. **Therapie** 1998 Jan-Feb;53(1):49–59 (47 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Promoting informed decision making: hormone replacement therapy. Bastian L, et al. **Cancer Treat Res** 1998;97:129–47 (98 ref.)
Nonalcoholic compounds of wine: the phytoestrogen resveratrol and moderate red wine consumption during menopause. Calabrese G. **Drugs Exp Clin Res** 1999; 25(2-3):111–4 (32 ref.)
Efficacy and safety of estrogen/androgen therapy. Menopausal symptoms, bone, and cardiovascular parameters. Barrett-Connor E. **J Reprod Med** 1998 Aug; 43(8 Suppl):746–52 (28 ref.)
Tibolone: a review. Albertazzi P, et al. **Maturitas** 1998 Nov 16;30(3):295–305 (57 ref.)
Helping women achieve long-term continuance of estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) [letter] Keenan NL, et al. **Menopause** 1999 Summer;6(2):179–80 (6 ref.)
Tamoxifen effects on menopause--associated risk factors and symptoms. Benshushan A, et al. **Obstet Gynecol Surv** 1999 Apr;54(4):272–8 (33 ref.)
Natural menopause and ovarian toxicity associated with breast cancer therapy. Knobf MT. **Oncol Nurs Forum** 1998 Oct;25(9):1519–30; quiz 1531–2 (131 ref.)
[Acceptability of hormonal substitution after menopause] Robyn C. **Rev Med Brux** 1998 Sep;19(4):A181–4 (11 ref.)

(Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Prescribing hormone replacement therapy for menopausal symptoms. McNagny SE. **Ann Intern Med** 1999 Oct 19; 131(8):605–16 (181 ref.)
Does estrogen stimulate osteoblast function in postmenopausal women? Tobias JH, et al. **Bone** 1999 Feb; 24(2):121–4 (48 ref.)
Migraine, female hormones, and stroke. Bousser MG. **Cephalalgia** 1999 Mar;19(2):75–9 (46 ref.)
Traversing the menopause: changes in energy expenditure and body composition. Poehlman ET, et al. **Coron Artery Dis** 1998;9(12):799–803 (28 ref.)
Menopause, central body fatness, and insulin resistance: effects of hormone–replacement therapy. Tchernof A, et al. **Coron Artery Dis** 1998;9(8):503–11 (65 ref.)
Wellness in women after 40 years of age: the role of sex hormones and pheromones. Cutler WB, et al. **Dis Mon** 1998 Sep;44(9):421–546 (255 ref.)
Perimenopause: the complex endocrinology of the menopausal transition. Prior JC. **Endocr Rev** 1998 Aug; 19(4):397–428 (199 ref.)
Neuroendocrine influences and repercussions of the menopause. Wise PM, et al. **Endocr Rev** 1999 Jun; 20(3):243–8 (60 ref.)
Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. Thom DH, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1411–7 (98 ref.)
The epidemiology of the association between hypertension and menopause. Staessen JA, et al. **J Hum Hypertens** 1998 Sep;12(9):587–92 (56 ref.)
Broadened spectrum of menopausal symptom relief. Sarrel PM. **J Reprod Med** 1998 Aug;43(8 Suppl):734–40 (29 ref.)
Plasma androgens in women. Vermeulen A. **J Reprod Med** 1998 Aug;43(8 Suppl):725–33 (61 ref.)
The endocrinology of the menopause. Burger HG. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):31–5 (21 ref.)
Menopause and the central nervous system: intervention options. Genazzani AR, et al. **Maturitas** 1999 Jan 4; 31(2):103–10 (88 ref.)
Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Solerte SB, et al. **Maturitas** 1999 Jan 4;31(2):95–101 (68 ref.)
Inhibin and reproductive aging in women. Soules MR, et al. **Maturitas** 1998 Oct 12;30(2):193–204 (16 ref.)
Age at menopause as a marker of reproductive ageing. te Velde ER, et al. **Maturitas** 1998 Oct 12;30(2):119–25 (42 ref.)
Exogenous and endogenous estrogens: an appreciation of biological complexity [editorial; comment] Kronenberg F, et al. **Menopause** 1999 Spring;6(1):4–6 (7 ref.) Comment on: Menopause 1999 Spring;6(1):7–13.
Migraine in the menopause. Fettes I. **Neurology** 1999;53(4 Suppl 1):S29–33 (35 ref.)
Epilepsy in the menopause. Lee MA. **Neurology** 1999;53(4 Suppl 1):S41 (4 ref.)
Aging, menopause, and free radicals. Schwenke DC. **Semin Reprod Endocrinol** 1998;16(4):281–308 (370 ref.)
[Laboratory follow–up in menopause] Groussin–Weyland M, et al. **Ann Biol Clin (Paris)** 1998 Mar–Apr;56(2):161–6 (17 ref.) (Eng. Abstr.) **(Fre)**
[The potential effects of alcohol on bone mass in menopausal women: review of the literature] Ganry O, et al. **Sante Publique** 1999 Mar;11(1):7–16 (41 ref.) (Eng. Abstr.) **(Fre)**
[Menopause and its sequelae: an interdisciplinary syndrome] Maurer–Major E, et al. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1697–702 (34 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Menopause as an issue for women with breast cancer. McPhail G. **Cancer Nurs** 1999 Apr;22(2):164–71 (98 ref.)
Mood disorders and the reproductive cycle: affective disorders during the menopause and premenstrual dysphoric disorder. Haynes P, et al. **Psychopharmacol Bull** 1998;34(3):313–8 (57 ref.)
Menopause: lessons from anthropology. Lock M. **Psychosom Med** 1998 Jul–Aug;60(4):410–9 (60 ref.)
[Inhibition of sexual desire associated with menopause] Mouchamps E, et al. **Rev Med Liege** 1999 May;54(5):489–94 (45 ref.) (Eng. Abstr.) **(Fre)**

MENOPAUSE, PREMATURE

Chemicals and menopause: effects on age at menopause and on health status in the postmenopausal period. Silbergeld EK, et al. **J Womens Health** 1999 Mar;8(2):227–34 (68 ref.)
Infertility and premature menopause in childhood cancer survivors. Byrne J. **Med Pediatr Oncol** 1999 Jul;33(1):24–8 (11 ref.)

MENORRHAGIA

ETIOLOGY

Clinical presentation of uterine fibroids. Lumsden MA, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):177–95 (88 ref.)

NURSING

Balloon endometrial ablation as a safe alternative to hysterectomy. Barrow C. **AORN J** 1999 Jul;70(1):80, 83–6, 89–90; quiz 92–6 (51 ref.)
Midwifery care of the woman with menorrhagia. Engstrom JL, et al. **J Nurse Midwifery** 1999 Mar–Apr;44(2):89–105 (95 ref.)

PHYSIOPATHOLOGY

Angiogenesis, vascular endothelial growth factor and the endometrium. Smith SK. **Hum Reprod Update** 1998 Sep–Oct;4(5):509–19 (130 ref.)

THERAPY

Balloon endometrial ablation as a safe alternative to hysterectomy. Barrow C. **AORN J** 1999 Jul;70(1):80, 83–6, 89–90; quiz 92–6 (51 ref.)
Menorrhagia. Ghosh AK. **J Indian Med Assoc** 1998 Jun; 96(6):183–5 (0 ref.)
Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. Stabinsky SA, et al. **Obstet Gynecol Surv** 1999 Jan;54(1):61–72 (178 ref.)
A patient with learning disability and menorrhagia. Wishart K, et al. **Practitioner** 1998 Jan;242(1582):9, 15 (0 ref.)
Dysfunctional uterine bleeding. Chen BH, et al. **West J Med** 1998 Nov;169(5):280–4 (32 ref.)

MENOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

MENOTROPINS

see related
RECEPTORS, GONADOTROPIN

MENSTRUAL CYCLE

Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis. Jatoi I. **Breast Cancer Res Treat** 1998;52(1–3):217–25 (51 ref.)

DRUG EFFECTS

Cycle control with oral contraceptives: A review of the literature. Thorneycroft IH. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 2):280–7 (14 ref.)

METABOLISM

Heat shock proteins in human endometrium throughout the menstrual cycle. Tabibzadeh S, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):5–9 (45 ref.)

PHYSIOLOGY

Whither menstrual synchrony? McClintock MK. **Annu Rev Sex Res** 1998;9:77–95 (43 ref.)
Sex–sensitive tasks in men and women: a search for performance fluctuations across the menstrual cycle. Epting LK, et al. **Behav Neurosci** 1998 Dec;112(6):1304–17 (110 ref.)
Do gastrointestinal symptoms vary with the menstrual cycle? Moore J, et al. **Br J Obstet Gynaecol** 1998 Dec; 105(12):1322–5 (19 ref.)
Menstrual synchrony pheromones: cause for doubt. Strassmann BI. **Hum Reprod** 1999 Mar;14(3):579–80 (28 ref.)
Apoptosis in the estrous and menstrual cycles. Andres AC, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):221–8 (49 ref.)
Menstrual cycling and breast cancer: an evolutionary perspective. Strassmann BI. **J Womens Health** 1999 Mar; 8(2):193–202 (58 ref.)
Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Gougeon A. **Maturitas** 1998 Oct 12;30(2):137–42 (35 ref.)
Follicle development during the normal menstrual cycle. Macklon NS, et al. **Maturitas** 1998 Oct 12;30(2):181–8 (39 ref.)
Inhibin and reproductive aging in women. Soules MR, et al. **Maturitas** 1998 Oct 12;30(2):193–204 (16 ref.)

PSYCHOLOGY

Mood disorders and the reproductive cycle: affective disorders during the menopause and premenstrual dysphoric disorder. Haynes P, et al. **Psychopharmacol Bull** 1998;34(3):313–8 (57 ref.)

MENSTRUAL CYCLE, FOLLICULAR PHASE see **FOLLICULAR PHASE**

MENSTRUAL CYCLE, LUTEAL PHASE see **LUTEAL PHASE**

MENSTRUAL PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

MENSTRUAL SECRETORY PHASE see **MENSTRUAL CYCLE**

MENSTRUATION

see related
PREMENSTRUAL SYNDROME

Paracrine regulation of menstruation. Bulletti C, et al. **J Reprod Immunol** 1998 Aug;39(1–2):89–104 (39 ref.)
[Menstruation still full of myths] Bergqvist A. **Lakartidningen** 1999 Apr 14;96(15):1860–7 (28 ref.) **(Swe)**

PHYSIOLOGY

Exercise and female adolescents: effects on the reproductive and skeletal systems. Warren MP, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):115–20, 138 (69 ref.)
Catamenial epilepsy: clinical aspects. Zahn C. **Neurology** 1999;53(4 Suppl 1):S34–7 (23 ref.)
Implications of decidualization–associated protease expression in implantation and menstruation. Schatz F, et al. **Semin Reprod Endocrinol** 1999;17(1):3–12 (49 ref.)

MENSTRUATION DISORDERS

Menstrual cycle abnormalities: diagnosis and management. Iglesias EA, et al. **Adolesc Med** 1999 Jun;10(2):255–73 (36 ref.)
Bleeding problems and treatment. March CM. **Clin Obstet Gynecol** 1998 Dec;41(4):928–39 (35 ref.)

DRUG THERAPY

Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Salonen R, et al. **Cephalalgia** 1999 Jan;19(1):16–9 (16 ref.)
[Gestagens have become of great clinical value. Disadvantages are irregular bleeding and bad temper] Landgren BM. **Lakartidningen** 1999 Mar 31;96(13):1578–81 (27 ref.) **(Swe)**

ETIOLOGY

Vegetarianism and menstrual cycle disturbances: is there an association? Barr SI. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):549S–54S (61 ref.)
Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. Gordon CM. **Pediatr Clin North Am** 1999 Jun;46(3):519–43 (118 ref.)
Obesity and reproductive disorders: a review. Norman RJ, et al. **Reprod Fertil Dev** 1998;10(1):55–63 (62 ref.)

GENETICS

Menstrual disorders and infertility caused by inactivating mutations of the luteinizing hormone receptor gene. Arnhold IJ, et al. **Fertil Steril** 1999 Apr;71(4):597–601 (32 ref.)

METABOLISM

Sex hormones and headache 1999 (menstrual migraine). Silberstein S, et al. **Neurology** 1999;53(4 Suppl 1):S3–13 (113 ref.)

PHYSIOPATHOLOGY

Leptin and reproduction: is it a critical link between adipose tissue, nutrition, and reproduction? Thong FS, et al. **Can J Appl Physiol** 1999 Aug;24(4):317–36 (101 ref.)
Sex hormones and headache 1999 (menstrual migraine). Silberstein S, et al. **Neurology** 1999;53(4 Suppl 1):S3–13 (113 ref.)

THERAPY

Management of menstrual migraine. Boyle CA. **Neurology** 1999;53(4 Suppl 1):S14–8 (34 ref.)

MENSTRUATION, FOLLICULAR PHASE see **FOLLICULAR PHASE**

MENSTRUATION, LUTEAL PHASE see **LUTEAL PHASE**

MENSTRUATION, RETROGRADE see **MENSTRUATION DISORDERS**

MENTAL COMPETENCY

Can acutely ill patients consent to research? Resolving an ethical dilemma with facts [editorial; comment] Fost N. **Acad Emerg Med** 1999 Aug;6(8):772–4 (11 ref.) Comment on: Acad Emerg Med 1999 Aug;6(8):776–80.
An AIDS patient's right to refuse life–sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161–4 (46 ref.)
On–road assessment of driving competence after brain impairment: review of current practice and recommendations for a standardized examination. Fox GK, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1288–96 (39 ref.)
Precedent autonomy: life–sustaining intervention and the demented patient. Newton MJ. **Camb Q Healthc Ethics** 1999 Spring;8(2):189–99 (63 ref.)
ACOG committee opinion. Sterilization of women, including those with mental disabilities. Number 216, April 1999

(replaces number 63, September 1988, and number 73, September 1989). Committee on Ethics. The American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet 1999 Jun;65(3):317–20 (3 ref.)

Can paternalism be justified in mental health care? Breeze J. **J Adv Nurs** 1998 Aug;28(2):260–5 (40 ref.)

Neuropsychological assessment of competency to stand trial evaluations: a practical conceptual model. Kirkish P, et al. **J Am Acad Psychiatry Law** 1999;27(1):101–13 (30 ref.)

Assessing competency without judging merit. May T.
J Clin Ethics 1998 Fall;9(3):247–57 (23 ref.)

Holy Grail, sliding scale, and refusal as symptom: competency determinations for medical and psychiatric patients. Farr M. **Pharos** 1999 Spring;62(2):2–9 (15 ref.)

Capacity to make health care decisions: its importance in clinical practice. Wong JG, et al. **Psychol Med** 1999 Mar; 29(2):437–46 (75 ref.)

LEGISLATION & JURISPRUDENCE

Neurobiologic correlates of violence: relevance to criminal responsibility. Berman ME, et al. **Behav Sci Law** 1998 Summer;16(3):303–18 (55 ref.)

Intoxication, the law and criminal responsibility—a sparkling cocktail at times: the case studies of Canada and Germany. Fischer B, et al. **Eur Addict Res** 1998 Sep;4(3):89–101 (53 ref.)

Psychiatric criteria of legal responsibility after the consumption of alcohol: the German situation. Kröber HL. **Eur Addict Res** 1998 Sep;4(3):107–12 (19 ref.)

The general psychiatrist's evaluation of competency. Miller MC. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):172–6 (18 ref.)

Mental incapacity: some proposals for legislative reform. McHale JV. **J Med Ethics** 1998 Oct;24(5):322–7 (67 ref.)

The right to refuse psychiatric treatment. Wettstein RM. **Psychiatr Clin North Am** 1999 Mar;22(1):173–82, viii (15 ref.)

MENTAL DEFICIENCY see **MENTAL RETARDATION**

MENTAL DISORDERS

Update in psychiatry. Schneider RK, et al.
Ann Intern Med 1999 Oct 5;131(7):514–21 (5 ref.)

Evolutionary psychopathology: why isn't the mind designed better than it is? Gilbert P. **Br J Med Psychol** 1998 Dec; 71 (Pt 4):353–73 (106 ref.)

Addressing mental health needs of infants and young children. Mayes LC.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):209–24 (20 ref.)

Drugs of abuse testing in a psychiatric outpatient service. Shearer DS, et al. **Clin Lab Med** 1998 Dec;18(4):713–26 (100 ref.)

Mental health problems in primary care: a research agenda. Klinkman MS, et al. **Int J Psychiatry Med** 1998; 28(4):361–74 (68 ref.)

Holy Grail, sliding scale, and refusal as symptom: competency determinations for medical and psychiatric patients. Farr M. **Pharos** 1999 Spring;62(2):2–9 (15 ref.)

Issues in the psychiatric treatment of African Americans. Baker FM, et al. **Psychiatr Serv** 1999 Mar;50(3):362–8 (66 ref.)

Advance directives for mental health treatment. Srebnik DS, et al. **Psychiatr Serv** 1999 Jul;50(7):919–25 (48 ref.)

[From sandbox to brainbox] Thomsen PH. **Ugeskr Laeger** 1999 Mar 8;161(10):1385–91 (36 ref.) **(Dan)**

[Behavior problems in patients with dementia. The impact on the career life] Garrido R, et al. **Arq Neuropsiquiatr** 1999 Jun;57(2B):427–34 (39 ref.) (Eng. Abstr.) **(Por)**

CHEMICALLY INDUCED

Alcohol and disinhibition. Källmén H, et al.
Eur Addict Res 1998 Dec;4(4):150–62 (176 ref.)

Future use of clomiphene in ovarian stimulation. Psychic effects of clomiphene citrate. Siedentopf F, et al.
Hum Reprod 1998 Nov;13(11):2986–7 (12 ref.)

Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Ketter TA, et al.
Neurology 1999;53(5 Suppl 2):S53–67 (288 ref.)

Neuropsychiatric toxicity associated with cytokine therapies. Lerner DM, et al. **Psychosomatics** 1999 Sep–Oct; 40(5):428–35 (29 ref.)

[Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports] Bango J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1998 Jul–Aug;26(4):260–3 (18 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Psychopathology: description and classification. Nathan PE, et al. **Annu Rev Psychol** 1999;50:79–107 (162 ref.)

The nature of psychiatric classification: issues beyond ICD–10 and DSM–IV. Jablensky A.
Aust N Z J Psychiatry 1999 Apr;33(2):137–44 (40 ref.)

Recognition and classification of psychopathology in preschool children. Pavuluri MN, et al.
Aust N Z J Psychiatry 1998 Oct;32(5):642–9 (53 ref.)

Culture and classification: the cross-cultural application of the DSM–IV. Thakker J, et al. **Clin Psychol Rev** 1998 Aug; 18(5):501–29 (131 ref.)

The place of culture in DSM–IV. Mezzich JE, et al.
J Nerv Ment Dis 1999 Aug;187(8):457–64 (50 ref.)

Problems with psychodiagnostics at "environmental patients". Tretter F. **Zentralbl Hyg Umweltmed** 1999 Aug; 202(2–4):139–51 (27 ref.)

COMPLICATIONS

Studies of suicide in later life: methodologic considerations and research directions. Pearson JL, et al.
Am J Geriatr Psychiatry 1999 Summer;7(3):203–10 (75 ref.)

Assessing communication in children with psychiatric and communication disorders. Kennedy MD.
Child Adolesc Psychiatr Clin N Am 1999 Jan;8(1):113–35, vii (90 ref.)

Assessing speech, language and communication. Paul R, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr; 8(2):297–322, vii (44 ref.)

Communicative intervention for children with psychiatric and communication disorders. Roth FP.
Child Adolesc Psychiatr Clin N Am 1999 Jan;8(1):137–52 (36 ref.)

Psychological aspects of endocrine disease. Sonino N, et al.
Clin Endocrinol (Oxf) 1998 Jul;49(1):1–7 (64 ref.)

Mental illness and substance abuse: implications for women's health and health care access. Reed BG, et al.
J Am Med Womens Assoc 1999 Spring;54(2):71–8 (171 ref.)

Psychopathology as risk for adolescent substance use disorders: a developmental psychopathology perspective. Cicchetti D, et al. **J Clin Child Psychol** 1999 Sep; 28(3):355–65 (49 ref.)

Child psychopathology risk factors for drug abuse: overview. Weinberg NZ, et al. **J Clin Child Psychol** 1999 Sep; 28(3):290–7 (49 ref.)

Supporting individuals with intellectual disability and challenging behaviour in integrated work settings: an overview and a model for service provision. Stevens P, et al. **J Intellect Disabil Res** 1999 Feb;43 (Pt 1):19–29 (98 ref.)

Behavioral issues in pediatric epilepsy. Dunn DW, et al.
Neurology 1999;53(5 Suppl 2):S96–100 (44 ref.)

Autoerythrocyte sensitization (psychogenic purpura): a case report and review of the literature. Anderson JE, et al.
Pediatr Emerg Care 1999 Feb;15(1):47–8 (4 ref.)

HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Sullivan G, et al. **Psychiatr Serv** 1999 May;50(5):648–52 (44 ref.)

Power spectral analysis of heart rate variability in psychiatry. Cohen H, et al. **Psychother Psychosom** 1999 Mar–Apr; 68(2):59–66 (55 ref.)

[Epilepsy and psychiatric disorders: epidemiological data] Vuilleumier P, et al. **Rev Neurol (Paris)** 1998 May; 154(4):305–17 (104 ref.) (Eng. Abstr.) **(Fre)**

[An autopsy case of intravascular malignant lymphomatosis with hemophagocytic syndrome, mental confusion and liver dysfunction] Onishi Y, et al. **Rinsho Ketsueki** 1998 Aug;39(8):586–92 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Psychological and social implications of epilepsy in adolescents] Artigas J. **Rev Neurol** 1999 Jan 1–15;28(1):43–9 (55 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Psychiatric illness in mentally retarded adolescents: clinical features. Masi G. **Adolescence** 1998 Summer;33(130):425–34 (35 ref.)

The psychiatric review of symptoms: a screening tool for family physicians. Carlat DJ. **Am Fam Physician** 1998 Nov 1;58(7):1617–24 (21 ref.)

School problems and the family physician. Phillips DM, et al. **Am Fam Physician** 1999 May 15;59(10):2816–24 (12 ref.)

Using DSM–IV primary care version: a guide to psychiatric diagnosis in primary care. Pingitore D, et al.
Am Fam Physician 1998 Oct 15;58(6):1347–52 (23 ref.)

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
Arthritis Rheum 1999 Apr;42(4):599–608 (123 ref.)

Reflections on the clinical utility of the ICD–10 and DSM–IV classifications and their diagnostic criteria. Bertelsen A. **Aust N Z J Psychiatry** 1999 Apr;33(2):166–73 (21 ref.)

A new conceptual paradigm from genetics and psychobiology for the science of mental health. Cloninger CR. **Aust N Z J Psychiatry** 1999 Apr;33(2):174–86 (31 ref.)

The nature of psychiatric classification: issues beyond ICD–10 and DSM–IV. Jablensky A.
Aust N Z J Psychiatry 1999 Apr;33(2):137–44 (40 ref.)

Limitations of the symptom-oriented approach to psychiatric research. Mojtabai R, et al. **Br J Psychiatry** 1998 Sep; 173:198–202 (37 ref.)

Systems for collaboration. Integrating multiple perspectives. Briggs MH. **Child Adolesc Psychiatr Clin N Am** 1999 Apr; 8(2):365–77 (24 ref.)

Diagnostic play interview. Its role in comprehensive psychiatric evaluation. Close N.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):239–55 (13 ref.)

Culturally sensitive assessment. Edwards CP, et al.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):409–24, ix (46 ref.)

Developmental and psychiatric evaluation in the preschool context. Kaplan MD.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):379–93 (29 ref.)

Assessment of caregiver–child interaction in the context of a preschool psychiatric evaluation. Keren M, et al.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):281–96 (55 ref.)

Psychiatric emergencies: rapid response and life–saving therapies. Kennedy GJ, et al. **Geriatrics** 1999 Sep; 54(9):38–42, 45–6 (18 ref.)

The amobarbital interview revisited: a review of the literature since 1966. Kavirajan H. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):153–65 (63 ref.)

Language, achievement, and cognitive processing in psychiatrically disturbed children with previously identified and unsuspected language impairments. Cohen NJ, et al. **J Child Psychol Psychiatry** 1998 Sep;39(6):865–77 (104 ref.)

Late–onset adrenoleukodystrophy associated with long–standing psychiatric symptoms. Garside S, et al.
J Clin Psychiatry 1999 Jul;60(7):460–8 (59 ref.)

Brain imaging correlates. Krishnan KR. **J Clin Psychiatry** 1999;60 Suppl 15:50–4 (30 ref.)

The Mini–International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM–IV and ICD–10. Sheehan DV, et al. **J Clin Psychiatry** 1998;59 Suppl 20:22–33;quiz 34–57 (25 ref.)

The art of assessment in psychology: ethics, expertise, and validity. Cates JA. **J Clin Psychol** 1999 May;55(5):631–41 (64 ref.)

The place of culture in DSM–IV. Mezzich JE, et al.
J Nerv Ment Dis 1999 Aug;187(8):457–64 (50 ref.)

The neurologic examination in adult psychiatry: from soft signs to hard science. Sanders RD, et al.
J Neuropsychiatry Clin Neurosci 1998 Fall;10(4):395–404 (130 ref.)

Psychotropic medication management in persons with co–occurring psychiatric and substance use disorders. Sowers W, et al. **J Psychoactive Drugs** 1999 Jan–Mar; 31(1):59–70 (57 ref.)

Does psychiatric disorder affect the likelihood of violent offending? A critique of the major findings. Mitchell EW. **Med Sci Law** 1999 Jan;39(1):23–30 (45 ref.)

Approaches to recognition and management of childhood psychiatric disorders in pediatric primary care. Cassidy LJ, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1037–52 (46 ref.)

Missed diagnoses in consultation liaison psychiatry. Antonowicz JL. **Psychiatr Clin North Am** 1998 Sep; 21(3):705–14, viii (20 ref.)

Frequently missed diagnoses in adolescent psychiatry. Berenson CK. **Psychiatr Clin North Am** 1998 Dec; 21(4):917–26, viii (37 ref.)

The underdiagnosis of neuropsychiatric Lyme disease in children and adults. Fallon BA, et al.
Psychiatr Clin North Am 1998 Sep;21(3):693–703, viii (21 ref.)

Missed diagnoses and misdiagnoses of environmental toxicant exposure. The psychiatry of toxic exposure and multiple chemical sensitivity. Hartman DE.
Psychiatr Clin North Am 1998 Sep;21(3):659–70, vii (33 ref.)

Subtle psychiatric presentations of endocrine diseases. Hutto B. **Psychiatr Clin North Am** 1998 Dec;21(4):905–16, viii (53 ref.)

Brain functions and psychiatric disorders. A clinical view. Othmer E, et al. **Psychiatr Clin North Am** 1998 Sep; 21(3):517–66, v (135 ref.)

Sleep disorders presenting as psychiatric disorders. Reite M. **Psychiatr Clin North Am** 1998 Sep;21(3):591–607 (85 ref.)

Substance use disorders. Difficulties in diagnoses. Ross SM, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):803–28 (37 ref.)

Unusual diagnoses among violent patients. Tardiff K.
Psychiatr Clin North Am 1998 Sep;21(3):567–76 (28 ref.)

Seizure disorders presenting with psychiatric symptomatology. Tucker GJ. **Psychiatr Clin North Am** 1998 Sep;21(3):625–35, vi (27 ref.)

Progress of ICD–10 (F) family in Japan: research, field trials and publications. Takada K, et al.
Psychiatry Clin Neurosci 1998 Dec;52 Suppl:S341–3 (15 ref.)

Ethological remarks on mannerisms. Conceptualisation and proposal for a definition. off Brüne M. **Psychopathology** 1998;31(4):188–96 (43 ref.)

Qualitative research in diagnostic processes. Frommer J.
Psychopathology 1999 May–Jun;32(3):121–6 (32 ref.)

The neuropathology of adult HIV infection. Bell JE.
Rev Neurol (Paris) 1998 Dec;154(12):816–29 (143 ref.)

The use of multivariate statistical methods in psychiatry. Everitt BS, et al. **Stat Methods Med Res** 1998 Sep; 7(3):253–77 (89 ref.)

Measurement reliability and agreement in psychiatry. Shrout PE. **Stat Methods Med Res** 1998 Sep;7(3):301–17 (77 ref.)

Psychological and psychiatric aspects of fibromyalgia syndrome (FMS). Keel P. **Z Rheumatol** 1998;57 Suppl 2:97–100 (15 ref.)

[Psychiatry and the neurosciences] Cešková E.
Cas Lek Cesk 1999 Apr 19;138(8):227–9 (25 ref.) (Eng. Abstr.) **(Cze)**

[Cerebral dysfunction occurring after years of latency] Arlien–Søborg P, et al. **Ugeskr Laeger** 1999 Feb 1; 161(5):578–81 (19 ref.) (Eng. Abstr.) **(Dan)**

[Diagnostic imaging techniques in psychiatry] Hulshoff Pol HE, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17;

142(42):2285–90 (35 ref.) (Eng. Abstr.) **(Dut)**

[Clinical case observations: lessons for empirical research] Swendsen J, et al. **Encephale** 1999 Jan–Feb;25(1):16–20 (20 ref.) (Eng. Abstr.) **(Fre)**

[Affective disorders due to the loss of mental self–activation. Comparison with athymhormia] Laplane D, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):35–9 (22 ref.) (Eng. Abstr.) **(Fre)**

[Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference] Kuwert T, et al. **Nervenarzt** 1998 Dec;69(12):1045–60 (234 ref.) (Eng. Abstr.) **(Ger)**

[How can psychodynamic diagnosis in childhood and adolescence be operationalized?] Schulte–Markwort M, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug; 26(3):211–20 (53 ref.) (Eng. Abstr.) **(Ger)**

[The study of regional cerebral blood flow in psychiatric disorders] Minkowski K. **Psychiatr Pol** 1998 May–Jun; 32(3):341–6 (11 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Placebos, drug effects, and study design: a clinician's guide. Quitkin FM. **Am J Psychiatry** 1999 Jun;156(6):829–36 (72 ref.)

Use of psychotropic medications in breast–feeding women: acute and prophylactic treatment. Austin MP, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):778–84 (40 ref.)

Ethical and pragmatic issues in the use of psychotropic agents in young children. Jensen PS. **Can J Psychiatry** 1998 Aug; 43(6):585–8 (13 ref.)

Drug metabolism and psychiatry: introduction. Baker GB. **Cell Mol Neurobiol** 1999 Jun;19(3):301–8 (38 ref.)

Alternatives to placebo–controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. European College of Neuropsychopharmacology. Montgomery SA. **Eur Neuropsychopharmacol** 1999 Mar;9(3):265–9 (4 ref.)

The failure of placebo–controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Montgomery SA. **Eur Neuropsychopharmacol** 1999 Mar;9(3):271–6 (10 ref.)

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Krystal JH, et al. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):125–43 (214 ref.)

Primary and drug–induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Siegel AJ, et al. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):190–200 (53 ref.)

Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. Stahl SM. **J Affect Disord** 1998 Dec;51(3):215–35 (131 ref.)

Anxiolytics, adrenergic agents, and naltrexone. Riddle MA, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May; 38(5):546–56 (110 ref.)

The role of typical and atypical antipsychotic medications in the management of agitation and aggression. Buckley PF. **J Clin Psychiatry** 1999;60 Suppl 10:52–60 (83 ref.)

SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. Gorman JM, et al. **J Clin Psychiatry** 1999;60 Suppl 4:33–8; discussion 39 (35 ref.)

Use of atypical neuroleptics in child and adolescent psychiatry. Toren P, et al. **J Clin Psychiatry** 1998 Dec; 59(12):644–56 (105 ref.)

Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. Verma SD, et al. **J Clin Psychiatry** 1998;59 Suppl 19:50–5 (32 ref.)

D–3 receptor agonists: combined action neurologic and neuropsychiatric agents [editorial; comment] Cummings JL. **J Neurol Sci** 1999 Feb 1;163(1):2–3 (17 ref.) Comment on: J Neurol Sci 1999 Feb 1;163(1):25–31.

Psychotropic medication management in persons with co–occurring psychiatric and substance use disorders. Sowers W, et al. **J Psychoactive Drugs** 1999 Jan–Mar; 31(1):59–70 (57 ref.)

Psychopharmacology and the human condition [see comments] Charlton BG. **J R Soc Med** 1998 Nov; 91(11):599–601 (11 ref.) Comment in: J R Soc Med 1999 Feb;92(2):101–2. Comment in: J R Soc Med 1999 Mar;92(3):156. Comment in: J R Soc Med 1999 May;92(5):269–70.

Psychopharmacotherapy in children and adults with intellectual disability. Santosh PJ, et al. **Lancet** 1999 Jul 17;354(9174):233–42 (82 ref.)

Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Dursun SM, et al. **Med Hypotheses** 1999 Feb; 52(2):101–9 (78 ref.)

Psychotropic medications in pregnant women: treatment dilemmas. Austin MP, et al. **Med J Aust** 1998 Oct 19; 169(8):428–31 (41 ref.)

Child and adolescent psychopharmacology. Important developmental issues. Tosyali MC, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1021–35, vii (90 ref.)

Use of herbal medicine for treating psychiatric disorders in Japan. Kanba S, et al. **Psychiatry Clin Neurosci** 1998 Dec; 52 Suppl:S331–3 (4 ref.)

Transcultural psychopharmacology: present and future. Pi EH. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S185–7 (36 ref.)

The uses of psychotropics in symptom management in advanced cancer. Bruera E, et al. **Psychooncology** 1998 Jul–Aug;7(4):346–58 (105 ref.)

[Society before and after the introduction of psychotropic drugs in therapeutic use] Juillet P. **Ann Pharm Fr** 1998; 56(2):49–54 (8 ref.) (Eng. Abstr.) **(Fre)**

["Judicious" use of neuroleptic drugs in the treatment of behavioral symptoms in the course of Alzheimer disease] Riva E, et al. **Recenti Prog Med** 1998 Nov;89(11):598–603 (20 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

Research policy implications of cost–of–illness studies for mental disorders. Rupp A, et al. **Br J Psychiatry Suppl** 1998;(36):19–25 (25 ref.)

[Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature] Frasch K, et al. **Nervenarzt** 1999 May; 70(5):387–90 (27 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Monoamine oxidase in neuropsychiatry and behavior. Shih JC, et al. **Am J Hum Genet** 1999 Sep;65(3):593–8 (56 ref.)

EPIDEMIOLOGY

Optimality of the birth population reduces learning and behaviour disorders and sudden infant death after the first month. Saugstad LF. **Acta Paediatr Suppl** 1999 May; 88(429):9–28 (171 ref.)

Generalized anxiety disorder and its comorbidities: disputes at the boundaries. Maser JD. **Acta Psychiatr Scand Suppl** 1998;393:12–22 (100 ref.)

The influence of alcohol drinking and alcohol use disorders on psychiatric disorders and suicidal behavior. Berglund M, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):333S–345S (112 ref.)

Studies of suicide in later life: methodologic considerations and research directions. Pearson JL, et al. **Am J Geriatr Psychiatry** 1999 Summer;7(3):203–10 (75 ref.)

The global burden of mental disorders [see comments] Ustün TB. **Am J Public Health** 1999 Sep;89(9):1315–8 (24 ref.) Comment in: Am J Public Health 1999 Sep;89(9):1309–11.

Sport psychiatry. Macleod AD. **Aust N Z J Psychiatry** 1998 Dec;32(6):860–6 (66 ref.)

Mental illness and violence: an epidemiological appraisal of the evidence. Arboleda–Flórez J. **Can J Psychiatry** 1998 Dec;43(10):989–96 (69 ref.)

Comorbidity of psychiatric and communication disorders in children. Giddan JJ, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):19–36, v (80 ref.)

Psychiatric comorbidity with substance misuse in children and teenagers. Zeitlin H. **Drug Alcohol Depend** 1999 Jul 1;55(3):225–34 (51 ref.)

The epidemiology of child and adolescent psychiatric disorders: recent developments and issues [editorial] Fombonne E. **Epidemiol Psichiatr Soc** 1998 Sep–Dec; 7(3):161–6 (53 ref.)

Education and mental disorders. Isohanni I, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):188–94 (53 ref.)

Risk factors and prognosis for psychiatric morbidity in children and adolescents. Koskinen M, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):170–9 (68 ref.)

Health trends in northern Finland. Näyhä S, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):94–103 (51 ref.)

Psychiatric disorders and their predictors in young adulthood in Finland. Veijola J, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):195–201 (57 ref.)

Comorbidity. Angold A, et al. **J Child Psychol Psychiatry** 1999 Jan;40(1):57–87 (276 ref.)

Methods of adolescent suicide prevention. Shaffer D, et al. **J Clin Psychiatry** 1999;60 Suppl 2:70–4; discussion 75–6, 113–6 (19 ref.)

Gender differences in psychiatric illness and treatments: a critical review. Gold JH. **J Nerv Ment Dis** 1998 Dec; 186(12):769–75 (70 ref.)

Nosology and epidemiology of addictive disorders and their comorbidity. Bucholz KK. **Psychiatr Clin North Am** 1999 Jun;22(2):221–40 (28 ref.)

Overview of psychiatric comorbidity. Practical and theoretic considerations. Goldsmith RJ. **Psychiatr Clin North Am** 1999 Jun;22(2):331–49, ix (43 ref.)

Mental disorder and violence: results of epidemiological studies in the era of de–institutionalization [editorial] Angermeyer MC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S1–6 (34 ref.)

Understanding causal paths between mental illness and violence. Arboleda–Flórez J, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S38–46 (96 ref.)

The psychiatric epidemiology of violent behaviour. Eronen M, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S13–23 (60 ref.)

Epidemiological investigations of the associations between major mental disorders and crime: methodological limitations and validity of the conclusions. Hodgins S. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S29–37 (57 ref.)

Mental illness and criminal violence. Tehrani JA, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S81–5 (19 ref.)

Psychiatric epidemiology. Pickles A. **Stat Methods Med Res** 1998 Sep;7(3):235–51 (72 ref.)

Statistical methods in psychiatric genetics. Sham PC. **Stat Methods Med Res** 1998 Sep;7(3):279–300 (32 ref.)

[Epilepsy and psychiatric disorders: epidemiological data] Vuilleumier P, et al. **Rev Neurol (Paris)** 1998 May; 154(4):305–17 (104 ref.) (Eng. Abstr.) **(Fre)**

[Mentally ill patients--a danger?] Angermeyer MC, et al. **Psychiatr Prax** 1998 Sep;25(5):211–20 (55 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Mental health of elderly Asians in the UK. Ananthanarayanan TS, et al. **Hosp Med** 1999 Jun; 60(6):407–9 (32 ref.)

Clinical relevance of contemporary cultural psychiatry. Alarcón RD, et al. **J Nerv Ment Dis** 1999 Aug; 187(8):465–71 (69 ref.)

Ethnicity and psychiatry. Turner T. **Practitioner** 1997 Oct; 241(1579):612–4 (4 ref.)

ETIOLOGY

Domestic terrorism with chemical or biological agents: psychiatric aspects. DiGiovanni C Jr. **Am J Psychiatry** 1999 Oct;156(10):1500–5 (59 ref.)

Qigong–induced mental disorders: a review. Ng BY. **Aust N Z J Psychiatry** 1999 Apr;33(2):197–206 (66 ref.)

Psychiatric issues affecting long duration space missions. Kanas N. **Aviat Space Environ Med** 1998 Dec;69(12):1211–6 (42 ref.)

Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Leroi I, et al. **Can J Psychiatry** 1998 Nov;43(9):933–40 (65 ref.)

Becoming modern after all these years: social change and mental health in Latin America. Almeida–Filho N. **Cult Med Psychiatry** 1998 Sep;22(3):285–316 (73 ref.)

Neurosteroids, brain damage, and mental illness. Herbert J. **Exp Gerontol** 1998 Nov–Dec;33(7–8):713–27 (56 ref.)

Psychiatric disorders and gynecological oncology: a review of the literature. Thompson DS, et al. **Gen Hosp Psychiatry** 1998 Jul;20(4):241–7 (35 ref.)

The moon and madness reconsidered. Raison CL, et al. **J Affect Disord** 1999 Apr;53(1):99–106 (38 ref.)

Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. Ghika J, et al. **J Neurosurg** 1999 Aug;91(2):313–21 (114 ref.)

Brain N–acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. Poland RE, et al. **J Psychiatr Res** 1999 Jan–Feb;33(1):41–51 (126 ref.)

Food, nutrition, anti–social behaviour and criminality. Dickerson JW. **J R Soc Health** 1998 Aug;118(4):224–6 (11 ref.)

Unproven assumptions about the impact of bereavement on children. Harrington R, et al. **J R Soc Med** 1999 May; 92(5):230–3 (37 ref.)

Psychiatric aspects of portal–systemic encephalopathy. Wiltfang J, et al. **Metab Brain Dis** 1998 Dec;13(4):379–89 (65 ref.)

Psychiatric illness and the workplace: perspectives for occupational medicine in the military. Pflanz S. **Mil Med** 1999 Jun;164(6):401–6 (62 ref.)

The behavioral morbidity of obstructive sleep apnea. Day R, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):341–54 (80 ref.)

Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Goodman SH, et al. **Psychol Rev** 1999 Jul;106(3):458–90 (300 ref.)

A review of the effects of moderate alcohol intake on psychiatric and sleep disorders. Castaneda R, et al. **Recent Dev Alcohol** 1998;14:197–226 (189 ref.)

The neuropathology of adult HIV infection. Bell JE. **Rev Neurol (Paris)** 1998 Dec;154(12):816–29 (143 ref.)

Clinical ecology--an unproved approach in the context of environmental medicine. Eis D. **Zentralbl Hyg Umweltmed** 1999 Aug;202(2–4):291–330 (97 ref.)

Psychiatric disorders related to solvent–exposure. Trabert W. **Zentralbl Hyg Umweltmed** 1999 Aug;202(2–4):121–6 (13 ref.)

[Perplexing acute or chronic somatic or psychiatric symptoms: possibly due to porphyria] Schattenberg AV, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1801–4 (17 ref.) (Eng. Abstr.) **(Dut)**

[Theoretical bases of semiology in pediatric psychiatry. I. Theoretical models] Brunod R. **Arch Pediatr** 1999 Mar; 6(3):307–13 (48 ref.) (Eng. Abstr.) **(Fre)**

[Neuropsychological sequelae of children treated for brain tumors: evaluation and risk factors] Grill J, et al. **Arch Pediatr** 1998 Feb;5(2):167–73 (62 ref.) (Eng. Abstr.) **(Fre)**

["Judicious" use of neuroleptic drugs in the treatment of behavioral symptoms in the course of Alzheimer disease] Riva E, et al. **Recenti Prog Med** 1998 Nov;89(11):598–603 (20 ref.) (Eng. Abstr.) **(Ita)**

[Mental disorders in patients with chronic hepatitis]

Podrezova LA, et al. **Klin Med (Mosk)** 1998;76(11):36–9 (7 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

A new conceptual paradigm from genetics and psychobiology for the science of mental health. Cloninger CR. **Aust N Z J Psychiatry** 1999 Apr;33(2):174–86 (31 ref.)

Basic concepts in the study of diseases with complex genetics. Burmeister M. **Biol Psychiatry** 1999 Mar 1;45(5):522–32 (47 ref.)

Benefits and pitfalls encountered in psychiatric genetic association studies. Malhotra AK, et al. **Biol Psychiatry** 1999 Mar 1;45(5):544–50 (78 ref.)

Science, medicine, and the future. Behaviour and genes. McGuffin P, et al. **BMJ** 1999 Jul 3;319(7201):37–40 (26 ref.)

Neurogenetic determinism and the new euphenics [see comments] Rose SP. **BMJ** 1998 Dec 19–26;317(7174):1707–8 (5 ref.) Comment in: BMJ 1999 May 29;318(7196):1488; discussion 1489. Comment in: BMJ 1999 May 29;318(7196):1488–9.

Psychiatric genetics: a genetic basis for health? Flint J, et al. **Curr Biol** 1999 May 6;9(9):R326–8 (18 ref.)

Mapping genes for psychiatric disorders and behavioral traits. McInnes LA, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):287–92 (46 ref.)

Genetics of childhood disorders: IV. Linkage analysis. Pauls D. **J Am Acad Child Adolesc Psychiatry** 1999 Jul;38(7):932–4 (6 ref.)

Genetics and child psychiatry: II Empirical research findings. Rutter M, et al. **J Child Psychol Psychiatry** 1999 Jan;40(1):19–55 (485 ref.)

Genetics and child psychiatry: I Advances in quantitative and molecular genetics. Rutter M, et al. **J Child Psychol Psychiatry** 1999 Jan;40(1):3–18 (485 ref.)

Psychiatric genetics: progress, problems, and potential. Owen MJ, et al. **Lancet** 1999 Jul;354 Suppl 1:SI11–4 (30 ref.)

Chromosomal fragility may be indicative of altered higher-order DNA organization as the underlying genetic diathesis in complex neurobehavioural disorders. Gericke GS. **Med Hypotheses** 1999 Mar;52(3):201–8 (80 ref.)

New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Horrobin DF, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar;60(3):141–67 (330 ref.)

Statistical methods in psychiatric genetics. Sham PC. **Stat Methods Med Res** 1998 Sep;7(3):279–300 (32 ref.)

[Complex hereditary diseases with psychiatric symptoms] Wetterberg L. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):839–45 (52 ref.) (Eng. Abstr.) **(Nor)**

IMMUNOLOGY

[Clinical and immunological studies in borderline mental disorders: problems and solutions] Aleksandrovskiĭ IuA, et al. **Vestn Ross Akad Med Nauk** 1999;(7):12–5 (7 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Drug metabolism and psychiatry: introduction. Baker GB. **Cell Mol Neurobiol** 1999 Jun;19(3):301–8 (38 ref.)

The time course of nerve growth factor content in different neuropsychiatric diseases—a unifying hypothesis. Hellweg R, et al. **J Neural Transm** 1998;105(8–9):871–903 (213 ref.)

New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Horrobin DF, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar;60(3):141–67 (330 ref.)

[Nerve growth factor system in health and disease] Kliushnik TP. **Vestn Ross Akad Med Nauk** 1999;(1):25–8 (77 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

PANDAS: the search for environmental triggers of pediatric neuropsychiatric disorders. Lessons from rheumatic fever. Garvey MA, et al. **J Child Neurol** 1998 Sep;13(9):413–23 (123 ref.)

Neurovirology. Microbes and the brain. Lipkin WI, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV21 (5 ref.)

MORTALITY

Excess mortality of mental disorder. Harris EC, et al. **Br J Psychiatry** 1998 Jul;173:11–53 (167 ref.)

Life-threatening psychiatric emergencies in the elderly: overview. Tueth MJ, et al. **J Geriatr Psychiatry Neurol** 1999 Summer;12(2):60–6 (65 ref.)

NURSING

Homeless people & mental health. Walker C. **Am J Nurs** 1998 Nov;98(11):26–32; quiz 33 (8 ref.)

Restraints and the elderly with mental illness: ethical issues and moral reasoning [see comments] Dawkins VH. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):22–7 (12 ref.) Comment in: J Psychosoc Nurs Ment Health Serv 1998 Dec;36(12):6.

Current understanding of violence and aggression: assessment and treatment. Littrell KH, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Dec;36(12):18–24 (40 ref.)

Nursing case management for psychogeriatric patients and their families: description of a clinical model. Borgermans LA, et al. **Nurs Clin North Am** 1998 Sep;33(3):529–42 (49 ref.)

PATHOLOGY

Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging. Callicott JH, et al. **Eur J Radiol** 1999 May;30(2):95–104 (104 ref.)

[Neuronal death is basic problem of neurology and psychiatry] Zavalishin IA, et al. **Vestn Ross Akad Med Nauk** 1999;(1):28–33 (45 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Sarter M, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:368–82 (73 ref.)

The spectrum of behaviors influenced by serotonin. Lucki I. **Biol Psychiatry** 1998 Aug 1;44(3):151–62 (115 ref.)

Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Rozanski A, et al. **Circulation** 1999 Apr 27;99(16):2192–217 (279 ref.)

Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging. Callicott JH, et al. **Eur J Radiol** 1999 May;30(2):95–104 (104 ref.)

Cognitive and behavioral function in children with sickle cell disease: a review and discussion of methodological issues. White DA, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct;20(5):458–62 (22 ref.)

Assessing the machinery of mind: synapses in neuropsychiatric disorders. Honer WG. **J Psychiatry Neurosci** 1999 Mar;24(2):116–21 (21 ref.)

Some neurobiological aspects of psychotherapy. A review. Liggan DY, et al. **J Psychother Pract Res** 1999 Spring;8(2):103–14 (137 ref.)

The role of brain insulin in the neurophysiology of serious mental disorders: review. Holden RJ. **Med Hypotheses** 1999 Mar;52(3):193–200 (64 ref.)

Cytokine interactions and cytokine balance in the brain: relevance to neurology and psychiatry. Plata-Salamán C, et al. **Mol Psychiatry** 1999 Jul;4(4):302–6 (33 ref.)

Functional neuroimaging in psychiatry. Fu CH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29;354(1387):1359–70 (124 ref.)

The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Farber NB, et al. **Prog Brain Res** 1998;116:421–37 (60 ref.)

The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Maddock RJ. **Trends Neurosci** 1999 Jul;22(7):310–6 (65 ref.)

Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Sarter M, et al. **Trends Neurosci** 1999 Feb;22(2):67–74 (95 ref.)

[5HT-moduline an new peptide specifically interactive with the serotonergic system: physiopathologic implications] Fillion G. **Ann Pharm Fr** 1998;56(4):145–7 (7 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Evaluation of indicated preventive intervention (secondary prevention) mental health programs for children and adolescents. Durlak JA, et al. **Am J Community Psychol** 1998 Oct;26(5):775–802 (151 ref.)

Mind matters: the importance of mental disorders in public health's 21st century mission [editorial; comment] Neugebauer R. **Am J Public Health** 1999 Sep;89(9):1309–11 (30 ref.) Comment on: Am J Public Health 1999 Sep;89(9):1315–8.

The global burden of mental disorders [see comments] Ustün TB. **Am J Public Health** 1999 Sep;89(9):1315–8 (24 ref.) Comment in: Am J Public Health 1999 Sep;89(9):1309–11.

Social, community, and preventive interventions. Reppucci ND, et al. **Annu Rev Psychol** 1999;50:387–418 (192 ref.)

Hormone replacement therapy. Indications, benefits and risk. Davis S. **Aust Fam Physician** 1999 May;28(5):437–45 (37 ref.)

Use of psychotropic medications in breast-feeding women: acute and prophylactic treatment. Austin MP, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):778–84 (40 ref.)

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms. Breton JJ. **Can J Psychiatry** 1999 Apr;44(3):227–34 (76 ref.)

The pediatrician as therapist. II: Approaches to prevention of mental health problems and to behavior management. Howard BJ. **J Dev Behav Pediatr** 1998 Dec;19(6):420–3 (15 ref.)

An introduction to consumer politics. Epstein M, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Aug;36(8):40–9 (13 ref.)

The clinician's role in assessing workplace violence. Lion JR. **Psychiatr Clin North Am** 1999 Mar;22(1):101–8, vii (68 ref.)

PSYCHOLOGY

Psychiatric issues affecting long duration space missions. Kanas N. **Aviat Space Environ Med** 1998 Dec;69(12):1211–6 (42 ref.)

Cognitive approaches to delusions: a critical review of theories and evidence. Garety PA, et al. **Br J Clin Psychol** 1999 Jun;38 (Pt 2):113–54 (109 ref.)

Homicides by people with mental illness: myth and reality. Taylor PJ, et al. **Br J Psychiatry** 1999 Jan;174:9–14 (33 ref.)

The achievement by proxy spectrum in youth sports. Historical perspective and clinical approach to pressured and high-achieving children and adolescents. Tofler IR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):803–20, ix (47 ref.)

Implications of attachment theory for developmental psychopathology. Sroufe LA, et al. **Dev Psychopathol** 1999 Winter;11(1):1–13 (60 ref.)

The general psychiatrist's evaluation of competency. Miller MC. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):172–6 (18 ref.)

Issues of non-compliance in mental health. Lowry DA. **J Adv Nurs** 1998 Aug;28(2):280–7 (51 ref.)

The moon and madness reconsidered. Raison CL, et al. **J Affect Disord** 1999 Apr;53(1):99–106 (38 ref.)

Understanding developmental psychopathology: how useful are evolutionary accounts? [see comments] Leckman JF, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Oct;37(10):1011–21 (90 ref.) Comment in: J Am Acad Child Adolesc Psychiatry 1999 Jun;38(6):641–2. Comment in: J Am Acad Child Adolesc Psychiatry 1999 Aug;38(8):939.

Are the mentally ill dangerous? Binder RL. **J Am Acad Psychiatry Law** 1999;27(2):189–201 (33 ref.)

Clinical relevance of contemporary cultural psychiatry. Alarcón RD, et al. **J Nerv Ment Dis** 1999 Aug;187(8):465–71 (69 ref.)

Psychiatric illness and the workplace: perspectives for occupational medicine in the military. Pflanz S. **Mil Med** 1999 Jun;164(6):401–6 (62 ref.)

Spiritual and religious dimensions of mental illness recovery narratives. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):35–44 (18 ref.)

Research on religion and serious mental illness. Koenig HG, et al. **New Dir Ment Health Serv** 1998 Winter;(80):81–95 (60 ref.)

Recoiling, regrouping, and recovering: first-person accounts of the role of spirituality in the course of serious mental illness. Sullivan WP. **New Dir Ment Health Serv** 1998 Winter;(80):25–33 (29 ref.)

Disaster mental health: current status and future directions. Young BH, et al. **New Dir Ment Health Serv** 1999 Summer;(82):53–64 (94 ref.)

Frontal lobe psychopathology: mania, depression, confabulation, catatonia, perseveration, obsessive compulsions, and schizophrenia. Joseph R. **Psychiatry** 1999 Summer;62(2):138–72 (260 ref.)

Families, culture, and mental illness: constructing new realities. Lefley HP. **Psychiatry** 1998 Winter;61(4):335–55 (90 ref.)

Mental disorders associated with childbearing: report of the Biennial Meeting of the Marcé Society. Stuart S, et al. **Psychopharmacol Bull** 1998;34(3):333–8 (19 ref.)

[The risk of suicide] Cremniter D, et al. **Presse Med** 1998 Dec 19;27(40):2151–6 (48 ref.) (Eng. Abstr.) **(Fre)**

[Behavioral psychotherapy: possibilities in the framework of general medicine] Leclerc V. **Presse Med** 1998 Dec 19;27(40):2179–84 (55 ref.) (Eng. Abstr.) **(Fre)**

[Homeless and mentally ill. Review of recent research and results on a doubly disadvantaged minority] Kellinghaus C, et al. **Fortschr Neurol Psychiatr** 1999 Mar;67(3):108–21 (140 ref.) (Eng. Abstr.) **(Ger)**

[Occultism, parapsychology and the esoteric from the perspective of psychopathology] Scharfetter C. **Fortschr Neurol Psychiatr** 1998 Oct;66(10):474–82 (29 ref.) (Eng. Abstr.) **(Ger)**

[Methodology of psychiatric case histories] Scherbaum N, et al. **Fortschr Neurol Psychiatr** 1999 May;67(5):229–36 (44 ref.) (Eng. Abstr.) **(Ger)**

[Assessing the quality of life of children and adolescents with psychiatric disorders—a review] Mattejat F, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug;26(3):183–96 (45 ref.) **(Ger)**

[Suffering. The old-fashioned considerations of a psychopathologist (editorial)] Callieri B. **Recenti Prog Med** 1999 Jun;90(6):334–7 (31 ref.) **(Ita)**

RADIONUCLIDE IMAGING

Neurology and psychiatry. Ell PJ, et al. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):529–36 (15 ref.)

REHABILITATION

"Nothing about me, without me": participatory action research with self-help/mutual aid organizations for psychiatric consumer/survivors. Nelson G, et al. **Am J Community Psychol** 1998 Dec;26(6):881–912 (92 ref.)

Elements of the art of practice in mental health. Weinstein E. **Am J Occup Ther** 1998 Jul–Aug;52(7):579–85 (38 ref.)

Purposeful activity for people with enduring mental health problems: reflections from a case study. Mitchell D. **Arch Psychiatr Nurs** 1998 Oct;12(5):282–7 (26 ref.)

Impaired doctors. The modern approach of medical boards.

Breen KJ, et al. **Aust Fam Physician** 1998 Nov; 27(11):1005–8 (0 ref.)

The active ingredients of effective case management: a research synthesis. Rapp CA.
Community Ment Health J 1998 Aug;34(4):363–80 (60 ref.)

Deinstitutionalization at the beginning of the new millennium. Lamb HR. **Harv Rev Psychiatry** 1998 May–Jun;6(1):1–10 (65 ref.)

Psychiatric rehabilitation technology: operationalizing the "black box" of the psychiatric rehabilitation process. Anthony WA. **New Dir Ment Health Serv** 1998 Fall; (79):79–87 (41 ref.)

An interactive approach to training teams and developing programs. Corrigan PW, et al.
New Dir Ment Health Serv 1998 Fall;(79):3–12 (34 ref.)

Training professionals for rehabilitation teams. Lefley HP. **New Dir Ment Health Serv** 1998 Fall;(79):13–23 (22 ref.)

Consumers as providers in psychiatric rehabilitation. Solomon P, et al. **New Dir Ment Health Serv** 1998 Fall; (79):65–77 (31 ref.)

Psychiatric disability, employment and the Americans with Disabilities Act. Wylonis L. **Psychiatr Clin North Am** 1999 Mar;22(1):147–58 (38 ref.)

Describing and evaluating jail diversion services for persons with serious mental illness. Draine J, et al.
Psychiatr Serv 1999 Jan;50(1):56–61 (25 ref.)

Community treatment of severely mentally ill offenders under the jurisdiction of the criminal justice system: a review. Lamb HR, et al. **Psychiatr Serv** 1999 Jul;50(7):907–13 (65 ref.)

[What are the goals of psychiatric rehabilitation, and which have been accomplished?] Priebe S. **Psychiatr Prax** 1999 Apr;26 Suppl 1:S36–40 (17 ref.) **(Ger)**

THERAPY

Individual psychotherapy outcome and process research: challenges leading to greater turmoil or a positive transition? Kopta SM, et al. **Annu Rev Psychol** 1999; 50:441–69 (208 ref.)

Transcranial magnetic stimulation: applications in neuropsychiatry [comment] George MS, et al.
Arch Gen Psychiatry 1999 Apr;56(4):300–11 (148 ref.)
Comment on: Arch Gen Psychiatry 1999 Apr;56(4):315–20.

Herbal remedies in psychiatric practice. Wong AH, et al. **Arch Gen Psychiatry** 1998 Nov;55(11):1033–44 (303 ref.)

An integrated treatment algorithm for pharmacotherapy and psychotherapy. Kisely SR, et al.
Aust N Z J Psychiatry 1999 Apr;33(2):207–16 (49 ref.)

From consultation-liaison psychiatry to psychosocial advocacy: maintaining psychiatry's scope. Smith GC.
Aust N Z J Psychiatry 1998 Dec;32(6):753–61; discussion 762–6 (75 ref.)

Individual psychopathology and marital distress. Analyzing the association and implications for therapy. Halford WK, et al. **Behav Modif** 1999 Feb;23(2):179–216 (155 ref.)

The dissemination of empirically supported treatments: a view to the future. Barlow DH, et al. **Behav Res Ther** 1999 Jul;37 Suppl 1:S147–62 (70 ref.)

Gene transfer to the brain: emerging therapeutic strategy in psychiatry? Lesch KP. **Biol Psychiatry** 1999 Feb 1; 45(3):247–53 (44 ref.)

Systematic review of the effectiveness of planned short hospital stays for mental health care. Johnstone P, et al. **BMJ** 1999 May 22;318(7195):1387–90 (27 ref.)

Narrative based medicine: a narrative approach to mental health in general practice. Launer J. **BMJ** 1999 Jan 9; 318(7176):117–9 (21 ref.)

Inequalities in mental health. Henderson C, et al.
Br J Psychiatry 1998 Aug;173:105–9 (31 ref.)

Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Leroi I, et al.
Can J Psychiatry 1998 Nov;43(9):933–40 (65 ref.)

Empirical foundations for writing in prevention and psychotherapy: mental and physical health outcomes. Esterling BA, et al. **Clin Psychol Rev** 1999 Jan;19(1):79–96 (76 ref.)

Foundations of behavior therapy in the contemporary healthcare context. Sloan DM, et al. **Clin Psychol Rev** 1999 Apr;19(3):255–74 (94 ref.)

Psychiatric emergencies: rapid response and life-saving therapies. Kennedy GJ, et al. **Geriatrics** 1999 Sep; 54(9):38–42, 45–6 (18 ref.)

Sharing the responsibility for improved care: the example of the Lundbeck International Psychiatric Institute. Joubert AF. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S41–8 (21 ref.)

The assessment and treatment of deaf children with psychiatric disorders. Roberts C, et al.
J Child Psychol Psychiatry 1999 Feb;40(2):151–67 (122 ref.)

Toward an ethical standard for coerced mental health treatment: least restrictive or most therapeutic? Olsen DP. **J Clin Ethics** 1998 Fall;9(3):235–46 (36 ref.)

Gender differences in psychiatric illness and treatments: a critical review. Gold JH. **J Nerv Ment Dis** 1998 Dec; 186(12):769–75 (70 ref.)

Energy healing with women and children. Starn JR.
J Obstet Gynecol Neonatal Nurs 1998 Sep–Oct;27(5):576–84 (48 ref.)

Transcranial magnetic stimulation: using a law of physics to treat psychopathology. Hasey GM.
J Psychiatry Neurosci 1999 Mar;24(2):97–101 (28 ref.)

Current understanding of violence and aggression: assessment and treatment. Littrell KH, et al.
J Psychosoc Nurs Ment Health Serv 1998 Dec;36(12):18–24 (40 ref.)

Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Fishbain DA. **Med Clin North Am** 1999 May;83(3):737–60, vii (93 ref.)

Approaches to recognition and management of childhood psychiatric disorders in pediatric primary care. Cassidy LJ, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1037–52 (46 ref.)

Review of integrated mental health and substance abuse treatment for patients with dual disorders. Drake RE, et al. **Schizophr Bull** 1998;24(4):589–608 (119 ref.)

Clinical trials in psychiatry: background and statistical perspective. Johnson T. **Stat Methods Med Res** 1998 Sep; 7(3):209–34 (118 ref.)

[Theoretical bases of semiology in pediatric psychiatry. I. Theoretical models] Brunod R. **Arch Pediatr** 1999 Mar; 6(3):307–13 (48 ref.) (Eng. Abstr.) **(Fre)**

[Sex differences relating to psychiatric treatment] Godfroid IO. **Can J Psychiatry** 1999 May;44(4):362–7 (61 ref.) (Eng. Abstr.) **(Fre)**

[Initial care of psychiatric emergency patients] König F, et al. **Anaesthesist** 1999 Aug;48(8):542–8 (31 ref.) (Eng. Abstr.) **(Ger)**

[Disorder-specific psychotherapy in child and adolescent psychiatry] Warnke A, et al.
Z Kinder Jugendpsychiatr Psychother 1998 Aug; 26(3):197–210 (30 ref.) **(Ger)**

[Types of ambulatory services for the elderly with cognitive and mental disturbances: current status] Heinik J, et al. **Harefuah** 1998 Aug;135(3–4):124–6 (19 ref.) **(Heb)**

[Home care in psychiatry] Moldavsky D, et al. **Harefuah** 1998 Aug;135(3–4):127–30 (18 ref.) **(Heb)**

VETERINARY

[Abnormal behavior and adaptation problems in dogs and cats and their pharmacologic control] Jöchle W.
Tierarztl Prax Ausg K Klientiere Heimtiere 1998 Nov; 26(6):410–21 (62 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

[Borna disease virus and psychiatric diseases. Fact or artefact?] Lieb K, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1217–8 (0 ref.) **(Ger)**

MENTAL DISORDERS, ORGANIC see **DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS**

MENTAL FATIGUE

DIAGNOSIS

Measurement of fatigue in industries. Saito K. **Ind Health** 1999 Apr;37(2):134–42 (12 ref.)

ETIOLOGY

Measurement of fatigue in industries. Saito K. **Ind Health** 1999 Apr;37(2):134–42 (12 ref.)

PREVENTION & CONTROL

International standards on mental work-load--the ISO 10,075 series. Nachreiner F. **Ind Health** 1999 Apr; 37(2):125–33 (14 ref.)

MENTAL HEALING

Religious and spiritual case reports on MEDLINE: a systematic analysis of records from 1980 to 1996. Lukoff D, et al. **Altern Ther Health Med** 1999 Jan;5(1):64–70 (68 ref.)

Not just a time-out: change dynamics of prayer for religious couples in conflict situations. Butler MH, et al.
Fam Process 1998 Winter;37(4):451–78 (70 ref.)

Spiritual and religious dimensions of mental illness recovery narratives. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):35–44 (18 ref.)

The place of spirituality and religion in mental health services. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):3–12 (35 ref.)

Research on religion and serious mental illness. Koenig HG, et al. **New Dir Ment Health Serv** 1998 Winter;(80):81–95 (60 ref.)

Recoiling, regrouping, and recovering: first-person accounts of the role of spirituality in the course of serious mental illness. Sullivan WP. **New Dir Ment Health Serv** 1998 Winter;(80):25–33 (29 ref.)

Sharing the pain: response of the churches in Papua New Guinea to the AIDS pandemic. Bouten M.
P N G Med J 1996 Sep;39(3):220–4 (0 ref.)

MENTAL HEALTH

Progress in adolescent mental health. Weist MD, et al.
Adolesc Med 1999 Feb;10(1):165–74, vii (33 ref.)

Narrative based medicine: a narrative approach to mental health in general practice. Launer J. **BMJ** 1999 Jan 9; 318(7176):117–9 (21 ref.)

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms. Breton JJ.
Can J Psychiatry 1999 Apr;44(3):227–34 (76 ref.)

Empirical foundations for writing in prevention and psychotherapy: mental and physical health outcomes. Esterling BA, et al. **Clin Psychol Rev** 1999 Jan;19(1):79–96 (76 ref.)

Becoming modern after all these years: social change and mental health in Latin America. Almeida-Filho N.
Cult Med Psychiatry 1998 Sep;22(3):285–316 (73 ref.)

Can light or moderate drinking benefit mental health? Chick J. **Eur Addict Res** 1999 Jun;5(2):74–81 (66 ref.)

Mental health of elderly Asians in the UK. Ananthanarayanan TS, et al. **Hosp Med** 1999 Jun; 60(6):407–9 (32 ref.)

The use of public health approaches in mental health programmes. Sartorius N. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S1–5 (3 ref.)

What kind of person is a thirty-year-old? Isohanni M, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):202–10 (14 ref.)

Long-term outcome of migration in childhood and adolescence. Moilanen I, et al.
Int J Circumpolar Health 1998 Jul;57(2–3):180–7 (38 ref.)

Inflammatory bowel disease in children and adolescents: mental health and family functioning. Engstrom I.
J Pediatr Gastroenterol Nutr 1999 Apr;28(4):S28–33 (21 ref.)

Recollections of parental behaviour, adult attachment and mental health: mediating and moderating effects. Gittleman MG, et al. **Psychol Med** 1998 Nov;28(6):1443–55 (46 ref.)

Comprehensive evaluation of current and past mental health in women. Endicott J. **Psychopharmacol Bull** 1998; 34(3):283–7 (18 ref.)

Future directions for studies of women's mental health. Halbreich U. **Psychopharmacol Bull** 1998;34(3):327–31 (22 ref.)

Evaluation of mental health and depression during pregnancy: position paper. Hendrick V, et al.
Psychopharmacol Bull 1998;34(3):297–9 (20 ref.)

Clinically relevant basic science studies of gender differences and sex hormone effects. McEwen BS, et al.
Psychopharmacol Bull 1998;34(3):251–9 (91 ref.)

Cognitive assessment for postmenopausal women and general assessment of their mental health. Sherwin BB.
Psychopharmacol Bull 1998;34(3):323–6 (28 ref.)

Geography and mental health: a review. Holley HL.
Soc Psychiatry Psychiatr Epidemiol 1998 Nov; 33(11):535–42 (106 ref.)

Migration and health in the European Union [see comments] Carballo M, et al. **Trop Med Int Health** 1998 Dec; 3(12):936–44 (79 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):933–4.

Mental health, psychosocial functioning, and quality of life in patients with bladder exstrophy and epispadias - an overview. Diseth TH, et al. **World J Urol** 1999 Aug; 17(4):239–48 (66 ref.)

[Management of mental health and primary care. Development and evaluation of a training program based on the PLISSIT approach] Vauth R, et al. **Nervenarzt** 1999 Jan;70(1):54–63 (32 ref.) (Eng. Abstr.) **(Ger)**

[Issues in mental health services for children and adolescents] Shevchenko IuS, et al.
Zh Nevrol Psikhiatr Im S S Korsakova 1998;98(9):37–40 (15 ref.) (Eng. Abstr.) **(Rus)**

MENTAL HEALTH SERVICES

Evidence based medicine and evaluation of mental health services: methodological issues and future directions. Barnes J, et al. **Arch Dis Child** 1999 Mar;80(3):280–5 (62 ref.)

Psychiatry in transition: outcomes of mental health policy shift in Italy. Barbato A. **Aust N Z J Psychiatry** 1998 Oct; 32(5):673–9 (25 ref.)

Mental health services in schools: utilization, effectiveness, and consent. Evans SW. **Clin Psychol Rev** 1999 Mar; 19(2):165–78 (67 ref.)

Perceptions of dementia, caregiving, and help seeking among Asian and Pacific Islander Americans. Braun KL, et al. **Health Soc Work** 1998 Nov;23(4):262–74 (67 ref.)

The tyranny of names in mental health care [editorial; comment] Schwenk TL. **J Am Board Fam Pract** 1999 Jan–Feb;12(1):99–101 (11 ref.) Comment on: J Am Board Fam Pract 1999 Jan–Feb;12(1):21–31.

Brief therapy in college counseling and mental health [see comments] Cooper S, et al. **J Am Coll Health** 1999 Jul; 48(1):21–8 (47 ref.) Comment in: J Am Coll Health 1999 Jul;48(1):3–6.

The Second National Mental Health Plan: an opportunity to take stock and move forward [see comments] Singh BS, et al. **Med J Aust** 1998 Oct 19;169(8):435–7 (14 ref.) Comment in: Med J Aust 1999 May 3;170(9):452.

Renewing Australia's mental health strategy [see comments] Whiteford HA. **Med J Aust** 1998 Oct 19;169(8):432–4 (12 ref.) Comment in: Med J Aust 1999 May 3;170(9):452.

The place of spirituality and religion in mental health services. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):3–12 (35 ref.)

Sexual offender treatment in Europe: an impression of cross-cultural differences. Frenken J. **Sex Abuse** 1999 Jan; 11(1):87–93 (2 ref.)

[How do we utilize our knowledge of psychiatry?]

Magnussen F, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30; 118(23):3659–62 (5 ref.) **(Nor)**

ECONOMICS

Mental health in schools and system restructuring. Adelman HS, et al. **Clin Psychol Rev** 1999 Mar;19(2):137–63 (102 ref.)

Cost–effectiveness of substance abuse services. Implications for public policy. Shepard DS, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):385–400, x (14 ref.)

LEGISLATION & JURISPRUDENCE

Advance directives for mental health treatment. Srebnik DS, et al. **Psychiatr Serv** 1999 Jul;50(7):919–25 (48 ref.)

ORGANIZATION & ADMINISTRATION

Privatization and the rise and fall of the public mental health safety net. Schnapp WB, et al. **Adm Policy Ment Health** 1999 Jan;26(3):221–5 (9 ref.)

Developing mental health services for Native American children. Barlow A, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):555–77, ix (45 ref.)

Addressing mental health needs of infants and young children. Mayes LC. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):209–24 (20 ref.)

Training and supervision in effective cross–cultural mental health services. Bhui K, et al. **Hosp Med** 1998 Nov; 59(11):861–5 (20 ref.)

Sharing the responsibilities: the roles of the government. Gjerris A. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S7–9 (9 ref.)

Behavioral health care: the keys to successful planning and management. Bender PA, et al. **J Health Care Finance** 1998 Winter;25(2):63–6 (0 ref.)

Regulating managed care: interest group competition for control and behavioral health care. Ross EC. **J Health Polit Policy Law** 1999 Jun;24(3):599–625 (58 ref.)

Family involvement in expanded school mental health. Bickham NL, et al. **J Sch Health** 1998 Dec;68(10):425–8 (8 ref.)

Optimizing the roles of school mental health professionals. Flaherty LT, et al. **J Sch Health** 1998 Dec;68(10):420–4 (34 ref.)

Mental health carve–outs: effects and implications. Grazier KL, et al. **Med Care Res Rev** 1999;56 Suppl 2:37–59 (40 ref.)

An interactive approach to training teams and developing programs. Corrigan PW, et al. **New Dir Ment Health Serv** 1998 Fall;(79):3–12 (34 ref.)

A systems approach to developing staff training. Giffort DW. **New Dir Ment Health Serv** 1998 Fall;(79):25–33 (23 ref.)

Training professionals for rehabilitation teams. Lefley HP. **New Dir Ment Health Serv** 1998 Fall;(79):13–23 (22 ref.)

Total quality management in behavioral health care. Sluyter GV. **New Dir Ment Health Serv** 1998 Fall;(79):35–43 (29 ref.)

Collaborative care in the United Kingdom. Jenkins GC. **Prim Care** 1999 Jun;26(2):411–22 (41 ref.)

Models of collaboration. Lorenz AD, et al. **Prim Care** 1999 Jun;26(2):401–10 (14 ref.)

Ten dimensions of public–sector managed care [see comments] Hoge MA, et al. **Psychiatr Serv** 1999 Jan; 50(1):51–5 (27 ref.) Comment in: Psychiatr Serv 1999 Jan;50(1):7.

A critique of seven assumptions behind psychological trauma programmes in war–affected areas. Summerfield D. **Soc Sci Med** 1999 May;48(10):1449–62 (52 ref.)

[The monitoring, evaluation and programming of mental health departments. A regional system of indicators. The Evaluation Center, the QUALI DSM Project, the Lazio region] **Epidemiol Psichiatr Soc** 1998 Sep–Dec;7(3 Suppl):1–39 (0 ref.) **(Ita)**

[Issues in mental health services for children and adolescents] Shevchenko IuS, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(9):37–40 (15 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Individual psychotherapy outcome and process research: challenges leading to greater turmoil or a positive transition? Kopta SM, et al. **Annu Rev Psychol** 1999; 50:441–69 (208 ref.)

GP referrals to adult psychological services: a research agenda for promoting needs–led practice through the involvement of mental health clinicians. Ross H, et al. **Br J Med Psychol** 1999 Mar;72 (Pt 1):75–91 (87 ref.)

Suicide and suicidal behaviours: implications for mental health services [see comments] Rhodes AE, et al. **Can J Psychiatry** 1998 Oct;43(8):785–91 (76 ref.) Comment in: Can J Psychiatry 1998 Oct;43(8):783.

NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. **Eur Addict Res** 1999 Mar;5(1):50–1 (0 ref.)

Assessing the quality of psychiatric care: research methods and application in clinical practice. Dickey B, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):88–96 (67 ref.)

Promoting adolescent mental health in primary care: a review of the literature. Walker Z, et al. **J Adolesc** 1998 Oct; 21(5):621–34 (104 ref.)

HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Sullivan G, et al. **Psychiatr Serv** 1999 May;50(5):648–52 (44 ref.)

Managed care and women's mental health: a focus on depression. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):47S–56S (41 ref.)

[Issues in mental health services for children and adolescents] Shevchenko IuS, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(9):37–40 (15 ref.) (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Mental health services and research in the Arab world [see comments] Okasha A, et al. **Acta Psychiatr Scand** 1998 Nov;98(5):406–13 (6 ref.) Comment in: Acta Psychiatr Scand 1998 Nov;98(5):345–7.

SUPPLY & DISTRIBUTION

Evaluation of indicated preventive intervention (secondary prevention) mental health programs for children and adolescents. Durlak JA, et al. **Am J Community Psychol** 1998 Oct;26(5):775–802 (151 ref.)

Inequalities in mental health. Henderson C, et al. **Br J Psychiatry** 1998 Aug;173:105–9 (31 ref.)

Mental health in schools and system restructuring. Adelman HS, et al. **Clin Psychol Rev** 1999 Mar;19(2):137–63 (102 ref.)

Responding to the mental health needs of Latino children and families through school–based services. Garrison EG, et al. **Clin Psychol Rev** 1999 Mar;19(2):199–219 (98 ref.)

Integrating health and mental health services in schools: psychologists collaborating with primary care providers. Kubiszyn T. **Clin Psychol Rev** 1999 Mar;19(2):179–98 (104 ref.)

Toward collaboration in the growing education–mental health interface. Waxman RP, et al. **Clin Psychol Rev** 1999 Mar;19(2):239–53 (62 ref.)

Deinstitutionalization at the beginning of the new millennium. Lamb HR. **Harv Rev Psychiatry** 1998 May–Jun;6(1):1–10 (65 ref.)

Disaster mental health: current status and future directions. Young BH, et al. **New Dir Ment Health Serv** 1999 Summer; (82):53–64 (94 ref.)

TRENDS

The impact of managed care on mental health services for children and their families. Stroul BA, et al. **Future Child** 1998 Summer–Fall;8(2):119–33 (25 ref.)

Disaster mental health: current status and future directions. Young BH, et al. **New Dir Ment Health Serv** 1999 Summer; (82):53–64 (94 ref.)

UTILIZATION

Suicide and recency of health care contacts. A systematic review. Pirkis J, et al. **Br J Psychiatry** 1998 Dec;173:462–74 (37 ref.)

Mental health issues for Asian Americans. Lin KM, et al. **Psychiatr Serv** 1999 Jun;50(6):774–80 (70 ref.)

MENTAL HEALTH SERVICES, COMMUNITY see **COMMUNITY MENTAL HEALTH SERVICES**

MENTAL HOSPITALS see **HOSPITALS, PSYCHIATRIC**

MENTAL HYGIENE see **MENTAL HEALTH**

MENTAL HYGIENE SERVICES see **MENTAL HEALTH SERVICES**

MENTAL PROCESSES

Unconscious processes, subliminal stimulation, and anxiety. Mayer B, et al. **Clin Psychol Rev** 1999 Aug;19(5):571–90 (92 ref.)

Some neurobiological aspects of psychotherapy. A review. Liggan DY, et al. **J Psychother Pract Res** 1999 Spring; 8(2):103–14 (137 ref.)

CLASSIFICATION

Emotional processing, three modes of mind and the prevention of relapse in depression. Teasdale JD. **Behav Res Ther** 1999 Jul;37 Suppl 1:S53–77 (61 ref.)

PHYSIOLOGY

Consciousness and the integration of information in the brain. Tononi G, et al. **Adv Neurol** 1998;77:245–79; discussion 279–80 (83 ref.)

The basal forebrain corticopetal system revisited. Zaborszky L, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:339–67 (130 ref.)

High–level scene perception. Henderson JM, et al. **Annu Rev Psychol** 1999;50:243–71 (132 ref.)

Processing capacity defined by relational complexity: implications for comparative, developmental, and cognitive psychology. Halford GS, et al. **Behav Brain Sci** 1998 Dec; 21(6):803–31; discussion 831–64 (243 ref.)

The associative parietal cortex and spatial processing in rodents. Thinus–Blanc C, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):179–83 (45 ref.)

Hierarchical somatosensory processing. Iwamura Y. **Curr Opin Neurobiol** 1998 Aug;8(4):522–8 (90 ref.)

Cortical processing of complex sounds. Rauschecker JP. **Curr Opin Neurobiol** 1998 Aug;8(4):516–21 (53 ref.)

Panic disorder from a monistic perspective: integrating neurobiological and psychological approaches. Windmann S. **J Anxiety Disord** 1998 Sep–Oct;12(5):485–507 (107 ref.)

Aging, culture, and cognition. Park DC, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 Mar;54(2):P75–84 (72 ref.)

The predictive brain: temporal coincidence and temporal order in synaptic learning mechanisms. Montague PR, et al. **Learn Mem** 1994 May–Jun;1(1):1–33 (165 ref.)

Is integer arithmetic fundamental to mental processing?: the mind's secret arithmetic. Snyder AW, et al. **Proc R Soc Lond B Biol Sci** 1999 Mar 22;266(1419):587–92 (49 ref.)

Frontal midline theta rhythm and mental activity. Inanaga K. **Psychiatry Clin Neurosci** 1998 Dec;52(6):555–66 (57 ref.)

Eye movements in reading and information processing: 20 years of research. Rayner K. **Psychol Bull** 1998 Nov; 124(3):372–422 (927 ref.)

Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Bergman H, et al. **Trends Neurosci** 1998 Jan;21(1):32–8 (58 ref.)

Gauging sensory representations in the brain. Buracas GT, et al. **Trends Neurosci** 1999 Jul;22(7):303–9 (41 ref.)

Abstract representations of numbers in the animal and human brain [published erratum appears in Trends Neurosci 1998 Dec;21(12):509] Dehaene S, et al. **Trends Neurosci** 1998 Aug;21(8):355–61 (73 ref.)

On brain lesions, the milkman and Sigmunda [see comments] Izquierdo I, et al. **Trends Neurosci** 1998 Oct;21(10):423–6 (46 ref.) Comment in: Trends Neurosci 1999 Feb;22(2):61.

[The EEG, spike activity and the brain processor: an attempt at paradigm analysis] Kozlov MK. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan–Feb; 49(1):141–54 (40 ref.) (Eng. Abstr.) **(Rus)**

MENTAL RETARDATION

see related
CRETINISM
MENTALLY DISABLED PERSONS

Assessing social integration in employment settings: current knowledge and future directions. Hughes C, et al. **Am J Ment Retard** 1998 Sep;103(2):173–85 (36 ref.)

COMPLICATIONS

Review of strategies for treating sleep problems in persons with severe or profound mental retardation or multiple handicaps. Lancioni GE, et al. **Am J Ment Retard** 1999 Mar;104(2):170–86 (82 ref.)

Psychiatric aspects of sexual abuse involving persons with developmental disabilities. McCreary BD, et al. **Can J Psychiatry** 1999 May;44(4):350–5 (24 ref.)

Communication disorders and children with mental retardation. Cascella PW. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):61–75 (57 ref.)

A review of behavioral and pharmacological treatments for habit disorders in individuals with mental retardation. Long ES, et al. **J Behav Ther Exp Psychiatry** 1998 Jun; 29(2):143–56 (100 ref.)

Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. Alvarez N, et al. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:1–15 (58 ref.)

Barbiturates in the treatment of epilepsy in people with intellectual disability. Alvarez N. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:16–23 (63 ref.)

Lamotrigine in the treatment of epilepsy in people with intellectual disability. Besag FM. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:50–6 (30 ref.)

Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. Duggan L, et al. **J Intellect Disabil Res** 1999 Apr; 43 (Pt 2):94–104 (56 ref.)

Valproate in the treatment of epilepsy in people with intellectual disability. Friis ML. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:32–5 (26 ref.)

Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability. Iivanainen M. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:24–31 (28 ref.)

Benzodiazepines in the treatment of epilepsy in people with intellectual disability. Isojärvi JI, et al. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:80–92 (84 ref.)

Age–related fractures in people with intellectual disability and epilepsy. Jancar J, et al. **J Intellect Disabil Res** 1998 Oct;42 (Pt 5):429–33 (20 ref.)

Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy. Kälviäinen R. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:63–7 (27 ref.)

Supporting individuals with intellectual disability and challenging behaviour in integrated work settings: an overview and a model for service provision. Stevens P, et al. **J Intellect Disabil Res** 1999 Feb;43 (Pt 1):19–29 (98 ref.)

Carbamazepine in the treatment of epilepsy in people with intellectual disability. Waisburg H, et al. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:36–40 (39 ref.)

Mood stabilizers and anticonvulsants. Kowatch RA, et al.

Pediatr Clin North Am 1998 Oct;45(5):1173–86, ix–x (78 ref.)
[A case of hereditary motor and sensory neuropathy with pyramidal tract sign, optic nerve atrophy and mental retardation] Adachi T, et al. **Rinsho Shinkeigaku** 1998 Dec; 38(12):1037–41 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Psychiatric illness in mentally retarded adolescents: clinical features. Masi G. **Adolescence** 1998 Summer;33(130):425–34 (35 ref.)
School problems and the family physician. Phillips DM, et al. **Am Fam Physician** 1999 May 15;59(10):2816–24 (12 ref.)

DRUG THERAPY

Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. Duggan L, et al. **J Intellect Disabil Res** 1999 Apr; 43 (Pt 2):94–104 (56 ref.)

ETIOLOGY

Cognitive impairment in neurofibromatosis type 1. Ozonoff S. **Am J Med Genet** 1999 Mar 26;89(1):45–52 (51 ref.)
Cognitive function and prenatal exposure to ionizing radiation. Schull WJ, et al. **Teratology** 1999 Apr;59(4):222–6 (35 ref.)
Congenital hypothyroidism: etiologies, diagnosis, and management. LaFranchi S. **Thyroid** 1999 Jul;9(7):735–40 (27 ref.)

GENETICS

Molecular dissection of Norrie disease. Berger W. **Acta Anat (Basel)** 1998;162(2–3):95–100 (48 ref.)
X-linked mental retardation. Neri G, et al. **Adv Genet** 1999; 41:55–94 (188 ref.)
XLMR genes: update 1998. Lubs H, et al. **Am J Med Genet** 1999 Apr 2;83(4):237–47 (102 ref.)
De novo complete trisomy 5p: clinical report and FISH studies. Reichenbach H, et al. **Am J Med Genet** 1999 Aug 27;85(5):447–51 (12 ref.)
Characterization of a partial trisomy 16q with FISH. Report of a patient and review of the literature. Engelen JJ, et al. **Ann Genet** 1999;42(2):101–4 (17 ref.)
A patient with 13q-syndrome with mild mental retardation and with growth retardation. Stoll C, et al. **Ann Genet** 1998; 41(4):209–12 (11 ref.)
Severe mental retardation-distal arthrogryposis in the upper limbs and complex chromosomal rearrangements resulting from a 10q25—>qter deletion. Lukusa T, et al. **Clin Genet** 1998 Sep;54(3):224–30 (26 ref.)
Chromosomal breakage syndromes. Carney JP. **Curr Opin Immunol** 1999 Aug;11(4):443–7 (47 ref.)
[Clinical approach to mental retardation of genetic origin] Livet MO, et al. **Rev Neurol (Paris)** 1999 Sep;155(8):593–5 (10 ref.) (Eng. Abstr.) **(Fre)**
[Genetic causes of mental retardation—diagnostic possibilities] Tranebjaerg L. **Tidsskr Nor Laegeforen** 1999 Aug 30;119(20):3028–34 (37 ref.) (Eng. Abstr.) **(Nor)**

MORTALITY

Mortality among people with mental retardation living in the United States: research review and policy application. Hayden MF. **Ment Retard** 1998 Oct;36(5):345–59 (42 ref.)

PATHOLOGY

Bladder carcinoma in Costello syndrome: report on a patient born to consanguineous parents and review. Franceschini P, et al. **Am J Med Genet** 1999 Sep 10;86(2):174–9 (26 ref.)
Smith-Fineman-Myers syndrome in apparently monozygotic twins. Guion-Almeida ML, et al. **Am J Med Genet** 1998 Sep 23;79(3):205–8 (4 ref.)
Microcephalic osteodysplastic primordial dwarfism type II: report of three cases and review. Majewski F, et al. **Am J Med Genet** 1998 Oct 30;80(1):25–31 (18 ref.)
Costello syndrome: report and review. van Eeghen AM, et al. **Am J Med Genet** 1999 Jan 15;82(2):187–93 (38 ref.)

PHYSIOPATHOLOGY

Aging and dementia of the Alzheimer type in persons with mental retardation. Wisniewski HM, et al. **Adv Exp Med Biol** 1998;446:223–5 (12 ref.)

PSYCHOLOGY

Adolescents with borderline intellectual functioning: psychopathological risk. Masi G, et al. **Adolescence** 1998 Summer;33(130):415–24 (20 ref.)
Empirically based methods to assess the preferences of individuals with severe disabilities. Lohrmann-O'Rourke S, et al. **Am J Ment Retard** 1998 Sep;103(2):146–61 (42 ref.)
Psychopharmacotherapy in children and adults with intellectual disability. Santosh PJ, et al. **Lancet** 1999 Jul 17;354(9174):233–42 (82 ref.)
People with mental retardation as witnesses in court: a review. Kebbell MR, et al. **Ment Retard** 1999 Jun; 37(3):179–87 (75 ref.)
The savant syndrome: intellectual impairment and exceptional skill. Miller LK. **Psychol Bull** 1999 Jan; 125(1):31–46 (155 ref.)

RADIOGRAPHY

Osteogenesis imperfecta-like syndrome with severe mental retardation and extrapyramidal tract signs. Nishimura G, et al. **Pediatr Radiol** 1998 Nov;28(11):856–8 (5 ref.)
[The cerebrocostomandibular syndrome] Cohnen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):160–2 (10 ref.) **(Ger)**

REHABILITATION

Quality of health care for people with developmental disabilities: the challenge of managed care. Walsh KK, et al. **Ment Retard** 1999 Feb;37(1):1–15 (60 ref.)
A review of research on physical exercise with people with severe and profound developmental disabilities. Lancioni GE, et al. **Res Dev Disabil** 1998 Nov-Dec;19(6):477–92 (80 ref.)

THERAPY

Mental retardation and decision making: balancing autonomy and protection. Van Hoof TJ, et al. **Conn Med** 1998 Aug; 62(8):455–60 (23 ref.)
Acknowledging barriers in adopting person-centered planning. Holburn S, et al. **Ment Retard** 1999 Apr; 37(2):117–24 (24 ref.)
[Clinical approach to mental retardation of genetic origin] Livet MO, et al. **Rev Neurol (Paris)** 1999 Sep;155(8):593–5 (10 ref.) (Eng. Abstr.) **(Fre)**

MENTAL RETARDATION, PSYCHOSOCIAL see **MENTAL RETARDATION**

MENTAL STATUS SCHEDULE

[The mini-mental state examination in screening of cognitive dysfunction and dementia] Lomholt RK, et al. **Ugeskr Laeger** 1998 Dec 7;160(50):7251–4 (20 ref.) (Eng. Abstr.) **(Dan)**

STANDARDS

The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. Cassano GB, et al. **J Affect Disord** 1999 Aug;54(3):319–28 (62 ref.)

MENTAL TESTS see **INTELLIGENCE TESTS**

MENTALLY DISABLED see **MENTALLY DISABLED PERSONS**

MENTALLY DISABLED PERSONS

see related
MENTAL RETARDATION

[The concept of handicap must be discussed in psychiatry!] Grunewald K. **Lakartidningen** 1999 Mar 10;96(10):1153–8 (14 ref.) **(Swe)**

LEGISLATION & JURISPRUDENCE

Mental incapacity: some proposals for legislative reform. McHale JV. **J Med Ethics** 1998 Oct;24(5):322–7 (67 ref.)

PSYCHOLOGY

Police officer attitudes and use of discretion in situations involving the mentally ill. The need to narrow the focus. Patch PC, et al. **Int J Law Psychiatry** 1999 Jan-Feb; 22(1):23–35 (56 ref.)

MENTALLY HANDICAPPED see **MENTALLY DISABLED PERSONS**

MENTORS

Mentorship in nursing: a literature review. Andrews M, et al. **J Adv Nurs** 1999 Jan;29(1):201–7 (52 ref.)

MENTORSHIPS see **MENTORS**

MEPACRINE see **QUINACRINE**

MEPARTRICIN

THERAPEUTIC USE

Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin. Boehm S, et al. **Wien Klin Wochenschr** 1998 Dec 11; 110(23):817–23 (51 ref.)

MEPERIDINE

ADMINISTRATION & DOSAGE

[Should pethidine still be administered to women in labor? (see comments)] Matheson I, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):234–6 (33 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1999 Mar 20;119(8):1194. **(Nor)**

MERACTINOMYCIN see **DACTINOMYCIN**

MERCAPTO COMPOUNDS see **SULFHYDRYL COMPOUNDS**

2-MERCAPTOETHANESULFONATE see **MESNA**

6-MERCAPTOPURINE

METABOLISM

Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Krynetski EY, et al. **Pharm Res** 1999 Mar;16(3):342–9 (56 ref.)

MERCAPTOVALINE see **PENICILLAMINE**

MERCAPTURIC ACID see **ACETYLCYSTEINE**

MERCUROTHIOLATE see **THIMEROSAL**

MERCURY

[The use of gallium-based metal-containing filling materials as a replacement for mercury] Iankelich OV. **Stomatologiia (Mosk)** 1999;78(4):54–5 (21 ref.) **(Rus)**

ADVERSE EFFECTS

Immunological disorders in men exposed to metallic mercury vapour. A review. Moszczyński P. **Cent Eur J Public Health** 1999 Feb;7(1):10–4 (57 ref.)
Summary report for the expert panel review of the toxicological profile for mercury. Risher JF, et al. **Toxicol Ind Health** 1999 Aug;15(5):483–516 (5 ref.)
Updated toxicological profile for mercury [letter] Risher JF, et al. **Toxicol Ind Health** 1999 Aug;15(5):[illegible] (10 ref.)

IMMUNOLOGY

Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Bagenstose LM, et al. **Immunol Res** 1999;20(1):67–78 (92 ref.)

METABOLISM

Methylmercury-induced generation of free radicals: biological implications. Sarafian TA. **Met Ions Biol Syst** 1999;36:415–44 (162 ref.)

PHARMACOLOGY

[Distribution of mercury resistance transposons in natural bacteria populations] Nikiforov VG, et al. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):55–62 (32 ref.) **(Rus)**

TOXICITY

Mercury. Top of the hit parade for eight years. Nickle RA. **Drug Chem Toxicol** 1999 Feb;22(1):129–42 (22 ref.)
Reproductive toxicity of occupational mercury. A review of the literature. Schuurs AH. **J Dent** 1999 May; 27(4):249–56 (101 ref.)
Methylmercury-induced generation of free radicals: biological implications. Sarafian TA. **Met Ions Biol Syst** 1999;36:415–44 (162 ref.)
Broadsheet number 48: Mercury, cadmium and arsenic: toxicology and laboratory investigation. Campbell BG. **Pathology** 1999 Feb;31(1):17–22 (54 ref.)
Updated toxicological profile for mercury [letter] Risher JF, et al. **Toxicol Ind Health** 1999 Aug;15(5):480–2 (10 ref.)
Summary report for the expert panel review of the toxicological profile for mercury. Risher JF, et al. **Toxicol Ind Health** 1999 Aug;15(5):483–516 (5 ref.)

MERCURY COMPOUNDS

ANALYSIS

Uncertainty analysis methods for comparing predictive models and biomarkers: A case study of dietary methyl mercury exposure. Ponce RA, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):96–105 (36 ref.)

MERCURY POISONING

DRUG THERAPY

Treatment of mercury intoxication. Baum CR. **Curr Opin Pediatr** 1999 Jun;11(3):265–8 (16 ref.)

MERCY KILLING see **EUTHANASIA**

MERGER, HEALTH FACILITY see **HEALTH FACILITY MERGER**

MERISTEM

EMBRYOLOGY

Shoot meristem formation and maintenance. Lenhard M, et al. **Curr Opin Plant Biol** 1999 Feb;2(1):44–50 (45 ref.)

GROWTH & DEVELOPMENT

Cell type specification and self renewal in the vegetative

MERISTEM

shoot apical meristem. Barton MK.
Curr Opin Plant Biol 1998 Feb;1(1):37–42 (39 ref.)

METABOLISM

Shoot meristems: Intercellular signals keep the balance. Doerner P. **Curr Biol** 1999 May 20;9(10):R377–80 (18 ref.)

MERKEL CELL TUMOR see **CARCINOMA, MERKEL CELL**

MERKEL CELLS

see related
CARCINOMA, MERKEL CELL

MEROSIN see **LAMININ**

MERPHALAN see **MELPHALAN**

MERRF SYNDROME

[MERRF] Fukuhara N. **Ryoikibetsu Shokogun Shirizu** 1999; (27 Pt 2):188–90 (9 ref.) **(Jpn)**

MESALAMINE

ADMINISTRATION & DOSAGE

Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Prakash A, et al. **Drugs** 1999 Mar;57(3):383–408 (94 ref.)
Metastatic Crohn's disease: remission induced by mesalamine and prednisone. Gilson MR, et al.
J Am Acad Dermatol 1999 Sep;41(3 Pt 1):476–9 (15 ref.)
[Clinical effects of 5-aminosalicylic acid preparations in Crohn disease] Fleig WE. **Med Klin** 1999 Feb 15;94 Suppl 1:22–5 (14 ref.) (Eng. Abstr.) **(Ger)**
[Clinical effect of various 5-ASA preparations in ulcerative colitis] Kruis W, et al. **Med Klin** 1999 Feb 15;94 Suppl 1:26–30 (11 ref.) (Eng. Abstr.) **(Ger)**
[Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease] Stange EF. **Med Klin** 1999 Feb 15;94 Suppl 1:39–41 (14 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature. Sentongo TA, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep; 27(3):344–7 (21 ref.)
Mesalazine-induced eosinophilic pneumonia. Tanigawa K, et al. **Respiration** 1999;66(1):69–72 (18 ref.)
[Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature] Decocq G, et al. **Therapie** 1999 Jan–Feb; 54(1):41–8 (32 ref.) (Eng. Abstr.) **(Fre)**
[Acute myocarditis due to mesalazine in a patient with ulcerative colitis] Masutani M, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 May;96(5):524–9 (21 ref.) **(Jpn)**
[A case of ulcerative colitis associated with interstitial pneumonitis during administration of 5-aminosalicylic acid] Ogino H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):164–9 (14 ref.) **(Jpn)**
[Non-immunoallergic hepatotoxicity due to mesalazine] Barroso N, et al. **Gastroenterol Hepatol** 1999 Apr; 22(4):176–9 (30 ref.) (Eng. Abstr.) **(Spa)**
[5-Aminosalicylic acid-induced acute pancreatitis (letter)] Marí B, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):28–9 (10 ref.) **(Spa)**
[Renal involvement in patients with chronic inflammatory intestinal disease treated with mesalazine. How to prevent its nephrotoxicity? (letter)] Bonet J, et al.
Med Clin (Barc) 1999 Jul 10;113(5):199 (8 ref.) **(Spa)**

PHARMACOKINETICS

[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations] Klotz U. **Med Klin** 1999 Feb 15; 94 Suppl 1:16–22 (53 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease. Feagan BG.
Eur J Surg 1998 Dec;164(12):903–9 (29 ref.)

MESALAZINE see **MESALAMINE**

MESANGIOCAPILLARY GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MESANGIUM, GLOMERULAR see **GLOMERULAR MESANGIUM**

MESENCEPHALIC CENTRAL GRAY see **PERIAQUEDUCTAL GRAY**

MESENCEPHALON

[A cryptococcal granuloma of the midbrain] Konovalov AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr–Jun; (2):33–6 (34 ref.) (Eng. Abstr.) **(Rus)**

INJURIES

Apomorphine and levodopa challenge in patients with a focal midbrain lesion. Moro E, et al. **Mov Disord** 1999 Mar; 14(2):269–75 (22 ref.)

PHYSIOLOGY

Forebrain and midbrain structures involved in prey-catching behaviour of toads: stimulus-response mediating circuits and their modulating loops. Ewert JP, et al.
Eur J Morphol 1999 Apr;37(2–3):172–6 (18 ref.)
Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain dopamine. Vezina P, et al. **Neurosci Biobehav Rev** 1999 Mar; 23(4):577–89 (135 ref.)
Maps versus clusters: different representations of auditory space in the midbrain and forebrain. Cohen YE, et al.
Trends Neurosci 1999 Mar;22(3):128–35 (113 ref.)
Is the short-latency dopamine response too short to signal reward error? Redgrave P, et al. **Trends Neurosci** 1999 Apr; 22(4):146–51 (40 ref.)

MESENCHYME see **MESODERM**

MESENCHYMOMA

Malignant mesenchymoma arising in an incisional scar of the abdominal wall. Sato N, et al. **Eur J Surg Oncol** 1998 Oct; 24(5):449–50 (10 ref.)
Germ cell, mesenchymal, and thymic tumors of the mediastinum. Billmire DF. **Semin Pediatr Surg** 1999 May; 8(2):85–91 (49 ref.)

COMPLICATIONS

Malignant hypoglycemia associated with a large mesenchymal tumor: case report and review of the literature. Rose MG, et al. **Cancer J Sci Am** 1999 Jan–Feb; 5(1):48–51 (17 ref.)

DIAGNOSIS

[Cardiac tumors. Our experience with 4 cases] Torres Borrego J, et al. **An Esp Pediatr** 1999 Jan;50(1):61–4 (24 ref.) **(Spa)**

GENETICS

Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. Kitamura Y, et al. **Ann Chir Gynaecol** 1998;87(4):282–6 (33 ref.)
DNA copy number changes in gastrointestinal stromal tumors--a distinct genetic entity. el-Rifai W, et al.
Ann Chir Gynaecol 1998;87(4):287–90 (21 ref.)

PATHOLOGY

CD34 and factor XIIIa-positive microvascular dendritic cells and the family of fibrohistiocytic mesenchymal tumors [letter; comment] Silverman JS, et al.
Am J Dermatopathol 1998 Oct;20(5):533–6 (39 ref.)
Comment on: Am J Dermatopathol 1996 Jun;18(3):283–8.
Comment on: Am J Dermatopathol 1998 Jun;20(3):317–22.
Prognosis and surveillance of gastrointestinal stromal/smooth muscle tumors. Emory TS, et al. **Ann Chir Gynaecol** 1998; 87(4):306–10 (29 ref.)
Gastrointestinal stromal tumours. Miettinen M, et al.
Ann Chir Gynaecol 1998;87(4):278–81 (27 ref.)
Chondrolipoma of the breast: a case report and review of the literature. Greer J, et al. **Conn Med** 1999 Jun; 63(6):327–9 (6 ref.)
Benign mesenchymoma of the cheek: report of a case and review of the literature. Sakurai K, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Jul;88(1):74–9 (24 ref.)
"Mesenchymal tumor" or "decidual-like reaction"? Karbe E. **Toxicol Pathol** 1999 May-Jun;27(3):354–62 (29 ref.)
Mesenchymal tumors of mouse urinary bladder: neoplasm or reactive change? Thake DC. **Toxicol Pathol** 1999 May-Jun;27(3):363 (6 ref.)

MESENTERIC ARTERIES

[Ischemic disease of the intestine] Suzuki K, et al.
Nippon Rinsho 1998 Sep;56(9):2365–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Small-bowel investigation in occult gastrointestinal bleeding. Morris AJ. **Semin Gastrointest Dis** 1999 Apr;10(2):65–70 (31 ref.)

PATHOLOGY

Histologic spectrum of arterial and arteriolar lesions in acute and chronic cocaine-induced mesenteric ischemia: report of three cases and literature review. Hoang MP, et al.
Am J Surg Pathol 1998 Nov;22(11):1404–10 (25 ref.)
Magnetic resonance angiography of mesenteric arteries. A review. Heiss SG, et al. **Invest Radiol** 1998 Sep;33(9):670–81 (58 ref.)

MESENTERIC ARTERY, INFERIOR

SURGERY

Preservation and peeling of the inferior mesenteric artery in the anterior resection for complicated diverticular disease. Messinetti S, et al. **Ann Ital Chir** 1998 Jul–Aug; 69(4):479–82; discussion 482–3 (13 ref.)

MESENTERIC ARTERY, SUPERIOR

see related
SUPERIOR MESENTERIC ARTERY SYNDROME

ULTRASONOGRAPHY

[Digestive system's large and changing needs of blood supply] Waaler BA, et al. **Tidsskr Nor Laegeforen** 1999 Feb 20;119(5):664–6 (11 ref.) (Eng. Abstr.) **(Nor)**

MESENTERIC CIRCULATION see **SPLANCHNIC CIRCULATION**

MESENTERIC CYST

PATHOLOGY

Müllerian cysts of the mesentery and retroperitoneum: a case report and literature review. Lee J, et al. **Pathol Int** 1998 Nov;48(11):902–6 (9 ref.)

MESENTERIC DUODENAL COMPRESSION SYNDROME see **SUPERIOR MESENTERIC ARTERY SYNDROME**

MESENTERIC VASCULAR OCCLUSION

Young woman's digestive arterial occlusion--a case report and literature review. Crètel E, et al. **Angiology** 1998 Nov; 49(11):929–36 (28 ref.)
Mesenteric ischemia in the elderly. Ruotolo RA, et al.
Clin Geriatr Med 1999 Aug;15(3):527–57 (93 ref.)
Intestinal (mesenteric) vasculopathy. I. Acute superior mesenteric arteriopathy and venopathy. Cappell MS.
Gastroenterol Clin North Am 1998 Dec;27(4):783–825, vi (285 ref.)
Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Cappell MS.
Gastroenterol Clin North Am 1998 Dec;27(4):827–60, vi (355 ref.)
Mesenteric venous thrombosis. Hassan HA, et al.
South Med J 1999 Jun;92(6):558–62 (61 ref.)

DIAGNOSIS

Magnetic resonance angiography of mesenteric arteries. A review. Heiss SG, et al. **Invest Radiol** 1998 Sep;33(9):670–81 (58 ref.)

ETIOLOGY

Mesenteric pseudoaneurysm resulting from septic embolism. Cassada DC, et al. **Ann Vasc Surg** 1998 Nov;12(6):597–600 (7 ref.)
Mesenteric venous thrombosis in protein S deficiency: case report and literature review. Lau LL, et al.
Ulster Med J 1999 May;68(1):33–5 (10 ref.)

RADIOGRAPHY

[An arterial compression syndrome due to the ligamentum arcuatum mediale of the diaphragm] Rietzler B, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jul;171(1):76–8 (8 ref.) **(Ger)**

SURGERY

[Mesenteric infarct--when is the vascular surgeon needed?] Kniemeyer HW. **Zentralbl Chir** 1998;123(12):1411–7 (40 ref.) (Eng. Abstr.) **(Ger)**
[Surgical therapy of mesenteric infarct] Lagana S, et al.
Zentralbl Chir 1998;123(12):1405–10 (23 ref.) (Eng. Abstr.) **(Ger)**
[Vascular surgical approach to mesenteric ischemia] Kenichi K, et al. **Nippon Geka Gakkai Zasshi** 1999 May;100(5):352–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

MESENTERIC VEINS

Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. Hassan HA.
J Clin Gastroenterol 1999 Jul;29(1):90–5 (54 ref.)
Mesenteric venous thrombosis associated with protein C deficiency. Mitani M, et al. **J Gastroenterol** 1999 Jun; 34(3):387–9 (17 ref.)

ANATOMY & HISTOLOGY

'Nonportal' splanchnic venous supply to the liver: abnormal findings on CT, US and MRI. Itai Y, et al. **Eur Radiol** 1999;9(2):237–43 (35 ref.)

PATHOLOGY

Phlebosclerosis of the colon with positive anti-centromere

antibody [see comments] Kitamura T, et al. **Intern Med** 1999 May;38(5):416–21 (18 ref.) Comment in: Intern Med 1999 May;38(5):381.

RADIOGRAPHY

Venous intravasation of Gastrografin: a serious but underestimated complication. Glauser T, et al. **Eur J Surg** 1999 Mar;165(3):274–7 (25 ref.)

SURGERY

[An iliac–mesenteric–atrial shunt in the Budd–Chiari syndrome with extensive thrombosis of the inferior vena cava] Bancu S, et al. **Chirurgia (Bucur)** 1998 May–Jun; 93(3):165–9 (7 ref.) (Eng. Abstr.) **(Rum)**

MESENTERY

Sonographic findings of malignant fibrous histiocytoma of the mesentery–report of two cases. Shibuya T, et al. **Eur J Ultrasound** 1998 Dec;8(3):207–12 (11 ref.)

A mesenteric liposarcoma with production of granulocyte colony–stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884–90 (37 ref.)

Sclerosing mesenteritis seen clinically as pancreatic pseudotumor: two cases and a review. Sheikh RA, et al. **Pancreas** 1999 Apr;18(3):316–21 (31 ref.)

[Complete remission of a mesenteric fibromatosis after taking sulindac] D'Alteroche L, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1098–101 (21 ref.) (Eng. Abstr.) **(Fre)**

[Isolated mesenteric fibromatosis. A clinical case] De Toma G, et al. **G Chir** 1999 May;20(5):222–4 (14 ref.) (Eng. Abstr.) **(Ita)**

[Cystic lymphangioma of the mesentery. A case of intestinal obstruction and a brief review of the literature] Fundarò S, et al. **Minerva Chir** 1998 Nov;53(11):939–42 (19 ref.) (Eng. Abstr.) **(Ita)**

[Sclerosing mesenteritis: a disease of malignant appearance] Muñoz–Juárez M, et al. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4):224–30 (85 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Management of acute mesenteric ischemia. Mansour MA. **Arch Surg** 1999 Mar;134(3):328–30; discussion 331 (15 ref.)

[Acute mesenteric ischemia—current diagnostic and therapeutic problems] Konturek A, et al. **Przegl Lek** 1999; 56(3):231–5 (31 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Mesenteric fibromatosis: case report and literature review. Al Jadaan SA, et al. **J Pediatr Surg** 1999 Jul;34(7):1130–2 (17 ref.)

RADIOGRAPHY

Imaging of pediatric mesenteric abnormalities. Zarewych ZM, et al. **Pediatr Radiol** 1999 Sep;29(9):711–9 (24 ref.)

MESMERISM see **HYPNOSIS**

MESNA

ANALOGS & DERIVATIVES

Modulation of platinum–induced toxicities and therapeutic index: mechanistic insights and first– and second–generation protecting agents. Hausheer FH, et al. **Semin Oncol** 1998 Oct;25(5):584–99 (56 ref.)

THERAPEUTIC USE

Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links M, et al. **Drugs** 1999 Mar; 57(3):293–308 (94 ref.)

MESOCOLON

INJURIES

Isolated transverse mesocolon laceration during routine colonoscopy. Hernandez EJ, et al. **J Clin Gastroenterol** 1999 Jan;28(1):46–8 (12 ref.)

PATHOLOGY

[Encapsulated hematoma of the sigmoid mesocolon. Apropos of an unusual case in Niger] Théry Y, et al. **J Radiol** 1999 Mar;80(3):312–6 (19 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Pictorial review: Subperitoneal spaces of the broad ligament and sigmoid mesocolon—imaging findings. Hashimoto M, et al. **Clin Radiol** 1998 Dec;53(12):875–81 (9 ref.)

MESODERM

Radiation treatment of benign mesenchymal disease. Suit H, et al. **Semin Radiat Oncol** 1999 Apr;9(2):171–8 (47 ref.)

CYTOLOGY

Mesenchymal stem cells in osteobiology and applied bone regeneration. Bruder SP, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S247–56 (60 ref.)

Transcriptional regulation during mesenchymal cell differentiation: the role of coactivators. St–Arnaud R. **Crit Rev Eukaryot Gene Expr** 1998;8(2):191–202 (81 ref.)

Morphological foundations of precartilage development in mesenchyme. Wezeman FH. **Microsc Res Tech** 1998 Oct 15;43(2):91–101 (97 ref.)

Pathological relevance of epithelial and mesenchymal phenotype plasticity. Guarino M, et al. **Pathol Res Pract** 1999;195(6):379–89 (59 ref.)

Activin as a morphogen in Xenopus mesoderm induction. McDowell N, et al. **Semin Cell Dev Biol** 1999 Jun; 10(3):311–7 (39 ref.)

PATHOLOGY

Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c–kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Chan JK. **Adv Anat Pathol** 1999 Jan;6(1):19–40 (112 ref.)

Case report of a 22–week fetus with 47,XXX karyotype and multiple lower mesodermal defects. Hoang MP, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):58–61 (17 ref.)

[Congenital diaphragmatic hernia. I. Simple defect of the diaphragm or anomaly of the pulmonary mesenchyme?] Thébaud B, et al. **Arch Pediatr** 1998 Sep;5(9):1009–19 (86 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Relevance of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Wallner EI, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F467–77 (128 ref.)

Intestinal epithelial–mesenchymal cell interactions. Kedinger M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:1–17 (72 ref.)

Regulation by members of the transforming growth factor beta superfamily of the digital and interdigital fates of the autopodial limb mesoderm. Macias D, et al. **Cell Tissue Res** 1999 Apr;296(1):95–102 (51 ref.)

Determination and development of the larval muscle pattern in Drosophila melanogaster. Paululat A, et al. **Cell Tissue Res** 1999 Apr;296(1):151–60 (93 ref.)

Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Xu X, et al. **Cell Tissue Res** 1999 Apr;296(1):33–43 (102 ref.)

Uno, nessuno e centomila: searching for the identity of mesodermal progenitors. Bianco P, et al. **Exp Cell Res** 1999 Sep 15;251(2):257–63 (62 ref.)

The molecular ZPA. Pearse RV 2nd, et al. **J Exp Zool** 1998 Dec 15;282(6):677–90 (117 ref.)

Pattern formation in dissociated limb bud mesenchyme in vitro and in vivo. Ide H, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):398–402 (12 ref.)

Role of hair papilla cells on induction and regeneration processes of hair follicles. Matsuzaki T, et al. **Wound Repair Regen** 1998 Nov–Dec;6(6):524–30 (46 ref.)

[Receptors and development of endothelial and hematopoietic cells] Eichmann A, et al. **J Soc Biol** 1999; 193(2):155–7 (31 ref.) (Eng. Abstr.) **(Fre)**

MESOMORPH see **SOMATOTYPES**

MESONEPHROS

EMBRYOLOGY

Functional development of the meso– and metanephros. Moritz KM, et al. **Pediatr Nephrol** 1999 Feb;13(2):171–8 (48 ref.)

PHYSIOLOGY

[The molecular mechanism of hematopoietic stem cell development in the AGM region] Takakura N. **Rinsho Ketsueki** 1999 Apr;40(4):262–7 (15 ref.) **(Jpn)**

[Hematopoietic stem cells and stromal cells in AGM region of mouse embryo] Tuji K. **Rinsho Ketsueki** 1999 Apr; 40(4):268–71 (7 ref.) **(Jpn)**

MESOPLODON see **WHALES**

MESOSIGMOID see **MESOCOLON**

MESOTHELIOMA

Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Plas E, et al. **Cancer** 1998 Dec 15;83(12):2437–46 (61 ref.)

Localized fibrous tumours of the pleura: 15 new cases and review of the literature. Suter M, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):453–9 (33 ref.)

Malignant mesothelioma of the pleural space. Grondin SC, et al. **Oncology (Huntingt)** 1999 Jul;13(7):919–26; discussion 926, 931–2 (45 ref.)

CHEMICALLY INDUCED

Salud ocupacional [letter] Castleman B, et al. **Int J Occup Med Environ Health** 1998;11(2):195–7 (10 ref.)

Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. Murthy SS, et al. **J Cell Physiol** 1999 Aug;180(2):150–7 (66 ref.)

[Synthetic mineral fibers] Boillat MA. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):468–74 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

In search of a positive immunohistochemical marker for mesothelioma: an update. Ordóñez NG. **Adv Anat Pathol** 1998 Jan;5(1):53–60 (56 ref.)

Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Ordóñez NG. **Am J Clin Pathol** 1999 Jul;112(1):75–89 (144 ref.)

Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Ordóñez NG. **Am J Surg Pathol** 1998 Oct;22(10):1203–14 (85 ref.)

Pleural mesothelioma. Astoul P. **Curr Opin Pulm Med** 1999 Jul;5(4):259–68 (81 ref.)

Malignant pleural mesothelioma [see comments] Boutin C, et al. **Eur Respir J** 1998 Oct;12(4):972–81 (113 ref.) Comment in: Eur Respir J 1999 Mar;13(3):706.

The immunohistochemical diagnosis of epithelial mesothelioma. Ordóñez NG. **Hum Pathol** 1999 Mar; 30(3):313–23 (107 ref.)

Ultrastructural features of diffuse malignant mesotheliomas. Oury TD, et al. **Hum Pathol** 1998 Dec;29(12):1382–92 (26 ref.)

[Pleural mesothelioma. A case report] Della Vittoria Scarpati M, et al. **Recenti Prog Med** 1999 Jun;90(6):327–30 (18 ref.) (Eng. Abstr.) **(Ita)**

[Modern approach to malignant pleural mesothelioma. 1) Pretherapeutic evaluation] Dagović A, et al. **Srp Arh Celok Lek** 1998 Jul–Aug;126(7–8):290–4 (19 ref.) (Eng. Abstr.) **(Scc)**

EPIDEMIOLOGY

Asbestos and cancer: An overview of current trends in Europe. Albin M, et al. **Environ Health Perspect** 1999 May; 107 Suppl 2:289–98 (73 ref.)

New molecular and epidemiological issues in mesothelioma: role of SV40. Carbone M, et al. **J Cell Physiol** 1999 Aug; 180(2):167–72 (34 ref.)

ETIOLOGY

Asbestos and cancer: An overview of current trends in Europe. Albin M, et al. **Environ Health Perspect** 1999 May; 107 Suppl 2:289–98 (73 ref.)

The hazards of chrysotile asbestos: a critical review. Landrigan PJ, et al. **Ind Health** 1999 Jul;37(3):271–80 (21 ref.)

Mesothelioma: cases associated with non–occupational and low dose exposures. Hillerdal G. **Occup Environ Med** 1999 Aug;56(8):505–13 (142 ref.)

Malignant pleural mesothelioma: a problematic review. Moskal TL, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):5–12 (62 ref.)

[Asbestos exposure and pleuropulmonary cancer] Begin R. **Rev Mal Respir** 1998 Dec;15(6):723–30 (41 ref.) (Eng. Abstr.) **(Fre)**

[Asbestos–related diseases] Paris C, et al. **Rev Prat** 1998 Jun 15;48(12):1292–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Chemical and physical characteristics and toxicology of man–made mineral fibers] Foà V, et al. **Med Lav** 1999 Jan–Feb;90(1):10–52 (100 ref.) (Eng. Abstr.) **(Ita)**

[Extrapleural mesothelioma] Lalowicz I. **Pol Merkuriusz Lek** 1999 Jan;6(31):47–9 (31 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Evidence for and implications of SV40–like sequences in human mesotheliomas and osteosarcomas. Rizzo P, et al. **Dev Biol Stand** 1998;94:33–40 (19 ref.)

Somatic genetic alterations in human malignant mesothelioma (review). Lee WC, et al. **Int J Oncol** 1999 Jan;14(1):181–8 (73 ref.)

METABOLISM

The immunohistochemical diagnosis of epithelial mesothelioma. Ordóñez NG. **Hum Pathol** 1999 Mar; 30(3):313–23 (107 ref.)

PATHOLOGY

Malignant mesothelioma of the tunica vaginalis testis: a report of two cases and review of literature. Gupta NP, et al. **J Surg Oncol** 1999 Apr;70(4):251–4 (18 ref.)

Epithelial mesothelioma with deciduoid features. Orosz Z, et al. **Virchows Arch** 1999 Mar;434(3):263–6 (16 ref.)

[Pleural mesotheliomas. Current knowledge] Evrard C, et al. **Ann Chir** 1999;53(4):314–23 (45 ref.) (Eng. Abstr.) **(Fre)**

[Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation] Okamoto T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug;36(8):696–701 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Malignant pleural mesothelioma with an unusual radiologic manifestation] Jover–Sáenz A, et al. **An Med Interna** 1999 Jul;16(7):354–6 (22 ref.) (Eng. Abstr.) **(Spa)**

MESOTHELIOMA

SURGERY

Indications for pneumonectomy. Extrapleural pneumonectomy. Rusch VW. **Chest Surg Clin N Am** 1999 May;9(2):327–38, x (42 ref.)

[Treatment strategy in pleural mesothelioma] Schirren J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:498–506 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Advances in the treatment of malignant pleural mesothelioma. Sterman DH, et al. **Chest** 1999 Aug; 116(2):504–20 (146 ref.)

Pleural mesothelioma. Astoul P. **Curr Opin Pulm Med** 1999 Jul;5(4):259–68 (81 ref.)

Malignant pleural mesothelioma [see comments] Boutin C, et al. **Eur Respir J** 1998 Oct;12(4):972–81 (113 ref.) Comment in: Eur Respir J 1999 Mar;13(3):706.

[Therapy of malignant pleural mesothelioma—a permanent dilemma] von Bültzingslöwen F, et al. **Pneumologie** 1999 May;53(5):266–75 (103 ref.) (Eng. Abstr.) **(Ger)**

[Malignant mesothelioma: to treat or not to treat?] Bendayan D, et al. **Harefuah** 1998 Oct;135(7–8):315–8 (24 ref.) **(Heb)**

[Malignant pleural mesothelioma. II. Modern therapeutic concepts] Dagović A, et al. **Srp Arh Celok Lek** 1998 Nov–Dec;126(11–12):472–7 (31 ref.) (Eng. Abstr.) **(Scc)**

ULTRASTRUCTURE

Ultrastructural features of diffuse malignant mesotheliomas. Oury TD, et al. **Hum Pathol** 1998 Dec;29(12):1382–92 (26 ref.)

VIROLOGY

Detectic . SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases. Galateau-Salle F, et al. **Dev Biol Stand** 1998;94:147–52 (28 ref.)

SV40 DNA sequences in mesotheliomas. Gibbs AR, et al. **Dev Biol Stand** 1998;94:41–5 (8 ref.)

Detection of SV40 sequences in human mesothelioma. Griffiths DJ, et al. **Dev Biol Stand** 1998;94:127–36 (20 ref.)

Further validation of SV40-like DNA in human pleural mesotheliomas. Pass H, et al. **Dev Biol Stand** 1998;94:143–5 (6 ref.)

SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Procopio A, et al. **Dev Biol Stand** 1998;94:361–7 (16 ref.)

Search for SV40 in human mesotheliomas. Shah KV. **Dev Biol Stand** 1998;94:67–8 (5 ref.)

MESOTHELIOMA, CYSTIC

DIAGNOSIS

Giant benign cystic peritoneal mesothelioma: US, CT, and MRI findings. Ozgen A, et al. **Abdom Imaging** 1998 Sep–Oct;23(5):502–4 (21 ref.)

MESOTHELIUM see **EPITHELIUM**

MESOZOA see **INVERTEBRATES**

MESSENGER RNA see **RNA, MESSENGER**

MESSENGER RNA, POLYADENYLATED see **RNA, MESSENGER**

MESULAM SYNDROME see **APHASIA, PRIMARY PROGRESSIVE**

META-ANALYSIS

see related
REVIEW LITERATURE

Communicating with clients about treatment outcomes: the use of meta-analytic evidence in collaborative treatment planning. Tickle-Degnen L. **Am J Occup Ther** 1998 Jul–Aug;52(7):526–30 (15 ref.)

Has the use of meta-analysis enhanced our understanding of therapies for postoperative nausea and vomiting? [editorial; comment] White PF, et al. **Anesth Analg** 1999 Jun;88(6):1200–2 (28 ref.) Comment on: Anesth Analg 1999 Jun;88(6):1354–61. Comment on: Anesth Analg 1999 Jun;88(6):1362–9. Comment on: Anesth Analg 1999 Jun;88(6):1370–9.

Metaanalytic revision of endpoints [editorial; comment] Gallagher EJ. **Ann Emerg Med** 1999 Jul;34(1):91–5 (44 ref.) Comment on: Ann Emerg Med 1999 Jul;34(1):8–18.

Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. Smeeth L, et al. **BMJ** 1999 Jun 5;318(7197):1548–51 (32 ref.)

Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Moher D, et al. **Health Technol Assess** 1999;3(12):i–iv, 1–98 (122 ref.)

Systematic review and meta-analysis in anatomic pathology: the value of nuclear DNA content in predicting progression in low grade CIN, the significance of the histological subtype on prognosis in cervical carcinoma. Heatley MK. **Histol Histopathol** 1999 Jan;14(1):203–15 (108 ref.)

Traditional reviews, meta-analyses and pooled analyses in epidemiology. Blettner M, et al. **Int J Epidemiol** 1999 Feb; 28(1):1–9 (47 ref.)

Deriving treatment recommendations from evidence within randomized trials. The role and limitation of meta-analysis. Freemantle N, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):304–15 (46 ref.)

Resolving discrepancies between a meta-analysis and a subsequent large controlled trial. DerSimonian R, et al. **JAMA** 1999 Aug 18;282(7):664–70 (47 ref.)

Pooling research results: benefits and limitations of meta-analysis. Ioannidis JP, et al. **Jt Comm J Qual Improv** 1999 Sep;25(9):462–9 (41 ref.)

Assessing "best evidence": issues in grading the quality of studies for systematic reviews. Lohr KN, et al. **Jt Comm J Qual Improv** 1999 Sep;25(9):470–9 (36 ref.)

Meta-analysis. Fitzmaurice G. **Nutrition** 1999 Feb; 15(2):174–6 (7 ref.)

Interpreting meta-analyses of pharmacologic interventions: the pitfalls and how to identify them. Etminan M, et al. **Pharmacotherapy** 1999 Jun;19(6):741–5 (27 ref.)

Meta-analysis: formulating, evaluating, combining, and reporting. Normand SL. **Stat Med** 1999 Feb 15; 18(3):321–59 (28 ref.)

Generalized linear mixed models for meta-analysis. Platt RW, et al. **Stat Med** 1999 Mar 30;18(6):643–54 (23 ref.)

An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Schmid CH, et al. **Stat Med** 1998 Sep 15; 17(17):1923–42 (75 ref.)

Promises and pitfalls of meta-analysis in vaccine research. Jacobson RM. **Vaccine** 1999 Mar 26;17(13–14):1628–34 (85 ref.)

[Application of meta-analysis in epidemiological study of occupational neoplasms] Chen R, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):307–9 (8 ref.) **(Chi)**

[The practice of systematic reviews. IV. Pooling results from separate studies] Scholten RJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):786–91 (22 ref.) (Eng. Abstr.) **(Dut)**

[Under the meta-scope: possibilities and limits of meta-analyses] Egger M. **Schweiz Med Wochenschr** 1998 Nov 28;128(48):1893–901 (44 ref.) (Eng. Abstr.) **(Ger)**

[Quality aspects in internal medicine—from anamnesis to meta-analysis] Battegay M, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24;87(51–52):1785–92 (22 ref.) (Eng. Abstr.) **(Ger)**

[Methodology of meta analysis and internal diseases—therapy of hypertension complicated by diabetes as an example] Nago N, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):355–61 (15 ref.) **(Jpn)**

METABOLIC ACTIVATION see **BIOTRANSFORMATION**

METABOLIC CLEARANCE RATE

A personal history of the early development of the concept and methods of measurement of the metabolic clearance rate particularly of steroid hormones. Tait JF, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S101–18 (79 ref.)

METABOLIC DETOXICATION, DRUG

Drug metabolizing enzymes in lymphocytes. Raucy JL, et al. **J Biochem Mol Toxicol** 1999;13(3–4):223–6 (22 ref.)

Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Tucker GT, et al. **Xenobiotica** 1998 Dec;28(12):1255–73 (57 ref.)

[Pharmacological principles for the treatment of heroin abuse] Oye I. **Tidsskr Nor Laegeforen** 1999 May 30; 119(14):2066–9 (15 ref.) **(Nor)**

METABOLIC DISEASES

CHEMICALLY INDUCED

[Metabolic disorders due to HIV-1 protease inhibitors (editorial)] Liguori M, et al. **Recenti Prog Med** 1998 Dec; 89(12):652–3 (14 ref.) **(Ita)**

COMPLICATIONS

Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Müller-Wieland D, et al. **Basic Res Cardiol** 1998;93 Suppl 2:131–4 (16 ref.)

The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders. Massieu L, et al. **Neurobiology (Bp)** 1998;6(1):99–108 (54 ref.)

[Dementia associated with metabolic diseases] Amano T. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):767–73 (13 ref.) **(Jpn)**

[Metabolic tubulo-interstitial nephropathies] Iino Y. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1459–62 (6 ref.) **(Jpn)**

DIAGNOSIS

Endocrinologic and metabolic complications in the intensive care unit. Martinez FJ, et al. **Clin Chest Med** 1999 Jun; 20(2):401–21, ix (105 ref.)

Nongynecologic healthcare screening in women. Krueger PM. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S15–9 (24 ref.)

Proton MR spectroscopy of pediatric brain metabolic disorders. Wang ZJ, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):781–807 (79 ref.)

ENZYMOLOGY

[Regulation of intracellular CoA pool as one of approaches to correction of metabolic disorders] Sheĭbak VM. **Vopr Med Khim** 1999 Mar–Apr;45(2):97–104 (50 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Metabolic problems in inflammatory bowel disease. Allan RN. **Neth J Med** 1998 Dec;53(6):S9–12 (13 ref.)

Long-term metabolic complications. Legendre C. **Transplant Proc** 1999 Feb–Mar;31(1–2):1278–9 (15 ref.)

[Digestive and metabolic diseases] Stüber E, et al. **Internist (Berl)** 1999 Apr;40(4):407–13 (43 ref.) **(Ger)**

[Neuroendocrine disorders cause stress-related disease. "Civilization syndrome" is a growing health problem] Björntorp P, et al. **Lakartidningen** 1999 Feb 24;96(8):893–6 (21 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Metabolic consequences of the West African diaspora: lessons from the thrifty gene. Osei K. **J Lab Clin Med** 1999 Feb; 133(2):98–111 (65 ref.)

Mitochondrial diseases in man and mouse. Wallace DC. **Science** 1999 Mar 5;283(5407):1482–8 (101 ref.)

METABOLISM

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151–9 (97 ref.)

Mitochondrial medicine—recent advances. Graff C, et al. **J Intern Med** 1999 Jul;246(1):11–23 (108 ref.)

Contributions of studies on uncoupling proteins to research on metabolic diseases. Ricquier D, et al. **J Intern Med** 1999 Jun;245(6):637–42 (27 ref.)

PATHOLOGY

Histopathologic approach to metabolic liver disease: Part 1. Jevon GP, et al. **Pediatr Dev Pathol** 1998 May–Jun; 1(3):179–99 (121 ref.)

PHYSIOPATHOLOGY

Metabolic and nutritional consequences of chronic hypoxia. Leverve X. **Clin Nutr** 1998 Dec;17(6):241–51 (94 ref.)

Clinical manifestation of myeloperoxidase deficiency. Lanza F. **J Mol Med** 1998 Sep;76(10):676–81 (48 ref.)

The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases. Hässig A, et al. **Med Hypotheses** 1998 Jul;51(1):59–63 (28 ref.)

SURGERY

Indications for pediatric liver transplantation. McDiarmid SV, et al. **Pediatr Transplant** 1998 May;2(2):106–16 (81 ref.)

THERAPY

Endocrinologic and metabolic complications in the intensive care unit. Martinez FJ, et al. **Clin Chest Med** 1999 Jun; 20(2):401–21, ix (105 ref.)

VETERINARY

Toxic and metabolic causes of seizures. O'Brien D. **Clin Tech Small Anim Pract** 1998 Aug;13(3):159–66 (53 ref.)

METABOLIC PROCESSES see **METABOLISM**

METABOLIC PUMP see **BIOLOGICAL TRANSPORT, ACTIVE**

METABOLISM

Potential mechanisms of metabolic imprinting that lead to chronic disease. Waterland RA, et al. **Am J Clin Nutr** 1999 Feb;69(2):179–97 (13 ref.)

Modelling metabolism in vivo: approaches using NMR. Iles RA, et al. **Biochem Soc Trans** 1999 Feb;27(2):289–94 (21 ref.)

New insights into metabolic pathway optimization by analogy with industrial manufacturing processes. Ortega F, et al. **Biochem Soc Trans** 1999 Feb;27(2):276–81 (15 ref.)

Live control of the living cell. van Heeswijk WC, et al. **Biochem Soc Trans** 1999 Feb;27(2):261–4 (11 ref.)

The discovery of metabolic co-operation. Pitts JD. **Bioessays** 1998 Dec;20(12):1047–51 (41 ref.)

Metabolic pathway analysis: basic concepts and scientific applications in the post-genomic era. Schilling CH, et al. **Biotechnol Prog** 1999 May–Jun;15(3):296–303 (52 ref.)

Mathematical models of metabolic pathways. Varner J, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):146–50 (61 ref.)

Haemodialysis and peritoneal dialysis: metabolic alterations and nutritional status [see comments] Cano N.

Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):329–33 (65 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.
The use of stable isotope techniques for nutritional and metabolic research in paediatrics. Koletzko B, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S77–97 (39 ref.)
Utility and importance of gene knockout animals for nutritional and metabolic research. Hui DY. **J Nutr** 1998 Nov;128(11):2052–7 (63 ref.)
Detection of elementary flux modes in biochemical networks: a promising tool for pathway analysis and metabolic engineering. Schuster S, et al. **Trends Biotechnol** 1999 Feb; 17(2):53–60 (33 ref.)

DRUG EFFECTS

The anti-catabolic effects of n-3 fatty acids. Ross JA, et al. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):219–26 (57 ref.)

GENETICS

Metabolic engineering with recombinant adenoviruses. Antinozzi PA, et al. **Annu Rev Nutr** 1999;19:511–44 (122 ref.)

PHYSIOLOGY

Metabolic depression in animals: physiological perspectives and biochemical generalizations. Guppy M, et al. **Biol Rev Camb Philos Soc** 1999 Feb;74(1):1–40 (246 ref.)
Two research paths for probing the roles of oxygen in metabolic regulation. Hochachka PW. **Braz J Med Biol Res** 1999 Jun;32(6):661–72 (51 ref.)
Exercise metabolism and beta-blocker therapy. An update. Head A. **Sports Med** 1999 Feb;27(2):81–96 (127 ref.)

METABOLISM AND ENDOCRINOLOGY (SPECIALTY) see **ENDOCRINOLOGY**

METABOLISM, BASAL see **BASAL METABOLISM**

METABOLISM, INBORN ERRORS

see related
ANEMIA, HEMOLYTIC, CONGENITAL
MENTAL RETARDATION

Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. Hoffmann GF, et al. **J Inherit Metab Dis** 1999 Jun;22(4):381–91 (30 ref.)

COMPLICATIONS

The liver and metabolic diseases of childhood. McDiarmid SV. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S34–50 (140 ref.)

DIAGNOSIS

Carnitine-acylcarnitine translocase deficiency. Pande SV. **Am J Med Sci** 1999 Jul;318(1):22–7 (32 ref.)
Inborn and induced defects of mitochondria. Schapira AH. **Arch Neurol** 1998 Oct;55(10):1293–6 (36 ref.)
Reye's syndrome: hold the obituary [editorial; comment] Sarnaik AP. **Crit Care Med** 1999 Aug;27(8):1674–6 (19 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1582–7.
Tandem mass spectrometry--the potential. Bartlett K, et al. **J Inherit Metab Dis** 1999 Jun;22(4):568–71 (12 ref.)
Population newborn screening for inherited metabolic disease: current UK perspectives. Green A, et al. **J Inherit Metab Dis** 1999 Jun;22(4):572–9 (27 ref.)
Prevalence of myeloperoxidase deficiency: population studies using Bayer-Technicon automated hematology. Kutter D. **J Mol Med** 1998 Sep;76(10):669–75 (8 ref.)
A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. Thomason MJ, et al. **J Public Health Med** 1998 Sep;20(3):331–43 (63 ref.)
Proton MR spectroscopy of pediatric brain metabolic disorders. Wang ZJ, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):781–807 (79 ref.)
Continuing education in neurometabolic disorders--serine deficiency disorders. de Koning TJ, et al. **Neuropediatrics** 1999 Feb;30(1):1–4 (14 ref.)
Cerebellar involvement in metabolic disorders: a pattern-recognition approach. Steinlin M, et al. **Neurorradiology** 1998 Jun;40(6):347–54 (41 ref.)
Inborn errors of metabolism in infancy: a guide to diagnosis. Burton BK. **Pediatrics** 1998 Dec;102(6):E69 (19 ref.)
Diffusion-weighted magnetic resonance imaging: theory and potential applications to child neurology. Beaulieu C, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):87–100 (41 ref.)
Proton magnetic resonance spectroscopy: clinical applications in children with nervous system diseases. Shevell MI, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):68–77 (24 ref.)
Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. Hyland K. **Semin Perinatol** 1999 Apr;23(2):194–203 (67 ref.)
Application of electrospray tandem mass spectrometry to neonatal screening. Rashed MS, et al. **Semin Perinatol** 1999 Apr;23(2):183–93 (55 ref.)
Neonatal metabolic myopathies. Tein I. **Semin Perinatol** 1999 Apr;23(2):125–51 (262 ref.)
[Clinical and laboratory basis for the diagnosis and understanding of neonatal metabolic diseases] Bispo MA, et al. **Acta Med Port** 1998 Jul;11(7):675–81 (7 ref.) (Eng. Abstr.) **(Por)**
[Approximation to the diagnosis of congenital metabolic disorders with neuroimaging] Campistol J. **Rev Neurol** 1999 Jan 1–15;28(1):16–23 (46 ref.) (Eng. Abstr.) **(Spa)**
[Usefulness of neurophysiological techniques in the diagnosis of metabolic disorders] Pascual-Pascual SI. **Rev Neurol** 1999 Jan 1–15;28(1):24–32 (73 ref.) (Eng. Abstr.) **(Spa)**
[Advances in biochemistry in the understanding of neurometabolic disorders] Ribes A, et al. **Rev Neurol** 1999 Jan 1–15;28(1):11–5 (27 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Respiratory chain complex in deficiency with pruritus: a novel vitamin responsive clinical feature. Mowat D, et al. **J Pediatr** 1999 Mar;134(3):352–4 (13 ref.)

ENZYMOLOGY

Carnitine-acylcarnitine translocase deficiency. Pande SV. **Am J Med Sci** 1999 Jul;318(1):22–7 (32 ref.)

ETIOLOGY

Inborn errors of bile acid biosynthesis and transport. Novel forms of metabolic liver disease. Balistreri WF. **Gastroenterol Clin North Am** 1999 Mar;28(1):145–72, vii (85 ref.)

GENETICS

Molecular mechanisms of cholestasis: causes and consequences of impaired bile formation. Koopen NR, et al. **Biochim Biophys Acta** 1998 Oct 22;1408(1):1–17 (209 ref.)
Mitochondrial genotype and clinical phenotype. Chinnery PF, et al. **J Inherit Metab Dis** 1998 Jun;21(4):321–5 (29 ref.)

METABOLISM

Other hereditary diseases and the liver. Poley JR, et al. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):369–407 (154 ref.)

PATHOLOGY

Histopathologic approach to metabolic liver disease: Part 2. Jevon GP, et al. **Pediatr Dev Pathol** 1998 Jul–Aug; 1(4):261–9 (37 ref.)

PHYSIOPATHOLOGY

Clinical manifestation of myeloperoxidase deficiency. Lanza F. **J Mol Med** 1998 Sep;76(10):676–81 (48 ref.)
[Hereditary metabolic diseases in adults] Saudubray JM, et al. **Rev Med Interne** 1998;19 Suppl 3:366S–375S (10 ref.) **(Fre)**

SURGERY

Liver transplant pathology in pediatric metabolic disorders. Jaffe R. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):102–17 (93 ref.)

THERAPY

Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Krivit W, et al. **Curr Opin Neurol** 1999 Apr; 12(2):167–76 (81 ref.)
Nontransplant alternatives for the treatment of patients with metabolic disease. Hesham A-Kader H, et al. **Semin Liver Dis** 1998;18(3):255–61 (38 ref.)
Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. Hyland K. **Semin Perinatol** 1999 Apr;23(2):194–203 (67 ref.)

METABOLITE MARKERS, NEOPLASM see **TUMOR MARKERS, BIOLOGICAL**

METABOTROPIC GLUTAMATE RECEPTORS see **RECEPTORS, METABOTROPIC GLUTAMATE**

METACARPOPHALANGEAL JOINT

INJURIES

Complete dorsal dislocation of the metacarpophalangeal joint of the thumb. Takami H, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):21–4 (10 ref.)
[Clenched fist injuries from teeth: not to be disregarded] van der Velde-Zimmermann D, et al. **Ned Tijdschr Geneeskd** 1998 Jun 6;142(23):1297–9 (5 ref.) (Eng. Abstr.) **(Dut)**

SURGERY

Arthroplasty of the hand and wrist: surgeon's perspective [see comments] Kozin SH. **J Hand Ther** 1999 Apr–Jun; 12(2):123–32 (63 ref.) Comment in: J Hand Ther 1999 Apr–Jun;12(2):133–4.

METACARPUS

Aetiopathogenesis of parasagittal fractures of the distal condyles of the third metacarpal and third metatarsal bones--review of the literature [see comments] Riggs CM. **Equine Vet J** 1999 Mar;31(2):116–20 (14 ref.) Comment in: Equine Vet J 1999 Mar;31(2):96.

ABNORMALITIES

Long first metacarpal in monozygotic twins with probable Baller-Gerold syndrome. Franceschini P, et al. **Am J Med Genet** 1998 Dec 4;80(4):303–8 (26 ref.)

INJURIES

Avulsion fracture of the second metacarpal base by the extensor carpi radialis longus. Takami H, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):109–10 (4 ref.)
Calving chain fractures. Radiographic assessment of healing. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):221–30, v (0 ref.)
[Are there guidelines for treatment of metacarpal fractures? Personal results and literature analysis of the last 12 years] Prokop A, et al. **Unfallchirurg** 1999 Jan;102(1):50–8 (34 ref.) (Eng. Abstr.) **(Ger)**

METAETHICS see **ETHICS**

METAGONIMIASIS see **TREMATODE INFECTIONS**

METAL ANTAGONISTS see **CHELATING AGENTS**

METAL METABOLISM, INBORN ERRORS

GENETICS

Genetic determinants of trace element metabolism. Templeton DM. **Ann Clin Lab Sci** 1999 Jan–Mar; 29(1):24–32 (76 ref.)
Inherited disorders of iron metabolism. Födinger M, et al. **Kidney Int Suppl** 1999 Mar;69:S22–34 (94 ref.)
[Mice with mottled mutation--a model for defective copper metabolism in humans] Lenartowicz M. **Postepy Hig Med Dosw** 1998;52(5):527–41 (45 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Genetic determinants of trace element metabolism. Templeton DM. **Ann Clin Lab Sci** 1999 Jan–Mar; 29(1):24–32 (76 ref.)

METALLO-ORGANIC COMPOUNDS see **ORGANOMETALLIC COMPOUNDS**

METALLOPORPHYRINS

[Optical oxygen sensing technology using methallo-porphyrins] Amao Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1492–6 (7 ref.) **(Jpn)**

THERAPEUTIC USE

Metalloporphyrin class of therapeutic catalytic antioxidants. Patel M, et al. **Trends Pharmacol Sci** 1999 Sep;20(9):359–64 (74 ref.)

METALLOPROTEASES see **METALLOPROTEINASES**

METALLOPROTEINASES

ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. Tang BL, et al. **FEBS Lett** 1999 Feb 26;445(2–3):223–5 (15 ref.)
[Matrix metalloproteases in digestive pathology] Aparicio T, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):330–41 (112 ref.) **(Fre)**

ANALYSIS

Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Chen WT, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:361–71 (52 ref.)
Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Zucker S, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:212–27 (75 ref.)
Metalloproteinases and tissue inhibitors of metalloproteinases. Toi M, et al. **Breast Cancer Res Treat** 1998;52(1–3):113–24 (89 ref.)

ANTAGONISTS & INHIBITORS

Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Arthur MJ, et al. **Alcohol Clin Exp Res** 1999 May;23(5):940–3 (28 ref.)
Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Kähäri VM, et al. **Ann Med** 1999 Feb;31(1):34–45 (129 ref.)
Insights into MMP-TIMP interactions. Bode W, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:73–91 (72 ref.)
The next generation of MMP inhibitors. Design and

synthesis. De B, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:40–60 (19 ref.)
Preclinical and clinical studies of MMP inhibitors in cancer. Drummond AH, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:228–35 (24 ref.)
The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Jones L, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:288–307 (127 ref.)
MMP inhibition in prostate cancer. Lokeshwar BL. **Ann N Y Acad Sci** 1999 Jun 30;878:271–89 (71 ref.)
Design and synthetic considerations of matrix metalloproteinase inhibitors. Skotnicki JS, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:61–72 (35 ref.)
Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Woessner JF Jr. **Ann N Y Acad Sci** 1999 Jun 30;878:388–403 (111 ref.)
Clinical studies with matrix metalloproteinase inhibitors. Brown PD. **APMIS** 1999 Jan;107(1):174–80 (41 ref.)
Roles of the matrix metalloproteinases in mammary gland development and cancer. Benaud C, et al. **Breast Cancer Res Treat** 1998 Jul;50(2):97–116 (142 ref.)
Matrix metalloproteinase inhibitors. Brown PD. **Breast Cancer Res Treat** 1998;52(1–3):125–36 (59 ref.)
Marimastat (BB2516): current status of development. Steward WP. **Cancer Chemother Pharmacol** 1999;43 Suppl:S56–60 (18 ref.)
Matrix metalloproteinases. Johnson LL, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):466–71 (51 ref.)
Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. George SJ. **Curr Opin Lipidol** 1998 Oct; 9(5):413–23 (134 ref.)
Novel approaches in development for the treatment of pancreatic cancer. Butera J, et al. **Front Biosci** 1998 Nov 1;3:E226–9 (45 ref.)
Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. Arthur MJ, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S33–8 (59 ref.)
[Matrix metalloproteinases. Potential targets for new treatments in inflammatory demyelinating diseases of the nervous system] Kieseier BC, et al. **Nervenarzt** 1999 Jun; 70(6):509–16 (54 ref.) (Eng. Abstr.) **(Ger)**
[Matrix metalloproteases and their inhibitors in the pleura] Eickelberg O, et al. **Pneumologie** 1998 Sep;52(9):526–30 (33 ref.) **(Ger)**

BIOSYNTHESIS

Matrix metalloproteinases and their expression in mammary gland. Uria JA, et al. **Cell Res** 1998 Sep;8(3):187–94 (20 ref.)

CHEMISTRY

Insights into MMP-TIMP interactions. Bode W, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:73–91 (72 ref.)
Structural properties of matrix metalloproteinases. Bode W, et al. **Cell Mol Life Sci** 1999 Apr;55(4):639–52 (89 ref.)
Snake venom hemorrhagins. Hati R, et al. **Crit Rev Toxicol** 1999 Jan;29(1):1–19 (142 ref.)
Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Pearce DA. **Hum Genet** 1999 Jun;104(6):443–8 (54 ref.)
Matrix metalloproteases: variations on a theme. Borkakoti N. **Prog Biophys Mol Biol** 1998;70(1):73–94 (76 ref.)

DEFICIENCY

Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Carmeliet P, et al. **Thromb Res** 1998 Sep 15;91(6):255–85 (254 ref.)

GENETICS

Extracellular matrix remodeling during morphogenesis. Werb Z, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:110–8 (33 ref.)
Matrix metalloproteinases and their inhibitors. Kugler A. **Anticancer Res** 1999 Mar–Apr;19(2C):1589–92 (21 ref.)
Regulation of matrix metalloproteinase expression in tumor invasion. Westermarck J, et al. **FASEB J** 1999 May; 13(8):781–92 (115 ref.)
Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Pearce DA. **Hum Genet** 1999 Jun;104(6):443–8 (54 ref.)
Matrix metalloproteinases. Nagase H, et al. **J Biol Chem** 1999 Jul 30;274(31):21491–4 (91 ref.)

IMMUNOLOGY

ADAM family proteins in the immune system. Yamamoto S, et al. **Immunol Today** 1999 Jun;20(6):278–84 (54 ref.)
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. Cuzner ML, et al. **J Neuroimmunol** 1999 Feb 1;94(1–2):1–14 (111 ref.)

METABOLISM

Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Kähäri VM, et al. **Ann Med** 1999 Feb;31(1):34–45 (129 ref.)
Tissue inhibitors of matrix metalloproteinases in cancer. Blavier L, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:108–19 (60 ref.)
Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Killar L, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:442–52 (69 ref.)
The significance of matrix metalloproteinases during early stages of tumor progression. Lochter A, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:180–93 (54 ref.)
Evaluation of some newer matrix metalloproteinases. Murphy G, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:25–39 (29 ref.)
Engineering of selective TIMPs. Nagase H, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:1–11 (32 ref.)
Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Pilcher BK, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:12–24 (34 ref.)
Matrix metalloproteinases and their inhibitors. Kugler A. **Anticancer Res** 1999 Mar–Apr;19(2C):1589–92 (21 ref.)
Mechanisms for pro matrix metalloproteinase activation. Murphy G, et al. **APMIS** 1999 Jan;107(1):38–44 (49 ref.)
Characterization of the tumour necrosis factor alpha-converting enzyme, TACE/ADAM17. Cerretti DP. **Biochem Soc Trans** 1999 Feb;27(2):219–23 (20 ref.)
Roles of the matrix metalloproteinases in mammary gland development and cancer. Benaud C, et al. **Breast Cancer Res Treat** 1998 Jul;50(2):97–116 (142 ref.)
Matrix metalloproteinases and metastasis. Kleiner DE, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S42–51 (67 ref.)
Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. Miyazaki K, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S52–5 (33 ref.)
Cell surface activation of progelatinase A (proMMP-2) and cell migration. Nagase H. **Cell Res** 1998 Sep;8(3):179–86 (20 ref.)
Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds [editorial] Mann DL, et al. **Circulation** 1998 Oct 27;98(17):1699–702 (20 ref.)
ADAMs: focus on the protease domain. Black RA, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):654–9 (41 ref.)
Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Shapiro SD. **Curr Opin Cell Biol** 1998 Oct;10(5):602–8 (51 ref.)
Matrix metalloproteinases. Johnson LL, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):466–71 (51 ref.)
BMPs, Smads and metalloproteases: extracellular and intracellular modes of negative regulation. Cho KW, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):443–9 (55 ref.)
Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. George SJ. **Curr Opin Lipidol** 1998 Oct; 9(5):413–23 (134 ref.)
Matrix metalloproteinases, prostaglandins and endothelins: paracrine regulators of implantation. Cameron IT. **Gynecol Endocrinol** 1998 Dec;12(6):415–9 (38 ref.)
Matrix-metalloproteinases in bronchopulmonary carcinomas. Martinella-Catusse C, et al. **Histol Histopathol** 1999 Jul; 14(3):839–43 (27 ref.)
Matrix metalloproteinases. Nagase H, et al. **J Biol Chem** 1999 Jul 30;274(31):21491–4 (91 ref.)
Matrix metalloproteinases in cerebrovascular disease. Mun-Bryce S, et al. **J Cereb Blood Flow Metab** 1998 Nov; 18(11):1163–72 (84 ref.)
Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. Bramhall SR. **J Hepatobiliary Pancreat Surg** 1998;5(4):392–401 (108 ref.)
Metalloproteinases in the pathogenesis of diabetic nephropathy [editorial] Suzuki D. **Nephron** 1998 Oct; 80(2):125–33 (88 ref.)
Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Kieseier BC, et al. **Neurology** 1999 Jul 13;53(1):20–5 (49 ref.)
Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives. Roques BP. **Pathol Biol (Paris)** 1998 Mar;46(3):191–200 (31 ref.)
Matrix metalloproteases: variations on a theme. Borkakoti N. **Prog Biophys Mol Biol** 1998;70(1):73–94 (76 ref.)
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Cox G, et al. **Thorax** 1999 Feb; 54(2):169–79 (208 ref.)
Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Pérez JC, et al. **Toxicon** 1999 May;37(5):703–28 (116 ref.)
[Matrix metalloproteinases. Potential targets for new treatments in inflammatory demyelinating diseases of the nervous system] Kieseier BC, et al. **Nervenarzt** 1999 Jun; 70(6):509–16 (54 ref.) (Eng. Abstr.) **(Ger)**
[Matrix metalloproteases and their inhibitors in the pleura] Eickelberg O, et al. **Pneumologie** 1998 Sep;52(9):526–30 (33 ref.) **(Ger)**

PHARMACOLOGY

Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Pellizzari R, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):259–68 (149 ref.)

PHYSIOLOGY

Matrix metalloproteinases. Matrix degradation and more. Shapiro SD, et al. **Am J Respir Cell Mol Biol** 1999 Jun; 20(6):1100–2 (10 ref.)
Matrilysin in early stage intestinal tumorigenesis. Fingleton BM, et al. **APMIS** 1999 Jan;107(1):102–10 (50 ref.)
An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. Lochter A, et al. **APMIS** 1999 Jan; 107(1):128–36 (96 ref.)
Mechanisms for pro matrix metalloproteinase activation. Murphy G, et al. **APMIS** 1999 Jan;107(1):38–44 (49 ref.)
Membrane-type matrix metalloproteinases. Seiki M. **APMIS** 1999 Jan;107(1):137–43 (60 ref.)
Matrix-degrading proteases and angiogenesis during development and tumor formation. Werb Z, et al. **APMIS** 1999 Jan;107(1):11–8 (28 ref.)
Mammalian sperm-egg recognition: does fertilin beta have a major role to play? Frayne J, et al. **Bioessays** 1999 Mar; 21(3):183–7 (20 ref.)
Complex role of matrix metalloproteinases in angiogenesis. Sang QX. **Cell Res** 1998 Sep;8(3):171–7 (20 ref.)
Proteinase-antiproteinase imbalance in the pathogenesis of emphysema: the role of metalloproteinases in lung damage. Pardo A, et al. **Histol Histopathol** 1999 Jan;14(1):227–33 (76 ref.)
Membrane-type metalloproteinases in tumor invasion. Polette M, et al. **Int J Biochem Cell Biol** 1998 Nov; 30(11):1195–202 (42 ref.)
New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Clark AF. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2514–6 (22 ref.)
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. Stetler-Stevenson WG. **J Clin Invest** 1999 May;103(9):1237–41 (24 ref.)
Dissemination of T cell lymphoma to target organs: a post-homing event implicating ICAM-1 and matrix metalloproteinases. St-Pierre Y, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):53–61 (55 ref.)
Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Shah PK. **Vasc Med** 1998; 3(3):199–206 (91 ref.)
[Focalized matrix proteolysis and inflammation] Gaudin P, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec;56(6):661–9 (62 ref.) (Eng. Abstr.) **(Fre)**
[Integrins and metalloproteinases: an efficient collaboration in the invasive process] Rémy L, et al. **Bull Cancer** 1999 Feb;86(2):154–8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Implication of VEGF and MMPs in hepatic metastasis of human colon cancer] Arii S, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):436–40 (8 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis (Review). Weeks BS. **Int J Mol Med** 1998 Feb;1(2):361–6 (54 ref.)

THERAPEUTIC USE

[Staphylokinase] Helft G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):582–8 (35 ref.) (Eng. Abstr.) **(Fre)**

METALLOPROTEINS

Metallo-beta-lactamases: a class apart. Bush K. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S48–53 (51 ref.)

CHEMISTRY

Quadrupolar metal ion NMR studies of metalloproteins. Aramini JM, et al. **Biochem Cell Biol** 1998;76(2–3):210–22 (80 ref.)
NMR spectroscopic studies of I = 1/2 metal ions in biological systems. Oz G, et al. **Biochem Cell Biol** 1998; 76(2–3):223–34 (88 ref.)
A structural comparison of molybdenum cofactor-containing enzymes. Kisker C, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):503–21 (73 ref.)
Effects of nitric oxide on iron or hemoprotein-catalyzed oxidative reactions. Jourd'heuil D, et al. **Methods Enzymol** 1999;301:437–44 (20 ref.)

METABOLISM

Dimethylsulphoxide reductase from purple phototrophic bacteria: structures and mechanism(s). McEwan AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):390–6 (34 ref.)
CuI-semiquinone radical species in plant copper-amine oxidases. Medda R, et al. **FEBS Lett** 1999 Jun 18; 453(1–2):1–5 (32 ref.)
The mechanism of "Fenton-like" reactions and their importance for biological systems. A biologist's view. Liochev SI. **Met Ions Biol Syst** 1999;36:1–39 (169 ref.)

PHYSIOLOGY

Role of metalloproteinases in liver fibrosis. Rojkind M. **Alcohol Clin Exp Res** 1999 May;23(5):934–9 (50 ref.)
[Synergistic function of TAL1 and LMO in hematopoietic differentiation and T cell tumorigenesis] Ono Y. **Seikagaku** 1999 Apr;71(4):269–73 (18 ref.) **(Jpn)**

METALLOTHIONEIN

BIOSYNTHESIS

Induction of metallothionein by stress and its molecular mechanisms. Jacob ST, et al. **Gene Expr** 1999;7(4–6):301–10 (56 ref.)
Regulation of the synthesis of brain metallothioneins. Hidalgo J, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):661–6 (56 ref.)
[Metallothionein and carcinogenesis] Deng XZ, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):356–8 (7 ref.) **(Chi)**

CHEMISTRY

Application of 113Cd NMR to metallothioneins. Vašák M. **Biodegradation** 1998;9(6):501–12 (28 ref.)
[Plant metallothioneins] Ruchko MV, et al. **Ukr Biokhim Zh** 1998 Nov–Dec;70(6):24–34 (63 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Metal regulation of metallothionein gene transcription in mammals. Remondelli P, et al. **Adv Exp Med Biol** 1999; 448:223–36 (54 ref.)

IMMUNOLOGY

Zinc, T-cell pathways, aging: role of metallothioneins. Mocchegiani E, et al. **Mech Ageing Dev** 1998 Dec 1; 106(1–2):183–204 (117 ref.)

METABOLISM

Bioaccumulation of heavy metals with protein fusions of metallothionein to bacterial OMPs. Valls M, et al. **Biochimie** 1998 Oct;80(10):855–61 (35 ref.)
Metallothionein (MT) isoforms in the central nervous system (CNS): regional and cell-specific distribution and potential functions as an antioxidant. Aschner M. **Neurotoxicology** 1998 Aug–Oct;19(4–5):653–60 (77 ref.)
Toxicokinetics and biochemistry of cadmium with special emphasis on the role of metallothionein. Jin T, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):529–35 (70 ref.)

PHYSIOLOGY

Metallothionein: an intracellular protein to protect against cadmium toxicity. Klaassen CD, et al. **Annu Rev Pharmacol Toxicol** 1999;39:267–94 (205 ref.)
Metallothionein transgenic and knock-out mouse models in the study of cadmium toxicity. Klaassen CD, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:97–102 (24 ref.)
Metallothionein (MT) isoforms in the central nervous system (CNS): regional and cell-specific distribution and potential functions as an antioxidant. Aschner M. **Neurotoxicology** 1998 Aug–Oct;19(4–5):653–60 (77 ref.)
Metallothionein in radiation exposure: its induction and protective role. Cai L, et al. **Toxicology** 1999 Feb 15; 132(2–3):85–98 (102 ref.)

METALLURGY

A metallurgical approach to metal contact dermatitis. Flint GN. **Contact Dermatitis** 1998 Nov;39(5):213–21 (50 ref.)

METALS

see related

ORGANOMETALLIC COMPOUNDS

Transition-metal-mediated reactions in combinatorial synthesis. Andres CJ, et al. **Curr Opin Chem Biol** 1998 Jun; 2(3):353–62 (41 ref.)
Combinatorial libraries of transition-metal complexes, catalysts and materials. Francis MB, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):422–8 (19 ref.)
Metal stents for benign and malignant bile duct strictures stents for benign and malignant bile duct strictures. Rösch T. **Endoscopy** 1998 Nov;30(9):A247–52 (64 ref.)
Involvement of metal ions in lipid peroxidation: biological implications. Sergent O, et al. **Met Ions Biol Syst** 1999; 36:251–87 (188 ref.)
A review of metallic, ceramic and surface-treated metals used for bearing surfaces in human joint replacements. Dearnley PA. **Proc Inst Mech Eng [H]** 1999;213(2):107–35 (87 ref.)
Metals that cause sarcoidosis. Newman LS. **Semin Respir Infect** 1998 Sep;13(3):212–20 (88 ref.)
[Self-expanding metallic stents in the palliative treatment of colorectal neoplastic stenoses. Report of two cases] el Khaddari S, et al. **Gastroenterol Clin Biol** 1999 May; 23(5):569–72 (13 ref.) (Eng. Abstr.) **(Fre)**
[Metal stents in the biliopancreatic duct system--assessment of current status] Hoepffner N, et al. **Z Gastroenterol** 1998 Dec;36(12):1059–73 (123 ref.) (Eng. Abstr.) **(Ger)**
[Percutaneous transhepatic metal stents in therapy of bile duct stenoses] von Bubnoff AC, et al. **Z Gastroenterol** 1998 Dec;36(12):1037–46 (36 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

A metallurgical approach to metal contact dermatitis. Flint GN. **Contact Dermatitis** 1998 Nov;39(5):213–21 (50 ref.)
Are metals dietary carcinogens? Rojas E, et al. **Mutat Res** 1999 Jul 15;443(1–2):157–81 (260 ref.)
Carcinogenic metals. Costa M. **Sci Prog** 1998;81 (Pt 4):329–39 (19 ref.)

ANALYSIS

Flame, flameless, and plasma spectroscopy. Komaromy-Hiller G. **Anal Chem** 1999 Jun 15; 71(12):338R–342R (127 ref.)
Advances in instrumental methods for the measurement and speciation of trace metals. Savory J, et al. **Ann Clin Lab Sci** 1999 Apr–Jun;29(2):118–26 (47 ref.)
Chemical modification of analytes in speciation analysis by capillary electrophoresis, liquid chromatography and gas chromatography. Liu W, et al. **J Chromatogr A** 1999 Feb 26;834(1–2):45–63 (123 ref.)
Liquid chromatography: a tool for the analysis of metal species. Sarzanini C. **J Chromatogr A** 1999 Jul 30; 850(1–2):213–28 (141 ref.)
Are metals dietary carcinogens? Rojas E, et al. **Mutat Res** 1999 Jul 15;443(1–2):157–81 (260 ref.)

CHEMISTRY

A metallurgical approach to metal contact dermatitis. Flint GN. **Contact Dermatitis** 1998 Nov;39(5):213–21 (50 ref.)
Dynamic kinetic resolution. Gihani MT, et al. **Curr Opin Chem Biol** 1999 Feb;3(1):11–5 (19 ref.)
Chemical modification of analytes in speciation analysis by capillary electrophoresis, liquid chromatography and gas chromatography. Liu W, et al. **J Chromatogr A** 1999 Feb 26;834(1–2):45–63 (123 ref.)
Metal-catalyzed asymmetric oxidations. Bolm C. **Med Res Rev** 1999 Sep;19(5):348–56 (47 ref.)
Inorganic semiconductors as photosensitizers in biochemical redox reactions. Nikandrov VV. **Membr Cell Biol** 1998; 12(5):755–69 (47 ref.)
The efficacy of paramagnetic ions on spin lattice relaxation time in biological systems. Akber SF. **Physiol Chem Phys Med NMR** 1998;30(2):175–84 (38 ref.)

METABOLISM

Structure and function of metal chelators produced by plants: the case for organic acids, amino acids, phytin, and metallothioneins. Rauser WE. **Cell Biochem Biophys** 1999; 31(1):19–48 (174 ref.)
Combinatorial libraries: studies in molecular recognition. Nestler HP, et al. **Comb Chem High Throughput Screen** 1998 Oct;1(3):113–26 (129 ref.)
Developments in terrestrial bacterial remediation of metals. Stephen JR, et al. **Curr Opin Biotechnol** 1999 Jun; 10(3):230–3 (36 ref.)
Redox metals and neurodegenerative disease. Sayre LM, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):220–5 (48 ref.)
Metal ion transporters and homeostasis. Nelson N. **EMBO J** 1999 Aug 16;18(16):4361–71 (106 ref.)
Cellular thiol production and oxidation of low-density lipoprotein. Graham A. **Free Radic Res** 1998 Jun; 28(6):611–21 (105 ref.)
Regulation of transition metal transport across the yeast plasma membrane. Radisky D, et al. **J Biol Chem** 1999 Feb 19;274(8):4481–4 (42 ref.)
Sequence analyses and phylogenetic characterization of the ZIP family of metal ion transport proteins. Eng BH, et al. **J Membr Biol** 1998 Nov 1;166(1):1–7 (24 ref.)
Asymmetric DDE (D35E)-like sequences in the RAG proteins: implications for V(D)J recombination and retroviral pathogenesis. Dreyfus DH, et al. **Med Hypotheses** 1999 Jun;52(6):545–9 (32 ref.)
Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Atwood CS, et al. **Met Ions Biol Syst** 1999;36:309–64 (317 ref.)
Thiyl radicals in biochemically important thiols in the presence of metal ions. Hartmann HJ, et al. **Met Ions Biol Syst** 1999;36:389–413 (81 ref.)
Detection of chromatin-associated hydroxyl radicals generated by DNA-bound metal compounds and antitumor antibiotics. Makrigiorgos GM. **Met Ions Biol Syst** 1999; 36:521–45 (75 ref.)
Metal binding and radical generation of proteins in human neurological diseases and aging. Multhaup G, et al. **Met Ions Biol Syst** 1999;36:365–87 (105 ref.)
Recent advances in the mechanistic understanding of metal mobility and interaction with microbial biomass. Tsezos M, et al. **Res Microbiol** 1997 Jul–Aug;148(6):515–7 (13 ref.)
Multivariate analysis of metal concentration profiles in mushrooms. Siobud-Dorocant E, et al. **SAR QSAR Environ Res** 1999;10(4):315–70 (155 ref.)
[Chemical elements in hair--biochemical and diagnostic aspects] Karczewski JK. **Postepy Hig Med Dosw** 1998; 52(3):283–95 (38 ref.) (Eng. Abstr.) **(Pol)**
[Effect of transition metal cations on Na+-Ca2+-exchange in cell membrane] Man'ko VV. **Ukr Biokhim Zh** 1998 Nov–Dec;70(6):3–12 (78 ref.) (Eng. Abstr.) **(Ukr)**

PHARMACOKINETICS

Uptake of metals in the brain via olfactory pathways. Tjälve H, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):181–95 (110 ref.)

PHARMACOLOGY

Metal-catalysed cleavage of Na,K-ATPase as a tool for study of structure-function relations. Goldshleger R, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:89–97 (24 ref.)
Experimental study of oxidative DNA damage. Loft S, et al. **Free Radic Res** 1998 Dec;29(6):525–39 (149 ref.)

POISONING

[Metal poisoning] Inoue N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):618–22 (12 ref.) **(Jpn)**

TOXICITY

Plant responses to metal toxicity. Briat JF, et al. **C R Acad Sci III** 1999 Jan;322(1):43–54 (130 ref.)
Role of free radicals in metal-induced carcinogenesis. Landolph JR. **Met Ions Biol Syst** 1999;36:445–83 (67 ref.)
Carcinogenicity of metal compounds: possible role of DNA repair inhibition. Hartwig A. **Toxicol Lett** 1998 Dec 28; 102–103:235–9 (20 ref.)

METALS, HEAVY

Multiple stressors in the Sacramento River watershed. Hinton DE. **EXS** 1998;86:303–17 (58 ref.)
Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Gerhard I, et al. **Hum Reprod Update** 1998 May–Jun;4(3):301–9 (56 ref.)

ADVERSE EFFECTS

[The effect of heavy metals (lead, cadmium, and manganese) on the function of the visual system] Mulak M. **Med Pr** 1998;49(6):603–7 (28 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Chelant extraction of heavy metals from contaminated soils. Peters RW. **J Hazard Mater** 1999 Apr 23;66(1–2):151–210 (91 ref.)
Organochlorine residues and elemental contaminants in U.S. freshwater fish, 1976–1986: National Contaminant Biomonitoring Program. Schmitt CJ, et al. **Rev Environ Contam Toxicol** 1999;162:43–104 (160 ref.)

CHEMISTRY

Chelant extraction of heavy metals from contaminated soils. Peters RW. **J Hazard Mater** 1999 Apr 23;66(1–2):151–210 (91 ref.)

METABOLISM

Effects of processing of heavy metal content of foods. Morgan JN. **Adv Exp Med Biol** 1999;459:195–211 (25 ref.)
Metal contaminated soil--is natural attenuation acceptable? Eccles H. **Biochem Soc Trans** 1998 Nov;26(4):657–61 (10 ref.)
Fungi as potential bioremediation agents in soil contaminated with heavy or radioactive metals. Gray SN. **Biochem Soc Trans** 1998 Nov;26(4):666–70 (34 ref.)
Bioaccumulation of heavy metals with protein fusions of metallothionein to bacterial OMPs. Valls M, et al. **Biochimie** 1998 Oct;80(10):855–61 (35 ref.)
Transition metal ion-catalyzed oxygen activation during pathogenic processes. Hippeli S, et al. **FEBS Lett** 1999 Jan 22;443(1):1–7 (88 ref.)
Families of soft-metal-ion-transporting ATPases. Rensing C, et al. **J Bacteriol** 1999 Oct;181(19):5891–7 (63 ref.)
Alcaligenes eutrophus as a model system for bacterial interactions with heavy metals in the environment. Taghavi S, et al. **Res Microbiol** 1997 Jul–Aug;148(6):536–51 (95 ref.)

PHARMACOLOGY

Microbial heavy-metal resistance. Nies DH. **Appl Microbiol Biotechnol** 1999 Jun;51(6):730–50 (260 ref.)
Heavy metal resistance genes and proteins in bacteria and their application. Brown NL, et al. **Biochem Soc Trans** 1998 Nov;26(4):662–5 (32 ref.)

THERAPEUTIC USE

Medicinal applications of heavy-metal compounds. Reedijk J. **Curr Opin Chem Biol** 1999 Apr;3(2):236–40 (44 ref.)

METALS, LIGHT

ADVERSE EFFECTS

Gold allergy and artificial sweat [letter] Möller H, et al. **Contact Dermatitis** 1999 Jul;41(1):57–60 (16 ref.)

METAMORPHOSIS, BIOLOGICAL

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Ann Endocrinol (Paris)** 1998;59(6):433–42 (56 ref.)

GENETICS

Isolation of genes involved in intestinal remodeling during anuran metamorphosis. Amano T. **Wound Repair Regen** 1998 Jul–Aug;6(4):302–13 (80 ref.)
Thyroid hormone regulation of Xenopus laevis metamorphosis: functions of thyroid hormone receptors and roles of extracellular matrix remodeling. Shi YB, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):314–22 (63 ref.)

METAMORPHOSIS, BIOLOGICAL

IMMUNOLOGY

Metamorphosis and the amphibian immune system. Rollins-Smith LA. **Immunol Rev** 1998 Dec;166:221-30 (140 ref.)

PHYSIOLOGY

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Biochimie** 1999 Apr;81(4):359-66 (63 ref.)

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Cell Res** 1998 Dec;8(4):259-72 (63 ref.)

The molecular basis of thyroid hormone-dependent central nervous system remodeling during amphibian metamorphosis. Denver RJ. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):219-28 (101 ref.)

Molecular and cellular basis of tissue remodeling during amphibian metamorphosis. Su Y, et al. **Histol Histopathol** 1999 Jan;14(1):175-83 (83 ref.)

[Marine natural products influencing larval settlement and metamorphosis of marine sessile organisms] Tsukamoto S. **Yakugaku Zasshi** 1999 Jul;119(7):457-71 (45 ref.) (Eng. Abstr.) **(Jpn)**

METANDIENONE see **METHANDROSTENOLONE**

METAPHASE

Towards a unifying model for the metaphase/anaphase transition. Kirsch-Volders M, et al. **Mutagenesis** 1998 Jul; 13(4):321-35 (137 ref.)

PHYSIOLOGY

The metaphase to anaphase transition: a case of productive destruction. Farr KA, et al. **Eur J Biochem** 1999 Jul; 263(1):14-9 (52 ref.)

METAPHOR

The Cartesian clock metaphor for pineal gland operation pervades the origin of modern chronobiology. Barrera-Mera B, et al. **Neurosci Biobehav Rev** 1998; 23(1):1-4 (35 ref.)

Meaning and metaphor in psychoanalytic education. Gargiulo GJ. **Psychoanal Rev** 1998 Jun;85(3):413-22 (8 ref.)

METAPHOS see **METHYL PARATHION**

METAPLASIA

see related
MYELOID METAPLASIA

ETIOLOGY

Stress: metaplastic effects in the hippocampus. Kim JJ, et al. **Trends Neurosci** 1998 Dec;21(12):505-9 (61 ref.)

METAPROTERENOL see **ORCIPRENALINE**

METASTASIS see **NEOPLASM METASTASIS**

METATARSAL BONES

Aetiopathogenesis of parasagittal fractures of the distal condyles of the third metacarpal and third metatarsal bones--review of the literature [see comments] Riggs CM. **Equine Vet J** 1999 Mar;31(2):116-20 (14 ref.) Comment in: Equine Vet J 1999 Mar;31(2):96.

ABNORMALITIES

Brachymetatarsia: congenitally short third and fourth metatarsals treated by distraction lengthening--a case report and literature summary. Robinson JF, et al. **Foot Ankle Int** 1998 Oct;19(10):713-8 (42 ref.)

INJURIES

Fractures of the proximal fifth metatarsal. Strayer SM, et al. **Am Fam Physician** 1999 May 1;59(9):2516-22 (17 ref.)

Calving chain fractures. Radiographic assessment of healing. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):221-30, v (0 ref.)

[Injuries of the tarsus and mid-foot] Randt T, et al. **Unfallchirurg** 1998 Dec;101(12):935-49; quiz 949 (14 ref.) **(Ger)**

PATHOLOGY

Metastatic prostate carcinoma to the foot with magnetic resonance imaging and pathologic correlation. Schwartz ED, et al. **Foot Ankle Int** 1998 Sep;19(9):594-7 (14 ref.)

SURGERY

Brachymetatarsia: congenitally short third and fourth metatarsals treated by distraction lengthening--a case report and literature summary. Robinson JF, et al. **Foot Ankle Int** 1998 Oct;19(10):713-8 (42 ref.)

Bilateral sudden sensorineural hearing loss following non-otologic surgery. de la Cruz M, et al. **J Laryngol Otol** 1998 Aug;112(8):769-71 (16 ref.)

METATARSAL DEFORMITY see **FOOT DEFORMITIES**

METATARSALS see **METATARSAL BONES**

METATARSOPHALANGEAL JOINT

Great toe neuroarthropathy: a report of two cases. Beals TC, et al. **Foot Ankle Int** 1998 Sep;19(9):631-3 (6 ref.)

Disorders of the hallux sesamoid complex: MR features. Karasick D, et al. **Skeletal Radiol** 1998 Aug;27(8):411-8 (30 ref.)

ABNORMALITIES

An accessory ossification centre in the calcaneus with talonavicular and second metatarsocuneiform coalitions. Turhan AU, et al. **Eur Radiol** 1999;9(3):481-2 (4 ref.)

SURGERY

Arthroscopy of the great toe. Frey C, et al. **Instr Course Lect** 1999;48:343-6 (4 ref.)

[Experimental and clinical studies of small joint transplantation] Chen M, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1997 May;13(3):205-7 (23 ref.) **(Chi)**

METATARSUS

see related
METATARSAL BONES

METENCEPHALON see **PONS**

METEORITES see **METEOROIDS**

METEOROIDS

Life on Mars: chemical arguments and clues from Martian meteorites. Brack A, et al. **Extremophiles** 1998 Aug; 2(3):313-9 (44 ref.)

Carbonaceous micrometeorites and the origin of life. Maurette M. **Orig Life Evol Biosph** 1998 Oct; 28(4-6):385-412 (68 ref.)

METEOROLOGICAL FACTORS

[Heliogeophysical factors and ENT diseases] Kubyshkina IV. **Vestn Otorinolaringol** 1998;(6):54-6 (39 ref.) **(Rus)**

METEORS see **METEOROIDS**

METFORMIN

ADVERSE EFFECTS

Metformin and contrast media--a dangerous combination? McCartney MM, et al. **Clin Radiol** 1999 Jan;54(1):29-33 (37 ref.)

Metformin-associated lactic acidosis: a rare or very rare clinical entity? Chan NN, et al. **Diabet Med** 1999 Apr; 16(4):273-81 (123 ref.)

PHARMACOLOGY

Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Wiernsperger NF. **Diabetes Metab** 1999 Jun;25(2):110-27 (174 ref.)

A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate. McCarty MF. **Med Hypotheses** 1999 Feb;52(2):89-93 (41 ref.)

THERAPEUTIC USE

A risk-benefit assessment of metformin in type 2 diabetes mellitus. Howlett HC, et al. **Drug Saf** 1999 Jun; 20(6):489-503 (183 ref.)

[Therapeutic utility of biguanides in the treatment of NIDDM] Fujimoto S. **Nippon Rinsho** 1999 Mar; 57(3):657-62 (15 ref.) (Eng. Abstr.) **(Jpn)**

METHACRYLATES

ADVERSE EFFECTS

Allergic contact dermatitis from 2-hydroxyethyl methacrylate in an adhesive on an electrosurgical earthing plate. Kanerva L, et al. **Eur J Dermatol** 1998 Oct-Nov; 8(7):521-4 (31 ref.)

PHARMACOLOGY

Review of the biological response to a novel bone cement containing poly(ethyl methacrylate) and n-butyl methacrylate. Revell PA, et al. **Biomaterials** 1998 Sep; 19(17):1579-86 (24 ref.)

METHADONE

ADMINISTRATION & DOSAGE

Treatment considerations in the opioid dependent patient. Wartenberg AA. **Med Health R I** 1999 Mar;82(3):91-4 (20 ref.)

Effectiveness of methadone maintenance for heroin addiction. Murray JB. **Psychol Rep** 1998 Aug;83(1):295-302 (50 ref.)

METABOLISM

[Drug interactions of methadone with CNS-active agents] Moreno Brea MR, et al. **Actas Esp Psiquiatr** 1999 Mar-Apr; 27(2):103-10 (61 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

The methadone-maintained pregnancy. Kandall SR, et al. **Clin Perinatol** 1999 Mar;26(1):173-83 (63 ref.)

Methadone in the management of narcotic addiction in pregnancy [editorial] Archie C. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):435-40 (25 ref.)

NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. **Eur Addict Res** 1999 Mar;5(1):50-1 (0 ref.)

Therapeutic drug monitoring for methadone: scanning the horizon. Wolff K, et al. **Eur Addict Res** 1999 Mar;5(1):36-42 (85 ref.)

Methadone: where are we now? Henry JA. **Hosp Med** 1999 Mar;60(3):161-4 (15 ref.)

Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment [see comments] Lewis DC. **J Addict Dis** 1999; 18(2):5-21 (82 ref.) Comment in: J Addict Dis 1999 ;18(2):1-4.

Methadone patients and alcohol abuse. Ottomanelli G. **J Subst Abuse Treat** 1999 Mar;16(2):113-21 (33 ref.)

Role of maintenance treatment in opioid dependence [see comments] Ward J, et al. **Lancet** 1999 Jan 16; 353(9148):221-6 (48 ref.) Comment in: Lancet 1999 Mar 27;353(9158):1101. Comment in: Lancet 1999 Apr 10;353(9160):1278.

[Substitution therapy of drug addicts] Weber JC, et al. **Presse Med** 1998 Dec 12;27(39):2088-99 (108 ref.) (Eng. Abstr.) **(Fre)**

[The practitioner and reduction of risks] Leckie M. **Rev Med Suisse Romande** 1998 Sep;118(9):739-42 (12 ref.) **(Fre)**

[Drug substitution in heroin dependence with methadone] Krausz M, et al. **Internist (Berl)** 1999 Jun;40(6):645-50 (27 ref.) **(Ger)**

[What effects does methadone maintenance treatment have on the rehabilitation of heroin addicts? (see comments)] Hermstad R, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30; 118(20):3139-41 (30 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1998 Sep 30;118(23):3673. **(Nor)**

[Use of methadone in the treatment of narcotic addiction] Tiljak H. **Lijec Vjesn** 1998 May;120(5):125-31 (79 ref.) (Eng. Abstr.) **(Scr)**

[Drug interactions of methadone with CNS-active agents] Moreno Brea MR, et al. **Actas Esp Psiquiatr** 1999 Mar-Apr; 27(2):103-10 (61 ref.) (Eng. Abstr.) **(Spa)**

METHADYL ACETATE

ADMINISTRATION & DOSAGE

Treatment considerations in the opioid dependent patient. Wartenberg AA. **Med Health R I** 1999 Mar;82(3):91-4 (20 ref.)

METHAMPHETAMINE

ANALYSIS

Methamphetamine--properties and analytical methods of enantiomer determination. Jirovský D, et al. **Forensic Sci Int** 1998 Aug 31;96(1):61-70 (79 ref.)

CHEMISTRY

Methamphetamine and the expanding complications of amphetamines [see comments] Albertson TE, et al. **West J Med** 1999 Apr;170(4):214-9 (83 ref.) Comment in: West J Med 1999 Apr;170(4):232.

METABOLISM

Methamphetamine--properties and analytical methods of enantiomer determination. Jirovský D, et al. **Forensic Sci Int** 1998 Aug 31;96(1):61-70 (79 ref.)

METHANDIENONE see **METHANDROSTENOLONE**

METHANDROSTENOLONE

ADVERSE EFFECTS

[Severe cholestasis with kidney failure from anabolic steroids in a body builder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Sep 10;124(36):1029-32 (17 ref.) (Eng. Abstr.) **(Ger)**

METHANE

METABOLISM

Enzymology of one-carbon metabolism in methanogenic pathways. Ferry JG. **FEMS Microbiol Rev** 1999 Jan; 23(1):13-38 (141 ref.)

Biochemistry of methanogenesis: a tribute to Marjory

Stephenson. 1998 Marjory Stephenson Prize Lecture. Thauer RK. **Microbiology** 1998 Sep;144 (Pt 9):2377–406 (319 ref.)
[The biology of bacteria that assimilate C1—C2 compounds and the biotechnology aspects of their use] Malashenko IuP, et al. **Mikrobiol Z** 1998 Nov–Dec;60(6):38–55 (67 ref.) (Eng. Abstr.) **(Rus)**

METHANE-OXIDIZING BACTERIA see **METHYLOCOCCACEAE**

METHANOBACTERIA see **METHANOGENS**

METHANOCOCCUS

GENETICS

Genetics of Methanococcus: possibilities for functional genomics in Archaea. Tumbula DL, et al. **Mol Microbiol** 1999 Jul;33(1):1–7 (39 ref.)

METHANOGENS

ENZYMOLOGY

Structure and function of the A1A0-ATPases from methanogenic Archaea. Müller V, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):15–27 (84 ref.)

METABOLISM

Novel reactions involved in energy conservation by methanogenic archaea. Deppenmeier U, et al. **FEBS Lett** 1999 Sep 3;457(3):291–7 (49 ref.)
Biochemistry of methanogenesis: a tribute to Marjory Stephenson. 1998 Marjory Stephenson Prize Lecture. Thauer RK. **Microbiology** 1998 Sep;144 (Pt 9):2377–406 (319 ref.)

METHANOL

POISONING

[Motor neuropathy, putamen necrosis and optic nerve atrophy after acute methanol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1998 Dec;154(12):862–5 (12 ref.) (Eng. Abstr.) **(Fre)**
[Methanol intoxication] Hashiguchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):67–9 (15 ref.) **(Jpn)**

METHANOMONADACEAE see **METHYLOCOCCACEAE**

METHBIPYRANONE see **METYRAPONE**

METHEMOGLOBIN

METABOLISM

Formation of methemoglobin and free radicals in erythrocytes. Nohl H, et al. **Met Ions Biol Syst** 1999; 36:289–307 (30 ref.)

METHEMOGLOBINEMIA

CHEMICALLY INDUCED

The toxicology of silver nitrate. Humphreys SD, et al. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep; 17(2–3):115–43 (91 ref.)
When patients become cyanotic: acquired methemoglobinemia. Wilburn-Goo D, et al. **J Am Dent Assoc** 1999 Jun;130(6):826–31 (25 ref.)

ETIOLOGY

Infantile methemoglobinemia: reexamining the role of drinking water nitrates. Avery AA. **Environ Health Perspect** 1999 Jul;107(7):583–6 (37 ref.)

METHICILLIN

see related
METHICILLIN RESISTANCE

PHARMACOLOGY

Phenotypic characteristics of coagulase-negative staphylococci: typing and antibiotic susceptibility. Jarløv JO. **APMIS Suppl** 1999;91:1–42 (92 ref.)

THERAPEUTIC USE

Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis—a novel hazard emerging on the horizon [editorial] Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):2999–3001 (14 ref.)

METHICILLIN RESISTANCE

Methicillin-resistant Staphylococcus aureus: long-term care concerns. Bradley SF. **Am J Med** 1999 May 3; 106(5A):2S–10S; discussion 48S–52S (40 ref.)
Control of methicillin-resistant Staphylococcus aureus in the hospital setting. Herwaldt LA. **Am J Med** 1999 May 3; 106(5A):11S–18S; discussion 48S–52S (52 ref.)
Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Monnet DL. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):552–9 (100 ref.)
A patient who survived total colonic type ulcerative colitis complicated by toxic megacolon, disseminated intravascular coagulation, methicillin-resistant Staphylococcus aureus infection and bilateral femoral phlebothrombosis. Arai H, et al. **J Gastroenterol** 1999 Jun; 34(3):395–9 (8 ref.)
MRSA in cystic fibrosis. London, 16 June 1997. **J Hosp Infect** 1998 Nov;40(3):179–91 (17 ref.)
[Methicillin-resistant Staphylococcus aureus: evolution and epidemiology, clinical impact, and prevention] Brun-Buisson C. **Pathol Biol (Paris)** 1998 Apr;46(4):227–34 (80 ref.) (Eng. Abstr.) **(Fre)**
[Methicillin-cephem-resistant Staphylococcus aureus enteritis] Agawa S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):453–5 (15 ref.) **(Jpn)**
[Methicillin resistant Staphylococcus aureus infection] Fukayama M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):179–81 (6 ref.) **(Jpn)**

GENETICS

Epidemiology of methicillin-resistant Staphylococcus aureus. Fluckiger U, et al. **Chemotherapy** 1999 Mar–Apr; 45(2):121–34 (106 ref.)
Methicillin-resistance in Staphylococcus aureus - molecular basis, novel targets and antibiotic therapy. Ehlert K. **Curr Pharm Des** 1999 Feb;5(2):45–55 (111 ref.)

PHYSIOLOGY

Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis—a novel hazard emerging on the horizon [editorial] Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):2999–3001 (14 ref.)
Acquisition of methicillin resistance and progression of multiantibiotic resistance in methicillin-resistant Staphylococcus aureus. Ito T, et al. **Yonsei Med J** 1998 Dec;39(6):526–33 (31 ref.)

METHIMAZOLE

TOXICITY

Methimazole embryopathy: delineation of the phenotype. Clementi M, et al. **Am J Med Genet** 1999 Mar 5;83(1):43–6 (16 ref.)

METHIONINE

ADMINISTRATION & DOSAGE

Application of methionine-free nutrition as an anticancer treatment. Yoshido S. **Nutrition** 1999 May;15(5):422–4 (13 ref.)

GENETICS

[Hereditary amyloid cardiomyopathy related to a mutation at transthyretin protein number 111. A clinical, genetic and echocardiographic study of an affected Danish family] Svendsen IH, et al. **Ugeskr Laeger** 1999 Sep 6; 161(36):4995–9 (20 ref.) (Eng. Abstr.) **(Dan)**

METABOLISM

Amino acid metabolism in liver disease. Holm E, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):47–53 (80 ref.)
Homocysteine—a pathophysiological cornerstone in obstetrical and gynaecological disorders? Obwegeser R, et al. **Hum Reprod Update** 1999 Jan–Feb;5(1):64–72 (131 ref.)

PHARMACOLOGY

Cephalosporin C production by Cephalosporium acremonium: the methionine story. Demain AL, et al. **Crit Rev Biotechnol** 1998;18(4):283–94 (45 ref.)

METHIONINE ADENOSYLTRANSFERASE

[Recent progress on the study of methionine adenosyltransferase] Horikawa S. **Seikagaku** 1999 Apr; 71(4):286–90 (14 ref.) **(Jpn)**

METHIONINE ENKEPHALIN see **ENKEPHALIN, METHIONINE**

METHODOLOGIES, COMPUTING see **COMPUTING METHODOLOGIES**

METHODOLOGY RESEARCH, NURSING see **NURSING METHODOLOGY RESEARCH**

METHOPYRAPONE see **METYRAPONE**

METHOTREXATE

ADMINISTRATION & DOSAGE

Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. Kanda Y, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):193–7 (19 ref.)
[Methotrexate in therapy of gastrointestinal diseases] Schröder O, et al. **Z Gastroenterol** 1999 Jul;37(7):623–37 (103 ref.) (Eng. Abstr.) **(Ger)**
[Methotrexate and folates in rheumatoid arthritis] Endresen GK, et al. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):534–7 (32 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Georgescu L, et al. **Drug Saf** 1999 Jun;20(6):475–87 (105 ref.)
Multiple stress fractures in a scleroderma patient on methotrexate therapy. Singwe M, et al. **Rev Rhum Engl Ed** 1998 Jul–Sep;65(7–9):508–10 (14 ref.)
Developmental delay in fetal aminopterin/methotrexate syndrome. Del Campo M, et al. **Teratology** 1999 Jul; 60(1):10–2 (10 ref.)

PHARMACOLOGY

Molecular and cellular effects of methotrexate. Seitz M. **Curr Opin Rheumatol** 1999 May;11(3):226–32 (86 ref.)
Augmentation of methotrexate resistance with coexpression of metabolically related genes. Mineishi S. **Prog Exp Tumor Res** 1999;36:95–106 (55 ref.)
[Improving the anti-tumor activity of 5-fluorouracil by methotrexate] Konishi T, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):431–9 (32 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Should methotrexate be a first-line treatment for rheumatoid arthritis? Wilke WS. **Cleve Clin J Med** 1999 Apr; 66(4):207–8 (16 ref.)
Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis [editorial; comment] Ferraccioli GF, et al. **Clin Exp Rheumatol** 1998 Nov–Dec;16(6):662–6 (57 ref.) Comment on: Clin Exp Rheumatol 1998 Nov–Dec;16(6):695–701.
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis. Furst DE. **Clin Exp Rheumatol** 1999 Jan–Feb; 17(1):39–40 (2 ref.)
On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Wallace CA. **Clin Exp Rheumatol** 1999 Jul–Aug;17(4):499–504 (40 ref.)
Medical management of ectopic pregnancy. Buster JE, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):23–30; quiz 55–6 (33 ref.)
Medical management of interstitial ectopic pregnancy: a case report and literature review. Fisch JD, et al. **Hum Reprod** 1998 Jul;13(7):1981–6 (25 ref.)
Prognostic factors for an unsatisfactory primary methotrexate treatment of cervical pregnancy: a quantitative review. Hung TH, et al. **Hum Reprod** 1998 Sep;13(9):2636–42 (45 ref.)
Early diagnosis of ectopic pregnancy and treatment with methotrexate. Fylstra DL. **J S C Med Assoc** 1999 Feb; 95(2):59–63 (32 ref.)
Therapeutic interventions in systemic sclerosis. van den Hoogen FH. **Neth J Med** 1998 Sep;53(3):137–8 (13 ref.)
Medications used in the treatment of multiple sclerosis. Schapiro RT. **Phys Med Rehabil Clin N Am** 1999 May; 10(2):437–46, ix (48 ref.)
Methotrexate for sarcoidosis. Baughman RP. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):147–9 (27 ref.)
A clinical approach to the use of methotrexate for sarcoidosis. Baughman RP, et al. **Thorax** 1999 Aug;54(8):742–6 (61 ref.)

METHOXSALEN

ANALOGS & DERIVATIVES

5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. McNeely W, et al. **Drugs** 1998 Oct;56(4):667–90 (80 ref.)

PHARMACOLOGY

Modulation of cytokine production by 8-methoxypsoralen and UVA. Tokura Y. **J Dermatol Sci** 1999 Feb;19(2):114–22 (56 ref.)

THERAPEUTIC USE

PUVA therapy: current concerns in Japan. Danno K. **J Dermatol Sci** 1999 Feb;19(2):89–105 (138 ref.)

8-METHOXYPSORALEN see **METHOXSALEN**

5-METHOXYTRYPTAMINE

PHYSIOLOGY

Melatonin and 5-methoxytryptamine in non-metazoans.

5-METHOXYTRYPTAMINE

Hardeland R. **Reprod Nutr Dev** 1999 May-Jun; 39(3):399-408 (43 ref.)

N-METHYL-D-ASPARTATE RECEPTORS see **RECEPTORS, N-METHYL-D-ASPARTATE**

METHYL CHLORIDE

TOXICITY

Methyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:737-47 (38 ref.)

METHYL ETHERS

Use of propofol and sevoflurane in moyamoya disease--case reports and literature review. Khan-Ghori SN, et al. **Middle East J Anesthesiol** 1999 Feb;15(1):73-83 (39 ref.)

Desflurane and sevoflurane. New volatile anesthetic agents. Clarke KW. **Vet Clin North Am Small Anim Pract** 1999 May;29(3):793-810, viii (95 ref.)

[Low-flow and minimal-flow anesthesia with sevoflurane] Baum J, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S70-6 (35 ref.) (Eng. Abstr.) **(Ger)**

[Mask induction and one-lung ventilation with sevoflurane] Janshon GP, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S52-7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane in obstetric anesthesia] Olthoff D, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S63-9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane in elderly patients] Reeker W, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S58-62 (39 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane in pediatric anesthesia. Malignant hyperthermia] Scholz J. **Anaesthesist** 1998 Nov;47 Suppl 1:S43-8 (53 ref.) (Eng. Abstr.) **(Ger)**

[A role for sevoflurane in ambulatory surgery] White PF. **Anaesthesist** 1998 Nov;47 Suppl 1:S49-51 (19 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Renal effects of sevoflurane during conditions of possible increased risk [comment] Artru AA. **J Clin Anesth** 1998 Nov;10(7):531-8 (54 ref.) Comment on: J Clin Anesth 1998 Nov;10(7):539-45.

[Kidney function in test subjects: published results and clinical relevance] Frink EJ. **Anaesthesist** 1998 Nov;47 Suppl 1:S33-6 (12 ref.) (Eng. Abstr.) **(Ger)**

[Occupational exposure and environmental pollution: the role of inhalation anesthetics with special consideration of sevoflurane] Hobbhahn J, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S77-86 (46 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane: metabolism and toxicity] Nuscheler M, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S24-32 (41 ref.) (Eng. Abstr.) **(Ger)**

[Cardiovascular effects of sevoflurane] Rolf N, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S11-8 (46 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane and the nervous system] Schwender D, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S37-42 (59 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

[Costs of sevoflurane in the perioperative setting] Bach A. **Anaesthesist** 1998 Nov;47 Suppl 1:S87-96 (44 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

[Compound A: toxicology and clinical relevance] Kharasch ED. **Anaesthesist** 1998 Nov;47 Suppl 1:S7-10 (34 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane: metabolism and toxicity] Nuscheler M, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S24-32 (41 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Clinical pharmacokinetics of sevoflurane. Behne M, et al. **Clin Pharmacokinet** 1999 Jan;36(1):13-26 (104 ref.)

[Uptake and distribution of sevoflurane] Dudziak R, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S1-6 (25 ref.) (Eng. Abstr.) **(Ger)**

[Perfusion and metabolism of liver and splanchnic nerve area under sevoflurane anesthesia] Schindler E, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S19-23 (60 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

[Progress in the study of carcinogenic effect of methyl-tertiary-buty ether] Zhou W, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Mar; 31(2):124-6 (16 ref.) **(Chi)**

METHYL METHANESULFONATE

TOXICITY

The role of mutation frequency decline and SOS repair systems in methyl methanesulfonate mutagenesis. Grzesiuk E. **Acta Biochim Pol** 1998;45(2):523-33 (60 ref.)

METHYL PARATHION

POISONING

[Acute methyl parathion poisoning with extrapyramidal manifestations not previously reported] Montoya-Cabrera MA, et al. **Gac Med Mex** 1999 Jan-Feb;135(1):79-82 (27 ref.) (Eng. Abstr.) **(Spa)**

METHYL VIOLET see **GENTIAN VIOLET**

METHYL VIOLOGEN see **PARAQUAT**

METHYLADENINE RECEPTORS see **RECEPTORS, PURINERGIC**

N-METHYLASPARTATE

see related
RECEPTORS, N-METHYL-D-ASPARTATE

PHYSIOLOGY

Modulation of motor behaviour by NMDA- and cholecystokinin-antagonism. Broberger C, et al. **Amino Acids** 1998;14(1-3):25-31 (34 ref.)

[Long-term potentiation of the NMDA-dependent component of the EPSP in the hippocampus] Kleshchevnikov AM. **Usp Fiziol Nauk** 1998 Oct-Dec; 29(4):6-23 (97 ref.) (Eng. Abstr.) **(Rus)**

N-METHYL-D-ASPARTATE see **N-METHYLASPARTATE**

METHYLATED-DNA-PROTEIN-CYSTEINE S-METHYLTRANSFERASE see **O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE**

METHYLCELLULOSE

Thermal analysis of hydroxypropylmethylcellulose and methylcellulose: powders, gels and matrix tablets. Ford JL. **Int J Pharm** 1999 Mar 15;179(2):209-28 (67 ref.)

ANALOGS & DERIVATIVES

Thermal analysis of hydroxypropylmethylcellulose and methylcellulose: powders, gels and matrix tablets. Ford JL. **Int J Pharm** 1999 Mar 15;179(2):209-28 (67 ref.)

[The use of viscoelastic compounds in cataract surgery] Stefan C, et al. **Oftalmologia** 1998;44(3):32-5 (17 ref.) (Eng. Abstr.) **(Rum)**

METHYLENE BICHLORIDE see **METHYLENE CHLORIDE**

METHYLENE BLUE

ADVERSE EFFECTS

Teratogen update: methylene blue. Cragan JD. **Teratology** 1999 Jul;60(1):42-8 (85 ref.)

THERAPEUTIC USE

Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Link EM. **Hybridoma** 1999 Feb;18(1):77-82 (34 ref.)

METHYLENE CHLORIDE

ADVERSE EFFECTS

Dichloromethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 1:251-315 (253 ref.)

METHYLENE DICHLORIDE see **METHYLENE CHLORIDE**

3,4-METHYLENEDIOXYAMPHETAMINE

ADVERSE EFFECTS

[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity] de Visme PG. **Ugeskr Laeger** 1998 Oct 12;160(42):6088-91 (40 ref.) (Eng. Abstr.) **(Dan)**

ANALOGS & DERIVATIVES

3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Hegadoren KM, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):539-53 (163 ref.)

TOXICITY

3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Hegadoren KM, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):539-53 (163 ref.)

METHYLENEDIOXYMETHAMPHETAMINE see **N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE**

METHYLGLUCAMINE see **MEGLUMINE**

METHYLGLUCAMINE DIATRIZOATE see **DIATRIZOATE MEGLUMINE**

METHYLGLYOXAL see **PYRUVALDEHYDE**

METHYLGLYOXALASE see **LACTOYLGLUTATHIONE LYASE**

O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy. Kleibl K, et al. **Neoplasma** 1998;45(4):181-6 (33 ref.)

GENETICS

O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Davis BM, et al. **Prog Exp Tumor Res** 1999;36:65-81 (69 ref.)

[Gene therapy using anticancer drug-resistance genes] Sugimoto Y. **Gan To Kagaku Ryoho** 1999 Jan;26(1):1-9 (27 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Repair of DNA lesion O6-methylguanine in hepatocellular carcinogenesis. Major GN, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):355-66 (123 ref.)

PHYSIOLOGY

Alkylation carcinogenesis in mice with altered levels of DNA repair methyltransferase. Sekiguchi M, et al. **Prog Exp Tumor Res** 1999;35:25-36 (46 ref.)

O(6)-METHYLGUANINE METHYLTRANSFERASE see **O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE**

METHYLHYDROXYPROGESTERONE see **MEDROXYPROGESTERONE**

METHYLMALONIC ACID

URINE

Methylmalonic aciduria (cblF): case report and response to therapy. Waggoner DJ, et al. **Am J Med Genet** 1998 Oct 12;79(5):373-5 (9 ref.)

METHYLMALONYL-COA ISOMERASE see **METHYLMALONYL-COA MUTASE**

METHYLMALONYL-COA MUTASE

CHEMISTRY

Mechanistic and structural studies on methylmalonyl-CoA mutase. Thomä NH, et al. **Biochem Soc Trans** 1998 Aug; 26(3):293-8 (31 ref.)

METABOLISM

Mechanistic and structural studies on methylmalonyl-CoA mutase. Thomä NH, et al. **Biochem Soc Trans** 1998 Aug; 26(3):293-8 (31 ref.)

METHYLMETHACRYLATE

ADVERSE EFFECTS

Porosity reduction in acrylic cement is clinically irrelevant. Ling RS, et al. **Clin Orthop** 1998 Oct;(355):249-53 (31 ref.)

CHEMISTRY

Porosity reduction in acrylic cement is clinically irrelevant. Ling RS, et al. **Clin Orthop** 1998 Oct;(355):249-53 (31 ref.)

METHYLMETHACRYLATE METHYL MONOMER see **METHYLMETHACRYLATE**

METHYLMETHANE SULFONATE see **METHYL METHANESULFONATE**

N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE

Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. Rochester JA, et al. **J Am Board Fam Pract** 1999 Mar-Apr;12(2):137-42 (48 ref.)

Ten years of 'ecstasy'. Milroy CM. **J R Soc Med** 1999 Feb; 92(2):68-71 (41 ref.)

ADVERSE EFFECTS

[Clinical and toxicologic aspects of the use of Ecstasy (see comments)] Pennings EJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1942–6 (36 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 17;142(42):2321–2. **(Dut)**

[Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports] Bango J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1998 Jul–Aug;26(4):260–3 (18 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Serotonergic basis of antipsychotic drug effects in schizophrenia. Lieberman JA, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1099–117 (213 ref.)

[Ecstasy: a pharmacological review] Ferigolo M, et al. **Rev Saude Publica** 1998 Oct;32(5):487–95 (49 ref.) (Eng. Abstr.) **(Por)**

POISONING

Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Jones AL, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):129–33 (56 ref.)

TOXICITY

[Clinical and toxicologic aspects of the use of Ecstasy (see comments)] Pennings EJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1942–6 (36 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 17;142(42):2321–2. **(Dut)**

METHYLMETHYLERGONOVINE see **METHYSERGIDE**

METHYLNITROPHOS see **FENITROTHION**

METHYLNITROSOUREA

PHARMACOLOGY

Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Bosland MC. **Eur Urol** 1999; 35(5–6):459–63 (17 ref.)

METHYLOCOCCACEAE

ENZYMOLOGY

Methanotrophs, Methylosinus trichosporium OB3b, sMMO, and their application to bioremediation. Sullivan JP, et al. **Crit Rev Microbiol** 1998;24(4):335–73 (165 ref.)

METABOLISM

[The biology of bacteria that assimilate C1—C2 compounds and the biotechnology aspects of their use] Malashenko IuP, et al. **Mikrobiol Z** 1998 Nov–Dec;60(6):38–55 (67 ref.) (Eng. Abstr.) **(Rus)**

METHYLOMONADACEAE see **METHYLOCOCCACEAE**

METHYLPARTRICIN see **MEPARTRICIN**

METHYLPHENIDATE

ADMINISTRATION & DOSAGE

[Central stimulants in adults with AD/HD. Do they help? (see comments)] Lie N. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4223–7 (40 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1999 Jan 10;119(1):82–3. **(Nor)**

PHARMACOLOGY

Anti-hyperactivity medication: methylphenidate and amphetamine [see comments] Seeman P, et al. **Mol Psychiatry** 1998 Sep;3(5):386–96 (105 ref.) Comment in: Mol Psychiatry 1998 Sep;3(5):370–2.

THERAPEUTIC USE

Stimulants and tic disorders: from dogma to data [comment] Castellanos FX. **Arch Gen Psychiatry** 1999 Apr;56(4):337–8 (18 ref.) Comment on: Arch Gen Psychiatry 1999 Apr;56(4):330–6.

National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Robison LM, et al. **Clin Pediatr (Phila)** 1999 Apr; 38(4):209–17 (30 ref.)

A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. Higgins ES. **J Fam Pract** 1999 Jan;48(1):15–20 (50 ref.)

Anti-hyperactivity medication: methylphenidate and amphetamine [see comments] Seeman P, et al. **Mol Psychiatry** 1998 Sep;3(5):386–96 (105 ref.) Comment in: Mol Psychiatry 1998 Sep;3(5):370–2.

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE

[Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease] Matsubara K. **Nippon Hoigaku Zasshi** 1998 Oct;52(5):301–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[MPTP parkinsonism] Kondo T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):37–40 (14 ref.) **(Jpn)**

TOXICITY

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. Grünblatt E, et al. **J Neural Transm Suppl** 1999;55:57–70 (58 ref.)

METHYLPREDNISOLONE

ADMINISTRATION & DOSAGE

[A case report of steroid-responsive progressive encephalomyelitis with rigidity showing muscle stiffness limited to the upper body] Matsuno S, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):680–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Corticosteroid-induced epidural lipomatosis. Efficacy of medical treatment] Lemaire M, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):459–63 (20 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Levels of evidence for the pharmacological effectiveness of prolonged methylprednisolone treatment in unresolving acute respiratory distress syndrome. Meduri GU. **Minerva Anestesiol** 1999 May;65(5):193–6 (12 ref.)

Glucocorticosteroids in the management of rheumatoid arthritis. Laan RF, et al. **Rheumatology (Oxford)** 1999 Jan; 38(1):6–12 (49 ref.)

METHYLROSANILINE CHLORIDE see **GENTIAN VIOLET**

METHYLSTANAZOL see **STANOZOLOL**

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE

see related
HOMOCYSTINURIA

METHYLTHIONINE CHLORIDE see **METHYLENE BLUE**

METHYLTRANSFERASES

GENETICS

Why has phosphatidylethanolamine N-methyltransferase survived in evolution? Vance DE, et al. **Biochem Soc Trans** 1998 Aug;26(3):337–40 (24 ref.)

Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Krynetski EY, et al. **Pharm Res** 1999 Mar;16(3):342–9 (56 ref.)

METABOLISM

Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Weinshilboum RM, et al. **Annu Rev Pharmacol Toxicol** 1999;39:19–52 (157 ref.)

Why has phosphatidylethanolamine N-methyltransferase survived in evolution? Vance DE, et al. **Biochem Soc Trans** 1998 Aug;26(3):337–40 (24 ref.)

Novel reactions involved in energy conservation by methanogenic archaea. Deppenmeier U, et al. **FEBS Lett** 1999 Sep 3;457(3):291–7 (49 ref.)

Enzymology of one-carbon metabolism in methanogenic pathways. Ferry JG. **FEMS Microbiol Rev** 1999 Jan; 23(1):13–38 (141 ref.)

Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Lennard L. **Ther Drug Monit** 1998 Oct;20(5):527–31 (33 ref.)

METHYMAZOL see **METHIMAZOLE**

METHYSERGIDE

THERAPEUTIC USE

Methysergide. Silberstein SD. **Cephalalgia** 1998 Sep; 18(7):421–35 (152 ref.)

METOPROLOL

THERAPEUTIC USE

Beta-blockers for heart failure: is slowing of heart rate essential? [editorial; comment] Tendera M. **Eur Heart J** 1999 Apr;20(8):560–1 (5 ref.) Comment on: Eur Heart J 1999 Apr;20(8):575–83.

METRIAL GLAND

CYTOLOGY

Granulated metrial gland cells in 'minor' species. Stewart IJ. **J Reprod Immunol** 1998 Nov;40(2):129–46 (76 ref.)

METRIFONATE see **TRICHLORFON**

METRONIDAZOLE

Clindamycin, metronidazole, and chloramphenicol. Kasten MJ. **Mayo Clin Proc** 1999 Aug;74(8):825–33 (105 ref.)

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Lamp KC, et al. **Clin Pharmacokinet** 1999 May;36(5):353–73 (130 ref.)

PHARMACOLOGY

Why metronidazole is active against both bacteria and parasites. Samuelson J. **Antimicrob Agents Chemother** 1999 Jul;43(7):1533–41 (102 ref.)

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Lamp KC, et al. **Clin Pharmacokinet** 1999 May;36(5):353–73 (130 ref.)

Trichomonads, hydrogenosomes and drug resistance. Kulda J. **Int J Parasitol** 1999 Feb;29(2):199–212 (73 ref.)

THERAPEUTIC USE

Review article: the management of Giardiasis. Vesy CJ, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):843–50 (44 ref.)

Use of topical products for maintaining remission in rosacea [editorial; comment] Wilkin JK. **Arch Dermatol** 1999 Jan; 135(1):79–80 (6 ref.) Comment on: Arch Dermatol 1994 Mar;130(3):359–62. Comment on: Arch Dermatol 1998 Jun;134(6):679–83.

Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. de Boer WA. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):697–700 (40 ref.)

[Treatment of Helicobacter pylori infections] van der Hulst RW, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20; 143(8):395–400 (37 ref.) (Eng. Abstr.) **(Dut)**

METRORRHAGIA

DIAGNOSIS

[Role of diagnostic hysteroscopy in the exploration of postmenopausal metrorrhagia] Roger V, et al. **Presse Med** 1998 Sep 5;27(25):1294–5 (6 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Role of diagnostic hysteroscopy in the exploration of postmenopausal metrorrhagia] Roger V, et al. **Presse Med** 1998 Sep 5;27(25):1294–5 (6 ref.) (Eng. Abstr.) **(Fre)**

METYRAPONE

ADMINISTRATION & DOSAGE

Long-term medical treatment of ectopic ACTH syndrome. Comi RJ, et al. **South Med J** 1998 Nov;91(11):1014–8 (25 ref.)

MEVALONIC ACID

METABOLISM

Mevalonate biosynthesis in plants. Bach TJ, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):107–22 (90 ref.)

Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Elson CE, et al. **Proc Soc Exp Biol Med** 1999 Sep;221(4):294–311 (315 ref.)

MEVINOLIN see **LOVASTATIN**

MEXICAN AMERICANS

Grieving and death rituals of Latinos. Munet-Vilaró F. **Oncol Nurs Forum** 1998 Nov–Dec;25(10):1761–3 (16 ref.)

PSYCHOLOGY

Patterns of mental health care among Mexican Americans. Bechtel GA, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Nov;36(11):20–7 (28 ref.)

MEXILETINE

MEXILETINE

THERAPEUTIC USE

Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Jarvis B, et al. **Drugs** 1998 Oct;56(4):691–707 (139 ref.)

MGADP see **ADENOSINE DIPHOSPHATE**

MGATP see **ADENOSINE TRIPHOSPHATE**

MGDF FACTOR see **THROMBOPOIETIN**

MGI-1 see **COLONY-STIMULATING FACTORS**

MGI-2 see **INTERLEUKIN-6**

MGN see **GLOMERULONEPHRITIS, MEMBRANOUS**

MHC CLASS I GENES see **GENES, MHC CLASS I**

MHC CLASS II GENES see **GENES, MHC CLASS II**

MIANSERIN

ANALOGS & DERIVATIVES

Mirtazapine: a newer antidepressant. Hartmann PM. **Am Fam Physician** 1999 Jan 1;59(1):159–61 (26 ref.)

Mirtazapine: a review of its use in major depression. Holm KJ, et al. **Drugs** 1999 Apr;57(4):607–31 (107 ref.)

Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Fawcett J, et al. **J Affect Disord** 1998 Dec;51(3):267–85 (79 ref.)

Mirtazapine: other indications. Falkai P. **J Clin Psychiatry** 1999;60 Suppl 17:36–40; discussion 46–8 (30 ref.)

Mirtazapine: clinical overview. Gorman JM. **J Clin Psychiatry** 1999;60 Suppl 17:9–13; discussion 46–8 (24 ref.)

Care of depressed patients with anxiety symptoms. Nutt DJ. **J Clin Psychiatry** 1999;60 Suppl 17:23–7; discussion 46–8 (26 ref.)

Tolerability and patient compliance. Roose SP. **J Clin Psychiatry** 1999;60 Suppl 17:14–7; discussion 46–8 (13 ref.)

Antidepressant treatment of the depressed patient with insomnia. Thase ME. **J Clin Psychiatry** 1999;60 Suppl 17:28–31; discussion 46–8 (8 ref.)

Mirtazapine versus selective serotonin reuptake inhibitors. Thompson C. **J Clin Psychiatry** 1999;60 Suppl 17:18–22; discussion 46–8 (8 ref.)

Pharmacology of antidepressants: selectivity or multiplicity? Westenberg HG. **J Clin Psychiatry** 1999;60 Suppl 17:4–8; discussion 46–8 (10 ref.)

[Two new antidepressants: mirtazapine and venlafaxine] Birkenhäger TK, et al. **Ned Tijdschr Geneeskd** 1999 May 1;143(18):934–7 (26 ref.) (Eng. Abstr.) **(Dut)**

MIBELLI POROKERATOSIS see **POROKERATOSIS**

MIBG see **3-IODOBENZYLGUANIDINE**

MICE

Cloned mice raise possibility of human cloning. Nasir J. **Clin Genet** 1999 Jan;55(1):11–2 (3 ref.)

BLOOD

Hemostasis in the mouse (Mus musculus): a review. Tsakiris DA, et al. **Thromb Haemost** 1999 Feb;81(2):177–88 (187 ref.)

EMBRYOLOGY

The organizer of the gastrulating mouse embryo. Camus A, et al. **Curr Top Dev Biol** 1999;45:117–53 (161 ref.)

GENETICS

Of mice and genes: evolution of vertebrate brain development. Fritzsch B. **Brain Behav Evol** 1998; 52(4–5):207–17 (71 ref.)

Modifiable gene expression in mice: kidney-specific deletion of a target gene via the cre-loxP system. Stec DE, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):568–75 (41 ref.)

Mouse mutagenesis-systematic studies of mammalian gene function. Brown SD, et al. **Hum Mol Genet** 1998; 7(10):1627–33 (45 ref.)

Thirteen years of manipulating the mouse genome: a personal history. Bradley A, et al. **Int J Dev Biol** 1998;42(7 Spec No):943–50 (37 ref.)

Genetics of mouse growth. Efstratiadis A. **Int J Dev Biol** 1998;42(7 Spec No):955–76 (225 ref.)

Mouse chimaeras revisited: recollections and reflections. Tarkowski AK. **Int J Dev Biol** 1998;42(7 Spec No):903–8 (65 ref.)

Comprehensive mammalian genetics: history and future prospects of gene trapping in the mouse. Zambrowicz BP, et al. **Int J Dev Biol** 1998;42(7 Spec No):1025–36 (70 ref.)

Induced lipase mutations in the mouse. Semenkovich CF. **Methods Mol Biol** 1999;109:343–55 (21 ref.)

Multiple genes governing biological functions in the genetic backgrounds of laboratory mice and Asian wild mice. Moriwaki K, et al. **Prog Exp Tumor Res** 1999;35:1–12 (19 ref.)

Appendix: imprinted genes and regions in mouse and human. Beechey CV. **Results Probl Cell Differ** 1999;25:303–23 (97 ref.)

GROWTH & DEVELOPMENT

Genetics of mouse growth. Efstratiadis A. **Int J Dev Biol** 1998;42(7 Spec No):955–76 (225 ref.)

Developmental fates of the mouse germ cell line. Matsui Y. **Int J Dev Biol** 1998;42(7 Spec No):1037–42 (44 ref.)

IMMUNOLOGY

Biological effects of microorganisms and their substances in mice. Anderlik P, et al. **Acta Microbiol Immunol Hung** 1998; 45(3–4):323–8 (20 ref.)

MICROBIOLOGY

Batrachomyomachia: frogs 1, mice 0. Klein J. **Scand J Immunol** 1999 Jan;49(1):11–3 (9 ref.)

PARASITOLOGY

The use of confocal laser scanning microscopy to analyze the process of parasitic protozoon-host cell interaction. de-Souza W, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1459–70 (49 ref.)

PHYSIOLOGY

Mouse models of airway responsiveness: physiological basis of observed outcomes and analysis of selected examples using these outcome indicators. Drazen JM, et al. **Annu Rev Physiol** 1999;61:593–625 (25 ref.)

Of mice and genes: evolution of vertebrate brain development. Fritzsch B. **Brain Behav Evol** 1998; 52(4–5):207–17 (71 ref.)

Mouse sperm cryopreservation: a legacy in the making [editorial; comment] Pinkert CA. **Lab Anim Sci** 1998 Jun; 48(3):224 (5 ref.) Comment on: Lab Anim Sci 1998 Jun;48(3):275–81.

[Cryopreservation of mouse embryo and gametes and their application] Nakagata N. **Exp Anim** 1998 Jul;47(3):suppl 131–8 (25 ref.) **(Jpn)**

PSYCHOLOGY

The developmental psychobiology of behavioural plasticity in mice: the role of social experiences in the family unit. Laviola G, et al. **Neurosci Biobehav Rev** 1998;23(2):197–213 (123 ref.)

MICE, HAIRLESS see **MICE, INBRED HRS**

MICE, HOUSE see **MICE**

MICE, INBRED C57BL

PHYSIOLOGY

What do comparative studies of inbred mice add to current investigations on the neural basis of spatial behaviors? Rossi-Arnaud C, et al. **Exp Brain Res** 1998 Nov; 123(1–2):36–44 (48 ref.)

MICE, INBRED CBA

Advantages of the CBA mouse in leukemogenesis research. Rithidech KN, et al. **Blood Cells Mol Dis** 1999 Feb; 25(1):38–45 (69 ref.)

MICE, INBRED DBA

PHYSIOLOGY

What do comparative studies of inbred mice add to current investigations on the neural basis of spatial behaviors? Rossi-Arnaud C, et al. **Exp Brain Res** 1998 Nov; 123(1–2):36–44 (48 ref.)

MICE, INBRED HRS

GENETICS

Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. Panteleyev AA, et al. **Exp Dermatol** 1998 Oct;7(5):249–67 (138 ref.)

PHYSIOLOGY

Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. Panteleyev AA, et al. **Exp Dermatol** 1998 Oct;7(5):249–67 (138 ref.)

MICE, INBRED NOD

IMMUNOLOGY

Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model. Toyoda H, et al. **Bioessays** 1998 Sep;20(9):750–7 (66 ref.)

MICE, INBRED STRAINS

GENETICS

Genes involved in animal models of obesity and anorexia. Schalling M, et al. **J Intern Med** 1999 Jun;245(6):613–9 (49 ref.)

Genetically engineered mice: the holes in the sum of the parts [editorial] Brownstein DG. **Lab Anim Sci** 1998 Apr; 48(2):121–2 (0 ref.)

Myeloid leukemia: disease genes and mouse models. Copeland NG, et al. **Prog Exp Tumor Res** 1999;35:53–63 (35 ref.)

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64–77 (32 ref.)

Inheritance of pulmonary adenoma susceptibility in mice. Malkinson AM. **Prog Exp Tumor Res** 1999;35:78–94 (95 ref.)

VIROLOGY

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64–77 (32 ref.)

MICE, KNOCKOUT

Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Couse JF, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):143–8 (51 ref.)

Transgenic mice in drug dependence research. Pich EM, et al. **Ann Med** 1998 Aug;30(4):390–6 (46 ref.)

Murine mentors: transgenic and knockout models of surgical disease. Arbeit JM, et al. **Ann Surg** 1999 Jan;229(1):21–40 (166 ref.)

Use of knockout mice to study surfactant protein structure and function. Weaver TE, et al. **Biol Neonate** 1999 Jun;76 Suppl 1:15–8 (10 ref.)

Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis. Gonzalez FJ, et al. **Cancer Lett** 1999 Sep 1;143(2):199–204 (43 ref.)

Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Rosenberg MP, et al. **Cancer Metastasis Rev** 1998–99;17(3):295–9 (0 ref.)

DNA repair: knockouts still mutating after first round. Wood RD. **Curr Biol** 1998 Oct 22;8(21):R757–60 (17 ref.)

Cytochrome P450-null mice. Buters JT, et al. **Drug Metab Rev** 1999 May;31(2):437–47 (32 ref.)

Estrogen receptor null mice: what have we learned and where will they lead us? [published erratum appears in Endocr Rev 1999 Aug;20(4):459] Couse JF, et al. **Endocr Rev** 1999 Jun;20(3):358–417 (511 ref.)

Gene-knockout mice with abnormal epidermal and hair follicular development. Yamanishi K. **J Dermatol Sci** 1998 Nov;18(2):75–89 (108 ref.)

Utility and importance of gene knockout animals for nutritional and metabolic research. Hui DY. **J Nutr** 1998 Nov;128(11):2052–7 (63 ref.)

Interpretation of phenotype in genetically engineered mice [see comments] Doetschman T. **Lab Anim Sci** 1999 Apr; 49(2):137–43 (67 ref.) Comment in: Lab Anim Sci 1999 Apr;49(2):134.

Preparation of knockout mice. Osada J, et al. **Methods Mol Biol** 1998;110:79–92 (7 ref.)

Transgenic studies of pain. Mogil JS, et al. **Pain** 1998 Aug; 77(2):107–28 (216 ref.)

Using knockout and transgenic mice to study neurophysiology and behavior. Picciotto MR, et al. **Physiol Rev** 1998 Oct;78(4):1131–63 (305 ref.)

GENETICS

Genetic engineering in mice: impact on insulin signalling and action. Lamothe B, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):193–204 (107 ref.)

Transgenic and knockout mice in research on prion diseases. Raeber AJ, et al. **Brain Pathol** 1998 Oct;8(4):715–33 (147 ref.)

Cytochrome P450 knockout mice: new toxicological models. McKinnon RA, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):783–7 (38 ref.)

The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. Bonventre JV. **J Am Soc Nephrol** 1999 Feb;10(2):404–12 (76 ref.)

Lessons on renal physiology from transgenic mice lacking aquaporin water channels. Verkman AS. **J Am Soc Nephrol** 1999 May;10(5):1126–35 (48 ref.)

Beyond 'knock-out' mice: new perspectives for the programmed modification of the mammalian genome. Cohen-Tannoudji M, et al. **Mol Hum Reprod** 1998 Oct; 4(10):929–38 (81 ref.)

The value of gene 'knock-out' for assessing the role of cell adhesion molecules in renal disease. McGinty A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:27–9 (19 ref.)

Mouse models in tumor suppression. Ghebranious N, et al. **Oncogene** 1998 Dec 24;17(25):3385–400 (243 ref.)

Genetic analysis of NOS isoforms using nNOS and eNOS knockout animals. Huang PL, et al. **Prog Brain Res** 1998; 118:13–25 (88 ref.)

Cancer predisposition in mutant mice defective in the XPC DNA repair gene. Friedberg EC, et al. **Prog Exp Tumor Res** 1999;35:37–52 (45 ref.)

Apc gene knockout mice as a model for familial adenomatous polyposis. Taketo MM. **Prog Exp Tumor Res** 1999; 35:109–19 (44 ref.)
Overview of transgenic and gene knockout mice. Yamamura K. **Prog Exp Tumor Res** 1999;35:13–24 (60 ref.)
Genetic dissection of the molecular target(s) of anesthetics with the gene knockout approach in mice. Homanics GE, et al. **Toxicol Lett** 1998 Nov 23;100–101:301–7 (18 ref.)
Utilization of genetically altered animals in the pharmaceutical industry. Rudmann DG, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):111–4 (51 ref.)
[Functional analysis of non-HLA genes within MHC region with knockout-mouse technology] Matsumoto M. **Seikagaku** 1999 May;71(5):323–32 (55 ref.) **(Jpn)**
[Genetic modification of the mouse] Andersson KB, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3952–7 (21 ref.) (Eng. Abstr.) **(Nor)**

GROWTH & DEVELOPMENT

The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Los M, et al. **Immunity** 1999 Jun;10(6):629–39 (87 ref.)

IMMUNOLOGY

The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Los M, et al. **Immunity** 1999 Jun;10(6):629–39 (87 ref.)

METABOLISM

Genetic analysis of NOS isoforms using nNOS and eNOS knockout animals. Huang PL, et al. **Prog Brain Res** 1998; 118:13–25 (88 ref.)

PHYSIOLOGY

The role of phospholamban and SERCA3 in regulation of smooth muscle–endothelial cell signalling mechanisms: evidence from gene-ablated mice. Paul RJ. **Acta Physiol Scand** 1998 Dec;164(4):589–97 (54 ref.)
Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Crawley JN. **Brain Res** 1999 Jul 17;835(1):18–26 (77 ref.)
Sex with knockout models: behavioral studies of estrogen receptor alpha. Rissman EF, et al. **Brain Res** 1999 Jul 17; 835(1):80–90 (88 ref.)
The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. Bonventre JV. **J Am Soc Nephrol** 1999 Feb;10(2):404–12 (76 ref.)
Role of L1 in neural development: what the knockouts tell us. Kamiguchi H, et al. **Mol Cell Neurosci** 1998 Sep; 12(1–2):48–55 (54 ref.)
ACE knockout mice—lessons for adult nephrology [editorial] Bernstein KE. **Nephrol Dial Transplant** 1998 Dec; 13(12):2991–4 (19 ref.)

MICE, LABORATORY see **MICE**

MICE, MUTANT STRAINS

Rodent mutant models of obesity and their correlations to human obesity. Augustine KA, et al. **Anat Rec** 1999 Apr 15;257(2):64–72 (31 ref.)
The mouse with trisomy 16 as a model of human hearts with common atrioventricular junction. Anderson RH, et al. **Cardiovasc Res** 1998 Jul;39(1):155–64 (29 ref.)
Seizure disorders in mutant mice: relevance to human epilepsies. Puranam RS, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):281–7 (61 ref.)
Spontaneous and engineered mutant mice as models for experimental and comparative pathology: history, comparison, and developmental technology. Roths JB, et al. **Lab Anim Sci** 1999 Feb;49(1):12–34 (228 ref.)
Genetic analysis of mammalian G-protein signalling. Offermanns S, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1375–81 (66 ref.)

GENETICS

The role of mouse mutants in the identification of human hereditary hearing loss genes. Probst FJ, et al. **Hear Res** 1999 Apr;130(1–2):1–6 (63 ref.)
Mouse models of genetic disease: new approaches, new paradigms. Brown SD. **J Inherit Metab Dis** 1998 Aug; 21(5):532–9 (35 ref.)
Mouse alleles: if you've seen one, you haven't seen them all. Davis AP, et al. **Trends Genet** 1998 Nov;14(11):438–41 (23 ref.)
[Mutant mice as a model of human diseases of aging. Defective transcription and premature aging] de Boer J, et al. **Tijdschr Gerontol Geriatr** 1999 Aug;30(4):168–70 (13 ref.) (Eng. Abstr.) **(Dut)**
[Genetics of the limb pattern formation in mouse] Masuya H. **Kaibogaku Zasshi** 1998 Dec;73(6):687–97 (36 ref.) (Eng. Abstr.) **(Jpn)**
[Saturation mutagenesis in mice] Yamamura K. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2233–7 (12 ref.) **(Jpn)**

MICE, NEUROLOGIC MUTANTS

EMBRYOLOGY

The reeler mouse as a model of brain development. Lambert de Rouvroit C, et al. **Adv Anat Embryol Cell Biol** 1998; 150:1–106 (428 ref.)

GENETICS

Cell cycle events in neurons. Proliferation or death? Zhu X, et al. **Am J Pathol** 1999 Aug;155(2):327–9 (34 ref.)
The lurcher mutation and ionotropic glutamate receptors: contributions to programmed neuronal death in vivo. De Jager PL, et al. **Brain Pathol** 1998 Oct;8(4):795–807 (67 ref.)
Mouse models of spike-wave epilepsy. Barclay J, et al. **Epilepsia** 1999;40 Suppl 3:17–22 (26 ref.)

MICE, OBESE

Rodent mutant models of obesity and their correlations to human obesity. Augustine KA, et al. **Anat Rec** 1999 Apr 15;257(2):64–72 (31 ref.)
CNS regulation of energy balance and body weight: insights from rodent models. Elmquist JK. **Lab Anim Sci** 1998 Dec; 48(6):630–7 (0 ref.)

MICE, RED-BACKED see **MICROTINAE**

MICE, SCID

The SCID-hu xenogeneic transplantation model: complex but telling. Boehncke WH. **Arch Dermatol Res** 1999 Jul–Aug;291(7–8):367–73 (46 ref.)

MICE, TRANSGENIC

Transgenic mouse model of ethanol as a cofactor in HIV disease. Prakash O, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):266S–268S (39 ref.)
Transgenic mice in drug dependence research. Pich EM, et al. **Ann Med** 1998 Aug;30(4):390–6 (46 ref.)
Murine mentors: transgenic and knockout models of surgical disease. Arbeit JM, et al. **Ann Surg** 1999 Jan;229(1):21–40 (166 ref.)
Transgenic models of growth hormone action. Kopchick JJ, et al. **Annu Rev Nutr** 1999;19:437–61 (162 ref.)
Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Rosenberg MP, et al. **Cancer Metastasis Rev** 1998–99;17(3):295–9 (0 ref.)
Genetically altered mouse models for identifying carcinogens. Tennant RW, et al. **IARC Sci Publ** 1999; (146):123–50 (85 ref.)
Antisense strategies: functions and applications in immunology. Varga LV, et al. **Immunol Lett** 1999 Aug 3;69(2):217–24 (45 ref.)
Transgenic mice—the early days. Palmiter RD. **Int J Dev Biol** 1998;42(7 Spec No):847–54 (59 ref.)
Cardiac transgenic and gene-targeted mice as models of cardiac hypertrophy and failure: a problem of (new) riches [editorial; comment] Izumo S, et al. **J Card Fail** 1998 Dec; 4(4):263–70 (46 ref.) Comment on: J Card Fail 1998 Dec;4(4):349–61.
Genetically engineered mice: model systems for left ventricular failure [see comments] Kadambi VJ, et al. **J Card Fail** 1998 Dec;4(4):349–61 (59 ref.) Comment in: J Card Fail 1998 Dec;4(4):263–70.
Insights into apolipoprotein B biology from transgenic and gene-targeted mice. Véniant MM, et al. **J Nutr** 1999 Feb; 129(2S Suppl):451S–455S (37 ref.)
Insights into cancer from transgenic mouse models. Macleod KF, et al. **J Pathol** 1999 Jan;187(1):43–60 (232 ref.)
Inherited neurodegenerative diseases and transgenic models. Borchelt DR. **Lab Anim Sci** 1998 Dec;48(6):604–10 (0 ref.)
Interpretation of phenotype in genetically engineered mice [see comments] Doetschman T. **Lab Anim Sci** 1999 Apr; 49(2):137–43 (67 ref.) Comment in: Lab Anim Sci 1999 Apr;49(2):134.
Generation of transgenic mice. Hofker MH, et al. **Methods Mol Biol** 1998;110:63–78 (21 ref.)
Production and growth of conditionally immortal cell lines from the H-2KbtsA58 transgenic mouse. Noble M. **Methods Mol Biol** 1999;97:139–58 (93 ref.)
Application of lacZ transgenic mice to cell lineage studies. Trainor PA, et al. **Methods Mol Biol** 1999;97:183–200 (18 ref.)
Transgenic models to study the actions of cytokines in the central nervous system. Campbell IL, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):126–35 (58 ref.)
Using knockout and transgenic mice to study neurophysiology and behavior. Picciotto MR, et al. **Physiol Rev** 1998 Oct;78(4):1131–63 (305 ref.)
Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium. Beermann F, et al. **Pigment Cell Res** 1999 Apr;12(2):71–80 (71 ref.)
Animal models of human leukocyte antigen B27-linked arthritides [published erratum appears in Rheum Dis Clin North Am 1998 Feb;25(1):preceding Preface] Khare SD, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):883–94, xi–xii (66 ref.)
A new approach for studying gene regulation by distant DNA elements in transgenic mice. Nielsen LB, et al. **Scand J Clin Lab Invest Suppl** 1999;229:33–9 (17 ref.)
Genetic neurodegenerative diseases: the human illness and transgenic models. Price DL, et al. **Science** 1998 Nov 6; 282(5391):1079–83 (63 ref.)
Retinoblastoma in transgenic mice: models of hereditary retinoblastoma. Mills MD, et al. **Surv Ophthalmol** 1999 May–Jun;43(6):508–18 (105 ref.)
The potential of genetically altered mice as animal models for carcinogen identification. Maronpot RR. **Toxicol Pathol** 1998 Jul–Aug;26(4):579–81 (21 ref.)
Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing. van Steeg H, et al. **Toxicol Pathol** 1998 Nov–Dec;26(6):742–9 (63 ref.)
[Construction of HCV transgenic mice with Cre/loxP switching expression system] Wakita T. **Uirusu** 1998 Jun; 48(1):9–18 (32 ref.) **(Jpn)**

EMBRYOLOGY

Reporter genes for the study of transcriptional regulation in transgenic mouse embryos. Gilthorpe JD, et al. **Methods Mol Biol** 1999;97:159–82 (65 ref.)

GENETICS

Lessons from genetically engineered animal models. I. Physiological studies with gastrin in transgenic mice. Wang TC, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):G6–11 (20 ref.)
Genetic engineering in mice: impact on insulin signalling and action. Lamothe B, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):193–204 (107 ref.)
Transgenic models of neurodegeneration. Neurodegeneration: of (transgenic) mice and men. Aguzzi A, et al. **Brain Pathol** 1998 Oct;8(4):695–7 (17 ref.)
Transgenic mice in the study of polyglutamine repeat expansion diseases. Bates GP, et al. **Brain Pathol** 1998 Oct; 8(4):699–714 (53 ref.)
Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. Borchelt DR, et al. **Brain Pathol** 1998 Oct;8(4):735–57 (281 ref.)
Transgenic mice in the study of ALS: the role of neurofilaments. Julien JP, et al. **Brain Pathol** 1998 Oct; 8(4):759–69 (88 ref.)
Transgenic and knockout mice in research on prion diseases. Raeber AJ, et al. **Brain Pathol** 1998 Oct;8(4):715–33 (147 ref.)
Mouse models of myelin diseases. Werner H, et al. **Brain Pathol** 1998 Oct;8(4):771–93 (194 ref.)
Recombinogenic targeting: a new approach to genomic analysis—a review. Shashikant CS, et al. **Gene** 1998 Nov 26;223(1–2):9–20 (83 ref.)
WAT-free mice: diabetes without obesity. McKnight SL. **Genes Dev** 1998 Oct 15;12(20):3145–48 (20 ref.)
Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. Yamashita T, et al. **J Endocrinol** 1998 Oct;159(1):1–8 (13 ref.)
Application of exogenously regulatable promoter systems to transgenic models for the study of aging. Morgan WW, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jan;54(1):B30–40; discussion B41–2 (68 ref.)
Transgenic mouse strain rescue by frozen ovaries. Sztein JM, et al. **Lab Anim Sci** 1999 Feb;49(1):99–100 (13 ref.)
Transgenic mouse models for gonadal tumorigenesis. Rahman NA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):167–74 (70 ref.)
Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Dean SW, et al. **Mutagenesis** 1999 Jan;14(1):141–51 (115 ref.)
An estimator of the mutant frequency in assays using transgenic animals. Delongchamp RR, et al. **Mutat Res** 1999 Mar 15;440(1):101–8 (20 ref.)
Spontaneous mutations in the Big Blue transgenic system are primarily mouse derived. Hill KA, et al. **Mutat Res** 1999 Jan;436(1):11–9 (49 ref.)
Overview of transgenic and gene knockout mice. Yamamura K. **Prog Exp Tumor Res** 1999;35:13–24 (60 ref.)
Cloning the laboratory mouse. Wakayama T, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):253–8 (46 ref.)
Utilization of genetically altered animals in the pharmaceutical industry. Rudmann DG, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):111–4 (51 ref.)

IMMUNOLOGY

The use of human leucocyte antigen class I transgenic mice to investigate human immune function. Faulkner L, et al. **J Immunol Methods** 1998 Dec 1;221(1–2):1–16 (83 ref.)

METABOLISM

Transgenic mice expressing Alzheimer amyloid precursor proteins. Hsiao K. **Exp Gerontol** 1998 Nov–Dec; 33(7–8):883–9 (39 ref.)

PHYSIOLOGY

Lessons from genetically engineered animal models. II. Disorders of enteric neuronal development: insights from transgenic mice. Gershon MD. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G262–7 (35 ref.)
Behavioral phenotyping of transgenic and knockout mice:

experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Crawley JN. **Brain Res** 1999 Jul 17;835(1):18–26 (77 ref.)

Genetically–targeted and conditionally–regulated ablation of astroglial cells in the central, enteric and peripheral nervous systems in adult transgenic mice. Sofroniew MV, et al. **Brain Res** 1999 Jul 17;835(1):91–5 (34 ref.)

Analysing hippocampal function in transgenic mice: an ethological perspective. Gerlai R, et al. **Trends Neurosci** 1999 Feb;22(2):47–51 (40 ref.)

MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY see **CHROMATOGRAPHY, MICELLAR ELECTROKINETIC CAPILLARY**

MICELLES

Self–evolving microstructured systems upon enzymatic catalysis [published erratum appears in Biochimie 1998 Jul;80(7):634] Chopineau J, et al. **Biochimie** 1998 May–Jun; 80(5–6):421–35 (106 ref.)

Polymeric micelles – a new generation of colloidal drug carriers. Jones M, et al. **Eur J Pharm Biopharm** 1999 Sep; 48(2):101–11 (102 ref.)

Micelle stability: kappa–casein structure and function. Creamer LK, et al. **J Dairy Sci** 1998 Nov;81(11):3004–12 (38 ref.)

[Interaction of apolipoprotein A1 with phospholipids and structure of mixed micelles] Misharin AIu. **Bioorg Khim** 1998 Aug;24(8):563–85 (205 ref.) (Eng. Abstr.) **(Rus)**

MICROABRASION, DENTAL see **ENAMEL MICROABRASION**

MICROABRASION, ENAMEL see **ENAMEL MICROABRASION**

MICROANGIOPATHY, DIABETIC see **DIABETIC ANGIOPATHIES**

MICROBIAL SENSITIVITY TESTS

see related
DRUG RESISTANCE, MICROBIAL

[Antibiotic sensitivity to isolated bacteria in pediatric urinary tract infections] Vu–Thien H. **Arch Pediatr** 1998;5 Suppl 3:266S–268S (8 ref.) (Eng. Abstr.) **(Fre)**

[New clinical tests that physicians should know for diagnosis of infectious diseases] Yamane N. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2039–45 (7 ref.) **(Jpn)**

METHODS

[Antimicrobial resistance testing of H. pylori epsilometer test and disk diffusion test] Fukazawa K, et al. **Nippon Rinsho** 1999 Jan;57(1):76–80 (12 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Principles to guide international standard tests for liquid chemical germicides: a proposal. Miner N. **J AOAC Int** 1999 May–Jun;82(3):669–75 (21 ref.)

Standardization of antifungal susceptibility testing and clinical relevance [published erratum appears in Med Mycol 1999 Apr;37(2):147] Espinel–Ingroff A, et al. **Med Mycol** 1998;36 Suppl 1:68–78 (80 ref.)

Antimicrobial resistance in gram–positive bacteria: the myth of the MIC. Minimum inhibitory concentration. Rapp RP. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):112S–119S; discussion 133S–137S (40 ref.)

[Multidrug–resistant tuberculosis. 1. Drug susceptibility testing and its standardization] Abe C. **Kekkaku** 1998 Nov; 73(11):649–55 (20 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIAL SUPERINVASION see **SUPERINFECTION**

MICROBIOLOGIC PHENOMENA

see related
BACTERIAL PHYSIOLOGY
VIRAL PHYSIOLOGY

MICROBIOLOGICAL TECHNIQUES

Molecular diagnostics for existing and emerging infections. Complementary tools for a new era of clinical microbiology. Dumler JS, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S33–9 (57 ref.)

Clinical analyzers. Microbiology. Mouritsen CL, et al. **Anal Chem** 1999 Jun 15;71(12):366R–372R (79 ref.)

How will bioinformatics influence metabolic engineering? Edwards JS, et al. **Biotechnol Bioeng** 1998 Apr 20–May 5;58(2–3):162–9 (26 ref.)

Science, medicine, and the future. Near patient microbiological tests. Borriello SP. **BMJ** 1999 Jul 31; 319(7205):298–301 (12 ref.)

The application of near patient testing to microbiology. Bevan VM, et al. **Commun Dis Public Health** 1999 Jan; 2(1):14–21 (28 ref.)

In situ methods for assessment of microorganisms and their activities. Amann R, et al. **Curr Opin Microbiol** 1998 Jun; 1(3):352–8 (66 ref.)

Methods for the differentiation of microorganisms. Busch U, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1–2):263–78 (134 ref.)

Sequencing microbial genomes--what will it do for microbiology? Jenks PJ. **J Med Microbiol** 1998 May; 47(5):375–82 (43 ref.)

The rapid method in microbiology using chemical method and immunochemical method. Shiba K. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):73–81 (8 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Hypothetical model for monitoring microbial growth by using capacitance measurements--a minireview. Noble PA. **J Microbiol Methods** 1999 Jul;37(1):45–9 (30 ref.)

TRENDS

Recent advances: medical microbiology. Richardson H, et al. **BMJ** 1998 Oct 17;317(7165):1060–2 (21 ref.)

MICROBIOLOGY

see related
ARCHAEA
BACTERIA
FUNGI
PROTOZOA
VIRUSES

Clinical microbiology quality assurance program: a Taiwan experience. Tsai WC, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 May;28(2):95–108 (31 ref.)

Clinical Microbiology Reviews: genesis of a journal. Morello JA. **Clin Microbiol Rev** 1999 Apr;12(2):183–6 (5 ref.)

Microdermatology: cell surface in the interaction of microbes with the external world. Nikaido H. **J Bacteriol** 1999 Jan; 181(1):4–8 (51 ref.)

Why do microbes have toxins? Williams PH, et al. **Soc Appl Bacteriol Symp Ser** 1998;27:1S–6S (25 ref.)

[The management and information technology applicable to clinical microbiology laboratories] Brezmes Valdivieso MF, et al. **Enferm Infecc Microbiol Clin** 1999 May; 17(5):231–41 (65 ref.) **(Spa)**

HISTORY

Biochemistry of methanogenesis: a tribute to Marjory Stephenson. 1998 Marjory Stephenson Prize Lecture. Thauer RK. **Microbiology** 1998 Sep;144 (Pt 9):2377–406 (319 ref.)

INSTRUMENTATION

Clinical analyzers. Microbiology. Mouritsen CL, et al. **Anal Chem** 1999 Jun 15;71(12):366R–372R (79 ref.)

TRENDS

Recent advances: medical microbiology. Richardson H, et al. **BMJ** 1998 Oct 17;317(7165):1060–2 (21 ref.)

Controversies affecting the future practice of clinical microbiology. Robinson A, et al. **J Clin Microbiol** 1999 Apr;37(4):883–9 (49 ref.)

MICROBODIES

see related
PEROXISOME PROLIFERATORS

CHEMISTRY

Import of proteins into peroxisomes. Hettema EH, et al. **Biochim Biophys Acta** 1999 Aug 12;1451(1):17–34 (121 ref.)

DRUG EFFECTS

[Peroxisomes and peroxisome proliferators. Specific environmental poisons and therapeutic agents affecting lipid metabolism and hormone release] Hammer TA, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3603–8 (66 ref.) (Eng. Abstr.) **(Nor)**

ENZYMOLOGY

Current cytochemical techniques for the investigation of peroxisomes. A review. Fahimi HD, et al. **J Histochem Cytochem** 1999 Oct;47(10):1219–32 (135 ref.)

Peroxisomal beta–oxidation enzymes. Hashimoto T. **Neurochem Res** 1999 Apr;24(4):551–63 (94 ref.)

METABOLISM

The role of the carnitine system in peroxisomal fatty acid oxidation. Ramsay RR. **Am J Med Sci** 1999 Jul; 318(1):28–35 (41 ref.)

Genetic peroxisomal disorders: why, when, and how to test [editorial; comment] Moser HW, et al. **Ann Neurol** 1998 Nov;44(5):713–5 (14 ref.) Comment on: Ann Neurol 1998 Nov;44(5):720–30.

The non–specific lipid transfer protein (sterol carrier protein 2) acts as a peroxisomal fatty acyl–CoA binding protein. Wirtz KW, et al. **Biochem Soc Trans** 1998 Aug;26(3):374–8 (29 ref.)

Peroxisome biogenesis: from yeast to man. Kunau WH. **Curr Opin Microbiol** 1998 Apr;1(2):232–7 (61 ref.)

Peroxisomes in lipid metabolism. Seedorf U. **J Cell Biochem Suppl** 1998;30–31:158–67 (65 ref.)

Lipid metabolism in peroxisomes in relation to human disease. Wanders RJ, et al. **Mol Aspects Med** 1998 Apr;19(2):69–154 (305 ref.)

Lipidic signaling and peroxisomal function. Masters C. **Subcell Biochem** 1998;30:437–52 (35 ref.)

New insights in peroxisomal beta–oxidation. Implications for human peroxisomal disorders. Van Veldhoven PP. **Verh K Acad Geneeskd Belg** 1998;60(3):195–214 (97 ref.)

PHYSIOLOGY

On the role of the peroxisome in cell differentiation and carcinogenesis. Masters C, et al. **Mol Cell Biochem** 1998 Oct;187(1–2):85–97 (71 ref.)

Peroxin puzzles and folded freight: peroxisomal protein import in review. Crookes WJ, et al. **Naturwissenschaften** 1999 Feb;86(2):51–61 (126 ref.)

ULTRASTRUCTURE

Current cytochemical techniques for the investigation of peroxisomes. A review. Fahimi HD, et al. **J Histochem Cytochem** 1999 Oct;47(10):1219–32 (135 ref.)

MICROCAPSULES see **CAPSULES**

MICROCEPHALY

GENETICS

Chromosomal breakage syndromes. Carney JP. **Curr Opin Immunol** 1999 Aug;11(4):443–7 (47 ref.)

Syndrome of microcephaly, Dandy–Walker malformation, and Wilms tumor caused by mosaic variegated aneuploidy with premature centromere division (PCD): report of a new case and review of the literature. Kawame H, et al. **J Hum Genet** 1999;44(4):219–24 (16 ref.)

PATHOLOGY

Microcephalic osteodysplastic primordial dwarfism type II: report of three cases and review. Majewski F, et al. **Am J Med Genet** 1998 Oct 30;80(1):25–31 (18 ref.)

Microcephalic osteodysplastic primordial dwarfism Taybi–Linder type: report of four cases and review of the literature. Sigaudy S, et al. **Am J Med Genet** 1998 Oct 30;80(1):16–24 (23 ref.)

MICROCHEMISTRY

Microfabricated liquid chromatography columns based on collocated monolith support structures. He B, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):925–32 (32 ref.)

It's a noisy business! Genetic regulation at the nanomolar scale. McAdams HH, et al. **Trends Genet** 1999 Feb; 15(2):65–9 (41 ref.)

METHODS

Femtochemistry uncovers the nature of electron transfer reactions. Castleman AW Jr, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4219–20 (28 ref.)

[Establishment of microanalysis of prostaglandin metabolites by GC/MS and its clinical application] Mizugaki M. **Yakugaku Zasshi** 1999 Jan;119(1):61–80 (39 ref.) (Eng. Abstr.) **(Jpn)**

MICROCIRCULATION

Potential role of the microvasculature in progression of heart failure. Liu PP, et al. **Am J Cardiol** 1999 Aug 19; 84(4A):23L–26L (38 ref.)

Disturbed blood flow structuring as critical factor of hemorheological disorders in microcirculation. Mchedlishvili G. **Clin Hemorheol Microcirc** 1998 Dec; 19(4):315–25 (63 ref.)

CYTOLOGY

Do adhesion molecules importantly regulate leukocyte kinetics within intraacinar microvessels of the lung? Yamaguchi K, et al. **Histol Histopathol** 1998 Oct; 13(4):1089–102 (70 ref.)

DRUG EFFECTS

Vitamin E: focus on microcirculation. Lehr HA, et al. **Microcirculation** 1998;5(2–3):117–28 (140 ref.)

ENZYMOLOGY

Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels. Hauck W, et al. **Semin Perinatol** 1999 Jun;23(3):250–60 (92 ref.)

IMMUNOLOGY

[Skin microcirculation, adherence molecules and inflammatory dermatoses] Henry F, et al. **Rev Med Liege** 1998 Aug;53(8):479–82 (15 ref.) (Eng.

Abstr.) **(Fre)**

PATHOLOGY

Microvascular involvement in cardiac pathology. Gavin JB, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2531–40 (130 ref.)

PHYSIOLOGY

Age-related changes in the microcirculation of skeletal muscle. Degens H. **Adv Exp Med Biol** 1998;454:343–8 (35 ref.)

Overview of microcirculatory oxygen measurements and their contribution to our understanding of oxygen delivery to tissue. Johnson PC. **Adv Exp Med Biol** 1998;454:361–5 (19 ref.)

Endometrial microvascular growth in normal and dysfunctional states. Rogers PA, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):503–8 (27 ref.)

Control of microvascular resistance in physiological conditions and reperfusion. DeFily DV. **J Mol Cell Cardiol** 1998 Dec;30(12):2547–54 (56 ref.)

Cytokines and the microcirculation in ischemia and reperfusion. Frangogiannis NG, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2567–76 (48 ref.)

Life and death in the microcirculation: a role for angiotensin II. Greene AS. **Microcirculation** 1998;5(2–3):101–7 (42 ref.)

Potassium channels and regulation of the microcirculation. Jackson WF. **Microcirculation** 1998;5(2–3):85–90 (25 ref.)

Measurement of microvascular transport parameters of macromolecules in tissues and organs of intact animals. Renkin EM, et al. **Microcirculation** 1998;5(2–3):139–52 (28 ref.)

[Coronary microcirculation. Physiologic and pathologic aspects] Garot P, et al. **Arch Mal Coeur Vaiss** 1999 Jun; 92(6):741–55 (70 ref.) (Eng. Abstr.) **(Fre)**

[Cerebrovascular aging] Buée L. **Therapie** 1999 Jan–Feb; 54(1):155–65 (94 ref.) (Eng. Abstr.) **(Fre)**

[Methods for vascular exploration in man: microcirculation and veins] Carpentier PH. **Therapie** 1999 May–Jun; 54(3):369–74 (30 ref.) (Eng. Abstr.) **(Fre)**

[Microcirculatory derangement and ischemia of the pancreas] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 May; 100(5):342–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Critical threshold cerebral hypoperfusion causes Alzheimer's disease? de la Torre JC. **Acta Neuropathol (Berl)** 1999 Jul; 98(1):1–8 (70 ref.)

Microcirculatory oxygenation and shunting in sepsis and shock [see comments] Ince C, et al. **Crit Care Med** 1999 Jul;27(7):1369–77 (75 ref.) Comment in: Crit Care Med 1999 Jul;27(7):1400–1.

Inflammatory alterations in the myocardial microcirculation. Hansen PR. **J Mol Cell Cardiol** 1998 Dec;30(12):2555–9 (45 ref.)

Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. Korthuis RJ, et al. **J Vasc Res** 1999;36 Suppl 1:15–23 (31 ref.)

Diabetes and peripheral vascular disease. Akbari CM, et al. **J Vasc Surg** 1999 Aug;30(2):373–84 (111 ref.)

SURGERY

Review of significant microvascular surgical breakthroughs involving the heart and lungs in rats. Chung WS, et al. **Microsurgery** 1999;19(2):71–7 (66 ref.)

MICROCOCCACEAE

ISOLATION & PURIFICATION

Central nervous system infections due to Stomatococcus mucilaginosus in immunocompromised hosts. Goldman M, et al. **Clin Infect Dis** 1998 Nov;27(5):1241–6 (13 ref.)

MICROCOCCUS LUTEUS

Micrococcus luteus endocarditis: case report and review of the literature. Seifert H, et al. **Zentralbl Bakteriol** 1995 Oct; 282(4):431–5 (24 ref.)

MICROCOMPUTERS

Future of bradyarrhythmia therapy systems: automaticity. Jones BR, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):192D–201D (64 ref.)

How smart should pacemakers Be? Saoudi N, et al. **Am J Cardiol** 1999 Mar 11;83(5B):180D–186D (32 ref.)

Implantable brain chips? Time for debate. Maguire GQ Jr, et al. **Hastings Cent Rep** 1999 Jan–Feb;29(1):7–13 (35 ref.)

Video transmission for telemedicine. Squibb NJ. **J Telemed Telecare** 1999;5(1):1–10 (11 ref.)

Clinical documentation: the handheld computer as a survival tool. Wofford MM, et al. **MD Comput** 1998 Nov–Dec; 15(6):352–4, 356, 358 (30 ref.)

The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)

MICRODIALYSIS

Assessment of pharmacodynamic and pharmacokinetic characteristics of drugs using microdialysis sampling and capillary electrophoresis. Denoroy L, et al. **Electrophoresis** 1998 Nov;19(16–17):2841–7 (43 ref.)

Pharmacokinetic and metabolism studies using microdialysis sampling. Hansen DK, et al. **J Pharm Sci** 1999 Jan; 88(1):14–27 (113 ref.)

Neurochemical monitoring of the acutely injured human brain. Hillered L, et al. **Scand J Clin Lab Invest Suppl** 1999; 229:9–18 (57 ref.)

METHODS

Measurement of histamine release in intact human skin by microdialysis technique. Clinical and experimental findings. Petersen LJ. **Dan Med Bull** 1998 Sep;45(4):383–401 (303 ref.)

In vivo neurochemical correlates of cognitive processes: methodological and conceptual challenges. Bruno JP, et al. **Rev Neurosci** 1999;10(1):25–48 (88 ref.)

[Microdialysis. A method for measurement of local tissue metabolism] Nielsen PS, et al. **Ugeskr Laeger** 1999 Mar 22;161(12):1735–8 (40 ref.) (Eng. Abstr.) **(Dan)**

STATISTICS & NUMERICAL DATA

In vivo microdialysis sampling: theory and applications. Chaurasia CS. **Biomed Chromatogr** 1999 Aug;13(5):317–32 (155 ref.)

MICROENCAPSULATION see **DRUG COMPOUNDING**

MICROFILAMENT PROTEINS

The coronin family of actin-associated proteins. de Hostos EL. **Trends Cell Biol** 1999 Sep;9(9):345–50 (29 ref.)

[Molecular functions of cofilin which regulates reorganization of actin cytoskeleton] Moriyama K, et al. **Seikagaku** 1999 Feb;71(2):101–14 (60 ref.) **(Jpn)**

CHEMISTRY

Structural modules in actin-binding proteins: towards a new classification. Van Troys M, et al. **Biochim Biophys Acta** 1999 Jan 11;1448(3):323–48 (160 ref.)

The fibrillins. Ramirez F, et al. **Int J Biochem Cell Biol** 1999 Feb;31(2):255–9 (13 ref.)

ADF/cofilin weakens lateral contacts in the actin filament. McGough A, et al. **J Mol Biol** 1999 Aug 20;291(3):513–9 (39 ref.)

CLASSIFICATION

Structural modules in actin-binding proteins: towards a new classification. Van Troys M, et al. **Biochim Biophys Acta** 1999 Jan 11;1448(3):323–48 (160 ref.)

GENETICS

Marfan syndrome: new clues to genotype-phenotype correlations. Ramirez F, et al. **Ann Med** 1999 Jun; 31(3):202–7 (30 ref.)

Transcriptional regulation of the desmin and SM22 genes in vascular smooth muscle cells. Mericskay M, et al. **Curr Top Pathol** 1999;93:7–17 (51 ref.)

METABOLISM

Regulation of cortical structure by the ezrin-radixin-moesin protein family. Bretscher A. **Curr Opin Cell Biol** 1999 Feb; 11(1):109–16 (56 ref.)

The fibrillins. Ramirez F, et al. **Int J Biochem Cell Biol** 1999 Feb;31(2):255–9 (13 ref.)

Location of the binding site of the mannose-specific lectin comitin on F-actin. Fulgenzi G, et al. **J Mol Biol** 1998 Dec 18;284(5):1255–63 (38 ref.)

Actin binding proteins that change extent and rate of actin monomer-polymer distribution by different mechanisms. Weber A. **Mol Cell Biochem** 1999 Jan;190(1–2):67–74 (31 ref.)

[Cofilin phosphorylation and regulation of actin cytoskeletal reorganization by LIM-kinase] Mizuno K. **Seikagaku** 1999 May;71(5):345–50 (21 ref.) **(Jpn)**

PHYSIOLOGY

Putting a new twist on actin: ADF/cofilins modulate actin dynamics. Bamburg JR, et al. **Trends Cell Biol** 1999 Sep; 9(9):364–70 (69 ref.)

ERM proteins in cell adhesion and membrane dynamics. Mangeat P, et al. **Trends Cell Biol** 1999 May;9(5):187–92 (59 ref.)

[Novel F-actin-binding proteins involved in cell-cell adhesion] Nakanishi H. **Seikagaku** 1999 Jan;71(1):51–5 (14 ref.) **(Jpn)**

MICROFILAMENTS

PHYSIOLOGY

Spatial control of actin filament assembly: lessons from Listeria. Beckerle MC. **Cell** 1998 Dec 11;95(6):741–8 (46 ref.)

Cardiac contractility: how calcium activates the myofilaments. Rüegg JC. **Naturwissenschaften** 1998 Dec; 85(12):575–82 (70 ref.)

Rnd proteins: a new family of Rho-related proteins that interfere with the assembly of filamentous actin structures and cell adhesion. Chardin P. **Prog Mol Subcell Biol** 1999; 22:39–50 (33 ref.)

MICROFILARIA

ISOLATION & PURIFICATION

Diagnostics in onchocerciasis: future challenges. Boatin BA, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S41–5 (16 ref.)

MICROFLUOROMETRY see **CYTOPHOTOMETRY**

MICROFLUOROMETRY, FLOW see **FLOW CYTOMETRY**

MICROGLIA

Microglia in cell culture and in transplantation therapy for central nervous system disease. Dobrenis K. **Methods** 1998 Nov;16(3):320–44 (205 ref.)

CYTOLOGY

Origin and the functional role of microglia. Woźniak W. **Folia Morphol (Warsz)** 1998;57(4):277–85 (83 ref.)

The origin and differentiation of microglial cells during development. Cuadros MA, et al. **Prog Neurobiol** 1998 Oct; 56(2):173–89 (177 ref.)

[Involvement of proteinases produced by both neurons and microglia in neuronal lesion and death pathways] Nakanishi H, et al. **Nippon Yakurigaku Zasshi** 1998 Aug;112(2):77–88 (52 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Schubert P, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S21–8 (45 ref.)

Microglia and the immune pathology of Alzheimer disease. Giulian D. **Am J Hum Genet** 1999 Jul;65(1):13–8 (30 ref.)

Microglia and Alzheimer's disease. Kalaria RN. **Curr Opin Hematol** 1999 Jan;6(1):15–24 (105 ref.)

Inflammation and glial responses in ischemic brain lesions. Stoll G, et al. **Prog Neurobiol** 1998 Oct;56(2):149–71 (204 ref.)

METABOLISM

Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions. Levi G, et al. **Biochimie** 1998 Nov;80(11):899–904 (49 ref.)

Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. Mayer AM. **Medicina (B Aires)** 1998;58(4):377–85 (137 ref.)

PATHOLOGY

Reactive microgliosis. Streit WJ, et al. **Prog Neurobiol** 1999 Apr;57(6):563–81 (158 ref.)

PHYSIOLOGY

Microglia as mediators of inflammatory and degenerative diseases. González-Scarano F, et al. **Annu Rev Neurosci** 1999;22:219–40 (134 ref.)

Origin and the functional role of microglia. Woźniak W. **Folia Morphol (Warsz)** 1998;57(4):277–85 (83 ref.)

Functional roles of microglia in the central nervous system. Nakajima K, et al. **Hum Cell** 1998 Sep;11(3):141–55 (118 ref.)

Estrogen and microglia: A regulatory system that affects the brain. Mor G, et al. **J Neurobiol** 1999 Sep 15;40(4):484–96 (130 ref.)

The role of microglia and macrophages in the pathophysiology of the CNS. Stoll G, et al. **Prog Neurobiol** 1999 Jun;58(3):233–47 (187 ref.)

[Microglia: mechanisms of activation and significance in pathogenesis of neuropsychiatric illnesses] Gebicke-Haerter PJ, et al. **Nervenarzt** 1998 Sep; 69(9):752–62 (126 ref.) (Eng. Abstr.) **(Ger)**

[Apoptosis and microglia] Sawada M. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:15P–19P (21 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Colonisation of the developing human brain and spinal cord by microglia: a review. Rezaie P, et al. **Microsc Res Tech** 1999 Jun 15;45(6):359–82 (241 ref.)

VIROLOGY

Benzodiazepines, glia, and HIV-1 neuropathogenesis. Lokensgard JR, et al. **Mol Neurobiol** 1998 Aug;18(1):23–33 (69 ref.)

MICROGNATHISM

RADIOGRAPHY

[The cerebrocostomandibular syndrome] Cohnen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999

MICROGNATHISM

Aug;171(2):160–2 (10 ref.) **(Ger)**

MICROGRAPHIC SURGERY, MOHS see **MOHS SURGERY**

MICROGRAVITY see **WEIGHTLESSNESS**

MICROINJECTIONS

Spermatid injection: reconsidering spermatid injection. Prapas Y, et al. **Hum Reprod** 1999 Sep;14(9):2186–8 (36 ref.)

Can we justify spermatid microinjection for severe male factor infertility? Aslam I, et al. **Hum Reprod Update** 1998 May–Jun;4(3):213–22 (93 ref.)

Micro- and macro-consequences of ooplasmic injections of early haploid male gametes. Sofikitis N, et al. **Hum Reprod Update** 1998 May–Jun;4(3):197–212 (87 ref.)

Genetic concerns for the subfertile male in the era of ICSI. Kim ED, et al. **Prenat Diagn** 1998 Dec;18(13):1349–65 (130 ref.)

METHODS

Insertional mutagenesis in transgenic mice generated by the pronuclear microinjection procedure. Woychik RP, et al. **Int J Dev Biol** 1998;42(7 Spec No):1009–17 (68 ref.)

Reversible inactivation of subcortical sites by drug injection. Malpeli JG. **J Neurosci Methods** 1999 Jan;86(2):119–28 (30 ref.)

Transgenesis. Meng A, et al. **Methods Cell Biol** 1999; 60:133–48 (28 ref.)

Microinjection of mitotic cells. Wadsworth P. **Methods Cell Biol** 1999;61:219–31 (47 ref.)

Microinjection of DNA, RNA, and protein into the fertilized zebrafish egg for analysis of gene function. Holder N, et al. **Methods Mol Biol** 1999;97:487–90 (9 ref.)

Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells. Wilcox RA, et al. **Methods Mol Biol** 1999;114:193–208 (26 ref.)

MICROINTERFEROMETRY see **MICROSCOPY, INTERFERENCE**

MICROMANIPULATION

INSTRUMENTATION

Laser micromanipulation systems as universal tools in cellular and molecular biology and in medicine. Schütze K, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):735–46 (33 ref.)

METHODS

Laser micromanipulation systems as universal tools in cellular and molecular biology and in medicine. Schütze K, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):735–46 (33 ref.)

Postimplantation mouse development: whole embryo culture and micro-manipulation. Tam PP. **Int J Dev Biol** 1998;42(7 Spec No):895–902 (65 ref.)

Micromanipulation of chromosomes and spindles in insect spermatocytes. Zhang D, et al. **Methods Cell Biol** 1999; 61:209–18 (18 ref.)

[Nanometer/piconewton manipulation of single membrane protein molecules by laser tweezers] Kusumi A. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):906–11 (21 ref.) **(Jpn)**

MICRONUCLEI

Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Hagmar L, et al. **Recent Results Cancer Res** 1998;154:177–84 (7 ref.)

MICRONUTRIENTS

see related
TRACE ELEMENTS

Micronutrient malnutrition: policies and programs for control and their implications. Underwood BA, et al. **Annu Rev Nutr** 1999;19:303–24 (107 ref.)

Micronutrients and the pathogenesis of human immunodeficiency virus infection. Semba RD, et al. **Br J Nutr** 1999 Mar;81(3):181–9 (99 ref.)

Separate and joint effects of micronutrient deficiencies on linear growth. Rosado JL. **J Nutr** 1999 Feb;129(2S Suppl):531S–533S (25 ref.)

Toward a new definition of essential nutrients: is it now time for a third 'vitamin' paradigm? Challem JJ. **Med Hypotheses** 1999 May;52(5):417–22 (48 ref.)

Diet, micronutrients, and the prostate gland. Thomas JA. **Nutr Rev** 1999 Apr;57(4):95–103 (101 ref.)

Micronutrients, vitamins, and cancer risk. Schorah CJ. **Vitam Horm** 1999;57:1–23 (131 ref.)

[Correction of micronutrient deficiency--the most important aspect of healthy nutrition conception for the Russian population] Tutel'lan VA, et al. **Vopr Pitan** 1999;68(1):3–11 (47 ref.) **(Rus)**

ANALYSIS

Nutritional and biochemical properties of human milk: II. Lipids, micronutrients, and bioactive factors. Rodriguez-Palmero M, et al. **Clin Perinatol** 1999 Jun; 26(2):335–59 (132 ref.)

Nutritional genomics: manipulating plant micronutrients to improve human health. DellaPenna D. **Science** 1999 Jul 16;285(5426):375–9 (42 ref.)

MICROPHTHALMOS

GENETICS

Another observation of microphthalmia in an XX male: microphthalmia with linear skin defects syndrome without linear skin lesions. Kono T, et al. **J Hum Genet** 1999; 44(1):63–8 (34 ref.)

[Isoform multiplicity of microphthalmia-associated transcription factor] Yasumoto K, et al. **Seikagaku** 1999 Jan;71(1):61–4 (15 ref.) **(Jpn)**

MICROPROCESSORS see **MICROCOMPUTERS**

MICROPUNCTURES see **PUNCTURES**

MICROSATELLITE MARKERS see **MICROSATELLITE REPEATS**

MICROSATELLITE REPEATS

Use of cosmid-derived and chromosome-specific canine microsatellites. Dickens HF, et al. **J Hered** 1999 Jan–Feb; 90(1):52–4 (17 ref.)

Transient appearance of the mutator phenotype during carcinogenesis as a possible explanation for the lack of mini/microsatellite instability in many late stage tumors. Stark AA. **Mutat Res** 1998 Nov 3;421(2):221–5 (65 ref.)

The application of microsatellites in molecular pathology. Naidoo R, et al. **Pathol Oncol Res** 1998;4(4):310–5 (48 ref.)

[Microsatellite instability and mismatch repair system] Uchida T. **Nippon Hinyokika Gakkai Zasshi** 1998 Dec; 89(12):917–30 (96 ref.) **(Jpn)**

GENETICS

The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Oliveira C, et al. **Am J Pathol** 1998 Oct;153(4):1211–9 (44 ref.)

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Boland CR, et al. **Cancer Res** 1998 Nov 15;58(22):5248–57 (119 ref.)

Testing tumors for microsatellite instability. de la Chapelle A. **Eur J Hum Genet** 1999 May–Jun;7(4):407–8 (7 ref.)

Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Claij N, et al. **Exp Cell Res** 1999 Jan 10;246(1):1–10 (137 ref.)

Microsatellite and trinucleotide-repeat evolution: evidence for mutational bias and different rates of evolution in different lineages. Rubinsztein DC, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1095–9 (31 ref.)

Microsatellites in the HLA region: 1998 update. Foissac A, et al. **Tissue Antigens** 1998 Oct;52(4):318–52 (352 ref.)

MICROSCOPY

From the histophotometer to the confocal microscope: the evolution of analytical microscopy. Benedetti PA. **Eur J Histochem** 1998;42 Spec No:11–7 (23 ref.)

Up close and personal to atoms [news] Yazdani A, et al. **Nature** 1999 Sep 16;401(6750):227–30 (35 ref.)

INSTRUMENTATION

Scanning near-field optical microscopy in cell biology and microbiology. Meixner AJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):673–88 (52 ref.)

METHODS

Scanning near-field optical microscopy in cell biology and microbiology. Meixner AJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):673–88 (52 ref.)

New time-resolved techniques in two-photon microscopy. So PT, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul; 44(5):771–93 (85 ref.)

Imaging techniques in microbiology. Fung DC, et al. **Curr Opin Microbiol** 1998 Jun;1(3):346–51 (46 ref.)

Soft x-ray microscopy. Jacobsen C. **Trends Cell Biol** 1999 Feb;9(2):44–7 (39 ref.)

Use of caged fluorochromes to track macromolecular movement in living cells. Politz JC. **Trends Cell Biol** 1999 Jul;9(7):284–7 (30 ref.)

[Computer-based image analysis for experimental and clinical morphology--principles, utilization and marginal limits] Seufert R, et al. **Zentralbl Gynakol** 1999;121(5):260–4 (9 ref.) (Eng. Abstr.) **(Ger)**

MICROSCOPY, ATOMIC FORCE

see related
MICROSCOPY, SCANNING TUNNELING

Near-field scanning optical microscopy. Shiku H, et al. **Anal Chem** 1999 Jan 1;71(1):23A–29A (38 ref.)

Studying receptor-mediated cell adhesion at the single molecule level. Pierres A, et al. **Cell Adhes Commun** 1998 Jul;5(5):375–95 (102 ref.)

Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579–84 (57 ref.)

Facilitated target location on DNA by individual Escherichia coli RNA polymerase molecules observed with the scanning force microscope operating in liquid. Bustamante C, et al. **J Biol Chem** 1999 Jun 11;274(24):16665–8 (19 ref.)

METHODS

Atomic force microscopy: a forceful way with single molecules. Engel A, et al. **Curr Biol** 1999 Feb 25; 9(4):R133–6 (20 ref.)

Molecular self-recognition and adhesion via proteoglycan to proteoglycan interactions as a pathway to multicellularity: atomic force microscopy and color coded bead measurements in sponges. Misevic GN. **Microsc Res Tech** 1999 Feb 15;44(4):304–9 (40 ref.)

Deposition of supercoiled DNA on mica for scanning force microscopy imaging. Samori B, et al. **Scanning Microsc** 1996;10(4):953–60; discussion 960–2 (36 ref.)

Spatially resolved force spectroscopy of biological surfaces using the atomic force microscope. Heinz WF, et al. **Trends Biotechnol** 1999 Apr;17(4):143–50 (74 ref.)

Atomic force microscopy: a powerful tool to observe biomolecules at work. Engel A, et al. **Trends Cell Biol** 1999 Feb;9(2):77–80 (39 ref.)

Near-field scanning optical microscopy in cell biology. Lewis A, et al. **Trends Cell Biol** 1999 Feb;9(2):70–3 (34 ref.)

MICROSCOPY, CONFOCAL

Confocal microscopy of the mitochondrial permeability transition in necrotic cell killing, apoptosis and autophagy. Lemasters JJ, et al. **Biofactors** 1998;8(3–4):283–5 (11 ref.)

Confocal microscopy of the cornea. Böhnke M, et al. **Prog Retin Eye Res** 1999 Sep;18(5):553–628 (190 ref.)

Airway structure: a role for confocal microscopy? Goldie RG, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec; 11(5–6):349–54 (68 ref.)

INSTRUMENTATION

Acousto-optic random-access laser scanning microscopy: fundamentals and applications to optical recording of neuronal activity. Saggau P, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):827–46 (21 ref.)

Two-photon excitation imaging based on a compact scanning head. Diaspro A, et al. **IEEE Eng Med Biol Mag** 1999 Sep–Oct;18(5):18–22, 30 (20 ref.)

METHODS

Acousto-optic random-access laser scanning microscopy: fundamentals and applications to optical recording of neuronal activity. Saggau P, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):827–46 (21 ref.)

Modern microscopy in biofilm research: confocal microscopy and other approaches. Palmer RJ Jr, et al. **Curr Opin Biotechnol** 1999 Jun;10(3):263–8 (44 ref.)

Application of real-time confocal microscopy for observation of living cells in tissue specimens. Satoh Y, et al. **Hum Cell** 1998 Dec;11(4):191–8 (21 ref.)

Innovations in two-photon deep tissue microscopy. Buehler C, et al. **IEEE Eng Med Biol Mag** 1999 Sep–Oct; 18(5):23–30 (29 ref.)

Two-photon excitation imaging based on a compact scanning head. Diaspro A, et al. **IEEE Eng Med Biol Mag** 1999 Sep–Oct;18(5):18–22, 30 (20 ref.)

Confocal microscopic analysis of morphogenetic movements. Cooper MS, et al. **Methods Cell Biol** 1999;59:179–204 (27 ref.)

Using time-lapse confocal microscopy for analysis of centromere dynamics in human cells. Sullivan KF, et al. **Methods Cell Biol** 1999;58:183–202 (26 ref.)

Preparation of yeast cells for confocal microscopy. Atkin AL. **Methods Mol Biol** 1999;122:131–9 (17 ref.)

Imaging gene expression using antibody probes. Brown NL. **Methods Mol Biol** 1999;122:75–91 (24 ref.)

Practical considerations for collecting confocal images. Carter D. **Methods Mol Biol** 1999;122:35–57 (7 ref.)

Analyzing morphogenetic cell behaviors in vitally stained zebrafish embryos. Cooper MS, et al. **Methods Mol Biol** 1999;122:185–204 (12 ref.)

Measurement in the confocal microscope. Cox G. **Methods Mol Biol** 1999;122:357–71 (5 ref.)

Confocal methods for Caenorhabditis elegans. Crittenden SL, et al. **Methods Mol Biol** 1999;122:141–51 (19 ref.)

Fluorescent probes for confocal microscopy. Cullander C. **Methods Mol Biol** 1999;122:59–73 (20 ref.)

Measuring dynamic cell volume in situ by confocal

microscopy. Errington RJ, et al. **Methods Mol Biol** 1999; 122:315–40 (12 ref.)
Live confocal analysis with fluorescently labeled proteins. Francis-Lang H, et al. **Methods Mol Biol** 1999;122:223–39 (24 ref.)
Presentation of confocal images. Halder G, et al. **Methods Mol Biol** 1999;122:373–84 (8 ref.)
Overview of fluorescence analysis with the confocal microscope. Harvath L. **Methods Mol Biol** 1999;115:149–58 (23 ref.)
Morphing confocal images and digital movie production. Hazen E. **Methods Mol Biol** 1999;122:421–41 (6 ref.)
Imaging sea urchin fertilization. Holy JM. **Methods Mol Biol** 1999;122:153–66 (41 ref.)
Imaging thick tissues with confocal microscopy. Imbert D, et al. **Methods Mol Biol** 1999;122:341–55 (14 ref.)
Confocal imaging of living cells in intact embryos. Kulesa PM, et al. **Methods Mol Biol** 1999;122:205–22 (6 ref.)
Imaging immunolabeled Drosophila embryos by confocal microscopy. Langeland JA. **Methods Mol Biol** 1999; 122:167–72 (4 ref.)
The preparation of stereoscopic 3D illustrations of confocal data sets for publications and slides. Martins GG, et al. **Methods Mol Biol** 1999;122:385–401 (4 ref.)
Confocal microscopy. Theory and applications. Mongan LC, et al. **Methods Mol Biol** 1999;114:51–74 (29 ref.)
Fluorescent calcium indicators: subcellular behavior and use in confocal imaging. O'Malley DM, et al. **Methods Mol Biol** 1999;122:261–303 (107 ref.)
Intracellular pH and pCa measurement. Opas M, et al. **Methods Mol Biol** 1999;122:305–13 (15 ref.)
An introduction to confocal imaging. Paddock SW. **Methods Mol Biol** 1999;122:1–34 (34 ref.)
Confocal microscopy on Xenopus laevis oocytes and embryos. Robb DL, et al. **Methods Mol Biol** 1999; 122:173–83 (11 ref.)
Confocal microscopy of plant cells. Wymer CL, et al. **Methods Mol Biol** 1999;122:103–30 (35 ref.)
Use of in vivo confocal microscopy to understand the pathology of accidental ocular irritation. Maurer JK, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):44–7 (24 ref.)

TRENDS

Light microscopy of living tissue: the state and future of the art. Cullander C. **J Investig Dermatol Symp Proc** 1998 Aug;3(2):166–71 (35 ref.)

MICROSCOPY, CONFOCAL, LASER SCANNING see **MICROSCOPY, CONFOCAL**

MICROSCOPY, ELECTRON

Electron microscopic tomography of rat-liver mitochondria and their interaction with the endoplasmic reticulum. Mannella CA, et al. **Biofactors** 1998;8(3–4):225–8 (6 ref.)
Electron microscopy in tumour diagnosis: continuing to complement other diagnostic techniques. Eyden B. **Histopathology** 1999 Aug;35(2):102–8 (46 ref.)
Electron microscopy for tumour diagnosis: is it redundant? Mierau GW. **Histopathology** 1999 Aug;35(2):99–101 (17 ref.)
Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. Erlandson RA, et al. **Hum Pathol** 1998 Dec; 29(12):1372–81 (71 ref.)
Neuroendocrine carcinomas: role of immunocytochemistry and electron microscopy. Hammond EH, et al. **Hum Pathol** 1998 Dec;29(12):1367–71 (31 ref.)
Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era. Ordóñez NG, et al. **Hum Pathol** 1998 Dec;29(12):1403–11 (60 ref.)
Ultrastructural features of diffuse malignant mesotheliomas. Oury TD, et al. **Hum Pathol** 1998 Dec;29(12):1382–92 (26 ref.)
Web-based telemicroscopy. Hadida-Hassan M, et al. **J Struct Biol** 1999 Apr-May;125(2–3):235–45 (29 ref.)
The Electron Microscopy Outreach Program: A Web-based resource for research and education. Sosinsky GE, et al. **J Struct Biol** 1999 Apr-May;125(2–3):246–52 (17 ref.)
As You Like It, Part 2: A critique and historical review of the electron microscopy literature. Ghadially FN. **Ultrastruct Pathol** 1999 Jan-Feb;23(1):1–17 (54 ref.)
The value of electron microscopy in the diagnosis and clinical management of lupus nephritis. Herrera GA. **Ultrastruct Pathol** 1999 Mar-Apr;23(2):63–77 (73 ref.)

INSTRUMENTATION

In situ transmission electron microscopy employed for studies of effects of ion and electron irradiation on materials. Allen CW, et al. **Microsc Res Tech** 1998 Aug 15;42(4):255–9 (16 ref.)
Use of quantitative convergent-beam electron diffraction in materials science. Holmestad R, et al. **Microsc Res Tech** 1999 Jul 15;46(2):130–45 (75 ref.)
Introduction to electron crystallography. Tivol WF. **Microsc Res Tech** 1999 Jul 15;46(2):69–74 (19 ref.)

METHODS

The structural study of membrane proteins by electron crystallography. Fujiyoshi Y. **Adv Biophys** 1998;35:25–80 (42 ref.)
Ultrastructural in situ hybridization: a review of technical aspects. Le Guellec D. **Biol Cell** 1998 Jul;90(4):297–306 (51 ref.)
Cationized ferritin as a stain for electron microscopic observation of bacterial ultrastructure. Anderson KL. **Biotech Histochem** 1998 Sep;73(5):278–88 (47 ref.)
Macromolecular structure determination by electron microscopy: new advances and recent results. Stowell MH, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):595–600 (42 ref.)
Special techniques in diagnostic electron microscopy. Howell DN, et al. **Hum Pathol** 1998 Dec;29(12):1339–46 (74 ref.)
Three-dimensional transmission electron microscopy and its application to mitosis research. McEwen BF, et al. **Methods Cell Biol** 1999;61:81–111 (89 ref.)
Electron microscopic enzyme cytochemistry. Araki N, et al. **Methods Mol Biol** 1999;117:159–65 (7 ref.)
General preparation of material and staining of sections. Davies HA. **Methods Mol Biol** 1999;117:1–11 (5 ref.)
Microwave processing techniques for electron microscopy: a four-hour protocol. Giberson RT, et al. **Methods Mol Biol** 1999;117:145–58 (17 ref.)
Low-temperature embedding in acrylic resins. Gounon P. **Methods Mol Biol** 1999;117:111–24 (19 ref.)
Preparation of double/single-stranded DNA and RNA molecules for electron microscopy. Hajibagheri MA. **Methods Mol Biol** 1999;117:209–27 (26 ref.)
Negative staining of thinly spread biological particulates. Harris JR. **Methods Mol Biol** 1999;117:13–30 (11 ref.)
High-pressure freezing for preservation of high resolution fine structure and antigenicity for immunolabeling. McDonald K. **Methods Mol Biol** 1999;117:77–97 (28 ref.)
Applications of electron microscopy for studying protein-DNA complexes. Schnos M, et al. **Methods Mol Biol** 1999;117:229–43 (6 ref.)
Microwave procedures for electron microscopy and resin-embedded sections. Leong AS, et al. **Micron** 1998 Oct;29(5):397–409 (90 ref.)
Vertical Pt-C replication for TEM, a revolution in imaging non-periodic macromolecules, biological gels and low-density polymer networks. Ruben GC. **Micron** 1998 Oct;29(5):359–96 (93 ref.)
Maximum entropy methods in electron crystallography. Gilmore CJ. **Microsc Res Tech** 1999 Jul 15;46(2):117–29 (60 ref.)
Use of quantitative convergent-beam electron diffraction in materials science. Holmestad R, et al. **Microsc Res Tech** 1999 Jul 15;46(2):130–45 (75 ref.)
Electron crystallography in surface structure analysis. Leslie C, et al. **Microsc Res Tech** 1999 Aug 1;46(3):160–77 (122 ref.)
Introduction to electron crystallography. Tivol WF. **Microsc Res Tech** 1999 Jul 15;46(2):69–74 (19 ref.)
Electron tomography of molecules and cells. Baumeister W, et al. **Trends Cell Biol** 1999 Feb;9(2):81–5 (42 ref.)

TRENDS

Macromolecular structure determination by electron microscopy: new advances and recent results. Stowell MH, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):595–600 (42 ref.)
Diagnostic electron microscopy is still a timely and rewarding method. Biel SS, et al. **J Clin Virol** 1999 Jun; 13(1–2):105–19 (104 ref.)

MICROSCOPY, ELECTRON, SCANNING

Computer-generated three-dimensional reconstructions of serially sectioned mouse embryos. Kaufman MH, et al. **J Anat** 1998 Oct;193 (Pt 3):323–36 (24 ref.)

INSTRUMENTATION

Electron nanodiffraction. Cowley JM. **Microsc Res Tech** 1999 Jul 15;46(2):75–97 (90 ref.)

METHODS

Microfabrication techniques using focused ion beams and emergent applications. Vasile MJ, et al. **Micron** 1999 Jun; 30(3):235–44 (36 ref.)
Electron nanodiffraction. Cowley JM. **Microsc Res Tech** 1999 Jul 15;46(2):75–97 (90 ref.)

MICROSCOPY, ELECTRON, TRANSMISSION see **MICROSCOPY, ELECTRON**

MICROSCOPY, ELECTRON, X-RAY MICROANALYSIS see **ELECTRON PROBE MICROANALYSIS**

MICROSCOPY, FLUORESCENCE

[Near-field optics: principle and application to the studies of biosciences] Saito K, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):807–11 (8 ref.) **(Jpn)**

INSTRUMENTATION

Evanescent-wave microscopy: a new tool to gain insight into the control of transmitter release. Oheim M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):307–18 (87 ref.)

METHODS

Following single cell dynamics with native fluorescence microscopy. Yeung ES. **Anal Chem** 1999 Aug 1; 71(15):522A–529A (50 ref.)
Fluorescence microscopy of calcium and synaptic vesicle dynamics during synapse formation in tissue culture. Dai Z, et al. **Histochem J** 1998 Mar;30(3):189–96 (22 ref.)
Innovations in two-photon deep tissue microscopy. Buehler C, et al. **IEEE Eng Med Biol Mag** 1999 Sep-Oct; 18(5):23–30 (29 ref.)
Two-photon excitation imaging based on a compact scanning head. Diaspro A, et al. **IEEE Eng Med Biol Mag** 1999 Sep-Oct;18(5):18–22, 30 (20 ref.)
GFP biofluorescence: imaging gene expression and protein dynamics in living cells. Design considerations for a fluorescence imaging laboratory. Goodwin PC. **Methods Cell Biol** 1999;58:343–67 (33 ref.)
Visualizing protein interactions in living cells using digitized GFP imaging and FRET microscopy. Periasamy A, et al. **Methods Cell Biol** 1999;58:293–314 (98 ref.)
Single-molecule fluorescence detection of green fluorescence protein and application to single-protein dynamics. Pierce DW, et al. **Methods Cell Biol** 1999;58:49–73 (33 ref.)
Fluorescent speckle microscopy of spindle microtubule assembly and motility in living cells. Waterman-Storer C, et al. **Methods Cell Biol** 1999;61:155–73 (25 ref.)
Overview of fluorescence analysis with the confocal microscope. Harvath L. **Methods Mol Biol** 1999;115:149–58 (23 ref.)
Cell migration into a wounded area in vitro. Lampugnani MG. **Methods Mol Biol** 1999;96:177–82 (33 ref.)
Immunofluorescence of cultured cells. Marchisio PC, et al. **Methods Mol Biol** 1999;96:85–92 (2 ref.)
Overview of fluorochromes. Mullins JM. **Methods Mol Biol** 1999;115:97–105 (24 ref.)
Postembedding labeling methods. Oliver C. **Methods Mol Biol** 1999;115:347–54 (14 ref.)
Overview of laser microbeam applications as related to antibody targeting. Pine PS. **Methods Mol Biol** 1999; 115:159–74 (29 ref.)
Fluorescence labeling of surface antigens of attached or suspended tissue-culture cells. Willingham MC. **Methods Mol Biol** 1999;115:113–9 (5 ref.)
Visualizing protein-protein interactions in the nucleus of the living cell. Day RN, et al. **Mol Endocrinol** 1999 Apr; 13(4):517–26 (63 ref.)
Fluorescence lifetime imaging microscopy: spatial resolution of biochemical processes in the cell. Bastiaens PI, et al. **Trends Cell Biol** 1999 Feb;9(2):48–52 (35 ref.)
Automated analysis of patterns in fluorescence-microscope images. Boland MV, et al. **Trends Cell Biol** 1999 May; 9(5):201–2 (5 ref.)
Dual-colour imaging with GFP variants. Ellenberg J, et al. **Trends Cell Biol** 1999 Feb;9(2):52–6 (31 ref.)
Imaging living cells and tissues by two-photon excitation microscopy. Piston DW. **Trends Cell Biol** 1999 Feb; 9(2):66–9 (15 ref.)
Photobleaching GFP reveals protein dynamics inside live cells. White J, et al. **Trends Cell Biol** 1999 Feb;9(2):61–5 (29 ref.)
[Multi-photon excitation fluorescence microscopy and its application to the studies of intracellular signal transduction] Sako Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1927–30 (11 ref.) **(Jpn)**

MICROSCOPY, IMMUNOELECTRON

Update on immunoelectron microscopy in diagnostic dermatopathology and cutaneous biology. Schaumburg-Lever G. **Dermatol Clin** 1999 Jul; 17(3):691–704, x (29 ref.)
In situ localization of pollen allergens by immunogold electron microscopy: allergens at unexpected sites. Grote M. **Int Arch Allergy Immunol** 1999 Jan;118(1):1–6 (43 ref.)
Plural immunoglobulin synthesis in a single cell: an ultrastructural study of two cases with three M-proteins. Saito N, et al. **Ultrastruct Pathol** 1998 Nov-Dec; 22(6):421–9 (26 ref.)

METHODS

Preparation of the fission yeast Schizosaccharomyces pombe for ultrastructural and immunocytochemical study. Hajibagheri MA, et al. **Methods Mol Biol** 1999;117:183–207 (43 ref.)
Pre-embedding labeling methods. Oliver C. **Methods Mol Biol** 1999;115:341–5 (3 ref.)
Preparation of colloidal gold. Oliver C. **Methods Mol Biol** 1999;115:327–30 (10 ref.)
Colloidal gold/streptavidin methods. Oliver C. **Methods Mol Biol** 1999;115:335–9 (6 ref.)
The application of LR gold resin for immunogold labeling. Thorpe JR. **Methods Mol Biol** 1999;117:99–110 (15 ref.)
The production of cryosections through fixed and cryoprotected biological material and their use in immunocytochemistry. Webster P. **Methods Mol Biol** 1999; 117:49–76 (27 ref.)
Preparation, use, and enlargement of ultrasmall gold particles in immunoelectron microscopy. Baschong W, et al. **Microsc Res Tech** 1998 Jul 1;42(1):66–79 (161 ref.)

MICROSCOPY, IMMUNOFLUORESCENCE see

MICROSCOPY, IMMUNOFLUORESCENCE

MICROSCOPY, FLUORESCENCE

MICROSCOPY, INTERFERENCE

[Light microscopic visualization of exocytosis] Terakawa S. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1945–50 (13 ref.) **(Jpn)**

MICROSCOPY, POLARIZATION

METHODS

Polarized light microscopy of spindles. Oldenbourg R. **Methods Cell Biol** 1999;61:175–208 (75 ref.)

MICROSCOPY, POLARIZED LIGHT see **MICROSCOPY, POLARIZATION**

MICROSCOPY, SCANNING TUNNELING

see related
MICROSCOPY, ATOMIC FORCE

METHODS

[Scanning probe microscopy and medico-biological nanotechnology: history and prospects] Permiakov NK, et al. **Arkh Patol** 1998 Sep–Oct;60(5):9–13 (24 ref.) (Eng. Abstr.) **(Rus)**

MICROSCOPY, VIDEO

Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Chambers AF, et al. **Cancer Metastasis Rev** 1998–99;17(3):263–9 (31 ref.)

Visualization of neuronal form and function in brain slices by infrared videomicroscopy. Dodt HU, et al. **Histochem J** 1998 Mar;30(3):141–52 (45 ref.)

INSTRUMENTATION

Following single cell dynamics with native fluorescence microscopy. Yeung ES. **Anal Chem** 1999 Aug 1; 71(15):522A–529A (50 ref.)

METHODS

Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. Morris VL, et al. **Invasion Metastasis** 1997;17(6):281–96 (56 ref.)

Microtubules and microscopes: how the development of light microscopic imaging technologies has contributed to discoveries about microtubule dynamics in living cells. Waterman-Storer CM. **Mol Biol Cell** 1998 Dec; 9(12):3263–71 (44 ref.)

Video-assisted thoracic surgery: a renaissance in surgical therapy. Yim AP, et al. **Respirology** 1999 Mar;4(1):1–8 (37 ref.)

MICROSOMES

ENZYMOLOGY

Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Hengstler JG, et al. **Recent Results Cancer Res** 1998; 154:47–85 (178 ref.)

Macrolide antibiotics, drug interactions and microsomal enzymes: implications for veterinary medicine. Anadón A, et al. **Res Vet Sci** 1999 Jun;66(3):197–203 (70 ref.)

IMMUNOLOGY

[Microsomal antibody] Kuwabara A, et al. **Nippon Rinsho** 1999 Aug;57(8):1815–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

MICROSOMES, LIVER

DRUG EFFECTS

[Cytokines and microsomal oxidation] Sibiriak SV, et al. **Eksp Klin Farmakol** 1998 Sep–Oct;61(5):75–80 (72 ref.) **(Rus)**

METABOLISM

Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Rodrigues AD. **Biochem Pharmacol** 1999 Mar 1; 57(5):465–80 (49 ref.)

MICROSPHERES

see related
ENZYMES, IMMOBILIZED

From flow injection to bead injection. Ruzicka J, et al. **Anal Chem** 1999 Apr 1;71(7):257A–263A (20 ref.)

Diblock copolymer nanoparticles for drug delivery. Kwon GS. **Crit Rev Ther Drug Carrier Syst** 1998;15(5):481–512 (93 ref.)

MICROSPORA

GENETICS

Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia. Franzen C, et al. **Clin Microbiol Rev** 1999 Apr;12(2):243–85 (397 ref.)

MICROSPORA INFECTIONS

[Cryptosporidium, Cyclospora, Microsporidia] Ajisawa A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):97–9 (6 ref.) **(Jpn)**

COMPLICATIONS

Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Leder K, et al. **Scand J Infect Dis** 1998;30(4):331–8 (42 ref.)

DIAGNOSIS

Detection of Enterocytozoon bieneusi in two human immunodeficiency virus-negative patients with chronic diarrhea by polymerase chain reaction in duodenal biopsy specimens and review. Gainzarain JC, et al. **Clin Infect Dis** 1998 Aug;27(2):394–8 (27 ref.)

Microsporidia infection in transplant patients. Gumbo T, et al. **Transplantation** 1999 Feb 15;67(3):482–4 (8 ref.)

[Cryptosporidiosis and microsporidiosis in immune deficiency] Petry F, et al. **Fortschr Med** 1998 Jul 20; 116(20–21):29–31 (0 ref.) **(Ger)**

EPIDEMIOLOGY

Cryptosporidia and microsporidia--waterborne diseases in the immunocompromised host. Franzen C, et al. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):245–62 (140 ref.)

ETIOLOGY

Animal models of human microsporidial infections. Snowden KF, et al. **Lab Anim Sci** 1998 Dec;48(6):589–92 (40 ref.)

PATHOLOGY

[Human microsporidiosis: emergence of a new opportunistic microorganism in patients infected with the human immunodeficiency virus (HIV)] Boldorini R, et al. **Pathologica** 1998 Aug;90(4):412–3 (6 ref.) **(Ita)**

MICROSPORIDA

Cryptosporidia and microsporidia--waterborne diseases in the immunocompromised host. Franzen C, et al. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):245–62 (140 ref.)

Microsporidia infection in transplant patients. Gumbo T, et al. **Transplantation** 1999 Feb 15;67(3):482–4 (8 ref.)

[Human microsporidiosis: emergence of a new opportunistic microorganism in patients infected with the human immunodeficiency virus (HIV)] Boldorini R, et al. **Pathologica** 1998 Aug;90(4):412–3 (6 ref.) **(Ita)**

ISOLATION & PURIFICATION

Detection of Enterocytozoon bieneusi in two human immunodeficiency virus-negative patients with chronic diarrhea by polymerase chain reaction in duodenal biopsy specimens and review. Gainzarain JC, et al. **Clin Infect Dis** 1998 Aug;27(2):394–8 (27 ref.)

PATHOGENICITY

Animal models of human microsporidial infections. Snowden KF, et al. **Lab Anim Sci** 1998 Dec;48(6):589–92 (40 ref.)

MICROSPORON see **MICROSPORUM**

MICROSPORUM

ISOLATION & PURIFICATION

Parasitic relationship between Microsporum canis and the cat. Pier AC, et al. **Med Mycol** 1998;36 Suppl 1:271–5 (19 ref.)

MICROSURGERY

The case for radiosurgery. Alexander E 3rd, et al. **Clin Neurosurg** 1999;45:32–40 (53 ref.)

Radiosurgery versus surgery for arteriovenous malformations: the case for radiosurgery. Friedman WA. **Clin Neurosurg** 1999;45:18–20 (16 ref.)

Outcome after microvascular decompression for typical trigeminal neuralgia, hemifacial spasm, tinnitus, disabling positional vertigo, and glossopharyngeal neuralgia (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997; 44:331–83 (119 ref.)

Surgical treatment of brain metastases. Sawaya R. **Clin Neurosurg** 1999;45:41–7 (34 ref.)

The case for aggressive resection. Sekhar LN, et al. **Clin Neurosurg** 1999;45:263–78 (18 ref.)

New concepts and materials in microvascular grafting: prosthetic graft endothelial cell seeding and gene therapy. Da Lio AL, et al. **Microsurgery** 1998;18(4):263–6 (35 ref.)

[Progresses in the study of microsurgery in China, 1997] Zhu J. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):911–2 (0 ref.) **(Chi)**

[Complications of tubal sterilization by minilaparotomy under local anesthesia] Cisse CT, et al. **Dakar Med** 1997; 42(2):96–8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Techniques for postoperative monitoring of tissue circulation after free microvascular tissue transplantation] Machens HG, et al. **Handchir Mikrochir Plast Chir** 1999 Mar; 31(2):107–12 (40 ref.) (Eng. Abstr.) **(Ger)**

[Clinical and electrophysiologic studies of facial nerve function after hypoglossal-facial nerve anastomosis] Riemann R, et al. **Laryngorhinootologie** 1999 May; 78(5):244–53 (69 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Operative techniques and clinicopathologic correlation in the surgical treatment of cranial rhizopathies (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:181–95 (18 ref.)

Microfabrication techniques using focused ion beams and emergent applications. Vasile MJ, et al. **Micron** 1999 Jun; 30(3):235–44 (36 ref.)

[Microdissection. Use in molecular oncologic dermatology] Böni R, et al. **Hautarzt** 1999 Feb;50(2):98–102 (20 ref.) (Eng. Abstr.) **(Ger)**

[Progress in molecular medicine: "laser capture microdissection" (see comments)] Bornstein SR, et al. **Med Klin** 1998 Dec 15;93(12):739–43 (29 ref.) (Eng. Abstr.) Comment in: Med Klin 1998 Dec 15;93(12):738. **(Ger)**

[Neuronavigation. Methods and prospects] Wirtz CR, et al. **Nervenarzt** 1998 Dec;69(12):1029–36 (29 ref.) (Eng. Abstr.) **(Ger)**

[Trabeculotomy, deep sclerectomy and viscocanalostomy. Non-fistulating microsurgical glaucoma operation ab externo] Schwenn O, et al. **Ophthalmologe** 1998 Dec; 95(12):835–43 (30 ref.) (Eng. Abstr.) **(Ger)**

[Microsurgical lumbar intervertebral disk operation. Technique and complications] Merk H, et al. **Orthopade** 1999 Jul;28(7):593–7 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Primary transsphenoidal microsurgery in the treatment of craniopharyngiomas. Norris JS, et al. **Br J Neurosurg** 1998 Aug;12(4):305–12 (35 ref.)

Selection criteria for the treatment of cranial rhizopathies by microvascular decompression (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:69–77 (31 ref.)

Surgery for voice. Davies DG. **Hosp Med** 1999 Mar; 60(3):196–201 (11 ref.)

Efficacy of microsurgical free-tissue transfer in chronic osteomyelitis of the leg and foot: review of 22 cases. Musharafieh R, et al. **J Reconstr Microsurg** 1999 May; 15(4):239–44 (59 ref.)

Review of significant microvascular surgical breakthroughs involving the heart and lungs in rats. Chung WS, et al. **Microsurgery** 1999;19(2):71–7 (66 ref.)

[Current possibilities in microsurgery of the external and middle ear, and the mastoid] Mudry A. **Rev Med Suisse Romande** 1998 Oct;118(10):881–7 (39 ref.) **(Fre)**

[Colloid cysts in the 3rd ventricle: a microsurgical series and new perspectives] Brunori A, et al. **Ann Ital Chir** 1999 Jan–Feb;70(1):23–7; discussion 28 (42 ref.) (Eng. Abstr.) **(Ita)**

[Revascularization of the corpora cavernosa in vasculogenic impotence] Sica GS, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):129–34 (16 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

Organ transplantation in mice: current status and future prospects. Zhong R. **Microsurgery** 1999;19(2):52–5 (38 ref.)

MICROSURGERY, LASER see **LASER SURGERY**

MICROSURGICAL REVASCULARIZATION, CEREBRAL see **CEREBRAL REVASCULARIZATION**

MICROTINAE

ANATOMY & HISTOLOGY

Mechanical advantage of area of origin for the external pterygoid muscle in two murid rodents, Apodemus speciosus and Clethrionomys rufocanus. Satoh K. **J Morphol** 1999 Apr;240(1):1–14 (48 ref.)

METABOLISM

Cytochrome P450 induction in feral Cricetid rodents: a review of field and laboratory investigations. Qualls CW Jr, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):55–63 (35 ref.)

PHYSIOLOGY

Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Insel TR, et al. **Adv Exp Med Biol** 1998; 449:215–24 (50 ref.)

Voles and vasopressin: a review of molecular, cellular, and behavioral studies of pair bonding and paternal behaviors. Wang Z, et al. **Prog Brain Res** 1998;119:483–99 (79 ref.)

MICROTINES see **MICROTINAE**

MICROTOMY

METHODS

General preparation of material and staining of sections. Davies HA. **Methods Mol Biol** 1999;117:1–11 (5 ref.)

MICROTRABECULAR LATTICE see **CYTOSKELETON**

MICROTUBULE-ASSOCIATED PROTEIN KINASES see **CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE**

MICROTUBULE-ASSOCIATED PROTEINS

SF-assemblin, striated fibers, and segmented coiled coil proteins. Lechtreck KF, et al. **Cell Motil Cytoskeleton** 1998; 41(4):289–96 (46 ref.)

ANALYSIS

Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Cariou S, et al. **Breast Cancer Res Treat** 1998;52(1–3):29–41 (95 ref.)

GENETICS

Making sense of the multiple MAP-2 transcripts and their role in the neuron. Shafit-Zagardo B, et al. **Mol Neurobiol** 1998 Apr;16(2):149–62 (105 ref.)

New insights into the tumor suppression function of P27(kip1) [comment] Clurman BE, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15158–60 (56 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15653–8.

[Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP 17)] Nakano I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):20–3 (14 ref.) **(Jpn)**

METABOLISM

p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Lloyd RV, et al. **Am J Pathol** 1999 Feb;154(2):313–23 (120 ref.)

Role of p27 in prostate carcinogenesis. Macri E, et al. **Cancer Metastasis Rev** 1998–99;17(4):337–44 (70 ref.)

Cytoplasmic dynein and dynactin in cell division and intracellular transport. Karki S, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):45–53 (93 ref.)

CDK inhibitors: positive and negative regulators of G1-phase progression. Sherr CJ, et al. **Genes Dev** 1999 Jun 15; 13(12):1501–12 (148 ref.)

Using green fluorescent protein fusion proteins to quantitate microtubule and spindle dynamics in budding yeast. Bloom KS, et al. **Methods Cell Biol** 1999;61:369–83 (38 ref.)

MAPs, MARKs and microtubule dynamics. Drewes G, et al. **Trends Biochem Sci** 1998 Aug;23(8):307–11 (50 ref.)

PHYSIOLOGY

Intestinal cell differentiation: cellular mechanisms and the search for the perfect model focus on "involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation". Evers BM. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1243–4 (16 ref.)

The role of microtubule-based motor proteins in maintaining the structure and function of the Golgi complex. Burkhardt JK. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):113–26 (89 ref.)

Role of p27 in prostate carcinogenesis. Macri E, et al. **Cancer Metastasis Rev** 1998–99;17(4):337–44 (70 ref.)

Accessory protein regulation of microtubule dynamics throughout the cell cycle. Cassimeris L. **Curr Opin Cell Biol** 1999 Feb;11(1):134–41 (62 ref.)

Recombinant p50/dynamitin as a tool to examine the role of dynactin in intracellular processes. Wittmann T, et al. **Methods Cell Biol** 1999;61:137–43 (11 ref.)

Making sense of the multiple MAP-2 transcripts and their role in the neuron. Shafit-Zagardo B, et al. **Mol Neurobiol** 1998 Apr;16(2):149–62 (105 ref.)

THERAPEUTIC USE

The growing role for the cyclin kinase inhibitor p27Kip1 in renal disease [editorial; comment] Shankland SJ. **Kidney Int** 1998 Dec;54(6):2241–2 (14 ref.) Comment on: Kidney Int 1998 Dec;54(6):1923–33.

MICROTUBULE-ORGANIZING CENTER see **CENTROSOME**

MICROTUBULE PROTEINS

ANALYSIS

GFP fusions to a microtubule motor protein to visualize meiotic and mitotic spindle dynamics in Drosophila. Endow SA. **Methods Cell Biol** 1999;58:153–63 (21 ref.)

METABOLISM

Microtubule dynamics in Xenopus egg extracts. Shirasu M, et al. **Microsc Res Tech** 1999 Mar 15;44(6):435–45 (70 ref.)

MICROTUBULES

Formin' the connection between microtubules and the cell cortex. Heil-Chapdelaine RA, et al. **J Cell Biol** 1999 Mar 8;144(5):809–11 (20 ref.)

CHEMISTRY

Characterization of two African horse sickness virus nonstructural proteins, NS1 and NS3. van Staden V, et al. **Arch Virol Suppl** 1998;14:251–8 (17 ref.)

Structures of kinesin and kinesin-microtubule interactions. Mandelkow E, et al. **Curr Opin Cell Biol** 1999 Feb; 11(1):34–44 (90 ref.)

Organisation and structure of microtubules and microtubule-motor protein complexes. Wade RH, et al. **Eur Biophys J** 1998;27(5):446–54 (59 ref.)

DRUG EFFECTS

How Taxol stabilises microtubule structure. Amos LA, et al. **Chem Biol** 1999 Mar;6(3):R65–9 (21 ref.)

METABOLISM

Microtubule treadmilling: what goes around comes around. Margolis RL, et al. **Bioessays** 1998 Oct;20(10):830–6 (55 ref.)

Microtubule dynamics: Controlling split ends. McNally FJ. **Curr Biol** 1999 Apr 22;9(8):R274–6 (12 ref.)

Positive feedback interactions between microtubule and actin dynamics during cell motility. Waterman-Storer CM, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):61–7 (58 ref.)

Tubulin structure: insights into microtubule properties and functions. Downing KH, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):785–91 (50 ref.)

PHYSIOLOGY

Microtubule involvement in regulating cell contractility and adhesion-dependent signalling: a possible mechanism for polarization of cell motility. Elbaum M, et al. **Biochem Soc Symp** 1999;65:147–72 (197 ref.)

Centrosomes, microtubules and cell migration. Schliwa M, et al. **Biochem Soc Symp** 1999;65:223–31 (33 ref.)

Balanced regulation of microtubule dynamics during the cell cycle: a contemporary view [published erratum appears in Bioessays 1999 Apr;21(4):363] Andersen SS. **Bioessays** 1999 Jan;21(1):53–60 (84 ref.)

Microtubule severing. Quarmby LM, et al. **Cell Motil Cytoskeleton** 1999;43(1):1–9 (40 ref.)

Accessory protein regulation of microtubule dynamics throughout the cell cycle. Cassimeris L. **Curr Opin Cell Biol** 1999 Feb;11(1):134–41 (62 ref.)

Microtubules and signal transduction. Gundersen GG, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):81–94 (165 ref.)

In vitro approaches to study actin and microtubule dependent cell processes. Moreau V, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):152–8 (72 ref.)

Action at the ends of microtubules. Saunders WS. **Curr Opin Cell Biol** 1999 Feb;11(1):129–33 (35 ref.)

Amorphous no longer: the centrosome comes into focus. Zimmerman W, et al. **Curr Opin Cell Biol** 1999 Feb; 11(1):122–8 (60 ref.)

Microtubule-based motor function in mitosis. Heald R, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):268–74 (47 ref.)

Motor and cargo interactions. Sheetz MP. **Eur J Biochem** 1999 May;262(1):19–25 (97 ref.)

Role of microtubules in the organization of the Golgi complex. Thyberg J, et al. **Exp Cell Res** 1999 Feb 1; 246(2):263–79 (234 ref.)

Centrosomes and microtubule organisation during Drosophila development. González C, et al. **J Cell Sci** 1998 Sep;111 (Pt 18):2697–706 (106 ref.)

The fission yeast microtubule cytoskeleton. Hagan IM. **J Cell Sci** 1998 Jun;111 (Pt 12):1603–12 (92 ref.)

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Dumontet C, et al. **J Clin Oncol** 1999 Mar;17(3):1061–70 (116 ref.)

Using green fluorescent protein fusion proteins to quantitate microtubule and spindle dynamics in budding yeast. Bloom KS, et al. **Methods Cell Biol** 1999;61:369–83 (38 ref.)

Fluorescent speckle microscopy of spindle microtubule assembly and motility in living cells. Waterman-Storer C, et al. **Methods Cell Biol** 1999;61:155–73 (25 ref.)

Microtubule dynamics in Xenopus egg extracts. Shirasu M, et al. **Microsc Res Tech** 1999 Mar 15;44(6):435–45 (70 ref.)

Microtubules and microscopes: how the development of light microscopic imaging technologies has contributed to discoveries about microtubule dynamics in living cells. Waterman-Storer CM. **Mol Biol Cell** 1998 Dec; 9(12):3263–71 (44 ref.)

Microtubules and neuronal polarity: lessons from mitosis. Baas PW. **Neuron** 1999 Jan;22(1):23–31 (49 ref.)

Microtubule-dependent vesicle transport: modulation of channel and transporter activity in liver and kidney. Hamm-Alvarez SF, et al. **Physiol Rev** 1998 Oct; 78(4):1109–29 (167 ref.)

MAPs, MARKs and microtubule dynamics. Drewes G, et al. **Trends Biochem Sci** 1998 Aug;23(8):307–11 (50 ref.)

ULTRASTRUCTURE

Balanced regulation of microtubule dynamics during the cell cycle: a contemporary view [published erratum appears in Bioessays 1999 Apr;21(4):363] Andersen SS. **Bioessays** 1999 Jan;21(1):53–60 (84 ref.)

Microtubules and microscopes: how the development of light microscopic imaging technologies has contributed to discoveries about microtubule dynamics in living cells. Waterman-Storer CM. **Mol Biol Cell** 1998 Dec; 9(12):3263–71 (44 ref.)

MICROTUS see **MICROTINAE**

MICROVASCULAR PERMEABILITY see **CAPILLARY PERMEABILITY**

MICROVILLI

PHYSIOLOGY

Microvillar Ca++ signaling: a new view of an old problem. Lange K. **J Cell Physiol** 1999 Jul;180(1):19–34 (77 ref.)

MICROWAVES

see related
DIATHERMY

Radiofrequency (RF) sickness in the Lilienfeld Study: an effect of modulated microwaves? Johnson Liakouris AG. **Arch Environ Health** 1998 May-Jun;53(3):236–8 (27 ref.)

Behavioral evaluation of microwave irradiation. D'Andrea JA. **Bioelectromagnetics** 1999;Suppl 4:64–74 (50 ref.)

Calibration and standardization of microwave ovens for fixation of brain and peripheral nerve tissue. Login GR, et al. **Methods** 1998 Jun;15(2):107–17 (49 ref.)

Microwave processing techniques for electron microscopy: a four-hour protocol. Giberson RT, et al. **Methods Mol Biol** 1999;117:145–58 (17 ref.)

Microwave procedures for electron microscopy and resin-embedded sections. Leong AS, et al. **Micron** 1998 Oct;29(5):397–409 (90 ref.)

[Microwave-assisted extraction and its application in the analysis of organic pollutants] Luo J. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):55–6 (6 ref.) **(Chi)**

ADVERSE EFFECTS

Health effects of microwave exposures: a review of the recent (1995–1998) literature. Jauchem JR. **J Microw Power Electromagn Energy** 1998;33(4):263–74 (122 ref.)

Problems and artifacts of microwave accelerated procedures in neurohistotechnology and resolutions. Horobin RW. **Methods** 1998 Jun;15(2):101–6 (27 ref.)

Biological effects of amplitude-modulated radiofrequency radiation [see comments] Juutilainen J, et al. **Scand J Work Environ Health** 1998 Aug;24(4):245–54 (64 ref.) Comment in: Scand J Work Environ Health 1998 Aug;24(4):241–3.

Intrauterine effects in animals exposed to radiofrequency and microwave fields. O'Connor ME. **Teratology** 1999 Apr; 59(4):287–91 (60 ref.)

[Effects of the microwave radiation from the cellular phones on humans and animals] Galeev AL. **Ross Fiziol Zh Im I M Sechenova** 1998 Nov; 84(11):1293–302 (42 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

Microwave applications in neuromorphology and neurochemistry: safety precautions and techniques. Marani E. **Methods** 1998 Jun;15(2):87–99 (161 ref.)

THERAPEUTIC USE

Transurethral microwave thermotherapy. Lynch JH, et al. **Eur Urol** 1999 Feb;35(2):129–37 (36 ref.)

Office treatment of benign prostatic hyperplasia. Ramsey EW. **Urol Clin North Am** 1998 Nov;25(4):571–80 (46 ref.)

Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? Djavan B, et al. **Urology** 1998 Dec;52(6):935–47 (100 ref.)

[The development of microwave coagulation therapy for hepatocellular carcinoma] Tabuse K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May;96(5):493–501 (31 ref.) **(Jpn)**

MIDAZOLAM

ADMINISTRATION & DOSAGE

Use of intramuscular midazolam for status epilepticus. Towne AR, et al. **J Emerg Med** 1999 Mar-Apr;17(2):323–8 (44 ref.)

[Midazolam (Dormicum) in terminal anxiety and agitation. The last choice alternative in palliative care] Jakobsson M, et al. **Lakartidningen** 1999 Apr 28;96(17):2079–81 (9 ref.) (Eng. Abstr.) **(Swe)**

MIDAZOLAM

PHARMACOKINETICS

Effect of age on pharmacokinetics and pharmacodynamics in man. Klotz U. **Int J Clin Pharmacol Ther** 1998 Nov; 36(11):581–5 (16 ref.)

THERAPEUTIC USE

Use of midazolam in the treatment of refractory status epilepticus. Hanley DF, et al. **Clin Ther** 1998 Nov–Dec; 20(6):1093–105 (44 ref.)

Use of midazolam for refractory status epilepticus in pediatric patients. Pellock JM. **J Child Neurol** 1998 Dec;13(12):581–7 (58 ref.)

Midazolam and pentobarbital for refractory status epilepticus. Holmes GL, et al. **Pediatr Neurol** 1999 Apr;20(4):259–64 (37 ref.)

[Midazolam in sedation in intensive therapy] Braschi A, et al. **Minerva Anestesiol** 1998 Dec;64(12 Suppl 1):7–10 (7 ref.) **(Ita)**

MIDBRAIN see **MESENCEPHALON**

MIDBRAIN CENTRAL GRAY see **PERIAQUEDUCTAL GRAY**

MIDDLE EAR CHOLESTEATOMA see **CHOLESTEATOMA, MIDDLE EAR**

MIDDLE EAR EFFUSION see **OTITIS MEDIA WITH EFFUSION**

MIDDLE EAR VENTILATION

New aspects of secretory otitis media, eustachian tube function and middle ear gas. Ovesen T, et al. **Ear Nose Throat J** 1998 Sep;77(9):770–7 (68 ref.)

The effects of venting on in-the-ear, in-the-canal, and completely-in-the-canal hearing aid shell frequency responses: real-ear measures. Stuart A, et al. **J Speech Lang Hear Res** 1999 Aug;42(4):804–13 (39 ref.)

Role of surgery for otitis media in the era of resistant bacteria. Bluestone CD. **Pediatr Infect Dis J** 1998 Nov; 17(11):1090–8; discussion 1099–100 (44 ref.)

INSTRUMENTATION

Tympanostomy tubes: types, indications, techniques, and complications. Morris MS. **Otolaryngol Clin North Am** 1999 Jun;32(3):385–90 (21 ref.)

METHODS

Systematic review of autoinflation for treatment of glue ear in children. Reidpath DD, et al. **BMJ** 1999 May 1; 318(7192):1177 (5 ref.)

MIDDLE PROMOTERS see **PROMOTER REGIONS (GENETICS)**

MIDWIFERY

see related

NURSE MIDWIVES

Acupuncture and acupressure. Applications to women's reproductive health care. Beal MW. **J Nurse Midwifery** 1999 May–Jun;44(3):217–30 (57 ref.)

Herbs and the childbearing woman. Guidelines for midwives. Belew C. **J Nurse Midwifery** 1999 May–Jun;44(3):231–52 (103 ref.)

Homeopathic remedies in prenatal care. Brennan P. **J Nurse Midwifery** 1999 May–Jun;44(3):291–9 (20 ref.)

Homeopathy. A theoretical framework and clinical application. Castro M. **J Nurse Midwifery** 1999 May–Jun; 44(3):280–90 (24 ref.)

Monitoring women at risk for preterm labor. Chern–Hughes B. **J Nurse Midwifery** 1998 Sep–Oct;43(5):393–4 (0 ref.)

Midwifery care of the woman with menorrhagia. Engstrom JL, et al. **J Nurse Midwifery** 1999 Mar–Apr;44(2):89–105 (95 ref.)

Therapeutic touch. A viable link to midwifery practice. Fischer S, et al. **J Nurse Midwifery** 1999 May–Jun; 44(3):300–9 (44 ref.)

Introducing herbal medicine into conventional health care settings. Lee L. **J Nurse Midwifery** 1999 May–Jun; 44(3):253–66 (66 ref.)

The use of complementary therapies in midwifery in the UK. Liburd A. **J Nurse Midwifery** 1999 May–Jun;44(3):325–9 (27 ref.)

Complementary and alternative medicine in women's health. Developing a research agenda. Murphy PA, et al. **J Nurse Midwifery** 1999 May–Jun;44(3):192–204 (107 ref.)

Identification and management of pregnancy-related low back pain. Perkins J, et al. **J Nurse Midwifery** 1998 Sep–Oct;43(5):331–40 (39 ref.)

The midwifery model of care [see comments] Rooks JP. **J Nurse Midwifery** 1999 Jul–Aug;44(4):370–4 (38 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

The pregnant addict: treat or prosecute? Implications for midwifery management. Stephany TM. **J Nurse Midwifery** 1999 Mar–Apr;44(2):154–6 (27 ref.)

Alternative therapies for nausea and vomiting of pregnancy. Zeidenstein L. **J Nurse Midwifery** 1998 Sep–Oct; 43(5):392–3 (0 ref.)

EDUCATION

Evolution and current status of direct-entry midwifery education, regulation, and practice in the United States, with examples from Washington State [see comments] Myers–Ciecko JA. **J Nurse Midwifery** 1999 Jul–Aug; 44(4):384–93 (58 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

LEGISLATION & JURISPRUDENCE

Evolution and current status of direct-entry midwifery education, regulation, and practice in the United States, with examples from Washington State [see comments] Myers–Ciecko JA. **J Nurse Midwifery** 1999 Jul–Aug; 44(4):384–93 (58 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

METHODS

Comfort in labor and midwifery art. Schuiling KD, et al. **Image J Nurs Sch** 1999;31(1):77–81 (40 ref.)

[Management of pregnant women and newborns in low-risk pregnancies. Evaluation of the literature] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:8–20 (52 ref.) **(Fre)**

STANDARDS

A systematic review comparing continuity of midwifery care with standard maternity services. Waldenström U, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1160–70 (32 ref.)

The traditional birth attendant: a reality and a challenge. Kamal IT. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S43–52 (11 ref.)

The midwife and her functions by level of care. Segovia I. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S61–6 (10 ref.)

Clinical guidelines in nursing, midwifery and the therapies: a systematic review. Thomas LH, et al. **J Adv Nurs** 1999 Jul;30(1):40–50 (40 ref.)

Evidence-based practice and its application to childbirth care for low-risk women [see comments] Rooks JP. **J Nurse Midwifery** 1999 Jul–Aug;44(4):355–69 (122 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

Preserving midwifery practice in a managed care environment [see comments] Williams DR. **J Nurse Midwifery** 1999 Jul–Aug;44(4):375–83 (54 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

MIFEPRISTONE

Research on mifepristone and levonorgestrel in comparison with the Yuzpe regimen. von Hertzen H. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):222–4, 232 (20 ref.)

ADMINISTRATION & DOSAGE

[Early medical abortion. An update] Lidegaard O, et al. **Ugeskr Laeger** 1999 May 31;161(22):3275–7 (14 ref.) (Eng. Abstr.) **(Dan)**

PHARMACOLOGY

Contraceptive use of antiprogestin. Bygdeman M, et al. **Eur J Contracept Reprod Health Care** 1999 Jun;4(2):103–7 (24 ref.)

MIGRAINE

Migraine: a "woman's disease?" Warshaw LJ, et al. **Women Health** 1998;28(2):79–99 (52 ref.)

[Migraine: epidemiology, clinical aspects and diagnosis] Diener HC, et al. **Dtsch Med Wochenschr** 1998 Nov 20; 123(47):1417–8 (10 ref.) **(Ger)**

[Current viewpoints on etiology and physiopathology of migraine] Salvesen R. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1437–43 (69 ref.) (Eng. Abstr.) **(Nor)**

[Migraine and quality of life] Lainez Andrés JM. **Neurologia** 1998 Oct;13 Suppl 2:1–8 (44 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

[The alterations of lipid spectrum in patients with migraine] Shestakov VV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(5):8–10 (23 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Comorbidity in migraine—causes and effects. Lipton RB. **Cephalalgia** 1998 Aug;18 Suppl 22:8–11; discussion 11–4 (17 ref.)

Migraine in pregnancy. Aubé M. **Neurology** 1999;53(4 Suppl 1):S26–8 (16 ref.)

Use of oral contraceptives in patients with migraine. Becker WJ. **Neurology** 1999;53(4 Suppl 1):S19–25 (39 ref.)

DIAGNOSIS

Is cyclical vomiting an abdominal form of migraine in children? Symon DN. **Dig Dis Sci** 1999 Aug;44(8 Suppl):23S–25S (21 ref.)

[Chronic paroxysmal hemicrania] Sawrasewicz-Rybak M. **Wiad Lek** 1999;52(1–2):56–60 (14 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D, et al. **Acta Neurol Belg** 1999 Jun;99(2):85–95 (89 ref.)

Naratriptan: an alternative for migraine. Dulli DA. **Ann Pharmacother** 1999 Jun;33(6):704–11 (39 ref.)

Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Dahlöf CG, et al. **Cephalalgia** 1998 Nov;18(9):593–604 (146 ref.)

Appropriate migraine therapy for children and adolescents. Farkas V. **Cephalalgia** 1999 Mar;19 Suppl 23:24–6; discussion 26–8 (26 ref.)

Acetylsalicylic acid in the treatment of headache. Limmroth V, et al. **Cephalalgia** 1999 Jul;19(6):545–51 (36 ref.)

Assessing new migraine therapies in Japan. Sakai F, et al. **Cephalalgia** 1999 Mar;19 Suppl 23:9–12; discussion 12–4 (5 ref.)

Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Salonen R, et al. **Cephalalgia** 1999 Jan;19(1):16–9 (16 ref.)

Methysergide. Silberstein SD. **Cephalalgia** 1998 Sep; 18(7):421–35 (152 ref.)

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen P. **Cephalalgia** 1998 Oct;18(8):532–8 (56 ref.)

Symptomatic and prophylactic treatment of migraine: a critical reappraisal. Deleu D, et al. **Clin Neuropharmacol** 1998 Sep–Oct;21(5):267–79 (123 ref.)

Present and future of 5-HT receptor agonists as antimigraine drugs. Pauwels PJ, et al. **Clin Neuropharmacol** 1999 May–Jun;22(3):123–36 (137 ref.)

Migraine in pregnancy: what are the safest treatment options? Pfaffenrath V, et al. **Drug Saf** 1998 Nov;19(5):383–8 (52 ref.)

Diclofenac-potassium in migraine: a review. McNeely W, et al. **Drugs** 1999 Jun;57(6):991–1003 (40 ref.)

Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. De Vries P, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):61–74 (176 ref.)

Treatment of migraine headaches. Bartleson JD. **Mayo Clin Proc** 1999 Jul;74(7):702–8 (10 ref.)

Current concepts of migraine and its treatment. Dahlöf CG. **Neurologia** 1999 Feb;14(2):67–77 (72 ref.)

Effective headache management. Strategies to help patients gain control over pain. Jackson CM. **Postgrad Med** 1998 Nov;104(5):133–6, 139–40, 143–7 (22 ref.)

Effective treatments for migraine. Gruffydd-Jones K. **Practitioner** 1997 Sep;241(1578):501–4, 506, 508–9 (4 ref.)

Serotonin in migraine: theories, animal models and emerging therapies. Johnson KW, et al. **Prog Drug Res** 1998; 51:219–44 (123 ref.)

[Anti-migraine treatment: present and future] Schoenen J. **Rev Med Liege** 1999 Feb;54(2):79–86 (52 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of acute migraine attacks and prevention of migraine] Diener HC, et al. **Dtsch Med Wochenschr** 1998 Nov 27;123(48):1449–53 (23 ref.) **(Ger)**

[Migraine and other "vascular" headache] Diener HC. **Internist (Berl)** 1999 Feb;40(2):153–61 (45 ref.) **(Ger)**

[New migraine treatments in review] Müller C, et al. **Pharm Unserer Zeit** 1998 Sep;27(5):209–15 (22 ref.) **(Ger)**

[The prospects in the treatment of hemicrania] Puca F. **Recenti Prog Med** 1999 Jun;90(6):315–20 (16 ref.) **(Ita)**

[The role of nitrogen oxide in migraine attack] Stępień A. **Neurol Neurochir Pol** 1999 Mar–Apr;33(2):435–44 (20 ref.) (Eng. Abstr.) **(Pol)**

[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stępień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341–3 (28 ref.) (Eng. Abstr.) **(Pol)**

[Clinical efficacy of zolmitriptan in migraine] Leira R, et al. **Neurologia** 1998 Oct;13 Suppl 2:16–24 (20 ref.) (Eng. Abstr.) **(Spa)**

[Safety profile of 311C90 (zolmitriptan)] Morales Asín F. **Neurologia** 1998 Oct;13 Suppl 2:25–30 (13 ref.) (Eng. Abstr.) **(Spa)**

[Mechanism of action of zolmitriptan] Pascual J. **Neurologia** 1998 Oct;13 Suppl 2:9–15 (49 ref.) (Eng. Abstr.) **(Spa)**

[New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses] Dahlöf CG. **Lakartidningen** 1998 Nov 11;95(46):5175, 5178–82, 5184–6 (60 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Cutting the costs of migraine: role of the employee health unit. Warshaw LJ, et al. **J Occup Environ Med** 1998 Nov; 40(11):943–53 (61 ref.)

ETIOLOGY

Scientific basis of migraine: speculation on the relationship to cyclic vomiting. Welch KM. **Dig Dis Sci** 1999 Aug;44(8

Suppl):26S–30S (42 ref.)
The relationship between stress and migraine. Fanciullacci C, et al. **Funct Neurol** 1998 Jul–Sep;13(3):215–23 (51 ref.)
Medicolegal issues: headache. Saper JR. **Neurol Clin** 1999 May;17(2):197–214 (63 ref.)
Involvement of the 5-HT7 receptor in craniovascular vasodilatation: potential impact in migraine. Terrón JA. **Proc West Pharmacol Soc** 1998;41:247–51 (78 ref.)
[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stępień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341–3 (28 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Migraine, ataxia and epilepsy: a challenging spectrum of genetically determined calcium channelopathies. Dutch Migraine Genetics Research Group. Terwindt GM, et al. **Eur J Hum Genet** 1998 Jul–Aug;6(4):297–307 (113 ref.)
CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others [editorial; comment] Tournier-Lasserve E. **Neurology** 1999 Jul 13;53(1):3–4 (14 ref.) Comment on: Neurology 1999 Jul 13;53(1):26–33. Comment on: Neurology 1999 Jul 13;53(1):34–7. Comment on: Neurology 1999 Jul 13;53(1):38–43.
[Channelopathies: a genetic explanation of migraine and other paroxysmal neurologic disorders] Terwindt GM, et al. **Ned Tijdschr Geneeskd** 1998 May 2;142(18):1015–9 (20 ref.) (Eng. Abstr.) **(Dut)**

METABOLISM

Sex hormones and headache 1999 (menstrual migraine). Silberstein S, et al. **Neurology** 1999;53(4 Suppl 1):S3–13 (113 ref.)
Serotonin in migraine: theories, animal models and emerging therapies. Johnson KW, et al. **Prog Drug Res** 1998; 51:219–44 (123 ref.)
[The role of nitrogen oxide in migraine attack] Stępień A. **Neurol Neurochir Pol** 1999 Mar–Apr;33(2):435–44 (20 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Migraine and stroke—a review of cerebral blood flow. **Cephalalgia** 1998 Aug;18 Suppl 22:22–5 (11 ref.)
Migraine, female hormones, and stroke. Bousser MG. **Cephalalgia** 1999 Mar;19(2):75–9 (46 ref.)
Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Dahlöf CG, et al. **Cephalalgia** 1998 Nov;18(9):593–604 (146 ref.)
Pathophysiological mechanisms of tension-type headache: a review of epidemiological and experimental studies. Jensen R. **Cephalalgia** 1999 Jul;19(6):602–21 (188 ref.)
Calcium channelopathies in the central nervous system. Jen J. **Curr Opin Neurobiol** 1999 Jun;9(3):274–80 (52 ref.)
The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. May A, et al. **J Cereb Blood Flow Metab** 1999 Feb;19(2):115–27 (142 ref.)
Migraine in pregnancy. Aubé M. **Neurology** 1999;53(4 Suppl 1):S26–8 (16 ref.)
Migraine in the menopause. Fettes I. **Neurology** 1999;53(4 Suppl 1):S29–33 (35 ref.)
Sex hormones and headache 1999 (menstrual migraine). Silberstein S, et al. **Neurology** 1999;53(4 Suppl 1):S3–13 (113 ref.)
[Physiopathology of migraine] Vincent MB. **Arq Neuropsiquiatr** 1998 Dec;56(4):841–51 (60 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Feverfew as a preventive treatment for migraine: a systematic review. Vogler BK, et al. **Cephalalgia** 1998 Dec; 18(10):704–8 (30 ref.)
A practical guide to the management and prevention of migraine. Diener HC, et al. **Drugs** 1998 Nov;56(5):811–24 (90 ref.)
Taking control of migraine and headache. Knott L. **Practitioner** 1999 Jan;243(1594):33–8 (9 ref.)
Divalproex sodium—review of prophylactic migraine efficacy, safety and dosage, with recommendations. Landy SH, et al. **Tenn Med** 1999 Apr;92(4):135–6 (19 ref.)
[Valproic acid in prophylactic treatment of migraine] Arnold G, et al. **Nervenarzt** 1998 Oct;69(10):913–8 (28 ref.) (Eng. Abstr.) **(Ger)**
[Migraine and prevention of migraine: the value of magnesium] Schuck P, et al. **Schweiz Med Wochenschr** 1999 Jan 23;129(3):63–70 (74 ref.) (Eng. Abstr.) **(Ger)**
[Update on migraine prophylactic treatment] Krymchantowski AV, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2B):513–9 (51 ref.) (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Psychiatric comorbidity in migraine. Breslau N. **Cephalalgia** 1998 Aug;18 Suppl 22:56–8; discussion 58–61 (10 ref.)
The relationship between stress and migraine. Fanciullacci C, et al. **Funct Neurol** 1998 Jul–Sep;13(3):215–23 (51 ref.)

THERAPY

A practical guide to the management and prevention of migraine. Diener HC, et al. **Drugs** 1998 Nov;56(5):811–24 (90 ref.)
Mechanisms and management of headache. Goadsby PJ. **J R Coll Physicians Lond** 1999 May–Jun;33(3):228–34 (47 ref.)
Management of menstrual migraine. Boyle CA. **Neurology** 1999;53(4 Suppl 1):S14–8 (34 ref.)

MIGRANTS see **TRANSIENTS AND MIGRANTS**

MIGRATION, CELL see **CELL MOVEMENT**

MIGRATION INHIBITION FACTORS, MACROPHAGE see **MACROPHAGE MIGRATION-INHIBITORY FACTORS**

MIKAMYCIN see **VIRGINIAMYCIN**

MIL-RAF PROTEIN KINASES see **PROTO-ONCOGENE PROTEINS C-RAF**

MILIARIA

ETIOLOGY

Neoprene splinting: dermatological issues. Stern EB, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):573–8 (40 ref.)

MILIARIA RUBRA see **MILIARIA**

MILITARY ANTI-SHOCK TROUSERS see **G SUITS**

MILITARY DENTISTRY

METHODS

The management of endodontically treated teeth using a Computer-Aided Design and Computer-Assisted Manufacturing/Computer-Aided Design and Computer-Integrated Manufacturing system. Foerster JG, et al. **Mil Med** 1999 Jan;164(1):37–40 (21 ref.)

MILITARY MEDICINE

Dermatologists and the burn center. Barillo DJ, et al. **Dermatol Clin** 1999 Jan;17(1):61–75, viii (36 ref.)
The dermatologist's Baedeker. Preparation for medical assistance missions. Norton SA. **Dermatol Clin** 1999 Jan; 17(1):187–208, ix–x (41 ref.)
Lasers in the military for cutaneous disease and wound healing. Ross EV, et al. **Dermatol Clin** 1999 Jan; 17(1):135–50, ix (67 ref.)
Advanced laboratory techniques at the Armed Forces Institute of Pathology applicable to diagnosis and research in dermatology. Skelton HG, et al. **Dermatol Clin** 1999 Jan; 17(1):125–34, ix (53 ref.)
Biomedical research: its mission within the French Military Medical Service. Binder P. **Mil Med** 1999 May; 164(5):341–5 (29 ref.)
Nitroaromatic munition compounds: environmental effects and screening values. Talmage SS, et al. **Rev Environ Contam Toxicol** 1999;161:1–156 (278 ref.)
[Modern principles of supplying drugs to military medical establishments] Khveshchuk PF, et al. **Voen Med Zh** 1999 May;320(5):67–73 (37 ref.) **(Rus)**

CLASSIFICATION

Levels of medical support for United Nations peacekeeping operations. Seet B. **Mil Med** 1999 Jul;164(7):451–6 (24 ref.)

METHODS

Removal of unexploded ordnance from patients: a 50-year military experience and current recommendations. Lein B, et al. **Mil Med** 1999 Mar;164(3):163–5 (9 ref.)
[Problems in the medical evaluation of the combat fitness of Armed Forces personnel] Zhiliaev EG, et al. **Voen Med Zh** 1999 Mar;320(3):56–61 (17 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

The dermatologist in military operations. Keeling JH, et al. **Dermatol Clin** 1999 Jan;17(1):209–34, x (36 ref.)
Evaluation and management of nonmelanoma skin cancer. The military perspective. Welch ML, et al. **Dermatol Clin** 1999 Jan;17(1):19–28, vii (36 ref.)
The medical department in military operations other than war. Part I. Planning for deployment. Baker MS, et al. **Mil Med** 1999 Aug;164(8):572–9 (22 ref.)
Academic medical centers: a prescription for success in an era of managed care and capitation. Huntsinger CR Jr, et al. **Mil Med** 1999 Aug;164(8):585–9 (11 ref.)
Levels of medical support for United Nations peacekeeping operations. Seet B. **Mil Med** 1999 Jul;164(7):451–6 (24 ref.)

MILITARY PERSONNEL

see related
VETERANS

Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army Personnel. O'Malley PG, et al. **Am Heart J** 1999 May; 137(5):932–41 (38 ref.)
Peptic ulcer disease in the military aviator: a management approach. Lang KA, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1100–3 (15 ref.)
Coccidioidomycosis—the airborne assault continues: an unusual presentation with a review of the history, epidemiology, and military relevance. Olivere JW, et al. **Aviat Space Environ Med** 1999 Aug;70(8):790–6 (38 ref.)
Idiopathic hypersomnia in an aircrew member. Withers BG, et al. **Aviat Space Environ Med** 1999 Aug;70(8):797–801 (19 ref.)
The United States military and leishmaniasis. Kenner JR, et al. **Dermatol Clin** 1999 Jan;17(1):77–92, viii (77 ref.)
Unusual cutaneous infectious and parasitic diseases. Lemons-Estes FM, et al. **Dermatol Clin** 1999 Jan; 17(1):151–85, ix (64 ref.)
Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections. Mayers DL. **Dermatol Clin** 1999 Jan;17(1):29–40, vii–viii (69 ref.)
Environmental skin diseases and the impact of common dermatoses on medical readiness. Meffert JJ. **Dermatol Clin** 1999 Jan;17(1):1–17, vii (143 ref.)
Lasers in the military for cutaneous disease and wound healing. Ross EV, et al. **Dermatol Clin** 1999 Jan; 17(1):135–50, ix (67 ref.)
Recognition and management of high-risk cutaneous tumors. Schoelch SB, et al. **Dermatol Clin** 1999 Jan;17(1):93–111, viii–ix (104 ref.)
The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these finding to other dermatologic conditions and wound healing. Smith KJ. **Dermatol Clin** 1999 Jan;17(1):41–60, viii (52 ref.)
Military intervention and humanitarian action: trends and issues. Pugh M. **Disasters** 1998 Dec;22(4):339–51 (30 ref.)
Respiratory diseases among U.S. military personnel: countering emerging threats. Gray GC, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):379–85 (80 ref.)
Resumption of diving after illness or injury. Benton PJ. **J R Nav Med Serv** 1998;84(1):14–8 (17 ref.)
Splenic syndrome in sickle cell trait: four case presentations and a review of the literature. Franklin QJ, et al. **Mil Med** 1999 Mar;164(3):230–3 (17 ref.)
Removal of unexploded ordnance from patients: a 50-year military experience and current recommendations. Lein B, et al. **Mil Med** 1999 Mar;164(3):163–5 (9 ref.)
Carbohydrate loading and deploying forces. Sandberg PR. **Mil Med** 1999 Sep;164(9):636–42 (41 ref.)
Field treatment of snakebites in the Israel Defense Forces. Haviv J, et al. **Public Health Rev** 1998;26(3):247–56 (17 ref.)
Physical training and exercise-related injuries. Surveillance, research and injury prevention in military populations. Jones BH, et al. **Sports Med** 1999 Feb;27(2):111–25 (61 ref.)
[Optimizing the choice of drugs in sexually transmitted diseases] Khveshchuk PF, et al. **Voen Med Zh** 1999 Mar; 320(3):22–8 (28 ref.) **(Rus)**
[The neurochemical mechanisms and pharmacological routes to eliminate vomiting in seasickness] Naletov SV, et al. **Voen Med Zh** 1998 Sep;319(9):74–6 (20 ref.) **(Rus)**
[The prevention of stroke: the traditions and the outlook] Simonenko VB, et al. **Voen Med Zh** 1999 Apr;320(4):31–4, 110 (21 ref.) (Eng. Abstr.) **(Rus)**
[Problems in the medical evaluation of the combat fitness of Armed Forces personnel] Zhiliaev EG, et al. **Voen Med Zh** 1999 Mar;320(3):56–61 (17 ref.) **(Rus)**

PSYCHOLOGY

Suicidal ideation and sense of coherence in male conscripts. Mehlum L. **Acta Psychiatr Scand** 1998 Dec;98(6):487–92 (37 ref.)
Trauma-induced dissociative amnesia in World War I combat soldiers. van der Hart O, et al. **Aust N Z J Psychiatry** 1999 Feb;33(1):37–46 (62 ref.)
A theoretical model for the study of active and passive smoking in military women: an at-risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475–80 (56 ref.)
Psychiatric illness and the workplace: perspectives for occupational medicine in the military. Pflanz S. **Mil Med** 1999 Jun;164(6):401–6 (62 ref.)

STATISTICS & NUMERICAL DATA

Leishmaniasis in the United States military. Martin S, et al. **Mil Med** 1998 Dec;163(12):801–7 (85 ref.)
Military parachuting injuries: a literature review. Bricknell MC, et al. **Occup Med (Lond)** 1999 Jan;49(1):17–26 (27 ref.)

MILK

see related
LACTATION

Nutritional adequacy of cow's milk substitutes. Lombardo G, et al. **Allergy** 1998;53(46 Suppl):118–21 (50 ref.)

ADVERSE EFFECTS

Soy protein for the prevention and treatment of children with cow-milk allergy. Businco L, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1447S–1452S (78 ref.)
Cow's milk and type 1 diabetes: the real debate is about mucosal immune function. Harrison LC, et al. **Diabetes**

MILK

1999 Aug;48(8):1501–7 (81 ref.)

CHEMISTRY

Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. Parodi PW. **J Dairy Sci** 1999 Jun; 82(6):1339–49 (98 ref.)

Some practical implications of the milk mucins. Patton S. **J Dairy Sci** 1999 Jun;82(6):1115–7 (11 ref.)

Bioactive lipids naturally occurring in bovine milk. Molkentin J. **Nahrung** 1999 Jun;43(3):185–9 (95 ref.)

Loss in milk yield and related composition changes resulting from clinical mastitis in dairy cows. Hortet P, et al. **Prev Vet Med** 1998 Dec 1;37(1–4):1–20 (66 ref.)

CYTOLOGY

Calculated milk production losses associated with elevated somatic cell counts in dairy cows: review and critical discussion. Hortet P, et al. **Vet Res** 1998 Nov–Dec; 29(6):497–510 (41 ref.)

IMMUNOLOGY

Production of recombinant antibodies in the milk of transgenic animals. Young MW, et al. **Res Immunol** 1998 Jul–Aug;149(6):609–10 (4 ref.)

METABOLISM

Lactoferrin secretion into mouse milk. Development of secretory activity, the localization of lactoferrin in the secretory pathway, and interactions of lactoferrin with milk iron. Neville MC, et al. **Adv Exp Med Biol** 1998;443:141–53 (39 ref.)

MICROBIOLOGY

Structure and functional characteristics of bacterial biofilms in fluid processing operations. Mittelman MW. **J Dairy Sci** 1998 Oct;81(10):2760–4 (39 ref.)

SECRETION

Mammary involution in dairy animals. Capuco AV, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):137–44 (38 ref.)

Transcription factor activities and gene expression during mouse mammary gland involution. Marti A, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):145–52 (53 ref.)

Control of milk secretion and apoptosis during mammary involution. Wilde CJ, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):129–36 (53 ref.)

Effects of disease on milk production in the dairy cow: a review. Fourichon C, et al. **Prev Vet Med** 1999 Jun 29; 41(1):1–35 (49 ref.)

Calculated milk production losses associated with elevated somatic cell counts in dairy cows: review and critical discussion. Hortet P, et al. **Vet Res** 1998 Nov–Dec; 29(6):497–510 (41 ref.)

STANDARDS

Producer quality assurance programs. Kla J, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):197–208 (5 ref.)

The national milk safety program and drug residues in milk. Talley MR. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):63–73 (7 ref.)

[Feeding of milk from cows with diseased udders to calves from the viewpoint of public health] Hässig M. **Schweiz Arch Tierheilkd** 1999;141(3):125–9 (0 ref.) (Eng. Abstr.) **(Ger)**

MILK-ALKALI SYNDROME see **HYPERCALCEMIA**

MILK EJECTION

DRUG EFFECTS

Anthelmintic treatment of dairy cows and its effect on milk production. Gross SJ, et al. **Vet Rec** 1999 May 22; 144(21):581–7 (91 ref.)

MILK FACTOR see **MAMMARY TUMOR VIRUSES, MOUSE**

MILK, HUMAN

see related
BREAST FEEDING
LACTATION

The use of human milk and breastfeeding in premature infants. Schanler RJ, et al. **Clin Perinatol** 1999 Jun; 26(2):379–98, vii (118 ref.)

The role of human milk fortification for premature infants. Schanler RJ. **Clin Perinatol** 1998 Sep;25(3):645–57, ix (69 ref.)

Breast milk and breastfeeding in the 1990s. Kelleher DK, et al. **Curr Opin Pediatr** 1999 Jun;11(3):275–80 (20 ref.)

Neonatal dietary gangliosides. Rueda R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S135–47 (60 ref.)

Nutrition–gene interactions during intrauterine life and lactation. Hay WW Jr. **Nutr Rev** 1999 May;57(5 Pt 2):S20–9; discussion S29–30 (83 ref.)

Prematurity, immune function and infant feeding practices. Hampton SM. **Proc Nutr Soc** 1999 Feb;58(1):75–8 (16 ref.)

CHEMISTRY

Improvements in human health through production of human milk proteins in transgenic food plants. Arakawa T, et al. **Adv Exp Med Biol** 1999;464:149–59 (50 ref.)

Expression of functional immunomodulatory and anti–inflammatory factors in human milk. Garofalo RP, et al. **Clin Perinatol** 1999 Jun;26(2):361–77 (115 ref.)

Drugs and breastfeeding. Howard CR, et al. **Clin Perinatol** 1999 Jun;26(2):447–78 (128 ref.)

Nutritional and biochemical properties of human milk, Part I: General aspects, proteins, and carbohydrates. Kunz C, et al. **Clin Perinatol** 1999 Jun;26(2):307–33 (110 ref.)

Nutritional and biochemical properties of human milk: II. Lipids, micronutrients, and bioactive factors. Rodriguez–Palmero M, et al. **Clin Perinatol** 1999 Jun; 26(2):335–59 (132 ref.)

Human milk glycoconjugates that inhibit pathogens. Newburg DS. **Curr Med Chem** 1999 Feb;6(2):117–27 (33 ref.)

Breast Milk Monitoring Programs (BMMPs): world–wide early warning system for polyhalogenated POPs and for targeting studies in children's environmental health [comment] Hooper K. **Environ Health Perspect** 1999 Jun; 107(6):429–30 (14 ref.) Comment on: Environ Health Perspect 1999 Jun;107(6):447–57. Comment on: Environ Health Perspect 1999 Jun;107(6):459–62.

Hexachlorobenzene as a possible major contributor to the dioxin activity of human milk. van Birgelen AP. **Environ Health Perspect** 1998 Nov;106(11):683–8 (100 ref.)

Association of atopic diseases with breast–feeding: food allergens, fatty acids, and evolution [editorial; comment] Goldman AS. **J Pediatr** 1999 Jan;134(1):5–7 (22 ref.) Comment on: J Pediatr 1999 Jan;134(1):27–32.

Protective function of human milk: the milk fat globule. Hamosh M, et al. **Semin Perinatol** 1999 Jun;23(3):242–9 (65 ref.)

[Effects of environmental chemicals transferred through human milk on the development of breast–feeding infants] Lu R, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):51–2 (10 ref.) **(Chi)**

IMMUNOLOGY

The influence of the diet on the maturation of the immune system. Hughes DA. **Allergy** 1998;53(46 Suppl):26–8 (19 ref.)

Breastfeeding provides passive and likely long–lasting active immunity [published erratum appears in Ann Allergy Asthma Immunol 1999 May;82(5):478] Hanson LA. **Ann Allergy Asthma Immunol** 1998 Dec;81(6):523–33; quiz 533–4, 537 (155 ref.)

Expression of functional immunomodulatory and anti–inflammatory factors in human milk. Garofalo RP, et al. **Clin Perinatol** 1999 Jun;26(2):361–77 (115 ref.)

METABOLISM

Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Setchell KD, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1453S–1461S (86 ref.)

Phytoestrogens in human biomatrices including breast milk. Franke AA, et al. **Biochem Soc Trans** 1999 Feb;27(2):308–18 (66 ref.)

Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast–feeding. Yoshida K, et al. **J Psychopharmacol** 1999;13(1):64–80 (115 ref.)

Breastmilk nucleotides [editorial] Ebrahim GJ. **J Trop Pediatr** 1998 Dec;44(6):318–9 (11 ref.)

PHYSIOLOGY

–Bioactive factors in milk– Buts JP. **Arch Pediatr** 1998 Mar; 5(3):298–306 (67 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Transmission of human immunodeficiency virus type 1 through breast–feeding: how can it be prevented? Van de Perre P. **J Infect Dis** 1999 May;179 Suppl 3:S405–7 (17 ref.)

Cytomegalovirus (CMV) in cervical secretion and breast milk. A thirty years perspective. Diosi P. **Roum Arch Microbiol Immunol** 1997 Jul–Dec; 56(3–4):165–78 (88 ref.)

MILK HYPERSENSITIVITY

see related
LACTOSE INTOLERANCE

Cow's milk allergy. Moneret–Vautrin DA. **Allerg Immunol (Paris)** 1999 Jun;31(6):201–10 (98 ref.)

Adverse reactions to cow's milk proteins [see comments] Martin Esteban M, et al. **Allergol Immunopathol (Madr)** 1998 Jul–Aug;26(4):171–94 (128 ref.) Comment in: Allergol Immunopathol (Madr) 1998 Jul–Aug;26(4):167–70.

Clinical course of cow's milk protein allergy and intolerance. Høst A. **Pediatr Allergy Immunol** 1998;9(11 Suppl):48–52 (28 ref.)

BLOOD

Markedly high eosinophilia and an elevated serum IL–5 level in an infant with cow milk allergy. Matsumoto T, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):253–6 (11 ref.)

DIET THERAPY

Soy protein for the prevention and treatment of children with cow–milk allergy. Businco L, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1447S–1452S (78 ref.)

ETIOLOGY

The influence of the diet on the maturation of the immune system. Hughes DA. **Allergy** 1998;53(46 Suppl):26–8 (19 ref.)

Legumes, eggs, and milk. Sampson HA. **Allergy** 1998;53(46 Suppl):38–43 (60 ref.)

PREVENTION & CONTROL

Soy protein for the prevention and treatment of children with cow–milk allergy. Businco L, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1447S–1452S (78 ref.)

MILK PROTEINS

ADVERSE EFFECTS

Adverse reactions to cow's milk proteins [see comments] Martin Esteban M, et al. **Allergol Immunopathol (Madr)** 1998 Jul–Aug;26(4):171–94 (128 ref.) Comment in: Allergol Immunopathol (Madr) 1998 Jul–Aug;26(4):167–70.

Cow's milk proteins and insulin–dependent diabetes mellitus. Something to worry about? Alting AC, et al. **Nahrung** 1999 Jun;43(3):209–10 (13 ref.)

CHEMISTRY

Lactokinins: whey protein–derived ACE inhibitory peptides. FitzGerald RJ, et al. **Nahrung** 1999 Jun;43(3):165–7 (15 ref.)

Antihypertensive peptides derived from milk proteins. Yamamoto N, et al. **Nahrung** 1999 Jun;43(3):159–64 (58 ref.)

GENETICS

Improvements in human health through production of human milk proteins in transgenic food plants. Arakawa T, et al. **Adv Exp Med Biol** 1999;464:149–59 (50 ref.)

Regulation of milk protein gene expression. Rosen JM, et al. **Annu Rev Nutr** 1999;19:407–36 (177 ref.)

IMMUNOLOGY

Cow's milk allergens. Wal JM. **Allergy** 1998 Nov; 53(11):1013–22 (71 ref.)

Controversial topics series: milk proteins and diabetes. Norris JM, et al. **J Endocrinol Invest** 1999 Jul–Aug;22(7):568–80 (91 ref.)

Beta–casein in cow's milk: a major antigenic determinant for type 1 diabetes? Pozzilli P. **J Endocrinol Invest** 1999 Jul–Aug;22(7):562–7 (39 ref.)

Hidden presence of cow's milk proteins in foods. Cantani A. **J Investig Allergol Clin Immunol** 1999 May–Jun; 9(3):141–5 (37 ref.)

Clinical course of cow's milk protein allergy and intolerance. Høst A. **Pediatr Allergy Immunol** 1998;9(11 Suppl):48–52 (28 ref.)

PHARMACOLOGY

Lactokinins: whey protein–derived ACE inhibitory peptides. FitzGerald RJ, et al. **Nahrung** 1999 Jun;43(3):165–7 (15 ref.)

Antihypertensive peptides derived from milk proteins. Yamamoto N, et al. **Nahrung** 1999 Jun;43(3):159–64 (58 ref.)

MILK SUBSTITUTES see **MILK**

MILKER'S NODES see **POXVIRIDAE INFECTIONS**

MILLER FISHER SYNDROME

see related
POLYRADICULITIS

[Miller Fisher syndrome] Odaka M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):470–4 (11 ref.) **(Jpn)**

DIAGNOSIS

Abducens nerve enhancement in acute ophthalmoparesis. Shibata A, et al. **Radiat Med** 1998 Sep–Oct;16(5):375–7 (7 ref.)

[Comments on the article: "Ophthalmoplegia–ataxia–areflexia in pediatrics. 3 new cases and a review of the literature" (letter; comment)] Benito–León J, et al. **An Esp Pediatr** 1999 Jan;50(1):100–1 (6 ref.) Comment on: An Esp Pediatr 1998 May;48(5):483–88. **(Spa)**

ETIOLOGY

Fisher's syndrome and group A streptococcal infection. Yuki N, et al. **J Neurol Sci** 1998 Sep 18;160(1):64–6 (9 ref.)

[Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies] Kusunoki S. **Rinsho Shinkeigaku** 1999 Jan;39(1):93–5 (10 ref.) (Eng.

Abstr.) (Jpn)

MILROY'S DISEASE see **LYMPHEDEMA**

MIMA see **ACINETOBACTER**

MIMAE INFECTIONS see **ACINETOBACTER INFECTIONS**

MIMETIC MUSCLES see **FACIAL MUSCLES**

MIMICRY, MOLECULAR see **MOLECULAR MIMICRY**

MINAMATA DISEASE see **MERCURY POISONING**

MIND-BODY RELATIONS (METAPHYSICS)

see related
PSYCHOPHYSIOLOGY

The construct of control in mind-body medicine: implications for healthcare. Astin JA, et al. **Altern Ther Health Med** 1999 Mar;5(2):42-7 (72 ref.)

Cognitive development: children's knowledge about the mind. Flavell JH. **Annu Rev Psychol** 1999;50:21-45 (111 ref.)

The body is the shadow of the soul. Hassed C. **Aust Fam Physician** 1999 Jun;28(6):613-4 (11 ref.)

Memory, learning and metacognition. Jacob P. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):253-9 (32 ref.)

Attitude and disposition: Do they make a difference in cancer survival? Creagan ET. **J Prosthet Dent** 1999 Sep; 82(3):352-5 (24 ref.)

Estranged bodies, simulated harmony, and misplaced cultures: neurasthenia in contemporary Chinese society [see comments] Lee S. **Psychosom Med** 1998 Jul-Aug; 60(4):448-57 (52 ref.) Comment in: Psychosom Med 1998 Jul-Aug;60(4):389-93.

Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Coker KH. **Semin Urol Oncol** 1999 May;17(2):111-8 (30 ref.)

MIND-BODY RELATIONS (NON-PHYSIOLOGY) see **MIND-BODY RELATIONS (METAPHYSICS)**

MIND-BODY RELATIONS (PHYSIOLOGY) see **PSYCHOPHYSIOLOGY**

MINERAL FIBERS

see related
PNEUMOCONIOSIS

[Chemical and physical characteristics and toxicology of man-made mineral fibers] Foà V, et al. **Med Lav** 1999 Jan-Feb;90(1):10-52 (100 ref.) (Eng. Abstr.) (Ita)

ADVERSE EFFECTS

Influence of characteristics of inhaled fibres on development of tumours in the rat lung. Miller BG, et al. **Ann Occup Hyg** 1999 Apr;43(3):167-79 (39 ref.)

The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Gulumian M. **Mol Cell Biochem** 1999 Jun; 196(1-2):69-77 (106 ref.)

ANALYSIS

Influence of characteristics of inhaled fibres on development of tumours in the rat lung. Miller BG, et al. **Ann Occup Hyg** 1999 Apr;43(3):167-79 (39 ref.)

TOXICITY

[Synthetic mineral fibers] Boillat MA. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):468-74 (30 ref.) (Eng. Abstr.) (Fre)

MINERALOCORTICOIDS

Mineralocorticoid hypertension. Stewart PM. **Lancet** 1999 Apr 17;353(9161):1341-7 (65 ref.)

[Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements] Fardella CE, et al. **Rev Med Chil** 1999 May;127(5):604-10 (41 ref.) (Eng. Abstr.) (Spa)

METABOLISM

Extra-adrenal mineralocorticoids and cardiovascular tissue. Slight SH, et al. **J Mol Cell Cardiol** 1999 Jun;31(6):1175-84 (71 ref.)

[11 beta-hydroxysteroid dehydrogenases: key enzymes in the action of mineralocorticoids and glucocorticoids] Diederich S, et al. **Dtsch Med Wochenschr** 1999 Jan 22; 124(3):51-5 (43 ref.) (Ger)

PHYSIOLOGY

Cortisol as a mineralocorticoid in human disease. Stewart PM. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):403-8 (51 ref.)

MINERALS

Prebiotic synthesis on minerals: bridging the prebiotic and RNA worlds. Ferris JP. **Biol Bull** 1999 Jun;196(3):311-4 (14 ref.)

ADVERSE EFFECTS

[Is supplementation of vitamins and minerals dangerous?] Poleszynski DV. **Tidsskr Nor Laegeforen** 1999 May 20; 119(13):1926-9 (36 ref.) (Nor)

[The effect of the mineral composition of drinking water on the health of the population (a review)] Mudryĭ IV. **Gig Sanit** 1999 Jan-Feb;(1):15-8 (44 ref.) (Rus)

ANALYSIS

Wheat minerals--a review. Anglani C. **Plant Foods Hum Nutr** 1998;52(2):177-86 (37 ref.)

CHEMISTRY

Application of remedy studies to the development of a soil washing pilot plant that uses mineral processing technology: a practical experience. Richardson WS 3rd, et al. **J Hazard Mater** 1999 Apr 23;66(1-2):47-65 (20 ref.)

METABOLISM

The impact of food processing on the nutritional quality of vitamins and minerals. Reddy MB, et al. **Adv Exp Med Biol** 1999;459:99-106 (50 ref.)

Recent insights into the coordinate regulation of body water and divalent mineral ion metabolism. Baum MA, et al. **Am J Med Sci** 1998 Nov;316(5):321-8 (79 ref.)

[Effect of dietary fiber on the nutritional utilization of proteins and minerals] Ruiz-Roso B, et al. **Nutr Hosp** 1999 Jan-Feb;14(1):7-13 (37 ref.) (Eng. Abstr.) (Spa)

PHARMACOKINETICS

Nondigestible carbohydrates and mineral bioavailability. Greger JL. **J Nutr** 1999 Jul;129(7 Suppl):1434S-5S (22 ref.)

The regulation of mineral absorption in the gastrointestinal tract. Powell JJ, et al. **Proc Nutr Soc** 1999 Feb;58(1):147-53 (41 ref.)

MINIATURIZATION

INSTRUMENTATION

Inkjet dispensing technology: applications in drug discovery. Lemmo AV, et al. **Curr Opin Biotechnol** 1998 Dec; 9(6):615-7 (5 ref.)

Microreactors for chemical synthesis. DeWitt SH. **Curr Opin Chem Biol** 1999 Jun;3(3):350-6 (36 ref.)

MINIMAL ACCESS SURGICAL PROCEDURES see **SURGICAL PROCEDURES, MINIMALLY INVASIVE**

MINIMAL BRAIN DYSFUNCTION see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

MINIMAL RESIDUAL DISEASE see **NEOPLASM, RESIDUAL**

MINIMAL SURGICAL PROCEDURES see **SURGICAL PROCEDURES, MINIMALLY INVASIVE**

MINIMALLY INVASIVE SURGICAL PROCEDURES see **SURGICAL PROCEDURES, MINIMALLY INVASIVE**

MINIMUM INHIBITORY CONCENTRATION see **MICROBIAL SENSITIVITY TESTS**

MINING

Some considerations on the impact on ecological chemical principles in practice with emphasis on gold mining and cyanide. Korte F, et al. **Ecotoxicol Environ Saf** 1998 Oct; 41(2):119-29 (74 ref.)

Multiple stressors in the Sacramento River watershed. Hinton DE. **EXS** 1998;86:303-17 (58 ref.)

Creating alliances for disease management in industrial settings: a case study of HIV/AIDS in workers in South African gold mines. Williams B, et al. **Int J Occup Environ Health** 1998 Oct-Dec;4(4):257-64 (50 ref.)

MINISATELLITE REPEATS

see related
DNA FINGERPRINTING

Current and future contributions of transgenic mice to the analysis of germline toxicology. Collick A, et al. **Adv Exp Med Biol** 1998;444:119-25; discussion 125-7 (11 ref.)

Human minisatellites, repeat DNA instability and meiotic recombination. Jeffreys AJ, et al. **Electrophoresis** 1999 Jun; 20(8):1665-75 (38 ref.)

Mitochondrial DNA variable number tandem repeats (VNTRs): utility and problems in molecular ecology. Lunt DH, et al. **Mol Ecol** 1998 Nov;7(11):1441-55 (78 ref.)

MINK ENCEPHALOPATHY VIRUS see **PRIONS**

MINKE WHALE see **WHALES**

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY see **MMPI**

MINNOWS see **CYPRINIDAE**

MINOCYCLINE

ADMINISTRATION & DOSAGE

The use of locally delivered minocycline in the treatment of chronic periodontitis. A review of the literature. Vandekerckhove BN, et al. **J Clin Periodontol** 1998 Nov; 25(11 Pt 2):964-8; discussion 978-9 (34 ref.)

ADVERSE EFFECTS

Minocycline-related autoimmune hepatitis: case series and literature review. Teitelbaum JE, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1132-6 (13 ref.)

Oral and systemic effects of prolonged minocycline therapy. Patel K, et al. **Br Dent J** 1998 Dec 12-26;185(11-12):560-2 (19 ref.)

Minocycline and autoimmunity [editorial, comment] Hess EV. **Clin Exp Rheumatol** 1998 Sep-Oct;16(5):519-21 (11 ref.) Comment on: Clin Exp Rheumatol 1998 Sep-Oct;16(5):587-90.

Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Angulo JM, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):187-92 (41 ref.)

Minocycline-induced autoimmune syndromes: an overview. Elkayam O, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):392-7 (56 ref.)

[The black thyroid syndrome. A case report (letter)] Cos M, et al. **Rev Clin Esp** 1999 Jul;199(7):478-9 (10 ref.) (Spa)

THERAPEUTIC USE

Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? O'Dell JR. **Drugs** 1999 Mar; 57(3):279-82 (38 ref.)

Antibiotics for rheumatoid arthritis? Minocycline shows promise in some patients. Alarcón GS. **Postgrad Med** 1999 Apr;105(4):95-8 (25 ref.)

[Minocycline in the treatment of rheumatoid arthritis] Alušík S. **Vnitr Lek** 1998 Aug;44(8):502-4 (23 ref.) (Eng. Abstr.) (Cze)

MINOR HISTOCOMPATIBILITY ANTIGENS

GENETICS

Induction of a minor into the major league? Genomic identification of a human minor histocompatibility antigen [editorial; comment] Dupont B. **Tissue Antigens** 1998 Oct; 52(4):303-4 (20 ref.) Comment on: Tissue Antigens 1998 Oct;52(4):305-11. Comment on: Tissue Antigens 1998 Oct;52(4):312-7.

IMMUNOLOGY

Minor transplantation antigens: mouse models for human host-versus-graft, graft-versus-host and graft-versus-leukemia reactions. Simpson E. **Arch Immunol Ther Exp (Warsz)** 1998;46(6):331-9 (60 ref.)

MINOR HISTOCOMPATIBILITY PEPTIDES see **MINOR HISTOCOMPATIBILITY ANTIGENS**

MINORITY GROUPS

Physical activity interventions in low-income, ethnic minority, and populations with disability. Taylor WC, et al. **Am J Prev Med** 1998 Nov;15(4):334-43 (38 ref.)

Minorities and the orthopaedic profession. Ayers CE. **Clin Orthop** 1999 May;(362):58-64 (56 ref.)

The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL. **J Health Polit Policy Law** 1999 Jun;24(3):531-65 (35 ref.)

Selecting subjects for participation in clinical research: one sphere of justice. Weijer C. **J Med Ethics** 1999 Feb; 25(1):31-6 (34 ref.)

Medicaid's impact on access to and utilization of health care services among racial and ethnic minority children. Hall AG. **J Urban Health** 1998 Dec;75(4):677-92 (25 ref.)

The economic and social context of special populations. Ashford NA. **Occup Med** 1999 Jul-Sep;14(3):485-93 (32 ref.)

Minority workers and communities. Frumkin H, et al. **Occup Med** 1999 Jul-Sep;14(3):495-517 (174 ref.)

Special populations in occupational health. Frumkin H, et al. **Occup Med** 1999 Jul-Sep;14(3):479-84 (26 ref.)

Organizing marginalized workers. Taylor AK. **Occup Med** 1999 Jul-Sep;14(3):687-95 (24 ref.)

EDUCATION

Impact of minority physicians on health care. Thurmond VB, et al. **South Med J** 1998 Nov;91(11):1009-13 (25 ref.)

MINORITY GROUPS

LEGISLATION & JURISPRUDENCE

Legal solutions for the problems of special populations at risk. Spieler EA. **Occup Med** 1999 Jul-Sep;14(3):665-86 (68 ref.)

STATISTICS & NUMERICAL DATA

Health status and access to care among rural minorities. Mueller KJ, et al. **J Health Care Poor Underserved** 1999 May;10(2):230-49 (193 ref.)

MINOXIDIL

ANALOGS & DERIVATIVES

Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Dooley TP. **Exp Dermatol** 1999 Aug;8(4):328-9 (11 ref.)

THERAPEUTIC USE

Androgenetic alopecia in men: the scale of the problem and prospects for treatment. Rushton DH. **Int J Clin Pract** 1999 Jan-Feb;53(1):50-3 (35 ref.)

MINT see **LAMIACEAE**

MIOCAMYCIN

ANALOGS & DERIVATIVES

[Rokitamycin in the treatment of female genital Chlamydia and Mycoplasma infections. Comparative study vs josamycin] Colombo U, et al. **Minerva Ginecol** 1998 Nov; 50(11):491-7 (26 ref.) (Eng. Abstr.) **(Ita)**

MIOKAMYCIN see **MIOCAMYCIN**

MIOPITHECUS TALAPOIN see **CERCOPITHECIDAE**

MIOSIS

see related
MIOTICS

MIOTICS

see related
ADRENERGIC ANTAGONISTS
CHOLINESTERASE INHIBITORS
MUSCARINIC AGONISTS
PARASYMPATHOMIMETICS
SYMPATHOLYTICS

ADVERSE EFFECTS

Adverse events associated with commonly used glaucoma drugs. Vogel R, et al. **Int Ophthalmol Clin** 1999 Spring; 39(2):107-24 (82 ref.)

THERAPEUTIC USE

Topical therapies for glaucoma: what family physicians need to know. Lewis PR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1871-9, 1882 (30 ref.)

MIP-1 see **MACROPHAGE INFLAMMATORY PROTEIN-1**

MIP-1ALPHA see **MACROPHAGE INFLAMMATORY PROTEIN-1**

MIP-1BETA see **MACROPHAGE INFLAMMATORY PROTEIN-1**

MIRROR WRITING see **DOMINANCE, CEREBRAL**

MISARTICULATION see **ARTICULATION DISORDERS**

MISCARRIAGE see **ABORTION, SPONTANEOUS**

MISCARRIAGE, RECURRENT see **ABORTION, HABITUAL**

MISOPROSTOL

Misoprostol used alone for the termination of early pregnancy. A review of the evidence. Blanchard K, et al. **Contraception** 1999 Apr;59(4):209-17 (31 ref.)

Use of misoprostol in first and second trimester abortion: a review. Scheepers HC, et al. **Obstet Gynecol Surv** 1999 Sep;54(9):592-600 (74 ref.)

ADMINISTRATION & DOSAGE

Misoprostol for induction of labour: a systematic review. Hofmeyr GJ, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):798-803 (34 ref.)

ADVERSE EFFECTS

Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Plaut MM, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1535-42 (27 ref.)

Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Genest DR, et al. **Clin Dysmorphol** 1999 Jan;8(1):53-8 (24 ref.)

SUPPLY & DISTRIBUTION

Commercial availability of misoprostol and induced abortion in Brazil. Costa SH. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S131-9 (47 ref.)

THERAPEUTIC USE

Labor induction with misoprostol. Wing DA. **Am J Obstet Gynecol** 1999 Aug;181(2):339-45 (36 ref.)

Therapy for ulcers and erosions associated with nonsteroidal anti-inflammatory drugs. Freeman HJ. **Can J Gastroenterol** 1998 Nov-Dec;12(8):537-9 (0 ref.)

Arthrotec: the evidence speaks for itself. Morgan D. **Scand J Rheumatol Suppl** 1999;109:13-8 (52 ref.)

MISSIONS AND MISSIONARIES

PSYCHOLOGY

Critical incident stress debriefing in international aid workers. Townsend CJ, et al. **J Travel Med** 1998 Dec;5(4):226-7 (8 ref.)

MISSIONS, OFFICIAL MEDICAL see **MEDICAL MISSIONS, OFFICIAL**

MISUSE OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

MITE CONTROL see **TICK CONTROL**

MITE INFESTATIONS

[Ectoparasitic diseases and acari borne diseases] Uchikawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):508-17 (11 ref.) **(Jpn)**

VETERINARY

Inter- and intra-specific variation within the genus Psoroptes (Acari: Psoroptidae). Bates PG. **Vet Parasitol** 1999 Jun 30; 83(3-4):201-17 (105 ref.)

The poultry red mite Dermanyssus gallinae (De Geer, 1778): current situation and future prospects for control. Chauve C. **Vet Parasitol** 1998 Nov 16;79(3):239-45 (24 ref.)

A review of the use of a controlled-release formulation of ivermectin in the treatment and prophylaxis of Psoroptes ovis infestations in sheep. Forbes AB, et al. **Vet Parasitol** 1999 Jun 30;83(3-4):319-26 (21 ref.)

MITES

Reflections on the control of mites and mite allergens. de Boer R. **Allergy** 1998;53(48 Suppl):41-6 (72 ref.)

Feather or synthetic? That is the question [editorial; comment] [see comments] Custovic A, et al. **Clin Exp Allergy** 1999 Feb;29(2):144-7 (32 ref.) Comment on: Clin Exp Allergy 1999 Feb;29(2):182-5. Comment in: Clin Exp Allergy 1999 Apr;29(4):429-32.

[Allergy to dust mites (see comments)] Mosbech H. **Ugeskr Laeger** 1999 Jan 25;161(4):414-8 (14 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1998 Apr 20;160(17):2550-1. **(Dan)**

CLASSIFICATION

Taxonomy and identification of dust mites. Colloff MJ. **Allergy** 1998;53(48 Suppl):7-12 (23 ref.)

Occurrence of mites in Norway and the rest of Scandinavia. Mehl R. **Allergy** 1998;53(48 Suppl):28-35 (33 ref.)

ENZYMOLOGY

Mite allergens: significance of enzymatic activity. Hewitt CR, et al. **Allergy** 1998;53(48 Suppl):60-3 (15 ref.)

GENETICS

Inter- and intra-specific variation within the genus Psoroptes (Acari: Psoroptidae). Bates PG. **Vet Parasitol** 1999 Jun 30; 83(3-4):201-17 (105 ref.)

GROWTH & DEVELOPMENT

Quantification of house-dust-mite populations. Hill MR. **Allergy** 1998;53(48 Suppl):18-23 (37 ref.)

The poultry red mite Dermanyssus gallinae (De Geer, 1778): current situation and future prospects for control. Chauve C. **Vet Parasitol** 1998 Nov 16;79(3):239-45 (24 ref.)

IMMUNOLOGY

Allergens from mites: implications of cross-reactivity between invertebrate antigens. Aalberse RC. **Allergy** 1998; 53(48 Suppl):47-8 (13 ref.)

Risk levels for mite allergens. Are they meaningful? Custovic A, et al. **Allergy** 1998;53(48 Suppl):71-6 (41 ref.)

Mite allergens. Collection, determination, expression of results, and risk levels for sensitization and symptom induction. Dreborg S. **Allergy** 1998;53(48 Suppl):88-91 (15 ref.)

Mite-allergen levels in Norwegian homes. Gaarder PI. **Allergy** 1998;53(48 Suppl):58-9 (13 ref.)

House-dust mites and asthma. A review on house-dust mites as a domestic risk factor for mite asthma. Korsgaard J. **Allergy** 1998;53(48 Suppl):77-83 (32 ref.)

Identification and quantification of mite allergens. Luczynska CM. **Allergy** 1998;53(48 Suppl):54-7 (26 ref.)

House dust mite exposure as a risk factor for asthma: benefits of avoidance. Marks GB. **Allergy** 1998;53(48 Suppl):108-14 (58 ref.)

Risk levels for mite allergen: are they meaningful, where should samples be collected, and how should they be analyzed? Munir AK. **Allergy** 1998;53(48 Suppl):84-7 (25 ref.)

Mite sensitization in the Scandinavian countries and factors influencing exposure levels. Munir AK. **Allergy** 1998;53(48 Suppl):64-70 (56 ref.)

House-dust-mite allergens. Thomas WR, et al. **Allergy** 1998 Sep;53(9):821-32 (126 ref.)

House-dust mite hypersensitivity, eczema, and other nonpulmonary manifestations of allergy. Tupker RA, et al. **Allergy** 1998;53(48 Suppl):92-6 (33 ref.)

Allergy to mites: relation to lung function and airway hyperresponsiveness. van der Heide S, et al. **Allergy** 1998; 53(48 Suppl):104-7 (28 ref.)

Clinical and immunologic aspects of storage mite allergy. van Hage-Hamsten M, et al. **Allergy** 1998;53(48 Suppl):49-53 (34 ref.)

The role of dust mite antigen sensitization and atopic dermatitis [editorial; comment] Friedmann PS. **Clin Exp Allergy** 1999 Jul;29(7):869-72 (34 ref.) Comment on: Clin Exp Allergy 1999 Jul;29(7):920-5.

The interaction between the dust mite antigen Der p 1 and cell-signalling molecules in amplifying allergic disease. Schulz O, et al. **Clin Exp Allergy** 1999 Apr;29(4):439-44 (72 ref.)

House dust mites in atopic dermatitis. Fitzharris P, et al. **Int J Dermatol** 1999 Mar;38(3):173-5 (23 ref.)

Regulatory action criteria for filth and other extraneous materials. II. Allergenic mites: an emerging food safety issue. Olsen AR. **Regul Toxicol Pharmacol** 1998 Dec; 28(3):190-8 (89 ref.)

[Relationship of allergen structure and allergic reaction] Okumura Y. **Arerugi** 1998 Dec;47(12):1229-32 (13 ref.) **(Jpn)**

PHYSIOLOGY

Distribution and abundance of dust mites within homes. Colloff MJ. **Allergy** 1998;53(48 Suppl):24-7 (14 ref.)

Life cycle and reproduction of house-dust mites: environmental factors influencing mite populations. Hart BJ. **Allergy** 1998;53(48 Suppl):13-7 (48 ref.)

Epidemiology of house-dust mites. Korsgaard J. **Allergy** 1998;53(48 Suppl):36-40 (21 ref.)

Occurrence of mites in Norway and the rest of Scandinavia. Mehl R. **Allergy** 1998;53(48 Suppl):28-35 (33 ref.)

Mite sensitization in the Scandinavian countries and factors influencing exposure levels. Munir AK. **Allergy** 1998;53(48 Suppl):64-70 (56 ref.)

Creature comforts—living with mites and moulds [editorial; comment] Harrison PT. **Clin Exp Allergy** 1999 Feb; 29(2):148-9 (12 ref.) Comment on: Clin Exp Allergy 1999 Feb;29(2):186-92.

MITOCHONDRIA

The mitochondrial permeability transition pore and its role in cell death. Crompton M. **Biochem J** 1999 Jul 15;341 (Pt 2):233-49 (208 ref.)

Mitochondrial genotype and clinical phenotype. Chinnery PF, et al. **J Inherit Metab Dis** 1998 Jun;21(4):321-5 (29 ref.)

The point of no return: mitochondria, caspases, and the commitment to cell death. Green DR, et al. **Results Probl Cell Differ** 1998;24:45-61 (62 ref.)

CHEMISTRY

A novel electron transfer mechanism suggested by crystallographic studies of mitochondrial cytochrome bc1 complex. Xia D, et al. **Biochem Cell Biol** 1998;76(5):673-9 (27 ref.)

The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Brdiczka D, et al. **Biofactors** 1998;8(3-4):235-42 (44 ref.)

DRUG EFFECTS

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial] Brinkman K, et al. **AIDS** 1998 Oct 1;12(14):1735-44 (108 ref.)

The interaction of mitochondria with pulses of calcium. Gunter TE, et al. **Biofactors** 1998;8(3-4):205-7 (4 ref.)

Mitochondria as cell targets of AZT (zidovudine). Barile M, et al. **Gen Pharmacol** 1998 Oct;31(4):531-8 (53 ref.)

Manganese neurotoxicity: a mechanistic hypothesis. Verity MA. **Neurotoxicology** 1999 Apr-Jun;20(2-3):489-97 (41 ref.)

Mitochondria: a new target for K channel openers? Szewczyk A, et al. **Trends Pharmacol Sci** 1999 Apr;20(4):157-61 (55

ref.)

ENZYMOLOGY

Getting to the nucleus of mitochondrial disorders: identification of respiratory chain-enzyme genes causing Leigh syndrome [editorial; comment] Dahl HH. **Am J Hum Genet** 1998 Dec;63(6):1594–7 (19 ref.) Comment on: Am J Hum Genet 1998 Dec;63(6):1598–1608. Comment on: Am J Hum Genet 1998 Dec;63(6):1609–21.

Human mitochondrial complex I in health and disease. Smeitink J, et al. **Am J Hum Genet** 1999 Jun;64(6):1505–10 (38 ref.)

Expression and regulation of carnitine palmitoyltransferase-Ialpha and -Ibeta genes. Cook GA, et al. **Am J Med Sci** 1999 Jul;318(1):43–8 (47 ref.)

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Hegardt FG. **Biochem J** 1999 Mar 15;338 (Pt 3):569–82 (165 ref.)

The structure of bovine mitochondrial F1-ATPase: an example of rotary catalysis. Leslie AG, et al. **Biochem Soc Trans** 1999 Feb;27(2):37–42 (22 ref.)

Catalytic properties of mitochondrial NADH-ubiquinone reductase (Complex I). Vinogradov AD, et al. **Biochemistry (Mosc)** 1999 Feb;64(2):136–52 (160 ref.)

Transcriptional regulation of mitochondrial HMG-CoA synthase in the control of ketogenesis. Hegardt FG. **Biochimie** 1998 Oct;80(10):803–6 (17 ref.)

Energy transduction function of the quinone reactions in cytochrome bc complexes. Cramer WA, et al. **Biofactors** 1999;9(2–4):81–6 (22 ref.)

Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Wallimann T, et al. **Biofactors** 1998;8(3–4):229–34 (29 ref.)

A function for the vitamin E metabolite alpha-tocopherol quinone as an essential enzyme cofactor for the mitochondrial fatty acid desaturases. Infante JP. **FEBS Lett** 1999 Mar 5;446(1):1–5 (73 ref.)

Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Pearce DA. **Hum Genet** 1999 Jun;104(6):443–8 (54 ref.)

Disorders of mitochondrial fatty acyl-CoA beta-oxidation. Wanders RJ, et al. **J Inherit Metab Dis** 1999 Jun; 22(4):442–87 (176 ref.)

The preprotein translocase of the mitochondrial inner membrane: function and evolution. Rassow J, et al. **J Mol Biol** 1999 Feb 12;286(1):105–20 (117 ref.)

Abnormalities of mitochondrial enzymes in Alzheimer disease. Gibson GE, et al. **J Neural Transm** 1998; 105(8–9):855–70 (75 ref.)

Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach. Schlattner U, et al. **Mol Cell Biochem** 1998 Jul; 184(1–2):125–40 (127 ref.)

Oligomeric state and membrane binding behaviour of creatine kinase isoenzymes: implications for cellular function and mitochondrial structure. Stachowiak O, et al. **Mol Cell Biochem** 1998 Jul;184(1–2):141–51 (93 ref.)

[Cooperation of membrane proteins and cytosolic proteins in metabolic regulation--involvement of binding of hexokinase to mitochondria in regulation of glucose metabolism and association and complex formation between membrane proteins and cytosolic proteins in regulation of active oxygen production] Ishibashi S. **Yakugaku Zasshi** 1999 Jan;119(1):16–34 (49 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A test of Archonta monophyly and the phylogenetic utility of the mitochondrial gene 12S rRNA. McNiff BE, et al. **Am J Phys Anthropol** 1998 Nov;107(3):225–41 (78 ref.)

Ancient and recent horizontal transfer events: the origins of mitochondria. Andersson SG, et al. **APMIS Suppl** 1998; 84:5–14 (46 ref.)

The genome of Rickettsia prowazekii and some thoughts on the origin of mitochondria and hydrogenosomes. Müller M, et al. **Bioessays** 1999 May;21(5):377–81 (39 ref.)

Expression of mitochondrial marker proteins during spermatogenesis. Meinhardt A, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):108–19 (116 ref.)

Molecular characterization of the creatine kinases and some historical perspectives. Qin W, et al. **Mol Cell Biochem** 1998 Jul;184(1–2):153–67 (117 ref.)

Mitochondrial RNA processing and translation: link between mitochondrial mutations and hearing loss? Fischel-Ghodsian N. **Mol Genet Metab** 1998 Oct; 65(2):97–104 (67 ref.)

Pre-eclampsia: a disorder of placental mitochondria? Widschwendter M, et al. **Mol Med Today** 1998 Jul; 4(7):286–91 (45 ref.)

Mitochondrial evolution. Gray MW, et al. **Science** 1999 Mar 5;283(5407):1476–81 (63 ref.)

Mitochondrial diseases in man and mouse. Wallace DC. **Science** 1999 Mar 5;283(5407):1482–8 (101 ref.)

The machinery of mitochondrial inheritance and behavior. Yaffe MP. **Science** 1999 Mar 5;283(5407):1493–7 (72 ref.)

Selfishness and death: raison d'être of restriction, recombination and mitochondria. Kobayashi I. **Trends Genet** 1998 Sep;14(9):368–74 (34 ref.)

IMMUNOLOGY

PBC and AMA--what is the connection? Neuberger J, et al. **Hepatology** 1999 Jan;29(1):271–6 (66 ref.)

METABOLISM

Mitochondria, oxidative stress, and antioxidant defences. Lenaz G, et al. **Acta Biochim Pol** 1999;46(1):1–21 (135 ref.)

Mitochondrial free radical production and aging in mammals and birds. Barja G. **Ann N Y Acad Sci** 1998 Nov 20; 854:224–38 (72 ref.)

Mitochondrial aging: open questions. Beckman KB, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:118–27 (55 ref.)

Tissue-specific distribution of multiple mitochondrial DNA rearrangements during human aging. Kovalenko SA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:171–81 (42 ref.)

The biochemical, pathophysiological, and medical aspects of ubiquinone function. Nohl H, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:394–409 (25 ref.)

Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. Wei YH, et al. **Ann N Y Acad Sci** 1998 Nov 20; 854:155–70 (104 ref.)

Mitochondrial disorders: clinical and genetic features. Simon DK, et al. **Annu Rev Med** 1999;50:111–27 (96 ref.)

Inborn and induced defects of mitochondria. Schapira AH. **Arch Neurol** 1998 Oct;55(10):1293–6 (36 ref.)

Nitric oxide and mitochondrial respiration. Brown GC. **Biochim Biophys Acta** 1999 May 5;1411(2–3):351–69 (155 ref.)

Nitric oxide, mitochondria and neurological disease. Heales SJ, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):215–28 (95 ref.)

The interaction of mitochondria with pulses of calcium. Gunter TE, et al. **Biofactors** 1998;8(3–4):205–7 (4 ref.)

Protein translocation into mitochondria. Káldi K, et al. **Biofactors** 1998;8(3–4):221–4 (6 ref.)

Confocal microscopy of the mitochondrial permeability transition in necrotic cell killing, apoptosis and autophagy. Lemasters JJ, et al. **Biofactors** 1998;8(3–4):283–5 (11 ref.)

Localization and mobility of coenzyme Q in lipid bilayers and membranes. Lenaz G, et al. **Biofactors** 1999; 9(2–4):87–93 (21 ref.)

Imaging the mitochondrial permeability transition pore in intact cells. Petronilli V, et al. **Biofactors** 1998; 8(3–4):263–72 (38 ref.)

Interactions of nitric oxide with hemoproteins: roles of nitric oxide in mitochondria. Henry Y, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1003–14 (131 ref.)

Mechanisms of nitric oxide-dependent apoptosis: involvement of mitochondrial mediators. Boscá L, et al. **Cell Signal** 1999 Apr;11(4):239–44 (63 ref.)

Defects in mitochondrial beta-oxidation of fatty acids. Wood PA. **Curr Opin Lipidol** 1999 Apr;10(2):107–12 (41 ref.)

Structure and function of the cytochrome bc1 complex of mitochondria and photosynthetic bacteria. Crofts AR, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):501–9 (44 ref.)

Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM? Anderson RC. **Curr Pharm Des** 1998 Feb;4(1):1–16 (160 ref.)

The mechanism of proton transport mediated by mitochondrial uncoupling proteins. Garlid KD, et al. **FEBS Lett** 1998 Oct 30;438(1–2):10–4 (34 ref.)

Action of thyroid hormones at the cellular level: the mitochondrial target. Goglia F, et al. **FEBS Lett** 1999 Jun 11;452(3):115–20 (59 ref.)

BCL-2 family members and the mitochondria in apoptosis. Gross A, et al. **Genes Dev** 1999 Aug 1;13(15):1899–911 (122 ref.)

Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art. Smeitink JA, et al. **Hum Mol Genet** 1998;7(10):1573–9 (87 ref.)

Mitochondrial proteins at unexpected cellular locations: export of proteins from mitochondria from an evolutionary perspective. Soltys BJ, et al. **Int Rev Cytol** 2000;194:133–96 (265 ref.)

Cardiolipins and mitochondrial proton-selective leakage. Hoch FL. **J Bioenerg Biomembr** 1998 Dec;30(6):511–32 (173 ref.)

Transcription signals of mitochondrial and nuclear genes for mitochondrial proteins in dicot plants. Brennicke A, et al. **J Hered** 1999 May-Jun;90(3):345–50 (34 ref.)

RNA editing site recognition in higher plant mitochondria. Mulligan RM, et al. **J Hered** 1999 May-Jun;90(3):338–44 (65 ref.)

Mitochondrial medicine--recent advances. Graff C, et al. **J Intern Med** 1999 Jul;246(1):11–23 (108 ref.)

Is Brucella abortus a facultative intracellular pathogen with mitochondria-like activity? Ramirez-Romero R. **Med Hypotheses** 1998 Jul;51(1):41–5 (35 ref.)

Regulation of mitochondrial respiration by adenosine diphosphate, oxygen, and nitric oxide. Boveris A, et al. **Methods Enzymol** 1999;301:188–98 (23 ref.)

Top-down elasticity analysis and its application to energy metabolism in isolated mitochondria and intact cells. Brand MD. **Mol Cell Biochem** 1998 Jul;184(1–2):13–20 (49 ref.)

Mitochondrial RNA processing and translation: link between mitochondrial mutations and hearing loss? Fischel-Ghodsian N. **Mol Genet Metab** 1998 Oct; 65(2):97–104 (67 ref.)

Manganese and calcium transport in mitochondria: implications for manganese toxicity. Gavin CE, et al. **Neurotoxicology** 1999 Apr-Jun;20(2–3):445–53 (69 ref.)

Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation. Budd SL. **Pharmacol Ther** 1998 Nov;80(2):203–29 (179 ref.)

Oxidative phosphorylation at the fin de siècle. Saraste M. **Science** 1999 Mar 5;283(5407):1488–93 (50 ref.)

Mitochondrial glutathione: importance and transport. Fernández-Checa JC, et al. **Semin Liver Dis** 1998; 18(4):389–401 (99 ref.)

Mitochondrial-matrix proteins at unexpected locations: are they exported? Soltys BJ, et al. **Trends Biochem Sci** 1999 May;24(5):174–7 (53 ref.)

[Processing of mitochondrial protein precursors] Ito A. **Seikagaku** 1998 Dec;70(12):1401–12 (96 ref.) **(Jpn)**

PATHOLOGY

Mitochondrial involvement in Alzheimer's disease. Bonilla E, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):171–82 (96 ref.)

Mitochondria in organismal aging and degeneration. Cortopassi GA, et al. **Biochim Biophys Acta** 1999 Feb 9; 1410(2):183–93 (100 ref.)

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia [see comments] Schapira AH. **Biochim Biophys Acta** 1999 Feb 9;1410(2):159–70 (112 ref.) Comment in: Biochim Biophys Acta 1999 Feb 9;1410(2):99–102.

Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. Fiskum G, et al. **J Cereb Blood Flow Metab** 1999 Apr;19(4):351–69 (289 ref.)

Biology and pathology of the mitochondrion. Lloreta-Trull J, et al. **Ultrastruct Pathol** 1998 Sep-Oct;22(5):357–67 (80 ref.)

PHYSIOLOGY

Role and mechanisms of secondary mitochondrial failure. Siesjö BK, et al. **Acta Neurochir Suppl (Wien)** 1999;73:7–13 (78 ref.)

Mitochondrial dynamics in yeast. Hermann GJ, et al. **Annu Rev Cell Dev Biol** 1998;14:265–303 (155 ref.)

Apoptosis in neurodegenerative diseases: the role of mitochondria [see comments] Tatton WG, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):195–213 (209 ref.) Comment in: Biochim Biophys Acta 1999 Feb 9;1410(2):99–102.

Aging and mitochondria. Gadaleta MN, et al. **Biochimie** 1998 Oct;80(10):863–70 (82 ref.)

The evolution of a mechanism of cell suicide. Blackstone NW, et al. **Bioessays** 1999 Jan;21(1):84–8 (60 ref.)

Oxidative stress: role of mitochondria and protection by glutathione. Fernández-Checa JC, et al. **Biofactors** 1998; 8(1–2):7–11 (21 ref.)

Role of mitochondria in metabolism-secretion coupling of insulin release in the pancreatic beta-cell. Maechler P, et al. **Biofactors** 1998;8(3–4):255–62 (48 ref.)

Neuronal excitotoxicity: the role of mitochondria. Nicholls DG, et al. **Biofactors** 1998;8(3–4):287–99 (64 ref.)

Role of mitochondria in Parkinson disease. Kösel S, et al. **Biol Chem** 1999 Jul-Aug;380(7–8):865–70 (48 ref.)

An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Cassarino DS, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):1–25 (276 ref.)

Apoptosis: unmasking the executioner. Wilson MR. **Cell Death Differ** 1998 Aug;5(8):646–52 (53 ref.)

Oxidant, mitochondria and calcium: an overview. Chakraborti T, et al. **Cell Signal** 1999 Feb;11(2):77–85 (77 ref.)

N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Clark JB. **Dev Neurosci** 1998; 20(4–5):271–6 (34 ref.)

Mitochondrial disease and cyclic vomiting syndrome. Boles RG, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):103S–107S (22 ref.)

Mitochondrial fatty acid oxidation disorders and cyclic vomiting syndrome. Rinaldo P. **Dig Dis Sci** 1999 Aug;44(8 Suppl):97S–102S (38 ref.)

Mitochondria and cell death. Mechanistic aspects and methodological issues. Bernardi P, et al. **Eur J Biochem** 1999 Sep;264(3):687–701 (147 ref.)

A revolution in apoptosis: from a nucleocentric to a mitochondriocentric perspective. Brenner C, et al. **Exp Gerontol** 1998 Sep;33(6):543–53 (66 ref.)

Cells depleted of mitochondrial DNA (rho0) yield insight into physiological mechanisms. Chandel NS, et al. **FEBS Lett** 1999 Jul 9;454(3):173–6 (41 ref.)

Mitochondrial assembly in yeast. Grivell LA, et al. **FEBS Lett** 1999 Jun 4;452(1–2):57–60 (40 ref.)

Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Tsujimoto Y. **Genes Cells** 1998 Nov; 3(11):697–707 (75 ref.)

UCP1, UCP2 and UCP3: are they true uncouplers of respiration? Bouillaud F. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S19–23 (30 ref.)

The significance and mechanism of mitochondrial proton conductance. Brand MD, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S4–11 (60 ref.)

The long isoform uncoupling protein-3 (UCP3L) in human energy homeostasis. Chung WK, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S49–50

(14 ref.)
Mitochondria uncoupling proteins and obesity: molecular and genetic aspects of UCP1. Kozak LP, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S33–7 (29 ref.)
Uncoupling protein-3 (UCP3): a mitochondrial carrier in search of a function. Lowell BB. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S43–5 (13 ref.)
Genetics of uncoupling proteins in humans. Warden C. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S46–8 (14 ref.)
Characterization of the yeast mitochondria unselective channel: a counterpart to the mammalian permeability transition pore? Manon S, et al. **J Bioenerg Biomembr** 1998 Oct;30(5):419–29 (57 ref.)
Mitochondria in neurodegeneration: bioenergetic function in cell life and death. Murphy AN, et al. **J Cereb Blood Flow Metab** 1999 Mar;19(3):231–45 (162 ref.)
The enigmatic relationship between mitochondrial dysfunction and Leber's hereditary optic neuropathy [editorial; comment] Brown MD. **J Neurol Sci** 1999 May 1;165(1):1–5 (26 ref.) Comment on: J Neurol Sci 1999 May 1;165(1):10–7.
Mitochondria and childhood liver diseases. Sokol RJ, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):4–16 (59 ref.)
Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. Duchen MR. **J Physiol (Lond)** 1999 Apr 1;516 (Pt 1):1–17 (108 ref.)
Mitochondrial involvement in bladder function and dysfunction. Nevel-McGarvey CA, et al. **Mol Cell Biochem** 1999 Apr;194(1–2):1–15 (184 ref.)
Cytoskeleton and mitochondrial morphology and function. Rappaport L, et al. **Mol Cell Biochem** 1998 Jul; 184(1–2):101–5 (49 ref.)
The bottleneck: mitochondrial imperatives in oogenesis and ovarian follicular fate. Jansen RP, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):81–8 (52 ref.)
Apoptosis: checkpoint at the mitochondrial frontier. Bossy-Wetzel E, et al. **Mutat Res** 1999 Jul 30;434(3):243–51 (88 ref.)
Effects of leptin on mitochondrial 'proton leak' and uncoupling proteins: implications for mammalian energy metabolism. Porter RK, et al. **Proc Nutr Soc** 1998 Aug; 57(3):455–60 (86 ref.)
The machinery of mitochondrial inheritance and behavior. Yaffe MP. **Science** 1999 Mar 5;283(5407):1493–7 (72 ref.)
Biology and pathology of the mitochondrion. Lloreta-Trull J, et al. **Ultrastruct Pathol** 1998 Sep-Oct;22(5):357–67 (80 ref.)
[Mitochondria and aging] Tanaka M. **No To Shinkei** 1999 Jul;51(7):589–99 (22 ref.) **(Jpn)**
[Endoplasmic reticulum and mitochondria as elements of mechanism of intracellular signaling in neurons] Kostiuk PG, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):979–84 (14 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

The mitochondrial permeability transition. Bernardi P, et al. **Biofactors** 1998;8(3–4):273–81 (74 ref.)
Imaging the mitochondrial permeability transition pore in intact cells. Petronilli V, et al. **Biofactors** 1998; 8(3–4):263–72 (38 ref.)
Stimulation of apoptosis by sulindac and piroxicam. Waddell WR. **Clin Sci (Colch)** 1998 Sep;95(3):385–8 (34 ref.)

MITOCHONDRIA, HEART

ENZYMOLOGY

Three-dimensional structure and functions of bovine heart mitochondrial cytochrome bc1 complex. Yu CA, et al. **Biofactors** 1998;8(3–4):187–9 (6 ref.)
Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. Baines CP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):741–54 (111 ref.)
[Structure of cytochrome bc1 complex from bovine heart mitochondria] Iwata M, et al. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):643–54 (28 ref.) **(Jpn)**

METABOLISM

Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Liu Y, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:27–37 (30 ref.)
Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Gross GJ, et al. **Circ Res** 1999 May 14;84(9):973–9 (53 ref.)
Myocardial apoptosis in the overloaded and the aging heart: a critical role of mitochondria? Heinrich H, et al. **Eur Cytokine Netw** 1998 Dec;9(4):693–5 (14 ref.)
Postmitochondrial regulation of apoptosis during heart failure [comment] Reed JC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7614–6 (60 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8144–9.
Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes. Moreno AJ, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II63–77 (100 ref.)

MITOCHONDRIA, LIVER

DRUG EFFECTS

Effects of alcohol on hepatic mitochondrial function and DNA [editorial; comment] Cederbaum AI. **Gastroenterology** 1999 Jul;117(1):265–9 (39 ref.) Comment on: Gastroenterology 1999 Jul;117(1):181–90.

IMMUNOLOGY

Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Strassburg CP, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):595–601 (41 ref.)

METABOLISM

V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Lemasters JJ. **Am J Physiol** 1999 Jan;276(1 Pt 1):G1–6 (40 ref.)
Oxidative damage in the senescence-accelerated mouse. Mori A, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:239–50 (53 ref.)
Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling' the oxidation of fatty acids. McCarty MF, et al. **Med Hypotheses** 1999 May; 52(5):407–16 (97 ref.)
Disorders of the mitochondria. Treem WR, et al. **Semin Liver Dis** 1998;18(3):237–53 (68 ref.)

PHYSIOLOGY

[Role of mitochondria in drug-induced hepatotoxicity] Berson A, et al. **Gastroenterol Clin Biol** 1998 Jan; 22(1):59–72 (96 ref.) **(Fre)**

ULTRASTRUCTURE

Electron microscopic tomography of rat-liver mitochondria and their interaction with the endoplasmic reticulum. Mannella CA, et al. **Biofactors** 1998;8(3–4):225–8 (6 ref.)

MITOCHONDRIA, MUSCLE

see related
MITOCHONDRIAL ENCEPHALOMYOPATHIES
MITOCHONDRIAL MYOPATHIES

METABOLISM

Influences of caloric restriction on age-associated skeletal muscle fiber characteristics and mitochondrial changes in rats and mice. Lee CM, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:182–91 (48 ref.)

MITOCHONDRIAL CONTRACTION see **MITOCHONDRIA**

MITOCHONDRIAL DNA see **DNA, MITOCHONDRIAL**

MITOCHONDRIAL ENCEPHALOMYOPATHIES

[Mitochondrial abnormalities and nervous dysfunctions] Goto Y, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10; 88(5):787–92 (3 ref.) **(Jpn)**

DIAGNOSIS

[Genetic counseling and prenatal diagnosis in mitochondrial diseases] Klopstock T, et al. **Nervenarzt** 1999 Jun; 70(6):504–8 (21 ref.) (Eng. Abstr.) **(Ger)**
[Mitochondrial encephalomyopathies starting in childhood and adolescence] Castro-Gago M, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S61–71 (152 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Genetics and molecular pathogenesis of mitochondrial respiratory chain diseases. Hanna MG, et al. **Cell Mol Life Sci** 1999 May;55(5):691–706 (116 ref.)

GENETICS

Inborn and induced defects of mitochondria. Schapira AH. **Arch Neurol** 1998 Oct;55(10):1293–6 (36 ref.)
Genetics and molecular pathogenesis of mitochondrial respiratory chain diseases. Hanna MG, et al. **Cell Mol Life Sci** 1999 May;55(5):691–706 (116 ref.)
Mitochondrial encephalomyopathies. Shoubridge EA. **Curr Opin Neurol** 1998 Oct;11(5):491–6 (77 ref.)
Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. Cock H, et al. **Epilepsia** 1999;40 Suppl 3:33–40 (90 ref.)
[Genetic counseling and prenatal diagnosis in mitochondrial diseases] Klopstock T, et al. **Nervenarzt** 1999 Jun; 70(6):504–8 (21 ref.) (Eng. Abstr.) **(Ger)**
[Comparison of clinical pictures of mitochondrial encephalomyopathy with tRNA(Leu(UUR)) mutation in 3243 with that in 3254] Mitsuoka T, et al. **No To Shinkei** 1998 Dec;50(12):1089–92 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Mitochondrial encephalopathies: where are we going?] DiMauro S, et al. **Rev Neurol** 1999 Jan 16–31;28(2):164–8 (55 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

The enigmatic relationship between mitochondrial dysfunction and Leber's hereditary optic neuropathy [editorial; comment] Brown MD. **J Neurol Sci** 1999 May 1;165(1):1–5 (26 ref.) Comment on: J Neurol Sci 1999 May 1;165(1):10–7.

PHYSIOPATHOLOGY

[Current status of mitochondrial diseases] Lombès A. **Rev Neurol (Paris)** 1998 Apr;154(3):261–4 (21 ref.) **(Fre)**

MITOCHONDRIAL MYOPATHIES

Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Tyni T, et al. **Acta Paediatr** 1999 Mar;88(3):237–45 (66 ref.)
Mitochondrial myopathies. Clinical and diagnostic aspects. Tulinius MH. **Scand J Rehabil Med Suppl** 1999;39:42–6 (24 ref.)
[Mitochondrial diseases] D'Amati G, et al. **Pathologica** 1999 Feb;91(1):49–50 (6 ref.) **(Ita)**

CLASSIFICATION

[Classification of mitochondrial diseases] López de Munain A. **Rev Neurol** 1998 Apr;26 Suppl 1:S9–14 (69 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Diabetes mellitus and the nervous system. Watkins PJ, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):620–32 (113 ref.)
Early onset of diabetes mellitus associated with the mitochondrial DNA T14709C point mutation: patient report and literature review. Damore ME, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr;12(2):207–13 (47 ref.)
[Mitochondrial diseases and stroke] Irimia P, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S99–106 (81 ref.) (Eng. Abstr.) **(Spa)**
[Mitochondrial changes in neurodegenerative diseases] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S112–7 (111 ref.) (Eng. Abstr.) **(Spa)**
[Lipidic myopathies] Muñoz-Blanco JL. **Rev Neurol** 1998 Apr;26 Suppl 1:S72–80 (91 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Neonatal presentations of mitochondrial metabolic disorders. Sue CM, et al. **Semin Perinatol** 1999 Apr;23(2):113–24 (84 ref.)
[Clinical aspects of mitochondrial diseases] Guerrero A, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S50–60 (83 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

[Treatment of mitochondrial diseases in childhood and adolescence] Castro-Gago M, et al. **Rev Neurol** 1998 Apr; 26 Suppl 1:S92–8 (100 ref.) (Eng. Abstr.) **(Spa)**
[Treatment of mitochondrial diseases] Muñoz A, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S87–91 (63 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Treatment of mitochondrial diseases in childhood and adolescence] Castro-Gago M, et al. **Rev Neurol** 1998 Apr; 26 Suppl 1:S92–8 (100 ref.) (Eng. Abstr.) **(Spa)**
[Treatment of mitochondrial diseases] Muñoz A, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S87–91 (63 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

[Enzyme complex defects of the mitochondrial respiratory chain] Rubio JC, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S15–20 (46 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Secondary mitochondrial diseases] Cardellach F, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S81–6 (54 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. Cock H, et al. **Epilepsia** 1999;40 Suppl 3:33–40 (90 ref.)
Revolution in mitochondrial medicine. Larsson NG, et al. **FEBS Lett** 1999 Jul 23;455(3):199–202 (52 ref.)
Human mitochondrial diseases: answering questions and questioning answers. Howell N. **Int Rev Cytol** 1999; 186:49–116 (315 ref.)
X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)-MIM 302060 [editorial; comment] Barth PG, et al. **J Pediatr** 1999 Sep;135(3):273–6 (19 ref.) Comment on: J Pediatr 1999 Sep;135(3):311–5.
Mitochondrial diseases in man and mouse. Wallace DC. **Science** 1999 Mar 5;283(5407):1482–8 (101 ref.)
[Mitochondrial medicine: human chromosome 25 and mitochondrial diseases] Walker UA.

Dtsch Med Wochenschr 1999 Feb 19;124(7):189–92 (9 ref.) **(Ger)**
[The other genome: the clinical concept of mitochondrial cytopathies or disorders of pxidative phosphorylation] Barrera-Ramírez CF, et al. **Rev Invest Clin** 1999 Mar–Apr; 51(2):121–34 (106 ref.) (Eng. Abstr.) **(Spa)**
[Lipidic myopathies] Muñoz-Blanco JL. **Rev Neurol** 1998 Apr;26 Suppl 1:S72–80 (91 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Compromised fatty acid oxidation in mitochondrial disorders. Hagenfeldt L. **J Inherit Metab Dis** 1998 Aug;21(5):613–7 (8 ref.)
[Cerebral aging and mitochondria] Ortí-Pareja M, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S107–11 (77 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Morphological changes of mitochondrial myopathies] Cabello A, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S44–9 (21 ref.) (Eng. Abstr.) **(Spa)**
[Focal myositis: report of a case in pediatric age and review of the literature] Lorenzo-Sanz G, et al. **Rev Neurol** 1998 Sep;27(157):505–8 (28 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Current status of mitochondrial diseases] Lombès A. **Rev Neurol (Paris)** 1998 Apr;154(3):261–4 (21 ref.) **(Fre)**

THERAPY

[Mitochondrial diseases and stroke] Irimia P, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S99–106 (81 ref.) (Eng. Abstr.) **(Spa)**

MITOGEN-ACTIVATED PROTEIN KINASE see **CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE**

MITOGEN RECEPTORS see **RECEPTORS, MITOGEN**

MITOGENIC FACTORS, LYMPHOCYTE see **INTERLEUKIN-2**

MITOGENS

see related
RECEPTORS, MITOGEN

METABOLISM

Endothelin and restenosis. Kirchengast M, et al. **Cardiovasc Res** 1998 Sep;39(3):550–5 (51 ref.)

PHARMACOLOGY

Mitogenic effect of PDGF-AA on cardiac fibroblasts. Simm A, et al. **Basic Res Cardiol** 1998;93 Suppl 3:40–3 (27 ref.)
Mechanisms and assessment of lectin-mediated mitogenesis. Kilpatrick DC. **Mol Biotechnol** 1999 Feb;11(1):55–65 (86 ref.)
Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Fantus IG, et al. **Mol Cell Biochem** 1998 May;182(1–2):109–19 (89 ref.)

PHYSIOLOGY

Regulation of mitogenesis by water-soluble phospholipid intermediates. Kiss Z. **Cell Signal** 1999 Mar;11(3):149–57 (115 ref.)
Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Zhang N, et al. **Curr Opin Hematol** 1999 Jan; 6(1):44–50 (79 ref.)
Protein tyrosine phosphatases as negative regulators of mitogenic signaling. Chernoff J. **J Cell Physiol** 1999 Aug; 180(2):173–81 (94 ref.)
[Implication of HARP in angiogenesis and possible therapeutic role] Delbe J, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):352–7 (33 ref.) (Eng. Abstr.) **(Fre)**

MITOGENS, ENDOGENOUS see **GROWTH SUBSTANCES**

MITOMYCIN C

ADVERSE EFFECTS

Ocular toxicity of mitomycin-C. Hardten DR, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):79–90 (49 ref.)

METABOLISM

Current issues in the enzymology of mitomycin C metabolic activation. Spanswick VJ, et al. **Gen Pharmacol** 1998 Oct; 31(4):539–44 (58 ref.)

MITOMYCINS

THERAPEUTIC USE

European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Khayat D, et al. **Oncology (Huntingt)** 1998 Aug;12(8 Suppl 6):64–7 (12 ref.)

MITOSIS

see related
MATURATION-PROMOTING FACTOR
MITOGENS
"Dumb" versus "smart" kinetochore models for chromosome congression during mitosis in vertebrate somatic cells. Khodjakov A, et al. **Cell Motil Cytoskeleton** 1999; 43(3):179–85 (28 ref.)
Mitotic neurons: a dogma succumbs [comment] Raina AK, et al. **Exp Neurol** 1999 Sep;159(1):248–9 (19 ref.) Comment on: Exp Neurol 1999 Sep;159(1):237–47.
Polo-like kinases: a team that plays throughout mitosis. Glover DM, et al. **Genes Dev** 1998 Dec 15;12(24):3777–87 (72 ref.)
Three-dimensional transmission electron microscopy and its application to mitosis research. McEwen BF, et al. **Methods Cell Biol** 1999;61:81–111 (89 ref.)
Towards a unifying model for the metaphase/anaphase transition. Kirsch-Volders M, et al. **Mutagenesis** 1998 Jul; 13(4):321–35 (137 ref.)
The HORMA domain: a common structural denominator in mitotic checkpoints, chromosome synapsis and DNA repair. Aravind L, et al. **Trends Biochem Sci** 1998 Aug; 23(8):284–6 (23 ref.)
Segregation of minichromosomes in trypanosomes: implications for mitotic mechanisms. Gull K, et al. **Trends Microbiol** 1998 Aug;6(8):319–23 (26 ref.)

DRUG EFFECTS

Mechanisms and assessment of lectin-mediated mitogenesis. Kilpatrick DC. **Mol Biotechnol** 1999 Feb;11(1):55–65 (86 ref.)
The perturbation of apoptosis and mitosis by drugs and xenobiotics. Hasmall SC, et al. **Pharmacol Ther** 1999 Apr; 82(1):63–70 (67 ref.)

GENETICS

Sister chromatid cohesion in mitosis. Biggins S, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):769–75 (65 ref.)
Endoreduplication and development: rule without dividing? Traas J, et al. **Curr Opin Plant Biol** 1998 Dec;1(6):498–503 (27 ref.)
Mitosis in filamentous fungi: how we got where we are. Aist JR, et al. **Fungal Genet Biol** 1999 Jun;27(1):1–25 (229 ref.)
SMC-mediated chromosome mechanics: a conserved scheme from bacteria to vertebrates? Hirano T. **Genes Dev** 1999 Jan 1;13(1):11–9 (54 ref.)
[Update on genetic markers of cancer] Janoueix-Lerosey I, et al. **Bull Cancer** 1999 Jan;86(1):15–21 (51 ref.) **(Fre)**

PHYSIOLOGY

Kinetochores and the checkpoint mechanism that monitors for defects in the chromosome segregation machinery. Skibbens RV, et al. **Annu Rev Genet** 1998;32:307–37 (189 ref.)
Regulating the onset of mitosis. Ohi R, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):267–73 (65 ref.)
Interactions between mitogenic stimuli, or, a thousand and one connections. Schwartz MA, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):197–202 (51 ref.)
Microtubule-based motor function in mitosis. Heald R, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):268–74 (47 ref.)
Subunits and substrates of the anaphase-promoting complex. Peters JM. **Exp Cell Res** 1999 May 1;248(2):339–49 (102 ref.)
Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. Rozengurt E. **J Cell Physiol** 1998 Dec;177(4):507–17 (129 ref.)
GFP fusions to a microtubule motor protein to visualize meiotic and mitotic spindle dynamics in Drosophila. Endow SA. **Methods Cell Biol** 1999;58:153–63 (21 ref.)
The use and action of drugs in analyzing mitosis. Jordan MA, et al. **Methods Cell Biol** 1999;61:267–95 (133 ref.)
Methods for isolating and analyzing mitotic mutants in Aspergillus nidulans. Oakley BR. **Methods Cell Biol** 1999; 61:347–68 (41 ref.)
Correlative light and electron microscopy of mitotic cells in monolayer cultures. Rieder CL, et al. **Methods Cell Biol** 1999;61:297–315 (59 ref.)
Using sea urchin gametes for the study of mitosis. Sluder G, et al. **Methods Cell Biol** 1999;61:439–72 (10 ref.)
Enlightening mitosis: construction and expression of green fluorescent fusion proteins. Sullivan KF. **Methods Cell Biol** 1999;61:113–35 (33 ref.)
Identification and characterization of mitotic mutations in Drosophila. Theurkauf WE, et al. **Methods Cell Biol** 1999; 61:317–46 (41 ref.)
Microinjection of mitotic cells. Wadsworth P. **Methods Cell Biol** 1999;61:219–31 (47 ref.)
Using antisense technology to study mitosis. Wordeman L, et al. **Methods Cell Biol** 1999;61:245–66 (100 ref.)
Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Fantus IG, et al. **Mol Cell Biochem** 1998 May;182(1–2):109–19 (89 ref.)
Microtubules and neuronal polarity: lessons from mitosis. Baas PW. **Neuron** 1999 Jan;22(1):23–31 (49 ref.)
The mitotic machinery as a source of genetic instability in cancer. Pihan GA, et al. **Semin Cancer Biol** 1999 Aug; 9(4):289–302 (192 ref.)
Checkpoints on the road to mitosis. Russell P. **Trends Biochem Sci** 1998 Oct;23(10):399–402 (30 ref.)
The vertebrate cell kinetochore and its roles during mitosis. Rieder CL, et al. **Trends Cell Biol** 1998 Aug;8(8):310–8 (65 ref.)
[Phenomenon of karyolysis in cytophotomorphometric examinations] Parafiniuk M. **Ann Acad Med Stetin** 1998; Suppl 43:1–87 (108 ref.) (Eng. Abstr.) **(Pol)**

MITOSIS-PROMOTING FACTOR see **MATURATION-PROMOTING FACTOR**

MITOSPORIC FUNGI

Scopulariopsis: an invasive nasal infection. Jabor MA, et al. **Am J Rhinol** 1998 Sep-Oct;12(5):367–71 (8 ref.)

GENETICS

Gene organization and plasticity of the beta-lactam genes in different filamentous fungi. Gutiérrez S, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1–2):81–94 (90 ref.)
Transcriptional control of expression of fungal beta-lactam biosynthesis genes. Litzka O, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1–2):95–105 (60 ref.)
Molecular biology of mycotoxin biosynthesis. Sweeney MJ, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):149–63 (50 ref.)

GROWTH & DEVELOPMENT

Morphogenetic and biochemical effects of dissolved carbon dioxide on filamentous fungi in submerged cultivation. McIntyre M, et al. **Appl Microbiol Biotechnol** 1998 Sep; 50(3):291–8 (50 ref.)

METABOLISM

Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production. Martín JF, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb; 75(1–2):21–31 (90 ref.)
Compartmentalization and transport in beta-lactam antibiotic biosynthesis by filamentous fungi. van de Kamp M, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1–2):41–78 (420 ref.)
Engineering aspects of beta-lactam biosynthesis. van den Berg MA, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb; 75(1–2):155–61 (25 ref.)
Morphogenetic and biochemical effects of dissolved carbon dioxide on filamentous fungi in submerged cultivation. McIntyre M, et al. **Appl Microbiol Biotechnol** 1998 Sep; 50(3):291–8 (50 ref.)
Molecular biology of mycotoxin biosynthesis. Sweeney MJ, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):149–63 (50 ref.)
[Drugs of microbial origin for treatment of atherosclerosis] Bibikova MV, et al. **Antibiot Khimioter** 1998;43(8):34–9 (70 ref.) **(Rus)**

PATHOGENICITY

Virulence factors in fungi of systemic mycoses. Kurokawa CS, et al. **Rev Inst Med Trop Sao Paulo** 1998 May-Jun; 40(3):125–35 (130 ref.)

MITOTIC APPARATUS see **MITOTIC SPINDLE APPARATUS**

MITOTIC SPINDLE APPARATUS

see related
CENTROMERE
CENTROSOME
KINETOCHORES
MICROTUBULES
Microtubule motors in spindle and chromosome motility. Endow SA. **Eur J Biochem** 1999 May;262(1):12–8 (94 ref.)
Micromanipulation of chromosomes and spindles in insect spermatocytes. Zhang D, et al. **Methods Cell Biol** 1999; 61:209–18 (18 ref.)

IMMUNOLOGY

Obtaining antibodies to spindle components. Kuriyama R, et al. **Methods Cell Biol** 1999;61:233–44 (11 ref.)

METABOLISM

Beyond nuclear transport. Ran-GTP as a determinant of spindle assembly. Kahana JA, et al. **J Cell Biol** 1999 Sep 20;146(6):1205–10 (29 ref.)

PHYSIOLOGY

Cell cycle control and the mitotic spindle. Hagan IM, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:6–13 (74 ref.)
The spindle checkpoint. Amon A. **Curr Opin Genet Dev** 1999 Feb;9(1):69–75 (46 ref.)
Using green fluorescent protein fusion proteins to quantitate microtubule and spindle dynamics in budding yeast. Bloom

MITOTIC SPINDLE APPARATUS

KS, et al. **Methods Cell Biol** 1999;61:369–83 (38 ref.)
The use of Xenopus egg extracts to study mitotic spindle assembly and function in vitro. Desai A, et al. **Methods Cell Biol** 1999;61:385–412 (38 ref.)
Fluorescent speckle microscopy of spindle microtubule assembly and motility in living cells. Waterman-Storer C, et al. **Methods Cell Biol** 1999;61:155–73 (25 ref.)
[Regulation of cell division by ubiquitin-dependent proteolysis and spindle assembly checkpoint] Kazuo T. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):253–62 (41 ref.) **(Jpn)**

ULTRASTRUCTURE

Polarized light microscopy of spindles. Oldenbourg R. **Methods Cell Biol** 1999;61:175–208 (75 ref.)

MITRAL CLICK-MURMUR SYNDROME see **MITRAL VALVE PROLAPSE**

MITRAL INCOMPETENCE see **MITRAL VALVE INSUFFICIENCY**

MITRAL REGURGITATION see **MITRAL VALVE INSUFFICIENCY**

MITRAL STENOSIS see **MITRAL VALVE STENOSIS**

MITRAL VALVE

[Percutaneous mitral and aortic valve dilatation in the same session] Ramondo A, et al. **G Ital Cardiol** 1998 Jul; 28(7):800–5 (20 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

MR findings in Shone's complex of left heart obstructive lesions. Roche KJ, et al. **Pediatr Radiol** 1998 Nov; 28(11):841–5 (6 ref.)
[Valve replacement for congenital mitral stenosis associated with double orifice mitral valve: a case report and a review of Japanese literatures] Ogata T, et al. **Kyobu Geka** 1999 Apr;52(4):307–11 (43 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Native valve endocarditis due to a Nocardia-like organism. Dhawan VK, et al. **Clin Infect Dis** 1998 Oct;27(4):902–4 (9 ref.)

PATHOLOGY

Evaluation of mitral valve disease using transesophageal echocardiography. Takuma S, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):247–54 (56 ref.)
[Connective tissue dysplasia in idiopathic mitral valve prolapse] Martynov AI, et al. **Klin Med (Mosk)** 1998; 76(12):10–3 (42 ref.) **(Rus)**

SURGERY

Surgical repair for mitral valve disease. Radermecker MA. **Acta Chir Belg** 1998 Aug;98(4):142–7 (9 ref.)
Mitral valve repair vs replacement. Current recommendations and long-term results. Lawrie GM. **Cardiol Clin** 1998 Aug;16(3):437–48 (95 ref.)
Mitral valve repair for anterior leaflet papillary fibroelastoma: two case descriptions and a literature review. Di Mattia DG, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):103–7 (36 ref.)
Video-assisted and robotic mitral valve surgery: toward an endoscopic surgery. Chitwood WR Jr. **Semin Thorac Cardiovasc Surg** 1999 Jul;11(3):194–205 (39 ref.)
Evaluation of mitral valve disease using transesophageal echocardiography. Takuma S, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):247–54 (56 ref.)
[Mitral valves from the surgical-echocardiography viewpoint] Egloff L, et al. **Ther Umsch** 1998 Dec; 55(12):746–55 (34 ref.) (Eng. Abstr.) **(Ger)**
[The ablation of chronic atrial fibrillation during mitral surgery: a realistic prospect] Alfieri O, et al. **G Ital Cardiol** 1998 Nov;28(11):1317–21 (34 ref.) **(Ita)**
[Minimally invasive mitral surgery: mitral valve repair with a right-sided partial sternotomy] Kasegawa H. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):817–20 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Mitral valve surgery in elderly patients] Antunes MJ. **Rev Port Cardiol** 1999 May;18(5):483–8 (11 ref.) (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Systematic transesophageal echocardiographic examination in mitral valve repair: the evolution of a discipline into the twenty-first century [editorial; comment] Savage RM, et al. **Anesth Analg** 1999 Jun;88(6):1197–9 (14 ref.) Comment on: Anesth Analg 1999 Jun;88(6):1205–12.

MITRAL VALVE INCOMPETENCE see **MITRAL VALVE INSUFFICIENCY**

MITRAL VALVE INSUFFICIENCY

COMPLICATIONS

Pulmonary parenchymal manifestations of mitral valve disease. Woolley K, et al. **Radiographics** 1999 Jul-Aug; 19(4):965–72 (8 ref.)

DIAGNOSIS

[Optimal management of primary and secondary mitral regurgitation] Piper C, et al. **Herz** 1998 Nov;23(7):429–33 (17 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Predictive value of pulmonary venous flow patterns in detecting mitral regurgitation and left ventricular abnormalities. Hynes MS, et al. **Can J Cardiol** 1999 Jun; 15(6):665–70 (24 ref.)
[A case of emergency surgery for acute mitral regurgitation due to complete papillary muscle rupture as complication of acute inferior myocardial infarction] Yanagi H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct;46(10):1014–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Functional mitral regurgitation. Otsuji Y, et al. **Cardiologia** 1998 Oct;43(10):1011–6 (57 ref.)
Doing away with dogma: increasing afterload to reduce mitral regurgitation [editorial; comment] Wisenbaugh T. **J Am Coll Cardiol** 1999 Feb;33(2):546–8 (20 ref.) Comment on: J Am Coll Cardiol 1999 Feb;33(2):538–45.
[Functional mitral regurgitation. Physiopathology and impact of medical therapy and surgical techniques for left ventricle reduction] Comin J, et al. **Rev Esp Cardiol** 1999 Jul; 52(7):512–20 (62 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Pulmonary parenchymal manifestations of mitral valve disease. Woolley K, et al. **Radiographics** 1999 Jul-Aug; 19(4):965–72 (8 ref.)

SURGERY

Surgical repair for mitral valve disease. Radermecker MA. **Acta Chir Belg** 1998 Aug;98(4):142–7 (9 ref.)
Management of mitral regurgitation. Optimal timing for surgery. Quiñones MA. **Cardiol Clin** 1998 Aug; 16(3):421–35, viii (101 ref.)
Mitral valve replacement with preservation of the subvalvular apparatus. Reardon MJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):104–10 (49 ref.)
Mitral valve repair for anterior leaflet papillary fibroelastoma: two case descriptions and a literature review. Di Mattia DG, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):103–7 (36 ref.)
[A successful surgical repair of mitral stenosis and regurgitation with pulmonary arteriovenous fistula] Inoue T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):757–61 (13 ref.) (Eng. Abstr.) **(Jpn)**
[A case of emergency surgery for acute mitral regurgitation due to complete papillary muscle rupture as complication of acute inferior myocardial infarction] Yanagi H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct;46(10):1014–9 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A case of mitral valve replacement combined with idiopathic thrombocytopenic purpura (ITP)] Goshima M, et al. **Kyobu Geka** 1999 Jul;52(7):573–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Optimal management of primary and secondary mitral regurgitation] Piper C, et al. **Herz** 1998 Nov;23(7):429–33 (17 ref.) (Eng. Abstr.) **(Ger)**
[Functional mitral regurgitation. Physiopathology and impact of medical therapy and surgical techniques for left ventricle reduction] Comin J, et al. **Rev Esp Cardiol** 1999 Jul; 52(7):512–20 (62 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Systematic transesophageal echocardiographic examination in mitral valve repair: the evolution of a discipline into the twenty-first century [editorial; comment] Savage RM, et al. **Anesth Analg** 1999 Jun;88(6):1197–9 (14 ref.) Comment on: Anesth Analg 1999 Jun;88(6):1205–12.
Assessment of valvular regurgitation with Doppler echocardiography. Nagueh SF. **Cardiol Clin** 1998 Aug; 16(3):405–19, vii (42 ref.)

MITRAL VALVE PROLAPSE

COMPLICATIONS

[Mitral valve prolapse and respiratory diseases] Korytnikov KI. **Klin Med (Mosk)** 1999;77(4):15–8 (5 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

[Connective tissue dysplasia in idiopathic mitral valve prolapse] Martynov AI, et al. **Klin Med (Mosk)** 1998; 76(12):10–3 (42 ref.) **(Rus)**

SURGERY

Surgical repair for mitral valve disease. Radermecker MA. **Acta Chir Belg** 1998 Aug;98(4):142–7 (9 ref.)

MITRAL VALVE STENOSIS

Clinical assessment and management of mitral stenosis. Bruce CJ, et al. **Cardiol Clin** 1998 Aug;16(3):375–403 (92 ref.)

COMPLICATIONS

Pulmonary parenchymal manifestations of mitral valve disease. Woolley K, et al. **Radiographics** 1999 Jul-Aug; 19(4):965–72 (8 ref.)

DIAGNOSIS

[Mitral valve stenosis. Physiopathology, diagnosis] Cormier B. **Rev Prat** 1998 May 15;48(10):1147–50 (0 ref.) **(Fre)**
[Diagnosis and differential therapy of mitral stenosis] Fassbender D, et al. **Herz** 1998 Nov;23(7):420–8 (34 ref.) (Eng. Abstr.) **(Ger)**
[Acute pseudoabdomen and mitral stenosis. A clinical report of a very unique case] Bock M, et al. **Minerva Chir** 1999 Mar;54(3):167–70 (14 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[Mitral valve stenosis. Physiopathology, diagnosis] Cormier B. **Rev Prat** 1998 May 15;48(10):1147–50 (0 ref.) **(Fre)**

RADIOGRAPHY

Pulmonary parenchymal manifestations of mitral valve disease. Woolley K, et al. **Radiographics** 1999 Jul-Aug; 19(4):965–72 (8 ref.)

SURGERY

Mitral valve repair vs replacement. Current recommendations and long-term results. Lawrie GM. **Cardiol Clin** 1998 Aug;16(3):437–48 (95 ref.)
Mitral valve replacement with preservation of the subvalvular apparatus. Reardon MJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):104–10 (49 ref.)
[A successful surgical repair of mitral stenosis and regurgitation with pulmonary arteriovenous fistula] Inoue T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):757–61 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Valve replacement for congenital mitral stenosis associated with double orifice mitral valve: a case report and a review of Japanese literatures] Ogata T, et al. **Kyobu Geka** 1999 Apr;52(4):307–11 (43 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Percutaneous balloon mitral valvuloplasty: long-term follow-up [letter] Cheng TO. **Cardiol Rev** 1999 Jul-Aug; 7(4):245 (5 ref.)
Balloon valvuloplasty for mitral stenosis. Mazur W, et al. **Curr Opin Cardiol** 1999 Mar;14(2):95–103 (36 ref.)
Mid-term results of percutaneous mitral balloon valvotomy [editorial; comment] Iung B, et al. **Eur Heart J** 1999 Apr; 20(7):478–9 (6 ref.) Comment on: Eur Heart J 1999 Apr;20(7):519–26.
[Treatment of valve diseases] Stauffer JC. **Rev Med Suisse Romande** 1999 May;119(5):361–6 (12 ref.) **(Fre)**
[Diagnosis and differential therapy of mitral stenosis] Fassbender D, et al. **Herz** 1998 Nov;23(7):420–8 (34 ref.) (Eng. Abstr.) **(Ger)**

MIXED CONNECTIVE TISSUE DISEASE

[Mixed connective tissue disease and overlap syndrome] Nishimaki T. **Nippon Rinsho** 1999 Feb;57(2):355–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Respiratory complications in mixed connective tissue disease. Prakash UB. **Clin Chest Med** 1998 Dec;19(4):733–46, ix (75 ref.)

DIAGNOSIS

Mixed connective tissue disease. Kasukawa R. **Intern Med** 1999 May;38(5):386–93 (64 ref.)

MIXED FUNCTION OXIDASES

METABOLISM

Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism. Halpert JR, et al. **Drug Metab Dispos** 1998 Dec;26(12):1223–31 (69 ref.)

MIXED FUNCTION OXYGENASES see **MIXED FUNCTION OXIDASES**

MIXED SALIVARY GLAND TUMOR see **ADENOMA, PLEOMORPHIC**

MIXED TUMOR, MALIGNANT

Many faces of mixed medullary-follicular and papillary carcinoma of the thyroid [editorial; comment] Monden T, et al. **Intern Med** 1998 Nov;37(11):909-10 (12 ref.) Comment on: Intern Med 1998 Nov;37(11):955-7.

MIXED TUMOR, MESODERMAL

ULTRASONOGRAPHY

Ultrasonographic appearance of fallopian tube carcinoma. Ekici E, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):325-9 (24 ref.)

MIXED TUMOR, MULLERIAN

PATHOLOGY

Müllerian carcinofibroma of the uterus. A case report. Imai H, et al. **Acta Cytol** 1999 Jul-Aug;43(4):667-74 (11 ref.)

Malignant mixed Müllerian tumor with rhabdoid features: a report of two cases and a review of the literature. Baschinsky DY, et al. **Gynecol Oncol** 1999 Apr; 73(1):145-50 (23 ref.)

MK-421 see **ENALAPRIL**

MK-422 see **ENALAPRILAT**

MK-801 see **DIZOCILPINE MALEATE**

MMP-3 see **STROMELYSIN 1**

MMPI

MMPI, MMPI-2 and PTSD: overview of scores, scales, and profiles. Lyons JA, et al. **J Trauma Stress** 1999 Jan; 12(1):175-83 (22 ref.)

MN SIALOGLYCOPROTEIN see **GLYCOPHORIN**

MO1 ANTIGEN see **MACROPHAGE-1 ANTIGEN**

MOBILE DISPERSED GENETIC ELEMENTS see **RETROELEMENTS**

MOBILE GENETIC ELEMENTS see **INTERSPERSED REPETITIVE SEQUENCES**

MOBILUNCUS

ISOLATION & PURIFICATION

Severe sepsis caused by Mobiluncus curtisii subsp. curtisii in a previously healthy female: case report and review. Hill DA, et al. **J Infect** 1998 Sep;37(2):194-6 (10 ref.)

MOBILUNCUS CURTISII see **MOBILUNCUS**

MOBILUNCUS MULIERIS see **MOBILUNCUS**

MOBIUS SYNDROME see **FACIAL PARALYSIS**

MODELS, ANATOMIC

see related
MANIKINS

Computer-generated three-dimensional reconstructions of serially sectioned mouse embryos. Kaufman MH, et al. **J Anat** 1998 Oct;193 (Pt 3):323-36 (24 ref.)

Computer-aided interactive three-dimensional reconstruction of the embryonic human heart. Whiten S, et al. **J Anat** 1998 Oct;193 (Pt 3):337-45 (13 ref.)

Rapid prototyping for orthopaedic surgery. Potamianos P, et al. **Proc Inst Mech Eng [H]** 1998;212(5):383-93 (22 ref.)

MODELS, BIOLOGICAL

see related
BIONICS
DISEASE MODELS, ANIMAL

Muscle contraction as a Markov process. I: Energetics of the process. Schutt CE, et al. **Acta Physiol Scand** 1998 Aug; 163(4):307-23 (138 ref.)

From predisposition to psychosis: progression of symptoms in schizophrenia. Parnas J. **Acta Psychiatr Scand Suppl** 1999;395:20-9 (64 ref.)

Microbial models for drug metabolism. Azerad R. **Adv Biochem Eng Biotechnol** 1999;63:169-218 (245 ref.)

Induced potential model of muscular contraction mechanism and myosin molecular structure. Mitsui T. **Adv Biophys** 1999;36:107-58 (50 ref.)

Plasma source mass spectrometry in experimental nutrition. Barnes RM. **Adv Exp Med Biol** 1998;445:379-96 (108 ref.)

Cell culture models of neuronal degeneration and neuroprotection. Implications for Parkinson's disease. Leonardi ET, et al. **Adv Exp Med Biol** 1998;446:203-22 (136 ref.)

Crossbridge head detachment rate constants determined from a model that explains the behavior of both weakly- and strongly-binding crossbridges. Schoenberg M. **Adv Exp Med Biol** 1998;453:425-33; discussion 433-4 (21 ref.)

Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Vogel JS, et al. **Adv Exp Med Biol** 1998;445:397-410 (41 ref.)

Hebbian covariance learning. A nexus for respiratory variability, memory, and optimization? Young DL, et al. **Adv Exp Med Biol** 1998;450:73-83 (41 ref.)

Blood flow rate: an important determinant of urea clearance and delivered Kt/V [published erratum appears in Adv Ren Replace Ther 1999 Jul;6(3):following 293] Ward RA. **Adv Ren Replace Ther** 1999 Jan;6(1):75-9 (22 ref.)

Review article: clinical pharmacology models of irritable bowel syndrome. Malagelada JR. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:57-64 (31 ref.)

Model for the regulation of energy balance and adiposity by the central nervous system. Schwartz MW, et al. **Am J Clin Nutr** 1999 Apr;69(4):584-96 (180 ref.)

A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Majzoub JA, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S232-41 (71 ref.)

Towards a theory of modern human origins: geography, demography, and diversity in recent human evolution. Lahr MM, et al. **Am J Phys Anthropol** 1998;Suppl 27:137-76 (98 ref.)

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Ann Endocrinol (Paris)** 1998;59(6):433-42 (56 ref.)

Heat tolerance. A role for fever? Hales JR, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:188-205 (78 ref.)

Alternating oscillations and chaos in a model of two coupled biochemical oscillators driving successive phases of the cell cycle. Romond PC, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:180-93 (35 ref.)

Clothing evaporative heat resistance--proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339-46 (17 ref.) Comment in: Ann Occup Hyg 1999 Jul;43(5):347-52.

The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353-6 (15 ref.)

Transgenic models of growth hormone action. Kopchick JJ, et al. **Annu Rev Nutr** 1999;19:437-61 (162 ref.)

Cellular physiology and molecular events in hypoxia-induced apoptosis. Riva C, et al. **Anticancer Res** 1998 Nov-Dec; 18(6B):4729-36 (43 ref.)

Evolution of linguistic diversity in a simple communication system. Arita T, et al. **Artif Life** 1998 Winter;4(1):109-24 (18 ref.)

Defining, measuring, and predicting impulsive aggression: a heuristic model. Barratt ES, et al. **Behav Sci Law** 1998 Summer;16(3):285-302 (46 ref.)

Modelling lipid metabolism in plants: a slippery problem? Harwood JL, et al. **Biochem Soc Trans** 1999 Feb; 27(2):285-9 (20 ref.)

The structural design of glycolysis: an evolutionary approach. Heinrich R, et al. **Biochem Soc Trans** 1999 Feb; 27(2):294-8 (11 ref.)

Modelling metabolism in vivo: approaches using NMR. Iles RA, et al. **Biochem Soc Trans** 1999 Feb;27(2):289-94 (21 ref.)

Theoretical studies on how ATP supply meets ATP demand. Korzeniewski B. **Biochem Soc Trans** 1999 Feb;27(2):271-6 (21 ref.)

New insights into metabolic pathway optimization by analogy with industrial manufacturing processes. Ortega F, et al. **Biochem Soc Trans** 1999 Feb;27(2):276-81 (15 ref.)

Viruses: exquisite models for cell strategies. Bernardi F, et al. **Biochimie** 1998 Dec;80(12):1035-41 (47 ref.)

Mechanosensitive ion channels and their mode of activation. Ghazi A, et al. **Biochimie** 1998 May-Jun;80(5-6):357-62 (45 ref.)

Modeling the nuclear magnetic resonance behavior of lung: from electrical engineering to critical care medicine. Cutillo AG, et al. **Bioelectromagnetics** 1999;Suppl 4:110-9 (29 ref.)

Models of the elongation cycle: an evaluation. Spahn CM, et al. **Biol Chem** 1998 Jul;379(7):753-72 (127 ref.)

Contact stress at articular surfaces in total joint replacements. Part II: Analytical and numerical methods. Lewis G. **Biomed Mater Eng** 1998;8(5-6):259-78 (66 ref.)

Hypothetical reasons of the HIV1-AIDS "tritherapy" failure. A challenging model [editorial] [see comments] Mathé G. **Biomed Pharmacother** 1997;51(10):413-6 (39 ref.) Comment in: Biomed Pharmacother 1997 ;51(10):417-26.

The behaviour of ions in narrow water-filled pores. Edmonds DT. **Biosci Rep** 1998 Dec;18(6):313-27 (29 ref.)

Application of mathematical tools for metabolic design of microbial ethanol production. Hatzimanikatis V, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):154-61 (21 ref.)

A structured approach for selection among candidate metabolic network models and estimation of unknown stoichiometric coefficients. Vanrolleghem PA, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):133-8 (7 ref.)

The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Kjalke M, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S21-5 (14 ref.)

Expanding clinical applications of population pharmacodynamic modelling. Minto C, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):321-33 (90 ref.)

Reference frames and internal models for visuo-manual coordination: what can we learn from microgravity experiments? McIntyre J, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):143-54 (77 ref.)

Modelling motion sickness and subjective vertical mismatch detailed for vertical motions. Bos JE, et al. **Brain Res Bull** 1998 Nov 15;47(5):537-42 (15 ref.)

On the viability of a physiological system. Regulation of potassium by aldosterone. Auberlet JM, et al. **C R Acad Sci III** 1998 Oct;321(10):797-803 (20 ref.)

Modelling Escherichia coli. The concept of competitive coherence. Norris V. **C R Acad Sci III** 1998 Sep; 321(9):777-87 (49 ref.)

Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589-97 (71 ref.)

Multicellular spheroids as an in vitro tumor model. Hamilton G. **Cancer Lett** 1998 Sep 11;131(1):29-34 (40 ref.)

Cystic fibrosis and the salt controversy. Guggino WB. **Cell** 1999 Mar 5;96(5):607-10 (20 ref.)

A novel approach for studying angiogenesis: a human skin equivalent with a capillary-like network. Black AF, et al. **Cell Biol Toxicol** 1999 Apr;15(2):81-90 (78 ref.)

Reconstruction of the hematopoietic system after stem cell transplantation. Gordon MY, et al. **Cell Transplant** 1998 Jul-Aug;7(4):339-44 (23 ref.)

Dose-response analysis and biologically-based risk assessment for initiator and promoter carcinogens. Summary report of NATO/CCMS Study. Zapponi GA, et al. **Cent Eur J Public Health** 1998 Nov;6(4):317-20 (0 ref.)

Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. McCulloch EA. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2676-81 (81 ref.)

Methodological issues in pharmacokinetic-pharmacodynamic modelling. Bellissant E, et al. **Clin Pharmacokinet** 1998 Aug;35(2):151-66 (53 ref.)

Interchangeability and predictive performance of empirical tolerance models. Gårdmark M, et al. **Clin Pharmacokinet** 1999 Feb;36(2):145-67 (47 ref.)

Compartmental models for glycaemic prediction and decision-support in clinical diabetes care: promise and reality. Lehmann ED, et al. **Comput Methods Programs Biomed** 1998 May;56(2):193-204 (56 ref.)

Contraceptive testing of vaginal agents in rabbits. Castle PE, et al. **Contraception** 1998 Jul;58(1):51-60 (53 ref.)

Theoretical models for drug delivery to solid tumors. el-Kareh AW, et al. **Crit Rev Biomed Eng** 1997; 25(6):503-71 (250 ref.)

Membrane permeability modeling: Kedem-Katchalsky vs a two-parameter formalism. Kleinhans FW. **Cryobiology** 1998 Dec;37(4):271-89 (47 ref.)

Microbial models of mammalian metabolism of xenobiotics: An updated review. Abourashed EA, et al. **Curr Med Chem** 1999 May;6(5):359-74 (77 ref.)

Octanol-water partition: searching for predictive models. Buchwald P, et al. **Curr Med Chem** 1998 Oct;5(5):353-80 (308 ref.)

Manipulating flux through plant metabolic pathways. Kinney AJ. **Curr Opin Plant Biol** 1998 Apr;1(2):173-8 (21 ref.)

Parasitic plant responses to host plant signals: a model for subterranean plant-plant interactions. Yoder JI. **Curr Opin Plant Biol** 1999 Feb;2(1):65-70 (51 ref.)

Some historical and philosophical reflections on the myofibroblast concept. Gabbiani G. **Curr Top Pathol** 1999; 93:1-5 (40 ref.)

The use of models and metaphors in developmental biology. McLachlan JC. **Endeavour** 1999;23(2):51-5 (22 ref.)

Measurement error, biases, and the validation of complex models for blood lead levels in children. Carroll RJ, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1535-9 (4 ref.)

Some useful statistical methods for model validation. Marcus AH, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1541-50 (21 ref.)

Structure, use, and validation of the IEUBK model. Mickle MH. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1531-4 (13 ref.)

Evaluation (not validation) of quantitative models. Oreskes N. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1453-60 (62 ref.)

The conceptual structure of the integrated exposure uptake biokinetic model for lead in children. White PD, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1513-30 (99 ref.)

The integrated exposure uptake biokinetic model for lead in children: independent validation and verification. Zaragoza L, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1551-6 (40 ref.)

Fluctuation driven transport and models of molecular motors and pumps. Astumian RD, et al. **Eur Biophys J** 1998; 27(5):474-89 (71 ref.)

A mathematical approach to cytoskeletal assembly. Edelstein-Keshet L. **Eur Biophys J** 1998;27(5):521-31 (50 ref.)

Field homology: a meaningless concept. Northcutt RG. **Eur J Morphol** 1999 Apr;37(2-3):95-9 (31 ref.)

Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. De Vries P, et

al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):61-74 (176 ref.)
The nitric oxide hypothesis of aging. McCann SM, et al. **Exp Gerontol** 1998 Nov-Dec;33(7-8):813-26 (39 ref.)
Insights from mathematical modeling of renal tubular function. Weinstein AM. **Exp Nephrol** 1998 Sep-Oct; 6(5):462-8 (46 ref.)
Vitamin E and vascular homeostasis: implications for atherosclerosis. Keaney JF Jr, et al. **FASEB J** 1999 Jun; 13(9):965-75 (125 ref.)
Insulin-independent glucose transport regulates insulin sensitivity. Ebeling P, et al. **FEBS Lett** 1998 Oct 9; 436(3):301-3 (46 ref.)
A second mechanism of respiratory control. Kadenbach B, et al. **FEBS Lett** 1999 Mar 26;447(2-3):131-4 (64 ref.)
The molecular pathobiology of cell membrane iron: the sickle red cell as a model. Browne P, et al. **Free Radic Biol Med** 1998 Apr;24(6):1040-8 (69 ref.)
Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: an hypothesis. Clément MV, et al. **Free Radic Res** 1999 Apr;30(4):247-52 (44 ref.)
The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Scott LV, et al. **Funct Neurol** 1999 Jan-Mar;14(1):3-11 (59 ref.)
Evolutionary theories of aging: handle with care. Le Bourg E. **Gerontology** 1998;44(6):345-8 (20 ref.)
Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Rudling M, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:1-7 (41 ref.)
A four-state kinetic model of the temporary threshold shift after loud sound based on inactivation of hair cell transduction channels [published erratum appears in Hear Res 1999 Apr;130(1-2):231-2] Patuzzi R. **Hear Res** 1998 Nov;125(1-2):39-70 (75 ref.)
Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin [see comments] Andersen ME, et al. **Hum Exp Toxicol** 1998 Dec;17(12):683-90; discussion 701-4, 708-18 (36 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705-7; discussion 701-4, 716-8.
Mechanistic model predicts a U-shaped relation of radon exposure to lung cancer risk reflected in combined occupational and US residential data [see comments] Bogen KT. **Hum Exp Toxicol** 1998 Dec;17(12):691-6; discussion 701-4, 708-18 (31 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705-7; discussion 716-8.
A cancer risk model with adaptive repair [see comments] Downs T, et al. **Hum Exp Toxicol** 1998 Dec; 17(12):697-700; discussion 701-4, 711-8 (3 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705-7; discussion 716-8.
Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Balasch J, et al. **Hum Reprod** 1998 Oct;13(10):2718-30 (85 ref.)
The pecten oculi of the chicken: a model system for vascular differentiation and barrier maturation. Wolburg H, et al. **Int Rev Cytol** 1999;187:111-59 (230 ref.)
Evolution of the rearfoot. A model of adaptation with evidence from the fossil record. Kidd R. **J Am Podiatr Med Assoc** 1999 Jan;89(1):2-17 (63 ref.)
Artificial pigs in space: using artificial intelligence and artificial life techniques to design animal housing. Stricklin WR, et al. **J Anim Sci** 1998 Oct;76(10):2609-13 (18 ref.)
Animats: computer-simulated animals in behavioral research. Watts JM. **J Anim Sci** 1998 Oct;76(10):2596-604 (50 ref.)
Photoperiodic time measurement in insects: a review of clock models. Vaz Nunes M, et al. **J Biol Rhythms** 1999 Apr; 14(2):84-104 (144 ref.)
Electrical, chemical, and topological addressing of mammalian cells with microfabricated systems. Kapur R, et al. **J Biomech Eng** 1999 Feb;121(1):65-72 (50 ref.)
Evaluation of models for balancing the protein requirements of dairy cows. Kohn RA, et al. **J Dairy Sci** 1998 Dec; 81(12):3402-14 (23 ref.)
Integrating sociological and biological models [editorial] Fremont AM, et al. **J Health Soc Behav** 1999 Jun; 40(2):126-9 (17 ref.)
Hypothetical model for monitoring microbial growth by using capacitance measurements--a minireview. Noble PA. **J Microbiol Methods** 1999 Jul;37(1):45-9 (30 ref.)
The time course of nerve growth factor content in different neuropsychiatric diseases--a unifying hypothesis. Hellweg R, et al. **J Neural Transm** 1998;105(8-9):871-903 (213 ref.)
Experimental pathophysiology of panic. Griez E, et al. **J Psychosom Res** 1998 Dec;45(6):493-503 (87 ref.)
Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review. Heiene R, et al. **J Vet Intern Med** 1998 Nov-Dec;12(6):401-14 (86 ref.)
Modeling adverse environmental impacts on the reproductive system. Sussman NB, et al. **J Womens Health** 1999 Mar; 8(2):217-26 (25 ref.)
Finite element modelling of a residual lower-limb in a prosthetic socket: a survey of the development in the first decade. Zhang M, et al. **Med Eng Phys** 1998 Jul; 20(5):360-73 (73 ref.)
Free radicals and reactive oxygen species in programmed cell death. Anderson KM, et al. **Med Hypotheses** 1999 May; 52(5):451-63 (135 ref.)
Host metabolism: a target in clinical oncology? Argilés JM, et al. **Med Hypotheses** 1998 Nov;51(5):411-5 (37 ref.)
Toward a new definition of essential nutrients: is it now time for a third 'vitamin' paradigm? Challem JJ. **Med Hypotheses** 1999 May;52(5):417-22 (48 ref.)
HIV pathogenesis: gp120-antibody complexes bind CD4 and kill T4 cells--immunotoxin therapy should prevent the progression of HIV to AIDS. Chaplin JW. **Med Hypotheses** 1999 Feb;52(2):133-46 (126 ref.)
Front and rear: the pelvic floor is an integrated functional structure. Devroede G. **Med Hypotheses** 1999 Feb; 52(2):147-53 (64 ref.)
Asymmetric DDE (D35E)-like sequences in the RAG proteins: implications for V(D)J recombination and retroviral pathogenesis. Dreyfus DH, et al. **Med Hypotheses** 1999 Jun;52(6):545-9 (32 ref.)
Etiology of ovarian cancer: a proposed mechanism. Ghahremani M, et al. **Med Hypotheses** 1999 Jan;52(1):23-6 (18 ref.)
Organ metabolic rates and aging: two hypotheses. Greenberg JA. **Med Hypotheses** 1999 Jan;52(1):15-22 (49 ref.)
How HIV-1 lentivirus causes immune deficiency disease. Habeshaw JA, et al. **Med Hypotheses** 1999 Jan;52(1):59-67 (33 ref.)
Histamine and prostaglandins in schizophrenia: revisited. Heleniak E, et al. **Med Hypotheses** 1999 Jan;52(1):37-42 (59 ref.)
A role for oxygen-induced osmosis in hyperbaric oxygen therapy. Hills BA. **Med Hypotheses** 1999 Mar;52(3):259-63 (31 ref.)
Progression of cancer. Hirata Y. **Med Hypotheses** 1999 Jun; 52(6):511-3 (4 ref.)
Tumor necrosis factor-alpha: is there a continuum of liability between stress, anxiety states and anorexia nervosa? Holden RJ, et al. **Med Hypotheses** 1999 Feb;52(2):155-62 (83 ref.)
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review). Holden RJ, et al. **Med Hypotheses** 1999 Apr; 52(4):319-23 (55 ref.)
An ataxia telangiectasia model: inefficient cell differentiation and possible reversal by serine protease inhibitors, tumor necrosis factor inhibitors, dexamethasone, and glutathione enhancers. Knittweis J. **Med Hypotheses** 1998 Jul; 51(1):53-7 (88 ref.)
The somatic component of schizophrenia: a dissociation of the goals of visual attention and bifoveal fixation? Korn H. **Med Hypotheses** 1999 Feb;52(2):163-70 (24 ref.)
Aluminium-induced biphasic effect. Kumar S. **Med Hypotheses** 1999 Jun;52(6):557-9 (34 ref.)
Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. McCarty MF. **Med Hypotheses** 1999 May;52(5):465-77 (229 ref.)
Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? McCarty MF. **Med Hypotheses** 1999 May;52(5):397-400 (31 ref.)
Three molecular mechanisms to explain some biological effects of electromagnetic fields and hypogravity. Menéndez RG. **Med Hypotheses** 1999 Mar;52(3):239-45 (44 ref.)
The selenium link: the missing link in our understanding of biochemical trigger reactions? Nyberg-Swenson BE. **Med Hypotheses** 1999 Feb;52(2):125-31 (15 ref.)
Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. Olde Damink SW, et al. **Med Hypotheses** 1999 Jun;52(6):515-9 (37 ref.)
Magnetoreception attributed to the efficacy of light therapy. Partonen T. **Med Hypotheses** 1998 Nov;51(5):447-8 (4 ref.)
Does the impairment of the hypothalamic-pituitary-gonadal axis in anorexia nervosa depend on increased sensitivity to endogenous melatonin? Pawlikowski M, et al. **Med Hypotheses** 1999 Feb;52(2):111-3 (15 ref.)
Syndrome-AC: non-insulin-dependent diabetes mellitus and the anabolic/catabolic paradox. Provonsha S, et al. **Med Hypotheses** 1998 Nov;51(5):429-38 (14 ref.)
Sudden infant death syndrome: hypothalamic failure to sense elevated blood pyrogens. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):569-75 (69 ref.)
Sudden infant death syndrome: oxidative stress. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):577-80 (24 ref.)
Do insulin-like growth factors mediate the effect of alcohol on breast cancer risk? Yu H, et al. **Med Hypotheses** 1999 Jun;52(6):491-6 (76 ref.)
Structure, function, control: a system-constructive approach. Smolyaninov VV. **Membr Cell Biol** 1998;11(6):701-13 (9 ref.)
The mouse as a developmental model. Sharpe PT. **Methods Mol Biol** 1999;97:3-5 (11 ref.)
Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone. Stanislaus D, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1-2):1-10 (73 ref.)
Aquaporin-2 water channels and vasopressin antagonists in edematous disorders. Schrier RW, et al. **Mol Genet Metab** 1998 Dec;65(4):255-63 (56 ref.)
The modulation of membrane structure and stability by dimethyl sulphoxide (review). Yu ZW, et al. **Mol Membr Biol** 1998 Apr-Jun;15(2):59-68 (61 ref.)
A new view on grasping [see comments] Smeets JB, et al. **Motor Control** 1999 Jul;3(3):237-71 (86 ref.) Comment in: Motor Control 1999 Jul;3(3):272-5; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):276-9; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):280-4; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):285-8; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):289-97; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):298-301; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):302-6; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):307-11; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):312-5; discussion 316-25.
Mathematical models for prescription and delivery in peritoneal dialysis. Amici G. **Nephrol Dial Transplant** 1998; 13 Suppl 6:120-4 (48 ref.)
The current place of urea kinetic modelling with respect to different dialysis modalities. Gotch FA. **Nephrol Dial Transplant** 1998;13 Suppl 6:10-4 (10 ref.)
From channels to behavior: an integrative model of NaCl taste. Boughter JD Jr, et al. **Neuron** 1999 Feb;22(2):213-5 (17 ref.)
Ozone dose mapping and the utility of models. Anderson CW, et al. **Novartis Found Symp** 1999;220:80-96; discussion 96-100, 101-4 (11 ref.)
A research programme for testing the biological homology concept. Wagner GP. **Novartis Found Symp** 1999; 222:125-34; discussion 134-40 (50 ref.)
Measuring and modelling pollution for risk analysis. Zidek JV, et al. **Novartis Found Symp** 1999;220:105-16; discussion 116-21 (29 ref.)
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Holash J, et al. **Oncogene** 1999 Sep 20; 18(38):5356-62 (36 ref.)
From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'. Sudol M. **Oncogene** 1998 Sep 17;17(11 Reviews):1469-74 (64 ref.)
A unified paraxial approach to astigmatic optics. Harris WF. **Optom Vis Sci** 1999 Jul;76(7):480-99 (50 ref.)
Quantitative aspects of evaluating the consequences of pollution for parasite populations and communities. Lotz JM. **Parassitologia** 1997 Sep;39(3):243-8 (10 ref.)
Electrophysiology in the eukaryotic model cell Saccharomyces cerevisiae. Bertl A, et al. **Pflugers Arch** 1998 Nov;436(6):999-1013 (145 ref.)
Model scenarios for evolution of the eukaryotic cell cycle. Novak B, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Dec 29;353(1378):2063-76 (25 ref.)
Novel mechanisms of calcium handling by the osteoclast: A review-hypothesis. Zaidi M, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):319-27 (82 ref.)
Applications of computer modelling for the design of orthopaedic, dental and cardiovascular biomaterials. Vander Sloten J, et al. **Proc Inst Mech Eng [H]** 1998; 212(6):489-500 (90 ref.)
Childhood leukaemia: a model of pre-obesity. Ventham JC, et al. **Proc Nutr Soc** 1999 May;58(2):277-81 (45 ref.)
Modelling in nutrition: an introduction. Wilson PD, et al. **Proc Nutr Soc** 1999 Feb;58(1):133-8 (7 ref.)
The logic of Ménage à Trois. Enquist M, et al. **Proc R Soc Lond B Biol Sci** 1998 Apr 7;265(1396):609-13 (34 ref.)
A massively connected subthalamic nucleus leads to the generation of widespread pulses. Gillies AJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Nov 7;265(1410):2101-9 (45 ref.)
The spatial dynamics of prion disease. Payne RJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2341-6 (34 ref.)
Modeling metabolic dynamics. From cellular processes to organ and whole body responses. Cabrera ME, et al. **Prog Biophys Mol Biol** 1998;69(2-3):539-57 (53 ref.)
Synapse formation molecules in muscle and autonomic ganglia: the dual constraint hypothesis. Bennett MR. **Prog Neurobiol** 1999 Feb;57(2):225-87 (257 ref.)
Theoretical and experimental basis for the inhibition of cataract. Benedek GB, et al. **Prog Retin Eye Res** 1999 May; 18(3):391-402 (54 ref.)
Calcium-independent release of neurotransmitter in the retina: a "copernican" viewpoint change. Piccolino M, et al. **Prog Retin Eye Res** 1999 Jan;18(1):1-38 (89 ref.)
Bacterial rhodopsins: evolution of a mechanistic model for the ion pumps. Stoeckenius W. **Protein Sci** 1999 Feb; 8(2):447-59 (21 ref.)
Cardiac autonomic control buffers blood pressure variability responses to challenge: a psychophysiologic model of coronary artery disease. Sloan RP, et al. **Psychosom Med** 1999 Jan-Feb;61(1):58-68 (106 ref.)
Applications of amorphous track models in radiation biology. Cucinotta FA, et al. **Radiat Environ Biophys** 1999 Jul; 38(2):81-92 (78 ref.)
Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Carter-Su C, et al. **Recent Prog Horm Res** 1998;53:61-82; discussion 82-3 (78 ref.)
Vitamin E may slow kidney failure owing to oxidative stress. Fryer MJ. **Redox Rep** 1997 Oct-Dec;3(5-6):259-61 (32 ref.)
Estimation of dermal absorption using the exponential saturation model. Thongsinthusak T, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):37-43 (17 ref.)
Models for oxygen sensing in yeast: implications for oxygen-regulated gene expression in higher eucaryotes. Poyton RO. **Respir Physiol** 1999 Apr 1;115(2):119-33 (70 ref.)

Kinship and genomic imprinting. Trivers R, et al. **Results Probl Cell Differ** 1999;25:1-21 (70 ref.)
Trace element trophic transfer in aquatic organisms: a critique of the kinetic model approach. Reinfelder JR, et al. **Sci Total Environ** 1998 Aug 28;219(2-3):117-35 (124 ref.)
Morphogen propagation and action: towards molecular models. Kerszberg M. **Semin Cell Dev Biol** 1999 Jun; 10(3):297-302 (30 ref.)
Models for the study of uterine receptivity for blastocyst implantation. Sharpe-Timms KL, et al. **Semin Reprod Endocrinol** 1999;17(1):107-15 (73 ref.)
Time in human endurance models. From empirical models to physiological models. Billat LV, et al. **Sports Med** 1999 Jun;27(6):359-79 (79 ref.)
Tutorial in biostatistics. An introduction to hierarchical linear modelling. Sullivan LM, et al. **Stat Med** 1999 Apr 15; 18(7):855-88 (16 ref.)
Shaken not stirred: on permanence in ecological communities. Jansen VA, et al. **Theor Popul Biol** 1998 Dec;54(3):195-201 (48 ref.)
A heuristic model of mental depression derived from basic and applied research on thyrotropin-releasing hormone. Sattin A. **Thyroid** 1998 Oct;8(10):957-62 (67 ref.)
Neural sensitization model for multiple chemical sensitivity: overview of theory and empirical evidence. Bell IR, et al. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):295-304 (116 ref.)
Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship to addiction and abdiction. Miller CS. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):284-94 (39 ref.)
How regulated protein translocation can produce switch-like responses. Ferrell JE Jr. **Trends Biochem Sci** 1998 Dec; 23(12):461-5 (37 ref.)
Metabolic symbiosis at the origin of eukaryotes. López-Garc P, et al. **Trends Biochem Sci** 1999 Mar;24(3):88-93 (39 ref.)
Plant disease-resistance proteins and the gene-for-gene concept. Van der Biezen EA, et al. **Trends Biochem Sci** 1998 Dec;23(12):454-6 (25 ref.)
Detection of elementary flux modes in biochemical networks: a promising tool for pathway analysis and metabolic engineering. Schuster S, et al. **Trends Biotechnol** 1999 Feb; 17(2):53-60 (33 ref.)
Glycans in post-Golgi apical targeting: sorting signals or structural props? Rodriguez-Boulan E, et al. **Trends Cell Biol** 1999 Aug;9(8):291-4 (45 ref.)
Retroviruses as model systems for the study of nuclear RNA export pathways. Cullen BR. **Virology** 1998 Sep 30; 249(2):203-10 (39 ref.)
[Risk increase and economic consequences of the introduction of contagious animal diseases in the Netherlands] Horst HS. **Tijdschr Diergeneeskd** 1999 Feb 15;124(4):111-5 (9 ref.) (Eng. Abstr.) **(Dut)**
[Oocyte of domestic mammals: a model for the study of in vitro maturation] Mermillod P, et al. **Contracept Fertil Sex** 1999 Jun;27(6):440-8 (49 ref.) (Eng. Abstr.) **(Fre)**
[Modeling of elastic deformation and vascular resistance of arterial and venous vasa vasorum] Maurice G, et al. **J Mal Vasc** 1998 Oct;23(4):282-8 (21 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of insulin sensitivity: the HOMA and CIGMA models] Levy JC. **Journ Annu Diabetol Hotel Dieu** 1998; :179-92 (35 ref.) **(Fre)**
[Mathematical models in hemostasis physiology] Barynin IuA, et al. **Izv Akad Nauk Ser Biol** 1999 Jan-Feb;(1):59-66 (7 ref.) (Eng. Abstr.) **(Rus)**

MODELS, CARDIOVASCULAR

Models and remodeling: mechanisms and clinical implications. Sonnenblick EH, et al. **Cardiologia** 1999 Jul; 44(7):609-19 (63 ref.)
Regulation of cardiovascular collagen synthesis by mechanical load. Bishop JE, et al. **Cardiovasc Res** 1999 Apr;42(1):27-44 (181 ref.)
Regulation of basal myocardial function by NO. Kojda G, et al. **Cardiovasc Res** 1999 Mar;41(3):514-23 (100 ref.)
Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties. Mitcheson JS, et al. **Cardiovasc Res** 1998 Aug; 39(2):280-300 (121 ref.)
Chaos in the cardiovascular system: an update. Wagner CD, et al. **Cardiovasc Res** 1998 Nov;40(2):257-64 (87 ref.)
On the accuracy of intra-arterial pressure measurement: the pressure gradient effect [editorial; comment] Hynson JM, et al. **Crit Care Med** 1998 Oct;26(10):1623-4 (15 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1646-9.
The combination of magnetic resonance angiography and computational fluid dynamics: a critical review. Long Q, et al. **Crit Rev Biomed Eng** 1998;26(4):227-74 (125 ref.)
Electrophysiologic models of heart cells and cell networks. Thakor NV, et al. **IEEE Eng Med Biol Mag** 1998 Sep-Oct; 17(5):73-83 (61 ref.)
Atrial electrophysiologic remodeling: another vicious circle? Allessie MA. **J Cardiovasc Electrophysiol** 1998 Dec; 9(12):1378-93 (76 ref.)
Unipolar stimulation of cardiac tissue. Roth BJ, et al. **J Electrocardiol** 1998;31 Suppl:6-12 (30 ref.)
Insights into the relationship of fatty streaks to raised atherosclerotic lesions provided by the hemorheologic-hemodynamic theory of atherosclerotic lesions provided by the hemorheologic-hemodynamic theory of atherogenesis. Sloop GD. **Med Hypotheses** 1998 Nov;51(5):385-8 (21 ref.)
On the vital role of fluid movement in organisms and cells: a brief historical account from Harvey to Coulson, extending the hypothesis of circulation. Wheatley DN. **Med Hypotheses** 1999 Apr;52(4):275-84 (51 ref.)
Transendothelial pathways in venular microvessels exposed to agents which increase permeability: the gaps in our knowledge [editorial] Curry FE, et al. **Microcirculation** 1999 Mar;6(1):3-5 (5 ref.)
Estimation of blood perfusion using ultrasound. Jansson T, et al. **Proc Inst Mech Eng [H]** 1999;213(2):91-106 (110 ref.)
The numerical analysis of fluid-solid interactions for blood flow in arterial structures. Part 2: Development of coupled fluid-solid algorithms. Zhao SZ, et al. **Proc Inst Mech Eng [H]** 1998;212(4):241-52 (42 ref.)
The numerical analysis of fluid-solid interactions for blood flow in arterial structures. Part 1: A review of models for arterial wall behaviour. Zhao SZ, et al. **Proc Inst Mech Eng [H]** 1998;212(4):229-40 (73 ref.)
Wave propagation in cardiac tissue and effects of intracellular calcium dynamics (computer simulation study). Chudin E, et al. **Prog Biophys Mol Biol** 1998;69(2-3):225-36 (17 ref.)
Physical and geometrical modeling for image-based recovery of left ventricular deformation. Duncan J, et al. **Prog Biophys Mol Biol** 1998;69(2-3):333-51 (50 ref.)
Future directions for combining molecular and continuum models in protein simulations. Huber GA. **Prog Biophys Mol Biol** 1998;69(2-3):483-96 (99 ref.)
Modelling the mechanical properties of cardiac muscle. Hunter PJ, et al. **Prog Biophys Mol Biol** 1998; 69(2-3):289-331 (119 ref.)
Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models. Kohl P, et al. **Prog Biophys Mol Biol** 1999;71(1):91-138 (282 ref.)
Modeling the cellular basis of altered excitation-contraction coupling in heart failure. Winslow RL, et al. **Prog Biophys Mol Biol** 1998;69(2-3):497-514 (45 ref.)

MODELS, CHEMICAL

Expanding the model: anisotropic displacement parameters in protein structure refinement. Merritt EA. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1109-17 (44 ref.)
Biological monitoring: the role of toxicokinetics and physiologically based pharmacokinetic modeling. Mason H, et al. **Am Ind Hyg Assoc J** 1999 Mar-Apr;60(2):237-42 (31 ref.)
Calculation of standard transformed formation properties of biochemical reactants and standard apparent reduction potentials of half reactions. Alberty RA. **Arch Biochem Biophys** 1998 Oct 1;358(1):25-39 (50 ref.)
From computer simulations to human disease: emerging themes in protein folding. Radford SE, et al. **Cell** 1999 Apr 30;97(3):291-8 (42 ref.)
Fluorescence correlation spectroscopy as a tool to investigate chemical reactions in solutions and on cell surfaces. Widengren J, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):857-79 (77 ref.)
The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Eisenreich W, et al. **Chem Biol** 1998 Sep;5(9):R221-33 (81 ref.)
Hydrogen tunneling in biology. Kohen A, et al. **Chem Biol** 1999 Jul;6(7):R191-8 (43 ref.)
Octanol-water partition: searching for predictive models. Buchwald P, et al. **Curr Med Chem** 1998 Oct;5(5):353-80 (308 ref.)
New developments in phase refinement. Abrahams JP, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):601-5 (22 ref.)
Recent developments for the efficient crystallographic refinement of macromolecular structures. Brünger AT, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):606-11 (40 ref.)
The use of chemical shifts and their anisotropies in biomolecular structure determination. Case DA. **Curr Opin Struct Biol** 1998 Oct;8(5):624-30 (80 ref.)
The use of computational chemistry in the study of sex steroid biosynthesis. Auchus RJ. **Endocr Res** 1998 Aug-Nov; 24(3-4):541-7 (24 ref.)
Comparison of various cosolvency models for calculating solute solubility in water-cosolvent mixtures. Jouyban-Gharamaleki A, et al. **Int J Pharm** 1999 Jan 15; 177(1):93-101 (35 ref.)
Mechanism from isotope effects. Cook PF. **Isotopes Environ Health Stud** 1998;34(1-2):3-17 (19 ref.)
Single-molecule enzymology. Xie XS, et al. **J Biol Chem** 1999 Jun 4;274(23):15967-70 (51 ref.)
Modeling of ion channels. Levitt DG. **J Gen Physiol** 1999 Jun;113(6):789-94 (26 ref.)
Progress and prospects in permeation. Nonner W, et al. **J Gen Physiol** 1999 Jun;113(6):773-82 (49 ref.)
Molecular crowding: analysis of effects of high concentrations of inert cosolutes on biochemical equilibria and rates in terms of volume exclusion. Minton AP. **Methods Enzymol** 1998;295:127-49 (41 ref.)
Structure-odour relationships: results of an applied electron-topological approach. Shvets NM, et al. **Nahrung** 1998 Dec;42(6):364-70 (18 ref.)
The Poisson-Nernst-Planck model. **Novartis Found Symp** 1999;225:146-52 (18 ref.)
Can we use rate constants and state models to describe ion transport through gramicidin channels? Hladky SB. **Novartis Found Symp** 1999;225:93-107; discussion 107-12 (38 ref.)
Applications of the case/multicase SAR method to environmental and public health situations. Rosenkranz HS, et al. **SAR QSAR Environ Res** 1999;10(2-3):263-76 (34 ref.)
Development, characterization and application of predictive-toxicology models. Rosenkranz HS, et al. **SAR QSAR Environ Res** 1999;10(2-3):277-98 (50 ref.)
[Microequilibrium of drug molecules] Noszál B, et al. **Acta Pharm Hung** 1999 Jun;69(3):108-14 (22 ref.) (Eng. Abstr.) **(Hun)**

MODELS, COMPUTER see **COMPUTER SIMULATION**

MODELS, DECISION SUPPORT see **DECISION SUPPORT TECHNIQUES**

MODELS, ECONOMETRIC

Identifying efficiently and economically operated hospitals: the prospects and pitfalls of applying frontier regression techniques. Chirikos TN. **J Health Polit Policy Law** 1998 Dec;23(6):879-904 (16 ref.)

MODELS, ECONOMIC

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. Hlatky MA. **Am Heart J** 1999 May;137(5):S41-6 (33 ref.)
The role of government in health insurance markets with adverse selection. Feldman R, et al. **Health Econ** 1998 Dec; 7(8):659-70 (32 ref.)
Excess capacity: markets regulation, and values [see comments] Madden CW. **Health Serv Res** 1999 Feb; 33(6):1651-68 (31 ref.) Comment in: Health Serv Res 1999 Feb;33(6):1669-82.
Income inequality, social cohesion, and class relations: a critique of Wilkinson's neo-Durkheimian research program. Muntaner C, et al. **Int J Health Serv** 1999; 29(1):59-81 (127 ref.)

MODELS, EDUCATIONAL

Course design: an integration of didactic and experiential approaches to graduate training of group therapy. Feiner SE. **Int J Group Psychother** 1998 Oct;48(4):439-60 (37 ref.)
[Educational plans as control instruments in youth care in the Netherlands] van den Bergh P, et al. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec; 47(10):767-72 (10 ref.) (Eng. Abstr.) **(Ger)**

MODELS, GENETIC

Multiple sequence alignment: algorithms and applications. Gotoh O. **Adv Biophys** 1999;36:159-206 (189 ref.)
A new model for coronavirus transcription. Sawicki SG, et al. **Adv Exp Med Biol** 1998;440:215-9 (14 ref.)
Concerted evolution: molecular mechanism and biological implications. Liao D. **Am J Hum Genet** 1999 Jan; 64(1):24-30 (33 ref.)
Mice and the role of unequal recombination in gene-family evolution. Schimenti JC. **Am J Hum Genet** 1999 Jan; 64(1):40-5 (42 ref.)
Segregation analysis of quantitative traits. Ginsburg E, et al. **Ann Hum Biol** 1999 Mar-Apr;26(2):103-29 (103 ref.)
Generation of evolutionary novelty by functional shift. Ganfornina MD, et al. **Bioessays** 1999 May;21(5):432-9 (61 ref.)
A structured approach for selection among candidate metabolic network models and estimation of unknown stoichiometric coefficients. Vanrolleghem PA, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):133-8 (7 ref.)
How to build a vertebrate hindbrain. Lessons from genetics. Schneider-Maunoury S, et al. **C R Acad Sci III** 1998 Oct; 321(10):819-34 (137 ref.)
Posterior gut development in Drosophila: a model system for identifying genes controlling epithelial morphogenesis. Lengyel JA, et al. **Cell Res** 1998 Dec;8(4):273-84 (29 ref.)
Rhyme or reason: RNA-arginine interactions and the genetic code. Knight RD, et al. **Chem Biol** 1998 Sep;5(9):R215-20 (23 ref.)
Sequence variation: looking for effects of genetic linkage. Charlesworth D, et al. **Curr Biol** 1998 Sep 10;8(18):R658-61 (15 ref.)
Linkage disequilibrium mapping of complex disease: fantasy or reality? Terwilliger JD, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):578-94 (156 ref.)
Applications of genetic algorithms in molecular diversity. Weber L. **Curr Opin Chem Biol** 1998 Jun;2(3):381-5 (28 ref.)
Who's related to whom? Recent results from molecular systematic studies. Kellogg EA. **Curr Opin Plant Biol** 1998 Apr;1(2):149-58 (85 ref.)
CpG methylation, chromatin structure and gene silencing-a three-way connection. Razin A. **EMBO J** 1998 Sep 1; 17(17):4905-8 (35 ref.)
Genetic epidemiology of infectious diseases in humans: design of population-based studies. Abel L, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):593-603 (74 ref.)
Review of inference procedures for the interclass correlation

coefficient with emphasis on applications to family studies. Donner A, et al. **Genet Epidemiol** 1998;15(6):627–46 (47 ref.)
Linkage and association. Elston RC. **Genet Epidemiol** 1998; 15(6):565–76 (66 ref.)
Models of molecular evolution and phylogeny. Liò P, et al. **Genome Res** 1998 Dec;8(12):1233–44 (86 ref.)
The relative power of family–based and case–control designs for linkage disequilibrium studies of complex human diseases I. DNA pooling. Risch N, et al. **Genome Res** 1998 Dec;8(12):1273–88 (23 ref.)
A hypothesis on the origin of germ cell mutation and evolutionary role of extraembryonic mutation. Persson JW. **Hum Reprod** 1999 Jul;14(7):1840–1 (21 ref.)
The chromosomal duplication model of the major histocompatibility complex. Kasahara M. **Immunol Rev** 1999 Feb;167:17–32 (121 ref.)
Genetic models of abnormal apoptosis in lymphocytes. Refaeli Y, et al. **Immunol Rev** 1999 Jun;169:273–82 (48 ref.)
Expanded (CAG)n, (CGG)n and (GAA)n trinucleotide repeat microsatellites, and mutant purine synthesis and pigmentation genes cause schizophrenia and autism. Fischer KM. **Med Hypotheses** 1998 Sep;51(3):223–33 (89 ref.)
Chromosomal fragility may be indicative of altered higher–order DNA organization as the underlying genetic diathesis in complex neurobehavioural disorders. Gericke GS. **Med Hypotheses** 1999 Mar;52(3):201–8 (80 ref.)
New genetic hypothesis of schizophrenia. Guidry J, et al. **Med Hypotheses** 1999 Jan;52(1):69–75 (66 ref.)
On ring chromatids. Matioli GT. **Med Hypotheses** 1999 Jun; 52(6):521–3 (9 ref.)
A constructionist model predicting the emergence, complementarity and classification of the nucleotide bases. Mussat M, et al. **Med Hypotheses** 1998 Dec;51(6):511–23 (24 ref.)
DNA bending and wrapping around RNA polymerase: a "revolutionary" model describing transcriptional mechanisms. Coulombe B, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):457–78 (169 ref.)
Are minichromosomes valid model systems for DNA replication control? Lessons learned from Escherichia coli. Asai T, et al. **Mol Microbiol** 1998 Aug;29(3):671–5 (27 ref.)
Towards a unifying model for the metaphase/anaphase transition. Kirsch–Volders M, et al. **Mutagenesis** 1998 Jul; 13(4):321–35 (137 ref.)
Principal causes of hot spots for cytosine to thymine mutations at sites of cytosine methylation in growing cells. A model, its experimental support and implications. Lutsenko E, et al. **Mutat Res** 1999 Jul;437(1):11–20 (66 ref.)
Challenges to evolution theory. Rörsch A. **Mutat Res** 1999 Jan 25;423(1–2):F3–19 (22 ref.)
From genomics to vaccines: malaria as a model system [comment] Hoffman SL, et al. **Nat Med** 1998 Dec; 4(12):1351–3 (12 ref.) Comment on: Nat Med 1998 Dec;4(12):1360–2.
Homology and homoplasy: the retention of genetic programmes. Meyer A. **Novartis Found Symp** 1999; 222:141–53; discussion 153–7 (27 ref.)
Codons and hypercycles. Yčas M. **Orig Life Evol Biosph** 1999 Jan;29(1):95–108 (21 ref.)
Tet B or not tet B: advances in tetracycline–inducible gene expression [comment] Blau HM, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):797–9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 2;96(3):1013–8.
Sorting out mutation rates. Foster PL. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7617–8 (10 ref.)
Lineage selection and the evolution of multistage carcinogenesis. Nunney L. **Proc R Soc Lond B Biol Sci** 1999 Mar 7;266(1418):493–8 (30 ref.)
The mechanisms of genomic imprinting. Horsthemke B, et al. **Results Probl Cell Differ** 1999;25:91–118 (110 ref.)
Spermatogenesis as a model system for developmental analysis of regulatory mechanisms associated with tissue–specific gene expression [see comments] McCarrey JR. **Semin Cell Dev Biol** 1998 Aug;9(4):459–66 (28 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379–91.
Statistical methods in psychiatric genetics. Sham PC. **Stat Methods Med Res** 1998 Sep;7(3):279–300 (32 ref.)
Distance measures in terms of substitution processes. Baake E, et al. **Theor Popul Biol** 1999 Apr;55(2):166–75 (31 ref.)
Coalescing into the 21st century: An overview and prospects of coalescent theory. Fu YX, et al. **Theor Popul Biol** 1999 Aug;56(1):1–10 (72 ref.)
A natural example of protein trans–splicing. Perler FB. **Trends Biochem Sci** 1999 Jun;24(6):209–11 (27 ref.)
Forty years under the central dogma [see comments] Thieffry D, et al. **Trends Biochem Sci** 1998 Aug;23(8):312–6 (36 ref.) Comment in: Trends Biochem Sci 1998 Dec;23(12):468.
Electronic PCR: bridging the gap between genome mapping and genome sequencing. Schuler GD. **Trends Biotechnol** 1998 Nov;16(11):456–9 (16 ref.)
Sex biases in the mutation rate. Hurst LD, et al. **Trends Genet** 1998 Nov;14(11):446–52 (77 ref.)
Monoallelic expression: 'there can only be one' [see comments] Ohlsson R, et al. **Trends Genet** 1998 Nov; 14(11):435–8 (29 ref.) Comment in: Trends Genet 1999 Mar;15(3):95–6.
[Is the replicon model applicable to higher eukaryotes?] de Recondo AM. **C R Acad Sci III** 1998 Dec;321(12):961–78 (32 ref.) (Eng. Abstr.) **(Fre)**
[Haldane's rule and somatic mutations] Gorshkov VG, et al. **Genetika** 1999 Jun;35(6):725–32 (38 ref.) (Eng. Abstr.) **(Rus)**

MODELS, IMMUNOLOGICAL

Repeated allergen challenge as a new research model for studying allergic reactions. de Bruin–Weller MS, et al. **Clin Exp Allergy** 1999 Feb;29(2):159–65 (51 ref.)
Cytokine responses in virus infections: effects on pathogenesis, recovery and persistence. Estcourt MJ, et al. **Curr Opin Microbiol** 1998 Aug;1(4):411–8 (55 ref.)
Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Bonini S, et al. **Curr Probl Dermatol** 1999; 28:88–94 (20 ref.)
Peyer's patch organogenesis as a programmed inflammation: a hypothetical model. Nishikawa S, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):213–20 (52 ref.)
Live attenuated SIV—a model of a vaccine for AIDS. Almond N, et al. **Immunol Lett** 1999 Mar;66(1–3):167–70 (30 ref.)
The human thymus. A chimeric organ comprised of central and peripheral lymphoid components [corrected and republished article originally printed in Immunol Res 1998;18(2):61–78] Haynes BF, et al. **Immunol Res** 1998; 18(3):175–92 (70 ref.)
Ichthyophthirius multifiliis: a model of cutaneous infection and immunity in fishes. Dickerson H, et al. **Immunol Rev** 1998 Dec;166:377–84 (62 ref.)
Evolution of immune surveillance and tumor immunity: studies in Xenopus. Robert J, et al. **Immunol Rev** 1998 Dec; 166:231–43 (86 ref.)
A kinetic differentiation model for the action of altered TCR ligands. Lord GM, et al. **Immunol Today** 1999 Jan; 20(1):33–9 (48 ref.)
Away with words: commentary on the Atlan–Cohen essay 'Immune information, self–organization and meaning'. Langman RE, et al. **Int Immunol** 1999 Jun;11(6):865–70 (39 ref.)
Hypothesis: A recurrent, moderate activation fosters systemic autoimmunity—the apoptotic roles of TCR, IL–2 and Fas ligand. Matsui K, et al. **J Biomed Sci** 1999 Sep–Oct; 6(5):306–13 (57 ref.)
Treatment of an autoimmune disease with "classical" T cell veto: a proposal. Staerz UD, et al. **J Clin Immunol** 1999 Jul;19(4):195–202 (97 ref.)
Mobilizing dendritic cells for tolerance, priming, and chronic inflammation [comment] Sallusto F, et al. **J Exp Med** 1999 Feb 15;189(4):611–4 (33 ref.) Comment on: J Exp Med 1999 Feb 15;189(4):627–35.
On the role of feedback in promoting conflicting goals of the adaptive immune system. Segel LA, et al. **J Immunol** 1999 Aug 1;163(3):1342–9 (24 ref.)
Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus? Ilan Y, et al. **Med Hypotheses** 1999 Jun;52(6):505–9 (41 ref.)
Tuberculosis I: a conceptual frame for the immunopathology of the disease. Maes HH, et al. **Med Hypotheses** 1999 Jun; 52(6):583–93 (81 ref.)
Natural killer cell reactivity: activation and cytolysis mechanism models, involving heat shock protein, haemopoietic histocompatibility, major histocompatibility complex and complement molecules. Manzo G. **Med Hypotheses** 1998 Jul;51(1):5–9 (30 ref.)
On the possibility of preventing multiple sclerosis. Marcinkowski T. **Med Hypotheses** 1998 Nov;51(5):445–6 (9 ref.)
Immunologic tolerance: self–nonself discrimination versus costimulatory factors and second signals. Simon Z, et al. **Med Hypotheses** 1998 Jul;51(1):1–3 (11 ref.)
Origins and development of peptide antibiotic research. From extracts to abstracts to contracts. Spitznagel JK. **Mol Biotechnol** 1998 Dec;10(3):237–45 (74 ref.)
The self–nonself discrimination in the context of function. Cohn M. **Theor Med Bioeth** 1998 Sep;19(5):475–84; discussion 485–504 (6 ref.)
Paradigm changes in organ transplantation: a journey toward selflessness? Schaffner KF. **Theor Med Bioeth** 1998 Sep; 19(5):425–40 (55 ref.)
Transplantation tolerance, microchimerism, and the two–way paradigm [see comments] Starzl TE, et al. **Theor Med Bioeth** 1998 Sep;19(5):441–55 (83 ref.) Comment in: Theor Med Bioeth 1998 Sep;19(5):457–73.
Conceptual shifts in immunology: comments on the "two–way paradigm" [comment] Tauber AI. **Theor Med Bioeth** 1998 Sep;19(5):457–73 (39 ref.) Comment on: Theor Med Bioeth 1998 Sep;19(5):441–55.
Immunity and tolerance are related, and governed by antigen migration and localization. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1406–11 (62 ref.)
[Psychoimmunology: a model in question] Vuitton DA. **Rev Med Interne** 1998;19 Suppl 3:343S–346S (12 ref.) **(Fre)**

MODELS, LINEAR see **LINEAR MODELS**

MODELS, LOGISTIC see **LOGISTIC MODELS**

MODELS, MOLECULAR

Molecular dynamics simulations of membranes with embedded proteins and peptides: porin, alamethicin and influenza virus M2. Sansom MS, et al. **Biochem Soc Trans** 1998 Aug;26(3):438–43 (27 ref.)
Three–dimensional models of glutamate receptors. Sutcliffe MJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):450–8 (50 ref.)
Lever arm model of force generation by actin–myosin–ATP. Highsmith S. **Biochemistry** 1999 Aug 3;38(31):9791–7 (58 ref.)
Viral ion channels: molecular modeling and simulation. Sansom MS, et al. **Bioessays** 1998 Dec;20(12):992–1000 (71 ref.)
Protein structure prediction and design. Morea V, et al. **Biotechnol Annu Rev** 1998;4:177–214 (160 ref.)
Usefulness and limitations of linear approximations to the understanding of Ca++ signals [published erratum appears in Cell Calcium 1999 Mar;25(3):275] Neher E. **Cell Calcium** 1998 Nov–Dec;24(5–6):345–57 (76 ref.)
A preliminary comparison of structural models for catalytic intermediates of acetylcholinesterase. Silman I, et al. **Chem Biol Interact** 1999 May 14;119–120:43–52 (36 ref.)
'In vivo' models of hapten generation. Bolzacchini E, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:83–6 (11 ref.)
Structure–based drug design: combinatorial chemistry and molecular modeling. Kirkpatrick DL, et al. **Comb Chem High Throughput Screen** 1999 Aug;2(4):211–21 (54 ref.)
NMR spectroscopy in structure–based drug design. Roberts GC. **Curr Opin Biotechnol** 1999 Feb;10(1):42–7 (73 ref.)
Evolutionary anomalies among the aminoacyl–tRNA synthetases. Doolittle RF, et al. **Curr Opin Genet Dev** 1998 Dec;8(6):630–6 (49 ref.)
Recent developments for the efficient crystallographic refinement of macromolecular structures. Brünger AT, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):606–11 (40 ref.)
The use of chemical shifts and their anisotropies in biomolecular structure determination. Case DA. **Curr Opin Struct Biol** 1998 Oct;8(5):624–30 (80 ref.)
Validation of protein models derived from experiment. Laskowski RA, et al. **Curr Opin Struct Biol** 1998 Oct; 8(5):631–9 (55 ref.)
Deciphering the timescales and mechanisms of protein folding using minimal off–lattice models. Thirumalai D, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):197–207 (91 ref.)
Design of intramolecularly activated prodrugs. Testa B, et al. **Drug Metab Rev** 1998 Nov;30(4):787–807 (31 ref.)
Recent developments towards a unified theory for separation science (minireview). Bowser MT, et al. **Electrophoresis** 1998 Jul;19(10):1586–9 (34 ref.)
Theory and practice of isoelectric focusing of interacting systems. Cann JR. **Electrophoresis** 1998 Jul;19(10):1577–85 (42 ref.)
Fishing for folding nuclei in lattice models and proteins. Thirumalai D, et al. **Fold Des** 1998;3(6):R112–8; discussion R107 (27 ref.)
Analogy and solution scattering modelling: new structural strategies for the multidomain proteins of complement, cartilage and the immunoglobulin superfamily. Perkins SJ, et al. **Immunol Rev** 1998 Jun;163:237–50 (50 ref.)
The complement regulator C4b–binding protein analyzed by molecular modeling, bioinformatics and computer–aided experimental design. Vilioutreix BO, et al. **Immunopharmacology** 1999 May;42(1–3):121–34 (94 ref.)
Self–organizing neural networks bridge the biomolecular resolution gap. Wriggers W, et al. **J Mol Biol** 1998 Dec 18;284(5):1247–54 (47 ref.)
Molecular simulation of the primary and secondary structures of the Abeta(1–42)–peptide of Alzheimer's disease. Mager PP. **Med Res Rev** 1998 Nov;18(6):403–30 (54 ref.)
DNA bending and wrapping around RNA polymerase: a "revolutionary" model describing transcriptional mechanisms. Coulombe B, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):457–78 (169 ref.)
Structure–odour relationships: results of an applied electron–topological approach. Shvets NM, et al. **Nahrung** 1998 Dec;42(6):364–70 (18 ref.)
Allosteric receptors after 30 years. Changeux JP, et al. **Neuron** 1998 Nov;21(5):959–80 (272 ref.)
The mechanism of channel formation by alamethicin as viewed by molecular dynamics simulations. Sansom MS, et al. **Novartis Found Symp** 1999;225:128–41; discussion 141–5 (35 ref.)
Molecular basis of receptor/G–protein–coupling selectivity. Wess J. **Pharmacol Ther** 1998 Dec;80(3):231–64 (345 ref.)
Travelling through conformational space: an approach for analyzing the conformational behaviour of flexible molecules. Koča J. **Prog Biophys Mol Biol** 1998; 70(2):137–73 (112 ref.)
Molecular modelling of the 5–hydroxytryptamine receptors. Wishart G, et al. **Receptors Channels** 1999;6(4):317–35 (127 ref.)
New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Darden T, et al. **Structure Fold Des** 1999 Mar 15;7(3):R55–60 (54 ref.)
Beyond proteins. Robson B. **Trends Biotechnol** 1999 Aug; 17(8):311–5 (22 ref.)

MODELS, NEURAL NETWORK see **NEURAL NETWORKS (COMPUTER)**

MODELS, NEUROLOGICAL

see related
KINDLING (NEUROLOGY)

Schizophrenia and the disconnection hypothesis. Friston KJ. **Acta Psychiatr Scand Suppl** 1999;395:68–79 (49 ref.)
Neural systems for control of voluntary action—a hypothesis. Hikosaka O. **Adv Biophys** 1998;35:81–102 (43 ref.)
The neuronal basis of visual memory and imagery in the primate: a neurophysiological approach. Nakahara K, et al. **Adv Biophys** 1998;35:103–19 (43 ref.)
Theoretical basis and problems of quantification of movement disorders. Kraus PH, et al. **Adv Neurol** 1999;80:443–5 (10 ref.)
Do the models offer testable proposals of brain functions for conscious experience? Libet B. **Adv Neurol** 1998; 77:213–7 (19 ref.)
Idiopathic Parkinson's disease: a genetic and environmental model. Williams AC, et al. **Adv Neurol** 1999;80:215–8 (21 ref.)
Neural network applications in physical medicine and rehabilitation. Ohno-Machado L, et al. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):392–8 (38 ref.)
Zebrafish as a model system for studying neuronal circuits and behavior. Fetcho JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:333–45 (53 ref.)
Intersegmental coordination of swimmeret movements: mathematical models and neural circuits. Mulloney B, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:266–80 (32 ref.)
A simple molecular model of neurulation. Kerszberg M, et al. **Bioessays** 1998 Sep;20(9):758–70 (70 ref.)
A neuronal model of attentional spotlight: parietal guiding the temporal. Vidyasagar TR. **Brain Res Brain Res Rev** 1999 Jul;30(1):66–76 (104 ref.)
Modeling memory: what do we learn from attractor neural networks? Brunel N, et al. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):249–52 (19 ref.)
Hierarchical neuronal modeling of cognitive functions: from synaptic transmission to the Tower of London. Changeux JP, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):241–7 (39 ref.)
The relationships between working memory and long-term memory. van der Linden M. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):175–7 (13 ref.)
Cortical populations and behaviour: Hebb's thread. Amirikian B, et al. **Can J Exp Psychol** 1999 Mar;53(1):21–34 (55 ref.)
Detecting connectedness. Roelfsema PR, et al. **Cereb Cortex** 1998 Jul–Aug;8(5):385–96 (57 ref.)
Temporal coding as a means of information transfer in the primate visual system. Gawne TJ. **Crit Rev Neurobiol** 1999; 13(1):83–101 (89 ref.)
Vision: modular analysis—or not? Burr D. **Curr Biol** 1999 Feb 11;9(3):R90–2 (12 ref.)
Neural models of memory. Hasselmo ME, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):184–8 (54 ref.)
Feedforward, horizontal, and feedback processing in the visual cortex. Lamme VA, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):529–35 (83 ref.)
Population coding in the retina. Nirenberg S, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):488–93 (18 ref.)
Mechanisms of stereoscopic vision: the disparity energy model. Ohzawa I. **Curr Opin Neurobiol** 1998 Aug; 8(4):509–15 (30 ref.)
Drug dependence: stress and dysregulation of brain reward pathways. Kreek MJ, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):23–47 (285 ref.)
Relapse to drug-seeking: neural and molecular mechanisms. Self DW, et al. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):49–60 (135 ref.)
Drug-activation of brain reward pathways. Wise RA. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):13–22 (121 ref.)
Interneurones are not so dormant in temporal lobe epilepsy: a critical reappraisal of the dormant basket cell hypothesis. Bernard C, et al. **Epilepsy Res** 1998 Sep;32(1–2):93–103 (61 ref.)
The role of basal ganglia in the control of generalized absence seizures. Deransart C, et al. **Epilepsy Res** 1998 Sep; 32(1–2):213–23 (84 ref.)
Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Ebert U, et al. **Eur J Clin Invest** 1998 Nov;28(11):944–9 (65 ref.)
Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Floyd RA. **Free Radic Biol Med** 1999 May; 26(9–10):1346–55 (110 ref.)
Developmental and aging aspects of the cholinergic innervation of the olfactory bulb. Durand M, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):777–85 (93 ref.)
Selection of actions in the basal ganglia–thalamocortical circuits: review and model. Kropotov JD, et al. **Int J Psychophysiol** 1999 Mar;31(3):197–217 (104 ref.)
Early development of the Drosophila neuromuscular junction: a model for studying neuronal networks in development. Chiba A. **Int Rev Neurobiol** 1999;43:1–24 (104 ref.)
Axon guidance of outgrowing corticospinal fibres in the rat. Joosten EA, et al. **J Anat** 1999 Jan;194 (Pt 1):15–32 (99 ref.)
Towards an analytic framework for the visuospatial domain: spatial reference frames, cognitive operations, and neural systems. Jagaroo V. **J Clin Exp Neuropsychol** 1999 Feb; 21(1):134–46 (89 ref.)
Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy. Carlsson ML. **J Neural Transm** 1998; 105(4–5):525–35 (72 ref.)
Neural model of first-order and second-order motion perception and magnocellular dynamics. Baloch AA, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 May; 16(5):953–78 (121 ref.)
The stochastic diffusion models of nerve membrane depolarization and interspike interval generation. Lánský P, et al. **J Peripher Nerv Syst** 1999;4(1):27–42 (81 ref.)
Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis. Fisher A, et al. **J Physiol Paris** 1998 Oct–Dec; 92(5–6):337–40 (20 ref.)
Late-training amnesic deficits in probabilistic category learning: a neurocomputational analysis. Gluck MA, et al. **Learn Mem** 1996 Nov–Dec;3(4):326–40 (68 ref.)
The treatment of spinocerebellar ataxias: facts and hypotheses. Botez MI, et al. **Med Hypotheses** 1998 Nov; 51(5):381–4 (45 ref.)
The 'anti-delirium' theory of electroconvulsive therapy action. Charlton BG. **Med Hypotheses** 1999 Jun; 52(6):609–11 (13 ref.)
The handshaking model of brain function: notes toward a theory. Lauter JL. **Med Hypotheses** 1999 May;52(5):435–45 (34 ref.)
Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. McShea A, et al. **Med Hypotheses** 1999 Jun;52(6):525–7 (31 ref.)
Differences in radiosensitivity between brain, small and large arteriovenous malformations. A tentative explanation of the incongruent results of radiotherapy. Pellettieri L, et al. **Med Hypotheses** 1999 Jun;52(6):551–6 (12 ref.)
Cognition, emotion and the brain: a different view. Savitzky A. **Med Hypotheses** 1999 May;52(5):357–62 (22 ref.)
Delusions, superstitious conditioning and chaotic dopamine neurodynamics. Shaner A. **Med Hypotheses** 1999 Feb; 52(2):119–23 (19 ref.)
Can molecules explain long-term potentiation? Sanes JR, et al. **Nat Neurosci** 1999 Jul;2(7):597–604 (122 ref.)
The development of animal behavior: from Lorenz to neural nets. Bolhuis JJ. **Naturwissenschaften** 1999 Mar; 86(3):101–11 (69 ref.)
On the matter of rules. Past-tense formation and its significance for cognitive neuroscience. Pulvermüller F. **Network** 1998 Aug;9(3):R1–52 (94 ref.)
A cerebellar model of timing and prediction in the control of reaching. Barto AG, et al. **Neural Comput** 1999 Apr 1;11(3):565–94 (90 ref.)
Computing with self-excitatory cliques: A model and an application to hyperacuity-scale computation in visual cortex. Miller DA, et al. **Neural Comput** 1999 Jan 1; 11(1):21–66 (105 ref.)
The dystrophinopathies: an alternative to the structural hypothesis. Carlson CG. **Neurobiol Dis** 1998 Jul;5(1):3–15 (110 ref.)
Neuroscience of addiction. Koob GF, et al. **Neuron** 1998 Sep;21(3):467–76 (86 ref.)
Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Weiss SR, et al. **Neuropsychobiology** 1998 Oct;38(3):167–80 (87 ref.)
Internal models for motor control. Kawato M, et al. **Novartis Found Symp** 1998;218:291–304; discussion 304–7 (35 ref.)
Statistical limitations in functional neuroimaging. I. Non-inferential methods and statistical models. Petersson KM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29;354(1387):1239–60 (174 ref.)
The theory of multistage integration in the visual brain. Bartels A, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2327–32 (55 ref.)
The psychophysics of perceptual memory. Magnussen S, et al. **Psychol Res** 1999;62(2–3):81–92 (74 ref.)
Identification of neural circuits underlying P300 abnormalities in schizophrenia. O'Donnell BF, et al. **Psychophysiology** 1999 May;36(3):388–98 (99 ref.)
NPY and food intake: discrepancies in the model. Woods SC, et al. **Regul Pept** 1998 Sep 25;75–76:403–8 (38 ref.)
Ca2+–calmodulin and protein kinase Cs: a hypothetical synthesis of their conflicting convergences on shared substrate domains. Chakravarthy B, et al. **Trends Neurosci** 1999 Jan;22(1):12–6 (38 ref.)
Fifty years of a command neuron: the neurobiology of escape behavior in the crayfish. Edwards DH, et al. **Trends Neurosci** 1999 Apr;22(4):153–61 (79 ref.)
Where the abstract feature maps of the brain might come from. Kohonen T, et al. **Trends Neurosci** 1999 Mar; 22(3):135–9 (44 ref.)
Excitable dendrites and spines: earlier theoretical insights elucidate recent direct observations. Segev I, et al. **Trends Neurosci** 1998 Nov;21(11):453–60 (93 ref.)
Active sensing—closing multiple loops. König P, et al. **Z Naturforsch [C]** 1998 Jul–Aug;53(7–8):542–9 (62 ref.)
Solutions for the binding problem. Roelfsema PR. **Z Naturforsch [C]** 1998 Jul–Aug;53(7–8):691–715 (138 ref.)
[For a "neurocognitive" approach to memory: value of neuropsychology] Dubois B. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):235–9 (11 ref.) (Eng. Abstr.) **(Fre)**
[Do systems theory models promote understanding of disorders of sensorimotor function in neurology?] Glasauer S, et al. **Nervenarzt** 1998 Oct;69(10):919–23 (18 ref.) **(Ger)**

MODELS, NONLINEAR see **NONLINEAR DYNAMICS**

MODELS, NURSING

Nursing in Thailand: western concepts vs Thai tradition. Ekintumas D. **Int Nurs Rev** 1999 Mar–Apr;46(2):55–7 (19 ref.)
Who cares? Who cures? The ongoing debate in the provision of health care. Baumann AO, et al. **J Adv Nurs** 1998 Nov; 28(5):1040–5 (24 ref.)
Paradigm dialogues and dogma: finding a place for research, nursing models and reflective practice. Heath H. **J Adv Nurs** 1998 Aug;28(2):288–94 (71 ref.)
Health-within-illness: concept development through research and practice. Moch SD. **J Adv Nurs** 1998 Aug; 28(2):305–10 (38 ref.)
The professional identity of the nurse: concept analysis and development. Ohlén J, et al. **J Adv Nurs** 1998 Oct; 28(4):720–7 (40 ref.)
Homophobia: an evolutionary analysis of the concept as applied to nursing. Richmond JP, et al. **J Adv Nurs** 1998 Aug;28(2):362–9 (95 ref.)
Nursing work redesign in response to managed care. Hoover KW. **J Nurs Adm** 1998 Nov;28(11):9–18 (54 ref.)
Impact of unlicensed assistive personnel on patient satisfaction: an integrative review of the literature. Siehoff AM. **J Nurs Care Qual** 1998 Dec;13(2):1–10 (22 ref.)
The midwifery model of care [see comments] Rooks JP. **J Nurse Midwifery** 1999 Jul–Aug;44(4):370–4 (38 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.
The geriatric resource nurse model of care: a [illegible] for the future. Francis D, et al. **Nurs Clin North Am** 1998 Sep; 33(3):481–96 (29 ref.)
A patient-centered model of acute care for elders. Kresevic DM, et al. **Nurs Clin North Am** 1998 Sep;33(3):515–27 (6 ref.)
Conceptualizing battered women as a vulnerable population: a case study report. Tyson S, et al. **Nurs Clin North Am** 1999 Jun;34(2):301–12 (48 ref.)
Community health nursing practice and the Roy Adaptation Model. Dixon EL. **Public Health Nurs** 1999 Aug; 16(4):290–300 (35 ref.)
The Corbin and Strauss Chronic Illness Trajectory model: an update. Corbin JM. **Sch Inq Nurs Pract** 1998 Spring; 12(1):33–41 (10 ref.)
A conceptual model of collaborative nurse-physician interactions: the management of traditional influences and personal tendencies. Corser WD. **Sch Inq Nurs Pract** 1998 Winter;12(4):325–41; discussion 343–6 (113 ref.)
A theoretical analysis of Carper's ways of knowing using a model of social cognition. Stein KF, et al. **Sch Inq Nurs Pract** 1998 Spring;12(1):43–60; discussion 61–4 (58 ref.)

MODELS, ORGANIZATIONAL

Analysis of third-party certification approaches using an occupational health and safety conformity-assessment model. Redinger CF, et al. **Am Ind Hyg Assoc J** 1998 Nov; 59(11):802–12 (48 ref.)
Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Glasgow RE, et al. **Am J Public Health** 1999 Sep;89(9):1322–7 (88 ref.)
Depolarising the 'broadened' and 'back-to-basics' relief models. Jackson S, et al. **Disasters** 1999 Jun;23(2):93–114 (31 ref.)
Cultural sensitivity in public health: defined and demystified. Resnicow K, et al. **Ethn Dis** 1999 Winter;9(1):10–21 (98 ref.)
Multiple-perspectives model of medical technology. Geisler E. **Health Care Manage Rev** 1999 Summer;24(3):55–63 (29 ref.)
A model for chronic care of obesity through dietary treatment. Nonas CA. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S16–22 (39 ref.)
Health promotion in a hospital ward; reality or asking the impossible? Coakley AL. **J R Soc Health** 1998 Aug; 118(4):217–20 (25 ref.)
Potential effects of managed care organizations in rural communities: a framework. Christianson J. **J Rural Health** 1998 Summer;14(3):169–79 (2 ref.)
Overview: working inside, outside, and side by side to improve the quality of health care. Wasson JH, et al. **Jt Comm J Qual Improv** 1998 Oct;24(10):513–7 (7 ref.)
Models of collaboration. Lorenz AD, et al. **Prim Care** 1999 Jun;26(2):401–10 (14 ref.)
[Different organizational modalities in perinatal care as a function of demographic context and budgetary constraints] Papiernik E. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:76–84 (17 ref.) **(Fre)**
[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:94–103 (40 ref.) **(Fre)**

MODELS, PROPORTIONAL HAZARDS

MODELS, PROPORTIONAL HAZARDS see **PROPORTIONAL HAZARDS MODELS**

MODELS, PSYCHOLOGICAL

Reinterpreting physical violence: outcome of intense stimulation-seeking behavior [letter] Mawson AR. **Acad Emerg Med** 1999 Aug;6(8):863-5 (12 ref.)

Dual diagnosis: a review of etiological theories. Mueser KT, et al. **Addict Behav** 1998 Nov-Dec;23(6):717-34 (163 ref.)

Experience of cognitive behaviour therapy in psychiatric practice in Nigeria: 1: The model and the method. Ohaeri JU. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):115-8 (25 ref.)

Theoretical perspectives on female sexual behaviour in Africa: a review and conceptual model. Djamba YK. **Afr J Reprod Health** 1997 Sep;1(2):67-78 (57 ref.)

Cognitive development: children's knowledge about the mind. Flavell JH. **Annu Rev Psychol** 1999;50:21-45 (111 ref.)

Do personality disorders exist? On the validity of the concept and its cognitive-behavioral formulation and treatment. Arntz A. **Behav Res Ther** 1999 Jul;37 Suppl 1:S97-134 (109 ref.)

A cognitive behavioural theory of anorexia nervosa. Fairburn CG, et al. **Behav Res Ther** 1999 Jan;37(1):1-13 (56 ref.)

Defining, measuring, and predicting impulsive aggression: a heuristic model. Barratt ES, et al. **Behav Sci Law** 1998 Summer;16(3):285-302 (46 ref.)

Cognitive approaches to delusions: a critical review of theories and evidence. Garety PA, et al. **Br J Clin Psychol** 1999 Jun;38 (Pt 2):113-54 (109 ref.)

Can social cognitive models contribute to the effectiveness of HIV-preventive behavioural interventions? A brief review of the literature and a reply to Joffe (1996; 1997) and Fife-Schaw (1997) [comment] Abraham C, et al. **Br J Med Psychol** 1998 Sep;71 (Pt 3):297-310 (73 ref.) Comment on: Br J Med Psychol 1996 Sep;69 (Pt 3):169-90. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):65-73. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):75-83.

Modeling memory: what do we learn from attractor neural networks? Brunel N, et al. **C R Acad Sci III** 1998 Feb-Mar; 321(2-3):249-52 (19 ref.)

Beyond pain: the role of fear and avoidance in chronicity. Asmundson GJ, et al. **Clin Psychol Rev** 1999 Jan; 19(1):97-119 (100 ref.)

Models of human memory and their implications for research on aging and psychopathology. Estes WK. **Dev Psychopathol** 1998 Fall;10(4):607-24 (82 ref.)

Drug dependence: stress and dysregulation of brain reward pathways. Kreek MJ, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):23-47 (285 ref.)

A review of the phenomenology and cognitive neuropsychological origins of the Capgras syndrome. Edelstyn NM, et al. **Int J Geriatr Psychiatry** 1999 Jan; 14(1):48-59 (225 ref.)

The evaluation of the 'stages of change' model for use in counselling client's undergoing predictive testing for Huntington's disease. Houlihan GD. **J Adv Nurs** 1999 May; 29(5):1137-43 (38 ref.)

Dietary applications of the stages of change model. Greene GW, et al. **J Am Diet Assoc** 1999 Jun;99(6):673-8 (46 ref.)

How can stages of change be best used in dietary interventions? Kristal AR, et al. **J Am Diet Assoc** 1999 Jun;99(6):679-84 (17 ref.)

Time and memory: towards a pacemaker-free theory of interval timing [see comments] Staddon JE, et al. **J Exp Anal Behav** 1999 Mar;71(2):215-51 (143 ref.) Comment in: J Exp Anal Behav 1999 Mar;71(2):253-6; discussion 293-301. Comment in: J Exp Anal Behav 1999 Mar;71(2):257-63; discussion 293-301. Comment in: J Exp Anal Behav 1999 Mar;71(2):264-71; discussion 293-301. Comment in: J Exp Anal Behav 1999 Mar;71(2):272-5; discussion 293-301. Comment in: J Exp Anal Behav 1999 Mar;71(2):275-80; discussion 293-301. Comment in: J Exp Anal Behav 1999 Mar;71(2):281-4. Comment in: J Exp Anal Behav 1999 Mar;71(2):284-88. Comment in: J Exp Anal Behav 1999 Mar;71(2):288-91.

Process, not representation: reply to Radvansky (1999). Anderson JR, et al. **J Exp Psychol Gen** 1999 Jun; 128(2):207-10 (12 ref.)

The fan effect: a tale of two theories. Radvansky GA. **J Exp Psychol Gen** 1999 Jun;128(2):198-206 (45 ref.)

A psychodynamic model of behavior after acute central nervous system damage. Groswasser Z, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):69-79 (20 ref.)

Integrating sociological and biological models [editorial] Fremont AM, et al. **J Health Soc Behav** 1999 Jun; 40(2):126-9 (17 ref.)

Approaching psychotherapy of the personality disorders from the Millon perspective. Dorr D. **J Pers Assess** 1999 Jun;72(3):407-25 (35 ref.)

The biographical component of schizophrenia: a two-faced definition of relationship? Korn H. **Med Hypotheses** 1999 Jun;52(6):539-44 (32 ref.)

The handshaking model of brain function: notes toward a theory. Lauter JL. **Med Hypotheses** 1999 May;52(5):435-45 (34 ref.)

Social interpersonal dimensions of the psychoses. Lindsay JS. **Med Hypotheses** 1999 Apr;52(4):335-47 (28 ref.)

Cognition, emotion and the brain: a different view. Savitzky A. **Med Hypotheses** 1999 May;52(5):357-62 (22 ref.)

Emotions at work [editorial] Moodie R, et al. **Med J Aust** 1999 Apr 5;170(7):296-7 (18 ref.)

A theoretical model for the study of active and passive smoking in military women: an at-risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475-80 (56 ref.)

A bimodal model of the mechanism of action of lithium. Jope RS. **Mol Psychiatry** 1999 Jan;4(1):21-5 (35 ref.)

The development of animal behavior: from Lorenz to neural nets. Bolhuis JJ. **Naturwissenschaften** 1999 Mar; 86(3):101-11 (69 ref.)

Phamacokinetic-pharmacodynamic modelling of behavioural responses. Della Paschoa OE, et al. **Neurosci Biobehav Rev** 1998;23(2):229-36 (42 ref.)

The elevated T-maze as an experimental model of anxiety. Graeff FG, et al. **Neurosci Biobehav Rev** 1998;23(2):237-46 (61 ref.)

A conceptual model of collaborative nurse-physician interactions: the management of traditional influences and personal tendencies. Corser WD. **Sch Inq Nurs Pract** 1998 Winter;12(4):325-41; discussion 343-6 (113 ref.)

In defense of the assault cycle: a commentary. Carich MS. **Sex Abuse** 1999 Jul;11(3):249-51 (8 ref.)

Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247-61 (81 ref.)

The use of multivariate statistical methods in psychiatry. Everitt BS, et al. **Stat Methods Med Res** 1998 Sep; 7(3):253-77 (89 ref.)

[Theoretical bases of semiology in pediatric psychiatry. I. Theoretical models] Brunod R. **Arch Pediatr** 1999 Mar; 6(3):307-13 (48 ref.) (Eng. Abstr.) **(Fre)**

[For a "neurocognitive" approach to memory: value of neuropsychology] Dubois B. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):235-9 (11 ref.) (Eng. Abstr.) **(Fre)**

[Psychoimmunology: a model in question] Vuitton DA. **Rev Med Interne** 1998;19 Suppl 3:343S-346S (12 ref.) **(Fre)**

[A stimulus barrier model of early onset schizophrenia: an integrative etiological and therapeutic approach] Eggers C. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec; 47(10):740-53 (67 ref.) (Eng. Abstr.) **(Ger)**

MODELS, STATISTICAL

see related
META-ANALYSIS

Invited commentary: propensity scores. Joffe MM, et al. **Am J Epidemiol** 1999 Aug 15;150(4):327-33 (40 ref.)

Methods for analyzing health care utilization and costs. Diehr P, et al. **Annu Rev Public Health** 1999;20:125-44 (35 ref.)

Cardiac surgical mortality: comparison among different additive risk-scoring models in a multicenter sample. Pons JM, et al. **Arch Surg** 1998 Oct;133(10):1053-7 (19 ref.)

An allometric model for predicting blood ethanol elimination in mammals. Matsumoto H, et al. **Biochem Pharmacol** 1999 Jan 15;57(2):219-23 (27 ref.)

Regulatory affairs in biotechnology: optimal statistical designs for biomedical experiments. Carriere KC. **Biotechnol Annu Rev** 1998;4:215-38 (59 ref.)

Caries prediction: a review of the literature. Powell LV. **Community Dent Oral Epidemiol** 1998 Dec;26(6):361-71 (48 ref.)

An introduction to the indirect exposure assessment approach: modeling human exposure using microenvironmental measurements and the recent National Human Activity Pattern Survey. Klepeis NE. **Environ Health Perspect** 1999 May;107 Suppl 2:365-74 (36 ref.)

Mathematical models for predicting indoor air quality from smoking activity. Ott WR. **Environ Health Perspect** 1999 May;107 Suppl 2:375-81 (37 ref.)

Convergent approaches to electrophysiological and hemodynamic investigations of memory. Rugg MD. **Hum Brain Mapp** 1998;6(5-6):394-8 (10 ref.)

An EM algorithm for dynamic SPECT. Bauschke HH, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):252-61 (38 ref.)

Modeling stress: a methodological review. Roesch SC. **J Behav Med** 1999 Jun;22(3):249-69 (152 ref.)

Ecological analysis of intended treatment effects: caveat emptor [comment] Naylor CD. **J Clin Epidemiol** 1999 Jan; 52(1):1-5 (11 ref.) Comment on: J Clin Epidemiol 1999 Jan;52(1):7-12.

Statistically derived predictive models. Caveat emptor [editorial] Iezzoni LI. **J Gen Intern Med** 1999 Jun; 14(6):388-9 (11 ref.)

Population pharmacokinetics in veterinary medicine: potential use for therapeutic drug monitoring and prediction of tissue residues. Martin-Jiménez T, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):167-89 (64 ref.)

A unifying review of linear gaussian models. Roweis S, et al. **Neural Comput** 1999 Feb 15;11(2):305-45 (65 ref.)

The Poisson-Nernst-Planck model. **Novartis Found Symp** 1999;225:146-52 (18 ref.)

Ozone dose mapping and the utility of models. Anderson CW, et al. **Novartis Found Symp** 1999;220:80-96; discussion 96-100, 101-4 (11 ref.)

Can we use rate constants and state models to describe ion transport through gramicidin channels? Hladky SB. **Novartis Found Symp** 1999;225:93-107; discussion 107-12 (38 ref.)

Measuring and modelling pollution for risk analysis. Zidek JV, et al. **Novartis Found Symp** 1999;220:105-16; discussion 116-21 (29 ref.)

Quantifying the value of diagnostic tests. Lloyd JJ, et al. **Nucl Med Commun** 1998 Oct;19(10):999-1004 (7 ref.)

Statistical limitations in functional neuroimaging. I. Non-inferential methods and statistical models. Petersson KM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29;354(1387):1239-60 (174 ref.)

Application of mathematical methods in dynamic nuclear medicine studies. Lawson RS. **Phys Med Biol** 1999 Apr; 44(4):R57-98 (120 ref.)

How can statistical mechanics contribute to social science? Durlauf SN. **Proc Natl Acad Sci U S A** 1999 Sep 14; 96(19):10582-4 (11 ref.)

Ecological inference. Schuessler AA. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10578-81 (11 ref.)

Ionization and charge-transfer: basic data for track structure calculations. Toburen LH. **Radiat Environ Biophys** 1998 Dec;37(4):221-33 (59 ref.)

Uses and abuses of the analysis of covariance. Owen SV, et al. **Res Nurs Health** 1998 Dec;21(6):557-62 (19 ref.)

Medical practice variations: changing the theoretical approach. Westert GP, et al. **Scand J Public Health** 1999 Sep;27(3):173-80 (35 ref.)

Generalized linear mixed models for meta-analysis. Platt RW, et al. **Stat Med** 1999 Mar 30;18(6):643-54 (23 ref.)

Prognostic factors: guidelines for investigation design and state of the art analytical methods. Drew PJ, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):71-6 (31 ref.)

MODELS, THEORETICAL

Joint anatomy, design, and arthroses: insights of the Utah paradigm. Frost HM. **Anat Rec** 1999 Jun 1;255(2):162-74 (54 ref.)

Design of appointment systems for preanesthesia evaluation clinics to minimize patient waiting times: a review of computer simulation and patient survey studies. Dexter F. **Anesth Analg** 1999 Oct;89(4):925-31 (30 ref.)

Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Loeffler M, et al. **Ann Oncol** 1998;9 Suppl 5:S73-8 (10 ref.)

Molecular dynamics simulations of biomolecules: long-range electrostatic effects. Sagui C, et al. **Annu Rev Biophys Biomol Struct** 1999;28:155-79 (72 ref.)

Biot theory: a review of its application to ultrasound propagation through cancellous bone. Haire TJ, et al. **Bone** 1999 Apr;24(4):291-5 (53 ref.)

Laser tweezers and optical microsurgery in cellular and molecular biology. Working principles and selected applications. Greulich KO, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):701-10 (25 ref.)

Contagion in stress. An infectious disease model for posttraumatic stress in children. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):183-94, x (50 ref.)

The efficiency concept in pharmacodynamics. Alván G, et al. **Clin Pharmacokinet** 1999 May;36(5):375-89 (58 ref.)

Mathematical models of metabolic pathways. Varner J, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):146-50 (61 ref.)

Tumour biology, chaos and non-linear dynamics. Rew DA. **Eur J Surg Oncol** 1999 Feb;25(1):86-9 (17 ref.)

Homochirality and life. Bonner WA. **EXS** 1998;85:159-88 (89 ref.)

Mathematical analysis of lead field expansions. Taylor JG, et al. **IEEE Trans Med Imaging** 1999 Feb;18(2):151-63 (27 ref.)

A concept analysis of parent-infant attachment. Goulet C, et al. **J Adv Nurs** 1998 Nov;28(5):1071-81 (84 ref.)

Neurons and fractals: how reliable and useful are calculations of fractal dimensions? Jelinek HF, et al. **J Neurosci Methods** 1998 Jun 1;81(1-2):9-18 (62 ref.)

The conceptualization of health. Larson JS. **Med Care Res Rev** 1999 Jun;56(2):123-36 (50 ref.)

Applying a readiness model to increasing organ donation and transplantation. Robbins ML. **Med Health R I** 1998 Sep; 81(9):294-6 (21 ref.)

Deformable models in medical image analysis: a survey. McInerney T, et al. **Med Image Anal** 1996 Jun;1(2):91-108 (129 ref.)

Modeling human eye aberrations and their compensation for high-resolution retinal imaging. Zhu L, et al. **Optom Vis Sci** 1998 Nov;75(11):827-39 (37 ref.)

Procedures for calculating benchmark doses for health risk assessment. Gaylor D, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):150-64 (62 ref.)

Representing contrast detection as an eigenvalue problem. Stewart AL, et al. **Spat Vis** 1999;12(4):397-419 (26 ref.)

Mechanisms for spatial integration in visual detection: a model based on lateral interactions. Usher M, et al. **Spat Vis** 1999;12(2):187-209 (37 ref.)

The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621-44 (63 ref.)

Casuistry and principlism: the convergence of method in biomedical ethics. Kuczewski M. **Theor Med Bioeth** 1998 Dec;19(6):509-24 (40 ref.)

What the philosophy of medicine is. Pellegrino ED.

Theor Med Bioeth 1998 Aug;19(4):315–36 (103 ref.)
Theoretical background of effect mechanism by extracorporeal immunomodulation. Tani T, et al. **Ther Apher** 1997 Aug;1(3):219–23 (15 ref.)
The complexities of DNA computation. Cox JC, et al. **Trends Biotechnol** 1999 Apr;17(4):151–4 (29 ref.)
[Significance of philosophy, bio–mathematics, biometry and model theory for medicine] Gerok W. **Med Klin** 1998 Aug 15;93(8):501–6 (6 ref.) **(Ger)**
[Biotechnological functional systems] Bokser OIa. **Vestn Ross Akad Med Nauk** 1999;(6):29–34 (19 ref.) (Eng. Abstr.) **(Rus)**
[Hypothesis of the compression of morbidity: an example of theoretical development in epidemiology] López–Moreno S, et al. **Salud Publica Mex** 1998 Sep–Oct;40(5):442–9 (38 ref.) (Eng. Abstr.) **(Spa)**

MODELS, WEIGHTLESSNESS see **WEIGHTLESSNESS SIMULATION**

MODEMS see **TELECOMMUNICATIONS**

MODIFICATION METHYLASES see **DNA MODIFICATION METHYLASES**

MODS see **MULTIPLE ORGAN FAILURE**

MODY see **DIABETES MELLITUS, NON–INSULIN–DEPENDENT**

MOERSCH–WOLTMANN SYNDROME see **STIFF–MAN SYNDROME**

MOHAMMEDANISM see **ISLAM**

MOHS SURGERY

Mohs' micrographic surgery for basal cell carcinoma. Lawrence CM. **Clin Exp Dermatol** 1999 Mar;24(2):130–3 (57 ref.)
Linear basal cell carcinoma: report of seventeen cases and review of the presentation and treatment. Lim KK, et al. **Dermatol Surg** 1999 Jan;25(1):63–7 (13 ref.)

MOLAR

The management of endodontically treated teeth using a Computer–Aided Design and Computer–Assisted Manufacturing/Computer–Aided Design and Computer–Integrated Manufacturing system. Foerster JG, et al. **Mil Med** 1999 Jan;164(1):37–40 (21 ref.)

ANATOMY & HISTOLOGY

Mandibular first and second molar. The variability of roots and root canal system. Maggiore C, et al. **Minerva Stomatol** 1998 Sep;47(9):409–16 (43 ref.)

MOLAR PREGNANCY see **HYDATIDIFORM MOLE**

MOLAR, THIRD

Third molars: a dilemma! Or is it? Bishara SE. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):628–33 (30 ref.)
The third molar controversy: framing the controversy as a public health policy issue. Flick WG. **J Oral Maxillofac Surg** 1999 Apr;57(4):438–44; discussion 445 (29 ref.)

SURGERY

Wisdom tooth removal and lingual nerve damage [editorial] McGurk M, et al. **Br J Oral Maxillofac Surg** 1999 Aug; 37(4):253–4 (22 ref.)
Bilateral cervicofacial, axillary, and anterior mediastinal emphysema: a rare complication of third molar extraction. Capes JO, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):996–9 (12 ref.)

MOLECULAR BIOLOGY

Impact of yeast genetics and molecular biology on traditional and new biotechnology. Maráz A. **Acta Microbiol Immunol Hung** 1999;46(2–3):289–95 (15 ref.)
Cracking the auditory genetic code: nonsyndromic hereditary hearing impairment. Lalwani AK, et al. **Am J Otol** 1999 Jan;20(1):115–32 (142 ref.)
Internet biomolecular resources. Cook JL. **Anal Biochem** 1999 Mar 15;268(2):165–72 (18 ref.)
The molecular basis of thyroid hormone–dependent central nervous system remodeling during amphibian metamorphosis. Denver RJ. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):219–28 (101 ref.)
Molecular biology for the critical care physician. Part II: where are we now? Santis G, et al. **Crit Care Med** 1999 May;27(5):997–1003 (53 ref.)
Molecular biology and atrial fibrillation. Brugada R, et al. **Curr Opin Cardiol** 1999 May;14(3):269–73 (29 ref.)
Molecular and genetic approaches to the study of cardiovascular disease. Hallman DM, et al. **J Cardiovasc Risk** 1997 Oct–Dec;4(5–6):325–31 (69 ref.)
Molecular biology and reproduction. McDonough PG. **Keio J Med** 1999 Mar;48(1):12–21 (13 ref.)
Molecular biology of diabetic glomerulosclerosis. Del Prete D, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:20–5 (52 ref.)
Bioinformatics in support of molecular medicine. Altman RB. **Proc AMIA Symp** 1998;:53–61 (37 ref.)
1998 Curt P. Richter Award. Brain mechanisms in cytokine–induced anorexia. Plata–Salamán CR. **Psychoneuroendocrinology** 1999 Jan;24(1):25–41 (55 ref.)
Molecular biology and spinal disorders. A survey for the clinician. Altman DA, et al. **Spine** 1999 Apr 1;24(7):723–30 (14 ref.)
[Why a single molecule?] Ikai A. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):695–8 (4 ref.) **(Jpn)**
[Computer encyclopedia on human molecular and general biology] Aleksandrov AA, et al. **Mol Biol (Mosk)** 1999 Jan–Feb;33(1):80–5 (8 ref.) **(Rus)**
[Combined chemical and biomedicine: a new strategy in the development of antibiotics (editorial)] Vilar M, et al. **Rev Esp Quimioter** 1998 Dec;11(4):287–94 (41 ref.) **(Spa)**

INSTRUMENTATION

Molecular biology for the critical care physician part I: terminology and technology. Santis G, et al. **Crit Care Med** 1999 Apr;27(4):825–31 (5 ref.)

METHODS

Laser tweezers and optical microsurgery in cellular and molecular biology. Working principles and selected applications. Greulich KO, et al. **Cell Mol Biol (Noisy–le–grand)** 1998 Jul;44(5):701–10 (25 ref.)
Laser micromanipulation systems as universal tools in cellular and molecular biology and in medicine. Schütze K, et al. **Cell Mol Biol (Noisy–le–grand)** 1998 Jul;44(5):735–46 (33 ref.)
New time–resolved techniques in two–photon microscopy. So PT, et al. **Cell Mol Biol (Noisy–le–grand)** 1998 Jul; 44(5):771–93 (85 ref.)
Molecular biology for the critical care physician part I: terminology and technology. Santis G, et al. **Crit Care Med** 1999 Apr;27(4):825–31 (5 ref.)
Manipulation of single molecules in biology. Wang MD. **Curr Opin Biotechnol** 1999 Feb;10(1):81–6 (60 ref.)
Genetic and molecular analyses of motoneuron development. Eisen JS. **Curr Opin Neurobiol** 1998 Dec;8(6):697–704 (100 ref.)
Aptamers as tools in molecular biology and immunology. Famulok M, et al. **Curr Top Microbiol Immunol** 1999; 243:123–36 (74 ref.)
Peptide growth factors in amphibian embryogenesis: intersection of modern molecular approaches with traditional inductive interaction paradigms. Asashima M, et al. **Int J Dev Biol** 1999 Jan;43(1):1–10 (107 ref.)
Limitations of molecular biological techniques for assessing the virological safety of foods. Richards GP. **J Food Prot** 1999 Jun;62(6):691–7 (95 ref.)
Thrombopoietin signal transduction: studies from cell lines and primary cells. Drachman JG, et al. **Methods** 1999 Mar; 17(3):238–49 (80 ref.)
Application of molecular methods to the study of diseases prevalent in low income countries [see comments] Wilson SM. **Trans R Soc Trop Med Hyg** 1998 May–Jun;92(3):241–4 (25 ref.) Comment in: Trans R Soc Trop Med Hyg 1998 Nov–Dec;92(6):688.
Genetic optimization of recombinant glycoprotein production by mammalian cells. Fussenegger M, et al. **Trends Biotechnol** 1999 Jan;17(1):35–42 (121 ref.)
[Single molecule imaging of biological functions] Ishijima A, et al. **Tanpakushitsu Kakusan Koso** 1998 Aug; 43(10):1365–71 (12 ref.) **(Jpn)**

TRENDS

Advances in molecular hematopathology: T–cell receptor gamma and bcl–2 genes [see comments] Greiner TC. **Am J Pathol** 1999 Jan;154(1):7–9 (28 ref.) Comment in: Am J Pathol 1999 Jan;154(1):67–75. Comment in: Am J Pathol 1999 Jan;154(1):97–103.
The future role of molecular and cell biology in medical practice in the tropical countries. Weatherall D. **Br Med Bull** 1998;54(2):489–501 (33 ref.)
Ionic hopping defended. Miller C. **J Gen Physiol** 1999 Jun; 113(6):783–7 (23 ref.)
Molecular advances in cardiac and cardiovascular disease. Basile–Borgia A, et al. **Perfusion** 1999 Mar;14(2):89–99 (73 ref.)
Making the case for psychophysiology during the era of molecular biology. Anderson NB, et al. **Psychophysiology** 1999 Jan;36(1):1–13 (99 ref.)
Molecular imaging: exploring the next frontier [editorial] Weissleder R. **Radiology** 1999 Sep;212(3):609–14 (62 ref.)
[The present situation of physiology in cellular–molecular trends] Fu W, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):285–8 (7 ref.) **(Chi)**
[Understanding of molecular biology] Laudenbach V, et al. **Ann Fr Anesth Reanim** 1999 Aug;18(7):725–47 (112 ref.) (Eng. Abstr.) **(Fre)**

MOLECULAR BIOLOGY, COMPUTATIONAL see **COMPUTATIONAL BIOLOGY**

MOLECULAR CHAPERONES

see related
HEAT–SHOCK PROTEINS

[Calnexin is a molecular chaperone recognizing glycoproteins] Ihara Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2450–4 (21 ref.) **(Jpn)**

BIOSYNTHESIS

[Heat shock proteins and heart protection] Malyshev IIu, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):604–11 (37 ref.) **(Rus)**

CHEMISTRY

Calreticulin, a multifunctional Ca2+ binding chaperone of the endoplasmic reticulum. Michalak M, et al. **Biochem Cell Biol** 1998;76(5):779–85 (51 ref.)
Pilus biogenesis via the chaperone/usher pathway: an integration of structure and function. Hung DL, et al. **J Struct Biol** 1998 Dec 15;124(2–3):201–20 (119 ref.)
Chaperone rings in protein folding and degradation. Horwich AL, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28; 96(20):11033–40 (80 ref.)
Alpha–crystallin as a molecular chaperone. Derham BK, et al. **Prog Retin Eye Res** 1999 Jul;18(4):463–509 (306 ref.)
The hexamerization domain of N–ethylmaleimide–sensitive factor: structural clues to chaperone function. Neuwald AF. **Structure Fold Des** 1999 Feb 15;7(2):R19–23 (23 ref.)

METABOLISM

Protein disulfide isomerase assists protein folding as both an isomerase and a chaperone. Wang CC. **Ann N Y Acad Sci** 1998 Dec 13;864:9–13 (27 ref.)
Interferon–gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al. **Biochimie** 1998 Aug–Sep;80(8–9):729–37 (49 ref.)
Receptor–associated protein (RAP): a specialized chaperone for endocytic receptors. Willnow TE. **Biol Chem** 1998 Aug–Sep;379(8–9):1025–31 (54 ref.)
Oxidative stress: Protein folding with a novel redox switch. Ruddock LW, et al. **Curr Biol** 1999 Jun 3;9(11):R400–2 (11 ref.)
Proteolysis and chaperones: the destruction/reconstruction dilemma. Herman C, et al. **Curr Opin Microbiol** 1998 Apr; 1(2):204–9 (61 ref.)
Protein chaperones and the heat shock response in Saccharomyces cerevisiae. Morano KA, et al. **Curr Opin Microbiol** 1998 Apr;1(2):197–203 (44 ref.)
The chaperone/usher pathway: a major terminal branch of the general secretory pathway. Thanassi DG, et al. **Curr Opin Microbiol** 1998 Apr;1(2):223–31 (68 ref.)
The archaeal molecular chaperone machine: peculiarities and paradoxes. Macario AJ, et al. **Genetics** 1999 Aug; 152(4):1277–83 (56 ref.)
Folding of secretory and membrane proteins. Kuznetsov G, et al. **N Engl J Med** 1998 Dec 3;339(23):1688–95 (69 ref.)
Alpha–crystallin as a molecular chaperone. Derham BK, et al. **Prog Retin Eye Res** 1999 Jul;18(4):463–509 (306 ref.)

PHYSIOLOGY

Heat–shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Feder ME, et al. **Annu Rev Physiol** 1999;61:243–82 (373 ref.)
Molecular chaperones and the heat shock response. Sponsored by Cold Spring Harbor Laboratory, 6–10 May 1998. Kaufman RJ. **Biochim Biophys Acta** 1999 Jan 29; 1423(1):R13–27 (27 ref.)
Heat shock proteins chaperoning life and death. Vayssier M, et al. **Cell Stress Chaperones** 1998 Dec;3(4):221–7 (64 ref.)
Molecular chaperones: pathways and networks. Ellis RJ. **Curr Biol** 1999 Feb 25;9(4):R137–9 (12 ref.)
Molecular chaperones: How J domains turn on Hsp70s. Kelley WL. **Curr Biol** 1999 Apr 22;9(8):R305–8 (16 ref.)
Molecular chaperone function of the SV40 large T antigen. Pipas JM. **Dev Biol Stand** 1998;94:313–9 (16 ref.)
Copper chaperones: function, structure and copper–binding properties. Harrison MD, et al. **J Biol Inorg Chem** 1999 Apr;4(2):145–53 (90 ref.)
Pilus biogenesis via the chaperone/usher pathway: an integration of structure and function. Hung DL, et al. **J Struct Biol** 1998 Dec 15;124(2–3):201–20 (119 ref.)
Integration of endoplasmic reticulum signaling in health and disease. Aridor M, et al. **Nat Med** 1999 Jul;5(7):745–51 (80 ref.)
Molecular chaperones in the etiology and therapy of cancer. Soti C, et al. **Pathol Oncol Res** 1998;4(4):316–21 (94 ref.)
Molecular chaperones: biology and prospects for pharmacological intervention. Smith DF, et al. **Pharmacol Rev** 1998 Dec;50(4):493–514 (254 ref.)
The 90–kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Csermely P, et al. **Pharmacol Ther** 1998 Aug;79(2):129–68 (516 ref.)
HLA–DM – an endosomal and lysosomal chaperone for the immune system. Vogt AB, et al. **Trends Biochem Sci** 1999

MOLECULAR CHAPERONES

Apr;24(4):150–4 (48 ref.)
Are molecular chaperones microbial virulence factors? Lewthwaite J, et al. **Trends Microbiol** 1998 Nov; 6(11):426–8 (20 ref.)

MOLECULAR CLONING see **CLONING, MOLECULAR**

MOLECULAR CONFIGURATION see **MOLECULAR CONFORMATION**

MOLECULAR CONFORMATION

Impact of processing on formation of trans fatty acids. King JM, et al. **Adv Exp Med Biol** 1999;459:51–65 (52 ref.)
Stereochemical origin of some clinically significant drug safety concerns: lessons for future drug development [see comments] Shah RR, et al.
Adverse Drug React Toxicol Rev 1998 Jun–Sep; 17(2–3):145–90 (147 ref.) Comment in: Adverse Drug React Toxicol Rev 1998 Jun–Sep;17(2–3):60–2.
Vibrational circular dichroism: an incisive tool for stereochemical applications. Nafie LA, et al. **Enantiomer** 1998;3(4–5):283–97 (27 ref.)
Travelling through conformational space: an approach for analyzing the conformational behaviour of flexible molecules. Koča J. **Prog Biophys Mol Biol** 1998; 70(2):137–73 (112 ref.)
[Solid-state nuclear magnetic resonance] Fujiwara T, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):582–9 (22 ref.) **(Jpn)**

MOLECULAR EPIDEMIOLOGY see **EPIDEMIOLOGY, MOLECULAR**

MOLECULAR EVOLUTION see **EVOLUTION, MOLECULAR**

MOLECULAR EVOLUTION, DIRECTED see **DIRECTED MOLECULAR EVOLUTION**

MOLECULAR GENETICS see **GENETICS, BIOCHEMICAL**

MOLECULAR MIMICRY

Antibody catalysis based on functional mimicry. Avalle B, et al. **Appl Biochem Biotechnol** 1998 Oct;75(1):3–12 (56 ref.)
Removal of oestrogens and oestrogen mimics from the environment. Ridgway TJ, et al. **Biochem Soc Trans** 1998 Nov;26(4):675–80 (31 ref.)
Small molecule cytokine mimetics. Whitty A, et al. **Chem Biol** 1999 Apr;6(4):R107–18 (42 ref.)
Peptidomimetic design. Ripka AS, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):441–52 (65 ref.)
Molecular mimicry and immune-mediated diseases. Oldstone MB. **FASEB J** 1998 Oct;12(13):1255–65 (102 ref.)
Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. Apostolopoulos V, et al. **J Mol Med** 1999 May;77(5):427–36 (57 ref.)
Towards the rational design of molecularly imprinted polymers. Nicholls IA. **J Mol Recognit** 1998 Winter; 11(1–6):79–82 (31 ref.)
Molecular mimicry and multiple sclerosis--a possible role for degenerate T cell recognition in the induction of autoimmune responses. Gran B, et al. **J Neural Transm Suppl** 1999;55:19–31 (43 ref.)
The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. López-Larrea C, et al. **Mol Med Today** 1998 Dec;4(12):540–9 (49 ref.)
Plastic antibodies: developments and applications. Haupt K, et al. **Trends Biotechnol** 1998 Nov;16(11):468–75 (49 ref.)
[Preparation of glyco-replica peptides which mimic functional roles of carbohydrates by using phage-displayed peptide library] Ishikawa D, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2611–7 (30 ref.) **(Jpn)**
[Protein-RNA molecular mimicry] Nakamura Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1421–32 (45 ref.) **(Jpn)**
[TAFII230 regulates transcription by molecular mimicry of the TATA box] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):123–9 (60 ref.) **(Jpn)**

IMMUNOLOGY

Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Gran B, et al. **Ann Neurol** 1999 May;45(5):559–67 (93 ref.)
Molecular mimicry in autoimmune disease. Leech S. **Arch Dis Child** 1998 Nov;79(5):448–51 (28 ref.)
Helicobacter pylori LPS: molecular mimicry with the host and role in autoimmunity. Vandenbroucke-Grauls CM, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S259–60 (15 ref.)
Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Würzner R. **Mol Immunol** 1999 Mar–Apr;36(4–5):249–60 (101 ref.)

MOLECULAR MODELS see **MODELS, MOLECULAR**

MOLECULAR MOTORS

Manipulation of single molecules in biology. Wang MD. **Curr Opin Biotechnol** 1999 Feb;10(1):81–6 (60 ref.)
Biomechanics, one molecule at a time. Mehta AD, et al. **J Biol Chem** 1999 May 21;274(21):14517–20 (60 ref.)
ATP synthase: two motors, two fuels. Oster G, et al. **Structure** 1999 Apr 15;7(4):R67–72 (25 ref.)

CHEMISTRY

Lever arm model of force generation by actin-myosin-ATP. Highsmith S. **Biochemistry** 1999 Aug 3;38(31):9791–7 (58 ref.)
Fluctuation driven transport and models of molecular motors and pumps. Astumian RD, et al. **Eur Biophys J** 1998; 27(5):474–89 (71 ref.)
The role of the dynein stalk in cytoplasmic and flagellar motility. Gee M, et al. **Eur Biophys J** 1998;27(5):466–73 (64 ref.)
Organisation and structure of microtubules and microtubule-motor protein complexes. Wade RH, et al. **Eur Biophys J** 1998;27(5):446–54 (59 ref.)
Single-molecule biomechanics with optical methods. Mehta AD, et al. **Science** 1999 Mar 12;283(5408):1689–95 (81 ref.)
[Mechanisms of action and cellular functions of molecular motors] Chaussepied P, et al. **C R Seances Soc Biol Fil** 1998;192(2):319–34 (64 ref.) (Eng. Abstr.) **(Fre)**
[Protein motors: structure and generation of mechanical force] Zima VL. **Ukr Biokhim Zh** 1998 May-Jun; 70(3):23–38 (60 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Motors driving mRNA localization: new insights from in vivo imaging. Arn EA, et al. **Cell** 1998 Oct 16;95(2):151–4 (18 ref.)
Microtubule-based motor function in mitosis. Heald R, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):268–74 (47 ref.)
Fluctuation driven transport and models of molecular motors and pumps. Astumian RD, et al. **Eur Biophys J** 1998; 27(5):474–89 (71 ref.)
The role of the dynein stalk in cytoplasmic and flagellar motility. Gee M, et al. **Eur Biophys J** 1998;27(5):466–73 (64 ref.)
[Mechanisms of action and cellular functions of molecular motors] Chaussepied P, et al. **C R Seances Soc Biol Fil** 1998;192(2):319–34 (64 ref.) (Eng. Abstr.) **(Fre)**
[Protein motors: structure and generation of mechanical force] Zima VL. **Ukr Biokhim Zh** 1998 May-Jun; 70(3):23–38 (60 ref.) (Eng. Abstr.) **(Rus)**

MOLECULAR NEUROBIOLOGY see **NEUROBIOLOGY**

MOLECULAR PROBE TECHNIQUES

Amplified-fragment length polymorphism analysis: the state of an art. Savelkoul PH, et al. **J Clin Microbiol** 1999 Oct; 37(10):3083–91 (122 ref.)
Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists. Jacobson KA, et al. **Life Sci** 1995;56(11–12):823–30 (29 ref.)
Exploring the new world of the genome with DNA microarrays. Brown PO, et al. **Nat Genet** 1999 Jan;21(1 Suppl):33–7 (27 ref.)
Expression profiling using cDNA microarrays. Duggan DJ, et al. **Nat Genet** 1999 Jan;21(1 Suppl):10–4 (33 ref.)
Chemical genetics: exploring and controlling cellular processes with chemical probes. Crews CM, et al. **Trends Biochem Sci** 1999 Aug;24(8):317–20 (26 ref.)

TRENDS

Molecular imaging: exploring the next frontier [editorial] Weissleder R. **Radiology** 1999 Sep;212(3):609–14 (62 ref.)

MOLECULAR PROBES

Molecular probes in histochemistry and cytochemistry [editorial] Van Noorden CJ. **Acta Histochem** 1998 Nov; 100(4):337 (0 ref.)
Calcium and organelles: a two-sided story. Rutter GA, et al. **Biochem Biophys Res Commun** 1998 Dec 30; 253(3):549–57 (113 ref.)
Molecular rotors as fluorescent probes for biological studies. Viriot ML, et al. **Clin Hemorheol Microcirc** 1998 Oct; 19(2):151–60 (25 ref.)
Clostridial toxins: molecular probes of Rho-dependent signaling and apoptosis. Bobak DA. **Mol Cell Biochem** 1999 Mar;193(1–2):37–42 (28 ref.)
[Development of streptavidin-based neoglycoprotein as a glycoprobe] Hashimoto Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2479–83 (4 ref.) **(Jpn)**

CHEMISTRY

Rational recognition of nucleic acid sequences. Iida H, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):29–33 (38 ref.)

MOLECULAR SEQUENCE DATA

see related
SEQUENCE ALIGNMENT
An introduction to Internet resources for the molecular and genetic analysis of the lipases. Reue K. **Methods Mol Biol** 1999;109:309–28 (16 ref.)

MOLECULAR STEREOCHEMISTRY see **MOLECULAR CONFORMATION**

MOLECULAR STRUCTURE

see related
MODELS, MOLECULAR
The past and future of structure databases. Berman HM. **Curr Opin Biotechnol** 1999 Feb;10(1):76–80 (59 ref.)
The use of chemical shifts and their anisotropies in biomolecular structure determination. Case DA. **Curr Opin Struct Biol** 1998 Oct;8(5):624–30 (80 ref.)
Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. van de Waterbeemd H, et al. **J Drug Target** 1998;6(2):151–65 (58 ref.)

MOLECULAR VACCINES see **VACCINES, SYNTHETIC**

MOLESTATION, SEXUAL, CHILD see **CHILD ABUSE, SEXUAL**

MOLLICUTES

ENZYMOLOGY

Enzyme analysis. The rationale and use of enzyme assays in assigning function to gene nucleotide sequences and the procedures for the assay of three enzymatic functions conserved in mollicutes. Pollack JD. **Methods Mol Biol** 1998;104:79–93 (31 ref.)

GENETICS

Enzyme analysis. The rationale and use of enzyme assays in assigning function to gene nucleotide sequences and the procedures for the assay of three enzymatic functions conserved in mollicutes. Pollack JD. **Methods Mol Biol** 1998;104:79–93 (31 ref.)

IMMUNOLOGY

Transmission electron microscopy and immunogold staining of mollicute surface antigens. Christiansen G, et al. **Methods Mol Biol** 1998;104:309–18 (16 ref.)

PHYSIOLOGY

Mollicutes-wall-less bacteria with internal cytoskeletons. Trachtenberg S. **J Struct Biol** 1998 Dec 15;124(2–3):244–56 (148 ref.)

ULTRASTRUCTURE

Mollicutes-wall-less bacteria with internal cytoskeletons. Trachtenberg S. **J Struct Biol** 1998 Dec 15;124(2–3):244–56 (148 ref.)
Transmission electron microscopy and immunogold staining of mollicute surface antigens. Christiansen G, et al. **Methods Mol Biol** 1998;104:309–18 (16 ref.)

MOLLUSCA

see related
SHELLFISH
Isolation of centrosomes from Spisula solidissima oocytes. Palazzo RE, et al. **Methods Cell Biol** 1999;61:35–56 (17 ref.)

CHEMISTRY

Molluscan neuropeptides. Yasuda-Kamatani Y. **EXS** 1998; 85:37–56 (36 ref.)
Regulation by molluscan myosins. Szent-Györgyi AG, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):55–62 (23 ref.)
Marine polypropionates. Davies-Coleman MT, et al. **Nat Prod Rep** 1998 Oct;15(5):477–93 (149 ref.)

CYTOLOGY

Meiotic maturation in mollusc oocytes [see comments] Colas P, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):539–48 (90 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.

PHYSIOLOGY

Neuromodulation intrinsic to the central pattern generator for escape swimming in Tritonia. Katz PS. **Ann N Y Acad Sci** 1998 Nov 16;860:181–8 (39 ref.)
[Cellular and molecular mechanisms of the stress response in marine bivalves] Gourdon I, et al. **C R Seances Soc Biol Fil** 1998;192(4):749–74 (93 ref.) (Eng. Abstr.) **(Fre)**

MOLLUSCUM CONTAGIOSUM

[Molluscum contagiosum] Egawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):262–4 (15 ref.) **(Jpn)**
[Molluscum contagiosum (genital)] Honda M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):74–6 (5 ref.) **(Jpn)**

MOLLUSK VENOMS

CHEMISTRY

Post-translationally modified neuropeptides from Conus venoms. Craig AG, et al. **Eur J Biochem** 1999 Sep; 264(2):271-5 (46 ref.)
Toxins selective for subunit interfaces as probes of nicotinic acetylcholine receptor structure. Taylor P, et al. **J Physiol Paris** 1998 Apr;92(2):79-83 (21 ref.)
[Chemistry of conotoxins from cone snails] Sato K. **Seikagaku** 1999 Mar;71(3):183-92 (56 ref.) **(Jpn)**

GENETICS

Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Olivera BM, et al. **Ann N Y Acad Sci** 1999 May 18;870:223-37 (37 ref.)

THERAPEUTIC USE

Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Bowersox SS, et al. **Toxicon** 1998 Nov;36(11):1651-8 (32 ref.)

MOLSIDOMINE

THERAPEUTIC USE

[Molsidomine: importance in treatment of circulation disorders] Kmieć M, et al. **Przegl Lek** 1998;55(10):532-6 (47 ref.) (Eng. Abstr.) **(Pol)**

MOLTING

see related
ECDYSTERONE

PHYSIOLOGY

Calcium homeostasis in crustacea: the evolving role of branchial, renal, digestive and hypodermal epithelia. Wheatly MG. **J Exp Zool** 1999 Jun 1;283(7):620-40 (134 ref.)
Health and husbandry considerations of induced molting. Ruszler PL. **Poult Sci** 1998 Dec;77(12):1789-93 (32 ref.)

MOLYBDENUM

Mechanistic aspects of molybdenum-containing enzymes. Hille R, et al. **FEMS Microbiol Rev** 1998 Dec;22(5):489-501 (40 ref.)
A structural comparison of molybdenum cofactor-containing enzymes. Kisker C, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):503-21 (73 ref.)
Considerations for determining 'optimal nutrition' for copper, zinc, manganese and molybdenum. Failla ML. **Proc Nutr Soc** 1999 May;58(2):497-505 (74 ref.)

ADVERSE EFFECTS

Assessment of molybdenum toxicity in humans. Vyskocil A, et al. **J Appl Toxicol** 1999 May-Jun;19(3):185-92 (67 ref.)

PHYSIOLOGY

The role of copper, molybdenum, selenium, and zinc in nutrition and health. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):673-85 (54 ref.)

TOXICITY

Molybdenum. Barceloux DG. **J Toxicol Clin Toxicol** 1999; 37(2):231-7 (35 ref.)

MONGOLISM see **DOWN SYNDROME**

MONGOLOID RACE

Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S-759S (37 ref.)
The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S-754S (78 ref.)
Diabetes mellitus among ethnic seniors: contrasts with diabetes in whites. Kamel HK, et al. **Clin Geriatr Med** 1999 May;15(2):265-78 (127 ref.)
Paget's disease of the tibia. Wang CL, et al. **J Formos Med Assoc** 1999 Jun;98(6):444-7 (17 ref.)
Classical galactosaemia in Chinese: A case report and review of disease incidence [see comments] Cheung KL, et al. **J Paediatr Child Health** 1999 Aug;35(4):399-400 (14 ref.) Comment in: J Paediatr Child Health 1999 Aug;35(4):339-40.

GENETICS

Oculocutaneous albinism and analysis of tyrosinase gene in Japanese patients. Tomita Y, et al. **Nagoya J Med Sci** 1998 Oct;61(3-4):97-102 (18 ref.)

MONILIA see **CANDIDA**

MONILIASIS see **CANDIDIASIS**

MONILIASIS, CUTANEOUS see **CANDIDIASIS, CUTANEOUS**

MONILIASIS, ORAL see **CANDIDIASIS, ORAL**

MONILIASIS, VULVOVAGINAL see **CANDIDIASIS, VULVOVAGINAL**

MONITORING, AMBULATORY

Ambulatory EEG monitoring. Gilliam F, et al. **J Clin Neurophysiol** 1999 Mar;16(2):111-5 (29 ref.)
Monitoring women at risk for preterm labor. Chern-Hughes B. **J Nurse Midwifery** 1998 Sep-Oct;43(5):393-4 (0 ref.)

INSTRUMENTATION

The role of ambulatory EEG in the evaluation of patients for epilepsy surgery. Schomer DL, et al. **J Clin Neurophysiol** 1999 Mar;16(2):116-29 (46 ref.)

MONITORING, AMBULATORY BLOOD PRESSURE see **BLOOD PRESSURE MONITORING, AMBULATORY**

MONITORING, AMBULATORY ELECTROCARDIOGRAPHIC see **ELECTROCARDIOGRAPHY, AMBULATORY**

MONITORING, DRUG see **DRUG MONITORING**

MONITORING, ENVIRONMENTAL see **ENVIRONMENTAL MONITORING**

MONITORING, FETAL see **FETAL MONITORING**

MONITORING, HOLTER see **ELECTROCARDIOGRAPHY, AMBULATORY**

MONITORING, HOME BLOOD GLUCOSE see **BLOOD GLUCOSE SELF-MONITORING**

MONITORING, IMMUNE see **MONITORING, IMMUNOLOGIC**

MONITORING, IMMUNOLOGIC

Urinary markers of disease activity in multiple sclerosis. Giovannoni G, et al. **Mult Scler** 1998 Jun;4(3):247-53 (32 ref.)
[Immunologic safety of vaccines] Medunitsyn NV. **Patol Fiziol Eksp Ter** 1999 Jan-Mar;(1):20-2 (28 ref.) **(Rus)**

MONITORING, INTRAOPERATIVE

Intraoperative motor evoked potentials monitoring in spinal neurosurgery. Cioni B, et al. **Arch Ital Biol** 1999 May; 137(2-3):115-26 (36 ref.)
MR contribution in surgery of epilepsy. Meiners LC, et al. **Eur Radiol** 1999;9(3):493-507 (57 ref.)
Surgical monitoring of motor pathways [see comments] Burke D, et al. **J Clin Neurophysiol** 1998 May;15(3):194-205 (75 ref.) Comment in: J Clin Neurophysiol 1998 May;15(3):181-2.
Facial nerve electromyography and other cranial nerve monitoring [see comments] Harper CM, et al. **J Clin Neurophysiol** 1998 May;15(3):206-16 (18 ref.) Comment in: J Clin Neurophysiol 1998 May;15(3):181-2.
Generators of short latency human somatosensory-evoked potentials recorded over the spine and scalp. Lee EK, et al. **J Clin Neurophysiol** 1998 May;15(3):227-34 (65 ref.)
Spinal cord monitoring with somatosensory techniques. Nuwer MR. **J Clin Neurophysiol** 1998 May;15(3):183-93 (118 ref.)
Anesthetic effects on electrophysiologic recordings. Sloan TB. **J Clin Neurophysiol** 1998 May;15(3):217-26 (36 ref.)
Intra-operative monitoring in acoustic neuroma surgery. Kartush JM. **Neurol Res** 1998 Oct;20(7):593-6 (22 ref.)
Spinal cord monitoring: current state of the art. Padberg AM, et al. **Orthop Clin North Am** 1999 Jul;30(3):407-33, viii (71 ref.)
Monitoring of oxygen delivery in cardiac and vascular surgery. Spahn DR. **Vox Sang** 1998;74 Suppl 2:395-7 (17 ref.)
[Neuromuscular monitoring. Standard procedures] Fuchs-Buder T. **Anaesthesist** 1998 Aug;47(8):629-37 (65 ref.) (Eng. Abstr.) **(Ger)**
[The role of intraoperative echocardiography in surgery of the heart and large vessels] Kyo S, et al. **Masui** 1998 Dec; 47 Suppl:S155-9 (19 ref.) **(Jpn)**

METHODS

Transcranial Doppler: preventing stroke during carotid endarterectomy. Gaunt ME. **Ann R Coll Surg Engl** 1998 Nov;80(6):377-87 (43 ref.)
Evoked responses in anaesthesia. Thornton C, et al. **Br J Anaesth** 1998 Nov;81(5):771-81 (90 ref.)
Monitoring normovolaemic haemodilution. Trouwborst A, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:73-8 (70 ref.)
The role of intraoperative echocardiography in valve surgery. Grimm RA, et al. **Cardiol Clin** 1998 Aug; 16(3):477-89, ix (70 ref.)
One thousand and six consecutive laparoscopic intraoperative cholangiograms. Corbitt JD Jr, et al. **J Soc Laparoendosc Surg** 1997 Jan-Mar;1(1):13-6 (11 ref.)
Technical developments in intra-operative monitoring for the preservation of cranial motor nerves and hearing in skull base surgery. Schlake HP, et al. **Neurol Res** 1999 Jan; 21(1):11-24 (90 ref.)
Intraoperative transesophageal echocardiography in congenital heart disease. Bengur AR, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):255-64 (41 ref.)
Intraoperative echocardiography: interpretation of changes in left ventricular wall thickness. Spotnitz HM, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):273-83 (42 ref.)
Intraoperative electromyography during thoracolumbar spinal surgery. Holland NR. **Spine** 1998 Sep 1; 23(17):1915-22 (35 ref.)
Near-infrared spectrophotometry of the brain in cardiovascular surgery. Nollert G, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):167-75 (98 ref.)
[Delivery methods for infants weighing less than 2500 grams. Labor surveillance in cases of vaginal delivery] Carbonne B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:307-10 (14 ref.) **(Fre)**
[Neuromonitoring and anesthesia in surgery of the spine] Laureau E, et al. **Neurophysiol Clin** 1998 Sep;28(4):299-320 (106 ref.) (Eng. Abstr.) **(Fre)**
[Monitoring the neurogenic mixed evoked potentials during surgery of the spine: a good solution?] Péréon Y, et al. **Neurophysiol Clin** 1998 Sep;28(4):321-34 (64 ref.) (Eng. Abstr.) **(Fre)**
[Monitoring the anesthetic depth--with special reference to bispectral index] Ozaki S. **Masui** 1998 Dec;47 Suppl:S133-8 (20 ref.) **(Jpn)**
[Dosage of anesthetics--a tricky question] Enlund M, et al. **Lakartidningen** 1998 Nov 25;95(48):5477-8, 5481-2 (41 ref.) (Eng. Abstr.) **(Swe)**

NURSING

Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator. Rowlee SC. **Heart Lung** 1999 Sep-Oct;28(5):352-62; quiz 363-4 (34 ref.)

STANDARDS

What intraoperative monitoring makes sense? Brodsky JB. **Chest** 1999 May;115(5 Suppl):101S-105S (20 ref.)

TRENDS

Why and how we will monitor the state of anesthesia in 2010? Glass PS. **Acta Anaesthesiol Belg** 1999;50(1):35-44 (68 ref.)

MONITORING, OUTPATIENT see **MONITORING, AMBULATORY**

MONITORING, PHYSIOLOGIC

see related
SIGNAL PROCESSING, COMPUTER-ASSISTED

Hemodynamic monitoring during hemodialysis. Leypoldt JK, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):233-42 (68 ref.)
Postoperative care and monitoring. Naunheim KS. **Chest Surg Clin N Am** 1999 Aug;9(3):501-13 (35 ref.)
Outcomes analysis: intracranial pressure monitoring. Wilberger JE Jr. **Clin Neurosurg** 1997;44:439-48 (26 ref.)
Physiologic and biochemical monitoring during hyperbaric oxygenation: a review. Rogatsky GG, et al. **Undersea Hyperb Med** 1999 Summer;26(2):111-22 (193 ref.)
Circulatory effects of whole blood, packed red cells, albumin, starch, and crystalloids in resuscitation of shock and acute critical illness. Shoemaker WC, et al. **Vox Sang** 1998;74 Suppl 2:69-74 (17 ref.)
[Indications for monitoring intracranial pressure] Melon E. **Ann Fr Anesth Reanim** 1997;16(4):415-9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Volumetric hemodynamic monitoring] Pittoni G, et al. **Minerva Anestesiol** 1999 Jun;65(6):357-61 (20 ref.) **(Ita)**
[Cardiorespiratory monitoring in hospital and at home] Carnelli V, et al. **Pediatr Med Chir** 1998 Nov-Dec; 20(6):361-5 (10 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Monitoring in traumatic brain injury. Matz PG, et al. **Clin Neurosurg** 1997;44:267-94 (63 ref.)
Computerized physiologic monitoring. Booth FV. **Crit Care Clin** 1999 Jul;15(3):547-62, vi (40 ref.)
Instrumentation for the remote monitoring of physiological and behavioral variables. Andrews RD. **J Appl Physiol** 1998 Nov;85(5):1974-81 (12 ref.)
Performance of subcutaneously implanted glucose sensors: a review. Gerritsen M, et al. **J Invest Surg** 1998 May-Jun; 11(3):163-74 (83 ref.)
Use of heart rate monitors by endurance athletes: lessons from triathletes. O'Toole ML, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):181-7 (21 ref.)
Home telecare. Ruggiero C, et al. **J Telemed Telecare** 1999; 5(1):11-7 (17 ref.)

MONITORING, PHYSIOLOGIC

Human perspiration measurement. Ohhashi T, et al. **Physiol Meas** 1998 Nov;19(4):449–61 (29 ref.)
[Criteria of Rigiscan normalcy in aged men] Zimmern P, et al. **Prog Urol** 1999 Feb;9(1):37–44 (32 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Monitoring vascular access flow. Lindsay RM, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):273–7 (27 ref.)
Urea sensors—a world of possibilities. Sternby J. **Adv Ren Replace Ther** 1999 Jul;6(3):265–72 (26 ref.)
Scientific basis of a matrix metalloproteinase–8 specific chair–side test for monitoring periodontal and peri–implant health and disease. Sorsa T, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:130–40 (28 ref.)
Implantable cardioverter–defibrillator follow–up: what everyone needs to know. Wilbur SL, et al. **Cardiol Rev** 1999 Jul–Aug;7(4):176–90 (32 ref.)
Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Bidart JM, et al. **Clin Chem** 1999 Oct;45(10):1695–707 (164 ref.)
Monitoring patient mechanics during mechanical ventilation. Jubran A. **Crit Care Clin** 1998 Oct;14(4):629–53, vi (112 ref.)
Why, when, and how to insert a hepatic vein catheter in critically ill patients [editorial; comment] De Backer D, et al. **Crit Care Med** 1999 Aug;27(8):1680–1 (16 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1598–16–2.
Measurement inside the box [editorial; comment] Gibbons KJ. **Crit Care Med** 1999 May;27(5):869–70 (11 ref.) Comment on: Crit Care Med 1999 May;27(5):978–84.
In search of the Holy Grail: noninvasive or "low–invasive" cardiac output monitoring [editorial; comment] Soble JS. **Crit Care Med** 1998 Dec;26(12):1953–4 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2066–72.
Cardiac output minute to minute with a standard pulmonary artery catheter, without fluid overload? [editorial; comment] Tremper KK. **Crit Care Med** 1999 Aug; 27(8):1665–6 (16 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1505–10.
Monitoring the injured brain in intensive care: present and future. Gupta AK, et al. **Hosp Med** 1998 Sep;59(9):704–13 (27 ref.)
Temperature charts: a time for change? Zeal JD. **Hosp Med** 1998 Oct;59(10):766–8 (13 ref.)
Pad testing in incontinent women: a review. Ryhammer AM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(2):111–5 (38 ref.)
Suppression of gastric acid secretion: preventing excess gas [editorial; comment] Heard SO. **Intensive Care Med** 1998 Nov;24(11):1123–5 (26 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1139–43.
Performance of subcutaneously implanted glucose sensors: a review. Gerritsen M, et al. **J Invest Surg** 1998 May–Jun; 11(3):163–74 (83 ref.)
Intracranial pressure monitoring by time domain analysis. Penson RP, et al. **J R Soc Health** 1998 Oct;118(5):289–94 (09 ref.)
Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT–PCR. Tobal K, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):115–20 (39 ref.)
Detection of cerebral microemboli in APS—introducing a novel investigation method and implications of analogies with carotid artery disease. Specker C, et al. **Lupus** 1998; 7 Suppl 2:S75–80 (41 ref.)
Monitoring respiratory muscles. Nava S. **Monaldi Arch Chest Dis** 1998 Dec;53(6):640–3 (26 ref.)
Body fluid markers to monitor multiple sclerosis: the assays and the challenges. Laman JD, et al. **Mult Scler** 1998 Jun; 4(3):266–9 (21 ref.)
On–line monitoring and convective treatment modalities: short–term advantages. Locatelli F, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:92–7 (20 ref.)
More expanded scope: operational EMS [editorial; comment] Bogucki MS. **Prehosp Emerg Care** 1998 Oct–Dec; 2(4):330–3 (23 ref.) Comment on: Prehosp Emerg Care 1998 Oct–Dec;2(4):280–4.
Multiple sclerosis: use of MRI in evaluating new therapies. Miller DH. **Semin Neurol** 1998;18(3):317–25 (100 ref.)
Clinical aspects of immunologic monitoring. Chatenoud L, et al. **Transplant Proc** 1999 Jun;31(4):1812–3 (8 ref.)
[What are the indications and modalities of different monitoring techniques?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):85–105 (48 ref.) **(Fre)**
[Modalities and diagnostic criteria in esophageal ph monitoring] Bruley des Varannes S, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S21–30 (75 ref.) **(Fre)**
[What kind of monitoring of intracranial pressure] Citerio G, et al. **Minerva Anestesiol** 1999 May;65(5):318–21 (24 ref.) (Eng. Abstr.) **(Ita)**
[Monitoring exocytosis using patch–clamp capacitance measurement] Maruyama Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1770–6 (15 ref.) **(Jpn)**

TRENDS

The emerging needs of persons living with haemophilia and HIV/AIDS in British Columbia. Taylor G. **Haemophilia** 1999 Jan;5(1):1–8 (16 ref.)

MONITORING, RADIOIMMUNOLOGIC see **MONITORING, IMMUNOLOGIC**

MONITORING, SLEEP see **POLYSOMNOGRAPHY**

MONITORS, BLOOD PRESSURE see **BLOOD PRESSURE MONITORS**

MONKEY DISEASES

Diet, plasma lipoproteins and experimental atherosclerosis in baboons (Papio sp.). Kushwaha RS, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):420–9 (78 ref.)

ETIOLOGY

Nonhuman primate models of atherosclerosis. Clarkson TB. **Lab Anim Sci** 1998 Dec;48(6):569–72 (21 ref.)

PATHOLOGY

Review of exertional rhabdomyolysis and a case in a rhesus monkey (Macaca mulatta). Reuter JD, et al. **J Med Primatol** 1998 Dec;27(6):303–9 (29 ref.)

MONKEY HEMORRHAGIC DISEASE VIRUS see **ARTERIVIRUS**

MONKEY, PIG–TAILED see **MACACA NEMESTRINA**

MONKEY, RHESUS see **MACACA MULATTA**

MONKEY, SPIDER see **CEBIDAE**

MONKEY, SQUIRREL see **SAIMIRI**

MONKEY, TALAPOIN see **CERCOPITHECIDAE**

MONKEY, WOOLLY see **CEBIDAE**

MONKEYPOX VIRUS

Re–emergence of monkeypox in Africa: a review of the past six years. Heymann DL, et al. **Br Med Bull** 1998; 54(3):693–702 (9 ref.)

MONKEYS see **HAPLORHINI**

MONKEYS, NEW WORLD see **CEBIDAE**

MONKEYS, OLD WORLD see **CERCOPITHECIDAE**

MONOACYLGLYCEROL LIPASES

ANALYSIS

Assay of cellular diacylglycerol and monoacylglycerol lipases. Wolf BA. **Methods Mol Biol** 1998;105:167–74 (7 ref.)

MONOACYLGLYCEROLS see **GLYCERIDES**

MONO–ADP–RIBOSYLTRANSFERASE see **NADPH(+)–ARGININE ADP–RIBOSYLTRANSFERASE**

MONOAMINE OXIDASE

CHEMISTRY

Imidazoline binding domains on MAO–B. Localization and accessibility. Raddatz R, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:26–31 (17 ref.)

DEFICIENCY

[New neurometabolic disorders: indicative clinical signs] García–Silva MT. **Rev Neurol** 1999 Jan 1–15;28(1):4–11 (33 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Monoamine oxidase in neuropsychiatry and behavior. Shih JC, et al. **Am J Hum Genet** 1999 Sep;65(3):593–8 (56 ref.)
Monoamine oxidase: from genes to behavior. Shih JC, et al. **Annu Rev Neurosci** 1999;22:197–217 (120 ref.)

METABOLISM

Monoamine oxidase in neuropsychiatry and behavior. Shih JC, et al. **Am J Hum Genet** 1999 Sep;65(3):593–8 (56 ref.)
Imidazoline binding domains on MAO–B. Localization and accessibility. Raddatz R, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:26–31 (17 ref.)
Benzylamine analog binding studies as probes of the substrate sites of monoamine oxidases A and B. Edmondson DE. **Drug Metab Rev** 1999 Feb;31(1):235–45 (21 ref.)
[New neurometabolic disorders: indicative clinical signs] García–Silva MT. **Rev Neurol** 1999 Jan 1–15;28(1):4–11 (33 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. Usuki E, et al. **Drug Metab Rev** 1998 Nov;30(4):809–26 (106 ref.)

PHYSIOLOGY

Monoamine oxidase: from genes to behavior. Shih JC, et al. **Annu Rev Neurosci** 1999;22:197–217 (120 ref.)
Role of MAO A and B in neurotransmitter metabolism and behavior. Shih JC, et al. **Pol J Pharmacol** 1999 Jan–Feb; 51(1):25–9 (42 ref.)

MONOAMINE OXIDASE INHIBITORS

see related
ANTIDEPRESSIVE AGENTS

[A new generation of antidepressive agents -- monoamine oxidase inhibitors] Dubnitskaia EB. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(10):63–8 (104 ref.) **(Rus)**

ADVERSE EFFECTS

Monoamine oxidase inhibitors. A perspective on their use in the elderly. Volz HP, et al. **Drugs Aging** 1998 Nov; 13(5):341–55 (74 ref.)
Antidepressant–induced sexual dysfunction: review, classification, and suggestions for treatment. Ellison JM. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):177–89 (118 ref.)

PHARMACOKINETICS

Metabolism of monoamine oxidase inhibitors. Baker GB, et al. **Cell Mol Neurobiol** 1999 Jun;19(3):411–26 (63 ref.)

PHARMACOLOGY

Preclinical profile of befloxatone, a new reversible MAO–A inhibitor. Curet O, et al. **J Affect Disord** 1998 Dec; 51(3):287–303 (81 ref.)

THERAPEUTIC USE

Moclobemide in patients with dementia and depression. Amrein R, et al. **Adv Neurol** 1999;80:509–19 (71 ref.)
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives. Cesura AM, et al. **Adv Neurol** 1999;80:521–8 (42 ref.)
Pharmacotherapy for obsessive–compulsive disorder. Greist JH, et al. **Br J Psychiatry Suppl** 1998;(35):64–70 (92 ref.)
Treatment of geriatric depression. Small GW. **Depress Anxiety** 1998;8 Suppl 1:32–42 (102 ref.)
Recent developments in the drug treatment of Alzheimer's disease. Sramek JJ, et al. **Drugs Aging** 1999 May; 14(5):359–73 (150 ref.)
Pharmacotherapy of social anxiety disorder. Davidson JR. **J Clin Psychiatry** 1998;59 Suppl 17:47–53 (27 ref.)
Managing aggressive behavior in patients with obsessive–compulsive disorder and borderline personality disorder. Hollander E. **J Clin Psychiatry** 1999;60 Suppl 15:38–44 (36 ref.)
Antidepressants and posttraumatic stress disorder. Meek JK, et al. **J La State Med Soc** 1998 Oct;150(10):487–9 (16 ref.)
Monoamine oxidase and catechol–O–methyltransferase inhibitors. Siderowf A, et al. **Med Clin North Am** 1999 Mar;83(2):445–67 (131 ref.)

MONOAMINES, BIOGENIC see **BIOGENIC MONOAMINES**

MONOBACTAMS

Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Hellinger WC, et al. **Mayo Clin Proc** 1999 Apr; 74(4):420–34 (218 ref.)

THERAPEUTIC USE

Monobactams and carbapenems for treatment of intraabdominal infections. Brismar B, et al. **Infection** 1999 Mar–Apr;27(2):136–47 (25 ref.)

MONOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

MONOCLONAL ANTIBODIES see **ANTIBODIES, MONOCLONAL**

MONOCLONAL ANTIBODY OKT3 see **MUROMONAB–CD3**

MONOCLONAL GAMMOPATHIES see **PARAPROTEINEMIAS**

MONOCLONAL GAMMOPATHIES, BENIGN

[Essential hypergammaglobulinemia] Ito M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):527–30 (13 ref.) **(Jpn)**
[Monoclonal gammopathy of undetermined significance (MGUS)] Nakamura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):468–71 (11 ref.) **(Jpn)**

COMPLICATIONS

IgA antiglomerular basement membrane disease associated with bronchial carcinoma and monoclonal gammopathy. Maes B, et al. **Am J Kidney Dis** 1999 Feb;33(2):E3 (24

ref.)

PATHOLOGY

Angiomatosis of skin with local intravascular immunoglobulin deposits, associated with monoclonal gammopathy. A potential cutaneous marker for B-chronic lymphocytic leukemia. A report of unusual case with immunohistochemical and immunofluorescence correlation and review of the literature. Salama SS, et al. **J Cutan Pathol** 1999 Apr;26(4):206-12 (32 ref.)

MONOCROTALINE

ANALOGS & DERIVATIVES

Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system. Schultze AE, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct-Dec; 1(4):271-346 (381 ref.)

TOXICITY

Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system. Schultze AE, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct-Dec; 1(4):271-346 (381 ref.)

MONOCULAR VISION see **VISION, MONOCULAR**

MONOCYCLIC BETA-LACTAMS see **MONOBACTAMS**

MONOCYTE CHEMOATTRACTANT PROTEIN-1

BIOSYNTHESIS

The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Graves DT, et al. **Front Biosci** 1999 Jul 1;4:D571-80 (70 ref.)

METABOLISM

The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Graves DT. **Clin Infect Dis** 1999 Mar;28(3):482-90 (82 ref.)

PHYSIOLOGY

Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Mukaida N, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):9-23 (148 ref.)

MONOCYTE CHEMOTACTIC PROTEIN-1 see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

MONOCYTES

[Monocytosis] Motoyoshi K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):143-5 (8 ref.) **(Jpn)**

[Monocytic leukemoid reaction] Motoyoshi K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):146-8 (8 ref.) **(Jpn)**

[Morphofunctional characteristics of monocytes. Significance of nucleolar system studies (Review of literature)] Frolova OE. **Klin Lab Diagn** 1998 Oct;(10):3-8 (32 ref.) **(Rus)**

CYTOLOGY

Apoptosis in monocytes. Grage-Griebenow E, et al. **Eur Cytokine Netw** 1998 Dec;9(4):699-700 (17 ref.)

Myb-transformed hematopoietic cells as a model for monocyte differentiation into dendritic cells and macrophages. Banyer JL, et al. **J Leukoc Biol** 1999 Aug; 66(2):217-23 (82 ref.)

The role of cytokines in monocyte apoptosis. Flad HD, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):733-6 (11 ref.)

DRUG EFFECTS

The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Kjalke M, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S21-5 (14 ref.)

ENZYMOLOGY

Synthesis of cholesterol esterase by monocyte-derived macrophages: a potential role in the biodegradation of poly(urethane)s. Labow RS, et al. **J Biomater Appl** 1999 Jan;13(3):187-205 (75 ref.)

IMMUNOLOGY

Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Watanabe T, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S45-53; discussion S55 (57 ref.)

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. Andreesen R, et al. **J Leukoc Biol** 1998 Oct;64(4):419-26 (82 ref.)

Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. Dickensheets HL, et al. **J Leukoc Biol** 1999 Mar;65(3):307-12 (45 ref.)

Monocyte CD14: a multifunctional receptor engaged in apoptosis from both sides. Heidenreich S. **J Leukoc Biol** 1999 Jun;65(6):737-43 (66 ref.)

The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms. Williams MA, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):1-23 (123 ref.)

The potential for monocyte-mediated immunotherapy during infection and malignancy--Part II: in vivo activation by exogenous cytokines and clinical applications. Williams MA, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):207-30 (123 ref.)

In vitro and in vivo effects of n-3 polyunsaturated fatty acids on human monocyte function. Hughes DA. **Proc Nutr Soc** 1998 Nov;57(4):521-5 (49 ref.)

The role of cytokines in monocyte apoptosis. Flad HD, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):733-6 (11 ref.)

Human monocytes and cytokines. van Furth R. **Res Immunol** 1998 Sep-Oct;149(7-8):719-20 (3 ref.)

METABOLISM

Tissue factor expression by monocytes: regulation and pathophysiological roles. Osterud B. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S9-14 (36 ref.)

The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. Chisolm GM 3rd, et al. **J Biol Chem** 1999 Sep 10;274(37):25959-62 (119 ref.)

PATHOLOGY

Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes. Ferrario F, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1627-31 (37 ref.)

PHYSIOLOGY

Monocytes/macrophages in atherosclerosis. Plenz G, et al. **Eur Cytokine Netw** 1998 Dec;9(4):701-3 (6 ref.)

Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators. Lügering N, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):338-44 (62 ref.)

The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. Donnelly RP, et al. **J Interferon Cytokine Res** 1999 Jun; 19(6):563-73 (82 ref.)

Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Weinberg JB. **Mol Med** 1998 Sep;4(9):557-91 (154 ref.)

[The role of the blood monocytes in atherogenesis] Kondakov IK. **Tsitol Genet** 1999 Jan-Feb;33(1):70-80 (79 ref.) (Eng. Abstr.) **(Rus)**

MONOCYTES, ACTIVATED KILLER

see related
IMMUNOTHERAPY, ADOPTIVE

MONOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

MONODELPHIS see **OPOSSUMS**

MONODON see **WHALES**

MONODONTIDAE see **WHALES**

MONOGLYCERIDE ESTERASES see **MONOACYLGLYCEROL LIPASES**

MONOGLYCERIDE LIPASES see **MONOACYLGLYCEROL LIPASES**

MONOKINES

DRUG EFFECTS

Effects of muramyl peptides on macrophages, monokines, and sleep. Pabst MJ, et al. **Neuroimmunomodulation** 1999 Jul-Aug;6(4):261-83 (177 ref.)

L-MONOMETHYLARGININE see **OMEGA-N-METHYLARGININE**

MONONUCLEAR LEUKOCYTES see **LEUKOCYTES, MONONUCLEAR**

MONOPHENOL MONOOXYGENASE

see related
ALBINISM

GENETICS

Oculocutaneous albinism and analysis of tyrosinase gene in Japanese patients. Tomita Y, et al. **Nagoya J Med Sci** 1998 Oct;61(3-4):97-102 (18 ref.)

IMMUNOLOGY

The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Merimsky O, et al. **Clin Rev Allergy Immunol** 1998 Fall;16(3):227-36 (30 ref.)

MONOPHOSPHATIDYLGLYCEROLS see **PHOSPHATIDYLGLYCEROLS**

MONOSACCHARIDE TRANSPORT PROTEINS

[Nucleotide-sugar transporters: cDNA cloning, structures and expression] Ishida N, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2325-34 (32 ref.) **(Jpn)**

BIOSYNTHESIS

Searching for ways to upregulate GLUT4 glucose transporter expression in muscle. Zorzano A, et al. **Gen Pharmacol** 1998 Nov;31(5):705-13 (119 ref.)

Glucose transporter expression in developing fetal lungs and lung neoplasms. Ito T, et al. **Histol Histopathol** 1999 Jul; 14(3):895-904 (67 ref.)

CHEMISTRY

Structure and function of the Na+/glucose cotransporter. Wright EM, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:257-64 (25 ref.)

DRUG EFFECTS

Central role of the adipocyte in insulin resistance. Bergman RN, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2-4):205-21 (38 ref.)

GENETICS

The influence of mRNA stability on glucose transporter (GLUT1) gene expression. Qi C, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):265-9 (75 ref.)

How do yeast cells sense glucose? Kruckeberg AL, et al. **Bioessays** 1998 Dec;20(12):972-6 (36 ref.)

GLUT4 gene regulation and manipulation. Charron MJ, et al. **J Biol Chem** 1999 Feb 5;274(6):3253-6 (37 ref.)

Metabolic and therapeutic lessons from genetic manipulation of GLUT4. Charron MJ, et al. **Mol Cell Biochem** 1998 May;182(1-2):143-52 (73 ref.)

[Hexose transporters in humans: their role in insulin sensitivity of peripheral tissues] Bastard JP, et al. **Rev Med Interne** 1998 Feb;19(2):108-18 (67 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Structure and function of the Na+/glucose cotransporter. Wright EM, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:257-64 (25 ref.)

Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Cushman SW, et al. **Adv Exp Med Biol** 1998;441:63-71 (74 ref.)

Role of transverse tubules (T-tubules) in muscle glucose transport. Dohm GL, et al. **Adv Exp Med Biol** 1998; 441:27-34 (17 ref.)

Snareing GLUT4 at the plasma membrane in muscle and fat. Hashiramoto M, et al. **Adv Exp Med Biol** 1998; 441:47-61 (121 ref.)

GLUT5 expression and fructose transport in human skeletal muscle. Hundal HS, et al. **Adv Exp Med Biol** 1998; 441:35-45 (37 ref.)

Anatomy of glucose transporters in skeletal muscle. Effects of insulin and contractions. Ploug T, et al. **Adv Exp Med Biol** 1998;441:17-26 (41 ref.)

Journey beyond immunology. Regulation of receptor internalization by major histocompatibility complex class I (MHC-I) and effect of peptides derived from MHC-I. Stagsted J. **APMIS Suppl** 1998;85:1-40 (553 ref.)

GLUT4 trafficking in insulin-sensitive cells. A morphological review. Martin S, et al. **Cell Biochem Biophys** 1999;30(1):89-113 (126 ref.)

Insulin-independent glucose transport regulates insulin sensitivity. Ebeling P, et al. **FEBS Lett** 1998 Oct 9; 436(3):301-3 (46 ref.)

Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! Pessin JE, et al. **J Biol Chem** 1999 Jan 29;274(5):2593-6 (81 ref.)

From insulin receptor signalling to Glut 4 translocation abnormalities in obesity and insulin resistance. Le Marchand-Brustel Y, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1-4):217-28 (41 ref.)

Metabolic and therapeutic lessons from genetic manipulation of GLUT4. Charron MJ, et al. **Mol Cell Biochem** 1998 May;182(1-2):143-52 (73 ref.)

Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus [comment] Shepherd PR, et al. **N Engl J Med** 1999 Jul 22;341(4):248-57 (103 ref.) Comment on: N Engl J Med 1999 Jul 22;341(4):240-6.

PHYSIOLOGY

Human glucose transporters. Longo N, et al. **Adv Pediatr**

MONOSACCHARIDE TRANSPORT PROTEINS

1998;45:293–313 (90 ref.)
GLUT–4, tumor necrosis factor, essential fatty acids and daf–genes and their role in insulin resistance and non–insulin dependent diabetes mellitus. Das UN. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jan; 60(1):13–20 (43 ref.)
[Transepithelial transport of glucose] Takata K. **Kaibogaku Zasshi** 1998 Oct;73(5):485–95 (62 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Role of SNARE's in the GLUT4 translocation response to insulin in adipose cells and muscle. St–Denis JF, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):153–65 (42 ref.)

MONOSACCHARIDES

[Basic study on glyco chains] Suzuki A. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2631–9 (4 ref.) **(Jpn)**

METABOLISM

Monosaccharide esters: new tools in biomedical research. Malaisse WJ. **Mol Genet Metab** 1998 Oct;65(2):129–42 (45 ref.)

PHARMACOLOGY

Insulinotropic action of monosaccharide esters: therapeutic perspectives. Malaisse WJ. **Diabetologia** 1999 Mar; 42(3):286–91 (81 ref.)

THERAPEUTIC USE

Human glycosylation disorders and sugar supplement therapy. Freeze HH. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):189–93 (69 ref.)

MONOSIALOSYL TETRAGLYCOSYL CERAMIDE see **GM1 GANGLIOSIDE**

MONOSODIUM GLUTAMATE see **SODIUM GLUTAMATE**

MONOSOMY

GENETICS

Partial monosomy of distal 10q: three new cases and a review. Waggoner DJ, et al. **Am J Med Genet** 1999 Sep 3;86(1):1–5 (28 ref.)
Transient monosomy 7: a case series in children and review of the literature. Mantadakis E, et al. **Cancer** 1999 Jun 15; 85(12):2655–61 (36 ref.)
Turner syndrome and haploinsufficiency. Zinn AR, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):322–7 (48 ref.)
Monosomy X as the sole cytogenetic abnormality in acute lymphoblastic leukemia: a report of two new patients. Bueno JL, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):381–4 (14 ref.)

MONOSOMY, PARTIAL see **CHROMOSOME DELETION**

MONOSPORIUM APIOSPERMUM see **PSEUDALLESCHERIA**

MONOTREMATA

ANATOMY & HISTOLOGY

What can monotremes tell us about brain evolution? Krubitzer L. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1127–46 (90 ref.)

PHYSIOLOGY

Sex chromosomes and sex–determining genes: insights from marsupials and monotremes. Pask A, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):864–75 (76 ref.)
What can monotremes tell us about brain evolution? Krubitzer L. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1127–46 (90 ref.)
Sensory receptors in monotremes. Proske U, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1187–98 (45 ref.)
Monotremes and the evolution of rapid eye movement sleep. Siegel JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1147–57 (35 ref.)

MONTE CARLO METHOD

Relevance of accurate Monte Carlo modeling in nuclear medical imaging. Zaidi H. **Med Phys** 1999 Apr; 26(4):574–608 (288 ref.)
Practical aspects of Monte Carlo simulation of charged particle transport: mixed algorithms and variance reduction techniques. Salvat F, et al. **Radiat Environ Biophys** 1999 May;38(1):15–22 (23 ref.)
Applications of multiple imputation in medical studies: from AIDS to NHANES. Barnard J, et al. **Stat Methods Med Res** 1999 Mar;8(1):17–36 (44 ref.)
Multiple imputation: a primer. Schafer JL. **Stat Methods Med Res** 1999 Mar;8(1):3–15 (29 ref.)

MONTEGGIA'S FRACTURE

DIAGNOSIS

The pediatric Monteggia fracture. Kay RM, et al. **Am J Orthop** 1998 Sep;27(9):606–9 (31 ref.)

SURGERY

The pediatric Monteggia fracture. Kay RM, et al. **Am J Orthop** 1998 Sep;27(9):606–9 (31 ref.)

MOOD see **AFFECT**

MOOD DISORDERS

Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Joffe H, et al. **Biol Psychiatry** 1998 Nov 1;44(9):798–811 (125 ref.)
Children of affectively ill parents: a review of the past 10 years. Beardslee WR, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Nov; 37(11):1134–41 (67 ref.)
Psychoneuroendocrine aspects of temporolimbic epilepsy. Part I. Brain, reproductive steroids, and emotions. Herzog AG. **Psychosomatics** 1999 Mar–Apr;40(2):95–101 (82 ref.)

CHEMICALLY INDUCED

Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Brown ES, et al. **Neuropsychopharmacology** 1999 Oct;21(4):474–84 (121 ref.)

COMPLICATIONS

Sad, glad, or mad hearts? Epidemiological evidence for a causal relationship between mood disorders and coronary artery disease. Barrick CB. **J Affect Disord** 1999 May; 53(2):193–201 (63 ref.)

DIAGNOSIS

Functional brain imaging in neuropsychiatric disorders of childhood. O'Tuama LA, et al. **J Child Neurol** 1999 Apr; 14(4):207–21 (129 ref.)
Diagnoses commonly missed in childhood. Long–term outcome and implications for treatment. Burger FL, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):927–40, viii (59 ref.)
Diagnosis of obsessive–compulsive illness. Rothenberg A. **Psychiatr Clin North Am** 1998 Dec;21(4):791–801, vi (34 ref.)
Schizophrenia and severe affective illness alternating over time in some patients: a hypothesis. Sigman M. **Psychiatry** 1998 Fall;61(3):262–8 (39 ref.)
Hormone measures in reproductive endocrine–related mood disorders: diagnostic issues. Rubinow DR, et al. **Psychopharmacol Bull** 1998;34(3):289–90 (10 ref.)
Assessment of mood states in aphasia. Stern RA. **Semin Speech Lang** 1999;20(1):33–49; quiz 49–50 (76 ref.)
[Progresses in the study of psychiatry in China, 1997] Zhang M, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):925–6 (0 ref.) **(Chi)**

DRUG THERAPY

Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Levinson DF, et al. **Am J Psychiatry** 1999 Aug;156(8):1138–48 (64 ref.)
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Kroeze WK, et al. **Biol Psychiatry** 1998 Dec 1; 44(11):1128–42 (162 ref.)
The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Marek GJ, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1118–27 (85 ref.)
Psychopharmacology of affective disorders in the 21st century. Nemeroff CB. **Biol Psychiatry** 1998 Oct 1; 44(7):517–25 (24 ref.)
Mood stabilizers in children and adolescents. Ryan ND, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May; 38(5):529–36 (99 ref.)
Anticonvulsant therapy and suicide risk in affective disorders. Goodwin FK. **J Clin Psychiatry** 1999;60 Suppl 2:89–93; discussion 111–6 (54 ref.)
Modulation of CNS signal transduction pathways and gene expression by mood–stabilizing agents: therapeutic implications. Manji HK, et al. **J Clin Psychiatry** 1999;60 Suppl 2:27–39; discussion 40–1, 113–6 (138 ref.)
Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. Goldstein BJ, et al. **J Psychopharmacol** 1998;12(3 Suppl B):S55–87 (370 ref.)
Selective serotonin reuptake inhibitors in affective disorders—I. Basic pharmacology. Goodnick PJ, et al. **J Psychopharmacol** 1998;12(3 Suppl B):S5–20 (228 ref.)
Selective serotonin reuptake inhibitors in affective disorders—II. Efficacy and quality of life. Goodnick PJ, et al. **J Psychopharmacol** 1998;12(3 Suppl B):S21–54 (222 ref.)
A review of central 5–HT receptors and their function. Barnes NM, et al. **Neuropharmacology** 1999 Aug; 38(8):1083–152 (650 ref.)
The antipsychotics. A pediatric perspective. Findling RL, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1205–32 (202 ref.)
[Calcium antagonistic actions of drugs used in treatment of affective disorders] Langosch JM, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66(12):570–9 (92 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Sad, glad, or mad hearts? Epidemiological evidence for a causal relationship between mood disorders and coronary artery disease. Barrick CB. **J Affect Disord** 1999 May; 53(2):193–201 (63 ref.)
Annotation: mood disorder in suicidal children and adolescents: recent developments. Flisher AJ. **J Child Psychol Psychiatry** 1999 Mar;40(3):315–24 (51 ref.)
The vulnerable transition: puberty and the development of eating pathology and negative mood. Graber JA, et al. **Womens Health Issues** 1999 Mar–Apr;9(2):107–14 (47 ref.)

ETIOLOGY

Alcohol dependence and mood disorders. Raimo EB, et al. **Addict Behav** 1998 Nov–Dec;23(6):933–46 (58 ref.)
Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. Ghika J, et al. **J Neurosurg** 1999 Aug;91(2):313–21 (114 ref.)
Group therapy in the cancer setting. Fawzy FI, et al. **J Psychosom Res** 1998 Sep;45(3):191–200 (24 ref.)
The role of the clinical psychologist in gynecological cancer. Rieger E, et al. **J Psychosom Res** 1998 Sep;45(3):201–14 (88 ref.)
Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing. Beatty WW. **Mult Scler** 1999 Aug;5(4):239–43 (51 ref.)
Assessment of mood states in aphasia. Stern RA. **Semin Speech Lang** 1999;20(1):33–49; quiz 49–50 (76 ref.)

GENETICS

Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Lesch KP, et al. **Biol Psychiatry** 1998 Aug 1;44(3):179–92 (75 ref.)
Genetics of mood disorders—an overview. Part two. Oruč L, et al. **Med Arh** 1998;52(3):167–73 (151 ref.)
Genetics and pathophysiology of affective disorders: relationship to fibromyalgia. Ackenheil M. **Z Rheumatol** 1998;57 Suppl 2:5–7 (12 ref.)

IMMUNOLOGY

Mood and cognitive disorders in cancer patients receiving cytokine therapy. Meyers CA. **Adv Exp Med Biol** 1999; 461:75–81 (22 ref.)

NURSING

Guided imagery interventions for symptom management. Eller LS. **Annu Rev Nurs Res** 1999;17:57–84 (100 ref.)

PHYSIOPATHOLOGY

Natural history and preventative treatment of recurrent mood disorders. Frank E, et al. **Annu Rev Med** 1999;50:453–68 (80 ref.)
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Kroeze WK, et al. **Biol Psychiatry** 1998 Dec 1; 44(11):1128–42 (162 ref.)
Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Weiss SR, et al. **Neuropsychobiology** 1998 Oct;38(3):167–80 (87 ref.)
Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Mann JJ. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):99S–105S (65 ref.)
Psychoneuroendocrine aspects of temporolimbic epilepsy. Part I. Brain, reproductive steroids, and emotions. Herzog AG. **Psychosomatics** 1999 Mar–Apr;40(2):95–101 (82 ref.)
Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA. **Thyroid** 1999 Jul;9(7):691–7 (51 ref.)
[Impulse control disorders and other serotonin function disorders] Pöldinger W. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1348–55 (33 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Thought suppression and psychopathology. Purdon C. **Behav Res Ther** 1999 Nov;37(11):1029–54 (84 ref.)
Mood disorders and the reproductive cycle: affective disorders during the menopause and premenstrual dysphoric disorder. Haynes P, et al. **Psychopharmacol Bull** 1998;34(3):313–8 (57 ref.)
Perinatal mood disorders: position paper. Steiner M. **Psychopharmacol Bull** 1998;34(3):301–6 (72 ref.)
Assessing unipolar mood disorders in women. Yonkers KA. **Psychopharmacol Bull** 1998;34(3):261–6 (70 ref.)
[Current trends in the therapeutic use of thymic regulators]

Dardennes R, et al. **Presse Med** 1998 Dec 19;27(40):2157–63 (74 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Treatment of comorbid affective and substance use disorders. Therapeutic potential of anticonvulsants. Donovan SJ, et al. **Am J Addict** 1998 Summer;7(3):210–20 (70 ref.)

THERAPY

Sleep deprivation in depression: what do we know, where do we go? Wirz-Justice A, et al. **Biol Psychiatry** 1999 Aug 15;46(4):445–53 (76 ref.)

Practitioner review: electroconvulsive therapy in adolescents. Walter G, et al. **J Child Psychol Psychiatry** 1999 Mar;40(3):325–34 (67 ref.)

Repetitive transcranial magnetic stimulation as a neuropsychiatric tool: present status and future potential. Post RM, et al. **J ECT** 1999 Mar;15(1):39–59 (88 ref.)

Group therapy in the cancer setting. Fawzy FI, et al. **J Psychosom Res** 1998 Sep;45(3):191–200 (24 ref.)

The role of the clinical psychologist in gynecological cancer. Rieger E, et al. **J Psychosom Res** 1998 Sep;45(3):201–14 (88 ref.)

Exercise in the rehabilitation of breast cancer survivors. Pinto BM, et al. **Psychooncology** 1999 May-Jun;8(3):191–206 (89 ref.)

[Phototherapy in the clinic] Pracka D. **Postepy Hig Med Dosw** 1999;53(3):517–23 (26 ref.) (Eng. Abstr.) **(Pol)**

MOOD DISORDERS, PSYCHOTIC see **AFFECTIVE DISORDERS, PSYCHOTIC**

MOON

The moon and madness reconsidered. Raison CL, et al. **J Affect Disord** 1999 Apr;53(1):99–106 (38 ref.)

MORALS

see related
CONFLICT OF INTEREST

Sexuality and late modernity. Schmidt G. **Annu Rev Sex Res** 1998;9:224–41 (51 ref.)

How useful is Leuven personalism in the world of bioethics? The test case of artificial insemination. de Wachter MA. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):227–33 (35 ref.)

In vitro fertilisation: the ethics of illicitness? A personalist Catholic approach. Schotsmans PT. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):235–41 (14 ref.)

The authority of the clinical ethicist. Casarett DJ, et al. **Hastings Cent Rep** 1998 Nov-Dec;28(6):6–11 (19 ref.)

Epidemiology and virtue ethics. Weed DL, et al. **Int J Epidemiol** 1998 Jun;27(3):343–8; discussion 348–9 (61 ref.)

The moral metaphors of nursing. Wurzbach ME. **J Adv Nurs** 1999 Jul;30(1):94–9 (27 ref.)

Morality and multiplicity: perspectives on the treatment of violence in intimate life. Goldner V. **J Marital Fam Ther** 1999 Jun;25(3):325–36 (24 ref.)

Changing the present legal prohibitions on assisted suicide is a bad idea. Zimbelman J. **J Prof Nurs** 1999 May-Jun; 15(3):160–9 (46 ref.)

The moral appeal of assisted suicide in end-of-life decisions. Zimbelman J, et al. **J Prof Nurs** 1999 May-Jun;15(3):142–5 (9 ref.)

Moral dilemmas of tetraplegia; the 'locked-in' syndrome, the persistent vegetative state and brain death. Firsching R. **Spinal Cord** 1998 Nov;36(11):741–3 (17 ref.)

Casuistry and principlism: the convergence of method in biomedical ethics. Kuczewski M. **Theor Med Bioeth** 1998 Dec;19(6):509–24 (40 ref.)

[The moral and legal aspects of the dentist's activities today] Obraztsov IuL, et al. **Stomatologiia (Mosk)** 1999;78(4):51–3 (20 ref.) **(Rus)**

MORAXELLA (BRANHAMELLA) CATARRHALIS

Moraxella (Branhamella) catarrhalis: clinical, microbiological and immunological features in lower respiratory tract infections. Christensen JJ. **APMIS Suppl** 1999;88:1–36 (249 ref.)

Moraxella catarrhalis endocarditis: report of a case and literature review. Neumayer U, et al. **J Heart Valve Dis** 1999 Jan;8(1):114–7 (15 ref.)

Papilloedema secondary to acute purulent sinusitis. Kumar RK, et al. **J Paediatr Child Health** 1999 Aug;35(4):396–8 (11 ref.)

[Branhamella pneumonia] Miura H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):362–5 (12 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Moraxella catarrhalis bacteraemia. A report on 3 cases and a review of the literature. Thórsson B, et al. **Scand J Infect Dis** 1998;30(2):105–9 (39 ref.)

MORAXELLA CATARRHALIS see **MORAXELLA (BRANHAMELLA) CATARRHALIS**

MORBID OBESITY see **OBESITY, MORBID**

MORBIDITY

The global burden of mental disorders [see comments] Ustün TB. **Am J Public Health** 1999 Sep;89(9):1315–8 (24 ref.) Comment in: Am J Public Health 1999 Sep;89(9):1309–11.

Critical appraisal of the health research literature: prevalence or incidence of a health problem. Loney PL, et al. **Chronic Dis Can** 1998;19(4):170–6 (27 ref.)

Neonatal risk scoring systems. Can they predict mortality and morbidity? Richardson DK, et al. **Clin Perinatol** 1998 Sep;25(3):591–611 (126 ref.)

Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Contrib Nephrol** 1998;124:166–89; discussion 190–201 (115 ref.)

Severe OHSS: patients should be allowed to weigh the morbidity of OHSS against the benefits of parenthood. Mathur RS, et al. **Hum Reprod** 1999 Sep;14(9):2183–5 (15 ref.)

The saga of tobacco products liability litigation: a look back and a proposal for the future. Nusbaum NJ. **J Community Health** 1998 Oct;23(5):325–35 (43 ref.)

Disease, drugs and alcohol induced driving impairment: the law and the medicine. Marks P. **Med Leg J** 1998;66 (Pt 3):109–15 (27 ref.)

Review of social epidemiologic research on migrants' health: findings, methodological cautions, and theoretical perspectives. Friis R, et al. **Scand J Soc Med** 1998 Sep; 26(3):173–80 (58 ref.)

[Centenarians: exceptional elderly?] Martin JP. **Rev Prat** 1998 Jan 15;48(2):121–3 (11 ref.) **(Fre)**

[Body height and disease] Njølstad I. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1158–61 (34 ref.) **(Nor)**

[Hypothesis of the compression of morbidity: an example of theoretical development in epidemiology] López-Moreno S, et al. **Salud Publica Mex** 1998 Sep-Oct;40(5):442–9 (38 ref.) (Eng. Abstr.) **(Spa)**

MORBILLIVIRUS

ISOLATION & PURIFICATION

Morbillivirus infections in aquatic mammals. Kennedy S. **J Comp Pathol** 1998 Oct;119(3):201–25 (106 ref.)

MORBILLIVIRUS INFECTIONS

VETERINARY

Morbillivirus infections in aquatic mammals. Kennedy S. **J Comp Pathol** 1998 Oct;119(3):201–25 (106 ref.)

MORGAGNI-STEWART-MOREL SYNDROME see **HYPEROSTOSIS FRONTALIS INTERNA**

MORMONS see **CHRISTIANITY**

MORMYRID see **ELECTRIC FISH**

MORNING-AFTER PILL see **CONTRACEPTIVES, POSTCOITAL**

MORPHEA see **SCLERODERMA, CIRCUMSCRIBED**

MORPHINE

see related
RECEPTORS, OPIOID

ADMINISTRATION & DOSAGE

Peak plasma concentrations after oral morphine: a systematic review. Collins SL, et al. **J Pain Symptom Manage** 1998 Dec;16(6):388–402 (55 ref.)

Sublingual morphine: efficacy reviewed. Coluzzi PH. **J Pain Symptom Manage** 1998 Sep;16(3):184–92 (30 ref.)

Morphine in nonmalignant joint pain. Physiological rationale, value, and limitations. Perrot S. **Rev Rhum Engl Ed** 1999 May;66(5):271–7 (72 ref.)

Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)

ADVERSE EFFECTS

[Neurological adverse effects of morphine] Ikenaga M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):614–7 (15 ref.) **(Jpn)**

METABOLISM

The role of morphine glucuronides in cancer pain. Mercadante S. **Palliat Med** 1999 Mar;13(2):95–104 (77 ref.)

[Production of morphinone as a metabolite of morphine and its physiological role] Toki S, et al. **Yakugaku Zasshi** 1999 Apr;119(4):249–67 (63 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Gourlay GK. **Clin Pharmacokinet** 1998 Sep;35(3):173–90 (66 ref.)

PHARMACOLOGY

A therapeutic strategy to prevent morphine dependence and tolerance by coadministration of cAMP-related reagents with morphine. Itoh A, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):619–25 (25 ref.)

Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Mayer DJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7731–6 (47 ref.)

POISONING

[Morphine poisoning in chronic kidney failure. Morphine-6-glucuronide as a pharmacologically active morphine metabolite] Dubs A, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):896–8 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Pharmacological management of pain after intracranial surgery. Leith B. **J Neurosci Nurs** 1998 Aug;30(4):220–4 (27 ref.)

Sublingual morphine: efficacy reviewed. Coluzzi PH. **J Pain Symptom Manage** 1998 Sep;16(3):184–92 (30 ref.)

Injected morphine in postoperative pain: a quantitative systematic review. McQuay HJ, et al. **J Pain Symptom Manage** 1999 Mar;17(3):164–74 (48 ref.)

TOXICITY

Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors. Kobayashi H, et al. **J Toxicol Sci** 1999 Feb;24(1):1–16 (96 ref.)

MORPHINE ABUSE see **MORPHINE DEPENDENCE**

MORPHINE ADDICTION see **MORPHINE DEPENDENCE**

MORPHINE DEPENDENCE

PSYCHOLOGY

A therapeutic strategy to prevent morphine dependence and tolerance by coadministration of cAMP-related reagents with morphine. Itoh A, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):619–25 (25 ref.)

MORPHINE DERIVATIVES

POISONING

[Morphine poisoning in chronic kidney failure. Morphine-6-glucuronide as a pharmacologically active morphine metabolite] Dubs A, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):896–8 (18 ref.) (Eng. Abstr.) **(Ger)**

MORPHINE RECEPTORS see **RECEPTORS, OPIOID, MU**

MORPHINE SULFATE see **MORPHINE**

MORPHINE USERS see **MORPHINE DEPENDENCE**

MORPHOGENESIS

Laminin isoforms and epithelial development. Ekblom M, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:194–211 (68 ref.)

Extracellular matrix remodeling during morphogenesis. Werb Z, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:110–8 (33 ref.)

Mechanisms of Wnt signaling in development. Wodarz A, et al. **Annu Rev Cell Dev Biol** 1998;14:59–88 (147 ref.)

A simple molecular model of neurulation. Kerszberg M, et al. **Bioessays** 1998 Sep;20(9):758–70 (70 ref.)

Molecular mechanisms controlling lung morphogenesis. Perl AK, et al. **Clin Genet** 1999 Jul;56(1):14–27 (139 ref.)

Drosophila morphogenesis: orchestrating cell rearrangements. Knust E, et al. **Curr Biol** 1998 Nov 19; 8(23):R853–5 (13 ref.)

[Transcription factors of the Ets family and morphogenesis of the vascular tree] Mattot V, et al. **J Soc Biol** 1999; 193(2):147–53 (68 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular embryology of the lung: then, now, and in the future. Warburton D, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L697–704 (57 ref.)

Formin defines a large family of morphoregulatory genes and functions in establishment of the polarising region. Zeller R, et al. **Cell Tissue Res** 1999 Apr;296(1):85–93 (56 ref.)

The molecular basis for the role of zinc in developmental biology. Falchuk KH. **Mol Cell Biochem** 1998 Nov; 188(1-2):41–8 (59 ref.)

MORPHOGENESIS

Genetic control of murine limb morphogenesis: relationships with human syndromes and evolutionary relevance. Kondo T, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):3-8 (28 ref.)

[Structure and function of novel homeobox gene family six and implications in development and differentiation] Kawakami K, et al. **Tanpakushitsu Kakusan Koso** 1998 Nov; 43(14):2120-5 (25 ref.) **(Jpn)**

PHYSIOLOGY

The role of the neural growth associated protein B-50/GAP-43 in morphogenesis. Aarts LH, et al. **Adv Exp Med Biol** 1998;446:85-106 (117 ref.)

Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. Miyamoto S, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:119-29 (45 ref.)

Morphogenesis. Hogan BL. **Cell** 1999 Jan 22;96(2):225-33 (55 ref.)

Cell death in development. Vaux DL, et al. **Cell** 1999 Jan 22;96(2):245-54 (98 ref.)

Hox genes: from master genes to micromanagers. Akam M. **Curr Biol** 1998 Sep 24;8(19):R676-8 (13 ref.)

[Endothelial intercellular junctions: relationship between vascular adhesion and morphogenesis] Huber P. **J Soc Biol** 1999;193(2):181-7 (64 ref.) (Eng. Abstr.) **(Fre)**

MORPHOLINES

PHARMACOLOGY

Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist. Serradeil-Le Gal C. **Adv Exp Med Biol** 1998;449:427-38 (36 ref.)

The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? Healy D, et al. **J Affect Disord** 1998 Dec; 51(3):313-22 (57 ref.)

[Pharmacological effects of the gastroprokinetic agent mosapride citrate] Yoshida N. **Nippon Yakurigaku Zasshi** 1999 May;113(5):299-307 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Modulators of glycosphingolipid biosynthesis (PDMP): application to cell biology] Inokuchi J. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2495-502 (38 ref.) **(Jpn)**

THERAPEUTIC USE

Moroxydine: the story of a mislaid antiviral. Sheppard S. **Acta Derm Venereol Suppl (Stockh)** 1994;183:1-9 (42 ref.)

Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. Burrows GD, et al. **J Clin Psychiatry** 1998;59 Suppl 14:4-7 (12 ref.)

Chairman's overview. The place of reboxetine in antidepressant therapy. Montgomery SA. **J Clin Psychiatry** 1998;59 Suppl 14:26-9 (34 ref.)

[Landiolol hydrochloride, a new sympathetic beta blocker] Yoshiya I. **Masui** 1998 Dec;47 Suppl:S126-32 (17 ref.) **(Jpn)**

MORQUIO'S DISEASE see **MUCOPOLYSACCHARIDOSIS IV**

MORSYDOMINE see **MOLSIDOMINE**

MORTALITY

PM2.5 and mortality in long-term prospective cohort studies: cause-effect or statistical associations? Gamble JF. **Environ Health Perspect** 1998 Sep;106(9):535-49 (57 ref.)

African-American health: the role of the social environment. Williams DR. **J Urban Health** 1998 Jun;75(2):300-21 (93 ref.)

Alcohol and all-cause mortality: an overview. Rehm J, et al. **Novartis Found Symp** 1998;216:223-32; discussion 232-6 (58 ref.)

A review of the road transport of slaughter sheep. Knowles TG. **Vet Rec** 1998 Aug 22;143(8):212-9 (69 ref.)

TRENDS

Sounding the improvement in outcomes in pediatric critical care: are we listening for only what we want to hear? [editorial; comment] Vardis R, et al. **Crit Care Med** 1998 Oct;26(10):1635-6 (12 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1737-43.

Premature deaths and long-term mortality effects of air pollution [letter] Quénel P, et al. **Int J Epidemiol** 1999 Apr; 28(2):362 (7 ref.)

Age standardization of death rates: implementation of the year 2000 standard. Anderson RN, et al. **Natl Vital Stat Rep** 1998 Oct 7;47(3):1-16, 20 (27 ref.)

[Autopsy and modern medicine] Moch H, et al. **Schweiz Rundsch Med Prax** 1999 May 6;88(19):861-7 (52 ref.) **(Ger)**

[A review of original papers that analyze the effects of air pollution on mortality, 1994-1998] Tenías Burillo JM, et al. **Rev Esp Salud Publica** 1999 Mar-Apr;73(2):145-64 (63 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY, HOSPITAL see **HOSPITAL MORTALITY**

MORTIERELLA

METABOLISM

[Biosynthesis of triacylglycerol and related intracellular lipid transport in fungi and yeasts] Kamisaka Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1207-12 (35 ref.) **(Jpn)**

MORTUARY CUSTOMS see **FUNERAL RITES**

MOSAICISM

see related
MICE, TRANSGENIC

Trisomy 16 and trisomy 16 Mosaicism: a review. Benn P. **Am J Med Genet** 1998 Sep 1;79(2):121-33 (72 ref.)

Cutaneous mosaicism of lethal mutations. Hamm H. **Am J Med Genet** 1999 Aug 6;85(4):342-5 (20 ref.)

Segmental forms of autosomal dominant skin disorders: the puzzle of mosaicism. Itin PH, et al. **Am J Med Genet** 1999 Aug 6;85(4):351-4 (30 ref.)

Revertant mosaicism in human genetic disorders. Jonkman MF. **Am J Med Genet** 1999 Aug 6;85(4):361-4 (30 ref.)

Hypomelanosis of Ito: no entity, but a cutaneous sign of mosaicism. Küster W, et al. **Am J Med Genet** 1999 Aug 6;85(4):346-50 (50 ref.)

McCune-Albright syndrome: clinical and molecular evidence of mosaicism in an unusual giant patient. Tinschert S, et al. **Am J Med Genet** 1999 Mar 12;83(2):100-8 (8 ref.)

Mosaicism with a normal cell line and an unbalanced structural rearrangement. Zaslav AL, et al. **Am J Med Genet** 1999 Jan 1;82(1):15-9 (32 ref.)

Formation of supernumerary euchromatic short arm isochromosomes: parent and cell stage of origin in new cases and review of the literature. Eggermann T, et al. **Ann Genet** 1999;42(2):75-80 (18 ref.)

Confined placental mosaicism and intrauterine fetal growth. Lestou VS, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F223-6 (30 ref.)

Aging of C. elegans: mosaics and mechanisms. Wood WB. **Cell** 1998 Oct 16;95(2):147-50 (20 ref.)

Pigmentary mosaicism in hypomelanosis of Ito. Further evidence for functional disomy of Xp. Fritz B, et al. **Hum Genet** 1998 Oct;103(4):441-9 (51 ref.)

[Somatic mosaicism of CAG repeats size in the nervous system of dentatorubral-pallidoluysian atrophy (DRPLA)] Ito Y, et al. **Nippon Rinsho** 1999 Apr;57(4):850-5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of expanded CAG trinucleotide repeat in the neural and nonneural tissues of Machado-Joseph disease (MJD)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr; 57(4):838-42 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of expanded CAG trinucleotide repeat in spinal and bulbar muscular atrophy (SBMA)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr;57(4):862-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Three cases of mosaicism for balanced reciprocal translocations. Leegte B, et al. **Am J Med Genet** 1998 Oct 12;79(5):362-5 (22 ref.)

Child with mosaic variegated aneuploidy and embryonal rhabdomyosarcoma. Limwongse C, et al. **Am J Med Genet** 1999 Jan 1;82(1):20-4 (24 ref.)

Cytogenetic and molecular evidence for cutaneous mosaicism: the ectodermal origin of Blaschko lines. Moss C. **Am J Med Genet** 1999 Aug 6;85(4):330-3 (22 ref.)

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. Roach ES, et al. **J Child Neurol** 1998 Dec;13(12):624-8 (28 ref.)

Chimeras and mosaics in mouse mutant analysis. Rossant J, et al. **Trends Genet** 1998 Sep;14(9):358-63 (42 ref.)

MOSCHKOWITZ DISEASE see **PURPURA, THROMBOTIC THROMBOCYTOPENIC**

MOSQUITO CONTROL

see related
INSECTICIDE RESISTANCE
PEST CONTROL, BIOLOGICAL

Factors influencing the larvicidal activity of bacterial toxin. Chowanadisai L. **Indian J Malariol** 1998 Jun;35(2):117-22 (31 ref.)

A critical review of ultralow-volume aerosols of insecticide applied with vehicle-mounted generators for adult mosquito control. Mount GA. **J Am Mosq Control Assoc** 1998 Sep;14(3):305-34 (166 ref.)

ECONOMICS

Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Coleman PG, et al. **Trop Med Int Health** 1999 Mar; 4(3):175-86 (48 ref.)

INSTRUMENTATION

[Electronic repellents against mosquitoes: the propaganda and the reality] Coro F, et al. **Rev Cubana Med Trop** 1998; 50(2):89-92 (34 ref.) (Eng. Abstr.) **(Spa)**

MOSQUITOES see **CULICIDAE**

MOSSES

ENZYMOLOGY

Structure and functional analysis of the 26S proteasome subunits from plants. Fu H, et al. **Mol Biol Rep** 1999 Apr; 26(1-2):137-46 (30 ref.)

MOSSY FIBERS, CEREBELLAR see **NERVE FIBERS**

MOTH FLIES see **PSYCHODIDAE**

MOTHER CELLS see **STEM CELLS**

MOTHER-CHILD RELATIONS

Theory and observation of attachment and its relation to child maltreatment: a review. Morton N, et al. **Child Abuse Negl** 1998 Nov;22(11):1093-104 (85 ref.)

Children of Armageddon. Common developmental threats in high-conflict divorcing families. Roseby V, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):295-309, vi (26 ref.)

Children's illness cognition: what mothers think. Rubovits DS, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):99-105 (23 ref.)

[Child of a single mother] Berthier M, et al. **Arch Pediatr** 1998 Jan;5(1):71-8 (33 ref.) (Eng. Abstr.) **(Fre)**

[When daughter becomes mother] Naouri A. **Contracept Fertil Sex** 1999 May;27(5):376-82 (5 ref.) (Eng. Abstr.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. Psychological implications] Molénat F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:285-8 (8 ref.) **(Fre)**

[Contribution of maternal sensitivity in transgenerational promotion of binding quality] Ziegenhain U. **Prax Kinderpsychol Kinderpsychiatr** 1999 Feb;48(2):86-100 (40 ref.) (Eng. Abstr.) **(Ger)**

MOTHERS

see related
MATERNAL BEHAVIOR

What's a mother to do? Welfare, work, and family [editorial; comment] Chavkin W. **Am J Public Health** 1999 Apr; 89(4):477-9 (13 ref.) Comment on: Am J Public Health 1999 Apr;89(4):502-5.

Does assisted reproduction make an impact on the identity and self-esteem of infertile women during the transition to parenthood? McMahon CA. **J Assist Reprod Genet** 1999 Feb;16(2):59-62 (19 ref.)

Health-related problems in a vulnerable population: pregnant teens and adolescent mothers. Lesser J, et al. **Nurs Clin North Am** 1999 Jun;34(2):289-99 (48 ref.)

[Maternal elimination diet during pregnancy and lactation, and the development of allergies in infants] Oldak E. **Pol Merkuriusz Lek** 1998 Dec;5(30):387-9 (29 ref.) (Eng. Abstr.) **(Pol)**

EDUCATION

Listening to Hispanic mothers: guidelines for teaching. Wilson AH, et al. **J Soc Pediatr Nurs** 1999 Jul-Sep; 4(3):125-7 (10 ref.)

PSYCHOLOGY

Postadoptive reactions of the relinquishing mother: a review. Askren HA, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):395-400 (20 ref.)

A theoretical model for the study of active and passive smoking in military women: an at-risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475-80 (56 ref.)

Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Goodman SH, et al. **Psychol Rev** 1999 Jul;106(3):458-90 (300 ref.)

[Delivery methods for infants weighing less than 2500 grams. Psychological implications] Molénat F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:285-8 (8 ref.) **(Fre)**

MOTHERS, GESTATIONAL see **SURROGATE MOTHERS**

MOTHERS, SURROGATE see **SURROGATE MOTHERS**

MOTILIN

see related
GASTROINTESTINAL AGENTS

MOTILITY, CELL see **CELL MOVEMENT**

MOTION

see related
MOVEMENT

The child as a projectile [see comments] Tibbs RE Jr, et al. **Anat Rec** 1998 Dec;253(6):167–75 (21 ref.) Comment in: Anat Rec 1998 Dec;253(6):155.

Short-latency visual stabilization mechanisms that help to compensate for translational disturbances of gaze. Miles FA. **Ann N Y Acad Sci** 1999 May 28;871:260–71 (57 ref.)

Modelling motion sickness and subjective vertical mismatch detailed for vertical motions. Bos JE, et al. **Brain Res Bull** 1998 Nov 15;47(5):537–42 (15 ref.)

The puzzle of hydrodynamic information processing: how are complex water motions analyzed by the lateral line? Mogdans J, et al. **Eur J Morphol** 1999 Apr;37(2–3):195–9 (17 ref.)

MOTION PERCEPTION

PHYSIOLOGY

Alteration of eye movements and motion perception in microgravity. Clément G. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):161–72 (61 ref.)

Binocular vision: the neural integration of depth and motion. Freeman RD. **Curr Biol** 1998 Oct 22;8(21):R761–4 (10 ref.)

Central neural mechanisms for detecting second-order motion. Baker CL Jr. **Curr Opin Neurobiol** 1999 Aug; 9(4):461–6 (56 ref.)

Encoding of motion in real time by the fly visual system. Egelhaaf M, et al. **Curr Opin Neurobiol** 1999 Aug; 9(4):454–60 (65 ref.)

Complex motion perception and its deficits. Vaina LM. **Curr Opin Neurobiol** 1998 Aug;8(4):494–502 (75 ref.)

Working in a moving environment. Wertheim AH. **Ergonomics** 1998 Dec;41(12):1845–58 (70 ref.)

Neural model of first-order and second-order motion perception and magnocellular dynamics. Baloch AA, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 May; 16(5):953–78 (121 ref.)

Use of image-based information in judgments of surface-reflectance properties. Nishida S, et al. **J Opt Soc Am A Opt Image Sci Vis** 1998 Dec; 15(12):2951–65 (65 ref.)

Motion detection in insect orientation and navigation. Srinivasan MV, et al. **Vision Res** 1999 Aug;39(16):2749–66 (73 ref.)

MOTION PICTURES

see related
CINEANGIOGRAPHY

MOTION SICKNESS

COMPLICATIONS

Vestibular autonomic regulation (including motion sickness and the mechanism of vomiting). Balaban CD. **Curr Opin Neurol** 1999 Feb;12(1):29–33 (45 ref.)

DRUG THERAPY

[The role of neurochemical mechanisms in the pathogenesis of kinetoses and the therapeutic-prophylactic action of drugs] Shashkov VS, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):3–8 (39 ref.) (Eng. Abstr.) **(Rus)**

[The neurochemical mechanisms and pharmacological routes to eliminate vomiting in seasickness] Naletov SV, et al. **Voen Med Zh** 1998 Sep;319(9):74–6 (20 ref.) **(Rus)**

ETIOLOGY

[The role of neurochemical mechanisms in the pathogenesis of kinetoses and the therapeutic-prophylactic action of drugs] Shashkov VS, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):3–8 (39 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Motion sickness: only one provocative conflict? Bles W, et al. **Brain Res Bull** 1998 Nov 15;47(5):481–7 (43 ref.)

Modelling motion sickness and subjective vertical mismatch detailed for vertical motions. Bos JE, et al. **Brain Res Bull** 1998 Nov 15;47(5):537–42 (15 ref.)

Perspectives of electrogastrography and motion sickness. Cheung B, et al. **Brain Res Bull** 1998 Nov 15;47(5):421–31 (44 ref.)

Motion sickness and development of synergy within the spatial orientation system. A hypothetical unifying concept. Guedry FE, et al. **Brain Res Bull** 1998 Nov 15;47(5):475–80 (60 ref.)

Physiological basis and pharmacology of motion sickness: an update. Yates BJ, et al. **Brain Res Bull** 1998 Nov 15; 47(5):395–406 (173 ref.)

Illusory self-motion and motion sickness: a model for brain-gut interactions and nausea. Koch KL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):53S–57S (25 ref.)

Working in a moving environment. Wertheim AH. **Ergonomics** 1998 Dec;41(12):1845–58 (70 ref.)

MOTIVATION

see related
COGNITIVE DISSONANCE
LIBIDO

Interpersonal processes: the interplay of cognitive, motivational, and behavioral activities in social interaction. Snyder M, et al. **Annu Rev Psychol** 1999;50:273–303 (138 ref.)

Cadaveric organ donation: rethinking donor motivation [see comments] Sade RM. **Arch Intern Med** 1999 Mar 8; 159(5):438–42 (25 ref.) Comment in: Arch Intern Med 1999 Mar 8;159(5):427–8.

Health care incentives in immunisation. Achat H, et al. **Aust N Z J Public Health** 1999 Jun;23(3):285–8 (48 ref.)

Strategies for preparing clients for treatment. A review. Walitzer KS, et al. **Behav Modif** 1999 Jan;23(1):129–51 (60 ref.)

Emotion, motivation, and anxiety: brain mechanisms and psychophysiology. Lang PJ, et al. **Biol Psychiatry** 1998 Dec 15;44(12):1248–63 (84 ref.)

Social anxiety and drinking in college students: a social cognitive theory analysis. Burke RS, et al. **Clin Psychol Rev** 1999 Aug;19(5):513–30 (140 ref.)

Neural systems for behavioral activation and reward. Kalivas PW, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):223–7 (41 ref.)

Motivation for physical activity and weight management. Biddle SJ, et al. **Int J Obes Relat Metab Disord** 1998 Aug; 22 Suppl 2:S39–47 (57 ref.)

The real and imagined harmful effects of rewards: implications for clinical practice. Reitman D. **J Behav Ther Exp Psychiatry** 1998 Jun;29(2):101–13 (34 ref.)

Emotion and motivation: measuring affective perception. Lang PJ, et al. **J Clin Neurophysiol** 1998 Sep;15(5):397–408 (78 ref.)

Motivation, mobilization, and monitoring: the role of groups in health policy [editorial] Peterson MA. **J Health Polit Policy Law** 1999 Jun;24(3):415–20 (17 ref.)

Proposal for a mutual insurance pool for transplant organs. Schwindt R, et al. **J Health Polit Policy Law** 1998 Oct; 23(5):725–41 (44 ref.)

Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Balleine BW, et al. **Neuropharmacology** 1998 Apr–May;37(4–5):407–19 (50 ref.)

Neurotransmitter system interactions revealed by drug-induced changes in motivated behavior. Montgomery AM, et al. **Pharmacol Biochem Behav** 1999 Apr; 62(4):643–57 (170 ref.)

Patients with alcohol problems in primary care: understanding their resistance and motivating change. Botelho RJ, et al. **Prim Care** 1999 Jun;26(2):279–98 (50 ref.)

The primacy of primary control is a human universal: a reply to Gould's (1999) critique of the life-span theory of control. Heckhausen J, et al. **Psychol Rev** 1999 Jul;106(3):605–9 (36 ref.)

Determinants of positive and negative generation effects in free recall. Steffens MC, et al. **Q J Exp Psychol A** 1998 Nov;51(4):705–33 (62 ref.)

Mechanisms of alcohol craving and their clinical implications. Singleton EG, et al. **Recent Dev Alcohol** 1998;14:177–95 (92 ref.)

In vivo neurochemical correlates of cognitive processes: methodological and conceptual challenges. Bruno JP, et al. **Rev Neurosci** 1999;10(1):25–48 (88 ref.)

Cognitive and motivational operations in primate prefrontal neurons. Watanabe M. **Rev Neurosci** 1998;9(4):225–41 (133 ref.)

Motivation, cognition and pseudoscience. Lindeman M. **Scand J Psychol** 1998 Dec;39(4):257–65 (84 ref.)

[More tolerance in management of unmotivated elderly family members] Thomas PJ, et al. **Schweiz Rundsch Med Prax** 1999 Feb 4;88(6):223–32 (35 ref.) (Eng. Abstr.) **(Ger)**

[Adolescents and suicide. Some comments on the role of the pediatrician in researching the motivations for suicidal behaviors] Franchini F, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):251–3 (14 ref.) (Eng. Abstr.) **(Ita)**

[Prospective memory and its theoretical considerations] Umeda S, et al. **Shinrigaku Kenkyu** 1998 Oct;69(4):317–33 (124 ref.) (Eng. Abstr.) **(Jpn)**

[The dynamics of neocortical modifications: the dependence on motivational and emotiogenic systems] Kozhedub RG. **Usp Fiziol Nauk** 1999 Apr–Jun;30(2):21–40 (128 ref.) (Eng. Abstr.) **(Rus)**

[Motivational–emotional conflict: systemogenesis of goal-directed behavioral act] Kotov AV. **Vestn Ross Akad Med Nauk** 1999;(6):20–5 (10 ref.) (Eng. Abstr.) **(Rus)**

MOTOR ACTIVITY

see related
HYPERKINESIS

Review of objective topographic facial nerve evaluation methods. Dulguerov P, et al. **Am J Otol** 1999 Sep; 20(5):672–8 (32 ref.)

Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Ketelaar M, et al. **Clin Rehabil** 1998 Oct;12(5):369–80 (61 ref.)

Information coding in the cortex by independent or coordinated populations. deCharms RC. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15166–8 (36 ref.)

Assessment of motor functions. Nordgren B. **Scand J Rehabil Med Suppl** 1999;39:58–64 (17 ref.)

[Motor signs of depression] Lemke MR. **Nervenarzt** 1999 Jul; 70(7):600–12 (145 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Motor actions of cannabinoids in the basal ganglia output nuclei. Sañudo-Peña MC, et al. **Life Sci** 1999; 65(6–7):703–13 (33 ref.)

PHYSIOLOGY

Neural systems for control of voluntary action--a hypothesis. Hikosaka O. **Adv Biophys** 1998;35:81–102 (43 ref.)

Modulation of motor behaviour by NMDA- and cholecystokinin-antagonism. Broberger C, et al. **Amino Acids** 1998;14(1–3):25–31 (34 ref.)

Ligands of the NMDA receptor-associated glycine recognition site and motor behavior. Kretschmer BD. **Amino Acids** 1998;14(1–3):227–34 (36 ref.)

Physical exercise and antioxidant defenses in the heart. Atalay M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:169–77 (41 ref.)

Functional magnetic resonance imaging as a tool for investigating human cortical motor function. Porro CA, et al. **Arch Ital Biol** 1999 May;137(2–3):101–14 (106 ref.)

Tapping into spinal circuits to restore motor function. Barbeau H, et al. **Brain Res Brain Res Rev** 1999 Jul; 30(1):27–51 (203 ref.)

Role of gravity in the development of posture and locomotion in the neonatal rat. Clarac F, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):35–43 (49 ref.)

Cortical populations and behaviour: Hebb's thread. Amirikian B, et al. **Can J Exp Psychol** 1999 Mar;53(1):21–34 (55 ref.)

Impaired motor coordination in mice lacking prion protein. Katamine S, et al. **Cell Mol Neurobiol** 1998 Dec; 18(6):731–42 (56 ref.)

Cellular requirements of suprachiasmatic nucleus transplants for restoration of circadian rhythm. Boer GJ, et al. **Chronobiol Int** 1998 Sep;15(5):551–66 (50 ref.)

Biorobotic approaches to the study of motor systems. Beer RD, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):777–82 (54 ref.)

Sensory pathways and their modulation in the control of locomotion. Büschges A, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):733–9 (47 ref.)

Intersegmental coordination in invertebrates and vertebrates. Skinner FK, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):725–32 (54 ref.)

N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Adriani W, et al. **Exp Brain Res** 1998 Nov; 123(1–2):52–9 (55 ref.)

Early motor influences on visuomotor transformations for reaching: a positive image of optic ataxia. Battaglia Mayer A, et al. **Exp Brain Res** 1998 Nov;123(1–2):172–89 (104 ref.)

Self-perception and action in infancy. Rochat P. **Exp Brain Res** 1998 Nov;123(1–2):102–9 (22 ref.)

Parkinson's disease: a major hypokinetic basal ganglia disorder. Sian J, et al. **J Neural Transm** 1999; 106(5–6):443–76 (85 ref.)

Role of the endogenous cannabinoid system in the regulation of motor activity. Rodriguez de Fonseca F, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):483–501 (130 ref.)

Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain dopamine. Vezina P, et al. **Neurosci Biobehav Rev** 1999 Mar; 23(4):577–89 (135 ref.)

Cortical control of whole-arm motor tasks. Kalaska JF, et al. **Novartis Found Symp** 1998;218:176–90; discussion 190–201 (60 ref.)

Neuromuscular control: introduction and overview. van Leeuwen JL. **Philos Trans R Soc Lond B Biol Sci** 1999 May 29;354(1385):841–7 (33 ref.)

Movement-related gating of climbing fibre input to cerebellar cortical zones. Apps R. **Prog Neurobiol** 1999 Apr; 57(5):537–62 (138 ref.)

[The health and hygiene problems of motor activity in childhood and adolescence] Iotova E. **Probl Khig** 1997; 22:124–35 (35 ref.) (Eng. Abstr.) **(Bul)**

[The neurophysiological mechanisms in the selection of actions and their disturbance in the attention deficit syndrome] Kropotov IuD, et al. **Fiziol Cheloveka** 1999 Jan–Feb;25(1):115–24 (34 ref.) **(Rus)**

MOTOR CORTEX

ANATOMY & HISTOLOGY

Organization of the human motor system as studied by functional magnetic resonance imaging. Mattay VS, et al. **Eur J Radiol** 1999 May;30(2):105–14 (98 ref.)

DRUG EFFECTS

Pharmacological inactivation in the analysis of the central control of movement. Martin JH, et al.

MOTOR CORTEX

J Neurosci Methods 1999 Jan;86(2):145–59 (63 ref.)

PATHOLOGY

Alzheimer's disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Horoupian DS, et al.
Acta Neuropathol (Berl) 1999 Sep;98(3):317–22 (23 ref.)

PHYSIOLOGY

Experience-dependent changes in vibrissae evoked responses in the rodent barrel cortex. Glazewski S.
Acta Neurobiol Exp (Warsz) 1998;58(4):309–20 (70 ref.)
Neural aspects of anticipatory behavior. Brunia CH.
Acta Psychol (Amst) 1999 Apr;101(2–3):213–42 (92 ref.)
Functional magnetic resonance imaging as a tool for investigating human cortical motor function. Porro CA, et al. **Arch Ital Biol** 1999 May;137(2–3):101–14 (106 ref.)
Cortical populations and behaviour: Hebb's thread. Amirikian B, et al. **Can J Exp Psychol** 1999 Mar;53(1):21–34 (55 ref.)
The organization of the cortical motor system: new concepts. Rizzolatti G, et al. **Electroencephalogr Clin Neurophysiol** 1998 Apr;106(4):283–96 (104 ref.)
Organization of the human motor system as studied by functional magnetic resonance imaging. Mattay VS, et al. **Eur J Radiol** 1999 May;30(2):105–14 (98 ref.)
Pharmacological inactivation in the analysis of the central control of movement. Martin JH, et al.
J Neurosci Methods 1999 Jan;86(2):145–59 (63 ref.)
Corticomotoneuronal PSTH studies [editorial; comment] Mills KR. **Muscle Nerve** 1999 Mar;22(3):297–8 (13 ref.) Comment on: Muscle Nerve 1999 Mar;22(3):299–306.
Rhythmical corticomotor communication. Hari R, et al.
Neuroreport 1999 Feb 5;10(2):R1–10 (83 ref.)
Online visual control of the arm. Georgopoulos AP.
Novartis Found Symp 1998;218:147–64; discussion 164–70 (42 ref.)
Cortical control of whole-arm motor tasks. Kalaska JF, et al. **Novartis Found Symp** 1998;218:176–90; discussion 190–201 (60 ref.)
Internal models for motor control. Kawato M, et al.
Novartis Found Symp 1998;218:291–304; discussion 304–7 (35 ref.)
The importance of the cortico-motoneuronal system for control of grasp. Lemon RN, et al.
Novartis Found Symp 1998;218:202–15; discussion 215–8 (39 ref.)
The apraxias are higher-order defects of sensorimotor integration. Marsden CD. **Novartis Found Symp** 1998; 218:308–25; discussion 326–31 (79 ref.)
How do visual instructions influence the motor system? Passingham RE, et al. **Novartis Found Symp** 1998; 218:129–41; discussion 141–6 (52 ref.)
Grasping objects and grasping action meanings: the dual role of monkey rostroventral premotor cortex (area F5). Rizzolatti G, et al. **Novartis Found Symp** 1998;218:81–95; discussion 95–103 (46 ref.)
Motor areas on the medial wall of the hemisphere. Strick PL, et al. **Novartis Found Symp** 1998;218:64–75; discussion 75–80, 104–8 (42 ref.)
Information coding in the cortex by independent or coordinated populations. deCharms RC.
Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15166–8 (36 ref.)
[Functional localization of the somatomotor area by magnetoencephalography] Nagamine T.
Rinsho Shinkeigaku 1999 Jan;39(1):42–3 (4 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Pathophysiology of the motor cortex in patients with Parkinson's disease. Rothwell JC. **Adv Neurol** 1999;80:27–9 (15 ref.)
Intraoperative motor evoked potentials monitoring in spinal neurosurgery. Cioni B, et al. **Arch Ital Biol** 1999 May; 137(2–3):115–26 (36 ref.)
Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398–403 (70 ref.)
Gut feelings about recovery after stroke: the organization and reorganization of human swallowing motor cortex. Hamdy S, et al. **Trends Neurosci** 1998 Jul;21(7):278–82 (45 ref.)
[Do systems theory models promote understanding of disorders of sensorimotor function in neurology?] Glasauer S, et al. **Nervenarzt** 1998 Oct;69(10):919–23 (18 ref.) **(Ger)**

MOTOR ENDPLATE

GROWTH & DEVELOPMENT

Development of larval body wall muscles. Bate M, et al.
Int Rev Neurobiol 1999;43:25–44 (73 ref.)

PHYSIOLOGY

Ionic currents in larval muscles of Drosophila. Singh S, et al. **Int Rev Neurobiol** 1999;43:191–220 (118 ref.)

MOTOR EVOKED POTENTIALS see **EVOKED POTENTIALS, MOTOR**

MOTOR NEURON DISEASE

[Lower motor neuron disease (syndrome) associated with anti GM1 antibodies] Mezaki T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):350–3 (12 ref.) **(Jpn)**
[Hopkins syndrome (acute postasthmatic amyotrophy] Mezaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):354–5 (9 ref.) **(Jpn)**
[Acute motor neuropathy] Nagamatsu M, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):457–60 (7 ref.) **(Jpn)**

CHEMICALLY INDUCED

Neurotoxic mechanisms of degeneration in motor neuron diseases. Ludolph AC, et al. **Drug Metab Rev** 1999 Aug; 31(3):619–34 (75 ref.)
[Motor neuropathy, putamen necrosis and optic nerve atrophy after acute methanol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1998 Dec;154(12):862–5 (12 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Classification and clinical features of motor neurone diseases and motor neuropathies in adults. Donaghy M.
J Neurol 1999 May;246(5):331–3 (13 ref.)

COMPLICATIONS

Ethical and clinical issues in the use of home non-invasive mechanical ventilation for the palliation of breathlessness in motor neurone disease. Polkey MI, et al. **Thorax** 1999 Apr;54(4):367–71 (43 ref.)

DIAGNOSIS

Evaluation and rehabilitation of patients with adult motor neuron disease. Francis K, et al.
Arch Phys Med Rehabil 1999 Aug;80(8):951–63 (132 ref.)
Motor neuron disease and its management. Parton MJ, et al. **J R Coll Physicians Lond** 1999 May–Jun;33(3):212–8 (12 ref.)
Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Mayer NH. **Muscle Nerve Suppl** 1997;6:S1–13 (23 ref.)
Common patterns of clinical motor dysfunction. Mayer NH, et al. **Muscle Nerve Suppl** 1997;6:S21–35 (13 ref.)
Multifocal motor neuropathy: diagnosis and treatment. Pestronk A. **Neurology** 1998 Dec;51(6 Suppl 5):S22–4 (31 ref.)
[Neuroimaging of motor disturbances] Iwata M.
Rinsho Shinkeigaku 1998 Dec;38(12):1010–2 (6 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

IGIV in neurology--evidence and recommendations. Bril V, et al. **Can J Neurol Sci** 1999 May;26(2):139–52 (92 ref.)
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. Miller RG. **J Child Neurol** 1999 Mar;14(3):173–9 (41 ref.)

ENZYMOLOGY

Copper, zinc superoxide dismutase (SOD1) and its role in neuronal function and disease with particular relevance to motor neurone disease/amyotrophic lateral sclerosis. de Belleroche J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):476–80 (36 ref.)
Mutant CuZn superoxide dismutase in motor neuron disease. Gurney ME, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):587–97 (42 ref.)

ETIOLOGY

Motor neurone disease. Shaw PJ. **BMJ** 1999 Apr 24; 318(7191):1118–21 (28 ref.)
Retrograde axonal transport of neurotrophins: differences between neuronal populations and implications for motor neuron disease. Bartlett SE, et al. **Immunol Cell Biol** 1998 Oct;76(5):419–23 (61 ref.)

GENETICS

The genetic and molecular mechanisms of motor neuron disease. Wong PC, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):791–9 (84 ref.)
Mutant CuZn superoxide dismutase in motor neuron disease. Gurney ME, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):587–97 (42 ref.)
Androgen receptor mutation in Kennedy's disease. Fischbeck KH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29;354(1386):1075–8 (26 ref.)

METABOLISM

Oxidative stress and motor neurone disease. Cookson MR, et al. **Brain Pathol** 1999 Jan;9(1):165–86 (148 ref.)
Food toxins, ampa receptors, and motor neuron diseases. Spencer PS. **Drug Metab Rev** 1999 Aug;31(3):561–87 (99 ref.)

PATHOLOGY

Upper motor neuron predominant degeneration with frontal and temporal lobe atrophy. Konagaya M, et al.
Acta Neuropathol (Berl) 1998 Nov;96(5):532–6 (22 ref.)
Motor neuron disease and HIV-1 infection in a 30-year-old HIV-positive heroin abuser: a causal relationship? Galassi G, et al. **Clin Neuropathol** 1998 May–Jun;17(3):131–5 (23 ref.)
[Neuropathology of the motor neuron disease--Bunina body] Kusaka H. **Rinsho Shinkeigaku** 1999 Jan;39(1):65–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Classification and clinical features of motor neurone diseases and motor neuropathies in adults. Donaghy M.
J Neurol 1999 May;246(5):331–3 (13 ref.)
Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Mayer NH. **Muscle Nerve Suppl** 1997;6:S1–13 (23 ref.)

PSYCHOLOGY

Cognition, language and behaviour in motor neurone disease: evidence of frontotemporal dysfunction. Bak TH, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:29–32 (37 ref.)

REHABILITATION

Evaluation and rehabilitation of patients with adult motor neuron disease. Francis K, et al.
Arch Phys Med Rehabil 1999 Aug;80(8):951–63 (132 ref.)

THERAPY

Motor neuron disease and its management. Parton MJ, et al. **J R Coll Physicians Lond** 1999 May–Jun;33(3):212–8 (12 ref.)
Multifocal motor neuropathy: diagnosis and treatment. Pestronk A. **Neurology** 1998 Dec;51(6 Suppl 5):S22–4 (31 ref.)

MOTOR NEURONS

see related
MOTOR NEURON DISEASE
NEUROMUSCULAR JUNCTION

Control of muscle fibre and motoneuron diversification. Hughes SM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):54–64 (102 ref.)

CHEMISTRY

Differential expression and targeting of K+ channel genes in the lobster pyloric central pattern generator. Baro DJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:281–95 (53 ref.)
Vasopressin binding sites in the central nervous system: distribution and regulation. Tribollet E, et al.
Prog Brain Res 1998;119:45–55 (76 ref.)

CYTOLOGY

[Neuropathology of the motor neuron disease--Bunina body] Kusaka H. **Rinsho Shinkeigaku** 1999 Jan;39(1):65–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Mechanical and excitotoxic lesion of motoneurons: effects of neurotrophins and ciliary neurotrophic factor on survival and regeneration. Wiese S, et al.
Acta Neurochir Suppl (Wien) 1999;73:31–9 (53 ref.)

METABOLISM

Specification of neuronal connectivity: ETS marks the spot [comment] Ghosh A, et al. **Cell** 1998 Oct 30;95(3):303–6 (17 ref.) Comment on: Cell 1998 Oct 30;95(3):393–407.
Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture. Estévez AG, et al. **Prog Brain Res** 1998;118:269–80 (114 ref.)

PATHOLOGY

Mechanical and excitotoxic lesion of motoneurons: effects of neurotrophins and ciliary neurotrophic factor on survival and regeneration. Wiese S, et al.
Acta Neurochir Suppl (Wien) 1999;73:31–9 (53 ref.)
Upper motor neuron predominant degeneration with frontal and temporal lobe atrophy. Konagaya M, et al.
Acta Neuropathol (Berl) 1998 Nov;96(5):532–6 (22 ref.)
Axonal atrophy: the retraction reaction. Bernstein M, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):364–70 (52 ref.)

PHYSIOLOGY

Analysis of the central pattern generator for swimming in the mollusk Clione. Arshavsky YI, et al.
Ann N Y Acad Sci 1998 Nov 16;860:51–69 (49 ref.)
Differential expression and targeting of K+ channel genes in the lobster pyloric central pattern generator. Baro DJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:281–95 (53 ref.)
GABAergic control of spinal locomotor networks in the neonatal rat. Cazalets JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:168–80 (58 ref.)
Distributed effects of dopamine modulation in the crustacean pyloric network. Harris-Warrick RM, et al.
Ann N Y Acad Sci 1998 Nov 16;860:155–67 (48 ref.)
How do we approach the locomotor network in the mammalian spinal cord? Hultborn H, et al.

Ann N Y Acad Sci 1998 Nov 16;860:70–82 (36 ref.)
Initiation of locomotion in mammals. Jordan LM. **Ann N Y Acad Sci** 1998 Nov 16;860:83–93 (37 ref.)
Distribution of central pattern generators for rhythmic motor outputs in the spinal cord of limbed vertebrates. Kiehn O, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:110–29 (50 ref.)
Reorganization of locomotor activity during development in the prenatal rat. Kudo N, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:306–17 (36 ref.)
Modeling of the spinal neuronal circuitry underlying locomotion in a lower vertebrate. Lansner A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:239–49 (35 ref.)
Age-associated changes in the innervation of muscle fibers and changes in the mechanical properties of motor units. Luff AR. **Ann N Y Acad Sci** 1998 Nov 20;854:92–101 (67 ref.)
Neuronal basis of afferent-evoked enhancement of locomotor activity. McCrea DA. **Ann N Y Acad Sci** 1998 Nov 16; 860:216–25 (38 ref.)
Frequency control of a slow oscillatory network by a fast rhythmic input: pyloric to gastric mill interactions in the crab stomatogastric nervous system. Marder E, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:226–38 (41 ref.)
Intersegmental coordination of swimmeret movements: mathematical models and neural circuits. Mulloney B, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:266–80 (32 ref.)
Mechanisms of spontaneous activity in the developing spinal cord and their relevance to locomotion. O'Donovan MJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:130–41 (33 ref.)
Central circuits controlling locomotion in young frog tadpoles. Roberts A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:19–34 (39 ref.)
Basic principles for generating motor output in the stomatogastric ganglion. Selverston A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:35–50 (29 ref.)
Analysis and modeling of the locomotor central pattern generator as a network of coupled oscillators. Sigvardt KA, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:250–65 (63 ref.)
Spinal motor patterns in the turtle. Stein PS, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:142–54 (53 ref.)
Incomplete spinal cord injury: neuronal mechanisms of motor recovery and hyperreflexia. Little JW, et al. **Arch Phys Med Rehabil** 1999 May;80(5):587–99 (119 ref.)
Motor unit double discharges: statistical anomaly or functional entity? Garland SJ, et al. **Can J Appl Physiol** 1999 Apr;24(2):113–30 (64 ref.)
Gene regulation by patterned electrical activity during neural and skeletal muscle development. Buonanno A, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):110–20 (111 ref.)
Development and specification of muscle sensory neurons. Chen HH, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):405–9 (33 ref.)
Genetic and molecular analyses of motoneuron development. Eisen JS. **Curr Opin Neurobiol** 1998 Dec;8(6):697–704 (100 ref.)
Functional role of plateau potentials in vertebrate motor neurons. Kiehn O, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):746–52 (39 ref.)
Monitoring activity in neuronal populations with single-cell resolution in a behaving vertebrate. Fetcho JR, et al. **Histochem J** 1998 Mar;30(3):153–67 (34 ref.)
Development of electrical properties and synaptic transmission at the embryonic neuromuscular junction. Broadie KS. **Int Rev Neurobiol** 1999;43:45–67 (39 ref.)
Early development of the Drosophila neuromuscular junction: a model for studying neuronal networks in development. Chiba A. **Int Rev Neurobiol** 1999;43:1–24 (104 ref.)
Development of the adult neuromuscular system. Fernandes JJ, et al. **Int Rev Neurobiol** 1999;43:221–39 (89 ref.)
Assembly and maturation of the Drosophila larval neuromuscular junction. Gramates SL, et al. **Int Rev Neurobiol** 1999;43:93–117 (108 ref.)
Second messenger systems underlying plasticity at the neuromuscular junction. Hannan F, et al. **Int Rev Neurobiol** 1999;43:119–38 (108 ref.)
Ultrastructural correlates of neuromuscular junction development. Rheuben MB, et al. **Int Rev Neurobiol** 1999; 43:69–92 (51 ref.)
Vesicle recycling at the Drosophila neuromuscular junction. Stimson DT, et al. **Int Rev Neurobiol** 1999;43:163–89 (118 ref.)
Controlling the motor neuron. Trimarchi JR, et al. **Int Rev Neurobiol** 1999;43:241–64 (73 ref.)
1998 ISEK Congress Keynote Lecture: Motor units: how many, how large, what kind? International Society of Electrophysiology and Kinesiology. McComas AJ. **J Electromyogr Kinesiol** 1998 Dec;8(6):391–402 (67 ref.)
Mechanisms of spontaneous activity in developing spinal networks. O'Donovan MJ, et al. **J Neurobiol** 1998 Oct; 37(1):131–45 (73 ref.)
Orderly recruitment among motoneurons supplying different muscles. Cope TC, et al. **J Physiol Paris** 1999 Jan-Apr; 93(1-2):81–5 (26 ref.)
Role of neurotrophic factors in motoneuron development. Henderson CE, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):279–81 (13 ref.)
Discharge properties of motoneurones: how are they matched to the properties and use of their muscle units? Kernell D, et al. **J Physiol Paris** 1999 Jan-Apr; 93(1-2):87–96 (84 ref.)
Analysis of firing behaviour of human motoneurones within 'subprimary range'. Kudina LP. **J Physiol Paris** 1999 Jan-Apr;93(1-2):115–23 (22 ref.)
Studies of stimulus-evoked responses in single motoneurones in humans. Miles TS. **J Physiol Paris** 1999 Jan-Apr; 93(1-2):61–9 (14 ref.)
Corticomotoneuronal PSTH studies [editorial; comment] Mills KR. **Muscle Nerve** 1999 Mar;22(3):297–8 (13 ref.) Comment on: Muscle Nerve 1999 Mar;22(3):299–306.
Modification of glutamate receptor channels: molecular mechanisms and functional consequences. Hatt H. **Naturwissenschaften** 1999 Apr;86(4):177–86 (51 ref.)
LIMitless combinations? Appel B. **Neuron** 1999 Jan;22(1):3–5 (11 ref.)
Specifying motor neurons and their connections. Goulding M. **Neuron** 1998 Nov;21(5):943–6 (20 ref.)
Rhythmical corticomotor communication. Hari R, et al. **Neuroreport** 1999 Feb 5;10(2):R1–10 (83 ref.)
Construction of a reach-to-grasp. Gibson AR, et al. **Novartis Found Symp** 1998;218:233–45; discussion 245–51 (39 ref.)
Cerebellum and the sensory guidance of movement. Glickstein M. **Novartis Found Symp** 1998;218:252–66; discussion 266–71, 332–3 (56 ref.)
The importance of the cortico-motoneuronal system for control of grasp. Lemon RN, et al. **Novartis Found Symp** 1998;218:202–15; discussion 215–8 (39 ref.)
The cerebellum, predictive control and motor coordination. Miall RC. **Novartis Found Symp** 1998;218:272–84; discussion 284–90 (35 ref.)
Premotor potentials. Mandel JD. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):765–76, vi (21 ref.)
Vasopressin and oxytocin action in the brain: cellular neurophysiological studies. Raggenbass M, et al. **Prog Brain Res** 1998;119:263–73 (62 ref.)
Differences in the properties of sensory and motor axons. Burke D. **Rinsho Shinkeigaku** 1999 Jan;39(1):97 (5 ref.)
Patterning motoneurons in the vertebrate nervous system. Eisen JS. **Trends Neurosci** 1999 Jul;22(7):321–6 (95 ref.)
[Abnormal hyperexcitability in ALS] Kohara N. **Rinsho Shinkeigaku** 1999 Jan;39(1):61–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Recovery of locomotion following transplantation of monoaminergic neurons in the spinal cord of paraplegic rats. Gimenez y Ribotta M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:393–411 (73 ref.)

MOTOR SKILLS

Voluntary hand movements and brain relations. Robinson RO. **Dev Med Child Neurol** 1998 Nov;40(11):780–4 (14 ref.)

PHYSIOLOGY

Motor skills in motor disorders: measuring performance changes in tracking and other perceptual-motor tasks. Flowers KA. **Adv Neurol** 1999;80:41–8 (36 ref.)
Sex-sensitive tasks in men and women: a search for performance fluctuations across the menstrual cycle. Epting LK, et al. **Behav Neurosci** 1998 Dec;112(6):1304–17 (110 ref.)
Dynamics of effortful touch and interlimb coordination. Turvey MT. **J Biomech** 1998 Oct;31(10):873–82 (74 ref.)
From the big bang to the brain. Bolick CA, et al. **J Commun Disord** 1999 Jul-Aug;32(4):271–6 (12 ref.)
A comparative perspective on motor learning. Striedter GF. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):189–96 (35 ref.)
A role for the cerebellum in learning movement coordination. Thach WT. **Neurobiol Learn Mem** 1998 Jul-Sep; 70(1-2):177–88 (59 ref.)
Combination, complementarity and automatic control: a role for the cerebellum in learning movement coordination. Thach WT. **Novartis Found Symp** 1998;218:219–28; discussion 228–32 (30 ref.)
Functional roles of the proprioceptive system in the control of goal-directed movement. Park S, et al. **Percept Mot Skills** 1999 Apr;88(2):631–47 (60 ref.)

MOTOR SKILLS DISORDERS

REHABILITATION

Intervention approaches and children with developmental coordination disorder. Sugden DA, et al. **Pediatr Rehabil** 1998 Oct-Dec;2(4):139–47 (68 ref.)

MOTOR VEHICLES

see related
ACCIDENTS, TRAFFIC

MOTTLED ENAMEL see **FLUOROSIS, DENTAL**

MOULAGES see **MODELS, ANATOMIC**

MOUNTAINEERING

see related
ALTITUDE

Mountaineering fatalities on Mount Rainier, Washington, 1977–1997: autopsy and investigative findings. Christensen ED, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):173–9 (13 ref.)
Freezing to death—the treatment of accidental hypothermia in the Scottish mountains. Grant P, et al. **Scott Med J** 1998 Apr;43(2):36–7 (4 ref.)

PHYSIOLOGY

Nutrient requirements at high altitude. Butterfield GE. **Clin Sports Med** 1999 Jul;18(3):607–21, viii (86 ref.)
The brain at high altitude. Schoene RB. **Wilderness Environ Med** 1999 Summer;10(2):93–6 (19 ref.)
[Maximum respiratory flow on an expedition to the Himalaya] Borderias Clau L. **Arch Bronconeumol** 1999 May;35 Suppl 3:49–54 (26 ref.) **(Spa)**

MOURNING see **GRIEF**

MOUSE CYTOMEGALOVIRUS see **MUROMEGALOVIRUS**

MOUSE LEUKEMIA VIRUSES see **LEUKEMIA VIRUSES, MURINE**

MOUSE MAMMARY TUMOR VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

MOUSE POLIOVIRUSES see **THEILER MURINE ENCEPHALOMYELITIS VIRUS**

MOUSE THYMIC VIRUS see **HERPESVIRIDAE**

MOUTH

see related
SURGERY, ORAL

BLOOD SUPPLY

Nervous control of blood flow in the orofacial region. Izumi H. **Pharmacol Ther** 1999 Feb;81(2):141–61 (275 ref.)

EMBRYOLOGY

[Cell communication in the development of the oral cavity] Tripi TR, et al. **Minerva Stomatol** 1998 Oct;47(10):519–26 (32 ref.) (Eng. Abstr.) **(Ita)**

GROWTH & DEVELOPMENT

[Cell communication in the development of the oral cavity] Tripi TR, et al. **Minerva Stomatol** 1998 Oct;47(10):519–26 (32 ref.) (Eng. Abstr.) **(Ita)**

INJURIES

Minor oral injuries in children. Banks K, et al. **Mt Sinai J Med** 1998 Oct-Nov;65(5-6):333–42 (29 ref.)

MICROBIOLOGY

Bacterial degradation of immunoglobulin A1 in relation to periodontal diseases. Grønbaek Frandsen EV. **APMIS Suppl** 1999;87:1–54 (333 ref.)
Antibiotic resistance in oral/respiratory bacteria. Roberts MC. **Crit Rev Oral Biol Med** 1998;9(4):522–40 (140 ref.)
Oral pathogens: from dental plaque to cardiac disease. Meyer DH, et al. **Curr Opin Microbiol** 1998 Feb;1(1):88–95 (70 ref.)
Role of oral bacteria in respiratory infection. Scannapieco FA. **J Periodontol** 1999 Jul;70(7):793–802 (87 ref.)
Mouth bacteria as the cause of Paget's disease of bone. Dickinson CJ. **Med Hypotheses** 1999 Mar;52(3):209–12 (41 ref.)

PHYSIOLOGY

Upper airway function and dysfunction in respiration. Pierce RJ, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):1–10 (102 ref.)
The relationship between satisfaction with mouth and number and position of teeth. Elias AC, et al. **J Oral Rehabil** 1998 Sep;25(9):649–61 (118 ref.)
Dynamic control of reversible cell adhesion and actin cytoskeleton in the mouth of Beroë. Tamm SL. **Microsc Res Tech** 1999 Feb 15;44(4):293–303 (40 ref.)

SURGERY

Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Hall G, et al. **Clin Infect Dis** 1999 Jul; 29(1):1–8; quiz 9–10 (86 ref.)
Platysma myocutaneous flap for intraoral reconstruction: an option in the compromised patient. Berenholz L, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):285–7 (11 ref.)

VIROLOGY

Oral transmission of HIV [editorial] Rothenberg RB, et al. **AIDS** 1998 Nov 12;12(16):2095–105 (126 ref.)

MOUTH DISEASES

see related
HALITOSIS

MOUTH DISEASES

MOUTH REHABILITATION
ORAL HEALTH

DIAGNOSIS

Recurrent Kawasaki disease. Pemberton MN, et al. **Br Dent J** 1999 Mar 27;186(6):270–1 (13 ref.)

Lipoid proteinosis of the oral mucosa: case report and review of the literature. Aroni K, et al. **Pathol Res Pract** 1998; 194(12):855–9 (15 ref.)

[Collagen diseases and the involvement of the mouth in childhood] Di Pietro G, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):275–6 (11 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Treatment of oral chronic graft–versus–host disease with PUVA therapy: case report and literature review. Redding SW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):183–7 (28 ref.)

EPIDEMIOLOGY

[Oral health in Europe with changing socioeconomic structures as seen by the epidemiologist] Borutta A. **Gesundheitswesen** 1998 Nov;60(11):672–7 (36 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Oral health and the older diabetic. Martin W. **Clin Geriatr Med** 1999 May;15(2):339–50 (87 ref.)

Human immunodeficiency virus disease in the era of HAART: a reevaluation of the mucocutaneous manifestations. Johnson RA. **Curr Clin Top Infect Dis** 1999; 19:252–86 (210 ref.)

Oropharyngeal lesions in AIDS. Grimes RM, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):783–809 (67 ref.)

Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25–27, 1996. Zain RB, et al. **J Oral Pathol Med** 1999 Jan;28(1):1–4 (15 ref.)

Oral manifestations of systemic diseases. Long RG, et al. **Mt Sinai J Med** 1998 Oct–Nov;65(5–6):309–15 (52 ref.)

Oral manifestations of nutrient deficiencies. Touger–Decker R. **Mt Sinai J Med** 1998 Oct–Nov;65(5–6):355–61 (24 ref.)

Pediatric bone marrow transplantation: oral complications and recommendations for care. da Fonseca MA. **Pediatr Dent** 1998 Nov–Dec;20(7):386–94 (46 ref.)

IMMUNOLOGY

Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Chowdhury MM, et al. **Br J Dermatol** 1998 Sep; 139(3):500–3 (23 ref.)

Intraoral contact allergy: a literature review and case reports [see comments] De Rossi SS, et al. **J Am Dent Assoc** 1998 Oct;129(10):1435–41 (40 ref.) Comment in: J Am Dent Assoc 1999 Jan;130(1):24, 26.

Changing patterns of disease and mucosal immunity. Slavkin HC. **J Am Dent Assoc** 1999 May;130(5):735–8 (16 ref.)

MICROBIOLOGY

[Benign maxillofacial mucormycosis. Report of a case and review of the literature] Cangiano G, et al. **Minerva Stomatol** 1998 Nov;47(11):613–6 (27 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Osseous choristoma of oral cavity—report of two cases and review of the literature. Lin CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):727–33 (47 ref.)

Heterotopic oral gastrointestinal cyst: report of 2 cases and review of the literature. Said–Al–Naief N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jul;88(1):80–6 (91 ref.)

Bilateral congenital oral mucous extravasation cysts. Peters E, et al. **Pediatr Dent** 1999 Jul–Aug;21(4):285–8 (23 ref.)

[Erythema multiforme. A heterogeneous pathologic phenotype] Carrozzo M, et al. **Minerva Stomatol** 1999 May; 48(5):217–26 (83 ref.) (Eng. Abstr.) **(Ita)**

[Hyperpigmented spots on the lips, oral mucosa, fingers and nails] Paricio Rubio JF, et al. **Rev Clin Esp** 1998 Nov; 198(11):769–70 (13 ref.) **(Spa)**

PREVENTION & CONTROL

Prevention of oral diseases by polyphenols (review). Sakagami H, et al. **In Vivo** 1999 Mar–Apr;13(2):155–71 (179 ref.)

Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Barker GJ. **Support Care Cancer** 1999 Jan;7(1):17–20 (16 ref.)

SURGERY

[Progresses in the study of stomatology in China, 1997] Wang D. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):919–20 (0 ref.) **(Chi)**

[The new–generation laser surgical apparatus Doktor in the combined treatment of stomatological disease in an outpatient setting] Prokhonchukov AA, et al. **Stomatologiia (Mosk)** 1998;77(5):44–9 (14 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Pretherapy dental decisions in patients with head and neck cancer. A proposed model for dental decision support. Bruins HH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Sep;86(3):256–67 (71 ref.)

VETERINARY

Mucosotropic papillomavirus infections. Sundberg JP, et al. **Lab Anim Sci** 1998 Jun;48(3):240–2 (25 ref.)

Canine dental disease. Holmstrom SE. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1049–56, v (3 ref.)

Dental diseases of puppies and kittens. Lobprise HB, et al. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):871–93 (19 ref.)

VIROLOGY

Oral manifestations of HIV disease. Sirois DA. **Mt Sinai J Med** 1998 Oct–Nov;65(5–6):322–32 (59 ref.)

MOUTH DRYNESS see **XEROSTOMIA**

MOUTH, EDENTULOUS

see related
DENTURE, COMPLETE
ORAL SURGICAL PROCEDURES, PREPROSTHETIC

MICROBIOLOGY

Porphyromonas gingivalis in an edentulous proband. A case–report. Danser MM, et al. **J Clin Periodontol** 1998 Nov;25(11 Pt 1):933–6 (21 ref.)

MOUTH FLOOR

PATHOLOGY

Neuroendocrine (Merkel cell) carcinoma of the oral mucosa: report of a case with immunohistochemical study and review of the literature. Longo F, et al. **J Oral Pathol Med** 1999 Feb;28(2):88–91 (41 ref.)

MOUTH MUCOSA

DRUG EFFECTS

A brief overview of the oral complications in pediatric oncology patients and suggested management strategies. Chin EA. **ASDC J Dent Child** 1998 Nov–Dec;65(6):468–73 (50 ref.)

New frontiers in the management of chemotherapy–induced mucositis. Spijkervet FK, et al. **Curr Opin Oncol** 1998 Aug; 10 Suppl 1:S23–7 (15 ref.)

Tissue necrosis after subgingival irrigation with fluoride solution. Sjöström S, et al. **J Clin Periodontol** 1999 Apr; 26(4):257–60 (27 ref.)

Factors contributing to adverse soft tissue reactions due to the use of tartar control toothpastes: report of a case and literature review. DeLattre VF. **J Periodontol** 1999 Jul; 70(7):803–7 (36 ref.)

IMMUNOLOGY

Epithelial antimicrobial peptides: review and significance for oral applications. Weinberg A, et al. **Crit Rev Oral Biol Med** 1998;9(4):399–414 (94 ref.)

Oral tolerance and anti–pathological vaccines. Czerkinsky C, et al. **Curr Top Microbiol Immunol** 1999;236:79–91 (50 ref.)

Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. Leigh IM, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S49–57 (90 ref.)

Intraoral contact allergy: a literature review and case reports [see comments] De Rossi SS, et al. **J Am Dent Assoc** 1998 Oct;129(10):1435–41 (40 ref.) Comment in: J Am Dent Assoc 1999 Jan;130(1):24, 26.

MICROBIOLOGY

[Benign maxillofacial mucormycosis. Report of a case and review of the literature] Cangiano G, et al. **Minerva Stomatol** 1998 Nov;47(11):613–6 (27 ref.) (Eng. Abstr.) **(Ita)**

[Antibacterial activity of endodontic medications] Pettini F, et al. **Minerva Stomatol** 1998 Jul–Aug;47(7–8):309–14 (32 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Primary adenoid squamous cell carcinoma of the upper lip associated with a locoregional metastasis: a case report and review of the literature. Blackburn TK, et al. **J Oral Maxillofac Surg** 1999 May;57(5):612–6 (12 ref.)

Plasma cell mucositis: a review and case report. Smith ME, et al. **J Oral Pathol Med** 1999 Apr;28(4):183–6 (11 ref.)

Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25–27, 1996. Zain RB, et al. **J Oral Pathol Med** 1999 Jan;28(1):1–4 (15 ref.)

Oral mucositis in myelosuppressive cancer therapy. Epstein JB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):273–6 (12 ref.)

Multiple canalicular adenomas: a case report and review of the literature. Rousseau A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):346–50 (26 ref.)

Pyodermatitis–pyostomatitis vegetans: report of a case and review of the literature. Soriano ML, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):322–6 (35 ref.)

Lipoid proteinosis of the oral mucosa: case report and review of the literature. Aroni K, et al. **Pathol Res Pract** 1998; 194(12):855–9 (15 ref.)

[Erythema multiforme. A heterogeneous pathologic phenotype] Carrozzo M, et al. **Minerva Stomatol** 1999 May; 48(5):217–26 (83 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

A brief overview of the oral complications in pediatric oncology patients and suggested management strategies. Chin EA. **ASDC J Dent Child** 1998 Nov–Dec;65(6):468–73 (50 ref.)

VIROLOGY

Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431–5 (33 ref.)

MOUTH NEOPLASMS

Fortnightly review: oral cancer. Zakrzewska JM. **BMJ** 1999 Apr 17;318(7190):1051–4 (28 ref.)

Oral cancer and oral effects of anticancer therapy. Barasch A, et al. **Mt Sinai J Med** 1998 Oct–Nov;65(5–6):370–7 (58 ref.)

Oral and oropharyngeal squamous cell carcinoma in young adults: a report on 13 cases and review of the literature. Hart AK, et al. **Otolaryngol Head Neck Surg** 1999 Jun; 120(6):828–33 (24 ref.)

CHEMICALLY INDUCED

Smokeless tobacco and oral cancer: an assessment of evidence derived from laboratory animals. Grasso P, et al. **Food Chem Toxicol** 1998 Nov;36(11):1015–29 (61 ref.)

[Survey of the effects of smoking in an occupational cohort study. Value and limits of a new method] Moulin JJ, et al. **Rev Epidemiol Sante Publique** 1998 Sep;46(4):289–97 (31 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Immunohistochemical study of the expression of human chorionic gonadotropin–beta in oral squamous cell carcinoma. Bhalang K, et al. **Cancer** 1999 Feb 15; 85(4):757–62 (30 ref.)

DIAGNOSIS

Delayed diagnosis of cancer with emphasis on oral cavity cancers. Stoykova M. **Folia Med (Plovdiv)** 1999;41(1):132–5 (20 ref.)

Oral lymphoma in human immunodeficiency virus infection: a report of six cases and review of the literature. Jordan RC, et al. **Otolaryngol Head Neck Surg** 1998 Dec; 119(6):672–7 (43 ref.)

Squamous cell carcinoma of the oropharynx and oral cavity: how imaging makes a difference. Mukherji SK, et al. **Semin Ultrasound CT MR** 1998 Dec;19(6):463–75 (19 ref.)

[A clinical case of primary malignant melanoma of the oral cavity] Colella G, et al. **Minerva Stomatol** 1998 Oct; 47(10):535–40 (25 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Intra–oral squamous cell carcinoma in Ibadan: a review of 90 cases. Lawoyin JO, et al. **Afr J Med Med Sci** 1997 Sep–Dec;26(3–4):187–8 (13 ref.)

ETIOLOGY

Aetiology of oral cancer: alcohol. Ogden GR, et al. **Br J Oral Maxillofac Surg** 1998 Aug;36(4):247–51 (57 ref.)

Is pan masala–containing tobacco carcinogenic? Chaudhry K. **Natl Med J India** 1999 Jan–Feb;12(1):21–7 (78 ref.)

The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Lo Muzio L, et al. **Oral Oncol** 1998 Jul;34(4):239–46 (90 ref.)

Possible mechanisms by which alcohol may influence the development of oral cancer—a review. Wight AJ, et al. **Oral Oncol** 1998 Nov;34(6):441–7 (99 ref.)

PATHOLOGY

Intra–oral squamous cell carcinoma in Ibadan: a review of

90 cases. Lawoyin JO, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):187-8 (13 ref.)
Protocol for the examination of specimens removed from patients with carcinomas of the upper aerodigestive tract: carcinomas of the oral cavity including lip and tongue, nasal and paranasal sinuses, pharynx, larynx, salivary glands, hypopharynx, oropharynx, and nasopharynx. Cancer Committee, College of American Pathologists. Min KW, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):222-30 (58 ref.)
Fluorescence spectroscopy: a technique with potential to improve the early detection of aerodigestive tract neoplasia. Gillenwater A, et al. **Head Neck** 1998 Sep;20(6):556-62 (23 ref.)
Adenosquamous carcinoma of the mouth: a rare variant of squamous cell carcinoma. Scully C, et al.
Int J Oral Maxillofac Surg 1999 Apr;28(2):125-8 (24 ref.)
Infiltrating angiolipoma of the mucolabial fold: a case report and review of the literature. Sugiura J, et al.
J Oral Maxillofac Surg 1999 Apr;57(4):446-8 (9 ref.)
Neuroendocrine (Merkel cell) carcinoma of the oral mucosa: report of a case with immunohistochemical study and review of the literature. Longo F, et al.
J Oral Pathol Med 1999 Feb;28(2):88-91 (41 ref.)
Benign mesenchymoma of the cheek: report of a case and review of the literature. Sakurai K, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Jul;88(1):74-9 (24 ref.)
[Malignant tumors of the mouth cavity and oropharynx. Stage classification] Youssefzadeh S, et al. **Radiologe** 1999 Jul;39(7):513-24 (18 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Epidermal growth factor receptor (EGFR) biology and human oral cancer. Todd R, et al. **Histol Histopathol** 1999 Apr;14(2):491-500 (107 ref.)

PREVENTION & CONTROL

Oral cancer in the UK: to screen or not to screen. Rodrigues VC, et al. **Oral Oncol** 1998 Nov;34(6):454-65 (142 ref.)
[Correlation between dietary vitamin A consumption and onset of precancerous lesions in the oral cavity] Cianfriglia F, et al. **Minerva Stomatol** 1998 Jul-Aug;47(7-8):325-43 (32 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

A review of quality of life assessment in oral cancer. Rogers SN, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):99-117 (118 ref.)

SECONDARY

Primary adenoid squamous cell carcinoma of the upper lip associated with a locoregional metastasis: a case report and review of the literature. Blackburn TK, et al.
J Oral Maxillofac Surg 1999 May;57(5):612-6 (12 ref.)

SURGERY

Surgical management of the neck in squamous cell carcinoma of the floor of the mouth. Zupi A, et al. **Oral Oncol** 1998 Nov;34(6):472-5 (12 ref.)

VETERINARY

Maxillofacial surgery. Marretta SM.
Vet Clin North Am Small Anim Pract 1998 Sep; 28(5):1285-96, viii (29 ref.)

VIROLOGY

Molecular piracy: the viral link to carcinogenesis. Flaitz CM, et al. **Oral Oncol** 1998 Nov;34(6):448-53 (22 ref.)

MOUTH REHABILITATION

Considerations when planning occlusal rehabilitation: a review of the literature. Wassell RW, et al. **Int Dent J** 1998 Dec;48(6):571-81 (116 ref.)

MOUTH-TO-MOUTH RESUSCITATION see **CARDIOPULMONARY RESUSCITATION**

MOUTH ULCER see **ORAL ULCER**

MOUTHWASHES

see related
DENTIFRICES

MOVEMENT

see related
IMMOBILIZATION
MOTION

Set-up error & organ motion uncertainty: a review. Booth JT, et al. **Australas Phys Eng Sci Med** 1999 Jun;22(2):29-47 (84 ref.)
The skin and its response to movement. Ryan TJ.
Lymphology 1998 Sep;31(3):128-9 (4 ref.)
Limited joint mobility in diabetes. Aljahlan M, et al.
Postgrad Med 1999 Feb;105(2):99-101, 105-6 (20 ref.)

DRUG EFFECTS

Pharmacological inactivation in the analysis of the central control of movement. Martin JH, et al.
J Neurosci Methods 1999 Jan;86(2):145-59 (63 ref.)

PHYSIOLOGY

Complex movement patterns: modifiability and constraints. Bout RG. **Acta Anat (Basel)** 1998;163(3):144-56 (79 ref.)
Neural systems for control of voluntary action--a hypothesis. Hikosaka O. **Adv Biophys** 1998;35:81-102 (43 ref.)
Task-dependent reduction of the number of degrees of freedom in sensorimotor systems. Gielen CC, et al.
Brain Res Brain Res Rev 1998 Nov;28(1-2):136-42 (71 ref.)
Body orientation and control of coordinated movements in microgravity. Massion J, et al.
Brain Res Brain Res Rev 1998 Nov;28(1-2):83-91 (48 ref.)
The sensorimotor and cognitive integration of gravity. Pozzo T, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):92-101 (42 ref.)
A role for the cerebellum in the control of limb movement velocity. Ebner TJ. **Curr Opin Neurobiol** 1998 Dec; 8(6):762-9 (71 ref.)
Yawning and stretching--a behavioral syndrome associated with transcranial application of electromagnetic fields in multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul; 95(1-2):107-13 (47 ref.)
A theory of geometric constraints on neural activity for natural three-dimensional movement. Zhang K, et al.
J Neurosci 1999 Apr 15;19(8):3122-45 (124 ref.)
Pharmacological inactivation in the analysis of the central control of movement. Martin JH, et al.
J Neurosci Methods 1999 Jan;86(2):145-59 (63 ref.)
Undifferentiated lingual gestures in children with articulation/phonological disorders. Gibbon FE.
J Speech Lang Hear Res 1999 Apr;42(2):382-97 (76 ref.)
A new view on grasping [see comments] Smeets JB, et al. **Motor Control** 1999 Jul;3(3):237-71 (86 ref.) Comment in: Motor Control 1999 Jul;3(3):272-5; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):276-9; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):280-4; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):285-8; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):289-97; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):298-301; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):302-6; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):307-11; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):312-5; discussion 316-25.
A cerebellar model of timing and prediction in the control of reaching. Barto AG, et al. **Neural Comput** 1999 Apr 1;11(3):565-94 (90 ref.)
A comparative perspective on motor learning. Striedter GF. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):189-96 (35 ref.)
Who tells one hand what the other is doing: the neurophysiology of bimanual movements. Donchin O, et al. **Neuron** 1999 May;23(1):15-8 (20 ref.)
From eye to hand: planning goal-directed movements. Desmurget M, et al. **Neurosci Biobehav Rev** 1998 Oct; 22(6):761-88 (275 ref.)
Impaired movement control in Alzheimer's disease. Ghilardi MF, et al. **Neurosci Lett** 1999 Jan 22;260(1):45-8 (20 ref.)
Online visual control of the arm. Georgopoulos AP.
Novartis Found Symp 1998;218:147-64; discussion 164-70 (42 ref.)
Construction of a reach-to-grasp. Gibson AR, et al.
Novartis Found Symp 1998;218:233-45; discussion 245-51 (39 ref.)
Cerebellum and the sensory guidance of movement. Glickstein M. **Novartis Found Symp** 1998;218:252-66; discussion 266-71, 332-3 (56 ref.)
Vision for perception and vision for action in the primate brain. Goodale MA. **Novartis Found Symp** 1998;218:21-34; discussion 34-9 (47 ref.)
Grasping an object: one movement, several components. Jeannerod M, et al. **Novartis Found Symp** 1998;218:5-16; discussion 16-20 (41 ref.)
Internal models for motor control. Kawato M, et al.
Novartis Found Symp 1998;218:291-304; discussion 304-7 (35 ref.)
The importance of the cortico-motoneuronal system for control of grasp. Lemon RN, et al.
Novartis Found Symp 1998;218:202-15; discussion 215-8 (39 ref.)
Motor areas on the medial wall of the hemisphere. Strick PL, et al. **Novartis Found Symp** 1998;218:64-75; discussion 75-80, 104-8 (42 ref.)
Combination, complementarity and automatic control: a role for the cerebellum in learning movement coordination. Thach WT. **Novartis Found Symp** 1998;218:219-28; discussion 228-32 (30 ref.)
Functional roles of the proprioceptive system in the control of goal-directed movement. Park S, et al.
Percept Mot Skills 1999 Apr;88(2):631-47 (60 ref.)
Neuromuscular control: introduction and overview. van Leeuwen JL. **Philos Trans R Soc Lond B Biol Sci** 1999 May 29;354(1385):841-7 (33 ref.)
Movement-related gating of climbing fibre input to cerebellar cortical zones. Apps R. **Prog Neurobiol** 1999 Apr; 57(5):537-62 (138 ref.)
Involvement of basal ganglia transmitter systems in movement initiation. Hauber W. **Prog Neurobiol** 1998 Dec; 56(5):507-40 (365 ref.)

MOVEMENT, CELL see **CELL MOVEMENT**

MOVEMENT DISORDER AGENTS see **ANTI-DYSKINESIA AGENTS**

MOVEMENT DISORDER, STEREOTYPIC see **STEREOTYPIC MOVEMENT DISORDER**

MOVEMENT DISORDERS

see related
PSYCHOMOTOR DISORDERS

Gait disorders. Cantor CR. **Clin Podiatr Med Surg** 1999 Jan; 16(1):141-51 (10 ref.)
Movement disorders. Colcher A. **Clin Podiatr Med Surg** 1999 Jan;16(1):127-39 (34 ref.)
The limping child. Lawrence LL.
Emerg Med Clin North Am 1998 Nov;16(4):911-29, viii (31 ref.)
[Pure akinesia] Nakamura T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):70-3 (15 ref.) **(Jpn)**

COMPLICATIONS

Practical aspects of drug treatment in elderly patients with mobility problems. Thwaites JH. **Drugs Aging** 1999 Feb; 14(2):105-14 (47 ref.)
Female voiding dysfunction and movement disorders. Dmochowski RR.
Int Urogynecol J Pelvic Floor Dysfunct 1999;10(2):144-51 (36 ref.)
[Motor paroxysmal disorders] López-Terradas Covisa JM. **Rev Neurol** 1999 Jan 1-15;28(1):89-97 (58 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Development of perception in action in healthy and at-risk children. van der Meer AL, et al. **Acta Paediatr Suppl** 1999 May;88(429):29-36 (36 ref.)
Theoretical basis and problems of quantification of movement disorders. Kraus PH, et al. **Adv Neurol** 1999;80:443-5 (10 ref.)
The alien hand sign--case report and review of the literature. Tow AM, et al. **Ann Acad Med Singapore** 1998 Jul; 27(4):582-5 (29 ref.)
Differential diagnosis of parkinsonism. Stoessl AJ, et al.
Can J Neurol Sci 1999 Aug;26 Suppl 2:S1-4 (30 ref.)
Gait analysis in the therapeutic environment. Coutts F.
Man Ther 1999 Feb;4(1):2-10 (57 ref.)
[Non-epileptic paroxysmal movement disorders] Klein C, et al. **Nervenarzt** 1998 Aug;69(8):647-59 (177 ref.) (Eng. Abstr.) **(Ger)**
[Various practical considerations in the management of movement disorders in children] Fernández-Alvarez E. **Rev Neurol** 1999 Jan 1-15;28(1):53-6 (14 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Wenning GK, et al. **Adv Neurol** 1999;80:545-8 (25 ref.)
The role of botulinus toxin type A in treatment--with special reference to children. Gordon N. **Brain Dev** 1999 Apr; 21(3):147-51 (25 ref.)
Treating and preventing levodopa-induced dyskinesias: current and future strategies. Durif F. **Drugs Aging** 1999 May;14(5):337-45 (49 ref.)
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. Melamed E, et al. **J Neural Transm Suppl** 1999; 56:173-83 (40 ref.)

ETIOLOGY

Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Wenning GK, et al. **Adv Neurol** 1999;80:545-8 (25 ref.)
Cavernous angioma presenting with hemidystonia. Akbostanci MC, et al. **Clin Neurol Neurosurg** 1998 Sep; 100(3):234-7 (16 ref.)
Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. Jeste DV, et al. **J Psychiatr Res** 1998 May-Aug;32(3-4):201-14 (102 ref.)
Selected legal issues in movement disorders. Nora LM, et al. **Neurol Clin** 1999 May;17(2):257-66 (41 ref.)

GENETICS

Impaired motor coordination in mice lacking prion protein. Katamine S, et al. **Cell Mol Neurobiol** 1998 Dec; 18(6):731-42 (56 ref.)
[Channelopathies: a genetic explanation of migraine and other paroxysmal neurologic disorders] Terwindt GM, et al.
Ned Tijdschr Geneeskd 1998 May 2;142(18):1015-9 (20 ref.) (Eng. Abstr.) **(Dut)**

MOVEMENT DISORDERS

IMMUNOLOGY

Movement disorders of autoimmune origin. Valldeoriola F. **J Neurol** 1999 Jun;246(6):423–31 (72 ref.)

METABOLISM

Movement disorders with tau protein cytoskeletal pathology. Jellinger KA. **Adv Neurol** 1999;80:303–11 (36 ref.)

PATHOLOGY

Movement disorders with tau protein cytoskeletal pathology. Jellinger KA. **Adv Neurol** 1999;80:303–11 (36 ref.)

PHYSIOPATHOLOGY

Motor skills in motor disorders: measuring performance changes in tracking and other perceptual-motor tasks. Flowers KA. **Adv Neurol** 1999;80:41–8 (36 ref.)

Functional brain networks in movement disorders [editorial] Eidelberg D. **Curr Opin Neurol** 1998 Aug;11(4):319–26 (41 ref.)

Experimental developments in movement disorders: update on proposed free radical mechanisms. Przedborski S, et al. **Curr Opin Neurol** 1998 Aug;11(4):335–9 (339 ref.)

The paroxysmal dyskinesias. Bhatia KP. **J Neurol** 1999 Mar; 246(3):149–55 (56 ref.)

Orofacial dyskinesias and dystonia in rats infected with Borna disease virus; a model for tardive dyskinetic syndromes. Solbrig M, et al. **Mol Psychiatry** 1999 Jul;4(4):310–2 (40 ref.)

The apraxias are higher-order defects of sensorimotor integration. Marsden CD. **Novartis Found Symp** 1998; 218:308–25; discussion 326–31 (79 ref.)

Multiple sclerosis potpourri. Paroxysmal symptoms, seizures, fatigue, pregnancy, and more. Taylor RS. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):551–9, vi (31 ref.)

Pathophysiology of akinetic movement disorders: a paradigm for studies in fibromyalgia? Burgunder JM. **Z Rheumatol** 1998;57 Suppl 2:27–30 (21 ref.)

PREVENTION & CONTROL

Treating and preventing levodopa-induced dyskinesias: current and future strategies. Durif F. **Drugs Aging** 1999 May;14(5):337–45 (49 ref.)

[Ergonomic aspects in the prevention of occupational cumulative trauma disorders of the locomotor system] Swat K. **Med Pr** 1998;49(6):589–602 (37 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Cerebral implantation in movement disorders: state of the art [editorial] Lindvall O. **Mov Disord** 1999 Mar;14(2):201–5 (48 ref.)

The treatment of movement disorders using Gamma Knife stereotactic radiosurgery. Duma CM, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):379–89 (41 ref.)

Surgical palliation of dyskinesiae in Parkinson's disease. Brophy BP. **Stereotact Funct Neurosurg** 1998; 70(2–4):107–13 (31 ref.)

THERAPY

Chronic deep brain stimulation for movement disorders. Caparros-Lefebvre D, et al. **Adv Tech Stand Neurosurg** 1999;25:61–136; discussion 136–8 (208 ref.)

Long-term electrical inhibition of deep brain targets in movement disorders. Benabid AL, et al. **Mov Disord** 1998; 13 Suppl 3:119–25 (19 ref.)

[Neurosurgical treatment of abnormal movement disorders and spasticity] Heikkinen E. **Duodecim** 1995; 111(21):2058–65 (17 ref.) **(Fin)**

MOXIBUSTION

Treatment of tennis elbow by acupuncture and moxibustion. Guo Z, et al. **J Tradit Chin Med** 1998 Dec;18(4):304–7 (14 ref.)

A clinical study on acupuncture for prevention and treatment of toxic side-effects during radiotherapy and chemotherapy. Zhou J, et al. **J Tradit Chin Med** 1999 Mar; 19(1):16–21 (19 ref.)

MOXISYLYTE

THERAPEUTIC USE

Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. Marquer C, et al. **Fundam Clin Pharmacol** 1998; 12(4):377–87 (44 ref.)

MOYAMOYA DISEASE

see related
SUBARACHNOID HEMORRHAGE

COMPLICATIONS

Central deafness in a young child with Moyamoya disease: paternal linkage in a Caucasian family: two case reports and a review of the literature. Setzen G, et al. **Int J Pediatr Otorhinolaryngol** 1999 Apr 25;48(1):53–76 (115 ref.)

Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease. Tsuruta D, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):35–8 (17 ref.)

DIAGNOSIS

Moyamoya disease and pregnancy: case report and review of the literature. Komiyama M, et al. **Neurosurgery** 1998 Aug;43(2):360–8; discussion 368–9 (64 ref.)

[Moyamoya disease. A case report and review of the literature] Bretón Peña A, et al. **An Esp Pediatr** 1999 Jan; 50(1):65–8 (20 ref.) **(Spa)**

ETIOLOGY

Symptomatic moyamoya disease and aortic coarctation in a patient with Noonan's syndrome: strategies for management. Schuster JM, et al. **Pediatr Neurosurg** 1999 Apr;30(4):206–10 (37 ref.)

GENETICS

Central deafness in a young child with Moyamoya disease: paternal linkage in a Caucasian family: two case reports and a review of the literature. Setzen G, et al. **Int J Pediatr Otorhinolaryngol** 1999 Apr 25;48(1):53–76 (115 ref.)

SURGERY

Use of propofol and sevoflurane in moyamoya disease--case reports and literature review. Khan-Ghori SN, et al. **Middle East J Anesthesiol** 1999 Feb;15(1):73–83 (39 ref.)

[Cerebral revascularization surgery for moyamoya disease] Houkin K. **No Shinkei Geka** 1999 Mar;27(3):211–22 (33 ref.) **(Jpn)**

[Indirect anastomoses for moyamoya disease] Matsushima Y. **No Shinkei Geka** 1998 Sep;26(9):769–86 (92 ref.) **(Jpn)**

MPGN see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MPL LIGAND see **THROMBOPOIETIN**

MPTP see **1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE**

MR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

MR TOMOGRAPHY see **MAGNETIC RESONANCE IMAGING**

MR TOMOGRAPHY, ECHO-PLANAR see **ECHO-PLANAR IMAGING**

MRI ANGIOGRAPHY see **MAGNETIC RESONANCE ANGIOGRAPHY**

MRI, FUNCTIONAL see **MAGNETIC RESONANCE IMAGING**

MRI SCANS see **MAGNETIC RESONANCE IMAGING**

MRNA see **RNA, MESSENGER**

MRNA LEADER SEQUENCES see **5' UNTRANSLATED REGIONS**

MRNA, NON-POLYADENYLATED see **RNA, MESSENGER**

MRNA, POLYADENYLATED see **RNA, MESSENGER**

MSG see **SODIUM GLUTAMATE**

MSH

PHARMACOLOGY

Melanocortins and cardiovascular regulation. Versteeg DH, et al. **Eur J Pharmacol** 1998 Oct 30;360(1):1–14 (102 ref.)

PHYSIOLOGY

[The central melanocortin system and its role in energy homeostasis] Cone RD. **Ann Endocrinol (Paris)** 1999 Mar; 60(1):3–9 (50 ref.) (Eng. Abstr.) **(Fre)**

MSH, ALPHA see **ALPHA-MSH**

MTDNA see **DNA, MITOCHONDRIAL**

MTS1 GENES see **GENES, P16**

MTS1 PROTEIN see **PROTEIN P16**

MU-CHAIN DISEASE see **HEAVY CHAIN DISEASE**

MU IMMUNOGLOBULINS see **IMMUNOGLOBULINS, MU-CHAIN**

MU RECEPTORS see **RECEPTORS, OPIOID, MU**

MUC1 MUCIN see **CA-15-3 ANTIGEN**

MUCINOSES

PATHOLOGY

Self-healing juvenile cutaneous mucinosis. Aydingöz IE, et al. **Dermatology** 1999;199(1):57–9 (8 ref.)

VIROLOGY

Cutaneous mucinoses and HIV infection. Rongioletti F, et al. **Br J Dermatol** 1998 Dec;139(6):1077–80 (23 ref.)

MUCINOSIS, FOLLICULAR

COMPLICATIONS

Syringolymphoid hyperplasia and follicular mucinosis in a patient with cutaneous T-cell lymphoma. Tannous Z, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):303–8 (8 ref.)

MUCINS

Mammalian reproductive tract mucins. Lagow E, et al. **Hum Reprod Update** 1999 Jul–Aug;5(4):280–92 (143 ref.)

ANALYSIS

Strategic biochemical analysis of mucins. Van Klinken BJ, et al. **Anal Biochem** 1998 Dec 1;265(1):103–16 (88 ref.)

Expression of sulfated carbohydrate in Barrett's esophagus: sugar for sure? [editorial; comment] Adachi M, et al. **J Gastroenterol** 1998 Dec;33(6):914–5 (10 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):811–5.

GENETICS

Mucin gene and antigen expression in biliopancreatic carcinogenesis. Kim YS, et al. **Ann Oncol** 1999;10 Suppl 4:51–5 (31 ref.)

Mucin gene expression in the rat middle ear: an improved method for RNA harvest. Lin J, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):762–8 (36 ref.)

Mucin gene expression and mucin secretion in human airway epithelium. Yoon JH, et al. **Rhinology** 1998 Dec; 36(4):146–52 (71 ref.)

METABOLISM

The Sixth John M. Kinney-Nestlé Clinical Nutrition Award for Enteral Nutrition. Recombinant human tumor necrosis factor and recombinant murine interleukin-1 alter the binding of Escherichia coli to intestine, mucin glycoprotein, and the HT29-C1 intestinal cell line: a context [see comments] Wanke CA. **Nutrition** 1999 Jun;15(6):427–9 (20 ref.) Comment in: Nutrition 1999 Jun;15(6):430.

Signet ring cell adenoma of the thyroid with mucin predominance. Yoshida J, et al. **Thyroid** 1999 Apr; 9(4):401–4 (14 ref.)

PHYSIOLOGY

Intestinal mucins in colonization and host defense against pathogens. Belley A, et al. **Am J Trop Med Hyg** 1999 Apr; 60(4 Suppl):10–5 (56 ref.)

Mucin expression and function in the female reproductive tract. Carson DD, et al. **Hum Reprod Update** 1998 Sep–Oct; 4(5):459–64 (53 ref.)

Some practical implications of the milk mucins. Patton S. **J Dairy Sci** 1999 Jun;82(6):1115–7 (11 ref.)

SECRETION

Mucin hypersecreting neoplasms. Carr-Locke DL. **Ann Oncol** 1999;10 Suppl 4:99–103 (24 ref.)

Mucin gene expression and mucin secretion in human airway epithelium. Yoon JH, et al. **Rhinology** 1998 Dec; 36(4):146–52 (71 ref.)

MUCOCELE

COMPLICATIONS

Hematuria: an unusual presentation for mucocele of the appendix. Case report and review of the literature. Oliphant UJ, et al. **JSLS** 1999 Jan–Mar;3(1):71–4 (4 ref.)

RADIOGRAPHY

Concha bullosa pyocele--undiagnosed for 3 years. Dawlatly EE, et al. **Rhinology** 1999 Jun;37(2):90–2 (7 ref.)

SURGERY

Neurosurgical aspects of sphenoid sinus mucocele. Iqbal J, et al. **Br J Neurosurg** 1998 Dec;12(6):527–30 (23 ref.)

Intradural extension of mucocele complicating frontoethmoid sinus osteoma: case report. Manaka H, et al. **Surg Neurol** 1998 Nov;50(5):453–6 (13 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of dacryocystocele: a possible marker for syndromes. Sharony R, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):71–3 (14 ref.)

MUCOCILIARY CLEARANCE

Recirculation of mucus as a cause of persistent sinusitis. Kane KJ. **Am J Rhinol** 1997 Sep–Oct;11(5):361–9 (9 ref.)
Physiotherapy and bronchial mucus transport. van der Schans CP, et al. **Eur Respir J** 1999 Jun;13(6):1477–86 (121 ref.)

PHYSIOLOGY

The management of postnasal drip. Forer M, et al. **Aust Fam Physician** 1999 Mar;28(3):223–8 (22 ref.)
Mucociliary transport and its assessment: a review. Lale AM, et al. **Clin Otolaryngol** 1998 Oct;23(5):388–96 (121 ref.)
The rheology of nasal mucus: a review. Quraishi MS, et al. **Clin Otolaryngol** 1998 Oct;23(5):403–13 (128 ref.)
Regulation of mucociliary clearance in health and disease [see comments] Houtmeyers E, et al. **Eur Respir J** 1999 May;13(5):1177–88 (98 ref.) Comment in: Eur Respir J 1999 May;13(5):949–50.
Airway secretion and asthma [editorial;; comment] Smaldone GC. **Respiration** 1999;66(2):110–1 (4 ref.) Comment on: Respiration 1999 ;66(2):112–8.

MUCOCILIARY TRANSPORT see **MUCOCILIARY CLEARANCE**

MUCOCUTANEOUS LYMPH NODE SYNDROME

Kawasaki disease. Taubert KA, et al. **Am Fam Physician** 1999 Jun;59(11):3093–102, 3107–8 (40 ref.)
Report of the National Institutes of Health Workshop on Kawasaki Disease. Barron KS, et al. **J Rheumatol** 1999 Jan;26(1):170–90 (175 ref.)
Epidemiology, etiology, and management of Kawasaki disease: state of the art. Laupland KB, et al. **Pediatr Cardiol** 1999 May–Jun;20(3):177–83 (105 ref.)
Kawasaki syndrome. Rowley AH, et al. **Pediatr Clin North Am** 1999 Apr;46(2):313–29 (109 ref.)
[Kawasaki disease] Ayusawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):102–6 (15 ref.) **(Jpn)**

COMPLICATIONS

Kawasaki disease complicated by peripheral gangrene. Chang JS, et al. **Pediatr Cardiol** 1999 Mar–Apr;20(2):139–42 (7 ref.)

DIAGNOSIS

Recurrent Kawasaki disease. Pemberton MN, et al. **Br Dent J** 1999 Mar 27;186(6):270–1 (13 ref.)
[Atherosclerotic coronary ectasia or a lymphomucocutaneous syndrome in an adult (Kawasaki's disease)?] Lekuona I, et al. **Rev Esp Cardiol** 1999 Jan;52(1):63–6 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome] Marcinkiewicz J, et al. **Przegl Lek** 1998;55(11):611–3 (27 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The etiology of Kawasaki disease: superantigen or conventional antigen? Rowley AH. **Pediatr Infect Dis J** 1999 Jan;18(1):69–70 (13 ref.)
[Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome] Marcinkiewicz J, et al. **Przegl Lek** 1998;55(11):611–3 (27 ref.) (Eng. Abstr.) **(Pol)**

MUCOLYTIC AGENTS see **EXPECTORANTS**

MUCOPOLYSACCHARIDES see **GLYCOSAMINOGLYCANS**

MUCOPOLYSACCHARIDOSIS I

[Alder–Reilly anomaly] Shinjo K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):59–60 (14 ref.) **(Jpn)**

COMPLICATIONS

Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation [editorial; comment] Peters C, et al. **Pediatr Transplant** 1998 Nov;2(4):250–3 (20 ref.) Comment on: Pediatr Transplant 1998 Nov;2(4):299–304.

THERAPY

Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation [editorial; comment] Peters C, et al. **Pediatr Transplant** 1998 Nov;2(4):250–3 (20 ref.) Comment on: Pediatr Transplant 1998 Nov;2(4):299–304.

MUCOPOLYSACCHARIDOSIS II

COMPLICATIONS

Acute airway obstruction in Hunter syndrome. Yoskovitch A, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10; 44(3):273–8 (18 ref.)

GENETICS

Hunter disease in the Spanish population: molecular analysis in 31 families. Gort L, et al. **J Inherit Metab Dis** 1998 Aug;21(6):655–61 (18 ref.)

MUCOPOLYSACCHARIDOSIS IV

DIAGNOSIS

Morquio's syndrome. A case report and review of clinical findings. Fitzgerald J, et al. **N Y State Dent J** 1998 Oct; 64(8):48–50 (8 ref.)

MUCOPOLYSACCHARIDOSIS V see **MUCOPOLYSACCHARIDOSIS I**

MUCOPOLYSACCHARIDOSIS VI

PATHOLOGY

Mild form of Maroteaux–Lamy syndrome: corneal histopathology and ultrastructure. Laver NM, et al. **Cornea** 1998 Nov;17(6):664–8 (25 ref.)

MUCOPOLYSACCHARIDOSIS VII

COMPLICATIONS

Intrauterine growth acceleration in the case of a severe form of mucopolysaccharidosis type VII. Tokieda K, et al. **J Perinat Med** 1998;26(3):235–9 (12 ref.)

PATHOLOGY

Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. Vogler C, et al. **J Inherit Metab Dis** 1998 Aug;21(5):575–86 (41 ref.)

THERAPY

Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. Vogler C, et al. **J Inherit Metab Dis** 1998 Aug;21(5):575–86 (41 ref.)

MUCOPROTEINS

IMMUNOLOGY

MAdCAM-1 dependent colonization of developing lymph nodes involves a unique subset of CD4+CD3– hematolymphoid cells. Mebius RE, et al. **Cell Adhes Commun** 1998;6(2–3):97–103 (50 ref.)
An endogenous human immunostimulant acting on mononuclear phagocytes: a study in laboratory mice. Briend E, et al. **Res Immunol** 1998 Sep–Oct;149(7–8):703–9 (40 ref.)

MUCORMYCOSIS

Pulmonary mucormycosis: the last 30 years. Lee FY, et al. **Arch Intern Med** 1999 Jun 28;159(12):1301–9 (98 ref.)
[Rhinocerebral mucormycosis and systemic mucormycosis] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):367–8 (4 ref.) **(Jpn)**

COMPLICATIONS

Fatal invasive gastric mucormycosis occurring with emphysematous gastritis: case report and literature review. Cherney CL, et al. **Am J Gastroenterol** 1999 Jan;94(1):252–6 (31 ref.)
Two cases of disseminated mucormycosis in patients with hematological malignancies and literature review. Cuvelier I, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec; 17(12):859–63 (15 ref.)

DIAGNOSIS

Two cases of disseminated mucormycosis in patients with hematological malignancies and literature review. Cuvelier I, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec; 17(12):859–63 (15 ref.)
Primary renal mucormycosis. Lussier N, et al. **Urology** 1998 Nov;52(5):900–3 (22 ref.)
[Benign maxillofacial mucormycosis. Report of a case and review of the literature] Cangiano G, et al. **Minerva Stomatol** 1998 Nov;47(11):613–6 (27 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Rhinocerebral mucormycosis in patients with burns: case report and review of the literature. Stern LE, et al. **J Burn Care Rehabil** 1999 Jul–0Aug;20(4):303–6 (33 ref.)

PATHOLOGY

Zygomycosis due to Apophysomyces elegans: report of 2 cases and review of the literature. Kimura M, et al. **Arch Pathol Lab Med** 1999 May;123(5):386–90 (22 ref.)

MUCOSA see **MUCOUS MEMBRANE**

MUCOSAL DISEASE VIRUS see **DIARRHEA VIRUS, BOVINE VIRAL**

MUCOSAL IMMUNITY see **IMMUNITY, MUCOSAL**

MUCOSAL TISSUE see **MUCOUS MEMBRANE**

MUCOUS MEMBRANE

Alcohol intake-associated skin and mucosal cancer. Merimsky O, et al. **Clin Dermatol** 1999 Jul–Aug; 17(4):447–55 (48 ref.)

IMMUNOLOGY

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Zeitlin L, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):54–64 (127 ref.)

METABOLISM

Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Rothenberg ME. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):291–5 (37 ref.)

SURGERY

[Endoscopic resection of the digestive tract mucosa] de la Torre Bravo A. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4 Suppl 1):S32–7 (30 ref.) (Eng. Abstr.) **(Spa)**

MUCOVISCIDOSIS see **CYSTIC FIBROSIS**

MUCUS

METABOLISM

Physiological basis of cystic fibrosis: a historical perspective. Quinton PM. **Physiol Rev** 1999 Jan;79(1 Suppl):S3–S22 (277 ref.)

PHYSIOLOGY

Cystic fibrosis and the salt controversy. Guggino WB. **Cell** 1999 Mar 5;96(5):607–10 (20 ref.)
Physiotherapy and bronchial mucus transport. van der Schans CP, et al. **Eur Respir J** 1999 Jun;13(6):1477–86 (121 ref.)

SECRETION

Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Fukushima N, et al. **Adv Anat Pathol** 1999 Mar;6(2):65–77 (53 ref.)
Mucobilia: the clinical spectrum, diagnosis and treatment. Chen MF. **J Gastroenterol Hepatol** 1998 Nov; 13(11):1084–90 (60 ref.)
Barrier function of gastric mucus. Kaunitz JD. **Keio J Med** 1999 Jun;48(2):63–8 (28 ref.)

MUERTO CANYON VIRUS see **HANTAVIRUS**

MULES see **EQUIDAE**

MULIBREY NANISM see **DWARFISM**

MULLERIAN DUCTS

ABNORMALITIES

US and MRI in a case of persistent Müllerian duct syndrome. Di Cesare E, et al. **Pediatr Radiol** 1998 Nov;28(11):865–7 (4 ref.)
[Anomalies of Müllerian duct fusion. A report of 3 cases of uterus didelphys associated with a double vagina and ipsilateral renal agenesis] Ruibal Francisco JL, et al. **An Esp Pediatr** 1999 Jun;50(6):616–8 (14 ref.) **(Spa)**
[The persistence of the müllerian duct] Vegas Gómez A, et al. **Arch Esp Urol** 1999 Jun;52(5):513–7 (12 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

US and MRI in a case of persistent Müllerian duct syndrome. Di Cesare E, et al. **Pediatr Radiol** 1998 Nov;28(11):865–7 (4 ref.)

ULTRASONOGRAPHY

US and MRI in a case of persistent Müllerian duct syndrome. Di Cesare E, et al. **Pediatr Radiol** 1998 Nov;28(11):865–7 (4 ref.)

MULTICENTER STUDIES

see related
CLINICAL TRIALS, PHASE III
Are ethics committees retarding the improvement of health

MULTICENTER STUDIES

services in Australia? [see comments] Jamrozik K, et al. **Med J Aust** 1999 Jan 4;170(1):26–8 (10 ref.) Comment in: Med J Aust 1999 Jan 4;170(1):9–10. Comment in: Med J Aust 1999 Jul 5;171(1):51. Comment in: Med J Aust 1999 Jul 5;171(1):51–2. Comment in: Med J Aust 1999 Jul 5;171(1):52. Comment in: Med J Aust 1999 Jul 5;171(1):53.

Ethics committees: is reform in order? [editorial; comment] [see comments] Loblay RH, et al. **Med J Aust** 1999 Jan 4;170(1):9–10 (16 ref.) Comment on: Med J Aust 1999 Jan 4;170(1):26–8. Comment in: Med J Aust 1999 Jul 5;171(1):51–2.

[New multicentric studies in hypertension] Román O. **Rev Med Chil** 1998 Oct;126(10):1238–46 (63 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Managing the informed consent process in large multicenter projects. Mark BA, et al. **Nurs Res** 1999 Mar–Apr; 48(2):114–7 (10 ref.)

Some controversies in planning and analysing multi-centre trials. Senn S. **Stat Med** 1998 Aug 15–30;17(15–16):1753–65; discussion 1799–800 (8 ref.)

MULTICENTER TRIALS see **MULTICENTER STUDIES**

MULTICULTURALISM see **CULTURAL DIVERSITY**

MULTIDISCIPLINARY PAIN CENTERS see **PAIN CLINICS**

MULTIDRUG RESISTANCE see **DRUG RESISTANCE, MULTIPLE**

MULTIDRUG RESISTANCE GENE see **GENES, MDR**

MULTIDRUG TRANSPORTER see **P-GLYCOPROTEIN**

MULTIENZYME COMPLEXES

A self-compartmentalizing protease in Rhodococcus: the 20S proteasome. De Mot R, et al. **Antonie Van Leeuwenhoek** 1998 Jul–Oct;74(1–3):83–7 (25 ref.)

Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. Funaro A, et al. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):54–61 (121 ref.)

[Human diseases associated with ubiquitin/proteasome proteolytic system] Anan T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):776–86 (45 ref.) **(Jpn)**

BIOSYNTHESIS

Microbial polyketide synthases: more and more prolific [comment] Hutchinson CR. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3336–8 (33 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1846–51. Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3622–7.

CHEMISTRY

The proteasome. Bochtler M, et al. **Annu Rev Biophys Biomol Struct** 1999;28:295–317 (117 ref.)

The membrane-integral domain of succinate:quinone oxidoreductases--a secretive haem-containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408–13 (33 ref.)

Structure and functions of arthropod proteasomes. Mykles DL. **Mol Biol Rep** 1999 Apr;26(1–2):103–11 (54 ref.)

DEFICIENCY

[Enzyme complex defects of the mitochondrial respiratory chain] Rubio JC, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S15–20 (46 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Proteasome inhibitors: valuable new tools for cell biologists. Lee DH, et al. **Trends Cell Biol** 1998 Oct;8(10):397–403 (49 ref.)

GENETICS

The proteasome, a novel protease regulated by multiple mechanisms. DeMartino GN, et al. **J Biol Chem** 1999 Aug 6;274(32):22123–6 (63 ref.)

Proteasomes and other self-compartmentalizing proteases in prokaryotes. De Mot R, et al. **Trends Microbiol** 1999 Feb; 7(2):88–92 (33 ref.)

IMMUNOLOGY

The role of the proteasome system and the proteasome activator PA28 complex in the cellular immune response. Kloetzel PM, et al. **Biol Chem** 1999 Mar;380(3):293–7 (43 ref.)

The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Tanaka K, et al. **Immunol Rev** 1998 Jun;163:161–76 (127 ref.)

CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation [comment] Iwata S, et al. **J Exp Med** 1999 Aug 2;190(3):301–6 (30 ref.) Comment on: J Exp Med 1999 Aug 2;190(3):311–22.

METABOLISM

The proteasome. Bochtler M, et al. **Annu Rev Biophys Biomol Struct** 1999;28:295–317 (117 ref.)

Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Bonifacino JS, et al. **Annu Rev Cell Dev Biol** 1998;14:19–57 (164 ref.)

The membrane-integral domain of succinate:quinone oxidoreductases--a secretive haem-containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408–13 (33 ref.)

The role of the ubiquitin-proteasome pathway in apoptosis. Orlowski RZ. **Cell Death Differ** 1999 Apr;6(4):303–13 (115 ref.)

The proteasome. Pals-Rylaarsdam R. **Curr Biol** 1998 Dec 17–31;8(25):R902 (8 ref.)

Combinatorial biosynthesis for new drug discovery. Hutchinson CR. **Curr Opin Microbiol** 1998 Jun;1(3):319–29 (74 ref.)

Cellulose, cellulases and cellulosomes. Bayer EA, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):548–57 (66 ref.)

Structure and function of the cytochrome bc1 complex of mitochondria and photosynthetic bacteria. Crofts AR, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):501–9 (44 ref.)

The ubiquitin-proteasome pathway: on protein death and cell life. Ciechanover A. **EMBO J** 1998 Dec 15;17(24):7151–60 (75 ref.)

The proteasome: a protein-destroying machine. Tanaka K, et al. **Genes Cells** 1998 Aug;3(8):499–510 (80 ref.)

Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. Lecker SH, et al. **J Nutr** 1999 Jan;129(1S Suppl):227S–237S (103 ref.)

Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Attaix D, et al. **Mol Biol Rep** 1999 Apr;26(1–2):77–82 (43 ref.)

Phosphorylation of proteasomes in mammalian cells. Bose S, et al. **Mol Biol Rep** 1999 Apr;26(1–2):11–4 (25 ref.)

Proteasome-dependent degradation of human CDC25B phosphatase. Cans C, et al. **Mol Biol Rep** 1999 Apr; 26(1–2):53–7 (36 ref.)

Functional analysis of the proteasome regulatory particle. Glickman MH, et al. **Mol Biol Rep** 1999 Apr;26(1–2):21–8 (44 ref.)

Role of the ubiquitin-proteasome pathway in sepsis-induced muscle catabolism. Hasselgren PO. **Mol Biol Rep** 1999 Apr; 26(1–2):71–6 (39 ref.)

Activator complexes containing the proteasomal regulatory ATPases S10b (SUG2) and S6(TBP1) in different tissues and organisms. Hastings R, et al. **Mol Biol Rep** 1999 Apr; 26(1–2):35–8 (12 ref.)

Relationships between proteasomes and viral gene products. Jarrousse AS, et al. **Mol Biol Rep** 1999 Apr;26(1–2):113–7 (54 ref.)

Structure and functions of arthropod proteasomes. Mykles DL. **Mol Biol Rep** 1999 Apr;26(1–2):103–11 (54 ref.)

The proteasome-dependent proteolytic system. Tanahashi N, et al. **Mol Biol Rep** 1999 Apr;26(1–2):3–9 (36 ref.)

Combinatorial biosynthesis: lesson learned from nature. Reynolds KA. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):12744–6 (23 ref.)

Dealing with energy demand: the AMP-activated protein kinase. Kemp BE, et al. **Trends Biochem Sci** 1999 Jan; 24(1):22–5 (44 ref.)

Proteasomes and other self-compartmentalizing proteases in prokaryotes. De Mot R, et al. **Trends Microbiol** 1999 Feb; 7(2):88–92 (33 ref.)

PHYSIOLOGY

AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Winder WW, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E1–10 (91 ref.)

Role for NADPH/NADH oxidase in the modulation of vascular tone. Münzel T, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:386–400 (47 ref.)

Chromatin remodeling: a marriage between two families? Pollard KJ, et al. **Bioessays** 1998 Sep;20(9):771–80 (68 ref.)

The proteasome. Pals-Rylaarsdam R. **Curr Biol** 1998 Dec 17–31;8(25):R902 (8 ref.)

Specificity of the proteasome and the TAP transporter. Uebel S, et al. **Curr Opin Immunol** 1999 Apr;11(2):203–8 (38 ref.)

Nature and role of proteasomes in maturation of fish oocytes. Tokumoto T. **Int Rev Cytol** 1999;186:261–94 (111 ref.)

Apoptosis and the proteasome. Grimm LM, et al. **Results Probl Cell Differ** 1999;23:209–28 (89 ref.)

A surprising role for the proteasome in the regulation of herpesvirus infection. Everett RD. **Trends Biochem Sci** 1999 Aug;24(8):293–5 (29 ref.)

[Molecular mechanism of ubiquitin proteasome-regulated quality control in the endoplasmic reticulum] Tokunaga F. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):766–75 (67 ref.) **(Jpn)**

MULTIFACTORIAL CAUSALITY see **CAUSALITY**

MULTIFACTORIAL INHERITANCE see **POLYGENIC INHERITANCE**

MULTIFUNCTIONAL ENZYMES see **MULTIENZYME COMPLEXES**

MULTIGENE FAMILY

see related
GENE DUPLICATION
REPETITIVE SEQUENCES, NUCLEIC ACID

Specificity within the ets family of transcription factors. Graves BJ, et al. **Adv Cancer Res** 1998;75:1–55 (236 ref.)

Mice and the role of unequal recombination in gene-family evolution. Schimenti JC. **Am J Hum Genet** 1999 Jan; 64(1):40–5 (42 ref.)

Cytochrome P450 and the individuality of species. Nelson DR. **Arch Biochem Biophys** 1999 Sep 1;369(1):1–10 (64 ref.)

Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Miyazono K. **Bone** 1999 Jul;25(1):91–3 (39 ref.)

Expression, regulation, and function of the SPR family of proteins. A review. Tesfaigzi J, et al. **Cell Biochem Biophys** 1999;30(2):243–65 (47 ref.)

Formin defines a large family of morphoregulatory genes and functions in establishment of the polarising region. Zeller R, et al. **Cell Tissue Res** 1999 Apr;296(1):85–93 (56 ref.)

Vertebrate genomics: More fishy tales about Hox genes. Meyer A, et al. **Curr Biol** 1999 Mar 25;9(6):R210–3 (21 ref.)

Vertebrate hox gene regulation: clustering and/or colinearity? Duboule D. **Curr Opin Genet Dev** 1998 Oct; 8(5):514–8 (58 ref.)

Protein families in multicellular organisms. Copley RR, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):408–15 (61 ref.)

The MCP/eotaxin subfamily of CC chemokines. Van Coillie E, et al. **Cytokine Growth Factor Rev** 1999 Mar;10(1):61–86 (245 ref.)

TNF receptor associated factors in cytokine signaling. Wajant H, et al. **Cytokine Growth Factor Rev** 1999 Mar; 10(1):15–26 (114 ref.)

Molecular genetics of the human MHC complement gene cluster. Yu CY. **Exp Clin Immunogenet** 1998;15(4):213–30 (105 ref.)

Clusters of resistance genes in plants evolve by divergent selection and a birth-and-death process. Michelmore RW, et al. **Genome Res** 1998 Nov;8(11):1113–30 (105 ref.)

The thioredoxin superfamily: redundancy, specificity, and gray-area genomics. Aslund F, et al. **J Bacteriol** 1999 Mar; 181(5):1375–9 (53 ref.)

The multifunctional Drosophila melanogaster V-ATPase is encoded by a multigene family. Dow JA. **J Bioenerg Biomembr** 1999 Feb;31(1):75–83 (59 ref.)

Molecular characterization of a novel family of low voltage-activated, T-type, calcium channels. Perez-Reyes E. **J Bioenerg Biomembr** 1998 Aug;30(4):313–8 (62 ref.)

Na+-dependent phosphate cotransporters: the NaPi protein families. Werner A, et al. **J Exp Biol** 1998 Dec;201 (Pt 23):3135–42 (61 ref.)

The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. Rebouillat D, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):295–308 (108 ref.)

The evolution of the type I interferons [published erratum appears in J Interferon Cytokine Res 1999 Apr;19(4):427] Roberts RM, et al. **J Interferon Cytokine Res** 1998 Oct; 18(10):805–16 (54 ref.)

Apoptosis in the estrous and menstrual cycles. Andres AC, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):221–8 (49 ref.)

Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. Schorr K, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):153–64 (92 ref.)

The family of Na+/Cl- neurotransmitter transporters. Nelson N. **J Neurochem** 1998 Nov;71(5):1785–803 (176 ref.)

The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)

Functional diversity of the DNA photolyase/blue light receptor family. Todo T. **Mutat Res** 1999 Jun 23; 434(2):89–97 (50 ref.)

Isovariant dynamics expand and buffer the responses of complex systems: the diverse plant actin gene family. Meagher RB, et al. **Plant Cell** 1999 Jun;11(6):995–1006 (122 ref.)

Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family. Schwartz NB, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 62:177–225 (151 ref.)

The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? Bennett PM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:203–34 (101 ref.)

Hyperpolarization-activated cation channels: a multi-gene family. Biel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 136:165–81 (60 ref.)

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Hammarström S. **Semin Cancer Biol** 1999 Apr; 9(2):67–81 (104 ref.)

The complexity of gene families involved in epithelial differentiation. Keratin genes and the epidermal differentiation complex. Mischke D. **Subcell Biochem** 1998;

31:71–104 (159 ref.)
Gene-cluster analysis in chloroplast genomics. Stoebe B, et al. **Trends Genet** 1999 Sep;15(9):344–7 (33 ref.)
[ERBB: an exemplary family (editorial)] Birnbaum D. **Ann Pathol** 1999 Apr;19(2):91–3 (17 ref.) **(Fre)**
[Structure and function of novel homeobox gene family six and implications in development and differentiation] Kawakami K, et al. **Tanpakushitsu Kakusan Koso** 1998 Nov; 43(14):2120–5 (25 ref.) **(Jpn)**
[Sialyltransferase superfamily: structure and function] Tsuji S. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2338–48 (49 ref.) **(Jpn)**
[Family of hsp70 stress genes in mammals] Lisowska K, et al. **Postepy Biochem** 1998;44(3):179–92 (197 ref.) **(Pol)**

GENETICS

Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Dooley TP. **Exp Dermatol** 1999 Aug;8(4):328–9 (11 ref.)
Molecular evolution of the opioid/orphanin gene family. Danielson PB, et al. **Gen Comp Endocrinol** 1999 Feb; 113(2):169–86 (150 ref.)
Clustering of COL7A1 mutations in exon 73: implications for mutation analysis in dystrophic epidermolysis bullosa [letter] Mecklenbeck S, et al. **J Invest Dermatol** 1999 Mar; 112(3):398–400 (14 ref.)

PHYSIOLOGY

GLUT-4, tumor necrosis factor, essential fatty acids and daf-genes and their role in insulin resistance and non-insulin dependent diabetes mellitus. Das UN. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jan; 60(1):13–20 (43 ref.)

MULTI-HOSPITAL INFORMATION SYSTEMS see **HOSPITAL INFORMATION SYSTEMS**

MULTILINGUALISM

Severe developmental disorders and bilingualism. Toppelberg CO, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Sep; 38(9):1197–9 (17 ref.)
Cognitive integration of language and memory in bilinguals: semantic representation. Francis WS. **Psychol Bull** 1999 Mar;125(2):193–222 (165 ref.)

MULTIMEDIA

The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)

TRENDS

Multimedia electronic medical record systems. Lowe HJ. **Acad Med** 1999 Feb;74(2):146–52 (56 ref.)

MULTIMODAL TREATMENT see **COMBINED MODALITY THERAPY**

MULTINUCLEATED GIANT CELLS see **GIANT CELLS**

MULTIPARITY see **PARITY**

MULTIPHASIC SCREENING

[Multilevel automatic monitoring system for epidemiological tuberculous process in the north-western region, project and implementation] Nechaeva NE, et al. **Probl Tuberk** 1999;(3):10–4 (6 ref.) (Eng. Abstr.) **(Rus)**

MULTIPLE BIRTH OFFSPRING

STATISTICS & NUMERICAL DATA

Iatrogenic multiple birth, multiple pregnancy and assisted reproductive technologies. Keith L, et al. **Int J Gynaecol Obstet** 1999 Jan;64(1):11–25 (48 ref.)

MULTIPLE CARBOXYLASE DEFICIENCY

[Biotin-dependent carboxylase deficiency] Hirasawa A, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):232–4 (11 ref.) **(Jpn)**

MULTIPLE CAUSATION see **CAUSALITY**

MULTIPLE CHEMICAL SENSITIVITY

see related
PERSIAN GULF SYNDROME

Developing case definitions for symptom-based conditions: the problem of specificity. Hyams KC. **Epidemiol Rev** 1998; 20(2):148–56 (124 ref.)
Multiple chemical sensitivities: the social construction of an illness. Lax MB. **Int J Health Serv** 1998;28(4):725–45 (55 ref.)
[Similarities of chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivity] Csef H. **Dtsch Med Wochenschr** 1999 Feb 12;124(6):163–9 (43 ref.) **(Ger)**

CLASSIFICATION

"Eco-syndrome" ("multiple chemical sensitivity"--MCS). Ring J, et al. **Zentralbl Hyg Umweltmed** 1999 Aug; 202(2–4):207–18 (33 ref.)

DIAGNOSIS

The credible forensic psychiatric evaluation in multiple chemical sensitivity litigation. Simon RI. **J Am Acad Psychiatry Law** 1998;26(3):361–74 (40 ref.)
Missed diagnoses and misdiagnoses of environmental toxicant exposure. The psychiatry of toxic exposure and multiple chemical sensitivity. Hartman DE. **Psychiatr Clin North Am** 1998 Sep;21(3):659–70, vii (33 ref.)
[Multiple chemical sensitivity: a new type of toxicity?] Gralewicz S. **Med Pr** 1998;49(5):473–81 (42 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

A review of multiple chemical sensitivity. Graveling RA, et al. **Occup Environ Med** 1999 Feb;56(2):73–85 (71 ref.)
Olfaction and symptoms in the multiple chemical sensitivities syndrome. Ross PM, et al. **Prev Med** 1999 May; 28(5):467–80 (140 ref.)
Evolutionary game theory and multiple chemical sensitivity. Newlin DB. **Toxicol Ind Health** 1999 Apr-Jun; 15(3–4):313–22 (56 ref.)
Multiple chemical sensitivity as a conditional response. Siegel S. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):323–30 (71 ref.)
["Multiple chemical sensitivity syndrome"] Wolf C. **Schweiz Med Wochenschr** 1998 Aug 15;128(33):1217–22 (32 ref.) (Eng. Abstr.) **(Ger)**
[Multiple chemical sensitivity: theories of etiopathogenesis] Ugrenović Z, et al. **Arh Hig Rada Toksikol** 1998 Jun; 49(2):189–205 (128 ref.) (Eng. Abstr.) **(Scr)**

PATHOLOGY

Neural sensitization model for multiple chemical sensitivity: overview of theory and empirical evidence. Bell IR, et al. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):295–304 (116 ref.)

PHYSIOPATHOLOGY

Multiple chemical sensitivity: a test of the olfactory-limbic model. Brown-DeGagne AM, et al. **J Occup Environ Med** 1999 May;41(5):366–77 (71 ref.)
Links between multiple chemical sensitivity and asthma in a rat model of cholinergic hypersensitivity: a brief review. Overstreet DH, et al. **Toxicol Ind Health** 1999 Aug; 15(5):517–21 (43 ref.)
'Multiple chemical sensitivity', the relevance of toxic, neurobiological and psychic effect mechanisms. Kiesswetter E. **Zentralbl Hyg Umweltmed** 1999 Aug; 202(2–4):191–205 (61 ref.)

PREVENTION & CONTROL

Low-level chemical sensitivity: implications for research and social policy. Ashford NA. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):421–7 (27 ref.)
Developing a pesticide policy for individuals with multiple chemical sensitivity: considerations for institutions. Brown AE. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):432–7 (13 ref.)

PSYCHOLOGY

'Multiple chemical sensitivity', the relevance of toxic, neurobiological and psychic effect mechanisms. Kiesswetter E. **Zentralbl Hyg Umweltmed** 1999 Aug; 202(2–4):191–205 (61 ref.)
[Idiopathic environmental intolerance (IPI)--formerly multiple chemical sensitivity (MCS)--from the psychiatric perspective] Blaschko S, et al. **Fortschr Neurol Psychiatr** 1999 Apr;67(4):175–87 (112 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Neurotoxicity in single photon emission computed tomography brain scans of patients reporting chemical sensitivities. Ross GH, et al. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):415–20 (26 ref.)

MULTIPLE ENDOCRINE NEOPLASIA

DIAGNOSIS

Genetic testing in multiple endocrine neoplasia and related syndromes. Calender A. **Forum (Genova)** 1998 Apr-Jun; 8(2):146–59 (95 ref.)

GENETICS

Hereditary endocrinopathies. Moley JF, et al. **Curr Probl Surg** 1999 Sep;36(9):653–762 (329 ref.)
Genetic testing in multiple endocrine neoplasia and related syndromes. Calender A. **Forum (Genova)** 1998 Apr-Jun; 8(2):146–59 (95 ref.)
[Multiple endocrine neoplasia] Ritter MM, et al. **Internist (Berl)** 1999 May;40(5):486–92 (21 ref.) **(Ger)**

PATHOLOGY

Thymic carcinoid in the pancreas: metastatic disease or new primary tumours. Axelson J, et al. **Eur J Surg** 1999 Mar; 165(3):270–3 (16 ref.)

SURGERY

Current perspectives in the surgery of multiple endocrine neoplasias [see comments] Proye CA, et al. **Aust N Z J Surg** 1999 Feb;69(2):106–16 (123 ref.) Comment in: Aust N Z J Surg 1999 Feb;69(2):83.

MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

[Multiple endocrine neoplasia Type I. Diagnosis and therapy in a case with classical family history] Lamberts R, et al. **Med Klin** 1999 Aug 15;94(8):447–52 (63 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Multiple endocrine neoplasia type 1: current concepts in diagnosis and management [see comments] Burgess JR. **Med J Aust** 1999 Jun 21;170(12):605–8 (36 ref.) Comment in: Med J Aust 1999 Jun 21;170(12):575.
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Carty SE, et al. **Surgery** 1998 Dec;124(6):1106–13; discussion 1113–4 (23 ref.)

GENETICS

The gene for multiple endocrine neoplasia type 1: recent findings. Marx SJ, et al. **Bone** 1999 Jul;25(1):119–22 (40 ref.)
Menin and MEN 1 gene: a model of tumour suppressor system [editorial] Hory B, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2176–9 (48 ref.)
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Carty SE, et al. **Surgery** 1998 Dec;124(6):1106–13; discussion 1113–4 (23 ref.)

PHYSIOPATHOLOGY

[Clinicogenetic study of MEN1: recent physiopathological data and clinical applications. Study Group of Multiple Endocrine Neoplasia (GENEM)] Calender A, et al. **Ann Endocrinol (Paris)** 1998;59(6):444–51 (36 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)

SURGERY

Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Thompson NW. **Surg Oncol Clin N Am** 1998 Oct;7(4):881–91 (34 ref.)

THERAPY

Multiple endocrine neoplasia type 1: current concepts in diagnosis and management [see comments] Burgess JR. **Med J Aust** 1999 Jun 21;170(12):605–8 (36 ref.) Comment in: Med J Aust 1999 Jun 21;170(12):575.

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A

DIAGNOSIS

RET protooncogene analysis in the diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type II. Matias-Guiu X. **Adv Anat Pathol** 1998 May;5(3):196–201 (19 ref.)

ETIOLOGY

Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M, et al. **Recent Results Cancer Res** 1998; 154:229–36 (22 ref.)

GENETICS

Different mutations of the RET gene cause different human tumoral diseases. Santoro M, et al. **Biochimie** 1999 Apr; 81(4):397–402 (57 ref.)
The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Ponder BA. **Cancer Res** 1999 Apr 1;59(7 Suppl):1736s–1741s; discussion 1742s (78 ref.)
Sporadic multiple endocrine neoplasia type 2A [editorial; comment] Yamashita S. **Intern Med** 1999 Feb;38(2):80 (6 ref.) Comment on: Intern Med 1999 Feb;38(2):145–9.
RET proto-oncogene in the development of human cancer. Eng C. **J Clin Oncol** 1999 Jan;17(1):380–93 (127 ref.)
[Multiple endocrine neoplasia-type medullary thyroid

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A

carcinoma in three generations of a family] Takácsi NZ, et al. **Orv Hetil** 1998 Nov 29;139(48):2883–8 (39 ref.) (Eng. Abstr.) **(Hun)**

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

[Multiple endocrine adenomatosis IIB] Dohán O, et al. **Orv Hetil** 1998 Dec 27;139(52):3117–20 (14 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

Different mutations of the RET gene cause different human tumoral diseases. Santoro M, et al. **Biochimie** 1999 Apr; 81(4):397–402 (57 ref.)

The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Ponder BA. **Cancer Res** 1999 Apr 1;59(7 Suppl):1736s–1741s; discussion 1742s (78 ref.)

MULTIPLE EPIPHYSEAL DYSPLASIA see **OSTEOCHONDRODYSPLASIAS**

MULTIPLE HAMARTOMA SYNDROME see **HAMARTOMA SYNDROME, MULTIPLE**

MULTIPLE MYELOMA

[Clinical characteristics of multiple myeloma] Kano T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1897–903 (22 ref.) **(Jpn)**

[Myeloma kidney] Arai T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):476–9 (14 ref.) **(Jpn)**

[IgM myeloma] Hayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):411–2 (10 ref.) **(Jpn)**

[Multiple myeloma with hyperammonemia] Izumi T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):446–8 (15 ref.) **(Jpn)**

[Non-secretory multiple myeloma] Kanamori H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):431–3 (14 ref.) **(Jpn)**

[Aggressive multiple myeloma] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):427–30 (13 ref.) **(Jpn)**

[Smoldering multiple myeloma] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):422–6 (16 ref.) **(Jpn)**

[Multiple myeloma with localized tumor] Masaoka T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):434–6 (1 ref.) **(Jpn)**

[IgE myeloma] Nakano T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):413–6 (14 ref.) **(Jpn)**

[Hyperviscosity syndrome] Sato T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):609–10 (11 ref.) **(Jpn)**

[IgD myeloma] Takahashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):408–10 (7 ref.) **(Jpn)**

[IgG, IgA, Bence Jones protein (BJP) myeloma] Takahashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):403–7 (20 ref.) **(Jpn)**

[Biclonal myeloma] Uike N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):442–5 (15 ref.) **(Jpn)**

[Multiple myeloma and other plasma cell dyscrasias] del Potro Gómez E, et al. **Rev Clin Esp** 1999 Apr;199 Suppl 1:52–7 (45 ref.) **(Spa)**

BLOOD

The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance? Brigden ML. **Postgrad Med** 1999 Aug; 106(2):135–42; quiz 185 (26 ref.)

CHEMICALLY INDUCED

Benzene and multiple myeloma: appraisal of the scientific evidence. Bergsagel DE, et al. **Blood** 1999 Aug 15; 94(4):1174–82 (81 ref.)

COMPLICATIONS

Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189–91 (14 ref.)

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Clark AD, et al. **Blood Rev** 1999 Jun;13(2):79–90 (116 ref.)

Bone disease in multiple myeloma. Croucher PI, et al. **Br J Haematol** 1998 Dec;103(4):902–10 (92 ref.)

Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43–55; discussion 55–63 (92 ref.)

Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Ben-Chetrit E, et al. **J Intern Med** 1998 Aug;244(2):175–8 (11 ref.)

The role of bisphosphonates for the treatment of bone disease in multiple myeloma. Musto P. **Leuk Lymphoma** 1998 Nov; 31(5–6):453–62 (80 ref.)

Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Kyrtsonis MC, et al. **Med Oncol** 1999 Jul;16(2):73–7 (35 ref.)

Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma. San Miguel JF, et al. **Med Oncol** 1998 Aug;15 Suppl 1:S29–34 (39 ref.)

[Amyloidosis associated with multiple myeloma] Hirota K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):480–3 (11 ref.) **(Jpn)**

DIAGNOSIS

Multiple myeloma: recognition and management. George ED, et al. **Am Fam Physician** 1999 Apr 1;59(7):1885–94 (31 ref.)

Primary myeloid leukemia presenting concomitantly with primary multiple myeloma: two cases and an update of the literature. Anderson CM, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):385–90 (23 ref.)

Clinical aspects of multiple myeloma and related disorders including amyloidosis. Kyle RA. **Pathol Biol (Paris)** 1999 Feb;47(2):148–57 (34 ref.)

The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance? Brigden ML. **Postgrad Med** 1999 Aug; 106(2):135–42; quiz 185 (26 ref.)

[Magnetic resonance imaging of multiple myeloma (editorial)] Rahmouni A. **J Radiol** 1998 Apr;79(4):299–300 (19 ref.) **(Fre)**

[Diagnostic and prognostic value of magnetic resonance imaging in multiple myeloma: the clinician's point of view (editorial)] Sibilia J, et al. **J Radiol** 1998 Apr;79(4):303–4 (16 ref.) **(Fre)**

[Diagnosis and treatment of multiple myeloma] Kogo Y. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):537–40 (7 ref.) **(Jpn)**

[An association of multiple myeloma and megaloblastic anemia (letter)] Marcos Sánchez F, et al. **An Med Interna** 1999 Jan;16(1):51–2 (9 ref.) **(Spa)**

[Pulmonary involvement in IgA multiple myeloma. A case report and review of the literature (letter)] Conesa Bernal C, et al. **Arch Bronconeumol** 1999 Jan;35(1):54–5 (6 ref.) **(Spa)**

DRUG THERAPY

Reversal of multidrug resistance in hematological malignancies. Vossebeld PJ, et al. **Blood Rev** 1999 Jun; 13(2):67–78 (129 ref.)

Advances in the biology and treatment of multiple myeloma. Varterasian ML. **Curr Opin Oncol** 1999 Jan;11(1):3–8 (79 ref.)

Current drug therapy for multiple myeloma. Huang YW, et al. **Drugs** 1999 Apr;57(4):485–506 (201 ref.)

Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Pilarski LM, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):199–210 (71 ref.)

Anti-tumour activity of bisphosphonates in human myeloma cells. Shipman CM, et al. **Leuk Lymphoma** 1998 Dec; 32(1–2):129–38 (55 ref.)

Bisphosphonates in multiple myeloma. Apperley JF, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):178–81 (23 ref.)

Intensive therapy in multiple myeloma. Harousseau JL. **Pathol Biol (Paris)** 1999 Feb;47(2):203–9 (27 ref.)

Drug resistance in multiple myeloma. Sonneveld P. **Pathol Biol (Paris)** 1999 Feb;47(2):182–7 (56 ref.)

The use of topoisomerase I inhibitors in multiple myeloma. Kraut EH, et al. **Semin Hematol** 1998 Jul;35(3 Suppl 4):32–8 (49 ref.)

[Glucocorticoids and multiple myeloma. Mechanism of action, resistance and clinical use] Paule B, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):502–7 (54 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

[Neuron specific enolase producing multiple myeloma] Ogura M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):440–1 (6 ref.) **(Jpn)**

[Amylase-producing myeloma] Ogura M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):437–9 (18 ref.) **(Jpn)**

ETIOLOGY

Advances in the biology and treatment of multiple myeloma. Varterasian ML. **Curr Opin Oncol** 1999 Jan;11(1):3–8 (79 ref.)

The role of human herpesvirus-8, (HHV-8), in multiple myeloma pathogenesis. Vescio RA, et al. **Curr Top Microbiol Immunol** 1999;246:403–8; discussion 409 (27 ref.)

Role of cytokines in multiple myeloma. Anderson KC, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):14–20 (42 ref.)

Initiation and maintenance of multiple myeloma. Berenson JR, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):9–13 (29 ref.)

GENETICS

Gene marking and gene therapy in multiple myeloma. Gahrton G, et al. **Adv Exp Med Biol** 1998;451:493–7 (15 ref.)

Advances in the biology and treatment of myeloma. Morgan GJ. **Br J Haematol** 1999 Apr;105 Suppl 1:4–6 (14 ref.)

Unusual presentation of multiple myeloma with "jumping translocation" involving 1q21. A case report and review of the literature. Keung YK, et al. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):135–9 (46 ref.)

Chromosome 13 deletion in myeloma. Shaughnessy J, et al. **Curr Top Microbiol Immunol** 1999;246:199–203 (20 ref.)

Molecular analysis of immunoglobulin genes in multiple myeloma. Kosmas C, et al. **Leuk Lymphoma** 1999 Apr; 33(3–4):253–65 (71 ref.)

[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases] Beltinger C, et al. **Klin Padiatr** 1998 Jul–Aug;210(4):153–8 (37 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Graft-versus-myeloma. Mehta J, et al. **Bone Marrow Transplant** 1998 Nov;22(9):835–43 (67 ref.)

Activation molecules on human myeloma cells. Klein B, et al. **Curr Top Microbiol Immunol** 1999;246:335–41 (30 ref.)

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Greil R, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):477–90 (69 ref.)

Molecular analysis of immunoglobulin genes in multiple myeloma. Kosmas C, et al. **Leuk Lymphoma** 1999 Apr; 33(3–4):253–65 (71 ref.)

Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Kyrtsonis MC, et al. **Med Oncol** 1999 Jul;16(2):73–7 (35 ref.)

Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Almeida J, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):119–27 (61 ref.)

Multiple myeloma and related disorders. Lessons from an animal model. Radl J. **Pathol Biol (Paris)** 1999 Feb; 47(2):109–14 (30 ref.)

B cell maturation in relation to multiple myeloma. Stevenson FK, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):89–97 (65 ref.)

Homing mechanisms of myeloma cells. Van Riet I. **Pathol Biol (Paris)** 1999 Feb;47(2):98–108 (76 ref.)

Idiotypic vaccination as therapy for multiple myeloma. Kwak LW, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):34–7 (15 ref.)

DNA vaccination against multiple myeloma. Stevenson FK, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):38–42 (10 ref.)

METABOLISM

The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Børset M, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):249–56 (60 ref.)

Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Seidel C, et al. **Med Oncol** 1998 Sep; 15(3):145–53 (72 ref.)

Role of cytokines in multiple myeloma. Anderson KC, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):14–20 (42 ref.)

[Cytokines in multiple myeloma] Wierzbowska A, et al. **Pol Arch Med Wewn** 1998 Mar;99(3):245–53 (54 ref.) **(Pol)**

MORTALITY

Prognosis in multiple myeloma. Fonseca R, et al. **Cancer Treat Res** 1999;99:155–70 (87 ref.)

PATHOLOGY

Breast metastasis from multiple myeloma: report of a case and review of the literature. Ampil FL. **Eur J Gynaecol Oncol** 1998;19(6):534–5 (13 ref.)

Biological significance of heterogeneity in human myeloma cells. Ishikawa H, et al. **Int J Hematol** 1998 Dec; 68(4):363–70 (51 ref.)

Nodular lesions of the liver revealing multiple myeloma. Chemlal K, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):389–92 (15 ref.)

Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Dhodapkar MV, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):35–43 (53 ref.)

Interleukin-10 and Gp130 cytokines in human multiple myeloma. Klein B, et al. **Leuk Lymphoma** 1999 Jun; 34(1–2):63–70 (66 ref.)

IgE multiple myeloma. Macro M, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):597–603 (42 ref.)

Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Pilarski LM, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):199–210 (71 ref.)

Homing behaviour of the malignant cell clone in multiple myeloma. Van Riet I, et al. **Med Oncol** 1998 Sep; 15(3):154–64 (78 ref.)

Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS. Bartl R, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):158–68 (84 ref.)

[Refractory multiple myeloma preceded by extramedullary plasmacytoma of lymph node—a case report and review of the literature] Ise M, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):505–10 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Effect of high-dose melphalan and peripheral blood stem

cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189–91 (14 ref.)

High-dose treatment of multiple myeloma. Gahrton G, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):173–80 (67 ref.)

Renal impairment in myeloma: time for a reappraisal? Mallick NP, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:30–2 (10 ref.)

Homing mechanisms in the biology of multiple myeloma. Van Camp B, et al. **Verh K Acad Geneeskd Belg** 1998; 60(3):163–94 (117 ref.)

PREVENTION & CONTROL

Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine. Mellstedt H, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):211–5 (21 ref.)

RADIOGRAPHY

Nodular lesions of the liver revealing multiple myeloma. Chemlal K, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):389–92 (15 ref.)

THERAPY

Current role of immunotherapy in multiple myeloma. Hájek R, et al. **Acta Med Austriaca** 1998;25(3):79–85 (90 ref.)

Gene marking and gene therapy in multiple myeloma. Gahrton G, et al. **Adv Exp Med Biol** 1998;451:493–7 (15 ref.)

Multiple myeloma: recognition and management. George ED, et al. **Am Fam Physician** 1999 Apr 1;59(7):1885–94 (31 ref.)

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Clark AD, et al. **Blood Rev** 1999 Jun;13(2):79–90 (116 ref.)

Graft-versus-myeloma. Mehta J, et al. **Bone Marrow Transplant** 1998 Nov;22(9):835–43 (67 ref.)

Stem cell mobilisation in lymphoproliferative diseases. Russell NH, et al. **Bone Marrow Transplant** 1998 Nov; 22(10):935–40 (41 ref.)

Intensive treatment for multiple myeloma: where do we stand? Lokhorst HM, et al. **Br J Haematol** 1999 Jul; 106(1):18–27 (73 ref.)

Novel biologic approaches to hematologic malignancies. Dutcher JP, et al. **Cancer Treat Res** 1999;99:275–306 (210 ref.)

Bone marrow and stem cell transplantation for multiple myeloma. Vesole DH. **Cancer Treat Res** 1999;99:171–94 (89 ref.)

Advances in therapy of multiple myeloma: lessons from acute leukemia. Barlogie B. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2605–13 (81 ref.)

Evolution of treatment strategies in multiple myeloma. Owen RG, et al. **Clin Lab Haematol** 1998 Aug;20(4):199–206 (93 ref.)

Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43–55; discussion 55–63 (92 ref.)

High-dose treatment of multiple myeloma. Gahrton G, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):173–80 (67 ref.)

Recent advances in the treatment of multiple myeloma. Desikan KR, et al. **Curr Opin Hematol** 1999 Jul;6(4):216–21 (56 ref.)

Recent advances in the treatment of multiple myeloma. Henick K, et al. **Curr Opin Hematol** 1998 Jul;5(4):254–8 (50 ref.)

New advances in multiple myeloma. Reece DE. **Curr Opin Hematol** 1998 Nov;5(6):460–4 (48 ref.)

Bone marrow transplantation in multiple myeloma. Schlossman RL, et al. **Curr Opin Oncol** 1999 Mar; 11(2):102–8 (59 ref.)

Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Harousseau JL. **Haematologica** 1999 Jun;84(6):548–53 (45 ref.)

Treatment of multiple myeloma. San Miguel JF, et al. **Haematologica** 1999 Jan;84(1):36–58 (242 ref.)

Therapeutic strategies and controversies in the treatment of multiple myeloma. Bladé J. **Pathol Biol (Paris)** 1999 Feb; 47(2):192–8 (53 ref.)

Bcl-2 antisense therapy in multiple myeloma. Bloem A, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):216–20 (44 ref.)

The role of autologous stem cell transplantation in the management of multiple myeloma. Fermand JP, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):199–202 (15 ref.)

Allogeneic bone marrow transplantation in multiple myeloma. Gahrton G. **Pathol Biol (Paris)** 1999 Feb; 47(2):188–91 (18 ref.)

Treatment of myeloma. Smith ML, et al. **QJM** 1999 Jan; 92(1):11–4 (24 ref.)

Myeloma overview. Soutar RL. **Scott Med J** 1998 Apr; 43(2):38–41 (51 ref.)

Management of multiple myeloma today. Anderson KC, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):3–8 (23 ref.)

Idiotypic vaccination as therapy for multiple myeloma. Kwak LW, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):34–7 (15 ref.)

Antibody therapy for treatment of multiple myeloma. Maloney DG, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):30–3 (13 ref.)

Introduction: immunotherapy for multiple myeloma--insights and advances. Stevenson F, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):1–2 (9 ref.)

DNA vaccination against multiple myeloma. Stevenson FK, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):38–42 (10 ref.)

High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Kyle RA. **Semin Oncol** 1999 Feb; 26(1):74–83 (53 ref.)

[Multiple myeloma; treatment in the year 1998] Lokhorst HM, et al. **Ned Tijdschr Geneeskd** 1998 Jul 11; 142(28):1596–602 (26 ref.) (Eng. Abstr.) **(Dut)**

[Standard treatment of multiple myeloma] Facon T. **Rev Med Interne** 1999 Jul;20(7):611–21 (105 ref.) (Eng. Abstr.) **(Fre)**

[Stem cell transplantation in multiple myeloma] Fukuda S, et al. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1407–14 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of multiple myeloma] Kogo Y. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):537–40 (7 ref.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 4. Malignant lymphoma and multiple myeloma] Tanosaki R. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1483–7 (4 ref.) **(Jpn)**

[Fulminant angiopathy caused by allogenic transplantation of bone marrow with cerebral involvement: clinico-pathologic correlation] Guerrero AL, et al. **An Med Interna** 1998 Oct;15(10):545–7 (15 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

HHV-8 is present in multiple myeloma patients. Berenson JR, et al. **Blood** 1999 May 15;93(10):3157–9; discussion 3164–6 (29 ref.)

Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Tarte K, et al. **Blood** 1999 May 15;93(10):3159–63; discussion 3163–4 (41 ref.)

HHV-8 and multiple myeloma. Berenson JR, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):115–8 (25 ref.)

The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Cesarman E, et al. **Semin Cancer Biol** 1999 Jun;9(3):165–74 (92 ref.)

MULTIPLE ORGAN DYSFUNCTION SYNDROME see **MULTIPLE ORGAN FAILURE**

MULTIPLE ORGAN FAILURE

[Etiology and therapy of multiple organ failure] Imaizumi H, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1263–70 (6 ref.) **(Jpn)**

COMPLICATIONS

Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650–1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429–36.

DRUG THERAPY

Total splanchnic resuscitation, SIRS, and MODS [editorial; comment] Marik PE. **Crit Care Med** 1999 Feb;27(2):257–8 (43 ref.) Comment on: Crit Care Med 1999 Feb;27(2):394–400.

Deciphering the oxyradical inflammation Rosetta stone: $O2^{\bullet}$-$NO^{\bullet}$, OONO-, polymorphonuclear neutrophils, poly(ADP-ribose) synthetase, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome [editorial; comment] Vaughan D, et al. **Crit Care Med** 1999 Aug;27(8):1666–9 (30 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1517–23. Comment on: Crit Care Med 1999 Aug;27(8):1524–32.

ETIOLOGY

Pancreatitis, cytokines, and SIRS: déjà vu all over again? [editorial; comment] Giroir BP. **Crit Care Med** 1999 Apr; 27(4):680–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):749–55.

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733–40.

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Kollias G, et al. **Immunol Rev** 1999 Jun;169:175–94 (198 ref.)

Multisystem organ failure secondary to increased intraabdominal pressure. Sugerman HJ, et al. **Infection** 1999 Jan-Feb;27(1):61–6 (33 ref.)

The role of the gut in major surgical postoperative morbidity. Chieveley-Williams S, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):81–110 (133 ref.)

Erythropoietic protoporphyria with fatal liver failure. Ishibashi A, et al. **J Gastroenterol** 1999 Jun;34(3):405–9 (17 ref.)

The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Asherson RA. **Lupus** 1998;7 Suppl 2:S55–62 (34 ref.)

The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation. Haire WD. **Semin Thromb Hemost** 1999;25(2):223–37 (93 ref.)

[Intestinal ischemic reperfusion syndrome: pathophysiology, clinical significance, therapy] Schwarz B, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):539–48 (115 ref.) (Eng. Abstr.) **(Ger)**

[Sepsis and organ failure--its pathogenesis and treatment] Hanasawa K, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug; 99(8):523–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Organ failure during the perioperative period: pathophysiology and strategy] Murakami M, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):518–22 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The pathogenesis of multiple organ failure in severe mechanical trauma] Sheiko VD. **Klin Khir** 1999;(6):39–42 (43 ref.) **(Ukr)**

GENETICS

The molecular pathogenesis of endotoxic shock and organ failure. Karima R, et al. **Mol Med Today** 1999 Mar; 5(3):123–32 (58 ref.)

IMMUNOLOGY

Acute-phase responses and SIRS/MODS: the good, the bad, and the nebulous [editorial; comment] Deutschman CS. **Crit Care Med** 1998 Oct;26(10):1630–1 (22 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1683–9.

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733–40.

METABOLISM

Limitations of nutrient intake. The effect of stressors: trauma, sepsis and multiple organ failure. Campbell IT. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S143–7 (56 ref.)

[Endotoxin and its binding protein in organ failure] Usui M, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):504–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

[Bacterial translocation in multiple organ failure] Fukushima R, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug; 99(8):497–503 (33 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[The ultrastructural bases of multiple organ failure in the pathogenesis of endotoxic shock] Bardakhch'ian EA, et al. **Patol Fiziol Eksp Ter** 1999 Jul-Sep;(3):22–5 (39 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Quantification of organ dysfunction: seeking standardization [editorial; comment] Bernard GR. **Crit Care Med** 1998 Nov; 26(11):1767–8 (19 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1793–800.

The role of the gut in major surgical postoperative morbidity. Chieveley-Williams S, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):81–110 (133 ref.)

Multiple organ failure. How valid is the "two hit" model? Saadia R, et al. **J Accid Emerg Med** 1999 May;16(3):163–6; discussion 166–7 (40 ref.)

The molecular pathogenesis of endotoxic shock and organ failure. Karima R, et al. **Mol Med Today** 1999 Mar; 5(3):123–32 (58 ref.)

[A new concept of the development of organ failure] Ogawa M. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):480–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Inflammatory mediator and organ dysfunction syndrome] Shimada H, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug; 99(8):490–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of the development of organ failure] Ura H, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):485–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Ischemia/reperfusion injury and organ failure] Yasuhara H, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):510–7 (38 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Pancreatitis, cytokines, and SIRS: déjà vu all over again? [editorial; comment] Giroir BP. **Crit Care Med** 1999 Apr; 27(4):680–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):749–55.

Sepsis, multi-organ dysfunction syndrome (MODS) and multiple organ failure (MOF). Prevention is better than treatment. Baue AE. **Minerva Anestesiol** 1999 Jul-Aug; 65(7-8):477–80; discussion 481 (10 ref.)

Sepsis and organ dysfunction/failure. An overview. Gullo A. **Minerva Anestesiol** 1999 Jul-Aug;65(7-8):529–40 (80 ref.)

THERAPY

The oxygen delivery debate--a review. Raghuram J, et al. **Ann Acad Med Singapore** 1998 May;27(3):404–8 (50 ref.)

ABC of dysfunction: organ dysfunction. Evans TW, et al. **BMJ** 1999 Jun 12;318(7198):1606–9 (0 ref.)

Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome. Stegmayr B. **Clin Chem Lab Med** 1999 Mar;37(3):327–32

MULTIPLE ORGAN FAILURE

(73 ref.)
Present and future options in continuous renal replacement therapies of sepsis and MOF. Tetta C, et al. **Minerva Anestesiol** 1999 Jun;65(6):419–26 (63 ref.)
Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? [see comments] Baue AE, et al. **Shock** 1998 Aug;10(2):79–89 (121 ref.) Comment in: Shock 1998 Nov;10(5):383–4.
[Current topics on hyperbaric oxygenation therapy—application of hyperbaric oxygenation to multiple organ failure] Arikawa K. **Masui** 1998 Dec;47 Suppl:S46–51 (19 ref.) **(Jpn)**

VIROLOGY

Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Hilts AE, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2528–33 (38 ref.)

MULTIPLE PERSONALITY DISORDER

DIAGNOSIS

["Multiple personality disorder" in childhood and adolescence] Hocke V, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Dec; 26(4):273–84 (70 ref.) (Eng. Abstr.) **(Ger)**

MULTIPLE SCLEROSIS

Demyelinating disease: evolution of a paradigm. Waksman BH. **Neurochem Res** 1999 Apr;24(4):491–5 (23 ref.)
Managing early multiple sclerosis. Jordan N. **Practitioner** 1998 May;242(1586):400–4 (7 ref.)
[Changes in the concept of multiple sclerosis] Guseo A. **Orv Hetil** 1998 Nov 29;139(48):2875–81 (41 ref.) (Eng. Abstr.) **(Hun)**
[Magnetic resonance imaging in multiple sclerosis] Saida T. **Rinsho Shinkeigaku** 1999 Jan;39(1):114–5 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Multiple sclerosis] Itoyama Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):417–22 (8 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. Weller RO. **J Neuropathol Exp Neurol** 1998 Oct;57(10):885–94 (89 ref.)

CLASSIFICATION

Quantification of impairment in MS: discussion of the scales in use. Amato MP, et al. **Mult Scler** 1999 Aug;5(4):216–9 (17 ref.)
Use of composite scores in the quantification of deterioration in multiple sclerosis. Lienert C, et al. **Mult Scler** 1999 Aug; 5(4):220–2 (8 ref.)
The revision of the International Classification of Impairments, Disabilities and Handicaps and its application in MS. Lux JB, et al. **Mult Scler** 1999 Aug;5(4):291–2 (4 ref.)
Measuring handicap in multiple sclerosis. Thompson AJ. **Mult Scler** 1999 Aug;5(4):260–2 (17 ref.)

COMPLICATIONS

Ankylosing spondylitis and multiple sclerosis. Libbrecht N, et al. **Acta Clin Belg** 1999 Jan–Feb;54(1):30–2 (6 ref.)
The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis. Fowler CJ. **Baillieres Clin Neurol** 1997 Oct;6(3):447–66 (48 ref.)
Spasticity, ataxia and fatigue in multiple sclerosis. Kesselring J, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):429–45 (82 ref.)
Cranial polyneuropathies in multiple sclerosis: case report and literature review. Thomas RW, et al. **Ear Nose Throat J** 1999 Feb;78(2):118–21 (15 ref.)
Evaluation and management of lower urinary tract disorders in women with multiple sclerosis. Rackley RR, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):139–43 (25 ref.)
Multiple sclerosis and the urologist [published erratum appears in J Urol 1999 Jul;162(1):172] Litwiller SE, et al. **J Urol** 1999 Mar;161(3):743–57 (182 ref.)
Speech-language pathology and dysphagia in multiple sclerosis. Merson RM, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):631–41 (38 ref.)
Multiple sclerosis and the neurogenic bladder. Rashid TM, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):615–29 (34 ref.)
Presentations of multiple sclerosis. Kidd D. **Practitioner** 1999 Jan;243(1594):24–6, 28–30 (1 ref.)
[determining factors of depression in multiple sclerosis: review of the literature] Even C, et al. **Encephale** 1999 Jan–Feb;25(1):78–85 (87 ref.) (Eng. Abstr.) **(Fre)**
['Fatigue' in multiple sclerosis] Zimmermann C, et al. **Nervenarzt** 1999 Jun;70(6):566–74 (42 ref.) (Eng. Abstr.) **(Ger)**
[Memory in multiple sclerosis: review of performance and relationship with clinical variables and neuroimaging] Porcel J, et al. **Rev Neurol** 1998 Dec;27(160):1034–42 (81 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

MR imaging investigations in a non-human primate model of multiple sclerosis [editorial; comment] Genain CP. **AJNR Am J Neuroradiol** 1999 Jun–Jul;20(6):955–7 (20 ref.) Comment on: AJNR Am J Neuroradiol 1999 Jun–Jul;20(6):965–76.
Perspectives on multiple sclerosis. Grossman RI, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1251–65 (190 ref.)
Magnetic resonance imaging in multiple sclerosis. Clanet M, et al. **Curr Opin Neurol** 1998 Aug;11(4):299–303 (44 ref.)
Monitoring relapsing remitting MS patients. Bourdette D, et al. **J Neuroimmunol** 1999 Jul 1;98(1):16–21 (24 ref.)
Clinical and magnetic resonance imaging heterogeneity in multiple sclerosis [editorial; comment] Miller DH. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):139 (5 ref.) Comment on: J Neurol Neurosurg Psychiatry 1999 Aug;67(2):153–7.
The role of magnetic resonance imaging studies in multiple sclerosis. Cerreta E. **J Neurosci Nurs** 1998 Oct; 30(5):290–301 (91 ref.)
Newer magnetic resonance techniques and disease activity in multiple sclerosis: new concepts and new concerns. Filippi M, et al. **Mult Scler** 1998 Dec;4(6):469–70 (16 ref.)
Identification of brain atrophy with MRI in MS. Thompson AJ. **Mult Scler** 1998 Jun;4(3):257–9 (12 ref.)
Neurologic degenerative disorders. Ross AP. **Nurs Clin North Am** 1999 Sep;34(3):725–42 (14 ref.)
Correlations of evoked potentials with MR imaging and MR spectroscopy in multiple sclerosis. Kraft GH, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):561–7, vi (57 ref.)
Diagnosis of multiple sclerosis. Miller A. **Semin Neurol** 1998; 18(3):309–16 (99 ref.)
[MRI visualization of multiple sclerosis lesions] Berry I, et al. **Rev Neurol (Paris)** 1998 Sep;154(8–9):607–17 (61 ref.) (Eng. Abstr.) **(Fre)**
[Multiple sclerosis and pregnancy: clinical issues] Confavreux C, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):186–91 (35 ref.) (Eng. Abstr.) **(Fre)**
[MRI follow-up in multiple sclerosis. A guideline for quality assurance] Gass A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):581–6 (51 ref.) (Eng. Abstr.) **(Ger)**
[A case of primary Sjögren's syndrome with CNS disease mimicking chronic progressive multiple sclerosis] Watanabe S, et al. **Rinsho Shinkeigaku** 1998 Jul; 38(7):658–62 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Pregnancy in women with multiple sclerosis (MS): a report of 2 cases] Starnawski M, et al. **Ginekol Pol** 1998 Dec; 69(12):1032–4 (9 ref.) (Eng. Abstr.) **(Pol)**
[A case of primary progressive multiple sclerosis in childhood] Efimenko VN, et al. **Lik Sprava** 1998 Jun; (4):139–41 (6 ref.) **(Rus)**

DRUG THERAPY

Meeting the challenge of multiple sclerosis. Part II [published erratum appears in Am J Nurs 1999 Jan;99(1 Pt 1):10] Halper J, et al. **Am J Nurs** 1998 Nov;98(11):39–45; quiz 46 (8 ref.)
Herpesviruses—a rationale for antiviral treatment in multiple sclerosis. Bergström T. **Antiviral Res** 1999 Feb;41(1):1–19 (160 ref.)
Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Rudick RA. **Arch Neurol** 1999 Sep; 56(9):1079–84 (49 ref.)
Multiple sclerosis: therapeutic update. Tselis AC, et al. **Arch Neurol** 1999 Mar;56(3):277–80 (17 ref.)
Copolymer-1. Comi G, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):495–509 (46 ref.)
Treatment of multiple sclerosis with interferon beta 1b. Dhib-Jalbut S, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):467–80 (80 ref.)
Other immunomodulatory therapies in multiple sclerosis. Polman CH. **Baillieres Clin Neurol** 1997 Oct;6(3):511–24 (80 ref.)
Interferon beta 1a. Pozzilli C, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):481–93 (34 ref.)
Choosing drug therapy for multiple sclerosis. An update. van Oosten BW, et al. **Drugs** 1998 Oct;56(4):555–69 (97 ref.)
Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. Cohen JA, et al. **J Neuroimmunol** 1999 Jul 1;98(1):29–36 (33 ref.)
Glucocorticosteroid therapy for multiple sclerosis: a critical review. Andersson PB, et al. **J Neurol Sci** 1998 Sep 18; 160(1):16–25 (89 ref.)
A review on traditional Chinese medicine in prevention and treatment of multiple sclerosis. Sun Y, et al. **J Tradit Chin Med** 1999 Mar;19(1):65–73 (17 ref.)
Recent developments in drug therapy for multiple sclerosis. Smith PF, et al. **Mult Scler** 1999 Apr;5(2):110–20 (161 ref.)
Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Goodin DS. **Neuroepidemiology** 1999;18(2):53–63 (33 ref.)
Medications used in the treatment of multiple sclerosis. Schapiro RT. **Phys Med Rehabil Clin N Am** 1999 May; 10(2):437–46, ix (48 ref.)
Oral tolerance with copolymer 1 for the treatment of multiple sclerosis [comment] Weiner HL. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3333–5 (53 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3842–7.
[Beta interferon in multiple sclerosis: pharmacological differences] Allain H, et al. **Rev Neurol (Paris)** 1999;155 Suppl 2:S24–30 (39 ref.) (Eng. Abstr.) **(Fre)**
[Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis] Gusev EI, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(4):33–6 (18 ref.) **(Rus)**

ENZYMOLOGY

Gelatinase B in multiple sclerosis and experimental autoimmune encephalomyelitis. Dubois B, et al. **Acta Neurol Belg** 1999 Mar;99(1):53–6 (31 ref.)

EPIDEMIOLOGY

Databases in MS research: pitfalls and promises. Weinshenker BG. **Mult Scler** 1999 Aug;5(4):206–11 (18 ref.)

ETIOLOGY

Mechanisms of demyelination and tissue damage in multiple sclerosis. Lassmann H. **Acta Neurol Belg** 1999 Mar; 99(1):6–10 (37 ref.)
On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Kollias G, et al. **Immunol Rev** 1999 Jun;169:175–94 (198 ref.)
A proposed role for nerve growth factor in the etiology of multiple sclerosis. Olson RC. **Med Hypotheses** 1998 Dec; 51(6):493–8 (111 ref.)
Progress in determining the causes and treatment of multiple sclerosis. Noseworthy JH. **Nature** 1999 Jun 24;399(6738 Suppl):A40–7 (100 ref.)
Etiology and pathogenesis of multiple sclerosis. Sørensen TL, et al. **Semin Neurol** 1998;18(3):287–94 (86 ref.)
[Infection and multiple sclerosis] Yamamura T. **Rinsho Shinkeigaku** 1999 Jan;39(1):24–5 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Modern views on etiopathogenesis of Alzheimer's disease] Kloszewska I, et al. **Psychiatr Pol** 1998 Sep–Oct; 32(5):557–72 (80 ref.) (Eng. Abstr.) **(Pol)**
[Hepatitis B vaccine and multiple sclerosis (editorial)] Campins Martí M, et al. **An Esp Pediatr** 1998 Dec; 49(6):555–7 (15 ref.) **(Spa)**

GENETICS

Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis? Kalman B, et al. **Acta Neurol Scand** 1998 Oct;98(4):232–7 (57 ref.)
The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Chataway J, et al. **Brain** 1998 Oct;121 (Pt 10):1869–87 (87 ref.)
Inheritance of susceptibility to multiple sclerosis. Sawcer S, et al. **Curr Opin Immunol** 1998 Dec;10(6):697–703 (121 ref.)
Transgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis. Wong FS, et al. **Immunol Rev** 1999 Jun;169:93–104 (71 ref.)
A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. Bhatti MT, et al. **J Neuroophthalmol** 1999 Mar;19(1):28–33 (27 ref.)
Genetics of multiple sclerosis. Ebers GC, et al. **Semin Neurol** 1998;18(3):295–9 (29 ref.)
[Genetic susceptibility to multiple sclerosis (MS). INSERM Network of Clinical Research on the Genetic Susceptibility to MS] Fontaine B. **Rev Neurol (Paris)** 1998 Sep; 154(8–9):601–5 (19 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

The pathology of multiple sclerosis: a historical perspective. Hickey WF. **J Neuroimmunol** 1999 Jul 1;98(1):37–44 (61 ref.)

IMMUNOLOGY

Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting. Stinissen P, et al. **Acta Neurol Belg** 1999 Mar;99(1):65–9 (29 ref.)
Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Gran B, et al. **Ann Neurol** 1999 May;45(5):559–67 (93 ref.)
The immunopathogenesis of multiple sclerosis. Giovannoni G. **Baillieres Clin Neurol** 1997 Oct;6(3):387–407 (165 ref.)
Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis. Ohsako S, et al. **Cell Death Differ** 1999 Jan;6(1):13–21 (75 ref.)
Recent advances in immunology in multiple sclerosis. Liblau RS, et al. **Curr Opin Neurol** 1998 Aug;11(4):293–8 (48 ref.)
CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Laman JD, et al. **Dev Immunol** 1998; 6(3–4):215–22 (50 ref.)
Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis. Anderton S, et al. **Immunol Rev** 1999 Jun;169:123–37 (78 ref.)

The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Tuohy VK, et al. **Immunol Rev** 1998 Aug; 164:93–100 (41 ref.)

Transgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis. Wong FS, et al. **Immunol Rev** 1999 Jun;169:93–104 (71 ref.)

Immunity to heat shock proteins and neurological disorders of women. Birnbaum G, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):39–48 (56 ref.)

T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. de Rosbo NK, et al. **J Autoimmun** 1998 Aug;11(4):287–99 (120 ref.)

The cellular immunology of multiple sclerosis. Al-Omaishi J, et al. **J Leukoc Biol** 1999 Apr;65(4):444–52 (68 ref.)

The multiple sclerosis lesion: initiated by a localized hypoperfusion in a central nervous system where mechanisms allowing leukocyte infiltration are readily upregulated? Juurlink BH. **Med Hypotheses** 1998 Oct; 51(4):299–303 (41 ref.)

Candidate autoantigens in multiple sclerosis. Schmidt S. **Mult Scler** 1999 Jun;5(3):147–60 (163 ref.)

Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis. Stinissen P, et al. **Mult Scler** 1998 Jun; 4(3):203–11 (70 ref.)

Immune pathogenesis of multiple sclerosis. Brain autoimmune reactivity and its control by neuronal function. Wekerle H. **Mult Scler** 1998 Jun;4(3):136–7 (17 ref.)

The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Conlon P, et al. **Neurobiol Dis** 1999 Jun;6(3):149–66 (139 ref.)

Immunologic aspects of multiple sclerosis. Taylor RS. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):525–36, v (36 ref.)

The small heat shock protein alpha B-crystallin as key autoantigen in multiple sclerosis. Van Noort JM, et al. **Prog Brain Res** 1998;117:435–52 (73 ref.)

[Neurotransmitters in mechanisms of relations between nervous and immune systems in multiple sclerosis] Barkhatova VP, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):51–4 (32 ref.) **(Rus)**

[Treatment of multiple sclerosis—2. Application of a new immunological basic research is close] Svenningsson A, et al. **Lakartidningen** 1998 Dec 2;95(49):5631–5 (15 ref.) (Eng. Abstr.) **(Swe)**

METABOLISM

Remyelination in demyelinating disease. Scolding NJ, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):525–48 (125 ref.)

Biological markers in body fluids for activity and progression in multiple sclerosis. Sørensen PS. **Mult Scler** 1999 Aug; 5(4):287–90 (34 ref.)

[Neurotransmitters in mechanisms of relations between nervous and immune systems in multiple sclerosis] Barkhatova VP, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):51–4 (32 ref.) **(Rus)**

MICROBIOLOGY

[Are multiple sclerosis, gastric dyspepsia, asthma, atherosclerosis...infectious diseases?] Gomis M, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):49–50 (0 ref.) **(Spa)**

NURSING

Meeting the challenge of multiple sclerosis. Part I. Treating the person and the disease. Halper J, et al. **Am J Nurs** 1998 Oct;98(10):26–31; quiz 32 (6 ref.)

Meeting the challenge of multiple sclerosis. Part II [published erratum appears in Am J Nurs 1999 Jan;99(1 Pt 1):10] Halper J, et al. **Am J Nurs** 1998 Nov;98(11):39–45; quiz 46 (8 ref.)

Home care by and for relatives of MS patients. Duijnstee MS, et al. **J Neurosci Nurs** 1998 Dec;30(6):356–60 (18 ref.)

PATHOLOGY

The mechanisms of lesion genesis in multiple sclerosis? [editorial; comment] Wolinsky JS. **Brain** 1999 Jul;122 (Pt 7):1211–2 (10 ref.) Comment on: Brain 1999 Jul;122 (Pt 7):1261–70.

Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul;95(1–2):133–40 (58 ref.)

Magnetic resonance spectroscopy: imaging axonal damage in MS. Arnold DL. **J Neuroimmunol** 1999 Jul 1;98(1):2–6 (12 ref.)

The origin of remyelinating cells in the central nervous system. Blakemore WF, et al. **J Neuroimmunol** 1999 Jul 1;98(1):69–76 (56 ref.)

The pathology of multiple sclerosis: a historical perspective. Hickey WF. **J Neuroimmunol** 1999 Jul 1;98(1):37–44 (61 ref.)

From enhancing lesions to brain atrophy in relapsing MS. Simon JH. **J Neuroimmunol** 1999 Jul 1;98(1):7–15 (37 ref.)

Pathogenesis of tissue injury in MS lesions. Trapp BD, et al. **J Neuroimmunol** 1999 Jul 1;98(1):49–56 (45 ref.)

MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Barkhof F. **Mult Scler** 1999 Aug;5(4):283–6 (35 ref.)

Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Filippi M, et al. **Mult Scler** 1999 Aug;5(4):273–82 (86 ref.)

Are there any body fluid markers of brain atrophy in multiple sclerosis? Giovannoni G, et al. **Mult Scler** 1998 Jun; 4(3):138–42 (40 ref.)

Neuropathology in multiple sclerosis: new concepts. Lassmann H. **Mult Scler** 1998 Jun;4(3):93–8 (74 ref.)

Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Stevenson VL, et al. **Mult Scler** 1999 Aug;5(4):268–72 (49 ref.)

Pathological correlates of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis. Brochet B, et al. **Neurology** 1999;53(5 Suppl 3):S12–7 (17 ref.)

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Fazekas F, et al. **Neurology** 1999 Aug 11;53(3):448–56 (72 ref.)

Magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions. Filippi M. **Neurology** 1999;53(5 Suppl 3):S18–22 (56 ref.)

Application of magnetization transfer imaging to multiple sclerosis. Grossman RI. **Neurology** 1999;53(5 Suppl 3):S8–11 (34 ref.)

The physical basis of magnetization transfer imaging. McGowan JC. **Neurology** 1999;53(5 Suppl 3):S3–7 (32 ref.)

Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. Richert ND, et al. **Neurology** 1999;53(5 Suppl 3):S29–32 (38 ref.)

Correlations between magnetization transfer metrics and other magnetic resonance abnormalities in multiple sclerosis. Rovaris M, et al. **Neurology** 1999;53(5 Suppl 3):S40–5 (46 ref.)

Standardization of magnetization transfer imaging for multicenter studies. Silver NC, et al. **Neurology** 1999;53(5 Suppl 3):S33–9 (48 ref.)

Magnetization transfer histogram methodology: its clinical and neuropsychological correlates. van Buchem MA, et al. **Neurology** 1999;53(5 Suppl 3):S23–8 (43 ref.)

Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. van Waesberghe JH, et al. **Neurology** 1999;53(5 Suppl 3):S46–8 (11 ref.)

Correlating MR lesions and functional deficits in multiple sclerosis patients. Anatomical atlas registration. Gardner JC, et al. **Phys Med Rehabil Clin N Am** 1998 Aug; 9(3):569–86, vi (68 ref.)

Multiple sclerosis: lessons from neuropathology. Lucchinetti CF, et al. **Semin Neurol** 1998;18(3):337–49 (217 ref.)

Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Matthews PM, et al. **Semin Neurol** 1998;18(3):327–36 (49 ref.)

PHYSIOPATHOLOGY

The mechanisms of lesion genesis in multiple sclerosis? [editorial; comment] Wolinsky JS. **Brain** 1999 Jul;122 (Pt 7):1211–2 (10 ref.) Comment on: Brain 1999 Jul;122 (Pt 7):1261–70.

Respiratory muscle involvement in multiple sclerosis. Gosselink R, et al. **Eur Respir J** 1999 Feb;13(2):449–54 (49 ref.)

Yawning and stretching—a behavioral syndrome associated with transcranial application of electromagnetic fields in multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul; 95(1–2):107–13 (47 ref.)

Molecular mimicry and multiple sclerosis—a possible role for degenerate T cell recognition in the induction of autoimmune responses. Gran B, et al. **J Neural Transm Suppl** 1999;55:19–31 (43 ref.)

Multiple sclerosis—emerging concepts of disease pathogenesis. Antel J. **J Neuroimmunol** 1999 Jul 1; 98(1):45–8 (24 ref.)

The origin of remyelinating cells in the central nervous system. Blakemore WF, et al. **J Neuroimmunol** 1999 Jul 1;98(1):69–76 (56 ref.)

Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. Ransohoff RM. **J Neuroimmunol** 1999 Jul 1;98(1):57–68 (107 ref.)

Pathogenesis of tissue injury in MS lesions. Trapp BD, et al. **J Neuroimmunol** 1999 Jul 1;98(1):49–56 (45 ref.)

Clinical and magnetic resonance imaging heterogeneity in multiple sclerosis [editorial; comment] Miller DH. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):139 (5 ref.) Comment on: J Neurol Neurosurg Psychiatry 1999 Aug;67(2):153–7.

Benign multiple sclerosis [editorial; comment] Thompson AJ. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):138 (7 ref.) Comment on: J Neurol Neurosurg Psychiatry 1999 Aug;67(2):148–52.

The role of nitric oxide in the pathogenesis of multiple sclerosis. Santiago E, et al. **J Physiol Biochem** 1998 Dec; 54(4):229–37 (87 ref.)

Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. Comi G, et al. **Mult Scler** 1998 Jun;4(3):260–5 (74 ref.)

Measuring evoked responses in multiple sclerosis. Comi G, et al. **Mult Scler** 1999 Aug;5(4):263–7 (55 ref.)

Newer magnetic resonance techniques and disease activity in multiple sclerosis: new concepts and new concerns. Filippi M, et al. **Mult Scler** 1998 Dec;4(6):469–70 (16 ref.)

Body fluid markers to monitor multiple sclerosis: the assays and the challenges. Laman JD, et al. **Mult Scler** 1998 Jun; 4(3):266–9 (21 ref.)

Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? Massaro AR. **Mult Scler** 1998 Jun;4(3):228–31 (29 ref.)

Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Sharief MK. **Mult Scler** 1998 Jun; 4(3):169–73 (35 ref.)

The natural history of multiple sclerosis and its diagnosis. Rosenblum D, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):537–49, v (57 ref.)

Multiple sclerosis potpourri. Paroxysmal symptoms, seizures, fatigue, pregnancy, and more. Taylor RS. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):551–9, vi (31 ref.)

Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Wolswijk G. **Prog Brain Res** 1998;117:233–47 (82 ref.)

The natural history of multiple sclerosis: update 1998. Weinshenker BG. **Semin Neurol** 1998;18(3):301–7 (52 ref.)

Recommendations for physical activity in patients with multiple sclerosis. Petajan JH, et al. **Sports Med** 1999 Mar; 27(3):179–91 (81 ref.)

[Is it possible to predict the evolution of multiple sclerosis?] Confavreux C, et al. **Rev Neurol (Paris)** 1998 Sep; 154(8–9):624–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Experimental autoimmune encephalomyelitis] Cornet A, et al. **Rev Neurol (Paris)** 1998 Sep;154(8–9):586–91 (52 ref.) (Eng. Abstr.) **(Fre)**

[S100B: pathogenetic and pathophysiologic significance in neurology] Schmidt S. **Nervenarzt** 1998 Aug;69(8):639–46 (94 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

On the possibility of preventing multiple sclerosis. Marcinkowski T. **Med Hypotheses** 1998 Nov;51(5):445–6 (9 ref.)

PSYCHOLOGY

Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing. Beatty WW. **Mult Scler** 1999 Aug;5(4):239–43 (51 ref.)

Recent developments in the assessment of quality of life in multiple sclerosis (MS). Fischer JS, et al. **Mult Scler** 1999 Aug;5(4):251–9 (52 ref.)

Magnetization transfer histogram methodology: its clinical and neuropsychological correlates. van Buchem MA, et al. **Neurology** 1999;53(5 Suppl 3):S23–8 (43 ref.)

Neuropsychologic aspects of multiple sclerosis. Taylor A, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):643–57, vii–viii (71 ref.)

REHABILITATION

Rehabilitation principles for patients with multiple sclerosis. Kraft GH. **J Spinal Cord Med** 1998 Apr;21(2):117–20 (12 ref.)

Physical and occupational therapy in the treatment of patients with multiple sclerosis. LaBan MM, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):603–14, vii (31 ref.)

Multiple sclerosis: rehabilitation measures. Thompson AJ. **Semin Neurol** 1998;18(3):397–403 (71 ref.)

Recommendations for physical activity in patients with multiple sclerosis. Petajan JH, et al. **Sports Med** 1999 Mar; 27(3):179–91 (81 ref.)

SURGERY

[Indications for surgical treatment of tremor] Bötzel K, et al. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):287–90 (13 ref.) **(Ger)**

THERAPY

Immunological basis for the therapy of multiple sclerosis. Hohlfeld R. **Acta Neurol Belg** 1999 Mar;99(1):40–3 (16 ref.)

Meeting the challenge of multiple sclerosis. Part I. Treating the person and the disease. Halper J, et al. **Am J Nurs** 1998 Oct;98(10):26–31; quiz 32 (6 ref.)

Immunologic therapy of multiple sclerosis. Arnason BG. **Annu Rev Med** 1999;50:291–302 (28 ref.)

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? [see comments] Rice G, et al. **Arch Neurol** 1998 Dec;55(12):1578–80 (12 ref.) Comment in: Arch Neurol 1998 Dec;55(12):1581–3.

Outcome measures in multiple sclerosis clinical trials. Andersson PB, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):409–28 (75 ref.)

Symptomatic treatment in multiple sclerosis. Thompson AJ. **Curr Opin Neurol** 1998 Aug;11(4):305–9 (42 ref.)

Interferon beta-1a in relapsing-remitting multiple sclerosis. Blumhardt L. **Hosp Med** 1999 Mar;60(3):192–5 (20 ref.)

Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. Rudick RA, et al. **J Neuroimmunol** 1999 Jul 1;98(1):22–8 (36 ref.)

The use and effectiveness of alternative therapies in multiple sclerosis. Newland P. **J Neurosci Nurs** 1999 Feb;31(1):43–6 (23 ref.)

The Multiple Sclerosis Functional Composite Measure

MULTIPLE SCLEROSIS

(MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Fischer JS, et al. **Mult Scler** 1999 Aug;5(4):244–50 (25 ref.)

Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Liu C, et al. **Mult Scler** 1999 Feb;5(1):22–8 (55 ref.)

Progress in determining the causes and treatment of multiple sclerosis. Noseworthy JH. **Nature** 1999 Jun 24;399(6738 Suppl):A40–7 (100 ref.)

Intravenous immunoglobulins in multiple sclerosis. Lisak RP. **Neurology** 1998 Dec;51(6 Suppl 5):S25–9 (42 ref.)

Neurologic degenerative disorders. Ross AP. **Nurs Clin North Am** 1999 Sep;34(3):725–42 (14 ref.)

Improving health care delivery for persons with multiple sclerosis. Kraft GH. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):703–15, viii–ix (50 ref.)

Bioelectromagnetic applications for multiple sclerosis. Richards TL, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):659–74 (99 ref.)

Therapeutic and symptomatic treatment of multiple sclerosis. Rosenblum D, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):587–601, vi–vii (105 ref.)

Treating the family with multiple sclerosis. White DM. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):675–87 (38 ref.)

Future options for therapies to limit damage and enhance recovery. Compston A. **Semin Neurol** 1998;18(3):405–14 (81 ref.)

Multiple sclerosis: symptomatic therapies. Metz L. **Semin Neurol** 1998;18(3):389–95 (48 ref.)

Multiple sclerosis: use of MRI in evaluating new therapies. Miller DH. **Semin Neurol** 1998;18(3):317–25 (100 ref.)

Multiple sclerosis clinical trials: old and new challenges. Noseworthy JH. **Semin Neurol** 1998;18(3):377–88 (100 ref.)

Statistical methods for evaluating multiple sclerosis therapies. Petkau J. **Semin Neurol** 1998;18(3):351–75 (36 ref.)

[Non-specific immunosuppression and multiple sclerosis] Brochet B. **Rev Neurol (Paris)** 1998 Sep;154(8–9):629–34 (48 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of multiple sclerosis] Bereznai B, et al. **Dtsch Med Wochenschr** 1999 May 14;124(19):595–9 (37 ref.) **(Ger)**

[MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis (see comments)] **Nervenarzt** 1999 Apr;70(4):371–86 (87 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1999 Apr;70(4):297. **(Ger)**

[Bone marrow and stem cell transplantation in multiple sclerosis?] Haase CG, et al. **Nervenarzt** 1999 Feb; 70(2):178–81 (23 ref.) **(Ger)**

[Promoting remyelination as a future therapeutic principle in multiple sclerosis?] Pöhlau D, et al. **Nervenarzt** 1998 Oct; 69(10):841–50 (112 ref.) (Eng. Abstr.) **(Ger)**

[Comprehensive rehabilitation of multiple sclerosis patients] Opara J. **Neurol Neurochir Pol** 1998 May–Jun;32(3):623–32 (23 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of multiple sclerosis—1. New drugs may be effective but there still are frequent relapses] Svenningsson A, et al. **Lakartidningen** 1998 Dec 2;95(49):5623–7, 5630 (19 ref.) (Eng. Abstr.) **(Swe)**

URINE

Urinary markers of disease activity in multiple sclerosis. Giovannoni G, et al. **Mult Scler** 1998 Jun;4(3):247–53 (32 ref.)

Myelin basic protein-like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes. Whitaker JN. **Mult Scler** 1998 Jun;4(3):243–6 (51 ref.)

VIROLOGY

Herpesviruses—a rationale for antiviral treatment in multiple sclerosis. Bergström T. **Antiviral Res** 1999 Feb;41(1):1–19 (160 ref.)

Viruses and multiple sclerosis. Monteyne P, et al. **Curr Opin Neurol** 1998 Aug;11(4):287–91 (38 ref.)

Association of human herpesvirus-6 and multiple sclerosis: here we go again? [editorial; comment] Jacobson S. **J Neurovirol** 1998 Oct;4(5):471–3 (18 ref.) Comment on: J Neurovirol 1998 Oct;4(5):474–85. Comment on: J Neurovirol 1998 Oct;4(5):486–94. Comment on: J Neurovirol 1998 Oct;4(5):495–511.

[MSRV retrovirus and gliotoxin protein: potential biological markers in multiple sclerosis?] Perron H. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):427–38 (52 ref.) (Eng. Abstr.) **(Fre)**

MULTIPLE SYSTEM ATROPHY

[Striatonigral degeneration (SND)] Kita K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):254–6 (5 ref.) **(Jpn)**

[Striatonigral degeneration (SND)] Koyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):49–51 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Multiple system atrophy: the putative causative role of environmental toxins. Hanna PA, et al. **Arch Neurol** 1999 Jan;56(1):90–4 (41 ref.)

COMPLICATIONS

[Effective nasal CPAP therapy for heavy snoring and paradoxical respiration during sleep in a case of multiple system atrophy] Miyamoto M, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1059–63 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Separating the primary autonomic failure syndromes, multiple system atrophy, and pure autonomic failure from Parkinson's disease. Mathias CJ, et al. **Adv Neurol** 1999; 80:353–61 (28 ref.)

Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Gilman S, et al. **Clin Auton Res** 1998 Dec;8(6):359–62 (26 ref.)

Multiple system atrophy. Kaufmann H. **Curr Opin Neurol** 1998 Aug;11(4):351–5 (31 ref.)

Consensus statement on the diagnosis of multiple system atrophy. Gilman S, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):189–92 (26 ref.)

Consensus statement on the diagnosis of multiple system atrophy [see comments] Gilman S, et al. **J Neurol Sci** 1999 Feb 1;163(1):94–8 (26 ref.) Comment in: J Neurol Sci 1999 Feb 1;163(1):4–5.

The definition of multiple system atrophy: a review of recent developments. Lantos PL. **J Neuropathol Exp Neurol** 1998 Dec;57(12):1099–111 (100 ref.)

Multiple system atrophy. Siemers E. **Med Clin North Am** 1999 Mar;83(2):381–92 (32 ref.)

Multiple system atrophy. Swan L, et al. **Phys Ther** 1999 May; 79(5):488–94 (38 ref.)

[Clinical diagnostic criteria for multiple system atrophy] Vidailhet M, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):17–21 (59 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Multiple system atrophy. Kulczycki J. **Folia Neuropathol** 1997;35(4):209–13 (18 ref.)

Multiple system atrophy. Oertel WH, et al. **J Neural Transm Suppl** 1999;56:155–64 (43 ref.)

SURGERY

Neural transplantation in animal models of multiple system atrophy: a review. Wenning GK, et al. **J Neural Transm Suppl** 1999;55:103–13 (52 ref.)

MULTIPLE TRAUMA

Tracheobronchial avulsion and associated innominate artery injury in blunt trauma: case report and literature review. Hemmila MR, et al. **J Trauma** 1999 Mar;46(3):505–12 (31 ref.)

[Latest results of intensive care of sepsis, septic shock and multiple organ injuries] Incze F. **Orv Hetil** 1999 Mar 7; 140(10):515–20 (49 ref.) (Eng. Abstr.) **(Hun)**

CLASSIFICATION

Scores in polytrauma—do they help? Waydhas C, et al. **Langenbecks Arch Surg** 1998 Aug;383(3–4):209–13 (37 ref.)

COMPLICATIONS

Ventilation in the trauma and surgical patient. Battistella FD. **Crit Care Clin** 1998 Oct;14(4):731–42 (61 ref.)

Analgesia for trauma and burns. Hedderich R, et al. **Crit Care Clin** 1999 Jan;15(1):167–84 (49 ref.)

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733–40.

Staphylococcus aureus infections in trauma patients [editorial; comment] Sheagren JN. **Crit Care Med** 1999 Apr; 27(4):692–3 (8 ref.) Comment on: Crit Care Med 1999 Apr;27(4):798–801.

Pneumopericardium and pneumoperitoneum after penetrating chest injury. Rashid MA, et al. **Eur J Surg** 1999 Mar;165(3):278–9 (8 ref.)

Venous thromboembolism in multiple trauma patients. Erstad BL. **Pharmacotherapy** 1998 Sep–Oct;18(5):1011–23 (70 ref.)

DIAGNOSIS

Complete pyelo-calyceal avulsion as a result of blunt abdominal trauma. Pagano S, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):66–8 (8 ref.)

[The course of the traumatic disease in multiple trauma] Sheĭko VD. **Klin Khir** 1998;(9–10):70–3; discussion 73–4 (49 ref.) **(Ukr, Rus)**

IMMUNOLOGY

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733–40.

METABOLISM

Limitations of nutrient intake. The effect of stressors: trauma, sepsis and multiple organ failure. Campbell IT. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S143–7 (56 ref.)

PHYSIOPATHOLOGY

Clinical and pathophysiological significance of severe neurotrauma in polytraumatized patients. Meixensberger J, et al. **Langenbecks Arch Surg** 1998 Aug;383(3–4):214–9 (46 ref.)

Mediators in polytrauma—pathophysiological significance and clinical relevance. Rose S, et al. **Langenbecks Arch Surg** 1998 Aug;383(3–4):199–208 (81 ref.)

PREVENTION & CONTROL

[Current status and developments in vehicular safety of automobiles] Miltner E. **Unfallchirurg** 1998 Oct; 101(10):796–8 (24 ref.) **(Ger)**

RADIOGRAPHY

The diagnostic problem associated with blunt traumatic azygous vein injury: delayed appearance of right haemothorax after blunt chest trauma. Sugimoto K, et al. **Injury** 1998 Jun;29(5):380–2 (11 ref.)

Bilateral traumatic hip dislocation in a child: a case report and review of the literature. Sahin V, et al. **J Trauma** 1999 Mar;46(3):500–4 (23 ref.)

SURGERY

Pitfalls in the care of the injured patient. Wall MJ Jr, et al. **Curr Probl Surg** 1998 Dec;35(12):1019–74 (78 ref.)

Traumatic aortic rupture and retroperitoneal haematoma—treatment including combined operative and endovascular approach. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):451–5 (6 ref.)

[Mutilating complex trauma of the pelvis] Rieger H, et al. **Chirurg** 1998 Nov;69(11):1275–9 (19 ref.) (Eng. Abstr.) **(Ger)**

[Fixed rotatory subluxation of the atlanto-axial joint in polytrauma patients] Weisskopf M, et al. **Chirurg** 1999 Jul; 70(7):818–22 (25 ref.) (Eng. Abstr.) **(Ger)**

[Injuries of the thoracic and lumbar spine] Eggers C, et al. **Unfallchirurg** 1998 Oct;101(10):779–90 (11 ref.) **(Ger)**

[Traumatic peripheral vascular injuries] Markgraf E, et al. **Unfallchirurg** 1998 Jul;101(7):508–19 (64 ref.) (Eng. Abstr.) **(Ger)**

[Quality management of early clinical treatment of severely injured patients] Nast-Kolb D, et al. **Unfallchirurg** 1999 May;102(5):338–46 (52 ref.) (Eng. Abstr.) **(Ger)**

[Intensive care for patients with multiple injuries] Waydhas C, et al. **Unfallchirurg** 1999 Jun;102(6):474–91 (82 ref.) **(Ger)**

THERAPY

ABC of intensive care: neurological support. Grant IS, et al. **BMJ** 1999 Jul 10;319(7202):110–3 (0 ref.)

Impalement and anorectal injuries in childhood: a retrospective study of 12 cases. Beiler HA, et al. **J Pediatr Surg** 1998 Aug;33(8):1287–91 (11 ref.)

Bilateral traumatic hip dislocation in a child: a case report and review of the literature. Sahin V, et al. **J Trauma** 1999 Mar;46(3):500–4 (23 ref.)

Outcome after polytrauma. Bouillon B, et al. **Langenbecks Arch Surg** 1998 Aug;383(3–4):228–34 (44 ref.)

Management priorities in patients with polytrauma. Krettek C, et al. **Langenbecks Arch Surg** 1998 Aug;383(3–4):220–7 (61 ref.)

[What is the strategy for management of a multiple trauma patient with a severe head injury?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):123–34 (47 ref.) **(Fre)**

[The polytraumatized patient. II (published erratum appears in Anasthesiol Intensivmed Notfallmed Schmerzther 1998 Dec;33(12):818)] Mauritz W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Sep; 33(9):565–80 (14 ref.) **(Ger)**

[Management of polytrauma patients in an international comparison] Oestern HJ. **Unfallchirurg** 1999 Feb; 102(2):80–91 (60 ref.) (Eng. Abstr.) **(Ger)**

[Cranial trauma and multiple trauma: from the street to the operating room] Stocchetti N, et al. **Minerva Anestesiol** 1999 Jun;65(6):353–6 (6 ref.) (Eng. Abstr.) **(Ita)**

[The principles of treating the traumatic disease in multiple injuries] Sheĭko VD. **Klin Khir** 1998;(11):44–7 (51 ref.) **(Ukr)**

ULTRASONOGRAPHY

Focused Assessment with Sonography for Trauma (FAST): results from an international consensus conference. Scalea TM, et al. **J Trauma** 1999 Mar;46(3):466–72 (25 ref.)

MULTIPLICATION-STIMULATING ACTIVITY see **INSULIN-LIKE GROWTH FACTOR II**

MULTIPOTENTIAL COLONY-STIMULATING FACTOR see **INTERLEUKIN-3**

MULTIVARIATE ANALYSIS

Linkage and association. Elston RC. **Genet Epidemiol** 1998; 15(6):565–76 (66 ref.)

Multivariate calibration: applications to pharmaceutical analysis. Forina M, et al. **J Pharm Biomed Anal** 1998 Oct;

18(1-2):21-33 (11 ref.)
The use of multivariate statistical methods in psychiatry. Everitt BS, et al. **Stat Methods Med Res** 1998 Sep; 7(3):253-77 (89 ref.)

MUMPS

[Mumps (epidemic parotitis)] Takita S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):154-7 (3 ref.) **(Jpn)**

[Wide-spread inflammation of the parotid glands (mumps): an underestimated disease. II. Development, use, efficacy and safety of mumps vaccines] Gałązka A, et al. **Przegl Epidemiol** 1998;52(4):401-12 (57 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Acute dysautonomia following mumps. Mathuranath PS, et al. **Neurol India** 1999 Jun;47(2):130-2 (12 ref.)

MUMPS VACCINE

Immunisation and type 1 diabetes mellitus: is there a link? Hiltunen M, et al. **Drug Saf** 1999 Mar;20(3):207-12 (36 ref.)

ECONOMICS

[Wide-spread inflammation of the parotid glands (mumps): an underestimated disease. II. Development, use, efficacy and safety of mumps vaccines] Gałązka A, et al. **Przegl Epidemiol** 1998;52(4):401-12 (57 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

[Wide-spread inflammation of the parotid glands (mumps): an underestimated disease. II. Development, use, efficacy and safety of mumps vaccines] Gałązka A, et al. **Przegl Epidemiol** 1998;52(4):401-12 (57 ref.) (Eng. Abstr.) **(Pol)**

MUNCHAUSEN SYNDROME

DIAGNOSIS

Munchausen's syndrome. Still alive and well. Baker PG. **Aust Fam Physician** 1999 Aug;28(8):805-7 (25 ref.)
Munchausen's syndrome. A case of factitious hemoptysis. Saed G, et al. **Panminerva Med** 1999 Mar;41(1):62-7 (23 ref.)
[Three cases of Munchausen's syndrome mimicking connective tissue diseases] Takahashi S, et al. **Ryumachi** 1998 Aug;38(4):618-22 (13 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

[Factitious disorders and Munchausens's syndrome. The state of research] Eckhardt-Henn A. **Psychother Psychosom Med Psychol** 1999 Mar-Apr; 49(3-4):75-89 (124 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Munchausen's syndrome. Still alive and well. Baker PG. **Aust Fam Physician** 1999 Aug;28(8):805-7 (25 ref.)

MUNCHAUSEN SYNDROME BY PROXY

Munchausen syndrome by proxy. Souid AK, et al. **Clin Pediatr (Phila)** 1998 Aug;37(8):497-503 (55 ref.)

DIAGNOSIS

Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Ben-Chetrit E, et al. **J Intern Med** 1998 Aug;244(2):175-8 (11 ref.)

MUPIROCIN

THERAPEUTIC USE

Opportunities for mupirocin calcium cream in the emergency department. Williford PM. **J Emerg Med** 1999 Jan-Feb; 17(1):213-20 (74 ref.)
New strategies for the use of mupirocin for the prevention of serious infection. Mehtar S. **J Hosp Infect** 1998 Sep;40 Suppl B:S39-44 (33 ref.)

MUR-NAC-L-ALA-D-ISOGLN see **ACETYLMURAMYL-ALANYL-ISOGLUTAMINE**

MURAMIC ACIDS

PHARMACOLOGY

Effects of muramyl peptides on macrophages, monokines, and sleep. Pabst MJ, et al. **Neuroimmunomodulation** 1999 Jul-Aug;6(4):261-83 (177 ref.)

MURAMIDASE

CHEMISTRY

Chimeras of human lysozyme and alpha-lactalbumin: an interesting tool for studying partially folded states during protein folding. Van Dael H. **Cell Mol Life Sci** 1998 Nov; 54(11):1217-30 (104 ref.)
Class-directed structure determination: foundation for a protein structure initiative. Terwilliger TC, et al. **Protein Sci** 1998 Sep;7(9):1851-6 (54 ref.)

IMMUNOLOGY

Antimicrobial and cytolytic polypeptides of amoeboid protozoa--effector molecules of primitive phagocytes. Leippe M. **Dev Comp Immunol** 1999 Jun-Jul;23(4-5):267-79 (64 ref.)
Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Braden BC, et al. **Immunol Rev** 1998 Jun; 163:45-57 (44 ref.)

MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE

Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Goffin C, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1079-93 (74 ref.)

METABOLISM

Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. Chambers HF. **J Infect Dis** 1999 Mar;179 Suppl 2:S353-9 (58 ref.)

MURAMYL DIPEPTIDE see **ACETYLMURAMYL-ALANYL-ISOGLUTAMINE**

MURDER see **HOMICIDE**

MUREIN see **PEPTIDOGLYCAN**

MURIDAE

ANATOMY & HISTOLOGY

Mechanical advantage of area of origin for the external pterygoid muscle in two murid rodents, Apodemus speciosus and Clethrionomys rufocanus. Satoh K. **J Morphol** 1999 Apr;240(1):1-14 (48 ref.)

GENETICS

Wild mice as a source of genetic polymorphism. Guénet JL. **Pathol Biol (Paris)** 1998 Nov;46(9):685-8 (7 ref.) **(Eng, Fre)**
Multiple genes governing biological functions in the genetic backgrounds of laboratory mice and Asian wild mice. Moriwaki K, et al. **Prog Exp Tumor Res** 1999;35:1-12 (19 ref.)

MURIDS see **MURIDAE**

MURINE HERPESVIRUS 1 see **MUROMEGALOVIRUS**

MURINE LEUKEMIA VIRUSES see **LEUKEMIA VIRUSES, MURINE**

MUROMEGALOVIRUS

IMMUNOLOGY

Cytomegaloviral control of MHC class I function in the mouse. Hengel H, et al. **Immunol Rev** 1999 Apr;168:167-76 (65 ref.)

MUROMONAB-CD3

THERAPEUTIC USE

New usage paradigms in antibody therapy: safety of the new agents. Pescovitz MD. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1201-2 (27 ref.)

MUS see **MURIDAE**

MUS MUSCULUS see **MICE**

MUSCA AUTUMNALIS see **MUSCIDAE**

MUSCA DOMESTICA see **HOUSEFLIES**

MUSCARINIC ACETYLCHOLINE RECEPTORS see **RECEPTORS, MUSCARINIC**

MUSCARINIC AGENTS see **CHOLINERGIC AGENTS**

MUSCARINIC AGONISTS

METABOLISM

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6-7):511-8 (17 ref.)

PHARMACOLOGY

Positive effects of allosteric modulators on the binding properties and the function of muscarinic acetylcholine receptors. Tuček S, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):241-3 (28 ref.)
Sixth International Symposium on Subtypes of Muscarinic Receptors. Summary and closing comments. Jenden DJ. **Life Sci** 1995;56(11-12):993-1000 (8 ref.)

THERAPEUTIC USE

Muscarinic receptor ligands and their therapeutic potential. Eglen RM, et al. **Curr Opin Chem Biol** 1999 Aug; 3(4):426-32 (43 ref.)
Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis. Fisher A, et al. **J Physiol Paris** 1998 Oct-Dec; 92(5-6):337-40 (20 ref.)
Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Flynn DD, et al. **Life Sci** 1995;56(11-12):869-76 (32 ref.)
The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Nusair S, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):360-7 (24 ref.)
[Medical treatment of gastroesophageal reflux by prokinetic drugs] Coffin B. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S90-6 (85 ref.) **(Fre)**
[Pilocarpine--new use for an old drug] Tishler M. **Harefuah** 1998 Aug;135(3-4):150-2 (25 ref.) **(Heb)**

MUSCARINIC ANTAGONISTS

see related
PARASYMPATHOLYTICS

ADVERSE EFFECTS

Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy. Schwantes U, et al. **Int J Clin Pharmacol Ther** 1999 May; 37(5):209-18 (79 ref.)

METABOLISM

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6-7):511-8 (17 ref.)

PHARMACOLOGY

Muscarinic regulation of Ca2+ signaling in mammalian atrial and ventricular myocardium. Endoh M. **Eur J Pharmacol** 1999 Jun 30;375(1-3):177-96 (104 ref.)
Positive effects of allosteric modulators on the binding properties and the function of muscarinic acetylcholine receptors. Tuček S, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):241-3 (28 ref.)
Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists. Jacobson KA, et al. **Life Sci** 1995;56(11-12):823-30 (29 ref.)
Sixth International Symposium on Subtypes of Muscarinic Receptors. Summary and closing comments. Jenden DJ. **Life Sci** 1995;56(11-12):993-1000 (8 ref.)
Muscarinic antagonists in development for disorders of smooth muscle function. Wallis RM, et al. **Life Sci** 1999; 64(6-7):395-401 (19 ref.)
Muscarinic receptor antagonists. Watson N, et al. **Pulm Pharmacol Ther** 1999;12(2):115-8 (41 ref.)

THERAPEUTIC USE

Factors involved in the success of antimuscarinic treatment. Abrams P, et al. **BJU Int** 1999 Mar;83 Suppl 2:42-7 (26 ref.)
Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. Kobelt G, et al. **BJU Int** 1999 Apr;83(6):583-90 (30 ref.)
Muscarinic receptor ligands and their therapeutic potential. Eglen RM, et al. **Curr Opin Chem Biol** 1999 Aug; 3(4):426-32 (43 ref.)
Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Barnes PJ, et al. **Life Sci** 1995; 56(11-12):853-9 (47 ref.)
Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Disse B, et al. **Life Sci** 1999;64(6-7):457-64 (20 ref.)
Can we justify ipratropium therapy as initial management of acute exacerbations of COPD? Demirkan K, et al. **Pharmacotherapy** 1999 Jul;19(7):838-43 (21 ref.)
Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Guay DR. **Pharmacotherapy** 1999 Mar;19(3):267-80 (26 ref.)

MUSCARINIC RECEPTORS see **RECEPTORS,**

MUSCARINIC RECEPTORS

MUSCARINIC

MUSCI see **MOSSES**

MUSCIDAE

DRUG EFFECTS

Influence of permethrin, diazinon and ivermectin treatments on insecticide resistance in the horn fly (Diptera: Muscidae). Byford RL, et al. **Int J Parasitol** 1999 Jan; 29(1):125–35; discussion 137–8 (38 ref.)

MUSCIMOL

see related
RECEPTORS, GABA-A

MUSCLE CONTRACTION

see related
MUSCLE FATIGUE
MUSCLE RELAXATION

Force generation simplified. Insights from laser temperature-jump experiments on contracting muscle fibers. Davis JS. **Adv Exp Med Biol** 1998;453:343–51; discussion 351–2 (20 ref.)

Work production and work absorption in muscle strips from vertebrate cardiac and insect flight muscle fibers. Maughan D, et al. **Adv Exp Med Biol** 1998;453:471–80 (9 ref.)

Crossbridge head detachment rate constants determined from a model that explains the behavior of both weakly- and strongly-binding crossbridges. Schoenberg M. **Adv Exp Med Biol** 1998;453:425–33; discussion 433–4 (21 ref.)

Dynamically determined contractile states of airway smooth muscle. Raboudi SH, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S176–8 (10 ref.)

The contractile apparatus of airway smooth muscle. Biophysics and biochemistry. Stephens NL, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S80–94 (44 ref.)

Obesity and increased contractile activity influence the protein content of UCP2 in human skeletal muscle. Simoneau JA, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S68–71 (28 ref.)

Cytoplasmic free concentrations of Ca2+ and Mg2+ in skeletal muscle fibers at rest and during contraction. Konishi M. **Jpn J Physiol** 1998 Dec;48(6):421–38 (114 ref.)

Contractile role of M2 and M3 muscarinic receptors in gastrointestinal smooth muscle [published erratum appears in Life Sci 1999;64(26):2535] Ehlert FJ, et al. **Life Sci** 1999; 64(6–7):387–94 (52 ref.)

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Hegde SS, et al. **Life Sci** 1999;64(6–7):419–28 (60 ref.)

Measurement tools used in the study of eccentric contraction-induced injury. Warren GL, et al. **Sports Med** 1999 Jan;27(1):43–59 (132 ref.)

[Calcium regulation of contraction and relaxation in skeletal muscle] Morimoto S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1744–52 (42 ref.) **(Jpn)**

DRUG EFFECTS

From pharmacomechanical coupling to G-proteins and myosin phosphatase [published erratum appears in Acta Physiol Scand 1999 Apr;165(4):423] Somlyo AP, et al. **Acta Physiol Scand** 1998 Dec;164(4):437–48 (74 ref.)

Effects of nitric oxide on the contraction of skeletal muscle. Maréchal G, et al. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1088–102 (142 ref.)

Preclinical pharmacology of alpha1-adrenoceptor antagonists. Martin DJ. **Eur Urol** 1999;36 Suppl 1:35–41; discussion 65 (23 ref.)

Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story. Herrmann-Frank A, et al. **J Muscle Res Cell Motil** 1999 Feb;20(2):223–37 (85 ref.)

PHYSIOLOGY

A molecular model for muscle contraction. Holmes KC. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):789–97 (40 ref.)

Vestibular evoked myogenic potentials in humans: a review. Ferber-Viart C, et al. **Acta Otolaryngol (Stockh)** 1999 Jan; 119(1):6–15 (51 ref.)

Cross-bridge cycling in smooth muscle: a short review. Arner A, et al. **Acta Physiol Scand** 1998 Dec;164(4):363–72 (123 ref.)

Involvement of small GTPases in the regulation of smooth muscle contraction. Pfitzer G, et al. **Acta Physiol Scand** 1998 Dec;164(4):449–56 (62 ref.)

Muscle contraction as a Markov process. I: Energetics of the process. Schutt CE, et al. **Acta Physiol Scand** 1998 Aug; 163(4):307–23 (138 ref.)

From pharmacomechanical coupling to G-proteins and myosin phosphatase [published erratum appears in Acta Physiol Scand 1999 Apr;165(4):423] Somlyo AP, et al. **Acta Physiol Scand** 1998 Dec;164(4):437–48 (74 ref.)

Induced potential model of muscular contraction mechanism and myosin molecular structure. Mitsui T. **Adv Biophys** 1999;36:107–58 (50 ref.)

Role of nitric oxide in contraction induced glucose transport. Balon TW. **Adv Exp Med Biol** 1998;441:87–95 (40 ref.)

Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Cushman SW, et al. **Adv Exp Med Biol** 1998;441:63–71 (74 ref.)

Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Hespel P, et al. **Adv Exp Med Biol** 1998;441:97–106 (53 ref.)

Amino acid transport during muscle contraction and its relevance to exercise. Rennie MJ, et al. **Adv Exp Med Biol** 1998;441:299–305 (13 ref.)

Regulation of second messengers associated with airway smooth muscle contraction and relaxation. Hakonarson H, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S115–22 (51 ref.)

Regulation and tuning of smooth muscle myosin. Sweeney HL. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S95–9 (37 ref.)

Task-specific design of skeletal muscle: balancing muscle structural composition. Lindstedt SL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):35–40 (28 ref.)

Intersegmental coordination in invertebrates and vertebrates. Skinner FK, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):725–32 (54 ref.)

Co-contraction of antagonistic muscles in man. Nielsen JB. **Dan Med Bull** 1998 Sep;45(4):423–35 (108 ref.)

Neurophysiology of positive and negative myoclonus [published erratum appears in Electroencephalogr Clin Neurophysiol 1999 Apr;110(4):785] Tassinari CA, et al. **Electroencephalogr Clin Neurophysiol** 1998 Sep; 107(3):181–95 (116 ref.)

Muscarinic regulation of Ca2+ signaling in mammalian atrial and ventricular myocardium. Endoh M. **Eur J Pharmacol** 1999 Jun 30;375(1–3):177–96 (104 ref.)

Muscarinic receptors in the failing human heart. Giessler C, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):197–202 (70 ref.)

Excitation–contraction–relaxation cycle: role of Ca2+-regulatory membrane proteins in normal, stimulated and pathological skeletal muscle (review). Murray BE, et al. **Int J Mol Med** 1998 Apr;1(4):677–87 (109 ref.)

Conformational changes of contractile proteins and their role in muscle contraction. Borovikov YS. **Int Rev Cytol** 1999; 189:267–301 (150 ref.)

Length dependence of active force production in skeletal muscle. Rassier DE, et al. **J Appl Physiol** 1999 May; 86(5):1445–57 (89 ref.)

1998 ISEK Congress Keynote Lecture: Motor units: how many, how large, what kind? International Society of Electrophysiology and Kinesiology. McComas AJ. **J Electromyogr Kinesiol** 1998 Dec;8(6):391–402 (67 ref.)

EMG assessment of back muscle function during cyclical lifting. Roy SH, et al. **J Electromyogr Kinesiol** 1998 Aug; 8(4):233–45 (33 ref.)

Functional role of M2 muscarinic receptors in the guinea pig ileum. Ehlert FJ, et al. **Life Sci** 1995;56(11–12):965–71 (26 ref.)

Professor Ebashi's impact on the study of the regulation of striated muscle contraction. Gergely J. **Mol Cell Biochem** 1999 Jan;190(1–2):5–8 (57 ref.)

Calcium ion regulation of muscle contraction: the regulatory role of troponin T. Ohtsuki I. **Mol Cell Biochem** 1999 Jan; 190(1–2):33–8 (40 ref.)

Control of calcium in skeletal muscle excitation–contraction coupling: implications for malignant hyperthermia. Wingertzahn MA, et al. **Mol Genet Metab** 1998 Oct; 65(2):113–20 (69 ref.)

What does chronic electrical stimulation teach us about muscle plasticity? Pette D, et al. **Muscle Nerve** 1999 Jun; 22(6):666–77 (190 ref.)

Ventrolateral medullary control of cardiovascular activity during muscle contraction. Ally A. **Neurosci Biobehav Rev** 1998;23(1):65–86 (206 ref.)

Regulation of cross-bridge cycling by Ca2+ in smooth muscle. Arner A, et al. **Rev Physiol Biochem Pharmacol** 1999;134:63–146 (527 ref.)

Comparative aspects of muscle elastic proteins. Maruyama K. **Rev Physiol Biochem Pharmacol** 1999;138:1–18 (62 ref.)

Physical biodynamics and performance capacities of muscle in patients with fibromyalgia syndrome. Jacobsen S. **Z Rheumatol** 1998;57 Suppl 2:43–6 (57 ref.)

[Study of molecular mechanisms of muscle contraction using polarization fluorometry] Borovikov IuS. **Tsitologiia** 1998; 40(8–9):715–34 (131 ref.) (Eng. Abstr.) **(Rus)**

MUSCLE CRAMP

EPIDEMIOLOGY

Satoyoshi's syndrome in an adult: a review of the literature of adult onset cases. Ikeda K, et al. **Intern Med** 1998 Sep; 37(9):784–7 (19 ref.)

PHYSIOPATHOLOGY

Past and current understanding of the pathophysiology of muscle cramps: why treatment of varicose veins does not relieve leg cramps. Jansen PH, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):222–9 (62 ref.)

THERAPY

Should people with nocturnal leg cramps drink tonic water and bitter lemon? Brasić JR. **Psychol Rep** 1999 Apr; 84(2):355–67 (69 ref.)

MUSCLE DYSTONIA see **DYSTONIA**

MUSCLE FATIGUE

[Muscle fatigue and dyspnea] Anania A, et al. **Minerva Med** 1998 Oct;89(10):365–9 (11 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Sarcoplasmic reticulum Ca(2+) release and muscle fatigue. Favero TG. **J Appl Physiol** 1999 Aug;87(2):471–83 (145 ref.)

Mechanisms of sarcopenia of aging. Short KR, et al. **J Endocrinol Invest** 1999;22(5 Suppl):95–105 (89 ref.)

Surface EMG and fatigue. Jurell KC. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):933–47, viii–ix (64 ref.)

Physical biodynamics and performance capacities of muscle in patients with fibromyalgia syndrome. Jacobsen S. **Z Rheumatol** 1998;57 Suppl 2:43–6 (57 ref.)

[Effect of high performance sports on energy metabolism] Schmidt W, et al. **Wien Med Wochenschr** 1998; 148(10):239–42 (34 ref.) (Eng. Abstr.) **(Ger)**

MUSCLE FIBERS

CHEMISTRY

Force generation simplified. Insights from laser temperature-jump experiments on contracting muscle fibers. Davis JS. **Adv Exp Med Biol** 1998;453:343–51; discussion 351–2 (20 ref.)

Why adult mammalian intrafusal and extrafusal fibers contain different myosin heavy-chain isoforms. Walro JM, et al. **Trends Neurosci** 1999 Apr;22(4):180–4 (49 ref.)

CYTOLOGY

Myoblast cell grafting into heart muscle: cellular biology and potential applications. Kessler PD, et al. **Annu Rev Physiol** 1999;61:219–42 (165 ref.)

METABOLISM

Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex. Grozdanovic Z, et al. **Histol Histopathol** 1999 Jan; 14(1):243–56 (116 ref.)

Cytoplasmic free concentrations of Ca2+ and Mg2+ in skeletal muscle fibers at rest and during contraction. Konishi M. **Jpn J Physiol** 1998 Dec;48(6):421–38 (114 ref.)

PHYSIOLOGY

Force generation simplified. Insights from laser temperature-jump experiments on contracting muscle fibers. Davis JS. **Adv Exp Med Biol** 1998;453:343–51; discussion 351–2 (20 ref.)

Insulin sensitivity, muscle fibre types, and membrane lipids. Helge JW, et al. **Adv Exp Med Biol** 1998;441:129–38 (56 ref.)

Work production and work absorption in muscle strips from vertebrate cardiac and insect flight muscle fibers. Maughan D, et al. **Adv Exp Med Biol** 1998;453:471–80 (9 ref.)

Influences of caloric restriction on age-associated skeletal muscle fiber characteristics and mitochondrial changes in rats and mice. Lee CM, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:182–91 (48 ref.)

Age-associated changes in the innervation of muscle fibers and changes in the mechanical properties of motor units. Luff AR. **Ann N Y Acad Sci** 1998 Nov 20;854:92–101 (67 ref.)

The alpha7beta1 integrin in muscle development and disease. Burkin DJ, et al. **Cell Tissue Res** 1999 Apr;296(1):183–90 (43 ref.)

Discharge properties of motoneurones: how are they matched to the properties and use of their muscle units? Kernell D, et al. **J Physiol Paris** 1999 Jan–Apr; 93(1–2):87–96 (84 ref.)

[Pathophysiology in muscle fiber necrosis and regeneration with a particular reference to regenerating process] Nonaka I. **Rinsho Shinkeigaku** 1998 Dec;38(12):997–1000 (10 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Muscle as a collagen fiber reinforced composite: a review of force transmission in muscle and whole limb. Huijing PA. **J Biomech** 1999 Apr;32(4):329–45 (71 ref.)

MUSCLE FIBERS, FAST-TWITCH

Control of muscle fibre and motoneuron diversification. Hughes SM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):54–64 (102 ref.)

METABOLISM

The role of hedgehog proteins in vertebrate slow and fast

skeletal muscle patterning. Hughes SM, et al. **Acta Physiol Scand** 1998 Jul;163(3):S7-10 (39 ref.)

PATHOLOGY

Hypertrophic branchial myopathy with uniform type 2 fibers: a case report. Kitagawa Y, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):465-71; discussion 471-2 (17 ref.)

MUSCLE FIBERS, INTERMEDIATE see **MUSCLE FIBERS, SLOW-TWITCH**

MUSCLE FIBERS, RED see **MUSCLE FIBERS, FAST-TWITCH**

MUSCLE FIBERS, SLOW-TWITCH

Control of muscle fibre and motoneuron diversification. Hughes SM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):54-64 (102 ref.)

METABOLISM

The role of hedgehog proteins in vertebrate slow and fast skeletal muscle patterning. Hughes SM, et al. **Acta Physiol Scand** 1998 Jul;163(3):S7-10 (39 ref.)

MUSCLE FIBERS, TYPE I see **MUSCLE FIBERS, SLOW-TWITCH**

MUSCLE FIBERS, TYPE II see **MUSCLE FIBERS, FAST-TWITCH**

MUSCLE FIBERS, WHITE see **MUSCLE FIBERS, FAST-TWITCH**

MUSCLE HYPERTONIA

DRUG THERAPY

Treatment of hyperfunctional lines of the face with botulinum toxin A. Binder WJ, et al. **Dermatol Surg** 1998 Nov; 24(11):1198-205 (32 ref.)

MUSCLE, INVOLUNTARY see **MUSCLE, SMOOTH**

MUSCLE NEOPLASMS

Common musculoskeletal tumors of childhood and adolescence. Arndt CA, et al. **N Engl J Med** 1999 Jul 29; 341(5):342-52 (100 ref.)

COMPLICATIONS

Epstein-Barr virus-associated renal smooth muscle neoplasm: report of a case with review of the literature. Creager AJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):277-81 (32 ref.)

Fibrous dysplasia with intramuscular myxoma (Mazabraud's syndrome). Report of a case and review of the literature. Thomachot B, et al. **Rev Rhum Engl Ed** 1999 Mar; 66(3):180-3 (15 ref.)

[Recurrent spontaneous pneumothorax as the earliest indication of the pulmonary metastasis of a synovial sarcoma?] Bode F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):318-20 (10 ref.) **(Ger)**

DIAGNOSIS

Malignant tumors about the knee. Frink SJ, et al. **Am J Knee Surg** 1998 Fall;11(4):257-66 (33 ref.)

Evaluation and management of tumors about the knee. Yaw KM. **Am J Knee Surg** 1998 Fall;11(4):241-5 (3 ref.)

Magnetic resonance imaging of musculoskeletal tumors: skeletal and soft tissue masses. Ma LD. **Curr Probl Diagn Radiol** 1999 Mar-Apr;28(2):29-62 (32 ref.)

Follow-up of musculoskeletal tumours. 2. Metastatic disease. Bearcroft PW, et al. **Eur Radiol** 1999;9(2):192-200 (100 ref.)

Destruction of the glenoid joint fossa by a tenosynovial giant-cell tumour of the skull base: a case report. Stojadinovic S, et al. **Int J Oral Maxillofac Surg** 1999 Apr; 28(2):132-4 (11 ref.)

[Diaphragmatic or juxtadiaphragmatic schwannoma?] Prudhomme M, et al. **Chirurgie** 1998 Jun;123(3):300-3 (11 ref.) (Eng. Abstr.) **(Fre)**

[Ewing's sarcoma of the soft tissues: apropos of 3 cases and review of the literature] Paoletti H, et al. **J Radiol** 1999 May;80(5):477-82 (26 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. Graadt van Roggen JF, et al. **J Pathol** 1998 Sep;186(1):3-7 (43 ref.)

PATHOLOGY

Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Nielsen GP, et al. **Am J Surg Pathol** 1998 Oct;22(10):1222-7 (14 ref.)

[Staging of musculoskeletal tumors in diagnostic imaging] Funovics M, et al. **Radiologe** 1999 Jul;39(7):591-9 (48 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

A case of a solitary metastatic diaphragmatic tumor--relation to the peritoneal stomata of the diaphragm. Funatsu K, et al. **Radiat Med** 1998 Sep-Oct;16(5):363-5 (6 ref.)

SECONDARY

Bone and skeletal muscle metastases from gastric adenocarcinoma: unusual radiographic, CT and scintigraphic features. Narváez JA, et al. **Eur Radiol** 1998; 8(8):1366-9 (23 ref.)

A case of a solitary metastatic diaphragmatic tumor--relation to the peritoneal stomata of the diaphragm. Funatsu K, et al. **Radiat Med** 1998 Sep-Oct;16(5):363-5 (6 ref.)

Port site recurrence of unexpected gallbladder carcinoma after a laparoscopic cholecystectomy: report of a case. Ohmura Y, et al. **Surg Today** 1999;29(1):71-5 (13 ref.)

[A gastric cancer showing an exclusive metastatic nest at the gastroenemius muscle] Kobayashi D, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1013-7 (24 ref.) **(Jpn)**

SURGERY

Re-implantation of autoclaved bone segments in musculoskeletal tumor surgery. Clinical experience in 9 patients followed for 1.1-8.4 years and review of the literature. Böhm P, et al. **Arch Orthop Trauma Surg** 1998; 118(1-2):57-65 (59 ref.)

ULTRASONOGRAPHY

Ultrasound in musculoskeletal tumors with emphasis on its role in tumor follow-up. Van der Woude HJ, et al. **Radiol Clin North Am** 1999 Jul;37(4):753-66 (24 ref.)

VETERINARY

Musculoskeletal system neoplasia. Schooley EK, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):535-42, vi (27 ref.)

MUSCLE PROTEINS

ANALYSIS

Structure and assembly of the sarcomeric M band. Fürst DO, et al. **Rev Physiol Biochem Pharmacol** 1999;138:163-202 (128 ref.)

CHEMISTRY

Regulation of the cross-bridge cycle: the effects of MgADP, LC17 isoforms and telokin. Somlyo AV, et al. **Acta Physiol Scand** 1998 Dec;164(4):381-8 (64 ref.)

Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579-84 (57 ref.)

Single-molecule biomechanics with optical methods. Mehta AD, et al. **Science** 1999 Mar 12;283(5408):1689-95 (81 ref.)

GENETICS

Transcriptional regulation of smooth muscle contractile apparatus expression. Solway J, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S100-8 (98 ref.)

The role of Pax3 and Pax7 in development and cancer. Mansouri A. **Crit Rev Oncog** 1998;9(2):141-9 (62 ref.)

Transcriptional regulation of the desmin and SM22 genes in vascular smooth muscle cells. Mericskay M, et al. **Curr Top Pathol** 1999;93:7-17 (51 ref.)

Involvement of IGF2 and H19 imprinting in choriocarcinoma development. Wake N, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S1-8 (21 ref.)

Differentiating one smooth operator from another [comment] Luft FC. **J Mol Med** 1999 Feb;77(2):255-7 (8 ref.) Comment on: J Mol Med 1999 Feb;77(2):294-8.

Development of the neuromuscular junction: genetic analysis in mice. Sanes JR, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):167-72 (26 ref.)

The genetics and molecular biology of the titin/connectin-like proteins of invertebrates. Benian GM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:235-68 (119 ref.)

The titin cDNA sequence and partial genomic sequences: insights into the molecular genetics, cell biology and physiology of the titin filament system. Kolmerer B, et al. **Rev Physiol Biochem Pharmacol** 1999;138:19-55 (82 ref.)

METABOLISM

The role of hedgehog proteins in vertebrate slow and fast skeletal muscle patterning. Hughes SM, et al. **Acta Physiol Scand** 1998 Jul;163(3):S7-10 (39 ref.)

Ryanodine receptor isoforms in excitation-contraction coupling. Ogawa Y, et al. **Adv Biophys** 1999;36:27-64 (209 ref.)

Gaining weight: the scientific basis of increasing skeletal muscle mass. Houston ME. **Can J Appl Physiol** 1999 Aug; 24(4):305-16 (48 ref.)

Discrepancy between muscle and whole body protein turnover. Deutz NE, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):29-32 (12 ref.)

Pathways of muscle protein breakdown in injury and sepsis. Hasselgren PO. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):155-60 (37 ref.)

Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. Lecker SH, et al. **J Nutr** 1999 Jan;129(1S Suppl):227S-237S (103 ref.)

Transfections of primary muscle cell cultures with plasmids coding for GFP linked to full-length and truncated muscle proteins. Dabiri GA, et al. **Methods Cell Biol** 1999; 58:239-60 (44 ref.)

Cardiac myofibrillar proteins: biochemical markers to estimate myocardial injury. Haider KH, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):31-9 (135 ref.)

Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure. Garibotto G. **Nutrition** 1999 Feb;15(2):145-55 (82 ref.)

Insulin action on skeletal muscle protein metabolism during catabolic states. Grizard J, et al. **Reprod Nutr Dev** 1999 Jan-Feb;39(1):61-74 (89 ref.)

PHYSIOLOGY

Regulation of smooth muscle actin-myosin interaction and force by calponin. Winder SJ, et al. **Acta Physiol Scand** 1998 Dec;164(4):415-26 (119 ref.)

Defining actin filament length in striated muscle: rulers and caps or dynamic stability? Littlefield R, et al. **Annu Rev Cell Dev Biol** 1998;14:487-525 (194 ref.)

Formation of the neuromuscular junction: molecules and mechanisms. Meier T, et al. **Bioessays** 1998 Oct; 20(10):819-29 (83 ref.)

Muscle assembly: a titanic achievement? Gregorio CC, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):18-25 (54 ref.)

Conformational changes of contractile proteins and their role in muscle contraction. Borovikov YS. **Int Rev Cytol** 1999; 189:267-301 (150 ref.)

Control of sarcomeric assembly: the flow of information on titin. Gautel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 138:97-137 (173 ref.)

The physiological role of titin in striated muscle. Horowits R. **Rev Physiol Biochem Pharmacol** 1999;138:57-96 (108 ref.)

[Cadherins, the development and regeneration of the neuromuscular axis] Mege RM, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):796-801 (58 ref.) (Eng. Abstr.) **(Fre)**

MUSCLE RELAXANTS, CENTRAL

ADMINISTRATION & DOSAGE

Intrathecal baclofen in the treatment of dystonia. Ford B, et al. **Adv Neurol** 1998;78:199-210 (56 ref.)

ADVERSE EFFECTS

Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Glynne P, et al. **Am J Kidney Dis** 1999 Jan;33(1):133-7 (22 ref.)

EEG changes in intrathecal baclofen overdose: a case report and review of the literature. Fakhoury T, et al. **Electroencephalogr Clin Neurophysiol** 1998 Nov; 107(5):339-42 (24 ref.)

[Tizanidine-induced toxic hepatitis (letter)] Afonso Pérez E, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):478-9 (9 ref.) **(Spa)**

ECONOMICS

The new relaxants: are they worth it? Bevan DR. **Can J Anaesth** 1999 May;46(5 Pt 2):R88-100 (32 ref.) **(Eng, Fre)**

THERAPEUTIC USE

An approach to switching patients from baclofen to tizanidine. Brenner R, et al. **Hosp Med** 1998 Oct; 59(10):778-82 (12 ref.)

Malignant hyperthermia [see comments] Denborough M. **Lancet** 1998 Oct 3;352(9134):1131-6 (57 ref.) Comment in: Lancet 1998 Nov 28;352(9142):1785. Comment in: Lancet 1998 Nov 28;352(9142):1785-6.

Antispasticity medications. Nance PW, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):337-55, viii (96 ref.)

Special considerations for medication use in children with developmental disabilities. Rempel G, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):493-509 (81 ref.)

Pharmacologic therapies. Von Feldt JM, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):473-87, ix (46 ref.)

MUSCLE RELAXANTS, DEPOLARIZING see **NEUROMUSCULAR DEPOLARIZING AGENTS**

MUSCLE RELAXANTS, NON-DEPOLARIZING see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

MUSCLE RELAXATION

[Calcium regulation of contraction and relaxation in skeletal muscle] Morimoto S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1744–52 (42 ref.) **(Jpn)**

PHYSIOLOGY

G protein signalling pathways in myometrium: affecting the balance between contraction and relaxation. Sanborn BM, et al. **Rev Reprod** 1998 Sep;3(3):196–205 (77 ref.)

MUSCLE RIGIDITY

ETIOLOGY

[A case report of steroid-responsive progressive encephalomyelitis with rigidity showing muscle stiffness limited to the upper body] Matsuno S, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):680–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

MUSCLE, SKELETAL

Using skeletal muscle as an artificial endocrine tissue. MacColl GS, et al. **J Endocrinol** 1999 Jul;162(1):1–9 (70 ref.)

[Recurrent spontaneous pneumothorax as the earliest indication of the pulmonary metastasis of a synovial sarcoma?] Bode F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):318–20 (10 ref.) **(Ger)**

ABNORMALITIES

Asymptomatic accessory soleus muscle. John MM, et al. **J Foot Ankle Surg** 1999 Mar–Apr;38(2):150–3 (21 ref.)

Accessory soleus muscle: a case report and review of the literature. Palaniappan M, et al. **Pediatr Radiol** 1999 Aug; 29(8):610–2 (12 ref.)

ANATOMY & HISTOLOGY

Length dependence of active force production in skeletal muscle. Rassier DE, et al. **J Appl Physiol** 1999 May; 86(5):1445–57 (89 ref.)

Anomalous extensor muscles of the hand: a review. Tan ST, et al. **J Hand Surg [Am]** 1999 May;24(3):449–55 (49 ref.)

Anatomical and technical considerations in surface electromyography. Ferdjallah M, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):925–31 (38 ref.)

[Functional imaging of human muscle] Leroy-Willig A, et al. **Rev Neurol (Paris)** 1998 Jun;154(5):379–88 (70 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Local and systemic consequences of severe ischemia and reperfusion of the skeletal muscle. Physiopathology and prevention. Defraigne JO, et al. **Acta Chir Belg** 1998 Aug; 98(4):176–86 (62 ref.)

Aprotinin attenuates platelet accumulation in ischaemia-reperfusion-injured porcine skeletal muscle. Birk-Sørensen L, et al. **Blood Coagul Fibrinolysis** 1999 Jun; 10(4):157–65 (62 ref.)

The role of prophylactic fasciotomy and medical treatment in limb ischemia and revascularization. Hofmeister EP, et al. **Hand Clin** 1998 Aug;14(3):457–65, x (53 ref.)

Vascular control of nutrient delivery by flow redistribution within muscle: implications for exercise and post-exercise muscle metabolism. Clark MG, et al. **Int J Sports Med** 1998 Aug;19(6):391–400 (70 ref.)

Control of skeletal muscle perfusion at the onset of dynamic exercise. Delp MD. **Med Sci Sports Exerc** 1999 Jul; 31(7):1011–8 (99 ref.)

Cardiovascular dynamics at the onset of exercise. Hughson RL, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):1005–10 (41 ref.)

Muscle blood flow during exercise: the limits of reductionism. Joyner MJ, et al. **Med Sci Sports Exerc** 1999 Jul; 31(7):1036–40 (29 ref.)

Adaptation of blood flow during the rest to work transition in humans. Shoemaker JK, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):1019–26 (87 ref.)

Is physiological angiogenesis in skeletal muscle regulated by changes in microcirculation? Hudlicka O. **Microcirculation** 1998;5(1):5–23 (85 ref.)

Microvascular pathophysiology of skeletal muscle ischemia-reperfusion. Durán WN, et al. **Semin Vasc Surg** 1998 Sep;11(3):203–14 (63 ref.)

Buerger's disease: the role of omental transfer [letter] Puneet, et al. **Trop Doct** 1999 Apr;29(2):118–20 (4 ref.)

[Pathophysiology and clinical aspects of ischemia-reperfusion damage to skeletal muscles] Schellong SM, et al. **Vasa** 1998 Nov;27(4):207–15 (108 ref.) (Eng. Abstr.) **(Ger)**

[Bilateral diabetic infarction of the thigh adductor muscles in a diabetic female patient-- A case report and review of the literature] Satoh A, et al. **Rinsho Shinkeigaku** 1999 Feb-Mar;39(2-3):321–6 (27 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Extracellular modifications to muscle collagen: implications for meat quality. McCormick RJ. **Poult Sci** 1999 May; 78(5):785–91 (30 ref.)

CYTOLOGY

Insulin sensitivity, muscle fibre types, and membrane lipids. Helge JW, et al. **Adv Exp Med Biol** 1998;441:129–38 (56 ref.)

Aprotinin attenuates platelet accumulation in ischaemia-reperfusion-injured porcine skeletal muscle. Birk-Sørensen L, et al. **Blood Coagul Fibrinolysis** 1999 Jun; 10(4):157–65 (62 ref.)

Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. Goldspink G. **J Anat** 1999 Apr;194 (Pt 3):323–34 (67 ref.)

[Gene transfer in skeletal muscle cell and gene therapy] Tian J, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jul;77(7):556–8 (14 ref.) **(Chi)**

DRUG EFFECTS

Nutritional antioxidants as therapeutic and preventive modalities in exercise-induced muscle damage. Goldfarb AH. **Can J Appl Physiol** 1999 Jun;24(3):249–66 (74 ref.)

Effects of nitric oxide on the contraction of skeletal muscle. Maréchal G, et al. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1088–102 (142 ref.)

Effect of growth hormone on adipose tissue and skeletal muscle lipoprotein lipase activity in humans. Richelsen B. **J Endocrinol Invest** 1999;22(5 Suppl):10–5 (31 ref.)

Effects of testosterone and growth hormone on muscle function. Urban RJ. **J Lab Clin Med** 1999 Jul;134(1):7–10 (34 ref.)

Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story. Herrmann-Frank A, et al. **J Muscle Res Cell Motil** 1999 Feb;20(2):223–37 (85 ref.)

Insulin action on skeletal muscle protein metabolism during catabolic states. Grizard J, et al. **Reprod Nutr Dev** 1999 Jan-Feb;39(1):61–74 (89 ref.)

Lysine 49 phospholipase A2 proteins. Ownby CL, et al. **Toxicon** 1999 Mar;37(3):411–45 (120 ref.)

[Blockade of the ion channels of the skeletal muscle acetylcholine receptor] Danilov AF. **Eksp Klin Farmakol** 1998 Nov-Dec;61(6):73–5 (22 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Extrinsic influences on limb muscle organisation. Blagden CS, et al. **Cell Tissue Res** 1999 Apr;296(1):141–50 (139 ref.)

Genetic and epigenetic control of muscle development in vertebrates. Brand-Saberi B, et al. **Cell Tissue Res** 1999 Apr;296(1):199–212 (181 ref.)

Muscle development during vertebrate limb outgrowth. Büscher D, et al. **Cell Tissue Res** 1999 Apr;296(1):131–9 (78 ref.)

Transcriptional mechanisms regulating MyoD expression in the mouse. Chen JC, et al. **Cell Tissue Res** 1999 Apr; 296(1):213–9 (59 ref.)

Regulation of hypaxial muscle development. Dietrich S. **Cell Tissue Res** 1999 Apr;296(1):175–82 (59 ref.)

The recombinant limb as a model for the study of limb patterning, and its application to muscle development. Fernandez-Teran M, et al. **Cell Tissue Res** 1999 Apr; 296(1):121–9 (58 ref.)

Myotome formation: a multistage process. Kalcheim C, et al. **Cell Tissue Res** 1999 Apr;296(1):161–73 (71 ref.)

M-cadherin and its sisters in development of striated muscle. Kaufmann U, et al. **Cell Tissue Res** 1999 Apr;296(1):191–8 (77 ref.)

Fibroblast-growth-factor-induced additional limbs in the study of initiation of limb formation, limb identity, myogenesis, and innervation. Ohuchi H, et al. **Cell Tissue Res** 1999 Apr;296(1):45–56 (79 ref.)

Determination and development of the larval muscle pattern in Drosophila melanogaster. Paululat A, et al. **Cell Tissue Res** 1999 Apr;296(1):151–60 (93 ref.)

Gene regulation by patterned electrical activity during neural and skeletal muscle development. Buonanno A, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):110–20 (111 ref.)

Integrins during muscle development and in muscular dystrophies. Gullberg D, et al. **Front Biosci** 1998 Oct 15; 3:D1039–50 (101 ref.)

[Molecular mechanism of limb muscle patterning] Yamamoto M. **Kaibogaku Zasshi** 1998 Dec;73(6):667–76 (56 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Hormone-sensitive lipase (HSL) expression and regulation in skeletal muscle. Langfort J, et al. **Adv Exp Med Biol** 1998;441:219–28 (23 ref.)

Lipoprotein lipase and the disposition of dietary fatty acids. Fielding BA, et al. **Br J Nutr** 1998 Dec;80(6):495–502 (61 ref.)

The effects of endurance training on muscle fibre types and enzyme activities. Taylor AW, et al. **Can J Appl Physiol** 1999 Feb;24(1):41–53 (76 ref.)

Sarco/endoplasmic reticulum Ca2+ (SERCA)-pumps: link to heart beats and calcium waves. Misquitta CM, et al. **Cell Calcium** 1999 Apr;25(4):277–90 (126 ref.)

Control levels of acetylcholinesterase expression in the mammalian skeletal muscle. Grubic Z, et al. **Chem Biol Interact** 1999 May 14;119–120:309–19 (32 ref.)

Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism. Vestergaard H. **Dan Med Bull** 1999 Feb;46(1):13–34 (293 ref.)

Age-related chemical modification of the skeletal muscle sarcoplasmic reticulum Ca-ATPase of the rat. Schöneich C, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):221–31 (69 ref.)

Contribution of muscle proteinases to meat tenderization. Jiang ST. **Proc Natl Sci Counc Repub China B** 1998 Jul; 22(3):97–107 (102 ref.)

GROWTH & DEVELOPMENT

The role of hedgehog proteins in vertebrate slow and fast skeletal muscle patterning. Hughes SM, et al. **Acta Physiol Scand** 1998 Jul;163(3):S7–10 (39 ref.)

M-cadherin and its sisters in development of striated muscle. Kaufmann U, et al. **Cell Tissue Res** 1999 Apr;296(1):191–8 (77 ref.)

Muscle development: electrical control of gene expression. Hughes SM. **Curr Biol** 1998 Dec 3;8(24):R892–4 (11 ref.)

Muscle minus myoD. Olson EN, et al. **Dev Biol** 1998 Oct 15;202(2):153–6 (23 ref.)

Zinc finger proteins: watchdogs in muscle development. Krempler A, et al. **Mol Gen Genet** 1999 Mar;261(2):209–15 (72 ref.)

Influence of growth factors on poultry myogenic satellite cells. McFarland DC. **Poult Sci** 1999 May;78(5):747–58 (139 ref.)

Absence of growth hormone-induced avian muscle growth in vivo. Vasilatos-Younken R. **Poult Sci** 1999 May; 78(5):759–68 (108 ref.)

Dietary supplements and the promotion of muscle growth with resistance exercise. Kreider RB. **Sports Med** 1999 Feb; 27(2):97–110 (103 ref.)

Why adult mammalian intrafusal and extrafusal fibers contain different myosin heavy-chain isoforms. Walro JM, et al. **Trends Neurosci** 1999 Apr;22(4):180–4 (49 ref.)

INJURIES

Post-traumatic ectopic calcification in the muscles of athletes: a review. King JB. **Br J Sports Med** 1998 Dec; 32(4):287–90 (20 ref.)

Radical species in inflammation and overtraining. Tiidus PM. **Can J Physiol Pharmacol** 1998 May;76(5):533–8 (77 ref.)

Muscle injuries associated with soccer. Saartok T. **Clin Sports Med** 1998 Oct;17(4):811–7, viii (29 ref.)

Muscle strain injury: diagnosis and treatment. Noonan TJ, et al. **J Am Acad Orthop Surg** 1999 Jul-Aug;7(4):262–9 (20 ref.)

Isolated and combined lesions of the axillary nerve. A review of 146 cases. Bonnard C, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):212–7 (25 ref.)

The management of shock and local injury in traumatic rhabdomyolysis. Nespoli A, et al. **Minerva Anestesiol** 1999 May;65(5):256–62 (36 ref.)

Exercise-induced muscle damage and potential mechanisms for the repeated bout effect. McHugh MP, et al. **Sports Med** 1999 Mar;27(3):157–70 (76 ref.)

[Diagnosis, first aid and classification of muscle injuries in sports medicine] Bily W, et al. **Sportverletz Sportschaden** 1998 Sep;12(3):87–93 (70 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Activity-dependent regulation of muscle genes: repressive and stimulatory effects of innervation. Buonanno A, et al. **Acta Physiol Scand** 1998 Jul;163(3):217–26 (66 ref.)

Neural regulation of myosin gene expression in regenerating skeletal muscle. Schiaffino S, et al. **Acta Physiol Scand** 1998 Jul;163(3):S11–5 (32 ref.)

Enhancement and resetting of locomotor activity by muscle afferents. Pearson KG, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:203–15 (36 ref.)

Specification of neuronal connectivity: ETS marks the spot [comment] Ghosh A, et al. **Cell** 1998 Oct 30;95(3):303–6 (17 ref.) Comment on: Cell 1998 Oct 30;95(3):393–407.

Muscle development: electrical control of gene expression. Hughes SM. **Curr Biol** 1998 Dec 3;8(24):R892–4 (11 ref.)

Isolated and combined lesions of the axillary nerve. A review of 146 cases. Bonnard C, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):212–7 (25 ref.)

Anatomic and technical considerations in needle electromyography of the lumbar spine. Frank LW, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):795–814, vi–vii (76 ref.)

[Dorsoventral limb patterning based on anatomical analysis of muscles and nerve plexuses] Akita K. **Kaibogaku Zasshi** 1998 Dec;73(6):643–54 (143 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The role of hedgehog proteins in vertebrate slow and fast skeletal muscle patterning. Hughes SM, et al. **Acta Physiol Scand** 1998 Jul;163(3):S7–10 (39 ref.)

Skeletal muscle fatty acid transport and transporters. Bonen A, et al. **Adv Exp Med Biol** 1998;441:193–205 (72 ref.)

Role of transverse tubules (T-tubules) in muscle glucose

transport. Dohm GL, et al. **Adv Exp Med Biol** 1998; 441:27–34 (17 ref.)
Intracellular transport of fatty acids in muscle. Role of cytoplasmic fatty acid–binding protein. Glatz JF, et al. **Adv Exp Med Biol** 1998;441:207–18 (56 ref.)
Anaplerosis of the tricarboxylic acid cycle in human skeletal muscle during exercise. Magnitude, sources, and potential physiological significance. Graham TE, et al. **Adv Exp Med Biol** 1998;441:271–86 (44 ref.)
Pyruvate dehydrogenase complex activation status and acetyl group availability as a site of interchange between anaerobic and oxidative metabolism during intense exercise. Greenhaff PL, et al. **Adv Exp Med Biol** 1998;441:287–98 (51 ref.)
Snareing GLUT4 at the plasma membrane in muscle and fat. Hashiramoto M, et al. **Adv Exp Med Biol** 1998; 441:47–61 (121 ref.)
GLUT5 expression and fructose transport in human skeletal muscle. Hundal HS, et al. **Adv Exp Med Biol** 1998; 441:35–45 (37 ref.)
Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. Ruderman NB, et al. **Adv Exp Med Biol** 1998; 441:263–70 (31 ref.)
Transport of long-chain fatty acids across the muscular endothelium. Van der Vusse GJ, et al. **Adv Exp Med Biol** 1998;441:181–91 (32 ref.)
Training induced changes in the fatty acid composition of skeletal muscle lipids. Functional aspects. Vessby B, et al. **Adv Exp Med Biol** 1998;441:139–45 (29 ref.)
Protein and amino acid metabolism in human muscle. Wagenmakers AJ. **Adv Exp Med Biol** 1998;441:307–19 (39 ref.)
Applications of NMR spectroscopy to study muscle glycogen metabolism in man. Roden M, et al. **Annu Rev Med** 1999; 50:277–90 (56 ref.)
Regulation of fatty acid oxidation in skeletal muscle. Rasmussen BB, et al. **Annu Rev Nutr** 1999;19:463–84 (85 ref.)
Complex interactions between skeletal muscle ryanodine receptor and dihydropyridine receptor proteins. Leong P, et al. **Biochem Cell Biol** 1998;76(5):681–94 (188 ref.)
Musculoskeletal change during spaceflight: a new view of an old problem. Goode A. **Br J Sports Med** 1999 Jun; 33(3):154 (9 ref.)
Glutamine: a potentially useful supplement for athletes. Antonio J, et al. **Can J Appl Physiol** 1999 Feb;24(1):1–14 (64 ref.)
The effects of endurance training on muscle fibre types and enzyme activities. Taylor AW, et al. **Can J Appl Physiol** 1999 Feb;24(1):41–53 (76 ref.)
Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. Apple FS. **Clin Chim Acta** 1999 Jun 30;284(2):151–9 (24 ref.)
Role of fats in exercise. Types and quality. Turcotte LP. **Clin Sports Med** 1999 Jul;18(3):485–98 (81 ref.)
Counter-regulatory hormones and mechanisms in amino acid metabolism with special reference to the catabolic response in skeletal muscle. Hasselgren PO, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):9–14 (50 ref.)
Inter-organ protein and carbohydrate metabolic relationships during sepsis: necessary evils or uncanny coincidences? Vary TC. **Curr Opin Clin Nutr Metab Care** 1999 May; 2(3):235–42 (64 ref.)
Muscle differentiation: more complexity to the network of myogenic regulators. Arnold HH, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):539–44 (51 ref.)
Recent advances in skeletal-muscle-based gene therapy. Marshall DJ, et al. **Curr Opin Genet Dev** 1998 Jun; 8(3):360–5 (35 ref.)
Searching for ways to upregulate GLUT4 glucose transporter expression in muscle. Zorzano A, et al. **Gen Pharmacol** 1998 Nov;31(5):705–13 (119 ref.)
Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin–glycoprotein complex. Grozdanovic Z, et al. **Histol Histopathol** 1999 Jan; 14(1):243–56 (116 ref.)
Excitation–contraction–relaxation cycle: role of Ca2+–regulatory membrane proteins in normal, stimulated and pathological skeletal muscle (review). Murray BE, et al. **Int J Mol Med** 1998 Apr;1(4):677–87 (109 ref.)
Skeletal muscle substrate metabolism. Hoppeler H. **Int J Obes Relat Metab Disord** 1999 Apr;23 Suppl 3:S7–10 (18 ref.)
Uncoupling protein-2 (UCP2) and uncoupling protein-3 (UCP3) expression in adipose tissue and skeletal muscle in humans. Langin D, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S64–7 (36 ref.)
Obesity and increased contractile activity influence the protein content of UCP2 in human skeletal muscle. Simoneau JA, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S68–71 (28 ref.)
Effects of exercise on dietary protein requirements. Lemon PW. **Int J Sport Nutr** 1998 Dec;8(4):426–47 (95 ref.)
Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. Goldspink G. **J Anat** 1999 Apr;194 (Pt 3):323–34 (67 ref.)
Mechanisms of insulin resistance in non-oxidative glucose metabolism: the role of glycogen synthase. Beck-Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):255–79 (39 ref.)
Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. Ruderman NB, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):295–308 (52 ref.)
Lactate transport in skeletal muscle – role and regulation of the monocarboxylate transporter. Juel C, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):633–42 (65 ref.)
1997 Sir William Refshauge Lecture. Skeletal muscle glucose metabolism during exercise: implications for health and performance. Hargreaves M. **J Sci Med Sport** 1998 Dec; 1(4):195–202 (59 ref.)
Cytoplasmic free concentrations of Ca2+ and Mg2+ in skeletal muscle fibers at rest and during contraction. Konishi M. **Jpn J Physiol** 1998 Dec;48(6):421–38 (114 ref.)
Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Luiken JJ, et al. **Lipids** 1999;34 Suppl:S169–75 (41 ref.)
The peculiar collagens of mussel byssus. Waite JH, et al. **Matrix Biol** 1998 Jun;17(2):93–106 (69 ref.)
Complementary measures for promoting insulin sensitivity in skeletal muscle. McCarty MF. **Med Hypotheses** 1998 Dec;51(6):451–64 (193 ref.)
Muscle blood flow during exercise: the limits of reductionism. Joyner MJ, et al. **Med Sci Sports Exerc** 1999 Jul; 31(7):1036–40 (29 ref.)
Exercise training–induced alterations in skeletal muscle antioxidant capacity: a brief review. Powers SK, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):987–97 (101 ref.)
Transfections of primary muscle cell cultures with plasmids coding for GFP linked to full-length and truncated muscle proteins. Dabiri GA, et al. **Methods Cell Biol** 1999; 58:239–60 (44 ref.)
Adaptation of the ubiquitin–proteasome proteolytic pathway in cancer cachexia. Attaix D, et al. **Mol Biol Rep** 1999 Apr;26(1–2):77–82 (43 ref.)
Role of the ubiquitin–proteasome pathway in sepsis-induced muscle catabolism. Hasselgren PO. **Mol Biol Rep** 1999 Apr; 26(1–2):71–6 (39 ref.)
Comparison of properties of Ca2+ release channels between rabbit and frog skeletal muscles. Ogawa Y, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):191–201 (80 ref.)
Insulin action in skeletal muscle from patients with NIDDM. Zierath JR, et al. **Mol Cell Biochem** 1998 May; 182(1–2):153–60 (65 ref.)
Molecular mechanisms and putative signalling events controlling utrophin expression in mammalian skeletal muscle fibres. Gramolini AO, et al. **Neuromuscul Disord** 1998 Aug;8(6):351–61 (144 ref.)
Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure. Garibotto G. **Nutrition** 1999 Feb;15(2):145–55 (82 ref.)
Expression of the ryanodine receptor type 3 in skeletal muscle. A new partner in excitation–contraction coupling? Sorrentino V, et al. **Trends Cardiovasc Med** 1999 Jan–Feb; 9(1–2):54–61 (41 ref.)
[Gene transfer DNA drugs directed into skeletal muscle and its uses in cardiovascular diseases] Tang J, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct;77(10):799–800 (21 ref.) (Eng. Abstr.) **(Chi)**
[Regulation of mammalian muscle myosin gene expression] Nieznański K. **Postepy Biochem** 1999;45(1):12–20 (136 ref.) **(Pol)**

PATHOLOGY

Magnetic resonance imaging of regenerating and dystrophic mouse muscle. McIntosh LM, et al. **Biochem Cell Biol** 1998; 76(2–3):532–41 (61 ref.)
Etiology of exercise–induced muscle damage. Clarkson PM, et al. **Can J Appl Physiol** 1999 Jun;24(3):234–48 (93 ref.)
Chiropractic intervention in the treatment of joint and soft tissue disorders. Crawford JP. **Can J Appl Physiol** 1999 Jun;24(3):279–89 (66 ref.)
Massage and ultrasound as therapeutic modalities in exercise–induced muscle damage. Tiidus PM. **Can J Appl Physiol** 1999 Jun;24(3):267–78 (50 ref.)
Tubular aggregates in skeletal muscle: their functional significance and mechanisms of pathogenesis [editorial] Morgan-Hughes JA. **Curr Opin Neurol** 1998 Oct; 11(5):439–42 (22 ref.)
Acute swelling of the limbs: magnetic resonance pictorial review of fascial and muscle signal changes. Révelon G, et al. **Eur J Radiol** 1999 Apr;30(1):11–21 (14 ref.)
Transgenic mouse models of muscle aging. Musarò A, et al. **Exp Gerontol** 1999 Apr;34(2):147–56 (33 ref.)
Focal myositis of the sternocleidomastoid muscle. Cain AJ, et al. **J Laryngol Otol** 1998 Jul;112(7):687–9 (10 ref.)
Spinal muscle pathology. Valberg SJ. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):87–96, vi–vii (15 ref.)
Morphologic aspects of fibromyalgia. Pongratz DE, et al. **Z Rheumatol** 1998;57 Suppl 2:47–51 (14 ref.)
[Muscle biopsy: an essential stage in the diagnosis of myopathic syndromes of the girdle (editorial)] Navarro C. **Neurologia** 1999 Jun–Jul;14(6):262–5 (14 ref.) **(Spa)**
[Focal myositis: report of a case in pediatric age and review of the literature] Lorenzo-Sanz G, et al. **Rev Neurol** 1998 Sep;27(157):505–8 (28 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Activity-dependent regulation of muscle genes: repressive and stimulatory effects of innervation. Buonanno A, et al. **Acta Physiol Scand** 1998 Jul;163(3):217–26 (66 ref.)
The age-related motor disability: underlying mechanisms in skeletal muscle at the motor unit, cellular and molecular level. Larsson L. **Acta Physiol Scand** 1998 Jul;163(3):S27–9 (24 ref.)
Neural regulation of myosin gene expression in regenerating skeletal muscle. Schiaffino S, et al. **Acta Physiol Scand** 1998 Jul;163(3):S11–5 (32 ref.)
Role of nitric oxide in contraction induced glucose transport. Balon TW. **Adv Exp Med Biol** 1998;441:87–95 (40 ref.)
Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Cushman SW, et al. **Adv Exp Med Biol** 1998;441:63–71 (74 ref.)
Age-related changes in the microcirculation of skeletal muscle. Degens H. **Adv Exp Med Biol** 1998;454:343–8 (35 ref.)
Insulin signaling and glucose transport in insulin resistant skeletal muscle. Special reference to GLUT4 transgenic and GLUT4 knockout mice. Galuska D, et al. **Adv Exp Med Biol** 1998;441:73–85 (67 ref.)
Insulin sensitivity, muscle fibre types, and membrane lipids. Helge JW, et al. **Adv Exp Med Biol** 1998;441:129–38 (56 ref.)
Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Hespel P, et al. **Adv Exp Med Biol** 1998;441:97–106 (53 ref.)
Training and fatty acid metabolism. Kiens B. **Adv Exp Med Biol** 1998;441:229–38 (36 ref.)
Anatomy of glucose transporters in skeletal muscle. Effects of insulin and contractions. Ploug T, et al. **Adv Exp Med Biol** 1998;441:17–26 (41 ref.)
Amino acid transport during muscle contraction and its relevance to exercise. Rennie MJ, et al. **Adv Exp Med Biol** 1998;441:299–305 (13 ref.)
Training effects on muscle glucose transport during exercise. Richter EA, et al. **Adv Exp Med Biol** 1998;441:107–16 (56 ref.)
Regulation of fat/carbohydrate interaction in human skeletal muscle during exercise. Spriet LL. **Adv Exp Med Biol** 1998; 441:249–61 (45 ref.)
An overview of muscle glucose uptake during exercise. Sites of regulation. Wasserman DH, et al. **Adv Exp Med Biol** 1998;441:1–16 (122 ref.)
Intramuscular mechanisms regulating fatty acid oxidation during exercise. Winder WW. **Adv Exp Med Biol** 1998; 441:239–48 (36 ref.)
Fat metabolism in exercise. Wolfe RR. **Adv Exp Med Biol** 1998;441:147–56 (16 ref.)
Intrinsic and extrinsic factors in muscle aging. Cannon JG. **Ann N Y Acad Sci** 1998 Nov 20;854:72–7 (30 ref.)
Age-associated changes in the response of skeletal muscle cells to exercise and regeneration. Grounds MD. **Ann N Y Acad Sci** 1998 Nov 20;854:78–91 (110 ref.)
Oxidative stress and aging. Role of exercise and its influences on antioxidant systems. Ji LL, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:102–17 (78 ref.)
Influences of caloric restriction on age-associated skeletal muscle fiber characteristics and mitochondrial changes in rats and mice. Lee CM, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:182–91 (48 ref.)
Age-associated changes in the innervation of muscle fibers and changes in the mechanical properties of motor units. Luff AR. **Ann N Y Acad Sci** 1998 Nov 20;854:92–101 (67 ref.)
Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Black BL, et al. **Annu Rev Cell Dev Biol** 1998;14:167–96 (141 ref.)
Defining actin filament length in striated muscle: rulers and caps or dynamic stability? Littlefield R, et al. **Annu Rev Cell Dev Biol** 1998;14:487–525 (194 ref.)
Magnetic resonance imaging of regenerating and dystrophic mouse muscle. McIntosh LM, et al. **Biochem Cell Biol** 1998; 76(2–3):532–41 (61 ref.)
Determinants and control of breathing during muscular exercise. Whipp BJ, et al. **Br J Sports Med** 1998 Sep; 32(3):199–211 (84 ref.)
Gaining weight: the scientific basis of increasing skeletal muscle mass. Houston ME. **Can J Appl Physiol** 1999 Aug; 24(4):305–16 (48 ref.)
Dystroglycan versatility. Hemler ME. **Cell** 1999 May 28; 97(5):543–6 (18 ref.)
The alpha7beta1 integrin in muscle development and disease. Burkin DJ, et al. **Cell Tissue Res** 1999 Apr;296(1):183–90 (43 ref.)
Studies of evolutionary temperature adaptation: muscle function and locomotor performance in Antarctic fish. Franklin CE. **Clin Exp Pharmacol Physiol** 1998 Sep; 25(9):753–6 (30 ref.)
The biomechanics of kicking in soccer. Barfield WR. **Clin Sports Med** 1998 Oct;17(4):711–28, vi (52 ref.)
The physiology and biomechanics of competitive swimming. Troup JP. **Clin Sports Med** 1999 Apr;18(2):267–85 (69 ref.)
Task-specific design of skeletal muscle: balancing muscle structural composition. Lindstedt SL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):35–40 (28 ref.)
Co-contraction of antagonistic muscles in man. Nielsen JB. **Dan Med Bull** 1998 Sep;45(4):423–35 (108 ref.)
The mechanics of quadrupedal locomotion. How is the body propelled by muscles? Schamhardt HC. **Eur J Morphol** 1998 Dec;36(4–5):272–9 (14 ref.)

MUSCLE, SKELETAL

Muscle activity in the slalom turn of alpine skiing and in-line skating. Zeglinksi CM, et al. **Int J Sports Med** 1998 Oct; 19(7):447-54 (22 ref.)

Length dependence of active force production in skeletal muscle. Rassier DE, et al. **J Appl Physiol** 1999 May; 86(5):1445-57 (89 ref.)

Transmission of forces within mammalian skeletal muscles. Monti RJ, et al. **J Biomech** 1999 Apr;32(4):371-80 (69 ref.)

1998 ISEK Congress Keynote Lecture: Motor units: how many, how large, what kind? International Society of Electrophysiology and Kinesiology. McComas AJ. **J Electromyogr Kinesiol** 1998 Dec;8(6):391-402 (67 ref.)

1998 ISEK Congress Keynote Lecture: The use of electromyography in applied physiology. International Society of Electrophysiology and Kinesiology. Moritani T, et al. **J Electromyogr Kinesiol** 1998 Dec;8(6):363-81 (100 ref.)

EMG assessment of back muscle function during cyclical lifting. Roy SH, et al. **J Electromyogr Kinesiol** 1998 Aug; 8(4):233-45 (33 ref.)

Ca2+ sparks in frog skeletal muscle: generation by one, some, or many SR Ca2+ release channels? Schneider MF. **J Gen Physiol** 1999 Mar;113(3):365-72 (23 ref.)

Early days in the research to localize skeletal muscle acetylcholinesterases. Couteaux R. **J Physiol Paris** 1998 Apr;92(2):59-62 (26 ref.)

Professor Ebashi's impact on the study of the regulation of striated muscle contraction. Gergely J. **Mol Cell Biochem** 1999 Jan;190(1-2):5-8 (57 ref.)

In situ measurements of creatine kinase flux by NMR. The lessons from bioengineered mice. Nicolay K, et al. **Mol Cell Biochem** 1998 Jul;184(1-2):195-208 (56 ref.)

Body composition, skeletal muscle function, and exercise performance in chronic respiratory disease. Fitting JW. **Monaldi Arch Chest Dis** 1998 Oct;53(5):574-6 (20 ref.)

What does chronic electrical stimulation teach us about muscle plasticity? Pette D, et al. **Muscle Nerve** 1999 Jun; 22(6):666-77 (190 ref.)

Sensory input and control of grip. Johansson RS. **Novartis Found Symp** 1998;218:45-59; discussion 59-63 (40 ref.)

Neuromuscular control: introduction and overview. van Leeuwen JL. **Philos Trans R Soc Lond B Biol Sci** 1999 May 29;354(1385):841-7 (33 ref.)

Surface EMG and fatigue. Jurell KC. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):933-47, viii-ix (64 ref.)

Functional properties of myosin isoforms in avian muscle. Bandman E. **Poult Sci** 1999 May;78(5):729-34 (79 ref.)

The physiological role of titin in striated muscle. Horowits R. **Rev Physiol Biochem Pharmacol** 1999;138:57-96 (108 ref.)

Comparative aspects of muscle elastic proteins. Maruyama K. **Rev Physiol Biochem Pharmacol** 1999;138:1-18 (62 ref.)

The effects of functional knee bracing on muscle function and performance. Styf J. **Sports Med** 1999 Aug;28(2):77-81 (35 ref.)

Oxygen uptake kinetics during exercise. Xu F, et al. **Sports Med** 1999 May;27(5):313-27 (100 ref.)

Desmin cytoskeleton in muscle integrity and function. Capetanaki Y, et al. **Subcell Biochem** 1998;31:463-95 (146 ref.)

Regeneration of skeletal and cardiac muscle in mammals: do nonprimate models resemble human pathology? Borisov AB. **Wound Repair Regen** 1999 Jan-Feb;7(1):26-35 (88 ref.)

[Functional imaging of human muscle] Leroy-Willig A, et al. **Rev Neurol (Paris)** 1998 Jun;154(5):379-88 (70 ref.) (Eng. Abstr.) **(Fre)**

[Neuromuscular monitoring. Standard procedures] Fuchs-Buder T. **Anaesthesist** 1998 Aug;47(8):629-37 (65 ref.) (Eng. Abstr.) **(Ger)**

[Physical activity and aging] Kressig R, et al. **Schweiz Med Wochenschr** 1998 Aug 4;128(31-32):1181-6 (43 ref.) (Eng. Abstr.) **(Ger)**

[Calcium regulation of contraction and relaxation in skeletal muscle] Morimoto S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1744-52 (42 ref.) **(Jpn)**

[Sarcopenia: definition and clinical implications] Kostka T. **Pol Merkuriusz Lek** 1999 Feb;6(32):89-91 (32 ref.) (Eng. Abstr.) **(Pol)**

[Biotechnological functional systems] Bokser Ola. **Vestn Ross Akad Med Nauk** 1999;(6):29-34 (19 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 2):S1-40 (577 ref.)

Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Casaburi R. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):407-18 (89 ref.)

Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Tenover JS. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):419-25 (39 ref.)

Central role of peripheral mechanisms in exercise intolerance in chronic heart failure: the muscle hypothesis. Piepoli M. **Cardiologia** 1998 Sep;43(9):909-17 (84 ref.)

Exercise capacity and skeletal muscle myosin heavy chains in CHF [editorial] Vescovo G, et al. **G Ital Cardiol** 1999 Feb;29(2):214-9 (49 ref.)

Characteristics of skeletal muscle in mdx mutant mice. De la Porte S, et al. **Int Rev Cytol** 1999;191:99-148 (329 ref.)

Anabolic therapies in chronic obstructive pulmonary disease. Casaburi R. **Monaldi Arch Chest Dis** 1998 Aug;53(4):454-9 (94 ref.)

Peripheral skeletal muscles and exercise performance in patients with chronic obstructive pulmonary disease. Gosselink R, et al. **Monaldi Arch Chest Dis** 1998 Aug; 53(4):419-23 (39 ref.)

[Research respects and status of functional neuromuscular stimulation] Dou H, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):81-6 (25 ref.) (Eng. Abstr.) **(Chi)**

SURGERY

Specialized surgical exposure for revision total knee: quadriceps snip and patellar turndown. Barrack RI. **Instr Course Lect** 1999;48:149-52 (13 ref.)

Vastus slide and controlled perforations. Head WC, et al. **Instr Course Lect** 1999;48:13-7 (9 ref.)

TRANSPLANTATION

[Serratus anterior muscle flap: indications and sequelae. 26 cases and review of the literature] Fassio E, et al. **Ann Chir Plast Esthet** 1999 Apr;44(2):175-82; discussion 183 (34 ref.) (Eng. Abstr.) **(Fre)**

[Muscle-aponeurotic transposition for treatment of anal incontinence] Sobrado CW, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Jul-Aug; 53(4):205-13 (74 ref.) (Eng. Abstr.) **(Por)**

ULTRASTRUCTURE

Role of transverse tubules (T-tubules) in muscle glucose transport. Dohm GL, et al. **Adv Exp Med Biol** 1998; 441:27-34 (17 ref.)

Defining actin filament length in striated muscle: rulers and caps or dynamic stability? Littlefield R, et al. **Annu Rev Cell Dev Biol** 1998;14:487-525 (194 ref.)

Muscle as a collagen fiber reinforced composite: a review of force transmission in muscle and whole limb. Huijing PA. **J Biomech** 1999 Apr;32(4):329-45 (71 ref.)

MUSCLE, SMOOTH

Epstein-Barr virus-associated renal smooth muscle neoplasm: report of a case with review of the literature. Creager AJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):277-81 (32 ref.)

The myofibroblast in neoplasia. Schürch W. **Curr Top Pathol** 1999;93:135-48 (57 ref.)

ANATOMY & HISTOLOGY

Applicability of the sliding filament/crossbridge paradigm to smooth muscle. Gunst SJ. **Rev Physiol Biochem Pharmacol** 1999;134:7-61 (255 ref.)

[Assessment of the tunica muscularis mucosae of the bladder wall: necropsy study] Vera-Sempere FJ, et al. **Actas Urol Esp** 1998 Oct;22(9):726-34 (22 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Cross-bridge cycling in smooth muscle: a short review. Arner A, et al. **Acta Physiol Scand** 1998 Dec;164(4):363-72 (123 ref.)

Measurement of [Ca2+]i in smooth muscle strips using front-surface fluorimetry. Kanaide H. **Methods Mol Biol** 1999;114:269-77 (9 ref.)

CYTOLOGY

Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Powell DW, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):C183-201 (232 ref.)

Cellular and molecular mechanisms regulating airway smooth muscle proliferation and cell adhesion molecule expression. Panettieri RA Jr. **Am J Respir Crit Care Med** 1998 Nov; 158(5 Pt 3):S133-40 (62 ref.)

Some historical and philosophical reflections on the myofibroblast concept. Gabbiani G. **Curr Top Pathol** 1999; 93:1-5 (40 ref.)

Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Gauldie J, et al. **Curr Top Pathol** 1999;93:35-45 (38 ref.)

Modulation of myofibroblast and smooth-muscle phenotypes in the lung. Low RB. **Curr Top Pathol** 1999;93:19-26 (29 ref.)

Molecular mechanism of phenotypic modulation of smooth muscle cells. Sobue K, et al. **Horm Res** 1998;50 Suppl 2:15-24 (81 ref.)

Differentiating one smooth operator from another [comment] Luft FC. **J Mol Med** 1999 Feb;77(2):255-7 (8 ref.) Comment on: J Mol Med 1999 Feb;77(2):294-8.

Molecular and cellular phenotypes and their regulation in smooth muscle. Sartore S, et al. **Rev Physiol Biochem Pharmacol** 1999;134:235-320 (383 ref.)

[Airway myocytes as immune effector cells in the pathogenesis of bronchial asthma. Myocyte culture as an in vitro model] John M, et al. **Pneumologie** 1999 Jun; 53(6):302-6 (40 ref.) **(Ger)**

DRUG EFFECTS

From pharmacomechanical coupling to G-proteins and myosin phosphatase [published erratum appears in Acta Physiol Scand 1999 Apr;165(4):423] Somlyo AP, et al. **Acta Physiol Scand** 1998 Dec;164(4):437-48 (74 ref.)

Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle. Audolfsson G, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:39-47 (16 ref.)

Pharmacology of airway smooth muscle. Barnes PJ. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S123-32 (147 ref.)

Airway smooth muscle as a target of glucocorticoid action in the treatment of asthma. Hirst SJ, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S201-6 (63 ref.)

Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future. Truss MC, et al. **BJU Int** 1999 Mar;83 Suppl 2:36-41 (33 ref.)

Vitamin E and atherosclerosis. Chan AC. **J Nutr** 1998 Oct; 128(10):1593-6 (56 ref.)

Muscarinic antagonists in development for disorders of smooth muscle function. Wallis RM, et al. **Life Sci** 1999; 64(6-7):395-401 (19 ref.)

Cytokines induce airway smooth muscle cell hyperresponsiveness to contractile agonists. Amrani Y, et al. **Thorax** 1998 Aug;53(8):713-6 (47 ref.)

ENZYMOLOGY

Myosin light chain kinase: functional domains and structural motifs. Stull JT, et al. **Acta Physiol Scand** 1998 Dec; 164(4):471-82 (72 ref.)

Solid-phase ELISA for tissue transglutaminase, an endomysial target for possible serological diagnosis of celiac disease. Freeman HJ. **Can J Gastroenterol** 1998 Jul-Aug;12(5):323-4 (0 ref.)

Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Somlyo AP, et al. **Rev Physiol Biochem Pharmacol** 1999;134:201-34 (169 ref.)

IMMUNOLOGY

Mechanisms of immune sensitization of human bronchus. Rabe KF. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S161-70 (64 ref.)

INNERVATION

Autonomic regulation. i-NANC/e-NANC. Widdicombe JG. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S171-5 (51 ref.)

The central control of micturition and continence: implications for urology. Blok BF, et al. **BJU Int** 1999 Mar;83 Suppl 2:1-6 (32 ref.)

The enigma of autonomic failure in diabetes. Watkins PJ. **J R Coll Physicians Lond** 1998 Jul-Aug;32(4):360-5 (35 ref.)

METABOLISM

Focus on: "G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor" [editorial; comment] Galligan JJ. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1407-8 (14 ref.) Comment on: Am J Physiol 1998 Dec;275(6 Pt 1):C1409-16.

Muscarinic receptors and control of airway smooth muscle. Fryer AD, et al. **Am J Respir Crit Care Med** 1998 Nov; 158(5 Pt 3):S154-60 (63 ref.)

Regulation of second messengers associated with airway smooth muscle contraction and relaxation. Hakonarson H, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S115-22 (51 ref.)

The beta-adrenoceptor. Johnson M. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S146-53 (60 ref.)

Calcium release and calcium-activated chloride channels in airway smooth muscle cells. Kotlikoff MI, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S109-14 (24 ref.)

Transcriptional regulation of smooth muscle contractile apparatus expression. Solway J, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S100-8 (98 ref.)

Epithelium smooth muscle regulation and interactions. Spina D. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S141-5 (79 ref.)

Regulation and tuning of smooth muscle myosin. Sweeney HL. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S95-9 (37 ref.)

Calcium handling in airway smooth muscle: mechanisms and therapeutic implications. Janssen LJ. **Can Respir J** 1998 Nov-Dec;5(6):491-8 (26 ref.)

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Schmidt AM, et al. **Circ Res** 1999 Mar 19;84(5):489-97 (89 ref.)

Lipid oxidation products and vascular function. Bruckdorfer KR. **Free Radic Res** 1998 Jun;28(6):573-81 (74 ref.)

Redox regulation of signal transduction in cardiac and smooth muscle. Suzuki YJ, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):345-53 (72 ref.)

Differentiating one smooth operator from another [comment] Luft FC. **J Mol Med** 1999 Feb;77(2):255–7 (8 ref.) Comment on: J Mol Med 1999 Feb;77(2):294–8.
Expressional regulation of smooth muscle cell–specific genes in association with phenotypic modulation. Sobue K, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):105–18 (130 ref.)
[Regulatory mechanism of smooth muscle myosin] Katoh T. **Seikagaku** 1999 Apr;71(4):290–4 (21 ref.) **(Jpn)**
[Regulation of mammalian muscle myosin gene expression] Nieznański K. **Postepy Biochem** 1999;45(1):12–20 (136 ref.) **(Pol)**
[Formation and regulation of myosin light chain kinase and phosphatase complex in smooth muscle: the outlook] Sobieszek A. **Tsitologiia** 1998;40(6):568–78 (35 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Airway remodeling: potential contributions of subepithelial fibrosis and airway smooth muscle hypertrophy/hyperplasia to airway narrowing in asthma. Bento AM, et al. **Allergy Asthma Proc** 1998 Nov–Dec; 19(6):353–8 (46 ref.)
Glomerulosclerosis: the role of interstitial myofibroblasts in its progression. el Nahas M, et al. **Curr Top Pathol** 1999; 93:167–71 (31 ref.)
The myofibroblast as an inflammatory cell in pulmonary fibrosis. Phan SH, et al. **Curr Top Pathol** 1999;93:173–82 (57 ref.)
Myofibroblastic differentiation and extracellular matrix deposition in early stages of cholestatic fibrosis in rat liver. Tuchweber B, et al. **Curr Top Pathol** 1999;93:103–9 (30 ref.)
[Myotomy for esophageal muscular hypertrophy with eosinophil infiltration of the esophagus associated with toxocariasis revealed by esophageal motor disorder] D'Alteroche L, et al. **Gastroenterol Clin Biol** 1998 May; 22(5):541–5 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cross-bridge cycling in smooth muscle: a short review. Arner A, et al. **Acta Physiol Scand** 1998 Dec;164(4):363–72 (123 ref.)
Control of cross-bridge cycling by myosin light chain phosphorylation in mammalian smooth muscle. Butler TM, et al. **Acta Physiol Scand** 1998 Dec;164(4):389–400 (56 ref.)
Structural interactions between actin, tropomyosin, caldesmon and calcium binding protein and the regulation of smooth muscle thin filaments. Marston S, et al. **Acta Physiol Scand** 1998 Dec;164(4):401–14 (64 ref.)
PKC-dependent signalling mechanisms in differentiated smooth muscle. Morgan KG, et al. **Acta Physiol Scand** 1998 Dec;164(4):495–505 (112 ref.)
Inhibitory mechanisms for cross-bridge cycling: the nitric oxide–cGMP signal transduction pathway in smooth muscle relaxation. Murphy RA, et al. **Acta Physiol Scand** 1998 Dec;164(4):373–80 (66 ref.)
Involvement of small GTPases in the regulation of smooth muscle contraction. Pfitzer G, et al. **Acta Physiol Scand** 1998 Dec;164(4):449–56 (62 ref.)
From pharmacomechanical coupling to G-proteins and myosin phosphatase [published erratum appears in Acta Physiol Scand 1999 Apr;165(4):423] Somlyo AP, et al. **Acta Physiol Scand** 1998 Dec;164(4):437–48 (74 ref.)
Myosin light chain kinase: functional domains and structural motifs. Stull JT, et al. **Acta Physiol Scand** 1998 Dec; 164(4):471–82 (72 ref.)
Regulation of smooth muscle actin–myosin interaction and force by calponin. Winder SJ, et al. **Acta Physiol Scand** 1998 Dec;164(4):415–26 (119 ref.)
Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Powell DW, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):C183–201 (232 ref.)
Myofibroblasts. I. Paracrine cells important in health and disease. Powell DW, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):C1–9 (269 ref.)
Dynamically determined contractile states of airway smooth muscle. Raboudi SH, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S176–8 (10 ref.)
The contractile apparatus of airway smooth muscle. Biophysics and biochemistry. Stephens NL, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S80–94 (44 ref.)
Role of galanin in the gastrointestinal sphincters. Rattan S, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:143–55 (82 ref.)
Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Black BL, et al. **Annu Rev Cell Dev Biol** 1998;14:167–96 (141 ref.)
Excitation–contraction coupling in gastrointestinal and other smooth muscles. Bolton TB, et al. **Annu Rev Physiol** 1999; 61:85–115 (250 ref.)
Ionic conductances in gastrointestinal smooth muscles and interstitial cells of Cajal. Farrugia G. **Annu Rev Physiol** 1999;61:45–84 (130 ref.)
Cellular and molecular basis for electrical rhythmicity in gastrointestinal muscles. Horowitz B, et al. **Annu Rev Physiol** 1999;61:19–43 (136 ref.)
What's new in human wound-healing myofibroblasts? Moulin V, et al. **Curr Top Pathol** 1999;93:123–33 (35 ref.)
Non-adrenergic non-cholinergic relaxation of the rat stomach. Currò D, et al. **Gen Pharmacol** 1998 Nov; 31(5):697–703 (77 ref.)
Postnatal development of purinoceptors in rat visceral smooth muscle preparations. Hourani SM. **Gen Pharmacol** 1999 Jan;32(1):3–7 (47 ref.)
Molecular mechanism of phenotypic modulation of smooth muscle cells. Sobue K, et al. **Horm Res** 1998;50 Suppl 2:15–24 (81 ref.)
Electrophysiological properties of the bladder. Fry CH, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(5):291–8 (62 ref.)
Analysis of firing behaviour of human motoneurones within 'subprimary range'. Kudina LP. **J Physiol Paris** 1999 Jan–Apr;93(1–2):115–23 (22 ref.)
Functional role of M2 muscarinic receptors in the guinea pig ileum. Ehlert FJ, et al. **Life Sci** 1995;56(11–12):965–71 (26 ref.)
Contractile role of M2 and M3 muscarinic receptors in gastrointestinal smooth muscle [published erratum appears in Life Sci 1999;64(26):2535] Ehlert FJ, et al. **Life Sci** 1999, 64(6–7):387–94 (52 ref.)
Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Hegde SS, et al. **Life Sci** 1999;64(6–7):419–28 (60 ref.)
M2 signaling in smooth muscle cells. Kotlikoff MI, et al. **Life Sci** 1999;64(6–7):437–42 (29 ref.)
Regulation of uterine smooth muscle function during gestation. Riemer RK, et al. **Pediatr Res** 1998 Nov; 44(5):615–27 (146 ref.)
Myogenic and neurogenic factors in the control of pyeloureteral motility and ureteral peristalsis. Santicioli P, et al. **Pharmacol Rev** 1998 Dec;50(4):683–722 (248 ref.)
Regulation of cross-bridge cycling by Ca2+ in smooth muscle. Arner A, et al. **Rev Physiol Biochem Pharmacol** 1999;134:63–146 (527 ref.)
Applicability of the sliding filament/crossbridge paradigm to smooth muscle. Gunst SJ. **Rev Physiol Biochem Pharmacol** 1999;134:7–61 (255 ref.)
Calcium permeant ion channels in smooth muscle. Kotlikoff MI, et al. **Rev Physiol Biochem Pharmacol** 1999;134:147–99 (269 ref.)
Molecular and cellular phenotypes and their regulation in smooth muscle. Sartore S, et al. **Rev Physiol Biochem Pharmacol** 1999;134:235–320 (383 ref.)
Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Somlyo AP, et al. **Rev Physiol Biochem Pharmacol** 1999;134:201–34 (169 ref.)
[Electrophysiology and calcium signalling in human bronchial smooth muscle] Marthan R, et al. **Therapie** 1999 Jan–Feb;54(1):79–83 (29 ref.) (Eng. Abstr.) **(Fre)**
[Role of ciliary muscle in ocular physiology and disease] Nesterov AP, et al. **Vestn Oftalmol** 1999 Mar–Apr; 115(2):13–5 (10 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Structural and functional changes in the airway smooth muscle of asthmatic subjects. Seow CY, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S179–86 (57 ref.)
The physiology of ileo-anal pouch function. Levitt MD, et al. **Am J Surg** 1998 Oct;176(4):384–9 (78 ref.)
Overactive detrusor. Sullivan J, et al. **Curr Opin Urol** 1999 Jul;9(4):291–6 (54 ref.)
Interplay of matrix and myofibroblasts during hepatic fibrogenesis. Schuppan D, et al. **Curr Top Pathol** 1999; 93:205–18 (68 ref.)
Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptácek LJ. **Dig Dis Sci** 1999 Aug;44(8 Suppl):94S–96S (22 ref.)
Bladder instability and detrusor smooth muscle function. Fry CH, et al. **Exp Physiol** 1999 Jan;84(1):161–9 (37 ref.)
Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Jester JV, et al. **Prog Retin Eye Res** 1999 May;18(3):311–56 (111 ref.)
Airway hyperreactivity: direct smooth muscle approach. Stephens NL, et al. **Pulm Pharmacol Ther** 1999;12(2):97–101 (10 ref.)
Mechanisms of bladder smooth-muscle hypertrophy and decompensation: lessons from normal development and the response to outlet obstruction. Zderic SA, et al. **World J Urol** 1998;16(5):350–8 (50 ref.)

SURGERY

[Myotomy for esophageal muscular hypertrophy with eosinophil infiltration of the esophagus associated with toxocariasis revealed by esophageal motor disorder] D'Alteroche L, et al. **Gastroenterol Clin Biol** 1998 May; 22(5):541–5 (28 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

The aging bladder: morphology and urodynamics. Elbadawi A, et al. **World J Urol** 1998;16 Suppl 1:S10–34 (196 ref.)

MUSCLE, SMOOTH, VASCULAR

CHEMISTRY

Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. Heinecke JW. **FASEB J** 1999 Jul;13(10):1113–20 (79 ref.)
Heterogeneous activation mechanisms in the renal microvasculature. Navar LG, et al. **Kidney Int Suppl** 1998 Sep;67:S17–21 (30 ref.)

CYTOLOGY

Smooth muscle cell origin and its relation to heterogeneity in development and disease. Gittenberger-de Groot AC, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1589–94 (58 ref.)
Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Weber AA, et al. **Basic Res Cardiol** 1998;93 Suppl 3:54–7 (20 ref.)
Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. Hungerford JE, et al. **J Vasc Res** 1999 Jan–Feb;36(1):2–27 (300 ref.)
The mechanics of vascular cell motility. Shuster CB, et al. **Microcirculation** 1998;5(4):239–57 (186 ref.)
Role of integrin alpha(v)beta3 in vascular biology. Byzova TV, et al. **Thromb Haemost** 1998 Nov;80(5):726–34 (138 ref.)
Regulation of smooth muscle cell proliferation and migration. Clowes AW. **Transplant Proc** 1999 Feb–Mar;31(1–2):810–1 (12 ref.)

DRUG EFFECTS

Effect of the angiotensin-(1–7) peptide on nitric oxide release. Brosnihan KB. **Am J Cardiol** 1998 Nov 19;82(10A):17S–19S (12 ref.)
The role of corticosteriods in the regulation of vascular tone. Ullian ME. **Cardiovasc Res** 1999 Jan;41(1):55–64 (115 ref.)
Anti-atherosclerotic action of vascular D1 receptors. Yasunari K, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S36–40 (54 ref.)
Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. San Antonio JD, et al. **Connect Tissue Res** 1998;37(1–2):87–103 (96 ref.)
The differential effects of oestrogens and progestins on vascular tone [see comments] Sarrel PM. **Hum Reprod Update** 1999 May–Jun;5(3):205–9 (52 ref.) Comment in: Hum Reprod Update 1999 May–Jun;5(3):189–90.
Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. Schini-Kerth VB. **J Endocrinol Invest** 1999;22(5 Suppl):82–8 (38 ref.)
[Vascular effects of gestagens--biochemistry versus epidemiology] Kuhl H. **Zentralbl Gynakol** 1999; 121(2):67–78 (99 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

A common pathway for regulation of nutritive blood flow to the brain: arterial muscle membrane potential and cytochrome P450 metabolites. Harder DR, et al. **Acta Physiol Scand** 1998 Dec;164(4):527–32 (33 ref.)
MAP kinases and vascular smooth muscle function. Takahashi E, et al. **Acta Physiol Scand** 1998 Dec; 164(4):611–21 (106 ref.)
Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Hecker M, et al. **Gen Pharmacol** 1999 Jan;32(1):9–16 (86 ref.)
Cyclo-oxygenase-2 in vascular smooth muscle. Bishop-Bailey D, et al. **Int J Mol Med** 1999 Jan;3(1):41–8 (70 ref.)
Signal transduction in arteriosclerosis: mechanical stress-activated MAP kinases in vascular smooth muscle cells (review). Zou Y, et al. **Int J Mol Med** 1998 May; 1(5):827–34 (60 ref.)

GROWTH & DEVELOPMENT

Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. Hungerford JE, et al. **J Vasc Res** 1999 Jan–Feb;36(1):2–27 (300 ref.)

IMMUNOLOGY

Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Nicoletti A, et al. **Cardiovasc Res** 1999 Mar;41(3):532–43 (123 ref.)

INJURIES

Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Thyberg J. **Histol Histopathol** 1998 Jul;13(3):871–91 (279 ref.)

METABOLISM

Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. Hannan KM, et al. **Biochem Cell Biol** 1998;76(5):751–9 (85 ref.)
Cellular adhesion molecules on vascular smooth muscle cells. Braun M, et al. **Cardiovasc Res** 1999 Feb;41(2):395–401 (69 ref.)
Collagen synthesis in atherosclerosis: too much and not enough. Rekhter MD. **Cardiovasc Res** 1999 Feb; 41(2):376–84 (118 ref.)
Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Bornfeldt KE, et al. **Cell Signal** 1999 Jul;11(7):465–77 (170 ref.)
A novel Ca2+ channel in vascular smooth muscle? [editorial;

comment] Evans J, et al. **Circ Res** 1999 Oct 1;85(7):651-2 (13 ref.) Comment on: Circ Res 1999 Oct 1;85(7):596-605.
Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox [editorial] Sobel BE. **Circulation** 1999 May 18;99(19):2496-8 (41 ref.)
Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Waldron GJ, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):180-4 (39 ref.)
Molecular and cellular changes in vein grafts: influence of pulsatile stretch. Powell JT, et al. **Curr Opin Cardiol** 1998 Nov;13(6):453-8 (27 ref.)
Transcriptional regulation of the desmin and SM22 genes in vascular smooth muscle cells. Mericskay M, et al. **Curr Top Pathol** 1999;93:7-17 (51 ref.)
Structure and activation of the large latent transforming growth factor-Beta complex. Nunes I, et al. **J Am Optom Assoc** 1998 Oct;69(10):643-8 (45 ref.)
Mechanisms involved in the cellular calcium homeostasis in vascular smooth muscle: calcium pumps. Marin J, et al. **Life Sci** 1999;64(5):279-303 (253 ref.)
Angiotensin II and nitric oxide: a question of balance. Millatt LJ, et al. **Regul Pept** 1999 May 31;81(1-3):1-10 (83 ref.)
Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. Christ M, et al. **Steroids** 1999 Jan-Feb;64(1-2):35-41 (48 ref.)
[The individualization of activities of blood vessels] Chen MQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):203-9 (18 ref.) (Eng. Abstr.) **(Chi)**

PATHOLOGY

Irradiation for the treatment of intimal hyperplasia. Fortunato JE, et al. **Ann Vasc Surg** 1998 Sep;12(5):495-503 (53 ref.)
Mechanisms of plaque rupture: mechanical and biologic interactions. Arroyo LH, et al. **Cardiovasc Res** 1999 Feb; 41(2):369-75 (56 ref.)
Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Bennett MR. **Cardiovasc Res** 1999 Feb;41(2):361-8 (99 ref.)
Fibrous cap formation or destruction--the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Newby AC, et al. **Cardiovasc Res** 1999 Feb;41(2):345-60 (221 ref.)
Sarcoplasmic reticulum in vascular cells in hypertension and during proliferation. Lompré AM. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):553-7 (24 ref.)
Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Thyberg J. **Histol Histopathol** 1998 Jul;13(3):871-91 (279 ref.)
Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis (review). Andres V. **Int J Mol Med** 1998 Jul;2(1):81-9 (152 ref.)

PHYSIOLOGY

Gap junctions in vascular smooth muscle. Brink PR. **Acta Physiol Scand** 1998 Dec;164(4):349-56 (42 ref.)
A common pathway for regulation of nutritive blood flow to the brain: arterial muscle membrane potential and cytochrome P450 metabolites. Harder DR, et al. **Acta Physiol Scand** 1998 Dec;164(4):527-32 (33 ref.)
Long-term effects of intracellular calcium and growth factors on excitation and contraction in smooth muscle. Hellstrand P. **Acta Physiol Scand** 1998 Dec;164(4):637-44 (43 ref.)
Role of tyrosine phosphorylation in excitation-contraction coupling in vascular smooth muscle. Hughes AD, et al. **Acta Physiol Scand** 1998 Dec;164(4):457-69 (139 ref.)
Ca2+ channels, ryanodine receptors and Ca(2+)-activated K+ channels: a functional unit for regulating arterial tone. Jaggar JH, et al. **Acta Physiol Scand** 1998 Dec; 164(4):577-87 (69 ref.)
Interactions between membrane potential and intracellular calcium concentration in vascular smooth muscle. Nilsson H. **Acta Physiol Scand** 1998 Dec;164(4):559-66 (69 ref.)
Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function. Ohanian J, et al. **Acta Physiol Scand** 1998 Dec; 164(4):533-48 (138 ref.)
Molecular control of vascular smooth muscle cell differentiation. Owens GK. **Acta Physiol Scand** 1998 Dec; 164(4):623-35 (124 ref.)
The role of phospholamban and SERCA3 in regulation of smooth muscle-endothelial cell signalling mechanisms: evidence from gene-ablated mice. Paul RJ. **Acta Physiol Scand** 1998 Dec;164(4):589-97 (54 ref.)
The cytoskeleton of the vertebrate smooth muscle cell. Small JV, et al. **Acta Physiol Scand** 1998 Dec;164(4):341-8 (63 ref.)
K+ channel modulation in arterial smooth muscle. Standen NB, et al. **Acta Physiol Scand** 1998 Dec;164(4):549-57 (60 ref.)
MAP kinases and vascular smooth muscle function. Takahashi E, et al. **Acta Physiol Scand** 1998 Dec; 164(4):611-21 (106 ref.)
Impact of endothelin-1 on vascular structure and function. Stewart DJ. **Am J Cardiol** 1998 Nov 19;82(10A):14S-16S (12 ref.)
Activation of the mitogen-activated protein kinase pathway via the 5-HT2A receptor. Watts SW. **Ann N Y Acad Sci** 1998 Dec 15;861:162-8 (20 ref.)
Redox regulation of c-Ha-ras and osteopontin signaling in vascular smooth muscle cells: implications in chemical atherogenesis. Ramos KS. **Annu Rev Pharmacol Toxicol** 1999;39:243-65 (145 ref.)
Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Johnson RA, et al. **Braz J Med Biol Res** 1999 Jan;32(1):1-14 (57 ref.)
The myogenic response: established facts and attractive hypotheses. Schubert R, et al. **Clin Sci (Colch)** 1999 Apr; 96(4):313-26 (101 ref.)
Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. San Antonio JD, et al. **Connect Tissue Res** 1998;37(1-2):87-103 (96 ref.)
Insulin, cation metabolism and insulin resistance. Sowers JR, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):223-33 (65 ref.)
Mechanical influences on vascular smooth muscle cell function. Williams B. **J Hypertens** 1998 Dec;16(12 Pt 2):1921-9 (79 ref.)
Gender and vascular reactivity. Miller VM. **Lupus** 1999; 8(5):409-15 (76 ref.)
Signaling mechanisms underlying the vascular myogenic response. Davis MJ, et al. **Physiol Rev** 1999 Apr; 79(2):387-423 (402 ref.)
In vitro studies of the effects of beta-adrenergic drugs on retinal and posterior ciliary microarteries. Hoste AM. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S183-90 (66 ref.)
Regulation of smooth muscle cell proliferation and migration. Clowes AW. **Transplant Proc** 1999 Feb-Mar;31(1-2):810-1 (12 ref.)
[Effects of anesthetic agents on arterial reactivity] Boillot A, et al. **Ann Fr Anesth Reanim** 1999 Apr;18(4):415-29 (117 ref.) (Eng. Abstr.) **(Fre)**
[Endothelin-1 and cardiovascular diseases] Cracowski JL, et al. **Rev Med Interne** 1999 Jul;20(7):589-96 (58 ref.) (Eng. Abstr.) **(Fre)**
[Methods for exploring arteries in humans: application to the study of estrogens] Laurent S, et al. **Therapie** 1999 May-Jun;54(3):347-52 (27 ref.) (Eng. Abstr.) **(Fre)**
[Apoptosis and vascular remodeling] Tedgui A, et al. **Therapie** 1999 Jan-Feb;54(1):167-70 (31 ref.) (Eng. Abstr.) **(Fre)**
[Effect of cytochrome P450-dependent metabolites of arachidonic acid on the functional state of vessels] Krzhechkovskaia VV, et al. **Vopr Med Khim** 1998 Sep-Oct; 44(5):417-22 (28 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Growth factors and vascular smooth muscle cell growth responses. Delafontaine P. **Eur Heart J** 1998 Jul;19 Suppl G:G18-22 (47 ref.)
Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. Nakamura M. **J Card Fail** 1999 Jun; 5(2):127-38 (110 ref.)
Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Voelkel NF, et al. **Pulm Pharmacol Ther** 1997 Oct-Dec;10(5-6):231-41 (104 ref.)

RADIATION EFFECTS

Irradiation for the treatment of intimal hyperplasia. Fortunato JE, et al. **Ann Vasc Surg** 1998 Sep;12(5):495-503 (53 ref.)

ULTRASTRUCTURE

Gap junctions in vascular smooth muscle. Brink PR. **Acta Physiol Scand** 1998 Dec;164(4):349-56 (42 ref.)
The cytoskeleton of the vertebrate smooth muscle cell. Small JV, et al. **Acta Physiol Scand** 1998 Dec;164(4):341-8 (63 ref.)

VIROLOGY

Infectious agents in coronary artery disease: viral infection, aspirin, and gene expression in human coronary smooth muscle cells. Speir E, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II33-9 (60 ref.)

MUSCLE SPASTICITY

see related
SPASM

CLASSIFICATION

Beyond Ashworth. Electrophysiologic quantification of spasticity. Sehgal N, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):949-79, ix (175 ref.)

DIAGNOSIS

Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Mayer NH. **Muscle Nerve Suppl** 1997;6:S1-13 (23 ref.)
Common patterns of clinical motor dysfunction. Mayer NH, et al. **Muscle Nerve Suppl** 1997;6:S21-35 (13 ref.)
[Lower limb spasticity in adults. Clinical evaluation with motor block] Filipetti P, et al. **Neurochirurgie** 1998 Sep; 44(3):167-74 (18 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

An approach to switching patients from baclofen to tizanidine. Brenner R, et al. **Hosp Med** 1998 Oct; 59(10):778-82 (12 ref.)
Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Albany K. **Muscle Nerve Suppl** 1997;6:S221-31 (40 ref.)
Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Brin MF. **Muscle Nerve Suppl** 1997; 6:S208-20 (25 ref.)
Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Gracies JM, et al. **Muscle Nerve Suppl** 1997;6:S92-120 (162 ref.)
Traditional pharmacological treatments for spasticity. Part I: Local treatments. Gracies JM, et al. **Muscle Nerve Suppl** 1997;6:S61-91 (149 ref.)
Clinical trials of botulinum toxin in the treatment of spasticity. Simpson DM. **Muscle Nerve Suppl** 1997;6:S169-75 (24 ref.)
Antispasticity medications. Nance PW, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):337-55, viii (96 ref.)
[Treatment of spasticity with injections of botulinum toxin. Review of the literature] Fève A, et al. **Neurochirurgie** 1998 Sep;44(3):192-6 (33 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Spasticity, ataxia and fatigue in multiple sclerosis. Kesselring J, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):429-45 (82 ref.)

PHYSIOPATHOLOGY

Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Mayer NH. **Muscle Nerve Suppl** 1997;6:S1-13 (23 ref.)

REHABILITATION

Outcome measures in spasticity management. Pierson SH. **Muscle Nerve Suppl** 1997;6:S36-60 (43 ref.)

SURGERY

The surgical treatment of spasticity. Chambers HG. **Muscle Nerve Suppl** 1997;6:S121-8 (59 ref.)

THERAPY

A clinical overview of treatment decisions in the management of spasticity. Gormley ME Jr, et al. **Muscle Nerve Suppl** 1997;6:S14-20 (14 ref.)
Outcome measures in spasticity management. Pierson SH. **Muscle Nerve Suppl** 1997;6:S36-60 (43 ref.)
[Neurosurgical treatment of abnormal movement disorders and spasticity] Heikkinen E. **Duodecim** 1995; 111(21):2058-65 (17 ref.) **(Fin)**
[Lower limb spasticity in adults. Clinical evaluation with motor block] Filipetti P, et al. **Neurochirurgie** 1998 Sep; 44(3):167-74 (18 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of spasticity: an update] Teive HA, et al. **Arq Neuropsiquiatr** 1998 Dec;56(4):852-8 (30 ref.) (Eng. Abstr.) **(Por)**

MUSCLE SPINDLES

see related
REFLEX, STRETCH

MUSCLE, STRIATED see **MUSCLE, SKELETAL**

MUSCLE TENSION see **MUSCLE CONTRACTION**

MUSCLE TONUS

see related
DYSTONIA
MUSCLE HYPERTONIA

PHYSIOLOGY

Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension. Cardillo C, et al. **Vasc Med** 1998;3(2):138-44 (79 ref.)

MUSCLE, VOLUNTARY see **MUSCLE, SKELETAL**

MUSCLE WEAKNESS

New-onset sensory loss or alteration. Huff JS. **Emerg Med Clin North Am** 1998 Nov;16(4):811-24, vi-vii (16 ref.)

COMPLICATIONS

The role of muscle weakness in the pathogenesis of osteoarthritis. Hurley MV. **Rheum Dis Clin North Am** 1999 May;25(2):283-98, vi (125 ref.)

CONGENITAL

Congenital myasthenic syndromes. Engel AG. **J Child Neurol** 1999 Jan;14(1):38-41 (26 ref.)

ETIOLOGY

Neuromuscular blockade in the intensive care unit. Lewis KS, et al. **Am J Health Syst Pharm** 1999 Jan 1;56(1):72-5 (51 ref.)

Respiratory muscle function in endocrine diseases. Siafakas NM, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):154–9 (101 ref.)
Respiratory muscles in heart failure. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):150–3 (25 ref.)

METABOLISM

Fatty acid oxidation defects in muscle. Morris AA, et al. **Curr Opin Neurol** 1998 Oct;11(5):485–90 (50 ref.)

THERAPY

Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older? Zachwieja JJ, et al. **Phys Ther** 1999 Jan;79(1):76–82 (38 ref.)

MUSCLES

see related
SARCOLEMMA
SARCOPLASMIC RETICULUM

CHEMISTRY

A molecular model for muscle contraction. Holmes KC. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):789–97 (40 ref.)

CYTOLOGY

Using molecular genetics as a tool in understanding crawling cell locomotion in myoblasts. Peckham M, et al. **Biochem Soc Symp** 1999;65:281–99 (61 ref.)
Seeking muscle stem cells. Miller JB, et al. **Curr Top Dev Biol** 1999;43:191–219 (156 ref.)
Mechanisms of myofibroblast activity and phenotypic modulation. Serini G, et al. **Exp Cell Res** 1999 Aug 1; 250(2):273–83 (143 ref.)

DRUG EFFECTS

Nutritional supplements to increase muscle mass. Clarkson PM, et al. **Crit Rev Food Sci Nutr** 1999 Jul;39(4):317–28 (110 ref.)
Glucocorticoids and muscle catabolism. Hasselgren PO. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):201–5 (35 ref.)
Multiple sites of insulin resistance: muscle, liver and adipose tissue [comment] Stumvoll M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):107–10 (32 ref.) Comment on: Exp Clin Endocrinol Diabetes 1999 ;107(2):140–7.

EMBRYOLOGY

Myoblast cell grafting into heart muscle: cellular biology and potential applications. Kessler PD, et al. **Annu Rev Physiol** 1999;61:219–42 (165 ref.)
Muscle pattern diversification in Drosophila: the story of imaginal myogenesis. Roy S, et al. **Bioessays** 1999 Jun; 21(6):486–98 (78 ref.)
Essential genes for myoblast fusion in Drosophila embryogenesis. Paululat A, et al. **Mech Dev** 1999 May; 83(1–2):17–26 (87 ref.)
Comparison of foetal metabolic differentiation in three cattle muscles. Gagnière H, et al. **Reprod Nutr Dev** 1999 Jan–Feb; 39(1):105–12 (28 ref.)
[Cadherins, the development and regeneration of the neuromuscular axis] Mege RM, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):796–801 (58 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

The insulin receptor substrate 1 associates with phosphotyrosine phosphatase SHPTP2 in liver and muscle of rats. Lima MH, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1409–13 (17 ref.)
Glycogen storage diseases of muscle. DiMauro S, et al. **Curr Opin Neurol** 1998 Oct;11(5):477–84 (61 ref.)

GROWTH & DEVELOPMENT

Nutritional requirements to increase lean mass. Grandjean A. **Clin Sports Med** 1999 Jul;18(3):623–32 (18 ref.)

INJURIES

Painful conditions around the elbow. Putnam MD, et al. **Orthop Clin North Am** 1999 Jan;30(1):109–18 (32 ref.)
Measurement tools used in the study of eccentric contraction-induced injury. Warren GL, et al. **Sports Med** 1999 Jan;27(1):43–59 (132 ref.)

INNERVATION

Development and specification of muscle sensory neurons. Chen HH, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):405–9 (33 ref.)
Synapse formation molecules in muscle and autonomic ganglia: the dual constraint hypothesis. Bennett MR. **Prog Neurobiol** 1999 Feb;57(2):225–87 (257 ref.)

METABOLISM

Cellular mechanisms of insulin resistance in humans. Shulman GI. **Am J Cardiol** 1999 Jul 8;84(1A):3J–10J (28 ref.)
Glucocorticoids and muscle catabolism. Hasselgren PO. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):201–5 (35 ref.)
Fatty acid oxidation defects in muscle. Morris AA, et al. **Curr Opin Neurol** 1998 Oct;11(5):485–90 (50 ref.)
Molecular characterization of the creatine kinases and some historical perspectives. Qin W, et al. **Mol Cell Biochem** 1998 Jul;184(1–2):153–67 (117 ref.)
Creatine: a dietary supplement and ergogenic aid. Feldman EB. **Nutr Rev** 1999 Feb;57(2):45–50 (27 ref.)
Comparison of foetal metabolic differentiation in three cattle muscles. Gagnière H, et al. **Reprod Nutr Dev** 1999 Jan–Feb; 39(1):105–12 (28 ref.)
Intestinal absorption, blood transport and hepatic and muscle metabolism of fatty acids in preruminant and ruminant animals. Hocquette JF, et al. **Reprod Nutr Dev** 1999 Jan–Feb;39(1):27–48 (122 ref.)
[Antioxidative mechanisms in response to reactive forms of oxygen, apoptosis and differentiation of myogenic cells] Orzechowski A, et al. **Postepy Hig Med Dosw** 1998; 52(4):401–18 (73 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Mitochondria in organismal aging and degeneration. Cortopassi GA, et al. **Biochim Biophys Acta** 1999 Feb 9; 1410(2):183–93 (100 ref.)
Age-dependent atrophy and microgravity travel: what do they have in common? Wang E. **FASEB J** 1999;13 Suppl:S167–74 (72 ref.)
In utero fetal muscle biopsy: a precious aid for the prenatal diagnosis of Duchenne muscular dystrophy. Heckel S, et al. **Fetal Diagn Ther** 1999 May–Jun;14(3):127–32 (37 ref.)
[Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation] Okamoto T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug;36(8):696–701 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Muscle atrophy in isolated ACTH deficiency] Wada C, et al. **No To Shinkei** 1998 Sep;50(9):841–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

A molecular model for muscle contraction. Holmes KC. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):789–97 (40 ref.)
Muscle contraction as a Markov process. I: Energetics of the process. Schutt CE, et al. **Acta Physiol Scand** 1998 Aug; 163(4):307–23 (138 ref.)
Work production and work absorption in muscle strips from vertebrate cardiac and insect flight muscle fibers. Maughan D, et al. **Adv Exp Med Biol** 1998;453:471–80 (9 ref.)
Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Bross R, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):365–78 (45 ref.)
Muscle–tendon stresses and elastic energy storage during locomotion in the horse. Biewener AA. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):73–87 (44 ref.)
Selective gene expression during adaptation of muscle in response to different physiological demands. Goldspink G. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):5–15 (58 ref.)
Energy balance in muscle activity: simulations of ATPase coupled to oxidative phosphorylation and to creatine kinase. Kushmerick MJ. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):109–23 (33 ref.)
Some advances in integrative muscle physiology. Rome LC. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):51–72 (57 ref.)
Age-related physiological alterations to muscles and joints and potential exercise interventions for their improvement. Bemben MG. **J Okla State Med Assoc** 1999 Jan;92(1):13–20 (57 ref.)

TRANSPLANTATION

[Insufficiency of the anal sphincter--attempt at anorectal reconstruction] Bruch HP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:482–7 (16 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Monogenean neuromusculature: some structural and functional correlates. Halton DW, et al. **Int J Parasitol** 1998 Oct;28(10):1609–23 (33 ref.)

MUSCULAR ATROPHY

[Benign monomelic amyotrophy] Hamano T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):388–91 (12 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Myopathy in the course of corticosteroid treatment--new aspects] Wicher-Muniak E, et al. **Pol Arch Med Wewn** 1998 Sep;100(3):267–71 (25 ref.) **(Pol)**

METABOLISM

Discrepancy between muscle and whole body protein turnover. Deutz NE, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):29–32 (12 ref.)

PATHOLOGY

Mechanisms of sarcopenia of aging. Short KR, et al. **J Endocrinol Invest** 1999;22(5 Suppl):95–105 (89 ref.)
Morphologic aspects of fibromyalgia. Pongratz DE, et al. **Z Rheumatol** 1998;57 Suppl 2:47–51 (14 ref.)

THERAPY

Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older? Zachwieja JJ, et al. **Phys Ther** 1999 Jan;79(1):76–82 (38 ref.)

MUSCULAR ATROPHY, POSTPOLIOMYELITIS see **POSTPOLIOMYELITIS SYNDROME**

MUSCULAR ATROPHY, SPINAL

[Facioscapulohumeral SMA] Furukawa T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):382–3 (12 ref.) **(Jpn)**
[Wohlfart-Kugelberg-Welander disease (SMA type III)] Hirayama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):371–4 (10 ref.) **(Jpn)**
[Spinal progressive muscular atrophy] Shimizu T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):384–7 (16 ref.) **(Jpn)**
[Spinal and bulbar muscular atrophy (SBMA, Kennedy-Alter-Sung disease)] Tanaka F, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):375–8 (16 ref.) **(Jpn)**

COMPLICATIONS

Management of the respiratory complications of neuromuscular diseases in the pediatric intensive care unit. Birnkrant DJ, et al. **J Child Neurol** 1999 Mar;14(3):139–43 (13 ref.)

DRUG THERAPY

Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. Miller RG. **J Child Neurol** 1999 Mar;14(3):173–9 (41 ref.)

ETIOLOGY

[Spinal muscular atrophy: a hexosaminidase A deficiency phenotype] Kawanami T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):379–81 (15 ref.) **(Jpn)**

GENETICS

RNA splicing: more clues from spinal muscular atrophy. Matera AG. **Curr Biol** 1999 Feb 25;9(4):R140–2 (16 ref.)
Spinal muscular atrophy: molecular pathophysiology. Gendron NH, et al. **Curr Opin Neurol** 1999 Apr; 12(2):137–42 (70 ref.)
Spinal muscular atrophy. Talbot K. **J Inherit Metab Dis** 1999 Jun;22(4):545–54 (38 ref.)
Spinal muscular atrophy: untangling the knot? Biros I, et al. **J Med Genet** 1999 Jan;36(1):1–8 (66 ref.)
Androgen receptor mutation in Kennedy's disease. Fischbeck KH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29;354(1386):1075–8 (26 ref.)
Molecular basis of neuromuscular diseases. Chance PF, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):49–81, vi (226 ref.)
[X-chromosomal recessive spinobulbar muscular atrophy (Kennedy type). Description of a family, clinical aspects, molecular genetics, differential diagnosis and therapy] Kuhlenbäumer G, et al. **Nervenarzt** 1998 Aug;69(8):660–5 (19 ref.) (Eng. Abstr.) **(Ger)**
[Transcriptional regulation and subcellular localization of mutant androgen receptor in spinal and bulbar muscular atrophy] Miwa S, et al. **Nippon Rinsho** 1999 Apr; 57(4):869–73 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Somatic mosaicism of expanded CAG trinucleotide repeat in spinal and bulbar muscular atrophy (SBMA)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr;57(4):862–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

MUSCULAR ATROPHY, SPINAL, INFANTILE see **WERDNIG-HOFFMANN DISEASE**

MUSCULAR DISEASES

Obturator internus muscle abscess in children: report of seven cases and review. Viani RM, et al. **Clin Infect Dis** 1999 Jan;28(1):117–22 (14 ref.)
Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Buskila D. **Curr Opin Rheumatol** 1999 Mar; 11(2):119–26 (79 ref.)

CHEMICALLY INDUCED

Drugs and toxins associated with myopathies. Pascuzzi RM. **Curr Opin Rheumatol** 1998 Nov;10(6):511–20 (64 ref.)

MUSCULAR DISEASES

Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents. Brown MA, et al. **J Appl Toxicol** 1998 Nov-Dec; 18(6):393-408 (78 ref.)

COMPLICATIONS

Clostridium septicum myonecrosis and ovarian cancer: a case report and review of literature. Prinssen HM, et al. **Gynecol Oncol** 1999 Jan;72(1):116-9 (19 ref.)

CONGENITAL

The role of immunocytochemistry in congenital myopathies. Sewry CA. **Neuromuscul Disord** 1998 Aug;8(6):394-400 (22 ref.)

[Congenital mesothelial cyst of the diaphragm: imaging aspects. Apropos of 2 cases in adults and review of the literature] Sans N, et al. **J Radiol** 1999 Jun;80(6):593-6 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Muscle dysfunction in the intensive care unit. Anzueto A. **Clin Chest Med** 1999 Jun;20(2):435-52 (101 ref.)

Sarcoidosis presenting as a tumorlike muscular lesion. Case report and review of the literature. Zisman DA, et al. **Medicine (Baltimore)** 1999 Mar;78(2):112-22 (68 ref.)

The role of immunocytochemistry in congenital myopathies. Sewry CA. **Neuromuscul Disord** 1998 Aug;8(6):394-400 (22 ref.)

Neonatal metabolic myopathies. Tein I. **Semin Perinatol** 1999 Apr;23(2):125-51 (262 ref.)

Castleman's disease of the erector spinae muscle. Williams HR, et al. **Skeletal Radiol** 1998 Nov;27(11):637-40 (21 ref.)

DRUG THERAPY

Topical NSAIDs for musculoskeletal conditions. A review of the literature. Vaile JH, et al. **Drugs** 1998 Nov; 56(5):783-99 (95 ref.)

ETIOLOGY

Xanthomas of the Achilles tendon: report of a bilateral case and review of the literature. Carranza-Bencano A, et al. **Foot Ankle Int** 1999 May;20(5):314-6 (21 ref.)

Chronic renal failure causing brown tumors and myelopathy. Case report and review of pathophysiology and treatment. Fineman I, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):242-6 (18 ref.)

[The association between human toxocariasis and pyogenic abscesses] Rayes AA, et al. **Rev Soc Bras Med Trop** 1999 Jul-Aug;32(4):425-38 (110 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Structure-function relationships in the Ca(2+)-binding and translocation domain of SERCA1: physiological correlates in Brody disease. MacLennan DH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:55-67 (52 ref.)

Molecular therapy for genetic muscle diseases--status 1999. Karpati G, et al. **Clin Genet** 1999 Jan;55(1):1-8 (43 ref.)

Ion channel mutations affecting muscle and brain. Barchi RL. **Curr Opin Neurol** 1998 Oct;11(5):461-8 (52 ref.)

The anesthetic myopathies and malignant hyperthermias. Hogan K. **Curr Opin Neurol** 1998 Oct;11(5):469-76 (34 ref.)

Hereditary inclusion body myopathies. Tomé FM, et al. **Curr Opin Neurol** 1998 Oct;11(5):453-9 (52 ref.)

Genetics of the nemaline myopathies and the myotubular myopathies. Wallgren-Pettersson C. **Neuromuscul Disord** 1998 Aug;8(6):401-4 (28 ref.)

Neonatal metabolic myopathies. Tein I. **Semin Perinatol** 1999 Apr;23(2):125-51 (262 ref.)

[X-linked recessive myotubular myopathy with a splice-site mutation in the myotubularin gene] Watanabe T, et al. **No To Hattatsu** 1998 Nov;30(6):523-7 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Eosinophilic myopathic syndromes. Pickering MC, et al. **Curr Opin Rheumatol** 1998 Nov;10(6):504-10 (89 ref.)

METABOLISM

Excitation-contraction-relaxation cycle: role of Ca2+-regulatory membrane proteins in normal, stimulated and pathological skeletal muscle (review). Murray BE, et al. **Int J Mol Med** 1998 Apr;1(4):677-87 (109 ref.)

Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease. Oyama F, et al. **Neurosci Res** 1998 May;31(1):1-8 (70 ref.)

MICROBIOLOGY

Clostridium septicum myonecrosis and ovarian cancer: a case report and review of literature. Prinssen HM, et al. **Gynecol Oncol** 1999 Jan;72(1):116-9 (19 ref.)

PATHOLOGY

Tubular aggregates in skeletal muscle: their functional significance and mechanisms of pathogenesis [editorial] Morgan-Hughes JA. **Curr Opin Neurol** 1998 Oct; 11(5):439-42 (22 ref.)

PHYSIOPATHOLOGY

Critical illness neuropathy and myopathy. Gutmann L, et al. **Arch Neurol** 1999 May;56(5):527-8 (17 ref.)

Role of cysteine and glutathione in signal transduction, immunopathology and cachexia. Dröge W, et al. **Biofactors** 1998;8(1-2):97-102 (23 ref.)

Pelvic floor function/dysfunction and electrodiagnostic evaluation. Roberts MM, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):831-51, vii (80 ref.)

SURGERY

The Cobb procedure for stage II posterior tibial tendon dysfunction. Benton-Weil W, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):471-7 (11 ref.)

Treatment of posterior tibial tendon dysfunction with tendon procedures from the posterior muscle group. Fleischli JG, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):453-70 (39 ref.)

Calcaneal osteotomy for the treatment of posterior tibial tendon dysfunction. LaFontaine J, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):491-9 (21 ref.)

Triple arthrodesis and subtalar joint arthrodesis. For the treatment of end-stage posterior tibial tendon dysfunction. Laughlin TJ, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):527-55 (50 ref.)

Use of the Maxwell-Brancheau arthroereisis implant for the correction of posterior tibial tendon dysfunction. Maxwell JR, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):479-89 (20 ref.)

Talonavicular arthrodesis for correction of posterior tibial tendon dysfunction. Mothershed RA, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):501-26 (24 ref.)

THERAPY

Chiropractic intervention in the treatment of joint and soft tissue disorders. Crawford JP. **Can J Appl Physiol** 1999 Jun;24(3):279-89 (66 ref.)

Molecular therapy for genetic muscle diseases--status 1999. Karpati G, et al. **Clin Genet** 1999 Jan;55(1):1-8 (43 ref.)

Orthoses used in the management of neurologic and muscular disorders. McGuire JB. **Clin Podiatr Med Surg** 1999 Jan; 16(1):153-74 (10 ref.)

Conservative management of posterior tibial tendon dysfunction, subtalar joint complex, and pes planus deformity. Steb HS, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):439-51 (7 ref.)

[Therapy oriented neurology from repair to remedy] Kimura J. **Rinsho Shinkeigaku** 1998 Dec;38(12):969-73 (14 ref.) (Eng. Abstr.) **(Jpn)**

MUSCULAR DYSTROPHY

The muscular dystrophies. Emery AE. **BMJ** 1998 Oct 10; 317(7164):991-5 (34 ref.)

CLASSIFICATION

Assessment of motor functions. Nordgren B. **Scand J Rehabil Med Suppl** 1999;39:58-64 (17 ref.)

[Clinical-genetic classification of muscular dystrophies] López de Munain A, et al. **Med Clin (Barc)** 1998 Sep 5; 111(6):226-35 (168 ref.) **(Spa)**

COMPLICATIONS

Management of the respiratory complications of neuromuscular diseases in the pediatric intensive care unit. Birnkrant DJ, et al. **J Child Neurol** 1999 Mar;14(3):139-43 (13 ref.)

Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127-43 (67 ref.)

CONGENITAL

Congenital muscular dystrophy. Care of children and families. Eeg-Olofsson KE. **Scand J Rehabil Med Suppl** 1999;39:53-7 (20 ref.)

[Dystrophin and dystrophin-associated proteins. Their evaluation at the neuromuscular pathology laboratory] Navarro C. **Rev Neurol** 1999 Jan 16-31;28(2):154-8 (41 ref.) (Eng. Abstr.) **(Spa)**

[Muscular dystrophies due to alterations at extracellular space level: congenital muscular dystrophy caused by merosin deficiency] Smeyers P. **Rev Neurol** 1999 Jan 16-31; 28(2):141-9 (88 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Genotypic diagnosis of Duchenne and Becker muscular dystrophies] Tuffery-Giraud S, et al. **Ann Biol Clin (Paris)** 1999 Jul-Aug;57(4):417-26 (20 ref.) (Eng. Abstr.) **(Fre)**

[Current diagnosis in muscular dystrophies. New developments, methods of examination and case examples] Weilbach FX, et al. **Nervenarzt** 1999 Feb;70(2):89-100 (5 ref.) (Eng. Abstr.) **(Ger)**

[New advances in muscular dystrophy: an up-to-date diagnostic plan] Lin S, et al. **Schweiz Med Wochenschr** 1999 Aug 21;129(33):1141-51 (61 ref.) (Eng. Abstr.) **(Ger)**

[Molecular-genetic characteristics of mutations in dystrophin gene and clinical symptoms in Duchenne muscular dystrophy] Lisiecka D, et al. **Neurol Neurochir Pol** 1998 Sep-Oct;32(5):1069-79 (20 ref.) (Eng. Abstr.) **(Pol)**

[Muscle biopsy: an essential stage in the diagnosis of myopathic syndromes of the girdle (editorial)] Navarro C. **Neurologia** 1999 Jun-Jul;14(6):262-5 (14 ref.) **(Spa)**

[Limb girdle dystrophy: a syndrome clinically and genetically heterogeneous (editorial)] Urtasun M, et al. **Neurologia** 1999 Mar;14(3):97-101 (65 ref.) **(Spa)**

DRUG THERAPY

Steroids in muscular dystrophy: where do we stand? Dubrovsky AL, et al. **Neuromuscul Disord** 1998 Aug; 8(6):380-4 (34 ref.)

ENZYMOLOGY

Creatine kinase, cell membrane and Duchenne muscular dystrophy. Ozawa E, et al. **Mol Cell Biochem** 1999 Jan; 190(1-2):143-51 (97 ref.)

ETIOLOGY

Dystroglycan in development and disease. Durbeej M, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):594-601 (71 ref.)

The dystrophinopathies: an alternative to the structural hypothesis. Carlson CG. **Neurobiol Dis** 1998 Jul;5(1):3-15 (110 ref.)

[Muscular dystrophies due to alterations at extracellular space level: congenital muscular dystrophy caused by merosin deficiency] Smeyers P. **Rev Neurol** 1999 Jan 16-31; 28(2):141-9 (88 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The physiological evaluation of gene therapies of dystrophin-deficient muscles. Gillis JM, et al. **Adv Exp Med Biol** 1998;453:411-6; discussion 417 (26 ref.)

Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Engelman JA, et al. **Am J Hum Genet** 1998 Dec;63(6):1578-87 (49 ref.)

Making sense of the limb-girdle muscular dystrophies. Bushby KM. **Brain** 1999 Aug;122 (Pt 8):1403-20 (118 ref.)

The sarcoglycan complex in limb-girdle muscular dystrophy. Lim LE, et al. **Curr Opin Neurol** 1998 Oct;11(5):443-52 (103 ref.)

Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Funakoshi M, et al. **Neuromuscul Disord** 1999 Mar;9(2):108-14 (55 ref.)

Molecular basis of neuromuscular diseases. Chance PF, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):49-81, vi (226 ref.)

[Genotypic diagnosis of Duchenne and Becker muscular dystrophies] Tuffery-Giraud S, et al. **Ann Biol Clin (Paris)** 1999 Jul-Aug;57(4):417-26 (20 ref.) (Eng. Abstr.) **(Fre)**

[Fukutin, a novel protein product responsible for Fukuyama-type congenital muscular dystrophy] Toda T. **Seikagaku** 1999 Jan;71(1):55-61 (15 ref.) **(Jpn)**

[Molecular-genetic characteristics of mutations in dystrophin gene and clinical symptoms in Duchenne muscular dystrophy] Lisiecka D, et al. **Neurol Neurochir Pol** 1998 Sep-Oct;32(5):1069-79 (20 ref.) (Eng. Abstr.) **(Pol)**

[Regulation of human DMD gene expression. An example of multiple utilization of genetic information] Napierala D, et al. **Postepy Biochem** 1998;44(1):48-55 (43 ref.) **(Pol)**

[Molecular bases of progressive muscular dystrophy] Illarioshkin SN, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(10):55-62 (133 ref.) **(Rus)**

[Clinical-genetic classification of muscular dystrophies] López de Munain A, et al. **Med Clin (Barc)** 1998 Sep 5; 111(6):226-35 (168 ref.) **(Spa)**

[Limb girdle dystrophy: a syndrome clinically and genetically heterogeneous (editorial)] Urtasun M, et al. **Neurologia** 1999 Mar;14(3):97-101 (65 ref.) **(Spa)**

[Sarcoglycanopathies] Colomer J. **Rev Neurol** 1999 Jan 16-31;28(2):150-3 (30 ref.) (Eng. Abstr.) **(Spa)**

[Alterations in functional proteins. Calpaine-3 deficiency] López de Munain A, et al. **Rev Neurol** 1999 Jan 16-31; 28(2):158-64 (57 ref.) (Eng. Abstr.) **(Spa)**

[Dystrophin and dystrophin-associated proteins. Their evaluation at the neuromuscular pathology laboratory] Navarro C. **Rev Neurol** 1999 Jan 16-31;28(2):154-8 (41 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Culligan KG, et al. **Int J Mol Med** 1998 Dec;2(6):639-48 (120 ref.)

PATHOLOGY

The effects of myotonic dystrophy and Duchenne muscular dystrophy on the orofacial muscles and dentofacial morphology. Kiliaridis S, et al. **Acta Odontol Scand** 1998 Dec;56(6):369-74 (33 ref.)

Magnetic resonance imaging of regenerating and dystrophic mouse muscle. McIntosh LM, et al. **Biochem Cell Biol** 1998; 76(2-3):532-41 (61 ref.)

In utero fetal muscle biopsy: a precious aid for the prenatal diagnosis of Duchenne muscular dystrophy. Heckel S, et al. **Fetal Diagn Ther** 1999 May-Jun;14(3):127-32 (37 ref.)

PHYSIOPATHOLOGY

Integrins during muscle development and in muscular dystrophies. Gullberg D, et al. **Front Biosci** 1998 Oct 15; 3:D1039–50 (101 ref.)

REHABILITATION

Congenital muscular dystrophy. Care of children and families. Eeg-Olofsson KE. **Scand J Rehabil Med Suppl** 1999;39:53–7 (20 ref.)

Problems and solutions in the rehabilitation of patients with progressive muscular dystrophy. Kakulas BA. **Scand J Rehabil Med Suppl** 1999;39:23–37 (14 ref.)

Physiotherapy in muscular dystrophy. Kroksmark AK. **Scand J Rehabil Med Suppl** 1999;39:65–8 (11 ref.)

THERAPY

The physiological evaluation of gene therapies of dystrophin-deficient muscles. Gillis JM, et al. **Adv Exp Med Biol** 1998;453:411–6; discussion 417 (26 ref.)

[Gene transfer in skeletal muscle cell and gene therapy] Tian J, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jul;77(7):556–8 (14 ref.) **(Chi)**

MUSCULAR DYSTROPHY, ANIMAL

GENETICS

The physiological evaluation of gene therapies of dystrophin-deficient muscles. Gillis JM, et al. **Adv Exp Med Biol** 1998;453:411–6; discussion 417 (26 ref.)

PHYSIOPATHOLOGY

Characteristics of skeletal muscle in mdx mutant mice. De la Porte S, et al. **Int Rev Cytol** 1999;191:99–148 (329 ref.)

THERAPY

The physiological evaluation of gene therapies of dystrophin-deficient muscles. Gillis JM, et al. **Adv Exp Med Biol** 1998;453:411–6; discussion 417 (26 ref.)

MUSCULOSKELETAL ABNORMALITIES

DIAGNOSIS

Children's orthopaedics in primary care. McNab I, et al. **Practitioner** 1998 Nov;242(1592):785–9, 791–2 (8 ref.)

THERAPY

Modalities of ventilation in neuromuscular disorders and thoracic deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):552–5 (10 ref.)

MUSCULOSKELETAL DISEASES

Work-related upper extremity complaints. Vender M, et al. **Instr Course Lect** 1999;48:693–7 (20 ref.)

Office technology and musculoskeletal disorders: building an ecological model. Amick BC 3rd, et al. **Occup Med** 1999 Jan–Mar;14(1):97–112, iv (37 ref.)

Surveillance and the problems of assessing office-related injury. Morse T. **Occup Med** 1999 Jan–Mar;14(1):73–80, iii (13 ref.)

[Centrally disturbed pain modulation explains prolonged pain. New knowledge changes the view on the problematic patient] Lidbeck J. **Lakartidningen** 1999 Jun 9; 96(23):2843–8, 2850–1 (84 ref.) **(Swe)**

CHEMICALLY INDUCED

Oxidants, antioxidants and alcohol: implications for skeletal and cardiac muscle. Preedy VR, et al. **Front Biosci** 1999 Aug 1;4:e58–66 (70 ref.)

COMPLICATIONS

Musculoskeletal chest pain [letter; comment] Gorman RF. **Aust Fam Physician** 1998 Dec;27(12):1085–6 (5 ref.) Comment on: Aust Fam Physician 1998 Sep;27(9):827–8.

Genetic diseases with rheumatic manifestations in children. Prahalad S, et al. **Curr Opin Rheumatol** 1998 Sep; 10(5):488–93 (38 ref.)

Musculoskeletal manifestations of osteomalacia: report of 26 cases and literature review. Reginato AJ, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):287–304 (75 ref.)

DIAGNOSIS

Are growing pains a myth? [see comments] Manners P. **Aust Fam Physician** 1999 Feb;28(2):124–7 (4 ref.) Comment in: Aust Fam Physician 1999 May;28(5):427–8. Comment in: Aust Fam Physician 1999 May;28(5):428.

Molecular diagnostics for the detection of musculoskeletal infection. Hoeffel DP, et al. **Clin Orthop** 1999 Mar; (360):37–46 (39 ref.)

Women's orthopedic problems: a review of their occurrence and management. McLemore E, et al. **J Okla State Med Assoc** 1998 Oct;91(7):393–8 (17 ref.)

Magnetic resonance imaging in oncology: an overview. Wallis F, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):117–25 (48 ref.)

Physical assessment of the musculoskeletal system. Mangini M. **Nurs Clin North Am** 1998 Dec;33(4):643–52 (21 ref.)

DRUG THERAPY

Anti-inflammatory therapy. Canvin JM, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):301–17 (69 ref.)

Intrathecal drug therapy. Nance P, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):385–401, viii–ix (100 ref.)

Antispasticity medications. Nance PW, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):337–55, viii (96 ref.)

EPIDEMIOLOGY

Why do we need more information about the risk factors of the musculoskeletal pain disorders in childhood and adolescence? Zitting P, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):148–55 (39 ref.)

Musculoskeletal disorders in visual display unit work: gender and work demands. Punnett L, et al. **Occup Med** 1999 Jan–Mar;14(1):113–24, iv (39 ref.)

[The epidemiology of musculoskeletal changes due to biomechanical overload of the spine in the manual lifting of patients] Bordini L, et al. **Med Lav** 1999 Mar–Apr; 90(2):103–16 (47 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Musculoskeletal challenges of osteoporosis. Sinaki M. **Aging (Milano)** 1998 Jun;10(3):249–62 (68 ref.)

Current techniques for assessing physical exposure to work-related musculoskeletal risks, with emphasis on posture-based methods. Li G, et al. **Ergonomics** 1999 May; 42(5):674–95 (147 ref.)

Treatment of hip and knee problems in myelomeningocele. Greene WB. **Instr Course Lect** 1999;48:563–74 (49 ref.)

[Locomotor disorders in infectious diseases] Bogomolov BP. **Klin Med (Mosk)** 1998;76(9):20–4 (0 ref.) **(Rus)**

GENETICS

Genetic diseases with rheumatic manifestations in children. Prahalad S, et al. **Curr Opin Rheumatol** 1998 Sep; 10(5):488–93 (38 ref.)

PATHOLOGY

Musculoskeletal sonography and MR imaging. A role for both imaging methods. Jacobson JA. **Radiol Clin North Am** 1999 Jul;37(4):713–35 (45 ref.)

PHYSIOPATHOLOGY

Musculoskeletal diseases in aging. Sarkar RN, et al. **J Indian Med Assoc** 1998 May;96(5):151–4 (20 ref.)

PREVENTION & CONTROL

The bone and joint decade 2000–2010 for prevention and treatment of musculo-skeletal disorders. Lund, Sweden, April 17–18, 1998. Proceedings. **Acta Orthop Scand Suppl** 1998 Jun;281:1–86 (0 ref.)

Decade of the bone and joint [editorial] Drezner MK. **J Bone Miner Res** 1999 Jan;14(1):2 (0 ref.)

New assistive technology for passive standing. Gear AJ, et al. **J Burn Care Rehabil** 1999 Mar–Apr;20(2):164–9 (14 ref.)

[Prophylactic surgery of the musculoskeletal system] Kreklau B, et al. **Chirurg** 1999 Apr;70(4):364–72 (30 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Spiral CT and three-dimensional CT of musculoskeletal pathology. Emergency room applications. Pretorius ES, et al. **Radiol Clin North Am** 1999 Sep;37(5):953–74, vi (45 ref.)

REHABILITATION

Muscle rehabilitation in haemophilia. Beeton K, et al. **Haemophilia** 1998 Jul;4(4):532–7 (33 ref.)

Proprioceptive training in haemophilia. Buzzard BM. **Haemophilia** 1998 Jul;4(4):528–31 (14 ref.)

Perspectives on prognosis of soft tissue musculoskeletal disorders. Hudak PL, et al. **Int J Rehabil Res** 1998 Mar; 21(1):29–40 (38 ref.)

A primer on lower extremity outcome measurement instruments. Saltzman CL, et al. **Iowa Orthop J** 1998; 18:101–11 (35 ref.)

[Current status and perspectives of rehabilitation of musculoskeletal diseases] Jäckel WH. **Z Arztl Fortbild Qualitatssich** 1999 Jul;93(5):349–54 (14 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Prophylactic surgery of the musculoskeletal system] Kreklau B, et al. **Chirurg** 1999 Apr;70(4):364–72 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Are growing pains a myth? [see comments] Manners P. **Aust Fam Physician** 1999 Feb;28(2):124–7 (4 ref.) Comment in: Aust Fam Physician 1999 May;28(5):427–8. Comment in: Aust Fam Physician 1999 May;28(5):428.

Sports medicine at work. Brown GJ. **Br J Sports Med** 1999 Feb;33(1):5 (6 ref.)

The role of gene therapy. Fact or fiction? Muzzonigro TS, et al. **Clin Sports Med** 1999 Jan;18(1):223–39, vii–viii (79 ref.)

Maintenance of musculoskeletal function in people with haemophilia. Battistella LR. **Haemophilia** 1998;4 Suppl 2:26–32 (35 ref.)

Treatment of hip and knee problems in myelomeningocele. Greene WB. **Instr Course Lect** 1999;48:563–74 (49 ref.)

Women's orthopedic problems: a review of their occurrence and management. McLemore E, et al. **J Okla State Med Assoc** 1998 Oct;91(7):393–8 (17 ref.)

ULTRASONOGRAPHY

Infection: ultrasound-guided procedures. Craig JG. **Radiol Clin North Am** 1999 Jul;37(4):669–78 (55 ref.)

Musculoskeletal sonography and MR imaging. A role for both imaging methods. Jacobson JA. **Radiol Clin North Am** 1999 Jul;37(4):713–35 (45 ref.)

High-frequency ultrasound examination of the wrist and hand. Bianchi S, et al. **Skeletal Radiol** 1999 Mar;28(3):121–9 (59 ref.)

MUSCULOSKELETAL PHYSIOLOGY

Exercise and female adolescents: effects on the reproductive and skeletal systems. Warren MP, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):115–20, 138 (69 ref.)

Tensegrity and mechanoregulation: from skeleton to cytoskeleton. Chen CS, et al. **Osteoarthritis Cartilage** 1999 Jan;7(1):81–94 (75 ref.)

MUSCULOSKELETAL SYSTEM

Physical assessment of the musculoskeletal system. Mangini M. **Nurs Clin North Am** 1998 Dec;33(4):643–52 (21 ref.)

CYTOLOGY

Genetic control of cell differentiation in the skeleton. Ducy P, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):614–9 (50 ref.)

GROWTH & DEVELOPMENT

The young athlete [published erratum appears in Aust Fam Physician 1999 Jul;28(7):652] Fricker P. **Aust Fam Physician** 1999 Jun;28(6):543–7 (17 ref.)

INJURIES

The young athlete [published erratum appears in Aust Fam Physician 1999 Jul;28(7):652] Fricker P. **Aust Fam Physician** 1999 Jun;28(6):543–7 (17 ref.)

Emergency MR imaging of orthopedic trauma. Current and future directions. Eustace S, et al. **Radiol Clin North Am** 1999 Sep;37(5):975–94, vi (113 ref.)

Musculoskeletal ultrasound. The clinician's perspective. Primack SJ. **Radiol Clin North Am** 1999 Jul;37(4):617–22, vii (18 ref.)

Chronic avulsive injuries of childhood. Donnelly LF, et al. **Skeletal Radiol** 1999 Mar;28(3):138–44 (8 ref.)

[Sports as a health risk for the locomotor system] Menke W. **Versicherungsmedizin** 1998 Oct 1;50(5):186–9 (22 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Emergency MR imaging of orthopedic trauma. Current and future directions. Eustace S, et al. **Radiol Clin North Am** 1999 Sep;37(5):975–94, vi (113 ref.)

RADIOGRAPHY

Trends in pediatric emergency imaging. John SD. **Radiol Clin North Am** 1999 Sep;37(5):995–1034, vi (91 ref.)

ULTRASONOGRAPHY

Applications of musculoskeletal sonography. Hashimoto BE, et al. **J Clin Ultrasound** 1999 Jul–Aug;27(6):293–318 (153 ref.)

Future and new developments in musculoskeletal ultrasound. Adler RS. **Radiol Clin North Am** 1999 Jul;37(4):623–31 (23 ref.)

Musculoskeletal ultrasound. The clinician's perspective. Primack SJ. **Radiol Clin North Am** 1999 Jul;37(4):617–22, vii (18 ref.)

MUSHROOM POISONING

see related

MYCOTOXINS

[Hallucinogenic mushroom poisoning] Kamimura H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):676–8 (5 ref.) **(Jpn)**

COMPLICATIONS

Voluntary ingestion of Cortinarius mushrooms leading to chronic interstitial nephritis. Calviño J, et al. **Am J Nephrol** 1998;18(6):565–9 (19 ref.)

MUSHROOM POISONING

DIAGNOSIS

[Amanita phalloides poisoning--diagnosis, clinical course, treatment] Wiernikowski A, et al. **Przegl Lek** 1999; 56(6):450-4 (36 ref.) (Eng. Abstr.) **(Pol)**

[Differential diagnosis of mushroom poisoning] Gavornik P. **Vnitr Lek** 1998 Aug;44(8):496-501 (30 ref.) (Eng. Abstr.) **(Slo)**

THERAPY

[Amanita phalloides poisoning--diagnosis, clinical course, treatment] Wiernikowski A, et al. **Przegl Lek** 1999; 56(6):450-4 (36 ref.) (Eng. Abstr.) **(Pol)**

MUSHROOMS see **AGARICALES**

MUSIC

Functional specialization of human auditory cortex for musical processing [editorial; comment] Zatorre RJ. **Brain** 1998 Oct;121 (Pt 10):1817-8 (12 ref.) Comment on: Brain 1998 Oct;121 (Pt 10):1853-67.

Skin problems of musicians. Onder M, et al. **Int J Dermatol** 1999 Mar;38(3):192-5 (10 ref.)

MUSIC THERAPY

Music therapy and chiropractic: an integrative model of tonal and rhythmic spinal adjustment. Miller EB, et al. **Altern Ther Health Med** 1999 Mar;5(2):102-4 (8 ref.)

Music therapy. Snyder M, et al. **Annu Rev Nurs Res** 1999; 17:3-25 (110 ref.)

Bedside musical care: applications in pregnancy, childbirth, and neonatal care. Olson SL. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):569-75 (33 ref.)

[Significance of music in modern medicine] Escher J. **Schweiz Rundsch Med Prax** 1998 Aug 5;87(31-32):987-96 (5 ref.) **(Ger)**

MUSKRATS see **MICROTINAE**

MUSLIMS see **ISLAM**

MUSSELS

PHYSIOLOGY

Mussel byssus and biomolecular materials. Deming TJ. **Curr Opin Chem Biol** 1999 Feb;3(1):100-5 (42 ref.)

MUSTELIDAE see **CARNIVORA**

MUTAGEN SCREENING see **MUTAGENICITY TESTS**

MUTAGENESIS

see related
ANTIMUTAGENIC AGENTS
MUTAGENS

The role of mutation frequency decline and SOS repair systems in methyl methanesulfonate mutagenesis. Grzesiuk E. **Acta Biochim Pol** 1998;45(2):523-33 (60 ref.)

Evolution of the U-insertion/deletion RNA editing in mitochondria of kinetoplastid protozoa. Simpson L, et al. **Ann N Y Acad Sci** 1999 May 18;870:190-205 (64 ref.)

Repair and mutagenesis survey of 8-hydroxyguanine in bacteria and human cells. Le Page F, et al. **Biochimie** 1999 Jan-Feb;81(1-2):147-53 (54 ref.)

Mechanisms of mutagenesis in mammalian cells. Application to human thyroid tumours. Sarasin A, et al. **C R Acad Sci III** 1999 Feb-Mar;322(2-3):143-9 (24 ref.)

Novel DNA polymerases offer clues to the molecular basis of mutagenesis. Friedberg EC, et al. **Cell** 1999 Aug 20; 98(4):413-6 (19 ref.)

Mouse mutagenesis: from gene to phenotype and back again. Beddington R. **Curr Biol** 1998 Nov 19;8(23):R840-2 (11 ref.)

DNA repair: knockouts still mutating after first round. Wood RD. **Curr Biol** 1998 Oct 22;8(21):R757-60 (17 ref.)

Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Tlsty TD. **Curr Opin Cell Biol** 1998 Oct;10(5):647-53 (50 ref.)

Gene disruption to evaluate the role of fungal candidate virulence genes. Kwon-Chung K. **Curr Opin Microbiol** 1998 Aug;1(4):381-9 (59 ref.)

The use of transgenic animals in research. Heddle JA. **Environ Mol Mutagen** 1998;32(2):110-4 (29 ref.)

Transgenic animal models for mutagenesis studies: role in mutagenesis research and regulatory testing. MacGregor JT. **Environ Mol Mutagen** 1998;32(2):106-9 (26 ref.)

Mouse mutagenesis-systematic studies of mammalian gene function. Brown SD, et al. **Hum Mol Genet** 1998; 7(10):1627-33 (45 ref.)

Induction of mutations in transgenic animal models: BigBlue and Muta Mouse. Schmezer P, et al. **IARC Sci Publ** 1999; (146):367-94 (79 ref.)

Mutation in mammalian cells in vitro and in vivo as indicators of exposure to carcinogens. van Zeeland AA, et al. **IARC Sci Publ** 1999;(146):355-65 (48 ref.)

Early pressure screens. Beattie CE, et al. **Methods Cell Biol** 1999;60:71-86 (68 ref.)

Positional cloning of mutated zebrafish genes. Talbot WS, et al. **Methods Cell Biol** 1999;60:259-86 (47 ref.)

Developmental mutant screens in the zebrafish. van Eeden FJ, et al. **Methods Cell Biol** 1999;60:21-41 (46 ref.)

Analysis of mammalian cis-regulatory DNA elements by homologous recombination. Fiering S, et al. **Methods Enzymol** 1999;306:42-66 (81 ref.)

Mutagenesis and the selection of resistant mutants. Dix PJ. **Methods Mol Biol** 1999;111:309-18 (10 ref.)

Transposon mutagenesis. Voelker LL, et al. **Methods Mol Biol** 1998;104:235-8 (9 ref.)

SOS and Mayday: multiple inducible mutagenic pathways in Escherichia coli. Humayun MZ. **Mol Microbiol** 1998 Dec;30(5):905-10 (39 ref.)

Mutant manifestation: the time factor in somatic mutagenesis. Heddle JA. **Mutagenesis** 1999 Jan;14(1):1-3 (12 ref.)

Mitochondrial mutagenesis in human cells and tissues. Marcelino LA, et al. **Mutat Res** 1999 Jul 30;434(3):177-203 (208 ref.)

Mutators in Escherichia coli. Miller JH. **Mutat Res** 1998 Dec 14;409(3):99-106 (87 ref.)

Transposable elements as tools from mutagenesis and transgenesis of vertebrates. Plasterk RH, et al. **Pathol Biol (Paris)** 1998 Nov;46(9):674-5 (0 ref.) **(Eng, Fre)**

Understanding the structure and function of catalases: clues from molecular evolution and in vitro mutagenesis. Zámocký M, et al. **Prog Biophys Mol Biol** 1999;72(1):19-66 (247 ref.)

Mutation measurement in mammalian cells. IV: Comparison of gamma-ray and chemical mutagenesis. Puck TT, et al. **Somat Cell Mol Genet** 1998 Jan;24(1):1-11 (32 ref.)

Escherichia coli mutator genes. Horst JP, et al. **Trends Microbiol** 1999 Jan;7(1):29-36 (40 ref.)

[Saturation mutagenesis in mice] Yamamura K. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2233-7 (12 ref.) **(Jpn)**

DRUG EFFECTS

The results of assays in Drosophila as indicators of exposure to carcinogens. Vogel EW, et al. **IARC Sci Publ** 1999; (146):427-70 (207 ref.)

What is the significance of increases in background levels of carcinogen-derived protein and DNA adducts? Some considerations for incremental risk assessment. Farmer PB, et al. **Mutat Res** 1999 Mar 8;424(1-2):275-86 (88 ref.)

GENETICS

Functional genomics in the mouse: phenotype-based mutagenesis screens. Schimenti J, et al. **Genome Res** 1998 Jul;8(7):698-710 (80 ref.)

Mutation patterns in non-ras oncogenes and tumour suppressor genes in experimentally induced tumours. Perantoni AO, et al. **IARC Sci Publ** 1999;(146):87-122 (204 ref.)

PHYSIOLOGY

Developmental pathways: Sonic hedgehog-Patched-GLI. Walterhouse DO, et al. **Environ Health Perspect** 1999 Mar; 107(3):167-71 (65 ref.)

Scanning mutagenesis of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor. Hulme EC, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):269-74 (15 ref.)

[The role of reactive oxygen species in mutagenesis and carcinogenesis processes] Oliński R, et al. **Postepy Biochem** 1999;45(1):50-8 (51 ref.) **(Pol)**

RADIATION EFFECTS

Haploid screens and gamma-ray mutagenesis. Walker C. **Methods Cell Biol** 1999;60:43-70 (34 ref.)

MUTAGENESIS, CASSETTE see **MUTAGENESIS, INSERTIONAL**

MUTAGENESIS, INSERTIONAL

Mutagenesis via insertional- or restriction enzyme-mediated-integration (REMI) as a tool to tag pathogenicity related genes in plant pathogenic fungi. Maier FJ, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):855-64 (52 ref.)

Risk potential of the chromosomal insertion of foreign DNA. Kurth R. **Dev Biol Stand** 1998;93:45-56 (25 ref.)

Effects of Alu insertions on gene function. Szmulewicz MN, et al. **Electrophoresis** 1998 Jun;19(8-9):1260-4 (30 ref.)

Insertional mutagenesis in transgenic mice generated by the pronuclear microinjection procedure. Woychik RP, et al. **Int J Dev Biol** 1998;42(7 Spec No):1009-17 (68 ref.)

METHODS

Insertional mutagenesis of pathogenic fungi. Brown JS, et al. **Curr Opin Microbiol** 1998 Aug;1(4):390-4 (44 ref.)

Genetic analysis in fungi using restriction-enzyme-mediated integration. Riggle PJ, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):395-9 (38 ref.)

Insertional gene fusion technology. Doi N, et al. **FEBS Lett** 1999 Aug 20;457(1):1-4 (27 ref.)

Retrovirus-mediated insertional mutagenesis in zebrafish. Amsterdam A, et al. **Methods Cell Biol** 1999;60:87-98 (28 ref.)

PHYSIOLOGY

New lines of host defense: inhibition of Ty1 retrotransposition by Fus3p and NER/TFIIH. Curcio MJ, et al. **Trends Genet** 1999 Feb;15(2):43-5 (20 ref.)

MUTAGENESIS, OLIGONUCLEOTIDE-DIRECTED see **MUTAGENESIS, SITE-DIRECTED**

MUTAGENESIS, SITE-DIRECTED

Ribozyme chemogenetics. Strobel SA. **Biopolymers** 1998; 48(1):65-81 (108 ref.)

Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. Frillingos S, et al. **FASEB J** 1998 Oct;12(13):1281-99 (117 ref.)

Spatio-temporally-controlled somatic mutations in the mouse. Chambon P. **Pathol Biol (Paris)** 1998 Nov; 46(9):671-3 (17 ref.) **(Eng, Fre)**

GENETICS

The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Hulme EC, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):247-60 (83 ref.)

MUTAGENESIS, SITE-SPECIFIC see **MUTAGENESIS, SITE-DIRECTED**

MUTAGENICITY TESTS

see related
CARCINOGENICITY TESTS

Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: a pharmaceutical industry perspective. Krishna G, et al. **Environ Mol Mutagen** 1998;32(2):115-20 (33 ref.)

Mutation in mammalian cells in vitro and in vivo as indicators of exposure to carcinogens. van Zeeland AA, et al. **IARC Sci Publ** 1999;(146):355-65 (48 ref.)

Preclinical evaluation of radiopharmaceutical toxicological prerequisites. Marzin D. **Nucl Med Biol** 1998 Nov; 25(8):733-6 (10 ref.)

Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance. Zeiger E. **Regul Toxicol Pharmacol** 1998 Oct; 28(2):85-95 (66 ref.)

METHODS

Power-frequency fields and cancer. Moulder JE. **Crit Rev Biomed Eng** 1998;26(1-2):1-116 (411 ref.)

Transgenic animal models for mutagenesis studies: role in mutagenesis research and regulatory testing. MacGregor JT. **Environ Mol Mutagen** 1998;32(2):106-9 (26 ref.)

Chromosomes in the assessment of the effects of low levels of genotoxic agents. Leonard Sagan BELLE Award. Biological Effects of Low Level Exposure. Wolff S. **Hum Exp Toxicol** 1998 Nov;17(11):625-32 (39 ref.)

The use of short-and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. Consensus report. **IARC Sci Publ** 1999;(146):1-18 (2 ref.)

Use of tests in yeasts and fungi in the detection and evaluation of carcinogens. Parry JM. **IARC Sci Publ** 1999;(146):471-85 (66 ref.)

Identification of carcinogenic substances by means of short-term tests in bacteria. Quillardet P, et al. **IARC Sci Publ** 1999;(146):487-97 (46 ref.)

Induction of mutations in transgenic animal models: BigBlue and Muta Mouse. Schmezer P, et al. **IARC Sci Publ** 1999; (146):367-94 (79 ref.)

Short-term tests for defining mutagenic carcinogens. Waters MD, et al. **IARC Sci Publ** 1999;(146):499-536 (99 ref.)

Comet assay responses as indicators of carcinogen exposure. Anderson D, et al. **Mutagenesis** 1998 Nov;13(6):539-55 (245 ref.)

Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Dean SW, et al. **Mutagenesis** 1999 Jan;14(1):141-51 (115 ref.)

Failure to adequately use positive control data leads to poor quality mouse lymphoma data assessments. Moore MM, et al. **Mutagenesis** 1999 May;14(3):261-3 (19 ref.)

Issues for conducting the microtiter version of the mouse lymphoma thymidine kinase (tk) assay and a critical review of data generated in a collaborative trial using the microtiter method. Moore MM, et al. **Mutagenesis** 1999 May;14(3):271-81 (16 ref.)

Biomonitoring using accessible human cells for exposure and health risk assessment. Salama SA, et al. **Mutat Res** 1999 Jan;436(1):99-112 (125 ref.)

[Genotoxicity of stack gas condensates of Bavarian waste incineration plants. IV. Overview and short comments on the results] Raabe F, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):531-40 (16 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

The mouse lymphoma assay in the wake of ICH4--where are we now? Cole J, et al. **Mutagenesis** 1999 May; 14(3):265-70 (47 ref.)

Failure to adequately use positive control data leads to poor quality mouse lymphoma data assessments. Moore MM,

et al. **Mutagenesis** 1999 May;14(3):261-3 (19 ref.)
ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Müller L, et al. **Mutat Res** 1999 May;436(3):195-225 (46 ref.)

STATISTICS & NUMERICAL DATA

An estimator of the mutant frequency in assays using transgenic animals. Delongchamp RR, et al. **Mutat Res** 1999 Mar 15;440(1):101-8 (20 ref.)
Statistical methods for the Ames Salmonella assay: a review. Kim BS, et al. **Mutat Res** 1999 Jan;436(1):113-22 (29 ref.)

MUTAGENS

see related
ALKYLATING AGENTS
DNA ADDUCTS
MUTAGENESIS

Natural and man-made mutagens and carcinogens in the human diet. Ferguson LR. **Mutat Res** 1999 Jul 15; 443(1-2):1-10 (38 ref.)
Chlorothalonil: lack of genotoxic potential. Rosenkranz HS. **Mutat Res** 1999 Jan 25;423(1-2):183-6 (26 ref.)

ADVERSE EFFECTS

The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea. Yu IJ, et al. **Appl Occup Environ Hyg** 1999 Jun;14(6):356-8 (15 ref.)
Genetic toxicology of abused drugs: a brief review. Li JH, et al. **Mutagenesis** 1998 Nov;13(6):557-65 (138 ref.)
[Risks of using cytostatic drugs in veterinary medical practice] Pellicaan CH, et al. **Tijdschr Diergeneeskd** 1999 Apr 1;124(7):210-5 (25 ref.) (Eng. Abstr.) **(Dut)**

ANALYSIS

Clastogenic factors: biomarkers of oxidative stress of potential utility in the clinical chemistry laboratory. Liu TZ, et al. **Ann Clin Lab Sci** 1999 Apr-Jun;29(2):134-9 (42 ref.)
Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Dean SW, et al. **Mutagenesis** 1999 Jan;14(1):141-51 (115 ref.)
Are metals dietary carcinogens? Rojas E, et al. **Mutat Res** 1999 Jul 15;443(1-2):157-81 (260 ref.)

CHEMISTRY

Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Knize MG, et al. **Adv Exp Med Biol** 1999;459:179-93 (60 ref.)
Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity. A review with a case study: MX compounds. Tuppurainen K. **Chemosphere** 1999 Jun;38(13):3015-30 (84 ref.)
The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates. Miller JA. **Drug Metab Rev** 1998 Nov;30(4):645-74 (111 ref.)

CLASSIFICATION

Short-term tests for defining mutagenic carcinogens. Waters MD, et al. **IARC Sci Publ** 1999;(146):499-536 (99 ref.)

PHARMACOLOGY

Mutagenic properties of topoisomerase-targeted drugs. Baguley BC, et al. **Biochim Biophys Acta** 1998 Oct 1; 1400(1-3):213-22 (101 ref.)
Acetaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:319-35 (71 ref.)
Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Amundson SA, et al. **Oncogene** 1998 Dec 24;17(25):3287-99 (212 ref.)

TOXICITY

The role of mutation frequency decline and SOS repair systems in methyl methanesulfonate mutagenesis. Grzesiuk E. **Acta Biochim Pol** 1998;45(2):523-33 (60 ref.)
Repair and mutagenesis survey of 8-hydroxyguanine in bacteria and human cells. Le Page F, et al. **Biochimie** 1999 Jan-Feb;81(1-2):147-53 (54 ref.)
DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Schut HA, et al. **Carcinogenesis** 1999 Mar;20(3):353-68 (300 ref.)
Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity. A review with a case study: MX compounds. Tuppurainen K. **Chemosphere** 1999 Jun;38(13):3015-30 (84 ref.)
Cytogenetic effects of ethylene oxide, with an emphasis on population monitoring. Preston RJ. **Crit Rev Toxicol** 1999 May;29(3):263-82 (68 ref.)
Developmental pathways: Sonic hedgehog-Patched-GLI. Walterhouse DO, et al. **Environ Health Perspect** 1999 Mar; 107(3):167-71 (65 ref.)
Chromosomes in the assessment of the effects of low levels of genotoxic agents. Leonard Sagan BELLE Award. Biological Effects of Low Level Exposure. Wolff S. **Hum Exp Toxicol** 1998 Nov;17(11):625-32 (39 ref.)
Aziridine. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:337-44 (31 ref.)
Caprolactam. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:383-400 (90 ref.)
Dimethyl sulfate. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:575-88 (55 ref.)
1,2-Epoxybutane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:629-40 (46 ref.)
Ethylene dibromide (1,2-dibromoethane). **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:641-69 (126 ref.)
Hydrogen peroxide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:671-89 (94 ref.)
Hydroquinone. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:691-719 (130 ref.)
Methyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:721-35 (64 ref.)
Methyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:737-47 (38 ref.)
Phenol. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:749-68 (83 ref.)
Polychlorophenols and their sodium salts. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:769-816 (154 ref.)
1,1,2,2-Tetrachloroethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:817-27 (39 ref.)
Toluene. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:829-64 (144 ref.)
1,1,1-Trichloroethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:881-903 (93 ref.)
Tris(2,3-dibromopropyl) phosphate. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:905-21 (53 ref.)
Vinyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:923-8 (17 ref.)
DNA reactions, mutagenic action and stealth properties of polycyclic aromatic hydrocarbon carcinogens (review). Dipple A, et al. **Int J Oncol** 1999 Jan;14(1):103-11 (81 ref.)
Cytotoxic and genotoxic potential of dopamine. Stokes AH, et al. **J Neurosci Res** 1999 Mar 15;55(6):659-65 (70 ref.)
Genotoxic lipid peroxidation products: their DNA damaging properties and role in formation of endogenous DNA adducts. Burcham PC. **Mutagenesis** 1998 May; 13(3):287-305 (215 ref.)
Genetic toxicology of abused drugs: a brief review. Li JH, et al. **Mutagenesis** 1998 Nov;13(6):557-65 (138 ref.)
Epizootics of cancer in fish associated with genotoxins in sediment and water. Baumann PC. **Mutat Res** 1998 Nov; 411(3):227-33 (48 ref.)
A survey of EPA/OPP and open literature on selected pesticide chemicals. II. Mutagenicity and carcinogenicity of selected chloroacetanilides and related compounds. Dearfield KL, et al. **Mutat Res** 1999 Jul 15; 443(1-2):183-221 (67 ref.)
Genotoxicity testing of biotechnology-derived products. Report of a GUM task force.Gesellschaft für Umweltmutationsforschung. Gocke E, et al. **Mutat Res** 1999 Mar;436(2):137-56 (50 ref.)
Mutagenicity, carcinogenicity, and teratogenicity of acrylonitrile. Léonard A, et al. **Mutat Res** 1999 May; 436(3):263-83 (188 ref.)
A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Snyder RD. **Mutat Res** 1998 Nov;411(3):235-48 (57 ref.)
Genetic toxicology data in the evaluation of potential human environmental carcinogens. Waters MD, et al. **Mutat Res** 1999 Jul;437(1):21-49 (99 ref.)
Epigenetic events during the process of cell transformation induced by carcinogens (review). Nguyen-Ba G, et al. **Oncol Rep** 1999 Jul-Aug;6(4):925-32 (48 ref.)
Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. Dashwood RH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):239-43 (28 ref.)
A survey of the sequence-specific interaction of damaging agents with DNA: emphasis on antitumor agents. Murray V. **Prog Nucleic Acid Res Mol Biol** 1999;63:367-415 (296 ref.)
Hygienic classification of pesticides in the Russian Federation. Potapov AI, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):79-84 (4 ref.)
The photomutagenicity of fluoroquinolones and other drugs. Gocke E, et al. **Toxicol Lett** 1998 Dec 28;102-103:375-81 (20 ref.)
Epigenetic toxicology as toxicant-induced changes in intracellular signalling leading to altered gap junctional intercellular communication. Trosko JE, et al. **Toxicol Lett** 1998 Dec 28;102-103:71-8 (51 ref.)

MUTASES see **INTRAMOLECULAR TRANSFERASES**

MUTATION

see related
ANTIMUTAGENIC AGENTS
MUTAGENESIS
MUTAGENS
SUPPRESSION, GENETIC

The role of mutation frequency decline and SOS repair systems in methyl methanesulfonate mutagenesis. Grzesiuk E. **Acta Biochim Pol** 1998;45(2):523-33 (60 ref.)
Mutation spectrum of ATP7A, the gene defective in Menkes disease. Tümer Z, et al. **Adv Exp Med Biol** 1999;448:83-95 (67 ref.)
Screening for genetic risk of breast cancer [see comments] Rosenthal TC, et al. **Am Fam Physician** 1999 Jan 1; 59(1):99-104, 106 (23 ref.) Comment in: Am Fam Physician 1999 Jan 1;59(1):43-4, 46.
Nephrogenic diabetes insipidus. Bichet DG. **Am J Med** 1998 Nov;105(5):431-42 (79 ref.)
Vitamin D resistance. Malloy PJ, et al. **Am J Med** 1999 Mar; 106(3):355-70 (107 ref.)
Natural history of colorectal cancer. Winawer SJ. **Am J Med** 1999 Jan 25;106(1A):3S-6S; discussion 50S-51S (09 ref.)
Revertant mosaicism in human genetic disorders. Jonkman MF. **Am J Med Genet** 1999 Aug 6;85(4):361-4 (30 ref.)
The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Oliveira C, et al. **Am J Pathol** 1998 Oct;153(4):1211-9 **(44 ref.)**
K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Westra WH, et al. **Am J Surg Pathol** 1998 Oct;22(10):1247-54 (33 ref.)
Voltage-dependent calcium channel mutations in neurological disease. Burgess DL, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:199-212 (66 ref.)
The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes. Drake JW. **Ann N Y Acad Sci** 1999 May 18;870:100-7 (19 ref.)
Contingency loci, mutator alleles, and their interactions. Synergistic strategies for microbial evolution and adaptation in pathogenesis. Field D, et al. **Ann N Y Acad Sci** 1999 May 18;870:378-82 (17 ref.)
Mechanisms of mutation in nondividing cells. Insights from the study of adaptive mutation in Escherichia coli. Foster PL, et al. **Ann N Y Acad Sci** 1999 May 18;870:133-45 (82 ref.)
Tissue-specific distribution of multiple mitochondrial DNA rearrangements during human aging. Kovalenko SA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:171-81 (42 ref.)
Mechanisms of genome-wide hypermutation in stationary phase. Lombardo MJ, et al. **Ann N Y Acad Sci** 1999 May 18;870:275-89 (62 ref.)
Somatic mutation and aging. Morley A. **Ann N Y Acad Sci** 1998 Nov 20;854:20-2 (18 ref.)
Mitochondrial DNA mutations and age. Ozawa T. **Ann N Y Acad Sci** 1998 Nov 20;854:128-54 (164 ref.)
Predictability of mutant sequences. Relationships between mutational mechanisms and mutant specificity. Ripley LS. **Ann N Y Acad Sci** 1999 May 18;870:159-72 (36 ref.)
DNA-directed mutations. Leading and lagging strand specificity. Sinden RR, et al. **Ann N Y Acad Sci** 1999 May 18;870:173-89 (65 ref.)
Ki-ras oncogene mutations in chronic pancreatitis: which discriminating ability for malignant potential? van Laethem JL. **Ann N Y Acad Sci** 1999 Jun 30;880:210-8 (22 ref.)
Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool. Mulcahy H, et al. **Ann Oncol** 1999;10 Suppl 4:114-7 (28 ref.)
Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer. Tascilar M, et al. **Ann Oncol** 1999;10 Suppl 4:107-10 (70 ref.)
The association between familial distal renal tubular acidosis and mutations in the red cell anion exchanger (band 3, AE1) gene. Bruce LJ, et al. **Biochem Cell Biol** 1998;76(5):723-8 (31 ref.)
Cytoskeletal protein mutations and cell motility in Dictyostelium. Weber I, et al. **Biochem Soc Symp** 1999; 65:245-65 (69 ref.)
Mutants of Chlamydomonas: tools to study thylakoid membrane structure, function and biogenesis. de Vitry C, et al. **Biochimie** 1999 Jun;81(6):631-43 (77 ref.)
Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Pohlenz J, et al. **Biochimie** 1999 May; 81(5):469-76 (25 ref.)
Different mutations of the RET gene cause different human tumoral diseases. Santoro M, et al. **Biochimie** 1999 Apr; 81(4):397-402 (57 ref.)
Mutations of calcium channel beta subunit genes in mice. Freise D, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):897-902 (61 ref.)
Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Roemer K. **Biol Chem** 1999 Jul-Aug; 380(7-8):879-87 (86 ref.)
Non random DNA evolution. Valenzuela CY. **Biol Res** 1997; 30(3):117-23 (17 ref.)
Hematologically important mutations: red cell pyruvate kinase (2nd update). Baronciani L, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):273-9 (41 ref.)
Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis. Gallagher PG, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):539-43 (48 ref.)
Using genetic mutations to study the neural basis of behavior. Steele PM, et al. **Cell** 1998 Dec 23;95(7):879-82 (18 ref.)
Monogenetic determinants of Alzheimer's disease: APP mutations. Goate AM. **Cell Mol Life Sci** 1998 Sep;

54(9):897-901 (50 ref.)
Monogenic determinants of familial Alzheimer's disease: presenilin-1 mutations. Kovacs DM, et al. **Cell Mol Life Sci** 1998 Sep;54(9):902-9 (86 ref.)
Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations. Renbaum P, et al. **Cell Mol Life Sci** 1998 Sep;54(9):910-9 (74 ref.)
Presenilins in their infancy. Schweisguth F. **Chem Biol** 1999 Jul;6(7):R187-90 (30 ref.)
The different forms of neurofibromatosis. Ruggieri M. **Childs Nerv Syst** 1999 Jul;15(6-7):295-308 (113 ref.)
Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Mickle JE, et al. **Clin Chest Med** 1998 Sep;19(3):443-58, v (139 ref.)
Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Eccles MR, et al. **Clin Genet** 1999 Jul;56(1):1-9 (39 ref.)
Interrelationships between radiation-induced mutations and modifications in gene expression linked to cancer. Liber HL, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3-4):257-76 (209 ref.)
Evolutionary genetics: The economics of mutation. Rainey PB. **Curr Biol** 1999 May 20;9(10):R371-3 (17 ref.)
Mutations in extracellular matrix molecules. Gorski JP, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):586-93 (65 ref.)
Mutations in Na(K)Cl transporters in Gitelman's and Bartter's syndromes. Simon DB, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):450-4 (31 ref.)
Hypermutation in antibody affinity maturation. Wabl M, et al. **Curr Opin Immunol** 1999 Apr;11(2):186-9 (45 ref.)
Molecular pathogenesis of malignant gliomas. Rasheed BK, et al. **Curr Opin Oncol** 1999 May;11(3):162-7 (37 ref.)
Transgenic shuttle vector assays for assessing oxidative B-cell mutagenesis in vivo. Felix K, et al. **Curr Top Microbiol Immunol** 1999;246:369-75; discussion 376-7 (19 ref.)
The role of somatic hypermutation in the generation of deletions and duplications in human Ig V region genes and chromosomal translocations. Küppers R, et al. **Curr Top Microbiol Immunol** 1999;246:193-8 (15 ref.)
Microplate array diagonal gel electrophoresis for mutation research in DNA banks. Day IN, et al. **Electrophoresis** 1999 Jun;20(6):1250-7 (22 ref.)
Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Kutach LS, et al. **Electrophoresis** 1999 Jun;20(6):1204-10 (45 ref.)
Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Nataraj AJ, et al. **Electrophoresis** 1999 Jun;20(6):1177-85 (69 ref.)
Enzymatic and chemical cleavage methods. Taylor GR. **Electrophoresis** 1999 Jun;20(6):1125-30 (32 ref.)
Tumour suppressor gene mutations in humans and mice: parallels and contrasts. Hooper ML. **EMBO J** 1998 Dec 1;17(23):6783-9 (59 ref.)
Mutators and long-term molecular evolution of pathogenic Escherichia coli O157:H7. Whittam TS, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):615-7 (27 ref.)
Mutation rate: a simple concept has become complex. Thompson JN Jr, et al. **Environ Mol Mutagen** 1998; 32(4):292-300 (82 ref.)
Spectrum of mutations in fucosidosis. Willems PJ, et al. **Eur J Hum Genet** 1999 Jan;7(1):60-7 (40 ref.)
Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Derwahl M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S6-9 (41 ref.)
Clinical and molecular aspects of androgen receptor defects. Wieacker PF, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(6):446-53 (52 ref.)
Human hepatitis B virus mutants: significance of molecular changes. Chen WN, et al. **FEBS Lett** 1999 Jun 25; 453(3):237-42 (74 ref.)
Menstrual disorders and infertility caused by inactivating mutations of the luteinizing hormone receptor gene. Arnhold IJ, et al. **Fertil Steril** 1999 Apr;71(4):597-601 (32 ref.)
Retroviruses, ascorbate, and mutations, in the evolution of Homo sapiens. Challem JJ, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):130-2 (25 ref.)
Cystic fibrosis in Jews: frequency and mutation distribution. Kerem B, et al. **Genet Test** 1997;1(1):35-9 (35 ref.)
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. Neuhausen SL, et al. **Genet Test** 1997; 1(2):75-83 (79 ref.)
Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Schuchman EH, et al. **Genet Test** 1997;1(1):13-9 (34 ref.)
Preservation of duplicate genes by complementary, degenerative mutations. Force A, et al. **Genetics** 1999 Apr; 151(4):1531-45 (95 ref.)
The prothrombin gene variant 20210A in venous and arterial thromboembolism [see comments] Vicente V, et al. **Haematologica** 1999 Apr;84(4):356-62 (78 ref.) Comment in: Haematologica 1999 Apr;84(4):290.
The molecular basis of haemophilia B. Lillicrap D. **Haemophilia** 1998 Jul;4(4):350-7 (71 ref.)
The molecular basis of haemophilia A. Peake I. **Haemophilia** 1998 Jul;4(4):346-9 (21 ref.)
Recent advances in research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutations: neuronal Lewy body-like hyaline inclusions and astrocytic hyaline inclusions. Kato S, et al. **Histol Histopathol** 1999 Jul;14(3):973-89 (113 ref.)
Testing environment for single-gene disorders in U.S. reference laboratories. Amos J, et al. **Hum Mutat** 1998; 12(5):293-300 (13 ref.)
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Cleaver JE, et al. **Hum Mutat** 1999; 14(1):9-22 (110 ref.)
Mitochondrial deafness mutations reviewed. Fischel-Ghodsian N. **Hum Mutat** 1999;13(4):261-70 (69 ref.)
IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hernandez-Boussard T, et al. **Hum Mutat** 1999;14(1):1-8 (25 ref.)
WRN mutations in Werner syndrome [published erratum appears in Hum Mutat 1999;14(1):84-5] Moser MJ, et al. **Hum Mutat** 1999;13(4):271-9 (89 ref.)
Long-term effects of delayed parenthood. Tarin JJ, et al. **Hum Reprod** 1998 Sep;13(9):2371-6 (106 ref.)
Molecular genetics of C1 inhibitor [published erratum appears in Immunobiology 1999 Feb;200(1):166] Tosi M. **Immunobiology** 1998 Aug;199(2):358-65 (23 ref.)
Hot spots for molecular genetic alterations in lung cancer. Pitterle DM, et al. **In Vivo** 1998 Nov-Dec;12(6):643-58 (119 ref.)
ATM: the product of the gene mutated in ataxia-telangiectasia. Lavin MF. **Int J Biochem Cell Biol** 1999 Jul;31(7):735-40 (36 ref.)
The petite mutation in yeasts: 50 years on. Chen XJ, et al. **Int Rev Cytol** 2000;194:197-238 (256 ref.)
Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? Martinez JL, et al. **J Antimicrob Chemother** 1998 Dec;42(6):683-8 (64 ref.)
Ehlers-Danlos syndrome type VII: clinical features and molecular defects. Giunta C, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):225-38 (46 ref.)
The molecular basis of disorders of the red cell membrane. McMullin MF. **J Clin Pathol** 1999 Apr;52(4):245-8 (21 ref.)
The molecular basis of disorders of red cell enzymes. McMullin MF. **J Clin Pathol** 1999 Apr;52(4):241-4 (19 ref.)
Viral RNA and evolved mutational robustness. Wagner A, et al. **J Exp Zool** 1999 Aug 15;285(2):119-27 (54 ref.)
The haemochromatosis gene: a co-factor for chronic liver diseases? George DK, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):745-9 (50 ref.)
Genetic basis of progressive familial intrahepatic cholestasis. Jacquemin E, et al. **J Hepatol** 1999 Aug;31(2):377-81 (42 ref.)
A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). Wevers RA, et al. **J Inherit Metab Dis** 1999 Jun;22(4):364-73 (23 ref.)
Genes involved in animal models of obesity and anorexia. Schalling M, et al. **J Intern Med** 1999 Jun;245(6):613-9 (49 ref.)
The molecular genetics of inherited deafness--current and future applications. Bussoli TJ, et al. **J Laryngol Otol** 1998 Jun;112(6):523-30 (72 ref.)
Tobacco smoke carcinogens and lung cancer. Hecht SS. **J Natl Cancer Inst** 1999 Jul 21;91(14):1194-210 (249 ref.)
Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. Bennett WP, et al. **J Pathol** 1999 Jan;187(1):8-18 (126 ref.)
Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. Garcia SB, et al. **J Pathol** 1999 Jan;187(1):61-81 (287 ref.)
Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. Accili D, et al. **J Pediatr Endocrinol Metab** 1999 Jul-Aug;12(4):475-85 (62 ref.)
Congenital myasthenic syndromes: experiments of nature. Engel AG, et al. **J Physiol Paris** 1998 Apr;92(2):113-7 (25 ref.)
A hypothesis to explain the reduced blood levels of docosahexaenoic acid in inherited retinal degenerations caused by mutations in genes encoding retina-specific proteins. Anderson RE, et al. **Lipids** 1999;34 Suppl:S235-7 (25 ref.)
Phenotypic and biochemical consequences of collagen X mutations in mice and humans. Chan D, et al. **Matrix Biol** 1998 Jul;17(3):169-84 (80 ref.)
Mutation analysis and molecular genetics of epidermolysis bullosa. Pulkkinen L, et al. **Matrix Biol** 1999 Feb; 18(1):29-42 (91 ref.)
DNA damage and mutation: contributors to the age-related alterations in T cell-mediated immune responses? Barnett YA, et al. **Mech Ageing Dev** 1998 May 15;102(2-3):165-75 (49 ref.)
Genetic dissection of histone function. Smith MM, et al. **Methods** 1998 Aug;15(4):269-81 (76 ref.)
Methods for isolating and analyzing mitotic mutants in Aspergillus nidulans. Oakley BR. **Methods Cell Biol** 1999; 61:347-68 (41 ref.)
Mapping zebrafish mutations by AFLP. Ransom DG, et al. **Methods Cell Biol** 1999;60:195-211 (19 ref.)
Identification and characterization of mitotic mutations in Drosophila. Theurkauf WE, et al. **Methods Cell Biol** 1999; 61:317-46 (41 ref.)
Small-scale marker-based screening for mutations in zebrafish development. Currie PD, et al. **Methods Mol Biol** 1999;97:441-60 (38 ref.)
The generation of plastid mutants in vitro. Dix PJ. **Methods Mol Biol** 1999;111:319-26 (12 ref.)
Genetic selection of rRNA mutations. Gregory ST, et al. **Methods Mol Biol** 1998;77:271-81 (14 ref.)
Genes and premature ovarian failure. Christin-Maitre S, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):75-80 (40 ref.)
Genetics of male infertility. Hargreave TB, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):143-51 (67 ref.)
Mutations and polymorphisms in gonadotropin genes. Huhtaniemi I, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1-2):89-94 (39 ref.)
Genetic mutations resulting in estrogen insufficiency in the male. Simpson ER. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):55-9 (16 ref.)
G protein abnormalities in pituitary adenomas. Spada A, et al. **Mol Cell Endocrinol** 1998 Jul 25;142(1-2):1-14 (97 ref.)
Inactivating FSH receptor mutations and gonadal dysfunction. Tapanainen JS, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):129-35 (54 ref.)
Estrogen receptor mutations. Taylor JA, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):61-6 (59 ref.)
Activating and inactivating mutations in LH receptors. Themmen AP, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):137-42 (28 ref.)
Mitochondrial RNA processing and translation: link between mitochondrial mutations and hearing loss? Fischel-Ghodsian N. **Mol Genet Metab** 1998 Oct; 65(2):97-104 (67 ref.)
Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition. Todd RD, et al. **Mol Neurobiol** 1998 Apr;16(2):135-47 (67 ref.)
Mutant manifestation: the time factor in somatic mutagenesis. Heddle JA. **Mutagenesis** 1999 Jan;14(1):1-3 (12 ref.)
On clonal expansion and its effects on mutant frequencies, mutation spectra and statistics for somatic mutations in vivo. Heddle JA. **Mutagenesis** 1999 May;14(3):257-60 (19 ref.)
p53 mutations, benzo[a]pyrene and lung cancer [see comments] Krawczak M, et al. **Mutagenesis** 1998 Jul; 13(4):319-20 (7 ref.) Comment in: Mutagenesis 1998 Nov;13(6):537-8.
UV-induced mutations and skin cancer: how important is the link? Bridges BA. **Mutat Res** 1998 Nov 9;422(1):23-30 (38 ref.)
Spontaneous mutation in man. Crow JF. **Mutat Res** 1999 Jul;437(1):5-9 (22 ref.)
An estimator of the mutant frequency in assays using transgenic animals. Delongchamp RR, et al. **Mutat Res** 1999 Mar 15;440(1):101-8 (20 ref.)
Are adaptive mutations due to a decline in mismatch repair? The evidence is lacking. Foster PL. **Mutat Res** 1999 Mar; 436(2):179-84 (24 ref.)
Somatic hypermutation and the three R's: repair, replication and recombination. Harris RS, et al. **Mutat Res** 1999 Mar; 436(2):157-78 (166 ref.)
Mismatch repair is diminished during stationary-phase mutation. Harris RS, et al. **Mutat Res** 1999 Jul;437(1):51-60 (51 ref.)
Spontaneous mutations in the Big Blue transgenic system are primarily mouse derived. Hill KA, et al. **Mutat Res** 1999 Jan;436(1):11-9 (49 ref.)
Reflections in mutation research: an introductory essay. Hoffmann GR, et al. **Mutat Res** 1999 Mar;436(2):123-30 (19 ref.)
Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum. O'Neill JP, et al. **Mutat Res** 1998 Nov;411(3):179-214 (98 ref.)
Estrogen, DNA damage and mutations. Roy D, et al. **Mutat Res** 1999 Mar 8;424(1-2):107-15 (71 ref.)
Ionizing radiation and genetic risks IX. Estimates of the frequencies of mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective. Sankaranarayanan K. **Mutat Res** 1998 Sep;411(2):129-78 (285 ref.)
Transient appearance of the mutator phenotype during carcinogenesis as a possible explanation for the lack of mini/microsatellite instability in many late stage tumors. Stark AA. **Mutat Res** 1998 Nov 3;421(2):221-5 (65 ref.)
Human cancer, carcinogenic exposures and mutation spectra. Vineis P, et al. **Mutat Res** 1999 Mar;436(2):185-94 (43 ref.)
Single-gene mutations resulting in reproductive dysfunction in women. Adashi EY, et al. **N Engl J Med** 1999 Mar 4; 340(9):709-18 (75 ref.)
The expanding spectrum of G protein diseases. Farfel Z, et al. **N Engl J Med** 1999 Apr 1;340(13):1012-20 (54 ref.)
Molecular basis of the neurodegenerative disorders. Martin JB. **N Engl J Med** 1999 Jun 24;340(25):1970-80 (93 ref.)
Genetic disorders of renal electrolyte transport. Scheinman SJ, et al. **N Engl J Med** 1999 Apr 15;340(15):1177-87 (66 ref.)
Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Tomlinson I, et al. **Nat Med** 1999 Jan;5(1):11-2 (19 ref.)
Tau mutations cause frontotemporal dementias. Goedert M, et al. **Neuron** 1998 Nov;21(5):955-8 (20 ref.)

The human obesity gene map: the 1998 update. Pérusse L, et al. **Obes Res** 1999 Jan;7(1):111-29 (136 ref.)
Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer. Iwase H, et al. **Oncology** 1998 Dec;55 Suppl 1:11-6 (39 ref.)
What is the true rate of K-ras mutation in carcinoma of the pancreas? [editorial] Longnecker DS, et al. **Pancreas** 1998 Nov;17(4):323-4 (18 ref.)
Why are there so few resistance-associated mutations in insecticide target genes? ffrench-Constant RH, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1685-93 (61 ref.)
Androgen receptor mutation in Kennedy's disease. Fischbeck KH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29;354(1386):1075-8 (26 ref.)
CAG-polyglutamine-repeat mutations: independence from gene context. Ordway JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1083-8 (34 ref.)
Vasopressin receptor mutations causing nephrogenic diabetes insipidus. Bichet DG, et al. **Proc Assoc Am Physicians** 1998 Sep-Oct;110(5):387-94 (57 ref.)
Aquaporin-2 water channel mutations causing nephrogenic diabetes insipidus. van Os CH, et al. **Proc Assoc Am Physicians** 1998 Sep-Oct;110(5):395-400 (47 ref.)
Ion channel genes and human neurological disease: recent progress, prospects, and challenges. Cooper EC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4759-66 (102 ref.)
Sorting out mutation rates. Foster PL. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7617-8 (10 ref.)
Noninsulin-dependent diabetes mellitus as a mitochondrial genomic disease. Mathews CE, et al. **Proc Soc Exp Biol Med** 1998 Nov;219(2):97-108 (134 ref.)
Cataract mutations and lens development. Graw J. **Prog Retin Eye Res** 1999 Mar;18(2):235-67 (169 ref.)
Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. Dogliotti E, et al. **Recent Results Cancer Res** 1998;154:97-124 (107 ref.)
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M, et al. **Recent Results Cancer Res** 1998; 154:229-36 (22 ref.)
Neuronal nicotinic acetylcholine receptors: their properties and alterations in autosomal dominant nocturnal frontal lobe epilepsy. Bertrand D. **Rev Neurol (Paris)** 1999 Jul; 155(6-7):457-62 (30 ref.)
Gene defects in idiopathic epilepsy. Steinlein OK. **Rev Neurol (Paris)** 1999 Jul;155(6-7):450-3 (18 ref.)
Are mutations in the cystic fibrosis gene important in chronic pancreatitis? Cohn JA, et al. **Surg Clin North Am** 1999 Aug; 79(4):723-31, viii (30 ref.)
Neurofibromatosis type 2 with multiple primary brain tumors in monozygotic twins. Harada H, et al. **Surg Neurol** 1999 May;51(5):528-35 (30 ref.)
Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Brent RL. **Teratology** 1999 Apr;59(4):182-204 (125 ref.)
Life cycle of the mammalian germ cell: implication for spontaneous mutation frequencies. Lewis SE. **Teratology** 1999 Apr;59(4):205-9 (50 ref.)
The pathogenic consequences of a single mutated CFTR gene. Griesenbach U, et al. **Thorax** 1999 Aug;54 Suppl 2:S19-23 (36 ref.)
Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer. Roland M, et al. **Thorax** 1998 Nov;53(11):979-83 (52 ref.)
Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Kebebew E, et al. **Thyroid** 1999 Feb;9(2):127-31 (17 ref.)
Tumor suppressor genes in rodent lung carcinogenesis-mutation of p53 does not appear to be an early lesion in lung tumor pathogenesis. Miller MS. **Toxicol Appl Pharmacol** 1999 Apr 1;156(1):70-7 (104 ref.)
Photochemical genotoxicity and photochemical carcinogenesis--two sides of a coin? Müller L, et al. **Toxicol Lett** 1998 Dec 28;102-103:383-7 (18 ref.)
Mechanisms of disease and injury: utilization of mutants, monoclonals, and molecular methods. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):115-20 (59 ref.)
Sex biases in the mutation rate. Hurst LD, et al. **Trends Genet** 1998 Nov;14(11):446-52 (77 ref.)
Chimeras and mosaics in mouse mutant analysis. Rossant J, et al. **Trends Genet** 1998 Sep;14(9):358-63 (42 ref.)
Development of the vertebrate ear: insights from knockouts and mutants. Fekete DM. **Trends Neurosci** 1999 Jun; 22(6):263-9 (71 ref.)
[Diagnosis and treatment of primary hemochromatosis] Swinkels DW, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1404-8 (57 ref.) (Eng. Abstr.) **(Dut)**
[Physiopathology of calcium channels: identification of calcium channelopathies] Lory P, et al. **C R Seances Soc Biol Fil** 1998;192(1):137-47 (30 ref.) (Eng. Abstr.) **(Fre)**
[Mutations in TSH receptors: pathogenetic significance and clinical relevance] Führer D, et al. **Dtsch Med Wochenschr** 1999 May 28;124(21):662-9 (48 ref.) **(Ger)**
[Genetic instability in osteoblastic tumors of the skeletal system] Roessner A, et al. **Verh Dtsch Ges Pathol** 1998; 82:133-43 (71 ref.) (Eng. Abstr.) **(Ger)**
[Hereditary neoplastic diseases (genetic predisposition and cancer syndromes)] Oláh E. **Orv Hetil** 1999 Feb 28; 140(9):451-66 (82 ref.) (Eng. Abstr.) **(Hun)**
[Fulminant hepatitis and viral mutation] Yatsuhashi H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):664-9 (5 ref.) **(Jpn)**
[Dynamic mutation and its molecular cytogenetics] Hori T, et al. **Nippon Rinsho** 1999 Apr;57(4):771-7 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Familial cortisol resistance and mutations of the glucocorticoid receptor gene] Iida S, et al. **Nippon Rinsho** 1998 Jul;56(7):1887-91 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Endothelin B receptor system and Hirschsprung disease] Inoue M, et al. **Nippon Rinsho** 1998 Jul;56(7):1876-80 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Premutation in myotonic dystrophy] Komai K, et al. **Nippon Rinsho** 1999 Apr;57(4):927-31 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Disorders caused by mutations of the thyrotropin receptor] Kosugi S. **Nippon Rinsho** 1998 Jul;56(7):1856-60 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Mutations in the genes of the HNF-family cause maturity-onset diabetes of the young (MODY)] Takeda J. **Nippon Rinsho** 1998 Sep;56(9):2419-26 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Vasopressin type 2 receptor mutations in congenital diabetes insipidus] Tsukaguchi H, et al. **Nippon Rinsho** 1998 Jul; 56(7):1848-55 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular cytogenetics of fragile X syndrome] Yamauchi M, et al. **Nippon Rinsho** 1999 Apr;57(4):943-9 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Beta 3 adrenergic receptor polymorphism and obesity] Yoshida T, et al. **Nippon Rinsho** 1998 Jul;56(7):1871-5 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese] Yokoi T, et al. **Nippon Yakurigaku Zasshi** 1998 Jul; 112(1):5-14 (45 ref.) (Eng. Abstr.) **(Jpn)**
[X-linked recessive myotubular myopathy with a splice-site mutation in the myotubularin gene] Watanabe T, et al. **No To Hattatsu** 1998 Nov;30(6):523-7 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Globin gene mutation is a model of genetic abnormalities] Hattori Y. **Rinsho Byori** 1999 Mar;47(3):244-51 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Haldane's rule and somatic mutations] Gorshkov VG, et al. **Genetika** 1999 Jun;35(6):725-32 (38 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Use of protein repair therapy in the treatment of cystic fibrosis. Rubenstein RC, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):250-5 (46 ref.)
Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. Ananthaswamy HN, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):52-6 (71 ref.)
Polycyclic aromatic hydrocarbons: correlations between DNA adducts and ras oncogene mutations. Ross JA, et al. **Mutat Res** 1999 Mar 8;424(1-2):155-66 (59 ref.)

GENETICS

Signal transduction defects in growth hormone insensitivity. Clayton PE, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):174-8; discussion 179 (18 ref.)
Truncated growth hormone receptor isoforms. Ross RJ. **Acta Paediatr Suppl** 1999 Feb;88(428):164-6; discussion 167 (10 ref.)
Partial growth hormone insensitivity--idiopathic short stature is not always idiopathic. Saenger P. **Acta Paediatr Suppl** 1999 Feb;88(428):194-8 (20 ref.)
Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Woods KA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):158-62; discussion 163 (13 ref.)
Conformational alterations resulting from mutations in cytoplasmic domains of the alpha subunit of the Na,K-ATPase. Blostein R, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:275-81 (26 ref.)
Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Jones AC, et al. **Am J Hum Genet** 1999 May; 64(5):1305-15 (47 ref.)
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Coughlin SS, et al. **Am J Prev Med** 1999 Feb;16(2):91-8 (64 ref.)
Red blood cell membrane disorders. Tse WT, et al. **Br J Haematol** 1999 Jan;104(1):2-13 (117 ref.)
Clinical implications of p53 mutations. Wallace-Brodeur RR, et al. **Cell Mol Life Sci** 1999 Jan;55(1):64-75 (140 ref.)
Rapid detection of genetic mutations using the chemiluminescent hybridization protection assay (HPA): overview and comparison with other methods. Nelson NC. **Crit Rev Clin Lab Sci** 1998 Sep;35(5):369-414 (166 ref.)
Molecular biology and clinical importance of the Ca(2+)-sensing receptor. De Luca F, et al. **Curr Opin Pediatr** 1998 Aug;10(4):435-40 (28 ref.)
Genetic causes of rickets. Miller WL, et al. **Curr Opin Pediatr** 1999 Aug;11(4):333-9 (40 ref.)
RSH (so-called Smith-Lemli-Opitz) syndrome. Opitz JM. **Curr Opin Pediatr** 1999 Aug;11(4):353-62 (60 ref.)
Molecular genetics of long-QT syndrome. Wattanasirichaigoon D, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):628-34 (58 ref.)
Parathyroid hormone (PTH)/PTHrP receptor mutations in human chondrodysplasia [editorial; comment] Nissenson RA. **Endocrinology** 1998 Dec;139(12):4753-5 (21 ref.) Comment on: Endocrinology 1998 Dec;139(12):5255-8.
Genetic pathways in colorectal and other cancers. Ilyas M, et al. **Eur J Cancer** 1999 Mar;35(3):335-51 (209 ref.)
Cellular responses to radiation and risk of breast cancer. Jongmans W, et al. **Eur J Cancer** 1999 Apr;35(4):540-8 (117 ref.)
Mutations of the human E-cadherin (CDH1) gene. Berx G, et al. **Hum Mutat** 1998;12(4):226-37 (71 ref.)
The protein truncation test: A review. Den Dunnen JT, et al. **Hum Mutat** 1999;14(2):95-102 (51 ref.)
Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Oetting WS, et al. **Hum Mutat** 1999;13(2):99-115 (98 ref.)
A unifying hypothesis for the molecular mechanism of somatic mutation and gene conversion in rearranged immunoglobulin variable genes. Blanden RV, et al. **Immunol Cell Biol** 1998 Jun;76(3):288-93 (36 ref.)
EMS and UV-light-induced colony sectoring and delayed mutation in Chinese hamster cells. Stamato TD, et al. **Int J Radiat Biol** 1998 Dec;74(6):739-45 (45 ref.)
Clinical genetics: an overview. Nehring WM, et al. **J Cardiovasc Nurs** 1999 Jul;13(4):19-33 (29 ref.)
Clustering of COL7A1 mutations in exon 73: implications for mutation analysis in dystrophic epidermolysis bullosa [letter] Mecklenbeck S, et al. **J Invest Dermatol** 1999 Mar; 112(3):398-400 (14 ref.)
Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Dean SW, et al. **Mutagenesis** 1999 Jan;14(1):141-51 (115 ref.)
Environmentally responsive mutator systems: toward a unifying perspective. Lieber MM. **Riv Biol** 1998; 91(3):425-57 (61 ref.)
Reactivation of mutant p53: a new strategy for cancer therapy. Selivanova G, et al. **Semin Cancer Biol** 1998; 8(5):369-78 (70 ref.)
The genetic bases of the porphyrias. Frank J, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):297-309 (100 ref.)
Non-autoimmune hyper- and hypothyroidism due to mutations in the thyrotropin receptor gene. Vassart G. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:23-4 (11 ref.)
[Activating mutations of the gonadotrophin receptors] Beck-Peccoz P, et al. **Arch Pediatr** 1998;5 Suppl 4:380S-384S (17 ref.) (Eng. Abstr.) **(Fre)**
[Activating mutations of the parathyroid hormone and parathyroid hormone related peptide] David L. **Arch Pediatr** 1998;5 Suppl 4:385S-389S (22 ref.) (Eng. Abstr.) **(Fre)**
[Activating mutations of the TSH receptor: a synthesis highlighting certain pediatric aspects] Polak M. **Arch Pediatr** 1998;5 Suppl 4:375S-379S (32 ref.) (Eng. Abstr.) **(Fre)**
[Natural history of ovarian adenocarcinomas: from epidemiology to experimentation] Hamilton TC, et al. **Contracept Fertil Sex** 1998 Nov;26(11):800-4 (40 ref.) (Eng. Abstr.) **(Fre)**
[Hereditary neurological diseases caused by amplification of triplet repetitions] Warter JM, et al. **Presse Med** 1998 Feb 28;27(8):376-81 (70 ref.) (Eng. Abstr.) **(Fre)**
[Triple expansion diseases: a new mutational concept] Schorderet DF. **Rev Med Suisse Romande** 1999 Feb; 119(2):103-6 (6 ref.) (Eng. Abstr.) **(Fre)**
[New knowledge about obesity--news for obese patients?] Geyer G. **Acta Med Austriaca** 1998;25(4-5):117-25 (63 ref.) (Eng. Abstr.) **(Ger)**
[BRCA1 and BRCA2: mutations and other genetic changes--practical relevance] Scherneck S, et al. **Chirurg** 1999 Apr;70(4):373-9 (32 ref.) (Eng. Abstr.) **(Ger)**
[Pachyonychia congenita. Keratin gene mutations with pleiotropic effect] Swensson O. **Hautarzt** 1999 Jul; 50(7):483-90 (48 ref.) (Eng. Abstr.) **(Ger)**
[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases] Beltinger C, et al. **Klin Padiatr** 1998 Jul-Aug;210(4):153-8 (37 ref.) (Eng. Abstr.) **(Ger)**
[Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism] Derwahl M. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:25-8 (35 ref.) (Eng. Abstr.) **(Ger)**
[Do viruses participate in the origin of group outbursts of gene mutations occurring in natural Drosophila populations?] Gershenzon SM. **Tsitol Genet** 1998 Sep-Oct; 32(5):94-102 (26 ref.) (Eng. Abstr.) **(Rus)**
[Diabetes mellitus associated with the A3243G mutation of mitochondrial DNA. Apropos a case (see comments)] Biarnés J, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):99-101 (16 ref.) (Eng. Abstr.) Comment in: Med Clin (Barc) 1999

MUTATION

Jan 30;112(3):96–8. **(Spa)**

PHYSIOLOGY

Genetic lesions in Drosophila behavioural mutants. Pflugfelder GO. **Behav Brain Res** 1998 Sep;95(1):3–15 (125 ref.)

p53 and brain tumors: from gene mutations to gene therapy. Fulci G, et al. **Brain Pathol** 1998 Oct;8(4):599–613 (128 ref.)

An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Cassarino DS, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):1–25 (276 ref.)

Myosin V in the brain: mutations lead to neurological defects. Langford GM, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):1–8 (174 ref.)

Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Morrison BM, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):121–35 (140 ref.)

Benign familial neonatal epilepsy with mutations in two potassium channel genes. Leppert M, et al. **Curr Opin Neurol** 1999 Apr;12(2):143–7 (36 ref.)

The molecular basis of isolated 17,20 lyase deficiency. Miller WL, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):817–25 (45 ref.)

Aquaporin–2 water channel mutations and nephrogenic diabetes insipidus: new variations on a theme. Rutishauser J, et al. **Eur J Endocrinol** 1999 Feb;140(2):137–9 (18 ref.)

The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pritchard–Jones K. **Pediatr Nephrol** 1999 Sep;13(7):620–5 (37 ref.)

MUTATION, FRAMESHIFT see **FRAMESHIFT MUTATION**

MUTATION, GERM–LINE see **GERM–LINE MUTATION**

MUTATION, MISSENSE

see related
AMINO ACID SUBSTITUTION
POINT MUTATION

Analysis of somatic mutations of the p53 gene in human cancers: a tool to generate hypotheses about the natural history of cancer. Hernandez–Boussard T, et al. **IARC Sci Publ** 1999;(146):43–53 (33 ref.)

The molecular basis of von Willebrand disease. Mohlke KL, et al. **Int J Clin Lab Res** 1999;29(1):1–7 (55 ref.)

An inherited prion disease with a PrP P105L mutation: clinicopathologic and PrP heterogeneity. Yamada M, et al. **Neurology** 1999 Jul 13;53(1):181–8 (31 ref.)

GENETICS

Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. van Leeuwen FW, et al. **Trends Neurosci** 1998 Aug;21(8):331–5 (48 ref.)

MUTATION, POINT see **POINT MUTATION**

MUTATIONAL ANALYSIS, DNA see **DNA MUTATIONAL ANALYSIS**

MUTISM

CLASSIFICATION

Is selective mutism an anxiety disorder? Rethinking its DSM–IV classification. Anstendig KD. **J Anxiety Disord** 1999 Jul–Aug;13(4):417–34 (63 ref.)

ETIOLOGY

Is selective mutism an anxiety disorder? Rethinking its DSM–IV classification. Anstendig KD. **J Anxiety Disord** 1999 Jul–Aug;13(4):417–34 (63 ref.)

MYALGIA, EPIDEMIC see **PLEURODYNIA, EPIDEMIC**

MYASTHENIA GRAVIS

Abstracts of the International Myasthenia Gravis Workshop. November 8–10 (1998), Mysore, India. **J Neuroimmunol** 1998 Dec 1;92(1–2):1–7 (00 ref.)

Myasthenia gravis: clinical features, pathogenesis, evaluation, and medical management. Heitmiller RF. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):41–6 (22 ref.)

COMPLICATIONS

Thymoma associated with myasthenia gravis and minimal lesion nephrotic syndrome. Lasseur C, et al. **Am J Kidney Dis** 1999 May;33(5):e4 (19 ref.)

Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature. Mizobuchi S, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):696–701 (37 ref.)

A malignancy work–up in patients with cancer–associated (paraneoplastic) autoimmune diseases: pemphigus and myasthenic syndromes as cases in point (review). Sherer Y, et al. **Oncol Rep** 1999 May–Jun;6(3):665–8 (48 ref.)

[Myasthenia gravis presenting as isolated respiratory failure] Kishimoto N, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):891–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A case of nephrotic syndrome associated with myasthenia gravis and malignant thymoma] Tomida C, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):77–82 (19 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Congenital myasthenic syndromes: recent advances. Engel AG, et al. **Arch Neurol** 1999 Feb;56(2):163–7 (32 ref.)

Congenital myasthenic syndromes: experiments of nature. Engel AG, et al. **J Physiol Paris** 1998 Apr;92(2):113–7 (25 ref.)

[Diagnosis and therapy of congenital myasthenia syndrome] Sieb JP. **Dtsch Med Wochenschr** 1999 Jan 8;124(1–2):24–9 (42 ref.) **(Ger)**

DIAGNOSIS

Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. Chorzelski T, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):393–400 (42 ref.)

Neurologic degenerative disorders. Ross AP. **Nurs Clin North Am** 1999 Sep;34(3):725–42 (14 ref.)

[Myasthenia gravis with electrophysiological features of Lambert–Eaton myasthenic syndrome: usefulness of serum autoantibodies assay and neuromuscular junction biopsy] Matsumoto R, et al. **Rinsho Shinkeigaku** 1999 May; 39(5):531–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Congenital myasthenic syndromes: experiments of nature. Engel AG, et al. **J Physiol Paris** 1998 Apr;92(2):113–7 (25 ref.)

IMMUNOLOGY

Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Vincent A, et al. **Immunol Rev** 1998 Aug;164:157–68 (87 ref.)

PHYSIOPATHOLOGY

Course and treatment of myasthenia gravis during pregnancy. Batocchi AP, et al. **Neurology** 1999 Feb;52(3):447–52 (40 ref.)

RADIOTHERAPY

The long–term clinical outcome of myasthenia gravis in patients with thymoma. Bril V, et al. **Neurology** 1998 Oct; 51(4):1198–200 (10 ref.)

SURGERY

Thymectomy in the integrated management of myasthenia gravis. Wilkins KB, et al. **Adv Surg** 1999;32:105–33 (76 ref.)

Thoracoscopic thymectomy for myasthenia gravis: a case report. Sim EK, et al. **Ann Acad Med Singapore** 1998 Jul; 27(4):570–2 (7 ref.)

Video–assisted thoracic surgery thymectomy for myasthenia gravis. Mack MJ, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):809–25, viii; discussion 827–34 (27 ref.)

Preoperative preparation and anesthetic management of patients with myasthenia gravis. Krucylak PE, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):47–53 (53 ref.)

THERAPY

Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty–six cases and review of current management. Mahalati K, et al. **J Clin Apheresis** 1999; 14(1):1–8 (65 ref.)

Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Howard JF Jr. **Neurology** 1998 Dec;51(6 Suppl 5):S30–6 (73 ref.)

Neurologic degenerative disorders. Ross AP. **Nurs Clin North Am** 1999 Sep;34(3):725–42 (14 ref.)

MYASTHENIC SYNDROME, LAMBERT–EATON see **LAMBERT–EATON MYASTHENIC SYNDROME**

MYATONIA CONGENITA see **NEUROMUSCULAR DISEASES**

MYB GENES see **ONCOGENES**

MYC GENES see **GENES, MYC**

MYC PROTO–ONCOGENE PROTEINS see **PROTO–ONCOGENE PROTEINS C–MYC**

MYCETOMA see **MADUROMYCOSIS**

MYCOBACTERIA, ATYPICAL

Atypical mycobacterial lymphadenitis in childhood––a clinicopathological study of 17 cases. Evans MJ, et al. **J Clin Pathol** 1998 Dec;51(12):925–7 (10 ref.)

Successful treatment of disseminated Mycobacterium szulgai infection with ciprofloxacin, rifampicin, and ethambutol [letter] Fang CT, et al. **J Infect** 1999 May;38(3):195–7 (10 ref.)

ISOLATION & PURIFICATION

Nosocomial outbreaks/pseudo–outbreaks caused by nontuberculous mycobacteria. Wallace RJ Jr, et al. **Annu Rev Microbiol** 1998;52:453–90 (101 ref.)

[Pulmonary infection in the emphysematous bulla due to Mycobacterium szulgai diagnosed by percutaneus needle aspiration] Inoue Y, et al. **Kansenshogaku Zasshi** 1998 Nov; 72(11):1236–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of bronchiectasis with abundant expectoration of Mycobacterium gordonae] Itou Y, et al. **Kekkaku** 1998 Dec;73(12):719–22 (16 ref.) (Eng. Abstr.) **(Jpn)**

PATHOGENICITY

Emergence of a unique group of necrotizing mycobacterial diseases. Dobos KM, et al. **Emerg Infect Dis** 1999 May–Jun; 5(3):367–78 (64 ref.)

[Therapeutic innovations for environmental mycobacteria (editorial)] Caminero Luna JA, et al. **Arch Bronconeumol** 1999 Jan;35(1):5–8 (37 ref.) **(Spa)**

MYCOBACTERIAL CERVICAL LYMPHADENITIS see **TUBERCULOSIS, LYMPH NODE**

MYCOBACTERIOPHAGES

TB: the return of the phage. A review of fifty years of mycobacteriophage research. McNerney R. **Int J Tuberc Lung Dis** 1999 Mar;3(3):179–84 (67 ref.)

MYCOBACTERIUM

CHEMISTRY

[Biochemistry and bioactivities of mycobacterial components] Yano I. **Nippon Rinsho** 1998 Dec; 56(12):3008–16 (16 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Identification of Mycobacterium shimoidei by molecular techniques: case report and summary of the literature. Mayall B, et al. **Int J Tuberc Lung Dis** 1999 Feb;3(2):169–73 (23 ref.)

[Molecular typing of mycobacteria] Devallois A, et al. **Pathol Biol (Paris)** 1998 Oct;46(8):625–36 (111 ref.) (Eng. Abstr.) **(Fre)**

[Bacteriology of mycobacteria: taxonomic and morphological characteristics] Tomioka H. **Nippon Rinsho** 1998 Dec; 56(12):3001–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Epidemiology of mycobacterial resistance (especially Mycobacterium tuberculosis). Fischer B. **Chemotherapy** 1999 Mar–Apr;45(2):109–20 (45 ref.)

Antimycobacterial activities of riminophenazines. Reddy VM, et al. **J Antimicrob Chemother** 1999 May;43(5):615–23 (73 ref.)

Tuberculosis: a search for novel therapy starting with natural products. Mitscher LA, et al. **Med Res Rev** 1998 Nov; 18(6):363–74 (19 ref.)

Antibiotic resistance in mycobacteria. Davies J. **Novartis Found Symp** 1998;217:195–205; discussion 205–8 (32 ref.)

Interdependence of mycobacterial iron regulation, oxidative–stress response and isoniazid resistance. Dussurget O, et al. **Trends Microbiol** 1998 Sep;6(9):354–8 (34 ref.)

GENETICS

Mycobacteria: genetics of resistance and implications for treatment. Sander P, et al. **Chemotherapy** 1999 Mar–Apr; 45(2):95–108 (73 ref.)

Mycobacteria. Bugs and bugbears. Parish T, et al. **Methods Mol Biol** 1998;101:1–13 (49 ref.)

Mycobacterial promoters. Mulder MA, et al. **Tuber Lung Dis** 1997;78(5–6):211–23 (117 ref.)

[Molecular typing of mycobacteria] Devallois A, et al. **Pathol Biol (Paris)** 1998 Oct;46(8):625–36 (111 ref.) (Eng. Abstr.) **(Fre)**

[Molecular methods for the rapid diagnosis of mycobacterial infections] Devallois A, et al. **Pathol Biol (Paris)** 1998 Oct; 46(8):637–50 (104 ref.) (Eng. Abstr.) **(Fre)**

[Nucleic acid components of mycobacteria: recent studies on secreted protein genes] Matsuo K. **Nippon Rinsho** 1998 Dec;56(12):3017–22 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanisms of drug–resistance in mycobacteria] Ohno H, et al. **Nippon Rinsho** 1998 Dec;56(12):3023–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

GROWTH & DEVELOPMENT

Mycobacteria. General culture methodology and safety considerations. Allen BW. **Methods Mol Biol** 1998; 101:15–30 (48 ref.)

IMMUNOLOGY

DNA encoding individual mycobacterial antigens protects mice against tuberculosis. Silva CL, et al. **Braz J Med Biol Res** 1999 Feb;32(2):231–4 (16 ref.)

IL–12 and IFN–gamma in host defense against mycobacteria and salmonella in mice and men. Jouanguy E, et al.

Curr Opin Immunol 1999 Jun;11(3):346–51 (45 ref.)
New vaccines against tuberculosis. The status of current research. Orme IM. **Infect Dis Clin North Am** 1999 Mar; 13(1):169–85, vii–viii (101 ref.)
Mycobacterium w immunotherapy in leprosy [editorial] Whitty C. **Lepr Rev** 1998 Sep;69(3):222–4 (10 ref.)

ISOLATION & PURIFICATION

Mycobacterium neoaurum--an unusual cause of infection of vascular catheters: case report and review. George SL, et al. **Clin Infect Dis** 1999 Mar;28(3):682–3 (2 ref.)
Etiological role of mycobacterium in Crohn's disease: An assessment of the literature. Hubbard J, et al. **Dig Dis** 1999; 17(1):6–13 (43 ref.)
Mycobacteria as pathogens of respiratory infection. Griffith DE. **Infect Dis Clin North Am** 1998 Sep;12(3):593–611 (68 ref.)
[Recent advance in the isolation of mycobacteria] Abe C. **Nippon Rinsho** 1998 Dec;56(12):3047–50 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Advances in genetic diagnostics for mycobacterial infection] Koga H. **Nippon Rinsho** 1998 Dec;56(12):3051–6 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Bacteremia in tuberculosis and other mycobacterial infections] Puzanov VA, et al. **Probl Tuberk** 1999;(1):54–9 (76 ref.) **(Rus)**

METABOLISM

The outer parts of the mycobacterial envelope as permeability barriers. Draper P. **Front Biosci** 1998 Dec 15;3:D1253–61 (67 ref.)
Iron acquisition and metabolism by mycobacteria. De Voss JJ, et al. **J Bacteriol** 1999 Aug;181(15):4443–51 (85 ref.)

PATHOGENICITY

Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria. Lugton I. **Immunol Cell Biol** 1999 Aug;77(4):364–72 (102 ref.)
Recently recognized mycobacteria of clinical significance. Pozniak A, et al. **J Infect** 1999 May;38(3):157–61 (70 ref.)

PHYSIOLOGY

Interdependence of mycobacterial iron regulation, oxidative-stress response and isoniazid resistance. Dussurget O, et al. **Trends Microbiol** 1998 Sep;6(9):354–8 (34 ref.)

MYCOBACTERIUM AVIUM

CLASSIFICATION

Strain typing of the Mycobacterium avium complex. Inglis N, et al. **J Infect** 1999 May;38(3):151–6 (76 ref.)

CYTOLOGY

Mycobacterium avium interaction with macrophages and intestinal epithelial cells. Sangari FJ, et al. **Front Biosci** 1999 Jul 15;4:D582–8 (64 ref.)

IMMUNOLOGY

Modulation of phagosome processing as a key strategy for Mycobacterium avium survival within macrophages. de Chastellier C, et al. **Res Immunol** 1998 Sep–Oct; 149(7–8):699–702 (19 ref.)

PHYSIOLOGY

Mycobacterium avium interaction with macrophages and intestinal epithelial cells. Sangari FJ, et al. **Front Biosci** 1999 Jul 15;4:D582–8 (64 ref.)

MYCOBACTERIUM AVIUM COMPLEX

see related
MYCOBACTERIUM AVIUM

Mycobacterium tuberculosis and other mycobacteria. Mault JR, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):227–38, x (26 ref.)
Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Griffith DE. **Drug Saf** 1999 Aug; 21(2):137–52 (60 ref.)

DRUG EFFECTS

Prophylaxis against disseminated Mycobacterium avium complex in AIDS. Ong EL. **J Infect** 1999 Jan;38(1):6–8 (19 ref.)
[In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo] Sato K, et al. **Kekkaku** 1999 Jan;74(1):63–70 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immunological defense mechanisms in tuberculosis and MAC-infection. Hartmann P, et al.
Diagn Microbiol Infect Dis 1999 Jun;34(2):147–52 (45 ref.)

ISOLATION & PURIFICATION

Colonization with Mycobacterium avium complex--an outdated concept [editorial; comment] Rossman MD.
Eur Respir J 1999 Mar;13(3):479 (12 ref.) Comment on: Eur Respir J 1999 Mar;13(3):535–40.

PHYSIOLOGY

Co-infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages. Wahl SM, et al. **J Infect Dis** 1999 May;179 Suppl 3:S457–60 (18 ref.)

MYCOBACTERIUM AVIUM-INTRACELLULARE see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM AVIUM-INTRACELLULARE COMPLEX see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION

Mycobacterium tuberculosis and other mycobacteria. Mault JR, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):227–38, x (26 ref.)

DIAGNOSIS

Colonization with Mycobacterium avium complex--an outdated concept [editorial; comment] Rossman MD.
Eur Respir J 1999 Mar;13(3):479 (12 ref.) Comment on: Eur Respir J 1999 Mar;13(3):535–40.
[Intramedullary tuberculoma: a case report] Vukusic S, et al. **Rev Neurol (Paris)** 1998 Jul;154(6–7):535–8 (10 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Griffith DE. **Drug Saf** 1999 Aug; 21(2):137–52 (60 ref.)

ETIOLOGY

Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Roesler J, et al. **Exp Hematol** 1999 Sep;27(9):1368–74 (23 ref.)

IMMUNOLOGY

Immunological defense mechanisms in tuberculosis and MAC-infection. Hartmann P, et al.
Diagn Microbiol Infect Dis 1999 Jun;34(2):147–52 (45 ref.)

PATHOLOGY

Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'. Logani S, et al. **Am J Surg Pathol** 1999 Jun;23(6):656–61 (11 ref.)

PHYSIOPATHOLOGY

The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS. Horsburgh Jr CR.
J Infect Dis 1999 May;179 Suppl 3:S461–5 (17 ref.)

PREVENTION & CONTROL

Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. Shafran SD. **Int J Infect Dis** 1998 Jul–Sep;3(1):39–47 (71 ref.)
Prophylaxis against disseminated Mycobacterium avium complex in AIDS. Ong EL. **J Infect** 1999 Jan;38(1):6–8 (19 ref.)

MYCOBACTERIUM BOVIS

Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. Seelig MH, et al. **J Vasc Surg** 1999 Feb;29(2):377–81 (19 ref.)

MYCOBACTERIUM BURULI see **MYCOBACTERIUM ULCERANS**

MYCOBACTERIUM CHELONAE

Radiology case of the month. Nail puncture wound to the foot. Mycobacterium chelonei osteomyelitis. Wilson S, et al. **J La State Med Soc** 1999 May;151(5):251–2 (6 ref.)
Rapidly growing mycobacterial lung infection in association with esophageal disorders [see comments] Hadjiliadis D, et al. **Mayo Clin Proc** 1999 Jan;74(1):45–51 (25 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):744–5.

MYCOBACTERIUM CHELONEI see **MYCOBACTERIUM CHELONAE**

MYCOBACTERIUM DUVALII see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM FLAVESCENS see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM FORTUITUM

Rapidly growing mycobacterial lung infection in association with esophageal disorders [see comments] Hadjiliadis D, et al. **Mayo Clin Proc** 1999 Jan;74(1):45–51 (25 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):744–5.
Mycobacterium fortuitum meningitis associated with an epidural catheter: case report and a review of the literature. Madaras-Kelly KJ, et al. **Pharmacotherapy** 1999 May; 19(5):661–6 (26 ref.)
Mycobacterium fortuitum infection of ventriculoperitoneal shunt. Midani S, et al. **South Med J** 1999 Jul;92(7):705–7 (12 ref.)

ISOLATION & PURIFICATION

Central venous catheter-related infections due to nontuberculous Mycobacterium species. Swanson DS.
Pediatr Infect Dis J 1998 Dec;17(12):1163–4 (12 ref.)

MYCOBACTERIUM GILVUM see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM GORDONAE see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM INFECTIONS

Etiological role of mycobacterium in Crohn's disease: An assessment of the literature. Hubbard J, et al. **Dig Dis** 1999; 17(1):6–13 (43 ref.)
On the development of mycobacterial infections. I. A review concerning the common situation. Schütt-Gerowitt H.
Zentralbl Bakteriol 1995 Nov;283(1):5–13 (0 ref.)

CLASSIFICATION

[Classification and concept of mycobacterial infections] Kitamura S, et al. **Nippon Rinsho** 1998 Dec;56(12):3036–40 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Classification of mycobacterial infections] Kitamura S, et al. **Nippon Rinsho** 1998 Dec;56(12):2996–3000 (5 ref.) **(Jpn)**

COMPLICATIONS

Mycobacterial and fungal arthritis. Harrington JT.
Curr Opin Rheumatol 1998 Jul;10(4):335–8 (25 ref.)
Mycobacterium fortuitum meningitis associated with an epidural catheter: case report and a review of the literature. Madaras-Kelly KJ, et al. **Pharmacotherapy** 1999 May; 19(5):661–6 (26 ref.)
[Bacteremia in tuberculosis and other mycobacterial infections] Puzanov VA, et al. **Probl Tuberk** 1999;(1):54–9 (76 ref.) **(Rus)**

DIAGNOSIS

Nontuberculous mycobacteria and human infections. Van Vooren JP. **Monaldi Arch Chest Dis** 1998 Dec;53(6):693–6 (6 ref.)
[Molecular methods for the rapid diagnosis of mycobacterial infections] Devallois A, et al. **Pathol Biol (Paris)** 1998 Oct; 46(8):637–50 (104 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS] Pulido F, et al.
Enferm Infecc Microbiol Clin 1998;16 Suppl 1:20–8 (32 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antimycobacterial activities of riminophenazines. Reddy VM, et al. **J Antimicrob Chemother** 1999 May;43(5):615–23 (73 ref.)
Successful treatment of disseminated Mycobacterium szulgai infection with ciprofloxacin, rifampicin, and ethambutol [letter] Fang CT, et al. **J Infect** 1999 May;38(3):195–7 (10 ref.)
[Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS] Pulido F, et al.
Enferm Infecc Microbiol Clin 1998;16 Suppl 1:20–8 (32 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

HIV-associated mycobacteraemia in West Africa [letter] Bonard D, et al. **Int J Tuberc Lung Dis** 1999 Jun;3(6):546 (4 ref.)

GENETICS

Mendelian susceptibility to mycobacterial infection in man. Altare F, et al. **Curr Opin Immunol** 1998 Aug;10(4):413–7 (21 ref.)
Genetic susceptibility to mycobacteria and other infectious pathogens in humans. Bellamy R, et al.
Curr Opin Immunol 1998 Aug;10(4):483–7 (49 ref.)
Understanding the genetic basis of susceptibility to mycobacterial infection. Levin M, et al.
Proc Assoc Am Physicians 1999 Jul–Aug;111(4):308–12 (31 ref.)

MYCOBACTERIUM INFECTIONS

IMMUNOLOGY

Genetic susceptibility to mycobacteria and other infectious pathogens in humans. Bellamy R, et al. **Curr Opin Immunol** 1998 Aug;10(4):483–7 (49 ref.)

Mycobacterial infection in immunocompromised patients. Washington L, et al. **J Thorac Imaging** 1998 Oct; 13(4):271–81 (66 ref.)

MICROBIOLOGY

Mycobacterium neoaurum--an unusual cause of infection of vascular catheters: case report and review. George SL, et al. **Clin Infect Dis** 1999 Mar;28(3):682–3 (2 ref.)

Mycobacteria as pathogens of respiratory infection. Griffith DE. **Infect Dis Clin North Am** 1998 Sep;12(3):593–611 (68 ref.)

Recently recognized mycobacteria of clinical significance. Pozniak A, et al. **J Infect** 1999 May;38(3):157–61 (70 ref.)

Mycobacteria. Bugs and bugbears. Parish T, et al. **Methods Mol Biol** 1998;101:1–13 (49 ref.)

[Pulmonary infections during AIDS] Deslée G, et al. **Presse Med** 1998 May 23–30;27(19):927–33 (40 ref.) **(Fre)**

PATHOLOGY

Detection of mycobacterial infections using the Dieterle stain. Brady JG, et al. **Pediatr Dev Pathol** 1998 Jul–Aug; 1(4):309–13 (17 ref.)

PREVENTION & CONTROL

Mycobacteria. General culture methodology and safety considerations. Allen BW. **Methods Mol Biol** 1998; 101:15–30 (48 ref.)

RADIOGRAPHY

Mycobacterial infection in immunocompromised patients. Washington L, et al. **J Thorac Imaging** 1998 Oct; 13(4):271–81 (66 ref.)

THERAPY

Nontuberculous mycobacteria and human infections. Van Vooren JP. **Monaldi Arch Chest Dis** 1998 Dec;53(6):693–6 (6 ref.)

MYCOBACTERIUM INFECTIONS, ATYPICAL

Mycobacterium ulcerans--a mini-review [editorial] Johnson PD, et al. **J Med Microbiol** 1999 Jun;48(6):511–3 (21 ref.)

Mycobacterium ulcerans infection. van der Werf TS, et al. **Lancet** 1999 Sep 18;354(9183):1013–8 (31 ref.)

[Non-tuberculous mycobacteriosis] Koga T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):214–20 (9 ref.) **(Jpn)**

[Multi-drug resistant mycobacterial infection] Sakatani M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):195–7 (6 ref.) **(Jpn)**

[Disease from Mycobacterium kansasii] Repáraz J. **Enferm Infecc Microbiol Clin** 1999 Feb;17(2):85–90 (79 ref.) **(Spa)**

COMPLICATIONS

Rapidly growing mycobacterial lung infection in association with esophageal disorders [see comments] Hadjiliadis D, et al. **Mayo Clin Proc** 1999 Jan;74(1):45–51 (25 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):744–5.

DIAGNOSIS

Cutaneous Mycobacterium kansasii infection in a patient with systemic lupus erythematosus: case report and review. Czelusta A, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):359–63 (34 ref.)

Mycobacterium malmoense infection. An unusual cause of wrist swelling. Syed AA, et al. **J Hand Surg [Br]** 1998 Dec;23(6):811–2 (12 ref.)

Radiology case of the month. Nail puncture wound to the foot. Mycobacterium chelonei osteomyelitis. Wilson S, et al. **J La State Med Soc** 1999 May;151(5):251–2 (6 ref.)

[Pulmonary infection in the emphysematous bulla due to Mycobacterium szulgai diagnosed by percutaneus needle aspiration] Inoue Y, et al. **Kansenshogaku Zasshi** 1998 Nov; 72(11):1236–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of infections with difficulty in isolation and identification of the causative organisms. 3) Acid-fast bacterial infections (caused by Mycobacterium tuberculosis or atypical acid-fast organisms)] Watanabe A. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2203–10 (7 ref.) **(Jpn)**

[Clinical features and diagnosis of disease caused by nontuberculous mycobacteria] Tanaka E. **Nippon Rinsho** 1998 Dec;56(12):3195–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Opinions of Japanese Society for Tuberculosis committee on therapy of atypical mycobacterium infections] **Kekkaku** 1998 Oct;73(10):599–605 (29 ref.) **(Jpn)**

[Treatment and prognosis of nontuberculous mycobacterial pulmonary infection] Kurashima A. **Nippon Rinsho** 1998 Dec;56(12):3199–204 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Therapeutic innovations for environmental mycobacteria (editorial)] Caminero Luna JA, et al. **Arch Bronconeumol** 1999 Jan;35(1):5–8 (37 ref.) **(Spa)**

EPIDEMIOLOGY

Emergence of a unique group of necrotizing mycobacterial diseases. Dobos KM, et al. **Emerg Infect Dis** 1999 May–Jun; 5(3):367–78 (64 ref.)

ETIOLOGY

Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Roesler J, et al. **Exp Hematol** 1999 Sep;27(9):1368–74 (23 ref.)

Central venous catheter-related infections due to nontuberculous Mycobacterium species. Swanson DS. **Pediatr Infect Dis J** 1998 Dec;17(12):1163–4 (12 ref.)

Mycobacterium fortuitum infection of ventriculoperitoneal shunt. Midani S, et al. **South Med J** 1999 Jul;92(7):705–7 (12 ref.)

MICROBIOLOGY

Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Wallace RJ Jr, et al. **Annu Rev Microbiol** 1998;52:453–90 (101 ref.)

PATHOLOGY

Atypical mycobacterial lymphadenitis in childhood--a clinicopathological study of 17 cases. Evans MJ, et al. **J Clin Pathol** 1998 Dec;51(12):925–7 (10 ref.)

SURGERY

Surgical treatment of atypical mycobacterial cervicofacial adenitis in children. Fergusson JA, et al. **Aust N Z J Surg** 1999 Jun;69(6):426–9 (24 ref.)

THERAPY

Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Hazra R, et al. **Clin Infect Dis** 1999 Jan;28(1):123–9 (19 ref.)

MYCOBACTERIUM INTRACELLULARE see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM INTRACELLULARE INFECTION see **MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION**

MYCOBACTERIUM KANSASII

Cutaneous Mycobacterium kansasii infection in a patient with systemic lupus erythematosus: case report and review. Czelusta A, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):359–63 (34 ref.)

[Disease from Mycobacterium kansasii] Repáraz J. **Enferm Infecc Microbiol Clin** 1999 Feb;17(2):85–90 (79 ref.) **(Spa)**

MYCOBACTERIUM LEPRAE

see related
LEPROSTATIC AGENTS

GENETICS

Evolutionary bottlenecks in the agents of tuberculosis, leprosy, and paratuberculosis. Frothingham R. **Med Hypotheses** 1999 Feb;52(2):95–9 (40 ref.)

ISOLATION & PURIFICATION

Conjunctival biopsy in patients with leprosy. Campos WB, et al. **Indian J Lepr** 1998 Jul–Sep;70(3):291–4 (14 ref.)

PHYSIOLOGY

How Mycobacterium leprae infects peripheral nerves. Freedman VH, et al. **Lepr Rev** 1999 Jun;70(2):136–9 (13 ref.)

MYCOBACTERIUM OBUENSE see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM PARATUBERCULOSIS

Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. Van Kruiningen HJ. **Inflamm Bowel Dis** 1999 Aug;5(3):183–91 (92 ref.)

GENETICS

Evolutionary bottlenecks in the agents of tuberculosis, leprosy, and paratuberculosis. Frothingham R. **Med Hypotheses** 1999 Feb;52(2):95–9 (40 ref.)

ISOLATION & PURIFICATION

Crohn's disease: the case for bacteria. Prantera C, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):244–6 (39 ref.)

MYCOBACTERIUM SMEGMATIS

DRUG EFFECTS

Mechanisms for isoniazid action and resistance. Miesel L, et al. **Novartis Found Symp** 1998;217:209–20; discussion 220–1 (25 ref.)

MYCOBACTERIUM SZULGAI see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM TERRAE see **MYCOBACTERIA, ATYPICAL**

MYCOBACTERIUM TUBERCULOSIS

see related
ANTITUBERCULAR AGENTS

TB: the return of the phage. A review of fifty years of mycobacteriophage research. McNerney R. **Int J Tuberc Lung Dis** 1999 Mar;3(3):179–84 (67 ref.)

Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. Blower SM, et al. **J Mol Med** 1998 Aug;76(9):624–36 (19 ref.)

CLASSIFICATION

Strain typing of Mycobacterium tuberculosis. Saunders NA. **J Infect** 1999 Mar;38(2):80–6 (49 ref.)

DRUG EFFECTS

Epidemiology of mycobacterial resistance (especially Mycobacterium tuberculosis). Fischer B. **Chemotherapy** 1999 Mar–Apr;45(2):109–20 (45 ref.)

Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century [see comments] Heifets LB, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):564–81 (127 ref.) Comment in: Int J Tuberc Lung Dis 1999 Jul;3(7):549.

[In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo] Sato K, et al. **Kekkaku** 1999 Jan;74(1):63–70 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Approaches to combat tuberculosis. Young DB, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):650–2 (13 ref.)

Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. Cole ST. **FEBS Lett** 1999 Jun 4; 452(1–2):7–10 (37 ref.)

Evolutionary bottlenecks in the agents of tuberculosis, leprosy, and paratuberculosis. Frothingham R. **Med Hypotheses** 1999 Feb;52(2):95–9 (40 ref.)

Analysis of the genome of Mycobacterium tuberculosis H37Rv. Cole ST, et al. **Novartis Found Symp** 1998; 217:160–72; discussion 172–7 (27 ref.)

The impact of genomics on the search for novel tuberculosis drugs. Duncan K. **Novartis Found Symp** 1998;217:228–37; discussion 237–8 (30 ref.)

Bacterial genetics and strain variation. van Helden PD. **Novartis Found Symp** 1998;217:178–90; discussion 190–4 (30 ref.)

The role of rapid diagnostic tests for tuberculosis in Singapore. Lim TK. **Singapore Med J** 1999 Apr; 40(4):298–302 (33 ref.)

Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Telenti A. **Thorax** 1998 Sep; 53(9):793–7 (66 ref.)

[Molecular basis of rifampin resistance in mycobacterium tuberculosis] Cheng S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Jun; 20(3):183–6 (16 ref.) **(Chi)**

[Multidrug-resistant tuberculosis. 2. Mechanisms of drug-resistance in Mycobacterium tuberculosis--genetic mechanisms of drug-resistance] Ohno H, et al. **Kekkaku** 1998 Nov;73(11):657–63 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Biological significance of the complete sequencing of Mycobacterium tuberculosis] Yamada T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):65–70 (9 ref.) **(Jpn)**

[Contribution of molecular techniques to the study of tuberculosis transmission] Chaves Sánchez F. **Rev Clin Esp** 1998 Aug;198(8):529–36 (95 ref.) **(Spa)**

IMMUNOLOGY

Cell-mediated immunity: dealing a direct blow to pathogens. Kaufmann SH. **Curr Biol** 1999 Feb 11;9(3):R97–9 (10 ref.)

T cell mediated immunity to Mycobacterium tuberculosis. Stenger S, et al. **Curr Opin Microbiol** 1999 Feb;2(1):89–93 (57 ref.)

DNA vaccines: application to tuberculosis. Huygen K. **Int J Tuberc Lung Dis** 1998 Dec;2(12):971–8 (67 ref.)

[Immune protection against Mycobacterium tuberculosis. Role of interferon-gamma and T gamma-delta lymphocytes] Aspa Marco FJ, et al. **Arch Bronconeumol** 1998 Dec;34(11):547–53 (85 ref.) **(Spa)**

ISOLATION & PURIFICATION

Scrofuloderma of the lower extremity treated with wide resection: a case report and review of the literature. Connolly B, et al. **Am J Orthop** 1999 Jul;28(7):417–20 (24 ref.)

Tuberculosis in the 1990's: From bedside to bench and back. Jamieson FB, et al. **Can Respir J** 1999 Jul–Aug;6(4):341–4 (15 ref.)

Tuberculosis: 7. Laboratory aspects of diagnosis. Laszlo A. **CMAJ** 1999 Jun 15;160(12):1725–9 (13 ref.)

Molecular techniques for the diagnosis of respiratory bacterial infection. Gillespie S. **Curr Opin Pulm Med** 1999 May;5(3):174–8 (35 ref.)

Two cases of chronic arthritis of the forearm due to Mycobacterium tuberculosis. Hunfeld KP, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):344–8 (339 ref.)

Three cases of tuberculosis after heart transplantation in Spain. Muñoz RM, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):801–6 (15 ref.)

New tools for the diagnosis of tuberculosis: the perspective of developing countries [see comments] Foulds J, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):778–83 (32 ref.) Comment in: Int J Tuberc Lung Dis 1998 Oct;2(10):777.

Calvarial tuberculosis. Unüvar E, et al. **J Paediatr Child Health** 1999 Apr;35(2):221–2 (8 ref.)

Tuberculous pancreatic abscess in an HIV antibody-negative patient: case report and review. Jenney AW, et al. **Scand J Infect Dis** 1998;30(2):99–104 (42 ref.)

METABOLISM

Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key? Ehlers MR, et al. **Trends Microbiol** 1998 Aug;6(8):328–35 (54 ref.)

PATHOGENICITY

The role of macrophage cell death in tuberculosis. Kornfeld H, et al. **Cell Death Differ** 1999 Jan;6(1):71–8 (69 ref.)

The tuberculosis pandemic—which way now? Zumla A, et al. **J Infect** 1999 Mar;38(2):74–9 (41 ref.)

PHYSIOLOGY

Mycobacterium tuberculosis phagosome. Deretic V, et al. **Mol Microbiol** 1999 Mar;31(6):1603–9 (48 ref.)

MYCOBACTERIUM ULCERANS

Mycobacterium ulcerans infection. van der Werf TS, et al. **Lancet** 1999 Sep 18;354(9183):1013–8 (31 ref.)

PATHOGENICITY

Mycobacterium ulcerans--a mini-review [editorial] Johnson PD, et al. **J Med Microbiol** 1999 Jun;48(6):511–3 (21 ref.)

MYCOLIC ACIDS

CHEMISTRY

Mycolic acids: structure, biosynthesis and physiological functions. Barry CE 3rd, et al. **Prog Lipid Res** 1998 Jul–Aug;37(2–3):143–79 (288 ref.)

MYCOLOGICAL TYPING TECHNIQUES

Typing methods to approach Pneumocystis carinii genetic heterogeneity. Hauser PM, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):27–35 (46 ref.)

Molecular diagnosis and epidemiology of fungal infections. Reiss E, et al. **Med Mycol** 1998;36 Suppl 1:249–57 (46 ref.)

MYCOLOGY

[Past and present of mycology in German gynecology and obstetrics] Mendling W. **Mycoses** 1998;41 Suppl 2:26–30 (23 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

Teaching medical mycology in the year 2000. Negroni R, et al. **Med Mycol** 1998;36 Suppl 1:106–8 (4 ref.)

MYCOPHENOLIC ACID

ANALOGS & DERIVATIVES

Therapy of pemphigus vulgaris [editorial; comment] [see comments] Stanley JR. **Arch Dermatol** 1999 Jan;135(1):76–8 (33 ref.) Comment on: Arch Dermatol 1999 Jan;135(1):54–6. Comment in: Arch Dermatol 1999 Jul;135(7):853–4.

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Nicholls AJ. **Clin Biochem** 1998 Jul;31(5):329–33 (10 ref.)

The use of mycophenolate mofetil (Cellcept) in renal transplantation. Vanrenterghem Y. **Contrib Nephrol** 1998; 124:64–9; discussion 69–75 (31 ref.)

Mizoribine and mycophenolate mofetil. Ishikawa H. **Curr Med Chem** 1999 Jul;6(7):575–97 (82 ref.)

Mycophenolate mofetil as induction therapy after liver transplantation. McDiarmid SV. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S85–9 (19 ref.)

Mycophenolate-update after it has come of age [editorial] Grinyó JM. **Nephrol Dial Transplant** 1999 Jan;14(1):31–4 (14 ref.)

Mycophenolate mofetil--is it worth the cost? The in-favor opinion [see comments] Seikaly MG. **Pediatr Transplant** 1999 Feb;3(1):79–82 (19 ref.) Comment in: Pediatr Transplant 1999 Feb;3(1):5–9.

The current status of mycophenolate mofetil in pediatric renal transplantation [editorial; comment] Tönshoff B. **Pediatr Transplant** 1999 Feb;3(1):5–9 (29 ref.) Comment on: Pediatr Transplant 1999 Feb;3(1):33–7. Comment on: Pediatr Transplant 1999 Feb;3(1):79–82.

[Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants] van Gelder T, et al. **Ned Tijdschr Geneeskd** 1998 Jul 4;142(27):1550–4 (19 ref.) (Eng. Abstr.) **(Dut)**

[Use of mycophenolate mofetil (MMF) in kidney transplantation: results of a single center trial] Pastural M, et al. **Prog Urol** 1999 Feb;9(1):19–25 (13 ref.) (Eng. Abstr.) **(Fre)**

[Mycophenolate mofetil in comparison with other immunosuppressive drugs] Schnülle P, et al. **Internist (Berl)** 1998 Aug;39(8):879–86 (49 ref.) **(Ger)**

[Mycophenolatemofetil in ocular immunological disorders. A survey of the literature with 3 case reports] Reis A, et al. **Klin Monatsbl Augenheilkd** 1998 Nov;213(5):257–61 (28 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Shaw LM, et al. **Clin Biochem** 1998 Jul;31(5):323–8 (22 ref.)

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Shaw LM, et al. **Clin Biochem** 1998 Jul; 31(5):317–22 (42 ref.)

THERAPEUTIC USE

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Shaw LM, et al. **Clin Biochem** 1998 Jul; 31(5):317–22 (42 ref.)

MYCOPLASMA

Mycoplasma: a new potential vector for gene therapy? Berger F, et al. **Med Hypotheses** 1999 Jun;52(6):605–7 (14 ref.)

CHEMISTRY

Immunological and biochemical characterization of membrane proteins. Duffy MF, et al. **Methods Mol Biol** 1998;104:279–98 (34 ref.)

Polyacrylamide gel-electrophoresis separation of whole-cell proteins. Duffy MF, et al. **Methods Mol Biol** 1998; 104:267–77 (5 ref.)

Detection and analysis of mycoplasma adhesins. Sachse K. **Methods Mol Biol** 1998;104:299–307 (5 ref.)

CLASSIFICATION

Diagnostic application of monoclonal antibody (MAb)-based sandwich ELISAs. Ball HJ, et al. **Methods Mol Biol** 1998; 104:127–32 (5 ref.)

Identification of mycoplasmas by immunofluorescence. Bradbury JM. **Methods Mol Biol** 1998;104:119–25 (21 ref.)

Identification of mycoplasmas by dot immunobinding on membrane filtration (MF dot). Poumarat F. **Methods Mol Biol** 1998;104:113–8 (19 ref.)

Serological identification of mycoplasmas by growth and metabolic inhibition tests. Poveda JB, et al. **Methods Mol Biol** 1998;104:105–11 (5 ref.)

Biochemical characteristics in mycoplasma identification. Poveda JB. **Methods Mol Biol** 1998;104:69–78 (6 ref.)

Classification of isolates by DNA-DNA hybridization. Sachse K, et al. **Methods Mol Biol** 1998;104:189–95 (2 ref.)

Immunohistochemical staining of fixed tissues. Scanziani E. **Methods Mol Biol** 1998;104:133–40 (15 ref.)

GENETICS

Extraction of DNA from mycoplasmas. Bashiruddin JB. **Methods Mol Biol** 1998;104:141–4 (5 ref.)

Insertion sequence analysis. Frey J. **Methods Mol Biol** 1998; 104:197–205 (13 ref.)

Characterization of mycoplasmas by PCR and sequence analysis with universal 16S rDNA primers. Johansson KE, et al. **Methods Mol Biol** 1998;104:145–65 (41 ref.)

Transformation of mycoplasmas. Minion FC, et al. **Methods Mol Biol** 1998;104:227–34 (19 ref.)

Mycoplasma gene expression in Escherichia coli. Minion FC. **Methods Mol Biol** 1998;104:259–65 (9 ref.)

Characterization of mycoplasmas by RAPD fingerprinting. Rawadi GA. **Methods Mol Biol** 1998;104:179–87 (12 ref.)

Transposon mutagenesis. Voelker LL, et al. **Methods Mol Biol** 1998;104:235–8 (9 ref.)

Demonstration of extrachromosomal elements. Voelker LL, et al. **Methods Mol Biol** 1998;104:239–46 (8 ref.)

Molecular biology and pathogenicity of mycoplasmas. Razin S, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1094–156 (501 ref.)

ISOLATION & PURIFICATION

Primer mixture enhances PCR detection of Mycoplasma/Acholeplasma contaminants in cell cultures [letter] Tang J, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan;35(1):1–3 (16 ref.)

Recovery of mycoplasmas from birds. Bradbury JM. **Methods Mol Biol** 1998;104:45–51 (11 ref.)

Detection of mycoplasmas in cell cultures by fluorescence methods. Masover GK, et al. **Methods Mol Biol** 1998; 104:217–26 (13 ref.)

Detection of mycoplasmas in cell cultures by cultural methods. Masover GK, et al. **Methods Mol Biol** 1998; 104:207–15 (16 ref.)

Recovery of mycoplasmas from animals. Nicholas R, et al. **Methods Mol Biol** 1998;104:37–43 (7 ref.)

Recovery of human mycoplasmas. Taylor P. **Methods Mol Biol** 1998;104:25–35 (12 ref.)

METABOLISM

Determination of substrate utilization rates by mycoplasmas. Miles RJ, et al. **Methods Mol Biol** 1998;104:95–103 (11 ref.)

PATHOGENICITY

Molecular biology and pathogenicity of mycoplasmas. Razin S, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1094–156 (501 ref.)

Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases. Cole BC. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):45S–49S (26 ref.)

What is the role of mycoplasmas in human inflammatory rheumatic disorders? Schaeverbeke T, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):23S–27S (42 ref.)

[100 years of Mycoplasma--pathogenicity for domestic and farm animals] Kirchhoff H, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):387–92 (67 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Subversion and exploitation of host cells by mycoplasmas. Rottem S, et al. **Trends Microbiol** 1998 Nov;6(11):436–40 (47 ref.)

MYCOPLASMA INFECTIONS

Medical significance of mycoplasmas. Taylor P. **Methods Mol Biol** 1998;104:7–15 (37 ref.)

[Mycoplasmal urethritis] Matsukawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):27–9 (15 ref.) **(Jpn)**

[Endocarditis and myocarditis caused by Mycoplasma] Morimoto S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):244–8 (28 ref.) **(Jpn)**

COMPLICATIONS

Mycoplasma pneumoniae-associated bronchiolitis causing severe restrictive lung disease in adults: report of three cases and literature review. Chan ED, et al. **Chest** 1999 Apr;115(4):1188–94 (56 ref.)

Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases. Cole BC. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):45S–49S (26 ref.)

DIAGNOSIS

Diagnostic application of monoclonal antibody (MAb)-based sandwich ELISAs. Ball HJ, et al. **Methods Mol Biol** 1998; 104:127–32 (5 ref.)

[Cervicitis] Matsuda S. **Ryoikibetsu Shokogun Shirizu** 1999; (25 Pt 3):30–2 (8 ref.) **(Jpn)**

DRUG THERAPY

[Rokitamycin in the treatment of female genital Chlamydia and Mycoplasma infections. Comparative study vs josamycin] Colombo U, et al. **Minerva Ginecol** 1998 Nov; 50(11):491–7 (26 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Mycoplasma infections of aneurysms or vascular grafts. Fenollar F, et al. **Clin Infect Dis** 1999 Mar;28(3):694–5 (10 ref.)

Identification of mycoplasmas by immunofluorescence. Bradbury JM. **Methods Mol Biol** 1998;104:119–25 (21 ref.)

Characterization of mycoplasmas by RAPD fingerprinting. Rawadi GA. **Methods Mol Biol** 1998;104:179–87 (12 ref.)

Immunohistochemical staining of fixed tissues. Scanziani E. **Methods Mol Biol** 1998;104:133–40 (15 ref.)

Recovery of human mycoplasmas. Taylor P. **Methods Mol Biol** 1998;104:25–35 (12 ref.)

What is the role of mycoplasmas in human inflammatory rheumatic disorders? Schaeverbeke T, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):23S–27S (42 ref.)

MYCOPLASMA INFECTIONS

VETERINARY

Recovery of mycoplasmas from birds. Bradbury JM. **Methods Mol Biol** 1998;104:45–51 (11 ref.)

Recovery of mycoplasmas from animals. Nicholas R, et al. **Methods Mol Biol** 1998;104:37–43 (7 ref.)

The veterinary significance of mycoplasmas. Nicholas R. **Methods Mol Biol** 1998;104:17–23 (16 ref.)

Mycoplasmas in the etiology of multifactorial respiratory disease. Kleven SH. **Poult Sci** 1998 Aug;77(8):1146–9 (61 ref.)

[100 years of Mycoplasma––pathogenicity for domestic and farm animals] Kirchhoff H, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):387–92 (67 ref.) (Eng. Abstr.) **(Ger)**

MYCOPLASMA LAIDLAWII see **ACHOLEPLASMA LAIDLAWII**

MYCOPLASMA MYCOIDES

CLASSIFICATION

PCR and RFLP methods for the specific detection and identification of Mycoplasma mycoides subsp. mycoides SC. Bashiruddin JB. **Methods Mol Biol** 1998;104:167–78 (16 ref.)

GROWTH & DEVELOPMENT

The one-hundredth anniversary of the first culture of a mollicute, the contagious bovine peripneumonia microbe, by Nocard and Roux, with the collaboration of Borrel, Salimbeni, and Dujardin-Baumetz. Bové JM. **Res Microbiol** 1999 May;150(4):239–45 (31 ref.)

ISOLATION & PURIFICATION

PCR and RFLP methods for the specific detection and identification of Mycoplasma mycoides subsp. mycoides SC. Bashiruddin JB. **Methods Mol Biol** 1998;104:167–78 (16 ref.)

MYCOPLASMA PNEUMONIA see **PNEUMONIA, MYCOPLASMA**

MYCOPLASMA PNEUMONIAE

Mycoplasma pneumoniae-associated bronchiolitis causing severe restrictive lung disease in adults: report of three cases and literature review. Chan ED, et al. **Chest** 1999 Apr;115(4):1188–94 (56 ref.)

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. File TM Jr, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):569–92, vii (127 ref.)

ISOLATION & PURIFICATION

[Mycoplasma pneumoniae pneumopathy. 10 cases] Lesobre V, et al. **Presse Med** 1999 Jan 16;28(2):59–66 (56 ref.) (Eng. Abstr.) **(Fre)**

MYCOSES

see related

ANTIFUNGAL AGENTS

Fungal infections after bone marrow transplant. Wingard JR. **Biol Blood Marrow Transplant** 1999;5(2):55–68 (171 ref.)

Diagnosis and prevention of fungal infection in the immunocompromized patient. Richardson MD, et al. **Blood Rev** 1998 Dec;12(4):241–54 (114 ref.)

Fungal infections of the hand. Amadio PC. **Hand Clin** 1998 Nov;14(4):605–12 (57 ref.)

Fungal infection in acute necrotizing pancreatitis. Grewe M, et al. **J Am Coll Surg** 1999 Apr;188(4):408–14 (33 ref.)

Selected animal models: vaginal candidosis, Pneumocystis pneumonia, dermatophytosis and trichosporosis. Sobel JD, et al. **Med Mycol** 1998;36 Suppl 1:129–36 (43 ref.)

Pleural space infections: microbiology and antimicrobial therapy. Everts RJ, et al. **Semin Respir Infect** 1999 Mar; 14(1):18–30 (67 ref.)

[Past and present of mycology in German gynecology and obstetrics] Mendling W. **Mycoses** 1998;41 Suppl 2:26–30 (23 ref.) (Eng. Abstr.) **(Ger)**

[Bacterial and fungal colonization in indwelling total laryngectomy phonatory prostheses: identification of microbial agents, treatment protocol and prevention] Nazionale G, et al. **Acta Otorhinolaryngol Ital** 1998 Apr; 18(2):107–10 (21 ref.) (Eng. Abstr.) **(Ita)**

[Disseminated trichosporonosis] Tokimatsu I, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):390–2 (14 ref.) **(Jpn)**

[Multidrug resistant mycosis] Yasuoka A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):202–4 (3 ref.) **(Jpn)**

COMPLICATIONS

Mycobacterial and fungal arthritis. Harrington JT. **Curr Opin Rheumatol** 1998 Jul;10(4):335–8 (25 ref.)

Fusarium infections in patients with severe aplastic anemia: review and implications for management. Girmenia C, et al. **Haematologica** 1999 Feb;84(2):114–8 (17 ref.)

Invasive yeast infections other than Candida spp. in acute leukaemia. Krcmery V, et al. **J Hosp Infect** 1999 Mar; 41(3):181–94 (101 ref.)

DIAGNOSIS

Changing epidemiology of systemic fungal infections and the possibilities of laboratory diagnostics. Nagy E. **Acta Microbiol Immunol Hung** 1999;46(2–3):227–31 (17 ref.)

Diagnosis of invasive fungal infections: advances in nonculture systems. Walsh TJ, et al. **Curr Clin Top Infect Dis** 1998;18:101–53 (277 ref.)

Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Müller FM, et al. **Eur J Pediatr** 1999 Mar; 158(3):187–99 (111 ref.)

Endoscopic diagnosis of intestinal penicilliosis marneffei: report of three cases and review of the literature. Ko CI, et al. **Gastrointest Endosc** 1999 Jul;50(1):111–4 (19 ref.)

Serodiagnosis of histoplasmosis, paracoccidioidomycosis and penicilliosis marneffei; current status and future trends. Hamilton AJ. **Med Mycol** 1998 Dec;36(6):351–64 (148 ref.)

Molecular diagnosis and epidemiology of fungal infections. Reiss E, et al. **Med Mycol** 1998;36 Suppl 1:249–57 (46 ref.)

Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Verweij PE, et al. **Med Mycol** 1998;36 Suppl 1:146–55 (61 ref.)

Evaluation of new method for diagnosis of opportunistic fungal infection. Hashimoto A, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):187–92 (17 ref.)

HIV infection and AIDS. Lloyd A. **P N G Med J** 1996 Sep; 39(3):174–80 (2 ref.)

Molecular methods for epidemiological and diagnostic studies of fungal infections. Gottfredsson M, et al. **Pathology** 1998 Nov;30(4):405–18 (185 ref.)

[Fungi in the intestine. Clinical significance] Kreisel W. **Schweiz Rundsch Med Prax** 1999 Jan 7;88(1–2):5–10 (26 ref.) **(Ger)**

[AIDS and opportunistic visceral mycoses. A diagnostic and therapeutic update] Manfredi R. **Recenti Prog Med** 1998 Dec;89(12):657–67 (100 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis of infections with difficulty in isolation and identification of causative organisms. 4) Deep mycosis] Maezaki S, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2211–7 (5 ref.) **(Jpn)**

[Blood culture: gold standard for definitive diagnosis of bacterial and fungal infections––from the laboratory aspect] Yamane N. **Rinsho Byori** 1998 Sep;46(9):887–92 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A method for the diagnosis and phytotherapy of the mycosis caused by the fungus Alternaria alternata (Fr.) Keissler] Trikoz GA. **Lik Sprava** 1999 Mar;(2):128–30 (12 ref.) **(Rus)**

[Infectious esophagitis] Arenas Miravé JI, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):302–8 (65 ref.) **(Spa)**

DRUG THERAPY

Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Noskin G, et al. **Bone Marrow Transplant** 1999 Apr; 23(7):697–703 (28 ref.)

Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Böhme A, et al. **Chemotherapy** 1999 Sep–Oct;45(5):315–24 (62 ref.)

The challenge of invasive fungal infection. de Pauw BE, et al. **Chemotherapy** 1999 Jun;45 Suppl 1:1–14 (66 ref.)

Lipid formulations of amphotericin B. Jones E, et al. **Cleve Clin J Med** 1998 Sep;65(8):423–7 (8 ref.)

Antifungal therapy during pregnancy. King CT, et al. **Clin Infect Dis** 1998 Nov;27(5):1151–60 (106 ref.)

Current and emerging azole antifungal agents. Sheehan DJ, et al. **Clin Microbiol Rev** 1999 Jan;12(1):40–79 (274 ref.)

Current and future therapy of invasive fungal infections. Andriole VT. **Curr Clin Top Infect Dis** 1998;18:19–36 (63 ref.)

Treatment of fungal infections in neutropenic children [see comments] Lehrnbecher T, et al. **Curr Opin Pediatr** 1999 Feb;11(1):47–55 (112 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):31–2.

Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Brogden RN, et al. **Drugs** 1998 Sep; 56(3):365–83 (76 ref.)

High-dose fluconazole therapy in patients with severe fungal infections. Voss A, et al. **Eur J Clin Microbiol Infect Dis** 1999 Mar;18(3):165–74 (72 ref.)

Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review. Viscoli C, et al. **Int J Infect Dis** 1998–99 Winter;3(2):109–18 (73 ref.)

Endemic mycoses: a treatment update. Lortholary O, et al. **J Antimicrob Chemother** 1999 Mar;43(3):321–31 (88 ref.)

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. Root RK, et al. **J Infect Dis** 1999 Mar;179 Suppl 2:S342–52 (126 ref.)

Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Groll AH, et al. **Klin Padiatr** 1998 Jul–Aug; 210(4):264–73 (86 ref.)

New approaches to antifungal chemotherapy. Viviani MA, et al. **Med Mycol** 1998;36 Suppl 1:194–206 (176 ref.)

Management of intractable deep seated fungal infection. Niki Y. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):199–202 (14 ref.)

Uses of rifampin for infections other than tuberculosis. Loeffler AM. **Pediatr Infect Dis J** 1999 Jul;18(7):631–2 (14 ref.)

Lipid-based amphotericin B for the treatment of fungal infections. Slain D. **Pharmacotherapy** 1999 Mar; 19(3):306–23 (132 ref.)

Oral itraconazole therapy for superficial, subcutaneous, and systemic infections. A panoramic view. De Rosso JQ, et al. **Postgrad Med** 1999 Jul;Spec No:46–52 (63 ref.)

[New aspects in treatment of systemic mycoses] Presterl E, et al. **Wien Klin Wochenschr** 1998 Nov 13;110(21):740–50 (106 ref.) (Eng. Abstr.) **(Ger)**

[Mycoses and their treatment in malignant hemopathies] Martino P, et al. **Recenti Prog Med** 1999 Mar;90(3):160–8 (59 ref.) (Eng. Abstr.) **(Ita)**

[Advances in the treatment of severe refractory infections. 4) Deep fungal infection] Watanabe K. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2257–62 (9 ref.) **(Jpn)**

EPIDEMIOLOGY

Changing epidemiology of systemic fungal infections and the possibilities of laboratory diagnostics. Nagy E. **Acta Microbiol Immunol Hung** 1999;46(2–3):227–31 (17 ref.)

Imported mycoses in Europe. Warnock DW, et al. **Med Mycol** 1998;36 Suppl 1:87–94 (46 ref.)

Molecular methods for epidemiological and diagnostic studies of fungal infections. Gottfredsson M, et al. **Pathology** 1998 Nov;30(4):405–18 (185 ref.)

ETIOLOGY

Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Böhme A, et al. **Chemotherapy** 1999 Sep–Oct;45(5):315–24 (62 ref.)

Impact of nosocomial infections on outcome: myths and evidence [editorial; comment] Rello J. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):392–4 (15 ref.) Comment on: Infect Control Hosp Epidemiol 1999 Jun;20(6):396–401.

Hickman catheter-related infections in patients with cancer. Yip C, et al. **Int J Antimicrob Agents** 1998 Aug;10(3):181–9 (69 ref.)

Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. Richter S, et al. **J Clin Microbiol** 1999 Apr;37(4):1154–60 (37 ref.)

Indiscriminate use of corticosteroid-containing eyedrops. Baratz KH, et al. **Mayo Clin Proc** 1999 Apr;74(4):362–6 (35 ref.)

Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen––Chaetomium atrobrunneum: case report. Guppy KH, et al. **Neurosurgery** 1998 Dec;43(6):1463–9 (42 ref.)

Severe mycosis-factors with fungus and host. Maesaki S, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):193–7 (11 ref.)

Deep-seated fungal infection in surgery. Tsunoda T, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):203–9 (31 ref.)

Fungal peritonitis––current status 1998. Lo WK, et al. **Perit Dial Int** 1999;19 Suppl 2:S286–90 (32 ref.)

The lung in the immunocompromised patient. Infectious complications part 2. Tamm M. **Respiration** 1999; 66(3):199–207 (77 ref.)

[Infections in granulocytopenic patients] Funada H. **Rinsho Ketsueki** 1999 Mar;40(3):164–7 (9 ref.) **(Jpn)**

IMMUNOLOGY

Cytokines are critical in linking the innate and adaptive immune responses to bacterial, fungal, and parasitic infection. Seder RA, et al. **Adv Intern Med** 1999;44:353–88 (163 ref.)

Stress proteins in fungal diseases. Matthews RC, et al. **Med Mycol** 1998;36 Suppl 1:45–51 (42 ref.)

Type 1 and type 2 cytokines: from basic science to fungal infections. Murphy JW, et al. **Med Mycol** 1998;36 Suppl 1:109–18 (45 ref.)

Cytokines and mycoses [published erratum appears in Med Mycol 1998 Dec;36(6):443] Stevens DA, et al. **Med Mycol** 1998;36 Suppl 1:174–82 (81 ref.)

Killer antibodies in fungal infections. Conti S, et al. **Res Immunol** 1998 May–Jun;149(4–5):334–43; discussion 523 (75 ref.)

Complement activation by pathogenic fungi. Kozel TR. **Res Immunol** 1998 May–Jun;149(4–5):309–20; discussion 514–5 (70 ref.)

METABOLISM

The role of iron in protozoan and fungal infectious diseases. Weinberg ED. **J Eukaryot Microbiol** 1999 May–Jun; 46(3):231–8 (100 ref.)

MICROBIOLOGY

Scopulariopsis: an invasive nasal infection. Jabor MA, et al. **Am J Rhinol** 1998 Sep-Oct;12(5):367-71 (8 ref.)
Fungal sinusitis. Washburn RG. **Curr Clin Top Infect Dis** 1998;18:60-74 (102 ref.)
Reporters for the analysis of gene regulation in fungi pathogenic to man. Soll DR, et al. **Curr Opin Microbiol** 1998 Aug;1(4):400-5 (40 ref.)
Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. Richter S, et al. **J Clin Microbiol** 1999 Apr;37(4):1154-60 (37 ref.)
Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease. Roilides E, et al. **J Clin Microbiol** 1999 Jan; 37(1):18-25 (38 ref.)
Molecular phylogeny and taxonomy of medically important fungi. De Hoog GS, et al. **Med Mycol** 1998;36 Suppl 1:52-6 (31 ref.)
Standardization of antifungal susceptibility testing and clinical relevance [published erratum appears in Med Mycol 1999 Apr;37(2):147] Espinel-Ingroff A, et al. **Med Mycol** 1998;36 Suppl 1:68-78 (80 ref.)
Fate of transforming DNA in pathogenic fungi. Kwon-Chung KJ, et al. **Med Mycol** 1998;36 Suppl 1:38-44 (43 ref.)
Antifungal drug resistance in pathogenic fungi. Vanden Bossche H, et al. **Med Mycol** 1998;36 Suppl 1:119-28 (109 ref.)
Penicilliosis marneffei and pythiosis: emerging tropical diseases. Kaufman L. **Mycopathologia** 1998;143(1):3-7 (28 ref.)
Virulence factors in fungi of systemic mycoses. Kurokawa CS, et al. **Rev Inst Med Trop Sao Paulo** 1998 May-Jun; 40(3):125-35 (130 ref.)

PHYSIOPATHOLOGY

Host-fungal interactions in HIV infection. Levitz SM. **Res Immunol** 1998 May-Jun;149(4-5):489-93; discussion 516-7 (50 ref.)

PREVENTION & CONTROL

Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit? Böhme A, et al. **Chemotherapy** 1999 May-Jun;45(3):224-32 (58 ref.)
Development of vaccines and their use in the prevention of fungal infections. Dixon DM, et al. **Med Mycol** 1998;36 Suppl 1:57-67 (90 ref.)
Biosafety considerations in handling medically important fungi. Padhye AA, et al. **Med Mycol** 1998;36 Suppl 1:258-65 (28 ref.)
[Fungal and parasitic nosocomial infections: importance and limitations of disinfection methods] Lebeau B, et al. **Pathol Biol (Paris)** 1998 May;46(5):335-40 (38 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

The utility of CT in imaging chest infections in HIV-negative patients. Richenberg J, et al. **Curr Opin Pulm Med** 1999 May;5(3):179-84 (33 ref.)

THERAPY

What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis? Ferguson BJ. **Arch Otolaryngol Head Neck Surg** 1998 Oct;124(10):1174-8 (19 ref.)
Recent advances in the management of fungal infections. Sanchez J, et al. **Cancer Treat Res** 1998;96:167-82 (79 ref.)
Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Müller FM, et al. **Eur J Pediatr** 1999 Mar; 158(3):187-99 (111 ref.)
Atypical hand infections. Hoyen HA, et al. **Hand Clin** 1998 Nov;14(4):613-34, ix (101 ref.)
The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Roilides E, et al. **Med Mycol** 1998;36 Suppl 1:12-25 (191 ref.)
Cytokines as therapy for opportunistic fungal infections. Kullberg BJ, et al. **Res Immunol** 1998 May-Jun; 149(4-5):478-88; discussion 515 (150 ref.)

TRANSMISSION

[Sexually transmitted parasitoses and mycoses] Vahlensieck W. **Fortschr Med** 1999 May 10;117(13):32-5 (42 ref.) **(Ger)**

VETERINARY

Mycoses of fish. Tampieri MP. **Med Mycol** 1998;36 Suppl 1:216-9 (23 ref.)
Infectious diseases and parasites of ratites. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):455-83, iv (41 ref.)

MYCOSIS FUNGOIDES

Mycosis fungoides and the Sézary syndrome. Kim YH, et al. **Semin Oncol** 1999 Jun;26(3):276-89 (86 ref.)
[Mycosis fungoides] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):272-5 (10 ref.) **(Jpn)**

COMPLICATIONS

Cutaneous T-cell lymphoma and human immunodeficiency virus infection: 2 cases and a review of the literature. Muñoz-Pérez MA, et al. **Acta Derm Venereol** 1999 Mar; 79(2):153-5 (19 ref.)

DIAGNOSIS

Cutaneous T-cell lymphoma and human immunodeficiency virus infection: 2 cases and a review of the literature. Muñoz-Pérez MA, et al. **Acta Derm Venereol** 1999 Mar; 79(2):153-5 (19 ref.)

PATHOLOGY

Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Quaglino P, et al. **Dermatology** 1999;199(1):8-14 (41 ref.)
Granulomatous mycosis fungoides. Telle H, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):506-10 (29 ref.)
Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. Cather JC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):858-63 (54 ref.)

MYCOSIS, OCULAR see **EYE INFECTIONS, FUNGAL**

MYCOTIC ANEURYSM see **ANEURYSM, INFECTED**

MYCOTIC INFECTIONS, OCULAR see **EYE INFECTIONS, FUNGAL**

MYCOTOXINS

Recent progress in mycotoxin research. Varga J, et al. **Acta Microbiol Immunol Hung** 1999;46(2-3):233-43 (65 ref.)

ADVERSE EFFECTS

Mycotoxicosis in food producing animals. Hollinger K, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):133-65, x (74 ref.)
The role of ochratoxin A as a possible cause of Balkan endemic nephropathy and its risk evaluation. Stoev SD. **Vet Hum Toxicol** 1998 Dec;40(6):352-60 (90 ref.)

ANALYSIS

Mycotoxins in foods--occurrence, health & economic significance & food control measures. Vasanthi S, et al. **Indian J Med Res** 1998 Nov;108:212-24 (57 ref.)

BIOSYNTHESIS

Molecular biology of mycotoxin biosynthesis. Sweeney MJ, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):149-63 (50 ref.)
Mycotoxin production by Aspergillus, Fusarium and Penicillium species. Sweeney MJ, et al. **Int J Food Microbiol** 1998 Sep 8;43(3):141-58 (147 ref.)

CHEMISTRY

Effect of processing on Fusarium mycotoxins. Jackson LS, et al. **Adv Exp Med Biol** 1999;459:243-61 (99 ref.)

GENETICS

Molecular biology of mycotoxin biosynthesis. Sweeney MJ, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):149-63 (50 ref.)

IMMUNOLOGY

Killer antibodies in fungal infections. Conti S, et al. **Res Immunol** 1998 May-Jun;149(4-5):334-43; discussion 523 (75 ref.)

ISOLATION & PURIFICATION

Sample preparation and high-resolution separation of mycotoxins possessing carboxyl groups. Wilkes JG, et al. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9; 717(1-2):135-56 (107 ref.)

PHARMACOLOGY

Fumonisins and human health. Nair MG. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S47-52 (41 ref.)
Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. Séguy N, et al. **FEMS Immunol Med Microbiol** 1998 Sep; 22(1-2):145-9 (27 ref.)
Pharmacological activities of fusaric acid (5-butylpicolinic acid). Wang H, et al. **Life Sci** 1999;65(9):849-56 (46 ref.)

POISONING

[Fumonisins--mycotoxins produced by Fusarium moniliforme] Ribar S, et al. **Lijec Vjesn** 1998 Mar-Apr; 120(3-4):85-91 (110 ref.) (Eng. Abstr.) **(Ser)**

THERAPEUTIC USE

A transphyletic anti-infectious control strategy based on the killer phenomenon. Conti S, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):151-61 (61 ref.)

TOXICITY

Mycotoxins and health hazards: toxicological aspects and mechanism of action of fumonisins. Norred WP, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:160-4 (30 ref.)
Tubulotoxic mechanisms of ochratoxin A. Gekle M, et al. **Kidney Blood Press Res** 1998;21(2-4):277-9 (33 ref.)
DNA damage by mycotoxins. Wang JS, et al. **Mutat Res** 1999 Mar 8;424(1-2):167-81 (91 ref.)
Recent studies of mycotoxins. Moss MO. **Soc Appl Bacteriol Symp Ser** 1998;27:62S-76S (130 ref.)

MYDRIASIS

ETIOLOGY

[Mydriasis due to accidental contact with stramonium (Datura stramonium) (letter)] Alcaraz García SF, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):156 (9 ref.) **(Spa)**

MYELENCEPHALON see **MEDULLA OBLONGATA**

MYELIN see **MYELIN SHEATH**

MYELIN-ASSOCIATED GLYCOPROTEIN

CHEMISTRY

The structure and function of myelin oligodendrocyte glycoprotein. Johns TG, et al. **J Neurochem** 1999 Jan; 72(1):1-9 (47 ref.)

GENETICS

The structure and function of myelin oligodendrocyte glycoprotein. Johns TG, et al. **J Neurochem** 1999 Jan; 72(1):1-9 (47 ref.)
Evidence against altered forms of MAG in the dysmyelinated mouse mutant claw paw. Niemann S, et al. **Mamm Genome** 1998 Nov;9(11):903-4 (17 ref.)

IMMUNOLOGY

T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. de Rosbo NK, et al. **J Autoimmun** 1998 Aug;11(4):287-99 (120 ref.)
Cytokines and antibodies in myelin oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis. Hjelmström P, et al. **Res Immunol** 1998 Nov-Dec;149(9):794-804; discussion 847-8, 855-60 (81 ref.)
[Anti-MAG antibody associated neuropathy] Ogino M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):487-91 (15 ref.) **(Jpn)**

MYELIN BASIC PROTEINS

IMMUNOLOGY

Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein. Goverman J. **Immunol Rev** 1999 Jun;169:147-59 (111 ref.)
Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Lehmann PV, et al. **Immunol Rev** 1998 Aug;164:53-61 (59 ref.)
TCR peptide-reactive T cells and peripheral tolerance to myelin basic protein. Kumar V. **Res Immunol** 1998 Nov-Dec;149(9):827-34; discussion 852-4, 855-60 (66 ref.)

URINE

Myelin basic protein-like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes. Whitaker JN. **Mult Scler** 1998 Jun;4(3):243-6 (51 ref.)

MYELIN P0 PROTEIN

GENETICS

Myelin protein zero and membrane adhesion. Spiryda LB. **J Neurosci Res** 1998 Oct 15;54(2):137-46 (83 ref.)

MYELIN P2 PROTEIN

GENETICS

A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. Hegele RA. **Clin Biochem** 1998 Nov; 31(8):609-12 (26 ref.)

METABOLISM

Skeletal muscle fatty acid transport and transporters. Bonen A, et al. **Adv Exp Med Biol** 1998;441:193-205 (72 ref.)
Intracellular transport of fatty acids in muscle. Role of cytoplasmic fatty acid-binding protein. Glatz JF, et al. **Adv Exp Med Biol** 1998;441:207-18 (56 ref.)
Cellular uptake and intracellular trafficking of long chain

MYELIN P2 PROTEIN

fatty acids. McArthur MJ, et al. **J Lipid Res** 1999 Aug; 40(8):1371–83 (124 ref.)
Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Luiken JJ, et al. **Lipids** 1999;34 Suppl:S169–75 (41 ref.)

MYELIN PROTEINS

BIOSYNTHESIS

Transplanting myelin-forming cells into the central nervous system: principles and practice. Franklin RJ, et al. **Methods** 1998 Nov;16(3):311–9 (60 ref.)

GENETICS

Inherited neuropathies: from gene to disease. Keller MP, et al. **Brain Pathol** 1999 Apr;9(2):327–41 (134 ref.)
Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Nelis E, et al. **Hum Mutat** 1999;13(1):11–28 (135 ref.)
Charcot–Marie–Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Lupski JR. **Pediatr Res** 1999 Feb;45(2):159–65 (67 ref.)
[The involvement of myelin proteins in hereditary neuropathies] Sindou P, et al. **Rev Neurol (Paris)** 1999 Feb; 155(2):97–110 (179 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

[The involvement of myelin proteins in hereditary neuropathies] Sindou P, et al. **Rev Neurol (Paris)** 1999 Feb; 155(2):97–110 (179 ref.) (Eng. Abstr.) **(Fre)**
[Promoting remyelination as a future therapeutic principle in multiple sclerosis?] Pöhlau D, et al. **Nervenarzt** 1998 Oct; 69(10):841–50 (112 ref.) (Eng. Abstr.) **(Ger)**
[Myelin diseases affecting both the central and the peripheral nervous system] Hagen K, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3600–2 (20 ref.) (Eng. Abstr.) **(Nor)**

MYELIN PROTEOLIPID PROTEIN

GENETICS

Proteolipid protein gene: Pelizaeus–Merzbacher disease in humans and neurodegeneration in mice. Woodward K, et al. **Trends Genet** 1999 Apr;15(4):125–8 (31 ref.)

MYELIN SHEATH

see related
DEMYELINATING DISEASES
MYELIN PROTEINS

IMMUNOLOGY

Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis. Stinissen P, et al. **Mult Scler** 1998 Jun; 4(3):203–11 (70 ref.)
Phagocytosis of myelin in demyelinative disease: a review. Smith ME. **Neurochem Res** 1999 Feb;24(2):261–8 (54 ref.)

METABOLISM

Remyelination in demyelinating disease. Scolding NJ, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):525–48 (125 ref.)
RNA trafficking in myelinating cells. Carson JH, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):607–12 (44 ref.)

PATHOLOGY

Neuropathology in multiple sclerosis: new concepts. Lassmann H. **Mult Scler** 1998 Jun;4(3):93–8 (74 ref.)
The hypomyelinating neuropathies of mice and men. Ouvrier RA. **Rev Neurol (Paris)** 1998 Jul;154(6–7):481–7 (54 ref.)

PHYSIOLOGY

Neurotransmitter–mediated regulation of CNS myelination: a review. Belachew S, et al. **Acta Neurol Belg** 1999 Mar; 99(1):21–31 (336 ref.)
Reluctant remyelination: the missing precursors [editorial; comment] Perry VH. **Brain** 1998 Dec;121 (Pt 12):2219–20 (12 ref.) Comment on: Brain 1998 Dec;121 (Pt 12):2221–8.
Myelin dysfunction/degradation in the central nervous system: why are myelin sheaths susceptible to damage? Bradl M. **J Neural Transm Suppl** 1999;55:9–17 (51 ref.)
A unique population of circulating autoantibodies promotes central nervous system remyelination. Asakura K, et al. **Mult Scler** 1998 Jun;4(3):217–21 (55 ref.)
Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? Massaro AR. **Mult Scler** 1998 Jun;4(3):228–31 (29 ref.)
Cytokines in multiple sclerosis: pro–inflammation or pro–remyelination? Sharief MK. **Mult Scler** 1998 Jun; 4(3):169–73 (35 ref.)
[Candidate cells for remyelinating of the central nervous system] Nait Oumesmar B, et al. **Rev Neurol (Paris)** 1998 Sep;154(8–9):592–9 (95 ref.) **(Fre)**

ULTRASTRUCTURE

Fenestration nodes and the wide submyelinic space form the basis for the unusually fast impulse conduction of shrimp myelinated axons. Xu K, et al. **J Exp Biol** 1999 Aug;202 (Pt 15):1979–89 (35 ref.)

MYELINOCLASIS, CENTRAL PONTINE see **MYELINOLYSIS, CENTRAL PONTINE**

MYELINOCLASTIC DIFFUSE SCLEROSIS see **ENCEPHALITIS PERIAXIALIS**

MYELINOLYSIS, CENTRAL PONTINE

[Central pontine myelinolysis (CPM)] Katayama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):447–9 (13 ref.) **(Jpn)**

MYELITIS

[Myelitis] Shoji H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):46–8 (12 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Neurotoxicity of chinoform] Iwashita H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):602–5 (6 ref.) **(Jpn)**

COMPLICATIONS

[Myeloradiculitis] Shoji H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):49–51 (10 ref.) **(Jpn)**

ETIOLOGY

Radiation myelopathy. Rampling R, et al. **Curr Opin Neurol** 1998 Dec;11(6):627–32 (69 ref.)

IMMUNOLOGY

[DPB 1 *0501–associated opticomyelitis and atopic myelitis: novel disease entities] Kira J. **Rinsho Shinkeigaku** 1999 Jan; 39(1):19–20 (4 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Spinal cord involvement in pediatric systemic lupus erythematosus: case report and literature review. al–Mayouf SM, et al. **Clin Exp Rheumatol** 1999 Jul–Aug; 17(4):505–8 (20 ref.)
[Magnetic resonance findings in a case of herpes zoster myelitis] Pierallini A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):107–8 (15 ref.) **(Ita)**

RADIOTHERAPY

Prognostic factors for spinal cord myelitis—an analysis of compiled literature data. Velmurugan J, et al. **Indian J Cancer** 1998 Mar;35(1):33–7 (19 ref.)

VIROLOGY

[Magnetic resonance findings in a case of herpes zoster myelitis] Pierallini A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):107–8 (15 ref.) **(Ita)**

MYELITIS, TRANSVERSE

DIAGNOSIS

[Recurrent transverse myelitis. 2 cases and review of the literature] Kahl KG, et al. **Nervenarzt** 1998 Dec; 69(12):1115–22 (44 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Gharavi AE, et al. **Lupus** 1998;7 Suppl 2:S52–4 (25 ref.)
[A case of primary Sjögren's syndrome accompanied by transverse myelitis] Kaneko Y, et al. **Ryumachi** 1998 Aug; 38(4):600–4 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Acute transverse myelitis in systemic lupus erythematosus] Romero Ganuza FJ, et al. **Rev Clin Esp** 1999 Apr; 199(4):218–21 (37 ref.) (Eng. Abstr.) **(Spa)**

MYELOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOCELE see **MENINGOMYELOCELE**

MYELOCYTIC LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELODYSPLASIA see **NEURAL TUBE DEFECTS**

MYELODYSPLASTIC SYNDROMES

Myelodysplasia. Heaney ML, et al. **N Engl J Med** 1999 May 27;340(21):1649–60 (143 ref.)
[Trilineage myelodysplasia] Kuriyama K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):209–12 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Neuroblastoma and treatment–related myelodysplasia/leukemia: the Memorial Sloan–Kettering experience and a literature review. Kushner BH, et al. **J Clin Oncol** 1998 Dec;16(12):3880–9 (105 ref.)

CLASSIFICATION

Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Greenberg PL, et al. **Forum (Genova)** 1999 Jan–Mar;9(1):17–31 (99 ref.)

COMPLICATIONS

Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Lai R, et al. **Am J Clin Pathol** 1999 Mar;111(3):373–8 (21 ref.)
Catalase–negative Staphylococcus aureus septicaemia [letter] Turner DP, et al. **J Infect** 1999 Mar;38(2):132–3 (11 ref.)
Treatment of anaemia with rHuEpo in patients with MDS. Casadevall N. **Med Oncol** 1998 Aug;15 Suppl 1:S35–7 (17 ref.)
The association between Crohn disease and the myelodysplastic syndromes. Report of 3 cases and review of the literature. Bosch X, et al. **Medicine (Baltimore)** 1998 Nov;77(6):371–7 (22 ref.)

DIAGNOSIS

Myelodysplasia presenting with pulmonary manifestations associated with neutrophilic dermatosis. Peters FP, et al. **Ann Hematol** 1998 Sep;77(3):135–8 (20 ref.)
[Myelodysplastic syndromes] Aul C, et al. **Internist (Berl)** 1998 Nov;39(11):1168–80 (10 ref.) **(Ger)**

DRUG THERAPY

Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes. Estey EH. **Oncology (Huntingt)** 1998 Nov;12(11A):81–6 (14 ref.)
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. List AF. **Semin Oncol** 1999 Apr;26(2 Suppl 7):61–5 (30 ref.)
[Role of aggressive treatment strategies for myelodysplastic syndromes] Aul C, et al. **Schweiz Rundsch Med Prax** 1999 Mar 4;88(10):431–8 (36 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Greenberg PL. **Leuk Res** 1998 Dec;22(12):1123–36 (164 ref.)
[Therapy–related myelodysplastic syndrome (t–MDS)] Yoshida Y. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):206–8 (8 ref.) **(Jpn)**

GENETICS

Transient monosomy 7: a case series in children and review of the literature. Mantadakis E, et al. **Cancer** 1999 Jun 15; 85(12):2655–61 (36 ref.)
Cytogenetics of myelodysplastic syndromes. Mecucci C, et al. **Forum (Genova)** 1999 Jan–Mar;9(1):4–13 (61 ref.)
Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. Martinez–Climent JA, et al. **J Pediatr Hematol Oncol** 1999 Mar–Apr;21(2):91–102 (182 ref.)
5q(–)survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Pedersen B. **Leuk Lymphoma** 1998 Oct;31(3–4):325–34 (49 ref.)
High–risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Uchida T, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):9–18 (64 ref.)
Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Sawyers CL. **Leuk Res** 1998 Dec;22(12):1113–22 (88 ref.)
Molecular genetic features of myelodysplastic syndromes (MDS) [published erratum appears in Leukemia 1999 Feb;13(2):315] Willman CL. **Leukemia** 1998 Sep;12 Suppl 1:S2–6 (40 ref.)
[Molecular physiopathology and clinical picture of myelodysplastic syndrome] Toyama K. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1682–91 (26 ref.) **(Jpn)**
[t(3;5) (q21;q31) chromosomal abnormality in a patient with acute myelogenous leukemia with trilineage myelodysplasia] Sasai Y, et al. **Rinsho Ketsueki** 1998 Sep; 39(9):658–64 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic origin of malignant hematopoiesis well defined] Bernell P, et al. **Lakartidningen** 1998 Nov 25;95(48):5493–4, 5497–8 (15 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGY

Surface marker abnormalities in myelodysplastic syndromes. Elghetany MT. **Haematologica** 1998 Dec;83(12):1104–15 (105 ref.)
[Immunological abnormalities in myelodysplastic syndromes] Okamoto T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):213–6 (17 ref.) **(Jpn)**

PATHOLOGY

Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Kraus MD, et al. **Am J Surg Pathol** 1998 Oct;22(10):1255–66 (35 ref.)

Specific cutaneous lesions of the scalp in myelodysplastic syndrome with deletion of 20q. Namba Y, et al. **J Dermatol** 1999 Apr;26(4):220–4 (15 ref.)

Myelodysplastic syndrome and associated skin lesions: a review of the literature. Avivi I, et al. **Leuk Res** 1999 Apr; 23(4):323–30 (97 ref.)

Apoptosis and its significance in MDS: controversies revisited. Yoshida Y, et al. **Leuk Res** 1999 Sep;23(9):777–85 (62 ref.)

PHYSIOPATHOLOGY

Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria. Tooze JA, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):231–41 (104 ref.)

THERAPY

Differentiation therapy of myelodysplastic syndromes: fact or fiction? Santini V, et al. **Br J Haematol** 1998 Sep; 102(5):1124–38 (152 ref.)

Novel biologic approaches to hematologic malignancies. Dutcher JP, et al. **Cancer Treat Res** 1999;99:275–306 (210 ref.)

Advances in the therapy of the myelodysplastic syndromes. Kouides PA, et al. **Cancer Treat Res** 1999;99:335–62 (125 ref.)

Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia. Boogaerts MA. **Curr Opin Hematol** 1998 Nov;5(6):465–71 (38 ref.)

Stem cell transplantation in myelodysplastic syndromes. de Witte T. **Forum (Genova)** 1999 Jan–Mar;9(1):75–81 (53 ref.)

A patient-oriented approach to treatment of myelodysplastic syndromes. Cazzola M, et al. **Haematologica** 1998 Oct; 83(10):910–35 (220 ref.)

Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Matthews DC. **Leukemia** 1998 Sep;12 Suppl 1:S33–6 (12 ref.)

[Role of aggressive treatment strategies for myelodysplastic syndromes] Aul C, et al. **Schweiz Rundsch Med Prax** 1999 Mar 4;88(10):431–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Indication and results of hematopoietic stem cell transplantation. 3. Aplastic anemia and myelodysplastic syndrome] Sakamaki H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1477–82 (8 ref.) **(Jpn)**

VIROLOGY

Hypothesis: myelodysplastic syndromes may have a viral etiology. Raza A. **Int J Hematol** 1998 Oct;68(3):245–56 (82 ref.)

MYELOFIBROSIS

DIAGNOSIS

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Barosi G, et al. **Br J Haematol** 1999 Mar;104(4):730–7 (39 ref.)

ETIOLOGY

Idiopathic myelofibrosis: a clinical review. Manoharan A. **Int J Hematol** 1998 Dec;68(4):355–62 (66 ref.)

MYELOGENOUS LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOGENOUS LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOGENOUS LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELOGENOUS LEUKEMIA, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOGENOUS LEUKEMIA, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID DIFFERENTIATION-INDUCING PROTEIN see **INTERLEUKIN-6**

MYELOID LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOID LEUKEMIA, ACUTE, M1 see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M2 see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M3 see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M4 see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M5 see **LEUKEMIA, MONOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M6 see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M7 see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MYELOID LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELOID LEUKEMIA, NAEGELI-TYPE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOID LEUKEMIA, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOID LEUKEMIA, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID LEUKEMIA, PHILADELPHIA-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOID LEUKEMIA, PHILADELPHIA-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID LEUKEMIA, SCHILLING-TYPE see **LEUKEMIA, MONOCYTIC, ACUTE**

MYELOID METAPLASIA

COMPLICATIONS

Fine-needle aspiration of large cell lymphoma in a patient with agnogenic myeloid metaplasia: a case report and review of the literature. Liu K, et al. **Diagn Cytopathol** 1998 Sep;19(3):205–9 (25 ref.)

DIAGNOSIS

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Barosi G, et al. **Br J Haematol** 1999 Mar;104(4):730–7 (39 ref.)

MYELOLIPOMA

PATHOLOGY

Rupture and growth of adrenal myelolipoma in two patients [letter; comment] Hoeffel C. **Br J Radiol** 1998 Jun; 71(846):693 (10 ref.) Comment on: Br J Radiol 1996 Sep;69(825):873–5.

MYELOMA, PLASMA-CELL see **MULTIPLE MYELOMA**

MYELOMENINGOCELE see **MENINGOMYELOCELE**

MYELOMONOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOMONOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOMONOCYTIC, CHRONIC**

MYELOPATHIC MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

MYELOPEROXIDASE see **PEROXIDASE**

MYELOPOIESIS see **LEUKOPOIESIS**

MYELOPROLIFERATIVE DISORDERS

see related
LEUKEMIA

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Michiels JJ, et al. **Neth J Med** 1999 Feb;54(2):46–62 (70 ref.)

Introduction: overview of chronic myeloproliferative disorders. Tefferi A. **Semin Hematol** 1999 Jan;36(1 Suppl 2):1–2 (27 ref.)

[Chronic myeloproliferative syndromes] de Ozalla CB, et al. **Rev Clin Esp** 1999 Apr;199 Suppl 1:28–36 (19 ref.) **(Spa)**

COMPLICATIONS

Bleeding and thrombosis in myeloproliferative disorders. Landolfi R. **Curr Opin Hematol** 1998 Sep;5(5):327–31 (33 ref.)

DIAGNOSIS

The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview [see comments] Tefferi A. **Mayo Clin Proc** 1998 Dec; 73(12):1177–84 (10 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):742.

ETIOLOGY

Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Zipursky A, et al. **Clin Lab Med** 1999 Mar;19(1):157–67, vii (28 ref.)

Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Tefferi A. **Semin Hematol** 1999 Jan;36(1 Suppl 2):3–8 (72 ref.)

GENETICS

[The 8p11 myeloproliferative syndrome] Reither A, et al. **Med Klin** 1999 Apr 15;94(4):207–10 (44 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Tefferi A. **Semin Hematol** 1999 Jan;36(1 Suppl 2):3–8 (72 ref.)

PHYSIOPATHOLOGY

The role of the MPL receptor in myeloproliferative disorders. Kaushansky K. **Leukemia** 1998 Sep;12 Suppl 1:S47–50 (26 ref.)

THERAPY

The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview [see comments] Tefferi A. **Mayo Clin Proc** 1998 Dec; 73(12):1177–84 (10 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):742.

VETERINARY

Lymphoproliferative and myeloproliferative disorders. Savage CJ. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):563–78, vii (52 ref.)

MYELOSCLEROSIS see **MYELOFIBROSIS**

MYELOSIS, NONLEUKEMIC see **MYELOID METAPLASIA**

MYENTERIC PLEXUS

CYTOLOGY

["Interstitial cells of Cajal"] Nakamura K, et al. **Fukuoka Igaku Zasshi** 1998 Sep;89(9):255–60 (6 ref.) **(Jpn)**

PHYSIOLOGY

Connections between P2 purinoceptors and capsaicin-sensitive afferents in the intestine and other tissues. Barthó L, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):203–10 (103 ref.)

MYERS-BRIGGS TYPE INDICATOR see **PERSONALITY INVENTORY**

MYIASIS

PARASITOLOGY

An aural myiasis case in a 54-year-old male farmer in Korea. Cho JH, et al. **Korean J Parasitol** 1999 Mar;37(1):51–3 (13 ref.)

THERAPY

[Myasis due to Cordylobia anthrophaga (Diptera: Calliphoirdae): description of a clinical case and review of the literature] Urbani C, et al. **Parassitologia** 1998 Sep; 40(3):317–9 (16 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Traumatic myiasis of sheep in Europe: a review. Hall MJ. **Parassitologia** 1997 Dec;39(4):409–13 (50 ref.)

MYO-INOSITOL 1,4,5-TRISPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

MYOBLASTOMA see **NEOPLASMS, MUSCLE TISSUE**

MYOBLASTOMA, GRANULAR CELL see **GRANULAR CELL TUMOR**

MYOCARDIAL CONTRACTION

see related
CARDIOTONIC AGENTS
MYOCARDIAL STUNNING

Ventricular pressure-volume area (PVA) accounts for cardiac energy consumption of work production and absorption. Araki J, et al. **Adv Exp Med Biol** 1998; 453:491–7; discussion 497–8 (31 ref.)

Work production and work absorption in muscle strips from vertebrate cardiac and insect flight muscle fibers. Maughan D, et al. **Adv Exp Med Biol** 1998;453:471–80 (9 ref.)

Reappraisal of the multicellular preparation for the in vitro

physiopharmacological evaluation of myocardial performance. Sys SU, et al. **Adv Exp Med Biol** 1998; 453:441–50; discussion 451 (34 ref.)

Vascular endothelial cell–cardiac myocyte crosstalk in achieving a balance between energy supply and energy use. Winegrad S, et al. **Adv Exp Med Biol** 1998;453:507–14 (18 ref.)

The relationship between regional blood flow and contractile function in normal, ischemic, and reperfused myocardium. Schulz R, et al. **Basic Res Cardiol** 1998 Dec;93(6):455–62 (77 ref.)

Assessment of myocardial viability with stress echocardiography. Shan K, et al. **Cardiol Clin** 1999 Aug; 17(3):539–53, ix (77 ref.)

Congestive heart failure: role of cross-bridge cycle kinetics [editorial] de Tombe PP. **Cardiovasc Res** 1998 Dec; 40(3):440–3 (41 ref.)

Cellular and molecular aspects of contractile dysfunction in heart failure. Mittmann C, et al. **Cardiovasc Res** 1998 Aug; 39(2):267–75 (101 ref.)

Contractile reserve and coronary blood flow reserve in collateral-dependent myocardium [editorial; comment] Bonow RO. **J Am Coll Cardiol** 1999 Mar;33(3):705–7 (17 ref.) Comment on: J Am Coll Cardiol 1999 Mar;33(3):697–704.

Role of sarcoplasmic reticulum in the contractile dysfunction during myocardial ischaemia and reperfusion. Kaplán P, et al. **Physiol Res** 1997;46(5):333–9 (59 ref.)

Hibernating myocardium. Heusch G. **Physiol Rev** 1998 Oct; 78(4):1055–85 (222 ref.)

The role of calcium in the response of cardiac muscle to stretch. Calaghan SC, et al. **Prog Biophys Mol Biol** 1999; 71(1):59–90 (156 ref.)

Wave propagation in cardiac tissue and effects of intracellular calcium dynamics (computer simulation study). Chudin E, et al. **Prog Biophys Mol Biol** 1998;69(2–3):225–36 (17 ref.)

Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models. Kohl P, et al. **Prog Biophys Mol Biol** 1999;71(1):91–138 (282 ref.)

Assessment of left-ventricular function. Schertel ER. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:248–54 (22 ref.)

Clinical experience with blood cardioplegia. Schlensak C, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:282–5; discussion 286–7 (28 ref.)

Basics of myocardial pump function. von Spiegel T, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:237–41 (28 ref.)

DRUG EFFECTS

Effects of cytokines and nitric oxide on myocardial E-C coupling. Haque R, et al. **Basic Res Cardiol** 1998;93 Suppl 1:86–94 (98 ref.)

Adrenergic regulation of the force-frequency effect. Ross J Jr. **Basic Res Cardiol** 1998;93 Suppl 1:95–101 (32 ref.)

Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. Movsesian MA. **J Am Coll Cardiol** 1999 Aug;34(2):318–24 (60 ref.)

Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Hattori Y. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):123–31 (113 ref.)

PHYSIOLOGY

From overload to failure: what happens inside the myocyte. Harding SE, et al. **Ann Med** 1998 Aug;30 Suppl 1:14–23 (75 ref.)

Cellular adaptations of the heart muscle to exercise training. Moore RL. **Ann Med** 1998 Aug;30 Suppl 1:46–53 (123 ref.)

Force-frequency relations in nonfailing and failing animal myocardium. Crozatier B. **Basic Res Cardiol** 1998;93 Suppl 1:46–50 (39 ref.)

Left ventricular restoring forces: modulation by heart rate and contractility. LeWinter MM, et al. **Basic Res Cardiol** 1998;93 Suppl 1:143–7 (21 ref.)

Influence of SR Ca(2+)-ATPase and Na(+)-Ca(2+)-exchanger on the force-frequency relation. Schillinger W, et al. **Basic Res Cardiol** 1998;93 Suppl 1:38–45 (38 ref.)

Low dose dobutamine echocardiography in the assessment of contractile reserve to predict the outcome of valve replacement for chronic aortic regurgitation. Tam JW, et al. **Can J Cardiol** 1999 Jan;15(1):73–9 (30 ref.)

The search for the hibernating myocardium--have we reached the limit? Ferrari R. **Cardiovasc Drugs Ther** 1999 Apr;13(2):137–43 (50 ref.)

Regulation of basal myocardial function by NO. Kojda G, et al. **Cardiovasc Res** 1999 Mar;41(3):514–23 (100 ref.)

Prostaglandin--a pluralistic hormone embracing divergent signal properties [editorial] Sack S. **Cardiovasc Res** 1998 Dec;40(3):438–9 (20 ref.)

Physio-pharmacological evaluation of myocardial performance: an integrative approach. Shah AM, et al. **Cardiovasc Res** 1998 Jul;39(1):148–54 (85 ref.)

Physiopharmacological evaluation of myocardial performance: how to study modulation by cardiac endothelium and related humoral factors? Sys SU, et al. **Cardiovasc Res** 1998 Jul;39(1):136–47 (83 ref.)

Cardiac myosin binding protein C. Winegrad S. **Circ Res** 1999 May 28;84(10):1117–26 (78 ref.)

Growth hormone, cardiomyocyte contractile reserve, and heart failure [editorial; comment] Ross J Jr. **Circulation** 1999 Jan 5–12;99(1):15–7 (19 ref.) Comment on: Circulation 1999 Jan 5–12;99(1):127–34.

Effects of acute ischaemia on intramyocardial contraction heterogeneity; new ultrasound technologies to study an old phenomenon. Colonna P, et al. **Eur Heart J** 1999 Mar; 20(5):327–37 (71 ref.)

Measurement of coronary flow reserve: what does it tell us about myocardial viability? [editorial] Maurer G. **Eur Heart J** 1999 Feb;20(4):248–9 (7 ref.)

Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion. Cain BS, et al. **J Mol Cell Cardiol** 1999 May; 31(5):931–47 (142 ref.)

The structure and function of the cardiac myocyte: a review of fundamental concepts. Walker CA, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):375–82 (46 ref.)

Cardiac contractility: how calcium activates the myofilaments. Rüegg JC. **Naturwissenschaften** 1998 Dec; 85(12):575–82 (70 ref.)

Modelling the mechanical properties of cardiac muscle. Hunter PJ, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):289–331 (119 ref.)

Modeling the cellular basis of altered excitation–contraction coupling in heart failure. Winslow RL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):497–514 (45 ref.)

Cardiac MR imaging: a guide for the beginner. Boxt LM. **Radiographics** 1999 Jul–Aug;19(4):1009–25; discussion 1026–8 (25 ref.)

The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? Bennett PM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:203–34 (101 ref.)

Myocardial dysfunction in sepsis: clinical and experimental investigations. Suffredini AF. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1444–52 (51 ref.)

[Asynchrony of ventricular contraction and relaxation--pathophysiologically recognized phenomenon, now can be clinically assessed] Bruch C, et al. **Herz** 1998 Dec;23(8):506–15 (47 ref.) (Eng. Abstr.) **(Ger)**

[Heterogeneities of ventricular repolarization and vulnerability to arrhythmia. How to detect them with noninvasive methods?] De Ambroggi L. **Cardiologia** 1999 Apr;44(4):355–60 (53 ref.) (Eng. Abstr.) **(Ita)**

MYOCARDIAL DEPRESSANTS see **ANTI-ARRHYTHMIA AGENTS**

MYOCARDIAL DISEASES

[Cardiac amyloidosis] Matsuzaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):503–6 (6 ref.) **(Jpn)**

[Cardiomyopathies] Albanesi Filho F. **Arq Bras Cardiol** 1998 Aug;71(2):95–107 (94 ref.) **(Por)**

CHEMICALLY INDUCED

Cardiotoxicity of cancer therapy. Tolba KA, et al. **Cancer Invest** 1999;17(6):408–22 (165 ref.)

Role of iron in anthracycline cardiotoxicity: new tunes for an old song? [published erratum appears in FASEB J 1999 Mar;13(3):594] Minotti G, et al. **FASEB J** 1999 Feb; 13(2):199–212 (106 ref.)

Oxidants, antioxidants and alcohol: implications for skeletal and cardiac muscle. Preedy VR, et al. **Front Biosci** 1999 Aug 1;4:e58–66 (70 ref.)

Strategies for reduction of anthracycline cardiac toxicity. Speyer J, et al. **Semin Oncol** 1998 Oct;25(5):525–37 (94 ref.)

CLASSIFICATION

[The classification of cardiomyopathies (editorial)] Sinagra G, et al. **G Ital Cardiol** 1998 Nov;28(11):1191–9 (43 ref.) **(Ita)**

COMPLICATIONS

Autoimmune rheumatic diseases and the heart. Hussain S, et al. **Hosp Med** 1999 Feb;60(2):95–9 (23 ref.)

Cardiopulmonary dysfunction in cirrhosis. Liu H, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):600–8 (87 ref.)

[The role of myocardial apoptosis in the development of heart failure] Andréka P, et al. **Orv Hetil** 1999 Jan 17; 140(3):135–42 (50 ref.) (Eng. Abstr.) **(Hun)**

[Pericarditis secondary to the rupture of a hydatid cyst] Iglesias LF, et al. **Rev Esp Cardiol** 1999 Feb;52(2):135–8 (8 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Hypercalcemic cardiomyopathy associated with primary hyperparathyroidism mimicking primary obstructive hypertrophic cardiomyopathy. Demers C, et al. **Can J Cardiol** 1998 Nov;14(11):1397–400 (19 ref.)

Biochemical assessment of myocardial damage with new diagnostic tools. Panteghini M. **Cardiologia** 1999 May; 44(5):419–25 (35 ref.)

Rest-injected 201thallium in the evaluation of myocardial viability. Perrone-Filardi P, et al. **Cardiologia** 1999 Jun; 44(6):515–20 (31 ref.)

[The diagnosis of encephalopathy, neuropathy and myopathy in the critical patient] Lindner A, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):257–60 (34 ref.) **(Ger)**

[Intracardiac ectopic thyroid: a report of a clinical case with a long-term follow-up] Pistono M, et al. **Cardiologia** 1999 Jan;44(1):83–8 (10 ref.) (Eng. Abstr.) **(Ita)**

[Genetic counseling in cardiomyopathies (editorial)] Arbustini E. **G Ital Cardiol** 1999 May;29(5):505–13 (66 ref.) **(Ita)**

[The biochemical markers of myocardial damage. The Intersociety Interdisciplinary Study Group of the ANMCO-SIBioC-SIMeL, Markers of Myocardial Lesions. Associazione Nazionale Medici Cardiologi Ospedalieri-SIBioC-Società Italiana di Medicina di Laboratorio] Dolci A, et al. **G Ital Cardiol** 1999 Jun; 29(6):739–47 (46 ref.) **(Ita)**

[New aspects of idiopathic cardiomyopathy--from gene diagnosis to gene therapy] Toyooka T, et al. **Nippon Rinsho** 1999 Jul;57(7):1665–75 (29 ref.) **(Jpn)**

[A hydatid cyst in the vena cava inferior and right atrium with venous flow obstruction and pulmonary dissemination] Caballero J, et al. **Rev Esp Cardiol** 1999 Apr; 52(4):281–4 (8 ref.) (Eng. Abstr.) **(Spa)**

[Cardiac cysts. A case of isolated cardiac hydatidosis] Gómez-Aldaravi Gutiérrez R, et al. **Rev Esp Cardiol** 1999 May;52(5):355–8 (8 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Protein kinase C in normal and pathologic myocardial states. Cain BS, et al. **J Surg Res** 1999 Feb;81(2):249–59 (166 ref.)

ETIOLOGY

Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Schumacher B, et al. **Am J Cardiol** 1998 Oct 16;82(8A):29N–36N (82 ref.)

Subcellular remodeling and heart dysfunction in chronic diabetes [editorial] Dhalla NS, et al. **Cardiovasc Res** 1998 Nov;40(2):239–47 (130 ref.)

GENETICS

A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy [see comments] Walsh MT. **Am J Pathol** 1999 Jan;154(1):11–4 (37 ref.) Comment in: Am J Pathol 1999 Jan;154(1):221–7.

Genetic basis of cardiomyopathy. Durand JB. **Curr Opin Cardiol** 1999 May;14(3):225–9 (52 ref.)

Genetics of neonatal cardiomyopathy. Towbin JA, et al. **Curr Opin Cardiol** 1999 May;14(3):250–62 (80 ref.)

Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Funakoshi M, et al. **Neuromuscul Disord** 1999 Mar;9(2):108–14 (55 ref.)

[Hereditary amyloid cardiomyopathy related to a mutation at transthyretin protein number 111. A clinical, genetic and echocardiographic study of an affected Danish family] Svendsen IH, et al. **Ugeskr Laeger** 1999 Sep 6; 161(36):4995–9 (20 ref.) (Eng. Abstr.) **(Dan)**

[Genetics in cardiology. An update] Vosberg HP. **Internist (Berl)** 1999 May;40(5):522–33 (63 ref.) **(Ger)**

[Myocardiopathies] Tanaka H. **Nippon Naika Gakkai Zasshi** 1999 Feb 20;88 Suppl:50–4 (0 ref.) **(Jpn)**

[Cardiology review. Molecular and genetic aspects of cardiopathies] Jay D. **Arch Inst Cardiol Mex** 1999 Mar–Apr;69(2):157–62 (52 ref.) **(Spa)**

METABOLISM

Biochemical assessment of myocardial damage with new diagnostic tools. Panteghini M. **Cardiologia** 1999 May; 44(5):419–25 (35 ref.)

Role of iron in anthracycline cardiotoxicity: new tunes for an old song? [published erratum appears in FASEB J 1999 Mar;13(3):594] Minotti G, et al. **FASEB J** 1999 Feb; 13(2):199–212 (106 ref.)

Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Rösen P, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):103–11 (64 ref.)

[Cardiology review. Molecular and genetic aspects of cardiopathies] Jay D. **Arch Inst Cardiol Mex** 1999 Mar–Apr;69(2):157–62 (52 ref.) **(Spa)**

PATHOLOGY

Histiocytoid cardiomyopathy: three new cases and a review of the literature. Shehata BM, et al. **Pediatr Dev Pathol** 1998 Jan–Feb;1(1):56–69 (45 ref.)

[Cell death in inflammatory heart muscle diseases--apoptosis or necrosis?] Pankuweit S, et al. **Herz** 1999 May;24(3):211–8 (31 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. Flack JM, et al. **Miner Electrolyte Metab** 1998;24(6):412–22 (106 ref.)

Development of cardiac sensitivity to oxygen deficiency: comparative and ontogenetic aspects. Ostadal B, et al. **Physiol Rev** 1999 Jul;79(3):635–59 (258 ref.)

Postmitochondrial regulation of apoptosis during heart failure [comment] Reed JC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7614–6 (60 ref.) Comment on: Proc Natl Acad

Sci U S A 1999 Jul 6;96(14):8144-9.

PREVENTION & CONTROL

Alternatives for myocardial protection: adenosine-enhanced ischemic preconditioning. McCully JD, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:295-305 (60 ref.)

Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Rösen P, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):103-11 (64 ref.)

RADIONUCLIDE IMAGING

Positron emission tomography in paediatric cardiology. Quinlivan RM, et al. **Arch Dis Child** 1998 Dec;79(6):520-2 (38 ref.)

beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Nishimura T. **Int J Card Imaging** 1999 Feb;15(1):41-8 (30 ref.)

BMIPP compared with thallium redistribution. Taki J, et al. **Int J Card Imaging** 1999 Feb;15(1):49-59 (58 ref.)

Future aspects of BMIPP. Tamaki N, et al. **Int J Card Imaging** 1999 Feb;15(1):79-89 (64 ref.)

Nuclear cardiology [see comments] Prvulovich E. **J R Coll Physicians Lond** 1998 Nov-Dec;32(6):520-5 (26 ref.) Comment in: J R Coll Physicians Lond 1999 Jan-Feb;33(1):94-5.

[The significance of radioisotopic methods in internal diseases diagnosis] Rogulski B, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):44-6 (10 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

[New aspects of idiopathic cardiomyopathy--from gene diagnosis to gene therapy] Toyooka T, et al. **Nippon Rinsho** 1999 Jul;57(7):1665-75 (29 ref.) **(Jpn)**

ULTRASONOGRAPHY

Calcification of the fetal heart--four case reports and a literature review. Hajdu J, et al. **Prenat Diagn** 1998 Nov; 18(11):1186-90 (13 ref.)

[Detection of myocardial viability by stress echocardiography] Habis M. **Ann Cardiol Angeiol (Paris)** 1998 Dec;47(10):748-52 (43 ref.) (Eng. Abstr.) **(Fre)**

[The echocardiographic examination in adult cardiomyopathy] Dubourg O, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12 Suppl):35-42 (20 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of doppler imaging of the myocardium to the study of cardiomyopathies] Pellerin D, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12 Suppl):51-8 (31 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

[Hepatitis C virus infection and cardiomyopathy] Matsumori A. **Nippon Rinsho** 1999 Feb;57(2):455-63 (12 ref.) (Eng. Abstr.) **(Jpn)**

MYOCARDIAL DISEASES, PRIMARY see **MYOCARDIAL DISEASES**

MYOCARDIAL DISEASES, SECONDARY see **MYOCARDIAL DISEASES**

MYOCARDIAL HIBERNATION see **MYOCARDIAL STUNNING**

MYOCARDIAL INFARCTION

see related
HEART RUPTURE, POST-INFARCTION

Myocardial infarction in young patients. Choudhury L, et al. **Am J Med** 1999 Sep;107(3):254-61 (78 ref.)

Prehospital management of acute myocardial infarction: Electrocardiogram acquisition and interpretation, and thrombolysis by prehospital care providers. Myers RB. **Can J Cardiol** 1998 Oct;14(10):1231-40 (56 ref.)

Improved outlook for patients with acute myocardial infarction: an interim progress report [editorial; comment] Califf RM, et al. **Eur Heart J** 1998 Oct;19(10):1416-8 (12 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1512-7.

Q-wave versus non-Q wave myocardial infarction: a meaningless distinction. Phibbs B, et al. **J Am Coll Cardiol** 1999 Feb;33(2):576-82 (64 ref.)

Acute myocardial infarction. Extended review. Dana A, et al. **J R Coll Physicians Lond** 1999 Mar-Apr;33(2):131-40 (65 ref.)

If ischemic preconditioning is the gold standard, has a platinum standard of cardioprotection arrived? Comparison with NHE inhibition. Gumina RJ, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):39-44 (37 ref.)

Women's narratives: evolving symptoms of myocardial infarction. McSweeney JC. **J Women Aging** 1998; 10(2):67-83 (30 ref.)

Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Creager MA. **Vasc Med** 1998; 3(3):257-60 (8 ref.)

[Myocardial infarct. Epidemiology, physiopathology, diagnosis, evolution, complications, treatment] Leroy G. **Rev Prat** 1998 Jun 1;48(11):1263-73 (0 ref.) **(Fre)**

[Echocardiographic findings, pro-ANP and treatment in acute myocardial infarction without overt heart failure] Otterstad JE, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20; 119(19):2802-5 (10 ref.) (Eng. Abstr.) **(Nor)**

BLOOD

Understanding true risk: evaluating troponins in the emergency setting [editorial; comment] Gibler WB. **Am Heart J** 1999 Jun;137(6):985-6 (11 ref.) Comment on: Am Heart J 1999 Jun;137(6):1137-44.

IIb/IIIa inhibitors in acute myocardial infarction. Montalescot G. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S71-5 (41 ref.)

Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis. Galvani M, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S55-61 (32 ref.)

Cardiac markers: present and future. Plebani M, et al. **Int J Clin Lab Res** 1999;29(2):56-63 (49 ref.)

Intercellular adhesion molecule--sICAM-1: an emerging cardiovascular risk factor. Drown DJ. **Prog Cardiovasc Nurs** 1998 Fall;13(4):30, 23 (4 ref.)

Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM). Wu AH. **Scand J Clin Lab Invest Suppl** 1999;230:74-82 (44 ref.)

[Biochemical markers of myocardial damage in acute coronary syndromes. Suggestions for their optimal use in clinical practice] Panteghini M, et al. **G Ital Cardiol** 1999 Jul;29(7):810-5 (40 ref.) **(Ita)**

CHEMICALLY INDUCED

The safety of calcium-channel blockers. Massie BM. **Clin Cardiol** 1998 Dec;21(12 Suppl 2):II12-7 (32 ref.)

Acute myocardial infarction associated with anabolic steroids in a young HIV-infected patient. Varriale P, et al. **Pharmacotherapy** 1999 Jul;19(7):881-4 (26 ref.)

[Cocaine: its possible role in coronary arteriosclerosis and myocardial infarct. Case reports and review of the literature] Schär B, et al. **Schweiz Rundsch Med Prax** 1999 Jan 21;88(4):129-32 (25 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Diastolic dysfunction: old dog, new tricks [editorial; comment] Douglas PS. **Am Heart J** 1999 May;137(5):777-8 (9 ref.) Comment on: Am Heart J 1999 May;137(5):910-8.

Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction. Santoro GM, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):126-31 (47 ref.)

Pregnancy in women with diabetes and ischaemic heart disease. Bagg W, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):99-102 (22 ref.)

Role of ACE inhibition or AT1 blockade in the remodeling following myocardial infarction. Holtz J. **Basic Res Cardiol** 1998;93 Suppl 2:92-100 (65 ref.)

Antithrombotic agents in coronary artery disease. Cairns JA, et al. **Chest** 1998 Nov;114(5 Suppl):611S-633S (157 ref.)

Radiofrequency catheter ablation for postinfarct ventricular tachycardia. Miller JM, et al. **Curr Opin Cardiol** 1999 Jan; 14(1):30-5 (20 ref.)

Methods of identifying patients at high risk of subsequent arrhythmic death after myocardial infarction. Santoni-Rugiu F, et al. **Curr Probl Cardiol** 1999 Mar; 24(3):117-60 (104 ref.)

Cardiogenic shock: a failure in reperfusion. Time for a strategic change? [editorial; comment] Serruys PW, et al. **Eur Heart J** 1999 Jan;20(2):88-9 (10 ref.) Comment on: Eur Heart J 1999 Jan;20(2):128-35.

Diabetes and the heart. Hyde T, et al. **Hosp Med** 1999 Feb; 60(2):90-4 (33 ref.)

Is the postpacing interval of any value during ablation of postinfarction ventricular tachycardia? Friedman PL. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):52-5 (22 ref.)

Oral anticoagulants are effective long-term after acute myocardial infarction. Smith P. **J Intern Med** 1999 Apr; 245(4):383-7 (19 ref.)

Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. Simons GR, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2651-63 (74 ref.)

A patient with heart disease plans a long flight. Matthews S, et al. **Practitioner** 1997 Dec;241(1581):711-4, 716, 719 (0 ref.)

Heart failure: Part II. Wilkes MS, et al. **West J Med** 1999 Jun;170(6):339-42 (37 ref.)

[Risk stratification after myocardial infarction. Different methods for the prediction of life-threatening arrhythmias] Kluge P, et al. **Dtsch Med Wochenschr** 1998 Oct 16; 123(42):1250-7 (50 ref.) **(Ger)**

[Evaluation of ischemic risk in infarct patients submitted for fibronolysis: how and when should it be carried out?] Romano S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:89-93 (28 ref.) **(Ita)**

[The postinfarct stratification of arrhythmic risk: the return to favor of an obsolete fashion or an effective clinical necessity?] Salerno-Uriarte JA, et al. **Cardiologia** 1998 Nov; 43(11):1169-75 (64 ref.) **(Ita)**

[Recurrent ventricular fibrillation in acute myocardial infarct treated successfully by coronary angioplasty: a clinical case in favor of the hypothesis of the arrhythmogenicity of the coronary thrombus?] Trabattoni D, et al. **Cardiologia** 1998 Oct;43(10):1095-9 (19 ref.) (Eng. Abstr.) **(Ita)**

[Supraventricular arrhythmias and disorders of atrioventricular and intraventricular conduction in patients with acute myocardial infarct] Jurkovičová O, et al. **Bratisl Lek Listy** 1998 Mar-Apr;99(3-4):172-80 (62 ref.) (Eng. Abstr.) **(Slo)**

DIAGNOSIS

ST-segment elevation after myocardial infarction: what does it mean and when is it useful? [editorial; comment] Marwick TH. **Am Heart J** 1999 Jun;137(6):1002-4 (14 ref.) Comment on: Am Heart J 1999 Jun;137(6):1107-15.

Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ridker PM. **Ann Intern Med** 1999 Jun 1;130(11):933-7 (56 ref.)

A strategy for the use of cardiac injury markers (troponin I and T, creatine kinase-MB mass and isoforms, and myoglobin) in the diagnosis of acute myocardial infarction [see comments] Kost GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):245-51 (79 ref.) Comment in: Arch Pathol Lab Med 1998 Nov;122(11):949-50.

Chest pain emergency centers: improving acute myocardial infarction care. Ornato JP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV3-9 (25 ref.)

Cardiac markers: point of care testing. Hudson MP, et al. **Clin Chim Acta** 1999 Jun 30;284(2):223-37 (45 ref.)

The role of cardiac markers in the emergency department. Storrow AB, et al. **Clin Chim Acta** 1999 Jun 30; 284(2):187-96 (44 ref.)

Creatine kinase isoforms and myoglobin: early detection of myocardial infarction and reperfusion. Apple FS. **Coron Artery Dis** 1999;10(2):75-9 (32 ref.)

Cardiac troponin I and non-Q-wave myocardial infarction: how useful is it after coronary artery bypass surgery? [editorial; comment] Barron JT. **Crit Care Med** 1998 Dec; 26(12):1936-7 (9 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1986-90.

The QT interval and QT dispersion: the smaller, the better? [editorial; comment] Lombardi F. **Eur Heart J** 1998 Sep; 19(9):1279-81 (7 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1391-400.

Diagnostic strategies in myocardial infarction using myoglobin measurement. Plebani M, et al. **Eur Heart J** 1998 Nov;19 Suppl N:N12-5 (14 ref.)

Myocardial infarction during pregnancy and postpartum: a review. Patti G, et al. **G Ital Cardiol** 1999 Mar;29(3):333-8 (54 ref.)

Role of clinical presentation and ECG. Rowlands DJ. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S35-41 (21 ref.)

Unstable angina and non Q-wave myocardial infarction. Early risk stratification: role of silent ischemia and coronary morphology. Rusticali G, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S43-7 (27 ref.)

Appropriate roles of cardiac troponins in evaluating patients with chest pain. Rice MS, et al. **J Am Board Fam Pract** 1999 May-Jun;12(3):214-8 (15 ref.)

Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? Zaacks SM, et al. **J Am Coll Cardiol** 1999 Jan;33(1):107-18 (110 ref.)

Patient delay in seeking treatment for acute myocardial infarction symptoms. Zerwic JJ. **J Cardiovasc Nurs** 1999 Apr;13(3):21-32 (60 ref.)

Electrocardiographic manifestations: benign early repolarization. Brady WJ, et al. **J Emerg Med** 1999 May-Jun;17(3):473-8 (20 ref.)

Pathologic detection of early myocardial infarction: a critical review of the evolution and usefulness of modern techniques. Vargas SO, et al. **Mod Pathol** 1999 Jun; 12(6):635-45 (100 ref.)

Evidence based approach to practice guides and decision thresholds for cardiac markers. Christenson RH, et al. **Scand J Clin Lab Invest Suppl** 1999;230:90-102 (28 ref.)

[Biochemical diagnosis of acute coronary disorder] Horalík D, et al. **Vnitr Lek** 1998 Mar;44(3):170-5 (31 ref.) **(Cze)**

[Troponin, a new myocardial infarction marker] Chapelle JP. **Rev Med Liege** 1998 Oct;53(10):619-24 (26 ref.) (Eng. Abstr.) **(Fre)**

[QT-dispersion--analysis and prognostic implications] Schneider CA, et al. **Dtsch Med Wochenschr** 1999 Apr 1; 124(13):396-402 (44 ref.) **(Ger)**

[Risk assessment and measuring the need for revascularization on the basis of residual ischemia by means of dobutamine stress echocardiography in the early phase of the first myocardial infarction] Nyúzó B, et al. **Orv Hetil** 1999 Aug 29;140(35):1941-5 (38 ref.) (Eng. Abstr.) **(Hun)**

[Myocardial infarct with ST segment depression: an absolute contraindication to thrombolytic therapy?] Imperadore F, et al. **G Ital Cardiol** 1999 Jun;29(6):705-9 (25 ref.) (Eng. Abstr.) **(Ita)**

[The proposition of a rule for evaluating the percentage of health impairment due to occupationally related myocardial infarction] Szozda R, et al. **Med Pr** 1995;46(1):55-9 (8 ref.) (Eng. Abstr.) **(Pol)**

[Myopericarditis simulating a myocardial infarct in a child] Diez Tomás J, et al. **An Esp Pediatr** 1999 Jun;50(6):613-5 (13 ref.) **(Spa)**

[Identification of patients at high risk in the initial evaluation of unstable angina. Clinical importance of electrocardiogram, Holter and biochemical markers in

myocardial lesions] López de Sá E. **Rev Esp Cardiol** 1999; 52 Suppl 1:97–106 (85 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

IIb/IIIa receptor blockade in acute myocardial infarction. Ferguson JJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):164–70 (24 ref.)

Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. Ferrario M, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):121–5 (45 ref.)

Advances in antithrombotic therapy of acute myocardial infarction. Gensini GF, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):171–6 (41 ref.)

Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH. **Am Heart J** 1999 Apr;137(4 Pt 2):S9–S13 (23 ref.)

How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI. Maggioni AP, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):183–7 (32 ref.)

Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era [editorial; comment] Tan HL, et al. **Am Heart J** 1999 May;137(5):770–3 (27 ref.) Comment on: Am Heart J 1999 May;137(5):792–8. Comment on: Am Heart J 1999 May;137(5):799–805.

Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Avkiran M. **Am J Cardiol** 1999 May 20;83(10A):10G–17G; discussion 17G–18G (64 ref.)

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Buerke M, et al. **Am J Cardiol** 1999 May 20; 83(10A):19G–22G (35 ref.)

Protection of the myocardial cell during ischemia. Théroux P. **Am J Cardiol** 1999 May 20;83(10A):3G–9G (29 ref.)

Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Wooster MB, et al. **Ann Pharmacother** 1999 Mar;33(3):318–24 (17 ref.)

Role of ACE inhibition or AT1 blockade in the remodeling following myocardial infarction. Holtz J. **Basic Res Cardiol** 1998;93 Suppl 2:92–100 (65 ref.)

IIb/IIIa inhibitors in acute myocardial infarction. Montalescot G. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S71–5 (41 ref.)

Recent advances in the management of unstable angina and non-Q-wave myocardial infarction. Steeds RP, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):335–41 (66 ref.)

Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Massel D. **Can J Cardiol** 1999 Feb;15(2):173–9 (37 ref.)

Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. Cantor WJ, et al. **Cardiol Rev** 1999 Jul–Aug; 7(4):232–44 (75 ref.)

Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value [editorial; comment] Apstein CS, et al. **Cardiovasc Drugs Ther** 1999 May;13(3):185–9 (38 ref.) Comment on: Cardiovasc Drugs Ther 1999 May;13(3):191–200.

Coronary thrombolysis. Cairns JA, et al. **Chest** 1998 Nov; 114(5 Suppl):634S–657S (175 ref.)

Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial [editorial] Apstein CS. **Circulation** 1998 Nov 24; 98(21):2223–6 (27 ref.)

Prehospital thrombolysis: an idea whose time has come. Cannon CP, et al. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV10–9 (75 ref.)

Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV30–6 (31 ref.)

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV37–43 (57 ref.)

Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid-dependent rheumatoid arthritis. Kotha P, et al. **Clin Cardiol** 1998 Nov;21(11):853–6 (22 ref.)

New plasminogen activators: a clinical review. Ross AM. **Clin Cardiol** 1999 Mar;22(3):165–71 (54 ref.)

Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Bates ER. **Curr Opin Cardiol** 1998 Jul;13(4):274–9 (21 ref.)

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Goa KL, et al. **Drugs** 1999 Mar; 57(3):439–62 (74 ref.)

Utilisation of thrombolytic therapy in older patients with myocardial infarction. Woods KL, et al. **Drugs Aging** 1998 Dec;13(6):435–41 (25 ref.)

Cardiologists and their war on platelets [editorial] Ferrari R, et al. **Eur Heart J** 1999 Apr;20(8):557–8 (4 ref.)

Magnesium treatment in acute myocardial infarction: an unresolved consensus [editorial; comment] Oto A. **Eur Heart J** 1999 Jan;20(2):86–8 (10 ref.) Comment on: Eur Heart J 1999 Jan;20(2):111–20.

Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Ronner E, et al. **Eur Heart J** 1998 Nov; 19(11):1608–16 (86 ref.)

Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB, et al. **Eur J Emerg Med** 1998 Dec;5(4):391–402 (40 ref.)

Prehospital thrombolysis in acute myocardial infarction. Stern R, et al. **Eur J Emerg Med** 1998 Dec;5(4):471–9 (66 ref.)

Acute myocardial infarction: failed thrombolysis revisited [see comments] Sutton AG, et al. **Hosp Med** 1998 Oct; 59(10):797–802 (21 ref.) Comment in: Hosp Med 1999 Apr;60(4):309.

Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction. Ferrario M, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S63–71 (55 ref.)

GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction. Salame M, et al. **Int J Cardiol** 1999 Jun 1;69(3):231–6 (22 ref.)

Clinical profile of saruplase: angiographic findings. Meyer J. **Int J Clin Pract Suppl** 1998 Nov;99:9–15 (18 ref.)

What should a new thrombolytic bring us? Verheugt F. **Int J Clin Pract Suppl** 1998 Nov;99:3–5 (6 ref.)

Thrombolytic therapy versus primary angioplasty in the treatment of acute myocardial infarction. McErlean ES. **J Cardiovasc Nurs** 1999 Apr;13(3):46–59 (62 ref.)

Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both? Anthonio RL, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S1–8 (61 ref.)

Overview of the use of glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Joseph A. **J Emerg Med** 1999 May-Jun;17(3):567–73 (30 ref.)

Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. Kaplan AL, et al. **J Emerg Med** 1999 May-Jun;17(3):589–95 (24 ref.)

Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. Hudson MP, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):241–5 (21 ref.)

Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. Simons GR, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2651–63 (74 ref.)

Optimal thrombolytic strategies for acute myocardial infarction--bolus administration. McMechan SR, et al. **QJM** 1998 Nov;91(11):719–25 (24 ref.)

Antiplatelet drugs in secondary prevention after acute myocardial infarction. Thizon-de-Gaulle I. **Rev Port Cardiol** 1998 Dec;17(12):993–7 (12 ref.)

Biochemical markers of thrombolytic success. IFCC Committee on Standardization of Markers of Cardiac Damage. Apple FS. **Scand J Clin Lab Invest Suppl** 1999; 230:60–6 (25 ref.)

What an interventional cardiologist should know about the pharmacological treatment of acute myocardial infarction. Verheugt FW. **Semin Interv Cardiol** 1999 Mar;4(1):17–20 (18 ref.)

[Staphylokinase] Helft G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):582–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Low molecular weight heparin in unstable angina and myocardial infarction without Q wave] Choussat R, et al. **Presse Med** 1999 Jun 12;28(21):1128–34 (51 ref.) (Eng. Abstr.) **(Fre)**

[Secondary prevention of atherosclerosis in routine practice] Christ M, et al. **Internist (Berl)** 1998 Oct;39(10):1080–97 (0 ref.) **(Ger)**

[Statins in secondary prevention of coronary heart disease] Sandhofer F. **Wien Med Wochenschr** 1999;149(5–6):125–8 (8 ref.) (Eng. Abstr.) **(Ger)**

[Pre-infarction angina and post-thrombolysis recanalization] Andreotti F, et al. **Cardiologia** 1998 Sep;43(9):893–9 (67 ref.) **(Ita)**

[Myocardial infarct with ST segment depression: an absolute contraindication to thrombolytic therapy?] Imperadore F, et al. **G Ital Cardiol** 1999 Jun;29(6):705–9 (25 ref.) (Eng. Abstr.) **(Ita)**

[Pharmacological reperfusion in acute myocardial infarct] Lorenzoni R, et al. **G Ital Cardiol** 1998 Dec;28(12):1441–55 (83 ref.) **(Ita)**

[Circulatory diseases and anti-thrombotic therapy] Shimada K. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):507–11 (10 ref.) **(Jpn)**

[Short-term versus long-term use of nitrates in acute myocardial infarction] Nakamura Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2617–22 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Thrombolytic treatment of acute myocardial infarct. 1] Soares-Costa JT, et al. **Acta Med Port** 1998 May; 11(5):409–19 (0 ref.) (Eng. Abstr.) **(Por)**

[Thrombolytic treatment of acute myocardial infarct. 2] Soares-Costa TJ, et al. **Acta Med Port** 1998 May; 11(5):421–9 (0 ref.) (Eng. Abstr.) **(Por)**

[Antioxidants in the comprehensive therapy of myocardial infarction] Simonenko VB. **Klin Med (Mosk)** 1998; 76(11):20–5 (70 ref.) **(Rus)**

ECONOMICS

Comprehensive cardiac rehabilitation: is it cost-effective? Oldridge NB. **Eur Heart J** 1998 Nov;19 Suppl O:O42–50 (34 ref.)

ENZYMOLOGY

Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases. Costerousse O, et al. **Biol Res** 1998;31(3):161–7 (64 ref.)

Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Adgey AA, et al. **Clin Cardiol** 1999 Apr;22(4):257–65 (50 ref.)

EPIDEMIOLOGY

Clinical epidemiology of acute myocardial infarction. Tavazzi L. **Am Heart J** 1999 Aug;138(2 Pt 2):48–54 (46 ref.)

[Alcohol and myocardial infarct. Epidemiological and experimental studies on the effect of alcohol on vascular relaxation and coronary sclerosis (see comments)] Flesch M, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1490–6 (35 ref.) Comment in: Dtsch Med Wochenschr 1999 May 7;124(18):575. **(Ger)**

ETIOLOGY

Natural disaster plus wake-up time: a deadly combination of triggers [editorial; comment] Kloner RA, et al. **Am Heart J** 1999 May;137(5):779–81 (20 ref.) Comment on: Am Heart J 1999 May;137(5):830–6.

Atherosclerotic plaque rupture: emerging insights and opportunities. Plutzky J. **Am J Cardiol** 1999 Jul 8; 84(1A):15J–20J (23 ref.)

Mechanisms of plaque rupture: mechanical and biologic interactions. Arroyo LH, et al. **Cardiovasc Res** 1999 Feb; 41(2):369–75 (56 ref.)

Pathophysiology and clinical significance of atherosclerotic plaque rupture. Gutstein DE, et al. **Cardiovasc Res** 1999 Feb;41(2):323–33 (110 ref.)

Right ventricular infarction complicating right coronary angioplasty. Mikdadi G, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):327–30 (5 ref.)

Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Adgey AA, et al. **Clin Cardiol** 1999 Apr;22(4):257–65 (50 ref.)

Cardiac troponin I and non-Q-wave myocardial infarction: how useful is it after coronary artery bypass surgery? [editorial; comment] Barron JT. **Crit Care Med** 1998 Dec; 26(12):1936–7 (9 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1986–90.

Type 2 diabetic subjects without prior myocardial infarction are at the same risk of coronary events as non-diabetic subjects with prior myocardial infarction [editorial] Pyörälä K, et al. **Eur Heart J** 1999 Apr;20(7):473–5 (16 ref.)

Myocardial infarction and death after caesarean section in a woman with protein S deficiency and undiagnosed phaeochromocytoma. Zangrillo A, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):268–70 (9 ref.)

Activated protein C resistance and myocardial infarction [editorial] Laffan MA. **Heart** 1998 Oct;80(4):319–21 (27 ref.)

Pathophysiology of acute coronary syndromes leading to acute myocardial infarction. Doering LV. **J Cardiovasc Nurs** 1999 Apr;13(3):1–20; quiz 119 (105 ref.)

Idiopathic cystic medial necrosis of the coronary arteries leading to myocardial infarction, old and recent. Clinical pathologic correlation and historical review. Roscher AA, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):87–91 (19 ref.)

The role of systolic blood pressure in determining risk for cardiovascular disease. Levy D. **J Hypertens Suppl** 1999 Feb;17(1):S15–8 (19 ref.)

Cardiovascular risks of hypertension: lessons from observational studies. O'Donnell CJ, et al. **J Hypertens Suppl** 1998 Oct;16(6):S3–7 (21 ref.)

Exercise and cardiovascular events: a double-edged sword? [editorial] Franklin BA. **J Sports Sci** 1999 Jun;17(6):437–42 (26 ref.)

Antiphospholipid antibodies and myocardial infarction. Vaarala O. **Lupus** 1998;7 Suppl 2:S132–4 (20 ref.)

Alcohol intake, lipids and risks of myocardial infarction. Gaziano JM, et al. **Novartis Found Symp** 1998;216:86–95; discussion 95–110 (65 ref.)

Role of inflammation in the pathogenesis of unstable coronary artery diseases. Biasucci LM, et al. **Scand J Clin Lab Invest Suppl** 1999;230:12–22 (64 ref.)

What an interventional cardiologist should know about the pathophysiology of acute myocardial infarction. Kristensen SD, et al. **Semin Interv Cardiol** 1999 Mar;4(1):11–6 (45 ref.)

[Tobacco: an atherogenic, thrombogenic or spasmogenic factor?] Adnot S. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:53–8 (45 ref.) (Eng. Abstr.) **(Fre)**

[New thrombolytic agents in myocardial infarction] Helft G, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92(4):411–7 (34 ref.) (Eng. Abstr.) **(Fre)**

[Clinical case of the month. Inaugural myocardial infarction from a congenital coronary-cardiac fistula] Czajkowski V, et al. **Rev Med Liege** 1999 Jan;54(1):12–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Two cases of coronary artery bypass grafting associated with antiphospholipid syndrome in systemic lupus erythematosus] Jinno T, et al. **Kyobu Geka** 1999 Aug; 52(9):774–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases. Costerousse O, et al. **Biol Res** 1998;31(3):161–7 (64 ref.)

Genetic prediction of myocardial infarction. Cambien F. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S23–4 (18

ref.)

IMMUNOLOGY

Role of inflammation in the pathogenesis of unstable coronary artery diseases. Biasucci LM, et al.
Scand J Clin Lab Invest Suppl 1999;230:12–22 (64 ref.)

METABOLISM

Glucose–insulin–potassium (GIK) for acute myocardial infarction: a negative study with a positive value [editorial; comment] Apstein CS, et al. **Cardiovasc Drugs Ther** 1999 May;13(3):185–9 (38 ref.) Comment on: Cardiovasc Drugs Ther 1999 May;13(3):191–200.

Biochemistry of the infarcted heart. Bing RJ, et al.
Neurochem Res 1999 Sep;24(9):1143–5 (31 ref.)

MICROBIOLOGY

Lack of association of infectious agents with risk of future myocardial infarction and stroke: definitive evidence disproving the infection/coronary artery disease hypothesis? [editorial] Epstein SE, et al. **Circulation** 1999 Sep 28;100(13):1366–8 (14 ref.)

Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes. Schussheim AE, et al. **Drugs** 1999 Mar;57(3):283–91 (52 ref.)

[Chlamydia pneumoniae as a causative agent in atherosclerosis (see comments)] van Deventer SJ.
Ned Tijdschr Geneeskd 1999 Feb 6;143(6):288–90 (29 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Apr 3;143(14):761–2; discussion 763. Comment in: Ned Tijdschr Geneeskd 1999 Apr 3;143(14):762; discussion 763. Comment in: Ned Tijdschr Geneeskd 1999 Apr 3;143(14):762–3. **(Dut)**

[Infection and myocardial infarction--etiology or a coincidence?] Werkö L. **Lakartidningen** 1998 Dec 9; 95(50):5773–4 (6 ref.) **(Swe)**

MORTALITY

Depression and heart disease. Roose SP, et al.
Depress Anxiety 1998;7(4):158–65 (64 ref.)

Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus? The 'dead in bed' syndrome revisited [see comments] Weston PJ, et al.
Diabet Med 1999 Aug;16(8):626–31 (44 ref.) Comment in: Diabet Med 1999 Aug;16(8):623–5.

Antiarrhythmic therapy in the post–infarction setting: update from major amiodarone studies. Cairns JA.
Int J Clin Pract 1998 Sep;52(6):422–4 (28 ref.)

Percutaneous coronary intervention versus thrombolysis: the ongoing debate. Talley JD. **J Ark Med Soc** 1998 Oct; 95(5):191–6 (15 ref.)

Sex differences in survival rates after acute myocardial infarction. Marrugat J, et al. **J Cardiovasc Risk** 1999 Apr; 6(2):89–97 (54 ref.)

Decreasing mortality from acute myocardial infarction: effect of incidence and prognosis. Salomaa V, et al.
J Cardiovasc Risk 1999 Apr;6(2):69–75 (32 ref.)

Effects of cessation of smoking after myocardial infarction. Wilhelmsen L. **J Cardiovasc Risk** 1998 Jun;5(3):173–6 (24 ref.)

[Type 2 diabetes mellitus and coronary heart disease] Brändle M, et al. **Schweiz Med Wochenschr** 1999 May 8; 129(18):700–6 (50 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiology of coronary heart disease] Koenig W.
Z Kardiol 1998;87 Suppl 2:3–7 (23 ref.) (Eng. Abstr.) **(Ger)**

[Significantly reduced coronary mortality--searching for an explanation] Meland E. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3814–8 (44 ref.) **(Nor)**

NURSING

Family-centered care after acute myocardial infarction. Fleury J, et al. **J Cardiovasc Nurs** 1999 Apr;13(3):73–82 (56 ref.)

PATHOLOGY

New insights into cardioprotection by ischemic preconditioning and other forms of stress. de Zeeuw S, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:178–91 (70 ref.)

Cellular mechanisms of infarct size reduction with ischemic preconditioning. Role of calcium? Przyklenk K, et al.
Ann N Y Acad Sci 1999 Jun 30;874:192–210 (100 ref.)

Apoptosis and myocardial infarction. Anversa P, et al.
Basic Res Cardiol 1998;93 Suppl 3:8–12 (23 ref.)

Great expectations from a different approach to the treatment of acute myocardial infarction : cytoprotection. Castagnino HE. **Int J Cardiol** 1999 Apr 30;69(1):15–8 (28 ref.)

Cardiac myofibrillar proteins: biochemical markers to estimate myocardial injury. Haider KH, et al.
Mol Cell Biochem 1999 Apr;194(1–2):31–9 (135 ref.)

[Apoptosis--what is it? Significance in coronary heart disease and myocardial infarct] Holtz J, et al. **Herz** 1999 May; 24(3):196–210 (173 ref.) (Eng. Abstr.) **(Ger)**

[Cell death in inflammatory heart muscle diseases--apoptosis or necrosis?] Pankuweit S, et al. **Herz** 1999 May;24(3):211–8 (31 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Early predictors of left ventricular remodeling after acute myocardial infarction. Bolognese L, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):79–83 (49 ref.)

Old and new paradigms on diastolic function in acute myocardial infarction. Popovic AD. **Am Heart J** 1999 Aug; 138(2 Pt 2):84–8 (32 ref.)

Sexual activity as a trigger for cardiovascular events: what is the risk? Muller JE. **Am J Cardiol** 1999 Sep 9; 84(5B):2N–5N (22 ref.)

Heart rate is a simplistic marker of mortality in acute myocardial infarction. Futterman LG, et al.
Am J Crit Care 1999 May;8(3):197–9 (4 ref.)

Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Sun Y, et al. **Ann Med** 1998 Aug; 30 Suppl 1:3–8 (52 ref.)

Collagen organization in wound healing after myocardial injury. Whittaker P. **Basic Res Cardiol** 1998;93 Suppl 3:23–5 (10 ref.)

Thrombosis and coagulation abnormalities in the acute coronary syndromes. Fischer A, et al. **Cardiol Clin** 1999 May;17(2):283–94, viii (77 ref.)

Endothelial function and myocardial infarction. Bhagat K. **Cardiovasc Res** 1998 Aug;39(2):312–7 (73 ref.)

Early repolarization. Mehta M, et al. **Clin Cardiol** 1999 Feb; 22(2):59–65 (82 ref.)

The importance of the autonomic nervous system for risk stratification of post-myocardial infarction patients. Yap YG, et al. **Coron Artery Dis** 1998;9(6):353–8 (36 ref.)

Clinical effects of ischemic preconditioning. Schwarz ER, et al. **Curr Opin Cardiol** 1999 Jul;14(4):340–8 (98 ref.)

Left ventricular systolic function after acute myocardial infarction: prognostic importance, relation to congestive heart failure and as a target for intervention. Køber L. **Dan Med Bull** 1999 Jun;46(3):235–48 (53 ref.)

Right ventricular involvement in acute myocardial infarction. Burgess MI, et al. **Hosp Med** 1999 Jun;60(6):430–4 (21 ref.)

Clinical relevance of prodromal angina before acute myocardial infarction. Ottani F, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S103–8 (23 ref.)

What an interventional cardiologist should know about the pathophysiology of acute myocardial infarction. Kristensen SD, et al. **Semin Interv Cardiol** 1999 Mar;4(1):11–6 (45 ref.)

Infarct artery patency and survival following myocardial infarction. Hillis LD, et al.
Trans Am Clin Climatol Assoc 1999;110:93–102; discussion 102–4 (18 ref.)

[Analysis and quantification of longitudinal contraction of the left ventricle in myocardial infarction. Value of Doppler myocardial tissue imaging] Jamal F, et al.
Arch Mal Coeur Vaiss 1999 Mar;92(3):315–22 (30 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial viability. Myocardial viability post-infarct: contribution of dobutamine-echography] Monin JL, et al.
Presse Med 1998 Jun 13;27(21):1050–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Pathophysiology of coronary collateral circulation in the human] Wahl A, et al. **Schweiz Med Wochenschr** 1998 Oct 10;128(41):1527–37 (64 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial viability. Concept, physiopathology. Methods and diagnostic value] Aleixo A, et al. **Acta Med Port** 1998 May;11(5):465–71 (22 ref.) (Eng. Abstr.) **(Por)**

[High-resolution electrocardiography in acute myocardial infarct] Tuna JL. **Acta Med Port** 1998 May;11(5):473–82 (44 ref.) (Eng. Abstr.) **(Por)**

[Differences in the clinical presentation and prognosis of unstable angina and non-Q wave infarction] Sambola A, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:55–60 (47 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors. Frishman WH, et al. **Am Heart J** 1999 Apr;137(4 Pt 2):S25–S34 (104 ref.)

Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH. **Am Heart J** 1999 Apr;137(4 Pt 2):S9–S13 (23 ref.)

Statin trials and goals of cholesterol-lowering therapy after AMI. Pedersen TR. **Am Heart J** 1999 Aug;138(2 Pt 2):177–82 (20 ref.)

Strategies to achieve coronary arterial plaque stabilization. Rabbani R, et al. **Cardiovasc Res** 1999 Feb;41(2):402–17 (198 ref.)

Ischemic preconditioning in humans: models, mediators, and clinical relevance. Tomai F, et al. **Circulation** 1999 Aug 3;100(5):559–63 (44 ref.)

The warm-up phenomenon and ischaemic preconditioning: an uncertain relationship [editorial; comment] Cohen MV, et al. **Eur Heart J** 1999 Feb;20(3):167–8 (9 ref.) Comment on: Eur Heart J 1999 Feb;20(3):196–202. Comment on: Eur Heart J 1999 Feb;20(3):203–10.

Diagnosis and management of new cardiovascular risk factors. Cullen P, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O13–9 (44 ref.)

Heat stress response and myocardial protection. Joyeux M, et al. **Fundam Clin Pharmacol** 1999;13(1):1–10 (92 ref.)

Emerging role of ACE inhibitors in prevention of myocardial infarction and unstable angina. Krishnamoorthy KM.
Indian Heart J 1999 Mar–Apr;51(2):218–22 (33 ref.)

Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success [see comments] Chalmers J. **J Hypertens** 1998 Oct;16(10):1403–5 (16 ref.) Comment in: J Hypertens 1998 Oct;16(10):1401–2.

Oral anticoagulants are effective long-term after acute myocardial infarction. Smith P. **J Intern Med** 1999 Apr; 245(4):383–7 (19 ref.)

n-3 fatty acids and coronary heart disease--the urgent need of clinical trials. Schmidt EB, et al. **Lipids** 1999;34 Suppl:S303–5 (27 ref.)

Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? Patrono C.
Thromb Res 1998 Sep 15;92(1 Suppl 1):S7–12 (40 ref.)

[Predictive factors of smoking cessation after myocardial infarction. Review of the literature (see comments)] Aboyans V, et al. **Ann Cardiol Angeiol (Paris)** 1998 Mar; 47(3):177–82 (37 ref.) (Eng. Abstr.) Comment in: Ann Cardiol Angeiol (Paris) 1998 Mar;47(3):183–4. **(Fre)**

[Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct (editorial)] Di Pasquale G, et al. **Recenti Prog Med** 1998 Oct;89(10):514–9 (26 ref.) (Eng. Abstr.) **(Ita)**

[Secondary prevention of acute coronary syndrome] Motomiya T. **J Cardiol** 1999 Mar;33 Suppl 1:39–43 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Secondary prevention of myocardial infarct] Santos AL.
Acta Med Port 1998 May;11(5):483–91 (56 ref.) (Eng. Abstr.) **(Por)**

[Anticholesteremic statins reduce myocardial infarction. Milestone studies give a straight answer--at least concerning the males] Carlson LA. **Lakartidningen** 1999 Apr 7;96(14):1725–8 (16 ref.) **(Swe)**

[Excellence of the "Mediterranean diet" is a myth. There is no evidence that monounsaturated fats prevent myocardial infarction] Ravnskov U. **Lakartidningen** 1998 Oct 21; 95(43):4749–50 (16 ref.) **(Swe)**

[Further studies are required: in spite of positive effects of statins many patients still develop myocardial infarction] Werkö L. **Lakartidningen** 1998 Dec 2;95(49):5654–5 (8 ref.) **(Swe)**

PSYCHOLOGY

Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors [editorial] Nair GV, et al.
Am J Cardiol 1999 Aug 1;84(3):321–3, A8 (30 ref.)

Acute myocardial infarction and posttraumatic stress disorder: the consequences of cumulative adversity. Alonzo AA. **J Cardiovasc Nurs** 1999 Apr;13(3):33–45 (73 ref.)

Influence of psychosocial factors and biopsychosocial interventions on outcomes after myocardial infarction. Buselli EF, et al. **J Cardiovasc Nurs** 1999 Apr;13(3):60–72 (55 ref.)

Psychological factors in illness and recovery [see comments] Clarke DM. **N Z Med J** 1998 Oct 23;111(1076):410–2 (53 ref.) Comment in: N Z Med J 1999 Feb 26;112(1082):58–9.

RADIOGRAPHY

Acquired coronary cameral fistulas: are these collaterals losing their destination? Said SA, et al. **Clin Cardiol** 1999 Apr;22(4):297–302 (33 ref.)

Coronary angiography and revascularization following acute myocardial infarction [editorial; comment] Diver DJ, et al. **Eur Heart J** 1998 Sep;19(9):1274–6 (4 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1348–54.

A paradigm shift for acute myocardial infarction: from coronary patency to myocardial reperfusion. Steg PG, et al. **Eur Heart J** 1998 Sep;19(9):1282–6 (48 ref.)

RADIONUCLIDE IMAGING

Cardiac BMIPP imaging in acute myocardial infarction. Nakata T, et al. **Int J Card Imaging** 1999 Feb;15(1):21–6 (24 ref.)

The current role of infarct avid imaging. Khaw BA.
Semin Nucl Med 1999 Jul;29(3):259–70 (59 ref.)

REHABILITATION

Cardiac rehabilitation: the forgotten intervention. King KM, et al. **Can J Cardiol** 1999 Sep;15(9):979–85 (56 ref.) **(Eng, Fre)**

Optimal timing of rehabilitation after cardiac surgery: the surgeon's view. Carrel T, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O38–41 (23 ref.)

Optimal timing of phase II rehabilitation after cardiac surgery. The cardiologist's view. Dubach P, et al.
Eur Heart J 1998 Nov;19 Suppl O:O35–7 (24 ref.)

Cardiac rehabilitation: where are we going? Gohlke H, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O5–12 (122 ref.)

Cardiac rehabilitation. Gohlke H, et al. **Eur Heart J** 1998 Jul;19(7):1004–10 (120 ref.)

Interventional cardiology in perspective: impact on cardiac rehabilitation. Maier W, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O24–8 (20 ref.)

Comprehensive cardiac rehabilitation: is it cost-effective? Oldridge NB. **Eur Heart J** 1998 Nov;19 Suppl O:O42–50 (34 ref.)

Family-centered care after acute myocardial infarction. Fleury J, et al. **J Cardiovasc Nurs** 1999 Apr;13(3):73–82 (56 ref.)

[Postoperative patient management. Perioperative myocardial infarct] Fellahi JL, et al. **Presse Med** 1999 Jan 30;28(4):187–94 (51 ref.) (Eng. Abstr.) **(Fre)**

[Group therapy for heart patients--an assessment of current status] Heitkamp HC. **Herz** 1999 May;24(3):242–9 (40 ref.) **(Ger)**

SURGERY

Stents in acute myocardial infarction. Overlie PA. **Curr Opin Cardiol** 1998 Jul;13(4):280–8 (67 ref.)

Optimal timing of rehabilitation after cardiac surgery: the surgeon's view. Carrel T, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O38–41 (23 ref.)

Coronary angiography and revascularization following acute myocardial infarction [editorial; comment] Diver DJ, et al. **Eur Heart J** 1998 Sep;19(9):1274–6 (4 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1348–54.

Optimal timing of phase II rehabilitation after cardiac surgery. The cardiologist's view. Dubach P, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O35–7 (24 ref.)

[Arterial myocardial revascularization in the 9th decade of life. Personal results and review of the literature] Mortasawi A, et al. **Herz** 1999 Apr;24(2):158–70 (130 ref.) (Eng. Abstr.) **(Ger)**

[The surgical treatment of acute myocardial infarct in the 90s] de Oliveira JM. **Rev Port Cardiol** 1998 Dec; 17(12):967–73 (29 ref.) (Eng. Abstr.) **(Por)**

THERAPY

Microvascular integrity after reperfusion therapy. Agati L. **Am Heart J** 1999 Aug;138(2 Pt 2):76–8 (25 ref.)

Current role of stenting in acute myocardial infarction. Antoniucci D, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):147–52 (34 ref.)

Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Colombo A, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):153–7 (37 ref.)

Optimal management of acute myocardial infarction at the dawn of the next millennium. Gersh BJ. **Am Heart J** 1999 Aug;138(2 Pt 2):188–202 (101 ref.)

Infarct size: thrombolysis versus PTCA [editorial; comment] Keeley EC, et al. **Am Heart J** 1999 Jun;137(6):1007–9 (25 ref.) Comment on: Am Heart J 1999 Jun;137(6):1169–72.

Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry. L'Abbate A. **Am Heart J** 1999 Aug;138(2 Pt 2):89–95 (46 ref.)

Gene therapy for myocardial angiogenesis. Losordo DW, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):132–41 (41 ref.)

Coronary stent implantation in acute myocardial infarction. Mehta RH, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):603–11 (78 ref.)

Do new devices add to the results of PTCA in acute myocardial infarction? Moses J, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):158–63 (39 ref.)

Primary PTCA versus thrombolytic therapy: an evidence-based summary. Ryan TJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):96–104 (37 ref.)

Optimal treatment of patients with acute coronary syndromes and non-ST-elevation myocardial infarction. White HD. **Am Heart J** 1999 Aug;138(2 Pt 2):105–14 (52 ref.)

Current issues in reperfusion therapy. Gersh BJ. **Am J Cardiol** 1998 Oct 22;82(8B):3P–11P (77 ref.)

Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Manginas A, et al. **Am J Cardiol** 1999 Jun 1;83(11):1562–5, A7 (20 ref.)

Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)

Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Gibson CM. **Ann Intern Med** 1999 May 18;130(10):841–7 (33 ref.)

Pregnancy in women with diabetes and ischaemic heart disease. Bagg W, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):99–102 (22 ref.)

Occurrence of a saccular pseudoaneurysm formation two weeks after perforation of the left anterior descending coronary artery during balloon angioplasty in acute myocardial infarction. Schöbel WA, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):341–6 (98 ref.)

Reperfusion revisited: beyond TIMI 3 flow. Gassler JP, et al. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV20–9 (80 ref.)

Is coronary revascularization the optimum strategy for patients with non-Q wave myocardial infarction? A point-counterpoint. Gersh BJ, et al. **Clin Cardiol** 1998 Dec; 21(12 Suppl 2):II18–22 (17 ref.)

Time to treatment of acute myocardial infarction revisited. Cannon CP. **Curr Opin Cardiol** 1998 Jul;13(4):254–66 (112 ref.)

Rescue percutaneous transluminal coronary angioplasty. Flachskampf FA, et al. **Curr Opin Cardiol** 1998 Jul; 13(4):289–93 (32 ref.)

Thrombolysis versus primary angioplasty in older patients with acute myocardial infarction. Maynard C, et al. **Drugs Aging** 1999 Jun;14(6):427–35 (33 ref.)

Interventional cardiology in perspective: impact on cardiac rehabilitation. Maier W, et al. **Eur Heart J** 1998 Nov;19 Suppl O:O24–8 (20 ref.)

A paradigm shift for acute myocardial infarction: from coronary patency to myocardial reperfusion. Steg PG, et al. **Eur Heart J** 1998 Sep;19(9):1282–6 (48 ref.)

Acute myocardial infarction: thrombolysis, angioplasty or stenting. Ebersole DG, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:40–4 (25 ref.)

Role of PTCA and mechanical devices in cardiogenic shock. Shawl FA. **Indian Heart J** 1998 Oct;50 Suppl 1:57–61 (50 ref.)

Great expectations from a different approach to the treatment of acute myocardial infarction : cytoprotection. Castagnino HE. **Int J Cardiol** 1999 Apr 30;69(1):15–8 (28 ref.)

Update on mechanical revascularization in acute myocardial infarction: which role and when? Vassanelli C, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S11–4 (36 ref.)

Relationship between late infarct artery patency and outcome in the reperfusion era: is there a role for percutaneous revascularisation? White HD. **Int J Cardiol** 1999 Apr 10; 68 Suppl 1:S15–22 (42 ref.)

Guidelines for surgical standby for coronary angioplasty: should they be changed? [editorial; comment] Angelini P. **J Am Coll Cardiol** 1999 Apr;33(5):1266–8 (13 ref.) Comment on: J Am Coll Cardiol 1999 Apr;33(5):1257–65.

Management of older persons after myocardial infarction. Aronow WS. **J Am Geriatr Soc** 1998 Nov;46(11):1459–68 (105 ref.)

Therapy for acute myocardial infarction in older persons. Rich MW. **J Am Geriatr Soc** 1998 Oct;46(10):1302–7 (45 ref.)

Percutaneous coronary intervention versus thrombolysis: the ongoing debate. Talley JD. **J Ark Med Soc** 1998 Oct; 95(5):191–6 (15 ref.)

A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators [see comments] Naccarelli GV, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):864–91 (156 ref.) Comment in: J Cardiovasc Electrophysiol 1999 Mar;10(3):420–1.

Thrombolytic therapy versus primary angioplasty in the treatment of acute myocardial infarction. McErlean ES. **J Cardiovasc Nurs** 1999 Apr;13(3):46–59 (62 ref.)

Patient delay in seeking treatment for acute myocardial infarction symptoms. Zerwic JJ. **J Cardiovasc Nurs** 1999 Apr;13(3):21–32 (60 ref.)

Differences in the treatment of acute myocardial infarction between regions of countries and the impact on prognosis. Luepker RV, et al. **J Cardiovasc Risk** 1999 Apr;6(2):77–87 (83 ref.)

Primary stenting in acute myocardial infarction: paving the way to arterial patency [editorial; comment] Meredith IT. **Med J Aust** 1999 Jun 7;170(11):518–9 (19 ref.) Comment on: Med J Aust 1999 Jun 7;170(11):537–40.

The acute coronary syndromes: myocardial infarction and unstable angina. Thompson PL, et al. **Med J Aust** 1999 Aug 2;171(3):153–9 (34 ref.)

'Rescue' after failed thrombolysis for acute myocardial infarction [see comments] Mahy IR, et al. **Postgrad Med J** 1998 Jun;74(872):355–7 (20 ref.) Comment in: Postgrad Med J 1998 Nov;74(877):702–3.

Coronary intervention in acute myocardial infarction. al-Zaibag M. **Rev Port Cardiol** 1999 Feb;18 Suppl 1:I61–70 (78 ref.)

Primary mechanical reperfusion in acute myocardial infarction: the United States experience. Dangas G, et al. **Semin Interv Cardiol** 1999 Mar;4(1):21–33 (61 ref.)

The history of angioplasty therapy for acute myocardial infarction: buried alive but still kicking? Meier B. **Semin Interv Cardiol** 1999 Mar;4(1):3–10 (41 ref.)

Stenting in acute myocardial infarction. Morice MC, et al. **Semin Interv Cardiol** 1998 Jun;3(2):77–80 (7 ref.)

Experiences with primary angioplasty without on site-cardiac surgery. Ribichini F. **Semin Interv Cardiol** 1999 Mar;4(1):47–53 (50 ref.)

The emerging role of stenting for acute myocardial infarction. Suryapranata H. **Semin Interv Cardiol** 1999 Mar; 4(1):35–41 (42 ref.)

The use of platelet glycoprotein IIb/IIIa receptor antagonists during the acute phase of myocardial infarction. van den Brand M, et al. **Semin Interv Cardiol** 1999 Jun;4(2):85–8 (28 ref.)

Primary angioplasty for acute myocardial infarction: the Zwolle approach. Zijlstra F, et al. **Semin Interv Cardiol** 1999 Mar;4(1):55–8 (20 ref.)

Infarct artery patency and survival following myocardial infarction. Hillis LD, et al. **Trans Am Clin Climatol Assoc** 1999;110:93–102; discussion 102–4 (18 ref.)

[Pre-hospitalization management of evolving myocardial infarction. 2d conference of south-eastern region emergency medicine experts] Bonnet JL, et al. **Ann Fr Anesth Reanim** 1997;16(5):541–8 (34 ref.) **(Fre)**

[Fatal ventricular rupture after stent implantation in acute myocardial infarct with subsequent stent thrombosis: discussion of reperfusion injury as the cause] Schröter V, et al. **Z Kardiol** 1999 Jun;88(6):454–8 (14 ref.) (Eng. Abstr.) **(Ger)**

[Recurrent ventricular fibrillation in acute myocardial infarct treated successfully by coronary angioplasty: a clinical case in favor of the hypothesis of the arrhythmogenicity of the coronary thrombus?] Trabattoni D, et al. **Cardiologia** 1998 Oct;43(10):1095–9 (19 ref.) (Eng. Abstr.) **(Ita)**

[Thrombolytic treatment of acute myocardial infarct. 3] Gabriel HM, et al. **Acta Med Port** 1998 May;11(5):431–8 (0 ref.) **(Por)**

[Coronary angioplasty in the acute phase of myocardial infarct] Gabriel HM, et al. **Acta Med Port** 1998 May; 11(5):439–45 (61 ref.) (Eng. Abstr.) **(Por)**

[Treatment acute myocardial infarct in the pre-hospital phase] Mesquita A, et al. **Acta Med Port** 1998 May; 11(5):493–6 (17 ref.) (Eng. Abstr.) **(Por)**

[Acute myocardial infarct (editorial)] Soares-Costa JT. **Acta Med Port** 1998 May;11(5):403–7 (29 ref.) **(Por)**

[Therapy with glucose-insulin-potassium reduces the complications in the acute phase of myocardial infarct. Arguments in favor] Alegria Ezquerra E, et al. **Rev Esp Cardiol** 1998 Sep;51(9):720–6 (64 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Use of stress echocardiography for risk assessment of patients after myocardial infarction. Franklin KB, et al. **Cardiol Clin** 1999 Aug;17(3):521–38, ix (68 ref.)

Is tissue Doppler echocardiography ready for clinical application? [editorial; comment] Zamorano J. **Eur Heart J** 1999 Apr;20(8):558–60 (8 ref.) Comment on: Eur Heart J 1999 Apr;20(8):593–603.

[Applications of contrast echocardiography in the acute phase of myocardial infarction] Brochet E, et al. **Arch Mal Coeur Vaiss** 1999 Jul;92(7):909–14 (25 ref.) (Eng. Abstr.) **(Fre)**

[Asynchrony of ventricular contraction and relaxation--pathophysiologically recognized phenomenon, now can be clinically assessed] Bruch C, et al. **Herz** 1998 Dec;23(8):506–15 (47 ref.) (Eng. Abstr.) **(Ger)**

[The role of echocardiography in the first hours of a suspected or certain acute myocardial infarct] Butera A. **Cardiologia** 1999 Jan;44(1):19–24 (60 ref.) **(Ita)**

[Stress echocardiography in myocardial infarct] Mota P. **Acta Med Port** 1998 May;11(5):455–64 (48 ref.) (Eng. Abstr.) **(Por)**

MYOCARDIAL ISCHEMIA

see related
ISCHEMIC PRECONDITIONING, MYOCARDIAL
MYOCARDIAL INFARCTION
MYOCARDIAL REPERFUSION
MYOCARDIAL REVASCULARIZATION
MYOCARDIAL STUNNING

Effect of a single bolus of intracoronary basic fibroblast growth factor on perfusion in an ischemic porcine model. Devlin GP, et al. **Can J Cardiol** 1999 Jun;15(6):676–82 (27 ref.)

Animal models in the study of myocardial ischaemia and ischaemic syndromes. Verdouw PD, et al. **Cardiovasc Res** 1998 Jul;39(1):121–35 (191 ref.)

If ischemic preconditioning is the gold standard, has a platinum standard of cardioprotection arrived? Comparison with NHE inhibition. Gumina RJ, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):39–44 (37 ref.)

The challenge of acute coronary syndromes. Simoons ML, et al. **Lancet** 1999 Jun;353 Suppl 2:SII1–4 (34 ref.)

[Medicolegal aspects and molecular pathology of ischemic heart disease] Yoshida K. **Nippon Hoigaku Zasshi** 1998 Oct; 52(5):311–4 (21 ref.) **(Jpn)**

[Ischemic heart disease] Doi Y. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):817–20 (13 ref.) **(Jpn)**

BLOOD

Plasma gamma'/gamma fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Drouet L, et al. **Blood Coagul Fibrinolysis** 1999 Feb; 10 Suppl 1:S35–9 (30 ref.)

Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM). Wu AH. **Scand J Clin Lab Invest Suppl** 1999;230:74–82 (44 ref.)

[Fibrinolysis in ischemic cardiopathy: the role of plasminogen activator inhibitor 1] Cesari M, et al. **Cardiologia** 1999 Jan; 44(1):25–32 (89 ref.) **(Ita)**

CHEMICALLY INDUCED

Vinorelbine-related acute cardiopulmonary toxicity. Karminsky N, et al. **Cancer Chemother Pharmacol** 1999; 43(2):180–2 (11 ref.)

Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? Dahlöf CG, et al. **Cephalalgia** 1998 Oct; 18(8):539–45 (73 ref.)

CLASSIFICATION

[New strategies for the classification and treatment of acute ischemic coronary syndromes. A proposal] Jerjes-Sanchez Diaz C, et al. **Arch Inst Cardiol Mex** 1999 Mar-Apr; 69(2):163–75 (112 ref.) **(Spa)**

COMPLICATIONS

Modulation of the adaptive response to myocardial ischemia by coexisting disease [editorial] Kersten JR, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2268–70 (38 ref.)

Reversible biventricular dysfunction secondary to ischemia in a patient with acute airway obstruction: a case report

and review of the literature on reversible causes of acute ventricular dysfunction. Lee C, et al. **Can J Cardiol** 1999 Jun;15(6):705–8 (23 ref.)

Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia–induced ventricular fibrillation. Curtis MJ. **Cardiovasc Res** 1998 Jul; 39(1):194–215 (104 ref.)

Treating depression in patients with ischaemic heart disease: which agents are best to use and to avoid? Roose SP, et al. **Drug Saf** 1999 May;20(5):459–65 (25 ref.)

New perspectives on heart failure due to myocardial ischaemia. Fox KF, et al. **Eur Heart J** 1999 Feb; 20(4):256–62 (65 ref.)

Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. Cleland JG, et al. **J Cardiovasc Pharmacol** 1999 Jun;33 Suppl 3:S17–29 (95 ref.)

Anterior ischemic optic neuropathy: trouble waiting to happen [editorial; comment] Feldon SE. **Ophthalmology** 1999 Apr;106(4):651–2 (19 ref.) Comment on: Ophthalmology 1999 Apr;106(4):739–42.

[Progressive sensorineural hearing loss: metabolic, hormonal and vascular etiology] Ravecca F, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):42–50 (99 ref.) (Eng. Abstr.) **(Ita)**

[The clinical importance of myocardial vitality in chronic, postischemic left ventricular dysfunction] Agati L, et al. **Cardiologia** 1998 Jun;43 Suppl 1:95–8 (20 ref.) **(Ita)**

DIAGNOSIS

Postexercise systolic blood pressure response: clinical application to the assessment of ischemic heart disease. Taylor AJ, et al. **Am Fam Physician** 1998 Oct 1; 58(5):1126–30 (11 ref.)

Cardiac biomarkers: past, present, and future [see comments] Adams JE 3rd, et al. **Am J Crit Care** 1998 Nov;7(6):418–23; quiz 424–5 (11 ref.) Comment in: Am J Crit Care 1999 May;8(3):204.

Assessment for subclinical ischemia: bridging the gap between primary and secondary prevention. Brown BG. **Am J Med** 1999 Aug 23;107(2A):28S–30S (14 ref.)

Choosing the appropriate stress modality. A clinical cardiologist's perspective. Crawford MH. **Cardiol Clin** 1999 Aug;17(3):597–606, x (28 ref.)

Diagnosis and prognosis of silent ischemia. Krone RJ. **Cardiologia** 1998 Nov;43(11):1159–68 (65 ref.)

Rest–injected 201thallium in the evaluation of myocardial viability. Perrone–Filardi P, et al. **Cardiologia** 1999 Jun; 44(6):515–20 (31 ref.)

Impact of troponins on the evaluation and treatment of patients with acute coronary syndromes. Adams J 3rd. **Curr Opin Cardiol** 1999 Jul;14(4):310–3 (18 ref.)

Noninvasive coronary artery imaging in the diagnosis and management of patients with ischemic heart disease. Kates AM, et al. **Curr Opin Cardiol** 1999 Jul;14(4):314–20 (43 ref.)

Chest pain emergency units. Lewis WR, et al. **Curr Opin Cardiol** 1999 Jul;14(4):321–8 (48 ref.)

Transient left posterior hemiblock during myocardial ischemia–eliciting exercise treadmill testing: a report of a case and a critical analysis of the literature. Madias JE, et al. **J Electrocardiol** 1999 Jan;32(1):57–64 (41 ref.)

Acute coronary syndromes: diagnosis. Klootwijk P, et al. **Lancet** 1999 Jun;353 Suppl 2:SII10–5 (53 ref.)

Myocardial viability. Stillman AE, et al. **Radiol Clin North Am** 1999 Mar;37(2):361–78, vi (123 ref.)

Magnetic resonance spectroscopy of ischemic heart disease. Sardanelli F, et al. **Rays** 1999 Jan–Mar;24(1):149–64 (38 ref.) **(Eng, Ita)**

[Value of laboratory parameters in risk assessment of patients with coronary heart disease and chronic myocardial ischemia] Frey N, et al. **Z Kardiol** 1998;87 Suppl 2:100–5 (61 ref.) (Eng. Abstr.) **(Ger)**

[Relevance and methods for determining coronary flow reserve] Kelm M, et al. **Z Kardiol** 1998;87 Suppl 2:74–9 (28 ref.) (Eng. Abstr.) **(Ger)**

[Position of internal medicine in the preoperative evaluation of circulatory functions] Fujii T. **Masui** 1998 Dec;47 Suppl:S142–8 (12 ref.) **(Jpn)**

[Evaluation criteria in anesthesiology—with special reference to ischemic heart disease] Ishihara S. **Masui** 1998 Dec;47 Suppl:S149–54 (19 ref.) **(Jpn)**

[Troponin as myocardial cell injury marker] de Godoy MF, et al. **Arq Bras Cardiol** 1998 Oct;71(4):629–33 (30 ref.) **(Por)**

[Invasive diagnosis, transcatheter and surgical treatment of acute coronary syndromes] Fabián J, et al. **Bratisl Lek Listy** 1998 Mar–Apr;99(3–4):181–6 (39 ref.) (Eng. Abstr.) **(Slo)**

[Prognostic significance of biochemical markers in acute coronary syndromes] Pecháň I. **Bratisl Lek Listy** 1998 Mar–Apr;99(3–4):149–56 (95 ref.) (Eng. Abstr.) **(Slo)**

DRUG THERAPY

The future of antithrombotic and antiplatelet therapy for ischemic heart disease. Topol EJ. **Am Heart J** 1998 Oct; 136(4 Pt 2 Su):S66–8 (12 ref.)

Implications of the Organization to Assess Strategies for Ischemic Syndromes–2 (OASIS–2) study and the results in the context of other trials. Fox KA. **Am J Cardiol** 1999 Sep 2;84(5A):26M–31M (18 ref.)

The effects of angiotensin–converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. Pepine CJ. **Am J Cardiol** 1998 Nov 19; 82(10A):23S–27S (43 ref.)

A chronotherapeutic approach to the management of high–risk patients with hypertension/ischemic heart disease: introduction. Black HR. **Am J Hypertens** 1999 Feb; 12(2 Pt 2):33S–34S (6 ref.)

Individualizing beta–adrenergic blocker therapy: patient–specific target–based heart rate control [editorial; comment] Tuman KJ, et al. **Anesth Analg** 1999 Mar; 88(3):475–6 (10 ref.) Comment on: Anesth Analg 1999 Mar;88(3):477–82.

AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **Basic Res Cardiol** 1998;93 Suppl 2:85–91 (58 ref.)

Calcium channel blockers in myocardial and cerebral ischemia: a clinician's review from bench to bedside. Borger MA, et al. **Can J Cardiol** 1999 Mar;15(3):333–40 (59 ref.)

Treatment of chronic myocardial ischemia: rationale and treatment options. Cohn PF. **Cardiovasc Drugs Ther** 1998 Oct;12 Suppl 3:217–23 (37 ref.)

Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Bates SM, et al. **Cardiovasc Res** 1999 Feb;41(2):418–32 (127 ref.)

Potential cardiovascular applications of glutamate, aspartate, and other amino acids. Arsenian M. **Clin Cardiol** 1998 Sep; 21(9):620–4 (44 ref.)

Abciximab. An updated review of its use in ischaemic heart disease [published erratum appears in Drugs 1999 Jan;57(1):91] Foster RH, et al. **Drugs** 1998 Oct;56(4):629–65 (163 ref.)

Effect of ACE inhibition on myocardial ischaemia. Ferrari R. **Eur Heart J** 1998 Sep;19 Suppl J:J30–5 (40 ref.)

Rationale for ACE inhibition as an anti–ischaemic therapy. Pepine CJ. **Eur Heart J** 1998 Jul;19 Suppl G:G34–40 (50 ref.)

Sustained–release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use. Silvestry FE, et al. **Eur Heart J** 1998 Aug; 19 Suppl I:I8–14 (54 ref.)

Anti–ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials [published erratum appears in Eur Heart J 1998 Nov;19(11):1742] Yusuf S, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J36–44 (44 ref.)

Antithrombotic therapy in coronary ischaemia: the expanding role of low–molecular–weight heparin. Turpie AG. **Haemostasis** 1998;28 Suppl 3:35–42 (24 ref.)

Interventional therapy is the best approach for acute coronary syndromes. King SB 3rd. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S73–8 (27 ref.)

AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S129–36 (66 ref.)

Treatment of non–ST–segment–elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. Roe MT, et al. **J Emerg Med** 1999 May–Jun;17(3):581–8 (49 ref.)

Acute coronary syndromes: drug treatments. Verheugt FW. **Lancet** 1999 Jun;353 Suppl 2:SII20–3 (36 ref.)

Low dose warfarin and aspirin in preventing IHD. Meade T. **Practitioner** 1998 Nov;242(1592):799–803 (5 ref.)

Fibroblast growth factor–mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Gonçalves LM. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II11–20 (103 ref.)

Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Neumann FJ, et al. **Semin Interv Cardiol** 1998 Jun;3(2):81–90 (96 ref.)

Metabolic intervention for the ischemic and post–ischemic heart. Svedjeholm R, et al. **Wien Klin Wochenschr** 1999 Jul 9;111(13):501–11 (99 ref.)

[Glucose–insulin–potassium (GIK) in the reduction of acute myocardial ischemia after an aortocoronary bypass intervention] Dainese L, et al. **G Ital Cardiol** 1999 May; 29(5):575–9; discussion 580–2 (46 ref.) **(Ita)**

[Circulatory diseases and anti–thrombotic therapy] Shimada K. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):507–11 (10 ref.) **(Jpn)**

[Views on the use of calcium channel blockers in the treatment of heart ischemia and hypertension (editorial)] Halawa B. **Pol Merkuriusz Lek** 1998 Sep;5(27):107–10 (36 ref.) (Eng. Abstr.) **(Pol)**

[Glycoprotein (GP) IIb/IIIa platelet inhibitors in acute ischemic syndrome and percutaneous coronary intervention] Caramori PR, et al. **Arq Bras Cardiol** 1998 Nov;71(5):725–34 (114 ref.) **(Por)**

[Suppression of angiotensin–converting enzyme and myocardial ischemia] Eliseev OM. **Ter Arkh** 1999; 71(3):73–6 (3 ref.) **(Rus)**

[Experimental approaches to determining molecular mechanisms of antiarrhythmic and cardioprotective actions of new compounds] Dukhanin AS, et al. **Vestn Ross Akad Med Nauk** 1999;(3):7–15 (43 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Cardiac biomarkers: past, present, and future [see comments] Adams JE 3rd, et al. **Am J Crit Care** 1998 Nov;7(6):418–23; quiz 424–5 (11 ref.) Comment in: Am J Crit Care 1999 May;8(3):204.

Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Simkhovich BZ, et al. **Cardiovasc Res** 1998 Oct;40(1):9–22 (115 ref.)

Effect of ACE inhibition on myocardial ischaemia. Ferrari R. **Eur Heart J** 1998 Sep;19 Suppl J:J30–5 (40 ref.)

Effect of ACE inhibition on neurohormones. Remme WJ. **Eur Heart J** 1998 Sep;19 Suppl J:J16–23 (38 ref.)

EPIDEMIOLOGY

[Incidence and ranking of perioperative myocardial ischemias] Priebe HJ. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Mar; 34(3):177–81 (16 ref.) **(Ger)**

ETIOLOGY

Left ventricular hypertrophy as a risk factor in hypertension. Balogun MO, et al. **Afr J Med Med Sci** 1996 Sep; 25(3):277–83 (67 ref.)

Iron, atherosclerosis, and ischemic heart disease. de Valk B, et al. **Arch Intern Med** 1999 Jul 26;159(14):1542–8 (121 ref.)

Myocardial ischaemia in anaemic patients. Wahr JA. **Br J Anaesth** 1998 Dec;81 Suppl 1:10–5 (31 ref.)

Myocardial ischemia and infarction postthoracotomy. Herrington CS, et al. **Chest Surg Clin N Am** 1998 Aug; 8(3):495–502, vii (24 ref.)

Acute ischemic syndromes following coronary artery bypass graft surgery. Hirsch WS, et al. **Clin Cardiol** 1998 Sep; 21(9):625–32 (50 ref.)

Survival from ventricular fibrillation [editorial; comment] Dembo DH. **Crit Care Med** 1999 Aug;27(8):1671–2 (13 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1542–50.

Modulation of leukocyte–endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Grisham MB, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):404–33 (208 ref.)

Environmental tobacco smoke and ischaemic heart disease: a case study in applying causal criteria. Mengersen KL, et al. **Int Arch Occup Environ Health** 1999 May;72 Suppl:R1–40 (156 ref.)

Helicobacter pylori infection and ischaemic heart disease. Cammarota G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S304–6 (12 ref.)

Ischemic injury and its prevention. Riedel BJ. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):20–7; discussion 41–4 (73 ref.)

Ischaemic heart disease after renal transplantation: how to assess and minimize the risk [editorial] Wheeler DC. **Nephrol Dial Transplant** 1999 May;14(5):1075–7 (10 ref.)

Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Zhou J, et al. **Scand J Clin Lab Invest Suppl** 1999;230:3–11 (61 ref.)

[Major nutrition–related risk factors of ischemic heart disease: dyslipoproteinemia, obesity, hypertension, glucose intolerance] Pados G. **Orv Hetil** 1999 Jul 11; 140(28):1563–72 (50 ref.) (Eng. Abstr.) **(Hun)**

[Evaluation of ischemic risk in infarct patients submitted for fibronolysis: how and when should it be carried out?] Romano S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:89–93 (28 ref.) **(Ita)**

[The prevention and treatment for restenosis in coronary angioplasty] Degawa T, et al. **Nippon Rinsho** 1998 Oct; 56(10):2640–4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Postmenopausal arterial hypertension and cardiovascular risk] Artigao R. **Rev Esp Cardiol** 1998;51 Suppl 4:36–43 (37 ref.) (Eng. Abstr.) **(Spa)**

[The single coronary artery arising from the sinus of Valsalva. A rare cause of myocardial ischemia] Gómez–Aldaraví Gutiérrez R, et al. **Rev Esp Cardiol** 1998 Oct;51(10):847–9 (8 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genetic susceptibility and ischaemic stroke. Elbaz A, et al. **Curr Opin Neurol** 1999 Feb;12(1):47–55 (89 ref.)

The regulation of gene expression in myocardial ischemia. Schaper W. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:277–80; discussion 281 (21 ref.)

IMMUNOLOGY

Heat shock proteins and protection against ischemic injury. Dillmann WH. **Infect Dis Obstet Gynecol** 1999;7(1–2):55–7 (11 ref.)

METABOLISM

Fatty acid oxidation in the reperfused ischemic heart. Kantor PF, et al. **Am J Med Sci** 1999 Jul;318(1):3–14 (100 ref.)

Iron, atherosclerosis, and ischemic heart disease. de Valk B, et al. **Arch Intern Med** 1999 Jul 26;159(14):1542–8 (121 ref.)

The nitric oxide hypothesis of late preconditioning [editorial; see comments] Bolli R, et al. **Basic Res Cardiol** 1998 Oct; 93(5):325–38 (45 ref.) Comment in: Basic Res Cardiol 1998 Oct;93(5):422.

Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Wu AH, et al. **Clin Chim Acta** 1999 Jun 30;284(2):161–74 (36 ref.)

Features of short–term myocardial hibernation. Heusch G, et al. **Mol Cell Biochem** 1998 Sep;186(1–2):185–93 (45 ref.)

Metabolic disarrangement in ischemic heart disease and its therapeutic control. Ferrari R. **Rev Port Cardiol** 1998 Sep;

17(9):667–84 (69 ref.)
Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes. Moreno AJ, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II63–77 (100 ref.)
Metabolic intervention for the ischemic and post-ischemic heart. Svedjeholm R, et al. **Wien Klin Wochenschr** 1999 Jul 9;111(13):501–11 (99 ref.)
[Phagocyte-dependent free oxygen radical mechanisms of autoaggression in pathogenesis of internal diseases] Kogan AKh. **Vestn Ross Akad Med Nauk** 1999;(2):3–10 (47 ref.) **(Rus)**

MICROBIOLOGY

[Microorganisms in vascular pathology and myocardial ischemia] López-Sendón J, et al. **Rev Clin Esp** 1998 Sep; 198 Suppl 1:40–3 (22 ref.) **(Spa)**

MORTALITY

The Oxford Vegetarian Study: an overview. Appleby PN, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):525S–531S (21 ref.)
Relationship between socioeconomic status and ischaemic heart disease in cohort and case-control studies: 1960–1993. González MA, et al. **Int J Epidemiol** 1998 Jun;27(3):350–8 (90 ref.)
Hormone replacement therapy and ischaemic heart disease among postmenopausal women. Kardos A, et al. **J Cardiovasc Risk** 1999 Apr;6(2):105–12 (91 ref.)
[Risk assessment in coronary heart disease: ventricular arrhythmias, myocardial ischemia and sudden cardiac death] Meinertz T, et al. **Z Kardiol** 1998;87 Suppl 2:106–15 (85 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Coronary atherosclerosis: is the process focal or diffuse among patients with symptomatic or fatal myocardial ischemia? Roberts WC. **Am J Cardiol** 1998 Nov 26; 82(10B):41T–44T (16 ref.)
Cardiac cell volume: crystal clear or murky waters? A comparison with other cell types. Wright AR, et al. **Pharmacol Ther** 1998 Oct;80(1):89–121 (276 ref.)
Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Zhou J, et al. **Scand J Clin Lab Invest Suppl** 1999;230:3–11 (61 ref.)
[Advances in the technologies for pathologic diagnosis of early phase myocardial ischemia] Li F, et al. **Fa I Hsueh Tsa Chih** 1997;13(2):104–7 (35 ref.) **(Chi)**

PHYSIOPATHOLOGY

Postexercise systolic blood pressure response: clinical application to the assessment of ischemic heart disease. Taylor AJ, et al. **Am Fam Physician** 1998 Oct 1; 58(5):1126–30 (11 ref.)
Modulation of the adaptive response to myocardial ischemia by coexisting disease [editorial] Kersten JR, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2268–70 (38 ref.)
Myocardial adaptation to exercise training: a view through positron emission tomography. Voipio-Pulkki LM. **Ann Med** 1998 Aug;30 Suppl 1:54–60 (53 ref.)
Small heat shock proteins and protection against injury. Dillmann WH. **Ann N Y Acad Sci** 1999 Jun 30;874:66–8 (10 ref.)
Apoptosis in myocardial ischemia-reperfusion. Gottlieb RA, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:412–26 (56 ref.)
The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Karmazyn M. **Ann N Y Acad Sci** 1999 Jun 30;874:326–34 (33 ref.)
Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Vinten-Johansen J, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:354–70 (64 ref.)
Pharmacologic enhancement of tolerance to ischemic cardiac stress using monophosphoryl lipid A. A comparison with antecedent ischemia. Zhao L, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:222–35 (65 ref.)
The relationship between regional blood flow and contractile function in normal, ischemic, and reperfused myocardium. Schulz R, et al. **Basic Res Cardiol** 1998 Dec;93(6):455–62 (77 ref.)
Autonomic control of heart rate: pharmacological and nonpharmacological modulation. Vanoli E, et al. **Basic Res Cardiol** 1998;93 Suppl 1:133–42 (54 ref.)
Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Dhalla NS, et al. **Can J Cardiol** 1999 May;15(5):587–93 (64 ref.)
Diastolic function and dysfunction with exercise, hypertrophy, ischemia, and heart failure. Apstein CS, et al. **Cardiologia** 1998 Dec;43(12):1269–79 (81 ref.)
Myocardial ischaemia and the cardiac nervous system. Armour JA. **Cardiovasc Res** 1999 Jan;41(1):41–54 (119 ref.)
Pathophysiology and clinical management of right heart ischemia. Goldstein JA. **Curr Opin Cardiol** 1999 Jul; 14(4):329–39 (38 ref.)
Effects of acute ischaemia on intramyocardial contraction heterogeneity; new ultrasound technologies to study an old phenomenon. Colonna P, et al. **Eur Heart J** 1999 Mar; 20(5):327–37 (71 ref.)
Myocardial protection for cardiac surgery: classical views and new trends. Amrani M, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):39–53 (90 ref.)
The platelet in acute coronary syndromes: defining the pivotal role of platelet glycoprotein IIb/IIIa receptor blockade. Jesse RL. **J Emerg Med** 1999 May-Jun; 17(3):575–80 (24 ref.)
Modulation of the myocardial response to ischemia. Buja LM. **Lab Invest** 1998 Nov;78(11):1345–73 (352 ref.)
Acute coronary syndromes: biology. Fuster V, et al. **Lancet** 1999 Jun;353 Suppl 2:SII5–9 (40 ref.)
Hibernating myocardium: its pathophysiology and clinical role. Ferrari R, et al. **Mol Cell Biochem** 1998 Sep; 186(1-2):195–9 (16 ref.)
Features of short-term myocardial hibernation. Heusch G, et al. **Mol Cell Biochem** 1998 Sep;186(1-2):185–93 (45 ref.)
Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Carmeliet E. **Physiol Rev** 1999 Jul; 79(3):917–1017 (1193 ref.)
Physical and geometrical modeling for image-based recovery of left ventricular deformation. Duncan J, et al. **Prog Biophys Mol Biol** 1998;69(2-3):333–51 (50 ref.)
The regulation of gene expression in myocardial ischemia. Schaper W. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:277–80; discussion 281 (21 ref.)
[From the angiogenic response to ischemia to the validation of the concept of "therapeutic angiogenesis"] Van Belle E, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91(9):1159–70 (70 ref.) (Eng. Abstr.) **(Fre)**
[Metabolic aspects of myocardial ischemia] Deussen A, et al. **Z Kardiol** 1998;87 Suppl 2:37–40 (19 ref.) (Eng. Abstr.) **(Ger)**
[Transition of myocardial ischemia to heart failure] Ertl G, et al. **Z Kardiol** 1998 Sep;87(9):667–75 (36 ref.) (Eng. Abstr.) **(Ger)**
[Short-term hibernating myocardium: circulation, function and metabolism in sustained regional myocardial ischemia] Heusch G, et al. **Z Kardiol** 1998;87 Suppl 2:41–8 (44 ref.) (Eng. Abstr.) **(Ger)**
[Cardiac sympathetic nerve activity in ischemic heart failure] Richardt G, et al. **Z Kardiol** 1998;87 Suppl 2:33–6 (14 ref.) (Eng. Abstr.) **(Ger)**
[Myocardial ischemia and ventricular arrhythmia] Vester EG. **Z Kardiol** 1998;87 Suppl 2:49–60 (51 ref.) (Eng. Abstr.) **(Ger)**
[Myocardial ischemia in exertion: correlation of the Holter and ergometric test] Caruso D, et al. **Cardiologia** 1998 Jun; 43 Suppl 1:33–43 (30 ref.) **(Ita)**
[Silent myocardial ischemia: clinical relevance in hypertensive patients] Stramba-Badiale M. **Cardiologia** 1998 Jun;43 Suppl 1:29–31 (27 ref.) **(Ita)**

PREVENTION & CONTROL

Nut consumption, vegetarian diets, ischemic heart disease risk, and all-cause mortality: evidence from epidemiologic studies. Sabaté J. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):500S–503S (30 ref.)
Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. Bischoff H, et al. **Atherosclerosis** 1998 Sep;139 Suppl 1:S7–13 (22 ref.)
Monitoring platelet GPIIb/IIIa antagonist therapy. Coller BS. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S81–6 (40 ref.)
Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement [see comments] Pringle M. **BMJ** 1998 Oct 24;317(7166):1120–3; discussion 1124 (31 ref.) Comment in: BMJ 1998 Oct 24;317(7166):1093–4.
Treatment of stable angina. Thadani U. **Curr Opin Cardiol** 1999 Jul;14(4):349–58 (116 ref.)
Effect of ACE inhibition on neurohormones. Remme WJ. **Eur Heart J** 1998 Sep;19 Suppl J:J16–23 (38 ref.)
Myocardial protection for cardiac surgery: classical views and new trends. Amrani M, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):39–53 (90 ref.)
Heat stress proteins and myocardial protection: experimental model or potential clinical tool? Gray CC, et al. **Int J Biochem Cell Biol** 1999 May;31(5):559–73 (95 ref.)
Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. Levitsky J, et al. **J Clin Pharmacol** 1998 Oct;38(10):887–97 (74 ref.)
Cardiac production of angiotensin II and its pharmacologic inhibition: effects on the coronary circulation. Schmermund A, et al. **Mayo Clin Proc** 1999 May;74(5):503–13 (99 ref.)
[Secondary prevention of coronary disease in France. Result of the EUROASPIRE study: the Lille register of ischemic cardiopathies] Montaye M, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1211–20 (30 ref.) (Eng. Abstr.) **(Fre)**
[Hypolipemic treatment in prevention of secondary ischemic heart disease] Nessler J. **Przegl Lek** 1998;55(5):259–65 (40 ref.) (Eng. Abstr.) **(Pol)**
[Influence of coronary risk factors in secondary prevention: tobacco] López García-Aranda V, et al. **Rev Esp Cardiol** 1998;51 Suppl 6:10–7 (59 ref.) (Eng. Abstr.) **(Spa)**
[Regular physical activity reduces the risk of cardiovascular disease. Overweight is increasing--we have to exercise!] Henriksson J. **Lakartidningen** 1998 Dec 16; 95(51-52):5894–6 (20 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

[Psychological factors and heart diseases (see comments)] Hula J, et al. **Cas Lek Cesk** 1998 Nov 2;137(21):643–6 (21 ref.) (Eng. Abstr.) Comment in: Cas Lek Cesk 1999 Mar 1;138(5):156. **(Cze)**

RADIONUCLIDE IMAGING

Myocardial adaptation to exercise training: a view through positron emission tomography. Voipio-Pulkki LM. **Ann Med** 1998 Aug;30 Suppl 1:54–60 (53 ref.)
Trends in myocardial perfusion single-photon emission technique. Hesse B. **Clin Physiol** 1999 May;19(3):204–10 (23 ref.)
Nuclear cardiology in clinical practice. Appleby MA, et al. **Hosp Med** 1999 Mar;60(3):183–6 (14 ref.)
Acute myocardial perfusion imaging for the technologist. Mann A, et al. **J Nucl Cardiol** 1998 Nov-Dec;5(6):622–5 (16 ref.)
Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera. Sandler MP, et al. **J Nucl Med** 1998 Dec;39(12):2035–43 (71 ref.)
[Nuclear cardiology in ischemic heart disease] Høilund-Carlsen PF, et al. **Ugeskr Laeger** 1999 Apr 26; 161(17):2510–4 (10 ref.) **(Dan)**
[Diagnosis of myocardial viability in chronic myocardial ischemia with nuclear medicine techniques] vom Dahl J, et al. **Z Kardiol** 1998;87 Suppl 2:92–9 (61 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Predicting improved function after myocardial revascularization. Di Carli MF. **Curr Opin Cardiol** 1998 Nov;13(6):415–24 (60 ref.)
Improvement of myocardial ischemia by subclavian stent implantation in patients with internal mammary grafts: a case report and review of the literature. Patti G, et al. **G Ital Cardiol** 1999 Apr;29(4):431–4 (13 ref.)
Techniques in conduit harvesting. Levine AJ, et al. **Hosp Med** 1999 Mar;60(3):178–82 (19 ref.)
Current status of percutaneous transmyocardial revascularisation. Bhargava B, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:130–7 (41 ref.)
Transmyocardial laser revascularization and angiogenesis: the potential for therapeutic benefit. Lee LY, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):29–35 (86 ref.)
[Ischemic cardiomyopathy--transplantation and bridging with mechanical assist systems] Feindt P, et al. **Z Kardiol** 1998;87 Suppl 2:181–7 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Heparin-mediated extracorporeal LDL/fibrinogen precipitation--H.E.L.P.--in coronary and cerebral ischemia. Jaeger BR, et al. **Acta Neurochir Suppl (Wien)** 1999;73:81–4 (28 ref.)
Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry. L'Abbate A. **Am Heart J** 1999 Aug;138(2 Pt 2):89–95 (46 ref.)
Fatty acid oxidation in the reperfused ischemic heart. Kantor PF, et al. **Am J Med Sci** 1999 Jul;318(1):3–14 (100 ref.)
Therapeutic angiogenesis [see comments] Henry TD. **BMJ** 1999 Jun 5;318(7197):1536–9 (19 ref.) Comment in: BMJ 1999 Jun 5;318(7197):1500–1.
Cardiac management in the ICU. Ramsay JG. **Chest** 1999 May;115(5 Suppl):138S–144S (36 ref.)
Why we should attempt to eliminate (silent and symptomatic) ischemia in patients with chronic stable angina. Conti CR. **Clin Cardiol** 1998 Dec;21(12 Suppl 2):II8–11 (33 ref.)
Pathophysiology and clinical management of right heart ischemia. Goldstein JA. **Curr Opin Cardiol** 1999 Jul; 14(4):329–39 (38 ref.)
The care of patients with ischaemic heart disease from a gender perspective. Swahn E. **Eur Heart J** 1998 Dec; 19(12):1758–65 (80 ref.)
Myocardial hypothermia: a potential therapeutic technique for acute regional myocardial ischemia. Hale SL, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):405–13 (29 ref.)
Ischemic and nonischemic heart failure do not require different treatment strategies. Abraham WT, et al. **J Cardiovasc Pharmacol** 1999 Jun;33 Suppl 3:S1–7 (58 ref.)
Acute coronary syndromes: interventions. Verheugt FW. **Lancet** 1999 Jun;353 Suppl 2:SII16–9 (25 ref.)
Combination TMR and gene therapy. Sayeed-Shah U, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):36–9 (34 ref.)
Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Baumgartner I, et al. **Vasa** 1998 Nov;27(4):201–6 (76 ref.)
[Significance of silent myocardial ischemia for identification and optimal therapy of patients with latent coronary heart disease. Is there a marker for prognostic indication for PTCA?] Hering D, et al. **Herz** 1999 Feb;24(1):72–84 (70 ref.) (Eng. Abstr.) **(Ger)**
[Angiogenic gene therapy for ischemic heart disease] Ueno H. **Nippon Rinsho** 1998 Oct;56(10):2645–52 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Recent progress in the treatment of ischemic heart disease in the elderly] Doi Y. **Nippon Ronen Igakkai Zasshi** 1998 Sep;35(9):647–53 (52 ref.) **(Jpn)**
[The treatment of ischemic heart disease in patients with

chronic kidney failure] Diadyk AI, et al. **Lik Sprava** 1998 Jun;(4):42–5 (25 ref.) **(Rus)**

[The role of hyperbaric medicine in the treatment of cerebral and myocardial ischemic disease] Krgović M, et al. **Vojnosanit Pregl** 1998 Sep–Oct;55(5):523–8 (40 ref.) **(Scc)**

[Invasive diagnosis, transcatheter and surgical treatment of acute coronary syndromes] Fabián J, et al. **Bratisl Lek Listy** 1998 Mar–Apr;99(3–4):181–6 (39 ref.) (Eng. Abstr.) **(Slo)**

[New strategies for the classification and treatment of acute ischemic coronary syndromes. A proposal] Jerjes-Sanchez Díaz C, et al. **Arch Inst Cardiol Mex** 1999 Mar–Apr; 69(2):163–75 (112 ref.) **(Spa)**

ULTRASONOGRAPHY

Clinical applications of transpulmonary contrast echocardiography. Main ML, et al. **Am Heart J** 1999 Jan; 137(1):144–53 (61 ref.)

Three-dimensional echocardiography in ischemic heart disease. De Castro S, et al. **Coron Artery Dis** 1998; 9(7):427–34 (35 ref.)

[Contribution of ischemia tests in stress echocardiography] Habis M. **Ann Cardiol Angeiol (Paris)** 1998 May; 47(5):343–50 (81 ref.) (Eng. Abstr.) **(Fre)**

[Asynchrony of ventricular contraction and relaxation--pathophysiologically recognized phenomenon, now can be clinically assessed] Bruch C, et al. **Herz** 1998 Dec;23(8):506–15 (47 ref.) (Eng. Abstr.) **(Ger)**

[Chronic myocardial ischemia: indications and limits of dobutamine stress echocardiography] Kühl HP, et al. **Z Kardiol** 1998;87 Suppl 2:87–91 (25 ref.) (Eng. Abstr.) **(Ger)**

[Echocardiographic diagnosis of circulatory diseases] Kitabatake A. **Nippon Naika Gakkai Zasshi** 1999 Mar 10; 88(3):512–6 (10 ref.) **(Jpn)**

VIROLOGY

[Microorganisms in vascular pathology and myocardial ischemia] López-Sendón J, et al. **Rev Clin Esp** 1998 Sep; 198 Suppl 1:40–3 (22 ref.) **(Spa)**

MYOCARDIAL MITOCHONDRIA see **MITOCHONDRIA, HEART**

MYOCARDIAL PRECONDITIONING see **ISCHEMIC PRECONDITIONING, MYOCARDIAL**

MYOCARDIAL PREINFARCTION SYNDROME see **ANGINA, UNSTABLE**

MYOCARDIAL REMODELING, VENTRICULAR see **VENTRICULAR REMODELING**

MYOCARDIAL REPERFUSION

see related
ISCHEMIC PRECONDITIONING, MYOCARDIAL
MYOCARDIAL STUNNING

Microvascular integrity after reperfusion therapy. Agati L. **Am Heart J** 1999 Aug;138(2 Pt 2):76–8 (25 ref.)

Fatty acid oxidation in the reperfused ischemic heart. Kantor PF, et al. **Am J Med Sci** 1999 Jul;318(1):3–14 (100 ref.)

The relationship between regional blood flow and contractile function in normal, ischemic, and reperfused myocardium. Schulz R, et al. **Basic Res Cardiol** 1998 Dec;93(6):455–62 (77 ref.)

Is coronary revascularization the optimum strategy for patients with non-Q wave myocardial infarction? A point-counterpoint. Gersh BJ, et al. **Clin Cardiol** 1998 Dec; 21(12 Suppl 2):II18–22 (17 ref.)

Creatine kinase isoforms and myoglobin: early detection of myocardial infarction and reperfusion. Apple FS. **Coron Artery Dis** 1999;10(2):75–9 (32 ref.)

Time to treatment of acute myocardial infarction revisited. Cannon CP. **Curr Opin Cardiol** 1998 Jul;13(4):254–66 (112 ref.)

Long-term arterial patency after coronary reperfusion. Branzi A, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S29–33 (34 ref.)

Critical importance of myocardial salvage: relationship with the choice of reperfusion strategies. Coccolini S, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S79–83 (37 ref.)

Relationship between late infarct artery patency and outcome in the reperfusion era: is there a role for percutaneous revascularisation? White HD. **Int J Cardiol** 1999 Apr 10; 68 Suppl 1:S15–22 (42 ref.)

Therapy for acute myocardial infarction in older persons. Rich MW. **J Am Geriatr Soc** 1998 Oct;46(10):1302–7 (45 ref.)

Clinical experience with blood cardioplegia. Schlensak C, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:282–5; discussion 286–7 (28 ref.)

Infarct artery patency and survival following myocardial infarction. Hillis LD, et al. **Trans Am Clin Climatol Assoc** 1999;110:93–102; discussion 102–4 (18 ref.)

ECONOMICS

Cost-effectiveness of reperfusion strategies. Parmley WW. **Am Heart J** 1999 Aug;138(2 Pt 2):142–52 (17 ref.)

METHODS

Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry. L'Abbate A. **Am Heart J** 1999 Aug;138(2 Pt 2):89–95 (46 ref.)

Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction. Santoro GM, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):126–31 (47 ref.)

Current issues in reperfusion therapy. Gersh BJ. **Am J Cardiol** 1998 Oct 22;82(8B):3P–11P (77 ref.)

Effect of a single bolus of intracoronary basic fibroblast growth factor on perfusion in an ischemic porcine model. Devlin GP, et al. **Can J Cardiol** 1999 Jun;15(6):676–82 (27 ref.)

Cardiogenic shock: a failure in reperfusion. Time for a strategic change? [editorial; comment] Serruys PW, et al. **Eur Heart J** 1999 Jan;20(2):88–9 (10 ref.) Comment on: Eur Heart J 1999 Jan;20(2):128–35.

A paradigm shift for acute myocardial infarction: from coronary patency to myocardial reperfusion. Steg PG, et al. **Eur Heart J** 1998 Sep;19(9):1282–6 (48 ref.)

Overview of the use of glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Joseph A. **J Emerg Med** 1999 May–Jun;17(3):567–73 (30 ref.)

Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. Kaplan AL, et al. **J Emerg Med** 1999 May–Jun;17(3):589–95 (24 ref.)

Primary mechanical reperfusion in acute myocardial infarction: the United States experience. Dangas G, et al. **Semin Interv Cardiol** 1999 Mar;4(1):21–33 (61 ref.)

Experiences with primary angioplasty without on site-cardiac surgery. Ribichini F. **Semin Interv Cardiol** 1999 Mar;4(1):47–53 (50 ref.)

Primary angioplasty for acute myocardial infarction: the Zwolle approach. Zijlstra F, et al. **Semin Interv Cardiol** 1999 Mar;4(1):55–8 (20 ref.)

[Pharmacological reperfusion in acute myocardial infarct] Lorenzoni R, et al. **G Ital Cardiol** 1998 Dec;28(12):1441–55 (83 ref.) **(Ita)**

MYOCARDIAL REPERFUSION INJURY

see related
MYOCARDIAL STUNNING

[Myocardial reperfusion injury. Its impact on clinical practice. II.] de la Peña Almaguer E, et al. **Arch Inst Cardiol Mex** 1998 Nov–Dec;68(6):526–38 (160 ref.) **(Spa)**

COMPLICATIONS

[Reperfusion arrhythmias] Jurkovičová O, et al. **Bratisl Lek Listy** 1998 Mar–Apr;99(3–4):162–71 (89 ref.) (Eng. Abstr.) **(Slo)**

DIAGNOSIS

[The significance of endothelial adhesion molecules in heart surgery] Zünd G, et al. **Swiss Surg** 1998;Suppl 2:31–4 (33 ref.) (Eng. Abstr.) **(Ger)**

[Fatal ventricular rupture after stent implantation in acute myocardial infarct with subsequent stent thrombosis: discussion of reperfusion injury as the cause] Schröter V, et al. **Z Kardiol** 1999 Jun;88(6):454–8 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Avkiran M. **Am J Cardiol** 1999 May 20;83(10A):10G–17G; discussion 17G–18G (64 ref.)

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Buerke M, et al. **Am J Cardiol** 1999 May 20; 83(10A):19G–22G (35 ref.)

Protection of the myocardial cell during ischemia. Théroux P. **Am J Cardiol** 1999 May 20;83(10A):3G–9G (29 ref.)

AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **Basic Res Cardiol** 1998;93 Suppl 2:85–91 (58 ref.)

AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S129–36 (66 ref.)

ENZYMOLOGY

Protein kinase C in normal and pathologic myocardial states. Cain BS, et al. **J Surg Res** 1999 Feb;81(2):249–59 (166 ref.)

ETIOLOGY

Reperfusion injury: experimental evidence and clinical implications. Ambrosio G, et al. **Am Heart J** 1999 Aug; 138(2 Pt 2):69–75 (50 ref.)

[The role of nitric oxide in ischemia-reperfused heart] Nishida M, et al. **Nippon Rinsho** 1998 Oct;56(10):2515–20 (21 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Cardiac fatty acid metabolism and the induction of apoptosis. Sparagna GC, et al. **Am J Med Sci** 1999 Jul;318(1):15–21 (98 ref.)

The role of alcohol in the oxidant antioxidant balance in heart. McDonough KH. **Front Biosci** 1999 Jul 15;4:D601–6 (49 ref.)

Iron-mediated cardiovascular injury. Horwitz LD, et al. **Vasc Med** 1999;4(2):93–9 (68 ref.)

Myocardial angiotensin II receptor expression and ischemia-reperfusion injury. Yang B, et al. **Vasc Med** 1998; 3(2):121–30 (69 ref.)

PHYSIOPATHOLOGY

Apoptosis in myocardial ischemia-reperfusion. Gottlieb RA, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:412–26 (56 ref.)

The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Karmazyn M. **Ann N Y Acad Sci** 1999 Jun 30;874:326–34 (33 ref.)

Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Vinten-Johansen J, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:354–70 (64 ref.)

Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion. Cain BS, et al. **J Mol Cell Cardiol** 1999 May; 31(5):931–47 (142 ref.)

Control of microvascular resistance in physiological conditions and reperfusion. DeFily DV. **J Mol Cell Cardiol** 1998 Dec;30(12):2547–54 (56 ref.)

Role of the sodium-hydrogen exchanger in ischemia-reperfusion injury in diabetes. Goel DP, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):45–52 (94 ref.)

Role of sarcoplasmic reticulum in the contractile dysfunction during myocardial ischaemia and reperfusion. Kaplán P, et al. **Physiol Res** 1997;46(5):333–9 (59 ref.)

[Progresses in the study of physiopathology in China, 1997] Wu Y. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):936–8 (0 ref.) **(Chi)**

[Myocardial reperfusion injury: its clinical impact. I.] Férez Santander SM, et al. **Arch Inst Cardiol Mex** 1998 Sep–Oct; 68(5):431–7 (53 ref.) **(Spa)**

PREVENTION & CONTROL

Protective effects of anaesthetics in reversible and irreversible ischaemia-reperfusion injury. Ross S, et al. **Br J Anaesth** 1999 Apr;82(4):622–32 (98 ref.)

The end of the cold era: from intermittent cold to intermittent warm blood cardioplegia. Caputo M, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):467–75 (60 ref.)

It is time to ask what adenosine can do for cardioprotection. Kitakaze M, et al. **Heart Vessels** 1998;13(5):211–28 (129 ref.)

Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. Levitsky J, et al. **J Clin Pharmacol** 1998 Oct;38(10):887–97 (74 ref.)

Mechanisms of protection of the ischemic and reperfused myocardium by sodium-hydrogen exchange inhibition. Karmazyn M. **J Thromb Thrombolysis** 1999 Jul;8(1):33–8 (38 ref.)

Protection of the myocardium with sodium-hydrogen exchange inhibitors: A cardiac surgical perspective. Myers ML. **J Thromb Thrombolysis** 1999 Jul;8(1):53–60 (49 ref.)

MYOCARDIAL REVASCULARIZATION

Current status of transmyocardial laser revascularization: review of the literature. Abramov D, et al. **Can J Cardiol** 1999 Mar;15(3):303–10 (39 ref.)

Impact of residual plaque burden on clinical outcomes of coronary interventions [see comments] Honda Y, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):265–76 (56 ref.) Comment in: Catheter Cardiovasc Interv 1999 Mar;46(3):277–81.

Frontiers in interventional cardiology. Topol EJ, et al. **Circulation** 1998 Oct 27;98(17):1802–20 (198 ref.)

Advances in the medical management of acute coronary syndromes. Cannon CP. **Curr Opin Cardiol** 1998 Sep; 13(5):327–47 (157 ref.)

Predicting improved function after myocardial revascularization. Di Carli MF. **Curr Opin Cardiol** 1998 Nov;13(6):415–24 (60 ref.)

Myocardial revascularization without cardiopulmonary bypass [editorial] Calafiore AM, et al. **G Ital Cardiol** 1999 Jun;29(6):616–9 (7 ref.) **(Eng, Ita)**

Improvement of myocardial ischemia by subclavian stent implantation in patients with internal mammary grafts: a case report and review of the literature. Patti G, et al. **G Ital Cardiol** 1999 Apr;29(4):431–4 (13 ref.)

Myocardial hibernation and stunning: from physiological principles to clinical practice. Redwood SR, et al. **Heart** 1998 Sep;80(3):218–22 (47 ref.)

Relationship between late infarct artery patency and outcome in the reperfusion era: is there a role for percutaneous revascularisation? White HD. **Int J Cardiol** 1999 Apr 10; 68 Suppl 1:S15–22 (42 ref.)

[Coronary revascularization in the diabetic] Steg PG, et al. **Diabetes Metab** 1999 Jun;25 Suppl 3:53–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Arterial myocardial revascularization in the 9th decade of life. Personal results and review of the literature] Mortasawi A, et al. **Herz** 1999 Apr;24(2):158–70 (130 ref.) (Eng. Abstr.) **(Ger)**

MYOCARDIAL REVASCULARIZATION

[The recovery of vital contractile myocardium in coronary revascularization surgical intervention] Gallina S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:99–102 (29 ref.) **(Ita)**

[Transmyocardial laser revascularization] Tominaga R. **Fukuoka Igaku Zasshi** 1998 Dec;89(12):329–32 (7 ref.) **(Jpn)**

[Early percutaneous revascularization in patients with unstable angina. Current results and comparison with conservative medical treatment] Bethencourt A, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:117–30 (123 ref.) (Eng. Abstr.) **(Spa)**

[The role cardiac surgery in the myocardial revascularization of patients with unstable angina in the era of interventional cardiology] Pomar JL. **Rev Esp Cardiol** 1999;52 Suppl 1:141–7 (30 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Adgey AA, et al. **Clin Cardiol** 1999 Apr;22(4):257–65 (50 ref.)

INSTRUMENTATION

Coronary stent implantation in acute myocardial infarction. Mehta RH, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):603–11 (78 ref.)

Stenting in Europe, what lessons can we learn? Development of a stent classification system based on a survey of European clinical experiences [editorial] [see comments] Jost CM. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):217–32 (19 ref.) Comment in: Cathet Cardiovasc Diagn 1998 Nov;45(3):233–4.

METHODS

Transmyocardial laser revascularization. Horvath KA. **Adv Card Surg** 1998;10:141–54 (30 ref.)

Transmyocardial laser revascularization: experimental and clinical results. Hughes GC, et al. **Can J Cardiol** 1999 Jul; 15(7):797–806 (95 ref.)

Percutaneous transmyocardial laser revascularization: an overview [see comments] Kornowski R, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):354–9 (48 ref.) Comment in: Catheter Cardiovasc Interv 1999 Jul;47(3):360.

Carotid before coronary stenting: the way forward? [editorial; comment] Sigwart U. **Eur Heart J** 1998 Sep; 19(9):1278–9 (7 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1365–70.

Current status of percutaneous transmyocardial revascularisation. Bhargava B, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:130–7 (41 ref.)

Left anterior descending coronary ostial stenosis: balloon angioplasty, atherectomy, stenting, device synergy or bypass surgery. Gambhir DS, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:18–26 (81 ref.)

Exploring the scientific basis of surgery: transmyocardial revascularization. Korkola S, et al. **J Formos Med Assoc** 1999 May;98(5):301–8 (56 ref.)

Transmyocardial and percutaneous myocardial revascularization: current and future role in the treatment of coronary artery disease. Kantor B, et al. **Mayo Clin Proc** 1999 Jun;74(6):585–92 (79 ref.)

Management of coronary artery disease including transmyocardial laser revascularization. Gupta S, et al. **Md Med J** 1998 Nov;47(5):241–6 (17 ref.)

Transmyocardial laser revascularization and angiogenesis: the potential for therapeutic benefit. Lee LY, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):29–35 (86 ref.)

Combination TMR and gene therapy. Sayeed-Shah U, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):36–9 (34 ref.)

Surgical myocardial revascularization. Jones JW, et al. **Surg Clin North Am** 1998 Oct;78(5):705–27 (165 ref.)

[Transmyocardial laser revascularization] Lutter G, et al. **Zentralbl Chir** 1999;124(3):171–5 (50 ref.) (Eng. Abstr.) **(Ger)**

[Use of an internal mammary artery graft in the revascularization of the myocardium. A ten-year follow up study] Lukács L, et al. **Orv Hetil** 1998 Oct 11; 139(41):2427–32 (39 ref.) (Eng. Abstr.) **(Hun)**

[Noninvasive reperfusion tests: myth or reality?] Mazzoni V, et al. **G Ital Cardiol** 1999 May;29(5):562–4; discussion 565–7 (21 ref.) **(Ita)**

TRENDS

Coronary artery surgery: the end of the beginning. Loop FD. **Eur J Cardiothorac Surg** 1998 Dec;14(6):554–71 (132 ref.)

UTILIZATION

Coronary angiography and revascularization following acute myocardial infarction [editorial; comment] Diver DJ, et al. **Eur Heart J** 1998 Sep;19(9):1274–6 (4 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1348–54.

MYOCARDIAL STIMULANTS see **CARDIOTONIC AGENTS**

MYOCARDIAL STUNNING

[Reversible dysfunction of myocardial contraction] Mates M, et al. **Vnitr Lek** 1998 Oct;44(10):598–605 (47 ref.) (Eng. Abstr.) **(Cze)**

[Myocardial stunning and myocardial hibernation: an update for anesthesiologists] Piriou V, et al. **Can J Anaesth** 1998 Oct;45(10):997–1010 (70 ref.) **(Fre)**

[Defense mechanism of the myocardium] Miura M, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1588–94 (16 ref.) **(Jpn)**

COMPLICATIONS

Reversible congestive heart failure caused by myocardial hibernation. Wilson JM. **Tex Heart Inst J** 1999;26(1):19–27 (58 ref.)

DIAGNOSIS

Methods of assessment and clinical relevance of myocardial hibernation and stunning. Assessment of myocardial viability. Baer FM, et al. **Thorac Cardiovasc Surg** 1998 Sep; 46 Suppl 2:264–9 (41 ref.)

[Myocardial viability. Myocardial viability post-infarct: contribution of dobutamine-echography] Monin JL, et al. **Presse Med** 1998 Jun 13;27(21):1050–7 (42 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

The role of neurohormonal antagonists in hibernating myocardium. Lahiri A, et al. **J Cardiovasc Pharmacol** 1999 Jun;33 Suppl 3:S9–16 (72 ref.)

ETIOLOGY

[Myocardial stunning in the context of a subarachnoid hemorrhage] Delgado C, et al. **Rev Esp Cardiol** 1998 Oct; 51(10):840–3 (8 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Molecular and cellular mechanisms of myocardial stunning. Bolli R, et al. **Physiol Rev** 1999 Apr;79(2):609–34 (168 ref.)

PHYSIOPATHOLOGY

Ischemic preconditioning, myocardial stunning, and hibernation: basic aspects. Ferrari R, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):61–8 (65 ref.)

Resting myocardial flow in hibernating myocardium: validating animal models of human pathophysiology. Canty JM Jr, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H417–22 (48 ref.)

Concept and evaluation of hibernating myocardium. Rahimtoola SH. **Annu Rev Med** 1999;50:75–86 (33 ref.)

Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Dhalla NS, et al. **Can J Cardiol** 1999 May;15(5):587–93 (64 ref.)

Troponin I, stunning, hypertrophy, and failure of the heart [editorial; comment] Solaro RJ. **Circ Res** 1999 Jan 8–22; 84(1):122–4 (19 ref.) Comment on: Circ Res 1999 Jan 8–22;84(1):1–8. Comment on: Circ Res 1999 Jan 8–22;84(1):9–20.

Blood flow in myocardial hibernation. Camici PG, et al. **Curr Opin Cardiol** 1998 Nov;13(6):409–14 (29 ref.)

Myocardial hibernation and stunning: from physiological principles to clinical practice. Redwood SR, et al. **Heart** 1998 Sep;80(3):218–22 (47 ref.)

Contractile reserve and coronary blood flow reserve in collateral-dependent myocardium [editorial; comment] Bonow RO. **J Am Coll Cardiol** 1999 Mar;33(3):705–7 (17 ref.) Comment on: J Am Coll Cardiol 1999 Mar;33(3):697–704.

Hibernating myocardium. Heusch G. **Physiol Rev** 1998 Oct; 78(4):1055–85 (222 ref.)

Pathophysiology of hibernation, stunning, and ischemic preconditioning. Dörge H, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:255–62; discussion 263 (57 ref.)

[The basis of chronic ischemic reversible left ventricular dysfunction (hibernating myocardium)] Mates M, et al. **Cesk Fysiol** 1999 Feb;48(1):4–8 (33 ref.) (Eng. Abstr.) **(Cze)**

[Myocardial viability. The concept of myocardial viability] Cachin JC. **Presse Med** 1998 Jun 13;27(21):1038–42 (30 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial viability. Study of viability by myocardial scintigraphy] Pézard P, et al. **Presse Med** 1998 Jun 13; 27(21):1043–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Short-term hibernating myocardium: circulation, function and metabolism in sustained regional myocardial ischemia] Heusch G, et al. **Z Kardiol** 1998;87 Suppl 2:41–8 (44 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? [editorial; comment] Sias TM, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):206–9 (26 ref.) Comment on: Am Heart J 1999 Aug;138(2 Pt 1):369–75.

Nuclear cardiology, Part IV: Viability. Mesotten L, et al. **J Nucl Med Technol** 1999 Jun;27(2):93–102; quiz 104–5 (74 ref.)

MYOCARDIOPATHIES see **MYOCARDIAL DISEASES**

MYOCARDITIS

Myocarditis: a review. Brodison A, et al. **J Infect** 1998 Sep; 37(2):99–103 (35 ref.)

[Myopericarditis: clinical picture, diagnosis and treatment] Gurevich MA, et al. **Klin Med (Mosk)** 1999;77(7):33–6 (12 ref.) (Eng. Abstr.) **(Rus)**

[Pathogenesis, diagnosis and therapeutic policy in viral myocarditis and dilated cardiomyopathy] Paleev NR, et al. **Klin Med (Mosk)** 1998;76(8):9–14 (71 ref.) **(Rus)**

CHEMICALLY INDUCED

[Acute myocarditis due to mesalazine in a patient with ulcerative colitis] Masutani M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May;96(5):524–9 (21 ref.) **(Jpn)**

DIAGNOSIS

Myocarditis. Mason JW. **Adv Intern Med** 1999;44:293–310 (27 ref.)

A case of peripartum eosinophilic myocarditis. Pearce CB, et al. **Can J Cardiol** 1999 Apr;15(4):465–8 (26 ref.)

The use of molecular technologies for the detection of enteroviral ribonucleic acid in myocarditis. Micevski V. **J Cardiovasc Nurs** 1999 Jul;13(4):78–90 (31 ref.)

[Positive diagnosis and etiology of myocarditis] Hofman P. **Ann Pathol** 1999 Jun;19(3):238–46 (86 ref.) **(Fre)**

[Myocarditis and dilated cardiomyopathy in children. Old questions— new answers] Malčić I, et al. **Lijec Vjesn** 1999 Apr-May;121(4–5):129–36 (68 ref.) (Eng. Abstr.) **(Scr)**

[Myopericarditis simulating a myocardial infarct in a child] Diez Tomás J, et al. **An Esp Pediatr** 1999 Jun;50(6):613–5 (13 ref.) **(Spa)**

DRUG THERAPY

Myocarditis: how should we treat in 1998? [editorial] Parrillo JE. **J Heart Lung Transplant** 1998 Oct;17(10):941–4 (13 ref.)

[The drug correction of functional disorders of blood coagulation and lipid peroxidation in patients with infectious myocarditis] Doroshenko BH. **Lik Sprava** 1998 Dec;(8):3–6 (44 ref.) (Eng. Abstr.) **(Ukr)**

[The current principles of the treatment of infectious myocarditis] Doroshenko BH, et al. **Lik Sprava** 1998 Jun; (4):27–33 (55 ref.) **(Ukr)**

ETIOLOGY

Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Huber SA, et al. **Adv Virus Res** 1998;51:35–80 (245 ref.)

From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Kawai C. **Circulation** 1999 Mar 2;99(8):1091–100 (107 ref.)

[A case of recurrent Guillain-Barré syndrome with myocarditis] Okuma Y, et al. **No To Shinkei** 1999 Mar; 51(3):241–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

[Bacterial myocarditis] Hiramitsu S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):329–31 (8 ref.) **(Jpn)**

[Endocarditis and myocarditis caused by Mycoplasma] Morimoto S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):244–8 (28 ref.) **(Jpn)**

NURSING

Cardiac infections: medical and surgical therapies. Sparacino PS. **J Cardiovasc Nurs** 1999 Jan;13(2):49–65 (51 ref.)

PATHOLOGY

[Cell death in inflammatory heart muscle diseases--apoptosis or necrosis?] Pankuweit S, et al. **Herz** 1999 May;24(3):211–8 (31 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Friman G, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S172–82 (85 ref.)

VIROLOGY

The immune system in viral myocarditis: maintaining the balance [editorial; comment] Knowlton KU, et al. **Circ Res** 1999 Sep 17;85(6):559–61 (20 ref.) Comment on: Circ Res 1999 Sep 17;85(6):551–8.

The use of molecular technologies for the detection of enteroviral ribonucleic acid in myocarditis. Micevski V. **J Cardiovasc Nurs** 1999 Jul;13(4):78–90 (31 ref.)

[Molecular biology of viral cardiopathies] Di Nardo P, et al. **Cardiologia** 1998 Dec;43(12):1315–21 (26 ref.) **(Ita)**

[Viral myocarditis] Inoue K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):69–72 (15 ref.) **(Jpn)**

MYOCARDITIS, CHAGAS see **CHAGAS CARDIOMYOPATHY**

MYOCARDIUM

Regeneration of skeletal and cardiac muscle in mammals: do nonprimate models resemble human pathology? Borisov AB. **Wound Repair Regen** 1999 Jan-Feb;7(1):26-35 (88 ref.)

CHEMISTRY

Cardiac myosin binding protein C. Winegrad S. **Circ Res** 1999 May 28;84(10):1117-26 (78 ref.)

The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Forssmann WG, et al. **Histochem Cell Biol** 1998 Oct;110(4):335-57 (258 ref.)

Measurement of calcium and movement in heart cells. Ng LL, et al. **Methods Mol Biol** 1999;114:279-86 (6 ref.)

Molecular mechanisms of myocardial remodeling. Swynghedauw B. **Physiol Rev** 1999 Jan;79(1):215-62 (527 ref.)

Hormonal control of cardiac ion channels and transporters. Shimoni Y. **Prog Biophys Mol Biol** 1999;72(1):67-108 (409 ref.)

CYTOLOGY

Reappraisal of the multicellular preparation for the in vitro physiopharmacological evaluation of myocardial performance. Sys SU, et al. **Adv Exp Med Biol** 1998; 453:441-50; discussion 451 (34 ref.)

Cell cycle control in the terminally differentiated myocyte. A platform for myocardial repair? Williams RS. **Cardiol Clin** 1998 Nov;16(4):739-54, x (86 ref.)

Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Brooks G, et al. **Cardiovasc Res** 1998 Aug;39(2):301-11 (112 ref.)

Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties. Mitcheson JS, et al. **Cardiovasc Res** 1998 Aug; 39(2):280-300 (121 ref.)

Regulation of growth in the adult cardiomyocytes. Schlüter KD, et al. **FASEB J** 1999;13 Suppl:S17-22 (42 ref.)

The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. Antzelevitch C, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1124-52 (152 ref.)

The controversial M cell. Anyukhovsky EP, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):244-60 (101 ref.)

Cell biology for the nuclear cardiologist. Narula N, et al. **J Nucl Cardiol** 1998 Jul-Aug;5(4):426-37 (3 ref.)

Cell lineage tracing in heart development. Serluca FC, et al. **Methods Cell Biol** 1999;59:359-65 (18 ref.)

Measurement of calcium and movement in heart cells. Ng LL, et al. **Methods Mol Biol** 1999;114:279-86 (6 ref.)

Molecular and cellular mechanisms of myocardial stunning. Bolli R, et al. **Physiol Rev** 1999 Apr;79(2):609-34 (168 ref.)

[Advances in cardiac L-type calcium channel] Song LS, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):362-4 (8 ref.) **(Chi)**

[Properties and significance of the chloride current in mammalian ventricular myocytes] Zhou SS, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):359-61 (11 ref.) **(Chi)**

[Ca2+ signaling in cardiac E-C coupling and its modulation in cardiac hypertrophy and heart failure] Endoh M. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1753-60 (55 ref.) **(Jpn)**

ENZYMOLOGY

Crystal structural studies of a membrane protein complex, cytochrome c oxidase from bovine heart. Tsukihara T, et al. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):895-904 (60 ref.)

Angiotensin II formation in the human heart: an ACE or non-ACE-mediated pathway? Kokkonen JO, et al. **Ann Med** 1998 Aug;30 Suppl 1:9-13 (22 ref.)

Physical exercise and antioxidant defenses in the heart. Atalay M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:169-77 (41 ref.)

Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Simkhovich BZ, et al. **Cardiovasc Res** 1998 Oct;40(1):9-22 (115 ref.)

Nitric oxide synthases in the failing human heart: a doubled-edged sword? [editorial; comment] Drexler H. **Circulation** 1999 Jun 15;99(23):2972-5 (31 ref.) Comment on: Circulation 1999 Jun 15;99(23):3009-16.

Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease. Adams KF Jr. **Coron Artery Dis** 1998;9(10):675-84 (105 ref.)

Protein kinase C in normal and pathologic myocardial states. Cain BS, et al. **J Surg Res** 1999 Feb;81(2):249-59 (166 ref.)

Mathematical model of energy transfer in hearts with inhibited or ablated creatine kinase system. Saks V, et al. **MAGMA** 1998 Sep;6(2-3):124-5 (3 ref.)

[The biochemistry and physiology of Mg2+ in the heart and other organs] Rodriguez-Zavala JS. **Arch Inst Cardiol Mex** 1998 May-Jun;68(3):262-72 (55 ref.) **(Spa)**

METABOLISM

Fatty acid oxidation in the reperfused ischemic heart. Kantor PF, et al. **Am J Med Sci** 1999 Jul;318(1):3-14 (100 ref.)

Cardiac fatty acid metabolism and the induction of apoptosis. Sparagna GC, et al. **Am J Med Sci** 1999 Jul;318(1):15-21 (98 ref.)

Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges [editorial; comment] Auchampach JA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H1113-6 (31 ref.) Comment on: Am J Physiol 1999 Feb;276(2 Pt 2):H341-9.

Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. Wu AH. **Ann Clin Lab Sci** 1999 Jan-Mar;29(1):18-23 (42 ref.)

From overload to failure: what happens inside the myocyte. Harding SE, et al. **Ann Med** 1998 Aug;30 Suppl 1:14-23 (75 ref.)

B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Magga J, et al. **Ann Med** 1998 Aug;30 Suppl 1:39-45 (73 ref.)

Programmed cell death in the progression of heart failure. Sabbah HN, et al. **Ann Med** 1998 Aug;30 Suppl 1:33-8 (45 ref.)

Metabolic changes in the normal and hypoxic neonatal myocardium. Abdel-Aleem S, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:254-61 (17 ref.)

Regulation of cardiac sarcolemmal Na+/H+ exchanger activity by endogenous ligands. Relevance to ischemia. Avkiran M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:335-45 (77 ref.)

Effect of antioxidant trace elements on the response of cardiac tissue to oxidative stress. Barandier C, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:138-55 (84 ref.)

The ins and outs of caveolar signaling. m2 muscarinic cholinergic receptors and eNOS activation versus neuregulin and ErbB4 signaling in cardiac myocytes. Feron O, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:11-9 (39 ref.)

The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Karmazyn M. **Ann N Y Acad Sci** 1999 Jun 30;874:326-34 (33 ref.)

Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Sanguinetti MC. **Ann N Y Acad Sci** 1999 Apr 30;868:406-13 (55 ref.)

Interaction of bradykinin with angiotensin, prostacyclin, and nitric oxide in myocardial preservation. Sato M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:286-94 (61 ref.)

Regulation of natriuretic peptide secretion by the heart. Thibault G, et al. **Annu Rev Physiol** 1999;61:193-217 (143 ref.)

A strategy for the use of cardiac injury markers (troponin I and T, creatine kinase-MB mass and isoforms, and myoglobin) in the diagnosis of acute myocardial infarction [see comments] Kost GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):245-51 (79 ref.) Comment in: Arch Pathol Lab Med 1998 Nov;122(11):949-50.

Growth hormone: a new therapy for heart failure? Saccà L. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):217-31 (83 ref.)

The nitric oxide hypothesis of late preconditioning [editorial; see comments] Bolli R, et al. **Basic Res Cardiol** 1998 Oct; 93(5):325-38 (45 ref.) Comment in: Basic Res Cardiol 1998 Oct;93(5):422.

Spatial heterogeneity of myocardial perfusion and metabolism. Decking UK, et al. **Basic Res Cardiol** 1998 Dec;93(6):439-45 (65 ref.)

Influence of left ventricular pressures and heart rate on myocardial high-energy phosphate metabolism. Neubauer S. **Basic Res Cardiol** 1998;93 Suppl 1:102-7 (23 ref.)

Myocardial angiotensin receptors in human hearts. Regitz-Zagrosek V, et al. **Basic Res Cardiol** 1998;93 Suppl 2:37-42 (17 ref.)

Cardiac magnetic resonance spectroscopy. Deslauriers R, et al. **Biochem Cell Biol** 1998;76(2-3):510-21 (44 ref.)

Metabolic pathways in the regulation of invertebrate and vertebrate Na+/Ca2+ exchange. DiPolo R, et al. **Biochim Biophys Acta** 1999 Feb 25;1422(1):57-71 (82 ref.)

Non-enzymatic nitric oxide synthesis in biological systems. Zweier JL, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2-3):250-62 (39 ref.)

Is the failing heart energy depleted? Katz AM. **Cardiol Clin** 1998 Nov;16(4):633-44, viii (111 ref.)

Nitric oxide in the failing myocardium. Sawyer DB, et al. **Cardiol Clin** 1998 Nov;16(4):657-64, viii (53 ref.)

Basis of pyrimidine nucleotide metabolism in the myocardium. Rossi A, et al. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:171-7 (47 ref.)

Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleotide synthesis: studies with ribose, adenine, inosine, and orotic acid in rats. Zimmer HG. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:179-87 (41 ref.)

Regulation of cardiovascular collagen synthesis by mechanical load. Bishop JE, et al. **Cardiovasc Res** 1999 Apr;42(1):27-44 (181 ref.)

Congestive heart failure: role of cross-bridge cycle kinetics [editorial] de Tombe PP. **Cardiovasc Res** 1998 Dec; 40(3):440-3 (41 ref.)

Role of cardiac chloride currents in changes in action potential characteristics and arrhythmias. Hiraoka M, et al. **Cardiovasc Res** 1998 Oct;40(1):23-33 (118 ref.)

Regulation of basal myocardial function by NO. Kojda G, et al. **Cardiovasc Res** 1999 Mar;41(3):514-23 (100 ref.)

Cellular and molecular aspects of contractile dysfunction in heart failure. Mittmann C, et al. **Cardiovasc Res** 1998 Aug; 39(2):267-75 (101 ref.)

Prostaglandin--a pluralistic hormone embracing divergent signal properties [editorial] Sack S. **Cardiovasc Res** 1998 Dec;40(3):438-9 (20 ref.)

Damage-induced arrhythmias: reversal of excitation-contraction coupling. ter Keurs HE, et al. **Cardiovasc Res** 1998 Dec;40(3):444-55 (70 ref.)

Ins(1,4,5)P3 and cardiac dysfunction. Woodcock EA, et al. **Cardiovasc Res** 1998 Nov;40(2):251-6 (68 ref.)

Serotonin, I(f) and human atrial arrhythmia [editorial; comment] Workman AJ, et al. **Cardiovasc Res** 1998 Dec; 40(3):436-7 (12 ref.) Comment on: Cardiovasc Res 1998 Dec;40(3):516-22.

Cardiac myosin binding protein C. Winegrad S. **Circ Res** 1999 May 28;84(10):1117-26 (78 ref.)

Glucose for the heart. Depre C, et al. **Circulation** 1999 Feb 2;99(4):578-88 (152 ref.)

Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Chapelle JP. **Clin Chem Lab Med** 1999 Jan;37(1):11-20 (102 ref.)

Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. Apple FS. **Clin Chim Acta** 1999 Jun 30;284(2):151-9 (24 ref.)

Clinical insights on the use of highly sensitive cardiac troponin assays. Missov ED, et al. **Clin Chim Acta** 1999 Jun 30;284(2):175-85 (31 ref.)

A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. Wu AH. **Coron Artery Dis** 1999;10(2):69-74 (32 ref.)

Age-associated alterations in calcium current and its modulation in cardiac myocytes. Zhou YY, et al. **Drugs Aging** 1998 Aug;13(2):159-71 (113 ref.)

Mechanisms of control of heart glycolysis. Depré C, et al. **Eur J Biochem** 1998 Dec 1;258(2):277-90 (202 ref.)

The role of alcohol in the oxidant antioxidant balance in heart. McDonough KH. **Front Biosci** 1999 Jul 15;4:D601-6 (49 ref.)

Role of cardiac troponins for risk stratification in unstable coronary artery disease. Gambhir DS, et al. **Indian Heart J** 1999 Jan-Feb;51(1):35-6 (15 ref.)

Basic kinetics of 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in canine myocardium. Nohara R, et al. **Int J Card Imaging** 1999 Feb;15(1):11-20 (31 ref.)

Cardiolipin: biosynthesis, remodeling and trafficking in the heart and mammalian cells (Review). Hatch GM. **Int J Mol Med** 1998 Jan;1(1):33-41 (101 ref.)

Role of nitric oxide in ventricular dysfunction. Arstall MA, et al. **J Card Fail** 1998 Sep;4(3):249-60 (131 ref.)

Mechanisms underlying calcium sparks in cardiac muscle [published erratum appears in J Gen Physiol 1999 May;113(5):761] Cannell MB, et al. **J Gen Physiol** 1999 Mar;113(3):373-6 (29 ref.)

Regulatory function of Na-Ca exchange in the heart: milestones and outlook. Egger M, et al. **J Membr Biol** 1999 Mar 15;168(2):107-30 (208 ref.)

Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **J Mol Cell Cardiol** 1999 May;31(5):949-70 (156 ref.)

Redox regulation of signal transduction in cardiac and smooth muscle. Suzuki YJ, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):345-53 (72 ref.)

Dynamic regulation of K+ channel gene expression in differentiated cells. Levitan ES, et al. **J Neurobiol** 1998 Oct;37(1):60-8 (50 ref.)

Regulation of voltage-gated K+ channel expression in the developing mammalian myocardium. Nerbonne JM. **J Neurobiol** 1998 Oct;37(1):37-59 (178 ref.)

Functional characterization of cardiac myosin isoforms. Sugiura S, et al. **Jpn J Physiol** 1998 Jun;48(3):173-9 (65 ref.)

Impact of diffusional oxygen transport on oxidative metabolism in the heart. Takahashi E, et al. **Jpn J Physiol** 1998 Aug;48(4):243-52 (70 ref.)

Muscarinic cholinergic signaling in cardiac myocytes: dynamic targeting of M2AChR to sarcolemmal caveolae and eNOS activation. Feron O, et al. **Life Sci** 1999; 64(6-7):471-7 (24 ref.)

Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Luiken JJ, et al. **Lipids** 1999;34 Suppl:S169-75 (41 ref.)

Human cardiac MR spectroscopy--clinical methods and applications. Beer M, et al. **MAGMA** 1998 Sep;6(2-3):113-5 (15 ref.)

Human cardiac spectroscopy. Bottomley PA, et al. **MAGMA** 1998 Sep;6(2-3):157-60 (13 ref.)

13C-MR spectroscopy--how and why? Decking UK. **MAGMA** 1998 Sep;6(2-3):103-4 (20 ref.)

Cardiac 1H-MR spectroscopy. von Kienlin M. **MAGMA** 1998 Sep;6(2-3):107-8 (35 ref.)

Cardiac production of angiotensin II and its pharmacologic inhibition: effects on the coronary circulation. Schmermund A, et al. **Mayo Clin Proc** 1999 May;74(5):503-13 (99 ref.)

Transfections of primary muscle cell cultures with plasmids coding for GFP linked to full-length and truncated muscle proteins. Dabiri GA, et al. **Methods Cell Biol** 1999; 58:239-60 (44 ref.)

Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr;21(3):215-27 (134 ref.)

MYOCARDIUM

Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun;21(5):363–74 (113 ref.)

Solubilized muscarinic acetylcholine receptors from the rat myocardium: pharmacological and hydrodynamic characterization. Berrie CP, et al. **Methods Mol Biol** 1999; 106:73–87 (9 ref.)

Targets of oxidative stress in cardiovascular system. Chakraborti T, et al. **Mol Cell Biochem** 1998 Oct; 187(1–2):1–10 (61 ref.)

Features of short-term myocardial hibernation. Heusch G, et al. **Mol Cell Biochem** 1998 Sep;186(1–2):185–93 (45 ref.)

Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Makinde AO, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):49–56 (43 ref.)

Alcohol and the myocardium. Richardson PJ, et al. **Novartis Found Symp** 1998;216:35–45; discussion 45–50 (35 ref.)

Transcriptional regulation of metabolic processes: implications for cardiac metabolism. van Bilsen M, et al. **Pflugers Arch** 1998 Dec;437(1):2–14 (114 ref.)

Regulation of beta-adrenoceptor signaling in cardiac function and disease. Dzimiri N. **Pharmacol Rev** 1999 Sep; 51(3):465–501 (357 ref.)

Molecular and cellular mechanisms of myocardial stunning. Bolli R, et al. **Physiol Rev** 1999 Apr;79(2):609–34 (168 ref.)

Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Carmeliet E. **Physiol Rev** 1999 Jul; 79(3):917–1017 (1193 ref.)

Molecular mechanisms of myocardial remodeling. Swynghedauw B. **Physiol Rev** 1999 Jan;79(1):215–62 (527 ref.)

Main systems involved in calcium regulation in cardiac muscle cells and their functional relationship. Wrzosek A. **Pol J Pharmacol** 1999 Mar–Apr;51(2):187–200 (166 ref.)

Postmitochondrial regulation of apoptosis during heart failure [comment] Reed JC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7614–6 (60 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8144–9.

Wave propagation in cardiac tissue and effects of intracellular calcium dynamics (computer simulation study). Chudin E, et al. **Prog Biophys Mol Biol** 1998;69(2–3):225–36 (17 ref.)

SPECT and PET in the evaluation of coronary artery disease. Jadvar H, et al. **Radiographics** 1999 Jul–Aug;19(4):915–26 (62 ref.)

Metabolic disarrangement in ischemic heart disease and its therapeutic control. Ferrari R. **Rev Port Cardiol** 1998 Sep; 17(9):667–84 (69 ref.)

The thyrotropin-releasing hormone gene 1998: cloning, characterization, and transcriptional regulation in the central nervous system, heart, and testis. Wilber JF, et al. **Thyroid** 1998 Oct;8(10):897–901 (14 ref.)

Modulation of intracellular Ca2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Valdivia HH. **Trends Pharmacol Sci** 1998 Dec; 19(12):479–82 (27 ref.)

Myocardial angiotensin II receptor expression and ischemia-reperfusion injury. Yang B, et al. **Vasc Med** 1998; 3(2):121–30 (69 ref.)

[The biochemical markers of myocardial damage. The Intersociety Interdisciplinary Study Group of the ANMCO-SIBioC-SIMeL, Markers of Myocardial Lesions. Associazione Nazionale Medici Cardiologi Ospedalieri-SIBioC-Società Italiana di Medicina di Laboratorio] Dolci A, et al. **G Ital Cardiol** 1999 Jun; 29(6):739–47 (46 ref.) **(Ita)**

[Assessment of cardiac function and myocardial metabolism by nuclear medicine] Hasegawa S, et al. **Kaku Igaku** 1999 Apr;36(3):209–17 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The histamine receptors of the heart] Sergeev PV, et al. **Eksp Klin Farmakol** 1999 Jan–Feb;62(1):65–9 (63 ref.) (Eng. Abstr.) **(Rus)**

[Experimental approaches to determining molecular mechanisms of antiarrhythmic and cardioprotective actions of new compounds] Dukhanin AS, et al. **Vestn Ross Akad Med Nauk** 1999;(3):7–15 (43 ref.) (Eng. Abstr.) **(Rus)**

[Heat shock proteins: new prospects of myocardial cytoprotection] Shevchenko IuL, et al. **Vestn Ross Akad Med Nauk** 1999;(7):16–20 (53 ref.) **(Rus)**

[Structure and function of selected Ca(2+) transport systems in cardiac cells] Záčiková L, et al. **Cesk Fysiol** 1999 May; 48(2):62–76 (148 ref.) (Eng. Abstr.) **(Slo)**

PATHOLOGY

Potential role of the microvasculature in progression of heart failure. Liu PP, et al. **Am J Cardiol** 1999 Aug 19; 84(4A):23L–26L (38 ref.)

Right ventricular myocardial bridge in a patient with pulmonary hypertension--a case report. Gurewitch J, et al. **Angiology** 1999 Apr;50(4):345–7 (6 ref.)

A mechanistic analysis of the force-frequency relation in non-failing and progressively failing human myocardium. Alpert NR, et al. **Basic Res Cardiol** 1998;93 Suppl 1:23–32 (22 ref.)

Cardiotoxicity of cancer therapy. Tolba KA, et al. **Cancer Invest** 1999;17(6):408–22 (165 ref.)

Detection of anthracycline-induced cardiotoxicity. Meinardi MT, et al. **Cancer Treat Rev** 1999 Aug;25(4):237–47 (116 ref.)

Growth hormone, cardiomyocyte contractile reserve, and heart failure [editorial; comment] Ross J Jr. **Circulation** 1999 Jan 5–12;99(1):15–7 (19 ref.) Comment on: Circulation 1999 Jan 5–12;99(1):127–34.

Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Wu AH, et al. **Clin Chim Acta** 1999 Jun 30;284(2):161–74 (36 ref.)

Apoptosis in hypertensive heart disease. Díez J, et al. **Curr Opin Cardiol** 1998 Sep;13(5):317–25 (77 ref.)

The heart in systemic lupus erythematosus. Roberts WC, et al. **Curr Probl Cardiol** 1999 Jan;24(1):1–56 (117 ref.)

Myocardial apoptosis in the overloaded and the aging heart: a critical role of mitochondria? Heinrich H, et al. **Eur Cytokine Netw** 1998 Dec;9(4):693–5 (14 ref.)

Measurement of coronary flow reserve: what does it tell us about myocardial viability? [editorial] Maurer G. **Eur Heart J** 1999 Feb;20(4):248–9 (7 ref.)

Cell volume regulatory mechanisms in apoptotic cell death. Lang F, et al. **Herz** 1999 May;24(3):232–5 (28 ref.)

Caspase inhibitors in prevention of apoptosis. Rudel T. **Herz** 1999 May;24(3):236–41 (44 ref.)

Morphologic criteria and detection of apoptosis. Saraste A. **Herz** 1999 May;24(3):189–95 (27 ref.)

Post-mortem examination after cardiac surgery. Lee AH, et al. **Histopathology** 1998 Nov;33(5):399–405 (27 ref.)

Hypertension-induced end-organ damage : A new transgenic approach to an old problem. Luft FC, et al. **Hypertension** 1999 Jan;33(1 Pt 2):212–8 (76 ref.)

Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. Yamazaki T, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S43–7; discussion S49–50 (32 ref.)

Inflammatory alterations in the myocardial microcirculation. Hansen PR. **J Mol Cell Cardiol** 1998 Dec;30(12):2555–9 (45 ref.)

Pathologic detection of early myocardial infarction: a critical review of the evolution and usefulness of modern techniques. Vargas SO, et al. **Mod Pathol** 1999 Jun; 12(6):635–45 (100 ref.)

Alcohol and the myocardium. Richardson PJ, et al. **Novartis Found Symp** 1998;216:35–45; discussion 45–50 (35 ref.)

Histiocytoid cardiomyopathy: three new cases and a review of the literature. Shehata BM, et al. **Pediatr Dev Pathol** 1998 Jan–Feb;1(1):56–69 (45 ref.)

Cardiac cell volume: crystal clear or murky waters? A comparison with other cell types. Wright AR, et al. **Pharmacol Ther** 1998 Oct;80(1):89–121 (276 ref.)

Myocardial viability. Stillman AE, et al. **Radiol Clin North Am** 1999 Mar;37(2):361–78, vi (123 ref.)

MRI assessment of myocardial viability: comparison with other imaging techniques. Baer FM, et al. **Rays** 1999 Jan–Mar;24(1):96–108 (31 ref.) **(Eng, Ita)**

Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. Panteghini M, et al. **Scand J Clin Lab Invest Suppl** 1999;230:103–12 (48 ref.)

[Cell death in inflammatory heart muscle diseases--apoptosis or necrosis?] Pankuweit S, et al. **Herz** 1999 May;24(3):211–8 (31 ref.) (Eng. Abstr.) **(Ger)**

[The role of myocardial apoptosis in the development of heart failure] Andréka P, et al. **Orv Hetil** 1999 Jan 17; 140(3):135–42 (50 ref.) (Eng. Abstr.) **(Hun)**

[The clinical importance of myocardial vitality in chronic, postischemic left ventricular dysfunction] Agati L, et al. **Cardiologia** 1998 Jun;43 Suppl 1:95–8 (20 ref.) **(Ita)**

[Ventricular geometry and heart failure] Gomez Doblas JJ, et al. **Rev Esp Cardiol** 1999 Jan;52(1):47–52 (36 ref.) (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Subcellular remodeling and heart dysfunction in chronic diabetes [editorial] Dhalla NS, et al. **Cardiovasc Res** 1998 Nov;40(2):239–47 (130 ref.)

The structure and function of the cardiac myocyte: a review of fundamental concepts. Walker CA, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):375–82 (46 ref.)

MYOCLONIC EPILEPSY, PROGRESSIVE see **EPILEPSY, MYOCLONIC**

MYOCLONIC JERKING see **EPILEPSY, MYOCLONIC**

MYOCLONIC JERKING, MASSIVE see **SPASMS, INFANTILE**

MYOCLONUS

[Essential myoclonus (hereditary essential myoclonus)] Inazuki G. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):197–9 (16 ref.) **(Jpn)**

[Opsoclonus-polymyoclonia syndrome] Shimizu N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):203–5 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Lauterbach EC. **Clin Neuropharmacol** 1999 Mar–Apr; 22(2):87–92 (61 ref.)

COMPLICATIONS

Palatal myoclonus as a cause of objective tinnitus: a report of six cases and a review of the literature. Seidman MD, et al. **Ear Nose Throat J** 1999 Apr;78(4):292–4, 296–7 (27 ref.)

DRUG THERAPY

Melatonin treatment of non-epileptic myoclonus in children. Jan JE, et al. **Dev Med Child Neurol** 1999 Apr;41(4):255–9 (48 ref.)

Piracetam in the treatment of cortical myoclonus. Genton P, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:49–53 (28 ref.)

GENETICS

Inherited myoclonus-dystonia syndrome. Gasser T. **Adv Neurol** 1998;78:325–34 (37 ref.)

PHYSIOPATHOLOGY

Neurophysiology of positive and negative myoclonus [published erratum appears in Electroencephalogr Clin Neurophysiol 1999 Apr;110(4):785] Tassinari CA, et al. **Electroencephalogr Clin Neurophysiol** 1998 Sep; 107(3):181–95 (116 ref.)

MYOD PROTEIN

GENETICS

Transcriptional mechanisms regulating MyoD expression in the mouse. Chen JC, et al. **Cell Tissue Res** 1999 Apr; 296(1):213–9 (59 ref.)

Muscle differentiation: more complexity to the network of myogenic regulators. Arnold HH, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):539–44 (51 ref.)

METABOLISM

Muscle differentiation: more complexity to the network of myogenic regulators. Arnold HH, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):539–44 (51 ref.)

PHYSIOLOGY

Muscle minus myoD. Olson EN, et al. **Dev Biol** 1998 Oct 15;202(2):153–6 (23 ref.)

MYODYSTROPHIA FETALIS DEFORMANS see **ARTHROGRYPOSIS**

MYOEPITHELIAL TUMOR see **MYOEPITHELIOMA**

MYOEPITHELIOMA

DIAGNOSIS

Spindle cell tumours of the breast: practical approach to diagnosis. Al-Nafussi A. **Histopathology** 1999 Jul; 35(1):1–13 (192 ref.)

PATHOLOGY

Plasmacytoid myoepithelioma of the palate. Kanazawa H, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):857–60 (24 ref.)

Myoepithelioma of the lung: report of two cases and review of the literature. Higashiyama M, et al. **Lung Cancer** 1998 Apr;20(1):47–56 (16 ref.)

Myoepithelioma of soft tissue. Sasaguri T, et al. **Pathol Int** 1999 Jun;49(6):571–6 (19 ref.)

MYOFASCIAL PAIN DYSFUNCTION SYNDROME, TEMPOROMANDIBULAR JOINT see **TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME**

MYOFASCIAL PAIN SYNDROMES

DIAGNOSIS

Chronic neck syndromes: an update. Pawl RP. **Compr Ther** 1999 May;25(5):278–82 (32 ref.)

[Myofascial pain syndrome--frequent occurrence and often misdiagnosed] Pongratz DE, et al. **Fortschr Med** 1998 Sep 30;116(27):24–9 (31 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Trigger points and myofascial pain: toward understanding how they affect headaches. Davidoff RA. **Cephalalgia** 1998 Sep;18(7):436–48 (159 ref.)

MYOFIBRILS

see related
MUSCLE CONTRACTION

PHYSIOLOGY

Muscle assembly: a titanic achievement? Gregorio CC, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):18–25 (54 ref.)

Microfibrils from the arterial subendothelium. Fauvel-Lafève F. **Int Rev Cytol** 1999;188:1–40 (185 ref.)

The elastic filament system in myogenesis. Fulton AB. **Rev Physiol Biochem Pharmacol** 1999;138:139–61 (70 ref.)

MYOFIBROBLASTOMA see **NEOPLASMS, MUSCLE TISSUE**

MYOFIBROMA see **LEIOMYOMA**

MYOFIBROMATOSIS

Pancreatoduodenectomy for neonatal myofibromatosis of the pancreas. Morrow SE, et al. **J Pediatr Surg** 1999 Apr; 34(4):609–11 (22 ref.)

DIAGNOSIS

Pediatric myofibromatosis of the head and neck. Beck JC, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jan; 125(1):39–44 (20 ref.)

An unusual presentation of congenital infantile myofibromatosis arising from the interspinous ligament. Kubota A, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):138–9 (14 ref.)

MYOFILAMENTS see **MICROFILAMENTS**

MYOFUNCTIONAL THERAPY

see related
FACIAL MUSCLES

MYOGENIC REGULATORY FACTORS

PHARMACOLOGY

Influence of growth factors on poultry myogenic satellite cells. McFarland DC. **Poult Sci** 1999 May;78(5):747–58 (139 ref.)

MYOGLOBIN

ANALYSIS

Diagnostic strategies in myocardial infarction using myoglobin measurement. Plebani M, et al. **Eur Heart J** 1998 Nov;19 Suppl N:N12–5 (14 ref.)

BLOOD

Cardiac biomarkers: past, present, and future [see comments] Adams JE 3rd, et al. **Am J Crit Care** 1998 Nov;7(6):418–23; quiz 424–5 (11 ref.) Comment in: Am J Crit Care 1999 May;8(3):204.

Creatine kinase isoforms and myoglobin: early detection of myocardial infarction and reperfusion. Apple FS. **Coron Artery Dis** 1999;10(2):75–9 (32 ref.)

Cardiac markers: present and future. Plebani M, et al. **Int J Clin Lab Res** 1999;29(2):56–63 (49 ref.)

The use of cardiac markers in acute coronary syndromes. Agrawal B. **Scand J Clin Lab Invest Suppl** 1999;230:50–9 (64 ref.)

Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM). Wu AH. **Scand J Clin Lab Invest Suppl** 1999;230:74–82 (44 ref.)

[Biochemical markers of myocardial damage in acute coronary syndromes. Suggestions for their optimal use in clinical practice] Panteghini M, et al. **G Ital Cardiol** 1999 Jul;29(7):810–5 (40 ref.) **(Ita)**

GENETICS

Evolution of myoglobin. Suzuki T, et al. **Cell Mol Life Sci** 1998 Sep;54(9):979–1004 (208 ref.)

A myoglobin evolved from indoleamine 2,3-dioxygenase, a tryptophan-degrading enzyme. Suzuki T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):117–28 (65 ref.)

METABOLISM

A strategy for the use of cardiac injury markers (troponin I and T, creatine kinase-MB mass and isoforms, and myoglobin) in the diagnosis of acute myocardial infarction [see comments] Kost GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):245–51 (79 ref.) Comment in: Arch Pathol Lab Med 1998 Nov;122(11):949–50.

A myoglobin evolved from indoleamine 2,3-dioxygenase, a tryptophan-degrading enzyme. Suzuki T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):117–28 (65 ref.)

MYOINOSITOL see **INOSITOL**

MYOKYMIA see **FASCICULATION**

MYOMETRIAL CONTRACTION see **UTERINE CONTRACTION**

MYOMETRIUM

[Endometritis, myometritis] Matsumoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):212–4 (6 ref.) **(Jpn)**

ABNORMALITIES

[Diffuse myometrial hypertrophy. Cause of abnormal uterine bleeding. Clinico-pathological study of 4 cases and review of the literature] Mendoza Ramón HC, et al. **Ginecol Obstet Mex** 1999 Aug;67:370–3 (11 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Steroid hormone-dependent myometrial zonal differentiation in the non-pregnant human uterus. Brosens JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):247–51 (37 ref.)

CYTOLOGY

Myometrial zonal differentiation and uterine junctional zone hyperplasia in the non-pregnant uterus. Brosens JJ, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):496–502 (55 ref.)

METABOLISM

G protein signalling pathways in myometrium: affecting the balance between contraction and relaxation. Sanborn BM, et al. **Rev Reprod** 1998 Sep;3(3):196–205 (77 ref.)

PATHOLOGY

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):520–5 (37 ref.)

PHYSIOLOGY

Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium. Sanborn BM, et al. **Adv Exp Med Biol** 1998;449:277–86 (34 ref.)

Myometrial zonal differentiation and uterine junctional zone hyperplasia in the non-pregnant uterus. Brosens JJ, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):496–502 (55 ref.)

SURGERY

Hysterectomy and myomectomy by laparotomy. West CP. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):317–35 (41 ref.)

MYONEURAL JUNCTION see **NEUROMUSCULAR JUNCTION**

MYOPATHY, NEMALINE see **NEMALINE MYOPATHY**

MYOPIA

COMPLICATIONS

[Clinical course of diabetic retinopathy in myopia] Bol'shunov AV, et al. **Vestn Oftalmol** 1998 Nov–Dec; 114(6):54–5 (35 ref.) **(Rus)**

DRUG THERAPY

[Developmental mechanism of low myopia and therapeutic possibilities. A review] Tokoro T. **Nippon Ganka Gakkai Zasshi** 1998 Dec;102(12):796–812 (101 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Myopia: an epidemic of possibilities? [editorial] Mutti DO, et al. **Optom Vis Sci** 1999 May;76(5):257–8 (12 ref.)

ETIOLOGY

[Developmental mechanism of low myopia and therapeutic possibilities. A review] Tokoro T. **Nippon Ganka Gakkai Zasshi** 1998 Dec;102(12):796–812 (101 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Toward controlling myopia progression? [editorial; comment] Wildsoet CF, et al. **Optom Vis Sci** 1999 Jun; 76(6):341–2 (26 ref.) Comment on: Optom Vis Sci 1999 Jun;76(6):346–54. Comment on: Optom Vis Sci 1999 Jun;76(6):363–9. Comment on: Optom Vis Sci 1999 Jun;76(6):387–92. Comment on: Optom Vis Sci 1999 Jun;76(6):397–407. Comment on: Optom Vis Sci 1999 Jun;76(6):408–18. Comment on: Optom Vis Sci 1999 Jun;76(6):419–27.

SURGERY

Phakic intraocular lenses for correction of high myopia. Garrana RM, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):45–57 (51 ref.)

Laser in situ keratomileusis for the treatment of myopia. Yoo SH, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):37–44 (24 ref.)

Refractive surgery--then and now. Wee TL. **Singapore Med J** 1998 Jul;39(7):335–6 (6 ref.)

Surgical correction of moderate myopia: which method should you choose? III. Editorial. Dutton JJ. **Surv Ophthalmol** 1998 Sep–Oct;43(2):179–81 (9 ref.)

Surgical correction of moderate myopia: which method should you choose? I. Radial keratotomy will always have a place. Rowsey JJ, et al. **Surv Ophthalmol** 1998 Sep–Oct; 43(2):147–56 (86 ref.)

Surgical correction of moderate myopia: which method should you choose? II. PRK and LASIK are the treatments of choice. Steinert RF, et al. **Surv Ophthalmol** 1998 Sep–Oct;43(2):157–79 (248 ref.)

[Complications in photorefractive keratectomy for myopia correction] Quurke A, et al. **Ophthalmologe** 1998 Oct; 95(10):734–40 (7 ref.) **(Ger)**

THERAPY

[The possibilities of using the newest experimental results in the progressive myopia treatment] Czepita D. **Klin Oczna** 1999;101(2):145–7 (15 ref.) (Eng. Abstr.) **(Pol)**

MYOSARCOMA

PATHOLOGY

Low-grade myofibroblastic sarcoma: analysis of 18 cases in the spectrum of myofibroblastic tumors. Mentzel T, et al. **Am J Surg Pathol** 1998 Oct;22(10):1228–38 (31 ref.)

MYOSIN

The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? Bennett PM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:203–34 (101 ref.)

BIOSYNTHESIS

Neural regulation of myosin gene expression in regenerating skeletal muscle. Schiaffino S, et al. **Acta Physiol Scand** 1998 Jul;163(3):S11–5 (32 ref.)

CHEMISTRY

Cross-bridge cycling in smooth muscle: a short review. Arner A, et al. **Acta Physiol Scand** 1998 Dec;164(4):363–72 (123 ref.)

Induced potential model of muscular contraction mechanism and myosin molecular structure. Mitsui T. **Adv Biophys** 1999;36:107–58 (50 ref.)

Structure-mutation analysis of the ATPase site of Dictyostelium discoideum myosin II. Sasaki N, et al. **Adv Biophys** 1998;35:1–24 (25 ref.)

Lever arm model of force generation by actin-myosin-ATP. Highsmith S. **Biochemistry** 1999 Aug 3;38(31):9791–7 (58 ref.)

Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579–84 (57 ref.)

GENETICS

Neural regulation of myosin gene expression in regenerating skeletal muscle. Schiaffino S, et al. **Acta Physiol Scand** 1998 Jul;163(3):S11–5 (32 ref.)

[Molecular biology and molecular genetics in the field of otorhinolaryngology--isolation of genes responsible for deafness] Tamagawa T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Jul;101(7):932–5 (5 ref.) **(Jpn)**

[Regulation of mammalian muscle myosin gene expression] Nieznański K. **Postepy Biochem** 1999;45(1):12–20 (136 ref.) **(Pol)**

METABOLISM

Caldesmon: binding to actin and myosin and effects on elementary steps in the ATPase cycle. Chalovich JM, et al. **Acta Physiol Scand** 1998 Dec;164(4):427–35 (62 ref.)

Structure-mutation analysis of the ATPase site of Dictyostelium discoideum myosin II. Sasaki N, et al. **Adv Biophys** 1998;35:1–24 (25 ref.)

Vesicle budding on Golgi membranes: regulation by G proteins and myosin motors. Stow JL, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):161–71 (98 ref.)

Molecular mechanisms of nonmuscle myosin-II regulation. Bresnick AR. **Curr Opin Cell Biol** 1999 Feb;11(1):26–33 (75 ref.)

Calcium regulation of the actin-myosin interaction of Physarum polycephalum. Nakamura A, et al. **Int Rev Cytol** 1999;191:53–98 (142 ref.)

Functional properties of myosin isoforms in avian muscle. Bandman E. **Poult Sci** 1999 May;78(5):729–34 (79 ref.)

PHYSIOLOGY

Cross-bridge cycling in smooth muscle: a short review. Arner A, et al. **Acta Physiol Scand** 1998 Dec;164(4):363–72 (123 ref.)

Regulation of smooth muscle actin-myosin interaction and force by calponin. Winder SJ, et al. **Acta Physiol Scand** 1998 Dec;164(4):415–26 (119 ref.)

Induced potential model of muscular contraction mechanism and myosin molecular structure. Mitsui T. **Adv Biophys** 1999;36:107–58 (50 ref.)

Organization and polarity of actin filament networks in cells: implications for the mechanism of myosin-based cell motility. Cramer LP. **Biochem Soc Symp** 1999;65:173–205 (100 ref.)

How many is enough? Exploring the myosin repertoire in the model eukaryote Dictyostelium discoideum. Soldati T, et al. **Cell Biochem Biophys** 1999;30(3):389–411 (99 ref.)

MYOSIN

Functional characterization of cardiac myosin isoforms. Sugiura S, et al. **Jpn J Physiol** 1998 Jun;48(3):173–9 (65 ref.)
Regulation by molluscan myosins. Szent-Györgyi AG, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):55–62 (23 ref.)
[Regulatory mechanism of smooth muscle myosin] Katoh T. **Seikagaku** 1999 Apr;71(4):290–4 (21 ref.) **(Jpn)**
[Protein motors: structure and generation of mechanical force] Zima VL. **Ukr Biokhim Zh** 1998 May–Jun; 70(3):23–38 (60 ref.) (Eng. Abstr.) **(Rus)**

MYOSIN ADENOSINETRIPHOSPHATASE see **MYOSIN ATPASE**

MYOSIN ALKALI LIGHT CHAINS see **MYOSIN LIGHT CHAINS**

MYOSIN ATPASE

CHEMISTRY

Structure–mutation analysis of the ATPase site of Dictyostelium discoideum myosin II. Sasaki N, et al. **Adv Biophys** 1998;35:1–24 (25 ref.)

GENETICS

Myosin V in the brain: mutations lead to neurological defects. Langford GM, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):1–8 (174 ref.)

METABOLISM

Caldesmon: binding to actin and myosin and effects on elementary steps in the ATPase cycle. Chalovich JM, et al. **Acta Physiol Scand** 1998 Dec;164(4):427–35 (62 ref.)
Structure–mutation analysis of the ATPase site of Dictyostelium discoideum myosin II. Sasaki N, et al. **Adv Biophys** 1998;35:1–24 (25 ref.)
Myosin V in the brain: mutations lead to neurological defects. Langford GM, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):1–8 (174 ref.)
Functional characterization of cardiac myosin isoforms. Sugiura S, et al. **Jpn J Physiol** 1998 Jun;48(3):173–9 (65 ref.)

MYOSIN HEAVY CHAINS

GENETICS

Myosins and deafness. Rędowicz MJ.
J Muscle Res Cell Motil 1999 Apr;20(3):241–8 (39 ref.)

METABOLISM

Why adult mammalian intrafusal and extrafusal fibers contain different myosin heavy-chain isoforms. Walro JM, et al. **Trends Neurosci** 1999 Apr;22(4):180–4 (49 ref.)

PHYSIOLOGY

Exercise capacity and skeletal muscle myosin heavy chains in CHF [editorial] Vescovo G, et al. **G Ital Cardiol** 1999 Feb;29(2):214–9 (49 ref.)

MYOSIN ISOENZYMES see **MYOSIN ATPASE**

MYOSIN ISOZYMES see **MYOSIN ATPASE**

MYOSIN KINASE see **MYOSIN-LIGHT-CHAIN KINASE**

MYOSIN-LIGHT-CHAIN KINASE

[Formation and regulation of myosin light chain kinase and phosphatase complex in smooth muscle: the outlook] Sobieszek A. **Tsitologiia** 1998;40(6):568–78 (35 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Regulation of the cross-bridge cycle: the effects of MgADP, LC17 isoforms and telokin. Somlyo AV, et al.
Acta Physiol Scand 1998 Dec;164(4):381–8 (64 ref.)
Myosin light chain kinase: functional domains and structural motifs. Stull JT, et al. **Acta Physiol Scand** 1998 Dec; 164(4):471–82 (72 ref.)

PHYSIOLOGY

Myosin light chain kinase: functional domains and structural motifs. Stull JT, et al. **Acta Physiol Scand** 1998 Dec; 164(4):471–82 (72 ref.)
[Structure and regulation of myosin light chain kinase] Ikebe M. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1715–24 (53 ref.) **(Jpn)**

MYOSIN LIGHT CHAINS

CHEMISTRY

Regulation of the cross-bridge cycle: the effects of MgADP, LC17 isoforms and telokin. Somlyo AV, et al.
Acta Physiol Scand 1998 Dec;164(4):381–8 (64 ref.)

METABOLISM

Regulation and tuning of smooth muscle myosin. Sweeney HL. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S95–9 (37 ref.)
[Formation and regulation of myosin light chain kinase and phosphatase complex in smooth muscle: the outlook] Sobieszek A. **Tsitologiia** 1998;40(6):568–78 (35 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Control of cross-bridge cycling by myosin light chain phosphorylation in mammalian smooth muscle. Butler TM, et al. **Acta Physiol Scand** 1998 Dec;164(4):389–400 (56 ref.)

MYOSIN SUBFRAGMENTS

see related
MYOSIN ATPASE

MYOSITIS

Inflammatory myopathies [polymyositis, dermatomyositis, inclusion body myositis] Bertorini TE. **Compr Ther** 1998 Oct;24(10):494–502 (35 ref.)
Pyomyositis in children and adolescents: report of 12 cases and review of the literature. Spiegel DA, et al.
J Pediatr Orthop 1999 Mar–Apr;19(2):143–50 (62 ref.)
[Pyomyositis] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):589–92 (14 ref.) **(Jpn)**

DIAGNOSIS

Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Bousvaros A, et al. **Pediatr Pulmonol** 1998 Nov;26(5):365–9 (24 ref.)

EPIDEMIOLOGY

Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. Patrick M, et al.
J Rheumatol 1999 May;26(5):1094–100 (22 ref.)

ETIOLOGY

New developments in the role of cytokines and chemokines in inflammatory myopathies. Lundberg IE, et al.
Curr Opin Rheumatol 1998 Nov;10(6):521–9 (53 ref.)

MICROBIOLOGY

Cryptococcal myositis: a case report and review of the literature. O'Neill KM, et al. **Pathology** 1998 Aug; 30(3):316–7 (5 ref.)
Streptococcal pyomyositis: case report and review. Wheeler DS, et al. **Pediatr Emerg Care** 1998 Dec;14(6):411–2 (13 ref.)
[Clostridial myonecrosis] Shimazu T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):593–6 (7 ref.) **(Jpn)**

PATHOLOGY

Focal myositis of the sternocleidomastoid muscle. Cain AJ, et al. **J Laryngol Otol** 1998 Jul;112(7):687–9 (10 ref.)
[Facial myositis: a localized form of generalized myositis?] Lettry-Trouillat R, et al. **Rev Neurol (Paris)** 1999 Mar; 155(3):225–8 (11 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Tropical myositis] Saïssy JM, et al. **Med Trop (Mars)** 1998; 58(3):297–306 (68 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Role of rehabilitation in the management of myopathies. Hicks JE. **Curr Opin Rheumatol** 1998 Nov;10(6):548–55 (38 ref.)

THERAPY

Role of rehabilitation in the management of myopathies. Hicks JE. **Curr Opin Rheumatol** 1998 Nov;10(6):548–55 (38 ref.)

ULTRASONOGRAPHY

Ultrasound in inflammatory disease. Gibbon WW, et al.
Radiol Clin North Am 1999 Jul;37(4):633–51 (72 ref.)

MYOSITIS, INCLUSION BODY

DIAGNOSIS

Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Askanas V, et al.
Curr Opin Rheumatol 1998 Nov;10(6):530–42 (103 ref.)
Dermatomyositis, polymyositis and inclusion body myositis: current concepts [editorial] Illa I, et al.
Rev Neurol (Paris) 1998 Jan;154(1):13–6 (33 ref.)
[Inclusion body myositis] Kucharz EJ.
Pol Arch Med Wewn 1998 Sep;100(3):262–6 (24 ref.) **(Pol)**

GENETICS

Hereditary inclusion body myopathies. Tomé FM, et al.
Curr Opin Neurol 1998 Oct;11(5):453–9 (52 ref.)
Genetics of inclusion body myopathies. Argov Z, et al.
Curr Opin Rheumatol 1998 Nov;10(6):543–7 (34 ref.)

PATHOLOGY

Inclusion body myositis--a review. Vogel H.
Adv Anat Pathol 1998 May;5(3):164–9 (20 ref.)
Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging [editorial] Askanas V, et al. **Scand J Rheumatol** 1998;27(6):389–405 (135 ref.)

THERAPY

Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Dalakas MC. **Neurology** 1998 Dec;51(6 Suppl 5):S37–45 (30 ref.)

MYOSITIS, MULTIPLE see **POLYMYOSITIS**

MYOSITIS, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

MYOSITIS OSSIFICANS

ETIOLOGY

Post-traumatic ectopic calcification in the muscles of athletes: a review. King JB. **Br J Sports Med** 1998 Dec; 32(4):287–90 (20 ref.)
Myositis ossificans traumatica of the medial pterygoid muscle. Takahashi K, et al. **J Oral Maxillofac Surg** 1999 Apr; 57(4):451–6 (24 ref.)

MYOTONIA

DIAGNOSIS

Myotonic dystrophy and proximal myotonic myophathy. Ricker K. **J Neurol** 1999 May;246(5):334–8 (26 ref.)

GENETICS

Myotonic dystrophy and proximal myotonic myophathy. Ricker K. **J Neurol** 1999 May;246(5):334–8 (26 ref.)

MYOTONIA ATROPHICA

Dystrophia myotonica. Clinical, pathophysiological and molecular aspects. Edström L.
Scand J Rehabil Med Suppl 1999;39:47–52 (17 ref.)

DIAGNOSIS

Myotonic dystrophy and proximal myotonic myophathy. Ricker K. **J Neurol** 1999 May;246(5):334–8 (26 ref.)
[Current problems in myotonic dystrophy] Węglewski A, et al. **Neurol Neurochir Pol** 1998 Jul–Sep;32(4):903–11 (25 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Myotonic dystrophy: the role of RNA CUG triplet repeats. Timchenko LT. **Am J Hum Genet** 1999 Feb;64(2):360–4 (34 ref.)
Expanding complexity in myotonic dystrophy. Groenen P, et al. **Bioessays** 1998 Nov;20(11):901–12 (75 ref.)
Multiple pilomatrixomata and myotonic dystrophy: a familial association. Geh JL, et al. **Br J Plast Surg** 1999 Mar; 52(2):143–5 (17 ref.)
Myotonic dystrophy and proximal myotonic myophathy. Ricker K. **J Neurol** 1999 May;246(5):334–8 (26 ref.)
AFM/MDA 1st International Myotonic Dystrophy Consortium Conference 30 June–1 July 1997, Paris, France. **Neuromuscul Disord** 1998 Aug;8(6):432–7 (0 ref.)
Molecular basis of neuromuscular diseases. Chance PF, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):49–81, vi (226 ref.)
[Triple expansion diseases: a new mutational concept] Schorderet DF. **Rev Med Suisse Romande** 1999 Feb; 119(2):103–6 (6 ref.) (Eng. Abstr.) **(Fre)**
[Effect on gene expression of the expanded CTG repeat on 3'-untranslated region of myotonic dystrophy (DM) protein kinase] Furuya H, et al. **Nippon Rinsho** 1999 Apr; 57(4):932–6 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Correlation between CTG triplet repeat length and the extent of multisystesmic disorders in myotonic dystrophy] Kinoshita M, et al. **Nippon Rinsho** 1999 Apr;57(4):917–26 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Premutation in myotonic dystrophy] Komai K, et al.
Nippon Rinsho 1999 Apr;57(4):927–31 (17 ref.) (Eng. Abstr.) **(Jpn)**
[DM pathogenesis and expansion of CTG trinucleotide repeat within 3' untranslated region of DMPK gene] Takahashi N, et al. **Nippon Rinsho** 1999 Apr;57(4):937–42 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Current problems in myotonic dystrophy] Węglewski A, et al. **Neurol Neurochir Pol** 1998 Jul–Sep;32(4):903–11 (25 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

The effects of myotonic dystrophy and Duchenne muscular dystrophy on the orofacial muscles and dentofacial morphology. Kiliaridis S, et al. **Acta Odontol Scand** 1998 Dec;56(6):369–74 (33 ref.)

PHYSIOPATHOLOGY

AFM/MDA 1st International Myotonic Dystrophy Consortium Conference 30 June-1 July 1997, Paris, France. **Neuromuscul Disord** 1998 Aug;8(6):432-7 (0 ref.)

[Correlation between CTG triplet repeat length and the extent of multisystesmic disorders in myotonic dystrophy] Kinoshita M, et al. **Nippon Rinsho** 1999 Apr;57(4):917-26 (33 ref.) (Eng. Abstr.) **(Jpn)**

MYOTONIA DYSTROPHICA see **MYOTONIA ATROPHICA**

MYOTONIC DYSTROPHY see **MYOTONIA ATROPHICA**

MYOXIDAE see **RODENTIA**

MYRINGOPLASTY

see related
TYMPANOPLASTY

METHODS

[Prognostic factors in pediatric myringoplasty. A review of 90 cases] Lassaletta Atienza L, et al. **Acta Otorrinolaringol Esp** 1999 Jan-Feb;50(1):1-5 (90 ref.) (Eng. Abstr.) **(Spa)**

MYTHOLOGY

[Alternative medicine at the crossing of scientific reality and myth] Abramow M. **Rev Med Brux** 1998 Sep;19(4):A301-5 (15 ref.) **(Fre)**

[Menstruation still full of myths] Bergqvist A. **Lakartidningen** 1999 Apr 14;96(15):1860-7 (28 ref.) **(Swe)**

MYTILUS see **MUSSELS**

MYXEDEMA

see related
CRETINISM

COMPLICATIONS

[Thyrotoxic storm and myxedema coma] Takasu N. **Nippon Rinsho** 1999 Aug;57(8):1859-65 (2 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

[Myxedematous coma] Iglesias P, et al. **Rev Clin Esp** 1999 May;199(5):302-9 (53 ref.) **(Spa)**

IMMUNOLOGY

[Idiopathic myxedema and blocking type antibodies to TSH receptor] Mitsuma T. **Nippon Rinsho** 1999 Aug; 57(8):1759-63 (20 ref.) (Eng. Abstr.) **(Jpn)**

MYXEDEMA, CONGENITAL see **CRETINISM**

MYXOBACTERALES see **MYXOCOCCALES**

MYXOCOCCALES

CHEMISTRY

[Structural and functional analysis of gp64, a membrane protein of the cellular slime mold Polysphondylium pallidum] Saito T, et al. **Seikagaku** 1998 Jul;70(7):537-42 (16 ref.) **(Jpn)**

PHYSIOLOGY

How and why myxobacteria talk to each other. Kaiser D. **Curr Opin Microbiol** 1998 Dec;1(6):663-8 (46 ref.)

MYXOCOCCUS XANTHUS

GENETICS

The strategy of Myxococcus xanthus for group cooperative behavior. Koch AL. **Antonie Van Leeuwenhoek** 1998 May; 73(4):299-313 (50 ref.)

PHYSIOLOGY

The strategy of Myxococcus xanthus for group cooperative behavior. Koch AL. **Antonie Van Leeuwenhoek** 1998 May; 73(4):299-313 (50 ref.)

Cell fate and organogenesis in bacteria. Kaiser D. **Trends Genet** 1999 Jul;15(7):273-7 (35 ref.)

MYXOFIBROMA see **FIBROMA**

MYXOID CYST see **SYNOVIAL CYST**

MYXOMA

Intra-atrial myxomas, clinical-pathologic correlation based on two case studies including historical review. Roscher AA, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):131-7 (18 ref.)

COMPLICATIONS

Infected cardiac myxoma. Case report and literature review. Revankar SG, et al. **Medicine (Baltimore)** 1998 Sep; 77(5):337-44 (74 ref.)

Fibrous dysplasia with intramuscular myxoma (Mazabraud's syndrome). Report of a case and review of the literature. Thomachot B, et al. **Rev Rhum Engl Ed** 1999 Mar; 66(3):180-3 (15 ref.)

[Cardiac tamponade due to a right atrial myxoma] Ciliberti D, et al. **Cardiologia** 1998 Oct;43(10):1101-3 (5 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[The accidental diagnosis of a left atrial myxoma in an 80-year-old female] Tondi S, et al. **G Ital Cardiol** 1998 Aug;28(8):909-12 (12 ref.) (Eng. Abstr.) **(Ita)**

[Aggressive angiomyxoma in the scrotum: a case report] Ichiyanagi N, et al. **Hinyokika Kiyo** 1999 Jan;45(1):69-72 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Cardiac tumors. Our experience with 4 cases] Torres Borrego J, et al. **An Esp Pediatr** 1999 Jan;50(1):61-4 (24 ref.) **(Spa)**

PATHOLOGY

Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Nielsen GP, et al. **Am J Surg Pathol** 1998 Oct;22(10):1222-7 (14 ref.)

Myxomatous soft tissue tumors: correlation of cytopathology and histopathology. Wakely PE Jr. **Ann Diagn Pathol** 1999 Aug;3(4):227-42 (64 ref.)

Appraisal of histogenesis of cardiac myxoma: our experience of 78 cases and review of literature. Chopra P, et al. **Indian Heart J** 1999 Jan-Feb;51(1):69-74 (30 ref.)

Cardiac myxoma with glandular component: case report and review of the literature. Lindner V, et al. **Pathol Res Pract** 1999;195(4):267-72 (26 ref.)

[Percutaneous transvenous biopsy for the diagnosis of a right atrial myxoma] Nardi P, et al. **G Ital Cardiol** 1999 Mar; 29(3):308-11 (5 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Recurrent myxoma of the left ventricle. Case report and review of the literature. Bortolotti U, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):233-5 (8 ref.)

MYXOMA VIRUS

IMMUNOLOGY

Immunomodulation by viruses: the myxoma virus story. Nash P, et al. **Immunol Rev** 1999 Apr;168:103-20 (118 ref.)

MYXOMATOSIS, INFECTIOUS

IMMUNOLOGY

Immunomodulation by viruses: the myxoma virus story. Nash P, et al. **Immunol Rev** 1999 Apr;168:103-20 (118 ref.)

MYXOMATOSIS VIRUS see **MYXOMA VIRUS**

MYXOMYCETES

GENETICS

Group I twintrons: genetic elements in myxomycete and schizopyrenid amoeboflagellate ribosomal DNAs. Einvik C, et al. **J Biotechnol** 1998 Sep 17;64(1):63-74 (36 ref.)

PHYSIOLOGY

Slime molds, ascidians, and the utility of evolutionary theory [comment] Buss LW. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8801-3 (13 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):9148-53.

MYXOMYCOTA see **MYXOMYCETES**

MYXOVIRUS INFLUENZAE-A HOMINIS see **INFLUENZA A VIRUS, HUMAN**

MYXOVIRUS INFLUENZAE-A SUIS see **INFLUENZA A VIRUS, PORCINE**

MYXOVIRUS PESTIS GALLI see **INFLUENZA A VIRUS, AVIAN**

MYXOVIRUSES see **ORTHOMYXOVIRIDAE**

N-CADHERINS see **CADHERINS**

N-MYC GENES see **GENES, MYC**

N-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

N OMEGA-NITRO-L-ARGININE see **NITROARGININE**

N OMEGA-NITRO-L-ARGININE METHYL ESTER see **NG-NITROARGININE METHYL ESTER**

N-RAS GENES see **GENES, RAS**

NA(+)-CA(2+) EXCHANGER see **SODIUM-CALCIUM EXCHANGER**

NA(+)-H(+)-ANTIPORTER see **SODIUM-HYDROGEN ANTIPORTER**

NA(+)-H(+)-EXCHANGER see **SODIUM-HYDROGEN ANTIPORTER**

NA(+)-K(+)-EXCHANGING ATPASE

ANTAGONISTS & INHIBITORS

Natriuresis and inhibition of Na+/K(+)-ATPase: modulation of response by physiological manipulation. McDougall JG, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S57-60 (35 ref.)

CHEMISTRY

Structural changes associated with the coupling of ATP hydrolysis and cation transport by the Na pump. Kaplan JH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:99-105 (24 ref.)

Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Blanco G, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F633-50 (221 ref.)

Jeanne Mannery Fisher Memorial Lecture 1998. Structure-function studies of the sodium pump. Blostein R. **Biochem Cell Biol** 1999;77(1):1-10 (64 ref.)

DRUG EFFECTS

Effect of melittin on ion transport across cell membranes. Yang S, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan; 18(1):3-5 (31 ref.)

GENETICS

Metal-catalysed cleavage of Na,K-ATPase as a tool for study of structure-function relations. Goldshleger R, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:89-97 (24 ref.)

Structure-function relationships based on ATP binding and cation occlusion at equilibrium in Na,K-ATPase. Jorgensen PL, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:79-87 (40 ref.)

METABOLISM

Partial reactions of the Na,K-ATPase: kinetic analysis and transport properties. Apell HJ, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:235-45 (28 ref.)

Conformational alterations resulting from mutations in cytoplasmic domains of the alpha subunit of the Na,K-ATPase. Blostein R, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:275-81 (26 ref.)

Sorting of P-type ATPases in polarized epithelial cells. Dunbar LA, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:289-95 (23 ref.)

Metal-catalysed cleavage of Na,K-ATPase as a tool for study of structure-function relations. Goldshleger R, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:89-97 (24 ref.)

Structure-function relationships based on ATP binding and cation occlusion at equilibrium in Na,K-ATPase. Jorgensen PL, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:79-87 (40 ref.)

Structural changes associated with the coupling of ATP hydrolysis and cation transport by the Na pump. Kaplan JH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:99-105 (24 ref.)

Ligand binding sites of Na,K-ATPase. Lingrel JB, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:69-77 (44 ref.)

Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Blanco G, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F633-50 (221 ref.)

Polarization of the Na+, K(+)-ATPase in epithelia derived from the neuroepithelium. Rizzolo LJ. **Int Rev Cytol** 1999; 185:195-235 (148 ref.)

Effects of electromagnetic fields on membrane ion transport of cultured cells. Ikehara T, et al. **J Med Invest** 1998 Aug; 45(1-4):47-56 (52 ref.)

Regulation of the Na+/K+-ATPase by insulin: why and how? Sweeney G, et al. **Mol Cell Biochem** 1998 May; 182(1-2):121-33 (125 ref.)

Correlating structure and function in ATP-sensitive K+ channels. Ashcroft FM, et al. **Trends Neurosci** 1998 Jul; 21(7):288-94 (48 ref.)

[Reversible phosphorylation of catalytic subunit of monovalent cation-transporting ATPases by protein kinases and phosphatases] Kaya S. **Seikagaku** 1999 May; 71(5):341-5 (15 ref.) **(Jpn)**

PHYSIOLOGY

Jeanne Mannery Fisher Memorial Lecture 1998. Structure-function studies of the sodium pump. Blostein R. **Biochem Cell Biol** 1999;77(1):1-10 (64 ref.)

Is the slowly activating component of the delayed rectifier current, IKs' absent from undiseased human ventricular myocardium? [editorial; comment] Veldkamp MW. **Cardiovasc Res** 1998 Dec;40(3):433-5 (38 ref.) Comment on: Cardiovasc Res 1998 Dec;40(3):508-15.

NA(+)-K(+)-EXCHANGING ATPASE

Pathophysiology of abnormal cell volume in human red cells. Ellory JC, et al. **Contrib Nephrol** 1998;123:220–39 (72 ref.)
Volume regulation and 'cross-talk' in sodium-absorbing epithelial cells. Schultz SG, et al. **Contrib Nephrol** 1998; 123:205–19 (82 ref.)
Ion transport processes of crustacean epithelial cells. Ahearn GA, et al. **Physiol Biochem Zool** 1999 Jan–Feb;72(1):1–18 (101 ref.)
[Physiological and adaptive value of Na+,K+-ATPase isoenzymes] Kaplia AA. **Ukr Biokhim Zh** 1998 May–Jun; 70(3):3–11 (76 ref.) (Eng. Abstr.) **(Rus)**

NA(+)-K(+)-TRANSPORTING ATPASE see **NA(+)-K(+)-EXCHANGING ATPASE**

NAD

BIOSYNTHESIS

Enzymology of NAD+ synthesis. Magni G, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:135–82, xi (250 ref.)

METABOLISM

[Role of the NADH shuttle system in glucose-induced insulin secretion] Eto K, et al. **Nippon Rinsho** 1999 Mar; 57(3):503–14 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Does NADH play a central role in energy metabolism in Helicobacter pylori? Finel M. **Trends Biochem Sci** 1998 Nov;23(11):412–3 (19 ref.)

THERAPEUTIC USE

Is NADH effective in the treatment of Parkinson's disease? Swerdlow RH. **Drugs Aging** 1998 Oct;13(4):263–8 (31 ref.)

NAD+ ADP-RIBOSYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Deciphering the oxyradical inflammation Rosetta stone: $O_2^{\bullet}$-$NO^{\bullet}$, OONO-, polymorphonuclear neutrophils, poly(ADP-ribose) synthetase, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome [editorial; comment] Vaughan D, et al. **Crit Care Med** 1999 Aug;27(8):1666–9 (30 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1517–23. Comment on: Crit Care Med 1999 Aug;27(8):1524–32.

BIOSYNTHESIS

Poly(ADP-ribose) synthesis in cells undergoing apoptosis: an attempt to face death before PARP degradation. Scovassi AI, et al. **Eur J Histochem** 1998;42(4):251–8 (48 ref.)

CHEMISTRY

The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)

GENETICS

The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)

IMMUNOLOGY

Deciphering the oxyradical inflammation Rosetta stone: $O_2^{\bullet}$-$NO^{\bullet}$, OONO-, polymorphonuclear neutrophils, poly(ADP-ribose) synthetase, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome [editorial; comment] Vaughan D, et al. **Crit Care Med** 1999 Aug;27(8):1666–9 (30 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1517–23. Comment on: Crit Care Med 1999 Aug;27(8):1524–32.

METABOLISM

Characterization of glycosylphosphatidylinositiol-anchored, secreted, and intracellular vertebrate mono-ADP-ribosyltransferases. Okazaki IJ, et al. **Annu Rev Nutr** 1999;19:485–509 (110 ref.)
Involvement of poly(ADP-ribose) polymerase in base excision repair. Dantzer F, et al. **Biochimie** 1999 Jan–Feb; 81(1–2):69–75 (41 ref.)
Poly(ADP-ribose) polymerase and aging. Bürkle A. **Exp Gerontol** 1998 Sep;33(6):519–23 (32 ref.)
The nuclear protein PH5P of the inter-alpha-inhibitor superfamily: a missing link between poly(ADP-ribose)polymerase and the inter-alpha-inhibitor family and a novel actor of DNA repair? Jean L, et al. **FEBS Lett** 1999 Mar 5;446(1):6–8 (19 ref.)
Activation of toxin ADP-ribosyltransferases by eukaryotic ADP-ribosyiation factors. Moss J, et al. **Mol Cell Biochem** 1999 Mar;193(1–2):153–7 (30 ref.)

PHYSIOLOGY

Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. Oliver FJ, et al. **Am J Hum Genet** 1999 May;64(5):1282–8 (49 ref.)
Poly(ADP-ribose) synthesis in cells undergoing apoptosis: an attempt to face death before PARP degradation. Scovassi AI, et al. **Eur J Histochem** 1998;42(4):251–8 (48 ref.)
Regulatory mechanisms of poly(ADP-ribose) polymerase. Alvarez-Gonzalez R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):19–22 (37 ref.)
Poly (ADP-ribose) polymerase, nitric oxide and cell death. Pieper AA, et al. **Trends Pharmacol Sci** 1999 Apr; 20(4):171–81 (144 ref.)

NAD-ARGININE ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NAD ISOCITRATE DEHYDROGENASE see **ISOCITRATE DEHYDROGENASE**

NAD+ NUCLEOSIDASE

Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. Funaro A, et al. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):54–61 (121 ref.)

BIOSYNTHESIS

Retinoid-mediated signaling pathways in CD38 antigen expression in myeloid leukemia cells. Mehta K, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):441–9 (65 ref.)

METABOLISM

A unified mechanism of enzymatic synthesis of two calcium messengers: cyclic ADP-ribose and NAADP. Lee HC. **Biol Chem** 1999 Jul–Aug;380(7–8):785–93 (80 ref.)
[Cyclic ADP-ribose as a second messenger--intramembrane signal transduction from receptors to ADP-ribosyl cyclase] Higashida H, et al. **Seikagaku** 1998 Nov;70(11):1326–34 (79 ref.) **(Jpn)**

PHYSIOLOGY

The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. Ferrero E, et al. **J Leukoc Biol** 1999 Feb;65(2):151–61 (77 ref.)
Biology of CD34+CD38- cells in lymphohematopoiesis. Novelli EM, et al. **Leuk Lymphoma** 1998 Oct; 31(3–4):285–93 (80 ref.)

NAD(P)H DEHYDROGENASE (QUINONE)

GENETICS

Human mitochondrial complex I in health and disease. Smeitink J, et al. **Am J Hum Genet** 1999 Jun;64(6):1505–10 (38 ref.)
Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art. Smeitink JA, et al. **Hum Mol Genet** 1998;7(10):1573–9 (87 ref.)
Benzene, NQO1, and genetic susceptibility to cancer [comment] Smith MT. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7624–6 (46 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8150–5.

METABOLISM

Catalytic properties of mitochondrial NADH-ubiquinone reductase (Complex I). Vinogradov AD, et al. **Biochemistry (Mosc)** 1999 Feb;64(2):136–52 (160 ref.)
Proton translocation in the respiratory chain involving ubiquinone--a hypothetical semiquinone switch mechanism for complex I. Brandt U. **Biofactors** 1999;9(2–4):95–101 (30 ref.)
Enzymology of bioreductive drug activation. Ross D, et al. **Br J Cancer Suppl** 1996 Jul;27:S1–8 (89 ref.)

PHYSIOLOGY

The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption. Gonzalez FJ. **Toxicol Lett** 1998 Dec 28;102–103:161–6 (31 ref.)

NAD-PROTEIN ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NADASE see **NAD+ NUCLEOSIDASE**

NADH, NADPH OXIDOREDUCTASES

BIOSYNTHESIS

Strategies to enhance the coexpression of cytochrome P450 2E1 and reductase in bacteria. Porter TD, et al. **Drug Metab Rev** 1999 Feb;31(1):159–74 (32 ref.)

METABOLISM

Roles for NAD(P)H oxidases and reactive oxygen species in vascular oxygen sensing mechanisms. Wolin MS, et al. **Respir Physiol** 1999 Apr 1;115(2):229–38 (55 ref.)

PHYSIOLOGY

Role for NADPH/NADH oxidase in the modulation of vascular tone. Münzel T, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:386–400 (47 ref.)
Iron transport across biologic membranes. Andrews NC, et al. **Nutr Rev** 1999 Apr;57(4):114–23 (97 ref.)

NADIDE see **NAD**

NADP

ANALOGS & DERIVATIVES

A unified mechanism of enzymatic synthesis of two calcium messengers: cyclic ADP-ribose and NAADP. Lee HC. **Biol Chem** 1999 Jul–Aug;380(7–8):785–93 (80 ref.)
Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes. Lee HC, et al. **Mol Cell Biochem** 1999 Mar;193(1–2):89–98 (61 ref.)

PHYSIOLOGY

Role for NADPH/NADH oxidase in the modulation of vascular tone. Münzel T, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:386–400 (47 ref.)

NADP-ARGININE ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE

CHEMISTRY

The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)

GENETICS

The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Bortell R, et al. **Mol Cell Biochem** 1999 Mar; 193(1–2):61–8 (73 ref.)

METABOLISM

Endogenous relatives of ADP-ribosylating bacterial toxins in mice and men: potential regulators of immune cell function. Haag F, et al. **J Biol Regul Homeost Agents** 1998 Jul–Sep;12(3):53–62 (87 ref.)

PHYSIOLOGY

Bacterial toxins and the Rho GTP-binding protein: what microbes teach us about cell regulation. Fiorentini C, et al. **Cell Death Differ** 1998 Sep;5(9):720–8 (62 ref.)

NADPH CYTOCHROME C REDUCTASE see **NADPH-FERRIHEMOPROTEIN REDUCTASE**

NADPH CYTOCHROME P-450 OXIDOREDUCTASE see **NADPH-FERRIHEMOPROTEIN REDUCTASE**

NADPH CYTOCHROME P-450 REDUCTASE see **NADPH-FERRIHEMOPROTEIN REDUCTASE**

NADPH-FERRIHEMOPROTEIN REDUCTASE

METABOLISM

Flavodoxin as a model for the P450-interacting domain of NADPH cytochrome P450 reductase. Jenkins CM, et al. **Drug Metab Rev** 1999 Feb;31(1):195–203 (19 ref.)

NADPH OXIDASE

see related
GRANULOMATOUS DISEASE, CHRONIC

METABOLISM

Activation of the neutrophil respiratory burst oxidase. Clark RA. **J Infect Dis** 1999 Mar;179 Suppl 2:S309–17 (37 ref.)

PHYSIOLOGY

NADPH oxidase: an update. Babior BM. **Blood** 1999 Mar 1;93(5):1464–76 (117 ref.)

NADROPARIN

THERAPEUTIC USE

[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)] Martyin T, et al. **Orv Hetil** 1998 Dec 20;139(51):3065–9 (29 ref.) (Eng. Abstr.) **(Hun)**

NAEGLERIA FOWLERI

[Primary amebic meningoencephalitis (Naegleria)] Hashimoto R, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):412–4 (6 ref.) **(Jpn)**

NAFRONYL

THERAPEUTIC USE

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Girolami B, et al. **Arch Intern Med** 1999 Feb 22;159(4):337-45 (116 ref.)

NAFRONYLOXALATE see **NAFRONYL**

NAFTIDROFURYL see **NAFRONYL**

NAGANA see **TRYPANOSOMIASIS, AFRICAN**

NAIL BITING

Severe morbid onychophagia: the classification as self-mutilation and a proposed model of maintenance. Wells JH, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):534-45 (79 ref.)

NAIL DISEASES

CHEMICALLY INDUCED

Drug-induced nail disorders: incidence, management and prognosis. Piraccini BM, et al. **Drug Saf** 1999 Sep; 21(3):187-201 (51 ref.)

DIAGNOSIS

Current diagnosis and management of chronic fungal infection of the feet and nails. Liu V, et al. **Curr Clin Top Infect Dis** 1999;19:305-26 (115 ref.)

[Psoriasis of the nails] Duhard-Brohan E. **Ann Dermatol Venereol** 1999 May;126(5):445-9 (17 ref.) **(Fre)**

[A method for the diagnosis and phytotherapy of the mycosis caused by the fungus Alternaria alternata (Fr.) Keissler] Trikoz GA. **Lik Sprava** 1999 Mar;(2):128-30 (12 ref.) **(Rus)**

DRUG THERAPY

Current diagnosis and management of chronic fungal infection of the feet and nails. Liu V, et al. **Curr Clin Top Infect Dis** 1999;19:305-26 (115 ref.)

PATHOLOGY

Distal digital keratoacanthoma: a report of 12 cases and a review of the literature. Baran R, et al. **Br J Dermatol** 1998 Sep;139(3):512-5 (16 ref.)

[Hyperpigmented spots on the lips, oral mucosa, fingers and nails] Paricio Rubio JF, et al. **Rev Clin Esp** 1998 Nov; 198(11):769-70 (13 ref.) **(Spa)**

SURGERY

[What's new in nail surgery?] Dumontier C. **Ann Chir Plast Esthet** 1998 Dec;43(6):622-9 (80 ref.) (Eng. Abstr.) **(Fre)**

NAILING, INTRAMEDULLARY see **FRACTURE FIXATION, INTRAMEDULLARY**

NAILS

PATHOLOGY

Drug-induced nail disorders: incidence, management and prognosis. Piraccini BM, et al. **Drug Saf** 1999 Sep; 21(3):187-201 (51 ref.)

SURGERY

[What's new in nail surgery?] Dumontier C. **Ann Chir Plast Esthet** 1998 Dec;43(6):622-9 (80 ref.) (Eng. Abstr.) **(Fre)**

NAILS, MALFORMED

DIAGNOSIS

[Aplasia cutis congenita, epidermolysis bullosa and ungual dystrophy] Vázquez López ME, et al. **An Esp Pediatr** 1998 Sep;49(3):294-6 (11 ref.) **(Spa)**

NAKED DNA VACCINES see **VACCINES, DNA**

NALOXONE

THERAPEUTIC USE

Acts of omission and commission in pain management: the ethics of naloxone use. Fins JJ. **J Pain Symptom Manage** 1999 Feb;17(2):120-4 (26 ref.)

[Forced opioid detoxification under general anesthesia--a new challenge for anesthetists and intensive care physicians] [see comments] Hensel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 May; 34(5):261-8 (52 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1999 May;34(5):259-60. **(Ger)**

NALTREXONE

ANALOGS & DERIVATIVES

Nalmefene hydrochloride. Chumpa A. **Pediatr Emerg Care** 1999 Apr;15(2):141-3 (23 ref.)

THERAPEUTIC USE

Craving for alcohol: findings from the clinic and the laboratory. Sinha R, et al. **Alcohol Alcohol** 1999 Mar-Apr; 34(2):223-30 (32 ref.)

Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. O'Malley SS. **Alcohol Alcohol Suppl** 1996 Mar;1:77-81 (20 ref.)

Anxiolytics, adrenergic agents, and naltrexone. Riddle MA, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May; 38(5):546-56 (110 ref.)

L-NAME see **NG-NITROARGININE METHYL ESTER**

NAN3 see **SODIUM AZIDE**

NANDROLONE

ANALOGS & DERIVATIVES

Dienogest. Foster RH, et al. **Drugs** 1998 Nov;56(5):825-33; discussion 834-5 (50 ref.)

NANISM see **DWARFISM**

NANISM, MULIBREY see **DWARFISM**

NANISM, PITUITARY see **DWARFISM, PITUITARY**

NANNIZZIA see **ARTHRODERMATACEAE**

NANNOMONAS see **TRYPANOSOMA**

NAPHTHALENEDIONES see **NAPHTHOQUINONES**

NAPHTHALENES

PHARMACOLOGY

Drug interactions with itraconazole, fluconazole, and terbinafine and their management. Gupta AK, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):237-49 (225 ref.)

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Christians U, et al. **Pharmacol Ther** 1998 Oct;80(1):1-34 (317 ref.)

Nonpeptide antagonists for kinin receptors. Altamura M, et al. **Regul Pept** 1999 Mar 17;80(1-2):13-26 (94 ref.)

THERAPEUTIC USE

How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data [see comments] Epstein E. **Arch Dermatol** 1998 Dec; 134(12):1551-4 (28 ref.) Comment in: Arch Dermatol 1999 Jul;135(7):852-3.

Effective treatment of localized Darier's disease with adapalene 0.1% gel. English JC 3rd, et al. **Cutis** 1999 Apr; 63(4):227-30 (15 ref.)

Terbinafine. An update of its use in superficial mycoses. McClellan KJ, et al. **Drugs** 1999 Jul;58(1):179-202 (145 ref.)

Are there potential non-lipid-lowering uses of statins? Wheeler DC. **Drugs** 1998 Oct;56(4):517-22 (50 ref.)

Onychomycosis in diabetes. Management considerations. Albreski DA, et al. **Postgrad Med** 1999 Jul;Spec No:26-30 (26 ref.)

Itraconazole and terbinafine in perspective. From petri dish to patient. De Doncker P, et al. **Postgrad Med** 1999 Jul; Spec No:6-11 (19 ref.)

Management of tinea capitis. A status report. Del Rosso JQ, et al. **Postgrad Med** 1999 Jul;Spec No:38-45 (40 ref.)

Management of onychomycosis in children. Gupta AK, et al. **Postgrad Med** 1999 Jul;Spec No:31-7 (54 ref.)

[Adapalene--a new retinoid receptor agonist for the treatment of acne vulgaris] Petersen CS. **Ugeskr Laeger** 1998 Nov 9;160(46):6668-71 (22 ref.) **(Dan)**

[Terbinafine] Bouyssou-Gauthier ML, et al. **Ann Dermatol Venereol** 1999 Jan;126(1):81-9 (49 ref.) **(Fre)**

NAPHTHALENESULFONATES

[Inhibitor of calmodulin and calmodulin dependent enzyme] Hidaka H, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep; 43(12 Suppl):1732-8 (48 ref.) **(Jpn)**

NAPHTHOQUINONES

CHEMISTRY

Pyranonaphthoquinone antibiotics--isolation, structure and biological activity. Brimble MA, et al. **Nat Prod Rep** 1999 Jun;16(3):267-81 (174 ref.)

THERAPEUTIC USE

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Looareesuwan S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):533-41 (22 ref.)

NAPHTHYRIDINES

[Trovafloxacin] Azanza JR, et al. **Rev Med Univ Navarra** 1999 Jan-Mar;43(1):45-57 (26 ref.) **(Spa)**

PHARMACOLOGY

Trovafloxacin: fourth generation fluoroquinolone. McNabb J, et al. **Conn Med** 1998 Aug;62(8):483-7 (26 ref.)

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Pechère JC, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):405-12 (48 ref.)

THERAPEUTIC USE

Trovafloxacin: a new fluoroquinolone. Alghasham AA, et al. **Ann Pharmacother** 1999 Jan;33(1):48-60 (112 ref.)

Trovafloxacin: fourth generation fluoroquinolone. McNabb J, et al. **Conn Med** 1998 Aug;62(8):483-7 (26 ref.)

Trovafloxacin: an overview. Garey KW, et al. **Pharmacotherapy** 1999 Jan;19(1):21-34 (67 ref.)

[Pharmacokinetics and safety of trovafloxacin] Frias J, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:36-42; discussion 47-52 (29 ref.) **(Spa)**

[Is trovafloxacin an antibiotic exclusively for the treatment of respiratory infections?] Garau J. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:43-6; discussion 47-52 (24 ref.) **(Spa)**

NAPROXEN

ADVERSE EFFECTS

Pseudoporphyria induced by propionic acid derivatives. Al-Khenaizan S, et al. **J Cutan Med Surg** 1999 Jan; 3(3):162-6 (29 ref.)

Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Schaller S, et al. **Pediatr Emerg Care** 1998 Dec;14(6):416-8 (20 ref.)

NARCISSISTIC PERSONALITY DISORDER see **PERSONALITY DISORDERS**

NARCOLEPSY

DIAGNOSIS

Narcolepsy and other causes of excessive daytime sleepiness. Gerhardstein R, et al. **Respir Care Clin N Am** 1999 Sep; 5(3):427-46, viii-ix (49 ref.)

[Hypersomnia. Narcolepsy-cataplexy (Gélineau syndrome)] Carlander B, et al. **Presse Med** 1998 Nov 7;27(34):1748-53 (47 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Narcolepsy: a key role for hypocretins (orexins) [comment] Siegel JM. **Cell** 1999 Aug 20;98(4):409-12 (20 ref.) Comment on: Cell 1999 Aug 6;98(3):365-76. Comment on: Cell 1999 Aug 20;98(4):437-51.

VETERINARY

Genetic studies in narcolepsy, a disorder affecting REM sleep. Faraco J, et al. **J Hered** 1999 Jan-Feb;90(1):129-32 (34 ref.)

NARCOTIC ABUSE see **OPIOID-RELATED DISORDERS**

NARCOTIC ADDICTION see **OPIOID-RELATED DISORDERS**

NARCOTIC ANALGESICS see **ANALGESICS, OPIOID**

NARCOTIC ANTAGONISTS

ADMINISTRATION & DOSAGE

[Pharmacological principles for the treatment of heroin abuse] Oye I. **Tidsskr Nor Laegeforen** 1999 May 30; 119(14):2066-9 (15 ref.) **(Nor)**

CHEMISTRY

Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. Schiller PW, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul; 19(1-4):573-88 (33 ref.)

PHARMACOLOGY

Central mechanisms of pain modulation. Mason P. **Curr Opin Neurobiol** 1999 Aug;9(4):436-41 (33 ref.)

Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. Schiller PW, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul; 19(1-4):573-88 (33 ref.)

NARCOTIC ANTAGONISTS

THERAPEUTIC USE

Craving for alcohol: findings from the clinic and the laboratory. Sinha R, et al. **Alcohol Alcohol** 1999 Mar–Apr; 34(2):223–30 (32 ref.)

Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. O'Malley SS. **Alcohol Alcohol Suppl** 1996 Mar;1:77–81 (20 ref.)

Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Terra SG, et al. **Ann Pharmacother** 1998 Nov;32(11):1228–30 (29 ref.)

Rational treatment of addiction. Terenius L. **Curr Opin Chem Biol** 1998 Aug;2(4):541–7 (62 ref.)

Anxiolytics, adrenergic agents, and naltrexone. Riddle MA, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May; 38(5):546–56 (110 ref.)

Acts of omission and commission in pain management: the ethics of naloxone use. Fins JJ. **J Pain Symptom Manage** 1999 Feb;17(2):120–4 (26 ref.)

Nalmefene hydrochloride. Chumpa A. **Pediatr Emerg Care** 1999 Apr;15(2):141–3 (23 ref.)

[Forced opioid detoxification under general anesthesia—a new challenge for anesthetists and intensive care physicians] [see comments] Hensel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 May; 34(5):261–8 (52 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1999 May;34(5):259–60. **(Ger)**

NARCOTIC CONTROL see **DRUG AND NARCOTIC CONTROL**

NARCOTIC DEPENDENCE see **OPIOID-RELATED DISORDERS**

NARCOTIC LAWS see **LEGISLATION, DRUG**

NARCOTIC RECEPTORS see **RECEPTORS, OPIOID**

NARCOTICS

see related
ANALGESICS, OPIOID
COCAINE
OPIOID-RELATED DISORDERS
RECEPTORS, OPIOID

Medical consequences of substance abuse. Stein MD. **Psychiatr Clin North Am** 1999 Jun;22(2):351–70 (74 ref.)

Opioid tolerance in neonates: mechanisms, diagnosis, assessment, and management. Suresh S, et al. **Semin Perinatol** 1998 Oct;22(5):425–33 (48 ref.)

ADMINISTRATION & DOSAGE

Traditional analgesic agents: are parenteral narcotics passé and do inhalational agents still have a place in labour? Olofsson C, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):409–21 (72 ref.)

Pain management and weaning from narcotics and sedatives. Ganea GR, et al. **Curr Opin Pediatr** 1999 Jun;11(3):207–12 (29 ref.)

[Heroin-assisted treatment of opiate dependent patients. Experiences from Swiss trials for medical prescription of narcotics (PROVE)] Steffen T, et al. **Internist (Berl)** 1999 Jun;40(6):651–6 (30 ref.) **(Ger)**

ADVERSE EFFECTS

Opioids in pain management. McQuay H. **Lancet** 1999 Jun 26;353(9171):2229–32 (29 ref.)

[Drug-related emergencies with opiates] Pfab R, et al. **Internist (Berl)** 1999 Jun;40(6):611–6 (52 ref.) **(Ger)**

AGONISTS

Rational treatment of addiction. Terenius L. **Curr Opin Chem Biol** 1998 Aug;2(4):541–7 (62 ref.)

ANALYSIS

[Advances in the study on immunoassay of narcotic drugs] Li L, et al. **Fa I Hsueh Tsa Chih** 1997;13(4):225–6 (8 ref.) **(Chi)**

[Testing problems regarding narcotic substances in hair analysis] Kriukov VN, et al. **Sud Med Ekspert** 1999 May–Jun;42(3):18–20 (26 ref.) (Eng. Abstr.) **(Rus)**

[beta-Endorphins and the male reproductive system] Morales Martinez ME, et al. **Ginecol Obstet Mex** 1999 Apr;67:183–7 (33 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Burma: the political economy of violence. Brown C. **Disasters** 1999 Sep;23(3):234–56 (55 ref.)

IMMUNOLOGY

[Opioids and the immune system] Núñez G, et al. **Rev Med Chil** 1999 Mar;127(3):341–8 (53 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Kalra SP, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:236–40 (25 ref.)

Invertebrate opioid precursors: evolutionary conservation and the significance of enzymatic processing. Stefano GB, et al. **Int Rev Cytol** 1999;187:261–86 (83 ref.)

Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Fimiani C, et al. **Prostaglandins Other Lipid Mediat** 1999 Jan;57(1):23–34 (86 ref.)

Pharmacological and biochemical interactions between opioids and cannabinoids. Manzanares J, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):287–94 (69 ref.)

PHARMACOKINETICS

Pharmacokinetics of opioids in liver disease. Tegeder I, et al. **Clin Pharmacokinet** 1999 Jul;37(1):17–40 (257 ref.)

Formation and clearance of active and inactive metabolites of opiates in humans. Aderjan RE, et al. **Ther Drug Monit** 1998 Oct;20(5):561–9 (60 ref.)

PHARMACOLOGY

Do sex-related differences exist in the respiratory pharmacology of opioids? Sarton E, et al. **Adv Exp Med Biol** 1998;450:141–5 (15 ref.)

Opioid modulation of ventral pallidal inputs. Napier TC, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:176–201 (89 ref.)

The neurobiology of opiate reinforcement. Shippenberg TS, et al. **Crit Rev Neurobiol** 1998;12(4):267–303 (240 ref.)

Some new insights into the effects of opioids in phasic and tonic nociceptive tests. McCormack K, et al. **Pain** 1998 Nov;78(2):79–98 (222 ref.)

Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Harrison LM, et al. **Peptides** 1998;19(9):1603–30 (253 ref.)

The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Quock RM, et al. **Pharmacol Rev** 1999 Sep;51(3):503–32 (280 ref.)

Opioids, reward and addiction: An encounter of biology, psychology, and medicine. van Ree JM, et al. **Pharmacol Rev** 1999 Jun;51(2):341–96 (740 ref.)

Targeted mutagenesis of the murine opioid system. Hayward MD, et al. **Results Probl Cell Differ** 1999;26:169–91 (100 ref.)

Opioids: first lessons from knockout mice. Kieffer BL. **Trends Pharmacol Sci** 1999 Jan;20(1):19–26 (60 ref.)

Pharmacological and biochemical interactions between opioids and cannabinoids. Manzanares J, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):287–94 (69 ref.)

THERAPEUTIC USE

Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol Suppl** 1996 Mar;1:27–32 (51 ref.)

Substance abuse and HIV-gp120: are opiates protective? Stefano GB. **Arch Immunol Ther Exp (Warsz)** 1999; 47(2):99–106 (101 ref.)

Neuraxial opioids in labour. Wilson DJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):363–76 (67 ref.)

The methadone-maintained pregnancy. Kandall SR, et al. **Clin Perinatol** 1999 Mar;26(1):173–83 (63 ref.)

Methadone in the management of narcotic addiction in pregnancy [editorial] Archie C. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):435–40 (25 ref.)

NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. **Eur Addict Res** 1999 Mar;5(1):50–1 (0 ref.)

Therapeutic drug monitoring for methadone: scanning the horizon. Wolff K, et al. **Eur Addict Res** 1999 Mar;5(1):36–42 (85 ref.)

Methadone: where are we now? Henry JA. **Hosp Med** 1999 Mar;60(3):161–4 (15 ref.)

Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment [see comments] Lewis DC. **J Addict Dis** 1999; 18(2):5–21 (82 ref.) Comment in: J Addict Dis 1999 ;18(2):1–4.

Opioids in pain management. McQuay H. **Lancet** 1999 Jun 26;353(9171):2229–32 (29 ref.)

Role of maintenance treatment in opioid dependence [see comments] Ward J, et al. **Lancet** 1999 Jan 16; 353(9148):221–6 (48 ref.) Comment in: Lancet 1999 Mar 27;353(9158):1101. Comment in: Lancet 1999 Apr 10;353(9160):1278.

[The practitioner and reduction of risks] Leckie M. **Rev Med Suisse Romande** 1998 Sep;118(9):739–42 (12 ref.) **(Fre)**

[Use of methadone in the treatment of narcotic addiction] Tiljak H. **Lijec Vjesn** 1998 May;120(5):125–31 (79 ref.) (Eng. Abstr.) **(Scr)**

[Drug interactions of methadone with CNS-active agents] Moreno Brea MR, et al. **Actas Esp Psiquiatr** 1999 Mar–Apr; 27(2):103–10 (61 ref.) (Eng. Abstr.) **(Spa)**

NARRATIVE ETHICS see **ETHICS, MEDICAL**

NARWHALS see **WHALES**

NASAL BONE

see related
RHINOPLASTY

ANATOMY & HISTOLOGY

Use of the superior meatus and superior turbinate in the endoscopic approach to the sphenoid sinus. Bolger WE, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):308–13 (13 ref.)

NASAL CAVITY

Olfactory esthesioneuroblastoma (olfactory neuroblastoma/olfactory neuroepithelioma). Palacios E, et al. **Ear Nose Throat J** 1998 Nov;77(11):890–1 (0 ref.)

Teratocarcinosarcoma of the nasal cavity and ethmoid. Sharma HS, et al. **J Laryngol Otol** 1998 Jul;112(7):682–6 (15 ref.)

[Disk battery as nasal foreign body in a boy] Beluffi G, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):104–6 (16 ref.) **(Ita)**

ABNORMALITIES

[Congenital stenosis of the piriform aperture: a cause of respiratory distress in newborn infants. Review of the literature, from 2 cases] Goga D, et al. **Rev Stomatol Chir Maxillofac** 1998 Nov;99(4):203–6 (17 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Mucocutaneous angiomyolipoma. A report of 2 cases arising in the nasal cavity. Watanabe K, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):789–92 (27 ref.)

Metastatic melanoma of the nasal cavity in a patient with oculocutaneous albinism. Malaguarnera M, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):404–6 (34 ref.)

[Naso-alveolar cysts. A report of 10 new cases and a review of the literature] Lassaletta Atienza L, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):533–6 (16 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Upper airway function and dysfunction in respiration. Pierce RJ, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):1–10 (102 ref.)

RADIOGRAPHY

Squamous cell carcinoma of the sinonasal cavities. Hermans R, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):150–61 (12 ref.)

[Naso-alveolar cysts. A report of 10 new cases and a review of the literature] Lassaletta Atienza L, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):533–6 (16 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

The use of spacers to prevent postoperative middle meatal adhesions. Yanagisawa E, et al. **Ear Nose Throat J** 1999 Aug;78(8):530–2 (3 ref.)

Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314–7 (21 ref.)

NASAL DECONGESTANTS

ADVERSE EFFECTS

Treating allergic rhinitis in pregnancy. Safety considerations. Mazzotta P, et al. **Drug Saf** 1999 Apr;20(4):361–75 (54 ref.)

THERAPEUTIC USE

[Decongestants in treatment of nasal obstruction] Bogacka E. **Otolaryngol Pol** 1999;53(3):347–52 (20 ref.) (Eng. Abstr.) **(Pol)**

NASAL MUCOSA

Primary sinonasal mucosal melanoma: three different therapeutic approaches to inoperable local disease or recurrence and a review of the literature. De Meerleer GO, et al. **Melanoma Res** 1998 Oct;8(5):449–57 (52 ref.)

BLOOD SUPPLY

[Microcirculation in the nasal mucosa] Watanabe H, et al. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):211–8 (46 ref.) (Eng. Abstr.) **(Jpn)**

[On the impact of surgery on mucosal vessels of the turbinates (10 years of submucosal vasotomy)] Piskunov SZ. **Vestn Otorinolaringol** 1999;(2):19–22 (29 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Repeated allergen challenge as a new research model for studying allergic reactions. de Bruin-Weller MS, et al. **Clin Exp Allergy** 1999 Feb;29(2):159–65 (51 ref.)

IMMUNOLOGY

Nasal hyperreactivity. Gerth van Wijk RG, et al. **Rhinology** 1999 Jun;37(2):50–5 (49 ref.)

METABOLISM

Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. Marttin E, et al. **J Drug Target** 1998; 6(1):17–36 (98 ref.)

[Neuropeptides: their role in nasal physiology] Duroux S, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(1):25–8 (26 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Staphylococcus aureus infections in trauma patients [editorial; comment] Sheagren JN. **Crit Care Med** 1999 Apr; 27(4):692–3 (8 ref.) Comment on: Crit Care Med 1999 Apr;27(4):798–801.

[Carriers of Staphylococcus aureus as a source of nosocomial infections. Epidemiological and prophylactic aspects] Kolmos HJ. **Ugeskr Laeger** 1999 Mar 15;161(11):1580–4 (36 ref.) (Eng. Abstr.) **(Dan)**

PATHOLOGY

[Diagnostic values of nasal mucosa cytology] Miszke A, et al. **Otolaryngol Pol** 1999;53(2):153–6 (11 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Mucociliary transport and its assessment: a review. Lale AM, et al. **Clin Otolaryngol** 1998 Oct;23(5):388–96 (121 ref.)

The rheology of nasal mucus: a review. Quraishi MS, et al. **Clin Otolaryngol** 1998 Oct;23(5):403–13 (128 ref.)

SECRETION

The management of postnasal drip. Forer M, et al. **Aust Fam Physician** 1999 Mar;28(3):223–8 (22 ref.)

SURGERY

[Laser surgery for patients with nasal mucosal lesions] Suzaki H. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Jan;102(1):84–7 (3 ref.) **(Jpn)**

[On the impact of surgery on mucosal vessels of the turbinates (10 years of submucosal vasotomy)] Piskunov SZ. **Vestn Otorinolaringol** 1999;(2):19–22 (29 ref.) (Eng. Abstr.) **(Rus)**

NASAL OBSTRUCTION

Chronic nasal blockage. Wood S, et al. **Practitioner** 1999 Apr; 243(1597):251–6, 258 (0 ref.)

COMPLICATIONS

The nasal airway and obstructed breathing during sleep. Mirza N, et al. **Otolaryngol Clin North Am** 1999 Apr; 32(2):243–62 (61 ref.)

DIAGNOSIS

[Rhinomanometry: a method of objective study of nasal patency] Wojdas A, et al. **Otolaryngol Pol** 1997;51 Suppl 25:199–202 (10 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Decongestants in treatment of nasal obstruction] Bogacka E. **Otolaryngol Pol** 1999;53(3):347–52 (20 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Transglottic scleroma. Keschner D, et al. **Am J Otolaryngol** 1998 Nov–Dec;19(6):407–11 (11 ref.)

Primary amyloidosis presenting as a nasopharyngeal mass. Lim JS, et al. **Am J Rhinol** 1999 May–Jun;13(3):209–12 (14 ref.)

Isolated nasopharyngeal Hodgkin's disease presenting as nasal obstruction. Malis DD, et al. **Int J Clin Pract** 1998 Jul–Aug; 52(5):343–6 (28 ref.)

Chondroid hamartoma presenting as a neonatal nasal mass. Kim DW, et al. **Int J Pediatr Otorhinolaryngol** 1999 Mar 15;47(3):253–9 (17 ref.)

Concha bullosa pyocele—undiagnosed for 3 years. Dawlatly EE, et al. **Rhinology** 1999 Jun;37(2):90–2 (7 ref.)

[The nose in internal medicine (see comments)] Glück U. **Schweiz Med Wochenschr** 1998 Nov 14;128(46):1799–807 (50 ref.) (Eng. Abstr.) Comment in: Schweiz Med Wochenschr 1998 Nov 14;128(46):1797–8. **(Ger)**

MICROBIOLOGY

Scopulariopsis: an invasive nasal infection. Jabor MA, et al. **Am J Rhinol** 1998 Sep–Oct;12(5):367–71 (8 ref.)

PHYSIOPATHOLOGY

[Nasal obstruction. Physiology, etiology and review] Adant JP, et al. **Rev Med Liege** 1998 Nov;53(11):691–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Influence of nasal obstruction on sleep-associated breathing disorders] Dreher A, et al. **Laryngorhinootologie** 1999 Jun; 78(6):313–7 (82 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The nasal airway and obstructed breathing during sleep. Mirza N, et al. **Otolaryngol Clin North Am** 1999 Apr; 32(2):243–62 (61 ref.)

Controversies in the management of inferior turbinate hypertrophy: a comprehensive review. Jackson LE, et al. **Plast Reconstr Surg** 1999 Jan;103(1):300–12 (81 ref.)

[Treatment of nasal obstruction with subtotal inferior turbinectomy in chronic rhinitis: a retrospective study on 50 patients] Faulcon P, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115(4):228–33 (30 ref.) (Eng. Abstr.) **(Fre)**

[Increasing the length of the columella. Concepts and techniques] Schauss F. **HNO** 1999 Jul;47(7):663–73 (23 ref.) **(Ger)**

NASAL POLYPS

Rhinitis, sinusitis, and polyposis. Young MC. **Allergy Asthma Proc** 1998 Jul–Aug;19(4):211–8 (37 ref.)

A case of Pai syndrome. Mishima K, et al. **Plast Reconstr Surg** 1999 Jan;103(1):166–70 (27 ref.)

Nasal polyps: treat or refer? Slack R, et al. **Practitioner** 1997 Oct;241(1579):620 (1 ref.)

[Polypous ethmoiditis] Filatov VF, et al. **Vestn Otorinolaringol** 1999;(2):11–4 (11 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

[Corticotherapy in ENT. Subglottic laryngitis in children, acute sinusitis, naso-sinusal polyposis, sero-mucous otitis] De Corbiere S, et al. **Ann Med Interne (Paris)** 1998 Dec; 149(8):508–11 (16 ref.) (Eng. Abstr.) **(Fre)**

[Anti-recurrence treatment of polypous rhinosinusitis] Kondrat'ev VA, et al. **Vestn Otorinolaringol** 1999;(4):39 (3 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Nasal polyposis: eosinophils and interleukin-5. Kramer MF, et al. **Allergy** 1999 Jul;54(7):669–80 (127 ref.)

PATHOLOGY

[Diagnostic values of nasal mucosa cytology] Miszke A, et al. **Otolaryngol Pol** 1999;53(2):153–6 (11 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Surgical treatment of nasal polyps: past, present, and future. Stammberger H. **Allergy** 1999;54 Suppl 53:7–11 (9 ref.)

A case of metastatic nasopharyngeal carcinoma in benign nasal polyps. Sim RS, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):575–7 (5 ref.)

[After care of endonasal pansinus operations] Hörmann K, et al. **HNO** 1998 Dec;46(12):1004–14; quiz 1014 (9 ref.) **(Ger)**

[Selected aspects of endonasal paranasal sinus surgery] Reiss M. **Wien Med Wochenschr** 1998;148(20):469–73 (17 ref.) (Eng. Abstr.) **(Ger)**

[Day surgery for patients with nasal polyps] Moriyama H. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Mar;102(3):368–71 (4 ref.) **(Jpn)**

NASAL PROVOCATION TESTS

Experimental models in rhinitis. Demoly P, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:72–6 (17 ref.)

METHODS

Repeated allergen challenge as a new research model for studying allergic reactions. de Bruin-Weller MS, et al. **Clin Exp Allergy** 1999 Feb;29(2):159–65 (51 ref.)

NASAL SEPTUM

Rhinolithiasis associated with septal perforation. A case report. Kharoubi S. **Acta Otorhinolaryngol Belg** 1998; 52(3):241–5 (22 ref.)

INJURIES

Fracture of the anterior nasal spine. Escada P, et al. **Rhinology** 1999 Mar;37(1):40–2 (15 ref.)

SURGERY

Principles for correcting the septum in septorhinoplasty: two-point fixation. Jones NS. **J Laryngol Otol** 1999 May; 113(5):405–12 (11 ref.)

Craniofacial resection of a nasoseptal chondrosarcoma: case report and review of the literature. Kaufman JK, et al. **Surg Neurol** 1999 Sep;52(3):265–8; discussion 268–9 (20 ref.)

NASAL SINUSES see **PARANASAL SINUSES**

NASOLACRIMAL DUCT

SURGERY

Punctal occlusion [editorial] Cohen EJ. **Arch Ophthalmol** 1999 Mar;117(3):389–90 (9 ref.)

NASOPHARYNGEAL DISEASES

DIAGNOSIS

Flexible nasolaryngoscopy. A low-risk, high-yield procedure. Hayes JT, et al. **Postgrad Med** 1999 Sep; 106(3):107–10, 114 (7 ref.)

NASOPHARYNGEAL NEOPLASMS

Nasopharyngeal carcinoma research in Hong Kong in the past decade. Sham JS, et al. **Chin Med J (Engl)** 1997 Nov; 110(11):826–31 (49 ref.)

Nasopharyngeal carcinoma. Vokes EE, et al. **Lancet** 1997 Oct 11;350(9084):1087–91 (26 ref.)

COMPLICATIONS

Isolated nasopharyngeal Hodgkin's disease presenting as nasal obstruction. Malis DD, et al. **Int J Clin Pract** 1998 Jul–Aug; 52(5):343–6 (28 ref.)

DIAGNOSIS

Intracranial juvenile nasopharyngeal angiofibroma. Wylie JP, et al. **Clin Oncol (R Coll Radiol)** 1998;10(5):330–3 (10 ref.)

Carcinoma of the nasopharynx. Chong VF, et al. **Semin Ultrasound CT MR** 1998 Dec;19(6):449–62 (57 ref.)

DRUG THERAPY

Treatment of nasopharyngeal carcinoma: state of the art and new perspectives (review). Sanguineti G, et al. **Oncol Rep** 1999 Mar–Apr;6(2):377–91 (116 ref.)

EPIDEMIOLOGY

Nasopharyngeal mucosa-associated lymphoid tissue lymphoma in patients infected with the human immunodeficiency virus. Sundaram K, et al. **Am J Otolaryngol** 1999 Jan–Feb;20(1):56–8 (6 ref.)

ETIOLOGY

Aetiology of nasopharyngeal carcinoma. A review. Kumar S, et al. **Indian J Cancer** 1998 Jun;35(2):47–56 (65 ref.)

GENETICS

Child with mosaic variegated aneuploidy and embryonal rhabdomyosarcoma. Limwongse C, et al. **Am J Med Genet** 1999 Jan 1;82(1):20–4 (24 ref.)

PATHOLOGY

Management of the neck in nasopharyngeal carcinoma (NPC). Brown JJ, et al. **Otolaryngol Clin North Am** 1998 Oct;31(5):785–802 (54 ref.)

Epithelial-myoepithelial carcinoma arising in the nasal cavity: a case report and review of literature. Jin XL, et al. **Pathology** 1999 May;31(2):148–51 (27 ref.)

RADIOTHERAPY

Intracranial juvenile nasopharyngeal angiofibroma. Wylie JP, et al. **Clin Oncol (R Coll Radiol)** 1998;10(5):330–3 (10 ref.)

Treatment of nasopharyngeal carcinoma: state of the art and new perspectives (review). Sanguineti G, et al. **Oncol Rep** 1999 Mar–Apr;6(2):377–91 (116 ref.)

SURGERY

A case of metastatic nasopharyngeal carcinoma in benign nasal polyps. Sim RS, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):575–7 (5 ref.)

Salvage surgery for recurrent nasopharyngeal cancer. Morton RP. **Clin Otolaryngol** 1998 Oct;23(5):397–402 (43 ref.)

VIROLOGY

[Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma] Niedobitek G. **Pathologe** 1998 Sep;19(5):337–44 (16 ref.) (Eng. Abstr.) **(Ger)**

NASOPHARYNGITIS

DRUG THERAPY

[Systemic antibiotics in routine practice: ENT and lower respiratory tract infections. National Agency for Accreditation and Evaluation of Health (ANAES)] **Rev Pneumol Clin** 1999 Jun;55(3):127–54 (115 ref.) **(Fre)**

NASOPHARYNX

Primary amyloidosis presenting as a nasopharyngeal mass. Lim JS, et al. **Am J Rhinol** 1999 May–Jun;13(3):209–12 (14 ref.)

An unfortunate cause of death [letter] Baigel GD. **Anaesthesia** 1999 Sep;54(9):917–8 (3 ref.)

[Cancer of the rhinopharynx and the oropharynx. Epidemiology, diagnosis, complications a long time after treatment] Dehesdin D, et al. **Rev Prat** 1998 Mar 15; 48(6):667–74 (00 ref.) **(Fre)**

MICROBIOLOGY

Dynamics of nasopharyngeal colonization by Streptococcus

NASOPHARYNX

pneumoniae. Ghaffar F, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):638–46 (100 ref.)

[Microbial cenoses of the nasopharynx] Babich EM, et al. **Mikrobiol Z** 1999 May–Jun;61(3):63–70 (62 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Mechanisms and clinicophysiological implications of the sniff- and gasp-like aspiration reflex. Tomori Z, et al. **Respir Physiol** 1998 Oct;114(1):83–98 (52 ref.)

NATAL TEETH

PATHOLOGY

Epidermolysis bullosa simplex: review and report of case. Liu HH, et al. **ASDC J Dent Child** 1998 Sep–Oct; 65(5):349–53 (41 ref.)

NATIONAL AMBULATORY MEDICAL CARE SURVEY see **HEALTH CARE SURVEYS**

NATIONAL FORMULARY see **PHARMACOPOEIAS**

NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY see **NUTRITION SURVEYS**

NATIONAL HEALTH INSURANCE, NON-U.S. see **NATIONAL HEALTH PROGRAMS**

NATIONAL HEALTH INSURANCE, UNITED STATES

ECONOMICS

Financing children's health care needs in the next century. Schoen C, et al. **J Urban Health** 1998 Dec;75(4):639–59 (26 ref.)

LEGISLATION & JURISPRUDENCE

The missing millions: organized labor, business, and the defeat of Clinton's Health Security Act. Gottschalk M. **J Health Polit Policy Law** 1999 Jun;24(3):489–529 (176 ref.)

NATIONAL HEALTH PLANNING AND RESOURCES DEVELOPMENT ACT OF 1974 see **HEALTH PLANNING**

NATIONAL HEALTH POLICY see **HEALTH POLICY**

NATIONAL HEALTH PROGRAMS

see related
GOVERNMENT PROGRAMS

Onchocerciasis and Chagas' disease control: the evolution of control via applied research through changing development scenarios. Molyneux DH, et al. **Br Med Bull** 1998;54(2):327–39 (62 ref.)

Euthanasia and health reform in Canada. Stingl M. **Camb Q Healthc Ethics** 1998 Fall;7(4):348–62; discussion 363–70 (41 ref.)

Workshop report: research, policy and program planning on sun protective behaviours. Ashbury FD, et al. **Cancer Prev Control** 1998 Jun;2(3):129–32 (12 ref.)

Cancer in developing countries: Part II—Cancer control: strategies and priorities. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(5):283–7 (36 ref.)

How should the obese patient be managed? Possible approaches to a national obesity management network. Hainer V. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S14–8; discussion S18–9 (23 ref.)

The Second National Mental Health Plan: an opportunity to take stock and move forward [see comments] Singh BS, et al. **Med J Aust** 1998 Oct 19;169(8):435–7 (14 ref.) Comment in: Med J Aust 1999 May 3;170(9):452.

Renewing Australia's mental health strategy [see comments] Whiteford HA. **Med J Aust** 1998 Oct 19;169(8):432–4 (12 ref.) Comment in: Med J Aust 1999 May 3;170(9):452.

Status of hepatitis B immunization programmes in 1998. Kane MA. **Vaccine** 1998 Nov;16 Suppl:S104–8 (25 ref.)

[Quality recommendations of the German Society of Rheumatology. Basis for further responsibilities] Keitel W. **Z Rheumatol** 1998 Oct;57(5):355–7 (17 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Call for action: preventing and managing the expansive and expensive obesity epidemic [editorial; comment] [see comments] Lau DC. **CMAJ** 1999 Feb 23;160(4):503–6 (43 ref.) Comment on: CMAJ 1999 Feb 23;160(4):483–8. Comment on: CMAJ 1999 Feb 23;160(4):513–25. Comment in: CMAJ 1999 Jun 29;160(13):1821.

[Comment on the consensus report by medical staff on compensation for ambulatory and inpatient treatment] Hess R. **Chirurg** 1999 Feb;70(2):suppl 35–9 (0 ref.) **(Ger)**

[Quality management in the German health care system] Bangha E, et al. **Hautarzt** 1999 May;50(5):330–7 (53 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance for rational diagnosis and therapy in dermatology] Korting HC, et al. **Hautarzt** 1998 Oct; 49(10):755–61 (19 ref.) (Eng. Abstr.) **(Ger)**

[Allocation problems within the context of limited financial resources] Gandjour A, et al. **Internist (Berl)** 1999 Mar; 40(3):255–9 (12 ref.) **(Ger)**

[Rationing in medicine from the economic viewpoint] Obermann K. **Med Klin** 1999 Feb 15;94(2):110–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Managed care—a model also for ambulatory medical care in Germany?] Schucht C, et al. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):685–9 (32 ref.) (Eng. Abstr.) **(Ger)**

[Repositioning social work with the elderly? Effect of competitive elements and new guidance models on the profile of a profession] Schmidt R, et al. **Z Gerontol Geriatr** 1998 Oct;31(5):304–12 (54 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

What factors affect women's experiences with Medicaid managed care? Bernstein AB. **Womens Health Issues** 1998 Nov–Dec;8(6):325–38; discussion 350–8 (38 ref.)

[Change in legal assessment of unconventional medical methods in federal health insurance—consequences for social medicine expert assessment] Nüchtern E. **Gesundheitswesen** 1998 Aug–Sep;60(8–9):467–72 (26 ref.) (Eng. Abstr.) **(Ger)**

[Expert phoniatric assessment of voice adaptation in male to female transsexualism] Rosanowski F, et al. **HNO** 1999 Jun;47(6):556–62 (36 ref.) (Eng. Abstr.) **(Ger)**

[Indicators for quality evaluation of inpatient patient care in an ENT clinic (see comments)] Streppel M, et al. **HNO** 1998 Oct;46(10):864–9 (15 ref.) (Eng. Abstr.) Comment in: HNO 1998 Oct;46(10):840–1. **(Ger)**

[Definition of death and references on brain death, partial brain death and heart death] Angstwurm H. **Internist (Berl)** 1999 Mar;40(3):283–5 (3 ref.) **(Ger)**

[Allocation problems within the scope of organ transplantation] Neuhaus P. **Internist (Berl)** 1999 Mar; 40(3):270–5 (0 ref.) **(Ger)**

[Current prenatal care with reference to state of the art knowledge] Vogt HP. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1654–66 (42 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Medicare is fundamental to the health care of Australia [editorial] Brooks P. **Aust N Z J Public Health** 1999 Aug; 23(4):339–41 (11 ref.)

Divisions of population health: quantum leap forward or rearranging the deckchairs? Sainsbury P. **Aust N Z J Public Health** 1999 Apr;23(2):119–25 (30 ref.)

The human health programme under AMAP. AMAP Human Health Group. Arctic Monitoring and Assessment Program. Hansen JC. **Int J Circumpolar Health** 1998 Oct; 57(4):280–91 (6 ref.)

Creating alliances for disease management in industrial settings: a case study of HIV/AIDS in workers in South African gold mines. Williams B, et al. **Int J Occup Environ Health** 1998 Oct–Dec;4(4):257–64 (50 ref.)

Information management in national tuberculosis control programmes and national health information systems. Trébucq A, et al. **Int J Tuberc Lung Dis** 1998 Oct; 2(10):852–6 (6 ref.)

Access to medical care under strain: new pressures in Canada and Australia. Gray G. **J Health Polit Policy Law** 1998 Dec;23(6):905–47 (111 ref.)

German health care reform: the next steps. Jost T. **J Health Polit Policy Law** 1998 Aug;23(4):697–711 (42 ref.)

Update on health care in Canada: what's right, what's wrong, what's left. Livingston M. **J Public Health Policy** 1998; 19(3):267–88 (76 ref.)

When is research participatory? Reflections on a reproductive health project in Brazil. Diaz M, et al. **J Womens Health** 1999 Mar;8(2):175–84 (12 ref.)

National initiatives: management of heart disease and stroke. Westrick E. **Med Health R I** 1999 May;82(5):176–7 (3 ref.)

Developing health insurance in transitional Asia. Ensor T. **Soc Sci Med** 1999 Apr;48(7):871–9 (25 ref.)

Using social health insurance to meet policy goals. Normand C. **Soc Sci Med** 1999 Apr;48(7):865–9 (13 ref.)

Organizational changes in Canada. Décary F. **Vox Sang** 1998; 74 Suppl 2:527–9 (3 ref.)

Centralized or decentralized: philosophical considerations. Robinson EA. **Vox Sang** 1998;74 Suppl 2:535–7 (0 ref.)

STANDARDS

Quality in healthcare in the United Kingdom: lessons for Australia [see comments] Duggan JM. **Med J Aust** 1999 Feb 1;170(3):121–4 (16 ref.) Comment in: Med J Aust 1999 May 17;170(10):507. Comment in: Med J Aust 1999 May 17;170(10):507–8. Comment in: Med J Aust 1999 May 17;170(10):508. Comment in: Med J Aust 1999 May 17;170(10):508–9.

Governmental steering of highly specialized medical services [editorial] [see comments] Forfang K. **Scand Cardiovasc J** 1998;32(4):197–9 (5 ref.) Comment in: Scand Cardiovasc J 1998;32(4):195.

[Patients also desire standard therapies] Tanabe I. **Gan To Kagaku Ryoho** 1999 Apr;26(5):614–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Women, the welfare state, and their transnational dimension: the case of Mexico's community health worker programs. Ramirez-Valles J. **Int J Health Serv** 1999;29(3):597–621 (117 ref.)

[Do we really want managed care?] Geraedts M. **Gesundheitswesen** 1998 Aug–Sep;60(8–9):473–81 (46 ref.) (Eng. Abstr.) **(Ger)**

[Ethics in medicine: needs and forms] Reiter-Theil S, et al. **Internist (Berl)** 1999 Mar;40(3):246–54 (40 ref.) **(Ger)**

[Current responsibilities of health care research and political counseling] Wismar M. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):691–5 (15 ref.) (Eng. Abstr.) **(Ger)**

[Social work with the elderly—current orientation and strategies] Zeman P. **Z Gerontol Geriatr** 1998 Oct; 31(5):313–8 (34 ref.) (Eng. Abstr.) **(Ger)**

NATIONAL HEALTH SERVICE CORPS see **MEDICALLY UNDERSERVED AREA**

NATIONAL HEALTH SERVICE, BRITISH see **STATE MEDICINE**

NATIONAL HOSPITAL DISCHARGE SURVEY see **HEALTH CARE SURVEYS**

NATIONAL INSTITUTES OF HEALTH (U.S.)

A commentary on the new obesity guidelines from NIH. Ikeda JP, et al. **J Am Diet Assoc** 1999 Aug;99(8):918–9 (26 ref.)

The National Eye Institute outlines eye research goals. **J Am Optom Assoc** 1999 May;70(5):317–36 (0 ref.)

The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL. **J Health Polit Policy Law** 1999 Jun;24(3):531–65 (35 ref.)

ORGANIZATION & ADMINISTRATION

Prostate cancer research and the National Cancer Institute. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):235–40 (26 ref.)

National Institutes of Health (USA): role in tropical medicine research. Western KA. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):316–8 (0 ref.)

NATIONAL LIBRARY OF MEDICINE (U.S.)

see related
GRATEFUL MED

Web-based resources for retrieving health policy information: NLM and beyond. Cahn MA, et al. **J Urban Health** 1998 Dec;75(4):826–41 (26 ref.)

Sources used in health policy research and implications for information retrieval systems. Gray BH. **J Urban Health** 1998 Dec;75(4):842–52 (0 ref.)

Meeting information needs in health policy and public health: priorities for the National Library of Medicine and The National Network of Libraries of Medicine. Humphreys BL. **J Urban Health** 1998 Dec;75(4):878–83 (4 ref.)

NATIONALITY see **ETHNIC GROUPS**

NATIVE AMERICANS see **INDIANS, NORTH AMERICAN**

NATRIURESIS

Pathogenesis of ascites and renal salt retention in cirrhosis. Palmer BF. **J Investig Med** 1999 May;47(5):183–202 (181 ref.)

DRUG EFFECTS

Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. Hall JE, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S258–65 (33 ref.)

PHYSIOLOGY

Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Smyth DD, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:344–57 (72 ref.)

Natriuresis and inhibition of Na^+/K^+-ATPase: modulation of response by physiological manipulation. McDougall JG, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S57–60 (35 ref.)

Structural and functional evolution of the natriuretic peptide system in vertebrates. Takei Y. **Int Rev Cytol** 2000;194:1–66 (343 ref.)

Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. Ferrario CM, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1716–22 (73 ref.)

NATRIURETIC FACTOR see **NATRIURETIC HORMONE**

NATRIURETIC HORMONE

ANALYSIS

[Study and treatment of heart failure require new approaches. Natriuretic peptides can be safe and simple diagnostic and outcome measures] Lindstedt G, et al. **Lakartidningen** 1998 Nov 18;95(47):5311–5 (63 ref.) (Eng. Abstr.) **(Swe)**

METABOLISM

Regulation of natriuretic peptide secretion by the heart. Thibault G, et al. **Annu Rev Physiol** 1999;61:193–217 (143 ref.)

PHYSIOLOGY

Has the elusive "natriuretic factor" been discovered, and if so, is it a hormone? Wechter WJ, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):488–90 (12 ref.)

Vasoactive factors and tubulointerstitial injury. Wolf G. **Kidney Blood Press Res** 1999;22(1–2):62–70 (89 ref.)

A role for natriuretic peptides as well as endothelins in the hypoxic lungs of patients with chronic obstructive pulmonary disease [editorial; comment] Dorrington KL. **Respiration** 1999;66(3):208–9 (12 ref.) Comment on: Respiration 1999 ;66(3):212–9.

NATRIURETIC PEPTIDE, BRAIN

ANALYSIS

Brain natriuretic peptide in hypertrophic obstructive cardiomyopathy. Fujiwara H, et al. **Cardiologia** 1998 Sep; 43(9):901–8 (36 ref.)

BLOOD

Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Sagnella GA. **Clin Sci (Colch)** 1998 Nov;95(5):519–29 (95 ref.)

DIAGNOSTIC USE

Natriuretic peptides in assessment of left-ventricular dysfunction. Mair J, et al. **Scand J Clin Lab Invest Suppl** 1999;230:132–42 (21 ref.)

PHYSIOLOGY

Role of natriuretic peptides in ion transport mechanisms. Kourie JI, et al. **Med Res Rev** 1999 Jan;19(1):75–94 (120 ref.)

THERAPEUTIC USE

Potential future therapies: natriuretic peptides. Lisy O, et al. **Coron Artery Dis** 1999 Sep;10(6):389–94 (58 ref.)

NATRIURETIC PEPTIDE, C-TYPE

PHARMACOLOGY

[C-type natriuretic peptide: a novel cardiovascular active substance] Pei JM, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):271–3 (10 ref.) **(Chi)**

PHYSIOLOGY

C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. Chen HH, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S22–8 (60 ref.)

NATRIURETIC PEPTIDES, ATRIAL see **ATRIAL NATRIURETIC FACTOR**

NATURAL CHILDBIRTH

METHODS

Caring control: methodological issues in a discourse analysis of waterbirth texts. Redwood R. **J Adv Nurs** 1999 Apr; 29(4):914–21 (39 ref.)

STANDARDS

The traditional birth attendant: a reality and a challenge. Kamal IT. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S43–52 (11 ref.)

NATURAL DISASTERS

see related
RELIEF WORK

Natural disaster plus wake-up time: a deadly combination of triggers [editorial; comment] Kloner RA, et al. **Am Heart J** 1999 May;137(5):779–81 (20 ref.) Comment on: Am Heart J 1999 May;137(5):830–6.

A public mental health approach to the postdisaster treatment of children and adolescents. Pynoos RS, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):195–210, x (21 ref.)

US government natural disaster assistance: historical analysis and a proposal for the future. Barnett BJ. **Disasters** 1999 Jun;23(2):139–55 (55 ref.)

Race, ethnicity and disasters in the United States: a review of the literature. Fothergill A, et al. **Disasters** 1999 Jun; 23(2):156–73 (69 ref.)

Food aid in emergencies: a case for wheat? Landman J. **Proc Nutr Soc** 1999 May;58(2):355–61 (53 ref.)

Emergency management of disasters involving livestock in developing countries. Heath SE, et al. **Rev Sci Tech** 1999 Apr;18(1):256–71 (23 ref.)

Mitigation emerges as major strategy for reducing losses caused by natural disasters.Board of Natural Disasters. **Science** 1999 Jun 18;284(5422):1943–7 (20 ref.)

[The role of the veterinarian during natural disasters] Grandidier G. **Rev Sci Tech** 1999 Apr;18(1):239–55 (16 ref.) (Eng. Abstr.) **(Fre)**

NATURAL KILLER CELL STIMULATORY FACTOR see **INTERLEUKIN-12**

NATURAL KILLER CELLS see **KILLER CELLS, NATURAL**

NATURAL LANGUAGE PROCESSING

A methodology for partitioning a vocabulary hierarchy into trees. Gu H, et al. **Artif Intell Med** 1999 Jan;15(1):77–98 (35 ref.)

How knowledge drives understanding--matching medical ontologies with the needs of medical language processing. Hahn U, et al. **Artif Intell Med** 1999 Jan;15(1):25–51 (54 ref.)

Evaluating natural language processors in the clinical domain. Friedman C, et al. **Methods Inf Med** 1998 Nov; 37(4–5):334–44 (39 ref.)

Conceptual graph grammar--a simple formalism for sublanguage. Johnson SB. **Methods Inf Med** 1998 Nov; 37(4–5):345–52 (35 ref.)

The nature of lexical knowledge. McCray AT. **Methods Inf Med** 1998 Nov;37(4–5):353–60 (35 ref.)

Modeling concepts in medicine for medical language understanding. Rassinoux AM, et al. **Methods Inf Med** 1998 Nov;37(4–5):361–72 (0 ref.)

Concepts, knowledge and language in healthcare information systems: follow-up 30 months later. Scherrer JR. **Methods Inf Med** 1998 Nov;37(4–5):312–4 (23 ref.)

NATURAL RESOURCES see **CONSERVATION OF NATURAL RESOURCES**

NATURAL SELECTION see **SELECTION (GENETICS)**

NATUROPATHY

Mechanisms of autoprotection and the role of stress-proteins in natural defenses, autoprotection, and salutogenesis. Schaefer J, et al. **Med Hypotheses** 1998 Aug;51(2):153–63 (94 ref.)

NAUSEA

see related
ANTIEMETICS
EMETICS

CHEMICALLY INDUCED

Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Herrstedt J. **Dan Med Bull** 1998 Sep;45(4):412–22 (168 ref.)

Antiemetic therapy. Gralla RJ. **Semin Oncol** 1998 Oct; 25(5):577–83 (24 ref.)

[Anticipatory nausea and anticipatory vomiting, food aversion and anticipatory immunomodulation: classical conditioning in cytostatic drug treatment of pediatric chemotherapy patients] Stockhorst U, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1140–7 (37 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Adverse reactions to antinauseants in common use in the UK. Soukop M. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep; 17(2–3):91–113 (57 ref.)

Antiemetics. Wadibia EC. **South Med J** 1999 Feb;92(2):162–5; quiz 166 (8 ref.)

ETIOLOGY

Radiotherapy-induced emesis. An overview. Feyer P, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:56–61 (36 ref.)

NURSING

A symptom review: nausea and vomiting in HIV. Capili B, et al. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):47–56 (44 ref.)

PHYSIOPATHOLOGY

Illusory self-motion and motion sickness: a model for brain-gut interactions and nausea. Koch KL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):53S–57S (25 ref.)

PREVENTION & CONTROL

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery [see comments] **Am J Health Syst Pharm** 1999 Apr 15;56(8):729–64 (423 ref.) Comment in: Am J Health Syst Pharm 1999 Apr 15;56(8):728.

Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Herrstedt J. **Dan Med Bull** 1998 Sep;45(4):412–22 (168 ref.)

Guidelines for anti-emetic therapy: acute emesis. Fauser AA, et al. **Eur J Cancer** 1999 Mar;35(3):361–70 (94 ref.)

Antiemetic therapy. Gralla RJ. **Semin Oncol** 1998 Oct; 25(5):577–83 (24 ref.)

THERAPY

Alternative therapies for nausea and vomiting of pregnancy. Zeidenstein L. **J Nurse Midwifery** 1998 Sep–Oct; 43(5):392–3 (0 ref.)

Hypnotically induced control of nausea: a preliminary report. Renouf D. **J Psychosom Res** 1998 Sep;45(3):295–6 (13 ref.)

VIROLOGY

A symptom review: nausea and vomiting in HIV. Capili B, et al. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):47–56 (44 ref.)

NAUSEA AND VOMITING, POSTOPERATIVE see **POSTOPERATIVE NAUSEA AND VOMITING**

NAUTICAL MEDICINE see **NAVAL MEDICINE**

NAVAL MEDICINE

see related
DIVING
SHIPS

Diving and marine medicine review part I: diving physics and physiology. Spira A. **J Travel Med** 1999 Mar;6(1):32–44 (72 ref.)

NAVICULAR BONE OF FOOT see **TARSAL BONES**

NAVY PERSONNEL see **MILITARY PERSONNEL**

NCAM

GENETICS

Role of L1 in neural development: what the knockouts tell us. Kamiguchi H, et al. **Mol Cell Neurosci** 1998 Sep; 12(1–2):48–55 (54 ref.)

IMMUNOLOGY

L1 makes immunological progress by expanding its relations. Kadmon G, et al. **Dev Immunol** 1998;6(3–4):205–13 (40 ref.)

METABOLISM

The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Rønn LC, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):853–64 (99 ref.)

PHYSIOLOGY

Neural cell adhesion molecule L1: relating disease to function. Kenwrick S, et al. **Bioessays** 1998 Aug; 20(8):668–75 (57 ref.)

A role of adhesion molecules in neuroglial plasticity. Kiss JZ. **Mol Cell Endocrinol** 1998 May 25;140(1–2):89–94 (36 ref.)

Molecular mechanisms of commissural axon pathfinding. Stoeckli ET. **Prog Brain Res** 1998;117:105–14 (641 ref.)

[Molecular biological approach to functions of telencephalin, a cell adhesion molecule and HNK-1 carbohydrate epitope, which is commonly expressed on cell adhesion molecules in the nervous system] Oka S. **Yakugaku Zasshi** 1998 Oct; 118(10):431–46 (34 ref.) (Eng. Abstr.) **(Jpn)**

NEAR-DEATH EXPERIENCE see **DEATH**

NEAR DROWNING

Near drowning. Sachdeva RC. **Crit Care Clin** 1999 Apr; 15(2):281–96 (60 ref.)

ETIOLOGY

Kerosene-induced severe acute respiratory failure in near drowning: reports on four cases and review of the literature. Segev D, et al. **Crit Care Med** 1999 Aug; 27(8):1437–40 (14 ref.)

NEAR EAST EQUINE ENCEPHALOMYELITIS VIRUS see **BORNA DISEASE VIRUS**

NEARSIGHTEDNESS see **MYOPIA**

NEBULIZERS AND VAPORIZERS

see related
AEROSOLS

New delivery systems and propellants. Dolovich M. **Can Respir J** 1999 May–Jun;6(3):290–5 (20 ref.)

Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Keller M. **Int J Pharm** 1999 Sep

NEBULIZERS AND VAPORIZERS

10;186(1):81–90 (36 ref.)
Drug–surfactant–propellant interactions in HFA-formulations. Vervaet C, et al. **Int J Pharm** 1999 Sep 10;186(1):13–30 (84 ref.)
A critical review of ultralow-volume aerosols of insecticide applied with vehicle-mounted generators for adult mosquito control. Mount GA. **J Am Mosq Control Assoc** 1998 Sep;14(3):305–34 (166 ref.)
Drug administration by jet nebulization. Coates AL, et al. **Pediatr Pulmonol** 1998 Dec;26(6):412–23 (57 ref.)
[Good clinical practice in nebulization] Dautzenberg B, et al. **Ann Fr Anesth Reanim** 1998;17 Suppl 2:31s–36s (3 ref.) (Eng. Abstr.) **(Fre)**
[Nebulization: principles and generating process] Dessanges JF. **Ann Fr Anesth Reanim** 1998;17 Suppl 2:27s–30s (4 ref.) (Eng. Abstr.) **(Fre)**
[Preservatives in nebulizer solutions: risks without benefit] Hanquin JM. **J Pharm Belg** 1999 Mar–Apr;54(2):38–43 (0 ref.) **(Fre)**

STANDARDS

[Inhalation therapy in children younger than 2 years. II. The practice (see comments)] Griffioen RW, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1488–93 (15 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2212–3; discussion 2214–5. **(Dut)**
[Inhalation therapy in children younger than two years. I. From theory to practice (see comments)] Griffioen RW, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1484–8 (25 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2212–3; discussion 2214–5. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2213; discussion 2214–5. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2213–4; discussion 2214–5. **(Dut)**
[Anti-infective aerosols] Diot P, et al. **Rev Mal Respir** 1999 Jun;16(3):277–85 (40 ref.) (Eng. Abstr.) **(Fre)**

NECATOR AMERICANUS

[Wakana disease] Kojima S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):437–8 (1 ref.) **(Jpn)**

NECATORIASIS

[Wakana disease] Kojima S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):437–8 (1 ref.) **(Jpn)**

DRUG THERAPY

Parasitic infections. Treatment and developmental therapeutics. 1. Necatoriasis. Georgiev VS. **Curr Pharm Des** 1999 Jul;5(7):545–54 (142 ref.)

NECK

see related
CERVICAL VERTEBRAE
NECK MUSCLES

Cervical ectopic thyroid. Wong RJ, et al. **Am J Otolaryngol** 1998 Nov–Dec;19(6):397–400 (14 ref.)
Genodermatosis with reticulate, patchy and mottled pigmentation of the neck--a clue to rare dermatologic disorders. Itin PH, et al. **Dermatology** 1998;197(3):281–90 (133 ref.)
Reticulate, patchy and mottled pigmentation of the neck. Acquired forms. Lautenschlager S, et al. **Dermatology** 1998;197(3):291–6 (63 ref.)
Dumbbell lymphoma of the cervical spine in a child. Case report. Gezen F, et al. **J Neurosurg Sci** 1998 Dec;42(4):239–44 (27 ref.)
Primary amyloidosis presenting as massive cervical lymphadenopathy with severe dyspnea: a case report and review of the literature. Leach DB, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):560–4 (21 ref.)
Conservative neck surgery in squamous cell carcinoma. England RJ, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):91–4 (25 ref.)
[Acute tonsillitis, peritonsillitis, and deep neck infection] Nonomura N. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):304–6 (7 ref.) **(Jpn)**
[Deep neck infection and cervical necrotizing fasciitis due to odontogenic infections] Sakamoto H. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):360–2 (8 ref.) **(Jpn)**
[Deep neck infections] Pérez Plasencia D, et al. **An Otorrinolaringol Ibero Am** 1999;26(2):125–36 (12 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

[Surgical treatment of pterygium colli. A case report and review of the literature] Leandris M, et al. **Ann Chir Plast Esthet** 1997 Dec;42(6):615–22 (23 ref.) (Eng. Abstr.) **(Fre)**
[Congenital cysts and fistulas of the face and neck: often unrecognized dysembryoplasias] Jellouli Elloumi A, et al. **Tunis Med** 1999 Mar;77(3):117–26 (39 ref.) **(Fre)**

BLOOD SUPPLY

Head and neck vascular anomalies of childhood. Robertson RL, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):115–32 (59 ref.)

EMBRYOLOGY

Ultrasonography in the detection of fetal anomalies in early pregnancy. Economides DL, et al. **Br J Obstet Gynaecol** 1999 Jun;106(6):516–23 (50 ref.)
Prenatal ultrasonographic diagnosis of nuchal cord(s): disregard, inform, monitor or intervene? [editorial] Sherer DM, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):1–8 (58 ref.)
[Congenital cysts and fistulas of the face and neck: often unrecognized dysembryoplasias] Jellouli Elloumi A, et al. **Tunis Med** 1999 Mar;77(3):117–26 (39 ref.) **(Fre)**

INNERVATION

[Characteristics of the innervation of the head and neck] Neuhuber WL. **Orthopade** 1998 Dec;27(12):794–801 (56 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Endovascular occlusion of a carotid pseudoaneurysm complicating deep neck space infection in a child. Case report. Reisner A, et al. **J Neurosurg** 1999 Sep;91(3):510–4 (31 ref.)

PATHOLOGY

Congenital cystic masses of the neck: radiologic–pathologic correlation [published erratum appears in Radiographics 1999 Mar–Apr;19(2):282] Koeller KK, et al. **Radiographics** 1999 Jan–Feb;19(1):121–46; quiz 152–3 (95 ref.)

PHYSIOLOGY

The somatosensory system of the neck and its effects on the central nervous system. Bolton PS. **J Manipulative Physiol Ther** 1998 Oct;21(8):553–63 (84 ref.)
Cervicogenic headache: a critical review of the current diagnostic criteria. Leone M, et al. **Pain** 1998 Oct;78(1):1–5 (29 ref.)

RADIOGRAPHY

Congenital cystic masses of the neck: radiologic–pathologic correlation [published erratum appears in Radiographics 1999 Mar–Apr;19(2):282] Koeller KK, et al. **Radiographics** 1999 Jan–Feb;19(1):121–46; quiz 152–3 (95 ref.)

SURGERY

[Conservative cervico-facial facelift. Concept and preliminary results] Gola R. **Ann Chir Plast Esthet** 1997 Feb;42(1):9–20 (27 ref.) (Eng. Abstr.) **(Fre)**
[Surgical treatment of pterygium colli. A case report and review of the literature] Leandris M, et al. **Ann Chir Plast Esthet** 1997 Dec;42(6):615–22 (23 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Diagnosis and management of fetal nuchal translucency. Jackson M, et al. **Semin Roentgenol** 1998 Oct;33(4):333–8 (18 ref.)
First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: a happy union? Thilaganathan B. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):229–30 (23 ref.)

NECK INJURIES

Pediatric neck injuries. Hall DE, et al. **Pediatr Rev** 1999 Jan;20(1):13–9; quiz 20 (12 ref.)

COMPLICATIONS

Bilateral thrombosis of the internal carotid arteries after a closed trauma. Advantages of magnetic resonance imaging and review of the literature. Gouny P, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):417–24 (23 ref.)
Hypopharyngeal perforation after blunt neck trauma: case report and review of the literature. Jacobs I, et al. **J Trauma** 1999 May;46(5):957–8 (4 ref.)

DIAGNOSIS

Chronic neck syndromes: an update. Pawl RP. **Compr Ther** 1999 May;25(5):278–82 (32 ref.)

RADIOGRAPHY

Helical CT of cervical spine and soft tissue injuries of the neck. LeBlang SD, et al. **Radiol Clin North Am** 1999 May;37(3):515–32, v–vi (81 ref.)
[Therapeutic concept for injuries of the lower cervical spine] Hofmeister M, et al. **Orthopade** 1999 May;28(5):401–13 (39 ref.) (Eng. Abstr.) **(Ger)**
[Atlas fractures] Schären S, et al. **Orthopade** 1999 May;28(5):385–93 (54 ref.) (Eng. Abstr.) **(Ger)**

NECK MUSCLES

ANATOMY & HISTOLOGY

Anatomy of the platysma and lip depressor muscles. A simplified mnemonic approach. Hoefflin SM. **Dermatol Surg** 1998 Nov;24(11):1225–31 (17 ref.)

DRUG EFFECTS

Cosmetic use of botulinum A exotoxin for the aging neck. Brandt FS, et al. **Dermatol Surg** 1998 Nov;24(11):1232–4 (9 ref.)

PHYSIOLOGY

Vestibular evoked myogenic potentials in humans: a review. Ferber-Viart C, et al. **Acta Otolaryngol (Stockh)** 1999 Jan;119(1):6–15 (51 ref.)

TRANSPLANTATION

Platysma myocutaneous flap for intraoral reconstruction: an option in the compromised patient. Berenholz L, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):285–7 (11 ref.)

NECK NEOPLASMS see **HEAD AND NECK NEOPLASMS**

NECK PAIN

COMPLICATIONS

Concurrent cervical and craniofacial pain. A review of empiric and basic science evidence. Browne PA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):633–40 (89 ref.)

DIAGNOSIS

Chronic neck syndromes: an update. Pawl RP. **Compr Ther** 1999 May;25(5):278–82 (32 ref.)

ETIOLOGY

The syndrome of elongated styloid process. Ghosh LM, et al. **Auris Nasus Larynx** 1999 Apr;26(2):169–75 (28 ref.)
Acute neck pain and fever as the first manifestation of chondrocalcinosis with calcification of the transverse ligament of the atlas. Five case-reports with a literature review. Constantin A, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):583–5 (16 ref.)
[Surgical treatment of the rheumatic neck] Nygaard OP. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3965–9 (40 ref.) (Eng. Abstr.) **(Nor)**

PHYSIOPATHOLOGY

Concurrent cervical and craniofacial pain. A review of empiric and basic science evidence. Browne PA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):633–40 (89 ref.)
The clinical course and prognostic factors of non-specific neck pain: a systematic review. Borghouts JA, et al. **Pain** 1998 Jul;77(1):1–13 (35 ref.)

THERAPY

Management of neck pain: a primary care approach. Borenstein DG. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):147–50, 153–4, 160 (14 ref.)
Nonsurgical treatment of cervical degenerative disease. Rechtine GR. **Instr Course Lect** 1999;48:433–5 (18 ref.)
Managing pain from cervical spondylosis. Sari-Kouzel H, et al. **Practitioner** 1999 Apr;243(1597):334–8 (1 ref.)
A systematic review of randomized controlled trials of acupuncture for neck pain. White AR, et al. **Rheumatology (Oxford)** 1999 Feb;38(2):143–7 (46 ref.)
Nonoperative treatment of neck and arm pain [see comments] Dreyer SJ, et al. **Spine** 1998 Dec 15;23(24):2746–54 (78 ref.) Comment in: Spine 1999 Aug 15;24(16):1750–1.

NECKACHE see **NECK PAIN**

NECROBACILLOSIS see **FUSOBACTERIUM INFECTIONS**

NECROSIS

see related
TUMOR NECROSIS FACTOR

Cell death induced in lymphocytes expressing the elastin-laminin receptor by excess agonists: necrosis and apoptosis. Péterszegi G, et al. **Biomed Pharmacother** 1998;52(9):369–77 (33 ref.)
Apoptosis versus necrosis: the shape of neuronal cell death. Leist M, et al. **Results Probl Cell Differ** 1998;24:105–35 (273 ref.)
Biochemical determinants of apoptosis and necrosis. McConkey DJ. **Toxicol Lett** 1998 Nov 12;99(3):157–68 (100 ref.)
[Necrosis and apoptosis] Maruyama S. **Masui** 1998 Dec;47 Suppl:S77–80 (3 ref.) **(Jpn)**

NECROSIS, ASEPTIC, OF BONE see **OSTEONECROSIS**

NECROSIS, ASEPTIC, OF FEMUR HEAD see **FEMUR HEAD NECROSIS**

NECROSIS, AVASCULAR, OF BONE see **OSTEONECROSIS**

NECROSIS, AVASCULAR, OF FEMUR HEAD see **FEMUR HEAD NECROSIS**

NECROTIZING ARTERITIS see **POLYARTERITIS NODOSA**

NECROTIZING PANCREATITIS, ACUTE see **PANCREATITIS, ACUTE NECROTIZING**

NECROTIZING SCLERITIS see **SCLERITIS**

NEDOCROMIL

THERAPEUTIC USE

Treating severe eye allergy. Verin P. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:44–8 (14 ref.)

[Membrane stabilizers (chromones and ketotifen)] Mancel E, et al. **Allerg Immunol (Paris)** 1999 Apr;31(4):103–5 (9 ref.) (Eng. Abstr.) **(Fre)**

NEEDLES

Retrieval of a broken needle in the pterygomandibular space. Bedrock RD, et al. **J Am Dent Assoc** 1999 May; 130(5):685–7 (12 ref.)

Anatomic and technical considerations in needle electromyography of the lumbar spine. Frank LW, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):795–814, vi–vii (76 ref.)

NEEDLESTICK INJURIES

COMPLICATIONS

The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Blauvelt A. **Am J Med** 1997 May 19;102(5B):16–20 (31 ref.)

[The management of acute hepatitis C and needlestick accidents with hepatitis-C virus positive blood] Cooreman MP, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17; 142(42):2298–300 (12 ref.) (Eng. Abstr.) **(Dut)**

NEEDS ASSESSMENT

Linking public health education and practice: the Australian experience. Rotem A, et al. **Asia Pac J Public Health** 1998; 10(1):17–20 (10 ref.)

Lymphedema: patient and provider education: current status and future trends. Runowicz CD. **Cancer** 1998 Dec 15;83(12 Suppl American):2874–6 (5 ref.)

Addressing mental health needs of infants and young children. Mayes LC. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):209–24 (20 ref.)

The distinction between needs and wishes: implications for psychoanalytic theory and technique. Akhtar S. **J Am Psychoanal Assoc** 1999;47(1):113–51 (152 ref.)

When and why can an environmental epidemiologist legitimately refuse to undertake survey requested by public authorities (or other representatives of the population) on the ground that the proposal is insufficiently justified? [editorial] Terracini B. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):201–3 (10 ref.)

[Better assessment of the patients results in better nursing home care. A new system for development of geriatric care is being introduced] Ljunggren G. **Lakartidningen** 1998 Nov 4;95(45):4997–5000 (27 ref.) **(Swe)**

LEGISLATION & JURISPRUDENCE

[Effects exercised by the new federal German social legislation SGB III on assessing the incapacity to work by the medical experts of German statutory sickness insurance bodies] Nüchtern E. **Gesundheitswesen** 1999 Jun; 61(6):299–302 (1 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Cultural sensitivity in public health: defined and demystified. Resnicow K, et al. **Ethn Dis** 1999 Winter;9(1):10–21 (98 ref.)

Community analysis for health planning: strategies for primary care practitioners. Reece SM. **Nurse Pract** 1998 Oct;23(10):46, 49, 53–6 passim (23 ref.)

Organizing social work services with adult cancer patients: integrating empirical research. Cwikel JG, et al. **Soc Work Health Care** 1999;28(3):55–76 (94 ref.)

Issues at the interface between primary and secondary care in the management of common respiratory disease. 3: Providing better asthma care: what is there left to do? Neville RG, et al. **Thorax** 1999 Sep;54(9):813–7 (32 ref.)

NEF GENE PRODUCTS see **GENE PRODUCTS, NEF**

NEF PROTEIN see **GENE PRODUCTS, NEF**

NEFA see **FATTY ACIDS, NONESTERIFIED**

NEGATIVE BINOMIAL DISTRIBUTION see **BINOMIAL DISTRIBUTION**

NEGATIVE-PRESSURE VENTILATORS see **VENTILATORS, NEGATIVE-PRESSURE**

NEGATIVE REGULATORY ELEMENT, HIV see **HIV LONG TERMINAL REPEAT**

NEGATIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

NEGATIVE STAINING

METHODS

Negative staining of thinly spread biological particulates. Harris JR. **Methods Mol Biol** 1999;117:13–30 (11 ref.)

NEGATIVISTIC PERSONALITY DISORDER see **PASSIVE-AGGRESSIVE PERSONALITY DISORDER**

NEGATRONS see **ELECTRONS**

NEGLIGENCE, PROFESSIONAL see **MALPRACTICE**

NEGOTIATING

Communication and conflict resolution in emergency medicine. O'Mara K. **Emerg Med Clin North Am** 1999 May; 17(2):451–9, xii (36 ref.)

Understanding and applying alternative dispute resolution methods in modern medical conflicts. Liang BA. **J Leg Med** 1998 Sep;19(3):397–430 (53 ref.)

METHODS

The role of the psychologist in crisis/hostage negotiations. Hatcher C, et al. **Behav Sci Law** 1998 Autumn;16(4):455–72 (72 ref.)

PSYCHOLOGY

The role of the psychologist in crisis/hostage negotiations. Hatcher C, et al. **Behav Sci Law** 1998 Autumn;16(4):455–72 (72 ref.)

NEGROES see **BLACKS**

NEGROID RACE

see related
BLACKS

The role of hypertension, obesity, and diabetes in causing renal vascular disease. Crook ED. **Am J Med Sci** 1999 Mar;317(3):183–8 (36 ref.)

What is the role of obesity in hypertension and target organ injury in African Americans? Jones DW. **Am J Med Sci** 1999 Mar;317(3):147–51 (17 ref.)

Diabetes mellitus among ethnic seniors: contrasts with diabetes in whites. Kamel HK, et al. **Clin Geriatr Med** 1999 May;15(2):265–78 (127 ref.)

The prevention of cardiovascular disease in blacks. Ofili E, et al. **Curr Opin Cardiol** 1999 Mar;14(2):169–75 (38 ref.)

Xeroderma pigmentosum in black South Africans. Jacyk WK. **Int J Dermatol** 1999 Jul;38(7):511–4 (17 ref.)

Hypertension in black South Africans. Seedat YK. **J Hum Hypertens** 1999 Feb;13(2):96–103 (79 ref.)

Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. Flack JM, et al. **J Hypertens Suppl** 1999 Feb;17(1):S19–24 (45 ref.)

Whole organism physiology and ethnic differences in bone [editorial; comment] Heaney RP. **J Lab Clin Med** 1998 Nov;132(5):358–9 (8 ref.) Comment on: J Lab Clin Med 1998 Nov;132(5):383–9.

Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. Ijaduola TG, et al. **J Natl Med Assoc** 1998 Sep; 90(9):547–51 (45 ref.)

Is race an independent prognostic factor for survival from prostate cancer? Roach M 3rd. **J Natl Med Assoc** 1998 Nov;90(11 Suppl):S713–9 (58 ref.)

The management of hypertensive disease in black patients. Gibbs CR, et al. **QJM** 1999 Apr;92(4):187–92 (57 ref.)

Race and serum prostate-specific antigen levels: current status and future directions. Abdalla I, et al. **Semin Urol Oncol** 1998 Nov;16(4):207–13 (55 ref.)

Hereditary prostate cancer in African-American families. Cooney KA. **Semin Urol Oncol** 1998 Nov;16(4):202–6 (23 ref.)

Prostate cancer in the African American: is this a different disease? Powell IJ. **Semin Urol Oncol** 1998 Nov;16(4):221–6 (40 ref.)

Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Sakr WA, et al. **Semin Urol Oncol** 1998 Nov;16(4):214–20 (49 ref.)

Stroke mortality in blacks. Disturbing trends. Gillum RF. **Stroke** 1999 Aug;30(8):1711–5 (45 ref.)

Conjunctival melanoma in the black population. Singh AD, et al. **Surv Ophthalmol** 1998 Sep-Oct;43(2):127–33 (43 ref.)

[Hypertension in the Negro patient] Timmers GJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30;143(5):229–34 (37 ref.) (Eng. Abstr.) **(Dut)**

[Fatal asthma. Seven case reports observed in Black Africans and review of the literature] Koffi N, et al. **Rev Mal Respir** 1998 Sep;15(4):507–11 (34 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The role of genetic and environmental factors in cardiovascular disease in African Americans. Cooper R. **Am J Med Sci** 1999 Mar;317(3):208–13 (19 ref.)

Molecular genetics of prostate cancer: clinical applications. Morton RA Jr, et al. **J Natl Med Assoc** 1998 Nov;90(11 Suppl):S728–31 (44 ref.)

Differences between African American and white girls in the insulin-like growth factor-I and the binding proteins: importance of insulin resistance and hyperinsulinemia [editorial; comment] Caprio S. **J Pediatr** 1999 Sep; 135(3):270–1 (13 ref.) Comment on: J Pediatr 1999 Sep;135(3):296–300.

Epidemiology, demographics, and genetics of sarcoidosis. Rybicki BA, et al. **Semin Respir Infect** 1998 Sep; 13(3):166–73 (67 ref.)

NEIGHBORHOOD HEALTH CENTERS see **COMMUNITY HEALTH CENTERS**

NEISSERIA

METABOLISM

Iron acquisition systems in the pathogenic Neisseria. Schryvers AB, et al. **Mol Microbiol** 1999 Jun;32(6):1117–23 (41 ref.)

PATHOGENICITY

Pathogenic neisseriae: complexity of pathogen-host cell interplay. Meyer TF. **Clin Infect Dis** 1999 Mar;28(3):433–41 (45 ref.)

Fimbriae-mediated host-pathogen cross-talk. Abraham SN, et al. **Curr Opin Microbiol** 1998 Feb;1(1):75–81 (45 ref.)

NEISSERIA GONORRHOEAE

GENETICS

Competence for natural transformation in Neisseria gonorrhoeae: a model system for studies of horizontal gene transfer. Koomey M. **APMIS Suppl** 1998;84:56–61 (50 ref.)

IMMUNOLOGY

Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases—a review. Russell MW, et al. **Am J Reprod Immunol** 1999 Jul;42(1):58–63 (42 ref.)

Mechanisms of neisserial serum resistance. Vogel U, et al. **Mol Microbiol** 1999 Jun;32(6):1133–9 (46 ref.)

[Some aspects of the study of gonorrhea vaccine] He F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul; 32(4):248–50 (20 ref.) **(Chi)**

PATHOGENICITY

Host cell interactions and signalling with Neisseria gonorrhoeae. Naumann M, et al. **Curr Opin Microbiol** 1999 Feb;2(1):62–70 (71 ref.)

PHYSIOLOGY

Interactions of pathogenic Neisseria with host cells. Is it possible to assemble the puzzle? Nassif X, et al. **Mol Microbiol** 1999 Jun;32(6):1124–32 (60 ref.)

The role of neisserial Opa proteins in interactions with host cells. Dehio C, et al. **Trends Microbiol** 1998 Dec; 6(12):489–95 (69 ref.)

NEISSERIA MENINGITIDIS

Addressing emerging infections. The partnership between public health and primary care physicians. Danila RN, et al. **Postgrad Med** 1999 Aug;106(2):90–2, 97–8, 103–5 (15 ref.)

CLASSIFICATION

For discussion: live attenuated vaccines for group B meningococcus. Tang C, et al. **Vaccine** 1999 Jan;17(2):114–7 (30 ref.)

IMMUNOLOGY

Vaccination against meningococcus in complement-deficient individuals [comment] Morgan BP, et al. **Clin Exp Immunol** 1998 Dec;114(3):327–9 (28 ref.) Comment on: Clin Exp Immunol 1998 Dec;114(3):362–9.

Prophylaxis of bacterial meningitis. Peltola H. **Infect Dis Clin North Am** 1999 Sep;13(3):685–710, viii (138 ref.)

Mechanisms of neisserial serum resistance. Vogel U, et al. **Mol Microbiol** 1999 Jun;32(6):1133–9 (46 ref.)

For discussion: live attenuated vaccines for group B meningococcus. Tang C, et al. **Vaccine** 1999 Jan;17(2):114–7 (30 ref.)

[Anti-meningococcal vaccine: myth and reality] Nassif X. **Arch Pediatr** 1999;6 Suppl 3:647s–649s (13 ref.) **(Fre)**

ISOLATION & PURIFICATION

Neisseria meningitidis endogenous endophthalmitis: case report and literature review. Wong JS, et al. **J Pediatr Ophthalmol Strabismus** 1999 May-Jun;

NEISSERIA MENINGITIDIS

36(3):145–52 (40 ref.)

METABOLISM

Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Kahler CM, et al. **Crit Rev Microbiol** 1998;24(4):281–334 (250 ref.)

PATHOGENICITY

Interaction mechanisms of encapsulated meningococci with eucaryotic cells: what does this tell us about the crossing of the blood–brain barrier by Neisseria meningitidis? Nassif X. **Curr Opin Microbiol** 1999 Feb;2(1):71–7 (63 ref.)

PHYSIOLOGY

Interactions of pathogenic Neisseria with host cells. Is it possible to assemble the puzzle? Nassif X, et al. **Mol Microbiol** 1999 Jun;32(6):1124–32 (60 ref.)

The role of neisserial Opa proteins in interactions with host cells. Dehio C, et al. **Trends Microbiol** 1998 Dec; 6(12):489–95 (69 ref.)

NEISSERIACEAE INFECTIONS

[Branhamella pneumonia] Miura H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):362–5 (12 ref.) **(Jpn)**

COMPLICATIONS

Moraxella catarrhalis endocarditis: report of a case and literature review. Neumayer U, et al. **J Heart Valve Dis** 1999 Jan;8(1):114–7 (15 ref.)

DIAGNOSIS

Moraxella catarrhalis bacteraemia. A report on 3 cases and a review of the literature. Thórsson B, et al. **Scand J Infect Dis** 1998;30(2):105–9 (39 ref.)

MICROBIOLOGY

Moraxella (Branhamella) catarrhalis: clinical, microbiological and immunological features in lower respiratory tract infections. Christensen JJ. **APMIS Suppl** 1999;88:1–36 (249 ref.)

Pathogenic neisseriae: complexity of pathogen–host cell interplay. Meyer TF. **Clin Infect Dis** 1999 Mar;28(3):433–41 (45 ref.)

NELFINAVIR

THERAPEUTIC USE

Nelfinavir mesylate: a protease inhibitor. Pai VB, et al. **Ann Pharmacother** 1999 Mar;33(3):325–39 (64 ref.)

NELSON SYNDROME

PATHOLOGY

Progression of a Nelson's adenoma to pituitary carcinoma; a case report and review of the literature [published erratum appears in J Endocrinol Invest 1999 Jul–Aug;22(7):582] Kemink SA, et al. **J Endocrinol Invest** 1999 Jan;22(1):70–5 (43 ref.)

NEMALINE MYOPATHY

GENETICS

Genetics of the nemaline myopathies and the myotubular myopathies. Wallgren-Pettersson C. **Neuromuscul Disord** 1998 Aug;8(6):401–4 (28 ref.)

NEMATOCIDES see **ANTINEMATODAL AGENTS**

NEMATODA

see related
ANTINEMATODAL AGENTS

CHEMISTRY

Novel classes of fatty acid and retinol binding protein from nematodes. McDermott L, et al. **Mol Cell Biochem** 1999 Feb;192(1–2):69–75 (41 ref.)

GENETICS

Evolution of developmental mechanisms in nematodes. Félix MA. **J Exp Zool** 1999 Apr 15;285(1):3–18 (101 ref.)

Mitochondrial DNA diversity in nematodes. Blouin MS. **J Helminthol** 1998 Dec;72(4):285–9 (39 ref.)

The effects of mating probability on the population genetics of nematodes. Galvani A, et al. **J Helminthol** 1998 Dec; 72(4):295–300 (21 ref.)

Polymorphic DNA markers in the genome of parasitic nematodes. Roos MH, et al. **J Helminthol** 1998 Dec; 72(4):291–4 (38 ref.)

Caenorhabditis elegans is a nematode. Blaxter M. **Science** 1998 Dec 11;282(5396):2041–6 (45 ref.)

GROWTH & DEVELOPMENT

Evolution of developmental mechanisms in nematodes. Félix MA. **J Exp Zool** 1999 Apr 15;285(1):3–18 (101 ref.)

IMMUNOLOGY

Parasite immunology: pathways for expelling intestinal helminths. Maizels RM, et al. **Curr Biol** 1998 Oct 8; 8(20):R711–4 (25 ref.)

Intestinal nematode parasites, cytokines and effector mechanisms. Else KJ, et al. **Int J Parasitol** 1998 Aug; 28(8):1145–58 (104 ref.)

METABOLISM

Resistance of filarial nematode parasites to oxidative stress. Selkirk ME, et al. **Int J Parasitol** 1998 Sep;28(9):1315–32 (166 ref.)

Exploring the neurotransmitter labyrinth in nematodes. Brownlee DJ, et al. **Trends Neurosci** 1999 Jan;22(1):16–24 (86 ref.)

PHYSIOLOGY

The soybean cyst nematode, Heterodera glycines: a genetic model system for the study of plant-parasitic nematodes. Opperman CH, et al. **Curr Opin Plant Biol** 1998 Aug; 1(4):342–6 (27 ref.)

Plant nematode resistance genes. Williamson VM. **Curr Opin Plant Biol** 1999 Aug;2(4):327–31 (51 ref.)

Biological control of helminths. Larsen M. **Int J Parasitol** 1999 Jan;29(1):139–46; discussion 153–4 (80 ref.)

Production-based control of parasitic nematodes of cattle. Rew RS. **Int J Parasitol** 1999 Jan;29(1):177–82; discussion 183–4 (12 ref.)

International approaches to the concept of integrated control of nematode parasites of livestock. Waller PJ. **Int J Parasitol** 1999 Jan;29(1):155–64; discussion 183–4 (36 ref.)

NEMATODE INFECTIONS

see related
ANTINEMATODAL AGENTS

IMMUNOLOGY

Parasite immunology: pathways for expelling intestinal helminths. Maizels RM, et al. **Curr Biol** 1998 Oct 8; 8(20):R711–4 (25 ref.)

The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Finkelman FD, et al. **Curr Opin Immunol** 1999 Aug; 11(4):420–6 (84 ref.)

Intestinal nematode parasites, cytokines and effector mechanisms. Else KJ, et al. **Int J Parasitol** 1998 Aug; 28(8):1145–58 (104 ref.)

PREVENTION & CONTROL

Control strategies for human intestinal nematode infections. Albonico M, et al. **Adv Parasitol** 1999;42:277–341 (260 ref.)

Characterization of plant nematode genes: identifying targets for a transgenic defence. Lilley CJ, et al. **Parasitology** 1999; 118 Suppl:S63–72 (70 ref.)

VETERINARY

Progress and expectations for helminth vaccines. Meeusen EN, et al. **Adv Vet Med** 1999;41:241–56 (41 ref.)

Biological control of helminths. Larsen M. **Int J Parasitol** 1999 Jan;29(1):139–46; discussion 153–4 (80 ref.)

Production-based control of parasitic nematodes of cattle. Rew RS. **Int J Parasitol** 1999 Jan;29(1):177–82; discussion 183–4 (12 ref.)

Integrated control of nematode infections in cattle: a reality? A need? A future? Vercruysse J, et al. **Int J Parasitol** 1999 Jan;29(1):165–75; discussion 183–4 (50 ref.)

International approaches to the concept of integrated control of nematode parasites of livestock. Waller PJ. **Int J Parasitol** 1999 Jan;29(1):155–64; discussion 183–4 (36 ref.)

Nutrition–parasite interaction. Coop RL, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):187–204 (95 ref.)

Important parasites in poultry production systems. Ruff MD. **Vet Parasitol** 1999 Aug 1;84(3–4):337–47 (57 ref.)

NEMATOMORPHA see **HELMINTHS**

NEMATOMORPHA INFECTIONS see **HELMINTHIASIS**

NEOADJUVANT THERAPY

[Cancer of the esophagus: outcome of neoadjuvant therapy on surgical morbidity and mortality] Le Prisé EL. **Cancer Radiother** 1998 Dec;2(6):763–70 (36 ref.) (Eng. Abstr.) **(Fre)**

[Pancreatectomy after neoadjuvant chemoradiotherapy for potentially resectable exocrine adenocarcinoma of the pancreas] Partensky C, et al. **Cancer Radiother** 1998 Dec; 2(6):771–4 (13 ref.) (Eng. Abstr.) **(Fre)**

[Hypothetical and reliable aspects of pre-, intra- and postoperative adjuvant therapy of stomach carcinoma] Meyer HJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:312–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?] Fasolini F. **Zentralbl Chir** 1999; 124(5):441–5 (31 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy?] Maurer CA, et al. **Zentralbl Chir** 1999;124(5):401–7 (56 ref.) (Eng. Abstr.) **(Ger)**

[Stomach carcinoma. Optimizing therapy by neoadjuvant or adjuvant therapy?] Rosen H. **Zentralbl Chir** 1999; 124(5):387–93 (40 ref.) (Eng. Abstr.) **(Ger)**

[Application and limitation of neoadjuvant hormonal therapy for prostate cancer] Demura T, et al. **Nippon Rinsho** 1998 Aug;56(8):2150–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Radiation therapy with neoadjuvant hormonal therapy for prostate cancer confined to pelvis] Furuya Y, et al. **Nippon Rinsho** 1998 Aug;56(8):2181–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume] Hachiya T, et al. **Nippon Rinsho** 1998 Aug;56(8):2157–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Complications from induction regimens for thoracic malignancies. Perioperative considerations. Liptay MJ, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):79–95 (36 ref.)

METHODS

Neoadjuvant hormonal therapy in carcinoma of the prostate. Lee HH, et al. **BJU Int** 1999 Mar;83(4):438–48 (81 ref.)

NEOADJUVANT TREATMENT see **NEOADJUVANT THERAPY**

NEOBALAENIDAE see **WHALES**

NEOCORTEX

Neuromodulation, development and synaptic plasticity. Foehring RC, et al. **Can J Exp Psychol** 1999 Mar; 53(1):45–61 (125 ref.)

ABNORMALITIES

Neuronal migration disorders. Part II: Magnetic resonance imaging. Saatçi I, et al. **Turk J Pediatr** 1998 Oct–Dec; 40(4):481–90 (17 ref.)

Neuronal migration disorders. Part I: Terminology, classification, pathophysiology, EEG and epilepsy. Turanli G, et al. **Turk J Pediatr** 1998 Oct–Dec;40(4):473–80 (26 ref.)

CHEMISTRY

Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. van der Zee EA, et al. **Prog Neurobiol** 1999 Aug;58(5):409–71 (620 ref.)

CYTOLOGY

Cajal-Retzius cells, Reelin, and the formation of layers. Frotscher M. **Curr Opin Neurobiol** 1998 Oct;8(5):570–5 (49 ref.)

The G1 restriction point as critical regulator of neocortical neuronogenesis. Caviness VS Jr, et al. **Neurochem Res** 1999 Apr;24(4):497–506 (69 ref.)

PATHOLOGY

Selective vulnerability of neocortical association areas in Alzheimer's disease. Giannakopoulos P, et al. **Microsc Res Tech** 1998 Oct 1;43(1):16–23 (86 ref.)

Surgical pathology of epilepsy resections in childhood. Jay V, et al. **Semin Pediatr Neurol** 1995 Sep;2(3):227–36 (64 ref.)

PHYSIOLOGY

Electro-oscillographic correlation between dorsal raphe nucleus, neocortex and hippocampus during wakefulness before and after serotoninergic inactivation. Fonoff ET, et al. **Braz J Med Biol Res** 1999 Apr;32(4):469–72 (14 ref.)

Quantal analysis of synaptic processes in the neocortex. Thomson AM. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):131–3 (16 ref.)

Increased neocortical spiking and surgical outcome after selective amygdalo-hippocampectomy. Wennberg RA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998; 48:105–11 (23 ref.)

Correlation between mesial temporal and temporal neocortical interictal spiking in acute ECoG and chronic depth electrode recordings. Wennberg RA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:123–31 (52 ref.)

Cellular distribution of the calcium-binding proteins parvalbumin, calbindin, and calretinin in the neocortex of mammals: phylogenetic and developmental patterns. Hof PR, et al. **J Chem Neuroanat** 1999 Feb;16(2):77–116 (198 ref.)

[The dynamics of neocortical modifications: the dependence on motivational and emotiogenic systems] Kozhedub RG. **Usp Fiziol Nauk** 1999 Apr–Jun;30(2):21–40 (128 ref.) (Eng. Abstr.) **(Rus)**

NEOLIGNANS see **LIGNANS**

NEOMALTHUSIANISM see **POPULATION DYNAMICS**

NEOMYCIN PHOSPHOTRANSFERASE see **KANAMYCIN KINASE**

NEONATAL ABSTINENCE SYNDROME

COMPLICATIONS

Substance abuse: infant and childhood outcomes. D'Apolito K. **J Pediatr Nurs** 1998 Oct;13(5):307–16 (92 ref.)

DIAGNOSIS

Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Ostrea EM Jr. **Curr Probl Pediatr** 1999 Feb;29(2):37–56 (86 ref.)

EPIDEMIOLOGY

Neonatal drug addiction. Fabris C, et al. **Panminerva Med** 1998 Sep;40(3):239–43 (20 ref.)

THERAPY

Ethical challenges in the treatment of infants of drug-abusing mothers. Jain R, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):179–88 (37 ref.)

Treatment strategies for drug-exposed neonates. Kandall SR. **Clin Perinatol** 1999 Mar;26(1):231–43 (68 ref.)

NEONATAL CALF DIARRHEA VIRUS see **ROTAVIRUS**

NEONATAL IMMUNITY, MATERNALLY-ACQUIRED see **IMMUNITY, MATERNALLY-ACQUIRED**

NEONATAL INTENSIVE CARE see **INTENSIVE CARE, NEONATAL**

NEONATAL INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, NEONATAL**

NEONATAL MORTALITY see **INFANT MORTALITY**

NEONATAL NURSING

Systemic lupus erythematosus: perinatal and neonatal implications. Classen SR, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct; 27(5):493–500 (20 ref.)

Following the learning curve: the evolution of kinder, gentler neonatal respiratory technology. Lockridge T. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):443–55 (105 ref.)

Common orthopedic problems of the newborn. Fernbach SA. **Nurs Clin North Am** 1998 Dec;33(4):583–94 (60 ref.)

EDUCATION

Coping with transition: neonatal nurse practitioner education for the 21st century. Strodtbeck F, et al. **J Pediatr Nurs** 1998 Oct;13(5):272–8 (19 ref.)

LEGISLATION & JURISPRUDENCE

Legal issues in neonatal nursing: considerations for staff nurses and advanced practice nurses. Enzman Hagedorn MI, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):320–30 (29 ref.)

Strategies for reducing the risk of malpractice litigation in perinatal nursing. Koniak-Griffin D. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):291–9 (33 ref.)

Fetal surveillance and monitoring legal issues revisited. McRae MJ. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):310–9 (28 ref.)

Professional accountability and legal liability for the team leader and charge nurse. Mahlmeister L. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):300–9 (23 ref.)

METHODS

Neonatal skin care: the scientific basis for practice. Lund C, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):241–54 (100 ref.)

Neonatal skin: the ideal nursing interface. Lott JW, et al. **J Pediatr Nurs** 1998 Oct;13(5):302–6 (11 ref.)

ORGANIZATION & ADMINISTRATION

Career opportunities for neonatal nurses. Kenner C, et al. **J Pediatr Nurs** 1998 Oct;13(5):317–25 (30 ref.)

Coping with transition: neonatal nurse practitioner education for the 21st century. Strodtbeck F, et al. **J Pediatr Nurs** 1998 Oct;13(5):272–8 (19 ref.)

NEONATAL SCREENING

The European Consensus Development Conference on Neonatal Hearing Screening (Milan, May 15–16, 1998). Grandori F, et al. **Am J Audiol** 1999 Jun;8(1):19–20 (0 ref.)

The European Consensus Development Conference on Neonatal Hearing Screening (Milan, May 15–16, 1998) [letter] Grandori F. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):118 (0 ref.)

The European consensus development conference on neonatal hearing screening (Milan, 15–16 May, 1998). **Eur Arch Otorhinolaryngol** 1998;255(10):521–2 (0 ref.)

European Consensus Statement on Neonatal Hearing Screening. Finalised at the European Consensus Development Conference on Neonatal Hearing Screening, 15–16 May 1998, Milan. Grandori F, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 1O;44(3):309–10 (0 ref.)

Population newborn screening for inherited metabolic disease: current UK perspectives. Green A, et al. **J Inherit Metab Dis** 1999 Jun;22(4):572–9 (27 ref.)

European Consensus Statement on Neonatal Hearing Screening. Finalised at the European Consensus Development Conference on Neonatal Hearing Screening 15–16 May 1998, Milan [editorial] Tewfik TL, et al. **J Otolaryngol** 1999 Feb;28(1):1–2 (7 ref.) **(Eng, Fre)**

A project from the Biomedical and Health Programme European Commission – Biomed 2 –Directorate General XII. The European Consensus Development Conference on Neonatal Hearing Screening. Grandori F, et al. **J Perinat Med** 1998;26(4):330–1 (0 ref.)

European Consensus statement on neonatal hearing screening finalised at the European Consensus Development Conference on Neonatal Hearing Screening 15–16 May 1998, Milan, Italy. **Scand Audiol** 1998;27(4):259–60 (0 ref.)

Screening for congenital hypothyroidism used as an indicator of the degree of iodine deficiency and of its control. Delange F. **Thyroid** 1998 Dec;8(12):1185–92 (43 ref.)

[Neonatal hearing screening—consequences for public health policy] Henke KD, et al. **Gesundheitswesen** 1999 Feb; 61(2):86–92 (51 ref.) (Eng. Abstr.) **(Ger)**

[Neonatal hearing screening: screening test for hearing disorders in newborn infants. Report on the "European Consensus Development Conference on Neonatal Hearing Screening", Mailand, 15–16 May 1998] Welzl-Müller K. **HNO** 1998 Aug;46(8):704–7 (0 ref.) **(Ger)**

[Screening for retinopathy of prematurity: reliability] de la Cruz Bértolo FJ, et al. **An Esp Pediatr** 1999 Feb; 50(2):156–60 (45 ref.) **(Spa)**

METHODS

Evaluating newborn screening programmes based on dried blood spots: future challenges. Dezateux C. **Br Med Bull** 1998;54(4):877–90 (41 ref.)

Tandem spectrometry in newborn screening. Seashore MR. **Curr Opin Pediatr** 1998 Dec;10(6):609–14 (30 ref.)

Screening for cystic fibrosis. Murray J, et al. **Health Technol Assess** 1999;3(8):i–iv, 1–104 (455 ref.)

European Consensus Statement on Neonatal Hearing Screening [letter] Grandori F. **J Laryngol Otol** 1998 Dec; 112(12):1219 (2 ref.)

Application of electrospray tandem mass spectrometry to neonatal screening. Rashed MS, et al. **Semin Perinatol** 1999 Apr;23(2):183–93 (55 ref.)

[Why and how to examine the newborns' hips?] Philippet B, et al. **Rev Med Liege** 1998 Aug;53(8):470–4 (10 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

What should be the role of public health in newborn screening and prenatal diagnosis? Clayton EW. **Am J Prev Med** 1999 Feb;16(2):111–5 (20 ref.)

STANDARDS

Screening for neonatal hearing defects European consensus statement. Lutman ME, et al. **Eur J Pediatr** 1999 Feb; 158(2):95–6 (4 ref.)

A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. Thomason MJ, et al. **J Public Health Med** 1998 Sep;20(3):331–43 (63 ref.)

NEONATAL WITHDRAWAL SYNDROME see **NEONATAL ABSTINENCE SYNDROME**

NEONATE see **INFANT, NEWBORN**

NEONATOLOGY

see related
INFANT, NEWBORN

ECONOMICS

Neonatology in developing countries: problems, practices and prospects. Dawodu A. **Ann Trop Paediatr** 1998 Sep; 18 Suppl:S73–9 (35 ref.)

STANDARDS

A primer on clinical management guidelines in neonatology. Bowen FW. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S10–2 (36 ref.)

Administrative data for quality improvement. Schwartz RM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):291–301 (30 ref.)

[Consensus conference on prenatal care, delivery, and the newborn. Paris, France, 2–3 December 1998. Proceedings] **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:1–317 (0 ref.) **(Fre)**

TRENDS

Metabolic response to neonatal surgery. Pierro A. **Curr Opin Pediatr** 1999 Jun;11(3):230–6 (65 ref.)

NEONICOTINE see **ANABASINE**

NEOPLASIA, PROSTATIC INTRAEPITHELIAL see **PROSTATIC INTRAEPITHELIAL NEOPLASIA**

NEOPLASIA, CERVICAL INTRAEPITHELIAL see **CERVICAL INTRAEPITHELIAL NEOPLASIA**

NEOPLASIA, MULTIPLE ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

NEOPLASIA, MULTIPLE ENDOCRINE TYPE 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

NEOPLASIA, MULTIPLE ENDOCRINE TYPE 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

NEOPLASIA, MULTIPLE ENDOCRINE, TYPE 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

NEOPLASM ANTIBODIES see **ANTIBODIES, NEOPLASM**

NEOPLASM ANTIGENS see **ANTIGENS, NEOPLASM**

NEOPLASM CIRCULATING CELLS

New prognostic factors in melanoma: mRNA tumour markers. Keilholz U. **Eur J Cancer** 1998 Jul;34 Suppl 3:S37–41 (37 ref.)

Flow cytometry—principles and feasibility in transfusion medicine. Enumeration of epithelial derived tumor cells in peripheral blood. Terstappen LW, et al. **Vox Sang** 1998; 74 Suppl 2:269–74 (12 ref.)

[Neoplastic obstruction of the vena cava inferior in general surgery] Forni E, et al. **G Chir** 1999 Jun–Jul; 20(6–7):296–306 (70 ref.) (Eng. Abstr.) **(Ita)**

[Successful preoperative interferon-alpha therapy of renal cell carcinoma with tumor thrombus extending into the inferior vena cava—case report] Miki T, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):796–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Friedl P, et al. **Cell Adhes Commun** 1998; 6(2–3):225–36 (67 ref.)

How tumor cells make use of CD44. Herrlich P, et al. **Cell Adhes Commun** 1998;6(2–3):141–7 (52 ref.)

IMMUNOLOGY

How tumor cells make use of CD44. Herrlich P, et al. **Cell Adhes Commun** 1998;6(2–3):141–7 (52 ref.)

PATHOLOGY

The polymerase chain reaction in the detection of micrometastases and circulating tumor cells: present status and future potential. Ghossein RA, et al. **Anat Pathol** 1998; 3:233–51 (105 ref.)

Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. Morris VL, et al. **Invasion Metastasis** 1997;17(6):281–96 (56 ref.)

Cell adhesion molecules in the formation of liver metastasis. Jiang WG. **J Hepatobiliary Pancreat Surg** 1998;5(4):375–82 (49 ref.)

Adrenal neuroblastoma in an adult with tumor thrombus in the inferior vena cava. Custodio CM, et al. **J Magn Reson Imaging** 1999 Apr;9(4):621–3 (11 ref.)

[Immunocytochemical and molecular proof of disseminated tumor cells in bone marrow, peritoneal lavage, blood and regional lymph nodes. A review of the literature and own results] Broll R, et al. **Zentralbl Chir** 1999;124(4):286–91 (43 ref.) (Eng. Abstr.) **(Ger)**

[Carbohydrate chains and hematogenous metastasis: a review] Kawamura YJ, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul; 99(7):419–24 (20 ref.) (Eng. Abstr.) **(Jpn)**

NEOPLASM DNA see **DNA, NEOPLASM**

NEOPLASM INVASIVENESS

see related
LEUKEMIC INFILTRATION

Microinvasive carcinoma of the breast: a diagnosis in search of a definition. Schnitt SJ. **Adv Anat Pathol** 1998 Nov; 5(6):367–72 (36 ref.)

Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Kähäri VM, et al. **Ann Med** 1999 Feb;31(1):34–45 (129 ref.)

Cancer invasion and tissue remodeling—cooperation of protease systems and cell types. Danø K, et al. **APMIS** 1999 Jan;107(1):120–7 (102 ref.)

NEOPLASM INVASIVENESS

Extracellular regulation of cancer invasion: the E-cadherin-catenin and other pathways. Noë V, et al. **Biochem Soc Symp** 1999;65:43-62 (76 ref.)
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Johnsen M, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):667-71 (44 ref.)
Regulation of tumor cell invasion by extracellular matrix. Crowe DL, et al. **Histol Histopathol** 1999 Apr;14(2):665-71 (79 ref.)
Membrane-type metalloproteinases in tumor invasion. Polette M, et al. **Int J Biochem Cell Biol** 1998 Nov; 30(11):1195-202 (42 ref.)
Pathophysiologic significance of host reactions in human cancer tissue: desmoplasia and tumor immunity. Ohtani H. **Tohoku J Exp Med** 1999 Mar;187(3):193-202 (33 ref.)
[Integrins and metalloproteinases: an efficient collaboration in the invasive process] Rémy L, et al. **Bull Cancer** 1999 Feb;86(2):154-8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Induction of tumor invasion by lysophosphatidic acid and inhibition of tumor invasion by cyclic phosphatidic acid] Mukai M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1126-31 (16 ref.) **(Jpn)**

GENETICS

Regulation of matrix metalloproteinase expression in tumor invasion. Westermarck J, et al. **FASEB J** 1999 May; 13(8):781-92 (115 ref.)
[The alpha-catenin gene is a suppressor gene of neoplasm invasiveness] Mareel M, et al. **C R Seances Soc Biol Fil** 1998;192(2):231-4 (10 ref.) **(Fre)**

PATHOLOGY

Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Chen WT, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:361-71 (52 ref.)
The invasive front of carcinomas. The most important area for tumour prognosis? Bryne M, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4757-64 (63 ref.)
Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Albini A. **Pathol Oncol Res** 1998; 4(3):230-41 (148 ref.)

PHYSIOPATHOLOGY

Cellular and molecular mechanisms of tumor invasion. Rovensky YA. **Biochemistry (Mosc)** 1998 Sep; 63(9):1029-43 (169 ref.)
Regulation of matrix metalloproteinase expression in tumor invasion. Westermarck J, et al. **FASEB J** 1999 May; 13(8):781-92 (115 ref.)
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Reuning U, et al. **Int J Oncol** 1998 Nov;13(5):893-906 (207 ref.)
Hyaluronidases in tissue invasion. Csóka TB, et al. **Invasion Metastasis** 1997;17(6):297-311 (106 ref.)
[Extracellular proteases of stromal origin: contribution to tumor progression and therapeutic perspectives] Rio MC, et al. **C R Seances Soc Biol Fil** 1998;192(2):253-9 (21 ref.) (Eng. Abstr.) **(Fre)**
[Similarities between angiogenesis and neoplasm invasiveness] Stéhelin D. **C R Seances Soc Biol Fil** 1998;192(2):217-22 (21 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prophylactic treatment of superficial bladder tumor. Lee C, et al. **Int J Urol** 1998 Nov;5(6):511-20 (101 ref.)

RADIOGRAPHY

Pictorial review: Subperitoneal spaces of the broad ligament and sigmoid mesocolon--imaging findings. Hashimoto M, et al. **Clin Radiol** 1998 Dec;53(12):875-81 (9 ref.)

NEOPLASM METASTASIS

Cathepsin D in cancer metastasis: a protease and a ligand. Rochefort H, et al. **APMIS** 1999 Jan;107(1):86-95 (78 ref.)
Cutaneous lesions of metastatic visceral malignancy mimicking pyogenic granuloma. Hager CM, et al. **Cancer Invest** 1999;17(6):385-90 (22 ref.)
Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Lange PH, et al. **Cancer Metastasis Rev** 1998-99;17(4):331-6 (46 ref.)
Cancer metastasis: an update. Haylock PJ. **Semin Oncol Nurs** 1998 Aug;14(3):172-7 (42 ref.)
[Value of human colonic cancer models by surgical cecal implantation in nude mice] Pocard M, et al. **Ann Chir** 1999; 53(3):227-32 (42 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of post-operative recurrence of colorectal cancer] Kodaira S. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):206-10 (26 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The polymerase chain reaction in the detection of micrometastases and circulating tumor cells: present status and future potential. Ghossein RA, et al. **Anat Pathol** 1998; 3:233-51 (105 ref.)
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Lambrechts AC, et al. **Ann Oncol** 1998 Dec;9(12):1269-76 (60 ref.)
Fine needle aspiration biopsy of the liver. Principal diagnostic challenges. Pitman MB. **Clin Lab Med** 1998 Sep; 18(3):483-506, vi (64 ref.)
Detection and clinical importance of micrometastatic disease. Pantel K, et al. **J Natl Cancer Inst** 1999 Jul 7;91(13):1113-24 (180 ref.)
[Positron emission tomography of the skeletal system using 18FNa: frequency, distribution and appearance of skeletal metastases] Schirrmeister H, et al. **Rontgenpraxis** 1999; 52(1):19-25 (30 ref.) **(Ger)**
[Sister Mary Joseph's nodule. Its clinical significance and management] Giner Galvañ V. **An Med Interna** 1999 Jul; 16(7):365-70 (99 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Drug control of solid tumour metastases: a critical view. Sava G, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):1117-24 (83 ref.)
Anti-adhesion cancer therapy. Glinsky GV. **Cancer Metastasis Rev** 1998 Jun;17(2):177-85 (58 ref.)
The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Krüger A, et al. **Cancer Metastasis Rev** 1998-99;17(3):285-94 (35 ref.)
Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Wiseman LR, et al. **Drugs Aging** 1999 Jun;14(6):459-75 (89 ref.)

GENETICS

New genes potentially involved in breast cancer metastasis. Schwirzke M, et al. **Anticancer Res** 1999 May-Jun; 19(3A):1801-14 (135 ref.)
Metastasis-related genes in prostate cancer: the role of caveolin-1. Thompson TC. **Cancer Metastasis Rev** 1998-99; 17(4):439-42 (18 ref.)
Metastasis-Associated genes and metastatic tumor progression. Nicolson GL, et al. **In Vivo** 1998 Nov-Dec; 12(6):579-88 (57 ref.)
Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Hsieh HF, et al. **Mol Pathol** 1999 Feb; 52(1):25-8 (47 ref.)
Modeling metastasis in the mouse. McClatchey AI. **Oncogene** 1999 Sep 20;18(38):5334-9 (62 ref.)
[Oncogenic factors of metastatic dissemination in neuroblastoma] Da Silva J, et al. **C R Seances Soc Biol Fil** 1998;192(2):261-71 (26 ref.) (Eng. Abstr.) **(Fre)**
[Tumor metastasis. Molecular principles and therapeutic options] Ghadimi BM, et al. **Chirurg** 1998 Dec; 69(12):1315-22 (36 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

How tumor cells make use of CD44. Herrlich P, et al. **Cell Adhes Commun** 1998;6(2-3):141-7 (52 ref.)

PATHOLOGY

Disseminated tumor cells versus micrometastasis: definitions and problems. Hermanek P. **Anticancer Res** 1999 Jul-Aug; 19(4A):2771-4 (47 ref.)
Matrix metalloproteinases and metastasis. Kleiner DE, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S42-51 (67 ref.)
Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. Morris VL, et al. **Invasion Metastasis** 1997;17(6):281-96 (56 ref.)
Cell adhesion molecules in the formation of liver metastasis. Jiang WG. **J Hepatobiliary Pancreat Surg** 1998;5(4):375-82 (49 ref.)
Molecular mechanisms of tumor metastasis and angiogenesis. Böhle AS, et al. **Langenbecks Arch Surg** 1999 Apr; 384(2):133-40 (63 ref.)
Immunocytochemical and molecular strategies for the detection of micrometastases in patients with solid epithelial tumours: a review. Pantel K, et al. **Nucl Med Commun** 1998 Jun;19(6):521-7 (59 ref.)
[Tumor metastasis and cell adhesion molecules] Murata J, et al. **Gan To Kagaku Ryoho** 1999 Apr;26(5):715-23 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor metastases and adhesion molecules carbohydrates and lectins] Nemoto Y, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):849-56 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Experimental model for cancer metastasis] Takahashi Y. **Gan To Kagaku Ryoho** 1999 Feb;26(3):401-7 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Stimulation of the proliferation of metastatic cancer cells by environmental growth factors and cytokines] Yamori T, et al. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1209-13 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Are selectins involved in metastasis? Krause T, et al. **Clin Exp Metastasis** 1999 May;17(3):183-92 (69 ref.)
Metastasis in colorectal cancer: what makes the tumor aggressive? Hecht JR. **Eur J Surg Suppl** 1998;(582):104-10 (86 ref.)
Metastasis-Associated genes and metastatic tumor progression. Nicolson GL, et al. **In Vivo** 1998 Nov-Dec; 12(6):579-88 (57 ref.)
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Reuning U, et al. **Int J Oncol** 1998 Nov;13(5):893-906 (207 ref.)
Chemokines and their role in tumor growth and metastasis. Wang JM, et al. **J Immunol Methods** 1998 Nov 1; 220(1-2):1-17 (101 ref.)
The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis? Starzinski-Powitz A, et al. **Mol Med Today** 1999 Jul;5(7):304-9 (46 ref.)
[Tumor progression and angiogenesis] Maru Y. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1509-19 (29 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. Miyazaki K, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S52-5 (33 ref.)
Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Chambers AF, et al. **Cancer Metastasis Rev** 1998-99;17(3):263-9 (31 ref.)
Inhibition of metastases by anticoagulants. Hejna M, et al. **J Natl Cancer Inst** 1999 Jan 6;91(1):22-36 (236 ref.)
[Integrins and integrin-associated molecules: targets for the development of antimetastatic therapies] Velasco-Velázquez MA, et al. **Rev Invest Clin** 1999 May-Jun;51(3):183-93 (87 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Critical determinants of cancer metastasis: rationale for therapy. Fidler IJ. **Cancer Chemother Pharmacol** 1999;43 Suppl:S3-10 (94 ref.)

NEOPLASM METASTASIS, UNKNOWN PRIMARY see **NEOPLASMS, UNKNOWN PRIMARY**

NEOPLASM PROTEINS

ANTAGONISTS & INHIBITORS

Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy. Kleibl K, et al. **Neoplasma** 1998;45(4):181-6 (33 ref.)
[Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance] Pourquier P, et al. **Bull Cancer** 1998 Dec;Spec No:5-10 (29 ref.) (Eng. Abstr.) **(Fre)**
[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):81-4 (51 ref.) **(Rus)**

BIOSYNTHESIS

Melan-A, a new melanocytic differentiation marker. Busam KJ, et al. **Adv Anat Pathol** 1999 Jan;6(1):12-8 (27 ref.)
A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884-90 (37 ref.)

CHEMISTRY

Appearance of D-amino acids during aging: D-amino acids in tumor proteins. Fisher GH. **EXS** 1998;85:109-18 (53 ref.)

DRUG EFFECTS

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Mantovani G, et al. **Crit Rev Oncog** 1998; 9(2):99-106 (36 ref.)

GENETICS

HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Tallini G, et al. **Adv Anat Pathol** 1999 Sep;6(5):237-46 (94 ref.)
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Coughlin SS, et al. **Am J Prev Med** 1999 Feb;16(2):91-8 (64 ref.)
New genes potentially involved in breast cancer metastasis. Schwirzke M, et al. **Anticancer Res** 1999 May-Jun; 19(3A):1801-14 (135 ref.)
The genetic basis of breast cancer and its clinical implications. Bennett IC, et al. **Aust N Z J Surg** 1999 Feb;69(2):95-105 (124 ref.)
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Lo Coco F, et al. **Blood** 1999 Jul 1;94(1):12-22 (119 ref.)
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167-215 (605 ref.)
BRCA1 and BRCA2 in breast cancer. Yang X, et al. **Breast Cancer Res Treat** 1999 Mar;54(1):1-10 (78 ref.)
Terminal deletion of the long arm of chromosome 9 in acute promyelocytic leukemia with a cryptic PML/RAR alpha rearrangement. Yamamoto K, et al. **Cancer Genet Cytogenet** 1999 Sep;113(2):120-5 (3 ref.)
Inherited breast cancer: an emerging picture. Welcsh PL, et al. **Clin Genet** 1998 Dec;54(6):447-58 (139 ref.)
Biology and clinical significance of the TEL/AML1 rearrangement [see comments] Borkhardt A, et al. **Curr Opin Pediatr** 1999 Feb;11(1):33-8 (39 ref.) Comment

in: Curr Opin Pediatr 1999 Feb;11(1):31-2.
The BRCA paradox in breast and ovarian cancer. Ponzone R, et al. **Eur J Cancer** 1998 Jun;34(7):966-7 (9 ref.)
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. Neuhausen SL, et al. **Genet Test** 1997; 1(2):75-83 (79 ref.)
t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma. Amakawa R, et al. **Int J Hematol** 1999 Feb;69(2):65-9 (37 ref.)
BRCA-associated cancer risk: molecular biology and clinical practice. van Golen K, et al. **J Lab Clin Med** 1999 Jul; 134(1):11-8 (80 ref.)
The role of TEL fusion genes in pediatric leukemias. Rubnitz JE, et al. **Leukemia** 1999 Jan;13(1):6-13 (85 ref.)
Mdm2: the ups and downs. Juven-Gershon T, et al. **Mol Med** 1999 Feb;5(2):71-83 (110 ref.)
Menin and MEN 1 gene: a model of tumour suppressor system [editorial] Hory B, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2176-9 (48 ref.)
[Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes] Sobol H, et al. **Ann Endocrinol (Paris)** 1998;59(6):459-64 (71 ref.) (Eng. Abstr.) **(Fre)**
[Inhibitors of cyclins/CDK of the 9p21 chromosomal region and malignant hemopathies] Quesnel B. **Bull Cancer** 1998 Sep;85(9):747-54 (43 ref.) (Eng. Abstr.) **(Fre)**
[Mdm2, p53 and the cell cycle: when well enough is best left alone] Maréchal V. **Pathol Biol (Paris)** 1997 Dec; 45(10):824-32 (70 ref.) (Eng. Abstr.) **(Fre)**
[BRCA1 and BRCA2: mutations and other genetic changes--practical relevance] Scherneck S, et al. **Chirurg** 1999 Apr;70(4):373-9 (32 ref.) (Eng. Abstr.) **(Ger)**
[MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma] Bosserhoff AK, et al. **Hautarzt** 1998 Oct;49(10):762-9 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes. Zeuthen J, et al. **Bratisl Lek Listy** 1998 Aug-Sep;99(8-9):426-34 (68 ref.)
The potential of melanoma antigen expression in cancer therapy. Gillespie AM, et al. **Cancer Treat Rev** 1999 Aug; 25(4):219-27 (79 ref.)
Comparison of the conformations of two intact monoclonal antibodies with hinges. Harris LJ, et al. **Immunol Rev** 1998 Jun;163:35-43 (32 ref.)
Human chorionic gonadotropin as a target for cancer vaccines. Triozzi PL, et al. **Oncol Rep** 1999 Jan-Feb; 6(1):7-17 (98 ref.)
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3-15 (84 ref.)

METABOLISM

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167-215 (605 ref.)
Clinical aspects of altered glycosylation of glycoproteins in cancer. Orntoft TF, et al. **Electrophoresis** 1999 Feb; 20(2):362-71 (117 ref.)
Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Barnes DM, et al. **Eur J Cancer** 1998 Oct;34(11):1677-82 (28 ref.)
Mdm2: the ups and downs. Juven-Gershon T, et al. **Mol Med** 1999 Feb;5(2):71-83 (110 ref.)
Diagnostics of multidrug resistance in cancer. Szakács G, et al. **Pathol Oncol Res** 1998;4(4):251-7 (64 ref.)

PHYSIOLOGY

Small heat shock proteins and protection against injury. Dillmann WH. **Ann N Y Acad Sci** 1999 Jun 30;874:66-8 (10 ref.)
Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Salomon DS, et al. **Bioessays** 1999 Jan;21(1):61-70 (71 ref.)
Escaping cell death: survival proteins in cancer. Jäättelä M. **Exp Cell Res** 1999 Apr 10;248(1):30-43 (189 ref.)
The p53 pathway. Prives C, et al. **J Pathol** 1999 Jan; 187(1):112-26 (156 ref.)
The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia. Federici AB, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):491-9 (41 ref.)
Role of MRP1 in multidrug resistance in acute myeloid leukemia. Legrand O, et al. **Leukemia** 1999 Apr; 13(4):578-84 (76 ref.)
Modulation of the immune response and tumor growth by activated Ras. Weijzen S, et al. **Leukemia** 1999 Apr; 13(4):502-13 (107 ref.)
BRCA1 and BRCA2 proteins: roles in health and disease. Duncan JA, et al. **Mol Pathol** 1998 Oct;51(5):237-47 (85 ref.)
Cell cycle regulators and their abnormalities in breast cancer. Fernández PL, et al. **Mol Pathol** 1998 Dec;51(6):305-9 (78 ref.)
Role of interleukin-8 in tumor growth and metastasis of human melanoma. Bar-Eli M. **Pathobiology** 1999;67(1):12-8 (66 ref.)

NEOPLASM RECURRENCE, LOCAL

Stomal recurrence of bladder carcinoma after cystectomy. Wang DS, et al. **J Urol** 1999 Jul;162(1):157 (3 ref.)
Locoregional failure rates in patients with involved axillary nodes after mastectomy and systemic therapy. Recht A. **Semin Radiat Oncol** 1999 Jul;9(3):223-9 (50 ref.)
Total mesorectal excision in the treatment of rectal cancer: a view from the USA. Goldberg S, et al. **Semin Surg Oncol** 1998 Sep;15(2):87-90 (17 ref.)
Mesorectal excision for rectal cancer: a view from Europe. Wiig JN, et al. **Semin Surg Oncol** 1998 Sep;15(2):78-86 (104 ref.)
[Estrogen replacement therapy and ovarian cancer] Yang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1997 Dec; 32(12):753-5 (21 ref.) **(Chi)**
[Report of 2 cases of pleural recurrences of surgically treated bronchogenic carcinoids. Diagnostic and therapeutic problems] Bonnette P, et al. **Rev Mal Respir** 1999 Feb; 16(1):85-8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):200-5 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Superior vena cava syndrome. Haapoja IS, et al. **Semin Oncol Nurs** 1999 Aug;15(3):183-9 (24 ref.)

DIAGNOSIS

Acinic cell carcinoma of maxillary sinus. Fujii M, et al. **Auris Nasus Larynx** 1998 Dec;25(4):451-7 (23 ref.)
Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. Fouladi M, et al. **J Neurosurg** 1999 Sep;91(3):499-502 (17 ref.)
Recurrent ductal carcinoma in situ after total mastectomy. Clark L, et al. **J Surg Oncol** 1999 Jul;71(3):182-5 (17 ref.)
Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Smith BD, et al. **Radiat Oncol Investig** 1999; 7(3):125-44 (134 ref.)
How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Jhaveri FM, et al. **Semin Urol Oncol** 1999 Aug;17(3):130-4 (37 ref.)
Primary juxtacortical chondrosarcoma dedifferentiating after 20 years. Kumta SM, et al. **Skeletal Radiol** 1998 Oct; 27(10):569-73 (9 ref.)
[Can detection of cancer cells in bone marrow and peripheral blood be used in diagnosis and patient monitoring?] Werther K, et al. **Ugeskr Laeger** 1998 Oct 5;160(41):5923-6 (24 ref.) (Eng. Abstr.) **(Dan)**
[A magnetic resonance (MR) follow-up of central nervous system (CNS) tumors in children: recurrence or radionecrosis?] Bernácer Borja M, et al. **An Esp Pediatr** 1998 Dec;49(6):638-40 (14 ref.) **(Spa)**

DRUG THERAPY

Second-line chemotherapy and its evaluation in small cell lung cancer. Huisman C, et al. **Cancer Treat Rev** 1999 Aug; 25(4):199-206 (42 ref.)
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Bookman MA. **Oncologist** 1999;4(2):87-94 (31 ref.)
Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Shin DM, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):100-5 (34 ref.)
Chemotherapy of advanced and recurrent cervical carcinoma. Nguyen HN, et al. **Semin Surg Oncol** 1999 Apr-May;16(3):247-50 (28 ref.)
Hormonal manipulation for rising PSA after radical prostatectomy. Bhayani SB, et al. **Semin Urol Oncol** 1999 Aug;17(3):148-53 (45 ref.)

EPIDEMIOLOGY

Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Bijker N, et al. **Cancer** 1999 Apr 15; 85(8):1773-81 (42 ref.)
Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Wolf JK, et al. **Gynecol Oncol** 1999 Apr;73(1):35-41 (24 ref.)

ETIOLOGY

Port site recurrences after laparoscopy for malignant disease. Pearlstone DB, et al. **Semin Surg Oncol** 1999 Jun; 16(4):307-12 (64 ref.)

PATHOLOGY

Local recurrence after surgery for soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Trovik CS, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:45-6 (16 ref.)
Late relapse of ovarian dysgerminoma: case report and literature review. Bekaii-Saab T, et al. **Gynecol Oncol** 1999 Jan;72(1):111-2 (10 ref.)
Recurrent cervical smear abnormalities following treatment. Hammond R. **Hosp Med** 1999 Apr;60(4):250-3 (28 ref.)
A parapharyngeal myxoid liposarcoma. Fagan JJ, et al. **J Laryngol Otol** 1999 Feb;113(2):179-82 (14 ref.)
Recurrent intracranial Masson's vegetant intravascular hemangioendothelioma. Case report and review of the literature. Avellino AM, et al. **J Neurosurg** 1999 Aug; 91(2):308-12 (20 ref.)
Surgical management of advanced and recurrent cervical cancer. Estape R, et al. **Semin Surg Oncol** 1999 Apr-May; 16(3):236-41 (29 ref.)

PREVENTION & CONTROL

Surgical excision margins: a pathologist's perspective. Batsakis JG. **Adv Anat Pathol** 1999 May;6(3):140-8 (35 ref.)
Pre-operative chemoradiotherapy and total mesorectal excision surgery of rectal cancer: towards the eradication of pelvic failures? Bosset JF, et al. **Aust N Z J Surg** 1999 Sep;69(9):622-4 (32 ref.)
Mechanisms and prevention of recurrent colorectal cancer. Topal B, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):701-8 (80 ref.)
Prophylactic treatment of superficial bladder tumor. Lee C, et al. **Int J Urol** 1998 Nov;5(6):511-20 (101 ref.)
Estrogen replacement therapy in women with a history of breast cancer. Seifert M, et al. **Maturitas** 1999 Jun 21; 32(2):63-8 (40 ref.)
The role of dietary manipulation in biochemical recurrence of prostate cancer after radical prostatectomy. Lee CT, et al. **Semin Urol Oncol** 1999 Aug;17(3):154-63 (79 ref.)
[Radiation and concomitant chemotherapy after surgery for breast cancer: Arcosein study] Calais G. **Cancer Radiother** 1998 Sep-Oct;2(5):469-74 (31 ref.) (Eng. Abstr.) **(Fre)**
[Influence of locoregional irradiation on local control and survival in breast cancer] Cutuli B. **Cancer Radiother** 1998 Sep-Oct;2(5):446-59 (136 ref.) (Eng. Abstr.) **(Fre)**
[What should be done after curative surgery for adenocarcinoma of the colon?] Pol B. **Gastroenterol Clin Biol** 1998 Mar;22(3 Suppl):S249-54 (48 ref.) **(Fre)**
[Retroperitoneal sarcomas: 2. Surgical and complementary treatment] Bonvalot S. **J Chir (Paris)** 1999 Jun;136(2):61-6 (17 ref.) (Eng. Abstr.) **(Fre)**
[Surveillance of a woman treated for breast cancer] Lansac J, et al. **Rev Prat** 1998 Jan 1;48(1):71-6 (26 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L, et al. **Nucl Med Commun** 1999 Aug;20(8):689-96 (26 ref.)

RADIOTHERAPY

Primary sinonasal mucosal melanoma: three different therapeutic approaches to inoperable local disease or recurrence and a review of the literature. De Meerleer GO, et al. **Melanoma Res** 1998 Oct;8(5):449-57 (52 ref.)
Radiation therapy for a rising PSA level after radical prostatectomy. Tiguert R, et al. **Semin Urol Oncol** 1999 Aug;17(3):141-7 (35 ref.)
[Local control of the primary tumor. Necessary step in control of cancer (published erratum appears in Cancer Radiother 1999 Jan-Feb;3(1):85)] Gérard JP, et al. **Cancer Radiother** 1998 Dec;2(6):668-71 (13 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Simultaneous metastatic ameloblastoma and thyroid carcinoma in the cervical region: report of a case. Sugiyama M, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1255-8 (18 ref.)

SURGERY

Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Brandes AA, et al. **Am J Clin Oncol** 1999 Aug;22(4):387-90 (26 ref.)
A case of metastatic nasopharyngeal carcinoma in benign nasal polyps. Sim RS, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):575-7 (5 ref.)
Surgery during chemotherapy and at relapse of ovarian cancer. Berek JS, et al. **Ann Oncol** 1999;10 Suppl 1:3-7 (56 ref.)
Management of recurrent pilocytic astrocytoma with leptomeningeal dissemination in childhood. Tamura M, et al. **Childs Nerv Syst** 1998 Nov;14(11):617-22 (19 ref.)
Mohs' micrographic surgery for basal cell carcinoma. Lawrence CM. **Clin Exp Dermatol** 1999 Mar;24(2):130-3 (57 ref.)
High-risk nonmelanoma skin cancers. Demetrius RW, et al. **Dermatol Surg** 1998 Dec;24(12):1272-92; quiz 1293-4 (79 ref.)
Splenectomy in recurrent epithelial ovarian cancer. Gemignani ML, et al. **Gynecol Oncol** 1999 Mar; 72(3):407-10 (13 ref.)
Surgical treatment for recurrent tumors of primary malignant melanoma of the esophagus: a case report and review of the literature. Mukaiya M, et al. **Hepatogastroenterology**

NEOPLASM RECURRENCE, LOCAL

1999 Jan-Feb;46(25):295-8 (22 ref.)
Recurrent myxoma of the left ventricle. Case report and review of the literature. Bortolotti U, et al.
J Cardiovasc Surg (Torino) 1999 Apr;40(2):233-5 (8 ref.)
Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314-7 (21 ref.)
Primary sinonasal mucosal melanoma: three different therapeutic approaches to inoperable local disease or recurrence and a review of the literature. De Meerleer GO, et al. **Melanoma Res** 1998 Oct;8(5):449-57 (52 ref.)
Surgical management of advanced and recurrent cervical cancer. Estape R, et al. **Semin Surg Oncol** 1999 Apr-May; 16(3):236-41 (29 ref.)
Retroperitoneal sarcoma--the continued challenge for surgery and oncology. Herman K, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):77-81 (33 ref.)
[Surgical procedure in primary and metastatic breast carcinoma] Hampl M, et al. **Zentralbl Chir** 1998;123 Suppl 5:81-6 (37 ref.) (Eng. Abstr.) **(Ger)**
[Abdominosacral resection for locoregional recurrence rectal cancer] Meneu JC, et al. **Rev Esp Enferm Dig** 1999 May; 91(5):374-9 (30 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. Bomalaski JJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):11-5 (37 ref.)
Observation/delayed treatment for rising PSA after radical prostatectomy: pros and cons. Ruffion A, et al.
Semin Urol Oncol 1999 Aug;17(3):135-40 (64 ref.)
Rising PSAs after primary therapy: active or passive intervention. Slovin SF, et al. **Semin Urol Oncol** 1999 Aug; 17(3):164-73 (54 ref.)
[Re-irradiation with hyperthermia in patients with recurrent breast cancer] van der Zee J, et al.
Ned Tijdschr Geneeskd 1999 Jan 9;143(2):80-4 (23 ref.) (Eng. Abstr.) **(Dut)**

ULTRASONOGRAPHY

Left atrial leiomyosarcoma: double occurrence and double recurrence--report of one case. Minardi G, et al.
J Am Soc Echocardiogr 1998 Dec;11(12):1171-6 (38 ref.)

NEOPLASM REGRESSION, SPONTANEOUS

Evanescent exostosis. A new case. Revilla Y, et al.
Eur J Radiol 1999 Mar;29(3):270-2 (11 ref.)
Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Nakagawara A. **Hum Cell** 1998 Sep;11(3):115-24 (46 ref.)
Spontaneous regression of hepatocellular carcinoma. Misawa K, et al. **J Gastroenterol** 1999 Jun;34(3):410-4 (15 ref.)
Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Kovacs KA, et al.
Medicine (Baltimore) 1998 Nov;77(6):398-402 (26 ref.)
Spontaneous involution of a diencephalic astrocytoma. Kernan JC, et al. **Pediatr Neurosurg** 1998 Sep;29(3):149-53 (25 ref.)
Congenital mediastinal dumbbell neuroblastoma with spontaneous regression of liver metastases. Komuro H, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):86-8 (19 ref.)
[Spontaneous remission of breast cancer. A literature review] Larsen SU, et al. **Ugeskr Laeger** 1999 Jun 28;161(26):4001-4 (20 ref.) (Eng. Abstr.) **(Dan)**

PATHOLOGY

Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Kitaichi M, et al. **Eur Respir J** 1998 Jul;12(1):89-96 (33 ref.)

PHYSIOPATHOLOGY

Spontaneous regression of cancer: possible mechanisms. Papac RJ. **In Vivo** 1998 Nov-Dec;12(6):571-8 (100 ref.)

NEOPLASM REMISSION, SPONTANEOUS see **NEOPLASM REGRESSION, SPONTANEOUS**

NEOPLASM, RESIDUAL

DIAGNOSIS

Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Foroni L, et al. **Br J Haematol** 1999 Apr;105(1):7-24 (174 ref.)
Minimal residual disease. Negrin RS. **Curr Opin Hematol** 1998 Nov;5(6):488-93 (24 ref.)
Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Schultze JL, et al. **J Mol Med** 1999 Feb;77(2):259-65 (34 ref.)
Detection of minimal residual disease: methods and relationship to outcome in T-lineage acute lymphoblastic leukemia. Dibenedetto SP, et al. **Leuk Lymphoma** 1998 Dec; 32(1-2):65-75 (73 ref.)
Detection of residual disease in acute lymphoblastic leukemia of childhood. Estrov Z, et al. **Leuk Lymphoma** 1999 Mar; 33(1-2):47-52 (35 ref.)
Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Spencer CA, et al. **Thyroid** 1999 May;9(5):435-41 (11 ref.)

GENETICS

Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR. Tobal K, et al. **Leuk Lymphoma** 1998 Sep;31(1-2):115-20 (39 ref.)

PATHOLOGY

Detection and significance of minimal residual disease in colorectal cancer. Merrie AE, et al. **Histol Histopathol** 1999 Apr;14(2):561-9 (95 ref.)
Immunocytochemical and molecular strategies for the detection of micrometastases in patients with solid epithelial tumours: a review. Pantel K, et al. **Nucl Med Commun** 1998 Jun;19(6):521-7 (59 ref.)

RADIONUCLIDE IMAGING

Detection of residual and recurrent thyroid cancer by radionuclide imaging. Maxon HR. **Thyroid** 1999 May; 9(5):443-6 (11 ref.)

THERAPY

Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. Brugger W, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:363-71 (22 ref.)
Minimal residual disease in chronic myeloid leukaemia. Cross NC. **Hematol Cell Ther** 1998 Oct;40(5):224-8 (22 ref.)

NEOPLASM RNA see **RNA, NEOPLASM**

NEOPLASM SEEDING

The pneumoperitoneum and its role in tumor seeding. Reymond MA, et al. **Dig Surg** 1998;15(2):105-9 (48 ref.)
Port site recurrences after laparoscopic surgery. A review. Schaeff B, et al. **Dig Surg** 1998;15(2):124-34 (95 ref.)
Port site metastases from gallbladder cancer after laparoscopic cholecystectomy. Results of a Swedish survey and review of published reports. Lundberg O, et al.
Eur J Surg 1999 Mar;165(3):215-22 (86 ref.)
Risk factors contributing to early occurrence of port site metastases of laparoscopic surgery for malignancy. Wang PH, et al. **Gynecol Oncol** 1999 Jan;72(1):38-44 (77 ref.)
The pathogenesis of port-site recurrences. Reymond MA, et al. **J Gastrointest Surg** 1998 Sep-Oct;2(5):406-14 (88 ref.)
Review of investigations regarding the etiology of port site tumor recurrence. Whelan RL, et al.
J Laparoendosc Adv Surg Tech A 1999 Feb;9(1):1-16 (61 ref.)
Long-term consequences from bladder perforation and/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature. Mydlo JH, et al. **J Urol** 1999 Apr;161(4):1128-32 (39 ref.)
Port-site metastasis in the abdominal wall: fact or fiction? Savalgi RS. **Semin Surg Oncol** 1998 Oct-Nov;15(3):189-93 (26 ref.)
Port site recurrence of unexpected gallbladder carcinoma after a laparoscopic cholecystectomy: report of a case. Ohmura Y, et al. **Surg Today** 1999;29(1):71-5 (13 ref.)
Port site metastases following laparoscopic cholecystectomy for unsuspected carcinoma of the gallbladder. Reber PU, et al. **Z Gastroenterol** 1998 Oct;36(10):901-7 (61 ref.)
[New approaches in surgery--visceral surgery in the tension field between trauma from surgical access and radicality] Siewert JR, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:53-60 (13 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASM STAGING

The role of radiotherapy for early stage Hodgkin's disease: limitations and perspectives. Cosset JM, et al.
Ann Oncol 1998;9 Suppl 5:S57-62 (37 ref.)
Staging systems for pancreatic cancer: differences between the Japanese and UICC systems. Kobari M, et al.
J Hepatobiliary Pancreat Surg 1998;5(2):121-7 (16 ref.)
Magnetic resonance imaging in oncology: an overview. Wallis F, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):117-25 (48 ref.)
Molecular assessment of tumour stage and disease recurrence using PCR-based assays. Bustin SA, et al.
Mol Med Today 1998 Sep;4(9):389-96 (52 ref.)
The new lung cancer staging system: what does it mean? Burnett RJ, et al. **Surg Oncol Clin N Am** 1999 Apr; 8(2):231-44 (24 ref.)
[Management of non-small-cell bronchial cancers. Which chemotherapy for a stage IV?] Quoix E.
Rev Mal Respir 1999 Jan;16 Suppl 3:S122-5 (42 ref.) **(Fre)**

HISTORY

History and international developments in cancer staging. Gospodarowicz M, et al. **Cancer Prev Control** 1998 Dec; 2(6):262-8 (32 ref.)

METHODS

Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience. Rydholm A, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:50-7 (72 ref.)
The role of imaging in the staging of bone tumors. Peh WC.
Crit Rev Oncol Hematol 1999 Jul;31(2):147-67 (150 ref.)
Anatomic classification of intraosseous ameloblastoma as a guide to surgical management. Arotiba DT, et al.
East Afr Med J 1998 Jul;75(7):406-10 (37 ref.)
Staging laparoscopy: a peek may save a cut [editorial; comment] Saeian K, et al. **Endoscopy** 1999 Jun;31(5):389-91 (31 ref.) Comment on: Endoscopy 1999 Jun;31(5):342-7.
Laparoscopic ultrasonography--a method for staging of upper gastrointestinal cancer. Durup Scheel-Hincke J, et al. **Eur J Ultrasound** 1999 May;9(2):177-84 (31 ref.)
Laparoscopic ultrasonography for abdominal tumor staging. van Delden OM, et al. **Eur Radiol** 1998;8(8):1405-8 (29 ref.)
Laparoscopic staging of malignant disease. Payne JH Jr.
Hawaii Med J 1998 Nov;57(11):705-9 (27 ref.)
Staging and surgery for non-small cell lung cancer (NSCLC). Alpard SK, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):25-43 (103 ref.)
Review of staging modalities in clinically localized prostate cancer. Perrotti M, et al. **Urology** 1999 Aug;54(2):208-14 (58 ref.)
[Can detection of cancer cells in bone marrow and peripheral blood be used in diagnosis and patient monitoring?] Werther K, et al. **Ugeskr Laeger** 1998 Oct 5;160(41):5923-6 (24 ref.) (Eng. Abstr.) **(Dan)**
[Prognostic factors of infiltrating bladder tumors] Durdux C, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):491-8 (88 ref.) (Eng. Abstr.) **(Fre)**
[Value and limits of surgery in stage IIIB non-small-cell bronchial cancers] Grunenwald D. **Cancer Radiother** 1998 Sep-Oct;2(5):568-73 (30 ref.) (Eng. Abstr.) **(Fre)**
[Staging of exocrine pancreatic cancer] Sauvanet A, et al. **J Chir (Paris)** 1998 Feb;135(1):10-6 (31 ref.) (Eng. Abstr.) **(Fre)**
[Pathological anatomy of breast cancers] Contesso G, et al. **Rev Prat** 1998 Jan 1;48(1):29-35 (26 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic imaging in clinical tumor staging] Brodowicz T, et al. **Radiologe** 1999 Jul;39(7):508-12 (23 ref.) (Eng. Abstr.) **(Ger)**
[Esophageal carcinoma: accurate staging thanks to modern diagnostic methods open up new therapeutic strategies] Schmassmann A. **Schweiz Med Wochenschr** 1999 Aug 28; 129(34):1207-10 (12 ref.) (Eng. Abstr.) **(Ger)**
[Efficacy of transrectal ultrasonography in staging prostate cancer] Soh S, et al. **Nippon Rinsho** 1998 Aug;56(8):2036-41 (18 ref.) (Eng. Abstr.) **(Jpn)**
[A new method can result in more accurate staging of breast cancer. Sentinel node biopsy is a possible way to reduce axillary intervention] Bergkvist L. **Lakartidningen** 1999 Apr 7;96(14):1670-2 (19 ref.) **(Swe)**

NEOPLASM STRUCTURAL GENES see **GENES, STRUCTURAL, NEOPLASM**

NEOPLASM TRANSPLANTATION

Summary of observations on transplantable tumors of the rat thyroid gland. Wollman SH. **Biochimie** 1999 Apr; 81(4):409-12 (6 ref.)
Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Killion JJ, et al.
Cancer Metastasis Rev 1998-99;17(3):279-84 (31 ref.)

NEOPLASM VACCINES see **CANCER VACCINES**

NEOPLASMS

see related
ANTIBODIES, NEOPLASM
ANTICARCINOGENIC AGENTS
ANTIGENS, NEOPLASM
ANTINEOPLASTIC AGENTS
CARCINOGENS
DNA, NEOPLASM
GENES, SUPPRESSOR, TUMOR
ONCOGENIC VIRUSES
PLEURAL EFFUSION, MALIGNANT
PRECANCEROUS CONDITIONS
RNA, NEOPLASM

Cancer in old age--is it inadequately investigated and treated? Turner NJ, et al. **BMJ** 1999 Jul 31; 319(7205):309-12 (40 ref.)
The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Blancher C, et al.
Cancer Metastasis Rev 1998 Jun;17(2):187-94 (30 ref.)
From computer simulations to human disease: emerging themes in protein folding. Radford SE, et al. **Cell** 1999 Apr 30;97(3):291-8 (42 ref.)
Cancer in developing countries: Part I--Cancer burden, resources, epidemiology, aetiology and clinical practice. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(4):219-25 (45 ref.)
Developing a global strategy for cancer. Sikora K.
Eur J Cancer 1999 Jan;35(1):24-31 (20 ref.)
Tumour biology, chaos and non-linear dynamics. Rew DA.
Eur J Surg Oncol 1999 Feb;25(1):86-9 (17 ref.)

Cell proliferation and cancer. López-Sáez JF, et al. **Histol Histopathol** 1998 Oct;13(4):1197-214 (109 ref.)
Aging and neoplastic progression. Kaiser HE. **In Vivo** 1998 Nov-Dec;12(6):691-3 (32 ref.)
Cancer Information Network. Mizushima H. **Intern Med** 1999 Feb;38(2):192-4 (6 ref.)
Analyzing health surveys for cancer-related objectives. Graubard BI, et al. **J Natl Cancer Inst** 1999 Jun 16; 91(12):1005-16 (89 ref.)
Pregnancy outcome in long-term survivors of childhood cancer. Blatt J. **Med Pediatr Oncol** 1999 Jul;33(1):29-33 (32 ref.)
Pharmacological protection of the gonads. Howell SJ, et al. **Med Pediatr Oncol** 1999 Jul;33(1):41-5 (48 ref.)
Reproductive technologies 1998: options available for the cancer patient. Pfeifer SM, et al. **Med Pediatr Oncol** 1999 Jul;33(1):34-40 (31 ref.)
Connexins in tumour suppression and cancer therapy. Yamasaki H, et al. **Novartis Found Symp** 1999;219:241-54; discussion 254-60 (57 ref.)
Some elements of prognosis in terminal cancer. Lamont EB, et al. **Oncology (Huntingt)** 1999 Aug;13(8):1165-70; discussion 1172-4, 1179-80 (48 ref.)
"Spot 14" protein: a metabolic integrator in normal and neoplastic cells. Cunningham BA, et al. **Thyroid** 1998 Sep; 8(9):815-25 (89 ref.)
Pathophysiologic significance of host reactions in human cancer tissue: desmoplasia and tumor immunity. Ohtani H. **Tohoku J Exp Med** 1999 Mar;187(3):193-202 (33 ref.)
Endocytosis proteins and cancer: a potential link? Floyd S, et al. **Trends Cell Biol** 1998 Aug;8(8):299-301 (35 ref.)
[Fas system in the study of neoplasms] Li H, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jan;35(1):59-62 (25 ref.) **(Chi)**
[Transforming growth factors and cancer] Zhu ZW, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):335-7 (10 ref.) **(Chi)**
[Malignant solid tumors in children] Rechnitzer C, et al. **Ugeskr Laeger** 1999 Apr 12;161(15):2196-201 (17 ref.) (Eng. Abstr.) **(Dan)**

BLOOD

The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. Brünner N, et al. **APMIS** 1999 Jan;107(1):160-7 (62 ref.)
Venous thromboembolism and cancer. Kakkar AK, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):675-87 (77 ref.)
Cancer and blood coagulation: molecular aspects. Bromberg ME, et al. **Cancer J Sci Am** 1999 May-Jun;5(3):132-8 (74 ref.)
Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Bidart JM, et al. **Clin Chem** 1999 Oct;45(10):1695-707 (164 ref.)
Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Adamson JW, et al. **Oncology** 1999;56(1):46-53 (47 ref.)
The role of the plasminogen activation system in cancer. Carroll VA, et al. **Semin Thromb Hemost** 1999;25(2):183-97 (327 ref.)
The causes and prognostic significance of low hemoglobin levels in tumor patients. Manegold C. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:17-9 (13 ref.)

BLOOD SUPPLY

Control of tumor growth via inhibition of tumor angiogenesis. Plate KH. **Adv Exp Med Biol** 1998;451:57-61 (41 ref.)
Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology. Vaupel P, et al. **Adv Exp Med Biol** 1998; 454:591-602 (70 ref.)
Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. van Hinsbergh VW, et al. **Ann Oncol** 1999;10 Suppl 4:60-3 (52 ref.)
Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. Hayes AJ, et al. **BMJ** 1999 Mar 27;318(7187):853-6 (32 ref.)
Tumour vasculature as a target for cancer therapy. Chaplin DJ, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:57-64 (103 ref.)
The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Siemeister G, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):241-8 (70 ref.)
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Witte L, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):155-61 (21 ref.)
Cancer and atherosclerosis: the broad mandate of angiogenesis [editorial; comment] Isner JM. **Circulation** 1999 Apr 6;99(13):1653-5 (21 ref.) Comment on: Circulation 1999 Apr 6;99(13):1726-32.
New strategies in anti-vascular cancer therapy [see comments] Bloemendal HJ, et al. **Eur J Clin Invest** 1999 Sep;29(9):802-9 (78 ref.) Comment in: Eur J Clin Invest 1999 Sep;29(9):733-6.
Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Miles KA. **Eur J Radiol** 1999 Jun;30(3):198-205 (34 ref.)
The diagnostic and prognostic value of tumor angiogenesis. Szabo S, et al. **Eur J Surg Suppl** 1998;(582):99-103 (44 ref.)
Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications. Fontanini G, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):128-42 (76 ref.)
Tumor angiogenesis: biology and therapeutic prospects. Harris SR, et al. **In Vivo** 1998 Nov-Dec;12(6):563-70 (111 ref.)
Angiogenesis modulates the tumour immune response. Griffioen AW, et al. **Int J Exp Pathol** 1998 Dec;79(6):363-8 (44 ref.)
Influence of host microvascular environment on tumour vascular endothelium. Kubitza M, et al. **Int J Exp Pathol** 1999 Feb;80(1):1-10 (108 ref.)
Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now? Leenders WP. **Int J Exp Pathol** 1998 Dec;79(6):339-46 (67 ref.)
Localized paclitaxel delivery. Dhanikula AB, et al. **Int J Pharm** 1999 Jun 25;183(2):85-100 (80 ref.)
Regulating angiogenesis: a new therapeutic strategy. Gibaldi M. **J Clin Pharmacol** 1998 Oct;38(10):898-903 (23 ref.)
Tumor angiogenesis and endothelial cell modulatory factors [see comments] Desai SB, et al. **J Immunother** 1999 May; 22(3):186-211 (346 ref.) Comment in: J Immunother 1999 May;22(3):185.
Angiogenesis, a target for tumor therapy. Griffioen AW, et al. **J Lab Clin Med** 1998 Nov;132(5):363-8 (46 ref.)
Tumor angiogenesis. Voravud N, et al. **J Med Assoc Thai** 1999 Apr;82(4):394-404 (63 ref.)
Perspective: tumour spread--the problems of latency. Hart IR. **J Pathol** 1999 Jan;187(1):91-4 (27 ref.)
Molecular mechanisms of tumor metastasis and angiogenesis. Böhle AS, et al. **Langenbecks Arch Surg** 1999 Apr; 384(2):133-40 (63 ref.)
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Holash J, et al. **Oncogene** 1999 Sep 20; 18(38):5356-62 (36 ref.)
Blood flow and oxygenation status of human tumors. Clinical investigations. Feldmann HJ, et al. **Strahlenther Onkol** 1999 Jan;175(1):1-9 (91 ref.)
Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Reubi JC, et al. **Yale J Biol Med** 1997 Sep-Dec; 70(5-6):471-9 (27 ref.)
[Tumor angiogenesis inhibitors: media and scientific aspects] Raymond E. **Presse Med** 1998 Jul 4-11;27(24):1221-4 (12 ref.) (Eng. Abstr.) **(Fre)**
[Tumor angiogenesis] Bussolino F. **Recenti Prog Med** 1999 Jan;90(1):28-36 (43 ref.) (Eng. Abstr.) **(Ita)**
[The chronic reduction of tissue perfusion and neoplasm promotion (letter) (published erratum appears in Recenti Prog Med 1999 Apr;90(4):216)] Malossi M, et al. **Recenti Prog Med** 1999 Jan;90(1):46-8 (32 ref.) **(Ita)**
[Tumor progression and angiogenesis] Maru Y. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1509-19 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Antiangiogenic therapy] Toi M. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2003-9 (34 ref.) (Eng. Abstr.) **(Jpn)**
[Control of tumor-related angiogenesis] Oikawa T. **Hum Cell** 1998 Dec;11(4):201-6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor angiogenesis] Ono M, et al. **Seikagaku** 1998 Sep; 70(9):1159-70 (28 ref.) **(Jpn)**
[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):81-4 (51 ref.) **(Rus)**

CHEMICALLY INDUCED

Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Kessel E. **Adv Contracept** 1998 Jun;14(2):81-90 (37 ref.)
Role of quinoids in estrogen carcinogenesis. Bolton JL, et al. **Chem Res Toxicol** 1998 Oct;11(10):1113-27 (150 ref.)
Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment. van Delft JH, et al. **Crit Rev Toxicol** 1998 Sep;28(5):477-510 (176 ref.)
Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Pahor M, et al. **Drugs Aging** 1998 Aug;13(2):99-108 (43 ref.)
The adverse effects of hormone replacement therapy. Tavani A, et al. **Drugs Aging** 1999 May;14(5):347-57 (99 ref.)
1,3-Butadiene. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 1:109-225 (348 ref.)
Chloroprene. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 1:227-50 (87 ref.)
Dichloromethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 1:251-315 (253 ref.)
Acrylonitrile. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 1:43-108 (282 ref.)
Acetaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:319-35 (71 ref.)
Benzoyl peroxide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:345-58 (46 ref.)
alpha-Chlorinated toluenes and benzoyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:453-77 (83 ref.)
1,2-Dibromo-3-chloropropane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:479-500 (97 ref.)
Agent Orange in war medicine: an aftermath myth. Hardell L, et al. **Int J Health Serv** 1998;28(4):715-24 (45 ref.)
Can traditional epidemiology detect cancer risks caused by occupational exposure to pesticides? Georgellis A, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):159-66 (77 ref.)
Reduction of chromium(VI) and its relationship to carcinogenesis. Shi X, et al. **J Toxicol Environ Health B Crit Rev** 1999 Jan-Mar; 2(1):87-104 (84 ref.)
Role of free radicals in metal-induced carcinogenesis. Landolph JR. **Met Ions Biol Syst** 1999;36:445-83 (67 ref.)
Background DNA damage for endogenous and unavoidable exogenous carcinogens: a basis for spontaneous cancer incidence? [editorial] Gupta RC, et al. **Mutat Res** 1999 Mar 8;424(1-2):1-8 (57 ref.)
Dietary fibres may protect or enhance carcinogenesis. Harris PJ, et al. **Mutat Res** 1999 Jul 15;443(1-2):95-110 (120 ref.)
A comprehensive approach for integration of toxicity and cancer risk assessments. Butterworth BE, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):23-36 (86 ref.)
Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Collins JF, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):45-54 (73 ref.)
Pesticide exposure: human cancers on the horizon. Jaga K, et al. **Rev Environ Health** 1999 Jan-Mar;14(1):39-50 (47 ref.)
Carcinogenic metals. Costa M. **Sci Prog** 1998;81 (Pt 4):329-39 (19 ref.)
Cancer chemoprevention: future holds in multiple agents. Mukhtar H, et al. **Toxicol Appl Pharmacol** 1999 Aug 1; 158(3):207-10 (28 ref.)
Dose-response trend tests for tumorigenesis, adjusted for body weight. Gaylor DW, et al. **Toxicol Sci** 1999 Jun; 49(2):318-23 (5 ref.)
[Dioxins: current knowledge about health effects] Wissing M. **Rev Med Brux** 1998 Sep;19(4):A367-71 (24 ref.) (Eng. Abstr.) **(Fre)**
[Beneficial and deleterious effects of alcoholic beverages] Schlienger JL. **Rev Prat** 1999 Feb 15;49(4):367-72 (31 ref.) (Eng. Abstr.) **(Fre)**
[Endocrine disrupting chemicals and carcinogenicity] Ohi G. **Gan To Kagaku Ryoho** 1999 Feb;26(3):263-8 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Present and future cancer risk assessment of carcinogenic heterocyclic amines in humans] Manabe S, et al. **Nippon Eiseigaku Zasshi** 1998 Oct;53(3):521-8 (46 ref.) (Eng. Abstr.) **(Jpn)**
[Oncologic aspects of estrogen-replacement therapy] Berstein LM. **Vopr Onkol** 1998;44(4):378-82 (40 ref.) (Eng. Abstr.) **(Rus)**
[Once again about the issue of threshold in chemical carcinogenesis] Turusov VS, et al. **Vopr Onkol** 1998; 44(4):468-76 (48 ref.) **(Rus)**

CHEMISTRY

The 67 kDa laminin receptor as a prognostic factor in human cancer. Ménard S, et al. **Breast Cancer Res Treat** 1998; 52(1-3):137-45 (66 ref.)
Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Mason RP. **Curr Med Chem** 1999 Jun;6(6):481-99 (175 ref.)
Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Gregory JJ Jr, et al. **Drugs** 1999 Apr;57(4):463-7 (9 ref.)

CLASSIFICATION

Diagnosis and classification of the small round-cell tumors of childhood [comment] Cohn SL. **Am J Pathol** 1999 Jul; 155(1):11-5 (72 ref.) Comment on: Am J Pathol 1999 Jul;155(1):17-21.

COMPLICATIONS

Outpatient management of the febrile neutropenic child with cancer. Patrick CC, et al. **Adv Pediatr Infect Dis** 1999; 14:29-47 (64 ref.)
Neurologic complications of systemic cancer [published erratum appears in Am Fam Physician 1999 May 1;59(9):2435] Newton HB. **Am Fam Physician** 1999 Feb 15;59(4):878-86 (28 ref.)
Management of pain and spinal cord compression in patients with advanced cancer. ACP-ASIM End-of-life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Abrahm JL. **Ann Intern Med** 1999 Jul 6;131(1):37-46 (115 ref.)
Antiblastic chemotherapy in the presence of abdominal aorta aneurysm (AAA): guidelines. Lauro S, et al. **Anticancer Res** 1999 Mar-Apr;19(2B):1439-44 (26 ref.)
Cancer and chronic pain. Hassed C. **Aust Fam Physician** 1999 Jan;28(1):17-21, 23-4 (18 ref.)
Venous thromboembolism and cancer. Kakkar AK, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):675-87 (77 ref.)
Cytokines and biological response modifiers in the treatment of infection. Mueller BU, et al. **Cancer Treat Res** 1998; 96:201-22 (151 ref.)
Prevention of infection in immunocompromised hosts. Noskin GA. **Cancer Treat Res** 1998;96:223-46 (92 ref.)
Recent advances in the management of fungal infections. Sanchez J, et al. **Cancer Treat Res** 1998;96:167-82 (79 ref.)
Infections associated with solid tumors. Sutton SH, et al. **Cancer Treat Res** 1998;96:105-41 (124 ref.)
Epidemiology of infectious complications in cancer patients.

Zembower T. **Cancer Treat Res** 1998;96:33–75 (229 ref.)

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov–Dec;44(6):427–35 (23 ref.)

Palliative management of dyspnea in advanced cancer. LeGrand SB, et al. **Curr Opin Oncol** 1999 Jul;11(4):250–4 (35 ref.)

Fatigue in cancer patients. Simon AM, et al. **Curr Opin Oncol** 1999 Jul;11(4):244–9 (46 ref.)

A risk-benefit assessment of epoetin in the management of anaemia associated with cancer. Beguin Y. **Drug Saf** 1998 Oct;19(4):269–82 (68 ref.)

Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Wiseman LR, et al. **Drugs** 1998 Sep;56(3):385–403 (75 ref.)

Fatigue in patients with cancer [see comments] Stone P, et al. **Eur J Cancer** 1998 Oct;34(11):1670–6 (89 ref.) Comment in: Eur J Cancer 1998 Oct;34(11):1649–51.

Oxidant-induced lung injury in anticancer therapy. Beinert T, et al. **Eur J Med Res** 1999 Feb 25;4(2):43–53 (113 ref.)

Cancer and venous thromboembolism: an overview. Prandoni P, et al. **Haematologica** 1999 May;84(5):437–45 (102 ref.)

Mechanisms of hypercoagulation in malignancy and during chemotherapy. Falanga A. **Haemostasis** 1998;28 Suppl 3:50–60 (59 ref.)

Thromboprophylaxis in the cancer patient. Kakkar AK, et al. **Haemostasis** 1998;28 Suppl 3:61–5 (17 ref.)

Treatment of venous thromboembolism in cancer patients. Levine M, et al. **Haemostasis** 1998;28 Suppl 3:66–70 (17 ref.)

Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Rickles FR, et al. **Haemostasis** 1998;28 Suppl 3:43–9 (49 ref.)

The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Newton H. **Hum Reprod Update** 1998 May–Jun;4(3):237–47 (110 ref.)

Issues of thrombosis and hemorrhagic events in patients with cancer. Frenkel EP, et al. **In Vivo** 1998 Nov–Dec; 12(6):625–8 (35 ref.)

Selected coagulation disorders associated with cancer. Sallah S. **In Vivo** 1998 Nov–Dec;12(6):671–3 (11 ref.)

Thrombosis and malignancy: pathogenesis and prevention. Schwartz JD, et al. **In Vivo** 1998 Nov–Dec;12(6):619–24 (108 ref.)

A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours. Davies JM. **Infection** 1998 Nov–Dec;26(6):389–95 (54 ref.)

Hickman catheter-related infections in patients with cancer. Yip C, et al. **Int J Antimicrob Agents** 1998 Aug;10(3):181–9 (69 ref.)

Sensitive measures of the nutritional status of children with cancer in hospital and in the field. Brennan BM. **Int J Cancer Suppl** 1998;11:10–3 (20 ref.)

Sensitive measures of nutritional status in children in hospital and in the field. Motil KJ. **Int J Cancer Suppl** 1998;11:2–9 (27 ref.)

Aggressive oral, enteral or parenteral nutrition: prescriptive decisions in children with cancer. Pencharz PB. **Int J Cancer Suppl** 1998;11:73–5 (20 ref.)

Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review. Viscoli C, et al. **Int J Infect Dis** 1998–99 Winter;3(2):109–18 (73 ref.)

Transcending the physical: spiritual aspects of pain in patients with HIV and/or cancer. Newshan G. **J Adv Nurs** 1998 Dec;28(6):1236–41 (38 ref.)

Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review. Krcmery V Jr, et al. **J Chemother** 1999 Apr;11(2):131–6 (38 ref.)

Working group session report: cancer. Hirschfeld S. **J Nutr** 1999 Jan;129(1S Suppl):306S–307S (15 ref.)

Iron therapy and cancer. Weinberg ED. **Kidney Int Suppl** 1999 Mar;69:S131–4 (29 ref.)

Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Apr;13 Suppl 1:S14–8 (23 ref.)

Cancer pain management. Chang HM. **Med Clin North Am** 1999 May;83(3):711–36, vii (37 ref.)

Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Beguin Y. **Med Oncol** 1998 Aug;15 Suppl 1:S38–46 (36 ref.)

Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Nowrousian MR. **Med Oncol** 1998 Aug;15 Suppl 1:S19–28 (59 ref.)

Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Osterborg A. **Med Oncol** 1998 Aug;15 Suppl 1:S47–9 (21 ref.)

Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Thomas ML. **Med Oncol** 1998 Aug; 15 Suppl 1:S3–7 (31 ref.)

The role of cytokines in cancer cachexia. Argilés JM, et al. **Med Res Rev** 1999 May;19(3):223–48 (234 ref.)

Epoetin in cancer-related anaemia. Ludwig H. **Nephrol Dial Transplant** 1999;14 Suppl 2:85–92 (25 ref.)

End-of-life confusion in patients with cancer [see comments] Boyle DM, et al. **Oncol Nurs Forum** 1998 Sep;25(8):1335–43 (47 ref.) Comment in: Oncol Nurs Forum 1999 Apr;26(3):497–8.

Surviving the cancer, surviving the treatment: acute cardiac and pulmonary toxicity. Camp-Sorrell D. **Oncol Nurs Forum** 1999 Jul;26(6):983–90 (34 ref.)

A malignancy work-up in patients with cancer-associated (paraneoplastic) autoimmune diseases: pemphigus and myasthenic syndromes as cases in point (review). Sherer Y, et al. **Oncol Rep** 1999 May–Jun;6(3):665–8 (48 ref.)

Cancer-related fatigue: guidelines for evaluation and management [see comments] Portenoy RK, et al. **Oncologist** 1999;4(1):1–10 (84 ref.) Comment in: Oncologist 1999 ;4(1):i.

Progress toward guidelines for the management of fatigue. Cella D, et al. **Oncology (Huntingt)** 1998 Nov; 12(11A):369–77 (53 ref.)

Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Glaspy J, et al. **Oncology (Huntingt)** 1999 Apr;13(4):461–73; discussion 477–8, 483–8 (88 ref.)

Alternatives to oral opioids for cancer pain. Mercadante S, et al. **Oncology (Huntingt)** 1999 Feb;13(2):215–20, 225; discussion 226–9 (71 ref.)

Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. Payne R. **Oncology (Huntingt)** 1998 Nov;12(11A):169–75 (45 ref.)

Problems of long-term spinal opioid treatment in advanced cancer patients. Mercadante S. **Pain** 1999 Jan;79(1):1–13 (91 ref.)

Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Jenkins CA, et al. **Palliat Med** 1999 May; 13(3):183–96 (84 ref.)

The role of morphine glucuronides in cancer pain. Mercadante S. **Palliat Med** 1999 Mar;13(2):95–104 (77 ref.)

Neurologic complications of cancer, sickle cell disease, and hemophilia. Zuckerman GB, et al. **Pediatr Ann** 1998 Oct; 27(10):640–50 (53 ref.)

Management and long-term complications of pediatric cancer. Grossi M. **Pediatr Clin North Am** 1998 Dec; 45(6):1637–58 (213 ref.)

Renal involvement in children with malignancies. Rossi R, et al. **Pediatr Nephrol** 1999 Feb;13(2):153–62 (153 ref.)

Osteopenia in the patient with cancer. Croarkin E. **Phys Ther** 1999 Feb;79(2):196–201 (31 ref.)

Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Sellick SM, et al. **Psychooncology** 1999 Jul–Aug;8(4):315–33 (44 ref.)

Complications of cancer therapy in children: a radiologist's guide. Parisi MT, et al. **Radiographics** 1999 Mar–Apr; 19(2):283–97 (48 ref.)

Skeletal complications in pediatric oncology patients. Roebuck DJ. **Radiographics** 1999 Jul–Aug;19(4):873–85 (50 ref.)

Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Mercadante S. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):74–83 (65 ref.)

Paraneoplastic syndromes in metastatic disease. Zumsteg MM, et al. **Semin Oncol Nurs** 1998 Aug;14(3):220–9 (39 ref.)

Pathophysiology of the thrombophilic state in the cancer patient. Falanga A, et al. **Semin Thromb Hemost** 1999; 25(2):173–82 (115 ref.)

Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Gordon LI, et al. **Semin Thromb Hemost** 1999;25(2):217–21 (82 ref.)

Laboratory diagnosis of the thrombophilic state in cancer patients. Gouin-Thibault I, et al. **Semin Thromb Hemost** 1999;25(2):167–72 (47 ref.)

The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation. Haire WD. **Semin Thromb Hemost** 1999;25(2):223–37 (93 ref.)

Prevention of venous thromboembolism in cancer patients. Kakkar AK, et al. **Semin Thromb Hemost** 1999;25(2):239–43 (39 ref.)

The thrombophilic state induced by therapeutic agents in the cancer patient. Lee AY, et al. **Semin Thromb Hemost** 1999;25(2):137–45 (105 ref.)

Treatment of venous thromboembolism in cancer patients. Levine MN, et al. **Semin Thromb Hemost** 1999;25(2):245–9 (35 ref.)

Controversies over spinal treatment in advanced cancer patients [see comments] Mercadante S. **Support Care Cancer** 1998 Nov;6(6):495–502 (66 ref.) Comment in: Support Care Cancer 1998 Nov;6(6):488–9.

Management of dyspnea in advanced cancer patients [see comments] Ripamonti C. **Support Care Cancer** 1999 Jul; 7(4):233–43 (122 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):215–6.

Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)

[Cachexia in cancer: disturbances in the protein and aminoacid metabolism] de Blaauw I, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3;143(27):1408–13 (60 ref.) (Eng. Abstr.) **(Dut)**

[AIDS-related cancers] Blay JY, et al. **Bull Cancer** 1999 Jan; 86(1):53–6 (24 ref.) **(Fre)**

[Pain and cancer: update] Krakowski I. **Bull Cancer** 1999 Jan;86(1):105–13 (29 ref.) **(Fre)**

[Opioids in practice] Lossignol D. **Rev Med Brux** 1998 Sep; 19(4):A314–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Tumoral angiogenesis: physiopathology, prognostic value and therapeutic perspectives] André T, et al. **Rev Med Interne** 1998 Dec;19(12):904–13 (66 ref.) (Eng. Abstr.) **(Fre)**

[Desire for children in tumor patients] Dällenbach RZ, et al. **Ther Umsch** 1999 May;56(5):276–81 (26 ref.) (Eng. Abstr.) **(Ger)**

[Blood transfusion in oncologic surgery: the role of recombinant human erythropoietin (rHuEPO)] Mercuriali F, et al. **Tumori** 1998 Nov–Dec;84(6 Suppl 1):S3–14 (109 ref.) (Eng. Abstr.) **(Ita)**

[Cancer and thromboembolism] Hara N, et al. **Nippon Rinsho** 1999 Jul;57(7):1648–52 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Hypercalcemia caused by tumors] Tomašević Z, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):206–15 (60 ref.) **(Scc)**

[International COnference on Nutritional Morbidity in Children with Cancer (letter)] Ruiz-Argüelles GJ. **Rev Invest Clin** 1999 Mar–Apr;51(2):135–6 (0 ref.) **(Spa)**

CONGENITAL

Prenatal exposures and childhood cancer. Bolande RP. **Pediatr Dev Pathol** 1999 May–Jun;2(3):208–14 (74 ref.)

DIAGNOSIS

Screening for early detection of cancer--ethical aspects. Törnberg SA. **Acta Oncol** 1999;38(1):77–81 (17 ref.)

The rationale for early diagnosis of cancer--the example of breast cancer. Tubiana M, et al. **Acta Oncol** 1999; 38(3):295–303 (48 ref.)

DNA in situ hybridization as an adjunct in tumor diagnosis. Fletcher JA. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S11–8 (27 ref.)

Economic, regulatory, and practice issues in molecular pathology and diagnostics. Ross JS. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S7–10 (14 ref.)

Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Vasef MA, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S68–75 (101 ref.)

The changing role of surgery in the diagnosis and treatment of cancer. Mintzer D. **Am J Med** 1999 Jan;106(1):81–9 (98 ref.)

Diagnosis and classification of the small round-cell tumors of childhood [comment] Cohn SL. **Am J Pathol** 1999 Jul; 155(1):11–5 (72 ref.) Comment on: Am J Pathol 1999 Jul;155(1):17–21.

Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer. Glassman AB. **Ann Clin Lab Sci** 1998 Nov–Dec;28(6):324–30 (19 ref.)

Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Zucker S, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:212–27 (75 ref.)

Using evaluations of diagnostic tests: understanding their limitations and making the most of available evidence. Deeks JJ. **Ann Oncol** 1999 Jul;10(7):761–8 (37 ref.)

Quality requirements and control: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul–Aug;19(4A):2791–4 (12 ref.)

Human monoclonal antibodies: a tool for cancer detection in vivo. Ditzel HJ. **APMIS Suppl** 1999;94:5–42 (242 ref.)

Diagnosis of cancer in humans by 1H NMR of tissue biopsies. Smith IC, et al. **Biochem Cell Biol** 1998;76(2–3):472–6 (24 ref.)

Exploiting the p53 pathway for cancer diagnosis and therapy. Lane DP. **Br J Cancer** 1999 Jul;80 Suppl 1:1–5 (25 ref.)

Monitoring cancer by magnetic resonance. Stubbs M, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:86–94 (58 ref.)

Dynamic contrast-enhanced MRI studies in human tumours. Padhani AR. **Br J Radiol** 1999 May;72(857):427–31 (37 ref.)

MR imaging of synovial tumours and tumour-like lesions. Ritchie DA. **Br J Radiol** 1999 Feb;72(854):212–8 (8 ref.)

Molecular oncology: diagnostic and prognostic assessment of human cancers in the clinical laboratory. Tsongalis GJ, et al. **Cancer Invest** 1998;16(7):485–502 (104 ref.)

A summary of cancer screening guidelines. Lipskie TL. **Chronic Dis Can** 1998;19(3):112–30 (62 ref.)

The surgical pathologist's approach to fine needle aspiration. Dabbs DJ. **Clin Lab Med** 1998 Sep;18(3):357–72, v (24 ref.)

Cancer in developing countries: Part II--Cancer control: strategies and priorities. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(5):283–7 (36 ref.)

Cancer screening: an educational challenge? Moore MA, et al. **Eur J Cancer Prev** 1999 Feb;8(1):7–16 (113 ref.)

Tumour markers - new aspects of an old discussion? Fleischhacker M, et al. **Eur J Med Res** 1999 Apr 27; 4(4):144–8 (45 ref.)

Cancer screening in the elderly. van Dongen JA. **Eur J Surg Oncol** 1998 Oct;24(5):367–9 (15 ref.)

Electron microscopy in tumour diagnosis: continuing to complement other diagnostic techniques. Eyden B. **Histopathology** 1999 Aug;35(2):102–8 (46 ref.)

Electron microscopy for tumour diagnosis: is it redundant? Mierau GW. **Histopathology** 1999 Aug;35(2):99–101 (17 ref.)

Diagnostic electron microscopy of neoplasms [editorial] Dardick I, et al. **Hum Pathol** 1998 Dec;29(12):1335–8 (19 ref.)

Neuroendocrine carcinomas: role of immunocytochemistry and electron microscopy. Hammond EH, et al.

Hum Pathol 1998 Dec;29(12):1367–71 (31 ref.)
Special techniques in diagnostic electron microscopy. Howell DN, et al. **Hum Pathol** 1998 Dec;29(12):1339–46 (74 ref.)
Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era. Ordóñez NG, et al. **Hum Pathol** 1998 Dec;29(12):1403–11 (60 ref.)
Cytology: screening or diagnostic tool? Turbat-Herrera EA, et al. **Hum Pathol** 1998 Dec;29(12):1356–66 (24 ref.)
Clinical application of molecular diagnosis for cancer patients. Ueda R. **Intern Med** 1999 Feb;38(2):183–6 (9 ref.)
Nongynecologic healthcare screening in women. Krueger PM. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S15–9 (24 ref.)
Gel fiberglass membranes for affinity chromatography columns and their application to cancer detection. Zusman I. **J Chromatogr B Biomed Sci Appl** 1998 Sep 11; 715(1):297–306 (92 ref.)
How shall we apply the new biology to diagnostics in surgical pathology? Jones D, et al. **J Pathol** 1999 Jan;187(1):147–54 (67 ref.)
Overview of immunocytochemical approaches to the differential diagnosis of tumors. Frisman DM. **Methods Mol Biol** 1999;115:415–37 (58 ref.)
Molecular genetics in the diagnosis and prognosis of solid pediatric tumors. Thorner PS, et al. **Pediatr Dev Pathol** 1998 Sep-Oct;1(5):337–65 (279 ref.)
In vivo fluorescence spectroscopy and imaging for oncological applications. Wagnières GA, et al. **Photochem Photobiol** 1998 Nov;68(5):603–32 (400 ref.)
Screening for cancer in the patient with rheumatic disease. Bowles KE, et al. **Rheum Dis Clin North Am** 1999 Aug; 25(3):719–44, x (137 ref.)
The use of genetic instability as a clinical tool for cancer diagnosis. Bevilacqua RA, et al. **Semin Cancer Biol** 1998 Dec;8(6):447–53 (51 ref.)
Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Peller S. **Semin Cancer Biol** 1998;8(5):379–87 (95 ref.)
Beyond anatomy: MR imaging as a molecular diagnostic tool. Calvo BF, et al. **Surg Oncol Clin N Am** 1999 Jan; 8(1):171–83 (43 ref.)
Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Reiter Y, et al. **Trends Biotechnol** 1998 Dec;16(12):513–20 (54 ref.)
Health related behaviors and cancer screening of lesbians: results from the Boston Lesbian Health Project. Roberts SJ, et al. **Women Health** 1999;28(4):1–12 (32 ref.)
[Tumor and individual radiosensitivity. An introduction] Cosset JM, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):523–9 (50 ref.) (Eng. Abstr.) **(Fre)**
[Tumor radiosensitivity tests: state of assays in 1998] Girinsky T, et al. **Cancer Radiother** 1998 Sep-Oct;2(5):530–3 (24 ref.) (Eng. Abstr.) **(Fre)**
[Good clinical use of serum tumor markers] Boussen H, et al. **Tunis Med** 1998 Feb;76(2):1020–6 (30 ref.) **(Fre)**
[New trends in the follow-up of malignant diseases] Sauer H. **Versicherungsmedizin** 1999 Mar 1;51(1):18–23 (31 ref.) (Eng. Abstr.) **(Ger)**
[Interphase cytogenetics in oncologic diagnosis] Pajor L. **Orv Hetil** 1998 Dec 6;139(49):2939–46 (60 ref.) (Eng. Abstr.) **(Hun)**
[Diagnostic impact of cytogenetics for solid tumors (editorial)] Dal Cin P, et al. **Pathologica** 1998 Aug; 90(4):337–42 (18 ref.) **(Ita)**
[Clinical gene diagnosis] Funato T. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2046–50 (5 ref.) **(Jpn)**
[Current status of cancer therapy. 1. Progress in imaging diagnosis of cancer] Moriyama N. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1752–7 (0 ref.) **(Jpn)**
[Current status of cancer management. 2. Genetic diagnosis of cancer] Ueda R. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1758–62 (10 ref.) **(Jpn)**
[Carcinogenesis and genetic diagnosis] Matsuo F, et al. **Rinsho Byori** 1999 Feb;Suppl 109:151–8 (20 ref.) **(Jpn)**
[Making of guideline for gene diagnosis in familial tumors] Yuasa Y. **Tanpakushitsu Kakusan Koso** 1998 Aug; 43(10):1395–9 (6 ref.) **(Jpn)**
[Flow cytometry: diagnostic, therapeutic and prognostic usefulness in solid tumors] Iwaszkiewicz-Pawłowska A, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):104–6 (30 ref.) (Eng. Abstr.) **(Pol)**
[The role of cystatin in neoplastic progression and diagnosis] Warwas M, et al. **Postepy Hig Med Dosw** 1998;52(5):515–26 (59 ref.) (Eng. Abstr.) **(Pol)**
[Possibilities, failures and prospects of studies on tumor markers in oncological clinics. 1. (lecture)] Kushlinskii NE. **Klin Lab Diagn** 1999 Apr;(4):25–32 (10 ref.) **(Rus)**
[Possibilities, failures and prospects of studies on tumor markers in oncological clinics. 1. (lecture)] Kushlinskii NE. **Klin Lab Diagn** 1999 Mar;(3):25–32 (9 ref.) **(Rus)**
[The immunodiagnosis and immunotherapy of tumors] Kadagidze ZG. **Vestn Ross Akad Med Nauk** 1999;(5):19–22 (14 ref.) (Eng. Abstr.) **(Rus)**

DIET THERAPY

Interventional nutrition for the cancer patient. Ogilvie GK. **Clin Tech Small Anim Pract** 1998 Nov;13(4):224–31 (78 ref.)
Alternative nutritional cancer therapies. Weitzman S. **Int J Cancer Suppl** 1998;11:69–72 (31 ref.)
Application of methionine-free nutrition as an anticancer treatment. Yoshido S. **Nutrition** 1999 May;15(5):422–4 (13 ref.)
[Nutrition and cancer: causative, protective and therapeutic aspects] van den Brandt PA, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3;143(27):1414–20 (43 ref.) (Eng. Abstr.) **(Dut)**
[The importance of nutrition for cancer patients] Ose T, et al. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3466–70 (54 ref.) (Eng. Abstr.) **(Nor)**

DRUG THERAPY

Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Wang HK, et al. **Adv Exp Med Biol** 1998; 439:191–225 (99 ref.)
Preclinical and clinical studies of MMP inhibitors in cancer. Drummond AH, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:228–35 (24 ref.)
Essential drugs for cancer therapy: a World Health Organization consultation. Sikora K, et al. **Ann Oncol** 1999 Apr;10(4):385–90 (29 ref.)
Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. van Hinsbergh VW, et al. **Ann Oncol** 1999;10 Suppl 4:60–3 (52 ref.)
Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Cersosimo RJ. **Ann Pharmacother** 1998 Dec; 32(12):1334–43 (85 ref.)
Ambulatory management of chemotherapy-induced fever and neutropenia in adult cancer patients. Davis DD, et al. **Ann Pharmacother** 1998 Dec;32(12):1317–23 (22 ref.)
Resistance to cisplatin. Akiyama S, et al. **Anticancer Drug Des** 1999 Apr;14(2):143–51 (98 ref.)
Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Tomida A, et al. **Anticancer Drug Des** 1999 Apr;14(2):169–77 (83 ref.)
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM, et al. **Anticancer Drugs** 1998 Jul;9(6):479–90 (90 ref.)
Antitumor drug delivery by tissue electroporation. Singh BN, et al. **Anticancer Drugs** 1999 Feb;10(2):139–46 (64 ref.)
Clinical studies with matrix metalloproteinase inhibitors. Brown PD. **APMIS** 1999 Jan;107(1):174–80 (41 ref.)
The basic science underlying antiangiogenic therapies. Rundell K. **Biochim Biophys Acta** 1998 Oct 14; 1378(2):R27–31 (13 ref.)
CoQ10: could it have a role in cancer management? Hodges S, et al. **Biofactors** 1999;9(2–4):365–70 (17 ref.)
New drug development: its role in reversing drug resistance. Kaye SB. **Br J Cancer** 1999 Jul;80 Suppl 1:116–21 (50 ref.)
Exploiting the p53 pathway for cancer diagnosis and therapy. Lane DP. **Br J Cancer** 1999 Jul;80 Suppl 1:1–5 (25 ref.)
Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Lennard L. **Br J Clin Pharmacol** 1999 Feb; 47(2):131–43 (109 ref.)
Actions of heparin that may affect the malignant process. Engelberg H. **Cancer** 1999 Jan 15;85(2):257–72 (243 ref.)
The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Miller WH Jr. **Cancer** 1998 Oct 15;83(8):1471–82 (146 ref.)
Promising new developments in cancer chemotherapy. Ferrante K, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S61–8 (90 ref.)
Marimastat (BB2516): current status of development. Steward WP. **Cancer Chemother Pharmacol** 1999;43 Suppl:S56–60 (18 ref.)
Cardiotoxicity of cancer therapy. Tolba KA, et al. **Cancer Invest** 1999;17(6):408–22 (165 ref.)
One-hour paclitaxel infusions: review of safety and efficacy. Greco FA, et al. **Cancer J Sci Am** 1999 May-Jun; 5(3):179–91 (44 ref.)
PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Atadja P, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):163–8 (28 ref.)
An old paradigm for treating cancer and other diseases in the 21st century. Boehm T. **Cancer Metastasis Rev** 1998 Jun;17(2):149–54 (19 ref.)
Antisense comes of age. Flanagan WM. **Cancer Metastasis Rev** 1998 Jun;17(2):169–76 (45 ref.)
Anti-adhesion cancer therapy. Glinsky GV. **Cancer Metastasis Rev** 1998 Jun;17(2):177–85 (58 ref.)
Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Haq R, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):233–9 (57 ref.)
Pre-clinical development of farnesyltransferase inhibitors. Lobell RB, et al. **Cancer Metastasis Rev** 1998 Jun; 17(2):203–10 (54 ref.)
Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Mayer LD. **Cancer Metastasis Rev** 1998 Jun;17(2):211–8 (32 ref.)
Targeting DNA methyltransferase in cancer. Szyf M. **Cancer Metastasis Rev** 1998 Jun;17(2):219–31 (72 ref.)
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Witte L, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):155–61 (21 ref.)
Promoting informed decision making: hormone replacement therapy. Bastian L, et al. **Cancer Treat Res** 1998;97:129–47 (98 ref.)
The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer. Burke GA, et al. **Cancer Treat Rev** 1999 Feb; 25(1):13–27 (88 ref.)
Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cvitkovic E. **Cancer Treat Rev** 1998 Aug;24(4):265–81 (260 ref.)
Application of the area under the curve of carboplatin in predicting toxicity and efficacy. de Lemos ML. **Cancer Treat Rev** 1998 Dec;24(6):407–14 (50 ref.)
Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Mueller H. **Cell Mol Life Sci** 1998 Dec; 54(12):1291–8 (117 ref.)
Pharmacogenetics in cancer etiology and chemotherapy. Boddy AV, et al. **Clin Cancer Res** 1997 Jul;3(7):1025–30 (106 ref.)
Drug development in solid tumors: personal perspective of Dr. Emil J Freireich's contributions. Carbone PP. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2614–22 (109 ref.)
O6-benzylguanine and its role in chemotherapy. Dolan ME, et al. **Clin Cancer Res** 1997 Jun;3(6):837–47 (126 ref.)
Prognostic factors in clinical cancer trials. Estey E. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2591–3 (15 ref.)
The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Frei E 3rd, et al. **Clin Cancer Res** 1998 Sep; 4(9):2027–37 (81 ref.)
Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Malonne H, et al. **Clin Exp Metastasis** 1999 Feb;17(1):1–14 (183 ref.)
Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer [editorial] Del Rosso M, et al. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):389–93 (56 ref.)
The introduction of photodynamic therapy for tumorous patients in Croatia based on our experimental experiences and clinical approaches of the other groups. Doko M, et al. **Coll Antropol** 1998 Jun;22(1):315–9 (20 ref.)
Pulmonary complications of cancer therapy. Wesselius LJ. **Compr Ther** 1999 May;25(5):272–7 (20 ref.)
Cellular drug interaction in the fight against multidrug resistant cancer [editorial; comment] Albertson TE, et al. **Crit Care Med** 1999 Feb;27(2):244–5 (15 ref.) Comment on: Crit Care Med 1999 Feb;27(2):332–9.
Theoretical models for drug delivery to solid tumors. el-Kareh AW, et al. **Crit Rev Biomed Eng** 1997; 25(6):503–71 (250 ref.)
Folate-mediated targeting of therapeutic and imaging agents to cancers. Reddy JA, et al. **Crit Rev Ther Drug Carrier Syst** 1998;15(6):587–627 (123 ref.)
Biosynthetic anthracyclines. Arcamone F, et al. **Curr Med Chem** 1998 Oct;5(5):391–419 (261 ref.)
The discovery and validation of new drug targets in cancer. Courtneidge SA, et al. **Curr Opin Biotechnol** 1998 Dec; 9(6):632–6 (42 ref.)
n-3 polyunsaturated fatty acids and cancer. Bougnoux P. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):121–6 (50 ref.)
CDK inhibition and cancer therapy. Garrett MD, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):104–11 (111 ref.)
Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Fisher DC, et al. **Curr Opin Hematol** 1994 May;1(3):221–7 (46 ref.)
Chemotherapy targeted to tumor vasculature. Arap W, et al. **Curr Opin Oncol** 1998 Nov;10(6):560–5 (56 ref.)
Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Kaye SB. **Curr Opin Oncol** 1998 Aug;10 Suppl 1:S15–9 (37 ref.)
The rationale and future potential of angiogenesis inhibitors in neoplasia. Gasparini G. **Drugs** 1999 Jul;58(1):17–38 (196 ref.)
Photodynamic therapy in the treatment of cancer: current state of the art. Hsi RA, et al. **Drugs** 1999 May;57(5):725–34 (71 ref.)
Photodynamic therapy: a review. McCaughan JS Jr. **Drugs Aging** 1999 Jul;15(1):49–68 (144 ref.)
Ukrain (NSC-631570) in experimental and clinical studies: a review. Jagiello-Wójtowicz E, et al. **Drugs Exp Clin Res** 1998;24(5–6):213–9 (45 ref.)
Etoposide: four decades of development of a topoisomerase II inhibitor. Hande KR. **Eur J Cancer** 1998 Sep; 34(10):1514–21 (76 ref.)
Pharmacogenetics and cancer chemotherapy. Iyer L, et al. **Eur J Cancer** 1998 Sep;34(10):1493–9 (156 ref.)
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Lebwohl D, et al. **Eur J Cancer** 1998 Sep;34(10):1522–34 (132 ref.)
Camptothecins: a review of their development and schedules of administration. O'Leary J, et al. **Eur J Cancer** 1998 Sep; 34(10):1500–8 (113 ref.)
Cellular and molecular determinants of cisplatin resistance. Perez RP. **Eur J Cancer** 1998 Sep;34(10):1535–42 (108 ref.)
New strategies in anti-vascular cancer therapy [see comments] Bloemendal HJ, et al. **Eur J Clin Invest** 1999 Sep;29(9):802–9 (78 ref.) Comment in: Eur J Clin Invest 1999 Sep;29(9):733–6.
Multidrug resistance in oncology: diagnostic and therapeutic approaches. Robert J. **Eur J Clin Invest** 1999 Jun; 29(6):536–45 (95 ref.)
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Schally AV, et

al. **Eur J Endocrinol** 1999 Jul;141(1):1–14 (102 ref.)
Cancer vaccines: a step towards prevention and treatment of cancer. Pandey M, et al. **Eur J Surg Oncol** 1999 Apr; 25(2):209–14 (55 ref.)
Chemotherapy in the elderly. Wilking N. **Eur J Surg Oncol** 1998 Oct;24(5):412–7 (44 ref.)
Mechanisms of hypercoagulation in malignancy and during chemotherapy. Falanga A. **Haemostasis** 1998;28 Suppl 3:50–60 (59 ref.)
Bisphosphonates as cancer drugs. Mundy GR. **Hosp Pract (Off Ed)** 1999 May 15;34(5):81–4, 88–9, 93–4 (8 ref.)
Gonadal tissue cryopreservation in boys with paediatric cancers. Bahadur G, et al. **Hum Reprod** 1999 Jan;14(1):11–7 (81 ref.)
Drug trials in pediatric oncology: a multi-facetted problem. Boos J. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):613–20 (21 ref.)
Therapeutic potential of the anti-angiogenesis drug TNP-470. Gervaz P, et al. **Int J Exp Pathol** 1998 Dec; 79(6):359–62 (30 ref.)
New molecular targets for cancer chemotherapy. Nakano S. **Intern Med** 1999 Feb;38(2):186–90 (27 ref.)
Preservation of fertility in women undergoing chemotherapy: current approach and future prospects. Abir R, et al. **J Assist Reprod Genet** 1998 Sep;15(8):469–77 (82 ref.)
Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. Cortazar P, et al. **J Clin Oncol** 1999 May; 17(5):1625–31 (41 ref.)
Regulating angiogenesis: a new therapeutic strategy. Gibaldi M. **J Clin Pharmacol** 1998 Oct;38(10):898–903 (23 ref.)
Angiogenesis, a target for tumor therapy. Griffioen AW, et al. **J Lab Clin Med** 1998 Nov;132(5):363–8 (46 ref.)
Apoptosis and therapy. Schmitt CA, et al. **J Pathol** 1999 Jan;187(1):127–37 (163 ref.)
Phase I therapy trials in children with cancer. Shah S, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct;20(5):431–8 (65 ref.)
A clinical study on acupuncture for prevention and treatment of toxic side-effects during radiotherapy and chemotherapy. Zhou J, et al. **J Tradit Chin Med** 1999 Mar; 19(1):16–21 (19 ref.)
Iron therapy and cancer. Weinberg ED. **Kidney Int Suppl** 1999 Mar;69:S131–4 (29 ref.)
Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Richardson DR. **Leuk Lymphoma** 1998 Sep;31(1–2):47–60 (73 ref.)
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14–8 (23 ref.)
Antioxidant inhibitors for cancer therapy. Kong Q, et al. **Med Hypotheses** 1998 Nov;51(5):405–9 (51 ref.)
Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? Höglund M. **Med Oncol** 1998 Dec; 15(4):229–33 (48 ref.)
Cytoprotection in the treatment of pediatric cancer: review of current strategies in adults and their application to children. Bukowski R. **Med Pediatr Oncol** 1999 Feb; 32(2):124–34 (109 ref.)
STAT signaling in the pathogenesis and treatment of cancer. Frank DA. **Mol Med** 1999 Jul;5(7):432–56 (245 ref.)
Myb targeted therapeutics for the treatment of human malignancies. Gewirtz AM. **Oncogene** 1999 May 13; 18(19):3056–62 (73 ref.)
Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Gregoire V, et al. **Oncol Rep** 1999 Sep–Oct; 6(5):949–57 (61 ref.)
The University of Texas M. D. Anderson Cancer Center Orzel/UFT Investigators' Workshop and Consensus Conference. October 15–18, 1998. Proceedings. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):15–135 (0 ref.)
Clinical implications of dihydropyrimidine dehydrogenase inhibition. Diasio RB. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):17–21 (33 ref.)
The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Diasio RB. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):23–7 (37 ref.)
Neuraxial infusion in the management of cancer pain. Ferrante FM. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):30–6 (40 ref.)
Patient and family caregiver perspectives. Ferrell BR. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):15–9 (29 ref.)
Clinical trials referral resource. Clinical trials of single-agent oxaliplatin. Ivy SP, et al. **Oncology (Huntingt)** 1999 Jul; 13(7):966, 969–70 (0 ref.)
Practical issues when using neuraxial infusion. Krames ES. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):37–44 (28 ref.)
Toxicity of 5-fluorouracil. Macdonald JS. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):33–4 (11 ref.)
Clinical trials referral resource. Clinical trials of MGI-114. Murgo A, et al. **Oncology (Huntingt)** 1999 Feb;13(2):233, 237–8 (13 ref.)
Introduction. Beyond 5-fluorouracil. Pazdur R. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):15–6 (0 ref.)
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Rosen LS. **Oncology (Huntingt)** 1998 Aug;12(8 Suppl 6):103–9 (39 ref.)
Incorporating new modalities into practice guidelines: platelet growth factors. Rubenstein EB, et al. **Oncology (Huntingt)** 1998 Nov;12(11A):381–6 (15 ref.)
Biochemical and clinical pharmacology of 5-fluorouracil. Schilsky RL. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):13–8 (29 ref.)
Clinical trials referral resource. Clinical trials of dolastatin-10. Wright JJ, et al. **Oncology (Huntingt)** 1999 Jan;13(1):68–70, 75 (0 ref.)
Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Canal P, et al. **Pathol Oncol Res** 1998;4(3):171–8 (56 ref.)
Diagnostics of multidrug resistance in cancer. Szakács G, et al. **Pathol Oncol Res** 1998;4(4):251–7 (64 ref.)
Mushrooms, tumors, and immunity. Borchers AT, et al. **Proc Soc Exp Biol Med** 1999 Sep;221(4):281–93 (120 ref.)
What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Stewart F, et al. **Radiother Oncol** 1998 Sep;48(3):233–48 (160 ref.)
Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Peller S. **Semin Cancer Biol** 1998;8(5):379–87 (95 ref.)
Reactivation of mutant p53: a new strategy for cancer therapy. Selivanova G, et al. **Semin Cancer Biol** 1998; 8(5):369–78 (70 ref.)
The clinical pharmacology of topoisomerase I inhibitors. Abang AM. **Semin Hematol** 1998 Jul;35(3 Suppl 4):13–21 (39 ref.)
An overview of topoisomerase I-targeting agents. Arbuck SG, et al. **Semin Hematol** 1998 Jul;35(3 Suppl 4):3–12 (127 ref.)
Introduction: dose-intensive therapy for adult malignancies. Weiss RB. **Semin Oncol** 1999 Feb;26(1):1–5 (21 ref.)
Thrombotic complications of central venous catheters in cancer patients. Bona RD. **Semin Thromb Hemost** 1999; 25(2):147–55 (73 ref.)
The thrombophilic state induced by therapeutic agents in the cancer patient. Lee AY, et al. **Semin Thromb Hemost** 1999;25(2):137–45 (105 ref.)
Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Barker GJ. **Support Care Cancer** 1999 Jan;7(1):17–20 (16 ref.)
Heparin and cancer. Zacharski LR, et al. **Thromb Haemost** 1998 Jul;80(1):10–23 (203 ref.)
Pediatric oncology and AIDS: therapeutic lessons of relevance to generic drug use. Rodman J. **Transplant Proc** 1999 May;31(3A Suppl):13S–15S (18 ref.)
Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Pastor-Anglada M, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):424–30 (50 ref.)
Fluoropyrimidines in the treatment of advanced neoplastic diseases: role and advantages of UFT. Del Vecchio M, et al. **Tumori** 1999 Jan–Feb;85(1):6–11 (42 ref.)
Apoptosis: its relevance to carcinogenesis and anti-tumour drug sensitivity [editorial] Chresta CM, et al. **Urol Res** 1999; 27(1):1–2 (7 ref.)
[Photodynamic therapy. A new method for the treatment of cancer] Johansen LS. **Ugeskr Laeger** 1999 Jun 28; 161(26):3992–5 (40 ref.) (Eng. Abstr.) **(Dan)**
[Angiogenesis and the regulation of antitumor defense] Pappas NP, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1555–9 (22 ref.) (Eng. Abstr.) **(Dut)**
[Inhibition of tumor angiogenesis as a cancer treatment] Verheul HM, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1549–55 (50 ref.) (Eng. Abstr.) **(Dut)**
[The human E-cadherin/catenin complex: a potent invasion and tumor suppressor] Mareel M, et al. **Verh K Acad Geneeskd Belg** 1998;60(6):567–98 (70 ref.) (Eng. Abstr.) **(Dut)**
[Irinotecan: various administration schedules, study of drug combinations, phase I experience. Boige V, et al. **Bull Cancer** 1998 Dec;Spec No:26–32 (42 ref.) (Eng. Abstr.) **(Fre)**
[Clinical activity spectrum of irinotecan] Cottu PH, et al. **Bull Cancer** 1998 Dec;Spec No:21–5 (46 ref.) (Eng. Abstr.) **(Fre)**
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas] Couteau C, et al. **Bull Cancer** 1998 Dec;Spec No:47–50 (26 ref.) (Eng. Abstr.) **(Fre)**
[Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance] Pourquier P, et al. **Bull Cancer** 1998 Dec;Spec No:5–10 (29 ref.) (Eng. Abstr.) **(Fre)**
[Concurrent chemoradiotherapy update] Reboul F, et al. **Bull Cancer** 1999 Jan;86(1):77–83 (36 ref.) (Eng. Abstr.) **(Fre)**
[Anticancer chemotherapy. Prevention of toxicity] Chvetzoff G, et al. **Presse Med** 1998 Dec 12;27(39):2106–12 (44 ref.) (Eng. Abstr.) **(Fre)**
[Venous access in oncology] Lesimple T, et al. **Presse Med** 1998 Oct 31;27(33):1694–701 (30 ref.) (Eng. Abstr.) **(Fre)**
[Anticancer chemotherapy. Prevention of complications] Paule B, et al. **Presse Med** 1998 Dec 12;27(39):2113–9 (79 ref.) (Eng. Abstr.) **(Fre)**
[Tumor angiogenesis inhibitors: media and scientific aspects] Raymond E. **Presse Med** 1998 Jul 4–11;27(24):1221–4 (12 ref.) (Eng. Abstr.) **(Fre)**
[Cell adhesion molecules and pharmacologic applications. Round Table No 3 at Giens XIII] McGregor J, et al. **Therapie** 1998 Jul–Aug;53(4):371–9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Locoregional therapy methods] Kubicka S, et al. **Internist (Berl)** 1998 Nov;39(11):1139–47 (49 ref.) **(Ger)**
[Systemic cytostatic chemotherapy] Sauer H. **Internist (Berl)** 1998 Nov;39(11):1104–14 (42 ref.) **(Ger)**
[High dose therapy with stem cell transplantation] Wörmann B. **Internist (Berl)** 1998 Nov;39(11):1115–22 (36 ref.) **(Ger)**
[Role of high-dose chemotherapy in hematology and internal medicine/ oncology] Engert A, et al. **Med Klin** 1999 Aug 15;94(8):431–42 (96 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of cancer with cytostatics: results with high dose therapy with cyclophosphamide and drug targeting with doxorubicin] Busse D, et al. **Pharm Unserer Zeit** 1998 Sep; 27(5):216–22 (14 ref.) **(Ger)**
[New cytostatic drugs--indications and costs] Schefer H, et al. **Schweiz Rundsch Med Prax** 1999 Apr 29;88(18):791–801 (61 ref.) (Eng. Abstr.) **(Ger)**
[Implantable catheter systems] Willnow U. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1135–9 (26 ref.) (Eng. Abstr.) **(Ger)**
[Hemorrhagic cystitis after high dose chemotherapy. An interdisciplinary problem] Sommerkamp H. **Urologe A** 1998 Sep;37(5):516–21 (59 ref.) (Eng. Abstr.) **(Ger)**
[Quality of life and cytokines in oncological therapy] Leitgeb C. **Wien Med Wochenschr** 1998;148(18):424–6 (19 ref.) (Eng. Abstr.) **(Ger)**
[Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents] Jeney A, et al. **Orv Hetil** 1999 Jun 13;140(24):1339–45 (50 ref.) (Eng. Abstr.) **(Hun)**
[Evolution of cancer chemotherapy. Discovery of new active drugs. III] Lopez M. **Clin Ter** 1999 Mar–Apr;150(2):159–65 (29 ref.) **(Ita)**
[Combination chemotherapy--present status and problems] Furue H. **Gan To Kagaku Ryoho** 1999 Apr;26(5):589–96 (36 ref.) (Eng. Abstr.) **(Jpn)**
[Advance in cancer chemotherapy] Tsukagoshi S. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:23–31 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Current status of cancer management. 3. New molecular targets in cancer chemotherapy] Nakano S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1763–7 (28 ref.) **(Jpn)**
[Targeted immunotherapy for malignant tumors] Turuo T. **Rinsho Ketsueki** 1999 Jun;40(6):476–9 (7 ref.) **(Jpn)**
[Problems in oncologic pharmacology] Filov VA, et al. **Vopr Onkol** 1998;44(6):651–61 (70 ref.) **(Rus)**
[Melatonin and its wide-spectrum effects: use of melatonin in the treatment of tumors] Solár P. **Cesk Fysiol** 1999 Feb; 48(1):27–40 (149 ref.) (Eng. Abstr.) **(Slo)**
[Oral fluoropyrimidines in oncology] González Barón M. **An R Acad Nac Med (Madr)** 1998;115(3):721–45; discussion 745–6 (72 ref.) **(Spa)**

ECONOMICS

Rationing in cancer treatment: is the identification of essential cytotoxic drugs feasible? [editorial] Sessa C. **Ann Oncol** 1999 Apr;10(4):373–4 (5 ref.)
The economic evaluation of hematopoietic growth factors in high-dose chemotherapy. Le Corroller AG, et al. **Anticancer Drugs** 1998 Nov;9(10):917–24 (39 ref.)
Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Glaspy JA. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S21–7 (29 ref.)
Costs, benefits and limitations of genetic testing for cancer risk. Ponder BA. **Br J Cancer** 1999 Jul;80 Suppl 1:46–50 (36 ref.)
Using state and federal claims data to evaluate the patterns and costs of cancer care. Desch CE, et al. **Cancer Treat Res** 1998;97:53–69 (48 ref.)
Evaluating cancer costs in NCI trials. Schulman KA, et al. **Cancer Treat Res** 1998;97:37–52 (28 ref.)
Economic impact of infections in patients with cancer. Shulkin DJ, et al. **Cancer Treat Res** 1998;96:283–90 (30 ref.)
Costs and cost-effectiveness of new technologies in cancer. Waters TM. **Cancer Treat Res** 1998;97:25–36 (16 ref.)
Economic evaluation of cancer treatments: a review of the methods. Brown J. **Clin Oncol (R Coll Radiol)** 1999; 11(2):78–83 (42 ref.)
Techniques for health economics analysis in oncology: Part 2. Neymark N. **Crit Rev Oncol Hematol** 1999 Mar; 30(1):13–24 (24 ref.)
Techniques for health economics analysis in oncology: Part 1. Neymark N. **Crit Rev Oncol Hematol** 1999 Mar; 30(1):1–11 (27 ref.)
Is health economics useful in cancer? Williams CJ. **Crit Rev Oncol Hematol** 1999 Mar;30(1):25–33 (28 ref.)
A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review). Messori A, et al. **Oncol Rep** 1999 Sep–Oct;6(5):1135–41 (34 ref.)
Health economics of care for patients with cancer and intractable disease in Japan. Hisashige A, et al. **Support Care Cancer** 1998 Nov;6(6):503–10 (39 ref.)

ENZYMOLOGY

Telomerase activity in cancer: a magic bullet or a mirage? Soria JC, et al. **Adv Anat Pathol** 1998 Mar;5(2):86–94 (76 ref.)

Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Vasef MA, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S68–75 (101 ref.)
Telomerase in cancer: clinical applications. Urquidi V, et al. **Ann Med** 1998 Oct;30(5):419–30 (179 ref.)
Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. Balbin M, et al. **APMIS** 1999 Jan;107(1):45–53 (46 ref.)
Molecular regulation, membrane association and secretion of tumor cathepsin B. Frosch BA, et al. **APMIS** 1999 Jan; 107(1):28–37 (65 ref.)
Cathepsin D in cancer metastasis: a protease and a ligand. Rochefort H, et al. **APMIS** 1999 Jan;107(1):86–95 (78 ref.)
Critical targets of protein kinase C in differentiation of tumour cells. Watters DJ, et al. **Biochem Pharmacol** 1999 Aug 1;58(3):383–8 (63 ref.)
Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Oliff A. **Biochim Biophys Acta** 1999 May 31; 1423(3):C19–30 (63 ref.)
Proteases as prognostic markers in cancer. Duffy MJ. **Clin Cancer Res** 1996 Apr;2(4):613–8 (73 ref.)
Pharmacogenetics and cancer chemotherapy. Iyer L, et al. **Eur J Cancer** 1998 Sep;34(10):1493–9 (156 ref.)
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Kornberg LJ. **Head Neck** 1998 Dec;20(8):745–52 (52 ref.)
Role of caspases in apoptosis and disease. Khanna N, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):151–9 (50 ref.)
PKR, apoptosis and cancer. Jagus R, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):123–38 (192 ref.)
Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. Van Driel BE, et al. **J Histochem Cytochem** 1999 May; 47(5):575–82 (50 ref.)
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. Duffy MJ, et al. **J Surg Oncol** 1999 Jun;71(2):130–5 (59 ref.)
Applications of telomerase research in the fight against cancer. McKenzie KE, et al. **Mol Med Today** 1999 Mar; 5(3):114–22 (65 ref.)
Drug metabolism polymorphisms as modulators of cancer susceptibility. Taningher M, et al. **Mutat Res** 1999 May; 436(3):227–61 (170 ref.)
An overview of topoisomerase I–targeting agents. Arbuck SG, et al. **Semin Hematol** 1998 Jul;35(3 Suppl 4):3–12 (127 ref.)
Telomerase activation. One step on the road to cancer? Greider CW. **Trends Genet** 1999 Mar;15(3):109–12 (68 ref.)
[Telomerase and cancer] Soria JC, et al. **Ann Pathol** 1998 Nov;18(5):391–403 (111 ref.) **(Fre)**
[Telomerase—its potential and limits for clinical applicability] Hoos A, et al. **Dtsch Med Wochenschr** 1999 Feb 26; 124(8):223–30 (73 ref.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of cancer in patients with renal transplants. Davison AM. **Adv Nephrol Necker Hosp** 1998;28:171–94 (100 ref.)
Occupational cancer among women: research status and methodologic considerations. Blair A, et al. **Am J Ind Med** 1999 Jul;36(1):6–17 (42 ref.)
Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Hoyme HE, et al. **Am J Med Genet** 1998 Oct 2;79(4):274–8 (43 ref.)
Positive association between resting pulse and cancer incidence in current and former smokers. Cerhan JR, et al. **Ann Epidemiol** 1999 Jan;9(1):34–44 (31 ref.)
Nutrition, cancer, and aging. Dreosti IE. **Ann N Y Acad Sci** 1998 Nov 20;854:371–7 (21 ref.)
The effect of long-term dietary supplementation with antioxidants. Meydani M, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:352–60 (50 ref.)
Cancer in the developing world: a call to action. Jones SB. **BMJ** 1999 Aug 21;319(7208):505–8 (9 ref.)
Physical activity and cancer etiology: associations and mechanisms. McTiernan A, et al. **Cancer Causes Control** 1998 Oct;9(5):487–509 (208 ref.)
Power-frequency fields and cancer. Moulder JE. **Crit Rev Biomed Eng** 1998;26(1–2):1–116 (411 ref.)
Common cancers in the elderly. Hansen J. **Drugs Aging** 1998 Dec;13(6):467–78 (62 ref.)
Occupational cancer in France: epidemiology, toxicology, prevention, and compensation. Aubrun JC, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:245–52 (65 ref.)
Introduction: Epidemiologic research and prevention of occupational cancer in Europe. Boffetta P, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:229–31 (19 ref.)
Occupational cancer in Germany. Brüske-Hohlfeld I. **Environ Health Perspect** 1999 May;107 Suppl 2:253–8 (20 ref.)
Occupational cancer in the European part of the Commonwealth of Independent States. Bulbulyan MA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:283–8 (53 ref.)
Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)
Occupational cancer in the United Kingdom. Coggon D. **Environ Health Perspect** 1999 May;107 Suppl 2:239–44 (48 ref.)
Occupational cancer in central European countries. Fabiánová E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:279–82 (19 ref.)
Occupational cancer in Spain. González CA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:273–7 (36 ref.)
Occupational cancer research in the Nordic countries. Kjaerheim K. **Environ Health Perspect** 1999 May;107 Suppl 2:233–8 (113 ref.)
Occupational cancer in Italy. Merler E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:259–71 (142 ref.)
Childhood cancer: A growing problem. Schmidt CW. **Environ Health Perspect** 1998 Jan;106(1):A18–23 (0 ref.)
Dimethylformamide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:545–74 (120 ref.)
Dimethyl sulfate. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:575–88 (55 ref.)
1,4-Dioxane. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:589–602 (43 ref.)
Epichlorohydrin. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:603–28 (136 ref.)
Methyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:737–47 (38 ref.)
Phenol. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:749–68 (83 ref.)
Toluene. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:829–64 (144 ref.)
Polychlorophenols and their sodium salts. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:769–816 (154 ref.)
Ethylene dibromide (1,2-dibromoethane). **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:641–69 (126 ref.)
Hydrogen peroxide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:671–89 (94 ref.)
Hydroquinone. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:691–719 (130 ref.)
Methyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:721–35 (64 ref.)
Toluene diisocyanates. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:865–79 (45 ref.)
1,1,1-Trichloroethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:881–903 (93 ref.)
Health trends in northern Finland. Näyhä S, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):94–103 (51 ref.)
Evaluation of the completeness of cancer case ascertainment in the Seoul male cohort study: application of the capture–recapture method. Kim DS, et al. **J Epidemiol** 1999 Jun;9(3):146–54 (16 ref.)
Can traditional epidemiology detect cancer risks caused by occupational exposure to pesticides? Georgellis A, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):159–66 (77 ref.)
Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. Giovannucci E. **J Natl Cancer Inst** 1999 Feb 17;91(4):317–31 (125 ref.)
Molecular epidemiology in cancer research. Collins AR. **Mol Aspects Med** 1998 Dec;19(6):359–432 (173 ref.)
Carcinogens in the diet vs. overnutrition. Individual dietary habits, malnutrition, and genetic susceptibility modify carcinogenic potency and cancer risk. Lutz WK. **Mutat Res** 1999 Jul 15;443(1–2):251–8 (20 ref.)
Pediatric oncology in Brazil. Epelman S. **Pediatr Hematol Oncol** 1998 Sep–Oct;15(5):377–83 (29 ref.)
Tea flavonols in cardiovascular disease and cancer epidemiology. Hollman PC, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):198–202 (29 ref.)
Occupational cancer risk in pilots and flight attendants: current epidemiological knowledge. Blettner M, et al. **Radiat Environ Biophys** 1998 Jul;37(2):75–80 (24 ref.)
Work-related cancer in the Nordic countries. Andersen A, et al. **Scand J Work Environ Health** 1999;25 Suppl 2:1–116 (155 ref.)
Introduction: progress and enigmas in cancer epidemiology. Trichopoulos D, et al. **Semin Cancer Biol** 1998 Aug; 8(4):215–7 (28 ref.)
Epidemiology of cancer: global patterns and trends. Parkin DM. **Toxicol Lett** 1998 Dec 28;102–103:227–34 (23 ref.)
[Application of meta-analysis in epidemiological study of occupational neoplasms] Chen R, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):307–9 (8 ref.) **(Chi)**
[Molecular biologic markers and cancer risk assessment] Zi XL, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug;18(4):244–6 (19 ref.) **(Chi)**
[Cancer and depression: epidemiologic aspects] Nezelof S, et al. **Encephale** 1998 Dec;24 Spec No 2:59–65 (55 ref.) **(Fre)**

ETHNOLOGY

From the desert: transcultural aspects of cancer nursing care in Israel. Delbar V. **Cancer Nurs** 1999 Feb;22(1):45–51 (15 ref.)
The experience of having cancer in Latin America. Granda-Cameron C. **Cancer Nurs** 1999 Feb;22(1):51–7 (35 ref.)
Cultural views of cancer around the world. Navon L. **Cancer Nurs** 1999 Feb;22(1):39–45 (43 ref.)
The health status of American Indians and Alaska Natives: 2. Lessons for cancer educators. Mahoney MC, et al. **J Cancer Educ** 1999 Spring;14(1):23–7 (34 ref.)
Cancer epidemiology in migrant populations. McCredie M. **Recent Results Cancer Res** 1998;154:298–305 (26 ref.)

ETIOLOGY

Alcohol and risk of cancer. Ringborg U. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):323S–328S (111 ref.)
Health claims and observational human data: relation between dietary fat and cancer. Lewis CJ, et al. **Am J Clin Nutr** 1999 Jun;69(6):1357S–1364S (20 ref.)
Overview of the problem of cancer in organ transplant recipients. Penn I. **Ann Transplant** 1997;2(4):5–6 (0 ref.)
Etiology and pathogenesis of posttransplant tumors: new insights into viral oncogenesis. el-Sabrout R, et al. **Ann Transplant** 1997;2(4):67–9 (45 ref.)
Matrix-degrading proteases and angiogenesis during development and tumor formation. Werb Z, et al. **APMIS** 1999 Jan;107(1):11–8 (28 ref.)
Apoptosis and carcinogenesis. Wyllie AH, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:34–7 (39 ref.)
On the need to assess cancer risk in populations environmentally and occupationally exposed to virus and chemical agents in developing countries. Netto GF. **Cad Saude Publica** 1998;14 Suppl 3:87–98 (76 ref.)
Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Mason RP. **Cancer** 1999 May 15;85(10):2093–102 (90 ref.)
Environmental factors as regulators and effectors of multistep carcinogenesis. Minamoto T, et al. **Carcinogenesis** 1999 Apr;20(4):519–27 (157 ref.)
Pharmacogenetics in cancer etiology and chemotherapy. Boddy AV, et al. **Clin Cancer Res** 1997 Jul;3(7):1025–30 (106 ref.)
p53 in life and death. Shimamura A, et al. **Clin Cancer Res** 1996 Mar;2(3):435–40 (56 ref.)
Health effects of cigarette smoking. Skurnik Y, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):545–56 (106 ref.)
Power-frequency fields and cancer. Moulder JE. **Crit Rev Biomed Eng** 1998;26(1–2):1–116 (411 ref.)
General biological aspects of oncogenesis. D'Amato G, et al. **Crit Rev Oncog** 1998;9(3–4):275–373 (1018 ref.)
Primate retroviruses and oncogenesis. Sanguineti-Diaz C, et al. **Crit Rev Oncog** 1998;9(3–4):209–53 (471 ref.)
Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Jiang W, et al. **Crit Rev Oncol Hematol** 1999 Feb;29(3):209–48 (376 ref.)
Human immunodeficiency virus disease in the era of HAART: a reevaluation of the mucocutaneous manifestations. Johnson RA. **Curr Clin Top Infect Dis** 1999; 19:252–86 (210 ref.)
Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Ben-Ze'ev A, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):629–39 (97 ref.)
Three molecular determinants of malignant conversion and their potential as therapeutic targets [published erratum appears in Curr Opin Oncol 1999 Mar;11(2):145] Dome JS, et al. **Curr Opin Oncol** 1999 Jan;11(1):58–67 (112 ref.)
Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)
Cancer risk assessment of extremely low frequency electric and magnetic fields: a critical review of methodology. McCann J. **Environ Health Perspect** 1998 Nov; 106(11):701–17 (197 ref.)
Sugar consumption and human cancer in sites other than the digestive tract. Burley VJ. **Eur J Cancer Prev** 1998 Aug;7(4):253–77 (86 ref.)
Energy balance and cancers. Gerber M, et al. **Eur J Cancer Prev** 1999 Apr;8(2):77–89 (144 ref.)
Chronically elevated proliferation as a risk factor for neoplasia. Moore MA, et al. **Eur J Cancer Prev** 1998 Oct; 7(5):353–85 (634 ref.)
Cancer associations at the country level and shared risk factors—a fuzzy concept? Moore MA, et al. **Eur J Cancer Prev** 1999 Feb;8(1):63–5 (29 ref.)
Cyclin E in human cancers. Donnellan R, et al. **FASEB J** 1999 May;13(8):773–80 (109 ref.)
From in utero and childhood exposure to parental smoking to childhood cancer: a possible link and the need for action. Sasco AJ, et al. **Hum Exp Toxicol** 1999 Apr;18(4):192–201 (115 ref.)
Is there a link between exposure to power-frequency electric fields and cancer? Moulder JE, et al. **IEEE Eng Med Biol Mag** 1999 Mar–Apr;18(2):109–16 (68 ref.)
Risk factors and distinguishing features of cancer in IBD. Ekbom A. **Inflamm Bowel Dis** 1998 Aug;4(3):235–43 (86 ref.)
The decline in U.S. cancer mortality from 1991 to 1995: what's behind the numbers? Clapp RW. **Int J Health Serv** 1998;28(4):747–55 (7 ref.)
It's about health, it's about time: information everyone should

know. Cabelka JF 2nd. **J Med Assoc Ga** 1998 Nov; 87(4):328–9 (17 ref.)
Diet, genetic susceptibility and human cancer etiology. Sinha R, et al. **J Nutr** 1999 Feb;129(2S Suppl):556S–559S (40 ref.)
Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. Vanden Heuvel JP. **J Nutr** 1999 Feb;129(2S Suppl):575S–580S (60 ref.)
Hazards for nearby residents and cleanup workers of waste sites. Leigh JP, et al. **J Occup Environ Med** 1999 May; 41(5):331–48 (42 ref.)
Obesity as a risk factor for certain types of cancer. Carroll KK. **Lipids** 1998 Nov;33(11):1055–9 (83 ref.)
Congenital disorders sharing oxidative stress and cancer proneness as phenotypic hallmarks: prospects for joint research in pharmacology. Pagano G, et al. **Med Hypotheses** 1998 Sep;51(3):253–66 (163 ref.)
On the role of the peroxisome in cell differentiation and carcinogenesis. Masters C, et al. **Mol Cell Biochem** 1998 Oct;187(1–2):85–97 (71 ref.)
Transient appearance of the mutator phenotype during carcinogenesis as a possible explanation for the lack of mini/microsatellite instability in many late stage tumors. Stark AA. **Mutat Res** 1998 Nov 3;421(2):221–5 (65 ref.)
Dietary fat and carcinogenesis. Woutersen RA, et al. **Mutat Res** 1999 Jul 15;443(1–2):111–27 (183 ref.)
Cancer risk assessment: conceptual considerations for clinical practice. Mahon SM. **Oncol Nurs Forum** 1998 Oct; 25(9):1535–47 (34 ref.)
Cancers in children infected with the human immunodeficiency virus. Mueller BU. **Oncologist** 1999; 4(4):309–17 (100 ref.)
Cancers after stem cell transplantation in children: a cost of cure? Ship AM, et al. **Pediatr Transplant** 1997 Nov; 1(2):104–10 (38 ref.)
High-meat diets and cancer risk. Bingham SA. **Proc Nutr Soc** 1999 May;58(2):243–8 (52 ref.)
Epidemiological evidence of the effects of behaviour and the environment on the risk of human cancer. Doll R. **Recent Results Cancer Res** 1998;154:3–21 (43 ref.)
Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Hagmar L, et al. **Recent Results Cancer Res** 1998;154:177–84 (7 ref.)
Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Hengstler JG, et al. **Recent Results Cancer Res** 1998; 154:47–85 (178 ref.)
Overview of viruses, cancer, and vaccines in concept and in reality. Hilleman MR. **Recent Results Cancer Res** 1998; 154:345–62 (94 ref.)
Molecular epidemiology of human cancer. Hussain SP, et al. **Recent Results Cancer Res** 1998;154:22–36 (105 ref.)
Molecular epidemiology of environmental carcinogenesis. Perera FP. **Recent Results Cancer Res** 1998;154:39–46 (30 ref.)
Relevance of DNA repair to carcinogenesis and cancer therapy. Rajewsky MF, et al. **Recent Results Cancer Res** 1998;154:127–46 (109 ref.)
Perinatal determinants of adult cardiovascular disease and cancer. Signorello LB, et al. **Scand J Soc Med** 1998 Sep; 26(3):161–5 (57 ref.)
Work-related cancer in the Nordic countries. Andersen A, et al. **Scand J Work Environ Health** 1999;25 Suppl 2:1–116 (155 ref.)
Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Jung JU, et al. **Semin Cancer Biol** 1999 Jun; 9(3):231–9 (98 ref.)
Mouse models dissect the role of p53 in cancer and development. Lozano G, et al. **Semin Cancer Biol** 1998; 8(5):337–44 (56 ref.)
Venous thromboembolism as first manifestation of cancer. Monreal M, et al. **Semin Thromb Hemost** 1999;25(2):131–6 (31 ref.)
Life and death in the genesis of the tumour cell. Harrison DJ. **Toxicol Lett** 1998 Dec 28;102–103:115–9 (16 ref.)
Molecular epidemiology of human cancer. Hussain SP, et al. **Toxicol Lett** 1998 Dec 28;102–103:219–25 (44 ref.)
Factors influencing the carcinogenicity of food chemicals. Manson MM, et al. **Toxicology** 1999 Jun 15;134(2–3):93–108 (37 ref.)
Patterns of malignancies following renal transplantation. Sheil AG. **Transplant Proc** 1999 Feb–Mar;31(1–2):1263–5 (30 ref.)
Apoptosis: its relevance to carcinogenesis and anti-tumour drug sensitivity [editorial] Chresta CM, et al. **Urol Res** 1999; 27(1):1–2 (7 ref.)
[Vascular endothelial growth factor. From basic research to clinical application] Smirne C, et al. **Minerva Med** 1999 Jan–Feb;90(1–2):15–23 (100 ref.) (Eng. Abstr.) **(Ita)**
[Bacterial infection and malignancies] Saito D. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):417–20 (9 ref.) **(Jpn)**
[Virus-associated malignancies] Takada K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):421–4 (2 ref.) **(Jpn)**
[Ribosomal abnormalities and human diseases] Kenmochi N. **Seikagaku** 1999 Mar;71(3):205–10 (19 ref.) **(Jpn)**
[Human diseases associated with ubiquitin/proteasome proteolytic system] Anan T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):776–86 (45 ref.) **(Jpn)**
[Immunosuppressive treatment and risks of neoplasms] Magier K, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):50–2 (33 ref.) (Eng. Abstr.) **(Pol)**
[Role of the ubiquitin system in the etiology of cancer and other diseases] Argilés JM, et al. **Med Clin (Barc)** 1998 Oct 10;111(11):423–6 (23 ref.) **(Spa)**
[Physical inactivity and cancer—is this a causal relationship?] Gerhardsson de Verdier M. **Lakartidningen** 1999 Jan 20; 96(3):214–6 (11 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Hereditary cancer. Lindblom A, et al. **Acta Oncol** 1999; 38(4):439–47 (28 ref.)
The importance of heterogeneity in tumor pathology. Rew DA. **Adv Anat Pathol** 1998 May;5(3):156–63 (46 ref.)
HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Tallini G, et al. **Adv Anat Pathol** 1999 Sep;6(5):237–46 (94 ref.)
Myb and oncogenesis. Ganter B, et al. **Adv Cancer Res** 1999; 76:21–60 (289 ref.)
Expression genetics in cancer research, prognosis, and therapy. Martin KJ, et al. **Adv Exp Med Biol** 1998;451:1–7 (12 ref.)
Pathobiology and clinical significance of molecular genetic findings in childhood tumors. Rubnitz JE, et al. **Adv Pediatr** 1998;45:315–36 (129 ref.)
HER-2/neu testing comes of age [editorial; comment] Wiscarver JL. **Am J Clin Pathol** 1999 Mar;111(3):299–301 (12 ref.) Comment on: Am J Clin Pathol 1999 Mar;111(3):311–6.
Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Engelman JA, et al. **Am J Hum Genet** 1998 Dec;63(6):1578–87 (49 ref.)
DNA copy number losses in human neoplasms. Knuutila S, et al. **Am J Pathol** 1999 Sep;155(3):683–94 (197 ref.)
Warner-Lambert/Parke-Davis Award Lecture. Pathological and physiological double-strand breaks: roles in cancer, aging, and the immune system. Lieber MR. **Am J Pathol** 1998 Nov;153(5):1323–32 (73 ref.)
Dormant tumor-suppressor pathways in tumors [comment] Weintraub SJ. **Am J Respir Cell Mol Biol** 1999 Apr; 20(4):541–2 (13 ref.) Comment on: Am J Respir Cell Mol Biol 1999 Apr;20(4):543–9.
Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer. Glassman AB. **Ann Clin Lab Sci** 1998 Nov–Dec;28(6):324–30 (19 ref.)
Genetic susceptibility to cancer. ICRP publication 79. Approved by the Commission in May 1997. International Commission on Radiological Protection. **Ann ICRP** 1998; 28(1–2):1–157 (598 ref.)
The role of the FHIT/FRA3B locus in cancer. Huebner K, et al. **Annu Rev Genet** 1998;32:7–31 (92 ref.)
Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Waddick KG, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1411–26 (118 ref.)
Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Yamasaki L. **Biochim Biophys Acta** 1999 Mar 25;1423(2):M9–15 (58 ref.)
Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms. Cobaleda C, et al. **Bioessays** 1998 Nov;20(11):922–30 (73 ref.)
Oxidative DNA damage, antioxidants, and cancer [published erratum appears in Bioessays 1999 Jun;21(6):535] Collins AR. **Bioessays** 1999 Mar;21(3):238–46 (58 ref.)
Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Nakayama K, et al. **Bioessays** 1998 Dec;20(12):1020–9 (86 ref.)
The role of telomeres in ageing and cancer. Mera SL. **Br J Biomed Sci** 1998 Sep;55(3):221–5 (18 ref.)
Characterization of a multi-tissue tumour suppressor and senescence gene. Black DM. **Br J Cancer** 1999 Jul;80 Suppl 1:42–5 (46 ref.)
Target genes and target cells in carcinogenesis. Frame S, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:28–33 (58 ref.)
Costs, benefits and limitations of genetic testing for cancer risk. Ponder BA. **Br J Cancer** 1999 Jul;80 Suppl 1:46–50 (36 ref.)
Comparative genomic hybridization and chromosomal instability in solid tumours. Rooney PH, et al. **Br J Cancer** 1999 May;80(5–6):862–73 (124 ref.)
The p53 tumour suppressor gene. Steele RJ, et al. **Br J Surg** 1998 Nov;85(11):1460–7 (87 ref.)
Genetic polymorphism and their contribution to cancer susceptibility. Conforti-Froes N, et al. **Cad Saude Publica** 1998;14 Suppl 3:7–13 (41 ref.)
Genetic and epigenetic changes of intercellular communication genes during multistage carcinogenesis. Yamasaki H, et al. **Cancer Detect Prev** 1999;23(4):273–9 (41 ref.)
Psychosocial issues in cancer genetics: from the laboratory to the public. Bowen DJ, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 2):326–8 (12 ref.)
Molecular oncology: diagnostic and prognostic assessment of human cancers in the clinical laboratory. Tsongalis GJ, et al. **Cancer Invest** 1998;16(7):485–502 (104 ref.)
Antisense comes of age. Flanagan WM. **Cancer Metastasis Rev** 1998 Jun;17(2):169–76 (45 ref.)
Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Mayer LD. **Cancer Metastasis Rev** 1998 Jun;17(2):211–8 (32 ref.)
Targeting DNA methyltransferase in cancer. Szyf M. **Cancer Metastasis Rev** 1998 Jun;17(2):219–31 (72 ref.)
The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Yu D, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):195–202 (98 ref.)
The family history component of cancer genetic risk counseling. Loescher LJ. **Cancer Nurs** 1999 Feb; 22(1):96–102 (30 ref.)
Cancer as a complex developmental disorder--nineteenth Cornelius P. Rhoads Memorial Award Lecture. Dean M. **Cancer Res** 1998 Dec 15;58(24):5633–6 (50 ref.)
Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Feinberg AP. **Cancer Res** 1999 Apr 1;59(7 Suppl):1743s–1746s (42 ref.)
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Reed E. **Cancer Treat Rev** 1998 Oct;24(5):331–44 (97 ref.)
For better or worse? Telomerase inhibition and cancer. de Lange T, et al. **Cell** 1999 Aug 6;98(3):273–5 (21 ref.)
Homeobox genes: a link between development, cell cycle, and cancer? Ford HL. **Cell Biol Int** 1998;22(6):397–400 (28 ref.)
Clinical implications of p53 mutations. Wallace-Brodeur RR, et al. **Cell Mol Life Sci** 1999 Jan;55(1):64–75 (140 ref.)
Supernumerary centrosomes and cancer: Boveri's hypothesis resurrected. Brinkley BR, et al. **Cell Motil Cytoskeleton** 1998;41(4):281–8 (68 ref.)
Oncogenes and tumor suppressor genes: therapeutic implications. Stass SA, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 2):2687–95 (58 ref.)
Chronic retroviruses and oncogenesis. Patarca R. **Crit Rev Oncog** 1998;9(2):151–98 (375 ref.)
Negative control elements of the cell cycle in human tumors. Adams PD, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):791–7 (66 ref.)
The genetics of hereditary common cancers. de la Chapelle A, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):298–303 (42 ref.)
pRb and E2f-1 in mouse development and tumorigenesis. Macleod K. **Curr Opin Genet Dev** 1999 Feb;9(1):31–9 (64 ref.)
The oncogenic activation of beta-catenin. Polakis P. **Curr Opin Genet Dev** 1999 Feb;9(1):15–21 (71 ref.)
Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. Klein G. **Curr Top Microbiol Immunol** 1999;246:161–7 (17 ref.)
p53: prospects for cancer gene therapy. Soddu S, et al. **Cytokines Cell Mol Ther** 1998 Sep;4(3):177–85 (66 ref.)
Proteomics in human disease: cancer, heart and infectious diseases. Jungblut PR, et al. **Electrophoresis** 1999 Jul; 20(10):2100–10 (66 ref.)
Expression profiling in cancer using cDNA microarrays. Khan J, et al. **Electrophoresis** 1999 Feb;20(2):223–9 (19 ref.)
The use of arbitrarily primed polymerase chain reaction in cancer research. Navarro JM, et al. **Electrophoresis** 1999 Feb;20(2):283–90 (34 ref.)
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Besson A, et al. **Eur J Biochem** 1999 Aug; 263(3):605–11 (61 ref.)
Tumour markers - new aspects of an old discussion? Fleischhacker M, et al. **Eur J Med Res** 1999 Apr 27; 4(4):144–8 (45 ref.)
The evolutionary biology of death and human malignancy. Rew DA. **Eur J Surg Oncol** 1998 Dec;24(6):568–72 (37 ref.)
Homeobox genes and cancer. Cillo C, et al. **Exp Cell Res** 1999 Apr 10;248(1):1–9 (100 ref.)
Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Claij N, et al. **Exp Cell Res** 1999 Jan 10;246(1):1–10 (137 ref.)
Genomic imprinting and cancer. Jirtle RL. **Exp Cell Res** 1999 Apr 10;248(1):18–24 (83 ref.)
Gene silencing in the development of cancer. McBurney MW. **Exp Cell Res** 1999 Apr 10;248(1):25–9 (60 ref.)
Use of gene marking technologies in oncology. Brenner M. **Forum (Genova)** 1998 Oct–Dec;8(4):342–53 (67 ref.)
Restoration of tumour suppressor gene expression for cancer. Roth JA. **Forum (Genova)** 1998 Oct–Dec;8(4):368–76 (36 ref.)
The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Huang S. **Front Biosci** 1999 Jun 15;4:D528–32 (45 ref.)
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Ried T, et al. **Genes Chromosomes Cancer** 1999 Jul;25(3):195–204 (38 ref.)
IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hernandez-Boussard T, et al. **Hum Mutat** 1999;14(1):1–8 (25 ref.)
Mutations and altered expression of the human cancer genes: what they tell us about causes. Devereux TR, et al. **IARC Sci Publ** 1999;(146):19–42 (188 ref.)
Analysis of somatic mutations of the p53 gene in human cancers: a tool to generate hypotheses about the natural history of cancer. Hernandez-Boussard T, et al. **IARC Sci Publ** 1999;(146):43–53 (33 ref.)
Chromosomal changes. Preston RJ. **IARC Sci Publ** 1999; (146):395–408 (53 ref.)
Translational control: the cancer connection. Clemens MJ, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):1–23 (165 ref.)

eIF4E expression in tumors: its possible role in progression of malignancies. De Benedetti A, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):59–72 (105 ref.)
Translational infidelity and human cancer: role of the PTI-1 oncogene. Gopalkrishnan RV, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):151–62 (47 ref.)
Dr. Josef Steiner Cancer Research Prize Lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Strasser A. **Int J Cancer** 1999 May 17;81(4):505–11 (149 ref.)
Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related? Wang NM, et al. **Int J Mol Med** 1999 May;3(5):491–5 (54 ref.)
Symposium: Genetic testing and management of the cancer patient and cancer families. Webb MJ. **J Am Coll Surg** 1998 Oct;187(4):449–56 (04 ref.)
B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments. Sala A, et al. **J Cell Physiol** 1999 Jun;179(3):245–50 (49 ref.)
Testing for hereditary cancer risk: Pandora or Prometheus? Frank TS, et al. **J Clin Endocrinol Metab** 1999 Jun; 84(6):1882–5 (20 ref.)
Cancer control in susceptible groups: opportunities and challenges. Li FP. **J Clin Oncol** 1999 Feb;17(2):719–25 (92 ref.)
Why do almost all mammals have seven cervical vertebrae? Developmental constraints, Hox genes, and cancer. Galis F. **J Exp Zool** 1999 Apr 15;285(1):19–26 (55 ref.)
The patched signaling pathway in tumorigenesis and development: lessons from animal models. Hahn H, et al. **J Mol Med** 1999 Jun;77(6):459–68 (102 ref.)
The emerging p53 gene family. Kaelin WG Jr. **J Natl Cancer Inst** 1999 Apr 7;91(7):594–8 (86 ref.)
Oncogenes, cancer and imaging. Urbain JL. **J Nucl Med** 1999 Mar;40(3):498–504 (51 ref.)
Symposium: Interactions of Diet and Nutrition with Genetic Susceptibility in Cancer. Overview. Freudenheim JL, et al. **J Nutr** 1999 Feb;129(2S Suppl):550S–551S (7 ref.)
The role of interindividual variation in human carcinogenesis. Lai C, et al. **J Nutr** 1999 Feb;129(2S Suppl):552S–555S (34 ref.)
Perspective: cancer care and the new biology. Kaye SB. **J Pathol** 1999 Jan;187(1):4–7 (7 ref.)
Testing children for cancer genes: the rule of earliest onset. Kodish ED. **J Pediatr** 1999 Sep;135(3):390–5 (32 ref.)
Cancer and genetics: what we need to know now [see comments] Ruccione K. **J Pediatr Oncol Nurs** 1999 Jul; 16(3):156–71 (49 ref.) Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115–6.
Conventional and molecular cytogenetics in medicine. Mark HF. **Med Health R I** 1999 May;82(5):160–3 (22 ref.)
Abortive apoptosis as an initiator of chromosomal translocations. Khodarev NN, et al. **Med Hypotheses** 1999 May;52(5):373–6 (31 ref.)
Molecular epidemiology in cancer research. Collins AR. **Mol Aspects Med** 1998 Dec;19(6):359–432 (173 ref.)
Multidrug resistance in human tumors—molecular diagnosis and clinical significance. Ramachandran C, et al. **Mol Diagn** 1999 Jun;4(2):81–94 (145 ref.)
Molecular assessment of tumour stage and disease recurrence using PCR-based assays. Bustin SA, et al. **Mol Med Today** 1998 Sep;4(9):389–96 (52 ref.)
E-cadherin downregulation in cancer: fuel on the fire? Guilford P. **Mol Med Today** 1999 Apr;5(4):172–7 (43 ref.)
Radiation, DNA damage and cancer. Hall J, et al. **Mol Med Today** 1999 Apr;5(4):157–64 (61 ref.)
Genomic imprinting and cancer. Joyce JA, et al. **Mol Pathol** 1998 Aug;51(4):185–90 (117 ref.)
Demystified ... oncogenes. Wallis YL, et al. **Mol Pathol** 1999 Apr;52(2):55–63 (55 ref.)
Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Otteneder M, et al. **Mutat Res** 1999 Mar 8;424(1-2):237–47 (38 ref.)
Polymorphisms, genomic imprinting and cancer susceptibility. Pulford DJ, et al. **Mutat Res** 1999 Jan; 436(1):59–67 (79 ref.)
Transient appearance of the mutator phenotype during carcinogenesis as a possible explanation for the lack of mini/microsatellite instability in many late stage tumors. Stark AA. **Mutat Res** 1998 Nov 3;421(2):221–5 (65 ref.)
Drug metabolism polymorphisms as modulators of cancer susceptibility. Taningher M, et al. **Mutat Res** 1999 May; 436(3):227–61 (170 ref.)
Human cancer, carcinogenic exposures and mutation spectra. Vineis P, et al. **Mutat Res** 1999 Mar;436(2):185–94 (43 ref.)
Cancer epigenetics comes of age. Jones PA, et al. **Nat Genet** 1999 Feb;21(2):163–7 (74 ref.)
Genetic instabilities in human cancers. Lengauer C, et al. **Nature** 1998 Dec 17;396(6712):643–9 (95 ref.)
FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors. Smardová J. **Neoplasma** 1999; 46(2):80–8 (91 ref.)
The role of ATM in DNA damage responses and cancer. Canman CE, et al. **Oncogene** 1998 Dec 24;17(25):3301–8 (142 ref.)
Development of a flexible and specific gene delivery system for production of murine tumor models. Fisher GH, et al. **Oncogene** 1999 Sep 20;18(38):5253–60 (37 ref.)
Mouse models in tumor suppression. Ghebranious N, et al. **Oncogene** 1998 Dec 24;17(25):3385–400 (243 ref.)
Studying cancer in the mouse. Klausner RD. **Oncogene** 1999 Sep 20;18(38):5249–52 (0 ref.)
The inhibitors of apoptosis (IAPs) and their emerging role in cancer. LaCasse EC, et al. **Oncogene** 1998 Dec 24; 17(25):3247–59 (122 ref.)
MYC oncogenes and human neoplastic disease. Nesbit CE, et al. **Oncogene** 1999 May 13;18(19):3004–16 (214 ref.)
The INK4 family of cell cycle inhibitors in cancer. Roussel MF. **Oncogene** 1999 Sep 20;18(38):5311–7 (72 ref.)
Reassessing the role of C-MYB in tumorigenesis. Weston K. **Oncogene** 1999 May 13;18(19):3034–8 (57 ref.)
DNA testing for cancer predisposition. Loescher LJ. **Oncol Nurs Forum** 1998 Sep;25(8):1317–27 (38 ref.)
FHITness and cancer. Druck T, et al. **Oncol Res** 1998; 10(7):341–5 (27 ref.)
Molecular genetics in the diagnosis and prognosis of solid pediatric tumors. Thorner PS, et al. **Pediatr Dev Pathol** 1998 Sep–Oct;1(5):337–65 (279 ref.)
Convicting a human tumor virus: guilt by association? Blaho JA, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7619–21 (31 ref.)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Cantley LC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4240–5 (76 ref.)
Benzene, NQO1, and genetic susceptibility to cancer [comment] Smith MT. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7624–6 (46 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8150–5.
Lineage selection and the evolution of multistage carcinogenesis. Nunney L. **Proc R Soc Lond B Biol Sci** 1999 Mar 7;266(1418):493–8 (30 ref.)
Genetic disorders associated with cancer predisposition and genomic instability. Vessey CJ, et al. **Prog Nucleic Acid Res Mol Biol** 1999;63:189–221 (229 ref.)
Bad genes, bad diseases, and bad luck. Epstein RJ. **QJM** 1998 Dec;91(12):861–4 (21 ref.)
The ataxia telangiectasia gene in familial and sporadic cancer. Yuille MA, et al. **Recent Results Cancer Res** 1998; 154:156–73 (70 ref.)
Genomic imprinting and cancer. Tycko B. **Results Probl Cell Differ** 1999;25:133–69 (220 ref.)
Fusion genes in solid tumors. Aman P. **Semin Cancer Biol** 1999 Aug;9(4):303–18 (149 ref.)
On the origin of multiple mutations in human cancers. Jackson AL, et al. **Semin Cancer Biol** 1998 Dec;8(6):421–9 (104 ref.)
The mitotic machinery as a source of genetic instability in cancer. Pihan GA, et al. **Semin Cancer Biol** 1999 Aug; 9(4):289–302 (192 ref.)
Oncogene amplification in solid tumors. Schwab M. **Semin Cancer Biol** 1999 Aug;9(4):319–25 (46 ref.)
Evolution and the inevitability of human cancer. Simpson AJ, et al. **Semin Cancer Biol** 1998 Dec;8(6):439–45 (44 ref.)
Hypermutability and silent mutations in human carcinogenesis. Strauss BS. **Semin Cancer Biol** 1998 Dec; 8(6):431–8 (51 ref.)
Estimation of mutation frequencies in normal mammalian cells and the development of cancer. Turker MS. **Semin Cancer Biol** 1998 Dec;8(6):407–19 (141 ref.)
The INK4a/ARF tumor suppressor: one gene—two products—two pathways. Chin L, et al. **Trends Biochem Sci** 1998 Aug;23(8):291–6 (50 ref.)
RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Culbertson MR. **Trends Genet** 1999 Feb;15(2):74–80 (59 ref.)
[Function of p16 gene and correlation of p16 with human cancer] Sun M, et al. **Sheng Li Ke Hsueh Chin Chan** 1996 Jul;27(3):265–7 (10 ref.) **(Chi)**
[Update on genetic markers of cancer] Janoueix-Lerosey I, et al. **Bull Cancer** 1999 Jan;86(1):15–21 (51 ref.) **(Fre)**
[Mdm2, p53 and the cell cycle: when well enough is best left alone] Maréchal V. **Pathol Biol (Paris)** 1997 Dec; 45(10):824–32 (70 ref.) (Eng. Abstr.) **(Fre)**
[Hereditary neoplastic diseases (genetic predisposition and cancer syndromes)] Oláh E. **Orv Hetil** 1999 Feb 28; 140(9):451–66 (82 ref.) (Eng. Abstr.) **(Hun)**
[p53: prospects for gene therapy of cancer] Soddu S, et al. **Clin Ter** 1998 Jul–Aug;149(4):289–95 (46 ref.) (Eng. Abstr.) **(Ita)**
[Cancer-associated gene abnormalities and chemosensitivity] Sakamoto M, et al. **Gan To Kagaku Ryoho** 1998 Oct; 25(12):1819–31 (60 ref.) (Eng. Abstr.) **(Jpn)**
[Making of guideline for gene diagnosis in familial tumors] Yuasa Y. **Tanpakushitsu Kakusan Koso** 1998 Aug; 43(10):1395–9 (6 ref.) **(Jpn)**
[The genetic factors associated with pediatric cancers] Ferris i Tortajada J, et al. **An Esp Pediatr** 1999 Jan;50(1):4–13 (101 ref.) **(Spa)**
[Molecular cytogenetics of cancer in children: clinical applications] Martínez Climent JA, et al. **Med Clin (Barc)** 1998 Oct 3;111(10):389–97 (165 ref.) (Eng. Abstr.) **(Spa)**
[Identification of cancer genes has made the testing of predisposition possible. Genetic counseling and mutation screening can result in new therapeutic methods] Nordenskjöld M. **Lakartidningen** 1999 Aug 11; 96(32–33):3392–6 (8 ref.) **(Swe)**

HISTORY

The histopathology of tumors: past, present and future—a centenary essay for F. William Sunderman, Sr., M.D., Ph.D. Muschenheim F. **Ann Clin Lab Sci** 1999 Jul–Sep; 29(3):151–7 (20 ref.)
James Ewing: cancer man. Huvos AG. **Ann Diagn Pathol** 1998 Apr;2(2):146–8 (11 ref.)

IMMUNOLOGY

Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Schirrmacher V, et al. **Adv Exp Med Biol** 1998;451:251–7 (43 ref.)
Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. Vitaliano PP, et al. **Ann Behav Med** 1998 Summer;20(3):199–208 (91 ref.)
Tumor escape from immune surveillance. Costello RT, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):83–8 (58 ref.)
Dendritic cells: development, function and potential use for cancer immunotherapy. Avigan D. **Blood Rev** 1999 Mar; 13(1):51–64 (123 ref.)
Targeting human tumours with antigen-specific cytotoxic T-cells. Rickinson AB. **Br J Cancer** 1999 Jul;80 Suppl 1:51–6 (64 ref.)
Cancer-testis antigens: targets for cancer immunotherapy [comment] Chen YT, et al. **Cancer J Sci Am** 1999 Jan–Feb; 5(1):16–7 (11 ref.) Comment on: Cancer J Sci Am 1999 Jan–Feb;5(1):20–5.
The potential of melanoma antigen expression in cancer therapy. Gillespie AM, et al. **Cancer Treat Rev** 1999 Aug; 25(4):219–27 (79 ref.)
Malignancies associated with the immunocompromised state. Katariya K, et al. **Chest Surg Clin N Am** 1999 Feb; 9(1):63–77, viii (57 ref.)
How do lymphocytes kill tumor cells? Graubert TA, et al. **Clin Cancer Res** 1996 May;2(5):785–9 (52 ref.)
CD30 in normal and neoplastic cells. Chiarle R, et al. **Clin Immunol** 1999 Feb;90(2):157–64 (101 ref.)
Immunologic nonresponsiveness to tumors. Antonia SJ, et al. **Crit Rev Oncog** 1998;9(1):35–41 (62 ref.)
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Markiewicz MA, et al. **Crit Rev Oncog** 1999;10(3):247–60 (46 ref.)
Cells and cytokines in immunotherapy and gene therapy of cancer. Pawelec G, et al. **Crit Rev Oncog** 1999; 10(1-2):83–127 (382 ref.)
The role of CD4+ T cell responses in antitumor immunity. Pardoll DM, et al. **Curr Opin Immunol** 1998 Oct; 10(5):588–94 (49 ref.)
Tumor expression of Fas ligand (CD95L) and the consequences. Walker PR, et al. **Curr Opin Immunol** 1998 Oct;10(5):564–72 (73 ref.)
Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. Klein G. **Curr Top Microbiol Immunol** 1999;246:161–7 (17 ref.)
Prospects for the therapeutic use of anticancer vaccines. Chamberlain RS. **Drugs** 1999 Mar;57(3):309–25 (164 ref.)
The use of gene transfer in cancer immunotherapy. Dranoff G. **Forum (Genova)** 1998 Oct–Dec;8(4):357–64 (48 ref.)
A new era for cancer immunotherapy based on the genes that encode cancer antigens. Rosenberg SA. **Immunity** 1999 Mar;10(3):281–7 (79 ref.)
Tumor immunology: the glass is half full. Sogn JA. **Immunity** 1998 Dec;9(6):757–63 (73 ref.)
Control of tumor development by intratumoral cytokines. Pages F, et al. **Immunol Lett** 1999 May 3;68(1):135–9 (26 ref.)
Evolution of immune surveillance and tumor immunity: studies in Xenopus. Robert J, et al. **Immunol Rev** 1998 Dec; 166:231–43 (86 ref.)
Specific and nonspecific immunity in the prevention of spontaneous tumours. Lollini PL, et al. **Immunol Today** 1999 Aug;20(8):347–50 (23 ref.)
The Fas counterattack: cancer as a site of immune privilege. O'Connell J, et al. **Immunol Today** 1999 Jan;20(1):46–52 (118 ref.)
HLA and cancer: from research to clinical impact. Ruiz-Cabello F, et al. **Immunol Today** 1998 Dec; 19(12):539–42 (15 ref.)
Immunosuppressive factors: role in cancer development and progression. Botti C, et al. **Int J Biol Markers** 1998 Apr–Jun;13(2):51–69 (221 ref.)
CD40–CD154 interaction in experimental and human disease (review). Biancone L, et al. **Int J Mol Med** 1999 Apr; 3(4):343–53 (112 ref.)
Lymph nodes and human tumors (review). Lores B, et al. **Int J Mol Med** 1998 Apr;1(4):729–33 (51 ref.)
Neuroimmunoregulation and cancer (review). Berczi I, et al. **Int J Oncol** 1998 Nov;13(5):1049–60 (160 ref.)
Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. Andreesen R, et al. **J Leukoc Biol** 1998 Oct;64(4):419–26 (82 ref.)
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Greil R, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):477–90 (69 ref.)
Effects of TGF-beta on the immune system: implications for cancer immunotherapy. de Visser KE, et al. **Leukemia** 1999 Aug;13(8):1188–99 (152 ref.)
An immunological model connecting the pathogenesis of stress, depression and carcinoma. Holden RJ, et al. **Med Hypotheses** 1998 Oct;51(4):309–14 (60 ref.)

Oligoclonal T cells in human cancer. Halapi E. **Med Oncol** 1998 Dec;15(4):203–11 (104 ref.)
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Hicklin DJ, et al. **Mol Med Today** 1999 Apr;5(4):178–86 (50 ref.)
Cancer vaccines: novel approaches and new promise. Minev BR, et al. **Pharmacol Ther** 1999 Feb;81(2):121–39 (270 ref.)
On the role of immunological factors as mediators between psychosocial factors and cancer progression. Garssen B, et al. **Psychiatry Res** 1999 Jan 18;85(1):51–61 (64 ref.)
Cancer vaccines: reborn or just recycled? Berd D. **Semin Oncol** 1998 Dec;25(6):605–10 (23 ref.)
T cell receptor usage in malignant diseases. Halapi E, et al. **Springer Semin Immunopathol** 1999;21(1):19–35 (131 ref.)
The role of therapeutic apheresis in the treatment of cancer: a review. Lentz MR. **Ther Apher** 1999 Feb;3(1):40–9 (88 ref.)
SCC antigen in malignant and nonmalignant squamous lesions. Torre GC. **Tumour Biol** 1998;19(6):517–26 (69 ref.)
[Immunology in the clinical practice. XVI. Paraneoplastic syndromes of the nervous system: pathogenesis and diagnosis] Smitt PA, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1652–8 (29 ref.) (Eng. Abstr.) **(Dut)**
[Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives] Gaugler B, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):771–8 (64 ref.) (Eng. Abstr.) **(Fre)**
[Mechanisms of tumor escape from immunologic response] Costello RT, et al. **Rev Med Interne** 1999 Jul;20(7):579–88 (116 ref.) (Eng. Abstr.) **(Fre)**
[Innate nonspecific antiviral immunity] Błach-Olszewska Z. **Postepy Hig Med Dosw** 1999;53(1):3–21 (67 ref.) (Eng. Abstr.) **(Pol)**
[Immunology of cancer] Abelev GI. **Vestn Ross Akad Med Nauk** 1999;(4):21–5 (41 ref.) (Eng. Abstr.) **(Rus)**
[Dendritic cells and their role in pathology] Coronato S, et al. **Medicina (B Aires)** 1998;58(2):209–18 (69 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Immunohistochemical demonstration of lactoferrin in human neoplastic tissues. Tuccari G, et al. **Adv Exp Med Biol** 1998; 443:337–40 (22 ref.)
Abnormal cell cycle regulation in malignancy. Dictor M, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S40–52 (108 ref.)
The tumor-suppressor function of E-cadherin. Semb H, et al. **Am J Hum Genet** 1998 Dec;63(6):1588–93 (44 ref.)
p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Lloyd RV, et al. **Am J Pathol** 1999 Feb;154(2):313–23 (120 ref.)
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ambudkar SV, et al. **Annu Rev Pharmacol Toxicol** 1999;39:361–98 (169 ref.)
Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Murr C, et al. **Anticancer Res** 1999 May-Jun;19(3A):1721–8 (68 ref.)
Development of TGF-beta resistance during malignant progression. Kim YS, et al. **Arch Pharm Res** 1999 Feb; 22(1):1–8 (57 ref.)
Histamine, polyamines, and cancer. Medina MA, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1341–4 (42 ref.)
Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854–65 (80 ref.)
Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation. McCoy CL, et al. **Br J Cancer Suppl** 1996 Jul;27:S226–31 (58 ref.)
Cancer cell metabolism: its relevance to cancer treatment. Lupulescu A. **Cancer Invest** 1999;17(6):423–33 (70 ref.)
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Gelman L, et al. **Cell Mol Life Sci** 1999 Jun;55(6-7):932–43 (141 ref.)
Metabolic sequelae of cancers (excluding bone marrow transplantation). Body JJ. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):339–44 (46 ref.)
Modifying chromatin and concepts of cancer. Jacobson S, et al. **Curr Opin Genet Dev** 1999 Apr;9(2):175–84 (102 ref.)
Practical treatment guide for dose individualisation in cancer chemotherapy. Canal P, et al. **Drugs** 1998 Dec; 56(6):1019–38 (216 ref.)
Clinical aspects of altered glycosylation of glycoproteins in cancer. Orntoft TF, et al. **Electrophoresis** 1999 Feb; 20(2):362–71 (117 ref.)
HLA and cancer: from research to clinical impact. Ruiz-Cabello F, et al. **Immunol Today** 1998 Dec; 19(12):539–42 (15 ref.)
Translational control: the cancer connection. Clemens MJ, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):1–23 (165 ref.)
eIF4E expression in tumors: its possible role in progression of malignancies. De Benedetti A, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):59–72 (105 ref.)
Aspects of altered metabolism in children with cancer. Picton SV. **Int J Cancer Suppl** 1998;11:62–4 (20 ref.)
Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Chang NS. **Int J Mol Med** 1998 Dec;2(6):653–9 (53 ref.)
Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Chiarugi V, et al. **Int J Mol Med** 1998 Dec; 2(6):715–9 (35 ref.)
Emerging roles for proteinases in cancer. Noël A, et al. **Invasion Metastasis** 1997;17(5):221–39 (103 ref.)
Insulin-like growth factors and cancer. Yu H, et al. **J La State Med Soc** 1999 Apr;151(4):218–23 (53 ref.)
Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Hursting SD, et al. **J Natl Cancer Inst** 1999 Feb 3;91(3):215–25 (115 ref.)
Modulation of the immune response and tumor growth by activated Ras. Weijzen S, et al. **Leukemia** 1999 Apr; 13(4):502–13 (107 ref.)
Host metabolism: a target in clinical oncology? Argilés JM, et al. **Med Hypotheses** 1998 Nov;51(5):411–5 (37 ref.)
Role of free radicals in metal-induced carcinogenesis. Landolph JR. **Met Ions Biol Syst** 1999;36:445–83 (67 ref.)
Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Attaix D, et al. **Mol Biol Rep** 1999 Apr;26(1-2):77–82 (43 ref.)
STAT signaling in the pathogenesis and treatment of cancer. Frank DA. **Mol Med** 1999 Jul;5(7):432–56 (245 ref.)
The normal structure and function of CD44 and its role in neoplasia. Sneath RJ, et al. **Mol Pathol** 1998 Aug; 51(4):191–200 (114 ref.)
Recent advances in the analyses of the characteristics of tumors on FDG uptake. Waki A, et al. **Nucl Med Biol** 1998 Oct;25(7):589–92 (60 ref.)
Essential fatty acids and their metabolites and cancer [editorial; comment] Das UN. **Nutrition** 1999 Mar; 15(3):239–40 (33 ref.) Comment on: Nutrition 1999 Mar;15(3):208–12.
Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? Villunger A, et al. **Oncol Res** 1998; 10(11-12):541–50 (189 ref.)
Tumor markers. Introduction. Abelev GI, et al. **Semin Cancer Biol** 1999 Apr;9(2):61–5 (32 ref.)
Basic science of HER-2/neu: a review. Hung MC, et al. **Semin Oncol** 1999 Aug;26(4 Suppl 12):51–9 (102 ref.)
T cell receptor usage in malignant diseases. Halapi E, et al. **Springer Semin Immunopathol** 1999;21(1):19–35 (131 ref.)
Blood flow and oxygenation status of human tumors. Clinical investigations. Feldmann HJ, et al. **Strahlenther Onkol** 1999 Jan;175(1):1–9 (91 ref.)
Techniques to assess the oxygenation of human tumors. State of the art. Horsman MR, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:2–5 (37 ref.)
Can erythropoietin improve tumor oxygenation? Kelleher DK, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:20–3 (25 ref.)
Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Molls M, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:13–6 (35 ref.)
Oncogenic alterations of metabolism. Dang CV, et al. **Trends Biochem Sci** 1999 Feb;24(2):68–72 (37 ref.)
Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Reubi JC, et al. **Yale J Biol Med** 1997 Sep-Dec; 70(5-6):471–9 (27 ref.)
[Metallothionein and carcinogenesis] Deng XZ, et al. **Sheng Li Ke Hsueh Chin Chan** 1996 Oct;27(4):356–8 (7 ref.) **(Chi)**
[Cachexia in cancer: disturbances in the protein and aminoacid metabolism] de Blaauw I, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3;143(27):1408–13 (60 ref.) (Eng. Abstr.) **(Dut)**
[Angiogenesis and the regulation of antitumor defense] Pappas NP, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1555–9 (22 ref.) (Eng. Abstr.) **(Dut)**
[Inhibition of tumor angiogenesis as a cancer treatment] Verheul HM, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1549–55 (50 ref.) (Eng. Abstr.) **(Dut)**
[Hypoxia in solid tumors] Beinert T, et al. **Dtsch Med Wochenschr** 1999 Apr 30;124(17):534–40 (80 ref.) **(Ger)**
[PET evaluation of glucose metabolism in cancer] Yasuda S, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):756–61 (14 ref.) (Eng. Abstr.) **(Jpn)**
[CSF-producing tumor] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):25–7 (7 ref.) **(Jpn)**
[Fibrinolytic substances formation by cancer. Pathogenetic sequelae] Uszyński M. **Ginekol Pol** 1999 Feb;70(2):105–11 (18 ref.) (Eng. Abstr.) **(Pol)**
[Urokinase plasminogen activation system and its role in cancer progression] Blasiak J, et al. **Postepy Biochem** 1999; 45(1):42–50 (95 ref.) **(Pol)**
[The influence of type MDP immunomodulators on secretion and activity of cytokines] Dzierzbicka K, et al. **Postepy Biochem** 1998;44(3):216–9 (47 ref.) **(Pol)**
[The role of reactive oxygen species in mutagenesis and carcinogenesis processes] Oliński R, et al. **Postepy Biochem** 1999;45(1):50–8 (51 ref.) **(Pol)**
[Antiproteases in the pathogenesis of neoplastic diseases] Dąbrowska M. **Przegl Lek** 1998;55(9):475–9 (65 ref.) (Eng. Abstr.) **(Pol)**
[Sphingolipids and cancer] Diatlovitskaia EV. **Bioorg Khim** 1998 Oct;24(10):723–30 (115 ref.) (Eng. Abstr.) **(Rus)**
[Polymorphism of the genes of steroidogenesis and risk of malignant tumor development] Berstein LM, et al. **Vopr Onkol** 1999;45(3):213–8 (34 ref.) **(Rus)**

MICROBIOLOGY

Pharmacologic considerations with antimicrobials used in oncology. Postelnick M, et al. **Cancer Treat Res** 1998; 96:247–82 (146 ref.)
Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Groll AH, et al. **Klin Padiatr** 1998 Jul-Aug; 210(4):264–73 (86 ref.)

MORTALITY

Estimating relative survival among people registered with cancer in England and Wales. Reeves GK, et al. **Br J Cancer** 1999 Jan;79(1):18–22 (16 ref.)
Cancer mortality among Native Americans [editorial; comment] Burhansstipanov L. **Cancer** 1998 Dec 1; 83(11):2247–50 (17 ref.) Comment on: Cancer 1998 Dec 1;83(11):2377–83.
The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Viganò A, et al. **Cancer** 1999 Jul 1;86(1):170–6 (29 ref.)
Factors in improved survival from paediatric cancer. Taub JW. **Drugs** 1998 Nov;56(5):757–65 (89 ref.)
Interpretation of population-based cancer survival data. Black RJ, et al. **IARC Sci Publ** 1998;(145):13–7 (11 ref.)
Statistical methods for the analysis of cancer survival data. Black RJ, et al. **IARC Sci Publ** 1998;(145):3–7 (7 ref.)
The decline in U.S. cancer mortality from 1991 to 1995: what's behind the numbers? Clapp RW. **Int J Health Serv** 1998;28(4):747–55 (7 ref.)
It's about health, it's about time: information everyone should know. Cabelka JF 2nd. **J Med Assoc Ga** 1998 Nov; 87(4):328–9 (17 ref.)
Childhood energy intake and cancer mortality in adulthood. Must A, et al. **Nutr Rev** 1999 Jan;57(1):21–4 (8 ref.)
[Cholesterolemia and pathology: update] Schlienger JL, et al. **Rev Med Interne** 1998 Mar;19(3):180–4 (42 ref.) (Eng. Abstr.) **(Fre)**
[Extended life expectancy with physical activity] Heitkamp HC. **Wien Med Wochenschr** 1999;149(7):149–56 (47 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Complementary therapies: overview and state of the art. Cassileth BR. **Cancer Nurs** 1999 Feb;22(1):85–90 (5 ref.)
From the desert: transcultural aspects of cancer nursing care in Israel. Delbar V. **Cancer Nurs** 1999 Feb;22(1):45–51 (15 ref.)
The experience of having cancer in Latin America. Granda-Cameron C. **Cancer Nurs** 1999 Feb;22(1):51–7 (35 ref.)
A test of parenthood: dilemmas of parents of terminally ill adolescents. Hayout I, et al. **Cancer Nurs** 1999 Feb; 22(1):71–9 (26 ref.)
New strategies in the management of cancer. Kearney N. **Cancer Nurs** 1999 Feb;22(1):28–33 (26 ref.)
The family history component of cancer genetic risk counseling. Loescher LJ. **Cancer Nurs** 1999 Feb; 22(1):96–102 (30 ref.)
Cultural views of cancer around the world. Navon L. **Cancer Nurs** 1999 Feb;22(1):39–45 (43 ref.)
Prevention: tobacco control and cancer nursing. Sarna L. **Cancer Nurs** 1999 Feb;22(1):21–8 (80 ref.)
Family coping: issues and challenges for cancer nursing. Yates P. **Cancer Nurs** 1999 Feb;22(1):63–71 (35 ref.)
Cancer metastasis: an update. Haylock PJ. **Semin Oncol Nurs** 1998 Aug;14(3):172–7 (42 ref.)
Paraneoplastic syndromes in metastatic disease. Zumsteg MM, et al. **Semin Oncol Nurs** 1998 Aug;14(3):220–9 (39 ref.)

PATHOLOGY

Benign tumors and tumor-like lesions of the adult kidney. Part I: Benign renal epithelial neoplasms. Ligato S, et al. **Adv Anat Pathol** 1999 Jan;6(1):1–11 (63 ref.)
The importance of heterogeneity in tumor pathology. Rew DA. **Adv Anat Pathol** 1998 May;5(3):156–63 (46 ref.)
Fibronectin and its integrin receptors in cancer. Ruoslahti E. **Adv Cancer Res** 1999;76:1–20 (109 ref.)
p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Lloyd RV, et al. **Am J Pathol** 1999 Feb;154(2):313–23 (120 ref.)
Histopathological evaluation of apoptosis in cancer. Soini Y, et al. **Am J Pathol** 1998 Oct;153(4):1041–53 (171 ref.)
Tissue inhibitors of matrix metalloproteinases in cancer. Blavier L, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:108–19 (60 ref.)
The significance of matrix metalloproteinases during early stages of tumor progression. Lochter A, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:180–93 (54 ref.)
The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Tsihlias J, et al. **Annu Rev Med** 1999;50:401–23 (92 ref.)
Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Tomida A, et al. **Anticancer Drug Des** 1999 Apr;14(2):169–77 (83 ref.)
Disseminated tumor cells versus micrometastasis: definitions and problems. Hermanek P. **Anticancer Res** 1999 Jul-Aug; 19(4A):2771–4 (47 ref.)
Specimen banks for cancer prognostic factor research. Burke HB, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):871–4

(38 ref.)
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Hatse S, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):539–55 (177 ref.)
Inducers of the cytochrome P-450 superfamily as promoters of carcinogenesis. Koblyakov VA. **Biochemistry (Mosc)** 1998 Aug;63(8):885–98 (131 ref.)
The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency [editorial] Mathé G. **Biomed Pharmacother** 1998;52(10):413–20 (49 ref.)
Target genes and target cells in carcinogenesis. Frame S, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:28–33 (58 ref.)
Apoptosis and carcinogenesis. Wyllie AH, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:34–7 (39 ref.)
Biological implications of macrophage infiltration in human tumor angiogenesis. Ono M, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S69–71 (19 ref.)
The role of cytokines and chemokines on tumor progression: A review. Ardestani SK, et al. **Cancer Detect Prev** 1999; 23(3):215–25 (109 ref.)
Anti-adhesion cancer therapy. Glinsky GV. **Cancer Metastasis Rev** 1998 Jun;17(2):177–85 (58 ref.)
Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Haq R, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):233–9 (57 ref.)
Fenretinide and its relation to cancer. Ulukaya E, et al. **Cancer Treat Rev** 1999 Aug;25(4):229–35 (77 ref.)
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Ständer M, et al. **Cell Tissue Res** 1999 May;296(2):221–7 (48 ref.)
Photodynamic modulation of cellular function. Cui ZJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):297–303 (51 ref.)
Do overexpressed oncoproteins cause malignant growth of cancer cells?--Studied by antisense oligonucleotides. Lin SB. **Clin Chem Lab Med** 1998 Aug;36(8):541–4 (30 ref.)
Fine needle aspiration cytology of papillary neoplasms. Bardales RH. **Clin Lab Med** 1998 Sep;18(3):373–99, v (98 ref.)
Cell cycle and cancer. Pucci B, et al. **Clin Ter** 1999 Mar-Apr; 150(2):135–41 (72 ref.)
Mechanisms of apoptosis avoidance in cancer. Reed JC. **Curr Opin Oncol** 1999 Jan;11(1):68–75 (57 ref.)
Minimal access surgery for staging regional lymph nodes: the sentinel-node concept. Krag DN. **Curr Probl Surg** 1998 Nov;35(11):951–1016 (156 ref.)
The myofibroblast in neoplasia. Schürch W. **Curr Top Pathol** 1999;93:135–48 (57 ref.)
Sugar consumption and human cancer in sites other than the digestive tract. Burley VJ. **Eur J Cancer Prev** 1998 Aug;7(4):253–77 (86 ref.)
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Ried T, et al. **Genes Chromosomes Cancer** 1999 Jul;25(3):195–204 (38 ref.)
Grading and scoring in histopathology. Cross SS. **Histopathology** 1998 Aug;33(2):99–106 (26 ref.)
Immunohistochemistry of CA 125. Unusual expression in normal tissues, distribution in the human fetus and questions around its application in diagnostic pathology. Nap M. **Int J Biol Markers** 1998 Oct-Dec;13(4):210–5 (17 ref.)
Tumour growth and nitrogen metabolism in the host (Review). Argilés JM, et al. **Int J Oncol** 1999 Mar; 14(3):479–86 (142 ref.)
Intermediate filament proteins during carcinogenesis and apoptosis (Review). Prasad S, et al. **Int J Oncol** 1999 Mar; 14(3):563–70 (77 ref.)
Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. Morris VL, et al. **Invasion Metastasis** 1997;17(6):281–96 (56 ref.)
The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. Grothey A, et al. **J Cancer Res Clin Oncol** 1999;125(3-4):166–73 (77 ref.)
Proliferation markers in tumours: interpretation and clinical value. van Diest PJ, et al. **J Clin Pathol** 1998 Oct; 51(10):716–24 (156 ref.)
Chemokines and their role in tumor growth and metastasis. Wang JM, et al. **J Immunol Methods** 1998 Nov 1; 220(1-2):1–17 (101 ref.)
Apoptosis and therapy. Schmitt CA, et al. **J Pathol** 1999 Jan;187(1):127–37 (163 ref.)
Cellular senescence and cancer. Wynford-Thomas D. **J Pathol** 1999 Jan;187(1):100–11 (94 ref.)
What can we learn from the phenomenon of preferential lymph node metastasis in carcinoma? Gendreau KM, et al. **J Surg Oncol** 1999 Mar;70(3):199–204 (60 ref.)
Carcinogenesis and the plasma membrane. Stern RG, et al. **Med Hypotheses** 1999 May;52(5):367–72 (51 ref.)
E-cadherin and catenins: molecules with versatile roles in normal and neoplastic epithelial cell biology. El-Bahrawy MA, et al. **Microsc Res Tech** 1998 Nov 1;43(3):224–32 (150 ref.)
Dysregulation of the type I IGF receptor as a paradigm in tumor progression [published erratum appears in Mol Cell Endocrinol 1998 Nov 25;146(1-2):213] Werner H. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):1–5 (38 ref.)
Molecular assessment of tumour stage and disease recurrence using PCR-based assays. Bustin SA, et al. **Mol Med Today** 1998 Sep;4(9):389–96 (52 ref.)
Hematopoietic cell differentiation antigens (CD system 1997). Cancer research relevance. Chorváth B, et al. **Neoplasma** 1998;45(5):273–6 (20 ref.)
Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Kos J, et al. **Oncol Rep** 1998 Nov-Dec; 5(6):1349–61 (145 ref.)
Three-dimensional spheroid model in tumor biology. Santini MT, et al. **Pathobiology** 1999 May-Jun;67(3):148–57 (63 ref.)
Tossing monkey wrenches into the clock: new ways of treating cancer [comment] Lees JA, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4221–3 (18 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4325–9.
Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Peller S. **Semin Cancer Biol** 1998;8(5):379–87 (95 ref.)
The mitotic machinery as a source of genetic instability in cancer. Pihan GA, et al. **Semin Cancer Biol** 1999 Aug; 9(4):289–302 (192 ref.)
Neoplasms composed of eosinophilic polygonal cells: an overview with consideration of different cytomorphologic patterns. Nappi O, et al. **Semin Diagn Pathol** 1999 May; 16(2):82–90 (70 ref.)
Abnormalities in cell cycle control in cancer and their clinical implications. Sgambato A, et al. **Tumori** 1998 Jul-Aug; 84(4):421–33 (130 ref.)
[Progresses in the study of pathology in China, 1997] Fang W. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):939–40 (0 ref.) **(Chi)**
[Telomerase and cancer: importance of detection of telomerase activity in pathology (editorial)] Brousset P. **Ann Pathol** 1998 Nov;18(5):375–6 (16 ref.) **(Fre)**
[Apoptosis and cancer] Agnantis NJ, et al. **Bull Acad Natl Med** 1999;183(2):277–86; discussion 286–7 (48 ref.) (Eng. Abstr.) **(Fre)**
[Extracellular proteases of stromal origin: contribution to tumor progression and therapeutic perspectives] Rio MC, et al. **C R Seances Soc Biol Fil** 1998;192(2):253–9 (21 ref.) (Eng. Abstr.) **(Fre)**
[FDG-PET in oncology. Methodological principles and clinical applications] Kletter K, et al. **Radiologe** 1999 Jul; 39(7):600–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Tumor metastases and adhesion molecules carbohydrates and lectins] Nemoto Y, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):849–56 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Neovascularization and tumor development] Ono M, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1577–87 (12 ref.) **(Jpn)**
[Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?] Matsuda A, et al. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):1981–9 (12 ref.) **(Jpn)**
[Disturbance of the normal cell cycle by T antigens of SV40 viruses and JC cause some tumors] Kryńska B, et al. **Postepy Hig Med Dosw** 1998;52(3):237–57 (78 ref.) (Eng. Abstr.) **(Pol)**
[The importance of angiogenesis in tumor growth dynamics] Radzikowski C, et al. **Postepy Hig Med Dosw** 1998; 52(6):553–76 (114 ref.) (Eng. Abstr.) **(Pol)**
[Tumor growth: tissue, cells, molecules] Lichtenstein AV, et al. **Patol Fiziol Eksp Ter** 1998 Jul-Sep;(3):25–44 (18 ref.) **(Rus)**

PHYSIOPATHOLOGY

c-Src, receptor tyrosine kinases, and human cancer. Biscardi JS, et al. **Adv Cancer Res** 1999;76:61–119 (488 ref.)
Fibronectin and its integrin receptors in cancer. Ruoslahti E. **Adv Cancer Res** 1999;76:1–20 (109 ref.)
Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Taipale J, et al. **Adv Cancer Res** 1998;75:87–134 (440 ref.)
12(S)-HETE in cancer metastasis. Tang K, et al. **Adv Exp Med Biol** 1999;447:181–91 (84 ref.)
Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology. Vaupel P, et al. **Adv Exp Med Biol** 1998; 454:591–602 (70 ref.)
The significance of matrix metalloproteinases during early stages of tumor progression. Lochter A, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:180–93 (54 ref.)
Advances in cancer pain. Foley KM. **Arch Neurol** 1999 Apr; 56(4):413–7 (11 ref.)
The role of nitric oxide chemistry in cancer treatment. Wink DA, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):802–9 (65 ref.)
Intercellular adhesion in vascular biology, thrombosis and cancer. Giddings JC. **Br J Biomed Sci** 1999;56(1):66–77 (35 ref.)
Procedural pain management in pediatric oncology: a review of the literature. Conte PM, et al. **Cancer Invest** 1999; 17(6):448–59 (62 ref.)
Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture. Chabner BA, et al. **Cancer Res** 1998 Oct 1;58(19):4211–6 (66 ref.)
Cancer anorexia-cachexia syndrome: are neuropeptides the key? Inui A. **Cancer Res** 1999 Sep 15;59(18):4493–501 (156 ref.)
Host impairments in patients with neoplastic diseases. De Pauw BE, et al. **Cancer Treat Res** 1998;96:1–32 (112 ref.)
Breakthrough pain in cancer patients: pathophysiology and treatment. Mercadante S, et al. **Cancer Treat Rev** 1998 Dec; 24(6):425–32 (55 ref.)
Retinoid-induced apoptosis in normal and neoplastic tissues [see comments] Nagy L, et al. **Cell Death Differ** 1998 Jan; 5(1):11–9 (86 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1–3.
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Ständer M, et al. **Cell Tissue Res** 1999 May;296(2):221–7 (48 ref.)
Cancer and atherosclerosis: the broad mandate of angiogenesis [editorial; comment] Isner JM. **Circulation** 1999 Apr 6;99(13):1653–5 (21 ref.) Comment on: Circulation 1999 Apr 6;99(13):1726–32.
Cancer--a degenerative disorder? Rew DA. **Eur J Surg Oncol** 1998 Oct;24(5):362–6 (44 ref.)
Escaping cell death: survival proteins in cancer. Jäättelä M. **Exp Cell Res** 1999 Apr 10;248(1):30–43 (189 ref.)
Emerging roles for PAX transcription factors in cancer biology. Schäfer BW. **Gen Physiol Biophys** 1998 Sep; 17(3):211–24 (42 ref.)
The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Mitchell BS, et al. **Histol Histopathol** 1999 Jan;14(1):217–26 (70 ref.)
Spontaneous regression of cancer: possible mechanisms. Papac RJ. **In Vivo** 1998 Nov-Dec;12(6):571–8 (100 ref.)
Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Bergers G, et al. **Int J Dev Biol** 1998;42(7 Spec No):995–1002 (39 ref.)
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Reuning U, et al. **Int J Oncol** 1998 Nov;13(5):893–906 (207 ref.)
The p53 pathway. Prives C, et al. **J Pathol** 1999 Jan; 187(1):112–26 (156 ref.)
Progression of cancer. Hirata Y. **Med Hypotheses** 1999 Jun; 52(6):511–3 (4 ref.)
The p53 paradox in the pathogenesis of tumor progression. Holden RJ, et al. **Med Hypotheses** 1999 May;52(5):483–5 (26 ref.)
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review). Holden RJ, et al. **Med Hypotheses** 1999 Apr; 52(4):319–23 (55 ref.)
Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Kurbel S, et al. **Med Hypotheses** 1999 Apr;52(4):329–33 (52 ref.)
Three molecular mechanisms to explain some biological effects of electromagnetic fields and hypogravity. Menéndez RG. **Med Hypotheses** 1999 Mar;52(3):239–45 (44 ref.)
Cancer departments as a source of resistant bacteria and fungi? Krcméry V Jr. **Neoplasma** 1999;46(1):3–6 (34 ref.)
A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review). Messori A, et al. **Oncol Rep** 1999 Sep-Oct;6(5):1135–41 (34 ref.)
Psychotropic adjuvant analgesics for pain in cancer and AIDS. Breitbart W. **Psychooncology** 1998 Jul-Aug; 7(4):333–45 (118 ref.)
Pathophysiology of the thrombophilic state in the cancer patient. Falanga A, et al. **Semin Thromb Hemost** 1999; 25(2):173–82 (115 ref.)
[Palliation of dyspnea in malignant disease (see comments)] de la Fuente Fonnest I, et al. **Ugeskr Laeger** 1999 Jan 18; 161(3):244–8 (39 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 Mar 15;161(11):1621. Comment in: Ugeskr Laeger 1999 Mar 22;161(12):1781–2. **(Dan)**
[Differentiating the activity of anticancer drugs: the role of transcription factors] Gillet R, et al. **Ann Pharm Fr** 1998; 56(1):1–8 (37 ref.) (Eng. Abstr.) **(Fre)**
[Hypoxia and tumors: does HIF-1 transcription factor favor tumor growth or hypoxia?] Vandenbunder B. **Bull Cancer** 1998 Oct;85(10):843–5 (10 ref.) (Eng. Abstr.) **(Fre)**
[Cyclin A: a good markers for the study of cell cycle control and tumor progression?] Philips A, et al. **C R Seances Soc Biol Fil** 1998;192(2):223–30 (34 ref.) (Eng. Abstr.) **(Fre)**
[Physiopathology of tumor-induced osteolysis] Gouin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Mar; 85(1):58–68 (93 ref.) (Eng. Abstr.) **(Fre)**
[Pain therapy in oncology] Heidemann E. **Internist (Berl)** 1999 Feb;40(2):168–75 (8 ref.) **(Ger)**
[Diagnosis and therapy of neuropathic pain in tumor diseases] Kloke M. **Internist (Berl)** 1999 Feb;40(2):176–82 (19 ref.) **(Ger)**
[12 basic rules in drug therapy of tumor pain] Weber M, et al. **Med Klin** 1999 Jan 15;94(1):51–4 (5 ref.) (Eng. Abstr.) **(Ger)**
[Staged analgesic therapy in tumor pain] Zenz M, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1126–34 (10 ref.) (Eng. Abstr.) **(Ger)**
[The role of cystatin in neoplastic progression and diagnosis] Warwas M, et al. **Postepy Hig Med Dosw** 1998;52(5):515–26 (59 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Cardiovascular and renal benefits of dry bean and soybean

intake. Anderson JW, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):464S–474S (154 ref.)
Health-promoting properties of common herbs. Craig WJ. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):491S–499S (115 ref.)
Cereals, legumes, and chronic disease risk reduction: evidence from epidemiologic studies. Kushi LH, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):451S–458S (94 ref.)
Plausible mechanisms for the protectiveness of whole grains. Slavin JL, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):459S–463S (37 ref.)
Convergence of philosophy and science: the third international congress on vegetarian nutrition. Willett WC. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):434S–438S (41 ref.)
Advances in cancer vaccine development. Herlyn D, et al. **Ann Med** 1999 Feb;31(1):66–78 (171 ref.)
Control of immune responses by gene immunization. Lee DJ, et al. **Ann Med** 1998 Oct;30(5):460–8 (73 ref.)
Experimental studies on lignans and cancer. Thompson LU. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):691–705 (64 ref.)
Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Lin JK, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):911–5 (28 ref.)
Red wine, green tea and vitamins: do their antioxidants play a role in immunologic protection against cancer or even AIDS? [editorial] Mathé G. **Biomed Pharmacother** 1999 May;53(4):165–7 (19 ref.)
Diet and the prevention of cancer. Cummings JH, et al. **BMJ** 1998 Dec 12;317(7173):1636–40 (31 ref.)
Carotenoids and cancer: prevention and potential therapy. Smith TA. **Br J Biomed Sci** 1998 Dec;55(4):268–75 (52 ref.)
Retinoids: present role and future potential. Evans TR, et al. **Br J Cancer** 1999 Apr;80(1–2):1–8 (120 ref.)
Introduction to the post-Human Genome Project era, a target for interactions between polygenic and/or multiphenotypical components in cancer control in South America. Iscovich J. **Cad Saude Publica** 1998;14 Suppl 3:15–23 (28 ref.)
DHEA: panacea or snake oil? Sirrs SM, et al. **Can Fam Physician** 1999 Jul;45:1723–8 (35 ref.)
Exercise and resistance to neoplasia. Woods JA. **Can J Physiol Pharmacol** 1998 May;76(5):581–8 (83 ref.)
Physical activity and cancer etiology: associations and mechanisms. McTiernan A, et al. **Cancer Causes Control** 1998 Oct;9(5):487–509 (208 ref.)
Psychosocial issues in cancer genetics: from the laboratory to the public. Bowen DJ, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 2):326–8 (12 ref.)
Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Fournier DB, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov;7(11):1055–65 (137 ref.)
Exercise clinical trials in cancer prevention research: a call to action. McTiernan A, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Mar;8(3):201–7 (67 ref.)
Lipoxygenase inhibitors as potential cancer chemopreventives. Steele VE, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May;8(5):467–83 (244 ref.)
An international evaluation of the cancer preventive potential of carotenoids. Vainio H, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Aug;7(8):725–8 (25 ref.)
Prevention: tobacco control and cancer nursing. Sarna L. **Cancer Nurs** 1999 Feb;22(1):21–8 (80 ref.)
School-based smoking control: a research agenda [see comments] Manske SR, et al. **Cancer Prev Control** 1997 Aug;1(3):196–212 (110 ref.) Comment in: Cancer Prev Control 1997 Aug;1(3):190–1.
Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Ganther HE. **Carcinogenesis** 1999 Sep;20(9):1657–66 (86 ref.)
Development of cancer chemopreventive agents: oltipraz as a paradigm. Kensler TW, et al. **Chem Res Toxicol** 1999 Feb;12(2):113–26 (113 ref.)
Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Meyskens FL Jr, et al. **Clin Cancer Res** 1999 May;5(5):945–51 (78 ref.)
Cancer in developing countries: Part II—Cancer control: strategies and priorities. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(5):283–7 (36 ref.)
Behavioral science applied to cancer screening. Baker F. **Curr Opin Oncol** 1998 Sep;10(5):455–60 (38 ref.)
Occupational cancer in France: epidemiology, toxicology, prevention, and compensation. Aubrun JC, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:245–52 (65 ref.)
Introduction: Epidemiologic research and prevention of occupational cancer in Europe. Boffetta P, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:229–31 (19 ref.)
Occupational cancer in Germany. Brüske-Hohlfeld I. **Environ Health Perspect** 1999 May;107 Suppl 2:253–8 (20 ref.)
Occupational cancer in the European part of the Commonwealth of Independent States. Bulbulyan MA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:283–8 (53 ref.)
Occupational cancer in central European countries. Fabiánová E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:279–82 (19 ref.)
Occupational cancer in Spain. González CA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:273–7 (36 ref.)
Occupational cancer in Italy. Merler E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:259–71 (142 ref.)
Does blindness protect against cancers? [editorial; comment] Hahn RA. **Epidemiology** 1998 Sep;9(5):481–3 (19 ref.) Comment on: Epidemiology 1998 Sep;9(5):490–4.
Screening for cancer: future potential. Cuzick J. **Eur J Cancer** 1999 May;35(5):685–92 (53 ref.)
Protection against cancer by wheat bran: role of dietary fibre and phytochemicals. Ferguson LR, et al. **Eur J Cancer Prev** 1999 Feb;8(1):17–25 (91 ref.)
Implications of the hyperinsulinaemia–diabetes–cancer link for preventive efforts. Moore MA, et al. **Eur J Cancer Prev** 1998 Apr;7(2):89–107 (243 ref.)
The anti-carcinogenic role of lycopene, abundantly present in tomato. Sengupta A, et al. **Eur J Cancer Prev** 1999 Aug; 8(4):325–30 (47 ref.)
Intervention studies on cancer. Young KJ, et al. **Eur J Cancer Prev** 1999 Apr;8(2):91–103 (53 ref.)
Cancer vaccines: a step towards prevention and treatment of cancer. Pandey M, et al. **Eur J Surg Oncol** 1999 Apr; 25(2):209–14 (55 ref.)
Cancer screening in the elderly. van Dongen JA. **Eur J Surg Oncol** 1998 Oct;24(5):367–9 (15 ref.)
Simple, sensible preventive measures for managed care settings. Waltzer KB. **Geriatrics** 1998 Oct;53(10):65–8, 75–7, 81; quiz 82 (29 ref.)
Principles of human chemoprevention. Meyskens FL Jr. **Hematol Oncol Clin North Am** 1998 Oct;12(5):935–41, v (21 ref.)
Nutritional factors in cancer prevention. Rock CL. **Hematol Oncol Clin North Am** 1998 Oct;12(5):975–91 (63 ref.)
Preclinical drug development paradigms for chemopreventives. Steele VE, et al. **Hematol Oncol Clin North Am** 1998 Oct;12(5):943–61, v–vi (107 ref.)
Specific and nonspecific immunity in the prevention of spontaneous tumours. Lollini PL, et al. **Immunol Today** 1999 Aug;20(8):347–50 (23 ref.)
Cancer prevention. Tongaonkar HB. **Indian J Med Sci** 1998 Mar;52(3):108–13 (0 ref.)
Effect of dietary phytochemicals on cancer development (review) Waladkhani AR, et al. **Int J Mol Med** 1998 Apr; 1(4):747–53 (81 ref.)
Polyamine metabolism as target for cancer chemoprevention (review). Seiler N, et al. **Int J Oncol** 1998 Nov; 13(5):993–1006 (202 ref.)
Metabolism of retinoic acid: implications for development and cancer. Sonneveld E, et al. **Int J Vitam Nutr Res** 1998; 68(6):404–10 (47 ref.)
The contribution of nursing to cancer prevention. Cutler LR. **J Adv Nurs** 1999 Jan;29(1):169–77 (71 ref.)
Symposium: Genetic testing and management of the cancer patient and cancer families. Webb MJ. **J Am Coll Surg** 1998 Oct;187(4):449–56 (04 ref.)
An assessment of the scientific basis for attempting to define the Dietary Reference Intake for beta carotene. Omenn GS. **J Am Diet Assoc** 1998 Dec;98(12):1406–9 (28 ref.)
Smoking in women. Mueller L, et al. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S7–10 (29 ref.)
The health status of American Indians and Alaska Natives: 2. Lessons for cancer educators. Mahoney MC, et al. **J Cancer Educ** 1999 Spring;14(1):23–7 (34 ref.)
Cancer control in susceptible groups: opportunities and challenges. Li FP. **J Clin Oncol** 1999 Feb;17(2):719–25 (92 ref.)
Cancer control research and literacy [editorial] Michielutte R, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):281–97 (111 ref.)
Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. Giovannucci E. **J Natl Cancer Inst** 1999 Feb 17;91(4):317–31 (125 ref.)
Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Hursting SD, et al. **J Natl Cancer Inst** 1999 Feb 3;91(3):215–25 (115 ref.)
Cancer chemoprevention: progress and promise [see comments] Lippman SM, et al. **J Natl Cancer Inst** 1998 Oct 21;90(20):1514–28 (114 ref.) Comment in: J Natl Cancer Inst 1999 Mar 17;91(6):563–5.
Symposium: Steroid Hormone Receptor and Nutrient Interactions: Implications for Cancer Prevention. Introduction. Belury MA. **J Nutr** 1999 Feb;129(2S Suppl):569S–570S (4 ref.)
Lessons from basic research in selenium and cancer prevention. Ip C. **J Nutr** 1998 Nov;128(11):1845–54 (85 ref.)
Testing children for cancer genes: the role of earliest onset. Kodish ED. **J Pediatr** 1999 Sep;135(3):390–5 (32 ref.)
Dietary fibres may protect or enhance carcinogenesis. Harris PJ, et al. **Mutat Res** 1999 Jul 15;443(1–2):95–110 (120 ref.)
The anti-carcinogenic effects of dietary restriction: mechanisms and future directions. Hursting SD, et al. **Mutat Res** 1999 Jul 15;443(1–2):235–49 (121 ref.)
Antimutagenic and anticarcinogenic activity of tea polyphenols. Kuroda Y, et al. **Mutat Res** 1999 Jan; 436(1):69–97 (131 ref.)
The role of biotransformation in dietary (anti)carcinogenesis. van Iersel ML, et al. **Mutat Res** 1999 Jul 15;443(1–2):259–70 (86 ref.)
Phytoestrogens and human health effects: weighing up the current evidence. Humfrey CD. **Nat Toxins** 1998;6(2):51–9 (76 ref.)
Green tea and cancer in humans: a review of the literature. Bushman JL. **Nutr Cancer** 1998;31(3):151–9 (46 ref.)
Green tea polyphenols and cancer: biologic mechanisms and practical implications. Ahmad N, et al. **Nutr Rev** 1999 Mar; 57(3):78–83 (41 ref.)
Cancer risk assessment: conceptual considerations for clinical practice. Mahon SM. **Oncol Nurs Forum** 1998 Oct; 25(9):1535–47 (34 ref.)
Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants. Singh DK, et al. **Oncology (Huntingt)** 1998 Nov;12(11):1643–53, 1657–8; discussion 1659–60 (111 ref.)
Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. Singh DK, et al. **Oncology (Huntingt)** 1998 Dec; 12(12):1787–800; discussion 1802, 1805 (232 ref.)
Chemopreventive agents: selenium. Combs GF Jr, et al. **Pharmacol Ther** 1998 Sep;79(3):179–92 (179 ref.)
Antioxidant vitamins in the prevention of cancer. Lee IM. **Proc Assoc Am Physicians** 1999 Jan–Feb;111(1):10–5 (44 ref.)
Chemoprevention of cancer and cardiovascular disease by resveratrol. Lin JK, et al. **Proc Natl Sci Counc Repub China B** 1999 Jul;23(3):99–106 (99 ref.)
Mechanistic findings of green tea as cancer preventive for humans. Fujiki H, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):225–8 (14 ref.)
Mechanism of cancer chemopreventive activity of green Tea. Mukhtar H, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):234–8 (31 ref.)
Studies on some edible and medicinal plants of Mesoamerica. Kinghorn AD, et al. **Proc West Pharmacol Soc** 1998; 41:253–8 (37 ref.)
Rationale and mechanisms of cancer chemoprevention. De Flora S, et al. **Recent Results Cancer Res** 1999;151:29–44 (69 ref.)
Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Marks F, et al. **Recent Results Cancer Res** 1999; 151:45–67 (111 ref.)
Chemoprevention of human cancer: a reasonable strategy? Meyskens FL Jr. **Recent Results Cancer Res** 1999; 151:113–21 (42 ref.)
Associations between physical activity and susceptibility to cancer: possible mechanisms. Shephard RJ, et al. **Sports Med** 1998 Nov;26(5):293–315 (245 ref.)
Cancer chemoprevention: future holds in multiple agents. Mukhtar H, et al. **Toxicol Appl Pharmacol** 1999 Aug 1; 158(3):207–10 (28 ref.)
Micronutrients prevent cancer and delay aging. Ames BN. **Toxicol Lett** 1998 Dec 28;102–103:5–18 (147 ref.)
Arachidonic acid metabolism as a reporter of skin irritancy and target of cancer chemoprevention. Marks F, et al. **Toxicol Lett** 1998 Aug;96–97:111–8 (34 ref.)
Micronutrients, vitamins, and cancer risk. Schorah CJ. **Vitam Horm** 1999;57:1–23 (131 ref.)
Tea—a potent agent to prevent disease? [editorial] Najemnik C, et al. **Wien Klin Wochenschr** 1999 Apr 9;111(7):259–61 (21 ref.)
[Nutrition and cancer: causative, protective and therapeutic aspects] van den Brandt PA, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3;143(27):1414–20 (43 ref.) (Eng. Abstr.) **(Dut)**
[Waiting for the break through: a few tentative scenarios for cancer prevention and treatment in the coming decades] De Schryver A. **Verh K Acad Geneeskd Belg** 1999; 61(4):467–86; discussion 486–7 (33 ref.) (Eng. Abstr.) **(Dut)**
[Carotenoids: 2. Diseases and supplementation studies] Faure H, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):273–82 (77 ref.) (Eng. Abstr.) **(Fre)**
[Screening for cancer] Bjørge T, et al. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1129–36 (66 ref.) (Eng. Abstr.) **(Nor)**
[Fruit and vegetables in the prevention of cancer] Blomhoff R. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3462–5 (30 ref.) (Eng. Abstr.) **(Nor)**
[Adaptogens as agents for prophylactic oncology] Bocharova OA. **Vestn Ross Akad Med Nauk** 1999;(5):49–53 (76 ref.) (Eng. Abstr.) **(Rus)**
[Oncologic aspects of estrogen-replacement therapy] Berstein LM. **Vopr Onkol** 1998;44(4):378–82 (40 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Cancer pain—a provoker of emotional, social and existential distress. Strang P. **Acta Oncol** 1998;37(7–8):641–4 (31 ref.)
Clarification of the conceptualization and measurement of denial in psychosocial oncology research. Moyer A, et al. **Ann Behav Med** 1998 Summer;20(3):149–60 (119 ref.)
Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. Vitaliano PP, et al. **Ann Behav Med** 1998 Summer;20(3):199–208 (91 ref.)
Breaking bad news. 3: Encouraging the adoption of best

practices. Campbell EM, et al. **Behav Med** 1998 Summer; 24(2):73–80 (47 ref.)
Breaking bad news. 2: What evidence is available to guide clinicians? Walsh RA, et al. **Behav Med** 1998 Summer; 24(2):61–72 (65 ref.)
Is posttraumatic stress a viable model for understanding responses to childhood cancer? Stuber ML, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):169–82 (56 ref.)
Depression in cancer and HIV infection: research findings and implications of effective antidepressant treatment. Petitto JM, et al. **Depress Anxiety** 1998;8 Suppl 1:80–4 (42 ref.)
Psychosocial aspects of cancer in the elderly. Walker LG, et al. **Eur J Surg Oncol** 1998 Oct;24(5):375–8 (19 ref.)
Practitioner review: long-term consequences of childhood cancer. Eiser C. **J Child Psychol Psychiatry** 1998 Jul; 39(5):621–33 (60 ref.)
Siblings of children with cancer: a review of the literature. Murray JS. **J Pediatr Oncol Nurs** 1999 Jan;16(1):25–34 (20 ref.)
Young adult survivors of childhood cancer: attending to emerging medical and psychosocial needs [see comments] Richardson RC, et al. **J Pediatr Oncol Nurs** 1999 Jul; 16(3):136–44 (41 ref.) Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115–6.
Posttraumatic stress disorder: understanding the psychosocial impact of surviving childhood cancer into young adulthood [see comments] Rourke MT, et al. **J Pediatr Oncol Nurs** 1999 Jul;16(3):126–35 (25 ref.) Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115–6.
Conceptual understanding of resilience in the adolescent with cancer: Part I. Woodgate RL. **J Pediatr Oncol Nurs** 1999 Jan;16(1):35–43 (28 ref.)
A review of the literature on resilience in the adolescent with cancer: Part II. Woodgate RL. **J Pediatr Oncol Nurs** 1999 Apr;16(2):78–89 (57 ref.)
Attitude and disposition: Do they make a difference in cancer survival? Creagan ET. **J Prosthet Dent** 1999 Sep; 82(3):352–5 (24 ref.)
Psycho-oncology research: the road traveled, the road ahead [editorial] Breitbart W, et al. **J Psychosom Res** 1998 Sep; 45(3):185–9 (38 ref.)
Group therapy in the cancer setting. Fawzy FI, et al. **J Psychosom Res** 1998 Sep;45(3):191–200 (24 ref.)
Assessment and treatment of depression in the cancer patient. Newport DJ, et al. **J Psychosom Res** 1998 Sep;45(3):215–37 (215 ref.)
Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Thomas ML. **Med Oncol** 1998 Aug;15 Suppl 1:S13–8 (34 ref.)
Surviving cancer: the importance of sexual self-concept. Andersen BL. **Med Pediatr Oncol** 1999 Jul;33(1):15–23 (45 ref.)
On cancer control and the adolescent. Barr RD. **Med Pediatr Oncol** 1999 Jun;32(6):404–10 (86 ref.)
Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Schover LR. **Med Pediatr Oncol** 1999 Jul;33(1):53–9 (44 ref.)
Meeting impossible psychosocial demands in pediatric oncology: creative solutions to universal challenges [see comments] Whitsett SF, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):289–91 (0 ref.) Comment in: Med Pediatr Oncol 1999 Apr;32(4):292–3.
Psychological factors in illness and recovery [see comments] Clarke DM. **N Z Med J** 1998 Oct 23;111(1076):410–2 (53 ref.) Comment in: N Z Med J 1999 Feb 26;112(1082):58–9.
Active listening to cancer patients' stories. ten Kroode HF. **Neth J Med** 1998 Aug;53(2):41–52 (4 ref.)
On the role of immunological factors as mediators between psychosocial factors and cancer progression. Garssen B, et al. **Psychiatry Res** 1999 Jan 18;85(1):51–61 (64 ref.)
The uses of psychotropics in symptom management in advanced cancer. Bruera E, et al. **Psychooncology** 1998 Jul–Aug;7(4):346–58 (105 ref.)
Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions. Kalash GR. **Psychooncology** 1998 Jul–Aug;7(4):307–20 (21 ref.)
Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Twillman RK, et al. **Psychooncology** 1998 Jul–Aug; 7(4):285–90 (13 ref.)
Organizing social work services with adult cancer patients: integrating empirical research. Cwikel JG, et al. **Soc Work Health Care** 1999;28(3):55–76 (94 ref.)
Psychosocial issues of adolescents with cancer. Roberts CS, et al. **Soc Work Health Care** 1998;27(4):3–18 (33 ref.)
[Diagnostic disclosure. Psychological impact and practical aspects] Baillet F, et al. **Encephale** 1998 Dec;24 Spec No 2:35–41 (19 ref.) **(Fre)**
[Approach of psychology to health] Bruchon-Schweitzer M, et al. **Encephale** 1998 Dec;24 Spec No 2:2–14 (53 ref.) **(Fre)**
[Anxiety, depression, cancer: clinical aspects] Marx G, et al. **Encephale** 1998 Dec;24 Spec No 2:66–71 (40 ref.) **(Fre)**
[Iatrogenic psychopathology and cancerology] Ronson A, et al. **Encephale** 1998 Dec;24 Spec No 2:15–24 (63 ref.) **(Fre)**
[Measure of negative life events before onset of cancer] Saltel P, et al. **Encephale** 1998 Dec;24 Spec No 2:42–9 (19 ref.) **(Fre)**
[Coping--status of knowledge in the 90's] Heim E. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):321–37 (150 ref.) (Eng. Abstr.) **(Ger)**
[Psycho-oncologic interventions--critical review] Larbig W. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):381–9 (75 ref.) (Eng. Abstr.) **(Ger)**
[Development of QOL questionnaires in Japan] Kobayashi K. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):189–95 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Euthanasia and cancer] Norum J, et al. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):796–8 (11 ref.) (Eng. Abstr.) **(Nor)**
[Quality of life of oncologic patients] Ionova TI, et al. **Vopr Onkol** 1998;44(6):749–52 (38 ref.) **(Rus)**

RADIOGRAPHY

Response assessment using radiological methods. Gwyther SJ. **Crit Rev Oncol Hematol** 1999 Mar;30(1):45–62 (35 ref.)
Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Miles KA. **Eur J Radiol** 1999 Jun;30(3):198–205 (34 ref.)
A horizontal CT system dedicated to heavy-ion beam treatment. Kamada T, et al. **Radiother Oncol** 1999 Feb; 50(2):235–7 (4 ref.)
Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors. Brien EW, et al. **Skeletal Radiol** 1999 Jan; 28(1):1–20 (32 ref.)
[Diagnostic imaging in the assessment of the therapeutic response in oncology] Ferrozzi F, et al. **Radiol Med (Torino)** 1999 Jan–Feb;97(1–2):8–18 (58 ref.) **(Ita)**

RADIONUCLIDE IMAGING

Positron emission tomography as a diagnostic tool in oncology. Schiepers C, et al. **Eur Radiol** 1998;8(8):1481–94 (160 ref.)
18-Fluorodeoxyglucose imaging in oncology. Harolds JA. **J Okla State Med Assoc** 1999 Sep;92(9):457–61 (36 ref.)
Radionuclide imaging in cancer management. Maisey M. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):525–9 (20 ref.)
Nuclear medicine in cancer diagnosis. Eary JF. **Lancet** 1999 Sep 4;354(9181):853–7 (43 ref.)
Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Shreve PD, et al. **Radiographics** 1999 Jan–Feb;19(1):61–77; quiz 150–1 (39 ref.)
Benign causes of 18-FDG uptake on whole body imaging. Bakheet SM, et al. **Semin Nucl Med** 1998 Oct;28(4):352–8 (67 ref.)
Relevance of positron emission tomography (PET) in oncology. Weber WA, et al. **Strahlenther Onkol** 1999 Aug; 175(8):356–73 (168 ref.)
The radioimmunoguided surgery (RIGS) system as a diagnostic tool. Bakalakos EA, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):129–44 (37 ref.)
What is new in nuclear medicine imaging? Ferrand SK, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):185–204 (131 ref.)
Positron emission tomography (PET) in the evaluation of patients with cancer. Godwin HA Jr, et al. **Trans Am Clin Climatol Assoc** 1999;110:181–94 (25 ref.)
[Current data and perspectives on positron emission tomography oncology-radiotherapy] Lonneux M, et al. **Cancer Radiother** 1999 Jul–Aug;3(4):275–88 (64 ref.) (Eng. Abstr.) **(Fre)**
[Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies] Oriuchi N. **Gan To Kagaku Ryoho** 1999 May;26(6):762–7 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor imaging using 201Tl chloride and 67Ga citrate in nucleomedical surveys] Togawa T, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):749–55 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Nuclear oncology with monoclonal antibodies and peptides] Hosono M. **Kaku Igaku** 1998 Oct;35(8):681–7 (51 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Potential gains using high-energy protons for therapy of malignant tumours. Glimelius B, et al. **Acta Oncol** 1999; 38(2):137–45 (44 ref.)
Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Henriksson R, et al. **Acta Oncol** 1999;38(2):159–64 (37 ref.)
Modern radiotherapy. Does the GP have a role? MacLeod C, et al. **Aust Fam Physician** 1999 Feb;28(2):145–50 (39 ref.)
CHART (continuous, hyperfractionated, accelerated radiotherapy): a tale of two disciplines. Saunders MI, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:110–5 (52 ref.)
Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Saunders M, et al. **Br J Cancer Suppl** 1996 Jul;27:S271–8 (48 ref.)
Radiosensitivity and the cell cycle. Bernhard EJ, et al. **Cancer J Sci Am** 1999 Jul–Aug;5(4):194–204 (145 ref.)
Radiation biology and treatment options in radiation oncology. Withers HR. **Cancer Res** 1999 Apr 1;59(7 Suppl):1676s–1684s (70 ref.)
Conformal radiotherapy: a clinical review. Read G. **Clin Oncol (R Coll Radiol)** 1998;10(5):288–96 (87 ref.)
Pulmonary complications of cancer therapy. Wesselius LJ. **Compr Ther** 1999 May;25(5):272–7 (20 ref.)
Radiotherapy in the elderly. Pignon T, et al. **Eur J Surg Oncol** 1998 Oct;24(5):407–11 (34 ref.)
Tumor radiosensitivity and apoptosis. Zhivotovsky B, et al. **Exp Cell Res** 1999 Apr 10;248(1):10–7 (80 ref.)
Gonadal tissue cryopreservation in boys with paediatric cancers. Bahadur G, et al. **Hum Reprod** 1999 Jan;14(1):11–7 (81 ref.)
ACR appropriateness criteria. Expert Panel on Radiation Oncology. American College of Radiology [see comments] Leibel SA. **Int J Radiat Oncol Biol Phys** 1999 Jan 1; 43(1):125–68 (190 ref.) Comment in: Int J Radiat Oncol Biol Phys 1999 Jan 1;43(1):1–2.
A clinical study on acupuncture for prevention and treatment of toxic side-effects during radiotherapy and chemotherapy. Zhou J, et al. **J Tradit Chin Med** 1999 Mar; 19(1):16–21 (19 ref.)
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14–8 (23 ref.)
Hyperfractionated radiotherapy: tops or flops? Baumann M, et al. **Med Pediatr Oncol** 1999 Oct;33(4):399–402 (14 ref.)
Cytoprotection in the treatment of pediatric cancer: review of current strategies in adults and their application to children. Bukowski R. **Med Pediatr Oncol** 1999 Feb; 32(2):124–34 (109 ref.)
Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Gregoire V, et al. **Oncol Rep** 1999 Sep–Oct; 6(5):949–57 (61 ref.)
Improving monoclonal antibody pharmacokinetics via chemical modification. Sharifi J, et al. **Q J Nucl Med** 1998 Dec;42(4):242–9 (31 ref.)
Towards prediction and modulation of treatment response. Bartelink H, et al. **Radiother Oncol** 1999 Jan;50(1):1–11 (52 ref.)
A horizontal CT system dedicated to heavy-ion beam treatment. Kamada T, et al. **Radiother Oncol** 1999 Feb; 50(2):235–7 (4 ref.)
Radioprotective effects of amifostine. Wasserman T. **Semin Oncol** 1999 Apr;26(2 Suppl 7):89–94 (29 ref.)
Future development of amifostine as a radioprotectant. Werner-Wasik M. **Semin Oncol** 1999 Apr;26(2 Suppl 7):129–34 (28 ref.)
Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy. Fraass BA, et al. **Semin Radiat Oncol** 1999 Jan;9(1):60–77 (110 ref.)
Issues in quality of life assessment during cancer therapy. Scott CB. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):5–9 (21 ref.)
Blood flow and oxygenation status of human tumors. Clinical investigations. Feldmann HJ, et al. **Strahlenther Onkol** 1999 Jan;175(1):1–9 (91 ref.)
Principles of feeding cancer patients via enteral or parenteral nutrition during radiotherapy. Fietkau R. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:47–51 (18 ref.)
Clinical trial experience using erythropoietin during radiation therapy. Lavey RS. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:24–30 (15 ref.)
Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Molls M, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:13–6 (35 ref.)
[Biophysical principals in radiotherapy of malignant tumors] Vodička I. **Acta Medica (Hradec Kralove) Suppl** 1998; 41(2):105–63 (50 ref.) (Eng. Abstr.) **(Cze)**
[Concurrent chemoradiotherapy update] Reboul F, et al. **Bull Cancer** 1999 Jan;86(1):77–83 (36 ref.) (Eng. Abstr.) **(Fre)**
[Clinical evaluation of concomitant chemoradiotherapy and practical recommendations] Bosset JF, et al. **Cancer Radiother** 1998 Dec;2(6):665–7 (13 ref.) (Eng. Abstr.) **(Fre)**
[Biological principles of chemoradiotherapy] Bourhis J, et al. **Cancer Radiother** 1998 Dec;2(6):657–62 (41 ref.) (Eng. Abstr.) **(Fre)**
[Chemoradiotherapy: history and state of the art] Cosset JM. **Cancer Radiother** 1998 Dec;2(6):653–6 (19 ref.) (Eng. Abstr.) **(Fre)**
[Tumor and individual radiosensitivity. An introduction] Cosset JM, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):523–9 (50 ref.) (Eng. Abstr.) **(Fre)**
[Local control of the primary tumor. Necessary step in control of cancer (published erratum appears in Cancer Radiother 1999 Jan–Feb;3(1):85)] Gérard JP, et al. **Cancer Radiother** 1998 Dec;2(6):668–71 (13 ref.) (Eng. Abstr.) **(Fre)**
[Tumor radiosensitivity tests: state of assays in 1998] Girinsky T, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):530–3 (24 ref.) (Eng. Abstr.) **(Fre)**
[Combined chemoradiotherapy of tumors in the child (published erratum appears in Cancer Radiother 1999 Jan–Feb;3(1):85)] Habrand JL, et al. **Cancer Radiother** 1998 Dec;2(6):752–9 (70 ref.) (Eng. Abstr.) **(Fre)**
[Radiation sensitizing agents for hypoxic cells: past, present and future] Lartigau E. **Cancer Radiother** 1998 Dec; 2(6):775–80 (57 ref.) (Eng. Abstr.) **(Fre)**
[Use of G-CSF (Neupogen) in multimodal treatment in radiotherapy] Bartzsch O, et al. **Strahlenther Onkol** 1998

Nov;174(11):551–5 (19 ref.) (Eng. Abstr.) **(Ger)**

[Epoetin alfa in radiotherapy] Trodella L, et al. **Tumori** 1998 Nov-Dec;84(6 Suppl 1):S15–9 (44 ref.) (Eng. Abstr.) **(Ita)**

[History of radiotherapy for cancer] Okawa T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:15–22 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies] Oriuchi N. **Gan To Kagaku Ryoho** 1999 May;26(6):762–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Contribution of radiation biology to the development of radiation therapy] Shibamoto Y. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1242–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Organizing social work services with adult cancer patients: integrating empirical research. Cwikel JG, et al. **Soc Work Health Care** 1999;28(3):55–76 (94 ref.)

[Significance and problems of quality-of-life assessment in clinical trials] Shimozuma K, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):183–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Kurbel S, et al. **Med Hypotheses** 1999 Apr;52(4):329–33 (52 ref.)

SURGERY

The changing role of surgery in the diagnosis and treatment of cancer. Mintzer D. **Am J Med** 1999 Jan;106(1):81–9 (98 ref.)

Decision making on surgical palliation based on patient outcome data. Miner TJ, et al. **Am J Surg** 1999 Feb; 177(2):150–4 (32 ref.)

Perioperative management of the patient with cancer. Lefor AT. **Chest** 1999 May;115(5 Suppl):165S–171S (28 ref.)

The effect of surgical wounding on tumour development. Hofer SO, et al. **Eur J Surg Oncol** 1999 Jun;25(3):231–43 (153 ref.)

Surgical oncology. Sondak VK. **J Am Coll Surg** 1999 Feb; 188(2):178–83 (39 ref.)

Surgery and cancer: opinion, evidence, and proof [editorial] Burton RC. **J Surg Oncol** 1999 May;71(1):1–3 (19 ref.)

Introduction: dose-intensive therapy for adult malignancies. Weiss RB. **Semin Oncol** 1999 Feb;26(1):1–5 (21 ref.)

Pneumoperitoneum in the cancer patient: advantages and pitfalls. Greene FL. **Semin Surg Oncol** 1998 Oct-Nov; 15(3):151–4 (24 ref.)

Minimally invasive surgery for solid tumors. Holcomb GW 3rd. **Semin Surg Oncol** 1999 Mar;16(2):184–92 (60 ref.)

Port site recurrences after laparoscopy for malignant disease. Pearlstone DB, et al. **Semin Surg Oncol** 1999 Jun; 16(4):307–12 (64 ref.)

Port-site metastasis in the abdominal wall: fact or fiction? Savalgi RS. **Semin Surg Oncol** 1998 Oct-Nov;15(3):189–93 (26 ref.)

Intraoperative and laparoscopic ultrasound. Machi J. **Surg Oncol Clin N Am** 1999 Jan;8(1):205–26 (47 ref.)

Beyond the laparoscope: minimally invasive surgery in the new millennium. Rattner DW. **Surgery** 1999 Jan; 125(1):19–22 (8 ref.)

Endoscopic surgery: fit for malignancy? Müller JM, et al. **World J Surg** 1999 Aug;23(8):808–15 (54 ref.)

[Role of 18F-FDG positron emission tomography in surgical evaluation] Franzius C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:261–9 (53 ref.) (Eng. Abstr.) **(Ger)**

[Trends in surgical treatment in various malignancies] Taguchi T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:8–14 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Autotransfusion and oncologic surgery] Del Castillo Déjardin D, et al. **Sangre (Barc)** 1998 Aug;43(4):323–6 (29 ref.) **(Spa)**

[Pre-donated autotransfusion and oncologic surgery] Gumà J, et al. **Sangre (Barc)** 1998 Aug;43(4):311–5 (43 ref.) **(Spa)**

THERAPY

Craniofacial growth in children treated for malignant diseases. Dahllöf G. **Acta Odontol Scand** 1998 Dec; 56(6):378–82 (40 ref.)

Recent developments in palliative cancer care. Bruera E, et al. **Acta Oncol** 1998;37(7–8):749–57 (73 ref.)

The labyrinthine ways of cancer immunotherapy--T cell, tumor cell encounter: "how do I lose thee? Let me count the ways". Ellem KA, et al. **Adv Cancer Res** 1998;75:203–49 (247 ref.)

Targeted adenoviral vectors for cancer gene therapy. Bilbao G, et al. **Adv Exp Med Biol** 1998;451:365–74 (65 ref.)

Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols. Favrot MC, et al. **Adv Exp Med Biol** 1998;451:539–41 (13 ref.)

Expression genetics in cancer research, prognosis, and therapy. Martin KJ, et al. **Adv Exp Med Biol** 1998;451:1–7 (12 ref.)

Mood and cognitive disorders in cancer patients receiving cytokine therapy. Meyers CA. **Adv Exp Med Biol** 1999; 461:75–81 (22 ref.)

Control of tumor growth via inhibition of tumor angiogenesis. Plate KH. **Adv Exp Med Biol** 1998;451:57–61 (41 ref.)

Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Schirrmacher V, et al. **Adv Exp Med Biol** 1998;451:251–7 (43 ref.)

Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Aran JM, et al. **Adv Pharmacol** 1999;46:1–42 (212 ref.)

Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Ippoliti C. **Am J Health Syst Pharm** 1998 Aug 1;55(15):1573–80 (81 ref.)

Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. Brugger W, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:363–71 (22 ref.)

p53-oriented cancer therapies: current progress. Gallagher WM, et al. **Ann Oncol** 1999 Feb;10(2):139–50 (144 ref.)

Dendritic cells: a novel therapeutic modality. Luykx-de Bakker SA, et al. **Ann Oncol** 1999 Jan;10(1):21–7 (90 ref.)

Cytokine gene therapy: hopes and pitfalls. Nanni P, et al. **Ann Oncol** 1999 Mar;10(3):261–6 (86 ref.)

Access to quality cancer care: consensus statement of the American Federation of Clinical Oncologic Societies. Edwards MJ. **Ann Surg Oncol** 1998 Oct-Nov;5(7):657–9 (0 ref.)

Dendritic cell vaccines for cancer immunotherapy. Timmerman JM, et al. **Annu Rev Med** 1999;50:507–29 (111 ref.)

Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Syrigos KN, et al. **Anticancer Res** 1999 Jan-Feb; 19(1A):605–13 (77 ref.)

GP versus hospital follow up for cancer patients. Is the choice based on evidence? Weller D, et al. **Aust Fam Physician** 1999 Apr;28(4):356–9 (11 ref.)

Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Waddick KG, et al. **Biochem Pharmacol** 1999 Jan 1; 57(1):9–17 (72 ref.)

Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Waddick KG, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1411–26 (118 ref.)

The role of nitric oxide chemistry in cancer treatment. Wink DA, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):802–9 (65 ref.)

Clinical resistance to topoisomerase-targeted drugs. Dingemans AM, et al. **Biochim Biophys Acta** 1998 Oct 1; 1400(1-3):275–88 (90 ref.)

Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms. Cobaleda C, et al. **Bioessays** 1998 Nov;20(11):922–30 (73 ref.)

Survivors of cancer: organ preservation and reducing the morbidity of treatment in paediatric genitourinary oncology. Plowman PN. **BJU Int** 1999 Apr;83 Suppl 3:51–60 (43 ref.)

Dendritic cells: development, function and potential use for cancer immunotherapy. Avigan D. **Blood Rev** 1999 Mar; 13(1):51–64 (123 ref.)

Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Glaspy JA. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S21–7 (29 ref.)

Targeting cancer therapy. Begent RH. **Br J Cancer** 1999 Jul; 80 Suppl 1:104–9 (27 ref.)

Targeting human tumours with antigen-specific cytotoxic T-cells. Rickinson AB. **Br J Cancer** 1999 Jul;80 Suppl 1:51–6 (64 ref.)

In pursuit of excellence for patients with cancer: the Scottish Cancer Therapy Network model. Stroner PL, et al. **Br J Cancer** 1999 Apr;79(11–12):1641–5 (25 ref.)

The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Dachs GU, et al. **Br J Cancer Suppl** 1996 Jul;27:S126–32 (82 ref.)

The reproductive system after childhood cancer. Levitt GA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):946–53 (65 ref.)

In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Crystal RG. **Cancer Chemother Pharmacol** 1999;43 Suppl:S90–9 (107 ref.)

Development and application of adenoviral vectors for gene therapy of cancer. Zhang WW. **Cancer Gene Ther** 1999 Mar-Apr;6(2):113–38 (240 ref.)

Cancer cell metabolism: its relevance to cancer treatment. Lupulescu A. **Cancer Invest** 1999;17(6):423–33 (70 ref.)

Cancer-testis antigens: targets for cancer immunotherapy [comment] Chen YT, et al. **Cancer J Sci Am** 1999 Jan-Feb; 5(1):16–7 (11 ref.) Comment on: Cancer J Sci Am 1999 Jan-Feb;5(1):20–5.

Cancer therapy based on p53. McCormick F. **Cancer J Sci Am** 1999 May-Jun;5(3):139–44 (31 ref.)

The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Yu D, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):195–202 (98 ref.)

Complementary therapies: overview and state of the art. Cassileth BR. **Cancer Nurs** 1999 Feb;22(1):85–90 (5 ref.)

New strategies in the management of cancer. Kearney N. **Cancer Nurs** 1999 Feb;22(1):28–33 (26 ref.)

Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture. Chabner BA, et al. **Cancer Res** 1998 Oct 1;58(19):4211–6 (66 ref.)

Health service studies in the terminally ill cancer patient. Smith TJ. **Cancer Treat Res** 1998;97:81–97 (77 ref.)

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Bernsen MR, et al. **Cancer Treat Rev** 1999 Apr;25(2):73–82 (123 ref.)

The potential of melanoma antigen expression in cancer therapy. Gillespie AM, et al. **Cancer Treat Rev** 1999 Aug; 25(4):219–27 (79 ref.)

Genetically modified tumour vaccines--where we are today. Nawrocki S, et al. **Cancer Treat Rev** 1999 Feb;25(1):29–46 (112 ref.)

Summary of the first Emil J Freireich symposium. Bast RC Jr. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2708–10 (26 ref.)

Thermoradiotherapy in the management of superficial malignant tumors. Engin K, et al. **Clin Cancer Res** 1995 Feb;1(2):139–45 (73 ref.)

The future of clinical cancer research in the next millennium. Freireich EJ. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2563–70 (23 ref.)

The scientific basis of clinical trials: statistical aspects. Gehan EA. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2587–90 (22 ref.)

Advances in the biological therapy and gene therapy of malignant disease. Hersh EM, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2623–9 (49 ref.)

Foundations of clinical cancer research: perspective for the 21st century. Hersh EM. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2551–3 (30 ref.)

Clinical trials in cancer. Holland JF. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2585–6 (8 ref.)

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Mendelsohn J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2703–7 (48 ref.)

Prospects for cytokine and chemokine biotherapy. Oppenheim JJ, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2682–6 (36 ref.)

Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Reiter Y, et al. **Clin Cancer Res** 1996 Feb; 2(2):245–52 (62 ref.)

Oncogenes and tumor suppressor genes: therapeutic implications. Stass SA, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 2):2687–95 (58 ref.)

Development of dendritic cells and their use in tumor therapy. Björck P. **Clin Immunol** 1999 Aug;92(2):119–27 (73 ref.)

The development of monoclonal antibodies for the therapy of cancer. Farah RA, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3–4):321–56 (340 ref.)

Mechanisms of p53-mediated apoptosis. Ding HF, et al. **Crit Rev Oncog** 1998;9(1):83–98 (172 ref.)

Cells and cytokines in immunotherapy and gene therapy of cancer. Pawelec G, et al. **Crit Rev Oncog** 1999; 10(1-2):83–127 (382 ref.)

Recent developments in gene therapy for oncology and hematology. Roskrow MA, et al. **Crit Rev Oncol Hematol** 1998 Sep;28(3):139–51 (89 ref.)

Clinical applications of TNF-alpha in cancer. Lejeune FJ, et al. **Curr Opin Immunol** 1998 Oct;10(5):573–80 (42 ref.)

Adoptive immunotherapy after hematopoietic stem cell transplantation. Burt RK, et al. **Curr Opin Oncol** 1998 Nov; 10(6):525–32 (115 ref.)

Costimulatory approaches to adoptive immunotherapy. Liebowitz DN, et al. **Curr Opin Oncol** 1998 Nov; 10(6):533–41 (85 ref.)

Human dendritic cells: natural adjuvants in antitumor immunotherapy. Di Nicola M, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):265–73 (81 ref.)

p53: prospects for cancer gene therapy. Soddu S, et al. **Cytokines Cell Mol Ther** 1998 Sep;4(3):177–85 (66 ref.)

Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Waxman DJ, et al. **Drug Metab Rev** 1999 May;31(2):503–22 (65 ref.)

Edrecolomab (monoclonal antibody 17-1A). Adkins JC, et al. **Drugs** 1998 Oct;56(4):619–26; discussion 627–8 (41 ref.)

Prospects for the therapeutic use of anticancer vaccines. Chamberlain RS. **Drugs** 1999 Mar;57(3):309–25 (164 ref.)

Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Hoekman K, et al. **Drugs** 1999 Feb;57(2):133–55 (213 ref.)

Factors in improved survival from paediatric cancer. Taub JW. **Drugs** 1998 Nov;56(5):757–65 (89 ref.)

Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging. Panousis C, et al. **Drugs Aging** 1999 Jul;15(1):1–13 (88 ref.)

Psychosocial aspects of cancer in the elderly. Walker LG, et al. **Eur J Surg Oncol** 1998 Oct;24(5):375–8 (19 ref.)

The use of gene transfer in cancer immunotherapy. Dranoff G. **Forum (Genova)** 1998 Oct-Dec;8(4):357–64 (48 ref.)

Gene therapy: models to study the immunological way. Forni G. **Forum (Genova)** 1998 Oct-Dec;8(4):328–38 (66 ref.)

Targeted, non-viral gene delivery for cancer gene therapy. Cristiano RJ. **Front Biosci** 1998 Nov 15;3:D1161–70 (63 ref.)

Therapeutic potentials of angiostatin in the treatment of cancer. Cao Y. **Haematologica** 1999 Jul;84(7):643–50 (45 ref.)

Bone marrow and peripheral blood stem cell transplantation for malignancy. Johnson PW, et al. **Health Technol Assess** 1998;2(8):1–187 (209 ref.)

Grafting T cells with tumor specificity: the chimeric receptor

strategy for use in immunotherapy of malignant diseases. Hombach A, et al. **Hybridoma** 1999 Feb;18(1):57–61 (10 ref.)

A new era for cancer immunotherapy based on the genes that encode cancer antigens. Rosenberg SA. **Immunity** 1999 Mar;10(3):281–7 (79 ref.)

Advances in cancer immunotherapy. Ockert D, et al. **Immunol Today** 1999 Feb;20(2):63–5 (13 ref.)

Therapeutic intervention with complement and beta-glucan in cancer. Ross GD, et al. **Immunopharmacology** 1999 May; 42(1–3):61–74 (116 ref.)

Chronomedical aspects of oncology and geriatrics. Cornélissen G, et al. **In Vivo** 1999 Jan–Feb;13(1):77–82 (56 ref.)

Tumor angiogenesis: biology and therapeutic prospects. Harris SR, et al. **In Vivo** 1998 Nov–Dec;12(6):563–70 (111 ref.)

For the clinical application of thermochemotherapy given at mild temperatures. Urano M, et al. **Int J Hyperthermia** 1999 Mar–Apr;15(2):79–107 (101 ref.)

Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Golab J, et al. **Int J Mol Med** 1999 May;3(5):537–44 (83 ref.)

Lymph nodes and human tumors (review). Lores B, et al. **Int J Mol Med** 1998 Apr;1(4):729–33 (51 ref.)

Application of preformed hammerhead ribozymes in the gene therapy of cancer (review). Sioud M. **Int J Mol Med** 1999 Apr;3(4):381–4 (384 ref.)

Truth telling and palliative medicine. Kashiwagi T. **Intern Med** 1999 Feb;38(2):190–2 (4 ref.)

Therapy for Kaposi's sarcoma: recent advances and experimental approaches. Yarchoan R. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S66–73 (82 ref.)

Therapeutic benefits of qigong exercises in combination with drugs. Sancier KM. **J Altern Complement Med** 1999 Aug; 5(4):383–9 (38 ref.)

High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. Prasad KN, et al. **J Am Coll Nutr** 1999 Feb; 18(1):13–25 (71 ref.)

In pursuit of new developments for gene therapy of human diseases. Palù G, et al. **J Biotechnol** 1999 Feb 5;68(1):1–13 (45 ref.)

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. Liang R, et al. **J Clin Oncol** 1999 Jan; 17(1):394–8 (50 ref.)

Delivery of molecular and cellular medicine to solid tumors. Jain RK. **J Controlled Release** 1998 Apr 30;53(1–3):49–67 (151 ref.)

Peripheral blood stem cell mobilization for high-dose chemotherapy. Demirer T, et al. **J Hematother** 1999 Apr; 8(2):103–13 (103 ref.)

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. Andreesen R, et al. **J Leukoc Biol** 1998 Oct;64(4):419–26 (82 ref.)

Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. Apostolopoulos V, et al. **J Mol Med** 1999 May;77(5):427–36 (57 ref.)

Potential applications of PET imaging in developing novel cancer therapies. Hustinx R, et al. **J Nucl Med** 1999 Jun; 40(6):995–1002 (73 ref.)

Energy healing with women and children. Starn JR. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):576–84 (48 ref.)

The interaction between family physicians and palliative care consultants in the delivery of palliative care: clinical and educational issues. Brenneis C, et al. **J Palliat Care** 1998 Autumn;14(3):58–61 (21 ref.)

New approaches to cancer therapies. Fähraeus R, et al. **J Pathol** 1999 Jan;187(1):138–46 (90 ref.)

Perspective: cancer care and the new biology. Kaye SB. **J Pathol** 1999 Jan;187(1):4–7 (7 ref.)

Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer [see comments] McQuaid EL, et al. **J Pediatr Psychol** 1999 Aug;24(4):305–28 (63 ref.) Comment in: J Pediatr Psychol 1999 Aug;24(4):333–4.

Lipoplexes and tumours. A review. Dass CR, et al. **J Pharm Pharmacol** 1999 Jul;51(7):755–70 (198 ref.)

Hypnotically induced control of nausea: a preliminary report. Renouf D. **J Psychosom Res** 1998 Sep;45(3):295–6 (13 ref.)

The management of cancer in the elderly. Ashkanani F, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):2–10 (65 ref.)

Palliative medicine: is it really specialist territory? [see comments] Fordham S, et al. **J R Soc Med** 1998 Nov; 91(11):568–72 (78 ref.) Comment in: J R Soc Med 1998 Nov;91(11):563–4. Comment in: J R Soc Med 1999 Jan;92(1):53. Comment in: J R Soc Med 1999 Jan;92(1):54. Comment in: J R Soc Med 1999 Feb;92(2):100. Comment in: J R Soc Med 1999 Feb;92(2):100–1. Comment in: J R Soc Med 1999 Feb;92(2):101. Comment in: J R Soc Med 1999 Mar;92(3):157. Comment in: J R Soc Med 1999 May;92(5):269.

The potential for monocyte-mediated immunotherapy during infection and malignancy--Part II: in vivo activation by exogenous cytokines and clinical applications. Williams MA, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):207–30 (123 ref.)

The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms. Williams MA, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):1–23 (123 ref.)

Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Tarte K, et al. **Leukemia** 1999 May; 13(5):653–63 (127 ref.)

Does maximizing programmed cell death necessarily yield an optimum clinical advantage? Ou D, et al. **Med Hypotheses** 1999 Mar;52(3):235–8 (35 ref.)

Reproductive aspects of cancer treatment: an update. Kovacs GT, et al. **Med J Aust** 1999 May 17;170(10):495–7 (19 ref.)

Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer. Fleckenstein G, et al. **Med Oncol** 1998 Dec;15(4):212–21 (65 ref.)

Cancer gene and immunotherapy: recent developments. Jantscheff P, et al. **Med Oncol** 1999 Jul;16(2):78–85 (112 ref.)

New p53-based anti-cancer therapeutic strategies. Wiman KG. **Med Oncol** 1998 Dec;15(4):222–8 (49 ref.)

On cancer control and the adolescent. Barr RD. **Med Pediatr Oncol** 1999 Jun;32(6):404–10 (86 ref.)

Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Mulder JE. **Med Pediatr Oncol** 1999 Jul;33(1):46–52 (59 ref.)

The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Agrawal B, et al. **Mol Med Today** 1998 Sep;4(9):397–403 (48 ref.)

Why are dendritic cells central to cancer immunotherapy? Colaco CA. **Mol Med Today** 1999 Jan;5(1):14–7 (36 ref.)

Heat shock protein--peptide complexes as immunotherapy for human cancer. Przepiorka D, et al. **Mol Med Today** 1998 Nov;4(11):478–84 (48 ref.)

Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Romero P, et al. **Mol Med Today** 1998 Jul;4(7):305–12 (48 ref.)

Improving enzymes for cancer gene therapy. Encell LP, et al. **Nat Biotechnol** 1999 Feb;17(2):143–7 (55 ref.)

Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy. Kleibl K, et al. **Neoplasma** 1998;45(4):181–6 (33 ref.)

188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Iznaga-Escobar N. **Nucl Med Biol** 1998 Jul;25(5):441–7 (58 ref.)

Past and present herbs used to treat cancer: medicine, magic, or poison? Montbriand MJ. **Oncol Nurs Forum** 1999 Jan–Feb;26(1):49–60; quiz 61–2 (53 ref.)

Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Kos J, et al. **Oncol Rep** 1998 Nov–Dec; 5(6):1349–61 (145 ref.)

Human chorionic gonadotropin as a target for cancer vaccines. Triozzi PL, et al. **Oncol Rep** 1999 Jan–Feb; 6(1):7–17 (98 ref.)

Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? Villunger A, et al. **Oncol Res** 1998; 10(11–12):541–50 (189 ref.)

Long-term survivors of childhood cancer: the late effects of therapy. Schwartz CL. **Oncologist** 1999;4(1):45–54 (67 ref.)

Possible interactions between dietary antioxidants and chemotherapy. Labriola D, et al. **Oncology (Huntingt)** 1999 Jul;13(7):1003–8; discussion 1008, 1011–2 (47 ref.)

Total-body irradiation for bone marrow transplantation. Lawton C. **Oncology (Huntingt)** 1999 Jul;13(7):972, 975–8, 981–2 (1 ref.)

Oral mucositis in myelosuppressive cancer therapy. Epstein JB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):273–6 (12 ref.)

Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Hearn J, et al. **Palliat Med** 1998 Sep;12(5):317–32 (61 ref.)

Management and long-term complications of pediatric cancer. Grossi M. **Pediatr Clin North Am** 1998 Dec; 45(6):1637–58 (213 ref.)

Impediments to successful immunotherapy. Hersey P. **Pharmacol Ther** 1999 Feb;81(2):111–9 (102 ref.)

Tossing monkey wrenches into the clock: new ways of treating cancer [comment] Lees JA, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4221–3 (18 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4325–9.

Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Elson CE, et al. **Proc Soc Exp Biol Med** 1999 Sep;221(4):294–311 (315 ref.)

Complications of cancer therapy in children: a radiologist's guide. Parisi MT, et al. **Radiographics** 1999 Mar–Apr; 19(2):283–97 (48 ref.)

Skeletal complications in pediatric oncology patients. Roebuck DJ. **Radiographics** 1999 Jul–Aug;19(4):873–85 (50 ref.)

Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Amigorena S. **Res Immunol** 1998 Sep–Oct; 149(7–8):661–2 (5 ref.)

Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Leroy P, et al. **Res Immunol** 1998 Sep–Oct;149(7–8):681–4 (18 ref.)

Autologous human macrophages and anti-tumour cell therapy. Lesimple T, et al. **Res Immunol** 1998 Sep–Oct; 149(7–8):663–71 (70 ref.)

Could p53 be a target for therapeutic suppression? Komarova EA, et al. **Semin Cancer Biol** 1998;8(5):389–400 (92 ref.)

Amifostine and combined-modality therapeutic approaches. Mehta MP. **Semin Oncol** 1999 Apr;26(2 Suppl 7):95–101 (32 ref.)

Active immunization against cancer cells: impediments and advances. Velders MP, et al. **Semin Oncol** 1998 Dec; 25(6):697–706 (75 ref.)

An overview of monoclonal antibody therapy of cancer. Weiner LM. **Semin Oncol** 1999 Aug;26(4 Suppl 12):41–50 (43 ref.)

Challenge of supportive surgical care in pediatric oncology. Dillon PW. **Semin Surg Oncol** 1999 Mar;16(2):193–9 (68 ref.)

The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation. Haire WD. **Semin Thromb Hemost** 1999;25(2):223–37 (93 ref.)

Principles of feeding cancer patients via enteral or parenteral nutrition during radiotherapy. Fietkau R. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:47–51 (18 ref.)

Health economics of care for patients with cancer and intractable disease in Japan. Hisashige A, et al. **Support Care Cancer** 1998 Nov;6(6):503–10 (39 ref.)

Palliative care in the University Hospital Lausanne: from consultations to an integrated regional program. Mazzocato C, et al. **Support Care Cancer** 1999 Jul;7(4):221–3 (3 ref.)

Current practices for management of oral mucositis in cancer patients. Raber-Durlacher JE. **Support Care Cancer** 1999 Mar;7(2):71–4 (23 ref.)

The treatment of malignancy by hyperthermia. Christophi C, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):83–90 (93 ref.)

Beyond the laparoscope: minimally invasive surgery in the new millennium. Rattner DW. **Surgery** 1999 Jan; 125(1):19–22 (8 ref.)

Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. Byrne J. **Teratology** 1999 Apr; 59(4):210–5 (30 ref.)

Therapeutic apheresis in malignancy [editorial] Nand S. **Ther Apher** 1997 Feb;1(1):29–32 (25 ref.)

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Reiter Y, et al. **Trends Biotechnol** 1998 Dec;16(12):513–20 (54 ref.)

One hundred years of cancer immunotherapy: a critical appraisal. Ben-Efraim S. **Tumour Biol** 1999 Jan–Feb; 20(1):1–24 (185 ref.)

Ultrasound technology for hyperthermia. Diederich CJ, et al. **Ultrasound Med Biol** 1999 Jul;25(6):871–87 (138 ref.)

Gene and cell transfer for specific immunotherapy. Brenner MK, et al. **Vox Sang** 1998;74 Suppl 2:87–90 (20 ref.)

Mutated Ras peptides as vaccines in immunotherapy of cancer. Gjertsen MK, et al. **Vox Sang** 1998;74 Suppl 2:489–95 (49 ref.)

Artificial nutrition in cancer patients: which route, what composition? Bozzetti F, et al. **World J Surg** 1999 Jun; 23(6):577–83 (50 ref.)

[Late sequelae of oncologic treatment in children] Heikens J, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2191–5 (49 ref.) (Eng. Abstr.) **(Dut)**

[High-dose chemotherapy with stem cell support for solid tumors in adults] Rodenhuis S, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):731–8 (32 ref.) (Eng. Abstr.) **(Dut)**

[Hyperthermia in combination with radiotherapy (see comments)] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):76–80 (21 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):75–8. **(Dut)**

[Waiting for the break through: a few tentative scenarios for cancer prevention and treatment in the coming decades] De Schryver A. **Verh K Acad Geneeskd Belg** 1999; 61(4):467–86; discussion 486–7 (33 ref.) (Eng. Abstr.) **(Dut)**

[Use of antibodies or their fragments for the treatment of tumors] Dpuillard JY, et al. **Bull Cancer** 1998 Nov; 85(11):951–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Extracellular proteases of stromal origin: contribution to tumor progression and therapeutic perspectives] Rio MC, et al. **C R Seances Soc Biol Fil** 1998;192(2):253–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Fertility in women after cancer therapy] Marmor D. **Contracept Fertil Sex** 1999 Jun;27(6):417–22 (54 ref.) (Eng. Abstr.) **(Fre)**

[Intracellular antibodies: a new therapeutic concept for virus infections and neoplasms] zu Putlitz J, et al. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):357–60 (0 ref.) **(Ger)**

[Unconventional, alternative therapy methods in oncology] Kaiser G, et al. **Internist (Berl)** 1998 Nov;39(11):1159–67 (50 ref.) **(Ger)**

[Immunotherapy: cytokines and tumor cell vaccines] Pezzutto A. **Internist (Berl)** 1998 Nov;39(11):1131–8 (46 ref.) **(Ger)**

[Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia] Monnerat C, et al. **Schweiz Rundsch Med Prax** 1999 Jan 28;88(5):178–88 (93 ref.) (Eng. Abstr.) **(Ger)**

[Achieving self-destruction of cancer cells] Müller H. **Schweiz Rundsch Med Prax** 1999 Feb 25;88(9):374–6 (0 ref.) **(Ger)**

[New trends in the follow-up of malignant diseases] Sauer

H. **Versicherungsmedizin** 1999 Mar 1;51(1):18–23 (31 ref.) (Eng. Abstr.) **(Ger)**

[Parenteral and enteral nutrition in palliative medicine] Herrmann A, et al. **Zentralbl Chir** 1999;124(7):573–84 (24 ref.) (Eng. Abstr.) **(Ger)**

[Total parenteral nutrition in cancer patients] Cuocolo R, et al. **Minerva Anestesiol** 1981 Jul;47(7):351–4 (5 ref.) **(Ita)**

[Diagnostic imaging in the assessment of the therapeutic response in oncology] Ferrozzi F, et al. **Radiol Med (Torino)** 1999 Jan–Feb;97(1–2):8–18 (58 ref.) **(Ita)**

[Recent advances of supportive therapy for cancer patients] Ariyoshi Y. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:60–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Progress in palliative medicine] Ishitani K. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:70–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The advances of gene therapy in this quarter century] Ito Y, et al. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:51–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress in biological therapies for cancer] Saji S, et al. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:32–41 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Practice guidelines in western countries] Sasako M, et al. **Gan To Kagaku Ryoho** 1999 Apr;26(5):602–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Patients also desire standard therapies] Tanabe I. **Gan To Kagaku Ryoho** 1999 Apr;26(5):614–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

[New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes] Kawakami Y. **Nippon Naika Gakkai Zasshi** 1998 Dec 10; 87(12):2536–44 (12 ref.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 5. Solid tumor] Shimazaki C, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1488–94 (13 ref.) **(Jpn)**

[Therapy-related myelodysplastic syndrome (t-MDS)] Yoshida Y. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):206–8 (8 ref.) **(Jpn)**

[Apoptosis—new possibilities in the treatment of cancer (see comments)] Lømo J. **Tidsskr Nor Laegeforen** 1998 Sep 20; 118(22):3436–41 (44 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1998 Dec 10;118(30):4790. **(Nor)**

[Flow cytometry: diagnostic, therapeutic and prognostic usefulness in solid tumors] Iwaszkiewicz-Pawłowska A, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):104–6 (30 ref.) (Eng. Abstr.) **(Pol)**

[Clinical application of photodynamic method to the treatment of malignancies. Part II (editorial)] Domaniecki J, et al. **Wiad Lek** 1999;52(1–2):4–10 (20 ref.) (Eng. Abstr.) **(Pol)**

[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep–Oct;61(5):81–4 (51 ref.) **(Rus)**

[The immunodiagnosis and immunotherapy of tumors] Kadagidze ZG. **Vestn Ross Akad Med Nauk** 1999;(5):19–22 (14 ref.) (Eng. Abstr.) **(Rus)**

[Vaccination therapy for malignant tumors] Moiseenko VM, et al. **Vopr Onkol** 1999;45(3):327–32 (11 ref.) **(Rus)**

[Scientific evidence-based cancer treatments] Expósito Hernández J, et al. **Med Clin (Barc)** 1999 Apr 10; 112(12):465–9 (43 ref.) **(Spa)**

[Cancer-related pain requires targeted treatment. Analgesics are not the only therapeutic alternative] Strang P. **Lakartidningen** 1999 Jan 27;96(4):318–21 (26 ref.) (Eng. Abstr.) **(Swe)**

[Neo-adjuvant chemotherapy of malignant tumors (based on the materials presented on the 9th congress of the oncologists of the Ukraine)] Savran VR, et al. **Klin Khir** 1998;(5):36–40 (50 ref.) **(Ukr)**

ULTRASONOGRAPHY

Electron microscopy in tumour diagnosis: continuing to complement other diagnostic techniques. Eyden B. **Histopathology** 1999 Aug;35(2):102–8 (46 ref.)

Electron microscopy for tumour diagnosis: is it redundant? Mierau GW. **Histopathology** 1999 Aug;35(2):99–101 (17 ref.)

[Computer-assisted quantitative evaluation method of color Doppler images in tumor diagnosis] Huber S. **Radiologe** 1998 Oct;38(10):867–71 (31 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Diagnostic electron microscopy of neoplasms [editorial] Dardick I, et al. **Hum Pathol** 1998 Dec;29(12):1335–8 (19 ref.)

Special techniques in diagnostic electron microscopy. Howell DN, et al. **Hum Pathol** 1998 Dec;29(12):1339–46 (74 ref.)

Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells. Lavie Y, et al. **Lipids** 1999;34 Suppl:S57–63 (63 ref.)

URINE

Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies. Halliwell B. **Free Radic Res** 1998 Dec;29(6):469–86 (142 ref.)

Urinary nucleosides. Schram KH. **Mass Spectrom Rev** 1998 May–Jun;17(3):131–251 (112 ref.)

VETERINARY

Interventional nutrition for the cancer patient. Ogilvie GK. **Clin Tech Small Anim Pract** 1998 Nov;13(4):224–31 (78 ref.)

Epidemiologic studies of risk factors for cancer in pet dogs. Kelsey JL, et al. **Epidemiol Rev** 1998;20(2):204–17 (96 ref.)

Cachexia and nutritional issues in animals with cancer. Howard J, et al. **J Am Vet Med Assoc** 1999 Mar 1; 214(5):632–7 (74 ref.)

Epizootics of cancer in fish associated with genotoxins in sediment and water. Baumann PC. **Mutat Res** 1998 Nov; 411(3):227–33 (48 ref.)

Radiation therapy in the horse. Théon AP. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):673–88, viii (16 ref.)

VIROLOGY

AIDS-associated malignancies: research perspectives. Feigal EG. **Biochim Biophys Acta** 1999 Jan 29;1423(1):C1–9 (72 ref.)

Recent advances in the management of viral infections. Wingard JR. **Cancer Treat Res** 1998;96:183–200 (119 ref.)

SV40 as a putative human commensal. Levine A, et al. **Dev Biol Stand** 1998;94:245–69 (32 ref.)

Simian virus 40 footprints in normal human tissues, brain and bone tumours of different histotypes. Martini F, et al. **Dev Biol Stand** 1998;94:55–66 (30 ref.)

Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer--a review of the epidemiological evidence. Strickler HD, et al. **Dev Biol Stand** 1998;94:235–44 (26 ref.)

Polyomaviruses and human tumors: a brief review of current concepts and interpretations. Lednicky JA, et al. **Front Biosci** 1999 Feb 15;4:D153–64 (168 ref.)

Cell and molecular biology of simian virus 40: implications for human infections and disease. Butel JS, et al. **J Natl Cancer Inst** 1999 Jan 20;91(2):119–34 (134 ref.)

Yohei Ito Memorial Lecture: Papillomaviruses in human cancers. zur Hausen H. **Leukemia** 1999 Jan;13(1):1–5 (40 ref.)

Convicting a human tumor virus: guilt by association? Blaho JA, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7619–21 (31 ref.)

Viruses and human cancer. Eckhart W. **Sci Prog** 1998;81 (Pt 4):315–28 (11 ref.)

[Disturbance of the normal cell cycle by T antigens of SV40 viruses and JC cause some tumors] Kryńska B, et al. **Postepy Hig Med Dosw** 1998;52(3):237–57 (78 ref.) (Eng. Abstr.) **(Pol)**

NEOPLASMS, ADIPOSE TISSUE

PATHOLOGY

Lipoblastoma and liposarcoma in children: an analysis of 9 cases and a review of the literature. Miller GG, et al. **Can J Surg** 1998 Dec;41(6):455–8 (16 ref.)

[Tumors and other lesions composed of adipose tissue. Integrated diagnostic imaging] Ferrozzi F, et al. **Radiol Med (Torino)** 1998 Sep;96(3):168–77 (57 ref.) **(Ita)**

RADIOGRAPHY

[Tumors and other lesions composed of adipose tissue. Integrated diagnostic imaging] Ferrozzi F, et al. **Radiol Med (Torino)** 1998 Sep;96(3):168–77 (57 ref.) **(Ita)**

NEOPLASMS, BASAL CELL

DIAGNOSIS

Trichofolliculoma of the upper lip: report of a case. Mizutani H, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):135–6 (10 ref.)

PATHOLOGY

Malignant transformation of a giant proliferating trichilemmal tumor of the scalp: patient report and literature review. Markal N, et al. **Ann Plast Surg** 1998 Sep;41(3):314–6 (18 ref.)

NEOPLASMS, BREAST, MALE see **BREAST NEOPLASMS, MALE**

NEOPLASMS, CONNECTIVE AND SOFT TISSUE

DIAGNOSIS

Evaluation of soft-tissue tumors. Springfield D. **Instr Course Lect** 1999;48:617–9 (1 ref.)

Orthopaedic oncology for the nononcologist orthopaedist: introduction and common errors to avoid. Ward WG Sr. **Instr Course Lect** 1999;48:577–86 (10 ref.)

PATHOLOGY

Fine needle aspiration of soft-tissue lesions. Abdul-Karim FW, et al. **Clin Lab Med** 1998 Sep;18(3):507–40, vi (71 ref.)

Biopsy. Aboulafia AJ. **Instr Course Lect** 1999;48:587–90 (6 ref.)

Nuchal fibrocartilaginous pseudotumor: a clinicopathologic study of five cases and review of the literature. Laskin WB, et al. **Mod Pathol** 1999 Jul;12(7):663–8 (24 ref.)

SURGERY

Appropriate follow-up of orthopaedic oncology patients. Letson GD, et al. **Instr Course Lect** 1999;48:603–6 (10 ref.)

THERAPY

Treatment options for orthopaedic oncologic entities. Zehr RJ. **Instr Course Lect** 1999;48:591–602 (14 ref.)

NEOPLASMS, CONNECTIVE TISSUE

see related
SOFT TISSUE NEOPLASMS

NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS

GENETICS

Molecular genetics of ovarian carcinomas. Diebold J. **Histol Histopathol** 1999 Jan;14(1):269–77 (79 ref.)

PATHOLOGY

A clinicopathologic and immunohistochemical study of 22 intraductal papillary mucinous neoplasms of the pancreas, with a review of the literature. Paal E, et al. **Mod Pathol** 1999 May;12(5):518–28 (79 ref.)

NEOPLASMS, DENTAL TISSUE see **ODONTOGENIC TUMORS**

NEOPLASMS, EMBRYONAL AND MIXED see **NEOPLASMS, GERM CELL AND EMBRYONAL**

NEOPLASMS, EXPERIMENTAL

see related
NEOPLASM TRANSPLANTATION
TUMOR VIRUS INFECTIONS

[Value of human colonic cancer models by surgical cecal implantation in nude mice] Pocard M, et al. **Ann Chir** 1999; 53(3):227–32 (42 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Vascular targeting with phage peptide libraries. Pasqualini R. **Q J Nucl Med** 1999 Jun;43(2):159–62 (43 ref.)

[Tumor angiogenesis] Bussolino F. **Recenti Prog Med** 1999 Jan;90(1):28–36 (43 ref.) (Eng. Abstr.) **(Ita)**

[The chronic reduction of tissue perfusion and neoplasm promotion (letter) (published erratum appears in Recenti Prog Med 1999 Apr;90(4):216)] Malossi M, et al. **Recenti Prog Med** 1999 Jan;90(1):46–8 (32 ref.) **(Ita)**

[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep–Oct;61(5):81–4 (51 ref.) **(Rus)**

CHEMICALLY INDUCED

Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis. Gonzalez FJ, et al. **Cancer Lett** 1999 Sep 1;143(2):199–204 (43 ref.)

Short- and intermediate-term carcinogenicity testing--a review. Part 2: available experimental models. Enzmann H, et al. **Food Chem Toxicol** 1998 Nov;36(11):997–1013 (176 ref.)

A cancer risk model with adaptive repair [see comments] Downs T, et al. **Hum Exp Toxicol** 1998 Dec; 17(12):697–700; discussion 701–4, 711–8 (3 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705–7; discussion 716–8.

U-shaped dose-response curves for carcinogens [comment] Portier CJ, et al. **Hum Exp Toxicol** 1998 Dec;17(12):705–7; discussion 716–8 (10 ref.) Comment on: Hum Exp Toxicol 1998 Dec;17(12):683–90;discussion 701–4, 708–18. Comment on: Hum Exp Toxicol 1998 Dec;17(12):691–6; discussion 701–4, 708–18. Comment on: Hum Exp Toxicol 1998 Dec;17(12):697–700; discussion 701–4, 711–8.

Acetaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:319–35 (71 ref.)

Benzoyl peroxide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:345–58 (46 ref.)

n-Butyl acrylate. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:359–66 (25 ref.)

gamma-Butyrolactone. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:367–82 (57 ref.)

Caprolactam. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:383–400 (90 ref.)

Carbon tetrachloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:401–32 (160 ref.)

Catechol. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:433–51 (84 ref.)

alpha-Chlorinated toluenes and benzoyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt

2:453-77 (83 ref.)
1,2-Dibromo-3-chloropropane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:479-500 (97 ref.)
1,2-Dichloroethane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:501-29 (107 ref.)
Dimethylcarbamoyl chloride.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:531-43 (51 ref.)
Epichlorohydrin.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:603-28 (136 ref.)
1,4-Dioxane. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 2:589-602 (43 ref.)
Dimethyl sulfate.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:575-88 (55 ref.)
Dimethylformamide.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:545-74 (120 ref.)
Toluene. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:829-64 (144 ref.)
Toluene diisocyanates.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:865-79 (45 ref.)
1,1,1-Trichloroethane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:881-903 (93 ref.)
Tris(2,3-dibromopropyl) phosphate.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:905-21 (53 ref.)
Vinyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:923-8 (17 ref.)
Methyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:721-35 (64 ref.)
Hydrogen peroxide.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:671-89 (94 ref.)
1,2-Epoxybutane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:629-40 (46 ref.)
Ethylene dibromide (1,2-dibromoethane).
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:641-69 (126 ref.)
Polychlorophenols and their sodium salts.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:769-816 (154 ref.)
1,1,2,2-Tetrachloroethane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:817-27 (39 ref.)
Phenol. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:749-68 (83 ref.)
Methyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:737-47 (38 ref.)
1,3-Butadiene. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 1:109-225 (348 ref.)
Chloroprene. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 1:227-50 (87 ref.)
Dichloromethane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 1:251-315 (253 ref.)
Acrylonitrile. **IARC Monogr Eval Carcinog Risks Hum** 1999; 71 Pt 1:43-108 (282 ref.)
The use of short-and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. Consensus report. **IARC Sci Publ** 1999;(146):1-18 (2 ref.)
Use of non-mammalian species in bioassays for carcinogenicity. Bunton TE. **IARC Sci Publ** 1999; (146):151-84 (195 ref.)
Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals. Shirai T, et al.
IARC Sci Publ 1999;(146):251-72 (71 ref.)
Short-and medium-term carcinogenicity tests: simple initiation-promotion assay systems. Tsuda H, et al.
IARC Sci Publ 1999;(146):203-49 (290 ref.)
Chemically induced preneoplastic lesions in rodents as indicators of carcinogenic activity. Williams GM.
IARC Sci Publ 1999;(146):185-202 (216 ref.)
Alkylation carcinogenesis in mice with altered levels of DNA repair methyltransferase. Sekiguchi M, et al.
Prog Exp Tumor Res 1999;35:25-36 (46 ref.)
Nitrobenzene potential human cancer risk based on animal studies. Holder JW. **Toxicol Ind Health** 1999 Aug; 15(5):458-63 (29 ref.)
Molecular aspects of neoplasia of Syrian hamster cells transformed in vitro by chemical carcinogens. Notario V, et al. **Toxicol Lett** 1998 Aug;96-97:221-30 (29 ref.)
Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Mitsumori K, et al. **Toxicol Pathol** 1998 Jul-Aug;26(4):520-31 (50 ref.)
Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing. van Steeg H, et al.
Toxicol Pathol 1998 Nov-Dec;26(6):742-9 (63 ref.)
[Molecular mechanisms of chemically induced carcinogenesis] Palut D, et al. **Rocz Panstw Zakl Hig** 1998; 49(1):35-54 (70 ref.) (Eng. Abstr.) **(Pol)**

DIET THERAPY

Comparative anticancer effects of vaccination and dietary factors on experimentally-induced cancers. Zusman I. **In Vivo** 1998 Nov-Dec;12(6):675-89 (186 ref.)

DRUG THERAPY

Making the most of rodent tumour systems in cancer drug discovery. Bibby MC. **Br J Cancer** 1999 Apr; 79(11-12):1633-40 (86 ref.)
Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Killion JJ, et al.
Cancer Metastasis Rev 1998-99;17(3):279-84 (31 ref.)
Pre-clinical development of farnesyltransferase inhibitors. Lobell RB, et al. **Cancer Metastasis Rev** 1998 Jun; 17(2):203-10 (54 ref.)
Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Mayer LD. **Cancer Metastasis Rev** 1998 Jun;17(2):211-8 (32 ref.)
Combination of taxanes with radiation: preclinical studies. Milas L, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):12-26 (83 ref.)
Heparin and cancer. Zacharski LR, et al.
Thromb Haemost 1998 Jul;80(1):10-23 (203 ref.)
Tumor models: assessing toxicity in efficacy studies. Arp LH. **Toxicol Pathol** 1999 Jan-Feb;27(1):121-2 (7 ref.)

ENZYMOLOGY

Telomerase activity in experimental animal tumors. Tsujiuchi T, et al. **Exp Toxicol Pathol** 1998 Sep;50(4-6):371-4 (16 ref.)
Role of telomerase in cellular proliferation and cancer. Holt SE, et al. **J Cell Physiol** 1999 Jul;180(1):10-8 (104 ref.)
Alkylation carcinogenesis in mice with altered levels of DNA repair methyltransferase. Sekiguchi M, et al.
Prog Exp Tumor Res 1999;35:25-36 (46 ref.)

ETIOLOGY

Influence of characteristics of inhaled fibres on development of tumours in the rat lung. Miller BG, et al.
Ann Occup Hyg 1999 Apr;43(3):167-79 (39 ref.)

GENETICS

Cancer from the outside, aging from the inside: mouse models to study the consequences of defective nucleotide excision repair. de Boer J, et al. **Biochimie** 1999 Jan-Feb; 81(1-2):127-37 (52 ref.)
Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis. Gonzalez FJ, et al. **Cancer Lett** 1999 Sep 1;143(2):199-204 (43 ref.)
Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Mayer LD. **Cancer Metastasis Rev** 1998 Jun;17(2):211-8 (32 ref.)
For better or worse? Telomerase inhibition and cancer. de Lange T, et al. **Cell** 1999 Aug 6;98(3):273-5 (21 ref.)
A survey of web resources for basic cancer genetics research. Bult CJ, et al. **Genome Res** 1999 May;9(5):397-408 (17 ref.)
Mutation patterns in non-ras oncogenes and tumour suppressor genes in experimentally induced tumours. Perantoni AO, et al. **IARC Sci Publ** 1999;(146):87-122 (204 ref.)
Mutations in ras genes in experimental tumours of rodents. Sills RC, et al. **IARC Sci Publ** 1999;(146):55-86 (159 ref.)
Genetically altered mouse models for identifying carcinogens. Tennant RW, et al. **IARC Sci Publ** 1999; (146):123-50 (85 ref.)
Mutation in mammalian cells in vitro and in vivo as indicators of exposure to carcinogens. van Zeeland AA, et al.
IARC Sci Publ 1999;(146):355-65 (48 ref.)
Insights into cancer from transgenic mouse models. Macleod KF, et al. **J Pathol** 1999 Jan;187(1):43-60 (232 ref.)
Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Otteneder M, et al. **Mutat Res** 1999 Mar 8;424(1-2):237-47 (38 ref.)
Estimation of mutation frequencies in normal mammalian cells and the development of cancer. Turker MS.
Semin Cancer Biol 1998 Dec;8(6):407-19 (141 ref.)
Molecular aspects of neoplasia of Syrian hamster cells transformed in vitro by chemical carcinogens. Notario V, et al. **Toxicol Lett** 1998 Aug;96-97:221-30 (29 ref.)

IMMUNOLOGY

Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Ganss R, et al.
Immunol Rev 1999 Jun;169:263-72 (62 ref.)

METABOLISM

Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Burke F. **Cytokines Cell Mol Ther** 1999 Mar;5(1):51-61 (182 ref.)

PATHOLOGY

Multicellular spheroids as an in vitro tumor model. Hamilton G. **Cancer Lett** 1998 Sep 11;131(1):29-34 (40 ref.)
Chemically induced preneoplastic lesions in rodents as indicators of carcinogenic activity. Williams GM.
IARC Sci Publ 1999;(146):185-202 (216 ref.)
Ageing and the mechanisms of carcinogenesis: some practical implications. Anisimov VN. **J Exp Clin Cancer Res** 1998 Sep;17(3):263-8 (76 ref.)

PREVENTION & CONTROL

The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Kennedy AR. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1406S-1412S (75 ref.)
Prevention and therapy of cancer by dietary monoterpenes. Crowell PL. **J Nutr** 1999 Mar;129(3):775S-778S (64 ref.)
Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. Hecht SS. **J Nutr** 1999 Mar; 129(3):768S-774S (54 ref.)
Inhibitory effect of green and black tea on tumor growth. Conney AH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):229-33 (11 ref.)
Preclinical efficacy studies of green and black tea extracts. Steele VE, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):210-2 (5 ref.)
Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Yang CS, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):213-7 (31 ref.)
[Adaptogens as agents for prophylactic oncology] Bocharova OA. **Vestn Ross Akad Med Nauk** 1999;(5):49-53 (76 ref.) (Eng. Abstr.) **(Rus)**

RADIOTHERAPY

Relative biological effectiveness of proton beams in clinical therapy. Gerweck LE, et al. **Radiother Oncol** 1999 Feb; 50(2):135-42 (32 ref.)
Combination of taxanes with radiation: preclinical studies. Milas L, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):12-26 (83 ref.)

THERAPY

Murine metastatic tumour models for cancer gene therapy research. Kong HL. **Ann Acad Med Singapore** 1999 Jan; 28(1):112-9 (93 ref.)
Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Bernsen MR, et al. **Cancer Treat Rev** 1999 Apr;25(2):73-82 (123 ref.)
Therapeutic potentials of angiostatin in the treatment of cancer. Cao Y. **Haematologica** 1999 Jul;84(7):643-50 (45 ref.)
Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Xiang J. **Hum Antibodies** 1999;9(1):23-36 (125 ref.)
Comparative anticancer effects of vaccination and dietary factors on experimentally-induced cancers. Zusman I.
In Vivo 1998 Nov-Dec;12(6):675-89 (186 ref.)
Prevention and therapy of cancer by dietary monoterpenes. Crowell PL. **J Nutr** 1999 Mar;129(3):775S-778S (64 ref.)
[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):81-4 (51 ref.) **(Rus)**

VIROLOGY

Experimental tumour induction by SV40 transformed cells. Cook JL, et al. **Dev Biol Stand** 1998;94:303-9 (15 ref.)

NEOPLASMS, FIBROUS TISSUE

METABOLISM

Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia. Guglielmi A, et al.
J Hepatobiliary Pancreat Surg 1998;5(2):212-6 (17 ref.)

PATHOLOGY

Parasagittal solitary fibrous tumor of the meninges. Case report and review of the literature. Nikas DC, et al.
Acta Neurochir (Wien) 1999;141(3):307-13 (57 ref.)

NEOPLASMS, GERM CELL AND EMBRYONAL

DIAGNOSIS

Pineal region tumours in childhood. A 30-year experience. Drummond KJ, et al. **Childs Nerv Syst** 1999 Mar; 15(2-3):119-26; discussion 127 (23 ref.)
Dysembryoplastic neuroepithelial tumour. Tatke M, et al. **Childs Nerv Syst** 1998 Jul;14(7):293-6 (10 ref.)
[Bilateral testicular germ cell cancer] Lalowicz I.
Pol Merkuriusz Lek 1998 Sep;5(27):155-6 (18 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

[Molecular pathogenesis and prognostic factors in testicular tumor] Heidenreich A, et al. **Urologe A** 1998 Nov; 37(6):593-608 (113 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Sialoblastoma: clinicopathological/immunohistochemical study. Brandwein M, et al. **Am J Surg Pathol** 1999 Mar; 23(3):342-8 (23 ref.)
Pediatric germ cell tumors: protocol update for pathologists. Perlman EJ, et al. **Pediatr Dev Pathol** 1998 Jul-Aug; 1(4):328-35 (27 ref.)
Germ-cell tumors of the mediastinum. Weidner N.
Semin Diagn Pathol 1999 Feb;16(1):42-50 (47 ref.)

THERAPY

Pineal region tumours in childhood. A 30-year experience. Drummond KJ, et al. **Childs Nerv Syst** 1999 Mar;

15(2–3):119–26; discussion 127 (23 ref.)
[Bilateral testicular germ cell cancer] Lalowicz I. **Pol Merkuriusz Lek** 1998 Sep;5(27):155–6 (18 ref.) (Eng. Abstr.) **(Pol)**

NEOPLASMS, GLANDULAR AND EPITHELIAL

DIAGNOSIS

Lacrimal gland tumors and simulating lesions. Clinicopathologic and MR imaging features. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):219–39, xii (58 ref.)
Solid and papillary epithelial neoplasm of the pancreas, diagnosis by cytology. Crawford BE 2nd. **South Med J** 1998 Oct;91(10):973–7 (44 ref.)
Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Moll R. **Subcell Biochem** 1998; 31:205–62 (239 ref.)

DRUG THERAPY

Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis. Boone CW, et al. **Cancer Surv** 1998; 32:133–47 (40 ref.)

GENETICS

Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Bridge JA, et al. **Am J Surg Pathol** 1999 Feb;23(2):159–65 (30 ref.)
Molecular epidemiology of epithelial tumors. Ambrosone C, et al. **Curr Opin Oncol** 1998 Sep;10(5):467–74 (80 ref.)

METABOLISM

Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Moll R. **Subcell Biochem** 1998; 31:205–62 (239 ref.)

PATHOLOGY

[Epithelial skin tumors. Anatomo-pathological reminders] Verola O. **Ann Chir Plast Esthet** 1998 Aug;43(4):301–10 (2 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Molecular epidemiology of epithelial tumors. Ambrosone C, et al. **Curr Opin Oncol** 1998 Sep;10(5):467–74 (80 ref.)

SURGERY

Pancreatic cancer. Yeo CJ, et al. **Curr Probl Surg** 1999 Feb; 36(2):59–152 (155 ref.)

NEOPLASMS, HORMONE-DEPENDENT

see related
ANTINEOPLASTIC AGENTS, HORMONAL

Hormone replacement therapy and breast cancer [see comments] Pearlstone DB, et al. **Ann Surg Oncol** 1999 Mar; 6(2):208–17 (90 ref.) Comment in: Ann Surg Oncol 1999 Mar;6(2):135–6.
Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. MacKie RM. **Curr Opin Oncol** 1999 Mar;11(2):129–31 (15 ref.)
Malignant prolactinoma: case report and review of the literature. Popadić A, et al. **Surg Neurol** 1999 Jan; 51(1):47–54; discussion 54–5 (29 ref.)

CHEMICALLY INDUCED

[Hormones and cancer: risk-benefit] Sevelda P, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):61–3 (7 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl) ethylenediamine] platinum(II). Gust R, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):261–70 (31 ref.)
Theoretical considerations for the ideal aromatase inhibitor. Dowsett M. **Breast Cancer Res Treat** 1998;49 Suppl 1:S39–44; discussion S73–7 (27 ref.)
Endocrine therapy in pancreatic carcinoma. Yamashita J, et al. **Oncology** 1998 Dec;55 Suppl 1:17–22 (52 ref.)
Chemotherapy in advanced prostate cancer. Beedassy A, et al. **Semin Oncol** 1999 Aug;26(4):428–38 (50 ref.)
Paclitaxel in the treatment of hormone-refractory prostate cancer. Smith DC, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):109–11 (13 ref.)
[Action of SERM and SAS (tibolone) on breast tissue] Gompel A, et al. **Contracept Fertil Sex** 1999 May; 27(5):368–75 (25 ref.) (Eng. Abstr.) **(Fre)**
[The significance of estrogen metabolism for hormone-dependent neoplasms from the clinical-pharmacological viewpoint] Lippert TH, et al. **Arzneimittelforschung** 1999 Aug;49(8):649–62 (122 ref.) (Eng. Abstr.) **(Ger)**
[Endocrine therapy of solid tumors] Possinger K, et al. **Internist (Berl)** 1998 Nov;39(11):1123–30 (74 ref.) **(Ger)**
[Tamoxifen and breast cancer: is everything known already?] Marchetti P, et al. **Tumori** 1998 Nov-Dec;84(6):A1–5 (20 ref.) **(Ita)**
[Antiandrogen withdrawal syndrome] Akimoto S. **Nippon Rinsho** 1998 Aug;56(8):2135–9 (22 ref.) (Eng. Abstr.) **(Jpn)**
[High-dose intravenous diethylstilbestrol diphosphate therapy for hormone refractory prostate cancer] Honda M, et al. **Nippon Rinsho** 1998 Aug;56(8):2145–9 (18 ref.) **(Jpn)**
[Reevaluation and potential therapeutic effects of estrogen therapy to prostate cancer patients] Kato M, et al. **Nippon Rinsho** 1998 Aug;56(8):2140–4 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer] Kawai K, et al. **Nippon Rinsho** 1998 Aug;56(8):2108–13 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy for hormone-refractory prostate cancer] Tsushima T. **Nippon Rinsho** 1998 Aug;56(8):2167–72 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Drug therapy of hormone-dependent tumors] Jelić S, et al. **Srp Arh Celok Lek** 1999 Jan-Feb;127(1-2):54–64 (76 ref.) **(Scc)**

ENZYMOLOGY

Clinical importance of intratumoral aromatase. Miller WR, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S27–32; discussion S33–7 (18 ref.)

EPIDEMIOLOGY

Covariance of breast cancer incidence with smoking-, oestrogen- and diet-related cancers in pre- and postmenopausal women in Sweden. Manjer J, et al. **Med Hypotheses** 1999 Jun;52(6):561–8 (21 ref.)

ETIOLOGY

Growing evidence that several human cancers may originate in utero. Ekbom A. **Semin Cancer Biol** 1998 Aug; 8(4):237–44 (76 ref.)
The epidemiology of prostate cancer part II: the risk factors. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):193–201 (123 ref.)

GENETICS

Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer. Iwase H, et al. **Oncology** 1998 Dec;55 Suppl 1:11–6 (39 ref.)

METABOLISM

Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Goss PE. **Breast Cancer Res Treat** 1998;49 Suppl 1:S59–65; discussion S73–7 (21 ref.)
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Lønning PE. **Breast Cancer Res Treat** 1998;49 Suppl 1:S45–52; discussion S73–7 (49 ref.)
Pharmacological and clinical profile of anastrozole. Lønning PE, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S53–7; discussion S73–7 (26 ref.)
Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Smith IE, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S67–71; discussion S73–7 (18 ref.)
Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Yue W, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S1–7; discussion S33–7 (15 ref.)
Estrogen dependency in uterine endometrial cancers. Fujimoto J, et al. **Oncology** 1998 Dec;55 Suppl 1:53–9 (83 ref.)
Markers of androgen-independent progression of prostatic carcinoma. Daliani D, et al. **Semin Oncol** 1999 Aug; 26(4):399–406 (112 ref.)
The role of the androgen receptor in the development and progression of prostate cancer. Jenster G. **Semin Oncol** 1999 Aug;26(4):407–21 (173 ref.)
Molecular action of androgen in the normal and neoplastic prostate. Kokontis JM, et al. **Vitam Horm** 1999;55:219–307 (560 ref.)
[The significance of estrogen metabolism for hormone-dependent neoplasms from the clinical-pharmacological viewpoint] Lippert TH, et al. **Arzneimittelforschung** 1999 Aug;49(8):649–62 (122 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Steroid hormone receptors in breast cancer management. Osborne CK. **Breast Cancer Res Treat** 1998;51(3):227–38 (76 ref.)
S-phase fraction and breast cancer--a decade of experience. Wenger CR, et al. **Breast Cancer Res Treat** 1998; 51(3):255–65 (84 ref.)
Hormone resistance in prostate cancer. Pilat MJ, et al. **Cancer Metastasis Rev** 1998–99;17(4):373–81 (71 ref.)
Superior vena cava syndrome. Haapoja IS, et al. **Semin Oncol Nurs** 1999 Aug;15(3):183–9 (24 ref.)
[Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast] Nizze H, et al. **Zentralbl Chir** 1998;123 Suppl 5:14–8 (46 ref.) (Eng. Abstr.) **(Ger)**
[A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume] Hachiya T, et al. **Nippon Rinsho** 1998 Aug;56(8):2157–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Are pancreatic tumors hormone dependent?: A case report of unusual, rapidly growing pancreatic tumor during pregnancy, its possible relationship to female sex hormones, and review of the literature. Ganepola GA, et al. **Am Surg** 1999 Feb;65(2):105–11 (18 ref.)
[Development and progression of prostate cancer in relation with androgen dependency] Shimazaki J. **Nippon Rinsho** 1998 Aug;56(8):1953–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Theoretical considerations for the ideal aromatase inhibitor. Dowsett M. **Breast Cancer Res Treat** 1998;49 Suppl 1:S39–44; discussion S73–7 (27 ref.)
[Hormones and cancer: risk-benefit] Sevelda P, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):61–3 (7 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment options in androgen-independent prostate cancer. Lara PN Jr, et al. **Cancer Invest** 1999;17(2):137–44 (72 ref.)
Immunologic approaches to the treatment of prostate cancer. Harris DT, et al. **Semin Oncol** 1999 Aug;26(4):439–47 (47 ref.)
[Application and limitation of neoadjuvant hormonal therapy for prostate cancer] Demura T, et al. **Nippon Rinsho** 1998 Aug;56(8):2150–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Radiation therapy with neoadjuvant hormonal therapy for prostate cancer confined to pelvis] Furuya Y, et al. **Nippon Rinsho** 1998 Aug;56(8):2181–4 (11 ref.) (Eng. Abstr.) **(Jpn)**
[A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume] Hachiya T, et al. **Nippon Rinsho** 1998 Aug;56(8):2157–61 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical or medical castration with LH-RH analogue for prostatic cancer] Kameyama S, et al. **Nippon Rinsho** 1998 Aug;56(8):2114–8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Usefulness of initial chemoendocrine therapy for advanced prostate cancer] Kanetake H, et al. **Nippon Rinsho** 1998 Aug;56(8):2173–6 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Total androgen blockade--concept, theory, method and clinical application] Ozono S, et al. **Nippon Rinsho** 1998 Aug;56(8):2129–34 (27 ref.) (Eng. Abstr.) **(Jpn)**

NEOPLASMS, MESOTHELIAL

PATHOLOGY

Benign mesothelial cells in lymph node. Colby TV. **Adv Anat Pathol** 1999 Jan;6(1):41–8 (19 ref.)

NEOPLASMS, METACHRONOUS see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, METACHRONOUS SECOND PRIMARY see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, MULTIPLE ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

NEOPLASMS, MULTIPLE ENDOCRINE TYPE 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

NEOPLASMS, MULTIPLE ENDOCRINE TYPE 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

NEOPLASMS, MULTIPLE ENDOCRINE, TYPE 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

NEOPLASMS, MULTIPLE PRIMARY

see related
NEOPLASMS, SECOND PRIMARY

Evolving perspectives in contralateral breast cancer. Dawson LA, et al. **Eur J Cancer** 1998 Dec;34(13):2000–9 (128 ref.)
Left atrial leiomyosarcoma: double occurrence and double recurrence--report of one case. Minardi G, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1171–6 (38 ref.)
Multiple primary cancers of the esophagus and thyroid gland. Naomoto Y, et al. **Jpn J Clin Oncol** 1999 Jul;29(7):349–52 (17 ref.)
The Carney Triad: a lesson in observation, creativity, and perseverance [editorial; comment] Appelman HD. **Mayo Clin Proc** 1999 Jun;74(6):638–40 (15 ref.) Comment on: Mayo Clin Proc 1999 Jun;74(6):543–52.
Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment. Hiraki A, et al. **Oncol Rep** 1999 Jan-Feb;

6(1):75-80 (13 ref.)
[A case of synchronous triple primary cancers of prostate, kidney and bladder] Harima M, et al. **Hinyokika Kiyo** 1998 Sep;44(9):675-8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Bilateral simultaneous epididymal leiomyoma: a case report] Kimura T, et al. **Hinyokika Kiyo** 1998 Dec;44(12):901-3 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Bilateral renal cell carcinoma in a patient with chronic renal failure: a case report] Tsuchiya F, et al. **Hinyokika Kiyo** 1998 Nov;44(11):813-6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[A case of metachronous bilateral testicular tumors with burned-out histology in one side] Suzuki K, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Apr;90(4):526-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Clear cell carcinoma arising in extragonadal endometriosis in a Caeserean section scar during pregnancy [letter] Gücer F, et al. **Gynecol Oncol** 1999 May;73(2):337 (4 ref.)

DIAGNOSIS

Villoglandular papillary adenocarcinoma of the uterine cervix. Collinet P, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):101-3 (8 ref.)
Malignant peripheral nerve sheath tumor of the prostate: a rare manifestion of neurofibromatosis type 1. Rames RA, et al. **J Urol** 1999 Jul;162(1):165-6 (3 ref.)
Sclerotome distribution of melorheostosis and multicentric fibromatosis. Rhys R, et al. **Skeletal Radiol** 1998 Nov; 27(11):633-6 (16 ref.)
[Primary renal epithelioid angiosarcoma with transitional cell carcinoma in renal pelvis] Li N, et al. **Chung Hua Wai Ko Tsa Chih** 1997 May;35(5):294-5 (5 ref.) (Eng. Abstr.) **(Chi)**
[The rare differential diagnosis of a mediastinal space-occupying lesion] Bohle W, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):245-7 (9 ref.) (Eng. Abstr.) **(Ger)**
[The coexistence of 2 different neuroendocrine tumors of the upper gastrointestinal tract and pancreas (see comments)] Reusch J, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1472-7 (25 ref.) (Eng. Abstr.) Comment in: Dtsch Med Wochenschr 1999 Jun 4;124(22):712; discussion 713. **(Ger)**
[Von Recklinghausen type I neurofibromatosis and neuroendocrine tumor (somatostatinoma) in a 50-year-old woman] Reichardt M, et al. **Med Klin** 1998 Sep 15; 93(9):550-3 (26 ref.) (Eng. Abstr.) **(Ger)**
[Multiple brown tumors of the paranasal sinuses in tertiary hyperparathyroidism] Pöckler-Schöniger C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):72-5 (10 ref.) **(Ger)**
[Bilateral renal oncocytoma. A clinical case and review of the literature] Cudazzo E, et al. **Minerva Chir** 1998 Sep; 53(9):769-74 (32 ref.) (Eng. Abstr.) **(Ita)**
[Gastric adenocarcinoma and carcinoid] Cunha P, et al. **Acta Med Port** 1998 Jun;11(6):577-80 (9 ref.) (Eng. Abstr.) **(Por)**
[A tumor of the cerebellopontile angle and a large posterior mediastinal mass] Barón Saura JM, et al. **Rev Clin Esp** 1998 Nov;198(11):777-8 (4 ref.) **(Spa)**

EPIDEMIOLOGY

Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Bernardis V, et al. **Digestion** 1999 Jan-Feb;60(1):82-5 (16 ref.)
Multiple primary melanomas: analysis of 49 cases. Savoia P, et al. **Melanoma Res** 1998 Aug;8(4):361-6 (24 ref.)
Coexistence of an adrenocortical carcinoma with an abdominal ganglioneuroma in a child. Smets A, et al. **Pediatr Radiol** 1998 May;28(5):329-31 (7 ref.)

GENETICS

Neurofibromatosis type 2 with multiple primary brain tumors in monozygotic twins. Harada H, et al. **Surg Neurol** 1999 May;51(5):528-35 (30 ref.)
[Genetics of colorectal cancer. I. Non-polyposis and polyposis forms of hereditary colorectal cancer] Menko FH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1201-6 (37 ref.) (Eng. Abstr.) **(Dut)**
[Genetics of colorectal cancer. II. Hereditary background of sporadic and familial colorectal cancer] Menko FH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1207-11 (24 ref.) (Eng. Abstr.) **(Dut)**

METABOLISM

A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884-90 (37 ref.)

PATHOLOGY

Acrochordons are not a component of the Birt-Hogg-Dubé syndrome: does this syndrome exist? Case reports and review of the literature. De la Torre C, et al. **Am J Dermatopathol** 1999 Aug;21(4):369-74 (65 ref.)
Collision tumor: a peripheral neuroepithelioma and a transitional-cell carcinoma occurring simultaneously in the renal pelvis. Phan ST, et al. **Ann Diagn Pathol** 1997 Dec; 1(2):91-8 (46 ref.)
Hybrid carcinomas of salivary glands. Report of 4 cases and review of the literature. Croitoru CM, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):698-702 (11 ref.)
Involvement of the urogenital tract in patients with five or more separate malignant neoplasms. Case and review. Rohde D, et al. **Eur Urol** 1998 Dec;34(6):512-7 (31 ref.)
Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. Cather JC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):858-63 (54 ref.)
Secretory breast carcinoma in a 66 year old man. Kuwabara H, et al. **J Clin Pathol** 1998 Jul;51(7):545-7 (12 ref.)
Synchronous and metachronous gastric adenocarcinoma: case report and literature review. Gnanalingham KK, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):61-2 (15 ref.)
Double cancer of the gallbladder and common bile duct associated with an anomalous pancreaticobiliary ductal junction without a choledochal cyst: report of a case. Suzuki S, et al. **Surg Today** 1999;29(7):651-5 (21 ref.)
Littoral cell angioma of the spleen: an additional report of four cases with emphasis on the association with visceral organ cancers. Bisceglia M, et al. **Tumori** 1998 Sep-Oct; 84(5):595-9 (21 ref.)
[Clear cell odontogenic carcinoma in connection with squamous epithelial carcinoma. Case report and review of the literature] Vesper M, et al. **Mund Kiefer Gesichtschir** 1998 Sep;2(5):270-4 (22 ref.) (Eng. Abstr.) **(Ger)**
[Malignant phyllodes tumor with liposarcomatous differentiation. Description of a clinical case] Scala M, et al. **Minerva Chir** 1999 May;54(5):355-8 (25 ref.) (Eng. Abstr.) **(Ita)**
[A case of triple cancers with gastric, jejunal and colonic cancers] Nanba M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):953-8 (22 ref.) **(Jpn)**
[Extramedullary lesions in acute myeloblastic leukemia] Bialik TE, et al. **Ter Arkh** 1998;70(7):79-82 (33 ref.) **(Rus)**
[Discordant lymphoma: a report of 2 new cases and a review of the literature] Azaceta Reinares G, et al. **Rev Clin Esp** 1998 Nov;198(11):749-51 (11 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[A 47-year-old man with epigastric discomfort] San Román Montero JM, et al. **Rev Clin Esp** 1998 Nov;198(11):771-2 (6 ref.) **(Spa)**

SECONDARY

Simultaneous metastatic ameloblastoma and thyroid carcinoma in the cervical region: report of a case. Sugiyama M, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1255-8 (18 ref.)

SURGERY

A case of metastatic nasopharyngeal carcinoma in benign nasal polyps. Sim RS, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):575-7 (5 ref.)
Multifocal angiosarcoma of the scalp: a case report and review of the literature. Kacker A, et al. **Ear Nose Throat J** 1999 Apr;78(4):302-5 (14 ref.)
Surgical strategies for metastatic lung cancer. Olak J. **Surg Oncol Clin N Am** 1999 Apr;8(2):245-57 (64 ref.)
[Synchronous bilateral renal adenocarcinoma. Our experience with conservative kidney surgery] Pérez García FJ, et al. **Arch Esp Urol** 1999 Jun;52(5):471-7 (19 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Left atrial leiomyosarcoma: double occurrence and double recurrence--report of one case. Minardi G, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1171-6 (38 ref.)

NEOPLASMS, MUSCLE TISSUE

CLASSIFICATION

Myofibroblastic tumours: an update. Fletcher CD. **Verh Dtsch Ges Pathol** 1998;82:75-82 (74 ref.)

DIAGNOSIS

Spindle cell tumours of the breast: practical approach to diagnosis. Al-Nafussi A. **Histopathology** 1999 Jul; 35(1):1-13 (192 ref.)

PATHOLOGY

Myofibroblastic tumours: an update. Fletcher CD. **Verh Dtsch Ges Pathol** 1998;82:75-82 (74 ref.)

NEOPLASMS, NERVE TISSUE

Posterior mediastinal neurogenic tumors in infants and children. Saenz NC. **Semin Pediatr Surg** 1999 May; 8(2):78-84 (36 ref.)

DIAGNOSIS

Imaging of perineural tumor spread in head and neck cancer. Ginsberg LE. **Semin Ultrasound CT MR** 1999 Jun; 20(3):175-86 (19 ref.)

PATHOLOGY

[Cutaneous neural neoplasms--an update] Mentzel T. **Pathologe** 1999 Mar;20(2):98-109 (65 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Sonographic appearances of nerve tumors. Beggs I. **J Clin Ultrasound** 1999 Sep;27(7):363-8 (27 ref.)
Tendon and nerve sonography. Martinoli C, et al. **Radiol Clin North Am** 1999 Jul;37(4):691-711, viii (81 ref.)

NEOPLASMS, NEUROEPITHELIAL

Posterior mediastinal neurogenic tumors in infants and children. Saenz NC. **Semin Pediatr Surg** 1999 May; 8(2):78-84 (36 ref.)

DIAGNOSIS

Dysembryoplastic neuroepithelial tumour. Tatke M, et al. **Childs Nerv Syst** 1998 Jul;14(7):293-6 (10 ref.)

NEOPLASMS, OCCULT PRIMARY see **NEOPLASMS, UNKNOWN PRIMARY**

NEOPLASMS, POST-TRAUMATIC

ETIOLOGY

Squamous cell carcinoma in chronic ulcerative lesions: a case report and literature review. Hensel KS, et al. **Am J Orthop** 1999 Apr;28(4):253-6 (14 ref.)

NEOPLASMS, RADIATION-INDUCED

see related
LEUKEMIA, RADIATION-INDUCED
NEOPLASMS, SECOND PRIMARY

The role of animal models in the development of knowledge of radiation carcinogenesis and their potential contribution to judgements of risk at low doses. Cox R. **C R Acad Sci III** 1999 Feb-Mar;322(2-3):135-8 (26 ref.)
Radiation induced sarcoma of the head and neck. Patel SG, et al. **Head Neck** 1999 Jul;21(4):346-54 (56 ref.)
Effects of small doses of ionising radiation [see comments] Doll R. **J Radiol Prot** 1998 Sep;18(3):163-74 (70 ref.) Comment in: J Radiol Prot 1999 Mar;19(1):63-5.
The pathogenesis of melanoma induced by ultraviolet radiation. Gilchrest BA, et al. **N Engl J Med** 1999 Apr 29;340(17):1341-8 (94 ref.)

DIAGNOSIS

Radiation-induced changes in bone. Mitchell MJ, et al. **Radiographics** 1998 Sep-Oct;18(5):1125-36; quiz 1242-3 (29 ref.)
[Radiation-induced meningioma 20 years after operation and high-dose irradiation of an ependymoma] Daentzer D, et al. **Zentralbl Neurochir** 1999;60(1):27-32 (26 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Contribution of human data to the analysis of human carcinogenesis. Tubiana M. **C R Acad Sci III** 1999 Feb-Mar;322(2-3):215-24 (80 ref.)
Biological effects of electromagnetic fields and radiation [see comments] Sienkiewicz Z. **J Radiol Prot** 1998 Sep; 18(3):185-93 (34 ref.) Comment in: J Radiol Prot 1998 Sep;18(3):161-2.

ETIOLOGY

Somatic effects in nuclear medicine and radiology. Overbeek FJ, et al. **Appl Radiat Isot** 1999 Jan;50(1):63-72 (48 ref.)
The effects of neutrons in Hiroshima. Implications for the risk estimates. Kellerer AM. **C R Acad Sci III** 1999 Feb-Mar;322(2-3):229-37 (19 ref.)
Adaptive response and its relationship to hormesis and low dose cancer risk estimation. Olivieri G. **Hum Exp Toxicol** 1999 Jul;18(7):440-2 (21 ref.)
Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. Antley CA, et al. **J Cutan Pathol** 1999 Jan;26(1):48-50 (11 ref.)
Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Fusenig NE, et al. **Mol Carcinog** 1998 Nov;23(3):144-58 (78 ref.)
Influence of dietary factors on actinically-induced skin cancer. Black HS. **Mutat Res** 1998 Nov 9;422(1):185-90 (31 ref.)
UV-induced mutations and skin cancer: how important is the link? Bridges BA. **Mutat Res** 1998 Nov 9;422(1):23-30 (38 ref.)
Cell phones and cancer: what is the evidence for a connection? Moulder JE, et al. **Radiat Res** 1999 May; 151(5):513-31 (75 ref.)
Biological effects of amplitude-modulated radiofrequency radiation [see comments] Juutilainen J, et al. **Scand J Work Environ Health** 1998 Aug;24(4):245-54 (64 ref.) Comment in: Scand J Work Environ Health 1998

NEOPLASMS, RADIATION-INDUCED

Aug;24(4):241-3.
Childhood and adult cancer after intrauterine exposure to ionizing radiation. Boice JD Jr, et al. **Teratology** 1999 Apr; 59(4):227-33 (60 ref.)
[Radiation-induced cancers] Dutrillaux B. **Cancer Radiother** 1998 Sep-Oct;2(5):541-8 (8 ref.) (Eng. Abstr.) **(Fre)**
[UV-induced immunosuppression and skin cancers] Meunier L, et al. **Rev Med Interne** 1998 Apr;19(4):247-54 (72 ref.) (Eng. Abstr.) **(Fre)**
[Mammography and radiation risk (see comments)] Jung H. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):336-43 (20 ref.) (Eng. Abstr.) Comment in: Rofo Fortschr Geb Rontgenstr Neuen Bildge 1998 Oct;169(4):335. **(Ger)**
[Risk factors for the development of malignant melanomas] Itin PH. **Ther Umsch** 1999 Jun;56(6):298-301 (18 ref.) (Eng. Abstr.) **(Ger)**
[Photo-aging] Paredes BE, et al. **Ther Umsch** 1999 Apr; 56(4):188-93 (23 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Interrelationships between radiation-induced mutations and modifications in gene expression linked to cancer. Liber HL, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3-4):257-76 (209 ref.)
Cellular responses to radiation and risk of breast cancer. Jongmans W, et al. **Eur J Cancer** 1999 Apr;35(4):540-8 (117 ref.)
Evidence for a role of delayed death and genomic instability in radiation-induced neoplastic transformation of human hybrid cells. Mendonca MS, et al. **Int J Radiat Biol** 1998 Dec;74(6):755-64 (84 ref.)
Radiation-induced instability and its relation to radiation carcinogenesis. Ullrich RL, et al. **Int J Radiat Biol** 1998 Dec;74(6):747-54 (12 ref.)
Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Fusenig NE, et al. **Mol Carcinog** 1998 Nov;23(3):144-58 (78 ref.)
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Rabes HM, et al. **Recent Results Cancer Res** 1998;154:248-64 (92 ref.)

MORTALITY

Cohen's paradox [letter] Field RW, et al. **Health Phys** 1999 Sep;77(3):328-9 (21 ref.)

PATHOLOGY

Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Nikiforov YE, et al. **Adv Anat Pathol** 1999 Mar;6(2):78-91 (44 ref.)
Radiation-induced esophageal carcinoma 30 years after mediastinal irradiation: case report and review of the literature. Micke O, et al. **Jpn J Clin Oncol** 1999 Mar; 29(3):164-70 (43 ref.)

PREVENTION & CONTROL

Ultraviolet radiation exposure in children: a review of measurement strategies. Creech LL, et al. **Ann Behav Med** 1998 Fall;19(4):399-407 (83 ref.)
Do sunscreens prevent skin cancer? **Drug Ther Bull** 1998 Jul;36(7):49-51 (18 ref.)
Protection against solar ultraviolet radiation. Gies PH, et al. **Mutat Res** 1998 Nov 9;422(1):15-22 (37 ref.)
[Prevention of malignant melanoma] Blum A, et al. **Hautarzt** 1998 Nov;49(11):826-34 (54 ref.) (Eng. Abstr.) **(Ger)**
[Radiation exposure during thoracic radiography at the intensive care unit. Dose accumulation and risk of radiation-induced cancer in long-term therapy] Leppek R, et al. **Radiologe** 1998 Sep;38(9):730-6 (42 ref.) (Eng. Abstr.) **(Ger)**
[Prevention of ultraviolet ray damage: external and internal sunscreens] Grundmann JU, et al. **Ther Umsch** 1999 Apr; 56(4):225-32 (48 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Management of 29 children with thyroid cancer following the Chernobyl accident] Aurengo A, et al. **Bull Acad Natl Med** 1998;182(5):955-76; discussion 976-9 (77 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of non-melanocytic skin tumors] Hafner J. **Ther Umsch** 1998 Aug;55(8):515-21 (8 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

[Chronic damage in domestic animals after ionizing radiation (review)] von Zallinger C, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):457-63 (45 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASMS, SECOND PRIMARY

see related
NEOPLASMS, MULTIPLE PRIMARY

Radiation induced sarcoma of the head and neck. Patel SG, et al. **Head Neck** 1999 Jul;21(4):346-54 (56 ref.)
Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission. Shimizu K, et al. **Int J Hematol** 1999 Feb;69(2):96-100 (22 ref.)
[Secondary leukemia] Nakamura H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):177-9 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Secondary leukemias induced by topoisomerase-targeted drugs. Felix CA. **Biochim Biophys Acta** 1998 Oct 1; 1400(1-3):233-55 (276 ref.)
The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review. Law CH, et al. **Can J Surg** 1999 Jun;42(3):211-4 (20 ref.)
Acute leukemia following treatment of malignant glioma. Perry JR, et al. **J Neurooncol** 1998 Oct;40(1):39-46 (56 ref.)
Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: case report and review of the literature. Al-Fiar F, et al. **Leuk Res** 1999 Aug;23(8):719-21 (24 ref.)
[Late toxicity after chemotherapy of malignant testicular tumors] Jakob A, et al. **Urologe A** 1998 Nov;37(6):635-47 (111 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Lai R, et al. **Am J Clin Pathol** 1999 Mar;111(3):373-8 (21 ref.)

DIAGNOSIS

"Carcinoid tumorlets". Case report and review of the literature. Fabbri N, et al. **Ann Ital Chir** 1998 Jul-Aug; 69(4):509-11 (10 ref.)
Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Lonardo A, et al. **Dig Dis Sci** 1998 Nov;43(11):2489-92 (46 ref.)
Primary juxtacortical chondrosarcoma dedifferentiating after 20 years. Kumta SM, et al. **Skeletal Radiol** 1998 Oct; 27(10):569-73 (9 ref.)
Dedifferentiated parosteal osteosarcoma with high-grade osteoclast-rich osteogenic sarcoma at presentation. Shuhaibar H, et al. **Skeletal Radiol** 1998 Oct;27(10):574-7 (16 ref.)
Second primary renal cell carcinomas following solid tumors. Four case reports and review of the literature. Koumarianou AA, et al. **Tumori** 1998 Sep-Oct;84(5):600-2 (14 ref.)

DRUG THERAPY

[Chemotherapy in metastasized breast carcinoma (see comments)] Bontenbal M, et al. **Ned Tijdschr Geneeskd** 1998 Jul 25;142(30):1709-13 (37 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):59-60. **(Dut)**

EPIDEMIOLOGY

Angiosarcoma. A rare secondary malignancy after breast cancer treatment. Autio P, et al. **Eur J Dermatol** 1999 Mar; 9(2):118-21 (26 ref.)
Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Marchal C, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):113-9 (48 ref.)
Multiple primary melanomas: analysis of 49 cases. Savoia P, et al. **Melanoma Res** 1998 Aug;8(4):361-6 (24 ref.)

ETIOLOGY

Angiosarcoma of the breast following radiation therapy. Williams EV, et al. **Eur J Surg Oncol** 1999 Apr;25(2):221-2 (18 ref.)
Acute leukemias after treatment with radioiodine for thyroid cancer [letter] Roldán Schilling V, et al. **Haematologica** 1998 Aug;83(8):767-8 (6 ref.)
Acute lymphoblastic leukemia occurring as a second malignancy: report of a case and review of literature. Geetha N, et al. **Pediatr Hematol Oncol** 1999 May-Jun; 16(3):267-70 (10 ref.)

PATHOLOGY

Thymic carcinoid in the pancreas: metastatic disease or new primary tumours. Axelson J, et al. **Eur J Surg** 1999 Mar; 165(3):270-3 (16 ref.)
Glioblastoma multiforme in a mature ovarian teratoma with recurring brain tumours. Yadav A, et al. **Histopathology** 1999 Aug;35(2):170-3 (10 ref.)
Synchronous and metachronous gastric adenocarcinoma: case report and literature review. Gnanalingham KK, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):61-2 (15 ref.)
A case of chromophobe renal cell carcinoma with sarcomatoid foci and a small daughter lesion. Kuroda N, et al. **Pathol Int** 1998 Oct;48(10):812-7 (30 ref.)
[Primary non-Hodgkin's lymphoma of the esophagus following Hodgkin's disease (letter)] Fernández-Llamazares J, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):356-7 (10 ref.) **(Spa)**

PREVENTION & CONTROL

Tamoxifen and contralateral breast cancer [see comments] O'Regan R, et al. **J Am Coll Surg** 1999 Jun;188(6):678-83 (38 ref.) Comment in: J Am Coll Surg 1999 Jun;188(6):684.

RADIOTHERAPY

Brachytherapy for recurrent head and neck cancer. Senan S, et al. **Hematol Oncol Clin North Am** 1999 Jun; 13(3):531-42 (39 ref.)

SURGERY

Surgical strategies for metastatic lung cancer. Olak J. **Surg Oncol Clin N Am** 1999 Apr;8(2):245-57 (64 ref.)

THERAPY

[Hyperthermia in combination with radiotherapy (see comments)] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):76-80 (21 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):75-8. **(Dut)**

NEOPLASMS, SQUAMOUS CELL

GENETICS

Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Nathan CA, et al. **Laryngoscope** 1999 Aug;109(8):1253-8 (18 ref.)

PATHOLOGY

[A skin lymphoepithelial tumor (skin lymphadenoma)] Baptista AP, et al. **Acta Med Port** 1998 Jun;11(6):555-8 (21 ref.) (Eng. Abstr.) **(Por)**

NEOPLASMS, SYNCHRONOUS see **NEOPLASMS, MULTIPLE PRIMARY**

NEOPLASMS, SYNCHRONOUS MULTIPLE PRIMARY see **NEOPLASMS, MULTIPLE PRIMARY**

NEOPLASMS, THERAPY-RELATED see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, TREATMENT-RELATED see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, UNKNOWN PRIMARY

COMPLICATIONS

[Microangiopathic hemolytic anemia. A form of presentation of stomach neoplasm] Oliveira A, et al. **Acta Med Port** 1998 Jun;11(6):569-72 (12 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Metastatic adenocarcinoma of unknown primary origin. Hammar SP. **Hum Pathol** 1998 Dec;29(12):1393-402 (44 ref.)
Improving survival in metastatic carcinoma of unknown origin. Brigden ML, et al. **Postgrad Med** 1999 May 1; 105(5):63-4, 67-74 (23 ref.)
[Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide] Rischke HC, et al. **Dtsch Med Wochenschr** 1999 Feb 19;124(7):182-6 (21 ref.) (Eng. Abstr.) **(Ger)**
[Left supraclavicular adenopathy with a neuroendocrine pattern of unknown cause: prostatic carcinoma metastasis] Fernández Borrell A, et al. **Actas Urol Esp** 1999 Jul-Aug; 23(7):603-8 (22 ref.) (Eng. Abstr.) **(Spa)**
[A solitary cerebellar metastasis: a diagnostic exercise] Sousa Escandón MA, et al. **Actas Urol Esp** 1999 May;23(5):459-63 (16 ref.) (Eng. Abstr.) **(Spa)**
[Campylobacter fetus sepsis, pulmonary thromboembolism and an occult neoplasm (letter)] Conde Martel A, et al. **An Med Interna** 1999 Feb;16(2):103 (7 ref.) **(Spa)**

DRUG THERAPY

The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Greco FA, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):129-33 (14 ref.)

PATHOLOGY

Carcinoid tumor metastatic to the breast [see comments] Rubio IT, et al. **Arch Surg** 1998 Oct;133(10):1117-9 (10 ref.) Comment in: Arch Surg 1999 Apr;134(4):450. Comment in: Arch Surg 1999 May;134(5):575-6.
Clear cell (glycogen-rich) rhabdomyosarcoma presenting as cervical lymphadenopathy. Govender D, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan-Feb; 61(1):52-4 (9 ref.)
Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Lee JE, et al. **Surgery** 1998 Dec; 124(6):1115-22 (25 ref.)
[Mediastinal and hilar lymph node of cancer unknown origin: 3 case reports] Sakuraba M, et al.

Nihon Kokyuki Gakkai Zasshi 1999 Jan;37(1):72–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Occult carcinoma discovered after simple hysterectomy treated with postoperative radiotherapy. Crane CH, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1049–53 (16 ref.)

THERAPY

Improving survival in metastatic carcinoma of unknown origin. Brigden ML, et al. **Postgrad Med** 1999 May 1; 105(5):63–4, 67–74 (23 ref.)

NEOPLASMS, VASCULAR TISSUE

DIAGNOSIS

Vascular anomalies. A primer for pediatricians. Fishman SJ, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1455–77 (28 ref.)

PATHOLOGY

Selected cutaneous vascular neoplasms. A review. Prieto VG, et al. **Dermatol Clin** 1999 Jul;17(3):507–20, viii (100 ref.)

NEOPLASTIC CELLS, CULTURED see **TUMOR CELLS, CULTURED**

NEOPLASTIC ENDOCRINE-LIKE SYNDROMES

see related
ACTH SYNDROME, ECTOPIC

DIAGNOSIS

Pancreatic endocrine tumors: diagnostic pitfalls. Ectors N. **Hepatogastroenterology** 1999 Mar–Apr;46(26):679–90 (127 ref.)

NEOPLASTIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, NEOPLASTIC**

NEOPLASTIC PROCESSES

Understanding regulation of cell growth in childhood brain tumors. Khakoo Y, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):551–5 (49 ref.)

Ageing and the mechanisms of carcinogenesis: some practical implications. Anisimov VN. **J Exp Clin Cancer Res** 1998 Sep;17(3):263–8 (76 ref.)

NEOPLASTIC SYNDROMES, HEREDITARY

Gastrointestinal polyposis syndromes. Guillem JG, et al. **Curr Probl Surg** 1999 Apr;36(4):217–323 (354 ref.)

DIAGNOSIS

Screening for breast and ovarian cancer: the relevance of family history. Pharoah PD, et al. **Br Med Bull** 1998; 54(4):823–38 (40 ref.)

GENETICS

The genetics of melanoma: the UK experience. Newton Bishop JA, et al. **Clin Exp Dermatol** 1998 Jul;23(4):158–61 (23 ref.)

Genetic predisposition to ocular melanoma. Houlston RS, et al. **Eye** 1999;13 (Pt 1):43–6 (58 ref.)

Some neoplasms and some hamartomatous syndromes: genetic considerations. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1998 Oct;27(5):363–9 (37 ref.)

BRCA1 and BRCA2 proteins: roles in health and disease. Duncan JA, et al. **Mol Pathol** 1998 Oct;51(5):237–47 (85 ref.)

[What is the value of recent molecular biology knowledge for surgical oncologic therapy of soft tissue sarcoma?] Willeke F. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:393–8 (28 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASTIC TRANSFORMATION, CELL see **CELL TRANSFORMATION, NEOPLASTIC**

NEOPRENE

ADVERSE EFFECTS

Neoprene splinting: dermatological issues. Stern EB, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):573–8 (40 ref.)

NEOPTERIN

BIOSYNTHESIS

Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Murr C, et al. **Anticancer Res** 1999 May–Jun;19(3A):1721–8 (68 ref.)

PHYSIOLOGY

Neopterin: a review. Hamerlinck FF. **Exp Dermatol** 1999 Jun;8(3):167–76 (98 ref.)

NEORICKETTSIA see **RICKETTSIACEAE**

NEOSPORA

Neosporosis in cattle: biology and economic impact. Dubey JP. **J Am Vet Med Assoc** 1999 Apr 15;214(8):1160–3 (65 ref.)

[Diagnosis and epidemiology of Neospora caninum-associated abortions in cattle] Conraths FJ, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 May; 27(3):145–53 (99 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Polymerase chain reaction approaches for the detection of Neospora caninum and Toxoplasma gondii. Ellis JT. **Int J Parasitol** 1998 Jul;28(7):1053–60 (67 ref.)

PATHOGENICITY

Recent advances in Neospora and neosporosis. Dubey JP. **Vet Parasitol** 1999 Aug 1;84(3–4):349–67 (169 ref.)

PHYSIOLOGY

The host–parasite relationship in neosporosis. Hemphill A. **Adv Parasitol** 1999;43:47–104 (200 ref.)

NEOSPORA CANINUM see **NEOSPORA**

NEOSTRIATUM

DRUG EFFECTS

Release of endogenous excitatory amino acids in the neostriatum of the rat under physiological and pharmacologically-induced conditions. Herrera-Marschitz M, et al. **Amino Acids** 1998;14(1–3):197–203 (22 ref.)

PHYSIOLOGY

Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Zigmond MJ, et al. **Amino Acids** 1998;14(1–3):57–62 (16 ref.)

[The role of the striatum in the evolution of the mammalian forebrain] Tolkunov BF. **Zh Evol Biokhim Fiziol** 1998 Jul–Aug;34(4):392–400 (43 ref.) **(Rus)**

PHYSIOPATHOLOGY

Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Reader TA, et al. **Neurochem Int** 1999 Jan;34(1):1–21 (242 ref.)

NEOTOMA see **HESPEROMYINAE**

NEOVASCULARIZATION, CHOROIDAL see **CHOROIDAL NEOVASCULARIZATION**

NEOVASCULARIZATION, PATHOLOGIC

Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? [comment] Laurén J, et al. **Am J Pathol** 1998 Nov;153(5):1333–9 (79 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1459–66.

The significance of matrix metalloproteinases during early stages of tumor progression. Lochter A, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:180–93 (54 ref.)

Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Strohmeyer D. **Anticancer Res** 1999 Mar–Apr;19(2C):1557–61 (32 ref.)

Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. Jones A, et al. **BJU Int** 1999 Mar; 83(5):535–55; quiz 555–6 (230 ref.)

Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Carmeliet P, et al. **Cardiovasc Res** 1998 Jul;39(1):8–33 (287 ref.)

A novel approach for studying angiogenesis: a human skin equivalent with a capillary-like network. Black AF, et al. **Cell Biol Toxicol** 1999 Apr;15(2):81–90 (78 ref.)

Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Zhang N, et al. **Curr Opin Hematol** 1999 Jan; 6(1):44–50 (79 ref.)

Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Miles KA. **Eur J Radiol** 1999 Jun;30(3):198–205 (34 ref.)

The diagnostic and prognostic value of tumor angiogenesis. Szabo S, et al. **Eur J Surg Suppl** 1998;(582):99–103 (44 ref.)

Angiogenesis in malignancies of the female genital tract. Abulafia O, et al. **Gynecol Oncol** 1999 Feb;72(2):220–31 (84 ref.)

Angiogenesis: a new theory for endometriosis. Healy DL, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):736–40 (36 ref.)

Endometrial microvascular growth in normal and dysfunctional states. Rogers PA, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):503–8 (27 ref.)

Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Bergers G, et al. **Int J Dev Biol** 1998;42(7 Spec No):995–1002 (39 ref.)

Tumor angiogenesis and endothelial cell modulatory factors [see comments] Desai SB, et al. **J Immunother** 1999 May; 22(3):186–211 (346 ref.) Comment in: J Immunother 1999 May;22(3):185.

Role of vascular endothelial growth factor in the regulation of angiogenesis. Ferrara N. **Kidney Int** 1999 Sep; 56(3):794–814 (285 ref.)

Angiogenesis: possibilities for therapeutic interventions. Wynendaele W, et al. **Pharm World Sci** 1998 Dec; 20(6):225–35 (127 ref.)

Angiogenesis and arthritis. Walsh DA. **Rheumatology (Oxford)** 1999 Feb;38(2):103–12 (144 ref.)

Angiostatic treatment of neuroblastoma. Wassberg E. **Ups J Med Sci** 1999;104(1):1–24 (88 ref.)

Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Rubin MA, et al. **Urology** 1999 Mar;53(3):542–7 (26 ref.)

[Role of fibroblast growth factor-2 in tumor angiogenesis] Bikfalvi A. **Pathol Biol (Paris)** 1999 Apr;47(4):364–7 (25 ref.) (Eng. Abstr.) **(Fre)**

[Thrombospondins, tumor angiogenesis and breast cancer] Clézardin P, et al. **Pathol Biol (Paris)** 1999 Apr; 47(4):368–74 (39 ref.) (Eng. Abstr.) **(Fre)**

[Implication of HARP in angiogenesis and possible therapeutic role] Delbe J, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):352–7 (33 ref.) (Eng. Abstr.) **(Fre)**

[Angiogenesis and neuropathology] Ruchoux MM, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):385–96 (68 ref.) (Eng. Abstr.) **(Fre)**

[Tumoral angiogenesis: physiopathology, prognostic value and therapeutic perspectives] André T, et al. **Rev Med Interne** 1998 Dec;19(12):904–13 (66 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma] Konno H, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):441–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Neovascularization and tumor development] Ono M, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1577–87 (12 ref.) **(Jpn)**

[Diabetic retinopathy--the mechanisms of the ocular neovascularization and the development of anti-angiogenic drugs] Kuroki M, et al. **Nippon Rinsho** 1999 Mar; 57(3):584–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Tumor angiogenesis] Ono M, et al. **Seikagaku** 1998 Sep; 70(9):1159–70 (28 ref.) **(Jpn)**

DIAGNOSIS

Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Heimann R, et al. **Breast Cancer Res Treat** 1998;52(1–3):147–58 (62 ref.)

DRUG THERAPY

The basic science underlying antiangiogenic therapies. Rundell K. **Biochim Biophys Acta** 1998 Oct 14; 1378(2):R27–31 (13 ref.)

Targeting angiogenic pathways involving tumor–stromal interaction to treat advanced human prostate cancer. Sokoloff MH, et al. **Cancer Metastasis Rev** 1998–99; 17(4):307–15 (64 ref.)

Chemotherapy targeted to tumor vasculature. Arap W, et al. **Curr Opin Oncol** 1998 Nov;10(6):560–5 (56 ref.)

The rationale and future potential of angiogenesis inhibitors in neoplasia. Gasparini G. **Drugs** 1999 Jul;58(1):17–38 (196 ref.)

New strategies in anti-vascular cancer therapy [see comments] Bloemendal HJ, et al. **Eur J Clin Invest** 1999 Sep;29(9):802–9 (78 ref.) Comment in: Eur J Clin Invest 1999 Sep;29(9):733–6.

Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications. Fontanini G, et al. **Forum (Genova)** 1998 Apr–Jun;8(2):128–42 (76 ref.)

Therapeutic potential of the anti-angiogenesis drug TNP-470. Gervaz P, et al. **Int J Exp Pathol** 1998 Dec; 79(6):359–62 (30 ref.)

Regulating angiogenesis: a new therapeutic strategy. Gibaldi M. **J Clin Pharmacol** 1998 Oct;38(10):898–903 (23 ref.)

Angiogenesis, a target for tumor therapy. Griffioen AW, et al. **J Lab Clin Med** 1998 Nov;132(5):363–8 (46 ref.)

Natural products as angiogenesis inhibitors. Paper DH. **Planta Med** 1998 Dec;64(8):686–95 (124 ref.)

Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Harris AL. **Recent Results Cancer Res** 1998;152:341–52 (81 ref.)

[Antiangiogenic therapy] Toi M. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2003–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Ocular neovascularization: an epidemiologic review. Lee P, et al. **Surv Ophthalmol** 1998 Nov–Dec;43(3):245–69 (164 ref.)

ETIOLOGY

Vascular endothelial growth factor: environmental controls and effects in angiogenesis. Hlatky L, et al. **Br J Cancer Suppl** 1996 Jul;27:S151–6 (50 ref.)

Vascular endothelial growth factor: molecular and biological aspects. Ferrara N. **Curr Top Microbiol Immunol** 1999; 237:1–30 (205 ref.)
Tumor angiogenesis. Voravud N, et al. **J Med Assoc Thai** 1999 Apr;82(4):394–404 (63 ref.)
Role of interleukin-8 in tumor growth and metastasis of human melanoma. Bar-Eli M. **Pathobiology** 1999;67(1):12–8 (66 ref.)
VEGFs, receptors and angiogenesis. Veikkola T, et al. **Semin Cancer Biol** 1999 Jun;9(3):211–20 (99 ref.)

GENETICS

New molecular strategies to cure brain tumors. Fathallah-Shaykh H. **Arch Neurol** 1999 Apr;56(4):449–53 (35 ref.)
The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Blancher C, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):187–94 (30 ref.)

IMMUNOLOGY

Angiogenesis modulates the tumour immune response. Griffioen AW, et al. **Int J Exp Pathol** 1998 Dec;79(6):363–8 (44 ref.)

METABOLISM

Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Crew JP. **Eur Urol** 1999 Jan; 35(1):2–8 (87 ref.)
Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Chiarugi V, et al. **Int J Mol Med** 1998 Dec; 2(6):715–9 (35 ref.)
[Inhibition of tumor angiogenesis as a cancer treatment] Verheul HM, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1549–55 (50 ref.) (Eng. Abstr.) **(Dut)**

MICROBIOLOGY

Interactions of Bartonella henselae with vascular endothelial cells. Dehio C. **Curr Opin Microbiol** 1999 Feb;2(1):78–82 (36 ref.)

PATHOLOGY

Chronic inflammation: links with angiogenesis and wound healing [comment] Majno G. **Am J Pathol** 1998 Oct; 153(4):1035–9 (27 ref.) Comment on: Am J Pathol 1998 Oct;153(4):1099–112.
Angiogenesis: a new prognostic marker for breast cancer. Magennis DP. **Br J Biomed Sci** 1998 Sep;55(3):214–20 (55 ref.)
Biological implications of macrophage infiltration in human tumor angiogenesis. Ono M, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S69–71 (19 ref.)
Thrombospondin-1, PECAM-1, and regulation of angiogenesis. Sheibani N, et al. **Histol Histopathol** 1999 Jan;14(1):285–94 (81 ref.)
Molecular mechanisms of tumor metastasis and angiogenesis. Böhle AS, et al. **Langenbecks Arch Surg** 1999 Apr; 384(2):133–40 (63 ref.)
[Angiogenesis and endocrine tumors] Dumortier J, et al. **Bull Cancer** 1999 Feb;86(2):148–53 (44 ref.) (Eng. Abstr.) **(Fre)**
[Control of tumor-related angiogenesis] Oikawa T. **Hum Cell** 1998 Dec;11(4):201–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Angiogenesis in brain neoplasms--biological and clinical aspects] Wojtukiewicz MZ, et al. **Postepy Hig Med Dosw** 1998;52(6):577–90 (57 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? [comment] Bissell MJ. **Am J Pathol** 1999 Sep;155(3):675–9 (50 ref.) Comment on: Am J Pathol 1999 Sep;155(3):739–52.
The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Siemeister G, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):241–8 (70 ref.)
Cancer and atherosclerosis: the broad mandate of angiogenesis [editorial; comment] Isner JM. **Circulation** 1999 Apr 6;99(13):1653–5 (21 ref.) Comment on: Circulation 1999 Apr 6;99(13):1726–32.
Signal relays in the VEGF system. Ortega N, et al. **Front Biosci** 1999 Feb 1;4:D141–52 (130 ref.)
Tumor angiogenesis: biology and therapeutic prospects. Harris SR, et al. **In Vivo** 1998 Nov-Dec;12(6):563–70 (111 ref.)
Influence of host microvascular environment on tumour vascular endothelium. Kubitza M, et al. **Int J Exp Pathol** 1999 Feb;80(1):1–10 (108 ref.)
Angiogenesis: potential target for dermatologic intervention. Sauder DN. **J Cutan Med Surg** 1998 Jun;2 Suppl 4:S4–30–2 (22 ref.)
Angiogenesis and hypertension. le Noble FA, et al. **J Hypertens** 1998 Nov;16(11):1563–72 (103 ref.)
Role of vascular endothelial growth factor in the response to vessel injury. Alvarez Arroyo MV, et al. **Kidney Int Suppl** 1998 Dec;68:S7–9 (8 ref.)
The role of alphav integrins during angiogenesis. Eliceiri BP, et al. **Mol Med** 1998 Dec;4(12):741–50 (82 ref.)
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Holash J, et al. **Oncogene** 1999 Sep 20; 18(38):5356–62 (36 ref.)
Surgical implications of therapeutic angiogenesis. Zimmerman MA, et al. **Surgery** 1999 Mar;125(3):243–9 (58 ref.)
[Similarities between angiogenesis and neoplasm invasiveness] Stéhelin D. **C R Seances Soc Biol Fil** 1998;192(2):217–22 (21 ref.) (Eng. Abstr.) **(Fre)**
[Tumor angiogenesis] Bussolino F. **Recenti Prog Med** 1999 Jan;90(1):28–36 (43 ref.) (Eng. Abstr.) **(Ita)**
[Tumor progression and angiogenesis] Maru Y. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1509–19 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of angiogenesis-expression of VEGF receptors] Morita I. **Hum Cell** 1998 Dec;11(4):215–20 (15 ref.) (Eng. Abstr.) **(Jpn)**
[The importance of angiogenesis in tumor growth dynamics] Radzikowski C, et al. **Postepy Hig Med Dosw** 1998; 52(6):553–76 (114 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Control of tumor growth via inhibition of tumor angiogenesis. Plate KH. **Adv Exp Med Biol** 1998;451:57–61 (41 ref.)
Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. van Hinsbergh VW, et al. **Ann Oncol** 1999;10 Suppl 4:60–3 (52 ref.)
Phytoestrogens and inhibition of angiogenesis. Fotsis T, et al. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):649–66 (56 ref.)
Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. Hayes AJ, et al. **BMJ** 1999 Mar 27;318(7187):853–6 (32 ref.)
An old paradigm for treating cancer and other diseases in the 21st century. Boehm T. **Cancer Metastasis Rev** 1998 Jun;17(2):149–54 (19 ref.)
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Witte L, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):155–61 (21 ref.)
Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Malonne H, et al. **Clin Exp Metastasis** 1999 Feb;17(1):1–14 (183 ref.)
Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications. Fontanini G, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):128–42 (76 ref.)
Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. Konno H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):1–6 (30 ref.)
[Tumor angiogenesis inhibitors: media and scientific aspects] Raymond E. **Presse Med** 1998 Jul 4–11;27(24):1221–4 (12 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic influences on angiogenesis. "From bench to bedside"] Jaeger TM, et al. **Dtsch Med Wochenschr** 1999 Feb 5;124(5):121–3 (24 ref.) **(Ger)**
[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):81–4 (51 ref.) **(Rus)**

THERAPY

Tumour vasculature as a target for cancer therapy. Chaplin DJ, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:57–64 (103 ref.)
Therapeutic potentials of angiostatin in the treatment of cancer. Cao Y. **Haematologica** 1999 Jul;84(7):643–50 (45 ref.)
Tumor angiogenesis: biology and therapeutic prospects. Harris SR, et al. **In Vivo** 1998 Nov-Dec;12(6):563–70 (111 ref.)
Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now? Leenders WP. **Int J Exp Pathol** 1998 Dec;79(6):339–46 (67 ref.)
Perspective: tumour spread--the problems of latency. Hart IR. **J Pathol** 1999 Jan;187(1):91–4 (27 ref.)
Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Ryan AM, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):78–86 (75 ref.)
[Modulation of angiogenesis. A new therapeutic tool for vascular diseases] Blot E, et al. **J Mal Vasc** 1999 Jun; 24(3):189–93 (26 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

The assessment of ovarian tumor angiogenesis: what does three-dimensional power Doppler add? Kurjak A, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):136–46 (98 ref.)

VIROLOGY

Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma [comment] Mesri EA. **Blood** 1999 Jun 15;93(12):4031–3 (18 ref.) Comment on: Blood 1999 Jun 15;93(12):4034–43. Comment on: Blood 1999 Jun 15;93(12):4044–58.

NEOVASCULARIZATION, PHYSIOLOGIC

see related

COLLATERAL CIRCULATION

Matrix-degrading proteases and angiogenesis during development and tumor formation. Werb Z, et al. **APMIS** 1999 Jan;107(1):11–8 (28 ref.)
Therapeutic angiogenesis [see comments] Henry TD. **BMJ** 1999 Jun 5;318(7197):1536–9 (19 ref.) Comment in: BMJ 1999 Jun 5;318(7197):1500–1.
A novel approach for studying angiogenesis: a human skin equivalent with a capillary-like network. Black AF, et al. **Cell Biol Toxicol** 1999 Apr;15(2):81–90 (78 ref.)
Complex role of matrix metalloproteinases in angiogenesis. Sang QX. **Cell Res** 1998 Sep;8(3):171–7 (20 ref.)
Developmental hematopoiesis. Morales-Alcelay S, et al. **Crit Rev Immunol** 1998;18(6):485–501 (160 ref.)
Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. Damsky CH, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):660–6 (73 ref.)
Vascular endothelial growth factor: molecular and biological aspects. Ferrara N. **Curr Top Microbiol Immunol** 1999; 237:1–30 (205 ref.)
Role of platelet-derived growth factors in angiogenesis and alveogenesis. Lindahl P, et al. **Curr Top Pathol** 1999; 93:27–33 (34 ref.)
Transcription factor ETS-1 as a molecular target for angiogenesis inhibition. Sato Y. **Hum Cell** 1998 Dec; 11(4):207–14 (52 ref.)
Endometrial microvascular growth in normal and dysfunctional states. Rogers PA, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):503–8 (27 ref.)
Angiogenesis, vascular endothelial growth factor and the endometrium. Smith SK. **Hum Reprod Update** 1998 Sep-Oct;4(5):509–19 (130 ref.)
Vascular endothelial growth factor. Zachary I. **Int J Biochem Cell Biol** 1998 Nov;30(11):1169–74 (22 ref.)
Angiogenesis-related markers and their potential clinical significance. Malone C, et al. **Int J Biol Markers** 1999 Jan-Mar;14(1):3–7 (33 ref.)
Autoregulation of angiogenesis by cells of the vessel wall. Nicosia RF, et al. **Int Rev Cytol** 1999;185:1–43 (242 ref.)
Therapeutic angiogenesis: protein and gene therapy delivery strategies. Rosengart TK, et al. **J Cardiovasc Risk** 1999 Feb;6(1):29–40 (169 ref.)
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. Isner JM, et al. **J Clin Invest** 1999 May;103(9):1231–6 (28 ref.)
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. Stetler-Stevenson WG. **J Clin Invest** 1999 May;103(9):1237–41 (24 ref.)
Role of vascular endothelial growth factor in the regulation of angiogenesis. Ferrara N. **Kidney Int** 1999 Sep; 56(3):794–814 (285 ref.)
Is physiological angiogenesis in skeletal muscle regulated by changes in microcirculation? Hudlicka O. **Microcirculation** 1998;5(1):5–23 (85 ref.)
Where do new arterioles come from? Mechanical forces and microvessel adaptation. Skalak TC, et al. **Microcirculation** 1998;5(2-3):91–4 (15 ref.)
Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Badet J. **Pathol Biol (Paris)** 1999 Apr;47(4):345–51 (57 ref.)
Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Cao Y. **Prog Mol Subcell Biol** 1998;20:161–76 (67 ref.)
VEGFs, receptors and angiogenesis. Veikkola T, et al. **Semin Cancer Biol** 1999 Jun;9(3):211–20 (99 ref.)
[From the angiogenic response to ischemia to the validation of the concept of "therapeutic angiogenesis"] Van Belle E, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91(9):1159–70 (70 ref.) (Eng. Abstr.) **(Fre)**
[Emergence of the endothelial network during embryonic development] Dieterlen-Lièvre F, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):301–6 (17 ref.) (Eng. Abstr.) **(Fre)**
[VEGF in therapeutic coronary and peripheral artery angiogenesis] Elbaz M, et al. **Pathol Biol (Paris)** 1999 Apr; 47(4):380–4 (27 ref.) (Eng. Abstr.) **(Fre)**
[Activation of latent TGF-beta. A required mechanism for vascular integrity] Gleizes PE, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):322–9 (62 ref.) (Eng. Abstr.) **(Fre)**
[Angiogenesis (editorial)] Plouët J. **Pathol Biol (Paris)** 1999 Apr;47(4):300 (0 ref.) **(Fre)**
[Transcription factors and angiogenesis] Soncin F, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):358–63 (42 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic influences on angiogenesis. "From bench to bedside"] Jaeger TM, et al. **Dtsch Med Wochenschr** 1999 Feb 5;124(5):121–3 (24 ref.) **(Ger)**
[Coronary stenosis and mechanisms of collateral vessel growth] Iwakura A, et al. **Nippon Rinsho** 1998 Oct; 56(10):2504–8 (19 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis. Isner JM. **Am J Cardiol** 1998 Nov 19;82(10A):63S–64S (5 ref.)
Manipulating angiogenesis against vascular disease. Isner JM. **Hosp Pract (Off Ed)** 1999 Jun 15;34(6):69–74, 76, 79–80

passim (8 ref.)
Regulating angiogenesis: a new therapeutic strategy. Gibaldi M. **J Clin Pharmacol** 1998 Oct;38(10):898–903 (23 ref.)
Fibroblast growth factor–mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Gonçalves LM. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II11–20 (103 ref.)
Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Baumgartner I, et al. **Vasa** 1998 Nov;27(4):201–6 (76 ref.)
[Thrombospondins: multimodular proteins with angiostatic function] Feige JJ. **Pathol Biol (Paris)** 1999 Apr; 47(4):339–44 (33 ref.) (Eng. Abstr.) **(Fre)**
[Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease] Kalka C, et al. **Med Klin** 1999 Apr 15;94(4):193–201 (98 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Gene therapy for myocardial angiogenesis. Losordo DW, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):132–41 (41 ref.)
What guides early embryonic blood vessel formation? Weinstein BM. **Dev Dyn** 1999 May;215(1):2–11 (46 ref.)

PHYSIOLOGY

Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. Ortéga N, et al. **Biol Cell** 1998 Sep;90(5):381–90 (102 ref.)
Molecular angiogenesis. Klagsbrun M, et al. **Chem Biol** 1999 Aug;6(8):R217–24 (70 ref.)
Therapeutic angiogenesis: the new electrophysiology? [editorial; comment] Patterson C, et al. **Circulation** 1999 May 25;99(20):2614–6 (16 ref.) Comment on: Circulation 1999 May 25;99(20):2682–7.
Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Goligorsky MS, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):269–71 (18 ref.)
Angiogenesis in fracture repair. Glowacki J. **Clin Orthop** 1998 Oct;(355 Suppl):S82–9 (60 ref.)
What guides early embryonic blood vessel formation? Weinstein BM. **Dev Dyn** 1999 May;215(1):2–11 (46 ref.)
Signal relays in the VEGF system. Ortega N, et al. **Front Biosci** 1999 Feb 1;4:D141–52 (130 ref.)
Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Masuda S, et al. **Int J Hematol** 1999 Jul;70(1):1–6 (62 ref.)
The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. Eliceiri BP, et al. **J Clin Invest** 1999 May; 103(9):1227–30 (18 ref.)
Mechanisms of angiogenesis in the brain. Plate KH. **J Neuropathol Exp Neurol** 1999 Apr;58(4):313–20 (62 ref.)
Role of vascular endothelial growth factor in the response to vessel injury. Alvarez Arroyo MV, et al. **Kidney Int Suppl** 1998 Dec;68:S7–9 (8 ref.)
The role of alphav integrins during angiogenesis. Eliceiri BP, et al. **Mol Med** 1998 Dec;4(12):741–50 (82 ref.)
Is extravasation a Fas-regulated process? Walsh K, et al. **Mol Med Today** 1999 Feb;5(2):61–7 (63 ref.)
Angiogenesis of the endometrium. Abulafia O, et al. **Obstet Gynecol** 1999 Jul;94(1):148–53 (49 ref.)
Cell–matrix interactions, alterations with aging, involvement in angiogenesis. Labat-Robert J. **Pathol Biol (Paris)** 1998 Sep;46(7):527–33 (35 ref.)
CXC chemokines and angiogenesis/angiostasis. Keane MP, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug; 110(4):288–96 (75 ref.)
The AT2 receptor: fact, fancy and fantasy. de Gasparo M, et al. **Regul Pept** 1999 May 31;81(1–3):11–24 (154 ref.)
Surgical implications of therapeutic angiogenesis. Zimmerman MA, et al. **Surgery** 1999 Mar;125(3):243–9 (58 ref.)
The mast cell–nerve axis in wound healing: a hypothesis. Gottwald T, et al. **Wound Repair Regen** 1998 Jan–Feb; 6(1):8–20 (160 ref.)
[Angiogenesis in the human reproductive system] Pomyje J. **Ceska Gynekol** 1999 Jan;64(1):68–74 (95 ref.) **(Cze)**
[Angiogenesis in gynecology and obstetrics] Obermair A, et al. **Wien Klin Wochenschr** 1999 Apr 9;111(7):262–77 (131 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic neoangiogensis] Schmeisser A, et al. **Z Kardiol** 1999 Apr;88(4):241–4 (26 ref.) **(Ger)**
[Mucosal microcirculation and angiogenesis in gastrointestinal tract] Tsuji S, et al. **Nippon Rinsho** 1998 Sep;56(9):2247–52 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Recent progress in angiogenesis research] Sato Y. **Nippon Ronen Igakkai Zasshi** 1999 May;36(5):308–16 (66 ref.) **(Jpn)**

NEPHRECTOMY

Is there still a place for angiography in the management of renal mass lesions? Roy C, et al. **Eur Radiol** 1999; 9(2):329–35 (23 ref.)
Laparoscopic live donor nephrectomy: the four year Johns Hopkins University experience. Ratner LE, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2090–3 (10 ref.)
[Lymphatic metastases in renal cell carcinoma. What is the value of operation and adjuvant therapy?] Mickisch GH. **Urologe A** 1999 Jul;38(4):326–31 (29 ref.) (Eng. Abstr.) **(Ger)**
[The multifocality problem in elective partial nephrectomy for renal-cell carcinoma (editorial)] Cabezas CA, et al. **Actas Urol Esp** 1999 Jan;23(1):1–4 (18 ref.) **(Spa)**

METHODS

Nephron-sparing surgery for renal cell carcinoma. Novick AC. **Br J Urol** 1998 Sep;82(3):321–4 (19 ref.)
A 3 trocar technique for transperitoneal laparoscopic nephrectomy. Desgrandchamps F, et al. **J Urol** 1999 May; 161(5):1530–2 (13 ref.)
Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma. Duque JL, et al. **Urology** 1998 Oct;52(4):584–90 (26 ref.)
Laparoscopic live donor nephrectomy: con [editorial; comment] Novick AC. **Urology** 1999 Apr;53(4):668–70 (18 ref.) Comment on: Urology 1999 Apr;53(4):665–7.

NEPHRITIS

[Progresses in the study of nephrology in China, 1997] Zhang Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):887–8 (0 ref.) **(Chi)**
[Epstein syndrome] Maeda M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):314–5 (12 ref.) **(Jpn)**
[Fechtner syndrome] Ohata M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):322–5 (15 ref.) **(Jpn)**

CHEMICALLY INDUCED

Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. Ravnskov U. **Br J Clin Pharmacol** 1999 Feb;47(2):203–10 (85 ref.)

COMPLICATIONS

Henoch–Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Rieu P, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):151–9 (48 ref.)

IMMUNOLOGY

ICAM-1 interactions in the renal interstitium: a novel activator of fibroblasts during nephritis. Clayton A, et al. **Histol Histopathol** 1999 Jul;14(3):861–70 (67 ref.)

MICROBIOLOGY

[Specific infections of the kidney] Hirose T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):556–9 (10 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Cytokines and cellular activation in nephritis. Yokoyama H, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:39–41 (11 ref.)
Endothelial adhesion molecules in health and disease. Cotran RS, et al. **Pathol Biol (Paris)** 1998 Mar;46(3):164–70 (34 ref.)

NEPHRITIS, FAMILIAL see **NEPHRITIS, HEREDITARY**

NEPHRITIS, HEREDITARY

DIAGNOSIS

Alport syndrome and thin glomerular basement membrane disease. Kashtan CE. **J Am Soc Nephrol** 1998 Sep; 9(9):1736–50 (78 ref.)

GENETICS

Alport syndrome and thin glomerular basement membrane disease. Kashtan CE. **J Am Soc Nephrol** 1998 Sep; 9(9):1736–50 (78 ref.)
Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Kashtan CE. **Medicine (Baltimore)** 1999 Sep;78(5):338–60 (218 ref.)

NEPHRITIS, INTERSTITIAL

Tubulointerstitial nephritis and uveitis in children and adolescents. Four new cases and a review of the literature. Vohra S, et al. **Pediatr Nephrol** 1999 Jun;13(5):426–32 (35 ref.)
[Idiopathic tubulo-interstitial nephritis] Yamasaki Y, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1428–34 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Lithium intoxication. Timmer RT, et al. **J Am Soc Nephrol** 1999 Mar;10(3):666–74 (34 ref.)
Drug-induced acute interstitial nephritis. Alexopoulos E. **Ren Fail** 1998 Nov;20(6):809–19 (52 ref.)
[Impaired kidney function in lithium therapy] Gabutti L, et al. **Ther Umsch** 1998 Sep;55(9):562–4 (7 ref.) (Eng. Abstr.) **(Ger)**
[Drug-induced tubulo-interstitial nephropathies] Nakao A, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1439–45 (4 ref.) **(Jpn)**
[Toxic tubulo-interstitial nephropathies] Yanagisawa H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1446–53 (5 ref.) **(Jpn)**

COMPLICATIONS

[Development of arterial hypertension in urate tubulointerstitial renal damage (editorial)] Mukhin NA, et al. **Ter Arkh** 1999;71(6):23–7 (14 ref.) **(Rus)**

DRUG THERAPY

Treatment of acute interstitial nephritis. Reddy S, et al. **Ren Fail** 1998 Nov;20(6):829–38 (24 ref.)

EPIDEMIOLOGY

Renal disease in the elderly. Davison AM. **Contrib Nephrol** 1998;124:126–37; discussion 137–45 (42 ref.)
Acute interstitial nephritis in the elderly: a report from the UK MRC Glomerulonephritis Register and a review of the literature. Davison AM, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:12–6 (22 ref.)

ETIOLOGY

Voluntary ingestion of Cortinarius mushrooms leading to chronic interstitial nephritis. Calviño J, et al. **Am J Nephrol** 1998;18(6):565–9 (19 ref.)
New insights into the pathogenesis of interstitial nephritis. Meyers CM. **Curr Opin Nephrol Hypertens** 1999 May; 8(3):287–92 (40 ref.)
Nitric oxide in interstitial nephritis and other autoimmune diseases. Kelly CJ, et al. **Semin Nephrol** 1999 May; 19(3):288–95 (46 ref.)
[Tubulo-interstitial nephropathies caused by obstructive nephrosis] Fukuzaki A. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1475–9 (5 ref.) **(Jpn)**
[Radiation nephritis] Harada T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1463–6 (5 ref.) **(Jpn)**
[Metabolic tubulo-interstitial nephropathies] Iino Y. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1459–62 (6 ref.) **(Jpn)**
[Tubulo-interstitial nephropathies caused by electrolyte disturbances] Imai E. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1454–8 (6 ref.) **(Jpn)**
[Mechanism of the development of tubulo-interstitial nephropathies due to collagen diseases, angiitis, or granuloma and its significance] Imai H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1467–74 (9 ref.) **(Jpn)**
[Etiology and physiopathology of acute and chronic tubulo-interstitial nephritis] Mitarai T. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1417–22 (5 ref.) **(Jpn)**
[Mechanism of the development of tubulo-interstitial nephropathies caused by proteinuria] Saito T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1480–5 (7 ref.) **(Jpn)**
[Infectious tubulo-interstitial nephritis] Yamabe H. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1435–8 (5 ref.) **(Jpn)**
[Tubulointerstitial nephritis induced by chronic bacterial infection] Hirose T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):552–5 (13 ref.) **(Jpn)**

GENETICS

Renal–retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus [see comments] Caridi G, et al. **Am J Kidney Dis** 1998 Dec;32(6):1059–62 (12 ref.) Comment in: Am J Kidney Dis 1998 Dec;32(6):1084–5.
Chemokines and renal inflammation in proteinuric disorders: searching for the inciting stimulus [editorial; comment] Crisman JM, et al. **J Lab Clin Med** 1999 Jan;133(1):13–4 (13 ref.) Comment on: J Lab Clin Med 1999 Jan;133(1):41–7.

IMMUNOLOGY

Childhood membranous nephropathy, circulating antibodies to the 58-kD TIN antigen, and anti-tubular basement membrane nephritis: an 11-year follow-up. Iványi B, et al. **Am J Kidney Dis** 1998 Dec;32(6):1068–74 (38 ref.)
Autoimmune tubulointerstitial nephritis: insight from experimental models. Wüthrich RP, et al. **Exp Nephrol** 1998 Jul–Aug;6(4):288–93 (26 ref.)
Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane. Tokumoto M, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2210–5 (28 ref.)
Cellular immunity and the tubulointerstitium. Kelly CJ. **Semin Nephrol** 1999 Mar;19(2):182–7 (57 ref.)
[Clonality of infiltrative T cells in tubular dysfunction caused by Sjogren's syndrome] Murata H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1486–91 (5 ref.) **(Jpn)**
[Immunological mechanisms involved in renal tubular and interstitial lesions] Nangaku M. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1396–401 (5 ref.) **(Jpn)**

NEPHRITIS, INTERSTITIAL

METABOLISM

Modulatory proteins and processes in alliance with immune cells, mediators, and extracellular proteins in renal interstitial fibrosis. Wardle EN. **Ren Fail** 1999 Mar; 21(2):121-33 (110 ref.)

MICROBIOLOGY

Acute post streptococcal interstitial nephritis in an adult and review of the literature. Dharmarajan TS, et al. **Int Urol Nephrol** 1999;31(2):145-8 (15 ref.)

PATHOLOGY

Granulomatous interstitial nephritis in extrapulmonary sarcoidosis. Utaş C, et al. **Clin Nephrol** 1999 Apr; 51(4):252-4 (8 ref.)

Role of tubule epithelial cells in the pathogenesis of tubulointerstitial fibrosis induced by glomerular disease [editorial] Healy E, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):525-30 (57 ref.)

The evolving contribution of renal pathology to understanding interstitial nephritis. Alpers CE. **Ren Fail** 1998 Nov;20(6):763-71 (24 ref.)

[Pathology of tubulo-interstitial nephropathies] Taguchi T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1402-9 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Autoimmune tubulointerstitial nephritis: insight from experimental models. Wüthrich RP, et al. **Exp Nephrol** 1998 Jul-Aug;6(4):288-93 (26 ref.)

[Renal tubular dysfunctions and clinical symptoms of tubulo-interstitial nephropathies] Kato T. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1410-6 (1 ref.) **(Jpn)**

NEPHRITIS, LUPUS see **LUPUS NEPHRITIS**

NEPHRITIS, TUBULOINTERSTITIAL see **NEPHRITIS, INTERSTITIAL**

NEPHROBLASTOMA

see related
GENES, WILMS' TUMOR

Pediatric genitourinary tumors. Lee HH, et al. **Curr Opin Oncol** 1999 May;11(3):218-25 (57 ref.)

Wilms' tumor and related abnormalities in the fetus and newborn. Bove KE. **Semin Perinatol** 1999 Aug;23(4):310-8 (59 ref.)

DIAGNOSIS

Teratoid Wilms tumor arising as a botryoid growth within a supernumerary ectopic ureteropelvic structure. Pawel BR, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):925-8 (26 ref.)

Adult Wilms' tumour. A report of two cases and their treatment and prognosis. Akmansu M, et al. **Int Urol Nephrol** 1998;30(5):529-33 (15 ref.)

Imaging of patients with Wilms' tumor. Goske MJ, et al. **Semin Urol Oncol** 1999 Feb;17(1):11-20 (23 ref.)

DRUG THERAPY

Veno-occlusive disease of the liver in right-sided Wilms' tumours [see comments] Tornesello A, et al. **Eur J Cancer** 1998 Jul;34(8):1220-3 (21 ref.) Comment in: Eur J Cancer 1998 Jul;34(8):1145-7. Comment in: Eur J Cancer 1999 Mar;35(3):521-3.

GENETICS

Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Beckwith JB. **Am J Med Genet** 1998 Oct 2;79(4):268-73 (25 ref.)

Wilms tumor genetics. Huff V. **Am J Med Genet** 1998 Oct 2;79(4):260-7 (86 ref.)

The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Brigstock DR. **Endocr Rev** 1999 Apr;20(2):189-206 (158 ref.)

Genetics of kidney tumours. Fleming S. **Forum (Genova)** 1998 Apr-Jun;8(2):176-84 (33 ref.)

Syndrome of microcephaly, Dandy-Walker malformation, and Wilms tumor caused by mosaic variegated aneuploidy with premature centromere division (PCD): report of a new case and review of the literature. Kawame H, et al. **J Hum Genet** 1999;44(4):219-24 (16 ref.)

Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Schedl A, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):65-9 (35 ref.)

Genetics of Wilms' tumor. Coppes MJ, et al. **Semin Urol Oncol** 1999 Feb;17(1):2-10 (85 ref.)

NURSING

Diagnosis and referral of Wilms' tumor. Pye S. **Nurse Pract** 1999 May;24(5):121-2, 127 (6 ref.)

PATHOLOGY

Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Beckwith JB. **Am J Med Genet** 1998 Oct 2;79(4):268-73 (25 ref.)

A case of panlobar nephroblastomatosis with bilateral Wilms' tumour. The concept of "nephroblastomatosis" and its clinical importance. Lancaster EJ, et al. **Cent Afr J Med** 1998 Jul;44(7):182-7 (15 ref.)

Extrarenal Wilms' tumor of the uterus. Jiskoot P, et al. **Eur J Gynaecol Oncol** 1999;20(3):195-7 (7 ref.)

National Wilms Tumor Study: an update for pathologists. Beckwith JB. **Pediatr Dev Pathol** 1998 Jan-Feb;1(1):79-84 (14 ref.)

SECONDARY

Wilms' tumor in the adult--report of a case and review of the literature. Tawil A, et al. **Pathol Res Pract** 1999; 195(2):105-11; discussion 113-4 (29 ref.)

SURGERY

Risk-based management: current concepts of treating malignant solid tumors of childhood. Grosfeld JL. **J Am Coll Surg** 1999 Oct;189(4):407-25 (93 ref.)

THERAPY

Wilms' tumour. Optimal treatment strategies. Suryanarayan K, et al. **Drugs** 1998 Oct;56(4):598-605 (28 ref.)

Adult Wilms' tumour. A report of two cases and their treatment and prognosis. Akmansu M, et al. **Int Urol Nephrol** 1998;30(5):529-33 (15 ref.)

Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Egeler RM, et al. **Semin Urol Oncol** 1999 Feb;17(1):55-61 (35 ref.)

NEPHROCALCINOSIS

GENETICS

The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Thakker RV. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):385-8 (42 ref.)

RADIOGRAPHY

Abnormal calcifications in the urinary tract. Dyer RB, et al. **Radiographics** 1998 Nov-Dec;18(6):1405-24 (37 ref.)

NEPHROLITHOTOMY, PERCUTANEOUS see **NEPHROSTOMY, PERCUTANEOUS**

NEPHROLOGY

see related
KIDNEY DISEASES

Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Beckwith JB. **Am J Med Genet** 1998 Oct 2;79(4):268-73 (25 ref.)

Evidence-based nephrology. Haugh M, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:38-41 (8 ref.)

METHODS

Applications of capillary electrophoresis in nephrology. Stocking CJ, et al. **Exp Nephrol** 1998 Sep-Oct;6(5):415-20 (62 ref.)

Evidence-based medicine and its horizons: a useful tool for nephrologists? Liberati A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:46-52 (40 ref.)

Laparoscopy and retroperitoneoscopy--novel techniques of which clinical nephrologists should be aware. Rassweiler J, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):313-7 (7 ref.)

STANDARDS

How good are nephrologists at controlling blood pressure in renal patients? [editorial] Maschio G. **Nephrol Dial Transplant** 1999 Sep;14(9):2075-7 (20 ref.)

TRENDS

The future of end-stage renal disease care: nephrology enters a new millennium. Hoffart N, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):257-66 (34 ref.)

New insights related to aging and renal osteodystrophy. Hruska KA. **Geriatr Nephrol Urol** 1999;9(1):49-56 (41 ref.)

Nephrology. Reducing mortality and increasing awareness. Schieppati A, et al. **Lancet** 1998 Dec 19-26;352 Suppl 4:SIV20 (5 ref.)

Current knowledge of the pathogenesis of chronic allograft dysfunction. Paul LC. **Transplant Proc** 1999 Jun; 31(4):1793-5 (28 ref.)

[Nephrology] Sterzel RB. **Internist (Berl)** 1999 Apr; 40(4):386-90 (0 ref.) **(Ger)**

NEPHROMA, MESOBLASTIC

CONGENITAL

Classical congenital mesoblastic nephroma in an adult: a case report on an Ethiopian. Gemechu T, et al. **Ethiop Med J** 1997 Oct;35(4):257-62 (13 ref.)

PATHOLOGY

Mesoblastic nephroma in adulthood: a case report. Shiraishi K, et al. **Int J Urol** 1999 Aug;6(8):414-8 (23 ref.)

NEPHRONS

EMBRYOLOGY

Molecular regulation of nephron endowment. Clark AT, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):F485-97 (100 ref.)

METABOLISM

Nitric oxide, endothelin and nephron transport: potential interactions. Plato CF, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):262-8 (49 ref.)

PHYSIOPATHOLOGY

Nephron number: variability is the rule. Causes and consequences. Merlet-Bénichou C, et al. **Lab Invest** 1999 May;79(5):515-27 (142 ref.)

Nephrotoxicity of increased glomerular protein traffic. Abbate M, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):304-12 (78 ref.)

[Chronic renal insufficiency: 1) adaptation of nephron function in chronic renal insufficiency and 2) progression of chronic renal insufficiency] Savin M. **Srp Arh Celok Lek** 1998 Jul-Aug;126(7-8):261-70 (83 ref.) (Eng. Abstr.) **(Scc)**

TRANSPLANTATION

Distinguished Scientists Lecture Series. New developments in kidney development. Hammerman MR. **Nephron** 1999 Feb;81(2):131-5 (17 ref.)

NEPHROPATHIA EPIDEMICA see **HANTAVIRUS INFECTIONS**

NEPHROPATHY, BALKAN see **BALKAN NEPHROPATHY**

NEPHROPATHY, IGA see **GLOMERULONEPHRITIS, IGA**

NEPHROPATHY, MEMBRANOUS see **GLOMERULONEPHRITIS, MEMBRANOUS**

NEPHROPATHY, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

NEPHROSCLEROSIS

DIAGNOSIS

The clinical diagnosis of hypertensive nephrosclerosis--how reliable is it? [editorial] Caetano EP, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):288-90 (16 ref.)

ETIOLOGY

The kidney as part of the cardiovascular system. Ruilope LM. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S7-10; discussion S41-3 (50 ref.)

The clinical diagnosis of hypertensive nephrosclerosis--how reliable is it? [editorial] Caetano EP, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):288-90 (16 ref.)

PHYSIOPATHOLOGY

Progression of renal failure and hypertensive nephrosclerosis. Zucchelli P, et al. **Kidney Int Suppl** 1998 Dec;68:S55-9 (50 ref.)

Risk factors associated with hypertensive nephrosclerosis [editorial] Bleyer AJ, et al. **Nephron** 1999;82(3):193-8 (45 ref.)

NEPHROSIS

DRUG THERAPY

[Treatment of nephrosis in the child] Loirat C, et al. **Arch Pediatr** 1998;5 Suppl 2:142s-149s (72 ref.) **(Fre)**

NEPHROSIS, LIPOID

DIAGNOSIS

[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy] Branten AJ, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2832-8 (31 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy] Branten AJ, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2832-8 (31 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Thymoma associated with myasthenia gravis and minimal lesion nephrotic syndrome. Lasseur C, et al. **Am J Kidney Dis** 1999 May;33(5):e4 (19 ref.)

[A case of nephrotic syndrome associated with myasthenia gravis and malignant thymoma] Tomida C, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):77-82 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Thymoma associated with myasthenia gravis and minimal lesion nephrotic syndrome. Lasseur C, et al. **Am J Kidney Dis** 1999 May;33(5):e4 (19 ref.)

NEPHROSTOMY, PERCUTANEOUS

Do's and don't's of percutaneous nephrostomy. Zagoria RJ, et al. **Acad Radiol** 1999 Jun;6(6):370–7 (25 ref.)

Long-term outcome of caliceal diverticula following percutaneous endosurgical management. Shalhav AL, et al. **J Urol** 1998 Nov;160(5):1635–9 (25 ref.)

NEPHROTIC SYNDROME

The idiopathic nephrotic syndrome. Chesney RW. **Curr Opin Pediatr** 1999 Apr;11(2):158–61 (23 ref.)

[HIV-associated nephropathy in children] Cachat F, et al. **Arch Pediatr** 1998 Dec;5(12):1353–8 (39 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Drug-induced renal toxicity: diagnosis and prevention. Farrugia E. **Hosp Med** 1998 Feb;59(2):140–4 (11 ref.)

COMPLICATIONS

Nephrotic range proteinuria and hematuria in a white bisexual male. Paueksakon P, et al. **Am J Kidney Dis** 1999 Mar;33(3):607–12 (27 ref.)

Prevention of serious bacterial infection in children with nephrotic syndrome. McIntyre P, et al. **J Paediatr Child Health** 1998 Aug;34(4):314–7 (39 ref.)

Should hyperlipidemia in children with the nephrotic syndrome be treated? Querfeld U. **Pediatr Nephrol** 1999 Jan;13(1):77–84 (83 ref.)

[Renal manifestations of Kimura disease. Apropos of a case] Maheut H, et al. **Nephrologie** 1998;19(6):335–40 (40 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral infarction associated with nephrotic syndrome in a young adult: a case report] Izumi M, et al. **No To Shinkei** 1998 Dec;50(12):1119–24 (13 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy] Branten AJ, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2832–8 (31 ref.) (Eng. Abstr.) **(Dut)**

[Acute nephrotic syndrome. Physiopathology, diagnosis] Pouteil-Noble C. **Rev Prat** 1998 Jun 15;48(12):1337–44 (00 ref.) **(Fre)**

DRUG THERAPY

Treatment of childhood steroid-resistant idiopathic nephrotic syndrome. Niaudet P, et al. **Adv Nephrol Necker Hosp** 1998; 28:43–61 (100 ref.)

Reversal of nephrotic syndrome due to AA amyloidosis in psoriatic patients on long-term colchicine treatment. Case report and review of the literature. Kagan A, et al. **Nephron** 1999;82(4):348–53 (53 ref.)

[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy] Branten AJ, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2832–8 (31 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Rare syndromes in Hodgkin's disease. Cavalli F. **Ann Oncol** 1998;9 Suppl 5:S109–13 (26 ref.)

Primary antiphospholipid syndrome presented by total infarction of right kidney with nephrotic syndrome. Sá H, et al. **Clin Nephrol** 1999 Jul;52(1):56–60 (21 ref.)

[Reversible nephrotic syndrome in Crohn's disease complicated with renal amyloidosis] Larvol L, et al. **Gastroenterol Clin Biol** 1998 Jun-Jul;22(6–7):639–41 (26 ref.) (Eng. Abstr.) **(Fre)**

[Nephrotic syndrome. Development, complications and treatment] Sester U, et al. **Urologe A** 1998 Sep;37(5):537–45 (7 ref.) **(Ger)**

GENETICS

[Genetics and nephrotic syndrome] Niaudet P, et al. **Arch Pediatr** 1998;5 Suppl 2:152s–155s (17 ref.) **(Fre)**

METABOLISM

New insights into lipid metabolism in the nephrotic syndrome. Kaysen GA, et al. **Kidney Int Suppl** 1999 Jul; 71:S18–21 (27 ref.)

PATHOLOGY

A 46-year-old woman with nephrotic syndrome and persistent microscopic hematuria. Milord R, et al. **Am J Kidney Dis** 1998 Dec;32(6):1098–105 (51 ref.)

PHYSIOPATHOLOGY

Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy [editorial] Wang SN, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2072–4 (12 ref.)

[Acute nephrotic syndrome. Physiopathology, diagnosis] Pouteil-Noble C. **Rev Prat** 1998 Jun 15;48(12):1337–44 (00 ref.) **(Fre)**

[Nephrotic syndrome. What is new since the 1988 study?] Seves MG, et al. **Acta Med Port** 1998 Jul;11(7):631–4 (19 ref.) (Eng. Abstr.) **(Por)**

THERAPY

[Nephrotic syndrome] Orth SR, et al. **Internist (Berl)** 1998 Dec;39(12):1246–52 (36 ref.) **(Ger)**

NEPHROTIC SYNDROME, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

NEPRILYSIN

ANTAGONISTS & INHIBITORS

Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC Jr. **J Hypertens Suppl** 1999 Feb; 17(1):S27–43 (49 ref.)

PHYSIOLOGY

Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation. Koehne P, et al. **Allergy** 1998 Nov;53(11):1023–42 (248 ref.)

Neuroendocrine differentiation, neuropeptides, and neprilysin. Cohen AJ, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):1–3 (20 ref.)

Peptidases: structure, function and modulation of peptide-mediated effects in the human lung. van der Velden VH, et al. **Clin Exp Allergy** 1999 Apr;29(4):445–56 (50 ref.)

Regulation of airway neurogenic inflammation by neutral endopeptidase [see comments] Di Maria GU, et al. **Eur Respir J** 1998 Dec;12(6):1454–62 (109 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250–1.

[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors] Stanović S, et al. **Lijec Vjesn** 1998 May; 120(5):131–7 (56 ref.) (Eng. Abstr.) **(Scr)**

NERVE BLOCK

Epinephrine in digital blocks: revisited. Wilhelmi BJ, et al. **Ann Plast Surg** 1998 Oct;41(4):410–4 (62 ref.)

Thoracic paravertebral block [see comments] Richardson J, et al. **Br J Anaesth** 1998 Aug;81(2):230–8 (104 ref.) Comment in: Br J Anaesth 1999 Jan;82(1):149–50.

[Diagnostic assessment in lumbar back pain. II. Imaging and image-guided infiltrations] Pfirrmann CW, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):315–21 (19 ref.) (Eng. Abstr.) **(Ger)**

[Therapy oriented neurology from repair to remedy] Kimura J. **Rinsho Shinkeigaku** 1998 Dec;38(12):969–73 (14 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Complications of regional blocks: what do we really know? Brown DL. **Can J Anaesth** 1999 May;46(5 Pt 2):R10–7 (30 ref.) **(Eng, Fre)**

METHODS

Selective lumbar spinal nerve block, a review. Pang WW, et al. **Acta Anaesthesiol Sin** 1999 Mar;37(1):21–6 (48 ref.)

Intraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancer. Sakorafas GH, et al. **Eur J Surg Oncol** 1999 Aug;25(4):427–31 (25 ref.)

Conservative management of low back pain. Rosen NB, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):435–72, ix (110 ref.)

Routine anesthesia for circumcision. Two effective techniques. Mattson SR. **Postgrad Med** 1999 Jul; 106(1):107–9 (5 ref.)

Local and regional block in postoperative pain control. Peng PW, et al. **Surg Clin North Am** 1999 Apr;79(2):345–70 (181 ref.)

Palliation of pain in chronic pancreatitis. Use of neural blocks and neurotomy. Wong GY, et al. **Surg Clin North Am** 1999 Aug;79(4):873–93 (71 ref.)

NERVE CELLS see **NEURONS**

NERVE COMPRESSION SYNDROMES

Compression and entrapment neuropathies of the lower extremity. McCluskey LF, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):97–125, vii (25 ref.)

Multiple nerve entrapment syndromes in office workers. Novak CB, et al. **Occup Med** 1999 Jan-Mar;14(1):39–59, iii (92 ref.)

COMPLICATIONS

Abdominal wall pain caused by cutaneous nerve entrapment in an adolescent girl taking oral contraceptive pills. Peleg R. **J Adolesc Health** 1999 Jan;24(1):45–7 (13 ref.)

Unilateral trismus in a patient with trigeminal neuralgia due to microvascular compression of the trigeminal motor root. Thompson TP, et al. **J Oral Maxillofac Surg** 1999 Jan; 57(1):90–2 (13 ref.)

Nerve entrapment syndromes as a cause of pain in the hip, groin and buttock. McCrory P, et al. **Sports Med** 1999 Apr; 27(4):261–74 (74 ref.)

DIAGNOSIS

Uncommon nerve compression syndromes of the upper extremity. Lubahn JD, et al. **J Am Acad Orthop Surg** 1998 Nov-Dec;6(6):378–86 (38 ref.)

Disputed radial tunnel syndrome. Rosenbaum R. **Muscle Nerve** 1999 Jul;22(7):960–7 (46 ref.)

Femoral and obturator neuropathies. Busis NA. **Neurol Clin** 1999 Aug;17(3):633–53, vii (175 ref.)

Radial neuropathy. Carlson N, et al. **Neurol Clin** 1999 Aug; 17(3):499–523, vi (100 ref.)

Proximal neuropathies of the upper extremity. Goslin KL, et al. **Neurol Clin** 1999 Aug;17(3):525–48, vii (108 ref.)

Proximal median neuropathies. Gross PT, et al. **Neurol Clin** 1999 Aug;17(3):425–45, v (53 ref.)

Peroneal neuropathy. Katirji B. **Neurol Clin** 1999 Aug; 17(3):567–91, vii (19 ref.)

Ulnar neuropathy at the wrist. Kothari MJ. **Neurol Clin** 1999 Aug;17(3):463–76, vi (37 ref.)

Clinical neurophysiologic studies: which test is useful and when? Lomen-Hoerth C, et al. **Neurol Clin** 1999 Feb; 17(1):65–74 (27 ref.)

Entrapment neuropathies of the tibial (posterior tibial) nerve. Oh SJ, et al. **Neurol Clin** 1999 Aug;17(3):593–617, vii (77 ref.)

Distal median neuropathies. Preston DC. **Neurol Clin** 1999 Aug;17(3):407–24, v (24 ref.)

Proximal sensory neuropathies of the Leg. Reid V, et al. **Neurol Clin** 1999 Aug;17(3):655–67, viii (45 ref.)

Sciatic neuropathy. Yuen EC, et al. **Neurol Clin** 1999 Aug; 17(3):617–31, viii (95 ref.)

Electrodiagnostic evaluation of the foot. Park TA, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):871–96, vii–viii (96 ref.)

[Compressive ischemic neuropathies of the upper extremities and work] Kadaňka Z, et al. **Cas Lek Cesk** 1999 Apr 19; 138(8):230–4 (23 ref.) (Eng. Abstr.) **(Cze)**

EPIDEMIOLOGY

Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review. Kobata H, et al. **Neurosurgery** 1998 Dec; 43(6):1351–61; discussion 1361–2 (109 ref.)

ETIOLOGY

A ganglion of the spinoglenoid notch. Steinwachs MR, et al. **J Shoulder Elbow Surg** 1998 Sep-Oct;7(5):550–4 (25 ref.)

Cervical actinomycosis causing spinal cord compression and multisegmental root failure: case report and review of the literature. Oruçkaptan HH, et al. **Neurosurgery** 1998 Oct; 43(4):937–40 (20 ref.)

Suprascapular entrapment neuropathy and ganglion cysts about the shoulder. Ferrick MR, et al. **Orthopedics** 1999 Apr;22(4):430–4; discussion 434–5; quiz 436–7 (47 ref.)

[Cervical deficit radiculopathy in 3 cases of vertebral artery dissection] de Bray JM, et al. **Rev Neurol (Paris)** 1998 Nov; 154(11):762–6 (13 ref.) (Eng. Abstr.) **(Fre)**

[A rare cause of peracute vision loss: pseudotumor cerebri. Case report of course with recurrence after decompression of the optic nerve] Heckmann JG, et al. **Nervenarzt** 1998 Aug;69(8):702–6 (43 ref.) (Eng. Abstr.) **(Ger)**

[Unilateral visual field defect due to optic nerve compression by sclerotic internal carotid artery: a case report] Uchino M, et al. **No Shinkei Geka** 1999 Feb;27(2):189–94 (8 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[The cauda equina syndrome and a sacral lithic mass] Zambrana García JL, et al. **Rev Clin Esp** 1999 Jul; 199(7):471–2 (7 ref.) **(Spa)**

SURGERY

Operative techniques and clinicopathologic correlation in the surgical treatment of cranial rhizopathies (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:181–95 (18 ref.)

Outcome after microvascular decompression for typical trigeminal neuralgia, hemifacial spasm, tinnitus, disabling positional vertigo, and glossopharyngeal neuralgia (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997; 44:331–83 (119 ref.)

Selection criteria for the treatment of cranial rhizopathies by microvascular decompression (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:69–77 (31 ref.)

Surgery of common paralytic conditions. Duerkson F. **Lepr Rev** 1998 Dec;69(4):390–6 (0 ref.)

Nerve entrapments of the upper extremity: A surgical perspective. Levine BP, et al. **Neurol Clin** 1999 Aug; 17(3):549–65, vii (91 ref.)

Multisegmental cervical spondylotic myelopathy and radiculopathy treated by multilevel oblique corpectomies without fusion. George B, et al. **Neurosurgery** 1999 Jan; 44(1):81–90 (117 ref.)

[Anterior interosseous nerve syndrome] Grünert J, et al.

NERVE COMPRESSION SYNDROMES

Unfallchirurg 1999 May;102(5):384–90 (47 ref.) **(Ger)**

THERAPY

Uncommon nerve compression syndromes of the upper extremity. Lubahn JD, et al. **J Am Acad Orthop Surg** 1998 Nov–Dec;6(6):378–86 (38 ref.)

ULTRASONOGRAPHY

Tendon and nerve sonography. Martinoli C, et al. **Radiol Clin North Am** 1999 Jul;37(4):691–711, viii (81 ref.)

NERVE CONDUCTION see **NEURAL CONDUCTION**

NERVE CROSSOVER see **NERVE TRANSFER**

NERVE DEGENERATION

Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. McShea A, et al. **Med Hypotheses** 1999 Jun;52(6):525–7 (31 ref.)

Therapeutic potential of neurotrophins for treatment of hearing loss. Gao WQ. **Mol Neurobiol** 1998 Winter; 17(1–3):17–31 (88 ref.)

On the relationship between extracellular glutamate, hyperexcitation and neurodegeneration, in vivo. Tapia R, et al. **Neurochem Int** 1999 Jan;34(1):23–31 (111 ref.)

Nitric-oxide synthase and neurodegeneration/neuroprotection. Kaufman PL. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9455–6 (22 ref.)

Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interaction with insulin-like growth factor-1. Loddick SA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9449–51 (33 ref.)

[Perforant pathway degeneration as a system degeneration: secondary hippocampal degeneration in Alzheimer-type dementia] Mizutani T. **No To Shinkei** 1998 Oct; 50(10):895–905 (40 ref.) **(Jpn)**

[Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration] Ishiguro K. **Rinsho Byori** 1998 Oct; 46(10):1003–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Corticobasal degeneration (CBD)] Soma Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):52–4 (13 ref.) **(Jpn)**

[The amyloid and tau hypothesis in degenerative dementia] Fladby T, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10; 119(7):976–9 (36 ref.) (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Fadda F, et al. **Prog Neurobiol** 1998 Nov;56(4):385–431 (649 ref.)

DRUG THERAPY

Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Chabrier PE, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1029–35 (73 ref.)

Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Skaper SD, et al. **Mol Cell Neurosci** 1998 Nov;12(4–5):179–93 (127 ref.)

[Neurotrophic factor and nerve degenerative diseases] Taniwaki T. **Fukuoka Igaku Zasshi** 1998 Aug;89(8):221–4 (5 ref.) **(Jpn)**

ETIOLOGY

[Human diseases associated with ubiquitin/proteasome proteolytic system] Anan T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):776–86 (45 ref.) **(Jpn)**

GENETICS

Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Lesch KP, et al. **Biol Psychiatry** 1998 Aug 1;44(3):179–92 (75 ref.)

Transgenic models of neurodegeneration. Neurodegeneration: of (transgenic) mice and men. Aguzzi A, et al. **Brain Pathol** 1998 Oct;8(4):695–7 (17 ref.)

Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Morrison BM, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):121–35 (140 ref.)

Neural disease: Drosophila degenerates for a good cause. Mutsuddi M, et al. **Curr Biol** 1998 Nov 5;8(22):R809–11 (21 ref.)

Proteolipid protein gene: Pelizaeus-Merzbacher disease in humans and neurodegeneration in mice. Woodward K, et al. **Trends Genet** 1999 Apr;15(4):125–8 (31 ref.)

IMMUNOLOGY

The contribution of inflammation to acute and chronic neurodegeneration. Perry VH, et al. **Res Immunol** 1998 Sep–Oct;149(7–8):721–5 (34 ref.)

PATHOLOGY

Upper motor neuron predominant degeneration with frontal and temporal lobe atrophy. Konagaya M, et al. **Acta Neuropathol (Berl)** 1998 Nov;96(5):532–6 (22 ref.)

Mitochondria in organismal aging and degeneration. Cortopassi GA, et al. **Biochim Biophys Acta** 1999 Feb 9; 1410(2):183–93 (100 ref.)

'Like a thief in the night': the selectivity of degeneration in Parkinson's disease [editorial; comment] Saper CB. **Brain** 1999 Aug;122 (Pt 8):1401–2 (20 ref.) Comment on: Brain 1999 Aug;122 (Pt 8):1421–36. Comment on: Brain 1999 Aug;122 (Pt 8):1437–48.

Axonal atrophy: the retraction reaction. Bernstein M, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):364–70 (52 ref.)

Mitochondria in neurodegeneration: bioenergetic function in cell life and death. Murphy AN, et al. **J Cereb Blood Flow Metab** 1999 Mar;19(3):231–45 (162 ref.)

Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. Iqbal K, et al. **J Neural Transm Suppl** 1998;53:169–80 (59 ref.)

3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Alexi T, et al. **Neuroreport** 1998 Aug 3;9(11):R57–64 (72 ref.)

Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Cha JH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):981–9 (53 ref.)

[Neuropathologic markers in degenerative dementias] Hauw JJ, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S50–64 (115 ref.) (Eng. Abstr.) **(Fre)**

[Structure and functions of the macroglia in the central nervous system. Response to degenerative disorders] Ramírez-Expósito MJ, et al. **Rev Neurol** 1998 Apr; 26(152):600–11 (294 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Cell culture models of neuronal degeneration and neuroprotection. Implications for Parkinson's disease. Leonardi ET, et al. **Adv Exp Med Biol** 1998;446:203–22 (136 ref.)

Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Hirsch EC, et al. **Adv Neurol** 1999;80:9–18 (78 ref.)

Nitric oxide and basal ganglia degeneration. Rose S, et al. **Adv Neurol** 1999;80:247–57 (98 ref.)

Functional consequences of dopaminergic degeneration in Parkinson's disease. Tedroff JM. **Adv Neurol** 1999;80:67–70 (84 ref.)

Nitric oxide in cerebral ischemic neurodegeneration and excitotoxicity. Strijbos PJ. **Crit Rev Neurobiol** 1998; 12(3):223–43 (196 ref.)

Experimental developments in movement disorders: update on proposed free radical mechanisms. Przedborski S, et al. **Curr Opin Neurol** 1998 Aug;11(4):335–9 (339 ref.)

Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma. Tatton WG. **Eur J Ophthalmol** 1999 Jan–Mar;9 Suppl 1:S22–9 (52 ref.)

Neurodegeneration in ataxia-telangiectasia is caused by horror autotoxicus. Kuljis RO, et al. **Med Hypotheses** 1999 May;52(5):377–82 (50 ref.)

Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease. Kanfer JN, et al. **Neurosci Lett** 1998 Nov 27;257(2):93–6 (27 ref.)

Metabotropic glutamate receptors and neurodegeneration. Bruno V, et al. **Prog Brain Res** 1998;116:209–21 (98 ref.)

Glutamate toxicity in chronic neurodegenerative disease. Lancelot E, et al. **Prog Brain Res** 1998;116:331–47 (190 ref.)

Neurodegeneration and glutamate induced oxidative stress. Nakao N, et al. **Prog Brain Res** 1998;116:245–63 (116 ref.)

[Neurodegeneration and nitric oxide] Kluchova D. **Bratisl Lek Listy** 1999 Mar;100(3):144–8 (48 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Neufeld AH. **J Glaucoma** 1998 Dec;7(6):434–8 (44 ref.)

PSYCHOLOGY

[Dementias and memory impairment of degenerative origin] Baron JC. **Rev Neurol (Paris)** 1998;154 Suppl 2:S122–30 (57 ref.) (Eng. Abstr.) **(Fre)**

NERVE ENDINGS

see related

PRESYNAPTIC TERMINALS

Use of fluorescent probes to follow membrane traffic in nerve terminals. Guatimosim C, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1491–500 (60 ref.)

METABOLISM

Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. Garzón M, et al. **J Comp Neurol** 1999 Jul 26;410(2):197–210 (108 ref.)

PHYSIOLOGY

Carotid body glomus cells: chemical secretion and transmission (modulation?) across cell-nerve ending junctions. Eyzaguirre C, et al. **Respir Physiol** 1999 Apr 1;115(2):135–49 (47 ref.)

NERVE ENDINGS, PRESYNAPTIC see **PRESYNAPTIC TERMINALS**

NERVE ENDINGS, SENSORY see **RECEPTORS, SENSORY**

NERVE ENTRAPMENT see **NERVE COMPRESSION SYNDROMES**

NERVE FIBERS

METABOLISM

Distribution of calbindin D-28k and parvalbumin neurons and fibers in the rat basal ganglia. Hontanilla B, et al. **Brain Res Bull** 1998 Sep 15;47(2):107–16 (85 ref.)

PATHOLOGY

Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Weinreb RN, et al. **Eur J Ophthalmol** 1999 Jan–Mar;9 Suppl 1:S40–3 (29 ref.)

PHYSIOLOGY

Current concepts of climbing fiber function. Bloedel JR, et al. **Anat Rec** 1998 Aug;253(4):118–26 (28 ref.)

Tectal fiber connections in a non-teleost actinopterygian fish, the sturgeon Acipenser. Yamamoto N, et al. **Brain Behav Evol** 1999;53(3):142–55 (47 ref.)

Rapid structural changes in nerve fibers and cells associated with their excitation processes. Tasaki I. **Jpn J Physiol** 1999 Apr;49(2):125–38 (62 ref.)

Origin and neurochemical characteristics of nerve fibres supplying the mammalian vas deferens. Kaleczyc J. **Microsc Res Tech** 1998 Sep 15;42(6):409–22 (110 ref.)

Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system. Yew DT, et al. **Microsc Res Tech** 1999 Jun 15;45(6):389–400 (123 ref.)

Dissociation of dorsal root ganglion neurons into afferent and efferent-like neurons. Holzer P, et al. **Neuroscience** 1998 Sep;86(2):389–98 (101 ref.)

Movement-related gating of climbing fibre input to cerebellar cortical zones. Apps R. **Prog Neurobiol** 1999 Apr; 57(5):537–62 (138 ref.)

Efferent functions of C-fiber nociceptors. Sann H, et al. **Z Rheumatol** 1998;57 Suppl 2:8–13 (27 ref.)

ULTRASTRUCTURE

Fenestration nodes and the wide submyelinic space form the basis for the unusually fast impulse conduction of shrimp myelinated axons. Xu K, et al. **J Exp Biol** 1999 Aug;202 (Pt 15):1979–89 (35 ref.)

NERVE FIBERS, MYELINATED

METABOLISM

Ion channel redistribution and function during development of the myelinated axon. Vabnick I, et al. **J Neurobiol** 1998 Oct;37(1):80–96 (90 ref.)

NERVE GROWTH CONE MEMBRANE PROTEIN GAP-43 see **GAP-43 PROTEIN**

NERVE GROWTH FACTOR RECEPTORS see **RECEPTORS, NERVE GROWTH FACTOR**

NERVE GROWTH FACTORS

see related

RECEPTORS, NERVE GROWTH FACTOR

DCC and netrins. Culotti JG, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):609–13 (39 ref.)

Roles of neurotrophins on synaptic development and functions in the central nervous system. Takei N, et al. **Hum Cell** 1998 Sep;11(3):157–65 (64 ref.)

ADMINISTRATION & DOSAGE

Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Kordower JH, et al. **Exp Neurol** 1999 Sep;159(1):4–20 (73 ref.)

Nerve growth factor delivery systems. Haller MF, et al. **J Controlled Release** 1998 Apr 30;53(1–3):1–6 (54 ref.)

CHEMISTRY

Emerging themes in structural biology of neurotrophic factors [see comments] Ibáñez CF. **Trends Neurosci** 1998 Oct;21(10):438–44 (65 ref.) Comment in: Trends Neurosci 1999 Mar;22(3):108–9.

GENETICS

Transcriptional control of the galanin gene. Tissue-specific expression and induction by NGF, protein kinase C, and estrogen. Rökaeus A, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:1–13 (37 ref.)

Neurotrophin gene therapy in CNS models of trauma and degeneration. Blesch A, et al. **Prog Brain Res** 1998;

117:473–84 (116 ref.)
[Signal transduction of nerve growth factor (NGF) and its TrkA and p75NTR receptors] Niewiadomska G, et al. **Postepy Biochem** 1999;45(1):21–31 (79 ref.) **(Pol)**

IMMUNOLOGY

Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. Bonini S, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):159–62 (25 ref.)

ISOLATION & PURIFICATION

[Structure and function of a novel ErbB ligand, NTAK] Ishiguro H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):137–42 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

p75NTR and the concept of cellular dependence: seeing how the other half die [see comments] Bredesen DE, et al. **Cell Death Differ** 1998 May;5(5):365–71 (39 ref.) Comment in: Cell Death Differ 1998 May;5(5):343–5.

Signal transduction underlying growth cone guidance by diffusible factors. Song HJ, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):355–63 (88 ref.)

Retrograde axonal transport of neurotrophins: differences between neuronal populations and implications for motor neuron disease. Bartlett SE, et al. **Immunol Cell Biol** 1998 Oct;76(5):419–23 (61 ref.)

The time course of nerve growth factor content in different neuropsychiatric diseases—a unifying hypothesis. Hellweg R, et al. **J Neural Transm** 1998;105(8–9):871–903 (213 ref.)

Interaction of neurotrophins and retinoic acid in neuronal differentiation. Cheung WM, et al. **Mol Cells** 1998 Aug 31;8(4):496–502 (74 ref.)

Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Mufson EJ, et al. **Prog Neurobiol** 1999 Feb;57(4):451–84 (204 ref.)

Neurotrophin trafficking by anterograde transport [see comments] Altar CA, et al. **Trends Neurosci** 1998 Oct; 21(10):433–7 (45 ref.) Comment in: Trends Neurosci 1999 Mar;22(3):108–9.

Neurotrophins and depression. Altar CA. **Trends Pharmacol Sci** 1999 Feb;20(2):59–61 (30 ref.)

[Neurotrophic factors and spinal cord injury. A review] Liu W, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):19–21 (26 ref.) **(Chi)**

[Nerve growth factor system in health and disease] Kliushnik TP. **Vestn Ross Akad Med Nauk** 1999;(1):25–8 (77 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Role of NGF in axotomy-induced c-Jun expression in medial septal cholinergic neurons. Haas CA, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):691–703 (103 ref.)

Neurotrophin action on sensory neurons in adults: an extension of the neurotrophic hypothesis. Mendell LM. **Pain** 1999 Aug;Suppl 6:S127–32 (61 ref.)

PHYSIOLOGY

Mechanical and excitotoxic lesion of motoneurons: effects of neurotrophins and ciliary neurotrophic factor on survival and regeneration. Wiese S, et al. **Acta Neurochir Suppl (Wien)** 1999;73:31–9 (53 ref.)

Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Bradford HF, et al. **Adv Neurol** 1999; 80:19–25 (33 ref.)

Neurotrophic factors in the tongue: expression patterns, biological activity, relation to innervation and studies of neurotrophin knockout mice. Nosrat CA. **Ann N Y Acad Sci** 1998 Nov 30;855:28–49 (103 ref.)

Neurotrophins and synaptic plasticity. McAllister AK, et al. **Annu Rev Neurosci** 1999;22:295–318 (192 ref.)

Neurotrophic factors in peripheral neuropathies: therapeutic implications. Apfel SC. **Brain Pathol** 1999 Apr;9(2):393–413 (163 ref.)

Making and breaking the innervation of the ear: neurotrophic support during ear development and its clinical implications. Fritzsch B, et al. **Cell Tissue Res** 1999 Mar; 295(3):369–82 (97 ref.)

Shared resources between the neural and immune systems: semaphorins join the ranks. Spriggs MK. **Curr Opin Immunol** 1999 Aug;11(4):387–91 (58 ref.)

Development and specification of muscle sensory neurons. Chen HH, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):405–9 (33 ref.)

Neurotrophin regulation of synaptic transmission. Schuman EM. **Curr Opin Neurobiol** 1999 Feb;9(1):105–9 (45 ref.)

Pleiotropic functions of neurotrophins in development. Tessarollo L. **Cytokine Growth Factor Rev** 1998 Jun; 9(2):125–37 (154 ref.)

Biological actions of nerve growth factor in the peripheral nervous system. Rask CA. **Eur Neurol** 1999;41 Suppl 1:14–9 (67 ref.)

Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. Lessmann V. **Gen Pharmacol** 1998 Nov;31(5):667–74 (79 ref.)

Nerve growth factor: a survey of activity on immune and hematopoietic cells. Simone MD, et al. **Hematol Oncol** 1999 Mar;17(1):1–10 (59 ref.)

Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Nakagawara A. **Hum Cell** 1998 Sep;11(3):115–24 (46 ref.)

Cellular aspects of trophic actions in the nervous system. Weisenhorn DM, et al. **Int Rev Cytol** 1999;189:177–265 (645 ref.)

Trophic interactions between sensory nerves and their targets. Chen WP, et al. **J Biomed Sci** 1999 Mar–Apr; 6(2):79–85 (52 ref.)

Neurotrophins, neurones and peripheral nerve regeneration. Yin Q, et al. **J Hand Surg [Br]** 1998 Aug;23(4):433–7 (45 ref.)

Role of neurotrophic factors in motoneuron development. Henderson CE, et al. **J Physiol Paris** 1998 Jun–Aug; 92(3–4):279–81 (13 ref.)

Regulation of synaptic function by neurotrophic factors in vertebrates and invertebrates: implications for development and learning. McKay SE, et al. **Learn Mem** 1999 May–Jun; 6(3):193–215 (196 ref.)

A proposed role for nerve growth factor in the etiology of multiple sclerosis. Olson RC. **Med Hypotheses** 1998 Dec; 51(6):493–8 (111 ref.)

Nerve growth factor: a neurotrophin with activity on cells of the immune system. Aloe L, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):285–91 (109 ref.)

Neurotrophin-mediated potentiation of neuronal injury. Behrens MM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):276–84 (162 ref.)

Neurotrophin actions during the development of the peripheral nervous system. Fariñas I. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):233–42 (86 ref.)

Neurotrophins and other growth factors in the generation of retinal neurons. Frade JM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):243–51 (72 ref.)

Trks: signal transduction and intracellular pathways. Klesse LJ, et al. **Microsc Res Tech** 1999 May 15–Jun 1; 45(4–5):210–6 (73 ref.)

Neurotrophins, nociceptors, and pain. Mendell LM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):252–61 (99 ref.)

Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Skaper SD, et al. **Mol Cell Neurosci** 1998 Nov;12(4–5):179–93 (127 ref.)

Dissecting semaphorin signaling [comment] Roskies AL. **Neuron** 1998 Nov;21(5):935–6 (12 ref.) Comment on: Neuron 1998 Nov;21(5):1079–92. Comment on: Neuron 1998 Nov;21(5):1093–100.

The saga of the nerve growth factor. Levi-Montalcini R. **Neuroreport** 1998 Nov 16;9(16):R71–83 (59 ref.)

Neurotrophins and hyperalgesia. Shu XQ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7693–6 (40 ref.)

Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)

Semaphorin III: role in neuronal development and structural plasticity. Giger RJ, et al. **Prog Brain Res** 1998;117:133–49 (43 ref.)

Spinal cord injury: bridging the lesion and the role of neurotrophic factors in repair. Houweling DA, et al. **Prog Brain Res** 1998;117:455–71 (140 ref.)

Studying signal transduction in neuronal cells: the Trk/NGF system. Kaplan DR. **Prog Brain Res** 1998;117:35–46 (70 ref.)

Semaphorin-mediated neuronal growth cone guidance. Kolodkin AL. **Prog Brain Res** 1998;117:115–32 (95 ref.)

Instructive roles of neurotrophins in synaptic plasticity. Lo DC. **Prog Brain Res** 1998;117:65–70 (27 ref.)

Neurotrophin receptors in Alzheimer's disease. Salehi A, et al. **Prog Brain Res** 1998;117:71–89 (142 ref.)

Neurotrophins. Lederhaas G. **Reg Anesth Pain Med** 1999 May–Jun;24(3):250–1 (5 ref.)

Anterograde transport of neurotrophin proteins in the CNS—a reassessment of the neurotrophic hypothesis. Conner JM, et al. **Rev Neurosci** 1998;9(2):91–103 (100 ref.)

Emerging themes in structural biology of neurotrophic factors [see comments] Ibáñez CF. **Trends Neurosci** 1998 Oct;21(10):438–44 (65 ref.) Comment in: Trends Neurosci 1999 Mar;22(3):108–9.

[Research progress on the glia cell line-derived neurotrophic factor] Wan Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):301–6 (20 ref.) (Eng. Abstr.) **(Chi)**

[Neuronal growth factors—neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063–70 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3112–3. **(Dan)**

[S100B: pathogenetic and pathophysiologic significance in neurology] Schmidt S. **Nervenarzt** 1998 Aug;69(8):639–46 (94 ref.) (Eng. Abstr.) **(Ger)**

[Neurotrophins. I: Molecular features] Zazpe A, et al. **Rev Med Univ Navarra** 1997 Jul–Sep;41(3):173–9 (34 ref.) (Eng. Abstr.) **(Spa)**

[Indicators of oxidative stress in aging rat brain. The effect of nerve growth factor] Rodríguez-Capote K, et al. **Rev Neurol** 1998 Sep;27(157):494–500 (65 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy. Bohn MC. **Biochem Pharmacol** 1999 Jan 15;57(2):135–42 (72 ref.)

Peripheral nerve regeneration and neurotrophic factors. Terenghi G. **J Anat** 1999 Jan;194 (Pt 1):1–14 (219 ref.)

THERAPEUTIC USE

Neurotrophic factors in the therapy of diabetic neuropathy. Apfel SC. **Am J Med** 1999 Aug 30;107(2B):34S–42S (58 ref.)

Therapeutic potential of nerve growth factors in Parkinson's disease. Collier TJ, et al. **Drugs Aging** 1999 Apr; 14(4):261–87 (215 ref.)

Neurotrophic factors and diabetic peripheral neuropathy. Apfel SC. **Eur Neurol** 1999;41 Suppl 1:27–34 (60 ref.)

Peripheral nerve regeneration and neurotrophic factors. Terenghi G. **J Anat** 1999 Jan;194 (Pt 1):1–14 (219 ref.)

Therapeutic potential of neurotrophins for treatment of hearing loss. Gao WQ. **Mol Neurobiol** 1998 Winter; 17(1–3):17–31 (88 ref.)

[Neurotrophins. II: therapeutic potential] Zazpe A, et al. **Rev Med Univ Navarra** 1997 Jul–Sep;41(3):180–4 (32 ref.) (Eng. Abstr.) **(Spa)**

NERVE-MUSCLE PREPARATION see **NEUROMUSCULAR JUNCTION**

NERVE NET

ANATOMY & HISTOLOGY

Untying the Gordian knot: contemporary studies of neuronal organization. Ralston HJ 3rd. **Anat Rec** 1998 Oct; 253(5):139–42 (17 ref.)

Viruses as transneuronal tracers for defining neural circuits. Loewy AD. **Neurosci Biobehav Rev** 1998 Oct;22(6):679–84 (40 ref.)

DRUG EFFECTS

[Is there solid evidence for reorganization of the neural network associated with development of behavioral sensitization to psychostimulants?] Ujike H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Apr; 19(2):47–52 (30 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

The origin of spontaneous activity in developing networks of the vertebrate nervous system. O'Donovan MJ. **Curr Opin Neurobiol** 1999 Feb;9(1):94–104 (75 ref.)

GROWTH & DEVELOPMENT

Language and the infant brain. Bates E. **J Commun Disord** 1999 Jul–Aug;32(4):195–205 (28 ref.)

PHYSIOLOGY

Neural aspects of anticipatory behavior. Brunia CH. **Acta Psychol (Amst)** 1999 Apr;101(2–3):213–42 (92 ref.)

Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Knight RT, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):159–78 (115 ref.)

Neural systems for control of voluntary action—a hypothesis. Hikosaka O. **Adv Biophys** 1998;35:81–102 (43 ref.)

Corticothalamic networks, oscillations, and plasticity. Steriade M. **Adv Neurol** 1998;77:105–34 (91 ref.)

In search of common foundations for cortical computation. Phillips WA, et al. **Behav Brain Sci** 1997 Dec;20(4):657–83; discussion 683–722 (578 ref.)

The neural basis of cognitive development: a constructivist manifesto. Quartz SR, et al. **Behav Brain Sci** 1997 Dec; 20(4):537–56; discussion 556–96 (478 ref.)

Frontostriatal deficits in unipolar major depression. Rogers MA, et al. **Brain Res Bull** 1998 Nov 1;47(4):297–310 (165 ref.)

Modeling memory: what do we learn from attractor neural networks? Brunel N, et al. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):249–52 (19 ref.)

The neuronal zootype. An hypothesis. Deutsch J, et al. **C R Acad Sci III** 1998 Sep;321(9):713–9 (53 ref.)

Development of auditory brainstem circuitry. Activity-dependent and activity-independent processes. Friauf E, et al. **Cell Tissue Res** 1999 Aug;297(2):187–95 (88 ref.)

Cellular, synaptic, network, and modulatory mechanisms involved in rhythm generation. Calabrese RL. **Curr Opin Neurobiol** 1998 Dec;3(6):710–7 (45 ref.)

Hierarchical somatosensory processing. Iwamura Y. **Curr Opin Neurobiol** 1998 Aug;8(4):522–8 (90 ref.)

Human spatial navigation: cognitive maps, sexual dimorphism, and neural substrates. Maguire EA, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):171–7 (76 ref.)

Complex microstructures of sensory cortical connections. Rockland KS. **Curr Opin Neurobiol** 1998 Aug;8(4):545–51 (55 ref.)

Time as coding space? Singer W. **Curr Opin Neurobiol** 1999 Apr;9(2):189–94 (70 ref.)

Functional brain networks in movement disorders [editorial] Eidelberg D. **Curr Opin Neurol** 1998 Aug;11(4):319–26 (41 ref.)

Mechanisms of spontaneous activity in developing spinal networks. O'Donovan MJ, et al. **J Neurobiol** 1998 Oct;

37(1):131–45 (73 ref.)
Interactions between depression and facilitation within neural networks: updating the dual-process theory of plasticity. Prescott SA. **Learn Mem** 1998 Nov-Dec;5(6):446–66 (134 ref.)
Development of specific synaptic network functions in organotypic central nervous system (CNS) cultures: implications for transplantation of CNS neural cells in vivo. Crain SM. **Methods** 1998 Nov;16(3):228–38 (90 ref.)
Synchronized neuronal networks: the GnRH system. Witkin JW. **Microsc Res Tech** 1999 Jan 1;44(1):11–8 (60 ref.)
The development of animal behavior: from Lorenz to neural nets. Bolhuis JJ. **Naturwissenschaften** 1999 Mar; 86(3):101–11 (69 ref.)
Distributed memory for both short and long term. Fuster JM. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1–2):268–74 (17 ref.)
The neurophysiology of reminiscence. McNaughton BL. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1–2):252–67 (31 ref.)
Background gamma-oscillations in neuronal networks with interhemisphere connections. Sil'kis IG, et al. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):645–59 (48 ref.)
Adaptations and pathologies linked to dynamic stabilization of neural circuitry. Kavanau JL. **Neurosci Biobehav Rev** 1999 May;23(5):635–48 (133 ref.)
Rehabilitation of brain damage: brain plasticity and principles of guided recovery. Robertson IH, et al. **Psychol Bull** 1999 Sep;125(5):544–75 (263 ref.)
Anatomical loops and their electrical dynamics in relation to whisking by rat. Kleinfeld D, et al. **Somatosens Mot Res** 1999;16(2):69–88 (145 ref.)
Gauging sensory representations in the brain. Buracas GT, et al. **Trends Neurosci** 1999 Jul;22(7):303–9 (41 ref.)
Evidence for multi-functional interactions in early visual motion processing. Giese MA. **Trends Neurosci** 1999 Jul; 22(7):287–90 (35 ref.)
Recognition of slow processes in rhythmic networks. Golowasch J, et al. **Trends Neurosci** 1999 Sep;22(9):375–7 (24 ref.)
Where the abstract feature maps of the brain might come from. Kohonen T, et al. **Trends Neurosci** 1999 Mar; 22(3):135–9 (44 ref.)
Coherent oscillations and short-term plasticity in corticothalamic networks. Steriade M. **Trends Neurosci** 1999 Aug;22(8):337–45 (58 ref.)
Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Turrigiano GG. **Trends Neurosci** 1999 May;22(5):221–7 (58 ref.)

PHYSIOPATHOLOGY

Tourette's and comorbid syndromes: obsessive compulsive and attention deficit hyperactivity disorder. A common etiology? Sheppard DM, et al. **Clin Psychol Rev** 1999 Aug; 19(5):531–52 (133 ref.)
From the gate to the neuromatrix. Melzack R. **Pain** 1999 Aug;Suppl 6:S121–6 (13 ref.)

VIROLOGY

Practical considerations for the use of pseudorabies virus in transneuronal studies of neural circuitry. Card JP. **Neurosci Biobehav Rev** 1998 Oct;22(6):685–94 (46 ref.)
Viruses as transneuronal tracers for defining neural circuits. Loewy AD. **Neurosci Biobehav Rev** 1998 Oct;22(6):679–84 (40 ref.)
Herpes simplex virus as a transneuronal tracer. Norgren RB Jr, et al. **Neurosci Biobehav Rev** 1998 Oct;22(6):695–708 (167 ref.)

NERVE REGENERATION

Oligodendrocytes: from development to demyelinated lesion repair. Rogister B, et al. **Acta Neurol Belg** 1999 Mar; 99(1):32–9 (72 ref.)
The glial scar and central nervous system repair. Fawcett JW, et al. **Brain Res Bull** 1999 Aug;49(6):377–91 (216 ref.)
Nerve injury and regeneration: basic insights and therapeutic interventions. Müller HW, et al. **Curr Opin Neurol** 1998 Oct;11(5):557–62 (66 ref.)
Peripheral nerve regeneration and neurotrophic factors. Terenghi G. **J Anat** 1999 Jan;194 (Pt 1):1–14 (219 ref.)
Roger Sperry and his chemoaffinity hypothesis. Meyer RL. **Neuropsychologia** 1998 Oct;36(10):957–80 (166 ref.)
Cellular and molecular correlates of the regeneration of adult mammalian CNS axons into peripheral nerve grafts. Anderson PN, et al. **Prog Brain Res** 1998;117:211–32 (73 ref.)
Spinal cord injury: bridging the lesion and the role of neurotrophic factors in repair. Houweling DA, et al. **Prog Brain Res** 1998;117:455–71 (140 ref.)
Role for semaphorin III and its receptor neuropilin-1 in neuronal regeneration and scar formation? Pasterkamp RJ, et al. **Prog Brain Res** 1998;117:151–70 (157 ref.)
Boundary molecules during brain development, injury, and persistent neurogenesis--in vivo and in vitro studies. Steindler DA, et al. **Prog Brain Res** 1998;117:179–96 (63 ref.)
Advances in spinal cord regeneration. Lu J, et al. **Spine** 1999 May 1;24(9):926–30 (68 ref.)
Why does the central nervous system not regenerate after injury? Nicholls JG, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S136–41 (21 ref.)
[Basic fibroblast growth factor and nerve regeneration] Chi L, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Sep;11(5):269–71 (23 ref.) **(Chi)**
[Modern techniques of restoration of locomotion in paralyzed persons] Rabischong P. **Bull Acad Natl Med** 1999; 183(3):531–7; discussion 538–9 (49 ref.) (Eng. Abstr.) **(Fre)**
[Regularities of corneal tissue correlation and their biological significance for regeneration and pre-tumor growth] Beliaev VS. **Vestn Oftalmol** 1999 Mar-Apr;115(2):15–21 (28 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Introductory comments on neuroprotection. Kaufman PL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S89–90 (10 ref.)

GENETICS

Adenoviral-mediated gene transfer to enhance neuronal survival, growth, and regeneration. Smith GM, et al. **J Neurosci Res** 1999 Jan 15;55(2):147–57 (114 ref.)

IMMUNOLOGY

FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. Gold BG. **Drug Metab Rev** 1999 Aug; 31(3):649–63 (75 ref.)

PHYSIOLOGY

Targeted disruption of the murine galanin gene. Wynick D, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:22–47 (169 ref.)
Progenitor cell biology: implications for neural regeneration. Mehler MF, et al. **Arch Neurol** 1999 Jul;56(7):780–4 (60 ref.)
Remyelination in demyelinating disease. Scolding NJ, et al. **Baillieres Clin Neurol** 1997 Oct;6(3):525–48 (125 ref.)
Postnatal cerebral cortical multipotent progenitors: regulatory mechanisms and potential role in the development of novel neural regenerative strategies. Mehler MF, et al. **Brain Pathol** 1999 Jul;9(3):515–26 (82 ref.)
Nerve injury, axonal degeneration and neural regeneration: basic insights. Stoll G, et al. **Brain Pathol** 1999 Apr; 9(2):313–25 (123 ref.)
The CNS lesion scar: new vistas on an old regeneration barrier. Stichel CC, et al. **Cell Tissue Res** 1998 Oct; 294(1):1–9 (106 ref.)
Regeneration in the spinal cord. Bregman BS. **Curr Opin Neurobiol** 1998 Dec;8(6):800–7 (56 ref.)
Cellular and molecular bases of axonal regeneration in the fish central nervous system. Bernhardt RR. **Exp Neurol** 1999 Jun;157(2):223–40 (204 ref.)
The transitional zone and CNS regeneration. Fraher JP. **J Anat** 1999 Feb;194 (Pt 2):161–82 (135 ref.)
Neurotrophins, neurones and peripheral nerve regeneration. Yin Q, et al. **J Hand Surg [Br]** 1998 Aug;23(4):433–7 (45 ref.)
Role of thyroid hormones and their receptors in peripheral nerve regeneration. Barakat-Walter I. **J Neurobiol** 1999 Sep 15;40(4):541–59 (113 ref.)
Androgenic regulation of the central glia response following nerve damage. Jones KJ, et al. **J Neurobiol** 1999 Sep 15; 40(4):560–73 (101 ref.)
Ultrastructure and cellular biology of nerve regeneration. Thanos PK, et al. **J Reconstr Microsurg** 1998 Aug; 14(6):423–36 (165 ref.)
Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Frostick SP, et al. **Microsurgery** 1998; 18(7):397–405 (82 ref.)
Restricted inflammatory reaction in the CNS: a key impediment to axonal regeneration? Lazarov-Spiegler O, et al. **Mol Med Today** 1998 Aug;4(8):337–42 (52 ref.)
A unique population of circulating autoantibodies promotes central nervous system remyelination. Asakura K, et al. **Mult Scler** 1998 Jun;4(3):217–21 (55 ref.)
Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? Massaro AR. **Mult Scler** 1998 Jun;4(3):228–31 (29 ref.)
Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Sharief MK. **Mult Scler** 1998 Jun; 4(3):169–73 (35 ref.)
The benefits of adding insult to injury [comment] Filbin MT. **Neuron** 1999 May;23(1):2–4 (10 ref.) Comment on: Neuron 1999 May;23(1):83–91.
Craniocerebral trauma: protection and retrieval of the neuronal population after injury. Teasdale GM, et al. **Neurosurgery** 1998 Oct;43(4):723–37; discussion 737–8 (173 ref.)
Cellular activation in neuroregeneration. Schwaiger FW, et al. **Prog Brain Res** 1998;117:197–210 (129 ref.)
Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Wolswijk G. **Prog Brain Res** 1998;117:233–47 (82 ref.)
Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. Stichel CC, et al. **Prog Neurobiol** 1998 Oct;56(2):119–48 (467 ref.)
Factors intrinsic to the neuron can induce and maintain its ability to promote axonal outgrowth: a role for BCL2? Holm K, et al. **Trends Neurosci** 1999 Jun;22(6):269–73 (37 ref.)
Studies on the biological activity of the dermal regeneration template. Yannas IV. **Wound Repair Regen** 1998 Nov-Dec; 6(6):518–23 (42 ref.)
[Candidate cells for remyelinating of the central nervous system] Nait Oumesmar B, et al. **Rev Neurol (Paris)** 1998 Sep;154(8–9):592–9 (95 ref.) **(Fre)**
[New nerve cells for the adult brain. Adult neurogenesis and stem cell concepts in neurologic research] Kempermann G, et al. **Nervenarzt** 1998 Oct;69(10):851–7 (50 ref.) (Eng. Abstr.) **(Ger)**
[Neural transplantation and regeneration: current status and future perspective] Date I, et al. **No Shinkei Geka** 1998 Oct;26(10):860–72 (116 ref.) **(Jpn)**
[Functional reinnervation in patients with a diagnosis of lower motor neuron neurogenic bladder: prognostic and therapeutic considerations] Esteban Fuertes M, et al. **Arch Esp Urol** 1998 Oct;51(8):791–800 (39 ref.) (Eng. Abstr.) **(Spa)**

NERVE SHEATH TUMORS

CLASSIFICATION

[Cutaneous neural neoplasms--an update] Mentzel T. **Verh Dtsch Ges Pathol** 1998;82:309–16 (56 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Malignant peripheral nerve sheath tumor of the prostate: a rare manifestion of neurofibromatosis type 1. Rames RA, et al. **J Urol** 1999 Jul;162(1):165–6 (3 ref.)

PATHOLOGY

[Cutaneous neural neoplasms--an update] Mentzel T. **Verh Dtsch Ges Pathol** 1998;82:309–16 (56 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Primary intraosseous malignant peripheral nerve sheath tumor: a case report and review of the literature. Khan RJ, et al. **Pathology** 1998 Aug;30(3):237–41 (72 ref.)

NERVE TISSUE

[A case of a nasal glioma in a newborn infant] Casas Terrón E, et al. **An Esp Pediatr** 1998 Dec;49(6):624–6 (9 ref.) **(Spa)**

CHEMISTRY

In vivo neurochemical correlates of cognitive processes: methodological and conceptual challenges. Bruno JP, et al. **Rev Neurosci** 1999;10(1):25–48 (88 ref.)

EMBRYOLOGY

Neural transplantation: can we improve the symptomatic relief? Lindvall O. **Adv Neurol** 1999;80:635–40 (26 ref.)
The case for neural tissue transplantation as a treatment for Parkinson's disease. Widner H. **Adv Neurol** 1999;80:641–9 (34 ref.)

TRANSPLANTATION

Neural transplantation: potential role in traumatic brain injury. Kanelos SK, et al. **J Head Trauma Rehabil** 1998 Dec;13(6):1–9 (36 ref.)
Neural transplantation for neurodegenerative disorders. Borlongan CV, et al. **Lancet** 1999 Apr;353 Suppl 1:SI29–30 (11 ref.)

NERVE TISSUE PROTEIN S 100

ANALYSIS

[Pathophysiologic aspects of S-100beta protein: a new biological marker of brain pathology] Beaudeux J, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):261–72 (56 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[S-100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience] Jäckel A, et al. **Hautarzt** 1999 Apr;50(4):250–6 (35 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

A change-in-hand mechanism for S100 signalling. Smith SP, et al. **Biochem Cell Biol** 1998;76(2–3):324–33 (69 ref.)
Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Donato R. **Biochim Biophys Acta** 1999 Jul 8;1450(3):191–231 (357 ref.)
New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Heizmann CW, et al. **Biometals** 1998 Dec;11(4):383–97 (160 ref.)

METABOLISM

Calcium-binding protein S100A4 in health and disease. Barraclough R. **Biochim Biophys Acta** 1998 Dec 10; 1448(2):190–9 (67 ref.)
Functional roles of S100 proteins, calcium-binding proteins

of the EF-hand type. Donato R. **Biochim Biophys Acta** 1999 Jul 8;1450(3):191-231 (357 ref.)
New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Heizmann CW, et al. **Biometals** 1998 Dec;11(4):383-97 (160 ref.)
Ca2+-binding S100 proteins in the central nervous system. Heizmann CW. **Neurochem Res** 1999 Sep;24(9):1097-100 (31 ref.)
[Regulation of protein S100 expression during transcription] Leśniak W, et al. **Postepy Hig Med Dosw** 1999;53(2):183-93 (32 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Kerkhoff C, et al. **Biochim Biophys Acta** 1998 Dec 10;1448(2):200-11 (80 ref.)
The S100 family of multipurpose calcium-binding proteins. McNutt NS. **J Cutan Pathol** 1998 Nov;25(10):521-9 (109 ref.)

NERVE TISSUE PROTEINS

Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). Saarma M, et al. **Microsc Res Tech** 1999 May 15-Jun 1;45(4-5):292-302 (83 ref.)
[Neurotrophic factor and nerve degenerative diseases] Taniwaki T. **Fukuoka Igaku Zasshi** 1998 Aug;89(8):221-4 (5 ref.) **(Jpn)**
[Neuron-specific Ca(2+)-binding proteins] Kobayashi M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1681-7 (19 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Kordower JH, et al. **Exp Neurol** 1999 Sep;159(1):4-20 (73 ref.)

ANALYSIS

Receptors for collapsin/semaphorins. Fujisawa H, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):587-92 (61 ref.)
Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. Kimber TE, et al. **J Neurol Sci** 1998 Sep 18;160(1):33-40 (25 ref.)
[Age dependent and tissue specific FMR-1 gene expression in human organs] Ito M, et al. **Nippon Rinsho** 1999 Apr; 57(4):950-4 (15 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Chabrier PE, et al. **Cell Mol Life Sci** 1999 Jul;55(8-9):1029-35 (73 ref.)

BIOSYNTHESIS

Synaptic plasticity: regulated translation in dendrites. Huang EP. **Curr Biol** 1999 Mar 11;9(5):R168-70 (14 ref.)
mRNA trafficking and local protein synthesis at the synapse [comment] Schuman EM. **Neuron** 1999 Aug;23(4):645-8 (20 ref.) Comment on: Neuron 1999 Aug;23(4):641-4.
Making proteins at the synapse: activity-regulated translation and CPEB [see comments] Worley P. **Neuron** 1998 Nov; 21(5):936-8 (12 ref.) Comment in: Neuron 1998 Nov;21(5):1129-39.
Melatonin synthesis pathway: circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Bernard M, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):325-34 (44 ref.)

CHEMISTRY

Structure and functions of lectins in the central and peripheral nervous system. Zanetta JP. **Acta Anat (Basel)** 1998; 161(1-4):180-95 (116 ref.)
Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Mikoshiba K, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):59-67 (46 ref.)
D-amino acids in crustacean hyperglycemic neurohormones. Huberman A, et al. **EXS** 1998;85:73-83 (37 ref.)
SNAP-25. Hodel A. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1069-73 (11 ref.)
Wiskott-Aldrich syndrome protein, WASP. O'Sullivan E, et al. **Int J Biochem Cell Biol** 1999 Mar-Apr;31(3-4):383-7 (19 ref.)
The localization and interactions of huntingtin. Jones AL. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1021-7 (65 ref.)
Polyglutamine pathogenesis. Ross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1005-11 (82 ref.)

DIAGNOSTIC USE

Calretinin: a novel tool for diagnostic immunohistochemistry. Tos AP, et al. **Adv Anat Pathol** 1998 Jan;5(1):61-6 (21 ref.)

GENETICS

The role of the peripherin/RDS gene in retinal dystrophies. Kohl S, et al. **Acta Anat (Basel)** 1998;162(2-3):75-84 (69 ref.)
The role of dopamine, dynorphin, and CART systems in the ventral striatum and amygdala in cocaine abuse. Hurd YL, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:499-506 (38 ref.)
Polyglutamine expansion and Huntington's disease. Bates GP, et al. **Biochem Soc Trans** 1998 Aug;26(3):471-5 (38 ref.)
Genetics of Parkinson's disease. Mizuno Y, et al. **Biomed Pharmacother** 1999 Apr;53(3):109-16 (67 ref.)
The role of Pax3 and Pax7 in development and cancer. Mansouri A. **Crit Rev Oncog** 1998;9(2):141-9 (62 ref.)
RNA splicing: more clues from spinal muscular atrophy. Matera AG. **Curr Biol** 1999 Feb 25;9(4):R140-2 (16 ref.)
Amiloride-sensitive Na channels. Horisberger JD. **Curr Opin Cell Biol** 1998 Aug;10(4):443-9 (43 ref.)
BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Gary SC, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):576-81 (31 ref.)
Otx1 and Otx2 in the development and evolution of the mammalian brain. Simeone A. **EMBO J** 1998 Dec 1; 17(23):6790-8 (97 ref.)
The synuclein family. Lavedan C. **Genome Res** 1998 Sep; 8(9):871-80 (50 ref.)
The role of the SMN gene in proximal spinal muscular atrophy. Lefebvre S, et al. **Hum Mol Genet** 1998; 7(10):1531-6 (83 ref.)
Transgenic studies of peripheral and central glia. Messing A. **Int J Dev Biol** 1998;42(7 Spec No):1019-24 (43 ref.)
Molecular base of "de novo" DRPLA [editorial; comment] Abe K. **Intern Med** 1999 Mar;38(3):223 (7 ref.) Comment on: Intern Med 1999 Mar;38(3):287-9.
Developmental anatomy of the Drosophila brain: neuroanatomy is gene expression. Meinertzhagen IA, et al. **J Comp Neurol** 1998 Dec 7;402(1):1-9 (76 ref.)
Spinal muscular atrophy. Talbot K. **J Inherit Metab Dis** 1999 Jun;22(4):545-54 (38 ref.)
Spinal muscular atrophy: untangling the knot? Biros I, et al. **J Med Genet** 1999 Jan;36(1):1-8 (66 ref.)
Molecular aspects of Huntington's disease. Walling HW, et al. **J Neurosci Res** 1998 Nov 1;54(3):301-8 (88 ref.)
Development of the neuromuscular junction: genetic analysis in mice. Sanes JR, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):167-72 (26 ref.)
Otx genes and the genetic control of brain morphogenesis. Acampora D, et al. **Mol Cell Neurosci** 1999 Jan;13(1):1-8 (61 ref.)
Regulation of neuronal gene expression. Thiel G, et al. **Naturwissenschaften** 1999 Jan;86(1):1-7 (34 ref.)
Transgenic animals relevant to Alzheimer's disease. Seabrook GR, et al. **Neuropharmacology** 1999 Jan;38(1):1-17 (108 ref.)
Protein-synthesizing machinery in the axon compartment. Koenig E, et al. **Neuroscience** 1999 Mar;89(1):5-15 (72 ref.)
Are there multiple pathways in the pathogenesis of Huntington's disease? Aronin N, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):995-1003 (61 ref.)
Progress in pathogenesis studies of spinocerebellar ataxia type 1. Cummings CJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1079-81 (20 ref.)
CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci. Frontali M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1089-94 (38 ref.)
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101-18 (148 ref.)
Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Hackam AS, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1047-55 (45 ref.)
Molecular pathology of dentatorubral-pallidoluysian atrophy. Kanazawa I. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1069-74 (26 ref.)
Polyglutamine pathogenesis. Ross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1005-11 (82 ref.)
Transgenic models of Huntington's disease. Sathasivam K, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):963-9 (36 ref.)
Genetic aspects of Hirschsprung's disease. Kusafuka T, et al. **Semin Pediatr Surg** 1998 Aug;7(3):148-55 (97 ref.)
[Genetics of Parkinson disease] Brassat D, et al. **Rev Med Interne** 1999 Aug;20(8):709-14 (37 ref.) (Eng. Abstr.) **(Fre)**
[Cloning and characterization of cDNA for DRPLA interacting protein] Okamumoho Y, et al. **Nippon Rinsho** 1999 Apr;57(4):856-61 (18 ref.) (Eng. Abstr.) **(Jpn)**
[alpha-Synuclein and familial Parkinson's disease] Iwatsubo T. **No To Shinkei** 1999 Jun;51(6):481-6 (24 ref.) **(Jpn)**

METABOLISM

GABA and human spermatozoa: characterization and regulation of GABA transport proteins. Aanesen A. **Acta Physiol Scand Suppl** 1998 Nov;642:1-61 (243 ref.)
Interactions of presynaptic Ca2+ channels and snare proteins in neurotransmitter release. Catterall WA. **Ann N Y Acad Sci** 1999 Apr 30;868:144-59 (84 ref.)
Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Goedert M, et al. **Biochem Soc Trans** 1998 Aug;26(3):463-71 (49 ref.)
The Fe65 and X11 families of proteins: proteins that interact with the Alzheimer's disease amyloid precursor protein. McLoughlin DM, et al. **Biochem Soc Trans** 1998 Aug; 26(3):497-500 (28 ref.)
IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Grötzinger J, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):803-13 (77 ref.)
Twin peaks: Spitz and Argos star in patterning of the Drosophila egg [comment] Stevens L. **Cell** 1998 Oct 30; 95(3):291-4 (16 ref.) Comment on: Cell 1998 Oct 30;95(3):355-64.
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia [see comments] Trojanowski JQ, et al. **Cell Death Differ** 1998 Oct;5(10):832-7 (64 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803-4.
Transglutaminase-catalyzed protein cross-linking in the molecular program of apoptosis and its relationship to neuronal processes. Fesus L. **Cell Mol Neurobiol** 1998 Dec; 18(6):683-94 (68 ref.)
Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Mikoshiba K, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):59-67 (46 ref.)
To be or not to be an aggregate. Nasir J. **Clin Genet** 1999 Jan;55(1):9-10 (2 ref.)
SNAP-25. Hodel A. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1069-73 (11 ref.)
Wiskott-Aldrich syndrome protein, WASP. O'Sullivan E, et al. **Int J Biochem Cell Biol** 1999 Mar-Apr;31(3-4):383-7 (19 ref.)
Mechanisms of neurotransmitter release. Littleton JT, et al. **Int Rev Neurobiol** 1999;43:139-61 (94 ref.)
Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse. Nagano T, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):869-75 (74 ref.)
Interactions between presynaptic calcium channels and proteins implicated in synaptic vesicle trafficking and exocytosis. Seagar M, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):347-56 (58 ref.)
Metabolism and trafficking of N-type voltage-operated calcium channels in neurosecretory cells. Sher E, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):399-407 (110 ref.)
POU family transcription factors in the nervous system. Latchman DS. **J Cell Physiol** 1999 May;179(2):126-33 (68 ref.)
Proteolytic processing of Alzheimer's disease associated proteins. Haass C, et al. **J Neural Transm Suppl** 1998; 53:159-67 (39 ref.)
Molecular aspects of Huntington's disease. Walling HW, et al. **J Neurosci Res** 1998 Nov 1;54(3):301-8 (88 ref.)
Eph receptors, ephrins, and PDZs gather in neuronal synapses [comment] Hsueh YP, et al. **Neuron** 1998 Dec; 21(6):1227-9 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1453-63.
The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Storey E, et al. **Neuropathol Appl Neurobiol** 1999 Apr;25(2):81-97 (202 ref.)
Processing of ARIA and release from isolated nerve terminals. Han B, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):411-6 (39 ref.)
The localization and interactions of huntingtin. Jones AL. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1021-7 (65 ref.)
Calretinin--sensor or buffer--function still unclear. Billing-Marczak K, et al. **Pol J Pharmacol** 1999 Mar-Apr; 51(2):173-8 (44 ref.)
Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Mufson EJ, et al. **Prog Neurobiol** 1999 Feb;57(4):451-84 (204 ref.)
Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Liu Y, et al. **Trends Cell Biol** 1999 Sep;9(9):356-63 (73 ref.)
Cytoskeletal dynamics in dendritic spines: direct modulation by glutamate receptors? van Rossum D, et al. **Trends Neurosci** 1999 Jul;22(7):290-5 (80 ref.)
[Neurotrophic factors and spinal cord injury. A review] Liu W, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):19-21 (26 ref.) **(Chi)**
[Studies on the receptor for Clostridium botulinum neurotoxin] Kozaki S. **Nippon Saikingaku Zasshi** 1999 Apr; 54(2):401-14 (56 ref.) **(Jpn)**
[Hyaluronan aggregating proteoglycans] Bobiński R, et al. **Postepy Biochem** 1998;44(3):245-51 (75 ref.) **(Pol)**

PHARMACOLOGY

Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Ruggeri BA, et al. **Curr Med Chem** 1999 Sep;6(9):845-57 (104 ref.)
EEG correlates of the response to ECT: a possible antidepressant role of brain-derived neurotrophic factor. Krystal AD, et al. **J ECT** 1999 Mar;15(1):27-38 (73 ref.)

NERVE TISSUE PROTEINS

PHYSIOLOGY

Structure and functions of lectins in the central and peripheral nervous system. Zanetta JP. **Acta Anat (Basel)** 1998; 161(1–4):180–95 (116 ref.)

Mechanical and excitotoxic lesion of motoneurons: effects of neurotrophins and ciliary neurotrophic factor on survival and regeneration. Wiese S, et al. **Acta Neurochir Suppl (Wien)** 1999;73:31–9 (53 ref.)

Proteins implicated in Alzheimer disease. The role of FE65, a new adapter which binds to beta-amyloid precursor protein. Ermekova KS, et al. **Adv Exp Med Biol** 1998; 446:161–80 (120 ref.)

Neurotrophic factors in the tongue: expression patterns, biological activity, relation to innervation and studies of neurotrophin knockout mice. Nosrat CA. **Ann N Y Acad Sci** 1998 Nov 30;855:28–49 (103 ref.)

To fear or not to fear: what was the question? A potential role for Ras-GRF in memory. Finkbeiner S, et al. **Bioessays** 1998 Sep;20(9):691–5 (27 ref.)

Formation of the neuromuscular junction: molecules and mechanisms. Meier T, et al. **Bioessays** 1998 Oct; 20(10):819–29 (83 ref.)

Dynamic behavior and organization of cytoskeletal proteins in neurons: reconciling old and new findings. Nixon RA. **Bioessays** 1998 Oct;20(10):798–807 (85 ref.)

Neurotrophic factors in peripheral neuropathies: therapeutic implications. Apfel SC. **Brain Pathol** 1999 Apr;9(2):393–413 (163 ref.)

Slit branches out: a secreted protein mediates both attractive and repulsive axon guidance. Zinn K, et al. **Cell** 1999 Apr 2;97(1):1–4 (18 ref.)

The relationship between adhesion molecules and neuronal plasticity. Hoffman KB. **Cell Mol Neurobiol** 1998 Oct; 18(5):461–75 (126 ref.)

Signalling to actin: the Cdc42-N-WASP-Arp2/3 connection. Carlier MF, et al. **Chem Biol** 1999 Sep; 6(9):R235–40 (28 ref.)

Axon guidance: starting and stopping with slit. Guthrie S. **Curr Biol** 1999 Jun 17;9(12):R432–5 (16 ref.)

Endocytosis: an assembly protein for clathrin cages. McMahon HT. **Curr Biol** 1999 May 6;9(9):R332–5 (25 ref.)

Organization and regulation of proteins at synapses [published erratum appears in Curr Opin Cell Biol 1999 Jun;11(3):407–8] Kim JH, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):248–54 (64 ref.)

Shared resources between the neural and immune systems: semaphorins join the ranks. Spriggs MK. **Curr Opin Immunol** 1999 Aug;11(4):387–91 (58 ref.)

Neurotrophic factors: effects in modulating properties of the neuromuscular endplate. Sendtner M. **Cytokine Growth Factor Rev** 1998 Mar;9(1):1–7 (51 ref.)

Snare proteins essential for cyclic AMP-regulated exocytosis in salivary glands. Fujita-Yoshigaki J, et al. **Eur J Morphol** 1998 Aug;36 Suppl:46–9 (24 ref.)

The synuclein family. Lavedan C. **Genome Res** 1998 Sep; 8(9):871–80 (50 ref.)

CART, a new anorectic peptide. Thim L, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1281–4 (10 ref.)

Role of SNARE's in the GLUT4 translocation response to insulin in adipose cells and muscle. St-Denis JF, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):153–65 (42 ref.)

Differential expression and association of calcium channel subunits in development and disease. McEnery MW, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):409–18 (83 ref.)

Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. Sheng ZH, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):335–45 (80 ref.)

N-WASP is an important protein for the actin-based motility of Shigella flexneri in the infected epithelial cells. Suzuki T, et al. **Jpn J Med Sci Biol** 1998;51 Suppl:S63–8 (22 ref.)

GDNF family neurotrophic factor signaling: four masters, one servant? Airaksinen MS, et al. **Mol Cell Neurosci** 1999 May;13(5):313–25 (117 ref.)

Alpha-synuclein and Parkinson's disease [editorial] Golbe LI. **Mov Disord** 1999 Jan;14(1):6–9 (31 ref.)

Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Mezey E, et al. **Nat Med** 1998 Jul;4(7):755–7 (18 ref.)

Can molecules explain long-term potentiation? Sanes JR, et al. **Nat Neurosci** 1999 Jul;2(7):597–604 (122 ref.)

LIMitless combinations? Appel B. **Neuron** 1999 Jan;22(1):3–5 (11 ref.)

Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Greengard P, et al. **Neuron** 1999 Jul;23(3):435–47 (89 ref.)

Semaphorin signaling: a little less per-plexin. Yu HH, et al. **Neuron** 1999 Jan;22(1):11–4 (20 ref.)

Protein-protein interactions and protein modules in the control of neurotransmitter release. Benfenati F, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):243–57 (123 ref.)

Interactions between proteins implicated in exocytosis and voltage-gated calcium channels. Seagar M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):289–97 (49 ref.)

Nitric-oxide synthase and neurodegeneration/neuroprotection. Kaufman PL. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9455–6 (22 ref.)

Semaphorin-mediated neuronal growth cone guidance. Kolodkin AL. **Prog Brain Res** 1998;117:115–32 (95 ref.)

Role for semaphorin III and its receptor neuropilin-1 in neuronal regeneration and scar formation? Pasterkamp RJ, et al. **Prog Brain Res** 1998;117:151–70 (157 ref.)

Neurotrophins. Lederhaas G. **Reg Anesth Pain Med** 1999 May-Jun;24(3):250–1 (5 ref.)

Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444–9 (48 ref.)

CART peptides: novel addiction- and feeding-related neuropeptides. Kuhar MJ, et al. **Trends Neurosci** 1999 Jul; 22(7):316–20 (35 ref.)

The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. O'Donovan KJ, et al. **Trends Neurosci** 1999 Apr; 22(4):167–73 (52 ref.)

The amphiphysin family of proteins and their role in endocytosis at the synapse. Wigge P, et al. **Trends Neurosci** 1998 Aug;21(8):339–44 (49 ref.)

[A presynaptic Ca(2+)-binding protein--synaptotagmin] Qiang M, et al. **Sheng Li Ke Hsueh Chin Chan** 1996 Jul; 27(3):268–70 (10 ref.) **(Chi)**

[Research progress on the glia cell line-derived neurotrophic factor] Wan Y, et al. **Sheng Li Ke Hsueh Chin Chan** 1996 Oct;27(4):301–6 (20 ref.) (Eng. Abstr.) **(Chi)**

[Cadherins, the development and regeneration of the neuromuscular axis] Mege RM, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):796–801 (58 ref.) (Eng. Abstr.) **(Fre)**

[The function of Huntington disease gene product (huntingtin) and the pathomechanism of Huntington disease] Nukina N. **Nippon Rinsho** 1999 Apr;57(4):905–11 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Functional analysis of a novel cell adhesion molecule, gicerin] Taira E. **Nippon Yakurigaku Zasshi** 1999 Mar; 113(3):133–43 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Roles of C2 domains of synaptotagmin in the regulation of exocytosis] Ohara-Imaizumi M. **Seikagaku** 1998 Oct; 70(10):1283–8 (19 ref.) **(Jpn)**

[Role of inositol polyphosphates: implications for cellular function] Fukuda M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1784–8 (26 ref.) **(Jpn)**

[A functional role for PDZ proteins in synapse organization and synaptic plasticity] Inokuchi K. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1355–64 (49 ref.) **(Jpn)**

[Role of DARPP-32 in dopamine signal transduction in the striatum] Nishi A. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(15):2172–81 (55 ref.) **(Jpn)**

[Molecular biological approach to functions of telencephalin, a cell adhesion molecule and HNK-1 carbohydrate epitope, which is commonly expressed on cell adhesion molecules in the nervous system] Oka S. **Yakugaku Zasshi** 1998 Oct; 118(10):431–46 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Synucleins--the key to mechanisms of neurodegenerative diseases?] Buchman VL. **Mol Biol (Mosk)** 1998 Jul-Aug; 32(4):592–7 (54 ref.) **(Rus)**

SECRETION

A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy. Bohn MC. **Biochem Pharmacol** 1999 Jan 15;57(2):135–42 (72 ref.)

Slit branches out: a secreted protein mediates both attractive and repulsive axon guidance. Zinn K, et al. **Cell** 1999 Apr 2;97(1):1–4 (18 ref.)

Processing of ARIA and release from isolated nerve terminals. Han B, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):411–6 (39 ref.)

THERAPEUTIC USE

Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. Grondin R, et al. **J Neurol** 1998 Nov;245(11 Suppl 3):P35–42 (62 ref.)

NERVE TRANSFER

see related

NERVE REGENERATION

[Paralytic shoulder secondary to post-traumatic peripheral nerve lesions in the adult] Alnot JY. **Acta Orthop Belg** 1999 Mar;65(1):10–22 (50 ref.) (Eng. Abstr.) **(Fre)**

NERVE TRANSMITTER SUBSTANCES see **NEUROTRANSMITTERS**

NERVOUS MICE see **MICE, NEUROLOGIC MUTANTS**

NERVOUS SYSTEM

ANATOMY & HISTOLOGY

The neuroanatomy of visual consciousness. Koch C. **Adv Neurol** 1998;77:229–41; discussion 241–3 (66 ref.)

Comparative neuroanatomy of vasotocin and vasopressin in amphibians and other vertebrates. Moore FL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):251–60 (114 ref.)

Homology in the nervous system: of characters, embryology and levels of analysis. Striedter GF. **Novartis Found Symp** 1999;222:158–70; discussion 170–2 (43 ref.)

A primer of neuroanatomy and neurophysiology. Minton MS, et al. **Nurs Clin North Am** 1999 Sep;34(3):555–72 (7 ref.)

Back problems. Neuroanatomy and neurological examination. Blythe LL, et al. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):71–85, vi (10 ref.)

[New neuronal tracers and their combined use] Lanciego JL, et al. **Rev Med Univ Navarra** 1999 Jan-Mar;43(1):24–8 (10 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Structural biology of cadherins in the nervous system. Shapiro L, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):593–9 (38 ref.)

CYTOLOGY

Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. Edlund T, et al. **Cell** 1999 Jan 22;96(2):211–24 (141 ref.)

Plasticity and stem cells in the vertebrate nervous system. Panchision D, et al. **Curr Opin Cell Biol** 1998 Dec; 10(6):727–33 (75 ref.)

Structural biology of cadherins in the nervous system. Shapiro L, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):593–9 (38 ref.)

The saga of the nerve growth factor. Levi-Montalcini R. **Neuroreport** 1998 Nov 16;9(16):R71–83 (59 ref.)

I-type lectins in the nervous system. Probstmeier R, et al. **Prog Neurobiol** 1999 Jun;58(2):163–84 (253 ref.)

Patterning motoneurons in the vertebrate nervous system. Eisen JS. **Trends Neurosci** 1999 Jul;22(7):321–6 (95 ref.)

DRUG EFFECTS

Dioxin-like and non-dioxin-like toxic effects of polychlorinated biphenyls (PCBs): implications for risk assessment. Giesy JP, et al. **Crit Rev Toxicol** 1998 Nov; 28(6):511–69 (286 ref.)

Pharmacological activities of fusaric acid (5-butylpicolinic acid). Wang H, et al. **Life Sci** 1999;65(9):849–56 (46 ref.)

Cytokine-mediated or direct effects of thymulin on the nervous system as assessed by pain-related behavior. Safieh-Garabedian B, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):39–44 (34 ref.)

Neurologic protection by amifostine. DiPaola RS, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):82–8 (41 ref.)

[The neurobehavioral effects of solvents] Tsenova B. **Probl Khig** 1997;22:39–54 (19 ref.) (Eng. Abstr.) **(Bul)**

[Sevoflurane and the nervous system] Schwender D, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S37–42 (59 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

POU domain factors in neural development. Schonemann MD, et al. **Adv Exp Med Biol** 1998;449:39–53 (128 ref.)

Does gravity influence the early stages of the development of the nervous system in an amphibian? Duprat AM, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):19–24 (38 ref.)

Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. Edlund T, et al. **Cell** 1999 Jan 22;96(2):211–24 (141 ref.)

Fibroblast-growth-factor-induced additional limbs in the study of initiation of limb formation, limb identity, myogenesis, and innervation. Ohuchi H, et al. **Cell Tissue Res** 1999 Apr;296(1):45–56 (79 ref.)

Vertebrate development: a nervous vitamin. Maden M. **Curr Biol** 1998 Nov 19;8(23):R846–9 (11 ref.)

Epithelial cell movements and interactions in limb, neural crest and vasculature. Tickle C, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):455–60 (28 ref.)

The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Rønn LC, et al. **Exp Gerontol** 1998 Nov-Dec;33(7–8):853–64 (99 ref.)

Asymmetric cell division: from A to Z. Hawkins N, et al. **Genes Dev** 1998 Dec 1;12(23):3625–38 (120 ref.)

Neurulation in amniote vertebrates: a novel view deduced from the use of quail-chick chimeras. Le Douarin NM, et al. **Int J Dev Biol** 1998;42(7 Spec No):909–16 (31 ref.)

Genetic analysis of axon pattern formation in the embryonic CNS of Drosophila. Klämbt C, et al. **Invert Neurosci** 1997 Sep-Dec;3(2–3):165–74 (76 ref.)

Stem cells in the developing and adult nervous system. Alvarez-Buylla A, et al. **J Neurobiol** 1998 Aug; 36(2):105–10 (16 ref.)

Control of spontaneous activity during development. Moody WJ. **J Neurobiol** 1998 Oct;37(1):97–109 (80 ref.)

GFP as a cell and developmental marker in the Drosophila nervous system. Brand A. **Methods Cell Biol** 1999; 58:165–81 (40 ref.)

Techniques in neural development. Moens CB, et al. **Methods Cell Biol** 1999;59:253–72 (68 ref.)

Quail-chick chimeras. Teillet MA, et al. **Methods Mol Biol** 1999;97:305–18 (43 ref.)

Rearranging views on neurogenesis: neuronal death in the absence of DNA end-joining proteins. Chun J, et al. **Neuron** 1999 Jan;22(1):7–10 (20 ref.)

Hedgehog and patched in neural development and disease. Goodrich LV, et al. **Neuron** 1998 Dec;21(6):1243–57 (212 ref.)

Identifying the missing links: genes that connect neural induction and primary neurogenesis in vertebrate embryos. Sasai Y. **Neuron** 1998 Sep;21(3):455–8 (20 ref.)
The saga of the nerve growth factor. Levi-Montalcini R. **Neuroreport** 1998 Nov 16;9(16):R71–83 (59 ref.)
Semaphorin-mediated neuronal growth cone guidance. Kolodkin AL. **Prog Brain Res** 1998;117:115–32 (95 ref.)
The role of POU domain proteins in the regulation of mammalian pituitary and nervous system development. McEvilly RJ, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 63:223–55 (138 ref.)
Function of the neuropeptide head activator for early neural and neuroendocrine development. Hampe W, et al. **Results Probl Cell Differ** 1999;26:323–37 (30 ref.)
The specification of neuronal identity by graded Sonic Hedgehog signalling. Briscoe J, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):353–62 (60 ref.)
Neural induction. A bird's eye view. Streit A, et al. **Trends Genet** 1999 Jan;15(1):20–4 (57 ref.)
Schwann cells and their precursors emerge as major regulators of nerve development. Jessen KR, et al. **Trends Neurosci** 1999 Sep;22(9):402–10 (87 ref.)
[Cadherins, the development and regeneration of the neuromuscular axis] Mege RM, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):796–801 (58 ref.) (Eng. Abstr.) **(Fre)**
[Neurulational forms of the pathology of human nervous system] Savel'ev SV. **Arkh Patol** 1998 Sep–Oct;60(5):13–8 (39 ref.) (Eng. Abstr.) **(Rus)**
[Morphogenesis of neuronal systems in tissue culture repeats the evolution of simpler nervous systems] Sotnikov OS. **Morfologiia** 1999;115(2):7–23 (121 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Immunophilins: beyond immunosuppression. Hamilton GS, et al. **J Med Chem** 1998 Dec 17;41(26):5119–43 (245 ref.)
Nitric-oxide synthase and neurodegeneration/neuroprotection. Kaufman PL. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9455–6 (22 ref.)

GROWTH & DEVELOPMENT

The emergence of consciousness. Zelazo PR, et al. **Adv Neurol** 1998;77:149–63; discussion 164–5 (44 ref.)
Lessons from genetically engineered animal models. II. Disorders of enteric neuronal development: insights from transgenic mice. Gershon MD. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G262–7 (35 ref.)
Effect of gravity on vestibular neural development. Ross MD, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):44–51 (61 ref.)
Postnatal development under conditions of simulated weightlessness and space flight. Walton K. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):25–34 (35 ref.)
DCC and netrins. Culotti JG, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):609–13 (39 ref.)
Pleiotropic functions of neurotrophins in development. Tessarollo L. **Cytokine Growth Factor Rev** 1998 Jun; 9(2):125–37 (154 ref.)
White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Perlman JM. **Early Hum Dev** 1998 Dec;53(2):99–120 (134 ref.)
The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Rønn LC, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):853–64 (99 ref.)
Neural development in metatherian and eutherian mammals: variation and constraint. Darlington RB, et al. **J Comp Neurol** 1999 Aug 30;411(3):359–68 (21 ref.)
Stem cells in the developing and adult nervous system. Alvarez-Buylla A, et al. **J Neurobiol** 1998 Aug; 36(2):105–10 (16 ref.)
Adenoviral-mediated gene transfer to enhance neuronal survival, growth, and regeneration. Smith GM, et al. **J Neurosci Res** 1999 Jan 15;55(2):147–57 (114 ref.)
Regulation of synaptic function by neurotrophic factors in vertebrates and invertebrates: implications for development and learning. McKay SE, et al. **Learn Mem** 1999 May–Jun; 6(3):193–215 (196 ref.)
Polyunsaturated fatty acid status and neurodevelopment: a summary and critical analysis of the literature. Carlson SE, et al. **Lipids** 1999 Feb;34(2):171–8 (74 ref.)
The role of glycoproteins in neural development function, and disease. Breen KC, et al. **Mol Neurobiol** 1998 Apr; 16(2):163–220 (512 ref.)
Hedgehog and patched in neural development and disease. Goodrich LV, et al. **Neuron** 1998 Dec;21(6):1243–57 (212 ref.)
[Biological roles of HNK-1 carbohydrate epitope in the nervous system] Ohtsubo K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2366–72 (39 ref.) **(Jpn)**
[Molecular biological approach to functions of telencephalin, a cell adhesion molecule and HNK-1 carbohydrate epitope, which is commonly expressed on cell adhesion molecules in the nervous system] Oka S. **Yakugaku Zasshi** 1998 Oct; 118(10):431–46 (34 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The relationship between interleukin-6 and herpes simplex virus type 1: implications for behavior and immunopathology. Baker M, et al. **Brain Behav Immun** 1999 Sep;13(3):201–11 (64 ref.)

INJURIES

Genetic approaches to neurotrauma research: opportunities and potential pitfalls of murine models. Steward O, et al. **Exp Neurol** 1999 May;157(1):19–42 (130 ref.)
Neuropathic pain: new insights, new interventions. Bennett GJ. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):95–8, 101–4, 107–10 passim (9 ref.)
Androgenic regulation of the central glia response following nerve damage. Jones KJ, et al. **J Neurobiol** 1999 Sep 15; 40(4):560–73 (101 ref.)
Assaying structural changes after nerve damage, an essay on quantitative morphology. Coggeshall RE. **Pain** 1999 Aug;Suppl 6:S21–5 (23 ref.)
[Sports injuries of the nervous system] Lang C, et al. **Fortschr Neurol Psychiatr** 1999 Aug;67(8):373–84 (116 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Comparative neuroanatomy of vasotocin and vasopressin in amphibians and other vertebrates. Moore FL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):251–60 (114 ref.)
POU family transcription factors in the nervous system. Latchman DS. **J Cell Physiol** 1999 May;179(2):126–33 (68 ref.)
The role of glycoproteins in neural development function, and disease. Breen KC, et al. **Mol Neurobiol** 1998 Apr; 16(2):163–220 (512 ref.)
The existence of molecular water pumps in the nervous system: a review of the evidence. Baslow MH. **Neurochem Int** 1999 Jan;34(1):77–90 (49 ref.)
The ERK/MAP-kinases cascade in the nervous system. Derkinderen P, et al. **Neuroreport** 1999 Apr 6;10(5):R24–34 (199 ref.)
The complexity of intermediate filaments in the nervous system. Leung CL, et al. **Subcell Biochem** 1998;31:497–526 (186 ref.)
[Nerve growth factor system in health and disease] Kliushnik TP. **Vestn Ross Akad Med Nauk** 1999;(1):25–8 (77 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Paraneoplastic syndromes. Dalmau JO, et al. **Arch Neurol** 1999 Apr;56(4):405–8 (17 ref.)
Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Staley JK, et al. **Biol Psychiatry** 1998 Oct 1; 44(7):534–49 (148 ref.)
Neuropathology of prion diseases. Mikol J. **Biomed Pharmacother** 1999;53(1):19–26 (58 ref.)
Corpora-amylacea and the family of polyglucosan diseases. Cavanagh JB. **Brain Res Brain Res Rev** 1999 Apr; 29(2–3):265–95 (235 ref.)
Assaying structural changes after nerve damage, an essay on quantitative morphology. Coggeshall RE. **Pain** 1999 Aug;Suppl 6:S21–5 (23 ref.)
[Neuroimmunopathology] Kryzhanovskii GN. **Vestn Ross Akad Med Nauk** 1999;(4):18–20 (17 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Alteration in gastrointestinal and neurological function after electrical injury: a review of four cases. Buniak B, et al. **Am J Gastroenterol** 1999 Jun;94(6):1532–6 (31 ref.)
Neuropathic pain: new insights, new interventions. Bennett GJ. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):95–8, 101–4, 107–10 passim (9 ref.)
The neurobiology of pain. Dubner R, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7627–30 (25 ref.)
[Low back pain from the neurologic viewpoint] Wessely P. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):791–5 (15 ref.) **(Ger)**
[Physiology and pathophysiology of pain] Schäfer M. **Ther Umsch** 1999 Aug;56(8):426–30 (6 ref.) (Eng. Abstr.) **(Ger)**
[Can the nervous system functions of mammals be restored during deep cooling without warming? New facts and the evolution of views] Ivanov KP. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):73–89 (68 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Interventional neuroradiology. Recent developments and anaesthesiologic aspects. Luginbühl M, et al. **Minerva Anestesiol** 1999 Jun;65(6):445–54 (80 ref.)

ULTRASTRUCTURE

Glycolipid-enriched caveolae and caveolae-like domains in the nervous system. Masserini M, et al. **J Neurochem** 1999 Jul;73(1):1–11 (121 ref.)

VIROLOGY

Infection and spread of alphaherpesviruses in the nervous system. Enquist LW, et al. **Adv Virus Res** 1998;51:237–347 (482 ref.)
The relationship between interleukin-6 and herpes simplex virus type 1: implications for behavior and immunopathology. Baker M, et al. **Brain Behav Immun** 1999 Sep;13(3):201–11 (64 ref.)
Use of herpes simplex virus type 1 for transgene expression within the nervous system. Lachmann RH, et al. **Clin Sci (Colch)** 1999 Jun;96(6):533–41 (57 ref.)

NERVOUS SYSTEM DISEASES

Update in neurology. Samuels MA. **Ann Intern Med** 1998 Dec 1;129(11):878–85 (11 ref.)
Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Anders HJ, et al. **Int J STD AIDS** 1999 Mar;10(3):151–9; quiz 160–1 (89 ref.)
New order from neurological disorders. Price DL. **Nature** 1999 Jun 24;399(6738 Suppl):A3–5 (26 ref.)
[Visual hallucinations in ophthalmological and neurological diseases] Kerty E. **Tidsskr Nor Laegeforen** 1998 Dec 10; 118(30):4738–41 (17 ref.) (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Glial cells in neurotoxicity development. Aschner M, et al. **Annu Rev Pharmacol Toxicol** 1999;39:151–73 (132 ref.)
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Shehata N, et al. **Cancer Invest** 1999;17(3):201–5 (24 ref.)
Health effects of exposure to low doses of nerve agent--a review of present knowledge. Moore DH. **Drug Chem Toxicol** 1998;21 Suppl 1:123–30 (16 ref.)
Does levodopa accelerate Parkinson's disease? Simuni T, et al. **Drugs Aging** 1999 Jun;14(6):399–408 (98 ref.)
Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents. Brown MA, et al. **J Appl Toxicol** 1998 Nov–Dec; 18(6):393–408 (78 ref.)
Approach to neurotoxicity tort cases. Feldman RG, et al. **Neurol Clin** 1999 May;17(2):267–81 (36 ref.)
Manganese neurotoxicity in industrial exposures: proof of effects, critical exposure level, and sensitive tests. Iregren A. **Neurotoxicology** 1999 Apr–Jun;20(2–3):315–23 (27 ref.)
A brief history of the neurobehavioral toxicity of manganese: some unanswered questions. McMillan DE. **Neurotoxicology** 1999 Apr–Jun;20(2–3):499–507 (40 ref.)
Animal models of manganese's neurotoxicity. Newland MC. **Neurotoxicology** 1999 Apr–Jun;20(2–3):415–32 (87 ref.)
Manganese neurotoxicity: a review of clinical features, imaging and pathology. Pal PK, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):227–38 (139 ref.)
The neurotoxicity of polychlorinated biphenyls. Tilson HA, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):517–25 (77 ref.)
Manganese neurotoxicity: a mechanistic hypothesis. Verity MA. **Neurotoxicology** 1999 Apr–Jun;20(2–3):489–97 (41 ref.)
Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. Castagnoli N Jr, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):31–8 (40 ref.)
Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Fadda F, et al. **Prog Neurobiol** 1998 Nov;56(4):385–431 (649 ref.)
[Polyneuropathies from solvents] Neundörfer B, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66(12):539–44 (67 ref.) (Eng. Abstr.) **(Ger)**
[Neurologic disorders caused by adverse effects of drugs--with special reference to iatrogenic nervous system diseases of the current interest] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1885–91 (26 ref.) **(Jpn)**
[Neurological side-effects of circulation and metabolism enhancers] Hirai S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):587–92 (7 ref.) **(Jpn)**
[Neurological complications of ethanol] Hoshino H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):638–45 (17 ref.) **(Jpn)**
[Neurologic side effects of chemicals used in industry] Igisu H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):628–32 (16 ref.) **(Jpn)**
[Neuropathy induced by insecticides] Konno N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):623–7 (15 ref.) **(Jpn)**
[Neurological side-effects of antiallergic drug, colchicine and glucocorticoids] Tanaka C, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):606–9 (12 ref.) **(Jpn)**

COMPLICATIONS

Neurological disorders in the ageing population and their urological implications. Evans SN, et al. **Br J Urol** 1998 Dec;82 Suppl 1:71–8 (51 ref.)
Is psoriasis a neuroimmunologic disease? Farber EM, et al. **Int J Dermatol** 1999 Jan;38(1):12–5 (35 ref.)
Applying classifications of sleep disorders to children with neurologic conditions. Scher MS. **J Child Neurol** 1998 Nov; 13(11):525–36 (71 ref.)
Pain in children with significant neurological impairment. Oberlander TF, et al. **J Dev Behav Pediatr** 1999 Aug; 20(4):235–43 (71 ref.)
Neurology and the skin. Hurko O, et al.

NERVOUS SYSTEM DISEASES

J Neurol Neurosurg Psychiatry 1999 Apr;66(4):417–30 (115 ref.)

Are opioids effective in relieving neuropathic pain? Dellemijn P. **Pain** 1999 Apr;80(3):453–62 (90 ref.)

[Long-term ventilation at home in adults with neurological diseases] Raphaël JC, et al. **Rev Mal Respir** 1998 Sep; 15(4):495–505 (62 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of chronic neurogenic pain--clinical use of the DREZ operation] Spaic M, et al. **Vojnosanit Pregl** 1998 Sep–Oct;55(5):533–40 (48 ref.) **(Sec)**

DIAGNOSIS

Neurologic differential diagnosis in podiatry. Khella SL. **Clin Podiatr Med Surg** 1999 Jan;16(1):49–66, vi (34 ref.)

Paraneoplastic syndromes. Rees J. **Curr Opin Neurol** 1998 Dec;11(6):633–7 (30 ref.)

Spectral analysis methods for neurological signals. Muthuswamy J, et al. **J Neurosci Methods** 1998 Aug 31; 83(1):1–14 (21 ref.)

Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Reiber H. **Mult Scler** 1998 Jun;4(3):99–107 (26 ref.)

Manganese neurotoxicity: a review of clinical features, imaging and pathology. Pal PK, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):227–38 (139 ref.)

Frequently missed diagnosis in geriatric psychiatry. Bair BD. **Psychiatr Clin North Am** 1998 Dec;21(4):941–71, viii (152 ref.)

[The diagnosis of encephalopathy, neuropathy and myopathy in the critical patient] Lindner A, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):257–60 (34 ref.) **(Ger)**

[Leg pain--the contribution of the neurologist] Beer S, et al. **Ther Umsch** 1998 Oct;55(10):618–23 (31 ref.) (Eng. Abstr.) **(Ger)**

[A case of an anomaly of the upper thoracic spine with lower spastic paraplegia simulating progressive disease of the nervous system] Evtushenko SK, et al. **Lik Sprava** 1999 Mar;(2):126–8 (7 ref.) **(Rus)**

[Advances in biochemistry in the understanding of neurometabolic disorders] Ribes A, et al. **Rev Neurol** 1999 Jan 1–15;28(1):11–5 (27 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Inhibition of nitric oxide synthase as a potential therapeutic target. Hobbs AJ, et al. **Annu Rev Pharmacol Toxicol** 1999; 39:191–220 (209 ref.)

Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Farooqui AA, et al. **Brain Res Bull** 1999 Jun;49(3):139–53 (142 ref.)

Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Chabrier PE, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1029–35 (73 ref.)

Therapeutic approaches to the treatment of neuroinflammatory diseases. Hays SJ. **Curr Pharm Des** 1998 Aug;4(4):335–48 (112 ref.)

Adenosine and the nervous system: pharmacological data and therapeutic perspectives. Guieu R, et al. **Gen Pharmacol** 1998 Oct;31(4):553–61 (166 ref.)

D-3 receptor agonists: combined action neurologic and neuropsychiatric agents [editorial; comment] Cummings JL. **J Neurol Sci** 1999 Feb 1;163(1):2–3 (17 ref.) Comment on: J Neurol Sci 1999 Feb 1;163(1):25–31.

Brain cannabinoid systems as targets for the therapy of neurological disorders. Consroe P. **Neurobiol Dis** 1998 Dec; 5(6 Pt B):534–51 (159 ref.)

Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Yamada KA. **Neurobiol Dis** 1998 Aug;5(2):67–80 (84 ref.)

The glutamate synapse as a therapeutical target: perspectives for the future. Meldrum BS. **Prog Brain Res** 1998; 116:441–58 (132 ref.)

Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Gasior M, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):107–12 (60 ref.)

[Role of corticosteroid therapy in non-malignant diseases] Vignes S, et al. **Rev Med Interne** 1998 Nov;19(11):799–810 (87 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic update 1997–1998 (1). First part] Scheen AJ. **Rev Med Liege** 1998 Aug;53(8):459–66 (28 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Monoamine oxidase in neuropsychiatry and behavior. Shih JC, et al. **Am J Hum Genet** 1999 Sep;65(3):593–8 (56 ref.)

EPIDEMIOLOGY

Neurology without borders: neurological disease in a shrinking world. Bergen DC. **J Neurol Sci** 1999 Jun 1; 165(2):101–5 (38 ref.)

ETIOLOGY

Nitric oxide, mitochondria and neurological disease. Heales SJ, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):215–28 (95 ref.)

Neurologic complications in thoracic surgery. Feins RH. **Chest Surg Clin N Am** 1998 Aug;8(3):633–43 (26 ref.)

Evidence against permanent neurologic damage from nonconvulsive status epilepticus. Drislane FW. **J Clin Neurophysiol** 1999 Jul;16(4):323–31; discussion 353 (50 ref.)

Inborn errors of neurotransmitter receptors. Surtees R. **J Inherit Metab Dis** 1999 Jun;22(4):374–80 (21 ref.)

Neurological complications of radiotherapy and chemotherapy. Keime-Guibert F, et al. **J Neurol** 1998 Nov; 245(11):695–708 (85 ref.)

Neurological manifestations of malignant and non-malignant dysglobulinaemias. Steck AJ. **J Neurol** 1998 Oct; 245(10):634–9 (26 ref.)

Neurological manifestations of antiphospholipid antibody syndrome. Brey RL, et al. **Lupus** 1998;7 Suppl 2:S67–74 (84 ref.)

The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders. Massieu L, et al. **Neurobiology (Bp)** 1998;6(1):99–108 (54 ref.)

Expert witness testimony: A trial judge's perspective. Weinstein JB. **Neurol Clin** 1999 May;17(2):355–62 (34 ref.)

Neurologic complications of pediatric cardiac, gastrointestinal, and renal diseases. Sanchez JL, et al. **Pediatr Ann** 1998 Oct;27(10):625–33 (58 ref.)

Neurologic complications of cancer, sickle cell disease, and hemophilia. Zuckerman GB, et al. **Pediatr Ann** 1998 Oct; 27(10):640–50 (53 ref.)

Neurological complications of cardiac surgery: the need for new paradigms in prevention and treatment. Hogue CW Jr, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr; 11(2):105–15 (72 ref.)

Neurotoxicity in single photon emission computed tomography brain scans of patients reporting chemical sensitivities. Ross GH, et al. **Toxicol Ind Health** 1999 Apr–Jun;15(3–4):415–20 (26 ref.)

[Neuropsychological sequelae of children treated for brain tumors: evaluation and risk factors] Grill J, et al. **Arch Pediatr** 1998 Feb;5(2):167–73 (62 ref.) (Eng. Abstr.) **(Fre)**

[Gougerot-Sjögren syndrome. Neurologic complications] Amoura Z, et al. **Presse Med** 1999 Jun 19;28(22):1209–13 (64 ref.) (Eng. Abstr.) **(Fre)**

[Neurologic manifestations of primary Gougerot-Sjögren syndrome] Lafitte C. **Rev Neurol (Paris)** 1998 Oct; 154(10):658–73 (113 ref.) (Eng. Abstr.) **(Fre)**

[Critical polyneuropathy] Hund E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):334–9 (68 ref.) (Eng. Abstr.) **(Ger)**

[Neurology 1998: concepts in transition] Kesselring J. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2027–9 (15 ref.) **(Ger)**

[Neurologic diseases associated with malignant tumors] Asahina M, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):858–63 (5 ref.) **(Jpn)**

[Nervous system diseases associated with sarcoidosis] Iizuka T, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10; 88(5):808–17 (5 ref.) **(Jpn)**

[Nervous system dysfunctions due to collagen diseases] Kitagawa Y. **Nippon Naika Gakkai Zasshi** 1999 May 10; 88(5):799–807 (5 ref.) **(Jpn)**

GENETICS

Genetic linkage analysis. Pulst SM. **Arch Neurol** 1999 Jun; 56(6):667–72 (16 ref.)

Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Campbell IL, et al. **Brain Res** 1999 Jul 17;835(1):46–61 (81 ref.)

Myosin V in the brain: mutations lead to neurological defects. Langford GM, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):1–8 (174 ref.)

Genetic susceptibility to neurodevelopmental disorders. Ryan SG. **J Child Neurol** 1999 Mar;14(3):187–95 (57 ref.)

Chromosomal fragility may be indicative of altered higher-order DNA organization as the underlying genetic diathesis in complex neurobehavioural disorders. Gericke GS. **Med Hypotheses** 1999 Mar;52(3):201–8 (80 ref.)

CAG-polyglutamine-repeat mutations: independence from gene context. Ordway JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1083–8 (34 ref.)

Ion channel genes and human neurological disease: recent progress, prospects, and chalienges. Cooper EC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4759–66 (102 ref.)

[Hereditary neurological diseases caused by amplification of triplet repetitions] Warter JM, et al. **Presse Med** 1998 Feb 28;27(8):376–81 (70 ref.) (Eng. Abstr.) **(Fre)**

[Neurosurgery and molecular biology: (series 9). Application of molecular genetics for understanding of neurologic diseases] Tsuji S. **No Shinkei Geka** 1998 Dec;26(12):1043–54 (50 ref.) **(Jpn)**

IMMUNOLOGY

Autoimmunity in paraneoplastic neurological syndromes. Giometto B, et al. **Brain Pathol** 1999 Apr;9(2):261–73 (107 ref.)

Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies [editorial] Hartung HP, et al. **Curr Opin Neurol** 1998 Oct;11(5):497–513 (133 ref.)

Therapeutic approaches to the treatment of neuroinflammatory diseases. Hays SJ. **Curr Pharm Des** 1998 Aug;4(4):335–48 (112 ref.)

Paraneoplastic neurological disorders. Newsom-Davis J. **J R Coll Physicians Lond** 1999 May–Jun;33(3):225–7 (8 ref.)

[Immunology in the clinical practice. XVI. Paraneoplastic syndromes of the nervous system: pathogenesis and diagnosis] Smitt PA, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1652–8 (29 ref.) (Eng. Abstr.) **(Dut)**

METABOLISM

Metal binding and radical generation of proteins in human neurological diseases and aging. Multhaup G, et al. **Met Ions Biol Syst** 1999;36:365–87 (105 ref.)

The role of glycoproteins in neural development function, and disease. Breen KC, et al. **Mol Neurobiol** 1998 Apr; 16(2):163–220 (512 ref.)

[Nerve growth factor system in health and disease] Kliushnik TP. **Vestn Ross Akad Med Nauk** 1999;(1):25–8 (77 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

PANDAS: the search for environmental triggers of pediatric neuropsychiatric disorders. Lessons from rheumatic fever. Garvey MA, et al. **J Child Neurol** 1998 Sep;13(9):413–23 (123 ref.)

NURSING

Neuroscience nursing practice in a new millennium. Hickey JV, et al. **Nurs Clin North Am** 1999 Sep;34(3):541–54 (24 ref.)

Ethical perspectives in neuroscience nursing practice. Murphy WJ. **Nurs Clin North Am** 1999 Sep;34(3):621–35 (38 ref.)

Foundation for practice. Neuroassessment for neuroscience nurses. Neatherlin JS. **Nurs Clin North Am** 1999 Sep; 34(3):573–92 (9 ref.)

PATHOLOGY

Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Dalmau J, et al. **Brain Pathol** 1999 Apr; 9(2):275–84 (56 ref.)

The neuropathology of paraneoplastic syndromes. Scaravilli F, et al. **Brain Pathol** 1999 Apr;9(2):251–60 (83 ref.)

The neuropathology of organ transplantation: comparison and contrast in 500 patients. Martinez AJ. **Pathol Res Pract** 1998;194(7):473–86 (96 ref.)

A new approach to the genetic analysis of nervous system diseases: retrospective genotyping of archival brains. Kösel S, et al. **Prog Brain Res** 1998;117:307–13 (41 ref.)

PHYSIOPATHOLOGY

Oxidative injury in the nervous system. Delanty N, et al. **Acta Neurol Scand** 1998 Sep;98(3):145–53 (90 ref.)

Containing the contents. McComas AJ. **Adv Neurol** 1998; 77:135–48 (30 ref.)

Lessons from genetically engineered animal models. II. Disorders of enteric neuronal development: insights from transgenic mice. Gershon MD. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G262–7 (35 ref.)

The pathophysiology of paraneoplastic neurological syndromes. Liblau R, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):512–20 (44 ref.)

Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Sarter M, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:368–82 (73 ref.)

Neural cell adhesion molecule L1: relating disease to function. Kenwrick S, et al. **Bioessays** 1998 Aug; 20(8):668–75 (57 ref.)

Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Dalmau J, et al. **Brain Pathol** 1999 Apr; 9(2):275–84 (56 ref.)

Painful neuropathies. Koltzenburg M. **Curr Opin Neurol** 1998 Oct;11(5):515–21 (103 ref.)

Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptácek LJ. **Dig Dis Sci** 1999 Aug;44(8 Suppl):94S–96S (22 ref.)

Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Trojaborg W. **Electroencephalogr Clin Neurophysiol** 1998 Nov;107(5):303–16 (117 ref.)

The Brn-3a transcription factor. Latchman DS. **Int J Biochem Cell Biol** 1998 Nov;30(11):1153–7 (16 ref.)

Allosteric nicotinic receptors, human pathologies. Léna C, et al. **J Physiol Paris** 1998 Apr;92(2):63–74 (112 ref.)

Assessing the machinery of mind: synapses in neuropsychiatric disorders. Honer WG. **J Psychiatry Neurosci** 1999 Mar;24(2):116–21 (21 ref.)

Neuro-talk: an intervention to enhance communication. Gregory RJ. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):28–31 (10 ref.)

The role of glycoproteins in neural development function, and disease. Breen KC, et al. **Mol Neurobiol** 1998 Apr; 16(2):163–220 (512 ref.)

Cytokine interactions and cytokine balance in the brain: relevance to neurology and psychiatry. Plata-Salamán C, et al. **Mol Psychiatry** 1999 Jul;4(4):302–6 (33 ref.)

The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Muñoz-Fernández MA, et al. **Prog Neurobiol** 1998 Oct;

56(3):307–40 (486 ref.)
The role of integrins in immune-mediated diseases of the nervous system. Archelos JJ, et al. **Trends Neurosci** 1999 Jan;22(1):30–8 (56 ref.)
Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Sarter M, et al. **Trends Neurosci** 1999 Feb; 22(2):67–74 (95 ref.)
[Perineal neurologic pain] Amarenco G, et al. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B164–8 (22 ref.) **(Fre)**
[Mechanisms of paraneoplastic neurologic syndromes] Honnorat J, et al. **Rev Med Interne** 1999 Aug;20(8):670–80 (83 ref.) (Eng. Abstr.) **(Fre)**
[Critical polyneuropathy] Hund E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):334–9 (68 ref.) (Eng. Abstr.) **(Ger)**
[Gamma aminobutyric acid—its function, disorders and their sequelae] De Luka SR, et al. **Med Pregl** 1998 Jul–Aug; 51(7–8):319–24 (12 ref.) (Eng. Abstr.) **(Scr)**

PREVENTION & CONTROL

Limiting neurological damage after stroke: a review of pharmacological treatment options. Read SJ, et al. **Drugs Aging** 1999 Jan;14(1):11–39 (294 ref.)
An international network for evaluating neuroprotective therapy after severe birth asphyxia. Levene MI, et al. **Semin Perinatol** 1999 Jun;23(3):226–33 (50 ref.)
[Evaluation of the nervous system in workers as needed for preventive care. Methodical indicators. II. Objective examinations] Polakowska B. **Med Pr** 1995;46(1):61–5 (7 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Learning in preschool children with neurological disability. Stanley O, et al. **Arch Dis Child** 1999 May;80(5):481–4 (30 ref.)
Neuro-talk: an intervention to enhance communication. Gregory RJ. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):28–31 (10 ref.)

SURGERY

Transplantation of neural tissue into the brain—a new therapeutic modality for the 21st century. Itakura T, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):756–62 (21 ref.)

THERAPY

Orthoses used in the management of neurologic and muscular disorders. McGuire JB. **Clin Podiatr Med Surg** 1999 Jan; 16(1):153–74 (10 ref.)
Cellular and molecular treatments of neurological diseases. Isacson O, et al. **Exp Neurol** 1999 Sep;159(1):1–3 (16 ref.)
A review of the therapy of paraneoplastic neurologic syndromes. Das A, et al. **J Neurooncol** 1999 Jan; 41(2):181–94 (211 ref.)
Neurologic malpractice: the perspective of a patient's lawyer. Mackauf SH. **Neurol Clin** 1999 May;17(2):345–53 (4 ref.)
Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Dalakas MC. **Neurology** 1998 Dec;51(6 Suppl 5):S2–8 (69 ref.)
Therapeutic apheresis in neurological disorders. Khatri BO. **Ther Apher** 1999 May;3(2):161–71 (127 ref.)
[Advance of gene therapy for neurological diseases by direct in vivo gene transfer] Li BY, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):215–20 (20 ref.) (Eng. Abstr.) **(Chi)**
[Critical illness polyneuropathy—report of two cases] Mezödy M, et al. **Orv Hetil** 1999 May 23;140(21):1179–83 (39 ref.) (Eng. Abstr.) **(Hun)**
[Genetic therapy for the nervous system: a trend in modern neurology] González-Hoyuela M, et al. **Rev Neurol** 1998 Oct;27(158):625–30 (53 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans. Friedrich F. **Acta Virol** 1998 Jun; 42(3):187–94 (175 ref.)
Herpes simplex virus latency and the immune response. Daheshia M, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):430–5 (50 ref.)
[Hepatitis C and neurological disorders (editorial; comment)] Cacoub P. **Gastroenterol Clin Biol** 1998 Nov;22(11):889–90 (14 ref.) Comment on: Gastroenterol Clin Biol 1998 Nov;22(11):891–6. **(Fre)**

NERVOUS SYSTEM NEOPLASMS

DIAGNOSIS

Neurogenic tumors of the mediastinum in children. Inci I, et al. **Childs Nerv Syst** 1999 Aug;15(8):372–6 (47 ref.)

EPIDEMIOLOGY

[Epidemiological studies in neuro-oncology: the state of the art in Ukraine and abroad] Zozulia IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Jul–Sep;(3):50–4 (53 ref.) **(Rus)**

SURGERY

Neurogenic tumors of the mediastinum in children. Inci I, et al. **Childs Nerv Syst** 1999 Aug;15(8):372–6 (47 ref.)

NERVOUS SYSTEM PHYSIOLOGY

The problems of consciousness. Chalmers DJ. **Adv Neurol** 1998;77:7–16; discussion 16–8 (8 ref.)
What should we expect from a theory of consciousness? Churchland PS. **Adv Neurol** 1998;77:19–30; discussion 30–2 (34 ref.)
The emergence of consciousness. Zelazo PR, et al. **Adv Neurol** 1998;77:149–63; discussion 164–5 (44 ref.)
Neural selection and control of visually guided eye movements. Schall JD, et al. **Annu Rev Neurosci** 1999; 22:241–59 (86 ref.)
The neurochemical basis of learning and neurocomputation: the redox theory. Smythies J. **Behav Brain Res** 1999 Feb 15;99(1):1–6 (57 ref.)
Why is docosahexaenoic acid essential for nervous system function? Mitchell DC, et al. **Biochem Soc Trans** 1998 Aug; 26(3):365–70 (43 ref.)
Neurobiology of fish under altered gravity conditions. Anken RH, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):9–18 (36 ref.)
Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Herdegen T, et al. **Brain Res Brain Res Rev** 1998 Dec;28(3):370–490 (1440 ref.)
Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Raivich G, et al. **Brain Res Brain Res Rev** 1999 Jul;30(1):77–105 (313 ref.)
Angiotensin receptors in the nervous system. Allen AM, et al. **Brain Res Bull** 1998 Sep 1;47(1):17–28 (152 ref.)
The puzzle of hydrodynamic information processing: how are complex water motions analyzed by the lateral line? Mogdans J, et al. **Eur J Morphol** 1999 Apr;37(2–3):195–9 (17 ref.)
Neuropeptides in headache. Edvinsson L, et al. **Eur J Neurol** 1998 Jul;5(4):329–41 (92 ref.)
Neural mechanisms for synthesizing sensory information and producing adaptive behaviors. Stein BE. **Exp Brain Res** 1998 Nov;123(1–2):124–35 (75 ref.)
A possible paradigm of functional neurology. Moldovanu I, et al. **Funct Neurol** 1998 Oct–Dec;13(4):305–10 (31 ref.)
Adenosine and the nervous system: pharmacological data and therapeutic perspectives. Guieu R, et al. **Gen Pharmacol** 1998 Oct;31(4):553–61 (166 ref.)
Galanin and NPY, two peptides with multiple putative roles in the nervous system. Hökfelt T, et al. **Horm Metab Res** 1999 May;31(5):330–4 (48 ref.)
The mobile regulatory structures of the body. Wolf S. **Integr Physiol Behav Sci** 1999 Apr–Jun;34(2):103–9 (14 ref.)
Regulation of neurotrophic functions: proteinase inhibitors. Fumagalli L, et al. **Ital J Anat Embryol** 1999 Apr–Jun; 104(2):53–88 (110 ref.)
Neurobiological correlates of the antidepressant action of electroconvulsive therapy. Mann JJ. **J ECT** 1998 Sep; 14(3):172–80 (60 ref.)
Neural circuitry for communication and jamming avoidance in gymnotiform electric fish. Metzner W. **J Exp Biol** 1999 May;202 (Pt 10):1365–75 (96 ref.)
Transplantation as a tool to study progenitors within the vertebrate nervous system. Gaiano N, et al. **J Neurobiol** 1998 Aug;36(2):152–61 (85 ref.)
Glia as mediators of steroid hormone action on the nervous system: An overview. Jordan CL. **J Neurobiol** 1999 Sep 15;40(4):434–45 (84 ref.)
Molecular neurogenetics of biological rhythms. Hall JC. **J Neurogenet** 1998 Sep;12(3):115–81 (250 ref.)
The advantages and limitations of permanent or reversible deactivation techniques in the assessment of neural function. Lomber SG. **J Neurosci Methods** 1999 Jan; 86(2):109–17 (62 ref.)
Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Arimura A. **Jpn J Physiol** 1998 Oct; 48(5):301–31 (240 ref.)
Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task. Noda Y, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):607–11 (32 ref.)
Nitric oxide in invertebrates. Colasanti M, et al. **Mol Neurobiol** 1998 Winter;17(1–3):157–74 (105 ref.)
Homology and convergence in vertebrate and invertebrate nervous systems. Sandeman D. **Naturwissenschaften** 1999 Aug;86(8):378–87 (41 ref.)
Nervous control of the cerebrovascular system: doubts and facts. Sándor P. **Neurochem Int** 1999 Sep;35(3):237–59 (119 ref.)
Who tells one hand what the other is doing: the neurophysiology of bimanual movements. Donchin O, et al. **Neuron** 1999 May;23(1):15–8 (20 ref.)
Transcutaneous cranial electrical stimulation (TCES): a review 1998. Limoge A, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):529–38 (108 ref.)
Macronutrient-specific dietary selection in rodents and its neural bases. Thibault L, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):457–528 (151 ref.)
The role of chaos in neural systems. Rabinovich MI, et al. **Neuroscience** 1998 Nov;87(1):5–14 (19 ref.)
A primer of neuroanatomy and neurophysiology. Minton MS, et al. **Nurs Clin North Am** 1999 Sep;34(3):555–72 (7 ref.)
Primer in folic acid: folates and neuropsychiatry [editorial] Abalan F. **Nutrition** 1999 Jul–Aug;15(7–8):595–8 (46 ref.)
Pathophysiology of the kallikrein-kinin system in mammalian nervous tissue. Raidoo DM, et al. **Pharmacol Ther** 1998 Aug;79(2):105–27 (260 ref.)
Maturation of the mammalian respiratory system. Hilaire G, et al. **Physiol Rev** 1999 Apr;79(2):325–60 (500 ref.)
Using knockout and transgenic mice to study neurophysiology and behavior. Picciotto MR, et al. **Physiol Rev** 1998 Oct;78(4):1131–63 (305 ref.)
Mechanisms of NO neurotoxicity. Dalkara T, et al. **Prog Brain Res** 1998;118:231–9 (79 ref.)
Glial glutamate transport as target for nitric oxide: consequences for neurotoxicity. Ye ZC, et al. **Prog Brain Res** 1998;118:241–51 (42 ref.)
The Ca2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells. Solà C, et al. **Prog Neurobiol** 1999 Jun;58(3):207–32 (168 ref.)
Neurobiology of the Caenorhabditis elegans genome. Bargmann CI. **Science** 1998 Dec 11;282(5396):2028–33 (91 ref.)
Tripartite synapses: glia, the unacknowledged partner. Araque A, et al. **Trends Neurosci** 1999 May;22(5):208–15 (61 ref.)
Patterning motoneurons in the vertebrate nervous system. Eisen JS. **Trends Neurosci** 1999 Jul;22(7):321–6 (95 ref.)
Schwann cells and their precursors emerge as major regulators of nerve development. Jessen KR, et al. **Trends Neurosci** 1999 Sep;22(9):402–10 (87 ref.)
[Neuromuscular monitoring. Standard procedures] Fuchs-Buder T. **Anaesthesist** 1998 Aug;47(8):629–37 (65 ref.) (Eng. Abstr.) **(Ger)**
[Ca+ metabolism in the sarcoplasmic reticulum and the role of ryanodine and IP3 receptors in the nervous system] Nagata E, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2522–9 (30 ref.) **(Jpn)**
[Biological fluctuations and neuronal dynamics] Hidaka I, et al. **Nippon Ronen Igakkai Zasshi** 1999 Jan;36(1):8–15 (19 ref.) **(Jpn)**
[The neurophysiological mechanisms in the selection of actions and their disturbance in the attention deficit syndrome] Kropotov IuD, et al. **Fiziol Cheloveka** 1999 Jan–Feb;25(1):115–24 (34 ref.) **(Rus)**

DRUG EFFECTS

Neuropsychopharmacological properties of neuroactive steroids. Rupprecht R, et al. **Steroids** 1999 Jan–Feb; 64(1–2):83–91 (84 ref.)

NESIDIOBLASTOMA see **ADENOMA, ISLET CELL**

NESIDIOBLASTOSIS see **PANCREATIC DISEASES**

NESIDIOBLASTS see **ISLETS OF LANGERHANS**

NESTED CASE-CONTROL STUDIES see **CASE-CONTROL STUDIES**

NESTED PCR see **POLYMERASE CHAIN REACTION**

NETROPSIN

ANALOGS & DERIVATIVES

Progress in the design of DNA sequence-specific lexitropsins. Walker WL, et al. **Biopolymers** 1997;44(4):323–34 (44 ref.)

PHARMACOLOGY

Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues. Bailly C, et al. **Bioconjug Chem** 1998 Sep–Oct;9(5):513–38 (299 ref.)

NETWORK COMMUNICATION PROTOCOLS see **COMPUTER COMMUNICATION NETWORKS**

NEU PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

NEU RECEPTORS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

NEURAL CELL ADHESION MOLECULE see **NCAM**

NEURAL CONDUCTION

see related
NEURAL INHIBITION

The value of inching techniques in the diagnosis of focal nerve lesions. Inching is a useful technique. Campbell WW. **Muscle Nerve** 1998 Nov;21(11):1554–6; discussion 1561 (10 ref.)
The value of inching techniques in the diagnosis of focal nerve lesions. Inching techniques are of limited use. Geiringer SR. **Muscle Nerve** 1998 Nov;21(11):1557–9; discussion 1559–61 (18 ref.)
Neurophysiologic evaluation and clinical trials for neuromuscular diseases [editorial; comment] Olney RK.

NEURAL CONDUCTION

Muscle Nerve 1998 Nov;21(11):1365–7 (21 ref.) Comment on: Muscle Nerve 1998 Nov;21(11):1368–73.

PHYSIOLOGY

Myelin dysfunction/degradation in the central nervous system: why are myelin sheaths susceptible to damage? Bradl M. **J Neural Transm Suppl** 1999;55:9–17 (51 ref.)

Manic–depression neural conduction speeds and action potential event dyscorrelation. Newton JR. **Med Hypotheses** 1999 Jan;52(1):77–83 (41 ref.)

Lower extremity sensory nerve conduction studies. Blando AV. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):853–70, vii (83 ref.)

Considerations in reference values for nerve conduction studies. Wang SH, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):907–23, viii (58 ref.)

[Clinical and electrophysiologic studies of facial nerve function after hypoglossal–facial nerve anastomosis] Riemann R, et al. **Laryngorhinootologie** 1999 May; 78(5):244–53 (69 ref.) (Eng. Abstr.) **(Ger)**

NEURAL CREST

CYTOLOGY

Neural crest diversification. Groves AK, et al. **Curr Top Dev Biol** 1999;43:221–58 (278 ref.)

EMBRYOLOGY

Cell lineage in the developing neural tube. Kalyani AJ, et al. **Biochem Cell Biol** 1998;76(6):1051–68 (168 ref.)

Control of neurogenesis––lessons from frogs, fish and flies. Chitnis AB. **Curr Opin Neurobiol** 1999 Feb;9(1):18–25 (61 ref.)

Specification of dopaminergic and serotonergic neurons in the vertebrate CNS. Hynes M, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):26–36 (85 ref.)

Development of neural crest in Xenopus. Mayor R, et al. **Curr Top Dev Biol** 1999;43:85–113 (114 ref.)

Do corneal endothelial dystrophies represent ocular neurocristopathies? A discussion on the available evidence. Simmons IG, et al. **Eye** 1998;12 (Pt 3a):350–2 (21 ref.)

Regulation of neural crest cell populations: occurrence, distribution and underlying mechanisms. Vaglia JL, et al. **Int J Dev Biol** 1999 Mar;43(2):95–110 (184 ref.)

Minireview: summary of the initial development of the human nervous system. O'Rahilly R, et al. **Teratology** 1999 Jul;60(1):39–41 (14 ref.)

PATHOLOGY

[Neurulational forms of the pathology of human nervous system] Savel'ev SV. **Arkh Patol** 1998 Sep–Oct;60(5):13–8 (39 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Inhibitory interactions in the patterning of trunk neural crest migration. Krull CE. **Ann N Y Acad Sci** 1998 Oct 23; 857:13–22 (22 ref.)

Regulation of neural crest cell populations: occurrence, distribution and underlying mechanisms. Vaglia JL, et al. **Int J Dev Biol** 1999 Mar;43(2):95–110 (184 ref.)

Induction and patterning of the neural crest, a stem cell–like precursor population. LaBonne C, et al. **J Neurobiol** 1998 Aug;36(2):175–89 (117 ref.)

NEURAL INHIBITION

Perseveration, inhibition and the prefrontal cortex: a new look. Hauser MD. **Curr Opin Neurobiol** 1999 Apr; 9(2):214–22 (37 ref.)

Temporal inhibition in character identification. Busey TA. **Percept Psychophys** 1998 Nov;60(8):1285–304 (60 ref.)

GENETICS

Psychophysiological measures of (dis)inhibition as liability indicators for schizophrenia. Clementz BA. **Psychophysiology** 1998 Nov;35(6):648–68 (250 ref.)

PHYSIOLOGY

Opponent processes and anxiety: toward a neurophysiological formulation. Vincent JD, et al. **Acta Psychiatr Scand Suppl** 1998;393:50–5 (7 ref.)

Neuronal basis of afferent–evoked enhancement of locomotor activity. McCrea DA. **Ann N Y Acad Sci** 1998 Nov 16; 860:216–25 (38 ref.)

Cardiorenal effects of behavioral inhibition of breathing. Anderson DE. **Biol Psychol** 1998 Sep;49(1–2):151–63 (42 ref.)

Interactions between the presynaptic alpha2–autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Schlicker E, et al. **Brain Res Bull** 1998 Sep 15;47(2):129–32 (45 ref.)

Acute cellular alterations in the hippocampus after status epilepticus. Macdonald RL, et al. **Epilepsia** 1999;40 Suppl 1:S9–20; discussion S21–2 (65 ref.)

CREB can get you depressed [comment] Siegelbaum SA. **Neuron** 1999 Jul;23(3):414–5 (8 ref.) Comment on: Neuron 1999 Jul;23(3):559–68.

Recurrent inhibition in humans. Katz R, et al. **Prog Neurobiol** 1999 Feb;57(3):325–55 (81 ref.)

NEURAL INTERCONNECTIONS see **NEURAL PATHWAYS**

NEURAL NETWORK MODELS see **NEURAL NETWORKS (COMPUTER)**

NEURAL NETWORKS (ANATOMIC) see **NERVE NET**

NEURAL NETWORKS (COMPUTER)

Neural network applications in physical medicine and rehabilitation. Ohno–Machado L, et al. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):392–8 (38 ref.)

Neural networks in multivariate calibration. Despagne F, et al. **Analyst** 1998 Nov;123(11):157R–178R (99 ref.)

Analysis and modeling of the locomotor central pattern generator as a network of coupled oscillators. Sigvardt KA, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:250–65 (63 ref.)

Cortical populations and behaviour: Hebb's thread. Amirikian B, et al. **Can J Exp Psychol** 1999 Mar;53(1):21–34 (55 ref.)

Cardiac output minute to minute with a standard pulmonary artery catheter, without fluid overload? [editorial; comment] Tremper KK. **Crit Care Med** 1999 Aug; 27(8):1665–6 (16 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1505–10.

Artificial neural network and medicine. Khan ZH, et al. **Indian J Physiol Pharmacol** 1998 Jul;42(3):321–42 (53 ref.)

ECG pattern recognition and classification using non–linear transformations and neural networks: a review. Maglaveras N, et al. **Int J Med Inf** 1998 Oct–Dec;52(1–3):191–208 (54 ref.)

A survey of partially connected neural networks. Elizondo D, et al. **Int J Neural Syst** 1997 Oct–Dec;8(5–6):535–58 (93 ref.)

The prospects for analogue neural VLSI. Murray AF, et al. **Int J Neural Syst** 1997 Oct–Dec;8(5–6):559–79 (107 ref.)

The prediction of common bile duct stones using a neural network. Golub R, et al. **J Am Coll Surg** 1998 Dec; 187(6):584–90 (64 ref.)

A neural network explanation of posttraumatic stress disorder. Tryon WW. **J Anxiety Disord** 1998 Jul–Aug; 12(4):373–85 (45 ref.)

Self–organizing neural networks bridge the biomolecular resolution gap. Wriggers W, et al. **J Mol Biol** 1998 Dec 18;284(5):1247–54 (47 ref.)

Application of neural networks in structure–activity relationships. Kövesdi I, et al. **Med Res Rev** 1999 May; 19(3):249–69 (229 ref.)

A model of cortical associative memory based on a horizontal network of connected columns. Fransén E, et al. **Network** 1998 May;9(2):235–64 (81 ref.)

Recurrent sampling models for the Helmholtz machine. Dayan P. **Neural Comput** 1999 Apr 1;11(3):653–78 (44 ref.)

Parameter convergence and learning curves for neural networks. Fine TL, et al. **Neural Comput** 1999 Apr 1; 11(3):747–70 (22 ref.)

Collective behavior of networks with linear (VLSI) integrate–and–fire neurons. Fusi S, et al. **Neural Comput** 1999 Apr 1;11(3):633–52 (22 ref.)

Discontinuities in recurrent neural networks. Gavaldá R, et al. **Neural Comput** 1999 Apr 1;11(3):715–46 (25 ref.)

Feature extraction through LOCOCODE. Hochreiter S, et al. **Neural Comput** 1999 Apr 1;11(3):679–714 (61 ref.)

Discriminant component pruning. Regularization and interpretation of multi–layered back–propagation networks. Koene RA, et al. **Neural Comput** 1999 Apr 1;11(3):783–802 (19 ref.)

Computing with self–excitatory cliques: A model and an application to hyperacuity–scale computation in visual cortex. Miller DA, et al. **Neural Comput** 1999 Jan 1; 11(1):21–66 (105 ref.)

A unifying review of linear gaussian models. Roweis S, et al. **Neural Comput** 1999 Feb 15;11(2):305–45 (65 ref.)

Artificial neural network as a novel method to optimize pharmaceutical formulations. Takayama K, et al. **Pharm Res** 1999 Jan;16(1):1–6 (38 ref.)

Artificial neural networks for computer–based molecular design. Schneider G, et al. **Prog Biophys Mol Biol** 1998; 70(3):175–222 (272 ref.)

Machine learning approaches for the prediction of signal peptides and other protein sorting signals. Nielsen H, et al. **Protein Eng** 1999 Jan;12(1):3–9 (39 ref.)

Connectionist modeling of speech perception. Protopapas A. **Psychol Bull** 1999 Jul;125(4):410–36 (145 ref.)

Applying neural networks as software sensors for enzyme engineering. Linko S, et al. **Trends Biotechnol** 1999 Apr; 17(4):155–62 (56 ref.)

The Human Brain Project: neuroinformatics tools for integrating, searching and modeling multidisciplinary neuroscience data. Shepherd GM, et al. **Trends Neurosci** 1998 Nov;21(11):460–8 (27 ref.)

Advanced statistical techniques: how to use your data more effectively? [comment] Vandewalle J. **Ultrasound Obstet Gynecol** 1999 Jan;13(1):8–10 (8 ref.) Comment on: Ultrasound Obstet Gynecol 1999 Jan;13(1):11–6. Comment on: Ultrasound Obstet Gynecol 1999 Jan;13(1):17–25.

[Do systems theory models promote understanding of disorders of sensorimotor function in neurology?] Glasauer S, et al. **Nervenarzt** 1998 Oct;69(10):919–23 (18 ref.) **(Ger)**

NEURAL PATHWAYS

Neuronal activity during development: permissive or instructive? Crair MC. **Curr Opin Neurobiol** 1999 Feb; 9(1):88–93 (52 ref.)

Synchronized neuronal networks: the GnRH system. Witkin JW. **Microsc Res Tech** 1999 Jan 1;44(1):11–8 (60 ref.)

Tracking neural pathways with MRI. Rye DB. **Trends Neurosci** 1999 Sep;22(9):373–4 (31 ref.)

The feedback pathway from horizontal cells to cones. A mini review with a look ahead. Kamermans M, et al. **Vision Res** 1999 Jul;39(15):2449–68 (117 ref.)

EMBRYOLOGY

[Molecular mechanisms of the pathway formation in the fetal rat cerebral neocortex] Kawano H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Apr; 19(2):79–84 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

A new view of specific and nonspecific thalamocortical connections. Jones EG. **Adv Neurol** 1998;77:49–71; discussion 72–3 (69 ref.)

Making brain connections: neuroanatomy and the work of TPS Powell, 1923–1996. Jones EG. **Annu Rev Neurosci** 1999;22:49–103 (369 ref.)

An fMRI study of Stroop word–color interference: evidence for cingulate subregions subserving multiple distributed attentional systems. Peterson BS, et al. **Biol Psychiatry** 1999 May 15;45(10):1237–58 (100 ref.)

Sensory pathways and their modulation in the control of locomotion. Büschges A, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):733–9 (47 ref.)

Spontaneous correlated activity in developing neural circuits. Feller MB. **Neuron** 1999 Apr;22(4):653–6 (22 ref.)

From membrane to cytoskeleton: enabling a connection. Hu S, et al. **Neuron** 1999 Mar;22(3):419–22 (21 ref.)

Application of Pavlovian higher–order conditioning to the analysis of the neural substrates of fear conditioning. Gewirtz JC, et al. **Neuropharmacology** 1998 Apr–May; 37(4–5):453–9 (60 ref.)

Microcircuitry of the direct and indirect pathways of the basal ganglia. Smith Y, et al. **Neuroscience** 1998 Sep; 86(2):353–87 (344 ref.)

From electrical wiring to plastic neurons: evolving approaches to the study of pain. Jabbur SJ, et al. **Pain** 1999 Aug;Suppl 6:S87–92 (49 ref.)

NEURAL TRANSMISSION see **SYNAPTIC TRANSMISSION**

NEURAL TUBE DEFECTS

CLASSIFICATION

The Chiari malformations: a constellation of anomalies. Shuman RM. **Semin Pediatr Neurol** 1995 Sep;2(3):220–6 (36 ref.)

DIAGNOSIS

[Nuclear magnetic resonance brain imaging in the prenatal period] Girard N, et al. **Arch Pediatr** 1998;5 Suppl 2:171s–174s (27 ref.) **(Fre)**

[Treatment and decision tree in ante– and perinatal neurologic pathology] Marret S, et al. **Arch Pediatr** 1998; 5 Suppl 2:174s–179s (21 ref.) **(Fre)**

ETIOLOGY

A possible link between neural tube defects and ultraviolet light exposure. Jablonski NG. **Med Hypotheses** 1999 Jun; 52(6):581–2 (11 ref.)

GENETICS

[Neural tube defects and holoprosencephaly] Shiota K, et al. **No To Shinkei** 1999 Aug;51(8):659–66 (26 ref.) **(Jpn)**

METABOLISM

The role of folate transport and metabolism in neural tube defect risk. Barber RC, et al. **Mol Genet Metab** 1999 Jan; 66(1):1–9 (72 ref.)

PREVENTION & CONTROL

American College of Preventive Medicine public policy statement. Folic acid fortification of grain products in the U.S. to prevent neural tube defects. Bentley JR, et al. **Am J Prev Med** 1999 Apr;16(3):264–7 (40 ref.)

[Prevention using folic acid––a good method for reduction of neural tube defects in Poland] Lech M. **Przegl Lek** 1998; 55(6):334–6 (22 ref.) (Eng. Abstr.) **(Pol)**

[A strategy for reduction of the number of neural tube defects is needed] Bruce A. **Lakartidningen** 1999 Apr 21; 96(16):1924–6 (13 ref.) **(Swe)**

[Folic acid protects against neural tube defects. But how many women of reproductive age have been informed about this fact?] Kihlberg R, et al. **Lakartidningen** 1999 Apr 21;96(16):1961–3 (77 ref.) (Eng. Abstr.) **(Swe)**

NEURALGIA

[Centrally disturbed pain modulation explains prolonged pain. New knowledge changes the view on the problematic patient] Lidbeck J. **Lakartidningen** 1999 Jun 9; 96(23):2843–8, 2850–1 (84 ref.) **(Swe)**

DIAGNOSIS

Nerve trunk pain: physical diagnosis and treatment. Hall TM, et al. **Man Ther** 1999 May;4(2):63–73 (62 ref.)

DRUG THERAPY

Pain: nocistatin spells relief. Martin WJ, et al. **Curr Biol** 1998 Jul 16;8(15):R525–7 (12 ref.)

Neuropathic pain: new insights, new interventions. Bennett GJ. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):95–8, 101–4, 107–10 passim (9 ref.)

Treatment of postherpetic neuralgia. Menke JJ, et al. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr;39(2):217–21 (21 ref.)

Are opioids effective in relieving neuropathic pain? Dellemijn P. **Pain** 1999 Apr;80(3):453–62 (90 ref.)

[Symptomatic treatment of painful diabetic neuropathies] Luft D. **Internist (Berl)** 1999 Feb;40(2):140–7 (65 ref.) **(Ger)**

EPIDEMIOLOGY

Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review. Kobata H, et al. **Neurosurgery** 1998 Dec; 43(6):1351–61; discussion 1361–2 (109 ref.)

ETIOLOGY

Are opioids effective in relieving neuropathic pain? Dellemijn P. **Pain** 1999 Apr;80(3):453–62 (90 ref.)

[Herpes Zoster and post-herpetic neuralgia: everything to revise?] Pasqualucci A. **Minerva Anestesiol** 1999 Jul–Aug; 65(7–8):541–8 (48 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Postherpetic neuralgia in immunocompetent elderly people. Schmader K. **Vaccine** 1998 Nov;16(18):1768–70 (34 ref.)

PHYSIOPATHOLOGY

Neuropathic pain: new insights, new interventions. Bennett GJ. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):95–8, 101–4, 107–10 passim (9 ref.)

Causalgia and reflex sympathetic dystrophy: does the sympathetic nervous system contribute to the generation of pain? Baron R, et al. **Muscle Nerve** 1999 Jun;22(6):678–95 (179 ref.)

Postherpetic neuralgia: irritable nociceptors and deafferentation. Fields HL, et al. **Neurobiol Dis** 1998 Oct; 5(4):209–27 (178 ref.)

Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Mayer DJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7731–6 (47 ref.)

[Physiopathology of neuropathic pain syndromes] Lantéri-Minet M. **Therapie** 1999 Jan–Feb;54(1):117–20 (18 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Postherpetic neuralgia: the importance of preventing this intractable end-stage disorder. Watson CP. **J Infect Dis** 1998 Nov;178 Suppl 1:S91–4 (19 ref.)

REHABILITATION

Nerve trunk pain: physical diagnosis and treatment. Hall TM, et al. **Man Ther** 1999 May;4(2):63–73 (62 ref.)

SURGERY

Stereotactic treatment of central pain. Ohye C. **Stereotact Funct Neurosurg** 1998;70(2–4):71–6 (26 ref.)

THERAPY

Multidisciplinary approach for the management of post-herpetic neuralgia in elderly patients. Ackerman WE 3rd, et al. **J Ark Med Soc** 1999 May;95(12):528–31 (13 ref.)

Postherpetic neuralgia in immunocompetent elderly people. Schmader K. **Vaccine** 1998 Nov;16(18):1768–70 (34 ref.)

[Diagnosis and therapy of neuropathic pain in tumor diseases] Kloke M. **Internist (Berl)** 1999 Feb;40(2):176–82 (19 ref.) **(Ger)**

[Herpes Zoster and post-herpetic neuralgia: everything to revise?] Pasqualucci A. **Minerva Anestesiol** 1999 Jul–Aug; 65(7–8):541–8 (48 ref.) (Eng. Abstr.) **(Ita)**

NEURALGIA, GENICULATE see **HERPES ZOSTER OTICUS**

NEURALGIC AMYOTROPHY see **CERVICO-BRACHIAL NEURALGIA**

NEURAMINIC ACIDS

[The molecular basis for the absence of N-glycolylneuraminic acid in humans] Irie A, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2404–9 (26 ref.) **(Jpn)**

NEURAMINIDASE

[Recent progress in mammalian sialidase research] Miyagi T. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2358–65 (35 ref.) **(Jpn)**

[Influenza viruses and their receptor sugar recognition] Suzuki Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2559–66 (33 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection. Costa F, et al. **Braz J Med Biol Res** 1999 Feb; 32(2):235–9 (25 ref.)

ANTAGONISTS & INHIBITORS

Neuraminidase inhibitors as anti-influenza virus agents. Kim CU, et al. **Antivir Chem Chemother** 1999 Jul;10(4):141–54 (56 ref.)

New approaches to influenza chemotherapy. Neuraminidase inhibitors. Calfee DP, et al. **Drugs** 1998 Oct;56(4):537–53 (63 ref.)

GENETICS

[Sialidosis type 1] Suzuki Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):166–8 (7 ref.) **(Jpn)**

[Sialidosis type 2] Suzuki Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):169–70 (3 ref.) **(Jpn)**

NEURASTHENIA

see related
FATIGUE SYNDROME, CHRONIC

DIAGNOSIS

Doctors' diagnoses and patients' perceptions. Lessons from chronic fatigue syndrome [editorial] Sharpe M. **Gen Hosp Psychiatry** 1998 Nov;20(6):335–8 (27 ref.)

ETHNOLOGY

Estranged bodies, simulated harmony, and misplaced cultures: neurasthenia in contemporary Chinese society [see comments] Lee S. **Psychosom Med** 1998 Jul–Aug; 60(4):448–57 (52 ref.) Comment in: Psychosom Med 1998 Jul–Aug;60(4):389–93.

PSYCHOLOGY

Doctors' diagnoses and patients' perceptions. Lessons from chronic fatigue syndrome [editorial] Sharpe M. **Gen Hosp Psychiatry** 1998 Nov;20(6):335–8 (27 ref.)

NEURASTHENIC NEUROSES see **NEURASTHENIA**

NEURENTERIC CYST see **SPINA BIFIDA OCCULTA**

NEURILEMMOMA

[Duodenal schwannoma. Clinical considerations] Fraipont G, et al. **Minerva Chir** 1998 May;53(5):419–26 (12 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Trigeminal neurinoma presenting as intratumoral hemorrhage—case report. Lieu AS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Mar; 14(3):181–5 (15 ref.)

DIAGNOSIS

Radiologic and pathologic findings of intracerebral schwannoma. Zagardo MT, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1290–3 (38 ref.)

Solitary olfactory groove schwannoma: case report with review of the literature. Praharaj SS, et al. **Clin Neurol Neurosurg** 1999 Mar;101(1):26–8 (12 ref.)

Malignant cervical schwannoma: An unusual pelvic tumor. Lallas TA, et al. **Gynecol Oncol** 1999 Feb;72(2):238–42 (2 ref.)

Schwannoma of posterior mediastinum: a case report and concise review. Khanlou H, et al. **Heart Lung** 1998 Sep–Oct;27(5):344–7 (14 ref.)

Benign retroperitoneal schwannoma mimicking a pancreatic cystic tumor: case report and literature review. Hsiao WC, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2418–20 (9 ref.)

Greater superficial petrosal nerve neurinoma. Case report. Kumon Y, et al. **J Neurosurg** 1999 Oct;91(4):691–6 (22 ref.)

Thoracic intramedullary schwannoma. Lee DY, et al. **J Spinal Disord** 1999 Apr;12(2):174–6 (22 ref.)

Slow-growing labyrinthine masses: contribution of MRI to diagnosis, follow-up and treatment. Deux JF, et al. **Neuroradiology** 1998 Oct;40(10):684–9 (21 ref.)

[Diaphragmatic or juxtadiaphragmatic schwannoma?] Prudhomme M, et al. **Chirurgie** 1998 Jun;123(3):300–3 (11 ref.) (Eng. Abstr.) **(Fre)**

[Giants schwannoma of the sacrum. Apropos of 3 cases and review of the literature] Anract P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):239–46 (18 ref.) (Eng. Abstr.) **(Fre)**

[A benign retroperitoneal schwannoma: a review of the literature and a report of a new case] Cortés Aránguez I, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):621–4 (15 ref.) (Eng. Abstr.) **(Spa)**

[A retroperitoneal cellular schwannoma] Ortiz Rey JA, et al. **Actas Urol Esp** 1999 May;23(5):455–8 (12 ref.) (Eng. Abstr.) **(Spa)**

[A tumor of the cerebellopontile angle and a large posterior mediastinal mass] Barón Saura JM, et al. **Rev Clin Esp** 1998 Nov;198(11):777–8 (4 ref.) **(Spa)**

PATHOLOGY

Primary malignant schwannoma of the uterine cervix: a case report and literature review. Bernstein HB, et al. **Gynecol Oncol** 1999 Aug;74(2):288–92 (17 ref.)

Schwannoma of the pancreas: a report of two cases and a review of the literature. Brown SZ, et al. **Mod Pathol** 1998 Dec;11(12):1178–82 (25 ref.)

Schwannoma of the liver: report of two surgical cases. Wada Y, et al. **Pathol Int** 1998 Aug;48(8):611–7 (17 ref.)

Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Carney JA, et al. **Semin Diagn Pathol** 1998 Aug;15(3):216–24 (15 ref.)

SURGERY

Dumbbell-shaped hypoglossal neurinoma: surgical removal via a dorsolateral transcondylar approach. A case report and review of the literature. Spinnato S, et al. **Acta Neurochir (Wien)** 1998;140(8):827–32 (63 ref.)

A skull base extradural hypoglossal neurilemmoma resected via an extended posterolateral approach. Myatt HM, et al. **J Laryngol Otol** 1998 Nov;112(11):1052–7 (18 ref.)

Triton tumor [letter; comment] [published erratum appears in J Neurosurg 1999 Aug;91(2):354] Fagan P, et al. **J Neurosurg** 1999 May;90(5):987–9 (19 ref.) Comment on: J Neurosurg 1998 Oct;89(4):653–8.

Trigeminal neurinomas extending into multiple fossae: surgical methods and review of the literature. Yoshida K, et al. **J Neurosurg** 1999 Aug;91(2):202–11 (65 ref.)

Vestibular schwannoma management in the next century: a radiosurgical perspective. Pollock BE, et al. **Neurosurgery** 1998 Sep;43(3):475–81; discussion 481–3 (48 ref.)

[The retro-auricular, transmastoid, infralabyrinth approach. A simple route for excision of tumors of the jugular foramen] Fournier HD, et al. **Neurochirurgie** 1998 Apr; 44(2):111–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Dumbbell type schwannoma of the posterior mediastinum: a report of two cases with different surgical approaches] Hattori Y, et al. **Kyobu Geka** 1999 Aug;52(9):728–32 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case of tracheal neurilemomal] Kase M, et al. **Kyobu Geka** 1999 Apr;52(4):336–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Trigeminal neurinoma] Yoshida K, et al. **No Shinkei Geka** 1999 May;27(5):407–16 (94 ref.) **(Jpn)**

NEURILEMMOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

NEURILEMMOSARCOMA see **NEURILEMMOMA**

NEURINOMA see **NEURILEMMOMA**

NEURINOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

NEURITE OUTGROWTH FACTOR see **NERVE GROWTH FACTORS**

NEURITES

see related
GROWTH CONES
NERVE GROWTH FACTORS

PHYSIOLOGY

Molecular mechanisms of neurite extension. Valtorta F, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):387–94 (80 ref.)

ULTRASTRUCTURE

Molecular mechanisms of neurite extension. Valtorta F, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):387–94 (80 ref.)

NEURITIC PLAQUES see **SENILE PLAQUES**

NEURITIS

Vestibular neuritis. Strupp M, et al. **Adv Otorhinolaryngol** 1999;55:111–36 (87 ref.)

CHEMICALLY INDUCED

Morphological, biochemical and behavioural changes

NEURITIS

induced by neurotoxic and inflammatory insults to the nucleus basalis. Casamenti F, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):705-14 (67 ref.)

ETIOLOGY

[Facial neuritis: the current views on its etiology, pathogenesis and treatment] Chupryna HM, et al. **Lik Sprava** 1998 Jul-Aug;(5):19-26 (43 ref.) **(Ukr)**

PATHOLOGY

Neuropathology in multiple sclerosis: new concepts. Lassmann H. **Mult Scler** 1998 Jun;4(3):93-8 (74 ref.)

PHYSIOPATHOLOGY

Painful diabetic neuropathy. Benbow SJ, et al. **Diabet Med** 1999 Aug;16(8):632-44 (226 ref.)

Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Trojaborg W. **Electroencephalogr Clin Neurophysiol** 1998 Nov;107(5):303-16 (117 ref.)

SURGERY

Medial collateral ligament instability and ulnar neuritis in the athlete's elbow. Ciccotti MG, et al. **Instr Course Lect** 1999;48:383-91 (36 ref.)

THERAPY

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Hahn AF. **Neurology** 1998 Dec;51(6 Suppl 5):S16-21 (31 ref.)

NEURITIS, EXPERIMENTAL ALLERGIC

see related
MYELIN P2 PROTEIN

METABOLISM

Chemokines and peripheral nerve demyelination. Fujioka T, et al. **J Neurovirol** 1999 Feb;5(1):27-31 (40 ref.)

NEUROANATOMY

HISTORY

Making brain connections: neuroanatomy and the work of TPS Powell, 1923-1996. Jones EG. **Annu Rev Neurosci** 1999;22:49-103 (369 ref.)

METHODS

Exploring brain circuitry with neurotropic viruses: new horizons in neuroanatomy. Card JP. **Anat Rec** 1998 Dec; 253(6):176-85 (44 ref.)

Field homology: a meaningless concept. Northcutt RG. **Eur J Morphol** 1999 Apr;37(2-3):95-9 (31 ref.)

[New neuronal tracers and their combined use] Lanciego JL, et al. **Rev Med Univ Navarra** 1999 Jan-Mar;43(1):24-8 (10 ref.) (Eng. Abstr.) **(Spa)**

NEUROBIOLOGY

Bench to bedside in medical education. Turnbull J. **Acad Med** 1999 Jun;74(6):664-6 (12 ref.)

Neurobiological basis of consciousness. Young GB, et al. **Arch Neurol** 1999 Feb;56(2):153-7 (23 ref.)

The impact of genomics on mammalian neurobiology. Hochgeschwender U, et al. **Bioessays** 1999 Feb; 21(2):157-63 (61 ref.)

Neurobiology of mother-infant interactions: experience and central nervous system plasticity across development and generations. Fleming AS, et al. **Neurosci Biobehav Rev** 1999 May;23(5):673-85 (106 ref.)

TRENDS

The neurobiology of multimodal sensory integration. Freeman WJ. **Integr Physiol Behav Sci** 1998 Apr-Jun; 33(2):124-9 (36 ref.)

Recent progress in the neurology of learning: memory molecules in the developing brain. Johnston MV, et al. **J Dev Behav Pediatr** 1999 Feb;20(1):50-6 (50 ref.)

NEUROBLASTOMA

Tumor progression, micrometastasis, and genetic instability tracked with histochemical marker genes. Culp LA, et al. **Prog Histochem Cytochem** 1998;33(3-4):XI-XV, 329-48 (35 ref.)

Neuroblastoma in the neonate. Lukens JN. **Semin Perinatol** 1999 Aug;23(4):263-73 (64 ref.)

COMPLICATIONS

Coarctation of the aorta associated with neuroblastoma. Friedman DM, et al. **Pediatr Cardiol** 1998 Nov-Dec; 19(6):480-1 (10 ref.)

CONGENITAL

Congenital mediastinal dumbbell neuroblastoma with spontaneous regression of liver metastases. Komuro H, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):86-8 (19 ref.)

DIAGNOSIS

Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Zumkeller W, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):138-41 (57 ref.)

Adrenal neuroblastoma in an adult with tumor thrombus in the inferior vena cava. Custodio CM, et al. **J Magn Reson Imaging** 1999 Apr;9(4):621-3 (11 ref.)

Report of the 1998 Consensus Conference on Neuroblastoma Screening [see comments] **Med Pediatr Oncol** 1999 Oct; 33(4):357-9 (0 ref.) Comment in: Med Pediatr Oncol 1999 Oct;33(4):355-6. Comment in: Med Pediatr Oncol 1999 Oct;33(4):360-1.

Prenatally diagnosed cystic neuroblastoma. Hamada Y, et al. **Pediatr Surg Int** 1999;15(1):71-4 (19 ref.)

Current aspects of biology, risk assessment, and treatment of neuroblastoma. Haase GM, et al. **Semin Surg Oncol** 1999 Mar;16(2):91-104 (166 ref.)

[Fetal cystic neuroblastoma: apropos 2 cases] Ferrer Ferrán J, et al. **An Esp Pediatr** 1998 Sep;49(3):299-301 (20 ref.) **(Spa)**

DRUG THERAPY

Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Zumkeller W, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):138-41 (57 ref.)

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. Kushner BH, et al. **J Clin Oncol** 1998 Dec;16(12):3880-9 (105 ref.)

Angiostatic treatment of neuroblastoma. Wassberg E. **Ups J Med Sci** 1999;104(1):1-24 (88 ref.)

EPIDEMIOLOGY

Mass screening for neuroblastoma by HPLC and by non-HPLC: a review. Nishi M, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1399-402 (15 ref.)

ETIOLOGY

Neuroblastoma as a neurobiological disease. Schor NF. **J Neurooncol** 1999 Jan;41(2):159-66 (70 ref.)

GENETICS

Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. Bordow SB, et al. **J Clin Oncol** 1998 Oct;16(10):3286-94 (59 ref.)

Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Schwab M. **Naturwissenschaften** 1999 Feb;86(2):71-8 (53 ref.)

[Oncogenic factors of metastatic dissemination in neuroblastoma] Da Silva J, et al. **C R Seances Soc Biol Fil** 1998;192(2):261-71 (26 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. Bordow SB, et al. **J Clin Oncol** 1998 Oct;16(10):3286-94 (59 ref.)

PATHOLOGY

Tagged tumor cells reveal regulatory steps during earliest stages of tumor progression and micrometastasis. Culp LA, et al. **Histol Histopathol** 1999 Jul;14(3):879-86 (31 ref.)

Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Nakagawara A. **Hum Cell** 1998 Sep;11(3):115-24 (46 ref.)

From fish to FISH: the comparative pathology of neuroblastomas in humans, mice and fish. Schwab M. **J Cancer Res Clin Oncol** 1999;125(3-4):141-9 (57 ref.)

[Oncogenic factors of metastatic dissemination in neuroblastoma] Da Silva J, et al. **C R Seances Soc Biol Fil** 1998;192(2):261-71 (26 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Schwab M. **Naturwissenschaften** 1999 Feb;86(2):71-8 (53 ref.)

PREVENTION & CONTROL

Screening for neuroblastoma: progress and pitfalls. Ross JA, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Feb; 8(2):189-94 (82 ref.)

Report of the 1998 Consensus Conference on Neuroblastoma Screening [see comments] **Med Pediatr Oncol** 1999 Oct; 33(4):357-9 (0 ref.) Comment in: Med Pediatr Oncol 1999 Oct;33(4):355-6. Comment in: Med Pediatr Oncol 1999 Oct;33(4):360-1.

RADIOTHERAPY

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Tepmongkol S, et al. **Med Pediatr Oncol** 1999 Jun;32(6):427-31; discussion 432 (63 ref.)

SECONDARY

Congenital mediastinal dumbbell neuroblastoma with spontaneous regression of liver metastases. Komuro H, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):86-8 (19 ref.)

SURGERY

Risk-based management: current concepts of treating malignant solid tumors of childhood. Grosfeld JL. **J Am Coll Surg** 1999 Oct;189(4):407-25 (93 ref.)

THERAPY

Doctor-patient relationships in primary care. Doctor, help! My child has cancer. **BMJ** 1999 Aug 28;319(7209):554-6 (0 ref.)

Neuroblastoma as a neurobiological disease. Schor NF. **J Neurooncol** 1999 Jan;41(2):159-66 (70 ref.)

Current aspects of biology, risk assessment, and treatment of neuroblastoma. Haase GM, et al. **Semin Surg Oncol** 1999 Mar;16(2):91-104 (166 ref.)

[Malignant tumors in childhood] Fujimoto T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:191-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy and hematopoietic stem cell transplant in the treatment of advanced neuroblastoma] Mugishima H. **Gan To Kagaku Ryoho** 1999 Jul; 26(8):1056-67 (38 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Prenatal diagnosis of congenital neuroblastoma. Analysis of 4 cases and review of the literature. Heling KS, et al. **Fetal Diagn Ther** 1999 Jan-Feb;14(1):47-52 (28 ref.)

NEUROBLASTOMA, OLFACTORY see **ESTHESIONEUROBLASTOMA**

NEUROBLASTOMA, RETINAL see **RETINOBLASTOMA**

NEUROCHEMISTRY

HISTORY

Microwave applications in neuromorphology and neurochemistry: safety precautions and techniques. Marani E. **Methods** 1998 Jun;15(2):87-99 (161 ref.)

METHODS

Clinical neurochemistry: developments in dementia research based on brain bank material. Perry E, et al. **J Neural Transm** 1998;105(8-9):915-33 (59 ref.)

Problems and artifacts of microwave accelerated procedures in neurohistotechnology and resolutions. Horobin RW. **Methods** 1998 Jun;15(2):101-6 (27 ref.)

In vivo neurochemical correlates of cognitive processes: methodological and conceptual challenges. Bruno JP, et al. **Rev Neurosci** 1999;10(1):25-48 (88 ref.)

NEUROCIRCULATORY ASTHENIA

DIAGNOSIS

[Diagnosis of functional heart complaints from the psychosomatic viewpoint] Langkafel M, et al. **Herz** 1999 Apr;24(2):107-13 (20 ref.) (Eng. Abstr.) **(Ger)**

NEUROCYSTICERCOSIS

[Neurocysticercosis] Isozumi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):504-7 (15 ref.) **(Jpn)**

DIAGNOSIS

Neurocysticercosis. Garg RK. **Postgrad Med J** 1998 Jun; 74(872):321-6 (46 ref.)

ETHNOLOGY

[Neurocysticercosis in Spain. Apropos 4 cases seen in immigrant patients from endemic countries] Font Puig C, et al. **An Med Interna** 1999 Feb;16(2):89-91 (20 ref.) (Eng. Abstr.) **(Spa)**

NEUROCYTOMA

DIAGNOSIS

Atypical central neurocytoma: report of a case. Chou YY, et al. **J Formos Med Assoc** 1999 Aug;98(8):573-7 (19 ref.)

[Central neurocytoma: analysis of three cases and review of the literature] Katati MJ, et al. **Rev Neurol** 1999 Apr 1-15; 28(7):713-7 (38 ref.) (Eng. Abstr.) **(Spa)**

NEURODEGENERATIVE DISEASES

[Recent progress in the research field on triplet repeat diseases] Kakizuka A. **Rinsho Shinkeigaku** 1998 Dec; 38(12):988-92 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Pallido-nigro-luysial atrophy] Hasegawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):78-81 (6 ref.) **(Jpn)**

[Dentatorubral-pallidoluysian atrophy (DRPLA: differential diagnosis of progressive myoclonus epilepsy] Naito H.

Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):163–5 (13 ref.) **(Jpn)**

[Thalamic degeneration] Sahashi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):402–5 (15 ref.) **(Jpn)**

[Dentatorubral–pallidoluysian atrophy (DRPLA: Naito–Oyanagi disease)] Tsuji S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):275–9 (17 ref.) **(Jpn)**

[Dentatorubral–pallidoluysian atrophy (DRPLA: differential diagnosis of chorea)] Tsuji S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):101–3 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Experimental aluminum encephalomyelopathy. Relationship to human neurodegenerative disease. Rao JK, et al. **Clin Lab Med** 1998 Dec;18(4):687–98, viii (65 ref.)

Neurotoxins and neurodegenerative disorders. Vécsei L, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):511–4 (29 ref.)

CLASSIFICATION

Genetic classification of primary neurodegenerative disease. Hardy J, et al. **Science** 1998 Nov 6;282(5391):1075–9 (53 ref.)

COMPLICATIONS

Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Knoll JL 4th, et al. **Schizophr Bull** 1998; 24(3):365–79 (99 ref.)

[Mitochondrial changes in neurodegenerative diseases] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S112–7 (111 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism [see comments] Woods BT. **Am J Psychiatry** 1998 Dec;155(12):1661–70 (108 ref.) Comment in: Am J Psychiatry 1998 Dec;155(12):1657–9.

Pathways to primary neurodegenerative disease. Hardy J. **Mayo Clin Proc** 1999 Aug;74(8):835–7 (21 ref.)

Key developments in neurology. Martin R, et al. **Practitioner** 1999 Jan;243(1594):16–8, 20, 23 (12 ref.)

[Multisystem degenerative diseases with Parkinsom syndrome. Differential diagnosis and differential therapeutic aspects] Benecke R. **Nervenarzt** 1999 Jan;70 Suppl 1:S35–41 (26 ref.) **(Ger)**

DRUG THERAPY

Caspases as treatment targets in stroke and neurodegenerative diseases. Schulz JB, et al. **Ann Neurol** 1999 Apr;45(4):421–9 (80 ref.)

Antisense technologies have a future fighting neurodegenerative diseases. Seidman S, et al. **Antisense Nucleic Acid Drug Dev** 1999 Aug;9(4):333–40 (69 ref.)

Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Beal MF. **Biofactors** 1999; 9(2–4):261–6 (35 ref.)

The glycine site on the NMDA receptor: structure–activity relationships and possible therapeutic applications. Dannhardt G, et al. **Curr Med Chem** 1998 Aug;5(4):253–63 (58 ref.)

Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Skaper SD, et al. **Mol Cell Neurosci** 1998 Nov;12(4–5):179–93 (127 ref.)

Neuropharmacology of AMPA and kainate receptors. Bleakman D, et al. **Neuropharmacology** 1998 Oct–Nov; 37(10–11):1187–204 (275 ref.)

Experimental therapeutics of neurodegenerative disorders: unmet needs. Shoulson I. **Science** 1998 Nov 6; 282(5391):1072–4 (20 ref.)

[Multisystem degenerative diseases with Parkinsom syndrome. Differential diagnosis and differential therapeutic aspects] Benecke R. **Nervenarzt** 1999 Jan;70 Suppl 1:S35–41 (26 ref.) **(Ger)**

ENZYMOLOGY

Abnormalities of protein kinases in neurodegenerative diseases. Wagey RT, et al. **Prog Drug Res** 1998;51:133–83 (248 ref.)

ETIOLOGY

Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Paulson HL. **Am J Hum Genet** 1999 Feb;64(2):339–45 (37 ref.)

Apoptosis in neurodegenerative diseases: the role of mitochondria [see comments] Tatton WG, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):195–213 (209 ref.) Comment in: Biochim Biophys Acta 1999 Feb 9;1410(2):99–102.

Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Floyd RA. **Free Radic Biol Med** 1999 May; 26(9–10):1346–55 (110 ref.)

Did consumption of flour bleached by the agene process contribute to the incidence of neurological disease? Shaw CA, et al. **Med Hypotheses** 1998 Dec;51(6):477–81 (42 ref.)

Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Mezey E, et al. **Nat Med** 1998 Jul;4(7):755–7 (18 ref.)

The role of excitotoxicity in neurodegenerative disease: implications for therapy. Doble A. **Pharmacol Ther** 1999 Mar;81(3):163–221 (694 ref.)

[Transporter and neurological disease] Kawakami H. **Rinsho Shinkeigaku** 1999 Jan;39(1):7–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Neuronal cell death in neurodegenerative disorders and oxidative stress] Shimohama S, et al. **Rinsho Shinkeigaku** 1999 Jan;39(1):4–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Factors that lead to death of neurons in neurodegenerative diseases] Pavón N, et al. **Rev Neurol** 1998 Apr; 26(152):554–60 (75 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Biological implications of the DNA structures associated with disease-causing triplet repeats. Sinden RR. **Am J Hum Genet** 1999 Feb;64(2):346–53 (32 ref.)

Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Kish SJ, et al. **Arch Neurol** 1998 Oct;55(10):1299–304 (29 ref.)

Genetic linkage analysis. Pulst SM. **Arch Neurol** 1999 Jun; 56(6):667–72 (16 ref.)

The three-dimensional structure of prion protein: implications for prion disease. Baldwin MA, et al. **Biochem Soc Trans** 1998 Aug;26(3):481–6 (64 ref.)

Mitochondria in organismal aging and degeneration. Cortopassi GA, et al. **Biochim Biophys Acta** 1999 Feb 9; 1410(2):183–93 (100 ref.)

Transgenic mice in the study of polyglutamine repeat expansion diseases. Bates GP, et al. **Brain Pathol** 1998 Oct; 8(4):699–714 (53 ref.)

Toxic neuronal apoptosis and modifications of tau and APP gene and protein expressions. Hugon J, et al. **Drug Metab Rev** 1999 Aug;31(3):635–47 (38 ref.)

Damage and repair of nerve cell DNA in toxic stress. Kisby GE, et al. **Drug Metab Rev** 1999 Aug;31(3):589–618 (149 ref.)

Molecular base of "de novo" DRPLA [editorial; comment] Abe K. **Intern Med** 1999 Mar;38(3):223 (7 ref.) Comment on: Intern Med 1999 Mar;38(3):287–9.

Paul Dyken Lecture of the Southern Pediatric Neurology Society. Inherited neurodegenerative disease: the evolution of our thinking. Percy AK. **J Child Neurol** 1999 Apr; 14(4):256–62 (32 ref.)

Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. Cooper AJ, et al. **J Neurochem** 1999 Mar;72(3):889–99 (98 ref.)

Unstable mutations and neurodegenerative disorders. Brice A. **J Neurol** 1998 Aug;245(8):505–10 (58 ref.)

Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. Kimber TE, et al. **J Neurol Sci** 1998 Sep 18;160(1):33–40 (25 ref.)

Nuclear inclusions in CAG repeat diseases: toxic or protective? Hernandez D. **Mol Med Today** 1999 Jan;5(1):7 (2 ref.)

Molecular basis of the neurodegenerative disorders. Martin JB. **N Engl J Med** 1999 Jun 24;340(25):1970–80 (93 ref.)

Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101–18 (148 ref.)

Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Lunkes A, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1013–9 (38 ref.)

Amyloid diseases: abnormal protein aggregation in neurodegeneration. Koo EH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9989–90 (21 ref.)

Neurodegenerative Alzheimer-like pathology in PDAPP 717V—>F transgenic mice. Chen KS, et al. **Prog Brain Res** 1998;117:327–34 (37 ref.)

Strain dependent and invariant features of transgenic mice expressing Alzheimer amyloid precursor proteins. Hsiao K. **Prog Brain Res** 1998;117:335–41 (31 ref.)

Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions. Ross CA, et al. **Prog Brain Res** 1998;117:397–419 (160 ref.)

Genetic classification of primary neurodegenerative disease. Hardy J, et al. **Science** 1998 Nov 6;282(5391):1075–9 (53 ref.)

Genetic neurodegenerative diseases: the human illness and transgenic models. Price DL, et al. **Science** 1998 Nov 6; 282(5391):1079–83 (63 ref.)

Glutamine repeats and neurodegenerative diseases: molecular aspects. Perutz MF. **Trends Biochem Sci** 1999 Feb; 24(2):58–63 (40 ref.)

Aggregates in neurodegenerative disease: crowds and power? Tran PB, et al. **Trends Neurosci** 1999 May;22(5):194–7 (40 ref.)

[Cellular bases of neurodegenerative processes] Nieoullon A. **Therapie** 1998 Jan–Feb;53(1):21–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Triplet repeat] Abe K. **Nippon Rinsho** 1999 Apr;57(4):768–70 (5 ref.) **(Jpn)**

[Dynamic mutation and its molecular cytogenetics] Hori T, et al. **Nippon Rinsho** 1999 Apr;57(4):771–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of CAG repeats size in the nervous system of dentatorubral–pallidoluysian atrophy (DRPLA)] Ito Y, et al. **Nippon Rinsho** 1999 Apr;57(4):850–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Advances in understanding of clinical presentations and molecular mechanisms of triplet repeat diseases] Tsuji S. **Nippon Rinsho** 1999 Apr;57(4):778–86 (55 ref.) (Eng. Abstr.) **(Jpn)**

[Future prospect of molecular genetics studies on DRPLA] Tsuji S. **Nippon Rinsho** 1999 Apr;57(4):843–9 (33 ref.) **(Jpn)**

[Dynamic mutations in hereditary neurodegenerative disorders] Nilssen O. **Tidsskr Nor Laegeforen** 1999 Aug 30;119(20):3021–7 (61 ref.) (Eng. Abstr.) **(Nor)**

[Growing genes cause neurological diseases] Johansson J, et al. **Lakartidningen** 1999 Feb 24;96(8):897–900 (25 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGY

Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. McGeer PL, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S1–6 (40 ref.)

Immune-derived cytokines in the nervous system: epigenetic instructive signals or neuropathogenic mediators? Ensoli F, et al. **Crit Rev Immunol** 1999;19(2):97–116 (211 ref.)

Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. Cotter RL, et al. **J Leukoc Biol** 1999 Apr;65(4):416–27 (136 ref.)

Innate and acquired immunity in neurodegenerative disorders. Gendelman HE, et al. **J Leukoc Biol** 1999 Apr; 65(4):407–8 (9 ref.)

METABOLISM

Redox metals and neurodegenerative disease. Sayre LM, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):220–5 (48 ref.)

Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Floyd RA. **Free Radic Biol Med** 1999 May; 26(9–10):1346–55 (110 ref.)

Oxidative stress and neurodegenerative disorders. Sun AY, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):401–14 (196 ref.)

Pathways to primary neurodegenerative disease. Hardy J. **Mayo Clin Proc** 1999 Aug;74(8):835–7 (21 ref.)

The role of copper in neurodegenerative disease. Waggoner DJ, et al. **Neurobiol Dis** 1999 Aug;6(4):221–30 (98 ref.)

REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Tolnay M, et al. **Neuropathol Appl Neurobiol** 1999 Jun;25(3):171–87 (111 ref.)

Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Raffa RB. **Neurosci Biobehav Rev** 1998 Oct;22(6):789–813 (307 ref.)

Nitric oxide in neurodegeneration. Dawson VL, et al. **Prog Brain Res** 1998;118:215–29 (143 ref.)

[Oxidative stress in neurodegeneration] González-Fraguela ME, et al. **Rev Neurol** 1999 Mar 1–15;28(5):504–11 (132 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Alzheimer's disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Horoupian DS, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):317–22 (23 ref.)

Cell cycle events in neurons. Proliferation or death? Zhu X, et al. **Am J Pathol** 1999 Aug;155(2):327–9 (34 ref.)

Transgenic mice in the study of polyglutamine repeat expansion diseases. Bates GP, et al. **Brain Pathol** 1998 Oct; 8(4):699–714 (53 ref.)

Bcl-2 family members in the development and degenerative pathologies of the nervous system [see comments] Sadoul R. **Cell Death Differ** 1998 Oct;5(10):805–15 (101 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

Filamentous nerve cell inclusions in neurodegenerative diseases. Goedert M, et al. **Curr Opin Neurobiol** 1998 Oct; 8(5):619–32 (92 ref.)

Grafting mouse brains: from neurocarcinogenesis to neurodegeneration. Aguzzi A. **EMBO J** 1998 Nov 2; 17(21):6107–14 (76 ref.)

Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. Fiskum G, et al. **J Cereb Blood Flow Metab** 1999 Apr;19(4):351–69 (289 ref.)

Disturbances of the functioning of endoplasmic reticulum: a key mechanism underlying neuronal cell injury? [see comments] Paschen W, et al. **J Cereb Blood Flow Metab** 1999 Jan;19(1):1–18 (188 ref.) Comment in: J Cereb Blood Flow Metab 1999 Jan;19(1):19–26.

Parkinson's disease--a multifactorial neurodegenerative disorder. Riess O, et al. **J Neural Transm Suppl** 1999; 56:113–25 (42 ref.)

Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. Cooper AJ, et al. **J Neurochem** 1999 Mar;72(3):889–99 (98 ref.)

NEURODEGENERATIVE DISEASES

Neurons and mechanisms of neuronal death in neurodegenerative diseases: a brief review. Waggie KS, et al. **Lab Anim Sci** 1999 Aug;49(4):358–62 (55 ref.)

Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout? Kim TW, et al. **Neuron** 1998 Oct;21(4):657–9 (19 ref.)

REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Tolnay M, et al. **Neuropathol Appl Neurobiol** 1999 Jun;25(3):171–87 (111 ref.)

Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101–18 (148 ref.)

Amyloid diseases: abnormal protein aggregation in neurodegeneration. Koo EH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9989–90 (21 ref.)

Neurodegenerative Alzheimer-like pathology in PDAPP 717V—>F transgenic mice. Chen KS, et al. **Prog Brain Res** 1998;117:327–34 (37 ref.)

Strain dependent and invariant features of transgenic mice expressing Alzheimer amyloid precursor proteins. Hsiao K. **Prog Brain Res** 1998;117:335–41 (31 ref.)

Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions. Ross CA, et al. **Prog Brain Res** 1998;117:397–419 (160 ref.)

Tau protein pathology in neurodegenerative diseases. Spillantini MG, et al. **Trends Neurosci** 1998 Oct; 21(10):428–33 (66 ref.)

[Cellular bases of neurodegenerative processes] Nieoullon A. **Therapie** 1998 Jan–Feb;53(1):21–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Apoptotic cell death in child-onset neurodegenerative disorders] Hayashi M. **No To Hattatsu** 1999 Mar; 31(2):146–52 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Factors that lead to death of neurons in neurodegenerative diseases] Pavón N, et al. **Rev Neurol** 1998 Apr; 26(152):554–60 (75 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Goedert M, et al. **Biochem Soc Trans** 1998 Aug;26(3):463–71 (49 ref.)

An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Cassarino DS, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):1–25 (276 ref.)

Why do mature CNS neurons of mammals fail to re-establish connections following injury—functions of bcl-2 [see comments] Chen DF, et al. **Cell Death Differ** 1998 Oct; 5(10):816–22 (51 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

ICE, neuronal apoptosis and neurodegeneration [see comments] Friedlander RM, et al. **Cell Death Differ** 1998 Oct;5(10):823–31 (83 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

Bcl-2 family members in the development and degenerative pathologies of the nervous system [see comments] Sadoul R. **Cell Death Differ** 1998 Oct;5(10):805–15 (101 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

Free radicals as mediators of neuronal injury. Facchinetti F, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):667–82 (126 ref.)

Neuropharmacologic aspects of apoptosis: significance for neurodegenerative diseases. Michel PP, et al. **Clin Neuropharmacol** 1999 May–Jun;22(3):137–50 (296 ref.)

Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Kertesz A, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:46–9 (33 ref.)

Oxidative stress and neurodegenerative disorders. Sun AY, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):401–14 (196 ref.)

Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease [comment] Lansbury PT Jr. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3342–4 (37 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3590–4.

Ubiquitin and its role in neurodegeneration. Arnold J, et al. **Prog Brain Res** 1998;117:23–34 (53 ref.)

The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Bazan NG. **Prog Brain Res** 1998; 118:281–91 (42 ref.)

Ubiquitin, cellular inclusions and their role in neurodegeneration. Alves-Rodrigues A, et al. **Trends Neurosci** 1998 Dec;21(12):516–20 (60 ref.)

Acetylcholine in mind: a neurotransmitter correlate of consciousness? Perry E, et al. **Trends Neurosci** 1999 Jun; 22(6):273–80 (101 ref.)

Tau protein pathology in neurodegenerative diseases. Spillantini MG, et al. **Trends Neurosci** 1998 Oct; 21(10):428–33 (66 ref.)

[Neuronal growth factors—neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063–70 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3112–3. **(Dan)**

[Cerebrovascular aging] Buée L. **Therapie** 1999 Jan–Feb; 54(1):155–65 (94 ref.) (Eng. Abstr.) **(Fre)**

[PET study of cholinergic system in the brain] Shinotoh H. **Rinsho Shinkeigaku** 1999 Jan;39(1):33–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Semantic dysfunction in frontotemporal lobar degeneration. Snowden JS. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:33–6 (8 ref.)

Behavioral symptomatology and care of patients with frontotemporal lobe degeneration – based on the aspects of the phylogenetic and ontogenetic processes. Tanabe H, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:50–4 (22 ref.)

SURGERY

Neural transplantation for neurodegenerative disorders. Borlongan CV, et al. **Lancet** 1999 Apr;353 Suppl 1:SI29–30 (11 ref.)

Review of allo- and xenogeneic neural grafts in neurodegenerative disorders. Neural Tissue Transplantation Team(NETTLU). Widner H. **Transplant Proc** 1999 Feb–Mar;31(1–2):936–8 (18 ref.)

THERAPY

Gene transfer to the brain: emerging therapeutic strategy in psychiatry? Lesch KP. **Biol Psychiatry** 1999 Feb 1; 45(3):247–53 (44 ref.)

Sertoli cell transplants: their use in the treatment of neurodegenerative disease. Willing AE, et al. **Mol Med Today** 1998 Nov;4(11):471–7 (45 ref.)

The education of a brain transplant [comment] Marshall JF. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9976–8 (29 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10524–9.

Neurotrophin gene therapy in CNS models of trauma and degeneration. Blesch A, et al. **Prog Brain Res** 1998; 117:473–84 (116 ref.)

Towards gene therapy of neurodegenerative disease. Federoff HJ, et al. **Prog Brain Res** 1998;117:503–10 (48 ref.)

Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Mufson EJ, et al. **Prog Neurobiol** 1999 Feb;57(4):451–84 (204 ref.)

[Pharmacology of neurodegenerative diseases: perspectives on cellular and gene therapies] Finiels F. **Therapie** 1998 Jan–Feb;53(1):31–4 (9 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Viral-induced neurodegenerative disease. Buchmeier MJ, et al. **Curr Opin Microbiol** 1999 Aug;2(4):398–402 (38 ref.)

NEURODERMATITIS, ATOPIC see **DERMATITIS, ATOPIC**

NEURODERMATITIS, DISSEMINATED see **DERMATITIS, ATOPIC**

NEUROECTODERMAL TUMOR, MELANOTIC

PATHOLOGY

Melanotic progonoma of the brain: a case report and review. Rickert CH, et al. **Childs Nerv Syst** 1998 Aug;14(8):389–93 (36 ref.)

NEUROECTODERMAL TUMOR, PERIPHERAL

DIAGNOSIS

[Malignant small-cell thoracic pulmonary tumor (Askin tumor)] Kabiri H, et al. **Rev Pneumol Clin** 1999 Mar; 55(1):21–5 (12 ref.) (Eng. Abstr.) **(Fre)**

NEUROECTODERMAL TUMOR, PRIMITIVE

DIAGNOSIS

Peripheral primitive neuroectodermal tumors of bone. A review of three cases. Augé B, et al. **Rev Rhum Engl Ed** 1999 Feb;66(2):92–6 (12 ref.)

[Primitive carcinoid tumor of the middle ear: a case report and review of literature] Ferri E, et al. **Acta Otorhinolaryngol Ital** 1999 Apr;19(2):91–6 (53 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Primitive peripheral neuroectodermal tumors Mayagüez Medical Center experience. Camps JI, et al. **Bol Asoc Med P R** 1998 Apr–Jun;90(4–6):79–81 (12 ref.)

MORTALITY

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Saran FH, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):959–67 (62 ref.)

PATHOLOGY

Primitive neuroectodermal tumor in sinonasal region. Toda T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):83–90 (29 ref.)

Primitive neuroectodermal tumor of the orbit in an adult. A case report and literature review. Kiratli H, et al. **Ophthalmology** 1999 Jan;106(1):98–102 (31 ref.)

RADIOGRAPHY

Primitive neuroectodermal tumor in sinonasal region. Toda T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):83–90 (29 ref.)

RADIOTHERAPY

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Saran FH, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):959–67 (62 ref.)

SURGERY

Adult primitive neuroectodermal tumour. A case report and review of the literature. Tripathy LN, et al. **Br J Neurosurg** 1999 Feb;13(1):90–2 (9 ref.)

NEUROECTODERMAL TUMORS

PATHOLOGY

Trilateral retinoblastoma: is the location of the intracranial tumor important? [see comments] Paulino AC. **Cancer** 1999 Jul 1;86(1):135–41 (45 ref.) Comment in: Cancer 1999 Jul 1;86(1):3–5.

NEUROENDOCRINE SYSTEM see **NEUROSECRETORY SYSTEMS**

NEUROENDOCRINE TUMORS

A review of neuroendocrine neoplasms of the larynx: update on diagnosis and treatment. Ferlito A, et al. **J Laryngol Otol** 1998 Sep;112(9):827–34 (91 ref.)

Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. Wiedenmann B, et al. **J Mol Med** 1998 Aug;76(9):637–47 (103 ref.)

CHEMISTRY

[Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors] Mure A, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):809–18 (71 ref.) **(Fre)**

DIAGNOSIS

Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Oberg K. **Ann Oncol** 1999;10 Suppl 2:S3–8 (30 ref.)

Neuroendocrine small cell uterine cervix cancer in pregnancy: long-term survival following combined therapy. Balderston KD, et al. **Gynecol Oncol** 1998 Oct; 71(1):128–32 (16 ref.)

Pancreatic endocrine tumors: diagnostic pitfalls. Ectors N. **Hepatogastroenterology** 1999 Mar–Apr;46(26):679–90 (127 ref.)

Biochemical diagnosis of neuroendocrine GEP tumor. Oberg K. **Yale J Biol Med** 1997 Sep–Dec;70(5–6):501–8 (21 ref.)

[The coexistence of 2 different neuroendocrine tumors of the upper gastrointestinal tract and pancreas (see comments)] Reusch J, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1472–7 (25 ref.) (Eng. Abstr.) Comment in: Dtsch Med Wochenschr 1999 Jun 4;124(22):712; discussion 713. **(Ger)**

[Left supraclavicular adenopathy with a neuroendocrine pattern of unknown cause: prostatic carcinoma metastasis] Fernández Borrell A, et al. **Actas Urol Esp** 1999 Jul–Aug; 23(7):603–8 (22 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Eriksson B, et al. **Ann Oncol** 1999;10 Suppl 2:S31–8 (63 ref.)

The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Degen L, et al. **Digestion** 1999;60 Suppl 2:9–14 (30 ref.)

METABOLISM

Biochemical diagnosis of neuroendocrine GEP tumor. Oberg K. **Yale J Biol Med** 1997 Sep–Dec;70(5–6):501–8 (21 ref.)

PATHOLOGY

Primary hepatic neuroendocrine tumor: successful hepatectomy in two cases and review of the literature. Rückert RI, et al. **Digestion** 1999 Mar–Apr;60(2):110–6 (36 ref.)

Neuroendocrine differentiation in prostatic carcinoma. Abrahamsson PA. **Prostate** 1999 May;39(2):135–48 (159 ref.)

Oncocytic lesions of the neuroendocrine system. Baloch ZW, et al. **Semin Diagn Pathol** 1999 May;16(2):190–9 (113 ref.)

RADIOTHERAPY

Radiolabelled somatostatins: towards the magic bullet? [editorial] Buscombe JR, et al. **Nucl Med Commun** 1999 Apr;20(4):299–301 (22 ref.)

SURGERY

Primary hepatic neuroendocrine tumor: successful hepatectomy in two cases and review of the literature. Rückert RI, et al. **Digestion** 1999 Mar–Apr;60(2):110–6 (36 ref.)

Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Thompson NW. **Surg Oncol Clin N Am** 1998 Oct;7(4):881–91 (34 ref.)

[Therapeutic alternative in metastasizing neuroendocrine tumors. In carefully selected cases liver transplantation is possible] Oberg K. **Lakartidningen** 1999 Sep 8; 96(36):3745–7 (16 ref.) **(Swe)**

THERAPY

Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Oberg K. **Ann Oncol** 1999;10 Suppl 2:S3–8 (30 ref.)

Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Pelley RJ, et al. **Curr Opin Oncol** 1999 Jan;11(1):32–7 (64 ref.)

Embolization and chemoembolization therapy for neuroendocrine tumors. Venook AP. **Curr Opin Oncol** 1999 Jan;11(1):38–41 (29 ref.)

Therapeutic alternatives in metastatic neuroendocrine tumors. Miller CA, et al. **Surg Oncol Clin N Am** 1998 Oct; 7(4):863–79 (57 ref.)

NEUROENDOCRINOLOGY

TRENDS

The psychology in psychoneuroendocrinology. Ursin H. **Psychoneuroendocrinology** 1998 Aug;23(6):555–70 (83 ref.)

NEUROEPITHELIOMA

DIAGNOSIS

Olfactory esthesioneuroblastoma (olfactory neuroblastoma/olfactory neuroepithelioma). Palacios E, et al. **Ear Nose Throat J** 1998 Nov;77(11):890–1 (0 ref.)

PATHOLOGY

Collision tumor: a peripheral neuroepithelioma and a transitional-cell carcinoma occurring simultaneously in the renal pelvis. Phan ST, et al. **Ann Diagn Pathol** 1997 Dec; 1(2):91–8 (46 ref.)

Peripheral neuroepithelioma with ganglion cells: report of two cases and review of the literature. Williams S, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):42–9 (47 ref.)

SURGERY

[Plastic repair of a defect in the base of the skull with soft tissues from the orbit after the removal of an extensive esthesioneuroepithelioma] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr–Jun; (2):25–7 (24 ref.) (Eng. Abstr.) **(Rus)**

NEUROFIBRILLARY TANGLES

see related
NEUROFILAMENT PROTEINS

GENETICS

Reduced neuronal activity and reactivation in Alzheimer's disease. Swaab DF, et al. **Prog Brain Res** 1998;117:343–77 (277 ref.)

Transgenic animals in Alzheimer's disease research. Sturchler-Pierrat C, et al. **Rev Neurosci** 1999;10(1):15–24 (68 ref.)

Tau protein pathology in neurodegenerative diseases. Spillantini MG, et al. **Trends Neurosci** 1998 Oct; 21(10):428–33 (66 ref.)

METABOLISM

Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias. Delacourte A. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:75–9 (19 ref.)

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part III: animal model. Chen M. **Front Biosci** 1998 Jun 17;3:A47–51 (42 ref.)

PATHOLOGY

Fibrillogenesis of beta-amyloid. Allsop D, et al. **Biochem Soc Trans** 1998 Aug;26(3):459–63 (51 ref.)

Neurofibrillary tangles and Alzheimer's disease. Brion JP. **Eur Neurol** 1998 Oct;40(3):130–40 (115 ref.)

Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. Iqbal K, et al. **J Neural Transm Suppl** 1998;53:169–80 (59 ref.)

Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Gärtner U, et al. **Neuroscience** 1999;91(1):1–5 (35 ref.)

Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Goedert M. **Prog Brain Res** 1998;117:287–306 (119 ref.)

PHYSIOLOGY

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part II: therapeutic rationale. Chen M. **Front Biosci** 1998 Jun 8;3:A32–7 (37 ref.)

NEUROFIBRILS

see related
AMYLOID BETA-PROTEIN

PATHOLOGY

Basement membranes, microfibrils and beta amyloid fibrillogenesis in Alzheimer's disease: high resolution ultrastructural findings. Inoue S, et al. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):218–31 (92 ref.)

Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. Iqbal K, et al. **J Neural Transm Suppl** 1998;53:169–80 (59 ref.)

NEUROFIBROMA

GENETICS

Ras activation in astrocytomas and neurofibromas. Guha A. **Can J Neurol Sci** 1998 Nov;25(4):267–81 (165 ref.)

PATHOLOGY

Neurofibroma of the urinary bladder. Cheng L, et al. **Cancer** 1999 Aug 1;86(3):505–13 (40 ref.)

Pacinian neurofibroma of the hand: a case report and literature review. MacLennan SE, et al. **J Hand Surg [Am]** 1999 Mar;24(2):413–6 (13 ref.)

SURGERY

Thoracoscopic resection of intrathoracic vagus neurofibroma. Yamagishi T, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):122–4 (8 ref.)

NEUROFIBROMA, PLEXIFORM

DIAGNOSIS

Plexiform neurofibromas. Korf BR. **Am J Med Genet** 1999 Mar 26;89(1):31–7 (21 ref.)

ETIOLOGY

Neurofibromatosis types I and II: radiological appearance. Romanowski CA, et al. **Hosp Med** 1998 Feb;59(2):134–9 (13 ref.)

SURGERY

Plexiform neurofibromas. Korf BR. **Am J Med Genet** 1999 Mar 26;89(1):31–7 (21 ref.)

NEUROFIBROMATOSIS

Neurofibromatosis: a common neurocutaneous disorder. Karnes PS. **Mayo Clin Proc** 1998 Nov;73(11):1071–6 (54 ref.)

[Neurofibromatosis] Hara T, et al. **No To Shinkei** 1999 Jan; 51(1):17–31 (139 ref.) **(Jpn)**

CLASSIFICATION

The different forms of neurofibromatosis. Ruggieri M. **Childs Nerv Syst** 1999 Jul;15(6–7):295–308 (113 ref.)

COMPLICATIONS

Bilateral central giant cell granulomas in a patient with neurofibromatosis: report of a case and review of the literature. Ardekian L, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):869–72 (24 ref.)

What level of care for the neurofibromatoses? [published erratum appears in Lancet 1999 Apr 17;353(9161):1366] Huson SM. **Lancet** 1999 Apr 3;353(9159):1114–6 (15 ref.)

GENETICS

The different forms of neurofibromatosis. Ruggieri M. **Childs Nerv Syst** 1999 Jul;15(6–7):295–308 (113 ref.)

PATHOLOGY

The neuropathology of selected neurocutaneous diseases. Nelson JS. **Semin Pediatr Neurol** 1995 Sep;2(3):192–9 (42 ref.)

THERAPY

What level of care for the neurofibromatoses? [published erratum appears in Lancet 1999 Apr 17;353(9161):1366] Huson SM. **Lancet** 1999 Apr 3;353(9159):1114–6 (15 ref.)

NEUROFIBROMATOSIS 1

see related
GENES, NEUROFIBROMATOSIS 1

COMPLICATIONS

A case of multiple subungual glomus tumors associated with neurofibromatosis type 1. Okada O, et al. **J Dermatol** 1999 Aug;26(8):535–7 (7 ref.)

Breast cancer associated with Recklinghausen's disease: report of a case. Nakamura M, et al. **Nippon Geka Hokan** 1998 Mar 1;67(1):3–9 (29 ref.)

Spondyloptosis of the cervical spine in neurofibromatosis. A case report. Goffin J, et al. **Spine** 1999 Mar 15; 24(6):587–90 (18 ref.)

Cerebral aneurysm associated with von Recklinghausen's neurofibromatosis: a case report. Zhao JZ, et al. **Surg Neurol** 1998 Dec;50(6):592–6 (37 ref.)

[Giant retroperitoneal hematoma in a patient with von Recklinghausen's disease] Shimizu T, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Oct;89(10):846–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Severe stenosis of the internal carotid artery and intracerebral hematoma associated with neurofibromatosis type 1: a case report] Fujimoto K, et al. **No Shinkei Geka** 1999 Jan;27(1):61–5 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Malignant lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease)] Itoh T, et al. **Rinsho Ketsueki** 1998 Sep;39(9):698–702 (5 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Plexiform neurofibromas. Korf BR. **Am J Med Genet** 1999 Mar 26;89(1):31–7 (21 ref.)

Neurofibromatosis types I and II: radiological appearance. Romanowski CA, et al. **Hosp Med** 1998 Feb;59(2):134–9 (13 ref.)

Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. Perilongo G, et al. **J Child Neurol** 1999 Jun;14(6):352–6 (13 ref.)

Malignant peripheral nerve sheath tumor of the prostate: a rare manifestion of neurofibromatosis type 1. Rames RA, et al. **J Urol** 1999 Jul;162(1):165–6 (3 ref.)

Proton MR spectroscopy in psychiatric and neurodevelopmental childhood disorders: early experience. Castillo M, et al. **Neuroimaging Clin N Am** 1998 Nov; 8(4):901–12 (20 ref.)

Parallels between tuberous sclerosis complex and neurofibromatosis 1: common threads in the same tapestry. Gutmann DH. **Semin Pediatr Neurol** 1998 Dec;5(4):276–86 (74 ref.)

Neurofibromatosis 1 in childhood. North KN. **Semin Pediatr Neurol** 1998 Dec;5(4):231–42 (53 ref.)

[Von Recklinghausen type I neurofibromatosis and neuroendocrine tumor (somatostatinoma) in a 50-year-old woman] Reichardt M, et al. **Med Klin** 1998 Sep 15; 93(9):550–3 (26 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of neurofibromatosis type 1. Friedman JM. **Am J Med Genet** 1999 Mar 26;89(1):1–6 (82 ref.)

Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Bernardis V, et al. **Digestion** 1999 Jan–Feb;60(1):82–5 (16 ref.)

GENETICS

Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders. Carey JC, et al. **Am J Med Genet** 1999 Mar 26; 89(1):7–13 (60 ref.)

Epidemiology of neurofibromatosis type 1. Friedman JM. **Am J Med Genet** 1999 Mar 26;89(1):1–6 (82 ref.)

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Weiss B, et al. **Am J Med Genet** 1999 Mar 26; 89(1):14–22 (103 ref.)

[Neurofibromatosis] Wolkenstein P, et al. **Neurochirurgie** 1998 Nov;44(4):267–72 (25 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Woodruff JM. **Am J Med Genet** 1999 Mar 26;89(1):23–30 (39 ref.)

[Gastrointestinal autonomic nerve tumor (GANT) associated with Von Recklinghausen's disease] Damiani S, et al. **Pathologica** 1998 Dec;90(6):792–7 (18 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Intracranial gliomas in neurofibromatosis type 1. Listernick R, et al. **Am J Med Genet** 1999 Mar 26;89(1):38–44 (26 ref.)

Neurofibromatosis type 1: piecing the puzzle together. Feldkamp MM, et al. **Can J Neurol Sci** 1998 Aug; 25(3):181–91 (142 ref.)

PSYCHOLOGY

Cognitive impairment in neurofibromatosis type 1. Ozonoff S. **Am J Med Genet** 1999 Mar 26;89(1):45–52 (51 ref.)

RADIOGRAPHY

[Pulmonary nodules in a patient with von Recklinghausen's disease] Diaz Pollán B, et al. **Rev Clin Esp** 1999 Jul;

NEUROFIBROMATOSIS 1

199(7):465–6 (9 ref.) **(Spa)**

SURGERY

Plexiform neurofibromas. Korf BR. **Am J Med Genet** 1999 Mar 26;89(1):31–7 (21 ref.)
Neurofibromatosis in children: the role of the orthopaedist. Crawford AH, et al. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):217–30 (63 ref.)

THERAPY

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Weiss B, et al. **Am J Med Genet** 1999 Mar 26; 89(1):14–22 (103 ref.)

NEUROFIBROMATOSIS 1 GENES see **GENES, NEUROFIBROMATOSIS 1**

NEUROFIBROMATOSIS 2

see related
GENES, NEUROFIBROMATOSIS 2

COMPLICATIONS

[Oto-neuro-surgical approach and accessibility to the cochlear nuclei. Significance in auditory brain stem implant] Vautrin R, et al.
Rev Laryngol Otol Rhinol (Bord) 1998;119(3):171–6 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Neurofibromatosis types I and II: radiological appearance. Romanowski CA, et al. **Hosp Med** 1998 Feb;59(2):134–9 (13 ref.)
Otoneurosyphilis masquerading as neurofibromatosis type II. Ahmad I, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb;61(1):37–40 (17 ref.)
The diagnosis and management of neurofibromatosis 2 in childhood. MacCollin M, et al. **Semin Pediatr Neurol** 1998 Dec;5(4):243–52 (43 ref.)

GENETICS

Merlin: the neurofibromatosis 2 tumor suppressor. Gusella JF, et al. **Biochim Biophys Acta** 1999 Mar 25; 1423(2):M29–36 (49 ref.)
Structure–function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein. Turunen O, et al.
Biochim Biophys Acta 1998 Sep 8;1387(1–2):1–16 (106 ref.)
Neurofibromatosis type 2 with multiple primary brain tumors in monozygotic twins. Harada H, et al. **Surg Neurol** 1999 May;51(5):528–35 (30 ref.)
[Neurofibromatosis] Wolkenstein P, et al. **Neurochirurgie** 1998 Nov;44(4):267–72 (25 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Management of neurofibromatosis type 2 [see comments] Bance M, et al. **Ear Nose Throat J** 1999 Feb;78(2):91–4, 96 (15 ref.) Comment in: Ear Nose Throat J 1999 Feb;78(2):74.

NEUROFIBROMATOSIS 2 GENES see **GENES, NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, CENTRAL, NF2 see **NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, PERIPHERAL, NF1 see **NEUROFIBROMATOSIS 1**

NEUROFILAMENT PROTEINS

GENETICS

Transgenic mice in the study of ALS: the role of neurofilaments. Julien JP, et al. **Brain Pathol** 1998 Oct; 8(4):759–69 (88 ref.)
Neurofilaments in health and disease. Julien JP, et al.
Prog Nucleic Acid Res Mol Biol 1998;61:1–23 (129 ref.)

METABOLISM

Neurofilaments in health and disease. Julien JP, et al.
Prog Nucleic Acid Res Mol Biol 1998;61:1–23 (129 ref.)
[Molecular mechanisms of axonal transport] Toyoshima I. **No To Shinkei** 1998 Aug;50(8):691–702 (83 ref.) **(Jpn)**

PHYSIOLOGY

Transgenic mice in the study of ALS: the role of neurofilaments. Julien JP, et al. **Brain Pathol** 1998 Oct; 8(4):759–69 (88 ref.)
Gene targeting studies begin to reveal the function of neurofilament proteins [comment] [published erratum appears in J Cell Biol 1998 Nov 16;143(4):1142] Hirokawa N, et al. **J Cell Biol** 1998 Oct 5;143(1):1–4 (36 ref.) Comment on: J Cell Biol 1998 Oct 5;143(1):171–81. Comment on: J Cell Biol 1998 Oct 5;143(1):183–93. Comment on: J Cell Biol 1998 Oct 5;143(1):195–205.

NEUROGENIC INFLAMMATION

see related
NEUROIMMUNOMODULATION

ETIOLOGY

Neural modulation of inflammatory reactions in dental tissues incident to orthodontic tooth movement. A review of the literature. Vandevska-Radunovic V. **Eur J Orthod** 1999 Jun;21(3):231–47 (176 ref.)

NEUROGLIA

Intracranial extracerebral neuroglial heterotopia: A case report and review of the literature. Gyure KA, et al.
Ann Diagn Pathol 1999 Jun;3(3):182–6 (28 ref.)
Glial choristoma of the tongue: a case report and review of the literature. Abdelsayed RA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Feb;87(2):215–22 (36 ref.)
[Glial hamartoma of the papilla] Cernea P, et al.
Oftalmologia 1998;44(3):84–7 (11 ref.) (Eng. Abstr.) **(Rum)**

CYTOLOGY

The subependymal layer in rodents: a site of structural plasticity and cell migration in the adult mammalian brain. Peretto P, et al. **Brain Res Bull** 1999 Jul 1;49(4):221–43 (184 ref.)
A new role for glia: generation of neurons! Barres BA. **Cell** 1999 Jun 11;97(6):667–70 (23 ref.)
BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Gary SC, et al.
Curr Opin Neurobiol 1998 Oct;8(5):576–81 (31 ref.)
In vitro central nervous system models of mechanically induced trauma: a review. Morrison B 3rd, et al.
J Neurotrauma 1998 Nov;15(11):911–28 (137 ref.)
Glial progenitor cells in normal and pathological states. Nishiyama A. **Keio J Med** 1998 Dec;47(4):205–8 (28 ref.)

ENZYMOLOGY

Expression of nitric oxide synthase-2 in glia associated with CNS pathology. Loihl AK, et al. **Prog Brain Res** 1998; 118:253–67 (122 ref.)

IMMUNOLOGY

Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. McGeer PL, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S1–6 (40 ref.)

METABOLISM

VIP and PACAP in the CNS: regulators of glial energy metabolism and modulators of glutamatergic signaling. Magistretti PJ, et al. **Ann N Y Acad Sci** 1998 Dec 11; 865:213–25 (38 ref.)
Landmarks in the application of 13C-magnetic resonance spectroscopy to studies of neuronal/glial relationships. Bachelard H. **Dev Neurosci** 1998;20(4–5):277–88 (70 ref.)
Effects of steroid hormones on gene expression of glial markers in the central and peripheral nervous system: variations induced by aging. Melcangi RC, et al.
Exp Gerontol 1998 Nov-Dec;33(7–8):827–36 (45 ref.)
Estrogen receptor immunoreactivity in Schwann-like brain macroglia. Gudiño-Cabrera G, et al. **J Neurobiol** 1999 Sep 15;40(4):458–70 (106 ref.)
Steroid metabolism and effects in central and peripheral glial cells. Melcangi RC, et al. **J Neurobiol** 1999 Sep 15; 40(4):471–83 (126 ref.)
Glial progenitor cells in normal and pathological states. Nishiyama A. **Keio J Med** 1998 Dec;47(4):205–8 (28 ref.)
Glial reaction in aging and Alzheimer's disease. Unger JW. **Microsc Res Tech** 1998 Oct 1;43(1):24–8 (45 ref.)
Glial glutamate transport as target for nitric oxide: consequences for neurotoxicity. Ye ZC, et al.
Prog Brain Res 1998;118:241–51 (42 ref.)
Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444–9 (48 ref.)

PATHOLOGY

Glia: a curtain raiser. Wilkin GP, et al. **Adv Neurol** 1999; 80:3–7 (38 ref.)
Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. Schubert P, et al. **J Neural Transm Suppl** 1998;54:167–74 (29 ref.)
Age-related changes in the brains of senescence-accelerated mice (SAM): association with glial and endothelial reactions. Kawamata T, et al. **Microsc Res Tech** 1998 Oct 1;43(1):59–67 (71 ref.)
Glial reaction in aging and Alzheimer's disease. Unger JW. **Microsc Res Tech** 1998 Oct 1;43(1):24–8 (45 ref.)
Congenital thyroid teratoma: a case with persistent neuroglial involvement of cervical lymph nodes. Keen CE, et al.
Pediatr Dev Pathol 1998 Jul–Aug;1(4):322–7 (11 ref.)

PHYSIOLOGY

Molecular signals for glial activation: pro- and anti-inflammatory cytokines in the injured brain. Raivich G, et al. **Acta Neurochir Suppl (Wien)** 1999;73:21–30 (87 ref.)
Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Hirsch EC, et al.
Adv Neurol 1999;80:9–18 (78 ref.)
Glia: a curtain raiser. Wilkin GP, et al. **Adv Neurol** 1999; 80:3–7 (38 ref.)
Glial cells in neurotoxicity development. Aschner M, et al. **Annu Rev Pharmacol Toxicol** 1999;39:151–73 (132 ref.)
Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Raivich G, et al. **Brain Res Brain Res Rev** 1999 Jul;30(1):77–105 (313 ref.)
The glial scar and central nervous system repair. Fawcett JW, et al. **Brain Res Bull** 1999 Aug;49(6):377–91 (216 ref.)
Calcium signalling in glial cells. Deitmer JW, et al.
Cell Calcium 1998 Nov–Dec;24(5–6):405–16 (105 ref.)
From neuro-glue ('Nervenkitt') to glia: a prologue. Dermietzel R, et al. **Glia** 1998 Sep;24(1):1–7 (88 ref.)
Gap junction-mediated loops of neuronal-glial interactions. Fróes MM, et al. **Glia** 1998 Sep;24(1):97–107 (117 ref.)
Heterotypic coupling between glial cells of the mammalian central nervous system. Zahs KR. **Glia** 1998 Sep; 24(1):85–96 (130 ref.)
Transgenic studies of peripheral and central glia. Messing A. **Int J Dev Biol** 1998;42(7 Spec No):1019–24 (43 ref.)
Androgenic regulation of the central glia response following nerve damage. Jones KJ, et al. **J Neurobiol** 1999 Sep 15; 40(4):560–73 (101 ref.)
Glia as mediators of steroid hormone action on the nervous system: An overview. Jordan CL. **J Neurobiol** 1999 Sep 15;40(4):434–45 (84 ref.)
Steroid metabolism and effects in central and peripheral glial cells. Melcangi RC, et al. **J Neurobiol** 1999 Sep 15; 40(4):471–83 (126 ref.)
Glial responses to steroids as markers of brain aging. Nichols NR. **J Neurobiol** 1999 Sep 15;40(4):585–601 (144 ref.)
Glial-neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids. Ojeda SR, et al. **J Neurobiol** 1999 Sep 15;40(4):528–40 (95 ref.)
Glucocorticoid control of glial gene expression. Vardimon L, et al. **J Neurobiol** 1999 Sep 15;40(4):513–27 (132 ref.)
Progesterone as a neurosteroid: synthesis and actions in rat glial cells. Jung-Testas I, et al.
J Steroid Biochem Mol Biol 1999 Apr–Jun;69(1–6):97–107 (34 ref.)
Apoptotic cell death in neurons and glial cells: implications for Alzheimer's disease. Kitamura Y, et al.
Jpn J Pharmacol 1999 Jan;79(1):1–5 (31 ref.)
Production, regulation and role of nitric oxide in glial cells. Vincent VA, et al. **Mediators Inflamm** 1998;7(4):239–55 (372 ref.)
The role of glial cells in synaptic function. Bacci A, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):403–9 (52 ref.)
The Ca2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells. Solà C, et al. **Prog Neurobiol** 1999 Jun;58(3):207–32 (168 ref.)
Brain, heal thyself. Lowenstein DH, et al. **Science** 1999 Feb 19;283(5405):1126–7 (13 ref.)
Tripartite synapses: glia, the unacknowledged partner. Araque A, et al. **Trends Neurosci** 1999 May;22(5):208–15 (61 ref.)

SECRETION

A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy. Bohn MC. **Biochem Pharmacol** 1999 Jan 15;57(2):135–42 (72 ref.)
Therapeutic approaches to the treatment of neuroinflammatory diseases. Hays SJ. **Curr Pharm Des** 1998 Aug;4(4):335–48 (112 ref.)

ULTRASTRUCTURE

[Structure and functions of the macroglia in the central nervous system. Response to degenerative disorders] Ramírez-Expósito MJ, et al. **Rev Neurol** 1998 Apr; 26(152):600–11 (294 ref.) (Eng. Abstr.) **(Spa)**

NEUROHEMAL ORGAN see **NEUROSECRETORY SYSTEMS**

NEUROHUMOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROHUMORS see **NEUROTRANSMITTERS**

NEUROHYPOPHYSIS see **PITUITARY GLAND, POSTERIOR**

NEUROIMMUNE PROCESSES see **NEUROIMMUNOMODULATION**

NEUROIMMUNOMODULATION

see related
NEUROGENIC INFLAMMATION
Neuropeptides in atopic dermatitis. Giannetti A.
Curr Probl Dermatol 1999;28:51–5 (8 ref.)

Adrenergic/cholinergic immunomodulation in the rat model--in vivo veritas? Rinner I, et al. **Dev Immunol** 1998; 6(3–4):245–52 (35 ref.)
Neuroimmunoregulation and cancer (review). Berczi I, et al. **Int J Oncol** 1998 Nov;13(5):1049–60 (160 ref.)
Neural–immune interactions--an evolutionary perspective. Clatworthy AL. **Neuroimmunomodulation** 1998 May–Aug; 5(3–4):136–42 (51 ref.)
[Interaction between breast cancer, psychosocial stress and the immune response] Boermeester MA, et al. **Ned Tijdschr Geneeskd** 1999 Apr 17;143(16):838–42 (35 ref.) (Eng. Abstr.) **(Dut)**
[Recent advance in neuroimmunology] Arimura K, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):993–6 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Relation and interactions between the immune and neuroendocrine systems] Ferenčík M, et al. **Bratisl Lek Listy** 1998 Aug–Sep;99(8–9):454–64 (85 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

Immunomodulating effects of methionine enkephalin. Li XY. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):3–6 (30 ref.)
Hypothalamic–pituitary–adrenal axis suppression and inhaled corticosteroid therapy. I. General principles. Chrousos GP, et al. **Neuroimmunomodulation** 1998 Nov–Dec;5(6):277–87 (61 ref.)
Hypothalamic–pituitary–adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature. Chrousos GP, et al. **Neuroimmunomodulation** 1998 Nov–Dec;5(6):288–308 (70 ref.)

IMMUNOLOGY

Adrenergic/cholinergic immunomodulation in the rat model--in vivo veritas? Rinner I, et al. **Dev Immunol** 1998; 6(3–4):245–52 (35 ref.)
Neuroimmunoregulation and natural immunity. Berczi I, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):273–81 (30 ref.)
Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine–immunological sexual dimorphism. Gaillard RC, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):345–52 (18 ref.)
Immune and endocrine regulation of food intake in sick animals. Johnson RW. **Domest Anim Endocrinol** 1998 Sep; 15(5):309–19 (81 ref.)
Neuroendocrine–immune interactions in the neonate. Matteri RL, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):397–407 (76 ref.)
Coordinated host defense through an integration of the neural, immune and haemopoietic systems. Miyan JA, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):297–304 (20 ref.)
Endocrine modulation of physiological responses to catabolic disease. Sartin JL, et al. **Domest Anim Endocrinol** 1998 Sep; 15(5):423–9 (38 ref.)
Do only circulating pyrogenic cytokines act as mediators in the febrile response? A hypothesis. Netea MG, et al. **Eur J Clin Invest** 1999 Apr;29(4):351–6 (52 ref.)
Annual review prize lecture cytokines – killers in the brain? Rothwell NJ. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):3–17 (126 ref.)
Neuroimmunomodulatory actions of hypothalamic interferon-alpha. Hori T, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):172–7 (63 ref.)
Peptide modulation of inflammatory processes within the brain. Lipton JM, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):178–83 (50 ref.)
Role of the brain in interleukin-6 modulation. Terreni L, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):214–9 (72 ref.)
New vistas in immunopsychopharmacology. Herman ZS. **Pol J Pharmacol** 1998 Nov–Dec;50(6):377–86 (108 ref.)
[Neuroimmunopathology] Kryzhanovskiĭ GN. **Vestn Ross Akad Med Nauk** 1999;(4):18–20 (17 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Sleep as a behavioral model of neuro-immune interactions. Opp MR, et al. **Acta Neurobiol Exp (Warsz)** 1999; 59(1):45–53 (71 ref.)
Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Chikanza IC. **Ann N Y Acad Sci** 1999 Jun 22;876:119–30 (82 ref.)
Role of serotonin in the immune system and in neuroimmune interactions. Mössner R, et al. **Brain Behav Immun** 1998 Dec;12(4):249–71 (135 ref.)
The molecular basis for bidirectional communication between the immune and neuroendocrine systems. Jiang CL, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):363–9 (21 ref.)
Balancing function vs. self defense: the CNS as an active regulator of immune responses. Carson MJ, et al. **J Neurosci Res** 1999 Jan 1;55(1):1–8 (72 ref.)
Role of nitric oxide and carbon monoxide in modulating the ACTH response to immune and nonimmune signals. Rivier C. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):203–13 (65 ref.)
[Paraventriculovagal path of carbohydrate homeostasis regulation--a perspective biological model in studies on neuroimmunoendocrine interactions] Akmaev IG. **Biull Eksp Biol Med** 1999 Feb;127(2):124–8 (35 ref.) **(Rus)**
[Opioids and the immune system] Núñez G, et al. **Rev Med Chil** 1999 Mar;127(3):341–8 (53 ref.) (Eng. Abstr.) **(Spa)**

NEUROKININ A

see related
RECEPTORS, NEUROKININ-2

NEUROKININ A RECEPTORS see **RECEPTORS, NEUROKININ-2**

NEUROKININ B RECEPTORS see **RECEPTORS, NEUROKININ-3**

NEUROKININ K

see related
RECEPTORS, NEUROKININ-3

NEUROKININ-1 RECEPTORS see **RECEPTORS, NEUROKININ-1**

NEUROKININ-2 RECEPTORS see **RECEPTORS, NEUROKININ-2**

NEUROKININ-3 RECEPTORS see **RECEPTORS, NEUROKININ-3**

NEUROLEPTANALGESIA

Neuroleptanesthesia: current status. Bissonnette B, et al. **Can J Anaesth** 1999 Feb;46(2):154–68 (104 ref.)

NEUROLEPTIC MALIGNANT SYNDROME

Neuroleptic malignant syndrome: a review. Pelonero AL, et al. **Psychiatr Serv** 1998 Sep;49(9):1163–72 (71 ref.)
[Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate] Noda S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):538–41 (15 ref.) **(Jpn)**

DIAGNOSIS

Neuroleptic malignant syndrome in children and adolescents. Silva RR, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Feb;38(2):187–94 (73 ref.)

EPIDEMIOLOGY

Epidemiology of neuroleptic malignant syndrome. Adityanjee, et al. **Clin Neuropharmacol** 1999 May–Jun; 22(3):151–8 (79 ref.)

ETIOLOGY

Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Gurrera RJ. **Am J Psychiatry** 1999 Feb;156(2):169–80 (167 ref.)
Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Karagianis JL, et al. **Ann Pharmacother** 1999 May;33(5):623–30 (43 ref.)
Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Assion HJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1998;248(5):231–9 (45 ref.)
[Toxic and adverse neurologic effects of neuroleptics] Nakayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):532–7 (14 ref.) **(Jpn)**
[Neuroleptic malignant syndrome associated with olanzapine (letter)] García López MM, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (8 ref.) **(Spa)**

THERAPY

Specific treatment of the neuroleptic malignant syndrome [editorial] Caroff SN, et al. **Biol Psychiatry** 1998 Sep 15; 44(6):378–81 (44 ref.)
Neuroleptic malignant syndrome in children and adolescents. Silva RR, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Feb;38(2):187–94 (73 ref.)

NEUROLEPTICS see **ANTIPSYCHOTIC AGENTS**

NEUROLIN see **ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE**

NEUROLOGIC EXAMINATION

The neurologic examination in adult psychiatry: from soft signs to hard science. Sanders RD, et al. **J Neuropsychiatry Clin Neurosci** 1998 Fall;10(4):395–404 (130 ref.)
Donal Munro Lecture: Functional and neurologic recovery following acute SCI. Waters RL, et al. **J Spinal Cord Med** 1998 Jul;21(3):195–9 (11 ref.)
Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Flyckt L, et al. **Psychiatry Res** 1999 May 31;86(2):113–29 (50 ref.)
[Diagnostic assessment in lumbar back pain. I. Anamnesis and clinical examination] Boos N, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):305–13 (13 ref.) (Eng. Abstr.) **(Ger)**
[Leg pain--the contribution of the neurologist] Beer S, et al. **Ther Umsch** 1998 Oct;55(10):618–23 (31 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Sensory examination. Comparison of instruments. Song J, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):29–48, v–vi (73 ref.)
Technology review: the Neurometer Current Perception Threshold (CPT). AAEM Equipment and Computer Committee. American Association of Electrodiagnostic Medicine. **Muscle Nerve** 1999 Apr;22(4):523–31 (56 ref.)

METHODS

The neurologic examination of the podiatric patient. Spadone SJ. **Clin Podiatr Med Surg** 1999 Jan;16(1):1–17, v (10 ref.)
Foundation for practice. Neuroassessment for neuroscience nurses. Neatherlin JS. **Nurs Clin North Am** 1999 Sep; 34(3):573–92 (9 ref.)
Identifying diabetic patients at high risk for amputation. Umeh L, et al. **Nurse Pract** 1999 Aug;24(8):56, 60, 63–6, 70 (29 ref.)
[Physical diagnostics--tendon reflexes] Stam J. **Ned Tijdschr Geneeskd** 1999 Apr 17;143(16):848–51 (9 ref.) (Eng. Abstr.) **(Dut)**
[What is the strategy to follow for carrying out examinations of diagnostic imaging?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):47–57 (68 ref.) **(Fre)**
[Evaluation of the nervous system in workers as needed for preventive care. Methodical indicators. II. Objective examinations] Polakowska B. **Med Pr** 1995;46(1):61–5 (7 ref.) (Eng. Abstr.) **(Pol)**

NURSING

Assessment of cognition in the elderly: pieces of a complex puzzle. Dellasega C. **Nurs Clin North Am** 1998 Sep; 33(3):395–405 (21 ref.)

STANDARDS

NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Bril V. **Eur Neurol** 1999;41 Suppl 1:8–13 (32 ref.)

NEUROLOGIC MODELS see **MODELS, NEUROLOGICAL**

NEUROLOGY

see related
NERVOUS SYSTEM DISEASES

Stroke: how large a public health problem, and how can the neurologist help? Hankey GJ. **Arch Neurol** 1999 Jun; 56(6):748–54 (36 ref.)
A possible paradigm of functional neurology. Moldovanu I, et al. **Funct Neurol** 1998 Oct–Dec;13(4):305–10 (31 ref.)
[Implementation of neurological expertise] Brion S. **Rev Neurol (Paris)** 1998 Jan;154(1):62–9 (19 ref.) **(Fre)**
[The use of echocardiographic studies in neurology] Mendel T. **Neurol Neurochir Pol** 1999 Mar–Apr;33(2):413–25 (30 ref.) (Eng. Abstr.) **(Pol)**
[Neuronal death is basic problem of neurology and psychiatry] Zavalishin IA, et al. **Vestn Ross Akad Med Nauk** 1999;(1):28–33 (45 ref.) (Eng. Abstr.) **(Rus)**
[Intensive neurology. Past, present, and future] Tellería-Díaz A. **Rev Neurol** 1998 Nov;27(159):830–2 (17 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

The history of the Golgi apparatus in neurones from its discovery in 1898 to electron microscopy. Dröscher A. **Brain Res Bull** 1998 Oct;47(3):199–203 (62 ref.)
1898–1998: Camillo Golgi and "the Golgi": one hundred years of terminological clones [editorial] Fabene PF, et al. **Brain Res Bull** 1998 Oct;47(3):195–8 (8 ref.)

INSTRUMENTATION

MRI-based brain volumetrics: emergence of a developmental brain science. Caviness VS Jr, et al. **Brain Dev** 1999 Jul; 21(5):289–95 (69 ref.)

LEGISLATION & JURISPRUDENCE

Documentation and informed consent. Weintraub MI. **Neurol Clin** 1999 May;17(2):371–81 (29 ref.)

METHODS

Interventional neuroradiology. Nakstad PH. **Acta Radiol** 1999 Jul;40(4):344–59 (148 ref.)
Noradrenaline spillover and microneurography measurements in patients with primary hypertension. Jennings GL. **J Hypertens Suppl** 1998 Aug;16(3):S35–8 (41 ref.)
Transplantation as a tool to study progenitors within the vertebrate nervous system. Gaiano N, et al. **J Neurobiol** 1998 Aug;36(2):152–61 (85 ref.)
The advantages and limitations of permanent or reversible

deactivation techniques in the assessment of neural function. Lomber SG. **J Neurosci Methods** 1999 Jan; 86(2):109–17 (62 ref.)
Contribution of the neuro-intensivist in the choice of treatment of patients with aneurysm. Levati A, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):113–6 (21 ref.)

TRENDS

A new epileptic seizure classification based exclusively on ictal semiology [editorial] Lüders H, et al. **Acta Neurol Scand** 1999 Mar;99(3):137–41 (26 ref.)
New aspects in the pathophysiology of dyskinesia. Salpêtrière Deep Brain Stimulation Group. Damier P. **Adv Neurol** 1999;80:611–7 (13 ref.)
Treatment of aphasia. Albert ML. **Arch Neurol** 1998 Nov; 55(11):1417–9 (27 ref.)
Recent Advances. Neurology. Larner AJ, et al. **BMJ** 1999 Aug 7;319(7206):362–6 (30 ref.)
Imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts). Farsang C, et al. **Brain Res Bull** 1999 Jul 15;49(5):317–31 (241 ref.)
New developments in understanding the etiology of Parkinson's disease and in its treatment. Lozano AM, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):783–90 (68 ref.)
Recent advances on the pathogenesis of Huntington's disease. Petersén A, et al. **Exp Neurol** 1999 May;157(1):1–18 (168 ref.)
Jaws: diversities of gnathological history and temporomandibular joint enterprise. Nelson DA, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):141–7 (80 ref.)
Neurology without borders: neurological disease in a shrinking world. Bergen DC. **J Neurol Sci** 1999 Jun 1; 165(2):101–5 (38 ref.)
Management of intracranial aneurysms: "state of the art". Chiappetta F, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):5–13 (53 ref.)
Epilepsy surgery: past, present and future [editorial] Wieser HG. **Seizure** 1998 Jun;7(3):173–84 (98 ref.)
[Genetic therapy for the nervous system: a trend in modern neurology] González-Hoyuela M, et al. **Rev Neurol** 1998 Oct;27(158):625–30 (53 ref.) (Eng. Abstr.) **(Spa)**

NEUROLYMPHOMATOSIS see **MAREK'S DISEASE**

NEUROLYMPHOMATOSIS VIRUS see **HERPESVIRUS 2, GALLID**

NEUROMA

DIAGNOSIS

Tibial neuroma presenting as a Baker cyst. A case report. DeLuca PF, et al. **J Bone Joint Surg Am** 1999 Jun; 81(6):856–8 (10 ref.)

NEUROMA, ACOUSTIC

SURGERY

Stereotactic radiosurgery for acoustic neuroma: a Canadian perspective [see comments] Ross IB, et al. **Can J Neurol Sci** 1998 Nov;25(4):310–4 (20 ref.) Comment in: Can J Neurol Sci 1999 May;26(2):154–5.
Vestibular neurilemmomas (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:529–48 (31 ref.)
Intra-operative monitoring in acoustic neuroma surgery. Kartush JM. **Neurol Res** 1998 Oct;20(7):593–6 (22 ref.)
Can hearing improve after acoustic tumor radiosurgery? Niranjan A, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):305–15 (27 ref.)
[Neurosurgical management of extracerebral tumors] Antoniadis G, et al. **Rontgenpraxis** 1998;51(8–9):304–10 (26 ref.) **(Ger)**

NEUROMA, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

NEUROMA, ACOUSTIC, UNILATERAL see **NEUROMA, ACOUSTIC**

NEUROMEDIATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROMEDIN B RECEPTORS see **RECEPTORS, BOMBESIN**

NEUROMODULATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROMODULATORS see **NEUROTRANSMITTERS**

NEUROMODULIN see **GAP-43 PROTEIN**

NEUROMUSCULAR AGENTS

ADMINISTRATION & DOSAGE

Treatment of hyperfunctional lines of the face with botulinum toxin A. Binder WJ, et al. **Dermatol Surg** 1998 Nov; 24(11):1198–205 (32 ref.)
Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Edelstein C, et al. **Dermatol Surg** 1998 Nov; 24(11):1208–12 (12 ref.)
Botulinum toxin. The Newport Beach experience. Fulton JE. **Dermatol Surg** 1998 Nov;24(11):1219–24 (8 ref.)
Dilution and storage of botulinum toxin. Klein AW. **Dermatol Surg** 1998 Nov;24(11):1179–80 (7 ref.)
Electromyographic guidance in injecting botulinum toxin. Klein AW, et al. **Dermatol Surg** 1998 Nov;24(11):1184–6 (10 ref.)
Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Lowe NJ. **Dermatol Surg** 1998 Nov;24(11):1216–8 (15 ref.)
Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. Mandel L, et al. **J Oral Maxillofac Surg** 1999 Aug;57(8):1017–9 (15 ref.)

ADVERSE EFFECTS

Complications of botulinum A exotoxin for hyperfunctional lines. Matarasso SL. **Dermatol Surg** 1998 Nov; 24(11):1249–54 (21 ref.)

THERAPEUTIC USE

Botulinum toxin type A injection for the treatment of frown lines. Song KH. **Ann Pharmacother** 1998 Dec;32(12):1365–7 (17 ref.)
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Naumann M, et al. **Arch Neurol** 1999 Aug;56(8):914–6 (11 ref.)
The role of botulinus toxin type A in treatment—with special reference to children. Gordon N. **Brain Dev** 1999 Apr; 21(3):147–51 (25 ref.)
Cosmetic use of botulinum A exotoxin for the aging neck. Brandt FS, et al. **Dermatol Surg** 1998 Nov;24(11):1232–4 (9 ref.)
Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Carruthers A, et al. **Dermatol Surg** 1998 Nov;24(11):1189–94 (11 ref.)
The adjunctive usage of botulinum toxin. Carruthers J, et al. **Dermatol Surg** 1998 Nov;24(11):1244–7 (11 ref.)
Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region. Wieder JM, et al. **Dermatol Surg** 1998 Nov;24(11):1172–4 (8 ref.)
Aesthetic uses of botulinum toxin A. Niamtu J 3rd. **J Oral Maxillofac Surg** 1999 Oct;57(10):1228–33 (7 ref.)
Increased stability of airflow following botulinum toxin injection. Finnegan EM, et al. **Laryngoscope** 1999 Aug; 109(8):1300–6 (22 ref.)
Cosmetic indications for botulinum A toxin. Foster JA, et al. **Semin Ophthalmol** 1998 Sep;13(3):142–8 (22 ref.)

NEUROMUSCULAR BLOCKADE

see related
NEUROMUSCULAR BLOCKING AGENTS

Adjuncts to analgesia. Sedation and neuromuscular blockade. Lowson SM, et al. **Crit Care Clin** 1999 Jan;15(1):119–41, vii (132 ref.)
Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator. Rowlee SC. **Heart Lung** 1999 Sep–Oct;28(5):352–62; quiz 363–4 (34 ref.)
[Neuromuscular monitoring. Standard procedures] Fuchs-Buder T. **Anaesthesist** 1998 Aug;47(8):629–37 (65 ref.) (Eng. Abstr.) **(Ger)**

NEUROMUSCULAR BLOCKING AGENTS

Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator. Rowlee SC. **Heart Lung** 1999 Sep–Oct;28(5):352–62; quiz 363–4 (34 ref.)
Why, how and when to monitor neuromuscular function. Viby-Mogensen J. **Minerva Anestesiol** 1999 May; 65(5):239–44 (19 ref.)
Newer neuromuscular blockers. Is the practitioner ready for muscle relaxants? Martinez EA. **Vet Clin North Am Small Anim Pract** 1999 May;29(3):811–7 (16 ref.)
[New muscle relaxants] Suzuki F. **Masui** 1998 Dec;47 Suppl:S113–7 (13 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Adjuncts to analgesia. Sedation and neuromuscular blockade. Lowson SM, et al. **Crit Care Clin** 1999 Jan;15(1):119–41, vii (132 ref.)

ADVERSE EFFECTS

Neuromuscular blockade in the intensive care unit. Lewis KS, et al. **Am J Health Syst Pharm** 1999 Jan 1;56(1):72–5 (51 ref.)
Drugs and toxins associated with myopathies. Pascuzzi RM. **Curr Opin Rheumatol** 1998 Nov;10(6):511–20 (64 ref.)
Adverse effects of neuromuscular blockers and their antagonists. Naguib M, et al. **Middle East J Anesthesiol** 1998 Jun;14(5):341–73 (164 ref.)
[Toxic and adverse effects of local anesthetics/neuromuscular blocker: lidocaine, succinylcholine] Takagi A. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):542–4 (4 ref.) **(Jpn)**

METABOLISM

[Cholinesterases] Lejus C, et al. **Ann Fr Anesth Reanim** 1998; 17(9):1122–35 (175 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Eriksson LI. **Anesth Analg** 1999 Jul;89(1):243–51 (67 ref.)
[Blockade of the ion channels of the skeletal muscle acetylcholine receptor] Danilov AF. **Eksp Klin Farmakol** 1998 Nov-Dec;61(6):73–5 (22 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Effect of pharmaceutical services on adherence to criteria-for-use guidelines in the operating room. Higgins B, et al. **Am J Health Syst Pharm** 1999 May 15; 56(10):977–82 (7 ref.)
Clinical uses and controversies of neuromuscular blocking agents in infants and children. Martin LD, et al. **Crit Care Med** 1999 Jul;27(7):1358–68 (128 ref.)

NEUROMUSCULAR BLOCKING AGENTS, COMPETITIVE see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

NEUROMUSCULAR DEPOLARIZING AGENTS

[New muscle relaxants] Suzuki F. **Masui** 1998 Dec;47 Suppl:S113–7 (13 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Severe laryngospasm without intravenous access—a case report and literature review of the non-intravenous routes of administration of suxamethonium. Seah TG, et al. **Singapore Med J** 1998 Jul;39(7):328–30 (21 ref.)

PHARMACOLOGY

The activation of glutamate receptors by kainic acid and domoic acid. Hampson DR, et al. **Nat Toxins** 1998; 6(3–4):153–8 (60 ref.)

NEUROMUSCULAR DISEASES

[McLeod syndrome] Nishizawa M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):92–4 (7 ref.) **(Jpn)**

CLASSIFICATION

2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26–28 September 1997, Naarden, The Netherlands. **Neuromuscul Disord** 1998 Aug;8(6):426–31 (28 ref.)
Electrodiagnosis in neuromuscular disease. Krivickas LS. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):83–114, vi (80 ref.)

COMPLICATIONS

Lower extremity manifestations of neuromuscular diseases. Ramcharitar SI, et al. **Clin Podiatr Med Surg** 1998 Oct; 15(4):705–37, vi–vii (115 ref.)
Noninvasive ventilation in neuromuscular disease. Bonekat HW. **Crit Care Clin** 1998 Oct;14(4):775–97 (114 ref.)
Noninvasive management of pediatric neuromuscular ventilatory failure: a viable alternative [editorial; comment] Barnes SD. **Crit Care Med** 1998 Dec;26(12):1952–3 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2061–5.
The treatment of neuromuscular scoliosis. Banta JV, et al. **Instr Course Lect** 1999;48:551–62 (84 ref.)
Problems and management of the rearfoot in neuromuscular disease. A report of ten cases. Sobel E, et al. **J Am Podiatr Med Assoc** 1999 Jan;89(1):24–38 (71 ref.)
Respiratory aspects of neurological disease. Polkey MI, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):5–15 (170 ref.)
Is early noninvasive mechanical ventilation of first choice in stable restrictive patients with chronic respiratory failure? Raphaël JC, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):90–7 (95 ref.)
Management of neuromuscular scoliosis. McCarthy RE. **Orthop Clin North Am** 1999 Jul;30(3):435–49, viii (99 ref.)
Management of pulmonary complications in neuromuscular disease. Benditt JO. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):167–85 (57 ref.)
Spinal deformity in progressive neuromuscular disease. Natural history and management. Hart DA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):213–32, viii (92 ref.)
Management of cardiac complications in neuromuscular disease. Lewis WR, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):145–66, vii (177 ref.)
Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127–43 (67 ref.)

Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. McDonald CM. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):187–211 (67 ref.)
Cognitive, psychosocial, and educational issues in neuromuscular disease. Sigford BJ, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):249–70 (88 ref.)
[Neuromuscular diseases with eosinophilia] Pellissier JF, et al. **Med Trop (Mars)** 1998;58(4 Suppl):471–6 (24 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

[Congenital myasthenic syndromes] Eymard B. **Rev Prat** 1998 Mar 15;48(6):587–91 (17 ref.) **(Fre)**

DIAGNOSIS

Diagnostic algorithms for neuromuscular diseases. Mañon-Espaillat R, et al. **Clin Podiatr Med Surg** 1999 Jan; 16(1):67–79 (28 ref.)
Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Koch KL. **Dig Dis Sci** 1999 Jun; 44(6):1061–75 (66 ref.)
Ion channels and neurological disease: DNA based diagnosis is now possible, and ion channels may be important in common paroxysmal disorders [editorial] Hanna MG, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):427–31 (66 ref.)
Acquired binocular horizontal diplopia. Brazis PW, et al. **Mayo Clin Proc** 1999 Sep;74(9):907–16 (117 ref.)
Neurophysiologic evaluation and clinical trials for neuromuscular diseases [editorial; comment] Olney RK. **Muscle Nerve** 1998 Nov;21(11):1365–7 (21 ref.) Comment on: Muscle Nerve 1998 Nov;21(11):1368–73.
Selected legal issues in movement disorders. Nora LM, et al. **Neurol Clin** 1999 May;17(2):257–66 (41 ref.)
The role of physiatry in the management of neuromuscular disease. Fowler WM Jr, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):1–8, v (23 ref.)
Electrodiagnosis in neuromuscular disease. Krivickas LS. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):83–114, vi (80 ref.)
Clinical approach to the diagnostic evaluation of progressive neuromuscular diseases. McDonald CM. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):9–48 (63 ref.)
[New clinical tests that physicians should know for diagnosis of neuromuscular diseases] Kuroiwa Y. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2034–8 (2 ref.) **(Jpn)**

DRUG THERAPY

Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Albany K. **Muscle Nerve Suppl** 1997;6:S221–31 (40 ref.)
Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Brin MF. **Muscle Nerve Suppl** 1997; 6:S208–20 (25 ref.)
Traditional pharmacological treatments for spasticity. Part I: Local treatments. Gracies JM, et al. **Muscle Nerve Suppl** 1997;6:S61–91 (149 ref.)
Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Gracies JM, et al. **Muscle Nerve Suppl** 1997;6:S92–120 (162 ref.)
Clinical trials of botulinum toxin in the treatment of spasticity. Simpson DM. **Muscle Nerve Suppl** 1997;6:S169–75 (24 ref.)
Neuromuscular blockers. Gracies JM, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):357–83, viii (212 ref.)
Intrathecal drug therapy. Nance P, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):385–401, viii–ix (100 ref.)

ETIOLOGY

Acquired neuromuscular disorders in critically ill patients: a systematic review. Groupe de Reflexion et d'Etude sur les Neuromyopathies En Reanimation. De Jonghe B, et al. **Intensive Care Med** 1998 Dec;24(12):1242–50 (36 ref.)
Subaxial cervical synovial cyst presenting with myelopathy. Report of three cases. Cudlip S, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):141–4 (17 ref.)
Neuromuscular complications of kidney diseases. Galassi G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:41–7 (43 ref.)
Calcium channelopathies. Benatar MG. **QJM** 1999 Mar; 92(3):133–41 (40 ref.)
[Gait disorders] Müngersdorf M, et al. **Internist (Berl)** 1999 Jan;40(1):W83–93 (93 ref.) **(Ger)**
[Neuromuscular scoliosis] Carstens C. **Orthopade** 1999 Jul; 28(7):622–33 (2 ref.) **(Ger)**

GENETICS

Ion channels and neurological disease: DNA based diagnosis is now possible, and ion channels may be important in common paroxysmal disorders [editorial] Hanna MG, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):427–31 (66 ref.)
2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26–28 September 1997, Naarden, The Netherlands. **Neuromuscul Disord** 1998 Aug;8(6):426–31 (28 ref.)
The contribution of molecular genetics in the diagnosis and management of neuromuscular disorders. Kakulas BA, et al. **Scand J Rehabil Med Suppl** 1999;39:5–22 (49 ref.)
[Diagnosis of neuromuscular diseases: progress with molecular genetic techniques] Gencik M, et al. **Dtsch Med Wochenschr** 1999 Jan 29;124(4):85–7 (5 ref.) **(Ger)**
[Molecular-genetic analysis of hereditary neurological diseases] Slominskiĭ PA. **Mol Biol (Mosk)** 1999 Jan-Feb; 33(1):74–9 (79 ref.) **(Rus)**

PHYSIOPATHOLOGY

Disorders of neuromuscular junction ion channels. Boonyapisit K, et al. **Am J Med** 1999 Jan;106(1):97–113 (180 ref.)
The alpha7beta1 integrin in muscle development and disease. Burkin DJ, et al. **Cell Tissue Res** 1999 Apr;296(1):183–90 (43 ref.)
Respiratory muscle function in patients with neuromuscular disorders and cardiopulmonary diseases. Syabbalo N. **Int J Clin Pract** 1998 Jul-Aug;52(5):319–29 (129 ref.)
Is early noninvasive ventilation the first choice in stable restrictive patients with chronic respiratory failure? Shneerson J. **Monaldi Arch Chest Dis** 1999 Feb;54(1):87–9 (8 ref.)
Animal models of neuromuscular diseases: pathophysiology and implications for rehabilitation. Abresch RT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):285–99 (70 ref.)

PSYCHOLOGY

Quality of life. Issues for persons with neuromuscular diseases. Abresch RT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):233–48 (29 ref.)
Cognitive, psychosocial, and educational issues in neuromuscular disease. Sigford BJ, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):249–70 (88 ref.)

REHABILITATION

Rehabilitation in neuromuscular disorders and thoracic wall deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Aug;53(4):415–8 (26 ref.)
Outcome measures in spasticity management. Pierson SH. **Muscle Nerve Suppl** 1997;6:S36–60 (43 ref.)
Animal models of neuromuscular diseases: pathophysiology and implications for rehabilitation. Abresch RT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):285–99 (70 ref.)
The role of exercise in neuromuscular disease. Kilmer DD. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):115–25, vi (48 ref.)

SURGERY

Surgical treatment for dysphagia of neuromuscular origin. Shin T, et al. **Folia Phoniatr Logop** 1999 Jul-Oct; 51(4–5):213–9 (16 ref.)
The surgical treatment of spasticity. Chambers HG. **Muscle Nerve Suppl** 1997;6:S121–8 (59 ref.)
[Soft tissue operations in neuromuscular foot deformities] Döderlein L. **Orthopade** 1999 Feb;28(2):151–8 (15 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of brachial plexus injury. Nagano A. **J Orthop Sci** 1998;3(1):71–80 (30 ref.)
Modalities of ventilation in neuromuscular disorders and thoracic deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):552–5 (10 ref.)
Outcome measures in spasticity management. Pierson SH. **Muscle Nerve Suppl** 1997;6:S36–60 (43 ref.)
The role of physiatry in the management of neuromuscular disease. Fowler WM Jr, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):1–8, v (23 ref.)

VETERINARY

Electromyography in the horse in veterinary medicine and in veterinary research--a review. van Wessum R, et al. **Vet Q** 1999 Jan;21(1):3–7 (36 ref.)

NEUROMUSCULAR JUNCTION

see related
NEUROMUSCULAR BLOCKING AGENTS
NEUROMUSCULAR DEPOLARIZING AGENTS
RECEPTORS, CHOLINERGIC

DRUG EFFECTS

The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Eriksson LI. **Anesth Analg** 1999 Jul;89(1):243–51 (67 ref.)
Concurrent medication and the neuromuscular junction. Haywood PT, et al. **Eur J Anaesthesiol** 1999 Feb; 16(2):77–91 (139 ref.)
Neuromuscular toxicity of anticholinesterase agents. Chang CC. **J Toxicol Sci** 1998 Jul;23 Suppl 2:117–21 (18 ref.)

ENZYMOLOGY

Acetylcholinesterase in the neuromuscular junction. Gaspersic R, et al. **Chem Biol Interact** 1999 May 14; 119–120:301–8 (42 ref.)

GROWTH & DEVELOPMENT

Development of the vertebrate neuromuscular junction. Sanes JR, et al. **Annu Rev Neurosci** 1999;22:389–442 (332 ref.)
Clinical uses and controversies of neuromuscular blocking agents in infants and children. Martin LD, et al. **Crit Care Med** 1999 Jul;27(7):1358–68 (128 ref.)
Development of larval body wall muscles. Bate M, et al. **Int Rev Neurobiol** 1999;43:25–44 (73 ref.)
Early development of the Drosophila neuromuscular junction: a model for studying neuronal networks in development. Chiba A. **Int Rev Neurobiol** 1999;43:1–24 (104 ref.)
Development of the adult neuromuscular system. Fernandes JJ, et al. **Int Rev Neurobiol** 1999;43:221–39 (89 ref.)
Assembly and maturation of the Drosophila larval neuromuscular junction. Gramates SL, et al. **Int Rev Neurobiol** 1999;43:93–117 (108 ref.)
Ultrastructural correlates of neuromuscular junction development. Rheuben MB, et al. **Int Rev Neurobiol** 1999; 43:69–92 (51 ref.)

METABOLISM

Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Tzartos SJ, et al. **Immunol Rev** 1998 Jun; 163:89–120 (239 ref.)
Mechanisms of neurotransmitter release. Littleton JT, et al. **Int Rev Neurobiol** 1999;43:139–61 (94 ref.)
Processing of ARIA and release from isolated nerve terminals. Han B, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):411–6 (39 ref.)

PATHOLOGY

[Myasthenia gravis with electrophysiological features of Lambert-Eaton myasthenic syndrome: usefulness of serum autoantibodies assay and neuromuscular junction biopsy] Matsumoto R, et al. **Rinsho Shinkeigaku** 1999 May; 39(5):531–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Formation of the neuromuscular junction: molecules and mechanisms. Meier T, et al. **Bioessays** 1998 Oct; 20(10):819–29 (83 ref.)
Modulation of vertebrate and invertebrate neuromuscular junctions. Worden MK. **Curr Opin Neurobiol** 1998 Dec; 8(6):740–5 (47 ref.)
Neurotrophic factors: effects in modulating properties of the neuromuscular endplate. Sendtner M. **Cytokine Growth Factor Rev** 1998 Mar;9(1):1–7 (51 ref.)
Development of electrical properties and synaptic transmission at the embryonic neuromuscular junction. Broadie KS. **Int Rev Neurobiol** 1999;43:45–67 (39 ref.)
Second messenger systems underlying plasticity at the neuromuscular junction. Hannan F, et al. **Int Rev Neurobiol** 1999;43:119–38 (108 ref.)
Ionic currents in larval muscles of Drosophila. Singh S, et al. **Int Rev Neurobiol** 1999;43:191–220 (118 ref.)
Vesicle recycling at the Drosophila neuromuscular junction. Stimson DT, et al. **Int Rev Neurobiol** 1999;43:163–89 (118 ref.)
Strength of synaptic transmission at neuromuscular junctions of crustaceans and insects in relation to calcium entry. Atwood HL, et al. **Invert Neurosci** 1997 Sep-Dec; 3(2–3):81–7 (39 ref.)
Neuromuscular glutamatergic and GABAergic channels. Dudel J, et al. **Invert Neurosci** 1997 Sep-Dec;3(2–3):89–92 (26 ref.)
Orderly recruitment among motoneurons supplying different muscles. Cope TC, et al. **J Physiol Paris** 1999 Jan-Apr; 93(1–2):81–5 (26 ref.)
Early days in the research to localize skeletal muscle acetylcholinesterases. Couteaux R. **J Physiol Paris** 1998 Apr;92(2):59–62 (26 ref.)
The Schwann cell at the neuromuscular junction. Koenig J, et al. **J Physiol Paris** 1998 Jun-Aug;92(3–4):153–5 (15 ref.)
Targeting acetylcholinesterase molecules to the neuromuscular synapse. Rotundo RL, et al. **J Physiol Paris** 1998 Jun-Aug;92(3–4):195–8 (23 ref.)
Development of the neuromuscular junction: genetic analysis in mice. Sanes JR, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3–4):167–72 (26 ref.)
Sympathetic neuromuscular transmission at a varicosity in a syncytium. Bennett MR, et al. **Microsc Res Tech** 1998 Sep 15;42(6):433–50 (59 ref.)
Activity and synaptic receptor targeting: the long view. Craig AM. **Neuron** 1998 Sep;21(3):459–62 (20 ref.)

NEUROMUSCULAR JUNCTION

Learning something ORIGINal at the Drosophila neuromuscular junction [comment] DiAntonio A. **Neuron** 1999 May;23(1):1-2 (10 ref.) Comment on: Neuron 1999 May;23(1):45-54.

Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction. Ruegg MA, et al. **Trends Neurosci** 1998 Jan;21(1):22-7 (74 ref.)

[Desensitizing function of calcium mobilized by the postsynaptic neuronal-type nicotinic acetylcholine receptors at the neuromuscular junction] Kimura I, et al. **Yakugaku Zasshi** 1999 Jan;119(1):1-15 (55 ref.) (Eng. Abstr.) **(Jpn)**

[Modulating role of ATP in the neuromuscular junction] Giniatullin RA, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):1132-8 (41 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Disorders of neuromuscular junction ion channels. Boonyapisit K, et al. **Am J Med** 1999 Jan;106(1):97-113 (180 ref.)

SECRETION

Processing of ARIA and release from isolated nerve terminals. Han B, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):411-6 (39 ref.)

ULTRASTRUCTURE

Ultrastructural correlates of neuromuscular junction development. Rheuben MB, et al. **Int Rev Neurobiol** 1999; 43:69-92 (51 ref.)

NEUROMUSCULAR NONDEPOLARIZING AGENTS

see related
NICOTINIC ANTAGONISTS

[The use of curare-like agents in resuscitation] Suppini A, et al. **Ann Fr Anesth Reanim** 1999 Mar;18(3):341-54 (142 ref.) (Eng. Abstr.) **(Fre)**

[New curare agents in pediatric anesthesia] Guberti A, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):53-7 (25 ref.) **(Ita)**

[New muscle relaxants] Suzuki F. **Masui** 1998 Dec;47 Suppl:S113-7 (13 ref.) **(Jpn)**

PHARMACOKINETICS

Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Atherton DP, et al. **Clin Pharmacokinet** 1999 Mar;36(3):169-89 (118 ref.)

PHARMACOLOGY

[What are the indications and what are the modalities of sedation and curarization except for the specific treatment of intracranial hypertension?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):79-84 (28 ref.) **(Fre)**

NEUROMYELITIS OPTICA

PATHOLOGY

Devic's neuromyelitis optica: a clinicopathological review of the literature in connection with a case showing fatal dysautonomia. Baudoin D, et al. **Clin Neuropathol** 1998 Jul-Aug;17(4):175-83 (40 ref.)

NEURON DEGENERATION see **NERVE DEGENERATION**

NEURON-GLIA ADHESION MOLECULES see **CELL ADHESION MOLECULES, NEURON-GLIA**

NEURON-GLIA CELL ADHESION MOLECULES see **CELL ADHESION MOLECULES, NEURON-GLIA**

NEURON-SPECIFIC ENOLASE see **PHOSPHOPYRUVATE HYDRATASE**

NEURONAL CELL ADHESION MOLECULES see **CELL ADHESION MOLECULES, NEURONAL**

NEURONAL CEROID-LIPOFUSCINOSIS

[Neuronal ceroid lipofuscinosis] Inoue Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):171-6 (15 ref.) **(Jpn)**

CLASSIFICATION

Paul Dyken Lecture of the Southern Pediatric Neurology Society. Inherited neurodegenerative disease: the evolution of our thinking. Percy AK. **J Child Neurol** 1999 Apr; 14(4):256-62 (32 ref.)

COMPLICATIONS

The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Weleber RG. **Eye** 1998;12 (Pt 3b):580-90 (54 ref.)

ENZYMOLOGY

Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5. Mole SE, et al. **Hum Mutat** 1999;14(3):199-215 (81 ref.)

GENETICS

Molecular genetics of the neuronal ceroid lipofuscinoses. Mole S, et al. **Epilepsia** 1999;40 Suppl 3:29-32 (21 ref.)

The neuronal ceroid-lipofuscinoses (Batten disease): a new class of lysosomal storage diseases. Bennett MJ, et al. **J Inherit Metab Dis** 1999 Jun;22(4):535-44 (46 ref.)

Batten disease: four genes and still counting. Mole SE. **Neurobiol Dis** 1998 Nov;5(5):287-303 (150 ref.)

PATHOLOGY

Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview. Birch DG. **Mol Genet Metab** 1999 Apr;66(4):356-66 (27 ref.)

Progress in neuropathology of the neuronal ceroid lipofuscinoses. Goebel HH, et al. **Mol Genet Metab** 1999 Apr;66(4):367-72 (29 ref.)

NEURONAL PLASTICITY

The subependymal layer in rodents: a site of structural plasticity and cell migration in the adult mammalian brain. Peretto P, et al. **Brain Res Bull** 1999 Jul 1;49(4):221-43 (184 ref.)

The relationship between adhesion molecules and neuronal plasticity. Hoffman KB. **Cell Mol Neurobiol** 1998 Oct; 18(5):461-75 (126 ref.)

Topographic maps: developing roles of synaptic plasticity. Cline HT. **Curr Biol** 1998 Nov 19;8(23):R836-9 (21 ref.)

Plasticity and stem cells in the vertebrate nervous system. Panchision D, et al. **Curr Opin Cell Biol** 1998 Dec; 10(6):727-33 (75 ref.)

Roles of neurotrophins on synaptic development and functions in the central nervous system. Takei N, et al. **Hum Cell** 1998 Sep;11(3):157-65 (64 ref.)

Plasticity of feedback inputs in the apteronotid electrosensory system. Bastian J. **J Exp Biol** 1999 May;202 (Pt 10):1327-37 (41 ref.)

Synaptic plasticity in the mormyrid electrosensory lobe. Bell CC, et al. **J Exp Biol** 1999 May;202 (Pt 10):1339-47 (26 ref.)

Establishment and plasticity of neuronal polarity. Mattson MP. **J Neurosci Res** 1999 Sep 1;57(5):577-89 (51 ref.)

The molecular basis for electrogenic computation in the brain: you can't step in the same river twice. Waxman SG. **Mol Psychiatry** 1999 May;4(3):222-8 (45 ref.)

Roger Sperry and his chemoaffinity hypothesis. Meyer RL. **Neuropsychologia** 1998 Oct;36(10):957-80 (166 ref.)

Rehabilitation of brain damage: brain plasticity and principles of guided recovery. Robertson IH, et al. **Psychol Bull** 1999 Sep;125(5):544-75 (263 ref.)

Spinal cord injury in small animals. 1. Mechanisms of spontaneous recovery. Jeffery ND, et al. **Vet Rec** 1999 Apr 10;144(15):407-13 (81 ref.)

DRUG EFFECTS

Steroid-induced developmental plasticity in hypothalamic astrocytes: implications for synaptic patterning. Mong JA, et al. **J Neurobiol** 1999 Sep 15;40(4):602-19 (153 ref.)

[Is there solid evidence for reorganization of the neural network associated with development of behavioral sensitization to psychostimulants?] Ujike H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Apr; 19(2):47-52 (30 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Immediate-early genes and synaptic function. Lanahan A, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):37-43 (34 ref.)

Molecular, cellular, and neuroanatomical substrates of place learning. Silva AJ, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):44-61 (84 ref.)

[Structure and function of neural plasticity-related gene products] Yamagata K, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):133-6 (9 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Schizophrenia and the disconnection hypothesis. Friston KJ. **Acta Psychiatr Scand Suppl** 1999;395:68-79 (49 ref.)

Bioactive lipids and gene expression in neuronal plasticity. Bazan NG. **Adv Exp Med Biol** 1998;446:37-49 (70 ref.)

Surface protein phosphorylation by ecto-protein kinases. Role in neuronal development and synaptic plasticity. Ehrlich YH, et al. **Adv Exp Med Biol** 1998;446:51-71 (85 ref.)

Metabotropic glutamate receptors in the plasticity of excitatory responses in the hippocampus. Clinical impact. Merlin LR. **Adv Exp Med Biol** 1998;446:131-44 (70 ref.)

Avian hippocampus as a model to study spatial orientation-related synaptic plasticity. Wieraszko A. **Adv Exp Med Biol** 1998;446:107-29 (150 ref.)

Corticothalamic networks, oscillations, and plasticity. Steriade M. **Adv Neurol** 1998;77:105-34 (91 ref.)

Neurotrophins and synaptic plasticity. McAllister AK, et al. **Annu Rev Neurosci** 1999;22:295-318 (192 ref.)

Stress and hippocampal plasticity. McEwen BS. **Annu Rev Neurosci** 1999;22:105-22 (111 ref.)

Neural plasticity and the development of sex differences. Juraska JM. **Annu Rev Sex Res** 1998;9:2?-38 (61 ref.)

Mechanisms of axonal plasticity. Strata P, et al. **Arch Ital Biol** 1999 May;137(2-3):181-92 (58 ref.)

Rattlesnake hunting behavior: correlations between plasticity of predatory performance and neuroanatomy. Kardong KV, et al. **Brain Behav Evol** 1999;53(1):20-8 (83 ref.)

Establishment and properties of neural stem cell clones: plasticity in vitro and in vivo. Vescovi AL, et al. **Brain Pathol** 1999 Jul;9(3):569-98 (143 ref.)

DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Nestler EJ, et al. **Brain Res** 1999 Jul 17;835(1):10-7 (38 ref.)

Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Anwyl R. **Brain Res Brain Res Rev** 1999 Jan;29(1):83-120 (349 ref.)

Neuronal plasticity: adaptation and readaptation to the environment of space. Correia MJ. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):61-5 (25 ref.)

Post-spaceflight orthostatic intolerance: possible relationship to microgravity-induced plasticity in the vestibular system. Yates BJ, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):73-82 (61 ref.)

A molecular biological approach to synaptic plasticity and learning. Davis S, et al. **C R Acad Sci III** 1998 Feb-Mar; 321(2-3):97-107 (109 ref.)

Quantal analysis and long-term potentiation. Korn H, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):125-30 (48 ref.)

A genetic switch for long-term memory. Pittenger C, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):91-6 (36 ref.)

Neuromodulation, development and synaptic plasticity. Foehring RC, et al. **Can J Exp Psychol** 1999 Mar; 53(1):45-61 (125 ref.)

The first panic attack: a neurobiological theory. Jacobs WJ, et al. **Can J Exp Psychol** 1999 Mar;53(1):92-107 (148 ref.)

Ontogenetic constraints on neural and behavioral plasticity: evidence from imprinting and face processing. Johnson MH. **Can J Exp Psychol** 1999 Mar;53(1):77-91 (81 ref.)

Synaptic plasticity and the organization of behaviour after early and late brain injury. Kolb B. **Can J Exp Psychol** 1999 Mar;53(1):62-76 (63 ref.)

Ca2+ and synaptic plasticity. Chittajallu R, et al. **Cell Calcium** 1998 Nov-Dec;24(5-6):377-85 (79 ref.)

Environmental influences on neural plasticity, the limbic system, emotional development and attachment: a review. Joseph R. **Child Psychiatry Hum Dev** 1999 Spring; 29(3):189-208 (97 ref.)

Synaptic plasticity: regulated translation in dendrites. Huang EP. **Curr Biol** 1999 Mar 11;9(5):R168-70 (14 ref.)

Synaptic plasticity: step-wise strengthening. Murthy VN. **Curr Biol** 1998 Sep 10;8(18):R650-3 (9 ref.)

Molecular mechanisms of synaptic plasticity and memory. Elgersma Y, et al. **Curr Opin Neurobiol** 1999 Apr; 9(2):209-13 (43 ref.)

Structure, development, and plasticity of dendritic spines. Harris KM. **Curr Opin Neurobiol** 1999 Jun;9(3):343-8 (63 ref.)

Synaptic plasticity in cortical systems. Klintsova AY, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):203-8 (79 ref.)

Calcium- and activity-dependent synaptic plasticity. Zucker RS. **Curr Opin Neurobiol** 1999 Jun;9(3):305-13 (104 ref.)

Lesion-induced plasticity as a potential mechanism for recovery and rehabilitative training. Witte OW. **Curr Opin Neurol** 1998 Dec;11(6):655-62 (120 ref.)

Neural plasticity and emotional memory. Post RM, et al. **Dev Psychopathol** 1998 Fall;10(4):829-55 (112 ref.)

Imaging recovery from stroke. Weiller C. **Exp Brain Res** 1998 Nov;123(1-2):13-7 (51 ref.)

The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Rønn LC, et al. **Exp Gerontol** 1998 Nov-Dec;33(7-8):853-64 (99 ref.)

Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Woolley CS. **Horm Behav** 1998 Oct;34(2):140-8 (47 ref.)

Insulin-like growth factors as mediators of functional plasticity in the adult brain. Torres-Aleman I. **Horm Metab Res** 1999 Feb-Mar;31(2-3):114-9 (66 ref.)

Plasticity-related serine proteases in the brain (review). Yoshida S, et al. **Int J Mol Med** 1999 Apr;3(4):405-9 (55 ref.)

Second messenger systems underlying plasticity at the neuromuscular junction. Hannan F, et al. **Int Rev Neurobiol** 1999;43:119-38 (108 ref.)

Drosophila melanogaster as a model system for the study of the function of calcium/calmodulin-dependent protein kinase II in synaptic plasticity. Griffith LC. **Invert Neurosci** 1997 Sep-Dec;3(2-3):93-102 (72 ref.)

Studies of neuroplasticity with transcranial magnetic stimulation. Cohen LG, et al. **J Clin Neurophysiol** 1998 Jul;15(4):305-24 (215 ref.)

Role of astroglia in estrogen regulation of synaptic plasticity and brain repair. Garcia-Segura LM, et al. **J Neurobiol** 1999 Sep 15;40(4):574-84 (99 ref.)

From cortical plasticity to unawareness of visual field defects. Safran AB, et al. **J Neuroophthalmol** 1999 Jun;19(2):84-8 (31 ref.)

Some cholinergic themes related to Alzheimer's disease: synaptology of the nucleus basalis, location of m2 receptors,

interactions with amyloid metabolism, and perturbations of cortical plasticity. Mesulam MM. **J Physiol Paris** 1998 Jun-Aug;92(3-4):293-8 (56 ref.)
Cellular mechanisms of visual cortical plasticity: a game of cat and mouse. Gordon JA. **Learn Mem** 1997 Sep-Oct; 4(3):245-61 (113 ref.)
Interactions between depression and facilitation within neural networks: updating the dual-process theory of plasticity. Prescott SA. **Learn Mem** 1998 Nov-Dec;5(6):446-66 (134 ref.)
Regulation of neuronal plasticity in the central nervous system by phosphorylation and dephosphorylation. Tokuda M, et al. **Mol Neurobiol** 1998 Winter;17(1-3):137-56 (131 ref.)
Integrated regulation of signal coding and plasticity by NMDA receptors at a central synapse. D'Angelo E, et al. **Neural Plast** 1998 Jul-Sep;6(3):8-16 (38 ref.)
Synaptic plasticity and learning and memory: 15 years of progress. Baudry M. **Neurobiol Learn Mem** 1998 Jul-Sep; 70(1-2):113-8 (19 ref.)
Contributions of cell adhesion molecules to altered synaptic weightings during memory consolidation. Murphy KJ, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):73-81 (35 ref.)
Physiological memory in primary auditory cortex: characteristics and mechanisms. Weinberger NM. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):226-51 (81 ref.)
Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Impey S, et al. **Neuron** 1999 May; 23(1):11-4 (21 ref.)
The return of the spike: postsynaptic action potentials and the induction of LTP and LTD. Linden DJ. **Neuron** 1999 Apr;22(4):661-6 (54 ref.)
CREB can get you depressed [comment] Siegelbaum SA. **Neuron** 1999 Jul;23(3):414-5 (8 ref.) Comment on: Neuron 1999 Jul;23(3):559-68.
Hippocampal contributions to cortical plasticity. Nadel L, et al. **Neuropharmacology** 1998 Apr-May;37(4-5):431-9 (41 ref.)
Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Azmitia EC. **Neuropsychopharmacology** 1999 Aug; 21(2 Suppl):33S-45S (137 ref.)
Neuroanatomy, circuitry and plasticity of word reading. Posner MI, et al. **Neuroreport** 1999 Feb 25;10(3):R12-23 (88 ref.)
Synaptic plasticity in the hippocampus during afferent activation reproducing the pattern of the theta rhythm (theta plasticity). Kleshchevnikov AM. **Neurosci Behav Physiol** 1999 Mar-Apr;29(2):185-96 (76 ref.)
Neurobiology of mother-infant interactions: experience and central nervous system plasticity across development and generations. Fleming AS, et al. **Neurosci Biobehav Rev** 1999 May;23(5):673-85 (106 ref.)
Stress, glucocorticoids and structural plasticity of the hippocampus. Fuchs E, et al. **Neurosci Biobehav Rev** 1998; 23(2):295-300 (77 ref.)
Synaptic PDZ domain-containing proteins. Hata Y, et al. **Neurosci Res** 1998 Sep;32(1):1-7 (65 ref.)
Primitivism and plasticity of pain--implication of polymodal receptors. Kumazawa T. **Neurosci Res** 1998 Sep;32(1):9-31 (218 ref.)
Immediate and long-term plasticity in human somatosensory thalamus and its involvement in phantom limbs. Dostrovsky JO. **Pain** 1999 Aug;Suppl 6:S37-43 (28 ref.)
From electrical wiring to plastic neurons: evolving approaches to the study of pain. Jabbur SJ, et al. **Pain** 1999 Aug;Suppl 6:S87-92 (49 ref.)
Is most of neural plasticity in the thalamus cortical? [comment] Kaas JH. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7622-3 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8200-5.
Monocular focal retinal lesions induce short-term topographic plasticity in adult cat visual cortex. Calford MB, et al. **Proc R Soc Lond B Biol Sci** 1999 Mar 7; 266(1418):499-507 (37 ref.)
Nonsynaptic diffusion neurotransmission and some other emerging concepts. Bach-y-Rita P. **Proc West Pharmacol Soc** 1998;41:211-8 (89 ref.)
The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Bazan NG. **Prog Brain Res** 1998; 118:281-91 (42 ref.)
Synaptic plasticity in ischemia: role of NMDA receptors. Crépel V, et al. **Prog Brain Res** 1998;116:273-85 (110 ref.)
Semaphorin III: role in neuronal development and structural plasticity. Giger RJ, et al. **Prog Brain Res** 1998;117:133-49 (43 ref.)
Instructive roles of neurotrophins in synaptic plasticity. Lo DC. **Prog Brain Res** 1998;117:65-70 (27 ref.)
Learning-induced physiological plasticity in the thalamo-cortical sensory systems: a critical evaluation of receptive field plasticity, map changes and their potential mechanisms. Edeline JM. **Prog Neurobiol** 1999 Feb; 57(2):165-224 (369 ref.)
Correlations between electrophysiological observations of synaptic plasticity modifications and behavioral performance in mammals. Roman FS, et al. **Prog Neurobiol** 1999 May;58(1):61-87 (175 ref.)
Plasticity in the tectum of Xenopus laevis: binocular maps. Udin SB, et al. **Prog Neurobiol** 1999 Oct;59(2):81-106 (162 ref.)
Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. van der Zee EA, et al. **Prog Neurobiol** 1999 Aug;58(5):409-71 (620 ref.)
Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Klann E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):359-76 (94 ref.)
Potential circuit mechanisms underlying concurrent thalamic and cortical plasticity. Nicolelis MA, et al. **Rev Neurosci** 1998 Jul-Dec;9(3):213-24 (41 ref.)
FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? Girault JA, et al. **Trends Neurosci** 1999 Jun;22(6):257-63 (100 ref.)
Recognition of slow processes in rhythmic networks. Golowasch J, et al. **Trends Neurosci** 1999 Sep;22(9):375-7 (24 ref.)
Glutamatergic synapses onto hippocampal interneurons: precision timing without lasting plasticity. McBain CJ, et al. **Trends Neurosci** 1999 May;22(5):228-35 (61 ref.)
A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Paulsen O, et al. **Trends Neurosci** 1998 Jul;21(7):273-8 (61 ref.)
Auditory cortical plasticity: a comparison with other sensory systems. Rauschecker JP. **Trends Neurosci** 1999 Feb; 22(2):74-80 (91 ref.)
Coherent oscillations and short-term plasticity in corticothalamic networks. Steriade M. **Trends Neurosci** 1999 Aug;22(8):337-45 (58 ref.)
Plasticity of the olivocerebellar pathway. Strata P, et al. **Trends Neurosci** 1998 Sep;21(9):407-13 (72 ref.)
Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Turrigiano GG. **Trends Neurosci** 1999 May;22(5):221-7 (58 ref.)
[Brief history of long-term synaptic depression of the cerebellum] Levenes C, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):109-19 (86 ref.) **(Fre)**
[Post-lesional plasticity of somatosensory cortex maps: a review] Xerri C. **C R Acad Sci III** 1998 Feb-Mar; 321(2-3):135-51 (113 ref.) **(Fre)**
[Brain plasticity during development: physiological bases and functional MRI approach] Hertz-Pannier L. **J Neuroradiol** 1999 Mar;26(1):S66-74 (62 ref.) (Eng. Abstr.) **(Fre)**
[Functional MRI: brain plasticity, brain disease and functional recovery] Lehéricy S, et al. **J Neuroradiol** 1999 Mar; 26(1):S75-81 (36 ref.) (Eng. Abstr.) **(Fre)**
[A functional role for PDZ proteins in synapse organization and synaptic plasticity] Inokuchi K. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1355-64 (49 ref.) **(Jpn)**
[Long-term depression of synaptic transmission] Shibuki K. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1849-54 (45 ref.) **(Jpn)**

NEURONS

see related

NEURAL CONDUCTION

Finding a partner in a crowd: neuronal diversity and synaptogenesis. Serafini T. **Cell** 1999 Jul 23;98(2):133-6 (20 ref.)
The right neuron at the wrong place: biology of heterotopic neurons in cortical neuronal migration disorders, with special reference to associated pathologies. Chevassus-au-Louis N, et al. **Cell Mol Life Sci** 1999 Aug 15;55(10):1206-15 (111 ref.)
Neuronal diversity: too many cell types for comfort? Stevens CF. **Curr Biol** 1998 Oct 8;8(20):R708-10 (7 ref.)
Neuronal migration disorders. Part I: Terminology, classification, pathophysiology, EEG and epilepsy. Turanli G, et al. **Turk J Pediatr** 1998 Oct-Dec;40(4):473-80 (26 ref.)

CHEMISTRY

The bacterial K+ channel structure and its implications for neuronal channels. Yellen G. **Curr Opin Neurobiol** 1999 Jun;9(3):267-73 (52 ref.)
A new approach to estimate the number, density and variability of receptors at central synapses. Nusser Z. **Eur J Neurosci** 1999 Mar;11(3):745-52 (52 ref.)
The presence, origin, and significance of A beta peptide in the cell bodies of neurons. Rosenblum WI. **J Neuropathol Exp Neurol** 1999 Jun;58(6):575-81 (58 ref.)
Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Pertwee RG. **Life Sci** 1999;65(6-7):597-605 (54 ref.)
Distribution and functional anatomy of amine-containing neurons in decapod crustaceans. Beltz BS. **Microsc Res Tech** 1999 Jan 15-Feb 1;44(2-3):105-20 (94 ref.)
Cytoarchitecture of histamine-, dopamine-, serotonin- and octopamine-containing neurons in the cricket ventral nerve cord. Hörner M. **Microsc Res Tech** 1999 Jan 15-Feb 1; 44(2-3):137-65 (155 ref.)
Biogenic amine systems in the fruit fly Drosophila melanogaster. Monastirioti M. **Microsc Res Tech** 1999 Apr 15;45(2):106-21 (90 ref.)
Octopamine in the locust brain: cellular distribution and functional significance in an arousal mechanism. Stern M. **Microsc Res Tech** 1999 May 1;45(3):135-41 (41 ref.)
GABA and serotonin immunoreactivity during postembryonic brain development in the beetle Tenebrio molitor. Wegerhoff R. **Microsc Res Tech** 1999 May 1; 45(3):154-64 (55 ref.)
Subcellular localization of mRNA in neuronal cells. Contributions of high-resolution in situ hybridization techniques. Martone ME, et al. **Mol Neurobiol** 1998 Dec; 18(3):227-46 (122 ref.)
Modulation of ion channels: a "current" view of AKAPs. Fraser ID, et al. **Neuron** 1999 Jul;23(3):423-6 (20 ref.)
The diversity of cadherins and implications for a synaptic adhesive code in the CNS. Shapiro L, et al. **Neuron** 1999 Jul;23(3):427-30 (20 ref.)
Spatial distribution of NA+ and K+ channels in spinal dorsal horn neurones: role of the soma, axon and dendrites in spike generation. Safronov BV. **Prog Neurobiol** 1999 Oct; 59(3):217-41 (125 ref.)
Neuronal chemistry and functional organization in the primate visual system. Hendry SH, et al. **Trends Neurosci** 1998 Aug;21(8):344-9 (82 ref.)
Low-voltage-activated (T-type) calcium-channel genes identified. Huguenard JR. **Trends Neurosci** 1998 Nov; 21(11):451-2 (36 ref.)
[Chemical neuroanatomy of cholinergic neurons] Kimura H, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1005-8 (8 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Futerman AH. **Acta Biochim Pol** 1998;45(2):469-78 (33 ref.)
Untying the Gordian knot: contemporary studies of neuronal organization. Ralston HJ 3rd. **Anat Rec** 1998 Oct; 253(5):139-42 (17 ref.)
VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Brenneman DE, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:207-12 (24 ref.)
Deconstructing cell determination: proneural genes and neuronal identity. Brunet JF, et al. **Bioessays** 1999 Apr; 21(4):313-8 (39 ref.)
Origins, functions, and potential of adult neural stem cells. Kuhn HG, et al. **Bioessays** 1999 Aug;21(8):625-30 (50 ref.)
Building brains: neural chimeras in the study of nervous system development and repair. Brüstle O. **Brain Pathol** 1999 Jul;9(3):527-45 (152 ref.)
Genetic regulatory elements introduced into neural stem and progenitor cell populations. Foster GA, et al. **Brain Pathol** 1999 Jul;9(3):547-67 (215 ref.)
Human neural stem cells: isolation, expansion and transplantation. Svendsen CN, et al. **Brain Pathol** 1999 Jul; 9(3):499-513 (93 ref.)
Establishment and properties of neural stem cell clones: plasticity in vitro and in vivo. Vescovi AL, et al. **Brain Pathol** 1999 Jul;9(3):569-98 (143 ref.)
Neuromodulation, development and synaptic plasticity. Foehring RC, et al. **Can J Exp Psychol** 1999 Mar; 53(1):45-61 (125 ref.)
A new role for glia: generation of neurons! Barres BA. **Cell** 1999 Jun 11;97(6):667-70 (23 ref.)
Apoptosis and cell death in neuronal cells: where does Ca2+ fit in? Toescu EC. **Cell Calcium** 1998 Nov-Dec; 24(5-6):387-403 (84 ref.)
Transglutaminase-catalyzed protein cross-linking in the molecular program of apoptosis and its relationship to neuronal processes. Fesus L. **Cell Mol Neurobiol** 1998 Dec; 18(6):683-94 (68 ref.)
Development of the cholinergic neurotransmitter phenotype in postganglionic sympathetic neurons. Ernsberger U, et al. **Cell Tissue Res** 1999 Sep;297(3):339-61 (137 ref.)
Stem cells and neurogenesis in the adult brain. Cameron HA, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):677-80 (45 ref.)
Stem cells of the central nervous system. Gage FH. **Curr Opin Neurobiol** 1998 Oct;8(5):671-6 (35 ref.)
Optical detection of synaptic vesicle exocytosis and endocytosis. Murthy VN. **Curr Opin Neurobiol** 1999 Jun; 9(3):314-20 (51 ref.)
N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Clark JB. **Dev Neurosci** 1998; 20(4-5):271-6 (34 ref.)
HIF-1alpha and p53 promote hypoxia-induced delayed neuronal death in models of CNS ischemia. Halterman MW, et al. **Exp Neurol** 1999 Sep;159(1):65-72 (65 ref.)
Mitotic neurons: a dogma succumbs [comment] Raina AK, et al. **Exp Neurol** 1999 Sep;159(1):248-9 (19 ref.) Comment on: Exp Neurol 1999 Sep;159(1):237-47.
Visualization of neuronal form and function in brain slices by infrared videomicroscopy. Dodt HU, et al. **Histochem J** 1998 Mar;30(3):141-52 (45 ref.)
Distribution of central catecholaminergic neurons: a comparison between ungulates, humans and other species. Tillet Y, et al. **Histol Histopathol** 1998 Oct;13(4):1163-77 (74 ref.)
Neurogenesis, cell death and regeneration in the adult gymnotiform brain. Zupanc GK. **J Exp Biol** 1999 May;202 (Pt 10):1435-46 (111 ref.)
Neural stem cells: from fly to vertebrates. Doe CQ, et al. **J Neurobiol** 1998 Aug;36(2):111-27 (119 ref.)
Role of cell-cell interactions in the developmental regulation of Ca2+-activated K+ currents in vertebrate neurons. Dryer SE. **J Neurobiol** 1998 Oct;37(1):23-36 (65 ref.)

NEURONS

Architecture and cell types of the adult subventricular zone: in search of the stem cells. García-Verdugo JM, et al. **J Neurobiol** 1998 Aug;36(2):234–48 (119 ref.)

Establishment and plasticity of neuronal polarity. Mattson MP. **J Neurosci Res** 1999 Sep 1;57(5):577–89 (51 ref.)

In vitro central nervous system models of mechanically induced trauma: a review. Morrison B 3rd, et al. **J Neurotrauma** 1998 Nov;15(11):911–28 (137 ref.)

Generation and regulation of developing immortalized neural cell lines. Gökhan S, et al. **Methods** 1998 Nov;16(3):345–58 (64 ref.)

Neurotrophins and other growth factors in the generation of retinal neurons. Frade JM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):243–51 (72 ref.)

Neurotrophins, nociceptors, and pain. Mendell LM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):252–61 (99 ref.)

Interaction of neurotrophins and retinoic acid in neuronal differentiation. Cheung WM, et al. **Mol Cells** 1998 Aug 31;8(4):496–502 (74 ref.)

"Turning brain into blood"—clinical applications of stem-cell research in neurobiology and hematology. Moore MA. **N Engl J Med** 1999 Aug 19;341(8):605–7 (8 ref.)

The G1 restriction point as critical regulator of neocortical neuronogenesis. Caviness VS Jr, et al. **Neurochem Res** 1999 Apr;24(4):497–506 (69 ref.)

Neuronal cell death during sexual differentiation and lateralisation of vocal communication. Holman SD. **Neurosci Biobehav Rev** 1998 Oct;22(6):725–34 (94 ref.)

Neural cells derived by in vitro differentiation of P19 and embryonic stem cells. Bain G, et al. **Perspect Dev Neurobiol** 1998;5(2–3):175–8 (15 ref.)

GABA-immunoreactive cells of the cortical primordium contribute to distinctly fated neuronal populations. Fairén A, et al. **Perspect Dev Neurobiol** 1998;5(2–3):159–73 (93 ref.)

Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)

Neuronal cell death: an updated view. Rubin LL. **Prog Brain Res** 1998;117:3–8 (26 ref.)

Cellular activation in neuroregeneration. Schwaiger FW, et al. **Prog Brain Res** 1998;117:197–210 (129 ref.)

Corticosteroid hormones and neuronal vulnerability: towards identification of candidate vulnerability genes. Vreugdenhil E, et al. **Prog Brain Res** 1998;117:9–22 (92 ref.)

Apoptosis versus necrosis: the shape of neuronal cell death. Leist M, et al. **Results Probl Cell Differ** 1998;24:105–35 (273 ref.)

Prevention of neuronal cell death by Bcl-2. Tsujimoto Y. **Results Probl Cell Differ** 1998;24:137–55 (103 ref.)

New nerve cells for the adult brain. Kempermann G, et al. **Sci Am** 1999 May;280(5):48–53 (4 ref.)

Neuronal guidance. A genetic perspective. Tear G. **Trends Genet** 1999 Mar;15(3):113–8 (44 ref.)

Perspective: virus infections and the death of neurons. Griffin DE, et al. **Trends Microbiol** 1999 Apr;7(4):155–60 (44 ref.)

Perineuronal nets: past and present. Celio MR, et al. **Trends Neurosci** 1998 Dec;21(12):510–5 (162 ref.)

Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias [see comments] West MJ. **Trends Neurosci** 1999 Feb;22(2):51–61 (49 ref.) Comment in: Trends Neurosci 1999 Aug;22(8):345–6. Comment in: Trends Neurosci 1999 Aug;22(8):346–7.

DRUG EFFECTS

PACAP-38 protects cerebellar granule cells from apoptosis. Journot L, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:100–10 (53 ref.)

Sympathetic neurons of the chick embryo are rescued by PACAP from apoptotic death. Wakade AR, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:176–80 (20 ref.)

Neuronal excitotoxicity: the role of mitochondria. Nicholls DG, et al. **Biofactors** 1998;8(3–4):287–99 (64 ref.)

Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Grilli M, et al. **Cell Death Differ** 1999 Jan;6(1):22–7 (77 ref.)

Oxygen toxicity induces apoptosis in neuronal cells. Satoh T, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):649–66 (68 ref.)

Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Tredici G, et al. **Drugs Exp Clin Res** 1999;25(2–3):99–103 (21 ref.)

Leptin sensitive neurons in the hypothalamus. Baskin DG, et al. **Horm Metab Res** 1999 May;31(5):345–50 (83 ref.)

Role of NGF in axotomy-induced c-Jun expression in medial septal cholinergic neurons. Haas CA, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7–8):691–703 (103 ref.)

Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Mattson MP, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7–8):737–53 (99 ref.)

Excitotoxins in neuronal apoptosis and necrosis. Nicotera P, et al. **J Cereb Blood Flow Metab** 1999 Jun;19(6):583–91 (80 ref.)

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. Decker MW, et al. **J Physiol Paris** 1998 Jun-Aug;92(3–4):221–4 (17 ref.)

Effects of dietary polyunsaturated fatty acids on neuronal function. Fernstrom JD. **Lipids** 1999 Feb;34(2):161–9 (62 ref.)

Neuronal nicotinic acetylcholine receptors: a new target site of ethanol. Narahashi T, et al. **Neurochem Int** 1999 Aug; 35(2):131–41 (124 ref.)

Regulation of neuronal voltage-gated calcium channels by ethanol. Walter HJ, et al. **Neurochem Int** 1999 Aug; 35(2):95–101 (71 ref.)

Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death. Schröder HC, et al. **Neurotoxicology** 1998 Aug-Oct;19(4–5):683–8 (30 ref.)

Autoregulation of serotonin neurons: role in antidepressant drug action. Piñeyro G, et al. **Pharmacol Rev** 1999 Sep; 51(3):533–91 (787 ref.)

Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Corasaniti MT, et al. **Pharmacol Toxicol** 1998 Jul;83(1):1–7 (53 ref.)

Oxytocin and neuroadaptation to cocaine. Sarnyai Z. **Prog Brain Res** 1998;119:449–66 (72 ref.)

Effects of vasopressin and related peptides on neurons of the rat lateral septum and ventral hippocampus. Urban IJ. **Prog Brain Res** 1998;119:285–310 (168 ref.)

Neuronal nicotinic acetylcholine receptor modulation by general anesthetics. Flood P, et al. **Toxicol Lett** 1998 Nov 23;100–101:149–53 (26 ref.)

Interactions of excitatory neurotransmitters and xenobiotics in excitotoxicity and oxidative stress: glutamate and lead. Savolainen KM, et al. **Toxicol Lett** 1998 Dec 28; 102–103:363–7 (25 ref.)

ENZYMOLOGY

Neuronal NOS: gene structure, mRNA diversity, and functional relevance. Wang Y, et al. **Crit Rev Neurobiol** 1999;13(1):21–43 (124 ref.)

Brain protein serine/threonine phosphatases. Price NE, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):336–42 (68 ref.)

Localization of choline acetyltransferase-expressing neurons in Drosophila nervous system. Yasuyama K, et al. **Microsc Res Tech** 1999 Apr 15;45(2):65–79 (75 ref.)

Recent advances on neuronal caspases in development and neurodegeneration. Marks N, et al. **Neurochem Int** 1999 Sep;35(3):195–220 (271 ref.)

IMMUNOLOGY

Immunologic complexity in neurons. Darnell RB. **Neuron** 1998 Nov;21(5):947–50 (20 ref.)

[Mechanisms of paraneoplastic neurologic syndromes] Honnorat J, et al. **Rev Med Interne** 1999 Aug;20(8):670–80 (83 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons. Gainer H. **Adv Exp Med Biol** 1998; 449:15–27 (59 ref.)

Destruction of catecholamine-containing neurons by 6-hydroxydopa, an endogenous amine oxidase cofactor. Kostrzewa RM, et al. **Amino Acids** 1998;14(1–3):175–9 (21 ref.)

Following single cell dynamics with native fluorescence microscopy. Yeung ES. **Anal Chem** 1999 Aug 1; 71(15):522A–529A (50 ref.)

Molecular diversity of neuronal nicotinic acetylcholine receptors. McGehee DS. **Ann N Y Acad Sci** 1999 Apr 30; 868:565–77 (79 ref.)

Functional and molecular aspects of voltage-gated K+ channel beta subunits. Pongs O, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:344–55 (34 ref.)

The olfactory origin of luteinizing hormone-releasing hormone (LHRH) neurons. A new era in reproduction physiology. Daikoku S. **Arch Histol Cytol** 1999 May; 62(2):107–17 (65 ref.)

Membrane traffic in polarized neurons. Bradke F, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):245–58 (136 ref.)

Knockout of REST/NRSF shows that the protein is a potent repressor of neuronally expressed genes in non-neural tissues. Jones FS, et al. **Bioessays** 1999 May;21(5):372–6 (26 ref.)

Distribution of calbindin D-28k and parvalbumin neurons and fibers in the rat basal ganglia. Hontanilla B, et al. **Brain Res Bull** 1998 Sep 15;47(2):107–16 (85 ref.)

Selectivity in the distribution of glutamate receptors in neurons. Petralia RS, et al. **Cell Biol Int** 1998; 22(9–10):603–8 (36 ref.)

Structure and function of neuronal Ca2+ channels and their role in neurotransmitter release. Catterall WA. **Cell Calcium** 1998 Nov-Dec;24(5–6):307–23 (151 ref.)

Local Ca2+ signaling in neurons. Llinás R, et al. **Cell Calcium** 1998 Nov-Dec;24(5–6):359–66 (84 ref.)

Neuronal calcium stores. Verkhratsky AJ, et al. **Cell Calcium** 1998 Nov-Dec;24(5–6):333–43 (108 ref.)

Neuronal ion channel signalling pathways: modulation by angiotensin II. Sumners C, et al. **Cell Signal** 1998 May; 10(5):303–11 (109 ref.)

Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Braunewell KH, et al. **Cell Tissue Res** 1999 Jan;295(1):1–12 (129 ref.)

Expression of candidate pheromone receptor genes in vomeronasal neurons. Dulac C, et al. **Chem Senses** 1998 Aug;23(4):467–75 (44 ref.)

Clearance of glutamate inside the synapse and beyond. Bergles DE, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):293–8 (64 ref.)

Landmarks in the application of 13C-magnetic resonance spectroscopy to studies of neuronal/glial relationships. Bachelard H. **Dev Neurosci** 1998;20(4–5):277–88 (70 ref.)

Functional energy metabolism: in vivo 13C-NMR spectroscopy evidence for coupling of cerebral glucose consumption and glutamatergic neuronalactivity. Sibson NR, et al. **Dev Neurosci** 1998;20(4–5):321–30 (56 ref.)

Retrograde axonal transport of neurotrophins: differences between neuronal populations and implications for motor neuron disease. Bartlett SE, et al. **Immunol Cell Biol** 1998 Oct;76(5):419–23 (61 ref.)

The Brn-3a transcription factor. Latchman DS. **Int J Biochem Cell Biol** 1998 Nov;30(11):1153–7 (16 ref.)

Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy. Carlsson ML. **J Neural Transm** 1998; 105(4–5):525–35 (72 ref.)

Intracellular calcium regulation of channel and receptor expression in the plasmalemma: potential sites of sensitivity along the pathways linking transcription, translation, and insertion. Barish ME. **J Neurobiol** 1998 Oct;37(1):146–57 (101 ref.)

Ca2+ channel-regulated neuronal gene expression. Finkbeiner S, et al. **J Neurobiol** 1998 Oct;37(1):171–89 (130 ref.)

When, where, and how much? Expression of the Kv3.1 potassium channel in high-frequency firing neurons. Gan L, et al. **J Neurobiol** 1998 Oct;37(1):69–79 (44 ref.)

Dynamic regulation of K+ channel gene expression in differentiated cells. Levitan ES, et al. **J Neurobiol** 1998 Oct;37(1):60–8 (50 ref.)

Astrocytes: glutamate producers for neurons. Hertz L, et al. **J Neurosci Res** 1999 Aug 15;57(4):417–28 (133 ref.)

Acetylcholine release. Reconstitution of the elementary quantal mechanism. Israël M, et al. **J Physiol Paris** 1998 Apr;92(2):123–8 (35 ref.)

Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons. Hille B, et al. **Life Sci** 1995; 56(11–12):989–92 (34 ref.)

Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Hansen HS, et al. **Lipids** 1999;34 Suppl:S327–30 (37 ref.)

Nitrinergic neurons in the developing and adult human telencephalon: transient and permanent patterns of expression in comparison to other mammals. Judas M, et al. **Microsc Res Tech** 1999 Jun 15;45(6):401–19 (178 ref.)

FMRFamide neuropeptides and neuropeptide-associated enzymes in Drosophila. Taghert PH. **Microsc Res Tech** 1999 Apr 15;45(2):80–95 (75 ref.)

Synchronized neuronal networks: the GnRH system. Witkin JW. **Microsc Res Tech** 1999 Jan 1;44(1):11–8 (60 ref.)

Interaction of neurotrophins and retinoic acid in neuronal differentiation. Cheung WM, et al. **Mol Cells** 1998 Aug 31;8(4):496–502 (74 ref.)

Regulation of ion channel expression in neural cells by hormones and growth factors. Chew LJ, et al. **Mol Neurobiol** 1998 Dec;18(3):175–225 (374 ref.)

Angiotensin II type 1 receptor-modulated signaling pathways in neurons. Richards EM, et al. **Mol Neurobiol** 1999 Feb; 19(1):25–41 (117 ref.)

Pharmacologic and therapeutic aspects of the developmentally regulated expression of GABA(A) and GABA(B) receptors: cerebellar granule cells as a model system. Schousboe A. **Neurochem Int** 1999 May;34(5):373–7 (50 ref.)

Nomadic AMPA receptors and LTP [comment] Morales M, et al. **Neuron** 1999 Jul;23(3):431–4 (20 ref.) Comment on: Neuron 1998 Aug;21(2):267–70.

Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Hölscher C, et al. **Neurosci Biobehav Rev** 1999;23(3):399–410 (125 ref.)

Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Savolainen KM, et al. **Neurotoxicology** 1998 Aug-Oct; 19(4–5):669–74 (51 ref.)

Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation. Budd SL. **Pharmacol Ther** 1998 Nov;80(2):203–29 (179 ref.)

Monitoring neuronal NO release in vivo in cerebellum, thalamus and hippocampus. Vincent SR, et al. **Prog Brain Res** 1998;118:27–35 (91 ref.)

The organization and regulation of non-NMDA receptors in neurons. Wenthold RJ, et al. **Prog Brain Res** 1998; 116:133–52 (139 ref.)

The specification of neuronal identity by graded Sonic Hedgehog signalling. Briscoe J, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):353–62 (60 ref.)

Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Alkon DL, et al. **Trends Neurosci** 1998 Dec;21(12):529–37 (97 ref.)

Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Nataf S, et al. **Trends Neurosci** 1999 Sep; 22(9):397–402 (70 ref.)

[Mechanisms of selective vulnerability of cholinergic neurons to neurotoxic stimuli] Szutowicz A, et al. **Postepy Hig Med Dosw** 1999;53(2):263–75 (62 ref.) (Eng. Abstr.) **(Pol)**

[Alzheimer's disease and cellular membranes] Coria Balanzat

F. **Neurologia** 1998 Oct;13(8):395–9 (41 ref.) **(Spa)**

PATHOLOGY

Disturbance of endoplasmic reticulum functions: a key mechanism underlying cell damage? Paschen W, et al. **Acta Neurochir Suppl (Wien)** 1999;73:1–5 (54 ref.)

Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Sonsalla PK, et al. **Amino Acids** 1998;14(1–3):69–74 (13 ref.)

Cell biology of the hippocampal formation in schizophrenia. Weinberger DR. **Biol Psychiatry** 1999 Feb 15;45(4):395–402 (50 ref.)

The neuronal cytoskeleton in acute brain injury. Fitzpatrick MO, et al. **Br J Neurosurg** 1998 Aug;12(4):313–7 (37 ref.)

Neuronal death and survival in two models of hypoxic–ischemic brain damage. Walton M, et al. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):137–68 (388 ref.)

Multiple constraint organization in the brain: a theory for schizophrenia. Peled A. **Brain Res Bull** 1999 Jul 1; 49(4):245–50 (40 ref.)

Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia [see comments] Trojanowski JQ, et al. **Cell Death Differ** 1998 Oct;5(10):832–7 (64 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

Filamentous nerve cell inclusions in neurodegenerative diseases. Goedert M, et al. **Curr Opin Neurobiol** 1998 Oct; 8(5):619–32 (92 ref.)

Recent advances in research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutations: neuronal Lewy body–like hyaline inclusions and astrocytic hyaline inclusions. Kato S, et al. **Histol Histopathol** 1999 Jul;14(3):973–89 (113 ref.)

Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul;95(1–2):133–40 (58 ref.)

Disturbances of the functioning of endoplasmic reticulum: a key mechanism underlying neuronal cell injury? [see comments] Paschen W, et al. **J Cereb Blood Flow Metab** 1999 Jan;19(1):1–18 (188 ref.) Comment in: J Cereb Blood Flow Metab 1999 Jan;19(1):19–26.

HIV-1–induced neuronal injury in the developing brain. Epstein LG, et al. **J Leukoc Biol** 1999 Apr;65(4):453–7 (63 ref.)

Evolution of neuronal changes in the course of Alzheimer's disease. Braak H, et al. **J Neural Transm Suppl** 1998; 53:127–40 (55 ref.)

Mechanism and consequences of nerve cell death in Parkinson's disease. Hirsch EC. **J Neural Transm Suppl** 1999;56:127–37 (60 ref.)

Neurons and mechanisms of neuronal death in neurodegenerative diseases: a brief review. Waggie KS, et al. **Lab Anim Sci** 1999 Aug;49(4):358–62 (55 ref.)

The cell division cycle and the pathophysiology of Alzheimer's disease. Nagy Z, et al. **Neuroscience** 1998 Dec; 87(4):731–9 (79 ref.)

Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Cha JH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):981–9 (53 ref.)

Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha–synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101–18 (148 ref.)

The localization and interactions of huntingtin. Jones AL. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1021–7 (65 ref.)

[A process of programmed cell death as a mechanisms of neuronal death in prion diseases] Chrétien F, et al. **Clin Exp Pathol** 1999;47(3–4):181–91 (89 ref.) (Eng. Abstr.) **(Fre)**

[Cellular bases of neurodegenerative processes] Nieoullon A. **Therapie** 1998 Jan–Feb;53(1):21–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Neuronal death is basic problem of neurology and psychiatry] Zavalishin IA, et al. **Vestn Ross Akad Med Nauk** 1999;(1):28–33 (45 ref.) (Eng. Abstr.) **(Rus)**

[Factors that lead to death of neurons in neurodegenerative diseases] Pavón N, et al. **Rev Neurol** 1998 Apr; 26(152):554–60 (75 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Futerman AH. **Acta Biochim Pol** 1998;45(2):469–78 (33 ref.)

The neuronal basis of visual memory and imagery in the primate: a neurophysiological approach. Nakahara K, et al. **Adv Biophys** 1998;35:103–19 (43 ref.)

Electrophysiological distinctions between oxytocin and vasopressin neurons in the supraoptic nucleus. Armstrong WE, et al. **Adv Exp Med Biol** 1998;449:67–77 (47 ref.)

Surface protein phosphorylation by ecto–protein kinases. Role in neuronal development and synaptic plasticity. Ehrlich YH, et al. **Adv Exp Med Biol** 1998;446:51–71 (85 ref.)

Mechanisms of neuroendocrine cell excitability. Hatton GI, et al. **Adv Exp Med Biol** 1998;449:79–95 (86 ref.)

Intrahypothalamic vasopressin release. An inhibitor of systemic vasopressin secretion? Ludwig M, et al. **Adv Exp Med Biol** 1998;449:163–73 (50 ref.)

New aspects of firing pattern autocontrol in oxytocin and vasopressin neurones. Moos F, et al. **Adv Exp Med Biol** 1998;449:153–62 (32 ref.)

GABAB receptors and supraoptic neuronal activity. Pittman QJ, et al. **Adv Exp Med Biol** 1998;449:107–15 (38 ref.)

Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. Gerlach M, et al. **Adv Neurol** 1999;80:219–25 (44 ref.)

Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Hirsch EC, et al. **Adv Neurol** 1999;80:9–18 (78 ref.)

Mechanisms of neuronal death in idiopathic parkinsonism. Lee CS. **Adv Neurol** 1999;80:205–14 (82 ref.)

Dopamine cell death by a single genetic mechanism: phenotypic analysis and linkage study of autosomal recessive juvenile parkinsonism. Matsumine H, et al. **Adv Neurol** 1999;80:187–94 (25 ref.)

GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Vitek JL, et al. **Adv Neurol** 1998;78:211–9 (32 ref.)

Cell cycle events in neurons. Proliferation or death? Zhu X, et al. **Am J Pathol** 1999 Aug;155(2):327–9 (34 ref.)

V. Genes, lineages, and tissue interactions in the development of the enteric nervous system. Gershon MD. **Am J Physiol** 1998 Nov;275(5 Pt 1):G869–73 (30 ref.)

The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Loopuijt LD, et al. **Amino Acids** 1998;14(1–3):17–23 (41 ref.)

Role of somatodendritic 5–HT autoreceptors in modulating 5–HT neurotransmission. Blier P, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:204–16 (51 ref.)

Hypothalamic neurons. Mechanisms of sensitivity to temperature. Boulant JA. **Ann N Y Acad Sci** 1998 Sep 29; 856:108–15 (16 ref.)

The PACAP ligand/receptor system regulates cerebral cortical neurogenesis. Dicicco–Bloom E, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:274–89 (49 ref.)

Zebrafish as a model system for studying neuronal circuits and behavior. Fetcho JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:333–45 (53 ref.)

Vertebrate locomotion—a lamprey perspective. Grillner S, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:1–18 (70 ref.)

Mechanisms of pituitary adenylate cyclase activating polypeptide (PACAP)–induced depolarization of sympathetic superior cervical ganglion (SCG) neurons. May V, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:164–75 (54 ref.)

Opioid modulation of ventral pallidal inputs. Napier TC, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:176–201 (89 ref.)

Modulation of cell firing in the nucleus accumbens. O'Donnell P, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:157–75 (81 ref.)

Galanin activates an inwardly rectifying potassium conductance and inhibits a voltage–dependent calcium conductance in mudpuppy parasympathetic neurons. Parsons RL, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:156–69 (34 ref.)

Electrophysiologic effects of galanin on neurons of the central nervous system. Pieribone VA, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:264–73 (53 ref.)

The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c–fos gene expression. Vaudry D, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:92–9 (25 ref.)

Mesolimbic neuronal activity across behavioral states. Woodward DJ, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:91–112 (58 ref.)

The basal forebrain corticopetal system revisited. Zaborszky L, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:339–67 (130 ref.)

Cellular and molecular determinants of sympathetic neuron development. Francis NJ, et al. **Annu Rev Neurosci** 1999; 22:541–66 (148 ref.)

Central nervous system neuronal migration. Hatten ME. **Annu Rev Neurosci** 1999;22:511–39 (124 ref.)

The specification of dorsal cell fates in the vertebrate central nervous system. Lee KJ, et al. **Annu Rev Neurosci** 1999; 22:261–94 (140 ref.)

Synaptic mechanisms for coding timing in auditory neurons. Trussell LO. **Annu Rev Physiol** 1999;61:477–96 (118 ref.)

Resonance behaviors and mirror neurons. Rizzolatti G, et al. **Arch Ital Biol** 1999 May;137(2–3):85–100 (43 ref.)

Intraneuronal filamentous tau protein and alpha–synuclein deposits in neurodegenerative diseases. Goedert M, et al. **Biochem Soc Trans** 1998 Aug;26(3):463–71 (49 ref.)

Presenilins—in search of functionality. Karran EH, et al. **Biochem Soc Trans** 1998 Aug;26(3):491–6 (48 ref.)

"Painting" the target: how local molecular cues define synaptic relationships. Chiba A, et al. **Bioessays** 1998 Nov; 20(11):941–8 (68 ref.)

Origins, functions, and potential of adult neural stem cells. Kuhn HG, et al. **Bioessays** 1999 Aug;21(8):625–30 (50 ref.)

Nuclear calcium: a key regulator of gene expression. Hardingham GE, et al. **Biometals** 1998 Dec;11(4):345–58 (120 ref.)

Branching and/or collateral projections of spinal dorsal horn neurons. Lu GW, et al. **Brain Res Brain Res Rev** 1999 Jan; 29(1):50–82 (231 ref.)

A neuronal model of attentional spotlight: parietal guiding the temporal. Vidyasagar TR. **Brain Res Brain Res Rev** 1999 Jul;30(1):66–76 (104 ref.)

The subependymal layer in rodents: a site of structural plasticity and cell migration in the adult mammalian brain. Peretto P, et al. **Brain Res Bull** 1999 Jul 1;49(4):221–43 (184 ref.)

Interactions between the presynaptic alpha2–autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Schlicker E, et al. **Brain Res Bull** 1998 Sep 15;47(2):129–32 (45 ref.)

Hierarchical neuronal modeling of cognitive functions: from synaptic transmission to the Tower of London. Changeux JP, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):241–7 (39 ref.)

The neuronal zootype. An hypothesis. Deutsch J, et al. **C R Acad Sci III** 1998 Sep;321(9):713–9 (53 ref.)

Cortical populations and behaviour: Hebb's thread. Amirikian B, et al. **Can J Exp Psychol** 1999 Mar;53(1):21–34 (55 ref.)

Myocardial ischaemia and the cardiac nervous system. Armour JA. **Cardiovasc Res** 1999 Jan;41(1):41–54 (119 ref.)

Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. Thibault O, et al. **Cell Calcium** 1998 Nov–Dec;24(5–6):417–33 (193 ref.)

Why do mature CNS neurons of mammals fail to re–establish connections following injury—functions of bcl–2 [see comments] Chen DF, et al. **Cell Death Differ** 1998 Oct; 5(10):816–22 (51 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

ICE, neuronal apoptosis and neurodegeneration [see comments] Friedlander RM, et al. **Cell Death Differ** 1998 Oct;5(10):823–31 (83 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

Acousto–optic random–access laser scanning microscopy: fundamentals and applications to optical recording of neuronal activity. Saggau P, et al. **Cell Mol Biol (Noisy–le–grand)** 1998 Jul;44(5):827–46 (21 ref.)

Free radicals as mediators of neuronal injury. Facchinetti F, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):667–82 (126 ref.)

Transglutaminase–catalyzed protein cross–linking in the molecular program of apoptosis and its relationship to neuronal processes. Fesus L. **Cell Mol Neurobiol** 1998 Dec; 18(6):683–94 (68 ref.)

Development of the cholinergic neurotransmitter phenotype in postganglionic sympathetic neurons. Ernsberger U, et al. **Cell Tissue Res** 1999 Sep;297(3):339–61 (137 ref.)

From perception to action: temporal integrative functions of prefrontal and parietal neurons. Quintana J, et al. **Cereb Cortex** 1999 Apr–May;9(3):213–21 (52 ref.)

Inositol 1,3,4,5–tetrakisphosphate as a second messenger—a special role in neurones? Irvine RF, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):49–57 (50 ref.)

Cellular requirements of suprachiasmatic nucleus transplants for restoration of circadian rhythm. Boer GJ, et al. **Chronobiol Int** 1998 Sep;15(5):551–66 (50 ref.)

The SCN is comprised of a population of coupled oscillators. Miller JD. **Chronobiol Int** 1998 Sep;15(5):489–511 (133 ref.)

Restoration of circadian behavior by anterior hypothalamic grafts containing the suprachiasmatic nucleus: graft/host interconnections. Sollars PJ, et al. **Chronobiol Int** 1998 Sep; 15(5):513–33 (104 ref.)

Electrophysiological and cellular effects of estrogen on neuronal function. Woolley CS. **Crit Rev Neurobiol** 1999; 13(1):1–20 (118 ref.)

Early effects of hypoxia on brain cell function. Krnjević K. **Croat Med J** 1999 Sep;40(3):375–80 (78 ref.)

Binocular vision: the neural integration of depth and motion. Freeman RD. **Curr Biol** 1998 Oct 22;8(21):R761–4 (10 ref.)

Sensory neuroscience: visualizing the auditory cortex. King AJ, et al. **Curr Biol** 1998 Nov 5;8(22):R784–7 (16 ref.)

Retinal processing: amacrine cells keep it short and sweet. Lagnado L. **Curr Biol** 1998 Aug 27;8(17):R598–600 (8 ref.)

Electrical synapses: beyond speed and synchrony to computation. Marder E. **Curr Biol** 1998 Nov 5; 8(22):R795–7 (9 ref.)

Synaptic vesicle docking and fusion. Bajjalieh SM. **Curr Opin Neurobiol** 1999 Jun;9(3):321–8 (96 ref.)

Cellular, synaptic, network, and modulatory mechanisms involved in rhythm generation. Calabrese RL. **Curr Opin Neurobiol** 1998 Dec;8(6):710–7 (45 ref.)

Cajal–Retzius cells, Reelin, and the formation of layers. Frotscher M. **Curr Opin Neurobiol** 1998 Oct;8(5):570–5 (49 ref.)

Molecular clocks [editorial] Hall JC, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):633–4 (3 ref.)

Regulation of back–propagating action potentials in hippocampal neurons. Johnston D, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):288–92 (34 ref.)

Neural substrates of Drosophila rhythms revealed by mutants and molecular manipulations. Kaneko M. **Curr Opin Neurobiol** 1998 Oct;8(5):652–8 (75 ref.)

Assembly of signaling machinery at the postsynaptic membrane. Kirsch J. **Curr Opin Neurobiol** 1999 Jun; 9(3):329–35 (61 ref.)

Cortical processing of complex sounds. Rauschecker JP. **Curr Opin Neurobiol** 1998 Aug;8(4):516–21 (53 ref.)

Time as coding space? Singer W. **Curr Opin Neurobiol** 1999 Apr;9(2):189–94 (70 ref.)

Calcium– and activity–dependent synaptic plasticity. Zucker RS. **Curr Opin Neurobiol** 1999 Jun;9(3):305–13 (104 ref.)

Neurons and their dendrites in frontotemporal dementia. Ferrer I. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:55–60 (15 ref.)

Neural induction in embryos. Tiedemann H, et al. **Dev Growth Differ** 1998 Aug;40(4):363–76 (139 ref.)
The 'pharmacology' of neuronal rescue with cerebral hypothermia. Gunn AJ, et al. **Early Hum Dev** 1998 Nov; 53(1):19–35 (90 ref.)
Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19–26 (35 ref.)
Interaction between superficial layers of the entorhinal cortex and the hippocampus in normal and epileptic temporal lobe. Gloveli T, et al. **Epilepsy Res** 1998 Sep;32(1–2):183–93 (81 ref.)
Gonadal steroid-dependent neuronal circuitries in avian limbic and preoptic regions. Panzica GC, et al. **Eur J Morphol** 1999 Apr;37(2–3):112–6 (21 ref.)
Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: implications for the pathogenesis of Alzheimer's disease. Behl C. **Exp Gerontol** 1998 Nov–Dec;33(7–8):689–96 (51 ref.)
Molecular biology of neuronal voltage-gated calcium channels. Chin H. **Exp Mol Med** 1998 Sep 30;30(3):123–30 (49 ref.)
Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Boonman Z, et al. **Exp Neurol** 1999 Mar;156(1):1–15 (146 ref.)
Cellular mechanism of pulsatile LHRH release. Terasawa E. **Gen Comp Endocrinol** 1998 Dec;112(3):283–95 (135 ref.)
Gap junction-mediated loops of neuronal-glial interactions. Fróes MM, et al. **Glia** 1998 Sep;24(1):97–107 (117 ref.)
Bridging the gap: integrating cellular and functional magnetic resonance imaging studies of the hippocampus. Stern CE, et al. **Hippocampus** 1999;9(1):45–53 (103 ref.)
Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions [see comments] Vizi ES, et al. **Hippocampus** 1998;8(6):566–607 (384 ref.) Comment in: Hippocampus 1998 ;8(6):565.
Visualization of neuronal form and function in brain slices by infrared videomicroscopy. Dodt HU, et al. **Histochem J** 1998 Mar;30(3):141–52 (45 ref.)
Calcium imaging and multielectrode recordings of global patterns of activity in the developing nervous system. Wong RO. **Histochem J** 1998 Mar;30(3):217–29 (48 ref.)
Voltage-sensitive dyes for monitoring multineuronal activity in the intact central nervous system. Wu JY, et al. **Histochem J** 1998 Mar;30(3):169–87 (83 ref.)
Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Gibbs RB, et al. **Horm Behav** 1998 Oct;34(2):98–111 (117 ref.)
Leptin sensitive neurons in the hypothalamus. Baskin DG, et al. **Horm Metab Res** 1999 May;31(5):345–50 (83 ref.)
[Apoptosis-inducing and -preventing signal transduction pathways in cultured cerebellar granule neurons] Ikeuchi T, et al. **Hum Cell** 1998 Sep;11(3):125–40 (88 ref.)
Immunolesion of the cholinergic basal forebrain: effects on functional properties of hippocampal and septal neurons. Bassant MH, et al. **Int J Dev Neurosci** 1998 Nov–Dec; 16(7–8):613–32 (109 ref.)
Stress and the adaptive self-organization of neuronal connectivity during early childhood. Huether G. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):297–306 (58 ref.)
Neuronal life and death decisions functional antagonism between the Trk and p75 neurotrophin receptors. Majdan M, et al. **Int J Dev Neurosci** 1999 Jun;17(3):153–61 (87 ref.)
The neural mechanisms underlying cholinergic cell death within the basal forebrain. Wenk GL, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):729–35 (97 ref.)
The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al. **J Chem Neuroanat** 1999 May;16(3):153–65 (36 ref.)
New approaches to functional neuroenergetics. Fitzpatrick SM, et al. **J Cogn Neurosci** 1999 Jul;11(4):467–71 (26 ref.)
Single-cell analyses of nitrergic neurons in simple nervous systems. Moroz LL, et al. **J Exp Biol** 1999 Feb;202 (Pt 4):333–41 (81 ref.)
Physiology of electrosensory lateral line lobe neurons in Gnathonemus petersii. Sugawara Y, et al. **J Exp Biol** 1999 May;202 (Pt 10):1301–9 (38 ref.)
Neurotrophins, neurones and peripheral nerve regeneration. Yin Q, et al. **J Hand Surg [Br]** 1998 Aug;23(4):433–7 (45 ref.)
Simulation of cortical cholinergic deficits--a novel experimental approach to study pathogenetic aspects of Alzheimer's disease. Bigl V, et al. **J Neural Transm Suppl** 1998;54:237–47 (42 ref.)
Stem cells in the developing and adult nervous system. Alvarez-Buylla A, et al. **J Neurobiol** 1998 Aug; 36(2):105–10 (16 ref.)
The neuronal stem cell of the olfactory epithelium. Calof AL, et al. **J Neurobiol** 1998 Aug;36(2):190–205 (71 ref.)
Multipotent progenitor cells in the adult dentate gyrus. Gage FH, et al. **J Neurobiol** 1998 Aug;36(2):249–66 (102 ref.)
Orchestration of neuronal migration by activity of ion channels, neurotransmitter receptors, and intracellular Ca2+ fluctuations. Komuro H, et al. **J Neurobiol** 1998 Oct; 37(1):110–30 (129 ref.)
Induction and patterning of the neural crest, a stem cell-like precursor population. LaBonne C, et al. **J Neurobiol** 1998 Aug;36(2):175–89 (117 ref.)
Neuroblasts of the postnatal mammalian forebrain: their phenotype and fate. Luskin MB. **J Neurobiol** 1998 Aug; 36(2):221–33 (87 ref.)
Control of spontaneous activity during development. Moody WJ. **J Neurobiol** 1998 Oct;37(1):97–109 (80 ref.)
Glial-neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids. Ojeda SR, et al. **J Neurobiol** 1999 Sep 15;40(4):528–40 (95 ref.)
Stem cells in the embryonic cerebral cortex: their role in histogenesis and patterning. Shen Q, et al. **J Neurobiol** 1998 Aug;36(2):162–74 (78 ref.)
Development of electrical excitability in embryonic neurons: mechanisms and roles. Spitzer NC, et al. **J Neurobiol** 1998 Oct;37(1):190–7 (86 ref.)
Monitoring early neuronal differentiation by ion channels in ascidian embryos. Takahashi K, et al. **J Neurobiol** 1998 Oct;37(1):3–22 (60 ref.)
CNS stem cells: where's the biology (a.k.a. beef)? Weiss S, et al. **J Neurobiol** 1998 Aug;36(2):307–14 (51 ref.)
The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. Waagepetersen HS, et al. **J Neurochem** 1999 Oct; 73(4):1335–42 (97 ref.)
A theory of geometric constraints on neural activity for natural three-dimensional movement. Zhang K, et al. **J Neurosci** 1999 Apr 15;19(8):3122–45 (124 ref.)
Neurons and fractals: how reliable and useful are calculations of fractal dimensions? Jelinek HF, et al. **J Neurosci Methods** 1998 Jun 1;81(1–2):9–18 (62 ref.)
Establishment and plasticity of neuronal polarity. Mattson MP. **J Neurosci Res** 1999 Sep 1;57(5):577–89 (51 ref.)
Potassium currents and excitability in second-order auditory and vestibular neurons. Peusner KD, et al. **J Neurosci Res** 1998 Sep 1;53(5):511–20 (76 ref.)
Adenoviral-mediated gene transfer to enhance neuronal survival, growth, and regeneration. Smith GM, et al. **J Neurosci Res** 1999 Jan 15;55(2):147–57 (114 ref.)
Essential fatty acids are mediators of brain biochemistry and cognitive functions. Yehuda S, et al. **J Neurosci Res** 1999 Jun 15;56(6):565–70 (51 ref.)
The stochastic diffusion models of nerve membrane depolarization and interspike interval generation. Lánský P, et al. **J Peripher Nerv Syst** 1999;4(1):27–42 (81 ref.)
Allosteric modulation of neuronal nicotinic acetylcholine receptors. Buisson B, et al. **J Physiol Paris** 1998 Apr; 92(2):89–100 (122 ref.)
Regulated exocytosis in neurons and neurosecretory cells: structural events and expression competence. Meldolesi J. **J Physiol Paris** 1998 Apr;92(2):119–21 (10 ref.)
From the cholinergic gene locus to the cholinergic neuron. Weihe E, et al. **J Physiol Paris** 1998 Oct–Dec;92(5–6):385–8 (20 ref.)
Apoptotic cell death in neurons and glial cells: implications for Alzheimer's disease. Kitamura Y, et al. **Jpn J Pharmacol** 1999 Jan;79(1):1–5 (31 ref.)
Neuronal tuning and associative mechanisms in form representation. Sakai K, et al. **Learn Mem** 1994 Jul–Aug; 1(2):83–105 (137 ref.)
Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Fryer AD, et al. **Life Sci** 1999;64(6–7):449–55 (49 ref.)
Pacemaker neurons of the forebrain medical septal area and theta rhythm of the hippocampus. Vinogradova OS, et al. **Membr Cell Biol** 1998;11(6):715–25 (27 ref.)
Neurotrophin-mediated potentiation of neuronal injury. Behrens MM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):276–84 (162 ref.)
Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Schwanzel-Fukuda M. **Microsc Res Tech** 1999 Jan 1;44(1):2–10 (70 ref.)
Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system. Yew DT, et al. **Microsc Res Tech** 1999 Jun 15;45(6):389–400 (123 ref.)
Activation and degeneration during aging: a morphometric study of the human hypothalamus. Zhou JN, et al. **Microsc Res Tech** 1999 Jan 1;44(1):36–48 (90 ref.)
GDNF family neurotrophic factor signaling: four masters, one servant? Airaksinen MS, et al. **Mol Cell Neurosci** 1999 May;13(5):313–25 (117 ref.)
Ovarian steroids and serotonin neural function. Bethea CL, et al. **Mol Neurobiol** 1998 Oct;18(2):87–123 (269 ref.)
Neuronal signaling systems and ethanol dependence. Pandey SC. **Mol Neurobiol** 1998 Winter;17(1–3):1–15 (100 ref.)
Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Schmitz D, et al. **Mol Neurobiol** 1998 Winter;17(1–3):59–72 (85 ref.)
Making sense of the multiple MAP-2 transcripts and their role in the neuron. Shafit-Zagardo B, et al. **Mol Neurobiol** 1998 Apr;16(2):149–62 (105 ref.)
The regulation of neurotransmitter secretion by protein kinase C. Vaughan PF, et al. **Mol Neurobiol** 1998 Oct; 18(2):125–55 (237 ref.)
The molecular basis for electrogenic computation in the brain: you can't step in the same river twice. Waxman SG. **Mol Psychiatry** 1999 May;4(3):222–8 (45 ref.)
Immune pathogenesis of multiple sclerosis. Brain autoimmune reactivity and its control by neuronal function. Wekerle H. **Mult Scler** 1998 Jun;4(3):136–7 (17 ref.)
Hepatocyte growth factor, a versatile signal for developing neurons. Maina F, et al. **Nat Neurosci** 1999 Mar;2(3):213–7 (50 ref.)
Neuronal control of mammalian vocalization, with special reference to the squirrel monkey. Jürgens U. **Naturwissenschaften** 1998 Aug;85(8):376–88 (53 ref.)
Regulation of neuronal gene expression. Thiel G, et al. **Naturwissenschaften** 1999 Jan;86(1):1–7 (34 ref.)
A review of methods for spike sorting: the detection and classification of neural action potentials. Lewicki MS. **Network** 1998 Nov;9(4):R53–78 (52 ref.)
Collective behavior of networks with linear (VLSI) integrate-and-fire neurons. Fusi S, et al. **Neural Comput** 1999 Apr 1;11(3):633–52 (22 ref.)
Structural basis of the cholinergic and serotonergic modulation of GABAergic neurons in the hippocampus. Gulyás AI, et al. **Neurochem Int** 1999 May;34(5):359–72 (102 ref.)
Microtubules and neuronal polarity: lessons from mitosis. Baas PW. **Neuron** 1999 Jan;22(1):23–31 (49 ref.)
Rearranging views on neurogenesis: neuronal death in the absence of DNA end-joining proteins. Chun J, et al. **Neuron** 1999 Jan;22(1):7–10 (20 ref.)
Neuronal polarity and the epithelial metaphor [comment] Colman DR. **Neuron** 1999 Aug;23(4):649–51 (15 ref.) Comment on: Neuron 1999 Aug;23(4):637–40.
Generation and maintenance of neuronal polarity: mechanisms of transport and targeting [comment] [see comments] Foletti DL, et al. **Neuron** 1999 Aug;23(4):641–4 (20 ref.) Comment on: Neuron 1999 Aug;23(4):637–40. Comment in: Neuron 1999 Aug;23(4):645–8.
Reading neural representations. Groh JM. **Neuron** 1998 Oct; 21(4):661–4 (11 ref.)
Eph receptors, ephrins, and PDZs gather in neuronal synapses [comment] Hsueh YP, et al. **Neuron** 1998 Dec; 21(6):1227–9 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1453–63.
From membrane to cytoskeleton: enabling a connection. Hu S, et al. **Neuron** 1999 Mar;22(3):419–22 (21 ref.)
Silencing the controversy in LTP? [comment] Malinow R. **Neuron** 1998 Dec;21(6):1226–7 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1443–51.
The neural code of the retina. Meister M, et al. **Neuron** 1999 Mar;22(3):435–50 (125 ref.)
Synaptic [Ca2+]: intracellular stores spill their guts. Svoboda K, et al. **Neuron** 1999 Mar;22(3):427–30 (20 ref.)
The middle and the end: slit brings guidance and branching together in axon pathway selection. Van Vactor D, et al. **Neuron** 1999 Apr;22(4):649–52 (24 ref.)
Neuronal polarity: controlling the sorting and diffusion of membrane components [see comments] Winckler B, et al. **Neuron** 1999 Aug;23(4):637–40 (21 ref.) Comment in: Neuron 1999 Aug;23(4):641–4. Comment in: Neuron 1999 Aug;23(4):649–51.
Tailoring uniform coats for synaptic vesicles during endocytosis. Zhang B, et al. **Neuron** 1999 Jul;23(3):419–22 (21 ref.)
Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Azmitia EC. **Neuropsychopharmacology** 1999 Aug; 21(2 Suppl):33S–45S (137 ref.)
Serotonin and hippocampal neurogenesis. Gould E. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):46S–51S (64 ref.)
Activity of serotonergic neurons in behaving animals. Jacobs BL, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):9S–15S (26 ref.)
Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Yang CR, et al. **Neuropsychopharmacology** 1999 Aug;21(2):161–94 (369 ref.)
The saga of the nerve growth factor. Levi-Montalcini R. **Neuroreport** 1998 Nov 16;9(16):R71–83 (59 ref.)
Question of time in studies of the neuronal correlates of behavior. Tolkunov BF. **Neurosci Behav Physiol** 1998 Jul–Aug;28(4):447–50 (12 ref.)
Neuronal cell death during sexual differentiation and lateralisation of vocal communication. Holman SD. **Neurosci Biobehav Rev** 1998 Oct;22(6):725–34 (94 ref.)
Alpha oscillations shed new light on relation between EEG and single neurons. Schürmann M, et al. **Neurosci Res** 1999 Feb;33(2):79–80 (12 ref.)
Dissociation of dorsal root ganglion neurons into afferent and efferent-like neurons. Holzer P, et al. **Neuroscience** 1998 Sep;86(2):389–98 (101 ref.)
Microcircuitry of the direct and indirect pathways of the basal ganglia. Smith Y, et al. **Neuroscience** 1998 Sep; 86(2):353–87 (344 ref.)
Modeling dopamine system dysfunction in experimental animals. Hantraye P. **Nucl Med Biol** 1998 Nov;25(8):721–8 (31 ref.)
Unexplained peculiarities of the dorsal root ganglion. Devor M. **Pain** 1999 Aug;Suppl 6:S27–35 (44 ref.)
From electrical wiring to plastic neurons: evolving approaches to the study of pain. Jabbur SJ, et al. **Pain** 1999 Aug;Suppl 6:S87–92 (49 ref.)
From the gate to the neuromatrix. Melzack R. **Pain** 1999 Aug;Suppl 6:S121–6 (13 ref.)
Brain waves and brain wiring: the role of endogenous and sensory-driven neural activity in development. Penn AA, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):447–58 (201 ref.)
GABAergic cells and signals in CNS development. Barker JL, et al. **Perspect Dev Neurobiol** 1998;5(2–3):305–22 (56

ref.)
GABA as a trophic factor for developing monoamine neurons. Lauder JM, et al. **Perspect Dev Neurobiol** 1998; 5(2–3):247–59 (90 ref.)
Autoregulation of serotonin neurons: role in antidepressant drug action. Piñeyro G, et al. **Pharmacol Rev** 1999 Sep; 51(3):533–91 (787 ref.)
Hypoxia and neuronal function under in vitro conditions. Nieber K. **Pharmacol Ther** 1999 Apr;82(1):71–86 (180 ref.)
Information coding in the cortex by independent or coordinated populations. deCharms RC.
Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15166–8 (36 ref.)
Supraspinal contributions to hyperalgesia. Urban MO, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7687–92 (53 ref.)
Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Yu XM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7697–704 (118 ref.)
Cellular and molecular correlates of the regeneration of adult mammalian CNS axons into peripheral nerve grafts. Anderson PN, et al. **Prog Brain Res** 1998;117:211–32 (73 ref.)
Glutamate induced cell death: apoptosis or necrosis? Ankarcrona M. **Prog Brain Res** 1998;116:265–72 (66 ref.)
Phenotypic and state-dependent expression of the electrical and morphological properties of oxytocin and vasopressin neurones. Armstrong WE, et al. **Prog Brain Res** 1998; 119:101–13 (91 ref.)
Osmoregulation of vasopressin neurons: a synergy of intrinsic and synaptic processes. Bourque CW. **Prog Brain Res** 1998; 119:59–76 (120 ref.)
Regulation of brain-derived neurotrophic factor mRNA levels in hippocampus by neuronal activity. Castrén E, et al. **Prog Brain Res** 1998;117:57–64 (28 ref.)
Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)
Semaphorin III: role in neuronal development and structural plasticity. Giger RJ, et al. **Prog Brain Res** 1998;117:133–49 (43 ref.)
Neurophysiology of magnocellular neuroendocrine cells: recent advances. Hatton GI, et al. **Prog Brain Res** 1998; 119:77–99 (130 ref.)
Studying signal transduction in neuronal cells: the Trk/NGF system. Kaplan DR. **Prog Brain Res** 1998;117:35–46 (70 ref.)
Vasopressin acting at V1-type receptors produces membrane depolarization in neonatal rat spinal lateral column neurons. Kolaj M, et al. **Prog Brain Res** 1998;119:275–84 (63 ref.)
Semaphorin-mediated neuronal growth cone guidance. Kolodkin AL. **Prog Brain Res** 1998;117:115–32 (95 ref.)
Instructive roles of neurotrophins in synaptic plasticity. Lo DC. **Prog Brain Res** 1998;117:65–70 (27 ref.)
Role for semaphorin III and its receptor neuropilin-1 in neuronal regeneration and scar formation? Pasterkamp RJ, et al. **Prog Brain Res** 1998;117:151–70 (157 ref.)
Cellular activation in neuroregeneration. Schwaiger FW, et al. **Prog Brain Res** 1998;117:197–210 (129 ref.)
Discrete clusters of axonin-1 and NgCAM at neuronal contact sites: facts and speculations on the regulation of axonal fasciculation. Sonderegger P, et al.
Prog Brain Res 1998;117:93–104 (39 ref.)
Boundary molecules during brain development, injury, and persistent neurogenesis—in vivo and in vitro studies. Steindler DA, et al. **Prog Brain Res** 1998;117:179–96 (63 ref.)
Reduced neuronal activity and reactivation in Alzheimer's disease. Swaab DF, et al. **Prog Brain Res** 1998;117:343–77 (277 ref.)
The magnocellular neurons of the hypothalamo-neurohypophyseal system display remarkable neuropeptidergic phenotypes leading to novel insights in neuronal cell biology. van Leeuwen FW, et al.
Prog Brain Res 1998;119:115–26 (62 ref.)
Corticosteroid hormones and neuronal vulnerability: towards identification of candidate vulnerability genes. Vreugdenhil E, et al. **Prog Brain Res** 1998;117:9–22 (92 ref.)
The concept of a calcium sensor in transmitter release. Bennett MR. **Prog Neurobiol** 1999 Oct;59(3):243–77 (161 ref.)
The role of basal forebrain neurons in tonic and phasic activation of the cerebral cortex. Détári L, et al.
Prog Neurobiol 1999 Jun;58(3):249–77 (196 ref.)
Cold injury in mice: a model to study mechanisms of brain edema and neuronal apoptosis. Murakami K, et al.
Prog Neurobiol 1999 Feb;57(3):289–99 (42 ref.)
The Ca2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells. Solà C, et al. **Prog Neurobiol** 1999 Jun;58(3):207–32 (168 ref.)
Neuronal death in glaucoma. Quigley HA.
Prog Retin Eye Res 1999 Jan;18(1):39–57 (87 ref.)
Ubiquitous molecular substrates for associative learning and activity-dependent neuronal facilitation. Matzel LD, et al.
Rev Neurosci 1998 Jul–Dec;9(3):129–67 (280 ref.)
Cognitive and motivational operations in primate prefrontal neurons. Watanabe M. **Rev Neurosci** 1998;9(4):225–41 (133 ref.)
Brain, heal thyself. Lowenstein DH, et al. **Science** 1999 Feb 19;283(5405):1126–7 (13 ref.)
Consciousness and complexity. Tononi G, et al. **Science** 1998 Dec 4;282(5395):1846–51 (51 ref.)
A neurobehavioral model for rapid actions of corticosterone on sensorimotor integration. Rose JD, et al. **Steroids** 1999 Jan–Feb;64(1–2):92–9 (29 ref.)
Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Alkon DL, et al. **Trends Neurosci** 1998 Dec;21(12):529–37 (97 ref.)
Neuronal chemistry and functional organization in the primate visual system. Hendry SH, et al.
Trends Neurosci 1998 Aug;21(8):344–9 (82 ref.)
Low-voltage-activated (T-type) calcium-channel genes identified. Huguenard JR. **Trends Neurosci** 1998 Nov; 21(11):451–2 (36 ref.)
Where the abstract feature maps of the brain might come from. Kohonen T, et al. **Trends Neurosci** 1999 Mar; 22(3):135–9 (44 ref.)
Seeing what is coming: building collision-sensitive neurones. Rind FC, et al. **Trends Neurosci** 1999 May;22(5):215–20 (47 ref.)
Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction. Ruegg MA, et al.
Trends Neurosci 1998 Jan;21(1):22–7 (74 ref.)
Calcium and neuronal ageing [see comments] Verkhratsky A, et al. **Trends Neurosci** 1998 Jan;21(1):2–7 (76 ref.) Comment in: Trends Neurosci 1998 Jul;21(7):286; discussion 287.
Neuronal cell death: a demise with different shapes. Nicotera P, et al. **Trends Pharmacol Sci** 1999 Feb;20(2):46–51 (56 ref.)
Motion detection in insect orientation and navigation. Srinivasan MV, et al. **Vision Res** 1999 Aug;39(16):2749–66 (73 ref.)
Visual recognition based on temporal cortex cells: viewer-centred processing of pattern configuration. Perrett DI, et al. **Z Naturforsch [C]** 1998 Jul–Aug;53(7–8):518–41 (108 ref.)
Solutions for the binding problem. Roelfsema PR.
Z Naturforsch [C] 1998 Jul–Aug;53(7–8):691–715 (138 ref.)
[Neuronal growth factors—neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063–70 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3112–3. **(Dan)**
[Are active neurons a better defense against aging in Alzheimer's disease?] Lucassen PJ, et al.
Tijdschr Gerontol Geriatr 1998 Aug;29(4):177–84 (47 ref.) (Eng. Abstr.) **(Dut)**
[Molecular biology of neurosecretion and its inhibition bu tetanus and botulinum toxins (review)] Veit M.
Berl Munch Tierarztl Wochenschr 1999 Jun;112(5):186–91 (20 ref.) (Eng. Abstr.) **(Ger)**
[Molecular cloning for gene expression of nerve activity] Kojima N, et al. **Nippon Seirigaku Zasshi** 1998; 60(7–8):301–17 (11 ref.) **(Jpn)**
[Regulation of neuronal death by endogenous protective factors] Akaike A, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):177–86 (48 ref.) (Eng. Abstr.) **(Jpn)**
[The precise characterization and the crucial mechanism of NO-induced cytotoxicity] Okuma Y, et al.
Nippon Yakurigaku Zasshi 1998 Sep;112(3):187–94 (48 ref.) (Eng. Abstr.) **(Jpn)**
[Neuronal cell death—what we can see and what we cannot] Nukina N. **Rinsho Shinkeigaku** 1999 Jan;39(1):2–3 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Neuronal cell death in neurodegenerative disorders and oxidative stress] Shimohama S, et al.
Rinsho Shinkeigaku 1999 Jan;39(1):4–6 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Morphogenesis of neuronal systems in tissue culture repeats the evolution of simpler nervous systems] Sotnikov OS.
Morfologiia 1999;115(2):7–23 (121 ref.) (Eng. Abstr.) **(Rus)**
[Electrical feedback in the chemical synapses] Byzov AL, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):1074–84 (19 ref.) (Eng. Abstr.) **(Rus)**
[Endoplasmic reticulum and mitochondria as elements of mechanism of intracellular signaling in neurons] Kostiuk PG, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):979–84 (14 ref.) (Eng. Abstr.) **(Rus)**
[Differentiation of dopaminergic neurones in situ, in vitro, and in the transplant] Ugriumov MV.
Ross Fiziol Zh Im I M Sechenova 1998 Oct;84(10):1019–28 (25 ref.) (Eng. Abstr.) **(Rus)**
[How to construct a neural tube: molecular genetics of neuro-embryological development] Sarnat HB.
Rev Neurol 1999 Jan 16–31;28(2):110–6 (48 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Problems and artifacts of microwave accelerated procedures in neurohistotechnology and resolutions. Horobin RW.
Methods 1998 Jun;15(2):101–6 (27 ref.)
Microwave applications in neuromorphology and neurochemistry: safety precautions and techniques. Marani E. **Methods** 1998 Jun;15(2):87–99 (161 ref.)

SECRETION

The regulation of galanin gene expression in gonadotropin-releasing hormone neurons. Finn PD, et al.
Mol Cell Endocrinol 1998 May 25;140(1–2):137–42 (34 ref.)
The kinetics of nerve-evoked quantal secretion. Fesce R.
Philos Trans R Soc Lond B Biol Sci 1999 Feb 28; 354(1381):319–29 (32 ref.)

TRANSPLANTATION

Neural transplantation for Parkinson's disease. Date I, et al.
Cell Mol Neurobiol 1999 Feb;19(1):67–78 (67 ref.)
Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Boonman Z, et al.
Exp Neurol 1999 Mar;156(1):1–15 (146 ref.)
Cellular and molecular treatments of neurological diseases. Isacson O, et al. **Exp Neurol** 1999 Sep;159(1):1–3 (16 ref.)
Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Kordower JH, et al. **Exp Neurol** 1999 Sep;159(1):4–20 (73 ref.)
Efficacy of grafted immortalized dopamine neurons in an animal model of parkinsonism: a review. Prasad KN, et al. **Mol Genet Metab** 1998 Sep;65(1):1–9 (66 ref.)
Prospectives for cell and gene therapy in Huntington's disease. Bachoud-Lévi AC, et al. **Prog Brain Res** 1998; 117:511–24 (117 ref.)
[Neural transplantation and regeneration: current status and future perspective] Date I, et al. **No Shinkei Geka** 1998 Oct;26(10):860–72 (116 ref.) **(Jpn)**
[Differentiation of dopaminergic neurones in situ, in vitro, and in the transplant] Ugriumov MV.
Ross Fiziol Zh Im I M Sechenova 1998 Oct;84(10):1019–28 (25 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Creating intracellular structural domains: spatial segregation of actin and tropomyosin isoforms in neurons. Gunning P, et al. **Bioessays** 1998 Nov;20(11):892–900 (75 ref.)
Dynamic behavior and organization of cytoskeletal proteins in neurons: reconciling old and new findings. Nixon RA.
Bioessays 1998 Oct;20(10):798–807 (85 ref.)
Branching and/or collateral projections of spinal dorsal horn neurons. Lu GW, et al. **Brain Res Brain Res Rev** 1999 Jan; 29(1):50–82 (231 ref.)
The history of the Golgi apparatus in neurones from its discovery in 1898 to electron microscopy. Dröscher A.
Brain Res Bull 1998 Oct;47(3):199–203 (62 ref.)
Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout? Kim TW, et al.
Neuron 1998 Oct;21(4):657–9 (19 ref.)
Chemo- and thermosensory neurons: structure and function in animal parasitic nematodes. Ashton FT, et al.
Vet Parasitol 1999 Aug 1;84(3–4):297–316 (49 ref.)

VIROLOGY

Practical considerations for the use of pseudorabies virus in transneuronal studies of neural circuitry. Card JP.
Neurosci Biobehav Rev 1998 Oct;22(6):685–94 (46 ref.)
A review of alphavirus replication in neurons. Griffin DE.
Neurosci Biobehav Rev 1998 Oct;22(6):721–3 (30 ref.)
Viruses as transneuronal tracers for defining neural circuits. Loewy AD. **Neurosci Biobehav Rev** 1998 Oct;22(6):679–84 (40 ref.)
Herpes simplex virus as a transneuronal tracer. Norgren RB Jr, et al. **Neurosci Biobehav Rev** 1998 Oct;22(6):695–708 (167 ref.)
Perspective: virus infections and the death of neurons. Griffin DE, et al. **Trends Microbiol** 1999 Apr;7(4):155–60 (44 ref.)

NEURONS, AFFERENT

see related
RECEPTORS, SENSORY

DRUG EFFECTS

Neurotrophin action on sensory neurons in adults: an extension of the neurotrophic hypothesis. Mendell LM.
Pain 1999 Aug;Suppl 6:S127–32 (61 ref.)

IMMUNOLOGY

Neural-immune interactions—an evolutionary perspective. Clatworthy AL. **Neuroimmunomodulation** 1998 May–Aug; 5(3–4):136–42 (51 ref.)

METABOLISM

Specification of neuronal connectivity: ETS marks the spot [comment] Ghosh A, et al. **Cell** 1998 Oct 30;95(3):303–6 (17 ref.) Comment on: Cell 1998 Oct 30;95(3):393–407.
Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. Garzón M, et al.
J Comp Neurol 1999 Jul 26;410(2):197–210 (108 ref.)
Effects of ion channel activity on development of dorsal root ganglion neurons. Fields RD. **J Neurobiol** 1998 Oct; 37(1):158–70 (89 ref.)
Classical and novel directions in neurotrophin transport and research: anterograde transport of brain-derived neurotrophic factor by sensory neurons. Tonra JR.
Microsc Res Tech 1999 May 15–Jun 1;45(4–5):225–32 (122 ref.)
Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Alvares D, et al. **Pain** 1999 Aug;Suppl

6:S71–85 (193 ref.)
The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Waxman SG. **Pain** 1999 Aug;Suppl 6:S133–40 (59 ref.)
Neurotrophin trafficking by anterograde transport [see comments] Altar CA, et al. **Trends Neurosci** 1998 Oct; 21(10):433–7 (45 ref.) Comment in: Trends Neurosci 1999 Mar;22(3):108–9.

PATHOLOGY

Correlation between autotomy-behavior and current theories of neuropathic pain. Kauppila T. **Neurosci Biobehav Rev** 1998;23(1):111–29 (304 ref.)

PHYSIOLOGY

Regulation of insulin secretion by nerves and neuropeptides. Ahrén B. **Ann Acad Med Singapore** 1999 Jan;28(1):99–104 (16 ref.)
Compensatory responses to early olfactory restriction. Leon M. **Ann N Y Acad Sci** 1998 Nov 30;855:104–8 (21 ref.)
Enhancement and resetting of locomotor activity by muscle afferents. Pearson KG, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:203–15 (36 ref.)
Galanin in somatosensory function. Wiesenfeld-Hallin Z, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:383–9 (42 ref.)
Molecular development of sensory maps: representing sights and smells in the brain. O'Leary DD, et al. **Cell** 1999 Jan 22;96(2):255–69 (87 ref.)
Development and specification of muscle sensory neurons. Chen HH, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):405–9 (33 ref.)
Connections between P2 purinoceptors and capsaicin-sensitive afferents in the intestine and other tissues. Barthó L, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):203–10 (103 ref.)
The activation of bladder wall afferent nerves. Morrison J. **Exp Physiol** 1999 Jan;84(1):131–6 (28 ref.)
Airway nerves and protein phosphatases. Harrison S, et al. **Gen Pharmacol** 1999 Mar;32(3):287–98 (186 ref.)
Trophic interactions between sensory nerves and their targets. Chen WP, et al. **J Biomed Sci** 1999 Mar–Apr; 6(2):79–85 (52 ref.)
Origin and neurochemical characteristics of nerve fibres supplying the mammalian vas deferens. Kaleczyc J. **Microsc Res Tech** 1998 Sep 15;42(6):409–22 (110 ref.)
Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Waxman SG, et al. **Muscle Nerve** 1999 Sep;22(9):1177–87 (62 ref.)
Feature extraction through LOCOCODE. Hochreiter S, et al. **Neural Comput** 1999 Apr 1;11(3):679–714 (61 ref.)
Firing rate distributions and efficiency of information transmission of inferior temporal cortex neurons to natural visual stimuli. Treves A, et al. **Neural Comput** 1999 Apr 1;11(3):601–32 (39 ref.)
Synaptic plasticity in the hippocampus during afferent activation reproducing the pattern of the theta rhythm (theta plasticity). Kleshchevnikov AM. **Neurosci Behav Physiol** 1999 Mar–Apr;29(2):185–96 (76 ref.)
Cerebellum and the sensory guidance of movement. Glickstein M. **Novartis Found Symp** 1998;218:252–66; discussion 266–71, 332–3 (56 ref.)
Sensory input and control of grip. Johansson RS. **Novartis Found Symp** 1998;218:45–59; discussion 59–63 (40 ref.)
The cerebellum, predictive control and motor coordination. Miall RC. **Novartis Found Symp** 1998;218:272–84; discussion 284–90 (35 ref.)
The changing sensitivity in the life of the nociceptor. Koltzenburg M. **Pain** 1999 Aug;Suppl 6:S93–102 (132 ref.)
The primary afferent nociceptor as pattern generator. Reichling DB, et al. **Pain** 1999 Aug;Suppl 6:S103–9 (99 ref.)
The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Waxman SG. **Pain** 1999 Aug;Suppl 6:S133–40 (59 ref.)
Differentially expressed GABAA-receptor subunits result in structurally and functionally receptor assemblies following excitatory afferent synaptic transmission. Grayson DR, et al. **Perspect Dev Neurobiol** 1998;5(2–3):193–205 (72 ref.)
Lower extremity sensory nerve conduction studies. Blando AV. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):853–70, vii (83 ref.)
The postnatal development of spinal sensory processing. Fitzgerald M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7719–22 (49 ref.)
Causalgia, pathological pain, and adrenergic receptors. Perl ER. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7664–7 (39 ref.)
Sodium channels and pain. Waxman SG, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7635–9 (53 ref.)
Vasopressin and sensory circumventricular organs. Jurzak M, et al. **Prog Brain Res** 1998;119:221–45 (181 ref.)
Electrophysiological studies of neurohypophysial neurons and peptides. Pittman QJ, et al. **Prog Brain Res** 1998; 119:311–20 (57 ref.)
The synaptic pharmacology underlying sensory processing in the superior colliculus. Binns KE. **Prog Neurobiol** 1999 Oct;59(2):129–59 (172 ref.)
Modulation of sensory nerve function in the airways. Spina D. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):319–30 (160 ref.)
Differences in the properties of sensory and motor axons. Burke D. **Rinsho Shinkeigaku** 1999 Jan;39(1):97 (5 ref.)
Transduction and transmission properties of primary nociceptive afferents. Treede RD. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):205–11 (45 ref.)
Gauging sensory representations in the brain. Buracas GT, et al. **Trends Neurosci** 1999 Jul;22(7):303–9 (41 ref.)

NEURONS, EFFERENT

PHYSIOLOGY

Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Sarter M, et al. **Trends Neurosci** 1999 Feb; 22(2):67–74 (95 ref.)

NEURONS, MOTOR see **MOTOR NEURONS**

NEURONS, OLFACTORY RECEPTOR see **OLFACTORY RECEPTOR NEURONS**

NEURONS, SENSORY see **NEURONS, AFFERENT**

NEUROPAPILLITIS see **OPTIC NEURITIS**

NEUROPATHIES, AMYLOID see **AMYLOID NEUROPATHIES**

NEUROPATHIES, HEREDITARY MOTOR AND SENSORY

CLASSIFICATION

2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26-28 September 1997, Naarden, The Netherlands. **Neuromuscul Disord** 1998 Aug;8(6):426–31 (28 ref.)

COMPLICATIONS

[A case of hereditary motor and sensory neuropathy with pyramidal tract sign, optic nerve atrophy and mental retardation] Adachi T, et al. **Rinsho Shinkeigaku** 1998 Dec; 38(12):1037–41 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26-28 September 1997, Naarden, The Netherlands. **Neuromuscul Disord** 1998 Aug;8(6):426–31 (28 ref.)
Congenital hypomyelinating neuropathy: two patients with long-term follow-up. Phillips JP, et al. **Pediatr Neurol** 1999 Mar;20(3):226–32 (28 ref.)

GENETICS

Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Nelis E, et al. **Hum Mutat** 1999;13(1):11–28 (135 ref.)

NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC

DIAGNOSIS

[Monozygotic twins with suspected hereditary sensory and autonomic neuropathy (HSAN) type V] Itoh Y, et al. **No To Hattatsu** 1999 Jan;31(1):63–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

NEUROPATHY, TYPE I HEREDITARY MOTOR AND SENSORY see **CHARCOT-MARIE DISEASE**

NEUROPEPTIDE PHI 27 see **PEPTIDE PHI**

NEUROPEPTIDE RECEPTORS see **RECEPTORS, NEUROPEPTIDE**

NEUROPEPTIDE Y

see related
RECEPTORS, NEUROPEPTIDE Y

ANALYSIS

Peptidergic peripheral nervous systems in the mammalian pineal gland. Matsushima S, et al. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):265–80 (77 ref.)

BIOSYNTHESIS

Expression of non-classical islet hormone-like peptides during the embryonic development of the pancreas. Mulder H, et al. **Microsc Res Tech** 1998 Nov 15;43(4):313–21 (70 ref.)

PHYSIOLOGY

Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Kalra SP, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:236–40 (25 ref.)
Y do we drink? Tecott LH, et al. **Cell** 1998 Dec 11; 95(6):733–5 (22 ref.)
Central control of feeding behavior by neuropeptide Y. Zimanyi IA, et al. **Curr Pharm Des** 1998 Aug;4(4):349–66 (196 ref.)
Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19–26 (35 ref.)
Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Krysiak R, et al. **Eur J Endocrinol** 1999 Feb;140(2):130–6 (65 ref.)
Galanin and NPY, two peptides with multiple putative roles in the nervous system. Hökfelt T, et al. **Horm Metab Res** 1999 May;31(5):330–4 (48 ref.)
Metabolic control of sexual function and growth: role of neuropeptide Y and leptin. Aubert ML, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):107–13 (32 ref.)
Neuropeptide Y: a key molecule in anorexia and cachexia in wasting disorders? Inui A. **Mol Med Today** 1999 Feb; 5(2):79–85 (44 ref.)
Life without neuropeptide Y. Palmiter RD, et al. **Recent Prog Horm Res** 1998;53:163–99 (115 ref.)
NPY and food intake: discrepancies in the model. Woods SC, et al. **Regul Pept** 1998 Sep 25;75–76:403–8 (38 ref.)
Neuropeptide Y and limbic seizures. Baraban SC. **Rev Neurosci** 1998;9(2):117–28 (94 ref.)
Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Vezzani A, et al. **Trends Neurosci** 1999 Jan;22(1):25–30 (65 ref.)
[From Claude Bernard to the regulatory system between the hypothalamus and the periphery: implications for homeostasis of body weight and obesity] Jeanrenaud B, et al. **C R Seances Soc Biol Fil** 1998;192(5):829–41 (48 ref.) (Eng. Abstr.) **(Fre)**

NEUROPEPTIDE Y-LIKE IMMUNOREACTIVE PEPTIDE see **NEUROPEPTIDE Y**

NEUROPEPTIDE Y RECEPTORS see **RECEPTORS, NEUROPEPTIDE Y**

NEUROPEPTIDES

see related
RECEPTORS, NEUROPEPTIDE

Variations on a theme: testis-derived neuropeptide hormones [comment] DiMeglio LA, et al. **Eur J Endocrinol** 1998 Oct; 139(4):361–2 (11 ref.) Comment on: Eur J Endocrinol 1998 Oct;139(4):424–7.
[Discovery of prolactin-releasing peptide in the brain] Oda H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):881–6 (24 ref.) **(Jpn)**
[Orexins--new hypothalamic peptides that stimulate appetite] Meister B, et al. **Lakartidningen** 1998 Dec 16; 95(51–52):5885–7 (10 ref.) (Eng. Abstr.) **(Swe)**

ANALYSIS

Tachykinin-related peptides in invertebrates: a review. Nässel DR. **Peptides** 1999;20(1):141–58 (113 ref.)

BIOSYNTHESIS

Control of ecdysteroidogenesis: activation and inhibition of prothoracic gland activity. Gilbert LI, et al. **Invert Neurosci** 1997 Sep–Dec;3(2–3):205–16 (83 ref.)
[Synthesis and release of neuropeptides in immune system] Xing YT, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):261–4 (10 ref.) **(Chi)**

CHEMISTRY

Solution structure comparison of the VIP/PACAP family of peptides by NMR spectroscopy. Wray V, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:37–44 (17 ref.)
Post-translationally modified neuropeptides from Conus venoms. Craig AG, et al. **Eur J Biochem** 1999 Sep; 264(2):271–5 (46 ref.)
Molluscan neuropeptides. Yasuda-Kamatani Y. **EXS** 1998; 85:37–56 (36 ref.)
[Strategy for identification of new neuropeptides] Chartrel N, et al. **C R Seances Soc Biol Fil** 1998;192(4):619–38 (74 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Developmental regulation of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 in rat brain: function of PACAP as a neurotrophic factor. Lindholm D, et al. **Ann N Y Acad Sci** 1998 Dec 11;

865:189–96 (17 ref.)
A common theme for LIM homeobox gene function across phylogeny? Hobert O, et al. **Biol Bull** 1998 Dec; 195(3):377–80 (12 ref.)
When, where, and how much? Expression of the Kv3.1 potassium channel in high-frequency firing neurons. Gan L, et al. **J Neurobiol** 1998 Oct;37(1):69–79 (44 ref.)
Multiple genes for neuropeptides and their receptors: co-evolution and physiology. Darlison MG, et al. **Trends Neurosci** 1999 Feb;22(2):81–8 (74 ref.)
[Changes in excitability of the spinal cord and dorsal column nucleus and gene expression in neuropathic pain models] Noguchi K. **Masui** 1998 Dec;47 Suppl:S218–23 (7 ref.) **(Jpn)**

ISOLATION & PURIFICATION

The quest for novel bioactive peptides utilizing orphan seven-transmembrane-domain receptors. Hinuma S, et al. **J Mol Med** 1999 Jun;77(6):495–504 (64 ref.)

METABOLISM

Effects of alcohol on the synthesis and expression of hypothalamic peptides. Madeira MD, et al. **Brain Res Bull** 1999 Jan 1;48(1):3–22 (218 ref.)
Apoptosis: Ras to the rescue in the fly eye. McNeill H, et al. **Curr Biol** 1999 Mar 11;9(5):R176–9 (16 ref.)
Peptidylglycine alpha-amidating mono-oxygenase: neuropeptide amidation as a target for drug design. Bolkenius FN, et al. **Gen Pharmacol** 1998 Nov;31(5):655–9 (60 ref.)
Astroglial modulation of neurotransmitter/peptide release from the neurohypophysis: present status. Hatton GI. **J Chem Neuroanat** 1999 May;16(3):203–21 (147 ref.)
Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain. Baram TZ, et al. **Trends Neurosci** 1998 Nov;21(11):471–6 (86 ref.)
[Neuropeptides: their role in nasal physiology] Duroux S, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(1):25–8 (26 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

PACAP-38 protects cerebellar granule cells from apoptosis. Journot L, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:100–10 (53 ref.)
The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c-fos gene expression. Vaudry D, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:92–9 (25 ref.)
Sympathetic neurons of the chick embryo are rescued by PACAP from apoptotic death. Wakade AR, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:176–80 (20 ref.)
Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. de Wied D. **Eur J Pharmacol** 1999 Jun 30;375(1-3):1–11 (85 ref.)
The effect of neuropeptides/hormones on Langerhans cells. Torii H, et al. **J Dermatol Sci** 1998 May;20(1):21–8 (47 ref.)
The role of TRH and related peptides in the mechanism of action of ECT. Sattin A. **J ECT** 1999 Mar;15(1):76–92 (103 ref.)
Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. Debeljuk L, et al. **Peptides** 1999; 20(2):285–99 (139 ref.)

PHYSIOLOGY

Membrane excitability in the neurohypophysis. Wilke RA, et al. **Adv Exp Med Biol** 1998;449:193–200 (28 ref.)
Neuroendocrine differentiation, neuropeptides, and neprilysin. Cohen AJ, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):1–3 (20 ref.)
Regulation of insulin secretion by nerves and neuropeptides. Ahrén B. **Ann Acad Med Singapore** 1999 Jan;28(1):99–104 (16 ref.)
Is there appetite after GLP-1 and PACAP? Christophe J. **Ann N Y Acad Sci** 1998 Dec 11;865:323–35 (88 ref.)
The PACAP ligand/receptor system regulates cerebral cortical neurogenesis. Dicicco-Bloom E, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:274–89 (49 ref.)
VIP and PACAP in the CNS: regulators of glial energy metabolism and modulators of glutamatergic signaling. Magistretti PJ, et al. **Ann N Y Acad Sci** 1998 Dec 11; 865:213–25 (38 ref.)
Molecular, cellular and physiological characteristics of 5-HT-moduline, a novel endogenous modulator of 5-HT1B receptor subtype. Massot O, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:174–82 (17 ref.)
Mechanisms of pituitary adenylate cyclase activating polypeptide (PACAP)-induced depolarization of sympathetic superior cervical ganglion (SCG) neurons. May V, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:164–75 (54 ref.)
Cytokine-induced anorexia. Behavioral, cellular, and molecular mechanisms. Plata-Salamán CR. **Ann N Y Acad Sci** 1998 Sep 29;856:160–70 (63 ref.)
Neuropeptides: mediators of inflammation and tissue repair? Schäffer M, et al. **Arch Surg** 1998 Oct;133(10):1107–16 (170 ref.)
Serotonin and neuropeptides in affiliative behaviors. Insel TR, et al. **Biol Psychiatry** 1998 Aug 1;44(3):207–19 (45 ref.)
Neurotransmitters and neuropeptides in the developing human central nervous system. A review. Yew DT, et al. **Biol Signals Recept** 1999 May-Jun;8(3):149–59 (58 ref.)
Cancer anorexia-cachexia syndrome: are neuropeptides the key? Inui A. **Cancer Res** 1999 Sep 15;59(18):4493–501 (156 ref.)
Narcolepsy: a key role for hypocretins (orexins) [comment] Siegel JM. **Cell** 1999 Aug 20;98(4):409–12 (20 ref.) Comment on: Cell 1999 Aug 6;98(3):365–76. Comment on: Cell 1999 Aug 20;98(4):437–51.
Peptidases: structure, function and modulation of peptide-mediated effects in the human lung. van der Velden VH, et al. **Clin Exp Allergy** 1999 Apr;29(4):445–56 (50 ref.)
Calcitropic peptides: neural perspectives. Hull KL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):389–410 (309 ref.)
Evolution of neuroendocrine peptide systems: gonadotropin-releasing hormone and somatostatin. Lin XW, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):375–88 (105 ref.)
Neuropeptides in atopic dermatitis. Giannetti A. **Curr Probl Dermatol** 1999;28:51–5 (8 ref.)
The anti-gonadotropic effects of cytokines: the role of neuropeptides. Kalra PS, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):321–32 (55 ref.)
Hormonal effects on epilepsy in women. Klein P, et al. **Epilepsia** 1998;39 Suppl 8:S9–16 (92 ref.)
Immunomodulation by UV light: role of neuropeptides. Luger TA. **Eur J Dermatol** 1998 Apr-May;8(3):198–9 (18 ref.)
Neuropeptides in headache. Edvinsson L, et al. **Eur J Neurol** 1998 Jul;5(4):329–41 (92 ref.)
Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. Unger JW, et al. **Histol Histopathol** 1998 Oct;13(4):1215–24 (74 ref.)
State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Mark AL, et al. **Hypertension** 1999 Jan;33(1 Pt 2):537–41 (40 ref.)
Astroglial modulation of neurotransmitter/peptide release from the neurohypophysis: present status. Hatton GI. **J Chem Neuroanat** 1999 May;16(3):203–21 (147 ref.)
Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Arimura A. **Jpn J Physiol** 1998 Oct; 48(5):301–31 (240 ref.)
Sudden infant death syndrome and the modulation of neuropeptides released during shock. Reid GM. **Med Hypotheses** 1998 Jul;51(1):23–6 (26 ref.)
Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system. Yew DT, et al. **Microsc Res Tech** 1999 Jun 15;45(6):389–400 (123 ref.)
Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide. Blázquez E, et al. **Mol Neurobiol** 1998 Oct; 18(2):157–73 (80 ref.)
Neuropeptides, the hypothalamus and obesity: insights into the central control of body weight. Thorburn AW, et al. **Pathology** 1998 Aug;30(3):229–36 (109 ref.)
Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Nussdorfer GG, et al. **Peptides** 1998;19(8):1443–67 (346 ref.)
A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Porreca F, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7640–4 (41 ref.)
Endogenous and exogenous factors on sleep-wake cycle regulation. García-García F, et al. **Prog Neurobiol** 1999 Jul;58(4):297–314 (294 ref.)
Possible role of neuropeptides in obsessive compulsive disorder. McDougle CJ, et al. **Psychoneuroendocrinology** 1999 Jan;24(1):1–24 (150 ref.)
Invertebrate neurohormones and their receptors. Grimmelikhuijzen CJ, et al. **Results Probl Cell Differ** 1999; 26:339–62 (70 ref.)
Function of the neuropeptide head activator for early neural and neuroendocrine development. Hampe W, et al. **Results Probl Cell Differ** 1999;26:323–37 (30 ref.)
Humoral mechanisms and clinical aspects of biliary tract motility. Lonovics J, et al. **Scand J Gastroenterol Suppl** 1998;228:73–89 (186 ref.)
Paracrinology of endometrial neuropeptides: corticotropin-releasing hormone and opioids. Gravanis A, et al. **Semin Reprod Endocrinol** 1999;17(1):29–38 (87 ref.)
Modulation of reconstructed peptidergic synapses and electrical synapses by general anaesthetics. Winlow W, et al. **Toxicol Lett** 1998 Nov 23;100-101:77–84 (38 ref.)
Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444–9 (48 ref.)
Feeding and body-weight regulation by hypothalamic neuropeptides--mediation of the actions of leptin. Inui A. **Trends Neurosci** 1999 Feb;22(2):62–7 (83 ref.)
VIP and PACAP: very important in pain? Dickinson T, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):324–9 (77 ref.)
[Pituitary adenylate cyclase-activating polypeptide] Gonzalez BJ, et al. **Ann Endocrinol (Paris)** 1998 Dec; 59(5):364–405 (454 ref.) (Eng. Abstr.) **(Fre)**
[5HT-moduline an new peptide specifically interactive with the serotonergic system: physiopathologic implications] Fillion G. **Ann Pharm Fr** 1998;56(4):145–7 (7 ref.) (Eng. Abstr.) **(Fre)**
[Strategy for identification of new neuropeptides] Chartrel N, et al. **C R Seances Soc Biol Fil** 1998;192(4):619–38 (74 ref.) (Eng. Abstr.) **(Fre)**
[Understanding the action of the circadian clock: from phenomenologic ideas to molecular activity] Serviere J. **C R Seances Soc Biol Fil** 1998;192(4):683–710 (120 ref.) (Eng. Abstr.) **(Fre)**
[From neuropeptides and cytokines to psychotherapy. Skin diseases between psychoneuroimmunology research and psychosomatic treatment] Niemeier V, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:14–8 (45 ref.) (Eng. Abstr.) **(Ger)**
[Microcirculatory hemodynamics in oral tissues with reference to neurogenic response and reactive oxygen species interaction] Okabe E, et al. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):219–25 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Hippocampal cholinergic neurostimulating peptide] Ojika K. **Seikagaku** 1998 Sep;70(9):1175–80 (18 ref.) **(Jpn)**
[Pituitary adenylate cyclase activating peptide (PACAP)--its polyfunctionality in the mechanisms of brain protection] Chepurnov SA, et al. **Usp Fiziol Nauk** 1999 Apr-Jun; 30(2):3–20 (123 ref.) (Eng. Abstr.) **(Rus)**
[Neuropeptides, endogenous opioid peptides and cell proliferation] Stanović S, et al. **Lijec Vjesn** 1999 Mar; 121(3):82–7 (66 ref.) (Eng. Abstr.) **(Scr)**

NEUROPHARMACOLOGY

METHODS

Neuropharmacology of brain-stimulation-evoked aggression. Siegel A, et al. **Neurosci Biobehav Rev** 1999;23(3):359–89 (234 ref.)

TRENDS

Brain drugs of the future. Greenfield S. **BMJ** 1998 Dec 19–26; 317(7174):1698–701 (13 ref.)
Neuropsychopharmacology at the new millennium: new industry directions. Tallman JF. **Neuropsychopharmacology** 1999 Feb;20(2):99–105 (27 ref.)

NEUROPHYSIOLOGY

Neurophysiologic evaluation and clinical trials for neuromuscular diseases [editorial; comment] Olney RK. **Muscle Nerve** 1998 Nov;21(11):1365–7 (21 ref.) Comment on: Muscle Nerve 1998 Nov;21(11):1368–73.
[The importance of recent neuropsychological and neurophysiological studies for social psychiatry (editorial)] Galderisi S. **Epidemiol Psichiatr Soc** 1998 May-Aug; 7(2):82–8 (64 ref.) **(Ita)**

METHODS

Neurophysiological tests for the assessment of tremors. Deuschl G. **Adv Neurol** 1999;80:57–65 (51 ref.)
Neurophysiological evaluation of pain. Bromm B, et al. **Electroencephalogr Clin Neurophysiol** 1998 Oct; 107(4):227–53 (288 ref.)
The value of inching techniques in the diagnosis of focal nerve lesions. Inching is a useful technique. Campbell WW. **Muscle Nerve** 1998 Nov;21(11):1554–6; discussion 1561 (10 ref.)
The value of inching techniques in the diagnosis of focal nerve lesions. Inching techniques are of limited use. Geiringer SR. **Muscle Nerve** 1998 Nov;21(11):1557–9; discussion 1559–61 (18 ref.)
Practical considerations for the use of pseudorabies virus in transneuronal studies of neural circuitry. Card JP. **Neurosci Biobehav Rev** 1998 Oct;22(6):685–94 (46 ref.)
[The use of neurophysiopathological technics in assessing pain syndromes in industrial medicine and rehabilitation] Buonocore M, et al. **G Ital Med Lav Ergon** 1997 Oct-Dec; 19(4):164–71 (47 ref.) (Eng. Abstr.) **(Ita)**
[The present and future of neurophysiological examination] Ishiyama Y. **Rinsho Byori** 1998 Sep;46(9):879–86 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Contrast and color sensitivity in the diagnosis of glaucoma: neurophysiological aspects] Aref'eva IuA. **Vestn Oftalmol** 1998 Jul-Aug;114(4):49–51 (77 ref.) **(Rus)**

NEUROPIL

METABOLISM

Energetics of functional activation in neural tissues. Sokoloff L. **Neurochem Res** 1999 Feb;24(2):321–9 (31 ref.)

PATHOLOGY

The reduced neuropil hypothesis: a circuit based model of schizophrenia. Selemon LD, et al. **Biol Psychiatry** 1999 Jan 1;45(1):17–25 (91 ref.)

NEUROPROTECTIVE AGENTS

VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Brenneman DE, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:207-12 (24 ref.)

Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Inestrosa NC, et al. **Mol Neurobiol** 1998 Winter;17(1-3):73-86 (124 ref.)

ADMINISTRATION & DOSAGE

New concepts for drug therapy after stroke. Can we enhance recovery? Wahlgren NG, et al. **Cerebrovasc Dis** 1998;8 Suppl 5:33-8 (23 ref.)

METABOLISM

Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Offen D, et al. **Adv Neurol** 1999;80:265-9 (38 ref.)

PHARMACOLOGY

Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Gassen M, et al. **Adv Neurol** 1999;80:297-302 (37 ref.)

Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Offen D, et al. **Adv Neurol** 1999;80:265-9 (38 ref.)

Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Schubert P, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S21-8 (45 ref.)

Neuroprotection--rationale for pharmacological modulation of Na(+)-channels. Urenjak J, et al. **Amino Acids** 1998; 14(1-3):151-8 (67 ref.)

PACAP-38 protects cerebellar granule cells from apoptosis. Journot L, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:100-10 (53 ref.)

The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c-fos gene expression. Vaudry D, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:92-9 (25 ref.)

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Polinsky RJ. **Clin Ther** 1998 Jul-Aug; 20(4):634-47 (25 ref.)

The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Dannhardt G, et al. **Curr Med Chem** 1998 Aug;5(4):253-63 (58 ref.)

Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Kobayashi T, et al. **Eur J Pharmacol** 1998 Dec 11;363(1):1-15 (110 ref.)

New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Neufeld AH. **J Glaucoma** 1998 Dec;7(6):434-8 (44 ref.)

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. Grünblatt E, et al. **J Neural Transm Suppl** 1999;55:57-70 (58 ref.)

Craniocerebral trauma: protection and retrieval of the neuronal population after injury. Teasdale GM, et al. **Neurosurgery** 1998 Oct;43(4):723-37; discussion 737-8 (173 ref.)

Piracetam and platelets--a review of laboratory and clinical data. Evers S, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:44-8 (20 ref.)

Potent neuroprotectants linked to bifunctional inhibition [comment] Dawson VL. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10557-8 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10824-9.

Neuroprotective properties of statins in cerebral ischemia and stroke. Vaughan CJ, et al. **Stroke** 1999 Sep;30(9):1969-73 (40 ref.)

Introductory comments on neuroprotection. Kaufman PL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S89-90 (10 ref.)

Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Rupprecht R, et al. **Trends Neurosci** 1999 Sep;22(9):410-6 (63 ref.)

[New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)] Kapl D, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):317-21 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Challenges in translating the efficacy of neuroprotective agents in experimental models into knowledge of clinical benefits in head injured patients. Teasdale GM, et al. **Acta Neurochir Suppl (Wien)** 1999;73:111-6 (23 ref.)

Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Mielke R, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S29-35 (21 ref.)

New drugs for Alzheimer's disease. Delagarza VW. **Am Fam Physician** 1998 Oct 1;58(5):1175-82 (25 ref.)

Pharmacological advance in the treatment of acute brain injury. Tasker RC. **Arch Dis Child** 1999 Jul;81(1):90-5 (36 ref.)

New and emerging therapies for Parkinson disease. Jankovic J. **Arch Neurol** 1999 Jul;56(7):785-90 (56 ref.)

Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Ay H, et al. **Cerebrovasc Dis** 1999 May-Jun;9(3):131-5 (41 ref.)

Novel targets for therapeutic intervention against ischemic brain injury. Sun A, et al. **Clin Neuropharmacol** 1999 May-Jun;22(3):164-71 (66 ref.)

Clinical trial update: neuroprotection against acute ischaemic stroke. Devuyst G, et al. **Curr Opin Neurol** 1999 Feb; 12(1):73-9 (41 ref.)

Recent advances in developing neuroprotective strategies for perinatal asphyxia. Robertson NJ, et al. **Curr Opin Pediatr** 1998 Dec;10(6):575-80 (82 ref.)

Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Rother M, et al. **Dement Geriatr Cogn Disord** 1998 Jul;9 Suppl 1:36-43 (26 ref.)

Drug therapy for acute ischaemic stroke: risks versus benefits. Lindley RI. **Drug Saf** 1998 Nov;19(5):373-82 (40 ref.)

Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Rodnitzky RL. **Drugs** 1999 Jun; 57(6):845-9 (35 ref.)

Clinical pharmacology of dopamine agonists in Parkinson's disease. Lange KW. **Drugs Aging** 1998 Nov;13(5):381-9 (83 ref.)

Limiting neurological damage after stroke: a review of pharmacological treatment options. Read SJ, et al. **Drugs Aging** 1999 Jan;14(1):11-39 (294 ref.)

Rivastigmine. A review of its use in Alzheimer's disease. Spencer CM, et al. **Drugs Aging** 1998 Nov;13(5):391-411 (42 ref.)

Mechanisms of neuroprotection and applications in ocular disease. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S52-81; quiz S82-4 (0 ref.)

Psychophysical endpoints. Johnson CA. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S48-51 (10 ref.)

Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Weinreb RN, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S40-3 (29 ref.)

Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. Stoof JC, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):75-86 (107 ref.)

Neuroprotective agents in acute ischemic stroke. Hock NH. **J Cardiovasc Nurs** 1998 Oct;13(1):17-25 (27 ref.)

The pathophysiology of brain injury: understanding innovative drug therapies. Zafonte R, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):1-10 (73 ref.)

Therapeutic strategies based on immunological hypotheses of Alzheimer's disease. Möller HJ. **J Neural Transm Suppl** 1998;54:175-86 (28 ref.)

Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. Grondin R, et al. **J Neurol** 1998 Nov;245(11 Suppl 3):P35-42 (62 ref.)

Investigational neuroprotective drugs in traumatic brain injury. Cawley MJ, et al. **J Neurosci Nurs** 1998 Dec; 30(6):369-74 (36 ref.)

Neuroprotective and thrombolytic agents: advances in stroke treatment. Hock N. **J Neurosci Nurs** 1998 Jun;30(3):175-84 (51 ref.)

Management of amyotrophic lateral sclerosis with riluzole. Neatherlin JS. **J Neurosci Nurs** 1998 Aug;30(4):257-60 (14 ref.)

Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. McIntosh TK, et al. **J Neurotrauma** 1998 Oct;15(10):731-69 (548 ref.)

Neuroprotective therapies. Simon DK, et al. **Med Clin North Am** 1999 Mar;83(2):509-23, viii (99 ref.)

Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Skaper SD, et al. **Mol Cell Neurosci** 1998 Nov;12(4-5):179-93 (127 ref.)

Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Dunnett SB, et al. **Nature** 1999 Jun 24;399(6738 Suppl):A32-9 (99 ref.)

The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage. Dorsch NW. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:156-60 (13 ref.)

Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Bullock MR, et al. **Neurosurgery** 1999 Aug;45(2):207-17; discussion 217-20 (82 ref.)

Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy. Green AR. **Pharmacol Ther** 1998 Nov;80(2):123-47 (238 ref.)

Piracetam in the treatment of cortical myoclonus. Genton P, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:49-53 (28 ref.)

The effectiveness of piracetam in vertigo. Oosterveld WJ. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:54-60 (23 ref.)

Neuroprotective agents. Richardson JS. **Phys Med Rehabil Clin N Am** 1999 May;10(2):447-61 (89 ref.)

Oxidative damage in the central nervous system: protection by melatonin. Reiter RJ. **Prog Neurobiol** 1998 Oct; 56(3):359-84 (290 ref.)

Experimental therapeutics of neurodegenerative disorders: unmet needs. Shoulson I. **Science** 1998 Nov 6; 282(5391):1072-4 (20 ref.)

Neuroprotective therapy. Hickenbottom SL, et al. **Semin Neurol** 1998;18(4):485-92 (46 ref.)

Neuroprotection for acute stroke: making clinical trials work. Muir KW, et al. **Stroke** 1999 Jan;30(1):180-2 (13 ref.)

Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Levin LA. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S98-101 (26 ref.)

Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Osborne NN, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S102-28 (235 ref.)

Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Bowersox SS, et al. **Toxicon** 1998 Nov;36(11):1651-8 (32 ref.)

Snake envenomation and protective natural endogenous proteins: a mini review of the recent developments (1991-1997). Thwin MM, et al. **Toxicon** 1998 Nov; 36(11):1471-82 (64 ref.)

[Neuroprotective effects of anesthetics] Mantz J. **Ann Fr Anesth Reanim** 1999 May;18(5):588-92 (36 ref.) (Eng. Abstr.) **(Fre)**

[Prospects in the medical treatment of glaucomatous neuropathy. Basics of neuroprotection] Detry-Morel M. **J Fr Ophtalmol** 1999 Feb;22(1):122-34 (45 ref.) **(Fre)**

[Neuroprotection in stroke. A critical overview] Block F, et al. **Nervenarzt** 1999 Feb;70(2):101-10 (98 ref.) (Eng. Abstr.) **(Ger)**

[New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)] Kapl D, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):317-21 (26 ref.) (Eng. Abstr.) **(Ger)**

[Amyotrophic lateral sclerosis] Iwanowski L. **Neurol Neurochir Pol** 1999 Mar-Apr;33(2):445-50 (38 ref.) (Eng. Abstr.) **(Pol)**

[The application of cerebrolysine in ischemic stroke] Vilenskii BS, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999; 99(4):65-9 (43 ref.) **(Rus)**

[Pharmacologic cytoprotection of the central nervous system] Saniova B. **Bratisl Lek Listy** 1999 Mar; 100(3):156-60 (40 ref.) (Eng. Abstr.) **(Slo)**

[Riluzole as a treatment for amyotrophic lateral sclerosis] Borrás-Blasco J, et al. **Rev Neurol** 1998 Dec;27(160):1021-7 (47 ref.) (Eng. Abstr.) **(Spa)**

NEUROPSYCHOLOGICAL TESTS

Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Gallhofer B, et al. **Acta Psychiatr Scand Suppl** 1999;395:118-28 (102 ref.)

Backward masking performance as an indicator of vulnerability to schizophrenia. Green MF, et al. **Acta Psychiatr Scand Suppl** 1999;395:34-40 (30 ref.)

Rate of progression of mental decline in Alzheimer disease: summary of European studies. Bracco L, et al. **Alzheimer Dis Assoc Disord** 1998 Dec;12(4):347-55 (36 ref.)

Frontal, temporal and lateralized brain function in children with attention-deficit hyperactivity disorder: a psychophysiological and neuropsychological viewpoint on development. Oades RD. **Behav Brain Res** 1998 Jul; 94(1):83-95 (131 ref.)

An fMRI study of Stroop word-color interference: evidence for cingulate subregions subserving multiple distributed attentional systems. Peterson BS, et al. **Biol Psychiatry** 1999 May 15;45(10):1237-58 (100 ref.)

The Corsi block-tapping task: methodological and theoretical considerations. Berch DB, et al. **Brain Cogn** 1998 Dec; 38(3):317-38 (92 ref.)

Physical and occupational therapy. Case-Smith J, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):323-45 (72 ref.)

Comparative cognitive neuropsychological studies of frontal lobe function: implications for therapeutic strategies in frontal variant frontotemporal dementia. Rahman S, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:15-28 (93 ref.)

Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Simard M, et al. **Drugs Aging** 1999 Mar;14(3):197-230 (180 ref.)

Neuropsychological assessment of competency to stand trial evaluations: a practical conceptual model. Kirkish P, et al. **J Am Acad Psychiatry Law** 1999;27(1):101-13 (30 ref.)

Research on chronic, low-level exposure to formaldehyde: implications for neuropsychological assessment. Williams CW, et al. **J Clin Psychol** 1998 Oct;54(6):851-62 (90 ref.)

Future directions for the neuropsychological assessment of sports concussion. Bleiberg J, et al. **J Head Trauma Rehabil** 1998 Apr;13(2):36-44 (19 ref.)

The neuropsychiatry of chronic cocaine abuse. Bolla KI, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer; 10(3):280-9 (82 ref.)

Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. Lauterbach EC, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer; 10(3):249-66 (256 ref.)

The antisaccade: a review of basic research and clinical studies. Everling S, et al. **Neuropsychologia** 1998 Sep; 36(9):885-99 (133 ref.)

Connectionist investigations of individual differences in Stroop performance. Phaf RH, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):899-914 (21 ref.)

Should schizophrenia be treated as a neurocognitive disorder? Green MF, et al. **Schizophr Bull** 1999;25(2):309-19 (60 ref.)

The effects of clozapine, risperidone, and olanzapine on

cognitive function in schizophrenia. Meltzer HY, et al. **Schizophr Bull** 1999;25(2):233–55 (115 ref.)
Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. Spaulding WD, et al. **Schizophr Bull** 1999;25(2):275–89 (65 ref.)
The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)
[Neuropsychological sequelae of children treated for brain tumors: evaluation and risk factors] Grill J, et al. **Arch Pediatr** 1998 Feb;5(2):167–73 (62 ref.) (Eng. Abstr.) **(Fre)**
[Stroop test and schizophrenia] Grapperon J, et al. **Encephale** 1999 Jan–Feb;25(1):50–8 (63 ref.) (Eng. Abstr.) **(Fre)**
[Neuropsychological aspects of dementia diagnosis] Forster E. **Ther Umsch** 1999 Feb;56(2):83–7 (11 ref.) (Eng. Abstr.) **(Ger)**
[Hepatic encephalopathy: neuropsychological and neurophysiological diagnosis] Kuhlbusch R, et al. **Z Gastroenterol** 1998 Dec;36(12):1075–83 (30 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Brain is related to behavior ($p<.05$). Zakzanis KK. **J Clin Exp Neuropsychol** 1998 Jun;20(3):419–27 (67 ref.)

NEUROPSYCHOLOGY

[For a "neurocognitive" approach to memory: value of neuropsychology] Dubois B. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):235–9 (11 ref.) (Eng. Abstr.) **(Fre)**
[The importance of recent neuropsychological and neurophysiological studies for social psychiatry (editorial)] Galderisi S. **Epidemiol Psichiatr Soc** 1998 May–Aug; 7(2):82–8 (64 ref.) **(Ita)**

HISTORY

[Outstanding neuropsychiatric scientific activities of physicians at the Lipótmező mental institution from the institute's foundation to the 1950's] Kárpáti M. **Orv Hetil** 1999 Mar 21;140(12):661–6 (64 ref.) **(Hun)**

METHODS

Early diagnosis of dementia: neuropsychology. Pasquier F. **J Neurol** 1999 Jan;246(1):6–15 (102 ref.)

TRENDS

Current trends in cognitive rehabilitation for memory disorders. Kashima H, et al. **Keio J Med** 1999 Jun; 48(2):79–86 (55 ref.)

NEURORADIOGRAPHY

Neuroradiologic review of intracranial infection. Smith RR, et al. **Curr Probl Diagn Radiol** 1999 Jan–Feb;28(1):1–26 (332 ref.)
Proton magnetic resonance spectroscopy in pediatric neuroradiology. Moore GJ. **Pediatr Radiol** 1998 Nov; 28(11):805–14 (41 ref.)

METHODS

Case presentations of neuroradiologic interventions for acute cerebrovascular disease. Bader MK. **J Cardiovasc Nurs** 1998 Oct;13(1):1–16 (26 ref.)

NEURORECEPTORS see **RECEPTORS, SENSORY**

NEUROREGULATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROREGULATORS see **NEUROTRANSMITTERS**

NEUROSCIENCES

Childhood anxiety: integrating developmental psychopathology and affective neuroscience. Pine DS, et al. **J Child Adolesc Psychopharmacol** 1999;9(1):1–12 (90 ref.)
Outcomes research and the neuroscience nurse: what's in it for clinical practice? Mitchell PH. **J Neurosci Nurs** 1998 Oct;30(5):318–21 (35 ref.)
Neuroscience nursing practice in a new millennium. Hickey JV, et al. **Nurs Clin North Am** 1999 Sep;34(3):541–54 (24 ref.)
Ethical perspectives in neuroscience nursing practice. Murphy WJ. **Nurs Clin North Am** 1999 Sep;34(3):621–35 (38 ref.)
The brain and child development: time for some critical thinking [see comments] Bruer JT. **Public Health Rep** 1998 Sep–Oct;113(5):388–97 (37 ref.) Comment in: Public Health Rep 1998 Nov–Dec;113(6):480–1.
[The Miguel F. Jiménez Annual Conference. Neurosciences and their role in contemporary medicine] Aréchiga–Urtuzuástegui H. **Gac Med Mex** 1998 Sep–Oct; 134(5):567–73 (38 ref.) **(Spa)**

TRENDS

The promise of the neurosciences. Daniels AM. **BMJ** 1998 Dec 19–26;317(7174):1728 (4 ref.)
Mitotic neurons: a dogma succumbs [comment] Raina AK, et al. **Exp Neurol** 1999 Sep;159(1):248–9 (19 ref.) Comment on: Exp Neurol 1999 Sep;159(1):237–47.
A philosopher looks at neuroscience. Beedle AS. **J Neurosci Res** 1999 Jan 15;55(2):141–6 (13 ref.)
The Human Brain Project: neuroinformatics tools for integrating, searching and modeling multidisciplinary neuroscience data. Shepherd GM, et al. **Trends Neurosci** 1998 Nov;21(11):460–8 (27 ref.)
[Brain science in the 21st century] Ito M. **No To Hattatsu** 1999 Mar;31(2):114–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

NEUROSECRETION

PHYSIOLOGY

Docking and fusion in neurosecretion. Robinson LJ, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):483–92 (74 ref.)
Neurohormonal responses during positive pressure mechanical ventilation. Frazier SK. **Heart Lung** 1999 May–Jun;28(3):149–65; quiz 166–7 (58 ref.)

NEUROSECRETORY SYSTEMS

see related
NEUROIMMUNOMODULATION
NEUROSECRETION

CYTOLOGY

Biogenesis of secretory granules in the trans-Golgi network of neuroendocrine and endocrine cells. Tooze SA. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):231–44 (110 ref.)
Neuroendocrine and immune mediators in prostate cancer progression. Hoosein NM. **Front Biosci** 1998 Dec 15; 3:D1274–9 (50 ref.)
Gastric neuroendocrine cells and secretory products. Oberg K. **Yale J Biol Med** 1998 May–Aug;71(3–4):149–54 (37 ref.)

DRUG EFFECTS

Selective serotonin reuptake inhibitors and neuroendocrine function. Raap DK, et al. **Life Sci** 1999;65(12):1217–35 (228 ref.)

EMBRYOLOGY

Maternal endocrine adaptations to placental hormones in humans. Evain-Brion D. **Acta Paediatr Suppl** 1999 Feb; 88(428):12–6 (46 ref.)
Function of the neuropeptide head activator for early neural and neuroendocrine development. Hampe W, et al. **Results Probl Cell Differ** 1999;26:323–37 (30 ref.)

IMMUNOLOGY

Integration of neuro–endocrine immune responses in defense of mucosal surfaces. Befus AD, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):26–34 (94 ref.)
Neuroimmunoregulation and natural immunity. Berczi I, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):273–81 (30 ref.)
Endotoxins and endocrine system. Bertók L. **Domest Anim Endocrinol** 1998 Sep;15(5):305–8 (21 ref.)
Sex- and stress–steroids interactions and the immune system: evidence for a neuroendocrine–immunological sexual dimorphism. Gaillard RC, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):345–52 (18 ref.)
Neuroendocrine–immune interactions in the neonate. Matteri RL, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):397–407 (76 ref.)
Coordinated host defense through an integration of the neural, immune and haemopoietic systems. Miyan JA, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):297–304 (20 ref.)
Cytokines in the neuroendocrine system. Gaillard RC. **Int Rev Immunol** 1998;17(1–4):181–216 (229 ref.)
[Liver and endocrine system. Part I: pituitary–thyroid axis activity disorders] Marek B, et al. **Wiad Lek** 1998; 51(5–6):271–6 (23 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Neuroendocrine activation in left ventricular dysfunction [editorial; comment] Ferrari R, et al. **Eur Heart J** 1998 Oct;19(10):1423–4 (8 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1552–63.
Metabolism and trafficking of N-type voltage–operated calcium channels in neurosecretory cells. Sher E, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):399–407 (110 ref.)
Thymic expression of neuroendocrine self–peptide precursors: role in T cell survival and self–tolerance. Geenen V, et al. **J Neuroendocrinol** 1998 Nov;10(11):811–22 (137 ref.)
Release of vasopressin within the brain contributes to neuroendocrine and behavioral regulation. Landgraf R, et al. **Prog Brain Res** 1998;119:201–20 (99 ref.)
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Rupprecht R, et al. **Trends Neurosci** 1999 Sep;22(9):410–6 (63 ref.)

PATHOLOGY

Imaging of neuroendocrine disorders of childhood. Poussaint TY, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):157–75 (120 ref.)
Oncocytic lesions of the neuroendocrine system. Baloch ZW, et al. **Semin Diagn Pathol** 1999 May;16(2):190–9 (113 ref.)

PHYSIOLOGY

Maternal endocrine adaptations to placental hormones in humans. Evain-Brion D. **Acta Paediatr Suppl** 1999 Feb; 88(428):12–6 (46 ref.)
Neuroendocrine regulation of food intake. Seeley RJ, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):58–61 (37 ref.)
Mechanisms of neuroendocrine cell excitability. Hatton GI, et al. **Adv Exp Med Biol** 1998;449:79–95 (86 ref.)
Neuroendocrine differentiation, neuropeptides, and neprilysin. Cohen AJ, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):1–3 (20 ref.)
The pulmonary neuroendocrine system: the past decade. Van Lommel A, et al. **Arch Histol Cytol** 1999 Mar;62(1):1–16 (111 ref.)
Fish as models for the neuroendocrine regulation of reproduction and growth. Blázquez M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):345–64 (214 ref.)
Evolution of neuroendocrine peptide systems: gonadotropin–releasing hormone and somatostatin. Lin XW, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):375–88 (105 ref.)
Photo–neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283–94 (78 ref.)
Counter–regulatory hormones and mechanisms in amino acid metabolism with special reference to the catabolic response in skeletal muscle. Hasselgren PO, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):9–14 (50 ref.)
The molecular basis for bidirectional communication between the immune and neuroendocrine systems. Jiang CL, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):363–9 (21 ref.)
Neuroendocrine influences and repercussions of the menopause. Wise PM, et al. **Endocr Rev** 1999 Jun; 20(3):243–8 (60 ref.)
Neuroregulation of ProTRH biosynthesis and processing. Nillni EA. **Endocrine** 1999 Jun;10(3):185–99 (208 ref.)
The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Kuiper GG, et al. **Front Neuroendocrinol** 1998 Oct;19(4):253–86 (170 ref.)
Extrapineal melatonin: location and role within diffuse neuroendocrine system. Kvetnoy IM. **Histochem J** 1999 Jan;31(1):1–12 (70 ref.)
Glial–neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids. Ojeda SR, et al. **J Neurobiol** 1999 Sep 15;40(4):528–40 (95 ref.)
Regulated exocytosis in neurons and neurosecretory cells: structural events and expression competence. Meldolesi J. **J Physiol Paris** 1998 Apr;92(2):119–21 (10 ref.)
Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Arimura A. **Jpn J Physiol** 1998 Oct; 48(5):301–31 (240 ref.)
Multifactorial control of the release of hormones from the locust retrocerebral complex. Vullings HG, et al. **Microsc Res Tech** 1999 May 1;45(3):142–53 (105 ref.)
Epidermal growth factor tyrosine kinase receptors and the neuroendocrine control of mammalian puberty. Ojeda SR, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):101–6 (49 ref.)
Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Murphy LL, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):432–46 (126 ref.)
The thymic repertoire of neuroendocrine–related self antigens: biological role in T–cell selection and pharmacological implications. Geenen V, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):115–25 (107 ref.)
Luteolysis: a neuroendocrine–mediated event. McCracken JA, et al. **Physiol Rev** 1999 Apr;79(2):263–323 (751 ref.)
Neuroendocrine control of growth hormone secretion. Müller EE, et al. **Physiol Rev** 1999 Apr;79(2):511–607 (1131 ref.)
The suprachiasmatic nucleus–paraventricular nucleus interactions: a bridge to the neuroendocrine and autonomic nervous system. Buijs RM, et al. **Prog Brain Res** 1998; 119:365–82 (93 ref.)
Physiological pathways regulating the activity of magnocellular neurosecretory cells. Leng G, et al. **Prog Neurobiol** 1999 Apr;57(6):625–55 (278 ref.)
Neuroendocrine perspectives on social attachment and love. Carter CS. **Psychoneuroendocrinology** 1998 Nov; 23(8):779–818 (205 ref.)
Vasopressin receptors: structural functional relationships and role in neural and endocrine regulation. Schoots O, et al. **Results Probl Cell Differ** 1999;26:107–33 (90 ref.)
Acute and prolonged critical illness are two distinct neuroendocrine paradigms. Van den Berghe GH. **Verh K Acad Geneeskd Belg** 1998;60(6):487–518; discussion 518–20 (95 ref.)
[Physiological and sensorial determinism of maternal behavior in mammals] Lévy F. **Contracept Fertil Sex** 1998 Oct;26(10):718–27 (78 ref.) (Eng. Abstr.) **(Fre)**

NEUROSECRETORY SYSTEMS

[Neuroendocrine regulation of the mucosal immune system] Nagura H. **Arerugi** 1999 Apr;48(4):409–13 (24 ref.) **(Jpn)**
[Extrapineal melatonin: its place and role in the neuroendocrine regulation of homeostasis] Kvetnoi IM, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):364–70 (60 ref.) **(Rus)**

PHYSIOPATHOLOGY

Neuroendocrine aspects of chronic fatigue syndrome: a commentary. Demitrack MA. **Am J Med** 1998 Sep 28; 105(3A):11S–14S (17 ref.)
Neuroendocrine immune features of pediatric inflammatory rheumatic diseases. Chikanza IC. **Ann N Y Acad Sci** 1999 Jun 22;876:71–80; discussion 80–2 (47 ref.)
Physiology and pathophysiology of baroreceptor function and neuro-hormonal abnormalities in heart failure. Kirchheim HR, et al. **Basic Res Cardiol** 1998;93 Suppl 1:1–22 (192 ref.)
The neuroendocrine stress response and modern intensive care: the concept revisited. Van den Berghe GH. **Burns** 1999 Feb;25(1):7–16 (98 ref.)
Neuroendocrine activity and memory-related impairments in posttraumatic stress disorder. Golier J, et al. **Dev Psychopathol** 1998 Fall;10(4):857–69 (63 ref.)
Neuroendocrine aspects of polycystic ovary syndrome. Marshall JC, et al. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):295–324 (88 ref.)
Effects of epilepsy on women's reproductive health. Morrell MJ. **Epilepsia** 1998;39 Suppl 8:S32–7 (61 ref.)
Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Griffiths K, et al. **Eur Urol** 1999;35(5–6):443–55 (78 ref.)
The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Bohus B, et al. **Prog Brain Res** 1998;119:555–73 (112 ref.)
Psychological stress and neuroendocrine function in humans: the last two decades of research. Biondi M, et al. **Psychother Psychosom** 1999;68(3):114–50 (210 ref.)

ULTRASTRUCTURE

Protein hormone storage in secretory granules: mechanisms for concentration and sorting. Dannies PS. **Endocr Rev** 1999 Feb;20(1):3–21 (200 ref.)

NEUROSES see **NEUROTIC DISORDERS**

NEUROSES, ANXIETY see **ANXIETY DISORDERS**

NEUROSES, NEURASTHENIC see **NEURASTHENIA**

NEUROSES, PHOBIC see **PHOBIC DISORDERS**

NEUROSES, POST-TRAUMATIC see **STRESS DISORDERS, POST-TRAUMATIC**

NEUROSES, WAR see **COMBAT DISORDERS**

NEUROSIS, DEPRESSIVE see **DEPRESSIVE DISORDER**

NEUROSIS, HYPOCHONDRIACAL see **HYPOCHONDRIASIS**

NEUROSIS, OBSESSIVE-COMPULSIVE see **OBSESSIVE-COMPULSIVE DISORDER**

NEUROSPORA

GENETICS

Seeing the light: news in Neurospora blue light signal transduction. Linden H, et al. **Adv Genet** 1999;41:35–54 (66 ref.)

PHYSIOLOGY

Time at the end of the millennium: the Neurospora clock. Loros JJ. **Curr Opin Microbiol** 1998 Dec;1(6):698–706 (96 ref.)

RADIATION EFFECTS

Seeing the light: news in Neurospora blue light signal transduction. Linden H, et al. **Adv Genet** 1999;41:35–54 (66 ref.)

NEUROSPORA CRASSA

CYTOLOGY

Cell-to-cell communication in differentiation of mycelial fungi. Belozerskaya TA. **Membr Cell Biol** 1998; 11(6):831–40 (61 ref.)

ENZYMOLOGY

The structure of the vacuolar ATPase in Neurospora crassa. Margolles-Clark E, et al. **J Bioenerg Biomembr** 1999 Feb; 31(1):29–37 (51 ref.)

GENETICS

Differential stress gene expression during the development of Neurospora crassa and other fungi. Rensing L, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):159–66 (47 ref.)

GROWTH & DEVELOPMENT

Differential stress gene expression during the development of Neurospora crassa and other fungi. Rensing L, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):159–66 (47 ref.)

PHYSIOLOGY

Carbon catabolite repression of gene expression and conidiation in Neurospora crassa. Ebbole DJ. **Fungal Genet Biol** 1998 Oct;25(1):15–21 (50 ref.)
Microconidia of Neurospora crassa. Maheshwari R. **Fungal Genet Biol** 1999 Feb;26(1):1–18 (91 ref.)

NEUROSURGERY

see related
NEUROSURGICAL PROCEDURES

Latex allergy in neurosurgical practice. Mazagri R, et al. **Childs Nerv Syst** 1999 Aug;15(8):404–7 (45 ref.)
The peer-review process of the Journal of Neurosurgery. Firlik KS, et al. **J Neurosurg** 1999 Feb;90(2):364–70 (16 ref.)
Use of ADCON in neurosurgery: preclinical review. Lo H, et al. **Neurol Res** 1999;21 Suppl 1:S27–32 (21 ref.)
Geographical neurosurgery. Ohaegbulam SC. **Neurol Res** 1999 Mar;21(2):161–70 (206 ref.)
Outcomes research: a review [see comments] Gerszten PC. **Neurosurgery** 1998 Nov;43(5):1146–56 (78 ref.) Comment in: Neurosurgery 1999 Apr;44(4):919–20.
[Current trends and prospects of fetal neurosurgery] Pastore FS, et al. **Ann Ital Chir** 1998 May-Jun;69(3):295–301 (26 ref.) (Eng. Abstr.) **(Ita)**
[The use of computers and networking in the neurosurgical field] Oizumi T, et al. **Rinsho Byori** 1999 Feb;47(2):119–25 (3 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Image-guided neurosurgery/neuronavigation/the SurgiScope—reflexions on a theme. Haase J. **Minim Invasive Neurosurg** 1999 Jun;42(2):53–9 (37 ref.)

HISTORY

Sir Charles Ballance: pioneer British neurological surgeon. Stone JL. **Neurosurgery** 1999 Mar;44(3):610–31; discussion 631–2 (172 ref.)

INSTRUMENTATION

Use of surgical wands in neurosurgery. Zamorano L, et al. **Adv Tech Stand Neurosurg** 1998;24:77–128 (64 ref.)

METHODS

Intracranial endoscopy. Fries G, et al. **Adv Tech Stand Neurosurg** 1999;25:21–60 (145 ref.)
Applications of image-guided surgery to intraoperative electrophysiology. Alonso-Vanegas MA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:140–56 (76 ref.)
Neurosurgical tools and techniques—modern image-guided surgery. Haase J. **Neurol Med Chir (Tokyo)** 1998 Sep;38 Suppl:303–7 (18 ref.)
Comprehensive management of arteriovenous malformations. de Oliveira E, et al. **Neurol Res** 1998 Dec;20(8):673–83 (1 ref.)
Maternal shunt dependency: implications for obstetric care, neurosurgical management, and pregnancy outcomes and a review of selected literature. Bradley NK, et al. **Neurosurgery** 1998 Sep;43(3):448–60; discussion 460–1 (15 ref.)
[Colloid cysts in the 3rd ventricle: a microsurgical series and new perspectives] Brunori A, et al. **Ann Ital Chir** 1999 Jan-Feb;70(1):23–7; discussion 28 (42 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

Recent advances: neurosurgery. Powell M. **BMJ** 1999 Jan 2;318(7175):35–8 (17 ref.)
New developments in the surgery for Parkinson's disease. Honey C, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S45–52 (87 ref.)
Present technology and future applications. Bailes JE. **Clin Neurosurg** 1999;45:192–201 (16 ref.)
Neurological surgery. Sonntag VK, et al. **J Am Coll Surg** 1999 Feb;188(2):161–70 (45 ref.)

NEUROSURGICAL PROCEDURES

see related
NEUROSURGERY

Clinical significance of Candida species isolated from cerebrospinal fluid following neurosurgery. Geers TA, et al. **Clin Infect Dis** 1999 May;28(5):1139–47 (27 ref.)
Intraoperative cortical mapping as a guide to the surgical resection of gliomas. Matz PG, et al. **J Neurooncol** 1999 May;42(3):233–45 (27 ref.)
Basic surgical techniques in the resection of malignant gliomas. Toms SA, et al. **J Neurooncol** 1999 May; 42(3):215–26 (40 ref.)
[What are the indications for neurosurgery in the early stage of head injury?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):58–71 (31 ref.) **(Fre)**
[Low back pain: the neurosurgical viewpoint] Lanner G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec;33(12):798–800 (6 ref.) **(Ger)**
[The prevention of thromboembolic complications in neurosurgery] Polishchuk MIe, et al. **Klin Khir** 1998; (9–10):76–9 (22 ref.) **(Ukr)**

ADVERSE EFFECTS

[Central nervous system infections in neurosurgery. Cerebral ischemia] Ravussin P, et al. **Ann Fr Anesth Reanim** 1999 May;18(5):481–6 (32 ref.) **(Fre)**

HISTORY

Historical development of surgery for glial tumors. Salcman M. **J Neurooncol** 1999 May;42(3):195–204 (63 ref.)

INSTRUMENTATION

The role of image-guided technology in the surgical planning and resection of gliomas. Barnett GH. **J Neurooncol** 1999 May;42(3):247–58 (62 ref.)

METHODS

The sitting position in neurosurgery: a critical appraisal. Porter JM, et al. **Br J Anaesth** 1999 Jan;82(1):117–28 (84 ref.)
Neurosurgical aspects of sphenoid sinus mucocele. Iqbal J, et al. **Br J Neurosurg** 1998 Dec;12(6):527–30 (23 ref.)
Neurosurgical treatment of obsessive-compulsive disorder [see comments] Jenike MA. **Br J Psychiatry Suppl** 1998; (35):79–90 (100 ref.) Comment in: Br J Psychiatry 1998 Dec;173:537.
Application of skull base techniques to pediatric neurosurgery. Teo C, et al. **Childs Nerv Syst** 1999 Mar; 15(2–3):103–9 (18 ref.)
Image-guided neurosurgery/neuronavigation/the SurgiScope—reflexions on a theme. Haase J. **Minim Invasive Neurosurg** 1999 Jun;42(2):53–9 (37 ref.)
Intramedullary cavernous angioma. Resection by oblique corpectomy. Fontaine D, et al. **Surg Neurol** 1999 Apr; 51(4):435–41; discussion 441–2 (33 ref.)
[Neurosurgical treatment of abnormal movement disorders and spasticity] Heikkinen E. **Duodecim** 1995; 111(21):2058–65 (17 ref.) **(Fin)**
[The initial treatment and the site of care in brain injury] Helén P, et al. **Duodecim** 1995;111(21):1993–8 (19 ref.) **(Fin)**
[Pain surgery] Kivipelto L, et al. **Duodecim** 1995; 111(21):2066–70 (10 ref.) **(Fin)**
[Diagnosis and treatment of spinal cord tumors] Seppälä M. **Duodecim** 1995;111(21):2071–7 (17 ref.) **(Fin)**
[Treatment of pituitary tumors] Valtonen S, et al. **Duodecim** 1995;111(21):2013–9 (35 ref.) **(Fin)**
[The retro-auricular, transmastoid, infralabyrinth approach. A simple route for excision of tumors of the jugular foramen] Fournier HD, et al. **Neurochirurgie** 1998 Apr; 44(2):111–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Neuronavigation. Computer-assisted neurosurgery] Ostertag CB, et al. **Nervenarzt** 1999 Jun;70(6):517–21 (38 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. Bronstein JM, et al. **Arch Neurol** 1999 Sep;56(9):1064–9 (41 ref.)

TRENDS

Neurosurgery of the spine in the year 2001: a four-year review. Haid RW Jr, et al. **Clin Neurosurg** 1999;45:153–9 (18 ref.)
Historical perspective and future direction. Mapstone TB. **Clin Neurosurg** 1999;45:177–83 (18 ref.)
Trends in surgical management of astrocytomas and other brain gliomas. Palma L. **Forum (Genova)** 1998 Jul-Sep; 8(3):272–81 (110 ref.)
Neurological surgery. Sonntag VK, et al. **J Am Coll Surg** 1999 Feb;188(2):161–70 (45 ref.)
[The molecular genetics of gliomas and the outlook for molecular neurosurgery] Zozulia IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct-Dec; (4):45–51 (132 ref.) **(Rus)**

NEUROSYPHILIS

[General paresis] Kitagawa Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):318–23 (16 ref.) **(Jpn)**

COMPLICATIONS

De novo status epilepticus as the presenting sign of neurosyphilis. Primavera A, et al. **Epilepsia** 1998 Dec; 39(12):1367–9 (11 ref.)

DIAGNOSIS

The elderly psychiatric patient with positive syphilis serology: the problem of neurosyphilis. Bharwani IL, et al. **Int J Psychiatry Med** 1998;28(3):333–9 (27 ref.)
Otoneurosyphilis masquerading as neurofibromatosis type II.

Ahmad I, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb;61(1):37–40 (17 ref.)

NEUROTENDINOUS SPINDLES see **MECHANORECEPTORS**

NEUROTENSIN

see related
RECEPTORS, NEUROTENSIN

PHYSIOLOGY

Neurotensin and neurotensin receptors. Vincent JP, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):302–9 (67 ref.)

NEUROTENSIN RECEPTORS see **RECEPTORS, NEUROTENSIN**

NEUROTIC DISORDERS

[Neuroses in present-day internal medicine] Krylov AA, et al. **Klin Med (Mosk)** 1998;76(9):60–3 (11 ref.) **(Rus)**

PSYCHOLOGY

The uses of culture in the making of AIDS neurosis in Japan. Miller E. **Psychosom Med** 1998 Jul–Aug;60(4):402–9 (23 ref.)

The fibromyalgia syndrome as a manifestation of neuroticism? Netter P, et al. **Z Rheumatol** 1998;57 Suppl 2:105–8 (32 ref.)

[The psychophysiology of neuroses] Kharitonov SV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(6):59–62 (110 ref.) **(Rus)**

THERAPY

[Clinical hypnosis. Current status of theory and empirical aspects] Revenstorf D.
Psychother Psychosom Med Psychol 1999 Jan;49(1):5–13 (68 ref.) (Eng. Abstr.) **(Ger)**

NEUROTIZATION see **NERVE TRANSFER**

NEUROTOXINS

ADMINISTRATION & DOSAGE

Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. Chancellor MB, et al. **J Urol** 1999 Jul;162(1):3–11 (63 ref.)

ADVERSE EFFECTS

Long-term health effects of low dose exposure to nerve agent. Moore DH. **J Physiol Paris** 1998 Jun–Aug; 92(3–4):325–8 (16 ref.)

Approach to neurotoxicity tort cases. Feldman RG, et al. **Neurol Clin** 1999 May;17(2):267–81 (36 ref.)

[Behavioral effects of exposure as indicators of neurotoxicity] Gralewicz S. **Med Pr** 1998;49(4):407–14 (37 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. Castagnoli N Jr, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):31–8 (40 ref.)

CHEMISTRY

Polypeptide neurotoxins from spider venoms. Grishin E. **Eur J Biochem** 1999 Sep;264(2):276–80 (39 ref.)

Scorpion toxins specific for Na+-channels. Possani LD, et al. **Eur J Biochem** 1999 Sep;264(2):287–300 (156 ref.)

Snake venom alpha-neurotoxins and other 'three-finger' proteins. Tsetlin V. **Eur J Biochem** 1999 Sep;264(2):281–6 (60 ref.)

METABOLISM

N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease. Naoi M, et al. **Adv Neurol** 1999; 80:259–64 (17 ref.)

Fighting nerve agent chemical weapons with enzyme technology. LeJeune KE, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:153–70 (38 ref.)

Nitric oxide in cerebral ischemic neurodegeneration and excitotoxicity. Strijbos PJ. **Crit Rev Neurobiol** 1998; 12(3):223–43 (196 ref.)

The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders. Massieu L, et al. **Neurobiology (Bp)** 1998;6(1):99–108 (54 ref.)

Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease. Kanfer JN, et al. **Neurosci Lett** 1998 Nov 27;257(2):93–6 (27 ref.)

Prostaglandins as putative neurotoxins in Alzheimer's disease. Prasad KN, et al. **Proc Soc Exp Biol Med** 1998 Nov; 219(2):120–5 (82 ref.)

Glutamate toxicity in chronic neurodegenerative disease. Lancelot E, et al. **Prog Brain Res** 1998;116:331–47 (190 ref.)

Intracellular calcium and magnesium: critical determinants of excitotoxicity? Reynolds IJ. **Prog Brain Res** 1998; 116:225–43 (162 ref.)

Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain. Baram TZ, et al. **Trends Neurosci** 1998 Nov;21(11):471–6 (86 ref.)

PHARMACOLOGY

Mechanical and excitotoxic lesion of motoneurons: effects of neurotrophins and ciliary neurotrophic factor on survival and regeneration. Wiese S, et al.
Acta Neurochir Suppl (Wien) 1999;73:31–9 (53 ref.)

Role of iron in 6-hydroxydopamine neurotoxicity. Double KL, et al. **Adv Neurol** 1999;80:287–96 (83 ref.)

Cyclosporine neurotoxicity: a review. Gijtenbeek JM, et al. **J Neurol** 1999 May;246(5):339–46 (73 ref.)

Molecular mechanisms of lead neurotoxicity. Bressler J, et al. **Neurochem Res** 1999 Apr;24(4):595–600 (64 ref.)

Alpha neurotoxins and their relatives: foes and friends? Hall ZW. **Neuron** 1999 May;23(1):4–5 (8 ref.)

[Natural neurotoxins as pharmacological tools for the study of the central nervous system] Martínez-Martos JM, et al. **Rev Neurol** 1998 Apr;26(152):584–91 (156 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Neurotoxic mechanisms of degeneration in motor neuron diseases. Ludolph AC, et al. **Drug Metab Rev** 1999 Aug; 31(3):619–34 (75 ref.)

Morphological, biochemical and behavioural changes induced by neurotoxic and inflammatory insults to the nucleus basalis. Casamenti F, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):705–14 (67 ref.)

A new approach to insect-pest control--combination of neurotoxins interacting with voltage sensitive sodium channels to increase selectivity and specificity. Gordon D. **Invert Neurosci** 1997 Sep–Dec;3(2–3):103–16 (55 ref.)

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. Grünblatt E, et al.
J Neural Transm Suppl 1999;55:57–70 (58 ref.)

Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Hansen HS, et al.
Lipids 1999;34 Suppl:S327–30 (37 ref.)

3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Alexi T, et al. **Neuroreport** 1998 Aug 3;9(11):R57–64 (72 ref.)

Neurotoxins and neurodegenerative disorders. Vécsei L, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):511–4 (29 ref.)

NEUROTRANSMITTER AGENTS

PHARMACOLOGY

Cognition enhancement strategies by ion channel modulation of neurotransmission. Eid CN Jr, et al.
Curr Pharm Des 1999 May;5(5):345–61 (351 ref.)

THERAPEUTIC USE

Reappraising neurotransmitter-based strategies. Möller HJ. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl 2:S53–9 (56 ref.)

NEUROTRANSMITTER UPTAKE INHIBITORS

Tiagabine: a novel antiepileptic drug [see comments] Luer MS, et al. **Ann Pharmacother** 1998 Nov;32(11):1173–80 (48 ref.) Comment in: Ann Pharmacother 1998 Nov;32(11):1239–43.

NEUROTRANSMITTERS

see related
NEUROIMMUNOMODULATION
RECEPTORS, NEUROTRANSMITTER

ANALYSIS

Cytochemistry of neurotransmitters: from statical analysis to the understanding of dynamic processes. Bovolin P, et al. **Eur J Histochem** 1998;42 Spec No:55–62 (37 ref.)

ANTAGONISTS & INHIBITORS

The role of neurohormonal antagonists in hibernating myocardium. Lahiri A, et al. **J Cardiovasc Pharmacol** 1999 Jun;33 Suppl 3:S9–16 (72 ref.)

The role of excitotoxicity in neurodegenerative disease: implications for therapy. Doble A. **Pharmacol Ther** 1999 Mar;81(3):163–221 (694 ref.)

BIOSYNTHESIS

Transmitting transmitter phenotypes in brain development. Götz M. **Perspect Dev Neurobiol** 1998;5(2–3):145–57 (96 ref.)

Genetic analysis of the role of protein kinase C signaling pathways in behaviors by direct gene transfer with HSV-1 vectors. Geller AI. **Rev Neurosci** 1999;10(1):1–13 (106 ref.)

BLOOD

The neurobiology of social phobia. Bell CJ, et al.
Eur Arch Psychiatry Clin Neurosci 1999;249 Suppl 1:S11–8 (53 ref.)

CHEMISTRY

Two isoforms of glutamate decarboxylase: why? Soghomonian JJ, et al. **Trends Pharmacol Sci** 1998 Dec; 19(12):500–5 (72 ref.)

GENETICS

Transcriptional control of neurotransmitter phenotype. Goridis C, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):47–53 (49 ref.)

Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy. Butterworth RF. **Metab Brain Dis** 1998 Dec;13(4):337–49 (70 ref.)

Exploring the neurotransmitter labyrinth in nematodes. Brownlee DJ, et al. **Trends Neurosci** 1999 Jan;22(1):16–24 (86 ref.)

METABOLISM

Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol Suppl** 1996 Mar; 1:17–25 (36 ref.)

Following single cell dynamics with native fluorescence microscopy. Yeung ES. **Anal Chem** 1999 Aug 1; 71(15):522A–529A (50 ref.)

Interactions of presynaptic Ca2+ channels and snare proteins in neurotransmitter release. Catterall WA.
Ann N Y Acad Sci 1999 Apr 30;868:144–59 (84 ref.)

Presynaptic ionotropic receptors and the control of transmitter release. MacDermott AB, et al.
Annu Rev Neurosci 1999;22:443–85 (216 ref.)

A sequential view of neurotransmitter release. Zheng X, et al. **Brain Res Bull** 1998 Sep 15;47(2):117–28 (171 ref.)

Structure and function of neuronal Ca2+ channels and their role in neurotransmitter release. Catterall WA.
Cell Calcium 1998 Nov–Dec;24(5–6):307–23 (151 ref.)

Non-adrenergic non-cholinergic relaxation of the rat stomach. Currò D, et al. **Gen Pharmacol** 1998 Nov; 31(5):697–703 (77 ref.)

Negative symptoms in schizophrenia: neurobiological models and treatment response. Goff DC, et al.
Harv Rev Psychiatry 1998 Jul–Aug;6(2):59–77 (208 ref.)

Mechanisms of neurotransmitter release. Littleton JT, et al.
Int Rev Neurobiol 1999;43:139–61 (94 ref.)

Regulation of intracellular membrane interactions: recent progress in the field of neurotransmitter release. Burger MM, et al. **J Cell Biochem Suppl** 1998;30–31:103–10 (35 ref.)

Astroglial modulation of neurotransmitter/peptide release from the neurohypophysis: present status. Hatton GI.
J Chem Neuroanat 1999 May;16(3):203–21 (147 ref.)

Neurotransmitter transporters: regulators of function and functional regulation. Beckman ML, et al.
J Membr Biol 1998 Jul 1;164(1):1–10 (73 ref.)

Multiple mechanisms of action: the pharmacological profile of budipine. Eltze M. **J Neural Transm Suppl** 1999; 56:83–105 (102 ref.)

The family of Na+/Cl- neurotransmitter transporters. Nelson N. **J Neurochem** 1998 Nov;71(5):1785–803 (176 ref.)

Protein interactions implicated in neurotransmitter release. el Far O, et al. **J Physiol Paris** 1998 Apr;92(2):129–33 (26 ref.)

Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Di Marzo V.
Life Sci 1999;65(6–7):645–55 (82 ref.)

Histochemistry of classical neurotransmitters in antennal lobes and mushroom bodies of the honeybee. Bicker G.
Microsc Res Tech 1999 May 1;45(3):174–83 (55 ref.)

Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Feuerstein TJ, et al.
Naunyn Schmiedebergs Arch Pharmacol 1999 May; 359(5):345–59 (23 ref.)

Forty years of amino acid transmission in the brain. Bennett MR, et al. **Neurochem Int** 1999 Oct;35(4):269–80 (118 ref.)

Neurotransmitter transporters in the central nervous system. Masson J, et al. **Pharmacol Rev** 1999 Sep;51(3):439–64 (325 ref.)

Ion channels in presynaptic nerve terminals and control of transmitter release. Meir A, et al. **Physiol Rev** 1999 Jul; 79(3):1019–88 (1014 ref.)

On some neurochemical aspects of kindling. Lasoń W.
Pol J Pharmacol 1999 Jan–Feb;51(1):95–8 (51 ref.)

Role of MAO A and B in neurotransmitter metabolism and behavior. Shih JC, et al. **Pol J Pharmacol** 1999 Jan–Feb; 51(1):25–9 (42 ref.)

Neurotransmitter transport: models in flux [comment] Kavanaugh MP. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):12737–8 (17 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):13260–5.

Release of neurotransmitters in the locus coeruleus. Singewald N, et al. **Prog Neurobiol** 1998 Oct;56(2):237–67 (328 ref.)

Calcium-independent release of neurotransmitter in the retina: a "copernican" viewpoint change. Piccolino M, et al. **Prog Retin Eye Res** 1999 Jan;18(1):1–38 (89 ref.)

Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Liu Y, et al. **Trends Cell Biol** 1999 Sep;9(9):356–63 (73 ref.)

Exploring the neurotransmitter labyrinth in nematodes. Brownlee DJ, et al. **Trends Neurosci** 1999 Jan;22(1):16–24 (86 ref.)

Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action [published erratum appears in Trends Neurosci 1999 Feb;22(2):80] Di Marzo V, et al. **Trends Neurosci** 1998 Dec;21(12):521–8 (80 ref.)

[Molecular mechanism of the assembly of neurotransmitter receptors and cell adhesion molecules at postsynaptic density] Hata Y. **Seikagaku** 1998 Dec;70(12):1414–8 (16 ref.) **(Jpn)**

[Neurotransmitters in mechanisms of relations between nervous and immune systems in multiple sclerosis] Barkhatova VP, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):51–4 (32 ref.) **(Rus)**

PHARMACOLOGY

Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. Hansen MB, et al. **Physiol Res** 1998;47(5):307–27 (130 ref.)

Acute pain mechanisms. Sorkin LS, et al. **Surg Clin North Am** 1999 Apr;79(2):213–29 (103 ref.)

Physiology of the ECL cells [comment] Håkanson R, et al. **Yale J Biol Med** 1998 May–Aug;71(3–4):163–71 (49 ref.) Comment on: Yale J Biol Med 1998 May–Aug;71(3–4):217–31.

PHYSIOLOGY

Neurotransmitter–mediated regulation of CNS myelination: a review. Belachew S, et al. **Acta Neurol Belg** 1999 Mar; 99(1):21–31 (336 ref.)

Transmitter dysfunction during the process of schizophrenia. Glenthøj BY, et al. **Acta Psychiatr Scand Suppl** 1999; 395:105–12 (81 ref.)

A three–pathway psychobiological model of craving for alcohol. Verheul R, et al. **Alcohol Alcohol** 1999 Mar–Apr; 34(2):197–222 (150 ref.)

The role of neurotransmitters in alcohol dependence: animal research. De Witte P. **Alcohol Alcohol Suppl** 1996 Mar; 1:13–6 (44 ref.)

Review of neurotransmitters and their role in alcoholism treatment. Erickson CK. **Alcohol Alcohol Suppl** 1996 Mar; 1:5–11 (34 ref.)

Neuromodulation intrinsic to the central pattern generator for escape swimming in Tritonia. Katz PS. **Ann N Y Acad Sci** 1998 Nov 16;860:181–8 (39 ref.)

Regulation of neurotransmitter interactions in the ventral striatum. McGinty JF. **Ann N Y Acad Sci** 1999 Jun 29; 877:129–39 (54 ref.)

Development and aminergic neuromodulation of a spinal locomotor network controlling swimming in Xenopus larvae. Sillar KT, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:318–32 (49 ref.)

Somesthesis. Craig JC, et al. **Annu Rev Psychol** 1999; 50:305–31 (210 ref.)

Regulation of cytokine and chemokine production by transmitters and co–transmitters of the autonomic nervous system. Haskó G, et al. **Biochem Pharmacol** 1998 Nov 1; 56(9):1079–87 (111 ref.)

Neurotransmitters and neuropeptides in the developing human central nervous system. A review. Yew DT, et al. **Biol Signals Recept** 1999 May–Jun;8(3):149–59 (58 ref.)

Transmitters involved in antinociception in the spinal cord. Fürst S. **Brain Res Bull** 1999 Jan 15;48(2):129–41 (97 ref.)

Food, mood and health: a neurobiologic outlook. Prasad C. **Braz J Med Biol Res** 1998 Dec;31(12):1517–27 (60 ref.)

Neuromodulation, development and synaptic plasticity. Foehring RC, et al. **Can J Exp Psychol** 1999 Mar; 53(1):45–61 (125 ref.)

Autoinhibition, sympathetic cotransmission and biphasic contractile responses to trains of nerve stimulation in the rodent vas deferens. Ventura S. **Clin Exp Pharmacol Physiol** 1998 Dec;25(12):965–73 (74 ref.)

Cellular, synaptic, network, and modulatory mechanisms involved in rhythm generation. Calabrese RL. **Curr Opin Neurobiol** 1998 Dec;8(6):710–7 (45 ref.)

The inhibitory glycine receptor: prospects for a therapeutic orphan? Breitinger HG, et al. **Curr Pharm Des** 1998 Aug; 4(4):315–34 (274 ref.)

Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit? Satin LS, et al. **Endocrine** 1998 Jun;8(3):213–23 (85 ref.)

Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Ribeiro JA. **Eur J Rheumatol** 1999 Jun 30;375(1–3):101–13 (136 ref.)

Reappraising neurotransmitter–based strategies. Möller HJ. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl 2:S53–9 (56 ref.)

Estrogen, the ovary, and neutotransmitters: factors associated with aging. Miller MM, et al. **Exp Gerontol** 1998 Nov–Dec; 33(7–8):729–57 (155 ref.)

Splanchnic circulatory physiology. Ralevic V. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1409–13 (35 ref.)

The canine sympathetic neuropeptide galanin: a neurotransmitter in pancreas, a neuromodulator in liver. Taborsky GJ Jr, et al. **Horm Metab Res** 1999 May; 31(5):351–4 (24 ref.)

Physiology to functionality: the brain and neurotransmitter activity. Racagni G, et al. **Int Clin Psychopharmacol** 1999 May;14 Suppl 1:S3–7 (22 ref.)

Neuronal nitric oxide synthase in the neural pathways of the urinary bladder. Zhou Y, et al. **J Anat** 1999 May;194 (Pt 4):481–96 (141 ref.)

Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. Reis DJ, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):80–5 (26 ref.)

Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. Francis GS. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S16–21 (71 ref.)

Astroglial modulation of neurotransmitter/peptide release from the neurohypophysis: present status. Hatton GI. **J Chem Neuroanat** 1999 May;16(3):203–21 (147 ref.)

Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy DL, et al. **J Clin Psychiatry** 1998;59 Suppl 15:4–12 (118 ref.)

Review: Central non–glucocorticoid inhibitors of the hypothalamo–pituitary–adrenal axis. Jessop DS. **J Endocrinol** 1999 Feb;160(2):169–80 (139 ref.)

Neural mechanisms of delirium: current hypotheses and evolving concepts. Flacker JM, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jun;54(6):B239–46 (128 ref.)

Inborn errors of neurotransmitter receptors. Surtees R. **J Inherit Metab Dis** 1999 Jun;22(4):374–80 (21 ref.)

Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. Carroll FI, et al. **J Med Chem** 1999 Jul 29; 42(15):2721–36 (196 ref.)

Neurotransmitter transporters: regulators of function and functional regulation. Beckman ML, et al. **J Membr Biol** 1998 Jul 1;164(1):1–10 (73 ref.)

Regulation of neurogenesis by growth factors and neurotransmitters. Cameron HA, et al. **J Neurobiol** 1998 Aug;36(2):287–306 (204 ref.)

Nitration modifying function of proteins, hormones and neurotransmitters. Nakaki T, et al. **Jpn J Pharmacol** 1999 Feb;79(2):125–9 (53 ref.)

Neurotransmitter regulation of circadian structural changes in the fly's visual system. Meinertzhagen IA, et al. **Microsc Res Tech** 1999 Apr 15;45(2):96–105 (75 ref.)

Glucagon–like peptide–1 (7–36) amide as a novel neuropeptide. Blázquez E, et al. **Mol Neurobiol** 1998 Oct; 18(2):157–73 (80 ref.)

Can molecules explain long–term potentiation? Sanes JR, et al. **Nat Neurosci** 1999 Jul;2(7):597–604 (122 ref.)

Gaba as an afferent neurotransmitter in the vestibular sensory periphery of vertebrates. Meza G. **Neurobiology (Bp)** 1998; 6(1):109–25 (85 ref.)

Changes in the physiological roles of neurotransmitters during individual development. Buznikov GA, et al. **Neurosci Behav Physiol** 1999 Jan–Feb;29(1):11–21 (105 ref.)

GABA as a developmental neurotransmitter in the outer plexiform layer of the vertebrate retina. Redburn–Johnson D. **Perspect Dev Neurobiol** 1998;5(2–3):261–7 (57 ref.)

Neurotransmitter system interactions revealed by drug–induced changes in motivated behavior. Montgomery AM, et al. **Pharmacol Biochem Behav** 1999 Apr; 62(4):643–57 (170 ref.)

New vistas in immunopsychopharmacology. Herman ZS. **Pol J Pharmacol** 1998 Nov–Dec;50(6):377–86 (108 ref.)

The neuromessenger platelet–activating factor in plasticity and neurodegeneration. Bazan NG. **Prog Brain Res** 1998; 118:281–91 (42 ref.)

Steroid hormone regulation of vasopressinergic neurotransmission in the central nervous system. Watters JJ, et al. **Prog Brain Res** 1998;119:247–61 (60 ref.)

Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Murad F. **Recent Prog Horm Res** 1998;53:43–59; discussion 59–60 (47 ref.)

Novel neurotransmitters for sleep and energy homeostasis. Sutcliffe JG, et al. **Results Probl Cell Differ** 1999;26:239–55 (30 ref.)

Beta–amyloid peptides as direct cholinergic neuromodulators: a missing link? Auld DS, et al. **Trends Neurosci** 1998 Jan;21(1):43–9 (83 ref.)

Acetylcholine in mind: a neurotransmitter correlate of consciousness? Perry E, et al. **Trends Neurosci** 1999 Jun; 22(6):273–80 (101 ref.)

Neurochemical pathogenesis of fibromyalgia. Russell IJ. **Z Rheumatol** 1998;57 Suppl 2:63–6 (35 ref.)

Pharmacology of pain processing systems. Schadrack J, et al. **Z Rheumatol** 1998;57 Suppl 2:1–4 (22 ref.)

[Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment] Glenthøj BY, et al. **Ugeskr Laeger** 1999 Mar 8; 161(10):1391–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Vasoactive transmitters in the coronary circulation] Opgård OS, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20; 119(19):2824–8 (96 ref.) (Eng. Abstr.) **(Nor)**

[The role of neurochemical mechanisms in the pathogenesis of kinetoses and the therapeutic–prophylactic action of drugs] Shashkov VS, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):3–8 (39 ref.) (Eng. Abstr.) **(Rus)**

[Electrical feedback in the chemical synapses] Byzov AL, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):1074–84 (19 ref.) (Eng. Abstr.) **(Rus)**

[Pituitary adenylate cyclase activating peptide (PACAP)—its polyfunctionality in the mechanisms of brain protection] Chepurnov SA, et al. **Usp Fiziol Nauk** 1999 Apr–Jun; 30(2):3–20 (123 ref.) (Eng. Abstr.) **(Rus)**

[The neurochemical mechanisms and pharmacological routes to eliminate vomiting in seasickness] Naletov SV, et al. **Voen Med Zh** 1998 Sep;319(9):74–6 (20 ref.) **(Rus)**

[Interneuronal signaling mediated by the trans–synaptic diffusion of neurotransmitters] Kopanitsia MV, et al. **Fiziol Zh** 1999;45(4):132–47 (95 ref.) (Eng. Abstr.) **(Ukr)**

SECRETION

Neurotransmitter release: variations on a theme. Edwards RH. **Curr Biol** 1998 Dec 3;8(24):R883–5 (21 ref.)

Antidepressants for the new millennium. Skolnick P. **Eur J Pharmacol** 1999 Jun 30;375(1–3):31–40 (72 ref.)

The regulation of neurotransmitter secretion by protein kinase C. Vaughan PF, et al. **Mol Neurobiol** 1998 Oct; 18(2):125–55 (237 ref.)

Protein–protein interactions and protein modules in the control of neurotransmitter release. Benfenati F, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):243–57 (123 ref.)

The kinetics of nerve–evoked quantal secretion. Fesce R. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):319–29 (32 ref.)

Synapsins as regulators of neurotransmitter release. Hilfiker S, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1381):269–79 (88 ref.)

Evanescent–wave microscopy: a new tool to gain insight into the control of transmitter release. Oheim M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):307–18 (87 ref.)

Multitude of ion channels in the regulation of transmitter release. Rahamimoff R, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):281–8 (125 ref.)

The concept of a calcium sensor in transmitter release. Bennett MR. **Prog Neurobiol** 1999 Oct;59(3):243–77 (161 ref.)

[Molecular biology of neurosecretion and its inhibition bu tetanus and botulinum toxins (review)] Veit M. **Berl Munch Tierarztl Wochenschr** 1999 Jun;112(5):186–91 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Brain drugs of the future. Greenfield S. **BMJ** 1998 Dec 19–26; 317(7174):1698–701 (13 ref.)

NEUROTRANSMITTERS, BIOGENIC AMINE see **BIOGENIC AMINE NEUROTRANSMITTERS**

NEUTRON ACTIVATION ANALYSIS

METHODS

On the analysis of iodine–129 and iodine–127 in environmental materials by accelerator mass spectrometry and ion chromatography. Schmidt A, et al. **Sci Total Environ** 1998 Nov 10;223(2–3):131–56 (102 ref.)

NEUTRONS

The effects of neutrons in Hiroshima. Implications for the risk estimates. Kellerer AM. **C R Acad Sci III** 1999 Feb–Mar;322(2–3):229–37 (19 ref.)

Neutron, proton, and photonuclear cross–sections for radiation therapy and radiation protection. Chadwick MB. **Radiat Environ Biophys** 1998 Dec;37(4):235–42 (39 ref.)

NEUTROPENIA

X–linked cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM 302060). Barth PG, et al. **J Inherit Metab Dis** 1999 Jun;22(4):555–67 (44 ref.)

[Thrombocytopenia and neutropenia] Hasegawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):329–31 (15 ref.) **(Jpn)**

[Shwachman syndrome] Higuchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):38–40 (10 ref.) **(Jpn)**

[Chronic idiopathic neutropenia] Kamakura M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):32–4 (9 ref.) **(Jpn)**

[Kostmann syndrome] Kawasaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):35–7 (15 ref.) **(Jpn)**

CHEMICALLY INDUCED

Vancomycin–induced neutropenia associated with fever: similarities between two immune–mediated drug reactions. Smith PF, et al. **Pharmacotherapy** 1999 Feb;19(2):240–4 (34 ref.)

Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Johnston EM, et al. **Semin Oncol** 1998 Oct;25(5):552–61 (48 ref.)

COMPLICATIONS

Diagnosis and prevention of fungal infection in the immunocompromized patient. Richardson MD, et al. **Blood Rev** 1998 Dec;12(4):241–54 (114 ref.)

Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation. Romano V, et al. **Bone Marrow Transplant** 1999 Feb;23(3):271–5 (14 ref.)

Approach to fever in the neutropenic host. Stoupis A, et al. **Cancer Treat Res** 1998;96:77–104 (114 ref.)

Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit? Böhme A, et al. **Chemotherapy** 1999 May–Jun;45(3):224–32 (58 ref.)

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov–Dec;44(6):427–35 (23 ref.)

The evolution of antibiotic therapy for neutropenic patients. Bodey GP. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2660–5 (32 ref.)

Treatment of fungal infections in neutropenic children [see comments] Lehrnbecher T, et al. **Curr Opin Pediatr** 1999 Feb;11(1):47–55 (112 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):31–2.

Viridans streptococcal infections in patients with neutropenia. Patrick CC. **Pediatr Infect Dis J** 1999 Mar; 18(3):280–1 (10 ref.)

Sepsis. Shelton BK. **Semin Oncol Nurs** 1999 Aug;15(3):209–21 (105 ref.)

[Antibiotic strategies in the febrile neutropenic patient] Marie JP. **Presse Med** 1998 Oct 10;27(30):1554–6 (3 ref.) **(Fre)**

[Respiratory involvement in neutropenic patients] Moldovan D, et al. **Pneumoftiziologia** 1998 Jul–Sep;47(3):185–8 (13 ref.) **(Rum)**

[The treatment of infections in patients with neutropenia (a review of the literature with the inclusion of the authors' own data)] Ptushkin VV, et al. **Ter Arkh** 1998;70(7):83–7 (31 ref.) **(Rus)**

[Prevention and treatment of infections in patients with neutropenia and fever: the role of Pseudomonas aeruginosa] Jiménez Martínez C, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:44–50 (32 ref.) **(Spa)**

[Cefepim in febrile neutropenic patients.] Gomis M, et al. **Rev Esp Quimioter** 1998 Mar;11(1):36–42 (42 ref.) **(Spa)**

CONGENITAL

Inflammatory pseudotumor of the liver in Kostmann's disease. Hsiao CC, et al. **Pediatr Surg Int** 1999; 15(3–4):266–9 (23 ref.)

DRUG THERAPY

Response to granulocyte colony-stimulating factor in an autoimmune neutropenic adult. Imoto S, et al. **Acta Haematol** 1999;101(3):153–6 (18 ref.)

Myeloid colony-stimulating factors: use in the newborn. Sreenan C, et al. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):984–8 (65 ref.)

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov–Dec;44(6):427–35 (23 ref.)

Current considerations in the management of fever and neutropenia. Alexander SW, et al. **Curr Clin Top Infect Dis** 1999;19:160–80 (124 ref.)

Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Schaison G, et al. **Eur J Pediatr** 1998 Dec;157(12):955–66 (76 ref.)

G-CSF: a very efficient therapy in chronic autoimmune neutropenia. A brief review of the literature. Bauduer F. **Hematol Cell Ther** 1998 Oct;40(5):189–91 (23 ref.)

Outpatient parenteral antibiotic therapy for fever and neutropenia. Tice AD. **Infect Dis Clin North Am** 1998 Dec; 12(4):963–77, viii (63 ref.)

Monotherapy versus combination therapy for febrile neutropenia. Ramphal R. **Int J Hematol** 1998 Oct;68 Suppl 1:S21–5 (12 ref.)

Stratification in clinical trials of febrile neutropenia. Elting LS. **Support Care Cancer** 1998 Sep;6(5):457–61 (28 ref.)

Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Feld R. **Support Care Cancer** 1998 Sep; 6(5):444–8 (14 ref.)

Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia. Paesmans M. **Support Care Cancer** 1998 Sep;6(5):438–43 (31 ref.)

Empiric therapy for the febrile neutropenic patient. Design bias. Schimpff SC. **Support Care Cancer** 1998 Sep; 6(5):449–56 (16 ref.)

[Hematopoietic growth factors in treatment of infections in children with cancer] Riikonen P. **Duodecim** 1995; 111(20):1931–5 (25 ref.) **(Fin)**

[Antibiotic therapy in leukopenia] Böhme A, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1120–5 (43 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia] Karthaus M, et al. **Wien Med Wochenschr** 1998;148(18):427–32 (39 ref.) (Eng. Abstr.) **(Ger)**

[Cefepim in febrile neutropenic patients.] Gomis M, et al. **Rev Esp Quimioter** 1998 Mar;11(1):36–42 (42 ref.) **(Spa)**

ECONOMICS

[Febrile neutropenia: practical aspects] Harten P, et al. **Med Klin** 1998 Oct 15;93(10):598–611 (131 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Benign ethnic neutropenia: what is a normal absolute neutrophil count? Haddy TB, et al. **J Lab Clin Med** 1999 Jan;133(1):15–22 (113 ref.)

ETIOLOGY

Interventional antimicrobial therapy in febrile neutropenic patients. Maschmeyer G. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):205–12 (38 ref.)

[Diagnostic assessment in neutropenia] Sommelet D. **Arch Pediatr** 1998;5 Suppl 2:120s–125s (20 ref.) **(Fre)**

[Chronic benign neutropenia] Kudoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):50–2 (12 ref.) **(Jpn)**

GENETICS

X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)–MIM 302060 [editorial; comment] Barth PG, et al. **J Pediatr** 1999 Sep;135(3):273–6 (19 ref.) Comment on: J Pediatr 1999 Sep;135(3):311–5.

[Neonatal neutropenia] Cartron J, et al. **Arch Pediatr** 1998; 5 Suppl 2:125s–128s (21 ref.) **(Fre)**

[Familial cyclic neutropenia] Shinozaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):46–9 (13 ref.) **(Jpn)**

IMMUNOLOGY

[Isoimmune neutropenia] Kamakura M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):41–2 (8 ref.) **(Jpn)**

[Autoimmune neutropenia] Uoshima N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):43–5 (12 ref.) **(Jpn)**

MICROBIOLOGY

Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Groll AH, et al. **Klin Padiatr** 1998 Jul–Aug; 210(4):264–73 (86 ref.)

PATHOLOGY

[Geotrichum capitatum infection in a neutropenic patient. Apropos of a case and review of the literature] Fouassier M, et al. **Rev Med Interne** 1998 Jun;19(6):431–3 (13 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models [see comments] Haurie C, et al. **Blood** 1998 Oct 15;92(8):2629–40 (206 ref.) Comment in: Blood 1999 Jun 1;93(11):4023–4.

[Management of febrile episodes in neutropenic patients] Herbrecht R. **Presse Med** 1998 Sep 5;27(25):1306–8 (3 ref.) **(Fre)**

[Neutropenia] Leite F, et al. **Acta Med Port** 1998 Nov; 11(11):989–96 (29 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Johnston EM, et al. **Semin Oncol** 1998 Oct;25(5):552–61 (48 ref.)

THERAPY

Outpatient management of the febrile neutropenic child with cancer. Patrick CC, et al. **Adv Pediatr Infect Dis** 1999; 14:29–47 (64 ref.)

Ambulatory management of chemotherapy-induced fever and neutropenia in adult cancer patients. Davis DD, et al. **Ann Pharmacother** 1998 Dec;32(12):1317–23 (22 ref.)

Hematopoietic supportive care. Hester J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2666–70 (27 ref.)

[Growth factors in oncology: effectiveness and prospects] Ottmann OG, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1153–9 (22 ref.) (Eng. Abstr.) **(Ger)**

NEUTROPHIL-ACTIVATING PEPTIDE, LYMPHOCYTE-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL-ACTIVATING PEPTIDE, MONOCYTE-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL-ACTIVATING PEPTIDES, FIBROBLAST-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL ACTIVATION

Leucocyte activation markers in clinical practice. Viedma Contreras JA. **Clin Chem Lab Med** 1999 Jun;37(6):607–22 (226 ref.)

Neutrophil activation and mediators of inflammation in chronic venous insufficiency. Smith PD. **J Vasc Res** 1999; 36 Suppl 1:24–36 (48 ref.)

Evidence for neutrophil activation in occupational asthma. Jung KS, et al. **Respirology** 1999 Sep;4(3):303–6 (16 ref.)

[Vascular disease and cellular activation: exploration of cell adhesion phenotype by quantitative flow cytometry] Latger V, et al. **J Mal Vasc** 1999 Feb;24(1):11–8 (59 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The multistep process of homotypic neutrophil aggregation: a review of the molecules and effects of hydrodynamics. Simon SI, et al. **Cell Adhes Commun** 1998;6(2–3):263–76 (61 ref.)

PHYSIOLOGY

Regulation of neutrophil activation in acute lung injury. Downey GP, et al. **Chest** 1999 Jul;116(1 Suppl):46S–54S (59 ref.)

NEUTROPHIL-DERIVED RELAXANT FACTOR see **ENDOTHELIUM-DERIVED RELAXING FACTOR**

NEUTROPHIL ELASTASE see **LEUKOCYTE ELASTASE**

NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE see **SWEET'S SYNDROME**

NEUTROPHILIC ECCRINE HIDRADENITIS see **HIDRADENITIS**

NEUTROPHILIC LEUKEMIA, CHRONIC see **LEUKEMIA, NEUTROPHILIC, CHRONIC**

NEUTROPHILS

[Diagnosis and treatment of systemic Candida infection in non-neutropenic patients] Aikawa N, et al. **Jpn J Antibiot** 1998 Dec;51(12):721–34 (28 ref.) **(Jpn)**

[Hereditary neutrophilia] Hato F, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):15–6 (3 ref.) **(Jpn)**

[Adrenocorticosteroid-induced neutrophilia] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):21–2 (6 ref.) **(Jpn)**

[Leukocytosis in pregnancy] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):23–4 (5 ref.) **(Jpn)**

[Neutrophil actin dysfunction] Okamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):73–5 (13 ref.) **(Jpn)**

[Neutrophil lactoferrin deficiency] Shinozaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):70–2 (12 ref.) **(Jpn)**

[Chronic idiopathic leukocytosis] Suzuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):17–8 (2 ref.) **(Jpn)**

[Pseudoneutrophilia] Suzuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):19–20 (4 ref.) **(Jpn)**

[Neutrophil ATP depletion] Yasui K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):91–3 (5 ref.) **(Jpn)**

CHEMISTRY

The multistep process of homotypic neutrophil aggregation: a review of the molecules and effects of hydrodynamics. Simon SI, et al. **Cell Adhes Commun** 1998;6(2–3):263–76 (61 ref.)

CYTOLOGY

The multistep process of homotypic neutrophil aggregation: a review of the molecules and effects of hydrodynamics. Simon SI, et al. **Cell Adhes Commun** 1998;6(2–3):263–76 (61 ref.)

Regulation of leukocyte trafficking by lipoxins. Diamond P, et al. **Clin Chem Lab Med** 1999 Mar;37(3):293–7 (58 ref.)

Neutrophil maturation and the role of retinoic acid. Lawson ND, et al. **Exp Hematol** 1999 Sep;27(9):1355–67 (132 ref.)

The neutrophil: one of the cellular targets of interleukin-10. Cassatella MA. **Int J Clin Lab Res** 1998;28(3):148–61 (114 ref.)

[Functions of neutrophil motility of human blood: locomotion and chemotaxis in simplified systems] Malawista SE, et al. **Bull Acad Natl Med** 1998;182(5):1011–21; discussion 1022–4 (35 ref.) (Eng. Abstr.) **(Fre)**

[Sebastian platelet syndrome] Maeda M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):320–1 (7 ref.) **(Jpn)**

DRUG EFFECTS

Pentoxifylline--more evidence that it improves host defenses during sepsis [editorial; comment] Reynolds H. **Crit Care Med** 1999 Apr;27(4):681–3 (41 ref.) Comment on: Crit Care Med 1999 Apr;27(4):756–63.

Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on neutrophil formation and function. Khwaja A, et al. **Curr Opin Hematol** 1994 May;1(3):216–20 (29 ref.)

Role of granulocyte colony-stimulating factor in infection and inflammation. Hartung T, et al. **Med Microbiol Immunol (Berl)** 1998 Oct;187(2):61–9 (113

ref.)
[Pore-forming leukotoxins from Staphylococcus aureus: variability of the target cells and 2 pharmacological processes] Prévost G, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):435–41 (40 ref.) (Eng. Abstr.) **(Fre)**
[The adult respiratory distress syndrome during the recovery of the neutrophil level after autologous bone marrow transplantation] Lisukov IA, et al. **Ter Arkh** 1998;70(7):78–9 (6 ref.) **(Rus)**

ENZYMOLOGY

Effect of 15-HETE on the 5-lipoxygenase pathway in neutrophils. Genuine inhibitor or alternative substrate? Schewe T, et al. **Adv Exp Med Biol** 1999;447:95–105 (25 ref.)
Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Jones D, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):229–44 (131 ref.)
Tyrosine kinases in neutrophils. Berton G.
Curr Opin Hematol 1999 Jan;6(1):51–8 (68 ref.)
Activation of the neutrophil respiratory burst oxidase. Clark RA. **J Infect Dis** 1999 Mar;179 Suppl 2:S309–17 (37 ref.)
Prevalence of myeloperoxidase deficiency: population studies using Bayer-Technicon automated hematology. Kutter D. **J Mol Med** 1998 Sep;76(10):669–75 (8 ref.)
Insights into myeloperoxidase biosynthesis from its inherited deficiency. Nauseef WM. **J Mol Med** 1998 Sep;76(10):661–8 (107 ref.)

IMMUNOLOGY

Neutrophil-derived proteins: selling cytokines by the pound. Cassatella MA. **Adv Immunol** 1999;73:369–509 (493 ref.)
The role of neutrophils in inflammation. Cox G.
Can Respir J 1998 Jul–Aug;5 Suppl A:37A–40A (17 ref.)
Polymorphonuclear granulocyte stimulation by cellulose-based hemodialysis membranes. Körmöczi GF, et al. **Clin Chem Lab Med** 1999 Mar;37(3):351–5 (60 ref.)
A potential role of an intracellular signaling defect in neutrophil functional abnormalities and promotion of tissue damage in patients with localized juvenile periodontitis. Leino L, et al. **Clin Chem Lab Med** 1999 Mar;37(3):215–22 (85 ref.)
Deciphering the oxyradical inflammation Rosetta stone: $O_2^{\bullet}$-NO$^{\bullet}$, OONO-, polymorphonuclear neutrophils, poly(ADP-ribose) synthetase, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome [editorial; comment] Vaughan D, et al.
Crit Care Med 1999 Aug;27(8):1666–9 (30 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1517–23. Comment on: Crit Care Med 1999 Aug;27(8):1524–32.
Neutrophils as a source of cytokines in inflammation. Matsukawa A, et al. **Histol Histopathol** 1999 Apr; 14(2):511–6 (63 ref.)
Innate immunity, cytokines, and pulmonary host defense. Nelson S, et al. **Infect Dis Clin North Am** 1998 Sep; 12(3):555–67, vii (59 ref.)
Cytosolic Ca2+ signalling in inflammatory neutrophils: implications for rheumatoid arthritis (Review). Davies EV, et al. **Int J Mol Med** 1998 Feb;1(2):485–90 (52 ref.)
Neutrophil migration during endotoxemia. Wagner JG, et al. **J Leukoc Biol** 1999 Jul;66(1):10–24 (228 ref.)
Leukocytes, the Janus cells in inflammatory disease. Nussler AK, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):222–32 (107 ref.)
The Sixth John M. Kinney International Awards for Nutrition and Metabolism . "Glutamine-enhanced bacterial killing by neutrophils from postoperative patients": background [see comments] Furukawa S. **Nutrition** 1999 Jun;15(6):439–42 (37 ref.) Comment in: Nutrition 1999 Jun;15(6):443.
[Neutrophilic dermatosis] Fria Ancona G, et al.
Rev Alerg Mex 1998 Nov–Dec;45(6):159–65 (19 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Adenosine. An endogenous inhibitor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Krump E, et al. **Adv Exp Med Biol** 1999;447:107–15 (65 ref.)
The 1996 Veylien Henderson Award of the Society of Toxicology of Canada. Current concepts: neutrophils and the activation of carcinogens in the breast and other organs. Josephy PD, et al. **Can J Physiol Pharmacol** 1998 Jul–Aug; 76(7–8):693–700 (99 ref.)
Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. Matsukawa A, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S137–44 (61 ref.)
Assay for oxidative metabolism. Harvath L, et al.
Methods Mol Biol 1999;115:309–15 (12 ref.)

PATHOLOGY

Neutrophilic lobular (pustular) panniculitis associated with rheumatoid arthritis: a case report and review of the literature. Tran TA, et al. **Am J Dermatopathol** 1999 Jun; 21(3):247–52 (62 ref.)
Neutrophil-mediated gastrointestinal injury. Elliott SN, et al. **Can J Gastroenterol** 1998 Nov–Dec;12(8):559–68 (102 ref.)
[Hereditary giant neutrophil leucocytes] Fuse I, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):84–5 (5 ref.) **(Jpn)**
[Alder-Reilly anomaly] Shinjo K, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):59–60 (14 ref.) **(Jpn)**
[50 years of LE cells: is it time for their retirement? (editorial)] Font J, et al. **Med Clin (Barc)** 1998 Dec 5; 111(19):737–8 (14 ref.) **(Spa)**

PHYSIOLOGY

Neutrophils and renal failure. Heinzelmann M, et al.
Am J Kidney Dis 1999 Aug;34(2):384–99 (121 ref.)
Neutrophil rheology and transit through capillaries and sinusoids [editorial; comment] Doerschuk CM.
Am J Respir Crit Care Med 1999 Jun;159(6):1693–5 (16 ref.) Comment on: Am J Respir Crit Care Med 1999 Jun;159(6):1696–702.
Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Hampton MB, et al. **Blood** 1998 Nov 1;92(9):3007–17 (165 ref.)
Adhesion molecules and cellular biomechanical changes in acute lung injury: Giles F. Filley Lecture. Doerschuk CM, et al. **Chest** 1999 Jul;116(1 Suppl):37S–43S (51 ref.)
Targeting the proteolytic arsenal of neutrophils. A promising approach for postpump syndrome and ARDS [editorial; comment] Shah PK. **Circulation** 1999 Jul 27;100(4):333–4 (25 ref.) Comment on: Circulation 1999 Jul 27;100(4):400–6.
Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium [see comments] Hiemstra PS, et al.
Eur Respir J 1998 Nov;12(5):1200–8 (103 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250–1.
Neutrophil and endothelial cell interactions in sepsis. The role of adhesion molecules. Parent C, et al.
Infect Dis Clin North Am 1999 Jun;13(2):427–47, x (208 ref.)
Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Goulding NJ, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S158–65 (68 ref.)
Adhesion molecules mediating neutrophil migration to arthritis in vivo and across endothelium and connective tissue barriers in vitro. Issekutz AC. **Inflamm Res** 1998 Oct; 47 Suppl 3:S123–32 (52 ref.)
The neutrophil: one of the cellular targets of interleukin-10. Cassatella MA. **Int J Clin Lab Res** 1998;28(3):148–61 (114 ref.)
Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Masuda S, et al. **Int J Hematol** 1999 Jul;70(1):1–6 (62 ref.)
Mechanisms of reperfusion injury after warm ischemia of the liver. Jaeschke H. **J Hepatobiliary Pancreat Surg** 1998; 5(4):402–8 (84 ref.)
Integrin-mediated signaling in human neutrophil functioning [published erratum appears in J Leukoc Biol 1999 Jul;66(1):194] Williams MA, et al. **J Leukoc Biol** 1999 Jun; 65(6):725–36 (136 ref.)
Neutrophil signaling alteration: an adverse inflammatory response after burn shock. Sayeed MM.
Medicina (B Aires) 1998;58(4):386–92 (19 ref.)
Polymorphonuclear neutrophils in acute renal failure: new insights [editorial] Caramelo C, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2185–8 (29 ref.)
The effects of dietary n-3 polyunsaturated fatty acids on neutrophils. Sperling RI. **Proc Nutr Soc** 1998 Nov; 57(4):527–34 (46 ref.)
The role of neutrophils in acute renal failure. Lauriat S, et al. **Semin Nephrol** 1998 Sep;18(5):498–504 (37 ref.)
Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1055–8 (18 ref.)
[Interaction between neutrophils and endothelial cells following ischemia/reperfusion] Yamaguchi Y, et al.
Nippon Geka Gakkai Zasshi 1999 May;100(5):319–24 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Roles of platelets and neutrophils in intimal thickening following endothelial injury] Umemura K.
Nippon Rinsho 1999 Jul;57(7):1480–5 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Neutrophil-endothelial cell interactions in gastrointestinal diseases] Yoshikawa T, et al. **Nippon Rinsho** 1998 Sep; 56(9):2240–6 (35 ref.) (Eng. Abstr.) **(Jpn)**
[Lazy-leukocyte syndrome] Koike T, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):79–80 (8 ref.) **(Jpn)**
[Neutrophil adherence-inhibiting factor, AIF, is released from lysosomes of activated platelets] Iwabuchi K, et al. **Seikagaku** 1999 May;71(5):353–8 (19 ref.) **(Jpn)**

ULTRASTRUCTURE

New insights into the mechanisms of nuclear segmentation in human neutrophils. Sanchez JA, et al.
J Cell Biochem 1999 Apr 1;73(1):1–10 (59 ref.)

NEVIRAPINE

ADVERSE EFFECTS

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Pollard RB, et al.
Clin Ther 1998 Nov–Dec;20(6):1071–92 (40 ref.)

THERAPEUTIC USE

[Nevirapine (Viramune): a new HIV inhibitor] De Wit S, et al. **Rev Med Brux** 1999 Apr;20(2):95–9 (12 ref.) (Eng. Abstr.) **(Fre)**

NEVOID BASAL CELL CARCINOMA SYNDROME see **BASAL CELL NEVUS SYNDROME**

NEVOXANTHOENDOTHELIOMA see **XANTHOGRANULOMA, JUVENILE**

NEVUS

Benign atypical naevi: diagnostic difficulties and continued controversy. Blessing K. **Histopathology** 1999 Mar; 34(3):189–98 (72 ref.)

COMPLICATIONS

The linear naevus sebaceus syndrome. van de Warrenburg BP, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):126–32 (57 ref.)

DIAGNOSIS

Moles and melanoma. Chamlin SL, et al.
Curr Opin Pediatr 1998 Aug;10(4):398–404 (80 ref.)
Epidermal naevus syndrome and hypophosphataemic rickets: description of a patient with central nervous system anomalies and review of the literature. Olivares JL, et al.
Eur J Pediatr 1999 Feb;158(2):103–7 (19 ref.)
[The atypical nevus: a risk situation?] Böni R, et al.
Schweiz Med Wochenschr 1999 Jun 5;129(22):825–32 (74 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Physiopathology of nevi and nevocytes] Grob JJ, et al.
Ann Dermatol Venereol 1998 Nov;125(11):860–7 (79 ref.) **(Fre)**

GENETICS

Paradominant inheritance, a hypothesis explaining occasional familial occurrence of sporadic syndromes. Steijlen PM, et al. **Am J Med Genet** 1999 Aug 6;85(4):359–60 (14 ref.)

PATHOLOGY

Nevoid hypertrichosis with multiple patches of hair that underwent almost complete spontaneous resolution. Dudding TE, et al. **Am J Med Genet** 1998 Sep 23; 79(3):195–6 (12 ref.)
[Linear and whorled nevoid hypermelanosis: report of two cases] Claudel P, et al. **Arch Pediatr** 1998 Oct; 5(10):1098–102 (22 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Physiopathology of nevi and nevocytes] Grob JJ, et al.
Ann Dermatol Venereol 1998 Nov;125(11):860–7 (79 ref.) **(Fre)**

SURGERY

Epidermal nevus syndrome: a review and case report. Losee JE, et al. **Ann Plast Surg** 1999 Aug;43(2):211–4 (9 ref.)

THERAPY

Moles and melanoma. Chamlin SL, et al.
Curr Opin Pediatr 1998 Aug;10(4):398–404 (80 ref.)

NEVUS, BLUE

COMPLICATIONS

[The blue rubber bleb nevus syndrome or Bean's syndrome. A rare cause of digestive hemorrhage] Silva A, et al.
Acta Med Port 1998 Dec;11(12):1131–4 (10 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Carney JA, et al. **Semin Diagn Pathol** 1998 Aug;15(3):216–24 (15 ref.)

NEVUS, DYSPLASTIC see **DYSPLASTIC NEVUS SYNDROME**

NEVUS, EPITHELIOID AND SPINDLE CELL

DIAGNOSIS

[Spitz nevus and Reed nevus: simulating melanoma in adults]

Paredes B, et al. **Pathologe** 1998 Nov;19(6):403–11 (39 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

The melanocyte differentiation pathway in spitz nevi. Cramer SF. **Am J Dermatopathol** 1998 Dec;20(6):555–70 (218 ref.)
Childhood melanoma. Barnhill RL. **Semin Diagn Pathol** 1998 Aug;15(3):189–94 (8 ref.)

NEVUS FLAMMEUS see **PORT-WINE STAIN**

NEVUS, HALO see **NEVUS, PIGMENTED**

NEVUS, MELANOCYTIC see **NEVUS, PIGMENTED**

NEVUS, PIGMENTED

[Melanocytic nevi] Crickx B. **Rev Prat** 1999 Apr 15; 49(8):829–32 (8 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

[Pigmented tumors of the caruncle. Review of the literature] Kodjikian L, et al. **J Fr Ophtalmol** 1999 Jun–Jul; 22(6):688–99 (83 ref.) **(Fre)**

DIAGNOSIS

Simultaneous occurrence of segmental odontomaxillary dysplasia and Becker's nevus. Jones AC, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1251–4 (17 ref.)
[Spitz nevus and Reed nevus: simulating melanoma in adults] Paredes B, et al. **Pathologe** 1998 Nov;19(6):403–11 (39 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Concept of twin spotting. Koopman RJ. **Am J Med Genet** 1999 Aug 6;85(4):355–8 (24 ref.)

PATHOLOGY

Naevi spili, Café-au-lait spots and melanocytic naevi aggregated alongside Blaschko's lines, with a review of segmental melanocytic lesions. Langenbach N, et al. **Acta Derm Venereol** 1998 Sep;78(5):378–80 (22 ref.)
Concept of twin spotting. Koopman RJ. **Am J Med Genet** 1999 Aug 6;85(4):355–8 (24 ref.)
Simulators of malignant melanoma of the skin. Cerroni L, et al. **Eur J Dermatol** 1998 Sep;8(6):388–96 (67 ref.)
Recognition and evaluation of cytological dysplasia in acquired melanocytic nevi. Murphy GF, et al. **Hum Pathol** 1999 May;30(5):506–12 (31 ref.)
Osteo-nevus of Nanta: a case report and review of the Japanese literature. Sasaki S, et al. **J Dermatol** 1999 Mar; 26(3):183–8 (32 ref.)
Ancient melanocytic nevus. Kerl H, et al. **Semin Diagn Pathol** 1998 Aug;15(3):210–5 (15 ref.)

NEVUS, SPINDLE CELL AND EPITHELIOID see **NEVUS, EPITHELIOID AND SPINDLE CELL**

NEVUS SYNDROME, BASAL CELL see **BASAL CELL NEVUS SYNDROME**

NEVUS SYNDROME, DYSPLASTIC see **DYSPLASTIC NEVUS SYNDROME**

NEW DEVICE APPROVAL see **DEVICE APPROVAL**

NEW DRUG APPROVAL see **DRUG APPROVAL**

NEWBORN INFANT SCREENING see **NEONATAL SCREENING**

NEWBORN INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, NEONATAL**

NEWCASTLE DISEASE VIRUS

IMMUNOLOGY

Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Schirrmacher V, et al. **Adv Exp Med Biol** 1998;451:251–7 (43 ref.)
Immunization with virus-modified tumor cells. Schirrmacher V, et al. **Semin Oncol** 1998 Dec;25(6):677–96 (66 ref.)

NEWSLETTERS see **PERIODICALS**

NEWSPAPERS

STATISTICS & NUMERICAL DATA

Public trust and accountability for clinical performance: lessons from the national press reportage of the Bristol hearing [see comments] Davies HT, et al. **J Eval Clin Pract** 1999 Aug;5(3):335–42 (28 ref.) Comment in: J Eval Clin Pract 1999 Aug;5(3):343–6.

NEWTS see **SALAMANDRIDAE**

NF-KAPPA B

ANTAGONISTS & INHIBITORS

The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Thurberg BL, et al. **Curr Opin Lipidol** 1998 Oct;9(5):387–96 (102 ref.)
Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB [comment] Paillard F. **Hum Gene Ther** 1999 Jan 1;10(1):1–3 (9 ref.) Comment on: Hum Gene Ther 1999 Jan 1;10(1):37–47.
Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy [see comments] Christman JW, et al. **Intensive Care Med** 1998 Nov;24(11):1131–8 (81 ref.) Comment in: Intensive Care Med 1998 Nov;24(11):1129–30.
A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex. Cramer P, et al. **Structure Fold Des** 1999 Jan 15;7(1):R1–6 (20 ref.)

BIOSYNTHESIS

Interleukin-1. Stylianou E, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1075–9 (13 ref.)

CHEMISTRY

IkappaB-NF-kappaB structures: at the interface of inflammation control [comment] Baeuerle PA. **Cell** 1998 Dec 11;95(6):729–31 (17 ref.) Comment on: Cell 1998 Dec 11;95(6):749–58. Comment on: Cell 1998 Dec 11;95(6):759–70.
A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex. Cramer P, et al. **Structure Fold Des** 1999 Jan 15;7(1):R1–6 (20 ref.)

GENETICS

Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. Roebuck KA, et al. **J Leukoc Biol** 1999 Mar;65(3):291–8 (93 ref.)
Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1. Gius D, et al. **Toxicol Lett** 1999 Jun 1;106(2–3):93–106 (94 ref.)
[Nuclear transcription factor kappa B (NF-kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945–7 (13 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Role of NF-kappaB in immune and inflammatory responses in the gut. Neurath MF, et al. **Gut** 1998 Dec;43(6):856–60 (76 ref.)
Nuclear factor kappaB--a new therapeutic approach? [editorial; comment] Böhrer H, et al. **Intensive Care Med** 1998 Nov;24(11):1129–30 (13 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1131–8. Comment on: Intensive Care Med 1998 Nov;24(11):1199–208.
Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy [see comments] Christman JW, et al. **Intensive Care Med** 1998 Nov;24(11):1131–8 (81 ref.) Comment in: Intensive Care Med 1998 Nov;24(11):1129–30.

METABOLISM

Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB. Marshall HE, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):296–7 (23 ref.)
Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Grilli M, et al. **Biochem Pharmacol** 1999 Jan 1;57(1):1–7 (60 ref.)
Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Waddick KG, et al. **Biochem Pharmacol** 1999 Jan 1; 57(1):9–17 (72 ref.)
Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Grilli M, et al. **Cell Death Differ** 1999 Jan;6(1):22–7 (77 ref.)
The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Thurberg BL, et al. **Curr Opin Lipidol** 1998 Oct;9(5):387–96 (102 ref.)
TRAIL induces apoptosis and activation of NFkappaB. Jeremias I, et al. **Eur Cytokine Netw** 1998 Dec;9(4):687–8 (14 ref.)
Is NF-kappaB the sensor of oxidative stress? Li N, et al. **FASEB J** 1999 Jul;13(10):1137–43 (55 ref.)
Regulation of NF-kappaB by the HTLV-1 Tax protein. Li XH, et al. **Gene Expr** 1999;7(4–6):233–45 (124 ref.)
A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Maniatis T. **Genes Dev** 1999 Mar 1;13(5):505–10 (38 ref.)
Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Roebuck KA. **Int J Mol Med** 1999 Sep;4(3):223–30 (102 ref.)
HIV infection and signal transduction. Bovolenta C, et al. **J Biol Regul Homeost Agents** 1998 Jul–Sep;12(3):63–6 (56 ref.)
Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis. Jue DM, et al. **J Korean Med Sci** 1999 Jun;14(3):231–8 (79 ref.)
NF-kappaB and apoptosis in mammary epithelial cells. Clarkson RW, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):165–75 (76 ref.)
Nf-kappa B: an important transcription factor in photobiology. Legrand-Poels S, et al. **J Photochem Photobiol B** 1998 Aug 21;45(1):1–8 (80 ref.)
Nuclear factor kappa B activity in response to oxidants and antioxidants. Janssen YM, et al. **Methods Enzymol** 1999; 300:363–74 (19 ref.)
NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Foo SY, et al. **Trends Genet** 1999 Jun; 15(6):229–35 (50 ref.)

PHYSIOLOGY

Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine. Aw TY. **Am J Clin Nutr** 1999 Oct;70(4):557–65 (67 ref.)
New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Chen F, et al. **Clin Chem** 1999 Jan;45(1):7–17 (116 ref.)
Multiple signals converging on NF-kappaB. Mercurio F, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):226–32 (50 ref.)
Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. McKay LI, et al. **Endocr Rev** 1999 Aug;20(4):435–59 (271 ref.)
NF-kappa B, liposomes and pathogenesis of hepatic injury and fibrosis. Wu J, et al. **Front Biosci** 1999 Jun 15;4:D520–7 (67 ref.)
Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB [comment] Paillard F. **Hum Gene Ther** 1999 Jan 1;10(1):1–3 (9 ref.) Comment on: Hum Gene Ther 1999 Jan 1;10(1):37–47.
A role for transcription factor NF-kappa B in intestinal inflammation. Schottelius AJ, et al. **Int J Colorectal Dis** 1999 Feb;14(1):18–28 (132 ref.)
Nuclear factor kappa B: important transcription factor and therapeutic target. Lee JI, et al. **J Clin Pharmacol** 1998 Nov;38(11):981–93 (81 ref.)
Regulation of gene expression by trans-synaptic activity: a role for the transcription factor NF-kappa B. Gisiger V. **J Physiol Paris** 1998 Jun–Aug;92(3–4):163–6 (35 ref.)
The central role of nuclear factor-kappa B in mesangial cell activation. Massy ZA, et al. **Kidney Int Suppl** 1999 Jul; 71:S76–9 (23 ref.)
Transcription factor NF-kappaB regulation of renal fibrosis during ureteral obstruction. Morrissey J, et al. **Semin Nephrol** 1998 Nov;18(6):603–11 (79 ref.)
[Nuclear transcription factor kappa B (NF-kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945–7 (13 ref.) (Eng. Abstr.) **(Fre)**

NF1 GENES see **GENES, NEUROFIBROMATOSIS 1**

NF2 GENES see **GENES, NEUROFIBROMATOSIS 2**

NG-CAM see **CELL ADHESION MOLECULES, NEURON-GLIA**

NG-MONOMETHYL-L-ARGININE see **OMEGA-N-METHYLARGININE**

NG-NITROARGININE see **NITROARGININE**

NG-NITRO-L-ARGININE see **NITROARGININE**

NG-NITROARGININE METHYL ESTER

PHARMACOLOGY

Chronic nitric oxide inhibition model six years on. Zatz R, et al. **Hypertension** 1998 Dec;32(6):958–64 (106 ref.)

THERAPEUTIC USE

[The role of nitrogen oxide in migraine attack] Stępień A. **Neurol Neurochir Pol** 1999 Mar–Apr;33(2):435–44 (20 ref.) (Eng. Abstr.) **(Pol)**

NG-NITRO-L-ARGININE METHYL ESTER see **NG-NITROARGININE METHYL ESTER**

NGF RECEPTORS see **RECEPTORS, NERVE GROWTH FACTOR**

NHANES see **NUTRITION SURVEYS**

NIACIN

Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine. Powers HJ. **Proc Nutr Soc** 1999 May;58(2):435–40 (47 ref.)

ADMINISTRATION & DOSAGE

Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Knopp RH. **Am J Cardiol** 1998 Dec 17; 82(12A):24U–28U; discussion 39U–41U (13 ref.)

NIACIN

ADVERSE EFFECTS

Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. Kristensen T, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):314–7 (26 ref.)

PHARMACOLOGY

Mechanistic studies of high-density lipoproteins. Kashyap ML. **Am J Cardiol** 1998 Dec 17;82(12A):42U–48U; discussion 85U–86U (26 ref.)

THERAPEUTIC USE

Effect of niacin on atherosclerotic cardiovascular disease. Guyton JR. **Am J Cardiol** 1998 Dec 17;82(12A):18U–23U; discussion 39U–41U (12 ref.)

Treatment of hyperlipidemia with combined niacin–statin regimens. Guyton JR, et al. **Am J Cardiol** 1998 Dec 17; 82(12A):82U–84U; discussion 85–86U (29 ref.)

NIACINAMIDE

THERAPEUTIC USE

Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Saunders M, et al. **Br J Cancer Suppl** 1996 Jul;27:S271–8 (48 ref.)

Nicotinamide in type 1 diabetes. Mechanism of action revisited. Kolb H, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B16–20 (54 ref.)

NICKEL

ADVERSE EFFECTS

Unusual responses to contact allergens [editorial; comment] Slavin RG. **Allergy Asthma Proc** 1999 Jul–Aug; 20(4):229–30 (11 ref.) Comment on: Allergy Asthma Proc 1999 Jul–Aug;20(4):235–42.

[Contact allergy to nickel] Slaweta G, et al. **Med Pr** 1998; 49(3):305–8 (24 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Active sites of transition-metal enzymes with a focus on nickel. Ermler U, et al. **Curr Opin Struct Biol** 1998 Dec; 8(6):749–58 (99 ref.)

METABOLISM

Structure/function relationships in nickel metallobiochemistry. Maroney MJ. **Curr Opin Chem Biol** 1999 Apr;3(2):188–99 (88 ref.)

TOXICITY

Nickel. Barceloux DG. **J Toxicol Clin Toxicol** 1999; 37(2):239–58 (144 ref.)

[The free radicals and nickel carcinogenesis] Ma X, et al. **Wei Sheng Yen Chiu** 1997 May;26(3):168–71 (13 ref.) (Eng. Abstr.) **(Chi)**

NICORANDIL

ADVERSE EFFECTS

Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. Shotts RH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):706–7 (5 ref.)

THERAPEUTIC USE

ATP dependent K+ channel: a novel therapeutic target in unstable angina [editorial; comment] Dana A, et al. **Eur Heart J** 1999 Jan;20(1):2–5 (21 ref.) Comment on: Eur Heart J 1999 Jan;20(1):51–7.

NICOTIANA see **TOBACCO**

NICOTINAMIDE see **NIACINAMIDE**

NICOTINAMIDE-ADENINE DINUCLEOTIDE see **NAD**

NICOTINAMIDE-ADENINE DINUCLEOTIDE PHOSPHATE see **NADP**

2-NICOTINAMIDOETHYL NITRATE see **NICORANDIL**

NICOTINE

Validity of the Fagerström test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Etter JF, et al. **Addiction** 1999 Feb;94(2):269–81 (38 ref.)

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Krystal JH, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S35–49 (128 ref.)

Taking aim at the bull's-eye: the nicotine in tobacco products [editorial] Douglas CE. **Tob Control** 1998 Autumn; 7(3):215–8 (92 ref.)

ADMINISTRATION & DOSAGE

The nicotine transdermal system. Gore AV, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):599–615 (105 ref.)

Prevention of lung cancer by long-term use of alternative nicotine delivery systems? Kunze U, et al. **Eur J Cancer** 1999 Feb;35(2):195–6 (19 ref.)

Smoking tobacco, microcirculatory changes and the role of nicotine. Haustein KO. **Int J Clin Pharmacol Ther** 1999 Feb;37(2):76–85 (69 ref.)

Smoking behaviour and compensation: a review of the literature. Scherer G. **Psychopharmacology (Berl)** 1999 Jul; 145(1):1–20 (185 ref.)

[Nicotine preparations and other preparations for smoking cessation] Tonstad S. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1289–93 (45 ref.) (Eng. Abstr.) **(Nor)**

[Nicotine replacement always better than further smoking or using snuff] Bolinder G, et al. **Lakartidningen** 1999 May 26;96(21):2614–8 (20 ref.) **(Swe)**

ADVERSE EFFECTS

Cigarette smoking, cutaneous immunity, and inflammatory response. Mills CM. **Clin Dermatol** 1998 Sep–Oct; 16(5):589–94 (38 ref.)

Adverse skin reactions to the nicotine transdermal system. Wolf R, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):617–23 (78 ref.)

Smoking and gastric ulcers: the possible role of nicotine. Ogle CW. **J Clin Pharmacol** 1999 May;39(5):448–53 (34 ref.)

Addressing nicotine addiction in women. Role of the midwife. Ward S. **J Nurse Midwifery** 1999 Jan–Feb; 44(1):3–18 (103 ref.)

Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Henningfield JE, et al. **Tob Control** 1998 Autumn; 7(3):281–93 (144 ref.)

ANALYSIS

Tracers for assessing exposure to environmental tobacco smoke: what are they tracing? Daisey JM. **Environ Health Perspect** 1999 May;107 Suppl 2:319–27 (58 ref.)

Exposure of U.S. workers to environmental tobacco smoke. Hammond SK. **Environ Health Perspect** 1999 May;107 Suppl 2:329–40 (48 ref.)

METABOLISM

Green tobacco sickness. McBride JS, et al. **Tob Control** 1998 Autumn;7(3):294–8 (33 ref.)

PHARMACOLOGY

What aspects of human performance are truly enhanced by nicotine? [editorial] Heishman SJ. **Addiction** 1998 Mar; 93(3):317–20 (36 ref.)

Heteromeric complexes of alpha 5 and/or alpha 7 subunits. Effects of calcium and potential role in nicotine-induced presynaptic facilitation. Girod R, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:578–90 (81 ref.)

Modulation by nicotine on muscarinic receptor–effector systems. Wang H. **Chung Kuo Yao Li Hsueh Pao** 1997 May; 18(3):193–7 (25 ref.)

Clinical pharmacology of nicotine. Zevin S, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):557–64 (59 ref.)

Common aspects of the action of nicotine and other drugs of abuse. Picciotto MR. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):165–72 (117 ref.)

POISONING

[Nicotine (tobacco) poisoning] Katoh T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):679–81 (4 ref.) **(Jpn)**

THERAPEUTIC USE

Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Sandborn WJ. **Am J Gastroenterol** 1999 May;94(5):1161–71 (102 ref.)

Nicotine replacement therapy. Thompson GH, et al. **Ann Pharmacother** 1998 Oct;32(10):1067–75 (43 ref.)

The benefits of smoking in skin diseases. Wolf R, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):641–7 (107 ref.)

Recent advances in the pharmacotherapy of smoking [see comments] Hughes JR, et al. **JAMA** 1999 Jan 6;281(1):72–6 (56 ref.) Comment in: JAMA 1999 Jun 2;281(21):1983; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21):1983–4; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21);1984; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21):1984–5.

Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Dursun SM, et al. **Med Hypotheses** 1999 Feb; 52(2):101–9 (78 ref.)

TOXICITY

Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors. Kobayashi H, et al. **J Toxicol Sci** 1999 Feb;24(1):1–16 (96 ref.)

NICOTINE DEPENDENCE see **TOBACCO USE DISORDER**

NICOTINE USE DISORDER see **TOBACCO USE DISORDER**

NICOTINIC ACETYLCHOLINE RECEPTORS see **RECEPTORS, NICOTINIC**

NICOTINIC ACID see **NIACIN**

NICOTINIC ACIDS

ADMINISTRATION & DOSAGE

Current research and future developments in retinoids: oral and topical agents. Chandraratna RA. **Cutis** 1998 Feb;61(2 Suppl):40–5 (19 ref.)

How and where tazarotene might fit into the current therapeutic armamentarium: an expert opinion. Koo JY. **Cutis** 1998 Feb;61(2 Suppl):36–7 (0 ref.)

Clinical efficacy and safety of tazarotene: optimizing clinical results. Lebwohl M. **Cutis** 1998 Feb;61(2 Suppl):27–9 (6 ref.)

The management of psoriasis–tazarotene: the bottom line. Weinstein GD. **Cutis** 1998 Feb;61(2 Suppl):38–9 (0 ref.)

ADVERSE EFFECTS

Pharmacokinetics and safety review of tazarotene. Marks R. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S134–8 (27 ref.)

CHEMISTRY

Current research and future developments in retinoids: oral and topical agents. Chandraratna RA. **Cutis** 1998 Feb;61(2 Suppl):40–5 (19 ref.)

PHARMACOKINETICS

Pharmacokinetics and safety review of tazarotene. Marks R. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S134–8 (27 ref.)

PHARMACOLOGY

Pharmacologic profile of tazarotene. Duvic M. **Cutis** 1998 Feb;61(2 Suppl):22–6 (26 ref.)

Rational design of receptor-selective retinoids. Chandraratna RA. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S124–8 (21 ref.)

The pathogenesis of psoriasis and the mechanism of action of tazarotene. Duvic M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S129–33 (27 ref.)

THERAPEUTIC USE

Tazarotene in combination with phototherapy. Koo JY. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S144–8 (29 ref.)

Tazarotene in combination with topical corticosteroids. Lebwohl M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S139–43 (15 ref.)

NICOTINIC AGENTS see **CHOLINERGIC AGENTS**

NICOTINIC AGONISTS

ADMINISTRATION & DOSAGE

Prevention of lung cancer by long-term use of alternative nicotine delivery systems? Kunze U, et al. **Eur J Cancer** 1999 Feb;35(2):195–6 (19 ref.)

Smoking behaviour and compensation: a review of the literature. Scherer G. **Psychopharmacology (Berl)** 1999 Jul; 145(1):1–20 (185 ref.)

[Nicotine preparations and other preparations for smoking cessation] Tonstad S. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1289–93 (45 ref.) (Eng. Abstr.) **(Nor)**

CHEMISTRY

Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist. Kem WR. **Invert Neurosci** 1997 Sep–Dec;3(2–3):251–9 (39 ref.)

PHARMACOLOGY

Common aspects of the action of nicotine and other drugs of abuse. Picciotto MR. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):165–72 (117 ref.)

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. Decker MW, et al. **J Physiol Paris** 1998 Jun–Aug;92(3–4):221–4 (17 ref.)

[Epibatidine. An old work principle rediscovered] Hecker T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):226–32 (41 ref.) **(Ger)**

THERAPEUTIC USE

Nicotine replacement therapy. Thompson GH, et al. **Ann Pharmacother** 1998 Oct;32(10):1067–75 (43 ref.)

Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Decker MW, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):917–23 (58 ref.)

Recent advances in the pharmacotherapy of smoking [see comments] Hughes JR, et al. **JAMA** 1999 Jan 6;281(1):72–6 (56 ref.) Comment in: JAMA 1999 Jun 2;281(21):1983; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21):1983–4; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21);1984; discussion 1984–5. Comment in:

JAMA 1999 Jun 2;281(21):1984–5.

NICOTINIC ANTAGONISTS

METABOLISM

Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor. Arias HR. **Biochim Biophys Acta** 1998 Aug 21;1376(2):173–220 (343 ref.)

NICOTINIC RECEPTORS see **RECEPTORS, NICOTINIC**

NIDATION see **OVUM IMPLANTATION**

NIDDM see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

NIEMANN-PICK DISEASE

[Niemann-Pick disease] Hirokawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):386–8 (13 ref.) **(Jpn)**

[Niemann-Pick disease type C and cholesterol] Ninomiya H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1213–8 (11 ref.) **(Jpn)**

GENETICS

Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Schuchman EH, et al. **Genet Test** 1997;1(1):13–9 (34 ref.)

Niemann-Pick C disease: cholesterol handling gone awry. Morris JA, et al. **Mol Med Today** 1998 Dec;4(12):525–31 (49 ref.)

METABOLISM

Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Vanier MT. **Neurochem Res** 1999 Apr;24(4):481–9 (59 ref.)

NIFEDIPINE

THERAPEUTIC USE

Raynaud's phenomenon: state of the art 1998 [editorial] Ho M, et al. **Scand J Rheumatol** 1998;27(5):319–22 (37 ref.)

[Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients] Carré A. **Drugs** 1998;56 Suppl 2:23–30 (20 ref.) (Eng. Abstr.) **(Fre)**

[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension] Krivitzky A, et al. **Drugs** 1998;56 Suppl 2:31–43 (38 ref.) (Eng. Abstr.) **(Fre)**

NIFTOLID see **FLUTAMIDE**

NIGHT BLINDNESS

GENETICS

Update in genetics: genetic eye diseases and the ophthalmologist. MacDonald IM. **Can J Ophthalmol** 1999 Apr;34(2):69–73 (10 ref.)

NIGHT TERRORS see **SLEEP DISORDERS**

NIGHTMARES see **DREAMS**

NIMODIPINE

THERAPEUTIC USE

The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage. Dorsch NW. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:156–60 (13 ref.)

NINTH CRANIAL NERVE see **GLOSSOPHARYNGEAL NERVE**

NIPECOTIC ACIDS

Tiagabine: a novel antiepileptic drug [see comments] Luer MS, et al. **Ann Pharmacother** 1998 Nov;32(11):1173–80 (48 ref.) Comment in: Ann Pharmacother 1998 Nov;32(11):1239–43.

THERAPEUTIC USE

Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy. Kälviäinen R. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:63–7 (27 ref.)

Clinical and EEG findings in complex partial status epilepticus with tiagabine [see comments] Trinka E, et al. **Seizure** 1999 Feb;8(1):41–4 (22 ref.) Comment in: Seizure 1999 May;8(3):197.

[GABA-ergic antiepileptic drugs: pharmacological action and spectrum of clinical activity of tiababine] Pita-Calandre E. **Rev Neurol** 1999 Mar 1–15;28(5):495–8 (33 ref.) (Eng. Abstr.) **(Spa)**

NIPPLES

Syringomatous adenoma of the nipple: report of a case. Toyoshima O, et al. **Surg Today** 1998;28(11):1196–9 (9 ref.)

PATHOLOGY

[Syringomatous tumor of the nipple. A case report and review of the literature] Corral HP, et al. **Ann Chir Plast Esthet** 1997 Dec;42(6):635–7 (12 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Nipple discharge disorders: current diagnostic management and the role of fiber-ductoscopy. Okazaki A, et al. **Eur Radiol** 1999;9(4):583–90 (82 ref.)

NIR SPECTROSCOPY see **SPECTROSCOPY, NEAR-INFRARED**

NISIN

PHARMACOLOGY

Mechanistic action of pediocin and nisin: recent progress and unresolved questions. Montville TJ, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):511–9 (72 ref.)

NISOLDIPINE

PHARMACOKINETICS

Clinical pharmacokinetics of nisoldipine coat-core [published erratum appears in Clin Pharmacokinet 1998 Nov;35(5):390] Heinig R. **Clin Pharmacokinet** 1998 Sep; 35(3):191–208 (75 ref.)

NISSEN OPERATION see **FUNDOPLICATION**

NITELLA see **ALGAE, GREEN**

NITRATE REDUCTASES

CLASSIFICATION

Definition and distinction between assimilatory, dissimilatory and respiratory pathways [letter] Moreno-Vivián C, et al. **Mol Microbiol** 1998 Jul;29(2):664–6 (17 ref.)

GENETICS

Dissimilatory nitrate reductases in bacteria. Philippot L, et al. **Biochim Biophys Acta** 1999 Jul 7;1446(1-2):1–23 (184 ref.)

METABOLISM

Definition and distinction between assimilatory, dissimilatory and respiratory pathways [letter] Moreno-Vivián C, et al. **Mol Microbiol** 1998 Jul;29(2):664–6 (17 ref.)

NITRATES

Protection against peroxynitrite. Arteel GE, et al. **FEBS Lett** 1999 Feb 26;445(2-3):226–30 (74 ref.)

ADVERSE EFFECTS

Infantile methemoglobinemia: reexamining the role of drinking water nitrates. Avery AA. **Environ Health Perspect** 1999 Jul;107(7):583–6 (37 ref.)

[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Direct and simultaneous ultraviolet second-derivative spectrophotometric determination of nitrite and nitrate in preparations of peroxynitrite. Bolzan RM, et al. **Methods Enzymol** 1999;301:178–87 (31 ref.)

Assessment of peroxynitrite scavengers in vitro. Halliwell B, et al. **Methods Enzymol** 1999;301:333–42 (64 ref.)

Peroxynitrite studied by stopped-flow spectroscopy. Kissner R, et al. **Methods Enzymol** 1999;301:342–52 (54 ref.)

Measurement of nitrite and nitrate by high-performance ion chromatography. Stratford MR. **Methods Enzymol** 1999; 301:259–69 (10 ref.)

CHEMISTRY

The basic chemistry of nitrogen monoxide and peroxynitrite [see comments] Koppenol WH. **Free Radic Biol Med** 1998 Sep;25(4–5):385–91 (84 ref.) Comment in: Free Radic Biol Med 1999 Mar;26(5–6):777–8.

Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Squadrito GL, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):392–403 (102 ref.)

Nitration modifying function of proteins, hormones and neurotransmitters. Nakaki T, et al. **Jpn J Pharmacol** 1999 Feb;79(2):125–9 (53 ref.)

Chemistry of peroxynitrite and its relevance to biological systems. Koppenol WH. **Met Ions Biol Syst** 1999; 36:597–619 (118 ref.)

Products from reaction of peroxynitrite with gamma-tocopherol. Hoglen NC, et al. **Methods Enzymol** 1999;301:483–90 (23 ref.)

Nitric oxide donor generation from reactions of peroxynitrite. White CR, et al. **Methods Enzymol** 1999;301:288–98 (45 ref.)

METABOLISM

Peroxynitrite in airway diseases. Sadeghi-Hashjin G, et al. **Clin Exp Allergy** 1998 Dec;28(12):1464–73 (97 ref.)

Peroxynitrite: reactive, invasive and enigmatic. Groves JT. **Curr Opin Chem Biol** 1999 Apr;3(2):226–35 (106 ref.)

Nitrate transport: a key step in nitrate assimilation. Daniel-Vedele F, et al. **Curr Opin Plant Biol** 1998 Jun; 1(3):235–9 (37 ref.)

Reactions of prostaglandin endoperoxide synthase with nitric oxide and peroxynitrite. Goodwin DC, et al. **Drug Metab Rev** 1999 Feb;31(1):273–94 (56 ref.)

Chemistry of peroxynitrite and its relevance to biological systems. Koppenol WH. **Met Ions Biol Syst** 1999; 36:597–619 (118 ref.)

Quantitative estimation of endogenous N-nitrosation in humans by monitoring N-nitrosoproline in urine. Ohshima H, et al. **Methods Enzymol** 1999;301:40–9 (34 ref.)

Peroxynitrite reactions with carbon dioxide-bicarbonate. Radi R, et al. **Methods Enzymol** 1999;301:353–67 (42 ref.)

Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Kettle AJ, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):257–8 (17 ref.)

PHARMACOKINETICS

[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. Zou M, et al. **Drug Metab Rev** 1999 May;31(2):343–9 (23 ref.)

Ulster says 'NO': explosion, resistance and tolerance. Nitric oxide and the actions of organic nitrates. Johnston GD. **Ulster Med J** 1998 Nov;67(2):79–90 (99 ref.)

[Modification of nitrate tolerance using antioxidants] Nickenig G, et al. **Dtsch Med Wochenschr** 1998 Dec 18; 123(51-52):1556–61 (46 ref.) **(Ger)**

[Superoxide, nitric oxide and peroxynitrite] Fukuyama N, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):169–76 (47 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Demyelination: the role of reactive oxygen and nitrogen species. Smith KJ, et al. **Brain Pathol** 1999 Jan;9(1):69–92 (264 ref.)

Peroxynitrite: an endogenous oxidizing and nitrating agent. Ducrocq C, et al. **Cell Mol Life Sci** 1999 Jul; 55(8-9):1068–77 (114 ref.)

Nitrate regulation of metabolism and growth. Stitt M. **Curr Opin Plant Biol** 1999 Jun;2(3):178–86 (79 ref.)

Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture. Estévez AG, et al. **Prog Brain Res** 1998;118:269–80 (114 ref.)

THERAPEUTIC USE

Clinical outcome studies of anti-anginal drug therapy for patients with stable coronary disease: an indication for clinical trials. Parker JD. **Eur Heart J** 1998 Aug;19 Suppl I:I15–9 (42 ref.)

Prospects for therapy of nitrate tolerance [see comments] Glasser SP. **Lancet** 1999 May 8;353(9164):1545–6 (8 ref.) Comment in: Lancet 1999 Jul 24;354(9175):338–9.

The role of organic nitrates in the treatment of heart failure. Elkayam U, et al. **Prog Cardiovasc Dis** 1999 Jan-Feb; 41(4):255–64 (62 ref.)

TOXICITY

Defenses against peroxynitrite. Briviba K, et al. **Methods Enzymol** 1999;301:301–11 (26 ref.)

Examining apoptosis in cultured cells after exposure to nitric oxide and peroxynitrite. Estévez AG, et al. **Methods Enzymol** 1999;301:393–402 (43 ref.)

The chemistry of DNA damage from nitric oxide and peroxynitrite. Burney S, et al. **Mutat Res** 1999 Mar 8; 424(1-2):37–49 (94 ref.)

NITRIC ACID

METABOLISM

Calcium-binding proteins and nitric oxide in retinal function and disease. Müller F, et al. **Acta Anat (Basel)** 1998; 162(2-3):142–50 (109 ref.)

Role of non-nitric oxide non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. Resende AC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1229–35 (58 ref.)

NITRIC OXIDE

see related
ENDOTHELIUM-DERIVED RELAXING FACTOR
NITRIC OXIDE DONORS

NITRIC OXIDE

Nitrogen monoxide-related disease and nitrogen monoxide scavengers as potential drugs. Fricker SP. **Met Ions Biol Syst** 1999;36:665–721 (178 ref.)

Nitric oxide (NO): formation and biological roles in mammalian systems. Fukuto JM, et al. **Met Ions Biol Syst** 1999;36:547–95 (214 ref.)

Therapeutics of nitric oxide modulation. Fung HL, et al. **Met Ions Biol Syst** 1999;36:723–49 (100 ref.)

Nitric oxide and apoptosis. Haendeler J, et al. **Vitam Horm** 1999;57:49–77 (131 ref.)

Nitric oxide and platelet aggregation. Riddell DR, et al. **Vitam Horm** 1999;57:25–48 (113 ref.)

ADMINISTRATION & DOSAGE

What do the bugs think about inhaled NO? [editorial; comment] deBoisblanc BP. **Crit Care Med** 1998 Nov; 26(11):1785–6 (19 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1857–62.

Low-dose inhaled nitric oxide and oxygenation in pediatric hypoxic respiratory failure. Wrong bullet, wrong target [editorial; comment] Tibby S, et al. **Crit Care Med** 1999 May;27(5):871–2 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):989–96.

Recent developments in inhaled nitric oxide therapy of the newborn. Kinsella JP, et al. **Curr Opin Pediatr** 1999 Apr; 11(2):121–5 (33 ref.)

Nitric oxide inhalation therapy for newborn infants. Skimming JW. **Curr Probl Pediatr** 1998 Sep;28(8):253–64 (110 ref.)

Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. Carrier M, et al. **J Heart Lung Transplant** 1999 Jul;18(7):664–7 (9 ref.)

Acute respiratory distress syndrome. Inhaled nitric oxide. Hanania NA, et al. **Respir Care Clin N Am** 1998 Dec; 4(4):695–709 (93 ref.)

[Inhaled nitric oxide: one modality in the treatment of ARDS] Carrillo-Esper R, et al. **Gac Med Mex** 1999 Jul–Aug; 135(4):417–21 (28 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Is the administration of inhaled nitric oxide (NO) associated with electroencephalogram abnormalities? There is NO harm in looking [editorial; comment] Kochanek PM, et al. **Crit Care Med** 1998 Nov;26(11):1788–9 (12 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1887–92.

Nitric oxide and intestinal barrier failure. Nadler EP, et al. **Semin Pediatr Surg** 1999 Aug;8(3):148–54 (88 ref.)

ANALYSIS

Nitric oxide in allergic rhinitis and asthma. Frieri M. **Allergy Asthma Proc** 1998 Nov–Dec;19(6):349–51 (42 ref.)

Managing asthmatic airway inflammation: what is the role of expired nitric oxide measurement? Gaston B. **Curr Probl Pediatr** 1998 Sep;28(8):245–52 (77 ref.)

Quantifying role of nitric oxide in endothelial barrier regulation. Alexander JS, et al. **Methods Enzymol** 1999; 301:3–13 (43 ref.)

Nitric oxide and superoxide detection in human platelets. Freedman JE, et al. **Methods Enzymol** 1999;301:61–70 (21 ref.)

Measuring nitric oxide production in human clinical studies. Granger DL, et al. **Methods Enzymol** 1999;301:49–61 (16 ref.)

Assay of antioxidant and antiinflammatory activity of nitric oxide in vivo. Higuchi H, et al. **Methods Enzymol** 1999; 301:424–36 (57 ref.)

Detection of reactive nitrogen species using 2,7-dichlorodihydrofluorescein and dihydrorhodamine 123. Ischiropoulos H, et al. **Methods Enzymol** 1999;301:367–73 (16 ref.)

Measurement of nitric oxide-mediated effects on zinc homeostasis and zinc finger transcription factors. Kröncke KD, et al. **Methods Enzymol** 1999;301:126–35 (23 ref.)

Determination of nitric oxide saturated solution by amperometry on modified microelectrode. Mesároš S. **Methods Enzymol** 1999;301:160–8 (17 ref.)

Analysis of aromatic nitration, chlorination, and hydroxylation by gas chromatography–mass spectrometry. van der Vliet A, et al. **Methods Enzymol** 1999;301:471–83 (48 ref.)

Iron diethyldithiocarbamate as spin trap for nitric oxide detection. Vanin AF. **Methods Enzymol** 1999;301:269–79 (36 ref.)

Nitrinergic neurons in the developing and adult human telencephalon: transient and permanent patterns of expression in comparison to other mammals. Judas M, et al. **Microsc Res Tech** 1999 Jun 15;45(6):401–19 (178 ref.)

[Spin trapping in the determination of nitric oxide (NO)] Weber H. **Pharm Unserer Zeit** 1999 May;28(3):138–46 (38 ref.) **(Ger)**

ANTAGONISTS & INHIBITORS

Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Muscará MN, et al. **Am J Physiol** 1999 Jun; 276(6 Pt 1):G1313–6 (26 ref.)

BIOSYNTHESIS

Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Pettersson A, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):808–13 (25 ref.)

Competition involving biogenic NO. Nedospasov AA. **Biochemistry (Mosc)** 1998 Jul;63(7):744–65 (132 ref.)

Overproduction of nitric oxide in pathophysiology of blood vessels. Stoclet JC, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):826–32 (111 ref.)

Nitric oxide in septic shock. Titheradge MA. **Biochim Biophys Acta** 1999 May 5;1411(2–3):437–55 (109 ref.)

Nitric oxide in bacteria: synthesis and consumption. Watmough NJ, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2–3):456–74 (135 ref.)

Non-enzymatic nitric oxide synthesis in biological systems. Zweier JL, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2–3):250–62 (39 ref.)

Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Boucher JL, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1015–28 (123 ref.)

Nitric oxide production with PMMA membrane. Amore A, et al. **Contrib Nephrol** 1999;125:182–96 (72 ref.)

Nitric oxide production in neonatal and pediatric sepsis [editorial; comment] Carcillo JA. **Crit Care Med** 1999 Jun; 27(6):1063–5 (19 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1187–90.

Catalysis by nitric oxide synthase. Marletta MA, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):656–63 (50 ref.)

The role of L-arginine in hypertension and nephrotoxicity. Klahr S. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):547–50 (25 ref.)

Regulation of vasodilator synthesis during lung development. Shaul PW. **Early Hum Dev** 1999 Apr;54(3):271–94 (87 ref.)

Improvement in functions of the central nervous system by estrogen replacement therapy might be related with an increased nitric oxide production. López-Jaramillo P, et al. **Endothelium** 1999;6(4):263–6 (27 ref.)

Nitric oxide synthesis in atherosclerosis. Toutouzas PC, et al. **Eur Heart J** 1998 Oct;19(10):1504–11 (105 ref.)

Nitric oxide and inflammatory bowel diseases. Guslandi M. **Eur J Clin Invest** 1998 Nov;28(11):904–7 (42 ref.)

Nitric oxide: physiological roles, biosynthesis and medical uses. Adams DR, et al. **Fortschr Chem Org Naturst** 1999; 76:1–211 (721 ref.)

Chronic nitric oxide inhibition model six years on. Zatz R, et al. **Hypertension** 1998 Dec;32(6):958–64 (106 ref.)

Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. Nakamura M. **J Card Fail** 1999 Jun; 5(2):127–38 (110 ref.)

Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. Schini-Kerth VB. **J Endocrinol Invest** 1999;22(5 Suppl):82–8 (38 ref.)

Regulation of NO synthesis in endothelial cells. Busse R, et al. **Kidney Blood Press Res** 1998;21(2–4):264–6 (12 ref.)

Modulation of nitric oxide production in vivo in the brain. Yamada K, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):601–5 (32 ref.)

Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Weinberg JB. **Mol Med** 1998 Sep;4(9):557–91 (154 ref.)

Tetrahydrobiopterin, cytokines, and nitric oxide synthesis. Werner ER, et al. **Proc Soc Exp Biol Med** 1998 Dec; 219(3):171–82 (154 ref.)

[Biosynthesis of nitric oxide in infection: should it be induced or avoided? (published erratum appears in Med Trop (Mars) 1999;59(1):8)] Millet P, et al. **Med Trop (Mars)** 1998; 58(4):331–5 (34 ref.) **(Fre)**

[Regulation of endothelial NO production by Rho GTPase] Laufs U, et al. **Med Klin** 1999 Apr 15;94(4):211–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[The role of nitrogen oxide in migraine attack] Stępień A. **Neurol Neurochir Pol** 1999 Mar–Apr;33(2):435–44 (20 ref.) (Eng. Abstr.) **(Pol)**

[The synthesis and effects of nitric oxide at the retinal level] Cruce M, et al. **Oftalmologia** 1998;42(2):9–12 (12 ref.) (Eng. Abstr.) **(Rum)**

[Interleukin-1 and nitric oxide involved in the pathogenesis of diabetes)] Sjöholm A. **Lakartidningen** 1999 May 12; 96(19):2338–41 (50 ref.) (Eng. Abstr.) **(Swe)**

BLOOD

Is the EDRF in the cerebral circulation NO? Its release by shear and the dangers in interpreting the effects of NOS inhibitors. Rosenblum WI. **Keio J Med** 1998 Sep; 47(3):142–9 (42 ref.)

Nitrite, endothelin and E-selectin plasma levels after arginine infusion in normal and vasculopathic subjects. Ferlito S, et al. **Minerva Cardioangiol** 1998 Dec;46(12):471–7 (38 ref.) **(Eng, Ita)**

CHEMISTRY

Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites:implications in inflammation. Grisham MB, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G315–21 (27 ref.)

The role of nitric oxide chemistry in cancer treatment. Wink DA, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):802–9 (65 ref.)

Guanylate cyclase and the .NO/cGMP signaling pathway. Denninger JW, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2–3):334–50 (124 ref.)

Nitric oxide and thiol groups. Gaston B. **Biochim Biophys Acta** 1999 May 5;1411(2–3):323–33 (76 ref.)

The reactions of copper proteins with nitric oxide. Torres J, et al. **Biochim Biophys Acta** 1999 May 5;1411(2–3):310–22 (60 ref.)

Neuroprotective versus neurodestructive effects of NO-related species. Lipton SA, et al. **Biofactors** 1998; 8(1–2):33–40 (34 ref.)

The basic chemistry of nitrogen monoxide and peroxynitrite [see comments] Koppenol WH. **Free Radic Biol Med** 1998 Sep;25(4–5):385–91 (84 ref.) Comment in: Free Radic Biol Med 1999 Mar;26(5–6):777–8.

Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Squadrito GL, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):392–403 (102 ref.)

Nitric oxide radical scavenging of flavonoids. Haenen GR, et al. **Methods Enzymol** 1999;301:490–503 (40 ref.)

Assessment of peroxynitrite scavengers in vitro. Halliwell B, et al. **Methods Enzymol** 1999;301:333–42 (64 ref.)

Gel electrofocusing method for studying protein S-nitrosylation. Ji Y, et al. **Methods Enzymol** 1999; 301:145–51 (15 ref.)

Effects of nitric oxide on iron or hemoprotein-catalyzed oxidative reactions. Jourd'heuil D, et al. **Methods Enzymol** 1999;301:437–44 (20 ref.)

Gas-phase oxidation of nitric oxide: chemical kinetics and rate constant. Tsukahara H, et al. **Nitric Oxide** 1999 Jun; 3(3):191–8 (54 ref.)

IMMUNOLOGY

Immune effector mechanism in parasitic infections. Liew FY, et al. **Immunol Lett** 1999 Jan;65(1–2):101–4 (39 ref.)

METABOLISM

Effect of the angiotensin-(1–7) peptide on nitric oxide release. Brosnihan KB. **Am J Cardiol** 1998 Nov 19;82(10A):17S–19S (12 ref.)

Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites:implications in inflammation. Grisham MB, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G315–21 (27 ref.)

Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB. Marshall HE, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):296–7 (23 ref.)

Effect of glutamate and angiotensin II on whole cell currents and release of nitric oxide in the rat subfornical organ. Schmid HA. **Amino Acids** 1998;14(1–3):113–9 (25 ref.)

Nitric oxide in septic shock: directions for future therapy? Hon WM, et al. **Ann Acad Med Singapore** 1998 May; 27(3):414–21 (70 ref.)

Interaction of bradykinin with angiotensin, prostacyclin, and nitric oxide in myocardial preservation. Sato M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:286–94 (61 ref.)

The nitric oxide hypothesis of late preconditioning [editorial; see comments] Bolli R, et al. **Basic Res Cardiol** 1998 Oct; 93(5):325–38 (45 ref.) Comment in: Basic Res Cardiol 1998 Oct;93(5):422.

Arginine metabolism: nitric oxide and beyond. Wu G, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):1–17 (306 ref.)

Interactions between nitric oxide and cytochrome P-450 in the liver. Khatsenko O. **Biochemistry (Mosc)** 1998 Jul; 63(7):833–9 (49 ref.)

Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854–65 (80 ref.)

NO-synthase and nitrite-reductase components of nitric oxide cycle. Reutov VP, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):874–84 (113 ref.)

Biochemical predetermination of the NO synthase and nitrite reductase components of the nitric oxide cycle. Reutov VP. **Biochemistry (Mosc)** 1999 May;64(5):528–42 (126 ref.)

Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. Vanin AF. **Biochemistry (Mosc)** 1998 Jul;63(7):782–93 (97 ref.)

Roles of nitric oxide in brain hypoxia-ischemia. Bolaños JP, et al. **Biochim Biophys Acta** 1999 May 5;1411(2–3):415–36 (277 ref.)

Nitric oxide and mitochondrial respiration. Brown GC. **Biochim Biophys Acta** 1999 May 5;1411(2–3):351–69 (155 ref.)

Nitric oxide and iron proteins. Cooper CE. **Biochim Biophys Acta** 1999 May 5;1411(2–3):290–309 (136 ref.)

Nitric oxide, mitochondria and neurological disease. Heales SJ, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):215–28 (95 ref.)

Nitric oxide and lipid peroxidation. Hogg N, et al. **Biochim Biophys Acta** 1999 May 5;1411(2–3):378–84 (48 ref.)

Nitric oxide metabolism and breakdown. Kelm M. **Biochim Biophys Acta** 1999 May 5;1411(2–3):273–89 (129 ref.)

Nitric oxide and hemoglobin interactions in the vasculature. Kosaka H. **Biochim Biophys Acta** 1999 May 5; 1411(2–3):370–7 (43 ref.)

Neuroprotective versus neurodestructive effects of NO-related species. Lipton SA, et al. **Biofactors** 1998; 8(1–2):33–40 (34 ref.)

Regulation of basal myocardial function by NO. Kojda G, et al. **Cardiovasc Res** 1999 Mar;41(3):514–23 (100 ref.)
Aspects of the involvement of interleukin-1 and nitric oxide in the pathogenesis of insulin-dependent diabetes mellitus. Sjöholm A. **Cell Death Differ** 1998 Jun;5(6):461–8 (67 ref.)
Nitrosative and oxidative modulation of iron regulatory proteins. Bouton C. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1043–53 (102 ref.)
S-nitrosylation of proteins. Broillet MC. **Cell Mol Life Sci** 1999 Jul;55(8–9):1036–42 (57 ref.)
Interactions of nitric oxide with hemoproteins: roles of nitric oxide in mitochondria. Henry Y, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1003–14 (131 ref.)
Mechanisms of nitric oxide-dependent apoptosis: involvement of mitochondrial mediators. Boscá L, et al. **Cell Signal** 1999 Apr;11(4):239–44 (63 ref.)
Nitric oxide in systemic sclerosis lung: controversies and expectations [editorial; comment] Rolla G, et al. **Clin Exp Rheumatol** 1998 Sep–Oct;16(5):522–4 (50 ref.) Comment on: Clin Exp Rheumatol 1998 Sep–Oct;16(5):547–52.
L-argine–nitric oxide metabolism. Glutamine: a new player in this metabolic game? [editorial; comment] Roth E. **Clin Nutr** 1998 Feb;17(1):1–2 (15 ref.) Comment on: Clin Nutr 1998 Feb;17(1):11–4.
Nitric oxide availability in diabetes mellitus. Honing ML, et al. **Diabetes Metab Rev** 1998 Sep;14(3):241–9 (95 ref.)
Reactions of prostaglandin endoperoxide synthase with nitric oxide and peroxynitrite. Goodwin DC, et al. **Drug Metab Rev** 1999 Feb;31(1):273–94 (56 ref.)
Ca2+–nitric oxide–cGMP signaling in rabbit parotid acinar cells. Sugiya H, et al. **Eur J Morphol** 1998 Aug;36 Suppl:194–7 (31 ref.)
Subcellular mechanisms of endothelin action in vascular system. Masaki T, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):133–8 (38 ref.)
Nitric oxide in arthritis. Jang D, et al. **Free Radic Biol Med** 1998 Jun;24(9):1511–9 (72 ref.)
Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Wink DA, et al. **Free Radic Biol Med** 1998 Sep; 25(4–5):434–56 (189 ref.)
Lipid oxidation products and vascular function. Bruckdorfer KR. **Free Radic Res** 1998 Jun;28(6):573–81 (74 ref.)
Nitric oxide and low-density lipoprotein oxidation. Hogg N, et al. **Free Radic Res** 1998 Jun;28(6):593–600 (57 ref.)
New peptides, hormones and parturition. Di Iorio R, et al. **Gynecol Endocrinol** 1998 Dec;12(6):429–34 (28 ref.)
Role of nitric oxide in ventricular dysfunction. Arstall MA, et al. **J Card Fail** 1998 Sep;4(3):249–60 (131 ref.)
Nitric oxide: a regulator of mucosal defense and injury. Elliott SN, et al. **J Gastroenterol** 1998 Dec;33(6):792–803 (103 ref.)
Nitric oxide and Alzheimer's disease. Lüth HJ, et al. **J Hirnforsch** 1998;39(2):245–51 (46 ref.)
Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. Britten MB, et al. **J Intern Med** 1999 Apr;245(4):315–27 (138 ref.)
Angiotensin II, nitric oxide, and end-organ damage in hypertension. Bataineh A, et al. **Kidney Int Suppl** 1998 Dec; 68:S14–9 (55 ref.)
The generation of nitric oxide by G protein-coupled receptors. Christopoulos A, et al. **Life Sci** 1999;64(1):1–15 (104 ref.)
Vascular nitric oxide may lessen Alzheimer's risk. McCarty MF. **Med Hypotheses** 1998 Dec;51(6):465–76 (173 ref.)
Novel nitric oxide–liberating heme proteins from the saliva of bloodsucking insects. Walker FA, et al. **Met Ions Biol Syst** 1999;36:621–63 (189 ref.)
Regulation of mitochondrial respiration by adenosine diphosphate, oxygen, and nitric oxide. Boveris A, et al. **Methods Enzymol** 1999;301:188–98 (23 ref.)
Defenses against peroxynitrite. Briviba K, et al. **Methods Enzymol** 1999;301:301–11 (26 ref.)
Nitration of unsaturated fatty acids by nitric oxide–derived reactive species. O'Donnell VB, et al. **Methods Enzymol** 1999;301:454–70 (46 ref.)
Antioxidant effects of nitric oxide. Wink DA, et al. **Methods Enzymol** 1999;301:413–24 (60 ref.)
Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. McCann SM, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):193–202 (55 ref.)
Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Herce-Pagliai C, et al. **Nitric Oxide** 1998;2(5):324–36 (68 ref.)
Nitric oxide: from molecular biology to clinical nephrology. Morin FC 3rd, et al. **Pediatr Nephrol** 1998 Aug; 12(6):504–11 (37 ref.)
Normal and pathological distribution of nitric oxide in the cardiovascular system. Malinski T. **Pol J Pharmacol** 1998 Nov–Dec;50(6):387–91 (29 ref.)
NO/cGMP/VASP pathway is involved in integrin activation. Fässler R. **Postepy Hig Med Dosw** 1999; 53(2):223 (0 ref.)
Nitric oxide signaling in the cardiovascular system--physiology and pathology. Malinski T. **Postepy Hig Med Dosw** 1999;53(2):205–7 (5 ref.)
Physiological reactions of nitric oxide and hemoglobin: a radical rethink. Gross SS, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9967–9 (49 ref.)
Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Dawson TM, et al. **Prog Brain Res** 1998;118:3–11 (56 ref.)
Nitric oxide in neurodegeneration. Dawson VL, et al. **Prog Brain Res** 1998;118:215–29 (143 ref.)
Interaction of nitric oxide and external calcium fluctuations: a possible substrate for rapid information retrieval. Egelman DM, et al. **Prog Brain Res** 1998;118:199–211 (29 ref.)
Redox modulation of the NMDA receptor by NO-related species. Lipton SA, et al. **Prog Brain Res** 1998;118:73–82 (46 ref.)
Monitoring neuronal NO release in vivo in cerebellum, thalamus and hippocampus. Vincent SR, et al. **Prog Brain Res** 1998;118:27–35 (91 ref.)
Modulation of LTP induction by NMDA receptor activation and nitric oxide release. Zorumski CF, et al. **Prog Brain Res** 1998;118:173–82 (58 ref.)
In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Fedele E, et al. **Prog Neurobiol** 1999 May;58(1):89–120 (168 ref.)
Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Fimiani C, et al. **Prostaglandins Other Lipid Mediat** 1999 Jan;57(1):23–34 (86 ref.)
Nitric oxide and biopterin in depression and stress. van Amsterdam JG, et al. **Psychiatry Res** 1999 Jan 18;85(1):33–8 (42 ref.)
Angiotensin II and nitric oxide: a question of balance. Millatt LJ, et al. **Regul Pept** 1999 May 31;81(1–3):1–10 (83 ref.)
NO and CO as second messengers in oxygen sensing in the carotid body. Prabhakar NR. **Respir Physiol** 1999 Apr 1; 115(2):161–8 (39 ref.)
Novel roles of nitric oxide in hemorrhagic shock. Szabó C, et al. **Shock** 1999 Jul;12(1):1–9 (113 ref.)
Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Neufeld AH. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S129–35 (54 ref.)
[Nitric oxide and neurological diseases] Yu FL, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):274–6 (10 ref.) **(Chi)**
[Nitric oxide and asthma] ten Hacken NH, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1606–11 (40 ref.) (Eng. Abstr.) **(Dut)**
[Biological significance of nitration, nitrosation and nitrosylation in vivo] Nakaki T, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):161–8 (35 ref.) (Eng. Abstr.) **(Jpn)**
[Nitric oxide in health and kidney diseases] Peco-Antić A. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):183–9 (68 ref.) **(Scc)**
[Nitric oxide in dengue pathology] Rodriguez-Ortega M. **Acta Cient Venez** 1998;49 Suppl 1:8–12 (41 ref.) (Eng. Abstr.) **(Spa)**
[Endothelial dysfunction: a global response] López-Farré A, et al. **Rev Esp Cardiol** 1998;51 Suppl 6:18–22 (33 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Tissue oxygenation modifies nitric oxide bioavailability. Heyman SN, et al. **Microcirculation** 1999 Sep;6(3):199–203 (37 ref.)

PHARMACOLOGY

Effects of cytokines and nitric oxide on myocardial E-C coupling. Haque R, et al. **Basic Res Cardiol** 1998;93 Suppl 1:86–94 (98 ref.)
Effects of nitric oxide on the contraction of skeletal muscle. Maréchal G, et al. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1088–102 (142 ref.)
Antiatherosclerotic activity of drugs in relation to nitric oxide function. Bult H, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):157–76 (200 ref.)
The inducible nitric oxide synthase in vascular and cardiac tissue. Stoclet JC, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):139–55 (226 ref.)
Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Grisham MB, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):404–33 (208 ref.)
Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Wink DA, et al. **Free Radic Biol Med** 1998 Sep; 25(4–5):434–56 (189 ref.)
Nitric oxide and low-density lipoprotein oxidation. Hogg N, et al. **Free Radic Res** 1998 Jun;28(6):593–600 (57 ref.)
Examining apoptosis in cultured cells after exposure to nitric oxide and peroxynitrite. Estévez AG, et al. **Methods Enzymol** 1999;301:393–402 (43 ref.)
Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation. Goss SP, et al. **Methods Enzymol** 1999;301:444–53 (27 ref.)
Neurohumoral fluid regulation in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):361–72 (107 ref.)
Ulster says 'NO'; explosion, resistance and tolerance. Nitric oxide and the actions of organic nitrates. Johnston GD. **Ulster Med J** 1998 Nov;67(2):79–90 (99 ref.)
[Nitric oxide as a regulator of hemodynamic changes in pregnancy] Genoveva Durán-Reyes MO, et al. **Ginecol Obstet Mex** 1999 Jan;67:29–36 (35 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The role of nitric oxide in sepsis--an overview. Kirkebøen KA, et al. **Acta Anaesthesiol Scand** 1999 Mar;43(3):275–88 (143 ref.)
Inhibitory mechanisms for cross-bridge cycling: the nitric oxide–cGMP signal transduction pathway in smooth muscle relaxation. Murphy RA, et al. **Acta Physiol Scand** 1998 Dec;164(4):373–80 (66 ref.)
Role of nitric oxide in contraction induced glucose transport. Balon TW. **Adv Exp Med Biol** 1998;441:87–95 (40 ref.)
Nitric oxide and circulatory shock. Rubanyi GM. **Adv Exp Med Biol** 1998;454:165–72 (62 ref.)
Nitric oxide in the pathogenesis of Parkinson's disease. Gerlach M, et al. **Adv Neurol** 1999;80:239–45 (38 ref.)
Nitric oxide and basal ganglia degeneration. Rose S, et al. **Adv Neurol** 1999;80:247–57 (98 ref.)
Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Perner A, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):135–44 (92 ref.)
Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: the role of nitric oxide. Cannon RO 3rd. **Am J Cardiol** 1998 Nov 19; 82(10A):8S–10S (10 ref.)
Hypertension, heart failure, and endothelial function. Drexler H. **Am J Cardiol** 1998 Nov 19;82(10A):20S–22S (16 ref.)
Factors involved in the maintenance of endothelial function. Drexler H. **Am J Cardiol** 1998 Nov 19;82(10A):3S–4S (14 ref.)
Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injury. Huang PL. **Am J Cardiol** 1998 Nov 19;82(10A):57S–59S (9 ref.)
Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Rudic RD, et al. **Am J Hum Genet** 1999 Mar;64(3):673–7 (34 ref.)
The potential clinical impact of 20 years of nitric oxide research [editorial] Cohen RA. **Am J Physiol** 1999 Apr; 276(4 Pt 2):H1404–7 (37 ref.)
Role of nitric oxide in the control of renin secretion. Kurtz A, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):F849–62 (159 ref.)
Nitric oxide. II. Nitric oxide protects in intestinal inflammation. Lefer AM, et al. **Am J Physiol** 1999 Mar; 276(3 Pt 1):G572–5 (26 ref.)
Nitric Oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Li J, et al. **Am J Physiol** 1999 May; 276(5 Pt 1):G1069–73 (25 ref.)
Nitric Oxide. III. A molecular prelude to intestinal inflammation. Miller MJ, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G795–9 (25 ref.)
Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Muscará MN, et al. **Am J Physiol** 1999 Jun; 276(6 Pt 1):G1313–6 (26 ref.)
Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic? Sanders SP. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):147–9 (27 ref.)
The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Gladwin MT, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1368–76 (87 ref.)
Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? van der Vliet A, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):1–9 (78 ref.)
Nitric oxide as a peripheral and central mediator in temperature regulation. Simon E. **Amino Acids** 1998; 14(1–3):87–93 (27 ref.)
Age-associated memory impairment. Assessing the role of nitric oxide. Meyer RC, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:307–17 (62 ref.)
Nitric oxide and the vascular endothelium in myocardial ischemia–reperfusion injury. Vinten-Johansen J, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:354–70 (64 ref.)
Nitric oxide and its implications in skin homeostasis and disease – a review. Bruch-Gerharz D, et al. **Arch Dermatol Res** 1998 Dec;290(12):643–51 (79 ref.)
Nitric oxide and infectious diseases. Burgner D, et al. **Arch Dis Child** 1999 Aug;81(2):185–8 (29 ref.)
Clinical implications of hemoglobin as a nitric oxide carrier. Veeramachaneni NK, et al. **Arch Surg** 1999 Apr; 134(4):434–7 (44 ref.)
Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. Liu Z, et al. **Atherosclerosis** 1998 Sep; 140(1):1–14 (170 ref.)
Apoptotic cell death and nitric oxide: activating and antagonistic transducing pathways. Brüne B, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):817–25 (55 ref.)
Stress, adaptation, and nitric oxide. Malyshev IY, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):840–53 (148 ref.)
Role of soluble guanylate cyclase in the molecular mechanism underlying the physiological effects of nitric oxide. Severina IS. **Biochemistry (Mosc)** 1998 Jul;63(7):794–801 (52 ref.)
The role of nitric oxide chemistry in cancer treatment. Wink DA, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):802–9 (65 ref.)
Oxidant--nitric oxide signalling mechanisms in vascular tissue. Wolin MS, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):810–6 (80 ref.)

Nitric oxide and cell death. Murphy MP. **Biochim Biophys Acta** 1999 May 5;1411(2-3):401-14 (158 ref.)

Biological aspects of reactive nitrogen species. Patel RP, et al. **Biochim Biophys Acta** 1999 May 5;1411(2-3):385-400 (139 ref.)

Role of nitric oxide in maternal hemodynamics and hormonal changes in pregnant rats. Salas SP. **Biol Res** 1998; 31(3):243-50 (37 ref.)

Demyelination: the role of reactive oxygen and nitrogen species. Smith KJ, et al. **Brain Pathol** 1999 Jan;9(1):69-92 (264 ref.)

Central actions of nitric oxide in regulation of autonomic functions. Krukoff TL. **Brain Res Brain Res Rev** 1999 Jul; 30(1):52-65 (210 ref.)

Nitric oxide in the failing myocardium. Sawyer DB, et al. **Cardiol Clin** 1998 Nov;16(4):657-64, viii (53 ref.)

Nitric oxide: a radical molecule in quest of free radicals in proteins. Guittet O, et al. **Cell Mol Life Sci** 1999 Jul; 55(8-9):1054-67 (75 ref.)

Role of nitric oxide in pathogenesis underlying ischemic cerebral damage. Matsui T, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):177-89 (53 ref.)

Nitric oxide: from a mysterious labile factor to the molecule of the Nobel Prize. Recent progress in nitric oxide research. Xu WM, et al. **Cell Res** 1998 Dec;8(4):251-8 (25 ref.)

Nitric oxide in adult lung disease. Hart CM. **Chest** 1999 May; 115(5):1407-17 (94 ref.)

Nitric oxide as a bifunctional regulator of apoptosis. Kim YM, et al. **Circ Res** 1999 Feb 19;84(3):253-6 (26 ref.)

Acute interactions between endothelin and nitric oxide in the control of renal haemodynamics. Baylis C. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):253-7 (59 ref.)

Restoration of nitric oxide function in human hyperlipidaemia, congestive heart failure and liver cirrhosis. Chin-Dusting JP, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):645-52 (101 ref.)

Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Goligorsky MS, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):269-71 (18 ref.)

Nitric oxide, endothelin and nephron transport: potential interactions. Plato CF, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):262-8 (49 ref.)

Chronic studies on the interaction between nitric oxide and endothelin in cardiovascular and renal function. Pollock DM. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):258-61 (27 ref.)

Relationships between the endothelin and nitric oxide pathways. Warner TD. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):247-52 (71 ref.)

Nitric oxide in atherosclerosis: vascular protector or villain? Dusting GJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S34-41 (65 ref.)

The role of nitric oxide in atherosclerosis. Maxwell AJ, et al. **Coron Artery Dis** 1999 Jul;10(5):277-86 (117 ref.)

Nitric oxide and pulmonary hypertension. Sperling RT, et al. **Coron Artery Dis** 1999 Jul;10(5):287-94 (119 ref.)

Nitric oxide and oxygen utilization: exercise, heart failure and diabetes. Zhao G, et al. **Coron Artery Dis** 1999 Jul; 10(5):315-20 (45 ref.)

Nitric oxide and the gut: one more piece in the puzzle [editorial; comment] Fink MP. **Crit Care Med** 1999 Feb; 27(2):248-9 (23 ref.) Comment on: Crit Care Med 1999 Feb;27(2):356-64.

Expired nitric oxide and shock in higher order species [editorial; comment] Traber DL. **Crit Care Med** 1999 Feb; 27(2):255-6 (11 ref.) Comment on: Crit Care Med 1999 Feb;27(2):385-93.

Nitric oxide in cerebral ischemic neurodegeneration and excitotoxicity. Strijbos PJ. **Crit Rev Neurobiol** 1998; 12(3):223-43 (196 ref.)

Neural mechanisms in nitric-oxide-deficient hypertension. Sander M, et al. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):61-73 (165 ref.)

Nitric oxide as a regulator of tissue oxygen consumption. Wolin MS, et al. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):97-103 (37 ref.)

Role of active oxygen species and NO in plant defence responses. Bolwell GP. **Curr Opin Plant Biol** 1999 Aug; 2(4):287-94 (72 ref.)

Therapeutic strategies for coronary artery disease beyond low density lipoprotein (LDL)--lowering. Arad Y, et al. **Curr Pharm Des** 1999 Jan;5(1):1-10 (170 ref.)

Nitric oxide and its role in lipid peroxidation. Violi F, et al. **Diabetes Metab Res Rev** 1999 Jul-Aug;15(4):283-8 (30 ref.)

Hypothalamic control of gonadotropin secretion by LHRH, FSHRF, NO, cytokines, and leptin. McCann SM, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):333-44 (53 ref.)

Modulation of drug metabolism in infectious and inflammatory diseases. Iber H, et al. **Drug Metab Rev** 1999 Feb;31(1):29-41 (41 ref.)

Nitric oxide and its role in apoptosis. Brüne B, et al. **Eur J Pharmacol** 1998 Jun 26;351(3):261-72 (138 ref.)

Functional role of nitric oxide in regulation of ocular blood flow. Koss MC. **Eur J Pharmacol** 1999 Jun 18;374(2):161-74 (200 ref.)

The nitric oxide hypothesis of aging. McCann SM, et al. **Exp Gerontol** 1998 Nov-Dec;33(7-8):813-26 (39 ref.)

Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. Goodwin DC, et al. **FASEB J** 1999 Jul; 13(10):1121-36 (104 ref.)

Nitric oxide: physiological roles, biosynthesis and medical uses. Adams DR, et al. **Fortschr Chem Org Naturst** 1999; 76:1-211 (721 ref.)

Nitric oxide in arthritis. Jang D, et al. **Free Radic Biol Med** 1998 Jun;24(9):1511-9 (72 ref.)

Nitric oxide and arginine. Vallance P. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:31-5 (43 ref.)

Role of nitric oxide in intestinal water and electrolyte transport. Mourad FH, et al. **Gut** 1999 Feb;44(2):143-7 (78 ref.)

Nitric oxide in liver injury. Clemens MG. **Hepatology** 1999 Jul;30(1):1-5 (84 ref.)

Nitric oxide in the stress axis. López-Figueroa MO, et al. **Histol Histopathol** 1998 Oct;13(4):1243-52 (90 ref.)

Nitric oxide in the endometrium. Cameron IT, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):565-9 (32 ref.)

Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? Kolb H, et al. **Immunol Today** 1998 Dec; 19(12):556-61 (84 ref.)

Nitric oxide in the pathogenesis of sepsis. Symeonides S, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):449-63, x (83 ref.)

Role of nitric oxide in the control of apoptosis in the microvasculature. López-Farré A, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1095-106 (41 ref.)

Erratic behavior of nitric oxide within the immune system: illustrative review of conflicting data and their immunopharmacological aspects. Zidek Z, et al. **Int J Immunopharmacol** 1998 Jul;20(7):319-43 (293 ref.)

Nitric oxide and endothelin-1 in coronary and pulmonary circulation. Rubino A, et al. **Int Rev Cytol** 1999;189:59-93 (185 ref.)

Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. Böger RH. **J Endocrinol Invest** 1999;22(5 Suppl):75-81 (42 ref.)

The role of nitric oxide in L-arginine-stimulated growth hormone release. Fisker S, et al. **J Endocrinol Invest** 1999; 22(5 Suppl):89-93 (31 ref.)

Single-cell analyses of nitrergic neurons in simple nervous systems. Moroz LL, et al. **J Exp Biol** 1999 Feb;202 (Pt 4):333-41 (81 ref.)

Role of nitric oxide following cardiac transplantation. Chester AH, et al. **J Hum Hypertens** 1998 Dec;12(12):833-7 (71 ref.)

NO: the primary EDRF. Fleming I, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):5-14 (90 ref.)

Strategies of protection from nitric oxide toxicity in islet inflammation. Rothe H, et al. **J Mol Med** 1999 Jan; 77(1):40-4 (51 ref.)

Role of nitric oxide in the uterus and cervix: implications for the management of labor. Chwalisz K, et al. **J Perinat Med** 1998;26(6):448-57 (51 ref.)

The role of nitric oxide in the pathogenesis of multiple sclerosis. Santiago E, et al. **J Physiol Biochem** 1998 Dec; 54(4):229-37 (87 ref.)

Nitric oxide: discovery and impact on clinical medicine. Moncada S. **J R Soc Med** 1999 Apr;92(4):164-9 (32 ref.)

Nitric oxide and the vascular surgeon. Makhoul RG, et al. **J Vasc Surg** 1999 Sep;30(3):569-72 (5 ref.)

Structural and molecular dissection of the juxtaglomerular apparatus: new aspects for the role of nitric oxide. Bachmann S, et al. **Kidney Int Suppl** 1998 Sep;67:S29-33 (32 ref.)

Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing. Bauer JA. **Med Hypotheses** 1998 Jul;51(1):65-7 (20 ref.)

Production, regulation and role of nitric oxide in glial cells. Vincent VA, et al. **Mediators Inflamm** 1998;7(4):239-55 (372 ref.)

Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging. Yamada K, et al. **Microsc Res Tech** 1998 Oct 1;43(1):68-74 (75 ref.)

Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. Eiserich JP, et al. **Mol Aspects Med** 1998 Aug-Oct;19(4-5):221-357 (671 ref.)

Nitric oxide in invertebrates. Colasanti M, et al. **Mol Neurobiol** 1998 Winter;17(1-3):157-74 (105 ref.)

Cyclic nucleotide-gated channels--mediators of NO:cGMP-regulated processes [see comments] Biel M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul; 358(1):140-4 (58 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111-2.

Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects [see comments] Smolenski A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul; 358(1):134-9 (40 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111-2.

Role of nitric oxide and carbon monoxide in modulating the ACTH response to immune and nonimmune signals. Rivier C. **Neuroimmunomodulation** 1998 May-Aug;5(3-4):203-13 (65 ref.)

Mechanisms of chondrocyte apoptosis. Lotz M, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):389-91 (14 ref.)

Nitric oxide in osteoarthritis. Studer R, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):377-9 (18 ref.)

Vascular endothelium and nitric oxide in childhood hypertension. Goonasekera CD, et al. **Pediatr Nephrol** 1998 Oct;12(8):676-89 (230 ref.)

Nitric oxide and the anticonvulsant action of antiepileptic drugs. Czuczwar SJ. **Pol J Pharmacol** 1999 Jan-Feb; 51(1):101-2 (18 ref.)

Potent neuroprotectants linked to bifunctional inhibition [comment] Dawson VL. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10557-8 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10824-9.

Asthma, viruses, and nitric oxide. Sanders SP. **Proc Soc Exp Biol Med** 1999 Mar;220(3):123-32 (162 ref.)

Why is the role of nitric oxide in NMDA receptor function and dysfunction so controversial? Aizenman E, et al. **Prog Brain Res** 1998;118:53-71 (106 ref.)

Nitric oxide as a signaling molecule in visual system development. Cramer KS, et al. **Prog Brain Res** 1998; 118:101-14 (109 ref.)

Mechanisms of NO neurotoxicity. Dalkara T, et al. **Prog Brain Res** 1998;118:231-9 (79 ref.)

Nitric oxide in neurodegeneration. Dawson VL, et al. **Prog Brain Res** 1998;118:215-29 (143 ref.)

Mechanisms involved in development of retinotectal connections: roles of Eph receptor tyrosine kinases, NMDA receptors and nitric oxide. Ernst AF, et al. **Prog Brain Res** 1998;118:115-31 (131 ref.)

Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture. Estévez AG, et al. **Prog Brain Res** 1998;118:269-80 (114 ref.)

Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Hawkins RD, et al. **Prog Brain Res** 1998;118:155-72 (137 ref.)

Dynamic modulation of cerebral cortex synaptic function by nitric oxide. Kara P, et al. **Prog Brain Res** 1998;118:183-98 (135 ref.)

The role of nitric oxide in development of the patch-cluster system and retinocollicular pathways in the rodent superior colliculus. Mize RR, et al. **Prog Brain Res** 1998;118:133-52 (92 ref.)

Glial glutamate transport as target for nitric oxide: consequences for neurotoxicity. Ye ZC, et al. **Prog Brain Res** 1998;118:241-51 (42 ref.)

Nitric oxide and airways. Matera MG. **Pulm Pharmacol Ther** 1998 Oct-Dec;11(5-6):341-8 (78 ref.)

Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Murad F. **Recent Prog Horm Res** 1998;53:43-59; discussion 59-60 (47 ref.)

The role of nitric oxide in articular cartilage damage. Lotz M. **Rheum Dis Clin North Am** 1999 May;25(2):269-82 (52 ref.)

Nitric oxide and glomerulonephritis. Cattell V. **Semin Nephrol** 1999 May;19(3):277-87 (68 ref.)

Role of nitric oxide in renal hemodynamics. Gabbai FB, et al. **Semin Nephrol** 1999 May;19(3):242-50 (98 ref.)

Duality of nitric oxide in acute renal injury. Goligorsky MS, et al. **Semin Nephrol** 1999 May;19(3):263-71 (58 ref.)

Nitric oxide in interstitial nephritis and other autoimmune diseases. Kelly CJ, et al. **Semin Nephrol** 1999 May; 19(3):288-95 (46 ref.)

Cell signaling by nitric oxide. Lane P, et al. **Semin Nephrol** 1999 May;19(3):215-29 (205 ref.)

Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Raij L. **Semin Nephrol** 1999 May; 19(3):296-303 (58 ref.)

Nitric oxide, sepsis, and the kidney. Schwartz D, et al. **Semin Nephrol** 1999 May;19(3):272-6 (28 ref.)

Nitric oxide and tubuloglomerular feedback. Welch WJ, et al. **Semin Nephrol** 1999 May;19(3):251-62 (79 ref.)

Vasomotor tone and the role of nitric oxide. Fields CE, et al. **Semin Vasc Surg** 1998 Sep;11(3):181-92 (69 ref.)

Exhaled nitric oxide during exercise. Sheel AW, et al. **Sports Med** 1999 Aug;28(2):83-90 (64 ref.)

The nitric oxide-cyclic 3',5'-guanosine monophosphate signal transduction pathway in the mechanism of action of general anesthetics. Vulliemoz Y. **Toxicol Lett** 1998 Nov 23;100-101:103-8 (31 ref.)

NO news from insect brains. Bicker G. **Trends Neurosci** 1998 Aug;21(8):349-55 (68 ref.)

Sight and insight--on the physiological role of nitric oxide in the visual system. Cudeiro J, et al. **Trends Neurosci** 1999 Mar;22(3):109-16 (104 ref.)

Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. Izzo AA, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):403-5 (28 ref.)

Poly (ADP-ribose) polymerase, nitric oxide and cell death. Pieper AA, et al. **Trends Pharmacol Sci** 1999 Apr; 20(4):171-81 (144 ref.)

[The Nobel Prize 1998 in physiology or medicine. Nitrogen oxide as a signal molecule in the cardiovascular system] Hansson GK, et al. **Ugeskr Laeger** 1998 Dec 21; 160(52):7571-8 (37 ref.) **(Dan)**

[Interactions between the renin-angiotensin system, nitric oxide and endothelin] Dussaule JC, et al. **Nephrologie** 1998; 19(7):437-41 (51 ref.) (Eng. Abstr.) **(Fre)**

[Role of endothelial nitric oxide in the regulation of the vasomotor system] Michel JB. **Pathol Biol (Paris)** 1998 Mar; 46(3):181-9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide (NO), vascular protection factor. Biology, physiological role and biochemistry of NO] Tiritilli A. **Presse Med** 1998 Jun 13;27(21):1061-4 (24 ref.) (Eng.

Abstr.) **(Fre)**

[Nitric oxide (NO), vascular protection factor. NO related cardiovascular diseases] Tiritilli A. **Presse Med** 1998 Jun 13;27(21):1065–70 (64 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide (NO), vascular protection factor. NO: role in aging] Tiritilli A. **Presse Med** 1998 Jun 13;27(21):1071–2 (10 ref.) (Eng. Abstr.) **(Fre)**

[The NO/cGMP signal transduction system: a central target for anesthetics? (see comments)] Tonner PH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Feb; 34(2):78–89 (145 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1999 Feb;34(2):77. **(Ger)**

[Leishmaniasis: principles of the immune response and function of nitric oxide] Bogdan C. **Berl Munch Tierarztl Wochenschr** 1998 Nov–Dec; 111(11–12):409–14 (54 ref.) (Eng. Abstr.) **(Ger)**

[Nitric oxide (NO). Its importance to heart function] Kojda G, et al. **Med Monatsschr Pharm** 1999 Apr;22(4):114–23 (93 ref.) **(Ger)**

[Current topics in the regulation of prostanoids—2. The interaction with cytokines and nitric oxide] Ohara M, et al. **Masui** 1998 Dec;47(12):1471–7 (27 ref.) (Eng. Abstr.) **(Jpn)**

[NO and pancreatic diseases] Shimosegawa T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):923–32 (86 ref.) **(Jpn)**

[Superoxide, nitric oxide and peroxynitrite] Fukuyama N, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):169–76 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Inhibition of cytochrome P450 by nitric oxide] Minamiyama Y, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):33–41 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The precise characterization and the crucial mechanism of NO-induced cytotoxicity] Okuma Y, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):187–94 (48 ref.) (Eng. Abstr.) **(Jpn)**

[Nitric oxide and hemoglobin] Yonetani T. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):155–60 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The role of nitric oxide in normal and pathologic immunologic reactions] Zdzisińska B, et al. **Postepy Hig Med Dosw** 1998;52(6):621–36 (90 ref.) (Eng. Abstr.) **(Pol)**

[The role of nitric oxide in transferring a signal between cells] Turpaev KT. **Mol Biol (Mosk)** 1998 Jul–Aug;32(4):581–91 (105 ref.) **(Rus)**

[Nitric oxide and its importance in the regulation of pulmonary function] Motavkin PA, et al. **Morfologiia** 1998; 114(5):99–111 (132 ref.) **(Rus)**

[The physiological role of nitric oxide] Urazaev AKh, et al. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):54–72 (314 ref.) (Eng. Abstr.) **(Rus)**

[Endothelins and nitric oxide: their significance in the regulation of ocular blood flow and intraocular pressure and their role in the pathogenesis of primary glaucoma] Bakshinskii PP. **Vestn Oftalmol** 1999 May–Jun;115(3):33–7 (73 ref.) **(Rus)**

[Neurodegeneration and nitric oxide] Kluchova D. **Bratisl Lek Listy** 1999 Mar;100(3):144–8 (48 ref.) (Eng. Abstr.) **(Slo)**

[Nitric oxide and inflammatory bowel disease (see comments)] Garcia-González MA, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):870–6 (61 ref.) (Eng. Abstr.) Comment in: Rev Esp Enferm Dig 1998 Dec;90(12):829–32. **(Spa)**

THERAPEUTIC USE

The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Gladwin MT, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1368–76 (87 ref.)

Inhaled and exhaled nitric oxide. Thébaud B, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1103–12 (87 ref.)

Management of postoperative chylothorax with nitric oxide: a critical review [editorial; comment] Mavroudis C. **Crit Care Med** 1999 May;27(5):877 (4 ref.) Comment on: Crit Care Med 1999 May;27(5):1022–4.

Inhaled nitric oxide therapy for pulmonary disease in pediatrics. Abman SH, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):236–42 (33 ref.)

Inhaled nitric oxide in the treatment of hypoxemic respiratory failure. Kass LJ, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):284–90 (27 ref.)

Nitric oxide in acute hypoxic respiratory failure: from the bench to the bedside and back again [editorial; comment] Bohn D. **J Pediatr** 1999 Apr;134(4):387–9 (29 ref.) Comment on: J Pediatr 1999 Apr;134(4):406–12.

New tools in ventilatory support: high frequency ventilation, nitric oxide, tracheal gas insufflation, non-invasive ventilation. Biarent D. **Pediatr Pulmonol Suppl** 1999; 18:178–81 (25 ref.)

Nitric oxide for ARDS—what is the evidence? Ferreira E, et al. **Pharmacotherapy** 1999 Jan;19(1):60–9 (36 ref.)

TOXICITY

Nitric Oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Li J, et al. **Am J Physiol** 1999 May; 276(5 Pt 1):G1069–73 (25 ref.)

The chemistry of DNA damage from nitric oxide and peroxynitrite. Burney S, et al. **Mutat Res** 1999 Mar 8; 424(1–2):37–49 (94 ref.)

NITRIC OXIDE DONORS

see related
NITRIC OXIDE

CHEMICAL SYNTHESIS

Heterocyclic NO prodrugs. Schönafinger K. **Farmaco** 1999 May 30;54(5):316–20 (35 ref.)

CHEMISTRY

Nitric oxide donor generation from reactions of peroxynitrite. White CR, et al. **Methods Enzymol** 1999;301:288–98 (45 ref.)

PHARMACOLOGY

Current trends in the development of nitric oxide donors. Hou YC, et al. **Curr Pharm Des** 1999 Jun;5(6):417–41 (117 ref.)

Functional role of nitric oxide in regulation of ocular blood flow. Koss MC. **Eur J Pharmacol** 1999 Jun 18;374(2):161–74 (200 ref.)

Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation. Goss SP, et al. **Methods Enzymol** 1999;301:444–53 (27 ref.)

The use of nitric oxide donors in pharmacological studies [see comments] Feelisch M. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul; 358(1):113–22 (77 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111–2.

[New non-steroidal anti-inflammatory drugs (NSAID's) with lesser side effects, and over-the-counter low-dose preparations] Tytgat GN. **Ned Tijdschr Geneeskd** 1998 Aug 1;142(31):1757–61 (34 ref.) (Eng. Abstr.) **(Dut)**

THERAPEUTIC USE

Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Muscará MN, et al. **Am J Physiol** 1999 Jun; 276(6 Pt 1):G1313–6 (26 ref.)

Opportunities for the treatment of erectile dysfunction by modulation of the NO axis—alternatives to sildenafil citrate. de Mey C. **Curr Med Res Opin** 1998;14(4):187–202 (133 ref.)

Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing. Bauer JA. **Med Hypotheses** 1998 Jul;51(1):65–7 (20 ref.)

Use of nitroglycerin for uterine relaxation. Smith GN, et al. **Obstet Gynecol Surv** 1998 Sep;53(9):559–65 (57 ref.)

NITRIC OXIDE, ENDOTHELIUM-DERIVED see
ENDOTHELIUM-DERIVED RELAXING FACTOR

NITRIC-OXIDE SYNTHASE

[Nitric oxide synthase (NOS)] Ogura T, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1725–31 (28 ref.) **(Jpn)**

ANALYSIS

Nitric oxide and endothelin-1 in coronary and pulmonary circulation. Rubino A, et al. **Int Rev Cytol** 1999;189:59–93 (185 ref.)

Scintillation proximity assay to measure nitroarginine and tetrahydrobiopterin binding to heme domain of neuronal nitric oxide synthase. Alderton WK, et al. **Methods Enzymol** 1999;301:114–25 (21 ref.)

Measuring nitric oxide production in human clinical studies. Granger DL, et al. **Methods Enzymol** 1999;301:49–61 (16 ref.)

Assay of inducible form of nitric oxide synthase activity: effect of flavonoids and plant extracts. Kobuchi H, et al. **Methods Enzymol** 1999;301:504–13 (30 ref.)

Assay of isoforms of Escherichia coli-expressed nitric oxide synthase. Martásek P, et al. **Methods Enzymol** 1999; 301:70–8 (43 ref.)

Electron spin resonance spin-trapping detection of superoxide generated by neuronal nitric oxide synthase. Vásquez-Vivar J, et al. **Methods Enzymol** 1999;301:169–77 (30 ref.)

Nitrinergic neurons in the developing and adult human telencephalon: transient and permanent patterns of expression in comparison to other mammals. Judas M, et al. **Microsc Res Tech** 1999 Jun 15;45(6):401–19 (178 ref.)

ANTAGONISTS & INHIBITORS

Inhibition of nitric oxide synthase as a potential therapeutic target. Hobbs AJ, et al. **Annu Rev Pharmacol Toxicol** 1999; 39:191–220 (209 ref.)

Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Chabrier PE, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1029–35 (73 ref.)

Nitric oxide synthase inhibition in septic shock—a question of the right time, the right drug, and the right model? [editorial; comment] Bone HG. **Crit Care Med** 1998 Dec; 26(12):1945–7 (18 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2021–8.

Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red [editorial; comment] Cobb JP. **Crit Care Med** 1999 May;27(5):855–6 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):913–22.

Nitric oxide synthase inhibitors—a mechanism-based treatment of septic shock [editorial; comment] Kilbourn R. **Crit Care Med** 1999 May;27(5):857–8 (13 ref.) Comment on: Crit Care Med 1999 May;27(5):913–22.

Design of isoform-selective inhibitors of nitric oxide synthase. Babu BR, et al. **Curr Opin Chem Biol** 1998 Aug; 2(4):491–500 (87 ref.)

Chronic nitric oxide inhibition model six years on. Zatz R, et al. **Hypertension** 1998 Dec;32(6):958–64 (106 ref.)

Role of nitric oxide in the control of apoptosis in the microvasculature. López-Farré A, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1095–106 (41 ref.)

Is the EDRF in the cerebral circulation NO? Its release by shear and the dangers in interpreting the effects of NOS inhibitors. Rosenblum WI. **Keio J Med** 1998 Sep; 47(3):142–9 (42 ref.)

Hypertension and impaired renal angiotensin II response in rats after chronic neuronal nitric oxide synthase inhibition. Persson AE, et al. **Kidney Int Suppl** 1998 Sep;67:S216–7 (22 ref.)

Nitric oxide synthases: catalytic function and progress towards selective inhibition [see comments] Mayer B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul; 358(1):127–33 (69 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111–2.

BIOSYNTHESIS

Nitric oxide in septic shock. Titheradge MA. **Biochim Biophys Acta** 1999 May 5;1411(2–3):437–55 (109 ref.)

Regulation of NO synthesis in endothelial cells. Busse R, et al. **Kidney Blood Press Res** 1998;21(2–4):264–6 (12 ref.)

Expression of nitric oxide synthase-2 in glia associated with CNS pathology. Loihl AK, et al. **Prog Brain Res** 1998; 118:253–67 (122 ref.)

CHEMISTRY

The versatile and complex enzymology of nitric oxide synthase. Gorren AC, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):734–43 (106 ref.)

Mammalian nitric oxide synthases. Stuehr DJ. **Biochim Biophys Acta** 1999 May 5;1411(2–3):217–30 (135 ref.)

Nitric oxide synthase structure and electron transfer. Ortiz de Montellano PR, et al. **Drug Metab Dispos** 1998 Dec; 26(12):1185–9 (39 ref.)

A new decoration for nitric oxide synthase – a Zn(Cys)4 site. Ludwig ML, et al. **Structure** 1999 Apr 15;7(4):R73–9 (35 ref.)

GENETICS

The potential mechanism of induction of inducible nitric oxide synthase mRNA in alveolar macrophages by lipopolysaccharide and its suppression by ethanol, in vivo. Greenberg SS, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):260S–265S (80 ref.)

Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injury. Huang PL. **Am J Cardiol** 1998 Nov 19;82(10A):57S–59S (9 ref.)

Inducible nitric oxide synthase in the liver: regulation and function. Taylor BS, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):766–81 (138 ref.)

Regulation of endothelial NO synthase mRNA stability: RNA-binding proteins crowd on the 3'-untranslated region [editorial; comment] Bloch KD. **Circ Res** 1999 Oct 1; 85(7):653–5 (10 ref.) Comment on: Circ Res 1999 Oct 1;85(7):588–95.

Nitric oxide synthases in the failing human heart: a doubled-edged sword? [editorial; comment] Drexler H. **Circulation** 1999 Jun 15;99(23):2972–5 (31 ref.) Comment on: Circulation 1999 Jun 15;99(23):3009–16.

Is it all in the genes...? Nitric oxide synthase and coronary vasospasm [editorial; comment] Lüscher TF, et al. **Circulation** 1999 Jun 8;99(22):2855–7 (29 ref.) Comment on: Circulation 1999 Jun 8;99(22):2864–70.

Neuronal NOS: gene structure, mRNA diversity, and functional relevance. Wang Y, et al. **Crit Rev Neurobiol** 1999;13(1):21–43 (124 ref.)

Nitric oxide synthase gene transfer to the vessel wall. Kibbe M, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):75–81 (45 ref.)

Nitric oxide synthase gene polymorphism and its influence on cardiovascular disease. Soma M, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):83–7 (43 ref.)

Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Hecker M, et al. **Gen Pharmacol** 1999 Jan;32(1):9–16 (86 ref.)

Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Weinberg JB. **Mol Med** 1998 Sep;4(9):557–91 (154 ref.)

Neuronal-type NO synthase: transcript diversity and expressional regulation. Boissel JP, et al. **Nitric Oxide** 1998; 2(5):337–49 (115 ref.)

Genetic analysis of NOS isoforms using nNOS and eNOS knockout animals. Huang PL, et al. **Prog Brain Res** 1998; 118:13–25 (88 ref.)

Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by

experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels. Hauck W, et al. **Semin Perinatol** 1999 Jun;23(3):250–60 (92 ref.)

METABOLISM

Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume. Braam B. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1551–61 (91 ref.)

Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB. Marshall HE, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):296–7 (23 ref.)

The ins and outs of caveolar signaling. m2 muscarinic cholinergic receptors and eNOS activation versus neuregulin and ErbB4 signaling in cardiac myocytes. Feron O, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:11–9 (39 ref.)

The versatile and complex enzymology of nitric oxide synthase. Gorren AC, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):734–43 (106 ref.)

NO-synthase and nitrite-reductase components of nitric oxide cycle. Reutov VP, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):874–84 (113 ref.)

Biochemical predetermination of the NO synthase and nitrite reductase components of the nitric oxide cycle. Reutov VP. **Biochemistry (Mosc)** 1999 May;64(5):528–42 (126 ref.)

Inducible nitric oxide synthase in the liver: regulation and function. Taylor BS, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):766–81 (138 ref.)

Mammalian nitric oxide synthases. Stuehr DJ. **Biochim Biophys Acta** 1999 May 5;1411(2–3):217–30 (135 ref.)

Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Boucher JL, et al. **Cell Mol Life Sci** 1999 Jul;55(8–9):1015–28 (123 ref.)

The controversy about spinal neuronal nitric oxide synthase: under which conditions is it up- or downregulated? Callsen-Cencic P, et al. **Cell Tissue Res** 1999 Feb; 295(2):183–94 (104 ref.)

Neuronal NOS: gene structure, mRNA diversity, and functional relevance. Wang Y, et al. **Crit Rev Neurobiol** 1999;13(1):21–43 (124 ref.)

Catalysis by nitric oxide synthase. Marletta MA, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):656–63 (50 ref.)

Heme-mediated oxygen activation in biology: cytochrome c oxidase and nitric oxide synthase. Poulos TL, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):131–7 (41 ref.)

Endothelial nitric oxide synthase expression and its functionality. Feron O. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):291–6 (38 ref.)

Intracellular localization and activation of endothelial nitric oxide synthase. Feron O. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):55–9 (23 ref.)

Nitric oxide synthase structure and electron transfer. Ortiz de Montellano PR, et al. **Drug Metab Dispos** 1998 Dec; 26(12):1185–9 (39 ref.)

The inducible nitric oxide synthase in vascular and cardiac tissue. Stoclet JC, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):139–55 (226 ref.)

Modulation of the nitric oxide synthase pathway in atherosclerosis. Maxwell AJ, et al. **Exp Physiol** 1998 Sep; 83(5):573–84 (83 ref.)

Nitric oxide: physiological roles, biosynthesis and medical uses. Adams DR, et al. **Fortschr Chem Org Naturst** 1999; 76:1–211 (721 ref.)

Nitric oxide in liver injury. Clemens MG. **Hepatology** 1999 Jul;30(1):1–5 (84 ref.)

Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex. Grozdanovic Z, et al. **Histol Histopathol** 1999 Jan; 14(1):243–56 (116 ref.)

Nitric oxide in the endometrium. Cameron IT, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):565–9 (32 ref.)

Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Chiarugi V, et al. **Int J Mol Med** 1998 Dec; 2(6):715–9 (35 ref.)

Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. Schini-Kerth VB. **J Endocrinol Invest** 1999;22(5 Suppl):82–8 (38 ref.)

Nitric oxide and Alzheimer's disease. Lüth HJ, et al. **J Hirnforsch** 1998;39(2):245–51 (46 ref.)

Structural and molecular dissection of the juxtaglomerular apparatus: new aspects for the role of nitric oxide. Bachmann S, et al. **Kidney Int Suppl** 1998 Sep;67:S29–33 (32 ref.)

Hypertension and impaired renal angiotensin II response in rats after chronic neuronal nitric oxide synthase inhibition. Persson AE, et al. **Kidney Int Suppl** 1998 Sep;67:S216–7 (22 ref.)

The generation of nitric oxide by G protein-coupled receptors. Christopoulos A, et al. **Life Sci** 1999;64(1):1–15 (104 ref.)

Muscarinic cholinergic signaling in cardiac myocytes: dynamic targeting of M2AChR to sarcolemmal caveolae and eNOS activation. Feron O, et al. **Life Sci** 1999; 64(6–7):471–7 (24 ref.)

Neuronal nitric oxide synthase and Hepatic Encephalopathy. Rao VL, et al. **Metab Brain Dis** 1998 Sep;13(3):175–89 (95 ref.)

Brain iNOS: current understanding and clinical implications. Licinio J, et al. **Mol Med Today** 1999 May;5(5):225–32 (57 ref.)

Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis. Needleman P, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):367–70 (28 ref.)

The subcellular distribution of nitric oxide synthase relative to the NR1 subunit of NMDA receptors in the cerebral cortex. Aoki C, et al. **Prog Brain Res** 1998;118:83–97 (40 ref.)

Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Dawson TM, et al. **Prog Brain Res** 1998;118:3–11 (56 ref.)

Angiotensin II and nitric oxide: a question of balance. Millatt LJ, et al. **Regul Pept** 1999 May 31;81(1–3):1–10 (83 ref.)

Localization and regulation of nitric oxide synthase isoforms in the kidney. Kone BC. **Semin Nephrol** 1999 May; 19(3):230–41 (131 ref.)

Novel roles of nitric oxide in hemorrhagic shock. Szabó C, et al. **Shock** 1999 Jul;12(1):1–9 (113 ref.)

[Nitric oxide and neurological diseases] Yu FL, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):274–6 (10 ref.) **(Chi)**

[Mechanisms of regulation by calmodulin of nitric oxide synthase] Gervaziev IuV, et al. **Vopr Med Khim** 1999 May-Jun;45(3):187–99 (51 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Focus on: "G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor" [editorial; comment] Galligan JJ. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1407–8 (14 ref.) Comment on: Am J Physiol 1998 Dec;275(6 Pt 1):C1409–16.

The role of nitric oxide in heart failure. Arstall MA, et al. **Coron Artery Dis** 1999 Jul;10(5):301–8 (115 ref.)

Effects of cytokines on nitric oxide pathways in human vasculature. Bhagat K, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):89–96 (52 ref.)

Role of macula densa NOS in tubuloglomerular feedback. Wilcox CS. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):443–9 (58 ref.)

Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Amin AR, et al. **Curr Opin Rheumatol** 1999 May;11(3):202–9 (58 ref.)

Functional role of nitric oxide in regulation of ocular blood flow. Koss MC. **Eur J Pharmacol** 1999 Jun 18;374(2):161–74 (200 ref.)

Neuronal nitric oxide synthase in the neural pathways of the urinary bladder. Zhou Y, et al. **J Anat** 1999 May;194 (Pt 4):481–96 (141 ref.)

Oxygen radical stress in vascular disease: the role of endothelial nitric oxide synthase. Stroes ES, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S14–21 (129 ref.)

Inducible NO synthase: role in cellular signalling. Beck KF, et al. **J Exp Biol** 1999 Mar;202 (Pt 6):645–53 (81 ref.)

Nitric-oxide synthase and neurodegeneration/neuroprotection. Kaufman PL. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9455–6 (22 ref.)

The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Muñoz-Fernández MA, et al. **Prog Neurobiol** 1998 Oct; 56(3):307–40 (486 ref.)

[NO synthase: biochemical properties and physiologic importance] Bernátová I, et al. **Bratisl Lek Listy** 1998 Aug-Sep;99(8–9):474–82 (94 ref.) (Eng. Abstr.) **(Slo)**

[Endothelial dysfunction: a global response] López-Farré A, et al. **Rev Esp Cardiol** 1998;51 Suppl 6:18–22 (33 ref.) (Eng. Abstr.) **(Spa)**

NITRILES

see related

CYANIDES

Chlorothalonil: lack of genotoxic potential. Rosenkranz HS. **Mutat Res** 1999 Jan 25;423(1–2):183–6 (26 ref.)

METABOLISM

Biotransformation of nitriles by rhodococci. Bunch AW. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1–3):89–97 (40 ref.)

Biochemistry and biotechnology of mesophilic and thermophilic nitrile metabolizing enzymes. Cowan D, et al. **Extremophiles** 1998 Aug;2(3):207–16 (70 ref.)

PHARMACOLOGY

Pharmacological and clinical profile of anastrozole. Lønning PE, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S53–7; discussion S73–7 (26 ref.)

Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Smith IE, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S67–71; discussion S73–7 (18 ref.)

THERAPEUTIC USE

Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Lamb HM, et al. **Drugs** 1998 Dec;56(6):1125–40 (54 ref.)

Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Wiseman LR, et al. **Drugs Aging** 1998 Oct;13(4):321–32 (34 ref.)

NITRITE REDUCTASES

METABOLISM

NO-synthase and nitrite-reductase components of nitric oxide cycle. Reutov VP, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):874–84 (113 ref.)

Biochemical predetermination of the NO synthase and nitrite reductase components of the nitric oxide cycle. Reutov VP. **Biochemistry (Mosc)** 1999 May;64(5):528–42 (126 ref.)

NITRITES

ANALYSIS

Direct and simultaneous ultraviolet second-derivative spectrophotometric determination of nitrite and nitrate in preparations of peroxynitrite. Bolzan RM, et al. **Methods Enzymol** 1999;301:178–87 (31 ref.)

Measurement of nitrite and nitrate by high-performance ion chromatography. Stratford MR. **Methods Enzymol** 1999; 301:259–69 (10 ref.)

CHEMISTRY

Nitrite and nitrosyl compounds in food preservation. Cammack R, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2–3):475–88 (116 ref.)

METABOLISM

Non-enzymatic nitric oxide synthesis in biological systems. Zweier JL, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2–3):250–62 (39 ref.)

Autocatalytic oxidation of hemoglobin by nitrite: a possible mechanism. Lissi E. **Free Radic Biol Med** 1998 Jun; 24(9):1535–6 (7 ref.)

Sources and sinks for ammonia and nitrite on the early Earth and the reaction of nitrite with ammonia. Summers DP. **Orig Life Evol Biosph** 1999 Jan;29(1):33–46 (31 ref.)

NITRO COMPOUNDS

ADVERSE EFFECTS

Nitroaromatic munition compounds: environmental effects and screening values. Talmage SS, et al. **Rev Environ Contam Toxicol** 1999;161:1–156 (278 ref.)

METABOLISM

Degradation of nitrate ester and nitroaromatic explosives by Enterobacter cloacae PB2. Basran A, et al. **Biochem Soc Trans** 1998 Nov;26(4):680–5 (18 ref.)

NITROARGININE

ANALYSIS

Scintillation proximity assay to measure nitroarginine and tetrahydrobiopterin binding to heme domain of neuronal nitric oxide synthase. Alderton WK, et al. **Methods Enzymol** 1999;301:114–25 (21 ref.)

NITROBENZENES

METABOLISM

Triglyceride lipase assays based on a novel fluorogenic alkyldiacyl glycerol substrate. Hermetter A. **Methods Mol Biol** 1999;109:19–29 (19 ref.)

TOXICITY

Nitrobenzene carcinogenicity in animals and human hazard evaluation. Holder JW. **Toxicol Ind Health** 1999 Aug; 15(5):445–57 (117 ref.)

Nitrobenzene potential human cancer risk based on animal studies. Holder JW. **Toxicol Ind Health** 1999 Aug; 15(5):458–63 (29 ref.)

NITROBENZOATES

THERAPEUTIC USE

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). Holme E, et al. **J Inherit Metab Dis** 1998 Aug;21(5):507–17 (23 ref.)

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Lock EA, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):498–506 (30 ref.)

TOXICITY

From toxicological problem to therapeutic use: the discovery of the mode of action of

2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Lock EA, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):498-506 (30 ref.)

NITROCELLULOSE see **COLLODION**

NITROGEN

see related
NITROGEN ISOTOPES

ANALYSIS

Air pollution. Fox DL. **Anal Chem** 1999 Jun 15; 71(12):109R-119R (333 ref.)

CHEMISTRY

[Active nitrogen species. A new research area for pharmaceutical chemistry] Duchstein HJ, et al. **Pharm Unserer Zeit** 1999 Jul;28(4):197-207 (101 ref.) **(Ger)**

METABOLISM

The role of fungi in the carbon- and nitrogen cycles. Vetter J. **Acta Microbiol Immunol Hung** 1999;46(2-3):197-8 (6 ref.)
The diversity of redox proteins involved in bacterial heterotrophic nitrification and aerobic denitrification. Richardson DJ, et al. **Biochem Soc Trans** 1998 Aug; 26(3):401-8 (20 ref.)
Inorganic nitrogen metabolism in bacteria. Richardson DJ, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):207-19 (49 ref.)
Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. Hanson ES, et al. **Gene Expr** 1999;7(4-6):367-76 (100 ref.)
Tumour growth and nitrogen metabolism in the host (Review). Argilés JM, et al. **Int J Oncol** 1999 Mar; 14(3):479-86 (142 ref.)
Significant role of the nitrogen recycling system through the ceca occurs in protein-depleted chickens. Karasawa Y. **J Exp Zool** 1999 Mar-Apr 1;283(4-5):418-25 (44 ref.)
Acute metabolic effects of human growth hormone on 15N-nitrogen balance in patients with thalassaemia as compared to patients with other types of short stature. Zachmann M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:851-6 (30 ref.)
Regulation of nitrogen metabolism in Bacillus subtilis: vive la différence! Fisher SH. **Mol Microbiol** 1999 Apr; 32(2):223-32 (60 ref.)
Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? [editorial] Bergström J, et al. **Perit Dial Int** 1998 Sep-Oct;18(5):467-73 (25 ref.)
Postoperative protein sparing. Wilmore DW. **World J Surg** 1999 Jun;23(6):545-52 (49 ref.)
[Active nitrogen species. A new research area for pharmaceutical chemistry] Duchstein HJ, et al. **Pharm Unserer Zeit** 1999 Jul;28(4):197-207 (101 ref.) **(Ger)**

TOXICITY

Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Halliwell B. **Mutat Res** 1999 Jul 15;443(1-2):37-52 (153 ref.)

NITROGEN COMPOUNDS

ANALYSIS

Detection of reactive nitrogen species using 2,7-dichlorodihydrofluorescein and dihydrorhodamine 123. Ischiropoulos H, et al. **Methods Enzymol** 1999;301:367-73 (16 ref.)
Immunohistochemical methods to detect nitrotyrosine. Viera L, et al. **Methods Enzymol** 1999;301:373-81 (34 ref.)

NITROGEN DIOXIDE

ADVERSE EFFECTS

Exposure to nitrogen dioxide (NO_2) and respiratory disease risk. Chauhan AJ, et al. **Rev Environ Health** 1998 Jan-Jun; 13(1-2):73-90 (93 ref.)

PHARMACOLOGY

Inflammatory mechanisms underlying potentiation of effects of inhaled aeroallergens in response to nitrogen dioxide in allergic airways disease [editorial; comment] Krishna MT, et al. **Clin Exp Allergy** 1999 Feb;29(2):150-4 (31 ref.) Comment on: Clin Exp Allergy 1999 Feb;29(2):234-40.

TOXICITY

Toxicological mechanisms underlying oxidant pollutant-induced airway injury. Krishna MT, et al. **Rev Environ Health** 1998 Jan-Jun;13(1-2):59-71 (75 ref.)

NITROGEN FIXATION

Biological nitrogen fixation and future challenges of agriculture. The endophytic connection. Sánchez F, et al. **Adv Exp Med Biol** 1999;464:107-15 (69 ref.)

GENETICS

Genes involved in the formation and assembly of rhizobial cytochromes and their role in symbiotic nitrogen fixation. Delgado MJ, et al. **Adv Microb Physiol** 1998;40:191-231 (160 ref.)

NITROGEN ISOTOPES

ANALYSIS

[Studying intestinal maturation in newborn infants by means of stable isotopes] Sáenz de Pipaón M, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):77-82 (59 ref.) (Eng. Abstr.) **(Spa)**

NITROGEN NARCOSIS see **INERT GAS NARCOSIS**

NITROGEN OXIDES

CHEMISTRY

Chemical approaches toward generation of nitroxyl. King SB, et al. **Methods Enzymol** 1999;301:211-20 (31 ref.)

METABOLISM

Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. Vanin AF. **Biochemistry (Mosc)** 1998 Jul;63(7):782-93 (97 ref.)

PHARMACOLOGY

Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitrone and vitamin E. Butterfield DA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:448-62 (61 ref.)

NITROGLYCERIN

ADMINISTRATION & DOSAGE

[Short-term versus long-term use of nitrates in acute myocardial infarction] Nakamura Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2617-22 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? [editorial; comment] Sias TM, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):206-9 (26 ref.) Comment on: Am Heart J 1999 Aug;138(2 Pt 1):369-75.

PHARMACOLOGY

How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions? Jost S, et al. **Int J Card Imaging** 1998 Dec;14(6):357-72 (105 ref.)
The effects on the central nervous system of nitroglycerin--putative mechanisms and mediators. Tassorelli C, et al. **Prog Neurobiol** 1999 Apr;57(6):607-24 (127 ref.)

THERAPEUTIC USE

Glyceryl trinitrate for anal fissure? **Drug Ther Bull** 1998 Jul; 36(7):55-6 (21 ref.)
Use of nitroglycerin for uterine relaxation. Smith GN, et al. **Obstet Gynecol Surv** 1998 Sep;53(9):559-65 (57 ref.)
[The treatment of chronic fissure in ano with nitrate ointment (see comments)] Stassen LP, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):13-6 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Feb 13;143(7):381. **(Dut)**

NITROIMIDAZOLES

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Lamp KC, et al. **Clin Pharmacokinet** 1999 May;36(5):353-73 (130 ref.)

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Lamp KC, et al. **Clin Pharmacokinet** 1999 May;36(5):353-73 (130 ref.)

THERAPEUTIC USE

Microbiological aspects of antibiotic resistant Helicobacter pylori strains. Monteiro L, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S329-33 (24 ref.)

4-NITROPHENOL-2-HYDROXYLASE see **CYTOCHROME P-450 CYP2E1**

NITROPHENOLS

ANALYSIS

Measurement and significance of free and protein-bound 3-nitrotyrosine, 3-chlorotyrosine, and free 3-nitro-4-hydroxyphenylacetic acid in biologic samples: a high-performance liquid chromatography method using electrochemical detection. Crow JP. **Methods Enzymol** 1999;301:151-60 (28 ref.)

NITROPHOS see **FENITROTHION**

NITROSAMINES

ADVERSE EFFECTS

Tobacco smoke carcinogens and lung cancer. Hecht SS. **J Natl Cancer Inst** 1999 Jul 21;91(14):1194-210 (249 ref.)
A qualitative and quantitative risk assessment of snuff dipping [published erratum appears in Regul Toxicol Pharmacol 1999 Feb;29(1):97] Nilsson R. **Regul Toxicol Pharmacol** 1998 Aug;28(1):1-16 (112 ref.)

TOXICITY

DNA adduct formation from tobacco-specific N-nitrosamines. Hecht SS. **Mutat Res** 1999 Mar 8; 424(1-2):127-42 (95 ref.)
The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Chung FL. **Proc Soc Exp Biol Med** 1999 Apr;220(4):244-8 (28 ref.)
[Nitrosamines] Jabłoński J, et al. **Med Pr** 1995;46(1):67-74 (45 ref.) (Eng. Abstr.) **(Pol)**

URINE

Quantitative estimation of endogenous N-nitrosation in humans by monitoring N-nitrosoproline in urine. Ohshima H, et al. **Methods Enzymol** 1999;301:40-9 (34 ref.)

NITROSATION

Quantitative estimation of endogenous N-nitrosation in humans by monitoring N-nitrosoproline in urine. Ohshima H, et al. **Methods Enzymol** 1999;301:40-9 (34 ref.)

NITROSO COMPOUNDS

ADVERSE EFFECTS

N-Nitroso compounds in the diet. Lijinsky W. **Mutat Res** 1999 Jul 15;443(1-2):129-38 (50 ref.)

ANALYSIS

Detection of S-nitrosothiols by fluorometric and colorimetric methods. Wink DA, et al. **Methods Enzymol** 1999; 301:201-11 (31 ref.)

CHEMISTRY

Stability of S-nitrosothiols in presence of copper, zinc-superoxide dismutase. Jourd'heuil D, et al. **Methods Enzymol** 1999;301:220-7 (19 ref.)

METABOLISM

Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. Vanin AF. **Biochemistry (Mosc)** 1998 Jul;63(7):782-93 (97 ref.)
S-nitrosylation of proteins. Broillet MC. **Cell Mol Life Sci** 1999 Jul;55(8-9):1036-42 (57 ref.)

NITROSODIETHYLAMINE see **DIETHYLNITROSAMINE**

NITROSOMETHYLUREA see **METHYLNITROSOUREA**

NITROSOMONAS

ENZYMOLOGY

Consideration of a phlorin structure for haem P-460 of hydroxylamine oxidoreductase and its implications regarding reaction mechanism. Arciero DM, et al. **Biochem Soc Trans** 1998 Aug;26(3):385-9 (41 ref.)

NITROSOUREA COMPOUNDS

ADMINISTRATION & DOSAGE

[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature] Terheyden P, et al. **Hautarzt** 1998 Oct;49(10):770-3 (23 ref.) (Eng. Abstr.) **(Ger)**

NK CELLS see **KILLER CELLS, NATURAL**

NK-1 RECEPTORS see **RECEPTORS, NEUROKININ-1**

NK-2 RECEPTORS see **RECEPTORS, NEUROKININ-2**

NK-3 RECEPTORS see **RECEPTORS, NEUROKININ-3**

NMDA

NMDA see **N-METHYLASPARTATE**

NMDA RECEPTOR-IONOPHORE COMPLEX see **RECEPTORS, N-METHYL-D-ASPARTATE**

NMDA RECEPTORS see **RECEPTORS, N-METHYL-D-ASPARTATE**

D-NMMA see **OMEGA-N-METHYLARGININE**

L-NMMA see **OMEGA-N-METHYLARGININE**

NMR, BIOMOLECULAR see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

NMR, HETERONUCLEAR see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

NMR IMAGING see **MAGNETIC RESONANCE IMAGING**

NMR, MULTINUCLEAR see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

NMR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

NMR SPECTROSCOPY, IN VIVO see **NUCLEAR MAGNETIC RESONANCE**

NMR SPECTROSCOPY, PROTEIN see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

NMR TOMOGRAPHY see **MAGNETIC RESONANCE IMAGING**

NO-FAULT INSURANCE see **INSURANCE, LIABILITY**

NO SYNTHASE see **NITRIC-OXIDE SYNTHASE**

NOARG see **NITROARGININE**

NOBEL PRIZE

The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621–44 (63 ref.)

Therapeutic effectiveness and social context: the case of lobotomy in a California state hospital, 1947–1954. Braslow J. **West J Med** 1999 May;170(5):293–6 (31 ref.)

[The Nobel Prize 1998 in physiology or medicine. Nitrogen oxide as a signal molecule in the cardiovascular system] Hansson GK, et al. **Ugeskr Laeger** 1998 Dec 21; 160(52):7571–8 (37 ref.) **(Dan)**

[50 years of steroid treatment of rheumatoid arthritis (Philip Hench)] Bálint G, et al. **Orv Hetil** 1998 Oct 18; 139(42):2521–3 (32 ref.) **(Hun)**

NOBLE GASES

DIAGNOSTIC USE

[Magnetic resonance tomography with inhalation of polarized noble gases: new perspectives in functional imaging diagnosis of emphysema] Kauczor HU, et al. **Pneumologie** 1998 Oct;52(10):563–7 (22 ref.) (Eng. Abstr.) **(Ger)**

NOCARDIA

[Mycetoma pedis (nocardiosis)] Yamamoto Y. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):247–8 (5 ref.) **(Jpn)**

METABOLISM

Biosynthesis and molecular genetics of cephamycins. Cephamycins produced by actinomycetes. Liras P. **Antonie Van Leeuwenhoek** 1999 Jan–Feb;75(1–2):109–24 (85 ref.)

NOCARDIA INFECTIONS

Nocardia, nocardiosis and mycetoma. Boiron P, et al. **Med Mycol** 1998;36 Suppl 1:26–37 (93 ref.)

[Pulmonary actinomycosis, pulmonary nocardiosis] Toyoda T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):396–9 (6 ref.) **(Jpn)**

DIAGNOSIS

Nocardia farcinica pneumonia in chronic granulomatous disease. Shetty AK, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):961–4 (36 ref.)

MICROBIOLOGY

Native valve endocarditis due to a Nocardia-like organism. Dhawan VK, et al. **Clin Infect Dis** 1998 Oct;27(4):902–4 (9 ref.)

NOCICEPTION TESTS see **PAIN MEASUREMENT**

NOCICEPTORS

DRUG EFFECTS

Interleukin-1 and nociception in the rat. Bianchi M, et al. **J Neurosci Res** 1998 Sep 15;53(6):645–50 (67 ref.)

Recent advances in neuropharmacology of cutaneous nociceptors. Nakamura A, et al. **Jpn J Pharmacol** 1999 Apr; 79(4):427–31 (29 ref.)

Some new insights into the effects of opioids in phasic and tonic nociceptive tests. McCormack K, et al. **Pain** 1998 Nov;78(2):79–98 (222 ref.)

PHYSIOLOGY

Ion channels of nociception. McCleskey EW, et al. **Annu Rev Physiol** 1999;61:835–56 (133 ref.)

Transmitters involved in antinociception in the spinal cord. Fürst S. **Brain Res Bull** 1999 Jan 15;48(2):129–41 (97 ref.)

Central mechanisms of pain modulation. Mason P. **Curr Opin Neurobiol** 1999 Aug;9(4):436–41 (33 ref.)

Recent studies of cutaneous nociception in atopic and non-atopic subjects. Heyer GR, et al. **J Dermatol** 1999 Feb; 26(2):77–86 (43 ref.)

Neurotrophins, nociceptors, and pain. Mendell LM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):252–61 (99 ref.)

Primitivism and plasticity of pain--implication of polymodal receptors. Kumazawa T. **Neurosci Res** 1998 Sep;32(1):9–31 (218 ref.)

The changing sensitivity in the life of the nociceptor. Koltzenburg M. **Pain** 1999 Aug;Suppl 6:S93–102 (132 ref.)

Transgenic studies of pain. Mogil JS, et al. **Pain** 1998 Aug; 77(2):107–28 (216 ref.)

The primary afferent nociceptor as pattern generator. Reichling DB, et al. **Pain** 1999 Aug;Suppl 6:S103–9 (99 ref.)

Regulation of spinal nociceptive processing: where we went when we wandered onto the path marked by the gate. Yaksh TL. **Pain** 1999 Aug;Suppl 6:S149–52 (26 ref.)

Forebrain mechanisms of nociception and pain: analysis through imaging. Casey KL. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7668–74 (88 ref.)

Ion channels gated by heat. Cesare P, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7658–63 (32 ref.)

Neurotrophins and hyperalgesia. Shu XQ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7693–6 (40 ref.)

Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Thompson SW, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7714–8 (28 ref.)

Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7723–30 (83 ref.)

Transduction and transmission properties of primary nociceptive afferents. Treede RD. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):205–11 (45 ref.)

Acute pain mechanisms. Sorkin LS, et al. **Surg Clin North Am** 1999 Apr;79(2):213–29 (103 ref.)

Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Yaksh TL. **Trends Pharmacol Sci** 1999 Aug;20(8):329–37 (98 ref.)

[Pain in neonates (see comments)] Rønneberg M, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3610–3 (40 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1998 Nov 10;118(27):4270. **(Nor)**

[Newborn infants do feel pain! Technique and environment in connection with specimen collection can be improved] Finnström O, et al. **Lakartidningen** 1998 Dec 9; 95(50):5718–20 (20 ref.) **(Swe)**

[Centrally disturbed pain modulation explains prolonged pain. New knowledge changes the view on the problematic patient] Lidbeck J. **Lakartidningen** 1999 Jun 9; 96(23):2843–8, 2850–1 (84 ref.) **(Swe)**

PHYSIOPATHOLOGY

Peripheral contributions to visceral hyperalgesia. Gebhart GF. **Can J Gastroenterol** 1999 Mar;13 Suppl A:37A–41A (16 ref.)

Efferent functions of C-fiber nociceptors. Sann H, et al. **Z Rheumatol** 1998;57 Suppl 2:8–13 (27 ref.)

NOCTURIA see **URINATION DISORDERS**

NODDING SPASM see **SPASMS, INFANTILE**

NODES OF RANVIER see **RANVIER'S NODES**

NODULAR ELASTOIDOSIS see **FACIAL DERMATOSES**

NOISE

see related
ACOUSTIC STIMULATION
HEARING LOSS, NOISE-INDUCED

ADVERSE EFFECTS

Speech audiometry in noise-exposed workers: the SRT-PTA relationship revisited. Picard M, et al. **Audiology** 1999 Jan–Feb;38(1):30–43 (106 ref.)

[Socio-acousis. Non-occupationally-induced hearing loss due to noise, I] Plath P. **HNO** 1998 Oct;46(10):887–92 (46 ref.) **(Ger)**

[Hearing loss caused by leisure noise] Zenner HP, et al. **HNO** 1999 Apr;47(4):236–48 (69 ref.) (Eng. Abstr.) **(Ger)**

[The influence and sources of infrasound: review of literature] Pawlaczyk-Luszczyńska M. **Med Pr** 1998;49(5):489–92 (21 ref.) (Eng. Abstr.) **(Pol)**

NOISE, OCCUPATIONAL

ADVERSE EFFECTS

Noise-induced extra-aural pathology: a review and commentary. Alves-Pereira M. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A7–21 (98 ref.)

The vibroacoustic disease--an emerging pathology. Castelo Branco NA, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A1–6 (55 ref.)

NOMA

[Necrotizing stomatitis] Michiwaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):369–71 (3 ref.) **(Jpn)**

EPIDEMIOLOGY

[Progressive noma: apropos of 27 cases seen at the National Hospital Center of Ouagadougou] Ouoba K, et al. **Dakar Med** 1998;43(1):45–8 (11 ref.) (Eng. Abstr.) **(Fre)**

NOMENCLATURE see **TERMINOLOGY**

NON-HODGKIN LYMPHOMA see **LYMPHOMA, NON-HODGKIN**

NON-OBESE DIABETIC MICE see **MICE, INBRED NOD**

NONAGENARIANS see **AGED, 80 AND OVER**

NONHEME IRON PROTEINS

METABOLISM

Nitric oxide and iron proteins. Cooper CE. **Biochim Biophys Acta** 1999 May 5;1411(2–3):290–309 (136 ref.)

NON-HISTONE CHROMOSOMAL PROTEINS see **CHROMOSOMAL PROTEINS, NON-HISTONE**

NONINVASIVE LITHOLAPAXY see **LITHOTRIPSY**

NONLINEAR DYNAMICS

see related
FRACTALS

Alternating oscillations and chaos in a model of two coupled biochemical oscillators driving successive phases of the cell cycle. Romond PC, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:180–93 (35 ref.)

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms. Breton JJ. **Can J Psychiatry** 1999 Apr;44(3):227–34 (76 ref.)

Chaos in the cardiovascular system: an update. Wagner CD, et al. **Cardiovasc Res** 1998 Nov;40(2):257–64 (87 ref.)

Chaos theories and therapeutic commonalities among depression, Parkinson's disease, and cardiac arrhythmias. Toro MG, et al. **Compr Psychiatry** 1999 May–Jun; 40(3):238–44 (88 ref.)

Tumour biology, chaos and non-linear dynamics. Rew DA. **Eur J Surg Oncol** 1999 Feb;25(1):86–9 (17 ref.)

From crude cardiovascular signals to chaos. Persson PB, et al. **Fundam Clin Pharmacol** 1998;12 Suppl 1:6s–10s (18 ref.)

Nonlinear coordination of cardiovascular autonomic control. Hoyer D, et al. **IEEE Eng Med Biol Mag** 1998 Nov–Dec; 17(6):17–21 (24 ref.)

The role of chaos in neural systems. Rabinovich MI, et al. **Neuroscience** 1998 Nov;87(1):5–14 (19 ref.)

Nonlinearity in the epidemiology of complex health and disease processes. Philippe P, et al. **Theor Med Bioeth** 1998 Dec;19(6):591–607 (44 ref.)

NONLYMPHOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

NONLYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

NONODONTOGENIC CYSTS

CHEMICALLY INDUCED

Oral and systemic effects of prolonged minocycline therapy. Patel K, et al. **Br Dent J** 1998 Dec 12–26;185(11–12):560–2

(19 ref.)

NONOPIOID ANALGESICS see **ANALGESICS, NON-NARCOTIC**

NONPROFIT ORGANIZATIONS see **ORGANIZATIONS, NONPROFIT**

NONSENSE CODON see **CODON, NONSENSE**

NON-SMALL-CELL LUNG CARCINOMA see **CARCINOMA, NON-SMALL-CELL LUNG**

NON-STEROIDAL ANTI-INFLAMMATORY AGENTS see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

NONSTRUCTURAL PROTEINS, VIRAL see **VIRAL NONSTRUCTURAL PROTEINS**

NONVERBAL COMMUNICATION

Infant communication and the development of hypnotic responsivity. Vandenberg B. **Int J Clin Exp Hypn** 1998 Oct;46(4):334–50 (70 ref.)

PSYCHOLOGY

The misunderstood child: the child with a nonverbal learning disorder. Little L. **J Soc Pediatr Nurs** 1999 Jul–Sep; 4(3):113–21; quiz 123–4 (26 ref.)

NOONAN SYNDROME

COMPLICATIONS

Symptomatic moyamoya disease and aortic coarctation in a patient with Noonan's syndrome: strategies for management. Schuster JM, et al. **Pediatr Neurosurg** 1999 Apr;30(4):206–10 (37 ref.)

NOOTROPIC AGENTS

ADVERSE EFFECTS

[Adverse effects and drugs for Alzheimer's disease] Schück S, et al. **Therapie** 1999 Mar–Apr;54(2):237–42 (26 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Memory and the brain: unexpected chemistries and a new pharmacology. Lynch G. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):82–100 (94 ref.)

Piracetam and platelets--a review of laboratory and clinical data. Evers S, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:44–8 (20 ref.)

Piracetam: novelty in a unique mode of action. Müller WE, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:2–9 (59 ref.)

[Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways] Yoshii M, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:41P–43P (5 ref.) (Eng. Abstr.) **(Jpn)**

[Nootropic preparations, the achievements and new problems] Voronina TA, et al. **Eksp Klin Farmakol** 1998 Jul–Aug;61(4):3–9 (59 ref.) (Eng. Abstr.) **(Rus)**

[New trends in the search for nootropic preparations] Voronina TA. **Vestn Ross Akad Med Nauk** 1998;(11):16–21 (49 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Lemière J, et al. **Acta Neurol Belg** 1999 Jun;99(2):96–106 (113 ref.)

Harmony and consensus: cultural aspects of organization in international science. Gaines AD, et al. **Alzheimer Dis Assoc Disord** 1998 Dec;12(4):295–301 (24 ref.)

Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Flynn BL, et al. **Ann Pharmacother** 1999 Feb;33(2):188–97 (86 ref.)

Do we have drugs for dementia? No. Pryse-Phillips W. **Arch Neurol** 1999 Jun;56(6):735–7 (37 ref.)

Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment. van Reekum R, et al. **Can Fam Physician** 1999 Apr;45:945–52 (62 ref.)

The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist [see comments] Flint AJ, et al. **Can J Psychiatry** 1998 Sep;43(7):689–97 (56 ref.) Comment in: Can J Psychiatry 1998 Sep;43(7):679.

Donepezil update. **Drug Ther Bull** 1998 Aug;36(8):60–1 (9 ref.)

Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Simard M, et al. **Drugs Aging** 1999 Mar;14(3):197–230 (180 ref.)

Clinical benefits of a new piperidine-class AChE inhibitor. Doody RS. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl 2:S69–77 (29 ref.)

Rational design of anti-dementia therapy. Tiseo P. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl 2:S61–8 (46 ref.)

The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. Wimo A, et al. **Int J Geriatr Psychiatry** 1999 May;14(5):338–47 (92 ref.)

Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. Grundman M, et al. **J Neural Transm Suppl** 1998;53:255–75 (150 ref.)

The therapeutic potential of tacrine. Kurz A. **J Neural Transm Suppl** 1998;54:295–9 (12 ref.)

Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. Windisch M, et al. **J Neural Transm Suppl** 1998;53:289–98 (40 ref.)

The role of piracetam in the treatment of acute and chronic aphasia. Huber W. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:38–43 (46 ref.)

[Nootropic drug evaluation for general practice (see comments)] Ihl R, et al. **Nervenarzt** 1997 Nov;68(11):853–61 (61 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1998 Sep;69(9):826–8. **(Ger)**

[New drug therapy possibilities of Alzheimer disease] Bertoli S, et al. **Ther Umsch** 1999 Feb;56(2):98–103 (11 ref.) (Eng. Abstr.) **(Ger)**

[Effect pf anti-dementia drugs on the daily routine and attitude of dementia patients] Kurz A. **Z Gerontol Geriatr** 1999 Jun;32(3):167–71 (19 ref.) (Eng. Abstr.) **(Ger)**

[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA Azanza JR, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):109–18 (43 ref.) **(Spa)**

NORADRENALINE see **NOREPINEPHRINE**

NORANDROSTENOLONE see **NANDROLONE**

NORBORNANES

PHARMACOLOGY

Norbornane compounds in pharmaceutical research. Buchbauer G, et al. **Pharmazie** 1999 Jan;54(1):5–18 (198 ref.)

TOXICITY

5-Ethylidene-2-norbornene. Ballantyne B, et al. **J Appl Toxicol** 1999 Jul–Aug;19(4):291–4 (17 ref.)

NORCAMPHANES see **NORBORNANES**

NOREPHEDRINE see **PHENYLPROPANOLAMINE**

NOREPINEPHRINE

see related
RECEPTORS, ADRENERGIC

The functional anatomy of noradrenergic neurons in Parkinson's disease. Soldani P, et al. **Funct Neurol** 1999 Apr–Jun;14(2):97–109 (53 ref.)

ANALYSIS

The distribution of noradrenergic nerves in the human lower urinary tract. A review. Gosling JA, et al. **Eur Urol** 1999; 36 Suppl 1:23–30 (40 ref.)

Emotional stress and characteristics of brain noradrenaline release in the rat. Tanaka M. **Ind Health** 1999 Apr; 37(2):143–56 (27 ref.)

ANTAGONISTS & INHIBITORS

[Psychopharmacological profile of venlafaxine] Bourin M. **Encephale** 1999 Jun;25 Spec No 2:21–2; discussion 23–5 (7 ref.) (Eng. Abstr.) **(Fre)**

[Specifics of a dual action: toward new and more effective antidepressants?] Martin P. **Encephale** 1999 Jun;25 Spec No 2:5–20; discussion 23–5 (28 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Physiological importance of dopamine as a noradrenaline precursor in the corpus luteum. Kotwica J, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S29–35 (81 ref.)

BLOOD

Clonidine suppression test revisited. Lenz T, et al. **Blood Press** 1998 May;7(3):153–9 (28 ref.)

Noradrenaline spillover and microneurography measurements in patients with primary hypertension. Jennings GL. **J Hypertens Suppl** 1998 Aug;16(3):S35–8 (41 ref.)

DEFICIENCY

Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease. Narabayashi H. **Adv Neurol** 1999;80:501–4 (9 ref.)

METABOLISM

New approaches to rapid onset antidepressants [published erratum appears in Curr Pharm Des 1999 Feb;5(2):139] Briner K, et al. **Curr Pharm Des** 1998 Aug;4(4):291–302 (144 ref.)

Emotional stress and characteristics of brain noradrenaline release in the rat. Tanaka M. **Ind Health** 1999 Apr; 37(2):143–56 (27 ref.)

PHYSIOLOGY

Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Gurrera RJ. **Am J Psychiatry** 1999 Feb;156(2):169–80 (167 ref.)

Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Hökfelt T, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:252–63 (48 ref.)

Interactions between the presynaptic alpha2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Schlicker E, et al. **Brain Res Bull** 1998 Sep 15;47(2):129–32 (45 ref.)

The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Colucci WS. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I20–4 (42 ref.)

The role of circulating catecholamines in the regulation of fish metabolism: an overview. Fabbri E, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):177–92 (154 ref.)

The adrenergic stress response in fish: control of catecholamine storage and release. Reid SG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jul;120(1):1–27 (308 ref.)

Adrenergic/cholinergic immunomodulation in the rat model--in vivo veritas? Rinner I, et al. **Dev Immunol** 1998; 6(3–4):245–52 (35 ref.)

Predicting response: noradrenaline reuptake inhibition. Montgomery SA. **Int Clin Psychopharmacol** 1999 May;14 Suppl 1:S21–6 (29 ref.)

Physiology to functionality: the brain and neurotransmitter activity. Racagni G, et al. **Int Clin Psychopharmacol** 1999 May;14 Suppl 1:S3–7 (22 ref.)

Monoamine dysfunction and the pathophysiology and treatment of depression. Charney DS. **J Clin Psychiatry** 1998;59 Suppl 14:11–4 (22 ref.)

Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Schatzberg AF. **J Clin Psychiatry** 1998;59 Suppl 14:15–8 (32 ref.)

The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Gold PW, et al. **Proc Assoc Am Physicians** 1999 Jan–Feb; 111(1):22–34 (90 ref.)

SECRETION

Norepinephrine exocytosis stimulated by alpha-latrotoxin requires both external and stored Ca2+ and is mediated by latrophilin, G proteins and phospholipase C. Rahman MA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1381):379–86 (46 ref.)

[Characterization of the facilitatory modulation of adrenergic neurotransmission via prejunctional purinoceptors in rabbit ear artery] Ishii-Nozawa R, et al. **Yakugaku Zasshi** 1999 Jun;119(6):417–28 (47 ref.) (Eng. Abstr.) **(Jpn)**

NORFLOXACIN

ADVERSE EFFECTS

Norfloxacin-induced cholestatic jaundice [letter] Lucena MI, et al. **Am J Gastroenterol** 1998 Nov;93(11):2309–11 (14 ref.)

NORGESTREL

Research on mifepristone and levonorgestrel in comparison with the Yuzpe regimen. von Hertzen H. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):222–4, 232 (20 ref.)

L-NORGESTREL see **LEVONORGESTREL**

NORMAL DISTRIBUTION

A tale of 3 tails [editorial] McKinlay JB, et al. **Am J Public Health** 1999 Mar;89(3):295–8 (26 ref.)

A unifying review of linear gaussian models. Roweis S, et al. **Neural Comput** 1999 Feb 15;11(2):305–45 (65 ref.)

NORMAL SERUM GLOBULIN THERAPY see **IMMUNIZATION, PASSIVE**

NORMOBLASTS see **ERYTHROBLASTS**

NORPREGNENES

ADVERSE EFFECTS

Abdominal wall pain caused by cutaneous nerve entrapment in an adolescent girl taking oral contraceptive pills. Peleg R. **J Adolesc Health** 1999 Jan;24(1):45–7 (13 ref.)

THERAPEUTIC USE

Tibolone: a review. Albertazzi P, et al. **Maturitas** 1998 Nov 16;30(3):295–305 (57 ref.)

Tibolone and the serum lipid/lipoprotein profile: does this have a role in cardiovascular protection in postmenopausal women? [editorial; comment] Ginsburg J, et al. **Menopause** 1999 Summer;6(2):87–9 (34 ref.) Comment on:

NORPREGNENES

Menopause 1999 Summer;6(2):92–97. Comment on: Menopause 1999 Summer;6(2):98–104.
[Action of SERM and SAS (tibolone) on breast tissue] Gompel A, et al. **Contracept Fertil Sex** 1999 May; 27(5):368–75 (25 ref.) (Eng. Abstr.) **(Fre)**

NORSYNEPHRINE see **OCTOPAMINE**

NORTESTOSTERONE see **NANDROLONE**

NORTHERN BLOTTING see **BLOTTING, NORTHERN**

NORWALK VIRUS

IMMUNOLOGY

A new model system to study Norwalk virus immunity [editorial; comment] Matsui SM. **Gastroenterology** 1999 Jul; 117(1):255–7 (26 ref.) Comment on: Gastroenterology 1999 Jul;117(1):40–8.

NOSE

see related
RHINOPLASTY

Nasal cocaine abuse presenting as a central facial destructive granuloma. Sittel C, et al. **Ear Arch Otorhinolaryngol** 1998; 255(9):446–7 (5 ref.)
[Uses of nasal lavage in occupational medicine and environmental medicine] Qu R, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):378–9 (16 ref.) **(Chi)**

ABNORMALITIES

Acromelic frontonasal dysostosis. Slaney SF, et al. **Am J Med Genet** 1999 Mar 12;83(2):109–16 (30 ref.)
Half nose with ipsilateral eye and ear anomalies and facial asymmetry: report of a case with cephalometric analysis and orthodontic treatment. Motohashi N, et al. **Cleft Palate Craniofac J** 1999 Jul;36(4):353–60 (13 ref.)
Unilateral cleft rhinoplasty: a review. Madorsky SJ, et al. **Otolaryngol Clin North Am** 1999 Aug;32(4):669–82 (43 ref.)

ANATOMY & HISTOLOGY

The nasal airway and obstructed breathing during sleep. Mirza N, et al. **Otolaryngol Clin North Am** 1999 Apr; 32(2):243–62 (61 ref.)
[Surgical anatomy of the nose. I] Adant JP, et al. **Ann Chir Plast Esthet** 1998 Oct;43(5):499–510 (31 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

[Olfactory origin of luteinizing hormone-releasing hormone (LHRH) neurons] Daikoku S. **Nippon Ika Daigaku Zasshi** 1999 Apr;66(2):94–106 (101 ref.) **(Jpn)**

INJURIES

Jealousy and mutilation: nose-biting as retribution for adultery. Okimura JT, et al. **Lancet** 1998 Dec 19–26; 352(9145):2010–1 (21 ref.)

METABOLISM

The olfactory origin of luteinizing hormone-releasing hormone (LHRH) neurons. A new era in reproduction physiology. Daikoku S. **Arch Histol Cytol** 1999 May; 62(2):107–17 (65 ref.)

MICROBIOLOGY

The nose: an underestimated source of Staphylococcus aureus causing wound infection. Casewell MW. **J Hosp Infect** 1998 Sep;40 Suppl B:S3–11 (41 ref.)
Eradication of nasal carriage of Staphylococcus aureus—is it cost-effective? Davey P. **J Hosp Infect** 1998 Sep;40 Suppl B:S31–7 (14 ref.)
Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. Herwaldt LA. **J Hosp Infect** 1998 Sep;40 Suppl B:S13–23 (38 ref.)
Reduction of surgical site infections in major surgery by elimination of nasal carriage of Staphylococcus aureus. Kluytmans J. **J Hosp Infect** 1998 Sep;40 Suppl B:S25–9 (26 ref.)

PATHOLOGY

[On the problem of rhinophyma management] Szmeja Z, et al. **Otolaryngol Pol** 1999;53(1):29–33 (22 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Is there an inner nose? Elmes DG. **Chem Senses** 1998 Aug; 23(4):443–5 (21 ref.)
[The current methodological approaches in assessing nasal breathing function] Krotov AIu. **Vestn Otorinolaringol** 1998;(4):51–2 (30 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Nasal base surgery. Silver WE, et al. **Otolaryngol Clin North Am** 1999 Aug;32(4):653–68 (15 ref.)
[On the problem of rhinophyma management] Szmeja Z, et al. **Otolaryngol Pol** 1999;53(1):29–33 (22 ref.) (Eng. Abstr.) **(Pol)**

NOSE BLEED see **EPISTAXIS**

NOSE DEFORMITIES, ACQUIRED

SURGERY

Stenosis of the nasal vestibule and its treatment. Kotzur A, et al. **Aesthetic Plast Surg** 1999 Mar–Apr;23(2):86–92 (11 ref.)

NOSE DISEASES

[Rhinocerebral mucormycosis and systemic mucormycosis] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):367–8 (4 ref.) **(Jpn)**

COMPLICATIONS

Rhinolithiasis associated with septal perforation. A case report. Kharoubi S. **Acta Otorhinolaryngol Belg** 1998; 52(3):241–5 (22 ref.)

CONGENITAL

[Congenital stenosis of the piriform aperture: a cause of respiratory distress in newborn infants. Review of the literature, from 2 cases] Goga D, et al. **Rev Stomatol Chir Maxillofac** 1998 Nov;99(4):203–6 (17 ref.) (Eng. Abstr.) **(Fre)**
[A case of a nasal glioma in a newborn infant] Casas Terrón E, et al. **An Esp Pediatr** 1998 Dec;49(6):624–6 (9 ref.) **(Spa)**

DIAGNOSIS

Chondroid hamartoma presenting as a neonatal nasal mass. Kim DW, et al. **Int J Pediatr Otorhinolaryngol** 1999 Mar 15;47(3):253–9 (17 ref.)
Flexible nasolaryngoscopy. A low-risk, high-yield procedure. Hayes JT, et al. **Postgrad Med** 1999 Sep; 106(3):107–10, 114 (7 ref.)
What you need to know—objective assessment of nasal patency—why it is important. Wang DY, et al. **Singapore Med J** 1999 Mar;40(3):186–7 (4 ref.)

ETIOLOGY

Midfacial complications of prolonged cocaine snorting. Villa PD. **J Can Dent Assoc** 1999 Apr;65(4):218–23 (28 ref.)

PATHOLOGY

Verruciform xanthoma of the nose. Than T, et al. **J Laryngol Otol** 1999 Jan;113(1):79–81 (14 ref.)

RADIOGRAPHY

CT of unusual nasal masses. Grainger AJ, et al. **Br J Radiol** 1999 Mar;72(855):313–6 (8 ref.)

THERAPY

The management of postnasal drip. Forer M, et al. **Aust Fam Physician** 1999 Mar;28(3):223–8 (22 ref.)

NOSE NEOPLASMS

CHEMICALLY INDUCED

Squamous cell carcinoma of the nasal septum with Wegener's granulomatosis treated with cyclophosphamide and corticosteroids. Wakisaka N, et al. **Auris Nasus Larynx** 1998 Dec;25(4):393–6 (18 ref.)

DIAGNOSIS

Mucocutaneous angiomyolipoma. A report of 2 cases arising in the nasal cavity. Watanabe K, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):789–92 (27 ref.)
Olfactory esthesioneuroblastoma (olfactory neuroblastoma/olfactory neuroepithelioma). Palacios E, et al. **Ear Nose Throat J** 1998 Nov;77(11):890–1 (0 ref.)
Squamous cell carcinoma of the sinonasal cavities. Hermans R, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):150–61 (12 ref.)

PATHOLOGY

Protocol for the examination of specimens removed from patients with carcinomas of the upper aerodigestive tract: carcinomas of the oral cavity including lip and tongue, nasal and paranasal sinuses, pharynx, larynx, salivary glands, hypopharynx, oropharynx, and nasopharynx. Cancer Committee, College of American Pathologists. Min KW, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):222–30 (58 ref.)
Embryonal rhabdomyosarcoma of the nose in an elderly patient, case report and review of the literature. Jund R, et al. **Auris Nasus Larynx** 1998 Dec;25(4):445–50 (25 ref.)
Metastatic melanoma of the nasal cavity in a patient with oculocutaneous albinism. Malaguarnera M, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):404–6 (34 ref.)
Nasal haemangiopericytoma: report of two cases with literature review. Marianowski R, et al. **J Laryngol Otol** 1999 Mar;113(3):199–206 (51 ref.)
Teratocarcinosarcoma of the nasal cavity and ethmoid. Sharma HS, et al. **J Laryngol Otol** 1998 Jul;112(7):682–6 (15 ref.)

RADIOGRAPHY

Squamous cell carcinoma of the sinonasal cavities. Hermans R, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):150–61 (12 ref.)

SURGERY

Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314–7 (21 ref.)

VETERINARY

Equine nasal and paranasal sinus tumours. Part 1: review of the literature and tumour classification. Head KW, et al. **Vet J** 1999 May;157(3):261–78 (100 ref.)
An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors. Adams WM, et al. **Vet Radiol Ultrasound** 1998 Sep–Oct;39(5):475–81 (23 ref.)

NOSEBLEED see **EPISTAXIS**

NOSOCOMIAL INFECTIONS see **CROSS INFECTION**

NOTOCHORD

Neuroradiological characteristics of ecchordosis physaliphora. Case report and review of the literature. Toda H, et al. **J Neurosurg** 1998 Nov;89(5):830–4 (11 ref.)

ABNORMALITIES

A case of split notochord syndrome: presence of dorsal enteric diverticulum adjacent to the dorsal enteric fistula. Akgür FM, et al. **J Pediatr Surg** 1998 Aug;33(8):1317–9 (19 ref.)

CYTOLOGY

[Brachyury genes and notochord differentiation in chordate embryos] Takahashi H, et al. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1347–54 (34 ref.) **(Jpn)**

EMBRYOLOGY

The when and where of floor plate induction. Dodd J, et al. **Science** 1998 Nov 27;282(5394):1654–7 (33 ref.)

NOVELTY-SEEKING BEHAVIOR see **EXPLORATORY BEHAVIOR**

NOXAE

TOXICITY

Microarrays and toxicology: the advent of toxicogenomics. Nuwaysir EF, et al. **Mol Carcinog** 1999 Mar;24(3):153–9 (48 ref.)

NUCLEAR ACCIDENTS see **ACCIDENTS, RADIATION**

NUCLEAR AND CYTOPLASMIC RECEPTORS see **RECEPTORS, CYTOPLASMIC AND NUCLEAR**

NUCLEAR ENERGY

see related
RADIATION PROTECTION
RADIOACTIVE WASTE

NUCLEAR ENVELOPE see **NUCLEAR MEMBRANE**

NUCLEAR FACTOR KAPPA B see **NF-KAPPA B**

NUCLEAR FAMILY

Affected sib-pair methods for detecting linkage to dichotomous traits: review of the methodology. Holmans P. **Hum Biol** 1998 Dec;70(6):1025–40 (75 ref.)

PSYCHOLOGY

Lesbian parenthood: a review of the literature. Parks CA. **Am J Orthopsychiatry** 1998 Jul;68(3):376–89 (69 ref.)
Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Ben-Chetrit E, et al. **J Intern Med** 1998 Aug;244(2):175–8 (11 ref.)
Seasonal and weekly rhythms: windows into variability in family socialization experiences in early adolescence. Crouter AC, et al. **New Dir Child Dev** 1998 Winter; (82):69–82 (16 ref.)

NUCLEAR LOCALIZATION SIGNAL

Import(ance) of growth factors in(to) the nucleus. Keresztes M, et al. **J Cell Biol** 1999 May 3;145(3):421–4 (46 ref.)

PHYSIOLOGY

Nuclear import and export of proteins: the molecular basis for intracellular signaling. Sekimoto T, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):205–11 (61 ref.)

The hsp56 immunophilin component of steroid receptor heterocomplexes: could this be the elusive nuclear localization signal–binding protein? Pratt WB, et al. **J Steroid Biochem Mol Biol** 1993 Sep;46(3):269–79 (74 ref.)

NUCLEAR MAGNETIC RESONANCE

see related

MAGNETIC RESONANCE IMAGING

NMR studies of DNA duplexes containing alpha-anomeric nucleotides and polarity reversals. Aramini JM, et al. **Biochem Cell Biol** 1998;76(2–3):403–10 (37 ref.)

Quadrupolar metal ion NMR studies of metalloproteins. Aramini JM, et al. **Biochem Cell Biol** 1998;76(2–3):210–22 (80 ref.)

New perceptions of transcription factor properties from NMR. Bagby S, et al. **Biochem Cell Biol** 1998; 76(2–3):368–78 (85 ref.)

Cardiac magnetic resonance spectroscopy. Deslauriers R, et al. **Biochem Cell Biol** 1998;76(2–3):510–21 (44 ref.)

The NMR angle on troponin C. Gagné SM, et al. **Biochem Cell Biol** 1998;76(2–3):302–12 (45 ref.)

Structure–function relationships of antimicrobial peptides. Hwang PM, et al. **Biochem Cell Biol** 1998;76(2–3):235–46 (108 ref.)

Theoretical calculations of acid–dissociation constants of proteins. Juffer AH. **Biochem Cell Biol** 1998; 76(2–3):198–209 (88 ref.)

Human cerebral neoplasms studied using MR spectroscopy: a review. Kaibara T, et al. **Biochem Cell Biol** 1998; 76(2–3):477–86 (65 ref.)

NMR and CD conformational studies of bradykinin and its agonists and antagonists: application to receptor binding. Kotovych G, et al. **Biochem Cell Biol** 1998;76(2–3):257–66 (88 ref.)

A review of in vivo 1H magnetic resonance spectroscopy of cerebral ischemia in rats. Malisza KL, et al. **Biochem Cell Biol** 1998;76(2–3):487–96 (54 ref.)

NMR structural studies on antifreeze proteins. Sönnichsen FD, et al. **Biochem Cell Biol** 1998;76(2–3):284–93 (41 ref.)

Modeling the nuclear magnetic resonance behavior of lung: from electrical engineering to critical care medicine. Cutillo AG, et al. **Bioelectromagnetics** 1999;Suppl 4:110–9 (29 ref.)

In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Kegeles LS, et al. **Biol Psychiatry** 1998 Sep 15;44(6):382–98 (137 ref.)

Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Otvos J. **Clin Cardiol** 1999 Jun;22(6 Suppl):II21–7 (8 ref.)

Validation of protein models derived from experiment. Laskowski RA, et al. **Curr Opin Struct Biol** 1998 Oct; 8(5):631–9 (55 ref.)

Landmarks in the application of 13C–magnetic resonance spectroscopy to studies of neuronal/glial relationships. Bachelard H. **Dev Neurosci** 1998;20(4–5):277–88 (70 ref.)

NMR studies of salivary glands: from energy metabolism to morphology. Seo Y, et al. **Eur J Morphol** 1998 Aug;36 Suppl:98–102 (20 ref.)

Magnetic resonance spectroscopy: imaging axonal damage in MS. Arnold DL. **J Neuroimmunol** 1999 Jul 1;98(1):2–6 (12 ref.)

Application of NMR spectroscopy in biochemical studies of tumor cells sensitive and resistant to anticancer drugs. Hanusovská E, et al. **Neoplasma** 1998;45(4):187–97 (79 ref.)

Aspects of proton MR spectroscopy in the seizure patient. Achten E. **Neuroimaging Clin N Am** 1998 Nov;8(4):849–62 (59 ref.)

Proton MR spectroscopy of common brain tumors. Castillo M, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):733–52 (22 ref.)

Proton MR spectroscopy in psychiatric and neurodevelopmental childhood disorders: early experience. Castillo M, et al. **Neuroimaging Clin N Am** 1998 Nov; 8(4):901–12 (20 ref.)

Proton MR spectroscopy in inflammatory and infectious brain disorders. Cecil KM, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):863–80 (50 ref.)

Localized MR spectroscopy: basic principles. Kwock L. **Neuroimaging Clin N Am** 1998 Nov;8(4):713–31 (18 ref.)

In vitro 1H MR spectroscopy of squamous cell carcinoma of the extracranial head and neck. Mukherji SK, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):835–47 (47 ref.)

Proton MR spectroscopy in ischemic stroke and other vascular disorders. Ricci PE Jr. **Neuroimaging Clin N Am** 1998 Nov;8(4):881–900 (62 ref.)

In vivo MR spectroscopy of human dementia. Ross BD, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):809–22 (66 ref.)

Proton MR spectroscopy of pediatric brain tumors. Taylor JS, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):753–79 (53 ref.)

Proton MR spectroscopy of pediatric brain metabolic disorders. Wang ZJ, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):781–807 (79 ref.)

Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. Bell JD, et al. **NMR Biomed** 1998 Nov;11(7):354–9 (41 ref.)

NMR studies of phospholipid metabolism in hepatic lymphoma. Dixon RM. **NMR Biomed** 1998 Nov; 11(7):370–9 (49 ref.)

Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. Leach MO, et al. **NMR Biomed** 1998 Nov; 11(7):314–40 (106 ref.)

Phosphorus MR spectroscopy in the treatment of human extremity sarcomas. Sijens PE. **NMR Biomed** 1998 Nov; 11(7):341–53 (73 ref.)

Proton magnetic resonance spectroscopy in pediatric neuroradiology. Moore GJ. **Pediatr Radiol** 1998 Nov; 28(11):805–14 (41 ref.)

MR spectroscopy of Alzheimer disease. Rhinehart DL, et al. **Radiol Technol** 1998 Sep–Oct;70(1):23–8 (27 ref.)

Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Matthews PM, et al. **Semin Neurol** 1998;18(3):327–36 (49 ref.)

Unification of the quantum and classical theories of methyl NMR. Clough S. **Solid State Nucl Magn Reson** 1999 Jul; 14(2):73–9 (16 ref.)

[MR analysis of brain function] Nakada T. **No To Hattatsu** 1999 May;31(3):212–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Solid-state nuclear magnetic resonance] Fujiwara T, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):582–9 (22 ref.) **(Jpn)**

[New aspects is stable-isotope-assisted NMR techniques: application to be structural analysis of larger complexes between proteins and nucleic acids] Ohki S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):574–81 (56 ref.) **(Jpn)**

DIAGNOSTIC USE

Applications of NMR spectroscopy to study muscle glycogen metabolism in man. Roden M, et al. **Annu Rev Med** 1999; 50:277–90 (56 ref.)

Proton magnetic resonance spectroscopy in schizophrenia. Bertolino A, et al. **Eur J Radiol** 1999 May;30(2):132–41 (55 ref.)

Proton MRS in neurological disorders. Bonavita S, et al. **Eur J Radiol** 1999 May;30(2):125–31 (35 ref.)

Proton magnetic resonance spectroscopy of the brain in pediatric patients. Scarabino T, et al. **Eur J Radiol** 1999 May;30(2):142–53 (20 ref.)

Current clinical relevance of cardiovascular magnetic resonance and its relationship to nuclear cardiology [editorial] van der Wall EE, et al. **J Nucl Cardiol** 1999 Jul–Aug;6(4):462–9 (59 ref.)

Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Köstler H. **Metab Brain Dis** 1998 Dec; 13(4):291–301 (58 ref.)

Proton MR spectroscopy of the brain. Rand SD, et al. **Neuroimaging Clin N Am** 1999 May;9(2):379–95 (59 ref.)

Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. Nelson SJ, et al. **NMR Biomed** 1999 May;12(3):123–38 (119 ref.)

MRI and MRS in HMG-CoA lyase deficiency. Yalçinkaya C, et al. **Pediatr Neurol** 1999 May;20(5):375–80 (13 ref.)

Correlations of evoked potentials with MR imaging and MR spectroscopy in multiple sclerosis. Kraft GH, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):561–7, vi (57 ref.)

Magnetic resonance spectroscopy of ischemic heart disease. Sardanelli F, et al. **Rays** 1999 Jan–Mar;24(1):149–64 (38 ref.) **(Eng, Ita)**

Magnetic resonance spectroscopy in focal epilepsy: 31P and 1H spectroscopy. Kuzniecky R. **Rev Neurol (Paris)** 1999 Jul;155(6–7):495–8 (26 ref.)

Beyond anatomy: MR imaging as a molecular diagnostic tool. Calvo BF, et al. **Surg Oncol Clin N Am** 1999 Jan; 8(1):171–83 (43 ref.)

METHODS

Magnetic resonance imaging and temporal lobe epilepsy. King D, et al. **Acta Neurol Scand** 1998 Oct;98(4):217–23 (70 ref.)

Protein dynamics from NMR. Kay LE. **Biochem Cell Biol** 1998;76(2–3):145–52 (60 ref.)

Polyelectrolyte-induced domains in lipid bilayer membranes: the deuterium NMR perspective. Macdonald PM, et al. **Biochem Cell Biol** 1998;76(2–3):452–64 (56 ref.)

NMR spectroscopic studies of I = 1/2 metal ions in biological systems. Oz G, et al. **Biochem Cell Biol** 1998; 76(2–3):223–34 (88 ref.)

Solid-state NMR studies of proteins: the view from static 2H NMR experiments. Siminovitch DJ. **Biochem Cell Biol** 1998;76(2–3):411–22 (74 ref.)

Diagnosis of cancer in humans by 1H NMR of tissue biopsies. Smith IC, et al. **Biochem Cell Biol** 1998;76(2–3):472–6 (24 ref.)

NMR for the design of functional mimetics of protein–protein interactions: one key is in the building of bridges. Song J, et al. **Biochem Cell Biol** 1998;76(2–3):177–88 (67 ref.)

Protein chemical shift analysis: a practical guide. Wishart DS, et al. **Biochem Cell Biol** 1998;76(2–3):153–63 (57 ref.)

Recent developments in solid-state nuclear magnetic resonance of quadrupolar nuclei and applications to biological systems. Wu G. **Biochem Cell Biol** 1998; 76(2–3):429–42 (119 ref.)

Solid-state NMR for the study of membrane systems: the use of anisotropic interactions. Warschawski DE, et al. **Biochimie** 1998 May–Jun;80(5–6):437–50 (91 ref.)

Nuclear magnetic resonance in environmental engineering: principles and applications. Lens PN, et al. **Biodegradation** 1998;9(6):393–409 (107 ref.)

Application of 113Cd NMR to metallothioneins. Vašák M. **Biodegradation** 1998;9(6):501–12 (28 ref.)

Advanced imaging of bone macro and micro structure. Genant HK, et al. **Bone** 1999 Jul;25(1):149–52 (56 ref.)

Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Mason RP. **Curr Med Chem** 1999 Jun;6(6):481–99 (175 ref.)

NMR tools for biotechnology. Keifer PA. **Curr Opin Biotechnol** 1999 Feb;10(1):34–41 (86 ref.)

NMR screening in drug discovery. Moore JM. **Curr Opin Biotechnol** 1999 Feb;10(1):54–8 (24 ref.)

NMR spectroscopy in structure-based drug design. Roberts GC. **Curr Opin Biotechnol** 1999 Feb;10(1):42–7 (73 ref.)

NMR of drugs and ligands bound to membrane receptors. Watts A. **Curr Opin Biotechnol** 1999 Feb;10(1):48–53 (46 ref.)

New applications of paramagnetic NMR in chemical biology. Bertini I, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):145–51 (68 ref.)

NMR structure determination of proteins and protein complexes larger than 20 kDa. Clore GM, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):564–70 (51 ref.)

New approaches to structure determination by NMR spectroscopy. Dötsch V, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):619–23 (37 ref.)

NMR structural studies of membrane proteins. Marassi FM, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):640–8 (52 ref.)

Nuclear magnetic resonance spectroscopy: a non-invasive probe of kidney metabolism and function. Foxall PJ, et al. **Exp Nephrol** 1998 Sep–Oct;6(5):409–14 (38 ref.)

Nuclear magnetic resonance chromatography: applications of pulse field gradient diffusion NMR to mixture analysis and ligand–receptor interactions. Gounarides JS, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 2;725(1):79–90 (51 ref.)

The SPORT-NMR software: a tool for determining relaxation times in unresolved NMR spectra. Geppi M, et al. **J Magn Reson** 1999 Mar;137(1):177–85 (14 ref.)

A method for determining B1 field inhomogeneity. Are the biases assumed in heteronuclear relaxation experiments usually underestimated? Guenneugues M, et al. **J Magn Reson** 1999 Jan;136(1):118–26 (25 ref.)

Atlas of brain proton magnetic resonance spectra. Part I: General and methodological considerations. Vion-Dury J, et al. **J Neuroradiol** 1998 Oct;25(3):207–12 (19 ref.)

Innovations in neuroimaging and neurointerventional radiology. Tung GA, et al. **Med Health R I** 1999 Jun; 82(6):207–12 (23 ref.)

In situ measurements of creatine kinase flux by NMR. The lessons from bioengineered mice. Nicolay K, et al. **Mol Cell Biochem** 1998 Jul;184(1–2):195–208 (56 ref.)

Functional MR spectroscopy of the brain. Richards TL, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):823–34 (44 ref.)

Optimal time spacings for T2 measurements: monoexponential and biexponential systems. Shrager RI, et al. **NMR Biomed** 1998 Oct;11(6):297–305 (24 ref.)

Correlations of structure, dynamics and function in the gramicidin channel by solid-state NMR spectroscopy. Cross TA, et al. **Novartis Found Symp** 1999;225:4–16; discussion 16–22 (33 ref.)

In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate–glutamine neurotransmitter cycle and functional neuroenergetics. Rothman DL, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1165–77 (65 ref.)

NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR

INSTRUMENTATION

Proton magnetic resonance spectroscopy: clinical applications in children with nervous system diseases. Shevell MI, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):68–77 (24 ref.)

METHODS

Solid-state nuclear magnetic resonance investigation of protein and polypeptide structure. Fu R, et al. **Annu Rev Biophys Biomol Struct** 1999;28:235–68 (113 ref.)

Monitoring cancer by magnetic resonance. Stubbs M, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:86–94 (58 ref.)

NMR methods in combinatorial chemistry. Shapiro MJ, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):372–5 (36 ref.)

Human cardiac MR spectroscopy--clinical methods and applications. Beer M, et al. **MAGMA** 1998 Sep;6(2–3):113–5 (15 ref.)

Human cardiac spectroscopy. Bottomley PA, et al. **MAGMA** 1998 Sep;6(2–3):157–60 (13 ref.)

13C-MR spectroscopy--how and why? Decking UK. **MAGMA** 1998 Sep;6(2–3):103–4 (20 ref.)

Experimental spectroscopy. General methodology and applications for 31P. Horn M. **MAGMA** 1998 Sep; 6(2–3):100–2 (7 ref.)

NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR

MR spectroscopy of transgenic mice. Spindler M, et al. **MAGMA** 1998 Sep;6(2–3):109–10 (5 ref.)
Cardiac 1H-MR spectroscopy. von Kienlin M. **MAGMA** 1998 Sep;6(2–3):107–8 (35 ref.)
In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. Rudin M, et al. **NMR Biomed** 1999 Apr;12(2):69–97 (357 ref.)
Study of polyphosphate metabolism in intact cells by 31-P nuclear magnetic resonance spectroscopy. Chen KY. **Prog Mol Subcell Biol** 1999;23:253–73 (49 ref.)

NUCLEAR MAGNETIC RESONANCE, HETERONUCLEAR see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

NUCLEAR MATRIX

GENETICS

The Tpr protein: linking structure and function in the nuclear interior? Paddy MR. **Am J Hum Genet** 1998 Aug; 63(2):305–10 (34 ref.)

METABOLISM

Nuclear matrix and steroid hormone action. Barrett TJ, et al. **Vitam Horm** 1999;55:127–63 (217 ref.)

PHYSIOLOGY

Nuclear matrix as a target for hyperthermic killing of cancer cells. Roti Roti JL, et al. **Cell Stress Chaperones** 1998 Dec; 3(4):245–55 (53 ref.)
Chromatin, nuclear matrix and the cytoskeleton: role of cell structure in neoplastic transformation (review). Holth LT, et al. **Int J Oncol** 1998 Oct;13(4):827–37 (169 ref.)

NUCLEAR MEDICINE

see related
RADIOISOTOPES
Role of nuclear medicine in melanoma. Hoefnagel CA. **Eur J Nucl Med** 1998 Nov;25(11):1567–74 (47 ref.)
Wide area networking in nuclear cardiology. Bateman TM, et al. **J Nucl Cardiol** 1999 Mar–Apr;6(2):211–8 (22 ref.)
Antisense and nuclear medicine. Hnatowich DJ. **J Nucl Med** 1999 Apr;40(4):693–703 (96 ref.)
Nuclear medicine and the surgeon. Krag D, et al. **Lancet** 1999 Sep 18;354(9183):1019–22 (33 ref.)
Review of photon interaction cross section data in the medical and biological context. Hubbell JH. **Phys Med Biol** 1999 Jan;44(1):R1–22 (157 ref.)
Radiation detectors in nuclear medicine. Ranger NT. **Radiographics** 1999 Mar–Apr;19(2):481–502 (6 ref.)

ECONOMICS

Economic evaluation studies in nuclear medicine: the need for standardization. Dietlein M, et al. **Eur J Nucl Med** 1999 Jun;26(6):663–80 (60 ref.)

EDUCATION

Patient education: a mandate for health care in the 21st century. Davidhizar R, et al. **J Nucl Med Technol** 1998 Dec;26(4):235–41; quiz 243 (44 ref.)

INSTRUMENTATION

Advances in nuclear medicine instrumentation: considerations in the design and selection of an imaging system. Links JM. **Eur J Nucl Med** 1998 Oct;25(10):1453–66 (74 ref.)

METHODS

Nuclear medicine imaging in infection and inflammation. Peters AM. **J R Coll Physicians Lond** 1998 Nov–Dec; 32(6):512–9 (30 ref.)
Nuclear cardiology [see comments] Prvulovich E. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):520–5 (26 ref.) Comment in: J R Coll Physicians Lond 1999 Jan–Feb;33(1):94–5.
Advances in nuclear medicine: current concepts. Noto RB, et al. **Med Health R I** 1999 Jun;82(6):190–4 (16 ref.)
Humanity and radiation: the good, the bad, and the unusual. Holcomb WF. **Mil Med** 1999 Jul;164(7):520–5 (37 ref.)
Application of mathematical methods in dynamic nuclear medicine studies. Lawson RS. **Phys Med Biol** 1999 Apr; 44(4):R57–98 (120 ref.)

STANDARDS

Quality assurance in renography: a review. Cosgriff PS. **Nucl Med Commun** 1998 Jul;19(7):711–6 (50 ref.)
Radiation interactions and internal dosimetry in nuclear medicine. Simpkin DJ. **Radiographics** 1999 Jan–Feb; 19(1):155–67; quiz 153–4 (15 ref.)

TRENDS

SNM 1999. Fused image tomography: an integrating force [news] Wagner HN Jr. **J Nucl Med** 1999 Aug; 40(8):13N–14N, 17N–18N, 21N–22N passim (0 ref.)
Advances in nuclear medicine: current concepts. Noto RB, et al. **Med Health R I** 1999 Jun;82(6):190–4 (16 ref.)
[Present and future of nuclear medicine] Torizuka K. **Kaku Igaku** 1999 Feb;36(2):65–70 (33 ref.) (Eng. Abstr.) **(Jpn)**

NUCLEAR MEMBRANE

CHEMISTRY

Lamin assembly in vivo. Krohne G. **Subcell Biochem** 1998; 31:563–86 (81 ref.)

ENZYMOLOGY

GFP-labelling of 26S proteasomes in living yeast: insight into proteasomal functions at the nuclear envelope/rough ER. Enenkel C, et al. **Mol Biol Rep** 1999 Apr;26(1–2):131–5 (35 ref.)

GENETICS

Nuclear transport and transcriptional regulation. Turpin P, et al. **FEBS Lett** 1999 Jun 4;452(1–2):82–6 (41 ref.)

METABOLISM

Velcro in the nuclear envelope: LBR and LAPs. Chu A, et al. **FEBS Lett** 1998 Dec 18;441(2):165–9 (43 ref.)
Protein targeting to the nuclear pore. What can we learn from plants? Smith HM, et al. **Plant Physiol** 1999 Apr; 119(4):1157–64 (43 ref.)
Lamin assembly in vivo. Krohne G. **Subcell Biochem** 1998; 31:563–86 (81 ref.)
Nuclear lamin-binding proteins. Ye Q, et al. **Subcell Biochem** 1998;31:587–610 (130 ref.)

MICROBIOLOGY

Viruses, microorganisms and scientists meet the nuclear pore. Leysin, VD, Switzerland, February 26–March 1, 1998. Izaurralde E, et al. **EMBO J** 1999 Jan 15;18(2):289–96 (36 ref.)

PHYSIOLOGY

The nuclear pore complex: from molecular architecture to functional dynamics. Stoffler D, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):391–401 (65 ref.)
The nucleocytoplasmic continuum. Pushing the (nuclear) envelope [comment] Smith HB. **Plant Cell** 1999 Jun; 11(6):989–91 (12 ref.) Comment on: Plant Cell 1999 Jun;11(6):1117–28.
Getting across the nuclear pore complex. Talcott B, et al. **Trends Cell Biol** 1999 Aug;9(8):312–8 (38 ref.)

VIROLOGY

Viruses, microorganisms and scientists meet the nuclear pore. Leysin, VD, Switzerland, February 26–March 1, 1998. Izaurralde E, et al. **EMBO J** 1999 Jan 15;18(2):289–96 (36 ref.)

NUCLEAR POLYHEDROSIS VIRUS see **NUCLEOPOLYHEDROVIRUS**

NUCLEAR PORE see **NUCLEAR MEMBRANE**

NUCLEAR POWER PLANTS see **POWER PLANTS**

NUCLEAR PROTEINS

Nuclear matrix proteins and their potential applications to diagnostic pathology. Hughes JH, et al. **Am J Clin Pathol** 1999 Feb;111(2):267–74 (44 ref.)
[O-GlcNAc and its function] Akimoto Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2574–81 (62 ref.) **(Jpn)**

CHEMISTRY

RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198–200 (12 ref.)
Nuclear lamins: their structure, assembly, and interactions. Stuurman N, et al. **J Struct Biol** 1998;122(1–2):42–66 (186 ref.)
The localization and interactions of huntingtin. Jones AL. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1021–7 (65 ref.)
Polyglutamine pathogenesis. Ross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1005–11 (82 ref.)
Lamin assembly in vivo. Krohne G. **Subcell Biochem** 1998; 31:563–86 (81 ref.)

GENETICS

Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Hodges M, et al. **Am J Hum Genet** 1998 Aug;63(2):297–304 (68 ref.)
Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Ichinohasama R, et al. **Am J Surg Pathol** 1998 Dec; 22(12):1528–37 (45 ref.)
Polyglutamine expansion and Huntington's disease. Bates GP, et al. **Biochem Soc Trans** 1998 Aug;26(3):471–5 (38 ref.)
The Ifi 200 genes: an emerging family of IFN-inducible genes. Landolfo S, et al. **Biochimie** 1998 Aug–Sep; 80(8–9):721–8 (51 ref.)
Monoallelic expression of Pax5: a paradigm for the haploinsufficiency of mammalian Pax genes? Nutt SL, et al. **Biol Chem** 1999 Jun;380(6):601–11 (63 ref.)
Formin defines a large family of morphoregulatory genes and functions in establishment of the polarising region. Zeller R, et al. **Cell Tissue Res** 1999 Apr;296(1):85–93 (56 ref.)
Drosophila oogenesis: versatile spn doctors. Morris J, et al. **Curr Biol** 1999 Jan 28;9(2):R55–8 (20 ref.)
Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Semenza GL. **Curr Opin Genet Dev** 1998 Oct; 8(5):588–94 (62 ref.)
Activating inhibitors and inhibiting activators: a day in the life of a fly. Hardin PE. **Curr Opin Neurobiol** 1998 Oct; 8(5):642–7 (46 ref.)
Neural substrates of Drosophila rhythms revealed by mutants and molecular manipulations. Kaneko M. **Curr Opin Neurobiol** 1998 Oct;8(5):652–8 (75 ref.)
The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Huang S. **Front Biosci** 1999 Jun 15;4:D528–32 (45 ref.)
SMC-mediated chromosome mechanics: a conserved scheme from bacteria to vertebrates? Hirano T. **Genes Dev** 1999 Jan 1;13(1):11–9 (54 ref.)
t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma. Amakawa R, et al. **Int J Hematol** 1999 Feb;69(2):65–9 (37 ref.)
Treacher Collins syndrome: from linkage to prenatal testing. Dixon MJ. **J Laryngol Otol** 1998 Aug;112(8):705–9 (35 ref.)
Molecular aspects of Huntington's disease. Walling HW, et al. **J Neurosci Res** 1998 Nov 1;54(3):301–8 (88 ref.)
Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Iida S, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):25–33 (51 ref.)
Are there multiple pathways in the pathogenesis of Huntington's disease? Aronin N, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):995–1003 (61 ref.)
Progress in pathogenesis studies of spinocerebellar ataxia type 1. Cummings CJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1079–81 (20 ref.)
CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci. Frontali M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1089–94 (38 ref.)
Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Hackam AS, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1047–55 (45 ref.)
Polyglutamine pathogenesis. Ross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1005–11 (82 ref.)
Transgenic models of Huntington's disease. Sathasivam K, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):963–9 (36 ref.)

IMMUNOLOGY

[Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis] Romero Gómez M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):11–3 (24 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Utility of proliferation-associated marker MIB-1 in evaluating lesions of the uterine cervix. Mittal K. **Adv Anat Pathol** 1999 Jul;6(4):177–85 (22 ref.)
Nuclear transport: run by Ran? Dasso M, et al. **Am J Hum Genet** 1998 Aug;63(2):311–6 (35 ref.)
A new role of ran GTPase. Nishimoto T. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):571–4 (69 ref.)
The Fe65 and X11 families of proteins: proteins that interact with the Alzheimer's disease amyloid precursor protein. McLoughlin DM, et al. **Biochem Soc Trans** 1998 Aug; 26(3):497–500 (28 ref.)
Sir-Ku-itous routes to make ends meet. Haber JE. **Cell** 1999 Jun 25;97(7):829–32 (19 ref.)
RdgC/PP5-related phosphatases: novel components in signal transduction. Andreeva AV, et al. **Cell Signal** 1999 Aug; 11(8):555–62 (64 ref.)
To be or not to be an aggregate. Nasir J. **Clin Genet** 1999 Jan;55(1):9–10 (2 ref.)
Transcription in Archaea. Bell SD, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:41–51 (71 ref.)
Nuclear transport: randy couples. Macara IG. **Curr Biol** 1999 Jun 17;9(12):R436–9 (19 ref.)
Determinants of SR protein specificity. Tacke R, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):358–62 (42 ref.)
Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Semenza GL. **Curr Opin Genet Dev** 1998 Oct; 8(5):588–94 (62 ref.)
Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Horton JD, et al. **Curr Opin Lipidol** 1999 Apr;10(2):143–50 (36 ref.)
Nuclear protein transport pathways. Köhler M, et al. **Exp Nephrol** 1999 Jul–Aug;7(4):290–4 (19 ref.)
The nuclear protein PH5P of the inter-alpha-inhibitor

superfamily: a missing link between poly(ADP-ribose)polymerase and the inter-alpha-inhibitor family and a novel actor of DNA repair? Jean L, et al. **FEBS Lett** 1999 Mar 5;446(1):6-8 (19 ref.)

C/EBP and the control of phosphoenolpyruvate carboxykinase gene transcription in the liver. Croniger C, et al. **J Biol Chem** 1998 Nov 27;273(48):31629-32 (52 ref.)

Roles of CCAAT/enhancer-binding proteins in regulation of liver regenerative growth. Diehl AM. **J Biol Chem** 1998 Nov 20;273(47):30843-6 (65 ref.)

Biological role of the CCAAT/enhancer-binding protein family of transcription factors. Lekstrom-Himes J, et al. **J Biol Chem** 1998 Oct 30;273(44):28545-8 (87 ref.)

Communication between the cell membrane and the nucleus: role of protein compartmentalization. Lelièvre SA, et al. **J Cell Biochem Suppl** 1998;30-31:250-63 (140 ref.)

Beyond nuclear transport. Ran-GTP as a determinant of spindle assembly. Kahana JA, et al. **J Cell Biol** 1999 Sep 20;146(6):1205-10 (29 ref.)

Import(ance) of growth factors in(to) the nucleus. Keresztes M, et al. **J Cell Biol** 1999 May 3;145(3):421-4 (46 ref.)

The coactivators p300 and CBP have different functions during the differentiation of F9 cells. Ugai H, et al. **J Mol Med** 1999 Jun;77(6):481-94 (105 ref.)

The emerging p53 gene family. Kaelin WG Jr. **J Natl Cancer Inst** 1999 Apr 7;91(7):594-8 (86 ref.)

Molecular aspects of Huntington's disease. Walling HW, et al. **J Neurosci Res** 1998 Nov 1;54(3):301-8 (88 ref.)

The localization and interactions of huntingtin. Jones AL. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1021-7 (65 ref.)

Functions of SR and Tra2 proteins in pre-mRNA splicing regulation. Tacke R, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):59-63 (29 ref.)

Transcriptional coregulators in development. Mannervik M, et al. **Science** 1999 Apr 23;284(5414):606-9 (56 ref.)

Lamin assembly in vivo. Krohne G. **Subcell Biochem** 1998; 31:563-86 (81 ref.)

Nuclear lamin-binding proteins. Ye Q, et al. **Subcell Biochem** 1998;31:587-610 (130 ref.)

[Analysis of the unfolded protein response: an intracellular signaling pathway from the endoplasmic reticulum to the nucleus] Mori K. **Seikagaku** 1998 Jul;70(7):505-15 (42 ref.) **(Jpn)**

[Interaction of transcription factor PU. 1 with coactivator CBP] Yamamoto H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1389-95 (35 ref.) **(Jpn)**

[Cooperation of membrane proteins and cytosolic proteins in metabolic regulation--involvement of binding of hexokinase to mitochondria in regulation of glucose metabolism and association and complex formation between membrane proteins and cytosolic proteins in regulation of active oxygen production] Ishibashi S. **Yakugaku Zasshi** 1999 Jan;119(1):16-34 (49 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Proteins implicated in Alzheimer disease. The role of FE65, a new adapter which binds to beta-amyloid precursor protein. Ermekova KS, et al. **Adv Exp Med Biol** 1998; 446:161-80 (120 ref.)

Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1. Semenza GL, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:262-8 (33 ref.)

Nucleolin: a multifunctional major nucleolar phosphoprotein. Tuteja R, et al. **Crit Rev Biochem Mol Biol** 1998; 33(6):407-36 (164 ref.)

Transcriptional regulation: SWItching circuitry. Wade PA, et al. **Curr Biol** 1999 Mar 25;9(6):R221-4 (12 ref.)

Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Horton JD, et al. **Curr Opin Lipidol** 1999 Apr;10(2):143-50 (36 ref.)

PASting together the mammalian clock. Whitmore D, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):635-41 (45 ref.)

Nuclear import and export of proteins: the molecular basis for intracellular signaling. Sekimoto T, et al. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):205-11 (61 ref.)

HIF-1alpha and p53 promote hypoxia-induced delayed neuronal death in models of CNS ischemia. Halterman MW, et al. **Exp Neurol** 1999 Sep;159(1):65-72 (65 ref.)

New perspectives on retinoblastoma family functions in differentiation. Yee AS, et al. **Front Biosci** 1998 Jun 8; 3:D532-47 (100 ref.)

The C/EBP family of transcription factors in the liver and other organs. Takiguchi M. **Int J Exp Pathol** 1998 Dec; 79(6):369-91 (232 ref.)

CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review). Yamanaka R, et al. **Int J Mol Med** 1998 Jan;1(1):213-21 (106 ref.)

The role of C/EBP genes in adipocyte differentiation. Darlington GJ, et al. **J Biol Chem** 1998 Nov 13; 273(46):30057-60 (36 ref.)

The role of C/EBP isoforms in the control of inflammatory and native immunity functions. Poli V. **J Biol Chem** 1998 Nov 6;273(45):29279-82 (69 ref.)

Transcription and growth regulatory functions of the HIN-200 family of proteins. Johnstone RW, et al. **Mol Cell Biol** 1999 Sep;19(9):5833-8 (45 ref.)

Ku, a DNA repair protein with multiple cellular functions? Featherstone C, et al. **Mutat Res** 1999 May 14;434(1):3-15 (93 ref.)

Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Graña X, et al. **Oncogene** 1998 Dec 24;17(25):3365-83 (193 ref.)

The mammalian SWI/SNF complex and the control of cell growth [see comments] Muchardt C, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):189-95 (57 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Vanden Heuvel JP. **Toxicol Sci** 1999 Jan; 47(1):1-8 (72 ref.)

SMC proteins and chromosome structure. Strunnikov AV. **Trends Cell Biol** 1998 Nov;8(11):454-9 (48 ref.)

[Hypoxia and tumors: does HIF-1 transcription factor favor tumor growth or hypoxia?] Vandenbunder B. **Bull Cancer** 1998 Oct;85(10):843-5 (10 ref.) (Eng. Abstr.) **(Fre)**

[The function of Huntington disease gene product (huntingtin) and the pathomechanism of Huntington disease] Nukina N. **Nippon Rinsho** 1999 Apr;57(4):905-11 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Role of nuclear matrix proteins in the formation of heterochromatin] Lobov IB, et al. **Tsitologiia** 1999; 41(7):562-73 (119 ref.) (Eng. Abstr.) **(Rus)**

NUCLEAR RADIOLOGY see **NUCLEAR MEDICINE**

NUCLEAR REACTOR ACCIDENTS see **ACCIDENTS, RADIATION**

NUCLEAR REACTORS

see related
ACCIDENTS, RADIATION

NUCLEAR RNA see **RNA, NUCLEAR**

NUCLEAR TRACK DETECTION see **RADIOMETRY**

NUCLEAR TRANS-ACTING FACTOR see **TRANS-ACTIVATORS**

NUCLEAR WARFARE

Nuclear weapons and the law. Murray RK. **Med Confl Surviv** 1999 Apr-Jun;15(2):126-37 (6 ref.)

A-bomb survivors: reassessment of the radiation hazard. Stewart AM, et al. **Med Confl Surviv** 1999 Jan-Mar; 15(1):47-56 (14 ref.)

NUCLEAR WASTE see **RADIOACTIVE WASTE**

NUCLEAR WEAPONS TESTING see **NUCLEAR WARFARE**

NUCLEASES, DNA see **DEOXYRIBONUCLEASES**

NUCLEASES, RNA see **RIBONUCLEASES**

NUCLEIC ACID CONFORMATION

see related
POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL

The decisive role of the water structure in changes of conformation of nucleic acids. Barciszewski J, et al. **Acta Biochim Pol** 1999;46(1):133-44 (37 ref.)

Flexing DNA: HMG-box proteins and their partners. Bianchi ME, et al. **Am J Hum Genet** 1998 Dec;63(6):1573-7 (25 ref.)

Biological implications of the DNA structures associated with disease-causing triplet repeats. Sinden RR. **Am J Hum Genet** 1999 Feb;64(2):346-53 (32 ref.)

Base flipping. Roberts RJ, et al. **Annu Rev Biochem** 1998; 67:181-98 (62 ref.)

RNA folds: insights from recent crystal structures. Ferré-D'Amaré AR, et al. **Annu Rev Biophys Biomol Struct** 1999;28:57-73 (63 ref.)

NMR studies of DNA duplexes containing alpha-anomeric nucleotides and polarity reversals. Aramini JM, et al. **Biochem Cell Biol** 1998;76(2-3):403-10 (37 ref.)

Dimer formation by tRNAs. Kholod NS. **Biochemistry (Mosc)** 1999 Mar;64(3):298-306 (17 ref.)

DNA structure checkpoint pathways in Schizosaccharomyces pombe. Caspari T, et al. **Biochimie** 1999 Jan-Feb;81(1-2):173-81 (65 ref.)

Design, synthesis, and analysis of conformationally constrained nucleic acids. Glick GD. **Biopolymers** 1998; 48(1):83-96 (103 ref.)

New developments in structure determination of pseudoknots. Hilbers CW, et al. **Biopolymers** 1998; 48(2-3):137-53 (47 ref.)

On the role of magnesium ions in RNA stability. Misra VK, et al. **Biopolymers** 1998;48(2-3):113-35 (142 ref.)

DNA recognition by beta-sheets. Tateno M, et al. **Biopolymers** 1997;44(4):335-59 (44 ref.)

DNA recognition and nucleosome organization. Travers A, et al. **Biopolymers** 1997;44(4):423-33 (70 ref.)

Progress in the design of DNA sequence-specific lexitropsins. Walker WL, et al. **Biopolymers** 1997;44(4):323-34 (44 ref.)

Ribosomal mechanics, antibiotics, and GTP hydrolysis [comment] Porse BT, et al. **Cell** 1999 May 14;97(4):423-6 (16 ref.) Comment on: Cell 1999 May 14;97(4):491-502.

Nuclear snRNA and nuclear function (discovery of 5' cap structures in RNA). Ro-Choi TS. **Crit Rev Eukaryot Gene Expr** 1999;9(2):107-58 (304 ref.)

Mechanisms of DNA bending. Maher LJ 3rd. **Curr Opin Chem Biol** 1998 Dec;2(6):688-94 (41 ref.)

Combinatorial transcription factors. Wolberger C. **Curr Opin Genet Dev** 1998 Oct;8(5):552-9 (54 ref.)

DNA structure and transcription. Dai X, et al. **Curr Opin Microbiol** 1999 Apr;2(2):126-30 (50 ref.)

Multistranded DNA structures. Gilbert DE, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):305-14 (61 ref.)

Structure, folding and catalysis of the small nucleolytic ribozymes. Lilley DM. **Curr Opin Struct Biol** 1999 Jun; 9(3):330-8 (69 ref.)

Exposing the kinetic traps in RNA folding. Treiber DK, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):339-45 (47 ref.)

The role of water structure in conformational changes of nucleic acids in ambient and high-pressure conditions. Barciszewski J, et al. **Eur J Biochem** 1999 Mar; 260(2):293-307 (116 ref.)

Folding and catalysis by the hairpin ribozyme. Lilley DM. **FEBS Lett** 1999 Jun 4;452(1-2):26-30 (33 ref.)

DNA bending and wrapping around RNA polymerase: a "revolutionary" model describing transcriptional mechanisms. Coulombe B, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):457-78 (169 ref.)

DNA methylation in eukaryotic chromosome stability revisited: DNA methyltransferase in the management of DNA conformation space. Smith SS, et al. **Mol Carcinog** 1999 Sep;26(1):1-9 (58 ref.)

DNA curvature and deformation in protein-DNA complexes: a step in the right direction [comment] Crothers DM. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15163-5 (26 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15194-9.

DNA secondary structure: a common and causative factor for expansion in human disease. McMurray CT. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1823-5 (44 ref.)

The rise of single-molecule DNA biochemistry [comment] Rich A. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):13999-4000 (11 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14152-7.

Travelling through conformational space: an approach for analyzing the conformational behaviour of flexible molecules. Koča J. **Prog Biophys Mol Biol** 1998; 70(2):137-73 (112 ref.)

DNA conformation and dynamics. Ninaber A, et al. **Radiat Environ Biophys** 1999 May;38(1):23-9 (26 ref.)

New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Darden T, et al. **Structure Fold Des** 1999 Mar 15;7(3):R55-60 (54 ref.)

NUCLEIC ACID HETERODUPLEXES

see related
BASE PAIR MISMATCH

ANALYSIS

Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Nataraj AJ, et al. **Electrophoresis** 1999 Jun;20(6):1177-85 (69 ref.)

NUCLEIC ACID HYBRIDIZATION

Nucleic acid tests for the diagnosis of sexually transmitted diseases. Chernesky MA. **FEMS Immunol Med Microbiol** 1999 Jul 15;24(4):437-46 (46 ref.)

[Detection of human papillomavirus infection by the nucleic acid hybridization method (a multicenter study)] Deák J, et al. **Orv Hetil** 1999 Jan 17;140(3):115-20 (32 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

Progress and variations in two-hybrid and three-hybrid technologies. Drees BL. **Curr Opin Chem Biol** 1999 Feb; 3(1):64-70 (47 ref.)

METHODS

Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Nolte FS. **Adv Clin Chem** 1998;33:201-35 (87 ref.)

Comparative genomic hybridization and chromosomal instability in solid tumours. Rooney PH, et al. **Br J Cancer** 1999 May;80(5-6):862-73 (124 ref.)

Rapid detection of genetic mutations using the chemiluminescent hybridization protection assay (HPA): overview and comparison with other methods. Nelson NC. **Crit Rev Clin Lab Sci** 1998 Sep;35(5):369-414 (166 ref.)

Molecular cytogenetic techniques for the diagnosis of chromosomal abnormalities in childhood disease. Stumm M, et al. **Eur J Pediatr** 1999 Jul;158(7):531-6 (21 ref.)

Large-scale expression measurement by hybridization methods: from high-density membranes to "DNA chips". Jordan BR. **J Biochem (Tokyo)** 1998 Aug;124(2):251-8 (30 ref.)

The identification of signaling molecules by the yeast two-hybrid system. Biffo S, et al. **Methods Mol Biol** 1999; 96:211-20 (7 ref.)

NUCLEIC ACID HYBRIDIZATION

Classification of isolates by DNA-DNA hybridization. Sachse K, et al. **Methods Mol Biol** 1998;104:189-95 (2 ref.)
Microarrays and toxicology: the advent of toxicogenomics. Nuwaysir EF, et al. **Mol Carcinog** 1999 Mar;24(3):153-9 (48 ref.)
[Recent progress in DNA diagnosis of bacteria] Matsuoka Y. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):621-7 (10 ref.) **(Jpn)**

NUCLEIC ACID PROBES

see related
NUCLEIC ACID HYBRIDIZATION

NUCLEIC ACID REGULATORY SEQUENCES see **REGULATORY SEQUENCES, NUCLEIC ACID**

NUCLEIC ACID REPETITIVE SEQUENCES see **REPETITIVE SEQUENCES, NUCLEIC ACID**

NUCLEIC ACID SYNTHESIS INHIBITORS

THERAPEUTIC USE

Use of hydroxyurea in psoriasis. Smith CH. **Clin Exp Dermatol** 1999 Jan;24(1):2-6 (33 ref.)
Haemophilic synovitis: is rifampicin an alternative? Caviglia H, et al. **Haemophilia** 1998 Jul;4(4):514-7 (54 ref.)

NUCLEIC ACID VACCINES see **VACCINES, DNA**

NUCLEIC ACIDS

The role of water structure in conformational changes of nucleic acids in ambient and high-pressure conditions. Barciszewski J, et al. **Eur J Biochem** 1999 Mar; 260(2):293-307 (116 ref.)

ANALYSIS

Nucleic acid detection technologies -- labels, strategies, and formats. Kricka LJ. **Clin Chem** 1999 Apr;45(4):453-8 (74 ref.)
Amplification methods to increase the sensitivity of in situ hybridization: play card(s). Speel EJ, et al. **J Histochem Cytochem** 1999 Mar;47(3):281-8 (74 ref.)

CHEMICAL SYNTHESIS

Design, synthesis, and analysis of conformationally constrained nucleic acids. Glick GD. **Biopolymers** 1998; 48(1):83-96 (103 ref.)

CHEMISTRY

Possibilities of the method of step-by-step complication of ligand structure in studies of protein--nucleic acid interactions: mechanisms of functioning of some replication, repair, topoisomerization, and restriction enzymes. Bugreev DV, et al. **Biochemistry (Mosc)** 1999 Mar;64(3):237-49 (72 ref.)
NMR structure determination of proteins and protein complexes larger than 20 kDa. Clore GM, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):564-70 (51 ref.)
Thermodynamic analysis of biomolecules: a volumetric approach. Chalikian TV, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):657-64 (60 ref.)
Collective variable modelling of nucleic acids. Lafontaine I, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):170-6 (66 ref.)
Natural covalent complexes of nucleic acids and proteins: some comments on practice and theoryon the path from well-known complexes to new ones. Drygin YF. **Nucleic Acids Res** 1998 Nov 1;26(21):4791-6 (88 ref.)

METABOLISM

Possibilities of the method of step-by-step complication of ligand structure in studies of protein--nucleic acid interactions: mechanisms of functioning of some replication, repair, topoisomerization, and restriction enzymes. Bugreev DV, et al. **Biochemistry (Mosc)** 1999 Mar;64(3):237-49 (72 ref.)
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Rein A, et al. **Trends Biochem Sci** 1998 Aug;23(8):297-301 (54 ref.)

PHARMACOKINETICS

Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. Wang S, et al. **J Controlled Release** 1998 Apr 30;53(1-3):39-48 (34 ref.)

NUCLEOCAPSID

see related
NUCLEOCAPSID PROTEINS

NUCLEOCAPSID PROTEINS

CHEMISTRY

Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Rein A, et al. **Trends Biochem Sci** 1998 Aug;23(8):297-301 (54 ref.)

METABOLISM

Processive antitermination. Weisberg RA, et al. **J Bacteriol** 1999 Jan;181(2):359-67 (105 ref.)
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Rein A, et al. **Trends Biochem Sci** 1998 Aug;23(8):297-301 (54 ref.)

NUCLEOLAR ORGANIZER see **NUCLEOLUS ORGANIZER REGION**

NUCLEOLAR PROTEINS see **NUCLEAR PROTEINS**

NUCLEOLUS ORGANIZER REGION

Nucleolin: a multifunctional major nucleolar phosphoprotein. Tuteja R, et al. **Crit Rev Biochem Mol Biol** 1998; 33(6):407-36 (164 ref.)

GENETICS

Genetic organization of polytene chromosomes. Zhimulev IF. **Adv Genet** 1999;39:1-589 (2190 ref.)

PHYSIOLOGY

[The essential character of the Spemann's organizer] Hashimoto C. **Tanpakushitsu Kakusan Koso** 1998 Aug; 43(10):1336-46 (26 ref.) **(Jpn)**

NUCLEOLYSIS, INTERVERTEBRAL DISK see **INTERVERTEBRAL DISK CHEMOLYSIS**

NUCLEOPOLYHEDROVIRUS

An exegesis of IAPs: salvation and surprises from BIR motifs. Miller LK. **Trends Cell Biol** 1999 Aug;9(8):323-8 (43 ref.)

GENETICS

Expression and recovery of functional G-protein-coupled receptors using baculovirus expression systems. Bouvier M, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):522-7 (48 ref.)
One-step purification and biochemical characterization of recombinant pancreatic lipases expressed in insect cells. Bezzine S, et al. **Methods Mol Biol** 1999;109:187-202 (27 ref.)
High-level baculoviral expression of hormone-sensitive lipase. Holm C, et al. **Methods Mol Biol** 1999;109:165-75 (15 ref.)
High-level baculoviral expression of lysosomal acid lipase. Tilkorn AC, et al. **Methods Mol Biol** 1999;109:177-85 (5 ref.)

NUCLEOPROTEINS

PHYSIOLOGY

Analysis of protein and DNA-mediated contributions to cooperative assembly of protein-DNA complexes. Senear DF, et al. **Methods** 1998 Sep;16(1):3-20 (54 ref.)

NUCLEOSIDASES

CHEMISTRY

3-methyladenine DNA glycosylases: structure, function, and biological importance. Wyatt MD, et al. **Bioessays** 1999 Aug;21(8):668-76 (68 ref.)

METABOLISM

3-methyladenine DNA glycosylases: structure, function, and biological importance. Wyatt MD, et al. **Bioessays** 1999 Aug;21(8):668-76 (68 ref.)
Enzymatic processing of radiation-induced free radical damage in DNA. Wallace SS. **Radiat Res** 1998 Nov;150(5 Suppl):S60-79 (284 ref.)

NUCLEOSIDE-DIPHOSPHATE KINASE

PHYSIOLOGY

NM23-NDP kinase. Postel EH. **Int J Biochem Cell Biol** 1998 Dec;30(12):1291-5 (21 ref.)

NUCLEOSIDE-PHOSPHATE KINASE

CHEMISTRY

Nucleoside monophosphate kinases: structure, mechanism, and substrate specificity. Yan H, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:103-34, x (84 ref.)

METABOLISM

Nucleoside monophosphate kinases: structure, mechanism, and substrate specificity. Yan H, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:103-34, x (84 ref.)

NUCLEOSIDE SEQUENCE see **BASE SEQUENCE**

NUCLEOSIDES

ANALYSIS

Urinary nucleosides. Schram KH. **Mass Spectrom Rev** 1998 May-Jun;17(3):131-251 (112 ref.)

CHEMICAL SYNTHESIS

[Efficient synthesis of nucleosides labeled with stable isotopes and their application to structural biology] Kawashima E, et al. **Yakugaku Zasshi** 1999 May;119(5):299-318 (50 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Recent advances in L-nucleosides: chemistry and biology. Wang P, et al. **Antiviral Res** 1998 Dec;40(1-2):19-44 (118 ref.)

METABOLISM

Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Cass CE, et al. **Biochem Cell Biol** 1998;76(5):761-70 (75 ref.)

PHARMACOLOGY

Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Franchetti P, et al. **Curr Med Chem** 1999 Jul;6(7):599-614 (127 ref.)
Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Pastor-Anglada M, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):424-30 (50 ref.)

PHYSIOLOGY

Nucleosides and nucleotides in the lung: role in asthma. Fedan JS. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):7-9 (26 ref.)
Nucleoside transporters and liver cell growth. Pastor-Anglada M, et al. **Biochem Cell Biol** 1998; 76(5):771-7 (39 ref.)

THERAPEUTIC USE

Nucleoside transporters: molecular biology and implications for therapeutic development. Baldwin SA, et al. **Mol Med Today** 1999 May;5(5):216-24 (48 ref.)
Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Gregoire V, et al. **Oncol Rep** 1999 Sep-Oct; 6(5):949-57 (61 ref.)

URINE

Estimation of oxidative DNA damage in man from urinary excretion of repair products. Loft S, et al. **Acta Biochim Pol** 1998;45(1):133-44 (66 ref.)
Urinary nucleosides. Schram KH. **Mass Spectrom Rev** 1998 May-Jun;17(3):131-251 (112 ref.)

NUCLEOSOMES

CHEMISTRY

An engine for nucleosome remodeling. Travers A. **Cell** 1999 Feb 5;96(3):311-4 (17 ref.)
Nucleosome and chromatin structures and functions. Bradbury EM. **J Cell Biochem Suppl** 1998;30-31:177-84 (41 ref.)
The location of the linker histone on the nucleosome. Travers A. **Trends Biochem Sci** 1999 Jan;24(1):4-7 (34 ref.)

GENETICS

ATP-dependent remodeling of chromatin. Wu C, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:525-34 (46 ref.)

IMMUNOLOGY

Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Shen GQ, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):321-34 (93 ref.)
Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Berden JH, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):299-306 (57 ref.)

METABOLISM

Alteration of nucleosome structure as a mechanism of transcriptional regulation. Workman JL, et al. **Annu Rev Biochem** 1998;67:545-79 (270 ref.)
An engine for nucleosome remodeling. Travers A. **Cell** 1999 Feb 5;96(3):311-4 (17 ref.)
The nucleosome: a powerful regulator of transcription. Wolffe AP, et al. **Prog Nucleic Acid Res Mol Biol** 1998; 61:379-422 (166 ref.)

PHYSIOLOGY

Nucleosomes and regulation of gene expression. Structure of the HIV-1 5'LTR. Widlak P, et al. **Acta Biochim Pol** 1998;45(1):209-19 (28 ref.)
The key role of nucleosomes in lupus. Amoura Z, et al. **Arthritis Rheum** 1999 May;42(5):833-43 (124 ref.)
Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Kornberg RD, et al.

Cell 1999 Aug 6;98(3):285–94 (102 ref.)
Diversity of prokaryotic chromosomal proteins and the origin of the nucleosome. Sandman K, et al.
Cell Mol Life Sci 1998 Dec;54(12):1350–64 (145 ref.)
Regulation of transcription by multisubunit complexes that alter nucleosome structure. Steger DJ, et al.
Cold Spring Harb Symp Quant Biol 1998;63:483–91 (81 ref.)
Nucleosome and chromatin structures and functions. Bradbury EM. **J Cell Biochem Suppl** 1998;30–31:177–84 (41 ref.)

ULTRASTRUCTURE

DNA recognition and nucleosome organization. Travers A, et al. **Biopolymers** 1997;44(4):423–33 (70 ref.)
Regulation of transcription by multisubunit complexes that alter nucleosome structure. Steger DJ, et al.
Cold Spring Harb Symp Quant Biol 1998;63:483–91 (81 ref.)

NUCLEOTIDE EXCISION REPAIR see **DNA REPAIR**

NUCLEOTIDE SEQUENCE see **BASE SEQUENCE**

NUCLEOTIDES

see related
BASE SEQUENCE

In vitro engineering using synthetic tRNAs with altered anticodons including four-nucleotide anticodons. Kramer G, et al. **Methods Mol Biol** 1998;77:105–16 (22 ref.)
Perinatal and infant nutrition. Nucleotides. Cosgrove M. **Nutrition** 1998 Oct;14(10):748–51 (42 ref.)

ANALYSIS

Analysis of nucleotides by capillary electrophoresis. Geldart SE, et al. **J Chromatogr A** 1998 Dec 18;828(1–2):317–36 (59 ref.)

CHEMICAL SYNTHESIS

Synthesis and applications for unnatural sugar nucleotides. Elhalabi JM, et al. **Curr Med Chem** 1999 Feb;6(2):93–116 (164 ref.)

CHEMISTRY

NMR studies of DNA duplexes containing alpha-anomeric nucleotides and polarity reversals. Aramini JM, et al.
Biochem Cell Biol 1998;76(2–3):403–10 (37 ref.)

GENETICS

[Bacterial genomes: nucleoid, chromosome, nucleotide map] Prozorov AA. **Mikrobiologiia** 1998 Jul–Aug;67(4):437–51 (86 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Transporters of nucleotide sugars, ATP, and nucleotide sulfate in the endoplasmic reticulum and Golgi apparatus. Hirschberg CB, et al. **Annu Rev Biochem** 1998;67:49–69 (121 ref.)
Motor proteins of the kinesin family. Structures, variations, and nucleotide binding sites. Sack S, et al.
Eur J Biochem 1999 May;262(1):1–11 (52 ref.)
Breastmilk nucleotides [editorial] Ebrahim GJ.
J Trop Pediatr 1998 Dec;44(6):318–9 (11 ref.)
Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Gadsby DC, et al. **Physiol Rev** 1999 Jan;79(1 Suppl):S77–S107 (229 ref.)

PHARMACOLOGY

Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. King BF, et al.
Trends Pharmacol Sci 1998 Dec;19(12):506–14 (71 ref.)

PHYSIOLOGY

Nucleosides and nucleotides in the lung: role in asthma. Fedan JS. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):7–9 (26 ref.)

URINE

Estimation of oxidative DNA damage in man from urinary excretion of repair products. Loft S, et al.
Acta Biochim Pol 1998;45(1):133–44 (66 ref.)

NUCLEOTIDES, CYCLIC

METABOLISM

Cyclic nucleotide gated channels. Biel M, et al.
Adv Second Messenger Phosphoprotein Res 1999;33:231–50 (146 ref.)
Tuning Ca2+ permeation in cyclic nucleotide-gated channels [comment] Frings S. **J Gen Physiol** 1999 Jun; 113(6):795–8 (23 ref.) Comment on: J Gen Physiol 1999 Jun;113(6):799–817.
Structure and function of cyclic nucleotide-gated channels. Biel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 135:151–71 (110 ref.)

PHYSIOLOGY

Capillaries, caveolae, calcium and cyclic nucleotides: a new look at microvascular permeability. Michel CC.
J Mol Cell Cardiol 1998 Dec;30(12):2541–6 (40 ref.)

NUCLEOTOMY, PERCUTANEOUS see **DISKECTOMY, PERCUTANEOUS**

NUCLEUS ACCUMBENS

ANATOMY & HISTOLOGY

Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Zahm DS.
Ann N Y Acad Sci 1999 Jun 29;877:113–28 (92 ref.)

PHYSIOLOGY

Functional specificity of ventral striatal compartments in appetitive behaviors. Kelley AE. **Ann N Y Acad Sci** 1999 Jun 29;877:71–90 (115 ref.)
The synaptic framework for chemical signaling in nucleus accumbens. Meredith GE. **Ann N Y Acad Sci** 1999 Jun 29;877:140–56 (84 ref.)
Modulation of cell firing in the nucleus accumbens. O'Donnell P, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:157–75 (81 ref.)
Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Zahm DS.
Ann N Y Acad Sci 1999 Jun 29;877:113–28 (92 ref.)
Is the caudomedial shell of the nucleus accumbens part of the extended amygdala? A consideration of connections. Zahm DS. **Crit Rev Neurobiol** 1998;12(3):245–65 (163 ref.)
Drug addiction as dopamine-dependent associative learning disorder. Di Chiara G. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):13–30 (140 ref.)

PHYSIOPATHOLOGY

Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Di Chiara G, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:461–85 (96 ref.)
The role of dopamine, dynorphin, and CART systems in the ventral striatum and amygdala in cocaine abuse. Hurd YL, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:499–506 (38 ref.)

NUCLEUS BASALIS MAGNOCELLULARIS see **SUBSTANTIA INNOMINATA**

NUCLEUS BASALIS OF MEYNERT see **SUBSTANTIA INNOMINATA**

NUCLEUS BASALIS, OLIVARY see **OLIVARY NUCLEUS**

NUCLEUS RUBER see **RED NUCLEUS**

NUCLEUS SOLITARIUS see **SOLITARY NUCLEUS**

NULLIPARITY see **PARITY**

NUMERICAL ANALYSIS, COMPUTER-ASSISTED

The numerical analysis of fluid-solid interactions for blood flow in arterial structures. Part 1: A review of models for arterial wall behaviour. Zhao SZ, et al.
Proc Inst Mech Eng [H] 1998;212(4):229–40 (73 ref.)
The numerical analysis of fluid-solid interactions for blood flow in arterial structures. Part 2: Development of coupled fluid-solid algorithms. Zhao SZ, et al.
Proc Inst Mech Eng [H] 1998;212(4):241–52 (42 ref.)
Data compression methods for EEG. Ylöstalo J.
Technol Health Care 1999;7(4):285–300 (36 ref.)

NURSE ADMINISTRATORS

LEGISLATION & JURISPRUDENCE

Professional accountability and legal liability for the team leader and charge nurse. Mahlmeister L.
J Obstet Gynecol Neonatal Nurs 1999 May–Jun;28(3):300–9 (23 ref.)

NURSE CLINICIANS

Description of the role of nonphysician practitioners in radiation oncology. Kelvin JF, et al.
Int J Radiat Oncol Biol Phys 1999 Aug 1;45(1):163–9 (17 ref.)
Parkinson's disease nurse specialists: an important role in disease management. MacMahon DG. **Neurology** 1999;52(7 Suppl 3):S21–5 (4 ref.)

ORGANIZATION & ADMINISTRATION

The psychiatric clinical nurse specialist/nurse practitioner: an example of a combined role [comment] Cukr PL, et al. **Arch Psychiatr Nurs** 1998 Dec;12(6):311–8 (34 ref.) Comment on: Arch Psychiatr Nurs 1997 Feb;11(1):2–12.
Psychiatric nurse practitioner versus clinical nurse specialist: moving from debate to action on the future of advanced psychiatric nursing. McCabe S, et al.
Arch Psychiatr Nurs 1999 Jun;13(3):111–6 (9 ref.)
Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al.
J Psychosoc Nurs Ment Health Serv 1998 Oct;36(10):32–5 (11 ref.)

NURSE MIDWIVES

Unintended pregnancy. Consequences and solutions for a worldwide problem. Klima CS. **J Nurse Midwifery** 1998 Nov–Dec;43(6):483–91 (39 ref.)
Current issues in the midwifery management of women living with HIV/AIDS. MacLaren A, et al.
J Nurse Midwifery 1998 Nov–Dec;43(6):502–25 (156 ref.)
Early abortion. Update and implications for midwifery practice. Narrigan D. **J Nurse Midwifery** 1998 Nov–Dec; 43(6):492–501 (50 ref.)
[Management of pregnant women and newborns in low-risk pregnancies. Evaluation of the literature] Blondel B, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:8–20 (52 ref.) **(Fre)**

EDUCATION

Creating off-campus/distance learning courses for midwifery education. A brief introduction. Carr KC.
J Nurse Midwifery 1999 Jan–Feb;44(1):57–64 (12 ref.)

ORGANIZATION & ADMINISTRATION

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of nurse midwives] Caumel-Dauphin F.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:127–36 (14 ref.) **(Fre)**

PSYCHOLOGY

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of nurse midwives] Caumel-Dauphin F.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:127–36 (14 ref.) **(Fre)**

NURSE-PATIENT RELATIONS

To speak or not to speak? Self-disclosure with patients. Deering CG. **Am J Nurs** 1999 Jan;99(1 Pt 1):34–8; quiz 39 (12 ref.)
Rebels with a cause [see comments] Muscari ME.
Am J Nurs 1998 Dec;98(12):26–30; quiz 31 (12 ref.) Comment in: Am J Nurs 1999 Apr;99(4):14.
Caring and the science of unitary human beings. Smith MC.
ANS Adv Nurs Sci 1999 Jun;21(4):14–28 (63 ref.)
The Heideggerian view of person: a perspective conducive to the therapeutic encounter. Orbanic SD.
Arch Psychiatr Nurs 1999 Jun;13(3):137–44 (19 ref.)
A little lady called Pandora: an exploration of philosophical traditions of humanism and existentialism in nursing ill children. Holyoake DD. **Child Care Health Dev** 1998 Jul; 24(4):325–36 (51 ref.)
Learning to listen: serendipitous outcomes of a research training experience. Chambers-Evans J, et al.
J Adv Nurs 1999 Jun;29(6):1421–6 (12 ref.)
The power of the word: some post-structural considerations of qualitative approaches in nursing research. Crowe M.
J Adv Nurs 1998 Aug;28(2):339–44 (22 ref.)
Countertransference in the nurse-patient relationship: a review of the literature. O'Kelly G. **J Adv Nurs** 1998 Aug; 28(2):391–7 (60 ref.)
Homophobia: an evolutionary analysis of the concept as applied to nursing. Richmond JP, et al. **J Adv Nurs** 1998 Aug;28(2):362–9 (95 ref.)
Transcending behaviorism in communication education. Hartrick G. **J Nurs Educ** 1999 Jan;38(1):17–22 (35 ref.)
Theory and practice for teaching the childbearing couple. Farrell M, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):613–8 (22 ref.)
Story telling as a tool for providing holistic care to women. Banks-Wallace J. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):20–4 (28 ref.)
Home care: addressing the needs of people living with AIDS and their caregivers. Baker S. **Nurs Clin North Am** 1999 Mar;34(1):201–12 (43 ref.)
Grief work of HIV positive persons and their survivors. Mallinson RK. **Nurs Clin North Am** 1999 Mar;34(1):163–77 (43 ref.)
Moving beyond fear: lessons learned through a longitudinal review of the literature regarding health care providers and the care of people with HIV/AIDS. Sherman DW, et al. **Nurs Clin North Am** 1999 Mar;34(1):1–48 (117 ref.)
The dark side of nursing: impact of stigmatizing responses on patients. Corley MC, et al. **Sch Inq Nurs Pract** 1998 Summer;12(2):99–118; discussion 119–22 (83 ref.)
Nursing and communication: a reflection [comment] Kasch CR, et al. **Sch Inq Nurs Pract** 1998 Fall;12(3):289–300 (38 ref.) Comment on: Sch Inq Nurs Pract 1987 Fall;1(3):241–55.
The nurse's role in the informed consent process. Rosse PA, et al. **Semin Oncol Nurs** 1999 May;15(2):116–23 (28 ref.)

NURSE-PHYSICIAN RELATIONS see **PHYSICIAN-NURSE RELATIONS**

NURSE PRACTITIONERS

Description of the role of nonphysician practitioners in radiation oncology. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):163–9 (17 ref.)

Lecturer practitioner: a concept analysis. Elcock K. **J Adv Nurs** 1998 Nov;28(5):1092–8 (55 ref.)

A conceptual framework for evaluating the nurse practitioner role in acute care settings. Sidani S, et al. **J Adv Nurs** 1999 Jul;30(1):58–66 (54 ref.)

Evaluating alternative treatments for HIV infection. Freeman EM, et al. **Nurs Clin North Am** 1999 Mar;34(1):147–62 (69 ref.)

Rheumatoid arthritis: a case study. Hartzheim LA, et al. **Nurs Clin North Am** 1998 Dec;33(4):595–602 (20 ref.)

Primary care and case management of persons with HIV/AIDS. Kirton CA, et al. **Nurs Clin North Am** 1999 Mar;34(1):71–94 (27 ref.)

Tardive dyskinesia [letter] Barron M. **Nurse Pract** 1999 Apr; 24(4):144–7 (5 ref.)

Using the transtheoretical model in guiding smoking cessation [letter] Coward R. **Nurse Pract** 1999 Feb;24(2):146–50 (6 ref.)

Review, critique, and guidelines for the use of herbs and homeopathy. Glisson J, et al. **Nurse Pract** 1999 Apr; 24(4):44–6, 53, 60 passim; quiz 68–9 (73 ref.)

Keeping up with current drug approvals [see comments] Kupecz D. **Nurse Pract** 1999 Feb;24(2):44–8, 54, 56–7; quiz 58–9 (0 ref.) Comment in: Nurse Pract 1999 May;24(5):20.

Community analysis for health planning: strategies for primary care practitioners. Reece SM. **Nurse Pract** 1998 Oct;23(10):46, 49, 53–6 passim (23 ref.)

Acute ischemic stroke. Schretzman D. **Nurse Pract** 1999 Feb; 24(2):71–2, 75, 79–82 passim (34 ref.)

EDUCATION

Coping with transition: neonatal nurse practitioner education for the 21st century. Strodtbeck F, et al. **J Pediatr Nurs** 1998 Oct;13(5):272–8 (19 ref.)

LEGISLATION & JURISPRUDENCE

Legal issues in neonatal nursing: considerations for staff nurses and advanced practice nurses. Enzman Hagedorn MI, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):320–30 (29 ref.)

ORGANIZATION & ADMINISTRATION

The psychiatric clinical nurse specialist/nurse practitioner: an example of a combined role [comment] Cukr PL, et al. **Arch Psychiatr Nurs** 1998 Dec;12(6):311–8 (34 ref.) Comment on: Arch Psychiatr Nurs 1997 Feb;11(1):2–12.

Psychiatric nurse practitioner versus clinical nurse specialist: moving from debate to action on the future of advanced psychiatric nursing. McCabe S, et al. **Arch Psychiatr Nurs** 1999 Jun;13(3):111–6 (9 ref.)

Collaboration between GPs and nurse practitioners. The overseas experience and lessons for Australia. Whitecross L. **Aust Fam Physician** 1999 Apr;28(4):349–53 (40 ref.)

Coping with transition: neonatal nurse practitioner education for the 21st century. Strodtbeck F, et al. **J Pediatr Nurs** 1998 Oct;13(5):272–8 (19 ref.)

STANDARDS

Red flags in common pediatric symptoms. Wetzel GV. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):37–44; quiz 45 (19 ref.)

NURSERIES

see related
CHILD DAY CARE CENTERS

[Child-adult transmission in the nursery] Cohen R. **Arch Pediatr** 1999;6 Suppl 3:625s–627s (20 ref.) **(Fre)**

[Digestive infections and nurseries] Gendrel D. **Arch Pediatr** 1999;6 Suppl 3:628s–632s (17 ref.) **(Fre)**

[Respiratory and community infections] Ovetchkine P, et al. **Arch Pediatr** 1999;6 Suppl 3:633s–635s (12 ref.) **(Fre)**

[At which age does one acquire immunity against the main pathogenic agents in the first years of life? Is there an ideal age for entering into the community?] Vigneron P, et al. **Arch Pediatr** 1999;6 Suppl 3:602s–610s (57 ref.) **(Fre)**

NURSERY SCHOOLS see **SCHOOLS, NURSERY**

NURSES

Euthanasia and assisted suicide in The Netherlands: clarifying the practice and the nurse's role. van der Arend AJ. **Int Nurs Rev** 1998 Sep–Oct;45(5):145–51 (16 ref.)

Who cares? Who cures? The ongoing debate in the provision of health care. Baumann AO, et al. **J Adv Nurs** 1998 Nov; 28(5):1040–5 (24 ref.)

Health promotion and health education: what role should the nurse adopt in practice? Norton L. **J Adv Nurs** 1998 Dec;28(6):1269–75 (32 ref.)

Teaching complementary healing therapies to nurses. Breda KL, et al. **J Nurs Educ** 1998 Dec;37(9):394–7 (19 ref.)

Culture and loss: a project of self-reflection. Lewis ML. **J Nurs Educ** 1998 Dec;37(9):398–400 (19 ref.)

Shift report: a time for learning. Yurkovich E, et al. **J Nurs Educ** 1998 Dec;37(9):401–3 (12 ref.)

Why nurses must actively participate in the debate on assisted suicide: a symposium. White BC, et al. **J Prof Nurs** 1999 May–Jun;15(3):139–41 (17 ref.)

ORGANIZATION & ADMINISTRATION

The healthcare marketplace in the next millennium and nurses' roles in infection prevention and control. Jackson MM. **Nurs Clin North Am** 1999 Jun;34(2):411–26 (46 ref.)

PSYCHOLOGY

To speak or not to speak? Self-disclosure with patients. Deering CG. **Am J Nurs** 1999 Jan;99(1 Pt 1):34–8; quiz 39 (12 ref.)

On "being inspired" by Husserl's Phenomenology: reflections on Omery's exposition of phenomenology as a method of nursing research. Porter EJ. **ANS Adv Nurs Sci** 1998 Sep; 21(1):16–28 (53 ref.)

Writing poetry: a way of knowing nursing. Holmes V, et al. **J Adv Nurs** 1998 Dec;28(6):1191–4 (11 ref.)

Story telling: is it really research? Koch T. **J Adv Nurs** 1998 Dec;28(6):1182–90 (54 ref.)

The professional identity of the nurse: concept analysis and development. Ohlén J, et al. **J Adv Nurs** 1998 Oct; 28(4):720–7 (40 ref.)

On the phenomenology of empathy in nursing: empathy or sympathy? Yegdich T. **J Adv Nurs** 1999 Jul;30(1):83–93 (57 ref.)

STANDARDS

Performance improvement in transfusion medicine. What do nurses need and want? Mancini ME. **Arch Pathol Lab Med** 1999 Jun;123(6):496–502 (14 ref.)

[Roles of nurses in clinical trials of anticancer drug development] Matsuura C. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):231–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Work-related low-back problems in nursing. Lagerström M, et al. **Scand J Work Environ Health** 1998 Dec;24(6):449–64 (86 ref.)

Suicide in nurses. Hawton K, et al. **Suicide Life Threat Behav** 1999 Spring;29(1):86–95 (48 ref.)

NURSES' AIDES

STANDARDS

Impact of unlicensed assistive personnel on patient satisfaction: an integrative review of the literature. Siehoff AM. **J Nurs Care Qual** 1998 Dec;13(2):1–10 (22 ref.)

NURSES, HEAD see **NURSING, SUPERVISORY**

NURSES PERFORMANCE EVALUATION see **EMPLOYEE PERFORMANCE APPRAISAL**

NURSES, PUPIL see **STUDENTS, NURSING**

NURSES, VETERINARY see **ANIMAL TECHNICIANS**

NURSING

see related
EDUCATION, NURSING
HISTORY OF NURSING

Evaluating community-based Parkinson's disease nurse specialists: rationale, methodology, and representativeness of patient sample in a large randomized controlled trial. Hurwitz B, et al. **Adv Neurol** 1999;80:431–8 (10 ref.)

A telehealth odyssey. Chaffee M. **Am J Nurs** 1999 Jul; 99(7):27–32; quiz 32–3 (10 ref.)

Patient-centered communication. Brown SJ. **Annu Rev Nurs Res** 1999;17:85–104 (80 ref.)

Nursing research in Italy. Zanotti R. **Annu Rev Nurs Res** 1999;17:295–322 (208 ref.)

Morally autonomous practice? Scott PA. **ANS Adv Nurs Sci** 1998 Dec;21(2):69–79 (20 ref.)

The idea of nursing science. Edwards SD. **J Adv Nurs** 1999 Mar;29(3):563–9 (34 ref.)

Writing poetry: a way of knowing nursing. Holmes V, et al. **J Adv Nurs** 1998 Dec;28(6):1191–4 (11 ref.)

A concept analysis of autonomy. Keenan J. **J Adv Nurs** 1999 Mar;29(3):556–62 (25 ref.)

Considering the nature of intersubjectivity within professional nursing. Pierson W. **J Adv Nurs** 1999 Aug; 30(2):294–302 (46 ref.)

Professional nurse autonomy: concept analysis and application to nursing education. Wade GH. **J Adv Nurs** 1999 Aug;30(2):310–8 (61 ref.)

Promoting women's health via the World Wide Web. Hern MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):606–10 (6 ref.)

The dynamics of leaving and recovering from an abusive relationship. Landenburger KM. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):700–6 (30 ref.)

Culture and systems of oppression in abused women's lives. Phillips DS. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):678–83 (16 ref.)

Nursing e-journals: are current models using the web's potential? Murray PJ, et al. **Medinfo** 1998;9 Pt 1:135–9 (9 ref.)

Sterilization vs. disinfection vs. clean. Alvarado CJ. **Nurs Clin North Am** 1999 Jun;34(2):483–91 (34 ref.)

Women, welfare, and work: one view of the debate. Schroeder C, et al. **Nurs Outlook** 1998 Sep–Oct; 46(5):226–32 (34 ref.)

The thread that links: continuity of patient care. Canady DM. **Prog Cardiovasc Nurs** 1999 Spring;14(2):69–71 (5 ref.)

METHODS

Toward an understanding of art in nursing. LeVasseur JJ. **ANS Adv Nurs Sci** 1999 Jun;21(4):48–63 (48 ref.)

Multiple paradigms of nursing science. Monti EJ, et al. **ANS Adv Nurs Sci** 1999 Jun;21(4):64–80 (38 ref.)

Historic and future health promotion contexts for nursing. Morgan IS, et al. **Image J Nurs Sch** 1998;30(4):379–83 (43 ref.)

Learning to listen: serendipitous outcomes of a research training experience. Chambers-Evans J, et al. **J Adv Nurs** 1999 Jun;29(6):1421–6 (12 ref.)

The contribution of nursing to cancer prevention. Cutler LR. **J Adv Nurs** 1999 Jan;29(1):169–77 (71 ref.)

Evidence-based nursing practice: both state of the art in general and specific to pressure sores. Buss IC, et al. **J Prof Nurs** 1999 Mar–Apr;15(2):73–83 (68 ref.)

ORGANIZATION & ADMINISTRATION

Evaluating the benefits of a clinical ladder for nursing staff: an international review. Buchan J. **Int J Nurs Stud** 1999 Apr;36(2):137–44 (37 ref.)

Nursing in Thailand: western concepts vs Thai tradition. Ekintumas D. **Int Nurs Rev** 1999 Mar–Apr;46(2):55–7 (19 ref.)

The new public management and the new nursing: related by rhetoric? Some reflections on the policy process and nursing. Hewison A. **J Adv Nurs** 1999 Jun;29(6):1377–84 (49 ref.)

The nature of philosophy of science, theory and knowledge relating to nursing and professionalism. Rutty JE. **J Adv Nurs** 1998 Aug;28(2):243–50 (63 ref.)

Harnessing innovative technologies: what can you do with a shoe? Brennan PF. **Nurs Outlook** 1999 May–Jun; 47(3):128–32 (14 ref.)

Interdisciplinary team: the nursing perspective is essential. McCloskey JC, et al. **Nurs Outlook** 1998 Jul–Aug; 46(4):157–63 (33 ref.)

ReVisions in knowledge development: a passion for substance. Meleis AI. **Sch Inq Nurs Pract** 1998 Spring; 12(1):65–77; discussion 79–94 (26 ref.)

STANDARDS

Evaluating community-based Parkinson's disease nurse specialists: rationale, methodology, and representativeness of patient sample in a large randomized controlled trial. Hurwitz B, et al. **Adv Neurol** 1999;80:431–8 (10 ref.)

Clinical guidelines in nursing, midwifery and the therapies: a systematic review. Thomas LH, et al. **J Adv Nurs** 1999 Jul;30(1):40–50 (40 ref.)

STATISTICS & NUMERICAL DATA

Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990–1996. Chang WY, et al. **Nurs Res** 1999 Mar–Apr;48(2):94–104 (110 ref.)

TRENDS

Nursing informatics. Issues for critical care medicine. Jastremski CA. **Crit Care Clin** 1999 Jul;15(3):563–76 (34 ref.)

Historic and future health promotion contexts for nursing. Morgan IS, et al. **Image J Nurs Sch** 1998;30(4):379–83 (43 ref.)

Evolutionary principles can guide nursing's future development. Gottlieb LN, et al. **J Adv Nurs** 1998 Nov; 28(5):1099–105 (41 ref.)

Preparing for the 21st century: diversity in nursing education, research, and practice. Gary FA, et al. **J Prof Nurs** 1998 Sep–Oct;14(5):272–9 (40 ref.)

NURSING ADMINISTRATION RESEARCH

METHODS

Review of nursing turnover research, 1977–1996. Tai TW, et al. **Soc Sci Med** 1998 Dec;47(12):1905–24 (73 ref.)

NURSING ASSESSMENT

Instruments for assessment of auditory hallucinations. Frederick JA, et al. **Arch Psychiatr Nurs** 1998 Oct; 12(5):255–63 (24 ref.)

Culture, conceptive technology, and nursing. Sandelowski M. **Int J Nurs Stud** 1999 Feb;36(1):13–20 (56 ref.)

The immunocompromised host and risk for cardiovascular infection. Schell HM. **J Cardiovasc Nurs** 1999 Jan; 13(2):31–48 (50 ref.)

Cardiac infections: medical and surgical therapies. Sparacino PS. **J Cardiovasc Nurs** 1999 Jan;13(2):49–65 (51 ref.)

Older adults living with chronic pain: an opportunity for improvement. Ebener MK. **J Nurs Care Qual** 1999 Apr; 13(4):1-7 (22 ref.)
Breast health care. A review. McCool WF, et al. **J Nurse Midwifery** 1998 Nov-Dec;43(6):406-30 (179 ref.)
Assessment of women for partner abuse. Fishwick NJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec; 27(6):661-70 (15 ref.)
Working with childhood sexual abuse survivors during pregnancy, labor, and birth. Heritage C. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec; 27(6):671-7 (17 ref.)
Interpersonal violence and the pregnant homeless woman. Robrecht LC, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec;27(6):684-91 (32 ref.)
Patterns of mental health care among Mexican Americans. Bechtel GA, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Nov;36(11):20-7 (28 ref.)
Current understanding of violence and aggression: assessment and treatment. Littrell KH, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Dec;36(12):18-24 (40 ref.)
Red flags in common pediatric symptoms. Wetzel GV. **MCN Am J Matern Child Nurs** 1999 Jan-Feb;24(1):37-44; quiz 45 (19 ref.)
Neglect in the elderly patient. Fulmer T, et al. **Nurs Clin North Am** 1998 Sep;33(3):457-66 (26 ref.)
Rheumatoid arthritis: a case study. Hartzheim LA, et al. **Nurs Clin North Am** 1998 Dec;33(4):595-602 (20 ref.)
Physical assessment of the musculoskeletal system. Mangini M. **Nurs Clin North Am** 1998 Dec;33(4):643-52 (21 ref.)
Delirium in the hospitalized elderly: nursing assessment and management. Milisen K, et al. **Nurs Clin North Am** 1998 Sep;33(3):417-39 (86 ref.)
Differentiated nursing assessment of depressive symptoms in community-dwelling elders. Onega LL, et al. **Nurs Clin North Am** 1998 Sep;33(3):407-16 (42 ref.)
Hyperbilirubinemia in the healthy term newborn. Augustine MC. **Nurse Pract** 1999 Apr;24(4):24-6, 29-32, 34-6 passim; quiz 42-3 (30 ref.)
Subtle clues of alcohol use in elderly women [letter] Martsolf DS, et al. **Nurse Pract** 1999 Feb;24(2):24-6 (19 ref.)
Recognizing aneurysmal subarachnoid hemorrhage [letter] Routson JL. **Nurse Pract** 1999 Apr;24(4):19-20 (9 ref.)
Acute ischemic stroke. Schretzman D. **Nurse Pract** 1999 Feb; 24(2):71-2, 75, 79-82 passim (34 ref.)
Evaluating mild to moderate hypertension. Tobin LJ. **Nurse Pract** 1999 May;24(5):22, 25-6, 29-30 passim; quiz 42-3 (42 ref.)
Coronary subclavian steal syndrome: implications for nursing care. Ferrara LE, et al. **Prog Cardiovasc Nurs** 1998 Fall; 13(4):24-9 (16 ref.)
Cerebral vascular accident after cardiac surgery: its impact on nursing care. Lindsay M. **Prog Cardiovasc Nurs** 1999 Spring;14(2):47-52 (25 ref.)

METHODS

Assessment of functional status in patients with cardiac disease. Coyne KS, et al. **Heart Lung** 1998 Jul-Aug; 27(4):263-73 (23 ref.)
Clinical recognition of adverse drug reactions: obstacles and opportunities for the nursing profession. Arnold GJ. **J Nurs Care Qual** 1998 Dec;13(2):45-55; quiz 86-7 (27 ref.)
Assessment of stressors in families with a child who has a chronic condition. Burke SO, et al. **MCN Am J Matern Child Nurs** 1999 Mar-Apr;24(2):98-106 (30 ref.)
Functional assessment for transitions in patient acuity and care. Barad MB. **Nurs Clin North Am** 1999 Sep; 34(3):607-20 (13 ref.)
Foundation for practice. Neuroassessment for neuroscience nurses. Neatherlin JS. **Nurs Clin North Am** 1999 Sep; 34(3):573-92 (9 ref.)
Recognizing the various presentations of appendicitis. Pisarra VH. **Nurse Pract** 1999 Aug;24(8):42, 44, 49, 52-3; quiz 54-5 (16 ref.)
Identifying diabetic patients at high risk for amputation. Umeh L, et al. **Nurse Pract** 1999 Aug;24(8):56, 60, 63-6, 70 (29 ref.)
Cancer risk assessment: conceptual considerations for clinical practice. Mahon SM. **Oncol Nurs Forum** 1998 Oct; 25(9):1535-47 (34 ref.)

NURSING AUXILIARIES see **NURSES' AIDES**

NURSING CARE

Gemcitabine: a pharmacologic and clinical overview. Barton-Burke M. **Cancer Nurs** 1999 Apr;22(2):176-83 (46 ref.)
Is caring a virtue? Allmark P. **J Adv Nurs** 1998 Sep; 28(3):466-72 (34 ref.)
Conceptualization and measurement of quality of life as an outcome variable for health care intervention and research. Anderson KL, et al. **J Adv Nurs** 1999 Feb;29(2):298-306 (58 ref.)
Evidence-based nursing: a stereotyped view of quantitative and experimental research could work against professional autonomy and authority. Bonell C. **J Adv Nurs** 1999 Jul; 30(1):18-23 (40 ref.)
Facing the issue of dependence: some implications from the literature for the hospice and hospice nurses. Flanagan J, et al. **J Adv Nurs** 1999 Mar;29(3):592-9 (47 ref.)
Contraceptive choice and patient compliance. The health care provider's challenge. Branden PS. **J Nurse Midwifery** 1998 Nov-Dec;43(6):471-82 (54 ref.)
Disparities of health in African Americans. Davis CM, et al. **Nurs Clin North Am** 1999 Jun;34(2):345-57 (65 ref.)
Health problems of Asian and Latino immigrants. Flaskerud JH, et al. **Nurs Clin North Am** 1999 Jun;34(2):359-80 (118 ref.)
Health-related problems in a vulnerable population: pregnant teens and adolescent mothers. Lesser J, et al. **Nurs Clin North Am** 1999 Jun;34(2):289-99 (48 ref.)
Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC. **Nurs Clin North Am** 1999 Mar;34(1):213-25 (11 ref.)
Palliative care: pain and symptom management in persons with HIV/AIDS. Newshan G, et al. **Nurs Clin North Am** 1999 Mar;34(1):131-45 (62 ref.)
The homeless as a vulnerable population. Strehlow AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):261-74 (50 ref.)
Conceptualizing battered women as a vulnerable population: a case study report. Tyson S, et al. **Nurs Clin North Am** 1999 Jun;34(2):301-12 (48 ref.)
Health problems of gay and bisexual men. Ungvarski PJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):313-31 (86 ref.)
Coronary subclavian steal syndrome: implications for nursing care. Ferrara LE, et al. **Prog Cardiovasc Nurs** 1998 Fall; 13(4):24-9 (16 ref.)

CLASSIFICATION

The ICNP's relevance in the US. Henry SB, et al. **Int Nurs Rev** 1998 Sep-Oct;45(5):153-9 (40 ref.)

METHODS

Shedding light on the sexual history. Warner PH, et al. **Am J Nurs** 1999 Jun;99(6):34-40; quiz 41 (11 ref.)
Care of the nursing-home resident with diabetes. Funnell MM. **Clin Geriatr Med** 1999 May;15(2):413-22 (42 ref.)
Health promotion and health education: what role should the nurse adopt in practice? Norton L. **J Adv Nurs** 1998 Dec;28(6):1269-75 (32 ref.)
Named nursing: in whose best interest? Steven A. **J Adv Nurs** 1999 Feb;29(2):341-7 (55 ref.)
Putting infection control principles into practice in home care. Friedman MM, et al. **Nurs Clin North Am** 1999 Jun; 34(2):463-82 (22 ref.)
Common infections acquired in the hospital: the nurse's role in prevention. Steed CJ. **Nurs Clin North Am** 1999 Jun; 34(2):443-61 (22 ref.)

STANDARDS

Patient outcomes. A measure of nursing's value. Oermann MH, et al. **Am J Nurs** 1999 Sep;99(9):40-7; quiz 48 (25 ref.)

STATISTICS & NUMERICAL DATA

Quantitative measurement of caring. Beck CT. **J Adv Nurs** 1999 Jul;30(1):24-32 (50 ref.)

NURSING CARE PLANS see **PATIENT CARE PLANNING**

NURSING DIAGNOSIS

Colonizing images and diagnostic labels: oppressive mechanisms for African American women's health. Taylor JY. **ANS Adv Nurs Sci** 1999 Mar;21(3):32-45 (58 ref.)
Skin care of the pediatric patient. Pallija G, et al. **J Pediatr Nurs** 1999 Apr;14(2):80-7 (19 ref.)

NURSING EDUCATION see **EDUCATION, NURSING**

NURSING EDUCATION, BACCALAUREATE see **EDUCATION, NURSING, BACCALAUREATE**

NURSING EDUCATION, CONTINUING see **EDUCATION, NURSING, CONTINUING**

NURSING EDUCATION, GRADUATE see **EDUCATION, NURSING, GRADUATE**

NURSING EDUCATION, POST-BASIC see **EDUCATION, NURSING, CONTINUING**

NURSING EDUCATION, POSTGRADUATE see **EDUCATION, NURSING, GRADUATE**

NURSING EDUCATION, POST-REGISTRATION see **EDUCATION, NURSING, CONTINUING**

NURSING ETHICS see **ETHICS, NURSING**

NURSING EVALUATION RESEARCH

A conceptual framework for evaluating the nurse practitioner role in acute care settings. Sidani S, et al. **J Adv Nurs** 1999 Jul;30(1):58-66 (54 ref.)
A computerized method of identifying potentially preventable heart failure admissions. Thomas V, et al. **J Nurs Care Qual** 1999 Jun;13(5):1-10 (25 ref.)

NURSING FACULTY see **FACULTY, NURSING**

NURSING, HOLISTIC see **HOLISTIC NURSING**

NURSING, HOME see **HOME NURSING**

NURSING HOMES

Methicillin-resistant Staphylococcus aureus: long-term care concerns. Bradley SF. **Am J Med** 1999 May 3; 106(5A):2S-10S; discussion 48S-52S (40 ref.)
Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Muder RR. **Am J Med** 1998 Oct;105(4):319-30 (134 ref.)
Fire ant attacks on residents in health care facilities: a report of two cases. deShazo RD, et al. **Ann Intern Med** 1999 Sep 21;131(6):424-9 (27 ref.)
Issues in the management of resistant bacteria in long-term-care facilities. Bradley SF. **Infect Control Hosp Epidemiol** 1999 May;20(5):362-6 (47 ref.)
What is the quality of the reporting of research ethics in publications of nursing home research? Karlawish JH, et al. **J Am Geriatr Soc** 1999 Jan;47(1):76-81 (58 ref.)
Nursing home-acquired pneumonia. Medina-Walpole AM, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1005-15 (102 ref.)
Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. Verma SD, et al. **J Clin Psychiatry** 1998;59 Suppl 19:50-5 (32 ref.)
Prevalence of heart disease in older women in a nursing home. Aronow WS. **J Womens Health** 1998 Nov; 7(9):1105-12 (50 ref.)
Psychotropic drug prescribing: first the good news [editorial; comment] Keks NA, et al. **Med J Aust** 1999 Apr 5; 170(7):293-4 (12 ref.) Comment on: Med J Aust 1999 Apr 5;170(7):299-301.
Pain assessment and management in the long-term care setting. Weissman DE, et al. **Theor Med Bioeth** 1999 Jan; 20(1):31-43 (53 ref.)

LEGISLATION & JURISPRUDENCE

Report of the Council on Scientific Affairs. Use of restraints for patients in nursing homes. Council on Scientific Affairs, American Medical Association. Guttman R, et al. **Arch Fam Med** 1999 Mar-Apr;8(2):101-5 (42 ref.)

ORGANIZATION & ADMINISTRATION

Long stay care and the NHS: discontinuities between policy and practice [see comments] Turrell AR, et al. **BMJ** 1998 Oct 3;317(7163):942-4 (21 ref.) Comment in: BMJ 1999 Mar 6;318(7184):668.

STANDARDS

Care of the nursing-home resident with diabetes. Funnell MM. **Clin Geriatr Med** 1999 May;15(2):413-22 (42 ref.)
[Better assessment of the patients results in better nursing home care. A new system for development of geriatric care is being introduced] Ljunggren G. **Lakartidningen** 1998 Nov 4;95(45):4997-5000 (27 ref.) **(Swe)**

STATISTICS & NUMERICAL DATA

Prevalence and treatment of pain in older adults in nursing homes and other long-term care institutions: a systematic review. Fox PL, et al. **CMAJ** 1999 Feb 9;160(3):329-33 (38 ref.)
Medication use in nursing homes for elderly people. Furniss L, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):433-9 (61 ref.)

TRENDS

Improving the emergency medical treatment of older nursing-home residents. Turrell AR, et al. **Age Ageing** 1999 Jan;28(1):77-82 (120 ref.)

NURSING, MATERNAL-CHILD see **MATERNAL-CHILD NURSING**

NURSING METHODOLOGY RESEARCH

Self-care agency: the concept and how it is measured. Carter PA. **J Nurs Meas** 1998 Winter;6(2):195-207 (25 ref.)

METHODS

Combining stories and numbers: a methodologic approach for a critical nursing science. Berman H, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):1-15 (51 ref.)
On "being inspired" by Husserl's Phenomenology: reflections on Omery's exposition of phenomenology as a method of nursing research. Porter EJ. **ANS Adv Nurs Sci** 1998 Sep; 21(1):16-28 (53 ref.)
Womanism: a methodologic framework for African American women. Taylor JY. **ANS Adv Nurs Sci** 1998 Sep; 21(1):53-64 (60 ref.)
The power of the word: some post-structural considerations of qualitative approaches in nursing research. Crowe M. **J Adv Nurs** 1998 Aug;28(2):339-44 (22 ref.)
Story telling: is it really research? Koch T. **J Adv Nurs** 1998 Dec;28(6):1182-90 (54 ref.)

NURSING METHODOLOGY RESEARCH

Collecting and analysing qualitative data: issues raised by the focus group. Sim J. **J Adv Nurs** 1998 Aug;28(2):345–52 (53 ref.)
Time and qualitative research. Sandelowski M. **Res Nurs Health** 1999 Feb;22(1):79–87 (31 ref.)

ORGANIZATION & ADMINISTRATION

Combining stories and numbers: a methodologic approach for a critical nursing science. Berman H, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):1–15 (51 ref.)
An emancipatory impulse: a feminist postmodern integrated turning point in nursing research. Glass N, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):43–52 (45 ref.)

NURSING MODELS see **MODELS, NURSING**

NURSING, ONCOLOGIC see **ONCOLOGIC NURSING**

NURSING, PATIENT-CENTERED see **PATIENT-CENTERED CARE**

NURSING, PRACTICAL

Non-physician practitioners in radiation oncology: advanced practice nurses and physician assistants. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):255–63 (14 ref.)

NURSING PROCESS

Certainty, leaps of faith, and tradition: rethinking clinical interventions [see comments] Dzurec LC. **ANS Adv Nurs Sci** 1998 Dec;21(2):52–61 (36 ref.) Comment in: ANS Adv Nurs Sci 1999 Jun;21(4):vii.
A concept analysis on the process of empowerment. Ellis-Stoll CC, et al. **ANS Adv Nurs Sci** 1998 Dec; 21(2):62–8 (35 ref.)
Brazilian nurses play pivotal role in organ transplant. Püschel VA. **Int Nurs Rev** 1998 Nov–Dec;45(6):168 (0 ref.)
Catching the wave: understanding the concept of critical thinking. Boychuk Duchscher JE. **J Adv Nurs** 1999 Mar; 29(3):577–83 (46 ref.)
Critical thinking as an outcome of nursing education. What is it? Why is it important to nursing practice? Daly WM. **J Adv Nurs** 1998 Aug;28(2):323–31 (55 ref.)
Paradigm dialogues and dogma: finding a place for research, nursing models and reflective practice. Heath H. **J Adv Nurs** 1998 Aug;28(2):288–94 (71 ref.)
Primary nursing: a mode of care or a philosophy of nursing? Pontin D. **J Adv Nurs** 1999 Mar;29(3):584–91 (94 ref.)
Shift report: a time for learning. Yurkovich E, et al. **J Nurs Educ** 1998 Dec;37(9):401–3 (12 ref.)
Cardiovascular effects of acute stroke. Kocan MJ. **Prog Cardiovasc Nurs** 1999 Spring;14(2):61–7 (43 ref.)
A theoretical analysis of Carper's ways of knowing using a model of social cognition. Stein KF, et al. **Sch Inq Nurs Pract** 1998 Spring;12(1):43–60; discussion 61–4 (58 ref.)

NURSING PROGRAM EVALUATION see **NURSING EVALUATION RESEARCH**

NURSING PROTOCOLS see **NURSING ASSESSMENT**

NURSING RECORDS

see related
FORMS AND RECORDS CONTROL

The ICNP's relevance in the US. Henry SB, et al. **Int Nurs Rev** 1998 Sep–Oct;45(5):153–9 (40 ref.)
A systematic review of the relationships between written manual nursing care planning, record keeping and patient outcomes. Moloney R, et al. **J Adv Nurs** 1999 Jul;30(1):51–7 (19 ref.)

NURSING RESEARCH

Wandering in dementia. Algase DL. **Annu Rev Nurs Res** 1999;17:185–217 (136 ref.)
The chronobiology, chronopharmacology, and chronotherapeutics of pain. Auvil-Novak SE. **Annu Rev Nurs Res** 1999;17:133–53 (87 ref.)
Patient-centered communication. Brown SJ. **Annu Rev Nurs Res** 1999;17:85–104 (80 ref.)
Guided imagery interventions for symptom management. Eller LS. **Annu Rev Nurs Res** 1999;17:57–84 (100 ref.)
Chronic low back pain: early interventions. Faucett J. **Annu Rev Nurs Res** 1999;17:155–82 (102 ref.)
Sleep promotion in adults. Floyd JA. **Annu Rev Nurs Res** 1999;17:27–56 (100 ref.)
Acute pain. Good M. **Annu Rev Nurs Res** 1999;17:107–32 (147 ref.)
Cognitive interventions among older adults. McDougall GJ Jr. **Annu Rev Nurs Res** 1999;17:219–40 (107 ref.)
Primary health care. McElmurry BJ, et al. **Annu Rev Nurs Res** 1999;17:241–68 (165 ref.)
Uncertainty in chronic illness. Mishel MH. **Annu Rev Nurs Res** 1999;17:269–94 (80 ref.)
Music therapy. Snyder M, et al. **Annu Rev Nurs Res** 1999; 17:3–25 (110 ref.)
Nursing research in Italy. Zanotti R. **Annu Rev Nurs Res** 1999;17:295–322 (208 ref.)
Critical nursing scholarship: exploring critical social theory with African American studies. Boutain DM. **ANS Adv Nurs Sci** 1999 Jun;21(4):37–47 (46 ref.)
Split-thickness skin graft donor site care: a quantitative synthesis of the research. Rakel BA, et al. **Appl Nurs Res** 1998 Nov;11(4):174–82 (29 ref.)
Evidence-based nursing: a stereotyped view of quantitative and experimental research could work against professional autonomy and authority. Bonell C. **J Adv Nurs** 1999 Jul; 30(1):18–23 (40 ref.)
Warrantable evidence in nursing science. Forbes DA, et al. **J Adv Nurs** 1999 Feb;29(2):373–9 (54 ref.)
Paradigm dialogues and dogma: finding a place for research, nursing models and reflective practice. Heath H. **J Adv Nurs** 1998 Aug;28(2):288–94 (71 ref.)
Health-within-illness: concept development through research and practice. Moch SD. **J Adv Nurs** 1998 Aug; 28(2):305–10 (38 ref.)
Publishing the results of factor analysis: interpretation and presentation. Watson R. **J Adv Nurs** 1998 Dec;28(6):1361–3 (21 ref.)
Reviewing the literature. Sharts-Hopko NC. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):87–9 (4 ref.)
Practical advice for planning and conducting focus groups. Côté-Arsenault D, et al. **Nurs Res** 1999 Sep–Oct; 48(5):280–3 (14 ref.)
An exploration of methodological pluralism in nursing research. Baker C, et al. **Res Nurs Health** 1998 Dec; 21(6):545–55 (93 ref.)
Interviewing children. Docherty S, et al. **Res Nurs Health** 1999 Apr;22(2):177–85 (74 ref.)

METHODS

Understanding women's risk of HIV infection in Thailand through critical hermeneutics. Ruangjiratain S, et al. **ANS Adv Nurs Sci** 1998 Dec;21(2):42–51 (28 ref.)
Nursing research in Finland from 1958 to 1995. Leino-Kilpi H, et al. **Image J Nurs Sch** 1998;30(4):363–7 (27 ref.)
Objectivity in nursing research: observations and objections. Avis M. **Int J Nurs Stud** 1998 Jun;35(3):141–5 (30 ref.)
Conceptualization and measurement of quality of life as an outcome variable for health care intervention and research. Anderson KL, et al. **J Adv Nurs** 1999 Feb;29(2):298–306 (58 ref.)
Establishing the credibility of qualitative research findings: the plot thickens. Cutcliffe JR, et al. **J Adv Nurs** 1999 Aug; 30(2):374–80 (43 ref.)
The critique of Heideggerian hermeneutical nursing research. Draucker CB. **J Adv Nurs** 1999 Aug;30(2):360–73 (61 ref.)
Social support: factors to consider when designing studies that measure social support. Hutchison C. **J Adv Nurs** 1999 Jun;29(6):1520–6 (46 ref.)
Analysing qualitative data: computerized and other approaches. Webb C. **J Adv Nurs** 1999 Feb;29(2):323–30 (29 ref.)
Getting the right tool for the job. Neatherlin J. **J Neurosci Nurs** 1998 Dec;30(6):375–7 (12 ref.)
A review of research instruments for use during the postpartum period. Beck CT. **MCN Am J Matern Child Nurs** 1998 Sep–Oct;23(5):254–61 (56 ref.)
The concept of adaptation: examining alternatives for the study of nursing phenomena. Duffy ME. **Sch Inq Nurs Pract** 1998 Summer;12(2):163–76; discussion 177–86 (28 ref.)
ReVisions in knowledge development: a passion for substance. Meleis AI. **Sch Inq Nurs Pract** 1998 Spring; 12(1):65–77; discussion 79–94 (26 ref.)

ORGANIZATION & ADMINISTRATION

Authorship, dissemination of research findings, and related matters. Duncan AM. **Appl Nurs Res** 1999 May;12(2):101–6 (23 ref.)
Nursing research in Finland from 1958 to 1995. Leino-Kilpi H, et al. **Image J Nurs Sch** 1998;30(4):363–7 (27 ref.)
Complementary and alternative medicine in women's health. Developing a research agenda. Murphy PA, et al. **J Nurse Midwifery** 1999 May–Jun;44(3):192–204 (107 ref.)
Electronic publishing and nursing research. Sparks SM. **Nurs Res** 1999 Jan–Feb;48(1):50–4 (3 ref.)
Nursing and communication: a reflection [comment] Kasch CR, et al. **Sch Inq Nurs Pract** 1998 Fall;12(3):289–300 (38 ref.) Comment on: Sch Inq Nurs Pract 1987 Fall;1(3):241–55.

STANDARDS

Objectivity in nursing research: observations and objections. Avis M. **Int J Nurs Stud** 1998 Jun;35(3):141–5 (30 ref.)
Reconceptualizing rigour: the case for reflexivity. Koch T, et al. **J Adv Nurs** 1998 Oct;28(4):882–90 (43 ref.)
Managing the informed consent process in large multicenter projects. Mark BA, et al. **Nurs Res** 1999 Mar–Apr; 48(2):114–7 (10 ref.)

STATISTICS & NUMERICAL DATA

Uses and abuses of the analysis of covariance. Owen SV, et al. **Res Nurs Health** 1998 Dec;21(6):557–62 (19 ref.)

TRENDS

Middle range theory: spinning research and practice to create knowledge for the new millennium. Liehr P, et al. **ANS Adv Nurs Sci** 1999 Jun;21(4):81–91 (46 ref.)
Advantages and disadvantages of collaborative research: a university and behavioral health care provider's experience. Jones SL, et al. **Arch Psychiatr Nurs** 1998 Oct;12(5):241–6 (30 ref.)
Preparing for the 21st century: diversity in nursing education, research, and practice. Gary FA, et al. **J Prof Nurs** 1998 Sep–Oct;14(5):272–9 (40 ref.)

NURSING RESEARCH, ADMINISTRATIVE see **NURSING ADMINISTRATION RESEARCH**

NURSING RESEARCH, CLINICAL see **CLINICAL NURSING RESEARCH**

NURSING SERVICE, HOSPITAL

ORGANIZATION & ADMINISTRATION

Nursing work redesign in response to managed care. Hoover KW. **J Nurs Adm** 1998 Nov;28(11):9–18 (54 ref.)

STANDARDS

Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Inouye SK, et al. **Am J Med** 1999 May;106(5):565–73 (103 ref.)

NURSING SERVICES

Access to health care. Gulzar L. **Image J Nurs Sch** 1999; 31(1):13–9 (80 ref.)

NURSING STAFF

Chemotherapy. Potential occupational hazards [see comments] Del Gaudio D, et al. **Am J Nurs** 1998 Nov; 98(11):59–65 (8 ref.) Comment in: Am J Nurs 1999 May;99(5):14.
Radiation safety. Shymko M, et al. **AORN J** 1998 Oct; 68(4):596–602; quiz 603–4, 606, 609–10 (35 ref.)

PSYCHOLOGY

Fear of contagion: a response to stress? Bennett J. **ANS Adv Nurs Sci** 1998 Sep;21(1):76–87 (45 ref.)
Countertransference in the nurse-patient relationship: a review of the literature. O'Kelly G. **J Adv Nurs** 1998 Aug; 28(2):391–7 (60 ref.)
Understanding Generation X employees. Kupperschmidt BR. **J Nurs Adm** 1998 Dec;28(12):36–43 (14 ref.)
The dark side of nursing: impact of stigmatizing responses on patients. Corley MC, et al. **Sch Inq Nurs Pract** 1998 Summer;12(2):99–118; discussion 119–22 (83 ref.)

SUPPLY & DISTRIBUTION

Use of immigration policy to manage nursing shortages. Glaessel-Brown EE. **Image J Nurs Sch** 1998;30(4):323–7 (30 ref.)
Review of nursing turnover research, 1977–1996. Tai TW, et al. **Soc Sci Med** 1998 Dec;47(12):1905–24 (73 ref.)

NURSING STAFF, HOSPITAL

Latex hypersensitivity/glove component reaction as a contributing factor to osteomyelitis of the hand: a case report and review of the literature. Duplechain MT, et al. **J La State Med Soc** 1998 Nov;150(11):527–32 (22 ref.)
[Instrumental studies in laboratories dedicated to the examination of disk overload in health workers] Frigo C. **Med Lav** 1999 Mar–Apr;90(2):117–30 (21 ref.) (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Legal issues in neonatal nursing: considerations for staff nurses and advanced practice nurses. Enzman Hagedorn MI, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):320–30 (29 ref.)

ORGANIZATION & ADMINISTRATION

Evaluating the benefits of a clinical ladder for nursing staff: an international review. Buchan J. **Int J Nurs Stud** 1999 Apr;36(2):137–44 (37 ref.)
Named nursing: in whose best interest? Steven A. **J Adv Nurs** 1999 Feb;29(2):341–7 (55 ref.)
Complaints against nurses: a reflection of 'the new managerialism' and consumerism in health care? Beardwood B, et al. **Soc Sci Med** 1999 Feb;48(3):363–74 (57 ref.)

NURSING, SUPERVISORY

Mentorship in nursing: a literature review. Andrews M, et al. **J Adv Nurs** 1999 Jan;29(1):201–7 (52 ref.)

NURSING THEORY

see related
MODELS, NURSING

Critical nursing scholarship: exploring critical social theory with African American studies. Boutain DM.

ANS Adv Nurs Sci 1999 Jun;21(4):37–47 (46 ref.)
Middle range theory: spinning research and practice to create knowledge for the new millennium. Liehr P, et al. **ANS Adv Nurs Sci** 1999 Jun;21(4):81–91 (46 ref.)
Illness as a problem of meaning: moving culture from the classroom to the clinic. McGrath BB. **ANS Adv Nurs Sci** 1998 Dec;21(2):17–29 (40 ref.)
Multiple paradigms of nursing science. Monti EJ, et al. **ANS Adv Nurs Sci** 1999 Jun;21(4):64–80 (38 ref.)
A commentary on Newman's theory of health as expanding consciousness. Yamashita M, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):65–75 (39 ref.)
Nursing practice theory of exercise as self–care. Ulbrich SL. **Image J Nurs Sch** 1999;31(1):65–70 (24 ref.)
Lecturer practitioner: a concept analysis. Elcock K. **J Adv Nurs** 1998 Nov;28(5):1092–8 (55 ref.)
Evolutionary principles can guide nursing's future development. Gottlieb LN, et al. **J Adv Nurs** 1998 Nov; 28(5):1099–105 (41 ref.)
A concept analysis of parent–infant attachment. Goulet C, et al. **J Adv Nurs** 1998 Nov;28(5):1071–81 (84 ref.)
Considering the nature of intersubjectivity within professional nursing. Pierson W. **J Adv Nurs** 1999 Aug; 30(2):294–302 (46 ref.)
The nature of philosophy of science, theory and knowledge relating to nursing and professionalism. Rutty JE. **J Adv Nurs** 1998 Aug;28(2):243–50 (63 ref.)
How can we achieve evidence–based practice if we have a theory–practice gap in nursing today? Upton DJ. **J Adv Nurs** 1999 Mar;29(3):549–55 (47 ref.)
Theory construction based on standards of care: a proposed theory of the peaceful end of life. Ruland CM, et al. **Nurs Outlook** 1998 Jul–Aug;46(4):169–75 (19 ref.)
Self–esteem and health behavior: theoretic and empirical links. Seigley LA. **Nurs Outlook** 1999 Mar–Apr;47(2):74–7 (36 ref.)
An exploration of methodological pluralism in nursing research. Baker C, et al. **Res Nurs Health** 1998 Dec; 21(6):545–55 (93 ref.)
The concept of adaptation: examining alternatives for the study of nursing phenomena. Duffy ME. **Sch Inq Nurs Pract** 1998 Summer;12(2):163–76; discussion 177–86 (28 ref.)
ReVisions in knowledge development: a passion for substance. Meleis AI. **Sch Inq Nurs Pract** 1998 Spring; 12(1):65–77; discussion 79–94 (26 ref.)
A theoretical analysis of Carper's ways of knowing using a model of social cognition. Stein KF, et al. **Sch Inq Nurs Pract** 1998 Spring;12(1):43–60; discussion 61–4 (58 ref.)

NURSING, TRANSCULTURAL see **TRANSCULTURAL NURSING**

NUTCRACKER ESOPHAGUS see **ESOPHAGEAL MOTILITY DISORDERS**

NUTMEG see **SPICES**

NUTRITION

see related
DIET
FOOD

Growth in Crohn's disease. Savage MO, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):89–92 (15 ref.)
Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Vogel JS, et al. **Adv Exp Med Biol** 1998;445:397–410 (41 ref.)
The efficacy of complementary medical treatments, as used by spas: a review of the evidence. Tabacchi MH. **Altern Ther Health Med** 1998 Nov;Suppl:1–5 (120 ref.)
Study design and hypothesis testing: issues in the evaluation of evidence from research in nutritional epidemiology. Freudenheim JL. **Am J Clin Nutr** 1999 Jun; 69(6):1315S–1321S (53 ref.)
Food and nutrient exposures: what to consider when evaluating epidemiologic evidence. Sempos CT, et al. **Am J Clin Nutr** 1999 Jun;69(6):1330S–1338S (60 ref.)
Vitamin D supplementation, 25–hydroxyvitamin D concentrations, and safety [see comments] Vieth R. **Am J Clin Nutr** 1999 May;69(5):842–56 (135 ref.) Comment in: Am J Clin Nutr 1999 May;69(5):825–6.
Potential mechanisms of metabolic imprinting that lead to chronic disease. Waterland RA, et al. **Am J Clin Nutr** 1999 Feb;69(2):179–97 (13 ref.)
Nutritional regulation of gene expression. Cousins RJ. **Am J Med** 1999 Jan 25;106(1A):20S–23S; discussion 50S–51S (14 ref.)
Nutrition, cancer, and aging. Dreosti IE. **Ann N Y Acad Sci** 1998 Nov 20;854:371–7 (21 ref.)
Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Joseph JA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:268–76 (62 ref.)
Nutrition, osteoporosis, and aging. Nordin BE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:336–51 (63 ref.)
Significance of bacterial translocation in nutrition. Waitzberg DL, et al. **Arq Gastroenterol** 1998 Apr–Jun;35(2):110–5 (52 ref.)
Nutrition for sport. Getting the most out of training. Burke L. **Aust Fam Physician** 1999 Jun;28(6):561–7 (9 ref.)
Nutrition in inflammatory bowel disease. Murch SH, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):719–38 (86 ref.)
Nutrition, ageing and ill health. Gariballa SE, et al. **Br J Nutr** 1998 Jul;80(1):7–23 (163 ref.)
Health benefits of probiotics. Goldin BR. **Br J Nutr** 1998 Oct;80(4):S203–7 (24 ref.)
Preventive nutritional factors in epidemiology: interaction between sodium and calcium. Mizushima S, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):573–5 (27 ref.)
The role of copper, molybdenum, selenium, and zinc in nutrition and health. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):673–85 (54 ref.)
Dietary examples. A practical approach to feeding athletes. Bloch TD, et al. **Clin Sports Med** 1999 Jul;18(3):703–11 (7 ref.)
Nutrition, exercise, and immune system function. Nieman DC. **Clin Sports Med** 1999 Jul;18(3):537–48 (86 ref.)
Nutrition in the exercising elderly. Sacheck JM, et al. **Clin Sports Med** 1999 Jul;18(3):565–84 (156 ref.)
Nutrition and exercise in individuals with diabetes. Zinker BA. **Clin Sports Med** 1999 Jul;18(3):585–606, vii–viii (133 ref.)
Lipid modification strategies in the production of nutritionally functional fats and oils. Willis WM, et al. **Crit Rev Food Sci Nutr** 1998 Nov;38(8):639–74 (142 ref.)
Perioperative nutrition [editorial] Allison SP, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):55–9 (15 ref.)
Antioxidants and nutrition support. Zeisel SH, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):1–3 (37 ref.)
Nutritional regulation of leptin in humans. Coleman RA, et al. **Diabetologia** 1999 Jun;42(6):639–46 (80 ref.)
Nutrition and fetal growth. Molina–Font JA. **Early Hum Dev** 1998 Dec;53 Suppl:S51–60 (49 ref.)
Maternal nutritional factors: significance for the fetus and the neonate. Urgell MR, et al. **Early Hum Dev** 1998 Dec; 53 Suppl:S61–76 (20 ref.)
WHO consensus statement on the role of nutrition in colorectal cancer. Scheppach W, et al. **Eur J Cancer Prev** 1999 Feb;8(1):57–62 (45 ref.)
Fitting nutrition into the medical model: the role of decision analytic cost–effectiveness techniques. Ross EM, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S25–8 (30 ref.)
Streamlining nutritional care for the physician's office. Wasson JH, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S97–100 (11 ref.)
Nutritional regulation of gastrointestinal growth. Klurfeld DM. **Front Biosci** 1999 Mar 15;4:D299–302 (39 ref.)
Alternative nutritional cancer therapies. Weitzman S. **Int J Cancer Suppl** 1998;11:69–72 (31 ref.)
Glycemic index—a new tool in sport nutrition? Burke LM, et al. **Int J Sport Nutr** 1998 Dec;8(4):401–15 (52 ref.)
Nutrition support programs for young adult athletes. Clark N. **Int J Sport Nutr** 1998 Dec;8(4):416–25 (33 ref.)
Position of the American Dietetic Association and Dietitians of Canada: women's health and nutrition. Affenito SG, et al. **J Am Diet Assoc** 1999 Jun;99(6):738–51 (227 ref.)
Nutrition and the management of type 2 diabetes. Nuttall FQ, et al. **J Fam Pract** 1998 Nov;47(5 Suppl):S45–53 (80 ref.)
Racial bias in federal nutrition policy, Part I: The public health implications of variations in lactase persistence. Bertron P, et al. **J Natl Med Assoc** 1999 Mar;91(3):151–7 (52 ref.)
Symposium: Steroid Hormone Receptor and Nutrient Interactions: Implications for Cancer Prevention. Introduction. Belury MA. **J Nutr** 1999 Feb;129(2S Suppl):569S–570S (4 ref.)
Nutritional aspects of calcium absorption. Bronner F, et al. **J Nutr** 1999 Jan;129(1):9–12 (49 ref.)
Symposium: Interactions of Diet and Nutrition with Genetic Susceptibility in Cancer. Overview. Freudenheim JL, et al. **J Nutr** 1999 Feb;129(2S Suppl):550S–551S (7 ref.)
Utility and importance of gene knockout animals for nutritional and metabolic research. Hui DY. **J Nutr** 1998 Nov;128(11):2052–7 (63 ref.)
Functional foods and health promotion. Milner JA. **J Nutr** 1999 Jul;129(7 Suppl):1395S–7S (25 ref.)
Concepts in functional foods: the case of inulin and oligofructose. Roberfroid MB. **J Nutr** 1999 Jul;129(7 Suppl):1398S–401S (27 ref.)
Vitamin A as "anti–infective" therapy, 1920–1940. Semba RD. **J Nutr** 1999 Apr;129(4):783–91 (97 ref.)
Dietary isoflavones: biological effects and relevance to human health. Setchell KD, et al. **J Nutr** 1999 Mar; 129(3):758S–767S (148 ref.)
Sphingolipids in food and the emerging importance of sphingolipids to nutrition. Vesper H, et al. **J Nutr** 1999 Jul;129(7):1239–50 (181 ref.)
Arginine and nutrition in renal disease. Efron DT, et al. **J Ren Nutr** 1999 Jul;9(3):142–4 (23 ref.)
Epidemiologic cohort studies of critical nutritional issues in the care of the dialysis patient: report of the epidemiology work group. McClellan W, et al. **J Ren Nutr** 1999 Jul; 9(3):133–7 (49 ref.)
Current topics in renal nutrition. McQuiston B. **J Ren Nutr** 1999 Jul;9(3):172–4 (15 ref.)
1999 Jonathan E. Rhoads lecture. Isotopic metaprobes, nutrition, and the roads ahead. Young VR, et al. **JPEN J Parenter Enteral Nutr** 1999 Jul–Aug;23(4):175–94 (134 ref.)
Toward a new definition of essential nutrients: is it now time for a third 'vitamin' paradigm? Challem JJ. **Med Hypotheses** 1999 May;52(5):417–22 (48 ref.)
Nutritional aspects of manganese from experimental studies. Keen CL, et al. **Neurotoxicology** 1999 Apr–Jun; 20(2–3):213–23 (67 ref.)
The significance of dietary boron, with particular reference to athletes. Naghii MR. **Nutr Health** 1999;13(1):31–7 (15 ref.)
Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Bravo L. **Nutr Rev** 1998 Nov; 56(11):317–33 (149 ref.)
Nutrition–gene interactions during intrauterine life and lactation. Hay WW Jr. **Nutr Rev** 1999 May;57(5 Pt 2):S20–9; discussion S29–30 (83 ref.)
Vitamin C nutriture and risk of atherosclerotic heart disease. Jacob RA. **Nutr Rev** 1998 Nov;56(11):334–7 (14 ref.)
Genetic variation and nutrition. Simopoulos AP. **Nutr Rev** 1999 May;57(5 Pt 2):S10–9 (99 ref.)
Implications of the human genome project for understanding gene–environment interactions. Velázquez A, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S39–41; discussion S41–2 (18 ref.)
Aging and the immune system: the role of micronutrient nutrition [editorial] Bogden JD, et al. **Nutrition** 1999 Jul–Aug;15(7–8):593–5 (24 ref.)
Nutritional and metabolic effects of alcoholism: their relationship with alcoholic liver disease. Bunout D. **Nutrition** 1999 Jul–Aug;15(7–8):583–9 (133 ref.)
Nutritional management of acute diarrhea. Sullivan PB. **Nutrition** 1998 Oct;14(10):758–62 (76 ref.)
Nutrition and cystic fibrosis. Wilson DC, et al. **Nutrition** 1998 Oct;14(10):792–5 (43 ref.)
Application of methionine–free nutrition as an anticancer treatment. Yoshido S. **Nutrition** 1999 May;15(5):422–4 (13 ref.)
Food aversion learning: a risk factor for nutritional problems in the elderly? Bernstein IL. **Physiol Behav** 1999 Apr; 66(2):199–201 (28 ref.)
Optimum nutrition: thiamin, biotin and pantothenate. Bender DA. **Proc Nutr Soc** 1999 May;58(2):427–33 (64 ref.)
Optimal nutrition: calcium, magnesium and phosphorus. Cashman KD, et al. **Proc Nutr Soc** 1999 May;58(2):477–87 (96 ref.)
Considerations for determining 'optimal nutrition' for copper, zinc, manganese and molybdenum. Failla ML. **Proc Nutr Soc** 1999 May;58(2):497–505 (74 ref.)
Optimal macronutrient balance. Gibney MJ. **Proc Nutr Soc** 1999 May;58(2):421–5 (31 ref.)
New understanding in obesity research. James WP, et al. **Proc Nutr Soc** 1999 May;58(2):385–93 (77 ref.)
Optimal nutrition: vitamin E. Morrissey PA, et al. **Proc Nutr Soc** 1999 May;58(2):459–68 (89 ref.)
Unsaturated fatty acids. Roche HM. **Proc Nutr Soc** 1999 May; 58(2):397–401 (31 ref.)
Optimal nutrition: fibre and phytochemicals. Rowland I. **Proc Nutr Soc** 1999 May;58(2):415–9 (22 ref.)
Methodological issues relating to the measurement of food, energy and nutrient intake in human laboratory–based studies. Stubbs RJ, et al. **Proc Nutr Soc** 1998 Aug; 57(3):357–72 (115 ref.)
Optimal nutrition: vitamin A and the carotenoids. Thurnham DI, et al. **Proc Nutr Soc** 1999 May;58(2):449–57 (64 ref.)
Modelling in nutrition: an introduction. Wilson PD, et al. **Proc Nutr Soc** 1999 Feb;58(1):133–8 (7 ref.)
The Rudolf Schoenheimer Centenary Lecture. Isotopes in nutrition research. Young VR, et al. **Proc Nutr Soc** 1999 Feb;58(1):15–32 (162 ref.)
Nutritional genomics: manipulating plant micronutrients to improve human health. DellaPenna D. **Science** 1999 Jul 16;285(5426):375–9 (42 ref.)
Cereal grains: humanity's double–edged sword. Cordain L. **World Rev Nutr Diet** 1999;84:19–73 (342 ref.)
Genetic variation and nutrition. Simopoulos AP. **World Rev Nutr Diet** 1999;84:118–40 (121 ref.)
Effect of diet and nutrition on the expression of cytochromes P450. Ioannides C. **Xenobiotica** 1999 Feb;29(2):109–54 (230 ref.)
[Nutrition in the critically ill. Consensus conference. Long text] **Ann Fr Anesth Reanim** 1998;17(10):1274–84 (0 ref.) **(Fre)**
[What is adequate nutrition?] Greubel S. **Med Monatsschr Pharm** 1999 Jan;22(1):8–13 (6 ref.) **(Ger)**
[Nutrition, aging, old age] Iván L. **Orv Hetil** 1998 Dec 6; 139(49):2951–6 (15 ref.) (Eng. Abstr.) **(Hun)**
[The nutrition of the elderly surgical patient] Nano M, et al. **Minerva Chir** 1999 Jan–Feb;54(1–2):67–71 (25 ref.) (Eng. Abstr.) **(Ita)**
[Update on the role of diet in recurrent nephrolithiasis] Riobó Serván P, et al. **Nutr Hosp** 1998 Jul–Aug;13(4):167–71 (28 ref.) (Eng. Abstr.) **(Spa)**
[Nutrition, energy balance, and obesity] Frühbeck G, et al. **Rev Med Univ Navarra** 1997 Jul–Sep;41(3):185–92 (78 ref.) (Eng. Abstr.) **(Spa)**

EDUCATION

Dutch research into the development and impact of computer–tailored nutrition education. Brug J. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S78–82 (21 ref.)
The relevance of clinical nutrition education and role models to the practice of medicine. Halsted CH. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S29–34 (36 ref.)

NUTRITION

Developments and challenges in family practice nutrition education for residents and practicing physicians: an overview of the North American experience. Kolasa KM. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S89–96 (85 ref.)

What nutrition knowledge and skills do primary care physicians need to have, and how should this be communicated? Truswell AS. **Eur J Clin Nutr** 1999 May; 53 Suppl 2:S67–71 (26 ref.)

Nutritional guidance in general practice—a conceptual framework. van Weel C. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S108–11 (18 ref.)

How to improve the impact of nutrition guidance by general physicians: public health versus individual patient? Worsley A. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S101–7 (56 ref.)

Effective nutrition support programs for college athletes. Vinci DM. **Int J Sport Nutr** 1998 Sep;8(3):308–20 (31 ref.)

How to make nutrition education more meaningful through facilitated group discussions. Abusabha R, et al. **J Am Diet Assoc** 1999 Jan;99(1):72–6 (28 ref.)

[Nutritional education of diabetic patients] Golay A, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:51–69 (41 ref.) **(Fre)**

[Preventive nutritional services for the elderly] Millen BE. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I80–8 (85 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The effect of blood draw methodology on selected nutritional parameters in chronic renal failure. Beto JA, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):85–92 (26 ref.)

Maternal nutrition and endocrine programming of fetal adipose tissue development. Symonds ME, et al. **Biochem Soc Trans** 1999 Feb;27(2):97–103 (46 ref.)

Functional food science and defence against reactive oxidative species. Diplock AT, et al. **Br J Nutr** 1998 Aug; 80 Suppl 1:S77–112 (279 ref.)

Regulatory signals in messenger RNA: determinants of nutrient-gene interaction and metabolic compartmentation [see comments] Hesketh JE, et al. **Br J Nutr** 1998 Oct; 80(4):307–21 (114 ref.) Comment in: Br J Nutr 1998 Oct;80(4):305–6.

Growth, development and differentiation: a functional food science approach. Koletzko B, et al. **Br J Nutr** 1998 Aug; 80 Suppl 1:S5–45 (417 ref.)

Prebiotics and synbiotics: concepts and nutritional properties. Roberfroid MB. **Br J Nutr** 1998 Oct;80(4):S197–202 (38 ref.)

Functional food science and substrate metabolism. Saris WH, et al. **Br J Nutr** 1998 Aug;80 Suppl 1:S47–75 (182 ref.)

Nutrition in the elderly. Refai W, et al. **Clin Geriatr Med** 1999 Aug;15(3):607–25 (102 ref.)

The role of nutrition before and after transplantation [editorial; comment] Allard JP. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):313–4 (5 ref.) Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):315–21. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):323–7. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):329–33.

Nutrition and osteoporosis. Lau EM, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):368–72 (52 ref.)

Adaptation of maternal lipid flux to pregnancy: research needs. Neville MC. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S120–3 (16 ref.)

Nutritional factors in cancer prevention. Rock CL. **Hematol Oncol Clin North Am** 1998 Oct;12(5):975–91 (63 ref.)

Nutrition, physical activity, and bone health in women. Lewis RD, et al. **Int J Sport Nutr** 1998 Sep;8(3):250–84 (162 ref.)

Nutritional and metabolic endpoints. Haymond MW. **J Nutr** 1999 Jan;129(1S Suppl):273S–278S (20 ref.)

Intrauterine nutrition: its importance during critical periods for cardiovascular and endocrine development. Hoet JJ, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):617–27 (91 ref.)

Nutrition versus toxicology of manganese in humans: evaluation of potential biomarkers. Greger JL. **Neurotoxicology** 1999 Apr–Jun;20(2–3):205–12 (74 ref.)

Nutrition Society Medal Lecture. Appetite, feeding behaviour and energy balance in human subjects. Stubbs RJ. **Proc Nutr Soc** 1998 Aug;57(3):341–56 (136 ref.)

NUTRITION ASSESSMENT

Taking a nutrition history: a practical approach for family physicians. Hark L, et al. **Am Fam Physician** 1999 Mar 15;59(6):1521–8, 1531–2 (30 ref.)

Evaluating epidemiologic evidence of the effects of food and nutrient exposures. Flegal KM. **Am J Clin Nutr** 1999 Jun; 69(6):1339S–1344S (51 ref.)

Assessment of nutritional status in clinical practice. Goulet O. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):647–69 (103 ref.)

Fitting nutrition into the medical model: the role of decision analytic cost-effectiveness techniques. Ross EM, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S25–8 (30 ref.)

Nutrient Intake Report: a coordination of patient dietary assessment between physicians and registered dietitians. Olendzki BC, et al. **J Am Diet Assoc** 1998 Oct; 98(10):1159–62 (20 ref.)

Nutrition in reproductive health [see comments] [published erratum appears in J Nurse Midwifery 1999 Mar–Apr;44(2):158] Hally SS. **J Nurse Midwifery** 1998 Nov–Dec;43(6):459–70 (74 ref.) Comment in: J Nurse Midwifery 1999 Mar–Apr;44(2):157–8.

Estimates of body composition as intermediate outcome variables: are DEXA and BIA ready for prime time? Chertow GM. **J Ren Nutr** 1999 Jul;9(3):138–41 (25 ref.)

The nutritional dimension of physical assessment. Hammond KA. **Nutrition** 1999 May;15(5):411–9 (17 ref.)

The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients [see comments] Vellas B, et al. **Nutrition** 1999 Feb;15(2):116–22 (33 ref.) Comment in: Nutrition 1999 Feb;15(2):159–61.

Problems of nutritional assessment in the acute setting. Baxter JP. **Proc Nutr Soc** 1999 Feb;58(1):39–46 (73 ref.)

Nutrition assessment methods for the older Irish adult in the clinical and community settings. Charles RP. **Proc Nutr Soc** 1998 Nov;57(4):599–602 (25 ref.)

Problems of nutritional assessment in the community. Edington J. **Proc Nutr Soc** 1999 Feb;58(1):47–51 (39 ref.)

New techniques in nutritional assessment: body composition methods. Elia M, et al. **Proc Nutr Soc** 1999 Feb;58(1):33–8 (28 ref.)

[Diet pattern of Chinese people and some risk factors harmful to health] Guo CS. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec; 18(6):375–6 (5 ref.) **(Chi)**

[Methods of nutritional assessment in chronic obstructive lung diseases] Doré MF, et al. **Rev Pneumol Clin** 1999 Jun; 55(3):155–67 (58 ref.) (Eng. Abstr.) **(Fre)**

[Nutrition in acute and chronic kidney replacement therapy] Hörl WH. **Internist (Berl)** 1999 Jan;40(1):49–54 (43 ref.) **(Ger)**

[A tool for nutritional anamnesis of elderly patients] Lauque S, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I45–54 (37 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis of zinc deficiency] Roth HP, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I55–63 (47 ref.) (Eng. Abstr.) **(Ger)**

[The importance of nutrition for cancer patients] Ose T, et al. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3466–70 (54 ref.) (Eng. Abstr.) **(Nor)**

NUTRITION DISORDERS

Undereating and undernutrition in old age: integrating bio–psychosocial aspects. Clarke DM, et al. **Age Ageing** 1998 Jul;27(4):527–34 (86 ref.)

Carcinogens in the diet vs. overnutrition. Individual dietary habits, malnutrition, and genetic susceptibility modify carcinogenic potency and cancer risk. Lutz WK. **Mutat Res** 1999 Jul 15;443(1–2):251–8 (20 ref.)

Malnutrition or healthy senescence. Chumlea WC, et al. **Proc Nutr Soc** 1998 Nov;57(4):593–8 (64 ref.)

[Intrauterine nutrition] Henriksen T, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3162–5 (36 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

The Barker hypothesis. An analysis. Wilson J. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):1–7 (36 ref.)

Micronutrients and the pathogenesis of human immunodeficiency virus infection. Semba RD, et al. **Br J Nutr** 1999 Mar;81(3):181–9 (99 ref.)

Malnutrition in tuberculosis. Macallan DC. **Diagn Microbiol Infect Dis** 1999 Jun;34(2):153–7 (14 ref.)

Aggressive oral, enteral or parenteral nutrition: prescriptive decisions in children with cancer. Pencharz PB. **Int J Cancer Suppl** 1998;11:73–5 (20 ref.)

Food, nutrition, anti-social behaviour and criminality. Dickerson JW. **J R Soc Health** 1998 Aug;118(4):224–6 (11 ref.)

Effectiveness of nutrition interventions in the management of malnourished patients treated with maintenance dialysis. Wolfson M. **J Ren Nutr** 1999 Jul;9(3):126–8 (15 ref.)

From malnutrition to obesity: changes in nutritional status associated with liver transplantation [editorial; comment] Hasse J. **Nutrition** 1999 Jun;15(6):507–8 (6 ref.) Comment on: Nutrition 1999 Jun;15(6):504–5.

Tuberculosis, HIV infection, and malnutrition: an infernal trio in central Africa [editorial] Perronne C. **Nutrition** 1999 Apr;15(4):321–2 (12 ref.)

Assessment and treatment of nutritional status in stroke patients. Gariballa SE, et al. **Postgrad Med J** 1998 Jul; 74(873):395–9 (29 ref.)

Malnutrition: organic and functional consequences. Mora RJ. **World J Surg** 1999 Jun;23(6):530–5 (76 ref.)

[Malnutrition and mental functions] Stähelin HB. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I27–30 (25 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative complications in malnourished patients: economic impact and predictive value of some nutritional indicators] Farré Rovira R, et al. **Nutr Hosp** 1998 Sep–Oct; 13(5):233–9 (38 ref.) (Eng. Abstr.) **(Spa)**

[The nutritional-viral etiology of epidemic neuropathy. The Group for the Study of Epidemic Neuropathy] de la Fuente J, et al. **Rev Cubana Med Trop** 1998;50 Suppl:235–40 (40 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Assessment of nutritional status in clinical practice. Goulet O. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):647–69 (103 ref.)

At which body mass index and degree of weight loss should hospitalized elderly patients be considered at nutritional risk? Beck AM, et al. **Clin Nutr** 1998 Oct;17(5):195–8 (34 ref.)

Sensitive measures of the nutritional status of children with cancer in hospital and in the field. Brennan BM. **Int J Cancer Suppl** 1998;11:10–3 (20 ref.)

Malnutrition: detection and intervention. McCann LM. **Perit Dial Int** 1999;19 Suppl 2:S527–32 (61 ref.)

Relationships between dialysis adequacy, dietary intake and nutritional status of patients treated with continuous ambulatory peritoneal dialysis (CAPD). Grzegorzewska AE. **Przegl Lek** 1998;55 Suppl 1:41–4 (36 ref.) **(Eng, Pol)**

[Methods of nutritional assessment in chronic obstructive lung diseases] Doré MF, et al. **Rev Pneumol Clin** 1999 Jun; 55(3):155–67 (58 ref.) (Eng. Abstr.) **(Fre)**

DIET THERAPY

Nutritional support in malnourished paediatric patients. Goulet O. **Baillieres Clin Gastroenterol** 1998 Dec; 12(4):843–76 (131 ref.)

Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423–43, ix (160 ref.)

DRUG THERAPY

Review article: malnutrition and maltreatment—a comment on orlistat for the treatment of obesity. Cahill A, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):997–1002 (27 ref.)

[Alzheimer's disease and nutrition] Guyonnet S, et al. **Rev Neurol (Paris)** 1999 May;155(5):343–9 (48 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Optimality of the birth population reduces learning and behaviour disorders and sudden infant death after the first month. Saugstad LF. **Acta Paediatr Suppl** 1999 May; 88(429):9–28 (171 ref.)

[The development of reference values for the brachial perimeter and body height in comparison with other indicators used for screening of the nutritional status] Mei Z, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):187–95 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Growth factors and malnutrition in chronic renal failure. Fouque DP, et al. **Adv Nephrol Necker Hosp** 1998; 28:259–85 (88 ref.)

Malnutrition, cardiac disease, and mortality: an integrated point of view [editorial] Bergström J, et al. **Am J Kidney Dis** 1998 Nov;32(5):834–41 (87 ref.)

Factors causing malnutrition in patients with chronic uremia. Mitch WE, et al. **Am J Kidney Dis** 1999 Jan;33(1):176–9 (22 ref.)

Alcoholism, malnutrition, vitamin deficiencies, and the skin. Fuchs J. **Clin Dermatol** 1999 Jul–Aug;17(4):457–61 (43 ref.)

Nutritional considerations in children undergoing bone marrow transplantation. Papadopoulou A. **Eur J Clin Nutr** 1998 Dec;52(12):863–71 (160 ref.)

Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423–43, ix (160 ref.)

Sensitive measures of the nutritional status of children with cancer in hospital and in the field. Brennan BM. **Int J Cancer Suppl** 1998;11:10–3 (20 ref.)

Identification of risk factors for malnutrition: is there some evidence for predisposition? Vega Franco L. **Int J Cancer Suppl** 1998;11:14–6 (19 ref.)

Malnutrition, cardiac disease, and mortality. Bergström J, et al. **Perit Dial Int** 1999;19 Suppl 2:S309–14 (66 ref.)

Malnutrition: detection and intervention. McCann LM. **Perit Dial Int** 1999;19 Suppl 2:S527–32 (61 ref.)

Nutrition in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Passadakis P, et al. **Perit Dial Int** 1999;19 Suppl 2:S248–54 (55 ref.)

Nutritional problems in peritoneal dialysis: an overview. Wang T, et al. **Perit Dial Int** 1999;19 Suppl 2:S297–303 (71 ref.)

[International COnference on Nutritional Morbidity in Children with Cancer (letter)] Ruiz-Argüelles GJ. **Rev Invest Clin** 1999 Mar–Apr;51(2):135–6 (0 ref.) **(Spa)**

IMMUNOLOGY

Nutritional depletion and dietary manipulation: effects on the immune response. Hulsewé KW, et al. **World J Surg** 1999 Jun;23(6):536–44 (97 ref.)

METABOLISM

Riboflavin metabolism—relevance to human nutrition. Lakshmi AV. **Indian J Med Res** 1998 Nov;108:182–90 (75 ref.)

Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Murry DJ, et al. **Int J Cancer Suppl** 1998;11:48–51 (32 ref.)

PHYSIOPATHOLOGY

Metabolic and nutritional consequences of chronic hypoxia. Leverve X. **Clin Nutr** 1998 Dec;17(6):241–51 (94 ref.)

Clinical undernutrition states and their influence on taste. Davidson HI, et al. **Proc Nutr Soc** 1998 Nov;57(4):633–8 (43 ref.)
[Pathophysiology of catabolism in undernurished elderly patients] Baez-Franceschi D, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I12–9 (74 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Micronutrient malnutrition: policies and programs for control and their implications. Underwood BA, et al. **Annu Rev Nutr** 1999;19:303–24 (107 ref.)
Enteral nutrition in intensive care patients: a practical approach. Working Group on Nutrition and Metabolism, ESICM. European Society of Intensive Care Medicine. Jolliet P, et al. **Intensive Care Med** 1998 Aug;24(8):848–59 (82 ref.)
Relationships between dialysis adequacy, dietary intake and nutritional status of patients treated with continuous ambulatory peritoneal dialysis (CAPD). Grzegorzewska AE. **Przegl Lek** 1998;55 Suppl 1:41–4 (36 ref.) **(Eng, Pol)**
[Nutritional support. Summary of the consensus development conference. French Society for Enteral and Parenteral Nutrition] **Presse Med** 1998 Jun 20;27(22):1108–11 (0 ref.) **(Fre)**

THERAPY

Aggressive oral, enteral or parenteral nutrition: prescriptive decisions in children with cancer. Pencharz PB. **Int J Cancer Suppl** 1998;11:73–5 (20 ref.)
Effectiveness of nutrition interventions in the management of malnourished patients treated with maintenance dialysis. Wolfson M. **J Ren Nutr** 1999 Jul;9(3):126–8 (15 ref.)
Total parenteral nutrition in the critically ill patient. Birmingham CL. **Lancet** 1999 Apr 3;353(9159):1116–7 (9 ref.)
The effect of medical nutrition therapy on malnutrition and clinical outcomes. Gallagher-Allred CR, et al. **Nutrition** 1999 Jun;15(6):512–4 (39 ref.)
[Management of malnutrition in chronic hemodialysis] Cano N, et al. **Nephrologie** 1998;19(6):353–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Correction of micronutrient deficiency--the most important aspect of healthy nutrition conception for the Russian population] Tutel'ian VA, et al. **Vopr Pitan** 1999;68(1):3–11 (47 ref.) **(Rus)**

NUTRITION DISORDERS, CHILD see **CHILD NUTRITION DISORDERS**

NUTRITION DISORDERS, INFANT see **INFANT NUTRITION DISORDERS**

NUTRITION, ENTERAL see **ENTERAL NUTRITION**

NUTRITION, HOME PARENTERAL see **PARENTERAL NUTRITION, HOME**

NUTRITION LABELING see **FOOD LABELING**

NUTRITION, PARENTERAL see **PARENTERAL NUTRITION**

NUTRITION POLICY

Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Carr AC, et al. **Am J Clin Nutr** 1999 Jun;69(6):1086–107 (238 ref.)
Vegetarian food guide pyramid: a conceptual framework. Haddad EH, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):615S–619S (37 ref.)
The optimal ratio of fat–to–carbohydrate in the diet. Grundy SM. **Annu Rev Nutr** 1999;19:325–41 (53 ref.)
Micronutrient malnutrition: policies and programs for control and their implications. Underwood BA, et al. **Annu Rev Nutr** 1999;19:303–24 (107 ref.)
Guidelines for sugar consumption in Europe: is a quantitative approach justified? Ruxton CH, et al. **Eur J Clin Nutr** 1999 Jul;53(7):503–13 (55 ref.)
Requirements of dietary fats to meet nutritional needs & prevent the risk of atherosclerosis--an Indian perspective. Ghafoorunissa. **Indian J Med Res** 1998 Nov;108:191–202 (52 ref.)
Prevention of osteoporosis. Patel JC. **Indian J Med Sci** 1998 Dec;52(12):562–6 (3 ref.)
Lack of a recommended dietary allowance for copper may be hazardous to your health. Klevay LM. **J Am Coll Nutr** 1998 Aug;17(4):322–6 (59 ref.)
Health claims: history, current regulatory status, and consumer research. Geiger CJ. **J Am Diet Assoc** 1998 Nov; 98(11):1312–22; discussion 1323–4 (79 ref.)
An assessment of the scientific basis for attempting to define the Dietary Reference Intake for beta carotene. Omenn GS. **J Am Diet Assoc** 1998 Dec;98(12):1406–9 (28 ref.)
Dietary Reference Intakes, antioxidants, and beta carotene. Rock CL. **J Am Diet Assoc** 1998 Dec;98(12):1410–1 (11 ref.)
Assessment of nutrient requirements for infant formulas [published erratum appears in J Nutr 1999 May;129(5):1090] **J Nutr** 1998 Nov;128(11 Suppl):i–iv, 2059S–2293S (1034 ref.)
Folate metabolism and requirements. Bailey LB, et al. **J Nutr** 1999 Apr;129(4):779–82 (36 ref.)
Criteria and recommendations for vitamin C intake. Ausman LM. **Nutr Rev** 1999 Jul;57(7):222–4 (9 ref.)
Dietary reference intakes for folate: the debut of dietary folate equivalents. Bailey LB. **Nutr Rev** 1998 Oct; 56(10):294–9 (58 ref.)
Biomarkers for establishing a tolerable upper intake level for vitamin C. Johnston CS. **Nutr Rev** 1999 Mar;57(3):71–7 (75 ref.)
Dietary guidelines for the year 2000: epidemiology in action. Nestle M. **Nutrition** 1999 Jun;15(6):510–1 (21 ref.)
Strategies for altering population intakes of fats and fatty acids. Gibney MJ. **Proc Nutr Soc** 1999 Feb;58(1):189–91 (12 ref.)
Vitamin A deficiency in Bangladesh: a review and recommendations for improvement. Ahmed F. **Public Health Nutr** 1999 Mar;2(1):1–14 (58 ref.)
Nutrition and bone health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food Nutrition Policy. **Rep Health Soc Subj (Lond)** 1998; 49:iii–xvii, 1–24 (321 ref.)
Iron supplementation in athletes. Current recommendations. Nielsen P, et al. **Sports Med** 1998 Oct;26(4):207–16 (45 ref.)
The human food safety evaluation of new animal drugs. Friedlander LG, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):1–11, vii (3 ref.)
[Overweight. II. Determinants of overweight and strategies for prevention (see comments)] Mathus-Vliegen EM. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1989–95 (52 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2374. **(Dut)**

LEGISLATION & JURISPRUDENCE

[Clinical significance of extra vitamin supplements and enriched food products] Hermus RJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 24;143(17):889–93 (22 ref.) (Eng. Abstr.) **(Dut)**

TRENDS

Dietary guidelines for children: where are we heading? Groziak SM, et al. **J Nutr** 1998 Oct;128(10):1836–8 (25 ref.)

NUTRITION SURVEYS

Validation of measures of food insecurity and hunger. Frongillo EA Jr. **J Nutr** 1999 Feb;129(2S Suppl):506S–509S (21 ref.)
[Correction of micronutrient deficiency--the most important aspect of healthy nutrition conception for the Russian population] Tutel'ian VA, et al. **Vopr Pitan** 1999;68(1):3–11 (47 ref.) **(Rus)**

NUTRITION, TOTAL PARENTERAL see **PARENTERAL NUTRITION, TOTAL**

NUTRITIONAL AVAILABILITY see **NUTRITIVE VALUE**

NUTRITIONAL REQUIREMENTS

Protein and energy requirements in healthy and ill paediatric patients. Bresson JL. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):631–45 (69 ref.)
Nutrient requirements at high altitude. Butterfield GE. **Clin Sports Med** 1999 Jul;18(3):607–21, viii (86 ref.)
Nutritional requirements to increase lean mass. Grandjean A. **Clin Sports Med** 1999 Jul;18(3):623–32 (18 ref.)
Nutritional needs of the female athlete. Manore MM. **Clin Sports Med** 1999 Jul;18(3):549–63 (66 ref.)
Adult human amino acid requirements. Young VR, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):39–45 (58 ref.)
Some current controversies on nutritional requirements of full-term and pre-term newborn infants. Bayés R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S3–13 (37 ref.)
Protein demand in the premature neonate and in the small for gestational age full-term neonate. Robles R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S15–21 (30 ref.)
Accounting for the effects of environment on the nutrient requirements of dairy cattle. Fox DG, et al. **J Dairy Sci** 1998 Nov;81(11):3085–95 (19 ref.)
Evaluation of models for balancing the protein requirements of dairy cows. Kohn RA, et al. **J Dairy Sci** 1998 Dec; 81(12):3402–14 (23 ref.)
The use of fiber concentrations for ration formulation. Varga GA, et al. **J Dairy Sci** 1998 Nov;81(11):3063–74 (63 ref.)
Requirements of fat-soluble vitamins for dairy cows: a review. Weiss WP. **J Dairy Sci** 1998 Sep;81(9):2493–501 (67 ref.)
Nutrition in reproductive health [see comments] [published erratum appears in J Nurse Midwifery 1999 Mar-Apr;44(2):158] Hally SS. **J Nurse Midwifery** 1998 Nov-Dec;43(6):459–70 (74 ref.) Comment in: J Nurse Midwifery 1999 Mar-Apr;44(2):157–8.
Assessment of nutrient requirements for infant formulas [published erratum appears in J Nutr 1999 May;129(5):1090] **J Nutr** 1998 Nov;128(11 Suppl):i–iv, 2059S–2293S (1034 ref.)
Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. Bailey LB, et al. **J Nutr** 1999 May; 129(5):919–22 (41 ref.)
Changing perspectives on aging and energy requirements: aging and energy intakes in humans, dogs and cats. Harper EJ. **J Nutr** 1998 Dec;128(12 Suppl):2623S–2626S (19 ref.)
Changing perspectives on aging and energy requirements: aging and digestive function in humans, dogs and cats. Harper EJ. **J Nutr** 1998 Dec;128(12 Suppl):2632S–2635S (26 ref.)
The nutritional requirements of exercising dogs. Hill RC. **J Nutr** 1998 Dec;128(12 Suppl):2686S–2690S (66 ref.)
Factorial calculation of nutrient requirements in lactating queens. Kienzle E. **J Nutr** 1998 Dec;128(12 Suppl):2609S–2614S (32 ref.)
Metabolic demands for amino acids and the human dietary requirement: Millward and rRvers (1988) revisited. Millward DJ. **J Nutr** 1998 Dec;128(12 Suppl):2563S–2576S (92 ref.)
Criteria and recommendations for vitamin C intake. Ausman LM. **Nutr Rev** 1999 Jul;57(7):222–4 (9 ref.)
The nutritional value of plant-based diets in relation to human amino acid and protein requirements. Millward DJ. **Proc Nutr Soc** 1999 May;58(2):249–60 (59 ref.)
Optimal intakes of protein in the human diet. Millward DJ. **Proc Nutr Soc** 1999 May;58(2):403–13 (64 ref.)
The nutritional adequacy of plant-based diets. Sanders TA. **Proc Nutr Soc** 1999 May;58(2):265–9 (37 ref.)
Development of farmed fish: a nutritionally necessary alternative to meat. Sargent JR, et al. **Proc Nutr Soc** 1999 May;58(2):377–83 (26 ref.)
Folate and vitamin B12. Scott JM. **Proc Nutr Soc** 1999 May; 58(2):441–8 (22 ref.)
Nutrition and bone health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food Nutrition Policy. **Rep Health Soc Subj (Lond)** 1998; 49:iii–xvii, 1–24 (321 ref.)
[Changes in the energy needs of the elderly: an often encountered cause of nutritional deficiencies and frailty] Van Staveren WA, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2400–4 (24 ref.) (Eng. Abstr.) **(Dut)**
[Nutritional needs in the normal adolescent] Vidailhet M. **Arch Pediatr** 1999;6 Suppl 2:149s–151s (13 ref.) **(Fre)**
[Changes in dietary management of diabetic patients] Monnier L, et al. **Diabetes Metab** 1998 Nov;24 Suppl 3:24–34 (52 ref.) (Eng. Abstr.) **(Fre)**
[Relationship between the number of daily meals and the energy and nutrient intake in the elderly. Effect on various cardiovascular risk factors] Ortega RM, et al. **Nutr Hosp** 1998 Jul-Aug;13(4):186–92 (42 ref.) (Eng. Abstr.) **(Spa)**

NUTRITIONAL STATUS

Potential interventions for the prevention of childhood pneumonia in developing countries: improving nutrition. Victora CG, et al. **Am J Clin Nutr** 1999 Sep;70(3):309–20 (99 ref.)
Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. McLeod RS. **Ann Oncol** 1999;10 Suppl 4:281–4 (21 ref.)
Assessment of nutritional status in clinical practice. Goulet O. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):647–69 (103 ref.)
Cystic fibrosis: nutritional consequences and management. Turck D, et al. **Baillieres Clin Gastroenterol** 1998 Dec; 12(4):805–22 (88 ref.)
Haemodialysis and peritoneal dialysis: metabolic alterations and nutritional status [see comments] Cano N. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):329–33 (65 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.
Nutritional support and aging in preoperative nutrition. Nourhashemi F, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):87–92 (36 ref.)
Gravity and space flight: effects on nutritional status. Smith SM, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul; 2(4):335–8 (35 ref.)
Diet & nutrition situation in rural India. Vijayaraghavan K, et al. **Indian J Med Res** 1998 Nov;108:243–53 (19 ref.)
Sensitive measures of the nutritional status of children with cancer in hospital and in the field. Brennan BM. **Int J Cancer Suppl** 1998;11:10–3 (20 ref.)
Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. Gómez-Almaguer D, et al. **Int J Cancer Suppl** 1998;11:52–5 (17 ref.)
Sensitive measures of nutritional status in children in hospital and in the field. Motil KJ. **Int J Cancer Suppl** 1998;11:2–9 (27 ref.)
Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Murry DJ, et al. **Int J Cancer Suppl** 1998;11:48–51 (32 ref.)
Nutritional and zinc status of head and neck cancer patients: an interpretive review. Prasad AS, et al. **J Am Coll Nutr** 1998 Oct;17(5):409–18 (38 ref.)
Biotin status: which are valid indicators and how do we know? Mock DM. **J Nutr** 1999 Feb;129(2S

Suppl):498S–503S (31 ref.)
Nutrition and health outcomes associated with food insecurity and hunger. Olson CM. **J Nutr** 1999 Feb;129(2S Suppl):521S–524S (14 ref.)
Influence of different treatments and schedules on the factors conditioning the nutritional status in dialysis patients. Lindholm B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:66–73 (86 ref.)
Cigarette use during adolescence: effects on nutritional status. Hampl JS, et al. **Nutr Rev** 1999 Jul;57(7):215–21 (63 ref.)
Global issues in pediatric nutrition: AIDS. Ball CS. **Nutrition** 1998 Oct;14(10):767–70 (31 ref.)
The stressful condition as a nutritionally dependent adaptive dichotomy. Ingenbleek Y, et al. **Nutrition** 1999 Apr; 15(4):305–20 (272 ref.)
Nutritional aspects of liver disease in children. Shetty AK, et al. **Nutrition** 1999 Sep;15(9):727–9 (23 ref.)
The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients [see comments] Vellas B, et al. **Nutrition** 1999 Feb;15(2):116–22 (33 ref.) Comment in: Nutrition 1999 Feb;15(2):159–61.
Resistance to growth hormone in children with chronic liver disease. Bucuvalas JC, et al. **Pediatr Transplant** 1997 Aug; 1(1):73–9 (46 ref.)
Functional indicators of iodine and selenium status. Arthur JR. **Proc Nutr Soc** 1999 May;58(2):507–12 (59 ref.)
Problems of nutritional assessment in the acute setting. Baxter JP. **Proc Nutr Soc** 1999 Feb;58(1):39–46 (73 ref.)
Vitamin C: prospective functional markers for defining optimal nutritional status. Benzie IF. **Proc Nutr Soc** 1999 May;58(2):469–76 (76 ref.)
Defining optimal body iron. Cook JD. **Proc Nutr Soc** 1999 May;58(2):489–95 (54 ref.)
Animal- and plant-food-based diets and iron status: benefits and costs. Hambraeus L. **Proc Nutr Soc** 1999 May; 58(2):235–42 (40 ref.)
Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine. Powers HJ. **Proc Nutr Soc** 1999 May;58(2):435–40 (47 ref.)
Nutrition and lung health. Sridhar MK. **Proc Nutr Soc** 1999 May;58(2):303–8 (52 ref.)
Vitamin D and prostate cancer. Blutt SE, et al. **Proc Soc Exp Biol Med** 1999 Jun;221(2):89–98 (143 ref.)
Relationships between dialysis adequacy, dietary intake and nutritional status of patients treated with continuous ambulatory peritoneal dialysis (CAPD). Grzegorzewska AE. **Przegl Lek** 1998;55 Suppl 1:41–4 (36 ref.) **(Eng, Pol)**
Nutrition and bone health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food Nutrition Policy. **Rep Health Soc Subj (Lond)** 1998; 49:iii–xvii, 1–24 (321 ref.)
Epidemiology of thyroid diseases in iodine sufficiency. Lind P, et al. **Thyroid** 1998 Dec;8(12):1179–83 (45 ref.)
Nutrition–parasite interaction. Coop RL, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):187–204 (95 ref.)
[What is adequate nutrition?] Greubel S. **Med Monatsschr Pharm** 1999 Jan;22(1):8–13 (6 ref.) **(Ger)**
[Physiological role of dietary carbohydrates in diet of hungarian population. Epidemiological study] Biro D, et al. **Vopr Pitan** 1998;(4):11–7 (21 ref.) (Eng. Abstr.) **(Rus)**
[Nutritional status of patients with HIV–AIDS infection (editorial)] López-Herce JA. **An Med Interna** 1998 Dec; 15(12):623–6 (58 ref.) **(Spa)**
[The development of reference values for the brachial perimeter and body height in comparison with other indicators used for screening of the nutritional status] Mei Z, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):187–95 (30 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Receptor-mediated signaling pathways: potential targets of modulation by dietary fatty acids. Hwang D, et al. **Am J Clin Nutr** 1999 Oct;70(4):545–56 (82 ref.)

NUTRITIONAL SUPPORT

Nutritional support during treatment of biliopancreatic malignancy. von Meyenfeldt MF. **Ann Oncol** 1999;10 Suppl 4:273–7 (82 ref.)
Glutamine supplementation in catabolic patients. Sacks GS. **Ann Pharmacother** 1999 Mar;33(3):348–54 (59 ref.)
Nutritional support in malnourished paediatric patients. Goulet O. **Baillieres Clin Gastroenterol** 1998 Dec; 12(4):843–76 (131 ref.)
Nutritional management in diarrhoeal disease. Guandalini S, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):697–717 (86 ref.)
Nutritional support of infants and children: supply and metabolism of lipids. Koletzko B, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):671–96 (93 ref.)
Nutrition in inflammatory bowel disease. Murch SH, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):719–38 (86 ref.)
Consensus Roundtable on Nutrition Support of Tube-Fed Patients with Diabetes, 28 February–1 March, 1998, Chicago, Illinois, USA. Introduction. Fürst P. **Clin Nutr** 1998 Sep;17 Suppl 2:3–6 (45 ref.)
Effect of critical illness and nutritional support on mucosal mass and function. Lara TM, et al. **Clin Nutr** 1998 Jun; 17(3):99–105 (61 ref.)
Nutrition recommendations for the person with diabetes. Muls E. **Clin Nutr** 1998 Sep;17 Suppl 2:18–25 (74 ref.)
Nutrition and lung function in the critically ill patient. Radrizzani D, et al. **Clin Nutr** 1998 Feb;17(1):7–10 (67 ref.)
Rationale for specialized nutrition support for hyperglycemic patients. Schrezenmeir J. **Clin Nutr** 1998 Sep;17 Suppl 2:26–34 (148 ref.)
The role of nutrition before and after transplantation [editorial; comment] Allard JP. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):313–4 (5 ref.) Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):315–21. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):323–7. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):329–33.
Glutamine in the support of patients following bone marrow transplantation [see comments] Wilmore DW, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):323–7 (34 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.
Gastric disorders and nutritional management. Kotler DP. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):825–40 (61 ref.)
Metabolic responses and nutritional therapy in patients with severe head injuries. Wilson RF, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):11–27 (113 ref.)
Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. Silani V, et al. **J Neurol** 1998 Aug; 245 Suppl 2:S13–9; discussion S29 (22 ref.)
Does nutritional intervention in protein-energy malnutrition improve morbidity or mortality? Koretz RL. **J Ren Nutr** 1999 Jul;9(3):119–21 (17 ref.)
Effectiveness of nutrition interventions in the management of malnourished patients treated with maintenance dialysis. Wolfson M. **J Ren Nutr** 1999 Jul;9(3):126–8 (15 ref.)
Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. Juurlink BH, et al. **J Spinal Cord Med** 1998 Oct;21(4):309–34 (285 ref.)
Nutrition support: ethical or expedient, and who will choose? Herrmann VM. **JPEN J Parenter Enteral Nutr** 1999 Jul–Aug;23(4):195–202 (53 ref.)
The effect of medical nutrition therapy on malnutrition and clinical outcomes. Gallagher-Allred CR, et al. **Nutrition** 1999 Jun;15(6):512–4 (39 ref.)
Ornithine alpha-ketoglutarate: the puzzle. Le Boucher J, et al. **Nutrition** 1998 Nov–Dec;14(11–12):870–3 (38 ref.)
Nutritional support in hepatic encephalopathy. Mizock BA. **Nutrition** 1999 Mar;15(3):220–8 (134 ref.)
Feeding the child with chronic liver disease. Protheroe SM. **Nutrition** 1998 Oct;14(10):796–800 (31 ref.)
Nutritional management of enteropathy. Walker-Smith JA. **Nutrition** 1998 Oct;14(10):775–9 (40 ref.)
Resistance to growth hormone in children with chronic liver disease. Bucuvalas JC, et al. **Pediatr Transplant** 1997 Aug; 1(1):73–9 (46 ref.)
Artificial nutritional support in patients with gastrointestinal fistulas. Dudrick SJ, et al. **World J Surg** 1999 Jun; 23(6):570–6 (29 ref.)
Postoperative protein sparing. Wilmore DW. **World J Surg** 1999 Jun;23(6):545–52 (49 ref.)
[Nutritional support. Summary of the consensus development conference. French Society for Enteral and Parenteral Nutrition] **Presse Med** 1998 Jun 20;27(22):1108–11 (0 ref.) **(Fre)**
[Advances in metabolic and nutritional management of patients in critical care] Hasebe M, et al. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):419–23 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Nutritional care of patients with respiratory insufficiency] Yoneda T, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):94–9 (10 ref.) **(Jpn)**
[Nutritional therapy] Kawamura T, et al. **Nippon Rinsho** 1998 Sep;56(9):2303–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Nutritional protocol after acute thermal injury. Vandevoort M. **Acta Chir Belg** 1999 Feb;99(1):9–16 (74 ref.)
Modality-specific nutrition support in ESRD: weighing the evidence. Chertow GM. **Am J Kidney Dis** 1999 Jan; 33(1):193–7 (20 ref.)
Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Kopple JD. **Am J Kidney Dis** 1999 Jan;33(1):180–5 (53 ref.)
Intraperitoneal nutrition. Wolfson M, et al. **Am J Kidney Dis** 1999 Jan;33(1):203–4 (10 ref.)
Cystic fibrosis: nutritional consequences and management. Turck D, et al. **Baillieres Clin Gastroenterol** 1998 Dec; 12(4):805–22 (88 ref.)
Liver cirrhosis: rationale and modalities for nutritional support—the European Society of Parenteral and Enteral Nutrition consensus and beyond. Lochs H, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):345–9 (22 ref.)
Nutritional and metabolic support strategies. Schols AM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):577–81 (32 ref.)
Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Kirschner BS. **Neth J Med** 1998 Dec;53(6):S13–8 (13 ref.)
Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127–43 (67 ref.)

STANDARDS

Nutrition and hydration: moral and pastoral reflections. National Conference of Catholic Bishops Committee for Pro-life Activities. **J Contemp Health Law Policy** 1999 Spring;15(2):455–77 (47 ref.)

VETERINARY

Interventional nutrition for the critical care patient: optimal diets. Michel KE. **Clin Tech Small Anim Pract** 1998 Nov; 13(4):204–10 (36 ref.)
Interventional nutrition for the cancer patient. Ogilvie GK. **Clin Tech Small Anim Pract** 1998 Nov;13(4):224–31 (78 ref.)
Nutritional support for dogs and cats with hepatobiliary disease. Center SA. **J Nutr** 1998 Dec;128(12 Suppl):2733S–2746S (24 ref.)

NUTRITIVE VALUE

Potential of vegetable processing to increase the delivery of carotenoids to man. van het Hof KH, et al. **Int J Vitam Nutr Res** 1998;68(6):366–70 (26 ref.)
Quantification of the "SLAMENGHI" factors for carotenoid bioavailability and bioconversion. West CE, et al. **Int J Vitam Nutr Res** 1998;68(6):371–7 (45 ref.)
The nutritional value of plant-based diets in relation to human amino acid and protein requirements. Millward DJ. **Proc Nutr Soc** 1999 May;58(2):249–60 (59 ref.)
[Effect of dietary fiber on the nutritional utilization of proteins and minerals] Ruiz-Roso B, et al. **Nutr Hosp** 1999 Jan–Feb;14(1):7–13 (37 ref.) (Eng. Abstr.) **(Spa)**

NUTS

Nut consumption, lipids, and risk of a coronary event. Fraser GE. **Clin Cardiol** 1999 Jul;22(7 Suppl):II11–5 (37 ref.)

ADVERSE EFFECTS

Allergy to pine nuts in children. Rubira N, et al. **Allerg Immunol (Paris)** 1998 Sep;30(7):212–6 (21 ref.)

CHEMISTRY

Nuts and their bioactive constituents: effects on serum lipids and other factors that affect disease risk. Kris-Etherton PM, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):504S–511S (44 ref.)

THERAPEUTIC USE

Nut consumption, vegetarian diets, ischemic heart disease risk, and all-cause mortality: evidence from epidemiologic studies. Sabaté J. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):500S–503S (30 ref.)

NYCTALOPIA see **NIGHT BLINDNESS**

NYCTEREUTES see **CARNIVORA**

NYCTIPHANES see **CRUSTACEA**

NYCTOHEMERAL RHYTHM see **CIRCADIAN RHYTHM**

NYCTURIA see **URINATION DISORDERS**

NYLONS

ADVERSE EFFECTS

Nylon flock-associated interstitial lung disease. Eschenbacher WL, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):2003–8 (9 ref.)

NYSTAGMUS

see related
ELECTRONYSTAGMOGRAPHY

DIAGNOSIS

Diagnostic criteria for central versus peripheral positioning nystagmus and vertigo: a review. Büttner U, et al. **Acta Otolaryngol (Stockh)** 1999 Jan;119(1):1–5 (27 ref.)
[Paranystagmic ocular dyskinesias] Zolog I. **Oftalmologia** 1998;44(3):29–31 (10 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Drug therapy of nystagmus and saccadic intrusions. Büttner U, et al. **Adv Otorhinolaryngol** 1999;55:195–227 (165 ref.)

ETIOLOGY

[Bickerstaff's brainstem encephalitis associated with nystagmus] Odaka M, et al. **Rinsho Shinkeigaku** 1998 Apr; 38(4):319–22 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Nonpharmacological treatment of nystagmus. Leigh RJ. **Adv Otorhinolaryngol** 1999;55:228–40 (47 ref.)

NYSTAGMUS, BARANY see **NYSTAGMUS,**

PHYSIOLOGIC

NYSTAGMUS, CALORIC see **NYSTAGMUS, PHYSIOLOGIC**

NYSTAGMUS, END-POSITION see **NYSTAGMUS, PHYSIOLOGIC**

NYSTAGMUS, OPTOKINETIC

PHYSIOLOGY

Nonlinear dynamic systems evaluation of rhythmic' eye movements (optokinetic nystagmus). Shelhamer M. **J Neurosci Methods** 1998 Aug 31;83(1):45–56 (41 ref.)

NYSTAGMUS, PHYSIOLOGIC

see related
ELECTRONYSTAGMOGRAPHY

PHYSIOLOGY

Pathomechanism of mammalian downbeat nystagmus due to cerebellar lesion: a simple hypothesis. Böhmer A, et al. **Neurosci Lett** 1998 Jul 3;250(2):127–30 (16 ref.)

NYSTAGMUS, POSITIONAL see **NYSTAGMUS, PHYSIOLOGIC**

NYSTAGMUS, POST-ROTATORY see **NYSTAGMUS, PHYSIOLOGIC**

NYSTAGMUS, THERMAL see **NYSTAGMUS, PHYSIOLOGIC**

NYSTATIN

THERAPEUTIC USE

A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis. Alvarez Alvarez ME, et al. **Rev Esp Quimioter** 1998 Dec;11(4):295–315 (281 ref.)

O ANTIGENS

IMMUNOLOGY

[Common antigenicity of lipopolysaccharides between Rickettsiae and Proteus in the Weil-Felix test] Amano K. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):599–610 (43 ref.) **(Jpn)**

O-SPECIFIC POLYSACCHARIDES see **O ANTIGENS**

OATS

CHEMISTRY

Effect of beta-glucan from oats and yeast on serum lipids. Bell S, et al. **Crit Rev Food Sci Nutr** 1999 Mar;39(2):189–202 (33 ref.)

OBESE MICE see **MICE, OBESE**

OBESITY

see related
ANTI-OBESITY AGENTS
APPETITE DEPRESSANTS
DIET, REDUCING
LIPECTOMY

Evaluation and treatment of childhood obesity [see comments] Moran R. **Am Fam Physician** 1999 Feb 15; 59(4):861–8, 871–3 (35 ref.) Comment in: Am Fam Physician 1999 Feb 15;59(4):758, 761–2.

Workshop on childhood obesity: summary of the discussion. Bellizzi MC, et al. **Am J Clin Nutr** 1999 Jul;70(1):173S–5S (8 ref.)

Tracking of body mass index in children in relation to overweight in adulthood. Guo SS, et al. **Am J Clin Nutr** 1999 Jul;70(1):145S–8S (30 ref.)

Understanding ethnic differences in energy balance: can we get there from here? [editorial; comment] Kumanyika SK. **Am J Clin Nutr** 1999 Jul;70(1):1–2 (10 ref.) Comment on: Am J Clin Nutr 1999 Jul;70(1):13–20.

Fibrinogen, obesity and insulin resistance. Juhan-Vague I, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S25–8 (36 ref.)

Magic bullet for obesity. Hirsch J. **BMJ** 1998 Oct 24; 317(7166):1136–8 (8 ref.)

Childhood obesity. Strauss R. **Curr Probl Pediatr** 1999 Jan; 29(1):1–29 (251 ref.)

Obesity, diabetes and the central nervous system. Porte D Jr, et al. **Diabetologia** 1998 Aug;41(8):863–81 (233 ref.)

Is there a role for leptin in human reproduction? Macut D, et al. **Gynecol Endocrinol** 1998 Oct;12(5):321–6 (58 ref.)

The weight dilemma: a range of philosophical perspectives. Neumark-Sztainer D. **Int J Obes Relat Metab Disord** 1999 Mar;23 Suppl 2:S31–7 (53 ref.)

The dietitian's role in developing and implementing the first federal obesity guidelines [published erratum appears in J Am Diet Assoc 1998 Dec;98(12):1902] Van Horn L, et al. **J Am Diet Assoc** 1998 Oct;98(10):1115–7 (31 ref.)

Childhood obesity: addressing the issue. Rudloff LM, et al. **J Am Osteopath Assoc** 1999 Apr;99(4 Suppl):S1–6 (25 ref.)

Advances in the understanding and treatment of obesity. Still CD. **J Am Osteopath Assoc** 1999 Apr;99(4 Suppl):S7–11 (28 ref.)

New understanding in obesity research. James WP, et al. **Proc Nutr Soc** 1999 May;58(2):385–93 (77 ref.)

The Nutrition Society Medical Lecture. Obesity: from molecules to man. Jebb SA. **Proc Nutr Soc** 1999 Feb; 58(1):1–14 (145 ref.)

Obesity--an overview. Anate M, et al. **West Afr J Med** 1998 Oct-Dec;17(4):248–54 (29 ref.)

BLOOD

Physical activity, obesity and blood lipids. Hardman AE. **Int J Obes Relat Metab Disord** 1999 Apr;23 Suppl 3:S64–71 (84 ref.)

CHEMICALLY INDUCED

Prescription medications: a modifiable contributor to obesity. Cheskin LJ, et al. **South Med J** 1999 Sep;92(9):898–904 (44 ref.)

COMPLICATIONS

Medical aspects of obesity. Scheen AJ, et al. **Acta Chir Belg** 1999 May-Jun;99(3):135–9 (42 ref.)

Obesity as a risk factor for cardiovascular disease. Abate N. **Am J Med** 1999 Aug 23;107(2A):12S–13S (13 ref.)

The role of hypertension, obesity, and diabetes in causing renal vascular disease. Crook ED. **Am J Med Sci** 1999 Mar;317(3):183–8 (36 ref.)

The role of obesity and diet in urological carcinogenesis. Mydlo JH, et al. **BJU Int** 1999 Aug;84(3):225–34 (99 ref.)

A review of cost-of-illness studies on obesity. Kortt MA, et al. **Clin Ther** 1998 Jul-Aug;20(4):772–9 (20 ref.)

Obesity as a factor in penetrating keratoplasty. Johansen TR, et al. **Cornea** 1999 Jan;18(1):12–8 (10 ref.)

Dyslipidemia of central obesity and insulin resistance. Brunzell JD, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C10–3 (69 ref.)

Obesity and other risk factors in children. Falkner B, et al. **Ethn Dis** 1999 Spring-Summer;9(2):284–9 (20 ref.)

Weight, weight gain and coronary heart disease mortality [editorial; comment] Gunnell DJ, et al. **Eur Heart J** 1999 Feb;20(4):246–8 (6 ref.) Comment on: Eur Heart J 1999 Feb;20(4):269–77.

Energy balance and cancers. Gerber M, et al. **Eur J Cancer Prev** 1999 Apr;8(2):77–89 (144 ref.)

Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. Serrano Rios M. **Eur J Clin Invest** 1998 Sep;28 Suppl 2:14–7, discussion 17–8 (24 ref.)

Western nutrition and the insulin resistance syndrome: a link to breast cancer. Stoll BA. **Eur J Clin Nutr** 1999 Feb; 53(2):83–7 (52 ref.)

Risks and consequences of childhood and adolescent obesity. Must A, et al. **Int J Obes Relat Metab Disord** 1999 Mar; 23 Suppl 2:S2–11 (107 ref.)

Teenage obesity in relation to breast cancer risk. Stoll BA. **Int J Obes Relat Metab Disord** 1998 Nov;22(11):1035–40 (94 ref.)

Obesity and obstructive sleep apnea syndrome. Chin K, et al. **Intern Med** 1999 Feb;38(2):200–2 (20 ref.)

Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Funahashi T, et al. **Intern Med** 1999 Feb;38(2):202–6 (14 ref.)

How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome? Cortet-Rudelli C, et al. **J Endocrinol Invest** 1998 Oct;21(9):636–40 (38 ref.)

The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. Dessi-Fulgheri P, et al. **J Nephrol** 1998 Nov-Dec; 11(6):296–9 (11 ref.)

Obesity as a risk factor for certain types of cancer. Carroll KK. **Lipids** 1998 Nov;33(11):1055–9 (83 ref.)

Modalities of ventilation in obesity. Muir JF, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):556–9 (21 ref.)

High maternal body weight and pregnancy outcome. de Groot LC. **Nutr Rev** 1999 Feb;57(2):62–4 (15 ref.)

Waist circumference: a useful index in clinical care and health promotion. Vanltallie TB. **Nutr Rev** 1998 Oct;56(10):300–2 (12 ref.)

Use of preventive health care services by patients with obesity. Zayat EN, et al. **Obes Res** 1999 Mar;7(2):223–6 (22 ref.)

Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253–62 (34 ref.)

Obesity and hypertension. Mikhail N, et al. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):39–58 (152 ref.)

Obesity and reproductive disorders: a review. Norman RJ, et al. **Reprod Fertil Dev** 1998;10(1):55–63 (62 ref.)

"Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Wilcox I, et al. **Thorax** 1998 Oct; 53 Suppl 3:S25–8 (40 ref.)

[Pharma clinics. How I treat...a diabetic patient with severe obesity] Scheen AJ, et al. **Rev Med Liege** 1998 Jul; 53(7):386–9 (26 ref.) (Eng. Abstr.) **(Fre)**

[Cardiovascular sequelae and risks of obesity] Silberbauer K. **Acta Med Austriaca** 1998;25(4–5):133–5 (7 ref.) (Eng. Abstr.) **(Ger)**

[Overweight as a risk factor for cardiovascular diseases and its possible significance as a promotor of an increased inflammatory reaction] Halle M, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):905–9 (50 ref.) **(Ger)**

[Obesity: entrance port to multimorbidity] Sailer D. **Wien Med Wochenschr** 1998;148(17):388–92 (44 ref.) (Eng. Abstr.) **(Ger)**

[Lipid metabolic disorders in obesity: their epidemiology, physiopathology and clinico-therapeutic implications] Campanini M, et al. **Ann Ital Med Int** 1997 Oct-Dec; 12(4):223–9 (42 ref.) (Eng. Abstr.) **(Ita)**

[Tophaceous gout in plurimetabolic syndrome] Iannello S, et al. **Minerva Med** 1998 Nov-Dec;89(11-12):419–37 (168 ref.) (Eng. Abstr.) **(Ita)**

[Obesity and diseases. 2. Obesity and obstructive sleep apnea syndrome] Chin K, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1793–6 (18 ref.) **(Jpn)**

[Obesity and diseases. 4. Molecular mechanism involved in the onset of arteriosclerosis in obesity] Funahashi T, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1802–5 (5 ref.) **(Jpn)**

[Circulatory system in obese patients] Przywara B, et al. **Wiad Lek** 1998;51(5–6):277–83 (21 ref.) (Eng. Abstr.) **(Pol)**

[Obesity and arterial hypertension] Casasnovas Lenguas JA, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:15–8 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Introduction: the use of body mass index to assess obesity in children. Dietz WH, et al. **Am J Clin Nutr** 1999 Jul; 70(1):123S–5S (14 ref.)

Treating the obese patient. Suggestions for primary care practice. Anderson DA, et al. **Arch Fam Med** 1999 Mar-Apr;8(2):156–67 (98 ref.)

Newer aspects of the pathophysiology, evaluation, and management of obesity in childhood. Diamond FB Jr. **Curr Opin Pediatr** 1998 Aug;10(4):422–7 (49 ref.)

Endocrine and metabolism [editorial] Root A. **Curr Opin Pediatr** 1998 Aug;10(4):411–5 (18 ref.)

Adolescent obesity, a need for greater awareness and improved treatment. Trent ME, et al. **Curr Opin Pediatr** 1999 Aug;11(4):297–302 (55 ref.)

[How I evaluate ... a overweight or obese patient] Scheen AJ, et al. **Rev Med Liege** 1999 Jun;54(6):553–6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Reliable diagnosis of obesity] Wechsler JG. **Wien Med Wochenschr** 1998;148(17):393–6 (7 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

Role of genetic factors in childhood obesity and in susceptibility to dietary variations. Pérusse L, et al. **Ann Med** 1999 Apr;31 Suppl 1:19–25 (44 ref.)

Popular weight loss diets. Health and exercise implications. Riley RE. **Clin Sports Med** 1999 Jul;18(3):691–701, ix (9 ref.)

Obesity and low-fat diets in pediatrics. Rauh-Pfeiffer A, et al. **Curr Opin Pediatr** 1998 Jun;10(3):329–35 (50 ref.)

Diet, exercise and behavioural intervention: the nonpharmacological approach. Brownell KD. **Eur J Clin Invest** 1998 Sep;28 Suppl 2:19–21; discussion 22 (12 ref.)

Weight loss education: the challenge of a new paradigm. Gast J, et al. **Health Educ Behav** 1998 Aug;25(4):464–73 (43 ref.)

A model for chronic care of obesity through dietary treatment. Nonas CA. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S16–22 (39 ref.)

Issues and principles in dietary management. D'Angelo DW. **J Am Osteopath Assoc** 1999 Apr;99(4 Suppl):S12–4 (17 ref.)

How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome? Cortet-Rudelli C, et al. **J Endocrinol Invest** 1998 Oct;21(9):636–40 (38 ref.)

How effective are traditional dietary and exercise interventions for weight loss? Miller WC. **Med Sci Sports Exerc** 1999 Aug;31(8):1129–34 (68 ref.)

[Weight loss by changing eating behavior: the target goal in therapy of obesity] Pudel V. **Wien Med Wochenschr** 1998;148(17):397–9, 400 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Serious adverse reactions to anorectic agents. Thomas SH. **Adverse Drug React Toxicol Rev** 1998 Nov;17(4):209–25 (106 ref.)

Review article: malnutrition and maltreatment--a comment on orlistat for the treatment of obesity. Cahill A, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):997–1002 (27 ref.)

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Luque CA, et al. **Ann Pharmacother** 1999 Sep;33(9):968–78 (72 ref.)

Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Hansson L. **Blood Press** 1998;Suppl 3:20–2 (19 ref.)

New aspects in the management of obesity: operation and the impact of lipase inhibitors. Uusitupa M. **Curr Opin Lipidol** 1999 Feb;10(1):3–7 (25 ref.)

A risk-benefit assessment of anti-obesity drugs. Kolanowski J. **Drug Saf** 1999 Feb;20(2):119–31 (65 ref.)

Current concepts in the pharmacological management of

obesity. Carek PJ, et al. **Drugs** 1999 Jun;57(6):883–904 (125 ref.)
Sibutramine. A review of its contribution to the management of obesity. McNeely W, et al. **Drugs** 1998 Dec; 56(6):1093–124 (105 ref.)
Pharmacological intervention: the antiobesity approach. Rissanen A. **Eur J Clin Invest** 1998 Sep;28 Suppl 2:27–30 (25 ref.)
New approaches in the pharmacological treatment of obesity. Leonhardt M, et al. **Eur J Nutr** 1999 Feb;38(1):1–13 (168 ref.)
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Astrup A, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:29–34 (42 ref.)
Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Van Gaal LF, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:35–40 (22 ref.)
Pharmacological treatment of obesity: present status. Scheen AJ, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:47–53 (57 ref.)
Modern medical management of obesity: the role of pharmaceutical intervention. Aronne LJ. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S23–6 (14 ref.)
Pharmacological treatment of obesity: therapeutic strategies. Kordik CP, et al. **J Med Chem** 1999 Jan 28;42(2):181–201 (239 ref.)
Cutting fat absorption to halt weight gain. Lean M. **Practitioner** 1998 Dec;242(1593):860–5 (5 ref.)
Key developments in endocrinology. Weston PJ. **Practitioner** 1999 Feb;243(1595):83–4, 89–96 (7 ref.)
[Orlistat (Xenical)] Crenier L, et al. **Rev Med Brux** 1999 Jun; 20(3):159–63 (17 ref.) (Eng. Abstr.) **(Fre)**
[Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure] Astrup A. **Acta Med Austriaca** 1998;25(4–5):146–9 (9 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy of obesity] Wechsler JG. **Acta Med Austriaca** 1998;25(4–5):138–41 (12 ref.) (Eng. Abstr.) **(Ger)**
[Is orlistat medically essential for the treatment of obesity?] Fritze J. **Versicherungsmedizin** 1999 Mar 1;51(1):36–7 (15 ref.) (Eng. Abstr.) **(Ger)**
[What is the role of drugs in therapy of obesity?] Schusdziarra V. **Wien Med Wochenschr** 1998;148(17):401–2 (23 ref.) (Eng. Abstr.) **(Ger)**
[The principle of precaution and the drug treatment of obese subjects] C-Soriguer FJ, et al. **Med Clin (Barc)** 1999 Apr 17;112(13):503–7 (43 ref.) **(Spa)**

ECONOMICS

A review of cost-of-illness studies on obesity. Kortt MA, et al. **Clin Ther** 1998 Jul–Aug;20(4):772–9 (20 ref.)
Call for action: preventing and managing the expansive and expensive obesity epidemic [editorial; comment] [see comments] Lau DC. **CMAJ** 1999 Feb 23;160(4):503–6 (43 ref.) Comment on: CMAJ 1999 Feb 23;160(4):483–8. Comment on: CMAJ 1999 Feb 23;160(4):513–25. Comment in: CMAJ 1999 Jun 29;160(13):1821.
Societal and personal costs of obesity. Seidell JC. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:7–9 (15 ref.)
Burden of illness review of obesity: are the true costs realised? McIntyre AM. **J R Soc Health** 1998 Apr;118(2):76–84 (48 ref.)

ENZYMOLOGY

Effects of obesity on the cytochrome P450 enzyme system. Kotlyar M, et al. **Int J Clin Pharmacol Ther** 1999 Jan; 37(1):8–19 (55 ref.)

EPIDEMIOLOGY

Obesity: a growing problem. Seidell JC. **Acta Paediatr Suppl** 1999 Feb;88(428):46–50 (26 ref.)
Obesity: a major global public health problem. Khan LK, et al. **Annu Rev Nutr** 1999;19:xiii–xvii (29 ref.)
Obesity and aging. Kotz CM, et al. **Clin Geriatr Med** 1999 May;15(2):391–412 (104 ref.)
Abdominal obesity and associated cardiovascular comorbidities in the elderly. Kohrt WM. **Coron Artery Dis** 1998;9(8):489–94 (47 ref.)
Development of the multiple metabolic syndrome: an epidemiologic perspective. Liese AD, et al. **Epidemiol Rev** 1998;20(2):157–72 (209 ref.)
Obesity is a health problem. Laitinen J. **Int J Circumpolar Health** 1998 Jul;57(2–3):104–8 (45 ref.)
How physically active are American children and what can we do about it? Luepker RV. **Int J Obes Relat Metab Disord** 1999 Mar;23 Suppl 2:S12–7 (20 ref.)
Risks and consequences of childhood and adolescent obesity. Must A, et al. **Int J Obes Relat Metab Disord** 1999 Mar; 23 Suppl 2:S2–11 (107 ref.)
Overweight prevalence among youth in the United States: why so many different numbers? Troiano RP, et al. **Int J Obes Relat Metab Disord** 1999 Mar;23 Suppl 2:S22–7 (51 ref.)
Supplement. Obesity, hypertension, insulin resistance and lipid disorders: cross-sectional and longitudinal studies in Japanese adolescents and middle-aged men. Hirose H, et al. **Intern Med** 1999 Feb;38(2):198–200 (17 ref.)
Epidemiology of obesity: an epidemiological study in rural communities of Hokkaido, Japan. Saitoh S, et al. **Intern Med** 1999 Feb;38(2):195–7 (3 ref.)
Obesity in older persons. Jensen GL, et al. **J Am Diet Assoc** 1998 Nov;98(11):1308–11 (44 ref.)
Obesity and cultural environment in the Yucatan region. Arroyo P, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S78–82; discussion S83 (25 ref.)
The Pima Indians in Sonora, Mexico. Valencia ME, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S55–7; discussion S57–8 (15 ref.)
Is the prevalence of successful weight loss and maintenance higher in the general community than the research clinic? Bartlett SJ, et al. **Obes Res** 1999 Jul;7(4):407–13 (45 ref.)

ETHNOLOGY

Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S–759S (37 ref.)
The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S–754S (78 ref.)
What is the role of obesity in hypertension and target organ injury in African Americans? Jones DW. **Am J Med Sci** 1999 Mar;317(3):147–51 (17 ref.)

ETIOLOGY

Dietary fat intake does affect obesity! [see comments] Bray GA, et al. **Am J Clin Nutr** 1998 Dec;68(6):1157–73 (86 ref.) Comment in: Am J Clin Nutr 1998 Dec;68(6):1149–50.
Human obesity: a sufficient cause. Hirsch J. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):101–4 (10 ref.)
Central control of feeding behavior by neuropeptide Y. Zimanyi IA, et al. **Curr Pharm Des** 1998 Aug;4(4):349–66 (196 ref.)
Guidelines for sugar consumption in Europe: is a quantitative approach justified? Ruxton CH, et al. **Eur J Clin Nutr** 1999 Jul;53(7):503–13 (55 ref.)
Metabolic predictors of weight gain. Ravussin E, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:37–41 (44 ref.)
Childhood obesity [see comments] Holtz C, et al. **J Am Osteopath Assoc** 1999 Jul;99(7):366–71 (33 ref.) Comment in: J Am Osteopath Assoc 1999 Jul;99(7):357.
Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. Sawchenko PE. **J Comp Neurol** 1998 Dec 28;402(4):435–41 (70 ref.)
The influence of sex hormones on obesity across the female life span. Lovejoy JC. **J Womens Health** 1998 Dec; 7(10):1247–56 (53 ref.)
The Mexico City Diabetes Study: a population-based approach to the study of genetic and environmental interactions in the pathogenesis of obesity and diabetes. Gonzalez C, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S71–6; discussion S76–7 (21 ref.)
Genotype–environment interaction in human obesity. Pérusse L, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S31–7; discussion S37–8 (41 ref.)
From malnutrition to obesity: changes in nutritional status associated with liver transplantation [editorial; comment] Hasse J. **Nutrition** 1999 Jun;15(6):507–8 (6 ref.) Comment on: Nutrition 1999 Jun;15(6):504–5.
Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127–43 (67 ref.)
Childhood leukaemia: a model of pre-obesity. Ventham JC, et al. **Proc Nutr Soc** 1999 May;58(2):277–81 (45 ref.)
Obesity: genes, glands or gluttony? Chisholm DJ, et al. **Reprod Fertil Dev** 1998;10(1):49–53 (43 ref.)
[Fats in a fat time] Heitmann BL, et al. **Ugeskr Laeger** 1998 Dec 21;160(52):7601–5 (39 ref.) **(Dan)**
[11 beta-hydroxysteroid-dehydrogenase: characteristics and the clinical significance of a key enzyme in cortisol metabolism] Kerstens MN, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):509–14 (47 ref.) (Eng. Abstr.) **(Dut)**
[What role do physical activity and sedentary life style play in development and maintenance of excess pounds in the child? (editorial)] Maffeis C, et al. **Arch Pediatr** 1998 Nov; 5(11):1191–6 (66 ref.) **(Fre)**
[Juvenile obesity: the pathogenetic aspects and therapeutic outlook] Catassi C. **Recenti Prog Med** 1999 Apr; 90(4):196–201 (38 ref.) **(Ita)**
[Beta 3 adrenergic receptor polymorphism and obesity] Yoshida T, et al. **Nippon Rinsho** 1998 Jul;56(7):1871–5 (20 ref.) (Eng. Abstr.) **(Jpn)**
[New etiopathogenic aspects of obesity] Orozco P. **Aten Primaria** 1998 Nov 15;22(8):527–32 (23 ref.) **(Spa)**

GENETICS

Leptin and the genetics of obesity. Clément K. **Acta Paediatr Suppl** 1999 Feb;88(428):51–7 (49 ref.)
Role of genetic factors in childhood obesity and in susceptibility to dietary variations. Pérusse L, et al. **Ann Med** 1999 Apr;31 Suppl 1:19–25 (44 ref.)
Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Heisler LK, et al. **Ann N Y Acad Sci** 1998 Dec 15; 861:74–8 (30 ref.)
Animal models of obesity & their usefulness in molecular approach to obesity. Giridharan NV. **Indian J Med Res** 1998 Nov;108:225–42 (119 ref.)
Association between beta3-adrenoreceptor polymorphism with obesity and diabetes in Japan. Yoshida T, et al. **Intern Med** 1999 Feb;38(2):207–9 (21 ref.)
Genetic models for non insulin dependent diabetes mellitus in rodents. Kim JH, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):325–45 (62 ref.)
Adrenoceptor genes in human obesity. Arner P, et al. **J Intern Med** 1999 Jun;245(6):667–72 (49 ref.)
Genetics of human obesity: lessons from mouse models and candidate genes. Echwald SM. **J Intern Med** 1999 Jun; 245(6):653–66 (132 ref.)
Genes involved in animal models of obesity and anorexia. Schalling M, et al. **J Intern Med** 1999 Jun;245(6):613–9 (49 ref.)
A genetic mutation in PPAR gamma is associated with enhanced fat cell differentiation: implications for human obesity. Freake HC. **Nutr Rev** 1999 May;57(5 Pt 1):154–6 (12 ref.)
The Mexico City Diabetes Study: a population-based approach to the study of genetic and environmental interactions in the pathogenesis of obesity and diabetes. Gonzalez C, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S71–6; discussion S76–7 (21 ref.)
Genotype–environment interaction in human obesity. Pérusse L, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S31–7; discussion S37–8 (41 ref.)
The human obesity gene map: the 1998 update. Pérusse L, et al. **Obes Res** 1999 Jan;7(1):111–29 (136 ref.)
The genetics of complex traits: from diabetes mellitus to obesity. Froguel P. **Pathol Biol (Paris)** 1998 Nov; 46(9):713–4 (0 ref.) **(Eng, Fre)**
Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Neel JV, et al. **Perspect Biol Med** 1998 Autumn;42(1):44–74 (167 ref.)
ob gene mutations and human obesity. Farooqi S, et al. **Proc Nutr Soc** 1998 Aug;57(3):471–5 (26 ref.)
[New knowledge about obesity—news for obese patients?] Geyer G. **Acta Med Austriaca** 1998;25(4–5):117–25 (63 ref.) (Eng. Abstr.) **(Ger)**
[Evaluating genetics and environment in development of obesity] Lechleitner M, et al. **Acta Med Austriaca** 1998; 25(4–5):129–30 (6 ref.) (Eng. Abstr.) **(Ger)**
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin)] Ogawa Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1811–6 (16 ref.) **(Jpn)**
[Obesity and diseases. 5. Molecular mechanism involved in the onset of obesity and overview of its treatment] Yoshida T, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1806–10 (25 ref.) **(Jpn)**

METABOLISM

Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Levin BE, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1223–31 (114 ref.)
Functional food science and substrate metabolism. Saris WH, et al. **Br J Nutr** 1998 Aug;80 Suppl 1:S47–75 (182 ref.)
Leptin: physiology and pathophysiology. Frühbeck G, et al. **Clin Physiol** 1998 Sep;18(5):399–419 (155 ref.)
Glucocorticoids and insulin resistance: old hormones, new targets. Andrews RC, et al. **Clin Sci (Colch)** 1999 May; 96(5):513–23 (102 ref.)
The effect of under- and overnutrition on essential fatty acid metabolism in childhood. Decsi T, et al. **Eur J Clin Nutr** 1998 Aug;52(8):541–8 (54 ref.)
Tumour necrosis factor, a key role in obesity? Bulló-Bonet M, et al. **FEBS Lett** 1999 May 28;451(3):215–9 (72 ref.)
Catecholamine-induced lipolysis in obesity. Arner P. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:10–3 (18 ref.)
Effects of dietary deprivation, obesity and exercise on UCP3 mRNA levels. Giacobino JP. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S60–3 (20 ref.)
The regulation of obese (ob) gene expression by intracellular fatty acid concentration in adipocytes. Kawakami Y, et al. **Intern Med** 1999 Feb;38(2):213–5 (6 ref.)
Clinical implication of leptin, the obese gene product. Ogawa Y, et al. **Intern Med** 1999 Feb;38(2):210–2 (15 ref.)
Impact of diseases on detoxication. Blouin RA, et al. **J Biochem Mol Toxicol** 1999;13(3–4):215–8 (27 ref.)
The role of TNFalpha and TNF receptors in obesity and insulin resistance. Hotamisligil GS. **J Intern Med** 1999 Jun; 245(6):621–5 (37 ref.)
Genetically engineered mice in drug development. Livingston JN. **J Intern Med** 1999 Jun;245(6):627–35 (37 ref.)
Leptin and its potential role in human obesity. Lönnqvist F, et al. **J Intern Med** 1999 Jun;245(6):643–52 (66 ref.)
Pharmacokinetic considerations in obesity. Blouin RA, et al. **J Pharm Sci** 1999 Jan;88(1):1–7 (95 ref.)
From insulin receptor signalling to Glut 4 translocation abnormalities in obesity and insulin resistance. Le Marchand-Brustel Y, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):217–28 (41 ref.)
Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Zemel MB. **Mol Cell Biochem** 1998 Nov;

188(1-2):129-36 (69 ref.)
Insulin resistance in obesity: metabolic mechanisms and measurement methods. Belfiore F, et al. **Mol Genet Metab** 1998 Oct;65(2):121-8 (32 ref.)
Human uncoupling proteins and obesity. Schrauwen P, et al. **Obes Res** 1999 Jan;7(1):97-105 (51 ref.)
[The auto- and endocrine function of the adipose tissue. Significance for metabolic complications in obesity] Richelsen B, et al. **Ugeskr Laeger** 1998 Dec 7; 160(50):7246-50 (28 ref.) (Eng. Abstr.) **(Dan)**
[Hexose transporters in humans: their role in insulin sensitivity of peripheral tissues] Bastard JP, et al. **Rev Med Interne** 1998 Feb;19(2):108-18 (67 ref.) (Eng. Abstr.) **(Fre)**
[The significance of leptin for the pathogenesis of diabetes mellitus type 2. Direct effects on endocrine pancreas] Seufert J. **Internist (Berl)** 1999 Aug;40(8):894-7 (00 ref.) **(Ger)**
[Obesity and diseases. 3. Obesity and molecular structure of insulin resistance] Kadowaki T, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1797-801 (5 ref.) **(Jpn)**
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin). Additional report: Physiological regulation of ob gene expression] Kawakami Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1817-20 (12 ref.) **(Jpn)**
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin)] Ogawa Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1811-6 (16 ref.) **(Jpn)**
[Adipocyte--endocrine organ?] Karnafel W. **Pol Arch Med Wewn** 1998 Aug;100(2):173-9 (62 ref.) **(Pol)**
[Nutrition, energy balance, and obesity] Frühbeck G, et al. **Rev Med Univ Navarra** 1997 Jul-Sep;41(3):185-92 (78 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

What is the role of obesity in hypertension and target organ injury in African Americans? Jones DW. **Am J Med Sci** 1999 Mar;317(3):147-51 (17 ref.)
Rodent mutant models of obesity and their correlations to human obesity. Augustine KA, et al. **Anat Rec** 1999 Apr 15;257(2):64-72 (31 ref.)
The role of leptin in human obesity and disease: a review of current evidence. Mantzoros CS. **Ann Intern Med** 1999 Apr 20;130(8):671-80 (160 ref.)
Androgens and abdominal obesity. Mårin P, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):441-51 (64 ref.)
Abdominal obesity and cardiovascular risk in children. Goran MI, et al. **Coron Artery Dis** 1998;9(8):483-7 (35 ref.)
Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Lamarche B. **Coron Artery Dis** 1998;9(8):473-81 (58 ref.)
Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Large V, et al. **Diabetes Metab** 1998 Nov;24(5):409-18 (91 ref.)
Nutritional regulation of leptin in humans. Coleman RA, et al. **Diabetologia** 1999 Jun;42(6):639-46 (80 ref.)
What are the benefits of moderate weight loss? de Leiva A. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:10-3 (18 ref.)
What are the health risks? The medical consequences of obesity and its health risks. James WP. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:1-6 (17 ref.)
Leptin in human reproduction. Messinis IE, et al. **Hum Reprod Update** 1999 Jan-Feb;5(1):52-63 (111 ref.)
State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Mark AL, et al. **Hypertension** 1999 Jan;33(1 Pt 2):537-41 (40 ref.)
Leptin resistance in obese humans: does it exist and what does it mean? Arch JR, et al. **Int J Obes Relat Metab Disord** 1998 Dec;22(12):1159-63 (42 ref.)
Obesity and hypertension: from pathophysiology to treatment. Kolanowski J. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:42-6 (38 ref.)
Mitochondria uncoupling proteins and obesity: molecular and genetic aspects of UCP1. Kozak LP, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S33-7 (29 ref.)
Growth hormone in obesity. Scacchi M, et al. **Int J Obes Relat Metab Disord** 1999 Mar;23(3):260-71 (150 ref.)
Obesity and increased contractile activity influence the protein content of UCP2 in human skeletal muscle. Simoneau JA, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S68-71 (28 ref.)
Exercise training and substrate utilisation in obesity. van Baak MA. **Int J Obes Relat Metab Disord** 1999 Apr;23 Suppl 3:S11-7 (87 ref.)
Clinical endocrinology of human leptin. Van Gaal LF, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:29-36 (55 ref.)
Is the hypothalamic-pituitary-adrenal axis really hyperactivated in visceral obesity? [comment] Kopelman PG. **J Endocrinol Invest** 1999 Jan;22(1):76-9 (17 ref.) Comment on: J Endocrinol Invest 1998 Apr;21(4):268-71.
Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. McCarty MF. **Med Hypotheses** 1999 May;52(5):465-77 (229 ref.)
Mechanical ventilatory constraints in aging, lung disease, and obesity: perspectives and brief review. Babb TG. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S12-22 (44 ref.)
What do we most need to learn about food intake regulation? Flatt JP. **Obes Res** 1998 Jul;6(4):307-10 (40 ref.)
Neuropeptides, the hypothalamus and obesity: insights into the central control of body weight. Thorburn AW, et al. **Pathology** 1998 Aug;30(3):229-36 (109 ref.)
Exercise testing of the child with obesity. Owens S, et al. **Pediatr Cardiol** 1999 Jan-Feb;20(1):79-83; discussion 84 (33 ref.)
Regulation of body weight in humans. Jéquier E, et al. **Physiol Rev** 1999 Apr;79(2):451-80 (286 ref.)
Human and clinical perspectives on leptin. Blum WF, et al. **Proc Nutr Soc** 1998 Aug;57(3):477-85 (78 ref.)
Eating habits and appetite control: a psychobiological perspective. Rogers PJ. **Proc Nutr Soc** 1999 Feb; 58(1):59-67 (84 ref.)
The MONA LISA hypothesis in the time of leptin. Bray GA, et al. **Recent Prog Horm Res** 1998;53:95-117; discussion 117-8 (122 ref.)
[From Claude Bernard to the regulatory system between the hypothalamus and the periphery: implications for homeostasis of body weight and obesity] Jeanrenaud B, et al. **C R Seances Soc Biol Fil** 1998;192(5):829-41 (48 ref.) (Eng. Abstr.) **(Fre)**
[Effect of fat distribution on risk] Toplak H. **Acta Med Austriaca** 1998;25(4-5):131-2 (4 ref.) (Eng. Abstr.) **(Ger)**
[Obesity and leptin] Hauner H. **Dtsch Med Wochenschr** 1998 Oct 30;123(44):1315-6 (7 ref.) **(Ger)**
[Leptin--new knowledge on the pathogenesis of obesity] Spitzweg C, et al. **Med Klin** 1998 Aug 15;93(8):478-85 (106 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Neuroendocrine regulation of food intake. Seeley RJ, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):58-61 (37 ref.)
Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S-759S (37 ref.)
The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S-754S (78 ref.)
Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care [see comments] Douketis JD, et al. **CMAJ** 1999 Feb 23;160(4):513-25 (128 ref.) Comment in: CMAJ 1999 Feb 23;160(4):503-6. Comment in: CMAJ 1999 Jun 29;160(13):1820-1. Comment in: CMAJ 1999 Jun 29;160(13):1821. Comment in: ACP J Club 1999 Jul-Aug;131(1):20.
Who should be educated? Education strategies: could children educate their parents? Basdevant A, et al. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S10-2; discussion S12-3 (7 ref.)
How to tackle the problem early? The role of education in the prevention of obesity. Dietz W. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S7-9 (6 ref.)
Steps towards the prevention of obesity and associated complications. Falkenberg M. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S20-2 (16 ref.)
Role of physical activity in the prevention of obesity in children. Goran MI, et al. **Int J Obes Relat Metab Disord** 1999 Apr;23 Suppl 3:S18-33 (149 ref.)
School-based approaches for preventing and treating obesity. Story M. **Int J Obes Relat Metab Disord** 1999 Mar;23 Suppl 2:S43-51 (52 ref.)
Fat: can't live with it, can't live without it part II. Finn SC. **J Womens Health** 1999 Jan-Feb;8(1):33-8 (17 ref.)
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health [published erratum appears in Obes Res 1998 Nov;6(6):464] [see comments] **Obes Res** 1998 Sep;6 Suppl 2:51S-209S (769 ref.) Comment in: Obes Res 1998 Nov;6(6):461-2.
Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253-62 (34 ref.)
[Evaluation of assessment methods of obesity in children and adolescent] Meng S. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May; 32(3):185-6 (17 ref.) **(Chi)**
[Overweight. II. Determinants of overweight and strategies for prevention (see comments)] Mathus-Vliegen EM. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1989-95 (52 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2374. **(Dut)**
[Practice guideline for the diagnosis, prevention, treatment of obesity in France. Groupe de Travail chargede la mise au point des "Recommandations pour le diagnostic, la prévention et le traitement des Obésités en France" (see comments)] Basdevant A, et al. **Diabetes Metab** 1998;24 Suppl 2:10-42 (262 ref.) Comment in: Diabetes Metab 1998 ;24 Suppl 2:43-8. **(Fre)**
[The role of dietary fiber and its preparations in the protection and treatment of overweight] Witkowska A, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):224-6 (24 ref.) (Eng. Abstr.) **(Pol)**
[Regular physical activity reduces the risk of cardiovascular disease. Overweight is increasing--we have to exercise!] Henriksson J. **Lakartidningen** 1998 Dec 16; 95(51-52):5894-6 (20 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Body images and obesity risk among black females: a review of the literature. Flynn KJ, et al. **Ann Behav Med** 1998 Winter;20(1):13-24 (87 ref.)
Psychological symptoms in individuals successful at long-term maintenance of weight loss. Klem ML, et al. **Health Psychol** 1998 Jul;17(4):336-45 (55 ref.)
Behavioural treatment of childhood and adolescent obesity. Robinson TN. **Int J Obes Relat Metab Disord** 1999 Mar; 23 Suppl 2:S52-7 (24 ref.)
A commentary on the new obesity guidelines from NIH. Ikeda JP, et al. **J Am Diet Assoc** 1999 Aug;99(8):918-9 (26 ref.)
Promoting body size acceptance in weight management counseling. Parham ES. **J Am Diet Assoc** 1999 Aug; 99(8):920-5 (58 ref.)
Response to promoting size acceptance in weight management counseling. Strain GW. **J Am Diet Assoc** 1999 Aug;99(8):926-8 (17 ref.)
What do we most need to learn about food intake regulation? Flatt JP. **Obes Res** 1998 Jul;6(4):307-10 (40 ref.)
Assessment of body image disturbance in obesity. Thompson JK, et al. **Obes Res** 1998 Sep;6(5):375-7 (32 ref.)
Eating habits and appetite control: a psychobiological perspective. Rogers PJ. **Proc Nutr Soc** 1999 Feb; 58(1):59-67 (84 ref.)

REHABILITATION

The role of physical activity in the management of obesity. Harris JE. **J Am Osteopath Assoc** 1999 Apr;99(4 Suppl):S15-9 (15 ref.)

SURGERY

Severe/extreme obesity: a medical disease requiring a surgical treatment? [see comments] Scheen AJ, et al. **Acta Clin Belg** 1999 Jun;54(3):154-61 (44 ref.) Comment in: Acta Clin Belg 1999 Jun;54(3):141-6.
The role of surgery in the management of obesity. Thornley SJ, et al. **N Z Med J** 1998 Nov 27;111(1078):445-8 (49 ref.)
[Liposuction] Bloemenkamp DG, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1946-50 (26 ref.) (Eng. Abstr.) **(Dut)**
[Ultimate treatment of type 2 diabetes: intensive insulin therapy or bariatric surgery? Scheen AJ, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:81-97 (97 ref.) **(Fre)**
[Preoperative management of subjects at risk. Obese patients] Servin F. **Presse Med** 1998 Mar 7;27(9):452-4 (20 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Medical aspects of obesity. Scheen AJ, et al. **Acta Chir Belg** 1999 May-Jun;99(3):135-9 (42 ref.)
The war against obesity: attacking a new front [editorial; comment]]see comments] Klein S. **Am J Clin Nutr** 1999 Jun;69(6):1061-3 (13 ref.) Comment on: Am J Clin Nutr 1999 Jun;69(6):1108-16. Comment in: Am J Clin Nutr 1999 Jun;69(6):1059-60.
Treating the obese patient. Suggestions for primary care practice. Anderson DA, et al. **Arch Fam Med** 1999 Mar-Apr;8(2):156-67 (98 ref.)
Weight loss in the clinical setting: applications for cardiac rehabilitation. Harvey-Berino J. **Coron Artery Dis** 1998; 9(12):795-8 (29 ref.)
Newer aspects of the pathophysiology, evaluation, and management of obesity in childhood. Diamond FB Jr. **Curr Opin Pediatr** 1998 Aug;10(4):422-7 (49 ref.)
Endocrine and metabolism [editorial] Root A. **Curr Opin Pediatr** 1998 Aug;10(4):411-5 (18 ref.)
Adolescent obesity, a need for greater awareness and improved treatment. Trent ME, et al. **Curr Opin Pediatr** 1999 Aug;11(4):297-302 (55 ref.)
Diet, exercise and behavioural intervention: the nonpharmacological approach. Brownell KD. **Eur J Clin Invest** 1998 Sep;28 Suppl 2:19-21; discussion 22 (12 ref.)
Obesity--what are the current treatment options? Lean ME. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:22-6 (14 ref.)
How to tackle the problem early? The role of education in the prevention of obesity. Dietz W. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S7-9 (6 ref.)
Why should obesity be managed? The obese individual's perspective. Evans E. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S3-5; discussion S6 (11 ref.)
How should the obese patient be managed? Possible approaches to a national obesity management network. Hainer V. **Int J Obes Relat Metab Disord** 1999 May;23

Suppl 4:S14–8; discussion S18–9 (23 ref.)
Obesity and hypertension: from pathophysiology to treatment. Kolanowski J.
Int J Obes Relat Metab Disord 1999 Feb;23 Suppl 1:42–6 (38 ref.)
Maintenance programmes after weight reduction--how useful are they? Mustajoki P, et al.
Int J Obes Relat Metab Disord 1999 Jun;23(6):553–5 (21 ref.)
Behavioural treatment of childhood and adolescent obesity. Robinson TN. **Int J Obes Relat Metab Disord** 1999 Mar; 23 Suppl 2:S52–7 (24 ref.)
Visceral adipose tissue: a critical review of intervention strategies. Smith SR, et al.
Int J Obes Relat Metab Disord 1999 Apr;23(4):329–35 (38 ref.)
Obesity as an epidemic: facing the challenge. Coulston AM.
J Am Diet Assoc 1998 Oct;98(10 Suppl 2):S6–8 (18 ref.)
The dietitians' philosophy and practice in multidisciplinary weight management. Dalton S. **J Am Diet Assoc** 1998 Oct; 98(10 Suppl 2):S49–54 (49 ref.)
The role of the behavioral counselor in obesity treatment. Foreyt JP, et al. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S27–30 (42 ref.)
A multidisciplinary approach to obesity management: the physician's role and team care alternatives. Frank A.
J Am Diet Assoc 1998 Oct;98(10 Suppl 2):S44–8 (10 ref.)
Managing obesity in patients with comorbidities. Franz MJ.
J Am Diet Assoc 1998 Oct;98(10 Suppl 2):S39–43 (50 ref.)
A commentary on the new obesity guidelines from NIH. Ikeda JP, et al. **J Am Diet Assoc** 1999 Aug;99(8):918–9 (26 ref.)
Promoting body size acceptance in weight management counseling. Parham ES. **J Am Diet Assoc** 1999 Aug; 99(8):920–5 (58 ref.)
The role of physical activity in the prevention and management of obesity. Rippe JM, et al.
J Am Diet Assoc 1998 Oct;98(10 Suppl 2):S31–8 (94 ref.)
Obesity as a chronic disease: modern medical and lifestyle management. Rippe JM, et al. **J Am Diet Assoc** 1998 Oct; 98(10 Suppl 2):S9–15 (67 ref.)
Response to promoting size acceptance in weight management counseling. Strain GW. **J Am Diet Assoc** 1999 Aug;99(8):926–8 (17 ref.)
Childhood obesity [see comments] Holtz C, et al.
J Am Osteopath Assoc 1999 Jul;99(7):366–71 (33 ref.) Comment in: J Am Osteopath Assoc 1999 Jul;99(7):357.
Empirically supported treatments in pediatric psychology: pediatric obesity [see comments] Jelalian E, et al.
J Pediatr Psychol 1999 Jun;24(3):223–48 (97 ref.) Comment in: J Pediatr Psychol 1999 Jun;24(3):249–50. Comment in: J Pediatr Psychol 1999 Jun;24(3):251–2.
Individualizing the approach to treating obesity. Ammon PK.
Nurse Pract 1999 Feb;24(2):27–31, 36–8, 41; quiz 42–3 (47 ref.)
The importance of timing and accurate interpretation of the benefits of weight reduction on plasma lipids [editorial; comment] Eckel RH. **Obes Res** 1999 Mar;7(2):227–8 (19 ref.) Comment on: Obes Res 1999 Mar;7(2):170–8.
Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127–43 (67 ref.)
Treatment of obesity: theory into practice. Kirk SF.
Proc Nutr Soc 1999 Feb;58(1):53–8 (51 ref.)
Inhibitors of preadipocyte replication: opportunities for the treatment of obesity. Kirkland JL, et al.
Prog Mol Subcell Biol 1998;20:177–95 (99 ref.)
Medical management of obesity. Jensen MD.
Semin Gastrointest Dis 1998 Oct;9(4):156–62 (36 ref.)
Management of obesity in NIDDM (non-insulin-dependent diabetes mellitus). Cheah JS. **Singapore Med J** 1998 Aug; 39(8):380–4 (29 ref.)
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. **WMJ** 1998 Oct;97(9):20–1, 24–5, 27–37 (0 ref.)
[Overweight. III. Therapeutic strategies for weight reduction] Pijl H, et al. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1995–9 (46 ref.) (Eng. Abstr.) **(Dut)**
[Practice guideline for the diagnosis, prevention, treatment of obesity in France. Groupe de Travail chargede la mise au point des "Recommandations pour le diagnostic, la prévention et le traitement des Obésités en France" (see comments)] Basdevant A, et al. **Diabetes Metab** 1998;24 Suppl 2:10–42 (262 ref.) Comment in: Diabetes Metab 1998 ;24 Suppl 2:43–8. **(Fre)**
[How I evaluate ... a overweight or obese patient] Scheen AJ, et al. **Rev Med Liege** 1999 Jun;54(6):553–6 (14 ref.) (Eng. Abstr.) **(Fre)**
[Pharma clinics. How I treat...a diabetic patient with severe obesity] Scheen AJ, et al. **Rev Med Liege** 1998 Jul; 53(7):386–9 (26 ref.) (Eng. Abstr.) **(Fre)**
[Weight loss by increasing energy consumption and thermogenesis] Ludvik B. **Acta Med Austriaca** 1998; 25(4–5):136–7 (8 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of obesity in childhood and adolescence] Zwiauer K. **Wien Med Wochenschr** 1998;148(17):403–6 (17 ref.) (Eng. Abstr.) **(Ger)**
[The problem of evidence-based guidelines using the example of the treatment of obesity] Wiesemann A, et al.
Z Arztl Fortbild Qualitatssich 1999 Jul;93(5):363–7 (36 ref.) (Eng. Abstr.) **(Ger)**
[Obesity in children: a behavioral approach and programs of family treatment (editorial)] Bauer B.
Recenti Prog Med 1999 Apr;90(4):222–5 (21 ref.) **(Ita)**
[The role of dietary fiber and its preparations in the protection and treatment of overweight] Witkowska A, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):224–6 (24 ref.) (Eng. Abstr.) **(Pol)**
[Medical treatment of obesity from a multi professional perspective] Liberman C, et al. **Rev Med Chil** 1998 Nov; 126(11):1377–83 (40 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Advances in dietary management of obesity in dogs and cats. Butterwick RF, et al. **J Nutr** 1998 Dec;128(12 Suppl):2771S–2775S (33 ref.)
Obesity in dogs: effects on renal function, blood pressure, and renal disease. Joles JA. **Vet Q** 1998 Oct;20(4):117–20 (56 ref.)

VIROLOGY

[Viruses and the neuroendocrine system: model of murine obesity induced by cerebral infection by canine distemper virus] Bernard A, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):291–9 (56 ref.) (Eng. Abstr.) **(Fre)**

OBESITY IN DIABETES

COMPLICATIONS

Obesity and type 2 diabetes: a conflict of interests? Williams G. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S2–4 (8 ref.)

DIET THERAPY

Treating obesity in type 2 diabetes. Calories, composition, and control [editorial; comment] Gumbiner B.
Diabetes Care 1999 Jun;22(6):886–8 (23 ref.) Comment on: Diabetes Care 1999 Jun;22(6):889–95.

DRUG THERAPY

Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update. Weyer C, et al. **Diabetes Metab** 1999 Mar;25(1):11–21 (94 ref.)
The impact of pharmacotherapy on weight management in type 2 diabetes. Hauner H.
Int J Obes Relat Metab Disord 1999 Jun;23 Suppl 7:S12–7 (44 ref.)
[Thiazolidenediones, diabetes and adipogenesis (editorial)] Moreno L, et al. **Med Clin (Barc)** 1999 Apr 10; 112(12):457–8 (19 ref.) **(Spa)**

GENETICS

WAT-free mice: diabetes without obesity. McKnight SL.
Genes Dev 1998 Oct 15;12(20):3145–48 (20 ref.)
Metabolic consequences of the West African diaspora: lessons from the thrifty gene. Osei K. **J Lab Clin Med** 1999 Feb; 133(2):98–111 (65 ref.)

PHYSIOPATHOLOGY

[Obesity in NIDDM: relevance of the control of fat mass or its its distribution?] Després JP.
Journ Annu Diabetol Hotel Dieu 1998;:215–21 (23 ref.) **(Fre)**

THERAPY

Treating obese patients with poorly controlled diabetes: confessions of an insulin therapist. Kerr D, et al.
Diabetes Metab Res Rev 1999 May–Jun;15(3):219–25 (34 ref.)
The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. Foreyt JP, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S5–11 (64 ref.)
Obesity and type 2 diabetes: a conflict of interests? Williams G. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S2–4 (8 ref.)

OBESITY, MORBID

see related
BILIOPANCREATIC DIVERSION
GASTRIC BYPASS
GASTROPLASTY

COMPLICATIONS

Massive localized lymphedema in the morbidly obese: a histologically distinct reactive lesion simulating liposarcoma. Farshid G, et al. **Am J Surg Pathol** 1998 Oct; 22(10):1277–83 (4 ref.)
Diseases and problems secondary to massive obesity. Herrara MF, et al. **Eur J Gastroenterol Hepatol** 1999 Feb;11(2):63–7 (49 ref.)
Slipped capital femoral epiphysis in a 5 1/2-year-old obese male. Bandyopadhyay S, et al. **Pediatr Emerg Care** 1999 Apr;15(2):104–5 (19 ref.)
[An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity] Wildbrett J, et al.
Dtsch Med Wochenschr 1999 Mar 5;124(9):248–52 (24 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Indications for gastroplasty in the treatment of obesity] Giusti V, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):469–74 (10 ref.) **(Fre)**

DIET THERAPY

[Analysis of the results of treatment of obesity in the hospital outpatient department] Gómez Candela C, et al.
Nutr Hosp 1998 Sep–Oct;13(5):215–20 (38 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Anaesthetic management of the morbidly obese patient. Hunter JD, et al. **Hosp Med** 1998 Jun;59(6):481–3 (8 ref.)

SURGERY

Severe/extreme obesity: a medical disease requiring a surgical treatment? [see comments] Scheen AJ, et al.
Acta Clin Belg 1999 Jun;54(3):154–61 (44 ref.) Comment in: Acta Clin Belg 1999 Jun;54(3):141–6.
Surgery for morbid obesity. Overview. Deitel M.
Eur J Gastroenterol Hepatol 1999 Feb;11(2):57–61 (55 ref.)
Gastric banding for morbid obesity. Oria HE.
Eur J Gastroenterol Hepatol 1999 Feb;11(2):105–14 (95 ref.)
Bariatric surgery: a view on the future [editorial] Van Hee R. **G Chir** 1999 Mar;20(3):73–9 (60 ref.)
Patients with morbid obesity don't get life-saving bone marrow transplants. Clarke B, et al. **Obes Surg** 1999 Feb; 9(1):77–9 (13 ref.)
Restrictive versus malabsorptive procedures: criteria for patient selection. Forestieri P, et al. **Obes Surg** 1999 Feb; 9(1):48–50 (10 ref.)
Ilial transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Mason EE. **Obes Surg** 1999 Jun; 9(3):223–8 (35 ref.)
Gastrointestinal surgery for obesity. Brolin RE.
Semin Gastrointest Dis 1998 Oct;9(4):163–75 (61 ref.)
[Indications for gastroplasty in the treatment of obesity] Giusti V, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):469–74 (10 ref.) **(Fre)**
[Surgery for obesity--the most successful long-term therapy?] Husemann B. **Wien Med Wochenschr** 1998; 148(17):407–12 (51 ref.) (Eng. Abstr.) **(Ger)**
[Contemporary methods of treatment of morbid obesity] Wyleżol M, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):95–7 (33 ref.) (Eng. Abstr.) **(Pol)**

OBJECT ATTACHMENT

Mohawks and combat boots: the schizoid dilemma of punks. McAllister MJ. **Bull Menninger Clin** 1999 Winter; 63(1):89–102 (25 ref.)
Theory and observation of attachment and its relation to child maltreatment: a review. Morton N, et al.
Child Abuse Negl 1998 Nov;22(11):1093–104 (85 ref.)
Environmental influences on neural plasticity, the limbic system, emotional development and attachment: a review. Joseph R. **Child Psychiatry Hum Dev** 1999 Spring; 29(3):189–208 (97 ref.)
Neuropsychologic impact of facial deformities in children. Neurodevelopmental role of the face in communication and bonding. Perry BD, et al. **Clin Plast Surg** 1998 Oct; 25(4):587–97, ix (47 ref.)
Object relations theory and short-term dynamic psychotherapy: findings from the Quality of Object Relations Scale. Piper WE, et al. **Clin Psychol Rev** 1999 Sep;19(6):669–85 (69 ref.)
Dissociative detachment and memory impairment: reversible amnesia or encoding failure? Allen JG, et al.
Compr Psychiatry 1999 Mar–Apr;40(2):160–71 (77 ref.)
Implications of attachment theory for developmental psychopathology. Sroufe LA, et al. **Dev Psychopathol** 1999 Winter;11(1):1–13 (60 ref.)
Some thoughts concerning borderline pathology and fear of aloneness. Dazzi S. **J Am Acad Psychoanal** 1998 Spring; 26(1):69–84 (36 ref.)
Kleinian guilt, determinism, and free will: implications for clinical theory and treatment. Goodman G.
J Am Acad Psychoanal 1998 Spring;26(1):137–63 (52 ref.)
Recollections of parental behaviour, adult attachment and mental health: mediating and moderating effects. Gittleman MG, et al. **Psychol Med** 1998 Nov;28(6):1443–55 (46 ref.)
Neuroendocrine perspectives on social attachment and love. Carter CS. **Psychoneuroendocrinology** 1998 Nov; 23(8):779–818 (205 ref.)
Effects of early stress on adult affiliative behavior. Henry JP, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):863–75 (54 ref.)
Generic aspects of primate attachments: parents, offspring and mates. Mason WA, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):765–78 (97 ref.)
Attachment and interpersonal communication in somatization. Stuart S, et al. **Psychosomatics** 1999 Jan–Feb; 40(1):34–43 (68 ref.)
[Contribution of maternal sensitivity in transgenerational promotion of binding quality] Ziegenhain U.
Prax Kinderpsychol Kinderpsychiatr 1999 Feb;48(2):86–100 (40 ref.) (Eng. Abstr.) **(Ger)**
[Clinical significance of attachment research for the premature infant group: an overview of most recent

research] Buchheim A, et al.
Z Kinder Jugendpsychiatr Psychother 1999 May; 27(2):125–38 (105 ref.) **(Ger)**

OBJECT RELATIONS see **OBJECT ATTACHMENT**

OBLIGATION, SOCIAL see **SOCIAL RESPONSIBILITY**

OBSERVATION

[Clinical case observations: lessons for empirical research] Swendsen J, et al. **Encephale** 1999 Jan–Feb;25(1):16–20 (20 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Repeated measurement and analysis units. Review of basic principles. Ranstam J. **Acta Orthop Scand** 1998 Aug; 69(4):345–6 (2 ref.)
Qualitative studies. Their role in medical research. Huston P, et al. **Can Fam Physician** 1998 Nov;44:2453–8 (19 ref.)
Optimizing tuberculosis control in the inner city [editorial; comment] FitzGerald JM. **CMAJ** 1999 Mar 23;160(6):821–2 (14 ref.) Comment on: CMAJ 1999 Mar 23;160(6):789–94. Comment on: CMAJ 1999 Mar 23;160(6):799–802.

OBSERVER BIAS see **OBSERVER VARIATION**

OBSERVER VARIATION

[Observer variability] Burtin P, et al.
Gastroenterol Clin Biol 1998 Nov;22(11):897–905 (14 ref.) **(Fre)**

OBSESSIONS see **OBSESSIVE BEHAVIOR**

OBSESSIVE BEHAVIOR

Cognitive-behavioural approach to understanding obsessional thinking. Salkovskis PM, et al.
Br J Psychiatry Suppl 1998;(35):53–63 (34 ref.)
[Dependence and obsession] Nakazawa T.
Nihon Arukoru Yakubutsu Igakkai Zasshi 1999 Feb; 34(1):27–35 (25 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Craving and relapse measurement in alcoholism. Potgieter AS, et al. **Alcohol Alcohol** 1999 Mar–Apr;34(2):254–60 (30 ref.)

OBSESSIVE-COMPULSIVE DISORDER

Obsessive-compulsive disorder in children and adolescents. Riddle M. **Br J Psychiatry Suppl** 1998;(35):91–6 (46 ref.)
Body dysmorphic disorder: clinical aspects and treatment strategies. Phillips KA. **Bull Menninger Clin** 1998 Fall;62(4 Suppl A):A33–48 (55 ref.)
Obsessive-compulsive disorder: symptom overview and epidemiology. Pigott TA. **Bull Menninger Clin** 1998 Fall; 62(4 Suppl A):A4–32 (102 ref.)
Obsessive-compulsive disorder in children and adolescents. Robinson R. **Bull Menninger Clin** 1998 Fall;62(4 Suppl A):A49–64 (69 ref.)

COMPLICATIONS

Hoarding: a review. Stein DJ, et al.
Isr J Psychiatry Relat Sci 1999;36(1):35–46 (81 ref.)

DIAGNOSIS

The assessment and coordination of treatment of children and adolescents with OCD. King RA, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):577–97, xi (99 ref.)
The familial and developmental context of obsessive-compulsive disorder. Pollock RA, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):461–79, vii–viii (84 ref.)
Neuropsychological models of childhood obsessive-compulsive disorder. Schultz RT, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):513–31, viii (102 ref.)
Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. AACAP [see comments]
J Am Acad Child Adolesc Psychiatry 1998 Oct;37(10 Suppl):27S–45S (187 ref.) Comment in: J Am Acad Child Adolesc Psychiatry 1999 May;38(5):499–500.
Examining the evidence for anxiety-related cognitive biases in obsessive-compulsive disorder. Summerfeldt LJ, et al. **J Anxiety Disord** 1998 Nov–Dec;12(6):579–98 (112 ref.)
Obsessive-compulsive disorder: diagnosis and treatment. Goodman WK. **J Clin Psychiatry** 1999;60 Suppl 18:27–32 (67 ref.)
Diagnosis of obsessive-compulsive illness. Rothenberg A. **Psychiatr Clin North Am** 1998 Dec;21(4):791–801, vi (34 ref.)
[A hidden compulsion] van Vliet IM.
Ned Tijdschr Geneeskd 1999 Feb 20;143(8):385–8 (10 ref.) (Eng. Abstr.) **(Dut)**
[Compulsive buying: a new disorder?] de Lucas Taracena MT, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998 Jul–Aug;26(4):264–72 (47 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Blier P, et al. **Biol Psychiatry** 1998 Sep 1; 44(5):313–23 (61 ref.)
Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Delgado PL, et al. **Br J Psychiatry Suppl** 1998;(35):21–5 (30 ref.)
Pharmacotherapy for obsessive-compulsive disorder. Greist JH, et al. **Br J Psychiatry Suppl** 1998;(35):64–70 (92 ref.)
Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Grados M, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):617–34, x (131 ref.)
SSRIs in the treatment of obsessive-compulsive disorder. Cartwright C, et al. **Depress Anxiety** 1998;8 Suppl 1:105–13 (69 ref.)
Beyond depression: citalopram for obsessive-compulsive disorder. Pato MT. **Int Clin Psychopharmacol** 1999 May; 14 Suppl 2:S19–26 (45 ref.)
Nontricyclic antidepressants: current trends in children and adolescents. Emslie GJ, et al.
J Am Acad Child Adolesc Psychiatry 1999 May; 38(5):517–28 (108 ref.)
Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. Hollander E. **J Clin Psychiatry** 1999;60 Suppl 15:38–44 (36 ref.)
A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott TA, et al. **J Clin Psychiatry** 1999 Feb;60(2):101–6 (50 ref.)
Hallucinogens, serotonin and obsessive-compulsive disorder. Delgado PL, et al. **J Psychoactive Drugs** 1998 Oct–Dec; 30(4):359–66 (63 ref.)
Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Blier P, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):91S–98S (58 ref.)
Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Ellingrod VL.
Pharmacotherapy 1998 Sep–Oct;18(5):936–60 (98 ref.)

EPIDEMIOLOGY

Epidemiology of obsessive-compulsive disorder. Bebbington PE. **Br J Psychiatry Suppl** 1998;(35):2–6 (27 ref.)
Postinfectious and other forms of obsessive-compulsive disorder. Leonard HL, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):497–511 (60 ref.)
The inheritance of obsessive-compulsive disorder. Pauls DL, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jul; 8(3):481–96, viii (74 ref.)
The epidemiology of obsessive-compulsive disorder in children and adolescents. Zohar AH.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):445–60 (42 ref.)
Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. Tibbo P, et al.
J Psychiatry Neurosci 1999 Jan;24(1):15–24 (90 ref.)

ETIOLOGY

Multiple pathways to inflated responsibility beliefs in obsessional problems: possible origins and implications for therapy and research. Salkovskis P, et al.
Behav Res Ther 1999 Nov;37(11):1055–72 (40 ref.)
Understanding and treating obsessive-compulsive disorder. Salkovskis PM. **Behav Res Ther** 1999 Jul;37 Suppl 1:S29–52 (55 ref.)
Role of serotonin in obsessive-compulsive disorder. Baumgarten HG, et al. **Br J Psychiatry Suppl** 1998; (35):13–20 (73 ref.)
Preoccupations and behaviors associated with romantic and parental love. Perspectives on the origin of obsessive-compulsive disorder. Leckman JF, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):635–65 (152 ref.)
Postinfectious and other forms of obsessive-compulsive disorder. Leonard HL, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):497–511 (60 ref.)
Tourette's and comorbid syndromes: obsessive compulsive and attention deficit hyperactivity disorder. A common etiology? Sheppard DM, et al. **Clin Psychol Rev** 1999 Aug; 19(5):531–52 (133 ref.)
Role of dopamine systems in obsessive-compulsive disorder (OCD): implications from a novel psychostimulant-induced animal model. Szechtman H, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):55–61 (35 ref.)

GENETICS

The inheritance of obsessive-compulsive disorder. Pauls DL, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jul; 8(3):481–96, viii (74 ref.)

PATHOLOGY

Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder. An evolving perspective on brain and behaviour. Schwartz JM.
Br J Psychiatry Suppl 1998;(35):38–44 (59 ref.)
Neurobiology of childhood obsessive-compulsive disorder. Fitzgerald KD, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):533–75, ix (268 ref.)
Obsessive-compulsive disorders in dermatology. Monti M, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):103–8 (15 ref.)

PHYSIOPATHOLOGY

Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders: the role of serotonergic mechanisms in illness progression. Post RM, et al.
Biol Psychiatry 1998 Aug 1;44(3):193–206 (125 ref.)
Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Saxena S, et al.
Br J Psychiatry Suppl 1998;(35):26–37 (88 ref.)
Neurobiology of childhood obsessive-compulsive disorder. Fitzgerald KD, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):533–75, ix (268 ref.)
Possible role of neuropeptides in obsessive compulsive disorder. McDougle CJ, et al. **Psychoneuroendocrinology** 1999 Jan;24(1):1–24 (150 ref.)

PSYCHOLOGY

Multiple pathways to inflated responsibility beliefs in obsessional problems: possible origins and implications for therapy and research. Salkovskis P, et al.
Behav Res Ther 1999 Nov;37(11):1055–72 (40 ref.)
Preoccupations and behaviors associated with romantic and parental love. Perspectives on the origin of obsessive-compulsive disorder. Leckman JF, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):635–65 (152 ref.)
The familial and developmental context of obsessive-compulsive disorder. Pollock RA, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):461–79, vii–viii (84 ref.)
Neuropsychological models of childhood obsessive-compulsive disorder. Schultz RT, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):513–31, viii (102 ref.)
Psychopathological considerations on the relationship between bulimia and obsessive-compulsive disorder. Aragona M, et al. **Psychopathology** 1998;31(4):197–205 (46 ref.)

SURGERY

Neurosurgical treatment of obsessive-compulsive disorder [see comments] Jenike MA. **Br J Psychiatry Suppl** 1998; (35):79–90 (100 ref.) Comment in: Br J Psychiatry 1998 Dec;173:537.
[Capsulotomy as a last way out as far as no other alternative is available] Edman G, et al. **Lakartidningen** 1998 Nov 4; 95(45):5008–12 (20 ref.) **(Swe)**

THERAPY

Understanding and treating obsessive-compulsive disorder. Salkovskis PM. **Behav Res Ther** 1999 Jul;37 Suppl 1:S29–52 (55 ref.)
Out-patient, multi-modal behaviour therapy for obsessive-compulsive disorder. Hand I.
Br J Psychiatry Suppl 1998;(35):45–52 (30 ref.)
Treatment of obsessive-compulsive spectrum disorders with SSRIs. Hollander E. **Br J Psychiatry Suppl** 1998;(35):7–12 (50 ref.)
Cognitive-behavioural approach to understanding obsessional thinking. Salkovskis PM, et al.
Br J Psychiatry Suppl 1998;(35):53–63 (34 ref.)
The comparative effectiveness of treatments for obsessive-compulsive disorder. Greist JH.
Bull Menninger Clin 1998 Fall;62(4 Suppl A):A65–81 (93 ref.)
The assessment and coordination of treatment of children and adolescents with OCD. King RA, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jul;8(3):577–97, xi (99 ref.)
Cognitive behavioral therapy of childhood OCD. Piacentini J. **Child Adolesc Psychiatr Clin N Am** 1999 Jul;8(3):599–616 (77 ref.)
Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. AACAP [see comments]
J Am Acad Child Adolesc Psychiatry 1998 Oct;37(10 Suppl):27S–45S (187 ref.) Comment in: J Am Acad Child Adolesc Psychiatry 1999 May;38(5):499–500.
Summary of the practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. American Academy of Child and Adolescent Psychiatry.
J Am Acad Child Adolesc Psychiatry 1998 Oct; 37(10):1110–6 (2 ref.)
Obsessive-compulsive disorder: diagnosis and treatment. Goodman WK. **J Clin Psychiatry** 1999;60 Suppl 18:27–32 (67 ref.)

OBSESSIVE-COMPULSIVE DISORDER

The paraphilias, obsessive compulsive spectrum disorder, and the treatment of sexually deviant behaviour. Bradford JM. **Psychiatr Q** 1999 Fall;70(3):209–19 (44 ref.)

[Current developments in the treatment of obsessive-compulsive disorders in children and adolescents] Wewetzer C, et al. **Nervenarzt** 1999 Jan; 70(1):11–9 (64 ref.) (Eng. Abstr.) **(Ger)**

[Psychotherapeutic methods in the treatment of obsessive-compulsive disorder (OCD) in children and adolescents] Bryńska A, et al. **Psychiatr Pol** 1998 Nov–Dec; 32(6):723–38 (54 ref.) (Eng. Abstr.) **(Pol)**

[Is capsulotomy in obsessive-compulsive syndromes an unnecessary therapeutic method? Good results with drug therapy and behavior therapy] Bejerot S. **Lakartidningen** 1998 Nov 4;95(45):5003–5 (17 ref.) **(Swe)**

OBSTETRIC SURGICAL PROCEDURES

see related
OBSTETRICS

ADVERSE EFFECTS

Acute pancreatitis after gynecologic and obstetric surgery. Ramsey PS, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):542–6 (15 ref.)

OBSTETRICAL ANALGESIA see **ANALGESIA, OBSTETRICAL**

OBSTETRICAL FORCEPS

Forceps-assisted vaginal delivery. Gei AF, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):345–70 (112 ref.)

OBSTETRICAL NURSING

Current issues in the midwifery management of women living with HIV/AIDS. MacLaren A, et al. **J Nurse Midwifery** 1998 Nov–Dec;43(6):502–25 (156 ref.)

Postadoptive reactions of the relinquishing mother: a review. Askren HA, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):395–400 (20 ref.)

Theory and practice for teaching the childbearing couple. Farrell M, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):613–8 (22 ref.)

Assessment of women for partner abuse. Fishwick NJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):661–70 (15 ref.)

Technology and family-centered perinatal care: conflict or synergy? Gordin P, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):401–8 (28 ref.)

Continuous electronic fetal monitoring: contradictions between practice and research. Haggerty LA. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):409–16 (37 ref.)

Working with childhood sexual abuse survivors during pregnancy, labor, and birth. Heritage C. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):671–7 (17 ref.)

Fetal surgery: exploring the challenges in nursing care. Howell LJ, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):427–32 (17 ref.)

Maternal fatigue: implications of second stage labor nursing care. Mayberry LJ, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Mar–Apr; 28(2):175–81 (42 ref.)

Interpersonal violence and the pregnant homeless woman. Robrecht LC, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):684–91 (32 ref.)

Alternative health care: an overview. Tiedje LB. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):557–62 (26 ref.)

Pregnancy in women with spinal cord injuries. Atterbury JL, et al. **Nurs Clin North Am** 1998 Dec;33(4):603–13 (52 ref.)

TRENDS

Nurse versus machine: slaves or masters of technology? Buus-Frank M. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):433–41 (42 ref.)

OBSTETRICS

see related
OBSTETRIC SURGICAL PROCEDURES
PREGNANCY COMPLICATIONS

The obstetrician-gynecologist's role in the practical management of polycystic ovary syndrome. Berga SL. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 2):S109–S113 (28 ref.)

The role of the maternal-fetal medicine specialist. Philipson EH. **Cleve Clin J Med** 1999 Jul–Aug;66(7):407–9, 413–4 (10 ref.)

Primary care for women: the role of the obstetrician-gynecologist. Brown CV. **Clin Obstet Gynecol** 1999 Jun;42(2):306–13 (20 ref.)

Thoughts on the patient-doctor relationship in obstetrics and gynecology. Ludwig H. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):85–91 (59 ref.)

ACOG committee opinion. Ethical issues related to expert testimony by obstetricians and gynecologists. Number 217, April 1999 (replaces number 56, October 1987). Committee on Ethics. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jun;65(3):321–2 (3 ref.)

Logistic regression models in obstetrics and gynecology literature. Khan KS, et al. **Obstet Gynecol** 1999 Jun; 93(6):1014–20 (21 ref.)

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic obstetricians] Crézé B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:117–20 (3 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of obstetricians of general hospital centers] Dauptain G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:110–6 (13 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center obstetricians] Lévy G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:104–9 (9 ref.) **(Fre)**

[Past and present of mycology in German gynecology and obstetrics] Mendling W. **Mycoses** 1998;41 Suppl 2:26–30 (23 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

[Health economics of perinatal care and birth in Austria and Holland –a comparison] Brezinka C. **Gynakol Geburtshilfliche Rundsch** 1998;38(4):196–210 (48 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

Restructuring residency training in obstetrics and gynecology. Bissonnette JM, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):516–8 (8 ref.)

Obstetrics and gynaecology in the Asia and Oceania region: requirements for postgraduate training and certification. Zaidi S. **J Obstet Gynaecol Res** 1999 Apr;25(2):71–85 (22 ref.)

LEGISLATION & JURISPRUDENCE

Medicolegal issues in fertility regulation. Gupta S, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):818–26 (63 ref.)

Ambulatory obstetrical care: strategies to reduce telephone liability. Phelan JP. **Clin Obstet Gynecol** 1998 Sep; 41(3):640–6 (22 ref.)

METHODS

[The current potentials for optimal whole-blood transfusion and component therapy with blood products—erythrocytes in obstetrics and gynecology—the indications, means and methods] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):46–9 (25 ref.) **(Bul)**

[The potentials of current transfusion hematology for component therapy with thrombocytes, granulocytes, plasma and plasma factors in obstetrics and gynecology] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(4):50–2 (25 ref.) **(Bul)**

[Management of pregnant women and newborns in low-risk pregnancies. Evaluation of the literature] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:8–20 (52 ref.) **(Fre)**

[Delivery methods for infants of birthweight less than 2500 grams. Description of practices in France. The Obstetricians Sentinel Network A.U.D.I.P.O.G.] Mamelle N. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:269–74 (7 ref.) **(Fre)**

STANDARDS

Childbirth customs in Orthodox Jewish traditions. Bodo K, et al. **Can Fam Physician** 1999 Mar;45:682–6 (11 ref.)

Childbirth customs in Vietnamese traditions. Bodo K, et al. **Can Fam Physician** 1999 Mar;45:690–2, 695–7 (14 ref.)

ACOG practice bulletin. Premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Number 1, June 1998. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Oct;63(1):75–84 (70 ref.)

Evidence-based practice and its application to childbirth care for low-risk women [see comments] Rooks JP. **J Nurse Midwifery** 1999 Jul–Aug;44(4):355–69 (122 ref.) Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

[Consensus conference on prenatal care, delivery, and the newborn. Paris, France, 2–3 December 1998. Proceedings] **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:1–317 (0 ref.) **(Fre)**

TRENDS

Etiology and pathogenesis of preeclampsia: current concepts. Dekker GA, et al. **Am J Obstet Gynecol** 1998 Nov; 179(5):1359–75 (237 ref.)

Obstetrics and gynecology. Stovall TG. **J Am Coll Surg** 1999 Feb;188(2):136–9 (25 ref.)

OBSTETRICS AND GYNECOLOGY DEPARTMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

Perinatal information systems for quality improvement: visions for today. Slagle TA. **Pediatrics** 1999 Jan;103(1 Suppl E):266–77 (64 ref.)

OBTURATOR NERVE

Femoral and obturator neuropathies. Busis NA. **Neurol Clin** 1999 Aug;17(3):633–53, vii (175 ref.)

OCCIPITAL BONE

Intracranial osteosarcomas: report of four cases and review of the literature [see comments] Ashkan K, et al. **J Neurooncol** 1998 Oct;40(1):87–96 (41 ref.) Comment in: J Neurooncol 1999 May;43(1):93.

PATHOLOGY

The cluster of arachnoid diverticula in the occipital bone: report of two cases with literature review. Nakada M, et al. **Acta Neurochir (Wien)** 1998;140(7):647–50 (12 ref.)

SURGERY

Occipito-cervical fusion with the cervical Cotrel-Dubousset rod system. Heidecke V, et al. **Acta Neurochir (Wien)** 1998; 140(9):969–76 (31 ref.)

OCCIPITAL LOBE

Transitional cell carcinoma presenting as a solitary brain lesion: a case report and review of the world literature. Clatterbuck RE, et al. **J Neurooncol** 1998 Aug;39(1):91–4 (28 ref.)

PATHOLOGY

Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. Pavlakis SG, et al. **J Child Neurol** 1999 May;14(5):277–81 (36 ref.)

PHYSIOLOGY

Object vision and visual awareness. Logothetis N. **Curr Opin Neurobiol** 1998 Aug;8(4):536–44 (67 ref.)

PHYSIOPATHOLOGY

Reversible posterior leukoencephalopathy syndrome. Is it reversible and thus benign? [editorial; comment] Yamamoto T. **Intern Med** 1999 Jan;38(1):4–5 (9 ref.) Comment on: Intern Med 1999 Jan;38(1):54–8;. Comment on: Intern Med 1999 Jan;38(1):73.

OCCLUDING JUNCTIONS see **TIGHT JUNCTIONS**

OCCLUSAL GUIDANCE see **DENTAL OCCLUSION**

OCCLUSAL PLANE see **DENTAL OCCLUSION**

OCCLUSIVE DRESSINGS

Dohi Memorial Lecture. From occlusive to living membranes. Eaglstein WH. **J Dermatol** 1998 Dec; 25(12):766–74 (35 ref.)

OCCULT BLOOD

Review article: faecal occult blood testing for colorectal cancer. Allison JE. **Aliment Pharmacol Ther** 1998 Jan; 12(1):1–10 (52 ref.)

Colorectal cancer screening: A guide to the guidelines. Rex DK. **Can J Gastroenterol** 1999 Jun;13(5):397–402 (61 ref.)

Should there be mass screening using faecal occult blood tests for colorectal cancer? [see comments] Faivre J, et al. **Eur J Cancer** 1998 May;34(6):773–80 (22 ref.) Comment in: Eur J Cancer 1999 Feb;35(2):326.

Occult gastrointestinal bleeding. Rockey DC. **N Engl J Med** 1999 Jul 1;341(1):38–46 (74 ref.)

Fecal occult blood tests in occult gastrointestinal bleeding. Bond JH. **Semin Gastrointest Dis** 1999 Apr;10(2):48–52 (20 ref.)

The role of surgery in occult gastrointestinal bleeding. Katz LB. **Semin Gastrointest Dis** 1999 Apr;10(2):78–81 (9 ref.)

Medical and hormonal therapy in occult gastrointestinal bleeding. Lewis BS. **Semin Gastrointest Dis** 1999 Apr; 10(2):71–7 (49 ref.)

Small-bowel investigation in occult gastrointestinal bleeding. Morris AJ. **Semin Gastrointest Dis** 1999 Apr;10(2):65–70 (31 ref.)

Gastrointestinal tract evaluation in patients with iron deficiency anemia. Rockey DC. **Semin Gastrointest Dis** 1999 Apr;10(2):53–64 (63 ref.)

OCCULT PRIMARY NEOPLASMS see **NEOPLASMS, UNKNOWN PRIMARY**

OCCULT SPINA BIFIDA see **SPINA BIFIDA OCCULTA**

OCCULT SPINAL DYSRAPHISM see **SPINA BIFIDA OCCULTA**

OCCULTISM

PSYCHOLOGY

[Occultism, parapsychology and the esoteric from the perspective of psychopathology] Scharfetter C. **Fortschr Neurol Psychiatr** 1998 Oct;66(10):474–82 (29 ref.) (Eng. Abstr.) **(Ger)**

OCCUPATIONAL DERMATITIS see **DERMATITIS, OCCUPATIONAL**

OCCUPATIONAL AIR POLLUTANTS see **AIR POLLUTANTS, OCCUPATIONAL**

OCCUPATIONAL DISEASES

see related
ACCIDENTS, OCCUPATIONAL

Recent advances: occupational disease. Cherry N. **BMJ** 1999 May 22;318(7195):1397–9 (39 ref.)

Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Ippolito G, et al. **Clin Infect Dis** 1999 Feb; 28(2):365–83 (122 ref.)

Work-related upper extremity complaints. Vender M, et al. **Instr Course Lect** 1999;48:693–7 (20 ref.)

Vocal problems among teachers: a review of prevalence, causes, prevention, and treatment. Mattiske JA, et al. **J Voice** 1998 Dec;12(4):489–99 (42 ref.)

Office technology and musculoskeletal disorders: building an ecological model. Amick BC 3rd, et al. **Occup Med** 1999 Jan–Mar;14(1):97–112, iv (37 ref.)

Ambiguities in office-related injury: the poverty of present approaches. Cherniack M, et al. **Occup Med** 1999 Jan–Mar; 14(1):1–16, iii (69 ref.)

RSI: a perspective from its birthplace. Gun RT, et al. **Occup Med** 1999 Jan–Mar;14(1):81–95, iv (57 ref.)

Surveillance and the problems of assessing office-related injury. Morse T. **Occup Med** 1999 Jan–Mar;14(1):73–80, iii (13 ref.)

Multiple nerve entrapment syndromes in office workers. Novak CB, et al. **Occup Med** 1999 Jan–Mar;14(1):39–59, iii (92 ref.)

Ammonia exposure: a common cause for sinusitis. A case report and review of the literature. Brautbar N. **Toxicol Ind Health** 1998 Nov–Dec;14(6):891–5 (10 ref.)

[Latex allergy] Jeannet-Peter N. **Rev Med Suisse Romande** 1999 Mar;119(3):227–9 (5 ref.) **(Fre)**

[Occupational asthma] Zuškin E, et al. **Lijec Vjesn** 1998 Mar–Apr;120(3–4):79–85 (63 ref.) (Eng. Abstr.) **(Ser)**

CHEMICALLY INDUCED

Maintenance work and asbestos-related cancers in the refinery and petrochemical sector. Finkelstein MM. **Am J Ind Med** 1999 Feb;35(2):201–5 (18 ref.)

Nylon flock-associated interstitial lung disease. Eschenbacher WL, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):2003–8 (9 ref.)

Non-Hodgkin's lymphoma risk derived from exposure to organic solvents: a review of epidemiologic studies. Rêgo MA. **Cad Saude Publica** 1998;14 Suppl 3:41–66 (98 ref.)

The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these finding to other dermatologic conditions and wound healing. Smith KJ. **Dermatol Clin** 1999 Jan;17(1):41–60, viii (52 ref.)

Trichloroethylene. I. Carcinogenicity of trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):211–4 (37 ref.)

Prevention of occupational allergy caused by exposure to acid anhydrides. Yokota K, et al. **Ind Health** 1999 Jul; 37(3):281–8 (53 ref.)

Occupational risk to male reproduction [editorial; comment] Bonde JP. **Int Arch Occup Environ Health** 1999 May; 72(3):133–4 (17 ref.) Comment on: Int Arch Occup Environ Health 1999 May;72(3):135–41.

Multiple chemical sensitivities: the social construction of an illness. Lax MB. **Int J Health Serv** 1998;28(4):725–45 (55 ref.)

Salud ocupacional [letter] Castleman B, et al. **Int J Occup Med Environ Health** 1998;11(2):195–7 (10 ref.)

Research on chronic, low-level exposure to formaldehyde: implications for neuropsychological assessment. Williams CW, et al. **J Clin Psychol** 1998 Oct;54(6):851–62 (90 ref.)

Can traditional epidemiology detect cancer risks caused by occupational exposure to pesticides? Georgellis A, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):159–66 (77 ref.)

New mechanistic model for organic diisocyanate-induced respiratory disease. Savolainen H. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):465–7 (31 ref.)

[Synthetic mineral fibers] Boillat MA. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):468–74 (30 ref.) (Eng. Abstr.) **(Fre)**

[Polyneuropathy and encephalopathy caused by organic solvents and mixed solvent solutions. Occupational medicine and neurologic aspects of a new occupational disease] Triebig G, et al. **Nervenarzt** 1999 Apr;70(4):306–14 (59 ref.) (Eng. Abstr.) **(Ger)**

[Information on a new occupational disease: "Lung cancer caused by polycyclic aromatic hydrocarbons with evidence of the effect of a cumulative dose of at least 100 benzo(a)pyrene years ([microgram/m3] * years)] Praml G, et al. **Pneumologie** 1998 Dec;52(12):684–6 (20 ref.) **(Ger)**

[Acute dimethylformamide (DMF) poisoning: a case report] Amatimaggio F, et al. **Med Lav** 1998 Nov–Dec;89(6):533–7 (14 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

General psychosocial and work-related stress and reduced fertility. Henriksen TB. **Scand J Work Environ Health** 1999; 25 Suppl 1:38–9 (11 ref.)

DIAGNOSIS

Current diagnostic methods for diisocyanate induced occupational asthma. Bernstein DI, et al. **Am J Ind Med** 1999 Oct;36(4):459–68 (35 ref.)

Latex allergy: a patient and health care system emergency. Kelly KJ, et al. **Ann Emerg Med** 1998 Dec;32(6):723–9 (42 ref.)

Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al. **Ann Occup Hyg** 1999 Jul;43(5):367–76 (15 ref.)

Investigation of occupational asthma. Cartier A. **Can Respir J** 1998 Jul–Aug;5 Suppl A:71A–6A (45 ref.)

The case for confirming occupational asthma: why, how much, how far? (revisited) [editorial; comment] Malo JL. **Eur Respir J** 1999 Mar;13(3):477–8 (14 ref.) Comment on: Eur Respir J 1999 Mar;13(3):482–8. Comment on: Eur Respir J 1999 Mar;13(3):489–95.

Carpal tunnel syndrome: is it work-related? [published erratum appears in Hosp Pract (Off Ed) 1999 Apr 15;34(4):63] Atcheson SG. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):49–56; quiz 147 (8 ref.)

A minireview of studies conducted in japan using finger-skin temperature during cold-stress tests for the diagnosis of hand-arm vibration syndrome. Harada N, et al. **Int Arch Occup Environ Health** 1999 Aug;72(5):330–4 (54 ref.)

The vocal athlete and endotracheal intubation: a management protocol. Loucks TM, et al. **J Voice** 1998 Sep;12(3):349–59 (35 ref.)

Disability: how successful are we in determining disability? Carey TS. **Neurol Clin** 1999 Feb;17(1):167–78 (27 ref.)

Occupational asthma. Practical points for diagnosis and management. Kuschner WG, et al. **West J Med** 1998 Dec; 169(6):342–50 (59 ref.)

[Compressive ischemic neuropathies of the upper extremities and work] Kadaňka Z, et al. **Cas Lek Cesk** 1999 Apr 19; 138(8):230–4 (23 ref.) (Eng. Abstr.) **(Cze)**

[Occupational asthma] Pauli G, et al. **Rev Prat** 1998 Jun 15; 48(12):1309–12 (14 ref.) (Eng. Abstr.) **(Fre)**

[Supplementary history and occupational dermatologic evaluation of medical bath workers, masseurs, and physical therapists] Wessbecher R, et al. **Hautarzt** 1998 Dec; 49(12):912–9 (64 ref.) (Eng. Abstr.) **(Ger)**

[The use of neurophysiopathological technics in assessing pain syndromes in industrial medicine and rehabilitation] Buonocore M, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec; 19(4):164–71 (47 ref.) (Eng. Abstr.) **(Ita)**

[The proposition of a rule for evaluating the percentage of health impairment due to occupationally related myocardial infarction] Szozda R, et al. **Med Pr** 1995;46(1):55–9 (8 ref.) (Eng. Abstr.) **(Pol)**

[Ulcers and regional adenopathies in a butcher] Maradona Hidalgo JA, et al. **Rev Clin Esp** 1998 Nov;198(11):773–4 (4 ref.) **(Spa)**

DRUG THERAPY

Latex allergy: a patient and health care system emergency. Kelly KJ, et al. **Ann Emerg Med** 1998 Dec;32(6):723–9 (42 ref.)

ECONOMICS

Cutting the costs of migraine: role of the employee health unit. Warshaw LJ, et al. **J Occup Environ Med** 1998 Nov; 40(11):943–53 (61 ref.)

Managed occupational health. Harris JS. **Occup Med** 1998 Oct–Dec;13(4):625–43, iii (67 ref.)

EPIDEMIOLOGY

Occupational cancer among women: research status and methodologic considerations. Blair A, et al. **Am J Ind Med** 1999 Jul;36(1):6–17 (42 ref.)

Women's reproductive health: some recent developments in occupational epidemiology. Lindbohm ML. **Am J Ind Med** 1999 Jul;36(1):18–24 (51 ref.)

Latex allergy in neurosurgical practice. Mazagri R, et al. **Childs Nerv Syst** 1999 Aug;15(8):404–7 (45 ref.)

Ten years of the SWORD project. Surveillance of Work-related and Occupational Respiratory Disease [see comments] Ross DJ. **Clin Exp Allergy** 1999 Jun;29(6):750–3 (23 ref.) Comment in: Clin Exp Allergy 1999 Jun;29(6):725–8.

Asbestos and cancer: An overview of current trends in Europe. Albin M, et al. **Environ Health Perspect** 1999 May; 107 Suppl 2:289–98 (73 ref.)

Occupational cancer in France: epidemiology, toxicology, prevention, and compensation. Aubrun JC, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:245–52 (65 ref.)

Introduction: Epidemiologic research and prevention of occupational cancer in Europe. Boffetta P, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:229–31 (19 ref.)

Occupational cancer in Germany. Brüske-Hohlfeld I. **Environ Health Perspect** 1999 May;107 Suppl 2:253–8 (20 ref.)

Occupational cancer in the European part of the Commonwealth of Independent States. Bulbulyan MA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:283–8 (53 ref.)

Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)

Occupational cancer in the United Kingdom. Coggon D. **Environ Health Perspect** 1999 May;107 Suppl 2:239–44 (48 ref.)

Occupational cancer in central European countries. Fabiánová E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:279–82 (19 ref.)

Occupational cancer in Spain. González CA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:273–7 (36 ref.)

Occupational cancer research in the Nordic countries. Kjaerheim K. **Environ Health Perspect** 1999 May;107 Suppl 2:233–8 (113 ref.)

Occupational cancer in Italy. Merler E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:259–71 (142 ref.)

Developments in occupational cohort studies. Checkoway H, et al. **Epidemiol Rev** 1998;20(1):100–11 (137 ref.)

Health and work among women in Italy: an overview of the epidemiological literature. Pirastu R, et al. **Eur J Epidemiol** 1999 Jan;15(1):51–7 (67 ref.)

Exposure-response relationship in the hand-arm vibration syndrome: an overview of current epidemiology research. Bovenzi M. **Int Arch Occup Environ Health** 1998 Nov; 71(8):509–19 (61 ref.)

Hearing and occupation. Uimonen S, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):156–61 (31 ref.)

Health impact of occupational risks in the informal sector in Zimbabwe. Loewenson RH. **Int J Occup Environ Health** 1998 Oct–Dec;4(4):264–74 (31 ref.)

Can traditional epidemiology detect cancer risks caused by occupational exposure to pesticides? Georgellis A, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):159–66 (77 ref.)

The impact of lean production and related new systems of work organization on worker health. Landsbergis PA, et al. **J Occup Health Psychol** 1999 Apr;4(2):108–30 (132 ref.)

Minority workers and communities. Frumkin H, et al. **Occup Med** 1999 Jul–Sep;14(3):495–517 (174 ref.)

Musculoskeletal disorders in visual display unit work: gender and work demands. Punnett L, et al. **Occup Med** 1999 Jan–Mar;14(1):113–24, iv (39 ref.)

Risk factors for musculoskeletal disorders among computer users. Tittiranonda P, et al. **Occup Med** 1999 Jan–Mar; 14(1):17–38, iii (73 ref.)

Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr–Jun;14(2):247–84 (222 ref.)

SWORD '97: surveillance of work-related and occupational respiratory disease in the UK. Ross DJ, et al. **Occup Med (Lond)** 1998 Nov;48(8):481–5 (9 ref.)

Occupational cancer risk in pilots and flight attendants: current epidemiological knowledge. Blettner M, et al. **Radiat Environ Biophys** 1998 Jul;37(2):75–80 (24 ref.)

Work-related cancer in the Nordic countries. Andersen A, et al. **Scand J Work Environ Health** 1999;25 Suppl 2:1–116 (155 ref.)

Lymphatic and hematopoietic cancer in teachers. Baker P, et al. **Scand J Work Environ Health** 1999 Feb;25(1):5–17 (38 ref.)

Suicide in nurses. Hawton K, et al. **Suicide Life Threat Behav** 1999 Spring;29(1):86–95 (48 ref.)

[Application of meta-analysis in epidemiological study of occupational neoplasms] Chen R, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):307–9 (8 ref.) **(Chi)**

[Survey of the effects of smoking in an occupational cohort study. Value and limits of a new method] Moulin JJ, et al. **Rev Epidemiol Sante Publique** 1998 Sep;46(4):289–97 (31 ref.) (Eng. Abstr.) **(Fre)**

[Significance of the label "risk duplication" in occupational medicine expert opinion and redefinition of occupational diseases] Manz A. **Gesundheitswesen** 1999 Jul;61(7):331–6 (23 ref.) (Eng. Abstr.) **(Ger)**

[The epidemiology of musculoskeletal changes due to biomechanical overload of the spine in the manual lifting of patients] Bordini L, et al. **Med Lav** 1999 Mar–Apr; 90(2):103–16 (47 ref.) (Eng. Abstr.) **(Ita)**

[Limitations in using international occupational disease statistics for comparative analysis] Indulski JA, et al. **Med Pr** 1998;49(3):291–6 (9 ref.) (Eng. Abstr.) **(Pol)**

[Methodological issues in epidemiological studies of repetitive strain injuries] Santos Filho SB, et al. **Cad Saude Publica** 1998 Jul–Sep;14(3):555–63 (34 ref.) (Eng. Abstr.) **(Por)**

OCCUPATIONAL DISEASES

ETIOLOGY

Heat stress and protective clothing: an emerging approach from the United States. Bernard TE. **Ann Occup Hyg** 1999 Jul;43(5):321–7 (22 ref.)

Development of a draft British standard: the assessment of heat strain for workers wearing personal protective equipment. Hanson MA. **Ann Occup Hyg** 1999 Jul; 43(5):309–19 (38 ref.)

Heat balance when wearing protective clothing. Havenith G. **Ann Occup Hyg** 1999 Jul;43(5):289–96 (11 ref.)

Clothing evaporative heat resistance—proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339–46 (17 ref.) Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.

International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297–308 (28 ref.)

Mechanisms and mediators in coal dust induced toxicity: a review. Schins RP, et al. **Ann Occup Hyg** 1999 Jan; 43(1):7–33 (256 ref.)

Radiofrequency (RF) sickness in the Lilienfeld Study: an effect of modulated microwaves? Johnson Liakouris AG. **Arch Environ Health** 1998 May–Jun;53(3):236–8 (27 ref.)

Noise-induced extra-aural pathology: a review and commentary. Alves-Pereira M.
Aviat Space Environ Med 1999 Mar;70(3 Pt 2):A7–21 (98 ref.)

The vibroacoustic disease—an emerging pathology. Castelo Branco NA, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A1–6 (55 ref.)

On the need to assess cancer risk in populations environmentally and occupationally exposed to virus and chemical agents in developing countries. Netto GF.
Cad Saude Publica 1998;14 Suppl 3:87–98 (76 ref.)

What can we learn from late-onset and occupational asthma? Papi A, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:174–80; discussion 203–5 (55 ref.)

Environmental skin diseases and the impact of common dermatoses on medical readiness. Meffert JJ.
Dermatol Clin 1999 Jan;17(1):1–17, vii (143 ref.)

Asbestos and cancer: An overview of current trends in Europe. Albin M, et al. **Environ Health Perspect** 1999 May; 107 Suppl 2:289–98 (73 ref.)

Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)

Current techniques for assessing physical exposure to work-related musculoskeletal risks, with emphasis on posture-based methods. Li G, et al. **Ergonomics** 1999 May; 42(5):674–95 (147 ref.)

Hand and arm injuries associated with repetitive manual work in industry: a review of disorders, risk factors and preventive measures. Muggleton JM, et al. **Ergonomics** 1999 May;42(5):714–39 (133 ref.)

Standardized management of patients and employees exposed to pertussis [see comments] Haiduven DJ, et al.
Infect Control Hosp Epidemiol 1998 Nov;19(11):861–4 (09 ref.) Comment in: Infect Control Hosp Epidemiol 1998 Nov;19(11):825–8.

The international electronics industry. LaDou J, et al.
Int J Occup Environ Health 1998 Jan–Mar;4(1):1–18 (26 ref.)

Occupational asthma: what have we learned? Cartier A.
J Allergy Clin Immunol 1998 Nov;102(5):S90–5 (45 ref.)

Helicobacter pylori and endoscopy. Williams CL.
J Hosp Infect 1999 Apr;41(4):263–8 (56 ref.)

Ballet dancers—pregnancy outcomes. Barry S.
J R Soc Health 1998 Dec;118(6):360–2 (10 ref.)

Health hazards in the meatpacking industry. Campbell DS.
Occup Med 1999 Apr–Jun;14(2):351–72 (211 ref.)

Health and safety concerns in fisheries and aquaculture. Durborow RM. **Occup Med** 1999 Apr–Jun;14(2):373–406 (258 ref.)

Minority workers and communities. Frumkin H, et al.
Occup Med 1999 Jul–Sep;14(3):495–517 (174 ref.)

Occupational allergy to animals. Seward JP. **Occup Med** 1999 Apr–Jun;14(2):285–304 (130 ref.)

Illness and injury in animal confinement workers. Von Essen S, et al. **Occup Med** 1999 Apr–Jun;14(2):337–50 (69 ref.)

Work-related asthma and latex allergy. Sorting out the types, causes, and consequences. Avila PC, et al.
Postgrad Med 1999 Jun;105(7):39–46 (19 ref.)

Optical radiation hazards of welding arcs. Tenkate TD.
Rev Environ Health 1998 Jul–Sep;13(3):131–46 (99 ref.)

Work-related cancer in the Nordic countries. Andersen A, et al. **Scand J Work Environ Health** 1999;25 Suppl 2:1–116 (155 ref.)

Shift work, risk factors and cardiovascular disease. Bøggild H, et al. **Scand J Work Environ Health** 1999 Apr; 25(2):85–99 (112 ref.)

Shift work and reproductive health. Nurminen T.
Scand J Work Environ Health 1998;24 Suppl 3:28–34 (27 ref.)

Psychosocial aspects of stress, health and safety on North Sea installations. Parkes KR.
Scand J Work Environ Health 1998 Oct;24(5):321–33 (84 ref.)

The influence of occupation on lumbar degeneration. Videman T, et al. **Spine** 1999 Jun 1;24(11):1164–8 (31 ref.)

[Relationship between occupation and elbow pain, epicondylitis] Pedersen LK, et al. **Ugeskr Laeger** 1999 Aug 23;161(34):4751–5 (32 ref.) (Eng. Abstr.) **(Dan)**

[The vibration syndrome] Noël B. **J Mal Vasc** 1998 Oct; 23(4):251–6 (59 ref.) (Eng. Abstr.) **(Fre)**

[Psychosocial factors at work and cardiovascular diseases: contribution of the Effort-Reward Imbalance model] Niedhammer I, et al. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):398–410 (92 ref.) (Eng. Abstr.) **(Fre)**

[When work organization becomes the source of pathologies] Gonik V. **Rev Med Suisse Romande** 1999 Jul;119(7):549–54 (12 ref.) **(Fre)**

[Raynaud's phenomena of occupational origin] Hatron PY, et al. **Rev Prat** 1998 Oct 1;48(15):1653–8 (12 ref.) (Eng. Abstr.) **(Fre)**

[Allergologic significance of the epithelium of domestic animals] Wallenstein G. **Pneumologie** 1998 Nov; 52(11):602–7 (79 ref.) **(Ger)**

[Endotoxins in the workplace and in the environment] Danuser B, et al. **Schweiz Med Wochenschr** 1999 Mar 27; 129(12):475–83 (56 ref.) (Eng. Abstr.) **(Ger)**

[Chemical and physical characteristics and toxicology of man-made mineral fibers] Foà V, et al. **Med Lav** 1999 Jan–Feb;90(1):10–52 (100 ref.) (Eng. Abstr.) **(Ita)**

[Occupational respiratory allergopathies: environmental monitoring, air allergens, prevention] Previdi M, et al.
Med Lav 1998 Nov–Dec;89(6):481–98 (68 ref.) (Eng. Abstr.) **(Ita)**

[Polymorphism of protein systems and individual predisposition to broncho-pulmonary occupational diseases (literature review)] Kuz'mina LP. **Med Tr Prom Ekol** 1999; (5):28–31 (25 ref.) **(Rus)**

[Effects of iron-containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27–37 (123 ref.) **(Rus)**

GENETICS

Ethical issues in the use of genetic markers in occupational epidemiologic research. Schulte PA, et al.
J Occup Environ Med 1999 Aug;41(8):639–46 (36 ref.)

IMMUNOLOGY

Occupational respiratory allergy in bakery workers: a review of the literature. Houba R, et al. **Am J Ind Med** 1998 Dec; 34(6):529–46 (165 ref.)

What can we learn from late-onset and occupational asthma? Papi A, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:174–80; discussion 203–5 (55 ref.)

MICROBIOLOGY

Erysipelothrix rhusiopathiae: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. Brooke CJ, et al. **J Med Microbiol** 1999 Sep;48(9):789–99 (95 ref.)

[Capnocytophaga canimorsus infections: a possibly fatal complication of bite wounds] Kramer AM, et al.
Tijdschr Diergeneeskd 1999 Feb 15;124(4):108–10 (19 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOPATHOLOGY

Occupational and allergic rhinitis: impact on worker productivity and safety. Slavin RG.
Allergy Asthma Proc 1998 Sep–Oct;19(5):277–84 (58 ref.)

Heat balance when wearing protective clothing. Havenith G. **Ann Occup Hyg** 1999 Jul;43(5):289–96 (11 ref.)

Clothing evaporative heat resistance—proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339–46 (17 ref.) Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.

Working in a moving environment. Wertheim AH.
Ergonomics 1998 Dec;41(12):1845–58 (70 ref.)

Evidence for neutrophil activation in occupational asthma. Jung KS, et al. **Respirology** 1999 Sep;4(3):303–6 (16 ref.)

New mechanistic model for organic diisocyanate-induced respiratory disease. Savolainen H.
Schweiz Med Wochenschr 1999 Mar 27;129(12):465–7 (31 ref.)

PREVENTION & CONTROL

Protecting the health and safety of working teenagers. Rubenstein H, et al. **Am Fam Physician** 1999 Aug; 60(2):575–80, 587–8 (07 ref.)

Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al.
Ann Occup Hyg 1999 Jul;43(5):367–76 (15 ref.)

The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea. Yu IJ, et al.
Appl Occup Environ Hyg 1999 Jun;14(6):356–8 (15 ref.)

An overview of radiation safety regulatory recommendations and requirements. Balter S. **Catheter Cardiovasc Interv** 1999 Aug;47(4):469–74 (15 ref.)

Protection of personnel and environment against Creutzfeldt-Jakob disease in pathology laboratories. Richard M, et al. **Clin Exp Pathol** 1999;47(3–4):192–200 (23 ref.)

Occupational cancer in France: epidemiology, toxicology, prevention, and compensation. Aubrun JC, et al.
Environ Health Perspect 1999 May;107 Suppl 2:245–52 (65 ref.)

Introduction: Epidemiologic research and prevention of occupational cancer in Europe. Boffetta P, et al.
Environ Health Perspect 1999 May;107 Suppl 2:229–31 (19 ref.)

Occupational cancer in Germany. Brüske-Hohlfeld I.
Environ Health Perspect 1999 May;107 Suppl 2:253–8 (20 ref.)

Occupational cancer in the European part of the Commonwealth of Independent States. Bulbulyan MA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:283–8 (53 ref.)

Occupational cancer in central European countries. Fabiánová E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:279–82 (19 ref.)

Occupational cancer in Spain. González CA, et al.
Environ Health Perspect 1999 May;107 Suppl 2:273–7 (36 ref.)

Occupational cancer in Italy. Merler E, et al.
Environ Health Perspect 1999 May;107 Suppl 2:259–71 (142 ref.)

Hand and arm injuries associated with repetitive manual work in industry: a review of disorders, risk factors and preventive measures. Muggleton JM, et al. **Ergonomics** 1999 May;42(5):714–39 (133 ref.)

Occupational health psychology: an emerging discipline. Sauter SL, et al. **Ind Health** 1999 Apr;37(2):199–211 (90 ref.)

Prevention of occupational allergy caused by exposure to acid anhydrides. Yokota K, et al. **Ind Health** 1999 Jul; 37(3):281–8 (53 ref.)

Surveillance and occupational health. Fine LJ.
Int J Occup Environ Health 1999 Jan–Mar;5(1):26–9 (19 ref.)

Some theoretical remarks regarding the integration of somatic and psychosocial risk factors of coronary artery disease in preventive programmes in occupational medicine. Schmahl FW.
Int J Occup Med Environ Health 1998;11(4):285–9 (12 ref.)

Updating of hygiene standards for carbon disulfide based on health risk assessment. Stetkiewicz J, et al.
Int J Occup Med Environ Health 1998;11(2):129–43 (93 ref.)

Risk and prevention of hepatitis C virus infection. Implications for dentistry. Cleveland JL, et al.
J Am Dent Assoc 1999 May;130(5):641–7 (44 ref.)

Traumatic stress—is prevention better than cure? [see comments] Deahl M. **J R Soc Med** 1998 Oct;91(10):531–3 (21 ref.) Comment in: J R Soc Med 1999 Jan;92(1):52.

The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Gulumian M. **Mol Cell Biochem** 1999 Jun; 196(1–2):69–77 (106 ref.)

Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC.
Nurs Clin North Am 1999 Mar;34(1):213–25 (11 ref.)

The risk of occupational exposure and infection with infectious disease. Sharbaugh RJ. **Nurs Clin North Am** 1999 Jun;34(2):493–508 (29 ref.)

Health hazards in the meatpacking industry. Campbell DS.
Occup Med 1999 Apr–Jun;14(2):351–72 (211 ref.)

A strategic approach to occupational injuries. Comstock ML.
Occup Med 1998 Oct–Dec;13(4):823–40, v (23 ref.)

Health and safety concerns in fisheries and aquaculture. Durborow RM. **Occup Med** 1999 Apr–Jun;14(2):373–406 (258 ref.)

Prevention of work-related disability. Feldstein A, et al.
Occup Med 1998 Oct–Dec;13(4):841–50, v (13 ref.)

Occupational allergy to animals. Seward JP. **Occup Med** 1999 Apr–Jun;14(2):285–304 (130 ref.)

Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr–Jun;14(2):247–84 (222 ref.)

AIDS: what should nurses know? Richards T.
P N G Med J 1996 Sep;39(3):228–9 (2 ref.)

Infection control practices and the pregnant health care worker. Mirza A, et al. **Pediatr Infect Dis J** 1999 Jan; 18(1):18–22 (51 ref.)

Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity. Roels HA, et al.
Ren Fail 1999 May–Jul;21(3–4):251–62 (57 ref.)

Legionella infection and control in occupational and environmental health [published erratum appears in Rev Environ Health 1999 Jan–Mar;14(1):following table of contents] Fujii J, et al. **Rev Environ Health** 1998 Oct–Dec; 13(4):179–203 (46 ref.)

Work-related low-back problems in nursing. Lagerström M, et al. **Scand J Work Environ Health** 1998 Dec;24(6):449–64 (86 ref.)

The role of the supervisor in training social workers treating HIV infected persons in a hospital. Itzhaky H, et al.
Soc Work Health Care 1999;29(1):57–74 (32 ref.)

[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV] Dubey BR, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):587–92 (9 ref.) **(Fre)**

[RKI "Current version of prophylactic drug therapy after occupational HIV-exposure". Consensus conference 21 November 1997 in Munich] **Chirurg** 1998 Jul;69(7):suppl 224–6 (0 ref.) **(Ger)**

[German Society of Pneumology. Recommendations for prevention of occupational asthma] Baur X, et al.
Pneumologie 1998 Sep;52(9):504–14 (101 ref.) **(Ger)**

[Post-exposure prevention of HIV infection] Möst J.
Wien Med Wochenschr 1998;148(23–24):547–9 (5 ref.) (Eng.

Abstr.) **(Ger)**

[Role and significance of information tools in occupational asthma] Moscato G, et al. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):128–30 (18 ref.) (Eng. Abstr.) **(Ita)**

[Evaluation of the nervous system in workers as needed for preventive care. Methodical indicators. II. Objective examinations] Polakowska B. **Med Pr** 1995;46(1):61–5 (7 ref.) (Eng. Abstr.) **(Pol)**

[Ergonomic aspects in the prevention of occupational cumulative trauma disorders of the locomotor system] Swat K. **Med Pr** 1998;49(6):589–602 (37 ref.) (Eng. Abstr.) **(Pol)**

[The standardization of the criteria for the prevention of occupational postexposure to the human immunodeficiency virus] Haro Pérez AM, et al. **Rev Clin Esp** 1999 Apr; 199(4):233–8 (89 ref.) **(Spa)**

PSYCHOLOGY

Occupational health psychology: an emerging discipline. Sauter SL, et al. **Ind Health** 1999 Apr;37(2):199–211 (90 ref.)

[When work organization becomes the source of pathologies] Gonik V. **Rev Med Suisse Romande** 1999 Jul;119(7):549–54 (12 ref.) **(Fre)**

[Workload and stress in caring for the elderly: status of research and research agenda] Zimber A. **Z Gerontol Geriatr** 1998 Dec;31(6):417–25 (78 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[The use of neurophysiopathological technics in assessing pain syndromes in industrial medicine and rehabilitation] Buonocore M, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec; 19(4):164–71 (47 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Sports medicine at work. Brown GJ. **Br J Sports Med** 1999 Feb;33(1):5 (6 ref.)

The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these finding to other dermatologic conditions and wound healing. Smith KJ. **Dermatol Clin** 1999 Jan;17(1):41–60, viii (52 ref.)

State of the art case management. Hall JC. **Occup Med** 1998 Oct–Dec;13(4):705–15, iv (11 ref.)

OCCUPATIONAL EXPOSURE

see related
AIR POLLUTANTS, OCCUPATIONAL
MULTIPLE CHEMICAL SENSITIVITY

Women's reproductive health: some recent developments in occupational epidemiology. Lindbohm ML. **Am J Ind Med** 1999 Jul;36(1):18–24 (51 ref.)

Asbestosis: a marker for the increased risk of lung cancer among workers exposed to asbestos [see comments] [published erratum appears in Chest 1999 May;115(5):1485] Weiss W. **Chest** 1999 Feb;115(2):536–49 (79 ref.) Comment in: Chest 1999 Feb;115(2):320–2.

Diesel exhaust in the occupational setting. Current understanding of pulmonary health effects. Comstock ML. **Clin Lab Med** 1998 Dec;18(4):767–79 (45 ref.)

The toxicology of hydroquinone—relevance to occupational and environmental exposure. DeCaprio AP. **Crit Rev Toxicol** 1999 May;29(3):283–330 (414 ref.)

Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Sessink PJ, et al. **Drug Saf** 1999 Apr;20(4):347–59 (113 ref.)

Occupational heat exposure and male fertility: a review. Thonneau P, et al. **Hum Reprod** 1998 Aug;13(8):2122–5 (34 ref.)

Benzoyl peroxide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:345–58 (46 ref.)

The corruption process of a law enforcement officer: a paradigm of occupational stress and deviancy [see comments] McCafferty FL, et al. **J Am Acad Psychiatry Law** 1998;26(3):433–58 (85 ref.) Comment in: J Am Acad Psychiatry Law 1999;27(1):178–9.

Hepatitis viruses A, B, C, D, E and G: implications for dental personnel. Gillcrist JA. **J Am Dent Assoc** 1999 Apr; 130(4):509–20 (97 ref.)

Hazards for nearby residents and cleanup workers of waste sites. Leigh JP, et al. **J Occup Environ Med** 1999 May; 41(5):331–48 (42 ref.)

Hodgkin's disease, work, and the environment. A review. McCunney RJ. **J Occup Environ Med** 1999 Jan;41(1):36–46 (80 ref.)

The risk of occupational exposure and infection with infectious disease. Sharbaugh RJ. **Nurs Clin North Am** 1999 Jun;34(2):493–508 (29 ref.)

Effect of measurement error on epidemiological studies of environmental and occupational exposures. Armstrong BG. **Occup Environ Med** 1998 Oct;55(10):651–6 (7 ref.)

Respirable crystalline silica exposure associated with the installation and removal of RCF and conventional silica-containing refractories in industrial furnaces. Maxim DL, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):44–63 (68 ref.)

Lead contamination in Uruguay. Mañay N, et al. **Rev Environ Contam Toxicol** 1999;159:25–39 (21 ref.)

New mechanistic model for organic diisocyanate-induced respiratory disease. Savolainen H. **Schweiz Med Wochenschr** 1999 Mar 27;129(12):465–7 (31 ref.)

[Asbestos exposure and pleuropulmonary cancer] Begin R. **Rev Mal Respir** 1998 Dec;15(6):723–30 (41 ref.) (Eng. Abstr.) **(Fre)**

[Chemical and physical characteristics and toxicology of man-made mineral fibers] Foà V, et al. **Med Lav** 1999 Jan–Feb;90(1):10–52 (100 ref.) (Eng. Abstr.) **(Ita)**

[Manganism and parkinsonism] Kondo T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):41–4 (24 ref.) **(Jpn)**

[Characterization of exposure in studies on occupational epidemiology] Svendsen K. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4399–401 (19 ref.) **(Nor)**

[Role of emotional stress in development of somatic injuries in liquidators of the Chernobyl power plant accident irradiated with small doses] Moroz BB, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):97–105 (41 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Emergency medical services. Arndt SD. **Am J Med** 1997 May 19;102(5B):104–5 (09 ref.)

Legal and ethical issues in revising human immunodeficiency virus postexposure protocols. Barnes M. **Am J Med** 1997 May 19;102(5B):111–2; discussion 113–4 (05 ref.)

Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Bell DM. **Am J Med** 1997 May 19;102(5B):9–15 (56 ref.)

The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Blauvelt A. **Am J Med** 1997 May 19;102(5B):16–20 (31 ref.)

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117–24; discussion 125–6 (43 ref.)

Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)

Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Ciesielski CA, et al. **Am J Med** 1997 May 19;102(5B):115–6 (11 ref.)

Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98–101 (10 ref.)

Principles of clinical pharmacology in postexposure prophylaxis. Flexner CW. **Am J Med** 1997 May 19; 102(5B):32–8 (32 ref.)

Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Gerberding JL. **Am J Med** 1997 May 19;102(5B):85–9 (07 ref.)

Postexposure chemoprophylaxis against HIV: what are the implications for people with AIDS and the organizations that serve them? Hodel D. **Am J Med** 1997 May 19; 102(5B):106–10 (10 ref.)

Failures of zidovudine postexposure prophylaxis. Jochimsen EM. **Am J Med** 1997 May 19;102(5B):52–5; discussion 56–7 (20 ref.)

Issues complicating the implementation of postexposure prophylaxis. L'Ecuyer PB, et al. **Am J Med** 1997 May 19; 102(5B):90–4 (50 ref.)

Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Pinto LA, et al. **Am J Med** 1997 May 19;102(5B):21–4 (31 ref.)

Candidate antiretroviral agents for use in postexposure prophylaxis. Saag MS. **Am J Med** 1997 May 19; 102(5B):25–31 (38 ref.)

Toxicity of antiretroviral agents. Struble KA, et al. **Am J Med** 1997 May 19;102(5B):65–7; discussion 68–9 (00 ref.)

Chemotherapy. Potential occupational hazards [see comments] Del Gaudio D, et al. **Am J Nurs** 1998 Nov; 98(11):59–65 (8 ref.) Comment in: Am J Nurs 1999 May;99(5):14.

Speech audiometry in noise-exposed workers: the SRT-PTA relationship revisited. Picard M, et al. **Audiology** 1999 Jan–Feb;38(1):30–43 (106 ref.)

Pregnancy and in-flight cosmic radiation [see comments] Geeze DS. **Aviat Space Environ Med** 1998 Nov; 69(11):1061–4 (23 ref.) Comment in: Aviat Space Environ Med 1999 May;70(5):533.

On the need to assess cancer risk in populations environmentally and occupationally exposed to virus and chemical agents in developing countries. Netto GF. **Cad Saude Publica** 1998;14 Suppl 3:87–98 (76 ref.)

Non-Hodgkin's lymphoma risk derived from exposure to organic solvents: a review of epidemiologic studies. Rêgo MA. **Cad Saude Publica** 1998;14 Suppl 3:41–66 (98 ref.)

Immunological disorders in men exposed to metallic mercury vapour. A review. Moszczyński P. **Cent Eur J Public Health** 1999 Feb;7(1):10–4 (57 ref.)

Environmental skin diseases and the impact of common dermatoses on medical readiness. Meffert JJ. **Dermatol Clin** 1999 Jan;17(1):1–17, vii (143 ref.)

The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these finding to other dermatologic conditions and wound healing. Smith KJ. **Dermatol Clin** 1999 Jan;17(1):41–60, viii (52 ref.)

Maximum workplace concentration values and carcinogenicity classification for mixtures. Bartsch R, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1291–3 (18 ref.)

The case for confirming occupational asthma: why, how much, how far? (revisited) [editorial; comment] Malo JL. **Eur Respir J** 1999 Mar;13(3):477–8 (14 ref.) Comment on: Eur Respir J 1999 Mar;13(3):482–8. Comment on: Eur Respir J 1999 Mar;13(3):489–95.

Standardized management of patients and employees exposed to pertussis [see comments] Haiduven DJ, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):861–4 (09 ref.) Comment in: Infect Control Hosp Epidemiol 1998 Nov;19(11):825–8.

Occupational risk to male reproduction [editorial; comment] Bonde JP. **Int Arch Occup Environ Health** 1999 May; 72(3):133–4 (17 ref.) Comment on: Int Arch Occup Environ Health 1999 May;72(3):135–41.

Exposure-response relationship in the hand-arm vibration syndrome: an overview of current epidemiology research. Bovenzi M. **Int Arch Occup Environ Health** 1998 Nov; 71(8):509–19 (61 ref.)

Multiple chemical sensitivities: the social construction of an illness. Lax MB. **Int J Health Serv** 1998;28(4):725–45 (55 ref.)

The international electronics industry. LaDou J, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):1–18 (26 ref.)

Occupational epidemiology in agriculture: a case study in the southern African context. London L. **Int J Occup Environ Health** 1998 Oct–Dec;4(4):245–56 (47 ref.)

Toxic keratopathy. DeRosa AJ. **Int Ophthalmol Clin** 1998 Fall;38(4):15–22 (57 ref.)

Reproductive toxicity of occupational mercury. A review of the literature. Schuurs AH. **J Dent** 1999 May; 27(4):249–56 (101 ref.)

Helicobacter pylori and endoscopy. Williams CL. **J Hosp Infect** 1999 Apr;41(4):263–8 (56 ref.)

Ethical issues in the use of genetic markers in occupational epidemiologic research. Schulte PA, et al. **J Occup Environ Med** 1999 Aug;41(8):639–46 (36 ref.)

Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity? [editorial; comment] Brunt EM. **Liver** 1999 Aug;19(4):263–4 (12 ref.) Comment on: Liver 1999 Aug;19(4):299–304.

Health effects of asbestos exposure in humans: a quantitative assessment. Boffetta P. **Med Lav** 1998 Nov–Dec; 89(6):471–80 (33 ref.)

Manganese neurotoxicity in industrial exposures: proof of effects, critical exposure level, and sensitive tests. Iregren A. **Neurotoxicology** 1999 Apr–Jun;20(2–3):315–23 (27 ref.)

Peripheral biomarkers and exposure to manganese. Smargiassi A, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):401–6 (37 ref.)

Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC. **Nurs Clin North Am** 1999 Mar;34(1):213–25 (11 ref.)

Minority workers and communities. Frumkin H, et al. **Occup Med** 1999 Jul–Sep;14(3):495–517 (174 ref.)

Chemical hazards faced by animal handlers. Meggs WJ. **Occup Med** 1999 Apr–Jun;14(2):213–24 (63 ref.)

Anesthesia hazards to animal workers. Meyer RE. **Occup Med** 1999 Apr–Jun;14(2):225–34 (35 ref.)

Euthanasia hazards. Morrow WE. **Occup Med** 1999 Apr–Jun; 14(2):235–46 (52 ref.)

Optical radiation hazards of welding arcs. Tenkate TD. **Rev Environ Health** 1998 Jul–Sep;13(3):131–46 (99 ref.)

Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:40–3 (8 ref.)

Effects of occupational solvent exposure on fertility. Lindbohm ML. **Scand J Work Environ Health** 1999;25 Suppl 1:44–6 (10 ref.)

The influence of occupation on lumbar degeneration. Videman T, et al. **Spine** 1999 Jun 1;24(11):1164–8 (31 ref.)

Green tobacco sickness. McBride JS, et al. **Tob Control** 1998 Autumn;7(3):294–8 (33 ref.)

Immune parameters in biological monitoring of pesticide exposure: current knowledge and perspectives. Colosio C, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):285–95 (28 ref.)

[Risks of using cytostatic drugs in veterinary medical practice] Pellicaan CH, et al. **Tijdschr Diergeneeskd** 1999 Apr 1;124(7):210–5 (25 ref.) (Eng. Abstr.) **(Dut)**

[Indoor pollution and health] Kummer J. **Rev Med Brux** 1998 Sep;19(4):A363–6 (7 ref.) (Eng. Abstr.) **(Fre)**

[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV] Dubey BR, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):587–92 (9 ref.) **(Fre)**

[Risk and clinical surveillance of workers exposed to asbestos] Ameille J. **Rev Prat** 1998 Jun 15;48(12):1299–302 (10 ref.) (Eng. Abstr.) **(Fre)**

[Yesterday's and today's pneumoconiosis] De Vuyst P. **Rev Prat** 1998 Jun 15;48(12):1324–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Occupational exposure and environmental pollution: the role of inhalation anesthetics with special consideration of sevoflurane] Hobbhahn J, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S77–86 (46 ref.) (Eng. Abstr.) **(Ger)**

[Occupational and environmental bronchial asthma] Baur X.

Internist (Berl) 1999 Aug;40(8):844–8 (18 ref.) **(Ger)**
[Neurologic side effects of chemicals used in industry] Igisu H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):628–32 (16 ref.) **(Jpn)**
[Behavioral effects of exposure as indicators of neurotoxicity] Gralewicz S. **Med Pr** 1998;49(4):407–14 (37 ref.) (Eng. Abstr.) **(Pol)**
[The role of free radicals in mechanisms of biological function exposed to weak, constant and net magnetic fields] Zmyślony M, et al. **Med Pr** 1998;49(2):177–86 (40 ref.) (Eng. Abstr.) **(Pol)**
[The effect of the biological factors of an industrial environment on the health status of workers] Krasniuk EP, et al. **Lik Sprava** 1999 Jan–Feb;(1):11–8 (31 ref.) **(Rus)**
[The main pathogenetic mechanisms in occupational diseases of lungs of dust-related etiology. Part I. From an experiment to a concept] Velichnovskii BT. **Med Tr Prom Ekol** 1998;(10):28–38 (23 ref.) **(Rus)**

ANALYSIS

Studying the determinants of exposure: a review of methods. Burstyn I, et al. **Am Ind Hyg Assoc J** 1999 Jan–Feb; 60(1):57–72 (62 ref.)
Biological monitoring: the role of toxicokinetics and physiologically based pharmacokinetic modeling. Mason H, et al. **Am Ind Hyg Assoc J** 1999 Mar–Apr;60(2):237–42 (31 ref.)
Industrial hygiene chemistry: keeping pace with rapid change in the workplace. Draper WM, et al. **Anal Chem** 1999 Jun 15;71(12):33R–60R (657 ref.)
Exposure of U.S. workers to environmental tobacco smoke. Hammond SK. **Environ Health Perspect** 1999 May;107 Suppl 2:329–40 (48 ref.)
Workshop summary: assessing exposure to environmental tobacco smoke in the workplace. Samet JM. **Environ Health Perspect** 1999 May;107 Suppl 2:309–12 (20 ref.)
Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:40–3 (8 ref.)
Exposure and effect monitoring: a critical appraisal of their practical application. Aitio A, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):137–47 (39 ref.)
[Uses of nasal lavage in occupational medicine and environmental medicine] Qu R, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):378–9 (16 ref.) **(Chi)**
[Retrospective estimation methods of pesticide occupational exposure] Baldi I, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):165–74 (75 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Changes in the classification of carcinogenic chemicals in the work area. Section III of the German List of MAK and BAT Values. Neumann HG, et al. **Int Arch Occup Environ Health** 1998 Nov;71(8):566–74 (36 ref.)

PREVENTION & CONTROL

Sustainable production: a proposed strategy for the work environment. Quinn MM, et al. **Am J Ind Med** 1998 Oct; 34(4):297–304 (30 ref.)
Radiation safety. Shymko M, et al. **AORN J** 1998 Oct; 68(4):596–602; quiz 603–4, 606, 609–10 (35 ref.)
Buildings operations and ETS exposure. Spengler JD. **Environ Health Perspect** 1999 May;107 Suppl 2:313–7 (18 ref.)
Prudent management of minors with occupational exposures to hazardous agents: the radiation protection "standard of care". Emery RJ, et al. **Inj Prev** 1998 Sep;4(3):232–5 (28 ref.)
Surveillance and occupational health. Fine LJ. **Int J Occup Environ Health** 1999 Jan–Mar;5(1):26–9 (19 ref.)
Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. Henderson DK. **JAMA** 1999 Mar 10;281(10):931–6 (63 ref.)
Anesthesia hazards to animal workers. Meyer RE. **Occup Med** 1999 Apr–Jun;14(2):225–34 (35 ref.)
Euthanasia hazards. Morrow WE. **Occup Med** 1999 Apr–Jun; 14(2):235–46 (52 ref.)
Infection control practices and the pregnant health care worker. Mirza A, et al. **Pediatr Infect Dis J** 1999 Jan; 18(1):18–22 (51 ref.)
A review of infection control practices, risk reduction, and legislative regulations for blood-borne disease: applications for emergency medical services. Rinnert KJ. **Prehosp Emerg Care** 1998 Jan–Mar;2(1):70–5 (40 ref.)
Radiation safety considerations for diagnostic radiology personnel. Brateman L. **Radiographics** 1999 Jul–Aug; 19(4):1037–55 (33 ref.)
Minimizing occupational exposure. Shymko MJ. **Radiol Technol** 1998 Sep–Oct;70(1):89–90 (3 ref.)
Biological monitoring in occupational and environmental toxicology. Mutti A. **Toxicol Lett** 1999 Sep 5; 108(2–3):77–89 (52 ref.)
[Can we optimize radioprotection for medical workers?] Aubert B, et al. **J Radiol** 1998 Apr;79(4):307–12 (17 ref.) (Eng. Abstr.) **(Fre)**
[The toxicology and prevention of the risks of occupational exposure to aromatic polycyclic hydrocarbons. II. Toxicology. Exposure assessment. Environmental and biological monitoring] Apostoli P, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):137–51 (54 ref.) (Eng. Abstr.) **(Ita)**
[The toxicology and prevention of the risks of occupational exposure to aromatic polycyclic hydrocarbons. III. The effects: epidemiological evidence, early effects. Individual hypersusceptibility. Health surveillance] Porru S, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):152–63 (60 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea. Yu IJ, et al. **Appl Occup Environ Hyg** 1999 Jun;14(6):356–8 (15 ref.)
Updating of hygiene standards for carbon disulfide based on health risk assessment. Stetkiewicz J, et al. **Int J Occup Med Environ Health** 1998;11(2):129–43 (93 ref.)
Proposal for the assessment of quantitative dermal exposure limits in occupational environments: Part 1. Development of a concept to derive a quantitative dermal occupational exposure limit. Bos PM, et al. **Occup Environ Med** 1998 Dec;55(12):795–804 (48 ref.)
Occupational hygiene science and its application in occupational health policy, at home and abroad. Vincent JH. **Occup Med (Lond)** 1999 Jan;49(1):27–35 (22 ref.)
Biological monitoring of exposure to pesticides: current issues. He F. **Toxicol Lett** 1999 Sep 5;108(2–3):277–83 (43 ref.)

STATISTICS & NUMERICAL DATA

Occupational cancer among women: research status and methodologic considerations. Blair A, et al. **Am J Ind Med** 1999 Jul;36(1):6–17 (42 ref.)

OCCUPATIONAL GROUPS

see related
OCCUPATIONS

OCCUPATIONAL HEALTH

Sustainable production: a proposed strategy for the work environment. Quinn MM, et al. **Am J Ind Med** 1998 Oct; 34(4):297–304 (30 ref.)
Chemotherapy. Potential occupational hazards [see comments] Del Gaudio D, et al. **Am J Nurs** 1998 Nov; 98(11):59–65 (8 ref.) Comment in: Am J Nurs 1999 May;99(5):14.
Worksite physical activity interventions. Dishman RK, et al. **Am J Prev Med** 1998 Nov;15(4):344–61 (95 ref.)
Industrial hygiene databases: structure and function. Van Dyke MV. **Appl Occup Environ Hyg** 1999 Jul;14(7):427–32 (7 ref.)
Selection, training, and support of relief workers: an occupational health issue. McCall M, et al. **BMJ** 1999 Jan 9;318(7176):113–6 (27 ref.)
Protection of personnel and environment against Creutzfeldt-Jakob disease in pathology laboratories. Richard M, et al. **Clin Exp Pathol** 1999;47(3–4):192–200 (23 ref.)
Violence in the emergency department. Blanchard JC, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):717–31, viii (39 ref.)
Occupational cancer in France: epidemiology, toxicology, prevention, and compensation. Aubrun JC, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:245–52 (65 ref.)
Occupational cancer in central European countries. Fabiánová E, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:279–82 (19 ref.)
Occupational cancer in Spain. González CA, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:273–7 (36 ref.)
Effective presentation of radiation safety training--risk communication: an important function of radiation safety training. Johnson RH Jr. **Health Phys** 1999 Feb;76(2 Suppl):S10–5 (7 ref.)
Occupational health psychology: historical roots and future directions. Quick JC. **Health Psychol** 1999 Jan;18(1):82–8 (47 ref.)
Epidemiology of job stress and health in Japan: review of current evidence and future direction. Kawakami N, et al. **Ind Health** 1999 Apr;37(2):174–86 (112 ref.)
Ergonomic strategies for improving working conditions in some developing countries in Asia. Kawakami T, et al. **Ind Health** 1999 Apr;37(2):187–98 (33 ref.)
Occupational stress in human computer interaction. Smith MJ, et al. **Ind Health** 1999 Apr;37(2):157–73 (82 ref.)
Infection control in gene therapy [see comments] Evans ME, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):568–76 (71 ref.) Comment in: Infect Control Hosp Epidemiol 1999 Aug;20(8):530–2.
Prudent management of minors with occupational exposures to hazardous agents: the radiation protection "standard of care". Emery RJ, et al. **Inj Prev** 1998 Sep;4(3):232–5 (28 ref.)
Occupational health in Australia. Phoon WO. **Int Arch Occup Environ Health** 1998 Sep;71(6):363–71 (13 ref.)
Multiple chemical sensitivities: the social construction of an illness. Lax MB. **Int J Health Serv** 1998;28(4):725–45 (55 ref.)
The manipulation of international scientific organizations [editorial] Castleman BI, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):53–5 (17 ref.)
The role of information dissemination in sustainability of international partnerships. Delclos GL, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):203–8 (14 ref.)
Collaborative field research and training in occupational health and ergonomics. Kogi K. **Int J Occup Environ Health** 1998 Jul–Sep;4(3):189–95 (24 ref.)
The international electronics industry. LaDou J, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):1–18 (26 ref.)
Oxygen enrichment of room air to improve well-being and productivity at high altitude. West JB. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):187–93 (23 ref.)
The structure and function of the occupational health system in Thailand. Yingratanasuk T, et al. **Int J Occup Environ Health** 1998 Apr–Jun;4(2):121–30 (20 ref.)
Updating of hygiene standards for carbon disulfide based on health risk assessment. Stetkiewicz J, et al. **Int J Occup Med Environ Health** 1998;11(2):129–43 (93 ref.)
Measuring job stressors and studying the health impact of the work environment: an epidemiologic commentary [see comments] Kasl SV. **J Occup Health Psychol** 1998 Oct; 3(4):390–401 (38 ref.) Comment in: J Occup Health Psychol 1999 Jul;4(3):288–92.
Regulating and assessing risks of cholinesterase-inhibiting pesticides: divergent approaches and interpretations. Carlock LL, et al. **J Toxicol Environ Health B Crit Rev** 1999 Apr–Jun; 2(2):105–60 (69 ref.)
Optimum machine guarding. Brubaker SA. **Occup Health Saf** 1997 Dec;66(12):37–40 (12 ref.)
The economic and social context of special populations. Ashford NA. **Occup Med** 1999 Jul–Sep;14(3):485–93 (32 ref.)
Workers with disabilities. Blanck PD, et al. **Occup Med** 1999 Jul–Sep;14(3):581–93 (61 ref.)
Health hazards in the meatpacking industry. Campbell DS. **Occup Med** 1999 Apr–Jun;14(2):351–72 (211 ref.)
Young workers. Castillo DN, et al. **Occup Med** 1999 Jul–Sep; 14(3):519–36 (100 ref.)
Health, safety, and environmental concerns of farm animal waste. Cole DJ, et al. **Occup Med** 1999 Apr–Jun; 14(2):423–48 (177 ref.)
The role of prevention in workers' compensation managed care arrangements. Dembe AE, et al. **Occup Med** 1998 Oct–Dec;13(4):663–77, iii (48 ref.)
Health and safety concerns in fisheries and aquaculture. Durborow RM. **Occup Med** 1999 Apr–Jun;14(2):373–406 (258 ref.)
Special populations in occupational health. Frumkin H, et al. **Occup Med** 1999 Jul–Sep;14(3):479–84 (26 ref.)
Minority workers and communities. Frumkin H, et al. **Occup Med** 1999 Jul–Sep;14(3):495–517 (174 ref.)
Across the water and down the ladder: occupational health in the global economy. Frumkin H. **Occup Med** 1999 Jul–Sep;14(3):637–63 (114 ref.)
Safe handling of large animals. Grandin T. **Occup Med** 1999 Apr–Jun;14(2):195–212 (55 ref.)
Safe handling and disposal of laboratory animal waste. Hill D. **Occup Med** 1999 Apr–Jun;14(2):449–68 (41 ref.)
Physical hazards of animal handlers. Langley R. **Occup Med** 1999 Apr–Jun;14(2):181–94 (56 ref.)
Disability management and occupational health. Margoshes B. **Occup Med** 1998 Oct–Dec;13(4):693–703, iii (23 ref.)
Anesthesia hazards to animal workers. Meyer RE. **Occup Med** 1999 Apr–Jun;14(2):225–34 (35 ref.)
Genetically and medically susceptible workers. Mohr S, et al. **Occup Med** 1999 Jul–Sep;14(3):595–611 (163 ref.)
Euthanasia hazards. Morrow WE. **Occup Med** 1999 Apr–Jun; 14(2):235–46 (52 ref.)
Animal facility design. Rahija R. **Occup Med** 1999 Apr–Jun; 14(2):407–22 (36 ref.)
Occupational allergy to animals. Seward JP. **Occup Med** 1999 Apr–Jun;14(2):285–304 (130 ref.)
Women workers: the social construction of a special population. Stellman JM. **Occup Med** 1999 Jul–Sep; 14(3):559–80 (39 ref.)
Organizing marginalized workers. Taylor AK. **Occup Med** 1999 Jul–Sep;14(3):687–95 (24 ref.)
The occupational health status of hired farm workers. Villarejo D, et al. **Occup Med** 1999 Jul–Sep;14(3):613–35 (100 ref.)
Illness and injury in animal confinement workers. Von Essen S, et al. **Occup Med** 1999 Apr–Jun;14(2):337–50 (69 ref.)
Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr–Jun;14(2):247–84 (222 ref.)
Older workers. Wegman DH. **Occup Med** 1999 Jul–Sep; 14(3):537–57 (61 ref.)
Military parachuting injuries: a literature review. Bricknell MC, et al. **Occup Med (Lond)** 1999 Jan;49(1):17–26 (27 ref.)
A review of current literature on epidemiology of immediate glove irritation and latex allergy. Kujala V. **Occup Med (Lond)** 1999 Jan;49(1):3–9 (73 ref.)

Shift work, health, the working time regulations and health assessments. Nicholson PJ, et al. **Occup Med (Lond)** 1999 Apr;49(3):127–37 (157 ref.)
Occupational hygiene science and its application in occupational health policy, at home and abroad. Vincent JH. **Occup Med (Lond)** 1999 Jan;49(1):27–35 (22 ref.)
More expanded scope: operational EMS [editorial; comment] Bogucki MS. **Prehosp Emerg Care** 1998 Oct–Dec; 2(4):330–3 (23 ref.) Comment on: Prehosp Emerg Care 1998 Oct–Dec;2(4):280–4.
Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Hagmar L, et al. **Recent Results Cancer Res** 1998;154:177–84 (7 ref.)
Psychosocial aspects of stress, health and safety on North Sea installations. Parkes KR.
Scand J Work Environ Health 1998 Oct;24(5):321–33 (84 ref.)
[Can we optimize radioprotection for medical workers?] Aubert B, et al. **J Radiol** 1998 Apr;79(4):307–12 (17 ref.) (Eng. Abstr.) **(Fre)**
[Professional vision of flying personnel in the context of occupational health] Ushakov IB, et al.
Aviakosm Ekolog Med 1999;33(1):16–20 (10 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

Personal reflections on occupational health in the twentieth century: spiraling to the future. Cullen MR.
Annu Rev Public Health 1999;20:1–13 (31 ref.)

LEGISLATION & JURISPRUDENCE

The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea. Yu IJ, et al.
Appl Occup Environ Hyg 1999 Jun;14(6):356–8 (15 ref.)
Occupational health and safety policy in the UK: who is driving the agenda with the "greylisting" of health and safety activists? [editorial] Watterson A.
Int J Occup Environ Health 1998 Oct–Dec;4(4):275–7 (7 ref.)
Legal solutions for the problems of special populations at risk. Spieler EA. **Occup Med** 1999 Jul–Sep;14(3):665–86 (68 ref.)
[International comparison of occupational health related laws and occupational health systems on ethics] Maeda M, et al. **Sangyo Eiseigaku Zasshi** 1999 May;41(3):45–53 (35 ref.) (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Occupational medicine in Korea. Lee SH.
Int Arch Occup Environ Health 1999 Jan;72(1):1–6 (15 ref.)
Health impact of occupational risks in the informal sector in Zimbabwe. Loewenson RH.
Int J Occup Environ Health 1998 Oct–Dec;4(4):264–74 (31 ref.)

OCCUPATIONAL HEALTH SERVICES

The role of the EAP in the identification and treatment of substance abuse. Kramer RM. **Clin Lab Med** 1998 Dec; 18(4):747–53, x (0 ref.)
Evaluation research in occupational health services: general principles and a systematic review of empirical studies. Hulshof CT, et al. **Occup Environ Med** 1999 Jun; 56(6):361–77 (112 ref.)
An estimate of prostate cancer prevalence for a demographically similar workforce population. Westra CS, et al. **W V Med J** 1999 May–Jun;95(3):116–22 (14 ref.)

ECONOMICS

Cutting the costs of migraine: role of the employee health unit. Warshaw LJ, et al. **J Occup Environ Med** 1998 Nov; 40(11):943–53 (61 ref.)

ORGANIZATION & ADMINISTRATION

Priority care for employees: a blessing in disguise? Brouwer WB, et al. **Health Econ** 1999 Feb;8(1):65–73 (21 ref.)
Occupational health in Australia. Phoon WO.
Int Arch Occup Environ Health 1998 Sep;71(6):363–71 (13 ref.)
The structure and function of the occupational health system in Thailand. Yingratanasuk T, et al.
Int J Occup Environ Health 1998 Apr–Jun;4(2):121–30 (20 ref.)
Emotions at work [editorial] Moodie R, et al.
Med J Aust 1999 Apr 5;170(7):296–7 (18 ref.)
Occupational health practice in New Zealand [see comments] Gorman D, et al. **N Z Med J** 1999 Mar 12;112(1083):79–82 (18 ref.) Comment in: N Z Med J 1999 Apr 23;112(1086):147.
Evaluating the impact of managed health care in workers' compensation. Dembe AE. **Occup Med** 1998 Oct–Dec; 13(4):799–821, v (32 ref.)
24-hour programs: great idea or unrealistic? Igoe JA, et al. **Occup Med** 1998 Oct–Dec;13(4):727–33, iv (16 ref.)
Medical surveillance of animal handlers. McMurry FG, et al. **Occup Med** 1999 Apr–Jun;14(2):317–36 (78 ref.)
Disability management and occupational health. Margoshes B. **Occup Med** 1998 Oct–Dec;13(4):693–703, iii (23 ref.)
[Market effect on social security and occupational health services (comment) [see comments] Plomp HN, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1374–8 (10 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1369–73. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1379–82. **(Dut)**

STANDARDS

Polish approach to the quality assurance system in occupational health services. Indulski JA, et al.
Int J Occup Med Environ Health 1998;11(3):209–15 (7 ref.)
Managed care workers' compensation outcome measurements: how can a clinic compete? Mueller KL. **Occup Med** 1998 Oct–Dec;13(4):773–86, iv (35 ref.)
How I address quality and teamwork issues in the occupational health department. Addley K.
Occup Med (Lond) 1998 May;48(4):273–8 (6 ref.)

OCCUPATIONAL MEDICINE

see related
OCCUPATIONAL DISEASES
OCCUPATIONAL HEALTH SERVICES
PROTECTIVE DEVICES

The conflict-prone nature of occupational health research and practice. Nemery B. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):35–7 (12 ref.)
A review of the healthy worker effect in occupational epidemiology. Li CY, et al. **Occup Med (Lond)** 1999 May; 49(4):225–9 (27 ref.)

ECONOMICS

The market for occupational medicine managed care. Leone FH, et al. **Occup Med** 1998 Oct–Dec;13(4):869–79, v (4 ref.)

EDUCATION

Occupational health in Australia. Phoon WO.
Int Arch Occup Environ Health 1998 Sep;71(6):363–71 (13 ref.)
Occupational health practice in New Zealand [see comments] Gorman D, et al. **N Z Med J** 1999 Mar 12;112(1083):79–82 (18 ref.) Comment in: N Z Med J 1999 Apr 23;112(1086):147.
Total quality strategy in the formative process of the occupational physician. Franco G, et al.
Scand J Work Environ Health 1999 Apr;25(2):153–6 (12 ref.)

HISTORY

Personal reflections on occupational health in the twentieth century: spiraling to the future. Cullen MR.
Annu Rev Public Health 1999;20:1–13 (31 ref.)

LEGISLATION & JURISPRUDENCE

Preventive law by corporate professional team players: liability and responsibility in the work of company doctors. Draper E. **J Contemp Health Law Policy** 1999 Spring; 15(2):525–607 (99 ref.)
[Significance of the label "risk duplication" in occupational medicine expert opinion and redefinition of occupational diseases] Manz A. **Gesundheitswesen** 1999 Jul;61(7):331–6 (23 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Data management in occupational medicine. Schumann SC, et al. **Occup Med** 1998 Oct–Dec;13(4):735–46, iv (8 ref.)

ORGANIZATION & ADMINISTRATION

Occupational medicine in Korea. Lee SH.
Int Arch Occup Environ Health 1999 Jan;72(1):1–6 (15 ref.)
Occupational health practice in New Zealand [see comments] Gorman D, et al. **N Z Med J** 1999 Mar 12;112(1083):79–82 (18 ref.) Comment in: N Z Med J 1999 Apr 23;112(1086):147.
Managed occupational health. Harris JS. **Occup Med** 1998 Oct–Dec;13(4):625–43, iii (67 ref.)
[The French system of occupation medicine. II. Evolution of the French system of occupational medicine] Sibiński J. **Med Pr** 1995;46(1):75–80 (23 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Polish approach to the quality assurance system in occupational health services. Indulski JA, et al.
Int J Occup Med Environ Health 1998;11(3):209–15 (7 ref.)
Some theoretical remarks regarding the integration of somatic and psychosocial risk factors of coronary artery disease in preventive programmes in occupational medicine. Schmahl FW.
Int J Occup Med Environ Health 1998;11(4):285–9 (12 ref.)
Occupational medicine practice guidelines. Bruckman RZ, et al. **Occup Med** 1998 Oct–Dec;13(4):679–91 (19 ref.)
Performance measures in occupational medicine: a tool to manage quality. Rudolph L. **Occup Med** 1998 Oct–Dec; 13(4):747–53, iv (28 ref.)
[Limitations in using international occupational disease statistics for comparative analysis] Indulski JA, et al.
Med Pr 1998;49(3):291–6 (9 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

Sports medicine at work. Brown GJ. **Br J Sports Med** 1999 Feb;33(1):5 (6 ref.)
[The French system of occupation medicine. II. Evolution of the French system of occupational medicine] Sibiński J. **Med Pr** 1995;46(1):75–80 (23 ref.) (Eng. Abstr.) **(Pol)**
[Occupational psychiatry: major stages and prospects of development (review of literature)] Beliaeva GG.
Med Tr Prom Ekol 1999;(7):33–7 (37 ref.) **(Rus)**

OCCUPATIONAL NOISE see **NOISE, OCCUPATIONAL**

OCCUPATIONAL SAFETY see **OCCUPATIONAL HEALTH**

OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION (U.S.) see **UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION**

OCCUPATIONAL THERAPY

Assessment and intervention with clients with apraxia: contributions from the literature. Landry J, et al.
Can J Occup Ther 1999 Feb;66(1):52–61 (79 ref.)
The effectiveness of predischarge home assessment visits: a systematic review. Patterson CJ, et al. **Clin Rehabil** 1999 Apr;13(2):101–4 (14 ref.)
Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Albany K. **Muscle Nerve Suppl** 1997;6:S221–31 (40 ref.)
Physical and occupational therapy in the treatment of patients with multiple sclerosis. LaBan MM, et al.
Phys Med Rehabil Clin N Am 1998 Aug;9(3):603–14, vii (31 ref.)

EDUCATION

Transitional portfolios: orchestrating our professional competence. Crist P, et al. **Am J Occup Ther** 1998 Oct; 52(9):729–36 (24 ref.)

METHODS

Including the family perspective in sensory integration outcomes research. Cohn ES, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):540–6 (63 ref.)
How to detect effects: statistical power and evidence-based practice in occupational therapy research. Ottenbacher KJ, et al. **Am J Occup Ther** 1999 Mar–Apr;53(2):181–8 (38 ref.)
Rehabilitation in children with juvenile chronic arthritis. Häfner R, et al. **Baillieres Clin Rheumatol** 1998 May; 12(2):329–61 (19 ref.)
Physical and occupational therapy. Case-Smith J, et al.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):323–45 (72 ref.)

ORGANIZATION & ADMINISTRATION

Competence in scientific inquiry and research. Abreu BC, et al. **Am J Occup Ther** 1998 Oct;52(9):751–9 (61 ref.)
Competence and the occupational therapy entrepreneur. Foto M. **Am J Occup Ther** 1998 Oct;52(9):765–9 (8 ref.)
The ramifications of regulatory reform. Moyers PA.
Am J Occup Ther 1998 Oct;52(9):702–8 (28 ref.)
Management competencies required of administrative and clinical practitioners in the new millennium. Schell BA, et al. **Am J Occup Ther** 1998 Oct;52(9):744–50 (31 ref.)
Evolving competence in the practitioner role. Youngstrom MJ. **Am J Occup Ther** 1998 Oct;52(9):716–20 (10 ref.)

STANDARDS

Uniting practice and theory in an occupational framework. 1998 Eleanor Clarke Slagle Lecture. Fisher AG.
Am J Occup Ther 1998 Jul–Aug;52(7):509–21 (68 ref.)

OCCUPATIONS

see related
HEALTH OCCUPATIONS
WORKPLACE

The influence of occupation on lumbar degeneration. Videman T, et al. **Spine** 1999 Jun 1;24(11):1164–8 (31 ref.)

STATISTICS & NUMERICAL DATA

Hodgkin's disease, work, and the environment. A review. McCunney RJ. **J Occup Environ Med** 1999 Jan;41(1):36–46 (80 ref.)

OCEAN DOLPHINS see **DOLPHINS**

OCEANOGRAPHY

see related
MARINE BIOLOGY

OCELOTS see **CARNIVORA**

OCHRATOXINS

ADVERSE EFFECTS

The etiology of Balkan endemic nephropathy: still more

OCHRATOXINS

questions than answers. Tatu CA, et al. **Environ Health Perspect** 1998 Nov;106(11):689–700 (62 ref.)

The role of ochratoxin A as a possible cause of Balkan endemic nephropathy and its risk evaluation. Stoev SD. **Vet Hum Toxicol** 1998 Dec;40(6):352–60 (90 ref.)

TOXICITY

Tubulotoxic mechanisms of ochratoxin A. Gekle M, et al. **Kidney Blood Press Res** 1998;21(2–4):277–9 (33 ref.)

OCHRONOSIS

COMPLICATIONS

Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)

DIAGNOSIS

Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)

PATHOLOGY

Cutaneous deposition diseases. Part II. Touart DM, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):527–44; quiz 545–6 (169 ref.)

OCKELBO VIRUS see **ALPHAVIRUS**

9,12-OCTADECADIENOIC ACID see **LINOLEIC ACID**

9-OCTADECENOIC ACID see **OLEIC ACID**

OCTADECENOIC ACIDS see **OLEIC ACIDS**

OCTANOIC ACIDS

PHARMACOKINETICS

[Studying of gastric emptying for solids and liquids by means of using stable isotopes] González A, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):83–90 (60 ref.) (Eng. Abstr.) **(Spa)**

OCTANOLS

Octanol–water partition: searching for predictive models. Buchwald P, et al. **Curr Med Chem** 1998 Oct;5(5):353–80 (308 ref.)

OCTODON see **RODENTIA**

OCTOGENARIANS see **AGED, 80 AND OVER**

OCTOPAMINE

PHYSIOLOGY

Octopamine in the locust brain: cellular distribution and functional significance in an arousal mechanism. Stern M. **Microsc Res Tech** 1999 May 1;45(3):135–41 (41 ref.)

P-OCTOPAMINE see **OCTOPAMINE**

OCTOPUS VENOMS see **MOLLUSK VENOMS**

OCTOXYNOL

Detergent solubilization and immunoprecipitation of native NMDA receptors. Wenthold RJ, et al. **Methods Mol Biol** 1999;128:113–9 (11 ref.)

OCTREOTIDE

Somatostatin and octreotide: physiological background and pharmacological application. Beglinger C, et al. **Digestion** 1999;60 Suppl 2:2–8 (24 ref.)

DIAGNOSTIC USE

Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)

THERAPEUTIC USE

The role of octreotide in the prevention of complications following pancreatic resection. Berberat PO, et al. **Digestion** 1999;60 Suppl 2:15–22 (28 ref.)

The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Degen L, et al. **Digestion** 1999;60 Suppl 2:9–14 (30 ref.)

Role of octreotide and somatostatin in the treatment of intestinal fistulae. Dorta G. **Digestion** 1999;60 Suppl 2:53–6 (23 ref.)

Octreotide in the treatment of refractory diarrhea. Fried M. **Digestion** 1999;60 Suppl 2:42–6 (38 ref.)

Somatostatin or octreotide in acute variceal bleeding. Hadengue A. **Digestion** 1999;60 Suppl 2:31–41 (60 ref.)

The role of octreotide and somatostatin in acute and chronic pancreatitis. Uhl W, et al. **Digestion** 1999;60 Suppl 2:23–31 (95 ref.)

Radiolabelled somatostatins: towards the magic bullet? [editorial] Buscombe JR, et al. **Nucl Med Commun** 1999 Apr;20(4):299–301 (22 ref.)

The potential role of somatostatin analogues in breast cancer treatment. Pollak M. **Yale J Biol Med** 1997 Sep–Dec; 70(5–6):535–9 (40 ref.)

[Metastasized carcinoid tumor treated with interferon and octreotide] Szilvás A, et al. **Orv Hetil** 1998 Oct 11; 139(41):2455–8 (41 ref.) (Eng. Abstr.) **(Hun)**

OCTYLPHENOXYPOLYETHOXYETHANOLS see **OCTOXYNOL**

OCULAR FIXATION see **FIXATION, OCULAR**

OCULAR HERPES ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

OCULAR HYPERTENSION

DIAGNOSIS

Tonometry and corneal thickness [editorial; comment] Brubaker RF. **Arch Ophthalmol** 1999 Jan;117(1):104–5 (12 ref.) Comment on: Arch Ophthalmol 1999 Jan;117(1):14–6.

DRUG THERAPY

A preliminary risk–benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Eisenberg DL, et al. **Drug Saf** 1999 Jun; 20(6):505–14 (58 ref.)

OCULAR HYPOTENSION

COMPLICATIONS

Three types of retinal bleeding as a complication of hypotony after trabeculectomy. Suzuki R, et al. **Ophthalmologica** 1999;213(2):135–8 (11 ref.)

OCULAR HYPOTONY see **OCULAR HYPOTENSION**

OCULAR INFECTIONS see **EYE INFECTIONS**

OCULAR INFECTIONS, BACTERIAL see **EYE INFECTIONS, BACTERIAL**

OCULAR INFECTIONS, FUNGAL see **EYE INFECTIONS, FUNGAL**

OCULAR INFECTIONS, PARASITIC see **EYE INFECTIONS, PARASITIC**

OCULAR INFECTIONS, VIRAL see **EYE INFECTIONS, VIRAL**

OCULAR LARVA MIGRANS see **LARVA MIGRANS**

OCULAR MOTILITY DISORDERS

[Opsoclonus–polymyoclonia syndrome] Shimizu N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):203–5 (14 ref.) **(Jpn)**

DIAGNOSIS

[Paranystagmic ocular dyskinesias] Zolog I. **Oftalmologia** 1998;44(3):29–31 (10 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Neuropharmacologic aspects of the ocular motor system and the treatment of abnormal eye movements. Leigh RJ, et al. **Curr Opin Neurol** 1999 Feb;12(1):21–7 (31 ref.)

ETIOLOGY

Dissociated vertical divergence: a righting reflex gone wrong. Brodsky MC. **Arch Ophthalmol** 1999 Sep; 117(9):1216–22 (50 ref.)

PATHOLOGY

Ocular motility review 1996. Eggenberger ER, et al. **J Neuroophthalmol** 1998 Sep;18(3):211–26 (109 ref.)

OCULAR PHYSIOLOGY

Major review: ocular sighting dominance: a review and a study of athletic proficiency and eye–hand dominance in a collegiate baseball team [see comments] Portal JM, et al. **Binocul Vis Strabismus Q** 1998 Summer–Winter;13(2 2nd Qtr):125–32 (12 ref.) Comment in: Binocul Vis Strabismus Q 1998 Fall;13(3 3rd Qtr):165–6.

Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Benita S. **Biomed Pharmacother** 1999 May;53(4):193–206 (68 ref.)

The eye at altitude. Butler FK Jr. **Int Ophthalmol Clin** 1999 Spring;39(2):59–78 (88 ref.)

New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Clark AF. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2514–6 (22 ref.)

From eye to hand: planning goal-directed movements. Desmurget M, et al. **Neurosci Biobehav Rev** 1998 Oct; 22(6):761–88 (275 ref.)

[Interocular inhibition in strabismus] Herzau V. **Ophthalmologe** 1998 Oct;95(10):710–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Role of ciliary muscle in ocular physiology and disease] Nesterov AP, et al. **Vestn Oftalmol** 1999 Mar–Apr; 115(2):13–5 (10 ref.) (Eng. Abstr.) **(Rus)**

OCULAR REFRACTION see **REFRACTION, OCULAR**

OCULAR TENSION see **INTRAOCULAR PRESSURE**

OCULAR TORTICOLLIS see **OCULAR MOTILITY DISORDERS**

OCULAR TOXOPLASMOSIS see **TOXOPLASMOSIS, OCULAR**

OCULAR TUBERCULOSIS see **TUBERCULOSIS, OCULAR**

OCULOMOTOR MUSCLES

DRUG EFFECTS

Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Edelstein C, et al. **Dermatol Surg** 1998 Nov; 24(11):1208–12 (12 ref.)

PHYSIOLOGY

Vestibulo-oculomotor research and measurement technology for the space station era. Clarke AH. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):173–84 (72 ref.)

Learning in the oculomotor system: from molecules to behavior. Raymond JL. **Curr Opin Neurobiol** 1998 Dec; 8(6):770–6 (77 ref.)

Cognitive set and oculomotor control. Basso MA. **Neuron** 1998 Oct;21(4):665–8 (16 ref.)

Extraocular muscle proprioceptors and proprioception. Ruskell GL. **Prog Retin Eye Res** 1999 May;18(3):269–91 (129 ref.)

PHYSIOPATHOLOGY

Early motor influences on visuomotor transformations for reaching: a positive image of optic ataxia. Battaglia Mayer A, et al. **Exp Brain Res** 1998 Nov;123(1–2):172–89 (104 ref.)

A genetic approach to congenital extraocular muscle disorders. Engle E. **J Child Neurol** 1999 Jan;14(1):34–7 (18 ref.)

SURGERY

Adjustable sutures in pediatric ophthalmology and strabismus. Strominger MB, et al. **J Pediatr Ophthalmol Strabismus** 1999 May–Jun; 36(3):112–7; quiz 134–5 (49 ref.)

OCULOMOTOR NERVE

PHYSIOLOGY

Technical developments in intra-operative monitoring for the preservation of cranial motor nerves and hearing in skull base surgery. Schlake HP, et al. **Neurol Res** 1999 Jan; 21(1):11–24 (90 ref.)

OCULOMOTOR NERVE PALSY see **OCULOMOTOR NERVE PARALYSIS**

OCULOMOTOR NERVE PARALYSIS

DIAGNOSIS

The emerging role of magnetic resonance angiography in the management of patients with third cranial nerve palsy. Jacobson DM, et al. **Am J Ophthalmol** 1999 Jul;128(1):94–6 (28 ref.)

Diagnostic role of Mantoux test site biopsy in neurosarcoidosis. Mankodi AK, et al. **Neurology** 1998 Oct; 51(4):1216–8 (9 ref.)

ETIOLOGY

[Oculomotor paralysis and head trauma] Liguoro D, et al. **Neurochirurgie** 1998 Nov;44(4):253–7 (32 ref.) (Eng. Abstr.) **(Fre)**

OCULOMOTOR PARALYSIS see **OPHTHALMOPLEGIA**

OCULOMYCOSIS see **EYE INFECTIONS, FUNGAL**

OCYTOCIN see **OXYTOCIN**

ODDI'S SPHINCTER

see related
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE
SPHINCTEROTOMY, ENDOSCOPIC

Botulinum toxin: the overall cure for defective relaxation? Thumshirn M, et al. **Endoscopy** 1999 Jun;31(5):392–7 (59

ref.)
[Acute recurrent pancreatitis in a patient with Oddi's sphincter dysfunction] Tomás A, et al. **Gastroenterol Hepatol** 1999 Jun-Jul;22(6):279-81 (18 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Vector manometry of the sphincter of Oddi: a new parameter of pancreatobiliary physiology [editorial; comment] Okazaki K. **J Gastroenterol** 1998 Dec;33(6):922-3 (10 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):860-3.

PHYSIOLOGY

Vector manometry of the sphincter of Oddi: a new parameter of pancreatobiliary physiology [editorial; comment] Okazaki K. **J Gastroenterol** 1998 Dec;33(6):922-3 (10 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):860-3.
Humoral mechanisms and clinical aspects of biliary tract motility. Lonovics J, et al. **Scand J Gastroenterol Suppl** 1998;228:73-89 (186 ref.)

PHYSIOPATHOLOGY

Hypertensive pancreatic sphincter. Lehman GA, et al. **Can J Gastroenterol** 1998 Jul-Aug;12(5):333-7 (27 ref.)
Clinical impact of sphincter of Oddi dyskinesia. Allescher HD. **Endoscopy** 1998 Nov;30(9):A231-6 (57 ref.)

ODONTOBLASTS

PHYSIOLOGY

Odontoblast commitment and differentiation. Ruch JV. **Biochem Cell Biol** 1998;76(6):923-38 (122 ref.)

ODONTOCLASTS see **OSTEOCLASTS**

ODONTOGENESIS

Teeth. Where and how to make them. Peters H, et al. **Trends Genet** 1999 Feb;15(2):59-65 (57 ref.)

GENETICS

The genetic control of early odontogenesis. Cobourne MT. **Br J Orthod** 1999 Mar;26(1):21-8 (51 ref.)
Dynamic interactions and the evolutionary genetics of dental patterning. Weiss KM, et al. **Crit Rev Oral Biol Med** 1998; 9(4):369-98 (203 ref.)
Molecular genetics of tooth morphogenesis and patterning: the right shape in the right place. Tucker AS, et al. **J Dent Res** 1999 Apr;78(4):826-34 (58 ref.)

PHYSIOLOGY

Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Own observations and review of the literature. Van Erum R, et al. **Horm Res** 1998 Sep;50(3):141-6 (35 ref.)

ODONTOGENIC CYST, CALCIFYING

PATHOLOGY

Odontogenic ghost cell carcinoma: report of four new cases and review of the literature. Lu Y, et al. **J Oral Pathol Med** 1999 Aug;28(7):323-9 (34 ref.)

ODONTOGENIC CYSTS

PATHOLOGY

Glandular odontogenic cyst (sialo-odontogenic cyst): report of two cases and literature review of 45 previously reported cases. Koppang HS, et al. **J Oral Pathol Med** 1998 Oct; 27(9):455-62 (33 ref.)

RADIOGRAPHY

Glandular odontogenic cyst of the mandible. Chavez JA, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):461-4 (14 ref.)

ODONTOGENIC TUMOR, SQUAMOUS see **AMELOBLASTOMA**

ODONTOGENIC TUMORS

DIAGNOSIS

Combined central odontogenic fibroma and giant cell granuloma-like lesion of the mandible: report of a case and review of the literature. Mosqueda Taylor A, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1258-62 (24 ref.)
[Odontogenic tumors and neoplastic-like changes of the jaw bone. Clinical study and evaluation of treatment results] Stypułkowska J. **Folia Med Cracov** 1998;39(1-2):35-141 (227 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Odontogenic ghost cell carcinoma: report of a case. Kamijo R, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1266-70 (11 ref.)

PATHOLOGY

Central granular cell odontogenic tumor: case report and review of literature. Ardekian L, et al. **J Oral Maxillofac Surg** 1998 Nov;56(11):1343-5 (12 ref.)
Adenomatoid odontogenic tumour: facts and figures. Philipsen HP, et al. **Oral Oncol** 1999 Mar;35(2):125-31 (44 ref.)
[Clear cell odontogenic carcinoma in connection with squamous epithelial carcinoma. Case report and review of the literature] Vesper M, et al. **Mund Kiefer Gesichtschir** 1998 Sep;2(5):270-4 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Odontogenic tumors and neoplastic-like changes of the jaw bone. Clinical study and evaluation of treatment results] Stypułkowska J. **Folia Med Cracov** 1998;39(1-2):35-141 (227 ref.) (Eng. Abstr.) **(Pol)**

ODONTOID PROCESS

INJURIES

Evidence-based management of type II odontoid fractures. Traynelis VC. **Clin Neurosurg** 1997;44:41-9 (22 ref.)
[Surgical therapy of dens fracture] Roth R, et al. **Zentralbl Chir** 1998;123(8):914-8 (13 ref.) (Eng. Abstr.) **(Ger)**

ODONTOMA

PATHOLOGY

Multiple odontomas of the mandible: a case report. Iwamoto O, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):338-41 (5 ref.)

ODONTOMA, COMPOUND see **ODONTOMA**

ODONTOME see **TOOTH ABNORMALITIES**

ODORANT RECEPTORS see **RECEPTORS, ODORANT**

ODORS

see related
AROMATHERAPY
SMELL

Odor-mediated behavior of Afrotropical malaria mosquitoes. Takken W, et al. **Annu Rev Entomol** 1999;44:131-57 (195 ref.)
The naturally occurring furanones: formation and function from pheromone to food. Colin Slaughter J. **Biol Rev Camb Philos Soc** 1999 Aug;74(3):259-76 (110 ref.)
Origin, functions and chemistry of H-2 regulated odorants. Yamazaki K, et al. **Genetica** 1998-99;104(3):235-40 (59 ref.)
Potential for reduction of odorous compounds in swine manure through diet modification. Sutton AL, et al. **J Anim Sci** 1999 Feb;77(2):430-9 (59 ref.)
On the similarity of odor and language perception. Lorig TS. **Neurosci Biobehav Rev** 1999;23(3):391-8 (60 ref.)
Unique salience of maternal breast odors for newborn infants. Porter RH, et al. **Neurosci Biobehav Rev** 1999;23(3):439-49 (119 ref.)
Olfaction and symptoms in the multiple chemical sensitivities syndrome. Ross PM, et al. **Prev Med** 1999 May; 28(5):467-80 (140 ref.)
Multiple chemical sensitivity as a conditional response. Siegel S. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):323-30 (71 ref.)

ANALYSIS

A sensing system for odor plumes. Nakamoto T, et al. **Anal Chem** 1999 Aug 1;71(15):531A-537A (20 ref.)
Flavour of coffee. A review. Grosch W. **Nahrung** 1998 Dec; 42(6):344-50 (59 ref.)
Volatile flavour of wine: correlation between instrumental analysis and sensory perception. Rapp A. **Nahrung** 1998 Dec;42(6):351-63 (77 ref.)
Structure-odour relationships: results of an applied electron-topological approach. Shvets NM, et al. **Nahrung** 1998 Dec;42(6):364-70 (18 ref.)

OESTRADIOL see **ESTRADIOL**

OFFICE SURGERY see **AMBULATORY SURGICAL PROCEDURES**

OFFICE VISITS

An office approach to the diagnosis of chronic cough. Lawler WR. **Am Fam Physician** 1998 Dec;58(9):2015-22 (12 ref.)
Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1999 Aug;11(4):367-73 (45 ref.)
White coat hypertension: a recognised syndrome with uncertain implications. Landray MJ, et al. **J Hum Hypertens** 1999 Jan;13(1):5-8 (20 ref.)
Adolescent gynecology in the office setting. Acquavella AP, et al. **Pediatr Clin North Am** 1999 Jun;46(3):489-503 (47 ref.)
Pediatric dermatologic surgery for the primary care pediatrician. Babich D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1437-53 (47 ref.)
Attention-deficit disorder. A paradigm for psychotropic medication intervention in pediatrics. Block SL. **Pediatr Clin North Am** 1998 Oct;45(5):1053-83 (87 ref.)
Office management of female urinary incontinence. Iselin CE, et al. **Urol Clin North Am** 1998 Nov;25(4):625-45, ix (120 ref.)
Office evaluation of men with lower urinary tract symptoms. Jepsen JV, et al. **Urol Clin North Am** 1998 Nov; 25(4):545-54, vii (76 ref.)
Effective office management of chronic prostatitis. Nickel JC. **Urol Clin North Am** 1998 Nov;25(4):677-84 (34 ref.)
Office treatment of benign prostatic hyperplasia. Ramsey EW. **Urol Clin North Am** 1998 Nov;25(4):571-80 (46 ref.)
The office management of recurrent urinary tract infection and vesicoureteral reflux in children. Shapiro E, et al. **Urol Clin North Am** 1998 Nov;25(4):725-34, x (73 ref.)
Office evaluation and management of bladder neoplasms. Young MJ, et al. **Urol Clin North Am** 1998 Nov; 25(4):603-11 (43 ref.)

OFFSPRING OF IMPAIRED PARENTS see **CHILD OF IMPAIRED PARENTS**

OFLOXACIN

[Levofloxacin] Azanza JR, et al. **Rev Med Univ Navarra** 1998 Oct-Dec;42(4):220-5 (23 ref.) **(Spa)**

PHARMACOKINETICS

Levofloxacin, a second-generation fluoroquinolone. North DS, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):915-35 (158 ref.)

THERAPEUTIC USE

Levofloxacin in the treatment of community acquired pneumonia. File TM Jr. **Can Respir J** 1999 Jan-Feb;6 Suppl A:35A-9A (8 ref.)
Levofloxacin: a therapeutic review. Wimer SM, et al. **Clin Ther** 1998 Nov-Dec;20(6):1049-70 (82 ref.)
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Langtry HD, et al. **Drugs** 1998 Sep;56(3):487-515 (126 ref.)
Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Onrust SV, et al. **Drugs** 1998 Nov;56(5):895-928 (212 ref.)
Levofloxacin, a second-generation fluoroquinolone. North DS, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):915-35 (158 ref.)

OGILVIE DISEASE see **COLONIC PSEUDO-OBSTRUCTION**

6-OHDA see **OXIDOPAMINE**

OIL, IODIZED see **IODIZED OIL**

OILS

CHEMISTRY

Cyclodextrin derivatives as chiral selectors for direct gas chromatographic separation of enantiomers in the essential oil, aroma and flavour fields. Bicchi C, et al. **J Chromatogr A** 1999 May 28;843(1-2):99-121 (118 ref.)

METABOLISM

Rhamnose lipids--biosynthesis, microbial production and application potential. Lang S, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):22-32 (116 ref.)

OILS, ESSENTIAL see **OILS, VOLATILE**

OILS, PLANT see **PLANT OILS**

OILS, UNSATURATED see **FATS, UNSATURATED**

OILS, VEGETABLE see **PLANT OILS**

OILS, VOLATILE

see related
AROMATHERAPY

ADVERSE EFFECTS

Tea tree oil allergy: what is the offending agent? Report of three cases of tea tree oil allergy and review of the literature. Rubel DM, et al. **Australas J Dermatol** 1998 Nov; 39(4):244-7 (9 ref.)

ANALYSIS

Tea tree oil allergy: what is the offending agent? Report of three cases of tea tree oil allergy and review of the literature. Rubel DM, et al. **Australas J Dermatol** 1998 Nov; 39(4):244-7 (9 ref.)

METABOLISM

Monoterpenes in essential oils. Biosynthesis and properties.

OILS, VOLATILE

Loza-Tavera H. **Adv Exp Med Biol** 1999;464:49-62 (63 ref.)
Genetic engineering of essential oil production in mint [see comments] Lange BM, et al. **Curr Opin Plant Biol** 1999 Apr;2(2):139-44 (43 ref.) Comment in: Curr Opin Plant Biol 1999 Apr;2(2):121-2.

THERAPEUTIC USE

Efficacy and safety of tea tree oil as a topical antimicrobial agent. Carson CF, et al. **J Hosp Infect** 1998 Nov; 40(3):175-8 (30 ref.)

OINTMENT BASES

see related
OINTMENTS

ADVERSE EFFECTS

The myth of lanolin allergy. Kligman AM.
Contact Dermatitis 1998 Sep;39(3):103-7 (29 ref.)

OINTMENTS

see related
OINTMENT BASES
[Prevention of allergy by protective skin creams: possibilities and limits] Schliemann S, et al.
Schweiz Med Wochenschr 1999 Jul 3;129(26):996-1001 (23 ref.) (Eng. Abstr.) **(Ger)**
[Clinico-laboratory effectiveness of modern ointments with a polyethylene glycol base in the treatment of purulent wounds] Blatun LA, et al. **Antibiot Khimioter** 1999; 44(7):25-31 (12 ref.) (Eng. Abstr.) **(Rus)**

OK-432 see **PICIBANIL**

OKA VARICELLA VACCINE see **CHICKENPOX VACCINE**

OKADAIC ACID

PHARMACOLOGY

Molecular mechanisms underlying inhibition of protein phosphatases by marine toxins. Dawson JF, et al.
Front Biosci 1999 Oct 1;4:D646-58 (0 ref.)

TOXICITY

Unique features of the okadaic acid activity class of tumor promoters. Fujiki H, et al. **J Cancer Res Clin Oncol** 1999; 125(3-4):150-5 (39 ref.)

OKM5 ANTIGEN see **ANTIGENS, CD36**

OLD AGE HOMES see **HOMES FOR THE AGED**

OLDEST OLD see **AGED, 80 AND OVER**

OLEATE see **OLEIC ACID**

OLEIC ACID

PHARMACOLOGY

Direct vascular antiatherogenic effects of oleic acid: a clue to the cardioprotective effects of the Mediterranean diet. Massaro M, et al. **Cardiologia** 1999 Jun;44(6):507-13 (42 ref.)

OLEIC ACIDS

PHARMACOLOGY

The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Lambert DM, et al. **Curr Med Chem** 1999 Aug;6(8):757-73 (119 ref.)
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Boger DL, et al. **Curr Pharm Des** 1998 Aug; 4(4):303-14 (81 ref.)

OLFACTION see **SMELL**

OLFACTORY BULB

ANATOMY & HISTOLOGY

Structure and diversity in mammalian accessory olfactory bulb. Meisami E, et al. **Microsc Res Tech** 1998 Dec 15; 43(6):476-99 (134 ref.)

CHEMISTRY

Glycobiology of the olfactory system. Plendl J, et al.
Acta Anat (Basel) 1998;161(1-4):234-53 (188 ref.)

EMBRYOLOGY

Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Schwanzel-Fukuda M.
Microsc Res Tech 1999 Jan 1;44(1):2-10 (70 ref.)

METABOLISM

[Olfactory epithelium of the rat. Lectin-mediated histochemical studies] Melgarejo Moreno P, et al.
An Otorrinolaringol Ibero Am 1998;25(5):471-80 (43 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Olfactory epithelium of the rat. Lectin-mediated histochemical studies] Melgarejo Moreno P, et al.
An Otorrinolaringol Ibero Am 1998;25(5):471-80 (43 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Growth factors and their receptors in the olfactory system. Plendl J, et al. **Anat Histol Embryol** 1999 May;28(2):73-9 (78 ref.)
Heterogeneity in the accessory olfactory system. Halpern M, et al. **Chem Senses** 1998 Aug;23(4):477-81 (32 ref.)
Development of the vertebrate main olfactory system. Lin DM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):74-8 (41 ref.)
Developmental and aging aspects of the cholinergic innervation of the olfactory bulb. Durand M, et al.
Int J Dev Neurosci 1998 Nov-Dec;16(7-8):777-85 (93 ref.)
Neural pathway from the olfactory bulbs regulating tonic gonadotropin secretion. Pieper DR, et al.
Neurosci Biobehav Rev 1999 Mar;23(4):555-62 (80 ref.)

OLFACTORY CORTEX see **OLFACTORY PATHWAYS**

OLFACTORY MUCOSA

see related
VOMERONASAL ORGAN

CYTOLOGY

The neuronal stem cell of the olfactory epithelium. Calof AL, et al. **J Neurobiol** 1998 Aug;36(2):190-205 (71 ref.)

PATHOLOGY

Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia. Arnold SE, et al.
Ann N Y Acad Sci 1998 Nov 30;855:762-75 (74 ref.)

PHYSIOLOGY

Integration of chemosensory and hormonal input in the male Syrian hamster brain. Wood RI. **Ann N Y Acad Sci** 1998 Nov 30;855:362-72 (20 ref.)

PHYSIOPATHOLOGY

Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia. Arnold SE, et al.
Ann N Y Acad Sci 1998 Nov 30;855:762-75 (74 ref.)

OLFACTORY NERVE

CHEMISTRY

Glycobiology of the olfactory system. Plendl J, et al.
Acta Anat (Basel) 1998;161(1-4):234-53 (188 ref.)

PHYSIOLOGY

Molecular development of the olfactory nerve pathway. Key B. **Ann N Y Acad Sci** 1998 Nov 30;855:76-82 (35 ref.)

OLFACTORY PATHWAYS

DRUG EFFECTS

5-HT4 receptors: long-term blockade of K+ channels and effects on olfactory memory. Bockaert J, et al.
C R Acad Sci III 1998 Feb-Mar;321(2-3):217-21 (33 ref.)

EMBRYOLOGY

Induced peripheral sensitivity in the developing vertebrate olfactory system. Hudson R, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:109-15 (41 ref.)
Olfactory development in invertebrates. On the scent of central developmental issues. Tolbert LP.
Ann N Y Acad Sci 1998 Nov 30;855:95-103 (52 ref.)

METABOLISM

Histochemistry of classical neurotransmitters in antennal lobes and mushroom bodies of the honeybee. Bicker G.
Microsc Res Tech 1999 May 1;45(3):174-83 (55 ref.)
Uptake of metals in the brain via olfactory pathways. Tjälve H, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):181-95 (110 ref.)

PATHOLOGY

Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia. Arnold SE, et al.
Ann N Y Acad Sci 1998 Nov 30;855:762-75 (74 ref.)
Solitary olfactory groove schwannoma: case report with review of the literature. Praharaj SS, et al.
Clin Neurol Neurosurg 1999 Mar;101(1):26-8 (12 ref.)

PHYSIOLOGY

Growth factors and their receptors in the olfactory system. Plendl J, et al. **Anat Histol Embryol** 1999 May;28(2):73-9 (78 ref.)
Involvement of genes encoding a K+ channel (ether a go-go) and a Na+ channel (smellblind) in Drosophila olfaction. Dubin AE, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:212-22 (28 ref.)
Induced peripheral sensitivity in the developing vertebrate olfactory system. Hudson R, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:109-15 (41 ref.)
Compensatory responses to early olfactory restriction. Leon M. **Ann N Y Acad Sci** 1998 Nov 30;855:104-8 (21 ref.)
Vomeronasal, olfactory, hormonal convergence in the brain. Cooperation or coincidence? Meredith M.
Ann N Y Acad Sci 1998 Nov 30;855:349-61 (43 ref.)
Olfactory development in invertebrates. On the scent of central developmental issues. Tolbert LP.
Ann N Y Acad Sci 1998 Nov 30;855:95-103 (52 ref.)
Role of cyclic GMP in olfactory transduction and adaptation. Zufall F, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:199-204 (29 ref.)
Controversial issues in vertebrate olfactory transduction. Gold GH. **Annu Rev Physiol** 1999;61:857-71 (71 ref.)
Is there an inner nose? Elmes DG. **Chem Senses** 1998 Aug; 23(4):443-5 (21 ref.)
Olfactory memory: the long and short of it. White TL.
Chem Senses 1998 Aug;23(4):433-41 (93 ref.)
Neural pathway from the olfactory bulbs regulating tonic gonadotropin secretion. Pieper DR, et al.
Neurosci Biobehav Rev 1999 Mar;23(4):555-62 (80 ref.)
Sodefrin: a novel sex pheromone in a newt. Kikuyama S, et al. **Rev Reprod** 1999 Jan;4(1):1-4 (18 ref.)
Molecular aspects of pheromonal communication via the vomeronasal organ of mammals. Tirindelli R, et al.
Trends Neurosci 1998 Nov;21(11):482-6 (58 ref.)
[Olfactory training: memory systems in the rats] Chaillan FA, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):157-61 (16 ref.) **(Fre)**

PHYSIOPATHOLOGY

Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia. Arnold SE, et al.
Ann N Y Acad Sci 1998 Nov 30;855:762-75 (74 ref.)
Multiple chemical sensitivity: a test of the olfactory-limbic model. Brown-DeGagne AM, et al.
J Occup Environ Med 1999 May;41(5):366-77 (71 ref.)

RADIOGRAPHY

Solitary olfactory groove schwannoma: case report with review of the literature. Praharaj SS, et al.
Clin Neurol Neurosurg 1999 Mar;101(1):26-8 (12 ref.)

OLFACTORY RECEPTOR NEURONS

see related
RECEPTORS, ODORANT

PHYSIOLOGY

Growth factors and their receptors in the olfactory system. Plendl J, et al. **Anat Histol Embryol** 1999 May;28(2):73-9 (78 ref.)
GABAergic mechanisms that shape the temporal response to odors in moth olfactory projection neurons. Christensen TA, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:475-81 (38 ref.)
Induced peripheral sensitivity in the developing vertebrate olfactory system. Hudson R, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:109-15 (41 ref.)
Role of cyclic GMP in olfactory transduction and adaptation. Zufall F, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:199-204 (29 ref.)
The specification of olfactory neurons. Ebrahimi FA, et al.
Curr Opin Neurobiol 1998 Aug;8(4):453-7 (36 ref.)
Development of the vertebrate main olfactory system. Lin DM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):74-8 (41 ref.)
Calcium signalling and regulation in olfactory neurons. Menini A. **Curr Opin Neurobiol** 1999 Aug;9(4):419-26 (63 ref.)

OLFACTORY RECEPTOR PROTEINS see **RECEPTORS, ODORANT**

OLFACTORY TRACT see **OLFACTORY PATHWAYS**

OLFACTORY TUBERCLE see **OLFACTORY PATHWAYS**

2',5'-OLIGOADENYLATE POLYMERASE see **2',5'-OLIGOADENYLATE SYNTHETASE**

2',5'-OLIGOADENYLATE SYNTHETASE

METABOLISM

The human 2',5'-oligoadenylate synthetase family:

interferon-induced proteins with unique enzymatic properties. Rebouillat D, et al.
J Interferon Cytokine Res 1999 Apr;19(4):295-308 (108 ref.)

OLIGOCHAETA

IMMUNOLOGY

Cell adhesion and the immune system: a case study using earthworms. Cooper EL, et al. **Microsc Res Tech** 1999 Feb 15;44(4):237-53 (175 ref.)

OLIGODENDROBLASTOMA see **OLIGODENDROGLIOMA**

OLIGODENDROCYTES see **OLIGODENDROGLIA**

OLIGODENDROGLIA

CYTOLOGY

Regulation of oligodendrocyte development. Orentas DM, et al. **Mol Neurobiol** 1998 Dec;18(3):247-59 (90 ref.)
Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Wolswijk G. **Prog Brain Res** 1998;117:233-47 (82 ref.)

METABOLISM

RNA trafficking in myelinating cells. Carson JH, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):607-12 (44 ref.)

PATHOLOGY

Human oligodendroglial development: relationship to periventricular leukomalacia. Kinney HC, et al. **Semin Pediatr Neurol** 1998 Sep;5(3):180-9 (62 ref.)

PHYSIOLOGY

Oligodendrocytes: from development to demyelinated lesion repair. Rogister B, et al. **Acta Neurol Belg** 1999 Mar; 99(1):32-9 (72 ref.)
Reluctant remyelination: the missing precursors [editorial; comment] Perry VH. **Brain** 1998 Dec;121 (Pt 12):2219-20 (12 ref.) Comment on: Brain 1998 Dec;121 (Pt 12):2221-8.
Oligodendrocyte development and thyroid hormone. Rodríguez-Peña A. **J Neurobiol** 1999 Sep 15;40(4):497-512 (118 ref.)
Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Sharief MK. **Mult Scler** 1998 Jun; 4(3):169-73 (35 ref.)
Oligodendroglial response to the immune cytokine interferon gamma. Popko B, et al. **Neurochem Res** 1999 Feb; 24(2):331-8 (97 ref.)
Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Wolswijk G. **Prog Brain Res** 1998;117:233-47 (82 ref.)
[Morphological transformation of sensory ganglion neurons and satellite cells] Matsuda S, et al. **Kaibogaku Zasshi** 1998 Dec;73(6):603-13 (33 ref.) (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Transplanting myelin-forming cells into the central nervous system: principles and practice. Franklin RJ, et al. **Methods** 1998 Nov;16(3):311-9 (60 ref.)

OLIGODENDROGLIOMA

DRUG THERAPY

Current treatment of oligodendrogliomas. Perry JR, et al. **Arch Neurol** 1999 Apr;56(4):434-6 (12 ref.)

GENETICS

Familial gliomas : a case report. Bhatt AR, et al. **Neurol India** 1999 Jun;47(2):136-8 (16 ref.)

PATHOLOGY

Oligodendroglioma of the "widespread" type in the spinal cord. Ushida T, et al. **Childs Nerv Syst** 1998 Dec; 14(12):751-5 (19 ref.)
Diffuse leptomeningeal gliomatosis with oligodendroglioma. Ng HK, et al. **Pathology** 1999 Feb;31(1):59-63 (33 ref.)
[Grading of astrocytomas and oligodendrogliomas] Kolles H, et al. **Pathologe** 1998 Jul;19(4):259-68 (49 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

The ultrastructure of oligodendroglioma: personal experience and the review of the literature. Liberski PP. **Folia Neuropathol** 1996;34(4):206-11 (15 ref.)

OLIGODEOXYRIBONUCLEOTIDE PRIMERS see **DNA PRIMERS**

OLIGODEOXYRIBONUCLEOTIDE PROBES see **OLIGONUCLEOTIDE PROBES**

OLIGODEOXYRIBONUCLEOTIDES

PHARMACOLOGY

Immune recognition of foreign DNA: a cure for bioterrorism? Klinman DM, et al. **Immunity** 1999 Aug;11(2):123-9 (93 ref.)

OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP, et al. **Toxicol Pathol** 1999 Jan-Feb; 27(1):95-100 (35 ref.)

PHARMACOKINETICS

Brain as a unique antisense environment. Szklarczyk AW, et al. **Antisense Nucleic Acid Drug Dev** 1999 Feb; 9(1):105-16 (131 ref.)

PHARMACOLOGY

Brain as a unique antisense environment. Szklarczyk AW, et al. **Antisense Nucleic Acid Drug Dev** 1999 Feb; 9(1):105-16 (131 ref.)
Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Li JM, et al. **Eur Heart J** 1999 Mar;20(6):406-20 (124 ref.)

THERAPEUTIC USE

Antisense oligodeoxynucleotides for organ transplantation. Stepkowski SM. **Clin Biochem** 1998 Jul;31(5):375-9 (29 ref.)

OLIGOHYDRAMNIOS

COMPLICATIONS

Complications of prolonged PROM and oligohydramnios. Richards DS. **Clin Obstet Gynecol** 1998 Dec;41(4):817-26 (33 ref.)

DIAGNOSIS

[Nonimmunological fetal hydrops and the oligohydramnios deformation sequence as a manifestation of the twin-twin transfusion syndrome] González de Dios J, et al.
An Esp Pediatr 1998 Dec;49(6):627-30 (22 ref.) **(Spa)**

PATHOLOGY

Adams-Oliver syndrome: autosomal recessive inheritance and new phenotypic-anthropometric findings. Klinger G, et al. **Am J Med Genet** 1998 Sep 23;79(3):197-9 (13 ref.)

OLIGOMENORRHEA

see related
AMENORRHEA

OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS

see related
OLIGONUCLEOTIDE PROBES

Genomics and array technology. DeRisi JL, et al. **Curr Opin Oncol** 1999 Jan;11(1):76-9 (24 ref.)
A comparison of gel-based, nylon filter and microarray techniques to detect differential RNA expression in plants. Baldwin D, et al. **Curr Opin Plant Biol** 1999 Apr; 2(2):96-103 (71 ref.)
Molecular interactions on microarrays. Southern E, et al. **Nat Genet** 1999 Jan;21(1 Suppl):5-9 (37 ref.)
[Recent advances in the gene chip and its role in the post-genome era] Uchida K. **Seikagaku** 1999 Feb; 71(2):119-24 (14 ref.) **(Jpn)**
[DNA chip technologies and their applications: towards functional genomics] Kimizuka F, et al. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):2004-11 (37 ref.) **(Jpn)**

ECONOMICS

Options available--from start to finish--for obtaining expression data by microarray [published erratum appears in Nat Genet 1999 Feb;21(2):241] Bowtell DD. **Nat Genet** 1999 Jan;21(1 Suppl):25-32 (35 ref.)

INSTRUMENTATION

Differences in brain gene expression between sleep and waking as revealed by mRNA differential display and cDNA microarray technology. Cirelli C, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:44-52 (66 ref.)
Options available--from start to finish--for obtaining expression data by microarray [published erratum appears in Nat Genet 1999 Feb;21(2):241] Bowtell DD. **Nat Genet** 1999 Jan;21(1 Suppl):25-32 (35 ref.)
Making and reading microarrays. Cheung VG, et al. **Nat Genet** 1999 Jan;21(1 Suppl):15-9 (14 ref.)

METHODS

Accessing genomic information: alternatives to PCR. Isaksson A, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):11-5 (33 ref.)
Expression profiling in cancer using cDNA microarrays. Khan J, et al. **Electrophoresis** 1999 Feb;20(2):223-9 (19 ref.)
Applications of DNA chips for genomic analysis. Hacia JG, et al. **Mol Psychiatry** 1998 Nov;3(6):483-92 (49 ref.)
Exploring the new world of the genome with DNA microarrays. Brown PO, et al. **Nat Genet** 1999 Jan;21(1 Suppl):33-7 (27 ref.)
Making and reading microarrays. Cheung VG, et al. **Nat Genet** 1999 Jan;21(1 Suppl):15-9 (14 ref.)
The genetics of cancer--a 3D model. Cole KA, et al. **Nat Genet** 1999 Jan;21(1 Suppl):38-41 (47 ref.)
DNA microarrays in drug discovery and development. Debouck C, et al. **Nat Genet** 1999 Jan;21(1 Suppl):48-50 (19 ref.)
Expression profiling using cDNA microarrays. Duggan DJ, et al. **Nat Genet** 1999 Jan;21(1 Suppl):10-4 (33 ref.)
Resequencing and mutational analysis using oligonucleotide microarrays. Hacia JG. **Nat Genet** 1999 Jan;21(1 Suppl):42-7 (55 ref.)
High density synthetic oligonucleotide arrays. Lipshutz RJ, et al. **Nat Genet** 1999 Jan;21(1 Suppl):20-4 (32 ref.)
DNA chips: promising toys have become powerful tools. Gerhold D, et al. **Trends Biochem Sci** 1999 May; 24(5):168-73 (28 ref.)
[High throughput gene analysis with DNA array--from sequencing to expression monitoring] Hatakeyama K. **Nippon Rinsho** 1999 Feb;57(2):465-73 (16 ref.) (Eng. Abstr.) **(Jpn)**

OLIGONUCLEOTIDE ARRAYS see **OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS**

OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

OLIGONUCLEOTIDE PRIMERS see **DNA PRIMERS**

OLIGONUCLEOTIDE PROBES

see related
NUCLEIC ACID HYBRIDIZATION
OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS

DIAGNOSTIC USE

[Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes] al Saati T, et al. **Bull Cancer** 1998 Oct;85(10):847-54 (64 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Molecular interactions on microarrays. Southern E, et al. **Nat Genet** 1999 Jan;21(1 Suppl):5-9 (37 ref.)

OLIGONUCLEOTIDES

Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Jayasena SD. **Clin Chem** 1999 Sep;45(9):1628-50 (181 ref.)
Oligonucleotide libraries--variatio delectat. Famulok M, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):320-7 (69 ref.)

ANALYSIS

Advances in CE/MS. Ding J, et al. **Anal Chem** 1999 Jun 1;71(11):378A-385A (47 ref.)

CHEMICAL SYNTHESIS

Some aspects of oligoribonucleotides synthesis via the H-phosphonate approach. Stawiński J, et al. **Acta Biochim Pol** 1998;45(4):907-15 (51 ref.)
Artificial promoters for metabolic optimization. Jensen PR, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):191-5 (17 ref.)
High density synthetic oligonucleotide arrays. Lipshutz RJ, et al. **Nat Genet** 1999 Jan;21(1 Suppl):20-4 (32 ref.)
Making drugs out of oligonucleotides: a brief review and perspective. Cook PD. **Nucleosides Nucleotides** 1999 Jun-Jul;18(6-7):1141-62 (78 ref.)

CHEMISTRY

Modified oligonucleotides: synthesis and strategy for users. Verma S, et al. **Annu Rev Biochem** 1998;67:99-134 (292 ref.)
Bioanalytic applications of mass spectrometry. Costello CE. **Curr Opin Biotechnol** 1999 Feb;10(1):22-8 (60 ref.)
Oligonucleotide aptamers that recognize small molecules. Famulok M. **Curr Opin Struct Biol** 1999 Jun;9(3):324-9 (75 ref.)
Chemical etiology of nucleic acid structure. Eschenmoser A. **Science** 1999 Jun 25;284(5423):2118-24 (62 ref.)
[Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches] Ostendorf T, et al. **Med Klin** 1999 Apr 15;94(4):219-23 (14 ref.) (Eng. Abstr.) **(Ger)**

OLIGONUCLEOTIDES

GENETICS

Gene repair using chimeric RNA/DNA oligonucleotides. **Kren BT, et al. Semin Liver Dis** 1999;19(1):93–104 (44 ref.)

METABOLISM

Rhyme or reason: RNA–arginine interactions and the genetic code. **Knight RD, et al. Chem Biol** 1998 Sep;5(9):R215–20 (23 ref.)

[Oligonucleotides with aptameric properties] **Krakowiak A, et al. Postepy Biochem** 1998;44(4):306–17 (75 ref.) **(Pol)**

THERAPEUTIC USE

Cytokines and therapeutic oligonucleotides. **Hartmann G, et al. Cytokines Cell Mol Ther** 1997 Dec;3(4):247–56 (66 ref.)

Oligonucleotide therapy of allergic asthma. **Metzger WJ, et al. J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):260–6 (58 ref.)

[Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches] **Ostendorf T, et al. Med Klin** 1999 Apr 15;94(4):219–23 (14 ref.) (Eng. Abstr.) **(Ger)**

OLIGONUCLEOTIDES, ANTISENSE

An antisense oligonucleotide primer. **Hogrefe RI. Antisense Nucleic Acid Drug Dev** 1999 Aug;9(4):351–7 (50 ref.)

Antisense comes of age. **Flanagan WM. Cancer Metastasis Rev** 1998 Jun;17(2):169–76 (45 ref.)

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM–1. **Henry SP, et al. Toxicol Pathol** 1999 Jan–Feb; 27(1):95–100 (35 ref.)

[Analysis of physiological function by antisense oligonucleotide system] **Takeuchi T, et al. Nippon Seirigaku Zasshi** 1998;60(10):383–99 (17 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Antisense technologies have a future fighting neurodegenerative diseases. **Seidman S, et al. Antisense Nucleic Acid Drug Dev** 1999 Aug;9(4):333–40 (69 ref.)

[Protein and peptide construction for delivery of oligonucleotides and DNA into the cell] **Pozmogova GE, et al. Vopr Med Khim** 1998 Jul–Aug;44(4):331–7 (46 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

Monitoring antisense oligodeoxynucleotide activity in hematopoietic cells. **Sokol DL, et al. Methods** 1999 Mar; 17(3):219–30 (112 ref.)

DIAGNOSTIC USE

Imaging with radiolabeled antisense oligonucleotides for the detection of intracellular messenger RNA and cardiovascular disease. **Dewanjee MK, et al. J Nucl Cardiol** 1999 May–Jun;6(3):345–56 (10 ref.)

GENETICS

[Utilization of antisense oligonucleotide strategy in study of exposing and localization of rRNA on surface ribosomal subunits] **Sobkiewicz A, et al. Postepy Biochem** 1998; 44(1):55–63 (43 ref.) **(Pol)**

IMMUNOLOGY

New vistas in immunopsychopharmacology. **Herman ZS. Pol J Pharmacol** 1998 Nov–Dec;50(6):377–86 (108 ref.)

METABOLISM

[Antisense strategy—new trends] **Koziołkiewicz M. Postepy Biochem** 1998;44(2):125–35 (89 ref.) **(Pol)**

PHARMACOKINETICS

Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. **Boado RJ, et al. J Pharm Sci** 1998 Nov;87(11):1308–15 (69 ref.)

Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. **Juliano RL, et al. Pharm Res** 1999 Apr;16(4):494–502 (107 ref.)

PHARMACOLOGY

Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1–receptor messenger ribonucleic acid. **Phillips MI. Am J Cardiol** 1998 Nov 19;82(10A):60S–62S (8 ref.)

New insights into dopaminergic receptor function using antisense and genetically altered animals. **Sibley DR. Annu Rev Pharmacol Toxicol** 1999;39:313–41 (96 ref.)

Nucleic acid targeting: therapeutic strategies for the 21st century. **Thurston DE. Br J Cancer** 1999 Jul;80 Suppl 1:65–85 (114 ref.)

Diapedesis of leukocytes: antisense oligonucleotides for rescue. **Dragun D, et al. Exp Nephrol** 1999 Mar–Apr; 7(2):185–92 (68 ref.)

Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. **Juliano RL, et al. Pharm Res** 1999 Apr;16(4):494–502 (107 ref.)

Do unintended antisense transcripts contribute to sense cosuppression in plants? [letter; comment] **Jorgensen RA, et al. Trends Genet** 1999 Jan;15(1):11–2 (14 ref.) Comment on: Trends Genet 1998 Jul;14(7):255–8.

Insight into adenosine receptor function using antisense and gene–knockout approaches. **Nyce JW. Trends Pharmacol Sci** 1999 Feb;20(2):79–83 (46 ref.)

[Antisense oligonucleotides are clinically tested. They inhibit the expression of disease–related genes] **Sommer W, et al. Lakartidningen** 1999 Jan 27;96(4):348–54 (35 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Antisense—time to shoot the messenger. **Kuss B, et al. Ann Oncol** 1999 May;10(5):495–503 (57 ref.)

Antisense technologies have a future fighting neurodegenerative diseases. **Seidman S, et al. Antisense Nucleic Acid Drug Dev** 1999 Aug;9(4):333–40 (69 ref.)

Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. **Miyazaki K, et al. Cancer Chemother Pharmacol** 1999;43 Suppl:S52–5 (33 ref.)

Oligonucleotide–based gene therapy for cardiovascular disease. **Morishita R, et al. Clin Chem Lab Med** 1998 Aug; 36(8):529–34 (53 ref.)

Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer [editorial] **Del Rosso M, et al. Clin Exp Rheumatol** 1998 Jul–Aug;16(4):389–93 (56 ref.)

Antisense therapeutics. **Agrawal S, et al. Curr Opin Chem Biol** 1998 Aug;2(4):519–28 (52 ref.)

Antisense strategy in hematological malignancies. **Warzocha K. Cytokines Cell Mol Ther** 1999 Mar;5(1):15–23 (90 ref.)

Myb targeted therapeutics for the treatment of human malignancies. **Gewirtz AM. Oncogene** 1999 May 13; 18(19):3056–62 (73 ref.)

Bcl–2 antisense therapy in multiple myeloma. **Bloem A, et al. Pathol Biol (Paris)** 1999 Feb;47(2):216–20 (44 ref.)

Use of antisense vectors and oligodeoxynucleotides in neuro–oncology. **Engelhard HH, et al. Pediatr Neurosurg** 1998 Jun;28(6):279–85 (100 ref.)

Synthetic oligonucleotides: the development of antisense therapeutics. **Monteith DK, et al. Toxicol Pathol** 1999 Jan–Feb;27(1):8–13 (40 ref.)

[Antisense oligonucleotides: a new therapeutic approach] **Guinot P, et al. Pathol Biol (Paris)** 1998 May;46(5):347–54 (56 ref.) (Eng. Abstr.) **(Fre)**

[Trend in genetic medicine] **Shoji Y, et al. Nippon Rinsho** 1998 Aug;56(8):2186–95 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Antisense strategy—new trends] **Koziołkiewicz M. Postepy Biochem** 1998;44(2):125–35 (89 ref.) **(Pol)**

OLIGOPEPTIDES

[Imunofan: new–generation synthetic peptide agent] **Lebedev VV, et al. Vestn Ross Akad Med Nauk** 1999;(4):56–61 (11 ref.) (Eng. Abstr.) **(Rus)**

[Myelopeptides as a new group of regulatory peptides] **Mikhailova AA. Vestn Ross Akad Med Nauk** 1999;(4):49–52 (13 ref.) (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Small dipeptide–based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition–state mimic. **Kiso Y, et al. Biopolymers** 1999;51(1):59–68 (32 ref.)

The dolastatins, a family of promising antineoplastic agents. **Poncet J. Curr Pharm Des** 1999 Mar;5(3):139–62 (123 ref.)

CHEMISTRY

Vibrational circular dichroism spectroscopy of selected oligopeptide conformations. **Keiderling TA, et al. Bioorg Med Chem** 1999 Jan;7(1):133–41 (42 ref.)

Small dipeptide–based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition–state mimic. **Kiso Y, et al. Biopolymers** 1999;51(1):59–68 (32 ref.)

Combinatorial libraries of transition–metal complexes, catalysts and materials. **Francis MB, et al. Curr Opin Chem Biol** 1998 Jun;2(3):422–8 (19 ref.)

Subtleties of structure–agonist versus antagonist relationships of opioid peptides and peptidomimetics. **Schiller PW, et al. J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):573–88 (33 ref.)

What peptides these deltorphins be. **Lazarus LH, et al. Prog Neurobiol** 1999 Feb;57(4):377–420 (405 ref.)

DIAGNOSTIC USE

The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans. **Peino R, et al. Growth Horm IGF Res** 1999 Apr;9 Suppl A:101–5 (38 ref.)

Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. **Pinkas L, et al. Nucl Med Commun** 1999 Aug;20(8):689–96 (26 ref.)

GENETICS

Induction of a minor into the major league? Genomic identification of a human minor histocompatibility antigen [editorial; comment] **Dupont B. Tissue Antigens** 1998 Oct; 52(4):303–4 (20 ref.) Comment on: Tissue Antigens 1998 Oct;52(4):305–11. Comment on: Tissue Antigens 1998 Oct;52(4):312–7.

IMMUNOLOGY

Exploring immunological specificity using synthetic peptide combinatorial libraries. **Pinilla C, et al. Curr Opin Immunol** 1999 Apr;11(2):193–202 (65 ref.)

ISOLATION & PURIFICATION

Opioid peptides from frog skin. **Amiche M, et al. EXS** 1998; 85:57–71 (48 ref.)

Sodefrin: a novel sex pheromone in a newt. **Kikuyama S, et al. Rev Reprod** 1999 Jan;4(1):1–4 (18 ref.)

METABOLISM

A G–protein signaling network mediated by an RGS protein. **Guan KL, et al. Genes Dev** 1999 Jul 15;13(14):1763–7 (35 ref.)

Mechanisms of chromium action: low–molecular–weight chromium–binding substance. **Vincent JB. J Am Coll Nutr** 1999 Feb;18(1):6–12 (55 ref.)

PHARMACOLOGY

Src homology–2 domains: structure, mechanisms, and drug discovery. **Sawyer TK. Biopolymers** 1998;47(3):243–61 (44 ref.)

Subtleties of structure–agonist versus antagonist relationships of opioid peptides and peptidomimetics. **Schiller PW, et al. J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):573–88 (33 ref.)

Hematoregulators. A case history of a novel hematoregulatory peptide, SK&F 107647. **Bhatnagar PK, et al. Pharm Biotechnol** 1998;11:367–91 (128 ref.)

LHRH antagonists. **Haviv F, et al. Pharm Biotechnol** 1998; 11:131–49 (56 ref.)

Development of an orally active tripeptide arginal thrombin inhibitor. **Shuman RT, et al. Pharm Biotechnol** 1998; 11:57–80 (34 ref.)

[Effects of newly isolated opioid peptides on G–protein activation: usefulness of [35S] GTP gamma S binding study and its practical application] **Narita M. Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):107–16 (58 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of NC–1900: its ameliorating effects on impairments of learning and memory in the CA1 neurons and its intracellular signal transduction pathways] **Akaike N, et al. Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:44P–47P (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Molecular, cellular and physiological characteristics of 5–HT–moduline, a novel endogenous modulator of 5–HT1B receptor subtype. **Massot O, et al. Ann N Y Acad Sci** 1998 Dec 15;861:174–82 (17 ref.)

Growth hormone–releasing peptide (GHRP). **Bowers CY. Cell Mol Life Sci** 1998 Dec;54(12):1316–29 (62 ref.)

New insights into adipokinetic hormone signaling. **Vroemen SF, et al. Mol Cell Endocrinol** 1998 Jun 25;141(1–2):7–12 (40 ref.)

Oligopeptide signalling and the action of systemin. **Schaller A. Plant Mol Biol** 1999 Jul;40(5):763–9 (17 ref.)

What peptides these deltorphins be. **Lazarus LH, et al. Prog Neurobiol** 1999 Feb;57(4):377–420 (405 ref.)

[5HT–moduline an new peptide specifically interactive with the serotonergic system: physiopathologic implications] **Fillion G. Ann Pharm Fr** 1998;56(4):145–7 (7 ref.) (Eng. Abstr.) **(Fre)**

[New growth hormone secretagogues: from physiology to the first therapeutic applications] **Ahnfelt–Rønne I, et al. Arch Pediatr** 1998;5 Suppl 4:390S–396S (35 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Arg–gly–Asp (RGD) peptides and peptidomimetics as therapeutics: relevance for renal diseases. **Horton MA. Exp Nephrol** 1999 Mar–Apr;7(2):178–84 (47 ref.)

HLA–derived peptides as novel immunomodulatory therapeutics. **Murphy B, et al. J Am Soc Nephrol** 1999 Jun; 10(6):1346–55 (78 ref.)

Clinical trials referral resource. Clinical trials of dolastatin–10. **Wright JJ, et al. Oncology (Huntingt)** 1999 Jan;13(1):68–70, 75 (0 ref.)

[New growth hormone secretagogues: from physiology to the first therapeutic applications] **Ahnfelt–Rønne I, et al. Arch Pediatr** 1998;5 Suppl 4:390S–396S (35 ref.) (Eng. Abstr.) **(Fre)**

OLIGORIBONUCLEOTIDE PROBES see **OLIGONUCLEOTIDE PROBES**

OLIGORIBONUCLEOTIDES

GENETICS

Controlling gene expression with 2–5A antisense. Leaman DW, et al. **Methods** 1999 Jul;18(3):252–65 (48 ref.)

METABOLISM

The 2–5A system in viral infection and apoptosis. Castelli J, et al. **Biomed Pharmacother** 1998;52(9):386–90 (47 ref.)

OLIGORIBONUCLEOTIDES, ANTISENSE

GENETICS

Controlling gene expression with 2–5A antisense. Leaman DW, et al. **Methods** 1999 Jul;18(3):252–65 (48 ref.)

OLIGOSACCHARIDES

[Oligosaccharides as the elicitor signal for the activation of defense system in plants] Shibuya N, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2531–9 (58 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Dietary modulation of the human gut microflora using prebiotics. Gibson GR. **Br J Nutr** 1998 Oct;80(4):S209–12 (19 ref.)

Prebiotics and synbiotics: concepts and nutritional properties. Roberfroid MB. **Br J Nutr** 1998 Oct;80(4):S197–202 (38 ref.)

Effects of probiotics and prebiotics on blood lipids. Taylor GR, et al. **Br J Nutr** 1998 Oct;80(4):S225–30 (35 ref.)

Inulin and oligofructose: safe intakes and legal status. Coussement PA. **J Nutr** 1999 Jul;129(7 Suppl):1412S–7S (23 ref.)

Petfood applications of inulin and oligofructose. Hussein HS, et al. **J Nutr** 1999 Jul;129(7 Suppl):1454S–6S (28 ref.)

ANALYSIS

Overview of N- and O-linked oligosaccharide structures found in various yeast species. Gemmill TR, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):227–37 (96 ref.)

Methods to determine food inulin and oligofructose. Prosky L, et al. **J Nutr** 1999 Jul;129(7 Suppl):1418S–23S (16 ref.)

[Nutritional importance of oligosaccharides] Amarowicz R. **Rocz Panstw Zakl Hig** 1999;50(1):89–95 (37 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Combinatorial synthesis of carbohydrates. Schweizer F, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):291–8 (45 ref.)

CHEMICAL SYNTHESIS

Synthesis and applications for unnatural sugar nucleotides. Elhalabi JM, et al. **Curr Med Chem** 1999 Feb;6(2):93–116 (164 ref.)

Solid-phase oligosaccharide synthesis and related technologies. Ito Y, et al. **Curr Opin Chem Biol** 1998 Dec; 2(6):701–8 (36 ref.)

[Oligosaccharide sulfate inhibitors of selectin-sugar interactions in inflammatory processes] Auge C, et al. **Ann Pharm Fr** 1999 May;57(3):216–22 (12 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Structure and conformation of complex carbohydrates of glycoproteins, glycolipids, and bacterial polysaccharides. Bush CA, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:269–93 (150 ref.)

Alpha-Gal oligosaccharides: chemistry and potential biomedical application. Janczuk A, et al. **Curr Med Chem** 1999 Feb;6(2):155–64 (42 ref.)

Human milk glycoconjugates that inhibit pathogens. Newburg DS. **Curr Med Chem** 1999 Feb;6(2):117–27 (33 ref.)

Bioanalytic applications of mass spectrometry. Costello CE. **Curr Opin Biotechnol** 1999 Feb;10(1):22–8 (60 ref.)

Oligosaccharide signaling of plant cells. Etzler ME. **J Cell Biochem Suppl** 1998;30–31:123–8 (35 ref.)

Chemoselective ligation reactions with proteins, oligosaccharides and cells. Lemieux GA, et al. **Trends Biotechnol** 1998 Dec;16(12):506–13 (74 ref.)

[Conclusions and perspectives (glycochemistry: biological implications and therapeutic applications)] Lattes A. **Ann Pharm Fr** 1999 May;57(3):246–50 (9 ref.) **(Fre)**

[New antithrombotic oligosaccharides] Petitou M, et al. **Ann Pharm Fr** 1999 May;57(3):232–9 (15 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Evolutionary considerations in relating oligosaccharide diversity to biological function. Gagneux P, et al. **Glycobiology** 1999 Aug;9(8):747–55 (97 ref.)

ISOLATION & PURIFICATION

[Separation and analysis of saccharides--on mainly oligosaccharides] Koizumi K. **Yakugaku Zasshi** 1999 Mar; 119(3):199–214 (33 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Functional food properties of non-digestible oligosaccharides: a consensus report from the ENDO project (DGXII AIRII-CT94-1095) [see comments] Van Loo J, et al. **Br J Nutr** 1999 Feb;81(2):121–32 (66 ref.) Comment in: Br J Nutr 1999 Feb;81(2):83–4.

Oligosaccharide receptors for bacteria: a view to a kill. Lingwood CA. **Curr Opin Chem Biol** 1998 Dec; 2(6):695–700 (57 ref.)

Oligosaccharide recognition signals and defence reactions in marine plant-microbe interactions. Potin P, et al. **Curr Opin Microbiol** 1999 Jun;2(3):276–83 (64 ref.)

Evolutionary considerations in relating oligosaccharide diversity to biological function. Gagneux P, et al. **Glycobiology** 1999 Aug;9(8):747–55 (97 ref.)

Inulin and oligofructose: what are they? Niness KR. **J Nutr** 1999 Jul;129(7 Suppl):1402S–6S (77 ref.)

Caloric value of inulin and oligofructose. Roberfroid MB. **J Nutr** 1999 Jul;129(7 Suppl):1436S–7S (14 ref.)

Role for cell surface oligosaccharide in cell-cell recognition during implantation. Zhu ZM, et al. **Mol Hum Reprod** 1998 Aug;4(8):735–8 (30 ref.)

PHARMACOLOGY

Nondigestibility characteristics of inulin and oligofructose in humans. Andersson HB, et al. **J Nutr** 1999 Jul;129(7 Suppl):1428S–30S (24 ref.)

Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. Gibson GR. **J Nutr** 1999 Jul;129(7 Suppl):1438S–41S (22 ref.)

Nondigestible carbohydrates and mineral bioavailability. Greger JL. **J Nutr** 1999 Jul;129(7 Suppl):1434S–5S (22 ref.)

Inulin, oligofructose and intestinal function. Jenkins DJ, et al. **J Nutr** 1999 Jul;129(7 Suppl):1431S–3S (26 ref.)

Fiber, inulin and oligofructose: similarities and differences. Schneeman BO. **J Nutr** 1999 Jul;129(7 Suppl):1424S–7S (24 ref.)

THERAPEUTIC USE

Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. Reddy BS. **J Nutr** 1999 Jul;129(7 Suppl):1478S–82S (41 ref.)

Influence of inulin and oligofructose on breast cancer and tumor growth. Taper HS, et al. **J Nutr** 1999 Jul;129(7 Suppl):1488S–91S (25 ref.)

Effects of inulin on lipid parameters in humans. Williams CM. **J Nutr** 1999 Jul;129(7 Suppl):1471S–3S (14 ref.)

[Conclusions and perspectives (glycochemistry: biological implications and therapeutic applications)] Lattes A. **Ann Pharm Fr** 1999 May;57(3):246–50 (9 ref.) **(Fre)**

OLIGOSPERMIA

[Therapeutic strategies in azoospermia: management] Ohl J, et al. **Contracept Fertil Sex** 1998 Sep;26(9):656–62 (52 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Etiology and treatment of sterility due to azoospermia] Martin-du Pan RC, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):453–7 (28 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Human chromosome deletions in Yq11, AZF candidate genes and male infertility: history and update. Vogt PH. **Mol Hum Reprod** 1998 Aug;4(8):739–44 (51 ref.)

THERAPY

Assisted reproduction for the treatment of azoospermia. Safran A, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:47–60 (54 ref.)

[Etiology and treatment of sterility due to azoospermia] Martin-du Pan RC, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):453–7 (28 ref.) (Eng. Abstr.) **(Fre)**

OLIGURIA

CHEMICALLY INDUCED

Propofol toxicity in critically ill pediatric patients: show us the proof [editorial; comment] Susla GM. **Crit Care Med** 1998 Dec;26(12):1959–60 (15 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2087–92.

ETIOLOGY

Oliguria, an unusual presentation of primary signet ring-cell adenocarcinoma of the urinary bladder: a case report and review of the literature. Wong C, et al. **J Surg Oncol** 1999 Jan;70(1):64–7 (23 ref.)

OLIVARY NUCLEUS

CYTOLOGY

Microcircuitry and function of the inferior olive. De Zeeuw CI, et al. **Trends Neurosci** 1998 Sep;21(9):391–400 (113 ref.)

Plasticity of the olivocerebellar pathway. Strata P, et al. **Trends Neurosci** 1998 Sep;21(9):407–13 (72 ref.)

EMBRYOLOGY

Early developmental changes in the chemoarchitecture of the human inferior olive: a review. Armstrong DD, et al. **J Neuropathol Exp Neurol** 1999 Jan;58(1):1–11 (77 ref.)

PATHOLOGY

Hypertrophic olivary degeneration: case report in a child. Phatouros CC, et al. **Pediatr Radiol** 1998 Nov;28(11):830–1 (5 ref.)

[Cerebello-olivary atrophy (COA)] Mizusawa H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):239–42 (15 ref.) **(Jpn)**

PHYSIOLOGY

Microcircuitry and function of the inferior olive. De Zeeuw CI, et al. **Trends Neurosci** 1998 Sep;21(9):391–400 (113 ref.)

Plasticity of the olivocerebellar pathway. Strata P, et al. **Trends Neurosci** 1998 Sep;21(9):407–13 (72 ref.)

OLIVOPONTOCEREBELLAR ATROPHY

[Olivopontocerebellar atrophy (OPCA)] Kita K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):251–3 (7 ref.) **(Jpn)**

GENETICS

[Unstable expansion of CAG repeat and molecular mechanism of neurodegeneration in SCA1] Sasaki H. **Nippon Rinsho** 1999 Apr;57(4):801–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

The treatment of spinocerebellar ataxias: facts and hypotheses. Botez MI, et al. **Med Hypotheses** 1998 Nov; 51(5):381–4 (45 ref.)

OLIVOPONTOCEREBELLAR DEGENERATION see **OLIVOPONTOCEREBELLAR ATROPHY**

OLLIER'S DISEASE see **ENCHONDROMATOSIS**

OMEGA-3 FATTY ACIDS see **FATTY ACIDS, OMEGA-3**

OMEGA-N-METHYLARGININE

THERAPEUTIC USE

Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red [editorial; comment] Cobb JP. **Crit Care Med** 1999 May;27(5):855–6 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):913–22.

OMEGA PROTEIN see **DNA TOPOISOMERASE**

OMENTUM

Parasitic ovarian dermoid tumor of the omentum-A review of the literature and report of two new cases. Ushakov FB, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 81(1):77–82 (32 ref.)

Primary omental liposarcoma presenting with torsion: a case report. Tsutsumi H, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2110–2 (10 ref.)

BLOOD SUPPLY

[Primary idiopathic segmental infarction of the greater omentum (letter)] Louredo Méndez A, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):150–1 (6 ref.) **(Spa)**

PATHOLOGY

Primary tumours of the greater omentum. Ishida H, et al. **Eur Radiol** 1998;8(9):1598–601 (21 ref.)

A supernumerary ovary of the omentum with cystic change: report of two cases and review of the literature. Kuga T, et al. **Pathol Int** 1999 Jun;49(6):566–70 (14 ref.)

RADIOGRAPHY

Primary leiomyosarcoma of the greater omentum. Ishida J, et al. **J Clin Gastroenterol** 1999 Mar;28(2):167–70 (13 ref.)

SURGERY

Use of the greater omentum in colorectal surgery. O'Leary DP. **Dis Colon Rectum** 1999 Apr;42(4):533–9 (82 ref.)

Transposition of the great omentum for infected sternotomy wounds in cardiac surgery. Report of 16 cases and review of published reports. Moor EV, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):25–9 (35 ref.)

TRANSPLANTATION

Buerger's disease: the role of omental transfer [letter] Puneet, et al. **Trop Doct** 1999 Apr;29(2):118–20 (4 ref.)

OMEPRAZOLE

ADMINISTRATION & DOSAGE

[The treatment strategy of H. pylori infection and the new triple therapy] Hoshiya S, et al. **Nippon Rinsho** 1999 Jan; 57(1):121–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Omeprazole and vitamin B12 deficiency. Bradford GS, et al. **Ann Pharmacother** 1999 May;33(5):641–3 (12 ref.)

Safety profile of Lansoprazole: the US clinical trial experience. Freston JW, et al. **Drug Saf** 1999 Feb; 20(2):195–205 (22 ref.)

ANALOGS & DERIVATIVES

Safety profile of Lansoprazole: the US clinical trial experience. Freston JW, et al. **Drug Saf** 1999 Feb; 20(2):195–205 (22 ref.)

[Lansoprazol ++ : a new proton pump inhibitor] Baczek J, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):339–41 (25 ref.) (Eng. Abstr.) **(Pol)**

[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy] Gisbert JP. **Rev Esp Enferm Dig** 1999 Feb;91(2):133–43 (111 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. Israel DM, et al.
J Pediatr Gastroenterol Nutr 1998 Nov;27(5):568–79 (129 ref.)

THERAPEUTIC USE

Therapy for ulcers and erosions associated with nonsteroidal anti-inflammatory drugs. Freeman HJ.
Can J Gastroenterol 1998 Nov–Dec;12(8):537–9 (0 ref.)

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Langtry HD, et al. **Drugs** 1998 Sep;56(3):447–86 (126 ref.)

Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion [editorial; comment] Kuipers EJ, et al. **Gastroenterology** 1999 Feb; 116(2):479–83 (35 ref.) Comment on: Gastroenterology 1999 Feb;116(2):239–47. Comment on: Gastroenterology 1999 Feb;116(2):248–53.

[Mechanism of proton pump inhibitors in the treatment of Holicobacter pylori-associated ulcers] Huang J, et al.
Chung Hua Nei Ko Tsa Chih 1997 Jul;36(7):488–91 (20 ref.) **(Chi)**

[The role and significance of acid suppressive drugs in the eradication of H. pylori] Yakabi K, et al.
Nippon Rinsho 1999 Jan;57(1):53–60 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Omeprazole and gastric protection] Madridejos Mora R.
Aten Primaria 1999 Apr 30;23(7):441–4 (31 ref.) **(Spa)**

[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient? (see comments)] Gisbert JP, et al. **Rev Clin Esp** 1998 Oct;198(10):655–9 (37 ref.) (Eng. Abstr.) Comment in: Rev Clin Esp 1999 Jun;199(6):407. **(Spa)**

OMP PROTEINS see **BACTERIAL OUTER MEMBRANE PROTEINS**

OMPHALOCELE see **HERNIA, UMBILICAL**

ON-LINE SYSTEMS see **ONLINE SYSTEMS**

ONCHOCERCA

Pathogenesis of onchocercal keratitis (River blindness). Hall LR, et al. **Clin Microbiol Rev** 1999 Jul;12(3):445–53 (85 ref.)

DRUG EFFECTS

The impact of Mectizan on the transmission of onchocerciasis. Boatin BA, et al.
Ann Trop Med Parasitol 1998 Apr;92 Suppl 1:S46–60 (43 ref.)

ONCHOCERCA VOLVULUS

Onchocerciasis and Chagas' disease control: the evolution of control via applied research through changing development scenarios. Molyneux DH, et al.
Br Med Bull 1998;54(2):327–39 (62 ref.)

ONCHOCERCIASIS

[Onchocerciasis] Takeuchi T.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):455–7 (7 ref.) **(Jpn)**

DIAGNOSIS

Diagnostics in onchocerciasis: future challenges. Boatin BA, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S41–5 (16 ref.)

ECONOMICS

Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Benton B. **Ann Trop Med Parasitol** 1998 Apr; 92 Suppl 1:S33–9 (6 ref.)

PARASITOLOGY

Pathogenesis of onchocercal keratitis (River blindness). Hall LR, et al. **Clin Microbiol Rev** 1999 Jul;12(3):445–53 (85 ref.)

PREVENTION & CONTROL

Onchocerciasis and Chagas' disease control: the evolution of control via applied research through changing development scenarios. Molyneux DH, et al.
Br Med Bull 1998;54(2):327–39 (62 ref.)

[The campaign against onchocerciasis in Africa: update] Boussinesq M, et al. **Med Trop (Mars)** 1998;58(3):285–96 (118 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

The impact of Mectizan on the transmission of onchocerciasis. Boatin BA, et al.
Ann Trop Med Parasitol 1998 Apr;92 Suppl 1:S46–60 (43 ref.)

ONCHOCERCIASIS, OCULAR

DRUG THERAPY

Onchocercal eye disease and the impact of Mectizan treatment. Abiose A. **Ann Trop Med Parasitol** 1998 Apr; 92 Suppl 1:S11–22 (49 ref.)

ECONOMICS

Onchocerciasis: the burden of disease. Kale OO.
Ann Trop Med Parasitol 1998 Apr;92 Suppl 1:S101–15 (75 ref.)

ONCOCYTOMA see **ADENOMA, OXYPHILIC**

ONCOGENE PRODUCTS see **ONCOGENE PROTEINS**

ONCOGENE PROTEIN P21(RAS)

BIOSYNTHESIS

Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Gärtner U, et al. **Neuroscience** 1999;91(1):1–5 (35 ref.)

CHEMISTRY

Molecular reaction mechanisms of proteins monitored by time-resolved FTIR-spectroscopy. Gerwert K.
Biol Chem 1999 Jul–Aug;380(7–8):931–5 (29 ref.)

PHYSIOLOGY

The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Bredel M, et al. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):232–49 (257 ref.)

ONCOGENE PROTEIN P190(BCR-ABL) see **FUSION PROTEINS, BCR-ABL**

ONCOGENE PROTEIN P210(BCR-ABL) see **FUSION PROTEINS, BCR-ABL**

ONCOGENE PROTEIN PP60(SRC) see **ONCOGENE PROTEIN PP60(V-SRC)**

ONCOGENE PROTEIN PP60(V-SRC)

METABOLISM

Nongenomic signaling by vitamin D: a new face of Src. Gniadecki R. **Biochem Pharmacol** 1998 Nov 15; 56(10):1273–7 (27 ref.)

ONCOGENE PROTEINS

ANALYSIS

Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Behre G, et al.
Methods 1999 Mar;17(3):231–7 (61 ref.)

GENETICS

Gli genes and limb development. Theil T, et al.
Cell Tissue Res 1999 Apr;296(1):75–83 (79 ref.)

The involvement of Bcr in leukemias with the Philadelphia chromosome. Arlinghaus RB. **Crit Rev Oncog** 1998; 9(1):1–18 (97 ref.)

Translational infidelity and human cancer: role of the PTI-1 oncogene. Gopalkrishnan RV, et al.
Int J Biochem Cell Biol 1999 Jan;31(1):151–62 (47 ref.)

B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments. Sala A, et al.
J Cell Physiol 1999 Jun;179(3):245–50 (49 ref.)

METABOLISM

Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. Stunnenberg HG, et al.
Biochim Biophys Acta 1999 Jan 29;1423(1):F15–33 (159 ref.)

The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events. McCarty JH.
Bioessays 1998 Nov;20(11):913–21 (71 ref.)

Net results of nucleolar dynamics. Garcia SN, et al. **Cell** 1999 Jun 25;97(7):825–8 (21 ref.)

The involvement of Bcr in leukemias with the Philadelphia chromosome. Arlinghaus RB. **Crit Rev Oncog** 1998; 9(1):1–18 (97 ref.)

PHYSIOLOGY

Virocrine transformation: the intersection between viral transforming proteins and cellular signal transduction pathways. DiMaio D, et al. **Annu Rev Microbiol** 1998; 52:397–421 (142 ref.)

Do overexpressed oncoproteins cause malignant growth of cancer cells?--Studied by antisense oligonucleotides. Lin SB. **Clin Chem Lab Med** 1998 Aug;36(8):541–4 (30 ref.)

ONCOGENE PROTEINS, FUSION

GENETICS

Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Lo Coco F, et al. **Blood** 1999 Jul 1;94(1):12–22 (119 ref.)

Terminal deletion of the long arm of chromosome 9 in acute promyelocytic leukemia with a cryptic PML/RAR alpha rearrangement. Yamamoto K, et al.
Cancer Genet Cytogenet 1999 Sep;113(2):120–5 (3 ref.)

Fusion genes in solid tumors. Aman P.
Semin Cancer Biol 1999 Aug;9(4):303–18 (149 ref.)

ONCOGENE PROTEINS V-ABL

PHYSIOLOGY

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. Zou X, et al. **J Biol Chem** 1999 Jun 25; 274(26):18141–4 (77 ref.)

ONCOGENE PROTEINS, VIRAL

METABOLISM

The CCN family of angiogenic regulators: the integrin connection. Lau LF, et al. **Exp Cell Res** 1999 Apr 10; 248(1):44–57 (101 ref.)

ONCOGENES

Myb and oncogenesis. Ganter B, et al. **Adv Cancer Res** 1999; 76:21–60 (289 ref.)

Etiology and pathogenesis of posttransplant tumors: new insights into viral oncogenesis. el-Sabrout R, et al.
Ann Transplant 1997;2(4):67–9 (45 ref.)

Oncogenes and tumor suppressor genes: therapeutic implications. Stass SA, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 2):2687–95 (58 ref.)

Cell cycle and cancer. Pucci B, et al. **Clin Ter** 1999 Mar–Apr; 150(2):135–41 (72 ref.)

Acute retroviruses and oncogenesis. Arbelaez AM, et al.
Crit Rev Oncog 1999;10(1–2):17–81 (623 ref.)

Oncogenes and signal transduction pathways involved in the regulation of Na+ channel expression. Sashihara S, et al.
Crit Rev Oncog 1998;9(1):19–34 (142 ref.)

Cancer genetics: tumor suppressor meets oncogene. Fearon ER, et al. **Curr Biol** 1999 Jan 28;9(2):R62–5 (12 ref.)

The molecular genetics of head and neck cancer. Rowley H. **J Laryngol Otol** 1998 Jul;112(7):607–12 (54 ref.)

How can oncogenic transcription factors cause cancer: a critical review of the myb story. Introna M, et al.
Leukemia 1999 Sep;13(9):1301–6 (70 ref.)

Murine protein kinase CK2: gene and oncogene. Xu X, et al. **Mol Cell Biochem** 1999 Jan;191(1–2):65–74 (53 ref.)

Demystified ... oncogenes. Wallis YL, et al. **Mol Pathol** 1999 Apr;52(2):55–63 (55 ref.)

The first oncogene in Drosophila melanogaster. Baek KH.
Mutat Res 1999 Mar;436(2):131–6 (39 ref.)

Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Schwab M. **Naturwissenschaften** 1999 Feb;86(2):71–8 (53 ref.)

Regulation of cell proliferation by G proteins. Dhanasekaran N, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1383–94 (139 ref.)

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Porter AC, et al.
Oncogene 1998 Sep 17;17(11 Reviews):1343–52 (106 ref.)

Myeloid leukemia: disease genes and mouse models. Copeland NG, et al. **Prog Exp Tumor Res** 1999;35:53–63 (35 ref.)

Traps to catch unwary oncogenes. Hueber AO, et al.
Trends Genet 1998 Sep;14(9):364–7 (41 ref.)

[Oncogenes and function of the gonads] Zheng YH, et al.
Sheng Li Ko Hsueh Chin Chan 1996 Oct;27(4):344–6 (10 ref.) **(Chi)**

[Oncogenic factors of metastatic dissemination in neuroblastoma] Da Silva J, et al.
C R Seances Soc Biol Fil 1998;192(2):261–71 (26 ref.) (Eng.

Abstr.) **(Fre)**
[Carcinogenesis and genetic diagnosis] Matsuo F, et al. **Rinsho Byori** 1999 Feb;Suppl 109:151–8 (20 ref.) **(Jpn)**
[Identification of cancer genes has made the testing of predisposition possible. Genetic counseling and mutation screening can result in new therapeutic methods] Nordenskjöld M. **Lakartidningen** 1999 Aug 11; 96(32–33):3392–6 (8 ref.) **(Swe)**

GENETICS

Molecular genetics of brain tumors. Hill JR, et al. **Arch Neurol** 1999 Apr;56(4):439–41 (9 ref.)
Mutation patterns in non-ras oncogenes and tumour suppressor genes in experimentally induced tumours. Perantoni AO, et al. **IARC Sci Publ** 1999;(146):87–122 (204 ref.)
The myb gene family in cell growth, differentiation and apoptosis. Oh IH, et al. **Oncogene** 1999 May 13; 18(19):3017–33 (210 ref.)
Fusion genes in solid tumors. Aman P. **Semin Cancer Biol** 1999 Aug;9(4):303–18 (149 ref.)
Oncogene amplification in solid tumors. Schwab M. **Semin Cancer Biol** 1999 Aug;9(4):319–25 (46 ref.)

IMMUNOLOGY

LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Klein E, et al. **Immunol Lett** 1999 May 3;68(1):147–54 (33 ref.)

PHYSIOLOGY

Oncogenes, cancer and imaging. Urbain JL. **J Nucl Med** 1999 Mar;40(3):498–504 (51 ref.)
Reassessing the role of C-MYB in tumorigenesis. Weston K. **Oncogene** 1999 May 13;18(19):3034–8 (57 ref.)

ONCOGENIC VIRUSES

see related
TUMOR VIRUS INFECTIONS

GENETICS

Convicting a human tumor virus: guilt by association? Blaho JA, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7619–21 (31 ref.)

PATHOGENICITY

On the need to assess cancer risk in populations environmentally and occupationally exposed to virus and chemical agents in developing countries. Netto GF. **Cad Saude Publica** 1998;14 Suppl 3:87–98 (76 ref.)
Molecular piracy: the viral link to carcinogenesis. Flaitz CM, et al. **Oral Oncol** 1998 Nov;34(6):448–53 (22 ref.)

ONCOGENS see **CARCINOGENS**

ONCOLOGIC NURSING

Global perspectives on palliative care. Aranda S. **Cancer Nurs** 1999 Feb;22(1):33–9 (23 ref.)
Gemcitabine: a pharmacologic and clinical overview. Barton-Burke M. **Cancer Nurs** 1999 Apr;22(2):176–83 (46 ref.)
Complementary therapies: overview and state of the art. Cassileth BR. **Cancer Nurs** 1999 Feb;22(1):85–90 (5 ref.)
Breast self-examination training: a brief review. Clarke VA, et al. **Cancer Nurs** 1999 Aug;22(4):320–6 (57 ref.)
From the desert: transcultural aspects of cancer nursing care in Israel. Delbar V. **Cancer Nurs** 1999 Feb;22(1):45–51 (15 ref.)
Inherited predisposition to colon cancer. Glaser EM. **Cancer Nurs** 1998 Dec;21(6):377–83; quiz 383–4 (30 ref.)
The experience of having cancer in Latin America. Granda-Cameron C. **Cancer Nurs** 1999 Feb;22(1):51–7 (35 ref.)
A test of parenthood: dilemmas of parents of terminally ill adolescents. Hayout I, et al. **Cancer Nurs** 1999 Feb; 22(1):71–9 (26 ref.)
The family history component of cancer genetic risk counseling. Loescher LJ. **Cancer Nurs** 1999 Feb; 22(1):96–102 (30 ref.)
Menopause as an issue for women with breast cancer. McPhail G. **Cancer Nurs** 1999 Apr;22(2):164–71 (98 ref.)
Cultural views of cancer around the world. Navon L. **Cancer Nurs** 1999 Feb;22(1):39–45 (43 ref.)
Prevention: tobacco control and cancer nursing. Sarna L. **Cancer Nurs** 1999 Feb;22(1):21–8 (80 ref.)
New agents in gastrointestinal malignancies: Part 2: Gemcitabine in clinical practice. Stucky-Marshall L. **Cancer Nurs** 1999 Aug;22(4):290–6 (19 ref.)
New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice. Stucky-Marshall L. **Cancer Nurs** 1999 Jun;22(3):212–9 (22 ref.)
Family coping: issues and challenges for cancer nursing. Yates P. **Cancer Nurs** 1999 Feb;22(1):63–71 (35 ref.)
Nursing informatics as a support function for oncology nursing research. Ehrenberger H, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):21–6 (32 ref.)
Issues in the use of communications technologies in nursing research. Ehrenberger H, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):11–5 (26 ref.)
Multicultural considerations in the use of advance directives. Ersek M, et al. **Oncol Nurs Forum** 1998 Nov-Dec; 25(10):1683–90 (50 ref.)
The impact of the national information infrastructure on distance education and the changing role of the nurse. Gomez EG, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):16–20 (32 ref.)
Improving oncology nursing practice through understanding and exploring the Internet. Gomez EG, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):4–10 (13 ref.)
The cultural context of death rituals and mourning practices. Kagawa-Singer M. **Oncol Nurs Forum** 1998 Nov-Dec; 25(10):1752–6 (32 ref.)
Funeral rituals in Taiwan and Korea. Martinson IM. **Oncol Nurs Forum** 1998 Nov-Dec;25(10):1756–60 (8 ref.)
Past and present herbs used to treat cancer: medicine, magic, or poison? Montbriand MJ. **Oncol Nurs Forum** 1999 Jan-Feb;26(1):49–60; quiz 61–2 (53 ref.)
Grieving and death rituals of Latinos. Munet-Vilaró F. **Oncol Nurs Forum** 1998 Nov-Dec;25(10):1761–3 (16 ref.)
A closer look at psychosocial care. Powel LL. **Oncol Nurs Forum** 1998 Nov-Dec;25(10):1677 (9 ref.)
A global perspective on nurses' Internet access and information utilization. Uhlenhopp MB, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):27–32 (16 ref.)
Non-Hodgkin's lymphoma. Bilodeau BA, et al. **Semin Oncol Nurs** 1998 Nov;14(4):273–83 (59 ref.)
Lymphoma at the extremes of age. Boyle DA, et al. **Semin Oncol Nurs** 1998 Nov;14(4):302–11 (70 ref.)
Lymphomas: long-term sequelae and survivorship issues. Fernsler J, et al. **Semin Oncol Nurs** 1998 Nov;14(4):321–8 (82 ref.)
Cancer metastasis: an update. Haylock PJ. **Semin Oncol Nurs** 1998 Aug;14(3):172–7 (42 ref.)
Oncologic emergencies in the patient with lymphoma. Hogan DK, et al. **Semin Oncol Nurs** 1998 Nov;14(4):312–20 (38 ref.)
Metastases that interfere with circulation. Joyce M, et al. **Semin Oncol Nurs** 1998 Aug;14(3):230–9 (43 ref.)
Metastases involving the gastrointestinal system. Kelvin JF, et al. **Semin Oncol Nurs** 1998 Aug;14(3):187–98 (35 ref.)
Metastasis to skin. Manning MP. **Semin Oncol Nurs** 1998 Aug;14(3):240–3 (13 ref.)
Improving understanding of the informed consent process and document. Meade CD. **Semin Oncol Nurs** 1999 May; 15(2):124–37 (135 ref.)
National efforts to improve the informed consent process. Padberg RM, et al. **Semin Oncol Nurs** 1999 May; 15(2):138–44 (16 ref.)
The nurse's role in the informed consent process. Rosse PA, et al. **Semin Oncol Nurs** 1999 May;15(2):116–23 (28 ref.)
Central nervous system metastases. Sitton E. **Semin Oncol Nurs** 1998 Aug;14(3):210–9 (28 ref.)
Pulmonary metastasis. Smith EL. **Semin Oncol Nurs** 1998 Aug;14(3):178–86 (75 ref.)
Nursing management of the patient with bone metastases. Struthers C, et al. **Semin Oncol Nurs** 1998 Aug; 14(3):199–209 (62 ref.)
Paraneoplastic syndromes in metastatic disease. Zumsteg MM, et al. **Semin Oncol Nurs** 1998 Aug;14(3):220–9 (39 ref.)

METHODS

Facing the issue of dependence: some implications from the literature for the hospice and hospice nurses. Flanagan J, et al. **J Adv Nurs** 1999 Mar;29(3):592–9 (47 ref.)

TRENDS

New strategies in the management of cancer. Kearney N. **Cancer Nurs** 1999 Feb;22(1):28–33 (26 ref.)

ONCOLOGY, MEDICAL see **MEDICAL ONCOLOGY**

ONCOLOGY, RADIATION see **RADIATION ONCOLOGY**

ONCOLOGY SERVICE, HOSPITAL

GP versus hospital follow up for cancer patients. Is the choice based on evidence? Weller D, et al. **Aust Fam Physician** 1999 Apr;28(4):356–9 (11 ref.)

ONCOLYTIC VIRUSES see **VIRUSES**

ONCOPROTEINS see **ONCOGENE PROTEINS**

ONCORHYNCHUS GORBUSCHA see **SALMON**

ONCORHYNCHUS MYKISS

Whirling disease: re-emergence among wild trout. Hedrick RP, et al. **Immunol Rev** 1998 Dec;166:365–76 (54 ref.)

GENETICS

CK-1, a putative chemokine of rainbow trout (Oncorhynchus mykiss). Dixon B, et al. **Immunol Rev** 1998 Dec;166:341–8 (41 ref.)
Rainbow trout cytokine and cytokine receptor genes. Secombes C, et al. **Immunol Rev** 1998 Dec;166:333–40 (34 ref.)

METABOLISM

Rainbow trout cytochrome P450s: purification, molecular aspects, metabolic activity, induction and role in environmental monitoring. Buhler DR, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):107–37 (209 ref.)

PHYSIOLOGY

Identification of potential sites of cortisol actions on the reproductive axis in rainbow trout. Teitsma C, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):243–9 (33 ref.)

ONCORHYNCHUS NERKA see **SALMON**

ONCORHYNCHUS TSHAWYTSCHA see **SALMON**

ONCORNAVIRUSES see **RETROVIRIDAE**

ONCOVIRINAE see **RETROVIRIDAE**

ONCOVIRUSES see **RETROVIRIDAE**

ONCOVIRUSES, TYPE C see **RETROVIRIDAE**

ONCOVIRUSES, TYPE D see **RETROVIRUSES TYPE D**

ONDATRA see **MICROTINAE**

ONDINE'S CURSE see **SLEEP APNEA SYNDROMES**

ONLAYS see **INLAYS**

ONLINE SYSTEMS

On-line hemodiafiltration: technique and therapy. Ledebo I. **Adv Ren Replace Ther** 1999 Apr;6(2):195–208 (59 ref.)
SPEM: a parser for EMBL style flat file database entries. Pocock MR, et al. **Bioinformatics** 1998;14(9):823–4 (5 ref.)
Faculty experiences with providing online courses. Thorns among the roses. Cravener PA. **Comput Nurs** 1999 Jan-Feb; 17(1):42–7 (28 ref.)
"KARIBIN," an information resource for obtaining genomic information in a cytogenetic band. Zhang J, et al. **Genome Res** 1999 Jan;9(1):91–8 (17 ref.)
On-line haemodiafiltration: state of the art. Canaud B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:3–11 (55 ref.)
Clinical perspectives of on-line haemodiafiltration. Pizzarelli F, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:34–7 (46 ref.)

STANDARDS

Water quality for on-line haemodiafiltration. Cappelli G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:12–6 (34 ref.)

ONYCHOMYCOSIS

Onychomycosis: a compendium of facts and a clinical experience. Schlefman BS. **J Foot Ankle Surg** 1999 Jul-Aug;38(4):290–302 (48 ref.)
[Onychomycosis--more than a cosmetic problem] Pospíšilová A. **Cas Lek Cesk** 1999 Mar 15;138(6):166–9 (16 ref.) (Eng. Abstr.) **(Cze)**

CLASSIFICATION

A new classification of onychomycosis. Baran R, et al. **Br J Dermatol** 1998 Oct;139(4):567–71 (15 ref.)

DIAGNOSIS

Onychomycosis: recognition, diagnosis, and management. Jaffe R. **Arch Fam Med** 1998 Nov-Dec;7(6):587–92 (32 ref.)
Current topics in diagnosis and treatment of tinea unguium in Japan. Tanuma H. **J Dermatol** 1999 Feb;26(2):87–97 (79 ref.)
Onychomycosis: diagnosis and systemic treatment. Milles CL, et al. **Nurse Pract** 1998 Dec;23(12):40–2, 45–8, 51 (19 ref.)
[Diagnosis and therapy of onychomycoses] Pfister-Wartha A. **Fortschr Med** 1998 Oct 30;116(30):24–31 (20 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data [see comments] Epstein E. **Arch Dermatol** 1998 Dec; 134(12):1551–4 (28 ref.) Comment in: Arch Dermatol 1999 Jul;135(7):852–3.
Factors that may affect the response of onychomycosis to oral antifungal therapy. Gupta AK, et al. **Australas J Dermatol** 1998 Nov;39(4):222–4 (18 ref.)
Fluconazole for the treatment of onychomycosis: an update. Gupta AK, et al. **Int J Dermatol** 1998 Nov;37(11):815–20 (38 ref.)
Onychomycosis: therapeutic update. Scher RK. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 2):S21–6 (20 ref.)
Onychomycosis in children: prevalence and management. Gupta AK, et al. **Pediatr Dermatol** 1998 Nov-Dec; 15(6):464–71 (59 ref.)

ONYCHOMYCOSIS

Onychomycosis in diabetes. Management considerations. Albreski DA, et al. **Postgrad Med** 1999 Jul;Spec No:26–30 (26 ref.)
Itraconazole and terbinafine in perspective. From petri dish to patient. De Doncker P, et al. **Postgrad Med** 1999 Jul; Spec No:6–11 (19 ref.)
Oral itraconazole therapy for superficial, subcutaneous, and systemic infections. A panoramic view. De Rosso JQ, et al. **Postgrad Med** 1999 Jul;Spec No:46–52 (63 ref.)
Management of onychomycosis in children. Gupta AK, et al. **Postgrad Med** 1999 Jul;Spec No:31–7 (54 ref.)
[Therapy of nail mycoses] Büchner SA. **Ther Umsch** 1998 Aug;55(8):503–8 (6 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

A review of the epidemiology of tinea unguium in the community. Gill D, et al. **Australas J Dermatol** 1999 Feb; 40(1):6–13 (64 ref.)

MICROBIOLOGY

Onychomycosis caused by infection with Paecilomyces lilacinus [letter] Fletcher CL, et al. **Br J Dermatol** 1998 Dec;139(6):1133–5 (16 ref.)

PATHOLOGY

Proximal white subungual onychomycosis in the immunocompetent patient: report of two cases and review of the literature [letter] Weinberg JM, et al. **Acta Derm Venereol** 1999 Jan;79(1):81–2 (10 ref.)

THERAPY

Management of toenail onychomycosis. Tom CM, et al. **Am J Health Syst Pharm** 1999 May 1;56(9):865–71 (35 ref.)
Onychomycosis: recognition, diagnosis, and management. Jaffe R. **Arch Fam Med** 1998 Nov–Dec;7(6):587–92 (32 ref.)
Current topics in diagnosis and treatment of tinea unguium in Japan. Tanuma H. **J Dermatol** 1999 Feb;26(2):87–97 (79 ref.)
Onychomycosis: diagnosis and systemic treatment. Milles CL, et al. **Nurse Pract** 1998 Dec;23(12):40–2, 45–8, 51 (19 ref.)

ONYCHOPHAGIA see **NAIL BITING**

ONYGENALES

see related
CHRYSOSPORIUM

OOCYTE DONATION

Preparation of endometrium for egg donation. Devroey P, et al. **Hum Reprod Update** 1998 Nov–Dec;4(6):856–61 (44 ref.)
The impact of age on reproductive potential: lessons learned from oocyte donation. Sauer MV. **Maturitas** 1998 Oct 12; 30(2):221–5 (23 ref.)

OOCYTES

Screening oocytes and preimplantation embryos for aneuploidy. Handyside AH, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):301–5 (28 ref.)
Freezing of oocytes. Porcu E. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):297–300 (44 ref.)
Cryopreservation in human assisted reproduction is now routine for embryos but remains a research procedure for oocytes. Mandelbaum J, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:161–74;discussion175–7 (14 ref.)
Is the oocyte a non-professional phagocyte? Bronson R. **Hum Reprod Update** 1998 Nov–Dec;4(6):763–75 (111 ref.)

CHEMISTRY

Ras family proteins: new players involved in the diplotene arrest of Xenopus oocytes. Jessus C, et al. **Biol Cell** 1998 Nov;90(8):573–83 (78 ref.)
Endogenous ion channels in oocytes of xenopus laevis: recent developments. Weber WM. **J Membr Biol** 1999 Jul 1; 170(1):1–12 (153 ref.)

CYTOLOGY

Cytoplasmic factors that control nuclear behavior in mammalian oocytes: a re-evaluation of studies performed as a student of Yoshio Masui. Clarke HJ. **Biol Cell** 1998 Nov;90(8):549–55 (62 ref.)
Ras family proteins: new players involved in the diplotene arrest of Xenopus oocytes. Jessus C, et al. **Biol Cell** 1998 Nov;90(8):573–83 (78 ref.)
The legacy of lithium effects on development. Kao KR, et al. **Biol Cell** 1998 Nov;90(8):585–9 (74 ref.)
Nuclear responses to MPF activation and inactivation in Xenopus oocytes and early embryos. Lohka MJ. **Biol Cell** 1998 Nov;90(8):591–9 (98 ref.)
Oocyte growth in the chicken: receptors and more. Schneider WJ, et al. **Biol Chem** 1998 Aug–Sep;379(8–9):965–71 (32 ref.)
Gonadotropin-induced resumption of oocyte meiosis and meiosis-activating sterols. Andersen CY, et al. **Curr Top Dev Biol** 1999;41:163–85 (120 ref.)
Oocyte apoptosis: like sand through an hourglass. Morita Y, et al. **Dev Biol** 1999 Sep 1;213(1):1–17 (157 ref.)
Oocyte maturation. Trounson A, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:52–62; discussion 71–5 (13 ref.)
Meiotic maturation in mollusc oocytes [see comments] Colas P, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):539–48 (90 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Cell cycle arrest and release in starfish oocytes and eggs [see comments] Kishimoto T. **Semin Cell Dev Biol** 1998 Oct; 9(5):549–57 (50 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Ins and outs of meiosis in ascidians [see comments] Russo GL, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):559–67 (82 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–72.
Molecular mechanisms of meiotic maturation and arrest in fish and amphibian oocytes [see comments] Yamashita M. **Semin Cell Dev Biol** 1998 Oct;9(5):569–79 (84 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Progesterone induces meiotic division in the amphibian oocyte by releasing lipid second messengers from the plasma membrane. Morrill GA, et al. **Steroids** 1999 Jan–Feb;64(1–2):157–67 (45 ref.)

DRUG EFFECTS

The legacy of lithium effects on development. Kao KR, et al. **Biol Cell** 1998 Nov;90(8):585–9 (74 ref.)
Molecular and genetic basis of normal and toxicant-induced apoptosis in female germ cells. Tilly JL. **Toxicol Lett** 1998 Dec 28;102–103:497–501 (22 ref.)

ENZYMOLOGY

Nature and role of proteasomes in maturation of fish oocytes. Tokumoto T. **Int Rev Cytol** 1999;186:261–94 (111 ref.)

GROWTH & DEVELOPMENT

Twin peaks: Spitz and Argos star in patterning of the Drosophila egg [comment] Stevens L. **Cell** 1998 Oct 30; 95(3):291–4 (16 ref.) Comment on: Cell 1998 Oct 30;95(3):355–64.
Oocyte maturation and embryonic failure. Moor RM, et al. **Hum Reprod Update** 1998 May–Jun;4(3):223–36 (67 ref.)
Dynamics of human follicular growth and in-vitro oocyte maturation. Salha O, et al. **Hum Reprod Update** 1998 Nov–Dec;4(6):816–32 (179 ref.)
Nature and role of proteasomes in maturation of fish oocytes. Tokumoto T. **Int Rev Cytol** 1999;186:261–94 (111 ref.)
Control of oocyte growth and maturation by follicular cells and molecules present in follicular fluid. A review. Driancourt MA, et al. **Reprod Nutr Dev** 1998 Jul–Aug; 38(4):345–62 (120 ref.)
[Oocyte of domestic mammals: a model for the study of in vitro maturation] Mermillod P, et al. **Contracept Fertil Sex** 1999 Jun;27(6):440–8 (49 ref.) (Eng. Abstr.) **(Fre)**
[In vitro maturation of human oocytes] Plachot M. **Contracept Fertil Sex** 1999 Jun;27(6):434–9 (17 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Nuclear responses to MPF activation and inactivation in Xenopus oocytes and early embryos. Lohka MJ. **Biol Cell** 1998 Nov;90(8):591–9 (98 ref.)
RNA sorting in Drosophila oocytes and embryos [see comments] Lasko P. **FASEB J** 1999 Mar;13(3):421–33 (110 ref.) Comment in: FASEB J 1999 Mar;13(3):419–20.
RNA sorting in Xenopus oocytes and embryos [see comments] Mowry KL, et al. **FASEB J** 1999 Mar; 13(3):435–45 (98 ref.) Comment in: FASEB J 1999 Mar;13(3):419–20.
Analysis of translational activity of extracts derived from oocytes and eggs of Xenopus laevis. Pain VM, et al. **Methods Mol Biol** 1998;77:195–209 (20 ref.)
Role of cyclic nucleotide phosphodiesterases in resumption of meiosis. Conti M, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):9–14 (36 ref.)

PHYSIOLOGY

Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. Duesbery NS, et al. **Biol Cell** 1998 Oct;90(6–7):461–6 (72 ref.)
Recurring themes in oocyte maturation. Maller JL. **Biol Cell** 1998 Oct;90(6–7):453–60 (99 ref.)
Oocyte loss and the perimenopause. Bopp BL, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):898–911 (81 ref.)
Immature oocyte retrieval with in-vitro oocyte maturation. Russell JB. **Curr Opin Obstet Gynecol** 1999 Jun; 11(3):289–96 (26 ref.)
Comparative biology of calcium signaling during fertilization and egg activation in animals. Stricker SA. **Dev Biol** 1999 Jul 15;211(2):157–76 (306 ref.)
The role of luteinizing hormone in folliculogenesis and ovulation induction. Filicori M. **Fertil Steril** 1999 Mar; 71(3):405–14 (88 ref.)
Oocyte maturation. Trounson A, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:52–62; discussion 71–5 (13 ref.)
Genetic regulation of egg and embryo survival. Warner CM, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:178–90; discussion 191–6 (33 ref.)
The genetic origins of ovarian failure. Bondy CA, et al. **J Womens Health** 1998 Dec;7(10):1225–9 (23 ref.)
General ageing and ovarian ageing. Dorland M, et al. **Maturitas** 1998 Oct 12;30(2):113–8 (47 ref.)
Genetics of oocyte ageing. Eichenlaub-Ritter U. **Maturitas** 1998 Oct 12;30(2):143–69 (222 ref.)
Microtubule dynamics in Xenopus egg extracts. Shirasu M, et al. **Microsc Res Tech** 1999 Mar 15;44(6):435–45 (70 ref.)
The molecular basis of oocyte growth and development. Picton H, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):27–37 (79 ref.)
Sperm-induced calcium oscillations. Soluble factor, factors or receptors? Dale B, et al. **Mol Hum Reprod** 1999 Jan; 5(1):1–4 (65 ref.)
The molecular mechanisms of oocyte maturation and early embryonic development are unveiling new insights into reproductive medicine. Heikinheimo O, et al. **Mol Hum Reprod** 1998 Aug;4(8):745–56 (137 ref.)
[Molecular mechanisms of fertilization: the re-opening of the search for oscillin] Tesarik J. **Contracept Fertil Sex** 1998 Oct;26(10):693–5 (30 ref.) **(Fre)**

ULTRASTRUCTURE

Nuclear transfer in the rhesus monkey: practical and basic implications. Wolf DP, et al. **Biol Reprod** 1999 Feb; 60(2):199–204 (29 ref.)
Micro- and macro-consequences of ooplasmic injections of early haploid male gametes. Sofikitis N, et al. **Hum Reprod Update** 1998 May–Jun;4(3):197–212 (87 ref.)
Organisation of Xenopus oocyte and egg cortices. Chang P, et al. **Microsc Res Tech** 1999 Mar 15;44(6):415–29 (120 ref.)
Ultrastructural aspects of mammalian fertilization: new discoveries and inspirations from the work of Daniel Szöllösi. Sutovsky P, et al. **Reprod Nutr Dev** 1998 Nov–Dec;38(6):629–41 (105 ref.)

OOGENESIS

Recurring themes in oocyte maturation. Maller JL. **Biol Cell** 1998 Oct;90(6–7):453–60 (99 ref.)
Drosophila oogenesis: versatile spn doctors. Morris J, et al. **Curr Biol** 1999 Jan 28;9(2):R55–8 (20 ref.)
The polarisation of the anterior–posterior and dorsal–ventral axes during Drosophila oogenesis. van Eeden F, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):396–404 (63 ref.)
Role of cyclic nucleotide phosphodiesterases in resumption of meiosis. Conti M, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):9–14 (36 ref.)
The bottleneck: mitochondrial imperatives in oogenesis and ovarian follicular fate. Jansen RP, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):81–8 (52 ref.)
The molecular basis of oocyte growth and development. Picton H, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):27–37 (79 ref.)

GENETICS

Knockout mouse model and gametogenic failure. Grootegoed JA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):161–6 (45 ref.)

PHYSIOLOGY

Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. Duesbery NS, et al. **Biol Cell** 1998 Oct;90(6–7):461–6 (72 ref.)
EGF receptor signaling in Drosophila oogenesis. Nilson LA, et al. **Curr Top Dev Biol** 1999;44:203–43 (143 ref.)
Ovaries, oogenesis and insect phylogeny. Introductory remarks. Biliński SM. **Folia Histochem Cytobiol** 1998; 36(4):143–5 (27 ref.)
Diptera—ovary structure and oogenesis in midges and flies. Kubrakiewicz J, et al. **Folia Histochem Cytobiol** 1998; 36(4):197–203 (43 ref.)
S phase and differential DNA replication during Drosophila oogenesis. Royzman I, et al. **Genes Cells** 1998 Dec; 3(12):767–76 (30 ref.)
Organisation of Xenopus oocyte and egg cortices. Chang P, et al. **Microsc Res Tech** 1999 Mar 15;44(6):415–29 (120 ref.)
Interactions of mating, egg production and death rates in females of the Mediterranean fruit fly, Ceratitis capitata. Chapman T, et al. **Proc R Soc Lond B Biol Sci** 1998 Oct 7;265(1408):1879–94 (145 ref.)
Meiotic maturation in mollusc oocytes [see comments] Colas P, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):539–48 (90 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Cell cycle arrest and release in starfish oocytes and eggs [see comments] Kishimoto T. **Semin Cell Dev Biol** 1998 Oct; 9(5):549–57 (50 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Ins and outs of meiosis in ascidians [see comments] Russo GL, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):559–67 (82 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–72.
Molecular mechanisms of meiotic maturation and arrest in fish and amphibian oocytes [see comments] Yamashita M. **Semin Cell Dev Biol** 1998 Oct;9(5):569–79 (84 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.
Versatility in signalling: multiple responses to EGF receptor activation during Drosophila oogenesis. Van Buskirk C, et al. **Trends Cell Biol** 1999 Jan;9(1):1–4 (31 ref.)

OOPHORECTOMY see **OVARIECTOMY**

OOPHORITIS

[Adnexitis (salpingitis, oophoritis)] Matsuoka R, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):215–7 (2 ref.) **(Jpn)**

OPEN-ANGLE GLAUCOMA see **GLAUCOMA, OPEN-ANGLE**

OPEN BITE see **MALOCCLUSION**

OPEN READING FRAMES

GENETICS

The serine, threonine, and/or tyrosine-specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait. Shi L, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):229–53 (98 ref.)

OPERATING ROOM NURSING

Electrosurgical safety. Hutchisson B, et al. **AORN J** 1998 Nov;68(5):830–7; quiz 838–40, 843–4 (4 ref.)

Basic electrocardiogram interpretation for the OR nurse. Hutchisson B, et al. **AORN J** 1999 Jan;69(1):222–7, 229–39; quiz 240–2, 245–6 (2 ref.)

EDUCATION

Staff education and training for ultrasound-assisted lipoplasty. Mustoe TA. **Clin Plast Surg** 1999 Apr; 26(2):295–8; ix (3 ref.)

STANDARDS

Prion diseases—an evidence-based protocol for infection control. Steelman VM. **AORN J** 1999 May;69(5):946–54, 956–67 passim; quiz 968–76 (94 ref.)

OPERATING ROOMS

DNR in the OR: a goal-directed approach [see comments] Truog RD, et al. **Anesthesiology** 1999 Jan;90(1):289–95 (20 ref.) Comment in: Anesthesiology 1999 Jan;90(1):3–6.

Laminar airflow systems [letter; comment] Turpin IM. **AORN J** 1998 Sep;68(3):366–8 (9 ref.) Comment on: AORN J 1998 Apr;67(4):841–2, 845–51.

[Prevention of nosocomial infections in the intensive care unit and the operating room] Gastmeier P, et al. **Anaesthesist** 1999 Aug;48(8):575–90 (30 ref.) **(Ger)**

[Use of short wave ultraviolet radiation for disinfection in operating rooms] Bånrud H, et al. **Tidsskr Nor Laegeforen** 1999 Aug 10;119(18):2670–3 (45 ref.) (Eng. Abstr.) **(Nor)**

ORGANIZATION & ADMINISTRATION

Plea for a "surgical conscience" in the interventional radiology suite. Joffre F, et al. **Cardiovasc Intervent Radiol** 1998 Nov–Dec;21(6):445–7 (15 ref.)

OPERATIONS RESEARCH

see related
GAME THEORY

OPERATOR (GENETICS) see **OPERATOR REGIONS (GENETICS)**

OPERATOR REGIONS (GENETICS)

Visualization of large-scale chromatin structure and dynamics using the lac operator/lac repressor reporter system. Belmont AS, et al. **Methods Cell Biol** 1999; 58:203–22 (29 ref.)

The function of auxiliary operators. Müller-Hill B. **Mol Microbiol** 1998 Jul;29(1):13–8 (39 ref.)

OPERON

Experimental evolution of Ebg enzyme provides clues about the evolution of catalysis and to evolutionary potential. Hall BG. **FEMS Microbiol Lett** 1999 May 1;174(1):1–8 (27 ref.)

Transcriptional activation of the catechol and chlorocatechol operons: variations on a theme. McFall SM, et al. **Gene** 1998 Nov 26;223(1–2):257–67 (41 ref.)

Engineering of bacterial ribosomes: replacement of all seven Escherichia coli rRNA operons by a single plasmid-encoded operon [see comments] Nomura M. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1820–2 (25 ref.) Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1971–6.

Regulation of the Bacillus subtilis pyrimidine biosynthetic operon by transcriptional attenuation: control of gene expression by an mRNA-binding protein. Switzer RL, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:329–67 (82 ref.)

OPHTHALMIA see **ENDOPHTHALMITIS**

OPHTHALMIA NEONATORUM

Ophthalmia neonatorum revisited. van Bogaert LJ. **Afr J Reprod Health** 1998 Apr;2(1):81–6 (33 ref.)

[Ophthalmia neonatorum (neonatal conjunctivitis)] Iwata S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):181–2 (2 ref.) **(Jpn)**

DRUG THERAPY

Ocular medications in children. Wallace DK, et al. **Clin Pediatr (Phila)** 1998 Nov;37(11):645–52 (46 ref.)

OPHTHALMIA, SYMPATHETIC

Sympathetic ophthalmia: an autoimmune ocular inflammatory disease. Chan CC, et al. **Springer Semin Immunopathol** 1999;21(2):125–34 (91 ref.)

OPHTHALMIC ARTERY

SURGERY

A combined transorbital-transclinoid and transsylvian approach to carotid-ophthalmic aneurysms without retraction of the brain. Dolenc VV. **Acta Neurochir Suppl (Wien)** 1999;72:89–97 (97 ref.)

Surgical treatment of paraclinoid and ophthalmic aneurysms. Cawley CM, et al. **Neurosurg Clin N Am** 1998 Oct; 9(4):765–83 (31 ref.)

OPHTHALMIC NERVE

PHYSIOLOGY

Corneal sensation after cataract and refractive surgery. Kohlhaas M. **J Cataract Refract Surg** 1998 Oct; 24(10):1399–409 (48 ref.)

[Regularities of corneal tissue correlation and their biological significance for regeneration and pre-tumor growth] Beliaev VS. **Vestn Oftalmol** 1999 Mar–Apr;115(2):15–21 (28 ref.) (Eng. Abstr.) **(Rus)**

OPHTHALMIC SOLUTIONS

ADVERSE EFFECTS

Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Rait JL. **Aust N Z J Ophthalmol** 1999 Feb; 27(1):57–64 (60 ref.)

Toxicity of ocular surgical solutions. Anderson NJ, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):91–106 (56 ref.)

Toxic keratopathy. DeRosa AJ. **Int Ophthalmol Clin** 1998 Fall;38(4):15–22 (57 ref.)

PHARMACOKINETICS

Enhancement of ocular drug penetration. Sasaki H, et al. **Crit Rev Ther Drug Carrier Syst** 1999;16(1):85–146 (198 ref.)

THERAPEUTIC USE

Sore eyes and travelers. Leggat PA, et al. **J Travel Med** 1999 Mar;6(1):45–7 (6 ref.)

OPHTHALMOLOGIC SURGICAL PROCEDURES

see related
OPHTHALMOLOGY

A cautionary tale of innovation in refractive surgery. Waring GO 3rd. **Arch Ophthalmol** 1999 Aug;117(8):1069–73 (57 ref.)

Management of open globe injuries. Colby K. **Int Ophthalmol Clin** 1999 Winter;39(1):59–69 (15 ref.)

Surgical management of subretinal hemorrhage. Hochman MA, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):291–301 (45 ref.)

Surgical management of choroidal neovascular membranes. Hochman MA, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):303–15 (44 ref.)

Frozen-section diagnosis in ophthalmic surgery. Polcharoen W, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):195–211 (50 ref.)

The timing of surgical alignment for congenital (infantile) esotropia. Ing MR. **J Pediatr Ophthalmol Strabismus** 1999 Mar–Apr;36(2):61–8; quiz 85–6 (50 ref.)

Management of cytomegalovirus-related rhegmatogenous retinal detachments. Baumal CR, et al. **Ophthalmic Surg Lasers** 1998 Nov;29(11):916–25 (60 ref.)

Advances in refractive surgery. New options expand the scope of corrective procedures. Chaudhry IM, et al. **Postgrad Med** 1999 Sep;106(3):129–31, 135–7 (10 ref.)

Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Opremcak EM, et al. **Retina** 1999;19(1):1–5 (11 ref.)

[Videokeratoscopy] Assouline M, et al. **J Fr Ophtalmol** 1999 Mar;22(2):241–54 (47 ref.) **(Fre)**

[Anesthesia in dental, oral, jaw, facial, and ophthalmic surgery; therapeutics of the neck, nose, and eye . 1. General and specific aspects in dental, oral, jaw and facial surgery (published erratum appears in Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Mar;34(3):170)] Georgi R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan;34(1):45–65 (0 ref.) **(Ger)**

[Anesthesia for maxillofacial, ear, nose and throat surgery, otorhinolaryngology in ophthalmic procedures. 2. Specific aspects of otorhinolaryngology in ophthalmic procedures] Henn-Beilharz A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Mar; 34(3):147–70 (42 ref.) **(Ger)**

ADVERSE EFFECTS

LASIK: management of common complications. Laser in situ keratomileusis. Wilson SE. **Cornea** 1998 Sep;17(5):459–67 (14 ref.)

INSTRUMENTATION

Innovations in keratoprosthesis: proved and unproved. Yaghouti F, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):27–36 (40 ref.)

METHODS

Treatment of traumatic optic neuropathy. Pomeranz HD, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):185–94 (49 ref.)

Ophthalmic endoscopy: applications in intraocular surgery. Sheindlin JA, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):237–47 (20 ref.)

Head positioning compliance with spectacles after gas retinopexy. Boucher MC, et al. **Retina** 1999;19(2):177–8 (0 ref.)

Surgical correction of moderate myopia: which method should you choose? III. Editorial. Dutton JJ. **Surv Ophthalmol** 1998 Sep–Oct;43(2):179–81 (9 ref.)

Surgical correction of moderate myopia: which method should you choose? II. PRK and LASIK are the treatments of choice. Steinert RF, et al. **Surv Ophthalmol** 1998 Sep–Oct;43(2):157–79 (248 ref.)

[Retinal detachments and retinal surgery (published erratum appears in Ned Tijdschr Geneeskd 1999 May 8;143(19):1016)] La Heij EC, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):781–5 (16 ref.) (Eng. Abstr.) **(Dut)**

[Laser CO2 and ocular plastic surgery] Ameline-Audelan V, et al. **J Fr Ophtalmol** 1998 Mar;21(3):234–40 (42 ref.) **(Fre)**

[Expanders in plastic ophthalmologic surgery] Fadeeva EA, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):47–9 (26 ref.) **(Rus)**

STANDARDS

Keratolimbal allograft: recommendations for tissue procurement and preparation by eye banks, and standard surgical technique. Croasdale CR, et al. **Cornea** 1999 Jan; 18(1):52–8 (9 ref.)

TRENDS

Ophthalmology. Eifrig DE. **J Am Coll Surg** 1999 Feb; 188(2):140–2 (15 ref.)

Refractive surgery—then and now. Wee TL. **Singapore Med J** 1998 Jul;39(7):335–6 (6 ref.)

OPHTHALMOLOGY

see related
EYE DISEASES
OPHTHALMOLOGIC SURGICAL PROCEDURES
VISION

Sildenafil (Viagra) and ophthalmology [editorial] Marmor MF. **Arch Ophthalmol** 1999 Apr;117(4):518–9 (9 ref.)

Update in genetics: genetic eye diseases and the ophthalmologist. MacDonald IM. **Can J Ophthalmol** 1999 Apr;34(2):69–73 (10 ref.)

Scientific thinking in ophthalmology. Abraham C. **Indian J Ophthalmol** 1998 Jun;46(2):105–8 (47 ref.)

Photoreceptor membrane proteins, phototransduction, and retinal degenerative diseases. The Friedenwald Lecture. Molday RS. **Invest Ophthalmol Vis Sci** 1998 Dec; 39(13):2491–513 (183 ref.)

The National Eye Institute outlines eye research goals. **J Am Optom Assoc** 1999 May;70(5):317–36 (0 ref.)

Optometry and ophthalmology relations in managed care. Hettler DL. **J Am Optom Assoc** 1999 Feb;70(2):99–102 (28 ref.)

Telemedicine and ophthalmology. Li HK. **Surv Ophthalmol** 1999 Jul–Aug;44(1):61–72 (76 ref.)

The placebo effect. Margo CE. **Surv Ophthalmol** 1999 Jul–Aug;44(1):31–44 (180 ref.)

[Diabetic retinopathy. When should patients be referred to ophthalmologists for evaluation?] Ducrey N. **Rev Med Suisse Romande** 1998 Nov;118(11):933–5 (7 ref.) **(Fre)**

ECONOMICS

Introduction to capitation. Loewenstein JI. **Int Ophthalmol Clin** 1998 Summer;38(3):101–6 (12 ref.)

Developing capitation rates. Mildworm LL. **Int Ophthalmol Clin** 1998 Summer;38(3):107–25 (7 ref.)

EDUCATION

Studies of prevalence of blindness in the Asia-Pacific region and the worldwide initiative in ophthalmic education [editorial; comment] [published erratum appears in Am J Ophthalmol 1999 Mar;127(3):369] Tso MO, et al.

OPHTHALMOLOGY

Am J Ophthalmol 1998 Oct;126(4):582–5 (18 ref.) Comment on: Am J Ophthalmol 1998 Oct;126(4):506–14. Comment on: Am J Ophthalmol 1998 Oct;126(4):515–23.

METHODS

People and eyes: statistical approaches in ophthalmology. Murdoch IE, et al. **Br J Ophthalmol** 1998 Aug;82(8):971–3 (17 ref.)

Analgesics in ophthalmic practice: a review of the oral non-narcotic agent tramadol. Gaynes BI, et al. **Optom Vis Sci** 1999 Jul;76(7):455–61 (36 ref.)

[Ozone therapy in ophthalmology] Lapina IM, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):51–4 (48 ref.) **(Rus)**

[Lymphological methods of treatment in ophthalmology] Subbotina IN. **Vestn Oftalmol** 1999 Jan–Feb;115(1):36–7 (29 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Changing policies in the Veterans Health Administration. Will they make a difference? [editorial] Jones DB. **Arch Ophthalmol** 1999 Jan;117(1):106–7 (3 ref.)

STANDARDS

The CONSORT statement: will it lead to improved reporting of clinical trials in ophthalmology? Consolidated Standards of Reporting Trials. Hawkins BS. **Arch Ophthalmol** 1999 May;117(5):677–80 (45 ref.)

Overview of quality measurement and improvement. Loewenstein JI. **Int Ophthalmol Clin** 1998 Summer; 38(3):59–68 (33 ref.)

TRENDS

The role of departments of ophthalmology in the changing health care environment: resist or lead the change? [editorial] Clarkson JG. **Am J Ophthalmol** 1998 Nov; 126(5):713–6 (2 ref.)

Recent advances: ophthalmology. Fielder AR, et al. **BMJ** 1999 Mar 13;318(7185):717–20 (37 ref.)

Computers in ophthalmology practice. Rajeev B. **Indian J Ophthalmol** 1998 Sep;46(3):163–8 (2 ref.)

Key developments in ophthalmology. Salmon J, et al. **Practitioner** 1998 Dec;242(1593):831–5 (9 ref.)

[New priority trends in ocular traumatism] Gundorova RA, et al. **Vestn Oftalmol** 1999 Mar–Apr;115(2):3–5 (7 ref.) (Eng. Abstr.) **(Rus)**

OPHTHALMOPATHY, INFILTRATIVE see **GRAVES' DISEASE**

OPHTHALMOPATHY, THYROID-ASSOCIATED see **GRAVES' DISEASE**

OPHTHALMOPLEGIA

DIAGNOSIS

Bilateral internuclear ophthalmoplegia: an initial presenting sign of giant cell arteritis. Ahmad I, et al. **J Am Geriatr Soc** 1999 Jun;47(6):734–6 (30 ref.)

ETIOLOGY

Internuclear ophthalmoplegia following minor head injury: a case report. Constantoyannis C, et al. **Br J Neurosurg** 1998 Aug;12(4):377–9 (14 ref.)

Internuclear ophthalmoplegia in systemic lupus erythematosus. Galindo M, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):179–86 (52 ref.)

OPHTHALMOPLEGIA, CHRONIC PROGRESSIVE EXTERNAL

ETIOLOGY

[A case of Ramsay Hunt syndrome associated with local meningitis, multiple cranial neuropathy, and the second cervical nerve involvement] Nagano K, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):475–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

OPHTHALMOSCOPY

Ophthalmoscopic evaluation of the optic nerve head. Jonas JB, et al. **Surv Ophthalmol** 1999 Jan–Feb;43(4):293–320 (286 ref.)

[Ophthalmologic examination of the infant] Klaeger-Manzanell C. **Klin Monatsbl Augenheilkd** 1999 May;214(5):336–9 (13 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Optic nerve assessment: a clinical endpoint of optic neuropathy. Antón López A. **Eur J Ophthalmol** 1999 Jan–Mar;9 Suppl 1:S37–9 (11 ref.)

OPIATE ADDICTION see **OPIOID-RELATED DISORDERS**

OPIATE DEPENDENCE see **OPIOID-RELATED DISORDERS**

OPIATES see **NARCOTICS**

OPIATES, ENDOGENOUS see **OPIOID PEPTIDES**

OPIOID ANALGESICS see **ANALGESICS, OPIOID**

OPIOID ANTAGONISTS see **NARCOTIC ANTAGONISTS**

OPIOID PEPTIDES

see related
RECEPTORS, OPIOID

[Nociceptin and nociceptin receptor] Nishi M, et al. **Seikagaku** 1998 Jul;70(7):548–53 (13 ref.) **(Jpn)**

[Structure-activity studies on nociceptive peptides] Okada K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jul; 44(9):1369–77 (38 ref.) **(Jpn)**

CHEMISTRY

Subtleties of structure–agonist versus antagonist relationships of opioid peptides and peptidomimetics. Schiller PW, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):573–88 (33 ref.)

GENETICS

Molecular evolution of the opioid/orphanin gene family. Danielson PB, et al. **Gen Comp Endocrinol** 1999 Feb; 113(2):169–86 (150 ref.)

Targeted mutagenesis of the murine opioid system. Hayward MD, et al. **Results Probl Cell Differ** 1999;26:169–91 (100 ref.)

[The discovery of a novel opioid-receptor-like receptor and its endogenous ligand] Fang Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):210–4 (12 ref.) (Eng. Abstr.) **(Chi)**

[Cloning of prepronociceptin has led to the discovery of other biologically active peptides] Costentin J, et al. **C R Seances Soc Biol Fil** 1998;192(6):1099–109 (60 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Pain: nocistatin spells relief. Martin WJ, et al. **Curr Biol** 1998 Jul 16;8(15):R525–7 (12 ref.)

Subtleties of structure–agonist versus antagonist relationships of opioid peptides and peptidomimetics. Schiller PW, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):573–88 (33 ref.)

The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems. Ambrosio E, et al. **Life Sci** 1999;65(6–7):687–94 (52 ref.)

Nociceptin/orphanin FQ. A new opioid, a new analgesic? Taylor F, et al. **Neuroreport** 1998 Aug 24;9(12):R65–70 (43 ref.)

[Cloning of prepronociceptin has led to the discovery of other biologically active peptides] Costentin J, et al. **C R Seances Soc Biol Fil** 1998;192(6):1099–109 (60 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Role of opioid ligands in the irritable bowel syndrome. Corazziari E. **Can J Gastroenterol** 1999 Mar;13 Suppl A:71A–75A (42 ref.)

Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. Civelli O, et al. **Crit Rev Neurobiol** 1998;12(3):163–76 (104 ref.)

Memory mechanisms: the nociceptin connection. Goda Y, et al. **Curr Biol** 1998 Dec 3;8(24):R889–91 (15 ref.)

Endogenous opioids: overview and current issues. Akil H, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):127–40 (150 ref.)

Endogenous opiates: 1997. Olson GA, et al. **Peptides** 1998; 19(10):1791–843 (571 ref.)

Endogenous drug-like factors. Mrozikiewicz A. **Pol J Pharmacol** 1998 Nov–Dec;50(6):393–7 (26 ref.)

Nociceptin/orphanin FQ: role in nociceptive information processing. Yamamoto T, et al. **Prog Neurobiol** 1999 Apr; 57(5):527–35 (89 ref.)

Paracrinology of endometrial neuropeptides: corticotropin-releasing hormone and opioids. Gravanis A, et al. **Semin Reprod Endocrinol** 1999;17(1):29–38 (87 ref.)

[Effects of newly isolated opioid peptides on G-protein activation: usefulness of [35S] GTP gamma S binding study and its practical application] Narita M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):107–16 (58 ref.) (Eng. Abstr.) **(Jpn)**

[Neuropeptides, endogenous opioid peptides and cell proliferation] Stanović S, et al. **Lijec Vjesn** 1999 Mar; 121(3):82–7 (66 ref.) (Eng. Abstr.) **(Ser)**

OPIOID RECEPTORS see **RECEPTORS, OPIOID**

OPIOID RECEPTORS, DELTA see **RECEPTORS, OPIOID, DELTA**

OPIOID RECEPTORS, KAPPA see **RECEPTORS, OPIOID, KAPPA**

OPIOID RECEPTORS, MU see **RECEPTORS, OPIOID, MU**

OPIOID RECEPTORS, SIGMA see **RECEPTORS, SIGMA**

OPIOID-RELATED DISORDERS

The management of opiate addicts in police custody. Davison SE, et al. **Med Sci Law** 1999 Apr;39(2):153–60 (31 ref.)

COMPLICATIONS

[Drug-related emergencies with opiates] Pfab R, et al. **Internist (Berl)** 1999 Jun;40(6):611–6 (52 ref.) **(Ger)**

DRUG THERAPY

Controlled clinical evaluation of diacetyl morphine for treatment of intractable opiate dependence. Drucker E, et al. **Lancet** 1999 May 8;353(9164):1543–4 (1 ref.)

Treatment considerations in the opioid dependent patient. Wartenberg AA. **Med Health R I** 1999 Mar;82(3):91–4 (20 ref.)

[Progress in the researches on the treatment of opiumism] Liu GQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Dec; 16(12):754–6 (24 ref.) **(Chi)**

[Forced opioid detoxification under general anesthesia--a new challenge for anesthetists and intensive care physicians] [see comments] Hensel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 May; 34(5):261–8 (52 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1999 May;34(5):259–60. **(Ger)**

EPIDEMIOLOGY

Methadone patients and alcohol abuse. Ottomanelli G. **J Subst Abuse Treat** 1999 Mar;16(2):113–21 (33 ref.)

ETIOLOGY

Opioid use in the management of chronic pain. Savage SR. **Med Clin North Am** 1999 May;83(3):761–86 (62 ref.)

METABOLISM

Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Harrison LM, et al. **Peptides** 1998;19(9):1603–30 (253 ref.)

PHYSIOPATHOLOGY

The neurobiology of opiate reinforcement. Shippenberg TS, et al. **Crit Rev Neurobiol** 1998;12(4):267–303 (240 ref.)

REHABILITATION

Methadone in the management of narcotic addiction in pregnancy [editorial] Archie C. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):435–40 (25 ref.)

Role of maintenance treatment in opioid dependence [see comments] Ward J, et al. **Lancet** 1999 Jan 16; 353(9148):221–6 (48 ref.) Comment in: Lancet 1999 Mar 27;353(9158):1101. Comment in: Lancet 1999 Apr 10;353(9160):1278.

[Weaning modalities for opiate-dependent drug abusers. Short text of a consensus conference (see comments)] **Presse Med** 1998 Oct 24;27(32):1628–33 (00 ref.) Comment in: Presse Med 1998 Oct 24;27(32):1633–4. **(Fre)**

[Heroin-assisted treatment of opiate dependent patients. Experiences from Swiss trials for medical prescription of narcotics (PROVE)] Steffen T, et al. **Internist (Berl)** 1999 Jun;40(6):651–6 (30 ref.) **(Ger)**

THERAPY

Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. **JAMA** 1998 Dec 9; 280(22):1936–43 (63 ref.)

OPIOIDS see **NARCOTICS**

OPIPRAMOL

PHARMACOLOGY

[Opipramol in comparison to other drugs--new pharmacologic data] Müller WE, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66 Suppl 1:S9–12 (7 ref.) **(Ger)**

OPIUM

ECONOMICS

Burma: the political economy of violence. Brown C. **Disasters** 1999 Sep;23(3):234–56 (55 ref.)

TOXICITY

Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors. Kobayashi H, et al. **J Toxicol Sci** 1999 Feb;24(1):1–16 (96 ref.)

OPOSSUMS

EMBRYOLOGY

A review of histogenesis/organogenesis in the developing North American opossum (Didelphis virginiana). Krause WJ. **Adv Anat Embryol Cell Biol** 1998;143(2):1–115 (286 ref.)
A review of histogenesis/organogenesis in the developing North American opossum (Didelphis virginiana). Krause WJ. **Adv Anat Embryol Cell Biol** 1998;143(1):1–139 (292 ref.)

OPPENHEIM–ZIEHEN DISEASE see **DYSTONIA MUSCULORUM DEFORMANS**

OPPENHEIM'S DISEASE see **NEUROMUSCULAR DISEASES**

OPPORTUNISTIC INFECTIONS

Aspergillus and other fungi. Robinson LA.
Chest Surg Clin N Am 1999 Feb;9(1):193–225, x (86 ref.)
Opportunistic thoracic infections. Bacteria, viruses, and protozoa. Talbot EA, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):167–92, ix–x (91 ref.)
Invasive aspergillosis in transplant recipients. Paterson DL, et al. **Medicine (Baltimore)** 1999 Mar;78(2):123–38 (270 ref.)
[Opportunistic infections and their management] Nasu M. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1904–9 (11 ref.) **(Jpn)**
[Opportunistic infection] Masaoka T.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):403–6 (6 ref.) **(Jpn)**
[Endogenous infection] Matsumoto T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):399–402 (8 ref.) **(Jpn)**

COMPLICATIONS

Infections associated with solid tumors. Sutton SH, et al. **Cancer Treat Res** 1998;96:105–41 (124 ref.)
Mortality associated with concurrent strongyloidosis and cytomegalovirus infection in a patient on steroid therapy. Wang BY, et al. **Mt Sinai J Med** 1999 Mar;66(2):128–32 (35 ref.)
Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature. Hansen KE, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):193–9 (22 ref.)
[Infection and sickle cell anemia] Bégué P.
Pathol Biol (Paris) 1999 Jan;47(1):19–25 (26 ref.) (Eng. Abstr.) **(Fre)**
[Prevention and treatment of infections in patients with neutropenia and fever: the role of Pseudomonas aeruginosa] Jiménez Martínez C, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:44–50 (32 ref.) **(Spa)**

DIAGNOSIS

Role of the clinical microbiology laboratory in the diagnosis of infections. Thomson RB Jr, et al. **Cancer Treat Res** 1998; 96:143–65 (29 ref.)
Diagnosis and treatment of cytomegalovirus infection. Hebart H, et al. **Curr Opin Hematol** 1998 Nov;5(6):483–7 (41 ref.)
Cutaneous Mycobacterium kansasii infection in a patient with systemic lupus erythematosus: case report and review. Czelusta A, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):359–63 (34 ref.)
Opportunistic fungal pneumonia. Connolly JE Jr, et al.
J Thorac Imaging 1999 Jan;14(1):51–62 (60 ref.)
Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen—Chaetomium atrobrunneum: case report [letter] Segal R, et al.
Neurosurgery 1999 Jul;45(1):200 (3 ref.)
Evaluation of new method for diagnosis of opportunistic fungal infection. Hashimoto A, et al.
Nippon Ishinkin Gakkai Zasshi 1998;39(4):187–92 (17 ref.)
[Geotrichum capitatum infection in a neutropenic patient. Apropos of a case and review of the literature] Fouassier M, et al. **Rev Med Interne** 1998 Jun;19(6):431–3 (13 ref.) (Eng. Abstr.) **(Fre)**
[Babesiosis—a dangerous infection for splenectomized children and adults] Hohenschild S. **Klin Padiatr** 1999 May–Jun;211(3):137–40 (39 ref.) (Eng. Abstr.) **(Ger)**
[Diagnostic imaging in hepatosplenic candidiasis] Müller D, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jun;170(6):587–90 (24 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis of infections with difficulty in isolation and identification of causative organisms. 4) Deep mycosis] Maezaki S, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2211–7 (5 ref.) **(Jpn)**
[Laboratory diagnosis of viral infections. 7. Opportunistic infection by herpesviruses (human cytomegalovirus, Epstein-Barr virus, and human herpesvirus 8)] Okuno T. **Rinsho Byori** 1998 Nov;Suppl 108:98–104 (5 ref.) **(Jpn)**
[Endocarditis due to an alga of the genus Prototheca sp. A saprophyte of water and of tree sap?] Buendía A, et al. **Arch Inst Cardiol Mex** 1998 Jul–Aug;68(4):333–6 (11 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Groll AH, et al. **Klin Padiatr** 1998 Jul–Aug; 210(4):264–73 (86 ref.)
New approaches to antifungal chemotherapy. Viviani MA, et al. **Med Mycol** 1998;36 Suppl 1:194–206 (176 ref.)
Management of intractable deep seated fungal infection. Niki Y. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):199–202 (14 ref.)
[Antibiotic therapy in leukopenia] Böhme A, et al.
Schweiz Rundsch Med Prax 1998 Sep 2;87(36):1120–5 (43 ref.) (Eng. Abstr.) **(Ger)**
[New aspects in treatment of systemic mycoses] Presterl E, et al. **Wien Klin Wochenschr** 1998 Nov 13;110(21):740–50 (106 ref.) (Eng. Abstr.) **(Ger)**
[Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia] Karthaus M, et al. **Wien Med Wochenschr** 1998;148(18):427–32 (39 ref.) (Eng. Abstr.) **(Ger)**
[Mycoses and their treatment in malignant hemopathies] Martino P, et al. **Recenti Prog Med** 1999 Mar;90(3):160–8 (59 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

Economic impact of infections in patients with cancer. Shulkin DJ, et al. **Cancer Treat Res** 1998;96:283–90 (30 ref.)
[Febrile neutropenia: practical aspects] Harten P, et al.
Med Klin 1998 Oct 15;93(10):598–611 (131 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of infectious complications in cancer patients. Zembower T. **Cancer Treat Res** 1998;96:33–75 (229 ref.)

ETIOLOGY

Infections in solid organ transplant recipients. Kibbler CC. **Curr Top Pathol** 1999;92:19–35 (83 ref.)
Severe mycosis-factors with fungus and host. Maesaki S, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):193–7 (11 ref.)
Deep-seated fungal infection in surgery. Tsunoda T, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):203–9 (31 ref.)

IMMUNOLOGY

Cellulitis due to Escherichia coli in three immunocompromised subjects. Yoon TY, et al.
Br J Dermatol 1998 Nov;139(5):885–8 (19 ref.)
The immunocompromised host and risk for cardiovascular infection. Schell HM. **J Cardiovasc Nurs** 1999 Jan; 13(2):31–48 (50 ref.)
[Toxoplasmosis and immunosuppression]
Djurković-Djaković O. **Srp Arh Celok Lek** 1998 May–Jun; 126(5–6):197–203 (48 ref.) (Eng. Abstr.) **(Sec)**

MICROBIOLOGY

Fusarium infections in patients with severe aplastic anemia: review and implications for management. Girmenia C, et al. **Haematologica** 1999 Feb;84(2):114–8 (17 ref.)
Identification of Mycobacterium shimoidei by molecular techniques: case report and summary of the literature. Mayall B, et al. **Int J Tuberc Lung Dis** 1999 Feb;3(2):169–73 (23 ref.)
Importance of Candida species other than Candida albicans as opportunistic pathogens. Coleman DC, et al.
Med Mycol 1998;36 Suppl 1:156–65 (102 ref.)
[Psoas abscess caused Actinomyces israelii (letter)] Pérez AF, et al. **Enferm Infecc Microbiol Clin** 1998 Jun–Jul; 16(6):289–90 (9 ref.) **(Spa)**

NURSING

The immunocompromised host and risk for cardiovascular infection. Schell HM. **J Cardiovasc Nurs** 1999 Jan; 13(2):31–48 (50 ref.)

PATHOLOGY

Rhinocerebral zygomycosis following bone marrow transplantation in chronic myelogenous leukaemia. Report of a case and review of the literature. Nenoff P, et al.
Mycoses 1998 Nov;41(9–10):365–72 (12 ref.)

PREVENTION & CONTROL

Prevention of infection in immunocompromised hosts. Noskin GA. **Cancer Treat Res** 1998;96:223–46 (92 ref.)
Pharmacologic considerations with antimicrobials used in oncology. Postelnick M, et al. **Cancer Treat Res** 1998; 96:247–82 (146 ref.)
Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? [editorial; comment] Ginès P, et al.
J Hepatol 1998 Sep;29(3):490–4 (40 ref.) Comment on: J Hepatol 1998 Sep;29(3):430–6. Comment on: J Hepatol 1998 Sep;29(3):437–42.
[Prevention and treatment of infections in patients with neutropenia and fever: the role of Pseudomonas aeruginosa] Jiménez Martínez C, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:44–50 (32 ref.) **(Spa)**

PSYCHOLOGY

Autism and Clostridium tetani. Bolte ER.
Med Hypotheses 1998 Aug;51(2):133–44 (117 ref.)

THERAPY

Cytokines and biological response modifiers in the treatment of infection. Mueller BU, et al. **Cancer Treat Res** 1998; 96:201–22 (151 ref.)
Recent advances in the management of fungal infections. Sanchez J, et al. **Cancer Treat Res** 1998;96:167–82 (79 ref.)
Approach to fever in the neutropenic host. Stoupis A, et al. **Cancer Treat Res** 1998;96:77–104 (114 ref.)
The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Roilides E, et al. **Med Mycol** 1998;36 Suppl 1:12–25 (191 ref.)
Cytokines as therapy for opportunistic fungal infections. Kullberg BJ, et al. **Res Immunol** 1998 May–Jun; 149(4–5):478–88; discussion 515 (150 ref.)

TRANSMISSION

Nosocomial transmission of opportunistic infections. Gerberding JL. **Infect Control Hosp Epidemiol** 1998 Aug; 19(8):574–7 (31 ref.)

OPPORTUNISTIC INFECTIONS, AIDS-RELATED see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

OPPORTUNISTIC INFECTIONS, HIV-RELATED see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

OPPOSITIONAL DEFIANT DISORDER see **ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS**

OPSOCLONUS see **OCULAR MOTILITY DISORDERS**

OPSONINS

see related
PHAGOCYTOSIS

METABOLISM

Opsonic and nonopsonic interactions of C3 with Streptococcus pneumoniae. Hostetter MK.
Microb Drug Resist 1999 Summer;5(2):85–9 (29 ref.)

OPTIC ATROPHY

CHEMICALLY INDUCED

[Motor neuropathy, putamen necrosis and optic nerve atrophy after acute methanol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1998 Dec;154(12):862–5 (12 ref.) (Eng. Abstr.) **(Fre)**
[Amiodarone-induced bilateral optic atrophy—a case report] Gobbelé R, et al. **Nervenarzt** 1999 Jun;70(6):560–5 (39 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

[A case of hereditary motor and sensory neuropathy with pyramidal tract sign, optic nerve atrophy and mental retardation] Adachi T, et al. **Rinsho Shinkeigaku** 1998 Dec; 38(12):1037–41 (15 ref.) (Eng. Abstr.) **(Jpn)**

OPTIC ATROPHY, HEREDITARY

GENETICS

Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. Chalmers RM, et al. **Biochim Biophys Acta** 1999 Feb 9;1410(2):147–58 (118 ref.)
Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. Votruba M, et al.
J Med Genet 1998 Oct;35(10):793–800 (96 ref.)
A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. Bhatti MT, et al.
J Neuroophthalmol 1999 Mar;19(1):28–33 (27 ref.)

PATHOLOGY

The enigmatic relationship between mitochondrial dysfunction and Leber's hereditary optic neuropathy [editorial; comment] Brown MD. **J Neurol Sci** 1999 May 1;165(1):1–5 (26 ref.) Comment on: J Neurol Sci 1999 May 1;165(1):10–7.

OPTIC DISK

Ophthalmoscopic evaluation of the optic nerve head. Jonas JB, et al. **Surv Ophthalmol** 1999 Jan–Feb;43(4):293–320 (286 ref.)
[Glial hamartoma of the papilla] Cernea P, et al.
Oftalmologia 1998;44(3):84–7 (11 ref.) (Eng. Abstr.) **(Rum)**

BLOOD SUPPLY

Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma. Anderson DR. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S5–9 (27 ref.)
Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Chung HS, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S43–50 (64 ref.)
Physiology of perfusion as it relates to the optic nerve head. Orgül S, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S17–26 (144 ref.)

OPTIC DISK

Laser Doppler flowmetry of the optic nerve head in glaucoma. Piltz-Seymour JR. **Surv Ophthalmol** 1999 Jun; 43 Suppl 1:S191-8 (56 ref.)

PATHOLOGY

Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Weinreb RN, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S40-3 (29 ref.)

Optic disk appearances in primary open-angle glaucoma. Broadway DC, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S223-43 (246 ref.)

OPTIC DISK DRUSEN

COMPLICATIONS

Central retinal artery occlusion and optic disc drusen [letter] Farah SG, et al. **Eye** 1998;12 (Pt 3a):480-2 (26 ref.)

OPTIC DISK EDEMA see **PAPILLEDEMA**

OPTIC LOBE

PHYSIOLOGY

Experience-dependent development of the adult optic lobe and central brain in Drosophila melanogaster. Barth M. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):184-94 (41 ref.)

OPTIC NERVE

[Unilateral visual field defect due to optic nerve compression by sclerotic internal carotid artery: a case report] Uchino M, et al. **No Shinkei Geka** 1999 Feb;27(2):189-94 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of Ramsay Hunt syndrome associated with local meningitis, multiple cranial neuropathy, and the second cervical nerve involvement] Nagano K, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):475-7 (10 ref.) (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

MR imaging anatomy of the optic pathways. Tamraz JC, et al. **Radiol Clin North Am** 1999 Jan;37(1):1-36, ix (65 ref.)

BLOOD SUPPLY

Regulation of retinal and optic nerve blood flow [see comments] Harris A, et al. **Arch Ophthalmol** 1998 Nov; 116(11):1491-5 (72 ref.) Comment in: Arch Ophthalmol 1999 Jul;116(11):1491-5.

DRUG EFFECTS

Mechanisms of neuroprotection and applications in ocular disease. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S52-81; quiz S82-4 (0 ref.)

Cimetidine-associated optic neuropathy. Sa'adah MA, et al. **Eur Neurol** 1999 Jul;42(1):23-6 (14 ref.)

INJURIES

Treatment of traumatic optic neuropathy. Pomeranz HD, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):185-94 (49 ref.)

Blindness after reduction of facial fractures. Girotto JA, et al. **Plast Reconstr Surg** 1998 Nov;102(6):1821-34 (70 ref.)

[Controversies and current status of therapy of optic nerve damage in craniofacial traumatology and surgery] Gellrich NC. **Mund Kiefer Gesichtschir** 1999 Jul;3(4):176-94 (208 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Optic nerve assessment: a clinical endpoint of optic neuropathy. Antón López A. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S37-9 (11 ref.)

Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. van Waesberghe JH, et al. **Neurology** 1999;53(5 Suppl 3):S46-8 (11 ref.)

PHYSIOLOGY

GABA as a developmental signal in the inner retina and optic nerve. Sandell JH. **Perspect Dev Neurobiol** 1998; 5(2-3):269-78 (137 ref.)

PHYSIOPATHOLOGY

Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma. Tatton WG. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S22-9 (52 ref.)

[The prognostic significance of the electrophysiological indices of the retina and optic nerve in patients with opacities of the optical media of the eye] Lariukhina GM, et al. **Vestn Oftalmol** 1998 Sep-Oct;114(5):45-8 (10 ref.) (Eng. Abstr.) **(Rus)**

OPTIC NERVE DISEASES

CHEMICALLY INDUCED

Cimetidine-associated optic neuropathy. Sa'adah MA, et al. **Eur Neurol** 1999 Jul;42(1):23-6 (14 ref.)

COMPLICATIONS

Gradual painless visual loss: chronic optic neuropathies. Benes SC, et al. **Clin Geriatr Med** 1999 Feb;15(1):47-85, vi (130 ref.)

CONGENITAL

Congenital intraorbital optic nerve cyst. Case report. Kim KM, et al. **J Neurosurg** 1999 Aug;91(2):325-7 (13 ref.)

DIAGNOSIS

Sudden painless visual loss: optic nerve and circulatory disturbances. Kosmorsky GS. **Clin Geriatr Med** 1999 Feb; 15(1):1-13, v (70 ref.)

Optic nerve assessment: a clinical endpoint of optic neuropathy. Antón López A. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S37-9 (11 ref.)

Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Weinreb RN, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S40-3 (29 ref.)

Neuro-ophthalmology of the pregeniculate afferent visual system: December, 1997-May, 1998 (Part I). Balcer LJ, et al. **J Neuroophthalmol** 1999 Mar;19(1):17-27 (46 ref.)

[Glial hamartoma of the papilla] Cernea P, et al. **Oftalmologia** 1998;44(3):84-7 (11 ref.) (Eng. Abstr.) **(Rum)**

[New concept of glaucoma. Primarily an optic neuropathy, not a disease of the anterior chamber angle] Heijl A. **Lakartidningen** 1999 Apr 7;96(14):1688-91 (22 ref.) (Eng. Abstr.) **(Swe)**

DRUG THERAPY

Mechanisms of neuroprotection and applications in ocular disease. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S52-81; quiz S82-4 (0 ref.)

[Prospects in the medical treatment of glaucomatous neuropathy. Basics of neuroprotection] Detry-Morel M. **J Fr Ophtalmol** 1999 Feb;22(1):122-34 (45 ref.) **(Fre)**

ETIOLOGY

Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Giorgi D, et al. **Clin Rheumatol** 1999;18(2):124-31 (21 ref.)

Vascular dysregulation: a principal risk factor for glaucomatous damage? Flammer J, et al. **J Glaucoma** 1999 Jun;8(3):212-9 (112 ref.)

The clinico-ophthalmological spectrum of antiphospholipid syndrome. Giorgi D, et al. **Ocul Immunol Inflamm** 1998 Dec;6(4):269-73 (21 ref.)

[A rare cause of peracute vision loss: pseudotumor cerebri. Case report of course with recurrence after decompression of the optic nerve] Heckmann JG, et al. **Nervenarzt** 1998 Aug;69(8):702-6 (43 ref.) (Eng. Abstr.) **(Ger)**

[Glaucomatous optic neuropathy. Its etiopathogenetic aspects; the therapeutic consequences] Apostol S. **Oftalmologia** 1998;44(3):13-6 (10 ref.) (Eng. Abstr.) **(Rum)**

GENETICS

Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Eccles MR, et al. **Clin Genet** 1999 Jul;56(1):1-9 (39 ref.)

METABOLISM

An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Vorwerk CK, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S142-50 (98 ref.)

PREVENTION & CONTROL

New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Neufeld AH. **J Glaucoma** 1998 Dec;7(6):434-8 (44 ref.)

Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Levin LA. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S98-101 (26 ref.)

THERAPY

Treatment of traumatic optic neuropathy. Pomeranz HD, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):185-94 (49 ref.)

OPTIC NERVE HEAD see **OPTIC DISK**

OPTIC NERVE NEOPLASMS

DIAGNOSIS

Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. Perilongo G, et al. **J Child Neurol** 1999 Jun;14(6):352-6 (13 ref.)

Optic nerve sheath meningiomas. Role of MR imaging. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):37-58, ix (84 ref.)

OPTIC NEURITIS

Pediatric optic neuritis [editorial; comment] Cassidy L, et al. **J Aapos** 1999 Apr;3(2):68-9 (13 ref.) Comment on: J Aapos 1999 Apr;3(2):98-103.

CHEMICALLY INDUCED

Ocular toxicity from ethambutol: a review of four cases and recommended precautions [see comments] Sivakumaran P, et al. **N Z Med J** 1998 Nov 13;111(1077):428-30 (18 ref.) Comment in: N Z Med J 1999 Feb 26;112(1082):57-8.

[Neurotoxicity of chinoform] Iwashita H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):602-5 (6 ref.) **(Jpn)**

DIAGNOSIS

Leber's idiopathic stellate neuroretinitis: differential diagnosis and approach to management. Casson RJ, et al. **Aust N Z J Ophthalmol** 1999 Feb;27(1):65-9 (21 ref.)

Hughes-Stovin syndrome: a case report and review of the literature. Riantawan P, et al. **J Med Assoc Thai** 1999 Mar; 82(3):312-6 (7 ref.)

METABOLISM

A putative role for calpain in demyelination associated with optic neuritis. Banik NL, et al. **Histol Histopathol** 1999 Apr;14(2):649-56 (39 ref.)

PATHOLOGY

Tropical myeloneuropathies revisited. Román G. **Curr Opin Neurol** 1998 Oct;11(5):539-44 (92 ref.)

OPTIC NEUROPATHY, ISCHEMIC

Nonarteritic anterior ischemic optic neuropathy: enigma variations [editorial] Lessell S. **Arch Ophthalmol** 1999 Mar; 117(3):386-8 (27 ref.)

ETIOLOGY

Anterior ischemic optic neuropathy: a complication after extracorporal circulation. Busch T, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):354-8 (30 ref.)

Anterior ischemic optic neuropathy: trouble waiting to happen [editorial; comment] Feldon SE. **Ophthalmology** 1999 Apr;106(4):651-2 (19 ref.) Comment on: Ophthalmology 1999 Apr;106(4):739-42.

[Anterior ischemic optic neuropathy after systemic hypotension and anemia] Koos MJ, et al. **Oftalmologia** 1998; 44(3):79-83 (33 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOPATHOLOGY

Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Hayreh SS. **Prog Retin Eye Res** 1999 Mar;18(2):191-221 (168 ref.)

Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Chung HS, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S43-50 (64 ref.)

The role of age and cardiovascular disease in glaucomatous optic neuropathy. Hayreh SS. **Surv Ophthalmol** 1999 Jun; 43 Suppl 1:S27-42 (132 ref.)

OPTIC PAPILLA see **OPTIC DISK**

OPTIC PAPILLA EDEMA see **PAPILLEDEMA**

OPTIC TECTUM see **SUPERIOR COLLICULUS**

OPTICAL ILLUSIONS

Threshold effect in visual perception of geometrical figures. Di Maio V. **Percept Mot Skills** 1998 Aug;87(1):340-2 (9 ref.)

[Visual hallucinations and illusions, symptoms frequently misdiagnosed by the practitioner] Borruat FX. **Klin Monatsbl Augenheilkd** 1999 May;214(5):324-7 (16 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Finding out about filling-in: a guide to perceptual completion for visual science and the philosophy of perception. Pessoa L, et al. **Behav Brain Sci** 1998 Dec;21(6):723-48; discussion 748-802 (314 ref.)

OPTICAL READERS see **AUTOMATIC DATA PROCESSING**

OPTICAL STORAGE DEVICES

The DICOM image formatting standard: its role in echocardiography and angiography. Thomas JD. **Int J Card Imaging** 1998;14 Suppl 1:1-6 (13 ref.)

OPTICS

see related
VISION

Optical measurement of hematocrit and other biological constituents in renal therapy. Steuer RR, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):217-24 (27 ref.)

Ultrasmall optical sensors for cellular measurements. Tan W,

et al. **Anal Chem** 1999 Sep 1;71(17):606A–612A (41 ref.)
Physical techniques for the study of exocytosis in isolated cells. Henry JP, et al. **Biochimie** 1998 May–Jun; 80(5–6):371–7 (36 ref.)
Acousto-optic random-access laser scanning microscopy: fundamentals and applications to optical recording of neuronal activity. Saggau P, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):827–46 (21 ref.)
A unified paraxial approach to astigmatic optics. Harris WF. **Optom Vis Sci** 1999 Jul;76(7):480–99 (50 ref.)
Optical mapping and its potential for large-scale sequencing projects. Aston C, et al. **Trends Biotechnol** 1999 Jul; 17(7):297–302 (26 ref.)
[Near-field optics: principle and application to the studies of biosciences] Saito K, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):807–11 (8 ref.) **(Jpn)**

OPTOMETRY

Optometry and ophthalmology relations in managed care. Hettler DL. **J Am Optom Assoc** 1999 Feb;70(2):99–102 (28 ref.)
The importance of the therapeutic alliance. Kaplan S. **J Am Optom Assoc** 1998 Oct;69(10):637–42 (32 ref.)
The ratings war: news from the front line [editorial] Bullimore MA. **Optom Vis Sci** 1999 Mar;76(3):129 (7 ref.)

ORGANIZATION & ADMINISTRATION

Strategic plan. Connors VJ, et al. **J Am Optom Assoc** 1999 Jul;70(7):417–26 (0 ref.)

STANDARDS

Injury prevention: where do we go from here? Vinger PF. **J Am Optom Assoc** 1999 Feb;70(2):87–98 (0 ref.)

ORAL CHARACTER see **PSYCHOANALYTIC THEORY**

ORAL FISTULA

ETIOLOGY

Midfacial complications of prolonged cocaine snorting. Villa PD. **J Can Dent Assoc** 1999 Apr;65(4):218–23 (28 ref.)

ORAL HAIRY LEUKOPLAKIA see **LEUKOPLAKIA, HAIRY**

ORAL HEALTH

see related
MOUTH DISEASES
MOUTH REHABILITATION

Meeting primary oral health care needs of HIV-infected women [editorial; comment] Zabos GP. **Am J Public Health** 1999 Jun;89(6):818–9 (7 ref.) Comment on: Am J Public Health 1999 Jun;89(6):834–9.
A brief review of indigenous Australian health as it impacts on oral health. Martin-Iverson N, et al. **Aust Dent J** 1999 Jun;44(2):88–92 (53 ref.)
Inequalities in oral health: a review of the evidence and recommendations for action. Watt R, et al. **Br Dent J** 1999 Jul 10;187(1):6–12 (69 ref.)
Oral health and the older diabetic. Martin W. **Clin Geriatr Med** 1999 May;15(2):339–50 (87 ref.)
Using oral quality of life measures in geriatric dentistry. Jones JA. **Community Dent Health** 1998 Mar;15(1):13–8 (27 ref.)
Uses of oral health related quality of life measures in Public Health. Weintraub JA. **Community Dent Health** 1998 Mar; 15(1):8–12 (24 ref.)
Significance of oral health in persons with Down syndrome: a literature review. Hennequin M, et al. **Dev Med Child Neurol** 1999 Apr;41(4):275–83 (108 ref.)
Oral health and systemic disease: periodontitis and cardiovascular disease. Beck JD, et al. **J Dent Educ** 1998 Oct;62(10):859–70 (44 ref.)
Promoting oral health in institutionalised older adults: a nursing perspective. Holmes S. **J R Soc Health** 1998 Jun; 118(3):167–72 (64 ref.)
Oral health for the preschool child [editorial] [see comments] Kilpatrick N. **Med J Aust** 1999 Jan 4;170(1):6–7 (16 ref.) Comment in: Med J Aust 1999 May 3;170(9):455–6.
The influence of aging on oral health and consequences for taste and smell. Ship JA. **Physiol Behav** 1999 Apr; 66(2):209–15 (72 ref.)
[Oral health in Europe with changing socioeconomic structures as seen by the epidemiologist] Borutta A. **Gesundheitswesen** 1998 Nov;60(11):672–7 (36 ref.) (Eng. Abstr.) **(Ger)**

ORAL HEMORRHAGE

DIAGNOSIS

[Bullosa haemorrhagica oralis. A review of the literature and case report] von Arx T. **Schweiz Monatsschr Zahnmed** 1998; 108(10):989–96 (15 ref.) **(Ger, Fre)**

PATHOLOGY

Angina bullosa hemorrhagica. Grinspan D, et al. **Int J Dermatol** 1999 Jul;38(7):525–8 (19 ref.)

ORAL HYGIENE

see related
TOOTHBRUSHING

Significance of oral health in persons with Down syndrome: a literature review. Hennequin M, et al. **Dev Med Child Neurol** 1999 Apr;41(4):275–83 (108 ref.)

ORAL MEDICINE

see related
DENTISTRY
MOUTH DISEASES

ORAL MUCOSA see **MOUTH MUCOSA**

ORAL REHYDRATION THERAPY see **FLUID THERAPY**

ORAL SEX see **SEX BEHAVIOR**

ORAL SURGICAL PROCEDURES

see related
SURGERY, ORAL

[Anesthetic problems during long interventions in mouth, jaw and facial surgery] Birken T. **Anaesthesiol Reanim** 1999; 24(2):32–6 (22 ref.) (Eng. Abstr.) **(Ger)**
[Anesthesia in dental, oral, jaw, facial, and ophthalmic surgery; therapeutics of the neck, nose, and eye . I. General and specific aspects in dental, oral, jaw and facial surgery (published erratum appears in Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Mar;34(3):170)] Georgi R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan;34(1):45–65 (0 ref.) **(Ger)**
[Controversies and current status of therapy of optic nerve damage in craniofacial traumatology and surgery] Gellrich NC. **Mund Kiefer Gesichtschir** 1999 Jul;3(4):176–94 (208 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Dentists are innocent! "Everyday" bacteremia is the real culprit: a review and assessment of the evidence that dental surgical procedures are a principal cause of bacterial endocarditis in children. Roberts GJ. **Pediatr Cardiol** 1999 Sep-Oct;20(5):317–25 (40 ref.)

INSTRUMENTATION

[The new-generation laser surgical apparatus Doktor in the combined treatment of stomatological disease in an outpatient setting] Prokhonchukov AA, et al. **Stomatologiia (Mosk)** 1998;77(5):44–9 (14 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Palatally ectopic canines: closed eruption versus open eruption. Burden DJ, et al. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):640–4 (24 ref.)
State of the art in oral and maxillofacial surgery: treatment of maxillary hypoplasia and anterior palatal and alveolar clefts. Steinberg B, et al. **Cleft Palate Craniofac J** 1999 Jul;36(4):283–91 (44 ref.)
Propofol anesthesia for outpatient oral and maxillofacial surgery. Cillo JE Jr. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 May;87(5):530–8 (58 ref.)
[The coronal approach in maxillofacial surgery. Notes on the surgical anatomy] Salgarelli A, et al. **Minerva Chir** 1998 Jun;53(6):567–73 (19 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

Psychological assessment of patients requesting orthognathic surgery and the relevance of body dysmorphic disorder. Cunningham SJ, et al. **Br J Orthod** 1998 Nov;25(4):293–8 (22 ref.)
Patient understanding of postsurgical instruction forms. Alexander RE. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):153–8 (26 ref.)

VETERINARY

Maxillofacial surgery. Marretta SM. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1285–96, viii (29 ref.)
Exodontics. Smith MM. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1297–319, ix (7 ref.)

ORAL SURGICAL PROCEDURES, PREPROSTHETIC

The periodontist and the edentulous area--localised ridge augmentation. Cho JY. **Int Dent J** 1998 Jun;48(3 Suppl 1):326–9 (17 ref.)

ADVERSE EFFECTS

A classification system for sinus membrane perforations during augmentation procedures with options for repair. Vlassis JM, et al. **J Periodontol** 1999 Jun;70(6):692–9 (28 ref.)

ORAL TOBACCO see **TOBACCO, SMOKELESS**

ORAL ULCER

see related
GINGIVITIS, NECROTIZING ULCERATIVE
NOMA
STOMATITIS, APHTHOUS

CHEMICALLY INDUCED

Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. Shotts RH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):706–7 (5 ref.)

DIAGNOSIS

Diagnosis of oral ulcers. Schneider LC, et al. **Mt Sinai J Med** 1998 Oct-Nov;65(5–6):383–7 (14 ref.)

DRUG THERAPY

Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. Nousari HC, et al. **J Am Acad Dermatol** 1999 May; 40(5 Pt 1):750–4 (24 ref.)

ETIOLOGY

[An oral ulcer due to cytomegalovirus in a patient with the acquired immunodeficiency syndrome (letter)] Mendiburu Belzunegui L, et al. **An Med Interna** 1999 Jan;16(1):53 (10 ref.) **(Spa)**

MICROBIOLOGY

Oral histoplasmosis as an indicator of HIV infection. Economopoulou P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):203–6 (24 ref.)

ORBICULARIS OCULI REFLEX see **BLINKING**

ORBIT

ABNORMALITIES

Three-dimensional imaging of congenital disorders involving the orbit. Zonneveld FW, et al. **Radiol Clin North Am** 1998 Nov;36(6):1261–79, xii (78 ref.)
[Congenital orbital diseases] Behrendt S, et al. **Ophthalmologe** 1999 Feb;96(2):141–58 (105 ref.) **(Ger)**

ANATOMY & HISTOLOGY

Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Davis PC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):93–114 (80 ref.)

BLOOD SUPPLY

Orbital vascular malformations: a consensus statement on terminology and its clinical implications. Orbital Society. Harris GJ. **Am J Ophthalmol** 1999 Apr;127(4):453–5 (7 ref.)
Evaluation and endovascular treatment of juxtaorbital vascular anomalies. Aletich V, et al. **Radiol Clin North Am** 1999 Jan;37(1):123–33, x (42 ref.)
Orbital vascular lesions. Role of imaging. Bilaniuk LT. **Radiol Clin North Am** 1999 Jan;37(1):169–83, xi (56 ref.)
Color Doppler imaging of the retrobulbar circulation in glaucoma. Rankin SJ. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S176–82 (28 ref.)

INJURIES

CT of soft tissue injury and orbital fractures. Mauriello JA Jr, et al. **Radiol Clin North Am** 1999 Jan;37(1):241–52, xii (35 ref.)
Helical CT and three-dimensional CT of facial and orbital injury. Rhea JT, et al. **Radiol Clin North Am** 1999 May; 37(3):489–513 (73 ref.)

PATHOLOGY

Temporal dermoid with intracranial extension: report of a case. Niederhagen B, et al. **J Oral Maxillofac Surg** 1998 Nov;56(11):1352–4 (20 ref.)

SURGERY

A combined transorbital-transclinoid and transsylvian approach to carotid-ophthalmic aneurysms without retraction of the brain. Dolenc VV. **Acta Neurochir Suppl (Wien)** 1999;72:89–97 (97 ref.)
Erbium: YAG laser--an improved periorbital resurfacing device. Kopelman J. **Semin Ophthalmol** 1998 Sep; 13(3):136–41 (16 ref.)
[Surgery of orbital diseases--choice of surgical approach] Spaić M, et al. **Vojnosanit Pregl** 1999 Mar-Apr;56(2):181–4 (23 ref.) **(Sec)**

ORBIT

TRANSPLANTATION

[Plastic repair of a defect in the base of the skull with soft tissues from the orbit after the removal of an extensive esthesioneuroepithelioma] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr–Jun; (2):25–7 (24 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Transcranial and orbital Doppler ultrasound in normal pregnancy and preeclampsia. Belfort MA, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):479–506 (57 ref.)

Color Doppler imaging of the eye and orbit. Lieb WE. **Radiol Clin North Am** 1998 Nov;36(6):1059–71 (91 ref.)

ORBITAL DISEASES

[Orbital cellulitis] Ohshima K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):342–5 (5 ref.) **(Jpn)**

CONGENITAL

Three–dimensional imaging of congenital disorders involving the orbit. Zonneveld FW, et al. **Radiol Clin North Am** 1998 Nov;36(6):1261–79, xii (78 ref.)

[Congenital orbital diseases] Behrendt S, et al. **Ophthalmologe** 1999 Feb;96(2):141–58 (105 ref.) **(Ger)**

DIAGNOSIS

Sinonasal American Burkitt's lymphoma masquerading as a periorbital abscess. Gosselin BJ. **J Otolaryngol** 1998 Aug; 27(4):238–42 (20 ref.)

Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Davis PC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):93–114 (80 ref.)

MR imaging and CT of orbital infections and complications in acute rhinosinusitis. Eustis HS, et al. **Radiol Clin North Am** 1998 Nov;36(6):1165–83, xi (56 ref.)

Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Hidayat AA, et al. **Radiol Clin North Am** 1998 Nov;36(6):1229–40, xii (68 ref.)

Sarcoidosis of the eye, orbit, and central nervous system. Role of MR imaging. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):73–87, x (53 ref.)

Imaging of orbital lymphoproliferative disorders. Valvassori GE, et al. **Radiol Clin North Am** 1999 Jan;37(1):135–50, x–xi (48 ref.)

Fibro–osseous, osseous, and cartilaginous lesions of the orbit and paraorbital region. Correlative clinicopathologic and radiographic features, including the diagnostic role of CT and MR imaging. Wenig BM, et al. **Radiol Clin North Am** 1998 Nov;36(6):1241–59, xii (67 ref.)

Orbital pseudotumor: case report and literature review. Zurlo A, et al. **Tumori** 1999 Jan–Feb;85(1):68–70 (26 ref.)

ETIOLOGY

Fine–needle aspiration diagnosis of foreign body granulomatous reaction presenting as an orbital mass: case report and review of the literature. Iyer VK, et al. **Diagn Cytopathol** 1998 Oct;19(4):290–2 (18 ref.)

Ethmoid sinus osteoma presenting as epiphora and orbital cellulitis: case report and literature review. Mansour AM, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):413–26 (128 ref.)

MICROBIOLOGY

Aspergillus mycetoma in a secondary hydroxyapatite orbital implant: a case report and literature review. Oestreicher JH, et al. **Ophthalmology** 1999 May;106(5):987–91 (21 ref.)

PARASITOLOGY

Orbital cysticercosis. Pluschke M, et al. **Aust N Z J Ophthalmol** 1998 Nov;26(4):333–6 (34 ref.)

PATHOLOGY

Phakomatous choristoma may be located in the eyelid or orbit or both. Seregard S. **Acta Ophthalmol Scand** 1999 Jun;77(3):343–6 (15 ref.)

Ectopic brain tissue in the orbit. Scheiner AJ, et al. **Eye** 1999 Apr;13 (Pt 2):251–4 (7 ref.)

Subarachnoid hemorrhage caused by Aspergillus aneurysm as a complication of transcranial biopsy of an orbital apex lesion—case report. Okada Y, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):432–7 (37 ref.)

Kimura disease of the orbit and ocular adnexa. Buggage RR, et al. **Surv Ophthalmol** 1999 Jul–Aug;44(1):79–91 (41 ref.)

RADIOTHERAPY

Radiation therapy for benign disease of the orbit. Smitt MC, et al. **Semin Radiat Oncol** 1999 Apr;9(2):179–89 (58 ref.)

VETERINARY

The eye and orbit. Daniel GB, et al. **Clin Tech Small Anim Pract** 1999 Aug;14(3):160–9 (20 ref.)

ORBITAL FRACTURES

COMPLICATIONS

An unusual variant of a growing skull fracture in an adolescent. Colak A, et al. **Pediatr Neurosurg** 1998 Jul; 29(1):36–9 (14 ref.)

RADIOGRAPHY

CT of soft tissue injury and orbital fractures. Mauriello JA Jr, et al. **Radiol Clin North Am** 1999 Jan;37(1):241–52, xii (35 ref.)

SURGERY

Selection of materials for orbital floor reconstruction [see comments] Chowdhury K, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1398–401 (16 ref.) Comment in: Arch Otolaryngol Head Neck Surg 1998 Dec;124(12):1402. Comment in: Arch Otolaryngol Head Neck Surg 1998 Dec;124(12):1402–3.

Bone grafting for enophthalmos due to a medial orbital wall fracture: case report with 13 year follow–up. van der Wal KG, et al. **J Craniomaxillofac Surg** 1999 Jun;27(3):177–9 (10 ref.)

[Silastic implants and reconstruction of the orbital floor: review of twenty year's experience] Laxenaire A, et al. **Ann Chir Plast Esthet** 1996 Dec;41(6):631–8 (23 ref.) (Eng. Abstr.) **(Fre)**

ORBITAL GRANULOMA, PLASMA CELL see **GRANULOMA, PLASMA CELL, ORBITAL**

ORBITAL IMPLANTS

MICROBIOLOGY

Aspergillus mycetoma in a secondary hydroxyapatite orbital implant: a case report and literature review. Oestreicher JH, et al. **Ophthalmology** 1999 May;106(5):987–91 (21 ref.)

ORBITAL MYOSITIS see **GRANULOMA, PLASMA CELL, ORBITAL**

ORBITAL NEOPLASMS

see related
EYE NEOPLASMS

Mesenchymal extraskeletal chondrosarcoma of the orbit. Report of a case and review of the literature. Khouja N, et al. **Surg Neurol** 1999 Jul;52(1):50–3 (06 ref.)

DIAGNOSIS

Non–Hodgkin lymphoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyon. Jan NA, et al. **Am J Clin Oncol** 1999 Feb;22(1):82–3 (12 ref.)

Primary spheno–orbital angiosarcoma: case report and review of the literature. Lopes M, et al. **Neurosurgery** 1999 Feb;44(2):405–7; discussion 407–8 (39 ref.)

Juxtaorbital en plaque meningiomas. Report of four cases and review of literature. Charbel FT, et al. **Radiol Clin North Am** 1999 Jan;37(1):89–100, x (59 ref.)

Mesenchymal chondrosarcoma and simulating lesions of the orbit. Koeller KK. **Radiol Clin North Am** 1999 Jan; 37(1):203–17, xii (31 ref.)

Fibro–osseous, osseous, and cartilaginous lesions of the orbit and paraorbital region. Correlative clinicopathologic and radiographic features, including the diagnostic role of CT and MR imaging. Wenig BM, et al. **Radiol Clin North Am** 1998 Nov;36(6):1241–59, xii (67 ref.)

[Intraorbital tumors in children. Two cases and review of the literature] Battistella PA, et al. **Minerva Pediatr** 1998 Dec;50(12):519–28 (60 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Primary orbital Ewing's sarcoma: report of a case and review of the literature. Lam DS, et al. **Eye** 1999;13 (Pt 1):38–42 (21 ref.)

PATHOLOGY

Orbital fibrous histiocytoma: case report and literature review. Ulloa TK, et al. **J Am Optom Assoc** 1999 Apr; 70(4):253–60 (22 ref.)

Primitive neuroectodermal tumor of the orbit in an adult. A case report and literature review. Kiratli H, et al. **Ophthalmology** 1999 Jan;106(1):98–102 (31 ref.)

[A case of orbital mesenchymal chondrosarcoma] Takamura H, et al. **Nippon Ganka Gakkai Zasshi** 1998 Oct; 102(10):692–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Primary orbital Ewing's sarcoma: report of a case and review of the literature. Lam DS, et al. **Eye** 1999;13 (Pt 1):38–42 (21 ref.)

VETERINARY

Tumors of the eye and ocular adnexal tissues. Rebhun WC. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):579–606, vii (78 ref.)

ORCAELLA see **DOLPHINS**

ORCHIDECTOMY see **ORCHIECTOMY**

ORCHIECTOMY

Endocrine treatment of prostate cancer – recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side–effects. Schröder FH. **BJU Int** 1999 Jan;83(2):161–70 (00 ref.)

Hormonal ablation therapy for metastatic prostatic carcinoma: a review. Leewansangtong S, et al. **J Med Assoc Thai** 1999 Feb;82(2):192–205 (116 ref.)

Long–term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. Böhlen D, et al. **J Urol** 1999 Apr;161(4):1148–52 (37 ref.)

[Hormone therapy in advanced and generalized carcinoma of the prostate] Vachalovský V, et al. **Cas Lek Cesk** 1998 Aug 31;137(17):532–6 (39 ref.) (Eng. Abstr.) **(Cze)**

[Current therapeutic orientation toward testicular germ cell tumors] Catani M, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):113–7 (24 ref.) (Eng. Abstr.) **(Ita)**

[Surgical or medical castration with LH–RH analogue for prostatic cancer] Kameyama S, et al. **Nippon Rinsho** 1998 Aug;56(8):2114–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Total androgen blockade—concept, theory, method and clinical application] Ozono S, et al. **Nippon Rinsho** 1998 Aug;56(8):2129–34 (27 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Equine castration: review of anatomy, approaches, techniques and complications in normal, cryptorchid and monorchid horses. Searle D, et al. **Aust Vet J** 1999 Jul;77(7):428–34 (25 ref.)

ORCHITIS

COMPLICATIONS

[Testicular microlithiasis] Said M, et al. **Ann Urol (Paris)** 1998;32(5):321–4 (24 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Recurrent orchiepididymitis, 6 months after likely miliary tuberculosis] Lacambra Calvet C, et al. **Arch Esp Urol** 1999 Jun;52(5):518–20 (13 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Orchitis] Naide Y. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):241–2 (3 ref.) **(Jpn)**

ORCINUS see **DOLPHINS**

ORCIPRENALINE

ANALOGS & DERIVATIVES

Reproterol: beta–2–agonist, theophylline, or both? [editorial; comment] Virchow JC Jr. **Respiration** 1999;66(3):210–1 (12 ref.) Comment on: Respiration 1999 ;66(3):220–4.

ORGAN CULTURE

see related
CELLS, CULTURED
TISSUE CULTURE

Preservation of human skin structure and function in organ culture. Varani J. **Histol Histopathol** 1998 Jul;13(3):775–83 (53 ref.)

Fetal thymic organ culture in rotating bioreactors [letter] Tabourn B, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan; 35(1):4–7 (32 ref.)

Development of specific synaptic network functions in organotypic central nervous system (CNS) cultures: implications for transplantation of CNS neural cells in vivo. Crain SM. **Methods** 1998 Nov;16(3):228–38 (90 ref.)

Organ culture in the analysis of tissue interactions. Thesleff I, et al. **Methods Mol Biol** 1999;97:23–31 (17 ref.)

In vitro models of T cell development. Hare KJ, et al. **Semin Immunol** 1999 Feb;11(1):3–12 (66 ref.)

METHODS

Improved methods for blastocyst formation and culture. Ménézo Y, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:256–65 (48 ref.)

ORGAN DONORS see **TISSUE DONORS**

ORGAN DYSFUNCTION SYNDROME, MULTIPLE see **MULTIPLE ORGAN FAILURE**

ORGAN FAILURE, MULTIPLE see **MULTIPLE ORGAN FAILURE**

ORGAN GRAFTS see **TRANSPLANTS**

ORGAN OF CORTI

PHYSIOLOGY

[Molecular biology, and molecular genetics in the field of otorhinolaryngology--mechanism of neural transmission in the cochlea] Doi K. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Aug;101(8):1048–51 (4 ref.) **(Jpn)**

ORGAN PRESERVATION

Interaction of bradykinin with angiotensin, prostacyclin, and nitric oxide in myocardial preservation. Sato M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:286–94 (61 ref.)

Application of cryopreserved precision-cut liver slices in pharmacotoxicology--principles, literature data and own investigations with special reference to CYP1A1-mRNA induction. Glöckner R, et al. **Exp Toxicol Pathol** 1998 Sep; 50(4–6):440–9 (35 ref.)

Postischemic reperfusion injury and allograft dysfunction: is allograft rejection the result of a fateful confusion by the immune system of danger and benefit? Land W. **Transplant Proc** 1999 Feb–Mar;31(1–2):332–6 (20 ref.)

METHODS

Ischaemia–reperfusion injury of the liver: treatment in theory and in practice. Tredger JM. **Biofactors** 1998;8(1–2):161–4 (25 ref.)

Survival and function of isolated hepatocytes after cryopreservation. Guillouzo A, et al. **Chem Biol Interact** 1999 Jun 1;121(1):7–16 (32 ref.)

Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Li AP, et al. **Chem Biol Interact** 1999 Jun 1;121(1):117–23 (15 ref.)

Kidney preservation in the next millenium. Stubenitsky BM, et al. **Transpl Int** 1999;12(2):83–91 (108 ref.)

Decreasing the cold ischemia time. Abendroth D. **Transplant Proc** 1998 Dec;30(8):4288–90 (42 ref.)

What is a reasonably short cold ischemia time in kidney transplantation? Offermann G. **Transplant Proc** 1998 Dec; 30(8):4291–3 (8 ref.)

[Gaseous oxygen for protection and conditioning of organs during ischemia] Isselhard W, et al. **Zentralbl Chir** 1999; 124(4):252–9 (70 ref.) (Eng. Abstr.) **(Ger)**

ORGAN PRESERVATION SOLUTIONS

The efficacy of synthetic media in the storage of human platelets for transfusion. Murphy S. **Transfus Med Rev** 1999 Jul;13(3):153–63 (51 ref.)

Preservation solutions for transplantation. Mühlbacher F, et al. **Transplant Proc** 1999 Aug;31(5):2069–70 (15 ref.)

ORGAN PROCUREMENT

see related

TISSUE DONORS

Brazilian nurses play pivotal role in organ transplant. Püschel VA. **Int Nurs Rev** 1998 Nov–Dec;45(6):168 (0 ref.)

The ethical issues involved in organ transplant. Um YR. **Int Nurs Rev** 1998 Nov–Dec;45(6):167–8 (1 ref.)

How can we increase the number of organ and tissue donors? Howard RJ. **J Am Coll Surg** 1999 Mar;188(3):317–27 (74 ref.)

The commodification of human reproductive materials. Resnik DB. **J Med Ethics** 1998 Dec;24(6):388–93 (21 ref.)

Organ donation. Sarti A. **Paediatr Anaesth** 1999;9(4):287–94 (48 ref.)

A consideration of potential donors with active infection--is this a way to expand the donor pool? [editorial] Rubin RH, et al. **Transpl Int** 1998;11(5):333–5 (13 ref.)

[Organ procurement from cardiac arrest donors: outcome of kidney grafts and recommendations] Benoit G, et al. **Presse Med** 1999 Jan 9;28(1):3–7 (37 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Proposal for a mutual insurance pool for transplant organs. Schwindt R, et al. **J Health Polit Policy Law** 1998 Oct; 23(5):725–41 (44 ref.)

Paid organ donation--the grey basket concept [editorial] Daar AS. **J Med Ethics** 1998 Dec;24(6):365–8 (24 ref.)

LEGISLATION & JURISPRUDENCE

Rejecting organs: the organ allocation process and the Americans with Disabilities Act. Whitehead AT. **Am J Law Med** 1998;24(4):481–97 (0 ref.)

Legal developments in transplantation. Dickens BM. **Ann Transplant** 1998;3(3):30–7 (39 ref.)

Paid organ donation--the grey basket concept [editorial] Daar AS. **J Med Ethics** 1998 Dec;24(6):365–8 (24 ref.)

Cadaveric organ donation: comparison of legislation in various countries of Europe. Matesanz R. **Nephrol Dial Transplant** 1998 Jul;13(7):1632–5 (19 ref.)

METHODS

Organ donation: the family's right to make an informed choice. Beaulieu D. **J Neurosci Nurs** 1999 Feb;31(1):37–42 (25 ref.)

The ethics of organ transplantation reconsidered: paid organ donation and the use of executed prisoners as donors [see comments] Cameron JS, et al. **Kidney Int** 1999 Feb; 55(2):724–32 (45 ref.) Comment in: Kidney Int 1999 Feb;55(2):733.

Improving the approach to organ donation: a review. Jenkins DH, et al. **World J Surg** 1999 Jul;23(7):644–9 (66 ref.)

[Liver transplantation in the adult: who and when to transplant?] Le Treut YP, et al. **Rev Med Interne** 1998 Dec; 19(12):892–903 (91 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Keratolimbal allograft: recommendations for tissue procurement and preparation by eye banks, and standard surgical technique. Croasdale CR, et al. **Cornea** 1999 Jan; 18(1):52–8 (9 ref.)

Summary of guidelines on organ allocation and patient listing for liver transplantation. Keeffe EB. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S108–14 (20 ref.)

STATISTICS & NUMERICAL DATA

Are efforts at expanding the donor pool misdirected? Rayburn BK, et al. **J Heart Lung Transplant** 1998 Oct; 17(10):998–1003 (40 ref.)

TRENDS

Current status and future prospects for organ procurement and retrieval. Rapaport FT. **Transplant Proc** 1999 Jun; 31(4):1763–4 (11 ref.)

ORGAN PROCUREMENT FOUNDATIONS see **ORGAN PROCUREMENT**

ORGAN PROCUREMENT SYSTEMS see **ORGAN PROCUREMENT**

ORGAN RETRIEVAL see **ORGAN PROCUREMENT**

ORGAN SPECIFICITY

Determinants of organ tropism of sendai virus. Tashiro M, et al. **Front Biosci** 1999 Oct 1;4:D642–5 (26 ref.)

ORGAN SURVIVAL see **TISSUE SURVIVAL**

ORGAN TEMPERATURE see **BODY TEMPERATURE**

ORGAN TRANSPLANTATION

see related

TRANSPLANTATION IMMUNOLOGY

Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Exner BG, et al. **Acta Haematol** 1999;101(2):78–81 (30 ref.)

The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Allan JS. **Ann N Y Acad Sci** 1998 Dec 30;862:87–99 (76 ref.)

Analysis of factors for the prediction of the response to xenotransplantation. Daar AS. **Ann N Y Acad Sci** 1998 Dec 30;862:222–33 (45 ref.)

Immunosuppression by retroviruses: implications for xenotransplantation. Denner J. **Ann N Y Acad Sci** 1998 Dec 30;862:75–86 (38 ref.)

Infection and xenotransplantation. Developing strategies to minimize risk. Fishman JA. **Ann N Y Acad Sci** 1998 Dec 30;862:52–66 (78 ref.)

The risk of infection in xenotransplantation. Introduction. Fishman JA. **Ann N Y Acad Sci** 1998 Dec 30;862:45–51 (15 ref.)

Researcher-driven versus policy-driven economic appraisal. The case of xenotransplantation. Moatti JP. **Ann N Y Acad Sci** 1998 Dec 30;862:188–201 (28 ref.)

The future promises of xenotransplantation. Platt JL, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:5–18 (53 ref.)

Endogenous retroviruses: a potential problem for xenotransplantation? Stoye JP, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:67–74 (26 ref.)

Genetic engineering in the pig. Gene knockout and alternative techniques. Vanhove B, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:28–36 (59 ref.)

Skin cancers in organ transplant recipients. Euvrard S, et al. **Ann Transplant** 1997;2(4):28–32 (53 ref.)

Clinicopathologic features of posttransplant lymphoproliferative disorders. Nalesnik MA. **Ann Transplant** 1997;2(4):33–40 (113 ref.)

Overview of the problem of cancer in organ transplant recipients. Penn I. **Ann Transplant** 1997;2(4):5–6 (0 ref.)

Multiplicity of glucocorticoid action in inhibiting allograft rejection. Almawi WY, et al. **Cell Transplant** 1998 Nov–Dec;7(6):511–23 (199 ref.)

Overcoming the histocompatibility barrier: transferrins as carriers and modulators of immunogenic identity. Pierpaoli W. **Cell Transplant** 1998 Nov–Dec;7(6):541–8 (60 ref.)

Toxicology and adverse effects of drugs used for immunosuppression in organ transplantation. Philip AT, et al. **Clin Lab Med** 1998 Dec;18(4):755–65 (22 ref.)

Th1 and Th2 cytokines in organ transplantation: paradigm lost? Zhai Y, et al. **Crit Rev Immunol** 1999;19(2):155–72 (134 ref.)

What is new in mechanical properties of tissue-engineered organs. Auger FA, et al. **Curr Top Pathol** 1999;93:87–93 (38 ref.)

Porokeratosis and immunosuppression. Kanitakis J, et al. **Eur J Dermatol** 1998 Oct–Nov;8(7):459–65 (88 ref.)

Pneumonia in the compromised host including cancer patients and transplant patients. Collin BA, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):781–805, xi (160 ref.)

Renal failure in the recipients of nonrenal solid organ transplants. Wilkinson AH, et al. **J Am Soc Nephrol** 1999 May;10(5):1136–44 (70 ref.)

New directions in perioperative management for pediatric solid organ transplantation. Montenegro LM, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):457–72 (161 ref.)

Transesophageal echocardiography during organ transplantation. Suriani RJ. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6):686–94 (53 ref.)

Prevention of nosocomial infection in solid organ transplantation. Murphy OM, et al. **J Hosp Infect** 1999 Jul; 42(3):177–83 (42 ref.)

Traditional drug therapy of hypertension in transplant recipients. Elliott WJ. **J Hum Hypertens** 1998 Dec; 12(12):845–9 (44 ref.)

Effects of transplantation on the renin angiotensin system (RAS). Farge D, et al. **J Hum Hypertens** 1998 Dec; 12(12):827–32 (47 ref.)

Accelerated atherosclerosis in the transplant recipient: role of hypertension. Fellström B, et al. **J Hum Hypertens** 1998 Dec;12(12):851–4 (35 ref.)

Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. Reiter RJ, et al. **J Mol Med** 1999 Jan; 77(1):36–9 (43 ref.)

The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? Harlan DM, et al. **JAMA** 1999 Sep 15;282(11):1076–82 (68 ref.)

Xenotransplant-associated infections. Michaels MG. **Lab Anim Sci** 1998 Jun;48(3):228–33 (67 ref.)

Specific tolerance induction and organ transplantation. de Vries-van der Zwan A, et al. **Leuk Lymphoma** 1998 Sep; 31(1–2):131–42 (56 ref.)

Outcomes of recipients of both bone marrow and solid organ transplants. A review. Dey B, et al. **Medicine (Baltimore)** 1998 Sep;77(5):355–69 (107 ref.)

Invasive aspergillosis in transplant recipients. Paterson DL, et al. **Medicine (Baltimore)** 1999 Mar;78(2):123–38 (270 ref.)

Prevention of renal function loss after non-renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire? [editorial] Broekroelofs J, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1841–3 (13 ref.)

Corticosteroid elimination in pediatric solid organ transplantation [editorial; comment] Fine RN, et al. **Pediatr Transplant** 1998 Feb;2(1):3–5 (23 ref.) Comment on: Pediatr Transplant 1998 Feb;2(1):30–4. Comment on: Pediatr Transplant 1998 Feb;2(1):64–9. Comment on: Pediatr Transplant 1998 Feb;2(1):70–5.

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Christians U, et al. **Pharmacol Ther** 1998 Oct;80(1):1–34 (317 ref.)

Generic immunosuppressant use in solid organ transplantation. Alloway RR. **Transplant Proc** 1999 May; 31(3A Suppl):2S–5S (15 ref.)

Barriers to xenotransplantation. Bach FH, et al. **Transplant Proc** 1999 Jun;31(4):1819–20 (11 ref.)

Physiologic changes following brain death. Cooper DK, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1001–2 (13 ref.)

Clinical application of tolerance induction in solid organ transplantation. Cosimi AB. **Transplant Proc** 1999 Jun; 31(4):1803–5 (18 ref.)

Methodological issues in transplant compliance research. De Geest S, et al. **Transplant Proc** 1999 Jun;31(4A):81S–83S (9 ref.)

Are there markers to initiate treatment of chronic rejection? Fellström B, et al. **Transplant Proc** 1999 Jun;31(4):1796–8 (30 ref.)

What should be the role of the state in the development of transplantation? Gäbel H. **Transplant Proc** 1999 Jun; 31(4):1782–4 (9 ref.)

Cyclosporine: a revolution in transplantation. Kahan BD. **Transplant Proc** 1999 Feb–Mar;31(1–2A):14S–15S (27 ref.)

Therapeutic strategies for optimal use of novel immunosuppressants. Keown PA. **Transplant Proc** 1999 Jun;31(4):1790–2 (26 ref.)

A few steps along the path to adult transplantation tolerance. Lafferty KJ. **Transplant Proc** 1999 Feb–Mar; 31(1–2A):11S–13S (21 ref.)

Long-term metabolic complications. Legendre C. **Transplant Proc** 1999 Feb–Mar;31(1–2):1278–9 (15 ref.)

What should be the role of the state in the development of transplantation? Lloveras J. **Transplant Proc** 1999 Jun; 31(4):1765–8 (7 ref.)

The nature of ischemia/reperfusion injury. Massberg S, et al. **Transplant Proc** 1998 Dec;30(8):4217–23 (82 ref.)

Preservation solutions for transplantation. Mühlbacher F, et al. **Transplant Proc** 1999 Aug;31(5):2069–70 (15 ref.)

Activation of proinflammatory genes in somatic organs as a consequence of brain death. Pratschke J, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1003–5 (14 ref.)

Medication adherence and the transplant recipient: helping

patients at each stage of change. Robbins ML. **Transplant Proc** 1999 Jun;31(4A):29S–30S (17 ref.)

A medical anthropologist's view on posttransplant compliance: the underground economy of medical survival. Sharp LA. **Transplant Proc** 1999 Jun;31(4A):31S–33S (20 ref.)

Immunity and tolerance are related, and governed by antigen migration and localization. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1406–11 (62 ref.)

Cross-cultural issues in transplant compliance. Washington AW. **Transplant Proc** 1999 Jun;31(4A):27S–28S (7 ref.)

Literature update 1998, Part 1. Koulmanda M, et al. **Xenotransplantation** 1998 Aug;5(3):226–31 (102 ref.)

Human–porcine receptor–ligand compatibility within the immune system: relevance for xenotransplantation. Warrens AN, et al. **Xenotransplantation** 1999 May;6(2):75–8 (20 ref.)

[Progresses in the study of organ transplantation in China, 1997] Chen S, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):915–6 (0 ref.) **(Chi)**

[Xenogeneic antigens and immune response in pig to man xenograft] Li T, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):42–7 (29 ref.) (Eng. Abstr.) **(Chi)**

[Clinical xenotransplantation: current progress, problems and solutions] Li Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):99–107 (70 ref.) (Eng. Abstr.) **(Chi)**

[Contraceptive use in female transplant recipients] Rongières–Bertrand C, et al. **Contracept Fertil Sex** 1998 Dec;26(12):845–50 (38 ref.) (Eng. Abstr.) **(Fre)**

[Human Herpesvirus 6: general information and infections in organ transplantations and hematopoietic stem cell grafts] Fontan J, et al. **Presse Med** 1999 Jan 23;28(3):149–56 (60 ref.) (Eng. Abstr.) **(Fre)**

[Xenotransplantation of solid organs: study of rejection mechanisms and its prevention] Rodriguez Villa A, et al. **Rev Clin Esp** 1998 Oct;198(10):673–7 (63 ref.) **(Spa)**

ADVERSE EFFECTS

Treatment and prognosis of post–transplant lymphoproliferative disease. Mamzer–Bruneel MF, et al. **Ann Transplant** 1997;2(4):42–8 (72 ref.)

Etiology and pathogenesis of posttransplant tumors: new insights into viral oncogenesis. el–Sabrout R, et al. **Ann Transplant** 1997;2(4):67–9 (45 ref.)

Kaposi's sarcoma. Schwartz RA. **Ann Transplant** 1998; 3(1):5–12 (227 ref.)

Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients. King SM. **Antiviral Res** 1999 Jan;40(3):115–37 (150 ref.)

Thoracic complications in solid organ transplantation. Sommers KE, et al. **Chest Surg Clin N Am** 1999 Feb; 9(1):125–38, ix (32 ref.)

Infections in solid organ transplant recipients. Kibbler CC. **Curr Top Pathol** 1999;92:19–35 (83 ref.)

Primary malignancies of the hepato–biliary–pancreatic system in organ allograft recipients. Penn I. **J Hepatobiliary Pancreat Surg** 1998;5(2):157–64 (42 ref.)

Endoscopic diagnosis of lymphoproliferative disease after solid organ transplantation [editorial; comment] Kocoshis SA. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):375–6 (6 ref.) Comment on: J Pediatr Gastroenterol Nutr 1999 Apr;28(4):380–5.

The neuropathology of organ transplantation: comparison and contrast in 500 patients. Martinez AJ. **Pathol Res Pract** 1998;194(7):473–86 (96 ref.)

The antiviral prophylaxis of post–transplant lymphoproliferative disorder. Davis CL. **Springer Semin Immunopathol** 1998;20(3–4):437–53 (169 ref.)

Interferon–alpha and its effects on post–transplant lymphoproliferative disorders. Faro A. **Springer Semin Immunopathol** 1998;20(3–4):425–36 (55 ref.)

Role of donor versus recipient type Epstein–Barr virus in post–transplant lymphoproliferative disorders. Haque T, et al. **Springer Semin Immunopathol** 1998;20(3–4):375–87 (58 ref.)

The molecular genetics of post–transplantation lymphoproliferative disorders. Knowles DM. **Springer Semin Immunopathol** 1998;20(3–4):357–73 (69 ref.)

Clinical and pathological features of post–transplant lymphoproliferative disorders (PTLD). Nalesnik MA. **Springer Semin Immunopathol** 1998;20(3–4):325–42 (111 ref.)

Post–transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Tosato G, et al. **Springer Semin Immunopathol** 1998;20(3–4):405–23 (176 ref.)

[Infectious cutaneous pathology after organ transplantation] Euvrard S. **Ann Dermatol Venereol** 1998 Dec; 125(12):939–45 (37 ref.) **(Fre)**

ECONOMICS

The impact of generic drugs on the cost of transplantation medical care. Olyaei AJ, et al. **Transplant Proc** 1999 May; 31(3A Suppl):31S–34S (17 ref.)

LEGISLATION & JURISPRUDENCE

Legal developments in transplantation. Dickens BM. **Ann Transplant** 1998;3(3):30–7 (39 ref.)

What should be the role of the state in the development of transplantation? Lloveras J. **Transplant Proc** 1999 Jun; 31(4):1765–8 (7 ref.)

[Allocation problems within the scope of organ transplantation] Neuhaus P. **Internist (Berl)** 1999 Mar; 40(3):270–5 (0 ref.) **(Ger)**

METHODS

New strategies for allogeneic bone marrow transplantation and organ allografts. Ikehara S. **Acta Haematol** 1999; 101(2):68–77 (32 ref.)

Genetically engineered organs. John R, et al. **Adv Card Surg** 1998;10:229–44 (57 ref.)

Care of the pediatric solid organ transplant recipient. The primary care perspective. Kosmach B, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1395–418 (85 ref.)

Potential of gene transfer in transplantation. Wood KJ. **Transplant Proc** 1999 Jun;31(4):1814–6 (23 ref.)

[Gaseous oxygen for protection and conditioning of organs during ischemia] Isselhard W, et al. **Zentralbl Chir** 1999; 124(4):252–9 (70 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Brazilian nurses play pivotal role in organ transplant. Püschel VA. **Int Nurs Rev** 1998 Nov–Dec;45(6):168 (0 ref.)

The ethical issues involved in organ transplant. Um YR. **Int Nurs Rev** 1998 Nov–Dec;45(6):167–8 (1 ref.)

PATHOLOGY

The role of lipids in transplant vascular disease. McDonald PC, et al. **Lab Invest** 1998 Oct;78(10):1187–201 (125 ref.)

PHYSIOLOGY

Physiological obstacles after xenotransplantation. Hammer C. **Ann N Y Acad Sci** 1998 Dec 30;862:19–27 (38 ref.)

The role of nutrition before and after transplantation [editorial; comment] Allard JP. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):313–4 (5 ref.) Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):315–21. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):323–7. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):329–33.

Exercise and organ transplantation. Kjaer M, et al. **Scand J Med Sci Sports** 1999 Feb;9(1):1–14 (164 ref.)

PSYCHOLOGY

The role of the psychiatrist in organ transplantation. Klapheke MM. **Bull Menninger Clin** 1999 Winter; 63(1):13–39 (60 ref.)

[The subjective element in transplantation medicine. The importance of psychosocial indicators in transplantation and their effect on the quality of life] Johann B, et al. **Zentralbl Chir** 1999;124(2):84–9 (23 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

International issues in transplantation. Setting the scene and flagging the most urgent and controversial issues. Miranda B, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:129–43 (43 ref.)

STATISTICS & NUMERICAL DATA

Update in transplantation—1997. Ciancio G, et al. **Clin Transpl** 1997;:241–64 (328 ref.)

Applying a readiness model to increasing organ donation and transplantation. Robbins ML. **Med Health R I** 1998 Sep; 81(9):294–6 (21 ref.)

Brain death and its influence on donor organ quality and outcome after transplantation. Pratschke J, et al. **Transplantation** 1999 Feb 15;67(3):343–8 (56 ref.)

TRENDS

Transplantation. Teperman LW. **J Am Coll Surg** 1999 Feb; 188(2):184–90 (64 ref.)

Organ transplantation in mice: current status and future prospects. Zhong R. **Microsurgery** 1999;19(2):52–5 (38 ref.)

Paradigm changes in organ transplantation: a journey toward selflessness? Schaffner KF. **Theor Med Bioeth** 1998 Sep; 19(5):425–40 (55 ref.)

Conceptual shifts in immunology: comments on the "two–way paradigm" [comment] Tauber AI. **Theor Med Bioeth** 1998 Sep;19(5):457–73 (39 ref.) Comment on: Theor Med Bioeth 1998 Sep;19(5):441–55.

Lessons from transplantation and future perspectives [editorial] Birkeland SA. **Transpl Int** 1998;11(6):397–400 (35 ref.)

Future concepts in transplantation. Calne R. **Transplant Proc** 1999 Feb–Mar;31(1–2A):21S–24S (00 ref.)

ORGAN TRANSPLANTS see **TRANSPLANTS**

ORGANELLES

Organelle division: from coli to chloroplasts. Lutkenhaus J. **Curr Biol** 1998 Aug 27;8(17):R619–21 (24 ref.)

Subcellular fractionation, electromigration analysis and mapping of organelles. Pasquali C, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1–2):89–102 (74 ref.)

[Prostasomes enhance sperm capacity. Prostatic components, or antibodies against them, may be used in in vitro fertilization, as contraceptive agents and for the diagnosis of cancer] Ronquist G, et al. **Lakartidningen** 1998 Oct 21; 95(43):4724–5 (16 ref.) (Eng. Abstr.) **(Swe)**

ENZYMOLOGY

Organellar RNA polymerases of higher plants. Hess WR, et al. **Int Rev Cytol** 1999;190:1–59 (284 ref.)

GENETICS

The genome of Rickettsia prowazekii and some thoughts on the origin of mitochondria and hydrogenosomes. Müller M, et al. **Bioessays** 1999 May;21(5):377–81 (39 ref.)

Why have organelles retained genomes? Race HL, et al. **Trends Genet** 1999 Sep;15(9):364–70 (50 ref.)

METABOLISM

Calcium and organelles: a two–sided story. Rutter GA, et al. **Biochem Biophys Res Commun** 1998 Dec 30; 253(3):549–57 (113 ref.)

Coiled coils in both intracellular vesicle and viral membrane fusion. Skehel JJ, et al. **Cell** 1998 Dec 23;95(7):871–4 (19 ref.)

A primer on vesicle budding. Springer S, et al. **Cell** 1999 Apr 16;97(2):145–8 (18 ref.)

Multi–organellar disorders of pigmentation: tied up in traffic. Spritz RA. **Clin Genet** 1999 May;55(5):309–17 (113 ref.)

Delivery of proteins and organelles to the vacuole from the cytoplasm. Scott SV, et al. **Curr Opin Cell Biol** 1998 Aug; 10(4):523–9 (53 ref.)

Trichomonads, hydrogenosomes and drug resistance. Kulda J. **Int J Parasitol** 1999 Feb;29(2):199–212 (73 ref.)

Targeting GFP to organelles. De Giorgi F, et al. **Methods Cell Biol** 1999;58:75–85 (16 ref.)

Intracellular CFTR: localization and function. Bradbury NA. **Physiol Rev** 1999 Jan;79(1 Suppl):S175–91 (158 ref.)

The cellulosome concept as an efficient microbial strategy for the degradation of insoluble polysaccharides. Shoham Y, et al. **Trends Microbiol** 1999 Jul;7(7):275–81 (66 ref.)

PHYSIOLOGY

Coiled bodies and gems: Janus or gemini? Matera AG, et al. **Am J Hum Genet** 1998 Aug;63(2):317–21 (44 ref.)

Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Bonifacino JS, et al. **Annu Rev Cell Dev Biol** 1998;14:19–57 (164 ref.)

Isoform sorting and the creation of intracellular compartments. Gunning P, et al. **Annu Rev Cell Dev Biol** 1998;14:339–72 (166 ref.)

Genetics of synaptic vesicle function: toward the complete functional anatomy of an organelle. Fernández–Chacón R, et al. **Annu Rev Physiol** 1999;61:753–76 (106 ref.)

Crowded little caves: structure and function of caveolae. Schlegel A, et al. **Cell Signal** 1998 Jul;10(7):457–63 (62 ref.)

Quality control: from molecules to organelles. Luzikov VN. **FEBS Lett** 1999 Apr 9;448(2–3):201–5 (63 ref.)

Role of Bcl–2 family proteins in apoptosis: apoptosomes or mitochondria? Tsujimoto Y. **Genes Cells** 1998 Nov; 3(11):697–707 (75 ref.)

Apical organelles and host–cell invasion by Apicomplexa. Dubremetz JF, et al. **Int J Parasitol** 1998 Jul;28(7):1007–13 (40 ref.)

Diverse roles of single membrane organelles: factors establishing the acid lumenal pH. Futai M, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):259–67 (109 ref.)

Pictures in cell biology. Un–LOXing the door to organelle degradation. van Leyen K. **Trends Cell Biol** 1998 Nov; 8(11):436 (8 ref.)

Upheaval in the bacterial nucleoid. An active chromosome segregation mechanism. Sharpe ME, et al. **Trends Genet** 1999 Feb;15(2):70–4 (37 ref.)

ULTRASTRUCTURE

Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1–MMP, MMP–2, and TIMP–2 localization. Chen WT, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:361–71 (52 ref.)

Genetics of synaptic vesicle function: toward the complete functional anatomy of an organelle. Fernández–Chacón R, et al. **Annu Rev Physiol** 1999;61:753–76 (106 ref.)

Caveolae: from a morphological point of view. Fujimoto T, et al. **J Electron Microsc (Tokyo)** 1998;47(5):451–60 (82 ref.)

ORGANIC BRAIN SYNDROME, NONPSYCHOTIC see **DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS**

ORGANIC CHEMICALS

ANALYSIS

The human health programme under AMAP. AMAP Human Health Group. Arctic Monitoring and Assessment Program. Hansen JC. **Int J Circumpolar Health** 1998 Oct; 57(4):280–91 (6 ref.)

CHEMICAL SYNTHESIS

Combinatorial libraries by portioning and mixing. Furka A, et al. **Comb Chem High Throughput Screen** 1999 Apr;

2(2):105–22 (84 ref.)
Parallel synthesis with fluorous reagents and reactants. Curran DP. **Med Res Rev** 1999 Sep;19(5):432–8 (15 ref.)
Phase–trafficking reagents and phase–switching strategies for parallel synthesis. Flynn DL. **Med Res Rev** 1999 Sep; 19(5):408–31 (69 ref.)
Optimization of solid supports for combinatorial chemical synthesis. Mendonca AJ, et al. **Med Res Rev** 1999 Sep; 19(5):451–62 (88 ref.)
Can the time from synthesis design to validated chemistry be shortened? Pilipauskas DR. **Med Res Rev** 1999 Sep; 19(5):463–74 (9 ref.)
Optimization in organic synthesis. Snieckus V. **Med Res Rev** 1999 Sep;19(5):342–7 (48 ref.)

CHEMISTRY

Diversity assessment. Mason JS, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):342–9 (50 ref.)
Carbonaceous micrometeorites and the origin of life. Maurette M. **Orig Life Evol Biosph** 1998 Oct; 28(4–6):385–412 (68 ref.)
Illuminating single molecules in condensed matter. Moerner WE, et al. **Science** 1999 Mar 12;283(5408):1670–6 (75 ref.)

ISOLATION & PURIFICATION

Solution–phase chemical library synthesis using polymer–assisted purification techniques. Parlow JJ, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):320–36 (65 ref.)

METABOLISM

Development of hybrid strains for the mineralization of chloroaromatics by patchwork assembly. Reineke W. **Annu Rev Microbiol** 1998;52:287–331 (182 ref.)
Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. Kamisako T, et al. **J Gastroenterol Hepatol** 1999 May;14(5):405–12 (75 ref.)

PHARMACOKINETICS

Assessment of organic contaminant fate in waste water treatment plants. I: Selected compounds and physicochemical properties. Alcock RE, et al. **Chemosphere** 1999 Apr;38(10):2247–62 (60 ref.)
Toxicokinetics of organic solvents: a review of modifying factors. Löf A, et al. **Crit Rev Toxicol** 1998 Nov; 28(6):571–650 (650 ref.)

ORGANIC FOOD see **HEALTH FOOD**

ORGANIC MENTAL DISORDERS see **DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS**

ORGANIC MENTAL DISORDERS, PSYCHOTIC see **DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS**

ORGANIC MENTAL DISORDERS, SUBSTANCE–INDUCED see **SUBSTANCE–RELATED DISORDERS**

ORGANISMS, TRANSGENIC

Genetically modified animals in pharmacological research: future trends. Rudolph U, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):327–37 (87 ref.)

ORGANIZATION AND ADMINISTRATION, HOSPITAL see **HOSPITAL ADMINISTRATION**

ORGANIZATIONAL CHANGE see **ORGANIZATIONAL INNOVATION**

ORGANIZATIONAL CULTURE

The agenda of the organization. 1: A framework. Carroll M. **Occup Med (Lond)** 1998 Sep;48(6):411–2 (4 ref.)
[When work organization becomes the source of pathologies] Gonik V. **Rev Med Suisse Romande** 1999 Jul;119(7):549–54 (12 ref.) **(Fre)**

ORGANIZATIONAL DECISION MAKING see **DECISION MAKING, ORGANIZATIONAL**

ORGANIZATIONAL EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

ORGANIZATIONAL INNOVATION

The "new VA": a national laboratory for health care quality management. Kizer KW. **Am J Med Qual** 1999 Jan–Feb; 14(1):3–20 (108 ref.)
Organizational tactics for the successful assimilation of medical practice guidelines. Sonnad SS. **Health Care Manage Rev** 1998 Summer;23(3):30–7 (15 ref.)

ORGANIZATIONAL MODELS see **MODELS, ORGANIZATIONAL**

ORGANIZATIONAL OBJECTIVES

The agenda of the organization. 2: Interventions. Carroll M. **Occup Med (Lond)** 1998 Oct;48(7):447–9 (8 ref.)

ORGANIZATIONAL POLICY

[Need to establish academic research organization for cancer clinical trial and clinical research system having clinical investigators and study coordinators, with special reference to promotion of medical and life science research policy] Shimoyama M. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):235–46 (6 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATIONS, NONPROFIT

[Medico–social management of severe respiratory insufficiency. Role of Associations] Voisin C. **Bull Acad Natl Med** 1998;182(6):1159–71; discussion 1172 (25 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Those conversion blues. Forgione DA. **J Health Care Finance** 1999 Summer;25(4):38–46 (17 ref.)

LEGISLATION & JURISPRUDENCE

Lobbying and advocacy for the public's health: what are the limits for nonprofit organizations? Vernick JS. **Am J Public Health** 1999 Sep;89(9):1425–9 (31 ref.)
Should government intervene to protect nonprofits? Bloche MG. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):7–25 (43 ref.)

ORGANOCHLORINE INSECTICIDES see **INSECTICIDES, ORGANOCHLORINE**

ORGANOGENESIS see **FETAL DEVELOPMENT**

ORGANOMETALLIC COMPOUNDS

DIAGNOSTIC USE

Contrast–enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. Bagga H, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1509–11 (7 ref.)
Gadobenate dimeglumine (Gd–BOPTA). An overview. Kirchin MA, et al. **Invest Radiol** 1998 Nov;33(11):798–809 (76 ref.)

METABOLISM

Environmental effects and exposures to manganese from use of methylcyclopentadienyl manganese tricarbonyl (MMT) in gasoline. Lynam DR, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):145–50 (40 ref.)

POISONING

Therapeutic review: do diethyldithiocarbamate and disulfiram have a role in acute nickel carbonyl poisoning? Bradberry SM, et al. **J Toxicol Clin Toxicol** 1999; 37(2):259–64 (17 ref.)

THERAPEUTIC USE

Intriguing gastrointestinal properties of bismuth: a folk remedy brought into the realm of clinical and investigative medicine. Mishkin S. **Can J Gastroenterol** 1998 Nov–Dec; 12(8):569–70 (12 ref.)
[Nuclear oncology update] Maublant J, et al. **Bull Cancer** 1999 Jan;86(1):57–64 (66 ref.) **(Fre)**

TOXICITY

Inhalation health risks of manganese: an EPA perspective. Davis JM. **Neurotoxicology** 1999 Apr–Jun;20(2–3):511–8 (40 ref.)
A brief history of the neurobehavioral toxicity of manganese: some unanswered questions. McMillan DE. **Neurotoxicology** 1999 Apr–Jun;20(2–3):499–507 (40 ref.)

ORGANOPHOSPHATE INSECTICIDE ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

ORGANOPHOSPHATE INSECTICIDES see **INSECTICIDES, ORGANOPHOSPHATE**

ORGANOPHOSPHORUS COMPOUNDS

see related
CHOLINESTERASE INHIBITORS
CHOLINESTERASE REACTIVATORS
INSECTICIDES, ORGANOPHOSPHATE

ADMINISTRATION & DOSAGE

New photosensitizers for photodynamic therapy in gastroenterology. Bown SG, et al. **Can J Gastroenterol** 1999 Jun;13(5):389–92 (28 ref.)
[Immunochemotherapy of metastatic uveal melanoma with interferon alfa–2b, interleukin–2 and fotemustine. Case reports and review of the literature] Terheyden P, et al. **Hautarzt** 1998 Oct;49(10):770–3 (23 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

99m–Tc–tetrofosmin scintigraphy and breast cancer. Berghammer P, et al. **Gynecol Oncol** 1999 Apr;73(1):87–90 (16 ref.)

METABOLISM

Fighting nerve agent chemical weapons with enzyme technology. LeJeune KE, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:153–70 (38 ref.)
Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. Masson P, et al. **J Physiol Paris** 1998 Oct–Dec; 92(5–6):357–62 (30 ref.)

PHARMACOKINETICS

Alteromonas prolidase for organophosphorus G–agent decontamination. Cheng TC, et al. **Chem Biol Interact** 1999 May 14;119–120:455–62 (12 ref.)
Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases. Maxwell DM, et al. **Chem Biol Interact** 1999 May 14;119–120:419–28 (17 ref.)
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Cundy KC. **Clin Pharmacokinet** 1999 Feb;36(2):127–43 (63 ref.)
The role of phosphotriesterases in the detoxication of organophosphorus compounds. Vilanova E, et al. **Crit Rev Toxicol** 1999 Jan;29(1):21–57 (238 ref.)

PHARMACOLOGY

Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. Zabawski EJ Jr, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):741–5 (22 ref.)
Nonpeptide antagonists for kinin receptors. Altamura M, et al. **Regul Pept** 1999 Mar 17;80(1–2):13–26 (94 ref.)

POISONING

Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. Masson P, et al. **J Physiol Paris** 1998 Oct–Dec; 92(5–6):357–62 (30 ref.)

THERAPEUTIC USE

Cidofovir in the treatment of cytomegaloviral disease. Kendle JB, et al. **Ann Pharmacother** 1998 Nov;32(11):1181–92 (92 ref.)
Cidofovir in the treatment of cytomegalovirus (CMV) retinitis. Garcia CR, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):195–203 (40 ref.)
[Nuclear oncology update] Maublant J, et al. **Bull Cancer** 1999 Jan;86(1):57–64 (66 ref.) **(Fre)**

TOXICITY

Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases. Maxwell DM, et al. **Chem Biol Interact** 1999 May 14;119–120:419–28 (17 ref.)
NTE soluble isoforms: new perspectives for targets of neuropathy inducers and promoters. Vilanova E, et al. **Chem Biol Interact** 1999 May 14;119–120:525–40 (22 ref.)
Health effects of exposure to low doses of nerve agent—a review of present knowledge. Moore DH. **Drug Chem Toxicol** 1998;21 Suppl 1:123–30 (16 ref.)
Review of health consequences from high–, intermediate– and low–level exposure to organophosphorus nerve agents. Brown MA, et al. **J Appl Toxicol** 1998 Nov–Dec; 18(6):393–408 (78 ref.)

ORGANOPLATINUM COMPOUNDS

CHEMISTRY

Structure activity studies on leaving group derivatives of [meso–1,2–bis–(2,6–dichloro–4–hydroxyphenyl) ethylenediamine] platinum(II). Gust R, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):261–70 (31 ref.)
Relationships between reduction properties and cancer cell growth inhibitory activities of cis–dichloro– and cis–diiodo–Pt(IV)–ethylenediamines. Kratochwil NA, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):279–85 (30 ref.)

PHARMACOLOGY

Oxaliplatin: a review of preclinical and clinical studies. Raymond E, et al. **Ann Oncol** 1998 Oct;9(10):1053–71 (143 ref.)

THERAPEUTIC USE

Oxaliplatin: a review of preclinical and clinical studies. Raymond E, et al. **Ann Oncol** 1998 Oct;9(10):1053–71 (143 ref.)
Oxaliplatin in ovarian cancer. Sessa C, et al. **Ann Oncol** 1999; 10 Suppl 1:55–7 (12 ref.)
Structure activity studies on leaving group derivatives of [meso–1,2–bis–(2,6–dichloro–4–hydroxyphenyl) ethylenediamine] platinum(II). Gust R, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):261–70 (31 ref.)
Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Wiseman LR, et al. **Drugs Aging** 1999 Jun;14(6):459–75 (89 ref.)
Clinical trials referral resource. Clinical trials of single–agent

ORGANOPLATINUM COMPOUNDS

oxaliplatin. Ivy SP, et al. **Oncology (Huntingt)** 1999 Jul; 13(7):966, 969–70 (0 ref.)

ORGANOSELENIUM COMPOUNDS

THERAPEUTIC USE

Selenium-based antihypertensives. Rationale and potential. May SW, et al. **Drugs** 1998 Dec;56(6):959–64 (38 ref.)

ORGANOSILICON COMPOUNDS

THERAPEUTIC USE

Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Trachtman H, et al. **Curr Opin Pediatr** 1999 Apr;11(2):162–8 (51 ref.)

ORGANOTECHNETIUM COMPOUNDS

DIAGNOSTIC USE

99m-Tc-tetrofosmin scintigraphy and breast cancer. Berghammer P, et al. **Gynecol Oncol** 1999 Apr;73(1):87–90 (16 ref.)

Technetium-99m-EC and other potential new agents in renal nuclear medicine. Moran JK. **Semin Nucl Med** 1999 Apr; 29(2):91–101 (38 ref.)

ORGANOTHIOPHOSPHATE INSECTICIDE ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

ORGANOTHIOPHOSPHATE INSECTICIDES see **INSECTICIDES, ORGANOTHIOPHOSPHATE**

ORGANOTHIOPHOSPHORUS COMPOUNDS

see related
CHOLINESTERASE INHIBITORS
CHOLINESTERASE REACTIVATORS
INSECTICIDES, ORGANOTHIOPHOSPHATE

ORGANOTIN COMPOUNDS

METABOLISM

Organotin compounds and their interactions with microorganisms. White JS, et al. **Can J Microbiol** 1999 Jul; 45(7):541–54 (86 ref.)

ORGANUM VOMERONASALE see **VOMERONASAL ORGAN**

ORGASMIC DISORDER see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

ORI REGION see **REPLICATION ORIGIN**

ORIENTAL MEDICINE, TRADITIONAL see **MEDICINE, ORIENTAL TRADITIONAL**

ORIENTAL SORE see **LEISHMANIASIS, CUTANEOUS**

ORIENTATION

Recovery from aphasia and neglect. Ferro JM, et al. **Cerebrovasc Dis** 1999;9 Suppl 5:6–22 (229 ref.)

Three-dimensional object recognition based on the combination of views. Ullman S. **Cognition** 1998 Jul; 67(1–2):21–44 (55 ref.)

Spatial orientation of the angular vestibulo-ocular reflex. Cohen B, et al. **J Vestib Res** 1999;9(3):163–72 (49 ref.)

Unilateral spatial neglect in dissociable frames of reference: a comment on Farah, Brunn, Wong, Wallace, and Carpenter (1990) [comment] Hillis AE, et al. **Neuropsychologia** 1998 Nov;36(11):1257–62 (23 ref.) Comment on: Neuropsychologia 1990;28(4):335–47.

PHYSIOLOGY

Neuroethology of spatial learning: the birds and the bees. Capaldi EA, et al. **Annu Rev Psychol** 1999;50:651–82 (216 ref.)

Topographical disorientation: a synthesis and taxonomy. Aguirre GK, et al. **Brain** 1999 Sep;122 (Pt 9):1613–28 (95 ref.)

Perception of spatial orientation in microgravity. Glasauer S, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):185–93 (34 ref.)

The effect of gravity on human recognition of disoriented objects. Leone G. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):203–14 (113 ref.)

Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Reschke MF, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):102–17 (189 ref.)

Motion sickness and development of synergy within the spatial orientation system. A hypothetical unifying concept. Guedry FE, et al. **Brain Res Bull** 1998 Nov 15;47(5):475–80 (60 ref.)

Cortical populations and behaviour: Hebb's thread. Amirikian B, et al. **Can J Exp Psychol** 1999 Mar;53(1):21–34 (55 ref.)

Evidence accumulation in cell populations responsive to faces: an account of generalisation of recognition without mental transformations. Perrett DI, et al. **Cognition** 1998 Jul;67(1–2):111–45 (105 ref.)

Orientation in the dark: brain circuits involved in the perception of electric signals in mormyrid electric fish. von der Emde G. **Eur J Morphol** 1999 Apr;37(2–3):200–5 (21 ref.)

A theory of geometric constraints on neural activity for natural three-dimensional movement. Zhang K, et al. **J Neurosci** 1999 Apr 15;19(8):3122–45 (124 ref.)

Use of image-based information in judgments of surface-reflectance properties. Nishida S, et al. **J Opt Soc Am A Opt Image Sci Vis** 1998 Dec; 15(12):2951–65 (65 ref.)

A new view on grasping [see comments] Smeets JB, et al. **Motor Control** 1999 Jul;3(3):237–71 (86 ref.) Comment in: Motor Control 1999 Jul;3(3):272–5; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):276–9; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):280–4; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):285–8; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):289–97; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):298–301; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):302–6; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):307–11; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):312–5; discussion 316–25.

Vectors, routes and maps: new discoveries about navigation in insects. Giurfa M, et al. **Trends Neurosci** 1999 Jun; 22(6):237–42 (44 ref.)

ORIENTATION PROGRAMS, EMPLOYEE see **INSERVICE TRAINING**

ORIGIN OF LIFE see **BIOGENESIS**

ORIGIN OF REPLICATION see **REPLICATION ORIGIN**

ORMOND DISEASE see **RETROPERITONEAL FIBROSIS**

ORNITHINE

ANALOGS & DERIVATIVES

PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Rosowsky A. **Curr Med Chem** 1999 Apr;6(4):329–52 (30 ref.)

Ornithine alpha-ketoglutarate: the puzzle. Le Boucher J, et al. **Nutrition** 1998 Nov-Dec;14(11–12):870–3 (38 ref.)

ORNITHINE CARBAMOYLTRANSFERASE

DEFICIENCY

Evidence for a central cholinergic deficit in congenital ornithine transcarbamylase deficiency. Butterworth RF. **Dev Neurosci** 1998;20(4–5):478–84 (53 ref.)

Treatment of urea cycle disorders [editorial; comment] Thoene JG. **J Pediatr** 1999 Mar;134(3):255–6 (8 ref.) Comment on: J Pediatr 1999 Mar;134(3):268–72.

ORNITHINE CARBOXY-LYASE see **ORNITHINE DECARBOXYLASE**

ORNITHINE DECARBOXYLASE

ANTAGONISTS & INHIBITORS

Antizyme modifications affecting polyamine homoeostasis. Mitchell JL, et al. **Biochem Soc Trans** 1998 Nov;26(4):591–5 (29 ref.)

GENETICS

Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Shantz LM, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):107–22 (113 ref.)

METABOLISM

Regulation of mammalian ornithine decarboxylase. Persson L, et al. **Biochem Soc Trans** 1998 Nov;26(4):575–9 (50 ref.)

Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Shantz LM, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):107–22 (113 ref.)

The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Bernstein HG, et al. **Prog Neurobiol** 1999 Apr;57(5):485–505 (185 ref.)

ORNITHINE TRANSCARBAMYLASE see **ORNITHINE CARBAMOYLTRANSFERASE**

ORNITHOSIS

[Psittacosis] Katayama M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):226–9 (13 ref.) **(Jpn)**

VETERINARY

Compendium of chlamydiosis (psittacosis) control, 1999. Psittacosis Compendium Committee, National Association of State Public Health Veterinarians. Johnston WB, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):640–6 (10 ref.)

OROPHARYNGEAL NEOPLASMS

Oral and oropharyngeal squamous cell carcinoma in young adults: a report on 13 cases and review of the literature. Hart AK, et al. **Otolaryngol Head Neck Surg** 1999 Jun; 120(6):828–33 (24 ref.)

DIAGNOSIS

Squamous cell carcinoma of the oropharynx and oral cavity: how imaging makes a difference. Mukherji SK, et al. **Semin Ultrasound CT MR** 1998 Dec;19(6):463–75 (19 ref.)

EPIDEMIOLOGY

A qualitative and quantitative risk assessment of snuff dipping [published erratum appears in Regul Toxicol Pharmacol 1999 Feb;29(1):97] Nilsson R. **Regul Toxicol Pharmacol** 1998 Aug;28(1):1–16 (112 ref.)

PATHOLOGY

[Malignant tumors of the mouth cavity and oropharynx. Stage classification] Youssefzadeh S, et al. **Radiologe** 1999 Jul;39(7):513–24 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Standards, options and recommendations (SOR) for clinical care of squamous cell carcinoma of the oropharynx. Groupe de travail SOR] Renaud-Salis JL, et al. **Bull Cancer** 1999 Jun;86(6):550–72 (84 ref.) (Eng. Abstr.) **(Fre)**

OROPHARYNX

Management of ingested foreign bodies in childhood: our experience and review of the literature. Hachimi-Idrissi S, et al. **Eur J Emerg Med** 1998 Sep;5(3):319–23 (20 ref.)

Functional outcome assessment of adults with oropharyngeal dysphagia. McHorney CA, et al. **Semin Speech Lang** 1998; 19(3):235–46; quiz 247 (69 ref.)

[Cancer of the rhinopharynx and the oropharynx. Epidemiology, diagnosis, complications a long time after treatment] Dehesdin D, et al. **Rev Prat** 1998 Mar 15; 48(6):667–74 (00 ref.) **(Fre)**

PHYSIOLOGY

Some new developments in the understanding of oropharyngeal and postingestional controls of meal size. Davis JD. **Nutrition** 1999 Jan;15(1):32–9 (62 ref.)

PHYSIOPATHOLOGY

AGA technical review on management of oropharyngeal dysphagia. Cook IJ, et al. **Gastroenterology** 1999 Feb; 116(2):455–78 (197 ref.)

SURGERY

Oropharyngeal surgery in the management of upper airway obstruction during sleep. Coleman J, et al. **Otolaryngol Clin North Am** 1999 Apr;32(2):263–76 (33 ref.)

OROTIC ACID

METABOLISM

Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleotide synthesis: studies with ribose, adenine, inosine, and orotic acid in rats. Zimmer HG. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:179–87 (41 ref.)

OROYA FEVER see **BARTONELLA INFECTIONS**

ORPHANAGES

AIDS hospices and orphanages. Martin T. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S21–5 (25 ref.)

ORTHO-DIHYDROXYBENZENES see **CATECHOLS**

ORTHODONTIC APPLIANCE DESIGN

A reexamination of various extraoral appliances in light of recent research findings. Braun S, et al. **Angle Orthod** 1999 Feb;69(1):81–4 (14 ref.)

Rare earth magnets in orthodontics: an overview. Noar JH, et al. **Br J Orthod** 1999 Mar;26(1):29–37 (51 ref.)

ORTHODONTIC APPLIANCES

see related
DENTAL BONDING

Rare earth magnets in orthodontics: an overview. Noar JH, et al. **Br J Orthod** 1999 Mar;26(1):29–37 (51 ref.)

New frontiers in the management of obstructive sleep apnoea syndrome. Krieger J. **Monaldi Arch Chest Dis** 1998 Oct; 53(5):515–9 (29 ref.)

ADVERSE EFFECTS

Patients' anticipation of pain and pain-related side effects, and their perception of pain as a result of orthodontic treatment with fixed appliances. Firestone AR, et al. **Eur J Orthod** 1999 Aug;21(4):387–96 (38 ref.)

Sensory and motor changes of the human jaw muscles during induced orthodontic pain. Michelotti A, et al. **Eur J Orthod** 1999 Aug;21(4):397–404 (37 ref.)

ORTHODONTIC RETAINERS

Tooth stabilization for orthodontic retention. Josell SD. **Dent Clin North Am** 1999 Jan;43(1):151–65, vii (43 ref.)

ORTHODONTICS, CORRECTIVE

Half nose with ipsilateral eye and ear anomalies and facial asymmetry: report of a case with cephalometric analysis and orthodontic treatment. Motohashi N, et al. **Cleft Palate Craniofac J** 1999 Jul;36(4):353–60 (13 ref.)

Tooth stabilization for orthodontic retention. Josell SD. **Dent Clin North Am** 1999 Jan;43(1):151–65, vii (43 ref.)

Evidence-based care in orthodontics and periodontics: a review of the literature. Sanders NL. **J Am Dent Assoc** 1999 Apr;130(4):521–7 (103 ref.)

Current knowledge in cleft lip and palate treatment from an orthodontist's point of view. Friede H, et al. **J Orofac Orthop** 1998;59(6):313–30 (88 ref.) **(Eng, Ger)**

ADVERSE EFFECTS

Temporomandibular disorders and mandibular function in relation to Class II malocclusion and orthodontic treatment. A controlled, prospective and longitudinal study. Henrikson T. **Swed Dent J Suppl** 1999;134:1–144 (131 ref.)

METHODS

Third molars: a dilemma! Or is it? Bishara SE. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):628–33 (30 ref.)

The spheno-occipital synchondrosis: the missing link between the profession's concept of craniofacial growth and orthodontic treatment. Coben SE. **Am J Orthod Dentofacial Orthop** 1998 Dec;114(6):709–12; discussion 713–4 (31 ref.)

More than lip service: facial esthetics in orthodontics. Bowman SJ. **J Am Dent Assoc** 1999 Aug;130(8):1173–81 (87 ref.)

ORTHODONTICS, INTERCEPTIVE

Clinical aspects of orthodontic treatment for children with juvenile chronic arthritis. Pedersen TK. **Acta Odontol Scand** 1998 Dec;56(6):366–8 (32 ref.)

ORTHOMYXOVIRIDAE

[Influenza viruses and their receptor sugar recognition] Suzuki Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2559–66 (33 ref.) **(Jpn)**

CHEMISTRY

Structural intermediates in influenza haemagglutinin-mediated fusion. Chernomordik LV, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):33–42 (53 ref.)

CLASSIFICATION

The diagnosis and management of influenza. An update. Sintchenko V, et al. **Aust Fam Physician** 1999 Apr; 28(4):313–7 (13 ref.)

DRUG EFFECTS

Neuraminidase inhibitors as anti-influenza virus agents. Kim CU, et al. **Antivir Chem Chemother** 1999 Jul;10(4):141–54 (56 ref.)

PATHOGENICITY

Understanding influenza virus pathogenicity. Garten W, et al. **Trends Microbiol** 1999 Mar;7(3):99–100 (16 ref.)

Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Steinhauer DA. **Virology** 1999 May 25; 258(1):1–20 (240 ref.)

ORTHOMYXOVIRUS TYPE A see **INFLUENZA A VIRUS**

ORTHOMYXOVIRUS TYPE A, AVIAN see **INFLUENZA A VIRUS, AVIAN**

ORTHOMYXOVIRUS TYPE A, HUMAN see **INFLUENZA A VIRUS, HUMAN**

ORTHOMYXOVIRUS TYPE A, PORCINE see **INFLUENZA A VIRUS, PORCINE**

ORTHOMYXOVIRUSES TYPE B see **INFLUENZA B VIRUS**

ORTHOPANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

ORTHOPEDIC EQUIPMENT

ADVERSE EFFECTS

Erectile dysfunction induced by orthopedic trauma managed with a fracture table: a case report and review of the literature. Chan PT, et al. **J Trauma** 1999 Jul;47(1):183–5 (22 ref.)

ORTHOPEDIC FIXATION DEVICES

Orthopaedic applications for PLA-PGA biodegradable polymers. Athanasiou KA, et al. **Arthroscopy** 1998 Oct; 14(7):726–37 (95 ref.)

Composite technology in load-bearing orthopaedic implants. Evans SL, et al. **Biomaterials** 1998 Aug;19(15):1329–42 (84 ref.)

[Ankle orthotic devices. Review, areas of application and scientific results] Rosenbaum D, et al. **Orthopade** 1999 Jun; 28(6):559–64 (40 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Applications of computer modelling for the design of orthopaedic, dental and cardiovascular biomaterials. Vander Sloten J, et al. **Proc Inst Mech Eng [H]** 1998; 212(6):489–500 (90 ref.)

ORTHOPEDIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

ORTHOPEDIC NURSING

Pregnancy in women with spinal cord injuries. Atterbury JL, et al. **Nurs Clin North Am** 1998 Dec;33(4):603–13 (52 ref.)

Companion animals: social support for orthopedic clients. Carmack BJ. **Nurs Clin North Am** 1998 Dec;33(4):701–11 (59 ref.)

Laboratory tests and diagnostic procedures in orthopedic nursing practice. Corbett JV. **Nurs Clin North Am** 1998 Dec;33(4):685–700 (16 ref.)

Prevention of infection in the orthopedic surgery patient. DeBaun BJ. **Nurs Clin North Am** 1998 Dec;33(4):671–84 (93 ref.)

Biomedical and feminist perspectives on low back pain during pregnancy. DeJoseph JF, et al. **Nurs Clin North Am** 1998 Dec;33(4):713–24 (31 ref.)

Common orthopedic problems of the newborn. Fernbach SA. **Nurs Clin North Am** 1998 Dec;33(4):583–94 (60 ref.)

Osteoporosis in women. Goss GL. **Nurs Clin North Am** 1998 Dec;33(4):573–82 (30 ref.)

Rheumatoid arthritis: a case study. Hartzheim LA, et al. **Nurs Clin North Am** 1998 Dec;33(4):595–602 (20 ref.)

Physical assessment of the musculoskeletal system. Mangini M. **Nurs Clin North Am** 1998 Dec;33(4):643–52 (21 ref.)

Considerations for the orthopedic nurse in diagnosis and treatment of adolescent sports injuries. Randolph CL. **Nurs Clin North Am** 1998 Dec;33(4):615–28 (43 ref.)

Fibromyalgia syndrome. Smith WA. **Nurs Clin North Am** 1998 Dec;33(4):653–69 (75 ref.)

Preventing amputations in the diabetic population. Spollett GR. **Nurs Clin North Am** 1998 Dec;33(4):629–41 (44 ref.)

ORTHOPEDIC PROCEDURES

see related
ORTHOPEDICS

Frostbite: an orthopedic perspective. McAdams TR, et al. **Am J Orthop** 1999 Jan;28(1):21–6 (44 ref.)

Global blood management in orthopaedic surgery. Sculco TP. **Clin Orthop** 1998 Dec;(357):43–9 (31 ref.)

Outcomes assessment in the information age: available instruments, data collection, and utilization of data. Simmons BP, et al. **Instr Course Lect** 1999;48:667–85 (93 ref.)

Neurofibromatosis in children: the role of the orthopaedist. Crawford AH, et al. **J Am Acad Orthop Surg** 1999 Jul-Aug; 7(4):217–30 (63 ref.)

Management of hallux amputation. Levine SE, et al. **Orthopedics** 1999 Mar;22(3):330–3; quiz 334–5 (24 ref.)

Rapid prototyping for orthopaedic surgery. Potamianos P, et al. **Proc Inst Mech Eng [H]** 1998;212(5):383–93 (22 ref.)

[Guidelines for prevention of thrombosis in orthopedics] Pauschert R, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep-Oct; 136(5):471–9 (62 ref.) (Eng. Abstr.) **(Ger)**

[Rheumoorthopedics as an integral part of complex therapy of rheumatic diseases with joint involvement] Pavlov VP. **Vestn Ross Akad Med Nauk** 1998;(12):47–9 (11 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

Open surgical treatment of anterior glenohumeral instability: an historical perspective and review of the literature. Part II. Rokito AS, et al. **Am J Orthop** 1998 Dec;27(12):784–90 (60 ref.)

Open surgical treatment of anterior glenohumeral instability: an historical perspective and review of the literature. Part I. Rokito AS, et al. **Am J Orthop** 1998 Nov;27(11):723–5 (0 ref.)

INSTRUMENTATION

[Indication for and performance of articular cartilage drilling using the Pridie method] Müller B, et al. **Orthopade** 1999 Jan;28(1):4–10 (46 ref.) (Eng. Abstr.) **(Ger)**

METHODS

A new technique for removing noncemented acetabular components in revision total hip arthroplasty. Markovich GD, et al. **Am J Orthop** 1999 Jan;28(1):35–7 (10 ref.)

Articular cartilage lesions of the knee. Mandelbaum BR, et al. **Am J Sports Med** 1998 Nov-Dec;26(6):853–61 (53 ref.)

Arthroscopy of the great toe. Frey C, et al. **Instr Course Lect** 1999;48:343–6 (4 ref.)

Normalization of the coronal and sagittal profile in idiopathic scoliosis: options of treatment. Bridwell KH. **J Orthop Sci** 1998;3(2):125–34 (16 ref.)

Chronic slipped capital femoral epiphysis: treatment by pinning in situ. Givon U, et al. **J Pediatr Orthop B** 1999 Jul;8(3):216–22 (75 ref.)

Transverse subgluteal-ilioinguinal approach to the acetabulum. Amr S. **Microsurgery** 1998;18(7):432–41 (65 ref.)

TRENDS

Orthopaedics. Sadasivan KK. **J Am Coll Surg** 1999 Feb; 188(2):143–6 (23 ref.)

[Prophylactic surgery of the musculoskeletal system] Kreklau B, et al. **Chirurg** 1999 Apr;70(4):364–72 (30 ref.) (Eng. Abstr.) **(Ger)**

[The diabetic foot—state of the art from the orthopedic point of view] Schaefer D. **Schweiz Rundsch Med Prax** 1999 Jul 8;88(27-28):1196–9 (2 ref.) (Eng. Abstr.) **(Ger)**

ORTHOPEDIC SURGERY see **ORTHOPEDICS**

ORTHOPEDICS

see related
ORTHOPEDIC PROCEDURES

Prevention of osteoporotic fractures—should orthopedic surgeons care? Obrant KJ. **Acta Orthop Scand** 1998 Aug; 69(4):333–8 (39 ref.)

Future potentials for using osteogenic stem cells and biomaterials in orthopedics. Oreffo RO, et al. **Bone** 1999 Aug;25(2 Suppl):5S–9S (58 ref.)

Minorities and the orthopaedic profession. Ayers CE. **Clin Orthop** 1999 May;(362):58–64 (56 ref.)

Management of equinus contractures of the ankle in haemophilia. Ribbans WJ, et al. **Haemophilia** 1999 Mar;5 Suppl 1:46–52 (22 ref.)

Companion animals: social support for orthopedic clients. Carmack BJ. **Nurs Clin North Am** 1998 Dec;33(4):701–11 (59 ref.)

Prevention of infection in the orthopedic surgery patient. DeBaun BJ. **Nurs Clin North Am** 1998 Dec;33(4):671–84 (93 ref.)

The utility and prediction of allogeneic blood transfusion use in orthopedic surgery. Larocque B, et al. **Transfus Med Rev** 1999 Apr;13(2):124–31 (45 ref.)

[Low back pain: diagnosis and conservative therapy from the orthopedic viewpoint] Tilscher H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):795–8 (5 ref.) **(Ger)**

[Documentation. A prerequisite for quality management] Krämer KL. **Orthopade** 1999 Mar;28(3):191–200 (59 ref.) (Eng. Abstr.) **(Ger)**

[Extracorporeal shockwave therapy (ESWT) in orthopedic indications: a selective review] Fritze J. **Versicherungsmedizin** 1998 Oct 1;50(5):180–5 (51 ref.) (Eng. Abstr.) **(Ger)**

[Prevention and treatment of infections in orthopedic surgery. The role of antibiotic-loaded cements] Manfredi R, et al. **Recenti Prog Med** 1999 Jul-Aug;90(7–8):425–9 (45 ref.) **(Ita)**

EDUCATION

[Pain therapy in orthopedics—a contribution to the discussion on reformulating the order of continuing education] Schiltenwolf M. **Z Orthop Ihre Grenzgeb** 1999 Jan-Feb; 137(1):Oa10–2 (41 ref.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Medical malpractice: defending yourself. Yablon IG. **Instr Course Lect** 1999;48:699–703 (14 ref.)

[Legal grounds for patient information in orthopedics] Bergmann KO. **Orthopade** 1998 Oct;27(10):705–12 (69 ref.) **(Ger)**

MANPOWER

Is the orthopedic generalist moving toward extinction? Goldner JL, et al. **Am J Orthop** 1999 Jul;28(7):389–96 (16 ref.)

ORTHOPEDICS

METHODS

Current options and approaches for blood management in orthopaedic surgery. Keating EM. **Instr Course Lect** 1999; 48:655–65 (129 ref.)

The use of low-frequency vibration measurement in orthopaedics. Nokes LD. **Proc Inst Mech Eng [H]** 1999; 213(3):271–90 (88 ref.)

The use of ultrasonics in orthopaedics--a review. Maylia E, et al. **Technol Health Care** 1999;7(1):1–28 (24 ref.)

[Rheumoorthopedics as an integral part of complex therapy of rheumatic diseases with joint involvement] Pavlov VP. **Vestn Ross Akad Med Nauk** 1998;(12):47–9 (11 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

The bone and joint decade 2000–2010 for prevention and treatment of musculo-skeletal disorders. Lund, Sweden, April 17–18, 1998. Proceedings. **Acta Orthop Scand Suppl** 1998 Jun;281:1–86 (0 ref.)

TRENDS

Orthopaedics. Sadasivan KK. **J Am Coll Surg** 1999 Feb; 188(2):143–6 (23 ref.)

Hand care in the new millennium: surgeon's perspective. McAuliffe JA. **J Hand Ther** 1999 Apr–Jun;12(2):178–81 (12 ref.)

Quo vadis? The future of basic research in orthopedics in Japan [editorial] Hirotani H. **J Orthop Sci** 1999;4(1):1–4 (16 ref.)

[Relevance of life sciences for traumatologic and orthopedic surgery] Hanselmann R, et al. **Unfallchirurg** 1999 Apr; 102(4):250–66 (48 ref.) (Eng. Abstr.) **(Ger)**

ORTHOPSYCHIATRY

see related
MENTAL HEALTH

ORTHOSES see **ORTHOTIC DEVICES**

ORTHOSIS see **ORTHOTIC DEVICES**

ORTHOTIC DEVICES

Orthoses used in the management of neurologic and muscular disorders. McGuire JB. **Clin Podiatr Med Surg** 1999 Jan; 16(1):153–74 (10 ref.)

Conservative management of posterior tibial tendon dysfunction, subtalar joint complex, and pes planus deformity. Steb HS, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):439–51 (7 ref.)

Current concepts in myelomeningocele. Drennan JC. **Instr Course Lect** 1999;48:543–50 (20 ref.)

Orthoses in the treatment of rearfoot problems. Sobel E, et al. **J Am Podiatr Med Assoc** 1999 May;89(5):220–33 (151 ref.)

Shoe inserts and orthotics for sport and physical activities. Nigg BM, et al. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S421–8 (61 ref.)

Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. McDonald CM. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):187–211 (67 ref.)

A review of reciprocal walking systems for paraplegic patients: factors affecting choice and economic justification. Stallard J, et al. **Prosthet Orthot Int** 1998 Dec;22(3):240–7 (45 ref.)

[Ankle orthotic devices. Review, areas of application and scientific results] Rosenbaum D, et al. **Orthopade** 1999 Jun; 28(6):559–64 (40 ref.) (Eng. Abstr.) **(Ger)**

[Technical orthopedic therapy of diabetic foot] Stinus H. **Zentralbl Chir** 1999;124 Suppl 1:65–8 (13 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Asymptomatic brain abscess as a complication of halo orthosis: report of a case and review of the literature. Kameyama O, et al. **J Orthop Sci** 1999;4(1):39–41 (13 ref.)

ORYCTES VIRUSES see **BACULOVIRIDAE**

ORYZA see **RICE**

ORYZAVIRUS see **REOVIRIDAE**

ORYZIAS

[Regional group, the inbred strains, and the mutational strains of medaka] Wakamatsu Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1487–91 (5 ref.) **(Jpn)**

GENETICS

Molecular genetics of the complement C3 convertases in lower vertebrates. Nonaka M, et al. **Immunol Rev** 1998 Dec;166:59–65 (50 ref.)

ORYZOMYS see **HESPEROMYINAE**

OS TRIGONUM see **TALUS**

OSCILLATORS, ENDOGENOUS see **BIOLOGICAL CLOCKS**

OSCILLOMETRY

METHODS

[Measurement of resistance by the forced oscillation technique] Delacourt C. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S164–6 (11 ref.) **(Fre)**

OSGOOD-SCHLATTER DISEASE see **OSTEOCHONDRITIS**

OSLER-RENDU DISEASE see **TELANGIECTASIA, HEREDITARY HEMORRHAGIC**

OSLER-VAQUEZ DISEASE see **POLYCYTHEMIA VERA**

OSMIC ACID see **OSMIUM TETROXIDE**

OSMIUM TETROXIDE

Enzymatic and chemical cleavage methods. Taylor GR. **Electrophoresis** 1999 Jun;20(6):1125–30 (32 ref.)

THERAPEUTIC USE

Treatment of acute and chronic synovitis by non-surgical means. Fernandez-Palazzi F. **Haemophilia** 1998 Jul; 4(4):518–23 (21 ref.)

OSMOLALITY see **OSMOLAR CONCENTRATION**

OSMOLAR CONCENTRATION

Gene regulation by extracellular calcium, vitamin D and osmolarity. Okazaki T. **Endocr J** 1999 Feb;46(1):1–9 (53 ref.)

Regulation of compatible solute accumulation in bacteria. Poolman B, et al. **Mol Microbiol** 1998 Jul;29(2):397–407 (65 ref.)

OSMOLARITY see **OSMOLAR CONCENTRATION**

OSMOREGULATION see **WATER-ELECTROLYTE BALANCE**

OSMOSIS

PHYSIOLOGY

Bioenergetic aspects of halophilism. Oren A. **Microbiol Mol Biol Rev** 1999 Jun;63(2):334–48 (142 ref.)

OSMOTIC DIURETICS see **DIURETICS, OSMOTIC**

OSMOTIC FRAGILITY

[Osmotic fragility test of erythrocytes with a coil planet centrifuge] Kogawa H, et al. **C R Seances Soc Biol Fil** 1998;192(5):997–1006 (34 ref.) (Eng. Abstr.) **(Fre)**

OSMOTIC PRESSURE

Osmotic induction of signaling cascades: role in regulation of cell function. Häussinger D, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):551–5 (78 ref.)

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34–49 (78 ref.)

Intracellular signaling in response to osmotic stress. Kültz D, et al. **Contrib Nephrol** 1998;123:94–109 (70 ref.)

Managing hypoosmotic stress: aquaporins and mechanosensitive channels in Escherichia coli. Booth IR, et al. **Curr Opin Microbiol** 1999 Apr;2(2):166–9 (24 ref.)

Evolution of osmotic stress signaling via MAP kinase cascades. Kütz D, et al. **J Exp Biol** 1998 Nov;201 (Pt 22):3015–21 (37 ref.)

[Variants of hyperosmolarity syndrome in diabetes mellitus patients in critical conditions] Ruiatkina LA, et al. **Klin Med (Mosk)** 1998;76(9):37–43 (24 ref.) (Eng. Abstr.) **(Rus)**

OSMOTIC SHOCK see **OSMOTIC PRESSURE**

OSSEOINTEGRATED DENTAL IMPLANTATION see **DENTAL IMPLANTATION, ENDOSSEOUS**

OSSEOINTEGRATION

see related
ARTHROPLASTY
BONE SUBSTITUTES
DENTAL IMPLANTATION, ENDOSSEOUS
HIP PROSTHESIS

Implant fixation by bone ingrowth. Kienapfel H, et al. **J Arthroplasty** 1999 Apr;14(3):355–68 (146 ref.)

Biologic determinants of bone formation for osseointegration: clues for future clinical improvements. Cooper LF. **J Prosthet Dent** 1998 Oct;80(4):439–49 (87 ref.)

[The osseointegration process: a still open chapter in experimental and clinical research] Guzzardella GA, et al. **Acta Biomed Ateneo Parmense** 1996;67(1–2):55–60 (23 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

A review of nondestructive test methods and their application to measure the stability and osseointegration of bone anchored endosseous implants. Meredith N. **Crit Rev Biomed Eng** 1998;26(4):275–91 (35 ref.)

Proteoglycans at the bone–implant interface. Klinger MM, et al. **Crit Rev Oral Biol Med** 1998;9(4):449–63 (107 ref.)

OSSICULAR PROSTHESIS

see related
OSSICULAR REPLACEMENT

OSSICULAR PROSTHESIS IMPLANTATION see **OSSICULAR REPLACEMENT**

OSSICULAR REPLACEMENT

METHODS

Partial ossicular reconstruction in children: a review of 62 operations. Daniels RL, et al. **Laryngoscope** 1998 Nov; 108(11 Pt 1):1674–81 (24 ref.)

OSSIFICATION, HETEROTOPIC

see related
SYNOSTOSIS

Extensive arachnoid ossification with associated syringomyelia presenting as thoracic myelopathy. Case report and review of the literature. Slavin KV, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):223–9 (63 ref.)

COMPLICATIONS

Osseous metaplasia in caecal adenocarcinoma. Papadopoulos MC, et al. **J R Soc Med** 1998 Aug;91(8):434–5 (9 ref.)

Spinal cord compression caused by unusual location and extension of ossified ligamenta flava in a Caucasian male. A case report and literature review. van Oostenbrugge RJ, et al. **Spine** 1999 Mar 1;24(5):486–8 (21 ref.)

DIAGNOSIS

An accessory ossification centre in the calcaneus with talonavicular and second metatarsocuneiform coalitions. Turhan AU, et al. **Eur Radiol** 1999;9(3):481–2 (4 ref.)

ETIOLOGY

Current therapy in the management of heterotopic ossification of the elbow: a review with case studies. Ellerin BE, et al. **Am J Phys Med Rehabil** 1999 May–Jun; 78(3):259–71 (32 ref.)

Heterotopic ossification of soft tissue: a review with emphasis on ossification within abdominal surgical scars. Gaffey MJ, et al. **Anat Pathol** 1998;3:195–208 (52 ref.)

Heterotopic bone formation after joint replacement. Nilsson OS, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):127–31 (39 ref.)

Heterotopic bone formation in association with pelvic fracture and urethral disruption. Zagaja GP, et al. **J Urol** 1999 Jun;161(6):1950–3 (19 ref.)

PATHOLOGY

Heterotopic ossification of soft tissue: a review with emphasis on ossification within abdominal surgical scars. Gaffey MJ, et al. **Anat Pathol** 1998;3:195–208 (52 ref.)

Osteo-nevus of Nanta: a case report and review of the Japanese literature. Sasaki S, et al. **J Dermatol** 1999 Mar; 26(3):183–8 (32 ref.)

[Bone neogenesis in a rare space-occupying lesion of the inner ear canal] Relic A, et al. **HNO** 1999 Jun;47(6):563–8 (39 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[External radiotherapy or non-steroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement] Zouhair A, et al. **Schweiz Med Wochenschr** 1999 Mar 6;129(9):370–6 (41 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

The syndrome of elongated styloid process. Ghosh LM, et al. **Auris Nasus Larynx** 1999 Apr;26(2):169–75 (28 ref.)

[Idiopathic pulmonary ossification] Friedrich T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):267–73 (29 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Radiation therapy for heterotopic ossification. Lo TC. **Semin Radiat Oncol** 1999 Apr;9(2):163–70 (72 ref.)

[External radiotherapy or non-steroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement] Zouhair A, et al. **Schweiz Med Wochenschr** 1999 Mar 6;129(9):370–6 (41 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Ossification of transverse ligament of the atlas associated with atlanto-axial dislocation--case report. Hayashi T, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):425-8 (18 ref.)

THERAPY

Current therapy in the management of heterotopic ossification of the elbow: a review with case studies. Ellerin BE, et al. **Am J Phys Med Rehabil** 1999 May-Jun; 78(3):259-71 (32 ref.)

OSSIFICATION OF POSTERIOR LONGITUDINAL LIGAMENT

PATHOLOGY

Pathology of ossification of the posterior longitudinal ligament and ligamentum flavum. Ono K, et al. **Clin Orthop** 1999 Feb;(359):18-26 (27 ref.)

SURGERY

Expansive laminoplasty for myelopathy in ossification of the longitudinal ligament. Hirabayashi K, et al. **Clin Orthop** 1999 Feb;(359):35-48 (100 ref.)

OSSIFICATION, PATHOLOGIC see **OSSIFICATION, HETEROTOPIC**

OSSIFICATION, PHYSIOLOGIC see **OSTEOGENESIS**

OSTEITIS

DIAGNOSIS

Osteitis pubis: a diagnosis for the family physician. Andrews SK, et al. **J Am Board Fam Pract** 1998 Jul-Aug;11(4):291-5 (16 ref.)

[SAPHO syndrome and aseptic osteitis] Cotten A, et al. **Ann Radiol (Paris)** 1997;40(3):189-96 (29 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

The SAPHO syndrome in children: a rare cause of hyperostosis and osteitis. Letts M, et al. **J Pediatr Orthop** 1999 May-Jun;19(3):297-300 (21 ref.)

OSTEITIS DEFORMANS

COMPLICATIONS

Paget's disease of bone: rheumatologic complications. Altman RD. **Bone** 1999 May;24(5 Suppl):47S-48S (6 ref.)

Severe orthopaedic complications of Paget's disease. Kaplan FS. **Bone** 1999 May;24(5 Suppl):43S-46S (21 ref.)

DIAGNOSIS

[Paget's disease of the bones: diagnosis and treatment] Jacobs JW, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3; 143(14):719-25 (37 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Prediction and assessment of the response of Paget's disease to bisphosphonate treatment. Hosking DJ. **Bone** 1999 May; 24(5 Suppl):69S-71S (13 ref.)

Calcitonin, an update. Martin TJ. **Bone** 1999 May;24(5 Suppl):63S-65S (16 ref.)

The use of risedronate in Paget's disease. Miller PD. **Bone** 1999 May;24(5 Suppl):91S-92S (2 ref.)

Pamidronate in the treatment of Paget's disease. Selby PL. **Bone** 1999 May;24(5 Suppl):57S-58S (14 ref.)

[Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis] Chapurlat R, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(8):743-51 (54 ref.) (Eng. Abstr.) **(Fre)**

[Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders] Raue F. **Internist (Berl)** 1999 Apr;40(4):448-55 (61 ref.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of Paget's disease of bone. Cooper C, et al. **Bone** 1999 May;24(5 Suppl):3S-5S (15 ref.)

Paget's disease of bone: a review of 889 patients. Davie M, et al. **Bone** 1999 May;24(5 Suppl):11S-12S (0 ref.)

ETHNOLOGY

Paget's disease of the tibia. Wang CL, et al. **J Formos Med Assoc** 1999 Jun;98(6):444-7 (17 ref.)

GENETICS

Paget's disease from a genetic perspective. Van Hul W. **Bone** 1999 May;24(5 Suppl):29S-30S (24 ref.)

METABOLISM

Biochemical markers of bone turnover in Paget's disease of bone. Eastell R. **Bone** 1999 May;24(5 Suppl):49S-50S (9 ref.)

Cellular and molecular regulation of bone turnover. Mundy GR. **Bone** 1999 May;24(5 Suppl):35S-38S (37 ref.)

Mechanisms of abnormal bone turnover in Paget's disease. Roodman GD. **Bone** 1999 May;24(5 Suppl):39S-40S (10 ref.)

MICROBIOLOGY

Mouth bacteria as the cause of Paget's disease of bone. Dickinson CJ. **Med Hypotheses** 1999 Mar;52(3):209-12 (41 ref.)

NURSING

Caring for the patient with Paget's disease of the bone. Lewis T, et al. **Nurse Pract** 1999 Jul;24(7):50, 53, 57-8 passim (25 ref.)

THERAPY

Paget's disease of bone: treatment philosophy for the twenty-first century. Siris ES. **Bone** 1999 May;24(5 Suppl):55S-56S (5 ref.)

[Paget's disease of the bones: diagnosis and treatment] Jacobs JW, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3; 143(14):719-25 (37 ref.) (Eng. Abstr.) **(Dut)**

VIROLOGY

Paramyxoviruses and Paget's disease: the affirmative view. Mee AP. **Bone** 1999 May;24(5 Suppl):19S-21S (20 ref.)

Are paramyxoviruses involved in Paget's disease? A negative view. Ralston SH, et al. **Bone** 1999 May;24(5 Suppl):17S-18S (19 ref.)

Paramyxoviruses and chronic human diseases. Rima BK. **Bone** 1999 May;24(5 Suppl):23S-26S (16 ref.)

OSTEITIS FIBROSA DISSEMINATA see **FIBROUS DYSPLASIA OF BONE**

OSTEOARTHRITIS

Ankle osteoarthritis: distinctive characteristics. Buckwalter JA, et al. **Instr Course Lect** 1999;48:233-41 (48 ref.)

Immunohistochemistry in the study of normal and osteoarthritic articular cartilage. Ostergaard K, et al. **Prog Histochem Cytochem** 1998;33(2):93-165 (377 ref.)

BLOOD

Serum markers of articular cartilage damage and repair. Wollheim FA. **Rheum Dis Clin North Am** 1999 May; 25(2):417-32, viii (94 ref.)

CHEMICALLY INDUCED

Glenohumeral osteoarthritis following a "color test" during rotator cuff repair. A case report and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998; 57(4):216-8 (12 ref.)

Estrogen and osteoarthritis: how do we explain conflicting study results? [editorial; comment] Felson DT, et al. **Prev Med** 1999 May;28(5):445-8; discussion 449-50 (19 ref.) Comment on: Prev Med 1999 May;28(5):458-64.

DIAGNOSIS

The evolving role of direct amplification tests in diagnosing osteoarticular infections caused by mycobacteria and fungi. Harrington JT. **Curr Opin Rheumatol** 1999 Jul;11(4):289-92 (29 ref.)

The rotator cuff-deficient arthritic shoulder: diagnosis and surgical management. Zeman CA, et al. **J Am Acad Orthop Surg** 1998 Nov-Dec;6(6):337-48 (34 ref.)

Rotator cuff tear arthropathy. Jensen KL, et al. **J Bone Joint Surg Am** 1999 Sep;81(9):1312-24 (101 ref.)

[Haemophilus influenzae type b osteoarthritis. A report of 7 cases and a review of the literature] Otero Reigada MC, et al. **An Esp Pediatr** 1998 Dec;49(6):594-602 (102 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Glucosamine sulfate use in osteoarthritis. Runkel DR, et al. **Am J Health Syst Pharm** 1999 Feb 1;56(3):267-9 (20 ref.)

Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications. Leff RL. **Ann N Y Acad Sci** 1999 Jun 30;878:201-7 (12 ref.)

COX 2-selective NSAIDs: biology, promises, and concerns. Mandell BF. **Cleve Clin J Med** 1999 May;66(5):285-92 (17 ref.)

Intra-articular corticosteroid treatment in osteoarthritis. Creamer P. **Curr Opin Rheumatol** 1999 Sep;11(5):417-21 (49 ref.)

Effects of hyaluronic acid on cartilage degradation. Uebelhart D, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):427-35 (52 ref.)

Specific cyclooxygenase-2 (COX-2) inhibitors [see comments] Rubin BR. **J Am Osteopath Assoc** 1999 Jun; 99(6):322-5 (21 ref.) Comment in: J Am Osteopath Assoc 1999 Jun;99(6):300-1.

Viscosupplementation for osteoarthritis: current status, unresolved issues, and future directions [editorial; comment] Marshall KW. **J Rheumatol** 1998 Nov; 25(11):2056-8 (14 ref.) Comment on: J Rheumatol 1998 Nov;25(11):2203-12.

Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Bellamy N. **Osteoarthritis Cartilage** 1999 Jul;7(4):424-6 (15 ref.)

The influence of tissue cross-talking on OA progression: role of nonsteroidal antiinflammatory drugs. Pelletier JP. **Osteoarthritis Cartilage** 1999 Jul;7(4):374-6 (0 ref.)

Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Deal CL, et al. **Rheum Dis Clin North Am** 1999 May;25(2):379-95 (38 ref.)

Selective cyclooxygenase-2 inhibitors. Golden BD, et al. **Rheum Dis Clin North Am** 1999 May;25(2):359-78 (145 ref.)

The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Ghosh P. **Semin Arthritis Rheum** 1999 Feb;28(4):211-67 (390 ref.)

[Intra-articular glucocorticoid injections in joint diseases] Ostergaard M, et al. **Ugeskr Laeger** 1999 Feb 1;161(5):582-6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Assessment of the placebo effect of symptomatic slow-acting anti-arthritics] Villani P, et al. **Presse Med** 1998 Feb 7; 27(5):211-4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Do 'chondroprotective agents' agents exist in osteoarthritis? Required proof] Lequesne M, et al. **Therapie** 1998 Jan-Feb; 53(1):7-16 (56 ref.) (Eng. Abstr.) **(Fre)**

[Vitamin E in therapy of rheumatic diseases (see comments)] Sangha O, et al. **Z Rheumatol** 1998 Aug;57(4):207-14 (63 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1998 Aug;57(4):203-6. **(Ger)**

ECONOMICS

Evaluation of costs in rheumatic diseases: a literature review. Ruof J, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):104-9 (29 ref.)

ETIOLOGY

Paget's disease of bone: rheumatologic complications. Altman RD. **Bone** 1999 May;24(5 Suppl):47S-48S (6 ref.)

Is collagen fatigue failure a cause of osteoarthrosis and prosthetic component migration? A hypothesis [see comments] Freeman MA. **J Orthop Res** 1999 Jan;17(1):3-8 (12 ref.) Comment in: J Orthop Res 1999 Jan;17(1):1-2.

The role of COX-2 produced by cartilage in arthritis. Abramson SB. **Osteoarthritis Cartilage** 1999 Jul;7(4):380-1 (16 ref.)

Pathophysiology of osteoarthritis. Martel-Pelletier J. **Osteoarthritis Cartilage** 1998 Nov;6(6):374-6 (16 ref.)

Sports participation, sports injuries and osteoarthritis: implications for prevention. Saxon L, et al. **Sports Med** 1999 Aug;28(2):123-35 (80 ref.)

[The current concepts of the etiology and pathogenesis of osteoarthrosis] Zazirnyĭ IM. **Lik Sprava** 1999 Mar;(2):7-12 (40 ref.) **(Ukr)**

GENETICS

Genetics and osteoarthritis: exposing the iceberg. Holderbaum D, et al. **Arthritis Rheum** 1999 Mar; 42(3):397-405 (89 ref.)

Heritable osteoarthritis. Diagnosis and possible modes of cell and gene therapy. Prockop DJ. **Osteoarthritis Cartilage** 1999 Jul;7(4):364-6 (16 ref.)

IMMUNOLOGY

The urokinase-type plasminogen activator system and inflammatory joint diseases. Del Rosso M, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):485-98 (162 ref.)

METABOLISM

The urokinase-type plasminogen activator system and inflammatory joint diseases. Del Rosso M, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):485-98 (162 ref.)

What is the relation between crystals and osteoarthritis? Concoff AL, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):436-40 (33 ref.)

Molecular changes in bone collagen in osteoporosis and osteoarthritis in the elderly. Bailey AJ, et al. **Exp Gerontol** 1999 Jun;34(3):337-51 (61 ref.)

Nitric oxide in osteoarthritis. Studer R, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):377-9 (18 ref.)

Synovial fluid markers in osteoarthritis. Myers SL. **Rheum Dis Clin North Am** 1999 May;25(2):433-49, viii-ix (99 ref.)

The role of crystals in osteoarthritis. Ryan LM, et al. **Rheum Dis Clin North Am** 1999 May;25(2):257-67 (55 ref.)

Vitamins and arthritis. The roles of vitamins A, C, D, and E. Sowers M, et al. **Rheum Dis Clin North Am** 1999 May; 25(2):315-32 (79 ref.)

MICROBIOLOGY

The evolving role of direct amplification tests in diagnosing osteoarticular infections caused by mycobacteria and fungi. Harrington JT. **Curr Opin Rheumatol** 1999 Jul;11(4):289-92 (29 ref.)

PATHOLOGY

Joint anatomy, design, and arthroses: insights of the Utah paradigm. Frost HM. **Anat Rec** 1999 Jun 1;255(2):162-74 (54 ref.)

Anteroposterior atlantoaxial subluxation in cervical spine

osteoarthritis: case reports and review of the literature. Daumen-Legré V, et al. **J Rheumatol** 1999 Mar; 26(3):687-91 (30 ref.)

PHYSIOPATHOLOGY

Joint anatomy, design, and arthroses: insights of the Utah paradigm. Frost HM. **Anat Rec** 1999 Jun 1;255(2):162-74 (54 ref.)

The anterior cruciate ligament and arthritis. Clatworthy M, et al. **Clin Sports Med** 1999 Jan;18(1):173-98, vii (84 ref.)

Effect of knee pain on joint loading in patients with osteoarthritis. Hurwitz DE, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):422-6 (40 ref.)

Exercise and osteoarthritis. Lane NE, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):413-6 (14 ref.)

The aging knee joint--an insight. Muhury S. **J Indian Med Assoc** 1998 May;96(5):159-64 (9 ref.)

Altered mechanics of cartilage with osteoarthritis: human osteoarthritis and an experimental model of joint degeneration. Setton LA, et al. **Osteoarthritis Cartilage** 1999 Jan;7(1):2-14 (99 ref.)

Osteoarthritis: a problem of joint failure. Nuki G. **Z Rheumatol** 1999 Jun;58(3):142-7 (55 ref.)

The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. van den Berg WB. **Z Rheumatol** 1999 Jun;58(3):136-41 (12 ref.)

PREVENTION & CONTROL

Estrogen and osteoarthritis: how do we explain conflicting study results? [editorial; comment] Felson DT, et al. **Prev Med** 1999 May;28(5):445-8; discussion 449-50 (19 ref.) Comment on: Prev Med 1999 May;28(5):458-64.

[Do 'chondroprotective agents' agents exist in osteoarthritis? Required proof] Lequesne M, et al. **Therapie** 1998 Jan-Feb; 53(1):7-16 (56 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Patellar resurfacing. Results of a prospective randomized study] Schroeder-Boersch H, et al. **Orthopade** 1998 Sep; 27(9):642-50 (40 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Beyond disability: measuring the social and personal consequences of osteoarthritis. Carr AJ. **Osteoarthritis Cartilage** 1999 Mar;7(2):230-8 (49 ref.)

SURGERY

Periarticular osteotomies: the importance of limb alignment. Crawford HA, et al. **Instr Course Lect** 1999;48:279-85 (25 ref.)

Arthroscopic ankle debridement and fusion: indications, techniques, and results. Fitzgibbons TC. **Instr Course Lect** 1999;48:243-8 (38 ref.)

Arthrodesis of the ankle: technique, complications, and salvage treatment. Kitaoka HB. **Instr Course Lect** 1999; 48:255-61 (12 ref.)

Total ankle arthroplasty: state of the art. Saltzman CL. **Instr Course Lect** 1999;48:263-8 (24 ref.)

The rotator cuff-deficient arthritic shoulder: diagnosis and surgical management. Zeman CA, et al. **J Am Acad Orthop Surg** 1998 Nov-Dec;6(6):337-48 (34 ref.)

Total shoulder arthroplasty -- current problems and possible solutions. Skirving AP. **J Orthop Sci** 1999;4(1):42-53 (33 ref.)

[Ulna impaction syndrome therapy: decompressive surgical procedures of the head of the ulna] Krimmer H, et al. **Handchir Mikrochir Plast Chir** 1998 Nov;30(6):370-4 (20 ref.) (Eng. Abstr.) **(Ger)**

[Indication for and performance of articular cartilage drilling using the Pridie method] Müller B, et al. **Orthopade** 1999 Jan;28(1):4-10 (46 ref.) (Eng. Abstr.) **(Ger)**

[Anterior cruciate ligament-plasty and high valgus tibial osteotomy as a combined procedure in anterior instability and varus deviation] Roscher E, et al. **Zentralbl Chir** 1998; 123(9):1019-26 (42 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Arthritis: new agents herald more effective symptom management. Simon LS. **Geriatrics** 1999 Jun;54(6):37-42; quiz 44 (15 ref.)

Joint distraction as treatment for ankle osteoarthritis. van Roermund PM, et al. **Instr Course Lect** 1999;48:249-54 (20 ref.)

Clinical efficacy of low power laser therapy in osteoarthritis. Marks R, et al. **Physiother Res Int** 1999;4(2):141-57 (31 ref.)

Interpreting findings from therapeutic trials in chronic joint diseases. Saraux A, et al. **Rev Rhum Engl Ed** 1999 Feb; 66(2):70-2 (0 ref.)

Potential treatment of osteoarthritis by gene therapy. Evans CH, et al. **Rheum Dis Clin North Am** 1999 May; 25(2):333-44 (85 ref.)

ULTRASONOGRAPHY

Ultrasound in inflammatory disease. Gibbon WW, et al. **Radiol Clin North Am** 1999 Jul;37(4):633-51 (72 ref.)

Sonographic imaging of normal and osteoarthritic cartilage. Grassi W, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):398-403 (13 ref.)

OSTEOARTHRITIS, HIP

A rational approach to osteoarthritis. Dickson DJ. **Practitioner** 1997 Dec;241(1581):763-6 (3 ref.)

ETIOLOGY

[The Donauspital-Stolzalpe concept (Danube Hospital, Vienna, Austria). Corrective osteotomy with selective labrum surgery following preoperative MRI arthrography] Tschauner C, et al. **Orthopade** 1998 Nov;27(11):765-71 (42 ref.) (Eng. Abstr.) **(Ger)**

[Increased risk of knee and hip arthrosis among elite athletes. Lower level exercise and sports seem to be "harmless"] Roos H. **Lakartidningen** 1998 Oct 14;95(42):4606-10 (56 ref.) (Eng. Abstr.) **(Swe)**

PREVENTION & CONTROL

Preventing knee and hip osteoarthritis. Felson DT. **Bull Rheum Dis** 1998 Nov;47(7):1-4 (10 ref.)

[The Bernese method of periacetabular osteotomy] Leunig M, et al. **Orthopade** 1998 Nov;27(11):743-50 (38 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Radiographic assessment of osteoarthritis: comparison between existing methodologies. Buckland-Wright. **Osteoarthritis Cartilage** 1999 Jul;7(4):430-3 (15 ref.)

Radiologic progression of hip and knee osteoarthritis. Ravaud P, et al. **Osteoarthritis Cartilage** 1999 Mar;7(2):222-9 (53 ref.)

Radiographic assessment. Introduction: existing methodology. Rovati LC. **Osteoarthritis Cartilage** 1999 Jul; 7(4):427-9 (15 ref.)

Radiographic assessment of hip and knee osteoarthritis. Recommendations: recommended guidelines. Vignon E, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):434-6 (15 ref.)

SURGERY

Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Faulkner A, et al. **Health Technol Assess** 1998; 2(6):1-133 (128 ref.)

[Artificial hip replacement in young patients with hip dysplasia--long-term outcome after 10 years] Porsch M, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):548-53 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomized clinical trials. van Baar ME, et al. **Arthritis Rheum** 1999 Jul;42(7):1361-9 (57 ref.)

Exercise in the treatment of osteoarthritis. Minor MA. **Rheum Dis Clin North Am** 1999 May;25(2):397-415, viii (64 ref.)

OSTEOARTHRITIS, KNEE

A rational approach to osteoarthritis. Dickson DJ. **Practitioner** 1997 Dec;241(1581):763-6 (3 ref.)

DIAGNOSIS

Magnetic resonance imaging of osteoarthritis. Waldschmidt JG, et al. **Rheum Dis Clin North Am** 1999 May;25(2):451-65 (25 ref.)

DRUG THERAPY

Hyaluronic acid treatment (viscosupplementation) for OA of the knee. Cohen MD. **Bull Rheum Dis** 1998 Nov; 47(7):4-7 (15 ref.)

Hyaluronic acid treatment for osteoarthritis of the knee. Leslie M. **Nurse Pract** 1999 Jul;24(7):38, 41-8 (32 ref.)

Viscosupplementation therapy with intra-articular hyaluronic acid. Fact or fantasy? Simon LS. **Rheum Dis Clin North Am** 1999 May;25(2):345-57 (20 ref.)

EPIDEMIOLOGY

Anterior cruciate ligament reconstruction and the long-term incidence of gonarthrosis. Gillquist J, et al. **Sports Med** 1999 Mar;27(3):143-56 (132 ref.)

ETIOLOGY

Are there long-term sequelae from soccer? Roos H. **Clin Sports Med** 1998 Oct;17(4):819-31, viii (88 ref.)

The role of muscle weakness in the pathogenesis of osteoarthritis. Hurley MV. **Rheum Dis Clin North Am** 1999 May;25(2):283-98, vi (125 ref.)

Anterior cruciate ligament reconstruction and the long-term incidence of gonarthrosis. Gillquist J, et al. **Sports Med** 1999 Mar;27(3):143-56 (132 ref.)

[Current advances in sports-related cartilage research. Meniscus and ligament injuries are associated with increased risk of knee joint arthrosis] Messner K. **Lakartidningen** 1998 Oct 14;95(42):4611-2, 4615 (20 ref.) (Eng. Abstr.) **(Swe)**

[Increased risk of knee and hip arthrosis among elite athletes. Lower level exercise and sports seem to be "harmless"] Roos H. **Lakartidningen** 1998 Oct 14;95(42):4606-10 (56 ref.) (Eng. Abstr.) **(Swe)**

NURSING

Hyaluronic acid treatment for osteoarthritis of the knee. Leslie M. **Nurse Pract** 1999 Jul;24(7):38, 41-8 (32 ref.)

PHYSIOPATHOLOGY

Proprioceptive impairment in knee osteoarthritis. Sharma L. **Rheum Dis Clin North Am** 1999 May;25(2):299-314, vi (59 ref.)

PREVENTION & CONTROL

Preventing knee and hip osteoarthritis. Felson DT. **Bull Rheum Dis** 1998 Nov;47(7):1-4 (10 ref.)

RADIOGRAPHY

Radiographic assessment of osteoarthritis: comparison between existing methodologies. Buckland-Wright. **Osteoarthritis Cartilage** 1999 Jul;7(4):430-3 (15 ref.)

Radiologic progression of hip and knee osteoarthritis. Ravaud P, et al. **Osteoarthritis Cartilage** 1999 Mar;7(2):222-9 (53 ref.)

Radiographic assessment. Introduction: existing methodology. Rovati LC. **Osteoarthritis Cartilage** 1999 Jul; 7(4):427-9 (15 ref.)

Radiographic assessment of hip and knee osteoarthritis. Recommendations: recommended guidelines. Vignon E, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):434-6 (15 ref.)

Plain radiography as an outcome measure in clinical trials involving patients with knee osteoarthritis. Mazzuca SA, et al. **Rheum Dis Clin North Am** 1999 May;25(2):467-80, ix (37 ref.)

SURGERY

Unicondylar arthroplasty: an option for high-demand patients with gonarthrosis. Engh GA, et al. **Instr Course Lect** 1999;48:143-8 (18 ref.)

Proximal valgus tibial osteotomy for osteoarthritis of the knee. Hutchison CR, et al. **Instr Course Lect** 1999;48:131-4 (24 ref.)

Arthroscopic management for degenerative arthritis of the knee. Stuart MJ. **Instr Course Lect** 1999;48:135-41 (29 ref.)

Use of allografts in knee reconstruction: II. Surgical considerations. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May-Jun;6(3):169-75 (29 ref.)

Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. Brooks DH, et al. **J Arthroplasty** 1998 Sep;13(6):707-12 (15 ref.)

Current concepts of total knee arthroplasty. Martin SD, et al. **J Orthop Sports Phys Ther** 1998 Oct;28(4):252-61 (71 ref.)

Role of tibial osteotomy in the treatment of medial femorotibial osteoarthritis [editorial] Nizard RS. **Rev Rhum Engl Ed** 1998 Jul-Sep;65(7-9):443-6 (28 ref.)

Knee replacement surgery for osteoarthritis: effectiveness, practice variations, indications and possible determinants of utilization. Dieppe P, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):73-83 (90 ref.)

THERAPY

Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomized clinical trials. van Baar ME, et al. **Arthritis Rheum** 1999 Jul;42(7):1361-9 (57 ref.)

Exercise in the treatment of osteoarthritis. Minor MA. **Rheum Dis Clin North Am** 1999 May;25(2):397-415, viii (64 ref.)

[Treatment of knee osteoarthritis (see comments)] Aune AK, et al. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3785-90 (73 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1999 Jan 10;119(1):84-5. **(Nor)**

OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC

SURGERY

[Surgical management of neuropathy and osteoarthropathy of the diabetic food] Baumgartner R. **Zentralbl Chir** 1999; 124 Suppl 1:17-24 (10 ref.) (Eng. Abstr.) **(Ger)**

OSTEOARTHROSIS see **OSTEOARTHRITIS**

OSTEOARTHROSIS DEFORMANS see **OSTEOARTHRITIS**

OSTEOBLASTOMA

DIAGNOSIS

Clinicopathologic features, diagnosis, and treatment of osteoblastoma. Papagelopoulos PJ, et al. **Orthopedics** 1999 Feb;22(2):244-7; quiz 248-9 (31 ref.)

GENETICS

Genetic instability in osteoblastic tumors of the skeletal system. Radig K, et al. **Pathol Res Pract** 1998;

194(10):669–77 (71 ref.)
[Genetic instability in osteoblastic tumors of the skeletal system] Roessner A, et al. **Verh Dtsch Ges Pathol** 1998; 82:133–43 (71 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Genetic instability in osteoblastic tumors of the skeletal system] Roessner A, et al. **Verh Dtsch Ges Pathol** 1998; 82:133–43 (71 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Clinicopathologic features, diagnosis, and treatment of osteoblastoma. Papagelopoulos PJ, et al. **Orthopedics** 1999 Feb;22(2):244–7; quiz 248–9 (31 ref.)

OSTEOBLASTS

CYTOLOGY

Future potentials for using osteogenic stem cells and biomaterials in orthopedics. Oreffo RO, et al. **Bone** 1999 Aug;25(2 Suppl):5S–9S (58 ref.)
Genetic control of cell differentiation in the skeleton. Ducy P, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):614–9 (50 ref.)
Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. Ishida Y, et al. **J Bone Miner Res** 1998 Dec;13(12):1822–6 (81 ref.)
Bone stem cells. Aubin JE. **J Cell Biochem Suppl** 1998; 30–31:73–82 (35 ref.)
Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. Lian JB, et al. **J Cell Biochem Suppl** 1998;30–31:62–72 (91 ref.)
[Integrin signal transduction via FAK in osteoblasts—early differentiation triggered by osteopontin] Nemoto A, et al. **Seikagaku** 1999 Feb;71(2):140–5 (17 ref.) **(Jpn)**
[Morphofunctional characteristics of the endosteum in connection with bone remodeling] Denisov-Nikol'skiĭ IuI, et al. **Arkh Patol** 1998 Sep–Oct;60(5):19–23 (19 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Does estrogen stimulate osteoblast function in postmenopausal women? Tobias JH, et al. **Bone** 1999 Feb; 24(2):121–4 (48 ref.)

METABOLISM

Cellular and molecular mechanisms of osteoporosis. Manolagas SC. **Aging (Milano)** 1998 Jun;10(3):182–90 (69 ref.)
Estrogen regulation of gene expression in osteoblasts and osteoclasts. Oursler MJ. **Crit Rev Eukaryot Gene Expr** 1998; 8(2):125–40 (125 ref.)
The effect of microgravity on morphology and gene expression of osteoblasts in vitro. Carmeliet G, et al. **FASEB J** 1999;13 Suppl:S129–34 (53 ref.)
The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Graves DT, et al. **Front Biosci** 1999 Jul 1;4:D571–80 (70 ref.)
Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Lian JB, et al. **Vitam Horm** 1999;55:443–509 (261 ref.)

PHYSIOLOGY

Advances in the osteoblast lineage. Aubin JE. **Biochem Cell Biol** 1998;76(6):899–910 (107 ref.)
Extracellular matrix-integrin interactions in osteoblast function and tissue remodeling. Damsky CH. **Bone** 1999 Jul;25(1):95–6 (14 ref.)
Cellular and molecular alterations of osteoblasts in human disorders of bone formation. Marie PJ. **Histol Histopathol** 1999 Apr;14(2):525–38 (146 ref.)
The enkephalinergic osteoblast. Rosen H, et al. **J Bone Miner Res** 1998 Oct;13(10):1515–20 (45 ref.)
Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. Lian JB, et al. **J Cell Biochem Suppl** 1998;30–31:62–72 (91 ref.)

OSTEOCALCIN

BLOOD

Biochemical markers of bone metabolism in horses: potentials and limitations? [editorial; comment] Price JS. **Vet J** 1998 Nov;156(3):163–5 (16 ref.) Comment on: Vet J 1998 Nov;156(3):169–75.

GENETICS

Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. Lian JB, et al. **J Cell Biochem Suppl** 1998;30–31:62–72 (91 ref.)
Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Lian JB, et al. **Vitam Horm** 1999;55:443–509 (261 ref.)

OSTEOCHONDRITIS

COMPLICATIONS

Kienböck's disease and gout. Shin AY, et al. **J Hand Surg [Br]** 1999 Jun;24(3):363–5 (9 ref.)

SURGERY

[Indication for and performance of articular cartilage drilling using the Pridie method] Müller B, et al. **Orthopade** 1999 Jan;28(1):4–10 (46 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Osteochondrosis in cattle. Tryon KA, et al. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):265–74 (14 ref.)
Studies on growth cartilage in the horse and their application to aetiopathogenesis of dyschondroplasia (osteochondrosis) [see comments] Jeffcott LB, et al. **Vet J** 1998 Nov; 156(3):177–92 (124 ref.) Comment in: Vet J 1998 Nov;156(3):167–8.
Equine developmental osteochondral lesions: the role of biomechanics [editorial; comment] Whitton RC. **Vet J** 1998 Nov;156(3):167–8 (8 ref.) Comment on: Vet J 1998 Nov;156(3):177–92.

OSTEOCHONDRITIS DISSECANS

DIAGNOSIS

Osteochondritis dissecans of the knee. Williams JS Jr, et al. **Am J Knee Surg** 1998 Fall;11(4):221–32 (126 ref.)

SURGERY

Osteochondritis dissecans of the elbow. Peterson RK, et al. **Instr Course Lect** 1999;48:393–8 (32 ref.)
[Indication for and performance of articular cartilage drilling using the Pridie method] Müller B, et al. **Orthopade** 1999 Jan;28(1):4–10 (46 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Osteochondritis dissecans of the knee. Williams JS Jr, et al. **Am J Knee Surg** 1998 Fall;11(4):221–32 (126 ref.)

OSTEOCHONDRODYSPLASIAS

CLASSIFICATION

International nomenclature and classification of the osteochondrodysplasias (1997). Lachman RS. **Pediatr Radiol** 1998 Oct;28(10):737–44 (9 ref.)

COMPLICATIONS

Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1998 Dec;27(6):451–5 (28 ref.)
Gingival lesions in a patient with dermochondrocorneal dystrophy (François syndrome). A case report. Sardella A, et al. **J Clin Periodontol** 1998 Dec;25(12):1047–9 (9 ref.)

GENETICS

The long and the short of it: developmental genetics of the skeletal dysplasias. Dreyer SD, et al. **Clin Genet** 1998 Dec; 54(6):464–73 (83 ref.)
Parathyroid hormone (PTH)/PTHrP receptor mutations in human chondrodysplasia [editorial; comment] Nissenson RA. **Endocrinology** 1998 Dec;139(12):4753–5 (21 ref.) Comment on: Endocrinology 1998 Dec;139(12):5255–8.
Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1998 Dec;27(6):451–5 (28 ref.)
X-linked recessive spondyloepiphyseal dysplasia tarda. Clinical and radiographic evolution in a 6-generation kindred and review of the literature. Whyte MP, et al. **Medicine (Baltimore)** 1999 Jan;78(1):9–25 (60 ref.)
The type XI collagenopathies. Spranger J. **Pediatr Radiol** 1998 Oct;28(10):745–50 (31 ref.)

PATHOLOGY

Microcephalic osteodysplastic primordial dwarfism type II: report of three cases and review. Majewski F, et al. **Am J Med Genet** 1998 Oct 30;80(1):25–31 (18 ref.)
Microcephalic osteodysplastic primordial dwarfism Taybi–Linder type: report of four cases and review of the literature. Sigaudy S, et al. **Am J Med Genet** 1998 Oct 30;80(1):16–24 (23 ref.)
Spinal manifestations of skeletal dysplasias. Kornblum M, et al. **Orthop Clin North Am** 1999 Jul;30(3):501–20, x (119 ref.)

RADIOGRAPHY

X-linked recessive spondyloepiphyseal dysplasia tarda. Clinical and radiographic evolution in a 6-generation kindred and review of the literature. Whyte MP, et al. **Medicine (Baltimore)** 1999 Jan;78(1):9–25 (60 ref.)
Trichorhinophalangeal syndrome type I in monozygotic twins discordant for hip pathology. Report on the morphological evolution of cone-shaped epiphyses and the unusual pattern of skeletal maturation. Naselli A, et al. **Pediatr Radiol** 1998 Nov;28(11):851–5 (9 ref.)
Constitutional osteochondrodysplasias identifiable at birth. A short review on the state of the art in radiodiagnosis in the late 20th century. Gugliantini P, et al. **Radiol Med (Torino)** 1999 Mar;97(3):116–20 (12 ref.)

OSTEOCHONDROMA

COMPLICATIONS

Popliteal pseudoaneurysm caused by an adjacent osteochondroma: a case report and review of the literature. Wiater JM, et al. **Am J Orthop** 1999 Jul;28(7):412–6 (32 ref.)
Large bursa formation associated with osteochondroma of the scapula: a case report and review of the literature. Okada K, et al. **Jpn J Clin Oncol** 1999 Jul;29(7):356–60 (23 ref.)
The solitary intraspinal vertebral osteochondroma. An unusual cause of compressive myelopathy: features and literature review. Khosla A, et al. **Spine** 1999 Jan 1; 24(1):77–81 (16 ref.)
[Recurrent torticollis due to cervical osteochondroma. Case report and review of the literature] Caso Martinez J, et al. **An Esp Pediatr** 1998 Aug;49(2):177–8 (13 ref.) **(Spa)**

DIAGNOSIS

[Recurrent torticollis due to cervical osteochondroma. Case report and review of the literature] Caso Martinez J, et al. **An Esp Pediatr** 1998 Aug;49(2):177–8 (13 ref.) **(Spa)**

RADIOGRAPHY

Dural osteochondroma: case report, review of the literature and proposal of a new classification. Haddad GF, et al. **Br J Neurosurg** 1998 Aug;12(4):380–4 (35 ref.)
Evanescent exostosis. A new case. Revilla Y, et al. **Eur J Radiol** 1999 Mar;29(3):270–2 (11 ref.)

SURGERY

[Intra-thoracic costal sites of osteogenic exostoses in the child] Cottalorda J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):563–6 (12 ref.) (Eng. Abstr.) **(Fre)**

OSTEOCHONDROMAS, MULTIPLE see **EXOSTOSES, MULTIPLE HEREDITARY**

OSTEOCHONDROMATOSIS

PATHOLOGY

Bizarre parosteal osteochondromatous proliferation in the anterior maxilla: report of a case. Shankly PE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):351–6 (26 ref.)

OSTEOCHONDROMATOSIS, SYNOVIAL see **CHONDROMATOSIS, SYNOVIAL**

OSTEOCHONDROSIS see **OSTEOCHONDRITIS**

OSTEOCLASTIC BONE LOSS see **BONE RESORPTION**

OSTEOCLASTS

CYTOLOGY

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Takahashi N, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):449–55 (55 ref.)
Interleukins in the control of osteoclast differentiation. Martin TJ, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):107–23 (143 ref.)
Genetic control of cell differentiation in the skeleton. Ducy P, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):614–9 (50 ref.)
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Suda T, et al. **Endocr Rev** 1999 Jun; 20(3):345–57 (83 ref.)
Cell biology of the osteoclast. Roodman GD. **Exp Hematol** 1999 Aug;27(8):1229–41 (120 ref.)
Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Kong YY, et al. **Immunol Cell Biol** 1999 Apr; 77(2):188–93 (45 ref.)
[Role of osteoclast differentiation factor, the new member of the TNF ligand family, in osteoclast differentiation and function] Takahashi N, et al. **Seikagaku** 1999 Apr; 71(4):241–53 (66 ref.) **(Jpn)**
[Commitment and differentiation of osteoclast on stromal cells] Yamazaki H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):854–64 (63 ref.) **(Jpn)**
[Morphofunctional characteristics of the endosteum in connection with bone remodeling] Denisov-Nikol'skiĭ IuI, et al. **Arkh Patol** 1998 Sep–Oct;60(5):19–23 (19 ref.) (Eng. Abstr.) **(Rus)**

OSTEOCLASTS

ENZYMOLOGY

Plasma membrane V-ATPases in proton-transporting cells of the mammalian kidney and osteoclast. Gluck SL, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:203-12 (84 ref.)

METABOLISM

Cellular and molecular mechanisms of osteoporosis. Manolagas SC. **Aging (Milano)** 1998 Jun;10(3):182-90 (69 ref.)

Estrogen regulation of gene expression in osteoblasts and osteoclasts. Oursler MJ. **Crit Rev Eukaryot Gene Expr** 1998; 8(2):125-40 (125 ref.)

Novel mechanisms of calcium handling by the osteoclast: A review-hypothesis. Zaidi M, et al.
Proc Assoc Am Physicians 1999 Jul-Aug;111(4):319-27 (82 ref.)

PATHOLOGY

Tumors of the pancreas with osteoclast-like and pleomorphic giant cells: an immunohistochemical and ploidy study. Deckard-Janatpour K, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):266-72 (47 ref.)

Dedifferentiated parosteal osteosarcoma with high-grade osteoclast-rich osteogenic sarcoma at presentation. Shuhaibar H, et al. **Skeletal Radiol** 1998 Oct;27(10):574-7 (16 ref.)

PHYSIOLOGY

Commitment and differentiation of stem cells to the osteoclast lineage. Hayashi S, et al. **Biochem Cell Biol** 1998; 76(6):911-22 (136 ref.)

How the osteoclast degrades bone. Blair HC. **Bioessays** 1998 Oct;20(10):837-46 (87 ref.)

Osteoclast precursors as leukocytes: importance of the area code. Parfitt AM. **Bone** 1998 Dec;23(6):491-4 (43 ref.)

Bone remodelling: a signalling system for osteoclast regulation. Filvaroff E, et al. **Curr Biol** 1998 Sep 24; 8(19):R679-82 (25 ref.)

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Suda T, et al. **Endocr Rev** 1999 Jun; 20(3):345-57 (83 ref.)

Human osteoclast ontogeny and pathological bone resorption. Athanasou NA, et al. **Histol Histopathol** 1999 Apr;14(2):635-47 (119 ref.)

The role of integrins in osteoclast function. Duong LT, et al. **J Bone Miner Metab** 1999;17(1):1-6 (42 ref.)

Emerging insights into the role of calcium ions in osteoclast regulation. Zaidi M, et al. **J Bone Miner Res** 1999 May; 14(5):669-74 (65 ref.)

TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. Wong BR, et al.
J Leukoc Biol 1999 Jun;65(6):715-24 (75 ref.)

Regulation of osteoclast activity. Greenfield EM, et al.
Life Sci 1999;65(11):1087-102 (180 ref.)

OSTEOCYTES

CYTOLOGY

Establishment and characterization of an osteocyte-like cell line, MLO-Y4. Bonewald LF. **J Bone Miner Metab** 1999; 17(1):61-5 (32 ref.)

PHYSIOLOGY

Mechanical responses and signal transduction pathways in stretched osteocytes. Mikuni-Takagaki Y.
J Bone Miner Metab 1999;17(1):57-60 (20 ref.)

OSTEOGENESIS

Common molecular pathways in skeletal morphogenesis and repair. Ferguson CM, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:33-42 (33 ref.)

[Osteogenic characteristics of bone marrow and composite bone marrow transplantation. A review] Li Y, et al.
Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih 1998 Jan;12(1):39-41 (15 ref.) **(Chi)**

DRUG EFFECTS

Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. Ishida Y, et al. **J Bone Miner Res** 1998 Dec;13(12):1822-6 (81 ref.)

Molecular mechanism of action of fluoride on bone cells. Lau KH, et al. **J Bone Miner Res** 1998 Nov;13(11):1660-7 (67 ref.)

Bone morphogenetic proteins in orthopedics: from basic science to clinical practice. Croteau S, et al.
Orthopedics 1999 Jul;22(7):686-95; quiz 696-7 (153 ref.)

PHYSIOLOGY

Could some biomechanical effects of growth hormone help to explain its effects on bone formation and resorption? Frost HM. **Bone** 1998 Nov;23(5):395-8 (35 ref.)

Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis. Connolly JF. **Clin Orthop** 1998 Oct;(355 Suppl):S257-66 (69 ref.)

Osteoinduction by demineralised bone. Solheim E.
Int Orthop 1998;22(5):335-42 (96 ref.)

Control of bone formation and resorption: biological and clinical perspective. Rodan GA. **J Cell Biochem Suppl** 1998; 30-31:55-61 (36 ref.)

Biologic determinants of bone formation for osseointegration: clues for future clinical improvements. Cooper LF.
J Prosthet Dent 1998 Oct;80(4):439-49 (87 ref.)

Active role of chondrocyte apoptosis in endochondral ossification. Gibson G. **Microsc Res Tech** 1998 Oct 15; 43(2):191-204 (105 ref.)

All about new bone. Farrow CS.
Vet Clin North Am Food Anim Pract 1999 Jul;15(2):215-9, v (5 ref.)

OSTEOGENESIS, DISTRACTION

see related
EXTERNAL FIXATORS
ILIZAROV TECHNIQUE

Distraction osteogenesis--a review. Davies J, et al.
Br Dent J 1998 Nov 14;185(9):462-7 (31 ref.)

Molecular signaling in bone fracture healing and distraction osteogenesis. Liu Z, et al. **Histol Histopathol** 1999 Apr; 14(2):587-95 (90 ref.)

Distraction osteogenesis. Drew SJ, et al.
N Y State Dent J 1999 Jan;65(1):26-9 (9 ref.)

[Experimental and clinical study of distraction osteogenesis of the mandible] Yang P, et al.
Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 1997 May;13(3):208-11 (22 ref.) (Eng. Abstr.) **(Chi)**

METHODS

Applications of distraction osteogenesis. Part II. Netscher DT. **Clin Plast Surg** 1998 Oct;25(4):561-6, viii (11 ref.)

Brachymetatarsia: congenitally short third and fourth metatarsals treated by distraction lengthening--a case report and literature summary. Robinson JF, et al.
Foot Ankle Int 1998 Oct;19(10):713-8 (42 ref.)

Distraction osteogenesis of a fibula free flap used for mandibular reconstruction: preliminary report. Siciliano S, et al. **J Craniomaxillofac Surg** 1998 Dec;26(6):386-90 (20 ref.)

Index finger lengthening by gradual distraction and bone grafting. Gordon A, et al. **J Hand Surg [Br]** 1998 Dec; 23(6):785-7 (8 ref.)

VETERINARY

Distraction osteogenesis. Welch RD, et al.
Vet Clin North Am Small Anim Pract 1999 Sep; 29(5):1187-205, vii-viii (51 ref.)

OSTEOGENESIS IMPERFECTA

COMPLICATIONS

Aortic valve surgery in osteogenesis imperfecta: report of two cases and review of the literature. Zegdi R, et al.
J Heart Valve Dis 1998 Sep;7(5):510-4 (30 ref.)

RADIOGRAPHY

Osteogenesis imperfecta-like syndrome with severe mental retardation and extrapyramidal tract signs. Nishimura G, et al. **Pediatr Radiol** 1998 Nov;28(11):856-8 (5 ref.)

THERAPY

Osteogenesis imperfecta in childhood: treatment strategies. Engelbert RH, et al. **Arch Phys Med Rehabil** 1998 Dec; 79(12):1590-4 (63 ref.)

OSTEOLYSIS

DRUG THERAPY

Bisphosphonate treatment of lytic bone metastases. Lipton A, et al. **Drugs Aging** 1999 Apr;14(4):241-6 (26 ref.)

Bisphosphonates as cancer drugs. Mundy GR.
Hosp Pract (Off Ed) 1999 May 15;34(5):81-4, 88-9, 93-4 (8 ref.)

The role of bisphosphonates for the treatment of bone disease in multiple myeloma. Musto P. **Leuk Lymphoma** 1998 Nov; 31(5-6):453-62 (80 ref.)

ETIOLOGY

Osteolysis associated with cemented total knee arthroplasty. Griffin FM, et al. **J Arthroplasty** 1998 Aug;13(5):592-8 (10 ref.)

PATHOLOGY

The cluster of arachnoid diverticula in the occipital bone: report of two cases with literature review. Nakada M, et al. **Acta Neurochir (Wien)** 1998;140(7):647-50 (12 ref.)

A new classification system for the management of acetabular osteolysis after total hip arthroplasty. Rubash HE, et al. **Instr Course Lect** 1999;48:37-42 (42 ref.)

PHYSIOPATHOLOGY

[Physiopathology of tumor-induced osteolysis] Gouin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Mar; 85(1):58-68 (93 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Revision arthroplasty of the acetabulum in association with loss of bone stock. Gross AE, et al. **Instr Course Lect** 1999; 48:57-66 (58 ref.)

OSTEOLYSIS, ESSENTIAL

PATHOLOGY

[Gorham disease of the rib with osteolysis followed by bone remodeling. Study with magnetic resonance imaging] Sans N, et al. **Rev Mal Respir** 1999 Feb;16(1):98-101 (14 ref.) (Eng. Abstr.) **(Fre)**

OSTEOLYSIS, IDIOPATHIC MULTICENTRIC see **OSTEOLYSIS, ESSENTIAL**

OSTEOLYSIS, MASSIVE see **OSTEOLYSIS, ESSENTIAL**

OSTEOMA

COMPLICATIONS

Ethmoid sinus osteoma presenting as epiphora and orbital cellulitis: case report and literature review. Mansour AM, et al. **Surv Ophthalmol** 1999 Mar-Apr;43(5):413-26 (128 ref.)

DIAGNOSIS

Intradural extension of mucocele complicating frontoethmoid sinus osteoma: case report. Manaka H, et al.
Surg Neurol 1998 Nov;50(5):453-6 (13 ref.)

[Osteoma of the internal auditory canal. Presentation of a case and review of the bibliography] Torres-Valenzuela A. **Gac Med Mex** 1998 May-Jun;134(3):355-7 (9 ref.) (Eng. Abstr.) **(Spa)**

OSTEOMA, GIANT OSTEOID see **OSTEOBLASTOMA**

OSTEOMA, OSTEOID

SURGERY

[Post-traumatic osteoid osteoma of the hand. A rare cause of chronic pain. Case report and review of the literature] Rotzer A, et al. **Handchir Mikrochir Plast Chir** 1998 Sep; 30(5):335-7 (15 ref.) (Eng. Abstr.) **(Ger)**

OSTEOMALACIA

CHEMICALLY INDUCED

Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Sato K, et al. **Endocr J** 1998 Aug;45(4):431-9 (44 ref.)

[Drug-induced osteomalacia] D'Erasmo E, et al.
Recenti Prog Med 1998 Oct;89(10):529-33 (40 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Update on renal osteodystrophy: pathogenesis and clinical management. Sakhaee K, et al. **Am J Med Sci** 1999 Apr; 317(4):251-60 (66 ref.)

DIAGNOSIS

[Disease caused by lack of sunlight: rickets and osteomalacia] Wauters IM, et al. **Ned Tijdschr Geneeskd** 1999 Mar 20; 143(12):593-7 (22 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Musculoskeletal manifestations of osteomalacia: report of 26 cases and literature review. Reginato AJ, et al.
Semin Arthritis Rheum 1999 Apr;28(5):287-304 (75 ref.)

SURGERY

[Abrasion arthroplasty] Goymann V. **Orthopade** 1999 Jan; 28(1):11-8 (57 ref.) (Eng. Abstr.) **(Ger)**

OSTEOMYELITIS

Adult posttraumatic osteomyelitis of the tibia. Mader JT, et al. **Clin Orthop** 1999 Mar;(360):14-21 (53 ref.)

Rare bone infections "excluding the spine". Abd El Bagi ME, et al. **Eur Radiol** 1999;9(6):1078-87 (56 ref.)

[Osteomyelitis of the jaw] Kaneko A.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):357-9 (0 ref.) **(Jpn)**

[Osteomyelitis] Minami A, et al.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):265-7 (5 ref.) **(Jpn)**

[Osteomyelitis] Ono W, et al.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):599-602 (10 ref.) **(Jpn)**

COMPLICATIONS

Cat-scratch disease with paravertebral mass and osteomyelitis. Robson JM, et al. **Clin Infect Dis** 1999 Feb; 28(2):274-8 (22 ref.)

Infected tibial nonunions (1981–1995). The evolution of change. Cierny G 3rd. **Clin Orthop** 1999 Mar;(360):97–105 (69 ref.)
Infectious causes of heel pain. Kosinski M, et al. **J Am Podiatr Med Assoc** 1999 Jan;89(1):20–3 (33 ref.)
Neutrophilic dermatosis–associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review. Nurre LD, et al. **Pediatr Dermatol** 1999 May–Jun; 16(3):214–6 (9 ref.)

DIAGNOSIS

Abscess formation as a complication caused by postoperative osteomyelitis of the femur. Itokazu M, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):99–102 (7 ref.)
Spinal aspergillus osteomyelitis. Vinas FC, et al. **Clin Infect Dis** 1999 Jun;28(6):1223–9 (49 ref.)
Ewing's sarcoma masquerading as osteomyelitis. Durbin M, et al. **Clin Orthop** 1998 Dec;(357):176–85 (36 ref.)
Osteomyelitis: a review of currently used imaging techniques. Sammak B, et al. **Eur Radiol** 1999;9(5):894–900 (43 ref.)
Radiology case of the month. Nail puncture wound to the foot. Mycobacterium chelonei osteomyelitis. Wilson S, et al. **J La State Med Soc** 1999 May;151(5):251–2 (6 ref.)
Chronic recurrent multifocal osteomyelitis involving the mandible in a 4–year–old girl: a case report and a review of the literature. Otsuka K, et al. **J Oral Maxillofac Surg** 1999 Aug;57(8):1013–6 (15 ref.)
Management of vertebral diskitis and osteomyelitis. Khan IA, et al. **Orthopedics** 1999 Aug;22(8):758–65 (56 ref.)
MRI description of vertebral osteomyelitis, neoplasm, and compression fracture. Vaccaro AR, et al. **Orthopedics** 1999 Jan;22(1):67–73; quiz 74–5 (18 ref.)
Imaging osteomyelitis and the diabetic foot. Becker W. **Q J Nucl Med** 1999 Mar;43(1):9–20 (48 ref.)
Imaging techniques for evaluation of postoperative orthopedic infections. Seabold JE, et al. **Q J Nucl Med** 1999 Mar;43(1):21–8 (34 ref.)
[Diagnosis and therapy of pediatric and juvenile hematogenous osteomyelitis (see comments)] Dresing K, et al. **Unfallchirurg** 1998 Sep;101(9):662–73 (70 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1998 Sep;101(9):661. **(Ger)**

DRUG THERAPY

Antimicrobial treatment of chronic osteomyelitis. Mader JT, et al. **Clin Orthop** 1999 Mar;(360):47–65 (105 ref.)
Outpatient parenteral antimicrobial therapy for osteomyelitis. Tice AD. **Infect Dis Clin North Am** 1998 Dec;12(4):903–19 (78 ref.)

EPIDEMIOLOGY

Aggressive treatment of 119 open fracture wounds. DeLong WG Jr, et al. **J Trauma** 1999 Jun;46(6):1049–54 (25 ref.)

ETIOLOGY

Vertebral osteomyelitis associated with cat–scratch disease. Hulzebos CV, et al. **Clin Infect Dis** 1999 Jun;28(6):1310–2 (28 ref.)
Latex hypersensitivity/glove component reaction as a contributing factor to osteomyelitis of the hand: a case report and review of the literature. Duplechain MT, et al. **J La State Med Soc** 1998 Nov;150(11):527–32 (22 ref.)
Myelopathy secondary to spinal epidural abscess: case reports and a review. Yin KS, et al. **J Spinal Cord Med** 1998 Oct; 21(4):348–54 (32 ref.)

MICROBIOLOGY

Vertebral osteomyelitis due to salmonellae: report of two cases and review. Santos EM, et al. **Clin Infect Dis** 1998 Aug;27(2):287–95 (86 ref.)
Actinomyces pyogenes septic arthritis in a diabetic farmer. Lynch M, et al. **J Infect** 1998 Jul;37(1):71–3 (9 ref.)
Vertebral Aspergillus osteomyelitis and acute diskitis in patients with chronic obstructive pulmonary disease. Martinez M, et al. **Mayo Clin Proc** 1999 Jun;74(6):579–83 (31 ref.)
Group B streptococcal osteomyelitis in adults. García–Lechuz JM, et al. **Medicine (Baltimore)** 1999 May; 78(3):191–9 (68 ref.)
Clostridium septicum osteomyelitis: case report and review. Shetty AK, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):927–9 (13 ref.)

PHYSIOPATHOLOGY

Pathophysiology of posttraumatic osteomyelitis. Tsukayama DT. **Clin Orthop** 1999 Mar;(360):22–9 (61 ref.)

RADIOGRAPHY

Primary multifocal tuberculous osteomyelitis with involvement of the ribs. Chang DS, et al. **Skeletal Radiol** 1998 Nov;27(11):641–5 (21 ref.)

SURGERY

Prosthetic options for below knee amputations after osteomyelitis and nonunion of the tibia. Moshirfar A, et al. **Clin Orthop** 1999 Mar;(360):110–21 (41 ref.)
Osteomyelitis debridement techniques. Tetsworth K, et al. **Clin Orthop** 1999 Mar;(360):87–96 (38 ref.)
Efficacy of microsurgical free–tissue transfer in chronic osteomyelitis of the leg and foot: review of 22 cases. Musharafieh R, et al. **J Reconstr Microsurg** 1999 May; 15(4):239–44 (59 ref.)
[Nonbacterial osteomyelitis of the clavicle] Walz M, et al. **Chirurg** 1998 Nov;69(11):1244–51 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Osteomyelitis of the hand. Barbieri RA, et al. **Hand Clin** 1998 Nov;14(4):589–603, ix (133 ref.)
Management of vertebral diskitis and osteomyelitis. Khan IA, et al. **Orthopedics** 1999 Aug;22(8):758–65 (56 ref.)

VETERINARY

Treatment of severe orthopedic infections. Dernell WS. **Vet Clin North Am Small Anim Pract** 1999 Sep; 29(5):1261–74, ix (91 ref.)

OSTEONECROSIS

Osteonecrosis of the humeral head. Loebenberg MI, et al. **Instr Course Lect** 1999;48:349–57 (34 ref.)

DIAGNOSIS

[Role of arthroscopy in knee joint osteonecrosis] Baillon M, et al. **Acta Orthop Belg** 1999;65 Suppl 1:127–8 (8 ref.) **(Fre)**
[Vertebral necrosis] Legaye J. **Acta Orthop Belg** 1999;65 Suppl 1:97–8 (11 ref.) **(Fre)**

DRUG THERAPY

Cell biology during repair of osteonecrosis: implications for rational treatment. Glimcher MJ. **Acta Orthop Belg** 1999; 65 Suppl 1:17–22 (9 ref.)

ETIOLOGY

Coagulopathies and osteonecrosis. Jones JP Jr. **Acta Orthop Belg** 1999;65 Suppl 1:5–8 (24 ref.)
The pathogenesis of osteonecrosis and the relationships to corticosteroids. Mirzai R, et al. **J Asthma** 1999;36(1):77–95 (85 ref.)
Talar neck fractures and rates of avascular necrosis. Metzger MJ, et al. **J Foot Ankle Surg** 1999 Mar–Apr;38(2):154–62 (37 ref.)
[Incidence of humeral head osteonecrosis after fracture of the superior end of the humerus] Zygas P. **Acta Orthop Belg** 1999;65 Suppl 1:99–103 (19 ref.) **(Fre)**

PATHOLOGY

Osteonecrosis of the humeral head. Loebenberg MI, et al. **Instr Course Lect** 1999;48:349–57 (34 ref.)
[Use of needle biopsy in femoral condyle osteonecrosis] Ficat C. **Acta Orthop Belg** 1999;65 Suppl 1:123–6 (18 ref.) **(Fre)**

PHYSIOPATHOLOGY

Cell biology during repair of osteonecrosis: implications for rational treatment. Glimcher MJ. **Acta Orthop Belg** 1999; 65 Suppl 1:17–22 (9 ref.)

SURGERY

[Role of arthroscopy in knee joint osteonecrosis] Baillon M, et al. **Acta Orthop Belg** 1999;65 Suppl 1:127–8 (8 ref.) **(Fre)**

OSTEOPATHIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

OSTEOPATHIC MEDICINE

STANDARDS

[Osteopathy and chiropractic] Klein P. **Rev Med Brux** 1998 Sep;19(4):A283–9 (28 ref.) (Eng. Abstr.) **(Fre)**

OSTEOPATHY see **OSTEOPATHIC MEDICINE**

OSTEOPENIA see **BONE DISEASES, METABOLIC**

OSTEOPETROSIS

[Marble bone disease] Horiuchi A. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):149–51 (10 ref.) **(Jpn)**

COMPLICATIONS

Orthopedic management of osteopetrosis: results of a survey and review of the literature. Armstrong DG, et al. **J Pediatr Orthop** 1999 Jan–Feb;19(1):122–32 (63 ref.)

PHYSIOPATHOLOGY

Osteopetrosis as a model for studying bone resorption. Bénichou OD, et al. **Rev Rhum Engl Ed** 1998 Dec; 65(12):778–87 (98 ref.)

RADIOGRAPHY

[Osteopetrosis: a case report and review of literature] Sulko J, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):399–402 (18 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

[Bilateral total hip prosthesis in osteopetrosis. Apropos of a case. Review of the literature] Wodecki P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):558–62 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Orthopedic management of osteopetrosis: results of a survey and review of the literature. Armstrong DG, et al. **J Pediatr Orthop** 1999 Jan–Feb;19(1):122–32 (63 ref.)

OSTEOPHYTOSIS, SPINAL see **SPINAL OSTEOPHYTOSIS**

OSTEOPOROSIS

Diagnosis and treatment of glucocorticoid–induced osteoporosis. Zaqqa D, et al. **Cleve Clin J Med** 1999 Apr; 66(4):221–30 (60 ref.)
Management of osteoporosis. Miller PD. **Dis Mon** 1999 Feb; 45(2):21–54 (100 ref.)
Osteoporosis in older men: discovering when and how to treat it. Siddiqui NA, et al. **Geriatrics** 1999 Sep;54(9):20–2, 27–8, 30 passim (31 ref.)
ACOG educational bulletin. Osteoporosis. Number 246, April 1998 (replaces No. 167, May 1992). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Aug;62(2):193–201 (30 ref.)
Osteoporosis: an update. el–Hajj Fuleihan G. **J Med Liban** 1998 Jan–Feb;46(1):23–8 (56 ref.)
Report on osteoporosis in the European Community: current status and recommendations for the future. Working Party from European Union Member States. Compston JE, et al. **Osteoporos Int** 1998;8(6):531–4 (0 ref.)
Osteoporosis in end–state renal disease. Lindberg JS, et al. **Semin Nephrol** 1999 Mar;19(2):115–22 (61 ref.)
[Male osteoporosis] Trèves R, et al. **Presse Med** 1998 Oct 24;27(32):1647–51 (45 ref.) (Eng. Abstr.) **(Fre)**
[Osteoporosis and the prevention of age–related fractures] Takeuchi T. **Nippon Ika Daigaku Zasshi** 1998 Aug; 65(4):324–7 (6 ref.) **(Jpn)**
[Osteoporosis] Hosoi T. **Nippon Ronen Igakkai Zasshi** 1999 May;36(5):317–22 (18 ref.) **(Jpn)**

BLOOD

[The hematological aspects of osteoporosis] Zhulkevych IV, et al. **Lik Sprava** 1999 Mar;(2):12–7 (38 ref.) **(Ukr)**

CHEMICALLY INDUCED

Calcium in corticosteroid–induced osteoporosis. Lucas KH, et al. **Ann Pharmacother** 1998 Sep;32(9):970–2 (17 ref.)
The role of vitamin D in corticosteroid–induced osteoporosis: a meta–analytic approach. Amin S, et al. **Arthritis Rheum** 1999 Aug;42(8):1740–51 (67 ref.)
Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Ginzler EM, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):495–510 (102 ref.)
Metabolic bone disease in adults with inflammatory bowel disease. Adachi JD, et al. **Inflamm Bowel Dis** 1999 Aug; 5(3):200–11 (137 ref.)
Osteoporosis in the corticosteroid–treated patient with asthma. Ledford D, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):353–62 (87 ref.)
Glucocorticoid–induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. Ishida Y, et al. **J Bone Miner Res** 1998 Dec;13(12):1822–6 (81 ref.)
New developments in the pathogenesis and treatment of steroid–induced osteoporosis[Editorial] Manolagas SC, et al. **J Bone Miner Res** 1999 Jul;14(7):1061–6 (38 ref.)
A UK Consensus Group on management of glucocorticoid–induced osteoporosis: an update. Eastell R, et al. **J Intern Med** 1998 Oct;244(4):271–92 (129 ref.)
Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients? [editorial] Arlen DJ, et al. **J Nephrol** 1999 Jan–Feb; 12(1):5–8 (29 ref.)
Prevention and treatment of glucocorticoid–induced osteoporosis. Eggelmeijer F. **Pharm World Sci** 1998 Oct; 20(5):193–7 (50 ref.)
Steroid–induced osteoporosis. Are your asthmatic patients at risk? Niewoehner CB, et al. **Postgrad Med** 1999 Mar; 105(3):79–83, 87–8, 91 (21 ref.)
Bone loss and glucocorticoid therapy in patients with respiratory disease. Fairney A. **Thorax** 1999 Aug;54 Suppl 2:S52–7 (65 ref.)
[Corticosteroid osteoporosis in the adult] Weryha G, et al. **Presse Med** 1998 Oct 24;27(32):1641–6 (44 ref.) (Eng. Abstr.) **(Fre)**
[Post–steroidal osteoporosis] Drozdzowska B, et al. **Przegl Lek** 1999;56(2):157–60 (21 ref.) (Eng. Abstr.) **(Pol)**
[Glucocorticoid–induced osteoporosis] Povorozniuk VV, et al. **Lik Sprava** 1998 Jul–Aug;(5):34–41 (52 ref.) **(Ukr)**

COMPLICATIONS

Prevention of osteoporotic fractures—should orthopedic

surgeons care? Obrant KJ. **Acta Orthop Scand** 1998 Aug; 69(4):333–8 (39 ref.)

Are osteoporotic fractures due to osteoporosis? Impacts of a frailty pandemic in an aging world. Elffors L. **Aging (Milano)** 1998 Jun;10(3):191–204 (116 ref.)

Musculoskeletal challenges of osteoporosis. Sinaki M. **Aging (Milano)** 1998 Jun;10(3):249–62 (68 ref.)

Prevention of osteoporosis and fractures. Ullom-Minnich P. **Am Fam Physician** 1999 Jul;60(1):194–202 (43 ref.)

Changing perceptions in osteoporosis [see comments] Wilkin TJ. **BMJ** 1999 Mar 27;318(7187):862–4 (17 ref.) Comment in: BMJ 1999 Mar 27;318(7187):864–5.

Comments on the hypotheses underlying fracture risk assessment in osteoporosis as proposed by the World Health Organization. Sandor T, et al. **Calcif Tissue Int** 1999 Mar; 64(3):267–70 (18 ref.)

Managing acute osteoporotic vertebral fractures with calcitonin. Maksymowych WP. **Can Fam Physician** 1998 Oct;44:2160–6 (27 ref.)

Osteoporosis in patients with cystic fibrosis. Ott SM, et al. **Clin Chest Med** 1998 Sep;19(3):555–67 (45 ref.)

Osteopenia and osteoporosis in children. Cassidy JT. **Clin Exp Rheumatol** 1999 Mar–Apr;17(2):245–50 (107 ref.)

The female athlete triad. Putukian M. **Clin Sports Med** 1998 Oct;17(4):675–96, v (89 ref.)

A strategy for osteoporosis in gastroenterology. Scott EM, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):689–96; discussion 696–8 (80 ref.)

Developing a strategy for the prevention of hip fractures in the elderly due to osteoporosis: the application of economics to the findings from a clinical trial. Phillips CJ, et al. **Int J Clin Pract** 1998 Jul–Aug;52(5):335–40 (29 ref.)

Surgical treatment of acetabular fractures in elderly patients with osteoporotic bone. Mears DC. **J Am Acad Orthop Surg** 1999 Mar–Apr;7(2):128–41 (43 ref.)

Is Charcot arthropathy a late sequela of osteoporosis in patients with diabetes mellitus? Childs M, et al. **J Foot Ankle Surg** 1998 Sep–Oct;37(5):437–9; discussion 449 (22 ref.)

Management of patients with vertebral compression fractures. Lyles KW. **Pharmacotherapy** 1999 Jan;19(1 Pt 2):21S–24S (27 ref.)

The epidemiology of osteoporosis. Practical implications for patient care. Goddard D, et al. **Postgrad Med** 1998 Oct; 104(4):54–6, 65, 69–72 (27 ref.)

DIAGNOSIS

Treatment considerations in the management of age-related osteoporosis. Rubin CD. **Am J Med Sci** 1999 Sep; 318(3):158–70 (115 ref.)

Is screening for osteoporosis worthwhile? Walker-Bone K, et al. **Br Med Bull** 1998;54(4):915–27 (50 ref.)

Clinical utility of markers of bone turnover in children and adolescents. de Ridder CM, et al. **Curr Opin Pediatr** 1998 Aug;10(4):441–8 (28 ref.)

Bone densitometry in orthopaedic practice [see comments] Mirsky EC, et al. **J Bone Joint Surg Am** 1998 Nov; 80(11):1687–98 (80 ref.) Comment in: J Bone Joint Surg Am 1998 Nov;80(11):1567–9.

Osteoporosis: current approaches and future prospects in diagnosis, pathogenesis, and management. Raisz LG. **J Bone Miner Metab** 1999;17(2):79–89 (97 ref.)

Bone densitometry: the best way to detect osteoporosis and to monitor therapy. Miller PD, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1867–71 (36 ref.)

The diagnosis and treatment of osteoporosis: future prospects. Baylink DJ, et al. **Mol Med Today** 1999 Mar;5(3):133–40 (50 ref.)

Quantitative bone mineral assessment at the forearm: a review. Augat P, et al. **Osteoporos Int** 1998;8(4):299–310 (133 ref.)

How to get the most out of bone densitometry. Results can help assess fracture risk and guide therapy [published erratum appears in Postgrad Med 1999 Mar;105(3):39] Bracker MD, et al. **Postgrad Med** 1998 Oct;104(4):77–9, 83–6 (17 ref.)

Osteoporosis and bone densitometry. Ott K. **Radiol Technol** 1998 Nov–Dec;70(2):129–48; quiz 149–52 (37 ref.)

Osteoporosis and the individual patient. Paterson CR. **Scott Med J** 1998 Apr;43(2):35–6 (13 ref.)

CT and MR assessment of osteoporosis. Grampp S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):2–9 (66 ref.)

[Computer-assisted structure analysis of trabecular bone in the diagnosis of osteoporosis] Link TM, et al. **Radiologe** 1998 Oct;38(10):853–9 (75 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic procedure in the woman] Kraenzlin ME. **Ther Umsch** 1998 Nov;55(11):659–66 (40 ref.) (Eng. Abstr.) **(Ger)**

[Osteoporosis in the man: diagnosis and therapy] Ringe JD, et al. **Ther Umsch** 1998 Nov;55(11):717–23 (30 ref.) (Eng. Abstr.) **(Ger)**

[Biochemical markers of bone metabolism: clinical value in general practice] Seibel MJ. **Ther Umsch** 1998 Nov; 55(11):676–84 (24 ref.) (Eng. Abstr.) **(Ger)**

[Osteoporosis in developmental age: diagnostic and therapeutic problems] Chlebna-Sokół D. **Pol Merkuriusz Lek** 1998 Oct;5(28):229–32 (30 ref.) (Eng. Abstr.) **(Pol)**

[Biochemical indicators of metabolic disorders in bone tissue. I. Bone formation] Minchenko BI, et al. **Klin Lab Diagn** 1999 Apr;(4):11–7 (24 ref.) **(Rus)**

DIET THERAPY

Heritable and nutritional influences on bone mineral mass. Ferrari S, et al. **Aging (Milano)** 1998 Jun;10(3):205–13 (67 ref.)

[Osteoporosis and nutrition] Burckhardt P. **Ther Umsch** 1998 Nov;55(11):712–6 (35 ref.) (Eng. Abstr.) **(Ger)**

[Mechanisms of calcium absorption and absorption modifiers based in the elaboration of a low-cost diet for osteoporosis patients] Mota-Blancas E, et al. **Gac Med Mex** 1999 May–Jun;135(3):291–304 (88 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Bisphosphonates and osteoporosis treatment in Italy. Gennari C, et al. **Aging (Milano)** 1998 Aug;10(4):284–94 (67 ref.)

Pharmacological management of osteoporosis. Papapoulos SE. **Aging (Milano)** 1998 Jun;10(3):263–8 (25 ref.)

Recombinant human growth hormone as potential therapy for osteoporosis. Marcus R. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):251–60 (43 ref.)

The use of calcium in the management of osteoporosis. Kanis JA. **Bone** 1999 Apr;24(4):279–90 (168 ref.)

Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis. Kaufman JM, et al. **Calcif Tissue Int** 1999 Jul;65(1):4–7 (11 ref.)

Ultrasound and alendronate: new tools for osteoporosis screening and treatment [see comments] Tonino RP. **Cleve Clin J Med** 1998 Sep;65(8):398–401 (15 ref.) Comment in: Cleve Clin J Med 1998 Sep;65(8):403.

The effects of testosterone on osteoporosis in men. Francis RM. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):411–4 (43 ref.)

The interpretation of preclinical data in predicting bisphosphonate response in the treatment of osteoporosis. Ringe JD. **Clin Ther** 1998 Jul–Aug;20(4):648–60 (55 ref.)

Parathyroid hormone and parathyroid hormone-related protein: model systems for the development of an osteoporosis therapy. Mierke DF, et al. **Curr Pharm Des** 1999 Jan;5(1):21–36 (177 ref.)

Alternatives to the use of estrogen in postmenopausal women. Pinkerton JV, et al. **Endocr Rev** 1999 Jun;20(3):308–20 (128 ref.)

Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Meunier PJ. **Int J Clin Pract** 1999 Mar; 53(2):122–9 (68 ref.)

Stemming bone loss by suppressing apoptosis [comment] Hock JM. **J Clin Invest** 1999 Aug;104(4):371–3 (44 ref.) Comment on: J Clin Invest 1999 Aug;104(4):439–46.

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. Eastell R, et al. **J Intern Med** 1998 Oct;244(4):271–92 (129 ref.)

Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients? [editorial] Arlen DJ, et al. **J Nephrol** 1999 Jan–Feb; 12(1):5–8 (29 ref.)

Vitamin D and its metabolites in the treatment of osteoporosis. Burckhardt P, et al. **Osteoporos Int** 1998;8 Suppl 2:S40–4 (53 ref.)

Fluoride therapy in osteoporosis: the tide is ebbing. Kuntz D. **Rev Rhum Engl Ed** 1999 Feb;66(2):67–9 (46 ref.)

Preclinical development of agents for the treatment of osteoporosis. Hartke JR. **Toxicol Pathol** 1999 Jan–Feb; 27(1):143–7 (53 ref.)

[Fluoride treatment: a good choice in osteoporosis (see comments)] Duursma SA, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1915–9 (61 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Aug 22;142(34):1902–3. **(Dut)**

[Fluoride in osteoporosis: still an experimental and controversial treatment (see comments)] Lips P. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1913–5 (11 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Aug 22;142(34):1902–3. **(Dut)**

[Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis] Chapurlat R, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(8):743–51 (54 ref.) (Eng. Abstr.) **(Fre)**

[Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders] Raue F. **Internist (Berl)** 1999 Apr;40(4):448–55 (61 ref.) **(Ger)**

[The use of fluoride in the treatment of osteoporosis] Bohatyrewicz A. **Chir Narzadow Ruchu Ortop Pol** 1998; 63(3):267–71 (19 ref.) (Eng. Abstr.) **(Pol)**

[Calcitonin -- 1998] Lorenc RS. **Pol Merkuriusz Lek** 1998 Oct;5(28):236–7 (17 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Social and economic aspects of osteoporosis. Joel ME, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):362–7 (30 ref.)

ENZYMOLOGY

Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis. Needleman P, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):367–70 (28 ref.)

EPIDEMIOLOGY

Racial bias in federal nutrition policy, Part I: The public health implications of variations in lactase persistence. Bertron P, et al. **J Natl Med Assoc** 1999 Mar;91(3):151–7 (52 ref.)

Excess retinol intake may explain the high incidence of osteoporosis in northern Europe. Whiting SJ, et al. **Nutr Rev** 1999 Jun;57(6):192–5 (27 ref.)

Role of risk assessment and bone density monitoring in osteoporosis. Semla TP. **Pharmacotherapy** 1999 Jan;19(1 Pt 2):2S–6S (93 ref.)

ETIOLOGY

Secondary osteoporosis. Gennari C, et al. **Aging (Milano)** 1998 Jun;10(3):214–24 (146 ref.)

Osteoporosis for the allergist. Tangsinmankong N, et al. **Ann Allergy Asthma Immunol** 1999 Jan;82(1):5–12; quiz 13–4 (67 ref.)

Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation. Ng TM, et al. **Ann Pharmacother** 1999 Feb;33(2):233–5 (24 ref.)

Systemic lupus erythematosus and related disorders of childhood. Arkachaisri T, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):384–92 (63 ref.)

Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Ebeling PR. **Drugs Aging** 1998 Dec;13(6):421–34 (98 ref.)

Evaluation of risk in autonomously functioning thyroid nodules. Mann K. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S23–6 (43 ref.)

Inflammatory bowel disease and osteoporosis [editorial] Ljunghall S, et al. **Ital J Gastroenterol Hepatol** 1999 Mar; 31(2):103–9 (86 ref.)

Exercise-induced loss of bone density in athletes. Voss LA, et al. **J Am Acad Orthop Surg** 1998 Nov–Dec;6(6):349–57 (41 ref.)

Osteoporosis: implications for risk reduction in the college setting [see comments] Leslie M, et al. **J Am Coll Health** 1999 Sep;48(2):67–71 (25 ref.) Comment in: J Am Coll Health 1999 Sep;48(2):51–4.

Clinical review 106: Amenorrheic bone loss. Miller KK, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1775–83 (156 ref.)

Osteoporosis and eating disorders. Powers PS. **J Pediatr Adolesc Gynecol** 1999 May;12(2):51–7 (41 ref.)

Osteoporosis: gender differences and similarities. Khosla S, et al. **Lupus** 1999;8(5):393–6 (24 ref.)

Risk factors in osteoporosis. Kanis JA, et al. **Maturitas** 1998 Nov 16;30(3):229–33 (8 ref.)

Pathophysiology of osteoarthritis. Martel-Pelletier J. **Osteoarthritis Cartilage** 1999 Jul;7(4):371–3 (16 ref.)

Nutrition and bone health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food Nutrition Policy. **Rep Health Soc Subj (Lond)** 1998; 49:iii–xvii, 1–24 (321 ref.)

Asthma and chronic obstructive airway diseases are associated with osteoporosis and fractures: a literature review. Smith BJ, et al. **Respirology** 1999 Jun;4(2):101–9 (76 ref.)

Osteoporosis. Liggett NW, et al. **Scott Med J** 1997 Oct; 42(5):141–2 (17 ref.)

Severe kyphosis secondary to glucocorticoid-induced osteoporosis in a young adult with Cushing's disease. A case report and literature review. Freehill AK, et al. **Spine** 1999 Jan 15;24(2):189–93 (14 ref.)

The female athlete. The triad of disordered eating, amenorrhoea and osteoporosis. West RV. **Sports Med** 1998 Aug;26(2):63–71 (35 ref.)

[Differential osteoporosis diagnosis in the woman] Lippuner K, et al. **Ther Umsch** 1998 Nov;55(11):685–95 (127 ref.) (Eng. Abstr.) **(Ger)**

[Malnutrition and osteoporosis] Rizzoli R, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I31–7 (60 ref.) (Eng. Abstr.) **(Ger)**

[The influence of thyroid diseases and their treatment on the development of osteoporosis] Ciesielska-Kopacz N, et al. **Przegl Lek** 1998;55(5):271–3 (19 ref.) (Eng. Abstr.) **(Pol)**

[Rheumatoid arthritis and osteoporosis] Bazhenov AN, et al. **Klin Med (Mosk)** 1998;76(7):15–20 (108 ref.) **(Rus)**

[Positional regulators of bone tissue--a basis for the autoregulatory mechanism of the development and reproduction of osteoporosis] Avrunin AS, et al. **Morfologiia** 1998;114(4):7–12 (49 ref.) (Eng. Abstr.) **(Rus)**

[Osteoporosis in elderly patients suffering form rheumatoid arthritis] Revkovskaia NS. **Ter Arkh** 1998;70(11):69–71 (18 ref.) **(Rus)**

[Athletic amenorrhea and its consequences. Hard physical training at an early age can cause serious bone damage] Hirschberg AL, et al. **Lakartidningen** 1998 Dec 9; 95(50):5765–70 (43 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Heritable and nutritional influences on bone mineral mass. Ferrari S, et al. **Aging (Milano)** 1998 Jun;10(3):205–13 (67 ref.)

The genetics of osteoporosis. Ralston SH. **Bone** 1999 Jul; 25(1):85–6 (26 ref.)

Genetic aspects of osteoporosis. Ferrari S, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):294–300 (69 ref.)

Recent progress in understanding the genetic susceptibility to osteoporosis. Zmuda JM, et al. **Genet Epidemiol** 1999; 16(4):356–67 (64 ref.)
Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. Wonke B, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:795–801 (10 ref.)
[Genetic factors in osteoporosis] Lukaszkiewicz J, et al. **Pol Merkuriusz Lek** 1998 Oct;5(28):225–8 (29 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Calcium in corticosteroid-induced osteoporosis. Lucas KH, et al. **Ann Pharmacother** 1998 Sep;32(9):970–2 (17 ref.)
Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status. Rosen CJ, et al. **Postgrad Med** 1998 Oct;104(4):101–2, 107–10, 113–4 (23 ref.)

PATHOLOGY

Stemming bone loss by suppressing apoptosis [comment] Hock JM. **J Clin Invest** 1999 Aug;104(4):371–3 (44 ref.) Comment on: J Clin Invest 1999 Aug;104(4):439–46.
Mechanical analysis of bone and its microarchitecture based on in vivo voxel images. Ulrich D, et al. **Technol Health Care** 1998 Dec;6(5–6):421–7 (16 ref.)

PHYSIOPATHOLOGY

Cellular and molecular mechanisms of osteoporosis. Manolagas SC. **Aging (Milano)** 1998 Jun;10(3):182–90 (69 ref.)
Musculoskeletal challenges of osteoporosis. Sinaki M. **Aging (Milano)** 1998 Jun;10(3):249–62 (68 ref.)
Nutrition, osteoporosis, and aging. Nordin BE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:336–51 (63 ref.)
Nutrition and osteoporosis. Lau EM, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):368–72 (52 ref.)
Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status. Rosen CJ, et al. **Postgrad Med** 1998 Oct;104(4):101–2, 107–10, 113–4 (23 ref.)
A review of magnetic resonance (MR) imaging of trabecular bone micro-architecture: contribution to the prediction of biomechanical properties and fracture prevalence. Majumdar S. **Technol Health Care** 1998 Dec;6(5–6):321–7 (31 ref.)
[Bone densitometry by dual energy methods] Felsenberg D, et al. **Radiologe** 1999 Mar;39(3):186–93 (37 ref.) (Eng. Abstr.) **(Ger)**
[Pathophysiology and therapy of osteoporosis] Pietschmann P, et al. **Radiologe** 1999 Mar;39(3):228–34 (30 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prevention of osteoporotic fractures—should orthopedic surgeons care? Obrant KJ. **Acta Orthop Scand** 1998 Aug; 69(4):333–8 (39 ref.)
Prevention of osteoporosis and fractures. Ullom-Minnich P. **Am Fam Physician** 1999 Jul;60(1):194–202 (43 ref.)
Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Valentine JF, et al. **Am J Gastroenterol** 1999 Apr;94(4):878–83 (40 ref.)
Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation. Ng TM, et al. **Ann Pharmacother** 1999 Feb;33(2):233–5 (24 ref.)
Hormone replacement therapy. Indications, benefits and risk. Davis S. **Aust Fam Physician** 1999 May;28(5):437–45 (37 ref.)
Exercise as a therapy for osteoporosis: the drunk and the street lamp, revisited. Turner CH. **Bone** 1998 Aug; 23(2):83–5 (46 ref.)
A strategy for osteoporosis in gastroenterology. Scott EM, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):689–96; discussion 696–8 (80 ref.)
Simple, sensible preventive measures for managed care settings. Waltzer KB. **Geriatrics** 1998 Oct;53(10):65–8, 75–7, 81; quiz 82 (29 ref.)
Prevention of osteoporosis. Patel JC. **Indian J Med Sci** 1998 Dec;52(12):562–6 (3 ref.)
The role of vitamins in the prevention of osteoporosis—a brief status report. Weber P. **Int J Vitam Nutr Res** 1999 May;69(3):194–7 (41 ref.)
Osteoporosis: implications for risk reduction in the college setting [see comments] Leslie M, et al. **J Am Coll Health** 1999 Sep;48(2):67–71 (25 ref.) Comment in: J Am Coll Health 1999 Sep;48(2):51–4.
Osteoporosis in women: prevention and treatment. Willhite L. **J Am Pharm Assoc (Wash)** 1998 Sep–Oct;38(5):614–23; quiz 623–4 (86 ref.)
Menopause: when hormone replacement therapy is not an option. Part II. Waldman TN. **J Womens Health** 1998 Aug; 7(6):673–83 (41 ref.)
The effects of progressive resistance training on bone density: a review. Layne JE, et al. **Med Sci Sports Exerc** 1999 Jan; 31(1):25–30 (34 ref.)
Phytoestrogens and human health effects: weighing up the current evidence. Humfrey CD. **Nat Toxins** 1998;6(2):51–9 (76 ref.)
Prevention and treatment of osteoporosis in the elderly. O'Connell MB. **Pharmacotherapy** 1999 Jan;19(1 Pt 2):7S–20S (93 ref.)
Osteoporosis: prevention and treatment. Butler R. **Practitioner** 1999 Mar;243(1596):176–8, 183–4, 187–8 (11 ref.)
Nutrition and bone health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food Nutrition Policy. **Rep Health Soc Subj (Lond)** 1998; 49:iii–xvii, 1–24 (321 ref.)
Osteoporosis and the individual patient. Paterson CR. **Scott Med J** 1998 Apr;43(2):35–6 (13 ref.)
[Pharmacological prevention of osteoporosis in patients on corticosteroid medication] Lems WF, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1904–8 (39 ref.) (Eng. Abstr.) **(Dut)**
[Beneficial and deleterious effects of alcoholic beverages] Schlienger JL. **Rev Prat** 1999 Feb 15;49(4):367–72 (31 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of osteoporosis] Dambacher MA, et al. **Ther Umsch** 1998 Nov;55(11):702–11 (21 ref.) (Eng. Abstr.) **(Ger)**
[Osteoporosis is prevented by physical activity, calcium and hormone supplementation] Piehl-Aulin K, et al. **Lakartidningen** 1999 Jan 20;96(3):210–4 (103 ref.) (Eng. Abstr.) **(Swe)**

RADIOGRAPHY

Instrumental diagnosis of osteoporosis. Rossini M, et al. **Aging (Milano)** 1998 Jun;10(3):240–8 (62 ref.)
Quantitative diagnostic methods in osteoporosis: a review. Pocock NA. **Australas Radiol** 1998 Nov;42(4):327–34 (31 ref.)
Osteoporosis and bone densitometry. Moyer-Metzier W, et al. **Radiol Technol** 1999 May–Jun;70(5):471–4 (13 ref.)
[Micro-CT. Technology and application for assessing bone structure] Engelke K, et al. **Radiologe** 1999 Mar; 39(3):203–12 (38 ref.) (Eng. Abstr.) **(Ger)**
[Conventional radiology of osteoporosis and radiographic absorptiometry] Jergas M, et al. **Radiologe** 1999 Mar; 39(3):174–85 (106 ref.) (Eng. Abstr.) **(Ger)**
[Quantitative computer tomography] Prevrhal S, et al. **Radiologe** 1999 Mar;39(3):194–202 (62 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[Physical therapy in prevention and treatment of osteoporosis] Häuselmann HJ, et al. **Ther Umsch** 1998 Nov; 55(11):724–30 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of osteoporosis. Miller PD. **Adv Intern Med** 1999;44:175–207 (100 ref.)
Treatment considerations in the management of age-related osteoporosis. Rubin CD. **Am J Med Sci** 1999 Sep; 318(3):158–70 (115 ref.)
The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Amin S, et al. **Arthritis Rheum** 1999 Aug;42(8):1740–51 (67 ref.)
Osteoporosis and its management. Liggett NW, et al. **Hosp Med** 1999 Apr;60(4):238–42 (22 ref.)
Osteoporosis in women: prevention and treatment. Willhite L. **J Am Pharm Assoc (Wash)** 1998 Sep–Oct;38(5):614–23; quiz 623–4 (86 ref.)
Osteoporosis: current approaches and future prospects in diagnosis, pathogenesis, and management. Raisz LG. **J Bone Miner Metab** 1999;17(2):79–89 (97 ref.)
New developments in the pathogenesis and treatment of steroid-induced osteoporosis[Editorial] Manolagas SC, et al. **J Bone Miner Res** 1999 Jul;14(7):1061–6 (38 ref.)
The ongoing saga of osteoporosis treatment [published erratum appears in J Cell Biochem 1999 May 1;73(2):289] Komm BS, et al. **J Cell Biochem Suppl** 1998;30–31:277–83 (25 ref.)
Bone densitometry: the best way to detect osteoporosis and to monitor therapy. Miller PD, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1867–71 (36 ref.)
Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. Wonke B, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:795–801 (10 ref.)
The diagnosis and treatment of osteoporosis: future prospects. Baylink DJ, et al. **Mol Med Today** 1999 Mar;5(3):133–40 (50 ref.)
Prevention and treatment of glucocorticoid-induced osteoporosis. Eggelmeijer F. **Pharm World Sci** 1998 Oct; 20(5):193–7 (50 ref.)
Prevention and treatment of osteoporosis in the elderly. O'Connell MB. **Pharmacotherapy** 1999 Jan;19(1 Pt 2):7S–20S (93 ref.)
Interpreting findings from therapeutic trials in chronic joint diseases. Saraux A, et al. **Rev Rhum Engl Ed** 1999 Feb; 66(2):70–2 (0 ref.)
Osteoporosis. Liggett NW, et al. **Scott Med J** 1997 Oct; 42(5):141–2 (17 ref.)
[Osteoporosis therapy. A pluralistic approach] Lehmann R, et al. **Internist (Berl)** 1998 Dec;39(12):1253–63 (95 ref.) **(Ger)**
[Prevention and treatment of osteoporosis] Orimo H. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):480–4 (5 ref.) **(Jpn)**
[Osteoporosis in developmental age: diagnostic and therapeutic problems] Chlebna-Sokół D. **Pol Merkuriusz Lek** 1998 Oct;5(28):229–32 (30 ref.) (Eng. Abstr.) **(Pol)**
[Cryotherapy in osteoporosis] Księżopolska-Pietrzak K. **Pol Merkuriusz Lek** 1998 Oct;5(28):222–4 (21 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Enthusiasm for ultrasound for osteoporosis screening is premature [editorial; comment] Richmond BJ. **Cleve Clin J Med** 1998 Sep;65(8):403–4 (9 ref.) Comment on: Cleve Clin J Med 1998 Sep;65(8):398–401.
Ultrasound and alendronate: new tools for osteoporosis screening and treatment [see comments] Tonino RP. **Cleve Clin J Med** 1998 Sep;65(8):398–401 (15 ref.) Comment in: Cleve Clin J Med 1998 Sep;65(8):403.
Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities. Wüster C, et al. **Exp Clin Endocrinol Diabetes** 1998;106(4):277–88 (81 ref.)
Acoustic and ultrasonic tissue characterization—assessment of osteoporosis. Langton CM, et al. **Proc Inst Mech Eng [H]** 1999;213(3):261–9 (54 ref.)
Quantitative ultrasound in bone status assessment. Hans D, et al. **Rev Rhum Engl Ed** 1998 Jul–Sep;65(7–9):489–98 (90 ref.)
[Evaluation of osteoporosis with ultrasound] Roux C, et al. **Presse Med** 1998 Oct 24;27(32):1652–7 (37 ref.) (Eng. Abstr.) **(Fre)**
[Ultrasound—already clinically relevant?] Glüer CC, et al. **Ther Umsch** 1998 Nov;55(11):667–75 (34 ref.) (Eng. Abstr.) **(Ger)**

OSTEOPOROSIS, AGE-RELATED see **OSTEOPOROSIS**

OSTEOPOROSIS, POST-TRAUMATIC see **REFLEX SYMPATHETIC DYSTROPHY**

OSTEOPOROSIS, POSTMENOPAUSAL

The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Masiukiewicz US, et al. **Aging (Milano)** 1998 Jun; 10(3):232–9 (61 ref.)
Responsiveness of endpoints in osteoporosis clinical trials—an update. Cranney A, et al. **J Rheumatol** 1999 Jan; 26(1):222–8 (68 ref.)
Osteoporosis in women. Goss GL. **Nurs Clin North Am** 1998 Dec;33(4):573–82 (30 ref.)
Osteoporosis: diagnosis and prevention. Woodhead GA, et al. **Nurse Pract** 1998 Nov;23(11):18, 23–7, 31–2 passim; quiz 35–7 (30 ref.)
Postmenopausal osteoporosis. Watts NB. **Obstet Gynecol Surv** 1999 Aug;54(8):532–8 (29 ref.)
Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. **Osteoporos Int** 1998;8 Suppl 4:S7–80 (368 ref.)
An elderly woman with signs of osteoporosis. Tate P, et al. **Practitioner** 1997 Oct;241(1579):561–4, 566, 568 (0 ref.)
Osteoporosis in end-state renal disease. Lindberg JS, et al. **Semin Nephrol** 1999 Mar;19(2):115–22 (61 ref.)

COMPLICATIONS

Alendronate treatment to prevent osteoporotic fractures. Ragsdale AB, et al. **Arch Fam Med** 1998 Nov–Dec; 7(6):583–6 (14 ref.)
Menopause-related oral alveolar bone resorption: a review of relatively unexplored consequences of estrogen deficiency. Birkenfeld L, et al. **Menopause** 1999 Summer; 6(2):129–33 (25 ref.)
Using osteoporosis management to reduce fractures in elderly women. McClung BL. **Nurse Pract** 1999 Mar;24(3):26–7, 32, 35–8, passim; quiz 48–9 (37 ref.)
Stress fracture of the iliac wing due to bone insufficiency. Report of a case [letter; comment] Françon C, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):598–600 (11 ref.) Comment on: Rev Rhum Engl Ed 1997 Oct;64(10):542–8. Comment on: Rev Rhum Engl Ed 1997 Dec;64(12):853–4.

DIAGNOSIS

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Meunier PJ, et al. **Clin Ther** 1999 Jun;21(6):1025–44 (104 ref.)
Osteoporosis and bone densitometry: does the emperor have clothes? [editorial; comment] [see comments] Lentle BC. **CMAJ** 1998 Nov 17;159(10):1261–4 (27 ref.) Comment on: CMAJ 1998 Nov 17;159(10):1253–7. Comment in: CMAJ 1999 Jun 29;160(13):1822–3.
Improved strategies for diagnosis and treatment of osteoporosis. Epstein S, et al. **Menopause** 1999 Fall; 6(3):242–50 (61 ref.)
[Biochemical markers of bone turnover : clinical usefulness in osteoporosis] Garnero P, et al. **Ann Biol Clin (Paris)** 1999 Mar–Apr;57(2):137–48 (33 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic procedure in the woman] Kraenzlin ME.

Ther Umsch 1998 Nov;55(11):659–66 (40 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

[Osteoporosis and nutrition] Burckhardt P. **Ther Umsch** 1998 Nov;55(11):712–6 (35 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Etidronate and alendronate in the treatment of postmenopausal osteoporosis. Beauchesne MF, et al. **Ann Pharmacother** 1999 May;33(5):587–99 (39 ref.)

Pharmacokinetics of alendronate. Porras AG, et al. **Clin Pharmacokinet** 1999 May;36(5):315–28 (49 ref.)

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Meunier PJ, et al. **Clin Ther** 1999 Jun;21(6):1025–44 (104 ref.)

Hormone replacement therapy and ischaemic heart disease among postmenopausal women. Kardos A, et al. **J Cardiovasc Risk** 1999 Apr;6(2):105–12 (91 ref.)

The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer. Santen R, et al. **Obstet Gynecol Surv** 1998 Oct;53(10 Suppl):S1–83 (0 ref.)

What's new in preventing and treating osteoporosis? Andrews WC. **Postgrad Med** 1998 Oct;104(4):89–92, 95–7 (31 ref.)

Estrogens and osteoporosis. Ribot C, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):641–8 (75 ref.)

[Drug treatment of osteoporosis (in the woman)] Ziegler R. **Ther Umsch** 1998 Nov;55(11):696–701 (19 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Hormone replacement therapy for African American women: missed opportunities for effective intervention. Nicholson WK, et al. **Menopause** 1999 Summer;6(2):147–55 (105 ref.)

ETIOLOGY

Primary hyperparathyroidism and osteoporosis. Mazzuoli GF, et al. **Aging (Milano)** 1998 Jun;10(3):225–31 (75 ref.)

On the estrogen–bone relationship and postmenopausal bone loss: A new model. Frost HM. **J Bone Miner Res** 1999 Sep;14(9):1473–7 (19 ref.)

Mice, estrogen, and postmenopausal osteoporosis [editorial; comment] Turner RT. **J Bone Miner Res** 1999 Feb; 14(2):187–91 (26 ref.) Comment on: J Bone Miner Res 1999 Feb;14(2):178–86.

Non–primate models of osteoporosis. Hartke J. **Lab Anim Sci** 1998 Dec;48(6):623–9 (15 ref.)

Mechanical signaling in the development of postmenopausal osteoporosis. Turner RT. **Lupus** 1999;8(5):388–92 (10 ref.)

[Differential osteoporosis diagnosis in the woman] Lippuner K, et al. **Ther Umsch** 1998 Nov;55(11):685–95 (127 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Molecular changes in bone collagen in osteoporosis and osteoarthritis in the elderly. Bailey AJ, et al. **Exp Gerontol** 1999 Jun;34(3):337–51 (61 ref.)

PREVENTION & CONTROL

Raloxifene: a selective estrogen receptor modulator [see comments] Scott JA, et al. **Am Fam Physician** 1999 Sep 15;60(4):1131–9 (27 ref.) Comment in: Am Fam Physician 1999 Sep 15;60(4):1092, 1095.

Legumes and soybeans: overview of their nutritional profiles and health effects. Messina MJ. **Am J Clin Nutr** 1999 Sep; 70(3 Suppl):439S–450S (188 ref.)

Androgens and bone: clinical implications for menopausal women. Shoupe D. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):329–33 (19 ref.)

Clinical effects of raloxifene hydrochloride in women. Khovidhunkit W, et al. **Ann Intern Med** 1999 Mar 2; 130(5):431–9 (86 ref.)

Osteoporosis: current modes of prevention and treatment. Lane JM, et al. **J Am Acad Orthop Surg** 1999 Jan;7(1):19–31 (50 ref.)

Does estrogen adequately protect postmenopausal women against osteoporosis: an iconoclastic perspective. Orwoll ES, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1872–4 (14 ref.)

Adolescent nutrition in the prevention of postmenopausal osteoporosis. Weaver CM, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1839–43 (31 ref.)

Efficacy of calcium supplements on bone mass in postmenopausal women. Chiu KM. **J Gerontol A Biol Sci Med Sci** 1999 Jun;54(6):M275–80 (106 ref.)

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Davis L. **J Nurse Midwifery** 1998 Sep–Oct;43(5):395–6 (0 ref.)

Osteoporosis: intervention options. Netelenbos C. **Maturitas** 1998 Nov 16;30(3):235–9 (30 ref.)

Posi–menopausal women and osteoporosis: available choices for maintenance of skeletal health. Termine JD, et al. **Maturitas** 1998 Nov 16;30(3):241–5 (42 ref.)

Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy? Scheiber MD, et al. **Menopause** 1999 Fall;6(3):233–41 (61 ref.)

Using osteoporosis management to reduce fractures in elderly women. McClung BL. **Nurse Pract** 1999 Mar;24(3):26–7, 32, 35–8, passim; quiz 48–9 (37 ref.)

What's new in preventing and treating osteoporosis? Andrews WC. **Postgrad Med** 1998 Oct;104(4):89–92, 95–7 (31 ref.)

[When to prescribe hormone treatment to assure the best prevention of osteoporosis?] Ribot C. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27 Suppl 1:5–7 (17 ref.) **(Fre)**

[Can osteoporosis be prevented with low doses of estrogen?] Trémollières F. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27 Suppl 1:8–11 (24 ref.) **(Fre)**

[Hormone replacement therapy in the prevention of osteoporosis. Evolution of therapeutic methods] Trémollières F, et al. **Presse Med** 1999 Jun 19; 28(22):1188–94 (53 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of osteoporosis] Dambacher MA, et al. **Ther Umsch** 1998 Nov;55(11):702–11 (21 ref.) (Eng. Abstr.) **(Ger)**

[Biochemical markers of bone remodeling in the prevention of postmenopausal osteoporosis] Calleri L, et al. **Minerva Ginecol** 1998 Oct;50(10):423–8 (40 ref.) (Eng. Abstr.) **(Ita)**

[Osteoporosis is prevented by physical activity, calcium and hormone supplementation] Pichl–Aulin K, et al. **Lakartidningen** 1999 Jan 20;96(3):210–4 (103 ref.) (Eng. Abstr.) **(Swe)**

REHABILITATION

[Physical therapy in prevention and treatment of osteoporosis] Häuselmann HJ, et al. **Ther Umsch** 1998 Nov; 55(11):724–30 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Prevention and treatment of osteoporosis in primary biliary cirrhosis. Vleggaar FP, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):617–21 (50 ref.)

Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. Sato M, et al. **J Med Chem** 1999 Jan 14;42(1):1–24 (361 ref.)

Osteoporosis: intervention options. Netelenbos C. **Maturitas** 1998 Nov 16;30(3):235–9 (30 ref.)

Improved strategies for diagnosis and treatment of osteoporosis. Epstein S, et al. **Menopause** 1999 Fall; 6(3):242–50 (61 ref.)

Osteoporosis and exercise: a review. Sheth P. **Mt Sinai J Med** 1999 May;66(3):197–200 (29 ref.)

Prevention and treatment of postmenopausal osteoporosis. Hallworth RB. **Pharm World Sci** 1998 Oct;20(5):198–205 (70 ref.)

[Osteoporosis therapy. A pluralistic approach] Lehmann R, et al. **Internist (Berl)** 1998 Dec;39(12):1253–63 (95 ref.) **(Ger)**

ULTRASONOGRAPHY

[Evaluation of post–menopausal osteoporosis using ultrasound] Roux C, et al. **J Radiol** 1999 Mar;80(3):279–84 (69 ref.) (Eng. Abstr.) **(Fre)**

OSTEOPOROSIS, SENILE see **OSTEOPOROSIS**

OSTEORADIONECROSIS

DIAGNOSIS

Radiation–induced changes in bone. Mitchell MJ, et al. **Radiographics** 1998 Sep–Oct;18(5):1125–36; quiz 1242–3 (29 ref.)

OSTEOSARCOMA

Common musculoskeletal tumors of childhood and adolescence. Arndt CA, et al. **N Engl J Med** 1999 Jul 29; 341(5):342–52 (100 ref.)

DIAGNOSIS

Diagnosis and tumor response in osteosarcoma and Ewing's sarcoma, according to treatment protocols SSG II, SSG VIII, ISG/SSG I, SSG IV and SSG IX. Holmström T, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:27–9 (0 ref.)

Small cell osteosarcoma of the ulna: a case report and review of the literature. Mulligan ME, et al. **J Hand Surg [Am]** 1999 Mar;24(2):417–20 (12 ref.)

Intracranial osteosarcoma: report of four cases and review of the literature [letter; comment] Cohen IJ, et al. **J Neurooncol** 1999 May;43(1):93 (2 ref.) Comment on: J Neurooncol 1998 Oct;40(1):87–96.

Extraosseous osteogenic sarcoma--a rare pediatric malignancy: case report and review of the literature. Humphrey GM, et al. **J Pediatr Surg** 1999 Jun;34(6):1025–8 (29 ref.)

Pediatric bone tumors. Yaw KM. **Semin Surg Oncol** 1999 Mar;16(2):173–83 (30 ref.)

Primary juxtacortical chondrosarcoma dedifferentiating after 20 years. Kumta SM, et al. **Skeletal Radiol** 1998 Oct; 27(10):569–73 (9 ref.)

Dedifferentiated parosteal osteosarcoma with high–grade osteoclast–rich osteogenic sarcoma at presentation. Shuhaibar H, et al. **Skeletal Radiol** 1998 Oct;27(10):574–7 (16 ref.)

[Standards, options and recommendations (SOR) for diagnosis, treatment and follow–up of osteosarcoma. Groupe de travail SOR] Philip T, et al. **Bull Cancer** 1999 Feb;86(2):159–76 (145 ref.) (Eng. Abstr.) **(Fre)**

[Primary osteosarcoma of the kidney] Wikström M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):166–8 (10 ref.) **(Ger)**

GENETICS

Evidence for and implications of SV40–like sequences in human mesotheliomas and osteosarcomas. Rizzo P, et al. **Dev Biol Stand** 1998;94:33–40 (19 ref.)

METABOLISM

Small cell osteogenic sarcoma of the ribs: cytological, immunohistochemical, and ultrastructural study with literature review. Park SH, et al. **Ultrastruct Pathol** 1999 Mar–Apr;23(2):133–40 (19 ref.)

[Hormones and auto–paracrine tumor growth regulators in osteogenic sarcoma] Kushlinskii NE. **Vestn Ross Akad Med Nauk** 1998;(12):54–8 (32 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Polypoid osteosarcoma of the left atrium: report of a new case with autopsy confirmation and review of the literature. Zanella M, et al. **Ann Diagn Pathol** 1998 Jun;2(3):167–72 (31 ref.)

Primary osteogenic sarcoma of the tongue. Dubey SP, et al. **J Laryngol Otol** 1999 Apr;113(4):376–9 (8 ref.)

Primary hepatic osteosarcoma: case report and literature review. Govender D, et al. **Pathology** 1998 Aug;30(3):323–5 (13 ref.)

Practical approach to processing osteosarcomas in the surgical pathology laboratory. Wold LE. **Pediatr Dev Pathol** 1998 Sep–Oct;1(5):449–54 (4 ref.)

PHYSIOPATHOLOGY

[Bone matrix production in osteosarcoma] Schulz A, et al. **Verh Dtsch Ges Pathol** 1998;82:144–53 (38 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Intracranial osteosarcomas: report of four cases and review of the literature [see comments] Ashkan K, et al. **J Neurooncol** 1998 Oct;40(1):87–96 (41 ref.) Comment in: J Neurooncol 1999 May;43(1):93.

SECONDARY

Carcinosarcoma of the esophagus with metastases showing osteosarcoma: a case report and review of the literature. Kinoshita Y, et al. **Dis Esophagus** 1998 Jul;11(3):189–93 (14 ref.)

Osteosarcoma metastatic to the kidneys without lung involvement. Ogose A, et al. **Jpn J Clin Oncol** 1999 Aug; 29(8):395–8 (15 ref.)

SURGERY

Diagnosis and tumor response in osteosarcoma and Ewing's sarcoma, according to treatment protocols SSG II, SSG VIII, ISG/SSG I, SSG IV and SSG IX. Holmström T, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:27–9 (0 ref.)

Long–term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. Spiegel DA, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):848–55 (52 ref.)

Pediatric bone tumors. Yaw KM. **Semin Surg Oncol** 1999 Mar;16(2):173–83 (30 ref.)

[Surgical management of malignant bone tumors in the child. Saint–Etienne Hospital experience, apropos of 17 cases] Cottalorda J, et al. **Ann Chir** 1998;52(1):45–51 (20 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of osteogenic sarcoma in children] Glukhovskaia IIu, et al. **Klin Khir** 1998;(9–10):65–7 (30 ref.) **(Rus)**

THERAPY

Historical, current and future aspects of osteosarcoma treatment. Ham SJ, et al. **Eur J Surg Oncol** 1998 Dec; 24(6):584–600 (365 ref.)

[Standards, options and recommendations (SOR) for diagnosis, treatment and follow–up of osteosarcoma. Groupe de travail SOR] Philip T, et al. **Bull Cancer** 1999 Feb;86(2):159–76 (145 ref.) (Eng. Abstr.) **(Fre)**

[Combined multimodal therapy for osteosarcoma--neoadjuvant chemotherapy] Hirota T, et al. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1068–75 (20 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Small cell osteogenic sarcoma of the ribs: cytological, immunohistochemical, and ultrastructural study with literature review. Park SH, et al. **Ultrastruct Pathol** 1999 Mar–Apr;23(2):133–40 (19 ref.)

OSTEOSARCOMA, JUXTACORTICAL

DIAGNOSIS

Ossifying fibromyxoid tumor resembling parosteal osteosarcoma. Ogose A, et al. **Skeletal Radiol** 1998 Oct; 27(10):578–80 (12 ref.)

Dedifferentiated parosteal osteosarcoma with high-grade osteoclast-rich osteogenic sarcoma at presentation. Shuhaibar H, et al. **Skeletal Radiol** 1998 Oct;27(10):574–7 (16 ref.)

PATHOLOGY

The pathologist's role in the diagnosis of bone tumors: informed versus uninformed. Kilpatrick SE, et al. **Instr Course Lect** 1999;48:613–6 (7 ref.)

OSTEOSCLEROSIS

DIAGNOSIS

Erdheim–Chester disease: a case report and literature overview. Kenn W, et al. **Eur Radiol** 1999;9(1):153–8 (42 ref.)

PATHOLOGY

Erdheim–Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Egan AJ, et al. **Am J Surg Pathol** 1999 Jan; 23(1):17–26 (24 ref.)

RADIOGRAPHY

Long-term radiographic follow-up in a patient with osteosclerotic sarcoidosis of the spine and pelvis. Franco M, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):586–90 (17 ref.)

OSTEOSCLEROSIS FRAGILIS see **OSTEOPETROSIS**

OSTEOSYNTHESIS, FRACTURE see **FRACTURE FIXATION, INTERNAL**

OSTEOSYNTHESIS, FRACTURE, INTRAMEDULLARY see **FRACTURE FIXATION, INTRAMEDULLARY**

OSTEOTOMY

Role of tibial osteotomy in the treatment of medial femorotibial osteoarthritis [editorial] Nizard RS. **Rev Rhum Engl Ed** 1998 Jul–Sep;65(7–9):443–6 (28 ref.)

ADVERSE EFFECTS

Factors affecting heat generation during implant site preparation: a review of biologic observations and future considerations. Tehemar SH. **Int J Oral Maxillofac Implants** 1999 Jan–Feb;14(1):127–36 (86 ref.)

INSTRUMENTATION

[Indications and technique of bone cutting] Baumgart R, et al. **Chirurg** 1998 Nov;69(11):1188–96 (27 ref.) (Eng. Abstr.) **(Ger)**

[Osteotomy of the proximal femur for correction of post-traumatic changes] Strecker W, et al. **Chirurg** 1998 Nov;69(11):1153–60 (28 ref.) (Eng. Abstr.) **(Ger)**

[Supramalleolar corrective osteotomy] Verheyden P, et al. **Chirurg** 1998 Nov;69(11):1178–87 (26 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Acetabular reconstruction in revision total hip arthroplasty: a review of options. Markovich GD. **Am J Orthop** 1998 Oct;27(10):662–70 (63 ref.)

Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Van Royen BJ, et al. **Ann Rheum Dis** 1999 Jul;58(7):399–406 (65 ref.)

The influence of clinical and biomechanical factors on the results of valgus high tibial osteotomy. Catani F, et al. **Chir Organi Mov** 1998 Jul–Sep;83(3):249–62 (37 ref.) **(Eng, Ita)**

A comparison of different surgical approaches for the periacetabular osteotomy. Hussell JG, et al. **Clin Orthop** 1999 Jun;(363):64–72 (16 ref.)

Calcaneal osteotomy for the treatment of posterior tibial tendon dysfunction. LaFontaine J, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):491–9 (21 ref.)

Extended proximal femoral osteotomy. Aribindi R, et al. **Instr Course Lect** 1999;48:19–26 (16 ref.)

Periarticular osteotomies: the importance of limb alignment. Crawford HA, et al. **Instr Course Lect** 1999;48:279–85 (25 ref.)

Surgical approaches for revision total hip replacement surgery: the anterior trochanteric slide and the extended conventional osteotomy. Engh CA Jr, et al. **Instr Course Lect** 1999;48:3–8 (3 ref.)

Medial epicondylar osteotomy: a technique used with primary and revision total knee arthroplasty to improve surgical exposure and correct varus deformity. Engh GA. **Instr Course Lect** 1999;48:153–6 (1 ref.)

Proximal valgus tibial osteotomy for osteoarthritis of the knee. Hutchison CR, et al. **Instr Course Lect** 1999;48:131–4 (24 ref.)

Distal femoral varus osteotomy: indications and surgical technique. Phillips MI, et al. **Instr Course Lect** 1999; 48:125–9 (5 ref.)

Intertrochanteric corrective osteotomy for moderate and severe chronic slipped capital femoral epiphysis. Parsch K, et al. **J Pediatr Orthop B** 1999 Jul;8(3):223–30 (39 ref.)

Limb shortening for the management of leg length discrepancy. Coppola C, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):46–54 (107 ref.)

[Osteotomies of the mid- and back-foot in recurrent club foot] Dierauer S, et al. **Orthopade** 1999 Feb;28(2):117–24 (38 ref.) (Eng. Abstr.) **(Ger)**

[The Bernese method of periacetabular osteotomy] Leunig M, et al. **Orthopade** 1998 Nov;27(11):743–50 (38 ref.) (Eng. Abstr.) **(Ger)**

[Acetabular rotations y triple pelvic osteotomy by the Tönnis method] Tönnis D, et al. **Orthopade** 1998 Nov; 27(11):733–42 (30 ref.) (Eng. Abstr.) **(Ger)**

[Corrective osteotomies of the lower extremities following posttraumatic deformities] Siebert CH, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan–Feb;137(1):43–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Anterior cruciate ligament-plasty and high valgus tibial osteotomy as a combined procedure in anterior instability and varus deviation] Roscher E, et al. **Zentralbl Chir** 1998; 123(9):1019–26 (42 ref.) (Eng. Abstr.) **(Ger)**

OSTERTAGIA

IMMUNOLOGY

Mechanisms underlying resistance to nematode infection. Stear MJ, et al. **Int J Parasitol** 1999 Jan;29(1):51–6; discussion 73–5 (14 ref.)

OSTERTAGIA OSTERTAGI see **OSTERTAGIA**

OSTERTAGIASIS

VETERINARY

Mechanisms underlying resistance to nematode infection. Stear MJ, et al. **Int J Parasitol** 1999 Jan;29(1):51–6; discussion 73–5 (14 ref.)

OSTRICHES

Ratite production as an agricultural enterprise. Gillespie JM, et al. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):373–86 (15 ref.)

Health examinations and clinical diagnostic procedures of ratites. Tully TN Jr. **Vet Clin North Am Food Anim Pract** 1998 Nov;14(3):401–20 (12 ref.)

PHYSIOLOGY

Mechanisms of excreta formation and elimination in turkeys and ostriches. Duke GE. **J Exp Zool** 1999 Mar–Apr 1; 283(4–5):478–9 (7 ref.)

Restraint and housing of ratites. Raines AM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):387–99, v (1 ref.)

OTALGIA see **EARACHE**

OTC DRUGS see **DRUGS, NON-PRESCRIPTION**

OTITIS

DRUG THERAPY

[Corticotherapy in ENT. Subglottic laryngitis in children, acute sinusitis, naso-sinusal polyposis, sero-mucous otitis] De Corbiere S, et al. **Ann Med Interne (Paris)** 1998 Dec; 149(8):508–11 (16 ref.) (Eng. Abstr.) **(Fre)**

OTITIS EXTERNA

A GP strategy for otitis externa. Rea P, et al. **Practitioner** 1998 Jun;242(1587):466–8, 470–1 (6 ref.)

[External otitis] Takahashi S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):271–4 (7 ref.) **(Jpn)**

DIAGNOSIS

Practical guide to otitis externa. Boustred N. **Aust Fam Physician** 1999 Mar;28(3):217–21 (5 ref.)

ETIOLOGY

When not to syringe an ear. Blake P, et al. **N Z Med J** 1998 Nov 13;111(1077):422–4 (6 ref.)

THERAPY

Practical guide to otitis externa. Boustred N. **Aust Fam Physician** 1999 Mar;28(3):217–21 (5 ref.)

OTITIS MEDIA

Recent advances in otitis media. Report of the sixth research conference. **Ann Otol Rhinol Laryngol Suppl** 1998 Oct; 174:1–94 (808 ref.)

A systematic review of clinical research addressing the prevalence, aetiology, diagnosis, prognosis and therapy of otitis media in Australian Aboriginal children. Morris PS. **J Paediatr Child Health** 1998 Dec;34(6):487–97 (126 ref.)

Otitis media: the chinchilla model. Giebink GS. **Microb Drug Resist** 1999 Spring;5(1):57–72 (157 ref.)

[Acute otitis media] Sato K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):275–8 (14 ref.) **(Jpn)**

[Bullous myringitis] Satoh H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):283–5 (13 ref.) **(Jpn)**

[Chronic otitis media] Yamamoto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):279–82 (11 ref.) **(Jpn)**

[Acute otitis media in pediatrics] Richardson-López Collada V, et al. **Salud Publica Mex** 1998 Sep–Oct;40(5):450–5 (28 ref.) **(Spa)**

CLASSIFICATION

Classification of otitis media and surgical principles. Jung TT, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):369–83 (88 ref.)

COMPLICATIONS

Language, speech, and educational outcomes of otitis media. Gravel JS, et al. **J Otolaryngol** 1998;27 Suppl 2:17–25 (74 ref.)

DIAGNOSIS

Craniofacial anatomy and otitis media [letter] Kemaloğlu YK. **Am J Otol** 1999 Jul;20(4):556–8 (26 ref.)

Otitis media: back to basics. Faden H, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1105–12; quiz 1112–3 (83 ref.)

DRUG THERAPY

Pharmacotherapy to prevent the complications of allergic rhinitis. Beckman DB, et al. **Allergy Asthma Proc** 1999 Jul–Aug;20(4):215–23 (81 ref.)

Appropriate use of antibiotics for URIs in children: Part I. Otitis media and acute sinusitis. The Pediatric URI Consensus Team [see comments] Dowell SF, et al. **Am Fam Physician** 1998 Oct 1;58(5):1113–8, 1123 (39 ref.) Comment in: Am Fam Physician 1998 Oct 1;58(5):1066–8.

Otitis media: focus on antimicrobial resistance and new treatment options. Hoppe HL, et al. **Am J Health Syst Pharm** 1998 Sep 15;55(18):1881–97; quiz 1932–3 (99 ref.)

Strategies for dealing with amoxicillin failure in acute otitis media [see comments] Block SL. **Arch Fam Med** 1999 Jan–Feb;8(1):68–78 (103 ref.) Comment in: Arch Fam Med 1999 Jan–Feb;8(1):79–80.

Antibiotic treatment of acute otitis media in children under two years of age: evidence based? Damoiseaux RA, et al. **Br J Gen Pract** 1998 Dec;48(437):1861–4 (23 ref.)

Otitis media: To treat or not to treat? Schloss MD. **Can Respir J** 1999 Jan–Feb;6 Suppl A:51A–3A (15 ref.)

Drug-induced changes in eustachian tube function. Malm L, et al. **Ear Nose Throat J** 1998 Sep;77(9):778–82 (26 ref.)

Medical therapy of otitis media: use, abuse, efficacy, and morbidity. Bitnun A, et al. **J Otolaryngol** 1998;27 Suppl 2:26–36 (120 ref.)

When is it right to prescribe in URTI? Williamson I. **Practitioner** 1997 Dec;241(1581):724–6, 728, 730 (15 ref.)

[Otitis media in children] Dzierżanowska D. **Pol Merkuriusz Lek** 1998 May;4(23):281–3 (16 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Socioeconomic impact of otitis media in North America. Elden LM, et al. **J Otolaryngol** 1998;27 Suppl 2:9–16 (43 ref.)

EPIDEMIOLOGY

Otitis media: back to basics. Faden H, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1105–12; quiz 1112–3 (83 ref.)

ETIOLOGY

Complications of allergic rhinitis. Settipane RA. **Allergy Asthma Proc** 1999 Jul–Aug;20(4):209–13 (39 ref.)

Eustachian tube function and otitis media in children. Bylander-Groth A, et al. **Ear Nose Throat J** 1998 Sep; 77(9):762–4, 766, 768–9 (24 ref.)

[Labyrinthitis] Satoh H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):286–8 (13 ref.) **(Jpn)**

IMMUNOLOGY

Mucosal immunity and bacteriology of the eustachian tube. Sørensen CH, et al. **Ear Nose Throat J** 1998 Sep; 77(9):748–9, 752–3, 757–8 passim (100 ref.)

Immunization and protection in pneumococcal otitis media

studied in a rat model. Prellner K, et al.
Microb Drug Resist 1999 Spring;5(1):73–82 (37 ref.)

MICROBIOLOGY

Otitis media: focus on antimicrobial resistance and new treatment options. Hoppe HL, et al.
Am J Health Syst Pharm 1998 Sep 15;55(18):1881–97; quiz 1932–3 (99 ref.)

Strategies for dealing with amoxicillin failure in acute otitis media [see comments] Block SL. **Arch Fam Med** 1999 Jan–Feb;8(1):68–78 (103 ref.) Comment in: Arch Fam Med 1999 Jan–Feb;8(1):79–80.

Mucosal immunity and bacteriology of the eustachian tube. Sørensen CH, et al. **Ear Nose Throat J** 1998 Sep; 77(9):748–9, 752–3, 757–8 passim (100 ref.)

Clinical perspectives on sinusitis and otitis media. Blumer J. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S68–72 (33 ref.)

Acute otitis media: management and surveillance in an era of pneumococcal resistance—a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group [published erratum appears in Pediatr Infect Dis J 1999 Apr;18(4):341] [see comments] Dowell SF, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):1–9 (59 ref.) Comment in: Pediatr Infect Dis J 1999 Jun;18(6):571–2.

Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update. Jacobs MR.
Pediatr Infect Dis J 1998 Oct;17(10):947–52 (30 ref.)

PREVENTION & CONTROL

Immunization and protection in pneumococcal otitis media studied in a rat model. Prellner K, et al.
Microb Drug Resist 1999 Spring;5(1):73–82 (37 ref.)

SURGERY

Mastoid and tympanomastoid procedures in otitis media: classic mastoidectomy (simple, modified, and radical) and current adaptations; open-cavity, closed-cavity, and intact-bridge tympanomastoidectomy. Goycoolea MV.
Otolaryngol Clin North Am 1999 Jun;32(3):513–23 (4 ref.)

Classification of otitis media and surgical principles. Jung TT, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):369–83 (88 ref.)

Tympanoplasty: prudent considerations of silent otitis media and interactions of middle ear and inner ear. Vambutas A, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):505–12 (29 ref.)

Role of surgery for otitis media in the era of resistant bacteria. Bluestone CD. **Pediatr Infect Dis J** 1998 Nov; 17(11):1090–8; discussion 1099–100 (44 ref.)

[Principles of uncomplicated epi- and epimesotympanitis treatment] Melan'in VD, et al. **Vestn Otorinolaringol** 1999; (4):8–10 (3 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

No therapy: use, abuse, efficacy, and morbidity—the European versus the Third-World experience. Rutka J, et al. **J Otolaryngol** 1998;27 Suppl 2:43–8 (31 ref.)

[Otitis media] Morfin Maciel BM, et al. **Rev Alerg Mex** 1999 Jan–Feb;46(1):8–17 (33 ref.) (Eng. Abstr.) **(Spa)**

OTITIS MEDIA, PURULENT see **OTITIS MEDIA, SUPPURATIVE**

OTITIS MEDIA, SECRETORY see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SEROUS see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SUPPURATIVE

The flexible endaural tympanoplasty: pathology-guided, pathogenesis-oriented surgery for the middle ear. da Costa SS, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):413–41 (66 ref.)

MICROBIOLOGY

Otoneurosyphilis masquerading as neurofibromatosis type II. Ahmad I, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb;61(1):37–40 (17 ref.)

SURGERY

Chronic inflammatory ear disease and cholesteatoma: creation of auxiliary attic aeration pathways by microdissection. Palva T, et al. **Am J Otol** 1999 Mar; 20(2):145–51 (13 ref.)

THERAPY

Management of otitis media in a high risk population. Morris PS. **Aust Fam Physician** 1998 Nov;27(11):1021–9 (33 ref.)

OTITIS MEDIA WITH EFFUSION

Current management of glue ear. Slack R, et al.
Practitioner 1998 Jun;242(1587):455–7 (10 ref.)

[Advances in the study on middle ear effusion in secretory otitis media] Wang G, et al.
Lin Chuang Erh Pi Yen Hou Ko Tsa Chih 1997 Aug; 11(8):379–80 (15 ref.) **(Chi)**

COMPLICATIONS

Otitis media with effusion and early sequelae: flexible approach. Patterson M, et al.
Otolaryngol Clin North Am 1999 Jun;32(3):391–400 (19 ref.)

DIAGNOSIS

Otitis media: back to basics. Faden H, et al.
Pediatr Infect Dis J 1998 Dec;17(12):1105–12; quiz 1112–3 (83 ref.)

EPIDEMIOLOGY

Otitis media: back to basics. Faden H, et al.
Pediatr Infect Dis J 1998 Dec;17(12):1105–12; quiz 1112–3 (83 ref.)

SURGERY

Tympanostomy tubes: types, indications, techniques, and complications. Morris MS. **Otolaryngol Clin North Am** 1999 Jun;32(3):385–90 (21 ref.)

THERAPY

Management of otitis media in a high risk population. Morris PS. **Aust Fam Physician** 1998 Nov;27(11):1021–9 (33 ref.)

Systematic review of autoinflation for treatment of glue ear in children. Reidpath DD, et al. **BMJ** 1999 May 1; 318(7192):1177 (5 ref.)

New aspects of secretory otitis media, eustachian tube function and middle ear gas. Ovesen T, et al.
Ear Nose Throat J 1998 Sep;77(9):770–7 (68 ref.)

OTOACOUSTIC EMISSIONS, SPONTANEOUS

The role of otoacoustic emissions in screening and evaluation of noise damage. Prasher D, et al.
Int J Occup Med Environ Health 1999;12(2):183–92 (40 ref.)

[A new method for detecting congenital hearing disorders. Infants are screened by measuring otoacoustic emissions (see comments)] Hergils L. **Lakartidningen** 1999 Mar 10; 96(10):1166–8 (15 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Jun 9;96(23):2835–6. **(Swe)**

PHYSIOLOGY

Evoked otoacoustic emissions arise by two fundamentally different mechanisms: a taxonomy for mammalian OAEs. Shera CA, et al. **J Acoust Soc Am** 1999 Feb;105(2 Pt 1):782–98 (118 ref.)

OTOCONIA see **OTOLITHIC MEMBRANE**

OTOLARYNGOLOGY

see related
OTOLOGIC SURGICAL PROCEDURES
OTORHINOLARYNGOLOGIC DISEASES
OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES

Gene therapy for cystic fibrosis: perspectives for the otolaryngologist [editorial] Graham SM.
Clin Otolaryngol 1998 Dec;23(6):481–3 (23 ref.)

Gerontology in ENT (geriatric otolaryngology)—an overview. Sahoo GC. **J Indian Med Assoc** 1998 May; 96(5):145–6 (12 ref.)

[Anesthesia for maxillofacial, ear, nose and throat surgery, otorhinolaryngology in ophthalmic procedures. 2. Specific aspects of otorhinolaryngology in ophthalmic procedures] Henn-Beilharz A, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Mar; 34(3):147–70 (42 ref.) **(Ger)**

EDUCATION

Bones of contention. The supply of temporal bones for dissection: the legalities, problems and solutions. Morris DP, et al. **J Laryngol Otol** 1998 Dec;112(12):1138–41 (14 ref.)

LEGISLATION & JURISPRUDENCE

[Indicators for quality evaluation of inpatient patient care in an ENT clinic (see comments)] Streppel M, et al.
HNO 1998 Oct;46(10):864–9 (15 ref.) (Eng. Abstr.) Comment in: HNO 1998 Oct;46(10):840–1. **(Ger)**

METHODS

Geriatric demographics and the practice of otolaryngology [published erratum appears in Ear Nose Throat J 1999 Aug;78(8):548] Shapiro DP. **Ear Nose Throat J** 1999 Jun; 78(6):418–21 (5 ref.)

TRENDS

Key developments in otorhinolaryngology. Choa DI, et al.
Practitioner 1998 Jun;242(1587):478–81 (11 ref.)

OTOLITHIC MEMBRANE

Otoconia biogenesis, phylogeny, composition and functional attributes. Fermin CD, et al. **Histol Histopathol** 1998 Oct; 13(4):1103–54 (326 ref.)

PHYSIOLOGY

The interaction of otolith and proprioceptive information in the perception of verticality. The effects of labyrinthine and CNS disease. Bronstein AM. **Ann N Y Acad Sci** 1999 May 28;871:324–33 (25 ref.)

A review of otolith pathways to brainstem and cerebellum. Büttner-Ennever JA. **Ann N Y Acad Sci** 1999 May 28; 871:51–64 (86 ref.)

An alternative approach to the central processing of canal and otolith signals. Green AM, et al.
Ann N Y Acad Sci 1999 May 28;871:402–5 (8 ref.)

The role of the otoliths in perception of the vertical and in path integration. Mittelstaedt H. **Ann N Y Acad Sci** 1999 May 28;871:334–44 (31 ref.)

OTOLITHS see **OTOLITHIC MEMBRANE**

OTOLOGIC SURGICAL PROCEDURES

see related
OTOLARYNGOLOGY

METHODS

Image-guided surgical navigation in otology and neurotology. Selesnick SH, et al. **Am J Otol** 1999 Sep; 20(5):688–93; discussion 693–7 (21 ref.)

Vestibular surgery for Ménière's disease in the elderly: a review of techniques and indications. Rosenberg SI.
Ear Nose Throat J 1999 Jun;78(6):443–6 (9 ref.)

[Current possibilities in microsurgery of the external and middle ear, and the mastoid] Mudry A.
Rev Med Suisse Romande 1998 Oct;118(10):881–7 (39 ref.) **(Fre)**

OTOLOGY see **OTOLARYNGOLOGY**

OTORHINOLARYNGOLOGIC DISEASES

see related
EAR DISEASES
LARYNGEAL DISEASES
NOSE DISEASES
PHARYNGEAL DISEASES

Otolaryngologic manifestations of gastroesophageal reflux disease. Smullen JL, et al. **J La State Med Soc** 1999 Mar; 151(3):115–9 (7 ref.)

[Progresses in the study of otorhinolaryngology in China, 1997] Liu C, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):916–8 (0 ref.) **(Chi)**

[Head and neck tuberculosis] Kumoi K. **Nippon Rinsho** 1998 Dec;56(12):3148–52 (21 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Cystic fibrosis: an update for the otolaryngologist. Halvorson DJ. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):502–6 (50 ref.)

Recurrent ENT problems and wheezing in infants. Dutau G, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):18–22 (59 ref.)

[Otorhinolaryngologic causes of headache] Reiss M, et al. **Schweiz Rundsch Med Prax** 1999 May 27;88(22):992–7 (13 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Otolaryngologic manifestations of human immunodeficiency virus infection. Truitt TO, et al. **Med Clin North Am** 1999 Jan;83(1):303–15, xii (42 ref.)

[Flexible endoscopy in the ENT area] Hörmann K, et al. **HNO** 1998 Jul;46(7):654–9 (35 ref.) (Eng. Abstr.) **(Ger)**

[Otorhinolaryngologic findings in Horton temporal arteritis. Review of the literature and case report] Schmidt D, et al. **HNO** 1999 Mar;47(3):176–82 (119 ref.) (Eng. Abstr.) **(Ger)**

[Evidence-based medicine—a critical overview] Leuwer R, et al. **Laryngorhinootologie** 1999 Jul;78(7):359–64 (43 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

ENT issues in pregnancy. Lippincott LH, et al.
J La State Med Soc 1999 Jul;151(7):350–4 (13 ref.)

[Role of corticosteroid therapy in non-malignant diseases] Vignes S, et al. **Rev Med Interne** 1998 Nov;19(11):799–810 (87 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

ENT issues in pregnancy. Lippincott LH, et al.
J La State Med Soc 1999 Jul;151(7):350–4 (13 ref.)

[Otolaryngological manifestations of sarcoidosis. Report of 10 cases and review of the literature] Houliat T, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(1):19–23 (20 ref.) (Eng. Abstr.) **(Fre)**

[Heliogeophysical factors and ENT diseases] Kubyshkina IV. **Vestn Otorinolaringol** 1998;(6):54–6 (39 ref.) **(Rus)**

PATHOLOGY

Life and death in otolaryngology: mechanisms of apoptosis

and its role in the pathology and treatment of disease. Mostafapour SP, et al.
Arch Otolaryngol Head Neck Surg 1999 Jul;125(7):729–37 (105 ref.)

PREVENTION & CONTROL

Prevention of E.N.T. diseases. Apte NK, et al.
Indian J Med Sci 1998 Sep;52(9):383–94 (5 ref.)

SURGERY

Noval radiosurgical technique of cuts and hemostasis in otorhinolaryngology] Pogosov VS, et al.
Vestn Otorinolaringol 1999;(4):40–1 (6 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

[Possibilities and limits of Doppler ultrasound in the area of the head–neck] Issing PR. **HNO** 1999 Jan;47(1):6–13 (42 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Manifestations of AIDS in the head and neck. Reisacher WR, et al. **South Med J** 1999 Jul;92(7):684–97 (66 ref.)

OTORHINOLARYNGOLOGIC NEOPLASMS

DIAGNOSIS

Pediatric myofibromatosis of the head and neck. Beck JC, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jan; 125(1):39–44 (20 ref.)
[Flexible endoscopy in the ENT area] Hörmann K, et al. **HNO** 1998 Jul;46(7):654–9 (35 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Life and death in otolaryngology: mechanisms of apoptosis and its role in the pathology and treatment of disease. Mostafapour SP, et al.
Arch Otolaryngol Head Neck Surg 1999 Jul;125(7):729–37 (105 ref.)

SURGERY

Pilomatrixoma of the head and neck in children: a study of 38 cases and a review of the literature. Duflo S, et al.
Arch Otolaryngol Head Neck Surg 1998 Nov; 124(11):1239–42 (18 ref.)

THERAPY

[In search of new treatment methods for head–neck carcinoma] Kastenbauer E, et al. **Laryngorhinootologie** 1999 Jan;78(1):31–5 (41 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Possibilities and limits of Doppler ultrasound in the area of the head–neck] Issing PR. **HNO** 1999 Jan;47(1):6–13 (42 ref.) (Eng. Abstr.) **(Ger)**

OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES

see related
OTOLARYNGOLOGY

Otolaryngology. Woodson G. **J Am Coll Surg** 1999 Feb; 188(2):147–51 (39 ref.)
[Anesthesia in dental, oral, jaw, facial, and ophthalmic surgery; therapeutics of the neck, nose, and eye . I. General and specific aspects in dental, oral, jaw and facial surgery (published erratum appears in Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Mar;34(3):170)] Georgi R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan;34(1):45–65 (0 ref.) **(Ger)**
[The use of CO2 laser in otolaryngology] Budziński R.
Otolaryngol Pol 1999;53(3):343–6 (11 ref.) (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

[Fetal surgery in the head–neck area. Current status and new possibilities with the endoscope] Wagner W, et al.
HNO 1998 Nov;46(11):903–13 (86 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Recirculation of mucus as a cause of persistent sinusitis. Kane KJ. **Am J Rhinol** 1997 Sep–Oct;11(5):361–9 (9 ref.)
Use of the superior meatus and superior turbinate in the endoscopic approach to the sphenoid sinus. Bolger WE, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):308–13 (13 ref.)
[Day surgery for patients with nasal polyps] Moriyama H. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Mar;102(3):368–71 (4 ref.) **(Jpn)**
[Laser surgery in otolaryngology] Kubiczkowa J.
Otolaryngol Pol 1997;51 Suppl 25:95–104 (50 ref.) (Eng. Abstr.) **(Pol)**
Noval radiosurgical technique of cuts and hemostasis in otorhinolaryngology] Pogosov VS, et al.
Vestn Otorinolaringol 1999;(4):40–1 (6 ref.) (Eng. Abstr.) **(Rus)**

OTORHINOLARYNGOLOGY see **OTOLARYNGOLOGY**

OTOSCLEROSIS

COMPLICATIONS

Bilateral sudden sensorineural hearing loss following non-otologic surgery. de la Cruz M, et al.
J Laryngol Otol 1998 Aug;112(8):769–71 (16 ref.)
[Progressive sensorineural hearing loss in cochlear otosclerosis] Sellari-Franceschini S, et al.
Acta Otorhinolaryngol Ital 1998 Aug;18(4 Suppl 59):59–65 (59 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Complications in the surgical treatment of otosclerosis] Ristić B, et al. **Vojnosanit Pregl** 1999 Jan–Feb;56(1):69–72 (24 ref.) **(Sec)**

OTOSPONGIOSIS see **OTOSCLEROSIS**

OUABAIN

METABOLISM

Is ouabain produced by the adrenal gland? Foster RH, et al. **Gen Pharmacol** 1998 Oct;31(4):499–501 (35 ref.)

OUTBREAKS see **DISEASE OUTBREAKS**

OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)

Improving outcomes of percutaneous coronary intervention [editorial; comment] Nash IS. **Am Heart J** 1999 Jun; 137(6):979–82 (34 ref.) Comment on: Am Heart J 1999 Jun;137(6):1012–8.
Individual psychotherapy outcome and process research: challenges leading to greater turmoil or a positive transition? Kopta SM, et al. **Annu Rev Psychol** 1999; 50:441–69 (208 ref.)
Process and outcome in mental health care delivery: a model approach to treatment evaluation. Fonagy P.
Bull Menninger Clin 1999 Summer;63(3):288–304 (75 ref.)
Outcome science and stroke. Walters BC. **Clin Neurosurg** 1999;45:128–34 (40 ref.)
Review of available instruments and methods for assessing quality of life in anti-anginal trials. Bliven BD, et al.
Drugs Aging 1998 Oct;13(4):311–20 (49 ref.)
Assessing the performance of community systems for children. DuPlessis HM, et al. **Health Serv Res** 1998 Oct; 33(4 Pt 2):1111–42 (84 ref.)
Assessing the quality of healthcare provided to children. Mangione-Smith R, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1059–90 (80 ref.)
Does EMDR work? And if so, why?: a critical review of controlled outcome and dismantling research. Cahill SP, et al. **J Anxiety Disord** 1999 Jan–Apr;13(1–2):5–33 (72 ref.)
How well do physicians use electronic information retrieval systems? A framework for investigation and systematic review [see comments] Hersh WR, et al. **JAMA** 1998 Oct 21;280(15):1347–52 (35 ref.) Comment in: JAMA 1998 Oct 21;280(15):1363. Comment in: JAMA 1999 Apr 14;281(14):1272–3.
Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials. Schulman KA, et al. **Keio J Med** 1999 Mar; 48(1):1–11 (53 ref.)
Outcome after polytrauma. Bouillon B, et al.
Langenbecks Arch Surg 1998 Aug;383(3–4):228–34 (44 ref.)
Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. Tezcan H, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):273–85 (32 ref.)

METHODS

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. Murray JS, et al. **AIDS** 1999 May 7;13(7):797–804 (24 ref.)
Eye Movement Desensitization and Reprocessing: an analysis of specific versus nonspecific treatment factors. Lohr JM, et al. **J Anxiety Disord** 1999 Jan–Apr;13(1–2):185–207 (133 ref.)
Routine monitoring of the effectiveness of child psychotherapy. Weiss B. **J Child Psychol Psychiatry** 1998 Oct;39(7):943–50 (43 ref.)
Episodes of care: theoretical frameworks versus current operational realities. Rosen AK, et al.
Jt Comm J Qual Improv 1999 Mar;25(3):111–28 (51 ref.)
Administrative data for quality improvement. Schwartz RM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):291–301 (30 ref.)

ORGANIZATION & ADMINISTRATION

Promotion of evaluation as a strategy towards an effective substance prevention. Ostaszewski K. **Eur Addict Res** 1998 Sep;4(3):128–33 (33 ref.)
Measuring the benefits of clinical decision support: return on investment. Rosenstein AH.
Health Care Manage Rev 1999 Spring;24(2):32–43 (26 ref.)
Challenges in evaluating primary health care for teenagers. Research Sub–Committee of the Adolescent Working Party of the Royal College of General Practitioners, London, UK. Jacobson LD, et al. **J Eval Clin Pract** 1998 Aug; 4(3):183–9 (36 ref.)

STANDARDS

Quality and its measurement. Wilson LL.
J Qual Clin Pract 1998 Sep;18(3):163–70 (6 ref.)
The ethics of attribution: the case of health care outcome indicators. Russell E. **Soc Sci Med** 1998 Nov;47(9):1161–9 (75 ref.)

STATISTICS & NUMERICAL DATA

Studies of factors in relapse to alcohol, drug and nicotine use: a critical review of methodologies and findings. McKay JR. **J Stud Alcohol** 1999 Jul;60(4):566–76 (70 ref.)
Review of studies that compare the quality of cardiovascular care in HMO versus non-HMO settings. Seidman JJ, et al. **Med Care** 1998 Dec;36(12):1607–25 (51 ref.)

OUTCOME ASSESSMENT (HEALTH CARE)

Self-reported functional status: an important predictor of health outcomes among end-stage renal disease patients. Curtin RB, et al. **Adv Ren Replace Ther** 1999 Apr; 6(2):133–40 (46 ref.)
Asthma--a problem of health care delivery. Is it time for a new paradigm? Weinberger M. **Allergy Asthma Proc** 1999 Jan–Feb;20(1):57–65 (64 ref.)
Regionalization of infection prevention and control services in a publicly funded health care system. Wiens RM, et al. **Am J Infect Control** 1998 Aug;26(4):446–8 (5 ref.)
Patient outcomes. A measure of nursing's value. Oermann MH, et al. **Am J Nurs** 1999 Sep;99(9):40–7; quiz 48 (25 ref.)
Severity scoring systems in the modern intensive care unit. Clermont G, et al. **Ann Acad Med Singapore** 1998 May; 27(3):397–403 (44 ref.)
Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. Hecht FM, et al. **Ann Intern Med** 1999 Jul 20;131(2):136–43 (63 ref.)
Interventions for couples. Christensen A, et al.
Annu Rev Psychol 1999;50:165–90 (107 ref.)
Patient Outcomes Research Teams: contribution to outcomes and effectiveness research. Freund D, et al.
Annu Rev Public Health 1999;20:337–59 (78 ref.)
GP versus hospital follow up for cancer patients. Is the choice based on evidence? Weller D, et al.
Aust Fam Physician 1999 Apr;28(4):356–9 (11 ref.)
Are we providing adequate postnatal services? Cooke M, et al. **Aust N Z J Public Health** 1999 Apr;23(2):210–2 (16 ref.)
ABC of intensive care: outcome data and scoring systems. Gunning K, et al. **BMJ** 1999 Jul 24;319(7204):241–4 (0 ref.)
Systematic review of the effectiveness of planned short hospital stays for mental health care. Johnstone P, et al. **BMJ** 1999 May 22;318(7195):1387–90 (27 ref.)
Improving outcomes in the ICU setting: are we effectively using all of the information that is potentially available to us? [editorial; comment] Kollef MH. **Chest** 1999 Jun; 115(6):1490–2 (17 ref.) Comment on: Chest 1999 Jun;115(6):1627–31.
Biochemical risk factors and patient's outcome: the case of lipoprotein(a). Lippi G, et al. **Clin Chim Acta** 1999 Feb; 280(1–2):59–71 (95 ref.)
Outcome assessment in patients with primary Sjögren's syndrome [letter] Oxholm P, et al. **Clin Exp Rheumatol** 1998 Sep–Oct;16(5):627–8 (7 ref.)
Advertisements for ourselves--let's be cautious about interpreting outcome studies of critical care services [editorial; comment] Hall JB. **Crit Care Med** 1999 Feb; 27(2):229–30 (9 ref.) Comment on: Crit Care Med 1999 Feb;27(2):270–4.
Epidemiology, outcomes research, and drug interactions. Schein JR. **Drug Metabol Drug Interact** 1998;14(3):147–58 (34 ref.)
The midwife and her functions by level of care. Segovia I. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S61–6 (10 ref.)
Measuring morbidity in adult asthmatics. Pearce N, et al. **Int J Tuberc Lung Dis** 1999 Mar;3(3):185–91 (55 ref.)
A primer on lower extremity outcome measurement instruments. Saltzman CL, et al. **Iowa Orthop J** 1998; 18:101–11 (35 ref.)
A systematic review of the relationships between written manual nursing care planning, record keeping and patient outcomes. Moloney R, et al. **J Adv Nurs** 1999 Jul;30(1):51–7 (19 ref.)
Problems with evidence-based medicine. Lalwani SI, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):237–40 (9 ref.)
Analysis of laparoscopy in trauma. Villavicencio RT, et al. **J Am Coll Surg** 1999 Jul;189(1):11–20 (62 ref.)
Quality medical management of the geriatric population using practice guidelines, physician-managed home health services, and continuous quality-improvement management strategies. Reaves LA, et al. **J Am Osteopath Assoc** 1999 May;99(5):265–9 (32 ref.)
Outcomes research review. Douglas PS, et al.
J Am Soc Echocardiogr 1998 Sep;11(9):916–20 (3 ref.)

OUTCOME ASSESSMENT (HEALTH CARE)

Outcomes research, practice guidelines, and disease management in clinical gastroenterology. Johanson JF. **J Clin Gastroenterol** 1998 Dec;27(4):306–11 (11 ref.)

Developing an outcomes-oriented approach for the treatment of schizophrenia. Lehman AF. **J Clin Psychiatry** 1999;60 Suppl 19:30–5; discussion 36–7 (31 ref.)

Nutritional and metabolic endpoints. Haymond MW. **J Nutr** 1999 Jan;129(1S Suppl):273S–278S (20 ref.)

Outcome of bulimia nervosa: prognostic indicators. Vaz FJ. **J Psychosom Res** 1998 Nov;45(5):391–400 (70 ref.)

The effectiveness of hospital at home compared with in-patient hospital care: a systematic review. Shepperd S, et al. **J Public Health Med** 1998 Sep;20(3):344–50 (20 ref.)

Responsiveness of endpoints in osteoporosis clinical trials--an update. Cranney A, et al. **J Rheumatol** 1999 Jan; 26(1):222–8 (68 ref.)

The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. Ortiz Z, et al. **J Rheumatol** 1999 Jan; 26(1):210–6 (26 ref.)

Pediatric trauma systems: critical distinctions. Hulka F. **J Trauma** 1999 Sep;47(3 Suppl):S85–9 (28 ref.)

Systematic review of published evidence regarding trauma system effectiveness. Mann NC, et al. **J Trauma** 1999 Sep; 47(3 Suppl):S25–33 (72 ref.)

Statistical considerations when assessing outcomes following treatment for prostate cancer. Albertsen PC, et al. **J Urol** 1999 Aug;162(2):439–44 (20 ref.)

Medical outcomes studies in peripheral vascular disease. Murphy TP. **J Vasc Interv Radiol** 1998 Nov–Dec; 9(6):879–89 (50 ref.)

Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. Singhal S, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):287–94 (37 ref.)

Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: overview. Keller SD, et al. **Med Care** 1999 May;37(5 Suppl):MS1–9 (77 ref.)

Selection criteria and outcome assessment in pulmonary rehabilitation. ZuWallack RL. **Monaldi Arch Chest Dis** 1998 Aug;53(4):429–37 (35 ref.)

What are surrogate outcome measures and why do they fail in clinical research? Johnston K. **Neuroepidemiology** 1999; 18(4):167–73 (23 ref.)

Outcomes research: a review [see comments] Gerszten PC. **Neurosurgery** 1998 Nov;43(5):1146–56 (78 ref.) Comment in: Neurosurgery 1999 Apr;44(4):919–20.

Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Hearn J, et al. **Palliat Med** 1998 Sep;12(5):317–32 (61 ref.)

Outcome measures of interventions in the study of children of substance-abusing parents. Kumpfer KL. **Pediatrics** 1999 May;103(5 Pt 2):1128–44 (112 ref.)

Risk adjustment for quality improvement. Richardson D, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):255–65 (76 ref.)

Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)

Psychosocial outcome assessments for use in cardiac rehabilitation service evaluation: a 10-year systematic review. McGee HM, et al. **Soc Sci Med** 1999 May; 48(10):1373–93 (88 ref.)

Economic and outcome issues for therapeutic drug monitoring in medicine. Schumacher GE, et al. **Ther Drug Monit** 1998 Oct;20(5):539–42 (14 ref.)

The primary care of elder mistreatment. Hirsch CH, et al. **West J Med** 1999 Jun;170(6):353–8 (25 ref.)

[Health outcomes analysis and its applications] Carrera-Hueso FJ. **Rev Med Univ Navarra** 1997 Oct–Dec; 41(4):237–44 (47 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Scoring systems in the measurement of performance of ICUs. Miranda DR. **Intensive Care Med** 1999 Apr;25(4):418–9 (4 ref.)

ECONOMICS

Economics notes: measuring outcomes in economic evaluations. Torgerson D, et al. **BMJ** 1999 May 22; 318(7195):1413 (6 ref.)

Evidence-based medicine: a means of improving clinical outcome and cost-benefit ration. Sanguinetti CM. **Monaldi Arch Chest Dis** 1998 Dec;53(6):697–9 (25 ref.)

METHODS

Number needed to treat: a useful new method of assessing the magnitude of treatment effect and its application to the management of diabetic retinopathy. San Laureano JA, et al. **Aust N Z J Ophthalmol** 1999 Apr;27(2):137–42 (11 ref.)

Evaluation of early childhood programs. Schweinhart LJ. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):395–407, viii–ix (44 ref.)

Techniques for measurement and assessment of mobility in rehabilitation: a theoretical approach. Bussmann JB, et al. **Clin Rehabil** 1998 Dec;12(6):455–64 (69 ref.)

Severity scoring and outcome assessment. Computerized predictive models and scoring systems. Marik PE, et al. **Crit Care Clin** 1999 Jul;15(3):633–46, viii (67 ref.)

Using large-scale databases to measure outcomes in critical care. Pronovost P, et al. **Crit Care Clin** 1999 Jul; 15(3):615–31, vii–viii (44 ref.)

Issues in studying the effectiveness of health services for children. Lieu TA, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1041–58 (49 ref.)

Evaluating patient-based outcome measures for use in clinical trials. Fitzpatrick R, et al. **Health Technol Assess** 1998; 2(14):i–iv, 1–74 (208 ref.)

Measuring outcomes in cervical myelopathy and radiculopathy. Ludwig SC, et al. **Instr Course Lect** 1999; 48:417–21 (27 ref.)

Outcomes assessment in the information age: available instruments, data collection, and utilization of data. Simmons BP, et al. **Instr Course Lect** 1999;48:667–85 (93 ref.)

Conceptualization and measurement of quality of life as an outcome variable for health care intervention and research. Anderson KL, et al. **J Adv Nurs** 1999 Feb;29(2):298–306 (58 ref.)

The treatment of the long-term sequelae of child abuse. Stevenson J. **J Child Psychol Psychiatry** 1999 Jan; 40(1):89–111 (146 ref.)

Smallest detectable difference in outcome variables related to painful restriction of the temporomandibular joint. Kropmans TJ, et al. **J Dent Res** 1999 Mar;78(3):784–9 (50 ref.)

Clinimetric concepts in outcome assessment: the OMERACT filter. Bellamy N. **J Rheumatol** 1999 Apr;26(4):948–50 (19 ref.)

Comparison of the Dougados Functional Index and the Bath Ankylosing Spondylitis Functional Index. A literature review. Ruof J, et al. **J Rheumatol** 1999 Apr;26(4):955–60 (38 ref.)

Plain radiographs as an outcome measure in ankylosing spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr; 26(4):985–7 (17 ref.)

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):951–4 (12 ref.)

Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):1003–5 (16 ref.)

Population-based research assessing the effectiveness of trauma systems [see comments] Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S59–66 (32 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S67–8.

Invited commentary: panel reviews of trauma mortality. Trunkey DD. **J Trauma** 1999 Sep;47(3 Suppl):S44–5 (28 ref.)

A framework for drug utilization evaluation in depression: insights from outcomes research. Edgell ET, et al. **Med Care** 1999 Apr;37(4 Suppl Lilly):AS67–76 (55 ref.)

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Fischer JS, et al. **Mult Scler** 1999 Aug;5(4):244–50 (25 ref.)

Measuring handicap in multiple sclerosis. Thompson AJ. **Mult Scler** 1999 Aug;5(4):260–2 (17 ref.)

Purchasing population health: aligning financial incentives to improve health outcomes. Kindig DA. **Nurs Outlook** 1999 Jan–Feb;47(1):15–22 (87 ref.)

Evaluating the impact of managed health care in workers' compensation. Dembe AE. **Occup Med** 1998 Oct–Dec; 13(4):799–821, v (32 ref.)

Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. Hack M. **Pediatrics** 1999 Jan;103(1 Suppl E):319–28 (110 ref.)

Exercise in the rehabilitation of breast cancer survivors. Pinto BM, et al. **Psychooncology** 1999 May–Jun;8(3):191–206 (89 ref.)

A novel approach to outcome evaluation [see comments] Horn CK, et al. **Sex Transm Infect** 1999 Jun;75(3):195–7 (6 ref.) Comment in: Sex Transm Infect 1999 Jun;75(3):146–7. Comment in: Sex Transm Infect 1999 Jun;75(3):198–9.

Outcomes and effectiveness in reproductive health. Graham WJ. **Soc Sci Med** 1998 Dec;47(12):1925–36 (66 ref.)

[The practice of systematic reviews. IV. Pooling results from separate studies] Scholten RJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):786–91 (22 ref.) (Eng. Abstr.) **(Dut)**

ORGANIZATION & ADMINISTRATION

National intensive care unit datasets: lost at sea without a compass? [editorial; comment] Angus DC, et al. **Crit Care Med** 1999 Aug;27(8):1659–61 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1486–91.

Outcomes and effectiveness research in the private sector. Mendelson DN, et al. **Health Aff (Millwood)** 1998 Sep–Oct; 17(5):75–90 (19 ref.)

Satisfaction with palliative care: what should we be aware of? Fakhoury WK. **Int J Nurs Stud** 1998 Jun;35(3):171–6 (68 ref.)

Intensive care in developed and developing countries: are comparisons of ICU performance meaningful? [editorial; comment] Armaganidis A. **Intensive Care Med** 1998 Nov; 24(11):1126–8 (27 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1144–51.

Using outcomes to improve quality of research and quality of care. Deyo RA. **J Am Board Fam Pract** 1998 Nov–Dec; 11(6):465–73 (53 ref.)

Improving clinical outcome in bacteremia. Herchline T, et al. **J Eval Clin Pract** 1998 Aug;4(3):191–5 (22 ref.)

Outcomes research and the neuroscience nurse: what's in it for clinical practice? Mitchell PH. **J Neurosci Nurs** 1998 Oct;30(5):318–21 (35 ref.)

New practices in the transitional care center improve outcomes for babies and their families. Forsythe P. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S13–7 (4 ref.)

Outcomes assessment: implications for nursing education. Thompson C, et al. **J Prof Nurs** 1999 May–Jun;15(3):170–8 (24 ref.)

Managed care workers' compensation outcome measurements: how can a clinic compete? Mueller KL. **Occup Med** 1998 Oct–Dec;13(4):773–86, iv (35 ref.)

STANDARDS

Outcome measures in multiple sclerosis clinical trials. Andersson PB, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):409–28 (75 ref.)

The role of quality of life in functional gastrointestinal disorders: regulatory issues. Bergmann JF, et al. **Eur J Surg Suppl** 1998;(583):87–91 (14 ref.)

Scoring systems in the measurement of performance of ICUs. Miranda DR. **Intensive Care Med** 1999 Apr;25(4):418–9 (4 ref.)

Summary report: evidence for the effectiveness of rehabilitation for persons with traumatic brain injury. Chesnut RM, et al. **J Head Trauma Rehabil** 1999 Apr; 14(2):176–88 (55 ref.)

Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. Teasdale GM, et al. **J Neurotrauma** 1998 Aug;15(8):587–97 (23 ref.)

Improving health outcomes--a review of case studies from English health authorities. McColl A, et al. **J Public Health Med** 1998 Sep;20(3):302–11 (24 ref.)

Health-care performance measurement systems and the ACHS Care Evaluation Program. Australian Council on Healthcare Standards. Collopy BT. **J Qual Clin Pract** 1998 Sep;18(3):171–6 (6 ref.)

Outcome criteria for lupus nephritis trials: a critical overview. Boumpas DT, et al. **Lupus** 1998;7(9):622–9 (37 ref.)

Outcome measures in spasticity management. Pierson SH. **Muscle Nerve Suppl** 1997;6:S36–60 (43 ref.)

Outcome measures for low back pain research. A proposal for standardized use [published erratum appears in Spine 1999 Feb 15;24(4):418] Deyo RA, et al. **Spine** 1998 Sep 15;23(18):2003–13 (17 ref.)

New approach to assessing clinical quality of care for women: the QA Tool system. McGlynn EA, et al. **Womens Health Issues** 1999 Jul–Aug;9(4):184–92 (9 ref.)

[Roaming through methodology. XII. Pragmatic and pathophysiologic trials: a question of goal formulation (see comments)] Algra A, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):514–7 (11 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 May 15;143(20):1063. **(Dut)**

STATISTICS & NUMERICAL DATA

Guidelines for assessing outcomes of antihypertensive treatment. Weber M. **Am J Cardiol** 1999 Jul 22; 84(2A):2K–4K (4 ref.)

An ounce of prevention ... what are the returns? Second edition, 1999. Messonnier ML, et al. **Am J Prev Med** 1999 Apr;16(3):248–63 (90 ref.)

Statistically derived predictive mod.is. Caveat emptor [editorial] Iezzoni LI. **J Gen Intern Med** 1999 Jun; 14(6):388–9 (11 ref.)

Systematic review of trauma system effectiveness based on registry comparisons [see comments] Jurkovich GJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S46–55 (28 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S56–8.

[To what extent is it possible to integrated quality of life as a normative, subjective evaluation into scientific medicine?] Meran JG, et al. **Wien Med Wochenschr** 1998; 148(18):414–6 (19 ref.) (Eng. Abstr.) **(Ger)**

OUTCOME MEASUREMENT ERRORS see **BIAS (EPIDEMIOLOGY)**

OUTCOMES RESEARCH see **OUTCOME ASSESSMENT (HEALTH CARE)**

OUTER MEMBRANE PROTEINS, BACTERIAL see **BACTERIAL OUTER MEMBRANE PROTEINS**

OUTPATIENT CARE see **AMBULATORY CARE**

OUTPATIENT CLINICS see **AMBULATORY CARE FACILITIES**

OUTPATIENT CLINICS, HOSPITAL

see related
AMBULATORY CARE

[Analysis of the results of treatment of obesity in the hospital outpatient department] Gómez Candela C, et al.

Nutr Hosp 1998 Sep-Oct;13(5):215-20 (38 ref.) (Eng. Abstr.) **(Spa)**

OUTPATIENT HEALTH SERVICES see **AMBULATORY CARE**

OUTPATIENT INFUSION THERAPY see **HOME INFUSION THERAPY**

OUTPATIENT MONITORING see **MONITORING, AMBULATORY**

OUTPATIENT SURGERY see **AMBULATORY SURGICAL PROCEDURES**

OUTPATIENTS

Optimal management of the patient with an episode of atrial fibrillation in and out of the hospital: acute cardioversion or not? Knight BP, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):425-32 (53 ref.)

Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. Thibault B, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):472-81 (89 ref.)

[Ambulatory follow-up of patients with respiratory tract tuberculosis and ways of its improvement] Muminov TA, et al. **Probl Tuberk** 1999;(4):49-50 (6 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Coerced treatment in the community. Miller RD. **Psychiatr Clin North Am** 1999 Mar;22(1):183-96, ix (74 ref.)

OVALBUMIN

PHARMACOLOGY

Coupling of palmitate to ovalbumin inhibits the induction of oral tolerance. Oliveira FM, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1421-4 (20 ref.)

OVARIAN CYCLE see **MENSTRUAL CYCLE**

OVARIAN CYSTS

see related
OVARIAN HYPERSTIMULATION SYNDROME

DIAGNOSIS

Ovarian masses. Kozlowski KJ. **Adolesc Med** 1999 Jun; 10(2):337-50, vii (31 ref.)

SURGERY

Endoscopic management of adnexal masses. Mettler L, et al. **J Soc Laparoendosc Surg** 1997 Apr-Jun;1(2):103-12 (17 ref.)

Laparoscopic management of benign ovarian disease. Mane S, et al. **Semin Laparosc Surg** 1999 Jun;6(2):104-11 (25 ref.)

ULTRASONOGRAPHY

Fetal ovarian cysts: prenatal diagnosis and management. Report of two cases and review of literature. Armentano G, et al. **Clin Exp Obstet Gynecol** 1998;25(3):88-91 (14 ref.)

OVARIAN DISEASES

COMPLICATIONS

Streptococcus pneumoniae peritonitis secondary to a tubo-ovarian abscess. Abalde M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):671-3 (6 ref.)

DIAGNOSIS

Leiomyomatosis peritonealis disseminata complicated by sarcomatous transformation and ovarian torsion: presentation of two cases and review of the literature. Fulcher AS, et al. **Abdom Imaging** 1998 Nov-Dec; 23(6):640-4 (18 ref.)

[Evaluation of follicular reserve] Belaisch-Allart J. **Contracept Fertil Sex** 1999 Apr;27(4):259-62 (25 ref.) **(Fre)**

THERAPY

Trends in the management of pelvic abscesses. Mirhashemi R, et al. **J Am Coll Surg** 1999 May;188(5):567-72 (37 ref.)

OVARIAN FAILURE, PREMATURE

Premature ovarian failure. Kalantaridou SN, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):989-1006 (125 ref.)

Mouse models of ovarian failure. Elvin JA, et al. **Rev Reprod** 1998 Sep;3(3):183-95 (106 ref.)

DRUG THERAPY

Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Mulder JE. **Med Pediatr Oncol** 1999 Jul;33(1):46-52 (59 ref.)

ETIOLOGY

Gonadal damage from chemotherapy and radiotherapy. Howell S, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):927-43 (94 ref.)

Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Meirow D. **Leuk Lymphoma** 1999 Mar; 33(1-2):65-76 (69 ref.)

GENETICS

The genetic origins of ovarian failure. Bondy CA, et al. **J Womens Health** 1998 Dec;7(10):1225-9 (23 ref.)

Genes and premature ovarian failure. Christin-Maitre S, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):75-80 (40 ref.)

[Genes and ovarian insufficiency] Christin-Maitre S, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):118-22 (27 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Autoimmune premature ovarian failure--endocrine aspects of a T cell disease [editorial; comment] Melner MH, et al. **Endocrinology** 1999 Aug;140(8):3401-3 (15 ref.) Comment on: Endocrinology 1999 Aug;140(8):3720-6.

Biological bases of premature ovarian failure. Gosden RG, et al. **Reprod Fertil Dev** 1998;10(1):73-8 (26 ref.)

THERAPY

Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Meirow D. **Leuk Lymphoma** 1999 Mar; 33(1-2):65-76 (69 ref.)

OVARIAN FOLLICLE

see related
GRANULOSA CELLS
OVUM

CYTOLOGY

Cell-to-cell communication in the ovarian follicle: developmental and hormonal regulation of the expression of connexin43. Granot I, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:85-97 (46 ref.)

Development of the ovarian follicular epithelium. Rodgers RJ, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):171-9 (56 ref.)

GROWTH & DEVELOPMENT

Dynamics of human follicular growth and in-vitro oocyte maturation. Salha O, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):816-32 (179 ref.)

The bottleneck: mitochondrial imperatives in oogenesis and ovarian follicular fate. Jansen RP, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):81-8 (52 ref.)

Cell death and survival during ovarian follicle development. McGee EA, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1-2):15-8 (15 ref.)

[Induced ovarian follicular development: theoretical basis and therapeutic applications] Hazout A. **Contracept Fertil Sex** 1999 Mar;27(3):203-9 (20 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Polysystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles? Homburg R, et al. **J Endocrinol Invest** 1998 Oct;21(9):552-7 (43 ref.)

PHYSIOLOGY

The role of luteinizing hormone in folliculogenesis and ovulation induction. Filicori M. **Fertil Steril** 1999 Mar; 71(3):405-14 (88 ref.)

The role of intra-ovarian interactions in the regulation of follicle dominance. Baker SJ, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):153-65 (87 ref.)

Hyaluronan and proteoglycans in ovarian follicles. Salustri A, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):293-301 (79 ref.)

Ultrastructure and viability of isolated bovine preantral follicles. van den Hurk R, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):833-41 (49 ref.)

The IGF family and folliculogenesis. Adashi EY. **J Reprod Immunol** 1998 Aug;39(1-2):13-9 (21 ref.)

Paracrine mechanisms of ovarian follicle apoptosis. Chun SY, et al. **J Reprod Immunol** 1998 Aug;39(1-2):63-75 (45 ref.)

Ovarian follicular dynamics: from basic science to clinical practice. Pellicer A, et al. **J Reprod Immunol** 1998 Aug; 39(1-2):29-61 (110 ref.)

The genetic origins of ovarian failure. Bondy CA, et al. **J Womens Health** 1998 Dec;7(10):1225-9 (23 ref.)

Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Gougeon A. **Maturitas** 1998 Oct 12;30(2):137-42 (35 ref.)

Follicle development during the normal menstrual cycle. Macklon NS, et al. **Maturitas** 1998 Oct 12;30(2):181-8 (39 ref.)

Follicle selection in sheep with breed differences in ovulation rate. Baird DT, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):89-95 (28 ref.)

The role of estrogen in folliculogenesis. Drummond AE, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):57-64 (45 ref.)

[Evaluation of follicular reserve] Belaisch-Allart J. **Contracept Fertil Sex** 1999 Apr;27(4):259-62 (25 ref.) **(Fre)**

ULTRASTRUCTURE

Ultrastructure and viability of isolated bovine preantral follicles. van den Hurk R, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):833-41 (49 ref.)

OVARIAN FUNCTION TESTS

Ovarian reserve tests in infertility practice and normal fertile women. Broekmans FJ, et al. **Maturitas** 1998 Oct 12; 30(2):205-14 (32 ref.)

Interpretation of elevated FSH in the regular menstrual cycle. Lambalk CB, et al. **Maturitas** 1998 Oct 12; 30(2):215-20 (19 ref.)

METHODS

[Evaluation of follicular reserve] Belaisch-Allart J. **Contracept Fertil Sex** 1999 Apr;27(4):259-62 (25 ref.) **(Fre)**

OVARIAN HYPERSTIMULATION SYNDROME

Clinical aspects of ovarian hyperstimulation syndrome. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul; 85(1):13-20 (47 ref.)

COMPLICATIONS

Isolated pleural effusion in severe ovarian hyperstimulation: A case report. Gregory WT, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1468-71 (17 ref.)

Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Ludwig M, et al. **Hum Reprod** 1998 Aug;13(8):2082-7 (34 ref.)

EPIDEMIOLOGY

Severe OHSS: An 'epidemic' of severe OHSS: a price we have to pay? Abramov Y, et al. **Hum Reprod** 1999 Sep; 14(9):2181-3 (14 ref.)

Severe OHSS: patients should be allowed to weigh the morbidity of OHSS against the benefits of parenthood. Mathur RS, et al. **Hum Reprod** 1999 Sep;14(9):2183-5 (15 ref.)

Severe OHSS: An 'epidemic' caused by doctors. Roest J. **Hum Reprod** 1999 Sep;14(9):2183 (4 ref.)

ETIOLOGY

Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Balasch J, et al. **Hum Reprod** 1998 Oct;13(10):2718-30 (85 ref.)

Severe OHSS: An 'epidemic' caused by doctors. Roest J. **Hum Reprod** 1999 Sep;14(9):2183 (4 ref.)

GENETICS

Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Ludwig M, et al. **Hum Reprod** 1998 Aug;13(8):2082-7 (34 ref.)

PHYSIOPATHOLOGY

Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Balasch J, et al. **Hum Reprod** 1998 Oct;13(10):2718-30 (85 ref.)

PREVENTION & CONTROL

Prevention of ovarian hyperstimulation syndrome: novel strategies [see comments] Grudzinskas JG, et al. **Hum Reprod** 1998 Aug;13(8):2051-3 (29 ref.) Comment in: Hum Reprod 1999 Apr;14(4):1138.

Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome [see comments] Orvieto R, et al. **Hum Reprod** 1998 Dec;13(12):3306-9 (22 ref.) Comment in: Hum Reprod 1999 Jun;14(6):1664-5. Comment in: Hum Reprod 1999 Jul;14(7):1920.

THERAPY

[Severe ovarian hyperstimulation syndrome: an intensive care disease] Huneeus A, et al. **Rev Med Chil** 1998 Sep; 126(9):1117-25 (36 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

The role of ovarian volume in reproductive medicine. Lass A, et al. **Hum Reprod Update** 1999 May-Jun;5(3):256-66 (118 ref.)

OVARIAN NEOPLASMS

see related
PSEUDOMYXOMA PERITONEI

Ovarian cancer in infertility patients. Burmeister L, et al. **Ann Med** 1998 Dec;30(6):525–8 (18 ref.)

Epithelial ovarian cancer. Abu-Rustum NR, et al. **Curr Probl Surg** 1999 Jan;36(1):1–53 (97 ref.)

ACOG educational bulletin. Ovarian cancer. Number 250, August 1998 (replaces No. 141, May 1990). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Dec;63(3):301–10 (20 ref.)

Transgenic mouse models for gonadal tumorigenesis. Rahman NA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):167–74 (70 ref.)

Psammocarcinoma with an aggressive course. Poggi SH, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):659–61 (8 ref.)

[Epithelial ovarian cancers (advanced stage)] Spano JP, et al. **Bull Cancer** 1998 Nov;Suppl 2:5–23 (123 ref.) (Eng. Abstr.) **(Fre)**

[Gynecologic oncologists and their practice in the U.S.A.] Tsukamoto N. **Gan To Kagaku Ryoho** 1999 Jan;26(1):69–75 (13 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Tuxen MK, et al. **Gynecol Oncol** 1999 Jul; 74(1):12–22 (42 ref.)

BLOOD SUPPLY

The assessment of ovarian tumor angiogenesis: what does three-dimensional power Doppler add? Kurjak A, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):136–46 (98 ref.)

CHEMICALLY INDUCED

Fertility drugs and ovarian cancer. Glud E, et al. **Epidemiol Rev** 1998;20(2):237–57 (157 ref.)

Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment. Seoud M, et al. **Eur J Gynaecol Oncol** 1999;20(3):237–9 (29 ref.)

Induction of ovulation and borderline ovarian cancer--the hormonal connection? Shushan A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):71–4 (27 ref.)

COMPLICATIONS

Hilus cell tumour of the ovary in a virilized, premenopausal woman. Case report and review of hyperandrogenism of ovarian origin. Moore A, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):75–8 (16 ref.)

Clostridium septicum myonecrosis and ovarian cancer: a case report and review of literature. Prinssen HM, et al. **Gynecol Oncol** 1999 Jan;72(1):116–9 (19 ref.)

Sepsis. Shelton BK. **Semin Oncol Nurs** 1999 Aug;15(3):209–21 (105 ref.)

[Favorable outcome of a severe carcinoid cardiopathy after complete resection of the primary ovarian tumor] Kalinsky E, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):961–3 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Ovarian masses. Kozlowski KJ. **Adolesc Med** 1999 Jun; 10(2):337–50, vii (31 ref.)

Malignant melanoma of the ovary and exposure to clomiphene citrate: a case report and review of the literature. Fuller PN. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1499–503 (15 ref.)

Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Ordóñez NG. **Am J Surg Pathol** 1998 Oct;22(10):1203–14 (85 ref.)

The performance of screening tests for ovarian cancer: results of a systematic review. Bell R, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1136–47 (50 ref.)

Differential diagnosis of gynaecological "stained glass" tumours on MRI. Tanaka YO, et al. **Br J Radiol** 1999 Apr; 72(856):414–20 (8 ref.)

Screening for breast and ovarian cancer: the relevance of family history. Pharoah PD, et al. **Br Med Bull** 1998; 54(4):823–38 (40 ref.)

Significance of tissue polypeptide specific antigen (TPS) in diagnosis and monitoring of treatment in ovarian cancer. Zygmunt A, et al. **Eur J Gynaecol Oncol** 1998;19(5):484–6 (19 ref.)

Meigs' syndrome with elevated CA125: case report and review of the literature. Abad A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):97–9 (19 ref.)

CA 125: the past and the future. Bast RC Jr, et al. **Int J Biol Markers** 1998 Oct–Dec;13(4):179–87 (40 ref.)

CA 125 in benign gynecological conditions. Meden H, et al. **Int J Biol Markers** 1998 Oct–Dec;13(4):231–7 (50 ref.)

CA 125 in biological fluids. Molina R, et al. **Int J Biol Markers** 1998 Oct–Dec;13(4):224–30 (29 ref.)

The role of CA 125 in screening for ovarian cancer. Rosenthal AN, et al. **Int J Biol Markers** 1998 Oct–Dec; 13(4):216–20 (16 ref.)

Management of non-epithelial ovarian tumours. Bridgewater JA, et al. **Oncology** 1999;57(2):89–98 (131 ref.)

Sex cord-stromal and steroid cell tumors of the ovary. Outwater EK, et al. **Radiographics** 1998 Nov–Dec; 18(6):1523–46 (82 ref.)

Screening for gynecological malignancy. Dubbins PA, et al. **Semin Ultrasound CT MR** 1999 Aug;20(4):231–8 (60 ref.)

[The screening and diagnosis of ovarian cancer] Zlatkov V, et al. **Akush Ginekol (Sofiia)** 1998;37(3):54–6 (16 ref.) (Eng. Abstr.) **(Bul)**

[Cerebral ischemia as initial manifestation of neoplastic low-malignancy changes. 2 case reports and review of the literatures] Jahn K, et al. **Nervenarzt** 1999 Apr;70(4):342–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of pure stage one ovarian dysgerminoma in young women. Report of a case and review of the literature] Mazza D, et al. **Minerva Ginecol** 1999 Jan–Feb; 51(1–2):27–30 (17 ref.) (Eng. Abstr.) **(Ita)**

[Peritoneal carcinomatosis] Coelho SS, et al. **Acta Med Port** 1998 Jun;11(6):585–9 (17 ref.) (Eng. Abstr.) **(Por)**

[A case of disseminated intravascular coagulation--a paraneoplastic manifestation of a borderline ovarian tumor] Bălănescu I, et al. **Chirurgia (Bucur)** 1998 Sep–Oct; 93(5):331–41 (13 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model [see comments] Pusztai L, et al. **Acta Oncol** 1998; 37(7–8):629–40 (103 ref.) Comment in: Acta Oncol 1998 ;37(7–8):627–8.

Topoisomerase-I inhibitors in gynaecologic tumours. Verschraegen CF, et al. **Ann Acad Med Singapore** 1998 Sep;27(5):683–7 (47 ref.)

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? du Bois A, et al. **Ann Oncol** 1999;10 Suppl 1:35–41 (33 ref.)

Gemcitabine in the treatment of ovarian cancer. Hansen SW, et al. **Ann Oncol** 1999;10 Suppl 1:51–3 (14 ref.)

Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Ozols RF, et al. **Ann Oncol** 1999;10 Suppl 1:59–64 (33 ref.)

Oxaliplatin in ovarian cancer. Sessa C, et al. **Ann Oncol** 1999; 10 Suppl 1:55–7 (12 ref.)

The role of anthracyclines in epithelial ovarian cancer. Vermorken JB, et al. **Ann Oncol** 1999;10 Suppl 1:43–50 (70 ref.)

Dose intensity in advanced ovarian cancer: have we answered the question? Fennelly D. **Clin Cancer Res** 1995 Jun;1(6):575–82 (75 ref.)

Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Makhija S, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):23–7 (28 ref.)

Topotecan. A review of its potential in advanced ovarian cancer. Brogden RN, et al. **Drugs** 1998 Oct;56(4):709–23 (73 ref.)

An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Elit L, et al. **Gynecol Oncol** 1999 Jan;72(1):123–7 (29 ref.)

Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case. Shukunami K, et al. **Gynecol Oncol** 1999 Mar;72(3):431–2 (13 ref.)

Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Bookman MA. **Oncologist** 1999;4(2):87–94 (31 ref.)

Treatment of refractory and recurrent ovarian cancer. Alberts DS. **Semin Oncol** 1999 Feb;26(1 Suppl 1):8–14 (26 ref.)

High-dose chemotherapy in ovarian carcinoma. Herrin VE, et al. **Semin Oncol** 1999 Feb;26(1):99–105 (35 ref.)

Management of side effects in patients with recurrent ovarian cancer. Larrison EH. **Semin Oncol** 1999 Feb;26(1 Suppl 1):15–31 (14 ref.)

Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. Neijt JP, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):78–83 (33 ref.)

Paclitaxel plus carboplatin in the treatment of ovarian cancer. Ozols RF. **Semin Oncol** 1999 Feb;26(1 Suppl 2):84–9 (20 ref.)

Acute hypersensitivity reactions to chemotherapy. Labovich TM. **Semin Oncol Nurs** 1999 Aug;15(3):222–31 (23 ref.)

[The possibility for treating certain forms of endometrial and ovarian carcinomas with GnRH agonists] Nikolov A. **Akush Ginekol (Sofiia)** 1998;37(1):60–3 (24 ref.) **(Bul)**

["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"] Piccart MJ. **Bull Mem Acad R Med Belg** 1998;153(5–6):285–92; discussion 292–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Taxanes in the treatment of breast and ovarian cancers: current indications and results] Espié M, et al. **Contracept Fertil Sex** 1998 Nov;26(11):805–11 (63 ref.) (Eng. Abstr.) **(Fre)**

[Is there a standard therapy in advanced ovarian carcinoma?] Köchli OR. **Schweiz Rundsch Med Prax** 1999 Jan 21; 88(4):123–5 (9 ref.) **(Ger)**

[Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma] Meerpohl HG. **Schweiz Rundsch Med Prax** 1999 Mar 18;88(12):513–8 (14 ref.) (Eng. Abstr.) **(Ger)**

[Stem cell supported high dose chemotherapy (HDCT) in primary treatment of advanced ovarian carcinoma] Möbus V, et al. **Schweiz Rundsch Med Prax** 1999 Mar 18; 88(12):507–12 (20 ref.) (Eng. Abstr.) **(Ger)**

[Advanced cancer of the ovary. The paclitaxel–cisplatin combination as the first-line standard of treatment (editorial)] Pecorelli S. **Recenti Prog Med** 1999 Jun; 90(6):338–41 (16 ref.) **(Ita)**

ECONOMICS

Cost, quality of life and outcome measures in ovarian cancer. Abbas FM, et al. **Anticancer Drugs** 1998 Nov;9(10):859–67 (86 ref.)

Pharmacoeconomic profile of taxanes in advanced ovarian cancer. Messori A, et al. **Anticancer Drugs** 1998 Nov; 9(10):909–16 (34 ref.)

Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Patnaik A, et al. **Anticancer Drugs** 1998 Nov;9(10):869–78 (47 ref.)

Treating advanced ovarian cancer within the health maintenance organization: a Kaiser Permanente approach. Rarick M. **Semin Oncol** 1999 Feb;26(1 Suppl 1):52–8 (10 ref.)

ENZYMOLOGY

Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Sasano H, et al. **Endocr Rev** 1998 Oct;19(5):593–607 (154 ref.)

EPIDEMIOLOGY

Geographical epidemiology of ovarian and testicular germ cell cancers. Kamdar RH, et al. **Br J Cancer** 1998 Dec; 78(11):1401 (6 ref.)

Oral contraceptives and ovarian cancer. La Vecchia C, et al. **Eur J Cancer Prev** 1999 Aug;8(4):297–304 (52 ref.)

Ovarian cavernous hemangioma in an 8-year-old girl. Mirilas P, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):116–8 (15 ref.)

[Natural history of ovarian adenocarcinomas: from epidemiology to experimentation] Hamilton TC, et al. **Contracept Fertil Sex** 1998 Nov;26(11):800–4 (40 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Riman T, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):695–707 (154 ref.)

The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Dubeau L. **Gynecol Oncol** 1999 Mar;72(3):437–42 (30 ref.)

Possible role of ovarian epithelial inflammation in ovarian cancer. Ness RB, et al. **J Natl Cancer Inst** 1999 Sep 1; 91(17):1459–67 (144 ref.)

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone [see comments] Risch HA. **J Natl Cancer Inst** 1998 Dec 2;90(23):1774–86 (237 ref.) Comment in: J Natl Cancer Inst 1999 Apr 7;91(7):650–1.

Ovulation induction and ovarian tumours: the debate continues. Murad A. **JPMA J Pak Med Assoc** 1998 Nov; 48(11):353–6 (47 ref.)

Etiology of ovarian cancer: a proposed mechanism. Ghahremani M, et al. **Med Hypotheses** 1999 Jan;52(1):23–6 (18 ref.)

[Natural history of ovarian adenocarcinomas: from epidemiology to experimentation] Hamilton TC, et al. **Contracept Fertil Sex** 1998 Nov;26(11):800–4 (40 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary [see comments] Ross JS, et al. **Am J Clin Pathol** 1999 Mar; 111(3):311–6 (42 ref.) Comment in: Am J Clin Pathol 1999 Mar;111(3):299–301.

Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? Hamilton TC, et al. **Ann Oncol** 1999;10 Suppl 1:69–73 (50 ref.)

Forthnightly review: hereditary ovarian carcinoma. Kasprzak L, et al. **BMJ** 1999 Mar 20;318(7186):786–9 (46 ref.)

Ovarian cancer: an update on genetics and therapy. Penson RT, et al. **Compr Ther** 1998 Oct;24(10):477–87 (75 ref.)

Laboratory identification of hereditary risk of breast and ovarian cancer. Frank TS. **Curr Opin Biotechnol** 1999 Jun; 10(3):289–94 (55 ref.)

The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas. Weitzel JN. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):65–70 (45 ref.)

The BRCA paradox in breast and ovarian cancer. Ponzone R, et al. **Eur J Cancer** 1998 Jun;34(7):966–7 (9 ref.)

Genetic susceptibility testing and prophylactic oophorectomy. Berchuck A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):159–64 (42 ref.)

Testing for inherited susceptibility to breast and ovarian cancer. Brunner HG, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):143–6 (28 ref.)

Some genetic aspects of ovarian tumors. Van den Berghe

H, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec; 81(2):283–7 (65 ref.)

Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. Brown MR, et al. **Gynecol Oncol** 1999 Jul;74(1):98–102 (26 ref.)

Molecular aspects of ovarian cancer. Is gene therapy the solution? Tong XW, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):109–33, viii (163 ref.)

Molecular genetics of ovarian carcinomas. Diebold J. **Histol Histopathol** 1999 Jan;14(1):269–77 (79 ref.)

BRCA1 and BRCA2 proteins: roles in health and disease. Duncan JA, et al. **Mol Pathol** 1998 Oct;51(5):237–47 (85 ref.)

[CD44 gene expression and gynecologic neoplasms] Qu F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1997 Dec; 32(12):756–62 (22 ref.) **(Chi)**

[Activating mutations of the gonadotrophin receptors] Beck-Peccoz P, et al. **Arch Pediatr** 1998;5 Suppl 4:380S–384S (17 ref.) (Eng. Abstr.) **(Fre)**

[Genetic risk of breast and ovarian cancer] Eisinger F. **Chirurgie** 1998 Sep;123(4):399–403; discussion 403–4 (25 ref.) **(Fre)**

[Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma] Schmutzler RK, et al. **Dtsch Med Wochenschr** 1999 May 7; 124(18):563–6 (18 ref.) **(Ger)**

IMMUNOLOGY

Immune directed therapy for ovarian carcinoma. Vanderkwaak TJ, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):29–34 (38 ref.)

The role of macrophages in antitumor defense of patients with ovarian cancer. Zavadova E, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):135–44, ix (48 ref.)

Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review). Taylor DD, et al. **Oncol Rep** 1998 Nov–Dec;5(6):1519–24 (52 ref.)

METABOLISM

Regulation of CA 125 expression in cultured human carcinoma cells. Marth C, et al. **Int J Biol Markers** 1998 Oct–Dec;13(4):207–9 (18 ref.)

An autopsy case of hepatoid carcinoma of the ovary with PIVKA-II production: immunohistochemical study and literature review. Senzaki H, et al. **Pathol Int** 1999 Feb; 49(2):164–9 (22 ref.)

CA 125: fundamental and clinical aspects. Verheijen RH, et al. **Semin Cancer Biol** 1999 Apr;9(2):117–24 (59 ref.)

PATHOLOGY

Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Prat J. **Adv Anat Pathol** 1999 Sep;6(5):247–74 (110 ref.)

Dermoid cysts of the ovary with malignant transformation: MR appearance. Kido A, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):445–9 (12 ref.)

Histopathology and molecular biology of ovarian epithelial tumors. Chuaqui RF, et al. **Ann Diagn Pathol** 1998 Jun; 2(3):195–207 (92 ref.)

Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Eisenhauer EA, et al. **Ann Oncol** 1999;10 Suppl 1:9–15 (54 ref.)

Pathology of borderline ovarian tumours. Manek S, et al. **Clin Oncol (R Coll Radiol)** 1999;11(2):73–7 (42 ref.)

Cytologic diagnosis of metastatic ovarian adenocarcinoma in the urinary bladder: a case report and review of the literature. Edgerton ME, et al. **Diagn Cytopathol** 1999 Mar; 20(3):156–9 (14 ref.)

Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature. Duska LR, et al. **Eur J Gynaecol Oncol** 1998;19(5):441–3 (10 ref.)

Anaplastic nodules in an ovarian mucinous tumor. Case report and literature review. Hellemans H, et al. **Eur J Gynaecol Oncol** 1998;19(6):529–33 (19 ref.)

Parasitic ovarian dermoid tumor of the omentum–A review of the literature and report of two new cases. Ushakov FB, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 81(1):77–82 (32 ref.)

Late relapse of ovarian dysgerminoma: case report and literature review. Bekaii-Saab T, et al. **Gynecol Oncol** 1999 Jan;72(1):111–2 (10 ref.)

Malignant struma ovarii: two case reports and a review of the literature. Dardik RB, et al. **Gynecol Oncol** 1999 Jun; 73(3):447–51 (17 ref.)

Plasmacytoma of the ovary: a case report and literature review. Emery JD, et al. **Gynecol Oncol** 1999 Apr; 73(1):151–4 (18 ref.)

Splenectomy in recurrent epithelial ovarian cancer. Gemignani ML, et al. **Gynecol Oncol** 1999 Mar; 72(3):407–10 (13 ref.)

Ovarian metastasis in stage IB and II cervical adenocarcinoma. Natsume N, et al. **Gynecol Oncol** 1999 Aug;74(2):255–8 (11 ref.)

Primary angiosarcoma of the ovary: a case report and review of the literature. Platt JS, et al. **Gynecol Oncol** 1999 Jun; 73(3):443–6 (19 ref.)

Glioblastoma multiforme in a mature ovarian teratoma with recurring brain tumours. Yadav A, et al. **Histopathology** 1999 Aug;35(2):170–3 (10 ref.)

Stromal Leydig cell tumor of the ovary. Case report and literature review. Takeuchi S, et al. **Int J Gynecol Pathol** 1999 Apr;18(2):178–82 (9 ref.)

Primary peritoneal carcinoma: a review of the literature. Chu CS, et al. **Obstet Gynecol Surv** 1999 May;54(5):323–35 (130 ref.)

Primary ovarian angiosarcoma: a case report and literature review. Furihata M, et al. **Pathol Int** 1998 Dec; 48(12):967–73 (28 ref.)

Mouse model for malignant juvenile ovarian granulosa cell tumors. Beamer WG, et al. **Toxicol Pathol** 1998 Sep–Oct; 26(5):704–10 (57 ref.)

[Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?] Rochefort H. **C R Seances Soc Biol Fil** 1998;192(2):241–51 (35 ref.) (Eng. Abstr.) **(Fre)**

[Surgical strategy for peritoneal carcinosis of ovarian origin] Michel G, et al. **J Chir (Paris)** 1997 Nov;134(5–6):229–32 (26 ref.) (Eng. Abstr.) **(Fre)**

[Cancer chemo-endocrine therapy and its cell biological basis] Nishiya I. **Hum Cell** 1998 Sep;11(3):109–14 (0 ref.) (Eng. Abstr.) **(Jpn)**

[A rare case of ovarian leiomyoma. A case report with review of literature] Gut R, et al. **Ginekol Pol** 1997 Nov; 68(11):567–71 (13 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Hormonal interactions in ovarian cancer. Emons G, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):145–61, ix (103 ref.)

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone [see comments] Risch HA. **J Natl Cancer Inst** 1998 Dec 2;90(23):1774–86 (237 ref.) Comment in: J Natl Cancer Inst 1999 Apr 7;91(7):650–1.

PREVENTION & CONTROL

Screening for ovarian cancer. MacDonald ND, et al. **Ann Acad Med Singapore** 1998 Sep;27(5):676–82 (33 ref.)

Genetic susceptibility testing and prophylactic oophorectomy. Berchuck A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):159–64 (42 ref.)

Is there a place for screening in ovarian cancer? MacDonald ND, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb; 82(2):155–7 (16 ref.)

Prevention of ovarian cancer. Brewer MA, et al. **In Vivo** 1999 Jan–Feb;13(1):99–106 (100 ref.)

[Prevention of ovarian cancer by prophylactic ovariectomy] Dauplat J, et al. **Chirurgie** 1998 Sep;123(4):405–8; discussion 409 (16 ref.) **(Fre)**

[Oral contraceptives and endometrial and ovarian carcinomas] Medl M. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):105–8 (9 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Patnaik A, et al. **Anticancer Drugs** 1998 Nov;9(10):869–78 (47 ref.)

Psychological aspects of ovarian cancer. Hamilton AB. **Cancer Invest** 1999;17(5):335–41 (39 ref.)

A closer look at psychosocial care. Powel LL. **Oncol Nurs Forum** 1998 Nov–Dec;25(10):1677 (9 ref.)

Discussing disease progression and end-of-life decisions. Baile WF, et al. **Oncology (Huntingt)** 1999 Jul; 13(7):1021–31; discussion 1031–6, 1038 (57 ref.)

Quality of life issues in the management of ovarian cancer. Fish LS, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 1):32–9 (13 ref.)

RADIONUCLIDE IMAGING

Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L, et al. **Nucl Med Commun** 1999 Aug;20(8):689–96 (26 ref.)

RADIOTHERAPY

Radiotherapy for the treatment of metastatic granulosa cell tumor in the mediastinum: a case report. Lee IW, et al. **Gynecol Oncol** 1999 Jun;73(3):455–60 (12 ref.)

Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Wolf JK, et al. **Gynecol Oncol** 1999 Apr;73(1):35–41 (24 ref.)

REHABILITATION

[Hormonal replacement therapy in patients with cervical and ovarian cancers] Urdl W. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):89–92 (27 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Oophorectomy in women with colorectal cancer. Pitt J, et al. **Eur J Surg Oncol** 1999 Aug;25(4):432–8 (60 ref.)

Ovarian metastasis in stage IB and II cervical adenocarcinoma. Natsume N, et al. **Gynecol Oncol** 1999 Aug;74(2):255–8 (11 ref.)

SURGERY

Surgery during chemotherapy and at relapse of ovarian cancer. Berek JS, et al. **Ann Oncol** 1999;10 Suppl 1:3–7 (56 ref.)

Fertility-sparing treatment of patients with ovarian cancer. McHale MT, et al. **Compr Ther** 1999 Mar;25(3):144–50 (28 ref.)

Oophorectomy in women with colorectal cancer. Pitt J, et al. **Eur J Surg Oncol** 1999 Aug;25(4):432–8 (60 ref.)

Endoscopic management of adnexal masses. Mettler L, et al. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):103–12 (17 ref.)

[Favorable outcome of a severe carcinoid cardiopathy after complete resection of the primary ovarian tumor] Kalinsky E, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):961–3 (15 ref.) (Eng. Abstr.) **(Fre)**

[A rare case of ovarian leiomyoma. A case report with review of literature] Gut R, et al. **Ginekol Pol** 1997 Nov; 68(11):567–71 (13 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

New non-cytotoxic approaches to ovarian cancer. Kaye SB, et al. **Ann Oncol** 1999;10 Suppl 1:65–8 (26 ref.)

Contemporary treatment of borderline ovarian tumors. Gershenson DM. **Cancer Invest** 1999;17(3):206–10 (38 ref.)

Pathology of borderline ovarian tumours. Manek S, et al. **Clin Oncol (R Coll Radiol)** 1999;11(2):73–7 (42 ref.)

Ovarian cancer: an update on genetics and therapy. Penson RT, et al. **Compr Ther** 1998 Oct;24(10):477–87 (75 ref.)

The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. Bomalaski JJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):11–5 (37 ref.)

High dose chemotherapeutic strategies in the treatment of epithelial ovarian carcinoma. McAfee SL, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):17–21 (20 ref.)

Immune directed therapy for ovarian carcinoma. Vanderkwaak TJ, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):29–34 (38 ref.)

Molecular aspects of ovarian cancer. Is gene therapy the solution? Tong XW, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):109–33, viii (163 ref.)

Management of non-epithelial ovarian tumours. Bridgewater JA, et al. **Oncology** 1999;57(2):89–98 (131 ref.)

Quality of life issues in the management of ovarian cancer. Fish LS, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 1):32–9 (13 ref.)

Implementation of disease management guidelines in patients with advanced ovarian cancer. Hensley ML, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 1):46–51 (22 ref.)

Treating advanced ovarian cancer within the health maintenance organization: a Kaiser Permanente approach. Rarick M. **Semin Oncol** 1999 Feb;26(1 Suppl 1):52–8 (10 ref.)

Managing the care of patients with advanced ovarian cancer. Schink JC. **Semin Oncol** 1999 Feb;26(1 Suppl 1):59–61 (00 ref.)

Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Schink JC. **Semin Oncol** 1999 Feb;26(1 Suppl 1):2–7 (31 ref.)

[Estrogen replacement therapy and ovarian cancer] Yang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1997 Dec; 32(12):753–5 (21 ref.) **(Chi)**

[Hyperthermia in combination with chemotherapy in gynecological cancers (comment)] Rietbroek RC, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):85–8 (24 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):76–80. **(Dut)**

[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)] Wagner U, et al. **Zentralbl Gynakol** 1999;121(4):190–5 (18 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasound evaluation of pelvic masses: predictors of malignancy for the general gynecologist. van Nagell JR Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):45–9 (24 ref.)

The role of ovarian volume in reproductive medicine. Lass A, et al. **Hum Reprod Update** 1999 May–Jun;5(3):256–66 (118 ref.)

[Is ultrasound screening for ovarian cancer possible in 1998?] Descamps P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):476–81 (44 ref.) (Eng. Abstr.) **(Fre)**

[Ovarian tumors in childhood: apropos of a review of cases] Gonzalo Alonso E, et al. **An Esp Pediatr** 1998 Nov; 49(5):491–4 (23 ref.) (Eng. Abstr.) **(Spa)**

OVARIECTOMY

Role of androgens in surgical menopause. Gelfand MM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):325–7 (10 ref.)

Genetic susceptibility testing and prophylactic oophorectomy. Berchuck A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):159–64 (42 ref.)

Oophorectomy in women with colorectal cancer. Pitt J, et al. **Eur J Surg Oncol** 1999 Aug;25(4):432–8 (60 ref.)

[Prevention of ovarian cancer by prophylactic ovariectomy] Dauplat J, et al. **Chirurgie** 1998 Sep;123(4):405–8; discussion 409 (16 ref.) **(Fre)**

OVARIECTOMY

HISTORY

An historical perspective of natural and surgical menopause. Utian WH. **Menopause** 1999 Summer;6(2):83–6 (26 ref.)

METHODS

Laparoscopic management of benign ovarian disease. Mane S, et al. **Semin Laparosc Surg** 1999 Jun;6(2):104–11 (25 ref.)

OVARY

see related
OVARIECTOMY

A supernumerary ovary of the omentum with cystic change: report of two cases and review of the literature. Kuga T, et al. **Pathol Int** 1999 Jun;49(6):566–70 (14 ref.)

BLOOD SUPPLY

Spontaneous retroperitoneal hematoma from rupture of an aneurysm of the ovarian artery following delivery. Guillem P, et al. **Ann Vasc Surg** 1999 Jul;13(4):445–8 (9 ref.)

Polycystic ovaries: question of definition [comment] Mason H. **Ultrasound Obstet Gynecol** 1998 Sep;12(3):154–5 (19 ref.) Comment on: Ultrasound Obstet Gynecol 1998 Sep;12(3):180–7.

[Puerperal thrombophlebitis of the ovarian vein revealed by renal colic] Sappey O, et al. **Prog Urol** 1999 Apr;9(2):313–8 (20 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Intracellular mechanisms of ovarian cell apoptosis. Hsu SY, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):21–5 (23 ref.)

DRUG EFFECTS

Assisted reproduction–in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin–releasing hormone analogues. Barbieri RL, et al. **Endocr Rev** 1999 Jun;20(3):249–52 (27 ref.)

Insulin action in the normal and polycystic ovary. Franks S, et al. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):361–78 (46 ref.)

New approaches to ovarian stimulation. Diedrich K, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:1–13; discussion 14–7 (43 ref.)

Preserving ovarian function in patients receiving cyclophosphamide. Slater CA, et al. **Lupus** 1999;8(1):3–10 (66 ref.)

Natural menopause and ovarian toxicity associated with breast cancer therapy. Knobf MT. **Oncol Nurs Forum** 1998 Oct;25(9):1519–30; quiz 1531–2 (131 ref.)

Neuroendocrine and reproductive effects of contemporary–use pesticides. Cooper RL, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):26–36 (44 ref.)

GROWTH & DEVELOPMENT

Sexual dimorphism in the neonatal gonad. Hughes IA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):23–30 (54 ref.)

Cell death and survival during ovarian follicle development. McGee EA, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1–2):15–8 (15 ref.)

INNERVATION

Physiological importance of dopamine as a noradrenaline precursor in the corpus luteum. Kotwica J, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S29–35 (81 ref.)

METABOLISM

The molecular basis of oxytocin and oxytocin receptor gene expression in reproductive tissues. Ivell R, et al. **Adv Exp Med Biol** 1998;449:297–306 (46 ref.)

Ovarian markers of implantation potential in assisted reproduction. Gregory L. **Hum Reprod** 1998 Dec;13 Suppl 4:117–32 (38 ref.)

The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies. Barnes RB. **J Endocrinol Invest** 1998 Oct;21(9):567–79 (94 ref.)

Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Ibáñez L, et al. **J Endocrinol Invest** 1998 Oct; 21(9):558–66 (88 ref.)

[Oncogenes and function of the gonads] Zheng YH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):344–6 (10 ref.) **(Chi)**

PATHOLOGY

Dermoid cysts of the ovary with malignant transformation: MR appearance. Kido A, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):445–9 (12 ref.)

The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Dubeau L. **Gynecol Oncol** 1999 Mar;72(3):437–42 (30 ref.)

PHYSIOLOGY

Intragonadal regulation of male and female reproduction. Hillier SG. **Ann Endocrinol (Paris)** 1999 Jul;60(2):111–7 (84 ref.)

Adaptive interactions between cytokines and the hypothalamic–pituitary–gonadal axis. Cannon JG. **Ann N Y Acad Sci** 1998 Sep 29;856:234–42 (64 ref.)

Growth hormone and ovarian function. Franks S. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):331–40 (47 ref.)

Gonadotropin receptors and the control of gonadal steroidogenesis: physiology and pathology. Misrahi M, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):35–66 (170 ref.)

Regulation of the plasminogen activator system in the ovary. Liu YX. **Biol Signals Recept** 1999 May–Jun;8(3):160–77 (113 ref.)

Oocyte loss and the perimenopause. Bopp BL, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):898–911 (81 ref.)

The insulin–related ovarian regulatory system in health and disease. Poretsky L, et al. **Endocr Rev** 1999 Aug; 20(4):535–82 (811 ref.)

Estrogen, the ovary, and neutotransmitters: factors associated with aging. Miller MM, et al. **Exp Gerontol** 1998 Nov–Dec; 33(7–8):729–57 (155 ref.)

Physiological roles of integrin alpha 6 beta 1 in ovarian functions. Fujiwara H, et al. **Horm Res** 1998;50 Suppl 2:25–9 (15 ref.)

Follicle stimulating hormone and its receptor: future perspectives. Chappel S, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:18–35; discussion 47–51 (77 ref.)

New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127–36; discussion 145–7 (12 ref.)

Utero–ovarian interaction in the regulation of reproductive function. Alexander H, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):550–9 (35 ref.)

The role of ovarian volume in reproductive medicine. Lass A, et al. **Hum Reprod Update** 1999 May–Jun;5(3):256–66 (118 ref.)

The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Newton H. **Hum Reprod Update** 1998 May–Jun;4(3):237–47 (110 ref.)

Preservation of fertility in women undergoing chemotherapy: current approach and future prospects. Abir R, et al. **J Assist Reprod Genet** 1998 Sep;15(8):469–77 (82 ref.)

Review: effect of protein nutrition on ovarian and uterine physiology in dairy cattle. Butler WR. **J Dairy Sci** 1998 Sep;81(9):2533–9 (40 ref.)

IGFs and IGF–binding proteins in the regulation of human ovarian and endometrial function. Wang HS, et al. **J Endocrinol** 1999 Apr;161(1):1–13 (136 ref.)

Reproductive endocrinology of female elasmobranchs: lessons from the little skate (Raja erinacea) and spiny dogfish (Squalus acanthias). Koob TJ, et al. **J Exp Zool** 1999 Oct 1;284(5):557–74 (67 ref.)

Insulin–like growth factors and ovarian physiology. Yoshimura Y. **J Obstet Gynaecol Res** 1998 Oct;24(5):305–23 (117 ref.)

An anti–inflammatory role for glucocorticoids in the ovaries? Hillier SG, et al. **J Reprod Immunol** 1998 Aug;39(1–2):21–7 (36 ref.)

Broadened spectrum of menopausal symptom relief. Sarrel PM. **J Reprod Med** 1998 Aug;43(8 Suppl):734–40 (29 ref.)

General ageing and ovarian ageing. Dorland M, et al. **Maturitas** 1998 Oct 12;30(2):113–8 (47 ref.)

Ovarian ageing and the general biology of senescence. Kirkwood TB. **Maturitas** 1998 Oct 12;30(2):105–11 (41 ref.)

The potential role of interleukin–1 in the ovulatory process: an evolving hypothesis. Adashi EY. **Mol Cell Endocrinol** 1998 May 25;140(1–2):77–81 (50 ref.)

The role of anti–Müllerian hormone in gonadal development. Josso N, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):3–7 (23 ref.)

Molecular mechanisms of ovulation and luteinization. Richards JS, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):47–54 (73 ref.)

Developmental and endocrine aspects of normal ovarian aging. te Velde ER, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):67–73 (69 ref.)

Activating and inactivating mutations in LH receptors. Themmen AP, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):137–42 (28 ref.)

Ovarian steroids and serotonin neural function. Bethea CL, et al. **Mol Neurobiol** 1998 Oct;18(2):87–123 (269 ref.)

Gap junctional intercellular communication in the mouse ovarian follicle. Goodenough DA, et al. **Novartis Found Symp** 1999;219:226–35; discussion 235–40 (39 ref.)

Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Shiverick KT, et al. **Placenta** 1999 May; 20(4):265–72 (103 ref.)

Leptin and reproduction. Clarke IJ, et al. **Rev Reprod** 1999 Jan;4(1):48–55 (74 ref.)

[Value and contribution of ovarian reserve markers] Mahot P, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):319–28 (46 ref.) **(Fre)**

[Renin–angiotensin–aldosterone system in the reproductive system] Tanaka M, et al. **Nippon Rinsho** 1999 May; 57(5):1060–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Insulin action in the normal and polycystic ovary. Franks S, et al. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):361–78 (46 ref.)

Growth factor action on ovarian function in polycystic ovary syndrome. Giudice LC. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):325–39, vi (117 ref.)

Ovarian and adrenal function in polycystic ovary syndrome. Rosenfield RL. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):265–93 (139 ref.)

Effects of lifestyle and body composition on the ovary. Yen SS. **Endocrinol Metab Clin North Am** 1998 Dec; 27(4):915–26, ix (82 ref.)

New approaches to ovarian stimulation. Diedrich K, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:1–13; discussion 14–7 (43 ref.)

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36–46; discussion 47–51 (47 ref.)

Hyperandrogenic anovulation (the polycystic ovary syndrome)—back to the ovary? Ben–Shlomo I, et al. **Hum Reprod Update** 1998 May–Jun;4(3):296–300 (39 ref.)

Leptin, polycystic ovaries and polycystic ovary syndrome. Jacobs HS, et al. **Hum Reprod Update** 1999 Mar–Apr; 5(2):166–71 (70 ref.)

Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis. Franks S, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):269–72 (27 ref.)

Does the impairment of the hypothalamic–pituitary–gonadal axis in anorexia nervosa depend on increased sensitivity to endogenous melatonin? Pawlikowski M, et al. **Med Hypotheses** 1999 Feb;52(2):111–3 (15 ref.)

Inactivating FSH receptor mutations and gonadal dysfunction. Tapanainen JS, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):129–35 (54 ref.)

[How to assess ovarian reserve in 1999?] Hédon B, et al. **Contracept Fertil Sex** 1999 Jun;27(6):412–6 (18 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

[The risks of exposure to ionizing radiation during pregnancy and of the exposure of the gonads before conception] Moreno García M, et al. **Rev Clin Esp** 1999 Jul;199(7):442–8 (81 ref.) **(Spa)**

SURGERY

GnRH analogues and ovarian ablation: their integration in the adjuvant strategy. Pritchard KI. **Recent Results Cancer Res** 1998;152:285–97 (33 ref.)

Laparoscopic surgery of the fallopian tubes and ovaries. Dawood MY. **Semin Laparosc Surg** 1999 Jun;6(2):58–67 (50 ref.)

[Surgical options in the treatment of polycystic ovary syndrome] Zornoza A, et al. **Rev Med Univ Navarra** 1997 Oct–Dec;41(4):230–6 (38 ref.) (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Transgenic mouse strain rescue by frozen ovaries. Sztein JM, et al. **Lab Anim Sci** 1999 Feb;49(1):99–100 (13 ref.)

Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio–chemotherapy for hemato–oncological neoplasias and other cancers. Meirow D. **Leuk Lymphoma** 1999 Mar; 33(1–2):65–76 (69 ref.)

ULTRASONOGRAPHY

The role of ovarian volume in reproductive medicine. Lass A, et al. **Hum Reprod Update** 1999 May–Jun;5(3):256–66 (118 ref.)

OVER–THE–COUNTER DRUGS see **DRUGS, NON–PRESCRIPTION**

OVERDOSE

DIAGNOSIS

[Poisoning with amphetamines and designer drugs] Felgenhauer N, et al. **Internist (Berl)** 1999 Jun;40(6):617–23 (50 ref.) **(Ger)**

PATHOLOGY

[Phenomenology of ether administration. With a review of the literature] Kernbach–Wighton G, et al. **Arch Kriminol** 1998 Sep–Oct;202(3–4):87–94 (33 ref.) (Eng. Abstr.) **(Ger)**

OVEREATING see **HYPERPHAGIA**

OVERINCLUSION see **COGNITION DISORDERS**

OVERUSE SYNDROME see **CUMULATIVE TRAUMA DISORDERS**

OVERUTILIZATION OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

OVIDUCTS

ANATOMY & HISTOLOGY

Structure of the avian oviduct with emphasis on sperm storage in poultry. Bakst MR. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):618-26 (29 ref.)
Structure, function, and evolution of the oviducts of squamate reptiles, with special reference to viviparity and placentation. Blackburn DG. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):560-617 (314 ref.)
Survey of the oviduct of salamandrids with special reference to the viviparous species. Greven H. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):507-25 (80 ref.)
Oviduct structure and function and reproductive modes in amphibians. Wake MH, et al. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):477-506 (149 ref.)

PHYSIOLOGY

Oviductal sperm storage as a reproductive tactic of turtles. Gist DH, et al. **J Exp Zool** 1998 Nov-Dec 1; 282(4-5):526-34 (48 ref.)
Survey of the oviduct of salamandrids with special reference to the viviparous species. Greven H. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):507-25 (80 ref.)
Oviduct structure and function and reproductive modes in amphibians. Wake MH, et al. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):477-506 (149 ref.)

OVIDUCTS, MAMMALIAN see **FALLOPIAN TUBES**

OVINE CATARRHAL FEVER VIRUS see **BLUETONGUE VIRUS**

OVIPOSITION

Estrogen induction of VLDLy assembly in egg-laying hens. Walzem RL, et al. **J Nutr** 1999 Feb;129(2S Suppl):467S-472S (43 ref.)

OVOCYTES see **OOCYTES**

OVULATION

Molecular mechanisms of ovulation and luteinization. Richards JS, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):47-54 (73 ref.)

DRUG EFFECTS

Contraceptive use of antiprogestin. Bygdeman M, et al. **Eur J Contracept Reprod Health Care** 1999 Jun;4(2):103-7 (24 ref.)

GENETICS

Follicle selection in sheep with breed differences in ovulation rate. Baird DT, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):89-95 (28 ref.)

PHYSIOLOGY

Molecular aspects of mammalian ovulation. Tsafriri A, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):1-11 (140 ref.)
The role of intra-ovarian interactions in the regulation of follicle dominance. Baker SJ, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):153-65 (87 ref.)
Inhibins and activins in human ovulation, conception and pregnancy. Lockwood GM, et al. **Hum Reprod Update** 1998 May-Jun;4(3):284-95 (111 ref.)
Insulin-like growth factors and ovarian physiology. Yoshimura Y. **J Obstet Gynaecol Res** 1998 Oct;24(5):305-23 (117 ref.)
The potential role of interleukin-1 in the ovulatory process: an evolving hypothesis. Adashi EY. **Mol Cell Endocrinol** 1998 May 25;140(1-2):77-81 (50 ref.)
Energy balance and ovulation: small cages versus natural habitats. Bronson FH. **Reprod Fertil Dev** 1998;10(2):127-37 (77 ref.)

OVULATION INDUCTION

see related
OVARIAN HYPERSTIMULATION SYNDROME

Progress in ovarian stimulation. Macklon NS, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):137-42 (31 ref.)
Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues. Barbieri RL, et al. **Endocr Rev** 1999 Jun;20(3):249-52 (27 ref.)
New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization. Out HJ. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):21-2 (10 ref.)
The role of luteinizing hormone in folliculogenesis and ovulation induction. Filicori M. **Fertil Steril** 1999 Mar; 71(3):405-14 (88 ref.)
Follicle stimulating hormone and its receptor: future perspectives. Chappel S, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:18-35; discussion 47-51 (77 ref.)
New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127-36; discussion 145-7 (12 ref.)
Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36-46; discussion 47-51 (47 ref.)
What are the clinical benefits of recombinant gonadotrophins? The good,the bad and the ugly. Hernández ER. **Hum Reprod** 1999 Jun;14(6):1417-8 (9 ref.)
Future use of clomiphene in ovarian stimulation. Psychic effects of clomiphene citrate. Siedentopf F, et al. **Hum Reprod** 1998 Nov;13(11):2986-7 (12 ref.)
Oocyte maturation. Trounson A, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:52-62; discussion 71-5 (13 ref.)

ADVERSE EFFECTS

Short- and long-term effects of ovulation induction. Vollenhoven BJ, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):903-14, ix (45 ref.)
Induction of ovulation and borderline ovarian cancer--the hormonal connection? Shushan A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):71-4 (27 ref.)
Severe OHSS: An 'epidemic' of severe OHSS: a price we have to pay? Abramov Y, et al. **Hum Reprod** 1999 Sep; 14(9):2181-3 (14 ref.)
Ovulation induction and ovarian tumours: the debate continues. Murad A. **JPMA J Pak Med Assoc** 1998 Nov; 48(11):353-6 (47 ref.)

METHODS

Strategies to prevent multiple pregnancies in assisted conception programmes. Child TJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):131-46 (52 ref.)
New approaches to ovarian stimulation. Diedrich K, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:1-13; discussion 14-7 (43 ref.)
A rational approach to the management of low responders in in-vitro fertilization. Karande V, et al. **Hum Reprod** 1999 Jul;14(7):1744-8 (44 ref.)
[Is there a role for GnRH analogs in ovulation stimulation for in vitro fertilization?] Belaisch-Allart J, et al. **Contracept Fertil Sex** 1998 Nov;26(11):761-3 (17 ref.) **(Fre)**
[Induced ovarian follicular development: theoretical basis and therapeutic applications] Hazout A. **Contracept Fertil Sex** 1999 Mar;27(3):203-9 (20 ref.) (Eng. Abstr.) **(Fre)**
[Mechanism, regulation, and manipulations of follicular atresia] Monniaux D, et al. **Contracept Fertil Sex** 1998 Jul-Aug;26(7-8):528-35 (57 ref.) (Eng. Abstr.) **(Fre)**

OVUM

see related
OVARIAN FOLLICLE

Eggs and embryos from the Cambrian. Morris SC. **Bioessays** 1998 Aug;20(8):676-82 (57 ref.)

CYTOLOGY

Germline cysts: a conserved phase of germ cell development? Pepling ME, et al. **Trends Cell Biol** 1999 Jul;9(7):257-62 (53 ref.)

GROWTH & DEVELOPMENT

Egg culture: the foundation. Hammer RE. **Int J Dev Biol** 1998;42(7 Spec No):833-9 (60 ref.)

IMMUNOLOGY

HLA expression on immature and mature human germ cells. Hutter H, et al. **J Reprod Immunol** 1998 Jul;38(2):101-22 (99 ref.)

METABOLISM

Cytoskeletal mechanisms of ooplasmic segregation in annelid eggs. Shimizu T. **Int J Dev Biol** 1999 Jan;43(1):11-8 (53 ref.)
Analysis of translational activity of extracts derived from oocytes and eggs of Xenopus laevis. Pain VM, et al. **Methods Mol Biol** 1998;77:195-209 (20 ref.)

PHYSIOLOGY

Do human eggs attract spermatozoa? Eisenbach M, et al. **Bioessays** 1999 Mar;21(3):203-10 (68 ref.)
The role of carbohydrates in mammalian sperm-egg interactions: how important are carbohydrate epitopes? Zara J, et al. **Front Biosci** 1998 Oct 15;3:D1028-38 (96 ref.)
Early events in mammalian egg activation. Raz T, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:133-45 (93 ref.)

OVUM DONATION see **OOCYTE DONATION**

OVUM, FERTILIZED see **ZYGOTE**

OVUM IMPLANTATION

Apoptosis at the time of embryo implantation in mouse and rat. Pampfer S, et al. **Cell Death Differ** 1999 Jun;6(6):533-45 (154 ref.)
Postimplantation mouse development: whole embryo culture and micro-manipulation. Tam PP. **Int J Dev Biol** 1998;42(7 Spec No):895-902 (65 ref.)
Factors of importance for implantation and problems after treatment for childhood cancer. Critchley HO. **Med Pediatr Oncol** 1999 Jul;33(1):9-14 (41 ref.)
Models for the study of uterine receptivity for blastocyst implantation. Sharpe-Timms KL, et al. **Semin Reprod Endocrinol** 1999;17(1):107-15 (73 ref.)

IMMUNOLOGY

Cytokines in implantation. Rice A, et al. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):287-96 (128 ref.)

PHYSIOLOGY

Embryonic implantation. Simón C, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):134-6 (18 ref.)
Embryo-maternal interactions at the implantation site: a delicate equilibrium. Duc-Goiran P, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):85-100 (109 ref.)
Matrix metalloproteinases, prostaglandins and endothelins: paracrine regulators of implantation. Cameron IT. **Gynecol Endocrinol** 1998 Dec;12(6):415-9 (38 ref.)
Ovarian markers of implantation potential in assisted reproduction. Gregory L. **Hum Reprod** 1998 Dec;13 Suppl 4:117-32 (38 ref.)
Endometrial integrins and the establishment of uterine receptivity. Lessey BA. **Hum Reprod** 1998 Jun;13 Suppl 3:247-58; discussion 259-61 (81 ref.)
The role of leukemia inhibitory factor and interleukin-6 in human reproduction. Smith SK, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:237-43; discussion 244-6 (46 ref.)
Molecular control of the implantation window. Tabibzadeh S. **Hum Reprod Update** 1998 Sep-Oct;4(5):465-71 (74 ref.)
Cytokine pleiotropy and redundancy--gp130 cytokines in human implantation. Sánchez-Cuenca J, et al. **Immunol Today** 1999 Feb;20(2):57-9 (32 ref.)
Review: The role of leukaemia inhibitory factor in the establishment of pregnancy. Vogiagis D, et al. **J Endocrinol** 1999 Feb;160(2):181-90 (82 ref.)
IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. Wang HS, et al. **J Endocrinol** 1999 Apr;161(1):1-13 (136 ref.)
Molecular mechanism of embryo-endometrial adhesion in primates: a future task for implantation biologists. Ghosh D, et al. **Mol Hum Reprod** 1998 Aug;4(8):733-5 (33 ref.)
Role for cell surface oligosaccharide in cell-cell recognition during implantation. Zhu ZM, et al. **Mol Hum Reprod** 1998 Aug;4(8):735-8 (30 ref.)
Role of proteases in implantation. Salamonsen LA. **Rev Reprod** 1999 Jan;4(1):11-22 (98 ref.)
Integrins, endometrial maturation, & human embryo implantation. Coutifaris C, et al. **Semin Reprod Endocrinol** 1998;16(3):219-29 (87 ref.)
Implications of decidualization-associated protease expression in implantation and menstruation. Schatz F, et al. **Semin Reprod Endocrinol** 1999;17(1):3-12 (49 ref.)
[Role of the endometrium in human embryonic implantation] Merviel P, et al. **Contracept Fertil Sex** 1998 Nov; 26(11):751-60 (101 ref.) **(Fre)**

OVUM PROTEINS see **EGG PROTEINS**

OVUM-SPERM INTERACTIONS see **SPERM-OVUM INTERACTIONS**

OWNERSHIP

Nonprofit to for-profit conversions by hospitals, health insurers, and health plans. Needleman J. **Public Health Rep** 1999 Mar-Apr;114(2):108-19 (41 ref.)

LEGISLATION & JURISPRUDENCE

Nonprofit conversion: theory, evidence, and state policy options. Marsteller JA, et al. **Health Serv Res** 1998 Dec; 33(5 Pt 2):1495-535 (90 ref.)
Hospital conversion revenue: a critical analysis of present law and future proposals to reform the manner in which revenue generated from hospital conversions is employed. Standish JD. **J Contemp Health Law Policy** 1998 Fall; 15(1):131-82 (0 ref.)

OWREN DISEASE see **FACTOR V DEFICIENCY**

OXADIAZOLES

THERAPEUTIC USE

Antiviral therapy for enteroviral infections. Rotbart HA. **Pediatr Infect Dis J** 1999 Jul;18(7):632-3 (9 ref.)

OXALATES

see related
HYPEROXALURIA
HYPEROXALURIA, PRIMARY

METABOLISM

Glyoxylate synthesis, and its modulation and influence on

OXALATES

oxalate synthesis. Holmes RP, et al. **J Urol** 1998 Nov; 160(5):1617–24 (68 ref.)

OXALURIA see **HYPEROXALURIA**

OXALURIA, PRIMARY see **HYPEROXALURIA, PRIMARY**

OXAZINES

THERAPEUTIC USE

Efavirenz. Adkins JC, et al. **Drugs** 1998 Dec;56(6):1055–64; discussion 1065–6 (34 ref.)

A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection [news] Wolbach J, et al. **Nurse Pract** 1999 Jun;24(6):81–2, 87–90, 92 (27 ref.)

OXAZOLES

ADVERSE EFFECTS

[Safety profile of 311C90 (zolmitriptan)] Morales Asín F. **Neurologia** 1998 Oct;13 Suppl 2:25–30 (13 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Thiazole and oxazole peptides: biosynthesis and molecular machinery. Roy RS, et al. **Nat Prod Rep** 1999 Apr; 16(2):249–63 (124 ref.)

PHARMACOKINETICS

Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:420–9 (33 ref.)

PHARMACOLOGY

Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. Curet O, et al. **J Affect Disord** 1998 Dec; 51(3):287–303 (81 ref.)

Sympatho-adrenal mechanisms regulating cardiovascular hypertrophy in primary hypertension: a role for rilmenidine? Bobik A, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S51–4 (32 ref.)

4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Talley JJ, et al. **Med Res Rev** 1999 May;19(3):199–208 (29 ref.)

[Clinical pharmacology of hypotensive drugs acting on central imidazoline receptors] Drzewoski J, et al. **Pol Arch Med Wewn** 1998 Dec;100(6):561–9 (35 ref.) **(Pol)**

THERAPEUTIC USE

Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:420–9 (33 ref.)

[Clinical efficacy of zolmitriptan in migraine] Leira R, et al. **Neurologia** 1998 Oct;13 Suppl 2:16–24 (20 ref.) (Eng. Abstr.) **(Spa)**

[Mechanism of action of zolmitriptan] Pascual J. **Neurologia** 1998 Oct;13 Suppl 2:9–15 (49 ref.) (Eng. Abstr.) **(Spa)**

OXIDANTS

see related
ANTIOXIDANTS

Protection against peroxynitrite. Arteel GE, et al. **FEBS Lett** 1999 Feb 26;445(2–3):226–30 (74 ref.)

Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Alayash AI. **Nat Biotechnol** 1999 Jun; 17(6):545–9 (53 ref.)

Peroxide-modified titanium dioxide: a chemical analog of putative Martian soil oxidants. Quinn RC, et al. **Orig Life Evol Biosph** 1999 Jan;29(1):59–72 (27 ref.)

[Erythrocyte, plasma and substitute hemoglobins facing physiological oxidizing and reducing agents] Faivre-Fiorina B, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct; 56(5):545–56 (32 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Wine: risk factors for liver disease and antifibrotic compounds. Svegliati-Baroni G, et al. **Drugs Exp Clin Res** 1999;25(2–3):143–5 (13 ref.)

Oxidant-induced lung injury in anticancer therapy. Beinert T, et al. **Eur J Med Res** 1999 Feb 25;4(2):43–53 (113 ref.)

CHEMISTRY

Products from reaction of peroxynitrite with gamma-tocopherol. Hoglen NC, et al. **Methods Enzymol** 1999;301:483–90 (23 ref.)

METABOLISM

Iron and LDL-oxidation in atherogenesis. Yuan XM, et al. **APMIS** 1998 Sep;106(9):825–42 (142 ref.)

Oxidant--nitric oxide signalling mechanisms in vascular tissue. Wolin MS, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):810–6 (80 ref.)

The oxidant/antioxidant network: role of melatonin. Reiter RJ, et al. **Biol Signals Recept** 1999 Jan-Apr;8(1–2):56–63 (64 ref.)

Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Kettle AJ, et al. **Redox Rep** 1997 Oct-Dec;3(5–6):257–8 (17 ref.)

Oxidant/antioxidant imbalance in skin aging: environmental and adaptive factors. Mariéthoz E, et al. **Rev Environ Health** 1998 Jul-Sep;13(3):147–68 (133 ref.)

Prooxidant functions of coenzyme Q. Nohl H, et al. **Subcell Biochem** 1998;30:509–26 (32 ref.)

PHARMACOLOGY

The 2.2 A structure of a permanganate-sensitive DNA site bound by the Epstein-Barr virus origin binding protein, EBNA1. Bochkarev A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1273–8 (24 ref.)

[Superoxide, nitric oxide and peroxynitrite] Fukuyama N, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):169–76 (47 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

A study of the dual role of copper in superoxide dismutase as antioxidant and pro-oxidant in cellular models of amyotrophic lateral sclerosis. Carri MT, et al. **Adv Exp Med Biol** 1999;448:205–13 (38 ref.)

Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Hampton MB, et al. **Blood** 1998 Nov 1;92(9):3007–17 (165 ref.)

Demyelination: the role of reactive oxygen and nitrogen species. Smith KJ, et al. **Brain Pathol** 1999 Jan;9(1):69–92 (264 ref.)

Oxidant, mitochondria and calcium: an overview. Chakraborti T, et al. **Cell Signal** 1999 Feb;11(2):77–85 (77 ref.)

LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Aviram M, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):149–59 (76 ref.)

Targets of oxidative stress in cardiovascular system. Chakraborti T, et al. **Mol Cell Biochem** 1998 Oct; 187(1–2):1–10 (61 ref.)

TOXICITY

Oxidative stress induced in pathologies: the role of antioxidants. Gaté L, et al. **Biomed Pharmacother** 1999 May; 53(4):169–80 (151 ref.)

Defenses against peroxynitrite. Briviba K, et al. **Methods Enzymol** 1999;301:301–11 (26 ref.)

Examining apoptosis in cultured cells after exposure to nitric oxide and peroxynitrite. Estévez AG, et al. **Methods Enzymol** 1999;301:393–402 (43 ref.)

The chemistry of DNA damage from nitric oxide and peroxynitrite. Burney S, et al. **Mutat Res** 1999 Mar 8; 424(1–2):37–49 (94 ref.)

OXIDANTS, PHOTOCHEMICAL

ADVERSE EFFECTS

Ontario Medical Association position paper on health effects of ground-level ozone, acid aerosols and particulate matter. Boadway BT, et al. **Can Respir J** 1998 Sep-Oct;5(5):367–84 (77 ref.)

[Ozone and the immune system] Lacroix G, et al. **Rev Mal Respir** 1998 Dec;15(6):699–711 (103 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

[Ozone therapy in ophthalmology] Lapina IM, et al. **Vestn Oftalmol** 1998 Nov-Dec;114(6):51–4 (48 ref.) **(Rus)**

TOXICITY

Ozone-induced lung inflammation and mucosal barrier disruption: toxicology, mechanisms, and implications. Bhalla DK. **J Toxicol Environ Health B Crit Rev** 1999 Jan-Mar;2(1):31–86 (103 ref.)

Toxicological mechanisms underlying oxidant pollutant-induced airway injury. Krishna MT, et al. **Rev Environ Health** 1998 Jan-Jun;13(1–2):59–71 (75 ref.)

OXIDASES see **OXIDOREDUCTASES**

OXIDATION-REDUCTION

see related
ANTIOXIDANTS
OXIDANTS

The neurochemical basis of learning and neurocomputation: the redox theory. Smythies J. **Behav Brain Res** 1999 Feb 15;99(1):1–6 (57 ref.)

Does vitamin C act as a pro-oxidant under physiological conditions? Carr A, et al. **FASEB J** 1999 Jun;13(9):1007–24 (148 ref.)

Oxidants, antioxidants, alcohol and stroke. Hillbom M. **Front Biosci** 1999 Aug 15;4:e67–71 (40 ref.)

The role of alcohol in the oxidant antioxidant balance in heart. McDonough KH. **Front Biosci** 1999 Jul 15;4:D601–6 (49 ref.)

OXIDATIVE BURST see **RESPIRATORY BURST**

OXIDATIVE PHOSPHORYLATION

see related
UNCOUPLING AGENTS

Energy balance in muscle activity: simulations of ATPase coupled to oxidative phosphorylation and to creatine kinase. Kushmerick MJ. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):109–23 (33 ref.)

Is it possible to predict any properties of oxidative phosphorylation in a theoretical way? Korzeniewski B. **Mol Cell Biochem** 1998 Jul;184(1–2):345–58 (63 ref.)

Oxidative phosphorylation at the fin de siècle. Saraste M. **Science** 1999 Mar 5;283(5407):1488–93 (50 ref.)

[The other genome: the clinical concept of mitochondrial cytopathies or disorders of pxidative phosphorylation] Barrera-Ramirez CF, et al. **Rev Invest Clin** 1999 Mar-Apr; 51(2):121–34 (106 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Manganese and calcium transport in mitochondria: implications for manganese toxicity. Gavin CE, et al. **Neurotoxicology** 1999 Apr-Jun;20(2–3):445–53 (69 ref.)

OXIDATIVE STRESS

Mitochondria, oxidative stress, and antioxidant defences. Lenaz G, et al. **Acta Biochim Pol** 1999;46(1):1–21 (135 ref.)

Induction of oxidative stress by redox active flavonoids. Hodnick WF, et al. **Adv Exp Med Biol** 1998;439:131–50 (45 ref.)

Carbonyl stress and long-term uremic complications. Miyata T, et al. **Adv Nephrol Necker Hosp** 1998;28:311–9 (41 ref.)

Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Witko-Sarsat V, et al. **Adv Nephrol Necker Hosp** 1998; 28:321–41 (80 ref.)

Review article: the role of inflammation in the pathogenesis of gastric cancer. Ernst P. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:13–8 (18 ref.)

Oxidative stress and aging. Role of exercise and its influences on antioxidant systems. Ji LL, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:102–17 (78 ref.)

Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Joseph JA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:268–76 (62 ref.)

Recycling and redox cycling of phenolic antioxidants. Kagan VE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:425–34 (27 ref.)

Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Onorato JM, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:277–90 (75 ref.)

Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. Cotto JJ, et al. **Biochem Soc Symp** 1999;64:105–18 (55 ref.)

Transcriptional regulation via redox-sensitive iron-sulphur centres in an oxidative stress response. Demple B, et al. **Biochem Soc Symp** 1999;64:119–28 (53 ref.)

Roles of the AMP-activated/SNF1 protein kinase family in the response to cellular stress. Hardie DG. **Biochem Soc Symp** 1999;64:13–27 (75 ref.)

Cellular response to cancer chemopreventive agents: contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress. Hayes JD, et al. **Biochem Soc Symp** 1999;64:141–68 (114 ref.)

Oxidative DNA damage processing in nuclear and mitochondrial DNA. Bohr VA, et al. **Biochimie** 1999 Jan-Feb;81(1–2):155–60 (46 ref.)

Base excision repair of 8-hydroxyguanine protects DNA from endogenous oxidative stress. Boiteux S, et al. **Biochimie** 1999 Jan-Feb;81(1–2):59–67 (59 ref.)

Oxidative stress, antioxidant defences and aging. Lenaz G, et al. **Biofactors** 1998;8(3–4):195–204 (51 ref.)

Mechanisms of resistance to oxidative stress in Alzheimer's disease. Sagara Y, et al. **Biofactors** 1998;8(1–2):45–50 (33 ref.)

Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Benita S. **Biomed Pharmacother** 1999 May;53(4):193–206 (68 ref.)

Oxidative stress induced in pathologies: the role of antioxidants. Gaté L, et al. **Biomed Pharmacother** 1999 May; 53(4):169–80 (151 ref.)

Skin antioxidants: their role in aging and in oxidative stress--new approaches for their evaluation. Kohen R. **Biomed Pharmacother** 1999 May;53(4):181–92 (76 ref.)

Oxidative stress in bacterial meningitis. Koedel U, et al. **Brain Pathol** 1999 Jan;9(1):57–67 (116 ref.)

Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Dhalla NS, et al. **Can J Cardiol** 1999 May;15(5):587–93 (64 ref.)

Protection of coronary angioplasty-induced oxidative stress by Isovue used during angioplasty. Rajakumar AR, et al. **Can J Cardiol** 1999 Sep;15(9):989–98 (41 ref.) **(Eng, Fre)**

Diet, androgens, oxidative stress and prostate cancer susceptibility. Fleshner NE, et al. **Cancer Metastasis Rev** 1998–99;17(4):325–30 (75 ref.)

Oxidative stress and the pathogenesis of heart failure. Ball

AM, et al. **Cardiol Clin** 1998 Nov;16(4):665–75, viii–ix (127 ref.)

The role of oxidative stress in the genesis of heart disease [editorial] Singal PK, et al. **Cardiovasc Res** 1998 Dec; 40(3):426–32 (99 ref.)

Bridge over troubled waters: sensing stress by disulfide bond formation. Aslund F, et al. **Cell** 1999 Mar 19;96(6):751–3 (10 ref.)

Free radicals as mediators of neuronal injury. Facchinetti F, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):667–82 (126 ref.)

Source–sink regulation by sugar and stress. Roitsch T. **Curr Opin Plant Biol** 1999 Jun;2(3):198–206 (74 ref.)

Xenobiotic metabolism, oxidant stress and chronic pancreatitis. Focus on glutathione. Wallig MA. **Digestion** 1998;59 Suppl 4:13–24 (100 ref.)

Is NF–kappaB the sensor of oxidative stress? Li N, et al. **FASEB J** 1999 Jul;13(10):1137–43 (55 ref.)

On the path to the heat shock response: destabilization and formation of partially folded protein intermediates, a consequence of protein thiol modification. Freeman ML, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):737–45 (102 ref.)

Antioxidant actions of plant foods: use of oxidative DNA damage as a tool for studying antioxidant efficacy. Aruoma OI. **Free Radic Res** 1999 Jun;30(6):419–27 (40 ref.)

Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies. Halliwell B. **Free Radic Res** 1998 Dec;29(6):469–86 (142 ref.)

Oxidative stress in chronic renal failure. Hasselwander O, et al. **Free Radic Res** 1998 Jul;29(1):1–11 (118 ref.)

Experimental study of oxidative DNA damage. Loft S, et al. **Free Radic Res** 1998 Dec;29(6):525–39 (149 ref.)

Ethanol, oxidative stress, reactive aldehydes, and the fetus. Henderson GI, et al. **Front Biosci** 1999 Jun 15;4:D541–50 (90 ref.)

Aldehyde–protein adducts in the liver as a result of ethanol–induced oxidative stress. Niemelä O. **Front Biosci** 1999 Jun 1;4:D506–13 (90 ref.)

Familial Alzheimer's disease: oxidative stress, beta–amyloid, presenilins, and cell death. Velez–Pardo C, et al. **Gen Pharmacol** 1998 Nov;31(5):675–81 (108 ref.)

Oxidative stress and amyloidosis. Ando Y, et al. **Histol Histopathol** 1998 Jul;13(3):845–50 (59 ref.)

Lipid peroxidation and tissue damage. Mylonas C, et al. **In Vivo** 1999 May–Jun;13(3):295–309 (56 ref.)

Resistance of filarial nematode parasites to oxidative stress. Selkirk ME, et al. **Int J Parasitol** 1998 Sep;28(9):1315–32 (166 ref.)

Physical activity, fitness and integrated antioxidant system in healthy active elderly women. Kostka T, et al. **Int J Sports Med** 1998 Oct;19(7):462–7 (41 ref.)

Vitamin E in diabetes. Increased oxidative stress and its prevention as a strategy to prevent vascular complications? Rösen P, et al. **Int J Vitam Nutr Res** 1999 May;69(3):206–12 (62 ref.)

The isoprostanes: novel prostaglandin–like products of the free radical–catalyzed peroxidation of arachidonic acid. Liu T, et al. **J Biomed Sci** 1999 Jul–Aug;6(4):226–35 (45 ref.)

Oxidative stress and neurodegenerative disorders. Sun AY, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):401–14 (196 ref.)

Age–related changes in activation of mitogen–activated protein kinase cascades by oxidative stress. Guyton KZ, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):23–7 (36 ref.)

Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. Heinecke JW. **J Lab Clin Med** 1999 Apr;133(4):321–5 (32 ref.)

Alzheimer's disease––synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Münch G, et al. **J Neural Transm** 1998;105(4–5):439–61 (125 ref.)

Free radicals in Alzheimer's disease. Retz W, et al. **J Neural Transm Suppl** 1998;54:221–36 (108 ref.)

The Amoroso Lecture. The human spermatozoon––a cell in crisis? Aitken RJ. **J Reprod Fertil** 1999 Jan;115(1):1–7 (49 ref.)

Congenital disorders sharing oxidative stress and cancer proneness as phenotypic hallmarks: prospects for joint research in pharmacology. Pagano G, et al. **Med Hypotheses** 1998 Sep;51(3):253–66 (163 ref.)

Sudden infant death syndrome: oxidative stress. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):577–80 (24 ref.)

The keys of oxidative stress in acquired immune deficiency syndrome apoptosis. Romero–Alvira D, et al. **Med Hypotheses** 1998 Aug;51(2):169–73 (62 ref.)

Methylmercury–induced generation of free radicals: biological implications. Sarafian TA. **Met Ions Biol Syst** 1999;36:415–44 (162 ref.)

The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Gulumian M. **Mol Cell Biochem** 1999 Jun; 196(1–2):69–77 (106 ref.)

Glutamine, as a precursor of glutathione, and oxidative stress. Amores–Sánchez MI, et al. **Mol Genet Metab** 1999 Jun; 67(2):100–5 (47 ref.)

Endogenous oxidative damage of mtDNA. Beckman KB, et al. **Mutat Res** 1999 Mar 8;424(1–2):51–8 (65 ref.)

Repair of alkylation and oxidative damage in mitochondrial DNA. LeDoux SP, et al. **Mutat Res** 1999 Jul 30; 434(3):149–59 (63 ref.)

Mouse models of mitochondrial disease, oxidative stress, and senescence. Melov S, et al. **Mutat Res** 1999 Jul 30; 434(3):233–42 (50 ref.)

Etheno DNA–base adducts from endogenous reactive species. Nair J, et al. **Mutat Res** 1999 Mar 8;424(1–2):59–69 (57 ref.)

Bulky endogenous DNA modifications (I–compounds) –possible structural origins and functional implications. Randerath K, et al. **Mutat Res** 1999 Mar 8;424(1–2):183–94 (58 ref.)

Cytoprotective properties of melatonin: presumed association with oxidative damage and aging [see comments] Reiter RJ. **Nutrition** 1998 Sep;14(9):691–6 (80 ref.) Comment in: Nutrition 1998 Sep;14(9):712–3.

Good genes, oxidative stress and condition–dependent sexual signals. von Schantz T, et al. **Proc R Soc Lond B Biol Sci** 1999 Jan 7;266(1414):1–12 (162 ref.)

Vitamin E may slow kidney failure owing to oxidative stress. Fryer MJ. **Redox Rep** 1997 Oct–Dec;3(5–6):259–61 (32 ref.)

Oxidative stress in the liver and biliary tract diseases. Fehér J, et al. **Scand J Gastroenterol Suppl** 1998;228:38–46 (51 ref.)

Free radicals in disease. Hogg N. **Semin Reprod Endocrinol** 1998;16(4):241–8 (67 ref.)

Endometriosis: a disease of oxidative stress? Murphy AA, et al. **Semin Reprod Endocrinol** 1998;16(4):263–73 (81 ref.)

Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Nathan L, et al. **Semin Reprod Endocrinol** 1998;16(4):309–14 (44 ref.)

Inflammation, lipids, and free radicals: lessons learned from the atherogenic process. Rosenfeld ME. **Semin Reprod Endocrinol** 1998;16(4):249–61 (173 ref.)

Oxygen radicals, antioxidants, and lipid peroxidation. Santanam N, et al. **Semin Reprod Endocrinol** 1998; 16(4):275–80 (51 ref.)

Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. Koyama H, et al. **Thorax** 1998 Aug;53 Suppl 2:S10–4 (51 ref.)

Interactions of excitatory neurotransmitters and xenobiotics in excitotoxicity and oxidative stress: glutamate and lead. Savolainen KM, et al. **Toxicol Lett** 1998 Dec 28; 102–103:363–7 (25 ref.)

The role of oxidative stress in atherosclerosis: the hope and the hype. Runge MS. **Trans Am Clin Climatol Assoc** 1999; 110:119–29; discussion 129–30 (32 ref.)

Oxidative stress responses of the yeast Saccharomyces cerevisiae. Jamieson DJ. **Yeast** 1998 Dec;14(16):1511–27 (155 ref.)

[Diabetes mellitus and oxidative stress] Delattre J, et al. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):437–44 (58 ref.) **(Fre)**

[Tobacco: an atherogenic, thrombogenic or spasmogenic factor?] Adnot S. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:53–8 (45 ref.) (Eng. Abstr.) **(Fre)**

[Oxidative injury and its defense system in vivo] Niwa Y. **Rinsho Byori** 1999 Mar;47(3):189–209 (84 ref.) (Eng. Abstr.) **(Jpn)**

[Neuronal cell death in neurodegenerative disorders and oxidative stress] Shimohama S, et al. **Rinsho Shinkeigaku** 1999 Jan;39(1):4–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress of oxidized lipid] Nakagawa Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1234–5 (6 ref.) **(Jpn)**

DRUG EFFECTS

Does levodopa accelerate Parkinson's disease? Simuni T, et al. **Drugs Aging** 1999 Jun;14(6):399–408 (98 ref.)

Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Tredici G, et al. **Drugs Exp Clin Res** 1999;25(2–3):99–103 (21 ref.)

Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Mattson MP, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):737–53 (99 ref.)

Stress–inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Morimoto RI, et al. **Nat Biotechnol** 1998 Sep;16(9):833–8 (80 ref.)

Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Reiter RJ, et al. **Proc West Pharmacol Soc** 1998;41:229–36 (156 ref.)

GENETICS

Oxidative damage and mutation to mitochondrial DNA and age–dependent decline of mitochondrial respiratory function. Wei YH, et al. **Ann N Y Acad Sci** 1998 Nov 20; 854:155–70 (104 ref.)

Radical ideas: genetic responses to oxidative stress. Demple B. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):64–8 (41 ref.)

Oxidant stress regulation of IL–8 and ICAM–1 gene expression: differential activation and binding of the transcription factors AP–1 and NF–kappaB (Review). Roebuck KA. **Int J Mol Med** 1999 Sep;4(3):223–30 (102 ref.)

IMMUNOLOGY

Immunological adjuvance of metabolic origin: oxidative stress, postulated impaired function of thiol proteases and immunogenicity. Stark JM. **Scand J Immunol** 1998 Nov; 48(5):475–9 (39 ref.)

PHYSIOLOGY

Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine–induced apoptosis. Offen D, et al. **Adv Neurol** 1999;80:265–9 (38 ref.)

Molecular and cellular responses to oxidative stress and changes in oxidation–reduction imbalance in the intestine. Aw TY. **Am J Clin Nutr** 1999 Oct;70(4):557–65 (67 ref.)

Clastogenic factors: biomarkers of oxidative stress of potential utility in the clinical chemistry laboratory. Liu TZ, et al. **Ann Clin Lab Sci** 1999 Apr–Jun;29(2):134–9 (42 ref.)

Effect of antioxidant trace elements on the response of cardiac tissue to oxidative stress. Barandier C, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:138–55 (84 ref.)

Structural and functional changes in proteins induced by free radical–mediated oxidative stress and protective action of the antioxidants N–tert–butyl–alpha–phenylnitrone and vitamin E. Butterfield DA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:448–62 (61 ref.)

Redox regulation of the caspases during apoptosis. Hampton MB, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:328–35 (44 ref.)

Oxidative stress: role of mitochondria and protection by glutathione. Fernández–Checa JC, et al. **Biofactors** 1998; 8(1–2):7–11 (21 ref.)

Redox regulation of apoptotic cell death. Hampton MB, et al. **Biofactors** 1998;8(1–2):1–5 (22 ref.)

Regulation of tumour cell sensitivity to TNF–induced oxidative stress and cytotoxicity: role of glutathione. Obrador E, et al. **Biofactors** 1998;8(1–2):23–6 (20 ref.)

Oxidative stress in Huntington's disease. Browne SE, et al. **Brain Pathol** 1999 Jan;9(1):147–63 (105 ref.)

Oxidative stress and motor neurone disease. Cookson MR, et al. **Brain Pathol** 1999 Jan;9(1):165–86 (148 ref.)

Oxidative stress in brain ischemia. Love S. **Brain Pathol** 1999 Jan;9(1):119–31 (153 ref.)

An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Cassarino DS, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):1–25 (276 ref.)

Oxidative stress: Protein folding with a novel redox switch. Ruddock LW, et al. **Curr Biol** 1999 Jun 3;9(11):R400–2 (11 ref.)

Oxidative stress. Storz G, et al. **Curr Opin Microbiol** 1999 Apr;2(2):188–94 (70 ref.)

Experimental developments in movement disorders: update on proposed free radical mechanisms. Przedborski S, et al. **Curr Opin Neurol** 1998 Aug;11(4):335–9 (339 ref.)

Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Baynes JW, et al. **Diabetes** 1999 Jan;48(1):1–9 (91 ref.)

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Jellinger KA. **Drugs Aging** 1999 Feb;14(2):115–40 (305 ref.)

Role of oxidative stress in the pathogenesis of caerulein–induced acute pancreatitis. Dąbrowski A, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):1–11 (61 ref.)

Glucose–induced oxidative stress and programmed cell death in diabetic neuropathy. Greene DA, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):217–23 (85 ref.)

Effects of glucocorticoids on oxidative stress–induced hippocampal cell death: implications for the pathogenesis of Alzheimer's disease. Behl C. **Exp Gerontol** 1998 Nov–Dec;33(7–8):689–96 (51 ref.)

The biological significance of plasmalogens in defense against oxidative damage. Brosche T, et al. **Exp Gerontol** 1998 Aug; 33(5):363–9 (37 ref.)

Transition metal ion–catalyzed oxygen activation during pathogenic processes. Hippeli S, et al. **FEBS Lett** 1999 Jan 22;443(1):1–7 (88 ref.)

Can antioxidant vitamins maternally reduce oxidative damage in humans? McCall MR, et al. **Free Radic Biol Med** 1999 Apr;26(7–8):1034–53 (92 ref.)

Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. Juurlink BH, et al. **J Spinal Cord Med** 1998 Oct;21(4):309–34 (285 ref.)

Targets of oxidative stress in cardiovascular system. Chakraborti T, et al. **Mol Cell Biochem** 1998 Oct; 187(1–2):1–10 (61 ref.)

Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Witko–Sarsat V, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:76–8 (23 ref.)

Manganese neurotoxicity: a mechanistic hypothesis. Verity MA. **Neurotoxicology** 1999 Apr–Jun;20(2–3):489–97 (41 ref.)

Neurodegeneration and glutamate induced oxidative stress. Nakao N, et al. **Prog Brain Res** 1998;116:245–63 (116 ref.)

Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Behl C. **Prog Neurobiol** 1999 Feb;57(3):301–23 (294 ref.)

Oxidative damage in the central nervous system: protection by melatonin. Reiter RJ. **Prog Neurobiol** 1998 Oct; 56(3):359–84 (290 ref.)

Interdependence of mycobacterial iron regulation, oxidative–stress response and isoniazid resistance. Dussurget O, et al. **Trends Microbiol** 1998 Sep;6(9):354–8 (34 ref.)

[Regulated nuclear localization of transcription factors: nuclear export of yAP–1 is sensitive to oxidative stress] Kuge S. **Tanpakushitsu Kakusan Koso** 1999 Apr;

44(5):668–75 (41 ref.) **(Jpn)**
[Oxidative stress and gastrointestinal damage] Salas A, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):309–17 (80 ref.) **(Spa)**
[Is the lesion produced by oxidation a central part in the pathogenesis of Alzheimer's disease?] Perry G, et al. **Neurologia** 1999 Feb;14(2):78–84 (59 ref.) (Eng. Abstr.) **(Spa)**
[Oxidative stress in neurodegeneration] González–Fraguela ME, et al. **Rev Neurol** 1999 Mar 1–15;28(5):504–11 (132 ref.) (Eng. Abstr.) **(Spa)**
[Indicators of oxidative stress in aging rat brain. The effect of nerve growth factor] Rodriguez–Capote K, et al. **Rev Neurol** 1998 Sep;27(157):494–500 (65 ref.) (Eng. Abstr.) **(Spa)**

OXIDES

see related
CYCLIC N–OXIDES

CHEMISTRY

Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. Bonnemain B. **J Drug Target** 1998;6(3):167–74 (48 ref.)
[Soda lime: a review] Freys G. **Ann Fr Anesth Reanim** 1999 Mar;18(3):299–302 (29 ref.) **(Fre)**
[The soda–lime problem] Förster H. **Anaesthesist** 1999 Jun; 48(6):409–16 (71 ref.) **(Ger)**

DIAGNOSTIC USE

Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Reimer P, et al. **Eur Radiol** 1998; 8(7):1198–204 (38 ref.)

METABOLISM

Electrochemical concepts and techniques in the study of stainless steel ennoblement. Dickinson WH, et al. **Biodegradation** 1998;9(1):11–21 (43 ref.)

PHARMACOLOGY

The 2.2 A structure of a permanganate–sensitive DNA site bound by the Epstein–Barr virus origin binding protein, EBNA1. Bochkarev A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1273–8 (24 ref.)

THERAPEUTIC USE

Mineral trioxide aggregate: a new material for endodontics. Schwartz RS, et al. **J Am Dent Assoc** 1999 Jul; 130(7):967–75 (33 ref.)
[Progresses in the study of hematology in China, 1997] Zhang Z. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):890–1 (0 ref.) **(Chi)**

OXIDIZING AGENTS see **OXIDANTS**

OXIDOPAMINE

PHARMACOLOGY

Role of iron in 6–hydroxydopamine neurotoxicity. Double KL, et al. **Adv Neurol** 1999;80:287–96 (83 ref.)

TOXICITY

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6–hydroxydopamine induced neurotoxicity. Grünblatt E, et al. **J Neural Transm Suppl** 1999;55:57–70 (58 ref.)

OXIDOREDUCTASES

ANTAGONISTS & INHIBITORS

Clinical implications of dihydropyrimidine dehydrogenase inhibition. Diasio RB. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):17–21 (33 ref.)
Clinical development of eniluracil: current status. Hohneker JA. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):52–6 (17 ref.)
Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha–reductase. Frye SV, et al. **Pharm Biotechnol** 1998;11:393–422 (85 ref.)
Variegate porphyria: past, present and future. Frank J, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov–Dec; 11(6):310–20 (73 ref.)

CHEMISTRY

Recent advances in the structure and function of isopenicillin N synthase. Kreisberg–Zakarin R, et al. **Antonie Van Leeuwenhoek** 1999 Jan–Feb;75(1–2):33–9 (25 ref.)
The pyrroloquinoline quinone (PQQ)–containing quinoprotein dehydrogenases. Anthony C. **Biochem Soc Trans** 1998 Aug;26(3):413–7 (30 ref.)
Consideration of a phlorin structure for haem P–460 of hydroxylamine oxidoreductase and its implications regarding reaction mechanism. Arciero DM, et al. **Biochem Soc Trans** 1998 Aug;26(3):385–9 (41 ref.)
The membrane–integral domain of succinate:quinone oxidoreductases—a secretive haem–containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408–13 (33 ref.)
Dimethylsulphoxide reductase from purple phototrophic bacteria: structures and mechanism(s). McEwan AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):390–6 (34 ref.)
Mechanisms for regulating electron transfer in multi–centre redox proteins. Sharp RE, et al. **Biochim Biophys Acta** 1999 Jul 13;1432(2):143–58 (120 ref.)
A structural comparison of molybdenum cofactor–containing enzymes. Kisker C, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):503–21 (73 ref.)

DEFICIENCY

Prolonged severe 5–fluorouracil–associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Shehata N, et al. **Cancer Invest** 1999;17(3):201–5 (24 ref.)
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Van Kuilenburg AB, et al. **Hum Genet** 1999 Jan;104(1):1–9 (72 ref.)
Diagnosis and management of glutaric aciduria type I. Barić I, et al. **J Inherit Metab Dis** 1998 Jun;21(4):326–40 (29 ref.)

DRUG EFFECTS

The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5–FU pharmacology. Diasio RB. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):23–7 (37 ref.)
Biochemical and clinical pharmacology of 5–fluorouracil. Schilsky RL. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):13–8 (29 ref.)
Dihydropyrimidine dehydrogenase and resistance to 5–fluorouracil. Diasio RB. **Prog Exp Tumor Res** 1999; 36:115–23 (29 ref.)

GENETICS

Brain glyceraldehyde–3–phosphate dehydrogenase activity in human trinucleotide repeat disorders. Kish SJ, et al. **Arch Neurol** 1998 Oct;55(10):1299–304 (29 ref.)
RSH (so–called Smith–Lemli–Opitz) syndrome. Opitz JM. **Curr Opin Pediatr** 1999 Aug;11(4):353–62 (60 ref.)
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Van Kuilenburg AB, et al. **Hum Genet** 1999 Jan;104(1):1–9 (72 ref.)

METABOLISM

Comparative properties of three pteridine reductases. Chang CF, et al. **Adv Exp Med Biol** 1999;463:403–10 (20 ref.)
Physical exercise and antioxidant defenses in the heart. Atalay M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:169–77 (41 ref.)
Recent advances in the structure and function of isopenicillin N synthase. Kreisberg–Zakarin R, et al. **Antonie Van Leeuwenhoek** 1999 Jan–Feb;75(1–2):33–9 (25 ref.)
Brain glyceraldehyde–3–phosphate dehydrogenase activity in human trinucleotide repeat disorders. Kish SJ, et al. **Arch Neurol** 1998 Oct;55(10):1299–304 (29 ref.)
The pyrroloquinoline quinone (PQQ)–containing quinoprotein dehydrogenases. Anthony C. **Biochem Soc Trans** 1998 Aug;26(3):413–7 (30 ref.)
Consideration of a phlorin structure for haem P–460 of hydroxylamine oxidoreductase and its implications regarding reaction mechanism. Arciero DM, et al. **Biochem Soc Trans** 1998 Aug;26(3):385–9 (41 ref.)
The membrane–integral domain of succinate:quinone oxidoreductases—a secretive haem–containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408–13 (33 ref.)
Dimethylsulphoxide reductase from purple phototrophic bacteria: structures and mechanism(s). McEwan AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):390–6 (34 ref.)
Applications of oxidoreductases. May SW. **Curr Opin Biotechnol** 1999 Aug;10(4):370–5 (42 ref.)
Copper–containing oxidases. McGuirl MA, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):138–44 (40 ref.)
Proton translocation by bacteriorhodopsin and heme–copper oxidases. Wikström M. **Curr Opin Struct Biol** 1998 Aug; 8(4):480–8 (68 ref.)
Lanosterol 14alpha–demethylase (CYP51) and spermatogenesis. Rozman D, et al. **Drug Metab Dispos** 1998 Dec;26(12):1199–201 (11 ref.)
Is ascorbic acid an antioxidant for the plasma membrane? May JM. **FASEB J** 1999 Jun;13(9):995–1006 (100 ref.)
Novel reactions involved in energy conservation by methanogenic archaea. Deppenmeier U, et al. **FEBS Lett** 1999 Sep 3;457(3):291–7 (49 ref.)
Mechanistic aspects of molybdenum–containing enzymes. Hille R, et al. **FEMS Microbiol Rev** 1998 Dec;22(5):489–501 (40 ref.)
Antioxidant enzymes and their implications in pathophysiologic processes. Matés JM, et al. **Front Biosci** 1999 Mar 15;4:D339–45 (60 ref.)
Keto–acid oxidoreductases in the anaerobic protozoa. Upcroft JA, et al. **J Eukaryot Microbiol** 1999 Jul–Aug; 46(4):447–9 (20 ref.)
Enzymatic oxidations in the biosynthesis of complex alkaloids. Chou WM, et al. **Plant J** 1998 Aug;15(3):289–300 (73 ref.)

OXIDOREDUCTASES, N–DEMETHYLATING

ANTAGONISTS & INHIBITORS

Extensive impairment of triazolam and alprazolam clearance by short–term low–dose ritonavir: the clinical dilemma of concurrent inhibition and induction [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1999 Aug;19(4):293–6 (51 ref.)

METABOLISM

Electron transfer in trimethylamine dehydrogenase and electron–transferring flavoprotein. Scrutton NS, et al. **Biochem Soc Trans** 1999 Feb;27(2):196–201 (29 ref.)
The role of CYP2B6 in human xenobiotic metabolism. Ekins S, et al. **Drug Metab Rev** 1999 Aug;31(3):719–54 (194 ref.)
Role of P–glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. Wacher VJ, et al. **J Pharm Sci** 1998 Nov;87(11):1322–30 (83 ref.)

OXIDOREDUCTASES, O–DEMETHYLATING

METABOLISM

DNA demethylation [comment] Wolffe AP, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5894–6 (53 ref.) Comment on: Proc Natl Acad Sci U S A 1999 May 25;96(11):6107–12.

OXIDOREDUCTASES, NADH, NADPH see **NADH, NADPH OXIDOREDUCTASES**

OXILAPINE see **LOXAPINE**

OXIMES

PHARMACOLOGY

Role of edrophonium in prevention of the re–inhibition of acetylcholinesterase by phosphorylated oxime. Luo C, et al. **Chem Biol Interact** 1999 May 14;119–120:129–35 (8 ref.)
Sibrafiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):225–30; discussion 231–2 (9 ref.)

THERAPEUTIC USE

Sibrafiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):225–30; discussion 231–2 (9 ref.)

OXIMETRY

Fetal pulse oximetry. Luttkus AK, et al. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):481–6 (57 ref.)
[Arterial puncture or pulse oximetry?] Abdulla J, et al. **Ugeskr Laeger** 1999 Feb 22;161(8):1100–2 (25 ref.) (Eng. Abstr.) **(Dan)**

ADVERSE EFFECTS

[Skin burns in 2 premature newborns related to pulse oximetry (letter)] Sáenz González P, et al. **An Esp Pediatr** 1998 Dec;49(6):643–4 (7 ref.) **(Spa)**

INSTRUMENTATION

[Fetal pulse oximetry: from the first experimental studies of broad clinical use. An assessment of current status] Butterwegge M. **Z Geburtshilfe Neonatol** 1998 Nov–Dec; 202(6):227–34 (66 ref.) (Eng. Abstr.) **(Ger)**
[Techniques for automatic recording of the oxygen equilibrium curve: precision determination of gaseous ligand binding (1)] Imai K. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):706–13 (19 ref.) **(Jpn)**
[Techniques for automatic recording of the oxygen equilibrium curve: precision determination of gaseous ligand binding] Imai K, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):812–8 (58 ref.) **(Jpn)**

METHODS

Developing in vivo EPR oximetry for clinical use. Swartz HM, et al. **Adv Exp Med Biol** 1998;454:243–52 (31 ref.)
Pulse oximetry: principles and limitations. Sinex JE. **Am J Emerg Med** 1999 Jan;17(1):59–67 (76 ref.)
Continuous cardiac output and mixed venous oxygen saturation monitoring. Cariou A, et al. **J Crit Care** 1998 Dec;13(4):198–213 (101 ref.)
The measurement of oxygen in vivo using EPR techniques. Swartz HM, et al. **Phys Med Biol** 1998 Jul;43(7):1957–75 (100 ref.)
Near–infrared oximetry of the brain. Madsen PL, et al. **Prog Neurobiol** 1999 Aug;58(6):541–60 (192 ref.)
[Fetal pulse oximetry—a method for monitoring fetal status during labor] Nikolov A. **Akush Ginekol (Sofiia)** 1998; 37(4):35–40 (32 ref.) **(Bul)**
[Optical oxygen sensing technology using methallo–porphyrins] Amao Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1492–6 (7 ref.) **(Jpn)**

OXIMETRY, TRANSCUTANEOUS see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

OXO-ACID-LYASES

METABOLISM

MRI and MRS in HMG-CoA lyase deficiency. Yalçinkaya C, et al. **Pediatr Neurol** 1999 May;20(5):375–80 (13 ref.)

OXOCHOLESTEROLS see **KETOCHOLESTEROLS**

OXOGLUTARATES see **KETOGLUTARIC ACIDS**

5-OXOPROLYL-PEPTIDASE see **PYROGLUTAMYL-PEPTIDASE I**

OXOPROPANAL see **PYRUVALDEHYDE**

OXOQUINOLINES see **QUINOLONES**

OXYBATE SODIUM see **SODIUM OXYBATE**

OXYCEPHALY see **CRANIOSYNOSTOSES**

OXYCHLOROCHIN see **HYDROXYCHLOROQUINE**

OXYCHLOROQUINE see **HYDROXYCHLOROQUINE**

OXYGEN

see related
ANOXEMIA
ANOXIA
HYPEROXIA
OXYGEN ISOTOPES

ABC of oxygen: oxygen at high altitude. Peacock AJ. **BMJ** 1998 Oct 17;317(7165):1063–6 (0 ref.)

Diving and oxygen. Wilmshurst P. **BMJ** 1998 Oct 10; 317(7164):996–9 (0 ref.)

Oxygen enrichment of room air to improve well-being and productivity at high altitude. West JB. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):187–93 (23 ref.)

The Galilean satellites. Showman AP, et al. **Science** 1999 Oct 1;286(5437):77–84 (121 ref.)

ADMINISTRATION & DOSAGE

The oxygen delivery debate—a review. Raghuram J, et al. **Ann Acad Med Singapore** 1998 May;27(3):404–8 (50 ref.)

Does optimizing oxygen transport improve outcome in intensive care patients? Brazzi L, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:46–9 (28 ref.)

[Gaseous oxygen for protection and conditioning of organs during ischemia] Isselhard W, et al. **Zentralbl Chir** 1999; 124(4):252–9 (70 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Oxygen sensing by the global regulator, FNR: the role of the iron-sulfur cluster. Kiley PJ, et al. **FEMS Microbiol Rev** 1998 Dec;22(5):341–52 (45 ref.)

The measurement of oxygen in vivo using EPR techniques. Swartz HM, et al. **Phys Med Biol** 1998 Jul;43(7):1957–75 (100 ref.)

[Cerebral tissue oxygen monitoring: a useful thing?] Rossi S, et al. **Minerva Anestesiol** 1999 May;65(5):327–30 (19 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Spontaneous fluctuations in cerebral oxygen supply. An introduction. Hudetz AG, et al. **Adv Exp Med Biol** 1998; 454:551–9 (26 ref.)

Developing in vivo EPR oximetry for clinical use. Swartz HM, et al. **Adv Exp Med Biol** 1998;454:243–52 (31 ref.)

Hyperoxaemia in extreme haemodilution. Habler O, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:79–82 (29 ref.)

Functional magnetic resonance imaging: the basics of blood-oxygen-level dependent (BOLD) imaging. Forster BB, et al. **Can Assoc Radiol J** 1998 Oct;49(5):320–9 (43 ref.)

Oxygen carriers as blood substitutes. Past, present, and future. Goodnough LT, et al. **Clin Orthop** 1998 Dec;(357):89–100 (83 ref.)

PEEP: blood gas cosmetics or a therapy for ARDS? [editorial; comment] Pesenti A, et al. **Crit Care Med** 1999 Feb;27(2):253–4 (17 ref.) Comment on: Crit Care Med 1999 Feb;27(2):380–4.

Modifying perfusion, nutrition, and stress to promote wound healing in patients with acute wounds. Whitney JD, et al. **Heart Lung** 1999 Mar–Apr;28(2):123–33 (74 ref.)

Physiological effects of modified hemoglobin as an oxygen-carrying macromolecule. Nosé Y. **Keio J Med** 1999 Mar;48(1):38–43 (18 ref.)

A role for oxygen-induced osmosis in hyperbaric oxygen therapy. Hills BA. **Med Hypotheses** 1999 Mar;52(3):259–63 (31 ref.)

Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Alayash AI. **Nat Biotechnol** 1999 Jun; 17(6):545–9 (53 ref.)

When do infants need additional inspired oxygen? A review of the current literature. Poets CF. **Pediatr Pulmonol** 1998 Dec;26(6):424–8 (36 ref.)

Near-infrared oximetry of the brain. Madsen PL, et al. **Prog Neurobiol** 1999 Aug;58(6):541–60 (192 ref.)

Monitoring of oxygen delivery in cardiac and vascular surgery. Spahn DR. **Vox Sang** 1998;74 Suppl 2:395–7 (17 ref.)

[Arterial puncture or pulse oximetry?] Abdulla J, et al. **Ugeskr Laeger** 1999 Feb 22;161(8):1100–2 (25 ref.) (Eng. Abstr.) **(Dan)**

[Transcutaneous oxygen pressure (TcPO2): advantages and limitations] Got I. **Diabetes Metab** 1998 Sep;24(4):379–84 (30 ref.) (Eng. Abstr.) **(Fre)**

[Hemoglobin solutions: volume replacement or oxygen therapy?] Standl T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):699–714 (152 ref.) (Eng. Abstr.) **(Ger)**

[What will jugular bulb oxygen saturation monitoring tell?] Cormio M, et al. **Minerva Anestesiol** 1999 May;65(5):322–6 (25 ref.) (Eng. Abstr.) **(Ita)**

[Techniques for automatic recording of the oxygen equilibrium curve: precision determination of gaseous ligand binding (1)] Imai K. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):706–13 (19 ref.) **(Jpn)**

[Techniques for automatic recording of the oxygen equilibrium curve: precision determination of gaseous ligand binding] Imai K, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):812–8 (58 ref.) **(Jpn)**

[The slope of hemoglobin-oxygen equilibrium curve: implications hidden in the sigmoid curve] Kobayashi M, et al. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2110–9 (20 ref.) **(Jpn)**

[The role of the oxygen-binding properties of the blood in maintaining pro-oxidant-antioxidant equilibrium in the body] Zinchuk VV, et al. **Usp Fiziol Nauk** 1999 Jul-Sep; 30(3):38–48 (84 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

A discussion on the activation of oxygen in chemistry and enzymology. Akhtar M, et al. **Biochem Soc Trans** 1998 Aug; 26(3):322–5 (13 ref.)

Singlet molecular oxygen in photobiochemical systems: IR phosphorescence studies. Krasnovsky AA Jr. **Membr Cell Biol** 1998;12(5):665–90 (119 ref.)

METABOLISM

Overview of microcirculatory oxygen measurements and their contribution to our understanding of oxygen delivery to tissue. Johnson PC. **Adv Exp Med Biol** 1998;454:361–5 (19 ref.)

Pro-/anti-coagulants and oxygen transport in tissue. Kang KA. **Adv Exp Med Biol** 1998;454:667–70 (16 ref.)

Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology. Vaupel P, et al. **Adv Exp Med Biol** 1998; 454:591–602 (70 ref.)

Tissue oxygen sensing and the carotid body. Wilson DF, et al. **Adv Exp Med Biol** 1998;454:447–54 (26 ref.)

A discussion on the activation of oxygen in chemistry and enzymology. Akhtar M, et al. **Biochem Soc Trans** 1998 Aug; 26(3):322–5 (13 ref.)

Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery. Riess JG, et al. **Biomaterials** 1998 Aug;19(16):1529–39 (42 ref.)

Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation. McCoy CL, et al. **Br J Cancer Suppl** 1996 Jul;27:S226–31 (58 ref.)

Microcirculatory oxygenation and shunting in sepsis and shock [see comments] Ince C, et al. **Crit Care Med** 1999 Jul;27(7):1369–77 (75 ref.) Comment in: Crit Care Med 1999 Jul;27(7):1400–1.

Biological sensors: More than one way to sense oxygen. Pellequer JL, et al. **Curr Biol** 1999 Jun 3;9(11):R416–8 (12 ref.)

Dioxygen-activating bio-inorganic model complexes. Liang HC, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):168–75 (88 ref.)

Heme-mediated oxygen activation in biology: cytochrome c oxidase and nitric oxide synthase. Poulos TL, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):131–7 (41 ref.)

The aerobic/anaerobic interface. Sawers G. **Curr Opin Microbiol** 1999 Apr;2(2):181–7 (51 ref.)

Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases. Cashman JR. **Drug Metab Rev** 1998 Nov;30(4):675–707 (117 ref.)

The P450 catalytic cycle and oxygenation mechanism. Lewis DF, et al. **Drug Metab Rev** 1998 Nov;30(4):739–86 (175 ref.)

Chronic ethanol, oxygen tension and hepatocyte energy metabolism. Cunningham CC, et al. **Front Biosci** 1999 Jul 1;4:D551–6 (26 ref.)

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. Marnett LJ, et al. **J Biol Chem** 1999 Aug 13;274(33):22903–6 (58 ref.)

Impact of diffusional oxygen transport on oxidative metabolism in the heart. Takahashi E, et al. **Jpn J Physiol** 1998 Aug;48(4):243–52 (70 ref.)

The amount of DNA in cells of the granular layer of the cerebellum and their susceptibility to hypoxia. Kowalska E, et al. **Med Hypotheses** 1998 Nov;51(5):443–4 (29 ref.)

Erythropoietin levels can be used to determine tissue oxygenation in critically ill patients. Padayatty SJ. **Med Hypotheses** 1998 Jul;51(1):85–8 (41 ref.)

Singlet molecular oxygen in photobiochemical systems: IR phosphorescence studies. Krasnovsky AA Jr. **Membr Cell Biol** 1998;12(5):665–90 (119 ref.)

Free radicals as a result of dioxygen metabolism. Branchaud BP. **Met Ions Biol Syst** 1999;36:79–102 (51 ref.)

Regulation of mitochondrial respiration by adenosine diphosphate, oxygen, and nitric oxide. Boveris A, et al. **Methods Enzymol** 1999;301:188–98 (23 ref.)

A glycyl radical solution: oxygen-dependent interconversion of pyruvate formate-lyase. Sawers G, et al. **Mol Microbiol** 1998 Aug;29(4):945–54 (33 ref.)

Is cooperative oxygen binding by hemoglobin really understood? Eaton WA, et al. **Nat Struct Biol** 1999 Apr; 6(4):351–8 (45 ref.)

Will increased oxygen really decrease extended wear infections? [editorial] Efron N, et al. **Optom Vis Sci** 1999 Jul;76(7):435–6 (13 ref.)

The "physiologically effective" correlates: peDk/L and peDk. Hill RM. **Optom Vis Sci** 1999 Mar;76(3):135–40 (32 ref.)

Physiology of hyperbaric hyperoxia. Piantadosi CA. **Respir Care Clin N Am** 1999 Mar;5(1):7–19, v (46 ref.)

Assessment of tissue oxygenation. Robertson PW, et al. **Respir Care Clin N Am** 1999 Jun;5(2):221–63 (192 ref.)

Neuroepithelial bodies as airway oxygen sensors. Cutz E, et al. **Respir Physiol** 1999 Apr 1;115(2):201–14 (57 ref.)

K+ and Ca2+ channel activity and cytosolic [Ca2+] in oxygen-sensing tissues. López-Barneo J, et al. **Respir Physiol** 1999 Apr 1;115(2):215–27 (60 ref.)

Models for oxygen sensing in yeast: implications for oxygen-regulated gene expression in higher eucaryotes. Poyton RO. **Respir Physiol** 1999 Apr 1;115(2):119–33 (70 ref.)

NO and CO as second messengers in oxygen sensing in the carotid body. Prabhakar NR. **Respir Physiol** 1999 Apr 1; 115(2):161–8 (39 ref.)

Roles for NAD(P)H oxidases and reactive oxygen species in vascular oxygen sensing mechanisms. Wolin MS, et al. **Respir Physiol** 1999 Apr 1;115(2):229–38 (55 ref.)

Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Zhu H, et al. **Respir Physiol** 1999 Apr 1;115(2):239–47 (68 ref.)

Blood flow and oxygenation status of human tumors. Clinical investigations. Feldmann HJ, et al. **Strahlenther Onkol** 1999 Jan;175(1):1–9 (91 ref.)

[Oxygen delivery in sepsis. After 10 years more questions than answers] Bone HG, et al. **Anaesthesist** 1999 Feb; 48(2):63–79 (138 ref.) (Eng. Abstr.) **(Ger)**

[Supranormal oxygen delivery] Katsuya H. **Masui** 1998 Dec; 47 Suppl:S81–7 (16 ref.) **(Jpn)**

[Role of oxygen free radicals in the pathogenesis of lung diseases] Wlodarczyk R, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):41–3 (24 ref.) (Eng. Abstr.) **(Pol)**

[Oxygen metabolism disturbances in the pathogenesis of gastric and duodenal diseases] Swiątkowski M, et al. **Przegl Lek** 1999;56(3):220–6 (58 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Oxygen transport-1. Basic principles. Treacher DF, et al. **BMJ** 1998 Nov 7;317(7168):1302–6 (0 ref.)

PHARMACOLOGY

Oxygen tension and virus replication. Ebbesen P, et al. **Acta Virol** 1998 Dec;42(6):417–21 (38 ref.)

Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. Van Driel BE, et al. **J Histochem Cytochem** 1999 May; 47(5):575–82 (50 ref.)

Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. Zhou Y, et al. **J Reprod Immunol** 1998 Aug;39(1-2):197–213 (16 ref.)

PHYSIOLOGY

Two research paths for probing the roles of oxygen in metabolic regulation. Hochachka PW. **Braz J Med Biol Res** 1999 Jun;32(6):661–72 (51 ref.)

Perspectives on oxygen sensing. Semenza GL. **Cell** 1999 Aug 6;98(3):281–4 (21 ref.)

Endothelial cell responses to hypoxic stress. Faller DV. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):74–84 (176 ref.)

Singlet molecular oxygen ((1)O2): a possible effector of eukaryotic gene expression. Ryter SW, et al. **Free Radic Biol Med** 1998 Jun;24(9):1520–34 (134 ref.)

Oxygen-sensing potassium currents in pulmonary artery. McCulloch KM, et al. **Gen Pharmacol** 1999 Apr; 32(4):403–11 (54 ref.)

THERAPEUTIC USE

Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Saunders M, et al. **Br J Cancer Suppl** 1996 Jul;27:S271–8 (48 ref.)

Does heliox decrease the need for intubation in acute bronchiolitis? [editorial; comment] Barnes SD. **Crit Care Med** 1998 Oct;26(10):1633–5 (18 ref.) Comment

OXYGEN

on: Crit Care Med 1998 Oct;26(10):1731–6.
When do infants need additional inspired oxygen? A review of the current literature. Poets CF. **Pediatr Pulmonol** 1998 Dec;26(6):424–8 (36 ref.)
[Collective oxygen therapy and disaster medicine] Larcan A, et al. **Bull Acad Natl Med** 1998;182(6):1191–205; discussion 1206–8 (15 ref.) (Eng. Abstr.) **(Fre)**
[Oxygen treatment methods—a critical analysis of established and controversial procedures (II)] Lutz J. **Versicherungsmedizin** 1998 Oct 1;50(5):190–4 (24 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Oxygen toxicity induces apoptosis in neuronal cells. Satoh T, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):649–66 (68 ref.)
Pathways to cell death in hyperoxia. Horowitz S. **Chest** 1999 Jul;116(1 Suppl):64S–67S (33 ref.)
Oxygen toxicity and tolerance. Capellier G, et al. **Minerva Anestesiol** 1999 Jun;65(6):388–92 (51 ref.)
Toxicity of high PaO2. Kleen M, et al. **Minerva Anestesiol** 1999 Jun;65(6):393–6 (23 ref.)
Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Halliwell B. **Mutat Res** 1999 Jul 15;443(1–2):37–52 (153 ref.)
Physiologic and biochemical monitoring during hyperbaric oxygenation: a review. Rogatsky GG, et al. **Undersea Hyperb Med** 1999 Summer;26(2):111–22 (193 ref.)

OXYGEN CONSUMPTION

Age-related changes in the microcirculation of skeletal muscle. Degens H. **Adv Exp Med Biol** 1998;454:343–8 (35 ref.)
Spontaneous fluctuations in cerebral oxygen supply. An introduction. Hudetz AG, et al. **Adv Exp Med Biol** 1998; 454:551–9 (26 ref.)
Oxygen and ion concentrations in normoxic and hypoxic brain cells. Silver I, et al. **Adv Exp Med Biol** 1998;454:7–16 (45 ref.)
Developing in vivo EPR oximetry for clinical use. Swartz HM, et al. **Adv Exp Med Biol** 1998;454:243–52 (31 ref.)
Proton translocation in the respiratory chain involving ubiquinone—a hypothetical semiquinone switch mechanism for complex I. Brandt U. **Biofactors** 1999;9(2–4):95–101 (30 ref.)
Oxygen transport-2. Tissue hypoxia. Leach RM, et al. **BMJ** 1998 Nov 14;317(7169):1370–3 (0 ref.)
Does optimizing oxygen transport improve outcome in intensive care patients? Brazzi L, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:46–9 (28 ref.)
Monitoring normovolaemic haemodilution. Trouwborst A, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:73–8 (70 ref.)
Cigarette smoking, cutaneous vasculature, and tissue oxygen. Leow YH, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):579–84 (46 ref.)
Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Semenza GL. **Curr Opin Genet Dev** 1998 Oct; 8(5):588–94 (62 ref.)
Cardiac and peripheral responses to exercise in patients with chronic heart failure. Cohen-Solal A, et al. **Eur Heart J** 1999 Jul;20(13):931–45 (170 ref.)
Physical activity, fitness and integrated antioxidant system in healthy active elderly women. Kostka T, et al. **Int J Sports Med** 1998 Oct;19(7):462–7 (41 ref.)
Interaction of factors determining oxygen uptake at the onset of exercise. Tschakovsky ME, et al. **J Appl Physiol** 1999 Apr;86(4):1101–13 (105 ref.)
Measurement of volumetric (OUR) and determination of specific (qO2) oxygen uptake rates in animal cell cultures. Ruffieux PA, et al. **J Biotechnol** 1998 Aug 12;63(2):85–95 (60 ref.)
A role for oxygen-induced osmosis in hyperbaric oxygen therapy. Hills BA. **Med Hypotheses** 1999 Mar;52(3):259–63 (31 ref.)
Techniques to assess the oxygenation of human tumors. State of the art. Horsman MR, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:2–5 (37 ref.)

DRUG EFFECTS

Can erythropoietin improve tumor oxygenation? Kelleher DK, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:20–3 (25 ref.)

GENETICS

Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. Wei YH, et al. **Ann N Y Acad Sci** 1998 Nov 20; 854:155–70 (104 ref.)
Molecular genetics of the genus Paracoccus: metabolically versatile bacteria with bioenergetic flexibility. Baker SC, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1046–78 (351 ref.)

PHYSIOLOGY

Haemoglobin, blood volume, cardiac function, and aerobic power. Gledhill N, et al. **Can J Appl Physiol** 1999 Feb; 24(1):54–65 (45 ref.)
The gas transporting systems: limits and modifications with age and training. Paterson DH, et al. **Can J Appl Physiol** 1999 Feb;24(1):28–40 (48 ref.)
Nitric oxide as a regulator of tissue oxygen consumption. Wolin MS, et al. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):97–103 (37 ref.)
A second mechanism of respiratory control. Kadenbach B, et al. **FEBS Lett** 1999 Mar 26;447(2–3):131–4 (64 ref.)
Tissue oxygenation modifies nitric oxide bioavailability. Heyman SN, et al. **Microcirculation** 1999 Sep;6(3):199–203 (37 ref.)
Mechanism of impaired oxygen extraction in sepsis. Shunt and the pO2 gap [editorial] Ince C. **Minerva Anestesiol** 1999 Jun;65(6):337–9 (10 ref.)
Oxygen uptake kinetics during exercise. Xu F, et al. **Sports Med** 1999 May;27(5):313–27 (100 ref.)
Oxygenation of human tumors: the Mainz experience. Vaupel P, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:6–12 (47 ref.)

RADIATION EFFECTS

Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Molls M, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:13–6 (35 ref.)

OXYGEN DEFICIENCY see **ANOXIA**

OXYGEN INHALATION THERAPY

Long-term oxygen therapy in COPD patients with moderate hypoxaemia: does it add years to life? [editorial; comment] Zieliński J. **Eur Respir J** 1998 Oct;12(4):756–8 (32 ref.) Comment on: Eur Respir J 1998 Oct;12(4):780–4.
Oxygen therapy for cystic fibrosis. Dinwiddie R, et al. **J R Soc Med** 1999;92 Suppl 37:19–22 (10 ref.)
Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial [see comments] Scheinkestel CD, et al. **Med J Aust** 1999 Mar 1;170(5):203–10 (52 ref.) Comment in: Med J Aust 1999 Mar 1;170(5):197–9. Comment in: Med J Aust 1999 Jun 7;170(11):563; discussion 564–5. Comment in: Med J Aust 1999 Jun 7;170(11):563–4; discussion 564–5. Comment in: Med J Aust 1999 Jun 7;170(11):564–5. Comment in: ACP J Club 1999 Jul–Aug;131(1):11.
Compliance as a critical issue in long-term oxygen therapy. Avdeev SN, et al. **Monaldi Arch Chest Dis** 1999 Feb; 54(1):61–6 (56 ref.)
Nonconventional indications of long-term oxygen therapy: oxygen therapy during exercise. Crockett AJ, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):72–4 (28 ref.)
Nonconventional indications for LTOT: isolated nocturnal oxygen therapy in chronic lung disease. Fletcher EC. **Monaldi Arch Chest Dis** 1999 Feb;54(1):67–71 (32 ref.)
Conventional indications for long-term oxygen therapy and mechanical ventilation. Howard P. **Monaldi Arch Chest Dis** 1999 Feb;54(1):55–7 (2 ref.)
Controversial indications for long-term respiratory care: long-term oxygen therapy. Petty TL. **Monaldi Arch Chest Dis** 1999 Feb;54(1):58–60 (12 ref.)
Long-term ventilatory support. Wedzicha JA. **Monaldi Arch Chest Dis** 1998 Jun;53(3):317–20 (29 ref.)
Who benefits from oxygen therapy? Seemungal T, et al. **Practitioner** 1998 Mar;242(1584):167–8, 171–2, 175 (9 ref.)
[Arterial puncture or pulse oximetry?] Abdulla J, et al. **Ugeskr Laeger** 1999 Feb 22;161(8):1100–2 (25 ref.) (Eng. Abstr.) **(Dan)**
[New advances and debated questions in intensive care in the 90-s] Incze F. **Orv Hetil** 1998 Dec 20;139(51):3059–64 (31 ref.) (Eng. Abstr.) **(Hun)**
[Therapy of respiratory insufficiency. Oxygen inhalation therapy, including home oxygen therapy] Nishimura M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):51–6 (11 ref.) **(Jpn)**

ADVERSE EFFECTS

Resuscitation with room-air or oxygen supplementation. Saugstad OD. **Clin Perinatol** 1998 Sep;25(3):741–56, xi (73 ref.)

INSTRUMENTATION

Provision of oxygen at home. Rees PJ, et al. **BMJ** 1998 Oct 3;317(7163):935–8 (0 ref.)
Long-term oxygen therapy: advances and perspectives in technical devices. Keller RR. **Monaldi Arch Chest Dis** 1999 Feb;54(1):75–8 (30 ref.)
[Oxygen treatment methods—a critical analysis of established and controversial procedures (II)] Lutz J. **Versicherungsmedizin** 1998 Oct 1;50(5):190–4 (24 ref.) (Eng. Abstr.) **(Ger)**
[Oxygen treatment methods—a critical analysis of established and controversial procedures (I)] Lutz J. **Versicherungsmedizin** 1998 Aug 1;50(4):141–4 (0 ref.) **(Ger)**

METHODS

Resuscitation with room-air or oxygen supplementation. Saugstad OD. **Clin Perinatol** 1998 Sep;25(3):741–56, xi (73 ref.)
Does heliox decrease the need for intubation in acute bronchiolitis? [editorial; comment] Barnes SD. **Crit Care Med** 1998 Oct;26(10):1633–5 (18 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1731–6.
'Am I fit to fly'? Woods DP. **Practitioner** 1998 May; 242(1586):384–7 (2 ref.)
[Long-term oxygen inhalation therapy and home artificial respiration for chronic pulmonary heart disease] Köhler D, et al. **Internist (Berl)** 1999 Jul;40(7):756–63 (62 ref.) **(Ger)**

STANDARDS

Indications for long-term oxygen therapy: a reappraisal. Zieliński J. **Monaldi Arch Chest Dis** 1999 Apr;54(2):178–82 (31 ref.)

TRENDS

[Home oxygen therapy. What future awaits it?] Sebastián Ariño A, et al. **Arch Bronconeumol** 1999 May;35 Suppl 3:95–7 (24 ref.) **(Spa)**

VETERINARY

Cardiopulmonary resuscitation and oxygen therapy. Marks SL. **Vet Clin North Am Small Anim Pract** 1999 Jul; 29(4):959–69, vii (9 ref.)

OXYGEN ISOTOPES

[Stable oxygen and carbon isotopes in biological studies] Nazarov NM. **Aviakosm Ekolog Med** 1999;33(1):3–10 (62 ref.) (Eng. Abstr.) **(Rus)**

OXYGEN PARTIAL PRESSURE DETERMINATION, TRANSCUTANEOUS see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

OXYGEN SPECIES, REACTIVE see **REACTIVE OXYGEN SPECIES**

OXYGENASES

GENETICS

Engineering of improved microbes and enzymes for bioremediation. Chen W, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):137–41 (40 ref.)
Functional role of epoxyeicosatrienoic acids and their production in astrocytes: approaches for gene transfer and therapy (review). Medhora M, et al. **Int J Mol Med** 1998 Dec;2(6):661–9 (67 ref.)

METABOLISM

Occurrence of flavin-containing monooxygenases in non-mammalian eukaryotic organisms. Schlenk D. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):185–95 (63 ref.)
Methanotrophs, Methylosinus trichosporium OB3b, sMMO, and their application to bioremediation. Sullivan JP, et al. **Crit Rev Microbiol** 1998;24(4):335–73 (165 ref.)
P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Scarborough PE, et al. **Drug Metab Rev** 1999 Feb;31(1):205–34 (89 ref.)
Photochemically driven models of oxygenases based on the use of iron porphyrins. Maldotti A, et al. **J Biol Inorg Chem** 1999 Apr;4(2):154–61 (61 ref.)

PHARMACOLOGY

Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases. Cashman JR. **Drug Metab Rev** 1998 Nov;30(4):675–707 (117 ref.)

OXYGENATION, EXTRACORPOREAL MEMBRANE see **EXTRACORPOREAL MEMBRANE OXYGENATION**

OXYGENATION, HYPERBARIC see **HYPERBARIC OXYGENATION**

OXYGENATORS

Intravascular membrane oxygenator and carbon dioxide removal devices: a review of performance and improvements. Zwischenberger JB, et al. **ASAIO J** 1999 Jan–Feb;45(1):41–6 (24 ref.)

OXYGENATORS, MEMBRANE

Intravascular gas exchange. Keogh BF, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):38–42 (18 ref.)

OXYHEMOGLOBINS

METABOLISM

Overview of microcirculatory oxygen measurements and their contribution to our understanding of oxygen delivery to tissue. Johnson PC. **Adv Exp Med Biol** 1998;454:361–5 (19 ref.)
Nonconventional indications for LTOT: isolated nocturnal oxygen therapy in chronic lung disease. Fletcher EC. **Monaldi Arch Chest Dis** 1999 Feb;54(1):67–71 (32 ref.)

OXYNEURINE see **BETAINE**

OXYNTIC CELLS see **PARIETAL CELLS, GASTRIC**

OXYNTOMODULIN see **ENTEROGLUCAGON**

OXYPROLINE see **HYDROXYPROLINE**

OXYTOCICS

ADMINISTRATION & DOSAGE

Misoprostol for induction of labour: a systematic review. Hofmeyr GJ, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):798–803 (34 ref.)

ADVERSE EFFECTS

Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Plaut MM, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1535–42 (27 ref.)

A risk–benefit assessment of oxytocics in obstetric practice. Winkler M, et al. **Drug Saf** 1999 Apr;20(4):323–45 (125 ref.)

PHARMACOLOGY

Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. de Groot AN, et al. **Drugs** 1998 Oct;56(4):523–35 (77 ref.)

THERAPEUTIC USE

Current trends in cervical ripening and labor induction. Harman JH Jr, et al. **Am Fam Physician** 1999 Aug; 60(2):477–84 (27 ref.)

Labor induction with misoprostol. Wing DA. **Am J Obstet Gynecol** 1999 Aug;181(2):339–45 (36 ref.)

OXYTOCIN

see related
OXYTOCICS
RECEPTORS, OXYTOCIN

ANALOGS & DERIVATIVES

Something fishy in the rat brain: molecular genetics of the hypothalamo–neurohypophysial system. Murphy D, et al. **Bioessays** 1998 Sep;20(9):741–9 (62 ref.)

ANTAGONISTS & INHIBITORS

Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Bossmar T. **J Perinat Med** 1998;26(6):458–65 (67 ref.)

GENETICS

Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons. Gainer H. **Adv Exp Med Biol** 1998; 449:15–27 (59 ref.)

The molecular basis of oxytocin and oxytocin receptor gene expression in reproductive tissues. Ivell R, et al. **Adv Exp Med Biol** 1998;449:297–306 (46 ref.)

Phenotypic and state-dependent expression of the electrical and morphological properties of oxytocin and vasopressin neurones. Armstrong WE, et al. **Prog Brain Res** 1998; 119:101–13 (91 ref.)

PHARMACOLOGY

Electrophysiological effects of oxytocin within the bed nuclei of the stria terminalis: influence of reproductive stage and ovarian steroids. Wakerley JB, et al. **Prog Brain Res** 1998; 119:321–34 (57 ref.)

PHYSIOLOGY

Electrophysiological distinctions between oxytocin and vasopressin neurons in the supraoptic nucleus. Armstrong WE, et al. **Adv Exp Med Biol** 1998;449:67–77 (47 ref.)

Mechanisms of neuroendocrine cell excitability. Hatton GI, et al. **Adv Exp Med Biol** 1998;449:79–95 (86 ref.)

Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Insel TR, et al. **Adv Exp Med Biol** 1998; 449:215–24 (50 ref.)

New aspects of firing pattern autocontrol in oxytocin and vasopressin neurones. Moos F, et al. **Adv Exp Med Biol** 1998;449:153–62 (32 ref.)

Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium. Sanborn BM, et al. **Adv Exp Med Biol** 1998;449:277–86 (34 ref.)

Something fishy in the rat brain: molecular genetics of the hypothalamo–neurohypophysial system. Murphy D, et al. **Bioessays** 1998 Sep;20(9):741–9 (62 ref.)

Oxytocin, vasopressin, and autism: is there a connection? Insel TR, et al. **Biol Psychiatry** 1999 Jan 15;45(2):145–57 (85 ref.)

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

Comparative aspects of oxytocin in baboon (Papio hamadryus anubis) and human corpora lutea. Khan-Dawood FS, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):371–82 (100 ref.)

The role of sex steroids in the oxytocin hormone system. Ivell R, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1–2):95–101 (56 ref.)

Role of vasopressin and oxytocin in the control of social behavior in Syrian hamsters (Mesocricetus auratus). Albers HE, et al. **Prog Brain Res** 1998;119:395–408 (71 ref.)

Electrophysiological studies of neurohypophysial neurons and peptides. Pittman QJ, et al. **Prog Brain Res** 1998; 119:311–20 (57 ref.)

Vasopressin and oxytocin action in the brain: cellular neurophysiological studies. Raggenbass M, et al. **Prog Brain Res** 1998;119:263–73 (62 ref.)

Oxytocin and neuroadaptation to cocaine. Sarnyai Z. **Prog Brain Res** 1998;119:449–66 (72 ref.)

Physiological pathways regulating the activity of magnocellular neurosecretory cells. Leng G, et al. **Prog Neurobiol** 1999 Apr;57(6):625–55 (278 ref.)

Oxytocin and addiction: a review. Kovács GL, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):945–62 (66 ref.)

Oxytocin may mediate the benefits of positive social interaction and emotions. Uvnäs-Moberg K. **Psychoneuroendocrinology** 1998 Nov;23(8):819–35 (74 ref.)

Neural oxytocinergic systems as genomic targets for hormones and as modulators of hormone-dependent behaviors. Pfaff DW, et al. **Results Probl Cell Differ** 1999; 26:91–105 (75 ref.)

SECRETION

Differential central and peripheral release of vasopressin and oxytocin in response to swim stress in rats. Engelmann M, et al. **Adv Exp Med Biol** 1998;449:175–7 (15 ref.)

Dendritic release of vasopressin and oxytocin. Ludwig M. **J Neuroendocrinol** 1998 Dec;10(12):881–95 (182 ref.)

OXYTOCIN RECEPTORS see **RECEPTORS, OXYTOCIN**

OXYURIS VERMICULARIS INFECTION see **ENTEROBIASIS**

OZONE

Ozone dose mapping and the utility of models. Anderson CW, et al. **Novartis Found Symp** 1999;220:80–96; discussion 96–100, 101–4 (11 ref.)

A preliminary statistical examination of the effects of uncertainty and variability on environmental regulatory criteria for ozone. Cox LH, et al. **Novartis Found Symp** 1999;220:122–38; discussion 138–43 (12 ref.)

["Ozone holes"--ultraviolet radiation--heliotherapy] Slutskaia GF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep–Oct;(5):50–1 (19 ref.) **(Rus)**

ADVERSE EFFECTS

Ontario Medical Association position paper on health effects of ground-level ozone, acid aerosols and particulate matter. Boadway BT, et al. **Can Respir J** 1998 Sep–Oct;5(5):367–84 (77 ref.)

IMMUNOLOGY

[Ozone and the immune system] Lacroix G, et al. **Rev Mal Respir** 1998 Dec;15(6):699–711 (103 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

[The intracellular mechanisms of the therapeutic action of ozone in critical states] Chuev PN, et al. **Lik Sprava** 1998 Aug;(6):27–30 (21 ref.) **(Rus)**

[Ozone hemotherapy in the combined treatment of gestoses] Chuev PN, et al. **Lik Sprava** 1998 Oct–Nov;(7):36–8 (24 ref.) **(Rus)**

[Ozone therapy in ophthalmology] Lapina IM, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):51–4 (48 ref.) **(Rus)**

TOXICITY

Ozone-induced lung inflammation and mucosal barrier disruption: toxicology, mechanisms, and implications. Bhalla DK. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar;2(1):31–86 (103 ref.)

Toxicological mechanisms underlying oxidant pollutant-induced airway injury. Krishna MT, et al. **Rev Environ Health** 1998 Jan–Jun;13(1–2):59–71 (75 ref.)

P0 GLYCOPROTEIN see **MYELIN P0 PROTEIN**

P0 PROTEIN see **MYELIN P0 PROTEIN**

P1 PURINOCEPTORS see **RECEPTORS, PURINERGIC P1**

P2 PROTEIN see **MYELIN P2 PROTEIN**

P2 PURINOCEPTORS see **RECEPTORS, PURINERGIC P2**

P16 GENES see **GENES, P16**

P16INK4 GENES see **GENES, P16**

P16INK4 PROTEIN see **PROTEIN P16**

P16 PROTEIN see **PROTEIN P16**

P21(C-HA-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-KI-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(N-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(V-HA-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P21(V-KI-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P22 PHAGE see **BACTERIOPHAGE P22**

P34CDC2 PROTEIN see **PROTEIN P34CDC2**

P39(C-JUN) see **PROTO-ONCOGENE PROTEINS C-JUN**

P40(TAX) see **GENE PRODUCTS, TAX**

P42 MAP KINASE see **P42(MAPK) KINASE**

P42 MAPK see **P42(MAPK) KINASE**

P42(MAPK) KINASE

PHYSIOLOGY

The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Dent P, et al. **Leukemia** 1998 Dec;12(12):1843–50 (114 ref.)

P42(MITOGEN-ACTIVATED PROTEIN KINASE) see **P42(MAPK) KINASE**

P53 GENES see **GENES, P53**

P53 PROTEIN see **PROTEIN P53**

P55(C-FOS) see **PROTO-ONCOGENE PROTEINS C-FOS**

P56CDC13 see **CYCLIN B**

P56 LCK see **LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK)**

P62(C-MYC) see **PROTO-ONCOGENE PROTEINS C-MYC**

P68 KINASE see **EIF-2 KINASE**

P70 S6 KINASE see **RIBOSOMAL PROTEIN S6 KINASE**

P70S6K see **RIBOSOMAL PROTEIN S6 KINASE**

P105-RB PROTEIN see **RETINOBLASTOMA PROTEIN**

P145(C-KIT) see **PROTO-ONCOGENE PROTEINS C-KIT**

P185(C-NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

P300 EVENT-RELATED POTENTIALS see **EVENT-RELATED POTENTIALS, P300**

P450(C17) see **STEROID 17 ALPHA-MONOOXYGENASE**

P-ANCA see **ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC**

P-B ANTIBODIES see **ANTIBODIES, HETEROPHILE**

P-CADHERINS see **CADHERINS**

P-CELL STIMULATING FACTOR see **INTERLEUKIN-3**

P-GLYCOPROTEIN

see related
DRUG RESISTANCE, MULTIPLE

PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Atadja P, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):163–8 (28 ref.)

Visualization of multidrug resistance in vivo. Hendrikse NH, et al. **Eur J Nucl Med** 1999 Mar;26(3):283–93 (91 ref.)

BIOSYNTHESIS

Reversal of multidrug resistance in hematological malignancies. Vossebeld PJ, et al. **Blood Rev** 1999 Jun; 13(2):67–78 (129 ref.)

CHEMISTRY

Merck Frosst Award Lecture 1998. Molecular dissection of

P-GLYCOPROTEIN

the human multidrug resistance P-glycoprotein. Loo TW, et al. **Biochem Cell Biol** 1999;77(1):11-23 (111 ref.)
Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter. Sharom FJ, et al. **Biochem Cell Biol** 1998; 76(5):695-708 (69 ref.)

DRUG EFFECTS

Cancer multidrug resistance. Persidis A. **Nat Biotechnol** 1999 Jan;17(1):94-5 (15 ref.)

GENETICS

Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Aran JM, et al. **Adv Pharmacol** 1999;46:1-42 (212 ref.)
Multidrug resistance in oncology: diagnostic and therapeutic approaches. Robert J. **Eur J Clin Invest** 1999 Jun; 29(6):536-45 (95 ref.)
[Mechanisms of multidrug resistance in tumor cells and analytical methods for its detection] Takemura Y, et al. **Rinsho Byori** 1998 Aug;46(8):745-58 (88 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Yeast as an expression system for the study of P-glycoprotein and other ABC transporters. Gros P, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:219-25 (64 ref.)
The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Shapiro AB, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:227-34 (37 ref.)
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ambudkar SV, et al. **Annu Rev Pharmacol Toxicol** 1999;39:361-98 (169 ref.)
Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. Wacher VJ, et al. **J Pharm Sci** 1998 Nov;87(11):1322-30 (83 ref.)
Diagnostics of multidrug resistance in cancer. Szakács G, et al. **Pathol Oncol Res** 1998;4(4):251-7 (64 ref.)
The pharmacological role of P-glycoprotein in the intestinal epithelium. Van Asperen J, et al. **Pharmacol Res** 1998 Jun; 37(6):429-35 (40 ref.)
P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Tsuji A. **Ther Drug Monit** 1998 Oct;20(5):588-90 (20 ref.)
[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs] Machaczka M, et al. **Przegl Lek** 1998; 55(7-8):407-13 (53 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Recent progress in P-glycoprotein research. Ueda K, et al. **Anticancer Drug Des** 1999 Apr;14(2):115-21 (45 ref.)
Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein. Loo TW, et al. **Biochem Cell Biol** 1999;77(1):11-23 (111 ref.)
Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Eytan GD, et al. **Int Rev Cytol** 1999; 190:175-250 (171 ref.)

P-GLYCOPROTEINS

see related
DRUG RESISTANCE, MULTIPLE
GENES, MDR

CHEMISTRY

Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter. Sharom FJ, et al. **Biochem Cell Biol** 1998; 76(5):695-708 (69 ref.)

PHYSIOLOGY

Clinical imaging of multidrug resistance in cancer. Del Vecchio S, et al. **Q J Nucl Med** 1999 Jun;43(2):125-31 (47 ref.)

P SELECTIN see **P-SELECTIN**

PACEMAKER, ARTIFICIAL

What is the ideal rate-adaptive sensor for patients with implantable cardioverter defibrillators: lessons from cardiac pacing. Alt E. **Am J Cardiol** 1999 Mar 11;83(5B):17D-23D (10 ref.)
Clinical significance of multiple sensor options: rate response optimization, sensor blending, and trending. Clémenty J, et al. **Am J Cardiol** 1999 Mar 11;83(5B):166D-171D (20 ref.)
Pacemaker leads: performance and progress. de Voogt WG. **Am J Cardiol** 1999 Mar 11;83(5B):187D-191D (33 ref.)
Evolving indications for permanent pacing. Hayes DL. **Am J Cardiol** 1999 Mar 11;83(5B):161D-165D (36 ref.)
Future of bradyarrhythmia therapy systems: automaticity. Jones BR, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):192D-201D (64 ref.)
Effect of pacing mode on morbidity and mortality: update of clinical pacing trials. McComb JM, et al. **Am J Cardiol** 1999 Mar 11;83(5B):211D-213D (23 ref.)
Taking advantage of sophisticated pacemaker diagnostics. Nowak B. **Am J Cardiol** 1999 Mar 11;83(5B):172D-179D (22 ref.)
Multisite or alternate site pacing for the prevention of atrial fibrillation. Ramdat Misier A, et al. **Am J Cardiol** 1999 Mar 11;83(5B):237D-240D (63 ref.)
How smart should pacemakers Be? Saoudi N, et al. **Am J Cardiol** 1999 Mar 11;83(5B):180D-186D (32 ref.)
Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. The VIGOR CHF and VENTAK CHF Investigators. Saxon LA, et al. **Am J Cardiol** 1999 Mar 11;83(5B):120D-123D (20 ref.)
Mode switching for atrial tachyarrhythmias. Sutton R, et al. **Am J Cardiol** 1999 Mar 11;83(5B):202D-210D (12 ref.)
Atrioventricular nodal ablation and pacemaker implantation in patients with atrial fibrillation. Touboul P. **Am J Cardiol** 1999 Mar 11;83(5B):241D-245D (28 ref.)
Third degree atrio-ventricular-block caused by malignant non-Hodgkin's lymphoma: an unusual indication for epicardial pacing. Aleksic I, et al. **Cardiovasc Surg** 1999 Apr;7(3):378-80 (12 ref.)
Cardiac pacemakers: current and future status. Mitrani RD, et al. **Curr Probl Cardiol** 1999 Jun;24(6):341-420 (230 ref.)
Is sinus bradycardia a factor facilitating overt heart failure? Alboni P, et al. **Eur Heart J** 1999 Feb;20(4):252-5 (34 ref.)
Pacemaker lead infection: report of three cases and review of the literature. Voet JG, et al. **Heart** 1999 Jan;81(1):88-91 (17 ref.)
Optimization of ventricular pacing: where should we implant the leads? [editorial; comment] Gold MR. **J Am Coll Cardiol** 1999 Feb;33(2):324-6 (21 ref.) Comment on: J Am Coll Cardiol 1999 Feb;33(2):311-6. Comment on: J Am Coll Cardiol 1999 Feb;33(2):317-23.
Permanent pacemakers in older persons. Gregoratos G. **J Am Geriatr Soc** 1999 Sep;47(9):1125-35 (74 ref.)
Intraoperative pacemaker dysfunction caused by the use of electrocautery during a total hip arthroplasty. Nercessian OA, et al. **J Arthroplasty** 1998 Aug;13(5):599-602 (33 ref.)
The use of pacemakers as treatment for systolic dysfunction. Gottlieb SS. **J Card Fail** 1998 Jun;4(2):145-50 (68 ref.)
Exercise prescription for patients with pacemakers. Sharp CT, et al. **J Cardiopulm Rehabil** 1998 Nov-Dec; 18(6):421-31 (56 ref.)
Permanent cardiac pacemakers: issues relevant to the emergency physician, part II. Cardall TY, et al. **J Emerg Med** 1999 Jul-Aug;17(4):697-709 (75 ref.)
The current status of single lead dual chamber sensing and pacing. Tse HF, et al. **J Interv Card Electrophysiol** 1998 Sep;2(3):255-67 (55 ref.)
The slow pulse: is a pacemaker necessary? Corcoran SJ, et al. **Med J Aust** 1999 Jun 7;170(11):556-61 (20 ref.)
Pacemaker trials: software or hardware randomization? [editorial] Gribbin GM, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1503-7 (37 ref.)
The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation [editorial] Parsonnet V, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):695-7 (17 ref.)
NASPE expert consensus statement: physician workforce in cardiac electrophysiology and pacing. NASPE task force, Washington, D.C. [see comments] Reynolds DW, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1646-55 (25 ref.) Comment in: Pacing Clin Electrophysiol 1999 Apr;22(4 Pt 1):691.
New insights in antibradycardia pacing. Bongiorni MG, et al. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III9-14 (25 ref.)
[Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation] Madei W, et al. **Dtsch Med Wochenschr** 1999 Apr 23; 124(16):487-90 (16 ref.) (Eng. Abstr.) **(Ger)**
[Cardiac pacemaker and internal defibrillators (ICD). Basic principles and new important developments, status 1998] Deisenhofer I, et al. **Fortschr Med** 1998 Aug 20; 116(22-23):20-4, 26 (0 ref.) (Eng. Abstr.) **(Ger)**
[Sources of interference for cardiac pacemakers. Technical improvements of pacemakers--risks in the medical realm] Wilke A, et al. **Fortschr Med** 1998 Aug 20;116(22-23):27-31 (9 ref.) (Eng. Abstr.) **(Ger)**
[Advances in the technology of pacing] Dionísio P. **Rev Port Cardiol** 1999 Mar;18(3):289-98 (52 ref.) (Eng. Abstr.) **(Por)**
[The new indications for permanent cardiac pacing] Duarte JA, et al. **Rev Port Cardiol** 1999 Mar;18(3):281-8 (42 ref.) (Eng. Abstr.) **(Por)**
[Radiation therapy and cardiac pacemakers] Serafim P, et al. **Rev Port Cardiol** 1999 May;18(5):503-5 (7 ref.) (Eng. Abstr.) **(Por)**
[Transesophageal cardiac pacemakers] Ryzhikh AN, et al. **Med Tekh** 1999 May-Jun;(3):40-5 (20 ref.) (Eng. Abstr.) **(Rus)**
[The congenital long QT syndrome and its management with a permanent pacemaker] Espinosa Caleti B, et al. **Arch Inst Cardiol Mex** 1998 Mar-Apr;68(2):124-9 (18 ref.) (Eng. Abstr.) **(Spa)**
[Is the VVI pacemaker still useful? (editorial)] Garcia Hernández N. **Arch Inst Cardiol Mex** 1998 May-Jun; 68(3):203-5 (25 ref.) **(Spa)**
[A papillary fibroelastoma of the left ventricule in the presence of a mitral valve prosthesis. A case report and review of the literature] Román Herrera L, et al. **Arch Inst Cardiol Mex** 1998 May-Jun;68(3):232-8 (57 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Pacemaker-related endocarditis. Report of 7 cases and review of the literature. Laguno M, et al. **Cardiology** 1998; 90(4):244-8 (18 ref.)
Permanent cardiac pacemakers: issues relevant to the emergency physician, Part I. Cardall TY, et al. **J Emerg Med** 1999 May-Jun;17(3):479-89 (33 ref.)
[Systemic infection due to implanted leads of a cardiac pacemaker. Apropos of a case and review of the literature] Delpierre S, et al. **Ann Med Interne (Paris)** 1999 Apr; 150(3):265-8 (22 ref.) (Eng. Abstr.) **(Fre)**
[Infections secondary to implantation of cardiac pacemakers] Da Costa A, et al. **Arch Mal Coeur Vaiss** 1998 Jun; 91(6):753-7 (30 ref.) (Eng. Abstr.) **(Fre)**
[Chronic bacterial endocarditis on the electrical catheter in a pacemaker wearer: a clinical case report] Perrone C, et al. **G Ital Cardiol** 1999 May;29(5):558-61 (21 ref.) (Eng. Abstr.) **(Ita)**
[Natural-valve endocarditis in patients wearing pacemakers] Climent Payá V, et al. **Rev Clin Esp** 1999 Jan;199(1):28-30 (9 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Pacemaker-related endocarditis. Report of 7 cases and review of the literature. Laguno M, et al. **Cardiology** 1998; 90(4):244-8 (18 ref.)

PACEMAKERS, BIOLOGICAL see **BIOLOGICAL CLOCKS**

PACIFIC ISLAND AMERICANS see **ASIAN AMERICANS**

PACIFIERS see **INFANT CARE**

PACING, CARDIAC, ARTIFICIAL see **CARDIAC PACING, ARTIFICIAL**

PACKAGE INSERTS, DRUG see **DRUG LABELING**

PACKAGING, DRUG see **DRUG PACKAGING**

PACKAGING, FOOD see **FOOD PACKAGING**

PACKAGING, PRODUCT see **PRODUCT PACKAGING**

PACKAGING, VIRAL see **VIRUS ASSEMBLY**

PACKED RED-CELL VOLUME see **HEMATOCRIT**

PACLITAXEL

Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development. Cragg GM. **Med Res Rev** 1998 Sep;18(5):315-31 (35 ref.)
Camptothecin and taxol: discovery to clinic. Wall ME. **Med Res Rev** 1998 Sep;18(5):299-314 (45 ref.)

ADMINISTRATION & DOSAGE

Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Ozols RF, et al. **Ann Oncol** 1999;10 Suppl 1:59-64 (33 ref.)
One-hour paclitaxel infusions: review of safety and efficacy. Greco FA, et al. **Cancer J Sci Am** 1999 May-Jun; 5(3):179-91 (44 ref.)
Localized paclitaxel delivery. Dhanikula AB, et al. **Int J Pharm** 1999 Jun 25;183(2):85-100 (80 ref.)
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. Seidman AD, et al. **J Clin Oncol** 1998 Oct;16(10):3353-61 (37 ref.)
Antiproliferative stent coatings: Taxol and related compounds. Herdeg C, et al. **Semin Interv Cardiol** 1998 Sep-Dec;3(3-4):197-9 (26 ref.)
Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer. Di Leo A, et al. **Semin Oncol** 1999 Jun;26(3 Suppl 8):27-32 (17 ref.)
Gemcitabine plus taxane combinations in non-small cell lung cancer. Giaccone G. **Semin Oncol** 1999 Feb;26(1 Suppl 4):19-24 (21 ref.)
Paclitaxel plus nonanthracycline combinations in metastatic breast cancer. Perez EA. **Semin Oncol** 1999 Feb;26(1 Suppl 2):21-6 (24 ref.)
Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Ettinger DS. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):148-50 (20 ref.)
[New antitumor drugs for non-Hodgkin's lymphoma] Ohnishi K, et al. **Gan To Kagaku Ryoho** 1998 Dec; 25(14):2223-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Docetaxel in head and neck cancer: a review. Colevas AD, et al. **Am J Clin Oncol** 1998 Oct;21(5):482-6 (28 ref.)
Docetaxel: a taxoid for the treatment of metastatic breast cancer. Tankanow RM. **Am J Health Syst Pharm** 1998 Sep 1;55(17):1777-91 (131 ref.)
Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Schöffski P, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4751-6 (37 ref.)
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Couteau

C, et al. **Br J Cancer** 1999 Oct;81(3):457–62 (29 ref.)
Taxanes in the treatment of breast cancer: a prodigy comes of age. Miller KD, et al. **Cancer Invest** 1999;17(2):121–36 (156 ref.)
Role of taxanes in lung-cancer chemotherapy. Schiller JH. **Cancer Invest** 1998;16(7):471–7 (48 ref.)
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Crommentuyn KM, et al. **Cancer Treat Rev** 1998 Oct;24(5):345–66 (91 ref.)
Clinical pharmacokinetics of docetaxel. Clarke SJ, et al. **Clin Pharmacokinet** 1999 Feb;36(2):99–114 (94 ref.)
Future directions with taxane therapy. Cabral F, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):21–41, vii (87 ref.)
Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Belani CP. **Semin Oncol** 1999 Jun;26(3 Suppl 10):15–8 (31 ref.)
Single-agent docetaxel (Taxotere) in randomized phase III trials. Burris HA 3rd. **Semin Oncol** 1999 Jun;26(3 Suppl 9):1–6 (9 ref.)
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Costa SD, et al. **Semin Oncol** 1999 Jun;26(3 Suppl 9):24–31 (21 ref.)
Phase III randomized trials of docetaxel in patients with metastatic breast cancer. Crown J. **Semin Oncol** 1999 Jun; 26(3 Suppl 8):33–8 (35 ref.)
A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Crown J. **Semin Oncol** 1999 Feb;26(1 Suppl 3):5–9 (42 ref.)
Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Fossella FV. **Semin Oncol** 1999 Jun;26(3 Suppl 11):4–8 (34 ref.)
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Gandara DR, et al. **Semin Oncol** 1999 Jun;26(3 Suppl 10):3–7 (27 ref.)
Weekly administration of docetaxel (Taxotere): summary of clinical data. Hainsworth JD, et al. **Semin Oncol** 1999 Jun; 26(3 Suppl 10):19–24 (12 ref.)
An expanding role for docetaxel. Hortobagyi G. **Semin Oncol** 1998 Dec;25(6 Suppl 13):1–3 (25 ref.)
Recent progress in the clinical development of docetaxel (Taxotere). Hortobagyi GN. **Semin Oncol** 1999 Jun;26(3 Suppl 9):32–6 (19 ref.)
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans. Manegold C. **Semin Oncol** 1999 Jun;26(3 Suppl 11):23–7 (17 ref.)
Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer. Mattson K. **Semin Oncol** 1999 Jun;26(3 Suppl 10):25–8 (27 ref.)
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Nabholtz JM. **Semin Oncol** 1999 Jun;26(3 Suppl 9):7–13 (10 ref.)
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Nabholtz JM, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 3):10–6 (17 ref.)
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer. Ravdin PM. **Semin Oncol** 1999 Jun;26(3 Suppl 9):20–3 (12 ref.)
Docetaxel (Taxotere) and gemcitabine in combination therapy. Rizvi NA. **Semin Oncol** 1999 Jun;26(3 Suppl 11):19–22 (21 ref.)
New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations. Rosell R. **Semin Oncol** 1999 Jun; 26(3 Suppl 11):32–7 (29 ref.)
Phase I–II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Trudeau ME. **Semin Oncol** 1999 Jun;26(3 Suppl 8):21–6 (41 ref.)
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies. van Oosterom AT. **Semin Oncol** 1999 Jun;26(3 Suppl 10):8–11 (20 ref.)
Combination of taxanes with radiation: preclinical studies. Milas L, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):12–26 (83 ref.)
["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"] Piccart MJ. **Bull Mem Acad R Med Belg** 1998;153(5–6):285–92; discussion 292–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Taxanes in the treatment of breast and ovarian cancers: current indications and results] Espié M, et al. **Contracept Fertil Sex** 1998 Nov;26(11):805–11 (63 ref.) (Eng. Abstr.) **(Fre)**
[Taxotere as second-line for metastatic breast cancer] Culine S. **Rev Med Interne** 1999 Mar;20(3):277–80 (16 ref.) (Eng. Abstr.) **(Fre)**
[Current developments in use of docetaxel (taxotere) in gynecologic oncology] Jackisch C. **Med Klin** 1998 Sep 15; 93 Suppl 3:4–15 (45 ref.) **(Ger)**
[Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)] Manegold C. **Med Klin** 1998 Sep 15;93 Suppl 3:16–21 (55 ref.) (Eng. Abstr.) **(Ger)**
[Taxotere in various solid tumors] Orel NF. **Vopr Onkol** 1998; 44(5):639–44 (95 ref.) **(Rus)**

BIOSYNTHESIS

Tour de paclitaxel: biocatalysis for semisynthesis. Patel RN. **Annu Rev Microbiol** 1998;52:361–95 (97 ref.)

ECONOMICS

Pharmacoeconomic profile of taxanes in advanced ovarian cancer. Messori A, et al. **Anticancer Drugs** 1998 Nov; 9(10):909–16 (34 ref.)

METABOLISM

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Crommentuyn KM, et al. **Cancer Treat Rev** 1998 Oct;24(5):345–66 (91 ref.)

PHARMACOLOGY

How Taxol stabilises microtubule structure. Amos LA, et al. **Chem Biol** 1999 Mar;6(3):R65–9 (21 ref.)
Molecular effects of paclitaxel: myths and reality (a critical review). Blagosklonny MV, et al. **Int J Cancer** 1999 Oct 8;83(2):151–6 (96 ref.)
Combination of taxanes with radiation: preclinical studies. Milas L, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):12–26 (83 ref.)
[Pharmacological action of paclitaxel] Potemski P, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):27–9 (33 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Taxanes in the treatment of breast cancer: a prodigy comes of age. Miller KD, et al. **Cancer Invest** 1999;17(2):121–36 (156 ref.)
Role of taxanes in lung-cancer chemotherapy. Schiller JH. **Cancer Invest** 1998;16(7):471–7 (48 ref.)
The emerging role of paclitaxel in breast cancer therapy. Seidman AD. **Clin Cancer Res** 1995 Mar;1(3):247–56 (88 ref.)
Taxanes as radiosensitizers for head and neck cancer. Herscher LL, et al. **Curr Opin Oncol** 1999 May;11(3):183–6 (22 ref.)
Future directions with taxane therapy. Cabral F, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):21–41, vii (87 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. St. Thomas, U.S.Virgin Islands, March 25–29, 1998. Proceedings and abstracts. **Semin Oncol** 1999 Feb; 26(1 Suppl 2):1–155 (0 ref.)
The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Greco FA, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):129–33 (14 ref.)
The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Hainsworth JD, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):60–6 (21 ref.)
The current state of adjuvant therapy for breast cancer: focus on paclitaxel. Hudis CA. **Semin Oncol** 1999 Feb;26(1 Suppl 2):1–5 (22 ref.)
Single-agent paclitaxel in the treatment of breast cancer: phase I and II development. Seidman AD. **Semin Oncol** 1999 Jun;26(3 Suppl 8):14–20 (53 ref.)
Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Shin DM, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):100–5 (34 ref.)
Metastatic breast cancer: the role of chemotherapy. Sledge GW Jr, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):6–10 (18 ref.)
Paclitaxel in the treatment of hormone-refractory prostate cancer. Smith DC, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):109–11 (13 ref.)
Review and outlook for the role of paclitaxel in urothelial carcinoma. Vaughn DJ. **Semin Oncol** 1999 Feb;26(1 Suppl 2):117–22 (30 ref.)
Paclitaxel in the treatment of esophageal cancer. Weiner LM. **Semin Oncol** 1999 Feb;26(1 Suppl 2):106–8 (15 ref.)
Paclitaxel-based treatment of lymphoma. Younes A. **Semin Oncol** 1999 Feb;26(1 Suppl 2):123–8 (22 ref.)
Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. King TC, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):4–11 (58 ref.)
["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"] Piccart MJ. **Bull Mem Acad R Med Belg** 1998;153(5–6):285–92; discussion 292–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Taxanes in the treatment of breast and ovarian cancers: current indications and results] Espié M, et al. **Contracept Fertil Sex** 1998 Nov;26(11):805–11 (63 ref.) (Eng. Abstr.) **(Fre)**

PACS (RADIOLOGY) see **RADIOLOGY INFORMATION SYSTEMS**

PADUTIN see **KALLIKREIN**

PAECILOMYCES

ISOLATION & PURIFICATION

Onychomycosis caused by infection with Paecilomyces lilacinus [letter] Fletcher CL, et al. **Br J Dermatol** 1998 Dec;139(6):1133–5 (16 ref.)
Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Chan-Tack KM, et al. **Med Mycol** 1999 Feb;37(1):57–60 (26 ref.)

PAF-ACETHER see **PLATELET ACTIVATING FACTOR**

PAGET'S DISEASE, EXTRAMAMMARY

COMPLICATIONS

Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Fanning J, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):24–7 (13 ref.)

PATHOLOGY

Perianal Paget's disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression. Nowak MA, et al. **Arch Pathol Lab Med** 1998 Dec;122(12):1077–81 (22 ref.)
Paget's disease arising near a male areola without an underlying carcinoma. Takeuchi T, et al. **J Dermatol** 1999 Apr;26(4):248–52 (28 ref.)

SURGERY

Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Fanning J, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):24–7 (13 ref.)
Extramammary Paget's disease of the vulva: report of five cases and review of the literature. Piura B, et al. **Eur J Gynaecol Oncol** 1999;20(2):98–101 (26 ref.)

PAGET'S DISEASE OF BONE see **OSTEITIS DEFORMANS**

PAH see **P-AMINOHIPPURIC ACID**

PAHO see **PAN AMERICAN HEALTH ORGANIZATION**

PAI-1 see **PLASMINOGEN ACTIVATOR INHIBITOR 1**

PAI-2 see **PLASMINOGEN ACTIVATOR INHIBITOR 2**

PAIN

see related
ANALGESIA
ANALGESICS
HYPERALGESIA
PAIN INSENSITIVITY, CONGENITAL
PALLIATIVE CARE

Review article: gender-related differences in functional gastrointestinal disorders. Mayer EA, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:65–9 (44 ref.)
Targeted disruption of the murine galanin gene. Wynick D, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:22–47 (169 ref.)
Pain. A prelude. Lang JD Jr. **Crit Care Clin** 1999 Jan; 15(1):1–16 (30 ref.)
Painful diabetic neuropathy. Benbow SJ, et al. **Diabet Med** 1999 Aug;16(8):632–44 (226 ref.)
Acute scrotal pain. Burgher SW. **Emerg Med Clin North Am** 1998 Nov;16(4):781–809, vi (99 ref.)
The limping child. Lawrence LL. **Emerg Med Clin North Am** 1998 Nov;16(4):911–29, viii (31 ref.)
Empirically supported treatments in pediatric psychology: disease-related pain [see comments] Walco GA, et al. **J Pediatr Psychol** 1999 Apr;24(2):155–67; discussion 168–71 (58 ref.) Comment in: J Pediatr Psychol 1999 Apr;24(2):172–4.
Management of chronic pain. Ashburn MA, et al. **Lancet** 1999 May 29;353(9167):1865–9 (39 ref.)
Acute pain. Carr DB, et al. **Lancet** 1999 Jun 12; 353(9169):2051–8 (58 ref.)
Neuropathic pain: aetiology, symptoms, mechanisms, and management. Woolf CJ, et al. **Lancet** 1999 Jun 5; 353(9168):1959–64 (34 ref.)
Pain in the rheumatic diseases. Practical aspects of diagnosis and treatment. Rice JR, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):15–30 (46 ref.)
Neonatal analgesia and anesthesia. Introduction. Anand KJ. **Semin Perinatol** 1998 Oct;22(5):347–9 (9 ref.)
[Visceral sensitivity and digestive functional disorders. Clinical significance and therapeutic perspectives] Coffin B, et al. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B109–17 (114 ref.) **(Fre)**
[The provoking dimension of pain. From somatoform pain disorder to a phenomenological approach to illness] Célis-Gennart M. **Rev Med Suisse Romande** 1999 Apr; 119(4):273–80 (17 ref.) **(Fre)**
[Hip pain: diagnostic direction] Revel M, et al. **Rev Prat** 1998 Jun 1;48(11):1243–8 (0 ref.) **(Fre)**
[Painful erections related to sleeping] Menéndez López V, et al. **Actas Urol Esp** 1999 Jun;23(6):539–41 (7 ref.) (Eng. Abstr.) **(Spa)**
[A common symptom among athletes and persons who

exercise. Correct treatment of groin pain requires a meticulous diagnosis] Ekstrand J. **Lakartidningen** 1999 Feb 3;96(5):480–3 (20 ref.) (Eng. Abstr.) **(Swe)**

[Centrally disturbed pain modulation explains prolonged pain. New knowledge changes the view on the problematic patient] Lidbeck J. **Lakartidningen** 1999 Jun 9; 96(23):2843–8, 2850–1 (84 ref.) **(Swe)**

COMPLICATIONS

The meeting of pain and depression: comorbidity in women. Meana M. **Can J Psychiatry** 1998 Nov;43(9):893–9 (68 ref.)

Pain in children with significant neurological impairment. Oberlander TF, et al. **J Dev Behav Pediatr** 1999 Aug; 20(4):235–43 (71 ref.)

Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Fishbain DA. **Med Clin North Am** 1999 May;83(3):737–60, vii (93 ref.)

DIAGNOSIS

The measurement of paediatric pain [comment] Larsson BA. **Acta Paediatr** 1999 Feb;88(2):115–7 (32 ref.) Comment on: Acta Paediatr 1999 Feb;88(2):132–8.

Exercise-related chronic lower leg pain. Locke S. **Aust Fam Physician** 1999 Jun;28(6):569–73 (9 ref.)

Are growing pains a myth? [see comments] Manners P. **Aust Fam Physician** 1999 Feb;28(2):124–7 (4 ref.) Comment in: Aust Fam Physician 1999 May;28(5):427–8. Comment in: Aust Fam Physician 1999 May;28(5):428.

Neurophysiological evaluation of pain. Bromm B, et al. **Electroencephalogr Clin Neurophysiol** 1998 Oct; 107(4):227–53 (288 ref.)

Chronic pain: primary care treatment of the older patient. Leland JY. **Geriatrics** 1999 Jan;54(1):23–8, 33–4, 37 (26 ref.)

Vulvodynia—a dermatovenereologist's perspective. Mroczkowski TF. **Int J Dermatol** 1998 Aug;37(8):567–9 (14 ref.)

Assessing the pain of people with cognitive impairment. Cook AK, et al. **Int J Geriatr Psychiatry** 1999 Jun;14(6):421–5 (29 ref.)

Heel pain in children. Diagnosis and treatment. Kim CW, et al. **J Am Podiatr Med Assoc** 1999 Feb;89(2):67–74 (73 ref.)

Can fibromyalgia be separated from regional pain syndrome affecting the arm? [editorial] Wigley R. **J Rheumatol** 1999 Mar;26(3):515–6 (17 ref.)

[The use of neurophysiopathological technics in assessing pain syndromes in industrial medicine and rehabilitation] Buonocore M, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec; 19(4):164–71 (47 ref.) (Eng. Abstr.) **(Ita)**

[Anterior knee pain syndrome: a historical review] Witoński D. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):379–85 (63 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

A review of the use of fentanyl analgesia in the management of acute pain in adults. Peng PW, et al. **Anesthesiology** 1999 Feb;90(2):576–99 (195 ref.)

Oral corticosteroids for pain associated with herpes zoster. Ernst ME, et al. **Ann Pharmacother** 1998 Oct; 32(10):1099–103 (15 ref.)

Calcitonin in phantom limb pain. Wall GC, et al. **Ann Pharmacother** 1999 Apr;33(4):499–501 (22 ref.)

Neuraxial opioids in labour. Wilson DJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):363–76 (67 ref.)

Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Decker MW, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):917–23 (58 ref.)

Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. Mertens WC, et al. **CA Cancer J Clin** 1998 Nov–Dec;48(6):361–74, 321 (89 ref.)

Topical anesthesia. Keyes PD, et al. **Can Fam Physician** 1998 Oct;44:2152–6 (13 ref.)

Managing acute osteoporotic vertebral fractures with calcitonin. Maksymowych WP. **Can Fam Physician** 1998 Oct;44:2160–6 (27 ref.)

Mechanism of action of nonsteroidal anti-inflammatory drugs [see comments] Yaksh TL, et al. **Cancer Invest** 1998; 16(7):509–27 (154 ref.) Comment in: Cancer Invest 1998 ;16(7):538–9.

Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Gourlay GK. **Clin Pharmacokinet** 1998 Sep;35(3):173–90 (66 ref.)

Co-proxamol or paracetamol for acute pain? **Drug Ther Bull** 1998 Oct;36(10):80 (4 ref.)

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Krystal JH, et al. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):125–43 (214 ref.)

Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Ratanatharathorn V, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):1–18 (25 ref.)

Emerging molecular approaches to pain therapy. Williams M, et al. **J Med Chem** 1999 May 6;42(9):1481–500 (189 ref.)

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. Decker MW, et al. **J Physiol Paris** 1998 Jun–Aug;92(3–4):221–4 (17 ref.)

Opioids in pain management. McQuay H. **Lancet** 1999 Jun 26;353(9171):2229–32 (29 ref.)

Muscarinic-mediated analgesia. Eisenach JC. **Life Sci** 1999; 64(6–7):549–54 (29 ref.)

Opioid use in the management of chronic pain. Savage SR. **Med Clin North Am** 1999 May;83(3):761–86 (62 ref.)

Painful peripheral neuropathies. Vaillancourt PD, et al. **Med Clin North Am** 1999 May;83(3):627–42, vi (53 ref.)

Cannabinoid transmission and pain perception. Martin BR, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):447–61 (131 ref.)

Neuraxial infusion in the management of cancer pain. Ferrante FM. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):30–6 (40 ref.)

Patient and family caregiver perspectives. Ferrell BR. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):15–9 (29 ref.)

Practical issues when using neuraxial infusion. Krames ES. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):37–44 (28 ref.)

Alternatives to oral opioids for cancer pain. Mercadante S, et al. **Oncology (Huntingt)** 1999 Feb;13(2):215–20, 225; discussion 226–9 (71 ref.)

Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. Payne R. **Oncology (Huntingt)** 1998 Nov;12(11A):169–75 (45 ref.)

Management of breakthrough pain due to cancer. Simmonds MA. **Oncology (Huntingt)** 1999 Aug;13(8):1103–8; discussion 1110, 1113–4 (34 ref.)

Neuraxial infusion for pain control: when, why, and what to do after the implant. Staats PS. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):58–62 (23 ref.)

Problems of long-term spinal opioid treatment in advanced cancer patients. Mercadante S. **Pain** 1999 Jan;79(1):1–13 (91 ref.)

Pain in the very preterm baby: 'suffer little children?' McVey C. **Pediatr Rehabil** 1998 Apr–Jun;2(2):47–55 (106 ref.)

Safety issues in the pharmacologic management of chronic pain in the elderly. Shimp LA. **Pharmacotherapy** 1998 Nov–Dec;18(6):1313–22 (74 ref.)

Psychotropic adjuvant analgesics for pain in cancer and AIDS. Breitbart W. **Psychooncology** 1998 Jul–Aug; 7(4):333–45 (118 ref.)

Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Mercadante S. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):74–83 (65 ref.)

10 years of acute pain services—achievements and challenges. Rawal N. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):68–73 (16 ref.)

The use of analgesics in the management of pain in rheumatic diseases. Moreland LW, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):153–91, vii (272 ref.)

Aggressive pharmacologic treatment of pain. Pappagallo M. **Rheum Dis Clin North Am** 1999 Feb;25(1):193–213, vii (37 ref.)

Treatment of chronic pain with antiepileptic drugs: a new era. Hansen HC. **South Med J** 1999 Jul;92(7):642–9 (66 ref.)

Ions in the fire: recent ion-channel research and approaches to pain therapy. Eglen RM, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):337–42 (45 ref.)

[Treatment of different types of pain] Rouveix B, et al. **Bull Acad Natl Med** 1999;183(5):889–901; discussion 901–3 (18 ref.) (Eng. Abstr.) **(Fre)**

[Pain and cancer: update] Krakowski I. **Bull Cancer** 1999 Jan;86(1):105–13 (29 ref.) **(Fre)**

[Pharmacologic approach to chronic pain. Recent findings] Cesselin F. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B82–92 (125 ref.) **(Fre)**

[Opioids in practice] Lossignol D. **Rev Med Brux** 1998 Sep; 19(4):A314–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Pharma-clinics. The drug of the month. Aceclofenac (Biofenac)] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):62–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Update on the pharmacologic approach to pain] Brasseur L, et al. **Therapie** 1999 Jan–Feb;54(1):111–6 (50 ref.) (Eng. Abstr.) **(Fre)**

[Clinical study of antalgic drugs] Dubray C. **Therapie** 1999 Jan–Feb;54(1):135–45 (97 ref.) (Eng. Abstr.) **(Fre)**

[Enkephalin catabolism inhibitors and antalgics of the future: from preclinical research to clinical trials] Noble F, et al. **Therapie** 1999 Jan–Feb;54(1):121–33 (82 ref.) (Eng. Abstr.) **(Fre)**

[Special aspects of pain therapy in childhood] Führer M. **Internist (Berl)** 1999 Feb;40(2):183–9 (45 ref.) **(Ger)**

[Pain therapy in oncology] Heidemann E. **Internist (Berl)** 1999 Feb;40(2):168–75 (8 ref.) **(Ger)**

[12 basic rules in drug therapy of tumor pain] Weber M, et al. **Med Klin** 1999 Jan 15;94(1):51–4 (5 ref.) (Eng. Abstr.) **(Ger)**

[Cannabinoids as analgesics?] Keup W. **Med Monatsschr Pharm** 1998 Sep;21(9):275–83 (72 ref.) **(Ger)**

[Antidepressives in chronic pain. Significant analgesic therapy option] van Schayck R, et al. **Med Monatsschr Pharm** 1998 Oct;21(10):304–13 (27 ref.) **(Ger)**

[Opiates on the upswing—are there really unproblematic?] Neuenschwander H. **Schweiz Rundsch Med Prax** 1999 Apr 29;88(18):814–8 (6 ref.) (Eng. Abstr.) **(Ger)**

[Staged analgesic therapy in tumor pain] Zenz M, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1126–34 (10 ref.) (Eng. Abstr.) **(Ger)**

[Opioids in pain therapy] Jage J. **Ther Umsch** 1999 Aug; 56(8):435–40 (3 ref.) (Eng. Abstr.) **(Ger)**

[Co-analgesics in the treatment of chronic pain] Kopf A. **Ther Umsch** 1999 Aug;56(8):441–5 (5 ref.) (Eng. Abstr.) **(Ger)**

[Acute pain, analgesia and sedation in children (V): analgesia and sedation in pediatric intensive care] Valdivielso Serna A, et al. **An Esp Pediatr** 1998 Aug;49(2):193–208 (76 ref.) **(Spa)**

[Pain relief in sports injuries—emergency measures yield good results] Andrén-Sandberg A, et al. **Lakartidningen** 1999 Feb 3;96(5):476–9 (22 ref.) (Eng. Abstr.) **(Swe)**

[Pain in hernia has not only mechanical basis. Pharmacological treatment can open new possibilities] Udén A. **Lakartidningen** 1998 Dec 2;95(49):5590–1 (13 ref.) **(Swe)**

EPIDEMIOLOGY

Prevalence and treatment of pain in older adults in nursing homes and other long-term care institutions: a systematic review. Fox PL, et al. **CMAJ** 1999 Feb 9;160(3):329–33 (38 ref.)

Why do we need more information about the risk factors of the musculoskeletal pain disorders in childhood and adolescence? Zitting P, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):148–55 (39 ref.)

Prevalence of chronic benign pain disorder among adults: a review of the literature. Verhaak PF, et al. **Pain** 1998 Sep;77(3):231–9 (36 ref.)

[Migration and pain. Need for epidemiologic research] Moser J. **Rev Med Suisse Romande** 1999 Apr;119(4):265–7 (11 ref.) **(Fre)**

ETIOLOGY

Plantar fasciitis and other causes of heel pain. Barrett SJ, et al. **Am Fam Physician** 1999 Apr 15;59(8):2200–6 (19 ref.)

Vulvodynia and vulvar vestibulitis: challenges in diagnosis and management. Metts JF. **Am Fam Physician** 1999 Mar 15;59(6):1547–56, 1561–2 (29 ref.)

Evaluation of dysuria in men. Roberts RG, et al. **Am Fam Physician** 1999 Sep 1;60(3):865–72 (35 ref.)

Pain in childhood rheumatic arthritis. Kuis W, et al. **Baillieres Clin Rheumatol** 1998 May;12(2):229–44 (58 ref.)

Magnetic resonance imaging of the painful wrist. Seymour R, et al. **Br J Radiol** 1998 Dec;71(852):1323–30 (9 ref.)

Managing acute osteoporotic vertebral fractures with calcitonin. Maksymowych WP. **Can Fam Physician** 1998 Oct;44:2160–6 (27 ref.)

Diagnosing and treating plantar fasciitis: a conservative approach to plantar heel pain. Tisdel CL, et al. **Cleve Clin J Med** 1999 Apr;66(4):231–5 (11 ref.)

The painful eye: neuro-ophthalmic causes. Mehelas TJ. **Clin Geriatr Med** 1999 Feb;15(1):113–30, vii (20 ref.)

Analgesia for trauma and burns. Hedderich R, et al. **Crit Care Clin** 1999 Jan;15(1):167–84 (49 ref.)

Sensory and motor changes of the human jaw muscles during induced orthodontic pain. Michelotti A, et al. **Eur J Orthod** 1999 Aug;21(4):397–404 (37 ref.)

Intraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancer. Sakorafas GH, et al. **Eur J Surg Oncol** 1999 Aug;25(4):427–31 (25 ref.)

Why do we need more information about the risk factors of the musculoskeletal pain disorders in childhood and adolescence? Zitting P, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):148–55 (39 ref.)

Transcending the physical: spiritual aspects of pain in patients with HIV and/or cancer. Newshan G. **J Adv Nurs** 1998 Dec;28(6):1236–41 (38 ref.)

Hallucal sesamoid pain: causes and surgical treatment. Richardson EG. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):270–8 (18 ref.)

Heel pain in children. Diagnosis and treatment. Kim CW, et al. **J Am Podiatr Med Assoc** 1999 Feb;89(2):67–74 (73 ref.)

Infectious causes of heel pain. Kosinski M, et al. **J Am Podiatr Med Assoc** 1999 Jan;89(1):20–3 (33 ref.)

Physical and arthroscopic examination techniques of the patellofemoral joint. Nissen CW, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):277–85 (46 ref.)

Patellofemoral disorders: a classification system and clinical guidelines for nonoperative rehabilitation. Wilk KE, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):307–22 (139 ref.)

Postinjury neuropathic pain syndromes. Schwartzman RJ, et al. **Med Clin North Am** 1999 May;83(3):597–626 (112 ref.)

Painful peripheral neuropathies. Vaillancourt PD, et al. **Med Clin North Am** 1999 May;83(3):627–42, vi (53 ref.)

Forefoot problems in athletes. Hockenbury RT. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S448–58 (62 ref.)

Managing breast pain. Dixon JM. **Practitioner** 1999 Jun; 243(1599):484–6, 488–9, 491 (9 ref.)

Anorectal pain and irritation: anal fissure, levator syndrome, proctalgia fugax, and pruritus ani. Vincent C. **Prim Care** 1999 Mar;26(1):53–68 (92 ref.)

Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Mercadante S. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):74–83 (65 ref.)

Mechanisms of pain in fibromyalgia. Houvenagel E. **Rev Rhum Engl Ed** 1999 Feb;66(2):97–101 (36 ref.)

Pain in Parkinson's disease patients. Serratrice G, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):331–8 (79 ref.)

The use of analgesics in the management of pain in rheumatic

diseases. Moreland LW, et al.
Rheum Dis Clin North Am 1999 Feb;25(1):153–91, vii (272 ref.)

Causes of pain in children with arthritis. Schanberg LE, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):31–53, vi (72 ref.)

Pain in fibromyalgia. Winfield JB.
Rheum Dis Clin North Am 1999 Feb;25(1):55–79 (194 ref.)

Nerve entrapment syndromes as a cause of pain in the hip, groin and buttock. McCrory P, et al. **Sports Med** 1999 Apr; 27(4):261–74 (74 ref.)

Lower leg pain. Diagnosis and treatment of compartment syndromes and other pain syndromes of the leg. Touliopolous S, et al. **Sports Med** 1999 Mar;27(3):193–204 (73 ref.)

Palliation of pain in chronic pancreatitis. Use of enzymes. Mössner J. **Surg Clin North Am** 1999 Aug;79(4):861–72, xi (64 ref.)

Painful syndromes around the ankle and foot: magnetic resonance imaging evaluation. Steinbach LS.
Top Magn Reson Imaging 1998 Oct;9(5):311–26 (40 ref.)

Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Miller OF, et al. **Urology** 1998 Dec; 52(6):982–7 (23 ref.)

Other pain syndromes to be differentiated from fibromyalgia. Menninger H. **Z Rheumatol** 1998;57 Suppl 2:56–60 (9 ref.)

[Perineal neurologic pain] Amarenco G, et al.
Gastroenterol Clin Biol 1998 Jun;22(5 Suppl):B164–8 (22 ref.) **(Fre)**

[Management of pain in endoscopy: are there "gentle" alternatives to anesthesia?] Vallot T, et al.
Gastroenterol Clin Biol 1998 Jun;22(5 Suppl):B93–100 (61 ref.) **(Fre)**

[Opioids in practice] Lossignol D. **Rev Med Brux** 1998 Sep; 19(4):A314–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Malignant bone pain] Kopf A. **Anaesthesist** 1999 Aug; 48(8):549–57 (96 ref.) **(Ger)**

[Post-traumatic osteoid osteoma of the hand. A rare cause of chronic pain. Case report and review of the literature] Rotzer A, et al. **Handchir Mikrochir Plast Chir** 1998 Sep; 30(5):335–7 (15 ref.) (Eng. Abstr.) **(Ger)**

[Foot pain] Hefti F. **Orthopade** 1999 Feb;28(2):173–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Pain in the sole of the foot. Differential diagnosis and therapy] Strehle J. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):322–7 (7 ref.) (Eng. Abstr.) **(Ger)**

[Differential diagnosis of intermittent stress-related leg pain—not always an arterial problem] Canova CR, et al. **Ther Umsch** 1998 Oct;55(10):596–600 (6 ref.) (Eng. Abstr.) **(Ger)**

[Leg pain from the orthopedic viewpoint] Fellmann J, et al. **Ther Umsch** 1998 Oct;55(10):613–7 (5 ref.) (Eng. Abstr.) **(Ger)**

[Radicular and pseudo-radicular pain syndrome] Knutti O, et al. **Ther Umsch** 1998 Oct;55(10):601–12 (29 ref.) (Eng. Abstr.) **(Ger)**

[Biochemistry of pain] Ito S, et al. **Seikagaku** 1999 Jan; 71(1):17–33 (87 ref.) **(Jpn)**

[Anterior knee pain syndrome: a historical review] Witoński D. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):379–85 (63 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

The genetic mediation of individual differences in sensitivity to pain and its inhibition. Mogil JS.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7744–51 (151 ref.)

The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Uhl GR, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7752–5 (31 ref.)

HISTORY

The problem of pain in the clinicopathological method. Sullivan M. **Clin J Pain** 1998 Sep;14(3):197–201 (25 ref.)

METABOLISM

The neurobiology of pain. Besson JM. **Lancet** 1999 May 8; 353(9164):1610–5 (48 ref.)

Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Alvares D, et al. **Pain** 1999 Aug;Suppl 6:S71–85 (193 ref.)

NURSING

Sickle cell disease. Do you doubt your patient's pain? Gorman K. **Am J Nurs** 1999 Mar;99(3):38–43; quiz 44 (12 ref.)

The chronobiology, chronopharmacology, and chronotherapeutics of pain. Auvil-Novak SE.
Annu Rev Nurs Res 1999;17:133–53 (87 ref.)

Guided imagery interventions for symptom management. Eller LS. **Annu Rev Nurs Res** 1999;17:57–84 (100 ref.)

Music therapy. Snyder M, et al. **Annu Rev Nurs Res** 1999; 17:3–25 (110 ref.)

Older adults living with chronic pain: an opportunity for improvement. Ebener MK. **J Nurs Care Qual** 1999 Apr; 13(4):1–7 (22 ref.)

10 years of acute pain services—achievements and challenges. Rawal N. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):68–73 (16 ref.)

PATHOLOGY

Assaying structural changes after nerve damage, an essay on quantitative morphology. Coggeshall RE. **Pain** 1999 Aug;Suppl 6:S21–5 (23 ref.)

From electrical wiring to plastic neurons: evolving approaches to the study of pain. Jabbur SJ, et al. **Pain** 1999 Aug;Suppl 6:S87–92 (49 ref.)

Causes and consequences of sympathetic basket formation in dorsal root ganglia. Ramer MS, et al. **Pain** 1999 Aug; Suppl 6:S111–20 (77 ref.)

PHYSIOPATHOLOGY

Galanin expression in neuropathic pain: friend or foe? Ramer MS, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:390–401 (35 ref.)

Mechanisms of cardiac pain. Foreman RD.
Annu Rev Physiol 1999;61:143–67 (167 ref.)

Somesthesis. Craig JC, et al. **Annu Rev Psychol** 1999; 50:305–31 (210 ref.)

Physiology of pain in labour. Rowlands S, et al.
Baillieres Clin Obstet Gynaecol 1998 Sep;12(3):347–62 (86 ref.)

Transmitters involved in antinociception in the spinal cord. Fürst S. **Brain Res Bull** 1999 Jan 15;48(2):129–41 (97 ref.)

Pain management and pulmonary dysfunction. Desai PM. **Crit Care Clin** 1999 Jan;15(1):151–66, vii (48 ref.)

Pain. Basbaum AI, et al. **Curr Biol** 1999 Jun 17;9(12):R429–31 (5 ref.)

Painful neuropathies. Koltzenburg M. **Curr Opin Neurol** 1998 Oct;11(5):515–21 (103 ref.)

Effect of knee pain on joint loading in patients with osteoarthritis. Hurwitz DE, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):422–6 (40 ref.)

Neurogastroenterology—information processing from the viscera to the brain in humans. Enck P, et al.
DTW Dtsch Tierarztl Wochenschr 1998 Dec;105(12):468–71 (28 ref.)

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Whitehead WE, et al. **Gastroenterology** 1998 Nov;115(5):1263–71 (83 ref.)

Importance of sleep in the management of pediatric pain. Lewin DS, et al. **J Dev Behav Pediatr** 1999 Aug; 20(4):244–52 (75 ref.)

Phantom limb pain: a review of the literature on attributes and potential mechanisms. Hill A.
J Pain Symptom Manage 1999 Feb;17(2):125–42 (124 ref.)

Practice guidelines for the assessment of children with sickle cell pain. Beyer JE, et al. **J Soc Pediatr Nurs** 1999 Apr–Jun; 4(2):61–73 (49 ref.)

Recent advances in neuropharmacology of cutaneous nociceptors. Nakamura A, et al. **Jpn J Pharmacol** 1999 Apr; 79(4):427–31 (29 ref.)

In vivo molecular signal transduction of peripheral mechanisms of pain. Ueda H. **Jpn J Pharmacol** 1999 Mar; 79(3):263–8 (27 ref.)

The neurobiology of pain. Besson JM. **Lancet** 1999 May 8; 353(9164):1610–5 (48 ref.)

Visceral pain. Cervero F, et al. **Lancet** 1999 Jun 19; 353(9170):2145–8 (32 ref.)

Suffering: the contributions of persistent pain. Chapman CR, et al. **Lancet** 1999 Jun 26;353(9171):2233–7 (39 ref.)

Pain: an overview. Loeser JD, et al. **Lancet** 1999 May 8; 353(9164):1607–9 (13 ref.)

Assessment of patients' reporting of pain: an integrated perspective. Turk DC, et al. **Lancet** 1999 May 22; 353(9166):1784–8 (32 ref.)

Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Bennett RM. **Mayo Clin Proc** 1999 Apr;74(4):385–98 (180 ref.)

Postinjury neuropathic pain syndromes. Schwartzman RJ, et al. **Med Clin North Am** 1999 May;83(3):597–626 (112 ref.)

Central mechanisms in pain. Urban MO, et al.
Med Clin North Am 1999 May;83(3):585–96 (30 ref.)

Neurotrophins, nociceptors, and pain. Mendell LM, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):252–61 (99 ref.)

Animal models for pain research. Walker K, et al.
Mol Med Today 1999 Jul;5(7):319–21 (10 ref.)

Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Waxman SG, et al.
Muscle Nerve 1999 Sep;22(9):1177–87 (62 ref.)

Cannabinoid transmission and pain perception. Martin BR, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):447–61 (131 ref.)

Cytokine-mediated or direct effects of thymulin on the nervous system as assessed by pain-related behavior. Safieh-Garabedian B, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):39–44 (34 ref.)

Correlation between autotomy-behavior and current theories of neuropathic pain. Kauppila T.
Neurosci Biobehav Rev 1998;23(1):111–29 (304 ref.)

Primitivism and plasticity of pain—implication of polymodal receptors. Kumazawa T. **Neurosci Res** 1998 Sep;32(1):9–31 (218 ref.)

Endogenous mechanisms of sensory modulation. Dubner R, et al. **Pain** 1999 Aug;Suppl 6:S45–53 (56 ref.)

The changing sensitivity in the life of the nociceptor. Koltzenburg M. **Pain** 1999 Aug;Suppl 6:S93–102 (132 ref.)

From the gate to the neuromatrix. Melzack R. **Pain** 1999 Aug;Suppl 6:S121–6 (13 ref.)

Transgenic studies of pain. Mogil JS, et al. **Pain** 1998 Aug; 77(2):107–28 (216 ref.)

Topographical features of cutaneous tactile hypoesthetic and hyperesthetic abnormalities in chronic pain. Moriwaki K, et al. **Pain** 1999 May;81(1–2):1–6 (43 ref.)

Second messengers, the substantia gelatinosa and injury-induced persistent pain. Petersen-Zeitz KR, et al. **Pain** 1999 Aug;Suppl 6:S5–12 (87 ref.)

The primary afferent nociceptor as pattern generator. Reichling DB, et al. **Pain** 1999 Aug;Suppl 6:S103–9 (99 ref.)

The cortical representation of pain. Treede RD, et al.
Pain 1999 Feb;79(2–3):105–11 (58 ref.)

The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Waxman SG.
Pain 1999 Aug;Suppl 6:S133–40 (59 ref.)

Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Woolf CJ, et al. **Pain** 1999 Aug;Suppl 6:S141–7 (37 ref.)

Regulation of spinal nociceptive processing: where we went when we wandered onto the path marked by the gate. Yaksh TL. **Pain** 1999 Aug;Suppl 6:S149–52 (26 ref.)

Pain and functional imaging. Ingvar M.
Philos Trans R Soc Lond B Biol Sci 1999 Jul 29; 354(1387):1347–58 (140 ref.)

Distinct neurochemical features of acute and persistent pain. Basbaum AI. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7739–43 (47 ref.)

Pain perception: is there a role for primary somatosensory cortex? Bushnell MC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7705–9 (51 ref.)

Forebrain mechanisms of nociception and pain: analysis through imaging. Casey KL.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7668–74 (88 ref.)

Ion channels gated by heat. Cesare P, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7658–63 (32 ref.)

The neurobiology of pain. Dubner R, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7627–30 (25 ref.)

The postnatal development of spinal sensory processing. Fitzgerald M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7719–22 (49 ref.)

Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Gold MS. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7645–9 (69 ref.)

The genetic mediation of individual differences in sensitivity to pain and its inhibition. Mogil JS.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7744–51 (151 ref.)

Causalgia, pathological pain, and adrenergic receptors. Perl ER. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7664–7 (39 ref.)

A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Porreca F, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7640–4 (41 ref.)

Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Thompson SW, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7714–8 (28 ref.)

Implications of immune-to-brain communication for sickness and pain. Watkins LR, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7710–3 (34 ref.)

Sodium channels and pain. Waxman SG, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7635–9 (53 ref.)

A visceral pain pathway in the dorsal column of the spinal cord. Willis WD, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7675–9 (13 ref.)

Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7723–30 (83 ref.)

The spinal biology in humans and animals of pain states generated by persistent small afferent input. Yaksh TL, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7680–6 (80 ref.)

Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Yu XM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7697–704 (118 ref.)

The induction of pain: an integrative review. Millan MJ.
Prog Neurobiol 1999 Jan;57(1):1–164 (1895 ref.)

Nociceptin/orphanin FQ: role in nociceptive information processing. Yamamoto T, et al. **Prog Neurobiol** 1999 Apr; 57(5):527–35 (89 ref.)

Spinal mechanisms of acute and persistent pain. Basbaum AI.
Reg Anesth Pain Med 1999 Jan–Feb;24(1):59–67 (46 ref.)

Central modulation of pain perception. Crofford LJ, et al.
Rheum Dis Clin North Am 1999 Feb;25(1):1–13 (42 ref.)

The contribution of functional imaging techniques to our understanding of rheumatic pain. Jones AK.

Rheum Dis Clin North Am 1999 Feb;25(1):123–52 (123 ref.)
Pain in fibromyalgia. Winfield JB.
Rheum Dis Clin North Am 1999 Feb;25(1):55–79 (194 ref.)
Central pain following spinal and supraspinal lesions. Bowsher D. **Spinal Cord** 1999 Apr;37(4):235–8 (34 ref.)
Acute pain mechanisms. Sorkin LS, et al.
Surg Clin North Am 1999 Apr;79(2):213–29 (103 ref.)
VIP and PACAP: very important in pain? Dickinson T, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):324–9 (77 ref.)
Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Yaksh TL. **Trends Pharmacol Sci** 1999 Aug;20(8):329–37 (98 ref.)
Brain electrical correlates of pain processing. Miltner WH, et al. **Z Rheumatol** 1998;57 Suppl 2:14–8 (45 ref.)
[Physiology and pathophysiology of pain] Schäfer M.
Ther Umsch 1999 Aug;56(8):426–30 (6 ref.) (Eng. Abstr.) **(Ger)**
[Pain: recent progress and prospects] Blengini C.
Recenti Prog Med 1999 Jun;90(6):307–14 (49 ref.) **(Ita)**
[Changes in excitability of the spinal cord and dorsal column nucleus and gene expression in neuropathic pain models] Noguchi K. **Masui** 1998 Dec;47 Suppl:S218–23 (7 ref.) **(Jpn)**
[Pain control mechanism involving opioid receptors] Sato M. **Masui** 1998 Dec;47 Suppl:S211–7 (10 ref.) **(Jpn)**
[Neuropathic pain--variability in pain maintaining mechanism] Yamamoto T, et al. **Masui** 1998 Dec;47 Suppl:S224–8 (17 ref.) **(Jpn)**
[Molecular mechanism of pain and genetic pharmacology] Ito S. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1349–59 (39 ref.) **(Jpn)**
[New information concerning pain caused by herniated disk and sciatica. Exposure to disk tissue sensitizes the nerve roots] Olmarker K, et al. **Lakartidningen** 1998 Dec 2; 95(49):5618–22 (46 ref.) (Eng. Abstr.) **(Swe)**

PREVENTION & CONTROL

Strategies for reducing the pain and discomfort of nasogastric intubation [editorial; comment] Maglinte DD, et al.
Acad Emerg Med 1999 Mar;6(3):166–9 (14 ref.) Comment on: Acad Emerg Med 1999 Mar;6(3):184–90.
The substance-abusing parturient: implications for analgesia and anaesthesia management. Birnbach DJ, et al.
Baillieres Clin Obstet Gynaecol 1998 Sep;12(3):443–60 (120 ref.)
The long-term effects of analgesia in labour. Durbridge J, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):485–98 (55 ref.)
The effects of pain and its management on mother and fetus. May AE, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):423–41 (64 ref.)
Promising non-narcotic analgesic techniques for labour. Mercier FJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):397–407 (58 ref.)
Traditional analgesic agents: are parenteral narcotics passé and do inhalational agents still have a place in labour? Olofsson C, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep; 12(3):409–21 (72 ref.)
New epidural techniques for labour analgesia: patient-controlled epidural analgesia and combined spinal-epidural analgesia. Paech M.
Baillieres Clin Obstet Gynaecol 1998 Sep;12(3):377–95 (112 ref.)
Maternal satisfaction with labour analgesia. Ross A.
Baillieres Clin Obstet Gynaecol 1998 Sep;12(3):499–512 (88 ref.)
ABC of labour care. Relief of pain. Findley I, et al.
BMJ 1999 Apr 3;318(7188):927–30 (0 ref.)
Recent advances: control of chronic pain. Nurmikko TJ, et al. **BMJ** 1998 Nov 21;317(7170):1438–41 (40 ref.)
Terminal sedation as palliative care: revalidating a right to a good death. Smith GP 2nd. **Camb Q Healthc Ethics** 1998 Fall;7(4):382–7 (37 ref.)
Topical non-steroidal anti-inflammatory drugs are effective in acute and chronic pain conditions. Bijlsma JW.
Clin Exp Rheumatol 1999 Jan-Feb;17(1):40 (0 ref.)
Regional anesthesia techniques for pain control in the intensive care unit. Burton AW, et al. **Crit Care Clin** 1999 Jan;15(1):77–88, vi (28 ref.)
Pain management and pulmonary dysfunction. Desai PM. **Crit Care Clin** 1999 Jan;15(1):151–66, vii (48 ref.)
Analgesia for trauma and burns. Hedderich R, et al.
Crit Care Clin 1999 Jan;15(1):167–84 (49 ref.)
Intravenous analgesia. McArdle P. **Crit Care Clin** 1999 Jan; 15(1):89–104 (49 ref.)
Pain management in the pediatric intensive care unit. Macfadyen AJ, et al. **Crit Care Clin** 1999 Jan;15(1):185–200, viii (67 ref.)
Intrathecal and epidural analgesia. Mandabach MG.
Crit Care Clin 1999 Jan;15(1):105–18, vii (39 ref.)
Pharmacokinetic considerations. Volles DF, et al.
Crit Care Clin 1999 Jan;15(1):55–75 (80 ref.)
Empirically supported treatments in pediatric psychology: procedure-related pain [see comments] Powers SW.
J Pediatr Psychol 1999 Apr;24(2):131–45 (32 ref.)
Comment in: J Pediatr Psychol 1999 Apr;24(2):147–9.
Comment in: J Pediatr Psychol 1999 Apr;24(2):150–2.
Comment in: J Pediatr Psychol 1999 Apr;24(2):153–4.
Women's shoe wear: an orthopaedist's advice. Frey C, et al. **J Womens Health** 1999 Jan-Feb;8(1):45–9 (14 ref.)
Primary care and pain medicine. A community solution to the public health problem of chronic pain. Gallagher RM.
Med Clin North Am 1999 May;83(3):555–83, v (91 ref.)
Roadblocks to effective pain treatment. Stieg RL, et al.
Med Clin North Am 1999 May;83(3):809–21, viii (48 ref.)
Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Jenkins CA, et al. **Palliat Med** 1999 May; 13(3):183–96 (84 ref.)
The role of morphine glucuronides in cancer pain. Mercadante S. **Palliat Med** 1999 Mar;13(2):95–104 (77 ref.)
Use of topical lidocaine in pediatric laceration repair: a review of topical anesthetics. Stewart GM, et al.
Pediatr Emerg Care 1998 Dec;14(6):419–23 (39 ref.)
1998 Labat Lecture: the role of the neurolytic celiac plexus block in pancreatic cancer pain management: do we have the answers? Ischia S, et al. **Reg Anesth Pain Med** 1998 Nov-Dec;23(6):611–4 (52 ref.)
Environmental and behavioral strategies to prevent and manage neonatal pain. Franck LS, et al.
Semin Perinatol 1998 Oct;22(5):434–43 (85 ref.)
Palliation of pain in chronic pancreatitis. Use of enzymes. Mössner J. **Surg Clin North Am** 1999 Aug;79(4):861–72, xi (64 ref.)
[A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment] Jager PL, et al.
Ned Tijdschr Geneeskd 1999 May 8;143(19):969–73 (26 ref.) (Eng. Abstr.) **(Dut)**
[Management of pain in endoscopy: are there "gentle" alternatives to anesthesia?] Vallot T, et al.
Gastroenterol Clin Biol 1998 Jun;22(5 Suppl):B93–100 (61 ref.) **(Fre)**
[Pharma clinics. How I treat...or preventing pain with "patches"] Piérard GE. **Rev Med Liege** 1998 Oct; 53(10):586–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[Newborn infants do feel pain! Technique and environment in connection with specimen collection can be improved] Finnström O, et al. **Lakartidningen** 1998 Dec 9; 95(50):5718–20 (20 ref.) **(Swe)**

PSYCHOLOGY

Chronic pain and depression. Harris NL.
Aust Fam Physician 1999 Jan;28(1):36–9 (34 ref.)
The meeting of pain and depression: comorbidity in women. Meana M. **Can J Psychiatry** 1998 Nov;43(9):893–9 (68 ref.)
Beyond pain: the role of fear and avoidance in chronicity. Asmundson GJ, et al. **Clin Psychol Rev** 1999 Jan; 19(1):97–119 (100 ref.)
Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Whitehead WE, et al. **Gastroenterology** 1998 Nov;115(5):1263–71 (83 ref.)
An analysis of the concept of pain. Montes-Sandoval L.
J Adv Nurs 1999 Apr;29(4):935–41 (23 ref.)
Transcending the physical: spiritual aspects of pain in patients with HIV and/or cancer. Newshan G. **J Adv Nurs** 1998 Dec;28(6):1236–41 (38 ref.)
Children's memory for pain. Ornstein PA, et al.
J Dev Behav Pediatr 1999 Aug;20(4):262–77 (100 ref.)
Long-term effects of pain in infants. Porter FL, et al.
J Dev Behav Pediatr 1999 Aug;20(4):253–61 (133 ref.)
Practice guidelines for the assessment of children with sickle cell pain. Beyer JE, et al. **J Soc Pediatr Nurs** 1999 Apr-Jun; 4(2):61–73 (49 ref.)
Suffering: the contributions of persistent pain. Chapman CR, et al. **Lancet** 1999 Jun 26;353(9171):2233–7 (39 ref.)
Assessment of patients' reporting of pain: an integrated perspective. Turk DC, et al. **Lancet** 1999 May 22; 353(9166):1784–8 (32 ref.)
Pain: an unpleasant topic. Fields HL. **Pain** 1999 Aug;Suppl 6:S61–9 (48 ref.)
Physical therapists' perception of patients' pain and its effect on management. Askew R, et al. **Physiother Res Int** 1998; 3(1):37–57 (28 ref.)
Pain demands attention: a cognitive-affective model of the interruptive function of pain. Eccleston C, et al.
Psychol Bull 1999 May;125(3):356–66 (125 ref.)
Psychological and behavioral approaches to pain management for patients with rheumatic disease. Bradley LA, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):215–32, viii (110 ref.)
Central modulation of pain perception. Crofford LJ, et al.
Rheum Dis Clin North Am 1999 Feb;25(1):1–13 (42 ref.)
Negative affect and pain in arthritis. Huyser BA, et al.
Rheum Dis Clin North Am 1999 Feb;25(1):105–21, vi (80 ref.)
Measurement of pain. Katz J, et al. **Surg Clin North Am** 1999 Apr;79(2):231–52 (111 ref.)
[Some relations between pain and identity] Le Breton D.
Rev Med Suisse Romande 1999 Apr;119(4):259–64 (15 ref.) **(Fre)**
[Migration and pain. Need for epidemiologic research] Moser J. **Rev Med Suisse Romande** 1999 Apr;119(4):265–7 (11 ref.) **(Fre)**
[Violence our medical trauma in specialized multidisciplinary consultation] Albrecht E, et al.
Schweiz Rundsch Med Prax 1999 Feb 11;88(7):280–4 (4 ref.) (Eng. Abstr.) **(Fre)**
[Concept of interdisciplinary pain therapy] Eller U, et al.
Ther Umsch 1999 Aug;56(8):446–9 (6 ref.) (Eng. Abstr.) **(Ger)**
[Psychophysiology of pain] Kautzsch K. **Ther Umsch** 1999 Aug;56(8):431–4 (3 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

The contribution of functional imaging techniques to our understanding of rheumatic pain. Jones AK.
Rheum Dis Clin North Am 1999 Feb;25(1):123–52 (123 ref.)

RADIOTHERAPY

[Internal radiation therapy for malignant neoplasm] Yokoyama K, et al. **Gan To Kagaku Ryoho** 1999 May; 26(6):768–74 (9 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Shoulder and elbow injuries and painful syndromes. Kelly AM, et al. **Adolesc Med** 1998 Oct;9(3):569–87, vii (22 ref.)
Nonoperative treatment for patellofemoral pain. Brody LT, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):336–44 (71 ref.)
Rehabilitation of patellofemoral joint disorders: a critical review. Powers CM. **J Orthop Sports Phys Ther** 1998 Nov; 28(5):345–54 (67 ref.)
The role of physical therapy and physical modalities in pain management. Minor MA, et al.
Rheum Dis Clin North Am 1999 Feb;25(1):233–48, viii (82 ref.)
[Are so-called alternative therapeutic procedures in pain treatment the solution?] Ostendorf GM.
Versicherungsmedizin 1998 Aug 1;50(4):149–53 (27 ref.) (Eng. Abstr.) **(Ger)**
[The use of neurophysiopathological technics in assessing pain syndromes in industrial medicine and rehabilitation] Buonocore M, et al. **G Ital Med Lav Ergon** 1997 Oct-Dec; 19(4):164–71 (47 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Intraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancer. Sakorafas GH, et al. **Eur J Surg Oncol** 1999 Aug;25(4):427–31 (25 ref.)
[Surgical treatment of chronic neurogenic pain--clinical use of the DREZ operation] Spaić M, et al.
Vojnosanit Pregl 1998 Sep-Oct;55(5):533–40 (48 ref.) **(Scc)**

THERAPY

Management of pain and spinal cord compression in patients with advanced cancer. ACP-ASIM End-of-life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Abrahm JL. **Ann Intern Med** 1999 Jul 6;131(1):37–46 (115 ref.)
The surgical significance of therapeutic touch. Ramnarine-Singh S. **AORN J** 1999 Feb;69(2):358–69 (52 ref.)
Advances in cancer pain. Foley KM. **Arch Neurol** 1999 Apr; 56(4):413–7 (11 ref.)
Are growing pains a myth? [see comments] Manners P.
Aust Fam Physician 1999 Feb;28(2):124–7 (4 ref.) Comment in: Aust Fam Physician 1999 May;28(5):427–8. Comment in: Aust Fam Physician 1999 May;28(5):428.
Procedural pain management in pediatric oncology: a review of the literature. Conte PM, et al. **Cancer Invest** 1999; 17(6):448–59 (62 ref.)
Complications of sickle cell anemia in adults: guidelines for effective management. Ballas SK. **Cleve Clin J Med** 1999 Jan;66(1):48–58 (37 ref.)
The problem of pain in the clinicopathological method. Sullivan M. **Clin J Pain** 1998 Sep;14(3):197–201 (25 ref.)
Clinical management of vulvodynia. Davis GD, et al.
Clin Obstet Gynecol 1999 Jun;42(2):221–33 (20 ref.)
Prevalence and treatment of pain in older adults in nursing homes and other long-term care institutions: a systematic review. Fox PL, et al. **CMAJ** 1999 Feb 9;160(3):329–33 (38 ref.)
Pain management and weaning from narcotics and sedatives. Ganea GR, et al. **Curr Opin Pediatr** 1999 Jun;11(3):207–12 (29 ref.)
Sensory deprivation and chronic pain: a review of the literature. Schofield P, et al. **Disabil Rehabil** 1998 Oct; 20(10):357–66 (75 ref.)
Palliative care and AIDS: 1--pain. Meyer M.
Int J STD AIDS 1999 Feb;10(2):80–6; quiz 87–8 (42 ref.)
The ultimate panacea--relief of pain. Dutta S, et al.
J Indian Med Assoc 1998 Oct;96(10):312–4 (12 ref.)
Cancer pain management. Chang HM.
Med Clin North Am 1999 May;83(3):711–36, vii (37 ref.)
Treatment planning in pain medicine. Integrating medical, physical, and behavioral therapies. Gallagher RM.
Med Clin North Am 1999 May;83(3):823–49, viii (71 ref.)
Primary care and pain medicine. A community solution to the public health problem of chronic pain. Gallagher RM.
Med Clin North Am 1999 May;83(3):555–83, v (91 ref.)
Interventional pain management. Appropriate when less invasive therapies fail to provide adequate analgesia. Krames ES. **Med Clin North Am** 1999 May;83(3):787–808, vii–viii (73 ref.)
Roadblocks to effective pain treatment. Stieg RL, et al.
Med Clin North Am 1999 May;83(3):809–21, viii (48 ref.)
Management of chronic pain among elderly patients. Monti DA, et al. **Psychiatr Serv** 1998 Dec;49(12):1537–9 (13 ref.)
Pain in Parkinson's disease patients. Serratrice G, et al.
Rev Rhum Engl Ed 1999 Jun;66(6):331–8 (79 ref.)
Psychological and behavioral approaches to pain

management for patients with rheumatic disease. Bradley LA, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):215–32, viii (110 ref.)
The role of physical therapy and physical modalities in pain management. Minor MA, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):233–48, viii (82 ref.)
Organization of hospital-based acute pain management programs. Blau WS, et al. **South Med J** 1999 May; 92(5):465–71 (29 ref.)
Spinal cord stimulation in chronic pain syndromes. ten Vaarwerk IA, et al. **Spinal Cord** 1998 Oct;36(10):671–82 (80 ref.)
Pain assessment and management in the long-term care setting. Weissman DE, et al. **Theor Med Bioeth** 1999 Jan; 20(1):31–43 (53 ref.)
Supportive care, pain management, and quality of life in advanced prostate cancer. Esper P, et al. **Urol Clin North Am** 1999 May;26(2):375–89 (74 ref.)
[Are endoscopic treatments of pain during chronic pancreatitis justified] Lévy P. **Gastroenterol Clin Biol** 1999 Apr;23(4):465–8 (15 ref.) **(Fre)**
[Cold and cryotherapy. A review of the literature on general principles and practical applications] Kerschan-Schindl K, et al. **Acta Med Austriaca** 1998;25(3):73–8 (48 ref.) (Eng. Abstr.) **(Ger)**
[Chronic pain in herpes zoster] Mergenthaler HG, et al. **Internist (Berl)** 1999 Feb;40(2):162–7 (23 ref.) **(Ger)**
[Pain in chronic peripheral arterial occlusive disease. Pathogenesis and therapy] Rieger H, et al. **Internist (Berl)** 1999 Feb;40(2):133–9 (24 ref.) **(Ger)**
[Chronic pancreatitis: nutrition and pain therapy] Mössner J. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1548–57 (84 ref.) (Eng. Abstr.) **(Ger)**
[Concept of interdisciplinary pain therapy] Eller U, et al. **Ther Umsch** 1999 Aug;56(8):446–9 (6 ref.) (Eng. Abstr.) **(Ger)**
[Psychophysiology of pain] Kautzsch K. **Ther Umsch** 1999 Aug;56(8):431–4 (3 ref.) (Eng. Abstr.) **(Ger)**
[Pain therapy in orthopedics—a contribution to the discussion on reformulating the order of continuing education] Schiltenwolf M. **Z Orthop Ihre Grenzgeb** 1999 Jan–Feb; 137(1):Oa10–2 (41 ref.) **(Ger)**

VETERINARY

Analgesics and pain. Carroll GL. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):701–17, vi (66 ref.)
Newer analgesics. Nonsteroid anti-inflammatory drugs, opioids, and combinations. Taylor PM. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):719–35, vii (68 ref.)

PAIN ASSESSMENT see **PAIN MEASUREMENT**

PAIN CENTERS see **PAIN CLINICS**

PAIN CLINICS

10 years of acute pain services—achievements and challenges. Rawal N. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):68–73 (16 ref.)

PAIN DISORDER see **SOMATOFORM DISORDERS**

PAIN, FACIAL see **FACIAL PAIN**

PAIN INSENSITIVITY, CONGENITAL

PSYCHOLOGY

Consciousness and body image: lessons from phantom limbs, Capgras syndrome and pain asymbolia. Ramachandran VS. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1851–9 (38 ref.)

PAIN, INTRACTABLE

see related
PALLIATIVE CARE

Palliative care: pain and symptom management in persons with HIV/AIDS. Newshan G, et al. **Nurs Clin North Am** 1999 Mar;34(1):131–45 (62 ref.)

DRUG THERAPY

Recent developments in palliative cancer care. Bruera E, et al. **Acta Oncol** 1998;37(7–8):749–57 (73 ref.)
Acts of omission and commission in pain management: the ethics of naloxone use. Fins JJ. **J Pain Symptom Manage** 1999 Feb;17(2):120–4 (26 ref.)
Analgesics. Opioids, adjuvants, and others. Matthew MT, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):255–73, vii (56 ref.)
Controversies over spinal treatment in advanced cancer patients [see comments] Mercadante S. **Support Care Cancer** 1998 Nov;6(6):495–502 (66 ref.) Comment in: Support Care Cancer 1998 Nov;6(6):488–9.
Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)
[The therapeutic modalities of bone pain in prostate cancer] Cózar JM, et al. **Actas Urol Esp** 1999 May;23(5):464–70 (24 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Palliation of pain in chronic pancreatitis. Use of neural blocks and neurotomy. Wong GY, et al. **Surg Clin North Am** 1999 Aug;79(4):873–93 (71 ref.)
Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)

NURSING

Acute pain. Good M. **Annu Rev Nurs Res** 1999;17:107–32 (147 ref.)
Nursing management of the patient with bone metastases. Struthers C, et al. **Semin Oncol Nurs** 1998 Aug; 14(3):199–209 (62 ref.)

PHYSIOPATHOLOGY

Pathophysiological mechanisms of central neuropathic pain after spinal cord injury. Eide PK. **Spinal Cord** 1998 Sep; 36(9):601–12 (93 ref.)

PREVENTION & CONTROL

Palliation of pain in chronic pancreatitis. Use of neural blocks and neurotomy. Wong GY, et al. **Surg Clin North Am** 1999 Aug;79(4):873–93 (71 ref.)

PSYCHOLOGY

Cancer pain—a provoker of emotional, social and existential distress. Strang P. **Acta Oncol** 1998;37(7–8):641–4 (31 ref.)

REHABILITATION

Analgesics. Opioids, adjuvants, and others. Matthew MT, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):255–73, vii (56 ref.)
Antidepressants in rehabilitation. Teasell RW, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):237–53, vii (103 ref.)

SURGERY

[Pain surgery] Kivipelto L, et al. **Duodecim** 1995; 111(21):2066–70 (10 ref.) **(Fin)**

THERAPY

Cancer pain—a provoker of emotional, social and existential distress. Strang P. **Acta Oncol** 1998;37(7–8):641–4 (31 ref.)
Pain management of pancreatic cancer. Andrén-Sandberg A, et al. **Ann Oncol** 1999;10 Suppl 4:265–8 (35 ref.)
Palliation of pain and jaundice: an overview. Russell RC. **Ann Oncol** 1999;10 Suppl 4:165–9 (28 ref.)
Cancer and chronic pain. Hassed C. **Aust Fam Physician** 1999 Jan;28(1):17–21, 23–4 (18 ref.)
Breakthrough pain in cancer patients: pathophysiology and treatment. Mercadante S, et al. **Cancer Treat Rev** 1998 Dec; 24(6):425–32 (55 ref.)
Energy healing with women and children. Starn JR. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):576–84 (48 ref.)
[Cancer-related pain requires targeted treatment. Analgesics are not the only therapeutic alternative] Strang P. **Lakartidningen** 1999 Jan 27;96(4):318–21 (26 ref.) (Eng. Abstr.) **(Swe)**

PAIN MEASUREMENT

see related
PAIN THRESHOLD
SENSORY THRESHOLDS

The measurement of paediatric pain [comment] Larsson BA. **Acta Paediatr** 1999 Feb;88(2):115–7 (32 ref.) Comment on: Acta Paediatr 1999 Feb;88(2):132–8.
Assessment of patients' reporting of pain: an integrated perspective. Turk DC, et al. **Lancet** 1999 May 22; 353(9166):1784–8 (32 ref.)
Pain in the very preterm baby: 'suffer little children?' McVey C. **Pediatr Rehabil** 1998 Apr–Jun;2(2):47–55 (106 ref.)
Pain assessment and management in the long-term care setting. Weissman DE, et al. **Theor Med Bioeth** 1999 Jan; 20(1):31–43 (53 ref.)
[Special aspects of pain therapy in childhood] Führer M. **Internist (Berl)** 1999 Feb;40(2):183–9 (45 ref.) **(Ger)**

DRUG EFFECTS

Central mechanisms of pain modulation. Mason P. **Curr Opin Neurobiol** 1999 Aug;9(4):436–41 (33 ref.)

INSTRUMENTATION

Assessing the pain of people with cognitive impairment. Cook AK, et al. **Int J Geriatr Psychiatry** 1999 Jun;14(6):421–5 (29 ref.)

METHODS

Evaluation of pain in the critically ill patient. Hamill-Ruth RJ, et al. **Crit Care Clin** 1999 Jan;15(1):35–54, v–vi (58 ref.)
Practice guidelines for the assessment of children with sickle cell pain. Beyer JE, et al. **J Soc Pediatr Nurs** 1999 Apr–Jun; 4(2):61–73 (49 ref.)
Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Woolf CJ, et al. **Pain** 1999 Aug;Suppl 6:S141–7 (37 ref.)
Assessment of pain in the neonate. Abu-Saad HH, et al. **Semin Perinatol** 1998 Oct;22(5):402–16 (74 ref.)
Measurement of pain. Katz J, et al. **Surg Clin North Am** 1999 Apr;79(2):231–52 (111 ref.)
[How is postoperative pain evaluated?] Aubrun F. **Ann Fr Anesth Reanim** 1998;17(6):462–70 (14 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of postoperative pain] Benhamou D. **Ann Fr Anesth Reanim** 1998;17(6):555–72 (77 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Older adults living with chronic pain: an opportunity for improvement. Ebener MK. **J Nurs Care Qual** 1999 Apr; 13(4):1–7 (22 ref.)

PSYCHOLOGY

Psychosocial assessment of pain in patients having rheumatic diseases. Keefe FJ, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):81–103 (111 ref.)

PAIN, POSTOPERATIVE

Effect of minimally invasive thoracic surgical approaches on acute and chronic postoperative pain. Landreneau RJ, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):891–906 (70 ref.)

DIAGNOSIS

[Frequency, intensity, development and repercussions of postoperative pain as a function of the type of surgery] Beaussier M. **Ann Fr Anesth Reanim** 1998;17(6):471–93 (147 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of postoperative pain] Benhamou D. **Ann Fr Anesth Reanim** 1998;17(6):555–72 (77 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Postoperative pain management after intraoperative remifentanil. Albrecht S, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S40–5 (26 ref.)
Drug choices for intravenous and spinal analgesia. Fitzgibbon DR, et al. **Eur Surg Res** 1999;31(2):108–11 (17 ref.)
Patient-controlled analgesia: An efficient therapeutic tool in the postoperative setting. Lehmann KA. **Eur Surg Res** 1999; 31(2):112–21 (24 ref.)
Does effective postoperative pain management influence surgical morbidity? Rosenberg J, et al. **Eur Surg Res** 1999; 31(2):133–7 (13 ref.)
Pain management in dental practice: tramadol vs. codeine combinations. Moore PA. **J Am Dent Assoc** 1999 Jul; 130(7):1075–9 (29 ref.)
Pharmacological management of pain after intracranial surgery. Leith B. **J Neurosci Nurs** 1998 Aug;30(4):220–4 (27 ref.)
Injected morphine in postoperative pain: a quantitative systematic review. McQuay HJ, et al. **J Pain Symptom Manage** 1999 Mar;17(3):164–74 (48 ref.)
Post-thoracotomy analgesia and perioperative outcome. Sandler AN. **Minerva Anestesiol** 1999 May;65(5):267–74 (55 ref.)
Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Schmid RL, et al. **Pain** 1999 Aug; 82(2):111–25 (124 ref.)
[Intrathecal opioids in the treatment of postoperative pain] Nielsen IM. **Ugeskr Laeger** 1999 Jan 25;161(4):453–6 (34 ref.) **(Dan)**
[Management of postoperative pain in adults and children] **Ann Fr Anesth Reanim** 1998;17(6):445–61 (0 ref.) **(Fre)**
[Postoperative analgesia. Specificity in the elderly] Capdevila X, et al. **Ann Fr Anesth Reanim** 1998;17(6):642–8 (52 ref.) (Eng. Abstr.) **(Fre)**
[Management of postoperative pain in surgical units] Delbos A. **Ann Fr Anesth Reanim** 1998;17(6):649–62 (17 ref.) (Eng. Abstr.) **(Fre)**
[Repercussion of postoperative pain, benefits attending to treatment] Jayr C. **Ann Fr Anesth Reanim** 1998;17(6):540–54 (100 ref.) (Eng. Abstr.) **(Fre)**
[Patient-controlled analgesia. Benefits, risks, methods of monitoring] Langlade A. **Ann Fr Anesth Reanim** 1998; 17(6):585–98 (74 ref.) (Eng. Abstr.) **(Fre)**
[Conventional techniques for analgesia: opioids and non-opioids. Indications, adverse effects and monitoring] Mazoit JX. **Ann Fr Anesth Reanim** 1998;17(6):573–84 (90 ref.) (Eng. Abstr.) **(Fre)**
[Postoperative locoregional analgesia in the adult: epidural and peripheral techniques. Indications, adverse effects and monitoring] Muller L, et al. **Ann Fr Anesth Reanim** 1998; 17(6):599–612 (160 ref.) (Eng. Abstr.) **(Fre)**
[Postoperative patient management. Pain after surgical intervention] Chauvin M. **Presse Med** 1999 Jan 30; 28(4):203–11 (32 ref.) (Eng. Abstr.) **(Fre)**

PAIN, POSTOPERATIVE

[Postoperative epidural analgesia with S-ropivacaine] Wulf H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun;34(6):367–71 (24 ref.) **(Ger)**

[Preemptive analgesia or balanced perieemptive analgesia?] Amantea B, et al. **Minerva Anestesiol** 1999 Jan–Feb; 65(1–2):19–37 (112 ref.) (Eng. Abstr.) **(Ita)**

[Control of postoperative pain in pediatric patients] Borrometi F. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):65–9 (15 ref.) **(Ita)**

[Clinical experience in the use of clonidine in regional anesthesia and early postoperative period (1984–1989)] Dobrydnev IL, et al. **Anesteziol Reanimatol** 1999 May–Jun; (3):4–12 (132 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Frequency, intensity, development and repercussions of postoperative pain as a function of the type of surgery] Beaussier M. **Ann Fr Anesth Reanim** 1998;17(6):471–93 (147 ref.) (Eng. Abstr.) **(Fre)**

[The epideiology of postoperative pain] Brasseur L, et al. **Ann Fr Anesth Reanim** 1998;17(6):534–9 (41 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pharmacological management of pain after intracranial surgery. Leith B. **J Neurosci Nurs** 1998 Aug;30(4):220–4 (27 ref.)

Pain after laparoscopy. Mouton WG, et al. **Surg Endosc** 1999 May;13(5):445–8 (41 ref.)

NURSING

Acute pain. Good M. **Annu Rev Nurs Res** 1999;17:107–32 (147 ref.)

PHYSIOPATHOLOGY

[How is postoperative pain evaluated?] Aubrun F. **Ann Fr Anesth Reanim** 1998;17(6):462–70 (14 ref.) (Eng. Abstr.) **(Fre)**

[Repercussion of postoperative pain, benefits attending to treatment] Jayr C. **Ann Fr Anesth Reanim** 1998;17(6):540–54 (100 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Choices in pain management following thoracotomy. Peeters-Asdourian C, et al. **Chest** 1999 May;115(5 Suppl):122S–124S (19 ref.)

The acute pain service. Frenette L. **Crit Care Clin** 1999 Jan; 15(1):143–50 (24 ref.)

Pre-emptive analgesia: how important is it in clinical reality? Filos KS, et al. **Eur Surg Res** 1999;31(2):122–32 (46 ref.)

Use of postoperative steroids to reduce pain and inflammation. Fleischli JW, et al. **J Foot Ankle Surg** 1999 May–Jun;38(3):232–7 (31 ref.)

The effect of preemptive analgesia on subacute postoperative pain [editorial] Niv D, et al. **Minerva Anestesiol** 1999 Apr; 65(4):127–40; discussion 140–1 (122 ref.)

Experimental and clinical studies about the preemptive analgesia with local anesthetics. Possible reasons of the failure. Pasqualucci A. **Minerva Anestesiol** 1998 Oct; 64(10):445–57 (63 ref.)

Pediatric anesthesia and postoperative analgesia. Feldman D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1525–37 (16 ref.)

Analgesic agents for the postoperative period. Opioids. Austrup ML, et al. **Surg Clin North Am** 1999 Apr; 79(2):253–73 (49 ref.)

Patient-controlled analgesia. Etches RC. **Surg Clin North Am** 1999 Apr;79(2):297–312 (24 ref.)

Acute pain control and accelerated postoperative surgical recovery. Kehlet H. **Surg Clin North Am** 1999 Apr; 79(2):431–43 (36 ref.)

Pain management in cardiothoracic practice. Kruger M, et al. **Surg Clin North Am** 1999 Apr;79(2):387–400 (97 ref.)

Local and regional block in postoperative pain control. Peng PW, et al. **Surg Clin North Am** 1999 Apr;79(2):345–70 (181 ref.)

Analgesic agents for the postoperative period. Nonopioids. Power I, et al. **Surg Clin North Am** 1999 Apr;79(2):275–95 (141 ref.)

Epidural and spinal agents for postoperative analgesia. Rawal N. **Surg Clin North Am** 1999 Apr;79(2):313–44 (191 ref.)

Management of pain in intensive care settings. Stevens DS, et al. **Surg Clin North Am** 1999 Apr;79(2):371–86 (76 ref.)

Postoperative pain control in ambulatory surgery. Tong D, et al. **Surg Clin North Am** 1999 Apr;79(2):401–30 (130 ref.)

Pain after laparoscopy. Mouton WG, et al. **Surg Endosc** 1999 May;13(5):445–8 (41 ref.)

[Management of postoperative pain in adults and children. Consensus conference. Paris, France, 12 December 1997] **Ann Fr Anesth Reanim** 1998;17(6):444–662, fi117–22 (0 ref.) **(Fre)**

[Prevention of postoperative pain] Fletcher D. **Ann Fr Anesth Reanim** 1998;17(6):622–32 (68 ref.) (Eng. Abstr.) **(Fre)**

[Does a means exist for prevention of postoperative pain?] Gall O. **Ann Fr Anesth Reanim** 1998;17(6):527–33 (68 ref.) (Eng. Abstr.) **(Fre)**

[How can pain of surgery be limited?] Pélissier EP. **Ann Fr Anesth Reanim** 1998;17(6):613–21 (77 ref.) (Eng. Abstr.) **(Fre)**

[Preemptive analgesia or balanced perieemptive analgesia?] Amantea B, et al. **Minerva Anestesiol** 1999 Jan–Feb; 65(1–2):19–37 (112 ref.) (Eng. Abstr.) **(Ita)**

[Antinociceptive components of general anesthesia and postoperative analgesia] Osipova NA. **Anesteziol Reanimatol** 1998 Sep–Oct;(5):11–5 (21 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Pathogenesis and management of persistent postthoracotomy pain. d'Amours RH, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):703–22 (90 ref.)

Current concepts and practice in postoperative pain management: need for a change? Filos KS, et al. **Eur Surg Res** 1999;31(2):97–107 (42 ref.)

Con: every postthoracotomy patient does not deserve thoracic epidural analgesia. Grant RP. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):355–7 (43 ref.)

Pro: every postthoracotomy patient deserves thoracic epidural analgesia. Slinger PD. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):350–4 (43 ref.)

Post-thoracotomy spirometric lung function: the effect of analgesia. A review. Richardson J, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):445–56 (85 ref.)

[How is the management of postoperative pain in organized in surgical wards?] Bouaziz H. **Ann Fr Anesth Reanim** 1998; 17(6):494–501 (42 ref.) (Eng. Abstr.) **(Fre)**

[Benefit–risk and monitoring modalities of different techniques and methods of postoperative analgesia] Bruelle P, et al. **Ann Fr Anesth Reanim** 1998;17(6):502–26 (246 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative pain. Particularities in the child of less than 5 years, neonatology excluded] Joly A, et al. **Ann Fr Anesth Reanim** 1998;17(6):633–41 (49 ref.) (Eng. Abstr.) **(Fre)**

[Management of postoperative pain in adults and children] Bonnet F. **Presse Med** 1999 Mar 6;28(9):485–92 (0 ref.) **(Fre)**

[Postoperative pain therapy in children] Jöhr M. **Anaesthesist** 1998 Oct;47(10):889–99 (12 ref.) **(Ger)**

[Combination infusion analgesia: an alternative to PCA?] Spacek A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):363–6 (10 ref.) **(Ger)**

[Concepts for treatment of postoperative pain] Janson W, et al. **Ther Umsch** 1999 Aug;56(8):460–4 (10 ref.) (Eng. Abstr.) **(Ger)**

PAIN RECEPTORS see **NOCICEPTORS**

PAIN RELIEF UNITS see **PAIN CLINICS**

PAIN THRESHOLD

DRUG EFFECTS

[Oral premedication with clonidine as an alternative in dental practice. The effects on the pain threshold, blood pressure and salivary flow] Fanini D, et al. **Minerva Stomatol** 1998 Sep;47(9):453–64 (57 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Whitehead WE, et al. **Gastroenterology** 1998 Nov;115(5):1263–71 (83 ref.)

Brain electrical correlates of pain processing. Miltner WH, et al. **Z Rheumatol** 1998;57 Suppl 2:14–8 (45 ref.)

Pharmacology of pain processing systems. Schadrack J, et al. **Z Rheumatol** 1998;57 Suppl 2:1–4 (22 ref.)

PAINT

ADVERSE EFFECTS

Protecting children from lead poisoning and building healthy communities [editorial] Ryan D, et al. **Am J Public Health** 1999 Jun;89(6):822–4 (25 ref.)

[Chronic lead poisoning in children today. A pathology of poverty and social exclusion] Sinnaeve O, et al. **Arch Pediatr** 1999 Jul;6(7):762–7 (37 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Coatings. Anderson DG. **Anal Chem** 1999 Jun 15; 71(12):21R–32R (500 ref.)

TOXICITY

An ecological risk assessment for the use of Irgarol 1051 as an algaecide for antifoulant paints. Hall LW Jr, et al. **Crit Rev Toxicol** 1999 Jul;29(4):367–437 (103 ref.)

PAINTINGS

PSYCHOLOGY

[Integrative painting therapy. A therapeutic concept for psychiatric inpatients at the University clinic in Graz] Steinbauer M, et al. **Wien Klin Wochenschr** 1999 Jul 9; 111(13):525–32 (21 ref.) (Eng. Abstr.) **(Ger)**

PAIR BOND

Voles and vasopressin: a review of molecular, cellular, and behavioral studies of pair bonding and paternal behaviors. Wang Z, et al. **Prog Brain Res** 1998;119:483–99 (79 ref.)

Generic aspects of primate attachments: parents, offspring and mates. Mason WA, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):765–78 (97 ref.)

PALATAL EXPANSION TECHNIQUE

Structural dentofacial variations in maxilla expansion. Bertelè G, et al. **Minerva Stomatol** 1999 Apr;48(4):101–13 (36 ref.) **(Eng, Ita)**

PALATAL NEOPLASMS

PATHOLOGY

Isolated submandibular gland metastasis from oral cavity squamous cell carcinoma. Vaidya AM, et al. **Am J Otolaryngol** 1999 May–Jun;20(3):172–5 (21 ref.)

Palatal canalicular adenoma: report of 12 cases and review of the literature. Suarez P, et al. **Ann Diagn Pathol** 1998 Aug;2(4):224–8 (16 ref.)

Sialadenoma papilliferum of the palate: case report and literature review. Argyres MI, et al. **J Cutan Pathol** 1999 May;26(5):259–62 (34 ref.)

Plasmacytoid myoepithelioma of the palate. Kanazawa H, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):857–60 (24 ref.)

Extranodal follicular dendritic cell sarcoma of the palate. Araújo VC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):209–14 (30 ref.)

PALATE

[Infective stomatitis of the palate] Iriarte Ortabe JI, et al. **An Otorrinolaringol Ibero Am** 1999;26(2):137–61 (116 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Z-plasty closure of the donor defect of the radial forearm free flap. Hui KC, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):19–21 (10 ref.)

INNERVATION

Palatal myoclonus as a cause of objective tinnitus: a report of six cases and a review of the literature. Seidman MD, et al. **Ear Nose Throat J** 1999 Apr;78(4):292–4, 296–7 (27 ref.)

PATHOLOGY

Midfacial complications of prolonged cocaine snorting. Villa PD. **J Can Dent Assoc** 1999 Apr;65(4):218–23 (28 ref.)

SURGERY

Gigantiform Torus palatinus: review of the literature and report of a case. MacInnis EL, et al. **Int Dent J** 1998 Feb; 48(1):40–3 (21 ref.)

Z-plasty closure of the donor defect of the radial forearm free flap. Hui KC, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):19–21 (10 ref.)

Structural dentofacial variations in maxilla expansion. Bertelè G, et al. **Minerva Stomatol** 1999 Apr;48(4):101–13 (36 ref.) **(Eng, Ita)**

Maxillofacial surgery. Marretta SM. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1285–96, viii (29 ref.)

PALATE, HARD see **PALATE**

PALATE, SOFT

INJURIES

Intraoral blunt carotid injury in an adult: case report and review of the literature. Mikulaschek A, et al. **J Trauma** 1999 Jul;47(1):179–82 (43 ref.)

SURGERY

[Surgical therapy of sleep-related respiratory disorders] Hörmann K, et al. **HNO** 1999 Apr;47(4):226–35 (37 ref.) (Eng. Abstr.) **(Ger)**

PALATINE BONE see **PALATE**

PALATINE TONSIL see **TONSIL**

PALATOPHARYNGEAL INCOMPETENCE see **VELOPHARYNGEAL INSUFFICIENCY**

PALEONTOLOGY

Environmental hypotheses of hominin evolution. Potts R. **Am J Phys Anthropol** 1998;Suppl 27:93–136 (204 ref.)

Morphology, paleoanthropology, and Neanderthals. Tattersall I, et al. **Anat Rec** 1998 Aug;253(4):113–7 (20 ref.)

Early animal evolution: emerging views from comparative biology and geology. Knoll AH, et al. **Science** 1999 Jun 25;284(5423):2129–37 (121 ref.)

The evolution of dinosaurs. Sereno PC. **Science** 1999 Jun 25;284(5423):2137–47 (91 ref.)

HISTORY

Towards a theory of modern human origins: geography, demography, and diversity in recent human evolution. Lahr MM, et al. **Am J Phys Anthropol** 1998;Suppl 27:137–76 (98 ref.)

PALEOPATHOLOGY

Hyperostosis frontalis interna: an anthropological perspective. Hershkovitz I, et al. **Am J Phys Anthropol** 1999 Jul;109(3):303–25 (36 ref.)

PALEOSTRIATUM see **GLOBUS PALLIDUS**

PALESTINIANS see **ARABS**

PALLIATIVE CARE

Decision making on surgical palliation based on patient outcome data. Miner TJ, et al. **Am J Surg** 1999 Feb; 177(2):150–4 (32 ref.)

Discussing palliative care with patients. ACP–ASIM End–of–Life Care Consensus Panel. American College of Physicians–American Society of Internal Medicine. Lo B, et al. **Ann Intern Med** 1999 May 4;130(9):744–9 (27 ref.)

Surgical palliative treatment in bilio–pancreatic malignancy. Gouma DJ, et al. **Ann Oncol** 1999;10 Suppl 4:269–72 (26 ref.)

Palliation of pain and jaundice: an overview. Russell RC. **Ann Oncol** 1999;10 Suppl 4:165–9 (28 ref.)

AIDS hospices and orphanages. Martin T. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S21–5 (25 ref.)

An international work exchange: better than a midlife crisis. Bridge DT, et al. **BMJ** 1998 Dec 19–26;317(7174):1709–10 (6 ref.)

Is balloon dilation a reasonable option for the palliation of Fallot's tetralogy? [editorial; comment] Arnold R. **Cardiol Young** 1999 Jan;9(1):4–5 (15 ref.) Comment on: Cardiol Young 1999 Jan;9(1):24–36.

Incorporating palliative care into critical care education: principles, challenges, and opportunities [see comments] Danis M, et al. **Crit Care Med** 1999 Sep;27(9):2005–13 (59 ref.) Comment in: Crit Care Med 1999 Sep;27(9):2068–9.

Pelvic malignancy in female nonagenarians. Ampil FL, et al. **Eur J Gynaecol Oncol** 1999;20(2):102–4 (17 ref.)

Breast metastasis from multiple myeloma: report of a case and review of the literature. Ampil FL. **Eur J Gynaecol Oncol** 1998;19(6):534–5 (13 ref.)

Intraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancer. Sakorafas GH, et al. **Eur J Surg Oncol** 1999 Aug;25(4):427–31 (25 ref.)

Surgical palliation of carcinoma of the gallbladder. Baxter I, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):1572–7 (30 ref.)

Introduction to palliative care. Douglass AB. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):117–9 (0 ref.)

Palliative care and AIDS: 2––Gastrointestinal symptoms. Meyer M. **Int J STD AIDS** 1999 Aug;10(8):495–505; quiz 506–7 (42 ref.)

Palliative care and AIDS: 1––pain. Meyer M. **Int J STD AIDS** 1999 Feb;10(2):80–6; quiz 87–8 (42 ref.)

Truth telling and palliative medicine. Kashiwagi T. **Intern Med** 1999 Feb;38(2):190–2 (4 ref.)

Gemcitabine for palliative treatment in metastatic breast cancer. Lüftner D, et al. **J Cancer Res Clin Oncol** 1998; 124(10):527–31 (14 ref.)

The ultimate panacea––relief of pain. Dutta S, et al. **J Indian Med Assoc** 1998 Oct;96(10):312–4 (12 ref.)

Home care for children with life–threatening illness. Liben S, et al. **J Palliat Care** 1998 Autumn;14(3):33–8 (36 ref.)

Community education in palliative medicine. Shvartzman P, et al. **J Palliat Care** 1998 Autumn;14(3):75–8 (26 ref.)

Management of chronic pain. Ashburn MA, et al. **Lancet** 1999 May 29;353(9167):1865–9 (39 ref.)

Palliative care: pain and symptom management in persons with HIV/AIDS. Newshan G, et al. **Nurs Clin North Am** 1999 Mar;34(1):131–45 (62 ref.)

The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Fulfaro F, et al. **Pain** 1998 Dec;78(3):157–69 (99 ref.)

The role of endoscopic biliary stents in palliative care. Roth LJ, et al. **Palliat Med** 1999 Jan;13(1):63–8 (24 ref.)

The impact of different models of specialist palliative care on patients' quality of life: a systematic literature review. Salisbury C, et al. **Palliat Med** 1999 Jan;13(1):3–17 (97 ref.)

Patient and carer preference for, and satisfaction with, specialist models of palliative care: a systematic literature review. Wilkinson EK, et al. **Palliat Med** 1999 May; 13(3):197–216 (62 ref.)

Pain relief and functional recovery after endoscopic interventions for chronic pancreatitis. Pap A, et al. **Scand J Gastroenterol Suppl** 1998;228:98–106 (67 ref.)

Is euthanasia compatible with palliative care? Low JA, et al. **Singapore Med J** 1999 May;40(5):365–70 (24 ref.)

Ethical and clinical issues in the use of home non–invasive mechanical ventilation for the palliation of breathlessness in motor neurone disease. Polkey MI, et al. **Thorax** 1999 Apr;54(4):367–71 (43 ref.)

Supportive care, pain management, and quality of life in advanced prostate cancer. Esper P, et al. **Urol Clin North Am** 1999 May;26(2):375–89 (74 ref.)

Local and systemic radiation for palliation of metastatic disease. Friedland J. **Urol Clin North Am** 1999 May; 26(2):391–402, x (57 ref.)

Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile? van der Schelling GP, et al. **World J Surg** 1999 Sep;23(9):950–3 (19 ref.)

[Systemic palliative chemotherapy with 5–fluorouracil and leucovorin in disseminated colorectal cancer] Wiboltt K, et al. **Ugeskr Laeger** 1999 Jun 21;161(25):3827–32 (36 ref.) (Eng. Abstr.) **(Dan)**

[A strontium–89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment] Jager PL, et al. **Ned Tijdschr Geneeskd** 1999 May 8;143(19):969–73 (26 ref.) (Eng. Abstr.) **(Dut)**

[Carcinoid tumors of the intestines: developments in the Netherlands for diagnosis and palliative treatment (published erratum appears in Ned Tijdschr Geneeskd 1999 Apr 3;143(14):768)] Taal BG, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):445–51 (24 ref.) (Eng. Abstr.) **(Dut)**

[Palliative care for cancer patients with refractory ulcerating malignant skin tumors and skin metastases] van Leeuwen BL, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):561–4 (11 ref.) (Eng. Abstr.) **(Dut)**

[Position of adjuvant and palliative chemotherapy in colonic cancer treatment] Louvet C. **Gastroenterol Clin Biol** 1998 Mar;22(3 Suppl):S255–64 (91 ref.) **(Fre)**

[The status of regional long–term chemotherapy in liver metastasis] Lorenz M, et al. **Chirurg** 1999 Feb;70(2):141–53 (74 ref.) (Eng. Abstr.) **(Ger)**

[Primary liver and bile duct tumors: approach to conservative therapy] Henne–Bruns D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:343–7 (23 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic palliation in esophageal carcinoma] Criblez DH. **Schweiz Med Wochenschr** 1999 Aug 28;129(34):1217–23 (32 ref.) (Eng. Abstr.) **(Ger)**

[Chronic pancreatitis: nutrition and pain therapy] Mössner J. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1548–57 (84 ref.) (Eng. Abstr.) **(Ger)**

[Optimizing palliative therapy in pancreatic carcinoma] Böttger T. **Zentralbl Chir** 1999;124(5):394–400 (35 ref.) (Eng. Abstr.) **(Ger)**

[Parenteral and enteral nutrition in palliative medicine] Herrmann A, et al. **Zentralbl Chir** 1999;124(7):573–84 (24 ref.) (Eng. Abstr.) **(Ger)**

[Progress in palliative medicine] Ishitani K. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:70–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Current status of cancer therapy. 5. Informing patients the true nature of their illnesses and palliative treatment] Kashiwagi T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1772–6 (14 ref.) **(Jpn)**

[Adjuvant intraperitoneal chemotherapy in radical and palliative treatment of stomach neoplasms (review of foreign literature)] Chissov VI, et al. **Khirurgiia (Mosk)** 1999;(1):61–5 (57 ref.) **(Rus)**

[The indications for laparoscopic surgery in the palliative treatment of digestive cancer] Targarona EM, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):200–5 (72 ref.) **(Spa)**

[Spiritual needs of severely ill patients are neglected in health care] Einhorn S. **Lakartidningen** 1999 May 12;96(19):2362–6 (20 ref.) (Eng. Abstr.) **(Swe)**

[Midazolam (Dormicum) in terminal anxiety and agitation. The last choice alternative in palliative care] Jakobsson M, et al. **Lakartidningen** 1999 Apr 28;96(17):2079–81 (9 ref.) (Eng. Abstr.) **(Swe)**

[Palliative medicine. A new research field with specific demands] Strang P. **Lakartidningen** 1999 Jan 6;96(1–2):26–9 (15 ref.) (Eng. Abstr.) **(Swe)**

[Cancer–related pain requires targeted treatment. Analgesics are not the only therapeutic alternative] Strang P. **Lakartidningen** 1999 Jan 27;96(4):318–21 (26 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Patnaik A, et al. **Anticancer Drugs** 1998 Nov;9(10):869–78 (47 ref.)

The interaction between family physicians and palliative care consultants in the delivery of palliative care: clinical and educational issues. Brenneis C, et al. **J Palliat Care** 1998 Autumn;14(3):58–61 (21 ref.)

METHODS

Systemic bone–seeking radionuclides for palliation of painful osseous metastases: current concepts. Mertens WC, et al. **CA Cancer J Clin** 1998 Nov–Dec;48(6):361–74, 321 (89 ref.)

Health service studies in the terminally ill cancer patient. Smith TJ. **Cancer Treat Res** 1998;97:81–97 (77 ref.)

Prostate cancer: 9. Treatment of advanced disease. Gleave ME, et al. **CMAJ** 1999 Jan 26;160(2):225–32 (33 ref.)

Palliative management of dyspnea in advanced cancer. LeGrand SB, et al. **Curr Opin Oncol** 1999 Jul;11(4):250–4 (35 ref.)

Combined–modality therapy in the nonsurgical management of unresectable stage III non–small cell lung cancer. Hensing TA, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):194–200 (35 ref.)

Guidelines of the French Society of Digestive Endoscopy (SFED): esophageal prosthesis. Greff M. **Endoscopy** 1998 Oct;30(8):737–9 (11 ref.)

Surgical aspects and techniques of lung volume reduction surgery for severe emphysema. Klepetko W. **Eur Respir J** 1999 Apr;13(4):919–25 (42 ref.)

Radiological management of oesophageal strictures. Cowling MG, et al. **Hosp Med** 1998 Sep;59(9):693–7 (17 ref.)

Acts of omission and commission in pain management: the ethics of naloxone use. Fins JJ. **J Pain Symptom Manage** 1999 Feb;17(2):120–4 (26 ref.)

A guide to enternal drug administration in palliative care. Gilbar PJ. **J Pain Symptom Manage** 1999 Mar; 17(3):197–207 (57 ref.)

Recent advances in the surgical management of the single ventricle pediatric patient. Tweddell JS, et al. **Pediatr Clin North Am** 1999 Apr;46(2):465–80, xii (52 ref.)

Laparoscopic biliary bypass for inoperable pancreatic cancer. Scott–Conner CE. **Semin Laparosc Surg** 1998 Sep; 5(3):185–8 (19 ref.)

Laparoscopic biliary and enteric bypass. Chekan EG, et al. **Semin Surg Oncol** 1999 Jun;16(4):313–20 (21 ref.)

Surgical palliation of dyskinesiac in Parkinson's disease. Brophy BP. **Stereotact Funct Neurosurg** 1998; 70(2–4):107–13 (31 ref.)

[Palliative treatment of bone metastases with bone–seeking radionuclides (see comments)] De Klerk JM, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2618–22 (21 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 23;143(4):224. **(Dut)**

[Hyperthermia in combination with chemotherapy in gynecological cancers (comment)] Rietbroek RC, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):85–8 (24 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):76–80. **(Dut)**

[Re–irradiation with hyperthermia in patients with recurrent breast cancer] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):80–4 (23 ref.) (Eng. Abstr.) **(Dut)**

[Self–expanding metallic stents in the palliative treatment of colorectal neoplastic stenoses. Report of two cases] el Khaddari S, et al. **Gastroenterol Clin Biol** 1999 May; 23(5):569–72 (13 ref.) (Eng. Abstr.) **(Fre)**

[The practitioner and reduction of risks] Leckie M. **Rev Med Suisse Romande** 1998 Sep;118(9):739–42 (12 ref.) **(Fre)**

[Treatment of advanced prostate cancer] Leisinger HJ, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):507–11 (9 ref.) **(Fre)**

[Adjuvant chemotherapy in early soft tissue sarcoma and palliative chemotherapy in advanced soft tissue sarcoma in adults] Sauer H. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1066–71 (72 ref.) (Eng. Abstr.) **(Ger)**

[Surgical options in the palliative treatment of pancreatic cancer] Delrio P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S43–6 (20 ref.) (Eng. Abstr.) **(Ita)**

[Possibilities of palliation in pancreatic cancer] Di Costanzo F, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S47–53 (49 ref.) (Eng. Abstr.) **(Ita)**

[Role of endoscopy in the palliative therapy of pancreatic cancer] Spinelli P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S60–3 (26 ref.) (Eng. Abstr.) **(Ita)**

ORGANIZATION & ADMINISTRATION

Palliative care in managed Medicare: reasons for hope––and for concern. Rousseau P. **Geriatrics** 1998 Nov;53(11):59–60, 63–5; quiz 66 (20 ref.)

Incorporating education on palliative care into the long–term care setting. National Consensus Conference on Medical Education for Care Near the End of Life. Steel K, et al. **J Am Geriatr Soc** 1999 Jul;47(7):904–7 (15 ref.)

Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Hearn J, et al. **Palliat Med** 1998 Sep;12(5):317–32 (61 ref.)

Palliative care in the University Hospital Lausanne: from consultations to an integrated regional program. Mazzocato C, et al. **Support Care Cancer** 1999 Jul;7(4):221–3 (3 ref.)

PSYCHOLOGY

Autonomy, power, and control in palliative care. Scott PA. **Camb Q Healthc Ethics** 1999 Spring;8(2):139–47 (35 ref.)

Satisfaction with palliative care: what should we be aware of? Fakhoury WK. **Int J Nurs Stud** 1998 Jun;35(3):171–6 (68 ref.)

STANDARDS

Satisfaction with palliative care: what should we be aware of? Fakhoury WK. **Int J Nurs Stud** 1998 Jun;35(3):171–6 (68 ref.)

Conceptual models and the outcomes of caring. Byock IR. **J Pain Symptom Manage** 1999 Feb;17(2):83–92 (18 ref.)

Research agenda for developing measures to examine quality of care and quality of life of patients diagnosed with life–limiting illness. Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):75–82 (29 ref.)

For every numerator, you need a denominator: a simple statement but key to measuring the quality of care of the "dying". Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):109–13 (9 ref.)

PALLIATIVE CARE

Palliative medicine: is it really specialist territory? [see comments] Fordham S, et al. **J R Soc Med** 1998 Nov; 91(11):568–72 (78 ref.) Comment in: J R Soc Med 1998 Nov;91(11):563–4. Comment in: J R Soc Med 1999 Jan;92(1):53. Comment in: J R Soc Med 1999 Jan;92(1):54. Comment in: J R Soc Med 1999 Feb;92(2):100. Comment in: J R Soc Med 1999 Feb;92(2):100–1. Comment in: J R Soc Med 1999 Feb;92(2):101. Comment in: J R Soc Med 1999 Mar;92(3):157. Comment in: J R Soc Med 1999 May;92(5):269.

TRENDS

Recent developments in palliative cancer care. Bruera E, et al. **Acta Oncol** 1998;37(7–8):749–57 (73 ref.)

Global perspectives on palliative care. Aranda S. **Cancer Nurs** 1999 Feb;22(1):33–9 (23 ref.)

Incorporating palliative care into primary care education. National Consensus Conference on Medical Education for Care Near the End of Life. Block SD, et al. **J Gen Intern Med** 1998 Nov;13(11):768–73 (28 ref.)

Monotherapy of metastatic breast cancer: a review of newer agents. Vogel CL, et al. **Oncologist** 1999;4(1):17–33 (220 ref.)

PALLIATIVE TREATMENT see **PALLIATIVE CARE**

PALM-LEAF REACTION see **CERVIX MUCUS**

PALMITATES

METABOLISM

Signalling functions of protein palmitoylation. Dunphy JT, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):245–61 (109 ref.)

PHARMACOLOGY

Coupling of palmitate to ovalbumin inhibits the induction of oral tolerance. Oliveira FM, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1421–4 (20 ref.)

PALMITIC ACIDS

PHARMACOLOGY

The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Lambert DM, et al. **Curr Med Chem** 1999 Aug;6(8):757–73 (119 ref.)

PALMOPLANTAR KERATODERMA see **KERATODERMA, PALMOPLANTAR**

PALMOPLANTARIS PUSTULOSIS see **PSORIASIS**

PALPATION

Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. Obek C, et al. **J Urol** 1999 Feb;161(2):494–8; discussion 498–9 (20 ref.)

ADVERSE EFFECTS

[Pysical examination—rebound tenderness (see comments)] Bemelman WA, et al. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):300–3 (11 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 May 8;143(19):1011–2. **(Dut)**

METHODS

Management of palpable breast lumps. Consensus guideline for family physicians [see comments] Heisey R, et al. **Can Fam Physician** 1999 Aug;45:1926–32 (26 ref.) Comment in: Can Fam Physician 1999 Aug;45 :1849–54.

PALSY, PROGRESSIVE SUPRANUCLEAR see **SUPRANUCLEAR PALSY, PROGRESSIVE**

PAMPHLETS

A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Kenny T, et al. **Fam Pract** 1998 Oct;15(5):471–9 (96 ref.)

PAN AMERICAN HEALTH ORGANIZATION

[Epidemiologic surveillance for the prevention and control urban violence] Concha-Eastman A, et al. **Rev Panam Salud Publica** 1999 Apr–May;5(4–5):322–31 (49 ref.) (Eng. Abstr.) **(Spa)**

PANAX see **GINSENG**

PANCOAST'S SYNDROME

DIAGNOSIS

[Lung apex tumor] Turwoń A, et al. **Pneumonol Alergol Pol** 1997;65(11–12):843–8 (21 ref.) **(Pol)**

PANCREAS

see related
PANCREATECTOMY
PANCREATICOJEJUNOSTOMY

Processing, storage and experimental transplantation of human fetal pancreatic cells. Hayek A, et al. **Ann Transplant** 1997;2(3):46–54 (52 ref.)

Carcinoma in jejunal pancreatic heterotopia. Makhlouf HR, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):707–11 (30 ref.)

Pancreas-preserving total duodenectomy. Tsiotos GG, et al. **Dig Surg** 1998;15(5):398–403 (10 ref.)

Heterotopic pancreatic tissue at umbilicus. Avolio L, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):373–5 (6 ref.)

Cystic fibrosis and the pancreas: recent scientific advances. Nousia-Arvanitakis S. **J Clin Gastroenterol** 1999 Sep; 29(2):138–42 (22 ref.)

Ectopic pancreas as the cause of gastric outlet obstruction in a newborn. Hayes-Jordan A, et al. **Pediatr Radiol** 1998 Nov;28(11):868–70 (10 ref.)

[Cystic dystrophy of the duodenal wall in aberrant pancreas] Wind P, et al. **Ann Chir** 1999;53(2):164–7 (17 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Pancreas divisum. Varshney S, et al. **Int J Pancreatol** 1999 Apr;25(2):135–41 (56 ref.)

Embryogenesis of pancreaticobiliary maljunction inferred from development of duodenal atresia. Ando H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):50–4 (21 ref.)

Complete agenesis of the dorsal pancreas. Fukuoka K, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):94–7 (20 ref.)

[Anatomic abnormalities in the papillary region and pancreaticobiliary pathology] Fritsch J, et al. **Gastroenterol Clin Biol** 1999 Jun–Jul;23(6–7):717–29 (117 ref.) **(Fre)**

ANATOMY & HISTOLOGY

Vascular anatomy of the pancreaticoduodenal region: A review. Murakami G, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):55–68 (53 ref.)

BLOOD SUPPLY

Porcine islet xenotransplantation utilizing a vascularized bioartificial pancreas. Maki T, et al. **Ann Transplant** 1997; 2(3):69–71 (11 ref.)

Pancreaticoduodenal artery aneurysm—a life-threatening cause of gastrointestinal hemorrhage: case report and review of the literature. de Weerth A, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1651–4 (16 ref.)

Ischemic necrotizing pancreatitis. Two case reports and review of the literature. Sakorafas GH, et al. **Int J Pancreatol** 1998 Oct;24(2):117–21 (45 ref.)

Vascular anatomy of the pancreaticoduodenal region: A review. Murakami G, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):55–68 (53 ref.)

Pancreatic arteriovenous malformation observed to bleed from the bile duct and a duodenal ulcer: report of a case. Uda O, et al. **Surg Today** 1999;29(5):462–6 (17 ref.)

[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:72–7 (14 ref.) (Eng. Abstr.) **(Ger)**

[Microcirculatory derangement and ischemia of the pancreas] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 May; 100(5):342–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Protein tyrosine dephosphorylation and the maintenance of cell adhesions in the pancreas. Schnekenburger J, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:157–65 (31 ref.)

Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Bouwens L. **Microsc Res Tech** 1998 Nov 15;43(4):332–6 (40 ref.)

DRUG EFFECTS

Agonist-stimulated pathways of calcium signaling in pancreatic acinar cells. Schulz I, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):903–8 (33 ref.)

Effects of psychotropic medications on pancreatic function: a review. Cerulli TR, et al. **Harv Rev Psychiatry** 1999 May–Jun;7(1):54–60 (76 ref.)

EMBRYOLOGY

Transcribing pancreas. Edlund H. **Diabetes** 1998 Dec; 47(12):1817–23 (50 ref.)

On the development of the islets of Langerhans. Larsson LI. **Microsc Res Tech** 1998 Nov 15;43(4):284–91 (60 ref.)

Morphogenesis and differentiation of the avian endocrine pancreas, with particular reference to experimental studies on the chick embryo. Rawdon BB. **Microsc Res Tech** 1998 Nov 15;43(4):292–305 (125 ref.)

Molecular approaches to understanding organogenesis. Crisera CA, et al. **Semin Pediatr Surg** 1999 Aug;8(3):109–18 (61 ref.)

ENZYMOLOGY

Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes. Nishimori I, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:5–16 (57 ref.)

Structural basis for the substrate selectivity of pancreatic lipases and some related proteins. Carrière F, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):417–32 (47 ref.)

Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. Layer P, et al. **J Clin Gastroenterol** 1999 Jan;28(1):3–10 (80 ref.)

One-step purification and biochemical characterization of recombinant pancreatic lipases expressed in insect cells. Bezzine S, et al. **Methods Mol Biol** 1999;109:187–202 (27 ref.)

Assays for pancreatic triglyceride lipase and colipase. Lowe ME. **Methods Mol Biol** 1999;109:59–70 (31 ref.)

[Pancreatic lipase drug delivery with glyceride-containing prodrugs] Scriba GK. **Pharm Unserer Zeit** 1999 Mar; 28(2):87–94 (23 ref.) **(Ger)**

GROWTH & DEVELOPMENT

Gene expression in pancreatic adenocarcinoma. Frazier ML. **Ann N Y Acad Sci** 1999 Jun 30;880:1–4 (23 ref.)

Development of gastrointestinal and pancreatic functions in mammalians (mainly bovine and porcine species): influence of age and ingested food. Zabielski R, et al. **Reprod Nutr Dev** 1999 Jan–Feb;39(1):5–26 (153 ref.)

INJURIES

Imaging of pancreatic trauma. Patel SV, et al. **Br J Radiol** 1998 Sep;71(849):985–90 (9 ref.)

Management of pancreatic injuries. Asensio JA, et al. **Curr Probl Surg** 1999 May;36(5):325–419 (228 ref.)

Controversies in management of penetrating injuries of the pancreas. Degiannis E, et al. **S Afr J Surg** 1999 May; 37(2):38–40 (5 ref.)

METABOLISM

Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. Thompson PA, et al. **Mutat Res** 1999 Mar 8;424(1–2):263–74 (65 ref.)

[ZAP genes: characterizing the protein structure of a new family of proliferation associated genes in the exocrine pancreas] Günther R, et al. **Med Klin** 1999 Apr 15; 94(4):233–8 (22 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Serous cystadenoma of the pancreas with invasive growth: benign or malignant? Abe H, et al. **Am J Gastroenterol** 1998 Oct;93(10):1963–6 (12 ref.)

Fast MR imaging for evaluating the pancreaticobiliary system. Takehara Y. **Eur J Radiol** 1999 Mar;29(3):211–32 (58 ref.)

The impact of magnetic resonance cholangiopancreatography on ERCP. Devière J, et al. **Gastrointest Endosc** 1999 Jul;50(1):136–40; discussion 140–3 (23 ref.)

The morphological changes of exocrine pancreas in chronic pancreatitis. Ashizawa N, et al. **Histol Histopathol** 1999 Apr;14(2):539–52 (53 ref.)

Patterns of pancreatic cell death: apoptosis versus oncosis. Andersson R, et al. **Pancreas** 1998 Oct;17(3):281–8 (86 ref.)

Sarcoidosis and the pancreas. Siavelis HA, et al. **Surgery** 1999 Apr;125(4):456–61 (32 ref.)

[MRI cholangiopancreatography] Asselah T, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):320–7 (24 ref.) **(Fre)**

[Needle aspiration cytology of the pancreas] Zamboni G, et al. **Pathologica** 1998 Jun;90(3):318–20 (12 ref.) **(Ita)**

PHYSIOLOGY

Effects of psychotropic medications on pancreatic function: a review. Cerulli TR, et al. **Harv Rev Psychiatry** 1999 May–Jun;7(1):54–60 (76 ref.)

PHYSIOPATHOLOGY

Pancreas, diabetes mellitus and pancreatic transplantation—a retrospective survey. Adeghate E, et al. **Acta Chir Hung** 1998;37(1–2):133–51 (140 ref.)

Pain relief and functional recovery after endoscopic interventions for chronic pancreatitis. Pap A, et al. **Scand J Gastroenterol Suppl** 1998;228:98–106 (67 ref.)

[Pathophysiologically advisable operations on the biliary-hepatic-pancreatic system] Daskalov M. **Khirurgiia (Sofiia)** 1998;51(4):8–11 (0 ref.) (Eng. Abstr.) **(Bul)**

RADIOGRAPHY

Using sector endoluminal ultrasound to identify the normal pancreas when axial computed tomography is falsely positive. Bender GN, et al. **Invest Radiol** 1999 Jan; 34(1):71–4 (13 ref.)

CT demonstration of fibrous stroma in chronic pancreatitis: pathologic correlation. Kusano S, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):297–300 (11 ref.)

SECRETION

A review: acute and chronic effects of ethanol and alcoholic beverages on the pancreatic exocrine secretion in vivo and in vitro. Niebergall-Roth E, et al.
Alcohol Clin Exp Res 1998 Oct;22(7):1570–83 (153 ref.)
IAPP as a regulator of glucose homeostasis and pancreatic hormone secretion (review). Karlsson E.
Int J Mol Med 1999 Jun;3(6):577–84 (142 ref.)
[Exocrine pancreas] Kanno T.
Tanpakushitsu Kakusan Koso 1998 Sep;43(12 Suppl):1794–9 (23 ref.) **(Jpn)**

SURGERY

Exocrine pancreatic function following pancreatectomy. Ghaneh P, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:308–18 (39 ref.)
Management of pancreatic injuries. Asensio JA, et al.
Curr Probl Surg 1999 May;36(5):325–419 (228 ref.)
The role of octreotide in the prevention of complications following pancreatic resection. Berberat PO, et al.
Digestion 1999;60 Suppl 2:15–22 (28 ref.)
Controversies in management of penetrating injuries of the pancreas. Degiannis E, et al. **S Afr J Surg** 1999 May; 37(2):38–40 (5 ref.)
Laparoscopic pancreatic resections. Cuschieri SA, et al.
Semin Laparosc Surg 1998 Sep;5(3):168–79 (38 ref.)
[Pathophysiologically advisable operations on the biliary-hepatic-pancreatic system] Daskalov M.
Khirurgiia (Sofiia) 1998;51(4):8–11 (0 ref.) (Eng. Abstr.) **(Bul)**
[Intraoperative echography in biliopancreatic surgery] Marrano D, et al. **Ann Ital Chir** 1999 Mar-Apr;70(2):217–22 (24 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Using sector endoluminal ultrasound to identify the normal pancreas when axial computed tomography is falsely positive. Bender GN, et al. **Invest Radiol** 1999 Jan; 34(1):71–4 (13 ref.)

PANCREAS, ARTIFICIAL

Porcine islet xenotransplantation utilizing a vascularized bioartificial pancreas. Maki T, et al. **Ann Transplant** 1997; 2(3):69–71 (11 ref.)
Actual perspectives in biohybrid artificial pancreas for the therapy of type 1, insulin-dependent diabetes mellitus. Calafiore R. **Diabetes Metab Rev** 1998 Dec;14(4):315–24 (29 ref.)

PANCREAS, ARTIFICIAL ENDOCRINE see **INSULIN INFUSION SYSTEMS**

PANCREAS, ENDOCRINE see **ISLETS OF LANGERHANS**

PANCREAS, EXOCRINE see **PANCREAS**

PANCREAS TRANSPLANTATION

Pancreas, diabetes mellitus and pancreatic transplantation--a retrospective survey. Adeghate E, et al.
Acta Chir Hung 1998;37(1-2):133–51 (140 ref.)
Post-transplantation hypoglycaemia in type 1 diabetic pancreas allograft recipients. Osei K. **Acta Diabetol** 1998 Dec;35(4):176–82 (29 ref.)
Review of immunosuppressive usage in pancreas transplantation. Stratta RJ. **Clin Transplant** 1999 Feb;13(1 Pt 1):1–12 (86 ref.)
Vascularized pancreas allotransplantation--clinical indications and outcome. White SA, et al. **Diabet Med** 1999 Jul;16(7):533–43 (117 ref.)
Advances in pancreas transplantation for the treatment of diabetes. McChesney LP. **Dis Mon** 1999 Mar;45(3):88–100 (22 ref.)
Pancreas transplantation. Shapira Z, et al.
J Pediatr Endocrinol Metab 1999 Jan-Feb;12(1):3–15 (101 ref.)
Simultaneous pancreas-kidney transplantation: an overview of indications, complications, and outcomes. Freise CE, et al. **West J Med** 1999 Jan;170(1):11–8 (36 ref.)
[Current status and future prospect of pancreas and islet transplantation] Nakagawa Y, et al. **Nippon Rinsho** 1999 Mar;57(3):726–35 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Optimal immunosuppression in pancreas transplantation. Stratta RJ. **Transplant Proc** 1999 Feb-Mar;31(1-2):619–21 (17 ref.)

STATISTICS & NUMERICAL DATA

[Pancreas transplantation] Dubernard JM, et al.
Presse Med 1999 Feb 13;28(6):287–91 (33 ref.) **(Fre)**

PANCREASE see **PANCREATIN**

PANCREATECTOMY

see related
PANCREATICOJEJUNOSTOMY

Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)
Management of the pancreatic metastases from renal cell carcinoma: report of four resected cases. Hashimoto M, et al. **Hepatogastroenterology** 1998 Jul-Aug;45(22):1150–4 (18 ref.)
[Pancreatectomy after neoadjuvant chemoradiotherapy for potentially resectable exocrine adenocarcinoma of the pancreas] Partensky C, et al. **Cancer Radiother** 1998 Dec; 2(6):771–4 (13 ref.) (Eng. Abstr.) **(Fre)**
[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:72–7 (14 ref.) (Eng. Abstr.) **(Ger)**
[Pancreatic carcinoma--conclusions and prospects] Trede M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:411–20 (14 ref.) (Eng. Abstr.) **(Ger)**
[Secondary diabetes in pancreatic carcinoma and after pancreatectomy: pathophysiology, therapeutic peculiarities and prognosis] Pfeffer F, et al. **Z Gastroenterol** 1999 Jun; Suppl 1:10–4 (36 ref.) (Eng. Abstr.) **(Ger)**
[Isolation of islands of Langerhans from human and porcine pancreas for transplantation to humans] Brandhorst D, et al. **Zentralbl Chir** 1998;123(7):814–22 (113 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy] Sunamura M, et al.
Nippon Geka Gakkai Zasshi 1999 Feb;100(2):200–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Exocrine pancreatic function following pancreatectomy. Ghaneh P, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:308–18 (39 ref.)

METHODS

Standard surgical treatment in pancreatic cancer. Wagner M, et al. **Ann Oncol** 1999;10 Suppl 4:247–51 (55 ref.)
The impact of different types of surgery in pancreatic cancer. Friess H, et al. **Eur J Surg Oncol** 1999 Apr;25(2):124–31 (111 ref.)
Current status of laparoscopic surgery of the pancreas. Underwood RA, et al. **J Hepatobiliary Pancreat Surg** 1999; 6(2):154–64 (67 ref.)
Laparoscopic pancreatic resections. Cuschieri SA, et al.
Semin Laparosc Surg 1998 Sep;5(3):168–79 (38 ref.)

PANCREATIC ALPHA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC BETA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC CHOLERA see **VIPOMA**

PANCREATIC CYST

Ciliated foregut cyst of the pancreas. Munshi IA, et al.
HPB Surg 1998;11(2):117–9 (6 ref.)

BLOOD

Lymphoepithelial cyst of the pancreas: serum markers do not help. Chan SP, et al. **HPB Surg** 1998;11(2):121–4 (26 ref.)

DIAGNOSIS

Benign retroperitoneal schwannoma mimicking a pancreatic cystic tumor: case report and literature review. Hsiao WC, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2418–20 (9 ref.)
[Analysis and treatment of pancreatic cystic diseases] Gooszen HG, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):925–30 (34 ref.) (Eng. Abstr.) **(Dut)**
[Cystic lesions of the pancreas] Rosien U, et al.
Med Klin 1999 Jul 15;94(7):377–85 (62 ref.) (Eng. Abstr.) **(Ger)**
[Cystic lesions of the pancreas] Irimoto M, et al.
Nippon Rinsho 1998 Nov;56(11):2902–6 (10 ref.) (Eng. Abstr.) **(Jpn)**
[A case of lymphoepithelial cyst of the pancreas] Miyazaki J, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May; 96(5):550–7 (15 ref.) **(Jpn)**

METABOLISM

Solitary true cyst of the pancreas in two adults: analysis of cyst fluid and review of the literature. Tanno S, et al.
Am J Gastroenterol 1998 Oct;93(10):1972–5 (19 ref.)

PARASITOLOGY

Primary pancreatic hydatid disease in a child: case report and review of the literature. Erdener A, et al.
J Pediatr Surg 1999 Mar;34(3):491–2 (10 ref.)

PATHOLOGY

Cystic neoplasms of the pancreas [editorial] Yeoh KG.
Ital J Gastroenterol Hepatol 1999 Apr;31(3):183–5 (23 ref.)
Cystic lymphoepithelial lesions of the pancreas and peripancreatic region: report of two cases. Sako S, et al.
Surg Today 1999;29(5):467–71 (26 ref.)
[A case of adenosquamous pancreatic cancer with high serum level of parathyroid related protein in which both primary and liver metastatic lesions showed remarkable cystic changes] Hyodo N, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 Feb;96(2):181–8 (13 ref.) **(Jpn)**

THERAPY

[Analysis and treatment of pancreatic cystic diseases] Gooszen HG, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):925–30 (34 ref.) (Eng. Abstr.) **(Dut)**

PANCREATIC CYSTIC FIBROSIS see **CYSTIC FIBROSIS**

PANCREATIC DISEASES

see related
HYPERINSULINISM

Pancreatic diseases (excluding cystic fibrosis). Sarles J.
Baillieres Clin Gastroenterol 1998 Dec;12(4):799–803 (14 ref.)
Pancreatic tuberculosis in non-immunocompromised patients: reports of two cases, and a literature review. Ladas SD, et al. **Eur J Gastroenterol Hepatol** 1998 Nov; 10(11):973–6 (41 ref.)
Pancreatic disease. Keogh GW, et al. **Med J Aust** 1999 Mar 1;170(5):228–34 (32 ref.)
[Persistent hyperinsulinemic hypoglycemia in the newborn and infants] de Lonlay-Debeney P, et al. **Arch Pediatr** 1998 Dec;5(12):1347–52 (30 ref.) (Eng. Abstr.) **(Fre)**
[Anatomic abnormalities in the papillary region and pancreaticobiliary pathology] Fritsch J, et al.
Gastroenterol Clin Biol 1999 Jun-Jul;23(6-7):717–29 (117 ref.) **(Fre)**
[Hepatobiliary diseases in the elderly] Weik C, et al.
Dtsch Med Wochenschr 1999 Apr 16;124(15):466–71 (50 ref.) **(Ger)**
[Pancreatic abscess] Nishimura S, et al.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):510–3 (15 ref.) **(Jpn)**

COMPLICATIONS

[Secondary diabetes] Suzuki S. **Nippon Rinsho** 1999 Mar; 57(3):637–43 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Jaundice] Iakhontova OI, et al. **Klin Med (Mosk)** 1998; 76(10):59–64 (6 ref.) **(Rus)**

DIAGNOSIS

Diagnostic endoscopic retrograde cholangiopancreatography. Shimizu S, et al. **Endoscopy** 1999 Jan;31(1):74–9 (38 ref.)
Pediatric pancreas: an overview. Enriquez G, et al.
Eur Radiol 1998;8(7):1236–44 (21 ref.)
Magnetic resonance cholangiopancreatography. Coakley FV, et al. **J Magn Reson Imaging** 1999 Feb;9(2):157–62 (25 ref.)
Tuberculous pancreatic abscess in an HIV antibody-negative patient: case report and review. Jenney AW, et al.
Scand J Infect Dis 1998;30(2):99–104 (42 ref.)
[MRI cholangiopancreatography] Asselah T, et al.
Gastroenterol Clin Biol 1998 Mar;22(3):320–7 (24 ref.) **(Fre)**
[Value of magnetic resonance cholangiopancreatography in diagnosis of biliopancreatic diseases] Albert J, et al.
Dtsch Med Wochenschr 1998 Sep 25;123(39):1149–55 (59 ref.) **(Ger)**
[Usefulness of T2-weighted images using single shot fast spin echo (SSFSE) pulse sequence for the evaluation of pancreatobiliary diseases: comparison with MRCP using SSFSE] Kadoya M, et al. **Nippon Rinsho** 1998 Nov; 56(11):2836–41 (6 ref.) (Eng. Abstr.) **(Jpn)**
[MRCP in the diagnosis of pancreaticobiliary diseases--its progression and limitation] Sai J, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 Mar;96(3):259–65 (23 ref.) **(Jpn)**
[Recent advances in diagnostic imagings for the evaluation of pancreatic diseases] Saisho H, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 Apr;96(4):369–76 (42 ref.) **(Jpn)**

DRUG THERAPY

Somatostatin and the gastrointestinal tract. Tulassay Z.
Scand J Gastroenterol Suppl 1998;228:115–21 (45 ref.)
[Certain issues in the utilization of pancreatic enzyme preparations in therapeutic practice] Rapoport SI, et al.
Klin Med (Mosk) 1998;76(11):52–4 (33 ref.) **(Rus)**

METABOLISM

Role of extracellular matrix in pancreatic diseases. Gress TM, et al. **Digestion** 1998 Nov-Dec;59(6):625–37 (71 ref.)

PATHOLOGY

Pancreatic mucin-producing adenocarcinoma associated with a pancreatic stone: report of a case. Origuchi N, et al. **Surg Today** 1998;28(12):1261–5 (22 ref.)
Pancreatic arteriovenous malformation observed to bleed from the bile duct and a duodenal ulcer: report of a case. Uda O, et al. **Surg Today** 1999;29(5):462–6 (17 ref.)

PANCREATIC DISEASES

Pancreatic necrosis: an overview. Wig JD.
Trop Gastroenterol 1999 Apr-Jun;20(2):61-3 (28 ref.)
[Cholangiopancreatography with magnetic resonance: a new approach for assessing the bile and pancreatic ducts] Rocha MS, et al. **Rev Assoc Med Bras** 1998 Jul-Sep;44(3):226-8 (13 ref.) **(Por)**

PHYSIOPATHOLOGY

[NO and pancreatic diseases] Shimosegawa T, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 Aug;96(8):923-32 (86 ref.) **(Jpn)**

RADIOGRAPHY

Using CT to reveal fat-containing abnormalities of the pancreas. Katz DS, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):393-6 (8 ref.)
Spiral CT of the abdomen: increased diagnostic potential. El Sherif A, et al. **Eur J Radiol** 1999 Jul;31(1):43-52 (46 ref.)
Pancreatic disease in children and young adults: evaluation with CT. Vaughn DD, et al. **Radiographics** 1998 Sep-Oct; 18(5):1171-87 (45 ref.)

SURGERY

The Whipple procedure in the 1990s. Yeo CJ. **Adv Surg** 1999; 32:271-303 (73 ref.)
Laparoscopic pancreatic surgery. Park A, et al.
Am J Surg 1999 Feb;177(2):158-63 (41 ref.)
Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy [see comments] Povoski SP, et al. **Ann Surg** 1999 Aug;230(2):131-42 (54 ref.) Comment in: Ann Surg 1999 Aug;230(2):143-4.
Periampullary diverticula and pancreaticobiliary disease. Lobo DN, et al. **Br J Surg** 1999 May;86(5):588-97 (87 ref.)
Intraoperative abdominal ultrasonography. Luck AJ, et al. **Br J Surg** 1999 Jan;86(1):5-16 (65 ref.)
Management of pancreatic injuries. Asensio JA, et al.
Curr Probl Surg 1999 May;36(5):325-419 (228 ref.)
Therapeutic pancreatic endoscopy. Schmalz MJ, et al.
Endoscopy 1999 Jan;31(1):88-94 (48 ref.)
Current status of laparoscopic surgery of the pancreas. Underwood RA, et al. **J Hepatobiliary Pancreat Surg** 1999; 6(2):154-64 (67 ref.)
Pancreatic inflammatory tumour: a rare entity in childhood. Shankar KR, et al. **J R Coll Surg Edinb** 1998 Dec; 43(6):422-3 (10 ref.)
Laparoscopic pancreatic resections. Cuschieri SA, et al.
Semin Laparosc Surg 1998 Sep;5(3):168-79 (38 ref.)
Sarcoidosis and the pancreas. Siavelis HA, et al. **Surgery** 1999 Apr;125(4):456-61 (32 ref.)
[Successful endoscopic accessory sphincterotomy for pancreas divisum with a pancreatic stone] Sasada Y, et al.
Nippon Shokakibyo Gakkai Zasshi 1998 Dec;95(12):1387-91 (15 ref.) **(Jpn)**

THERAPY

Pancreatic stones: treat or ignore? Howell DA.
Can J Gastroenterol 1999 Jul-Aug;13(6):461-5 (19 ref.)
Technology status evaluation: endoscopic pancreatic therapy: update May 1998. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):723-6 (44 ref.)
Interventional radiology of the liver and pancreas. Newman J. **Radiol Technol** 1999 Jul-Aug;70(6):513-30; quiz 531-3 (25 ref.)
Pancreatic necrosis: an overview. Wig JD.
Trop Gastroenterol 1999 Apr-Jun;20(2):61-3 (28 ref.)

ULTRASONOGRAPHY

Endoscopic ultrasonography. Caletti G, et al. **Endoscopy** 1999 Jan;31(1):95-102 (42 ref.)

VETERINARY

Feline exocrine pancreatic disorders. Steiner JM, et al.
Vet Clin North Am Small Anim Pract 1999 Mar; 29(2):551-75 (133 ref.)

PANCREATIC DUCTS

Proximal migration of a pancreatic duct stent: endoscopic retrieval using interventional cardiology accessories. Baron TH, et al. **Gastrointest Endosc** 1999 Jul;50(1):124-5 (9 ref.)
Primary carcinoma of the duodenal minor papilla. Yamao K, et al. **Gastrointest Endosc** 1998 Dec;48(6):634-6 (13 ref.)
Intraductal pancreatic adenoma. Neff GW, et al. **Pancreas** 1999 Aug;19(2):205-7 (16 ref.)

ABNORMALITIES

Duodenal duplication cyst communicating with an accessory pancreatic duct of Santorini. Ogura Y, et al.
Hepatogastroenterology 1998 Sep-Oct;45(23):1613-8 (20 ref.)
Double cancer of the gallbladder and common bile duct associated with an anomalous pancreaticobiliary ductal junction without a choledochal cyst: report of a case. Suzuki S, et al. **Surg Today** 1999;29(7):651-5 (21 ref.)
[Successful endoscopic accessory sphincterotomy for pancreas divisum with a pancreatic stone] Sasada Y, et al.
Nippon Shokakibyo Gakkai Zasshi 1998 Dec;95(12):1387-91 (15 ref.) **(Jpn)**

METABOLISM

Focus on "multiple functional P2X and P2Y receptors in the luminal and basolateral membranes of pancreatic duct cells" [editorial; comment] Dubyak GR. **Am J Physiol** 1999 Aug; 277(2 Pt 1):C202-4 (21 ref.) Comment on: Am J Physiol 1999 Aug;277(2 Pt 1):C205-15.
Proteins expressed by pancreatic duct cells and their relatives. Hollingsworth MA. **Ann N Y Acad Sci** 1999 Jun 30; 880:38-49 (72 ref.)

PATHOLOGY

Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Fukushima N, et al.
Adv Anat Pathol 1999 Mar;6(2):65-77 (53 ref.)
Hyperplastic and metaplastic changes in pancreatic ducts: nomenclature and preneoplastic potential. Klöppel G, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:66-73 (23 ref.)
Magnetic resonance cholangiopancreatography in the evaluation of pancreatic duct pathology. Larena JA, et al.
Br J Radiol 1998 Oct;71(850):1100-4 (6 ref.)
Chronic pancreatitis with diffuse irregular narrowing of the main pancreatic duct. Wakabayashi T, et al.
Dig Dis Sci 1998 Nov;43(11):2415-25 (19 ref.)
Serous adenoma of the pancreas with multiple microcysts communicating with the pancreatic duct. Samel S, et al.
HPB Surg 1998;11(1):43-9 (21 ref.)
Magnetic resonance cholangiopancreatography. Coakley FV, et al. **J Magn Reson Imaging** 1999 Feb;9(2):157-62 (25 ref.)
A clinicopathologic and immunohistochemical study of 22 intraductal papillary mucinous neoplasms of the pancreas, with a review of the literature. Paal E, et al.
Mod Pathol 1999 May;12(5):518-28 (79 ref.)
[Extension of an acinar cell pancreatic carcinoma with cystic changes invading the Wirsung canal] Joubert M, et al.
Gastroenterol Clin Biol 1998 Apr;22(4):465-8 (10 ref.) (Eng. Abstr.) **(Fre)**
[On the subject of pancreatic ductal carcinoma] Pantalone D, et al. **Clin Ter** 1998 Jul-Aug;149(4):281-7 (68 ref.) (Eng. Abstr.) **(Ita)**
[The utilities and outlooks of MR cholangiography (MRCP) as a non contrast and noninvasive technique] Hachiya J, et al. **Nippon Rinsho** 1998 Nov;56(11):2747-54 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Maximum intensity projection (MIP) and multiplanar reformation (MPR) for post-processing cholangiopancreatographic data set--clinical application and pitfalls] Isogai S, et al. **Nippon Rinsho** 1998 Nov; 56(11):2760-7 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Basic principles and historical consideration of MR cholangiopancreatography] Ohgi K, et al.
Nippon Rinsho 1998 Nov;56(11):2755-9 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical evaluation of MRCP] Sai J, et al.
Nippon Rinsho 1998 Nov;56(11):2768-72 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Cholangiopancreatography with magnetic resonance: a new approach for assessing the bile and pancreatic ducts] Rocha MS, et al. **Rev Assoc Med Bras** 1998 Jul-Sep;44(3):226-8 (13 ref.) **(Por)**

PHYSIOLOGY

Induction of islet cell neogenesis in the adult pancreas: the partial duct obstruction model. Rosenberg L.
Microsc Res Tech 1998 Nov 15;43(4):337-46 (75 ref.)

PHYSIOPATHOLOGY

Interventional management of peripancreatic fluid collections. Traverso LW, et al. **Surg Clin North Am** 1999 Aug;79(4):745-57, viii-ix (4 ref.)

SURGERY

[Successful endoscopic accessory sphincterotomy for pancreas divisum with a pancreatic stone] Sasada Y, et al.
Nippon Shokakibyo Gakkai Zasshi 1998 Dec;95(12):1387-91 (15 ref.) **(Jpn)**

PANCREATIC ELASTASE see **PANCREATOPEPTIDASE**

PANCREATIC EXTRACTS

THERAPEUTIC USE

Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia. Anthony H, et al. **J Paediatr Child Health** 1999 Apr; 35(2):125-9 (42 ref.)
Palliation of pain in chronic pancreatitis. Use of enzymes. Mössner J. **Surg Clin North Am** 1999 Aug;79(4):861-72, xi (64 ref.)

PANCREATIC FISTULA

COMPLICATIONS

Pancreatic pseudocyst with fistula to the common bile duct presenting with gastrointestinal bleeding. Raimondo M, et al. **Dig Dis Sci** 1998 Dec;43(12):2622-6 (16 ref.)

ETIOLOGY

Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. Tung BY, et al. **Gastrointest Endosc** 1999 May;49(5):647-51 (18 ref.)

SURGERY

Interventional management of peripancreatic fluid collections. Traverso LW, et al. **Surg Clin North Am** 1999 Aug;79(4):745-57, viii-ix (4 ref.)

PANCREATIC FUNCTION TESTS

Diagnosis of chronic pancreatitis. Is a gold standard necessary? Clain JE, et al. **Surg Clin North Am** 1999 Aug; 79(4):829-45 (72 ref.)

PANCREATIC HORMONES

BIOSYNTHESIS

Thymic expression of the pancreatic endocrine hormones. Throsby M, et al. **Neuroimmunomodulation** 1999 Jan-Apr; 6(1-2):108-14 (48 ref.)

METABOLISM

Physiology of the ECL cells [comment] Håkanson R, et al.
Yale J Biol Med 1998 May-Aug;71(3-4):163-71 (49 ref.) Comment on: Yale J Biol Med 1998 May-Aug;71(3-4):217-31.

SECRETION

IAPP as a regulator of glucose homeostasis and pancreatic hormone secretion (review). Karlsson E.
Int J Mol Med 1999 Jun;3(6):577-84 (142 ref.)

PANCREATIC INSUFFICIENCY

[Shwachman syndrome] Higuchi T, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):38-40 (10 ref.) **(Jpn)**

DIAGNOSIS

"Mixed" triglyceride breath test: methodological problems and clinical applications. Perri F, et al.
Rev Med Univ Navarra 1998 Apr-Jun;42(2):99-103 (15 ref.)

ETIOLOGY

Exocrine pancreatic function following pancreatectomy. Ghaneh P, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:308-18 (39 ref.)

PHYSIOPATHOLOGY

Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. Layer P, et al.
J Clin Gastroenterol 1999 Jan;28(1):3-10 (80 ref.)

PANCREATIC ISLETS TRANSPLANTATION see **ISLETS OF LANGERHANS TRANSPLANTATION**

PANCREATIC JUICE

see related
TRYPSINOGEN

PHYSIOLOGY

Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Kimura W, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):532-9 (83 ref.)

PANCREATIC NEOPLASMS

Orthotopic models of human pancreatic cancer. Capellá G, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:103-9 (33 ref.)
Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eskelinen MJ, et al.
Eur J Surg 1999 Apr;165(4):292-306 (174 ref.)
Pancreatic cancer: 1998 update. Yeo CJ. **J Am Coll Surg** 1998 Oct;187(4):429-42 (86 ref.)
Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. Wiedenmann B, et al. **J Mol Med** 1998 Aug;76(9):637-47 (103 ref.)
Pancreatoduodenectomy for neonatal myofibromatosis of the pancreas. Morrow SE, et al. **J Pediatr Surg** 1999 Apr; 34(4):609-11 (22 ref.)
Sclerosing mesenteritis seen clinically as pancreatic pseudotumor: two cases and a review. Sheikh RA, et al.
Pancreas 1999 Apr;18(3):316-21 (31 ref.)
Pancreatic cancer: a continuum of care. Sauter PK, et al.
Semin Oncol Nurs 1999 Feb;15(1):36-47 (27 ref.)
[On the subject of pancreatic ductal carcinoma] Pantalone D, et al. **Clin Ter** 1998 Jul-Aug;149(4):281-7 (68 ref.) (Eng. Abstr.) **(Ita)**
[Conclusions of the First Workshop of the oncology societies

AIOM, AIRO and SICO about pancreatic cancer] Tonelli F, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S64-6 (00 ref.) **(Ita)**

[A case of adult T cell leukemia (lymphoma type) involving the pancreas] Ohnishi Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):64-9 (30 ref.) **(Jpn)**

[Vipoma of pancreas] Egorov AV, et al. **Khirurgiia (Mosk)** 1999;(4):68-72 (91 ref.) **(Rus)**

CHEMISTRY

[Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors] Mure A, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):809-18 (71 ref.) **(Fre)**

CLASSIFICATION

Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Solcia E, et al. **Ann Oncol** 1999;10 Suppl 2:S9-15 (47 ref.)

COMPLICATIONS

A rare combination consisting of primary hyperaldosteronism and glucagonoma. Abe H, et al. **Am J Gastroenterol** 1999 May;94(5):1397-401 (31 ref.)

Vagaries of clinical presentation of pancreatic and biliary tract cancer. Modolell I, et al. **Ann Oncol** 1999;10 Suppl 4:82-4 (34 ref.)

Intraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancer. Sakorafas GH, et al. **Eur J Surg Oncol** 1999 Aug;25(4):427-31 (25 ref.)

Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy. Kakizaki S, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):563-6 (18 ref.)

[Role of endoscopy in the palliative therapy of pancreatic cancer] Spinelli P, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S60-3 (26 ref.) (Eng. Abstr.) **(Ita)**

[Activation of blood coagulation in patients with pancreatic cancer] Piotrowski ZM, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):87-8 (27 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. Haycox A, et al. **Aliment Pharmacol Ther** 1998 Oct;12(10):937-48 (152 ref.)

Biliopancreatic malignancy: screening the at risk patient with molecular markers. Caldas C. **Ann Oncol** 1999;10 Suppl 4:153-6 (42 ref.)

Mucin hypersecreting neoplasms. Carr-Locke DL. **Ann Oncol** 1999;10 Suppl 4:99-103 (24 ref.)

Pancreatic cancer: clinical presentation, pitfalls and early clues. DiMagno EP. **Ann Oncol** 1999;10 Suppl 4:140-2 (44 ref.)

Biliopancreatic malignancy current diagnostic possibilities: an overview. Ferrucci JT. **Ann Oncol** 1999;10 Suppl 4:143-4 (8 ref.)

Role of tumour markers, cytogenetics. Lamerz R. **Ann Oncol** 1999;10 Suppl 4:145-9 (53 ref.)

Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. Oberg K. **Ann Oncol** 1999;10 Suppl 2:S3-8 (30 ref.)

Imaging and staging of bilio-pancreatic tumours: role of endoscopic and intraductal ultrasonography and guided cytology. Palazzo L. **Ann Oncol** 1999;10 Suppl 4:25-7 (33 ref.)

Usefulness of novel tumour markers. Rhodes JM. **Ann Oncol** 1999;10 Suppl 4:118-21 (22 ref.)

Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer. Tascilar M, et al. **Ann Oncol** 1999;10 Suppl 4:107-10 (70 ref.)

Pancreatic cancer in patients with chronic pancreatitis: a challenge from a surgical perspective. Sakorafas GH, et al. **Cancer Treat Rev** 1999 Aug;25(4):207-17 (154 ref.)

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Nguyen HN, et al. **Dig Dis Sci** 1999 Jun;44(6):1148-55 (37 ref.)

The standard diagnostic work-up and surgical treatment of pancreatic head tumours. Gouma DJ, et al. **Eur J Surg Oncol** 1999 Apr;25(2):113-23 (94 ref.)

Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562-7 (56 ref.)

Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses). Hes FJ, et al. **Eur Radiol** 1999;9(4):598-610 (142 ref.)

Primary carcinoma of the duodenal minor papilla. Yamao K, et al. **Gastrointest Endosc** 1998 Dec;48(6):634-6 (13 ref.)

Pancreatic endocrine tumors: diagnostic pitfalls. Ectors N. **Hepatogastroenterology** 1999 Mar-Apr;46(26):679-90 (127 ref.)

Benign retroperitoneal schwannoma mimicking a pancreatic cystic tumor: case report and literature review. Hsiao WC, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2418-20 (9 ref.)

Minute carcinoma of the pancreas measuring 1 cm or less in diameter--collective review of Japanese case reports. Ishikawa O, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):8-15 (43 ref.)

Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Kimura W, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):532-9 (83 ref.)

Health-related quality of life evaluations of gastric and pancreatic cancer. Schmier J, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1998-2004 (42 ref.)

An introduction to mucin-producing tumors of the pancreas: why they deserve more attention. Takada T, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):1967-72 (18 ref.)

Multifocal serous cystadenoma of the pancreas. A case report and review of the literature. Tanno S, et al. **Int J Pancreatol** 1998 Oct;24(2):129-32 (22 ref.)

Giant cell carcinoma of the pancreas: a case report and review of the literature. Jotsuka T, et al. **Pancreas** 1999 May;18(4):415-7 (14 ref.)

Intraductal pancreatic adenoma. Neff GW, et al. **Pancreas** 1999 Aug;19(2):205-7 (16 ref.)

Laparoscopic evaluation in pancreatic cancer. Merchant NB, et al. **Semin Surg Oncol** 1998 Oct-Nov;15(3):155-65 (53 ref.)

Solid and papillary epithelial neoplasm of the pancreas, diagnosis by cytology. Crawford BE 2nd. **South Med J** 1998 Oct;91(10):973-7 (44 ref.)

Pancreatic imaging. Baron PL, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):35-58 (67 ref.)

Insulinoma. Grant CS. **Surg Oncol Clin N Am** 1998 Oct; 7(4):819-44 (87 ref.)

Gastrinoma: advances in localization and treatment. Norton JA. **Surg Oncol Clin N Am** 1998 Oct;7(4):845-61 (62 ref.)

[Analysis and treatment of pancreatic cystic diseases] Gooszen HG, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):925-30 (34 ref.) (Eng. Abstr.) **(Dut)**

[Malignant pancreatic non-hodgkin's lymphoma manifesting as severe acute pancreatitis] Mofredj A, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):528-31 (21 ref.) (Eng. Abstr.) **(Fre)**

[The coexistence of 2 different neuroendocrine tumors of the upper gastrointestinal tract and pancreas (see comments)] Reusch J, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1472-7 (25 ref.) (Eng. Abstr.) Comment in: Dtsch Med Wochenschr 1999 Jun 4;124(22):712; discussion 713. **(Ger)**

[An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity] Wildbrett J, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):248-52 (24 ref.) (Eng. Abstr.) **(Ger)**

[Progress in diagnostic imaging in the area of the pancreas (CT, MRI, MR-angio, hydro-CT, MR cholangiopancreatography)] Gerhardt P. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:274-80 (16 ref.) (Eng. Abstr.) **(Ger)**

[Cystic lesions of the pancreas] Rosien U, et al. **Med Klin** 1999 Jul 15;94(7):377-85 (62 ref.) (Eng. Abstr.) **(Ger)**

[CA19-9 has no value as a tumor marker in obstructive jaundice] Peterli R, et al. **Schweiz Med Wochenschr** 1999 Jan 23;129(3):77-9 (14 ref.) (Eng. Abstr.) **(Ger)**

[Tumor markers in the diagnosis of pancreatic cancer] Cappelli G, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S19-21 (09 ref.) (Eng. Abstr.) **(Ita)**

[MR imaging of pancreatic neoplasms] Pavone P, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S6-10 (22 ref.) (Eng. Abstr.) **(Ita)**

[Endoscopy in the diagnosis and staging of pancreatic cancer] Spinelli P, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S14-8 (30 ref.) (Eng. Abstr.) **(Ita)**

[A case of pancreatoblastoma in an adult] Hayasaki N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May; 96(5):558-63 (14 ref.) **(Jpn)**

[Hormonal islet cell tumors. Proposition of a diagnostic-therapeutic model] Legutko J, et al. **Przegl Lek** 1998;55(9):463-8 (51 ref.) (Eng. Abstr.) **(Pol)**

[Cystic neoplasms of the pancreas: a review of the literature apropos 5 cases] Diaz de Liaño Argüelles A, et al. **Rev Clin Esp** 1999 May;199(5):288-93 (58 ref.) (Eng. Abstr.) **(Spa)**

[A pancreatic mucinous cystadenocarcinoma with diffuse spread (letter)] Reina Duarte A, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):227-9 (7 ref.) **(Spa)**

[Advances in the diagnosis and treatment of pancreatic carcinoma] Burgos L, et al. **Rev Med Chil** 1998 Dec; 126(12):1507-15 (39 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Jones L, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:288-307 (127 ref.)

Genetic prodrug activation therapy for pancreatic cancer. Rigg AS, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:319-25 (26 ref.)

Multidrug resistance: a solvable problem? Borst P. **Ann Oncol** 1999;10 Suppl 4:162-4 (13 ref.)

Chemotherapy for advanced pancreatic cancer: it may no longer be ignored. Cascinu S, et al. **Ann Oncol** 1999 Jan; 10(1):105-9 (34 ref.)

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Eriksson B, et al. **Ann Oncol** 1999;10 Suppl 2:S31-8 (63 ref.)

Experimental drugs and drug combinations in pancreatic cancer. Kroep JR, et al. **Ann Oncol** 1999;10 Suppl 4:234-8 (63 ref.)

Retinoids in pancreatic cancer. Riecken EO, et al. **Ann Oncol** 1999;10 Suppl 4:197-200 (35 ref.)

Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. van Groeningen CJ. **Ann Oncol** 1999;10 Suppl 4:305-7 (23 ref.)

Current chemotherapeutic possibilities in pancreaticobiliary cancer. van Riel JM, et al. **Ann Oncol** 1999;10 Suppl 4:157-61 (54 ref.)

Pancreatic endocrine tumours, immunotherapy and gene therapy: chemotherapy and interferon therapy of endocrine tumours. Veenhof CH. **Ann Oncol** 1999;10 Suppl 4:185-7 (6 ref.)

Chemoradiation for localized pancreatic cancer: another perspective [editorial; comment] Evans DB, et al. **Ann Surg Oncol** 1999 Jan-Feb;6(1):4-7 (9 ref.) Comment on: Ann Surg Oncol 1999 Jan-Feb;6(1):38-45.

Chemoradiotherapy in the management of localized tumors of the pancreas. Poen JC, et al. **Ann Surg Oncol** 1999 Jan-Feb;6(1):117-22 (21 ref.)

Gemcitabine: a pharmacologic and clinical overview. Barton-Burke M. **Cancer Nurs** 1999 Apr;22(2):176-83 (46 ref.)

New agents in gastrointestinal malignancies: Part 2: Gemcitabine in clinical practice. Stucky-Marshall L. **Cancer Nurs** 1999 Aug;22(4):290-6 (19 ref.)

New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice. Stucky-Marshall L. **Cancer Nurs** 1999 Jun;22(3):212-9 (22 ref.)

The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Degen L, et al. **Digestion** 1999;60 Suppl 2:9-14 (30 ref.)

CPT-11 in gastrointestinal cancer. Bleiberg H. **Eur J Cancer** 1999 Mar;35(3):371-9 (85 ref.)

Novel approaches in development for the treatment of pancreatic cancer. Butera J, et al. **Front Biosci** 1998 Nov 1;3:E226-9 (45 ref.)

Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma. Fisher WE, et al. **Int J Pancreatol** 1998 Dec;24(3):169-80 (88 ref.)

Chemotherapy in the treatment of cancer of the pancreas. Glimelius B. **J Hepatobiliary Pancreat Surg** 1998; 5(3):235-41 (55 ref.)

Endocrine therapy in pancreatic carcinoma. Yamashita J, et al. **Oncology** 1998 Dec;55 Suppl 1:17-22 (52 ref.)

Adjuvant therapy for pancreatic cancer. Ghaneh P, et al. **World J Surg** 1999 Sep;23(9):937-45 (98 ref.)

Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile? van der Schelling GP, et al. **World J Surg** 1999 Sep;23(9):950-3 (19 ref.)

[Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy?] Maurer CA, et al. **Zentralbl Chir** 1999;124(5):401-7 (56 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities of palliation in pancreatic cancer] Di Costanzo F, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S47-53 (49 ref.) (Eng. Abstr.) **(Ita)**

[Adjuvant concomitant chemotherapy in pancreatic cancer] Turci D, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S36-42 (48 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

Economic evaluations of gastric and pancreatic cancer. Elixhauser A, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1206-13 (20 ref.)

ENZYMOLOGY

The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Jones L, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:288-307 (127 ref.)

Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. Bramhall SR. **J Hepatobiliary Pancreat Surg** 1998;5(4):392-401 (108 ref.)

EPIDEMIOLOGY

Pancreatico-biliary malignancy: prevalence and risk factors. Lowenfels AB, et al. **Ann Oncol** 1999;10 Suppl 4:1-3 (21 ref.)

The increased incidence of cancer of the pancreas: is there a missing dietary factor? Can it be reversed? [see comments] Stephens FO. **Aust N Z J Surg** 1999 May;69(5):331-5 (77 ref.) Comment in: Aust N Z J Surg 1999 Jul;69(7):471.

Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Dhir V, et al. **Indian J Gastroenterol** 1999 Jan-Mar;18(1):24-8 (39 ref.)

Primary malignancies of the hepato-biliary-pancreatic system in organ allograft recipients. Penn I. **J Hepatobiliary Pancreat Surg** 1998;5(2):157-64 (42 ref.)

Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. Soga J, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):312-9 (23 ref.)

ETIOLOGY

Pancreatic cancer: development of a unifying etiologic concept. Lowenfels AB, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:191-200 (38 ref.)

Other risk factors for pancreatic cancer: hormonal aspects. Andrén-Sandberg A, et al. **Ann Oncol** 1999;10 Suppl

4:131-5 (61 ref.)
Remote partial gastrectomy as a risk factor for pancreatic cancer: potential for preventive strategies. van Rees BP, et al. **Ann Oncol** 1999;10 Suppl 4:204-7 (58 ref.)
The link between exocrine pancreatic cancer and the endocrine pancreas. Pour PM, et al. **Int J Pancreatol** 1999 Apr;25(2):77-87 (51 ref.)
Risk and genetic factors in pancreatic cancer [editorial] Gullo L, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):587-92 (92 ref.)
Dietary fat and carcinogenesis. Woutersen RA, et al. **Mutat Res** 1999 Jul 15;443(1-2):111-27 (183 ref.)

GENETICS

Detection of Ki-ras oncogene mutations in pancreatic diseases: helpful or irrelevant? Van Laethem JL. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):295-7 (33 ref.)
Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma. Bullock GJ, et al. **Am J Surg** 1999 Jan;177(1):15-8 (39 ref.)
K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Westra WH, et al. **Am J Surg Pathol** 1998 Oct;22(10):1247-54 (33 ref.)
Gene expression in pancreatic adenocarcinoma. Frazier ML. **Ann N Y Acad Sci** 1999 Jun 30;880:1-4 (23 ref.)
Molecular pathology of invasive carcinoma. Longnecker DS. **Ann N Y Acad Sci** 1999 Jun 30;880:74-82 (55 ref.)
Genomic anomalies in pancreatic tumors other than common adenocarcinoma. Scarpa A, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:179-90 (56 ref.)
Ki-ras oncogene mutations in chronic pancreatitis: which discriminating ability for malignant potential? van Laethem JL. **Ann N Y Acad Sci** 1999 Jun 30;880:210-8 (22 ref.)
Strategies for the detection of disease genes in pancreatic cancer. Wallrapp C, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:122-46 (47 ref.)
Progress in cancer genetics: lessons from pancreatic cancer. Goggins M, et al. **Ann Oncol** 1999;10 Suppl 4:4-8 (87 ref.)
Familial pancreatic cancer. Hruban RH, et al. **Ann Oncol** 1999;10 Suppl 4:69-73 (54 ref.)
Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool. Mulcahy H, et al. **Ann Oncol** 1999;10 Suppl 4:114-7 (28 ref.)
DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Schutte M. **Ann Oncol** 1999;10 Suppl 4:56-9 (43 ref.)
Novel technology for detection of genomic and transcriptional alterations in pancreatic cancer. Wallrapp C, et al. **Ann Oncol** 1999;10 Suppl 4:64-8 (31 ref.)
Molecular biology of pancreatic carcinoma. Yeung RS. **Cancer Treat Res** 1998;98:339-49 (74 ref.)
The molecular and cellular biology of pancreatic cancer. Perugini RA, et al. **Crit Rev Eukaryot Gene Expr** 1998; 8(3-4):377-93 (142 ref.)
Molecular pathobiology of pancreatic adenocarcinoma. Mangray S, et al. **Front Biosci** 1998 Nov 15;3:D1148-60 (75 ref.)
Molecular genetic basis of pancreatic adenocarcinoma. Hilgers W, et al. **Genes Chromosomes Cancer** 1999 Sep; 26(1):1-12 (109 ref.)
Tumor-suppressor genes in pancreatic cancer. Hruban RH, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):383-91 (75 ref.)
What is the true rate of K-ras mutation in carcinoma of the pancreas? [editorial] Longnecker DS, et al. **Pancreas** 1998 Nov;17(4):323-4 (18 ref.)
Tumor suppressor genes: a short review. Yeo CJ. **Surgery** 1999 Apr;125(4):363-6 (10 ref.)
[Pancreatic carcinoma: conclusive clinical consequences based on molecular biology knowledge for therapy] Ketterer K, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:405-10 (6 ref.) (Eng. Abstr.) **(Ger)**
[Development of insulinoma cells as therapy in insulin-dependent diabetes mellitus] Schnedl WJ. **Wien Klin Wochenschr** 1999 Jun 4;111(11):428-33 (47 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Single-chain antibodies in pancreatic cancer. Colcher D, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:263-80 (56 ref.)

METABOLISM

Growth factors and cytokines in pancreatic carcinogenesis. Friess H, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:110-21 (80 ref.)
Mucin gene and antigen expression in biliopancreatic carcinogenesis. Kim YS, et al. **Ann Oncol** 1999;10 Suppl 4:51-5 (31 ref.)
Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. Fearon KC, et al. **World J Surg** 1999 Jun;23(6):584-8 (25 ref.)

MORTALITY

Adjuvant chemoradiotherapy in pancreatic adenocarcinoma. Thomas PR. **Hepatogastroenterology** 1998 May-Jun; 45(21):610-2 (12 ref.)
Nonfunctioning islet cell carcinoma of the pancreas: an evaluation of seven patients who underwent resection followed by long-term survival. Eriguchi N, et al. **Surg Today** 1999;29(3):233-7 (15 ref.)

NURSING

New agents in gastrointestinal malignancies: Part 2: Gemcitabine in clinical practice. Stucky-Marshall L. **Cancer Nurs** 1999 Aug;22(4):290-6 (19 ref.)

PATHOLOGY

Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Fukushima N, et al. **Adv Anat Pathol** 1999 Mar;6(2):65-77 (53 ref.)
Serous cystadenoma of the pancreas with invasive growth: benign or malignant? Abe H, et al. **Am J Gastroenterol** 1998 Oct;93(10):1963-6 (12 ref.)
Invasion and metastasis in pancreatic cancer. Ellenrieder V, et al. **Ann Oncol** 1999;10 Suppl 4:46-50 (35 ref.)
Laparoscopic staging of biliopancreatic malignancy. Gouma DJ, et al. **Ann Oncol** 1999;10 Suppl 4:33-6 (24 ref.)
Pathology of incipient pancreatic cancer. Hruban RH, et al. **Ann Oncol** 1999;10 Suppl 4:9-11 (44 ref.)
Intraoperative methods to stage and localize pancreatic and duodenal tumors. Norton JA. **Ann Oncol** 1999;10 Suppl 4:182-4 (15 ref.)
Essentials in biliopancreatic staging: a decision analysis. Obertop H, et al. **Ann Oncol** 1999;10 Suppl 4:150-2 (21 ref.)
Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Solcia E, et al. **Ann Oncol** 1999;10 Suppl 2:S9-15 (47 ref.)
Tumors of the pancreas with osteoclast-like and pleomorphic giant cells: an immunohistochemical and ploidy study. Deckard-Janatpour K, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):266-72 (47 ref.)
Glucagonoma syndrome: a case report. Shyr YM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Sep; 62(9):639-43 (12 ref.)
Fine needle aspiration biopsy of the pancreas. Centeno BA. **Clin Lab Med** 1998 Sep;18(3):401-27, v-vi (83 ref.)
The tumours of the endocrine pancreas. Rindi G, et al. **Eur J Histochem** 1998;42 Spec No:63-6 (20 ref.)
Thymic carcinoid in the pancreas: metastatic disease or new primary tumours. Axelson J, et al. **Eur J Surg** 1999 Mar; 165(3):270-3 (16 ref.)
Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Klöppel G. **Hepatogastroenterology** 1998 Nov-Dec;45(24):1981-5 (30 ref.)
Observations on the etiology and pathogenesis of intraductal papillary-mucinous neoplasms of the pancreas. Longnecker DS. **Hepatogastroenterology** 1998 Nov-Dec;45(24):1973-80 (35 ref.)
Serous adenoma of the pancreas with multiple microcysts communicating with the pancreatic duct. Samel S, et al. **HPB Surg** 1998;11(1):43-9 (21 ref.)
The link between exocrine pancreatic cancer and the endocrine pancreas. Pour PM, et al. **Int J Pancreatol** 1999 Apr;25(2):77-87 (51 ref.)
Treatment of metastatic glucagonoma to the liver: case report and literature review. Casadei R, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):308-12 (34 ref.)
Cystic neoplasms of the pancreas [editorial] Yeoh KG. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):183-5 (23 ref.)
Pancreatic polypeptide islet cell tumor: case report and review of the literature. Bellows C, et al. **J Gastrointest Surg** 1998 Nov-Dec;2(6):526-32 (43 ref.)
Serous cystadenocarcinoma of the pancreas with liver metastases. Eriguchi N, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):467-70 (11 ref.)
Staging systems for pancreatic cancer: differences between the Japanese and UICC systems. Kobari M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(2):121-7 (16 ref.)
Pancreatic disease. Keogh GW, et al. **Med J Aust** 1999 Mar 1;170(5):228-34 (32 ref.)
Schwannoma of the pancreas: a report of two cases and a review of the literature. Brown SZ, et al. **Mod Pathol** 1998 Dec;11(12):1178-82 (25 ref.)
A clinicopathologic and immunohistochemical study of 22 intraductal papillary mucinous neoplasms of the pancreas, with a review of the literature. Paal E, et al. **Mod Pathol** 1999 May;12(5):518-28 (79 ref.)
Oncocytic and oncocytoid tumors of the exocrine pancreas, liver, and gastrointestinal tract. Papotti M, et al. **Semin Diagn Pathol** 1999 May;16(2):126-34 (71 ref.)
Pancreatic mucin-producing adenocarcinoma associated with a pancreatic stone: report of a case. Origuchi N, et al. **Surg Today** 1998;28(12):1261-5 (22 ref.)
Cystic lymphoepithelial lesions of the pancreas and peripancreatic region: report of two cases. Sako S, et al. **Surg Today** 1999;29(5):467-71 (26 ref.)
Pancreatic biopsy: why? When? How? Ihse I, et al. **World J Surg** 1999 Sep;23(9):896-900 (46 ref.)
[Are pancreatic cystadenocarcinomas degenerated mucinous cystadenomas? French Association of Surgery] Le Borgne J, et al. **Chirurgie** 1998 Sep;123(4):373-8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Extension of an acinar cell pancreatic carcinoma with cystic changes invading the Wirsung canal] Joubert M, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):465-8 (10 ref.) (Eng. Abstr.) **(Fre)**
[Staging of exocrine pancreatic cancer] Sauvanet A, et al. **J Chir (Paris)** 1998 Feb;135(1):10-6 (31 ref.) (Eng. Abstr.) **(Fre)**
[Radiologic staging of liver and pancreatic malignancies] Schima W, et al. **Radiologe** 1999 Jul;39(7):568-77 (53 ref.) (Eng. Abstr.) **(Ger)**
[Endocrine tumors of the pancreas. Review of 30 years of research] Bordi C. **Pathologica** 1998 Jun;90(3):215-21 (43 ref.) **(Ita)**
[The prognostic factors of pancreatic cancer--adhesion molecule CD44] Gotoda T, et al. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2036-42 (50 ref.) (Eng. Abstr.) **(Jpn)**
[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):200-5 (12 ref.) (Eng. Abstr.) **(Jpn)**
[A case report of pancreatic mucinous cystadenocarcinoma with penetration to the stomach] Baek Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):685-90 (12 ref.) **(Jpn)**
[A case of adenosquamous pancreatic cancer with high serum level of parathyroid related protein in which both primary and liver metastatic lesions showed remarkable cystic changes] Hyodo N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):181-8 (13 ref.) **(Jpn)**
[Mallison's tumor (glucagonoma)] Lakreeva MG, et al. **Khirurgiia (Mosk)** 1999;(2):63-6 (61 ref.) **(Rus)**

PHYSIOPATHOLOGY

Are pancreatic tumors hormone dependent?: A case report of unusual, rapidly growing pancreatic tumor during pregnancy, its possible relationship to female sex hormones, and review of the literature. Ganepola GA, et al. **Am Surg** 1999 Feb;65(2):105-11 (18 ref.)
Pain management of pancreatic cancer. Andrén-Sandberg A, et al. **Ann Oncol** 1999;10 Suppl 4:265-8 (35 ref.)
1998 Labat Lecture: the role of the neurolytic celiac plexus block in pancreatic cancer pain management: do we have the answers? Ischia S, et al. **Reg Anesth Pain Med** 1998 Nov-Dec;23(6):611-4 (52 ref.)
[Adenocarcinoma of the pancreas. General characteristics] André T, et al. **Presse Med** 1998 Mar 21;27(11):533-6 (27 ref.) (Eng. Abstr.) **(Fre)**
[Secondary diabetes in pancreatic carcinoma and after pancreatectomy: pathophysiology, therapeutic peculiarities and prognosis] Pfeffer F, et al. **Z Gastroenterol** 1999 Jun; Suppl 1:10-4 (36 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

An overview of preventive strategies for pancreatic cancer. Levin B. **Ann Oncol** 1999;10 Suppl 4:193-6 (34 ref.)

RADIOGRAPHY

Computed tomography in the diagnosis and staging of cholangiocarcinoma and pancreatic carcinoma. Freeny PC. **Ann Oncol** 1999;10 Suppl 4:12-7 (25 ref.)
Pancreatic disease in children and young adults: evaluation with CT. Vaughn DD, et al. **Radiographics** 1998 Sep-Oct; 18(5):1171-87 (45 ref.)
[Computerized tomography of pancreatic tumors] Fargnoli R, et al. **Tumori** 1999 Jan-Feb;85(1 Suppl 1):S3-5 (15 ref.) (Eng. Abstr.) **(Ita)**
[A 47-year-old man with epigastric discomfort] San Román Montero JM, et al. **Rev Clin Esp** 1998 Nov;198(11):771-2 (6 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies. Mariani G. **Ann Oncol** 1999;10 Suppl 4:37-40 (36 ref.)
18FDG-positron emission tomography in pancreatic cancer. Zimny M, et al. **Ann Oncol** 1999;10 Suppl 4:28-32 (57 ref.)
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Rose DM, et al. **Ann Surg** 1999 May;229(5):729-37; discussion 737-8 (42 ref.)
Diagnosis and staging of pancreatic cancer by positron emission tomography. Berberat P, et al. **World J Surg** 1999 Sep;23(9):882-7 (54 ref.)

RADIOTHERAPY

Future role of radiotherapy as a component of treatment in biliopancreatic cancers. Gunderson LL, et al. **Ann Oncol** 1999;10 Suppl 4:291-5 (30 ref.)
Studies of intraoperative radiotherapy in carcinoma of the pancreas. Sindelar WF, et al. **Ann Oncol** 1999;10 Suppl 4:226-30 (24 ref.)
Somatostatin receptor imaging and therapy of pancreatic endocrine tumors. van Eijck CH, et al. **Ann Oncol** 1999; 10 Suppl 4:177-81 (48 ref.)
Chemoradiation for localized pancreatic cancer: another perspective [editorial; comment] Evans DB, et al. **Ann Surg Oncol** 1999 Jan-Feb;6(1):4-7 (9 ref.) Comment on: Ann Surg Oncol 1999 Jan-Feb;6(1):38-45.
Chemoradiotherapy in the management of localized tumors of the pancreas. Poen JC, et al. **Ann Surg Oncol** 1999 Jan-Feb;6(1):117-22 (21 ref.)

Intraoperatic electron beam irradiation in pancreatic cancer. Willett CG, et al. **Front Biosci** 1998 Nov 15;3:E207–13 (33 ref.)
Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. King TC, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):4–11 (58 ref.)
Adjuvant therapy for pancreatic cancer. Ghaneh P, et al. **World J Surg** 1999 Sep;23(9):937–45 (98 ref.)
Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile? van der Schelling GP, et al. **World J Surg** 1999 Sep;23(9):950–3 (19 ref.)
[Concomitant chemoradiotherapy in the therapeutic strategy of adenocarcinoma of the exocrine pancreas and stomach] Mornex F, et al. **Cancer Radiother** 1998 Dec;2(6):696–702 (48 ref.) (Eng. Abstr.) **(Fre)**
[Pancreatectomy after neoadjuvant chemoradiotherapy for potentially resectable exocrine adenocarcinoma of the pancreas] Partensky C, et al. **Cancer Radiother** 1998 Dec; 2(6):771–4 (13 ref.) (Eng. Abstr.) **(Fre)**
[Intraoperative radiotherapy in the combined treatment of pancreatic cancers] Fellin G, et al. **Tumori** 1999 Jan–Feb; 85(1 Suppl 1):S33–5 (16 ref.) (Eng. Abstr.) **(Ita)**

SECONDARY

Metastases to the pancreas. Merkle EM, et al. **Br J Radiol** 1998 Nov;71(851):1208–14 (10 ref.)
Thymic carcinoid in the pancreas: metastatic disease or new primary tumours. Axelson J, et al. **Eur J Surg** 1999 Mar; 165(3):270–3 (16 ref.)
Management of the pancreatic metastases from renal cell carcinoma: report of four resected cases. Hashimoto M, et al. **Hepatogastroenterology** 1998 Jul–Aug;45(22):1150–4 (18 ref.)
Indications for surgical resection of metastatic ocular melanoma. A case report and review of the literature. Cunningham JD, et al. **Int J Pancreatol** 1998 Aug; 24(1):49–53 (17 ref.)

SECRETION

Mucobilia: the clinical spectrum, diagnosis and treatment. Chen MF. **J Gastroenterol Hepatol** 1998 Nov; 13(11):1084–90 (60 ref.)
Calcitonin–producing pancreatic somatostatinoma: report of a case. Sugimoto F, et al. **Surg Today** 1998;28(12):1279–82 (9 ref.)
Vasoactive intestinal polypeptide secreting islet cell tumors: a 15–year experience and review of the literature. Smith SL, et al. **Surgery** 1998 Dec;124(6):1050–5 (25 ref.)

SURGERY

Surgical palliative treatment in bilio–pancreatic malignancy. Gouma DJ, et al. **Ann Oncol** 1999;10 Suppl 4:269–72 (26 ref.)
Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. McLeod RS. **Ann Oncol** 1999;10 Suppl 4:281–4 (21 ref.)
The future of surgery for pancreatic cancer. Slavin J, et al. **Ann Oncol** 1999;10 Suppl 4:285–90 (104 ref.)
Standard surgical treatment in pancreatic cancer. Wagner M, et al. **Ann Oncol** 1999;10 Suppl 4:247–51 (55 ref.)
Adenosquamous carcinoma of the pancreas. Madura JA, et al. **Arch Surg** 1999 Jun;134(6):599–603 (36 ref.)
Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report. Pasieka JL, et al. **Can J Surg** 1999 Feb;42(1):55–8 (12 ref.)
Malignant fibrous histiocytoma of the pancreas: a case report with genetic analysis. Bastian D, et al. **Cancer** 1999 Jun 1;85(11):2352–8 (49 ref.)
Pancreatic cancer in patients with chronic pancreatitis: a challenge from a surgical perspective. Sakorafas GH, et al. **Cancer Treat Rev** 1999 Aug;25(4):207–17 (154 ref.)
Pancreatic cancer. Yeo CJ, et al. **Curr Probl Surg** 1999 Feb; 36(2):59–152 (155 ref.)
The impact of different types of surgery in pancreatic cancer. Friess H, et al. **Eur J Surg Oncol** 1999 Apr;25(2):124–31 (111 ref.)
The standard diagnostic work–up and surgical treatment of pancreatic head tumours. Gouma DJ, et al. **Eur J Surg Oncol** 1999 Apr;25(2):113–23 (94 ref.)
Surgical therapy of pancreatic cancer. Heywood G, et al. **Front Biosci** 1998 Nov 1;3:E175–80 (77 ref.)
The role of laparoscopy in the management of pancreatic cancer. Iannitti DA. **Front Biosci** 1998 Nov 1;3:E181–5 (41 ref.)
Surgery and multimodal treatments in pancreatic cancer––a review on the basis of future multimodal treatment concepts. Link KH, et al. **Gan To Kagaku Ryoho** 1999 Jan; 26(1):10–40 (111 ref.)
Management of the pancreatic metastases from renal cell carcinoma: report of four resected cases. Hashimoto M, et al. **Hepatogastroenterology** 1998 Jul–Aug;45(22):1150–4 (18 ref.)
Spindle cell carcinoma of the pancreas: a case report. Tsutsumi S, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):2015–7 (11 ref.)
A resected case of pancreatic metastasis from primary renal cell carcinoma. Eriguchi N, et al. **Kurume Med J** 1999; 46(2):119–22 (9 ref.)
Lymph–node dissection in pancreatic cancer –– what are the facts? Birk D, et al. **Langenbecks Arch Surg** 1999 Apr; 384(2):158–66 (64 ref.)
Laparoscopic biliary and enteric bypass. Chekan EG, et al. **Semin Surg Oncol** 1999 Jun;16(4):313–20 (21 ref.)
Laparoscopic evaluation in pancreatic cancer. Merchant NB, et al. **Semin Surg Oncol** 1998 Oct–Nov;15(3):155–65 (53 ref.)
Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Thompson NW. **Surg Oncol Clin N Am** 1998 Oct;7(4):881–91 (34 ref.)
Nonfunctioning islet cell carcinoma of the pancreas: an evaluation of seven patients who underwent resection followed by long–term survival. Eriguchi N, et al. **Surg Today** 1999;29(3):233–7 (15 ref.)
Calcitonin–producing pancreatic somatostatinoma: report of a case. Sugimoto F, et al. **Surg Today** 1998;28(12):1279–82 (9 ref.)
Laparoscopy and peripancreatic neoplasia. Westcott CJ, et al. **World J Surg** 1999 Apr;23(4):378–83 (49 ref.)
[Analysis and treatment of pancreatic cystic diseases] Gooszen HG, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):925–30 (34 ref.) (Eng. Abstr.) **(Dut)**
[Pancreatic carcinoma––conclusions and prospects] Trede M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:411–20 (14 ref.) (Eng. Abstr.) **(Ger)**
[Optimizing palliative therapy in pancreatic carcinoma] Böttger T. **Zentralbl Chir** 1999;124(5):394–400 (35 ref.) (Eng. Abstr.) **(Ger)**
[Is pancreaticoduodenectomy with portal vein resection indicated in patients with ductal pancreatic carcinoma?] Böttger T. **Zentralbl Chir** 1999;124(3):220–5 (24 ref.) (Eng. Abstr.) **(Ger)**
[Surgical options in the palliative treatment of pancreatic cancer] Delrio P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S43–6 (20 ref.) (Eng. Abstr.) **(Ita)**
[Intraoperative radiotherapy in the combined treatment of pancreatic cancers] Fellin G, et al. **Tumori** 1999 Jan–Feb; 85(1 Suppl 1):S33–5 (16 ref.) (Eng. Abstr.) **(Ita)**
[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy] Sunamura M, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):200–5 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Ways of improving long–term results of treatment in resectable pancreatic cancer] Patiutko Iul, et al. **Vopr Onkol** 1998;44(5):628–31 (33 ref.) **(Rus)**

THERAPY

Review article: current treatment and optimal patient management in pancreatic cancer. Haycox A, et al. **Aliment Pharmacol Ther** 1998 Oct;12(10):949–64 (178 ref.)
Treatment of cancer of the exocrine pancreas. Huguier M, et al. **Am J Surg** 1999 Mar;177(3):257–65 (99 ref.)
Gene therapy for pancreatic and biliary malignancies. Aspinall RJ, et al. **Ann Oncol** 1999;10 Suppl 4:188–92 (76 ref.)
Biliopancreatic malignancy: future prospects for progress. Ho JJ, et al. **Ann Oncol** 1999;10 Suppl 4:300–4 (77 ref.)
Pancreatic endocrine tumors: recent advances. Jensen RT. **Ann Oncol** 1999;10 Suppl 4:170–6 (54 ref.)
Neuroendocrine gastrointestinal tumors––a condensed overview of diagnosis and treatment. Oberg K. **Ann Oncol** 1999;10 Suppl 2:S3–8 (30 ref.)
Cystic pancreatic neoplasms. Rattner DW, et al. **Ann Oncol** 1999;10 Suppl 4:104–6 (16 ref.)
Chemoradiation for pancreatic and biliary cancer: current status of RTOG studies. Rich TA. **Ann Oncol** 1999;10 Suppl 4:231–3 (29 ref.)
Palliation of pain and jaundice: an overview. Russell RC. **Ann Oncol** 1999;10 Suppl 4:165–9 (28 ref.)
Pancreaticobiliary cancer: the future aspects of medical oncology. van Riel JM, et al. **Ann Oncol** 1999;10 Suppl 4:296–9 (45 ref.)
Nutritional support during treatment of biliopancreatic malignancy. von Meyenfeldt MF. **Ann Oncol** 1999;10 Suppl 4:273–7 (82 ref.)
Management of exocrine carcinoma of the pancreas. Hoffman JP, et al. **Cancer Treat Res** 1998;98:65–82 (106 ref.)
Practical recommendations for the management of adenocarcinoma of the pancreas. Sporn JR. **Drugs** 1999 Jan;57(1):69–79 (48 ref.)
Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long–acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)
(Neo)adjuvant treatment in pancreatic cancer––the need for future trials. van Eijck CH, et al. **Eur J Surg Oncol** 1999 Apr;25(2):132–7 (59 ref.)
Treatment of advanced and metastatic pancreatic cancer. Blaszkowsky L. **Front Biosci** 1998 Nov 1;3:E214–25 (123 ref.)
Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Breslin TM, et al. **Front Biosci** 1998 Nov 1; 3:E193–203 (44 ref.)
Gene therapy and pancreatic cancer. Pearson AS, et al. **Front Biosci** 1998 Nov 1;3:E230–7 (59 ref.)
Adjuvant therapy for pancreatic cancer: current status. Regine WF, et al. **Front Biosci** 1998 Nov 15;3:E186–92 (33 ref.)
Adjuvant postoperative radiation therapy +/– 5–FU in resected carcinoma of the pancreas. Foo ML, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):613–23 (38 ref.)
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Miller AR, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):624–33 (63 ref.)
Adjuvant chemoradiotherapy in pancreatic adenocarcinoma. Thomas PR. **Hepatogastroenterology** 1998 May–Jun; 45(21):610–2 (12 ref.)
Gene therapy for pancreatic cancer [editorial] Rigg AS, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):462–6 (44 ref.)
Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. Evans DB, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):242–50 (46 ref.)
Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. Hoffman JP, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):251–4 (22 ref.)
Evolving trends in combined modality therapy for pancreatic cancer. Regine WF, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):227–34 (53 ref.)
Pancreatic disease. Keogh GW, et al. **Med J Aust** 1999 Mar 1;170(5):228–34 (32 ref.)
Laparoscopic biliary bypass for inoperable pancreatic cancer. Scott–Conner CE. **Semin Laparosc Surg** 1998 Sep; 5(3):185–8 (19 ref.)
[Adenocarcinoma of the pancreas. Therapeutic strategies] André T, et al. **Presse Med** 1998 Mar 21;27(11):539–45 (65 ref.) (Eng. Abstr.) **(Fre)**
[Role of endoscopy in the palliative therapy of pancreatic cancer] Spinelli P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S60–3 (26 ref.) (Eng. Abstr.) **(Ita)**
[Cancer of the liver, pancreas, gallbladder, and bile duct] Furue H. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:139–44 (48 ref.) (Eng. Abstr.) **(Jpn)**
[Hormonal islet cell tumors. Proposition of a diagnostic–therapeutic model] Legutko J, et al. **Przegl Lek** 1998;55(9):463–8 (51 ref.) (Eng. Abstr.) **(Pol)**
[Advances in the diagnosis and treatment of pancreatic carcinoma] Burgos L, et al. **Rev Med Chil** 1998 Dec; 126(12):1507–15 (39 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Imaging and staging of biliopancreatic malignancy: role of ultrasound. Smits NJ, et al. **Ann Oncol** 1999;10 Suppl 4:20–4 (42 ref.)
Staging of pancreatic carcinoma by endoscopic ultrasonography. Palazzo L. **Endoscopy** 1998 Aug;30 Suppl 1:A103–7 (14 ref.)
Endoscopic ultrasound localization of a pancreatic insulinoma: case report and review of the localization techniques. Hall RS, et al. **Mil Med** 1998 Dec;163(12):853–6 (34 ref.)
Role of laparoscopic ultrasound in cancer management. Thompson DM, et al. **Semin Surg Oncol** 1998 Oct–Nov; 15(3):166–75 (34 ref.)
[Ultrasonography of pancreatic neoplasms] Innocenti P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S11–3 (11 ref.) (Eng. Abstr.) **(Ita)**
[The diagnosis and preoperative location of digestive endocrine tumors by endoscopic ultrasonography] Varas Lorenzo MJ, et al. **Gastroenterol Hepatol** 1999 May; 22(5):223–6 (24 ref.) (Eng. Abstr.) **(Spa)**

PANCREATIC POLYPEPTIDE

ANALYSIS

Pancreatic polypeptide islet cell tumor: case report and review of the literature. Bellows C, et al. **J Gastrointest Surg** 1998 Nov–Dec;2(6):526–32 (43 ref.)

BIOSYNTHESIS

Expression of non–classical islet hormone–like peptides during the embryonic development of the pancreas. Mulder H, et al. **Microsc Res Tech** 1998 Nov 15;43(4):313–21 (70 ref.)

BLOOD

Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report. Pasieka JL, et al. **Can J Surg** 1999 Feb;42(1):55–8 (12 ref.)

PANCREATIC PSEUDOCYST

COMPLICATIONS

Pancreatic pseudocyst with fistula to the common bile duct presenting with gastrointestinal bleeding. Raimondo M, et al. **Dig Dis Sci** 1998 Dec;43(12):2622–6 (16 ref.)
Pancreatic pseudocyst: heparin–induced haemorrhage through the ampulla of Vater. Hong D, et al. **J R Coll Surg Edinb** 1999 Aug;44(4):271–3 (30 ref.)

DIAGNOSIS

[Cystic lesions of the pancreas] Rosien U, et al. **Med Klin** 1999 Jul 15;94(7):377–85 (62 ref.) (Eng. Abstr.) **(Ger)**
[Cystic lesions of the pancreas] Irimoto M, et al. **Nippon Rinsho** 1998 Nov;56(11):2902–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

PANCREATIC PSEUDOCYST

SURGERY

Interventional management of peripancreatic fluid collections. Traverso LW, et al. **Surg Clin North Am** 1999 Aug;79(4):745–57, viii–ix (4 ref.)

[The percutaneous drainage of pancreatic pseudocysts] Mosca F. **Ann Ital Chir** 1999 Mar–Apr;70(2):173–6 (15 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Nonoperative management of pancreatic pseudocysts. Problems in differential diagnosis. Boggi U, et al. **Int J Pancreatol** 1999 Apr;25(2):123–33 (50 ref.)

[Pancreaticolithiasis and pancreatic pseudocysts--interventional therapy] Vogt W. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1558–62 (15 ref.) (Eng. Abstr.) **(Ger)**

[US or CT-guided percutaneous drainage of pancreatic pseudocyst] Palmeri R, et al. **Chir Ital** 1997;49(4–5):11–6 (26 ref.) (Eng. Abstr.) **(Ita)**

PANCREATIC SECRETORY TRYPSIN INHIBITOR, KAZAL see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

PANCREATIC TRYPSIN SECRETORY INHIBITOR, KAZAL see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

PANCREATICODUODENECTOMY

The Whipple procedure in the 1990s. Yeo CJ. **Adv Surg** 1999; 32:271–303 (73 ref.)

Pancreaticoduodenectomy for melanoma metastatic to the duodenum: a case report and review of the literature. Meyers MO, et al. **Am Surg** 1998 Dec;64(12):1174–6 (15 ref.)

Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. McLeod RS. **Ann Oncol** 1999;10 Suppl 4:281–4 (21 ref.)

Diffuse bile duct carcinoma treated by major hepatectomy and pancreatoduodenectomy with the aid of pre-operative portal vein embolization. Report of two cases. Chijiiwa K, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):1634–8 (13 ref.)

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Miller AR, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):624–33 (63 ref.)

Pancreaticoduodenectomy for chronic pancreatitis: a case report and literature review. Riker A, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):2005–10 (21 ref.)

Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. Evans DB, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):242–50 (46 ref.)

Pancreatoduodenectomy for neonatal myofibromatosis of the pancreas. Morrow SE, et al. **J Pediatr Surg** 1999 Apr; 34(4):609–11 (22 ref.)

ADVERSE EFFECTS

Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy [see comments] Povoski SP, et al. **Ann Surg** 1999 Aug;230(2):131–42 (54 ref.) Comment in: Ann Surg 1999 Aug;230(2):143–4.

MORTALITY

[Is pancreaticoduodenectomy with portal vein resection indicated in patients with ductal pancreatic carcinoma?] Böttger T. **Zentralbl Chir** 1999;124(3):220–5 (24 ref.) (Eng. Abstr.) **(Ger)**

PANCREATICOJEJUNOSTOMY

METHODS

The surgical management of chronic pancreatitis: the Frey procedure. Frey CF. **Adv Surg** 1999;32:41–85 (76 ref.)

PANCREATIN

ADVERSE EFFECTS

Colonic toxicity from pancreatins: a contemporary safety issue [see comments] Powell CJ. **Lancet** 1999 Mar 13; 353(9156):911–5 (37 ref.) Comment in: Lancet 1999 Jul 17;354(9174):249; discussion 251. Comment in: Lancet 1999 Jul 17;354(9174):249–50; discussion 251. Comment in: Lancet 1999 Jul 17;354(9174):250; discussion 251. Comment in: Lancet 1999 Jul 17;354(9174):250–1. Comment in: Lancet 1999 Jul 17;354(9174):251.

PANCREATITIS

Childhood pancreatitis. Uretsky G, et al. **Am Fam Physician** 1999 May 1;59(9):2507–12 (15 ref.)

Experimental models of pancreatitis. al-Mufti RA, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):133–40 (72 ref.)

Pancreatic disease in the elderly. Martin SP, et al. **Clin Geriatr Med** 1999 Aug;15(3):579–605 (140 ref.)

Disorders of the pancreas in children. Werlin SL. **Curr Opin Pediatr** 1998 Oct;10(5):507–11 (25 ref.)

Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. Tung BY, et al. **Gastrointest Endosc** 1999 May;49(5):647–51 (18 ref.)

[Acute pancreatitis] Shinagawa N. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):506–9 (7 ref.) **(Jpn)**

CHEMICALLY INDUCED

Drug-induced pancreatitis (lisinopril). Miller LG, et al. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):150–3 (17 ref.)

Asymptomatic pancreatitis associated with clozapine. Bergemann N, et al. **Pharmacopsychiatry** 1999 Mar; 32(2):78–80 (9 ref.)

Drug-induced hypertriglyceridemia with and without pancreatitis. Keung YK, et al. **South Med J** 1999 Sep; 92(9):912–4 (22 ref.)

[Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature] Decocq G, et al. **Therapie** 1999 Jan–Feb; 54(1):41–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[5-Aminosalicylic acid-induced acute pancreatitis (letter)] Mari B, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):28–9 (10 ref.) **(Spa)**

[Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease] Velicia MR, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):186–7 (15 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Acute pancreatitis. Classification, diagnosis, therapy] Sulkowski U, et al. **Anaesthesist** 1998 Sep;47(9):765–77 (103 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Post-traumatic pancreatitis with associated aneurysm of the splenic artery: report of 2 cases and review of the literature. Tandon V, et al. **Can J Surg** 1999 Jun;42(3):215–9 (28 ref.)

Pancreatitis, cytokines, and SIRS: déjà vu all over again? [editorial; comment] Giroir BP. **Crit Care Med** 1999 Apr; 27(4):680–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):749–55.

Primary hyperparathyroidism and acute pancreatitis during pregnancy. Report of a case and a review of the English and Japanese literature. Kondo Y, et al. **Int J Pancreatol** 1998 Aug;24(1):43–7 (24 ref.)

Complete agenesis of the dorsal pancreas. Fukuoka K, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):94–7 (20 ref.)

Palliation of pain in chronic pancreatitis. Use of enzymes. Mössner J. **Surg Clin North Am** 1999 Aug;79(4):861–72, xi (64 ref.)

Palliation of pain in chronic pancreatitis. Use of neural blocks and neurotomy. Wong GY, et al. **Surg Clin North Am** 1999 Aug;79(4):873–93 (71 ref.)

[Cystic dystrophy of the duodenal wall in aberrant pancreas] Wind P, et al. **Ann Chir** 1999;53(2):164–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Eosinophilic pancreatitis: a difficult diagnosis (letter)] Descamps C, et al. **Gastroenterol Clin Biol** 1998 Nov; 22(11):970–2 (9 ref.) **(Fre)**

[Secondary diabetes in chronic pancreatitis] Raue G, et al. **Z Gastroenterol** 1999 Jun;Suppl 1:4–9 (36 ref.) (Eng. Abstr.) **(Ger)**

[Gastric and duodenal intramural hematoma: report of two cases] Dibuz M, et al. **Orv Hetil** 1998 Dec 6;139(49):2963 (39 ref.) (Eng. Abstr.) **(Hun)**

[US or CT-guided percutaneous drainage of pancreatic pseudocyst] Palmeri R, et al. **Chir Ital** 1997;49(4–5):11–6 (26 ref.) (Eng. Abstr.) **(Ita)**

[Ischemic necrosis of the spleen and gastric fundus. A rare complication of acute pancreatitis (letter)] Soria Aledo V, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):209 (8 ref.) **(Spa)**

DIAGNOSIS

Amylase normal, lipase elevated: is it pancreatitis? A case series and review of the literature. Frank B, et al. **Am J Gastroenterol** 1999 Feb;94(2):463–9 (27 ref.)

Acute pancreatitis associated with viral hepatitis: a report of six cases with review of literature. Mishra A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2292–5 (27 ref.)

Phospholipases A2--what are they and what is their clinical significance in acute pancreatitis? Grönroos JM, et al. **Ann Chir Gynaecol** 1998;87(3):196–9 (27 ref.)

Diagnosis of acute pancreatitis. Kemppainen E, et al. **Ann Chir Gynaecol** 1998;87(3):191–4 (22 ref.)

Pancreatic cancer in patients with chronic pancreatitis: a challenge from a surgical perspective. Sakorafas GH, et al. **Cancer Treat Rev** 1999 Aug;25(4):207–17 (154 ref.)

First report of association of chronic pancreatitis, primary biliary cirrhosis, and systemic sclerosis. Hastier P, et al. **Dig Dis Sci** 1998 Nov;43(11):2426–8 (17 ref.)

Chronic pancreatitis with diffuse irregular narrowing of the main pancreatic duct. Wakabayashi T, et al. **Dig Dis Sci** 1998 Nov;43(11):2415–25 (19 ref.)

Autoimmune pancreatitis, pancreatic mass, and lower gastrointestinal bleed. Venu RP, et al. **J Clin Gastroenterol** 1999 Jun;28(4):364–7 (17 ref.)

When should you suspect pancreatitis? Larvin M. **Practitioner** 1997 Sep;241(1578):544–7 (8 ref.)

Diagnosis of chronic pancreatitis. Is a gold standard necessary? Clain JE, et al. **Surg Clin North Am** 1999 Aug; 79(4):829–45 (72 ref.)

[Eosinophilic pancreatitis: a difficult diagnosis (letter)] Descamps C, et al. **Gastroenterol Clin Biol** 1998 Nov; 22(11):970–2 (9 ref.) **(Fre)**

[Malignant pancreatic non-hodgkin's lymphoma manifesting as severe acute pancreatitis] Mofredj A, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):528–31 (21 ref.) (Eng. Abstr.) **(Fre)**

[The patient with isolated pancreatic enzyme elevation] Spangenberg HC. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1575–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Recent progress in diagnosis and treatment of chronic pancreatitis] Hayakawa T. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):1–7 (41 ref.) **(Jpn)**

[Acute recurrent pancreatitis in a patient with Oddi's sphincter dysfunction] Tomás A, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):279–81 (18 ref.) (Eng. Abstr.) **(Spa)**

[Macroamylasemia in the differential diagnosis of acute pancreatitis] Domènech Calvet J, et al. **Rev Clin Esp** 1999 Jul;199(7):440–1 (7 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Nutritional management of patients with feeding-induced pain: acute pancreatitis. Seidner DL, et al. **Semin Gastrointest Dis** 1998 Oct;9(4):200–9 (58 ref.)

DRUG THERAPY

Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis. Johnson CD. **Dig Surg** 1999;16(2):93–101 (85 ref.)

Chronic pancreatitis at Manchester, UK. Focus on antioxidant therapy. McCloy R. **Digestion** 1998;59 Suppl 4:36–48 (55 ref.)

The role of octreotide and somatostatin in acute and chronic pancreatitis. Uhl W, et al. **Digestion** 1999;60 Suppl 2:23–31 (95 ref.)

Selenium deficiency and chronic pancreatitis: disease mechanism and potential for therapy. Bowrey DJ, et al. **HPB Surg** 1999;11(4):207–15; discussion 215–6 (41 ref.)

The potential role of therapeutic cytokine manipulation in acute pancreatitis. Denham W, et al. **Surg Clin North Am** 1999 Aug;79(4):767–81 (79 ref.)

Palliation of pain in chronic pancreatitis. Use of enzymes. Mössner J. **Surg Clin North Am** 1999 Aug;79(4):861–72, xi (64 ref.)

[Synthetic protease inhibitors for human acute pancreatitis] Otani T. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov; 95(11):1205–11 (24 ref.) **(Jpn)**

ENZYMOLOGY

Phospholipases A2--what are they and what is their clinical significance in acute pancreatitis? Grönroos JM, et al. **Ann Chir Gynaecol** 1998;87(3):196–9 (27 ref.)

Xenobiotic metabolism, oxidant stress and chronic pancreatitis. Focus on glutathione. Wallig MA. **Digestion** 1998;59 Suppl 4:13–24 (100 ref.)

ETIOLOGY

Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? [see comments] Barthet M, et al. **Am J Gastroenterol** 1999 Aug;94(8):2141–8 (42 ref.) Comment in: Am J Gastroenterol 1999 Aug;94(8):2001.

Acute pancreatitis after gynecologic and obstetric surgery. Ramsey PS, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):542–6 (15 ref.)

Early ERCP is an essential part of the management of all cases of acute pancreatitis. Gupta R, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1):46–50 (23 ref.)

A framework for the aetiogenesis of chronic pancreatitis. Braganza JM. **Digestion** 1998;59 Suppl 4:1–12 (106 ref.)

Pancreatitis in Soweto, South Africa. Focus on alcohol-related disease. Segal I. **Digestion** 1998;59 Suppl 4:25–35 (95 ref.)

Xenobiotic metabolism, oxidant stress and chronic pancreatitis. Focus on glutathione. Wallig MA. **Digestion** 1998;59 Suppl 4:13–24 (100 ref.)

The role of ERCP and sphincterotomy in acute biliary pancreatitis. Fölsch UR. **Endoscopy** 1998 Nov;30(9):A253–5 (13 ref.)

Selenium deficiency and chronic pancreatitis: disease mechanism and potential for therapy. Bowrey DJ, et al. **HPB Surg** 1999;11(4):207–15; discussion 215–6 (41 ref.)

Biliary pancreatitis: a review. Emphasizing appropriate endoscopic intervention. Frakes JT. **J Clin Gastroenterol** 1999 Mar;28(2):97–109 (100 ref.)

Acute pancreatitis in adult type IV congenital cyst of bile ducts: report of two cases. Manes G, et al. **J Clin Gastroenterol** 1999 Jan;28(1):70–3 (24 ref.)

Nutritional management of patients with feeding-induced pain: acute pancreatitis. Seidner DL, et al. **Semin Gastrointest Dis** 1998 Oct;9(4):200–9 (58 ref.)

Etiopathogenesis of acute pancreatitis. Karne S, et al. **Surg Clin North Am** 1999 Aug;79(4):699–710 (64 ref.)

Acute cholangitis and pancreatitis secondary to common duct stones: management update. Raraty MG, et al.

World J Surg 1998 Nov;22(11):1155–61 (74 ref.)
[Acute biliary pancreatitis] Farinon AM. **Ann Ital Chir** 1998 Nov–Dec;69(6):751–63 (120 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Detection of Ki-ras oncogene mutations in pancreatic diseases: helpful or irrelevant? Van Laethem JL. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):295–7 (33 ref.)
Ki-ras oncogene mutations in chronic pancreatitis: which discriminating ability for malignant potential? van Laethem JL. **Ann N Y Acad Sci** 1999 Jun 30;880:210–8 (22 ref.)
Paediatric and hereditary aspects of chronic pancreatitis. Dodge JA. **Digestion** 1998;59 Suppl 4:49–59 (87 ref.)
Hereditary pancreatitis: new insights into acute and chronic pancreatitis. Whitcomb DC. **Gut** 1999 Sep;45(3):317–22 (79 ref.)
Three generations of hereditary chronic pancreatitis. Hoshina K, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1192–8 (44 ref.)
Are mutations in the cystic fibrosis gene important in chronic pancreatitis? Cohn JA, et al. **Surg Clin North Am** 1999 Aug; 79(4):723–31, viii (30 ref.)
Hereditary pancreatitis. Gene defects and their implications. Gates LK Jr, et al. **Surg Clin North Am** 1999 Aug; 79(4):711–22, vii–viii (22 ref.)
The pathogenic consequences of a single mutated CFTR gene. Griesenbach U, et al. **Thorax** 1999 Aug;54 Suppl 2:S19–23 (36 ref.)

IMMUNOLOGY

Pancreatitis, cytokines, and SIRS: déjà vu all over again? [editorial; comment] Giroir BP. **Crit Care Med** 1999 Apr; 27(4):680–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):749–55.

METABOLISM

Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis. Johnson CD. **Dig Surg** 1999;16(2):93–101 (85 ref.)
A framework for the aetiogenesis of chronic pancreatitis. Braganza JM. **Digestion** 1998;59 Suppl 4:1–12 (106 ref.)
Pancreatitis in Soweto, South Africa. Focus on alcohol-related disease. Segal I. **Digestion** 1998;59 Suppl 4:25–35 (95 ref.)
Role of oxidative stress in the pathogenesis of caerulein-induced acute pancreatitis. Dąbrowski A, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):1–11 (61 ref.)
[Inflammatory mediators in the acute pancreatitis] Markert R, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):100–3 (32 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

The role of infection in acute pancreatitis. Schmid SW, et al. **Gut** 1999 Aug;45(2):311–6 (83 ref.)

PATHOLOGY

A framework for the aetiogenesis of chronic pancreatitis. Braganza JM. **Digestion** 1998;59 Suppl 4:1–12 (106 ref.)
The morphological changes of exocrine pancreas in chronic pancreatitis. Ashizawa N, et al. **Histol Histopathol** 1999 Apr;14(2):539–52 (53 ref.)
Staging of acute pancreatitis. Is it important? McKay CJ, et al. **Surg Clin North Am** 1999 Aug;79(4):733–43 (38 ref.)

PHYSIOPATHOLOGY

Gut barrier dysfunction in experimental acute pancreatitis. Andersson R, et al. **Ann Acad Med Singapore** 1999 Jan; 28(1):141–6 (31 ref.)
New concepts in understanding the pathophysiology of chronic pancreatitis. Freedman SD. **Int J Pancreatol** 1998 Aug;24(1):1–8 (54 ref.)
The potential role of therapeutic cytokine manipulation in acute pancreatitis. Denham W, et al. **Surg Clin North Am** 1999 Aug;79(4):767–81 (79 ref.)
Early and late onset in idiopathic and alcoholic chronic pancreatitis. Different clinical courses. Layer P, et al. **Surg Clin North Am** 1999 Aug;79(4):847–60 (23 ref.)
[Are endoscopic treatments of pain during chronic pancreatitis justified] Lévy P. **Gastroenterol Clin Biol** 1999 Apr;23(4):465–8 (15 ref.) **(Fre)**
[Calculated gastric intramucosal pH changes in the early phase of acute pancreatitis] Kovács GC, et al. **Orv Hetil** 1999 Apr 25;140(17):941–5 (17 ref.) (Eng. Abstr.) **(Hun)**
[Endocrine organ function in chronic pancreatitis] Khrystych TM, et al. **Lik Sprava** 1998 Jun;(4):33–41 (55 ref.) **(Ukr)**

PREVENTION & CONTROL

Prophylactic antibiotics for severe acute pancreatitis: the beginning of an era. Kramer KM, et al. **Pharmacotherapy** 1999 May;19(5):592–602 (39 ref.)

RADIOGRAPHY

Acute pancreatitis: the role of diagnostic imaging. Dalzell DP, et al. **Crit Rev Diagn Imaging** 1998 Sep;39(5):339–63 (42 ref.)
CT demonstration of fibrous stroma in chronic pancreatitis: pathologic correlation. Kusano S, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):297–300 (11 ref.)
[Actinomycosis and chronic pancreatitis] Begemann P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):170–2 (0 ref.) **(Ger)**

SURGERY

The surgical management of chronic pancreatitis: the Frey procedure. Frey CF. **Adv Surg** 1999;32:41–85 (76 ref.)
The surgical management of chronic pancreatitis: pancreatic duct drainage. Harrison JL, et al. **Adv Surg** 1999;32:1–21 (53 ref.)
Surgical treatment of acute pancreatitis. Beger HG, et al. **Ann Chir Gynaecol** 1998;87(3):183–9 (11 ref.)
Pancreatic cancer in patients with chronic pancreatitis: a challenge from a surgical perspective. Sakorafas GH, et al. **Cancer Treat Rev** 1999 Aug;25(4):207–17 (154 ref.)
To what extent is surgery superior to endoscopic therapy in the management of chronic pancreatitis? Bassi C, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):571–9 (35 ref.)
Endoscopic treatment in chronic pancreatitis. Laugier R, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):566–70 (46 ref.)
Endoscopic sphincterotomy for acute pancreatitis: arguments against. Nitsche R, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):562–5 (9 ref.)
Endoscopic sphincterotomy for acute pancreatitis: arguments in favour. Uomo G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):557–61 (58 ref.)
Surgical treatment of chronic pancreatitis and quality of life after operation. Izbicki JR, et al. **Surg Clin North Am** 1999 Aug;79(4):913–44 (92 ref.)
Interventional treatment of acute and chronic pancreatitis. Endoscopic procedures. Norton ID, et al. **Surg Clin North Am** 1999 Aug;79(4):895–911, xii (82 ref.)
Interventional management of peripancreatic fluid collections. Traverso LW, et al. **Surg Clin North Am** 1999 Aug;79(4):745–57, viii–ix (4 ref.)

THERAPY

Current principles of treatment in acute pancreatitis. Puolakkainen P, et al. **Ann Chir Gynaecol** 1998;87(3):200–3 (27 ref.)
Non-surgical treatments for chronic pancreatitis. Suga T. **Hokkaido Igaku Zasshi** 1999 Mar;74(2):105–11 (11 ref.)
Biliary pancreatitis: a review. Emphasizing appropriate endoscopic intervention. Frakes JT. **J Clin Gastroenterol** 1999 Mar;28(2):97–109 (100 ref.)
Chronic pancreatitis: pathogenesis and management of pain [published erratum appears in J Clin Gastroenterol 1999 Mar;28(2):109] Pitchumoni CS. **J Clin Gastroenterol** 1998 Sep;27(2):101–7 (40 ref.)
Pain relief and functional recovery after endoscopic interventions for chronic pancreatitis. Pap A, et al. **Scand J Gastroenterol Suppl** 1998;228:98–106 (67 ref.)
[Randomized therapeutic trials in the treatment of acute pancreatitis: 1986–1996] Millat B, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):29–39 (80 ref.) **(Fre)**
[How to proceed? ERCP in acute pancreatitis?] Forssmann K, et al. **Schweiz Rundsch Med Prax** 1999 Jan 7; 88(1–2):13–7 (14 ref.) (Eng. Abstr.) **(Ger)**
[Chronic pancreatitis: nutrition and pain therapy] Mössner J. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1548–57 (84 ref.) (Eng. Abstr.) **(Ger)**
[Pancreaticolithiasis and pancreatic pseudocysts--interventional therapy] Vogt W. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1558–62 (15 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Dassopoulos T, et al. **Am J Med** 1999 Jul;107(1):78–84 (102 ref.)

PANCREATITIS, ACUTE NECROTIZING

CHEMICALLY INDUCED

Clozapine-associated pancreatitis. Cerulli TR. **Harv Rev Psychiatry** 1999 May–Jun;7(1):61–3 (15 ref.)

COMPLICATIONS

[Preventing the development of secondary infections in severe acute pancreatitis] Gürlich R, et al. **Rozhl Chir** 1999 Feb;78(2):63–7 (24 ref.) (Eng. Abstr.) **(Cze)**
[Splenic pseudoaneurysms following acute pancreatitis] Cirocchi R, et al. **Minerva Chir** 1999 Apr;54(4):277–82 (66 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Definition of predictors of a complicated course in acute pancreatitis] Uhl W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:427–33 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Nonsurgical management of acute pancreatitis. Use of antibiotics. Rünzi M, et al. **Surg Clin North Am** 1999 Aug; 79(4):759–65, ix (30 ref.)

ETIOLOGY

Acute pancreatitis as a complication of polyarteritis nodosa. Flaherty J, et al. **Int J Pancreatol** 1999 Feb;25(1):53–7 (24 ref.)
Ischemic necrotizing pancreatitis. Two case reports and review of the literature. Sakorafas GH, et al. **Int J Pancreatol** 1998 Oct;24(2):117–21 (45 ref.)

MICROBIOLOGY

Fungal infection in acute necrotizing pancreatitis. Grewe M, et al. **J Am Coll Surg** 1999 Apr;188(4):408–14 (33 ref.)

PHYSIOPATHOLOGY

[Role of protease activation in pathophysiology of acute pancreatitis] Lerch MM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:421–6 (5 ref.) (Eng. Abstr.) **(Ger)**
[Pathogenesis of pancreatogenic sepsis] Runkel N. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:439–42 (6 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical management of necrotizing pancreatitis. Beger HG, et al. **Surg Clin North Am** 1999 Aug;79(4):783–800, ix (50 ref.)
[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:72–7 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The management of severe acute necrotising pancreatitis: an evidence-based review of the literature. Wyncoll DL. **Intensive Care Med** 1999 Feb;25(2):146–56 (62 ref.)
Acute necrotizing pancreatitis [published erratum appears in N Engl J Med 1999 Aug 5;341(6):460] Baron TH, et al. **N Engl J Med** 1999 May 6;340(18):1412–7 (52 ref.)
[Acute pancreatitis: reliable and prospective conservative therapy] Schmidt J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:434–8 (41 ref.) (Eng. Abstr.) **(Ger)**
[Non-glucose carbohydrates in the parenteral nutrition of patients with systemic inflammatory response syndrome] López Martínez J, et al. **Nutr Hosp** 1999 Mar–Apr; 14(2):71–80 (35 ref.) (Eng. Abstr.) **(Spa)**

PANCREATITIS, ALCOHOLIC

CLASSIFICATION

Progression from acute to chronic pancreatitis: a physician's view. Lankisch PG. **Surg Clin North Am** 1999 Aug; 79(4):815–27, x (49 ref.)

COMPLICATIONS

[Splenic pseudoaneurysms following acute pancreatitis] Cirocchi R, et al. **Minerva Chir** 1999 Apr;54(4):277–82 (66 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Alcohol and the pancreas. Schenker S, et al. **Recent Dev Alcohol** 1998;14:41–65 (128 ref.)

PATHOLOGY

Progression from acute to chronic pancreatitis. A pathologist's view. Klöppel G. **Surg Clin North Am** 1999 Aug;79(4):801–14 (54 ref.)
Progression from acute to chronic pancreatitis: a physician's view. Lankisch PG. **Surg Clin North Am** 1999 Aug; 79(4):815–27, x (49 ref.)

PHYSIOPATHOLOGY

A review: acute and chronic effects of ethanol and alcoholic beverages on the pancreatic exocrine secretion in vivo and in vitro. Niebergall-Roth E, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1570–83 (153 ref.)
Early and late onset in idiopathic and alcoholic chronic pancreatitis. Different clinical courses. Layer P, et al. **Surg Clin North Am** 1999 Aug;79(4):847–60 (23 ref.)

SURGERY

Pancreaticoduodenectomy for chronic pancreatitis: a case report and literature review. Riker A, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):2005–10 (21 ref.)

PANCREATODUODENECTOMY see **PANCREATICODUODENECTOMY**

PANCREATOJEJUNOSTOMY see **PANCREATICOJEJUNOSTOMY**

PANCREATOPEPTIDASE

METABOLISM

Elastin-elastase-atherosclerosis revisited. Robert L, et al. **Atherosclerosis** 1998 Oct;140(2):281-95 (86 ref.)

PHYSIOLOGY

EVE and beyond, retro and prospective insights. Rabinovitch M. **Am J Physiol** 1999 Jul;277(1 Pt 1):L5-12 (34 ref.)

PANCREOZYMIN see **CHOLECYSTOKININ**

PANCREOZYMIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PANCYTOPENIA

ETIOLOGY

[Febrile pancytopenia in the course of AIDS: a hemophagocytic syndrome (letter)] Fiszbin M, et al. **Rev Med Interne** 1998 Sep;19(9):673-5 (14 ref.) **(Fre)**

PANDAS, GIANT see **BEARS**

PANDAS, GREATER see **BEARS**

PANDAS, LESSER see **CARNIVORA**

PANENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

PANIC ATTACKS see **PANIC DISORDER**

PANIC DISORDER

Relationship between panic and schizophrenia. Hofmann SG. **Depress Anxiety** 1999;9(3):101-6 (65 ref.)

Panic disorder and asthma. Carr RE. **J Asthma** 1999; 36(2):143-52 (72 ref.)

Panic disorder: the ultimate anxiety. Sansone RA, et al. **J Womens Health** 1998 Oct;7(8):983-9 (69 ref.)

COMPLICATIONS

[Atypical thoracic pain. Panic disorder] Kornreich Ch. **Rev Med Brux** 1998 Dec;19(6):508-10 (11 ref.) **(Fre)**

DIAGNOSIS

An investigation of anxious thought in patients with DSM-IV agoraphobia/panic disorder: rationale and design. Compton A. **J Am Psychoanal Assoc** 1998;46(3):691-721 (105 ref.)

Panic disorder in children and adolescents: new developments, new directions. Ollendick TH. **J Clin Child Psychol** 1998 Oct;27(3):234-45 (70 ref.)

Panic disorder in children and adolescents. Masi G, et al. **Panminerva Med** 1999 Jun;41(2):153-6 (32 ref.)

Blocking the cycle of panic disorder. Ways to gain control of the fear of fear. Vanin JR, et al. **Postgrad Med** 1999 May 1;105(5):141-6; quiz 205 (20 ref.)

DRUG THERAPY

Rational treatment of panic disorder with antidepressants. Mavissakalian MR, et al. **Ann Clin Psychiatry** 1998 Dec; 10(4):185-95 (29 ref.)

Serotonin and panic. Bell CJ, et al. **Br J Psychiatry** 1998 Jun;172:465-71 (42 ref.)

SSRIs in the treatment of panic disorder. Goddard AW, et al. **Depress Anxiety** 1998;8 Suppl 1:114-20 (54 ref.)

Comorbidity of panic and depression: implications for clinical management. Ballenger JC. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S13-7 (31 ref.)

Review of current treatment in panic disorder. den Boer JA, et al. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S25-30 (51 ref.)

The issue of comorbidity in the treatment of panic. Dunner DL. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S19-24 (40 ref.)

Antidepressants in panic disorder. Wade AG. **Int Clin Psychopharmacol** 1999 May;14 Suppl 2:S13-7 (19 ref.)

Current concepts in the treatment of panic disorder. Sheehan DV. **J Clin Psychiatry** 1999;60 Suppl 18:16-21 (43 ref.)

Panic disorder: long-term pharmacotherapy and discontinuation. Rickels K, et al. **J Clin Psychopharmacol** 1998 Dec;18(6 Suppl 2):12S-18S (45 ref.)

Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Blier P, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):91S-98S (58 ref.)

EPIDEMIOLOGY

Generalized anxiety disorder and its comorbidities: disputes at the boundaries. Maser JD. **Acta Psychiatr Scand Suppl** 1998;393:12-22 (100 ref.)

[Genetic epidemiology and psychiatry (I): scope and limitations of familial studies. Case of panic disorder] Gorwood P, et al. **Encephale** 1999 Jan-Feb;25(1):21-9 (47 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

The first panic attack: a neurobiological theory. Jacobs WJ, et al. **Can J Exp Psychol** 1999 Mar;53(1):92-107 (148 ref.)

Panic disorder from a monistic perspective: integrating neurobiological and psychological approaches. Windmann S. **J Anxiety Disord** 1998 Sep-Oct;12(5):485-507 (107 ref.)

Search for pathophysiology of panic disorder [see comments] Roy-Byrne PP, et al. **Lancet** 1998 Nov 21;352(9141):1646-7 (22 ref.) Comment in: Lancet 1999 Jan 23;353(9149):326-7.

GENETICS

[Genetic epidemiology and psychiatry (I): scope and limitations of familial studies. Case of panic disorder] Gorwood P, et al. **Encephale** 1999 Jan-Feb;25(1):21-9 (47 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Brain circuits in panic disorder. Coplan JD, et al. **Biol Psychiatry** 1998 Dec 15;44(12):1264-76 (67 ref.)

The neurobiology of social phobia. Bell CJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S11-8 (53 ref.)

The role of serotonin in panic, anxiety and depression. Deakin JF. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S1-5 (19 ref.)

The long-term course of panic disorder and its predictors. Katschnig H, et al. **J Clin Psychopharmacol** 1998 Dec;18(6 Suppl 2):6S-11S (37 ref.)

Experimental pathophysiology of panic. Griez E, et al. **J Psychosom Res** 1998 Dec;45(6):493-503 (87 ref.)

Search for pathophysiology of panic disorder [see comments] Roy-Byrne PP, et al. **Lancet** 1998 Nov 21;352(9141):1646-7 (22 ref.) Comment in: Lancet 1999 Jan 23;353(9149):326-7.

Do panic disorder and posttraumatic stress disorder share a common psychoneuroendocrinology? Kellner M, et al. **Psychoneuroendocrinology** 1999 Jul;24(5):485-504 (160 ref.)

PREVENTION & CONTROL

Blocking the cycle of panic disorder. Ways to gain control of the fear of fear. Vanin JR, et al. **Postgrad Med** 1999 May 1;105(5):141-6; quiz 205 (20 ref.)

PSYCHOLOGY

Unconscious pregnancy fantasies as an underlying dynamism in panic disorder. Milrod B. **J Am Psychoanal Assoc** 1998; 46(3):673-90 (24 ref.)

The impact of pregnancy and puerperium on panic disorder: a review. Hertzberg T, et al. **J Psychosom Obstet Gynaecol** 1999 Jun;20(2):59-64 (23 ref.)

THERAPY

Combined pharmacotherapy and cognitive behavior therapy in the treatment of panic disorder. Gelder MG. **J Clin Psychopharmacol** 1998 Dec;18(6 Suppl 2):2S-5S (13 ref.)

Panic control treatment and its applications. Hofmann SG, et al. **J Psychother Pract Res** 1999 Winter;8(1):3-11 (75 ref.)

Panic disorder in children and adolescents. Masi G, et al. **Panminerva Med** 1999 Jun;41(2):153-6 (32 ref.)

[Cognitive therapy has been shown to be effective in panic disorder] d'Elia G, et al. **Lakartidningen** 1998 Oct 28; 95(44):4869-72 (22 ref.) (Eng. Abstr.) **(Swe)**

PANNICULITIS

[Histiocytic cytophagic panniculitis, Weber-Christian disease and nodular fat necrosis] Kitamura K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):397-9 (5 ref.) **(Jpn)**

CHEMICALLY INDUCED

Panniculitis induced by collagen and plexiglas microsphere injections used for aesthetic treatment. Biasi D, et al. **Clin Rheumatol** 1999;18(4):328-9 (15 ref.)

CLASSIFICATION

[Current classification of panniculitis] Henry F, et al. **Rev Med Liege** 1998 Oct;53(10):603-9 (43 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Cytophagic histiocytic panniculitis--what is the best therapy? [editorial; comment] Okamura T, et al. **Intern Med** 1999 Mar;38(3):224-5 (11 ref.) Comment on: Intern Med 1999 Mar;38(3):296-301.

ETIOLOGY

Neutrophilic lobular (pustular) panniculitis associated with rheumatoid arthritis: a case report and review of the literature. Tran TA, et al. **Am J Dermatopathol** 1999 Jun; 21(3):247-52 (62 ref.)

Lipoatrophia semicircularis--a traumatic panniculitis: report of seven cases and review of the literature. Nagore E, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):879-81 (18 ref.)

Panniculitis in juvenile dermatomyositis. Ghali FE, et al. **Pediatr Dermatol** 1999 Jul-Aug;16(4):270-2 (11 ref.)

PATHOLOGY

Cytophagic histiocytic panniculitis--a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. Craig AJ, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):721-36 (71 ref.)

[Current classification of panniculitis] Henry F, et al. **Rev Med Liege** 1998 Oct;53(10):603-9 (43 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Panniculitis ossificans and review of the literature] Qi P, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):207-8 (8 ref.) (Eng. Abstr.) **(Chi)**

PANNICULITIS, NODULAR NONSUPPURATIVE

[Histiocytic cytophagic panniculitis, Weber-Christian disease and nodular fat necrosis] Kitamura K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):397-9 (5 ref.) **(Jpn)**

DIAGNOSIS

[Pfeifer-Weber-Christian disease with a 20-year course] Asauliuk IK, et al. **Lik Sprava** 1998 Oct-Nov;(7):154-9 (7 ref.) (Eng. Abstr.) **(Rus)**

PANNICULITIS, SUBACUTE NODULAR MIGRATORY see **PANNICULITIS**

PANORAMIC RADIOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTHERA see **CARNIVORA**

PANTHERS see **CARNIVORA**

PANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTOTHENIC ACID

Optimum nutrition: thiamin, biotin and pantothenate. Bender DA. **Proc Nutr Soc** 1999 May;58(2):427-33 (64 ref.)

ANALOGS & DERIVATIVES

[Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate] Noda S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):538-41 (15 ref.) **(Jpn)**

PAP-I see **ANNEXIN V**

PAPANICOLAOU SMEAR see **VAGINAL SMEARS**

PAPAVER

see related
OPIUM

PAPAVERETUM see **OPIUM**

PAPILLARY MUSCLES

see related
CHORDAE TENDINEAE

ABNORMALITIES

MR findings in Shone's complex of left heart obstructive lesions. Roche KJ, et al. **Pediatr Radiol** 1998 Nov; 28(11):841-5 (6 ref.)

CYTOLOGY

Reappraisal of the multicellular preparation for the in vitro physiopharmacological evaluation of myocardial performance. Sys SU, et al. **Adv Exp Med Biol** 1998; 453:441-50; discussion 451 (34 ref.)

EMBRYOLOGY

Myoblast cell grafting into heart muscle: cellular biology and potential applications. Kessler PD, et al. **Annu Rev Physiol** 1999;61:219-42 (165 ref.)

PATHOLOGY

Mitral valve repair for anterior leaflet papillary fibroelastoma: two case descriptions and a literature review. Di Mattia DG, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):103-7 (36 ref.)

PHYSIOLOGY

Reappraisal of the multicellular preparation for the in vitro physiopharmacological evaluation of myocardial performance. Sys SU, et al. **Adv Exp Med Biol** 1998; 453:441-50; discussion 451 (34 ref.)

SURGERY

Hypertrophic obstructive cardiomyopathy. Messmer BJ, et al. **Adv Card Surg** 1998;10:245-70 (60 ref.)

Mitral valve replacement with preservation of the subvalvular apparatus. Reardon MJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):104–10 (49 ref.)

PAPILLEDEMA

see related
OPHTHALMOSCOPY

DIAGNOSIS

[Bilateral optic disk edema in polyneuropathy, organomegaly, endocrinopathy, monoclonal proteins and skin changes (POEMS syndrome)] Barry JC, et al. **Klin Monatsbl Augenheilkd** 1999 Jul;215(1):59–63 (24 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Optic disc swelling in Crohn's disease [published erratum appears in Aust N Z J Ophthalmol 1999 Apr;27(2):161] Walker JC, et al. **Aust N Z J Ophthalmol** 1998 Nov; 26(4):329–32 (44 ref.)

Papilloedema secondary to acute purulent sinusitis. Kumar RK, et al. **J Paediatr Child Health** 1999 Aug;35(4):396–8 (11 ref.)

PATHOLOGY

[Papillary edema and the POEMS syndrome] Gatinel D, et al. **J Fr Ophtalmol** 1998 Feb;21(2):133–41 (39 ref.) (Eng. Abstr.) **(Fre)**

PAPILLOMA

see related
WARTS

Recurrent respiratory papillomatosis. Murray LN, et al. **J La State Med Soc** 1998 Oct;150(10):456–9 (15 ref.)

METABOLISM

Upregulation of E2F transcription factors in chemically induced mouse skin tumors. Balasubramanian S, et al. **Int J Oncol** 1999 Aug;15(2):387–90 (25 ref.)

PATHOLOGY

Solitary pulmonary papillomas in adults: a clinicopathologic and in situ hybridization study of 14 cases combined with 27 cases in the literature. Flieder DB, et al. **Am J Surg Pathol** 1998 Nov;22(11):1328–42 (67 ref.)

Intraductal proliferations of the breast: a review of histologic criteria for atypical intraductal hyperplasia and ductal carcinoma in situ, including apocrine and papillary lesions. Purcell CA, et al. **Ann Diagn Pathol** 1998 Apr;2(2):135–45 (12 ref.)

Sialadenoma papilliferum of the palate: case report and literature review. Argyres MI, et al. **J Cutan Pathol** 1999 May;26(5):259–62 (34 ref.)

Juvenile-onset recurrent respiratory papillomatosis involving the lung: A case report and review of the literature. Magid MS, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):157–63 (29 ref.)

SURGERY

Aural papillomatosis—treatment with the carbon dioxide laser. Blair RL, et al. **J Laryngol Otol** 1998 Jun;112(6):565–6 (6 ref.)

[Breast malignancy in girls] Rzepka-Górska I, et al. **Ginekol Pol** 1999 May;70(5):311–4 (16 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

[Diagnostic and oncologic updating on gallbladder papilloma. Personal experience and review of the literature] Di Rienzo M, et al. **Ann Ital Chir** 1998 Sep–Oct;69(5):627–37 (47 ref.) (Eng. Abstr.) **(Ita)**

VIROLOGY

[Virologic aspects of juvenile laryngeal papillomatosis] Major T, et al. **Orv Hetil** 1999 Feb 21;140(8):405–9 (33 ref.) (Eng. Abstr.) **(Hun)**

PAPILLOMA, CHOROID PLEXUS see **GLIOMA**

PAPILLOMA, INTRADUCTAL

SURGERY

[Intraductal papilloma of the parotid gland] Brehmer D, et al. **Laryngorhinootologie** 1999 Jun;78(6):332–4 (14 ref.) (Eng. Abstr.) **(Ger)**

PAPILLOMA, INVERTED

[Clinical studies on inverted papilloma of the urinary tract] Asano K, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Apr; 90(4):514–20 (42 ref.) (Eng. Abstr.) **(Jpn)**

PAPILLOMA, SHOPE see **TUMOR VIRUS INFECTIONS**

PAPILLOMA, SQUAMOUS CELL see **PAPILLOMA**

PAPILLOMATOSIS see **PAPILLOMA**

PAPILLOMAVIRUS

see related
CONDYLOMATA ACUMINATA

Transmission of cervical cancer-associated human papilloma viruses from mother to child. Cason J, et al. **Intervirology** 1998;41(4–5):213–8 (44 ref.)

Canine papillomavirus—A centenary review. Nicholls PK, et al. **J Comp Pathol** 1999 Apr;120(3):219–33 (95 ref.)

[Papillomavirus] Shirasawa H. **Uirusu** 1998 Jun;48(1):27–37 (87 ref.) **(Jpn)**

IMMUNOLOGY

Potential strategies utilised by papillomavirus to evade host immunity. Frazer IH, et al. **Immunol Rev** 1999 Apr; 168:131–42 (82 ref.)

ISOLATION & PURIFICATION

Mucosotropic papillomavirus infections. Sundberg JP, et al. **Lab Anim Sci** 1998 Jun;48(3):240–2 (25 ref.)

PAPILLOMAVIRUS, HUMAN

Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening and HPV testing. Sigurdsson K. **Acta Obstet Gynecol Scand** 1999 Jul; 78(6):467–77 (126 ref.)

Is human papillomavirus testing of value in clinical practice? Kaufman RH, et al. **Am J Obstet Gynecol** 1999 May; 180(5):1049–53 (27 ref.)

Papillomaviruses: prophylactic vaccine prospects. Lowy DR, et al. **Biochim Biophys Acta** 1999 Jan 29;1423(1):M1–8 (60 ref.)

Advances in the diagnosis and treatment of human papillomavirus infections. Sedlacek TV. **Clin Obstet Gynecol** 1999 Jun;42(2):206–20 (20 ref.)

Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Gillison ML, et al. **Curr Opin Oncol** 1999 May;11(3):191–9 (110 ref.)

Relevance of photo-immunosuppression for viral infections (i.e. human papilloma virus). Vermeer BJ, et al. **Eur J Dermatol** 1998 Apr–May;8(3):205–6 (12 ref.)

Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. Leigh IM, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S49–57 (90 ref.)

Human papillomavirus infection with particular reference to genital disease. Sonnex C. **J Clin Pathol** 1998 Sep; 51(9):643–8 (65 ref.)

Recurrent respiratory papillomatosis. Murray LN, et al. **J La State Med Soc** 1998 Oct;150(10):456–9 (15 ref.)

Yohei Ito Memorial Lecture: Papillomaviruses in human cancers. zur Hausen H. **Leukemia** 1999 Jan;13(1):1–5 (40 ref.)

Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Spitzer M. **Obstet Gynecol Surv** 1999 Feb;54(2):131–7 (51 ref.)

Human papillomavirus infection in adolescents. Moscicki AB. **Pediatr Clin North Am** 1999 Aug;46(4):783–807 (90 ref.)

Juvenile-onset recurrent respiratory papillomatosis involving the lung: A case report and review of the literature. Magid MS, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):157–63 (29 ref.)

Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus. El-Attar SM, et al. **Prim Care** 1999 Mar;26(1):81–100 (32 ref.)

High risk genital papillomavirus infections are not spread vertically. Dillner J, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):23–9 (63 ref.)

High risk genital papillomavirus infections are spread vertically. Rice PS, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):15–21 (52 ref.)

The role of human papillomaviruses in anogenital cancers. Melbye M, et al. **Semin Cancer Biol** 1998 Aug;8(4):307–13 (79 ref.)

[HPV infection and its significance in cervical oncogenesis] Zlatkov V. **Akush Ginekol (Sofiia)** 1998;37(1):45–6 (16 ref.) **(Bul)**

[Biology of papillomavirus infections. IV. Sero-epidemiological data] Seilles E, et al. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):393–400 (53 ref.) (Eng. Abstr.) **(Fre)**

[Characteristics of anal carcinoma with therapeutic consequences] Hohenberger P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:363–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women] Küppers V, et al. **Zentralbl Gynakol** 1999;121(1):27–30 (5 ref.) (Eng. Abstr.) **(Ger)**

[Verruca plana juvenilis] Egawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):259–61 (12 ref.) **(Jpn)**

[HPV infection of the genital system: new findings] Hrgović Z, et al. **Lijec Vjesn** 1999 Jun;121(6):198–203 (49 ref.) (Eng. Abstr.) **(Scr)**

[The current concepts of the clinical picture, diagnosis and treatment of papillomavirus lesions of the female genitalia] Lakatosh VP, et al. **Lik Sprava** 1999 Apr–May;(3):29–37 (72 ref.) **(Ukr)**

[The current concepts of papillomavirus infection and its role in the pathogenesis of pretumorous and tumorous processes of the cervix uteri] Lakatosh VP, et al. **Lik Sprava** 1999 Mar;(2):22–31 (83 ref.) **(Ukr)**

CLASSIFICATION

Human papillomavirus (HPV) typing as an adjunct to cervical cancer screening. Syrjänen KJ, et al. **Cytopathology** 1999 Feb;10(1):8–15 (49 ref.)

GENETICS

Detection of human papilloma virus type 56 in extragenital Bowen's disease. Uezato H, et al. **Acta Derm Venereol** 1999 Jul;79(4):311–3 (18 ref.)

The molecular genetics of cervical carcinoma. Lazo PA. **Br J Cancer** 1999 Aug;80(12):2008–18 (116 ref.)

Epidemiology of genital human papillomavirus. Tortolero-Luna G. **Hematol Oncol Clin North Am** 1999 Feb;13(1):245–57, x (55 ref.)

Role of human papillomaviruses in warts and cancer. Proby CM, et al. **Hosp Med** 1998 Jan;59(1):33–6 (20 ref.)

Papilloma virus: tools and vectors. Hewson R. **Mol Med Today** 1999 Jan;5(1):8 (1 ref.)

Role of human papillomaviruses in the malignant transformation of keratinocytes. Achim R. **Rom J Virol** 1997 Jan–Dec;48(1–4):71–83 (14 ref.)

[Roles of HPV genes in carcinogenesis] Kiyono T. **Uirusu** 1998 Dec;48(2):125–35 (75 ref.) **(Jpn)**

IMMUNOLOGY

Papillomavirus vaccines. Duggan-Keen MF, et al. **Front Biosci** 1998 Dec 1;3:D1192–208 (195 ref.)

Human papillomavirus vaccines for cervical cancer. Murakami M, et al. **J Immunother** 1999 May;22(3):212–8 (60 ref.)

Papillomavirus-like particle vaccines for cervical cancer. Schiller JT. **Mol Med Today** 1999 May;5(5):209–15 (33 ref.)

[How technology and vaccination have changed the Pap test] Bondi A, et al. **Pathologica** 1999 Feb;91(1):36–41 (28 ref.) **(Ita)**

ISOLATION & PURIFICATION

Detection of human papillomaviruses in tissue specimens. Poljak M, et al. **Adv Anat Pathol** 1998 Jul;5(4):216–34 (134 ref.)

HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. Apgar BS, et al. **Am Fam Physician** 1999 May 15;59(10):2794–801 (29 ref.)

Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to papanicolaou smear in the triage of women with cervical cytologic abnormalities. Franco EL, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):382–6 (10 ref.)

Human papillomavirus (HPV) typing as an adjunct to cervical cancer screening. Syrjänen KJ, et al. **Cytopathology** 1999 Feb;10(1):8–15 (49 ref.)

Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Fazel N, et al. **Dermatol Clin** 1999 Jul;17(3):521–36, viii (138 ref.)

Epidemiology of genital human papillomavirus. Tortolero-Luna G. **Hematol Oncol Clin North Am** 1999 Feb;13(1):245–57, x (55 ref.)

[Detection of human papillomavirus infection by the nucleic acid hybridization method (a multicenter study)] Deák J, et al. **Orv Hetil** 1999 Jan 17;140(3):115–20 (32 ref.) (Eng. Abstr.) **(Hun)**

PATHOGENICITY

New concepts on the role of human papillomavirus in cell cycle regulation. Syrjänen SM, et al. **Ann Med** 1999 Jun; 31(3):175–87 (128 ref.)

Molecular targets for human papillomaviruses: prospects for antiviral therapy. Phelps WC, et al. **Antivir Chem Chemother** 1998 Sep;9(5):359–77 (230 ref.)

Human papillomavirus and the development of non-melanoma skin cancer. Harwood CA, et al. **J Clin Pathol** 1999 Apr;52(4):249–53 (51 ref.)

Human papillomaviruses and cervical cancer [editorial] McCance DJ. **J Med Microbiol** 1998 May;47(5):371–3 (9 ref.)

The role of the human papilloma virus in esophageal cancer. Sur M, et al. **Pathology** 1998 Nov;30(4):348–54 (65 ref.)

PHYSIOLOGY

HPV and cancer: the story unfolds. Campo MS. **Trends Microbiol** 1998 Nov;6(11):424–6 (20 ref.)

PAPILLON-LEFEVRE DISEASE

DIAGNOSIS

[The Papillon-Lefevre syndrome. A clinical and ultrastructural study of 2 cases] Antoni R, et al. **Minerva Stomatol** 1998 Sep;47(9):433–41 (32 ref.) (Eng. Abstr.) **(Ita)**

PAPIO

The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Allan JS. **Ann N Y Acad Sci** 1998 Dec 30;862:87–99 (76 ref.)

Late luteal rescue in the baboon (Papio cynocephalus). Castracane VD, et al. **Hum Reprod Update** 1998 Jul–Aug; 4(4):383–8 (12 ref.)

Pregnancy maintenance and the regulation of placental progesterone biosynthesis in the baboon. Henson MC. **Hum Reprod Update** 1998 Jul–Aug;4(4):389–405 (92 ref.)

Diet, plasma lipoproteins and experimental atherosclerosis in baboons (Papio sp.). Kushwaha RS, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):420–9 (78 ref.)

Central integrative role of oestrogen in the regulation of placental steroidogenic maturation and the development of the fetal pituitary–adrenocortical axis in the baboon. Pepe GJ, et al. **Hum Reprod Update** 1998 Jul–Aug; 4(4):406–19 (127 ref.)

PHYSIOLOGY

Comparative aspects of oxytocin in baboon (Papio hamadryus anubis) and human corpora lutea. Khan-Dawood FS, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):371–82 (100 ref.)

Ageing and social rank effects on the reproductive system of free-ranging yellow baboons (Papio cynocephalus) at Mikumi National Park, Tanzania. Wasser SK, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):430–8 (40 ref.)

PAPOVAVIRIDAE INFECTIONS

Advances in the diagnosis and treatment of human papillomavirus infections. Sedlacek TV. **Clin Obstet Gynecol** 1999 Jun;42(2):206–20 (20 ref.)

Role of human papillomaviruses in warts and cancer. Proby CM, et al. **Hosp Med** 1998 Jan;59(1):33–6 (20 ref.)

Recurrent respiratory papillomatosis. Murray LN, et al. **J La State Med Soc** 1998 Oct;150(10):456–9 (15 ref.)

Post-transplantation polyomavirus infections. Boubenider S, et al. **J Nephrol** 1999 Jan–Feb;12(1):24–9 (44 ref.)

[HPV infection of the genital system: new findings] Hrgović Z, et al. **Lijec Vjesn** 1999 Jun;121(6):198–203 (49 ref.) (Eng. Abstr.) **(Scr)**

COMPLICATIONS

BK virus as a potential co-factor in human cancer. Harris KF, et al. **Dev Biol Stand** 1998;94:81–91 (53 ref.)

Relevance of photo-immunosuppression for viral infections (i.e. human papilloma virus). Vermeer BJ, et al. **Eur J Dermatol** 1998 Apr–May;8(3):205–6 (12 ref.)

Human papillomavirus and the development of non-melanoma skin cancer. Harwood CA, et al. **J Clin Pathol** 1999 Apr;52(4):249–53 (51 ref.)

Human papillomavirus infection with particular reference to genital disease. Sonnex C. **J Clin Pathol** 1998 Sep; 51(9):643–8 (65 ref.)

Cell and molecular biology of simian virus 40: implications for human infections and disease. Butel JS, et al. **J Natl Cancer Inst** 1999 Jan 20;91(2):119–34 (134 ref.)

Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Spitzer M. **Obstet Gynecol Surv** 1999 Feb;54(2):131–7 (51 ref.)

[HPV infection and its significance in cervical oncogenesis] Zlatkov V. **Akush Ginekol (Sofiia)** 1998;37(1):45–6 (16 ref.) **(Bul)**

[The current concepts of papillomavirus infection and its role in the pathogenesis of pretumorous and tumorous processes of the cervix uteri] Lakatosh VP, et al. **Lik Sprava** 1999 Mar;(2):22–31 (83 ref.) **(Ukr)**

DIAGNOSIS

Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening and HPV testing. Sigurdsson K. **Acta Obstet Gynecol Scand** 1999 Jul; 78(6):467–77 (126 ref.)

HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. Apgar BS, et al. **Am Fam Physician** 1999 May 15;59(10):2794–801 (29 ref.)

Is human papillomavirus testing of value in clinical practice? Kaufman RH, et al. **Am J Obstet Gynecol** 1999 May; 180(5):1049–53 (27 ref.)

[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women] Küppers V, et al. **Zentralbl Gynakol** 1999;121(1):27–30 (5 ref.) (Eng. Abstr.) **(Ger)**

[Detection of human papillomavirus infection by the nucleic acid hybridization method (a multicenter study)] Deák J, et al. **Orv Hetil** 1999 Jan 17;140(3):115–20 (32 ref.) (Eng. Abstr.) **(Hun)**

[Verruca plana juvenilis] Egawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):259–61 (12 ref.) **(Jpn)**

[Advances in the diagnosis and treatment of infections caused by herpesvirus and JC virus] Arribas JR, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:11–9 (38 ref.) (Eng. Abstr.) **(Spa)**

[The current concepts of the clinical picture, diagnosis and treatment of papillomavirus lesions of the female genitalia] Lakatosh VP, et al. **Lik Sprava** 1999 Apr–May;(3):29–37 (72 ref.) **(Ukr)**

DRUG THERAPY

[Advances in the diagnosis and treatment of infections caused by herpesvirus and JC virus] Arribas JR, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:11–9 (38 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of genital human papillomavirus. Tortolero-Luna G. **Hematol Oncol Clin North Am** 1999 Feb;13(1):245–57, x (55 ref.)

[Biology of papillomavirus infections. IV. Sero-epidemiological data] Seilles E, et al. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):393–400 (53 ref.) (Eng. Abstr.) **(Fre)**

[How technology and vaccination have changed the Pap test] Bondi A, et al. **Pathologica** 1999 Feb;91(1):36–41 (28 ref.) **(Ita)**

GENETICS

SV40 DNA sequences in mesotheliomas. Gibbs AR, et al. **Dev Biol Stand** 1998;94:41–5 (8 ref.)

Simian virus 40 footprints in normal human tissues, brain and bone tumours of different histotypes. Martini F, et al. **Dev Biol Stand** 1998;94:55–66 (30 ref.)

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. Rizzo P, et al. **Dev Biol Stand** 1998;94:33–40 (19 ref.)

Search for SV40 in human mesotheliomas. Shah KV. **Dev Biol Stand** 1998;94:67–8 (5 ref.)

New molecular and epidemiological issues in mesothelioma: role of SV40. Carbone M, et al. **J Cell Physiol** 1999 Aug; 180(2):167–72 (34 ref.)

IMMUNOLOGY

Potential strategies utilised by papillomavirus to evade host immunity. Frazer IH, et al. **Immunol Rev** 1999 Apr; 168:131–42 (82 ref.)

[The biology of papillomavirus infections. III. Immune response] Greslin I, et al. **Ann Biol Clin (Paris)** 1998 May–Jun;56(3):267–76 (39 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Detection of human papilloma virus type 56 in extragenital Bowen's disease. Uezato H, et al. **Acta Derm Venereol** 1999 Jul;79(4):311–3 (18 ref.)

Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Fazel N, et al. **Dermatol Clin** 1999 Jul;17(3):521–36, viii (138 ref.)

Oncogenic potential of human neurotropic papovavirus, JCV, in CNS. Gordon J, et al. **Dev Biol Stand** 1998; 94:93–101 (26 ref.)

Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. Palefsky JM. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S42–8 (28 ref.)

Juvenile-onset recurrent respiratory papillomatosis involving the lung: A case report and review of the literature. Magid MS, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):157–63 (29 ref.)

PREVENTION & CONTROL

Papillomavirus vaccines. Duggan-Keen MF, et al. **Front Biosci** 1998 Dec 1;3:D1192–208 (195 ref.)

SURGERY

Laser conization of cervical intraepithelial neoplasia grade 3: free resection margins indicative of lesion-free survival. Bertelsen B, et al. **Acta Obstet Gynecol Scand** 1999 Jan; 78(1):54–9 (42 ref.)

THERAPY

Human papillomavirus vaccines for cervical cancer. Murakami M, et al. **J Immunother** 1999 May;22(3):212–8 (60 ref.)

Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus. El-Attar SM, et al. **Prim Care** 1999 Mar;26(1):81–100 (32 ref.)

[Characteristics of anal carcinoma with therapeutic consequences] Hohenberger P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:363–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women] Küppers V, et al. **Zentralbl Gynakol** 1999;121(1):27–30 (5 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Gillison ML, et al. **Curr Opin Oncol** 1999 May;11(3):191–9 (110 ref.)

Transmission of cervical cancer-associated human papilloma viruses from mother to child. Cason J, et al. **Intervirology** 1998;41(4–5):213–8 (44 ref.)

High risk genital papillomavirus infections are not spread vertically. Dillner J, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):23–9 (63 ref.)

High risk genital papillomavirus infections are spread vertically. Rice PS, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):15–21 (52 ref.)

VETERINARY

Canine papillomavirus--A centenary review. Nicholls PK, et al. **J Comp Pathol** 1999 Apr;120(3):219–33 (95 ref.)

Mucosotropic papillomavirus infections. Sundberg JP, et al. **Lab Anim Sci** 1998 Jun;48(3):240–2 (25 ref.)

VIROLOGY

Detection of authentic SV40 DNA sequences in human brain and bone tumours. Butel JS, et al. **Dev Biol Stand** 1998; 94:23–32 (15 ref.)

Molecular biology and pathogenesis of human polyomavirus infections. Dörries K. **Dev Biol Stand** 1998;94:71–9 (24 ref.)

SV40 infections in simians and humans. Shah KV. **Dev Biol Stand** 1998;94:9–12 (12 ref.)

Simian virus 40 DNA sequences in human brain and bone tumours. Wang J, et al. **Dev Biol Stand** 1998;94:13–21 (27 ref.)

Polyomaviruses and human tumors: a brief review of current concepts and interpretations. Lednicky JA, et al. **Front Biosci** 1999 Feb 15;4:D153–64 (168 ref.)

Simian virus 40 infection via MHC class I molecules and caveolae. Norkin LC. **Immunol Rev** 1999 Apr;168:13–22 (55 ref.)

Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. Jensen PN, et al. **J Leukoc Biol** 1999 Apr;65(4):428–38 (99 ref.)

Yohei Ito Memorial Lecture: Papillomaviruses in human cancers. zur Hausen H. **Leukemia** 1999 Jan;13(1):1–5 (40 ref.)

The role of the human papilloma virus in esophageal cancer. Sur M, et al. **Pathology** 1998 Nov;30(4):348–54 (65 ref.)

Human papillomavirus infection in adolescents. Moscicki AB. **Pediatr Clin North Am** 1999 Aug;46(4):783–807 (90 ref.)

HPV and cancer: the story unfolds. Campo MS. **Trends Microbiol** 1998 Nov;6(11):424–6 (20 ref.)

PAPP-A see **PREGNANCY-ASSOCIATED ALPHA-PLASMA PROTEIN**

PAPP-D see **PLACENTAL LACTOGEN**

PAPRIKA see **CAPSICUM**

PAPULOSQUAMOUS DISORDERS see **SKIN DISEASES, PAPULOSQUAMOUS**

PARA-AMINOHIPPURIC ACID see **P-AMINOHIPPURIC ACID**

PARA-AMINOSALICYLIC ACID see **P-AMINOSALICYLIC ACID**

PARA-DIHYDROXYBENZENES see **HYDROQUINONES**

PARA-HYDROXYPHENYLPYRUVATE HYDROXYLASE see **4-HYDROXYPHENYLPYRUVATE DIOXYGENASE**

PARA-HYDROXYPHENYLPYRUVATE OXIDASE see **4-HYDROXYPHENYLPYRUVATE DIOXYGENASE**

PARA-OCTOPAMINE see **OCTOPAMINE**

PARACENTESIS

Part II: The use of arthrocentesis for treatment of temporomandibular joint disorders. Frost DE, et al. **J Oral Maxillofac Surg** 1999 May;57(5):583–7 (24 ref.)

PARACETAMOL see **ACETAMINOPHEN**

PARACHUTING see **AVIATION**

PARACOCCIDIOIDES

Immunity to Paracoccidioides brasiliensis infection. Calich VL, et al. **Res Immunol** 1998 May–Jun;149(4–5):407–17; discussion 499–500 (60 ref.)

GROWTH & DEVELOPMENT

[The Research Encouragement Award. Effects of sex hormones on sexual difference of experimental paracoccidioidomycosis] Sano A, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(1):1–8 (40 ref.) (Eng. Abstr.) **(Jpn)**

PARACOCCIDIOIDOMYCOSIS

[Exotic pulmonary mycoses] Dupont B. **Rev Pneumol Clin** 1998 Dec;54(6):301–8 (24 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Systemic paracoccidioidomycosis with central nervous system involvement] Duarte AL, et al. **Rev Soc Bras Med Trop** 1999 Jul–Aug;32(4):439–42 (16 ref.)

(Eng. Abstr.) **(Por)**

DIAGNOSIS

Paracoccidioidomycosis. Bethlem EP, et al.
Curr Opin Pulm Med 1999 Sep;5(5):319–25 (57 ref.)
Serodiagnosis of histoplasmosis, paracoccidioidomycosis and penicilliosis marneffei; current status and future trends. Hamilton AJ. **Med Mycol** 1998 Dec;36(6):351–64 (148 ref.)

IMMUNOLOGY

Immunity to Paracoccidioides brasiliensis infection. Calich VL, et al. **Res Immunol** 1998 May–Jun;149(4–5):407–17; discussion 499–500 (60 ref.)

MICROBIOLOGY

[The Research Encouragement Award. Effects of sex hormones on sexual difference of experimental paracoccidioidomycosis] Sano A, et al.
Nippon Ishinkin Gakkai Zasshi 1999;40(1):1–8 (40 ref.) (Eng. Abstr.) **(Jpn)**

PARACOCCUS

GENETICS

Molecular genetics of the genus Paracoccus: metabolically versatile bacteria with bioenergetic flexibility. Baker SC, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1046–78 (351 ref.)

METABOLISM

Molecular genetics of the genus Paracoccus: metabolically versatile bacteria with bioenergetic flexibility. Baker SC, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1046–78 (351 ref.)

PARACOLOBACTRUM see **ENTEROBACTERIACEAE**

PARACRINE COMMUNICATION

Inhibins: paracrine and endocrine effects in female reproductive function. Petraglia F, et al.
Curr Opin Obstet Gynecol 1999 Jun;11(3):241–7 (53 ref.)
Adipose tissue as an endocrine and paracrine organ. Mohamed-Ali V, et al. **Int J Obes Relat Metab Disord** 1998 Dec;22(12):1145–58 (152 ref.)
Autocrine–paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Nussdorfer GG, et al. **Pharmacol Rev** 1999 Sep;51(3):403–38 (402 ref.)
Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Murad F.
Recent Prog Horm Res 1998;53:43–59; discussion 59–60 (47 ref.)
[Hormones and auto-paracrine tumor growth regulators in osteogenic sarcoma] Kushlinskiĭ NE.
Vestn Ross Akad Med Nauk 1998;(12):54–8 (32 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Hormones as life regulators in the current molecular endocrinology. Pankov YA. **Biochemistry (Mosc)** 1998 Dec;63(12):1361–73 (125 ref.)
Regulation of parturition update. Endocrine and paracrine effectors of term and preterm labor. Kniss DA, et al.
Clin Perinatol 1998 Dec;25(4):819–36, v (128 ref.)
Growth hormone: a paracrine growth factor in embryonic development? Harvey S, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Jun;119(3):305–15 (103 ref.)
Vasopressin : a potent autocrine/paracrine regulator of mammal adrenal functions. Guillon G, et al.
Endocr Res 1998 Aug–Nov;24(3–4):703–10 (16 ref.)
Insulin-like growth factor I—a prototypic peripheral–paracrine hormone? [editorial; comment] Melmed S. **Endocrinology** 1999 Sep;140(9):3879–80 (14 ref.) Comment on: Endocrinology 1999 Sep;140(9):3881–9.
Paracrine neurotransmission in the CNS: involvement of 5-HT. Bunin MA, et al. **Trends Neurosci** 1999 Sep; 22(9):377–82 (50 ref.)
[Paracrine regulation of renal hemodynamics] Aki Y, et al.
Nippon Yakurigaku Zasshi 1998 Nov;112(5):287–98 (36 ref.) (Eng. Abstr.) **(Jpn)**

PARACRINE SIGNALING see **PARACRINE COMMUNICATION**

PARADENTIUM see **PERIODONTIUM**

PARADOXICAL SLEEP see **SLEEP, REM**

PARAFFIN

ADVERSE EFFECTS

[Paraffinoma—a rare complication following endonasal surgery] Bachor E, et al. **Laryngorhinootologie** 1999 Jun; 78(6):307–12 (31 ref.) (Eng. Abstr.) **(Ger)**

PARAFFIN EMBEDDING

Deparaffinization and processing of pathologic material. Cunningham RE. **Methods Mol Biol** 1999;115:275–9 (10 ref.)

PARAGANGLIOMA

The Carney Triad: a lesson in observation, creativity, and perseverance [editorial; comment] Appelman HD.
Mayo Clin Proc 1999 Jun;74(6):638–40 (15 ref.) Comment on: Mayo Clin Proc 1999 Jun;74(6):543–52.

DIAGNOSIS

Paraganglioma of the cauda equina region—report of two cases and review of the literature. Aghakhani N, et al.
Acta Neurochir (Wien) 1999;141(1):81–7 (46 ref.)
The incidental diagnosis. Silverberg LI.
J Am Osteopath Assoc 1999 Apr;99(4):214–6 (18 ref.)
Paraganglioma in the frontal skull base—case report. Yamauchi T, et al. **Neurol Med Chir (Tokyo)** 1999 Apr; 39(4):308–12 (16 ref.)

PATHOLOGY

Prostatic paraganglioma: 5-year followup. Jimenez RE, et al. **J Urol** 1999 Jun;161(6):1909–10 (4 ref.)

PHYSIOPATHOLOGY

[Two cases of retroperitoneal functioning paraganglioma] Maruyama T, et al. **Hinyokika Kiyo** 1998 Dec; 44(12):869–73 (12 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Bone metastases from a paraganglioma. A review of five cases. Razakaboay M, et al. **Rev Rhum Engl Ed** 1999 Feb; 66(2):86–91 (18 ref.)

SURGERY

Paraganglioma of the filum terminale: case report and literature review. Ashkenazi E, et al. **J Spinal Disord** 1998 Dec;11(6):540–2 (11 ref.)
Paraganglioma in the frontal skull base—case report. Yamauchi T, et al. **Neurol Med Chir (Tokyo)** 1999 Apr; 39(4):308–12 (16 ref.)
[Modern aspects of management of pheochromocytoma and abdominopelvic paraganglioma] Proye C. **Ann Chir** 1998; 52(7):643–56 (82 ref.) **(Fre)**

PARAGANGLIOMA, CAROTID BODY see **CAROTID BODY TUMOR**

PARAGANGLIOMA, EXTRA-ADRENAL

PATHOLOGY

A patient with extra-adrenal retroperitoneal paraganglioma and review of the literature. Alp H, et al.
J Pediatr Endocrinol Metab 1998 Nov–Dec;11(6):763–5 (7 ref.)

PARAGANGLIOMA, GANGLIOCYTIC see **PARAGANGLIOMA**

PARAGANGLIOMA, NONCHROMAFFIN see **PARAGANGLIOMA, EXTRA-ADRENAL**

PARAGONIMIASIS

[Paragonimiasis westermani] Yoshimatsu T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):485–7 (13 ref.) **(Jpn)**
[Paragonimiasis miyazakii] Yoshimatsu T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):488–9 (11 ref.) **(Jpn)**

PARASITOLOGY

Paragonimiasis and the genus Paragonimus. Blair D, et al. **Adv Parasitol** 1999;42:113–222 (720 ref.)

PARAGONIMUS

CLASSIFICATION

Paragonimiasis and the genus Paragonimus. Blair D, et al. **Adv Parasitol** 1999;42:113–222 (720 ref.)

PARAHEMOPHILIA see **FACTOR V DEFICIENCY**

PARAIMMUNOGLOBULINEMIAS see **PARAPROTEINEMIAS**

PARAINFLUENZA see **PARAMYXOVIRIDAE INFECTIONS**

PARAINFLUENZA VIRUS 3, BOVINE see **PARAMYXOVIRUS**

PARAINFLUENZA VIRUS 2, HUMAN

[Croup] Ieki R. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):80–2 (6 ref.) **(Jpn)**

PARAINFLUENZA VIRUS INFECTIONS see **PARAMYXOVIRIDAE INFECTIONS**

PARALYSIS

[Hopkins syndrome (acute postasthmatic amyotrophy] Mezaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):354–5 (9 ref.) **(Jpn)**

DIAGNOSIS

[Foix–Chavany–Marie syndrome in a child caused by a head trauma] Laurent-Vannier A, et al. **Rev Neurol (Paris)** 1999 May;155(5):387–90 (12 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Hypoglossal nerve injury as a complication of anterior surgery to the upper cervical spine. Sengupta DK, et al.
Eur Spine J 1999;8(1):78–80 (10 ref.)
Posterior interosseous nerve palsy in a patient with rheumatoid synovitis of the elbow: a case report and review of the literature. Westkaemper JG, et al.
J Hand Surg [Am] 1999 Jul;24(4):727–31 (10 ref.)
Thyrotoxic period paralysis: report of three cases and review of the literature. Papadopoulos KI, et al. **J Intern Med** 1997 Jun;241(6):521–4 (14 ref.)
Extensive arachnoid ossification with associated syringomyelia presenting as thoracic myelopathy. Case report and review of the literature. Slavin KV, et al.
J Neurosurg 1999 Oct;91(2 Suppl):223–9 (63 ref.)
[Paralytic shoulder secondary to post-traumatic peripheral nerve lesions in the adult] Alnot JY. **Acta Orthop Belg** 1999 Mar;65(1):10–22 (50 ref.) (Eng. Abstr.) **(Fre)**
[Foix–Chavany–Marie syndrome in a child caused by a head trauma] Laurent-Vannier A, et al. **Rev Neurol (Paris)** 1999 May;155(5):387–90 (12 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgery of common paralytic conditions. Duerkson F.
Lepr Rev 1998 Dec;69(4):390–6 (0 ref.)

THERAPY

[Modern techniques of restoration of locomotion in paralyzed persons] Rabischong P. **Bull Acad Natl Med** 1999; 183(3):531–7; discussion 538–9 (49 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Larkspur (Delphinium spp.) poisoning in livestock. Pfister JA, et al. **J Nat Toxins** 1999 Feb;8(1):81–94 (76 ref.)

PARALYSIS AGITANS see **PARKINSON DISEASE**

PARALYSIS, BULBAR

[Progressive bulbar paralysis in childhood (Fazio–Londe disease)] Shishikura K, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):339–42 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot–Marie–Tooth disease] Uno S, et al. **Rinsho Ketsueki** 1999 May;40(5):414–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Brown–Vialetto–Van Laere syndrome: a case with anti-ganglioside GM1 antibodies and literature review] Sztajzel R, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):51–4 (10 ref.) (Eng. Abstr.) **(Fre)**

PARALYSIS, FAMILIAL PERIODIC

COMPLICATIONS

Thyrotoxic periodic paralysis: a case report and review of the literature. Kodali VR, et al. **J Emerg Med** 1999 Jan–Feb;17(1):43–5 (12 ref.)

DIAGNOSIS

[Thyrotoxic hypokalemic periodic paralysis in a male Kurd] Gamper G, et al. **Acta Med Austriaca** 1998;25(3):106–8 (17 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

[HYPP: hyperkalemic periodic paralysis in the horse] Sloet van Oldruitenborgh-Oosterbaan MM.
Tijdschr Diergeneeskd 1999 Mar 15;124(6):176–81 (37 ref.) (Eng. Abstr.) **(Dut)**

PARALYSIS, GENERAL see **NEUROSYPHILIS**

PARALYSIS, PSEUDOBULBAR see **PARALYSIS**

PARALYTIC ILEUS

PARALYTIC ILEUS see **INTESTINAL PSEUDO-OBSTRUCTION**

PARAMAGNETIC RESONANCE see **ELECTRON SPIN RESONANCE SPECTROSCOPY**

PARAMEDICAL PERSONNEL see **ALLIED HEALTH PERSONNEL**

PARAMEDICS see **ALLIED HEALTH PERSONNEL**

PARAMEDICS, EMERGENCY see **EMERGENCY MEDICAL TECHNICIANS**

PARAMYOCLONUS MULTIPLEX see **MYOCLONUS**

PARAMYOSIN see **TROPOMYOSIN**

PARAMYXOVIRIDAE INFECTIONS

METABOLISM

Interaction of viral infections with muscarinic receptors. Jacoby DB, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:59–64 (41 ref.)

VIROLOGY

Paramyxoviruses and Paget's disease: the affirmative view. Mee AP. **Bone** 1999 May;24(5 Suppl):19S–21S (20 ref.)

Are paramyxoviruses involved in Paget's disease? A negative view. Ralston SH, et al. **Bone** 1999 May;24(5 Suppl):17S–18S (19 ref.)

Paramyxoviruses and chronic human diseases. Rima BK. **Bone** 1999 May;24(5 Suppl):23S–26S (16 ref.)

PARAMYXOVIRINAE

PATHOGENICITY

Paramyxoviruses and chronic human diseases. Rima BK. **Bone** 1999 May;24(5 Suppl):23S–26S (16 ref.)

PARAMYXOVIRUS

Gene therapy using HVJ–liposomes: the best of both worlds? Kaneda Y, et al. **Mol Med Today** 1999 Jul;5(7):298–303 (41 ref.)

[Preparation of unilamellar fusogenic liposomes using the Sendai virus] Nakanishi M, et al. **Nippon Yakurigaku Zasshi** 1998 Nov;112(5):299–305 (7 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Determinants of organ tropism of sendai virus. Tashiro M, et al. **Front Biosci** 1999 Oct 1;4:D642–5 (26 ref.)

Gene delivery systems using the Sendai virus. Nakanishi M, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):123–7 (22 ref.)

Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Nagai Y. **Rev Med Virol** 1999 Apr–Jun;9(2):83–99 (95 ref.)

PATHOGENICITY

Determinants of organ tropism of sendai virus. Tashiro M, et al. **Front Biosci** 1999 Oct 1;4:D642–5 (26 ref.)

Cellular proteinases trigger the infectivity of the influenza A and Sendai viruses. Kido H, et al. **Mol Cells** 1999 Jun 30;9(3):235–44 (37 ref.)

PARAMYXOVIRUS 1, AVIAN see **NEWCASTLE DISEASE VIRUS**

PARAMYXOVIRUS INFECTIONS

VIROLOGY

Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Nagai Y. **Rev Med Virol** 1999 Apr–Jun;9(2):83–99 (95 ref.)

PARANASAL SINUS DISEASES

DIAGNOSIS

Obliteration of the frontal sinus––state of the art and reflections on new materials. Weber R, et al. **Rhinology** 1999 Mar;37(1):1–15 (149 ref.)

[A clinical study of chronic perennial and permanent rhino–sinusal dysfunction. II. Clinical pattern of different pathologies] Bonfils P, et al. **Ann Otolaryngol Chir Cervicofac** 1999 Jun;116(3):126–36 (12 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Invasive sinus aspergillosis in apparently immunocompetent hosts. Clancy CJ, et al. **J Infect** 1998 Nov;37(3):229–40 (33 ref.)

Frontal sinolith. Grant DG, et al. **J Laryngol Otol** 1998 Jun; 112(6):570–2 (11 ref.)

PHYSIOPATHOLOGY

[A clinical study of chronic perennial and permanent rhino–sinusal dysfunction. II. Clinical pattern of different pathologies] Bonfils P, et al. **Ann Otolaryngol Chir Cervicofac** 1999 Jun;116(3):126–36 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Concha bullosa pyocele––undiagnosed for 3 years. Dawlatly EE, et al. **Rhinology** 1999 Jun;37(2):90–2 (7 ref.)

SURGERY

Use of intranasal endoscopic surgery to relieve ostiomeatal complex obstruction in fibrous dysplasia of the paranasal sinuses. Kessler A, et al. **Eur Arch Otorhinolaryngol** 1998; 255(9):454–6 (12 ref.)

Obliteration of the frontal sinus––state of the art and reflections on new materials. Weber R, et al. **Rhinology** 1999 Mar;37(1):1–15 (149 ref.)

[Navigation surgery in diseases of the paranasal sinuses] Grevers G, et al. **Laryngorhinootologie** 1999 Jan;78(1):41–6 (29 ref.) (Eng. Abstr.) **(Ger)**

PARANASAL SINUS NEOPLASMS

COMPLICATIONS

Ethmoid sinus osteoma presenting as epiphora and orbital cellulitis: case report and literature review. Mansour AM, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):413–26 (128 ref.)

DIAGNOSIS

Meningioma of the cavernous sinus in a child. Erşahin Y, et al. **Childs Nerv Syst** 1999 Jan;15(1):8–10 (16 ref.)

Intradural extension of mucocele complicating frontoethmoid sinus osteoma: case report. Manaka H, et al. **Surg Neurol** 1998 Nov;50(5):453–6 (13 ref.)

[Multiple brown tumors of the paranasal sinuses in tertiary hyperparathyroidism] Pöckler–Schöniger C, et al. **Rofo Fortschr Geb Roentgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):72–5 (10 ref.) **(Ger)**

[Esthesioneuroblastoma: review of literature and case report] Podoshin L, et al. **Otolaryngol Pol** 1997;51 Suppl 25:11–5 (0 ref.) (Eng. Abstr.) **(Pol)**

[Benign tumors of the nasal cavity, paranasal sinuses and nasopharynx in childhood] Bogomil'skiĭ MR, et al. **Vestn Otorinolaringol** 1999;(1):58–62 (70 ref.) **(Rus)**

PATHOLOGY

Sinonasal malignant lymphomas: a distinct clinicopathological category. Vidal RW, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):411–9 (40 ref.)

Primitive neuroectodermal tumor in sinonasal region. Toda T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):83–90 (29 ref.)

Teratocarcinosarcoma of the nasal cavity and ethmoid. Sharma HS, et al. **J Laryngol Otol** 1998 Jul;112(7):682–6 (15 ref.)

Oxyphilic proliferations of the respiratory tract and paranasal sinuses. Ritter JH, et al. **Semin Diagn Pathol** 1999 May; 16(2):105–16 (75 ref.)

[Spheno–ethmoidal rhinoscleroma. Report of a case and review of the literature] Evrard I, et al. **Ann Otolaryngol Chir Cervicofac** 1998 May;115(2):85–8 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Primitive neuroectodermal tumor in sinonasal region. Toda T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):83–90 (29 ref.)

RADIOTHERAPY

Primary sinonasal mucosal melanoma: three different therapeutic approaches to inoperable local disease or recurrence and a review of the literature. De Meerleer GO, et al. **Melanoma Res** 1998 Oct;8(5):449–57 (52 ref.)

SURGERY

Endoscopic management of low–grade papillary adenocarcinoma of the ethmoid sinus: case report and review of the literature. Shah UK, et al. **Am J Otolaryngol** 1999 May–Jun;20(3):190–4 (25 ref.)

A case of metastatic nasopharyngeal carcinoma in benign nasal polyps. Sim RS, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):575–7 (5 ref.)

Sinonasal mucosa–associated lymphoid tissue lymphoma. Babb MJ, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):585–8 (19 ref.)

Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314–7 (21 ref.)

[Selected aspects of endonasal paranasal sinus surgery] Reiss M. **Wien Med Wochenschr** 1998;148(20):469–73 (17 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Equine nasal and paranasal sinus tumours. Part 1: review of the literature and tumour classification. Head KW, et al. **Vet J** 1999 May;157(3):261–78 (100 ref.)

An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors. Adams WM, et al. **Vet Radiol Ultrasound** 1998 Sep–Oct;39(5):475–81 (23 ref.)

PARANASAL SINUSES

PATHOLOGY

Bone density measurements of the paranasal sinuses on plastinated whole–organ sections: anatomic data to prevent complications in endoscopic sinus surgery. Sprinzl GM, et al. **Laryngoscope** 1999 Mar;109(3):400–6 (33 ref.)

PHYSIOLOGY

[Paranasal sinuses: only one of nature's games? (see comments)] Bergler W, et al. **Laryngorhinootologie** 1998 Aug;77(8):454–61 (49 ref.) (Eng. Abstr.) Comment in: Laryngorhinootologie 1999 Feb;78(2):110–1. **(Ger)**

SURGERY

[Paraffinoma––a rare complication following endonasal surgery] Bachor E, et al. **Laryngorhinootologie** 1999 Jun; 78(6):307–12 (31 ref.) (Eng. Abstr.) **(Ger)**

[Computer assisted localization in endoscopic sinus surgery––state of the art? The Insta Trak system] Luxenberger W, et al. **Laryngorhinootologie** 1999 Jun; 78(6):318–25 (12 ref.) (Eng. Abstr.) **(Ger)**

PARANEOPLASTIC SYNDROMES

Rare case of small–cell carcinoma arising from the endometrium with paraneoplastic retinopathy. Sekiguchi I, et al. **Gynecol Oncol** 1998 Dec;71(3):454–7 (9 ref.)

[Paraneoplastic Cushing's syndrome and small cell bronchial carcinoma] Mennecier B, et al. **Rev Pneumol Clin** 1999 Apr; 55(2):77–80 (8 ref.) (Eng. Abstr.) **(Fre)**

[Neurologic diseases associated with malignant tumors] Asahina M, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):858–63 (5 ref.) **(Jpn)**

COMPLICATIONS

Oral manifestations as a hallmark of malignant acanthosis nigricans. Ramirez–Amador V, et al. **J Oral Pathol Med** 1999 Jul;28(6):278–81 (24 ref.)

Osseous metaplasia in caecal adenocarcinoma. Papadopoulos MC, et al. **J R Soc Med** 1998 Aug;91(8):434–5 (9 ref.)

A malignancy work–up in patients with cancer–associated (paraneoplastic) autoimmune diseases: pemphigus and myasthenic syndromes as cases in point (review). Sherer Y, et al. **Oncol Rep** 1999 May–Jun;6(3):665–8 (48 ref.)

Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May–Jun;85(3):199–204 (41 ref.)

[Paraneoplastic nephropathy associated with adult renal carcinoma (immunologic and clinicopathologic study)] Kiss B, et al. **Orv Hetil** 1999 Jan 10;140(2):75–80 (35 ref.) (Eng. Abstr.) **(Hun)**

DIAGNOSIS

Paraneoplastic syndromes. Rees J. **Curr Opin Neurol** 1998 Dec;11(6):633–7 (30 ref.)

Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. Chorzelski T, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):393–400 (42 ref.)

Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May–Jun;85(3):199–204 (41 ref.)

[Cerebral ischemia as initial manifestation of neoplastic low–malignancy changes. 2 case reports and review of the literatures] Jahn K, et al. **Nervenarzt** 1999 Apr;70(4):342–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[A case of disseminated intravascular coagulation––a paraneoplastic manifestation of a borderline ovarian tumor] Bălănescu I, et al. **Chirurgia (Bucur)** 1998 Sep–Oct; 93(5):331–41 (13 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Immunoablative high–dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. Nousari HC, et al. **J Am Acad Dermatol** 1999 May; 40(5 Pt 1):750–4 (24 ref.)

[Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders] Raue F. **Internist (Berl)** 1999 Apr;40(4):448–55 (61 ref.) **(Ger)**

ETIOLOGY

Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Bernardis V, et al. **Digestion** 1999 Jan–Feb;60(1):82–5 (16 ref.)

Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long–acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)

A mesenteric liposarcoma with production of granulocyte colony–stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884–90 (37 ref.)

IMMUNOLOGY

Autoimmunity in paraneoplastic neurological syndromes.

Giometto B, et al. **Brain Pathol** 1999 Apr;9(2):261–73 (107 ref.)
Antibodies to ion channels in paraneoplastic disorders. Vincent A. **Brain Pathol** 1999 Apr;9(2):285–91 (47 ref.)
Paraneoplastic neurological disorders. Newsom-Davis J. **J R Coll Physicians Lond** 1999 May–Jun;33(3):225–7 (8 ref.)
[Immunology in the clinical practice. XVI. Paraneoplastic syndromes of the nervous system: pathogenesis and diagnosis] Smitt PA, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1652–8 (29 ref.) (Eng. Abstr.) **(Dut)**
[Paraneoplastic pemphigus] Descamps V, et al. **Presse Med** 1999 Feb 20;28(7):363–7 (45 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Paraneoplastic syndromes in metastatic disease. Zumsteg MM, et al. **Semin Oncol Nurs** 1998 Aug;14(3):220–9 (39 ref.)

PATHOLOGY

Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Dalmau J, et al. **Brain Pathol** 1999 Apr; 9(2):275–84 (56 ref.)
Paraneoplastic syndromes. Giometto B, et al. **Brain Pathol** 1999 Apr;9(2):247–50 (31 ref.)
The neuropathology of paraneoplastic syndromes. Scaravilli F, et al. **Brain Pathol** 1999 Apr;9(2):251–60 (83 ref.)
Mucocutaneous paraneoplastic syndromes (MCPS). A clinical-pathologic review. Silvestris N, et al. **J Exp Clin Cancer Res** 1998 Dec;17(4):453–64 (58 ref.)
Paraneoplastic pemphigus: a review. Sklavounou A, et al. **Oral Oncol** 1998 Nov;34(6):437–40 (14 ref.)

PHYSIOPATHOLOGY

The pathophysiology of paraneoplastic neurological syndromes. Liblau R, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):512–20 (44 ref.)
Paraneoplastic syndromes. Dalmau JO, et al. **Arch Neurol** 1999 Apr;56(4):405–8 (17 ref.)
Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Dalmau J, et al. **Brain Pathol** 1999 Apr; 9(2):275–84 (56 ref.)
[Mechanisms of paraneoplastic neurologic syndromes] Honnorat J, et al. **Rev Med Interne** 1999 Aug;20(8):670–80 (83 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Guy J, et al. **Arch Ophthalmol** 1999 Apr;117(4):471–7 (36 ref.)
A review of the therapy of paraneoplastic neurologic syndromes. Das A, et al. **J Neurooncol** 1999 Jan; 41(2):181–94 (211 ref.)
[Treatment of the paraneoplastic Lambert-Eaton syndrome] Courau E, et al. **Rev Pneumol Clin** 1998 May;54(2):65–70 (36 ref.) (Eng. Abstr.) **(Fre)**
[Management of hematologic systemic diseases and rare tumor entities with manifestations in the oromaxillofacial area] Petrasch S. **Mund Kiefer Gesichtschir** 1998 Jul; 2(4):172–80 (74 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Paraneoplastic syndromes. Ogilvie GK. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):439–49, v (38 ref.)

PARANOIA see **PARANOID DISORDERS**

PARANOID DISORDER, SHARED see **SHARED PARANOID DISORDER**

PARANOID DISORDERS

COMPLICATIONS

[Paranoid nosogenic reactions in patients with somatoform disorders] Vybornykh DE. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(12):18–21 (34 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

[Paranoid nosogenic reactions in patients with somatoform disorders] Vybornykh DE. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(12):18–21 (34 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Caring for elderly patients who have paranoia. Davidhizar R, et al. **Radiol Technol** 1999 May–Jun;70(5):461–4 (18 ref.)

PARANOID PSYCHOSES see **PARANOID DISORDERS**

PARANOID SCHIZOPHRENIA see **SCHIZOPHRENIA, PARANOID**

PARAPARESIS, TROPICAL SPASTIC

[Recent advance in neuroimmunology] Arimura K, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):993–6 (7 ref.) (Eng. Abstr.) **(Jpn)**
[HTLV-I-associated myelopathy] Hiruma K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):122–5 (4 ref.) **(Jpn)**
[HTLV-I-associated myelopathy] Osame M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):41–5 (15 ref.) **(Jpn)**

COMPLICATIONS

Human T-cell lymphotropic virus type I and systemic lupus erythematosus [editorial; comment] Ijichi S, et al. **Intern Med** 1999 Jun;38(6):459–60 (24 ref.) Comment on: Intern Med 1999 Jun;38(6):512–5.

ETIOLOGY

HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis hypothesis. A shift of homologous peptides pairs, central nervous system (CNS)/HTLF-1, HTLV-1/thymus, thymus/CNS, in a thymus-like CNS environment, underlies the pathogenesis of HAM/TSP. Plumelle Y. **Med Hypotheses** 1999 Jun; 52(6):595–604 (99 ref.)

IMMUNOLOGY

Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Bangham CR, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):691–700 (76 ref.)
[Pathogenetic significance of HTLV-I infection and immune surveillance in HAM] Fujihara K. **Rinsho Shinkeigaku** 1999 Jan;39(1):21–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Pathogenesis and treatment of HTLV-I associated myelopathy. Taylor GP. **Sex Transm Infect** 1998 Oct; 74(5):316–22 (50 ref.)

VIROLOGY

Pathogenesis and treatment of HTLV-I associated myelopathy. Taylor GP. **Sex Transm Infect** 1998 Oct; 74(5):316–22 (50 ref.)

PARAPHILIAS

see related
SEX OFFENSES
ABC of sexual health. Sexual variations. de Silva WP. **BMJ** 1999 Mar 6;318(7184):654–6 (0 ref.)

DIAGNOSIS

Statistical adequacy of the Abel Assessment for Interest in Paraphilias. Fischer L, et al. **Sex Abuse** 1999 Jul; 11(3):195–205 (23 ref.)
Assessment of juvenile sexual offenders: reliability and validity of the Abel Assessment for Interest in Paraphilias. Smith G, et al. **Sex Abuse** 1999 Jul;11(3):207–16 (20 ref.)

DRUG THERAPY

Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents. Levitsky AM, et al. **J Am Geriatr Soc** 1999 Feb;47(2):231–4 (26 ref.)
Pharmacological treatment of paraphilias with a focus on antidepressants. Balon R. **J Sex Marital Ther** 1998 Oct-Dec;24(4):241–54 (62 ref.)

ETIOLOGY

Alcohol's possible covert role: brain dysfunction, paraphilias, and sexually aggressive behaviors. Williams S. **Sex Abuse** 1999 Apr;11(2):147–58 (54 ref.)

THERAPY

Sexual predators. Zonana HV, et al. **Psychiatr Clin North Am** 1999 Mar;22(1):109–27, vii (68 ref.)
The paraphilias, obsessive compulsive spectrum disorder, and the treatment of sexually deviant behaviour. Bradford JM. **Psychiatr Q** 1999 Fall;70(3):209–19 (44 ref.)
Are sex offenders treatable? A research overview [see comments] Grossman LS, et al. **Psychiatr Serv** 1999 Mar; 50(3):349–61 (98 ref.) Comment in: Psychiatr Serv 1999 Mar;50(3):295.

PARAPHRENIA, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

PARAPLEGIA

COMPLICATIONS

Aspergillus spondylodiscitis in an immunocompetent paraplegic patient. Schubert M, et al. **Spinal Cord** 1998 Nov;36(11):800–3 (7 ref.)

DIAGNOSIS

[A case of an anomaly of the upper thoracic spine with lower spastic paraplegia simulating progressive disease of the nervous system] Evtushenko SK, et al. **Lik Sprava** 1999 Mar;(2):126–8 (7 ref.) **(Rus)**

ETIOLOGY

Primary hydatid disease of the spine: an unusual cause of progressive paraplegia. Case report and review of the literature. Bhojraj SY, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):216–8 (16 ref.)
Surgical management for instability and paraplegia caused by spinal sarcoidosis. A case report. Tzagarakis GP, et al. **Spine** 1998 Aug 1;23(15):1711–4 (24 ref.)
[Paraplegia secondary to surgery of the abdominal aorta] Clavert P, et al. **J Mal Vasc** 1999 Jun;24(3):229–32 (11 ref.) (Eng. Abstr.) **(Fre)**
[Progressive paraparesis due to cervical spondyloptosis in a child with the Klippel-Feil syndrome] Martinez Campos M, et al. **An Esp Pediatr** 1998 Sep;49(3):302–4 (11 ref.) **(Spa)**

IMMUNOLOGY

Aspergillus spondylodiscitis in an immunocompetent paraplegic patient. Schubert M, et al. **Spinal Cord** 1998 Nov;36(11):800–3 (7 ref.)

REHABILITATION

Donal Munro Lecture: Functional and neurologic recovery following acute SCI. Waters RL, et al. **J Spinal Cord Med** 1998 Jul;21(3):195–9 (11 ref.)
A review of reciprocal walking systems for paraplegic patients: factors affecting choice and economic justification. Stallard J, et al. **Prosthet Orthot Int** 1998 Dec;22(3):240–7 (45 ref.)

SURGERY

Recovery of locomotion following transplantation of monoaminergic neurons in the spinal cord of paraplegic rats. Gimenez y Ribotta M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:393–411 (73 ref.)

PARAPLEGIA, SPASTIC see **PARAPLEGIA**

PARAPLEGIA, SPASTIC, HEREDITARY see **SPASTIC PARAPLEGIA, HEREDITARY**

PARAPOXVIRUS

GENETICS

Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts. Rziha HJ, et al. **J Biotechnol** 1999 Aug 20;73(2–3):235–42 (26 ref.)

IMMUNOLOGY

Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts. Rziha HJ, et al. **J Biotechnol** 1999 Aug 20;73(2–3):235–42 (26 ref.)

PARAPROTEINEMIAS

[Light chain deposition disease] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):585–7 (14 ref.) **(Jpn)**
[Anti-MAG antibody associated neuropathy] Ogino M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):487–91 (15 ref.) **(Jpn)**
[Multiple myeloma and other plasma cell dyscrasias] del Potro Gómez E, et al. **Rev Clin Esp** 1999 Apr;199 Suppl 1:52–7 (45 ref.) **(Spa)**

BLOOD

Evaluation of cryoglobulins. Kallemuchikkal U, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):119–25 (45 ref.)
Sequence of testing for monoclonal gammopathies. Kyle RA. **Arch Pathol Lab Med** 1999 Feb;123(2):114–8 (17 ref.)
The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance? Brigden ML. **Postgrad Med** 1999 Aug; 106(2):135–42; quiz 185 (26 ref.)

COMPLICATIONS

Renal and cardiac manifestations of B-cell dyscrasias with nonamyloidotic monoclonal light chain and light and heavy chain deposition diseases. Gallo GR, et al. **Adv Nephrol Necker Hosp** 1998;28:355–82 (51 ref.)
Neurological manifestations of malignant and non-malignant dysglobulinaemias. Steck AJ. **J Neurol** 1998 Oct; 245(10):634–9 (26 ref.)
The molecular bases of plasma cell dyscrasia-related renal diseases. Ronco PM, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:4–8 (17 ref.)
[Autoimmune nervous dysfunctions] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):826–31 (5 ref.) **(Jpn)**
[Plasma cell dyscrasia associated with polyneuropathy and endocrinological abnormality (Takatsuki disease)] Hata H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):472–5 (13 ref.) **(Jpn)**

PARAPROTEINEMIAS

DIAGNOSIS

Differential diagnosis of monoclonal gammopathies. Alexanian R, et al. **Arch Pathol Lab Med** 1999 Feb; 123(2):108–13 (16 ref.)

Introduction to the report of the consensus conference on monoclonal gammopathies. Goeken JA, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):104–5 (4 ref.)

Procedures for the evaluation of monoclonal immunoglobulins. Keren DF. **Arch Pathol Lab Med** 1999 Feb;123(2):126–32 (18 ref.)

Monoclonal gammopathies and associated skin disorders. Daoud MS, et al. **J Am Acad Dermatol** 1999 Apr; 40(4):507–35; quiz 536–8 (214 ref.)

The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance? Brigden ML. **Postgrad Med** 1999 Aug; 106(2):135–42; quiz 185 (26 ref.)

IMMUNOLOGY

Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Almeida J, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):119–27 (61 ref.)

Multiple myeloma and related disorders. Lessons from an animal model. Radl J. **Pathol Biol (Paris)** 1999 Feb; 47(2):109–14 (30 ref.)

METABOLISM

Soluble CD16 in plasma cell dyscrasias. Mathiot C, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):467–74 (48 ref.)

PATHOLOGY

Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS. Bartl R, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):158–68 (84 ref.)

PHYSIOPATHOLOGY

Paraproteinaemic neuropathies. Steck AJ, et al. **Brain Pathol** 1999 Apr;9(2):361–8 (59 ref.)

THERAPY

Plasmapheresis and paraproteinemia: cryoprotein–induced diseases, monoclonal gammopathy, Waldenström's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Siami GA, et al. **Ther Apher** 1999 Feb;3(1):8–19 (110 ref.)

URINE

Sequence of testing for monoclonal gammopathies. Kyle RA. **Arch Pathol Lab Med** 1999 Feb;123(2):114–8 (17 ref.)

PARAPROTEINS

ANALYSIS

The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance? Brigden ML. **Postgrad Med** 1999 Aug; 106(2):135–42; quiz 185 (26 ref.)

METABOLISM

Pathophysiology of paraprotein production. Maniatis A. **Ren Fail** 1998 Nov;20(6):821–8 (35 ref.)

PARAPSYCHOLOGY

[Occultism, parapsychology and the esoteric from the perspective of psychopathology] Scharfetter C. **Fortschr Neurol Psychiatr** 1998 Oct;66(10):474–82 (29 ref.) **(Ger)** (Eng. Abstr.)

PARAQUAT

ADVERSE EFFECTS

[Pneumocystis carinii pneumonia in an immunocompetent patient after paraquat spraying (letter)] Lillo A, et al. **An Med Interna** 1999 Jul;16(7):381 (9 ref.) **(Spa)**

PHARMACOKINETICS

The renal excretory mechanisms and the role of organic cations in modulating the renal handling of paraquat. Chan BS, et al. **Pharmacol Ther** 1998 Sep;79(3):193–203 (69 ref.)

POISONING

[Paraquat poisoning in children] Gerbaka B, et al. **J Med Liban** 1998 Mar–Apr;46(2):93–6 (25 ref.) **(Fre)**

TOXICITY

Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Corasaniti MT, et al. **Pharmacol Toxicol** 1998 Jul;83(1):1–7 (53 ref.)

PARASITE–HOST RELATIONS see **HOST–PARASITE RELATIONS**

PARASITES

see related
ANTHELMINTICS
ANTI–INFECTIVE AGENTS
ANTIPROTOZOAL AGENTS
FOOD PARASITOLOGY
HOST–PARASITE RELATIONS

CLASSIFICATION

Multilocus enzyme electrophoresis: a valuable technique for providing answers to problems in parasite systematics. Andrews RH, et al. **Int J Parasitol** 1999 Feb;29(2):213–53 (189 ref.)

The importance of systematics in parasitological research. Monis PT. **Int J Parasitol** 1999 Mar;29(3):381–8 (46 ref.)

Evaluation of environmental deterioration by analysing fish parasite biodiversity and community structure. D'Amelio S, et al. **Parassitologia** 1997 Sep;39(3):237–41 (7 ref.)

DRUG EFFECTS

Current strategies in the search for novel antiparasitic agents. Witty MJ. **Int J Parasitol** 1999 Jan;29(1):95–103; discussion 113–4 (15 ref.)

GENETICS

Genomics and the biology of parasites. Johnston DA, et al. **Bioessays** 1999 Feb;21(2):131–47 (138 ref.)

The importance of systematics in parasitological research. Monis PT. **Int J Parasitol** 1999 Mar;29(3):381–8 (46 ref.)

Data mining parasite genomes: haystack searching with a computer. Lawson D. **Parasitology** 1999;118 Suppl:S15–8 (9 ref.)

IMMUNOLOGY

Molecular mimicry between host and pathogen: examples from parasites and implication. Abu–Shakra M, et al. **Immunol Lett** 1999 Apr 1;67(2):147–52 (45 ref.)

ISOLATION & PURIFICATION

Patterns of macroparasite aggregation in wildlife host populations. Shaw DJ, et al. **Parasitology** 1998 Dec;117 (Pt 6):597–610 (79 ref.)

PATHOGENICITY

Intracellular life. Corsaro D, et al. **Crit Rev Microbiol** 1999; 25(1):39–79 (310 ref.)

Major histocompatibility complex class I genes in primates: co–evolution with pathogens. Vogel TU, et al. **Immunol Rev** 1999 Feb;167:327–37 (81 ref.)

Glycosaminoglycan–binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. Wadström T, et al. **J Med Microbiol** 1999 Mar;48(3):223–33 (90 ref.)

Experimental evolution of parasites. Ebert D. **Science** 1998 Nov 20;282(5393):1432–5 (78 ref.)

[The emergence of new pathogens. The human species in the living universe] Ciufecu C, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct–Dec; 43(4):211–4 (0 ref.) **(Rum)**

PHYSIOLOGY

Intracellular life. Corsaro D, et al. **Crit Rev Microbiol** 1999; 25(1):39–79 (310 ref.)

PARASITIC DISEASES

Pleural space infections: microbiology and antimicrobial therapy. Everts RJ, et al. **Semin Respir Infect** 1999 Mar; 14(1):18–30 (67 ref.)

Application of molecular methods to the study of diseases prevalent in low income countries [see comments] Wilson SM. **Trans R Soc Trop Med Hyg** 1998 May–Jun;92(3):241–4 (25 ref.) Comment in: Trans R Soc Trop Med Hyg 1998 Nov–Dec;92(6):688.

[Zoonotic parasitic diseases recently observed in Japan] Otsuru M. **Rinsho Byori** 1998 Nov;Suppl 108:160–5 (5 ref.) **(Jpn)**

[Rare forms of parasitic infections of the central nervous system] Raičević R, et al. **Vojnosanit Pregl** 1999 Mar–Apr; 56(2):207–12 (24 ref.) **(Scc)**

COMPLICATIONS

[Parasitic eosinophilic lungs] Vaylet F, et al. **Rev Pneumol Clin** 1998 Dec;54(6):329–39 (73 ref.) (Eng. Abstr.) **(Fre)**

[Eosinophilia induced by parasitic infection] Otsuki T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):134–7 (13 ref.) **(Jpn)**

DIAGNOSIS

[Recent trend in parasitic diseases in Japan (with a list of diagnosis and treatment of parasitic diseases)] Araki K. **Rinsho Byori** 1998 Nov;Suppl 108:133–51 (13 ref.) **(Jpn)**

[Diagnosis of parasitic diseases] Sato Y. **Rinsho Byori** 1998 Nov;Suppl 108:166–73 (5 ref.) **(Jpn)**

DRUG THERAPY

[Recent trend in parasitic diseases in Japan (with a list of diagnosis and treatment of parasitic diseases)] Araki K. **Rinsho Byori** 1998 Nov;Suppl 108:133–51 (13 ref.) **(Jpn)**

EPIDEMIOLOGY

Environmental determinants of infectious and parasitic diseases. Heller L. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:7–12 (13 ref.)

Tropical parasitic nephropathies. Barsoum RS. **Nephrol Dial Transplant** 1999;14 Suppl 3:79–91 (104 ref.)

[Parasitic zoonoses] Janitschke K. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):358–61 (20 ref.) (Eng. Abstr.) **(Ger)**

[Current status of imported parasitic diseases in Japan] Otomo H. **Rinsho Byori** 1998 Nov;Suppl 108:152–9 (5 ref.) **(Jpn)**

IMMUNOLOGY

Cytokines are critical in linking the innate and adaptive immune responses to bacterial, fungal, and parasitic infection. Seder RA, et al. **Adv Intern Med** 1999;44:353–88 (163 ref.)

Apoptosis in parasites and parasite–induced apoptosis in the host immune system: a new approach to parasitic diseases. Barcinski MA, et al. **Braz J Med Biol Res** 1999 Apr; 32(4):395–401 (50 ref.)

Molecular mimicry between host and pathogen: examples from parasites and implication. Abu–Shakra M, et al. **Immunol Lett** 1999 Apr 1;67(2):147–52 (45 ref.)

PARASITOLOGY

Population biology, evolution, and infectious disease: convergence and synthesis. Levin BR, et al. **Science** 1999 Feb 5;283(5403):806–9 (43 ref.)

PREVENTION & CONTROL

Vaccines against human parasitic diseases: an overview. Abath FG, et al. **Acta Trop** 1998 Nov 30;71(3):237–54 (80 ref.)

[Parasitic diseases control in the 21st century in China] Tang LH. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):112–3 (4 ref.) **(Chi)**

[Fungal and parasitic nosocomial infections: importance and limitations of disinfection methods] Lebeau B, et al. **Pathol Biol (Paris)** 1998 May;46(5):335–40 (38 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychogenic parasitosis. A case series and literature review. Slaughter JR, et al. **Psychosomatics** 1998 Nov–Dec; 39(6):491–500 (38 ref.)

TRANSMISSION

Transmission of parasites by blood transfusion. Dodd RY. **Vox Sang** 1998;74 Suppl 2:161–3 (14 ref.)

[Seafood transmitted diseases] Feldhusen F. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):319–25 (60 ref.) (Eng. Abstr.) **(Ger)**

[Sexually transmitted parasitoses and mycoses] Vahlensieck W. **Fortschr Med** 1999 May 10;117(13):32–5 (42 ref.) **(Ger)**

PARASITIC DISEASES, ANIMAL

Infectious diseases and parasites of ratites. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):455–83, iv (41 ref.)

DIAGNOSIS

PCR–based technology in veterinary parasitology. Gasser RB. **Vet Parasitol** 1999 Aug 1;84(3–4):229–58 (231 ref.)

DRUG THERAPY

Current strategies in the search for novel antiparasitic agents. Witty MJ. **Int J Parasitol** 1999 Jan;29(1):95–103; discussion 113–4 (15 ref.)

Anthelmintic treatment of dairy cows and its effect on milk production. Gross SJ, et al. **Vet Rec** 1999 May 22; 144(21):581–7 (91 ref.)

ECONOMICS

Improving the assessment of the economic impact of parasitic diseases and of their control in production animals. Perry BD, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):145–68 (55 ref.)

EPIDEMIOLOGY

The impact of parasites on wild animal populations. Gulland FM. **Parassitologia** 1997 Dec;39(4):287–91 (67 ref.)

The impact of parasites on marine mammals: a review. Raga JA, et al. **Parassitologia** 1997 Dec;39(4):293–6 (36 ref.)

[Parasitic zoonoses] Janitschke K. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):358–61 (20 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The development of marine environmental monitoring using

fish diseases. McVicar AH. **Parassitologia** 1997 Sep; 39(3):177–81 (15 ref.)

PARASITOLOGY

Isopods associated with fishes: a synopsis and corrections. Bunkley-Williams L, et al. **J Parasitol** 1998 Oct;84(5):893–6 (40 ref.)

Evaluation of environmental deterioration by analysing fish parasite biodiversity and community structure. D'Amelio S, et al. **Parassitologia** 1997 Sep;39(3):237–41 (7 ref.)

Freshwater fish parasites and environmental quality: an overview and caution. Kennedy CR. **Parassitologia** 1997 Sep;39(3):249–54 (12 ref.)

Quantitative aspects of evaluating the consequences of pollution for parasite populations and communities. Lotz JM. **Parassitologia** 1997 Sep;39(3):243–8 (10 ref.)

Parasites in cultured and feral fish. Scholz T. **Vet Parasitol** 1999 Aug 1;84(3–4):317–35 (175 ref.)

PREVENTION & CONTROL

Agricultural policy and sustainable livestock development. Schillhorn van Veen TW. **Int J Parasitol** 1999 Jan; 29(1):7–15 (32 ref.)

Integrated and biological control of parasites in organic and conventional production systems. Thamsborg SM, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):169–86 (67 ref.)

PARASITIC EYE INFECTIONS see **EYE INFECTIONS, PARASITIC**

PARASITIC INTESTINAL DISEASES see **INTESTINAL DISEASES, PARASITIC**

PARASITIC LIVER DISEASES see **LIVER DISEASES, PARASITIC**

PARASITIC LUNG DISEASES see **LUNG DISEASES, PARASITIC**

PARASITIC PREGNANCY COMPLICATIONS see **PREGNANCY COMPLICATIONS, PARASITIC**

PARASITIC SKIN DISEASES see **SKIN DISEASES, PARASITIC**

PARASITIC WORMS see **HELMINTHS**

PARASITICIDES see **ANTIPARASITIC AGENTS**

PARASYMPATHETIC-BLOCKING AGENTS see **PARASYMPATHOLYTICS**

PARASYMPATHETIC GANGLIA see **GANGLIA, PARASYMPATHETIC**

PARASYMPATHETIC NERVOUS SYSTEM

see related
PARASYMPATHOLYTICS
PARASYMPATHOMIMETICS

METABOLISM

Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Savolainen KM, et al. **Neurotoxicology** 1998 Aug–Oct; 19(4–5):669–74 (51 ref.)

PHYSIOLOGY

Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Gibbs RB, et al. **Horm Behav** 1998 Oct;34(2):98–111 (117 ref.)

Cholinergic innervation and function in the mammalian pineal gland. Phansuwan-Pujito P, et al. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):281–95 (115 ref.)

Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Auld DS, et al. **Trends Neurosci** 1998 Jan;21(1):43–9 (83 ref.)

[Modulatory mechanisms involved in the parasympathetic excitatory neuro-effector transmission in the airway and gastrointestinal tracts—perspective for a new drug creation] Ito Y. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:28P–31P (9 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Anxiety and cardiovascular reactivity: the basal forebrain cholinergic link. Berntson GG, et al. **Behav Brain Res** 1998 Aug;94(2):225–48 (280 ref.)

Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease [see comments] Poirier J. **J Psychiatry Neurosci** 1999 Mar;24(2):147–53 (32 ref.) Comment in: J Psychiatry Neurosci 1999 Mar;24(2):139–40.

PARASYMPATHOLYTICS

see related
ANTIPARKINSON AGENTS
ANTI-ULCER AGENTS
MUSCARINIC ANTAGONISTS

THERAPEUTIC USE

An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Goldenberg MM. **Clin Ther** 1999 Apr;21(4):634–42 (27 ref.)

Recent developments in drug therapy for multiple sclerosis. Smith PF, et al. **Mult Scler** 1999 Apr;5(2):110–20 (161 ref.)

Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Gracies JM, et al. **Muscle Nerve Suppl** 1997;6:S92–120 (162 ref.)

Traditional pharmacological treatments for spasticity. Part I: Local treatments. Gracies JM, et al. **Muscle Nerve Suppl** 1997;6:S61–91 (149 ref.)

[Choice of hemorrhoids treatment] Vorob'ev GI, et al. **Khirurgiia (Mosk)** 1999;(8):50–5 (43 ref.) **(Rus)**

PARASYMPATHOMIMETICS

see related
CHOLINESTERASE INHIBITORS
MUSCARINIC AGONISTS

THERAPEUTIC USE

Sjögren's syndrome: a critical review of clinical management. Bell M, et al. **J Rheumatol** 1999 Sep;26(9):2051–61 (31 ref.)

[Pilocarpine—new use for an old drug] Tishler M. **Harefuah** 1998 Aug;135(3–4):150–2 (25 ref.) **(Heb)**

PARATHION METHYL see **METHYL PARATHION**

PARATHYROID DISEASES

Parathyroid disorders of pregnancy. Mestman JH. **Semin Perinatol** 1998 Dec;22(6):485–96 (76 ref.)

PHYSIOPATHOLOGY

[Physiopathology of parathyroid hyperplasia] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1355–61 (59 ref.) **(Fre)**

RADIONUCLIDE IMAGING

Radionuclide scanning in parathyroid diseases. Pattou F, et al. **Br J Surg** 1998 Dec;85(12):1605–16 (130 ref.)

SURGERY

Mediastinal parathyroid cysts revisited. Shields TW, et al. **Ann Thorac Surg** 1999 Feb;67(2):581–90 (75 ref.)

ULTRASONOGRAPHY

Parathyroid cyst: a rare cause of an anterior neck mass. Jha BC, et al. **J Laryngol Otol** 1999 Jan;113(1):73–5 (16 ref.)

PARATHYROID GLANDS

see related
PARATHYROIDECTOMY

CYTOLOGY

[Ca2+ receptor in cell membrane] Lou SJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):252–4 (7 ref.) **(Chi)**

DRUG EFFECTS

Prevention of renal osteodystrophy in predialysis patients. Sanchez CP, et al. **Am J Med Sci** 1999 Jun;317(6):398–404 (59 ref.)

Tricking the parathyroid gland with novel calcimimetic agents [editorial] Nemeth EF, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1923–5 (9 ref.)

Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system. Capen CC. **Toxicol Lett** 1998 Dec 28;102–103:405–9 (7 ref.)

METABOLISM

Modulation of parathyroid cell function by calcium ion in health and uremia. Akizawa T, et al. **Am J Med Sci** 1999 Jun;317(6):358–62 (48 ref.)

Vitamin D and the parathyroid. Beckerman P, et al. **Am J Med Sci** 1999 Jun;317(6):363–9 (75 ref.)

Cell biology of parathyroid hyperplasia in uremia. Fukagawa M. **Am J Med Sci** 1999 Jun;317(6):377–82 (59 ref.)

The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Slatopolsky E, et al. **Am J Med Sci** 1999 Jun;317(6):370–6 (40 ref.)

PATHOLOGY

Cell biology of parathyroid hyperplasia in uremia. Fukagawa M. **Am J Med Sci** 1999 Jun;317(6):377–82 (59 ref.)

Parathyroid hyperplasia in chronic renal failure: role of calcium, phosphate, and calcitriol. Roussanne MC, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:68–9 (22 ref.)

Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Kebebew E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):721–48 (89 ref.)

Hyperfunctioning intrathyroid parathyroid adenoma: report of two cases. Kobayashi T, et al. **Surg Today** 1999; 29(8):766–8 (11 ref.)

[Physiopathology of parathyroid hyperplasia] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1355–61 (59 ref.) **(Fre)**

PHYSIOLOGY

Vitamin D and retinoids in parathyroid glands (review). Hellman P, et al. **Int J Mol Med** 1999 Apr;3(4):355–61 (79 ref.)

Direct effect of phosphate on parathyroid function. Rodriguez M. **Nephrol Dial Transplant** 1999;14 Suppl 1:70–2 (28 ref.)

PHYSIOPATHOLOGY

[Role of phosphate, vitamin D and acidosis in the secretion and synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1349–54 (59 ref.) **(Fre)**

SURGERY

Surgical management of secondary hyperparathyroidism in uremia. Tominaga Y. **Am J Med Sci** 1999 Jun;317(6):390–7 (50 ref.)

PARATHYROID HORMONE RECEPTORS see **RECEPTORS, PARATHYROID HORMONE**

PARATHYROID HORMONES

see related
HYPOPARATHYROIDISM

Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Jüppner H. **Bone** 1999 Jul;25(1):87–90 (61 ref.)

ADMINISTRATION & DOSAGE

The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Masiukiewicz US, et al. **Aging (Milano)** 1998 Jun; 10(3):232–9 (61 ref.)

GENETICS

Parathyroid hormone (PTH)/PTHrP receptor mutations in human chondrodysplasia [editorial; comment] Nissenson RA. **Endocrinology** 1998 Dec;139(12):4753–5 (21 ref.) Comment on: Endocrinology 1998 Dec;139(12):5255–8.

Protein-RNA interactions in the regulation of PTH gene expression by calcium and phosphate [editorial] Naveh-Many T, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):811–3 (17 ref.)

[Activating mutations of the parathyroid hormone and parathyroid hormone related peptide] David L. **Arch Pediatr** 1998;5 Suppl 4:385S–389S (22 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules [editorial; comment] Goltzman D. **J Bone Miner Res** 1999 Feb;14(2):173–7 (44 ref.) Comment on: J Bone Miner Res 1999 Feb;14(2):163–72.

PHARMACOLOGY

Stemming bone loss by suppressing apoptosis [comment] Hock JM. **J Clin Invest** 1999 Aug;104(4):371–3 (44 ref.) Comment on: J Clin Invest 1999 Aug;104(4):439–46.

PHYSIOLOGY

The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Masiukiewicz US, et al. **Aging (Milano)** 1998 Jun; 10(3):232–9 (61 ref.)

Parathyroid hormone-related peptide (PTHrP) and parathyroid hormone (PTH)/PTHrP receptor. Lanske B, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3–4):297–320 (107 ref.)

Calciotropic hormones and the skeleton in uraemia [comment] Lewin E, et al. **Eur J Clin Invest** 1999 Jun; 29(6):466–8 (13 ref.) Comment on: Eur J Clin Invest 1999 Jun;29(6):529–35.

Parathyroid hormone-related protein: roles in the glomerulus. Bosch RJ, et al. **Exp Nephrol** 1999 May–Jun; 7(3):212–6 (15 ref.)

Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development. Dunbar ME, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):21–34 (69 ref.)

Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Rostand SG, et al. **Kidney Int** 1999 Aug;56(2):383–92 (124 ref.)

PARATHYROID HORMONES

Functional analysis of the PTH/PTHrP network of ligands and receptors. Kronenberg HM, et al. **Recent Prog Horm Res** 1998;53:283–301; discussion 301–3 (38 ref.)

[Bone and hormones. Effects of parathyroid hormone on the bone] Chevalley T, et al. **Presse Med** 1999 Mar 13; 28(10):547–53 (75 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of bone resorption by hormone and cytokine] Miyaura C. **Seikagaku** 1998 Jul;70(7):516–30 (59 ref.) **(Jpn)**

SECRETION

Vitamin D receptor polymorphisms as a determinant of bone mass and PTH secretion: from facts to controversies [editorial] Bover J, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1066–8 (14 ref.)

[Role of phosphate, vitamin D and acidosis in the secretion and synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1349–54 (59 ref.) **(Fre)**

[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1338–48 (61 ref.) **(Fre)**

THERAPEUTIC USE

Parathyroid hormone and parathyroid hormone-related protein: model systems for the development of an osteoporosis therapy. Mierke DF, et al. **Curr Pharm Des** 1999 Jan;5(1):21–36 (177 ref.)

PARATHYROID NEOPLASMS

Parathyroid carcinoma in a child. Meier DE, et al. **J Pediatr Surg** 1999 Apr;34(4):606–8 (13 ref.)

COMPLICATIONS

Primary hyperparathyroidism and acute pancreatitis during pregnancy. Report of a case and a review of the English and Japanese literature. Kondo Y, et al. **Int J Pancreatol** 1998 Aug;24(1):43–7 (24 ref.)

ETIOLOGY

Mechanism of parathyroid tumourigenesis in uraemia. Tominaga Y. **Nephrol Dial Transplant** 1999;14 Suppl 1:63–5 (11 ref.)

GENETICS

Familial isolated hyperparathyroidism caused by single adenoma: a distinct entity different from multiple endocrine neoplasia. Watanabe T, et al. **Endocr J** 1998 Oct; 45(5):637–46 (50 ref.)

PATHOLOGY

Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Kovacs KA, et al. **Medicine (Baltimore)** 1998 Nov;77(6):398–402 (26 ref.)

Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Kebebew E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):721–48 (89 ref.)

Hyperfunctioning intrathyroid parathyroid adenoma: report of two cases. Kobayashi T, et al. **Surg Today** 1999; 29(8):766–8 (11 ref.)

PARATHYROIDECTOMY

Surgical management of secondary hyperparathyroidism in uremia. Tominaga Y. **Am J Med Sci** 1999 Jun;317(6):390–7 (50 ref.)

Hyperparathyroidism and pregnancy. Kort KC, et al. **Am J Surg** 1999 Jan;177(1):66–8 (27 ref.)

Tumoral calcinosis regression after subtotal parathyroidectomy: a case presentation and review of the literature. Thakur A, et al. **Surgery** 1999 Jul;126(1):95–8 (10 ref.)

[Anesthesia and postoperative recovery for parathyroid gland surgery] Roland E. **Ann Chir** 1999;53(2):150–61 (48 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Surgical treatment of thyroid disease, thyroidectomy and parathyroidectomy: a medical guide for doctors and nurses. Giddings AE. **J R Soc Med** 1998;91 Suppl 33:36–41 (0 ref.)

Thyroidectomy and parathyroidectomy: a guide for patients. Giddings AE. **J R Soc Med** 1998;91 Suppl 33:33–5 (0 ref.)

PARATUBERCULOSIS

Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. Van Kruiningen HJ. **Inflamm Bowel Dis** 1999 Aug;5(3):183–91 (92 ref.)

COMPLICATIONS

Crohn's disease: the case for bacteria. Prantera C, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):244–6 (39 ref.)

Measles, mycobacterium paratuberculosis and Crohn's disease. Rhodes J, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):255–7 (8 ref.)

PREVENTION & CONTROL

[Bovine paratuberuclosis: history and resulrs of new efforts to control an old disease] Gerlach GF, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):368–73 (95 ref.) (Eng. Abstr.) **(Ger)**

PARATYPHOID FEVER

Salmonella hepatitis. Pramoolsinsap C, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):745–50 (67 ref.)

[Typhoid fever--paratyphoid fever] Nagatake T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):486–9 (4 ref.) **(Jpn)**

PARATYPHOID VACCINE see **TYPHOID-PARATYPHOID VACCINES**

PARAVENTRICULAR HYPOTHALAMIC NUCLEUS

PHYSIOLOGY

Mechanisms of neuroendocrine cell excitability. Hatton GI, et al. **Adv Exp Med Biol** 1998;449:79–95 (86 ref.)

Intrahypothalamic vasopressin release. An inhibitor of systemic vasopressin secretion? Ludwig M, et al. **Adv Exp Med Biol** 1998;449:163–73 (50 ref.)

New aspects of firing pattern autocontrol in oxytocin and vasopressin neurones. Moos F, et al. **Adv Exp Med Biol** 1998;449:153–62 (32 ref.)

Galanin-galanin receptor systems in the hypothalamic paraventricular and supraoptic nuclei. Some recent findings and future challenges. Gundlach AL, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:241–51 (52 ref.)

Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19–26 (35 ref.)

The suprachiasmatic nucleus-paraventricular nucleus interactions: a bridge to the neuroendocrine and autonomic nervous system. Buijs RM, et al. **Prog Brain Res** 1998; 119:365–82 (93 ref.)

PARENT-CHILD RELATIONS

Family management of insulin-dependent diabetes mellitus: a practical problem-solving approach. Kassiou K, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):47–51 (34 ref.)

Including the family perspective in sensory integration outcomes research. Cohn ES, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):540–6 (63 ref.)

Counselling strategies for parents of infants with congenital heart disease. Menahem S. **Cardiol Young** 1998 Jul; 8(3):400–7 (22 ref.)

Clinical vicissitudes of adoption. Derdeyn AP, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):373–88 (54 ref.)

Bereavement and loss in childhood. Geis HK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):73–85, viii (65 ref.)

Assessment of caregiver-child interaction in the context of a preschool psychiatric evaluation. Keren M, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):281–96 (55 ref.)

Preoccupations and behaviors associated with romantic and parental love. Perspectives on the origin of obsessive-compulsive disorder. Leckman JF, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jul;8(3):635–65 (152 ref.)

Adult participation in youth sports. A developmental perspective. Libman S. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):725–44, vii (71 ref.)

Contagion in stress. An infectious disease model for posttraumatic stress in children. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):183–94, x (50 ref.)

Joint custody and shared parenting. Research and interventions. Pruett MK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):273–94, vi (76 ref.)

The achievement by proxy spectrum in youth sports. Historical perspective and clinical approach to pressured and high-achieving children and adolescents. Tofler IR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct; 7(4):803–20, ix (47 ref.)

Resilience in maltreated children: implications for special needs adoption. Henry DL. **Child Welfare** 1999 Sep–Oct; 78(5):519–40 (28 ref.)

Adopting children with attachment problems. Hughes DA. **Child Welfare** 1999 Sep–Oct;78(5):541–60 (19 ref.)

Parent-child relationship disorders: what do the Child Vulnerability Scale and the Parent Protection Scale measure? Thomasgard M, et al. **Clin Pediatr (Phila)** 1999 Jun;38(6):347–56 (30 ref.)

Clinical disturbances of attachment in infancy and early childhood. Boris NW, et al. **Curr Opin Pediatr** 1998 Aug; 10(4):365–8 (27 ref.)

Continuities--a search for causal mechanisms: comment on the special section [comment] Patterson GR. **Dev Psychol** 1998 Nov;34(6):1263–8 (62 ref.) Comment on: Dev Psychol 1998 Nov;34(6):1162–74. Comment on: Dev Psychol 1998 Nov;34(6):1175–88. Comment on: Dev Psychol 1998 Nov;34(6):1189–201. Comment on: Dev Psychol 1998 Nov;34(6):1202–8. Comment on: Dev Psychol 1998 Nov;34(6):1209–19. Comment on: Dev Psychol 1998 Nov;34(6):1209–19. Comment on: Dev Psychol 1998 Nov;34(6):1220–32. Comment on: Dev Psychol 1998 Nov;34(6):1233–45. Comment on: Dev Psychol 1998 Nov;34(6):1246–62.

A concept analysis of parent-infant attachment. Goulet C, et al. **J Adv Nurs** 1998 Nov;28(5):1071–81 (84 ref.)

The adjustment of children with divorced parents: a risk and resiliency perspective. Hetherington EM, et al. **J Child Psychol Psychiatry** 1999 Jan;40(1):129–40 (73 ref.)

Informed consent in school health research: why, how, and making it easy. Ross JG, et al. **J Sch Health** 1999 May; 69(5):171–6 (14 ref.)

Prevention and intervention strategies with children of alcoholics. Emshoff JG, et al. **Pediatrics** 1999 May;103(5 Pt 2):1112–21 (76 ref.)

Children of substance abusers: overview of research findings. Johnson JL, et al. **Pediatrics** 1999 May;103(5 Pt 2):1085–99 (202 ref.)

The role of parents in children's psychological development. Kagan J. **Pediatrics** 1999 Jul;104(1 Pt 2):164–7 (25 ref.)

Generic aspects of primate attachments: parents, offspring and mates. Mason WA, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):765–78 (97 ref.)

Consent (assent) for research with pediatric patients. Broome ME. **Semin Oncol Nurs** 1999 May;15(2):96–103 (23 ref.)

[The parental maturity of elderly dependent parents. Contributions to a contextual definition] Mahieu S, et al. **Tijdschr Gerontol Geriatr** 1999 Apr;30(2):64–72 (18 ref.) (Eng. Abstr.) **(Dut)**

[Parent-infant-program "Menschenskind"--concept and outcomes of the first three years] Barth R. **Prax Kinderpsychol Kinderpsychiatr** 1999 Mar;48(3):178–91 (47 ref.) (Eng. Abstr.) **(Ger)**

[Developmental problems and risks of children and adolescents with severe hearing impairment--a challenge for intervention by child and adolescent psychiatrists] Kammerer E. **Prax Kinderpsychol Kinderpsychiatr** 1999 May-Jun;48(5):351–65 (17 ref.) (Eng. Abstr.) **(Ger)**

PARENT, SINGLE see **SINGLE PARENT**

PARENTAL CONSENT see **THIRD-PARTY CONSENT**

PARENTAL IMPRINTING see **GENOMIC IMPRINTING**

PARENTAL LEAVE

STATISTICS & NUMERICAL DATA

Sickness absence: a review of performed studies with focused on levels of exposures and theories utilized. Alexanderson K. **Scand J Soc Med** 1998 Dec;26(4):241–9 (92 ref.)

PARENTERAL FEEDING see **PARENTERAL NUTRITION**

PARENTERAL FEEDING, HOME see **PARENTERAL NUTRITION, HOME**

PARENTERAL HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

PARENTERAL INFUSIONS see **INFUSIONS, PARENTERAL**

PARENTERAL NUTRITION

see related
FAT EMULSIONS, INTRAVENOUS

Parenteral nutrition in pediatrics. Indications and perspectives. Goulet O. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):210–5 (47 ref.)

Lipid emulsions in parenteral nutrition. Adolph M. **Ann Nutr Metab** 1999;43(1):1–13 (73 ref.)

Preoperative issues in clinical nutrition. McClave SA, et al. **Chest** 1999 May;115(5 Suppl):64S–70S (50 ref.)

Principles for formulating parenteral nutrition for neonates [see comments] Ball P. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):261–4 (28 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):259–60.

Percutaneous catheter use in newborn infants with parenteral nutrition. García del Río M, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S33–41 (10 ref.)

Aggressive oral, enteral or parenteral nutrition: prescriptive decisions in children with cancer. Pencharz PB. **Int J Cancer Suppl** 1998;11:73–5 (20 ref.)

Compatibility and stability of additives in parenteral nutrition admixtures. Allwood MC, et al. **Nutrition** 1998 Sep; 14(9):697–706 (78 ref.)

Safe practices in parenteral nutrition compounding--an international consensus? Allwood MC. **Nutrition** 1999 May; 15(5):409–10 (5 ref.)

Quality of life issues: parenteral nutrition to small bowel transplantation--a review. Brook G. **Nutrition** 1998 Oct;

14(10):813–6 (24 ref.)
State of artificial nutrition in Hungary: standpoint and methodologic recommendations. Harsányi L, et al. **Nutrition** 1999 Jan;15(1):40–3 (9 ref.)
Bacterial translocation during enteral and parenteral nutrition. Alexander JW. **Proc Nutr Soc** 1998 Aug; 57(3):389–93 (28 ref.)
Principles of feeding cancer patients via enteral or parenteral nutrition during radiotherapy. Fietkau R. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:47–51 (18 ref.)
[Management of malnutrition in chronic hemodialysis] Cano N, et al. **Nephrologie** 1998;19(6):353–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Parenteral and enteral feeding] Hackl JM. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):731–52 (39 ref.) **(Ger)**
[Prospective comparative study of different amino acid and lipid solutions in parenteral nutrition of patients undergoing bone marrow transplantation] Jiménez Jiménez FJ, et al. **Nutr Hosp** 1999 Mar–Apr;14(2):57–66 (47 ref.) (Eng. Abstr.) **(Spa)**
[Non-glucose carbohydrates in the parenteral nutrition of patients with systemic inflammatory response syndrome] López Martínez J, et al. **Nutr Hosp** 1999 Mar–Apr; 14(2):71–80 (35 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Monitoring and complications of parenteral nutrition. Meadows N. **Nutrition** 1998 Oct;14(10):806–8 (17 ref.)
[Parenteral nutrition associated cholestasis in the newborn] Schwenk RA, et al. **Klin Padiatr** 1998 Nov–Dec; 210(6):381–9 (106 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Pediatric experience with intradialytic parenteral nutrition and supplemental tube feeding. Brewer ED. **Am J Kidney Dis** 1999 Jan;33(1):205–7 (20 ref.)
An evidence-based evaluation of intradialytic parenteral nutrition [see comments] Foulks CJ. **Am J Kidney Dis** 1999 Jan;33(1):186–92 (56 ref.) Comment in: Am J Kidney Dis 1999 Jun;33(6):1202.
Immunonutrition in the critically ill. Jolliet P, et al. **Intensive Care Med** 1999 Jun;25(6):631–3 (3 ref.)
[The strategy and current potentials of parenteral feeding in surgery] Kostiuchenko AL. **Vestn Khir Im I I Grek** 1998; 157(4):116–20 (9 ref.) (Eng. Abstr.) **(Rus)**
[Non-glucose carbohydrates in the parenteral nutrition of patients with systemic inflammatory response syndrome] López Martínez J, et al. **Nutr Hosp** 1999 Mar–Apr; 14(2):71–80 (35 ref.) (Eng. Abstr.) **(Spa)**

PARENTERAL NUTRITION, HOME

Parenteral nutrition in pediatrics. Indications and perspectives. Goulet O. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):210–5 (47 ref.)
Home parenteral nutrition in adults: the current use of an experienced method. Van Gossum A, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):201–9 (126 ref.)
Preparing for parenteral nutrition therapy at home. Barnadas G. **Am J Health Syst Pharm** 1999 Feb 1;56(3):270–2 (4 ref.)
Home enteral and parenteral nutrition in children. Colomb V, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):877–94 (63 ref.)
Home parenteral nutrition: the pediatric point of view. Colomb V. **Nutrition** 1999 Feb;15(2):172–3 (21 ref.)

ADVERSE EFFECTS

Stability issues in home parenteral nutrition. Wormleighton CV, et al. **Clin Nutr** 1998 Oct;17(5):199–203 (45 ref.)

ECONOMICS

The economics of home parenteral nutrition. Puntis JW. **Nutrition** 1998 Oct;14(10):809–12 (28 ref.)

UTILIZATION

Home parenteral nutrition in acquired immunodeficiency syndrome patients [editorial] Melchior JC, et al. **Nutrition** 1999 Jan;15(1):68–9 (21 ref.)

PARENTERAL NUTRITION, TOTAL

Nutrition management in the ICU. Chan S, et al. **Chest** 1999 May;115(5 Suppl):145S–148S (23 ref.)
The effects of enteral tube feeding and parenteral nutrition on appetite sensations and food intake in health and disease. Stratton RJ, et al. **Clin Nutr** 1999 Apr;18(2):63–70 (79 ref.)
Glutamine-containing TPN: a question of life and death for intensive care unit-patients? Wernerman J. **Clin Nutr** 1998 Feb;17(1):3–6 (31 ref.)
Nutritional support of the pediatric surgical patient. Amii LA, et al. **Curr Opin Pediatr** 1999 Jun;11(3):237–40 (18 ref.)
Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423–43, ix (160 ref.)
Artificial nutrition in the critically ill. Weissman C. **Intensive Care Med** 1998 Sep;24(9):984–5 (3 ref.)
Total parenteral nutrition in the critically ill patient. Birmingham CL. **Lancet** 1999 Apr 3;353(9159):1116–7 (9 ref.)
Nutritional management of patients with feeding-induced pain: acute pancreatitis. Seidner DL, et al. **Semin Gastrointest Dis** 1998 Oct;9(4):200–9 (58 ref.)
Always remember chylothorax. Pérez J, et al. **South Med J** 1999 Aug;92(8):833–5 (31 ref.)
Artificial nutrition in cancer patients: which route, what composition? Bozzetti F, et al. **World J Surg** 1999 Jun; 23(6):577–83 (50 ref.)
Postoperative total parenteral nutrition. Waitzberg DL, et al. **World J Surg** 1999 Jun;23(6):560–4 (42 ref.)
[Parenteral and enteral nutrition in palliative medicine] Herrmann A, et al. **Zentralbl Chir** 1999;124(7):573–84 (24 ref.) (Eng. Abstr.) **(Ger)**
[Total parenteral nutrition in cancer patients] Cuocolo R, et al. **Minerva Anestesiol** 1981 Jul;47(7):351–4 (5 ref.) **(Ita)**

ADVERSE EFFECTS

New approaches to understanding the etiology and treatment of total parenteral nutrition-associated cholestasis. Moss RL, et al. **Semin Pediatr Surg** 1999 Aug;8(3):140–7 (101 ref.)

METHODS

[Prevention and principles of management in case of cardiac tamponade after catheterisation of the subclavian vein in parenteral nutrition] Gluszek S, et al. **Wiad Lek** 1999; 52(1–2):42–8 (16 ref.) (Eng. Abstr.) **(Pol)**

PARENTERALLY-TRANSMITTED NON-A, NON-B HEPATITIS see **HEPATITIS C**

PARENTING

Primary prevention of child abuse. Bethea L. **Am Fam Physician** 1999 Mar 15;59(6):1577–85, 1591–2 (37 ref.)
Lesbian parenthood: a review of the literature. Parks CA. **Am J Orthopsychiatry** 1998 Jul;68(3):376–89 (69 ref.)
Joint custody and shared parenting. Research and interventions. Pruett MK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):273–94, vi (76 ref.)

PSYCHOLOGY

Fathers, divorce, and their children. Pruett MK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):389–407, viii (45 ref.)
Child development and pediatrics for the 21st century: the healthy steps approach. McLearn KT, et al. **J Urban Health** 1998 Dec;75(4):704–23 (20 ref.)
Recollections of parental behaviour, adult attachment and mental health: mediating and moderating effects. Gittleman MG, et al. **Psychol Med** 1998 Nov;28(6):1443–55 (46 ref.)

PARENTS

see related
CHILD OF IMPAIRED PARENTS
SINGLE PARENT

Annotation: children's disengagement from medical homes--a neglected public health imperative [editorial] Irigoyen M, et al. **Am J Public Health** 1999 Feb;89(2):157–9 (25 ref.)
Child sexual abuse: victim age, victim gender, and observer gender as factors contributing to attributions of responsibility. Back S, et al. **Child Abuse Negl** 1998 Dec; 22(12):1239–52 (49 ref.)
Parent's participation and perspectives regarding clinical judgment and clinical guideline development. Pachter LM. **Curr Opin Pediatr** 1998 Oct;10(5):476–9 (12 ref.)
Using parents' concerns to detect and address developmental and behavioral problems. Glascoe FP. **J Soc Pediatr Nurs** 1999 Jan–Mar;4(1):24–35 (23 ref.)
Ethical considerations in prenatal surgical consultation [see comments] Caniano DA, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):303–9 (21 ref.) Comment in: Pediatr Surg Int 1999 Jul;15(5–6):301–2.
Neonatal intensive care: satisfaction measured from a parent's perspective. Conner JM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):336–49 (67 ref.)
[Parents judgement concerning family work of a child psychiatric ward] Romberg A. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec;47(10):773–8 (15 ref.) (Eng. Abstr.) **(Ger)**
[Family model and the educational role of parents in the formation of alcohol consumption pattern in adolescents] Pons Diez J. **Rev Esp Salud Publica** 1998 May–Jun; 72(3):251–66 (33 ref.) (Eng. Abstr.) **(Spa)**

EDUCATION

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Wahl RA, et al. **Curr Opin Pediatr** 1998 Dec;10(6):641–50 (78 ref.)
Parents and their child's fever: do as I say, not as I do? [editorial; comment] Kai J. **Fam Pract** 1998 Dec;15(6):505–6 (14 ref.) Comment on: Fam Pract 1998 Dec;15(6):513–8.
'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369–75 (4 ref.) Comment in: J Med Ethics 1998 Dec;24(6):363–4.
Empirically supported treatments in pediatric psychology: severe feeding problems [see comments] Kerwin ME. **J Pediatr Psychol** 1999 Jun;24(3):193–214; discussion 215–6 (92 ref.) Comment in: J Pediatr Psychol 1999 Jun;24(3):221–2.
Traveling with children. Leggat PA, et al. **J Travel Med** 1998 Sep;5(3):142–6 (14 ref.)
Guiding parents' use of the Internet for newborn education. Lamp JM, et al. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):33–6 (8 ref.)

PSYCHOLOGY

A test of parenthood: dilemmas of parents of terminally ill adolescents. Hayout I, et al. **Cancer Nurs** 1999 Feb; 22(1):71–9 (26 ref.)
Counselling strategies for parents of infants with congenital heart disease. Menahem S. **Cardiol Young** 1998 Jul; 8(3):400–7 (22 ref.)
Preoccupations and behaviors associated with romantic and parental love. Perspectives on the origin of obsessive-compulsive disorder. Leckman JF, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jul;8(3):635–65 (152 ref.)
Models of service support for parents of disabled children. What do we know? What do we need to know? Sloper P. **Child Care Health Dev** 1999 Mar;25(2):85–99 (61 ref.)
Decision-making and the role of surrogacy in withdrawal or withholding of therapy in neonates. Steinberg A. **Clin Perinatol** 1998 Sep;25(3):779–90, xii (42 ref.)
Continuities--a search for causal mechanisms: comment on the special section [comment] Patterson GR. **Dev Psychol** 1998 Nov;34(6):1263–8 (62 ref.) Comment on: Dev Psychol 1998 Nov;34(6):1162–74. Comment on: Dev Psychol 1998 Nov;34(6):1175–88. Comment on: Dev Psychol 1998 Nov;34(6):1189–201. Comment on: Dev Psychol 1998 Nov;34(6):1202–8. Comment on: Dev Psychol 1998 Nov;34(6):1209–19. Comment on: Dev Psychol 1998 Nov;34(6):1209–19. Comment on: Dev Psychol 1998 Nov;34(6):1220–32. Comment on: Dev Psychol 1998 Nov;34(6):1233–45. Comment on: Dev Psychol 1998 Nov;34(6):1246–62.
Parents and their child's fever: do as I say, not as I do? [editorial; comment] Kai J. **Fam Pract** 1998 Dec;15(6):505–6 (14 ref.) Comment on: Fam Pract 1998 Dec;15(6):513–8.
Building a support group for parents of children with brain tumors. McGee SJ, et al. **J Neurosci Nurs** 1998 Dec; 30(6):345–9 (7 ref.)
Nursing interventions to reduce stress in parents of hospitalized preterm infants. Griffin T, et al. **J Pediatr Nurs** 1998 Oct;13(5):290–5 (31 ref.)
Generic aspects of primate attachments: parents, offspring and mates. Mason WA, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):765–78 (97 ref.)
The drinker's children. Barber JG, et al. **Subst Use Misuse** 1999 Feb;34(3):383–402 (48 ref.)
Does child care involvement increase or decrease distress among dual-earner couples? Ozer EM, et al. **Womens Health** 1998 Winter;4(4):285–311 (71 ref.)

PARESIS

DRUG THERAPY

[The use of macrolide antibiotics in the treatment of postop intestinal paresis] Skomarovskii AA, et al. **Klin Khir** 1999; (1):55–6 (7 ref.) **(Rus)**

ETIOLOGY

[Acute symptom transverse laminectomy for a benign osteoclastoma of thethoracic spine--case report and review of the literature] Gruber AW, et al. **Zentralbl Neurochir** 1999;60(2):93–9 (18 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[The use of macrolide antibiotics in the treatment of postop intestinal paresis] Skomarovskii AA, et al. **Klin Khir** 1999; (1):55–6 (7 ref.) **(Rus)**

PARESTHESIA

ETIOLOGY

Anesthesia of the inferior alveolar and lingual nerves as a complication of a fractured condylar process. Griffiths H, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):77–9 (22 ref.)
[Tingling in the hands] Geelen JA, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1593–7 (9 ref.) (Eng. Abstr.) **(Dut)**

PARETIC NEUROSYPHILIS see **NEUROSYPHILIS**

PARIETAL BONE

Dural osteochondroma: case report, review of the literature and proposal of a new classification. Haddad GF, et al. **Br J Neurosurg** 1998 Aug;12(4):380–4 (35 ref.)
Intracranial osteosarcomas: report of four cases and review

PARIETAL BONE

of the literature [see comments] Ashkan K, et al. **J Neurooncol** 1998 Oct;40(1):87-96 (41 ref.) Comment in: J Neurooncol 1999 May;43(1):93.

PARIETAL CELLS, GASTRIC

see related
GASTRIC ACID

METABOLISM

CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Håkanson R, et al. **Regul Pept** 1999 Mar 17;80(1-2):1-12 (117 ref.)

PARIETAL LOBE

BLOOD SUPPLY

[A case of pure agraphia due to left parietal lobe infarction] Yaguchi H, et al. **Rinsho Shinkeigaku** 1998 Jun; 38(6):499-505 (24 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Parasagittal solitary fibrous tumor of the meninges. Case report and review of the literature. Nikas DC, et al. **Acta Neurochir (Wien)** 1999;141(3):307-13 (57 ref.)

Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. Pavlakis SG, et al. **J Child Neurol** 1999 May;14(5):277-81 (36 ref.)

PHYSIOLOGY

The contributions of vestibular signals to the representations of space in the posterior parietal cortex. Andersen RA, et al. **Ann N Y Acad Sci** 1999 May 28;871:282-92 (44 ref.)

Space and attention in parietal cortex. Colby CL, et al. **Annu Rev Neurosci** 1999;22:319-49 (84 ref.)

A neuronal model of attentional spotlight: parietal guiding the temporal. Vidyasagar TR. **Brain Res Brain Res Rev** 1999 Jul;30(1):66-76 (104 ref.)

The associative parietal cortex and spatial processing in rodents. Thinus-Blanc C, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):179-83 (45 ref.)

From perception to action: temporal integrative functions of prefrontal and parietal neurons. Quintana J, et al. **Cereb Cortex** 1999 Apr-May;9(3):213-21 (52 ref.)

Neurology of saccades and smooth pursuit. Gaymard B, et al. **Curr Opin Neurol** 1999 Feb;12(1):13-9 (56 ref.)

Parietal neglect and visual awareness. Driver J, et al. **Nat Neurosci** 1998 May;1(1):17-22 (45 ref.)

Functional anatomy of dominance for speech comprehension in left handers vs right handers. Tzourio N, et al. **Neuroimage** 1998 Jul;8(1):1-16 (100 ref.)

Posterior parietal areas specialized for eye movements (LIP) and reach (PRR) using a common coordinate frame. Andersen RA, et al. **Novartis Found Symp** 1998;218:109-22; discussion 122-8, 171-5 (32 ref.)

Cortical control of whole-arm motor tasks. Kalaska JF, et al. **Novartis Found Symp** 1998;218:176-90; discussion 190-201 (60 ref.)

The apraxias are higher-order defects of sensorimotor integration. Marsden CD. **Novartis Found Symp** 1998; 218:308-25; discussion 326-31 (79 ref.)

PARITY

see related
GRAVIDITY

Grandmultiparity. Is it a perinatal risk? Samueloff A, et al. **Clin Perinatol** 1998 Sep;25(3):529-38 (39 ref.)

Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. Thom DH, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1411-7 (98 ref.)

PARKINSON DISEASE

see related
ANTIPARKINSON AGENTS
LEWY BODIES

Science, medicine, and the future: Parkinson's disease. Schapira AH. **BMJ** 1999 Jan 30;318(7179):311-4 (17 ref.)

Experimental models of Parkinson's disease: insights from many models. Tolwani RJ, et al. **Lab Anim Sci** 1999 Aug; 49(4):363-71 (103 ref.)

Parkinson's: a strategy for management. Pentland B. **Practitioner** 1997 Sep;241(1578):512, 515-6, 518 (11 ref.)

[Diffuse Lewy body disease] Kosaka K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):82-5 (15 ref.) **(Jpn)**

[ALS and parkinsonism-dementia complex of Guam and western Pacific] Kuzuhara S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):330-4 (15 ref.) **(Jpn)**

[ALS and parkinsonism-dementia complex of Kii peninsula] Kuzuhara S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):335-8 (15 ref.) **(Jpn)**

[Parkinsonism-dementia complex on Guam] Murakami N. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):57-60 (12 ref.) **(Jpn)**

[Parkinson's disease] Yokochi M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):5-14 (32 ref.) **(Jpn)**

CLASSIFICATION

Parkinsonian and essential tremors: different entities or different manifestations of the same disorder? Lücking CH, et al. **Adv Neurol** 1999;80:335-9 (9 ref.)

Experimental models of Parkinson's disease: from the static to the dynamic. Bezard E, et al. **Rev Neurosci** 1998; 9(2):71-90 (252 ref.)

COMPLICATIONS

Visual and visual cognitive dysfunction in Parkinson's disease: spatial and chromatic vision. Bodis-Wollner IG, et al. **Adv Neurol** 1999;80:383-8 (30 ref.)

DOPA-responsive dystonic parkinsonism--pathophysiologic considerations. Segawa M, et al. **Adv Neurol** 1999; 80:389-400 (64 ref.)

Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Wenning GK, et al. **Adv Neurol** 1999;80:545-8 (25 ref.)

Rare and unusual parkinsonian syndromes. Wszolek ZK, et al. **Adv Neurol** 1999;80:369-76 (79 ref.)

Therapy of behavioral disorders in Parkinson's disease. Valldeoriola F, et al. **Biomed Pharmacother** 1999 Apr; 53(3):149-53 (56 ref.)

Sentence processing in Parkinson's disease. Grossman M. **Brain Cogn** 1999 Jul;40(2):387-413 (92 ref.)

Female voiding dysfunction and movement disorders. Dmochowski RR. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):144-51 (36 ref.)

Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. Melamed E, et al. **J Neural Transm Suppl** 1999; 56:173-83 (40 ref.)

Managing late complications of Parkinson's disease. Stacy M. **Med Clin North Am** 1999 Mar;83(2):469-81, vii (80 ref.)

Neural transplantation in Parkinson's disease and its effects on rest tremor: a review of the literature. Pogarell O, et al. **Mov Disord** 1998;13 Suppl 3:101-2 (14 ref.)

Pain in Parkinson's disease patients. Serratrice G, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):331-8 (79 ref.)

Shoulder pain in patients with Parkinson's disease. Vaserman-Lehuédé N, et al. **Rev Rhum Engl Ed** 1999 Apr; 66(4):220-3 (16 ref.)

[Cognitive deficits in Parkinson's disease] van Spaendonck KP, et al. **Tijdschr Gerontol Geriatr** 1998 Aug;29(4):189-95 (38 ref.) (Eng. Abstr.) **(Dut)**

[Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP 17)] Nakano I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):20-3 (14 ref.) **(Jpn)**

[Parkinson disease and cognition] Kulisevsky J, et al. **Neurologia** 1999 May;14 Suppl 1:72-81 (97 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Atypical presentations of dopa-responsive dystonia. Bandmann O, et al. **Adv Neurol** 1998;78:283-90 (43 ref.)

Preclinical diagnosis of Parkinson's disease. Horstink MW, et al. **Adv Neurol** 1999;80:327-33 (52 ref.)

Standardized quantitative measurements in Parkinson's disease. Korczyn AD, et al. **Adv Neurol** 1999;80:439-42 (14 ref.)

Separating the primary autonomic failure syndromes, multiple system atrophy, and pure autonomic failure from Parkinson's disease. Mathias CJ, et al. **Adv Neurol** 1999; 80:353-61 (28 ref.)

Parkinson's disease. A holistic approach. Barker S, et al. **Am J Nurs** 1998 Nov;98(11):48A-48G; quiz 48G-48H (27 ref.)

Lewy body dementia. Brown DF. **Ann Med** 1999 Jun; 31(3):188-96 (98 ref.)

Diagnostic criteria for Parkinson disease. Gelb DJ, et al. **Arch Neurol** 1999 Jan;56(1):33-9 (71 ref.)

Differential diagnosis of parkinsonism. Stoessl AJ, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S1-4 (30 ref.)

Differential diagnosis of tremor. Deuschl G. **J Neural Transm Suppl** 1999;56:211-20 (22 ref.)

A review of Lewy body disease, an emerging concept of cortical dementia. Papka M, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer;10(3):267-79 (73 ref.)

Differential diagnosis of Parkinson's disease. Adler CH. **Med Clin North Am** 1999 Mar;83(2):349-67 (116 ref.)

Clinical manifestations of Parkinson's disease. Colcher A, et al. **Med Clin North Am** 1999 Mar;83(2):327-47 (110 ref.)

Pregnancy in Parkinson's disease: a review of the literature and a case report [letter; comment] Benito-León J, et al. **Mov Disord** 1999 Jan;14(1):194 (6 ref.) Comment on: Mov Disord 1998 Jan;13(1):34-8.

Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Wolters EC. **Neurology** 1999;52(7 Suppl 3):S10-3 (26 ref.)

A brief history of the neurobehavioral toxicity of manganese: some unanswered questions. McMillan DE. **Neurotoxicology** 1999 Apr-Jun;20(2-3):499-507 (40 ref.)

Manganese neurotoxicity: a review of clinical features, imaging and pathology. Pal PK, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):227-38 (139 ref.)

Neurologic degenerative disorders. Ross AP. **Nurs Clin North Am** 1999 Sep;34(3):725-42 (14 ref.)

Parkinson's disease--the shaking palsy. Underlying factors, diagnostic considerations, and clinical course. Conley SC, et al. **Postgrad Med** 1999 Jul;106(1):39-42, 45-6, 49-50 passim (22 ref.)

[Parkinsonism. The differential diagnosis] de Leest BJ, et al. **Tijdschr Gerontol Geriatr** 1998 Oct;29(5):250-7 (45 ref.) (Eng. Abstr.) **(Dut)**

[Multisystem degenerative diseases with Parkinsom syndrome. Differential diagnosis and differential therapeutic aspects] Benecke R. **Nervenarzt** 1999 Jan;70 Suppl 1:S35-41 (26 ref.) **(Ger)**

[Value of functional imaging in Parkinson's disease and related movement disorders] Heiss WD, et al. **Nervenarzt** 1999 Jan;70 Suppl 1:S2-10 (71 ref.) (Eng. Abstr.) **(Ger)**

[Neuroimaging of motor disturbances] Iwata M. **Rinsho Shinkeigaku** 1998 Dec;38(12):1010-2 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Clinimetrics in parkinsonism] Opara J. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1497-511 (29 ref.) (Eng. Abstr.) **(Pol)**

[Current therapeutic problems. Solutions] Castro Garcia A, et al. **Neurologia** 1999 May;14 Suppl 1:34-45 (89 ref.) **(Spa)**

[The problem of accurate diagnosis of Parkinson disease] Giménez Roldán S, et al. **Neurologia** 1999 May;14 Suppl 1:3-16 (93 ref.) (Eng. Abstr.) **(Spa)**

[Parkinsonian syndromes and Parkinson's disease: differential clinical diagnosis] Litvan I. **Neurologia** 1998;13 Suppl 1:30-5 (49 ref.) **(Spa)**

[Neurophysiological examinations in Parkinson disease] Valls Solé J, et al. **Neurologia** 1999 Jun-Jul;14(6):289-305 (101 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Bradford HF, et al. **Adv Neurol** 1999; 80:19-25 (33 ref.)

Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Kuwana Y, et al. **Adv Neurol** 1999; 80:121-3 (13 ref.)

Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients. Rascol O, et al. **Adv Neurol** 1999; 80:485-90 (36 ref.)

COMT inhibition with entacapone in the treatment of Parkinson's disease. Rinne UK, et al. **Adv Neurol** 1999; 80:491-4 (24 ref.)

DOPA-responsive dystonic parkinsonism--pathophysiologic considerations. Segawa M, et al. **Adv Neurol** 1999; 80:389-400 (64 ref.)

Do we need more drugs to treat Parkinson's disease? Weiner WJ, et al. **Adv Neurol** 1999;80:481-3 (13 ref.)

Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Kuzel MD. **Am J Health Syst Pharm** 1999 Feb 1;56(3):217-24 (42 ref.)

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA [see comments] Fahn S. **Arch Neurol** 1999 May;56(5):529-35 (108 ref.) Comment in: Arch Neurol 1999 May;56(5):524.

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Shults CW, et al. **Biofactors** 1999;9(2-4):267-72 (27 ref.)

Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Blanchet PJ. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S21-6 (91 ref.)

Treatment of early Parkinson's disease. Grimes DA, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S39-44 (65 ref.)

Ropinirole and pramipexole, the new agonists. Hobson DE, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S27-33 (53 ref.)

Parkinson's disease--levodopa complications. King DB. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S13-20 (45 ref.)

COMT inhibitors in Parkinson's disease. Rivest J, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S34-8 (19 ref.)

Parkinson's disease. Barboi AC, et al. **Clin Neuropharmacol** 1999 Jul-Aug;22(4):184-91 (24 ref.)

The treatment of Parkinson's disease: current concepts and rationale. Hingtgen CM, et al. **Compr Ther** 1998 Nov-Dec; 24(11-12):560-6 (26 ref.)

Entacapone. A review of its use in Parkinson's disease. Holm KJ, et al. **Drugs** 1999 Jul;58(1):159-77 (58 ref.)

Therapeutic potential of nerve growth factors in Parkinson's disease. Collier TJ, et al. **Drugs Aging** 1999 Apr; 14(4):261-87 (215 ref.)

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Jellinger KA. **Drugs Aging** 1999 Feb;14(2):115-40 (305 ref.)

Clinical pharmacology of dopamine agonists in Parkinson's disease. Lange KW. **Drugs Aging** 1998 Nov;13(5):381-9 (83 ref.)

Does levodopa accelerate Parkinson's disease? Simuni T, et al. **Drugs Aging** 1999 Jun;14(6):399-408 (98 ref.)

Is NADH effective in the treatment of Parkinson's disease? Swerdlow RH. **Drugs Aging** 1998 Oct;13(4):263-8 (31 ref.)

Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. Stoof JC, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):75-86 (107 ref.)

Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease. Calne DB. **J Neural Transm Suppl** 1999;56:185–92 (20 ref.)

Free radical scavengers: chemical concepts and clinical relevance. Gassen M, et al. **J Neural Transm Suppl** 1999; 56:193–210 (83 ref.)

Clinical efficacy of budipine in Parkinson's disease. Przuntek H, et al. **J Neural Transm Suppl** 1999;56:75–82 (27 ref.)

Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? Rascol O. **J Neural Transm Suppl** 1999;55:33–45 (66 ref.)

Glial cell line–derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. Grondin R, et al. **J Neurol** 1998 Nov;245(11 Suppl 3):P35–42 (62 ref.)

COMT inhibition in the treatment of Parkinson's disease. Ruottinen HM, et al. **J Neurol** 1998 Nov;245(11 Suppl 3):P25–34 (61 ref.)

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease [see comments] Bennett JP Jr, et al. **J Neurol Sci** 1999 Feb 1;163(1):25–31 (34 ref.) Comment in: J Neurol Sci 1999 Feb 1;163(1):2–3.

Hypothesis: can N–acetylcysteine be beneficial in Parkinson's disease? Martínez M, et al. **Life Sci** 1999;64(15):1253–7 (45 ref.)

Dopamine agonists. Factor SA. **Med Clin North Am** 1999 Mar;83(2):415–43, vi–vii (94 ref.)

Management of early Parkinson's disease. Hauser RA, et al. **Med Clin North Am** 1999 Mar;83(2):393–414, vi (111 ref.)

Novel drugs for Parkinson's disease. Hubble JP. **Med Clin North Am** 1999 Mar;83(2):525–36 (37 ref.)

Monoamine oxidase and catechol–O–methyltransferase inhibitors. Siderowf A, et al. **Med Clin North Am** 1999 Mar;83(2):445–67 (131 ref.)

Neuroprotective therapies. Simon DK, et al. **Med Clin North Am** 1999 Mar;83(2):509–23, viii (99 ref.)

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Brotchie JM. **Mov Disord** 1998 Nov;13(6):871–6 (14 ref.)

Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Factor SA, et al. **Mov Disord** 1999 May;14(3):515–7 (31 ref.)

Pharmacologic treatment of tremor. Wasielewski PG, et al. **Mov Disord** 1998;13 Suppl 3:90–100 (152 ref.)

Catechol–0–methyl transferase inhibitors in the treatment of Parkinson's disease. Lees AJ. **Neurologia** 1998;13 Suppl 1:72–5 (17 ref.)

Levodopa effective parkinsonism associated with aqueductal stenosis: a case report and review of the literature. Asamoto S, et al. **No Shinkei Geka** 1998 Dec;26(12):1089–92 (6 ref.)

New, selective catechol–O–methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Bonifati V, et al. **Pharmacol Ther** 1999 Jan;81(1):1–36 (290 ref.)

Tolcapone, a selective catechol–O–methyltransferase inhibitor for treatment of Parkinson's disease. Guay DR. **Pharmacotherapy** 1999 Jan;19(1):6–20 (59 ref.)

Managing early Parkinson's disease. Clarke CE. **Practitioner** 1999 Jan;243(1594):39, 42–5, 47 (2 ref.)

Catechol–O–methyltransferase inhibitors: new options for Parkinson's disease. Leicht MJ, et al. **S D J Med** 1999 Aug; 52(8):295–7 (14 ref.)

Current therapy in Parkinson's disease. Brandabur MM. **Surg Neurol** 1999 Sep;52(3):318–22 (42 ref.)

[Drug therapy in Parkinson's disease] van Hilten JJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30;143(5):234–40 (27 ref.) (Eng. Abstr.) **(Dut)**

[Arguments in favor of the early treatment of Parkinson's disease with L–Dopa (see comments)] Broussolle E. **Rev Neurol (Paris)** 1999 Jan;155(1):27–33 (82 ref.) Comment in: Rev Neurol (Paris) 1999 Jan;155(1):43–5. **(Fre)**

[Controversial issues concerning the initial treatment of Parkinson's disease: L–Dopa or dopaminergic agonists? (comment)] Defer GL. **Rev Neurol (Paris)** 1999 Jan; 155(1):43–5 (12 ref.) Comment on: Rev Neurol (Paris) 1999 Jan;155(1):27–33. Comment on: Rev Neurol (Paris) 1999 Jan;155(1):35–42. **(Fre)**

[Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists (see comments)] Rascol O. **Rev Neurol (Paris)** 1999 Jan;155(1):35–42 (52 ref.) Comment in: Rev Neurol (Paris) 1999 Jan;155(1):43–5. **(Fre)**

[Pharmacologic approach to autonomic failure] Senard JM, et al. **Therapie** 1998 Jan–Feb;53(1):35–41 (80 ref.) (Eng. Abstr.) **(Fre)**

[Understanding and treating levodopa–induced dyskinesias] Hadj Tahar A, et al. **Tunis Med** 1998 Dec;76(12):437–47 (96 ref.) **(Fre)**

[Treatment strategies for de novo Parkinson patients] Baas H. **Nervenarzt** 1999 Jan;70 Suppl 1:S11–8 (91 ref.) **(Ger)**

[Multisystem degenerative diseases with Parkinsonism syndrome. Differential diagnosis and differential therapeutic aspects] Benecke R. **Nervenarzt** 1999 Jan;70 Suppl 1:S35–41 (26 ref.) **(Ger)**

[Progress in the treatment of Parkinson's disease] Nakamura S. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):465–9 (7 ref.) **(Jpn)**

[Parkinson's disease] Nakamura S. **Nippon Ronen Igakkai Zasshi** 1998 Aug;35(8):605–10 (24 ref.) **(Jpn)**

[The treatment of Parkinson disease (editorial; comment)] Jiménez–Jiménez FJ. **Med Clin (Barc)** 1999 Feb 27; 112(7):257–8 (15 ref.) Comment on: Med Clin (Barc) 1999 Feb 27;112(7):245–50. **(Spa)**

[Treatment of Parkinson's disease with COMT inhibitors: tolcapone] Avila A, et al. **Neurologia** 1998;13 Suppl 1:66–71 (35 ref.) **(Spa)**

[Long–term complications of treatment with levodopa] Castro García A, et al. **Neurologia** 1998;13 Suppl 1:41–8 (79 ref.) **(Spa)**

[Current therapeutic problems. Solutions] Castro García A, et al. **Neurologia** 1999 May;14 Suppl 1:34–45 (89 ref.) **(Spa)**

[Pharmacologic treatment in Parkinson disease] García de Yébenes J, et al. **Neurologia** 1999 May;14 Suppl 1:17–33 (82 ref.) **(Spa)**

[Therapeutic strategies in advanced Parkinson's disease] Giménez Roldán S. **Neurologia** 1998;13 Suppl 1:49–65 (156 ref.) **(Spa)**

[New pharmacologic strategies for the treatment of Parkinson disease] Tolosa E, et al. **Neurologia** 1999 May;14 Suppl 1:46–53 (57 ref.) (Eng. Abstr.) **(Spa)**

[Neurotrophins. II: therapeutic potential] Zazpe A, et al. **Rev Med Univ Navarra** 1997 Jul–Sep;41(3):180–4 (32 ref.) (Eng. Abstr.) **(Spa)**

[Motor complications of treatment with levodopa in Parkinson's disease] García–Escrig M, et al. **Rev Neurol** 1999 Apr 16–30;28(8):799–809 (198 ref.) (Eng. Abstr.) **(Spa)**

[Entacapone++ : a new catechol–O–methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function] Horga de la Parte JF. **Rev Neurol** 1999 Mar 1–15; 28(5):499–504 (31 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Molecular biology of catecholamine–related enzymes in relation to Parkinson's disease. Nagatsu T, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):57–66 (54 ref.)

EPIDEMIOLOGY

Epidemiology of Parkinson's disease. Tanner CM, et al. **Adv Neurol** 1999;80:153–9 (69 ref.)

Epidemiologic approaches to the study of Parkinson's disease etiology. Checkoway H, et al. **Epidemiology** 1999 May; 10(3):327–36 (157 ref.)

Parkinson's disease and the U.S. health care system. Fischer PP. **J Community Health Nurs** 1999;16(3):191–204 (57 ref.)

[Epidemiology of Parkinson disease] Benito–León J, et al. **Neurologia** 1998;13 Suppl 1:2–9 (132 ref.) **(Spa)**

ETIOLOGY

Chronic subdural haematomas and Parkinsonian syndromes. Wiest RG, et al. **Acta Neurochir (Wien)** 1999;141(7):753–7; discussion 757–8 (32 ref.)

Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Bradford HF, et al. **Adv Neurol** 1999; 80:19–25 (33 ref.)

Genetic and environmental factors in Parkinson's disease. Duvoisin RC. **Adv Neurol** 1999;80:161–3 (20 ref.)

Nitric oxide in the pathogenesis of Parkinson's disease. Gerlach M, et al. **Adv Neurol** 1999;80:239–45 (38 ref.)

Genetic and environmental factors in the pathogenesis of Parkinson's disease. Mizuno Y, et al. **Adv Neurol** 1999; 80:171–9 (81 ref.)

Etiology of Parkinson's disease: contributions from 18F–DOPA positron emission tomography. Piccini P, et al. **Adv Neurol** 1999;80:227–31 (24 ref.)

Idiopathic Parkinson's disease: a genetic and environmental model. Williams AC, et al. **Adv Neurol** 1999;80:215–8 (21 ref.)

Rare and unusual parkinsonian syndromes. Wszolek ZK, et al. **Adv Neurol** 1999;80:369–76 (79 ref.)

Etiology and pathogenesis of Parkinson's disease. Olanow CW, et al. **Annu Rev Neurosci** 1999;22:123–44 (133 ref.)

Pesticides and Parkinson's disease. Le Couteur DG, et al. **Biomed Pharmacother** 1999 Apr;53(3):122–30 (113 ref.)

Etiology of Parkinson's disease. Stoessl AJ. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S5–12 (117 ref.)

New developments in understanding the etiology of Parkinson's disease and in its treatment. Lozano AM, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):783–90 (68 ref.)

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Jellinger KA. **Drugs Aging** 1999 Feb;14(2):115–40 (305 ref.)

Epidemiologic approaches to the study of Parkinson's disease etiology. Checkoway H, et al. **Epidemiology** 1999 May; 10(3):327–36 (157 ref.)

Levodopa effective parkinsonism associated with aqueductal stenosis: a case report and review of the literature. Asamoto S, et al. **No Shinkei Geka** 1998 Dec;26(12):1089–92 (6 ref.)

[Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease] Matsubara K. **Nippon Hoigaku Zasshi** 1998 Oct;52(5):301–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Current knowledge of the etiopathogenesis of Parkinson disease] Luquin MR, et al. **Neurologia** 1998;13 Suppl 1:10–8 (102 ref.) **(Spa)**

GENETICS

Genetic and environmental factors in Parkinson's disease. Duvoisin RC. **Adv Neurol** 1999;80:161–3 (20 ref.)

Is Parkinson's disease an inherited condition? Gasser T. **Adv Neurol** 1999;80:143–52 (85 ref.)

Dopamine cell death by a single genetic mechanism: phenotypic analysis and linkage study of autosomal recessive juvenile parkinsonism. Matsumine H, et al. **Adv Neurol** 1999;80:187–94 (25 ref.)

Genetic and environmental factors in the pathogenesis of Parkinson's disease. Mizuno Y, et al. **Adv Neurol** 1999; 80:171–9 (81 ref.)

Mitochondrial DNA in Parkinson's disease. Schapira AH. **Adv Neurol** 1999;80:233–7 (23 ref.)

Idiopathic Parkinson's disease: a genetic and environmental model. Williams AC, et al. **Adv Neurol** 1999;80:215–8 (21 ref.)

Gene–environment interaction in late–onset Alzheimer disease: the role of apolipoprotein–epsilon4. Mayeux R. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 3:S10–5 (73 ref.)

Genetics of Parkinson's disease. Mizuno Y, et al. **Biomed Pharmacother** 1999 Apr;53(3):109–16 (67 ref.)

Genetic epidemiology of Parkinson's disease. Payami H, et al. **J Geriatr Psychiatry Neurol** 1998 Summer;11(2):98–106 (133 ref.)

The genetics of Parkinson's disease and parkinsonian syndromes. Bajaj NP, et al. **J Neurol** 1998 Oct; 245(10):625–33 (101 ref.)

Genetic dissection of familial Parkinson's disease. Riess O, et al. **Mol Med Today** 1998 Oct;4(10):438–44 (47 ref.)

Genetic polymorphisms in Parkinson's disease. Checkoway H, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):635–43 (95 ref.)

A new approach to the genetic analysis of nervous system diseases: retrospective genotyping of archival brains. Kösel S, et al. **Prog Brain Res** 1998;117:307–13 (41 ref.)

[Parkinson disease: monogenic forms and genetic susceptibility factors] Brice A. **Pathol Biol (Paris)** 1998 Nov;46(9):710–2 (0 ref.) (Eng. Abstr.) **(Fre)**

[Genetics of Parkinson disease] Brassat D, et al. **Rev Med Interne** 1999 Aug;20(8):709–14 (37 ref.) (Eng. Abstr.) **(Fre)**

[alpha–Synuclein and familial Parkinson's disease] Iwatsubo T. **No To Shinkei** 1999 Jun;51(6):481–6 (24 ref.) **(Jpn)**

[Cloning of Parkin gene and its function] Shimizu N, et al. **No To Shinkei** 1999 Jun;51(6):487–91 (18 ref.) **(Jpn)**

[A Parkin gene (PARK 2) and Parkinson's disease] Matsumine H. **Rinsho Shinkeigaku** 1999 Jan;39(1):9–12 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Lubag syndrome (Xq13–linked dystonia–parkinsonism)] Ishikawa A. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):148–50 (15 ref.) **(Jpn)**

[Hereditary Parkinson's disease mapped to chromosome 4q21–q23] Saito M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):24–6 (11 ref.) **(Jpn)**

[Hereditary Parkinson's disease mapped to chromosome 2p13] Saito M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):27–8 (7 ref.) **(Jpn)**

[Autosomal recessive early--onset parkinsonism (AR–EP)] Yamamura Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):16–9 (13 ref.) **(Jpn)**

[Genetic basis of Parkinson's disease: are we changing our thinking?] Ilić T, et al. **Vojnosanit Pregl** 1998 Nov–Dec; 55(6):617–21 (44 ref.) **(Scc)**

HISTORY

Art and Parkinson's disease. Lakke JP. **Adv Neurol** 1999; 80:471–9 (10 ref.)

METABOLISM

The metabolic landscape of Parkinson's disease. Eidelberg D. **Adv Neurol** 1999;80:87–97 (58 ref.)

Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease. Narabayashi H. **Adv Neurol** 1999;80:501–4 (9 ref.)

Adenosine receptor antagonists and Parkinson's disease: actions of the A2A receptor in the striatum. Richardson PJ, et al. **Adv Neurol** 1999;80:111–9 (40 ref.)

P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease. Riedl AG, et al. **Adv Neurol** 1999;80:271–86 (170 ref.)

COMT inhibition with entacapone in the treatment of Parkinson's disease. Rinne UK, et al. **Adv Neurol** 1999; 80:491–4 (24 ref.)

Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Sonsalla PK, et al. **Amino Acids** 1998;14(1–3):69–74 (13 ref.)

Hypothesis: can N–acetylcysteine be beneficial in Parkinson's disease? Martínez M, et al. **Life Sci** 1999;64(15):1253–7 (45 ref.)

NURSING

Parkinson's disease nurse specialists: an important role in disease management. MacMahon DG. **Neurology** 1999;52(7 Suppl 3):S21–5 (4 ref.)

PATHOLOGY

Glia: a curtain raiser. Wilkin GP, et al. **Adv Neurol** 1999; 80:3–7 (38 ref.)

Mitochondrial involvement in Parkinson's disease,

Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia [see comments] Schapira AH. **Biochim Biophys Acta** 1999 Feb 9;1410(2):159–70 (112 ref.) Comment in: Biochim Biophys Acta 1999 Feb 9;1410(2):99–102.

'Like a thief in the night': the selectivity of degeneration in Parkinson's disease [editorial; comment] Saper CB. **Brain** 1999 Aug;122 (Pt 8):1401–2 (20 ref.) Comment on: Brain 1999 Aug;122 (Pt 8):1421–36. Comment on: Brain 1999 Aug;122 (Pt 8):1437–48.

Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia [see comments] Trojanowski JQ, et al. **Cell Death Differ** 1998 Oct;5(10):832–7 (64 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803–4.

The functional anatomy of noradrenergic neurons in Parkinson's disease. Soldani P, et al. **Funct Neurol** 1999 Apr–Jun;14(2):97–109 (53 ref.)

Functional imaging of Parkinson's disease: is it possible to detect brain areas for specific symptoms? Brooks DJ. **J Neural Transm Suppl** 1999;56:139–53 (78 ref.)

Pathogenesis and preclinical course of Parkinson's disease. Foley P, et al. **J Neural Transm Suppl** 1999;56:31–74 (305 ref.)

Mechanism and consequences of nerve cell death in Parkinson's disease. Hirsch EC. **J Neural Transm Suppl** 1999;56:127–37 (60 ref.)

Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms? Jellinger KA. **J Neural Transm Suppl** 1999;56:1–29 (225 ref.)

Parkinson's disease: one disease entity or many? Korczyn AD. **J Neural Transm Suppl** 1999;56:107–11 (14 ref.)

What are the relations between Lewy body disease and AD? McKeith IG, et al. **J Neural Transm Suppl** 1998;54:107–16 (43 ref.)

Parkinson's disease—a multifactorial neurodegenerative disorder. Riess O, et al. **J Neural Transm Suppl** 1999; 56:113–25 (42 ref.)

Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Braak H, et al. **Prog Brain Res** 1998;117:267–85 (98 ref.)

A new approach to the genetic analysis of nervous system diseases: retrospective genotyping of archival brains. Kösel S, et al. **Prog Brain Res** 1998;117:307–13 (41 ref.)

[Hippocampal pathology in diffuse Lewy body disease] Iseki E, et al. **No To Shinkei** 1998 Oct;50(10):907–12 (11 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Visual and visual cognitive dysfunction in Parkinson's disease: spatial and chromatic vision. Bodis-Wollner IG, et al. **Adv Neurol** 1999;80:383–8 (30 ref.)

Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. Gerlach M, et al. **Adv Neurol** 1999;80:219–25 (44 ref.)

Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Hirsch EC, et al. **Adv Neurol** 1999;80:9–18 (78 ref.)

Mechanisms of neuronal death in idiopathic parkinsonism. Lee CS. **Adv Neurol** 1999;80:205–14 (82 ref.)

Neural transplantation: can we improve the symptomatic relief? Lindvall O. **Adv Neurol** 1999;80:635–40 (26 ref.)

Parkinsonian and essential tremors: different entities or different manifestations of the same disorder? Lücking CH, et al. **Adv Neurol** 1999;80:335–9 (9 ref.)

Dopamine cell death by a single genetic mechanism: phenotypic analysis and linkage study of autosomal recessive juvenile parkinsonism. Matsumine H, et al. **Adv Neurol** 1999;80:187–94 (25 ref.)

N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease. Naoi M, et al. **Adv Neurol** 1999; 80:259–64 (17 ref.)

Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Offen D, et al. **Adv Neurol** 1999;80:265–9 (38 ref.)

The cognitive neuropsychology of Parkinson's disease: a functional neuroimaging perspective. Owen AM, et al. **Adv Neurol** 1999;80:49–56 (43 ref.)

Pathophysiology of the motor cortex in patients with Parkinson's disease. Rothwell JC. **Adv Neurol** 1999;80:27–9 (15 ref.)

Clinicopathological heterogeneity and non-dopaminergic influences on behavior in Parkinson's disease. Sagar HJ. **Adv Neurol** 1999;80:409–17 (24 ref.)

Functional consequences of dopaminergic degeneration in Parkinson's disease. Tedroff JM. **Adv Neurol** 1999;80:67–70 (84 ref.)

Glia: a curtain raiser. Wilkin GP, et al. **Adv Neurol** 1999; 80:3–7 (38 ref.)

The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Loopuijt LD, et al. **Amino Acids** 1998;14(1–3):17–23 (41 ref.)

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Shults CW, et al. **Biofactors** 1999;9(2–4):267–72 (27 ref.)

Role of mitochondria in Parkinson disease. Kösel S, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):865–70 (48 ref.)

Pathophysiology of Parkinson's disease. Bonnet AM, et al. **Biomed Pharmacother** 1999 Apr;53(3):117–21 (48 ref.)

Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body Dementia: too much or too little cortical acetylcholine? Sarter M, et al. **Brain Cogn** 1998 Dec; 38(3):297–316 (135 ref.)

Parkinson's disease: a major hypokinetic basal ganglia disorder. Sian J, et al. **J Neural Transm** 1999; 106(5–6):443–76 (85 ref.)

Neuroprotective therapies. Simon DK, et al. **Med Clin North Am** 1999 Mar;83(2):509–23, viii (99 ref.)

Alpha-synuclein and Parkinson's disease [editorial] Golbe LI. **Mov Disord** 1999 Jan;14(1):6–9 (31 ref.)

Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Reader TA, et al. **Neurochem Int** 1999 Jan;34(1):1–21 (242 ref.)

Reaction time deficits and Parkinson's disease. Gauntlett-Gilbert J, et al. **Neurosci Biobehav Rev** 1998 Oct; 22(6):865–81 (74 ref.)

Tremulous jaw movements in rats: a model of parkinsonian tremor. Salamone JD, et al. **Prog Neurobiol** 1998 Dec; 56(6):591–611 (190 ref.)

Recent advances in dementia research in Japan: non-Alzheimer-type degenerative dementias. Kosaka K, et al. **Psychiatry Clin Neurosci** 1998 Aug;52(4):367–73 (93 ref.)

Experimental models of Parkinson's disease: from the static to the dynamic. Bezard E, et al. **Rev Neurosci** 1998; 9(2):71–90 (252 ref.)

[Iron homeostasis and Parkinson's disease] Faucheux BA, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:23–30 (66 ref.) **(Fre)**

[Vascular Parkinson syndromes: a controversial concept] Fénelon G, et al. **Rev Neurol (Paris)** 1998 May; 154(4):291–302 (81 ref.) (Eng. Abstr.) **(Fre)**

[Autonomic disturbances in Parkinson's disease and their treatment] Schneider E. **Nervenarzt** 1999 Jan;70 Suppl 1:S26–34 (66 ref.) (Eng. Abstr.) **(Ger)**

[Synucleins—the key to mechanisms of neurodegenerative diseases?] Buchman VL. **Mol Biol (Mosk)** 1998 Jul–Aug; 32(4):592–7 (54 ref.) **(Rus)**

[Pathophysiological bases, clinical results and indications for surgical treatment in Parkinson disease] Obeso JA, et al. **Neurologia** 1999 May;14 Suppl 1:54–71 (106 ref.) (Eng. Abstr.) **(Spa)**

[Physiopathology of Parkinson disease] Obeso JA, et al. **Neurologia** 1998;13 Suppl 1:19–29 (41 ref.) **(Spa)**

PREVENTION & CONTROL

Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Rodnitzky RL. **Drugs** 1999 Jun; 57(6):845–9 (35 ref.)

PSYCHOLOGY

Psychosis and hallucinations in Parkinson's disease. Godwin-Austen RB. **Adv Neurol** 1999;80:401–2 (9 ref.)

Hallucinations in Parkinson's disease: the clinical syndrome. Goetz CG. **Adv Neurol** 1999;80:419–23 (26 ref.)

The place of dementia in Parkinson's disease: a methodologic saga. Mindham RH. **Adv Neurol** 1999;80:403–8 (50 ref.)

The cognitive neuropsychology of Parkinson's disease: a functional neuroimaging perspective. Owen AM, et al. **Adv Neurol** 1999;80:49–56 (43 ref.)

Clinicopathological heterogeneity and non-dopaminergic influences on behavior in Parkinson's disease. Sagar HJ. **Adv Neurol** 1999;80:409–17 (24 ref.)

Attention and executive deficits in Alzheimer's disease. A critical review. Perry RJ, et al. **Brain** 1999 Mar;122 (Pt 3):383–404 (190 ref.)

Management of psychotic aspects of Parkinson's disease. Juncos JL. **J Clin Psychiatry** 1999;60 Suppl 8:42–53 (161 ref.)

Depression: impact and management by the patient and family. Cote L. **Neurology** 1999;52(7 Suppl 3):S7–9 (4 ref.)

Psychosis: impact on the patient and family. Melamed E, et al. **Neurology** 1999;52(7 Suppl 3):S14–6 (2 ref.)

Depression in Parkinson's disease: impediments to recognition and treatment options. Poewe W, et al. **Neurology** 1999;52(7 Suppl 3):S2–6 (46 ref.)

A review of health-related quality-of-life concepts and measures for Parkinson's disease. Damiano AM, et al. **Qual Life Res** 1999 May;8(3):235–43 (30 ref.)

[Lewy body dementia] Petit H, et al. **Rev Neurol (Paris)** 1998; 154 Suppl 2:S99–105 (48 ref.) (Eng. Abstr.) **(Fre)**

[Emotional and cognitive disorders in Parkinson disease] Arsland D, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20; 118(25):3959–63 (37 ref.) (Eng. Abstr.) **(Nor)**

RADIONUCLIDE IMAGING

Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Booij J, et al. **Eur J Nucl Med** 1999 Feb;26(2):171–82 (132 ref.)

Functional imaging of neurotransmitter systems in movement disorders. Ilgin N. **Q J Nucl Med** 1998 Sep;42(3):179–92 (106 ref.)

[Functional imaging for disorders of basal ganglia] Otsuka M, et al. **Rinsho Shinkeigaku** 1999 Jan;39(1):30–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Interdisciplinary rehabilitation in Parkinson's disease. Iansek R. **Adv Neurol** 1999;80:555–9 (23 ref.)

SURGERY

Current controversies in pallidal surgery. Hariz MI. **Adv Neurol** 1999;80:593–602 (87 ref.)

Neural transplantation: can we improve the symptomatic relief? Lindvall O. **Adv Neurol** 1999;80:635–40 (26 ref.)

The need for phase III studies in experimental surgical treatments of Parkinson's disease. Peschanski M, et al. **Adv Neurol** 1999;80:651–3 (17 ref.)

The case for neural tissue transplantation as a treatment for Parkinson's disease. Widner H. **Adv Neurol** 1999;80:641–9 (34 ref.)

Targeting the subthalamic nucleus in the treatment of Parkinson's disease [published erratum appears in Brain Res Bull 1998 Sep 15;47(2):193] Henderson JM, et al. **Brain Res Bull** 1998 Aug;46(6):467–74 (71 ref.)

New developments in the surgery for Parkinson's disease. Honey C, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S45–52 (87 ref.)

Neural transplantation for Parkinson's disease. Date I, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):67–78 (67 ref.)

Posterior ventral pallidotomy: techniques and theoretical considerations. Bakay RA, et al. **Clin Neurosurg** 1997; 44:197–210 (10 ref.)

Outcomes assessment for pallidotomy. Cosgrove GR, et al. **Clin Neurosurg** 1997;44:385–99 (18 ref.)

Selection of patients for surgery for Parkinson's disease. Tasker RR. **Clin Neurosurg** 1997;44:63–7 (18 ref.)

The treatment of Parkinson's disease: current concepts and rationale. Hingtgen CM, et al. **Compr Ther** 1998 Nov–Dec; 24(11–12):560–6 (26 ref.)

Fetal tissue transplantation [correction of transplanation] in Parkinson's disease. Tabbal S, et al. **Curr Opin Neurol** 1998 Aug;11(4):341–9 (104 ref.)

Neurosurgical interventions in the treatment of idiopathic Parkinson disease: neurostimulation and neural implantation. Kupsch A, et al. **J Mol Med** 1999 Jan; 77(1):178–84 (48 ref.)

Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. Ghika J, et al. **J Neurosurg** 1999 Aug;91(2):313–21 (114 ref.)

Surgical options in Parkinson's disease. Arle JE, et al. **Med Clin North Am** 1999 Mar;83(2):483–98, vii (85 ref.)

Cerebral implantation in movement disorders: state of the art [editorial] Lindvall O. **Mov Disord** 1999 Mar;14(2):201–5 (48 ref.)

Neural transplantation in Parkinson's disease and its effects on rest tremor: a review of the literature. Pogarell O, et al. **Mov Disord** 1998;13 Suppl 3:101–2 (14 ref.)

The treatment of movement disorders using Gamma Knife stereotactic radiosurgery. Duma CM, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):379–89 (41 ref.)

Ablative surgery and deep brain stimulation for Parkinson's disease. Starr PA, et al. **Neurosurgery** 1998 Nov; 43(5):989–1013; discussion 1013–5 (199 ref.)

Surgical palliation of dyskinesiae in Parkinson's disease. Brophy BP. **Stereotact Funct Neurosurg** 1998; 70(2–4):107–13 (31 ref.)

Stereotactic surgery and Parkinson's disease. Narabayashi H. **Stereotact Funct Neurosurg** 1998;70(2–4):114–21 (18 ref.)

Current therapy in Parkinson's disease. Brandabur MM. **Surg Neurol** 1999 Sep;52(3):318–22 (42 ref.)

[Indications for surgical treatment of tremor] Bötzel K, et al. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):287–90 (13 ref.) **(Ger)**

[Posteroventral pallidotomy in Parkinson's disease (editorial)] Giménez Roldán S. **Neurologia** 1999 Feb;14(2):49–52 (16 ref.) **(Spa)**

[Pathophysiological bases, clinical results and indications for surgical treatment in Parkinson disease] Obeso JA, et al. **Neurologia** 1999 May;14 Suppl 1:54–71 (106 ref.) (Eng. Abstr.) **(Spa)**

[Functional surgery in Parkinson disease: from the anatomic-functional organization and physiopathology of the basal ganglia to clinical practice] Linazasoro Cristóbal G, et al. **Rev Clin Esp** 1999 Jan;199(1):31–8 (43 ref.) **(Spa)**

[Transplanted nerve cells survive and are functional for many years] Björklund A, et al. **Lakartidningen** 1999 Aug 11; 96(32–33):3407–12 (20 ref.) (Eng. Abstr.) **(Swe)**

THERAPY

Pragmatic physical therapy in Parkinson's disease: any scientific basis? Hildick-Smith M. **Adv Neurol** 1999; 80:561–4 (33 ref.)

Evaluating community-based Parkinson's disease nurse specialists: rationale, methodology, and representativeness of patient sample in a large randomized controlled trial. Hurwitz B, et al. **Adv Neurol** 1999;80:431–8 (10 ref.)

Traditional and complementary therapies in Parkinson's disease. Manyam BV, et al. **Adv Neurol** 1999;80:565–74 (29 ref.)

Parkinson's disease. A holistic approach. Barker S, et al. **Am J Nurs** 1998 Nov;98(11):48A–48G; quiz 48G–48H (27 ref.)

New and emerging therapies for Parkinson disease. Jankovic J. **Arch Neurol** 1999 Jul;56(7):785–90 (56 ref.)

Chronic electrical stimulation of the left ventrointermediate (Vim) thalamic nucleus for the treatment of pharmacotherapy-resistant Parkinson's disease: a

differential impact on access to semantic and episodic memory? Tröster AI, et al. **Brain Cogn** 1998 Nov; 38(2):125–49 (120 ref.)

Targeting the subthalamic nucleus in the treatment of Parkinson's disease [published erratum appears in Brain Res Bull 1998 Sep 15;47(2):193] Henderson JM, et al. **Brain Res Bull** 1998 Aug;46(6):467–74 (71 ref.)

Parkinson's disease management: towards a new paradigm. Guttman M, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S53–7 (14 ref.)

Management of Parkinson's disease a review of current and new therapies. Mendis T, et al. **Can J Neurol Sci** 1999 May; 26(2):89–103 (186 ref.)

Deep brain stimulation reduces symptoms of Parkinson disease. Montgomery EB Jr. **Cleve Clin J Med** 1999 Jan; 66(1):9–11 (6 ref.)

The placebo response in Parkinson's disease. Parkinson Study Group. Shetty N, et al. **Clin Neuropharmacol** 1999 Jul–Aug; 22(4):207–12 (33 ref.)

Chaos theories and therapeutic commonalities among depression, Parkinson's disease, and cardiac arrhythmias. Toro MG, et al. **Compr Psychiatry** 1999 May–Jun; 40(3):238–44 (88 ref.)

New developments in understanding the etiology of Parkinson's disease and in its treatment. Lozano AM, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):783–90 (68 ref.)

Parkinson's disease and the U.S. health care system. Fischer PP. **J Community Health Nurs** 1999;16(3):191–204 (57 ref.)

Medical treatment of Parkinson's disease. Fahn S. **J Neurol** 1998 Nov;245(11 Suppl 3):P15–24 (23 ref.)

Advances in TCM treatment of paralysis agitans. Zhang Y, et al. **J Tradit Chin Med** 1997 Jun;17(2):148–53 (21 ref.)

Restorative gene therapy approaches to Parkinson's disease. Freese A. **Med Clin North Am** 1999 Mar;83(2):537–48 (55 ref.)

Managing late complications of Parkinson's disease. Stacy M. **Med Clin North Am** 1999 Mar;83(2):469–81, vii (80 ref.)

Efficacy of grafted immortalized dopamine neurons in an animal model of parkinsonism: a review. Prasad KN, et al. **Mol Genet Metab** 1998 Sep;65(1):1–9 (66 ref.)

Long-term electrical inhibition of deep brain targets in movement disorders. Benabid AL, et al. **Mov Disord** 1998; 13 Suppl 3:119–25 (19 ref.)

Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Dunnett SB, et al. **Nature** 1999 Jun 24;399(6738 Suppl):A32–9 (99 ref.)

Neurologic degenerative disorders. Ross AP. **Nurs Clin North Am** 1999 Sep;34(3):725–42 (14 ref.)

Medical and surgical treatment of Parkinson's disease. Strategies to slow symptom progression and improve quality of life. Conley SC, et al. **Postgrad Med** 1999 Aug; 106(2):41–4, 49, 52 (18 ref.)

The treatment of Parkinson's disease in older people. Lien CT, et al. **Scott Med J** 1997 Oct;42(5):147–50 (84 ref.)

[Autonomic disturbances in Parkinson's disease and their treatment] Schneider E. **Nervenarzt** 1999 Jan;70 Suppl 1:S26–34 (66 ref.) (Eng. Abstr.) **(Ger)**

[Modern therapeutic possibilities in Parkinson disease] Ludin HP. **Schweiz Med Wochenschr** 1999 May 15;129(19):741–7 (30 ref.) (Eng. Abstr.) **(Ger)**

PARKINSON DISEASE, POSTENCEPHALITIC

[Postencephalitic parkinsonism] Mori H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):32–5 (14 ref.) **(Jpn)**

HISTORY

Adolf Hitler's cognitive disorder and how it affected his conduct of World War II. Lieberman A. **Adv Neurol** 1999; 80:459–66 (22 ref.)

VIROLOGY

Postencephalitic parkinsonism—a review. Casals J, et al. **J Neural Transm** 1998;105(6–7):645–76 (144 ref.)

PARKINSON DISEASE, SYMPTOMATIC

Update on Parkinson's disease. Young R. **Am Fam Physician** 1999 Apr 15;59(8):2155–67, 2169–70 (40 ref.)

Experimental models of Parkinson's disease: insights from many models. Tolwani RJ, et al. **Lab Anim Sci** 1999 Aug; 49(4):363–71 (103 ref.)

Apomorphine and levodopa challenge in patients with a focal midbrain lesion. Moro E, et al. **Mov Disord** 1999 Mar; 14(2):269–75 (22 ref.)

[Drug-induced parkinsonism] Kuzuhara S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):29–31 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

[MPTP parkinsonism] Kondo T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):37–40 (14 ref.) **(Jpn)**

[Manganism and parkinsonism] Kondo T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):41–4 (24 ref.) **(Jpn)**

[Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate] Noda S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):538–41 (15 ref.) **(Jpn)**

CLASSIFICATION

[Classification of familial parkinsonian syndromes] Yamamura Y. **No To Shinkei** 1999 Jun;51(6):473–9 (45 ref.) **(Jpn)**

COMPLICATIONS

Chronic subdural haematomas and Parkinsonian syndromes. Wiest RG, et al. **Acta Neurochir (Wien)** 1999;141(7):753–7; discussion 757–8 (32 ref.)

DIAGNOSIS

Pathology of symptomatic tremors. Vidailhet M, et al. **Mov Disord** 1998;13 Suppl 3:49–54 (61 ref.)

[The diagnosis of the parkinsonian syndrome] Möller JC, et al. **Dtsch Med Wochenschr** 1999 Feb 19;124(7):193–6 (17 ref.) **(Ger)**

DRUG THERAPY

Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Brotchie JM, et al. **Adv Neurol** 1998; 78:41–52 (34 ref.)

Managing antipsychotic-induced parkinsonism. Mamo DC, et al. **Drug Saf** 1999 Mar;20(3):269–75 (49 ref.)

[The therapy of the parkinsonian syndrome] Möller JC, et al. **Dtsch Med Wochenschr** 1999 Feb 26;124(8):219–22 (7 ref.) **(Ger)**

[New dopaminergic agonists] de Mattos JP, et al. **Arq Neuropsiquiatr** 1999 Jun;57(2A):329–32 (16 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. Walker RH, et al. **Mov Disord** 1999 Mar;14(2):262–8 (40 ref.)

[Post-traumatic parkinsonism] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):61–2 (13 ref.) **(Jpn)**

GENETICS

The genetics of Parkinson's disease and parkinsonian syndromes. Bajaj NP, et al. **J Neurol** 1998 Oct; 245(10):625–33 (101 ref.)

[Classification of familial parkinsonian syndromes] Yamamura Y. **No To Shinkei** 1999 Jun;51(6):473–9 (45 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Bergman H, et al. **Trends Neurosci** 1998 Jan;21(1):32–8 (58 ref.)

RADIONUCLIDE IMAGING

Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Booij J, et al. **Eur J Nucl Med** 1999 Feb;26(2):171–82 (132 ref.)

SURGERY

Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. Bronstein JM, et al. **Arch Neurol** 1999 Sep;56(9):1064–9 (41 ref.)

THERAPY

Somatic gene therapy in animal models of Parkinson's disease. Bauer M, et al. **J Neural Transm Suppl** 1999;55:131–47 (111 ref.)

Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. Piallat B, et al. **J Neural Transm Suppl** 1999;55:71–7 (21 ref.)

PARKINSONIAN SYNDROME see **PARKINSON DISEASE, SYMPTOMATIC**

PARODONTOSIS see **PERIODONTAL DISEASES**

PARONYCHIA

ETIOLOGY

Latex hypersensitivity/glove component reaction as a contributing factor to osteomyelitis of the hand: a case report and review of the literature. Duplechain MT, et al. **J La State Med Soc** 1998 Nov;150(11):527–32 (22 ref.)

THERAPY

Infections of the fingertip. Paronychias and felons. Jebson PJ. **Hand Clin** 1998 Nov;14(4):547–55, viii (31 ref.)

PAROTID DISEASES

COMPLICATIONS

A megalith of the parotid salivary gland. Kesse WK, et al. **J Laryngol Otol** 1998 Aug;112(8):784–5 (6 ref.)

DIAGNOSIS

Nontyrosine crystalloids in fine-needle aspiration specimens of the parotid gland: a report of two cases and review of the literature. Granter SR, et al. **Diagn Cytopathol** 1999 Jan;20(1):44–6 (11 ref.)

[Parotid swelling with night sweat, fever and weight loss symptoms. A rare differential diagnosis] Herrmann G. **Dtsch Med Wochenschr** 1999 Feb 26;124(8):209–12 (25 ref.) (Eng. Abstr.) **(Ger)**

[A case of parotidomegaly associated with eating disorders (anorexia/bulimia)] Santoro V, et al. **Minerva Stomatol** 1998 Oct;47(10):565–71 (19 ref.) (Eng. Abstr.) **(Ita)**

PAROTID GLAND

Frey's syndrome and parotid surgery. Sood S, et al. **Clin Otolaryngol** 1998 Aug;23(4):291–301 (129 ref.)

CYTOLOGY

ADP-ribosylation factors in rat parotid acinar cells. Dohke Y, et al. **Eur J Morphol** 1998 Aug;36 Suppl:186–9 (19 ref.)

Ca2+-nitric oxide-cGMP signaling in rabbit parotid acinar cells. Sugiya H, et al. **Eur J Morphol** 1998 Aug;36 Suppl:194–7 (31 ref.)

Analysis of spatial and temporal characteristics of Ca2+ release in permeabilized parotid cells. Tanimura A, et al. **Eur J Morphol** 1998 Aug;36 Suppl:157–60 (13 ref.)

EMBRYOLOGY

The Chievitz juxtaparotid organ. D'Andrea V, et al. **G Chir** 1999 May;20(5):213–7 (37 ref.)

METABOLISM

ADP-ribosylation factors in rat parotid acinar cells. Dohke Y, et al. **Eur J Morphol** 1998 Aug;36 Suppl:186–9 (19 ref.)

Analysis of spatial and temporal characteristics of Ca2+ release in permeabilized parotid cells. Tanimura A, et al. **Eur J Morphol** 1998 Aug;36 Suppl:157–60 (13 ref.)

PATHOLOGY

Nontyrosine crystalloids in fine-needle aspiration specimens of the parotid gland: a report of two cases and review of the literature. Granter SR, et al. **Diagn Cytopathol** 1999 Jan;20(1):44–6 (11 ref.)

Mounting evidence against current histogenetic concepts for salivary gland tumorigenesis. Dardick I. **Eur J Morphol** 1998 Aug;36 Suppl:257–61 (47 ref.)

Parotid sialolithiasis. Bodner L. **J Laryngol Otol** 1999 Mar; 113(3):266–7 (15 ref.)

PHYSIOLOGY

Ca2+-nitric oxide-cGMP signaling in rabbit parotid acinar cells. Sugiya H, et al. **Eur J Morphol** 1998 Aug;36 Suppl:194–7 (31 ref.)

SECRETION

Divergence and convergence in regulated exocytosis: the characteristics of cAMP-dependent enzyme secretion of parotid salivary acinar cells. Fujita-Yoshigaki J. **Cell Signal** 1998 Jun;10(6):371–5 (52 ref.)

ULTRASTRUCTURE

Comparative ultrastructure of intercalated ducts in major salivary glands: a review. Tandler B, et al. **Anat Rec** 1998 Sep;252(1):64–91 (282 ref.)

PAROTID NEOPLASMS

DIAGNOSIS

[Basal cell adenocarcinoma of the parotid gland: a rare tumor entity. Case report and review of the literature] Franzen A, et al. **HNO** 1998 Sep;46(9):821–5 (26 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic methods in parotid gland pathology] Garzón Calles JA. **An Otorrinolaringol Ibero Am** 1999;26(1):15–27 (25 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[MALT lymphoma of the parotid gland associated with Sjögren syndrome. A case report and review of literature] Damborenea Tajada J, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):595–8 (23 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Concurrent cytogenetic, interphase fluorescence in situ hybridization and DNA flow cytometric analyses of a carcinoma ex-pleomorphic adenoma of parotid gland. el-Naggar AK, et al. **Cancer Genet Cytogenet** 1998 Dec; 107(2):132–6 (37 ref.)

[Cystadenolymphoma of the salivary glands: is there a

familial role?] Russo F, et al. **Ann Ital Chir** 1999 Mar–Apr; 70(2):233–7; discussion 237–8 (27 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Lymphoepithelial cyst with crystalloid formation. Cytologic features of two cases. López-Ríos F, et al. **Acta Cytol** 1999 Mar–Apr;43(2):277–80 (9 ref.)

Granular cell tumor of the parotid. Said-Al-Naief N, et al. **Ann Diagn Pathol** 1999 Feb;3(1):35–8 (15 ref.)

Pathologic quiz case 1. Acinic cell carcinoma of the deep lobe of the parotid gland involving the right parapharyngeal space. Dorn MT, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):694, 696–7 (10 ref.)

Leiomyosarcoma of the parotid gland: a case report and review of the literature. Kang J, et al. **Head Neck** 1999 Mar;21(2):168–71 (7 ref.)

Malignant oncocytoma of the parotid gland: case report and analysis of the literature. Ardekian L, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):325–8 (25 ref.)

Benign oncocytoma of the deep lobe of the parotid gland. Stafford RE, et al. **J Oral Maxillofac Surg** 1999 Mar; 57(3):346–50 (23 ref.)

Malignant tumors of Stensen's duct. Steiner M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):73–7 (24 ref.)

Multiple brain metastases from adenoid cystic carcinoma of the parotid gland. Case report and review of the literature. Kazumoto K, et al. **Surg Neurol** 1998 Nov;50(5):475–9 (32 ref.)

RADIOTHERAPY

Cerebral radionecrosis following the treatment of parotid tumours: a case report and review of the literature. Coghlan KM, et al. **Int J Oral Maxillofac Surg** 1999 Feb;28(1):50–2 (22 ref.)

SECONDARY

[Case report of epithelioid hemangioendothelioma of the frontal region metastatic to the parotid gland] Schneider B, et al. **Laryngorhinootologie** 1998 Dec;77(12):728–31 (27 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Short- and long-term results of parotidectomy, apropos of 24 cases at the Ougadougou University Hospital Center] Ouoba K, et al. **Dakar Med** 1998;43(1):114–7 (13 ref.) (Eng. Abstr.) **(Fre)**

[Parotid tumors: a report of 120 cases] Essaadi M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(3):177–82 (60 ref.) (Eng. Abstr.) **(Fre)**

[Intraductal papilloma of the parotid gland] Brehmer D, et al. **Laryngorhinootologie** 1999 Jun;78(6):332–4 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Parotid cancer. Stafford ND, et al. **Surg Oncol** 1997 Dec; 6(4):209–13 (36 ref.)

PAROTITIS

[Suppurative parotitis] Nishimura T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):300–2 (6 ref.) **(Jpn)**

DIAGNOSIS

[Inflammations of the major salivary glands. Acute and chronic sialadenitis] Chilla R. **HNO** 1999 Jun;47(6):582–97 (30 ref.) **(Ger)**

RADIOGRAPHY

Pneumoparotitis: diagnosis by computed tomography. Golz A, et al. **Am J Otolaryngol** 1999 Jan–Feb;20(1):68–71 (21 ref.)

PAROTITIS, EPIDEMIC see **MUMPS**

PARSONAGE-TURNER SYNDROME see **CERVICO-BRACHIAL NEURALGIA**

PARTIAL MASTECTOMY see **MASTECTOMY, SEGMENTAL**

PARTIAL MONOSOMY see **CHROMOSOME DELETION**

PARTIAL THROMBOPLASTIN TIME

[Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time] Kagawa K, et al. **Rinsho Byori** 1999 May;47(5):431–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

PARTICLE ACCELERATORS

see related
RADIOSURGERY

Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Vogel JS, et al. **Adv Exp Med Biol** 1998;445:397–410 (41 ref.)

Linear accelerator radiosurgery in brain tumor management. Foote KD, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):203–42 (175 ref.)

Biomedical applications of accelerator mass spectrometry–isotope measurements at the level of the atom. Barker J, et al. **Rapid Commun Mass Spectrom** 1999; 13(4):285–93 (42 ref.)

PARTICLE SIZE

Nanoparticle detection technology for chemical analysis. Koropchak JA, et al. **Anal Chem** 1999 Jun 1; 71(11):386A–394A (43 ref.)

Possible mechanisms by which electric fields from power lines might affect airborne particles harmful to health [see comments] Swanson J, et al. **J Radiol Prot** 1999 Sep; 19(3):213–29 (73 ref.) Comment in: J Radiol Prot 1999 Sep;19(3):199–200.

PARTNER ABUSE see **SPOUSE ABUSE**

PARTURITION see **LABOR**

PARVALBUMINS

METABOLISM

Distribution of calbindin D-28k and parvalbumin neurons and fibers in the rat basal ganglia. Hontanilla B, et al. **Brain Res Bull** 1998 Sep 15;47(2):107–16 (85 ref.)

Thermodynamic analyses of calcium binding to troponin C, calmodulin and parvalbumins by using microcalorimetry. Yamada K. **Mol Cell Biochem** 1999 Jan;190(1–2):39–45 (53 ref.)

PHYSIOLOGY

Cellular distribution of the calcium-binding proteins parvalbumin, calbindin, and calretinin in the neocortex of mammals: phylogenetic and developmental patterns. Hof PR, et al. **J Chem Neuroanat** 1999 Feb;16(2):77–116 (198 ref.)

PARVOVIRIDAE

CLASSIFICATION

[Comparative characteristics of some carnivore parvoviruses] Shestopalov AM, et al. **Vopr Virusol** 1998 Sep–Oct; 43(5):199–204 (58 ref.) **(Rus)**

PARVOVIRIDAE INFECTIONS

Parvovirus infection. Rodis JF. **Clin Obstet Gynecol** 1999 Mar;42(1):107–20; quiz 174–5 (38 ref.)

Parvovirus B19 infections in pregnancy. Markenson GR, et al. **Semin Perinatol** 1998 Aug;22(4):309–17 (60 ref.)

[Aplastic crisis (human parvovirus B19 infection)] Omine M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):152–7 (14 ref.) **(Jpn)**

[Parvovirus B19 infection] Araújo F, et al. **Acta Med Port** 1999 Apr–Jun;12(4–6):195–202 (51 ref.) (Eng. Abstr.) **(Por)**

BLOOD

Presence and significance of parvovirus B19 in blood and blood products. Siegl G, et al. **Biologicals** 1998 Jun; 26(2):89–94 (20 ref.)

COMPLICATIONS

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease. Osaki M, et al. **Ann Hematol** 1999 Feb;78(2):83–6 (16 ref.)

Human parvovirus B19 in rheumatoid arthritis. Takahashi Y, et al. **Int Rev Immunol** 1998;17(5–6):309–21 (61 ref.)

DIAGNOSIS

Human parvovirus B19 infection in organ transplant recipients. Marchand S, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):17–24 (63 ref.)

Parvovirus B19 infection in pregnancy. Eis-Hübinger AM, et al. **Intervirology** 1998;41(4–5):178–84 (59 ref.)

Human parvovirus B19: relevance in internal medicine. van Elsacker-Niele AM, et al. **Neth J Med** 1999 Jun; 54(6):221–30 (64 ref.)

Parvovirus B19–associated interstitial lung disease, hepatitis, and myositis. Bousvaros A, et al. **Pediatr Pulmonol** 1998 Nov;26(5):365–9 (24 ref.)

Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Trapani S, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):319–25 (27 ref.)

ETIOLOGY

Concomitant parvovirus B19 and cytomegalovirus infections after living-related renal transplantation. Keung YK, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):469–71 (26 ref.)

TRANSMISSION

Presence and significance of parvovirus B19 in blood and blood products. Siegl G, et al. **Biologicals** 1998 Jun; 26(2):89–94 (20 ref.)

The transfusion-associated transmission of parvovirus B19. Azzi A, et al. **Transfus Med Rev** 1999 Jul;13(3):194–204 (85 ref.)

PARVOVIRUS

GROWTH & DEVELOPMENT

Molecular and structural basis of the evolution of parvovirus tropism. Tijssen P. **Acta Vet Hung** 1999;47(3):379–94 (59 ref.)

PARVOVIRUS B19, HUMAN

see related
ERYTHEMA INFECTIOSUM

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease. Osaki M, et al. **Ann Hematol** 1999 Feb;78(2):83–6 (16 ref.)

Human parvovirus B19 infection in organ transplant recipients. Marchand S, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):17–24 (63 ref.)

Human parvovirus B19 in rheumatoid arthritis. Takahashi Y, et al. **Int Rev Immunol** 1998;17(5–6):309–21 (61 ref.)

Parvovirus B19 infection in pregnancy. Eis-Hübinger AM, et al. **Intervirology** 1998;41(4–5):178–84 (59 ref.)

Parvovirus B19–associated interstitial lung disease, hepatitis, and myositis. Bousvaros A, et al. **Pediatr Pulmonol** 1998 Nov;26(5):365–9 (24 ref.)

Parvovirus B19 infections in pregnancy. Markenson GR, et al. **Semin Perinatol** 1998 Aug;22(4):309–17 (60 ref.)

[Aplastic crisis (human parvovirus B19 infection)] Omine M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):152–7 (14 ref.) **(Jpn)**

[Parvovirus B19 infection] Araújo F, et al. **Acta Med Port** 1999 Apr–Jun;12(4–6):195–202 (51 ref.) (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

Presence and significance of parvovirus B19 in blood and blood products. Siegl G, et al. **Biologicals** 1998 Jun; 26(2):89–94 (20 ref.)

Human parvovirus B19: relevance in internal medicine. van Elsacker-Niele AM, et al. **Neth J Med** 1999 Jun; 54(6):221–30 (64 ref.)

The transfusion-associated transmission of parvovirus B19. Azzi A, et al. **Transfus Med Rev** 1999 Jul;13(3):194–204 (85 ref.)

PATHOGENICITY

Presence and significance of parvovirus B19 in blood and blood products. Siegl G, et al. **Biologicals** 1998 Jun; 26(2):89–94 (20 ref.)

Parvovirus B19: twenty-five years in perspective. Barton Rogers B. **Pediatr Dev Pathol** 1999 Jul–Aug;2(4):296–315 (156 ref.)

Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Trapani S, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):319–25 (27 ref.)

PARVOVIRUS INFECTIONS see **PARVOVIRIDAE INFECTIONS**

PARVOVIRUSES, INSECT see **DENSOVIRUS**

PAS see **P-AMINOSALICYLIC ACID**

PASSERIFORMES see **SONGBIRDS**

PASSIVE ADDICTION, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

PASSIVE-AGGRESSIVE PERSONALITY DISORDER

CLASSIFICATION

Passive-aggressive personality disorder: the demise of a syndrome. Wetzler S, et al. **Psychiatry** 1999 Spring; 62(1):49–59 (47 ref.)

DIAGNOSIS

Passive-aggressive personality disorder: the demise of a syndrome. Wetzler S, et al. **Psychiatry** 1999 Spring; 62(1):49–59 (47 ref.)

PASSIVE ANTIBODY TRANSFER see **IMMUNIZATION, PASSIVE**

PASSIVE RANGE OF MOTION see **RANGE OF MOTION, ARTICULAR**

PASSIVE SMOKING see **TOBACCO SMOKE POLLUTION**

PASSIVE TRANSFER OF IMMUNITY see **IMMUNIZATION, PASSIVE**

PASTES see **OINTMENTS**

PASTEURELLA INFECTIONS

[Pasteurella multocida pneumonia] Miyashita T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):384–6 (15 ref.) **(Jpn)**

MICROBIOLOGY

Neonatal meningitis due to a vertical transmission of Pasteurella multocida. Zaramella P, et al. **Pediatr Int** 1999 Jun;41(3):307–10 (23 ref.)

TRANSMISSION

Neonatal meningitis due to a vertical transmission of Pasteurella multocida. Zaramella P, et al. **Pediatr Int** 1999 Jun;41(3):307–10 (23 ref.)

PASTEURELLA MULTOCIDA

Neonatal meningitis due to a vertical transmission of Pasteurella multocida. Zaramella P, et al. **Pediatr Int** 1999 Jun;41(3):307–10 (23 ref.)

[Pasteurella multocida pneumonia] Miyashita T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):384–6 (15 ref.) **(Jpn)**

GENETICS

Candidate vaccine antigens and genes in Pasteurella multocida. Adler B, et al. **J Biotechnol** 1999 Aug 20; 73(2–3):83–90 (32 ref.)

IMMUNOLOGY

Candidate vaccine antigens and genes in Pasteurella multocida. Adler B, et al. **J Biotechnol** 1999 Aug 20; 73(2–3):83–90 (32 ref.)

PASTEURELLA TULARENSIS see **FRANCISELLA TULARENSIS**

PASTEURELLOSIS see **PASTEURELLA INFECTIONS**

PASTORAL CARE

Transcending the physical: spiritual aspects of pain in patients with HIV and/or cancer. Newshan G. **J Adv Nurs** 1998 Dec;28(6):1236–41 (38 ref.)

Clergy perspectives and practices regarding intimate violence: a rural view. Strickland GA, et al. **J Rural Health** 1998 Fall;14(4):305–11 (29 ref.)

[Spiritual needs of severely ill patients are neglected in health care] Einhorn S. **Lakartidningen** 1999 May 12;96(19):2362–6 (20 ref.) (Eng. Abstr.) **(Swe)**

METHODS

Cut from the right wood: spiritual and ethical pluralism in professional nursing practice. Cusveller B. **J Adv Nurs** 1998 Aug;28(2):266–73 (26 ref.)

PATCH-CLAMP TECHNIQUES

NMDA receptor pharmacology and analysis of patch-clamp recordings. Wright JM, et al. **Methods Mol Biol** 1999; 128:143–53 (16 ref.)

Novel tools for localizing ion channels in living cells. Lopatin AN, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):395–8 (29 ref.)

[Analysis of molecular basis of neuronal properties using the patch-clamp RT-PCR method] Tsuzuki K. **Nippon Rinsho** 1998 Jul;56(7):1681–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Analog-digital conversion using pCLAMP and DOS/V] Kohara M. **Nippon Seirigaku Zasshi** 1998;60(4):187–99 (6 ref.) **(Jpn)**

[Monitoring exocytosis using patch-clamp capacitance measurement] Maruyama Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1770–6 (15 ref.) **(Jpn)**

PATCH TESTS

Atopy patch testing--a diagnostic tool? de Bruin-Weller MS, et al. **Allergy** 1999 Aug;54(8):784–91 (59 ref.)

METHODS

Prognostic patch testing: the other kind of patch test. Jackson EM. **Am J Contact Dermat** 1998 Dec;9(4):237–9 (14 ref.)

Objective non-invasive assessment of patch tests with the laser Doppler perfusion scanning technique. Bjarnason B, et al. **Contact Dermatitis** 1999 May;40(5):251–60 (35 ref.)

[Allergy test batteries for leg ulcers] Truchetet F. **Ann Dermatol Venereol** 1999 Apr;126(4):364–8 (28 ref.) **(Fre)**

PATELLA

Unicameral bone cyst of the patella. Janjua KJ. **Am J Knee Surg** 1999 Spring;12(2):111–3 (12 ref.)

[Patellar resurfacing in total knee arthroplasty, current state of the controversy] Schroeder-Boersch H. **Orthopade** 1998 Sep;27(9):600–11 (140 ref.) (Eng. Abstr.) **(Ger)**

[Anterior knee pain syndrome: a historical review] Witoński D. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):379–85 (63 ref.) (Eng. Abstr.) **(Pol)**

INJURIES

Fractures of the patella after total knee replacement. Bourne RB. **Orthop Clin North Am** 1999 Apr;30(2):287–91 (16 ref.)

PHYSIOLOGY

The biomechanics of the patellofemoral joint. Grelsamer RP, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):286–98 (91 ref.)

SURGERY

Specialized surgical exposure for revision total knee: quadriceps snip and patellar turndown. Barrack RI. **Instr Course Lect** 1999;48:149–52 (13 ref.)

[Patellar resurfacing. Results of a prospective randomized study] Schroeder-Boersch H, et al. **Orthopade** 1998 Sep; 27(9):642–50 (40 ref.) (Eng. Abstr.) **(Ger)**

PATELLAR LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT
POSTERIOR CRUCIATE LIGAMENT

INJURIES

Patellar tendinopathy: some aspects of basic science and clinical management. Khan KM, et al. **Br J Sports Med** 1998 Dec;32(4):346–55 (115 ref.)

Patellar tendon ruptures. Enad JG. **South Med J** 1999 Jun; 92(6):563–6 (18 ref.)

TRANSPLANTATION

[Plea for accelerated rehabilitation after ligament plasty of the knee by a bone-patellar tendon-bone graft] Boileau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):475–90 (97 ref.) (Eng. Abstr.) **(Fre)**

PATENCY, VASCULAR see **VASCULAR PATENCY**

PATENT MEDICINES see **DRUGS, NON-PRESCRIPTION**

PATENTS

Experimental and modeling studies of diffusion in immobilized cell systems. A review of recent literature and patents. Riley MR, et al. **Appl Biochem Biotechnol** 1999 May;80(2):151–88 (175 ref.)

Franchise issues--exclusivity of territory. Allen JF. **Inquiry** 1999 Spring;36(1):8–11 (13 ref.)

Adjuvants and delivery issues related to immunization: a survey of the recent patent literature [editorial] Mrsny RJ. **J Drug Target** 1998;6(4):243–9 (9 ref.)

The making of an instrument: from concept to market. Christoudias GC. **J Soc Laparoendosc Surg** 1998 Jul-Sep; 2(3):301–7 (7 ref.)

LEGISLATION & JURISPRUDENCE

Ethics and medical patents [editorial] Packer S. **Arch Ophthalmol** 1999 Jun;117(6):824–6 (14 ref.)

Patenting in biotechnology: a review of the 20th symposium of ECB8. Szarka E. **J Biotechnol** 1999 Jan 8;67(1):1–11 (22 ref.)

PATERNAL AGE

Long-term effects of delayed parenthood. Tarin JJ, et al. **Hum Reprod** 1998 Sep;13(9):2371–6 (106 ref.)

PATERNAL BEHAVIOR

Voles and vasopressin: a review of molecular, cellular, and behavioral studies of pair bonding and paternal behaviors. Wang Z, et al. **Prog Brain Res** 1998;119:483–99 (79 ref.)

PATERNAL EXPOSURE

see related
MATERNAL EXPOSURE

Commentary: paternal legacies. Anderson D, et al. **Teratog Carcinog Mutagen** 1999;19(2):105–8 (14 ref.)

PATERNITY

see related
DNA FINGERPRINTING

PATERNITY LEAVE see **PARENTAL LEAVE**

PATEY MASTECTOMY see **MASTECTOMY, MODIFIED RADICAL**

PATHOGENS, BLOOD-BORNE see **BLOOD-BORNE PATHOGENS**

PATHOLOGICAL GAMBLING see **GAMBLING**

PATHOLOGICAL WASTE see **MEDICAL WASTE**

PATHOLOGY

Protection of personnel and environment against Creutzfeldt-Jakob disease in pathology laboratories. Richard M, et al. **Clin Exp Pathol** 1999;47(3-4):192–200 (23 ref.)

Molecular pathology and managed care: challenges and opportunities. Ross JS. **Diagn Mol Pathol** 1998 Aug; 7(4):189–91 (0 ref.)

The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621–44 (63 ref.)

Alternatives for morphometric and stereologic analysis in toxicopathology. Collan Y. **Toxicol Lett** 1998 Dec 28; 102–103:393–7 (34 ref.)

As You Like It, Part 2: A critique and historical review of the electron microscopy literature. Ghadially FN. **Ultrastruct Pathol** 1999 Jan-Feb;23(1):1–17 (54 ref.)

EDUCATION

Broadsheet number 46: Internet for pathologists. Weinstein S. **Pathology** 1998 Nov;30(4):364–8 (9 ref.)

[Autopsy: overlap of teaching and medical research (editorial)] Giarelli L, et al. **Pathologica** 1998 Aug; 90(4):343–50 (14 ref.) **(Ita)**

HISTORY

The histopathology of tumors: past, present and future--a centenary essay for F. William Sunderman, Sr., M.D., Ph.D. Muschenheim F. **Ann Clin Lab Sci** 1999 Jul-Sep; 29(3):151–7 (20 ref.)

METHODS

Practical lymphoma diagnosis: an approach to using the information organized in the REAL proposal. Revised European-American Lymphoid Neoplasm. Segal GH, et al. **Anat Pathol** 1998;3:147–68 (42 ref.)

The molecular pathology laboratory of the 21st century. Kiechle FL, et al. **Ann Clin Lab Sci** 1999 Jan-Mar; 29(1):59–77 (134 ref.)

Grading and scoring in histopathology. Cross SS. **Histopathology** 1998 Aug;33(2):99–106 (26 ref.)

Guidelines for the development of comparative pathology. Kaiser HE, et al. **In Vivo** 1998 Nov-Dec;12(6):639–42 (46 ref.)

Intelligent decision support in pathomorphology. Jelonek J, et al. **Pol J Pathol** 1999;50(2):115–8 (9 ref.)

The pathologist and toxicologist in pharmaceutical product discovery. Alden CL, et al. **Toxicol Pathol** 1999 Jan-Feb; 27(1):104–6 (4 ref.)

Mechanisms of disease and injury: utilization of mutants, monoclonals, and molecular methods. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):115–20 (59 ref.)

[General human pathology and methodology of medicine] Tsaregorodtsev GI. **Vestn Ross Akad Med Nauk** 1998; (10):41–5 (0 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Consensus report of the task force on standardisation of DNA flow cytometry in clinical pathology. DNA Flow Cytometry Task Force of the European Society for Analytical Cellular Pathology. Ormerod MG, et al. **Anal Cell Pathol** 1998;17(2):103–10 (27 ref.)

Problems arising from eastern and western classification systems for gastrointestinal dysplasia and carcinoma: are they resolvable? Riddell RH, et al. **Histopathology** 1998 Sep;33(3):197–202 (6 ref.)

TRENDS

The molecular pathology laboratory of the 21st century. Kiechle FL, et al. **Ann Clin Lab Sci** 1999 Jan-Mar; 29(1):59–77 (134 ref.)

Dermatopathology in Europe: dreams and realities. Kerl H. **Arch Dermatol** 1999 Jan;135(1):21–4 (12 ref.)

PATHOLOGY, CLINICAL

Economic, regulatory, and practice issues in molecular pathology and diagnostics. Ross JS. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S7–10 (14 ref.)

[Telomerase and cancer: importance of detection of telomerase activity in pathology (editorial)] Brousset P. **Ann Pathol** 1998 Nov;18(5):375–6 (16 ref.) **(Fre)**

[Application of clinical tests to routine medical practice] Kuwajima M. **Nippon Naika Gakkai Zasshi** 1998 Oct 10; 87(10):1968–74 (8 ref.) **(Jpn)**

[Appropriate use of clinical tests in health-insurance managed medical care] Mori M. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1985–92 (4 ref.) **(Jpn)**

[With special reference to clinical specimen handlings] Takagi Y. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1980–4 (2 ref.) **(Jpn)**

[Concept of standard value and range in clinical tests] Yoshida H, et al. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1975–9 (5 ref.) **(Jpn)**

[The state of the art of the computer applications in clinical laboratory medicine] Nishibori M, et al. **Rinsho Byori** 1999 Feb;47(2):132–45 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Expert systems and automatic diagnostic systems in histopathology--a review] Tamai S. **Rinsho Byori** 1999

PATHOLOGY, CLINICAL

Feb;47(2):126–31 (22 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Training in cervical cytology, past, present and future. Denton KJ. **Cytopathology** 1999 Jun;10(3):147–52 (6 ref.)

INSTRUMENTATION

[Sampling and quality assurance] Kayamori Y, et al. **Rinsho Byori** 1998 Dec;46(12):1190–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

MANPOWER

[Cooperation between clinicians and pathologists] Reiss M, et al. **Schweiz Rundsch Med Prax** 1999 Mar 11;88(11):471–5 (17 ref.) (Eng. Abstr.) **(Ger)**

METHODS

If cells could talk. The application of new techniques to cytopathology. Abati A, et al. **Clin Lab Med** 1998 Sep; 18(3):561–83 (66 ref.)

Diagnosis of central venous catheter related sepsis--a critical look inside. Dobbins BM, et al. **J Clin Pathol** 1999 Mar; 52(3):165–72 (69 ref.)

Molecular pathology in the preclinical development of biopharmaceuticals. Gillett NA, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):48–52 (62 ref.)

[Evaluation and usefulness of hypercoagulability markers in medical pathology] Iturbe T, et al. **Sangre (Barc)** 1998 Oct; 43(5):415–20 (88 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Modifying use of pathology services [editorial; comment] [published erratum appears in Med J Aust 1999 Feb 1;170(3):144] Conyers RA. **Med J Aust** 1999 Jan 4; 170(1):8–9 (11 ref.) Comment on: Med J Aust 1999 Jan 4;170(1):11–4.

TRENDS

Accreditation of clinical laboratories: current status. Khurana SK, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):499–512 (57 ref.)

PATHOLOGY, SURGICAL

Errors in histopathology reporting: detection and avoidance. Ramsay AD. **Histopathology** 1999 Jun;34(6):481–90 (94 ref.)

LEGISLATION & JURISPRUDENCE

Medicolegal issues and fine needle aspiration of the breast. What you can do to decrease your risk of being sued. DeMay RM. **Clin Lab Med** 1998 Sep;18(3):599–605, vii (18 ref.)

METHODS

Clarity on the diagnosis line (the devil is in the details). Heffner DK, et al. **Ann Diagn Pathol** 1999 Jun;3(3):187–91 (2 ref.)

The surgical pathologist's approach to fine needle aspiration. Dabbs DJ. **Clin Lab Med** 1998 Sep;18(3):357–72, v (24 ref.)

Neuropathological biopsy diagnoses in clinical practice: how thorough and reproducible are they? [letter] Ojeda VJ, et al. **Pathology** 1998 Aug;30(3):328–9 (14 ref.)

Practical approach to processing osteosarcomas in the surgical pathology laboratory. Wold LE. **Pediatr Dev Pathol** 1998 Sep–Oct;1(5):449–54 (4 ref.)

PATIENT ABANDONMENT see **REFUSAL TO TREAT**

PATIENT ACCEPTANCE OF HEALTH CARE

Perceived side effects and benefits of coronary angioplasty in the early recovery period. Kimble LP, et al. **Heart Lung** 1998 Sep–Oct;27(5):308–14 (17 ref.)

The combined oral contraceptive pill--are poor communication systems responsible for loss of confidence in this contraceptive method? Mills A, et al. **Hum Reprod** 1999 Jan;14(1):7–10 (22 ref.)

Acute myocardial infarction and posttraumatic stress disorder: the consequences of cumulative adversity. Alonzo AA. **J Cardiovasc Nurs** 1999 Apr;13(3):33–45 (73 ref.)

Patient delay in seeking treatment for acute myocardial infarction symptoms. Zerwic JJ. **J Cardiovasc Nurs** 1999 Apr;13(3):21–32 (60 ref.)

Capacity to make health care decisions: its importance in clinical practice. Wong JG, et al. **Psychol Med** 1999 Mar; 29(2):437–46 (75 ref.)

ETHNOLOGY

Asian-Islamic women and breast cancer screening: a socio-cultural analysis. Rajaram SS, et al. **Women Health** 1999;28(3):45–58 (45 ref.)

PSYCHOLOGY

Strategies for preparing clients for treatment. A review. Walitzer KS, et al. **Behav Modif** 1999 Jan;23(1):129–51 (60 ref.)

Barriers to accessing and accepting dental care. Freeman R. **Br Dent J** 1999 Jul 24;187(2):81–4 (14 ref.)

Nontraditional treatments for localized prostate cancer: ten rules to know before talking to my patients. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):64–9 (52 ref.)

[Acceptability of hormonal substitution after menopause] Robyn C. **Rev Med Brux** 1998 Sep;19(4):A181–4 (11 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Annotation: children's disengagement from medical homes--a neglected public health imperative [editorial] Irigoyen M, et al. **Am J Public Health** 1999 Feb;89(2):157–9 (25 ref.)

Reduction in health care resource utilization associated with extended-release theophylline. Schulz RM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):267–72 (23 ref.)

Suicide and recency of health care contacts. A systematic review. Pirkis J, et al. **Br J Psychiatry** 1998 Dec;173:462–74 (37 ref.)

Factors predicting delayed presentation of symptomatic breast cancer: a systematic review [see comments] Ramirez AJ, et al. **Lancet** 1999 Apr 3;353(9159):1127–31 (34 ref.) Comment in: Lancet 1999 Apr 3;353(9159):1112–3.

Influence of delay on survival in patients with breast cancer: a systematic review [see comments] Richards MA, et al. **Lancet** 1999 Apr 3;353(9159):1119–26 (103 ref.) Comment in: Lancet 1999 Apr 3;353(9159):1112–3. Comment in: Lancet 1999 Jun 19;353(9170):2154; discussion 2155. Comment in: Lancet 1999 Jun 19;353(9170):2155–6.

PATIENT ADMISSION

see related

PATIENT READMISSION

In-hospital management of adults who have community-acquired pneumonia. Ortqvist A. **Semin Respir Infect** 1999 Jun;14(2):135–50 (84 ref.)

[Principles of withdrawal from illicit drugs during inpatient therapy] Singer W, et al. **Internist (Berl)** 1999 Jun; 40(6):634–9 (21 ref.) **(Ger)**

ECONOMICS

[Comment on the consensus report by medical staff on compensation for ambulatory and inpatient treatment] Hess R. **Chirurg** 1999 Feb;70(2):suppl 35–9 (0 ref.) **(Ger)**

STANDARDS

ABC of intensive care. Criteria for admission. Smith G, et al. **BMJ** 1999 Jun 5;318(7197):1544–7 (0 ref.)

The thread that links: continuity of patient care. Canady DM. **Prog Cardiovasc Nurs** 1999 Spring;14(2):69–71 (5 ref.)

STATISTICS & NUMERICAL DATA

Women in the intensive care unit [editorial] Baggs JG. **Am J Crit Care** 1999 Jul;8(4):207–9 (24 ref.)

Nebulized ipratropium bromide in acute pediatric asthma: does it reduce hospital admissions among children presenting to the emergency department? Rowe BH, et al. **Ann Emerg Med** 1999 Jul;34(1):75–85 (34 ref.)

The nature and extent of drug-related hospitalisations in Australia. Roughead EE. **J Qual Clin Pract** 1999 Mar; 19(1):19–22 (8 ref.)

PATIENT ADVOCACY

Are physicians aware of what patients know about what physicians know? [editorial] Sabbioni ME, et al. **Ann Oncol** 1999 Jan;10(1):11–2 (8 ref.)

A concept analysis on the process of empowerment. Ellis-Stoll CC, et al. **ANS Adv Nurs Sci** 1998 Dec; 21(2):62–8 (35 ref.)

From consultation-liaison psychiatry to psychosocial advocacy: maintaining psychiatry's scope. Smith GC. **Aust N Z J Psychiatry** 1998 Dec;32(6):753–61; discussion 762–6 (75 ref.)

The rise of doctor-patient working groups. Williamson C. **BMJ** 1998 Nov 14;317(7169):1374–7 (31 ref.)

Environmental ethics and medical ethics: some implications for end-of-life care, Part II. Carrick P. **Camb Q Healthc Ethics** 1999 Spring;8(2):250–6 (15 ref.)

Ethical challenges in the treatment of infants of drug-abusing mothers. Jain R, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):179–88 (37 ref.)

Neonatal viability in the 1990s: held hostage by technology. Muraskas J, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):160–70; discussion 170–2 (43 ref.)

Precedent autonomy: life-sustaining intervention and the demented patient. Newton MJ. **Camb Q Healthc Ethics** 1999 Spring;8(2):189–99 (63 ref.)

Autonomy, power, and control in palliative care. Scott PA. **Camb Q Healthc Ethics** 1999 Spring;8(2):139–47 (35 ref.)

Terminal sedation as palliative care: revalidating a right to a good death. Smith GP 2nd. **Camb Q Healthc Ethics** 1998 Fall;7(4):382–7 (37 ref.)

Stewardship of the aged: meeting the ethical challenge of ageism. In honor of Joseph Fletcher. Thomasma DC. **Camb Q Healthc Ethics** 1999 Spring;8(2):148–59 (38 ref.)

American Cancer Society Lymphedema Workshop: Workgroup V: Collaboration and advocacy. Candeira M, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2888–90 (0 ref.)

Humanitarianism, pluralism and ombudsmen: do the pieces fit? Christoplos I. **Disasters** 1999 Jun;23(2):125–38 (21 ref.)

AZT trials and tribulations. Crouch RA, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):26–34 (32 ref.)

Time for new rules on human subjects research? Dresser R. **Hastings Cent Rep** 1998 Nov–Dec;28(6):23–4 (32 ref.)

Research in developing countries: taking "benefit" seriously. Glantz LH, et al. **Hastings Cent Rep** 1998 Nov–Dec; 28(6):38–42 (18 ref.)

Science in the service of healing. Grady C. **Hastings Cent Rep** 1998 Nov–Dec;28(6):34–8 (19 ref.)

Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations. Malm HM. **Hastings Cent Rep** 1999 Jan–Feb;29(1):26–37 (55 ref.)

Can paternalism be justified in mental health care? Breeze J. **J Adv Nurs** 1998 Aug;28(2):260–5 (40 ref.)

What is the quality of the reporting of research ethics in publications of nursing home research? Karlawish JH, et al. **J Am Geriatr Soc** 1999 Jan;47(1):76–81 (58 ref.)

Avoiding conflicts of interest in surrogate decision making: why ethics committees should assign surrogacy to a separate committee. Levine RS. **J Clin Ethics** 1998 Fall; 9(3):273–90 (87 ref.)

On and off the playing field: ethics in medicine [editorial] Young RC Jr, et al. **J Health Care Poor Underserved** 1999 May;10(2):178–85 (28 ref.)

Managed care: rationing without justice, but not unjustly [see comments] Buchanan A. **J Health Polit Policy Law** 1998 Aug;23(4):617–34 (16 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687–95.

Protecting patient welfare in managed care: six safeguards [see comments] Emanuel EJ, et al. **J Health Polit Policy Law** 1998 Aug;23(4):635–59 (71 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687–95.

Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. Avins AL. **J Med Ethics** 1998 Dec;24(6):401–8 (50 ref.)

Imperialism, research ethics and global health [editorial] [see comments] Benatar SR. **J Med Ethics** 1998 Aug;24(4):221–2 (14 ref.) Comment in: J Med Ethics 1999 Feb;25(1):62.

The scope for the involvement of patients in their consultations with health professionals: rights, responsibilities and preferences of patients. Buetow S. **J Med Ethics** 1998 Aug;24(4):243–7 (53 ref.)

Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's motives. Malyon D. **J Med Ethics** 1998 Dec;24(6):376–81 (31 ref.)

The cost of refusing treatment and equality of outcome. Savulescu J. **J Med Ethics** 1998 Aug;24(4):231–6 (23 ref.)

Selecting subjects for participation in clinical research: one sphere of justice. Weijer C. **J Med Ethics** 1999 Feb; 25(1):31–6 (34 ref.)

Articulating the concept of palliative care: philosophical and theological perspectives. Janssens RM, et al. **J Palliat Care** 1999 Summer;15(2):38–44 (29 ref.)

Why nurses must actively participate in the debate on assisted suicide: a symposium. White BC, et al. **J Prof Nurs** 1999 May–Jun;15(3):139–41 (17 ref.)

The moral appeal of assisted suicide in end-of-life decisions. Zimbelman J, et al. **J Prof Nurs** 1999 May–Jun;15(3):142–5 (9 ref.)

An introduction to consumer politics. Epstein M, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Aug;36(8):40–9 (13 ref.)

Access denied: taking action for medically underserved children. Redlener I. **J Urban Health** 1998 Dec; 75(4):724–31 (2 ref.)

Women, welfare, and work: one view of the debate. Schroeder C, et al. **Nurs Outlook** 1998 Sep–Oct; 46(5):226–32 (34 ref.)

Ethics perspectives on end-of-life care. Tilden VP. **Nurs Outlook** 1999 Jul–Aug;47(4):162–7 (88 ref.)

American Academy of Pediatrics. Pediatric Practice Action Group and Task Force on Medical Informatics. Privacy protection and health information: patient rights and pediatrician responsibilities. Chilton L, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):973–7 (27 ref.)

The nurse's role in the informed consent process. Rosse PA, et al. **Semin Oncol Nurs** 1999 May;15(2):116–23 (28 ref.)

Ethical considerations in psychotherapeutic systems. Bergsma J, et al. **Theor Med Bioeth** 1998 Aug;19(4):371–81 (21 ref.)

An analysis of "dignity". Johnson PR. **Theor Med Bioeth** 1998 Aug;19(4):337–52 (35 ref.)

Prescriptions: autonomy, humanism and the purpose of health technology. Krakauer EL. **Theor Med Bioeth** 1998 Dec; 19(6):525–45 (27 ref.)

[Medicine and humanism: clinical ethics and the community dimension of geriatrics] Forest MI, et al. **Rev Med Suisse Romande** 1998 Dec;118(12):1013–7 (13 ref.) (Eng. Abstr.) **(Fre)**

[Patient rights and the physician-patient relationship] Førde R. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1467–9 (30 ref.) (Eng. Abstr.) **(Nor)**

[Euthanasia and cancer] Norum J, et al. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):796–8 (11 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Special perspective an immodest proposal: should treating mental health professionals be barred from testifying about their patients? Shuman DW, et al. **Behav Sci Law** 1998 Autumn;16(4):509–23 (38 ref.)

Bioethics for clinicians: 16. Dealing with demands for inappropriate treatment [see comments] Weijer C, et al. **CMAJ** 1998 Oct 6;159(7):817–21 (39 ref.) Comment in: CMAJ 1999 Feb 9;160(3):309–10.

Asymptomatic HIV under the ADA: the invisible, yet legitimate disability. Davis CS.
J Contemp Health Law Policy 1998 Fall;15(1):357–400 (0 ref.)

Standards of care and standard form contracts: distinguishing patient rights and consumer rights in managed care. Mariner WK. **J Contemp Health Law Policy** 1998 Fall; 15(1):1–55 (0 ref.)

The Patients' Bill of Rights: managed care under siege. Misocky M. **J Contemp Health Law Policy** 1998 Fall; 15(1):57–100 (0 ref.)

Error in medicine: legal impediments to U.S. reform. Liang BA. **J Health Polit Policy Law** 1999 Feb;24(1):27–58 (101 ref.)

Understanding and applying alternative dispute resolution methods in modern medical conflicts. Liang BA.
J Leg Med 1998 Sep;19(3):397–430 (53 ref.)

Legal decisions and public opinion informing the debate on assisted suicide. Zimbelman J. **J Prof Nurs** 1999 May–Jun; 15(3):146–50 (30 ref.)

Changing the present legal prohibitions on assisted suicide is a bad idea. Zimbelman J. **J Prof Nurs** 1999 May–Jun; 15(3):160–9 (46 ref.)

The hospital doctor in legislation and medical deontology: tension between profession and institution. Schutyser K. **Med Law** 1998;17(4):519–44 (57 ref.)

Medicolegal issues: headache. Saper JR. **Neurol Clin** 1999 May;17(2):197–214 (63 ref.)

Babies born with major disabilities: the medical–legal interface. Ward C, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):310–9 (21 ref.)

The aggressive patient/inmate: beyond denial. Maier GJ.
Psychiatr Q 1999 Fall;70(3):199–208 (33 ref.)

[Judicial rights of patients in health facilities. Overview of current state of jurisdiction] Rieger HJ.
Dtsch Med Wochenschr 1999 Feb 5;124(5):130–2 (10 ref.) **(Ger)**

PATIENT AGENT see **PROXY**

PATIENT APPOINTMENTS see **APPOINTMENTS AND SCHEDULES**

PATIENT CARE

Care of burns victims in Europe. Wedler V, et al. **Burns** 1999 Mar;25(2):152–7 (23 ref.)

Can randomised trials inform clinical decisions about individual patients? [see comments] Mant D. **Lancet** 1999 Feb 27;353(9154):743–6 (31 ref.) Comment in: Lancet 1999 May 8;353(9164):1622.

METHODS

Evidence-based medicine as a tool. Straus SE. **Hosp Med** 1998 Oct;59(10):762–5 (17 ref.)

STANDARDS

1998 revision of the Canadian Asthma Consensus Guidelines. Asthma Consensus Conference Editorial Committee [editorial] Boulet LP, et al. **Can Respir J** 1999 May–Jun; 6(3):231–2 (19 ref.)

Bioethics for clinicians: 17. Conflict of interest in research, education and patient care [see comments] Lemmens T, et al. **CMAJ** 1998 Oct 20;159(8):960–5 (36 ref.) Comment in: CMAJ 1999 Mar 23;160(6):784.

Recent developments in medical care of Jehovah's Witnesses. Muramoto O. **West J Med** 1999 May;170(5):297–301 (22 ref.)

PATIENT CARE EPISODES see **EPISODE OF CARE**

PATIENT CARE MANAGEMENT

Primary health care. McElmurry BJ, et al.
Annu Rev Nurs Res 1999;17:241–68 (165 ref.)

A distributed system for diabetic patient management. Bellazzi R, et al. **Comput Methods Programs Biomed** 1998 May;56(2):93–107 (27 ref.)

Dermatologists and the burn center. Barillo DJ, et al.
Dermatol Clin 1999 Jan;17(1):61–75, viii (36 ref.)

Importance of venous flow assessment for clinical decision-making. Gudmundsson S.
Eur J Obstet Gynecol Reprod Biol 1999 Jun;84(2):173–8 (26 ref.)

Why should obesity be managed? The obese individual's perspective. Evans E. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S3–5; discussion S6 (11 ref.)

How should the obese patient be managed? Possible approaches to a national obesity management network. Hainer V. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S14–8; discussion S18–9 (23 ref.)

Evaluating alternative treatments for HIV infection. Freeman EM, et al. **Nurs Clin North Am** 1999 Mar;34(1):147–62 (69 ref.)

Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC. **Nurs Clin North Am** 1999 Mar;34(1):213–25 (11 ref.)

Palliative care: pain and symptom management in persons with HIV/AIDS. Newshan G, et al.
Nurs Clin North Am 1999 Mar;34(1):131–45 (62 ref.)

The care of women with AIDS: special needs and considerations. Sowell RL, et al. **Nurs Clin North Am** 1999 Mar;34(1):179–99 (147 ref.)

Adherence to highly active antiretroviral therapy. Williams AB. **Nurs Clin North Am** 1999 Mar;34(1):113–29 (88 ref.)

[Documentation. A prerequisite for quality management] Krämer KL. **Orthopade** 1999 Mar;28(3):191–200 (59 ref.) (Eng. Abstr.) **(Ger)**

[The place of positron–emission tomography in contemporary patient care] Borbély K. **Orv Hetil** 1999 Jan 24;140(4):171–8 (50 ref.) (Eng. Abstr.) **(Hun)**

STANDARDS

Controlled observations in critical care medicine: the therapeutic trial. Pinsky MR. **Ann Acad Med Singapore** 1998 May;27(3):387–96 (31 ref.)

Collaboration in improving care for patients: how can we find out what we haven't been able to figure out yet? Batalden PB, et al. **Jt Comm J Qual Improv** 1998 Oct; 24(10):609–18 (39 ref.)

PATIENT CARE PLANNING

see related
AFTERCARE
CONSUMER PARTICIPATION

A standard of care for radial artery grafting. Hayes EC, et al. **Am J Crit Care** 1998 Nov;7(6):429–35 (23 ref.)

Applying evidence to the individual patient. Straus SE, et al. **Ann Oncol** 1999 Jan;10(1):29–32 (21 ref.)

Dialysis or transplantation: fitting the treatment to the patient. Berkoben M, et al. **Annu Rev Med** 1999;50:193–205 (21 ref.)

The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer. Burke GA, et al. **Cancer Treat Rev** 1999 Feb; 25(1):13–27 (88 ref.)

Patient values: the guide to medical decision making. Miller DL, et al. **Clin Geriatr Med** 1998 Nov;14(4):813–29 (56 ref.)

A plastic surgery literature review to assist in the management of patients seeking elective esthetic dental treatments. Venot MG. **Dent Clin North Am** 1998 Oct; 42(4):789–98, xi (99 ref.)

Endovascular brachytherapy—treatment planning and radiation protection. Quast U, et al. **Herz** 1998 Sep; 23(6):337–46 (57 ref.)

Considerations when planning occlusal rehabilitation: a review of the literature. Wassell RW, et al. **Int Dent J** 1998 Dec;48(6):571–81 (116 ref.)

A systematic review of the relationships between written manual nursing care planning, record keeping and patient outcomes. Moloney R, et al. **J Adv Nurs** 1999 Jul;30(1):51–7 (19 ref.)

Approaching psychotherapy of the personality disorders from the Millon perspective. Dorr D. **J Pers Assess** 1999 Jun;72(3):407–25 (35 ref.)

Asthma in managed care. Lozano P, et al. **Pediatr Ann** 1999 Jan;28(1):74–80 (41 ref.)

Recognition and management of preoperative risk. Nierman E, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):585–622 (150 ref.)

Optimized planning using physical objectives and constraints. Bortfeld T. **Semin Radiat Oncol** 1999 Jan;9(1):20–34 (63 ref.)

[Crohn disease—principle of longitudinal therapy planning with early surgical indications] Jauch KW, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:160–5 (12 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Communicating with clients about treatment outcomes: the use of meta-analytic evidence in collaborative treatment planning. Tickle-Degnen L. **Am J Occup Ther** 1998 Jul–Aug;52(7):526–30 (15 ref.)

Colorectal cancer: A rational follow-up program adapted to patient's individual risk of recurrence and review of the literature. Schorr M, et al. **Eur J Med Res** 1999 Jul 28; 4(7):275–82 (48 ref.)

Comprehensive management of amyotrophic lateral sclerosis. Carter GT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb; 9(1):271–84, viii–ix (48 ref.)

[What are the therapeutic objectives in gastroesophageal reflux?] Wienbeck M. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S67–9 (12 ref.) **(Fre)**

[Asthma: has the time of therapeutic management come?] Uldry C. **Rev Med Suisse Romande** 1999 Mar;119(3):211–6 (32 ref.) **(Fre)**

STANDARDS

Theory construction based on standards of care: a proposed theory of the peaceful end of life. Ruland CM, et al.
Nurs Outlook 1998 Jul–Aug;46(4):169–75 (19 ref.)

PATIENT CARE TEAM

Interdisciplinary rehabilitation in Parkinson's disease. Iansek R. **Adv Neurol** 1999;80:555–9 (23 ref.)

The role of the health care team in the implementation of the National Kidney Foundation–Dialysis Outcomes Quality Initiative: a case study. Callahan MB, et al.
Adv Ren Replace Ther 1999 Jan;6(1):42–51 (34 ref.)

Breaking bad news. 1: Current best advice for clinicians. Girgis A, et al. **Behav Med** 1998 Summer;24(2):53–9 (42 ref.)

The role of the psychiatrist in organ transplantation. Klapheke MM. **Bull Menninger Clin** 1999 Winter; 63(1):13–39 (60 ref.)

Collaboration and teamwork in assessment for early intervention. Bagnato SJ, et al.
Child Adolesc Psychiatr Clin N Am 1999 Apr;8(2):347–63 (16 ref.)

Interdisciplinary care. Kresevic D, et al.
Clin Geriatr Med 1998 Nov;14(4):787–98 (12 ref.)

The neurosurgeon and the acute stroke patient in the emergency department: diagnosis and management. Selman W, et al. **Clin Neurosurg** 1999;45:74–85 (54 ref.)

A stage of change approach to addiction in the medical setting. Peteet JR, et al. **Gen Hosp Psychiatry** 1998 Sep; 20(5):267–73 (13 ref.)

Multisystemic treatment of criminality and violence in adolescents. Borduin CM.
J Am Acad Child Adolesc Psychiatry 1999 Mar;38(3):242–9 (36 ref.)

The dietitians' philosophy and practice in multidisciplinary weight management. Dalton S. **J Am Diet Assoc** 1998 Oct; 98(10 Suppl 2):S49–54 (49 ref.)

A multidisciplinary approach to obesity management: the physician's role and team care alternatives. Frank A.
J Am Diet Assoc 1998 Oct;98(10 Suppl 2):S44–8 (10 ref.)

A model for chronic care of obesity through dietary treatment. Nonas CA. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S16–22 (39 ref.)

The interaction between family physicians and palliative care consultants in the delivery of palliative care: clinical and educational issues. Brenneis C, et al. **J Palliat Care** 1998 Autumn;14(3):58–61 (21 ref.)

A nursing-centered treatment team in inpatient medical psychiatry. Norton JW, et al.
J Psychosoc Nurs Ment Health Serv 1999 Apr;37(4):39–41 (0 ref.)

The management of cancer in the elderly. Ashkanani F, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):2–10 (65 ref.)

The interdisciplinary team's approach to lupus nephritis. Crane M, et al. **Lupus** 1998;7(9):660–5 (19 ref.)

"You are a number, not a human being": Israeli breast cancer patients' experiences with the medical establishment. Sered S, et al. **Med Anthropol Q** 1999 Jun;13(2):223–52 (36 ref.)

Eating disorders revisited. II: Bulimia nervosa and related syndromes. Hay PJ, et al. **Med J Aust** 1998 Nov 2; 169(9):488–91 (30 ref.)

Rethinking geriatric nursing. Fulmer T, et al.
Nurs Clin North Am 1998 Sep;33(3):387–94 (3 ref.)

Primary care and case management of persons with HIV/AIDS. Kirton CA, et al. **Nurs Clin North Am** 1999 Mar;34(1):71–94 (27 ref.)

Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Hearn J, et al. **Palliat Med** 1998 Sep;12(5):317–32 (61 ref.)

Models of collaboration. Lorenz AD, et al. **Prim Care** 1999 Jun;26(2):401–10 (14 ref.)

Describing and evaluating jail diversion services for persons with serious mental illness. Draine J, et al.
Psychiatr Serv 1999 Jan;50(1):56–61 (25 ref.)

Clinical trials and tribulations: implementation processes in schizophrenia research outcome. Mason SE, et al.
Psychiatry 1998 Winter;61(4):288–301 (49 ref.)

Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. Spaulding WD, et al.
Schizophr Bull 1999;25(2):275–89 (65 ref.)

[Violence our medical trauma in specialized multidisciplinary consultation] Albrecht E, et al.
Schweiz Rundsch Med Prax 1999 Feb 11;88(7):280–4 (4 ref.) (Eng. Abstr.) **(Fre)**

[Mutilating complex trauma of the pelvis] Rieger H, et al.
Chirurg 1998 Nov;69(11):1275–9 (19 ref.) (Eng. Abstr.) **(Ger)**

[Nosocomial hepatitis B virus, hepatitis C virus and HIV infections by infectious medial personnel] Hasselhorn HM, et al. **Gesundheitswesen** 1998 Oct;60(10):545–51 (38 ref.) (Eng. Abstr.) **(Ger)**

[Ciaglia percutaneous dilatation tracheotomy with endoscopic control. Analysis of complication-fraught steps] Koitschev A, et al. **HNO** 1998 Jul;46(7):678–83 (20 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of sleep-related breathing disorders. 1: Terminology] Maurer JT, et al. **HNO** 1998 Dec; 46(12):958–68 (57 ref.) (Eng. Abstr.) **(Ger)**

[Ulcerative colitis, duration of conservative therapy and surgical sequelae] Buhr HJ, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:148–52 (11 ref.) (Eng. Abstr.) **(Ger)**

[Crohn disease—principle of longitudinal therapy planning with early surgical indications] Jauch KW, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:160–5 (12 ref.) (Eng. Abstr.) **(Ger)**

[Colorectal surgery--an integral part of general surgery!] Renzulli P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:619–26 (21 ref.) (Eng. Abstr.) **(Ger)**

[Progress in diagnostic imaging of the thorax (CT, MRI, intervention)--significance and value for the surgeon] Schildberg FW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:255–60 (0 ref.) (Eng. Abstr.) **(Ger)**

[Complications related to surgery in ulcerative colitis, pouchitis, special sequelae--internal medicine viewpoint] Zeitz M. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:154–9 (15 ref.) (Eng. Abstr.) **(Ger)**

[Long-term treatment of chronic schizophrenia (see comments)] Albers M. **Nervenarzt** 1998 Sep;69(9):737–51 (142 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1999 Mar;70(3):291–2. **(Ger)**

[Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference] Kuwert T, et al. **Nervenarzt** 1998 Dec;69(12):1045–60 (234 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of depressive disorders in general practice] Schüren A, et al. **Psychiatr Prax** 1999 Jul; 26(4):163–6 (25 ref.) (Eng. Abstr.) **(Ger)**

[Psycho-oncologic interventions--critical review] Larbig W. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):381–9 (75 ref.) (Eng. Abstr.) **(Ger)**

[Contribution of the clinical psychologists to rehabilitation of children with craniofacial abnormalities] Sarimski K. **Psychother Psychosom Med Psychol** 1998 Dec; 48(12):475–82 (30 ref.) (Eng. Abstr.) **(Ger)**

[Psychological problems and treatment possibilities in intensive care medicine exemplified by bone marrow transplantation] Schulz-Kindermann F, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):390–7 (55 ref.) (Eng. Abstr.) **(Ger)**

[Menopause and its sequelae: an interdisciplinary syndrome] Maurer-Major E, et al. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1697–702 (34 ref.) (Eng. Abstr.) **(Ger)**

[Significance of music in modern medicine] Escher J. **Schweiz Rundsch Med Prax** 1998 Aug 5;87(31–32):987–96 (5 ref.) **(Ger)**

[Cooperation between clinicians and pathologists] Reiss M, et al. **Schweiz Rundsch Med Prax** 1999 Mar 11;88(11):471–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation in COPD] Villiger B. **Ther Umsch** 1999 Mar; 56(3):131–5 (31 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of peripheral nerve injuries. The "integrated therapy concept"] Berger A, et al. **Unfallchirurg** 1999 Jan;102(1):59–68 (44 ref.) **(Ger)**

[Possibilities and limits of geriatric assessment in general practice] Fischer GC, et al. **Z Gerontol Geriatr** 1998 Oct; 31(5):348–54 (50 ref.) (Eng. Abstr.) **(Ger)**

[Mesenteric infarct--when is the vascular surgeon needed?] Kniemeyer HW. **Zentralbl Chir** 1998;123(12):1411–7 (40 ref.) (Eng. Abstr.) **(Ger)**

[Peripheral blood stem cell transplantation as an interdisciplinary challenge--theory and practice] Cassens U, et al. **Zentralbl Gynakol** 1998;120(8):367–72 (26 ref.) (Eng. Abstr.) **(Ger)**

[Integrated treatment of cleft lip and palate. Organization of a treatment team] Sánchez-Ruiz I, et al. **Cir Pediatr** 1999 Jan;12(1):4–10 (35 ref.) (Eng. Abstr.) **(Spa)**

[Rare disabilities--less known syndromes. A challenge for neuropsychiatric rehabilitation] Gillberg C, et al. **Lakartidningen** 1999 Apr 14;96(15):1824–6, 1829–30 (18 ref.) **(Swe)**

LEGISLATION & JURISPRUDENCE

[Rights and responsibilities of the radiologist in determining indications and applying radiologic procedures] Schunk K. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):7–15 (29 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Contributions of respiratory care practitioners to intensive care: a review. Yu NC, et al. **Ann Acad Med Singapore** 1998 May;27(3):422–5 (21 ref.)

The potential for improved teamwork to reduce medical errors in the emergency department. The MedTeams Research Consortium [see comments] Risser DT, et al. **Ann Emerg Med** 1999 Sep;34(3):373–83 (25 ref.) Comment in: Ann Emerg Med 1999 Sep;34(3):370–2.

Systems for collaboration. Integrating multiple perspectives. Briggs MH. **Child Adolesc Psychiatr Clin N Am** 1999 Apr; 8(2):365–77 (24 ref.)

The organization and delivery of craniofacial health services: the state of the art. Strauss RP. **Cleft Palate Craniofac J** 1999 May;36(3):189–95 (56 ref.)

A challenge for clinical nurses: a new nursing role [see comments] Balogh D, et al. **Heart Lung** 1998 Nov–Dec; 27(6):355–9 (11 ref.) Comment in: Heart Lung 1999 May–Jun;28(3):226.

Systematic review of the effectiveness of interprofessional education: towards transatlantic collaboration. Barr H, et al. **J Allied Health** 1999 Summer;28(2):104–8 (26 ref.)

Building community: developing skills for interprofessional health professions education and relationship-centered care. NLN Appointed Interdisciplinary Health Education Panel. Walker PH, et al. **J Allied Health** 1998 Fall; 27(3):173–8 (14 ref.)

Optimizing the roles of school mental health professionals. Flaherty LT, et al. **J Sch Health** 1998 Dec;68(10):420–4 (34 ref.)

Interdisciplinary collaborative training for school-based health professionals. Papa PA, et al. **J Sch Health** 1998 Dec;68(10):415–9 (13 ref.)

Collaboration in improving care for patients: how can we find out what we haven't been able to figure out yet? Batalden PB, et al. **Jt Comm J Qual Improv** 1998 Oct; 24(10):609–18 (39 ref.)

An interactive approach to training teams and developing programs. Corrigan PW, et al. **New Dir Ment Health Serv** 1998 Fall;(79):3–12 (34 ref.)

Training professionals for rehabilitation teams. Lefley HP. **New Dir Ment Health Serv** 1998 Fall;(79):13–23 (22 ref.)

Maintaining professional integrity in the midst of interdisciplinary collaboration. Lindeke LL, et al. **Nurs Outlook** 1998 Sep–Oct;46(5):213–8 (25 ref.)

Interdisciplinary team: the nursing perspective is essential. McCloskey JC, et al. **Nurs Outlook** 1998 Jul–Aug; 46(4):157–63 (33 ref.)

Comprehensive management of amyotrophic lateral sclerosis. Carter GT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb; 9(1):271–84, viii–ix (48 ref.)

The role of physiatry in the management of neuromuscular disease. Fowler WM Jr, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):1–8, v (23 ref.)

[Halitosis: a multidisciplinary problem] Bollen CM, et al. **Rev Med Liege** 1999 Jan;54(1):32–6 (25 ref.) (Eng. Abstr.) **(Fre)**

[Asthma: has the time of therapeutic management come?] Uldry C. **Rev Med Suisse Romande** 1999 Mar;119(3):211–6 (32 ref.) **(Fre)**

[Concept of interdisciplinary pain therapy] Eller U, et al. **Ther Umsch** 1999 Aug;56(8):446–9 (6 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Western medicine opens the door to alternative medicine. Boozang KM. **Am J Law Med** 1998;24(2–3):185–212 (165 ref.)

[Social work in public health service as reflected by selected studies--a description of current status] Reinicke P. **Gesundheitswesen** 1999 Apr;61(4):197–202 (19 ref.) (Eng. Abstr.) **(Ger)**

[Ambulatory nursing-care related social work] Jansen B. **Z Gerontol Geriatr** 1998 Oct;31(5):319–24 (15 ref.) (Eng. Abstr.) **(Ger)**

PATIENT-CENTERED CARE

Patient-centered communication. Brown SJ. **Annu Rev Nurs Res** 1999;17:85–104 (80 ref.)

Priorities for patient-centered research. Feussner JR. **Med Care** 1999 Sep;37(9):843–5 (11 ref.)

A patient-centered model of acute care for elders. Kresevic DM, et al. **Nurs Clin North Am** 1998 Sep;33(3):515–27 (6 ref.)

[Patient-centered consultation of "good practice guidelines": OncoDoc, a decision support system for the management of breast cancer patients] Bouaud J, et al. **Therapie** 1999 Mar-Apr;54(2):209–15 (7 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Uniting practice and theory in an occupational framework. 1998 Eleanor Clarke Slagle Lecture. Fisher AG. **Am J Occup Ther** 1998 Jul-Aug;52(7):509–21 (68 ref.)

STANDARDS

Acknowledging barriers in adopting person-centered planning. Holburn S, et al. **Ment Retard** 1999 Apr; 37(2):117–24 (24 ref.)

HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Sullivan G, et al. **Psychiatr Serv** 1999 May;50(5):648–52 (44 ref.)

PATIENT-CENTERED NURSING see **PATIENT-CENTERED CARE**

PATIENT COMPLIANCE

see related
PATIENT DROPOUTS
TREATMENT REFUSAL

Integrated approaches to management of hypertension: promoting treatment acceptance. McInnes GT. **Am Heart J** 1999 Sep;138(3 Pt 2):252–5 (20 ref.)

Compliance issues in the treatment of HIV infection. Tseng AL. **Am J Health Syst Pharm** 1998 Sep 1;55(17):1817–24 (35 ref.)

Assessing patient wellness: new perspectives on quality of life and compliance. Williams GH. **Am J Hypertens** 1998 Nov;11(11 Pt 2):186S–191S (27 ref.)

Effective management of gout: an analogy [see comments] Wortmann RL. **Am J Med** 1998 Dec;105(6):513–4 (08 ref.) Comment in: Am J Med 1998 Dec;105(6):549–50.

Improving adherence to hormone replacement therapy with effective patient-physician communication. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):337–40 (15 ref.)

Compliance with treatment protocols: interventions for children with chronic illness. Fielding D, et al. **Arch Dis Child** 1999 Feb;80(2):196–200 (42 ref.)

Compliance by collaboration: effectively addressing problems of treatment adherence. Lassleben M, et al. **Aust Fam Physician** 1999 Aug;28(8):850–3 (11 ref.)

Predictors of medication adherence in the elderly. Balkrishnan R. **Clin Ther** 1998 Jul-Aug;20(4):764–71 (24 ref.)

Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Farmer KC. **Clin Ther** 1999 Jun;21(6):1074–90; discussion 1073 (61 ref.)

Clinician/patient interaction: communicating the benefits and risks of oral contraceptives. Davis A, et al. **Contraception** 1999 Jan;59(1 Suppl):39S–42S (22 ref.)

The metabolic syndrome: overeating, inactivity, poor compliance or 'dud' advice? Petrie JR, et al. **Diabet Med** 1998 Nov;15 Suppl 3:S29–31 (25 ref.)

Beyond "compliance" is "adherence". Improving the prospect of diabetes care. Lutfey KE, et al. **Diabetes Care** 1999 Apr; 22(4):635–9 (44 ref.)

Once a day is best: evidence or assumption? The relationship between compliance and dosage frequency in older people. Pushpangadan M, et al. **Drugs Aging** 1998 Sep;13(3):223–7 (25 ref.)

Practical aspects of drug treatment in elderly patients with mobility problems. Thwaites JH. **Drugs Aging** 1999 Feb; 14(2):105–14 (47 ref.)

NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. **Eur Addict Res** 1999 Mar;5(1):50–1 (0 ref.)

Patient compliance and outcomes. Kane S. **Inflamm Bowel Dis** 1999 May;5(2):134–7 (26 ref.)

Managing the climacteric. Rozenberg S, et al. **Int J Fertil Womens Med** 1999 Jan–Feb;44(1):12–8 (32 ref.)

Medication compliance and older people: a review of the literature. Ryan AA. **Int J Nurs Stud** 1999 Apr;36(2):153–62 (63 ref.)

Why should obesity be managed? The obese individual's perspective. Evans E. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S3–5; discussion S6 (11 ref.)

Maintenance programmes after weight reduction--how useful are they? Mustajoki P, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23(6):553–5 (21 ref.)

Atypical neuroleptics: autonomy and compliance? Marland GR. **J Adv Nurs** 1999 Mar;29(3):615–22 (47 ref.)

Insight in severe mental illness: implications for treatment decisions. Husted JR. **J Am Acad Psychiatry Law** 1999; 27(1):33–49 (33 ref.)

Tolerability and patient compliance. Roose SP. **J Clin Psychiatry** 1999;60 Suppl 17:14–7; discussion 46–8 (13 ref.)

Contraceptive choice and patient compliance. The health care provider's challenge. Branden PS. **J Nurse Midwifery** 1998 Nov–Dec;43(6):471–82 (54 ref.)

Compliance as a critical issue in long-term oxygen therapy. Avdeev SN, et al. **Monaldi Arch Chest Dis** 1999 Feb; 54(1):61–6 (56 ref.)

Adherence to highly active antiretroviral therapy. Williams AB. **Nurs Clin North Am** 1999 Mar;34(1):113–29 (88 ref.)

Patient understanding of postsurgical instruction forms. Alexander RE. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):153–8 (26 ref.)

Steps to better compliance in diabetic patients. Gadsby R, et al. **Practitioner** 1999 Feb;243(1595):103, 106, 108 (6 ref.)

Compliance of patients with arterial hypertension to therapeutic recommendations. Więcek A. **Przegl Lek** 1998; 55 Suppl 1:65–6 (8 ref.) **(Eng, Pol)**

Head positioning compliance with spectacles after gas retinopexy. Boucher MC, et al. **Retina** 1999;19(2):177–8 (0 ref.)

Treatment adherence in juvenile rheumatoid arthritis--a review. Kroll T, et al. **Scand J Rheumatol** 1999;28(1):10–8 (33 ref.)

Consent (assent) for research with pediatric patients. Broome ME. **Semin Oncol Nurs** 1999 May;15(2):96–103 (23 ref.)

Prescription medications: a modifiable contributor to obesity. Cheskin LJ, et al. **South Med J** 1999 Sep;92(9):898–904 (44 ref.)

Practical issues in medication compliance. Cramer JA. **Transplant Proc** 1999 Jun;31(4A):7S–9S (12 ref.)

Methodological issues in transplant compliance research. De Geest S, et al. **Transplant Proc** 1999 Jun;31(4A):81S–83S (9 ref.)

Medication adherence and the transplant recipient: helping patients at each stage of change. Robbins ML. **Transplant Proc** 1999 Jun;31(4A):29S–30S (17 ref.)

A medical anthropologist's view on posttransplant compliance: the underground economy of medical survival. Sharp LA. **Transplant Proc** 1999 Jun;31(4A):31S–33S (20 ref.)

Cross-cultural issues in transplant compliance. Washington AW. **Transplant Proc** 1999 Jun;31(4A):27S–28S (7 ref.)

[The concept of compliance to diabetes treatment revisited] Tubiana-Rufi N, et al. **Diabetes Metab** 1999 Jun;25(2):172–6 (23 ref.) **(Fre)**

[Legal grounds for patient information in orthopedics] Bergmann KO. **Orthopade** 1998 Oct;27(10):705–12 (69 ref.)

(Ger)

[Compliance in antibiotic therapy of respiratory tract infections] Karpov OI. **Antibiot Khimioter** 1999;44(8):37–45 (47 ref.) (Rus)

ETHNOLOGY

Culturally competent professionals in therapeutic alliances enhance patient compliance [editorial] Langer N. **J Health Care Poor Underserved** 1999 Feb;10(1):19–26 (22 ref.)

PSYCHOLOGY

Stressors and concerns in teen asthma. Randolph C, et al. **Curr Probl Pediatr** 1999 Mar;29(3):82–93 (83 ref.)

Depo-Provera: an ideal contraceptive for adolescents? Boroditsky RS. **J Pediatr Adolesc Gynecol** 1999 May; 12(2):95–9 (26 ref.)

[The patient with glaucoma and his treatment: is there real perception?] Naacke H, et al. **J Fr Ophtalmol** 1999 Feb; 22(1):99–101 (16 ref.) (Fre)

[Compliance problems in treatment of schizophrenic patients] Barnas C, et al. **Wien Med Wochenschr** 1998; 148(11–12):281–3 (21 ref.) (Eng. Abstr.) (Ger)

STATISTICS & NUMERICAL DATA

A critical evaluation of the methodology of the literature on medication compliance. Nichol MB, et al. **Ann Pharmacother** 1999 May;33(5):531–40 (72 ref.)

Optimizing tuberculosis control in the inner city [editorial; comment] FitzGerald JM. **CMAJ** 1999 Mar 23;160(6):821–2 (14 ref.) Comment on: CMAJ 1999 Mar 23;160(6):789–94. Comment on: CMAJ 1999 Mar 23;160(6):799–802.

Reading between the lines: deciphering the connections between literacy and health [editorial; comment] Baker DW. **J Gen Intern Med** 1999 May;14(5):315–7 (30 ref.) Comment on: J Gen Intern Med 1999 May;14(5):267–73.

PATIENT COOPERATION see **PATIENT COMPLIANCE**

PATIENT CREDIT AND COLLECTION

ACC expert consensus document on ethical coding and billing practices for cardiovascular medicine specialists. American College of Cardiology. Blankenship JC, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):1076–86 (33 ref.)

PATIENT DATA PRIVACY see **CONFIDENTIALITY**

PATIENT DISCHARGE

Recovery from intensive care. Griffiths RD, et al. **BMJ** 1999 Aug 14;319(7207):427–9 (0 ref.)

Patients leaving hospital after administration of radioactive substances. Working Party of the Radiation Protection Committee of the British Institute of Radiology. **Br J Radiol** 1999 Feb;72(854):121–5 (12 ref.)

The effectiveness of predischarge home assessment visits: a systematic review. Patterson CJ, et al. **Clin Rehabil** 1999 Apr;13(2):101–4 (14 ref.)

Impact of early tracheal extubation on hospital discharge. Cheng DC. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):35–40; discussion 41–4 (60 ref.)

Patient selection and anesthetic management for early extubation and hospital discharge: CABG. Royston D. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):11–9 (57 ref.)

Discharge planning and home follow-up of the elderly patient with heart failure. Campbell RL, et al. **Nurs Clin North Am** 1998 Sep;33(3):497–513 (12 ref.)

The thread that links: continuity of patient care. Canady DM. **Prog Cardiovasc Nurs** 1999 Spring;14(2):69–71 (5 ref.)

[Early discharge from maternity and neonatal care units--limitations and perspectives (see comments)] Hansen TW. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1893–6 (45 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 20;119(16):2391–2. (Nor)

ECONOMICS

A review of guidelines for the discharge of premature infants: opportunities for improving cost effectiveness. Merritt TA, et al. **J Perinatol** 1998 Nov-Dec;18(6 Pt 2 Su):S27–37 (79 ref.)

LEGISLATION & JURISPRUDENCE

Early postpartum discharge. Brumfield CG. **Clin Obstet Gynecol** 1998 Sep;41(3):611–25 (57 ref.)

STANDARDS

Discharge criteria and complications after ambulatory surgery. Marshall SI, et al. **Anesth Analg** 1999 Mar; 88(3):508–17 (101 ref.)

Early discharge from the NICU. Gamblian V, et al. **J Pediatr Nurs** 1998 Oct;13(5):296–301 (11 ref.)

A review of guidelines for the discharge of premature infants: opportunities for improving cost effectiveness. Merritt TA, et al. **J Perinatol** 1998 Nov-Dec;18(6 Pt 2 Su):S27–37 (79 ref.)

STATISTICS & NUMERICAL DATA

Administrative data for quality improvement. Schwartz RM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):291–301 (30 ref.)

Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996. Graves EJ, et al. **Vital Health Stat 13** 1998 Sep;(138):i–iii, 1–151 (16 ref.)

TRENDS

Early discharge. Risks, benefits, and who decides. Kiely M, et al. **Clin Perinatol** 1998 Sep;25(3):539–53, vii–viii (62 ref.)

PATIENT DROPOUTS

Lost to follow-up: the problem of defaulters from diabetes clinics. Griffin SJ. **Diabet Med** 1998 Nov;15 Suppl 3:S14–24 (136 ref.)

Methodological issues concerning evaluation of treatment for sexual offenders: randomization, treatment dropouts, untreated controls, and within-treatment studies [see comments] McConaghy N. **Sex Abuse** 1999 Jul; 11(3):183–93 (32 ref.) Comment in: Sex Abuse 1999 Jul;11(3):179–81.

STATISTICS & NUMERICAL DATA

Annotation: children's disengagement from medical homes--a neglected public health imperative [editorial] Irigoyen M, et al. **Am J Public Health** 1999 Feb;89(2):157–9 (25 ref.)

PATIENT DUMPING see **PATIENT TRANSFER**

PATIENT EDUCATION

Health promotion for end-stage renal disease patients. Sadler JH. **Adv Ren Replace Ther** 1998 Oct;5(4):275–85 (58 ref.)

Effective management of gout: an analogy [see comments] Wortmann RL. **Am J Med** 1998 Dec;105(6):513–4 (08 ref.) Comment in: Am J Med 1998 Dec;105(6):549–50.

Putting prevention into practice: just do it [editorial] Litt J. **Aust Fam Physician** 1999 Jan;28 Suppl 1:S1–2 (15 ref.)

Children with chronic arthritis: the management of transition to adulthood. Ansell BM, et al. **Baillieres Clin Rheumatol** 1998 May;12(2):363–73 (30 ref.)

Conservative approaches to lymphedema treatment. Rinehart-Ayres ME. **Cancer** 1998 Dec 15;83(12 Suppl American):2828–32 (26 ref.)

Lymphedema: patient and provider education: current status and future trends. Runowicz CD. **Cancer** 1998 Dec 15;83(12 Suppl American):2874–6 (5 ref.)

American Cancer Society Lymphedema Workshop. Workgroup II: Patient education--pre-and posttreatment. Runowicz CD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2880–1 (0 ref.)

American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources--professional education and availability of patient services. Walley DR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2886–7 (0 ref.)

Breast self-examination training: a brief review. Clarke VA, et al. **Cancer Nurs** 1999 Aug;22(4):320–6 (57 ref.)

Prostate cancer: 6. Surgical treatment of localized disease. Goldenberg SL, et al. **CMAJ** 1998 Nov 17;159(10):1265–71 (25 ref.)

Prostate cancer: 7. Radiation therapy for localized disease. Warde P, et al. **CMAJ** 1998 Dec 1;159(11):1381–8 (33 ref.)

Answers to 10 key questions on diverticular disease of the colon. Kennedy MV, et al. **Compr Ther** 1998 Aug; 24(8):364–9 (15 ref.)

Clinician/patient interaction: communicating the benefits and risks of oral contraceptives. Davis A, et al. **Contraception** 1999 Jan;59(1 Suppl):39S–42S (22 ref.)

Dietary advice in British General Practice. Gray DP. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S3–8 (54 ref.)

Nutritional guidance in general practice--a conceptual framework. van Weel C. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S108–11 (18 ref.)

Streamlining nutritional care for the physician's office. Wasson JH, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S97–100 (11 ref.)

How to improve the impact of nutrition guidance by general physicians: public health versus individual patient? Worsley A. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S101–7 (56 ref.)

Who should provide genetic education prior to gene testing? Computers and other methods for improving patient understanding. Green MJ, et al. **Genet Test** 1997;1(2):131–6 (47 ref.)

Practical assessment of adult literacy in health care. Davis TC, et al. **Health Educ Behav** 1998 Oct;25(5):613–24 (58 ref.)

The combined oral contraceptive pill--are poor communication systems responsible for loss of confidence in this contraceptive method? Mills A, et al. **Hum Reprod** 1999 Jan;14(1):7–10 (22 ref.)

Effect of increased community and professional awareness of plaque control on the management of inflammatory periodontal diseases. Bartold PM, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):282–9 (45 ref.)

Managing the climacteric. Rozenberg S, et al. **Int J Fertil Womens Med** 1999 Jan-Feb;44(1):12–8 (32 ref.)

A review of the impact of pre-operative education on recovery from surgery. Shuldham C. **Int J Nurs Stud** 1999 Apr;36(2):171–7 (20 ref.)

Pre-operative education--a review of the research design. Shuldham C. **Int J Nurs Stud** 1999 Apr;36(2):179–87 (61 ref.)

Selecting pumps for breastfeeding mothers. Biancuzzo M. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):417–26 (20 ref.)

Theory and practice for teaching the childbearing couple. Farrell M, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec;27(6):613–8 (22 ref.)

Story telling as a tool for providing holistic care to women. Banks-Wallace J. **MCN Am J Matern Child Nurs** 1999 Jan-Feb;24(1):20–4 (28 ref.)

Grab their attention! Make your point! Gerstle DS. **MCN Am J Matern Child Nurs** 1999 Sep-Oct;24(5):257–61 (12 ref.)

Guiding parents' use of the Internet for newborn education. Lamp JM, et al. **MCN Am J Matern Child Nurs** 1999 Jan-Feb;24(1):33–6 (8 ref.)

Optimizing smoking cessation strategies. Andrews J. **Nurse Pract** 1998 Aug;23(8):47–8, 51–2, 57–8 passim (25 ref.)

Hyperbilirubinemia in the healthy term newborn. Augustine MC. **Nurse Pract** 1999 Apr;24(4):24–6, 29–32, 34–6 passim; quiz 42–3 (30 ref.)

Effectively managing asthma in young and middle adulthood. Autio L, et al. **Nurse Pract** 1999 Jan;24(1):100–2, 105–6, 108–11; quiz 112–3 (23 ref.)

Management of chronic stable angina. Beattie S. **Nurse Pract** 1999 May;24(5):44, 49, 53 passim (25 ref.)

Preventing human rabies before and after exposure. Garcia R. **Nurse Pract** 1999 Apr;24(4):91–2, 95–7, 101–2 passim (32 ref.)

Caring for the patient with Paget's disease of the bone. Lewis T, et al. **Nurse Pract** 1999 Jul;24(7):50, 53, 57–8 passim (25 ref.)

Using physiologic and pharmacologic stress testing in the evaluation of coronary artery disease. Meyer N. **Nurse Pract** 1999 Apr;24(4):70–2, 75–6, 78 passim (12 ref.)

Evaluating mild to moderate hypertension. Tobin LJ. **Nurse Pract** 1999 May;24(5):22, 25–6, 29–30 passim; quiz 42–3 (42 ref.)

Assessing and managing the patient with headaches. Weiss J. **Nurse Pract** 1999 Jul;24(7):18–20, 23–5, 28–9 passim quiz 36–7 (5 ref.)

Improving oncology nursing practice through understanding and exploring the Internet. Gomez EG, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):4–10 (13 ref.)

Explaining presbyopia to patients [editorial] [see comments] Shabany RY, et al. **Optom Vis Sci** 1998 Sep;75(9):627–8 (7 ref.) Comment in: Optom Vis Sci 1999 Feb;76(2):81.

Patient understanding of postsurgical instruction forms. Alexander RE. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):153–8 (26 ref.)

Advising patients about international travel. What they can do to protect their health and safety. Bratton RL. **Postgrad Med** 1999 Jul;106(1):57–64; quiz 143 (14 ref.)

Preventing diabetic foot complications. Tight glucose control and patient education are the keys. Culleton JL. **Postgrad Med** 1999 Jul;106(1):74–8, 83 (10 ref.)

Improving understanding of the informed consent process and document. Meade CD. **Semin Oncol Nurs** 1999 May; 15(2):124–37 (135 ref.)

The nurse's role in the informed consent process. Rosse PA, et al. **Semin Oncol Nurs** 1999 May;15(2):116–23 (28 ref.)

[Diabetology in the German medical system in 1998] Jörgens V, et al. **Diabetes Metab** 1998 Nov;24 Suppl 3:18–23 (12 ref.) (Eng. Abstr.) (Fre)

[Perception and understanding of insulin-dependent diabetes and its treatment by the child from 2 to 12 years] Ricard-Malivoir S. **Diabetes Metab** 1999 Mar;25(1):68–71 (5 ref.) (Fre)

[The patient with glaucoma and his treatment: is there real perception?] Naacke H, et al. **J Fr Ophtalmol** 1999 Feb; 22(1):99–101 (16 ref.) (Fre)

[Nutritional education of diabetic patients] Golay A, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:51–69 (41 ref.) (Fre)

[Effectiveness of back-school programs in controlled trials. A review of the literature] Lühmann D, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jul;93(5):341–8 (22 ref.) (Eng. Abstr.) (Ger)

[Prevention against asthma death: education program for doctors and self management for patients] Kokubu F, et al. **Arerugi** 1999 Jun;48(6):572–5 (9 ref.) (Jpn)

METHODS

Patient education and diabetes research: a failure! Going beyond the empirical approaches. Albano MG, et al. **Acta Diabetol** 1998 Dec;35(4):207–14 (21 ref.)

Compliance by collaboration: effectively addressing problems of treatment adherence. Lassleben M, et al. **Aust Fam Physician** 1999 Aug;28(8):850–3 (11 ref.)

Asthma education: what has been its impact? Boulet LP. **Can Respir J** 1998 Jul-Aug;5 Suppl A:91A–6A (31 ref.)

Asthma education, action plans, psychosocial issues and adherence. Kolbe J. **Can Respir J** 1999 May-Jun; 6(3):273–80 (78 ref.)

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Wahl RA,

et al. **Curr Opin Pediatr** 1998 Dec;10(6):641-50 (78 ref.)
What can we generalize from research on patient education and clinical health promotion to physician counseling on diet? Green LW. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S9-18 (92 ref.)
Minimal interventions for problem drinkers: a review of the literature. Watson HE. **J Adv Nurs** 1999 Aug;30(2):513-9 (39 ref.)
Computer-based approaches to patient education: a review of the literature. Lewis D. **J Am Med Inform Assoc** 1999 Jul-Aug;6(4):272-82 (68 ref.)
Interactive computer technology, behavioral science, and family practice. Glasgow RE, et al. **J Fam Pract** 1999 Jun; 48(6):464-70 (64 ref.)
Providing accurate information to women about tamoxifen therapy for breast cancer: current indications, effects, and controversies. Pasacreta JV, et al. **Oncol Nurs Forum** 1998 Oct;25(9):1577-83 (51 ref.)
Patient education: a tool in the outpatient management of deep vein thrombosis. Haines ST. **Pharmacotherapy** 1998 Nov-Dec;18(6 Pt 3):158S-164S (33 ref.)
Cognitive, psychosocial, and educational issues in neuromuscular disease. Sigford BJ, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):249-70 (88 ref.)
Nontraditional treatments for localized prostate cancer: ten rules to know before talking to my patients. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):64-9 (52 ref.)
Objectives, methods and content of patient education programmes for adults with asthma: systematic review of studies published between 1979 and 1998. Sudre P, et al. **Thorax** 1999 Aug;54(8):681-7 (101 ref.)
How patients use the web for second opinions. Patrick K. **West J Med** 1999 Jun;170(6):332-3 (5 ref.)

STANDARDS

Providing patients with written medication information. Buck ML. **Ann Pharmacother** 1998 Sep;32(9):962-9 (68 ref.)
Burning issues--a guide for patients. Gastrointestinal gas. Bursey RF. **Can J Gastroenterol** 1999 Jun;13(5):378 (0 ref.)
Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864-8 (2 ref.)
Patient education: a mandate for health care in the 21st century. Davidhizar R, et al. **J Nucl Med Technol** 1998 Dec;26(4):235-41; quiz 243 (44 ref.)

TRENDS

A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Kenny T, et al. **Fam Pract** 1998 Oct;15(5):471-9 (96 ref.)

PATIENT-FAMILY LODGING see **HOUSING**

PATIENT-FOCUSED CARE see **PATIENT-CENTERED CARE**

PATIENT FREEDOM OF CHOICE LAWS

STATISTICS & NUMERICAL DATA

The spread of state any willing provider laws. Ohsfeldt RL, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1537-62 (26 ref.)

PATIENT MONITORING see **MONITORING, PHYSIOLOGIC**

PATIENT NONCOMPLIANCE see **TREATMENT REFUSAL**

PATIENT OMBUDSMEN see **PATIENT ADVOCACY**

PATIENT OUTCOME ASSESSMENT see **OUTCOME ASSESSMENT (HEALTH CARE)**

PATIENT PARTICIPATION

Patients' preferences for participation in clinical decision making: a review of published surveys. Benbassat J, et al. **Behav Med** 1998 Summer;24(2):81-8 (53 ref.)
The rise of doctor-patient working groups. Williamson C. **BMJ** 1998 Nov 14;317(7169):1374-7 (31 ref.)
Autonomy, power, and control in palliative care. Scott PA. **Camb Q Healthc Ethics** 1999 Spring;8(2):139-47 (35 ref.)
Stewardship of the aged: meeting the ethical challenge of ageism. In honor of Joseph Fletcher. Thomasma DC. **Camb Q Healthc Ethics** 1999 Spring;8(2):148-59 (38 ref.)
Prostate cancer: 13. Whose prostate is it anyway? The view from the other side of the examining table. Gray RE, et al. **CMAJ** 1999 Mar 23;160(6):833-6 (16 ref.)
Parent's participation and perspectives regarding clinical judgment and clinical guideline development. Pachter LM. **Curr Opin Pediatr** 1998 Oct;10(5):476-9 (12 ref.)
Can paternalism be justified in mental health care? Breeze J. **J Adv Nurs** 1998 Aug;28(2):260-5 (40 ref.)
The scope for the involvement of patients in their consultations with health professionals: rights, responsibilities and preferences of patients. Buetow S. **J Med Ethics** 1998 Aug;24(4):243-7 (53 ref.)
Alternative health care: an overview. Tiedje LB. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):557-62 (26 ref.)
Family involvement in expanded school mental health. Bickham NL, et al. **J Sch Health** 1998 Dec;68(10):425-8 (8 ref.)
Holy Grail, sliding scale, and refusal as symptom: competency determinations for medical and psychiatric patients. Farr M. **Pharos** 1999 Spring;62(2):2-9 (15 ref.)
Whose consent is it anyway? A poststructuralist framing of the person in medical decision-making. Marta J. **Theor Med Bioeth** 1998 Aug;19(4):353-70 (33 ref.)

LEGISLATION & JURISPRUDENCE

Mental retardation and decision making: balancing autonomy and protection. Van Hoof TJ, et al. **Conn Med** 1998 Aug; 62(8):455-60 (23 ref.)

METHODS

Communicating with clients about treatment outcomes: the use of meta-analytic evidence in collaborative treatment planning. Tickle-Degnen L. **Am J Occup Ther** 1998 Jul-Aug;52(7):526-30 (15 ref.)

PSYCHOLOGY

Culturally competent professionals in therapeutic alliances enhance patient compliance [editorial] Langer N. **J Health Care Poor Underserved** 1999 Feb;10(1):19-26 (22 ref.)

PATIENT PREFERENCE see **PATIENT SATISFACTION**

PATIENT READMISSION

STANDARDS

Grappling with intensive care unit quality--does the readmission rate tell us anything? [editorial; comment] Angus DC. **Crit Care Med** 1998 Nov;26(11):1779-80 (12 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1834-41.

STATISTICS & NUMERICAL DATA

A computerized method of identifying potentially preventable heart failure admissions. Thomas V, et al. **J Nurs Care Qual** 1999 Jun;13(5):1-10 (25 ref.)
Predicting rehospitalization after bypass surgery: can we do it? Should we care? [editorial; comment] Kiefe C. **Med Care** 1999 Jul;37(7):621-4 (16 ref.) Comment on: Med Care 1999 Jul;37(7):625-36.

PATIENT RECORDS, COMPUTERIZED see **MEDICAL RECORDS SYSTEMS, COMPUTERIZED**

PATIENT RECRUITMENT see **PATIENT SELECTION**

PATIENT REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

PATIENT REPRESENTATIVES see **PATIENT ADVOCACY**

PATIENT SATISFACTION

see related
PATIENT ACCEPTANCE OF HEALTH CARE

Maternal satisfaction with labour analgesia. Ross A. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):499-512 (88 ref.)
A review of patient satisfaction: 1. Concepts of satisfaction. Newsome PR, et al. **Br Dent J** 1999 Feb 27;186(4 Spec No):161-5 (39 ref.)
A review of patient satisfaction: 2. Dental patient satisfaction: an appraisal of recent literature. Newsome PR, et al. **Br Dent J** 1999 Feb 27;186(4 Spec No):166-70 (60 ref.)
Utility assessment: methods and research. Chapman GB, et al. **Cancer Treat Res** 1998;97:13-23 (33 ref.)
The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. Bomalaski JJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):11-5 (37 ref.)
Doctor-patient communication and patient satisfaction: a review. Williams S, et al. **Fam Pract** 1998 Oct;15(5):480-92 (44 ref.)
A patient-oriented approach to treatment of myelodysplastic syndromes. Cazzola M, et al. **Haematologica** 1998 Oct; 83(10):910-35 (220 ref.)
Professional competence in medicine. Southgate L. **Hosp Med** 1999 Mar;60(3):203-5 (17 ref.)
Satisfaction with palliative care: what should we be aware of? Fakhoury WK. **Int J Nurs Stud** 1998 Jun;35(3):171-6 (68 ref.)
Managing the clinic wait: an important quality of care challenge. Rondeau KV. **J Nurs Care Qual** 1998 Dec; 13(2):11-20 (24 ref.)
Impact of unlicensed assistive personnel on patient satisfaction: an integrative review of the literature. Siehoff AM. **J Nurs Care Qual** 1998 Dec;13(2):1-10 (22 ref.)
A systematic review of the literature on patient priorities for general practice care. Part 1: Description of the research domain. Wensing M, et al. **Soc Sci Med** 1998 Nov; 47(10):1573-88 (67 ref.)
[Satisfaction with anesthesia: a review of the existing instruments] Gentile S, et al. **Presse Med** 1999 May 22-29; 28(19):1040-5 (49 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of patient satisfaction in health facilities. Review of the literature] Labarère J, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):175-84 (82 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of phantom pain with salmon calcitonin and effect on postoperative patient satisfaction] Simanski C, et al. **Chirurg** 1999 Jun;70(6):674-81 (67 ref.) (Eng. Abstr.) **(Ger)**
[Medical research on patients' experiences--structured questionnaires result in worthless answers] Kirkengen AL. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3449-52 (20 ref.) (Eng. Abstr.) **(Nor)**

STATISTICS & NUMERICAL DATA

Measuring patient satisfaction with anesthesia care: a review of current methodology [see comments] Fung D, et al. **Anesth Analg** 1998 Nov;87(5):1089-98 (56 ref.) Comment in: Anesth Analg 1999 Jul;89(1):255.

PATIENT SCHEDULES see **APPOINTMENTS AND SCHEDULES**

PATIENT SELECTION

Cochlear implants: selection criteria and shifting borders. Lenarz T. **Acta Otorhinolaryngol Belg** 1998;52(3):183-99 (27 ref.)
Primary prevention of coronary heart disease: selection of patients for aggressive cholesterol management. Grundy SM. **Am J Med** 1999 Aug 23;107(2A):2S-6S (41 ref.)
Who should be offered prenatal diagnosis? The 35-year-old question. Kuppermann M, et al. **Am J Public Health** 1999 Feb;89(2):160-3 (31 ref.)
Cadaveric organ donation: rethinking donor motivation [see comments] Sade RM. **Arch Intern Med** 1999 Mar 8; 159(5):438-42 (25 ref.) Comment in: Arch Intern Med 1999 Mar 8;159(5):427-8.
Nonoperative treatment of biliary tract disease. Beyer AJ 3rd, et al. **Arch Surg** 1998 Nov;133(11):1172-6 (5 ref.)
"Alternative" surgery in trauma management. Britt LD, et al. **Arch Surg** 1998 Nov;133(11):1177-81 (44 ref.)
Perforated duodenal ulcer: an alternative therapeutic plan. Donovan AJ, et al. **Arch Surg** 1998 Nov;133(11):1166-71 (34 ref.)
Alternative strategies in the management of primary breast cancer. Foster RS Jr, et al. **Arch Surg** 1998 Nov; 133(11):1182-6 (44 ref.)
Number needed to treat: a useful new method of assessing the magnitude of treatment effect and its application to the management of diabetic retinopathy. San Laureano JA, et al. **Aust N Z J Ophthalmol** 1999 Apr;27(2):137-42 (11 ref.)
The rationale for Healthy Start dialysis [editorial] Golper TA. **Blood Purif** 1999;17(1):1-9 (53 ref.)
Statistics notes. Treatment allocation in controlled trials: why randomise? Altman DG, et al. **BMJ** 1999 May 1; 318(7192):1209 (7 ref.)
Should all diabetic patients take ACE inhibitors, even those without proteinuria? Hoogwerf BJ. **Cleve Clin J Med** 1999 Apr;66(4):208-9 (10 ref.)
Should methotrexate be a first-line treatment for rheumatoid arthritis? Wilke WS. **Cleve Clin J Med** 1999 Apr; 66(4):207-8 (16 ref.)
Selection criteria for the treatment of cranial rhizopathies by microvascular decompression (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:69-77 (31 ref.)
Selection criteria for degenerative lumbar spine instability. McCormick PC. **Clin Neurosurg** 1997;44:29-39 (39 ref.)
Temporal lobe epilepsy. Ojemann GA. **Clin Neurosurg** 1997; 44:79-90 (56 ref.)
Criteria for patient selection: low-grade gliomas. Piepmeier JM. **Clin Neurosurg** 1997;44:51-62 (28 ref.)
Selection of patients for surgery for Parkinson's disease. Tasker RR. **Clin Neurosurg** 1997;44:63-7 (18 ref.)
Early discharge. Risks, benefits, and who decides. Kiely M, et al. **Clin Perinatol** 1998 Sep;25(3):539-53, vii-viii (62 ref.)
Decision-making and the role of surrogacy in withdrawal or withholding of therapy in neonates. Steinberg A. **Clin Perinatol** 1998 Sep;25(3):779-90, xii (42 ref.)
Population pharmacokinetics. A regulatory perspective. Sun H, et al. **Clin Pharmacokinet** 1999 Jul;37(1):41-58 (60 ref.)
Patient selection, planning, and marking in ultrasound-assisted lipoplasty. Hughes CE 3rd. **Clin Plast Surg** 1999 Apr;26(2):279-82; ix (0 ref.)
Prostate cancer: 6. Surgical treatment of localized disease. Goldenberg SL, et al. **CMAJ** 1998 Nov 17;159(10):1265-71 (25 ref.)
Prostate cancer screening: waiting for Godot [editorial; comment] Iscoe NA. **CMAJ** 1998 Dec 1;159(11):1375-7 (18 ref.) Comment on: CMAJ 1998 Dec 1;159(11):1368-72.
Sex or body size? Selection of dialysis type revisited [editorial; comment] Levin A. **CMAJ** 1999 Mar 23; 160(6):828-9 (10 ref.) Comment on: CMAJ 1999 Mar 23;160(6):818-9.
The ventilator: selection of mechanical ventilators. Grace K. **Crit Care Clin** 1998 Oct;14(4):563-80 (43 ref.)
Noninvasive management of pediatric neuromuscular

ventilatory failure: a viable alternative [editorial; comment] Barnes SD. **Crit Care Med** 1998 Dec;26(12):1952–3 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2061–5.

Why, when, and how to insert a hepatic vein catheter in critically ill patients [editorial; comment] De Backer D, et al. **Crit Care Med** 1999 Aug;27(8):1680–1 (16 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1598–16–2.

Percutaneous versus surgical tracheostomy: procedure of choice or choice of procedure [editorial; comment] Friedman Y, et al. **Crit Care Med** 1999 Aug;27(8):1684–5 (27 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1617–25.

High-frequency ventilation [editorial; comment] MacIntyre NR. **Crit Care Med** 1998 Dec;26(12):1955–6 (8 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2073–7.

The role of exercise-based prognosticating algorithms in the selection of patients for heart transplantation. Beniaminovitz A, et al. **Curr Opin Cardiol** 1999 Mar; 14(2):114–20 (28 ref.)

Selection of appropriate patients with heart failure for aortocoronary bypass surgery. Letsou GV. **Curr Opin Cardiol** 1999 May;14(3):230–3 (12 ref.)

The scope for rehabilitation in severely disabled stroke patients. Gladman JR, et al. **Disabil Rehabil** 1998 Oct; 20(10):391–4 (30 ref.)

Functional and morphological heterogeneity of emphysema and its implication for selection of patients for lung volume reduction surgery. Russi EW, et al. **Eur Respir J** 1999 Jul; 14(1):230–6 (48 ref.)

Liver transplantation: who to refer and when. Van Thiel DH, et al. **Forum (Genova)** 1999 Apr–Jun;9(2):157–63 (22 ref.)

Maintaining client safety and scientific integrity in research with battered women. Lutz KF. **Image J Nurs Sch** 1999; 31(1):89–93 (40 ref.)

Patient selection in outpatient parenteral antimicrobial therapy. Nolet BR. **Infect Dis Clin North Am** 1998 Dec; 12(4):835–47, v–vi (58 ref.)

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Modigliani R. **Inflamm Bowel Dis** 1998 Aug;4(3):244–7; discussion 253–4 (9 ref.)

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Schölmerich J. **Inflamm Bowel Dis** 1998 Aug;4(3):248–52; discussion 253–4 (21 ref.)

Phase I studies in patients with liver cirrhosis. Wensing G. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):599–603 (42 ref.)

Decision analytic modeling in health care decision making. Oversimplifying a complex world? Bloom LA, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):332–9 (31 ref.)

Management of the older person with ventricular arrhythmias. Aronow WS. **J Am Geriatr Soc** 1999 Jul; 47(7):886–95 (93 ref.)

How important is patient recruitment in performing clinical trials? [editorial; comment] Nathan RA. **J Asthma** 1999 May;36(3):213–6 (14 ref.) Comment on: J Asthma 1999 May;36(3):217–37.

Patient selection and anesthetic management for early extubation and hospital discharge: CABG. Royston D. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):11–9 (57 ref.)

Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach. Jackson R. **J Hum Hypertens** 1998 Sep;12(9):607–13 (16 ref.)

Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. Avins AL. **J Med Ethics** 1998 Dec;24(6):401–8 (50 ref.)

The cost of refusing treatment and equality of outcome. Savulescu J. **J Med Ethics** 1998 Aug;24(4):231–6 (23 ref.)

Selecting subjects for participation in clinical research: one sphere of justice. Weijer C. **J Med Ethics** 1999 Feb; 25(1):31–6 (34 ref.)

Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. Rudick RA, et al. **J Neuroimmunol** 1999 Jul 1;98(1):22–8 (36 ref.)

Selecting the appropriate setting for management of maxillofacial trauma. Haug RH. **J Oral Maxillofac Surg** 1999 Aug;57(8):983–9 (19 ref.)

Living with cerebral palsy and tube feeding: easier to feed but at what cost? [editorial; comment] Darwish H. **J Pediatr** 1999 Sep;135(3):272–3 (11 ref.) Comment on: J Pediatr 1999 Sep;135(3):307–10.

Depo-Provera: an ideal contraceptive for adolescents? Boroditsky RS. **J Pediatr Adolesc Gynecol** 1999 May; 12(2):95–9 (26 ref.)

Who is suitable for cognitive behavioural therapy? Blenkiron P. **J R Soc Med** 1999 May;92(5):222–9 (50 ref.)

Who should decide how effective cervical cancer screening will be? [editorial] Austin RM. **J Reprod Med** 1999 Apr; 44(4):317–20 (11 ref.)

One size does not fit all: questions to answer before intervening to change physician behavior. Poses RM. **Jt Comm J Qual Improv** 1999 Sep;25(9):486–95 (78 ref.)

Total parenteral nutrition in the critically ill patient. Birmingham CL. **Lancet** 1999 Apr 3;353(9159):1116–7 (9 ref.)

Pharmacokinetics and pharmacodynamics of qinghaosu derivatives: how do they impact on the choice of drug and the dosage regimens? Kyle DE, et al. **Med Trop (Mars)** 1998;58(3 Suppl):38–44 (32 ref.)

Selection criteria and outcome assessment in pulmonary rehabilitation. ZuWallack RL. **Monaldi Arch Chest Dis** 1998 Aug;53(4):429–37 (35 ref.)

Lung transplantation. Arcasoy SM, et al. **N Engl J Med** 1999 Apr 8;340(14):1081–91 (100 ref.)

Aneurysm geometry: an important criterion in selecting patients for Guglielmi detachable coiling. Debrun GM, et al. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:1–20 (139 ref.)

Patients with morbid obesity don't get life-saving bone marrow transplants. Clarke B, et al. **Obes Surg** 1999 Feb; 9(1):77–9 (13 ref.)

Restrictive versus malabsorptive procedures: criteria for patient selection. Forestieri P, et al. **Obes Surg** 1999 Feb; 9(1):48–50 (10 ref.)

Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications. Gerard MJ, et al. **Oncol Nurs Forum** 1998 Oct;25(9):1561–9 (63 ref.)

Lipid-lowering drugs in the management of hyperlipidaemia. Bhatnagar D. **Pharmacol Ther** 1998 Sep;79(3):205–30 (182 ref.)

Sampling biases in a marital study on severe major depression. Marin A, et al. **Psychopathology** 1999 Jan–Feb;32(1):12–22 (61 ref.)

Are anti-oxidant and anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. van Schayck CP, et al. **Respir Med** 1998 Nov;92(11):1259–64 (45 ref.)

Hair transplantation in women. Avram MR. **Semin Cutan Med Surg** 1999 Jun;18(2):172–6 (6 ref.)

Cosmetic surgery: surgical tools--psychosocial goals. Grossbart TA, et al. **Semin Cutan Med Surg** 1999 Jun; 18(2):101–11 (32 ref.)

Introduction: dose-intensive therapy for adult malignancies. Weiss RB. **Semin Oncol** 1999 Feb;26(1):1–5 (21 ref.)

Some controversies in planning and analysing multi-centre trials. Senn S. **Stat Med** 1998 Aug 15–30;17(15–16):1753–65; discussion 1799–800 (8 ref.)

Consensus conference on standardized listing criteria for renal transplant candidates. **Transplantation** 1998 Oct 15; 66(7):962–7 (0 ref.)

[Roaming through methodology. III. Randomization at the level of the physicians] van Houwelingen JC. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1662–5 (2 ref.) (Eng. Abstr.) **(Dut)**

[Cholinesterase inhibitors for Alzheimer disease: preliminary recommendations for treatment. Dutch Society for Psychiatry, Section of Geriatric Psychiatry (comment)] Verhey FR, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19; 142(38):2091–6 (24 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1998 Nov 28;142(48):2644; discussion 2645. Comment on: Ned Tijdschr Geneeskd 1998 Nov 28;142(48):2644–5; discussion 2645. **(Dut)**

[Serratus anterior muscle flap: indications and sequelae. 26 cases and review of the literature] Fassio E, et al. **Ann Chir Plast Esthet** 1999 Apr;44(2):175–82; discussion 183 (34 ref.) (Eng. Abstr.) **(Fre)**

[Immunosuppressive agents in Horton's disease. Which drug for which indication?] Roblot P. **Ann Med Interne (Paris)** 1998 Nov;149(7):441–7 (45 ref.) (Eng. Abstr.) **(Fre)**

[Sex differences relating to psychiatric treatment] Godfroid IO. **Can J Psychiatry** 1999 May;44(4):362–7 (61 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors of infiltrating bladder tumors] Durdux C, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):491–8 (88 ref.) (Eng. Abstr.) **(Fre)**

[Organ preservation in ORL oncology: myth or reality. The case for laryngeal preservation] Eschwège F, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):437–45 (44 ref.) (Eng. Abstr.) **(Fre)**

[Radiotherapy for non-small-cell bronchial cancers: definitions of volumes, patient selection. Recommendations of the International Association for the Study of Lung Cancer (IASLC)] Mornex F, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):579–89 (33 ref.) (Eng. Abstr.) **(Fre)**

[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700–4 (17 ref.) **(Fre)**

[Gastroesophageal reflux in the adult: initial therapeutic strategy] Couturier D, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S180–6 (45 ref.) **(Fre)**

[Medical-economic aspects of treatment of gastroesophageal reflux] De Winter B, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S292–6 (21 ref.) **(Fre)**

[Gastroesophageal reflux: initial therapeutic strategy] Guillemot F, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S302–6 (39 ref.) **(Fre)**

[Which patients should have an endoscopic percutaneous gastrostomy?] Hébuterne X, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1065–70 (49 ref.) **(Fre)**

[Gastroesophageal reflux in the adult: medical-economic aspects of therapeutic strategies] Lebrun T, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S165–75 (29 ref.) **(Fre)**

[Indications and contra-indications of surgical treatment of gastroesophageal reflux] Millat B, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S155–64 (94 ref.) **(Fre)**

[Treatment of liver metastases of colorectal cancers: how far should we go? (editorial; comment)] Penna C, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1046–7 (9 ref.) Comment on: Gastroenterol Clin Biol 1998 Dec;22(12):1048–55. **(Fre)**

[Should varicoceles be treated in the adolescent? How?] Becmeur F, et al. **J Chir (Paris)** 1999 Jun;136(2):93–6 (49 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of gastroesophageal reflux. Which technique to chose?] Chipponi J, et al. **J Chir (Paris)** 1998 Feb;135(1):31–6 (51 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic choices for cancer of the rectum: discussion and update of the consensus conference] de Calan L, et al. **J Chir (Paris)** 1998 May;135(2):51–6 (44 ref.) (Eng. Abstr.) **(Fre)**

[Nasogastric tubes after elective abdominal surgery is not justified] Gouzi JL, et al. **J Chir (Paris)** 1998 Dec; 135(6):273–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Adult fecal incontinence due to anal sphincter lesions: which preoperative preparations? Which surgical solutions?] Lehur PA, et al. **J Chir (Paris)** 1998 May;135(2):83–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. In cases of premature rupture of membranes, outside of labor] Batallan A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:292–4 (15 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. During labor, which delivery method should be chosen?] Boulot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:295–301 (22 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. In cases of in utero growth retardation, outside of labor] Fournié A. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:289–91 (7 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. In cases of cesareans, which particular techniques should be considered (excluding anesthetic techniques)?] Langer B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:302–6 (19 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. Which particular preventative modalities should be proposed for natural delivery?] Verspyck E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:311–3 (13 ref.) **(Fre)**

[Which calcium antagonists for hypertension?] Degaute JP. **Rev Med Brux** 1998 Sep;19(4):A389–92 (12 ref.) (Eng. Abstr.) **(Fre)**

[The decision to treat based on epidemiological methodology: the paradigm of hypercholesterolemia] Kornitzer M. **Rev Med Brux** 1999 Jun;20(3):135–41 (38 ref.) (Eng. Abstr.) **(Fre)**

[Decision analysis and initiation of an "empiric" therapy Van Meerhaeghe A. **Rev Med Brux** 1999 Feb;20(1):21–4 (14 ref.) (Eng. Abstr.) **(Fre)**

[Liver transplantation in the adult: who and when to transplant?] Le Treut YP, et al. **Rev Med Interne** 1998 Dec; 19(12):892–903 (91 ref.) (Eng. Abstr.) **(Fre)**

[Hormone replacement therapy: practical recommendations] Gaspard U, et al. **Rev Med Liege** 1999 May;54(5):481–8 (3 ref.) (Eng. Abstr.) **(Fre)**

[Why and how to examine the newborns' hips?] Philippet B, et al. **Rev Med Liege** 1998 Aug;53(8):470–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Hypercholesterolemia-related cardiovascular risk: a continuum from a notion of normality, intervention threshold and therapeutic objectives] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):17–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Diabetic retinopathy. When should patients be referred to ophthalmologists for evaluation?] Ducrey N. **Rev Med Suisse Romande** 1998 Nov;118(11):933–5 (7 ref.) **(Fre)**

[Indications for gastroplasty in the treatment of obesity] Giusti V, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):469–74 (10 ref.) **(Fre)**

[New indications for cardiac stimulation] Kappenberger L, et al. **Rev Med Suisse Romande** 1999 May;119(5):389–93 (16 ref.) **(Fre)**

[Treatment of valve diseases] Stauffer JC. **Rev Med Suisse Romande** 1999 May;119(5):361–6 (12 ref.) **(Fre)**

[Locoregional treatment of breast cancer: surgery and radiotherapy] Bobin JY, et al. **Rev Prat** 1998 Jan 1; 48(1):53–9 (36 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors and therapeutic strategy of breast cancer] Namer M, et al. **Rev Prat** 1998 Jan 1;48(1):45–51 (28 ref.) (Eng. Abstr.) **(Fre)**

[Antidepressive agents] Pringuey D, et al. **Rev Prat** 1999 Jan 15;49(2):209–14 (0 ref.) **(Fre)**

[Bone marrow allograft. Part 1: principles--modalities and indications] Ladeb S, et al. **Tunis Med** 1999 Apr; 77(4):185–90 (30 ref.) **(Fre)**

[Patient selection for direct and rescue angioplasty] Carvalho HC. **Rev Port Cardiol** 1999 Feb;18(2):193–9 (12 ref.) (Eng. Abstr.) **(Por)**

[Selection and evaluation of candidate patients for heart transplant] Castro PF, et al. **Rev Esp Cardiol** 1999 Aug; 52(8):604–16 (119 ref.) (Eng. Abstr.) **(Spa)**

[The ablation of ventricular tachycardias postinfarct: the search for tools and candidates (editorial)] Ruiz Granell

PATIENT SELECTION

R. **Rev Esp Cardiol** 1999 Mar;52(3):169–71 (11 ref.) **(Spa)**

PATIENT SELF-DETERMINATION ACT

see related
ADVANCE DIRECTIVES

Preserving end-of-life autonomy: the Patient Self-Determination Act and the Uniform Health Care Decisions Act. Galambos CM. **Health Soc Work** 1998 Nov; 23(4):275–81 (21 ref.)

Multicultural considerations in the use of advance directives. Ersek M, et al. **Oncol Nurs Forum** 1998 Nov–Dec; 25(10):1683–90 (50 ref.)

PATIENT TRANSFER

Functional assessment for transitions in patient acuity and care. Barad MB. **Nurs Clin North Am** 1999 Sep; 34(3):607–20 (13 ref.)

LEGISLATION & JURISPRUDENCE

The changing role of receiving hospitals under the Emergency Medical Treatment and Active Labor Act. Kuettel AC. **J Leg Med** 1998 Sep;19(3):351–76 (79 ref.)

METHODS

Intrahospital transport of critically ill children--should we pay attention? [editorial; comment] Venkataraman ST. **Crit Care Med** 1999 Apr;27(4):694–5 (7 ref.) Comment on: Crit Care Med 1999 Apr;27(4):802–6.

PATIENTS

see related
INPATIENTS
OUTPATIENTS

Consumers as providers in psychiatric rehabilitation. Solomon P, et al. **New Dir Ment Health Serv** 1998 Fall; (79):65–77 (31 ref.)

CLASSIFICATION

"Death by proxy": ethics and classification in epidemiology. Plant AJ, et al. **Soc Sci Med** 1998 Nov;47(9):1147–53 (21 ref.)

[Assessment of patients' health status--review of the literature and assessment methods] Andreassen S, et al. **Nord Med** 1998 Dec;113(10):360–2 (31 ref.) (Eng. Abstr.) **(Nor)**

PSYCHOLOGY

Strategic risk management: reducing malpractice claims through more effective patient-doctor communication. Virshup BB, et al. **Am J Med Qual** 1999 Jul–Aug; 14(4):153–9 (26 ref.)

The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals. Edwards SJ, et al. **BMJ** 1998 Oct 31; 317(7167):1209–12 (47 ref.)

Story telling: is it really research? Koch T. **J Adv Nurs** 1998 Dec;28(6):1182–90 (54 ref.)

[Integrative painting therapy. A therapeutic concept for psychiatric inpatients at the University clinic in Graz] Steinbauer M, et al. **Wien Klin Wochenschr** 1999 Jul 9; 111(13):525–32 (21 ref.) (Eng. Abstr.) **(Ger)**

[Difficulties in the physician-patient relationship in somaticizers (I). Patient expectations] García-Campayo J, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):102–5 (37 ref.) **(Spa)**

PATIENTS' RIGHTS see **PATIENT ADVOCACY**

PATTERN RECOGNITION

Pattern recognition and arrays: the times are a-changing [comment] Shibata D. **Am J Pathol** 1999 Apr;154(4):979–80 (9 ref.) Comment on: Am J Pathol 1999 Apr;154(4):981–6.

ECG pattern recognition and classification using non-linear transformations and neural networks: a review. Maglaveras N, et al. **Int J Med Inf** 1998 Oct–Dec;52(1–3):191–208 (54 ref.)

Feature extraction through LOCOCODE. Hochreiter S, et al. **Neural Comput** 1999 Apr 1;11(3):679–714 (61 ref.)

Machine learning approaches for the prediction of signal peptides and other protein sorting signals. Nielsen H, et al. **Protein Eng** 1999 Jan;12(1):3–9 (39 ref.)

PATTERN RECOGNITION, VISUAL

The objects of action and perception. Goodale MA, et al. **Cognition** 1998 Jul;67(1–2):181–207 (100 ref.)

Diagnostic recognition: task constraints, object information, and their interactions. Schyns PG. **Cognition** 1998 Jul; 67(1–2):147–79 (95 ref.)

Image-based object recognition in man, monkey and machine. Tarr MJ, et al. **Cognition** 1998 Jul;67(1–2):1–20 (80 ref.)

Three-dimensional object recognition based on the combination of views. Ullman S. **Cognition** 1998 Jul; 67(1–2):21–44 (55 ref.)

Dissociation of letter and picture naming resulting from callosal disconnection. Suzuki K, et al. **Neurology** 1998 Nov;51(5):1390–4 (21 ref.)

Threshold effect in visual perception of geometrical figures. Di Maio V. **Percept Mot Skills** 1998 Aug;87(1):340–2 (9 ref.)

Temporal inhibition in character identification. Busey TA. **Percept Psychophys** 1998 Nov;60(8):1285–304 (60 ref.)

PHYSIOLOGY

Sex-sensitive tasks in men and women: a search for performance fluctuations across the menstrual cycle. Epting LK, et al. **Behav Neurosci** 1998 Dec;112(6):1304–17 (110 ref.)

Evidence accumulation in cell populations responsive to faces: an account of generalisation of recognition without mental transformations. Perrett DI, et al. **Cognition** 1998 Jul;67(1–2):111–45 (105 ref.)

Firing rate distributions and efficiency of information transmission of inferior temporal cortex neurons to natural visual stimuli. Treves A, et al. **Neural Comput** 1999 Apr 1;11(3):601–32 (39 ref.)

Is face processing special? Tovée MJ. **Neuron** 1998 Dec; 21(6):1239–42 (19 ref.)

Reading skills in hyperlexia: a developmental perspective. Nation K. **Psychol Bull** 1999 May;125(3):338–55 (120 ref.)

The contralateral organization of visual memory: a theoretical concept and a research tool. Gratton G. **Psychophysiology** 1998 Nov;35(6):638–47 (60 ref.)

Mechanisms for spatial integration in visual detection: a model based on lateral interactions. Usher M, et al. **Spat Vis** 1999;12(2):187–209 (37 ref.)

Visual recognition based on temporal cortex cells: viewer-centred processing of pattern configuration. Perrett DI, et al. **Z Naturforsch [C]** 1998 Jul–Aug;53(7–8):518–41 (108 ref.)

PAUL-BUNNELL ANTIBODIES see **ANTIBODIES, HETEROPHILE**

PAVOR NOCTURNUS see **SLEEP DISORDERS**

PCBS see **POLYCHLORINATED BIPHENYLS**

PCNA see **PROLIFERATING CELL NUCLEAR ANTIGEN**

PCP see **PHENCYCLIDINE**

PCR see **POLYMERASE CHAIN REACTION**

PDGF RECEPTORS see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

PEAK EXPIRATORY FLOW RATE

The utility of peak flow measurements in guiding asthma management--what is the evidence? [editorial] Chee CB. **Singapore Med J** 1998 Nov;39(11):476–7 (11 ref.)

[Asthma management by peak expiratory flow] Tamura G. **Arerugi** 1999 May;48(5):493–5 (5 ref.) **(Jpn)**

DRUG EFFECTS

Intravenous magnesium sulfate treatment in a child with status asthmaticus. Dib JG, et al. **Am J Health Syst Pharm** 1999 May 15;56(10):997–1000 (24 ref.)

PEANUTS

ADVERSE EFFECTS

Peanut-induced anaphylactic reactions. Burks W, et al. **Int Arch Allergy Immunol** 1999 Jul;119(3):165–72 (43 ref.)

Peanut allergy: a major public health issue. Warner JO. **Pediatr Allergy Immunol** 1999 Feb;10(1):14–20 (49 ref.)

IMMUNOLOGY

Peanut allergens. Burks W, et al. **Allergy** 1998 Aug; 53(8):725–30 (33 ref.)

PEAT see **SOIL**

PECAM-1 see **ANTIGENS, CD31**

PECTEN OCULI see **RETINAL VESSELS**

PECTIN DEPOLYMERASE see **POLYGALACTURONASE**

PECTINASE see **POLYGALACTURONASE**

PECTINS

ISOLATION & PURIFICATION

[Microbial and enzymatic extraction of pectin. A review] Contreras-Esquivel JC, et al. **Arch Latinoam Nutr** 1997 Sep;47(3):208–16 (98 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

[Experience with and the outlook for the use of pectins in therapeutic practice] Lazareva EB, et al. **Antibiot Khimioter** 1999;44(2):37–40 (71 ref.) **(Rus)**

PECTORALIS MUSCLES

ABNORMALITIES

The chondroepitrochlearis muscle: case report. Di Gennaro GL, et al. **Chir Organi Mov** 1998 Oct–Dec;83(4):419–23 (16 ref.) **(Eng, Ita)**

Case report: bilateral sternalis muscles with a bilateral pectoralis major anomaly [letter] [see comments] O'Neill MN, et al. **J Anat** 1998 Aug;193 (Pt 2):289–92 (43 ref.) Comment in: J Anat 1999 Feb;194 (Pt 2):313–5.

PECTUS EXCAVATUM see **FUNNEL CHEST**

PEDIATRIC DENTISTRY

see related
DENTAL CARE FOR CHILDREN

PEDIATRIC INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, PEDIATRIC**

PEDIATRIC NURSING

see related
MATERNAL-CHILD NURSING

A little lady called Pandora: an exploration of philosophical traditions of humanism and existentialism in nursing ill children. Holyoake DD. **Child Care Health Dev** 1998 Jul; 24(4):325–36 (51 ref.)

Skin care of the pediatric patient. Pallija G, et al. **J Pediatr Nurs** 1999 Apr;14(2):80–7 (19 ref.)

Children and violence. Kelley B, et al. **J Soc Pediatr Nurs** 1998 Jul–Sep;3(3):127–9 (14 ref.)

Lymphoma at the extremes of age. Boyle DA, et al. **Semin Oncol Nurs** 1998 Nov;14(4):302–11 (70 ref.)

EDUCATION

In defense of pediatric nursing undergraduate education. Pawlik KM. **J Nurs Educ** 1998 Dec;37(9):418–21 (20 ref.)

METHODS

Nursing care of Arab children: consideration of cultural factors. Zahr LK, et al. **J Pediatr Nurs** 1998 Dec; 13(6):349–55 (24 ref.)

Listening to Hispanic mothers: guidelines for teaching. Wilson AH, et al. **J Soc Pediatr Nurs** 1999 Jul–Sep; 4(3):125–7 (10 ref.)

STANDARDS

Red flags in common pediatric symptoms. Wetzel GV. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):37–44; quiz 45 (19 ref.)

PEDIATRIC PSYCHOLOGY see **CHILD PSYCHOLOGY**

PEDIATRICS

Common errors in forensic pediatric pathology [see comments] Sturner WQ. **Am J Forensic Med Pathol** 1998 Dec;19(4):317–20 (6 ref.) Comment in: Am J Forensic Med Pathol 1999 Mar;20(1):101–2.

Priorities for research in emergency medical services for children: results of a consensus conference [see comments] Seidel JS, et al. **Ann Emerg Med** 1999 Feb;33(2):206–10 (9 ref.) Comment in: Ann Emerg Med 1999 Feb;33(2):214–7.

A review of randomised controlled trials published in Archives of Disease in Childhood from 1982–96. Campbell H, et al. **Arch Dis Child** 1998 Aug;79(2):192–7 (00 ref.)

The use of stable isotope techniques for nutritional and metabolic research in paediatrics. Koletzko B, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S77–97 (39 ref.)

Drug trials in pediatric oncology: a multi-facetted problem. Boos J. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):613–20 (21 ref.)

The pediatrician as therapist. II: Approaches to prevention of mental health problems and to behavior management. Howard BJ. **J Dev Behav Pediatr** 1998 Dec;19(6):420–3 (15 ref.)

Maturity-onset diabetes of the young (MODY): a new challenge for pediatric diabetologists. Guazzarotti L, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug;12(4):487–97 (60 ref.)

Role of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension in pediatric patients. Heyman MB, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep; 29(3):240–9 (44 ref.)

Vulvar disorders in prepubertal girls. A literature review. Fivozinsky KB, et al. **J Reprod Med** 1998 Sep;43(9):763–73 (64 ref.)

Meeting impossible psychosocial demands in pediatric oncology: creative solutions to universal challenges [see comments] Whitsett SF, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):289–91 (0 ref.) Comment in: Med Pediatr Oncol 1999 Apr;32(4):292–3.

Home parenteral nutrition: the pediatric point of view. Colomb V. **Nutrition** 1999 Feb;15(2):172–3 (21 ref.)
The role of the pediatrician in hearing loss. From detection to connection. Finitzo T, et al. **Pediatr Clin North Am** 1999 Feb;46(1):15–34, ix–x (25 ref.)
Priorities for research in emergency medical services for children: results of a consensus conference. Seidel JS, et al. **Pediatr Emerg Care** 1999 Feb;15(1):55–8 (9 ref.)
Research in pediatric radiology: preparing for our future. Strife JL, et al. **Pediatr Radiol** 1998 Aug;28(8):563–8 (13 ref.)
Ethical considerations in prenatal surgical consultation [see comments] Caniano DA, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):303–9 (21 ref.) Comment in: Pediatr Surg Int 1999 Jul;15(5–6):301–2.
American Academy of Pediatrics. Committee on Children With Disabilities. Care coordination: integrating health and related systems of care for children with special health care needs. Ziring PR, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):978–81 (20 ref.)
[Perinatal care: advantages and disadvantages of network functioning . Analysis and point-of-view of private clinic pediatricians] Buisson G.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:165–75 (18 ref.) **(Fre)**
[Analysis and point-of-view of mobile emergency service pediatricians] Chabernaud JL.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:176–81 (17 ref.) **(Fre)**
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center pediatricians] Rozé JC, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:153–61 (61 ref.) **(Fre)**
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of central general hospital pediatricians] Zaoui C.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:162–4 (21 ref.) **(Fre)**
[Multiresistant bacteria in pediatrics] Bonacorsi S, et al.
Pathol Biol (Paris) 1998 Apr;46(4):261–7 (54 ref.) (Eng. Abstr.) **(Fre)**
[Advances in the study of pediatric infectious diseases] Aristegui Fernández J, et al. **An Esp Pediatr** 1999 May; 50(5):525–30 (59 ref.) **(Spa)**
[Role of pediatricians in the prevention of adult hypertension] Lagomarsino E. **Rev Med Chil** 1999 Mar;127(3):349–57 (43 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Capitation payment rates and implications for the general pediatrician. Anderson GF, et al. **Curr Opin Pediatr** 1998 Oct;10(5):480–5 (32 ref.)

EDUCATION

Community-based paediatric curriculum: the Malawi experience. Broadhead RL. **Ann Trop Paediatr** 1998 Sep; 18 Suppl:S27–32 (6 ref.)
Tropical paediatrics and international child health in Liverpool, 1968–1998. Hendrickse RG.
Ann Trop Paediatr 1998 Sep;18 Suppl:S5–8 (5 ref.)
[Epidemiology and scientific methodology applied to Pediatrics II: designs in epidemiologic experimentation] Solis Sánchez G, et al. **An Esp Pediatr** 1998 Nov; 49(5):527–38 (41 ref.) **(Spa)**

HISTORY

[Pediatric cardiology from its beginnings to the century that approaches (editorial)] Attie F, et al.
Arch Inst Cardiol Mex 1998 Mar–Apr;68(2):101–5 (32 ref.) **(Spa)**

METHODS

Neonatal jaundice, animal-based injuries, and immunizations. Davis JJ, et al. **Curr Opin Pediatr** 1999 Aug;11(4):367–73 (45 ref.)
Recent advances in pediatric pulmonary imaging. Harty MP, et al. **Curr Opin Pediatr** 1998 Jun;10(3):227–35 (45 ref.)
Obesity and low-fat diets in pediatrics. Rauh-Pfeiffer A, et al. **Curr Opin Pediatr** 1998 Jun;10(3):329–35 (50 ref.)
Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Wahl RA, et al. **Curr Opin Pediatr** 1998 Dec;10(6):641–50 (78 ref.)
Practical issues in the care of pediatric trauma patients. Knapp JF. **Curr Probl Pediatr** 1998 Nov–Dec; 28(10):309–20 (77 ref.)
Empirically supported treatments in pediatric psychology: procedure-related pain [see comments] Powers SW.
J Pediatr Psychol 1999 Apr;24(2):131–45 (32 ref.) Comment in: J Pediatr Psychol 1999 Apr;24(2):147–9. Comment in: J Pediatr Psychol 1999 Apr;24(2):150–2. Comment in: J Pediatr Psychol 1999 Apr;24(2):153–4.
Pediatric dermatologic surgery for the primary care pediatrician. Babich D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1437–53 (47 ref.)
Attention-deficit disorder. A paradigm for psychotropic medication intervention in pediatrics. Block SL.
Pediatr Clin North Am 1998 Oct;45(5):1053–83 (87 ref.)
Pediatric stomas, tubes, and appliances. Borkowski S.
Pediatr Clin North Am 1998 Dec;45(6):1419–35 (18 ref.)
Care of the surgical intensive care nursery graduate. The primary care pediatrician's perspective. Brown RL, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1327–52 (60 ref.)
Approaches to recognition and management of childhood psychiatric disorders in pediatric primary care. Cassidy LJ, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1037–52 (46 ref.)
Pediatric and adolescent gynecology for the primary care pediatrician. Craighill MC. **Pediatr Clin North Am** 1998 Dec;45(6):1659–88 (28 ref.)
Pediatric anesthesia and postoperative analgesia. Feldman D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1525–37 (16 ref.)
Vascular anomalies. A primer for pediatricians. Fishman SJ, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1455–77 (28 ref.)
Management and long-term complications of pediatric cancer. Grossi M. **Pediatr Clin North Am** 1998 Dec; 45(6):1637–58 (213 ref.)
Care of the pediatric solid organ transplant recipient. The primary care perspective. Kosmach B, et al.
Pediatr Clin North Am 1998 Dec;45(6):1395–418 (85 ref.)
Antibiotic use at a pediatric age. Kim DS, et al.
Yonsei Med J 1998 Dec;39(6):595–603 (40 ref.)

ORGANIZATION & ADMINISTRATION

Creating systems of developmental health care for children. Hochstein M, et al. **J Urban Health** 1998 Dec;75(4):751–71 (48 ref.)

STANDARDS

Classification of childhood arthritis: a work in progress. Petty RE. **Baillieres Clin Rheumatol** 1998 May;12(2):181–90 (20 ref.)
Sounding the improvement in outcomes in pediatric critical care: are we listening for only what we want to hear? [editorial; comment] Vardis R, et al. **Crit Care Med** 1998 Oct;26(10):1635–6 (12 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1737–43.
Specific issues related to developing, disseminating, and implementing pediatric practice guidelines for physicians, patients, families, and other stakeholders. Bauchner H, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1161–77 (51 ref.)
Empirically supported treatments in pediatric psychology: pediatric obesity [see comments] Jelalian E, et al.
J Pediatr Psychol 1999 Jun;24(3):223–48 (97 ref.) Comment in: J Pediatr Psychol 1999 Jun;24(3):249–50. Comment in: J Pediatr Psychol 1999 Jun;24(3):251–2.
American Academy of Pediatrics. Pediatric Practice Action Group and Task Force on Medical Informatics. Privacy protection and health information: patient rights and pediatrician responsibilities. Chilton L, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):973–7 (27 ref.)
[Follow up of pediatric care is a good resource of knowledge that can be even better] Sjögren LH, et al.
Lakartidningen 1999 Mar 10;96(10):1201–5 (10 ref.) **(Swe)**

TRENDS

Recent advances: paediatric surgery. Losty PD. **BMJ** 1999 Jun 19;318(7199):1668–72 (40 ref.)
Advances in pediatric neuroimaging. Zimmerman RA, et al. **Brain Dev** 1998 Aug;20(5):275–89 (54 ref.)
Paediatric cardiology at the edge of the millennium and quality assessment [news] Daniels O. **Cardiol Young** 1999 Mar;9(2):230–2 (2 ref.)
Historical perspective and future direction. Mapstone TB. **Clin Neurosurg** 1999;45:177–83 (18 ref.)
Pediatric surgery. Rodgers BM. **J Am Coll Surg** 1999 Feb; 188(2):152–60 (60 ref.)
Child development and pediatrics for the 21st century: the healthy steps approach. McLearn KT, et al.
J Urban Health 1998 Dec;75(4):704–23 (20 ref.)
Paediatrics. Science and headlines--controversies continue. Jenney ME, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV23 (5 ref.)
Pediatric injury control in 1999: where do we go from here? Rivara FP. **Pediatrics** 1999 Apr;103(4 Pt 2):883–8 (75 ref.)
[What's new in pediatric cardiology?] Bonnet D, et al.
Arch Pediatr 1999 Jul;6(7):777–80 (19 ref.) (Eng. Abstr.) **(Fre)**
[Advances in pediatric emergency medicine] Benito Fernández J, et al. **An Esp Pediatr** 1999 Jan;50(1):91–6 (69 ref.) **(Spa)**

PEDICULOSIS see **LICE INFESTATIONS**

PEDICULUS

Evidence based case report: treatment for head lice [see comments] Dawes M, et al. **BMJ** 1999 Feb 6; 318(7180):385–6 (9 ref.) Comment in: BMJ 1999 May 22;318(7195):1422.

PEDIGREE

Review of inference procedures for the interclass correlation coefficient with emphasis on applications to family studies. Donner A, et al. **Genet Epidemiol** 1998;15(6):627–46 (47 ref.)
Comparison of family history measures used to identify high risk of coronary heart disease. Silberberg J, et al.
Genet Epidemiol 1999;16(4):344–55 (21 ref.)
Effects of misclassification on estimates of relative risk in family history studies. Szatmari P, et al.
Genet Epidemiol 1999;16(4):368–81 (32 ref.)

PEDOPHILIA

[Adolescents who sexually abuse children] Boden S, et al.
Rev Med Liege 1999 Jun;54(6):527–34 (26 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[Pedophilic behaviors: the psychopathological aspects] Callieri B. **Recenti Prog Med** 1998 Dec;89(12):621–2 (19 ref.) **(Ita)**

PEEP see **POSITIVE-PRESSURE RESPIRATION**

PEER GROUP

Peer relationships and quality of life. Bukowski WM, et al.
Acta Paediatr Suppl 1999 Feb;88(428):108–9 (10 ref.)
Peer relationships and social competence during early and middle childhood. Ladd GW. **Annu Rev Psychol** 1999; 50:333–59 (131 ref.)
Defining peer education. Shiner M. **J Adolesc** 1999 Aug; 22(4):555–66 (37 ref.)
Common reasons why peer education fails. Walker SA, et al. **J Adolesc** 1999 Aug;22(4):573–7 (10 ref.)
Date rape among adolescents and young adults. Rickert VI, et al. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):167–75 (74 ref.)
Consumers as providers in psychiatric rehabilitation. Solomon P, et al. **New Dir Ment Health Serv** 1998 Fall; (79):65–77 (31 ref.)

PEER REVIEW

The peer-review process of the Journal of Neurosurgery. Firlik KS, et al. **J Neurosurg** 1999 Feb;90(2):364–70 (16 ref.)
Basic philosophy and concepts underlying scientific peer review. Stehbens WE. **Med Hypotheses** 1999 Jan;52(1):31–6 (47 ref.)
The role of peer review in internal quality assurance in cytopathology. Zardawi IM, et al. **Pathology** 1998 Aug; 30(3):309–13 (11 ref.)

METHODS

[The practice of systematic reviews. I. Introduction] Offringa M, et al. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):653–6 (11 ref.) (Eng. Abstr.) **(Dut)**

STANDARDS

Reviewers, authors, and editors: balance of power. Bressler NM. **Arch Ophthalmol** 1999 Apr;117(4):524–6 (13 ref.)

PEER REVIEW, GRANTS see **PEER REVIEW, RESEARCH**

PEER REVIEW, HEALTH CARE

Professional competence in medicine. Southgate L.
Hosp Med 1999 Mar;60(3):203–5 (17 ref.)
Invited commentary: panel reviews of trauma mortality. Trunkey DD. **J Trauma** 1999 Sep;47(3 Suppl):S44–5 (28 ref.)
The performance of doctors: the new professionalism [see comments] Irvine D. **Lancet** 1999 Apr 3;353(9159):1174–7 (30 ref.) Comment in: Lancet 1999 Jul 10;354(9173):165.

METHODS

[The practice of systematic reviews. III. Evaluation of methodological quality of research studies] Assendelft WJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):714–9 (37 ref.) (Eng. Abstr.) **(Dut)**

PEER REVIEW, PUBLISHING see **PEER REVIEW, RESEARCH**

PEER REVIEW, RESEARCH

Evidence on peer review-scientific quality control or smokescreen? [see comments] Goldbeck-Wood S. **BMJ** 1999 Jan 2;318(7175):44–5 (21 ref.) Comment in: BMJ 1999 Jan 2;318(7175):4–5.

PEFLOXACIN

THERAPEUTIC USE

[Pharmacokinetic basis for the use of pefloxacin in severe forms of infectious-inflammatory diseases] Navashin PS, et al. **Antibiot Khimioter** 1998;43(12):30–8 (46 ref.) **(Rus)**

PELGER-HUET ANOMALY

[Pseudo Pelger-Huët anomaly] Kurokawa Y, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):94–5 (9 ref.) **(Jpn)**

PELGER-HUET ANOMALY

[Pelger-Huët anomaly] Shinjo K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):53-5 (17 ref.) **(Jpn)**

PELIZAEUS-MERZBACHER DISEASE see **CEREBRAL SCLEROSIS, DIFFUSE**

PELLETS, DRUG see **DRUG IMPLANTS**

PELVIC BONES

INJURIES

Hip, pelvic, and thigh injuries and disorders in the adolescent athlete. Mares SC. **Adolesc Med** 1998 Oct;9(3):551-68, vii (24 ref.)

Bowel entrapment within pelvic fractures: a case report and review of the literature. Stubbart JR, et al. **J Orthop Trauma** 1999 Feb;13(2):145-8 (24 ref.)

Pelvic fracture urethral injuries: the unresolved controversy. Koraitim MM. **J Urol** 1999 May;161(5):1433-41 (65 ref.)

Bladder entrapment during internal fixation of a pelvic fracture. Salomé F, et al. **J Urol** 1999 Jan;161(1):213-4 (2 ref.)

Heterotopic bone formation in association with pelvic fracture and urethral disruption. Zagaja GP, et al. **J Urol** 1999 Jun;161(6):1950-3 (19 ref.)

Non-accidental pediatric pelvic fracture: a case report. Prendergast NC, et al. **Pediatr Radiol** 1998 May;28(5):344-6 (9 ref.)

[Mutilating complex trauma of the pelvis] Rieger H, et al. **Chirurg** 1998 Nov;69(11):1275-9 (19 ref.) (Eng. Abstr.) **(Ger)**

PELVIC EXENTERATION

Critical care issues in cervical cancer management. Mirhashemi R, et al. **Semin Surg Oncol** 1999 Apr-May; 16(3):267-74 (48 ref.)

[Pelvic evisceration in locally advanced cancer of rectum with the ingrowth into urinary bladder] Odariuk TS, et al. **Khirurgiia (Mosk)** 1999;(7):58-63 (73 ref.) **(Rus)**

[Pelvic evisceration (exenteration) for rectal cancer] Timofeev IuM, et al. **Vopr Onkol** 1999;45(3):229-32 (31 ref.) **(Rus)**

ADVERSE EFFECTS

Urological problems and the treatment of gynaecological cancer. Davies Q, et al. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):401-3 (13 ref.)

PELVIC FLOOR

Pelvic floor changes in the older woman. Bidmead J, et al. **Br J Urol** 1998 Dec;82 Suppl 1:18-25 (69 ref.)

Epidemiology and natural history of pelvic floor dysfunction. Bump RC, et al. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):723-46 (129 ref.)

Physiologic evaluation of the pelvic floor. Coates KW. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):805-24 (88 ref.)

Pharmacologic management of pelvic floor dysfunction. Nygaard IE. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):867-82 (102 ref.)

The clinical evaluation of pelvic floor dysfunction. Theofrastous JP, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):783-804 (76 ref.)

Nonsurgical management of pelvic floor dysfunction. Visco AG, et al. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):849-65, vii (40 ref.)

Imaging studies of the pelvic floor. Weidner AC, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):825-48, vii (52 ref.)

ABNORMALITIES

Initial assessment: the history in women with pelvic floor problems. Brubaker L. **Clin Obstet Gynecol** 1998 Sep; 41(3):657-62 (0 ref.)

ANATOMY & HISTOLOGY

Normal pelvic floor anatomy. Strohbehn K. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):683-705 (90 ref.)

PATHOLOGY

Patterns of prolapse in women with symptoms of pelvic floor weakness: magnetic resonance imaging and laparoscopic treatment. Steiner RA, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):295-301 (42 ref.)

PHYSIOLOGY

The overactive bladder and the role of the pelvic floor muscles. Messelink EJ. **BJU Int** 1999 Mar;83 Suppl 2:31-5 (26 ref.)

Front and rear: the pelvic floor is an integrated functional structure. Devroede G. **Med Hypotheses** 1999 Feb; 52(2):147-53 (64 ref.)

Normal pelvic floor physiology. Wester C, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):707-22, v (62 ref.)

Pelvic floor function/dysfunction and electrodiagnostic evaluation. Roberts MM, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):831-51, vii (80 ref.)

SURGERY

Pelvic organ prolapse: anterior, superior, and posterior vaginal segment defects. Shull BL. **Am J Obstet Gynecol** 1999 Jul;181(1):6-11 (25 ref.)

Patterns of prolapse in women with symptoms of pelvic floor weakness: magnetic resonance imaging and laparoscopic treatment. Steiner RA, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):295-301 (42 ref.)

Management of pelvic organ prolapse. Cundiff GW, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):907-21, viii (67 ref.)

Consensus report on pelvic floor weakness of the elderly female. Stanton SL. **World J Urol** 1998;16 Suppl 1:S44-7 (27 ref.)

[Individualization of surgical treatment for female pelvic floor disorders] Skręt A. **Ginekol Pol** 1999 Jan;70(1):38-46 (17 ref.) (Eng. Abstr.) **(Pol)**

PELVIC INFECTION see **ADNEXITIS**

PELVIC INFLAMMATORY DISEASE see **ADNEXITIS**

PELVIC NEOPLASMS

[Pelvic lipomatosis] Prisco RM, et al. **Actas Urol Esp** 1998 Sep;22(8):717-20 (17 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Ordóñez NG. **Am J Surg Pathol** 1998 Nov;22(11):1314-27 (98 ref.)

DIAGNOSIS

Ultrafast MR imaging of the pelvis. Outwater EK. **Eur J Radiol** 1999 Mar;29(3):233-44 (54 ref.)

Biological considerations with pelvic neoplasms. Spratt JS, et al. **J Surg Oncol** 1999 Jul;71(3):198-205 (44 ref.)

Laparoscopy for diagnosis and staging of malignancy. Ramshaw BJ, et al. **Semin Surg Oncol** 1999 Jun; 16(4):279-83 (59 ref.)

MORTALITY

Pelvic malignancy in female nonagenarians. Ampil FL, et al. **Eur J Gynaecol Oncol** 1999;20(2):102-4 (17 ref.)

PATHOLOGY

Low-grade fibromyxoid sarcoma: clinicopathologic case report with review of the literature. Shidham VB, et al. **Am J Clin Oncol** 1999 Apr;22(2):150-5 (17 ref.)

Extraovarian granulosa cell tumor. Robinson JB, et al. **Gynecol Oncol** 1999 Jul;74(1):123-7 (15 ref.)

PREVENTION & CONTROL

Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Suwinski R, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):943-51 (56 ref.)

RADIOTHERAPY

Slipped capital femoral epiphysis associated with radiation therapy. Loder RT, et al. **J Pediatr Orthop** 1998 Sep-Oct; 18(5):630-6 (25 ref.)

SECONDARY

Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Suwinski R, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):943-51 (56 ref.)

SURGERY

[Modern aspects of management of pheochromocytoma and abdominopelvic paraganglioma] Proye C. **Ann Chir** 1998; 52(7):643-56 (82 ref.) **(Fre)**

THERAPY

Optimization of pelvic heating rate distributions with electromagnetic phased arrays. Paulsen KD, et al. **Int J Hyperthermia** 1999 May-Jun;15(3):157-86 (26 ref.)

Biological considerations with pelvic neoplasms. Spratt JS, et al. **J Surg Oncol** 1999 Jul;71(3):198-205 (44 ref.)

PELVIC PAIN

Pelvic pain. Economy KE, et al. **Adolesc Med** 1999 Jun; 10(2):291-304 (71 ref.)

DIAGNOSIS

Osteitis pubis: a diagnosis for the family physician. Andrews SK, et al. **J Am Board Fam Pract** 1998 Jul-Aug;11(4):291-5 (16 ref.)

Dysmenorrhea and pelvic pain in adolescents. Schroeder B, et al. **Pediatr Clin North Am** 1999 Jun;46(3):555-71 (78 ref.)

[Pelvic pain in women. Diagnostic trends] Chasset S, et al. **Rev Prat** 1998 Sep 1;48(13):1465-8 (3 ref.) **(Fre)**

ETIOLOGY

Endometriosis and pain. Martin DC, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):664-86 (155 ref.)

Role of laparoscopy in the management of chronic pelvic pain. Dwarakanath LS, et al. **Hosp Med** 1998 Aug; 59(8):627-31 (34 ref.)

Criteria that indicate endometriosis is the cause of chronic pelvic pain [see comments] Hurd WW. **Obstet Gynecol** 1998 Dec;92(6):1029-32 (12 ref.) Comment in: Obstet Gynecol 1999 Mar;93(3):473.

Diagnosis and treatment of chronic pelvic pain. Forbes P. **Practitioner** 1998 Feb;242(1583):120-3, 125 (6 ref.)

Nerve entrapment syndromes as a cause of pain in the hip, groin and buttock. McCrory P, et al. **Sports Med** 1999 Apr; 27(4):261-74 (74 ref.)

[The healing process following gynecologic laparoscopy: data on the significance of psychological factors] Szeverényi P, et al. **Orv Hetil** 1999 May 9;140(19):1043-8 (30 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

Surgical treatment for chronic pelvic pain. Carter JE. **J Soc Laparoendosc Surg** 1998 Apr-Jun;2(2):129-39 (77 ref.)

THERAPY

Chronic pelvic pain: the assessment as therapy [editorial] Price JR, et al. **J Psychosom Res** 1999 Jan;46(1):7-14 (28 ref.)

PELVIMETRY

see related
PELVIS

PELVIS

see related
ADNEXITIS
PELVIC EXENTERATION

Inflammatory pseudotumor of the pelvis: case report with review of recent developments. Dao AH, et al. **Am Surg** 1998 Dec;64(12):1188-91 (30 ref.)

Pelvic lipomatosis associated with proliferative cystitis: case report and review of the Japanese literature. Masumori N, et al. **Int J Urol** 1999 Jan;6(1):44-9 (23 ref.)

Does pelvic irradiation play a role in the management of prostate cancer? Stock RG, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1467-72; discussion 1472, 1475-6 (47 ref.)

Unenhanced CT of abdominal and pelvic hemorrhage. Katz DS, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):94-107 (56 ref.)

ANATOMY & HISTOLOGY

Laparoscopic anatomy of the pelvis. Scott-Conner CE, et al. **Semin Laparosc Surg** 1999 Jun;6(2):43-50 (16 ref.)

BLOOD SUPPLY

The morphogenesis of the arteries of the pelvic extremity. A comparative study of mammals with special reference to the tree shrew Tupaia belangeri (Tupaiidae, Scandentia, Mammalia). Funke C, et al. **Adv Anat Embryol Cell Biol** 1998;144:1-97 (115 ref.)

[Thrombosis of the deep leg and pelvic veins in congenital agenesis of the vena cava inferior] Klessen C, et al. **Dtsch Med Wochenschr** 1999 Apr 30;124(17):523-6 (17 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

MR imaging of musculoskeletal trauma to the pelvis and the lower limb. Brossmann J, et al. **Eur Radiol** 1999;9(2):183-91 (78 ref.)

Pelvic fracture injuries of the posterior urethra. Mundy AR. **World J Urol** 1999 Apr;17(2):90-5 (53 ref.)

[Mutilating complex trauma of the pelvis] Rieger H, et al. **Chirurg** 1998 Nov;69(11):1275-9 (19 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Ultrafast MR imaging of the pelvis. Outwater EK. **Eur J Radiol** 1999 Mar;29(3):233-44 (54 ref.)

MRI of the female pelvis. Kennedy AM, et al. **Semin Ultrasound CT MR** 1999 Aug;20(4):214-30 (35 ref.)

PHYSIOLOGY

The coordinated movement of the lumbo-pelvic-hip complex during running: a literature review. Schache AG, et al. **Gait Posture** 1999 Sep;10(1):30-47 (138 ref.)

RADIOGRAPHY

Pelvis-shoulder dysplasia. Hauser SE, et al. **Pediatr Radiol** 1998 Sep;28(9):681-2 (4 ref.)

Long-term radiographic follow-up in a patient with osteosclerotic sarcoidosis of the spine and pelvis. Franco M, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):586-90 (17 ref.)

SURGERY

Prophylactic and therapeutic use of antibiotics in pelvic surgery. Price SA, et al. **J Surg Oncol** 1999 Aug;71(4):261–8 (17 ref.)

ULTRASONOGRAPHY

Ultrasound evaluation of pelvic masses: predictors of malignancy for the general gynecologist. van Nagell JR Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):45–9 (24 ref.)

Tissue harmonic imaging: utility in abdominal and pelvic sonography. Desser TS, et al. **J Clin Ultrasound** 1999 Mar–Apr;27(3):135–42 (5 ref.)

PEMPHIGOID see **PEMPHIGOID, BULLOUS**

PEMPHIGOID, BENIGN MUCOUS MEMBRANE

Update on mucous membrane pemphigoid: a heterogeneous immune–mediated subepithelial blistering entity. Scully C, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Jul;88(1):56–68 (122 ref.)

CHEMICALLY INDUCED

Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. Liesegang TJ. **Cornea** 1998 Nov; 17(6):574–83 (88 ref.)

COMPLICATIONS

Cicatricial pemphigoid rarely involves the scalp. Ball S, et al. **Australas J Dermatol** 1998 Nov;39(4):258–60 (16 ref.)

Ocular cicatricial pemphigoid. Holsclaw DS.
Int Ophthalmol Clin 1998 Fall;38(4):89–106 (82 ref.)

IMMUNOLOGY

[Physiopathology of autoimmune bullous dermatoses of the basement membrane] Salmon–Ehr V, et al.
Ann Dermatol Venereol 1998 Nov;125(11):817–23 (37 ref.) **(Fre)**

[Autoantigens of cicatricial pemphigoid and their pathogenetic significance] Kirtschig G. **Hautarzt** 1998 Nov; 49(11):818–25 (49 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Peristomal subepidermal autoimmune blistering disease. Guillot B, et al. **Eur J Dermatol** 1999 Jul–Aug;9(5):385–6 (10 ref.)

PEMPHIGOID, BULLOUS

Pemphigus and bullous pemphigoid. Nousari HC, et al.
Lancet 1999 Aug 21;354(9179):667–72 (31 ref.)

COMPLICATIONS

Clinical features and management of 87 patients with pemphigoid gestationis. Jenkins RE, et al.
Clin Exp Dermatol 1999 Jul;24(4):255–9 (14 ref.)

Upper esophageal stricture secondary to dermatologic bullous disorders: a case report and review of the literature. Braghetto I, et al. **Dis Esophagus** 1998 Jul;11(3):198–201 (19 ref.)

DIAGNOSIS

Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy [editorial; comment] Korman NJ.
Arch Dermatol 1998 Sep;134(9):1137–41 (43 ref.) Comment on: Arch Dermatol 1998 Sep;134(9):1075–80.

Bullous pemphigoid presenting as generalized pruritus: observations in six patients. Alonso–Llamazares J, et al. **Int J Dermatol** 1998 Jul;37(7):508–14 (14 ref.)

IMMUNOLOGY

Childhood bullous pemphigoid: report of a case with characterization of the targeted antigens. Trüeb RM, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):338–44 (31 ref.)

[Physiopathology of autoimmune bullous dermatoses of the basement membrane] Salmon–Ehr V, et al.
Ann Dermatol Venereol 1998 Nov;125(11):817–23 (37 ref.) **(Fre)**

PHYSIOPATHOLOGY

Cytokines and bullous pemphigoid. D'Auria L, et al.
Eur Cytokine Netw 1999 Jun;10(2):123–34 (119 ref.)

THERAPY

Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy [editorial; comment] Korman NJ.
Arch Dermatol 1998 Sep;134(9):1137–41 (43 ref.) Comment on: Arch Dermatol 1998 Sep;134(9):1075–80.

PEMPHIGOID, CICATRICIAL see **PEMPHIGOID, BENIGN MUCOUS MEMBRANE**

PEMPHIGUS

Intercellular IgA dermatosis. Ongenae KC, et al.
Eur J Dermatol 1999 Mar;9(2):85–94 (66 ref.)

Pemphigus and bullous pemphigoid. Nousari HC, et al.
Lancet 1999 Aug 21;354(9179):667–72 (31 ref.)

CHEMICALLY INDUCED

Contact pemphigus induced by dihydrodiphenyltrichlorethane. Tsankov N, et al.
Eur J Dermatol 1998 Sep;8(6):442–3 (13 ref.)

CLASSIFICATION

Endemic pemphigus foliaceus (fogo selvagem)––1998. The Cooperative Group on Fogo Selvagem Research. Hans–Filho G, et al. **Clin Dermatol** 1999 Mar–Apr; 17(2):225–35; discussion 105–6 (88 ref.)

The new pemphigus variants [see comments] Robinson ND, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):649–71; quiz 672–3 (126 ref.) Comment in: J Am Acad Dermatol 1999 May;40(5 Pt 1):763–6.

COMPLICATIONS

A malignancy work–up in patients with cancer–associated (paraneoplastic) autoimmune diseases: pemphigus and myasthenic syndromes as cases in point (review). Sherer Y, et al. **Oncol Rep** 1999 May–Jun;6(3):665–8 (48 ref.)

CONGENITAL

Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Chowdhury MM, et al. **Br J Dermatol** 1998 Sep; 139(3):500–3 (23 ref.)

DIAGNOSIS

Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. Chorzelski T, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):393–400 (42 ref.)

DRUG THERAPY

Immunoablative high–dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. Nousari HC, et al. **J Am Acad Dermatol** 1999 May; 40(5 Pt 1):750–4 (24 ref.)

ETIOLOGY

Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Tur E, et al.
Arch Dermatol 1998 Nov;134(11):1406–10 (41 ref.)

Postsurgical pemphigus [letter] Micali G, et al.
Dermatology 1998;197(2):192–3 (14 ref.)

Pemphigus vulgaris on an old surgical scar: Koebner's phenomenon? Reichert–Penetrat S, et al.
Eur J Dermatol 1998 Jan–Feb;8(1):60–2 (21 ref.)

[Radiotherapy–induced pemphigus] Correia MP, et al.
Acta Med Port 1998 Jun;11(6):581–3 (15 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Autoimmunity against desmosomal cadherins in pemphigus. Amagai M. **J Dermatol Sci** 1999 Jun;20(2):92–102 (52 ref.)

[Paraneoplastic pemphigus] Descamps V, et al.
Presse Med 1999 Feb 20;28(7):363–7 (45 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pemphigus vulgaris on an old surgical scar: Koebner's phenomenon? Reichert–Penetrat S, et al.
Eur J Dermatol 1998 Jan–Feb;8(1):60–2 (21 ref.)

Paraneoplastic pemphigus: a review. Sklavounou A, et al.
Oral Oncol 1998 Nov;34(6):437–40 (14 ref.)

PEMPHIGUS VULGARIS see **PEMPHIGUS**

PENETRANCE

The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Carty SE, et al.
Surgery 1998 Dec;124(6):1106–13; discussion 1113–4 (23 ref.)

PENICILLAMINE

CHEMISTRY

Protein haptenation by drugs. Coleman JW.
Clin Exp Allergy 1998 Sep;28 Suppl 4:79–82 (16 ref.)

THERAPEUTIC USE

Treatment and management of Wilson's disease. Shimizu N, et al. **Pediatr Int** 1999 Aug;41(4):419–22 (21 ref.)

PENICILLANIC ACID

ANALOGS & DERIVATIVES

Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Perry CM, et al.
Drugs 1999 May;57(5):805–43 (167 ref.)

PENICILLIN, AMINOBENZYL see **AMPICILLIN**

PENICILLIN, DIMETHOXYPHENYL see **METHICILLIN**

PENICILLIN G

ADMINISTRATION & DOSAGE

[Reduced frequency of resistant pneumococci in Southern Sweden. Community based disease control projects to minimize antibiotic resistance] Ekdahl K, et al.
Lakartidningen 1999 Jun 16;96(24):2962–5 (39 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Treatment of pneumococcal pneumonia: the case for penicillin G. Bryan CS. **Am J Med** 1999 Jul 26; 107(1A):63S–68S (73 ref.)

PENICILLIN, PHENOXYMETHYL see **PENICILLIN V**

PENICILLIN RESISTANCE

Strategies in the treatment of penicillin–resistant Streptococcus pneumoniae. Lund BC, et al.
Am J Health Syst Pharm 1998 Oct 1;55(19):1987–94 (76 ref.)

Drug–resistant Streptococcus pneumoniae: rational antibiotic choices. Jacobs MR. **Am J Med** 1999 May 3; 106(5A):19S–25S; discussion 48S–52S (52 ref.)

Penicillin– and cephalosporin–resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem. Klugman KP, et al. **Drugs** 1999 Jul;58(1):1–4 (29 ref.)

Multi–resistant pneumococci in children in day–care centres [comment] Allen KD. **J Infect** 1998 Jul;37(1):5–8 (24 ref.) Comment on: J Infect 1998 Jul;37(1):9–14.

Failure of penicillin in Streptococcus pyogenes pharyngeal infection [comment] Gillespie SH. **Lancet** 1998 Dec 19–26; 352(9145):1954–6 (18 ref.) Comment on: Lancet 1998 Dec 19–26;352(9145):1974–7.

[A consideration on the results of nationwide surveillance of antimicrobial susceptibilities––gram–positive cocci and gram–negative cocci] Kuroyama M, et al.
Jpn J Antibiot 1998 Dec;51(12):764–78 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Penicillin resistant Streptococcus pneumoniae infection] Matsushima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):175–8 (5 ref.) **(Jpn)**

GENETICS

Bacterial gene transfer by natural genetic transformation. Håvarstein LS. **APMIS Suppl** 1998;84:43–6 (19 ref.)

PHYSIOLOGY

Penicillin–binding protein–mediated resistance in pneumococci and staphylococci. Chambers HF.
J Infect Dis 1999 Mar;179 Suppl 2:S353–9 (58 ref.)

PENICILLIN V

THERAPEUTIC USE

Failure of penicillin in Streptococcus pyogenes pharyngeal infection [comment] Gillespie SH. **Lancet** 1998 Dec 19–26; 352(9145):1954–6 (18 ref.) Comment on: Lancet 1998 Dec 19–26;352(9145):1974–7.

PENICILLINS

The penicillins. Wright AJ. **Mayo Clin Proc** 1999 Mar; 74(3):290–307 (58 ref.)

ADMINISTRATION & DOSAGE

[Reduced frequency of resistant pneumococci in Southern Sweden. Community based disease control projects to minimize antibiotic resistance] Ekdahl K, et al.
Lakartidningen 1999 Jun 16;96(24):2962–5 (39 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

T–cell response in penicillin allergy. Padovan E.
Clin Exp Allergy 1998 Sep;28 Suppl 4:33–6 (12 ref.)

Antibacterial–induced nephrotoxicity in the newborn. Fanos V, et al. **Drug Saf** 1999 Mar;20(3):245–67 (205 ref.)

Postmarketing surveillance: strengths and limitations. The flucloxacillin–dicloxacillin story. McNeil JJ, et al.
Med J Aust 1999 Mar 15;170(6):270–3 (20 ref.)

[Management and choice of antibiotics for patients with an allergy to penicillin (see comments)] Rijnders BJ, et al.
Ned Tijdschr Geneeskd 1999 Feb 13;143(7):336–41 (17 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1239. Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1239–40. **(Dut)**

PENICILLINS

[Drug-associated hemorrhagic enteritis] Sakurai Y. **Nippon Rinsho** 1998 Sep;56(9):2382-6 (16 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Transcriptional control of expression of fungal beta-lactam biosynthesis genes. Litzka O, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1-2):95-105 (60 ref.)

Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production. Martin JF, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb; 75(1-2):21-31 (90 ref.)

The optimization of penicillin biosynthesis in fungi. Peñalva MA, et al. **Trends Biotechnol** 1998 Nov;16(11):483-9 (55 ref.)

CHEMISTRY

Protein haptenation by drugs. Coleman JW. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:79-82 (16 ref.)

IMMUNOLOGY

Penicillins and cephalosporins as allergens--structural aspects of recognition and cross-reactions. Baldo BA. **Clin Exp Allergy** 1999 Jun;29(6):744-9 (29 ref.)

METABOLISM

T-cell response in penicillin allergy. Padovan E. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:33-6 (12 ref.)

Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Goffin C, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1079-93 (74 ref.)

PHARMACOLOGY

Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Perry CM, et al. **Drugs** 1999 May;57(5):805-43 (167 ref.)

Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Giesbrecht P, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1371-414 (146 ref.)

[A consideration on the results of nationwide surveillance of antimicrobial susceptibilities--gram-positive cocci and gram-negative cocci] Kuroyama M, et al. **Jpn J Antibiot** 1998 Dec;51(12):764-78 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Resolving the common clinical dilemmas of syphilis. Birnbaum NR, et al. **Am Fam Physician** 1999 Apr 15; 59(8):2233-40, 2245-6 (26 ref.)

Strategies for dealing with amoxicillin failure in acute otitis media [see comments] Block SL. **Arch Fam Med** 1999 Jan-Feb;8(1):68-78 (103 ref.) Comment in: Arch Fam Med 1999 Jan-Feb;8(1):79-80.

Failure of penicillin in Streptococcus pyogenes pharyngeal infection [comment] Gillespie SH. **Lancet** 1998 Dec 19-26; 352(9145):1954-6 (18 ref.) Comment on: Lancet 1998 Dec 19-26;352(9145):1974-7.

Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis--a novel hazard emerging on the horizon [editorial] Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):2999-3001 (14 ref.)

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group [published erratum appears in Pediatr Infect Dis J 1999 Apr;18(4):341] [see comments] Dowell SF, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):1-9 (59 ref.) Comment in: Pediatr Infect Dis J 1999 Jun;18(6):571-2.

[Practical implications of bacterial resistance to antibiotics. Attempts to fight it] Denys A. **Otolaryngol Pol** 1997;51 Suppl 25:171-4 (5 ref.) (Eng. Abstr.) **(Pol)**

PENICILLIUM

Endoscopic diagnosis of intestinal penicilliosis marneffei: report of three cases and review of the literature. Ko CI, et al. **Gastrointest Endosc** 1999 Jul;50(1):111-4 (19 ref.)

Serodiagnosis of histoplasmosis, paracoccidioidomycosis and penicilliosis marneffei; current status and future trends. Hamilton AJ. **Med Mycol** 1998 Dec;36(6):351-64 (148 ref.)

Penicilliosis marneffei and pythiosis: emerging tropical diseases. Kaufman L. **Mycopathologia** 1998;143(1):3-7 (28 ref.)

[Exotic pulmonary mycoses] Dupont B. **Rev Pneumol Clin** 1998 Dec;54(6):301-8 (24 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Characterization of allergens of Penicillium and Aspergillus species. Shen HD, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1998 Sep;31(3):141-5 (30 ref.)

METABOLISM

Mycotoxin production by Aspergillus, Fusarium and Penicillium species. Sweeney MJ, et al. **Int J Food Microbiol** 1998 Sep 8;43(3):141-58 (147 ref.)

PENICILLIUM CHRYSOGENUM

GENETICS

The optimization of penicillin biosynthesis in fungi. Peñalva MA, et al. **Trends Biotechnol** 1998 Nov;16(11):483-9 (55 ref.)

METABOLISM

The optimization of penicillin biosynthesis in fungi. Peñalva MA, et al. **Trends Biotechnol** 1998 Nov;16(11):483-9 (55 ref.)

PENICILLIUM NOTATUM see **PENICILLIUM CHRYSOGENUM**

PENILE DISEASES

[Abscess of corpus cavernosum: a case report] Kameda K, et al. **Hinyokika Kiyo** 1998 Dec;44(12):893-5 (10 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Priapism secondary to a bilateral abscess of the corpora cavernosa] Fernández Duran AM, et al. **Actas Urol Esp** 1999 Jan;23(1):64-6 (10 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Langerhans-cell histiocytosis of the penis] Seseke F, et al. **Urologe A** 1999 Jan;38(1):42-5 (10 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[The role of urethral catheterization in penile necrosis] Serrano Durba A, et al. **Actas Urol Esp** 1999 May; 23(5):444-6 (14 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Penile cutaneous horn. Report of a case and review of the literature] García Paños JM, et al. **Arch Esp Urol** 1999 Mar; 52(2):173-4 (6 ref.) (Eng. Abstr.) **(Spa)**

[Parameatal cyst: presentation of two cases and a review of the literature] Suárez Cuenca JA, et al. **Arch Esp Urol** 1998 Sep;51(7):716-8 (10 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The aging penis: erectile dysfunction. Monga M. **Geriatr Nephrol Urol** 1999;9(1):27-37 (41 ref.)

SURGERY

Medical indications for circumcision [published erratum appears in BJU Int 1999 May;83(7):881] Rickwood AM. **BJU Int** 1999 Jan;83 Suppl 1:45-51 (27 ref.)

Genital skin loss: unified reconstructive approach to a heterogeneous entity. Wessells H. **World J Urol** 1999 Apr; 17(2):107-14 (21 ref.)

THERAPY

The aging penis: erectile dysfunction. Monga M. **Geriatr Nephrol Urol** 1999;9(1):27-37 (41 ref.)

PENILE ERECTION

[Painful erections related to sleeping] Menéndez López V, et al. **Actas Urol Esp** 1999 Jun;23(6):539-41 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Drug-related erectile dysfunction. Keene LC, et al. **Adverse Drug React Toxicol Rev** 1999 Mar;18(1):5-24 (95 ref.)

Vitamin V: the sildenafil craze. Kuritzky L. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):163-5 (3 ref.)

[A new agent against impotence. Contraindicated in reduced renal and hepatic function, in angina and with simultaneously used nitroglycerin preparations] Hedelin H. **Lakartidningen** 1998 Oct 14;95(42):4558-60 (13 ref.) **(Swe)**

PHYSIOLOGY

Vacuum devices in erectile dysfunction: indications and efficacy. Oakley N, et al. **Br J Urol** 1998 Nov;82(5):673-81 (90 ref.)

Pharmacology of alpha-adrenoceptors in male sexual function. Rampin O. **Eur Urol** 1999;36 Suppl 1:103-6 (19 ref.)

The aging penis: erectile dysfunction. Monga M. **Geriatr Nephrol Urol** 1999;9(1):27-37 (41 ref.)

Erectile function and dysfunction. Jordan GH. **Postgrad Med** 1999 Feb;105(2):131-4, 137-8, 143-4 passim (31 ref.)

[Criteria of Rigiscan normalcy in aged men] Zimmern P, et al. **Prog Urol** 1999 Feb;9(1):37-44 (32 ref.) (Eng. Abstr.) **(Fre)**

[Sildenafil (Viagra). Hormonal properties, indications and legal problems] Ullrich T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):233-45 (84 ref.) **(Ger)**

PENILE IMPLANTATION

see related **PENILE PROSTHESIS**

PENILE INDURATION

Peyronie's disease: current management. Fitkin J, et al. **Am Fam Physician** 1999 Aug;60(2):549-52, 554 (19 ref.)

ETIOLOGY

Development of Peyronie's and Dupuytren's diseases in an individual after single episodes of trauma: a case report and review of the literature. Connelly TJ. **J Am Acad Dermatol** 1999 Jul;41(1):106-8 (40 ref.)

PENILE NEOPLASMS

PATHOLOGY

Rhabdomyosarcoma of the penis in a 15-month-old boy. Antoneli CB, et al. **J Urol** 1998 Dec;160(6 Pt 1):2200-1 (3 ref.)

Primary extraskeletal Ewing's sarcoma of the external genitalia. Toh KL, et al. **J Urol** 1999 Jul;162(1):159-60 (3 ref.)

Epithelioid sarcoma of the penis. Clinicopathologic study of a tumor with myogenic features and review of the literature concerning this unusual location. Corsi A, et al. **Pathol Res Pract** 1999;195(6):441-8; discussion 449 (50 ref.)

SECONDARY

[Successful multidisciplinary treatment for bladder cancer with priapism. A case report] Kitsukawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):788-91 (11 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Lymph node metastases in penis carcinoma. Therapeutic options and outcome] Wilbert DM. **Urologe A** 1999 Jul; 38(4):332-6 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Epidermoid carcinoma of the penis] Soria JC, et al. **Bull Cancer** 1998 Sep;85(9):773-84 (94 ref.) (Eng. Abstr.) **(Fre)**

[Successful multidisciplinary treatment for bladder cancer with priapism. A case report] Kitsukawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):788-91 (11 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

The role of human papillomaviruses in anogenital cancers. Melbye M, et al. **Semin Cancer Biol** 1998 Aug;8(4):307-13 (79 ref.)

PENILE PROSTHESIS

Treatment outcome after radical prostatectomy is not adversely affected by a pre-existing penile prosthesis. Tiguert R, et al. **Urology** 1998 Dec;52(6):1030-3 (16 ref.)

[Vascular surgery, implant surgery and vacuum erectile aids. Review-overview-prospects of 3 therapy options in erectile dysfunction] Manning M, et al. **Urologe A** 1998 Sep;37(5):509-15 (66 ref.) (Eng. Abstr.) **(Ger)**

PENIS

see related **CIRCUMCISION**

ABNORMALITIES

Diphallus associated with partial caudal duplication. Dewan PA, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):131-3 (10 ref.)

ANATOMY & HISTOLOGY

The prepuce. Cold CJ, et al. **BJU Int** 1999 Jan;83 Suppl 1:34-44 (104 ref.)

BLOOD SUPPLY

Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Tarcan T, et al. **Br J Urol** 1998 Dec; 82 Suppl 1:26-33 (65 ref.)

Penile arteriography. Borge MA. **Tech Urol** 1999 Jun; 5(2):81-6 (9 ref.)

[Vascular exploration of erectile dysfunction] Sussman H. **J Mal Vasc** 1999 May;24(2):143-7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Vascular surgery, implant surgery and vacuum erectile aids. Review-overview-prospects of 3 therapy options in erectile dysfunction] Manning M, et al. **Urologe A** 1998 Sep;37(5):509-15 (66 ref.) (Eng. Abstr.) **(Ger)**

[Revascularization of the corpora cavernosa in vasculogenic impotence] Sica GS, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):129-34 (16 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Immunological functions of the human prepuce. Fleiss PM, et al. **Sex Transm Infect** 1998 Oct;74(5):364-7 (97 ref.)

INJURIES

Development of Peyronie's and Dupuytren's diseases in an individual after single episodes of trauma: a case report and review of the literature. Connelly TJ.
J Am Acad Dermatol 1999 Jul;41(1):106–8 (40 ref.)
Penile fracture and testicular rupture. Haas CA, et al.
World J Urol 1999 Apr;17(2):101–6 (31 ref.)
[Traumatic rupture of the corpus cavernosum] Bennani S, et al. **Prog Urol** 1998 Sep;8(4):548–52 (36 ref.) (Eng. Abstr.) **(Fre)**
[Fractures of the penis: apropos of 56 cases] Nouri M, et al. **Prog Urol** 1998 Sep;8(4):542–7 (27 ref.) (Eng. Abstr.) **(Fre)**
[Rupture of the corpora cavernosa: its therapeutic assessment and management] Lorenzo Romero JG, et al.
Actas Urol Esp 1999 Jul–Aug;23(7):635–9 (10 ref.) (Eng. Abstr.) **(Spa)**

INNERVATION

[Total excision of the mesorectum and preservation of the genitourinary innervation in surgery of rectal cancer] Tiret E, et al. **Ann Chir** 1999;53(6):507–14 (16 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[The role of urethral catheterization in penile necrosis] Serrano Durba A, et al. **Actas Urol Esp** 1999 May; 23(5):444–6 (14 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Penile sensitivity in men: a composite of recent findings. Rowland DL. **Urology** 1998 Dec;52(6):1101–5 (23 ref.)

PHYSIOPATHOLOGY

Semen retrieval by penile vibratory stimulation in men with spinal cord injury. Brackett NL. **Hum Reprod Update** 1999 May–Jun;5(3):216–22 (46 ref.)

SURGERY

Surgical methods of restoring the prepuce: a critical review. Brandes SB, et al. **BJU Int** 1999 Jan;83 Suppl 1:109–13 (10 ref.)
Treatment of hypospadias: an update of current practice. Soomro NA, et al. **Hosp Med** 1998 Jul;59(7):553–6 (30 ref.)
[Augmentation phalloplasty according to the G. Tritto technique] Randone D, et al. **Arch Ital Urol Androl** 1998 Dec;70(5):235–9 (8 ref.) (Eng. Abstr.) **(Ita)**
[Posttraumatic priapism in a 6-year-old boy: a case report] Iwata K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):679–82 (20 ref.) (Eng. Abstr.) **(Jpn)**

PENIS, ARTIFICIAL see **PENILE PROSTHESIS**

PENSIONS

The Mexican Social Security counterreform: pensions for profit. Laurell AC. **Int J Health Serv** 1999;29(2):371–91 (48 ref.)
Pension integration and Social Security reform. Slusher C. **Soc Secur Bull** 1998;61(3):20–7 (10 ref.)

STATISTICS & NUMERICAL DATA

Retirement income security in the United Kingdom. Liu L. **Soc Secur Bull** 1999;62(1):23–46 (87 ref.)

PENTAGASTRIN

see related
GASTROINTESTINAL AGENTS

PENTAMIDINE

ADVERSE EFFECTS

[Hyperkalemia after trimethoprim or pentamidine. Until now, a little noticed side effect of antimicrobial therapeutic measures in AIDS patients] Gabriëls G, et al.
Dtsch Med Wochenschr 1998 Nov 6;123(45):1351–5 (25 ref.) **(Ger)**

PENTAMIDINE ISETHIONATE see **PENTAMIDINE**

PENTANOLS

METABOLISM

Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. A useful tool for studying protein prenylation. Corsini A, et al.
Methods Mol Biol 1999;116:125–44 (37 ref.)

PENTANUCLEOTIDE REPEATS see **MICROSATELLITE REPEATS**

PENTETATES see **PENTETIC ACID**

PENTETIC ACID

ANALOGS & DERIVATIVES

Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L, et al.
Nucl Med Commun 1999 Aug;20(8):689–96 (26 ref.)

DIAGNOSTIC USE

Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)

PENTHANIL see **PENTETIC ACID**

PENTHIOBARBITAL see **THIOPENTAL**

PENTOBARBITAL

POISONING

Exit association-mediated suicide: toxicologic and forensic aspects. Giroud C, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):40–4 (9 ref.)

THERAPEUTIC USE

Tale of two (or three or more) cities [editorial; comment] Gettes LS. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):165–7 (15 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Feb;10(2):154–64.
Midazolam and pentobarbital for refractory status epilepticus. Holmes GL, et al. **Pediatr Neurol** 1999 Apr;20(4):259–64 (37 ref.)

PENTOSAN POLYSULFATE see **PENTOSAN SULFURIC POLYESTER**

PENTOSAN SULFURIC POLYESTER

THERAPEUTIC USE

The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Ghosh P.
Semin Arthritis Rheum 1999 Feb;28(4):211–67 (390 ref.)

PENTOSEPHOSPHATES

METABOLISM

The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Eisenreich W, et al. **Chem Biol** 1998 Sep;5(9):R221–33 (81 ref.)

PENTOSTATIN

THERAPEUTIC USE

Treatment of hairy-cell leukemia: current views. Tallman MS, et al. **Semin Hematol** 1999 Apr;36(2):155–63 (109 ref.)
[Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy] Rucińska M, et al. **Przegl Lek** 1998;55(7–8):400–6 (38 ref.) (Eng. Abstr.) **(Pol)**

PENTOSYLTRANSFERASES

METABOLISM

[PyNPase expression and cancer progression in the colorectum] Monden T, et al.
Nippon Geka Gakkai Zasshi 1998 Jul;99(7):446–51 (4 ref.) (Eng. Abstr.) **(Jpn)**

PENTOXIFYLLINE

THERAPEUTIC USE

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Girolami B, et al. **Arch Intern Med** 1999 Feb 22;159(4):337–45 (116 ref.)
Pentoxifylline and skin inflammation. Bruynzeel I, et al.
Clin Exp Dermatol 1998 Jul;23(4):168–72 (66 ref.)
Pentoxifylline--more evidence that it improves host defenses during sepsis [editorial; comment] Reynolds H.
Crit Care Med 1999 Apr;27(4):681–3 (41 ref.) Comment on: Crit Care Med 1999 Apr;27(4):756–63.
Appraising the potential of pentoxifylline in septic premies [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):695–7 (32 ref.) Comment on: Crit Care Med 1999 Apr;27(4):807–14.
Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. McCarty MF.
Med Hypotheses 1999 May;52(5):465–77 (229 ref.)

PENTYL ALCOHOLS see **PENTANOLS**

PENTYMAL see **AMOBARBITAL**

PEOPLE WITH DISABILITIES see **DISABLED PERSONS**

PEPONOCEPHALA see **DOLPHINS**

PEPSIN see **PEPSIN A**

PEPSIN A

CHEMISTRY

Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors. Khan AR, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):10968–75 (66 ref.)

PEPSINOGEN see **PEPSINOGEN A**

PEPSINOGEN A

CHEMISTRY

Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Richter C, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):481–90 (93 ref.)

METABOLISM

Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Richter C, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):481–90 (93 ref.)

PEPSINOGEN C

CHEMISTRY

Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Richter C, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):481–90 (93 ref.)
Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors. Khan AR, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):10968–75 (66 ref.)

METABOLISM

Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Richter C, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):481–90 (93 ref.)

PEPSINOGEN I see **PEPSINOGEN A**

PEPSINOGEN II see **PEPSINOGEN C**

PEPSINOGEN 3, GROUP I see **PEPSINOGEN A**

PEPSINOGEN 5, GROUP I see **PEPSINOGEN A**

PEPTIC ULCER

see related
ANTI-ULCER AGENTS
GASTRECTOMY
ZOLLINGER-ELLISON SYNDROME

Gastroduodenal ulcers: causes, diagnosis, prevention and treatment. Brown LF, et al. **Compr Ther** 1999 Jan; 25(1):30–8 (68 ref.)
Scope and consequences of peptic ulcer disease. How important is asymptomatic Helicobacter pylori infection? Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):100–2, 105–8, 110 (38 ref.)
[Pharma clinics. How I diagnose and treat...stress ulcers] Fraipont V, et al. **Rev Med Liege** 1998 Aug;53(8):444–9 (23 ref.) (Eng. Abstr.) **(Fre)**
[Gastroduodenal erosions: etiology, pathogenesis, diagnosis, symptoms, classification, treatment] Tsimmerman IaS, et al. **Klin Med (Mosk)** 1999;77(3):9–15 (84 ref.) **(Rus)**

CHEMICALLY INDUCED

Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity. Soll A. **Am J Med** 1998 Nov 2;105(5A):10S–16S (43 ref.)
Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Ginzler EM, et al.
Baillieres Clin Rheumatol 1998 Aug;12(3):495–510 (102 ref.)
Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding. Lanas A. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S37–42 (46 ref.)
Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C, et al.
Ital J Gastroenterol Hepatol 1999;31 Suppl 1:S63–72 (113 ref.)
COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs [editorial] Schachna L, et al.
Med J Aust 1999 Aug 16;171(4):175–6 (20 ref.)
[Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity] Dammann HG. **Z Gastroenterol** 1999 Jan; 37(1):45–58 (129 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

[Double pylorus. Description of two new cases and survey of the literature] Tola M, et al. **Minerva Chir** 1998 Oct;

PEPTIC ULCER

53(10):801-5 (44 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Peptic ulcer disease in the military aviator: a management approach. Lang KA, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1100-3 (15 ref.)

Helicobacter pylori and gastroesophageal reflux disease: friends or foes? Gisbert JP, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1023-9 (70 ref.)

Recognizing peptic ulcer disease. Keys to clinical and laboratory diagnosis. Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):113-6, 121-3, 127-8 passim (31 ref.)

[The current approaches to the diagnosis and treatment of peptic ulcer] Tkach SM. **Lik Sprava** 1998 Oct-Nov; (7):15-20 (45 ref.) **(Rus)**

DRUG THERAPY

Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Scheiman J, et al. **Am J Med** 1998 Nov 2;105(5A):32S-38S (35 ref.)

Peptic ulcer disease in the military aviator: a management approach. Lang KA, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1100-3 (15 ref.)

Safety profile of Lansoprazole: the US clinical trial experience. Freston JW, et al. **Drug Saf** 1999 Feb; 20(2):195-205 (22 ref.)

Pathogenesis of peptic ulcer disease and current trends in therapy. Desai JK, et al. **Indian J Physiol Pharmacol** 1997 Jan;41(1):3-15 (87 ref.)

Anti-ulcer potential of flavonoids. Parmar NS, et al. **Indian J Physiol Pharmacol** 1998 Jul;42(3):343-51 (50 ref.)

New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report. Gasbarrini G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S244-7 (20 ref.)

Novel therapeutic approaches to the management of Helicobacter pylori infection. Montague S, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S334-8 (35 ref.)

Practical advice on eradicating Helicobacter pylori infection. Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):137-40, 145-8 (22 ref.)

Treatment of H. pylori infection: the reality. Vakil N. **Yale J Biol Med** 1998 Mar-Apr;71(2):119-24 (30 ref.)

[Proton pump inhibitors in pediatrics] Faure C, et al. **Arch Pediatr** 1999 Jun;6(6):650-6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Peptic ulcer, functional dyspepsia, Helicobacter pylori: a 1998 stock-taking on the topic of their correlation and therapeutic strategies] Dobrilla G. **Recenti Prog Med** 1999 Jun;90(6):347-54 (75 ref.) (Eng. Abstr.) **(Ita)**

[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy] Iwasaki A. **Nippon Rinsho** 1999 Jan;57(1):127-33 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The current approaches to the diagnosis and treatment of peptic ulcer] Tkach SM. **Lik Sprava** 1998 Oct-Nov; (7):15-20 (45 ref.) **(Rus)**

ECONOMICS

Economic perspectives in the management of Helicobacter pylori infections. Sonnenberg A, et al. **Curr Top Microbiol Immunol** 1999;241:237-60 (52 ref.)

EPIDEMIOLOGY

Helicobacter pylori, peptic ulcer and gastric cancer in China. Lam SK, et al. **Yale J Biol Med** 1998 Jan-Feb;71(1):1-6 (43 ref.)

ETIOLOGY

Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Hawkey CJ. **Aliment Pharmacol Ther** 1999 Jun; 13(6):695-702 (62 ref.)

The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Barkin J. **Am J Med** 1998 Nov 2;105(5A):22S-27S (51 ref.)

Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. McCarthy D. **Am J Med** 1998 Nov 2;105(5A):3S-9S (65 ref.)

Pathogenesis of peptic ulcer disease and current trends in therapy. Desai JK, et al. **Indian J Physiol Pharmacol** 1997 Jan;41(1):3-15 (87 ref.)

Helicobacter pylori and non-steroidal anti-inflammatory drugs: ulcers and bleeding ulcers. Russell RI. **Ital J Gastroenterol Hepatol** 1999 Mar;31(2):116-8 (16 ref.)

Deleterious action of vasopressin in gastroduodenal ulceration: experimental and clinical observations. László F, et al. **Scand J Gastroenterol Suppl** 1998;228:62-7 (59 ref.)

[Reductionism once again. The example of Helicobacter pylori (editorial)] Weiner H. **Psychother Psychosom Med Psychol** 1998 Nov;48(11):425-9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Selected problems concerning harmful effects of smoking on the upper segment of the alimentary tract] Semianów-Wejchert J. **Pol Merkuriusz Lek** 1998 Aug; 5(26):89-91 (29 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Hypotheses on the role of cytokines in peptic ulcer disease. Lehmann FS, et al. **Eur J Clin Invest** 1998 Jul;28(7):511-9 (136 ref.)

MICROBIOLOGY

The physiology and metabolism of the human gastric pathogen Helicobacter pylori. Kelly DJ. **Adv Microb Physiol** 1998;40:137-89 (164 ref.)

Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad [see comments] Richter JE, et al. **Am J Gastroenterol** 1998 Oct;93(10):1800-2 (26 ref.) Comment in: Am J Gastroenterol 1999 May;94(5):1420-1.

Understanding disease outcome following acquisition of Helicobacter pylori infection during childhood. Day AS, et al. **Can J Gastroenterol** 1999 Apr;13(3):229-34 (75 ref.)

Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Blaser MJ. **Gut** 1998 Nov; 43(5):721-7 (101 ref.)

Practical advice on eradicating Helicobacter pylori infection. Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):137-40, 145-8 (22 ref.)

[Eradication of Helicobacter pylori in peptic ulcer patients] Buzás GM, et al. **Orv Hetil** 1999 Jan 17;140(3):121-4 (32 ref.) (Eng. Abstr.) **(Hun)**

[Helicobacter pylori as a new paradigm in the pathogenesis of upper GI diseases] Sugiyama T, et al. **Nippon Rinsho** 1999 Jan;57(1):5-10 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Peptic ulcer disease and hemorrhagic gastritis with H. pylori infection] Yamamoto I, et al. **Nippon Rinsho** 1998 Sep; 56(9):2263-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Van Zanten SJ, et al. **Gastroenterology** 1999 May;116(5):1217-29 (164 ref.)

[Effect of the eradication of Helicobacter pylori on peptic ulcer healing] Harase I, et al. **Nippon Rinsho** 1999 Jan; 57(1):162-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers] Imaizumi H, et al. **Nippon Rinsho** 1999 Jan;57(1):167-72 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The mechanisms of gastrointestinal mucosal injury and repair] Kobayashi K, et al. **Nippon Rinsho** 1998 Sep; 56(9):2215-22 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular aspect of gastroduodenal ulcer healing] Terano A, et al. **Nippon Rinsho** 1998 Sep;56(9):2223-7 (18 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Hypotheses on the role of cytokines in peptic ulcer disease. Lehmann FS, et al. **Eur J Clin Invest** 1998 Jul;28(7):511-9 (136 ref.)

Peptides and peptic ulceration. Playford RJ, et al. **QJM** 1998 Oct;91(10):661-5 (22 ref.)

PREVENTION & CONTROL

Unconventional vaccine targets. Immunization for pregnancy, peptic ulcer, gastric cancer, cocaine abuse, and atherosclerosis. Lutwick LI. **Infect Dis Clin North Am** 1999 Mar;13(1):245-64, ix (115 ref.)

Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S63-72 (113 ref.)

COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs [editorial] Schachna L, et al. **Med J Aust** 1999 Aug 16;171(4):175-6 (20 ref.)

SURGERY

Remote partial gastrectomy as a risk factor for pancreatic cancer: potential for preventive strategies. van Rees BP, et al. **Ann Oncol** 1999;10 Suppl 4:204-7 (58 ref.)

[Relation of Helicobacter pylori and the stomach operated on for peptic ulcer] Hurtado-Andrade H. **Rev Gastroenterol Mex** 1998 Oct-Dec;63(4):187-97 (90 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Peptic-ulcer disease in the elderly. Borum ML. **Clin Geriatr Med** 1999 Aug;15(3):457-71 (93 ref.)

PEPTIC ULCER HEMORRHAGE

Ulcers and nonvariceal bleeding. Rollhauser C, et al. **Endoscopy** 1999 Jan;31(1):17-25 (50 ref.)

[Bleeding in chronic refractory peptic ulcer] Nakamura T, et al. **Nippon Rinsho** 1998 Sep;56(9):2343-8 (42 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Duodenal ulceration into the cystic artery with massive hemorrhage. Iwamura T, et al. **J Clin Gastroenterol** 1999 Mar;28(2):171-4 (23 ref.)

DIAGNOSIS

Preventing ulcer rebleeding: the role of second-look endoscopy. Chung SC. **Can J Gastroenterol** 1999 Jun; 13(5):409-11 (11 ref.)

[Early recurrent bleeding of ulcerative origin] Buka GIu. **Klin Khir** 1999;(5):45-7 (35 ref.) **(Rus)**

ETIOLOGY

Risk factors of acute ulcer bleeding. Shafi MA, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):727-31 (44 ref.)

The conflicting relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding [editorial; comment] Bianchi Porro G, et al. **Scand J Gastroenterol** 1999 Mar;34(3):225-8 (48 ref.) Comment on: Scand J Gastroenterol 1999 Mar;34(3):234-7.

[The hemorrhagic complication of peptic ulcer] Vadalà G, et al. **Minerva Chir** 1999 Mar;54(3):185-9 (33 ref.) (Eng. Abstr.) **(Ita)**

[Stress ulceration related bleeding (SURB) in intensive care unit] Kitamura N, et al. **Nippon Rinsho** 1998 Sep; 56(9):2396-400 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Abdominal aneurysm] Konno H. **Nippon Rinsho** 1998 Sep; 56(9):2401-4 (8 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Preventing ulcer rebleeding: the role of second-look endoscopy. Chung SC. **Can J Gastroenterol** 1999 Jun; 13(5):409-11 (11 ref.)

SURGERY

Changing trends in the management of ulcer bleeding. Sontheimer J. **Dig Surg** 1998;15(4):315-6 (7 ref.)

[The treatment of patients with peptic gastroduodenal ulcers and severe concomitant diseases] Chechurin NS. **Vestn Khir Im I I Grek** 1999;158(1):73-6 (50 ref.) **(Rus)**

THERAPY

Spots and clots - leave them or treat them? Why and how to treat. Jensen DM. **Can J Gastroenterol** 1999 Jun; 13(5):413-5 (9 ref.)

Management of duodenal ulcer bleeding. Lai KC, et al. **Chin Med J (Engl)** 1998 Jan;111(1):3-6 (30 ref.)

Treatment of acute nonvariceal upper gastrointestinal hemorrhage. Meier R, et al. **Digestion** 1999;60 Suppl 2:47-52 (67 ref.)

Endoscopic therapy for upper gastrointestinal hemorrhage: a state of the art. Simoens M, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):737-45 (114 ref.)

ULTRASONOGRAPHY

The role of endoscopic Doppler-sonography. Kohler B, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):732-6 (17 ref.)

PEPTIC ULCER PERFORATION

DIAGNOSIS

[Duodenal ulcer with penetration into the liver. Endoscopic-biopsy diagnosis] Mall K. **Med Klin** 1999 Feb 15;94(2):101-4 (17 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Duodenal tuberculosis presenting as acute ulcer perforation. Berney T, et al. **Am J Gastroenterol** 1998 Oct; 93(10):1989-91 (24 ref.)

Perforated peptic ulcer following gastric bypass for obesity. Macgregor AM, et al. **Am Surg** 1999 Mar;65(3):222-5 (21 ref.)

Perforated duodenal ulcer: an alternative therapeutic plan. Donovan AJ, et al. **Arch Surg** 1998 Nov;133(11):1166-71 (34 ref.)

SURGERY

Open vs. laparoscopic repair of perforated peptic ulcer [letter; comment] Bergamaschi R. **Surg Laparosc Endosc** 1998 Dec; 8(6):479-80 (8 ref.) Comment on: Surg Laparosc Endosc 1998 Apr;8(2):153-6.

[Functional disorders after organ salvaging surgery of perforative pyloroduodenal ulcer discovered in follow-up studies] Chislenko IV. **Klin Khir** 1999;(5):51-2 (6 ref.) **(Rus)**

[Organ-salvaging surgeries in combination with vagotomy for perforative pyloroduodenal ulcer] Chislenko IV. **Klin Khir** 1998;(5):40-2 (25 ref.) **(Rus)**

[Laparoscopic surgery in the treatment of perforating gastroduodenal ulcers] Shurkalin BK, et al. **Vestn Khir Im I I Grek** 1999;158(3):100-2 (39 ref.) **(Rus)**

THERAPY

Perforated duodenal ulcer: an alternative therapeutic plan. Donovan AJ, et al. **Arch Surg** 1998 Nov;133(11):1166-71 (34 ref.)

PEPTIDASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE ANTIBIOTICS see **ANTIBIOTICS, PEPTIDE**

PEPTIDE CHAIN ELONGATION

see related
PEPTIDE ELONGATION FACTORS
PROTEIN SYNTHESIS INHIBITORS

Models of the elongation cycle: an evaluation. Spahn CM, et al. **Biol Chem** 1998 Jul;379(7):753–72 (127 ref.)
Determination of the peptide elongation rate in vivo. Sørensen MA, et al. **Methods Mol Biol** 1998;77:129–42 (26 ref.)

PEPTIDE CHAIN INITIATION

see related
PEPTIDE INITIATION FACTORS
PROTEIN SYNTHESIS INHIBITORS

Control of translation initiation in animals. Gray NK, et al. **Annu Rev Cell Dev Biol** 1998;14:399–458 (381 ref.)

GENETICS

Initiation of translation in prokaryotes and eukaryotes. Kozak M. **Gene** 1999 Jul 8;234(2):187–208 (260 ref.)

PEPTIDE CHAIN TERMINATION

see related
PEPTIDE TERMINATION FACTORS

PHYSIOLOGY

RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Culbertson MR. **Trends Genet** 1999 Feb;15(2):74–80 (59 ref.)

PEPTIDE ELONGATION FACTOR TU

CHEMISTRY

Possible evolution of factors involved in protein biosynthesis. Nyborg J. **Acta Biochim Pol** 1998;45(4):883–94 (40 ref.)

METABOLISM

EF-Tu, a GTPase odyssey. Krab IM, et al. **Biochim Biophys Acta** 1998 Nov 26;1443(1–2):1–22 (211 ref.)
Mobile DNA elements: controlling transposition with ATP-dependent molecular switches. Stellwagen AE, et al. **Trends Biochem Sci** 1998 Dec;23(12):486–90 (45 ref.)

PEPTIDE ELONGATION FACTORS

CHEMISTRY

Protein engineering on enzymes of the peptide elongation cycle in Sulfolobus solfataricus. Bocchini V, et al. **Biochimie** 1998 Nov;80(11):895–8 (19 ref.)

METABOLISM

Functional interaction of yeast elongation factor 3 with yeast ribosomes. Chakraburtty K. **Int J Biochem Cell Biol** 1999 Jan;31(1):163–73 (50 ref.)
Initiation factors of protein biosynthesis in bacteria and their structural relationship to elongation and termination factors. Brock S, et al. **Mol Microbiol** 1998 Jul;29(2):409–17 (34 ref.)

PHYSIOLOGY

Multiple phosphorylation sites and quaternary organization of guanine-nucleotide exchange complex of elongation factor-1 (EF-1betagammadelta/ValRS) control the various functions of EF-1alpha. Minella O, et al. **Biosci Rep** 1998 Jun;18(3):119–27 (41 ref.)
HIV-1 Tat: coping with negative elongation factors. Garber ME, et al. **Curr Opin Immunol** 1999 Aug;11(4):460–5 (40 ref.)

PEPTIDE FRAGMENTS

The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Forssmann WG, et al. **Histochem Cell Biol** 1998 Oct;110(4):335–57 (258 ref.)

ANALYSIS

Identification of proteins by matrix-assisted laser desorption/ionization mass spectrometry using peptide and fragment ion masses. Courchesne PL, et al. **Methods Mol Biol** 1999;112:487–511 (28 ref.)
Characterizing proteins from 2-DE gels by internal sequence analysis of peptide fragments. Strategies for microsample handling. Erdjument-Bromage H, et al. **Methods Mol Biol** 1999;112:467–72 (10 ref.)

BIOSYNTHESIS

Presenilins and Alzheimer's disease: the role of A beta 42. Eckman CB. **J Neural Transm Suppl** 1998;53:181–4 (18 ref.)

CEREBROSPINAL FLUID

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. Galasko D. **J Neural Transm Suppl** 1998;53:209–21 (42 ref.)

CHEMISTRY

Structure and function of the core histone N-termini: more than meets the eye. Hansen JC, et al. **Biochemistry** 1998 Dec 22;37(51):17637–41 (58 ref.)
RNA recognition by arginine-rich peptide motifs. Weiss MA, et al. **Biopolymers** 1998;48(2–3):167–80 (71 ref.)
Peptide ligation and its application to protein engineering. Cotton GJ, et al. **Chem Biol** 1999 Sep;6(9):R247–56 (76 ref.)
Molecular simulation of the primary and secondary structures of the Abeta(1–42)-peptide of Alzheimer's disease. Mager PP. **Med Res Rev** 1998 Nov;18(6):403–30 (54 ref.)
Biochemistry of vasopressin fragments. Burbach JP, et al. **Prog Brain Res** 1998;119:127–36 (59 ref.)
Function and molecular basis of action of vasopressin 4–8 and its analogues in rat brain. Du YC, et al. **Prog Brain Res** 1998;119:163–75 (68 ref.)

IMMUNOLOGY

Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification. Nishimura Y, et al. **Intern Med** 1998 Oct;37(10):804–17 (96 ref.)
Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Gharavi AE, et al. **Lupus** 1998;7 Suppl 2:S52–4 (25 ref.)

METABOLISM

Haemorphin peptides may be endogenous ligands for brain angiotensin AT4 receptors. Moeller I, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S68–71 (45 ref.)
Metabolism of high density lipoprotein subfractions. Colvin PL, et al. **Curr Opin Lipidol** 1999 Aug;10(4):309–14 (33 ref.)
The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Storey E, et al. **Neuropathol Appl Neurobiol** 1999 Apr;25(2):81–97 (202 ref.)
Ilial transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Mason EE. **Obes Surg** 1999 Jun; 9(3):223–8 (35 ref.)
Biochemistry of vasopressin fragments. Burbach JP, et al. **Prog Brain Res** 1998;119:127–36 (59 ref.)
Vasopressin metabolites: a link between vasopressin and memory? Reijmers LG, et al. **Prog Brain Res** 1998; 119:523–35 (63 ref.)
Angiotensin-(1–7): a bioactive fragment of the renin-angiotensin system. Ferrario CM, et al. **Regul Pept** 1998 Nov 30;78(1–3):13–8 (67 ref.)

PHARMACOLOGY

Effect of the angiotensin-(1–7) peptide on nitric oxide release. Brosnihan KB. **Am J Cardiol** 1998 Nov 19;82(10A):17S–19S (12 ref.)
Journey beyond immunology. Regulation of receptor internalization by major histocompatibility complex class I (MHC-I) and effect of peptides derived from MHC-I. Stagsted J. **APMIS Suppl** 1998;85:1–40 (553 ref.)
Angiotensin-(1–7): a novel vasodilator of the coronary circulation. Brosnihan KB, et al. **Biol Res** 1998;31(3):227–34 (45 ref.)
Anti-adhesion cancer therapy. Glinsky GV. **Cancer Metastasis Rev** 1998 Jun;17(2):177–85 (58 ref.)
Angiotension-(1–7) and antihypertensive mechanisms. Ferrario CM. **J Nephrol** 1998 Nov-Dec;11(6):278–83 (71 ref.)
Effects of vasopressin and related peptides on neurons of the rat lateral septum and ventral hippocampus. Urban IJ. **Prog Brain Res** 1998;119:285–310 (168 ref.)

PHYSIOLOGY

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Nauck MA. **Acta Diabetol** 1998 Oct;35(3):117–29 (166 ref.)
Biology and functions of renal receptors for angiotensin II and its active fragments. Ardaillou R, et al. **Adv Nephrol Necker Hosp** 1998;28:225–57 (123 ref.)
Is there appetite after GLP-1 and PACAP? Christophe J. **Ann N Y Acad Sci** 1998 Dec 11;865:323–35 (88 ref.)
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)
Antihypertensive effects of angiotensin-(1–7). Chappell MC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1205–12 (51 ref.)
Is glucagon-like peptide 1 an incretin hormone? Nauck MA. **Diabetologia** 1999 Mar;42(3):373–9 (67 ref.)
Modular PH and C2 domains in membrane attachment and other functions. Katan M, et al. **FEBS Lett** 1999 Jun 4; 452(1–2):36–40 (61 ref.)
The role of A beta 42 in Alzheimer's disease. Younkin SG. **J Physiol Paris** 1998 Jun-Aug;92(3–4):289–92 (32 ref.)
Differential actions of angiotensin-(1–7) in the kidney. Chappell MC, et al. **Kidney Int Suppl** 1998 Dec;68:S3–6 (26 ref.)
Glucagon-like peptide-1 (7–36) amide as a novel neuropeptide. Blázquez E, et al. **Mol Neurobiol** 1998 Oct; 18(2):157–73 (80 ref.)
Fragments of functional proteins: role in endocrine regulation. Karelin AA, et al. **Neurochem Res** 1999 Sep; 24(9):1117–24 (55 ref.)
Function and molecular basis of action of vasopressin 4–8 and its analogues in rat brain. Du YC, et al. **Prog Brain Res** 1998;119:163–75 (68 ref.)
Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Cao Y. **Prog Mol Subcell Biol** 1998;20:161–76 (67 ref.)
Is Ps4 (prepro-TRH [160–169]) more than an enhancer for thyrotropin-releasing hormone? Pekary AE. **Thyroid** 1998 Oct;8(10):963–8 (41 ref.)

SECRETION

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Burcelin R, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:277–85 (42 ref.)

THERAPEUTIC USE

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Nauck MA. **Acta Diabetol** 1998 Oct;35(3):117–29 (166 ref.)
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Bates SM, et al. **Am J Cardiol** 1998 Oct 22; 82(8B):12P–18P (64 ref.)
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)
On the treatment of diabetes mellitus with glucagon-like peptide-1. Holst JJ, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:336–43 (37 ref.)
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)
Anti-adhesion cancer therapy. Glinsky GV. **Cancer Metastasis Rev** 1998 Jun;17(2):177–85 (58 ref.)
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links M, et al. **Drugs** 1999 Mar; 57(3):293–308 (94 ref.)
Therapeutic potentials of angiostatin in the treatment of cancer. Cao Y. **Haematologica** 1999 Jul;84(7):643–50 (45 ref.)
Regulating angiogenesis: a new therapeutic strategy. Gibaldi M. **J Clin Pharmacol** 1998 Oct;38(10):898–903 (23 ref.)
Potential applications of N-terminal recombinant fragments of bactericidal/permeability-increasing protein in liver surgery. Wiezer MJ, et al. **Liver Transpl Surg** 1999 Mar; 5(2):126–35 (107 ref.)
Mutated Ras peptides as vaccines in immunotherapy of cancer. Gjertsen MK, et al. **Vox Sang** 1998;74 Suppl 2:489–95 (49 ref.)
[GLP-1 (7–36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM] Gutniak M. **Journ Annu Diabetol Hotel Dieu** 1998;:157–71 (59 ref.) **(Fre)**
[Antiangiogenic therapy] Toi M. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2003–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

PEPTIDE HISTIDINE-ISOLEUCINE see **PEPTIDE PHI**

PEPTIDE HORMONE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE HYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE HYDROLASES

CHEMISTRY

Structure and functional analysis of the 26S proteasome subunits from plants. Fu H, et al. **Mol Biol Rep** 1999 Apr; 26(1–2):137–46 (30 ref.)
Assembly of the regulatory complex of the 26S proteasome. Gorbea C, et al. **Mol Biol Rep** 1999 Apr;26(1–2):15–9 (42 ref.)
Comparison of human COP9 signalsome and 26S proteasome lid. Henke W, et al. **Mol Biol Rep** 1999 Apr;26(1–2):29–34 (20 ref.)
[Structure and function of the yeast 26S proteasome] Tohe A. **Seikagaku** 1999 Mar;71(3):173–81 (51 ref.) **(Jpn)**

GENETICS

Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5. Mole SE, et al. **Hum Mutat** 1999;14(3):199–215 (81 ref.)

METABOLISM

D-amino acid hydrolysing enzymes. Yamada R, et al. **EXS** 1998;85:145–55 (35 ref.)
Phosphorylation of proteasomes in mammalian cells. Bose S, et al. **Mol Biol Rep** 1999 Apr;26(1–2):11–4 (25 ref.)
GFP-labelling of 26S proteasomes in living yeast: insight

into proteasomal functions at the nuclear envelope/rough ER. Enenkel C, et al. **Mol Biol Rep** 1999 Apr;26(1-2):131-5 (35 ref.)
Structure and functional analysis of the 26S proteasome subunits from plants. Fu H, et al. **Mol Biol Rep** 1999 Apr; 26(1-2):137-46 (30 ref.)
Assembly of the regulatory complex of the 26S proteasome. Gorbea C, et al. **Mol Biol Rep** 1999 Apr;26(1-2):15-9 (42 ref.)
Activator complexes containing the proteasomal regulatory ATPases S10b (SUG2) and S6(TBP1) in different tissues and organisms. Hastings R, et al. **Mol Biol Rep** 1999 Apr; 26(1-2):35-8 (12 ref.)
Comparison of human COP9 signalsome and 26S proteasome lid ! Henke W, et al. **Mol Biol Rep** 1999 Apr;26(1-2):29-34 (20 ref.)
[Fibrinolytic substances formation by cancer. Pathogenetic sequelae] Uszyński M. **Ginekol Pol** 1999 Feb;70(2):105-11 (18 ref.) (Eng. Abstr.) **(Pol)**
[Intracellular proteolysis] Staszczak M, et al. **Postepy Biochem** 1999;45(1):32-41 (95 ref.) **(Pol)**
[The role of proteolytic enzymes in apoptosis] Gacko M, et al. **Postepy Hig Med Dosw** 1998;52(6):601-19 (101 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

The ubiquitin-proteasome pathway and pathogenesis of human diseases. Schwartz AL, et al. **Annu Rev Med** 1999; 50:57-74 (79 ref.)
The cell biology of leukocyte-mediated proteolysis. Owen CA, et al. **J Leukoc Biol** 1999 Feb;65(2):137-50 (164 ref.)
The protease-antiprotease battle in the cystic fibrosis lung. Balfour-Lynn IM. **J R Soc Med** 1999;92 Suppl 37:23-30 (65 ref.)
[Structure and function of the yeast 26S proteasome] Tohe A. **Seikagaku** 1999 Mar;71(3):173-81 (51 ref.) **(Jpn)**

PEPTIDE INITIATION FACTOR EIF-2 see **EIF-2**

PEPTIDE INITIATION FACTORS

ANALYSIS

A fractionated reticulocyte lysate system for studies on protein synthesis initiation factors. Rau M, et al. **Methods Mol Biol** 1998;77:211-26 (24 ref.)

CHEMISTRY

Protein synthesis initiation factor 4G. Keiper BD, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):37-41 (16 ref.)
Translation initiation factor 4E. McKendrick L, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):31-5 (19 ref.)

GENETICS

eIF4E expression in tumors: its possible role in progression of malignancies. De Benedetti A, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):59-72 (105 ref.)
eIF4E activity is regulated at multiple levels. Raught B, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):43-57 (111 ref.)
Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Nathan CA, et al. **Laryngoscope** 1999 Aug;109(8):1253-8 (18 ref.)

METABOLISM

eIF4E expression in tumors: its possible role in progression of malignancies. De Benedetti A, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):59-72 (105 ref.)
Protein synthesis initiation factor 4G. Keiper BD, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):37-41 (16 ref.)
Translation initiation factor 4E. McKendrick L, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):31-5 (19 ref.)
eIF4E activity is regulated at multiple levels. Raught B, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):43-57 (111 ref.)

PEPTIDE LIBRARY

Catalyst discovery through combinatorial chemistry. Hoveyda AH. **Chem Biol** 1998 Aug;5(8):R187-91 (14 ref.)
Phage displayed peptide libraries. Cesareni G, et al. **Comb Chem High Throughput Screen** 1999 Feb;2(1):1-17 (171 ref.)
Combinatorial libraries: studies in molecular recognition. Nestler HP, et al. **Comb Chem High Throughput Screen** 1998 Oct;1(3):113-26 (129 ref.)
Epitope discovery using monoclonal antibodies and phage peptide libraries. Yip YL, et al. **Comb Chem High Throughput Screen** 1999 Jun;2(3):125-38 (148 ref.)
Phage-display technology--finding a needle in a vast molecular haystack. Rodi DJ, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):87-93 (64 ref.)
Biosynthetic polypeptide libraries. Shusta EV, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):117-22 (44 ref.)
Generation and screening of synthetic receptor libraries. de Miguel YR, et al. **Curr Opin Chem Biol** 1998 Jun; 2(3):417-21 (30 ref.)
Targeting growth factor and cytokine receptors with recombinant peptide libraries. Dower WJ. **Curr Opin Chem Biol** 1998 Jun;2(3):328-34 (35 ref.)
Combinatorial libraries of transition-metal complexes, catalysts and materials. Francis MB, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):422-8 (19 ref.)
Convergent peptide libraries, or mixotopes, to elicit or to identify specific immune responses. Gras-Masse H, et al. **Curr Opin Immunol** 1999 Apr;11(2):223-8 (48 ref.)
Exploring immunological specificity using synthetic peptide combinatorial libraries. Pinilla C, et al. **Curr Opin Immunol** 1999 Apr;11(2):193-202 (65 ref.)
Dynamic combinatorial chemistry: evolutionary formation and screening of molecular libraries. Eliseev AV, et al. **Curr Top Microbiol Immunol** 1999;243:159-72 (35 ref.)
In vitro selection methods for screening of peptide and protein libraries. Hanes J, et al. **Curr Top Microbiol Immunol** 1999;243:107-22 (38 ref.)
Phage display of combinatorial peptide and protein libraries and their applications in biology and chemistry. Johnsson K, et al. **Curr Top Microbiol Immunol** 1999;243:87-105 (100 ref.)
Peptide libraries in cellular immune recognition. Uebel S, et al. **Curr Top Microbiol Immunol** 1999;243:1-21 (92 ref.)
Mixture-based synthetic combinatorial libraries. Houghten RA, et al. **J Med Chem** 1999 Sep 23;42(19):3743-78 (187 ref.)
Identification of receptor ligands with phage display peptide libraries. Koivunen E, et al. **J Nucl Med** 1999 May; 40(5):883-8 (66 ref.)
The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. Hemmer B, et al. **J Pept Res** 1998 Nov;52(5):338-45 (42 ref.)
Coloured peptides: synthesis, properties and use in preparation of peptide sub-library kits. Sebestyén F, et al. **J Pept Sci** 1998 Jun;4(4):294-9 (24 ref.)
Peptide and peptidomimetic libraries. Molecular diversity and drug design. al-Obeidi F, et al. **Mol Biotechnol** 1998 Jun; 9(3):205-23 (59 ref.)
Advances in diversity profiling and combinatorial series design. Agrafiotis DK, et al. **Mol Divers** 1998-99;4(1):1-22 (77 ref.)
Analytical methods for quality control of combinatorial libraries. Fitch WL. **Mol Divers** 1998-99;4(1):39-45 (57 ref.)
Purification of combinatorial libraries. Weller HN. **Mol Divers** 1998-99;4(1):47-52 (27 ref.)
Vascular targeting with phage peptide libraries. Pasqualini R. **Q J Nucl Med** 1999 Jun;43(2):159-62 (43 ref.)
The emerging impact of phage display technology in thrombosis and haemostasis. Arza B, et al. **Thromb Haemost** 1998 Sep;80(3):354-65 (159 ref.)
Iterated profile searches with PSI-BLAST--a tool for discovery in protein databases. Altschul SF, et al. **Trends Biochem Sci** 1998 Nov;23(11):444-7 (30 ref.)
[Preparation of glyco-replica peptides which mimic functional roles of carbohydrates by using phage-displayed peptide library] Ishikawa D, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2611-7 (30 ref.) **(Jpn)**

PEPTIDE MAPPING

see related
PEPTIDE FRAGMENTS

METHODS

Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. Jensen ON, et al. **Methods Mol Biol** 1999;112:513-30 (56 ref.)
2-D phosphopeptide mapping. Nagahara H, et al. **Methods Mol Biol** 1999;112:271-9 (8 ref.)

TRENDS

Proteomics: quantitative and physical mapping of cellular proteins. Blackstock WP, et al. **Trends Biotechnol** 1999 Mar; 17(3):121-7 (44 ref.)

PEPTIDE NUCLEIC ACIDS

DNA biosensors based on peptide nucleic acid (PNA) recognition layers. A review. Wang J. **Biosens Bioelectron** 1998 Oct 1;13(7-8):757-62 (20 ref.)

CHEMISTRY

Applications of peptide nucleic acids. Nielsen PE. **Curr Opin Biotechnol** 1999 Feb;10(1):71-5 (47 ref.)
Peptide nucleic acids as therapeutic agents. Nielsen PE. **Curr Opin Struct Biol** 1999 Jun;9(3):353-7 (46 ref.)
[Stability and specificity of triplexes between a peptide-nucleic acid and DNA] Lazurkin IuS. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):94-9 (25 ref.) **(Rus)**

METABOLISM

Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function. Uhlmann E. **Biol Chem** 1998 Aug-Sep;379(8-9):1045-52 (45 ref.)

PHARMACOLOGY

Applications of peptide nucleic acids. Nielsen PE. **Curr Opin Biotechnol** 1999 Feb;10(1):71-5 (47 ref.)

THERAPEUTIC USE

Peptide nucleic acids as therapeutic agents. Nielsen PE. **Curr Opin Struct Biol** 1999 Jun;9(3):353-7 (46 ref.)

PEPTIDE PEPTIDOHYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE PEPTIDOHYDROLASES

Proteolytic targets in cell death. Watters D, et al. **Results Probl Cell Differ** 1998;24:25-44 (104 ref.)
[De-ubiquitinating enzyme: a large gene family] Suzuki T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):752-8 (18 ref.) **(Jpn)**

ANALYSIS

Membrane-bound cell surface peptidases in reproductive organs. Fujiwara H, et al. **Endocr J** 1999 Feb;46(1):11-25 (95 ref.)

CHEMISTRY

Endoproteinase-protein inhibitor interactions. Bode W, et al. **APMIS** 1999 Jan;107(1):3-10 (40 ref.)
Snake venom hemorrhagins. Hati R, et al. **Crit Rev Toxicol** 1999 Jan;29(1):1-19 (142 ref.)
The structures of picornaviral proteinases. Seipelt J, et al. **Virus Res** 1999 Aug;62(2):159-68 (60 ref.)
[Strategies for identification of secretases implicated in Alzheimer's disease] Marambaud P, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):277-84 (21 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Proteases of protozoan parasites. Rosenthal PJ. **Adv Parasitol** 1999;43:105-59 (270 ref.)

DEFICIENCY

Human genetic diseases of proteolysis. Kato GJ. **Hum Mutat** 1999;13(2):87-98 (99 ref.)

DRUG EFFECTS

Serine proteinase inhibitors in arthropod immunity. Kanost MR. **Dev Comp Immunol** 1999 Jun-Jul;23(4-5):291-301 (74 ref.)
Vipera palaestinae antivenin. Moroz C. **Public Health Rev** 1998;26(3):233-6 (8 ref.)

GENETICS

Proteinases and associated genes of parasitic helminths. Tort J, et al. **Adv Parasitol** 1999;43:161-266 (300 ref.)
Human genetic diseases of proteolysis. Kato GJ. **Hum Mutat** 1999;13(2):87-98 (99 ref.)

IMMUNOLOGY

Mite allergens: significance of enzymatic activity. Hewitt CR, et al. **Allergy** 1998;53(48 Suppl):60-3 (15 ref.)

METABOLISM

Proteases of protozoan parasites. Rosenthal PJ. **Adv Parasitol** 1999;43:105-59 (270 ref.)
Proteinases and associated genes of parasitic helminths. Tort J, et al. **Adv Parasitol** 1999;43:161-266 (300 ref.)
Mite allergens: significance of enzymatic activity. Hewitt CR, et al. **Allergy** 1998;53(48 Suppl):60-3 (15 ref.)
Enzymatic resolution of amino acids via ester hydrolysis. Miyazawa T. **Amino Acids** 1999;16(3-4):191-213 (88 ref.)
Proteases in cutaneous melanoma. Ferrier CM, et al. **Ann Med** 1998 Oct;30(5):431-42 (86 ref.)
The ubiquitin system. Hershko A, et al. **Annu Rev Biochem** 1998;67:425-79 (298 ref.)
Proteinase-activated receptors: a growing family of heptahelical receptors for thrombin, trypsin and tryptase. Déry O, et al. **Biochem Soc Trans** 1999 Feb;27(2):246-54 (50 ref.)
Angiotensin-converting enzyme and the amyloid precursor protein secretases. Hooper NM, et al. **Biochem Soc Trans** 1999 Feb;27(2):229-34 (31 ref.)
Mechanisms controlling the shedding of transmembrane molecules. Merlos-Suárez A, et al. **Biochem Soc Trans** 1999 Feb;27(2):243-6 (14 ref.)
Proteolytic processing and degradation of Alzheimer's disease relevant proteins. Steiner H, et al. **Biochem Soc Trans** 1999 Feb;27(2):234-42 (72 ref.)
Characterization of beta-secretase. Stephens DJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):500-4 (21 ref.)
Role for ADAM-family proteinases as membrane protein secretases. Turner AJ, et al. **Biochem Soc Trans** 1999 Feb; 27(2):255-9 (34 ref.)
Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Wolfe MS, et al. **Biochemistry** 1999 Aug 31; 38(35):11223-30 (81 ref.)
Extracellular proteolytic enzymes of filamentous fungi. Pavlukova EB, et al. **Biochemistry (Mosc)** 1998 Aug; 63(8):899-928 (203 ref.)
Inhibition of extracellular matrix-degrading endopeptidases: problems, comments, and hypotheses. Baici A. **Biol Chem** 1998 Aug-Sep;379(8-9):1007-18 (109 ref.)
Proteases as prognostic markers in cancer. Duffy MJ. **Clin Cancer Res** 1996 Apr;2(4):613-8 (73 ref.)
Regulation by proteolysis: developmental switches. Gottesman S. **Curr Opin Microbiol** 1999 Apr;2(2):142-7 (76 ref.)

Proteolysis and chaperones: the destruction/reconstruction dilemma. Herman C, et al. **Curr Opin Microbiol** 1998 Apr; 1(2):204–9 (61 ref.)
The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part IV: can calpain act as alpha-secretase? Chen M, et al. **Front Biosci** 1998 Dec 15; 3:A66–75 (79 ref.)
Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Maile LA, et al. **Growth Horm IGF Res** 1999 Apr; 9(2):85–95 (81 ref.)
Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Herouy Y, et al. **Int J Mol Med** 1999 May; 3(5):511–5 (25 ref.)
Proteolytic processing of Alzheimer's disease associated proteins. Haass C, et al. **J Neural Transm Suppl** 1998; 53:159–67 (39 ref.)
Contribution of muscle proteinases to meat tenderization. Jiang ST. **Proc Natl Sci Counc Repub China B** 1998 Jul; 22(3):97–107 (102 ref.)
Implications of decidualization-associated protease expression in implantation and menstruation. Schatz F, et al. **Semin Reprod Endocrinol** 1999;17(1):3–12 (49 ref.)
Apoptosis: cell death by proteolytic scalpel. Behrns KE, et al. **Surgery** 1999 Sep;126(3):463–8 (10 ref.)
Limited proteolysis and physiological regulation: an example from thyrotropin-releasing hormone metabolism. Prasad C. **Thyroid** 1998 Oct;8(10):969–75 (90 ref.)
Tripeptidyl peptidases: enzymes that count. Tomkinson B. **Trends Biochem Sci** 1999 Sep;24(9):355–9 (31 ref.)
Proteasome inhibitors: valuable new tools for cell biologists. Lee DH, et al. **Trends Cell Biol** 1998 Oct;8(10):397–403 (49 ref.)
Signal transduction by a protease cascade. LeMosy EK, et al. **Trends Cell Biol** 1999 Mar;9(3):102–7 (36 ref.)
Proteasomes and other self-compartmentalizing proteases in prokaryotes. De Mot R, et al. **Trends Microbiol** 1999 Feb; 7(2):88–92 (33 ref.)
[Extracellular proteases of stromal origin: contribution to tumor progression and therapeutic perspectives] Rio MC, et al. **C R Seances Soc Biol Fil** 1998;192(2):253–9 (21 ref.) (Eng. Abstr.) **(Fre)**
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer] Herszényi L, et al. **Orv Hetil** 1999 Aug 15;140(33):1833–6 (48 ref.) (Eng. Abstr.) **(Hun)**
[A role of heat-shock proteases in removal of denatured proteins from E. coli cells] Laskowska E, et al. **Postepy Biochem** 1998;44(4):334–44 (126 ref.) **(Pol)**
[Mastocyte proteinase] Olejnik AK, et al. **Postepy Hig Med Dosw** 1998;52(4):381–99 (86 ref.) (Eng. Abstr.) **(Pol)**
[Antiproteases in the pathogenesis of neoplastic diseases] Dąbrowska M. **Przegl Lek** 1998;55(9):475–9 (65 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. Danø K, et al. **APMIS** 1999 Jan;107(1):120–7 (102 ref.)
Involvement of proteases in apoptosis. Kutsyi MP, et al. **Biochemistry (Mosc)** 1999 Feb;64(2):115–26 (163 ref.)
Cathepsins as effector proteases in hepatocyte apoptosis. Roberts LR, et al. **Cell Biochem Biophys** 1999;30(1):71–88 (43 ref.)
Emerging roles for proteinases in cancer. Noël A, et al. **Invasion Metastasis** 1997;17(5):221–39 (103 ref.)
The ubiquitin-proteasome system and endocytosis. Strous GJ, et al. **J Cell Sci** 1999 May;112 (Pt 10):1417–23 (80 ref.)
Virus-encoded proteinases of the Togaviridae. ten Dam E, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1879–88 (72 ref.)
Cellular proteinases trigger the infectivity of the influenza A and Sendai viruses. Kido H, et al. **Mol Cells** 1999 Jun 30;9(3):235–44 (37 ref.)
Physiological roles of placental proteases in feto-placental homeostasis. Mizutani S. **Nagoya J Med Sci** 1998 Oct; 61(3–4):85–95 (73 ref.)
Kidney ectopeptidases. Structure, functions and clinical significance. Vlahović P, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):779–86 (80 ref.)
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Brown MS, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11041–8 (60 ref.)
Role of proteases in implantation. Salamonsen LA. **Rev Reprod** 1999 Jan;4(1):11–22 (98 ref.)
[Role of protease activation in pathophysiology of acute pancreatitis] Lerch MM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:421–6 (5 ref.) (Eng. Abstr.) **(Ger)**
[Brain proteinase activity and the mobilization of endogenous proteolytic inhibitors as factors in the development of the functional state of the body] Gurin VN, et al. **Fiziol Cheloveka** 1999 Jan–Feb;25(1):71–7 (36 ref.) **(Rus)**

PEPTIDE PHI

ANALYSIS

Vipergic innervation of the mammalian pineal gland. Cozzi B. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):257–64 (109 ref.)

PEPTIDE PHM see **PEPTIDE PHI**

PEPTIDE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE RECEPTORS, INVERTEBRATE see **RECEPTORS, INVERTEBRATE PEPTIDE**

PEPTIDE SYNTHASES

CHEMISTRY

Design and application of multimodular peptide synthetases. Mootz HD, et al. **Curr Opin Biotechnol** 1999 Aug; 10(4):341–8 (53 ref.)

METABOLISM

How do peptide synthetases generate structural diversity? Konz D, et al. **Chem Biol** 1999 Feb;6(2):R39–48 (68 ref.)
A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Maniatis T. **Genes Dev** 1999 Mar 1;13(5):505–10 (38 ref.)

PEPTIDE SYNTHESIS

see related
TRANSLATION, GENETIC

Solution-phase combinatorial chemistry. Coe DM, et al. **Mol Divers** 1998–99;4(1):31–8 (32 ref.)
New developments in solid phase synthesis supports. Sucholeiki I. **Mol Divers** 1998–99;4(1):25–30 (22 ref.)
Enzymatic formation of C-terminal amides. Kulathila R, et al. **Nat Prod Rep** 1999 Apr;16(2):145–54 (102 ref.)

PHYSIOLOGY

How do peptide synthetases generate structural diversity? Konz D, et al. **Chem Biol** 1999 Feb;6(2):R39–48 (68 ref.)

PEPTIDE SYNTHETASES see **PEPTIDE SYNTHASES**

PEPTIDE TERMINATION FACTORS

GENETICS

Termination of translation in eukaryotes: new results and new hypotheses. Kisselev LL, et al. **Biochemistry (Mosc)** 1999 Jan;64(1):8–16 (49 ref.)

METABOLISM

Initiation factors of protein biosynthesis in bacteria and their structural relationship to elongation and termination factors. Brock S, et al. **Mol Microbiol** 1998 Jul;29(2):409–17 (34 ref.)

PEPTIDE YY

ANALYSIS

Expression of non-classical islet hormone-like peptides during the embryonic development of the pancreas. Mulder H, et al. **Microsc Res Tech** 1998 Nov 15;43(4):313–21 (70 ref.)

PEPTIDES

see related
AMINO ACID SEQUENCE

Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Paulson HL. **Am J Hum Genet** 1999 Feb;64(2):339–45 (37 ref.)
Croxatto's fifty-year pursuit: from pepsanurin to the discovery of a new kininogen-derived peptide (PU-D1). Boric MP, et al. **Biol Res** 1998;31(3):117–29 (95 ref.)
MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Cunha-Neto E. **Braz J Med Biol Res** 1999 Feb; 32(2):199–205 (45 ref.)
Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Lin KC, et al. **Curr Opin Chem Biol** 1998 Aug; 2(4):453–7 (22 ref.)
Peptidomimetic design. Ripka AS, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):441–52 (65 ref.)
In vitro selection of peptides acting on NMDA receptors. Cwirla SE, et al. **Methods Mol Biol** 1999;128:131–41 (4 ref.)
Antibiotic peptides from higher eukaryotes: biology and applications. Ganz T, et al. **Mol Med Today** 1999 Jul; 5(7):292–7 (42 ref.)
The 'chicken and egg' problem of co-evolution of peptides and their cognate receptors: which came first? Darlison MG, et al. **Results Probl Cell Differ** 1999;26:1–11 (33 ref.)
[Adrenomedullin. A new peptide involved in the regulation of the cardiovascular system] Letizia C, et al. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):407–11 (37 ref.) (Eng. Abstr.) **(Ita)**
[Assay of protein phosphatase activities with phosphopeptide-magnetic bead conjugates] Kameshita I, et al. **Seikagaku** 1998 Nov;70(11):1360–3 (6 ref.) **(Jpn)**
[Preparation of glyco-replica peptides which mimic functional roles of carbohydrates by using phage-displayed peptide library] Ishikawa D, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2611–7 (30 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Prodrug approaches to the improved delivery of peptide drugs. Wang W, et al. **Curr Pharm Des** 1999 Apr; 5(4):265–87 (168 ref.)
Controlled release opportunities for oral peptide delivery in aquaculture. Schep LJ, et al. **J Controlled Release** 1999 May 1;59(1):1–14 (101 ref.)
Transdermal iontophoresis. Part II: Peptide and protein delivery. Pillai O, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr;21(3):229–40 (119 ref.)
Peptide drug delivery into the central nervous system. Prokai L. **Prog Drug Res** 1998;51:95–131 (108 ref.)

ANALYSIS

Separation and analysis of peptides and proteins. Larive CK, et al. **Anal Chem** 1999 Jun 15;71(12):389R–423R (80 ref.)
C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction. Giannobile WV. **Ann N Y Acad Sci** 1999 Jun 30;878:404–12 (24 ref.)
Bone markers in clinical practice. Souberbielle JC, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):312–9 (59 ref.)
High sensitivity analysis of proteins and peptides by capillary electrophoresis-tandem mass spectrometry: recent developments in technology and applications. Figeys D, et al. **Electrophoresis** 1998 May;19(6):885–92 (126 ref.)
Ultramicroanalysis of peptide profiles in biological samples using MALDI mass spectrometry. Jiménez CR, et al. **Exp Nephrol** 1998 Sep–Oct;6(5):421–8 (26 ref.)
Capillary electrophoresis of peptides and proteins in acidic, isoelectric buffers: recent developments. Righetti PG, et al. **J Biochem Biophys Methods** 1999 Jul 28;40(1–2):1–15 (29 ref.)
Analysis of lipophilic peptides and therapeutic drugs: on-line-nonaqueous capillary electrophoresis-mass spectrometry. Yang Q, et al. **J Biochem Biophys Methods** 1999 Jan 29;38(2):103–21 (49 ref.)
New information about gastrointestinal adrenomedullin [editorial; comment] Yoshikawa T. **J Gastroenterol** 1998 Dec;33(6):918–9 (8 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):828–34.
Identification of proteins by matrix-assisted laser desorption/ionization mass spectrometry using peptide and fragment ion masses. Courchesne PL, et al. **Methods Mol Biol** 1999;112:487–511 (28 ref.)
Peptide sequencing of 2-DE gel-isolated proteins by nanoelectrospray tandem mass spectrometry. Jensen ON, et al. **Methods Mol Biol** 1999;112:571–88 (34 ref.)

BLOOD

TPS monitoring in metastatic breast cancer. van Dalen A. **Int J Biol Markers** 1999 Jan–Mar;14(1):45–8 (21 ref.)
Biochemical markers of bone metabolism in horses: potentials and limitations? [editorial; comment] Price JS. **Vet J** 1998 Nov;156(3):163–5 (16 ref.) Comment on: Vet J 1998 Nov;156(3):169–75.

CHEMICAL SYNTHESIS

From beta-lactams to alpha- and beta-amino acid derived peptides. Palomo C, et al. **Amino Acids** 1999;16(3–4):321–43 (94 ref.)
Generation and screening of synthetic receptor libraries. de Miguel YR, et al. **Curr Opin Chem Biol** 1998 Jun; 2(3):417–21 (30 ref.)
Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives. Deghenghi R. **J Endocrinol Invest** 1998 Dec;21(11):787–93 (47 ref.)
From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins. Krebs S, et al. **Pharm Acta Helv** 1998 Dec;73(4):173–81 (53 ref.)
[Photo-activatable caged peptides and proteins] Tatsu Y, et al. **Seikagaku** 1999 Mar;71(3):197–201 (15 ref.) **(Jpn)**
[Peptide synthesis aiming at elucidation and creation of protein functions] Futaki S. **Yakugaku Zasshi** 1998 Nov; 118(11):493–510 (46 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Solid-state nuclear magnetic resonance investigation of protein and polypeptide structure. Fu R, et al. **Annu Rev Biophys Biomol Struct** 1999;28:235–68 (113 ref.)
Nitroxide spin-spin interactions: applications to protein structure and dynamics. Hustedt EJ, et al. **Annu Rev Biophys Biomol Struct** 1999;28:129–53 (71 ref.)
Helical structure and dynamics in membrane polypeptides. Dempsey CE, et al. **Biochem Soc Trans** 1998 Aug; 26(3):444–50 (37 ref.)
Peptide ligation and its application to protein engineering. Cotton GJ, et al. **Chem Biol** 1999 Sep;6(9):R247–56 (76 ref.)
How do peptide synthetases generate structural diversity? Konz D, et al. **Chem Biol** 1999 Feb;6(2):R39–48 (68 ref.)
Generation and screening of synthetic receptor libraries. de Miguel YR, et al. **Curr Opin Chem Biol** 1998 Jun;

2(3):417-21 (30 ref.)
Adaptive recognition in RNA complexes with peptides and protein modules. Patel DJ. **Curr Opin Struct Biol** 1999 Feb; 9(1):74-87 (59 ref.)
Polypeptide neurotoxins from spider venoms. Grishin E. **Eur J Biochem** 1999 Sep;264(2):276-80 (39 ref.)
Scorpion toxins specific for Na+-channels. Possani LD, et al. **Eur J Biochem** 1999 Sep;264(2):287-300 (156 ref.)
Occurrence and function of D-amino acid-containing peptides and proteins: antimicrobial peptides. Mignogna G, et al. **EXS** 1998;85:29-36 (26 ref.)
The dermaseptin precursors: a protein family with a common preproregion and a variable C-terminal antimicrobial domain. Amiche M, et al. **FEBS Lett** 1999 Aug 13; 456(3):352-6 (53 ref.)
Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Collins EJ, et al. **Immunol Rev** 1998 Jun;163:151-60 (66 ref.)
Structural and functional evolution of the natriuretic peptide system in vertebrates. Takei Y. **Int Rev Cytol** 2000;194:1-66 (343 ref.)
Peptide and protein identification by matrix-assisted laser desorption ionization (MALDI) and MALDI-post-source decay time-of-flight mass spectrometry. Chaurand P, et al. **J Am Soc Mass Spectrom** 1999 Feb;10(2):91-103 (67 ref.)
Analytical techniques and computer algorithms combined for the rapid characterization of structural peptide and protein features. Caporale C. **J Pept Res** 1998 Nov;52(5):421-9 (52 ref.)
Coloured peptides: synthesis, properties and use in preparation of peptide sub-library kits. Sebestyén F, et al. **J Pept Sci** 1998 Jun;4(4):294-9 (24 ref.)
Peptide and glycopeptide dendrimers. Part II. Veprek P, et al. **J Pept Sci** 1999 May;5(5):203-20 (154 ref.)
Solid-state chemical stability of proteins and peptides. Lai MC, et al. **J Pharm Sci** 1999 May;88(5):489-500 (81 ref.)
Charge derivatization of peptides for analysis by mass spectrometry. Roth KD, et al. **Mass Spectrom Rev** 1998 Jul-Aug;17(4):255-74 (73 ref.)
Ab initio characterization of building units in peptides and proteins. Császár AG, et al. **Prog Biophys Mol Biol** 1999; 71(2):243-309 (300 ref.)
Polypeptides from phage display. A superior source of in vivo imaging agents. Ladner RC. **Q J Nucl Med** 1999 Jun; 43(2):119-24 (44 ref.)
Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Buck M. **Q Rev Biophys** 1998 Aug;31(3):297-355 (263 ref.)
Is protein folding hierarchic? I. Local structure and peptide folding. Baldwin RL, et al. **Trends Biochem Sci** 1999 Jan; 24(1):26-33 (46 ref.)
[Protein and peptide construction for delivery of oligonucleotides and DNA into the cell] Pozmogova GE, et al. **Vopr Med Khim** 1998 Jul-Aug;44(4):331-7 (46 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Orthotopic cardiac transplantation after minimally invasive direct coronary artery bypass. Reardon MJ, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):390-1 (9 ref.)

GENETICS

Transgenic mice in the study of polyglutamine repeat expansion diseases. Bates GP, et al. **Brain Pathol** 1998 Oct; 8(4):699-714 (53 ref.)
Epitope discovery using monoclonal antibodies and phage peptide libraries. Yip YL, et al. **Comb Chem High Throughput Screen** 1999 Jun;2(3):125-38 (148 ref.)
Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? Rubinsztein DC, et al. **J Med Genet** 1999 Apr;36(4):265-70 (40 ref.)
Pathogenesis of polyglutamine-induced disease: A model for SCA1. Klement IA, et al. **Mol Genet Metab** 1999 Mar; 66(3):172-8 (38 ref.)
Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Lunkes A, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1013-9 (38 ref.)
CAG-polyglutamine-repeat mutations: independence from gene context. Ordway JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1083-8 (34 ref.)
Polyglutamine pathogenesis. Ross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1005-11 (82 ref.)
Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions. Ross CA, et al. **Prog Brain Res** 1998;117:397-419 (160 ref.)

IMMUNOLOGY

Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules. Unanue ER. **Am J Pathol** 1999 Mar;154(3):651-64 (75 ref.)
Degradation of cell proteins and the generation of MHC class I-presented peptides. Rock KL, et al. **Annu Rev Immunol** 1999;17:739-79 (211 ref.)
The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Murray K, et al. **Biol Chem** 1999 Mar;380(3):277-83 (37 ref.)
Liposomes: from biophysics to the design of peptide vaccines. Frézard F. **Braz J Med Biol Res** 1999 Feb;32(2):181-9 (37 ref.)
An accessory peptide binding site with allosteric effect on the formation of peptide-MHC-II complexes? Gerlier D, et al. **C R Acad Sci III** 1998 Jan;321(1):19-24 (23 ref.)
Convergent peptide libraries, or mixotopes, to elicit or to identify specific immune responses. Gras-Masse H, et al. **Curr Opin Immunol** 1999 Apr;11(2):223-8 (48 ref.)
HLA-peptide tetrameric complexes. Ogg GS, et al. **Curr Opin Immunol** 1998 Aug;10(4):393-6 (18 ref.)
Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Qiu J, et al. **Hybridoma** 1999 Feb;18(1):103-12 (59 ref.)
Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Collins EJ, et al. **Immunol Rev** 1998 Jun;163:151-60 (66 ref.)
Glimpses at the recognition of peptide/MHC complexes by T-cell antigen receptors. Mazza G, et al. **Immunol Rev** 1998 Jun;163:187-96 (34 ref.)
Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases. Nishimura Y, et al. **Int Rev Immunol** 1998;17(5-6):229-62 (82 ref.)
Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. Apostolopoulos V, et al. **J Mol Med** 1999 May;77(5):427-36 (57 ref.)
The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. Hemmer B, et al. **J Pept Res** 1998 Nov;52(5):338-45 (42 ref.)
Heat shock protein--peptide complexes as immunotherapy for human cancer. Przepiorka D, et al. **Mol Med Today** 1998 Nov;4(11):478-84 (48 ref.)
Antimicrobial peptides as mediators of epithelial host defense. Huttner KM, et al. **Pediatr Res** 1999 Jun;45(6):785-94 (192 ref.)
From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins. Krebs S, et al. **Pharm Acta Helv** 1998 Dec;73(4):173-81 (53 ref.)

ISOLATION & PURIFICATION

Purification of combinatorial libraries. Weller HN. **Mol Divers** 1998-99;4(1):47-52 (27 ref.)

METABOLISM

Degradation of cell proteins and the generation of MHC class I-presented peptides. Rock KL, et al. **Annu Rev Immunol** 1999;17:739-79 (211 ref.)
Polyglutamine expansion and Huntington's disease. Bates GP, et al. **Biochem Soc Trans** 1998 Aug;26(3):471-5 (38 ref.)
Peptide metabolism in cytoplasm of brain cells. O'Cuinn G. **Biochem Soc Trans** 1998 Aug;26(3):279-92 (129 ref.)
Trefoil peptides and surgical disease. Longman RJ, et al. **Br J Surg** 1999 Jun;86(6):740-8 (69 ref.)
Apoptosis: Ras to the rescue in the fly eye. McNeill H, et al. **Curr Biol** 1999 Mar 11;9(5):R176-9 (16 ref.)
Nonpeptidic ligands for peptide and protein receptors. Freidinger RM. **Curr Opin Chem Biol** 1999 Aug; 3(4):395-406 (51 ref.)
Noninvasive intracellular delivery of functional peptides and proteins. Hawiger J. **Curr Opin Chem Biol** 1999 Feb; 3(1):89-94 (31 ref.)
Description and prediction of peptide-MHC binding: the 'human MHC project'. Buus S. **Curr Opin Immunol** 1999 Apr;11(2):209-13 (47 ref.)
Signal transduction cascades regulating mating, filamentation, and virulence in Cryptococcus neoformans. Wang P, et al. **Curr Opin Microbiol** 1999 Aug;2(4):358-62 (33 ref.)
Plants embrace a stepchild: the discovery of peptide growth regulators. Franssen HJ. **Curr Opin Plant Biol** 1998 Oct; 1(5):384-7 (37 ref.)
Adaptive recognition in RNA complexes with peptides and protein modules. Patel DJ. **Curr Opin Struct Biol** 1999 Feb; 9(1):74-87 (59 ref.)
Biosynthesis of D-amino acid-containing peptides: exploring the role of peptide isomerases. Volkmann RA, et al. **EXS** 1998;85:87-105 (65 ref.)
D-amino acid hydrolysing enzymes. Yamada R, et al. **EXS** 1998;85:145-55 (35 ref.)
New peptides, hormones and parturition. Di Iorio R, et al. **Gynecol Endocrinol** 1998 Dec;12(6):429-34 (28 ref.)
Analytical techniques used to study the degradation of proteins and peptides: chemical instability. Reubsaet JL, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):955-78 (96 ref.)
Analytical techniques used to study the degradation of proteins and peptides: physical instability. Reubsaet JL, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):979-84 (44 ref.)
Measurement of [3H]PN200-110 and [125I]omega-conotoxin MVIIA binding. Hirota K, et al. **Methods Mol Biol** 1999; 114:149-61 (20 ref.)
Fluorescence measurement of lipid-binding affinity and interbilayer transfer of bimane-labeled lipidated peptides. Silvius JR. **Methods Mol Biol** 1999;116:177-86 (13 ref.)
Determination of the kinetics of intervesicle transfer and transbilayer diffusion of bimane-labeled lipidated peptides. Silvius JR. **Methods Mol Biol** 1999;116:187-91 (2 ref.)
Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Nir S, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):95-101 (36 ref.)
Peptide modulators of protein-protein interactions in intracellular signaling. Souroujon MC, et al. **Nat Biotechnol** 1998 Oct;16(10):919-24 (50 ref.)
Thiazole and oxazole peptides: biosynthesis and molecular machinery. Roy RS, et al. **Nat Prod Rep** 1999 Apr; 16(2):249-63 (124 ref.)
Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Forte LR. **Regul Pept** 1999 May 31;81(1-3):25-39 (109 ref.)
[Two recent topics in ribosome research] Endo Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2199-205 (22 ref.) **(Jpn)**

PHARMACOKINETICS

Prodrug approaches to the improved delivery of peptide drugs. Wang W, et al. **Curr Pharm Des** 1999 Apr; 5(4):265-87 (168 ref.)
Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. Marttin E, et al. **J Drug Target** 1998; 6(1):17-36 (98 ref.)
Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. Wacher VJ, et al. **J Pharm Sci** 1998 Nov;87(11):1322-30 (83 ref.)
Peptide drug delivery into the central nervous system. Prokai L. **Prog Drug Res** 1998;51:95-131 (108 ref.)

PHARMACOLOGY

Thymic peptides and preparations: an update. Cordero OJ, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):77-82 (40 ref.)
Magainins as paradigm for the mode of action of pore forming polypeptides. Matsuzaki K. **Biochim Biophys Acta** 1998 Nov 10;1376(3):391-400 (90 ref.)
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists. Kleiman NS. **Coron Artery Dis** 1998;9(9):603-16 (104 ref.)
Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland. Evans JJ. **Endocr Rev** 1999 Feb; 20(1):46-67 (322 ref.)
Interactions between presynaptic calcium channels and proteins implicated in synaptic vesicle trafficking and exocytosis. Seagar M, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):347-56 (58 ref.)
Metabolism and trafficking of N-type voltage-operated calcium channels in neurosecretory cells. Sher E, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):399-407 (110 ref.)
Database of biologically active peptide sequences. Dziuba J, et al. **Nahrung** 1999 Jun;43(3):190-5 (89 ref.)
Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Buku A. **Peptides** 1999; 20(3):415-20 (39 ref.)
Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action. Gonser S, et al. **Pharm Acta Helv** 1999 Jun; 73(6):265-73 (82 ref.)
Neurohumoral fluid regulation in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):361-72 (107 ref.)
Adrenomedullin in sepsis and septic shock [editorial; comment] Wang P. **Shock** 1998 Nov;10(5):383-4 (23 ref.) Comment on: Shock 1998 Jan;9(1):1-11. Comment on: Shock 1998 Aug;10(2):79-89. Comment on: Shock 1998 Aug;10(2):118-22. Comment on: Shock 1998 Oct;10(4):243-7.
Oncostatin M: development of a pleiotropic cytokine. Loy JK, et al. **Toxicol Pathol** 1999 Mar-Apr;27(2):151-5 (36 ref.)
[Adrenomedullin and lung disease] Li Q, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Apr; 20(2):109-11 (18 ref.) **(Chi)**
[Regulation of immune processes by peptides of natural origin] Besednova NN. **Antibiot Khimioter** 1999;44(1):31-5 (56 ref.) **(Rus)**

PHYSIOLOGY

The role of adrenomedullin. Charles CJ, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):166-73 (99 ref.)
Adrenomedullin and the control of fluid and electrolyte homeostasis. Samson WK. **Annu Rev Physiol** 1999; 61:363-89 (139 ref.)
Prolactin and prolactin-like polypeptides in rheumatoid arthritis. Neidhart M, et al. **Biomed Pharmacother** 1999 Jun; 53(5-6):218-22 (44 ref.)
Transgenic animal models for the functional analysis of vasoactive peptides. Bader M. **Braz J Med Biol Res** 1998 Sep;31(9):1171-83 (126 ref.)
Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases. Eto T, et al. **Clin Exp Pharmacol Physiol** 1999 May-Jun;26(5-6):371-80 (87 ref.)
T-cell development: a role for self-peptides in positive selection. Janeway CA Jr. **Curr Biol** 1999 May 6; 9(9):R342-5 (24 ref.)
Nutrient regulation of intestinal growth and adaptation: role of glucagon-like peptide 2 and the enteroendocrine cell [editorial; comment] Rubin DC. **Gastroenterology** 1999 Jul; 117(1):261-3 (39 ref.) Comment on: Gastroenterology 1999 Jul;117(1):99-105.
Trefoil peptides. Wong WM, et al. **Gut** 1999 Jun;44(6):890-5 (88 ref.)

Viral modulation of the host response via crmA/SPI-2 expression. Turner S, et al. **Immunol Cell Biol** 1999 Jun; 77(3):236-41 (88 ref.)
Role of activin and other peptide growth factors in body patterning in the early amphibian embryo. Asashima M, et al. **Int Rev Cytol** 1999;191:1-52 (171 ref.)
Structural and functional evolution of the natriuretic peptide system in vertebrates. Takei Y. **Int Rev Cytol** 2000;194:1-66 (343 ref.)
Peptides and membrane fusion: towards an understanding of the molecular mechanism of protein-induced fusion. Pécheur EI, et al. **J Membr Biol** 1999 Jan 1;167(1):1-17 (120 ref.)
Oligopeptide signalling and the action of systemin. Schaller A. **Plant Mol Biol** 1999 Jul;40(5):763-9 (17 ref.)
Growth-inhibiting N-substituted endogenous peptides. Elgjo K, et al. **Prog Mol Subcell Biol** 1998;20:143-59 (81 ref.)
Peptides and peptic ulceration. Playford RJ, et al. **QJM** 1998 Oct;91(10):661-5 (22 ref.)
The role of peptide presentation in the physiological function of HLA-G. Münz C, et al. **Semin Cancer Biol** 1999 Feb; 9(1):47-54 (35 ref.)
Adrenomedullin in sepsis and septic shock [editorial; comment] Wang P. **Shock** 1998 Nov;10(5):383-4 (23 ref.) Comment on: Shock 1998 Jan;9(1):1-11. Comment on: Shock 1998 Aug;10(2):79-89. Comment on: Shock 1998 Aug;10(2):118-22. Comment on: Shock 1998 Oct;10(4):243-7.
[Guanylin family: new intestinal peptides regulating salt and water homeostasis] Date Y, et al. **Nippon Rinsho** 1998 Sep; 56(9):2427-32 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Adrenomedullin and related peptides] Kitamura K. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):137-46 (50 ref.) (Eng. Abstr.) **(Jpn)**
[Adrenomedullin] Bełtowski J. **Postepy Hig Med Dosw** 1999; 53(1):99-123 (124 ref.) (Eng. Abstr.) **(Pol)**
[Current opinions about the role of peptide C in the human organism] Zdrojewicz Z, et al. **Postepy Hig Med Dosw** 1998;52(3):269-81 (47 ref.) (Eng. Abstr.) **(Pol)**
[Invertors--intracellular regulators of plasma membrane function] Frol'kis VV. **Fiziol Zh** 1999;45(1-2):6-15 (31 ref.) (Eng. Abstr.) **(Rus)**
[Peptide mediators in adrenal chromaffin cells: regulation of catecholamine selective secretion] Gomazkov OA, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):1139-45 (30 ref.) (Eng. Abstr.) **(Rus)**
[The peptide-dependent mechanisms of long-term posttetanic potentiation (the facts and a hypothesis)] Mokrushin AA, et al. **Usp Fiziol Nauk** 1999 Jan-Mar; 30(1):3-28 (294 ref.) (Eng. Abstr.) **(Rus)**
[Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation] Pastorova VE, et al. **Usp Fiziol Nauk** 1999 Apr-Jun;30(2):80-91 (66 ref.) (Eng. Abstr.) **(Rus)**
[Trefoil peptides, cellular repair and progression (editorial)] Soriano A. **Gastroenterol Hepatol** 1999 Apr;22(4):188-90 (19 ref.) **(Spa)**

THERAPEUTIC USE

Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM. **Am J Cardiol** 1998 Oct 22;82(8B):36P-42P (24 ref.)
Multiple sclerosis: therapeutic update. Tselis AC, et al. **Arch Neurol** 1999 Mar;56(3):277-80 (17 ref.)
Copolymer-1. Comi G, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):495-509 (46 ref.)
Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Goa KL, et al. **Drugs** 1999 Mar; 57(3):439-62 (74 ref.)
Pexiganan acetate. Lamb HM, et al. **Drugs** 1998 Dec; 56(6):1047-52; discussion 1053-4 (19 ref.)
Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives. Deghenghi R. **J Endocrinol Invest** 1998 Dec;21(11):787-93 (47 ref.)
Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. Soto C. **J Mol Med** 1999 May; 77(5):412-8 (74 ref.)
Oral tolerance with copolymer 1 for the treatment of multiple sclerosis [comment] Weiner HL. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3333-5 (53 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3842-7.
Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Bowersox SS, et al. **Toxicon** 1998 Nov;36(11):1651-8 (32 ref.)
[Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis] Gusev EI, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(4):33-6 (18 ref.) **(Rus)**
[Gastrointestinal peptides among new therapeutic agents used in type 2 diabetes] Efendic S, et al. **Lakartidningen** 1999 Feb 24;96(8):888-92 (15 ref.) (Eng. Abstr.) **(Swe)**

TOXICITY

Safety evaluation of peptides and proteins. Wong LC. **Chung Kuo Yao Li Hsueh Pao** 1998 Mar;19(2):175-81 (12 ref.)

PEPTIDES, CYCLIC

CHEMICAL SYNTHESIS

Design and preparation of cyclopeptamine antifungal agents. Klein LL, et al. **Curr Pharm Des** 1999 Feb;5(2):57-71 (37 ref.)

CHEMISTRY

Toxins selective for subunit interfaces as probes of nicotinic acetylcholine receptor structure. Taylor P, et al. **J Physiol Paris** 1998 Apr;92(2):79-83 (21 ref.)

PHARMACOLOGY

Molecular mechanisms underlying inhibition of protein phosphatases by marine toxins. Dawson JF, et al. **Front Biosci** 1999 Oct 1;4:D646-58 (0 ref.)
Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Hadley ME, et al. **Pharm Biotechnol** 1998;11:575-95 (71 ref.)

THERAPEUTIC USE

[Pregnancy in an acromegalic patient treated with lanreotide and bromocryptin (letter)] Sánchez R, et al. **Med Clin (Barc)** 1999 Jul 10;113(5):198 (4 ref.) **(Spa)**

PEPTIDOGLYCAN

BIOSYNTHESIS

Antibiotics, peptidoglycan synthesis and genomics: the chlamydial anomaly revisited. Chopra I, et al. **Microbiology** 1998 Oct;144 (Pt 10):2673-8 (40 ref.)

CHEMISTRY

Effects of muramyl peptides on macrophages, monokines, and sleep. Pabst MJ, et al. **Neuroimmunomodulation** 1999 Jul-Aug;6(4):261-83 (177 ref.)
Orientation of the peptidoglycan chains in the sacculus of Escherichia coli. Koch AL. **Res Microbiol** 1998 Nov-Dec; 149(10):689-701 (40 ref.)

METABOLISM

Layered murein revisited: a fundamentally new concept of bacterial cell wall structure, biogenesis and function. Dmitriev BA, et al. **Med Microbiol Immunol (Berl)** 1999 Mar;187(3):173-81 (65 ref.)
Endo-N-acetyl-beta-D-glucosaminidases and their potential substrates: structure/function relationships. Karamanos Y. **Res Microbiol** 1997 Nov;148(8):661-71 (68 ref.)

PEPTIDYL-DIPEPTIDASE A

Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases. Costerousse O, et al. **Biol Res** 1998;31(3):161-7 (64 ref.)
Examining the renin-angiotensin system one hundred years after its discovery. Bernstein KE. **Nephrologie** 1998; 19(7):391-5 (33 ref.)
[Forty years of studying angiotensin-converting enzyme: problems and accomplishments] Vernigora AN, et al. **Ukr Biokhim Zh** 1998 Mar-Apr;70(2):3-14 (117 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Angiotensin II and the control of cardiovascular structure. Pratt RE. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S120-8 (96 ref.)

DRUG EFFECTS

Effect of ACE inhibition on myocardial ischaemia. Ferrari R. **Eur Heart J** 1998 Sep;19 Suppl J:J30-5 (40 ref.)
Effect of ACE inhibition on neurohormones. Remme WJ. **Eur Heart J** 1998 Sep;19 Suppl J:J16-23 (38 ref.)
Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC Jr. **J Hypertens Suppl** 1999 Feb; 17(1):S37-43 (49 ref.)

GENETICS

Angiotensin-converting enzyme gene polymorphism: is there a link to nephropathy in patients with type 1 diabetes? Martin JK, et al. **Ann Pharmacother** 1999 Apr;33(4):474-9 (33 ref.)
Angiotensin-converting enzyme gene and diabetes mellitus. Kennon B, et al. **Diabet Med** 1999 Jun;16(6):448-58 (87 ref.)
Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis. Bauters C, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J24-9 (62 ref.)
Gene polymorphism of the renin-angiotensin system and progression of diabetic nephropathy. Orisio S. **J Nephrol** 1999 Jan-Feb;12(1):9-17 (104 ref.)
ACE knockout mice--lessons for adult nephrology [editorial] Bernstein KE. **Nephrol Dial Transplant** 1998 Dec; 13(12):2991-4 (19 ref.)

IMMUNOLOGY

Angiotensin-converting enzyme inhibitors in young patients with IgA nephropathy: effects against deterioration of renal function. A Biomedicine and Health Research Concerted Action. Coppo R. **Nephrol Dial Transplant** 1999 Apr; 14(4):840-1 (17 ref.)

METABOLISM

Angiotensin II formation in the human heart: an ACE or non-ACE-mediated pathway? Kokkonen JO, et al. **Ann Med** 1998 Aug;30 Suppl 1:9-13 (22 ref.)
Angiotensin-converting enzyme and the amyloid precursor protein secretases. Hooper NM, et al. **Biochem Soc Trans** 1999 Feb;27(2):229-34 (31 ref.)
Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease. Adams KF Jr. **Coron Artery Dis** 1998;9(10):675-84 (105 ref.)
Endothelial dysfunction and inhibition of converting enzyme. Vanhoutte PM. **Eur Heart J** 1998 Sep;19 Suppl J:J7-15 (78 ref.)
Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. Zhuo J, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2027-37 (102 ref.)
[Endothelial activation markers (thrombomodulin, Willebrand's factor antigen and angiotensin-converting enzyme): clinical significance] Nasonov EL, et al. **Klin Med (Mosk)** 1998;76(11):4-10 (116 ref.) **(Rus)**

PHYSIOLOGY

The functional role of angiotensin-converting enzyme as explored by using knockout mice. Bernstein KE, et al. **Adv Nephrol Necker Hosp** 1998;28:213-23 (33 ref.)
[Role of angiotensin II-forming enzymes, angiotensin-converting enzyme and chymase] Takai S, et al. **Nippon Rinsho** 1999 May;57(5):1078-83 (16 ref.) (Eng. Abstr.) **(Jpn)**

PEPTIDYL-PROLYL CIS-TRANS-ISOMERASE see **PEPTIDYLPROLYL ISOMERASE**

PEPTIDYLPROLYL ISOMERASE

CHEMISTRY

Peptidyl-prolyl cis-trans isomerases: structure and functions. Pliyev BK, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):738-51 (142 ref.)

IMMUNOLOGY

Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Brenner BG, et al. **Infect Dis Obstet Gynecol** 1999;7(1-2):80-90 (82 ref.)

METABOLISM

Peptidyl-prolyl cis-trans isomerases: structure and functions. Pliyev BK, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):738-51 (142 ref.)

PHYSIOLOGY

Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Göthel SF, et al. **Cell Mol Life Sci** 1999 Mar;55(3):423-36 (96 ref.)

PERCEPTION

see related

SENSATION

Taste and flavour perception. Woods MP. **Proc Nutr Soc** 1998 Nov;57(4):603-7 (37 ref.)
Gender differences in risk perception: theoretical and methodological perspectives. Gustafson PE. **Risk Anal** 1998 Dec;18(6):805-11 (34 ref.)
[Perception and understanding of insulin-dependent diabetes and its treatment by the child from 2 to 12 years] Ricard-Malivoir S. **Diabetes Metab** 1999 Mar;25(1):68-71 (5 ref.) **(Fre)**

PHYSIOLOGY

Development of perception in action in healthy and at-risk children. van der Meer AL, et al. **Acta Paediatr Suppl** 1999 May;88(429):29-36 (36 ref.)
5-HT4 receptors: gene, transduction and effects on olfactory memory. Bockaert J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:1-15 (61 ref.)
The dynamical hypothesis in cognitive science. van Gelder T. **Behav Brain Sci** 1998 Oct;21(5):615-28; discussion 629-65 (201 ref.)
Brainy mind. Gregory R. **BMJ** 1998 Dec 19-26; 317(7174):1693-5 (15 ref.)
Neural systems for behavioral activation and reward. Kalivas PW, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):223-7 (41 ref.)
Neurogastroenterology--information processing from the viscera to the brain in humans. Enck P, et al. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):468-71 (28 ref.)
Technology review: the Neurometer Current Perception Threshold (CPT). AAEM Equipment and Computer

PERCEPTION

Committee. American Association of Electrodiagnostic Medicine. **Muscle Nerve** 1999 Apr;22(4):523–31 (56 ref.)
On the similarity of odor and language perception. Lorig TS. **Neurosci Biobehav Rev** 1999;23(3):391–8 (60 ref.)
Pain perception: is there a role for primary somatosensory cortex? Bushnell MC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7705–9 (51 ref.)
Central modulation of pain perception. Crofford LJ, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):1–13 (42 ref.)

PERCEPTION, SOCIAL see **SOCIAL PERCEPTION**

PERCEPTRONS see **NEURAL NETWORKS (COMPUTER)**

PERCEPTUAL DISORDERS

DIAGNOSIS

Sentence processing in Parkinson's disease. Grossman M. **Brain Cogn** 1999 Jul;40(2):387–413 (92 ref.)
Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body Dementia: too much or too little cortical acetylcholine? Sarter M, et al. **Brain Cogn** 1998 Dec; 38(3):297–316 (135 ref.)
[Visual hallucinations and illusions, symptoms frequently misdiagnosed by the practitioner] Borruat FX. **Klin Monatsbl Augenheilkd** 1999 May;214(5):324–7 (16 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Sentence processing in Parkinson's disease. Grossman M. **Brain Cogn** 1999 Jul;40(2):387–413 (92 ref.)

PHYSIOPATHOLOGY

Complex motion perception and its deficits. Vaina LM. **Curr Opin Neurobiol** 1998 Aug;8(4):494–502 (75 ref.)
Unilateral spatial neglect in dissociable frames of reference: a comment on Farah, Brunn, Wong, Wallace, and Carpenter (1990) [comment] Hillis AE, et al. **Neuropsychologia** 1998 Nov;36(11):1257–62 (23 ref.)
Comment on: Neuropsychologia 1990;28(4):335–47.

REHABILITATION

Recovery from aphasia and neglect. Ferro JM, et al. **Cerebrovasc Dis** 1999;9 Suppl 5:6–22 (229 ref.)

PERCEPTUAL DISTORTION

see related
PERCEPTUAL DISORDERS

PERCEPTUAL MASKING

Backward masking in bipolar affective disorder. McClure RK. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Feb; 23(2):195–206 (13 ref.)

PHYSIOLOGY

Backward masking performance as an indicator of vulnerability to schizophrenia. Green MF, et al. **Acta Psychiatr Scand Suppl** 1999;395:34–40 (30 ref.)
Neural mechanisms for synthesizing sensory information and producing adaptive behaviors. Stein BE. **Exp Brain Res** 1998 Nov;123(1–2):124–35 (75 ref.)
Is the target-to-target interval a critical determinant of P3 amplitude? Gonsalvez CJ, et al. **Psychophysiology** 1999 Sep; 36(5):643–54 (45 ref.)
Dynamics of SCR, EEG, and ERP activity in an oddball paradigm with short interstimulus intervals. Lim CL, et al. **Psychophysiology** 1999 Sep;36(5):543–51 (80 ref.)

PERCEPTUAL MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

PERCHLORIC ACID

THERAPEUTIC USE

The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. Lawrence JE, et al. **J Endocrinol Invest** 1999 May;22(5):405–7 (16 ref.)

PERCUSSION

METHODS

Hoffman-Tinel sign. The realities. Alfonso MI, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):721–36, v (59 ref.)

PERCUTANEOUS ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

PERCUTANEOUS ELECTRIC NERVE STIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

PERCUTANEOUS NEPHROLITHOTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS NEPHROSTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY see **ANGIOPLASTY, BALLOON**

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

PERCUTANEOUS ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

PERFLUOROCARBONS see **FLUOROCARBONS**

PERFORANT PATHWAY

[Perforant pathway degeneration as a system degeneration: secondary hippocampal degeneration in Alzheimer-type dementia] Mizutani T. **No To Shinkei** 1998 Oct; 50(10):895–905 (40 ref.) **(Jpn)**

PATHOLOGY

[Hippocampal pathology in diffuse Lewy body disease] Iseki E, et al. **No To Shinkei** 1998 Oct;50(10):907–12 (11 ref.) **(Jpn)**

PERFORATING FASCICULUS see **PERFORANT PATHWAY**

PERFORMANCE APPRAISAL, EMPLOYEE see **EMPLOYEE PERFORMANCE APPRAISAL**

PERFUME

ADVERSE EFFECTS

Olfaction and symptoms in the multiple chemical sensitivities syndrome. Ross PM, et al. **Prev Med** 1999 May; 28(5):467–80 (140 ref.)

PERFUSION, PULSATILE see **PULSATILE FLOW**

PERFUSION PUMPS see **INFUSION PUMPS**

PERFUSION PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERFUSION, REGIONAL

TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Eggermont AM. **Anticancer Res** 1998 Sep–Oct;18(5D):3899–905 (80 ref.)
Clinical applications of TNF-alpha in cancer. Lejeune FJ, et al. **Curr Opin Immunol** 1998 Oct;10(5):573–80 (42 ref.)
Regional IL-2-based immunochemotherapy of colorectal liver metastases. Okuno K, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1263–7 (8 ref.)
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Schraffordt Koops H, et al. **Radiother Oncol** 1998 Jul; 48(1):1–4 (19 ref.)

METHODS

Isolated lung perfusion for the treatment of pulmonary metastases. Hendriks JM, et al. **Surg Oncol** 1998 Jul–Aug; 7(1–2):59–63 (33 ref.)
Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Bozzetti F, et al. **Tumori** 1998 Jul–Aug;84(4):483–8 (75 ref.)

PERIADENITIS MUCOSA NECROTICA RECURRENS see **STOMATITIS, APHTHOUS**

PERIANEURYSMAL FIBROSIS, INFLAMMATORY see **RETROPERITONEAL FIBROSIS**

PERIAORTITIS, CHRONIC see **RETROPERITONEAL FIBROSIS**

PERIAPICAL ABSCESS

DIAGNOSIS

Dentin malformation with alveolar bone loss and periapical abscess formation. Shintani S, et al. **Pediatr Dent** 1999 Mar–Apr;21(2):130–4 (10 ref.)

PERIAPICAL CYST see **RADICULAR CYST**

PERIAPICAL GRANULOMA

ETIOLOGY

[The role of cell adhesion molecules in the formation of periapical granulomas] Rapisarda E, et al. **Minerva Stomatol** 1998 Oct;47(10):509–17 (19 ref.) (Eng. Abstr.) **(Ita)**

PERIAPICAL PERIODONTITIS

IMMUNOLOGY

Periapical inflammatory responses and their modulation. Stashenko P, et al. **Crit Rev Oral Biol Med** 1998; 9(4):498–521 (272 ref.)

SURGERY

[Guided tissue regeneration in endodontics. Part 1] Gagnon K, et al. **J Can Dent Assoc** 1999 Jul–Aug;65(7):394–8 (37 ref.) (Eng. Abstr.) **(Fre)**

PERIAPICAL PERIODONTITIS, CHRONIC NONSUPPURATIVE see **PERIAPICAL GRANULOMA**

PERIAPICAL PERIODONTITIS, SUPPURATIVE see **PERIAPICAL ABSCESS**

PERIAQUEDUCTAL GRAY

CYTOLOGY

Parallel circuits for emotional coping behaviour: new pieces in the puzzle [comment] Bernard JF, et al. **J Comp Neurol** 1998 Nov 30;401(4):429–36 (130 ref.)
Comment on: J Comp Neurol 1998 Nov 30;401(4):437–54.
Comment on: J Comp Neurol 1998 Nov 30;401(4):455–79.
Comment on: J Comp Neurol 1998 Nov 30;401(4):480–505.

PERIARTERITIS NODOSA see **POLYARTERITIS NODOSA**

PERIARTHRITIS

RADIOGRAPHY

[Radiation therapy in humero-scapular peri-arthropathy. Indication, method, results obtained by authors, review of the literature] Heyd R, et al. **Rontgenpraxis** 1998; 51(11):403–12 (105 ref.) **(Ger)**

PERICARDIAL CYST see **MEDIASTINAL CYST**

PERICARDIAL EFFUSION

see related
CARDIAC TAMPONADE

COMPLICATIONS

[Ebstein's anomaly related with significant pericardial effusion. Report and analysis of a case] Llamas-Esperón G, et al. **Gac Med Mex** 1998 Jul–Aug;134(4):479–86 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Recurrent pericardial effusion due to gunshot wound of the heart in a hemodynamically stable child--a case report. Tutar HE, et al. **Angiology** 1999 Apr;50(4):337–40 (12 ref.)
Cardiac tamponade. Knoop T, et al. **Semin Oncol Nurs** 1999 Aug;15(3):168–73 (24 ref.)
[Association of acute pericarditis and acute renal insufficiency: causes and prognosis] Klisnick A, et al. **Presse Med** 1998 Oct 31;27(33):1668–73 (41 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Diagnostic problems in serous effusions. Bedrossian CW. **Diagn Cytopathol** 1998 Aug;19(2):131–7 (16 ref.)

SURGERY

Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Allen KB, et al. **Ann Thorac Surg** 1999 Feb;67(2):437–40 (28 ref.)
Video-assisted thoracic surgery pericardial resection for effusive disease. Flores RM, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):835–51 (54 ref.)

VIROLOGY

Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Chen Y, et al. **Am Heart J** 1999 Mar;137(3):516–21 (49 ref.)

PERICARDIECTOMY

INSTRUMENTATION

Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Allen KB, et al. **Ann Thorac Surg** 1999 Feb;67(2):437–40 (28 ref.)

METHODS

Video-assisted thoracic surgery pericardial resection for effusive disease. Flores RM, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):835–51 (54 ref.)

PERICARDIOTOMY see **PERICARDIECTOMY**

PERICARDITIS

[Current perspective of meningococcal pericariditis in children and adults] Finkelstein Y, et al. **Harefuah** 1998 Sep;135(5–6):226–9 (50 ref.) **(Heb)**

[Purulent pericarditis] Ashizawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):326–8 (16 ref.) **(Jpn)**

[Pericardial abscess] Yuasa N. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):340–2 (15 ref.) **(Jpn)**

[Myopericarditis: clinical picture, diagnosis and treatment] Gurevich MA, et al. **Klin Med (Mosk)** 1999;77(7):33–6 (12 ref.) (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature. Sentongo TA, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep; 27(3):344–7 (21 ref.)

COMPLICATIONS

[Association of acute pericarditis and acute renal insufficiency: causes and prognosis] Klisnick A, et al. **Presse Med** 1998 Oct 31;27(33):1668–73 (41 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Plain-film diagnosis of pericardial disease. Rozenshtein A, et al. **Semin Roentgenol** 1999 Jul;34(3):195–204 (67 ref.)

[Diagnosis of pericarditis] Janion M, et al. **Przegl Lek** 1999; 56(4):286–91 (26 ref.) (Eng. Abstr.) **(Pol)**

[Myopericarditis simulating a myocardial infarct in a child] Díez Tomás J, et al. **An Esp Pediatr** 1999 Jun;50(6):613–5 (13 ref.) **(Spa)**

EPIDEMIOLOGY

Pneumococcal pericarditis since 1980 [letter; comment] Go C, et al. **Clin Infect Dis** 1998 Nov;27(5):1338–40 (13 ref.) Comment on: Clin Infect Dis 1998 Mar;26(3):762–3.

ETIOLOGY

Steroid-responsive pleuropericarditis and livedo reticularis in an unusual case of adult-onset primary hyperoxaluria. Singh S, et al. **Am J Kidney Dis** 1999 Apr;33(4):e5 (36 ref.)

[Pericarditis secondary to the rupture of a hydatid cyst] Iglesias LF, et al. **Rev Esp Cardiol** 1999 Feb;52(2):135–8 (8 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

[Acute pericarditis of unusual etiology] Larive S, et al. **Rev Pneumol Clin** 1998 Jul;54(3):152–5 (21 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Cardiac infections: medical and surgical therapies. Sparacino PS. **J Cardiovasc Nurs** 1999 Jan;13(2):49–65 (51 ref.)

PHYSIOPATHOLOGY

Early repolarization. Mehta M, et al. **Clin Cardiol** 1999 Feb; 22(2):59–65 (82 ref.)

RADIOGRAPHY

Plain-film diagnosis of pericardial disease. Rozenshtein A, et al. **Semin Roentgenol** 1999 Jul;34(3):195–204 (67 ref.)

VIROLOGY

[Viral pericarditis] Suzuki S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):73–6 (12 ref.) **(Jpn)**

PERICARDITIS, CONSTRICTIVE

Constrictive pericarditis. Mehta A, et al. **Clin Cardiol** 1999 May;22(5):334–44 (135 ref.)

COMPLICATIONS

Combined idiopathic retroperitoneal and mediastinal fibrosis with pericardial involvement. Klisnick A, et al. **Clin Nephrol** 1999 Jul;52(1):51–5 (31 ref.)

DIAGNOSIS

Constrictive pericarditis: clinical and pathophysiologic characteristics. Myers RB, et al. **Am Heart J** 1999 Aug; 138(2 Pt 1):219–32 (77 ref.)

Case presentation and review: constrictive pericarditis. Osterberg L, et al. **West J Med** 1998 Oct;169(4):232–9 (38 ref.)

[Constrictive pericarditis and Behçet's disease: a very rare association] Moreno Izarra J, et al. **Rev Esp Cardiol** 1999 Mar;52(3):197–200 (9 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Rapidly evolving constrictive tuberculous pericarditis: case presentation and review of the literature. Gobeil F, et al. **Can J Cardiol** 1998 Dec;14(12):1467–9 (14 ref.)

Constrictive pericarditis after surgical closure of atrial septal defect in a child. Kim BJ, et al. **J Korean Med Sci** 1998 Dec;13(6):658–61 (15 ref.)

PHYSIOPATHOLOGY

Constrictive pericarditis: clinical and pathophysiologic characteristics. Myers RB, et al. **Am Heart J** 1999 Aug; 138(2 Pt 1):219–32 (77 ref.)

PERICARDITIS, TUBERCULOUS

[Tuberculous pericarditis] Ashizawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):198–200 (15 ref.) **(Jpn)**

PERICARDIUM

see related
PERICARDIECTOMY

Tumors of the heart and pericardium. McAllister HA Jr, et al. **Curr Probl Cardiol** 1999 Feb;24(2):57–116 (144 ref.)

Assessment of pericardium in cardiac bioprostheses. A review. García Páez JM, et al. **J Biomater Appl** 1999 Apr; 13(4):351–88 (150 ref.)

ABNORMALITIES

[The imaging diagnosis of pericardial agenesis] Rubio Alcaide A, et al. **Rev Esp Cardiol** 1999 Mar;52(3):211–4 (8 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Combined blunt cardiac and pericardial rupture: review of the literature and report of a new diagnostic algorithm. May AK, et al. **Am Surg** 1999 Jun;65(6):568–74 (12 ref.)

A case of traumatic pericardiophrenic rupture. Stefani A, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):859–61 (10 ref.)

RADIOGRAPHY

Plain-film diagnosis of pericardial disease. Rozenshtein A, et al. **Semin Roentgenol** 1999 Jul;34(3):195–204 (67 ref.)

PERICEMENTITIS see **PERIODONTITIS**

PERICYTES

PHYSIOLOGY

Gene expression during vascular pericyte differentiation. Doherty MJ, et al. **Crit Rev Eukaryot Gene Expr** 1999; 9(1):1–17 (142 ref.)

Role of the CNS microvascular pericyte in the blood–brain barrier. Balabanov R, et al. **J Neurosci Res** 1998 Sep 15; 53(6):637–44 (105 ref.)

Endothelium-derived agents in pericyte function/dysfunction. Chakravarthy U, et al. **Prog Retin Eye Res** 1999 Jul;18(4):511–27 (108 ref.)

PERIDURAL INJECTIONS see **INJECTIONS, EPIDURAL**

PERILYMPH

A critical appraisal of spontaneous perilymphatic fistulas of the inner ear. Friedland DR, et al. **Am J Otol** 1999 Mar; 20(2):261–76; discussion 276–9 (135 ref.)

PHYSIOLOGY

[Recent experimental and clinical findings retarding an interlabyrinthine connection] Schreiner L. **Laryngorhinootologie** 1999 Jul;78(7):387–93 (47 ref.) (Eng. Abstr.) **(Ger)**

PERILYMPHATIC DUCT see **COCHLEAR AQUEDUCT**

PERIMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

PERIMENOPAUSE see **PREMENOPAUSE**

PERIMETRY

METHODS

[Visual evoked potentials and static perimetry in functional visual deficits] Sobolewski P, et al. **Klin Oczna** 1998; 100(4):221–4 (25 ref.) (Eng. Abstr.) **(Pol)**

PERINATAL CARE

[Consensus conference on prenatal care, delivery, and the newborn. Paris, France, 2–3 December 1998. Proceedings] **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:1–317 (0 ref.) **(Fre)**

ECONOMICS

[Health economics of perinatal care and birth in Austria and Holland –a comparison] Brezinka C. **Gynakol Geburtshilfliche Rundsch** 1998;38(4):196–210 (48 ref.) (Eng. Abstr.) **(Ger)**

METHODS

ABC of labour care: care of the newborn in the delivery room. Hamilton P. **BMJ** 1999 May 22;318(7195):1403–6 (6 ref.)

ABC of labour care: assessment of mother and fetus in labour. Steer P. **BMJ** 1999 Mar 27;318(7187):858–61 (0 ref.)

Advances in perinatal medical care--from our experience. Sakamoto S, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S107–14 (9 ref.)

[Delivery methods for infants weighing less than 2500 grams. Which specific measures to consider for the newborn?] Bouillié J. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:314–7 (19 ref.) **(Fre)**

[Justification of a prevention policy of perinatal disease by group B streptococci (GBS). Recommendations] Andreu A, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):138–40 (8 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

The uses of comparative information in perinatal care. Gagnon DE. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S6–9 (5 ref.)

[Can we improve the neuro-intellectual and behavioral prognosis of premature infants by modifying their environment? (editorial)] Sizun J, et al. **Arch Pediatr** 1999 Jan;6(1):7–11 (37 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of sociologists] Akrich M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:197–204 (7 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of an epidemiologist] Bréart G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:189–90 (11 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of nurse midwives] Caumel-Dauphin F. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:127–36 (14 ref.) **(Fre)**

[Analysis and point-of-view of mobile emergency service pediatricians] Chabernaud JL. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:176–81 (17 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of the economist] Combier E. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:205–19 (13 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic obstetricians] Crézé B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:117–20 (3 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of obstetricians of general hospital centers] Dauptain G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:110–6 (13 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of Maternal-Infant Care physicians] Delour M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:137–46 (33 ref.) **(Fre)**

[Networks in perinatology. The French experience] Dreyfus M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:70–5 (13 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of the Council of the Order of Physicians] Dubois O. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:249–58 (22 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic anesthetists] Fillette D. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:186–8 (8 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of decision-makers. An example currently in place: the prenatal network for child abuse prevention] Hermange MT. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:237–46 (15 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center directors] Leclercq B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:229–31 (11 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center obstetricians] Lévy G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:104–9 (9 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of public health physicians] Lombrail P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:191–6 (29 ref.) **(Fre)**

[Networks and channels in perinatology. Definitions, typology and enterprises] Naiditch M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:52–61 (25 ref.) **(Fre)**

PERINATAL CARE

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of public hospital anesthetists] Palot M.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:182-5 (8 ref.) **(Fre)**

[Different organizational modalities in perinatal care as a function of demographic context and budgetary constraints] Papiernik E.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:76-84 (17 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center pediatricians] Rozé JC, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:153-61 (61 ref.) **(Fre)**

[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:94-103 (40 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of general physicians] Samuelson M.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:147-52 (42 ref.) **(Fre)**

[Arguments in favor of a relation between the organization of perinatal care and the optimal management of prematurity and multiple pregnancies] Truffert P.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:85-93 (37 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of central general hospital pediatricians] Zaoui C.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:162-4 (21 ref.) **(Fre)**

STANDARDS

Vital records for quality improvement. Gould JB.
Pediatrics 1999 Jan;103(1 Suppl E):278-90 (39 ref.)

STATISTICS & NUMERICAL DATA

Methodological issues in the study of rare exposures and rare outcomes in perinatal epidemiology. Bracken MB.
J Allergy Clin Immunol 1999 Feb;103(2 Pt 2):S354-5 (7 ref.)

PERINATAL MORTALITY see **INFANT MORTALITY**

PERINATAL NURSING see **NEONATAL NURSING**

PERINATOLOGY

see related
FETAL DISEASES
INFANT, NEWBORN, DISEASES
MATERNAL-CHILD NURSING
PERINATAL CARE
PREGNANCY COMPLICATIONS

The role of the maternal-fetal medicine specialist. Philipson EH. **Cleve Clin J Med** 1999 Jul-Aug;66(7):407-9, 413-4 (10 ref.)

Systematic reviews in perinatal medicine. Halliday HL.
J Perinat Med 1999;27(1):41-4 (23 ref.)

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of the Council of the Order of Physicians] Dubois O.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:249-58 (22 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Perinatal information systems for quality improvement: visions for today. Slagle TA. **Pediatrics** 1999 Jan;103(1 Suppl E):266-77 (64 ref.)

STANDARDS

What's new in perinatology. Chescheir NC, et al.
Pediatr Rev 1999 Feb;20(2):57-63 (11 ref.)

Administrative data for quality improvement. Schwartz RM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):291-301 (30 ref.)

[Consensus conference on prenatal care, delivery, and the newborn. Paris, France, 2-3 December 1998. Proceedings]
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:1-317 (0 ref.) **(Fre)**

PERINEUM

[Perineal neurologic pain] Amarenco G, et al.
Gastroenterol Clin Biol 1998 Jun;22(5 Suppl):B164-8 (22 ref.) **(Fre)**

[A strangulated perineal hernia. A rare case of intestinal obstruction] Sciacca P, et al. **Minerva Chir** 1998 Sep; 53(9):739-41 (5 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Pediatric rectal and perineal problems. Hendren WH.
Pediatr Clin North Am 1998 Dec;45(6):1353-72 (23 ref.)

INJURIES

[Pelvic and perineal sequelae of delivery] Fatton B, et al.
Rev Prat 1999 Jan 15;49(2):160-6 (29 ref.) (Eng. Abstr.) **(Fre)**

[Posttraumatic priapism in a 6-year-old boy: a case report] Iwata K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):679-82 (20 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Adenoid cystic carcinoma of Bartholin's gland: what is the optimal approach? Anaf V, et al. **Eur J Surg Oncol** 1999 Aug;25(4):406-9 (19 ref.)

PERINEURIUM see **PERIPHERAL NERVES**

PERINEURONAL SATELLITE CELLS see **OLIGODENDROGLIA**

PERIOCULAR DERMATITIS see **DERMATITIS, PERIORAL**

PERIODIC DISEASE

First International Conference on familial Mediterranean fever, Jerusalem, Israel, September 7-11, 1997. Direskeneli H, et al. **J Rheumatol** 1998 Nov;25(11):2236-9 (46 ref.)

[Familial Mediterranean fever] Hamai K, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):496-8 (13 ref.) **(Jpn)**

COMPLICATIONS

Pulmonary associations in familial Mediterranean fever. Livneh A, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):326-31 (66 ref.)

Familial Mediterranean fever: from inflammation to amyloidosis [editorial] Grateau G.
Nephrol Dial Transplant 1998 Aug;13(8):1919-20 (39 ref.)

DIAGNOSIS

Recurrent episodic fever. A presenting feature of familial Mediterranean fever. Majeed HA, et al. **J Med Liban** 1998 Jan-Feb;46(1):12-5 (19 ref.)

DRUG THERAPY

Colchicine: 1998 update. Ben-Chetrit E, et al.
Semin Arthritis Rheum 1998 Aug;28(1):48-59 (125 ref.)

GENETICS

Cloning of the familial Mediterranean fever gene: expectations for learning about the pathogenesis of amyloid A amyloidosis. Pras M. **Adv Nephrol Necker Hosp** 1998; 28:343-54 (25 ref.)

Hereditary fevers. Grateau G, et al.
Curr Opin Rheumatol 1999 Jan;11(1):75-8 (31 ref.)

Vasculopathy, Behçet's syndrome, and familial Mediterranean fever. Ozen S. **Curr Opin Rheumatol** 1999 Sep;11(5):393-8 (36 ref.)

The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Centola M, et al. **Hum Mol Genet** 1998;7(10):1581-8 (81 ref.)

PATHOLOGY

Glomerular lesions other than amyloidosis in patients with familial Mediterranean fever [editorial] Yalçinkaya F, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):21-3 (17 ref.)

PERIODICALS

A review of randomised controlled trials published in Archives of Disease in Childhood from 1982-96. Campbell H, et al. **Arch Dis Child** 1998 Aug;79(2):192-7 (00 ref.)

Clinical Microbiology Reviews: genesis of a journal. Morello JA. **Clin Microbiol Rev** 1999 Apr;12(2):183-6 (5 ref.)

The peer-review process of the Journal of Neurosurgery. Firlik KS, et al. **J Neurosurg** 1999 Feb;90(2):364-70 (16 ref.)

Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. **Med Educ** 1999 Jan;33(1):66-78 (00 ref.)

Nursing e-journals: are current models using the web's potential? Murray PJ, et al. **Medinfo** 1998;9 Pt 1:135-9 (9 ref.)

Electronic publishing and nursing research. Sparks SM.
Nurs Res 1999 Jan-Feb;48(1):50-4 (3 ref.)

[Preparing a manuscript for publication in a scientific journal] Claes L, et al. **Unfallchirurg** 1999 May;102(5):377-83 (6 ref.) (Eng. Abstr.) **(Ger)**

[The publication in biomedical journals of clinical trial protocols: a new way to improve research quality (editorial)] Bosch X. **Rev Esp Cardiol** 1999 May; 52(5):359-61 (29 ref.) **(Spa)**

HISTORY

The Journal of Virology: a personal retrospective. Wagner RR. **J Virol** 1999 May;73(5):3515-9 (4 ref.)

STANDARDS

What is the quality of the reporting of research ethics in publications of nursing home research? Karlawish JH, et al. **J Am Geriatr Soc** 1999 Jan;47(1):76-81 (58 ref.)

Misuse of correlation and regression in three medical journals. Porter AM. **J R Soc Med** 1999 Mar;92(3):123-8 (39 ref.)

The ratings war: news from the front line [editorial] Bullimore MA. **Optom Vis Sci** 1999 Mar;76(3):129 (7 ref.)

Your research: how to get it on paper and in print [see comments] Griscom NT. **Pediatr Radiol** 1999 Feb; 29(2):81-6 (12 ref.) Comment in: Pediatr Radiol 1999 Feb;29(2):79.

[The impact factor as an assessment criterion of scientific achievements--the right to equal chances] Lehrl S.
Strahlenther Onkol 1999 Apr;175(4):141-53 (61 ref.) (Eng. Abstr.) **(Ger)**

[The impact factor: a factor of impact or the impact of a (sole) factor? The limits of a bibliometric indicator as a candidate for an instrument to evaluate scientific production] Gensini GF, et al. **Ann Ital Med Int** 1999 Apr-Jun;14(2):130-3; discussion 134-5 (16 ref.) (Eng. Abstr.) **(Ita)**

[How to improve the statistical quality of articles presented to biomedical journals: a checklist for authors] Mora i Ripoll R. **Med Clin (Barc)** 1999 Jul 3;113(4):138-49 (144 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Sociodemographic factors in Health Psychology research: 12 years in review. Park TL, et al. **Health Psychol** 1998 Jul;17(4):381-3 (10 ref.)

Constructing violence as a public health problem. Winett LB. **Public Health Rep** 1998 Nov-Dec;113(6):498-507 (25 ref.)

[The impact factor: a critical analysis (see comments)] Golder W.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1998 Sep;169(3):220-6 (19 ref.) (Eng. Abstr.) Comment in: Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jun;170(6):615. **(Ger)**

[Nutrition surveys of Spanish school-age children: analysis of the period 1984-1994] Gorgojo L, et al.
Med Clin (Barc) 1999 Mar 20;112(10):368-74 (55 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

Publish or perish--and bankrupt the medical library while we're at it. Halperin EC. **Acad Med** 1999 May;74(5):470-2 (19 ref.)

PERIODICITY

see related
BIOLOGICAL CLOCKS
CIRCADIAN RHYTHM

Analysis of the central pattern generator for swimming in the mollusk Clione. Arshavsky YI, et al.
Ann N Y Acad Sci 1998 Nov 16;860:51-69 (49 ref.)

Differential expression and targeting of K+ channel genes in the lobster pyloric central pattern generator. Baro DJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:281-95 (53 ref.)

Neuromodulation intrinsic to the central pattern generator for escape swimming in Tritonia. Katz PS.
Ann N Y Acad Sci 1998 Nov 16;860:181-8 (39 ref.)

Distribution of central pattern generators for rhythmic motor outputs in the spinal cord of limbed vertebrates. Kiehn O, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:110-29 (50 ref.)

Frequency control of a slow oscillatory network by a fast rhythmic input: pyloric to gastric mill interactions in the crab stomatogastric nervous system. Marder E, et al.
Ann N Y Acad Sci 1998 Nov 16;860:226-38 (41 ref.)

NMDA receptor-mediated oscillatory properties: potential role in rhythm generation in the mammalian spinal cord. Schmidt BJ, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:189-202 (82 ref.)

Basic principles for generating motor output in the stomatogastric ganglion. Selverston A, et al.
Ann N Y Acad Sci 1998 Nov 16;860:35-50 (29 ref.)

Analysis and modeling of the locomotor central pattern generator as a network of coupled oscillators. Sigvardt KA, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:250-65 (63 ref.)

Spinal motor patterns in the turtle. Stein PS, et al.
Ann N Y Acad Sci 1998 Nov 16;860:142-54 (53 ref.)

Cellular and molecular basis for electrical rhythmicity in gastrointestinal muscles. Horowitz B, et al.
Annu Rev Physiol 1999;61:19-43 (136 ref.)

Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models [see comments] Haurie C, et al. **Blood** 1998 Oct 15;92(8):2629-40 (206 ref.) Comment in: Blood 1999 Jun 1;93(11):4023-4.

From a static to a dynamic concept of risk: the circadian epidemiology of cardiovascular events. Portaluppi F, et al. **Chronobiol Int** 1999 Jan;16(1):33-49 (160 ref.)

Temporal coding as a means of information transfer in the primate visual system. Gawne TJ. **Crit Rev Neurobiol** 1999; 13(1):83-101 (89 ref.)

Cellular, synaptic, network, and modulatory mechanisms involved in rhythm generation. Calabrese RL.
Curr Opin Neurobiol 1998 Dec;8(6):710-7 (45 ref.)

Development of rhythmic pattern generators. Fénelon VS, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):705-9 (47 ref.)

Proceedings of the 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. Milwaukee, Wisconsin, USA. April 17-18, 1998. **Dig Dis Sci** 1999 Aug;44(8 Suppl):1S-119S (0 ref.)

Cyclic vomiting syndrome: timing, targets, and treatment--a basic science perspective. Andrews PL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):31S-38S (41 ref.)
Mitochondrial disease and cyclic vomiting syndrome. Boles RG, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):103S-107S (22 ref.)
Psychological and social characteristics and precipitants of vomiting in children with cyclic vomiting syndrome. Forbes D, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):19S-22S (30 ref.)
Serotonin receptor physiology: relation to emesis. Hasler WL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):108S-113S (59 ref.)
Illusory self-motion and motion sickness: a model for brain-gut interactions and nausea. Koch KL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):53S-57S (25 ref.)
Noxious stimulation of emesis. Lang IM. **Dig Dis Sci** 1999 Aug;44(8 Suppl):58S-63S (60 ref.)
Consensus statement--2nd International Scientific Symposium on CVS. The Faculty of The 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. Li BU, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):9S-11S (0 ref.)
Cyclic vomiting syndrome: features to be explained by a pathophysiologic model. Li BU, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):13S-18S (28 ref.)
Central mechanisms of vomiting. Miller AD. **Dig Dis Sci** 1999 Aug;44(8 Suppl):39S-43S (56 ref.)
Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptácek LJ. **Dig Dis Sci** 1999 Aug;44(8 Suppl):94S-96S (22 ref.)
Mitochondrial fatty acid oxidation disorders and cyclic vomiting syndrome. Rinaldo P. **Dig Dis Sci** 1999 Aug;44(8 Suppl):97S-102S (38 ref.)
Tachykinins and in vivo gut motility. Sarna SK. **Dig Dis Sci** 1999 Aug;44(8 Suppl):114S-118S (28 ref.)
Is cyclical vomiting an abdominal form of migraine in children? Symon DN. **Dig Dis Sci** 1999 Aug;44(8 Suppl):23S-25S (21 ref.)
Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Taché Y. **Dig Dis Sci** 1999 Aug;44(8 Suppl):79S-86S (94 ref.)
Scientific basis of migraine: speculation on the relationship to cyclic vomiting. Welch KM. **Dig Dis Sci** 1999 Aug;44(8 Suppl):26S-30S (42 ref.)
Enteric nervous control of motility in the upper gastrointestinal tract in defensive states. Wood JD. **Dig Dis Sci** 1999 Aug;44(8 Suppl):44S-52S (15 ref.)
Cyclic vomiting syndrome: light emerging from the black box [editorial;comment] Li BU. **J Pediatr** 1999 Sep; 135(3):276-7 (13 ref.) Comment on: J Pediatr 1999 Sep;135(3):363-6.
Rhythmical corticomotor communication. Hari R, et al. **Neuroreport** 1999 Feb 5;10(2):R1-10 (83 ref.)
Seasonal and weekly rhythms: windows into variability in family socialization experiences in early adolescence. Crouter AC, et al. **New Dir Child Dev** 1998 Winter; (82):69-82 (16 ref.)
Periodic fever syndrome. Thomas KT, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):68-9 (11 ref.)
Comprehensive review of biorhythm theory. Hines TM. **Psychol Rep** 1998 Aug;83(1):19-64 (215 ref.)
Acetazolamide relieves concurrent episodic movement disorders encountered in Southern states. Olson WL Jr. **South Med J** 1999 Feb;92(2):228-32 (41 ref.)
Recognition of slow processes in rhythmic networks. Golowasch J, et al. **Trends Neurosci** 1999 Sep;22(9):375-7 (24 ref.)
[Periodic fever in the child. Survey of Marshall syndrome. Pediatric Infectious Disease Pathology Group] Reinert P, et al. **Arch Pediatr** 1998;5 Suppl 2:198s-199s (9 ref.) **(Fre)**
[Biological rhythms and drugs] Shibata S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Feb; 19(1):11-20 (45 ref.) (Eng. Abstr.) **(Jpn)**
[Episodic ataxia type 1] Yuasa T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):288-90 (11 ref.) **(Jpn)**
[Episodic ataxia type 2] Yuasa T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):291-4 (19 ref.) **(Jpn)**

PERIODONTAL ABSCESS

[Periodontal disease and periodontal abscess] Kaneko A. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):354-6 (0 ref.) **(Jpn)**

PERIODONTAL BONE LOSS see **ALVEOLAR BONE LOSS**

PERIODONTAL CYST

THERAPY

The buccal bifurcation cyst: in non-surgical treatment an option? David LA, et al. **J Can Dent Assoc** 1998 Nov; 64(10):712-6 (17 ref.)

PERIODONTAL CYST, APICAL see **RADICULAR CYST**

PERIODONTAL DISEASES

Awareness of periodontal disease--the role of industry. Ishikawa I, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):261-7 (68 ref.)
Evidence-based care in orthodontics and periodontics: a review of the literature. Sanders NL. **J Am Dent Assoc** 1999 Apr;130(4):521-7 (103 ref.)
Laboratory animal models in periodontology. Weinberg MA, et al. **J Clin Periodontol** 1999 Jun;26(6):335-40 (50 ref.)
Periodontal diseases: a new paradigm. Page RC. **J Dent Educ** 1998 Oct;62(10):812-21 (36 ref.)
Animal models for Porphyromonas gingivalis-mediated periodontal disease. Genco CA, et al. **Trends Microbiol** 1998 Nov;6(11):444-9 (35 ref.)

COMPLICATIONS

Oral pathogens: from dental plaque to cardiac disease. Meyer DH, et al. **Curr Opin Microbiol** 1998 Feb;1(1):88-95 (70 ref.)
Periodontal disease and tooth loss. Ong G. **Int Dent J** 1998 Jun;48(3 Suppl 1):233-8 (47 ref.)
The effects of dental disease on systemic disease. DeBowes LJ. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1057-62 (16 ref.)
[Dental infectious foci and their complications. Etiology, diagnosis, evolution, treatment] Ragot JP. **Rev Prat** 1998 Oct 1;48(15):1711-21 (4 ref.) **(Fre)**

DIAGNOSIS

C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction. Giannobile WV. **Ann N Y Acad Sci** 1999 Jun 30;878:404-12 (24 ref.)
Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Sorsa T, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:130-40 (28 ref.)
Practical periodontal screening and diagnosis. Corbet EF. **Int Dent J** 1998 Jun;48(3 Suppl 1):268-74 (75 ref.)
Awareness of periodontal diseases: the professional and the civil servant. Eaton KA. **Int Dent J** 1998 Jun;48(3 Suppl 1):248-55 (40 ref.)
Periodontal diagnosis: current status and future directions. Menassa G, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):275-81 (32 ref.)
Risk assessments in the diagnosis and treatment of periodontal diseases. Papapanou PN. **J Dent Educ** 1998 Oct; 62(10):822-39 (204 ref.)
Periodontal disease diagnosis and treatment: an exciting future. Williams RC, et al. **J Dent Educ** 1998 Oct; 62(10):871-81 (85 ref.)

DRUG THERAPY

Herbal medicine for periodontal diseases. Cao CF, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):316-22 (19 ref.)

EPIDEMIOLOGY

Aspects of dental health in adult rural population in Poland. Szymańska J, et al. **Ann Agric Environ Med** 1998;5(2):103-8 (32 ref.)
The periodontal disease problem. A comparison between industrialised and developing countries. Pilot T. **Int Dent J** 1998 Jun;48(3 Suppl 1):221-32 (228 ref.)
Risk for periodontal disease in a Swedish adult population. Cross-sectional and longitudinal studies over two decades. Norderyd O. **Swed Dent J Suppl** 1998;132:1-67 (121 ref.)

ETIOLOGY

Bacterial degradation of immunoglobulin A1 in relation to periodontal diseases. Grønbaek Frandsen EV. **APMIS Suppl** 1999;87:1-54 (333 ref.)
Cases of HIV-associated characteristic periodontal diseases. Pistorius A, et al. **Eur J Med Res** 1999 Mar 26;4(3):121-5 (32 ref.)
Immunologic and viral markers of HIV-1 disease progression: implications for dentistry. Patton LL, et al. **J Am Dent Assoc** 1999 Sep;130(9):1313-22 (66 ref.)
Casual or causal relationship between periodontal infection and non-oral disease? [editorial] Slots J. **J Dent Res** 1998 Oct;77(10):1764-5 (15 ref.)
The pathogenesis of periodontal diseases. **J Periodontol** 1999 Apr;70(4):457-70 (166 ref.)
Diabetes and periodontal diseases. Mealey B. **J Periodontol** 1999 Aug;70(8):935-49 (147 ref.)
[Periodontal aspects of cementation: materials, technics and their biologic reactions] De Boever JA, et al. **Rev Belge Med Dent** 1998;53(4):181-92 (27 ref.) (Eng. Abstr.) **(Fre)**
[Smoking and periodontal health] Obeid P, et al. **Rev Belge Med Dent** 1998;53(4):237-56 (123 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Oral pathogens: from dental plaque to cardiac disease. Meyer DH, et al. **Curr Opin Microbiol** 1998 Feb;1(1):88-95 (70 ref.)
Role of oral bacteria in respiratory infection. Scannapieco FA. **J Periodontol** 1999 Jul;70(7):793-802 (87 ref.)
Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Lamont RJ, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1244-63 (285 ref.)

SURGERY

The periodontal infrastructure. Galler C. **Dent Clin North Am** 1998 Oct;42(4):579-94 (54 ref.)
Anesthesia for periodontal surgery. Higgins MS. **Dent Clin North Am** 1999 Apr;43(2):263-87, vi (48 ref.)
Current periodontal plastic procedures around teeth and dental implants. Oringer RJ, et al. **N Y State Dent J** 1999 Jun-Jul;65(6):26-31 (25 ref.)
Guided tissue regeneration in the management of severe periodontal-endodontic lesions. Danesh-Meyer MJ. **N Z Dent J** 1999 Mar;95(419):7-10 (6 ref.)
[Is periodontal guided tissue regeneration a reproducible technic? A review of the literature] Zahedi S, et al. **Rev Belge Med Dent** 1998;53(4):217-36 (116 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Tooth stabilization and splinting before and after periodontal therapy with fixed partial dentures. Siegel SC, et al. **Dent Clin North Am** 1999 Jan;43(1):45-76 (95 ref.)
Periodontal needs of developing nations--the practitioner's view. Vecchini MF. **Int Dent J** 1998 Jun;48(3 Suppl 1):338-41 (24 ref.)
Risk assessments in the diagnosis and treatment of periodontal diseases. Papapanou PN. **J Dent Educ** 1998 Oct; 62(10):822-39 (204 ref.)
Periodontal disease diagnosis and treatment: an exciting future. Williams RC, et al. **J Dent Educ** 1998 Oct; 62(10):871-81 (85 ref.)
Periodontal treatment and its effects on glycemic control: a review of the evidence. Taylor GW. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):311-6 (58 ref.)

VETERINARY

Periodontal disease and diet in domestic pets. Gorrel C. **J Nutr** 1998 Dec;128(12 Suppl):2712S-2714S (29 ref.)
Prevention of periodontal disease. DuPont GA. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1129-45 (109 ref.)
Radiographic evaluation. Gorrel C. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1089-110 (34 ref.)
Treatment of periodontal disease. Grove TK. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1147-64, vi (12 ref.)
Periodontal disease in dogs. Etiopathogenesis, prevalence, and significance. Harvey CE. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1111-28, vi (56 ref.)
Oral and periodontal tissue. Maintenance, augmentation, rejuvenation, and regeneration. Wiggs RB, et al. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1165-88, vii (85 ref.)
[Dental problems in rabbits and rodents. I. Anatomy, physiology, symptomatology, diagnosis] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1;123(23):698-706 (30 ref.) (Eng. Abstr.) **(Dut)**
[Dental problems in rabbits and rodents. II. Dental treatment] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1; 123(23):707-13 (30 ref.) (Eng. Abstr.) **(Dut)**

PERIODONTAL LIGAMENT

see related
GUIDED TISSUE REGENERATION

PHYSIOLOGY

Compliant Keeper system replication of the periodontal ligament protective damping function for implants: Part I. Mensor MC, et al. **J Prosthet Dent** 1998 Nov;80(5):565-9 (23 ref.)
Compliant Keeper system replication of the periodontal ligament protective damping function for implants: part II. Mensor MC, et al. **J Prosthet Dent** 1999 Apr; 81(4):404-10 (15 ref.)

PERIODONTAL POCKET

MICROBIOLOGY

Tissue necrosis after subgingival irrigation with fluoride solution. Sjöström S, et al. **J Clin Periodontol** 1999 Apr; 26(4):257-60 (27 ref.)

PERIODONTAL RESORPTION see **ALVEOLAR BONE LOSS**

PERIODONTAL SPLINTS

Evaluation for tooth stabilization and treatment of traumatized teeth. McDonald N, et al. **Dent Clin North Am** 1999 Jan;43(1):135-49, vii (38 ref.)
Tooth stabilization and splinting before and after periodontal therapy with fixed partial dentures. Siegel SC, et al. **Dent Clin North Am** 1999 Jan;43(1):45-76 (95 ref.)
Anterior esthetic considerations when splinting teeth. Strassler HE, et al. **Dent Clin North Am** 1999 Jan; 43(1):167-78, vii (28 ref.)

PERIODONTAL SPLINTS

New-generation bonded reinforcing materials for anterior periodontal tooth stabilization and splinting. Strassler HE, et al. **Dent Clin North Am** 1999 Jan;43(1):105–26, vi (28 ref.)

PERIODONTICS

Annual review of selected dental literature: report of the Committee on Scientific Investigation of the American Academy of Restorative Dentistry. Allen EP, et al. **J Prosthet Dent** 1999 Jul;82(1):27–66 (309 ref.)

TRENDS

Periodontal disease diagnosis and treatment: an exciting future. Williams RC, et al. **J Dent Educ** 1998 Oct; 62(10):871–81 (85 ref.)

PERIODONTITIS

Periodontitis in the child and adolescent. Wara-aswapati N, et al. **ASDC J Dent Child** 1999 May-Jun;66(3):167–74, 154 (48 ref.)

Periodontal disease: an overview for physicians. Fenesy KE. **Mt Sinai J Med** 1998 Oct-Nov;65(5–6):362–9 (50 ref.)

[Periodontal disease and periodontal abscess] Kaneko A. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):354–6 (0 ref.) **(Jpn)**

COMPLICATIONS

Furcation diagnosis. Müller HP, et al. **J Clin Periodontol** 1999 Aug;26(8):485–98 (113 ref.)

Oral health and systemic disease: periodontitis and cardiovascular disease. Beck JD, et al. **J Dent Educ** 1998 Oct;62(10):859–70 (44 ref.)

Role of periodontitis in systemic health: spontaneous preterm birth. Offenbacher S, et al. **J Dent Educ** 1998 Oct; 62(10):852–8 (20 ref.)

DIAGNOSIS

Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Sorsa T, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:130–40 (28 ref.)

Current and future approaches for diagnosis of periodontal diseases. Papapanou PN, et al. **N Y State Dent J** 1999 Apr; 65(4):32–7 (16 ref.)

DRUG THERAPY

Chemical treatment of periodontitis: local delivery of antimicrobials. Killoy WJ. **Int Dent J** 1998 Jun;48(3 Suppl 1):305–15 (35 ref.)

Local delivery of tetracycline: from concept to clinical application. Tonetti MS. **J Clin Periodontol** 1998 Nov;25(11 Pt 2):969–77 (80 ref.)

The use of locally delivered minocycline in the treatment of chronic periodontitis. A review of the literature. Vandekerckhove BN, et al. **J Clin Periodontol** 1998 Nov; 25(11 Pt 2):964–8; discussion 978–9 (34 ref.)

[Antibiotics in periodontal therapy. Their use within the framework of a treatment concept] Mombelli A. **Schweiz Monatsschr Zahnmed** 1998;108(10):968–81 (23 ref.) **(Ger, Fre)**

EPIDEMIOLOGY

On oral disease, illness and impairment among 50-year-olds in two Swedish counties. Unell L. **Swed Dent J Suppl** 1999; 135:1–45 (105 ref.)

ETIOLOGY

The relationship between oral malodor, gingivitis, and periodontitis. A review. Ratcliff PA, et al. **J Periodontol** 1999 May;70(5):485–9 (32 ref.)

GENETICS

Inheritance as a determinant of susceptibility for periodontitis. Schenkein HA. **J Dent Educ** 1998 Oct; 62(10):840–51 (75 ref.)

IMMUNOLOGY

Host modulation as a therapeutic strategy in the treatment of periodontal disease. Kornman KS. **Clin Infect Dis** 1999 Mar;28(3):520–6 (52 ref.)

MICROBIOLOGY

Role of gingipains R in the pathogenesis of Porphyromonas gingivalis-mediated periodontal disease. Genco CA, et al. **Clin Infect Dis** 1999 Mar;28(3):456–65 (67 ref.)

[Study on stimulatory mechanism of inflammatory bone resorption induced by Porphyromonas gingivalis] Hanazawa S. **Nippon Saikingaku Zasshi** 1998 Nov; 53(4):571–86 (66 ref.) **(Jpn)**

PATHOLOGY

Destructive membranous periodontal disease (Ligneous periodontitis). Günhan O, et al. **J Periodontol** 1999 Aug; 70(8):919–25 (15 ref.)

PHYSIOPATHOLOGY

The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Graves DT. **Clin Infect Dis** 1999 Mar;28(3):482–90 (82 ref.)

Attrition, eruption, and the periodontium. Newman HN. **J Dent Res** 1999 Mar;78(3):730–4 (56 ref.)

Growth and development considerations in the diagnosis of gingivitis and periodontitis in children. Bimstein E, et al. **Pediatr Dent** 1999 May-Jun;21(3):186–91 (80 ref.)

PREVENTION & CONTROL

Effect of increased community and professional awareness of plaque control on the management of inflammatory periodontal diseases. Bartold PM, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):282–9 (45 ref.)

THERAPY

Host modulation as a therapeutic strategy in the treatment of periodontal disease. Kornman KS. **Clin Infect Dis** 1999 Mar;28(3):520–6 (52 ref.)

Treatment of periodontitis in the diabetic patient. A critical review. Gustke CJ. **J Clin Periodontol** 1999 Mar; 26(3):133–7 (46 ref.)

PERIODONTITIS, ACUTE NONSUPPURATIVE see **PERIAPICAL PERIODONTITIS**

PERIODONTITIS, APICAL see **PERIAPICAL PERIODONTITIS**

PERIODONTITIS, APICAL, CHRONIC NONSUPPURATIVE see **PERIAPICAL GRANULOMA**

PERIODONTITIS, APICAL, SUPPURATIVE see **PERIAPICAL ABSCESS**

PERIODONTITIS, JUVENILE

PATHOLOGY

A potential role of an intracellular signaling defect in neutrophil functional abnormalities and promotion of tissue damage in patients with localized juvenile periodontitis. Leino L, et al. **Clin Chem Lab Med** 1999 Mar;37(3):215–22 (85 ref.)

PERIODONTITIS, PREPUBERTAL see **PERIODONTITIS, JUVENILE**

PERIODONTIUM

ANATOMY & HISTOLOGY

The periodontal infrastructure. Galler C. **Dent Clin North Am** 1998 Oct;42(4):579–94 (54 ref.)

DRUG EFFECTS

Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Sorsa T, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:130–40 (28 ref.)

MICROBIOLOGY

Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Lamont RJ, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1244–63 (285 ref.)

PHYSIOLOGY

Oral and periodontal tissue. Maintenance, augmentation, rejuvenation, and regeneration. Wiggs RB, et al. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1165–88, vii (85 ref.)

[The effect of the use of chewing gum on the biomechanics of the masticatory system and periodontal tissue] Loginova NK, et al. **Stomatologiia (Mosk)** 1998;77(5):63–8 (102 ref.) **(Rus)**

[The biomechanical properties of the periodontal tissues] Solov'ev MM, et al. **Stomatologiia (Mosk)** 1999;78(3):61–7 (78 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Radiographic evaluation. Gorrel C. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1089–110 (34 ref.)

SURGERY

Current periodontal plastic procedures around teeth and dental implants. Oringer RJ, et al. **N Y State Dent J** 1999 Jun-Jul;65(6):26–31 (25 ref.)

PERIODONTOSIS see **PERIODONTITIS, JUVENILE**

PERIOPERATIVE CARE

Perioperative management of the patient with cancer. Lefor AT. **Chest** 1999 May;115(5 Suppl):165S–171S (28 ref.)

Perioperative blood transfusions: indications and options. McFarland JG. **Chest** 1999 May;115(5 Suppl):113S–121S (59 ref.)

Special problems in the elderly. Oskvig RM. **Chest** 1999 May; 115(5 Suppl):158S–164S (56 ref.)

Progress in perioperative enteral tube feeding. Bengmark S. **Clin Nutr** 1998 Aug;17(4):145–52 (100 ref.)

Controversies in perioperative medicine. Cheng HQ. **West J Med** 1998 Dec;169(6):351–5 (27 ref.)

[Pharmacotherapeutic choices for correction of disorders of primary hemostasis] Levi M, et al. **Ned Tijdschr Geneeskd** 1999 Feb 13;143(7):347–51 (42 ref.) (Eng. Abstr.) **(Dut)**

[Postoperative patient management. Perioperative myocardial infarct] Fellahi JL, et al. **Presse Med** 1999 Jan 30;28(4):187–94 (51 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Peri-operative steroid supplementation. Nicholson G, et al. **Anaesthesia** 1998 Nov;53(11):1091–104 (125 ref.)

Perioperative management of anaemia. Chen AY, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:20–4 (56 ref.)

Controversies in autologous blood procurement. Goodnough LT. **Br J Anaesth** 1998 Dec;81 Suppl 1:67–72 (71 ref.)

Preoperative packed cell volume necessary for patients undergoing elective surgery. Spence RK. **Br J Anaesth** 1998 Dec;81 Suppl 1:50–5 (46 ref.)

Perioperative management of the elderly trauma patient. Dickson RE, et al. **Hosp Med** 1999 Jun;60(6):425–9 (21 ref.)

Care of the surgical intensive care nursery graduate. The primary care pediatrician's perspective. Brown RL, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1327–52 (60 ref.)

Pediatric anesthesia and postoperative analgesia. Feldman D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1525–37 (16 ref.)

Potassium and anaesthesia. Reddy VG. **Singapore Med J** 1998 Nov;39(11):511–6 (56 ref.)

[Antithrombotic therapy. Modern therapeutic approaches] Harenberg J, et al. **Internist (Berl)** 1999 Aug;40(8):885–93 (61 ref.) **(Ger)**

TRENDS

New directions in perioperative management for pediatric solid organ transplantation. Montenegro LM, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):457–72 (161 ref.)

PERIOPERATIVE NURSING

see related
OPERATING ROOM NURSING

What perioperative nurses need to know about substance abuse. Bailes B. **AORN J** 1998 Oct;68(4):611–4, 617–22, 625–6 (50 ref.)

Balloon endometrial ablation as a safe alternative to hysterectomy. Barrow C. **AORN J** 1999 Jul;70(1):80, 83–6, 89–90; quiz 92–6 (51 ref.)

Minimally invasive direct coronary artery bypass surgery. Coulson AS, et al. **AORN J** 1997 Dec;66(6):1012–37; quiz 1039–42 (22 ref.)

Anatomy and physiology of the esophagus. Gavaghan M. **AORN J** 1999 Feb;69(2):372–86; quiz 387–9, 392, 393–4 (54 ref.)

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Management of hysteroscopic surgery complications. Morrison DM. **AORN J** 1999 Jan;69(1):194–7, 199–209; quiz 210, 213–5, 21 (35 ref.)

The surgical significance of therapeutic touch. Ramnarine-Singh S. **AORN J** 1999 Feb;69(2):358–69 (52 ref.)

Radiation safety. Shymko M, et al. **AORN J** 1998 Oct; 68(4):596–602; quiz 603–4, 606, 609–10 (35 ref.)

Pneumoperitoneum--physiology and nursing interventions [published erratum appears in AORN J 1999 Jan;69(1):21] Steuer K. **AORN J** 1998 Sep;68(3):412–25; quiz 426, 429–32 (54 ref.)

Cardiac explantation and autotransplantation. Wagner S, et al. **AORN J** 1999 Jul;70(1):99–100, 102, 104–7; quiz 108–12 (13 ref.)

Renal transplantation. Wallace MA. **AORN J** 1998 Dec; 68(6):964–6, 969–72 passim; quiz 995–1002 (43 ref.)

METHODS

Caring for the Islamic patient. McKennis AT. **AORN J** 1999 Jun;69(6):1187–96; quiz 1199–206 (18 ref.)

Perioperative management of burn patients. Rose DD, et al. **AORN J** 1999 Jun;69(6):1211–22; quiz 1223–30 (33 ref.)

STANDARDS

Improving glove barrier effectiveness. Rabussay DP, et al. **AORN J** 1997 Dec;66(6):1043–6, 1049–54, 1057–60 passim (55 ref.)

PERIORAL DERMATITIS see **DERMATITIS, PERIORAL**

PERIOSTEUM

PATHOLOGY

Bizarre parosteal osteochondromatous proliferation in the anterior maxilla: report of a case. Shankly PE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):351–6 (26 ref.)

PERIPHERAL ANGIOPATHIES see **PERIPHERAL VASCULAR DISEASES**

PERIPHERAL CATHETERIZATION see **CATHETERIZATION, PERIPHERAL**

PERIPHERAL NERVE DISEASES see **PERIPHERAL NERVOUS SYSTEM DISEASES**

PERIPHERAL NERVE NEOPLASMS

DIAGNOSIS

Paraganglioma of the cauda equina region--report of two cases and review of the literature. Aghakhani N, et al. **Acta Neurochir (Wien)** 1999;141(1):81–7 (46 ref.)

Tibial neuroma presenting as a Baker cyst. A case report. DeLuca PF, et al. **J Bone Joint Surg Am** 1999 Jun; 81(6):856–8 (10 ref.)

[Ewing's sarcoma of the soft tissues: apropos of 3 cases and review of the literature] Paoletti H, et al. **J Radiol** 1999 May;80(5):477–82 (26 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Woodruff JM. **Am J Med Genet** 1999 Mar 26;89(1):23–30 (39 ref.)

Malignant granular cell tumor: report of a case and review of the literature. Sonobe H, et al. **Pathol Res Pract** 1998; 194(7):507–13; discussion 515–6 (50 ref.)

Primary intraosseous malignant peripheral nerve sheath tumor: a case report and review of the literature. Khan RJ, et al. **Pathology** 1998 Aug;30(3):237–41 (72 ref.)

Peripheral neuroepithelioma with ganglion cells: report of two cases and review of the literature. Williams S, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):42–9 (47 ref.)

Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Carney JA, et al. **Semin Diagn Pathol** 1998 Aug;15(3):216–24 (15 ref.)

Mediastinal tumors of peripheral nervous system origin. Marchevsky AM. **Semin Diagn Pathol** 1999 Feb;16(1):65–78 (107 ref.)

Cavernous angiomas of the cauda equina: case report and review of the literature. Duke BJ, et al. **Surg Neurol** 1998 Nov;50(5):442–5 (20 ref.)

SURGERY

Paraganglioma of the filum terminale: case report and literature review. Ashkenazi E, et al. **J Spinal Disord** 1998 Dec;11(6):540–2 (11 ref.)

ULTRASONOGRAPHY

Sonographic appearances of nerve tumors. Beggs I. **J Clin Ultrasound** 1999 Sep;27(7):363–8 (27 ref.)

PERIPHERAL NERVES

see related
NERVE FIBERS

Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator. Rowlee SC. **Heart Lung** 1999 Sep–Oct;28(5):352–62; quiz 363–4 (34 ref.)

Abdominal wall pain caused by cutaneous nerve entrapment in an adolescent girl taking oral contraceptive pills. Peleg R. **J Adolesc Health** 1999 Jan;24(1):45–7 (13 ref.)

Neuropathic pain: aetiology, symptoms, mechanisms, and management. Woolf CJ, et al. **Lancet** 1999 Jun 5; 353(9168):1959–64 (34 ref.)

ABNORMALITIES

Marin-Amat syndrome: case report and review of the literature. Pavone P, et al. **J Child Neurol** 1999 Apr; 14(4):266–8 (12 ref.)

CYTOLOGY

Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)

GROWTH & DEVELOPMENT

Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Alvares D, et al. **Pain** 1999 Aug;Suppl 6:S71–85 (193 ref.)

INJURIES

Peripheral nerve surgery of the foot and ankle. A review of current principles. Downey MS, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):175–204 (74 ref.)

Nerve injury and regeneration: basic insights and therapeutic interventions. Müller HW, et al. **Curr Opin Neurol** 1998 Oct;11(5):557–62 (66 ref.)

Nerve injury and inflammatory cytokines modulate gap junctions in the peripheral nervous system. Chandross KJ. **Glia** 1998 Sep;24(1):21–31 (172 ref.)

Peripheral nerve injuries secondary to missiles. Katzman BM, et al. **Hand Clin** 1999 May;15(2):233–44, viii (67 ref.)

Management principles to treat nerve loss after violent trauma to the upper extremity. Thoder JJ, et al. **Hand Clin** 1999 May;15(2):289–98, ix (23 ref.)

Treatment of peripheral nerve injuries: surgeons' perspective. Seiler JG 3rd, et al. **J Hand Ther** 1999 Apr–Jun; 12(2):135–40 (23 ref.)

Evaluation and surgical management of peripheral nerve problems. Grant GA, et al. **Neurosurgery** 1999 Apr; 44(4):825–39; discussion 839–40 (122 ref.)

Causes and consequences of sympathetic basket formation in dorsal root ganglia. Ramer MS, et al. **Pain** 1999 Aug; Suppl 6:S111–20 (77 ref.)

Nerve irritation after laparoscopic hernia repair. Stark E, et al. **Surg Endosc** 1999 Sep;13(9):878–81 (39 ref.)

Does the right side know what the left is doing? Koltzenburg M, et al. **Trends Neurosci** 1999 Mar;22(3):122–7 (91 ref.)

VIP and PACAP: very important in pain? Dickinson T, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):324–9 (77 ref.)

[Advances in the study of lengthening of peripheral nerves and its related subjects] Wu J, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):32–4 (23 ref.) **(Chi)**

[The bikini incision: nice, but not without painful complications (see comments)] Huikeshoven FJ, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1481–3 (11 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2218. **(Dut)**

[Diagnosis and therapy of peripheral nerve injuries. The "integrated therapy concept"] Berger A, et al. **Unfallchirurg** 1999 Jan;102(1):59–68 (44 ref.) **(Ger)**

METABOLISM

Nerve injury and inflammatory cytokines modulate gap junctions in the peripheral nervous system. Chandross KJ. **Glia** 1998 Sep;24(1):21–31 (172 ref.)

Subcellular RNA compartmentalization. Mohr E. **Prog Neurobiol** 1999 Apr;57(5):507–25 (102 ref.)

MICROBIOLOGY

How Mycobacterium leprae infects peripheral nerves. Freedman VH, et al. **Lepr Rev** 1999 Jun;70(2):136–9 (13 ref.)

PHYSIOLOGY

The neurobiology of Schwann cells. Mirsky R, et al. **Brain Pathol** 1999 Apr;9(2):293–311 (179 ref.)

Nerve injury, axonal degeneration and neural regeneration: basic insights. Stoll G, et al. **Brain Pathol** 1999 Apr; 9(2):313–25 (123 ref.)

Effects of steroid hormones on gene expression of glial markers in the central and peripheral nervous system: variations induced by aging. Melcangi RC, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):827–36 (45 ref.)

Peripheral nerve regeneration and neurotrophic factors. Terenghi G. **J Anat** 1999 Jan;194 (Pt 1):1–14 (219 ref.)

Role of thyroid hormones and their receptors in peripheral nerve regeneration. Barakat-Walter I. **J Neurobiol** 1999 Sep 15;40(4):541–59 (113 ref.)

The stochastic diffusion models of nerve membrane depolarization and interspike interval generation. Lánský P, et al. **J Peripher Nerv Syst** 1999;4(1):27–42 (81 ref.)

Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Frostick SP, et al. **Microsurgery** 1998; 18(7):397–405 (82 ref.)

Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Alvares D, et al. **Pain** 1999 Aug;Suppl 6:S71–85 (193 ref.)

Special considerations in pediatric electromyography. Stempien LM. **Phys Med Rehabil Clin N Am** 1998 Nov; 9(4):897–906, viii (57 ref.)

Considerations in reference values for nerve conduction studies. Wang SH, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):907–23, viii (58 ref.)

Cellular and molecular correlates of the regeneration of adult mammalian CNS axons into peripheral nerve grafts. Anderson PN, et al. **Prog Brain Res** 1998;117:211–32 (73 ref.)

Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)

Spinal cord injury: bridging the lesion and the role of neurotrophic factors in repair. Houweling DA, et al. **Prog Brain Res** 1998;117:455–71 (140 ref.)

Role for semaphorin III and its receptor neuropilin-1 in neuronal regeneration and scar formation? Pasterkamp RJ, et al. **Prog Brain Res** 1998;117:151–70 (157 ref.)

SURGERY

Peripheral nerve surgery of the foot and ankle. A review of current principles. Downey MS, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):175–204 (74 ref.)

Treatment of peripheral nerve injuries: surgeons' perspective. Seiler JG 3rd, et al. **J Hand Ther** 1999 Apr–Jun; 12(2):135–40 (23 ref.)

[Advances in the study of lengthening of peripheral nerves and its related subjects] Wu J, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):32–4 (23 ref.) **(Chi)**

[Anterior interosseous nerve syndrome] Grünert J, et al. **Unfallchirurg** 1999 May;102(5):384–90 (47 ref.) **(Ger)**

TRANSPLANTATION

Isolated and combined lesions of the axillary nerve. A review of 146 cases. Bonnard C, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):212–7 (25 ref.)

Cellular and molecular correlates of the regeneration of adult mammalian CNS axons into peripheral nerve grafts. Anderson PN, et al. **Prog Brain Res** 1998;117:211–32 (73 ref.)

ULTRASONOGRAPHY

Tendon and nerve sonography. Martinoli C, et al. **Radiol Clin North Am** 1999 Jul;37(4):691–711, viii (81 ref.)

PERIPHERAL NERVOUS SYSTEM

see related
NEURAL PATHWAYS

ANATOMY & HISTOLOGY

Calibration and standardization of microwave ovens for fixation of brain and peripheral nerve tissue. Login GR, et al. **Methods** 1998 Jun;15(2):107–17 (49 ref.)

CHEMISTRY

Structure and functions of lectins in the central and peripheral nervous system. Zanetta JP. **Acta Anat (Basel)** 1998; 161(1–4):180–95 (116 ref.)

CYTOLOGY

Steroid metabolism and effects in central and peripheral glial cells. Melcangi RC, et al. **J Neurobiol** 1999 Sep 15; 40(4):471–83 (126 ref.)

DRUG EFFECTS

Volatile anesthetics significantly suppress central and peripheral mammalian sodium channels. Duch DS, et al. **Toxicol Lett** 1998 Nov 23;100–101:255–63 (47 ref.)

GROWTH & DEVELOPMENT

Neurotrophin actions during the development of the peripheral nervous system. Fariñas I. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):233–42 (86 ref.)

IMMUNOLOGY

Mechanisms of immune regulation in the peripheral nervous system. Gold R, et al. **Brain Pathol** 1999 Apr;9(2):343–60 (119 ref.)

METABOLISM

Steroid metabolism and effects in central and peripheral glial cells. Melcangi RC, et al. **J Neurobiol** 1999 Sep 15; 40(4):471–83 (126 ref.)

Properties of isolated gastric enterochromaffin-like cells. Zeng N, et al. **Yale J Biol Med** 1998 May–Aug; 71(3–4):233–46 (66 ref.)

PATHOLOGY

Pudendal neuropathy is predictive of failure following anterior overlapping sphincteroplasty. Gilliland R, et al. **Dis Colon Rectum** 1998 Dec;41(12):1516–22 (46 ref.)

PHYSIOLOGY

Somesthesis. Craig JC, et al. **Annu Rev Psychol** 1999; 50:305–31 (210 ref.)

Genetically-targeted and conditionally-regulated ablation of astroglial cells in the central, enteric and peripheral nervous systems in adult transgenic mice. Sofroniew MV, et al. **Brain Res** 1999 Jul 17;835(1):91–5 (34 ref.)

Biological actions of nerve growth factor in the peripheral nervous system. Rask CA. **Eur Neurol** 1999;41 Suppl 1:14–9 (67 ref.)

The transitional zone and CNS regeneration. Fraher JP. **J Anat** 1999 Feb;194 (Pt 2):161–82 (135 ref.)

Ultrastructure and cellular biology of nerve regeneration. Thanos PK, et al. **J Reconstr Microsurg** 1998 Aug; 14(6):423–36 (165 ref.)

[Neuronal growth factors--neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063–70 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3112–3. **(Dan)**

PHYSIOPATHOLOGY

Galanin expression in neuropathic pain: friend or foe? Ramer MS, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:390–401 (35 ref.)

In vivo molecular signal transduction of peripheral mechanisms of pain. Ueda H. **Jpn J Pharmacol** 1999 Mar;

79(3):263–8 (27 ref.)
[Physiopathology of diabetic neuropathies. Functional exploration of peripheral involvement] Raccah D. **Diabetes Metab** 1998 Nov;24 Suppl 3:73–8 (24 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Ultrastructure and cellular biology of nerve regeneration. Thanos PK, et al. **J Reconstr Microsurg** 1998 Aug; 14(6):423–36 (165 ref.)

PERIPHERAL NERVOUS SYSTEM DISEASES

see related
NEUROMUSCULAR DISEASES
SPINAL CORD DISEASES

Neuropathic pain: aetiology, symptoms, mechanisms, and management. Woolf CJ, et al. **Lancet** 1999 Jun 5; 353(9168):1959–64 (34 ref.)
Key developments in neurology. Silber E. **Practitioner** 1997 Sep;241(1578):494–6, 498 (0 ref.)
[Acute sensory neuropathy] Adachi H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):461–3 (16 ref.) **(Jpn)**
[Anti-sulfatide antibody associated neuropathy] Kaida K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):500–2 (11 ref.) **(Jpn)**
[Anti-MAG antibody associated neuropathy] Ogino M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):487–91 (15 ref.) **(Jpn)**
[Lewis-Sumner syndrome] Ogino Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):492–5 (12 ref.) **(Jpn)**
[Multifocal motor neuropathy (MMN)] Ozaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):483–6 (13 ref.) **(Jpn)**
[Myelin diseases affecting both the central and the peripheral nervous system] Hagen K, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3600–2 (20 ref.) (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Promotion of organophosphate induced delayed polyneuropathy by certain esterase inhibitors. Lotti M, et al. **Chem Biol Interact** 1999 May 14;119–120:519–24 (26 ref.)
NTE soluble isoforms: new perspectives for targets of neuropathy inducers and promoters. Vilanova E, et al. **Chem Biol Interact** 1999 May 14;119–120:525–40 (22 ref.)
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Moyle GJ, et al. **Drug Saf** 1998 Dec;19(6):481–94 (67 ref.)
[Neurologic dysfunctions due to poisoning] Yakushiji Y, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):780–6 (5 ref.) **(Jpn)**
[Neurological toxicities of antituberculous drugs] Ohno H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):558–63 (12 ref.) **(Jpn)**

COMPLICATIONS

Constipation: a common problem in patients with neurological abnormalities [published erratum appears in Ital J Gasroenterol Hepatol 1999 Apr;31(3):following 248] Bassotti G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):542–8 (108 ref.)
Respiratory aspects of neurological disease. Polkey MI, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):5–15 (170 ref.)
Postinjury neuropathic pain syndromes. Schwartzman RJ, et al. **Med Clin North Am** 1999 May;83(3):597–626 (112 ref.)

DIAGNOSIS

Peripheral neuropathy. Jude EB, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):81–96, vi (59 ref.)
Sensory examination. Comparison of instruments. Song J, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):29–48, v–vi (73 ref.)
The neurologic examination of the podiatric patient. Spadone SJ. **Clin Podiatr Med Surg** 1999 Jan;16(1):1–17, v (10 ref.)
A non-neurologist's guide to understanding the EMG/NCV report. Willis JD. **Clin Podiatr Med Surg** 1999 Jan; 16(1):19–28, v (9 ref.)
Nondiabetic peripheral neuropathies. Bromberg MB. **Compr Ther** 1998 Nov–Dec;24(11–12):545–52 (15 ref.)
NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Bril V. **Eur Neurol** 1999;41 Suppl 1:8–13 (32 ref.)
Diagnosis and management of diabetic peripheral neuropathy. Illa I. **Eur Neurol** 1999;41 Suppl 1:3–7 (30 ref.)
A minireview of studies conducted in japan using finger-skin temperature during cold-stress tests for the diagnosis of hand-arm vibration syndrome. Harada N, et al. **Int Arch Occup Environ Health** 1999 Aug;72(5):330–4 (54 ref.)
Sarcoidosis of the cauda equina mimicking leptomeningeal malignancy. Abrey LE, et al. **J Neurooncol** 1998 Sep; 39(3):261–5 (11 ref.)
Painful peripheral neuropathies. Vaillancourt PD, et al. **Med Clin North Am** 1999 May;83(3):627–42, vi (53 ref.)
Technology review: the Neurometer Current Perception Threshold (CPT). AAEM Equipment and Computer Committee. American Association of Electrodiagnostic Medicine. **Muscle Nerve** 1999 Apr;22(4):523–31 (56 ref.)
Critical illness polyneuropathy. Bolton CF, et al. **Muscle Nerve** 1999 Mar;22(3):419–24 (20 ref.)
The value of inching techniques in the diagnosis of focal nerve lesions. Inching is a useful technique. Campbell WW. **Muscle Nerve** 1998 Nov;21(11):1554–6; discussion 1561 (10 ref.)
The value of inching techniques in the diagnosis of focal nerve lesions. Inching techniques are of limited use. Geiringer SR. **Muscle Nerve** 1998 Nov;21(11):1557–9; discussion 1559–61 (18 ref.)
AAEM minimonograph 32: the electrodiagnostic examination in patients with radiculopathies. American Association of Electrodiagnostic Medicine. Wilbourn AJ, et al. **Muscle Nerve** 1998 Dec;21(12):1612–31 (147 ref.)
Clinical neurophysiologic studies: which test is useful and when? Lomen-Hoerth C, et al. **Neurol Clin** 1999 Feb; 17(1):65–74 (27 ref.)
Hoffman-Tinel sign. The realities. Alfonso MI, et al. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):721–36, v (59 ref.)
Anatomy and evaluation of the lumbosacral plexus. Fann AV. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):815–29 (65 ref.)
Median and ulnar nerves in the hand. Sable AW. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):737–53 (74 ref.)
[Diagnosis of polyneuropathies (see comments)] Crone C, et al. **Ugeskr Laeger** 1998 Nov 2;160(45):6503–15 (38 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 Feb 22;161(8):1133–4. **(Dan)**
[Peripheral electrodiagnosis in 1998] Métral S. **Neurophysiol Clin** 1999 Feb;29(1):107–10 (23 ref.) **(Fre)**
[Neurologic complications in ANCA-associated vasculitis] Arbusow V, et al. **Dtsch Med Wochenschr** 1999 Jul 9; 124(27):835–41 (33 ref.) **(Ger)**
[Clinical aspects and diagnosis of polyneuropathies] Neundörfer B. **Dtsch Med Wochenschr** 1998 Dec 11; 123(50):1519–22 (15 ref.) **(Ger)**

DRUG THERAPY

Intravenous immunoglobulin treatment in neurologic disorders: yes. Sorensen PS. **Arch Neurol** 1999 Aug; 56(8):1025–7 (52 ref.)
Neurotrophic factors and diabetic peripheral neuropathy. Apfel SC. **Eur Neurol** 1999;41 Suppl 1:27–34 (60 ref.)
Peripheral nerve regeneration and neurotrophic factors. Terenghi G. **J Anat** 1999 Jan;194 (Pt 1):1–14 (219 ref.)
The management of leprosy reversal reactions. Britton WJ. **Lepr Rev** 1998 Sep;69(3):225–34 (51 ref.)
Painful peripheral neuropathies. Vaillancourt PD, et al. **Med Clin North Am** 1999 May;83(3):627–42, vi (53 ref.)

ENZYMOLOGY

Promotion of organophosphate induced delayed polyneuropathy by certain esterase inhibitors. Lotti M, et al. **Chem Biol Interact** 1999 May 14;119–120:519–24 (26 ref.)
NTE soluble isoforms: new perspectives for targets of neuropathy inducers and promoters. Vilanova E, et al. **Chem Biol Interact** 1999 May 14;119–120:525–40 (22 ref.)

ETIOLOGY

Neonatal peroneal neurapraxia: a report of two cases and review of the literature. Godley DR. **Am J Orthop** 1998 Dec;27(12):803–4 (11 ref.)
Neuropsychiatric systemic lupus erythematosus. Sibbitt WL Jr, et al. **Compr Ther** 1999 Apr;25(4):198–208 (32 ref.)
Systemic lupus erythematosus demonstrating serum anti-GM1 antibody, with sudden onset of drop foot as the initial presentation [see comments] Matsuki Y, et al. **Intern Med** 1999 Sep;38(9):729–32 (25 ref.) Comment in: Intern Med 1999 Sep;38(9):689–90.
Posterior interosseous nerve palsy in a patient with rheumatoid synovitis of the elbow: a case report and review of the literature. Westkaemper JG, et al. **J Hand Surg [Am]** 1999 Jul;24(4):727–31 (10 ref.)
Chemokines and peripheral nerve demyelination. Fujioka T, et al. **J Neurovirol** 1999 Feb;5(1):27–31 (40 ref.)
The diversity of peripheral nervous system disorders in Sjögren's syndrome [editorial; comment] van Dijk GW, et al. **Neth J Med** 1998 Nov;53(5):193–5 (16 ref.) Comment on: Neth J Med 1998 Nov;53(5):196–200.
Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma). Knupp-Oliveira S, et al. **Scand J Rheumatol** 1999;28(4):260–1 (10 ref.)
[Gougerot-Sjögren syndrome. Neurologic complications] Amoura Z, et al. **Presse Med** 1999 Jun 19;28(22):1209–13 (64 ref.) (Eng. Abstr.) **(Fre)**
[Autoimmune nervous dysfunctions] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):826–31 (5 ref.) **(Jpn)**
[Neuro-Behcet disease] Wakayama Y, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):818–25 (6 ref.) **(Jpn)**
[Neurologic side effects of interferon therapy] Kohira I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):610–3 (15 ref.) **(Jpn)**
[Neurological complications in patients with chronic renal failure] Ejma M, et al. **Pol Merkuriusz Lek** 1998 Sep; 5(27):173–7 (34 ref.) (Eng. Abstr.) **(Pol)**
[The nutritional-viral etiology of epidemic neuropathy. The Group for the Study of Epidemic Neuropathy] de la Fuente J, et al. **Rev Cubana Med Trop** 1998;50 Suppl:235–40 (40 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Hereditary peripheral neuropathies: clinical forms, genetics, and molecular mechanisms. Warner LE, et al. **Annu Rev Med** 1999;50:263–75 (65 ref.)
Genetic basis of peripheral neuropathies. Valentijn LJ, et al. **Prog Brain Res** 1998;117:249–64 (128 ref.)

IMMUNOLOGY

Mechanisms of immune regulation in the peripheral nervous system. Gold R, et al. **Brain Pathol** 1999 Apr;9(2):343–60 (119 ref.)
Peripheral neuropathies in lupus patients with anti-GM1 antibodies [editorial; comment] Hashimoto H. **Intern Med** 1999 Sep;38(9):689–90 (8 ref.) Comment on: Intern Med 1999 Sep;38(9):729–32.
The management of leprosy reversal reactions. Britton WJ. **Lepr Rev** 1998 Sep;69(3):225–34 (51 ref.)
Autoantibodies associated with peripheral neuropathy. Quarles RH, et al. **Muscle Nerve** 1999 Jul;22(7):800–22 (197 ref.)
[Cytokines and peripheral neuropathies] Créange A, et al. **Rev Neurol (Paris)** 1998 Apr;154(3):208–16 (86 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Metabolic neuropathies. Comi G, et al. **Curr Opin Neurol** 1998 Oct;11(5):523–9 (46 ref.)

PHYSIOPATHOLOGY

Critical illness neuropathy and myopathy. Gutmann L, et al. **Arch Neurol** 1999 May;56(5):527–8 (17 ref.)
Neurotrophic factors in peripheral neuropathies: therapeutic implications. Apfel SC. **Brain Pathol** 1999 Apr;9(2):393–413 (163 ref.)
The neurobiology of Schwann cells. Mirsky R, et al. **Brain Pathol** 1999 Apr;9(2):293–311 (179 ref.)
Paraproteinaemic neuropathies. Steck AJ, et al. **Brain Pathol** 1999 Apr;9(2):361–8 (59 ref.)
Nerve injury, axonal degeneration and neural regeneration: basic insights. Stoll G, et al. **Brain Pathol** 1999 Apr; 9(2):313–25 (123 ref.)
Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Trojaborg W. **Electroencephalogr Clin Neurophysiol** 1998 Nov;107(5):303–16 (117 ref.)
Postinjury neuropathic pain syndromes. Schwartzman RJ, et al. **Med Clin North Am** 1999 May;83(3):597–626 (112 ref.)
[Cytokines and peripheral neuropathies] Créange A, et al. **Rev Neurol (Paris)** 1998 Apr;154(3):208–16 (86 ref.) (Eng. Abstr.) **(Fre)**
[Physiopathology of neuropathic pain syndromes] Lantéri-Minet M. **Therapie** 1999 Jan–Feb;54(1):117–20 (18 ref.) (Eng. Abstr.) **(Fre)**
[Clinical aspects and diagnosis of polyneuropathies] Neundörfer B. **Dtsch Med Wochenschr** 1998 Dec 11; 123(50):1519–22 (15 ref.) **(Ger)**
[Changes in excitability of the spinal cord and dorsal column nucleus and gene expression in neuropathic pain models] Noguchi K. **Masui** 1998 Dec;47 Suppl:S218–23 (7 ref.) **(Jpn)**
[Neuropathic pain--variability in pain maintaining mechanism] Yamamoto T, et al. **Masui** 1998 Dec;47 Suppl:S224–8 (17 ref.) **(Jpn)**

PREVENTION & CONTROL

Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Thomas PK. **Eur Neurol** 1999;41 Suppl 1:35–43 (62 ref.)

SURGERY

Treatment of brachial plexus injury. Nagano A. **J Orthop Sci** 1998;3(1):71–80 (30 ref.)

THERAPY

Diagnosis and management of diabetic peripheral neuropathy. Illa I. **Eur Neurol** 1999;41 Suppl 1:3–7 (30 ref.)
Critical illness polyneuropathy. Bolton CF, et al. **Muscle Nerve** 1999 Mar;22(3):419–24 (20 ref.)
Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Hahn AF. **Neurology** 1998 Dec;51(6 Suppl 5):S16–21 (31 ref.)
Axillary nerve injuries in contact sports: recommendations for treatment and rehabilitation. Perlmutter GS, et al. **Sports Med** 1998 Nov;26(5):351–61 (30 ref.)
[Therapy of polyneuropathies] Neundörfer B. **Dtsch Med Wochenschr** 1998 Dec 18;123(51–52):1553–5 (10 ref.) **(Ger)**

VIROLOGY

[The nutritional-viral etiology of epidemic neuropathy. The Group for the Study of Epidemic Neuropathy] de la Fuente J, et al. **Rev Cubana Med Trop** 1998;50 Suppl:235–40 (40 ref.) (Eng. Abstr.) **(Spa)**

PERIPHERAL RESISTANCE see **VASCULAR RESISTANCE**

PERIPHERAL STEM CELL TRANSPLANTATION see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

PERIPHERAL T-CELL LYMPHOMA see **LYMPHOMA, T-CELL, PERIPHERAL**

PERIPHERAL VASCULAR DISEASES

BLOOD

[Usefulness of blood and plasma viscosity measurements in the evaluation of arteriopathic patients] Laghi Pasini F, et al. **Minerva Cardioangiol** 1998 Apr;46(4):109–17 (55 ref.) (Eng. Abstr.) **(Ita)**

CLASSIFICATION

[Definition and epidemiology of vascular acrosyndromes] Carpentier PH. **Rev Prat** 1998 Oct 1;48(15):1641–6 (12 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Arterioportal fistula with portal hypertension after liver trauma and resection: a case report and review of the literature. Wolf S, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):821–6 (24 ref.)

The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Criqui MH, et al. **Vasc Med** 1998;3(3):241–5 (17 ref.)

DIAGNOSIS

Magnetic resonance angiography in nutcracker phenomenon [letter] Kaneko K, et al. **Clin Nephrol** 1999 Apr; 51(4):259–60 (6 ref.)

Contrast-enhanced magnetic resonance angiography of peripheral vessels. Different contrast agent applications and sequence strategies: a review. Boos M, et al. **Invest Radiol** 1998 Sep;33(9):538–46 (27 ref.)

Vascular disorders of the hand: surgeons' perspective. Levin LS, et al. **J Hand Ther** 1999 Apr-Jun;12(2):152–9 (14 ref.)

Ankle brachial index as a predictor of outcomes in peripheral arterial disease. McDermott MM. **J Lab Clin Med** 1999 Jan;133(1):33–40 (37 ref.)

Noninvasive approaches to peripheral vascular disease. What's new in evaluation and treatment? Powers KB, et al. **Postgrad Med** 1999 Sep;106(3):52–8, 62–64 (31 ref.)

[Contrast-enhanced magnetic resonance angiography] Leiner T, et al. **Ned Tijdschr Geneeskd** 1999 May 22; 143(21):1087–93 (27 ref.) (Eng. Abstr.) **(Dut)**

[Vascular syndromes of the extremities] Soulier-Parmeggiani L. **Rev Med Suisse Romande** 1998 Oct;118(10):839–45 (8 ref.) **(Fre)**

DRUG THERAPY

Antithrombotic therapy in peripheral arterial occlusive disease. Jackson MR, et al. **Chest** 1998 Nov;114(5 Suppl):666S–682S (221 ref.)

ETIOLOGY

Recurrent embolism caused by floating thrombus in the thoracic aorta. Lozano P, et al. **Ann Vasc Surg** 1998 Nov; 12(6):609–11 (27 ref.)

PHYSIOPATHOLOGY

Diabetes and peripheral vascular disease. Akbari CM, et al. **J Vasc Surg** 1999 Aug;30(2):373–84 (111 ref.)

RADIOGRAPHY

[Quantitative angiography: update for peripheral vascular applications] Beregi JP, et al. **J Radiol** 1999 Aug; 80(8):835–41 (26 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

The molecular and cellular biologic basis for the radiation treatment of benign proliferative diseases. Rubin P, et al. **Semin Radiat Oncol** 1999 Apr;9(2):203–14 (119 ref.)

Endovascular brachytherapy for peripheral vascular disease. Tripuraneni P, et al. **Semin Radiat Oncol** 1999 Apr; 9(2):190–202 (70 ref.)

REHABILITATION

Vascular disorders of the hand: therapist's commentary. Talley M. **J Hand Ther** 1999 Apr-Jun;12(2):160–3 (42 ref.)

SURGERY

Amputation surgery in peripheral vascular disease. Pinzur MS, et al. **Instr Course Lect** 1999;48:687–91 (33 ref.)

Vascular disorders of the hand: surgeons' perspective. Levin LS, et al. **J Hand Ther** 1999 Apr-Jun;12(2):152–9 (14 ref.)

Current trends in peripheral vascular surgery. When is surgical intervention the best option? Gorton ME. **Postgrad Med** 1999 Sep;106(3):87–94 (23 ref.)

A multi-modal approach to the management of bypass graft failure. Greenberg RK, et al. **Vasc Med** 1998;3(3):215–20 (19 ref.)

[Anti-platelet agents in peripheral vascular surgery] Van Damme H, et al. **Rev Med Liege** 1999 Feb;54(2):109–17 (47 ref.) (Eng. Abstr.) **(Fre)**

[Multiply distributed atherosclerotic arteriopathy. Indications and limits of surgical treatment] D'Addato M, et al. **Minerva Cardioangiol** 1998 Oct;46(10):423–7 (36 ref.) **(Ita)**

THERAPY

Infection of endovascular stents: an uncommon but important complication. Latham JA, et al. **Cardiovasc Surg** 1999 Mar; 7(2):179–82 (15 ref.)

Current status of medical therapy of peripheral arterial disease [editorial] Conti CR. **Clin Cardiol** 1999 May; 22(5):331–2 (11 ref.)

Acupuncture: neurophysiological perspectives. Hirokawa S. **Disabil Rehabil** 1999 Mar;21(3):131–2; discussion 137–8 (6 ref.)

Gene therapy as a therapeutic intervention for vascular disease. Meyerson SL, et al. **J Cardiovasc Nurs** 1999 Jul; 13(4):91–109 (136 ref.)

Medical outcomes studies in peripheral vascular disease. Murphy TP. **J Vasc Interv Radiol** 1998 Nov-Dec; 9(6):879–89 (50 ref.)

Noninvasive approaches to peripheral vascular disease. What's new in evaluation and treatment? Powers KB, et al. **Postgrad Med** 1999 Sep;106(3):52–8, 62–64 (31 ref.)

Vascular gene therapy. Thomas JW, et al. **Radiographics** 1998 Nov-Dec;18(6):1373–94 (109 ref.)

PERISTALSIS

PHYSIOLOGY

Intestinal peristalsis: a mammalian motor pattern controlled by enteric neural circuits. Costa M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:464–6 (12 ref.)

Megacystis-microcolon-intestinal hypoperistalsis syndrome associated with megaesophagus. Al Harbi A, et al. **Pediatr Surg Int** 1999;15(3–4):272–4 (19 ref.)

PERISTALTIC PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERITONEAL CAVITY

see related
ASCITIC FLUID
LAPAROSCOPY

Tissue-level transport mechanisms of intraperitoneally-administered monoclonal antibodies. Flessner MF, et al. **J Controlled Release** 1998 Apr 30; 53(1–3):69–75 (25 ref.)

The outcome of unretrieved gallstones in the peritoneal cavity during laparoscopic cholecystectomy. A prospective analysis. Memon MA, et al. **Surg Endosc** 1999 Sep; 13(9):848–57 (74 ref.)

PHYSIOLOGY

Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Jörres A, et al. **Kidney Int** 1998 Dec;54(6):2184–93 (78 ref.)

PERITONEAL DIALYSIS

see related
DIALYSIS SOLUTIONS
KIDNEY, ARTIFICIAL

The rationale for Healthy Start dialysis [editorial] Golper TA. **Blood Purif** 1999;17(1):1–9 (53 ref.)

Sex or body size? Selection of dialysis type revisited [editorial; comment] Levin A. **CMAJ** 1999 Mar 23; 160(6):828–9 (10 ref.) Comment on: CMAJ 1999 Mar 23;160(6):818–9.

Haemodialysis and peritoneal dialysis: metabolic alterations and nutritional status [see comments] Cano N. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):329–33 (65 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.

Pregnancy in chronic dialysis: a review and analysis of the literature. Chan WS, et al. **Int J Artif Organs** 1998 May; 21(5):259–68 (82 ref.)

What is the place of peritoneal dialysis in the integrated treatment of renal failure? Coles GA, et al. **Kidney Int** 1998 Dec;54(6):2234–40 (64 ref.)

Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Jörres A, et al. **Kidney Int** 1998 Dec;54(6):2184–93 (78 ref.)

Augmenting solute clearance in peritoneal dialysis. Krediet RT, et al. **Kidney Int** 1998 Dec;54(6):2218–25 (48 ref.)

Experimental models in peritoneal dialysis: a European experience. Lameire N, et al. **Kidney Int** 1998 Dec; 54(6):2194–206 (83 ref.)

Cardiovascular mortality and morbidity in dialysis patients. Eknoyan G. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1–2):100–4 (38 ref.)

Mathematical models for prescription and delivery in peritoneal dialysis. Amici G. **Nephrol Dial Transplant** 1998; 13 Suppl 6:120–4 (48 ref.)

The peritoneal dialysis system. Ronco C, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:94–9 (25 ref.)

Influence of different automated peritoneal dialysis schedules on solute and water removal. Twardowski ZJ. **Nephrol Dial Transplant** 1998;13 Suppl 6:103–11 (18 ref.)

Pathophysiology of peritoneal fluid eosinophilia in peritoneal dialysis patients [editorial] Ejaz AA, et al. **Nephron** 1999 Feb;81(2):125–30 (43 ref.)

Impact of peritoneal membrane function on long-term clinical outcome in peritoneal dialysis patients. Davies SJ, et al. **Perit Dial Int** 1999;19 Suppl 2:S91–4 (17 ref.)

The optimal approach to peritoneal dialysis prescription in children. Fischbach M, et al. **Perit Dial Int** 1999;19 Suppl 2:S462–6 (24 ref.)

Relationships between creatinine clearance and Kt/V in peritoneal dialysis: a defense of the DOQI document. Dialysis Outcomes Quality Initiative [editorial; comment] Gotch FA. **Perit Dial Int** 1999 Mar-Apr;19(2):107–12 (24 ref.) Comment on: Perit Dial Int 1998 May-Jun;18(3):252–5.

Impact of pretransplantation dialysis modality on patient outcome after renal transplantation: the role of peritoneal dialysis revisited [editorial] Van Biesen, et al. **Perit Dial Int** 1999 Mar-Apr;19(2):103–6 (33 ref.)

Principles of dialysis: special issues in women. Gipson D, et al. **Semin Nephrol** 1999 Mar;19(2):140–7 (78 ref.)

[Renal anemia and the effect of long-term dialysis] Opatrná S, et al. **Cas Lek Cesk** 1999 Feb 22;138(4):107–10 (44 ref.) (Eng. Abstr.) **(Cze)**

[Glucose polymer (icodextrin) as a component of fluid for peritoneal dialysis] Czyżewska K, et al. **Pol Arch Med Wewn** 1998 May;99(5):417–22 (44 ref.) **(Pol)**

ADVERSE EFFECTS

Peritoneal dialysis-associated peritonitis caused by Alcaligenes xylosoxidans. El-Shahawy MA, et al. **Am J Nephrol** 1998;18(5):452–5 (32 ref.)

Intraperitoneal thrombolytic therapy for peritoneal dialysis-associated peritonitis. Worland MA, et al. **Ann Pharmacother** 1998 Nov;32(11):1216–20 (22 ref.)

Peritonitis as a complication of peritoneal dialysis. Piraino B. **J Am Soc Nephrol** 1998 Oct;9(10):1956–64 (53 ref.)

What really happens to people on long-term peritoneal dialysis? Davies SJ, et al. **Kidney Int** 1998 Dec; 54(6):2207–17 (43 ref.)

Prevention of renal osteodystrophy in peritoneal dialysis. Weinreich T. **Kidney Int** 1998 Dec;54(6):2226–33 (64 ref.)

Iron status and iron supplementation in peritoneal dialysis patients. Vychytil A, et al. **Kidney Int Suppl** 1999 Mar; 69:S71–8 (91 ref.)

Peritoneal dialysis catheter related infections in children. Warady BA. **Pediatr Infect Dis J** 1998 Dec;17(12):1165–6 (12 ref.)

Cardiovascular problems in peritoneal dialysis patients: a short overview. Hoeben H, et al. **Perit Dial Int** 1999;19 Suppl 2:S150–8 (84 ref.)

Metabolic acidosis as a catabolic factor in peritoneal dialysis patients. Kang DH. **Perit Dial Int** 1999;19 Suppl 2:S304–8 (23 ref.)

Effect of peritoneal dialysis on peritoneal macrophages. Li FK. **Perit Dial Int** 1999;19 Suppl 2:S343–7 (49 ref.)

Malnutrition: detection and intervention. McCann LM. **Perit Dial Int** 1999;19 Suppl 2:S527–32 (61 ref.)

Peritoneal dialysis in children: issues for the 21st century. Salusky IB, et al. **Perit Dial Int** 1999;19 Suppl 2:S484–8 (22 ref.)

Beta2-microglobulin and renal bone disease. Wada T, et al. **Perit Dial Int** 1999;19 Suppl 2:S413–6 (21 ref.)

INSTRUMENTATION

[Dialysis approach for hemo- and peritoneal dialysis] Brunkhorst R, et al. **Internist (Berl)** 1999 Jan;40(1):13–21 (21 ref.) **(Ger)**

METHODS

Intraperitoneal nutrition. Wolfson M, et al. **Am J Kidney Dis** 1999 Jan;33(1):203–4 (10 ref.)

Peritoneal dialysis. Gokal R, et al. **Lancet** 1999 Mar 6; 353(9155):823–8 (39 ref.)

Implications of the Canada-USA (CANUSA) study of the adequacy of dialysis on peritoneal dialysis schedule. Churchill DN. **Nephrol Dial Transplant** 1998;13 Suppl 6:158–63 (32 ref.)

Effects of dialysate volume and flow on solute and water removal with different peritoneal dialysis schedules. Nolph KD. **Nephrol Dial Transplant** 1998;13 Suppl 6:100–2 (20 ref.)

[Adequate peritoneal dialysis: limitations of continuous ambulatory peritoneal dialysis (CAPD), place of automated peritoneal dialysis (APD)] Durand PY, et al. **Nephrologie** 1998;19(5):239–44 (44 ref.) (Eng. Abstr.) **(Fre)**

[Adequate dialysis treatment in hemodialysis and peritoneal dialysis patients] Felten H, et al. **Internist (Berl)** 1999 Jan; 40(1):22–36 (80 ref.) **(Ger)**

PERITONEAL DIALYSIS

STANDARDS

Practical guide to measuring adequacy of dialysis. Blake PG. **Adv Ren Replace Ther** 1999 Jan;6(1):80–4 (12 ref.)

Morbidity and mortality in redefining adequacy of peritoneal dialysis: a step beyond the National Kidney Foundation Dialysis Outcomes Quality Initiative. Chatoth DK, et al. **Am J Kidney Dis** 1999 Apr;33(4):617–32 (125 ref.)

Implications of the Canada–USA (CANUSA) study of the adequacy of dialysis on peritoneal dialysis schedule. Churchill DN. **Nephrol Dial Transplant** 1998;13 Suppl 6:158–63 (32 ref.)

TRENDS

Peritoneal dialysis. Gokal R, et al. **Lancet** 1999 Mar 6; 353(9155):823–8 (39 ref.)

PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire NH. **Contrib Nephrol** 1998; 124:76–93; discussion 93–102 (99 ref.)

Hypertension in dialysis patients. Bellinghieri G, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):84–9 (32 ref.)

CAPD to improve quality of life in patients with refractory heart failure. Elhalel-Dranitzki M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3041–2 (16 ref.)

The treatment of diabetic end-stage renal disease with peritoneal dialysis. Feriani M, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:53–6 (30 ref.)

What place diuretics in long-term CAPD? [editorial] Medcalf JF, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2193–4 (13 ref.)

Behaviour of phosphate removal with different dialysis schedules. Messa P, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:43–8 (29 ref.)

Continuous versus intermittent renal replacement therapy in the treatment of acute renal failure. Ronco C, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:79–85 (36 ref.)

Neuropathy and quality of life in diabetic continuous ambulatory peritoneal dialysis patients. Apostolou T, et al. **Perit Dial Int** 1999;19 Suppl 2:S242–7 (42 ref.)

Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients. Kim SB, et al. **Perit Dial Int** 1999;19 Suppl 2:S144–9 (59 ref.)

Nutrition in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Passadakis P, et al. **Perit Dial Int** 1999;19 Suppl 2:S248–54 (55 ref.)

Relationships between dialysis adequacy, dietary intake and nutritional status of patients treated with continuous ambulatory peritoneal dialysis (CAPD). Grzegorzewska AE. **Przegl Lek** 1998;55 Suppl 1:41–4 (36 ref.) **(Eng, Pol)**

[Adequate peritoneal dialysis: limitations of continuous ambulatory peritoneal dialysis (CAPD), place of automated peritoneal dialysis (APD)] Durand PY, et al. **Nephrologie** 1998;19(5):239–44 (44 ref.) (Eng. Abstr.) **(Fre)**

[Continuous ambulatory peritoneal dialysis for therapy of late-stage kidney failure] Nakayama M, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1329–34 (11 ref.) **(Jpn)**

[Home hemodialysis for therapy of late-stage kidney failure] Saito A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1323–8 (9 ref.) **(Jpn)**

[Adult-onset type II citrullinemia in a patient undergoing continuous ambulatory peritoneal dialysis] Ogawa K, et al. **Rinsho Shinkeigaku** 1998 Sep;38(9):826–30 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Continuous ambulatory peritoneal dialysis in diabetic patients] Stojimrović B, et al. **Srp Arh Celok Lek** 1998 Jul–Aug;126(7–8):277–82 (24 ref.) (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. Herwaldt LA. **J Hosp Infect** 1998 Sep;40 Suppl B:S13–23 (38 ref.)

The peritoneal membrane in chronic peritoneal dialysis [clinical conference] Krediet RT. **Kidney Int** 1999 Jan; 55(1):341–56 (152 ref.)

Influence of different treatments and schedules on the factors conditioning the nutritional status in dialysis patients. Lindholm B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:66–73 (86 ref.)

The peritoneal immune system and continuous ambulatory peritoneal dialysis [editorial] Rapoport J, et al. **Nephron** 1999;81(4):373–80 (32 ref.)

Hypertension in continuous ambulatory peritoneal dialysis patients: what do we know and what can we do about it? Cheigh JS, et al. **Perit Dial Int** 1999;19 Suppl 2:S138–43 (37 ref.)

Fungal peritonitis—current status 1998. Lo WK, et al. **Perit Dial Int** 1999;19 Suppl 2:S286–90 (32 ref.)

Nutritional problems in peritoneal dialysis: an overview. Wang T, et al. **Perit Dial Int** 1999;19 Suppl 2:S297–303 (71 ref.)

METHODS

Continuous renal replacement therapy or hemodialysis for acute renal failure? [editorial] Dillon JJ. **Int J Artif Organs** 1999 Mar;22(3):125–7 (12 ref.)

Adequacy in peritoneal dialysis: a true challenge [editorial] Locatelli A, et al. **Int J Artif Organs** 1999 Mar;22(3):123–4 (16 ref.)

Percutaneous radiologic placement of peritoneal dialysis catheters. Savader SJ. **J Vasc Interv Radiol** 1999 Mar; 10(3):249–56 (28 ref.)

The optimization of continuous ambulatory peritoneal dialysis [clinical conference] Oreopoulos DG. **Kidney Int** 1999 Mar;55(3):1131–49 (118 ref.)

Rationale for early incremental dialysis with continuous ambulatory peritoneal dialysis. Nolph KD. **Nephrol Dial Transplant** 1998;13 Suppl 6:117–9 (14 ref.)

[Alternative dialysis solutions in continuous ambulatory peritoneal dialysis] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):307–9 (30 ref.) (Eng. Abstr.) **(Pol)**

PERITONEAL DISEASES

COMPLICATIONS

Peritoneal sarcoidosis: case report and review of the literature. Uthman IW, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):351–4 (21 ref.)

DIAGNOSIS

Pedunculated exogastric leiomyosarcoma: case report and brief literature review. Shimoji H, et al. **Clin Imaging** 1999 Mar–Apr;23(2):94–8 (15 ref.)

[Encapsulated hematoma of the sigmoid mesocolon. Apropos of an unusual case in Niger] Théry Y, et al. **J Radiol** 1999 Mar;80(3):312–6 (19 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[The prevention of adhesions in surgery. A clinical review and experimental contribution] Palmieri B, et al. **Minerva Chir** 1998 Nov;53(11):953–62 (28 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Pictorial review: Subperitoneal spaces of the broad ligament and sigmoid mesocolon—imaging findings. Hashimoto M, et al. **Clin Radiol** 1998 Dec;53(12):875–81 (9 ref.)

Imaging of pediatric mesenteric abnormalities. Zarewych ZM, et al. **Pediatr Radiol** 1999 Sep;29(9):711–9 (24 ref.)

PERITONEAL EFFUSION see **ASCITIC FLUID**

PERITONEAL FLUID see **ASCITIC FLUID**

PERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

PERITONEAL IRRIGATION see **PERITONEAL LAVAGE**

PERITONEAL LAVAGE

METHODS

[Peritoneal lavage in standardized peritonitis models] Woltmann A, et al. **Zentralbl Chir** 1999;124(3):195–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[The application of laparocentesis and peritoneal lavage and the analysis of hemo-peritoneal volume in the diagnosis of closed abdominal wound] Tishchenko VV. **Klin Khir** 1999;(1):11–2 (2 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

[Peritoneal lavage in standardized peritonitis models] Woltmann A, et al. **Zentralbl Chir** 1999;124(3):195–8 (10 ref.) (Eng. Abstr.) **(Ger)**

PERITONEAL MACROPHAGES see **MACROPHAGES, PERITONEAL**

PERITONEAL NEOPLASMS

Psammocarcinoma with an aggressive course. Poggi SH, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):659–61 (8 ref.)

Primary peritoneal carcinoma: a review of the literature. Chu CS, et al. **Obstet Gynecol Surv** 1999 May;54(5):323–35 (130 ref.)

Peritoneal carcinomatosis: feature of dissemination. A review. Deraco M, et al. **Tumori** 1999 Jan–Feb;85(1):1–5 (39 ref.)

COMPLICATIONS

[Cystic lymphangioma of the mesentery. A case of intestinal obstruction and a brief review of the literature] Fundarò S, et al. **Minerva Chir** 1998 Nov;53(11):939–42 (19 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Leiomyomatosis peritonealis disseminata complicated by sarcomatous transformation and ovarian torsion: presentation of two cases and review of the literature. Fulcher AS, et al. **Abdom Imaging** 1998 Nov–Dec; 23(6):640–4 (18 ref.)

Giant benign cystic peritoneal mesothelioma: US, CT, and MRI findings. Ozgen A, et al. **Abdom Imaging** 1998 Sep–Oct;23(5):502–4 (21 ref.)

Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Ordóñez NG. **Am J Surg Pathol** 1998 Oct;22(10):1203–14 (85 ref.)

Primary tumours of the greater omentum. Ishida H, et al. **Eur Radiol** 1998;8(9):1598–601 (21 ref.)

Primary peritoneal psammocarcinoma: A case presenting with an upper abdominal mass and elevated CA–125. Whitcomb BP, et al. **Gynecol Oncol** 1999 May;73(2):331–4 (7 ref.)

Primary omental liposarcoma presenting with torsion: a case report. Tsutsumi H, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):2110–2 (10 ref.)

Mesenteric fibromatosis: case report and literature review. Al Jadaan SA, et al. **J Pediatr Surg** 1999 Jul;34(7):1130–2 (17 ref.)

[Intra-abdominal desmoplastic small-cell tumor—the rare differential diagnosis of a malignant peritoneal tumor] Rozeik C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):321–3 (10 ref.) **(Ger)**

[Isolated mesenteric fibromatosis. A clinical case] De Toma G, et al. **G Chir** 1999 May;20(5):222–4 (14 ref.) (Eng. Abstr.) **(Ita)**

[Peritoneal carcinomatosis] Coelho SS, et al. **Acta Med Port** 1998 Jun;11(6):585–9 (17 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

[Complete remission of a mesenteric fibromatosis after taking sulindac] D'Alteroche L, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1098–101 (21 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Extrapleural mesothelioma] Lalowicz I. **Pol Merkuriusz Lek** 1999 Jan;6(31):47–9 (31 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884–90 (37 ref.)

PATHOLOGY

Parasitic ovarian dermoid tumor of the omentum–A review of the literature and report of two new cases. Ushakov FB, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 81(1):77–82 (32 ref.)

Epithelial mesothelioma with deciduoid features. Orosz Z, et al. **Virchows Arch** 1999 Mar;434(3):263–6 (16 ref.)

PREVENTION & CONTROL

Inhibition of pristane-induced peritoneal plasmacytoma formation. Potter M, et al. **Curr Top Microbiol Immunol** 1999;246:351–61; discussion 361–2 (48 ref.)

RADIOGRAPHY

Primary leiomyosarcoma of the greater omentum. Ishida J, et al. **J Clin Gastroenterol** 1999 Mar;28(2):167–70 (13 ref.)

SECONDARY

Successful surgical treatment for implanted intraperitoneal metastases of ruptured small hepatocellular carcinoma: report of a case. Kosaka A, et al. **Surg Today** 1999; 29(5):453–7 (16 ref.)

Primary malignant fibrous histiocytoma of the ascending colon: report of a case. Udaka T, et al. **Surg Today** 1999; 29(2):160–4 (22 ref.)

[New philosophy in the treatment of peritoneal carcinomatosis of gastrointestinal origin] Jacquet N. **Bull Mem Acad R Med Belg** 1998;153(10–11):414–25; discussion 425–6 (7 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of peritoneal carcinosis of colorectal origin] Dubé P, et al. **J Chir (Paris)** 1997 Nov;134(5–6):233–6 (50 ref.) **(Fre)**

[Surgical strategy for peritoneal carcinosis of ovarian origin] Michel G, et al. **J Chir (Paris)** 1997 Nov;134(5–6):229–32 (26 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of postoperative recurrence of digestive cancers: peritonitis carcinomatosa] Yamaguchi T, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):211–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Extraneural metastasis of pineal germinoma through a ventriculoperitoneal shunt, following histological change] Uchino M, et al. **No Shinkei Geka** 1999 Mar;27(3):269–74 (23 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Successful surgical treatment for implanted intraperitoneal metastases of ruptured small hepatocellular carcinoma: report of a case. Kosaka A, et al. **Surg Today** 1999; 29(5):453–7 (16 ref.)

[New philosophy in the treatment of peritoneal carcinomatosis of gastrointestinal origin] Jacquet N. **Bull Mem Acad R Med Belg** 1998;153(10–11):414–25; discussion 425–6 (7 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Sonographic findings of malignant fibrous histiocytoma of the mesentery–report of two cases. Shibuya T, et al. **Eur J Ultrasound** 1998 Dec;8(3):207–12 (11 ref.)

PERITONEOSCOPY see **LAPAROSCOPY**

PERITONEUM

see related
ASCITIC FLUID
LAPAROSCOPY

DRUG EFFECTS

The effect of various dialysis solutions on peritoneal membrane viability. Krediet RT, et al. **Perit Dial Int** 1999; 19 Suppl 2:S257–66 (91 ref.)

[Alternative dialysis solutions in continuous ambulatory peritoneal dialysis] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):307–9 (30 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The peritoneal immune system and continuous ambulatory peritoneal dialysis [editorial] Rapoport J, et al. **Nephron** 1999;81(4):373–80 (32 ref.)

[Defense mechanisms in the peritoneum] Szczepanik M, et al. **Przegl Lek** 1999;56(3):227–30 (24 ref.) (Eng. Abstr.) **(Pol)**

INJURIES

[Peritonitis by fish bone. Review of the literature. Pathogenic discussion] Somian FE, et al. **Bull Soc Pathol Exot** 1999 Feb;92(1):18–9 (5 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Impact of peritoneal membrane function on long-term clinical outcome in peritoneal dialysis patients. Davies SJ, et al. **Perit Dial Int** 1999;19 Suppl 2:S91–4 (17 ref.)

PHYSIOPATHOLOGY

Pathogenesis of endometriosis: the role of peritoneal fluid. Koninckx PR, et al. **Gynecol Obstet Invest** 1999;47 Suppl 1:23–33 (138 ref.)

The peritoneal membrane in chronic peritoneal dialysis [clinical conference] Krediet RT. **Kidney Int** 1999 Jan; 55(1):341–56 (152 ref.)

RADIOGRAPHY

A case of a solitary metastatic diaphragmatic tumor––relation to the peritoneal stomata of the diaphragm. Funatsu K, et al. **Radiat Med** 1998 Sep–Oct;16(5):363–5 (6 ref.)

SURGERY

Simple technique for rectus sheath closure after laparoscopic surgery using straight needles, with review of the literature. Chatzipapas IK, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):205–9 (22 ref.)

[A surgical technic for cesarean section and gynecological laparotomy without suturing of the parietal and visceral peritoneum and the single-layer suturing of the uterus during the section (a review of the literature and initial experience)] Katsulov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):40–6 (25 ref.) **(Bul)**

[Total excision of the mesorectum and preservation of the genitourinary innervation in surgery of rectal cancer] Tiret E, et al. **Ann Chir** 1999;53(6):507–14 (16 ref.) (Eng. Abstr.) **(Fre)**

[The use of prosthetic materials placed intraperitoneally in the repair of large defects of the abdominal wall, reflections on a limited case series] Miro AG, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):277–81; discussion 281–2 (30 ref.) (Eng. Abstr.) **(Ita)**

[The application of laparocentesis and peritoneal lavage and the analysis of hemo-peritoneal volume in the diagnosis of closed abdominal wound] Tishchenko VV. **Klin Khir** 1999;(1):11–2 (2 ref.) (Eng. Abstr.) **(Rus)**

PERITONITIS

Epidemiology and pathophysiology of intraabdominal infections (IAI). Farthmann EH, et al. **Infection** 1998 Sep–Oct;26(5):329–34 (26 ref.)

[Pelvic peritonitis] Ishimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):625–7 (15 ref.) **(Jpn)**

DIAGNOSIS

Brucella spp. peritonitis [letter] Alcalá L, et al. **Am J Med** 1999 Sep;107(3):300 (11 ref.)

Cryptococcal peritonitis: report of a case and review of the literature. Stiefel P, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1618–22 (15 ref.)

Sclerosing mesenteritis seen clinically as pancreatic pseudotumor: two cases and a review. Sheikh RA, et al. **Pancreas** 1999 Apr;18(3):316–21 (31 ref.)

[Pysical examination––rebound tenderness (see comments)] Bemelman WA, et al. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):300–3 (11 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 May 8;143(19):1011–2. **(Dut)**

DRUG THERAPY

Intraperitoneal thrombolytic therapy for peritoneal dialysis–associated peritonitis. Worland MA, et al. **Ann Pharmacother** 1998 Nov;32(11):1216–20 (22 ref.)

[Antibiotic treatment of peritonitis] Chalfine A, et al. **J Chir (Paris)** 1999 Mar;136(1):15–20 (21 ref.) (Eng. Abstr.) **(Fre)**

[Lupus cystitis and peritonitis successfully treated with intravenous cyclophosphamide pulse therapy: a case report] Tsutsumino M, et al. **Ryumachi** 1998 Aug;38(4):611–7 (34 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Peritoneal dialysis–associated peritonitis caused by Alcaligenes xylosoxidans. El-Shahawy MA, et al. **Am J Nephrol** 1998;18(5):452–5 (32 ref.)

Streptococcus pneumoniae peritonitis secondary to a tubo-ovarian abscess. Abalde M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):671–3 (6 ref.)

Primary and secondary peritonitis: an update. Laroche M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug; 17(8):542–50 (79 ref.)

Peritonitis as a complication of peritoneal dialysis. Piraino B. **J Am Soc Nephrol** 1998 Oct;9(10):1956–64 (53 ref.)

Familial Mediterranean fever: from inflammation to amyloidosis [editorial] Grateau G. **Nephrol Dial Transplant** 1998 Aug;13(8):1919–20 (39 ref.)

Fungal peritonitis––current status 1998. Lo WK, et al. **Perit Dial Int** 1999;19 Suppl 2:S286–90 (32 ref.)

Generalized peritonitis with pneumoperitoneum caused by the spontaneous perforation of pyometra without malignancy: report of a case. Inui A, et al. **Surg Today** 1999;29(9):935–8 (15 ref.)

[Peritonitis by fish bone. Review of the literature. Pathogenic discussion] Somian FE, et al. **Bull Soc Pathol Exot** 1999 Feb;92(1):18–9 (5 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous bacterial peritonitis (see comments)] Zundler J, et al. **Med Klin** 1998 Oct 15;93(10):612–8 (74 ref.) (Eng. Abstr.) Comment in: Med Klin 1999 May 15;94(5):VII. **(Ger)**

[Treatment of postoperative recurrence of digestive cancers: peritonitis carcinomatosa] Yamaguchi T, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):211–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Peritonitis in the neonatal period] Simão C, et al. **Acta Med Port** 1998 Dec;11(12):1127–9 (11 ref.) (Eng. Abstr.) **(Por)**

[Recurrent spontaneous bacterial peritonitis due to encapsulated microorganisms (Haemophilus influenzae and Streptococcus pneumoniae) in a patient with liver cirrhosis (letter)] Salavert M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):30–1 (10 ref.) **(Spa)**

[Peritonitis secondary to perforated pyometra in a patient with cervical cancer: report of a case] Saleh Mata G, et al. **Ginecol Obstet Mex** 1998 Sep;66:389–91 (20 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Brucella spp. peritonitis [letter] Alcalá L, et al. **Am J Med** 1999 Sep;107(3):300 (11 ref.)

Pneumococcal peritonitis in previously healthy adults: case report and review. Hemsley C, et al. **Clin Infect Dis** 1998 Aug;27(2):376–9 (40 ref.)

Spontaneous bacterial peritonitis. Such J, et al. **Clin Infect Dis** 1998 Oct;27(4):669–74; quiz 675–6 (12 ref.)

Spontaneous non-typhoidal Salmonella peritonitis in patients with serious underlying disorders. de la Fuente-Aguado J, et al. **Infection** 1999 May–Jun;27(3):224–7 (21 ref.)

Spontaneous bacterial peritonitis caused by Streptococcus gordonii. Collazos J, et al. **J Clin Gastroenterol** 1999 Jan; 28(1):45–6 (12 ref.)

PATHOLOGY

Sclerosing encapsulating peritonitis: early and late results of surgical management in 32 cases. French Associations for Surgical Research. Célicout B, et al. **Dig Surg** 1998; 15(6):697–702 (35 ref.)

Primary and secondary peritonitis: an update. Laroche M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug; 17(8):542–50 (79 ref.)

PREVENTION & CONTROL

Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? [editorial; comment] Ginès P, et al. **J Hepatol** 1998 Sep;29(3):490–4 (40 ref.) Comment on: J Hepatol 1998 Sep;29(3):430–6. Comment on: J Hepatol 1998 Sep;29(3):437–42.

SURGERY

Sclerosing encapsulating peritonitis: early and late results of surgical management in 32 cases. French Associations for Surgical Research. Célicout B, et al. **Dig Surg** 1998; 15(6):697–702 (35 ref.)

Anastomic dehiscence and severe peritonitis. Frileux P, et al. **Infection** 1999 Jan–Feb;27(1):67–70 (14 ref.)

[Postoperative management. Critical care in intra-abdominal infection after surgical intervention] Montravers P, et al. **Presse Med** 1999 Jan 30;28(4):196–202 (51 ref.) (Eng. Abstr.) **(Fre)**

[Surgical management of peritonitis and sepsis] Bruch HP, et al. **Zentralbl Chir** 1999;124(3):176–80 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Operative and nonoperative therapy of intraabdominal infections. Wittmann DH. **Infection** 1998 Sep–Oct; 26(5):335–41 (56 ref.)

[Peritoneal lavage in standardized peritonitis models] Woltmann A, et al. **Zentralbl Chir** 1999;124(3):195–8 (10 ref.) (Eng. Abstr.) **(Ger)**

PERITONITIS, CHYLOUS see **CHYLOPERITONEUM**

PERITONITIS, TUBERCULOUS see **TUBERCULOSIS, PERITONEAL**

PERITONSILLAR ABSCESS

[Peritonsillar space infections––peritonsillar abscess] Harada T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):414–6 (13 ref.) **(Jpn)**

[Acute tonsillitis, peritonsillitis, and deep neck infection] Nonomura N. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):304–6 (7 ref.) **(Jpn)**

ETIOLOGY

Peritonsillar abscess and infectious mononucleosis: an association or a different presentation of the same condition. Monem SA, et al. **Ir Med J** 1999 Mar;92(2):278–80 (10 ref.)

PERIVASCULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

PERIVENTRICULAR LEUKOMALACIA see **LEUKOMALACIA, PERIVENTRICULAR**

PERMEABILITY, CAPILLARY see **CAPILLARY PERMEABILITY**

PERMEABILITY, CELL MEMBRANE see **CELL MEMBRANE PERMEABILITY**

PERMEABILITY, MICROVASCULAR see **CAPILLARY PERMEABILITY**

PERMEASES

CHEMISTRY

Structure/function studies on the lactose permease of Escherichia coli. Kaback HR. **Acta Physiol Scand Suppl** 1998 Aug;643:21–33 (72 ref.)

CLASSIFICATION

Molecular phylogeny as a basis for the classification of transport proteins from bacteria, archaea and eukarya. Saier MH Jr. **Adv Microb Physiol** 1998;40:81–136 (75 ref.)

GENETICS

Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. Frillingos S, et al. **FASEB J** 1998 Oct;12(13):1281–99 (117 ref.)

METABOLISM

Structure/function studies on the lactose permease of Escherichia coli. Kaback HR. **Acta Physiol Scand Suppl** 1998 Aug;643:21–33 (72 ref.)

PERONEAL NERVE

Compression and entrapment neuropathies of the lower extremity. McCluskey LF, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):97–125, vii (25 ref.)

Peroneal neuropathy. Katirji B. **Neurol Clin** 1999 Aug; 17(3):567–91, vii (19 ref.)

INJURIES

Neonatal peroneal neurapraxia: a report of two cases and review of the literature. Godley DR. **Am J Orthop** 1998 Dec;27(12):803–4 (11 ref.)

PEROPERATIVE CARE see **INTRAOPERATIVE CARE**

PEROPERATIVE COMPLICATIONS see **INTRAOPERATIVE COMPLICATIONS**

PEROXIDASE

The peroxidase-antiperoxidase (PAP) method and other all-immunologic detection methods. Bratthauer GL. **Methods Mol Biol** 1999;115:191–201 (8 ref.)

PEROXIDASE

BIOSYNTHESIS

Insights into myeloperoxidase biosynthesis from its inherited deficiency. Nauseef WM. **J Mol Med** 1998 Sep;76(10):661–8 (107 ref.)
Myeloperoxidase gene expression and regulation by myeloid cell growth factors in normal and leukemic cells. Tsuruta T, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):257–67 (107 ref.)

DEFICIENCY

Quality control in the endoplasmic reticulum: lessons from hereditary myeloperoxidase deficiency. Nauseef WM. **J Lab Clin Med** 1999 Sep;134(3):215–21 (53 ref.)
Prevalence of myeloperoxidase deficiency: population studies using Bayer–Technicon automated hematology. Kutter D. **J Mol Med** 1998 Sep;76(10):669–75 (8 ref.)
Clinical manifestation of myeloperoxidase deficiency. Lanza F. **J Mol Med** 1998 Sep;76(10):676–81 (48 ref.)
Insights into myeloperoxidase biosynthesis from its inherited deficiency. Nauseef WM. **J Mol Med** 1998 Sep;76(10):661–8 (107 ref.)
Molecular genetics of peroxidase deficiency. Petrides PE. **J Mol Med** 1998 Sep;76(10):688–98 (77 ref.)
[Myeloperoxidase deficiency] Okamura T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):64–6 (14 ref.) **(Jpn)**

GENETICS

Quality control in the endoplasmic reticulum: lessons from hereditary myeloperoxidase deficiency. Nauseef WM. **J Lab Clin Med** 1999 Sep;134(3):215–21 (53 ref.)
Molecular genetics of peroxidase deficiency. Petrides PE. **J Mol Med** 1998 Sep;76(10):688–98 (77 ref.)
Myeloperoxidase gene expression and regulation by myeloid cell growth factors in normal and leukemic cells. Tsuruta T, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):257–67 (107 ref.)
[Myeloperoxidase deficiency] Okamura T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):64–6 (14 ref.) **(Jpn)**

IMMUNOLOGY

Autoantibodies to myeloperoxidase: clinical and pathophysiological significance. Kallenberg CG. **J Mol Med** 1998 Sep;76(10):682–7 (38 ref.)
[A pediatric case of myeloperoxidase–antineutrophil cytoplasmic (ANCA)–related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves' disease] Kawasaki Y, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):612–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. Heinecke JW. **J Lab Clin Med** 1999 Apr;133(4):321–5 (32 ref.)
Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Kettle AJ, et al. **Redox Rep** 1997 Oct–Dec;3(5–6):257–8 (17 ref.)

PHYSIOLOGY

Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Hampton MB, et al. **Blood** 1998 Nov 1;92(9):3007–17 (165 ref.)

PEROXIDASE-ANTIPEROXIDASE COMPLEX TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASE-LABELED ANTIBODY TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASES

[Peroxiredoxin—a novel antioxidant system in vivo] Sato H, et al. **Seikagaku** 1999 May;71(5):333–7 (21 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

COX-1 and COX-2 inhibition: current status and future perspective. Greyn J, et al. **Acta Anaesthesiol Belg** 1998; 49(3):175–83 (39 ref.)

CHEMICAL SYNTHESIS

Chemical engineering of enzymes: altered catalytic activity, predictable selectivity and exceptional stability of the semisynthetic peroxidase seleno-subtilisin. Häring D, et al. **Naturwissenschaften** 1999 Jul;86(7):307–12 (32 ref.)

CHEMISTRY

Understanding heme cavity structure of peroxidases: comparison of electronic absorption and resonance Raman spectra with crystallographic results. Smulevich G. **Biospectroscopy** 1998;4(5 Suppl):S3–17 (101 ref.)

IMMUNOLOGY

[A case with rheumatoid arthritis complicated with ANCA-associated vasculitis] Amano K, et al. **Ryumachi** 1998 Oct;38(5):741–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Biotransformations with peroxidases. Adam W, et al. **Adv Biochem Eng Biotechnol** 1999;63:73–108 (167 ref.)
The Achilles' heel of trypanosomatids: trypanothione-mediated hydroperoxide metabolism. Flohé L. **Biofactors** 1998;8(1–2):87–91 (20 ref.)
Haloperoxidases and their role in biotransformation reactions. Littlechild J. **Curr Opin Chem Biol** 1999 Feb;3(1):28–34 (54 ref.)

PHYSIOLOGY

Role of cyclooxygenase-1 and -2 in health and disease. Lipsky PE. **Am J Orthop** 1999 Mar;28(3 Suppl):8–12 (29 ref.)

PEROXIDES

see related
BENZOYL PEROXIDE
LIPID PEROXIDES
REACTIVE OXYGEN SPECIES

ADVERSE EFFECTS

Safety assessment of peroxide antimalarials: clinical and chemical perspectives. Park BK, et al. **Br J Clin Pharmacol** 1998 Dec;46(6):521–9 (63 ref.)

PEROXISOMAL DISORDERS

[Newly identified peroxisomal disorders] Suzuki Y, et al. **No To Shinkei** 1999 Apr;51(4):295–302 (52 ref.) **(Jpn)**

CLASSIFICATION

Paul Dyken Lecture of the Southern Pediatric Neurology Society. Inherited neurodegenerative disease: the evolution of our thinking. Percy AK. **J Child Neurol** 1999 Apr; 14(4):256–62 (32 ref.)

GENETICS

Genetic peroxisomal disorders: why, when, and how to test [editorial; comment] Moser HW, et al. **Ann Neurol** 1998 Nov;44(5):713–5 (14 ref.) Comment on: Ann Neurol 1998 Nov;44(5):720–30.
Peroxisomal disorders: clinical, biochemical, and molecular aspects. Wanders RJ. **Neurochem Res** 1999 Apr; 24(4):565–80 (117 ref.)

METABOLISM

New insights in peroxisomal beta-oxidation. Implications for human peroxisomal disorders. Van Veldhoven PP. **Verh K Acad Geneeskd Belg** 1998;60(3):195–214 (97 ref.)

PHYSIOPATHOLOGY

Peroxisomal disorders: clinical, biochemical, and molecular aspects. Wanders RJ. **Neurochem Res** 1999 Apr; 24(4):565–80 (117 ref.)

PEROXISOME PROLIFERATORS

see related
MICROBODIES

METABOLISM

Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. Clarke SD, et al. **Am J Clin Nutr** 1999 Oct;70(4):566–71 (66 ref.)
Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. Rose ML, et al. **Drug Metab Rev** 1999 Feb;31(1):87–116 (81 ref.)

PHARMACOLOGY

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Gelman L, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):932–43 (141 ref.)

TOXICITY

Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. Holden PR, et al. **J Mol Endocrinol** 1999 Feb;22(1):1–8 (70 ref.)
Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Hertz R, et al. **Toxicol Lett** 1998 Dec 28;102–103:85–90 (40 ref.)
Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. James NH, et al. **Toxicol Lett** 1998 Dec 28;102–103:91–6 (40 ref.)
Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Vanden Heuvel JP. **Toxicol Sci** 1999 Jan; 47(1):1–8 (72 ref.)

PEROXISOMES see **MICROBODIES**

PERSIAN GULF SYNDROME

Developing case definitions for symptom-based conditions: the problem of specificity. Hyams KC. **Epidemiol Rev** 1998; 20(2):148–56 (124 ref.)

PHYSIOPATHOLOGY

Stress and immune dysfunction in Gulf War veterans. Everson MP, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:413–8 (27 ref.)

THERAPY

Patients with "Gulf War syndrome." Even without etiologic answers treatment studies are needed [editorial; comment] Schumacher HR Jr. **J Rheumatol** 1998 Nov;25(11):2059–61 (16 ref.) Comment on: J Rheumatol 1998 Nov;25(11):2228–35.

PERSISTENT COMMON ATRIOVENTRICULAR CANAL see **ENDOCARDIAL CUSHION DEFECTS**

PERSISTENT OSTIUM PRIMUM see **ENDOCARDIAL CUSHION DEFECTS**

PERSISTENT VEGETATIVE STATE

Moral dilemmas of tetraplegia; the 'locked-in' syndrome, the persistent vegetative state and brain death. Firsching R. **Spinal Cord** 1998 Nov;36(11):741–3 (17 ref.)
[Prognosis of the apallic syndrome. A literature review] Hagel K, et al. **Anaesthesist** 1998 Aug;47(8):677–82 (24 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[The brain hypothermia therapy for prevention of vegetation after severe brain injury] Hayashi N. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):443–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

[New research and considerations in managing minimally conscious coma patients] Zieger A. **Rehabilitation (Stuttg)** 1998 Nov;37(4):167–76 (100 ref.) (Eng. Abstr.) **(Ger)**

PERSONAL LIABILITY see **LIABILITY, LEGAL**

PERSONAL SATISFACTION

Interpersonal and psychological correlates of marital dissatisfaction in late life: a review. Gagnon MD, et al. **Clin Psychol Rev** 1999 Apr;19(3):359–78 (102 ref.)
Creating a life story: the task of reconciliation. Coleman PG. **Gerontologist** 1999 Apr;39(2):133–9 (33 ref.)
The relationship between satisfaction with mouth and number and position of teeth. Elias AC, et al. **J Oral Rehabil** 1998 Sep;25(9):649–61 (118 ref.)

PERSONAL SPACE

What does a home mean and when does it cease to be a home? Home as a setting for rehabilitation and care. Tamm M. **Disabil Rehabil** 1999 Feb;21(2):49–55 (33 ref.)

PERSONALITY

Defining, measuring, and predicting impulsive aggression: a heuristic model. Barratt ES, et al. **Behav Sci Law** 1998 Summer;16(3):285–302 (46 ref.)
Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Rozanski A, et al. **Circulation** 1999 Apr 27;99(16):2192–217 (279 ref.)
Ego autonomy and the healthy personality: psychodynamics, cognitive style, and clinical applications. Miller L. **Psychoanal Rev** 1998 Jun;85(3):423–48 (88 ref.)
The role of objective personality inventories in suicide risk assessment: an evaluation and proposal. Johnson WB, et al. **Suicide Life Threat Behav** 1999 Summer;29(2):165–85 (99 ref.)
[Stress, personality and cardiovascular diseases] Lahlou K, et al. **Rev Med Interne** 1998;19 Suppl 3:339S–342S (16 ref.) **(Fre)**
[Sensation seeking—critical review of personality psychological concepts and its application] Möller A, et al. **Fortschr Neurol Psychiatr** 1998 Nov;66(11):487–95 (89 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Four out of five ain't bad [comment] Widiger TA. **Arch Gen Psychiatry** 1998 Oct;55(10):865–6 (20 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):941–8.

GENETICS

Towards a genetics of anxious temperament: from mice to men. Gershenfeld HK, et al. **Acta Psychiatr Scand Suppl** 1998;393:56–65 (109 ref.)
Dopamine D4 receptor gene: novelty or nonsense? Paterson AD, et al. **Neuropsychopharmacology** 1999 Jul;21(1):3–16 (90 ref.)

PERSONALITY ASSESSMENT

Methodological issues in assessing resilience in maltreated children. Kinard EM. **Child Abuse Negl** 1998 Jul; 22(7):669–80 (45 ref.)

An integrative conceptual framework for assessing and treating suicidal behavior in adolescents. Rudd MD, et al. **J Adolesc** 1998 Aug;21(4):489–98 (25 ref.)
A process model for assessing adolescent risk for suicide. Stoelb M, et al. **J Adolesc** 1998 Aug;21(4):359–70 (36 ref.)
Assertive, offensive, protective, and defensive styles of self-presentation: a taxonomy. Schütz A. **J Psychol** 1998 Nov;132(6):611–28 (80 ref.)

STATISTICS & NUMERICAL DATA

[Assessing the quality of life of children and adolescents with psychiatric disorders--a review] Mattejat F, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug; 26(3):183–96 (45 ref.) **(Ger)**

PERSONALITY DEVELOPMENT

see related
SOCIALIZATION

Peer relationships and quality of life. Bukowski WM, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):108–9 (10 ref.)
Depressogenic cognitive styles: predictive validity, information processing and personality characteristics, and developmental origins. Alloy LB, et al. **Behav Res Ther** 1999 Jun;37(6):503–31 (120 ref.)
What if Astyanax had survived? War, children, and youth. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):137–51 (106 ref.)
The impact of trauma and disaster on young children. Gurwitch RH, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):19–32, vii–viii (68 ref.)
Developmental pathways to antisocial behavior: the delayed-onset pathway in girls. Silverthorn P, et al. **Dev Psychopathol** 1999 Winter;11(1):101–26 (110 ref.)
Implications of attachment theory for developmental psychopathology. Sroufe LA, et al. **Dev Psychopathol** 1999 Winter;11(1):1–13 (60 ref.)
What kind of person is a thirty-year-old? Isohanni M, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):202–10 (14 ref.)
Moving ahead: integrating influences of affective processes for development and for psychoanalysis. Emde RN. **Int J Psychoanal** 1999 Apr;80 (Pt 2):317–39 (198 ref.)
Religion, community service, and identity in American youth. Youniss J, et al. **J Adolesc** 1999 Apr;22(2):243–53 (23 ref.)
Annotation: the development of antisocial behavior: an integrative causal model. Lahey BB, et al. **J Child Psychol Psychiatry** 1999 Jul;40(5):669–82 (150 ref.)
Review: emotional and behavioral functioning in phenylketonuria. Sullivan JE, et al. **J Pediatr Psychol** 1999 Jun;24(3):281–99 (86 ref.)
A review of transpersonal theory and its application to the practice of psychotherapy. Kasprow MC, et al. **J Psychother Pract Res** 1999 Winter;8(1):12–23 (89 ref.)
How shall we speak of children's personalities in middle childhood? A preliminary taxonomy. Shiner RL. **Psychol Bull** 1998 Nov;124(3):308–32 (259 ref.)
Effects of early stress on adult affiliative behavior. Henry JP, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):863–75 (54 ref.)
Suicide across the life span: pathways to prevention. King CA. **Suicide Life Threat Behav** 1998 Winter;28(4):328–37 (31 ref.)
[Psychological and social etiology of drug dependence] Türk D, et al. **Internist (Berl)** 1999 Jun;40(6):583–9 (52 ref.) **(Ger)**
[Contribution of maternal sensitivity in transgenerational promotion of binding quality] Ziegenhain U. **Prax Kinderpsychol Kinderpsychiatr** 1999 Feb;48(2):86–100 (40 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY DISORDER, ANTISOCIAL see **ANTISOCIAL PERSONALITY DISORDER**

PERSONALITY DISORDER, BORDERLINE see **BORDERLINE PERSONALITY DISORDER**

PERSONALITY DISORDER, PASSIVE-AGGRESSIVE see **PASSIVE-AGGRESSIVE PERSONALITY DISORDER**

PERSONALITY DISORDER, SCHIZOID see **SCHIZOID PERSONALITY DISORDER**

PERSONALITY DISORDER, SCHIZOTYPAL see **SCHIZOTYPAL PERSONALITY DISORDER**

PERSONALITY DISORDERS

Manualized treatment for substance abusers with personality disorders: dual focus schema therapy. Ball SA. **Addict Behav** 1998 Nov-Dec;23(6):883–91 (30 ref.)
Anxious traits, anxious attachment, and anxious-cluster personality disorders. Paris J. **Harv Rev Psychiatry** 1998 Sep-Oct;6(3):142–8 (80 ref.)
Personality disorders in sociocultural perspective. Paris J. **J Personal Disord** 1998 Winter;12(4):289–301 (74 ref.)

CHEMICALLY INDUCED

Do hallucinogens cause residual neuropsychological toxicity? Halpern JH, et al. **Drug Alcohol Depend** 1999 Feb 1; 53(3):247–56 (103 ref.)

CLASSIFICATION

Four out of five ain't bad [comment] Widiger TA. **Arch Gen Psychiatry** 1998 Oct;55(10):865–6 (20 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):941–8.

COMPLICATIONS

Hoarding: a review. Stein DJ, et al. **Isr J Psychiatry Relat Sci** 1999;36(1):35–46 (81 ref.)

DIAGNOSIS

Central nervous system serotonin and personality as variables contributing to excessive alcohol consumption in non-human primates. Higley JD, et al. **Alcohol Alcohol** 1999 May-Jun;34(3):402–18 (152 ref.)
Four out of five ain't bad [comment] Widiger TA. **Arch Gen Psychiatry** 1998 Oct;55(10):865–6 (20 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):941–8.
Do personality disorders exist? On the validity of the concept and its cognitive-behavioral formulation and treatment. Arntz A. **Behav Res Ther** 1999 Jul;37 Suppl 1:S97–134 (109 ref.)
Do hallucinogens cause residual neuropsychological toxicity? Halpern JH, et al. **Drug Alcohol Depend** 1999 Feb 1; 53(3):247–56 (103 ref.)
Diagnosis of Holocaust survivors and their children. Kellermann NP. **Isr J Psychiatry Relat Sci** 1999;36(1):55–64 (38 ref.)
Approaching psychotherapy of the personality disorders from the Millon perspective. Dorr D. **J Pers Assess** 1999 Jun;72(3):407–25 (35 ref.)
Personality disorders in primary care. Paré MF, et al. **Prim Care** 1999 Jun;26(2):243–78 (66 ref.)
Recognizing comorbid personality disorder can help manage and treat the "untreatable". Benjamin LS, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):775–89, vi (23 ref.)
Assessment and importance of personality disorders in medical patients: an update [see comments] Dhossche DM, et al. **South Med J** 1999 Jun;92(6):546–56 (82 ref.) Comment in: South Med J 1999 Jun;92(6):639–40.

DRUG THERAPY

Special feature: pharmacotherapy in personality disorders. Kapfhammer HP, et al. **J Personal Disord** 1998 Fall; 12(3):277–88 (68 ref.)

ETIOLOGY

Central nervous system serotonin and personality as variables contributing to excessive alcohol consumption in non-human primates. Higley JD, et al. **Alcohol Alcohol** 1999 May-Jun;34(3):402–18 (152 ref.)

GENETICS

Special feature: family-genetic research strategies for personality disorders. Maier W, et al. **J Personal Disord** 1998 Fall;12(3):262–76 (66 ref.)

PSYCHOLOGY

Depressive personality disorder: theoretical issues, clinical findings, and future research questions. Huprich SK. **Clin Psychol Rev** 1998 Aug;18(5):477–500 (93 ref.)
Special feature: a multifacet circumplex model of personality as a basis for the description and therapy of personality disorders. Becker P. **J Personal Disord** 1998 Fall; 12(3):213–25 (30 ref.)
Evidence supporting the temporal lobe epilepsy personality syndrome. Blumer D. **Neurology** 1999;53(5 Suppl 2):S9–12 (18 ref.)
Evidence against the existence of a temporal lobe epilepsy personality syndrome. Devinsky O, et al. **Neurology** 1999; 53(5 Suppl 2):S13–25 (138 ref.)
[Personality and endogeneity in psychopathology] Ramos Gorostiza P. **Actas Esp Psiquiatr** 1999 May-Jun; 27(3):167–75 (24 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Effectiveness of psychotherapy for personality disorders. Perry JC, et al. **Am J Psychiatry** 1999 Sep;156(9):1312–21 (42 ref.)
Treatment of childhood memories: theory and practice. Arntz A, et al. **Behav Res Ther** 1999 Aug;37(8):715–40 (31 ref.)
Do personality disorders exist? On the validity of the concept and its cognitive-behavioral formulation and treatment. Arntz A. **Behav Res Ther** 1999 Jul;37 Suppl 1:S97–134 (109 ref.)
Psychotherapy for severe personality disorder: exploring the limits of evidence based purchasing [see comments] Kisely S. **BMJ** 1999 May 22;318(7195):1410–2 (25 ref.) Comment in: BMJ 1999 May 22;318(7195):1412.
Approaching psychotherapy of the personality disorders from the Millon perspective. Dorr D. **J Pers Assess** 1999 Jun;72(3):407–25 (35 ref.)
Special feature: a multifacet circumplex model of personality as a basis for the description and therapy of personality disorders. Becker P. **J Personal Disord** 1998 Fall; 12(3):213–25 (30 ref.)
Personality disorders in primary care. Paré MF, et al. **Prim Care** 1999 Jun;26(2):243–78 (66 ref.)
Recognizing comorbid personality disorder can help manage and treat the "untreatable". Benjamin LS, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):775–89, vi (23 ref.)
Sexual predators. Zonana HV, et al. **Psychiatr Clin North Am** 1999 Mar;22(1):109–27, vii (68 ref.)
Theoretical and treatment issues of personality disorders in individualistic and collectivistic societies. Kim HA. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S242–5 (12 ref.)

PERSONALITY INVENTORY

Experience with the alcohol use disorders identification test (AUDIT) in Mexico. Medina-Mora E, et al. **Recent Dev Alcohol** 1998;14:383–96 (32 ref.)
The role of objective personality inventories in suicide risk assessment: an evaluation and proposal. Johnson WB, et al. **Suicide Life Threat Behav** 1999 Summer;29(2):165–85 (99 ref.)

STATISTICS & NUMERICAL DATA

[Assessing the quality of life of children and adolescents with psychiatric disorders--a review] Mattejat F, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug; 26(3):183–96 (45 ref.) **(Ger)**

PERSONALITY TYPE A see **TYPE A PERSONALITY**

PERSONNEL ADMINISTRATION, HOSPITAL

Developing successful performance appraisals through choosing appropriate words to effectively describe work. Timmreck TC. **Health Care Manage Rev** 1998 Summer; 23(3):48–57 (14 ref.)

PERSONNEL DISCIPLINE see **EMPLOYEE DISCIPLINE**

PERSONNEL DOWNSIZING

ECONOMICS

Is downsizing and disbanding specialty care teams a counterproductive strategy for cost reduction in health care? Ryder M, et al. **Nutrition** 1998 Sep;14(9):725–8 (40 ref.)

PERSONNEL, HOSPITAL

Standardized management of patients and employees exposed to pertussis [see comments] Haiduven DJ, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):861–4 (09 ref.) Comment in: Infect Control Hosp Epidemiol 1998 Nov;19(11):825–8.

PERSONNEL, HOSPITAL, ORGANIZATION AND ADMINISTRATION see **PERSONNEL ADMINISTRATION, HOSPITAL**

PERSONNEL MANAGEMENT

see related
PERSONNEL ADMINISTRATION, HOSPITAL

METHODS

The agenda of the organization. 2: Interventions. Carroll M. **Occup Med (Lond)** 1998 Oct;48(7):447–9 (8 ref.)

PERSONNEL RECRUITMENT see **PERSONNEL SELECTION**

PERSONNEL SELECTION

Selection, training, and support of relief workers: an occupational health issue. McCall M, et al. **BMJ** 1999 Jan 9;318(7176):113–6 (27 ref.)

LEGISLATION & JURISPRUDENCE

Legal aspects of epilepsy. Finucane AK. **Neurol Clin** 1999 May;17(2):235–43 (42 ref.)

METHODS

Use of immigration policy to manage nursing shortages. Glaessel-Brown EE. **Image J Nurs Sch** 1998;30(4):323–7 (30 ref.)
Evaluating applicants to emergency medicine residency programs. Balentine J, et al. **J Emerg Med** 1999 Jan-Feb; 17(1):131–4 (32 ref.)
Understanding Generation X employees. Kupperschmidt BR. **J Nurs Adm** 1998 Dec;28(12):36–43 (14 ref.)

TRENDS

[The struggle with the ego: the assessment center in the selection of physicians-in-chief] Fritz T. **Chirurg** 1999 Apr; 70(4):493–6 (15 ref.) (Eng. Absir.) **(Ger)**

PERSONNEL STAFFING AND SCHEDULING

How to use light and dark to produce circadian adaptation to night shift work. Eastman CI, et al. **Ann Med** 1999 Apr; 31(2):87–98 (42 ref.)

Shift work, health, the working time regulations and health assessments. Nicholson PJ, et al. **Occup Med (Lond)** 1999 Apr;49(3):127–37 (157 ref.)

Is there an optimal sleep–wake pattern in shift work? Akerstedt T. **Scand J Work Environ Health** 1998;24 Suppl 3:18–27 (98 ref.)

[Work shifts, sleep and biological rhythms] Gaspar S, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):239–45 (13 ref.) **(Por)**

TRENDS

Innovative worktime arrangements. Knauth P. **Scand J Work Environ Health** 1998;24 Suppl 3:13–7 (15 ref.)

PERSONNEL TURNOVER

Understanding Generation X employees. Kupperschmidt BR. **J Nurs Adm** 1998 Dec;28(12):36–43 (14 ref.)

STATISTICS & NUMERICAL DATA

Review of nursing turnover research, 1977–1996. Tai TW, et al. **Soc Sci Med** 1998 Dec;47(12):1905–24 (73 ref.)

PERSONS WITH DISABILITIES see **DISABLED PERSONS**

PERSONS WITH HEARING IMPAIRMENTS see **HEARING IMPAIRED PERSONS**

PERSUASIVE COMMUNICATION

see related
SUGGESTION

PERTHES DISEASE see **LEGG-PERTHES DISEASE**

PERTUSSIGEN see **PERTUSSIS TOXINS**

PERTUSSIS see **WHOOPING COUGH**

PERTUSSIS TOXINS

METABOLISM

Bordatella pertussis adenylate cyclase: a toxin with multiple talents. Ladant D, et al. **Trends Microbiol** 1999 Apr; 7(4):172–6 (31 ref.)

[Signalling function of G proteins insensitive to PTX in the cell] Lachowicz A, et al. **Postepy Biochem** 1998;44(2):164–9 (65 ref.) **(Pol)**

PERTUSSIS VACCINE

ADMINISTRATION & DOSAGE

Whooping cough vaccines: where next? Elliman D. **Child Care Health Dev** 1998 Jul;24(4):259–65 (18 ref.)

Acellular pertussis vaccines in adults. Keitel WA, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):83–94, vi (65 ref.)

IMMUNOLOGY

Immunity to pertussis. Not all virulence factors are protective antigens. Robbins JB, et al. **Adv Exp Med Biol** 1998; 452:207–18 (124 ref.)

Acellular pertussis vaccines in adults. Keitel WA, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):83–94, vi (65 ref.)

New acellular pertussis-containing paediatric combined vaccines. Pines E, et al. **Vaccine** 1999 Mar 26; 17(13–14):1650–6 (51 ref.)

PHARMACOLOGY

A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity. Mills KH, et al. **Dev Biol Stand** 1998;95:31–41 (26 ref.)

STANDARDS

Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid. Robbins JB, et al. **Dev Biol Stand** 1998;95:155–8 (16 ref.)

PERVASIVE CHILD DEVELOPMENT DISORDERS see **CHILD DEVELOPMENT DISORDERS, PERVASIVE**

PERVASIVE DEVELOPMENT DISORDERS see **CHILD DEVELOPMENT DISORDERS, PERVASIVE**

PES CAVUS see **FOOT DEFORMITIES**

PES PLANUS see **FLATFOOT**

PESSARIES, INTRACERVICAL see **INTRAUTERINE DEVICES**

PESSARIES, INTRAUTERINE see **INTRAUTERINE DEVICES**

PEST CONTROL

Activity and biological effects of neem products against arthropods of medical and veterinary importance. Mulla MS, et al. **J Am Mosq Control Assoc** 1999 Jun;15(2):133–52 (122 ref.)

Food pollution. Trevino RJ. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):889–96 (34 ref.)

METHODS

Myths, models and mitigation of resistance to pesticides. Hoy MA. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1787–95 (46 ref.)

PEST CONTROL, BIOLOGICAL

Recent advances in cassava pest management. Bellotti AC, et al. **Annu Rev Entomol** 1999;44:343–70 (188 ref.)

Pathogens and predators of ticks and their potential in biological control. Samish M, et al. **Annu Rev Entomol** 1999;44:159–82 (215 ref.)

Management of ectoparasites with biological control organisms. Hogsette JA. **Int J Parasitol** 1999 Jan; 29(1):147–51; discussion 153–4 (19 ref.)

Biological control of helminths. Larsen M. **Int J Parasitol** 1999 Jan;29(1):139–46; discussion 153–4 (80 ref.)

METHODS

Biological control of agricultural pests by filamentous fungi. Manczinger L. **Acta Microbiol Immunol Hung** 1999; 46(2–3):259–67 (80 ref.)

Bacterial symbiosis in arthropods and the control of disease transmission. Beard CB, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):581–91 (84 ref.)

Biocontrol of plant disease: a (gram–) positive perspective. Emmert EA, et al. **FEMS Microbiol Lett** 1999 Feb 1; 171(1):1–9 (47 ref.)

A new approach to insect-pest control--combination of neurotoxins interacting with voltage sensitive sodium channels to increase selectivity and specificity. Gordon D. **Invert Neurosci** 1997 Sep–Dec;3(2–3):103–16 (55 ref.)

Integrated and biological control of parasites in organic and conventional production systems. Thamsborg SM, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):169–86 (67 ref.)

PESTE DE PETITS RUMINANTS see **RINDERPEST**

PESTICIDE RESIDUES

The legislation of toxicologic safety factors: the Food Quality Protection Act with chlorpyrifos as a test case. Schardein JL, et al. **Reprod Toxicol** 1999 Jan–Feb;13(1):1–14 (45 ref.)

Regulatory approaches for controlling pesticide residues in food animals. Landy RB, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):89–107 (30 ref.)

ADVERSE EFFECTS

[Influence of pesticide residues on human health] Charlier CJ, et al. **Acta Clin Belg Suppl** 1999;1:44–9 (31 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Pesticide residue analysis: 1997–1998. Sherma J. **J AOAC Int** 1999 May–Jun;82(3):561–74 (231 ref.)

Organochlorine residues and elemental contaminants in U.S. freshwater fish, 1976–1986: National Contaminant Biomonitoring Program. Schmitt CJ, et al. **Rev Environ Contam Toxicol** 1999;162:43–104 (160 ref.)

[Quality, the future for food agriculture! Producers, processors, consumers, same battle...] Bloom PJ. **Acta Clin Belg Suppl** 1999;1:50–3 (5 ref.) (Eng. Abstr.) **(Fre)**

POISONING

[Influence of pesticide residues on human health] Charlier CJ, et al. **Acta Clin Belg Suppl** 1999;1:44–9 (31 ref.) (Eng. Abstr.) **(Fre)**

PESTICIDES

Activity and biological effects of neem products against arthropods of medical and veterinary importance. Mulla MS, et al. **J Am Mosq Control Assoc** 1999 Jun;15(2):133–52 (122 ref.)

ADVERSE EFFECTS

Pesticides and Parkinson's disease. Le Couteur DG, et al. **Biomed Pharmacother** 1999 Apr;53(3):122–30 (113 ref.)

Occupational epidemiology in agriculture: a case study in the southern African context. London L. **Int J Occup Environ Health** 1998 Oct–Dec;4(4):245–56 (47 ref.)

Can traditional epidemiology detect cancer risks caused by occupational exposure to pesticides? Georgellis A, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):159–66 (77 ref.)

Pesticides primer for the primary care physician. Musharrafieh U, et al. **J Med Liban** 1998 Nov–Dec; 46(6):321–7 (21 ref.)

The impact of rice pesticides on the aquatic ecosystems of the Sacramento River and Delta (California). Byard JL. **Rev Environ Contam Toxicol** 1999;159:95–110 (32 ref.)

Developing a pesticide policy for individuals with multiple chemical sensitivity: considerations for institutions. Brown AE. **Toxicol Ind Health** 1999 Apr–Jun;15(3–4):432–7 (13 ref.)

The influence of various factors on immune toxicity assessment of pesticide chemicals. Banerjee BD. **Toxicol Lett** 1999 Jun 30;107(1–3):21–31 (34 ref.)

ANALYSIS

Trace analysis of pesticides by gas chromatography. van der Hoff GR, et al. **J Chromatogr A** 1999 May 28; 843(1–2):301–22 (159 ref.)

Biological monitoring of exposure to pesticides: current issues. He F. **Toxicol Lett** 1999 Sep 5;108(2–3):277–83 (43 ref.)

[Retrospective estimation methods of pesticide occupational exposure] Baldi I, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):165–74 (75 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Hygienic classification of pesticides in the Russian Federation. Potapov AI, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):79–84 (4 ref.)

ECONOMICS

The export of pesticides: shipments from U.S. ports, 1995–1996. Smith C, et al. **Int J Occup Environ Health** 1999 Apr–Jun;5(2):141–50 (45 ref.)

METABOLISM

Degradation of pesticides by actinomycetes. De Schrijver A, et al. **Crit Rev Microbiol** 1999;25(2):85–119 (179 ref.)

PHARMACOKINETICS

Estimation of dermal absorption using the exponential saturation model. Thongsinthusak T, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):37–43 (17 ref.)

PHARMACOLOGY

Annonaceous acetogenins: recent progress. Alali FQ, et al. **J Nat Prod** 1999 Mar;62(3):504–40 (138 ref.)

Myths, models and mitigation of resistance to pesticides. Hoy MA. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29; 353(1376):1787–95 (46 ref.)

POISONING

Rational use of cholinesterase activity testing in pesticide poisoning. Lessenger JE, et al. **J Am Board Fam Pract** 1999 Jul–Aug;12(4):307–14 (22 ref.)

Pesticides primer for the primary care physician. Musharrafieh U, et al. **J Med Liban** 1998 Nov–Dec; 46(6):321–7 (21 ref.)

[Acute poisoning from pesticides: human and economic costs] Garcia JE. **Rev Panam Salud Publica** 1998 Dec;4(6):383–7 (65 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

A survey of EPA/OPP and open literature on selected pesticide chemicals. II. Mutagenicity and carcinogenicity of selected chloroacetanilides and related compounds. Dearfield KL, et al. **Mutat Res** 1999 Jul 15; 443(1–2):183–221 (67 ref.)

Aggregate exposures under the Food Quality Protection Act: An approach using chlorpyrifos. Shurdut BA, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):165–77 (65 ref.)

Immunotoxicity of pesticides: a review. Voccia I, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):119–32 (115 ref.)

Xenoendocrine disrupters: laboratory studies on male reproductive effects. Gray LE Jr. **Toxicol Lett** 1998 Dec 28;102–103:331–5 (24 ref.)

[Nephrotoxicity of pesticides] Allazov S. **Urol Nefrol (Mosk)** 1998 Nov–Dec;(6):47–9 (79 ref.) **(Rus)**

PESTIVIRUS, BOVINE see **DIARRHEA VIRUS, BOVINE VIRAL**

PESTIVIRUS INFECTIONS

VETERINARY

Diva vaccines that reduce virus transmission. van Oirschot JT. **J Biotechnol** 1999 Aug 20;73(2–3):195–205 (69 ref.)

PET-HUMAN BONDING see **BONDING, HUMAN-PET**

PET SCAN see **TOMOGRAPHY, EMISSION-COMPUTED**

PETECHIAE see **PURPURA**

PETHIDINE see **MEPERIDINE**

PETIT MAL EPILEPSY see **EPILEPSY, ABSENCE**

PETIT MAL STATUS see **STATUS EPILEPTICUS**

PETRIELLIDIUM see **PSEUDALLESCHERIA**

PETROLEUM

Maintenance work and asbestos-related cancers in the refinery and petrochemical sector. Finkelstein MM. **Am J Ind Med** 1999 Feb;35(2):201–5 (18 ref.)

Psychosocial aspects of stress, health and safety on North Sea installations. Parkes KR. **Scand J Work Environ Health** 1998 Oct;24(5):321–33 (84 ref.)

ADVERSE EFFECTS

Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity? [editorial; comment] Brunt EM. **Liver** 1999 Aug;19(4):263–4 (12 ref.) Comment on: Liver 1999 Aug;19(4):299–304.

METABOLISM

Microbial desulfurization of organic sulfur compounds in petroleum. Ohshiro T, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):1–9 (92 ref.)

A review of the occurrence, toxicity, and biodegradation of condensed thiophenes found in petroleum. Kropp KG, et al. **Can J Microbiol** 1998 Jul;44(7):605–22 (95 ref.)

Bioremediation of petroleum hydrocarbon contaminants in marine habitats. Head IM, et al. **Curr Opin Biotechnol** 1999 Jun;10(3):234–9 (39 ref.)

TOXICITY

Development of toxicity criteria for petroleum hydrocarbon fractions in the Petroleum Hydrocarbon Criteria Working Group approach for risk-based management of total petroleum hydrocarbons in soil. Twerdok LE. **Drug Chem Toxicol** 1999 Feb;22(1):275–91 (31 ref.)

PETROUS BONE

PATHOLOGY

Merkel cell carcinoma of the external auditory canal invading the intracranial compartment. Litofsky NS, et al. **Am J Otolaryngol** 1998 Sep–Oct;19(5):330–4 (18 ref.)

RADIOGRAPHY

Merkel cell carcinoma of the external auditory canal invading the intracranial compartment. Litofsky NS, et al. **Am J Otolaryngol** 1998 Sep–Oct;19(5):330–4 (18 ref.)

PETROUS PYRAMID see **PETROUS BONE**

PETS see **ANIMALS, DOMESTIC**

PEUTZ-JEGHERS SYNDROME

Peutz-Jeghers syndrome: a new understanding. Choi HS, et al. **J Korean Med Sci** 1999 Feb;14(1):2–7 (37 ref.)

GENETICS

The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Hemminki A. **Cell Mol Life Sci** 1999 May; 55(5):735–50 (129 ref.)

[Genetics of colorectal cancer. I. Non-polyposis and polyposis forms of hereditary colorectal cancer] Menko FH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1201–6 (37 ref.) (Eng. Abstr.) **(Dut)**

PEYER'S PATCHES

CYTOLOGY

Development of Peyer's patches, follicle-associated epithelium and M cell: lessons from immunodeficient and knockout mice. Debard N, et al. **Semin Immunol** 1999 Jun; 11(3):183–91 (61 ref.)

Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer's patches--a personal and historical perspective. Owen RL. **Semin Immunol** 1999 Jun;11(3):157–63 (20 ref.)

EMBRYOLOGY

Peyer's patch organogenesis as a programmed inflammation: a hypothetical model. Nishikawa S, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):213–20 (52 ref.)

IMMUNOLOGY

[Mucosal immune system of the intestine] Miura S, et al. **Nippon Rinsho** 1998 Sep;56(9):2228–34 (18 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Peyer's patch organogenesis as a programmed inflammation: a hypothetical model. Nishikawa S, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):213–20 (52 ref.)

PHYSIOLOGY

Interaction of microorganisms, epithelium, and lymphoid cells of the mucosa-associated lymphoid tissue. Hamzaoui N, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:65–74 (53 ref.)

PEYRONIE'S DISEASE see **PENILE INDURATION**

PF1 PHAGE see **INOVIRUS**

PFAUNDLER-HURLER SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

PFEIFFER SYNDROME see **ACROCEPHALOSYNDACTYLIA**

PFIESTERIA PISCICIDA

PATHOGENICITY

Pfiesteria, "the cell from hell," and other toxic algal nightmares. Morris JG Jr. **Clin Infect Dis** 1999 Jun; 28(6):1191–6; quiz 1197–8 (22 ref.)

PG ANALOGS see **PROSTAGLANDINS, SYNTHETIC**

PGD see **PROSTAGLANDINS D**

PGD2 see **PROSTAGLANDIN D2**

PGE see **PROSTAGLANDINS E**

PGE RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGE1 see **ALPROSTADIL**

PGE2 see **DINOPROSTONE**

PGE2ALPHA see **DINOPROSTONE**

PGE2 RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGF see **PROSTAGLANDINS F**

PGF SYNETHETIC see **PROSTAGLANDINS F, SYNTHETIC**

PGF2 see **DINOPROST**

PGF2ALPHA see **DINOPROST**

PGH SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PGI2 see **EPOPROSTENOL**

PGX see **EPOPROSTENOL**

PH see **HYDROGEN-ION CONCENTRATION**

PH1 CHROMOSOME see **PHILADELPHIA CHROMOSOME**

PHACOEMULSIFICATION

Simplicity and complexity in topical anesthesia for cataract surgery [comment] Claoué C. **J Cataract Refract Surg** 1998 Dec;24(12):1546–7 (6 ref.) Comment on: J Cataract Refract Surg 1998 Dec;24(12):1562–5. Comment on: J Cataract Refract Surg 1998 Dec;24(12):1598–601. Comment on: J Cataract Refract Surg 1998 Dec;24(12):1602–8. Comment on: J Cataract Refract Surg 1998 Dec;24(12):1609–13.

ADVERSE EFFECTS

Inflammatory response after cataract surgery. Laurell CG. **Acta Ophthalmol Scand** 1998 Oct;76(5):632–3 (5 ref.)

Management of retained intravitreal lens fragments after cataract surgery. Monshizadeh R, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):397–404 (54 ref.)

PHAGE ATTACHMENT SITES see **ATTACHMENT SITES (MICROBIOLOGY)**

PHAGE FD see **INOVIRUS**

PHAGE IKE see **INOVIRUS**

PHAGE LAMBDA see **BACTERIOPHAGE LAMBDA**

PHAGE M13 see **BACTERIOPHAGE M13**

PHAGE P22 see **BACTERIOPHAGE P22**

PHAGE PF1 see **INOVIRUS**

PHAGE PHI 6 see **BACTERIOPHAGE PHI 6**

PHAGE PHI 29 see **BACILLUS PHAGES**

PHAGE PHI 105 see **BACILLUS PHAGES**

PHAGE RECEPTORS see **RECEPTORS, VIRUS**

PHAGE T4 see **BACTERIOPHAGE T4**

PHAGE T7 see **BACTERIOPHAGE T7**

PHAGES see **BACTERIOPHAGES**

PHAGOCYTE BACTERICIDAL DYSFUNCTION

[Lazy-leukocyte syndrome] Koike T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):79–80 (8 ref.) **(Jpn)**

[Neutrophil actin dysfunction] Okamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):73–5 (13 ref.) **(Jpn)**

[Congenital familial tuftsin deficiency] Otsuka T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):67–9 (11 ref.) **(Jpn)**

[Neutrophil lactoferrin deficiency] Shinozaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):70–2 (12 ref.) **(Jpn)**

PHAGOCYTES

Is the oocyte a non-professional phagocyte? Bronson R. **Hum Reprod Update** 1998 Nov–Dec;4(6):763–75 (111 ref.)

IMMUNOLOGY

Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. Cotter RL, et al. **J Leukoc Biol** 1999 Apr;65(4):416–27 (136 ref.)

METABOLISM

Interactions of surfactant protein A with epithelial cells and phagocytes. Tino MJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):241–63 (112 ref.)

Regulation of chemokine receptors in mononuclear phagocytes versus dendritic cells and in the amplification of Th1 versus Th2 responses. Mantovani A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):76–80 (28 ref.)

[Phagocyte-dependent free oxygen radical mechanisms of autoaggression in pathogenesis of internal diseases] Kogan AKh. **Vestn Ross Akad Med Nauk** 1999;(2):3–10 (47 ref.) **(Rus)**

PHYSIOLOGY

Mechanisms and consequences of phagocyte adhesion to endothelium. Repo H, et al. **Ann Med** 1999 Jun; 31(3):156–65 (99 ref.)

Aetiological agents: their molecular biology and phagocyte-host interaction. Koehler L, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):589–609 (64 ref.)

Ras, superoxide and signal transduction. Irani K, et al. **Biochem Pharmacol** 1998 May 1;55(9):1339–46 (90 ref.)

The role of phosphatidylserine in recognition of apoptotic cells by phagocytes [see comments] Fadok VA, et al. **Cell Death Differ** 1998 Jul;5(7):551–62 (128 ref.) Comment in: Cell Death Differ 1998 Jul;5(7):549–50.

Clearance: the last and often forgotten stage of apoptosis. Fadok VA. **J Mammary Gland Biol Neoplasia** 1999 Apr; 4(2):203–11 (86 ref.)

[Removal of apoptotic cells by phagocytosis] Nakanishi Y, et al. **Rinsho Ketsueki** 1999 Mar;40(3):172–6 (9 ref.) **(Jpn)**

[Elimination of unwanted cells by phagocytes] Shiratsuchi A, et al. **Seikagaku** 1999 Apr;71(4):282–6 (15 ref.) **(Jpn)**

PHAGOCYTOSIS

Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. Fadok VA, et al. **Biochem Soc Trans** 1998 Nov;26(4):653–6 (10 ref.)

Signaling pathways in phagocytosis. Kwiatkowska K, et al. **Bioessays** 1999 May;21(5):422–31 (92 ref.)

Phagocytosis of myelin in demyelinative disease: a review. Smith ME. **Neurochem Res** 1999 Feb;24(2):261–8 (54 ref.)

Recognizing death: the phagocytosis of apoptotic cells. Platt N, et al. **Trends Cell Biol** 1998 Sep;8(9):365–72 (59 ref.)

[Elimination of unwanted cells by phagocytes] Shiratsuchi A, et al. **Seikagaku** 1999 Apr;71(4):282–6 (15 ref.) **(Jpn)**

DRUG EFFECTS

[Macrolides and phagocytosis] Samsygina GA. **Antibiot Khimioter** 1999;44(2):33–6 (24 ref.) **(Rus)**

IMMUNOLOGY

Mechanisms of phagocytosis in macrophages. Aderem A, et al. **Annu Rev Immunol** 1999;17:593–623 (151 ref.)

Roles of ICAM-3 and CD14 in the recognition and phagocytosis of apoptotic cells by macrophages. Gregory

PHAGOCYTOSIS

CD, et al. **Biochem Soc Trans** 1998 Nov;26(4):644–9 (45 ref.)
You can lead a macrophage to an inflammatory site but can you make it eat? Hart SP, et al. **Biochem Soc Trans** 1998 Nov;26(4):650–2 (18 ref.)
Phagocytosis and development: back to the future. Franc NC, et al. **Curr Opin Immunol** 1999 Feb;11(1):47–52 (48 ref.)
Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Ramachandra L, et al. **Immunol Rev** 1999 Apr;168:217–39 (188 ref.)
Pulmonary host defenses. Twigg HL 3rd. **J Thorac Imaging** 1998 Oct;13(4):221–33 (88 ref.)
The macrophage—a cell for all seasons. Morrissette N, et al. **Trends Cell Biol** 1999 May;9(5):199–201 (0 ref.)

PHYSIOLOGY

Class A scavenger receptors and the phagocytosis of apoptotic cells. Platt N, et al. **Biochem Soc Trans** 1998 Nov; 26(4):639–44 (27 ref.)
Apoptosis: getting rid of the bodies. Fadok VA, et al. **Curr Biol** 1998 Sep 24;8(19):R693–5 (11 ref.)
C1q receptors: regulating specific functions of phagocytic cells. Tenner AJ. **Immunobiology** 1998 Aug;199(2):250–64 (70 ref.)
Class A scavenger receptors and the phagocytosis of apoptotic cells. Platt N, et al. **Immunol Lett** 1999 Jan; 65(1–2):15–9 (27 ref.)
Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis. Lennartz MR. **Int J Biochem Cell Biol** 1999 Mar–Apr; 31(3–4):415–30 (108 ref.)
Assay for phagocytosis. Harvath L, et al. **Methods Mol Biol** 1999;115:281–90 (18 ref.)
Reprogramming the phagocytic pathway—intracellular pathogens and their vacuoles (review). Haas A. **Mol Membr Biol** 1998 Jul–Sep;15(3):103–21 (175 ref.)
[Removal of apoptotic cells by phagocytosis] Nakanishi Y, et al. **Rinsho Ketsueki** 1999 Mar;40(3):172–6 (9 ref.) **(Jpn)**
[Phagocyte-dependent free oxygen radical mechanisms of autoaggression in pathogenesis of internal diseases] Kogan AKh. **Vestn Ross Akad Med Nauk** 1999;(2):3–10 (47 ref.) **(Rus)**

PHAGOLYSOSOMES see **PHAGOSOMES**

PHAGOSOMES

see related
PHAGOCYTOSIS

METABOLISM

Mycobacterium tuberculosis phagosome. Deretic V, et al. **Mol Microbiol** 1999 Mar;31(6):1603–9 (48 ref.)

PARASITOLOGY

The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Antoine JC, et al. **Trends Microbiol** 1998 Oct;6(10):392–401 (46 ref.)

PHYSIOLOGY

Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Hampton MB, et al. **Blood** 1998 Nov 1;92(9):3007–17 (165 ref.)
Antimicrobial and cytolytic polypeptides of amoeboid protozoa—effector molecules of primitive phagocytes. Leippe M. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):267–79 (64 ref.)

PHALLIC STAGE see **PSYCHOSEXUAL DEVELOPMENT**

PHANTOM LIMB

DRUG THERAPY

Calcitonin in phantom limb pain. Wall GC, et al. **Ann Pharmacother** 1999 Apr;33(4):499–501 (22 ref.)
[Therapy of phantom pain with salmon calcitonin and effect on postoperative patient satisfaction] Simanski C, et al. **Chirurg** 1999 Jun;70(6):674–81 (67 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Phantom limb pain: a review of the literature on attributes and potential mechanisms. Hill A. **J Pain Symptom Manage** 1999 Feb;17(2):125–42 (124 ref.)
Immediate and long-term plasticity in human somatosensory thalamus and its involvement in phantom limbs. Dostrovsky JO. **Pain** 1999 Aug;Suppl 6:S37–43 (28 ref.)

PSYCHOLOGY

Consciousness and body image: lessons from phantom limbs, Capgras syndrome and pain asymbolia. Ramachandran VS. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1851–9 (38 ref.)

PHANTOMS, IMAGING

Relevance of accurate Monte Carlo modeling in nuclear medical imaging. Zaidi H. **Med Phys** 1999 Apr; 26(4):574–608 (288 ref.)

PHANTOMS, RADIOGRAPHIC see **PHANTOMS, IMAGING**

PHANTOMS, RADIOLOGIC see **PHANTOMS, IMAGING**

PHARMACEUTIC AIDS

CHEMISTRY

Collagen—biomaterial for drug delivery. Friess W. **Eur J Pharm Biopharm** 1998 Mar;45(2):113–36 (320 ref.)

PHARMACEUTIC AIDS (PRESERVATIVES) see **PRESERVATIVES, PHARMACEUTICAL**

PHARMACEUTICAL ECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACEUTICAL POLICY see **DRUG AND NARCOTIC CONTROL**

PHARMACEUTICAL PREPARATIONS

see related
PHARMACOLOGY
PLANTS, MEDICINAL
RECEPTORS, DRUG

Bioactive agents from natural sources: trends in discovery and application. Grabley S, et al. **Adv Biochem Eng Biotechnol** 1999;64:101–54 (360 ref.)
Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Cramer CL, et al. **Curr Top Microbiol Immunol** 1999;240:95–118 (80 ref.)
New drugs of 1998. Hussar DA. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr;39(2):151–206; quiz 289–92 (0 ref.)
[Scientific and technological innovations in the search for new drugs] Hélène C. **C R Acad Sci III** 1999 Jul; 322(7):529–36 (15 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Fundamentals of electroporative delivery of drugs and genes. Neumann E, et al. **Bioelectrochem Bioenerg** 1999 Feb; 48(1):3–16 (46 ref.)
The potential of liposomes in oral drug delivery. Rogers JA, et al. **Crit Rev Ther Drug Carrier Syst** 1998;15(5):421–80 (254 ref.)
Drug dosage in the elderly. Is it rational? Turnheim K. **Drugs Aging** 1998 Nov;13(5):357–79 (292 ref.)
Percutaneous penetration enhancement and its quantification. Bach M, et al. **Eur J Pharm Biopharm** 1998 Jul;46(1):1–13 (172 ref.)
Iontophoresis and electroporation: comparisons and contrasts. Banga AK, et al. **Int J Pharm** 1999 Mar 1; 179(1):1–19 (102 ref.)
Reversible inactivation of subcortical sites by drug injection. Malpeli JG. **J Neurosci Methods** 1999 Jan;86(2):119–28 (30 ref.)
A guide to enternal drug administration in palliative care. Gilbar PJ. **J Pain Symptom Manage** 1999 Mar; 17(3):197–207 (57 ref.)
Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Kalow W, et al. **Pharmacology** 1999 Jun;58(6):281–4 (13 ref.)
Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers. Loftsson T. **Pharmazie** 1998 Nov;53(11):733–40 (44 ref.)
Ways to minimize adverse drug reactions. Individualized doses and common sense are key. Cohen JS. **Postgrad Med** 1999 Sep;106(3):163–8, 171–2 (29 ref.)
Modulation of drug response by rate of input into the body. du Souich P. **Proc West Pharmacol Soc** 1998;41:219–23 (49 ref.)
Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells? Kaiserlian D, et al. **Semin Immunol** 1999 Jun;11(3):217–24 (50 ref.)
Dose response studies: how do we make them conclusive? Källén A, et al. **Stat Med** 1999 Mar 30;18(6):629–41 (7 ref.)
[New distribution forms for pharmaceuticals—a logistic perspective] Grund J, et al. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4237–40 (24 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Failure to recognize adverse drug reactions despite warnings [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1999 Mar;18(1):1–3 (8 ref.)
European Union directives on medicinal products found to be seriously defective [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1999 Mar;18(1):3–4 (2 ref.)
Drug-related erectile dysfunction. Keene LC, et al. **Adverse Drug React Toxicol Rev** 1999 Mar;18(1):5–24 (95 ref.)
Ototoxicity. Tange RA. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep;17(2–3):75–89 (79 ref.)
Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Lewis DP, et al. **Ann Pharmacother** 1998 Sep;32(9):947–61 (85 ref.)
Medication bezoars: a literature review and report of a case. Taylor JR, et al. **Ann Pharmacother** 1998 Sep;32(9):940–6 (67 ref.)
Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Park BK, et al. **Chem Res Toxicol** 1998 Sep;11(9):969–88 (216 ref.)
New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Uetrecht JP. **Chem Res Toxicol** 1999 May; 12(5):387–95 (92 ref.)
The connection between basic research and clinical practice. Blanca M, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:87–91 (24 ref.)
Prevention of iatrogenic illness: adverse drug reactions and nosocomial infections in hospitalized older adults. Riedinger JL, et al. **Clin Geriatr Med** 1998 Nov; 14(4):681–98 (48 ref.)
Premarketing studies in the drug approval process: understanding their limitations regarding the assessment of drug safety. Laughren T. **Clin Ther** 1998;20 Suppl C:C12–9 (0 ref.)
Drugs and toxins: fact and fancy. Bernstein RM. **Curr Opin Rheumatol** 1999 Jan;11(1):79–82 (26 ref.)
Etiology and mechanisms of drug-induced lupus. Rubin RL. **Curr Opin Rheumatol** 1999 Sep;11(5):357–63 (58 ref.)
Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Lu AY. **Drug Metab Dispos** 1998 Dec;26(12):1217–22 (37 ref.)
Changing prescribing in the light of tolerability concerns: how is this best achieved? de Vries CS, et al. **Drug Saf** 1999 Sep;21(3):153–60 (66 ref.)
Biological interpretation of relative risk. Lanes SF. **Drug Saf** 1999 Aug;21(2):75–9 (21 ref.)
Mechanisms of drug-induced diarrhoea in the elderly. Ratnaike RN, et al. **Drugs Aging** 1998 Sep;13(3):245–53 (89 ref.)
Drug-induced immunotoxicity. Dansette PM, et al. **Eur J Drug Metab Pharmacokinet** 1998 Oct–Dec; 23(4):443–51 (70 ref.)
The adverse effects of drugs. Pirmohamed M, et al. **Hosp Med** 1999 May;60(5):348–52 (17 ref.)
Pill esophagitis. Kikendall JW. **J Clin Gastroenterol** 1999 Jun; 28(4):298–305 (39 ref.)
The perturbation of apoptosis and mitosis by drugs and xenobiotics. Hasmall SC, et al. **Pharmacol Ther** 1999 Apr; 82(1):63–70 (67 ref.)
Ways to minimize adverse drug reactions. Individualized doses and common sense are key. Cohen JS. **Postgrad Med** 1999 Sep;106(3):163–8, 171–2 (29 ref.)
Drug-induced lupus. Le Goff P, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):40–5 (57 ref.)
Prescription medications: a modifiable contributor to obesity. Cheskin LJ, et al. **South Med J** 1999 Sep;92(9):898–904 (44 ref.)
[Reactions and interactions of drugs. Safety measures from Drug Safety Committee of the United Kingdom] D'Arcy PF. **J Pharm Belg** 1999 Mar–Apr;54(2):44–7 (0 ref.) **(Fre)**
[Accompanying medication. Necessity, side effects and interactions in the perioperative phase] Roth A, et al. **Anaesthesist** 1999 Apr;48(4):267–83 (29 ref.) **(Ger)**
[Detection and evaluation of adverse drug reactions] Thürmann PA, et al. **Med Klin** 1998 Nov 15;93(11):687–92 (37 ref.) (Eng. Abstr.) **(Ger)**
[Liver damage caused by drugs] Strohmeyer G, et al. **Z Gastroenterol** 1999 May;37(5):367–78 (71 ref.) (Eng. Abstr.) **(Ger)**
[Drug-induced osteomalacia] D'Erasmo E, et al. **Recenti Prog Med** 1998 Oct;89(10):529–33 (40 ref.) (Eng. Abstr.) **(Ita)**
[Drug-induced stomach ulcers—the views of recent years] Gurin NN, et al. **Ter Arkh** 1998;70(8):84–6 (22 ref.) **(Rus)**

ANALYSIS

Forensic science. Brettell TA, et al. **Anal Chem** 1999 Jun 15;71(12):235R–255R (782 ref.)
Pharmaceuticals and related drugs. Gilpin RK, et al. **Anal Chem** 1999 Jun 15;71(12):217R–233R (562 ref.)
Nonaqueous capillary electrophoresis—its applicability in the analysis of food, pharmaceuticals and biological fluids. Bjørnsdottir I, et al. **Electrophoresis** 1998 Sep; 19(12):2179–86 (39 ref.)
Drug analysis by capillary electrophoresis and laser-induced fluorescence. Couderc F, et al. **Electrophoresis** 1998 Nov; 19(16–17):2777–90 (101 ref.)
Capillary electrophoresis in drug analysis. Thormann W, et al. **Electrophoresis** 1998 Nov;19(16–17):2691–4 (50 ref.)
Strategies for capillary electrophoresis: method development and validation for pharmaceutical and biological applications. Wätzig H, et al. **Electrophoresis** 1998 Nov; 19(16–17):2695–752 (840 ref.)
Methods for quantitative determination of drug localized in the skin. Touitou E, et al. **J Controlled Release** 1998 Dec 4;56(1–3):7–21 (51 ref.)
High-performance frontal analysis for drug-protein binding study. Shibukawa A, et al. **J Pharm Biomed Anal** 1999 Jan; 18(6):1047–55 (30 ref.)
Pharmacokinetic and metabolism studies using microdialysis

sampling. Hansen DK, et al. **J Pharm Sci** 1999 Jan; 88(1):14–27 (113 ref.)
[New discoveries in forensic medicine. Hair analysis] Kaempe B. **Ugeskr Laeger** 1999 Mar 29;161(13):1901–5 (16 ref.) (Eng. Abstr.) **(Dan)**
[Development of high-performance frontal analysis and application to drug-plasma protein binding study] Shibukawa A. **Yakugaku Zasshi** 1998 Dec;118(12):554–65 (30 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Recent advances in the solid phase synthesis of drug-like heterocyclic small molecules. Andres CJ, et al. **Comb Chem High Throughput Screen** 1999 Aug; 2(4):191–210 (57 ref.)

CHEMISTRY

NMR screening in drug discovery. Moore JM. **Curr Opin Biotechnol** 1999 Feb;10(1):54–8 (24 ref.)
[Capillary electrophoresis, an attractive method for enantiomer analysis] Chankvetadze B, et al. **Pharm Unserer Zeit** 1999 Jul;28(4):186–96 (51 ref.) **(Ger)**
[Microequilibrium of drug molecules] Noszál B, et al. **Acta Pharm Hung** 1999 Jun;69(3):108–14 (22 ref.) (Eng. Abstr.) **(Hun)**
[Chiral compounds and their pharmacologic effects] Slováková A, et al. **Ceska Slov Farm** 1999 May;48(3):107–12 (14 ref.) (Eng. Abstr.) **(Slo)**

CLASSIFICATION

The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. van de Waterbeemd H. **Eur J Pharm Sci** 1998 Dec;7(1):1–3 (17 ref.)

ISOLATION & PURIFICATION

Analyte identification in capillary electrophoretic separation techniques. Kok SJ, et al. **Electrophoresis** 1998 Nov; 19(16–17):2753–76 (319 ref.)
Separation of chiral compounds by capillary electrophoresis. Verleysen K, et al. **Electrophoresis** 1998 Nov; 19(16–17):2798–833 (360 ref.)
Chiral separation of pharmaceuticals possessing a carboxy moiety. Arai T. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9;717(1–2):295–311 (109 ref.)
Prospecting for potentially new pharmaceuticals from natural sources. Pandey RC. **Med Res Rev** 1998 Sep;18(5):333–46 (21 ref.)
[Modern directions in studying biologically active substances from basidial fungi] Feofilova EP. **Prikl Biokhim Mikrobiol** 1998 Nov–Dec;34(6):597–608 (73 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Microbial models for drug metabolism. Azerad R. **Adv Biochem Eng Biotechnol** 1999;63:169–218 (245 ref.)
Culturally competent drug administration. Kudzma EC. **Am J Nurs** 1999 Aug;99(8):46–51; quiz 52 (18 ref.)
Cytochrome P-450 3A4: regulation and role in drug metabolism. Guengerich FP. **Annu Rev Pharmacol Toxicol** 1999;39:1–17 (108 ref.)
Computational ligand design. Apostolakis J, et al. **Comb Chem High Throughput Screen** 1999 Apr;2(2):91–104 (108 ref.)
Structure-based and combinatorial search for new RNA-binding drugs. Afshar M, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):59–63 (47 ref.)
Rational recognition of nucleic acid sequences. Iida H, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):29–33 (38 ref.)
NMR of drugs and ligands bound to membrane receptors. Watts A. **Curr Opin Biotechnol** 1999 Feb;10(1):48–53 (46 ref.)
Multiple activated oxygen species in P450 catalysis: contributions To specificity in drug metabolism. Coon MJ, et al. **Drug Metab Dispos** 1998 Dec;26(12):1190–3 (28 ref.)
Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Guengerich FP, et al. **Drug Metab Dispos** 1998 Dec;26(12):1175–8 (36 ref.)
Molecular and physical mechanisms of first-pass extraction. Hall SD, et al. **Drug Metab Dispos** 1999 Feb;27(2):161–6 (39 ref.)
Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism. Halpert JR, et al. **Drug Metab Dispos** 1998 Dec;26(12):1223–31 (69 ref.)
N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Hawes EM. **Drug Metab Dispos** 1998 Sep;26(9):830–7 (75 ref.)
Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Lu AY. **Drug Metab Dispos** 1998 Dec;26(12):1217–22 (37 ref.)
The 1996 Bernard B. Brodie lecture: A journey in cytochrome P450 and drug metabolism research. Lu AY. **Drug Metab Dispos** 1998 Dec;26(12):1168–73 (52 ref.)
Short- and long-term projections about the use of drug metabolism in drug discovery and development. White RE. **Drug Metab Dispos** 1998 Dec;26(12):1213–6 (22 ref.)
Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison. Friedberg T, et al. **Drug Metab Rev** 1999 May;31(2):523–44 (56 ref.)
Modulation of drug metabolism in infectious and inflammatory diseases. Iber H, et al. **Drug Metab Rev** 1999 Feb;31(1):29–41 (41 ref.)
Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Ingelman-Sundberg M. **Drug Metab Rev** 1999 May; 31(2):449–59 (27 ref.)
Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Nebert DW, et al. **Drug Metab Rev** 1999 May;31(2):467–87 (72 ref.)
Controlling drug delivery across the placenta. Audus KL. **Eur J Pharm Sci** 1999 Jul;8(3):161–5 (38 ref.)
Gastrointestinal absorption of drugs: methods and studies. Barthe L, et al. **Fundam Clin Pharmacol** 1999;13(2):154–68 (89 ref.)
Drug transfer across the blood-brain barrier and improvement of brain delivery. Jolliet-Riant P, et al. **Fundam Clin Pharmacol** 1999;13(1):16–26 (74 ref.)
Interactions between drugs and vitamins at advanced age. Schümann K. **Int J Vitam Nutr Res** 1999 May;69(3):173–8 (54 ref.)
Extrahepatic drug metabolizing enzymes. Kapitulnik J, et al. **J Biochem Mol Toxicol** 1999;13(5):227–30 (17 ref.)
Pharmacokinetic and metabolism studies using microdialysis sampling. Hansen DK, et al. **J Pharm Sci** 1999 Jan; 88(1):14–27 (113 ref.)
Concentrations in human fluids: 101 drugs affecting the digestive system and metabolism. Repetto MR, et al. **J Toxicol Clin Toxicol** 1999;37(1):1–9 (20 ref.)
Drug metabolism polymorphisms as modulators of cancer susceptibility. Taningher M, et al. **Mutat Res** 1999 May; 436(3):227–61 (170 ref.)
Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Kalow W, et al. **Pharmacogenetics** 1998 Aug;8(4):283–9 (36 ref.)
Design of in vitro studies to predict in vivo inhibitory drug-drug interactions. Strolin Benedetti M, et al. **Pharmacol Res** 1998 Aug;38(2):81–8 (51 ref.)
The pharmacological role of P-glycoprotein in the intestinal epithelium. Van Asperen J, et al. **Pharmacol Res** 1998 Jun; 37(6):429–35 (40 ref.)
Is the role of the small intestine in first-pass metabolism overemphasized? Lin JH, et al. **Pharmacol Rev** 1999 Jun; 51(2):135–58 (149 ref.)
Clinically significant drug interactions. Johnson MD, et al. **Postgrad Med** 1999 Feb;105(2):193–5, 200, 205–6 passim (20 ref.)
Binding of drugs to eye melanin is not predictive of ocular toxicity. Leblanc B, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):124–32 (120 ref.)
DNA chips: promising toys have become powerful tools. Gerhold D, et al. **Trends Biochem Sci** 1999 May; 24(5):168–73 (28 ref.)
Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential. Rockett JC, et al. **Xenobiotica** 1999 Jul;29(7):655–91 (123 ref.)
[The ways of designing new-generation medicinal and biochemical agents by using ligand-receptor interactions for active membrane transport] Iurkevich AM, et al. **Vestn Ross Akad Med Nauk** 1999;(3):3–7 (14 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis. Kaufman JM, et al. **Calcif Tissue Int** 1999 Jul;65(1):4–7 (11 ref.)
Regulation of prescription drug promotion: direct-to-consumer advertising. Baylor-Henry M, et al. **Clin Ther** 1998;20 Suppl C:C86–95 (0 ref.)
Trends in stability testing, with emphasis on stability during distribution and storage. Kommanaboyina B, et al. **Drug Dev Ind Pharm** 1999 Jul;25(7):857–68 (74 ref.)
ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Müller L, et al. **Mutat Res** 1999 May;436(3):195–225 (46 ref.)
[High pressure liquid chromatographic methods for compendium of purity tests] Szász G, et al. **Acta Pharm Hung** 1999 Jun;69(3):97–102 (50 ref.) (Eng. Abstr.) **(Hun)**

PHARMACEUTICAL SERVICES

Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Hilts AE, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2528–33 (38 ref.)
Clinical pharmacy in primary care. Hawksworth GM, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):415–20 (78 ref.)
Medication challenges in the assisted living facility. Crutchfield DB. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr; 39(2):222–5; quiz 293–4 (5 ref.)
[New distribution forms for pharmaceuticals--a logistic perspective] Grund J, et al. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4237–40 (24 ref.) (Eng. Abstr.) **(Nor)**
[Modern principles of supplying drugs to military medical establishments] Khveshchuk PF, et al. **Voen Med Zh** 1999 May;320(5):67–73 (37 ref.) **(Rus)**

ECONOMICS

Billing third party payers for pharmaceutical care services. Poirier S, et al. **J Am Pharm Assoc (Wash)** 1999 Jan–Feb; 39(1):50–64; quiz 101–2 (22 ref.)

LEGISLATION & JURISPRUDENCE

Pharmacists' liability into the year 2000. Lynn NJ, et al. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec;38(6):747–52; quiz 753–4 (10 ref.)

STANDARDS

Report of the ASHP Task Force on Science: American Society of Health-System Pharmacists. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2519–24 (0 ref.)
Therapeutic selection during an emergency response. Montello MJ, et al. **Am J Health Syst Pharm** 1999 Feb 1;56(3):236–40 (4 ref.)

TRENDS

Telemedicine and telepharmacy: current status and future implications. Angaran DM. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1405–26 (128 ref.)

PHARMACEUTICAL SOLUTIONS

see related
SOLUTIONS

PHARMACISTS

Clinical and regulatory concerns in Alzheimer's disease management: role of the pharmacist. Feinberg MV, et al. **Am J Health Syst Pharm** 1998 Nov 1;55 Suppl 2:S26–31 (23 ref.)
Drug therapy and the older person: role of the pharmacist. Denham MJ, et al. **Drug Saf** 1998 Oct;19(4):243–50 (52 ref.)

LEGISLATION & JURISPRUDENCE

The Omnibus Reconciliation Act of 1990: redefining pharmacists' legal responsibilities. Huang SW. **Am J Law Med** 1998;24(4):417–42 (0 ref.)
Pharmacists' liability into the year 2000. Lynn NJ, et al. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec;38(6):747–52; quiz 753–4 (10 ref.)

PHARMACOECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACOEPIDEMIOLOGY

Statistical issues in pharmacoepidemiological case-control studies. Ashby D, et al. **Stat Med** 1998 Aug 15–30; 17(15–16):1839–50; discussion 1859–62 (32 ref.)
Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT. **Stat Med** 1998 Aug 15–30;17(15–16):1851–8; discussion 1859–62 (6 ref.)

STANDARDS

Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT. **Stat Med** 1998 Aug 15–30;17(15–16):1851–8; discussion 1859–62 (6 ref.)

TRENDS

[Clinical hepatology and pharmacoepidemiology: a pending multidisciplinary approach (editorial)] Andrade RJ, et al. **Gastroenterol Hepatol** 1998 Nov;21(9):449–51 (25 ref.) **(Spa)**

PHARMACOGENETICS

The challenges of psychopharmacogenetics. Catalano M. **Am J Hum Genet** 1999 Sep;65(3):606–10 (35 ref.)
Glucuronidation in humans. Pharmacogenetic and developmental aspects. de Wildt SN, et al. **Clin Pharmacokinet** 1999 Jun;36(6):439–52 (103 ref.)
Pharmacogenomics – it's not just pharmacogenetics. Bailey DS, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):595–601 (58 ref.)
Relevance of pheno- and genotyping in clinical drug development. Zühlsdorf MT. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):607–12 (15 ref.)
Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Krynetski EY, et al. **Pharm Res** 1999 Mar;16(3):342–9 (56 ref.)
Genetic determinants of drug responsiveness and drug interactions. Caraco Y. **Ther Drug Monit** 1998 Oct; 20(5):517–24 (48 ref.)
Ethnic differences in drug disposition and response. Wood AJ. **Ther Drug Monit** 1998 Oct;20(5):525–6 (11 ref.)

PHARMACOGENETICS

[Genetics and therapeutic intervention] Brousseau T. **Ann Pharm Fr** 1999 Jan;57(1):56–60 (18 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Fundamentals and applications of pharmacogenetics for the clinical laboratory. Linder MW, et al. **Ann Clin Lab Sci** 1999 Apr–Jun;29(2):140–9 (24 ref.)

From "magic bullet" to "specially engineered shotgun loads": the new genetics and the need for individualized pharmacotherapy. Erickson RP. **Bioessays** 1998 Aug; 20(8):683–5 (21 ref.)

Genetically modified animals in pharmacological research: future trends. Rudolph U, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):327–37 (87 ref.)

Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients. Yukawa E. **J Clin Pharm Ther** 1999 Apr;24(2):103–13 (95 ref.)

Concise review: gene expression applied to toxicology. Farr S, et al. **Toxicol Sci** 1999 Jul;50(1):1–9 (56 ref.)

PHARMACOKINETICS

Biological monitoring: the role of toxicokinetics and physiologically based pharmacokinetic modeling. Mason H, et al. **Am Ind Hyg Assoc J** 1999 Mar–Apr;60(2):237–42 (31 ref.)

Grapefruit juice–drug interactions. Bailey DG, et al. **Br J Clin Pharmacol** 1998 Aug;46(2):101–10 (110 ref.)

Expanding clinical applications of population pharmacodynamic modelling. Minto C, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):321–33 (90 ref.)

Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment. Glue P, et al. **Cell Mol Neurobiol** 1999 Jun;19(3):309–23 (79 ref.)

Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Park BK, et al. **Chem Res Toxicol** 1998 Sep;11(9):969–88 (216 ref.)

Kinetic aspects of drug disposition in the lungs. Upton RN, et al. **Clin Exp Pharmacol Physiol** 1999 May–Jun; 26(5–6):381–91 (80 ref.)

Methodological issues in pharmacokinetic–pharmacodynamic modelling. Bellissant E, et al. **Clin Pharmacokinet** 1998 Aug;35(2):151–66 (53 ref.)

Chronopharmacokinetics. Current status. Bruguerolle B. **Clin Pharmacokinet** 1998 Aug;35(2):83–94 (76 ref.)

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Fleisher D, et al. **Clin Pharmacokinet** 1999 Mar; 36(3):233–54 (185 ref.)

Effects of surgery on the pharmacokinetic parameters of drugs. Kennedy JM, et al. **Clin Pharmacokinet** 1998 Oct; 35(4):293–312 (126 ref.)

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro–in vivo correlations. Lavé T, et al. **Clin Pharmacokinet** 1999 Mar;36(3):211–31 (63 ref.)

The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Mahmood I, et al. **Clin Pharmacokinet** 1999 Jan;36(1):1–11 (58 ref.)

Population pharmacokinetics. A regulatory perspective. Sun H, et al. **Clin Pharmacokinet** 1999 Jul;37(1):41–58 (60 ref.)

Octanol–water partition: searching for predictive models. Buchwald P, et al. **Curr Med Chem** 1998 Oct;5(5):353–80 (308 ref.)

Pharmacokinetics and metabolism in early drug discovery. Smith DA, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):373–8 (52 ref.)

The application of population pharmacokinetics to the drug development process. Jackson KA, et al. **Drug Dev Ind Pharm** 1998 Dec;24(12):1155–62 (56 ref.)

Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Lin JH. **Drug Metab Dispos** 1998 Dec;26(12):1202–12 (83 ref.)

Important drug–nutrient interactions in the elderly. Thomas JA, et al. **Drugs Aging** 1998 Sep;13(3):199–209 (60 ref.)

Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment. Haddad S, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1377–84 (31 ref.)

Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. Yang RS, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1385–93 (65 ref.)

Percutaneous penetration enhancement and its quantification. Bach M, et al. **Eur J Pharm Biopharm** 1998 Jul;46(1):1–13 (172 ref.)

Gastrointestinal absorption of drugs: methods and studies. Barthe L, et al. **Fundam Clin Pharmacol** 1999;13(2):154–68 (89 ref.)

Effects of hyperbaric and hyperoxic conditions on the disposition of drugs: theoretical considerations and a review of the literature. Rump AF, et al. **Gen Pharmacol** 1999 Jan;32(1):127–33 (45 ref.)

Aging effects on drug disposition and effect. Abernethy DR. **Geriatr Nephrol Urol** 1999;9(1):15–9 (40 ref.)

Tobacco smoking, alcohol, and special diet in drug trials: exclusion criteria or target of specific investigations? Fuhr U. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):604–6 (20 ref.)

Pharmacokinetic studies in volunteers with renal impairment. Keller F, et al. **Int J Clin Pharmacol Ther** 1998 Nov; 36(11):594–8 (12 ref.)

Effects of obesity on the cytochrome P450 enzyme system. Kotlyar M, et al. **Int J Clin Pharmacol Ther** 1999 Jan; 37(1):8–19 (55 ref.)

Phase I studies in patients with liver cirrhosis. Wensing G. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):599–603 (42 ref.)

Use of pharmacokinetics in veterinary medicine. Article. II: Volume, clearance, and half-life. Martinez MN. **J Am Vet Med Assoc** 1998 Oct 15;213(8):1122–7 (38 ref.)

Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. Schuetz EG, et al. **J Biochem Mol Toxicol** 1999;13(3–4):219–22 (21 ref.)

Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients. Yukawa E. **J Clin Pharm Ther** 1999 Apr;24(2):103–13 (95 ref.)

Estimation of blood–brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. van de Waterbeemd H, et al. **J Drug Target** 1998;6(2):151–65 (58 ref.)

Pharmacokinetic considerations in obesity. Blouin RA, et al. **J Pharm Sci** 1999 Jan;88(1):1–7 (95 ref.)

Pharmacokinetic and metabolism studies using microdialysis sampling. Hansen DK, et al. **J Pharm Sci** 1999 Jan; 88(1):14–27 (113 ref.)

Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. Prausnitz MR, et al. **J Pharm Sci** 1998 Dec;87(12):1479–88 (51 ref.)

Use of immobilized artificial membrane chromatography for drug transport applications. Stewart BH, et al. **J Pharm Sci** 1998 Dec;87(12):1471–8 (53 ref.)

Tight binding influencing the future of pharmacokinetics. Brockmeier D. **Methods Find Exp Clin Pharmacol** 1998 Jul–Aug;20(6):505–16 (0 ref.)

Phamacokinetic–pharmacodynamic modelling of behavioural responses. Della Paschoa OE, et al. **Neurosci Biobehav Rev** 1998;23(2):229–36 (42 ref.)

Antibodies as carrier proteins. Rehlaender BN, et al. **Pharm Res** 1998 Nov;15(11):1652–6 (39 ref.)

Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Verbeeck RK, et al. **Pharm World Sci** 1998 Oct; 20(5):183–92 (104 ref.)

Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Ito K, et al. **Pharmacol Rev** 1998 Sep;50(3):387–412 (93 ref.)

Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers. Loftsson T. **Pharmazie** 1998 Nov;53(11):733–40 (44 ref.)

Coated stents: local pharmacology. Raman VK, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):133–7 (17 ref.)

Ethnic differences in drug disposition and response. Wood AJ. **Ther Drug Monit** 1998 Oct;20(5):525–6 (11 ref.)

Determination of drug–metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Tucker GT, et al. **Xenobiotica** 1998 Dec;28(12):1255–73 (57 ref.)

[Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects] Marquet P. **Acta Clin Belg Suppl** 1999; 1:2–12 (41 ref.) (Eng. Abstr.) **(Fre)**

[Clinical pharmacokinetics and pharmacodynamics in the elderly] Ishizaki T. **Nippon Ronen Igakkai Zasshi** 1999 Mar; 36(3):168–72 (12 ref.) **(Jpn)**

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (1): The role of general/safety pharmacology studies in the development of pharmaceuticals: international harmonization of guidelines] Fujimori K. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):31–40 (37 ref.) (Eng. Abstr.) **(Jpn)**

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (2): Pharmacokinetics] Ohno Y. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):41–5 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Volume kinetics--a new method to control intravenous fluid infusion] Svensén C, et al. **Lakartidningen** 1999 Apr 21; 96(16):1969–70, 1973–4 (12 ref.) (Eng. Abstr.) **(Swe)**

PHARMACOLOGY

see related

PHARMACEUTICAL PREPARATIONS

Expanding clinical applications of population pharmacodynamic modelling. Minto C, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):321–33 (90 ref.)

The efficiency concept in pharmacodynamics. Alván G, et al. **Clin Pharmacokinet** 1999 May;36(5):375–89 (58 ref.)

Methodological issues in pharmacokinetic–pharmacodynamic modelling. Bellissant E, et al. **Clin Pharmacokinet** 1998 Aug;35(2):151–66 (53 ref.)

Aging effects on drug disposition and effect. Abernethy DR. **Geriatr Nephrol Urol** 1999;9(1):15–9 (40 ref.)

Relevance of pheno- and genotyping in clinical drug development. Zühlsdorf MT. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):607–12 (15 ref.)

PET and drug research and development. Fowler JS, et al. **J Nucl Med** 1999 Jul;40(7):1154–63 (102 ref.)

Clinically significant drug interactions. Johnson MD, et al. **Postgrad Med** 1999 Feb;105(2):193–5, 200, 205–6 passim (20 ref.)

[Development of pharmaco-epidemiology in France] Guillemot D, et al. **Presse Med** 1999 Mar 6;28(9):493–9 (42 ref.) (Eng. Abstr.) **(Fre)**

[Clinical pharmacokinetics and pharmacodynamics in the elderly] Ishizaki T. **Nippon Ronen Igakkai Zasshi** 1999 Mar; 36(3):168–72 (12 ref.) **(Jpn)**

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (1): The role of general/safety pharmacology studies in the development of pharmaceuticals: international harmonization of guidelines] Fujimori K. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):31–40 (37 ref.) (Eng. Abstr.) **(Jpn)**

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (2): Pharmacokinetics] Ohno Y. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):41–5 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanism of pain and genetic pharmacology] Ito S. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1349–59 (39 ref.) **(Jpn)**

[Chiral compounds and their pharmacologic effects] Slováková A, et al. **Ceska Slov Farm** 1999 May;48(3):107–12 (14 ref.) (Eng. Abstr.) **(Slo)**

HISTORY

Traditional pharmacology and medicine in Africa. Ethnopharmacological themes in sub-Saharan art objects and utensils. De Smet PA. **J Ethnopharmacol** 1998 Nov; 63(1–2):1–175 (600 ref.)

METHODS

Genetically modified animals in pharmacological research: future trends. Rudolph U, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):327–37 (87 ref.)

Scientific aspects of traditional usage of bioresources. Thebtaranonth Y. **J Nat Toxins** 1999 Jun;8(2):279–84 (21 ref.)

Pharmaceutical applications of in vivo EPR. Mäder K. **Phys Med Biol** 1998 Jul;43(7):1931–5 (18 ref.)

STATISTICS & NUMERICAL DATA

Dose response studies: how do we make them conclusive? Källén A, et al. **Stat Med** 1999 Mar 30;18(6):629–41 (7 ref.)

PHARMACOLOGY, CLINICAL

Genetic determinants of drug responsiveness and drug interactions. Caraco Y. **Ther Drug Monit** 1998 Oct; 20(5):517–24 (48 ref.)

[Responsibilities of clinical pharmacology in the early phase of drug development] Kuhlmann J. **Med Klin** 1999 May 15;94(5):290–9 (16 ref.) (Eng. Abstr.) **(Ger)**

[An evaluation of non-clinical animal data from the point of view of a clinical pharmacologist] Uchida E. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):47–53 (13 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

Best practice in therapeutic drug monitoring [see comments] Gross AS. **Br J Clin Pharmacol** 1998 Aug;46(2):95–9 (23 ref.) Comment in: Br J Clin Pharmacol 1999 Jul;48(1):9–13.

STANDARDS

Clinical pharmacology and therapeutics in a changing world [editorial] Mucklow JC. **J R Coll Physicians Lond** 1999 May–Jun;33(3):205–7 (8 ref.)

TRENDS

Therapeutic drug monitoring beyond 2000 [see comments] Shenfield GM. **Br J Clin Pharmacol** 1998 Aug;46(2):93–4 (18 ref.) Comment in: Br J Clin Pharmacol 1999 Jul;48(1):9–13.

Clinical pharmacology and therapeutics in a changing world [editorial] Mucklow JC. **J R Coll Physicians Lond** 1999 May–Jun;33(3):205–7 (8 ref.)

Clinical pharmacology. Blue-chip technology. Flockhart DA, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV2 (5 ref.)

PHARMACOPOEIAS

[Silymarin-containing phytopharmaceuticals--biopharmacy as an essential therapeutic quality criterion] Frömming KH, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):VI–XI (20 ref.) **(Ger)**

STANDARDS

In situ degradation: a new concept for system suitability tests in monographs of the European Pharmacopoeia. Rose U. **J Pharm Biomed Anal** 1998 Oct;18(1–2):1–14 (12 ref.)

PHARMACOPOEIAS, HOMEOPATHIC

Similitude in modern pharmacology. Teixeira MZ. **Br Homeopath J** 1999 Jul;88(3):112–20 (126 ref.)

PHARMACOTHERAPY see **DRUG THERAPY**

PHARMACY

see related
LEGISLATION, PHARMACY
PHARMACY SERVICE, HOSPITAL
PRESCRIPTIONS, DRUG
TECHNOLOGY, PHARMACEUTICAL

STANDARDS

Clinical pharmacy--a hospital perspective. Calvert RT. **Br J Clin Pharmacol** 1999 Mar;47(3):231-8 (47 ref.)

TRENDS

Direct-to-consumer advertising: a pharmacy perspective. Maine LL. **Clin Ther** 1998;20 Suppl C:C104-10 (6 ref.)

PHARMACY ADMINISTRATION

see related
INSURANCE, PHARMACEUTICAL SERVICES

PHARMACY SERVICE, CLINICAL see **PHARMACY SERVICE, HOSPITAL**

PHARMACY SERVICE, HOSPITAL

Effect of pharmaceutical services on adherence to criteria-for-use guidelines in the operating room. Higgins B, et al. **Am J Health Syst Pharm** 1999 May 15; 56(10):977-82 (7 ref.)

Clinical pharmacy--a hospital perspective. Calvert RT. **Br J Clin Pharmacol** 1999 Mar;47(3):231-8 (47 ref.)

[Application of pharmacoeconomics studies in hospitals] Carrera-Hueso FJ. **Med Clin (Barc)** 1998 Sep 26; 111(9):347-53 (40 ref.) **(Spa)**

PHARYNGEAL ARCHES see **BRANCHIAL REGION**

PHARYNGEAL DISEASES

COMPLICATIONS

Acute post streptococcal interstitial nephritis in an adult and review of the literature. Dharmarajan TS, et al. **Int Urol Nephrol** 1999;31(2):145-8 (15 ref.)

DIAGNOSIS

Neonatal pharyngeal pseudodiverticulum mimicking esophageal atresia. Cason DL, et al. **South Med J** 1998 Dec;91(12):1163-6 (17 ref.)

[Pharyngeal tuberculosis: an analytical study and report of 10 cases] Kharoubi S. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(3):203-7 (21 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Failure of penicillin in Streptococcus pyogenes pharyngeal infection [comment] Gillespie SH. **Lancet** 1998 Dec 19-26; 352(9145):1954-6 (18 ref.) Comment on: Lancet 1998 Dec 19-26;352(9145):1974-7.

EMBRYOLOGY

Pharyngeal pituitary: development, malformation, and tumorigenesis. Hori A, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):262-72 (38 ref.)

ETIOLOGY

Oropharyngeal lesions in AIDS. Grimes RM, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):783-809 (67 ref.)

MICROBIOLOGY

Pharyngo-laryngeal histoplasmosis: one case in an immunocompetent child. Coiffier T, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 2;45(2):177-81 (18 ref.)

Endovascular occlusion of a carotid pseudoaneurysm complicating deep neck space infection in a child. Case report. Reisner A, et al. **J Neurosurg** 1999 Sep;91(3):510-4 (31 ref.)

[Pharyngeal tuberculosis: an analytical study and report of 10 cases] Kharoubi S. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(3):203-7 (21 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Immunohistochemical survey of migration of human anterior pituitary cells in developmental, pathological, and clinical aspects: a review. Hori A, et al. **Microsc Res Tech** 1999 Jul 1;46(1):59-68 (73 ref.)

PREVENTION & CONTROL

A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis. Alvarez Alvarez ME, et al. **Rev Esp Quimioter** 1998 Dec;11(4):295-315 (281 ref.)

PHARYNGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNGEAL MUSCLES

PHYSIOLOGY

The treatment of hypertonicity of the pharyngo-oesophageal segment after laryngectomy. Brok HA, et al. **Clin Otolaryngol** 1998 Aug;23(4):302-7 (51 ref.)

PHYSIOPATHOLOGY

Cricopharyngeal achalasia: case reports and review of the literature. De Caluwe D, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):109-12 (18 ref.)

[Dilator muscles of the pharynx and their implication in the sleep apnea syndrome of obstructive type. Review of the literature] Blumen M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 May;115(2):73-84 (91 ref.) (Eng. Abstr.) **(Fre)**

[Pharyngeal muscles and sleep obstructive apnea syndrome] Fleury B. **Rev Mal Respir** 1999 Feb;16(1):51-6 (44 ref.) (Eng. Abstr.) **(Fre)**

PHARYNGEAL NEOPLASMS

[Cancer of the rhinopharynx and the oropharynx. Epidemiology, diagnosis, complications a long time after treatment] Dehesdin D, et al. **Rev Prat** 1998 Mar 15; 48(6):667-74 (00 ref.) **(Fre)**

DIAGNOSIS

[A primary pleomorphic adenoma of the parapharyngeal space] Belli E, et al. **Minerva Chir** 1998 Jun;53(6):543-7 (11 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Synovial sarcoma in the parapharyngeal space: case report and review of the literature. Hanada T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):91-4 (24 ref.)

Pharyngeal localizations of branchial cysts. Paczona R, et al. **Eur Arch Otorhinolaryngol** 1998;255(7):379-81 (8 ref.)

RADIOGRAPHY

Synovial sarcoma in the parapharyngeal space: case report and review of the literature. Hanada T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):91-4 (24 ref.)

SECONDARY

Metastatic papillary thyroid carcinoma presenting as a retropharyngeal mass. DiLeo MD, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):404-6 (7 ref.)

PHARYNGEAL TONSIL see **ADENOIDS**

PHARYNGITIS

Periodic fever syndrome. Thomas KT, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):68-9 (11 ref.)

[Pharyngitis] Igarashi M. **Ryoikibetsu Shokogun Shirizu** 1999; (25 Pt 3):128-30 (0 ref.) **(Jpn)**

DIAGNOSIS

Lemierre syndrome: a complication of acute pharyngitis. Williams A, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):51-7 (5 ref.)

Sore throat, tonsillitis, and adenoiditis. Richardson MA. **Med Clin North Am** 1999 Jan;83(1):75-83, viii (16 ref.)

DRUG THERAPY

When is it right to prescribe in URTI? Williamson I. **Practitioner** 1997 Dec;241(1581):724-6, 728, 730 (15 ref.)

[Systemic antibiotics in routine practice: ENT and lower respiratory tract infections. National Agency for Accreditation and Evaluation of Health (ANAES)] **Rev Pneumol Clin** 1999 Jun;55(3):127-54 (115 ref.) **(Fre)**

[Cromones in the therapy of food-induced allergic rhinitis, pharyngitis and laryngitis] Buczyłko K. **Pol Merkuriusz Lek** 1998 Dec;5(30):357-9 (18 ref.) (Eng. Abstr.) **(Pol)**

[Pharyngotonsillitis in the adult (editorial)] Gobernado M. **Rev Esp Quimioter** 1998 Jun;11(2):105-9 (74 ref.) **(Spa)**

ECONOMICS

Management of sore throats in children: a cost-effectiveness analysis [see comments] Tsevat J, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):681-8 (73 ref.) Comment in: Arch Pediatr Adolesc Med 1999 Jul;153(7):672-4.

ETIOLOGY

Evaluation of the patient with sore throat, earache, and sinusitis: an evidence based approach. Stewart MH, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):153-87, ix (137 ref.)

[Cromones in the therapy of food-induced allergic rhinitis, pharyngitis and laryngitis] Buczyłko K. **Pol Merkuriusz Lek** 1998 Dec;5(30):357-9 (18 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

The changing face of rheumatic fever in the 20th century [editorial] Stollerman GH. **J Med Microbiol** 1998 Aug; 47(8):655-7 (30 ref.)

Lemierre's syndrome (necrobacillosis). Golpe R, et al. **Postgrad Med J** 1999 Mar;75(881):141-4 (31 ref.)

PATHOLOGY

Plasma cell mucositis: a review and case report. Smith ME, et al. **J Oral Pathol Med** 1999 Apr;28(4):183-6 (11 ref.)

PHARYNGO-CONJUNCTIVAL FEVER see **ADENOVIRUS INFECTIONS, HUMAN**

PHARYNGOESOPHAGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNX

INJURIES

Radiology of pharyngeal balling gun injuries. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):391-5, vii (0 ref.)

PHYSIOLOGY

Upper airway function and dysfunction in respiration. Pierce RJ, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):1-10 (102 ref.)

The treatment of hypertonicity of the pharyngo-oesophageal segment after laryngectomy. Brok HA, et al. **Clin Otolaryngol** 1998 Aug;23(4):302-7 (51 ref.)

RADIOGRAPHY

Upper airway assessment: radiographic and other imaging techniques. Schwab RJ, et al. **Otolaryngol Clin North Am** 1998 Dec;31(6):931-68 (111 ref.)

Radiology of pharyngeal balling gun injuries. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):391-5, vii (0 ref.)

SURGERY

The timing and management of dynamic muscular pharyngeal sphincter construction in velopharyngeal incompetence. Orticochea M. **Br J Plast Surg** 1999 Mar;52(2):85-7 (6 ref.)

PHASE I CLINICAL TRIALS see **CLINICAL TRIALS, PHASE I**

PHASE II CLINICAL TRIALS see **CLINICAL TRIALS, PHASE II**

PHASE III CLINICAL TRIALS see **CLINICAL TRIALS, PHASE III**

PHASEOLUS see **LEGUMES**

PHENACETIN O-DEALKYLASE see **CYTOCHROME P-450 CYP1A2**

PHENADONE see **METHADONE**

PHENANTHRIDINES

THERAPEUTIC USE

Laboratory and field evaluation of biodegradable polyesters for sustained release of isometamidium and ethidium. Geerts S, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr; 94(2):211-4 (17 ref.)

PHENAZINES

CHEMISTRY

Antimycobacterial activities of riminophenazines. Reddy VM, et al. **J Antimicrob Chemother** 1999 May;43(5):615-23 (73 ref.)

METABOLISM

Novel reactions involved in energy conservation by methanogenic archaea. Deppenmeier U, et al. **FEBS Lett** 1999 Sep 3;457(3):291-7 (49 ref.)

PHARMACOLOGY

Antimycobacterial activities of riminophenazines. Reddy VM, et al. **J Antimicrob Chemother** 1999 May;43(5):615-23 (73 ref.)

THERAPEUTIC USE

[Chemotherapeutic agents under study] Kawahara S. **Nippon Rinsho** 1998 Dec;56(12):3096-9 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHENCYCLIDINE

Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity.

PHENCYCLIDINE

Sams-Dodd F. **Rev Neurosci** 1999;10(1):59-90 (243 ref.)

ADVERSE EFFECTS

Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Deutsch SI, et al. **Clin Neuropharmacol** 1998 Nov-Dec;21(6):320-32 (29 ref.)

ANALOGS & DERIVATIVES

[The chromatographic analysis of phencyclidine, its metabolites and analogs in biological fluids] Veselovskaia NV, et al. **Sud Med Ekspert** 1999 Mar-Apr;42(2):20-5 (37 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

[The chromatographic analysis of phencyclidine, its metabolites and analogs in biological fluids] Veselovskaia NV, et al. **Sud Med Ekspert** 1999 Mar-Apr;42(2):20-5 (37 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task. Noda Y, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):607-11 (32 ref.)

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Jentsch JD, et al. **Neuropsychopharmacology** 1999 Mar;20(3):201-25 (250 ref.)

PHENEMAL see **PHENOBARBITAL**

PHENETHYLAMINES

PHARMACOLOGY

Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Marek GJ, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):189-98 (80 ref.)

THERAPEUTIC USE

Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Davis DR, et al. **Can J Cardiol** 1999 Feb;15(2):193-200 (47 ref.)

PHENFORMIN

ADVERSE EFFECTS

Phenformin and lactic acidosis: a case report and review. Kwong SC, et al. **J Emerg Med** 1998 Nov-Dec;16(6):881-6 (40 ref.)

PHENOBARBITAL

ADMINISTRATION & DOSAGE

Dose-dependent biphasic effects of phenobarbital on growth and differentiation of primary culture rat hepatocytes. Miyazaki M, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S78-82 (31 ref.)

IMMUNOLOGY

Comparison of the conformations of two intact monoclonal antibodies with hinges. Harris LJ, et al. **Immunol Rev** 1998 Jun;163:35-43 (32 ref.)

PHARMACOLOGY

Phenobarbital-mediated changes in gene expression in the liver. Meyer UA, et al. **Drug Metab Rev** 1999 May; 31(2):365-73 (32 ref.)

Regulation of cytochrome P450 gene transcription by phenobarbital. Kemper B. **Prog Nucleic Acid Res Mol Biol** 1998;61:23-64 (78 ref.)

THERAPEUTIC USE

Phenobarbital for alcohol withdrawal syndrome. Rodgers JE, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):175-8 (18 ref.)

PHENOBARBITONE see **PHENOBARBITAL**

PHENOL

PHARMACOLOGY

[Mechanism of the antistressor and antiradiation action of plant phenol compounds] Baraboi VA, et al. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):13-23 (82 ref.) (Eng. Abstr.) **(Rus)**

TOXICITY

Phenol. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:749-68 (83 ref.)

PHENOLOXIDASE see **MONOPHENOL MONOOXYGENASE**

PHENOLS

Antioxidant and other activities of phenolics in olives/olive oil, typical components of the Mediterranean diet. Galli C, et al. **Lipids** 1999;34 Suppl:S23-6 (14 ref.)

ANALYSIS

Analysis of tea polyphenols. Beecher GR, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):267-70 (31 ref.)

CHEMISTRY

Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Bravo L. **Nutr Rev** 1998 Nov; 56(11):317-33 (149 ref.)

METABOLISM

Recycling and redox cycling of phenolic antioxidants. Kagan VE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:425-34 (27 ref.)

Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Bravo L. **Nutr Rev** 1998 Nov; 56(11):317-33 (149 ref.)

Antioxidant capacity and polyphenolic components of teas: implications for altering in vivo antioxidant status. Prior RL, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):255-61 (40 ref.)

PHARMACOKINETICS

Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Yang CS, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):213-7 (31 ref.)

PHARMACOLOGY

Cardioprotection of red wine: role of polyphenolic antioxidants. Das DK, et al. **Drugs Exp Clin Res** 1999; 25(2-3):115-20 (25 ref.)

Beneficial effects of white wines. Lamuela-Raventós RM, et al. **Drugs Exp Clin Res** 1999;25(2-3):121-4 (21 ref.)

Wine and polyphenols related to platelet aggregation and atherothrombosis. Ruf JC. **Drugs Exp Clin Res** 1999; 25(2-3):125-31 (49 ref.)

Wine: risk factors for liver disease and antifibrotic compounds. Svegliati-Baroni G, et al. **Drugs Exp Clin Res** 1999;25(2-3):143-5 (13 ref.)

Antimutagenic and anticarcinogenic activity of tea polyphenols. Kuroda Y, et al. **Mutat Res** 1999 Jan; 436(1):69-97 (131 ref.)

Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death. Kong AN, et al. **Pharm Res** 1999 Jun;16(6):790-8 (122 ref.)

Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Rice-Evans C. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):262-6 (21 ref.)

Tea and health: the underlying mechanisms. Weisburger JH. **Proc Soc Exp Biol Med** 1999 Apr;220(4):271-5 (42 ref.)

THERAPEUTIC USE

Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Lin JK, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):911-5 (28 ref.)

Prevention of oral diseases by polyphenols (review). Sakagami H, et al. **In Vivo** 1999 Mar-Apr;13(2):155-71 (179 ref.)

Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. Halpern MJ, et al. **J Int Med Res** 1998 Aug-Sep;26(4):171-80 (53 ref.)

Green tea polyphenols and cancer: biologic mechanisms and practical implications. Ahmad N, et al. **Nutr Rev** 1999 Mar; 57(3):78-83 (41 ref.)

PHENOPROMIN see **AMPHETAMINE**

PHENOTHIAZINE ANTIPSYCHOTIC AGENTS see **ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE**

PHENOTHIAZINE TRANQUILIZERS see **ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE**

PHENOTHIAZINES

see related
ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE

[Inhibitor of calmodulin and calmodulin dependent enzyme] Hidaka H, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep; 43(12 Suppl):1732-8 (48 ref.) **(Jpn)**

ADVERSE EFFECTS

Use of phenothiazines as sedatives in children: what are the risks? Dyer KS, et al. **Drug Saf** 1999 Aug;21(2):81-90 (47 ref.)

THERAPEUTIC USE

Antitumor activity of benzo[a]phenothiazines. Motohashi N, et al. **Anticancer Res** 1999 May-Jun;19(3A):1837-42 (20 ref.)

PHENOTYPE

see related
SOMATOTYPES

Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Couse JF, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):143-8 (51 ref.)

Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Byrne CD. **Atherosclerosis** 1999 Jul;145(1):1-15 (115 ref.)

Schizophrenia: refining the phenotype, resolving endophenotypes. Lenzenweger MF. **Behav Res Ther** 1999 Mar;37(3):281-95 (80 ref.)

Transvection and chromosomal trans-interaction effects. Pirrotta V. **Biochim Biophys Acta** 1999 Jul 29;1424(1):M1-8 (29 ref.)

Alternative phenotypes for the complex genetics of schizophrenia. Freedman R, et al. **Biol Psychiatry** 1999 Mar 1;45(5):551-8 (40 ref.)

Modulation of myofibroblast and smooth-muscle phenotypes in the lung. Low RB. **Curr Top Pathol** 1999;93:19-26 (29 ref.)

Genotypes and phenotypes. Klose J. **Electrophoresis** 1999 Apr-May;20(4-5):643-52 (25 ref.)

Polycystic ovary syndrome. Phenotype to genotype. Legro RS. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):379-96 (45 ref.)

The behavioural phenotype in velo-cardio-facial syndrome (VCFS): from infancy to adolescence. Swillen A, et al. **Genet Couns** 1999;10(1):79-88 (17 ref.)

Relevance of pheno- and genotyping in clinical drug development. Zühlsdorf MT. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):607-12 (15 ref.)

Interpretation of phenotype in genetically engineered mice [see comments] Doetschman T. **Lab Anim Sci** 1999 Apr; 49(2):137-43 (67 ref.) Comment in: Lab Anim Sci 1999 Apr;49(2):134.

A role for modifier genes in genome imprinting. Martin CC, et al. **Results Probl Cell Differ** 1999;25:251-70 (100 ref.)

[The phenotype variation correlates with the size of CAG repeat in SCA2] Sasaki H, et al. **Nippon Rinsho** 1999 Apr; 57(4):818-21 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Studies of pathogenicity and characterization of molecular phenotype caused by mutations in human mitochondrial DNA] Bornstein B, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S36-43 (55 ref.) (Eng. Abstr.) **(Spa)**

PHENPROCOUMALOL see **PHENPROCOUMON**

PHENPROCOUMAROL see **PHENPROCOUMON**

PHENPROCOUMON

Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Haustein KO. **Semin Thromb Hemost** 1999;25(1):5-11 (20 ref.)

PHENTANYL see **FENTANYL**

PHENTERMINE

ADVERSE EFFECTS

Product liability and prescription diet drug cocktail, Fen-Phen: a hard combination to swallow. Crisanti CA. **J Contemp Health Law Policy** 1998 Fall;15(1):207-44 (0 ref.)

PHARMACOLOGY

Synergistic interactions between fenfluramine and phentermine. Wellman PJ, et al. **Int J Obes Relat Metab Disord** 1999 Jul;23(7):723-32 (65 ref.)

THERAPEUTIC USE

Aminorex to fen/phen: an epidemic foretold. Fishman AP. **Circulation** 1999 Jan 5-12;99(1):156-61 (55 ref.)

PHENYLACETATES

ANALYSIS

Measurement and significance of free and protein-bound 3-nitrotyrosine, 3-chlorotyrosine, and free 3-nitro-4-hydroxyphenylacetic acid in biologic samples: a high-performance liquid chromatography method using electrochemical detection. Crow JP. **Methods Enzymol** 1999;301:151-60 (28 ref.)

ISOLATION & PURIFICATION

Phenoxyacetic acids: separation and quantitative determination. Cserháti T, et al. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9; 717(1-2):157-78 (70 ref.)

PHENYLALANINE

ANALOGS & DERIVATIVES

[Non-SU, insulin secretagogues] Kikuchi M.

Nippon Rinsho 1999 Mar;57(3):702–8 (21 ref.) (Eng. Abstr.) (Jpn)

METABOLISM

Phenylketonuria: old disease, new approach to treatment [comment] Levy HL. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1811–3 (42 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2339–44.

PHENYLALANINE AMMONIA-LYASE

THERAPEUTIC USE

Phenylketonuria: old disease, new approach to treatment [comment] Levy HL. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1811–3 (42 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2339–44.

PHENYLALANINE MUSTARD see **MELPHALAN**

PHENYLAMINES see **ANILINE COMPOUNDS**

PHENYLBARBITAL see **PHENOBARBITAL**

PHENYLETHYLAMINES see **PHENETHYLAMINES**

PHENYLKETONURIA

Maternal phenylketonuria: a new cause for concern. Kirby RB. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):227–34 (19 ref.)

DIAGNOSIS

Neurological aspects of adult phenylketonuria. Pietz J. **Curr Opin Neurol** 1998 Dec;11(6):679–88 (59 ref.)

GENETICS

Phenylketonuria—a problem in eugenics. Penrose LS. **Ann Hum Genet** 1998 May;62 (Pt 3):193–202 (25 ref.)

Monogenic traits are not simple: lessons from phenylketonuria. Scriver CR, et al. **Trends Genet** 1999 Jul; 15(7):267–72 (63 ref.)

PSYCHOLOGY

Review: emotional and behavioral functioning in phenylketonuria. Sullivan JE, et al. **J Pediatr Psychol** 1999 Jun;24(3):281–99 (86 ref.)

THERAPY

New approaches to the treatment of phenylketonuria. de Freitas O, et al. **Nutr Rev** 1999 Mar;57(3):65–70 (53 ref.)

Phenylketonuria: old disease, new approach to treatment [comment] Levy HL. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1811–3 (42 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2339–44.

PHENYLKETONURIA, MATERNAL

DIAGNOSIS

Undiagnosed maternal phenylketonuria: the need for prenatal selective screening or case finding. Hanley WB, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):986–94 (25 ref.)

[Maternal PKU syndrome as an obstetric problem: literature review and own clinical experience] Rogowiecka E, et al. **Ginekol Pol** 1998 Dec;69(12):1007–15 (18 ref.) (Eng. Abstr.) (Pol)

PHENYLMERCURIC ACETATE

ANALOGS & DERIVATIVES

Studies on cell-specific cytotoxicities induced by p-aminophenyl-mercuric acetate (APMA). Kim HM, et al. **J Toxicol Sci** 1998 Oct;23 Suppl 4:653–6 (9 ref.)

PHENYLMETHYLAMINE see **BENZYLAMINES**

PHENYLPROPANOLAMINE

CHEMISTRY

Bioactive antinutritional peptides derived from cereal prolamins: a review. Silano M, et al. **Nahrung** 1999 Jun; 43(3):175–84 (127 ref.)

PHARMACOLOGY

Bioactive antinutritional peptides derived from cereal prolamins: a review. Silano M, et al. **Nahrung** 1999 Jun; 43(3):175–84 (127 ref.)

PHENYLPROPIONATES

METABOLISM

Phenylpropanoid biosynthesis and its regulation. Weisshaar B, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):251–7 (64 ref.)

PHARMACOLOGY

[Gamma-oryzanol: an important component in rice brain oil] Scavariello EM, et al. **Arch Latinoam Nutr** 1998 Mar; 48(1):7–12 (30 ref.) (Eng. Abstr.) (Spa)

PHENYLPROPYLHYDROXYCUMARINUM see **PHENPROCOUMON**

PHENYTOIN

ADMINISTRATION & DOSAGE

Pediatric use of intravenous and intramuscular phenytoin: lessons learned. Wheless JW. **J Child Neurol** 1998 Oct;13 Suppl 1:S11–4; discussion S30–2 (40 ref.)

ADVERSE EFFECTS

Ticlopidine-induced phenytoin toxicity. Klaassen SL. **Ann Pharmacother** 1998 Dec;32(12):1295–8 (18 ref.)

Phenytoin-induced dermatomyositis: case report and literature review. Dimachkie MM, et al. **J Child Neurol** 1998 Nov;13(11):577–80 (11 ref.)

Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability. Iivanainen M. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:24–31 (28 ref.)

Medically induced gingival hyperplasia [see comments] Meraw SJ, et al. **Mayo Clin Proc** 1998 Dec;73(12):1196–9 (42 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):742–3.

Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Micali G, et al. **Pharmacotherapy** 1999 Feb;19(2):223–7 (39 ref.)

[An increase in gingival volume induced by drugs (phenytoin, cyclosporine and calcium antagonists). A review of the literature] Garzino-Demo P, et al. **Minerva Stomatol** 1998 Sep;47(9):387–98 (115 ref.) (Eng. Abstr.) (Ita)

[Anticonvulsant hypersensitivity syndrome (letter)] Enrique E, et al. **Rev Clin Esp** 1999 Apr;199(4):257–8 (11 ref.) (Spa)

ANALOGS & DERIVATIVES

Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. Knapp LE, et al. **J Child Neurol** 1998 Oct;13 Suppl 1:S15–8; discussion S30–2 (22 ref.)

METABOLISM

Pharmacogenetics of CYP2C subfamily in a Japanese population. Ieiri I, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:129–31 (12 ref.)

PHEOCHROMOCYTOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. Mann SJ. **Arch Intern Med** 1999 Apr 12; 159(7):670–4 (14 ref.)

Malignant pheochromocytoma. Mundschenk J, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):373–6 (26 ref.)

[Current views on pheochromocytoma] Luk'anchikov VS, et al. **Ter Arkh** 1998;70(11):83–6 (80 ref.) (Rus)

BLOOD

[Bladder pheochromocytoma: a variation in the plasma catecholamines during micturition (letter)] Lecube A, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):477–8 (10 ref.) (Spa)

COMPLICATIONS

Myocardial infarction and death after caesarean section in a woman with protein S deficiency and undiagnosed phaeochromocytoma. Zangrillo A, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):268–70 (9 ref.)

Secondary hypertension in the elderly. Januszewicz W, et al. **J Hum Hypertens** 1998 Sep;12(9):603–6 (30 ref.)

[Bilateral pheochromocytomas with von Hippel-Lindau's disease: a case report] Kubota Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Aug;89(8):726–9 (11 ref.) (Eng. Abstr.) (Jpn)

DIAGNOSIS

Clonidine suppression test revisited. Lenz T, et al. **Blood Press** 1998 May;7(3):153–9 (28 ref.)

Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses). Hes FJ, et al. **Eur Radiol** 1999;9(4):598–610 (142 ref.)

Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-Up. Kebebew E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):765–89 (81 ref.)

Pheochromocytoma: evaluation, diagnosis, and treatment. Walther MM, et al. **World J Urol** 1999 Feb;17(1):35–9 (47 ref.)

[Pheochromocytoma associated with pregnancy. Report of 2 cases and review of the literature] Castaigne V, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):622–4 (11 ref.) (Eng. Abstr.) (Fre)

[Malignant pheochromocytoma. A case report and comments on a rare pathology] Boneschi M, et al. **Minerva Chir** 1999 Jan–Feb;54(1–2):73–8 (23 ref.) (Eng. Abstr.) (Ita)

[Pheochromocytoma. A case report] Garritano A, et al. **Minerva Chir** 1999 Apr;54(4):283–6 (22 ref.) (Eng. Abstr.) (Ita)

[Progress in diagnosis of secondary hypertension] Saito I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):236–40 (5 ref.) (Jpn)

[Pheochromocytoma. Methoxycatecholamines in nocturnal urine and chromogranin in EDTA-blood should be measured first] Lindstedt G, et al. **Lakartidningen** 1998 Oct 28;95(44):4859–61 (11 ref.) (Swe)

PATHOLOGY

Thoracic involvement with pheochromocytoma: a review. Sandur S, et al. **Chest** 1999 Feb;115(2):511–21 (93 ref.)

SECONDARY

[A case of surgical resection of metastatic multiple lung pheochromocytoma with long-term survival] Kido T, et al. **Kyobu Geka** 1999 Jun;52(6):458–62 (20 ref.) (Eng. Abstr.) (Jpn)

SECRETION

[Adrenal incidentaloma: a dopamine-secreting pheochromocytoma with an atypical clinical picture. A case report and review of the literature] Bartolacci M, et al. **Ann Ital Chir** 1998 Nov–Dec;69(6):805–14 (70 ref.) (Eng. Abstr.) (Ita)

SURGERY

An overview of anaesthetic issues in phaeochromocytoma. Singh G, et al. **Ann Acad Med Singapore** 1998 Nov; 27(6):843–8 (41 ref.)

Cardiac pheochromocytoma: resection after diagnosis by 111-indium octreotide scan. Lin JC, et al. **Ann Thorac Surg** 1999 Feb;67(2):555–8 (8 ref.)

Laparoscopic removal of a right adrenal pheochromocytoma in a pregnant woman. Demeure MJ, et al. **J Laparoendosc Adv Surg Tech A** 1998 Oct;8(5):315–9 (16 ref.)

Pheochromocytoma: evaluation, diagnosis, and treatment. Walther MM, et al. **World J Urol** 1999 Feb;17(1):35–9 (47 ref.)

[Modern aspects of management of pheochromocytoma and abdominopelvic paraganglioma] Proye C. **Ann Chir** 1998; 52(7):643–56 (82 ref.) (Fre)

[Laparoscopic adrenalectomy for pheochromocytoma. Case report and review of the literature] Abboud B, et al. **J Med Liban** 1998 Sep–Oct;46(5):291–4 (32 ref.) (Eng. Abstr.) (Fre)

[A case of surgical resection of metastatic multiple lung pheochromocytoma with long-term survival] Kido T, et al. **Kyobu Geka** 1999 Jun;52(6):458–62 (20 ref.) (Eng. Abstr.) (Jpn)

PHERESIS see **BLOOD COMPONENT REMOVAL**

PHEROMONES

Menstrual synchrony pheromones: cause for doubt. Strassmann BI. **Hum Reprod** 1999 Mar;14(3):579–80 (28 ref.)

BIOSYNTHESIS

Insect pheromones—an overview of biosynthesis and endocrine regulation. Tillman JA, et al. **Insect Biochem Mol Biol** 1999 Jun;29(6):481–514 (372 ref.)

METABOLISM

Quorum sensing and the cell-cell communication dependent regulation of gene expression in pathogenic and non-pathogenic bacteria. Hardman AM, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):199–210 (100 ref.)

Pheromone deactivation catalyzed by receptor molecules: a quantitative kinetic model. Kaissling KE. **Chem Senses** 1998 Aug;23(4):385–95 (40 ref.)

Insect pheromones—an overview of biosynthesis and endocrine regulation. Tillman JA, et al. **Insect Biochem Mol Biol** 1999 Jun;29(6):481–514 (372 ref.)

Fusion of a fission yeast. Davey J. **Yeast** 1998 Dec; 14(16):1529–66 (318 ref.)

PHARMACOLOGY

Electrophysiological and biochemical responses of mouse vomeronasal receptor cells to urine-derived compounds: possible mechanism of action. Moss RL, et al. **Chem Senses** 1998 Aug;23(4):483–9 (48 ref.)

PHYSIOLOGY

Pheromones, the vomeronasal system, and communication. From hormonal responses to individual recognition. Johnston RE. **Ann N Y Acad Sci** 1998 Nov 30;855:333–48 (62 ref.)

Pheromone signalling in the mouse: role of urinary proteins and vomeronasal organ. Cavaggioni A, et al. **Arch Ital Biol** 1999 May;137(2–3):193–200 (52 ref.)

PHEROMONES

Wellness in women after 40 years of age: the role of sex hormones and pheromones. Cutler WB, et al. **Dis Mon** 1998 Sep;44(9):421–546 (255 ref.)
Molecular aspects of pheromonal communication via the vomeronasal organ of mammals. Tirindelli R, et al. **Trends Neurosci** 1998 Nov;21(11):482–6 (58 ref.)

PHEROMONES, SEXUAL see **SEX ATTRACTANTS**

PHI PEPTIDE see **PEPTIDE PHI**

PHI 6 PHAGE see **BACTERIOPHAGE PHI 6**

PHILADELPHIA CHROMOSOME

see related
ONCOGENE PROTEINS, FUSION

The involvement of Bcr in leukemias with the Philadelphia chromosome. Arlinghaus RB. **Crit Rev Oncog** 1998; 9(1):1–18 (97 ref.)
Significance of BCR–ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Aviram A, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):77–82 (32 ref.)
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia [editorial] Drexler HG, et al. **Leuk Res** 1999 Mar;23(3):207–15 (84 ref.)
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview [see comments] Tefferi A. **Mayo Clin Proc** 1998 Dec; 73(12):1177–84 (10 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):742.

PHILANTHROPIC FUNDS see **FUND RAISING**

PHILATELY

Genetic landmarks through philately--Gregor Johann Mendel (1822–1884). Chudley AE. **Clin Genet** 1998 Aug; 54(2):121–3 (1 ref.)

PHILOSOPHY

Theories of consent [see comments] Alderson P, et al. **BMJ** 1998 Nov 7;317(7168):1313–5 (18 ref.) Comment in: BMJ 1999 Mar 13;318(7185):735–6.
The critique of Heideggerian hermeneutical nursing research. Draucker CB. **J Adv Nurs** 1999 Aug;30(2):360–73 (61 ref.)
The idea of nursing science. Edwards SD. **J Adv Nurs** 1999 Mar;29(3):563–9 (34 ref.)
A philosopher looks at neuroscience. Beedle AS. **J Neurosci Res** 1999 Jan 15;55(2):141–6 (13 ref.)

PHILOSOPHY, MEDICAL

Paradigms in epidemiology textbooks: in the footsteps of Thomas Kuhn. Bhopal R. **Am J Public Health** 1999 Aug; 89(8):1162–5 (49 ref.)
The essence of alternative medicine. A dermatologist's view from Germany. Happle R. **Arch Dermatol** 1998 Nov; 134(11):1455–60 (45 ref.)
Environmental ethics and medical ethics: some implications for end-of-life care, Part II. Carrick P. **Camb Q Healthc Ethics** 1999 Spring;8(2):250–6 (15 ref.)
Physician-assisted death: can philosophical bioethics aid social policy? Kuczewski MG. **Camb Q Healthc Ethics** 1998 Fall;7(4):339–47 (19 ref.)
Qualitative studies. Their role in medical research. Huston P, et al. **Can Fam Physician** 1998 Nov;44:2453–8 (19 ref.)
Humanitarianism, pluralism and ombudsmen: do the pieces fit? Christoplos I. **Disasters** 1999 Jun;23(2):125–38 (21 ref.)
Integrative thinking: the essence of good medical education and practice. Rosch PJ. **Integr Physiol Behav Sci** 1998 Apr–Jun;33(2):141–50 (8 ref.)
The dietitians' philosophy and practice in multidisciplinary weight management. Dalton S. **J Am Diet Assoc** 1998 Oct; 98(10 Suppl 2):S49–54 (49 ref.)
Articulating the concept of palliative care: philosophical and theological perspectives. Janssens RM, et al. **J Palliat Care** 1999 Summer;15(2):38–44 (29 ref.)
Philosophy of antiarrhythmic approaches to ventricular tachyarrhythmias close to the 21st century. Breithardt G, et al. **Rev Port Cardiol** 1998 Dec;17(12):981–91 (49 ref.)
Assignments of meaning in epidemiology. Little M. **Soc Sci Med** 1998 Nov;47(9):1135–45 (31 ref.)
"Death by proxy": ethics and classification in epidemiology. Plant AJ, et al. **Soc Sci Med** 1998 Nov;47(9):1147–53 (21 ref.)
The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621–44 (63 ref.)
The tacit–explicit connection: Polanyian integrative philosophy and a Neo–Polanyian medical epistemology. Jha SR. **Theor Med Bioeth** 1998 Dec;19(6):547–68 (24 ref.)
Prescriptions: autonomy, humanism and the purpose of health technology. Krakauer EL. **Theor Med Bioeth** 1998 Dec; 19(6):525–45 (27 ref.)
Whose consent is it anyway? A poststructuralist framing of the person in medical decision-making. Marta J. **Theor Med Bioeth** 1998 Aug;19(4):353–70 (33 ref.)
What the philosophy of medicine is. Pellegrino ED. **Theor Med Bioeth** 1998 Aug;19(4):315–36 (103 ref.)
[Paradigms and pragmatism] Healy MJ. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):185–9 (16 ref.) **(Fre)**
[Is there an essence of medicine?] Weber JC. **Rev Med Interne** 1998 Dec;19(12):924–7 (15 ref.) (Eng. Abstr.) **(Fre)**
[Significance of philosophy, bio–mathematics, biometry and model theory for medicine] Gerok W. **Med Klin** 1998 Aug 15;93(8):501–6 (6 ref.) **(Ger)**
[Reductionism once again. The example of Helicobacter pylori (editorial)] Weiner H. **Psychother Psychosom Med Psychol** 1998 Nov;48(11):425–9 (49 ref.) (Eng. Abstr.) **(Ger)**

PHILOSOPHY, NURSING

Community-based nursing: philosophy or setting? Hunt R. **Am J Nurs** 1998 Oct;98(10):44–7; quiz 48 (8 ref.)
Combining stories and numbers: a methodologic approach for a critical nursing science. Berman H, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):1–15 (51 ref.)
An emancipatory impulse: a feminist postmodern integrated turning point in nursing research. Glass N, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):43–52 (45 ref.)
Toward an understanding of art in nursing. LeVasseur JJ. **ANS Adv Nurs Sci** 1999 Jun;21(4):48–63 (48 ref.)
Multiple paradigms of nursing science. Monti EJ, et al. **ANS Adv Nurs Sci** 1999 Jun;21(4):64–80 (38 ref.)
On "being inspired" by Husserl's Phenomenology: reflections on Omery's exposition of phenomenology as a method of nursing research. Porter EJ. **ANS Adv Nurs Sci** 1998 Sep; 21(1):16–28 (53 ref.)
Caring and the science of unitary human beings. Smith MC. **ANS Adv Nurs Sci** 1999 Jun;21(4):14–28 (63 ref.)
Womanism: a methodologic framework for African American women. Taylor JY. **ANS Adv Nurs Sci** 1998 Sep; 21(1):53–64 (60 ref.)
A little lady called Pandora: an exploration of philosophical traditions of humanism and existentialism in nursing ill children. Holyoake DD. **Child Care Health Dev** 1998 Jul; 24(4):325–36 (51 ref.)
Nursing in Thailand: western concepts vs Thai tradition. Ekintumas D. **Int Nurs Rev** 1999 Mar–Apr;46(2):55–7 (19 ref.)
The power of the word: some post-structural considerations of qualitative approaches in nursing research. Crowe M. **J Adv Nurs** 1998 Aug;28(2):339–44 (22 ref.)
Primary nursing: a mode of care or a philosophy of nursing? Pontin D. **J Adv Nurs** 1999 Mar;29(3):584–91 (94 ref.)
The nature of philosophy of science, theory and knowledge relating to nursing and professionalism. Rutty JE. **J Adv Nurs** 1998 Aug;28(2):243–50 (63 ref.)
Using reflective thinking to develop personal professional philosophies. Brown SC, et al. **J Nurs Educ** 1999 Apr; 38(4):171–5 (20 ref.)
The philosophy of nursing. Fry ST. **Sch Inq Nurs Pract** 1999 Spring;13(1):5–15 (39 ref.)

PHIMOSIS

Phimosis. Fox E. **Practitioner** 1997 Sep;241(1578):534 (0 ref.)

DIAGNOSIS

[Phimosis, hydrocele and varicocele. 3 frequent pathologies in the male child and adolescent] Pereira NM. **Acta Med Port** 1999 Jan–Mar;12(1–3):137–43 (25 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Medical management of phimosis in children: our experience with topical steroids. Monsour MA, et al. **J Urol** 1999 Sep; 162(3 Pt 2):1162–4 (13 ref.)

PHLEBOGRAPHY

Current role of venography in the diagnosis of deep-vein thrombosis. Rossi R, et al. **Minerva Cardioangiol** 1998 Dec; 46(12):507–14 (56 ref.)

METHODS

MR assessment of the extremity veins. Polak JF, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):36–46 (27 ref.)
[Value of the functional investigation of the bone: intramedullary pressure measurement, trans-osseus phlebography and needle biopsy] Ficat C. **Acta Orthop Belg** 1999;65 Suppl 1:35–44 (31 ref.) **(Fre)**

PHLEBOTHROMBOSIS see **VENOUS THROMBOSIS**

PHLEBOTOMINAE see **PSYCHODIDAE**

PHLEBOTOMUS

[The Phlebotominae (Diptera, Phlebotomidae) as vectors of parasitic and viral diseases from the aspect of biomedical research] MišćevićZ, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):190–5 (42 ref.) **(Scc)**

PARASITOLOGY

The biology and control of phlebotomine sand flies. Killick-Kendrick R. **Clin Dermatol** 1999 May–Jun; 17(3):279–89 (156 ref.)

PHLEBOTOMY

see related
INFUSIONS, INTRAVENOUS
INJECTIONS, INTRAVENOUS

Management of hemochromatosis. Hemochromatosis Management Working Group. Barton JC, et al. **Ann Intern Med** 1998 Dec 1;129(11):932–9 (86 ref.)
[Diagnosis and treatment of primary hemochromatosis] Swinkels DW, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1404–8 (57 ref.) (Eng. Abstr.) **(Dut)**

METHODS

[Eisenmenger syndrome in adults] Roos-Hesselink JW, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):501–5 (22 ref.) (Eng. Abstr.) **(Dut)**

PHLEGMASIA ALBA DOLENS see **THROMBOPHLEBITIS**

PHLEGMON see **CELLULITIS**

PHOBIA, SCHOOL see **PHOBIC DISORDERS**

PHOBIA, SOCIAL see **PHOBIC DISORDERS**

PHOBIAS see **PHOBIC DISORDERS**

PHOBIC DISORDERS

DIAGNOSIS

The convergent validity of the Phobia Origins Questionnaire (POQ): a review of the evidence. Menzies RG, et al. **Behav Res Ther** 1998 Nov;36(11):1081–9 (42 ref.)
Social phobia: diagnosis, severity and implications for treatment. Montgomery SA. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S1–6 (35 ref.)
Social phobia: the nature of the disorder. Kasper S. **J Affect Disord** 1998 Sep;50 Suppl 1:S3–9 (25 ref.)
Subtypes of social phobia and comorbidity with depression and other anxiety disorders. Stein MB, et al. **J Affect Disord** 1998 Sep;50 Suppl 1:S11–6 (21 ref.)
Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Ballenger JC, et al. **J Clin Psychiatry** 1998;59 Suppl 17:54–60 (3 ref.)
Social anxiety disorder: etiology and early clinical presentation. Beidel DC. **J Clin Psychiatry** 1998;59 Suppl 17:27–32 (32 ref.)
How is recovery from social anxiety disorder defined? Bobes J. **J Clin Psychiatry** 1998;59 Suppl 17:12–9 (23 ref.)
Update on the diagnosis and treatment of social anxiety disorder. Liebowitz MR. **J Clin Psychiatry** 1999;60 Suppl 18:22–6 (34 ref.)
The history, epidemiology, and differential diagnosis of social anxiety disorder. Moutier CY, et al. **J Clin Psychiatry** 1999; 60 Suppl 9:4–8 (39 ref.)
Gender differences in the presentation and management of social anxiety disorder. Weinstock LS. **J Clin Psychiatry** 1999;60 Suppl 9:9–13 (51 ref.)
The nature of social anxiety disorder. Westenberg HG. **J Clin Psychiatry** 1998;59 Suppl 17:20–6 (14 ref.)
[A hidden compulsion] van Vliet IM. **Ned Tijdschr Geneeskd** 1999 Feb 20;143(8):385–8 (10 ref.) (Eng. Abstr.) **(Dut)**
[Neurotic syndrome: phobic neurosis. Diagnosis, treatment] Degiovanni A. **Rev Prat** 1998 Mar 15;48(6):685–7 (00 ref.) **(Fre)**

DRUG THERAPY

The clinical relevance of treating social phobia. Lader M. **J Affect Disord** 1998 Sep;50 Suppl 1:S29–34 (30 ref.)
The role of drug therapy in social phobia. Lydiard RB. **J Affect Disord** 1998 Sep;50 Suppl 1:S35–9 (35 ref.)
Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Ballenger JC, et al. **J Clin Psychiatry** 1998;59 Suppl 17:54–60 (3 ref.)
Pharmacotherapy of social anxiety disorder. Davidson JR. **J Clin Psychiatry** 1998;59 Suppl 17:47–53 (27 ref.)

EPIDEMIOLOGY

Social phobia and alcoholism: a complex relationship. Lépine JP, et al. **J Affect Disord** 1998 Sep;50 Suppl 1:S23–8 (36 ref.)
Comorbidity in social anxiety disorder: impact on disease burden and management. Lecrubier Y. **J Clin Psychiatry** 1998;59 Suppl 17:33–8 (15 ref.)

ETIOLOGY

The first panic attack: a neurobiological theory. Jacobs WJ, et al. **Can J Exp Psychol** 1999 Mar;53(1):92–107 (148 ref.)
Social anxiety disorder: etiology and early clinical presentation. Beidel DC. **J Clin Psychiatry** 1998;59 Suppl 17:27–32 (32 ref.)

PHYSIOPATHOLOGY

Current approaches to etiology and pathophysiology of specific phobia. Fyer AJ. **Biol Psychiatry** 1998 Dec 15; 44(12):1295–304 (78 ref.)
Neurobiological perspectives on social phobia: from affiliation to zoology. Stein MB. **Biol Psychiatry** 1998 Dec 15;44(12):1277–85 (74 ref.)
The neurobiology of social phobia. Bell CJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S11–8 (53 ref.)
Brain mechanisms of social anxiety disorder. Nutt DJ, et al. **J Clin Psychiatry** 1998;59 Suppl 17:4–11 (40 ref.)

PSYCHOLOGY

Current approaches to etiology and pathophysiology of specific phobia. Fyer AJ. **Biol Psychiatry** 1998 Dec 15; 44(12):1295–304 (78 ref.)
Social anxiety and social performance: why don't we see more catastrophes? Strahan EY, et al. **J Anxiety Disord** 1999 Jul–Aug;13(4):399–416 (52 ref.)

THERAPY

The treatment of social phobia: a critical assessment. Stravynski A, et al. **Acta Psychiatr Scand** 1998 Sep; 98(3):171–81 (68 ref.)
The neurobiology of social phobia. Bell CJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S11–8 (53 ref.)
Social phobia: diagnosis, severity and implications for treatment. Montgomery SA. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S1–6 (35 ref.)
Treatment of specific phobias with Eye Movement Desensitization and Reprocessing (EMDR): protocol, empirical status, and conceptual issues. De Jongh A, et al. **J Anxiety Disord** 1999 Jan–Apr;13(1–2):69–85 (54 ref.)
Update on the diagnosis and treatment of social anxiety disorder. Liebowitz MR. **J Clin Psychiatry** 1999;60 Suppl 18:22–6 (34 ref.)
Cognitive-behavioral therapy for social anxiety disorder: model, methods, and outcome. Otto MW. **J Clin Psychiatry** 1999;60 Suppl 9:14–9 (28 ref.)
Psychotherapy in the overall management strategy for social anxiety disorder. Shear MK, et al. **J Clin Psychiatry** 1998; 59 Suppl 17:39–46 (20 ref.)
[Neurotic syndrome: phobic neurosis. Diagnosis, treatment] Degiovanni A. **Rev Prat** 1998 Mar 15;48(6):685–7 (00 ref.) **(Fre)**

PHOBIC NEUROSES see **PHOBIC DISORDERS**

PHOBOS see **MARS**

PHOCOMELIA see **ECTROMELIA**

PHONATION

see related
VOICE QUALITY

[Video-laryngostroboscopy in phonation] Haddad AC, et al. **J Med Liban** 1998 May–Jun;46(3):140–5 (26 ref.) **(Fre)**
[Torpid pneumonia secondary to the aspiration of a phonation prosthesis (letter)] Garcia Gasalla M, et al. **Rev Clin Esp** 1999 Jul;199(7):481–2 (10 ref.) **(Spa)**

PHONATION DISORDERS see **VOICE DISORDERS**

PHONETICS

Phonology, semantics, and the role of the left inferior prefrontal cortex [editorial] Fiez JA. **Hum Brain Mapp** 1997;5(2):79–83 (39 ref.)
Phonological representations in deaf children: the importance of early linguistic experience. Leybaert J. **Scand J Psychol** 1998 Sep;39(3):169–73 (42 ref.)
Why is learning to read a hard task for some children? Lundberg I. **Scand J Psychol** 1998 Sep;39(3):155–7 (17 ref.)

PHORBOL MYRISTATE ACETATE see **TETRADECANOYLPHORBOL ACETATE**

PHORIAS see **STRABISMUS**

PHOSPHATASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHATE DIABETES see **HYPOPHOSPHATEMIA, FAMILIAL**

PHOSPHATES

see related
HYPOPHOSPHATEMIA
PHOSPHORIC ACID ESTERS

ADVERSE EFFECTS

Neutral phosphate-induced renal tubular metabolic alkalosis. Abdullah S, et al. **Burns** 1999 Jun;25(4):364–5 (6 ref.)

ANALYSIS

The phosphate sensor. Engblom SO. **Biosens Bioelectron** 1998 Oct 15;13(9):981–94 (72 ref.)

BLOOD

Hyperphosphataemia--a silent killer of patients with renal failure? [editorial] Amann K, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2085–7 (22 ref.)
Behaviour of phosphate removal with different dialysis schedules. Messa P, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:43–8 (29 ref.)
Control of serum phosphate in patients with renal failure--new approaches [editorial] Mucsi I, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2457–60 (16 ref.)
[Regulation of phosphatemia and hypophosphatemia] Essig M, et al. **Rev Prat** 1998 Jun 1;48(11):1218–25 (13 ref.) (Eng. Abstr.) **(Fre)**
[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Internist (Berl)** 1998 Aug;39(8):825–30 (6 ref.) **(Ger)**
[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Urologe A** 1999 May;38(3):285–95 (6 ref.) **(Ger)**

METABOLISM

Historical perspectives and current advancements in the bacteriology and medical therapy of struvite urinary stone disease. Schwartz BF. **Curr Pharm Des** 1999 Jul;5(7):503–13 (93 ref.)
Regulation of phosphate transport in the renal tubule through parathyroid hormone receptor: unexpected pathways. Silve C, et al. **Exp Nephrol** 1998 Jul–Aug;6(4):282–7 (16 ref.)
Protein–RNA interactions in the regulation of PTH gene expression by calcium and phosphate [editorial] Naveh-Many T, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):811–3 (17 ref.)
Struvite stones. Rodman JS. **Nephron** 1999;81 Suppl 1:50–9 (54 ref.)
Genetic improvement of bacteria for enhanced biological removal of phosphate from wastewater. Ohtake H, et al. **Prog Mol Subcell Biol** 1999;23:299–311 (33 ref.)
[Role of phosphate, vitamin D and acidosis in the secretion and synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1349–54 (59 ref.) **(Fre)**
[Anomalies of phosphate and calcium metabolism in chronic renal insufficiency] Drüeke TB. **Rev Prat** 1998 Jun 1; 48(11):1207–12 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Direct effect of phosphate on parathyroid function. Rodriguez M. **Nephrol Dial Transplant** 1999;14 Suppl 1:70–2 (28 ref.)

PHOSPHATES, INORGANIC see **PHOSPHATES**

PHOSPHATES, ORGANIC see **PHOSPHORIC ACID ESTERS**

PHOSPHATIDAL COMPOUNDS see **PLASMALOGENS**

PHOSPHATIDATE PHOSPHATASE

[Phosphatidic acid phosphatase] Kanoh H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):983–8 (28 ref.) **(Jpn)**

GENETICS

Molecular characterization of the type 2 phosphatidic acid phosphatase. Kanoh H, et al. **Chem Phys Lipids** 1999 Apr; 98(1–2):119–26 (46 ref.)

METABOLISM

Structural organization of mammalian lipid phosphate phosphatases: implications for signal transduction. Waggoner DW, et al. **Biochim Biophys Acta** 1999 Jul 30; 1439(2):299–316 (106 ref.)
Molecular characterization of the type 2 phosphatidic acid phosphatase. Kanoh H, et al. **Chem Phys Lipids** 1999 Apr; 98(1–2):119–26 (46 ref.)

PHYSIOLOGY

[Phosphatidic acid phosphatase (type 2), haloperoxidase family and germ cell migration] Wada I, et al. **Seikagaku** 1998 Sep;70(9):1185–8 (18 ref.) **(Jpn)**

PHOSPHATIDATE PHOSPHOHYDROLASE see **PHOSPHATIDATE PHOSPHATASE**

PHOSPHATIDES see **PHOSPHOLIPIDS**

PHOSPHATIDIC ACIDS

CHEMISTRY

Some aspects of oligoribonucleotides synthesis via the H-phosphonate approach. Stawiński J, et al. **Acta Biochim Pol** 1998;45(4):907–15 (51 ref.)

PHYSIOLOGY

A novel protein kinase target for the lipid second messenger phosphatidic acid. McPhail LC, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):277–90 (208 ref.)

PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE

ANALYSIS

Lecithin–cholesterol acyltransferase. Assay of cholesterol esterification and phospholipase A2 activities. Parks JS, et al. **Methods Mol Biol** 1999;109:123–31 (26 ref.)

BLOOD

Assays of lecithin cholesterol acyltransferase (LCAT). Dobiásová M, et al. **Methods Mol Biol** 1998;110:217–30 (33 ref.)
Regulation of lecithin cholesterol acyltransferase activity. Jonas A. **Prog Lipid Res** 1998 Sep;37(4):209–34 (156 ref.)

METABOLISM

Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. Dobiásová M, et al. **Clin Chim Acta** 1999 Aug;286(1–2):257–71 (75 ref.)
Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Dobiásová M, et al. **Physiol Res** 1998; 47(6):387–97 (74 ref.)

PHOSPHATIDYLCHOLINES

CHEMISTRY

Investigation of phase transitions in bilayer membranes. Mason JT. **Methods Enzymol** 1998;295:468–94 (21 ref.)
[Interaction of apolipoprotein A1 with phospholipids and structure of mixed micelles] Misharin ALu. **Bioorg Khim** 1998 Aug;24(8):563–85 (205 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Determination of phospholipase C- or phospholipase D-catalyzed phosphatidylcholine hydrolysis. Wakelam MJ, et al. **Methods Mol Biol** 1998;105:141–9 (9 ref.)
Oxidized phospholipids as a new landmark in atherosclerosis. Itabe H. **Prog Lipid Res** 1998 Jul–Aug;37(2–3):181–207 (171 ref.)
Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. Kent C, et al. **Trends Biochem Sci** 1999 Apr; 24(4):146–50 (45 ref.)

PHOSPHATIDYLETHANOLAMINES

METABOLISM

Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Hansen HS, et al. **Lipids** 1999;34 Suppl:S327–30 (37 ref.)

PHOSPHATIDYLGLYCEROLS

[Biosynthesis and function of phosphatidylglycerol and cardiolipin in animal cells] Kawasaki K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1167–72 (13 ref.) **(Jpn)**

PHOSPHATIDYLINOSITOL GLYCAN see **GLYCOSYLPHOSPHATIDYLINOSITOLS**

1-PHOSPHATIDYLINOSITOL 3-KINASE

PI 3-kinase. Krugmann S, et al. **Curr Biol** 1998 Nov 19; 8(23):R828 (5 ref.)
[Phosphoinositide 3-kinase] Hazeki O. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):961–8 (83 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Flavonoids and the inhibition of PKC and PI 3-kinase. Gamet-Payrastre L, et al. **Gen Pharmacol** 1999 Mar; 32(3):279–86 (51 ref.)

IMMUNOLOGY

Multiple roles for PI 3-kinase in the regulation of PLCgamma activity and Ca2+ mobilization in antigen-stimulated mast cells. Barker SA, et al. **J Leukoc Biol** 1999 Mar;65(3):321–9 (55 ref.)

METABOLISM

Phosphoinositide kinases. Fruman DA, et al. **Annu Rev Biochem** 1998;67:481–507 (153 ref.)
Molecular aspects of the endocytic pathway. Clague MJ. **Biochem J** 1998 Dec 1;336 (Pt 2):271–82 (237 ref.)
The role of PI 3-kinase in insulin action. Alessi DR, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):151–64 (95

ref.)
Structure and function of phosphoinositide 3-kinases. Wymann MP, et al. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):127-50 (311 ref.)
FYVE finger proteins as effectors of phosphatidylinositol 3-phosphate. Gaullier JM, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):87-94 (45 ref.)
Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors. Katada T, et al. **Chem Phys Lipids** 1999 Apr; 98(1-2):79-86 (30 ref.)
The role of phosphoinositide 3-kinase lipid products in cell function. Rameh LE, et al. **J Biol Chem** 1999 Mar 26; 274(13):8347-50 (94 ref.)
Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. Wurmser AE, et al. **J Biol Chem** 1999 Apr 2; 274(14):9129-32 (71 ref.)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Cantley LC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4240-5 (76 ref.)
Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Corvera S, et al. **Trends Cell Biol** 1998 Nov;8(11):442-6 (58 ref.)

PHYSIOLOGY

The complexities of CD28 and CTLA-4 signalling: PI3K and beyond. Ward SG. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):69-75 (51 ref.)
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Leevers SJ, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):219-25 (54 ref.)
Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. Anderson RA, et al. **J Biol Chem** 1999 Apr 9;274(15):9907-10 (65 ref.)
Novel pathways, membrane coats and PI kinase regulation in yeast lysosomal trafficking. Burd CG, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):527-33 (77 ref.)
[Signal transduction of PI3-kinase] Fukui Y. **Nippon Rinsho** 1998 Jul;56(7):1773-8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Role of PI signaling in early development] Kume S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1834-40 (28 ref.) **(Jpn)**

1-PHOSPHATIDYLINOSITOL 4-KINASE

[Phosphatidylinositol kinase: functional roles for PI4-kinase and PIP kinase in signal transduction] Itoh T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):949-60 (80 ref.) **(Jpn)**

ANALYSIS

Phosphatidylinositol 4-kinases. Assays and product analysis. Meyers RE, et al. **Methods Mol Biol** 1998;105:99-108 (12 ref.)

METABOLISM

Phosphoinositide kinases. Fruman DA, et al. **Annu Rev Biochem** 1998;67:481-507 (153 ref.)
Phosphatidylinositol 4-kinases. Balla T. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):69-85 (125 ref.)

PHYSIOLOGY

Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. Anderson RA, et al. **J Biol Chem** 1999 Apr 9;274(15):9907-10 (65 ref.)

PHOSPHATIDYLINOSITOL 3-KINASE see **1-PHOSPHATIDYLINOSITOL 3-KINASE**

PHOSPHATIDYLINOSITOL-3-OH KINASE see **1-PHOSPHATIDYLINOSITOL 3-KINASE**

PHOSPHATIDYLINOSITOL 4-KINASE see **1-PHOSPHATIDYLINOSITOL 4-KINASE**

PHOSPHATIDYLINOSITOL PHOSPHATES

ANALYSIS

Phosphatidylinositol(3,4,5)trisphosphate (Ptdins(3,4,5)P3) mass measurement using a radioligand displacement assay. van der Kaay J, et al. **Methods Mol Biol** 1998;105:109-25 (8 ref.)

BIOSYNTHESIS

Phosphoinositide kinases and the synthesis of polyphosphoinositides in higher plant cells. Drøbak BK, et al. **Int Rev Cytol** 1999;189:95-130 (127 ref.)
Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. Anderson RA, et al. **J Biol Chem** 1999 Apr 9;274(15):9907-10 (65 ref.)

METABOLISM

PIPkins1, their substrates and their products: new functions for old enzymes. Hinchliffe KA, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):87-104 (134 ref.)
FYVE finger proteins as effectors of phosphatidylinositol 3-phosphate. Gaullier JM, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):87-94 (45 ref.)
Regulation of phosphatidylinositol 4,5-bisphosphate levels and its roles in cytoskeletal re-organization and malignant transformation. Takenawa T, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):13-22 (68 ref.)
The role of phosphoinositide 3-kinase lipid products in cell function. Rameh LE, et al. **J Biol Chem** 1999 Mar 26; 274(13):8347-50 (94 ref.)

PHOSPHATIDYLINOSITOLS

ANALYSIS

Phosphoinositidase C activation assay. II. Simple analysis of recovered cellular phosphoinositides and phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:11-23 (23 ref.)
Phosphoinositidase C activation assay. III. HPLC analysis of cellular phosphoinositides and phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:25-45 (17 ref.)
Measurement of phosphoinositols and phosphoinositides using radio high-performance liquid chromatography flow detection. Zhang L, et al. **Methods Mol Biol** 1998;105:47-63 (11 ref.)

BIOSYNTHESIS

Phosphoinositide kinases. Fruman DA, et al. **Annu Rev Biochem** 1998;67:481-507 (153 ref.)

BLOOD

What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? Strunecká A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul;61(1):1-5 (47 ref.)

ISOLATION & PURIFICATION

Preparation of [3H]phosphoinositol standards and conversion of [3H]phosphoinositides to [3H]phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:65-76 (10 ref.)
Phosphoinositidase C activation assay. I. Cell labeling, stimulation, and recovery of cellular [3H]phosphoinositides and [3H]phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:1-9 (7 ref.)

METABOLISM

The structure of phospholipase C isoforms and the regulation of phosphoinositide hydrolysis. James S. **Biochem Soc Trans** 1998 Aug;26(3):354-9 (24 ref.)
Families of phosphoinositide-specific phospholipase C: structure and function. Katan M. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):5-17 (98 ref.)
Phosphoinositide binding domains: embracing 3-phosphate. Fruman DA, et al. **Cell** 1999 Jun 25;97(7):817-20 (19 ref.)
Mammalian phosphatidylinositol transfer proteins: emerging roles in signal transduction and vesicular traffic. Cockcroft S. **Chem Phys Lipids** 1999 Apr;98(1-2):23-33 (62 ref.)
Pathways for phosphoinositide synthesis. Tolias KF, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):69-77 (60 ref.)
Phosphoinositide kinases and the synthesis of polyphosphoinositides in higher plant cells. Drøbak BK, et al. **Int Rev Cytol** 1999;189:95-130 (127 ref.)
Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. Wurmser AE, et al. **J Biol Chem** 1999 Apr 2; 274(14):9129-32 (71 ref.)
Preparation of [3H]phosphoinositol standards and conversion of [3H]phosphoinositides to [3H]phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:65-76 (10 ref.)
[The role of phosphatidylinositol turnover in nuclear] Fukami K. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):969-75 (32 ref.) **(Jpn)**
[Signal transduction in the cell by phosphoinositide-specific phospholipase C isozymes] Pawełczyk T. **Postepy Hig Med Dosw** 1999;53(2):173-82 (40 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Martin TF. **Annu Rev Cell Dev Biol** 1998;14:231-64 (198 ref.)
Intracellular signalling: PDK1--a kinase at the hub of things. Belham C, et al. **Curr Biol** 1999 Feb 11;9(3):R93-6 (21 ref.)
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Leevers SJ, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):219-25 (54 ref.)
D-myo inositol 1,2,6, triphosphate (alpha-trinositol, pp56): selective antagonist at neuropeptide Y (NPY) Y-receptors or selective inhibitor of phosphatidylinositol cell signaling? Bell D, et al. **Gen Pharmacol** 1998 Nov;31(5):689-96 (79 ref.)
[Inositol phospholipid function in yeast] Kagiwada S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1194-9 (21 ref.) **(Jpn)**

PHOSPHATIDYLSERINES

BIOSYNTHESIS

[Phosphatidylserine biosynthesis and its regulation in mammalian cells] Saito K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1159-66 (35 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Separation procedures for phosphatidylserines. Abidi SL. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9; 717(1-2):279-93 (70 ref.)

METABOLISM

[Phosphatidylserine metabolism and biosynthetic regulation in mammalian cells] Kuge O. **Seikagaku** 1999 Jan;71(1):1-15 (47 ref.) **(Jpn)**
[Structure and function of phosphatidylserine-specific phospholipase A1: PS-PLA1] Aoki J. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1038-42 (26 ref.) **(Jpn)**
[Phosphatidylserine in Prokaryota and Eukaryota. Decarboxylation, synthesis and transport] Dygas A. **Postepy Biochem** 1998;44(4):292-8 (66 ref.) **(Pol)**

PHYSIOLOGY

The role of phosphatidylserine in recognition of apoptotic cells by phagocytes [see comments] Fadok VA, et al. **Cell Death Differ** 1998 Jul;5(7):551-62 (128 ref.) Comment in: Cell Death Differ 1998 Jul;5(7):549-50.

PHOSPHOCREATINE

METABOLISM

Influence of left ventricular pressures and heart rate on myocardial high-energy phosphate metabolism. Neubauer S. **Basic Res Cardiol** 1998;93 Suppl 1:102-7 (23 ref.)
Human cardiac spectroscopy. Bottomley PA, et al. **MAGMA** 1998 Sep;6(2-3):157-60 (13 ref.)

PHYSIOLOGY

[Phosphocreatine: physiologic role and practical application in cardiology] Golikov AP, et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):85-91 (40 ref.) **(Rus)**

PHOSPHODIESTERASE ANTAGONISTS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHODIESTERASE INHIBITORS

CONTRAINDICATIONS

[Sildenafil (Viagra). Tolerance, contraindications, drug interactions] Sperling H, et al. **Urologe A** 1999 Mar; 38(2):124-7 (3 ref.) (Eng. Abstr.) **(Ger)**
[A new agent against impotence. Contraindicated in reduced renal and hepatic function, in angina and with simultaneously used nitroglycerin preparations] Hedelin H. **Lakartidningen** 1998 Oct 14;95(42):4558-60 (13 ref.) **(Swe)**

PHARMACOLOGY

Overall cardiovascular profile of sildenafil citrate. Zusman RM, et al. **Am J Cardiol** 1999 Mar 4;83(5A):35C-44C (33 ref.)
Sildenafil (Viagra) and ophthalmology [editorial] Marmor MF. **Arch Ophthalmol** 1999 Apr;117(4):518-9 (9 ref.)
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Doherty AM. **Curr Opin Chem Biol** 1999 Aug; 3(4):466-73 (83 ref.)
Molecular mechanisms of the effects of sildenafil (VIAGRA). Glossmann H, et al. **Exp Gerontol** 1999 Jun;34(3):305-18 (55 ref.)
Pharmacology of sildenafil citrate. Umrani DN, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):160-4 (15 ref.)
Cyclic GMP phosphodiesterase-5: target of sildenafil. Corbin JD, et al. **J Biol Chem** 1999 May 14;274(20):13729-32 (70 ref.)
[Phosphodiesterase 5--the enzyme inhibited by sildenafil (Viagra)] Sandberg M, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):945-9 (31 ref.) (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

Newer pharmacologic alternatives for erectile dysfunction. Viera AJ, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1159-66, 1169, 1172 (23 ref.)
Cardiovascular effects of sildenafil citrate and recommendations for its use. Kloner RA, et al. **Am J Cardiol** 1999 Sep 9;84(5B):11N-17N (21 ref.)
Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Schmidt D, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:99-109 (109 ref.)
The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Spina D, et al.

Clin Exp Allergy 1998 Aug;28 Suppl 3:24–34 (100 ref.)
Pentoxifylline and skin inflammation. Bruynzeel I, et al. **Clin Exp Dermatol** 1998 Jul;23(4):168–72 (66 ref.)
Use of oral sildenafil (Viagra) in the treatment of erectile dysfunction. Licht MR. **Compr Ther** 1999 Feb;25(2):90–4 (13 ref.)
Chemotherapeutic potential of phosphodiesterase inhibitors. Perry MJ, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):472–81 (70 ref.)
Comparative tolerability and efficacy of treatments for impotence. Meinhardt W, et al. **Drug Saf** 1999 Feb; 20(2):133–46 (114 ref.)
Sildenafil: a review of its use in erectile dysfunction. Langtry HD, et al. **Drugs** 1999 Jun;57(6):967–89 (80 ref.)
Therapeutic potential of selective PDE inhibitors in asthma. Schudt C, et al. **Pulm Pharmacol Ther** 1999;12(2):123–9 (48 ref.)
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Torphy TJ, et al. **Pulm Pharmacol Ther** 1999;12(2):131–5 (22 ref.)
Viagra--after one year. Steers WD. **Urology** 1999 Jul; 54(1):12–7 (42 ref.)
[Erectile dysfunction--problem solved with sildenafil (Viagra)?] Hofer C, et al. **Internist (Berl)** 1998 Dec; 39(12):1232–6 (14 ref.) **(Ger)**
[Urology is more than Viagra. Potpourri of new developments in urology] Hobi C, et al. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2047–51 (3 ref.) **(Ger)**

PHOSPHODIESTERASES see **PHOSPHORIC DIESTER HYDROLASES**

PHOSPHOENOLPYRUVATE

METABOLISM

[Phosphoenolpyruvate: carbohydrate phosphotransferase system and its role in physiology of gram-negative bacteria] Gershanovich VN. **Mol Gen Mikrobiol Virusol** 1998; (3):8–15 (84 ref.) **(Rus)**

PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP)

GENETICS

Molecular and cellular adaptations to carbohydrate and fat intake. Leahy P, et al. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S6–13 (50 ref.)
Insulin regulates expression of metabolic genes through divergent signaling pathways. Hall RK, et al. **J Basic Clin Physiol Pharmacol** 1999;10(2):119–33 (47 ref.)
C/EBP and the control of phosphoenolpyruvate carboxykinase gene transcription in the liver. Croniger C, et al. **J Biol Chem** 1998 Nov 27;273(48):31629–32 (52 ref.)

PHOSPHOENOLPYRUVATE HEXOSE PHOSPHOTRANSFERASES see **PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM**

PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM

CHEMISTRY

The structure and function of HPr. Waygood EB. **Biochem Cell Biol** 1998;76(2–3):359–67 (53 ref.)
Mechanistic aspects of energy coupling in the Escherichia coli mannitol phosphotransferase system: a domain approach. Robillard GT, et al. **Biochem Soc Trans** 1998 Aug;26(3):532–8 (15 ref.)
Structure/function studies on the bacterial carbohydrate transporters, enzymes II, of the phosphoenolpyruvate-dependent phosphotransferase system. Robillard GT, et al. **Biochim Biophys Acta** 1999 Jul 6;1422(2):73–104 (139 ref.)

GENETICS

Coupling physiology and gene regulation in bacteria: the phosphotransferase sugar uptake system delivers the signals. Stülke J, et al. **Naturwissenschaften** 1998 Dec; 85(12):583–92 (95 ref.)

METABOLISM

Mechanistic aspects of energy coupling in the Escherichia coli mannitol phosphotransferase system: a domain approach. Robillard GT, et al. **Biochem Soc Trans** 1998 Aug;26(3):532–8 (15 ref.)

6-PHOSPHOFRUCTOKINASE

METABOLISM

Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism. Vestergaard H. **Dan Med Bull** 1999 Feb;46(1):13–34 (293 ref.)

3-PHOSPHOGLYCERALDEHYDE see **GLYCERALDEHYDE 3-PHOSPHATE**

PHOSPHOGLYCERALDEHYDE DEHYDROGENASE see **GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES**

PHOSPHOHYDROLASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOLS**

PHOSPHOLIPASE A1 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE A2 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE B see **LYSOPHOSPHOLIPASE**

PHOSPHOLIPASE C

[Development from actions of bacterial phospholipases C on eucaryotic plasma membranes to molecular biology of GPI-anchored proteins] Ikezawa H. **Yakugaku Zasshi** 1999 Jul;119(7):472–94 (86 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Phospholipase A2 and phosphatidylinositol-specific phospholipase C assays by HPLC and TLC with fluorescent substrate. Hendrickson HS. **Methods Mol Biol** 1999;109:1–6 (9 ref.)

CHEMISTRY

The structure of phospholipase C isoforms and the regulation of phosphoinositide hydrolysis. James S. **Biochem Soc Trans** 1998 Aug;26(3):354–9 (24 ref.)
Families of phosphoinositide-specific phospholipase C: structure and function. Katan M. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):5–17 (98 ref.)

IMMUNOLOGY

Multiple roles for PI 3-kinase in the regulation of PLCgamma activity and Ca2+ mobilization in antigen-stimulated mast cells. Barker SA, et al. **J Leukoc Biol** 1999 Mar;65(3):321–9 (55 ref.)

METABOLISM

Isozymes delta of phosphoinositide-specific phospholipase C. Pawelczyk T. **Acta Biochim Pol** 1999;46(1):91–8 (61 ref.)
The structure of phospholipase C isoforms and the regulation of phosphoinositide hydrolysis. James S. **Biochem Soc Trans** 1998 Aug;26(3):354–9 (24 ref.)
Families of phosphoinositide-specific phospholipase C: structure and function. Katan M. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):5–17 (98 ref.)
Regulation of phospholipase C isozymes: activation of phospholipase C-gamma in the absence of tyrosine-phosphorylation. Sekiya F, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):3–11 (41 ref.)
Determination of phospholipase C- or phospholipase D-catalyzed phosphatidylcholine hydrolysis. Wakelam MJ, et al. **Methods Mol Biol** 1998;105:141–9 (9 ref.)
Bacterial phospholipases and intracellular growth: the two distinct phospholipases C of Listeria monocytogenes. Goldfine H, et al. **Soc Appl Bacteriol Symp Ser** 1998; 27:7S–14S (53 ref.)
[Signal transduction in the cell by phosphoinositide-specific phospholipase C isozymes] Pawelczyk T. **Postepy Hig Med Dosw** 1999;53(2):173–82 (40 ref.) (Eng. Abstr.) **(Pol)**

PHOSPHOLIPASE D

Phospholipase D. Exton JH. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):105–15 (107 ref.)
[Roles of phospholipase D in signal transduction] Nakashima S, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):998–1006 (80 ref.) **(Jpn)**

BIOSYNTHESIS

Expression of phospholipase D isoforms in mammalian cells. Meier KE, et al. **Biochim Biophys Acta** 1999 Jul 30; 1439(2):199–213 (85 ref.)
Phospholipase D development during differentiation of human promyelocytic leukemic HL60 cells. Ohguchi K, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):215–27 (94 ref.)

CHEMISTRY

Phospholipase D structure and regulation. Frohman MA, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):127–40 (70 ref.)

GENETICS

The PLD superfamily: insights into catalysis. Waite M. **Biochim Biophys Acta** 1999 Jul 30;1439(2):187–97 (44 ref.)
Phospholipase D structure and regulation. Frohman MA, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):127–40 (70 ref.)

METABOLISM

Phospholipase D, tumor promoters, proliferation and prostaglandins. Daniel LW, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):265–76 (111 ref.)
Regulation of phospholipase D. Exton JH. **Biochim Biophys Acta** 1999 Jul 30;1439(2):121–33 (149 ref.)
Mammalian phospholipase D structure and regulation. Frohman MA, et al. **Biochim Biophys Acta** 1999 Jul 30; 1439(2):175–86 (83 ref.)
Regulation of phospholipase D by phosphorylation-dependent mechanisms. Houle MG, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):135–49 (143 ref.)
Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Jones D, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):229–44 (131 ref.)
Localization and possible functions of phospholipase D isozymes. Liscovitch M, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):245–63 (160 ref.)
A novel protein kinase target for the lipid second messenger phosphatidic acid. McPhail LC, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):277–90 (208 ref.)
Molecular and biochemical properties and physiological roles of plant phospholipase D. Pappan K, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):151–66 (102 ref.)
Regulation and function of PLDs in yeast. Rudge SA, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):167–74 (56 ref.)
Phospholipase D in cellular senescence. Venable ME, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):291–8 (67 ref.)
Possible role of phospholipase D in cellular differentiation and apoptosis. Nakashima S, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):153–64 (54 ref.)
Phospholipase D as an effector for ADP-ribosylation factor in the regulation of vesicular traffic. Roth MG, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):141–52 (93 ref.)
Measurement of phospholipase D activity. Bollag WB. **Methods Mol Biol** 1998;105:151–60 (11 ref.)
Determination of phospholipase C- or phospholipase D-catalyzed phosphatidylcholine hydrolysis. Wakelam MJ, et al. **Methods Mol Biol** 1998;105:141–9 (9 ref.)
Phospholipase A2 (EC 3.1.1.4) and D (EC 3.1.4.4) signalling in lymphocytes. Wakelam MJ, et al. **Proc Nutr Soc** 1998 Nov;57(4):551–4 (22 ref.)

PHYSIOLOGY

Phospholipase D: a novel major player in signal transduction. Gomez-Cambronero J, et al. **Cell Signal** 1998 Jun; 10(6):387–97 (161 ref.)
[Mechanism of phospholipase D regulation] Nakamura S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1007–12 (35 ref.) **(Jpn)**

PHOSPHOLIPASES

ANALYSIS

Fluorometric phospholipase assays based on polymerized liposome substrates. Cho W, et al. **Methods Mol Biol** 1999; 109:7–17 (14 ref.)

CHEMISTRY

Bacterial phospholipases. Titball RW. **Soc Appl Bacteriol Symp Ser** 1998;27:127S–137S (44 ref.)

DEFICIENCY

[Platelet phospholipase deficiency] Fuse I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):377–9 (6 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Purification of lipases and phospholipases by heparin-sepharose chromatography. Farooqui AA, et al. **Methods Mol Biol** 1999;109:133–43 (40 ref.)

METABOLISM

Isotopic efflux studies as indices of phospholipase activation. Vadakekalam J, et al. **Methods Mol Biol** 1998;105:175–85 (12 ref.)

PHYSIOLOGY

Role of phospholipases during sperm acrosomal exocytosis. Roldan ER. **Front Biosci** 1998 Nov 1;3:D1109–19 (122 ref.)
Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis. Lennartz MR. **Int J Biochem Cell Biol** 1999 Mar-Apr; 31(3–4):415–30 (108 ref.)
Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease. Kanfer JN, et al. **Neurosci Lett** 1998 Nov 27;257(2):93–6 (27 ref.)

PHOSPHOLIPASES A

Phospholipase A2: its usefulness in laboratory diagnostics. Kaiser E. **Crit Rev Clin Lab Sci** 1999 Apr;36(2):65–163 (700 ref.)
[PAF acetylhydrolase] Arai H.

PHOSPHOLIPASES A

Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1075–83 (52 ref.) **(Jpn)**

[Phospholipase A2] Kudo I, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1013–24 (59 ref.) **(Jpn)**

ANALYSIS

Phospholipase A2 and phosphatidylinositol-specific phospholipase C assays by HPLC and TLC with fluorescent substrate. Hendrickson HS.
Methods Mol Biol 1999;109:1–6 (9 ref.)

Lecithin–cholesterol acyltransferase. Assay of cholesterol esterification and phospholipase A2 activities. Parks JS, et al. **Methods Mol Biol** 1999;109:123–31 (26 ref.)

ANTAGONISTS & INHIBITORS

Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Farooqui AA, et al.
Brain Res Bull 1999 Jun;49(3):139–53 (142 ref.)

Discovery of bioavailable inhibitors of secretory phospholipase A2. Blanchard SG, et al.
Pharm Biotechnol 1998;11:445–63 (16 ref.)

BIOSYNTHESIS

Regulation and inhibition of phospholipase A2. Balsinde J, et al. **Annu Rev Pharmacol Toxicol** 1999;39:175–89 (84 ref.)

BLOOD

Phospholipases A2--what are they and what is their clinical significance in acute pancreatitis? Grönroos JM, et al.
Ann Chir Gynaecol 1998;87(3):196–9 (27 ref.)

Human plasma platelet-activating factor acetylhydrolase. Stafforini DM, et al. **Methods Mol Biol** 1999;109:49–58 (25 ref.)

CHEMISTRY

Binding of bee venom and human group IIa phospholipases A2 to membranes: a minor role for electrostatics. Lin Y, et al. **Biochem Soc Trans** 1998 Aug;26(3):341–5 (30 ref.)

New developments in phospholipase A2. Chaminade B, et al. **Lipids** 1999;34 Suppl:S49–55 (86 ref.)

Efficient immobilization of phospholipase A2. Cho W, et al. **Methods Mol Biol** 1999;109:303–7 (7 ref.)

Lysine 49 phospholipase A2 proteins. Ownby CL, et al. **Toxicon** 1999 Mar;37(3):411–45 (120 ref.)

[Structure and function of phosphatidylserine-specific phospholipase A1: PS-PLA1] Aoki J.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1038–42 (26 ref.) **(Jpn)**

CLASSIFICATION

Purification and assay of mammalian group I and group IIa secretory phospholipase A2. Cho W, et al.
Methods Mol Biol 1999;109:31–8 (16 ref.)

DRUG EFFECTS

Effect of ethanol on platelet function. Rubin R.
Alcohol Clin Exp Res 1999 Jun;23(6):1114–8 (58 ref.)

GENETICS

The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. Bonventre JV.
J Am Soc Nephrol 1999 Feb;10(2):404–12 (76 ref.)

What knockout mice can tell us about parturition. Kimura T, et al. **Rev Reprod** 1999 May;4(2):73–80 (71 ref.)

ISOLATION & PURIFICATION

Determination of plasmalogen-selective phospholipase A2 activity by radiochemical and fluorometric assay procedures. Farooqui AA, et al. **Methods Mol Biol** 1999; 109:39–47 (15 ref.)

METABOLISM

Regulation of cytosolic phospholipase A2 by phosphorylation. Börsch-Haubold AG.
Biochem Soc Trans 1998 Aug;26(3):350–4 (24 ref.)

Activation of calcium-independent phospholipase A2 by depletion of internal calcium stores. Gross RW.
Biochem Soc Trans 1998 Aug;26(3):345–9 (17 ref.)

Binding of bee venom and human group IIa phospholipases A2 to membranes: a minor role for electrostatics. Lin Y, et al. **Biochem Soc Trans** 1998 Aug;26(3):341–5 (30 ref.)

Anionic phospholipids and the regulation of cell functions. Wilton DC. **Biochem Soc Trans** 1998 Aug;26(3):378–83 (38 ref.)

Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. Gijón MA, et al.
J Leukoc Biol 1999 Mar;65(3):330–6 (48 ref.)

New developments in phospholipase A2. Chaminade B, et al. **Lipids** 1999;34 Suppl:S49–55 (86 ref.)

Monitoring of phospholipase A2 activation in cultured cells using tritiated arachidonic acid. Briand SI, et al.
Methods Mol Biol 1998;105:161–6 (7 ref.)

Phospholipase A2 (EC 3.1.1.4) and D (EC 3.1.4.4) signalling in lymphocytes. Wakelam MJ, et al. **Proc Nutr Soc** 1998 Nov;57(4):551–4 (22 ref.)

PHYSIOLOGY

Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms. Puri RN.
Int J Biochem Cell Biol 1998 Oct;30(10):1107–22 (152 ref.)

[Structure and function of phosphatidylserine-specific phospholipase A1: PS-PLA1] Aoki J.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1038–42 (26 ref.) **(Jpn)**

[Functional coupling between phospholipase A2 and cyclooxygenase] Murakami M, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1146–56 (38 ref.) **(Jpn)**

PHOSPHOLIPID ETHERS

PHARMACOLOGY

Cytotoxic etherphospholipid analogues. Berkovic D.
Gen Pharmacol 1998 Oct;31(4):511–7 (105 ref.)

PHOSPHOLIPIDS

see related
ANTIBODIES, ANTIPHOSPHOLIPID
ANTIPHOSPHOLIPID SYNDROME

[Bio-active lipids] Inoue K. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1067 (4 ref.) **(Jpn)**

BIOSYNTHESIS

Brain choline has a typical precursor profile. Löffelholz K.
J Physiol Paris 1998 Jun-Aug;92(3–4):235–9 (42 ref.)

BLOOD

Transmembrane phospholipid distribution in blood cells: control mechanisms and pathophysiological significance. Bevers EM, et al. **Biol Chem** 1998 Aug-Sep; 379(8–9):973–86 (173 ref.)

CHEMISTRY

The effects of phospholipid structure on the function of a calcium pump. Lee AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):359–65 (28 ref.)

The use of FT-IR for quantitative studies of the apparent pKa of lipid carboxyl groups and the dehydration degree of the phosphate group of phospholipids.
Gómez-Fernández JC, et al. **Chem Phys Lipids** 1998 Nov; 96(1–2):41–52 (35 ref.)

Biologically active oxidized phospholipids. McIntyre TM, et al. **J Biol Chem** 1999 Sep 3;274(36):25189–92 (86 ref.)

Structure and origin of ordered lipid domains in biological membranes. Brown DA, et al. **J Membr Biol** 1998 Jul 15; 164(2):103–14 (105 ref.)

Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Ferezou J, et al. **Nutrition** 1999 Jan;15(1):44–50 (46 ref.)

IMMUNOLOGY

Genetics of apolipoprotein H (beta2-glycoprotein I) and anionic phospholipid binding. Kamboh MI, et al. **Lupus** 1998;7 Suppl 2:S10–3 (24 ref.)

Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Rauch J.
Lupus 1998;7 Suppl 2:S29–31 (20 ref.)

Many faces of lupus anticoagulants. Triplett DA. **Lupus** 1998; 7 Suppl 2:S18–22 (30 ref.)

[Antiphospholipid-protein antibodies. Effects on the endothelium-platelet interaction] Forastiero RR, et al.
Sangre (Barc) 1999 Jun;44(3):223–30 (85 ref.) **(Spa)**

ISOLATION & PURIFICATION

HPLC analytical methods for the separation of molecular species of fatty acids in diacylglycerol and cellular phospholipids. Clejan S. **Methods Mol Biol** 1998;105:255–74 (14 ref.)

Separation and quantitation of phospholipid classes by HPLC. Patton GM, et al. **Methods Mol Biol** 1998; 110:193–215 (8 ref.)

METABOLISM

Influence of phospholipids and sequential kinase activities on tau in vitro. Shea TB, et al. **Adv Exp Med Biol** 1998; 446:181–201 (84 ref.)

How cytidylyltransferase uses an amphipathic helix to sense membrane phospholipid composition. Corneli RB.
Biochem Soc Trans 1998 Aug;26(3):539–44 (38 ref.)

The effects of phospholipid structure on the function of a calcium pump. Lee AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):359–65 (28 ref.)

Anionic phospholipids and the regulation of cell functions. Wilton DC. **Biochem Soc Trans** 1998 Aug;26(3):378–83 (38 ref.)

Phospholipid-binding protein domains. Bottomley MJ, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):165–83 (145 ref.)

Phospholipid signalling in the nucleus. Een DAG uit het leven van de inositide signalering in de nucleus. D'Santos CS, et al. **Biochim Biophys Acta** 1998 Dec 8; 1436(1–2):201–32 (338 ref.)

Annexin V and phospholipid metabolism. Russo-Marie F. **Clin Chem Lab Med** 1999 Mar;37(3):287–91 (36 ref.)

Oxidized phospholipids and isoprostanes in atherosclerosis. Witztum JL, et al. **Curr Opin Lipidol** 1998 Oct;9(5):441–8 (62 ref.)

Glutathione S-transferases and prevention of cellular free radical damage. Ketterer B. **Free Radic Res** 1998 Jun; 28(6):647–58 (70 ref.)

Enigmatic relationship of Pleckstrin homology domain with phospholipid breakdown mediated signal transduction. Tyagi MG, et al. **Indian J Exp Biol** 1999 Jan;37(1):1–5 (34 ref.)

Biologically active oxidized phospholipids. McIntyre TM, et al. **J Biol Chem** 1999 Sep 3;274(36):25189–92 (86 ref.)

Regulatory mechanisms of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling. Bevers EM, et al. **Lupus** 1998; 7 Suppl 2:S126–31 (77 ref.)

Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. Bell JD, et al.
NMR Biomed 1998 Nov;11(7):354–9 (41 ref.)

NMR studies of phospholipid metabolism in hepatic lymphoma. Dixon RM. **NMR Biomed** 1998 Nov; 11(7):370–9 (49 ref.)

Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Ferezou J, et al. **Nutrition** 1999 Jan;15(1):44–50 (46 ref.)

Genetic regulation of phospholipid metabolism: yeast as a model eukaryote. Henry SA, et al.
Prog Nucleic Acid Res Mol Biol 1998;61:133–79 (276 ref.)

Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Horrobin DF, et al.
Prostaglandins Leukot Essent Fatty Acids 1999 Apr; 60(4):217–34 (252 ref.)

New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Horrobin DF, et al.
Prostaglandins Leukot Essent Fatty Acids 1999 Mar; 60(3):141–67 (330 ref.)

1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2. Boyan BD, et al. **Steroids** 1999 Jan–Feb;64(1–2):129–36 (63 ref.)

PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Maehama T, et al. **Trends Cell Biol** 1999 Apr; 9(4):125–8 (32 ref.)

[Membrane phospholipid metabolism] Banno Y, et al.
Tanpakushitsu Kakusan Koso 1998 Sep;43(12 Suppl):1800–5 (34 ref.) **(Jpn)**

[Role of membrane phospholipid dynamics in cell division] Emoto K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1173–80 (26 ref.) **(Jpn)**

PHYSIOLOGY

Regulation of mitogenesis by water-soluble phospholipid intermediates. Kiss Z. **Cell Signal** 1999 Mar;11(3):149–57 (115 ref.)

[Role of membrane phospholipid dynamics in cytoskeletal organization] Emoto K, et al.
Tanpakushitsu Kakusan Koso 1998 Oct;43(13):1973–80 (26 ref.) **(Jpn)**

PHOSPHOMONOESTERASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHONOMYCIN see **FOSFOMYCIN**

PHOSPHOPEPTIDES

ANALYSIS

2-D phosphopeptide mapping. Nagahara H, et al.
Methods Mol Biol 1999;112:271–9 (8 ref.)

CHEMICAL SYNTHESIS

[Chemical synthesis of phosphopeptides] Otaka A, et al.
Tanpakushitsu Kakusan Koso 1999 Mar;44(4 Suppl):606–13 (21 ref.) **(Jpn)**

PHOSPHOPROTEIN PHOSPHATASE

ANALYSIS

[Assay of protein phosphatase activities with phosphopeptide-magnetic bead conjugates] Kameshita I, et al. **Seikagaku** 1998 Nov;70(11):1360–3 (6 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Molecular mechanisms underlying inhibition of protein phosphatases by marine toxins. Dawson JF, et al.
Front Biosci 1999 Oct 1;4:D646–58 (0 ref.)

Contractility and inhibition of protein phosphatases by cantharidin. Knapp J, et al. **Gen Pharmacol** 1998 Nov; 31(5):729–33 (50 ref.)

CHEMISTRY

Turn up the HEAT. Kobe B, et al. **Structure Fold Des** 1999 May;7(5):R91–7 (44 ref.)
Regulation of protein kinase cascades by protein phosphatase 2A. Millward TA, et al. **Trends Biochem Sci** 1999 May; 24(5):186–91 (89 ref.)

GENETICS

The serine, threonine, and/or tyrosine-specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait. Shi L, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):229–53 (98 ref.)

METABOLISM

From pharmacomechanical coupling to G-proteins and myosin phosphatase [published erratum appears in Acta Physiol Scand 1999 Apr;165(4):423] Somlyo AP, et al. **Acta Physiol Scand** 1998 Dec;164(4):437–48 (74 ref.)
RdgC/PP5-related phosphatases: novel components in signal transduction. Andreeva AV, et al. **Cell Signal** 1999 Aug; 11(8):555–62 (64 ref.)
Brain protein serine/threonine phosphatases. Price NE, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):336–42 (68 ref.)
Phosphorylase phosphatase: new horizons for an old enzyme. Lee EY, et al. **Front Biosci** 1999 Mar 15;4:D270–85 (142 ref.)
Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. Inagami T, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S57–61 (23 ref.)
Organization of kinases, phosphatases, and receptor signaling complexes. Schillace RV, et al. **J Clin Invest** 1999 Mar; 103(6):761–5 (27 ref.)
Proteasome-dependent degradation of human CDC25B phosphatase. Cans C, et al. **Mol Biol Rep** 1999 Apr; 26(1–2):53–7 (36 ref.)
Interactions of protein phosphatase type 1, with a focus on myosin phosphatase. Hartshorne DJ, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):79–84 (36 ref.)
Regulation of neuronal plasticity in the central nervous system by phosphorylation and dephosphorylation. Tokuda M, et al. **Mol Neurobiol** 1998 Winter;17(1–3):137–56 (131 ref.)
Protein phosphatase 2C (PP2C) function in higher plants. Rodriguez PL. **Plant Mol Biol** 1998 Dec;38(6):919–27 (68 ref.)
Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Klann E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):359–76 (94 ref.)
Regulation of protein kinase cascades by protein phosphatase 2A. Millward TA, et al. **Trends Biochem Sci** 1999 May; 24(5):186–91 (89 ref.)
[CD45, antigen with phosphatase activity, structure; function and role in T lymphocyte activation] Bohr I, et al. **Postepy Biochem** 1998;44(3):208–15 (79 ref.) **(Pol)**
[Formation and regulation of myosin light chain kinase and phosphatase complex in smooth muscle: the outlook] Sobieszek A. **Tsitologiia** 1998;40(6):568–78 (35 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Myosin phosphatase: subunits and interactions. Hartshorne DJ. **Acta Physiol Scand** 1998 Dec;164(4):483–93 (62 ref.)
Protein phosphatase 2A: who shall regulate the regulator? Goldberg Y. **Biochem Pharmacol** 1999 Feb 15;57(4):321–8 (78 ref.)
RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198–200 (12 ref.)
Protein dephosphorylation and the intracellular control of the cell number. Berndt N. **Front Biosci** 1999 Jan 1; 4:D22–42 (250 ref.)
Life among the primitives: protein O-phosphatases in prokaryotes. Kennelly PJ, et al. **Front Biosci** 1999 Mar 15; 4:D372–85 (138 ref.)
Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Rubin E, et al. **Front Biosci** 1998 Dec 1;3:D1209–19 (90 ref.)
Role of PP2A in intracellular signal transduction pathways. Schönthal AH. **Front Biosci** 1998 Dec 15;3:D1262–73 (145 ref.)
Airway nerves and protein phosphatases. Harrison S, et al. **Gen Pharmacol** 1999 Mar;32(3):287–98 (186 ref.)
Protein phosphatase-1 and insulin action. Ragolia L, et al. **Mol Cell Biochem** 1998 May;182(1–2):49–58 (72 ref.)
Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Greengard P, et al. **Neuron** 1999 Jul;23(3):435–47 (89 ref.)

PHOSPHOPROTEIN PHOSPHOHYDROLASE see **PHOSPHOPROTEIN PHOSPHATASE**

PHOSPHOPROTEIN PP53 see **PROTEIN P53**

PHOSPHOPROTEINS

CHEMISTRY

Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein. Turunen O, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1–2):1–16 (106 ref.)
Epidermal growth factor pathway substrate 15, Eps15. Salcini AE, et al. **Int J Biochem Cell Biol** 1999 Aug; 31(8):805–9 (20 ref.)
Structure and functions of nucleolin. Ginisty H, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):761–72 (179 ref.)

GENETICS

Syndromes associated with insulin resistance and acanthosis nigricans. Taylor SI, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):419–39 (76 ref.)
Treacher Collins syndrome: from linkage to prenatal testing. Dixon MJ. **J Laryngol Otol** 1998 Aug;112(8):705–9 (35 ref.)
Dishevelled: at the crossroads of divergent intracellular signaling pathways. Boutros M, et al. **Mech Dev** 1999 May; 83(1–2):27–37 (67 ref.)
Steroidogenic acute regulatory protein. Stocco DM. **Vitam Horm** 1999;55:399–441 (186 ref.)
[Mutations in the genes of the HNF-family cause maturity-onset diabetes of the young (MODY)] Takeda J. **Nippon Rinsho** 1998 Sep;56(9):2419–26 (24 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Lymphocyte signaling: adapting new adaptors. Rudd CE. **Curr Biol** 1998 Nov 5;8(22):R805–8 (18 ref.)
Regulation of cortical structure by the ezrin-radixin-moesin protein family. Bretscher A. **Curr Opin Cell Biol** 1999 Feb; 11(1):109–16 (56 ref.)
Determinants of SR protein specificity. Tacke R, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):358–62 (42 ref.)
The adaptor protein SLP-65/BLNK controls the calcium response in activated B cells. Wollscheid B, et al. **Curr Top Microbiol Immunol** 1999;246:283–8; discussion 288–9 (25 ref.)
Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic beta-cells. Jones PM, et al. **Endocr Rev** 1998 Aug;19(4):429–61 (361 ref.)
Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. Unger JW, et al. **Histol Histopathol** 1998 Oct;13(4):1215–24 (74 ref.)
Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse. Nagano T, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):869–75 (74 ref.)
Unveiling the mechanism of action and regulation of the steroidogenic acute regulatory protein. Kallen CB, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):39–45 (51 ref.)
NO/cGMP/VASP pathway is involved in integrin activation. Fässler R. **Postepy Hig Med Dosw** 1999; 53(2):223 (0 ref.)
Functions of SR and Tra2 proteins in pre-mRNA splicing regulation. Tacke R, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):59–63 (29 ref.)
Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Londos C, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):51–8 (41 ref.)

PHARMACOLOGY

Modulation of intracellular Ca2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Valdivia HH. **Trends Pharmacol Sci** 1998 Dec; 19(12):479–82 (27 ref.)

PHYSIOLOGY

Forkhead transcription factor HFH-4 and respiratory epithelial cell differentiation. Whitsett JA, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):153–4 (17 ref.)
The role of interferon regulatory factors in the interferon system and cell growth control. Harada H, et al. **Biochimie** 1998 Aug-Sep;80(8–9):641–50 (72 ref.)
Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Pitha PM, et al. **Biochimie** 1998 Aug-Sep;80(8–9):651–8 (50 ref.)
The insulin receptor substrate 1 associates with phosphotyrosine phosphatase SHPTP2 in liver and muscle of rats. Lima MH, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1409–13 (17 ref.)
Nucleolin: a multifunctional major nucleolar phosphoprotein. Tuteja R, et al. **Crit Rev Biochem Mol Biol** 1998; 33(6):407–36 (164 ref.)
Endocytosis: an assembly protein for clathrin cages. McMahon HT. **Curr Biol** 1999 May 6;9(9):R332–5 (25 ref.)
Endocytosis: EH domains lend a hand. Mayer BJ. **Curr Biol** 1999 Jan 28;9(2):R70–3 (29 ref.)
Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1. Taniguchi T, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):43–8 (48 ref.)
An update on the mechanism of action of the Steroidogenic Acute Regulatory (StAR) protein. Stocco DM. **Exp Clin Endocrinol Diabetes** 1999;107(4):229–35 (53 ref.)
New perspectives on retinoblastoma family functions in differentiation. Yee AS, et al. **Front Biosci** 1998 Jun 8; 3:D532–47 (100 ref.)
The role of the steroidogenic acute regulatory (StAR) protein in female reproductive tissues. Orly J, et al. **Horm Metab Res** 1999 Jul;31(7):389–98 (123 ref.)
Thymocyte selection in Vav and IRF-1 gene-deficient mice. Penninger JM, et al. **Immunol Rev** 1998 Oct;165:149–66 (213 ref.)
Paxillin. Turner CE. **Int J Biochem Cell Biol** 1998 Sep; 30(9):955–9 (18 ref.)
Osteopontin expression and function: role in bone remodeling. Denhardt DT, et al. **J Cell Biochem Suppl** 1998;30–31:92–102 (65 ref.)
Structure and functions of nucleolin. Ginisty H, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):761–72 (179 ref.)
Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. Miller WL, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1–6):131–41 (70 ref.)
Dishevelled: at the crossroads of divergent intracellular signaling pathways. Boutros M, et al. **Mech Dev** 1999 May; 83(1–2):27–37 (67 ref.)
Role of binding proteins to IRS-1 in insulin signalling. Ogawa W, et al. **Mol Cell Biochem** 1998 May;182(1–2):13–22 (108 ref.)
The IRS-signalling system: a network of docking proteins that mediate insulin action. White MF. **Mol Cell Biochem** 1998 May;182(1–2):3–11 (81 ref.)
Transcriptional regulation of the StAR gene. Reinhart AJ, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):161–9 (86 ref.)
The complex role of osteopontin in renal disease [editorial] Wüthrich RP. **Nephrol Dial Transplant** 1998 Oct; 13(10):2448–50 (45 ref.)
Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Graña X, et al. **Oncogene** 1998 Dec 24;17(25):3365–83 (193 ref.)
The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. White MF. **Recent Prog Horm Res** 1998;53:119–38 (125 ref.)
Protein and lipid sorting between the endoplasmic reticulum and the Golgi complex. Nickel W, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):493–501 (76 ref.)
ERM proteins in cell adhesion and membrane dynamics. Mangeat P, et al. **Trends Cell Biol** 1999 May;9(5):187–92 (59 ref.)
[Mechanism of COPI and COPII vesicle formation: coat assembly direct formation of coated vesicles] Matsuoka K. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):676–82 (29 ref.) **(Jpn)**
[A signal transducer involved in GalCer expression] Ogura K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2516–21 (21 ref.) **(Jpn)**

PHOSPHOPYRUVATE HYDRATASE

BIOSYNTHESIS

[Neuron specific enolase producing multiple myeloma] Ogura M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):440–1 (6 ref.) **(Jpn)**

CHEMISTRY

Mechanistically diverse enzyme superfamilies: the importance of chemistry in the evolution of catalysis. Gerlt JA, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):607–12 (39 ref.)

METABOLISM

Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation. Jørgensen LG. **Dan Med Bull** 1999 Feb;46(1):1–12 (200 ref.)

PHOSPHORESCENCE see **LUMINESCENCE**

PHOSPHORIBOSYL PYROPHOSPHATE

METABOLISM

Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleotide synthesis: studies with ribose, adenine, inosine, and orotic acid in rats. Zimmer HG. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:179–87 (41 ref.)

PHOSPHORIBOSYL PYROPHOSPHATE AMIDOTRANSFERASE see **AMIDOPHOSPHORIBOSYLTRANSFERASE**

PHOSPHORIC ACID ESTERS

CHEMISTRY

The use of FT-IR for quantitative studies of the apparent pKa of lipid carboxyl groups and the dehydration degree of the phosphate group of phospholipids. Gómez-Fernández JC, et al. **Chem Phys Lipids** 1998 Nov; 96(1–2):41–52 (35 ref.)

METABOLISM

Phosphoinositide binding domains: embracing 3-phosphate. Fruman DA, et al. **Cell** 1999 Jun 25;97(7):817–20 (19 ref.)
Mechanistic alternatives in phosphate monoester hydrolysis: what conclusions can be drawn from available experimental data? Aqvist J, et al. **Chem Biol** 1999 Mar;6(3):R71–80 (45

PHOSPHORIC ACID ESTERS

ref.)
Regulation of gene expression by multiple forms of TFIID and other novel TAFII-containing complexes. Bell B, et al. **Exp Cell Res** 1999 Jan 10;246(1):11-9 (93 ref.)
[Calcitonin and stanniocalcin. Particular aspects of the endocrine regulation of phospho-calcium metabolism in mammals and fish] Barlet JP, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):281-90 (130 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Costa LG, et al. **Chem Biol Interact** 1999 May 14;119-120:429-38 (48 ref.)

PHARMACOLOGY

Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity. Taylor P, et al. **Chem Biol Interact** 1999 May 14;119-120:3-15 (17 ref.)

TOXICITY

Promotion of organophosphate induced delayed polyneuropathy by certain esterase inhibitors. Lotti M, et al. **Chem Biol Interact** 1999 May 14;119-120:519-24 (26 ref.)
Tris(2,3-dibromopropyl) phosphate. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:905-21 (53 ref.)

PHOSPHORIC DIESTER HYDROLASE INHIBITORS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHORIC DIESTER HYDROLASES

GENETICS

[The molecular basis for the absence of N-glycolylneuraminic acid in humans] Irie A, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2404-9 (26 ref.) **(Jpn)**

METABOLISM

Chemotherapeutic potential of phosphodiesterase inhibitors. Perry MJ, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):472-81 (70 ref.)
Phosphoinositidase C activation assay. I. Cell labeling, stimulation, and recovery of cellular [3H]phosphoinositides and [3H]phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:1-9 (7 ref.)
Phosphoinositidase C activation assay. II. Simple analysis of recovered cellular phosphoinositides and phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:11-23 (23 ref.)
Phosphoinositidase C activation assay. III. HPLC analysis of cellular phosphoinositides and phosphoinositols. Bird IM. **Methods Mol Biol** 1998;105:25-45 (17 ref.)
[Phosphodiesterase 5--the enzyme inhibited by sildenafil (Viagra)] Sandberg M, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):945-9 (31 ref.) (Eng. Abstr.) **(Nor)**

PHOSPHORIC MONOESTER HYDROLASES

ANTAGONISTS & INHIBITORS

Inhibitors of inositol monophosphatase. Fauroux CM, et al. **J Enzyme Inhib** 1999;14(2):97-108 (41 ref.)

CHEMISTRY

Solution structure and mechanism of the MutT pyrophosphohydrolase. Mildvan AS, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:183-207 (55 ref.)

GENETICS

The MutT motif family of nucleotide phosphohydrolases in man and human pathogens (review). McLennan AG. **Int J Mol Med** 1999 Jul;4(1):79-89 (135 ref.)
Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related? Wang NM, et al. **Int J Mol Med** 1999 May;3(5):491-5 (54 ref.)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Cantley LC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4240-5 (76 ref.)

METABOLISM

Solution structure and mechanism of the MutT pyrophosphohydrolase. Mildvan AS, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:183-207 (55 ref.)
Preparation and properties of 6-substituted cyclohexane-1,2,4-triol derivatives: mechanistic probes for the inositol monophosphatase reaction. Schulz J, et al. **Biochem Soc Trans** 1998 Aug;26(3):315-22 (43 ref.)
If phosphatases go up, memory goes down. Riedel G. **Cell Mol Life Sci** 1999 Apr;55(4):549-53 (34 ref.)
Mechanistic alternatives in phosphate monoester hydrolysis: what conclusions can be drawn from available experimental data? Aqvist J, et al. **Chem Biol** 1999 Mar;6(3):R71-80 (45 ref.)
Serine/threonine protein kinases and phosphatases in filamentious fungi. Dickman MB, et al. **Fungal Genet Biol** 1999 Mar;26(2):99-117 (65 ref.)
Negative signaling in health and disease. Coggeshall KM. **Immunol Res** 1999;19(1):47-64 (165 ref.)
The role of phosphatases in inositol signaling reactions. Majerus PW, et al. **J Biol Chem** 1999 Apr 16; 274(16):10669-72 (57 ref.)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Cantley LC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4240-5 (76 ref.)
The role of SHIP in growth factor induced signalling. Huber M, et al. **Prog Biophys Mol Biol** 1999;71(3-4):423-34 (72 ref.)
Kinase-phosphatase competition regulates Bacillus subtilis development. Perego M. **Trends Microbiol** 1998 Sep; 6(9):366-70 (43 ref.)
[Reversible phosphorylation of catalytic subunit of monovalent cation-transporting ATPases by protein kinases and phosphatases] Kaya S. **Seikagaku** 1999 May; 71(5):341-5 (15 ref.) **(Jpn)**

PHYSIOLOGY

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Blakely RD, et al. **Biol Psychiatry** 1998 Aug 1;44(3):169-78 (65 ref.)
The role of the SRC homology 2-containing inositol 5'-phosphatase in Fc epsilon R1-induced signaling. Huber M, et al. **Curr Top Microbiol Immunol** 1999;244:29-41 (39 ref.)
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Besson A, et al. **Eur J Biochem** 1999 Aug; 263(3):605-11 (61 ref.)
Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Somlyo AP, et al. **Rev Physiol Biochem Pharmacol** 1999;134:201-34 (169 ref.)
PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Maehama T, et al. **Trends Cell Biol** 1999 Apr; 9(4):125-8 (32 ref.)
[Regulation of B cell receptor signaling through tyrosine kinases and phosphatases] Takata M, et al. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):655-67 (43 ref.) **(Jpn)**

PHOSPHORUS

see related
ORGANOPHOSPHORUS COMPOUNDS
PHOSPHORUS RADIOISOTOPES

Optimal nutrition: calcium, magnesium and phosphorus. Cashman KD, et al. **Proc Nutr Soc** 1999 May;58(2):477-87 (96 ref.)

CHEMISTRY

Experimental spectroscopy. General methodology and applications for 31P. Horn M. **MAGMA** 1998 Sep; 6(2-3):100-2 (7 ref.)

METABOLISM

The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Slatopolsky E, et al. **Am J Med Sci** 1999 Jun;317(6):370-6 (40 ref.)
Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. Felsenfeld AJ, et al. **J Am Soc Nephrol** 1999 Apr;10(4):878-90 (57 ref.)
Polyphosphate-accumulating bacteria and enhanced biological phosphorus removal. Kortstee GJ, et al. **Prog Mol Subcell Biol** 1999;23:275-97 (69 ref.)

PHARMACOKINETICS

Reducing phosphorus runoff and improving poultry production with alum. Moore PA Jr, et al. **Poult Sci** 1999 May;78(5):692-8 (26 ref.)

PHOSPHORUS COMPOUNDS

see related
ORGANOPHOSPHORUS COMPOUNDS

PHOSPHORUS-OXYGEN LYASES

METABOLISM

A unique reaction in a common pathway: mechanism and function of chorismate synthase in the shikimate pathway. Macheroux P, et al. **Planta** 1999 Jan;207(3):325-34 (70 ref.)

PHOSPHORUS RADIOISOTOPES

THERAPEUTIC USE

Radioactive stents. Fischell TA. **Semin Interv Cardiol** 1998 Jun;3(2):51-6 (18 ref.)

PHOSPHORYLASE

GENETICS

Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase. Shimada S, et al. **J Exp Clin Cancer Res** 1999 Mar;18(1):111-8 (38 ref.)

METABOLISM

Bacterial alpha-glucan phosphorylases. Schinzel R, et al. **FEMS Microbiol Lett** 1999 Feb 15;171(2):73-9 (34 ref.)

PHOSPHORYLASE KINASE

CHEMISTRY

Phosphorylase kinase: the complexity of its regulation is reflected in the complexity of its structure. Brushia RJ, et al. **Front Biosci** 1999 Sep 15;4:D618-41 (124 ref.)

METABOLISM

Phosphorylase kinase: the complexity of its regulation is reflected in the complexity of its structure. Brushia RJ, et al. **Front Biosci** 1999 Sep 15;4:D618-41 (124 ref.)

PHOSPHORYLATION

RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198-200 (12 ref.)
Protein dephosphorylation and the intracellular control of the cell number. Berndt N. **Front Biosci** 1999 Jan 1; 4:D22-42 (250 ref.)

PHOSPHORYLCHOLINE

Biomimicry 1: PC. Cumberland DC, et al. **Semin Interv Cardiol** 1998 Sep-Dec;3(3-4):149-50 (11 ref.)

PHOSPHORYLCHOLINE, ACETYL GLYCERYL ETHER see **PLATELET ACTIVATING FACTOR**

PHOSPHORYLCHOLINE CHLORIDE see **PHOSPHORYLCHOLINE**

PHOSPHOTRANSFERASES

METABOLISM

Pathways for phosphoinositide synthesis. Tolias KF, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):69-77 (60 ref.)
Phosphoinositide kinases and the synthesis of polyphosphoinositides in higher plant cells. Drøbak BK, et al. **Int Rev Cytol** 1999;189:95-130 (127 ref.)
Signalling pathways in two-component phosphorelay systems. Perraud AL, et al. **Trends Microbiol** 1999 Mar; 7(3):115-20 (38 ref.)

PHYSIOLOGY

Polyphosphate glucokinase. Phillips NF, et al. **Prog Mol Subcell Biol** 1999;23:101-25 (72 ref.)
Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Somlyo AP, et al. **Rev Physiol Biochem Pharmacol** 1999;134:201-34 (169 ref.)
[Phosphoenolpyruvate: carbohydrate phosphotransferase system and its role in physiology of gram-negative bacteria] Gershanovich VN. **Mol Gen Mikrobiol Virusol** 1998; (3):8-15 (84 ref.) **(Rus)**

PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR)

[Phosphatidylinositol 5-kinases] Shibasaki Y, et al. **Seikagaku** 1999 Mar;71(3):193-7 (15 ref.) **(Jpn)**
[Phosphatidylinositol kinase: functional roles for PI4-kinase and PIP kinase in signal transduction] Itoh T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):949-60 (80 ref.) **(Jpn)**

ANALYSIS

Sphingosine kinase. Assay and product analysis. Olivera A, et al. **Methods Mol Biol** 1998;105:233-42 (26 ref.)
Detection of phosphatidylinositol-4-phosphate 5-kinase activity using thin-layer chromatography. Parker GJ, et al. **Methods Mol Biol** 1998;105:127-39 (35 ref.)

CHEMISTRY

Phosphatidylinositol phosphate kinase: a link between protein kinase and glutathione synthase folds. Grishin NV. **J Mol Biol** 1999 Aug 13;291(2):239-47 (31 ref.)

GENETICS

The yeast connection to Friedreich ataxia. Knight SA, et

al. **Am J Hum Genet** 1999 Feb;64(2):365–71 (32 ref.)

METABOLISM

PIPkins1, their substrates and their products: new functions for old enzymes. Hinchliffe KA, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):87–104 (134 ref.)

PHYSIOLOGY

Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Dennis PB, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):49–54 (53 ref.)

Aminoglycoside resistance mediated by the bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase. Culebras E, et al. **Front Biosci** 1999 Jan 1;4:D1–8 (90 ref.)

PHOSPHOTRANSFERASES, ATP see **PHOSPHOTRANSFERASES**

PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR)

METABOLISM

Definitive enzymatic assays in polyphosphate analysis. Ault-Riché D, et al. **Prog Mol Subcell Biol** 1999;23:241–52 (25 ref.)

PHOSPHOTRIOSE ISOMERASE see **TRIOSE-PHOSPHATE ISOMERASE**

PHOSPHOTYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

PHOTIC STIMULATION

Photoentrainment in mammals: a role for cryptochrome? Lucas RJ, et al. **J Biol Rhythms** 1999 Feb;14(1):4–10 (45 ref.)

The picture exchange communication system. Bondy AS, et al. **Semin Speech Lang** 1998;19(4):373–88; quiz 389; 424 (42 ref.)

ADVERSE EFFECTS

[Generalized or focal photosensitive epilepsies] Parain D. **Rev Neurol (Paris)** 1998 Nov;154(11):757–61 (22 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Photic stimulation: standardization of screening methods. Kasteleijn-Nolst Trenité DG, et al. **Epilepsia** 1999;40 Suppl 4:75–9 (17 ref.)

PHOTOAGING OF SKIN see **SKIN AGING**

PHOTOALLERGY see **DERMATITIS, PHOTOALLERGIC**

PHOTOBIOLOGY

see related
LIGHT
PHOTOCHEMISTRY
PHOTOSYNTHESIS

Biochemical dissection of photorespiration. Douce R, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):214–22 (58 ref.)

Nf-kappa B: an important transcription factor in photobiology. Legrand-Poels S, et al. **J Photochem Photobiol B** 1998 Aug 21;45(1):1–8 (80 ref.)

Urocanic acid photochemistry and photobiology. Mohammad T, et al. **Photochem Photobiol** 1999 Feb; 69(2):115–35 (182 ref.)

PHOTOCHEMICAL REACTION CENTER, BACTERIAL see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

PHOTOCHEMICAL REACTION CENTER, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOCHEMISTRY

Singlet molecular oxygen in photobiochemical systems: IR phosphorescence studies. Krasnovsky AA Jr. **Membr Cell Biol** 1998;12(5):665–90 (119 ref.)

Inorganic semiconductors as photosensitizers in biochemical redox reactions. Nikandrov VV. **Membr Cell Biol** 1998; 12(5):755–69 (47 ref.)

Urocanic acid photochemistry and photobiology. Mohammad T, et al. **Photochem Photobiol** 1999 Feb; 69(2):115–35 (182 ref.)

PHOTOCHEMOTHERAPY

Current concepts in gastrointestinal photodynamic therapy. Webber J, et al. **Ann Surg** 1999 Jul;230(1):12–23 (134 ref.)

Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Villeneuve L. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):1–17 (294 ref.)

Photodynamic modulation of cellular function. Cui ZJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):297–303 (51 ref.)

The introduction of photodynamic therapy for tumorous patients in Croatia based on our experimental experiences and clinical approaches of the other groups. Doko M, et al. **Coll Antropol** 1998 Jun;22(1):315–9 (20 ref.)

Role of photodynamic therapy in the management of gastrointestinal cancer. Kubba AK. **Digestion** 1999 Jan-Feb;60(1):1–10 (121 ref.)

Therapeutic biliary endoscopy. Choudari CP, et al. **Endoscopy** 1999 Jan;31(1):80–7 (52 ref.)

Ablation therapy for Barrett's esophagus: is it time to choose our weapons? [editorial; comment] Lightdale CJ. **Gastrointest Endosc** 1999 Jan;49(1):122–5 (22 ref.) Comment on: Gastrointest Endosc 1999 Jan;49(1):1–7. Comment on: Gastrointest Endosc 1999 Jan;49(1):8–12. Comment on: Gastrointest Endosc 1999 Jan;49(1):97–101.

Current status of photodynamic therapy of Barrett's esophagus. Wang KK. **Gastrointest Endosc** 1999 Mar;49(3 Pt 2):S20–3 (21 ref.)

Tazarotene in combination with phototherapy. Koo JY. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S144–8 (29 ref.)

The photobiology of photodynamic therapy: cellular targets and mechanisms. Oleinick NL, et al. **Radiat Res** 1998 Nov; 150(5 Suppl):S146–56 (124 ref.)

What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Stewart F, et al. **Radiother Oncol** 1998 Sep;48(3):233–48 (160 ref.)

Principles of the photodynamic therapy and its impact on the immune system. Vančiková Z. **Sb Lek** 1998;99(1):1–11 (82 ref.)

The emerging role of photodynamic therapy in the management of Barrett's oesophagus. Kubba AK, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1121–9 (133 ref.)

Extracorporeal photochemotherapy: a treatment for organ graft rejection [editorial] Heshmati F, et al. **Ther Apher** 1997 May;1(2):121–5 (25 ref.)

[Photodynamic therapy. A new method for the treatment of cancer] Johansen LS. **Ugeskr Laeger** 1999 Jun 28; 161(26):3992–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Photomedicine in gynecology] Walt H. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1690–6 (21 ref.) (Eng. Abstr.) **(Ger)**

[Topical photodynamic therapy in dermatology] Grob M, et al. **Ther Umsch** 1998 Aug;55(8):529–32 (11 ref.) (Eng. Abstr.) **(Ger)**

[Photo oxidative reactions of psoralens and their role in therapy of dermatoses] Potapenko AIa, et al. **Vestn Ross Akad Med Nauk** 1999;(2):32–8 (35 ref.) (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Optical hair removal. Ort RJ, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):149–58 (42 ref.)

METHODS

New photosensitizers for photodynamic therapy in gastroenterology. Bown SG, et al. **Can J Gastroenterol** 1999 Jun;13(5):389–92 (28 ref.)

Results of photodynamic therapy in Barrett's esophagus: A review. Overholt BF. **Can J Gastroenterol** 1999 Jun; 13(5):393–6 (44 ref.)

Photodynamic therapy in the treatment of cancer: current state of the art. Hsi RA, et al. **Drugs** 1999 May;57(5):725–34 (71 ref.)

Photodynamic therapy: a review. McCaughan JS Jr. **Drugs Aging** 1999 Jul;15(1):49–68 (144 ref.)

Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. Krutmann J. **J Photochem Photobiol B** 1998 Jul 10;44(2):159–64 (39 ref.)

The application of antioxidants in investigations and optimization of photochemotherapy. Potapenko AY, et al. **Membr Cell Biol** 1998;12(2):269–78 (38 ref.)

[Endobronchial photodynamic therapy in France] Leroy M. **Presse Med** 1998 Jun 20;27(22):1121–3 (0 ref.) **(Fre)**

[Photodynamic therapy. Minimally invasive treatment of choroidal neovascularization] Schmidt-Erfurth U. **Ophthalmologe** 1998 Oct;95(10):725–31 (26 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application of photodynamic method to the treatment of malignancies. Part II (editorial)] Domaniecki J, et al. **Wiad Lek** 1999;52(1–2):4–10 (20 ref.) (Eng. Abstr.) **(Pol)**

PHOTOCHEMOTHERAPY, EXTRACORPOREAL see **PHOTOPHERESIS**

PHOTOCOAGULATION see **LIGHT COAGULATION**

PHOTODENSITOMETRY see **DENSITOMETRY, X-RAY**

PHOTODERMATITIS see **PHOTOSENSITIVITY DISORDERS**

PHOTODYNAMIC THERAPY see **PHOTOCHEMOTHERAPY**

PHOTOGRAPHY

Medical photography and genitourinary surgery. Ferro F, et al. **Br J Urol** 1998 Sep;82(3):325–30 (5 ref.)

INSTRUMENTATION

Use of digital cameras for radiographs: how to get the best pictures. Whitehouse RW. **J R Soc Med** 1999 Apr; 92(4):178–82 (6 ref.)

PHOTOKERATECTOMY see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

PHOTOMICROGRAPHY

METHODS

Overview of fluorescence photomicrography. Javois LC, et al. **Methods Mol Biol** 1999;115:175–9 (10 ref.)

PHOTONS

New time-resolved techniques in two-photon microscopy. So PT, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul; 44(5):771–93 (85 ref.)

Review of photon interaction cross section data in the medical and biological context. Hubbell JH. **Phys Med Biol** 1999 Jan;44(1):R1–22 (157 ref.)

PHOTOPERIOD

Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283–94 (78 ref.)

Insect circadian rhythms and photoperiodism. Saunders DS. **Invert Neurosci** 1997 Sep-Dec;3(2–3):155–64 (55 ref.)

Photoperiodic time measurement in insects: a review of clock models. Vaz Nunes M, et al. **J Biol Rhythms** 1999 Apr; 14(2):84–104 (144 ref.)

Melatonin and the seasonal control of reproduction. Malpaux B, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):355–66 (75 ref.)

PHOTOPHERESIS

The North American experience with photopheresis. Zic JA, et al. **Ther Apher** 1999 Feb;3(1):50–62 (90 ref.)

PHOTOPROTEINS see **LUMINESCENT PROTEINS**

PHOTORADIATION see **LIGHT**

PHOTORADIATION THERAPY see **PHOTOTHERAPY**

PHOTOREACTIVATING ENZYME see **DEOXYRIBODIPYRIMIDINE PHOTO-LYASE**

PHOTORECEPTORS

see related
PHOTOTRANSDUCTION
RETINAL PIGMENTS

METABOLISM

Heterogeneous N-terminal acylation of retinal proteins. DeMar JC Jr, et al. **Prog Lipid Res** 1999 Jan;38(1):49–90 (348 ref.)

PHYSIOLOGY

Hedgehog and Spitz: making a match between photoreceptor axons and their targets. Salecker I, et al. **Cell** 1998 Nov 25;95(5):587–90 (18 ref.)

Circadian rhythms: eyes of the clock. Van Gelder RN. **Curr Biol** 1998 Nov 5;8(22):R798–801 (18 ref.)

Cryptochromes: blue light receptors for plants and animals. Cashmore AR, et al. **Science** 1999 Apr 30;284(5415):760–5 (50 ref.)

Cryptochromes--bringing the blues to circadian rhythms. Devlin PF, et al. **Trends Cell Biol** 1999 Aug;9(8):295–8 (40 ref.)

[Role of calcium ions in photoreceptor light-adaptation] Kawamura S. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1806–13 (53 ref.) **(Jpn)**

[Phytochrome-like photoreceptor systems in cyanobacteria] Tretyn A. **Postepy Biochem** 1998;44(2):113–7 (14 ref.) **(Pol)**

PHOTORECEPTORS, CONE see **CONES (RETINA)**

PHOTORECEPTORS, INVERTEBRATE

CHEMISTRY

Histamine in the brain of insects: a review. Nässel DR. **Microsc Res Tech** 1999 Jan 15–Feb 1;44(2–3):121–36 (64 ref.)

PHYSIOLOGY

Insect circadian rhythms and photoperiodism. Saunders DS.

PHOTORECEPTORS, INVERTEBRATE

Invert Neurosci 1997 Sep-Dec;3(2-3):155-64 (55 ref.)
Neurotransmitter regulation of circadian structural changes in the fly's visual system. Meinertzhagen IA, et al. **Microsc Res Tech** 1999 Apr 15;45(2):96-105 (75 ref.)
From fruit flies to barnacles, histamine is the neurotransmitter of arthropod photoreceptors. Stuart AE. **Neuron** 1999 Mar; 22(3):431-3 (15 ref.)
Extraretinal photoreceptors and their regulation of temporal physiology. Foster RG, et al. **Rev Reprod** 1998 Sep; 3(3):145-50 (46 ref.)

PHOTORECEPTORS, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTORECEPTORS, RETINAL see **PHOTORECEPTORS**

PHOTORECEPTORS, ROD see **RODS (RETINA)**

PHOTORECEPTORS, VERTEBRATE

see related
PHOTOTRANSDUCTION
The roles of intrinsic and extrinsic cues and bHLH genes in the determination of retinal cell fates. Cepko CL. **Curr Opin Neurobiol** 1999 Feb;9(1):37-46 (55 ref.)
The photoreceptor mosaic. Ahnelt PK. **Eye** 1998;12 (Pt 3b):531-40 (82 ref.)

CYTOLOGY

Vertebrate photoreceptor cell development and disease. Morrow EM, et al. **Trends Cell Biol** 1998 Sep;8(9):353-8 (68 ref.)

METABOLISM

Cyclic nucleotide-gated channels. Molecular mechanisms of activation. Broillet MC, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:730-40 (54 ref.)

PATHOLOGY

Photoreceptor rescue. Luthert PJ, et al. **Eye** 1998;12 (Pt 3b):591-6 (60 ref.)

PHYSIOLOGY

Molecular mechanisms of vertebrate photoreceptor light adaptation. Pugh EN Jr, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):410-8 (61 ref.)
Photopigments and seeing--lessons from natural experiments: the Proctor lecture. Jacobs GH. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2204-16 (99 ref.)
Photoreceptor membrane proteins, phototransduction, and retinal degenerative diseases. The Friedenwald Lecture. Molday RS. **Invest Ophthalmol Vis Sci** 1998 Dec; 39(13):2491-513 (183 ref.)
Vertebrate phototransduction: activation, recovery, and adaptation. Jindrová H. **Physiol Res** 1998;47(3):155-68 (103 ref.)
Light adaptation and sensitivity controlling mechanisms in vertebrate photoreceptors. Perlman I, et al. **Prog Retin Eye Res** 1998 Oct;17(4):523-63 (132 ref.)

TRANSPLANTATION

Immunological problems of transplantation into the subretinal space. Enzmann V, et al. **Acta Anat (Basel)** 1998; 162(2-3):178-83 (51 ref.)

PHOTOSENSITIVITY DISORDERS

CHEMICALLY INDUCED

Antimicrobial photosensitive reactions. Vassileva SG, et al. **Arch Intern Med** 1998 Oct 12;158(18):1993-2000 (64 ref.)
Mechanisms of photosensitization by phototoxic drugs. Moore DE. **Mutat Res** 1998 Nov 9;422(1):165-73 (12 ref.)
Recent developments in fluoroquinolone phototoxicity. Man I, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):32-3 (17 ref.)

CLASSIFICATION

Photodermatoses in tropical countries. Dominguez-Soto L, et al. **Clin Dermatol** 1999 Mar-Apr;17(2):237-43; discussion 105-6 (52 ref.)

ETIOLOGY

Phytophotodermatitis. Bowers AG. **Am J Contact Dermat** 1999 Jun;10(2):89-93 (20 ref.)
Solar urticaria: the annoying photodermatosis. Roelandts R, et al. **Int J Dermatol** 1999 Jun;38(6):411-8 (123 ref.)
Skin manifestations of mitochondrial DNA syndromes: case report and review. Flynn MK, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):819-23 (33 ref.)

GENETICS

A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Cleaver JE, et al. **Hum Mutat** 1999; 14(1):9-22 (110 ref.)

PATHOLOGY

Actinic reticuloid. Zak-Prelich M, et al. **Int J Dermatol** 1999 May;38(5):335-42 (101 ref.)

PHYSIOPATHOLOGY

Mechanisms of photosensitization by phototoxic drugs. Moore DE. **Mutat Res** 1998 Nov 9;422(1):165-73 (12 ref.)

PHOTOSENSITIZERS see **PHOTOSENSITIZING AGENTS**

PHOTOSENSITIZING AGENTS

see related
PHOTOCHEMOTHERAPY
PUVA THERAPY
Inorganic semiconductors as photosensitizers in biochemical redox reactions. Nikandrov VV. **Membr Cell Biol** 1998; 12(5):755-69 (47 ref.)

ADMINISTRATION & DOSAGE

New photosensitizers for photodynamic therapy in gastroenterology. Bown SG, et al. **Can J Gastroenterol** 1999 Jun;13(5):389-92 (28 ref.)
Results of photodynamic therapy in Barrett's esophagus: A review. Overholt BF. **Can J Gastroenterol** 1999 Jun; 13(5):393-6 (44 ref.)
Photodynamic therapy: a review. McCaughan JS Jr. **Drugs Aging** 1999 Jul;15(1):49-68 (144 ref.)

ADVERSE EFFECTS

Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? Lindelöf B. **Drug Saf** 1999 Apr;20(4):289-97 (115 ref.)
Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Ernst E, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):589-94 (40 ref.)
Mechanisms of photosensitization by phototoxic drugs. Moore DE. **Mutat Res** 1998 Nov 9;422(1):165-73 (12 ref.)
Perspectives of photodynamic therapy for skin diseases. Colussi VC, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec;11(6):336-46 (78 ref.)

METABOLISM

The photodynamic and non-photodynamic actions of porphyrins. Afonso SG, et al. **Braz J Med Biol Res** 1999 Mar;32(3):255-66 (56 ref.)

PHARMACOLOGY

Photodynamic modulation of cellular function. Cui ZJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):297-303 (51 ref.)
Modulation of cytokine production by 8-methoxypsoralen and UVA. Tokura Y. **J Dermatol Sci** 1999 Feb;19(2):114-22 (56 ref.)
Photodynamic diagnosis and therapy in dermatology. Fritsch C, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):358-73 (74 ref.)

THERAPEUTIC USE

Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Villeneuve L. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):1-17 (294 ref.)
Photodynamic therapy in the treatment of cancer: current state of the art. Hsi RA, et al. **Drugs** 1999 May;57(5):725-34 (71 ref.)
PUVA therapy: current concerns in Japan. Danno K. **J Dermatol Sci** 1999 Feb;19(2):89-105 (138 ref.)
[Photo oxidative reactions of psoralens and their role in therapy of dermatoses] Potapenko AIa, et al. **Vestn Ross Akad Med Nauk** 1999;(2):32-8 (35 ref.) (Eng. Abstr.) **(Rus)**

TOXICITY

Photochemical genotoxicity and photochemical carcinogenesis--two sides of a coin? Müller L, et al. **Toxicol Lett** 1998 Dec 28;102-103:383-7 (18 ref.)

PHOTOSYNTHESIS

Photosynthetic accumulation of poly-(hydroxybutyrate) by cyanobacteria--the metabolism and potential for CO2 recycling. Asada Y, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):37-42 (21 ref.)
How photosynthetic bacteria harvest solar energy. Cogdell RJ, et al. **J Bacteriol** 1999 Jul;181(13):3869-79 (77 ref.)

PHYSIOLOGY

Light perception in higher plants. Batschauer A. **Cell Mol Life Sci** 1999 Feb;55(2):153-66 (165 ref.)
Photosynthetic reaction centers. Allen JP, et al. **FEBS Lett** 1998 Oct 30;438(1-2):5-9 (36 ref.)

PHOTOSYNTHETIC REACTION CENTER, BACTERIAL

CHEMISTRY

Relevance of the protein-lipid interaction on the functioning of the bacterial reaction center. Agostiano A, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:215-9 (10 ref.)
Protein engineering of the photoreaction centre from Rhodobacter sphaeroides. Ridge JP, et al. **Biochem Soc Trans** 1998 Aug;26(3):422-7 (41 ref.)
How photosynthetic bacteria harvest solar energy. Cogdell RJ, et al. **J Bacteriol** 1999 Jul;181(13):3869-79 (77 ref.)
Organization and role of the long-wave chlorophylls in the photosystem I of the Cyanobacterium spirulina. Karapetyan NV. **Membr Cell Biol** 1998;12(5):571-84 (45 ref.)

METABOLISM

Protein engineering of the photoreaction centre from Rhodobacter sphaeroides. Ridge JP, et al. **Biochem Soc Trans** 1998 Aug;26(3):422-7 (41 ref.)
Cytochrome b559 of photosystem II. Stewart DH, et al. **Biochim Biophys Acta** 1998 Oct 5;1367(1-3):63-87 (160 ref.)
Photosynthetic reaction centers. Allen JP, et al. **FEBS Lett** 1998 Oct 30;438(1-2):5-9 (36 ref.)
New and unexpected routes for ultrafast electron transfer in photosynthetic reaction centers. van Brederode ME, et al. **FEBS Lett** 1999 Jul 16;455(1-2):1-7 (43 ref.)
Organization and role of the long-wave chlorophylls in the photosystem I of the Cyanobacterium spirulina. Karapetyan NV. **Membr Cell Biol** 1998;12(5):571-84 (45 ref.)

PHOTOSYNTHETIC REACTION CENTER, PLANT

Photoreceptors of higher plants. Batschauer A. **Planta** 1998 Nov;206(4):479-92 (166 ref.)

CHEMISTRY

Subunit positioning in photosystem II revisited. Barber J, et al. **Trends Biochem Sci** 1999 Feb;24(2):43-5 (23 ref.)

GENETICS

Circadian expression of the light-harvesting complex protein genes in plants. Piechulla B. **Chronobiol Int** 1999 Mar; 16(2):115-28 (65 ref.)

METABOLISM

Herbicide resistance and supersensitivity in photosystem II. Oettmeier W. **Cell Mol Life Sci** 1999 Aug 15;55(10):1255-77 (141 ref.)
Seeing the world in red and blue: insight into plant vision and photoreceptors. Ahmad M. **Curr Opin Plant Biol** 1999 Jun;2(3):230-5 (43 ref.)
Photosynthetic reaction centers. Allen JP, et al. **FEBS Lett** 1998 Oct 30;438(1-2):5-9 (36 ref.)
New and unexpected routes for ultrafast electron transfer in photosynthetic reaction centers. van Brederode ME, et al. **FEBS Lett** 1999 Jul 16;455(1-2):1-7 (43 ref.)
The final stage of chlorophyll biosynthesis and formation of reaction centres of photosystems. Litvin FF, et al. **Membr Cell Biol** 1998;12(5):609-26 (124 ref.)

PHOTOSYSTEM I REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOSYSTEM II REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOTHERAPY

A turning point for seasonal affective disorder and light therapy research? [comment] Avery DH. **Arch Gen Psychiatry** 1998 Oct;55(10):863-4 (19 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):883-9. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):875-82. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):890-6.
Beginning to see the light [comment] Wirz-Justice A. **Arch Gen Psychiatry** 1998 Oct;55(10):861-2 (20 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):875-82. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):883-9. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):890-6.
Hair removal using a pulsed-intense light source. Tse Y. **Dermatol Clin** 1999 Apr;17(2):373-85, ix (25 ref.)
Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Molin L. **Dermatology** 1999;198(4):375-81 (31 ref.)
Melatonin, biological rhythm disorders and phototherapy. Srinivasan V. **Indian J Physiol Pharmacol** 1997 Oct; 41(4):309-28 (105 ref.)
Seasonal affective disorder. Partonen T, et al. **Lancet** 1998 Oct 24;352(9137):1369-74 (50 ref.)
Magnetoreception attributed to the efficacy of light therapy. Partonen T. **Med Hypotheses** 1998 Nov;51(5):447-8 (4 ref.)
[Management of hyperbilirubinemia of the term newborn in maternity wards] Di Maio M, et al. **Arch Pediatr** 1998 Oct; 5(10):1156-61 (11 ref.) (Eng. Abstr.) **(Fre)**

[Severe neonatal jaundice. Definition and management] Labrune P. **Arch Pediatr** 1998 Oct;5(10):1162–7 (24 ref.) (Eng. Abstr.) **(Fre)**
[Phototherapy in the clinic] Pracka D. **Postepy Hig Med Dosw** 1999;53(3):517–23 (26 ref.) (Eng. Abstr.) **(Pol)**

METHODS

How to use light and dark to produce circadian adaptation to night shift work. Eastman CI, et al. **Ann Med** 1999 Apr; 31(2):87–98 (42 ref.)
Efficacy and safety of treatment modalities for psoriasis. Tristani-Firouzi P, et al. **Cutis** 1998 Feb;61(2 Suppl):11–21 (69 ref.)
[Winter depression and light therapy] Honory A. **Psychiatr Pol** 1998 Sep–Oct;32(5):605–19 (74 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

Perspectives of photodynamic therapy for skin diseases. Colussi VC, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov–Dec;11(6):336–46 (78 ref.)

PHOTOTOXICITY see **DERMATITIS, PHOTOTOXIC**

PHOTOTRANSDUCTION

see related
PHOTORECEPTORS
PHOTORECEPTORS, VERTEBRATE

Light adaptation and sensitivity controlling mechanisms in vertebrate photoreceptors. Perlman I, et al. **Prog Retin Eye Res** 1998 Oct;17(4):523–63 (132 ref.)
[Early events occurring during light signal transduction in plants] Hasunuma K, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1443–52 (50 ref.) **(Jpn)**
[Diversity of visual pigments and phototransduction systems on the basis of both molecular phylogenetic and functional protein analyses] Terakita A, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):217–25 (35 ref.) **(Jpn)**

PHYSIOLOGY

Parallel processing in the mammalian retina: the Proctor Lecture. Boycott B, et al. **Invest Ophthalmol Vis Sci** 1999 Jun;40(7):1313–27 (134 ref.)
Photoreceptor membrane proteins, phototransduction, and retinal degenerative diseases. The Friedenwald Lecture. Molday RS. **Invest Ophthalmol Vis Sci** 1998 Dec; 39(13):2491–513 (183 ref.)
Rhodopsin and phototransduction. Pepe IM. **J Photochem Photobiol B** 1999 Jan;48(1):1–10 (171 ref.)
Vertebrate phototransduction: activation, recovery, and adaptation. Jindrová H. **Physiol Res** 1998;47(3):155–68 (103 ref.)
Role of calcium ions in vertebrate phototransduction. Gorczyca WA. **Pol J Pharmacol** 1999 Mar–Apr; 51(2):167–72 (47 ref.)
[Structural view of mechanism of photo-signal transduction related with rhodopsin and heterotrimeric G protein] Fujiyoshi Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):347–54 (7 ref.) **(Jpn)**

PHOTOTROPHIC BACTERIA

METABOLISM

How photosynthetic bacteria harvest solar energy. Cogdell RJ, et al. **J Bacteriol** 1999 Jul;181(13):3869–79 (77 ref.)

PHRENIC NERVE

GROWTH & DEVELOPMENT

An overview of phrepic nerve and diaphragm muscle development in the perinatal rat. Greer JJ, et al. **J Appl Physiol** 1999 Mar;86(3):779–86 (34 ref.)

INJURIES

Phrenic nerve injury following cardiac surgery: a review. Tripp HF, et al. **J Card Surg** 1998 May;13(3):218–23 (29 ref.)

PHTHALAZINES

ADMINISTRATION & DOSAGE

Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. Golden SJ, et al. **J Am Osteopath Assoc** 1999 Jul;99(7 Suppl):S7–12 (35 ref.)

PHARMACOKINETICS

[Second generation topical antihistaminics] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May;6(35):277–80 (59 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. Lieberman P. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S400–4 (39 ref.)

PHTHALIMIDES

PHARMACOLOGY

Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton. Shimazawa R, et al. **J Enzyme Inhib** 1999;14(4):259–75 (67 ref.)

PHYCODNAVIRIDAE

ENZYMOLOGY

Microbial glycoconjugates. Mengeling BJ, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):572–7 (45 ref.)

PHYCOMYCES

ISOLATION & PURIFICATION

Zygomycosis due to Apophysomyces elegans: report of 2 cases and review of the literature. Kimura M, et al. **Arch Pathol Lab Med** 1999 May;123(5):386–90 (22 ref.)

PHYCOMYCOSIS see **ZYGOMYCOSIS**

PHYLLODES TUMOR

DIAGNOSIS

Spindle cell tumours of the breast: practical approach to diagnosis. Al-Nafussi A. **Histopathology** 1999 Jul; 35(1):1–13 (192 ref.)

PATHOLOGY

[Malignant phyllodes tumor with liposarcomatous differentiation. Description of a clinical case] Scala M, et al. **Minerva Chir** 1999 May;54(5):355–8 (25 ref.) (Eng. Abstr.) **(Ita)**

PHYLLOQUINONE see **PHYTONADIONE**

PHYLLOQUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

PHYLOGENY

Molecular phylogeny as a basis for the classification of transport proteins from bacteria, archaea and eukarya. Saier MH Jr. **Adv Microb Physiol** 1998;40:81–136 (75 ref.)
A test of Archonta monophyly and the phylogenetic utility of the mitochondrial gene 12S rRNA. McNiff BE, et al. **Am J Phys Anthropol** 1998 Nov;107(3):225–41 (78 ref.)
Cytochrome P450 and the individuality of species. Nelson DR. **Arch Biochem Biophys** 1999 Sep 1;369(1):1–10 (64 ref.)
Retroviruses: ancient and modern. Weiss RA, et al. **Arch Virol Suppl** 1999;15:171–7 (30 ref.)
Phylogenetic characterization of novel transport protein families revealed by genome analyses. Saier MH Jr, et al. **Biochim Biophys Acta** 1999 Feb 25;1422(1):1–56 (134 ref.)
A common theme for LIM homeobox gene function across phylogeny? Hobert O, et al. **Biol Bull** 1998 Dec; 195(3):377–80 (12 ref.)
Building large trees by combining phylogenetic information: a complete phylogeny of the extant Carnivora (Mammalia). Bininda-Emonds OR, et al. **Biol Rev Camb Philos Soc** 1999 May;74(2):143–75 (293 ref.)
Tunicate tails, stolons, and the origin of the vertebrate trunk. Lacalli TC. **Biol Rev Camb Philos Soc** 1999 May; 74(2):177–98 (142 ref.)
Classification and evolution of EF-hand proteins. Kawasaki H, et al. **Biometals** 1998 Dec;11(4):277–95 (75 ref.)
Crustacean–insect relationships: the use of brain characters to derive phylogeny amongst segmented invertebrates. Strausfeld NJ. **Brain Behav Evol** 1998;52(4–5):186–206 (102 ref.)
Stepping into the same river twice: homologues as recurring attractors in epigenetic landscapes. Striedter GF. **Brain Behav Evol** 1998;52(4–5):218–31 (116 ref.)
Developmental homologues: lineages and analysis. Trevarrow B. **Brain Behav Evol** 1998;52(4–5):243–53 (54 ref.)
The neuronal zootype. An hypothesis. Deutsch J, et al. **C R Acad Sci III** 1998 Sep;321(9):713–9 (53 ref.)
Big trees from little genomes: mitochondrial gene order as a phylogenetic tool. Boore JL, et al. **Curr Opin Genet Dev** 1998 Dec;8(6):668–74 (50 ref.)
Early branching eukaryotes? Embley TM, et al. **Curr Opin Genet Dev** 1998 Dec;8(6):624–9 (52 ref.)
The recent origins of spliceosomal introns revisited. Logsdon JMJr. **Curr Opin Genet Dev** 1998 Dec;8(6):637–48 (92 ref.)
Metazoan phylogenies: falling into place or falling to pieces? A palaeontological perspective. Morris SC. **Curr Opin Genet Dev** 1998 Dec;8(6):662–7 (53 ref.)
How good are deep phylogenetic trees? Philippe H, et al. **Curr Opin Genet Dev** 1998 Dec;8(6):616–23 (68 ref.)
Phylogenetic development of the cochlea and its innervation. Manley GA, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):468–74 (42 ref.)
Ovaries, oogenesis and insect phylogeny. Introductory remarks. Biliński SM. **Folia Histochem Cytobiol** 1998; 36(4):143–5 (27 ref.)
The number that counts. Phylogenetic implications of the number of nurse cells in ovarian follicles of Coleoptera-Adephaga. Jaglarz MK. **Folia Histochem Cytobiol** 1998;36(4):167–78 (69 ref.)
Heteropteran ovaries: variations on the theme. Simiczyjew B, et al. **Folia Histochem Cytobiol** 1998;36(4):147–56 (51 ref.)
The ovaries of scale insects (Hemiptera, Coccinea). Morphology and phylogenetic conclusions. Szklarzewicz T. **Folia Histochem Cytobiol** 1998;36(4):157–65 (57 ref.)
Gonadotropin-releasing hormone genes: phylogeny, structure, and functions. Fernald RD, et al. **Front Neuroendocrinol** 1999 Jul;20(3):224–40 (74 ref.)
Models of molecular evolution and phylogeny. Liò P, et al. **Genome Res** 1998 Dec;8(12):1233–44 (86 ref.)
Non-monophyly of the monogeneans? Justine JL. **Int J Parasitol** 1998 Oct;28(10):1653–7 (35 ref.)
A phylogenetic analysis of the relationship between sub-adult mortality and mode of subsistence. Sellen DW, et al. **J Biosoc Sci** 1999 Jan;31(1):1–16 (59 ref.)
Phylogeny and evolution of chemical communication: an endocrine approach. Stoka AM. **J Mol Endocrinol** 1999 Jun;22(3):207–25 (155 ref.)
Emotion and phylogeny. Cabanac M. **Jpn J Physiol** 1999 Feb;49(1):1–10 (74 ref.)
Molecular phylogeny and taxonomy of medically important fungi. De Hoog GS, et al. **Med Mycol** 1998;36 Suppl 1:52–6 (31 ref.)
Protein phylogenies and signature sequences: A reappraisal of evolutionary relationships among archaebacteria, eubacteria, and eukaryotes. Gupta RS. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1435–91 (264 ref.)
Base compositional bias and phylogenetic analyses: a test of the "flying DNA" hypothesis. Van Den Bussche RA, et al. **Mol Phylogenet Evol** 1998 Dec;10(3):408–16 (61 ref.)
Bacterial population genetics, evolution and epidemiology. Spratt BG, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29;354(1384):701–10 (53 ref.)
SINEs of the perfect character [comment] Hillis DM. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9979–81 (34 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10261–6.
The question of metazoan monophyly and the fossil record. Conway Morris S. **Prog Mol Subcell Biol** 1998;21:1–19 (155 ref.)
Caenorhabditis elegans is a nematode. Blaxter M. **Science** 1998 Dec 11;282(5396):2041–6 (45 ref.)
Phylogenetic classification and the universal tree. Doolittle WF. **Science** 1999 Jun 25;284(5423):2124–9 (43 ref.)
The taxonomy of developmental control in Caenorhabditis elegans [see comments] Ruvkun G, et al. **Science** 1998 Dec 11;282(5396):2033–41 (51 ref.) Comment in: Science 1998 Dec 11;282(5396):1972–4. Comment in: Science 1999 Jul 9;285(5425):167.
Distance measures in terms of substitution processes. Baake E, et al. **Theor Popul Biol** 1999 Apr;55(2):166–75 (31 ref.)
Coalescing into the 21st century: An overview and prospects of coalescent theory. Fu YX, et al. **Theor Popul Biol** 1999 Aug;56(1):1–10 (72 ref.)
[Phylogenetic preservation of genetic study stocks of Saccharomyces cerevisiae] Harashima S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):278–82 (28 ref.) **(Jpn)**
[Phylogenetic preservation of genetic study stocks of Schizosaccharomyces pombe] Shimoda C. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):282–4 (9 ref.) **(Jpn)**
[Diversity of visual pigments and phototransduction systems on the basis of both molecular phylogenetic and functional protein analyses] Terakita A, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):217–25 (35 ref.) **(Jpn)**
[Phylogenesis and formation of fatty acid transport in cells (review of the literature)] Titov VN. **Klin Lab Diagn** 1999 Mar;(3):3–8 (37 ref.) **(Rus)**

PHYSALIA see **JELLYFISH**

PHYSARUM POLYCEPHALUM

PHYSIOLOGY

Calcium regulation of the actin-myosin interaction of Physarum polycephalum. Nakamura A, et al. **Int Rev Cytol** 1999;191:53–98 (142 ref.)

PHYSCOMITRELLA see **MOSSES**

PHYSETER see **WHALES**

PHYSETERIDAE see **WHALES**

PHYSIATRY see **PHYSICAL MEDICINE**

PHYSICAL CONDITIONING, ANIMAL

Amino acid transport during muscle contraction and its relevance to exercise. Rennie MJ, et al. **Adv Exp Med Biol** 1998;441:299–305 (13 ref.)
Training induced changes in the fatty acid composition of skeletal muscle lipids. Functional aspects. Vessby B, et al.

PHYSICAL CONDITIONING, ANIMAL

Adv Exp Med Biol 1998;441:139–45 (29 ref.)
Field exercise testing for assessing fitness in French standardbred trotters. Courouce A. **Vet J** 1999 Mar; 157(2):112–22 (50 ref.)

PHYSIOLOGY

Fat metabolism in exercise. Wolfe RR.
Adv Exp Med Biol 1998;441:147–56 (16 ref.)
Effects of furosemide on athletic performance and exercise-induced pulmonary hemorrhage in horses. Hinchcliff KW. **J Am Vet Med Assoc** 1999 Sep 1; 215(5):630–5 (48 ref.)
Interaction of factors determining oxygen uptake at the onset of exercise. Tschakovsky ME, et al. **J Appl Physiol** 1999 Apr;86(4):1101–13 (105 ref.)

PHYSICAL CONDITIONING, HUMAN see **PHYSICAL FITNESS**

PHYSICAL EDUCATION AND TRAINING

Effects of physical activity interventions in youth. Review and synthesis. Stone EJ, et al. **Am J Prev Med** 1998 Nov; 15(4):298–315 (108 ref.)
Markers of excessive exercise. McKenzie DC.
Can J Appl Physiol 1999 Feb;24(1):66–73 (36 ref.)
The gas transporting systems: limits and modifications with age and training. Paterson DH, et al.
Can J Appl Physiol 1999 Feb;24(1):28–40 (48 ref.)
Athletic training issues in synchronized swimming. Chu DA. **Clin Sports Med** 1999 Apr;18(2):437–45, ix (2 ref.)
Fat metabolism during exercise: a review--part II: regulation of metabolism and the effects of training. Jeukendrup AE, et al. **Int J Sports Med** 1998 Jul;19(5):293–302 (130 ref.)
Relationship between sport knowledge, sport performance and academic ability: empirical evidence from GCSE Physical Education. General Certificate of Secondary Education. Dexter T. **J Sports Sci** 1999 Apr;17(4):283–95 (41 ref.)
Physical training and exercise-related injuries. Surveillance, research and injury prevention in military populations. Jones BH, et al. **Sports Med** 1999 Feb;27(2):111–25 (61 ref.)
Overtraining and recovery. A conceptual model. Kenttä G, et al. **Sports Med** 1998 Jul;26(1):1–16 (53 ref.)
[Athletic training of children and adolescents: growth and maturation more important than training for endurance in the young] Andrén-Sandberg A. **Lakartidningen** 1998 Oct 7;95(41):4480–4, 4487 (35 ref.) (Eng. Abstr.) **(Swe)**
[Training and sports competition during pregnancy and after childbirth. Physical training is beneficial for mother and child] Henriksson-Larsén K. **Lakartidningen** 1999 Apr 28; 96(17):2097–100 (46 ref.) (Eng. Abstr.) **(Swe)**

ORGANIZATION & ADMINISTRATION

Injuries and considerations in masters aquatics sports. Miller JW. **Clin Sports Med** 1999 Apr;18(2):413–26, viii–ix (16 ref.)

PHYSICAL EFFORT see **EXERTION**

PHYSICAL ENDURANCE

Carbohydrate loading and deploying forces. Sandberg PR. **Mil Med** 1999 Sep;164(9):636–42 (41 ref.)
Iron supplementation in athletes. Current recommendations. Nielsen P, et al. **Sports Med** 1998 Oct;26(4):207–16 (45 ref.)
[Current knowledge on muscle training: endurance and strength yield complementary effects] Henriksson J, et al. **Lakartidningen** 1999 Jan 6;96(1-2):56–60 (24 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

Nutritional supplements: fact vs. fiction. Johnson WA, et al. **Adolesc Med** 1998 Oct;9(3):501–13, vi (69 ref.)
Leucine supplementation and intensive training. Mero A. **Sports Med** 1999 Jun;27(6):347–58 (56 ref.)

PHYSIOLOGY

Haemoglobin, blood volume, cardiac function, and aerobic power. Gledhill N, et al. **Can J Appl Physiol** 1999 Feb; 24(1):54–65 (45 ref.)
The gas transporting systems: limits and modifications with age and training. Paterson DH, et al.
Can J Appl Physiol 1999 Feb;24(1):28–40 (48 ref.)
The effects of endurance training on muscle fibre types and enzyme activities. Taylor AW, et al.
Can J Appl Physiol 1999 Feb;24(1):41–53 (76 ref.)
The efficacy of carbohydrate supplementation and chronic high- carbohydrate diets for improving endurance performance. Jacobs KA, et al. **Int J Sport Nutr** 1999 Mar; 9(1):92–115 (104 ref.)
Use of heart rate monitors by endurance athletes: lessons from triathletes. O'Toole ML, et al.
J Sports Med Phys Fitness 1998 Sep;38(3):181–7 (21 ref.)
Time in human endurance models. From empirical models to physiological models. Billat LV, et al. **Sports Med** 1999 Jun;27(6):359–79 (79 ref.)

PHYSICAL EXAMINATION

A review of measures of lymphedema. Gerber LH.
Cancer 1998 Dec 15;83(12 Suppl American):2803–4 (12 ref.)
Patient evaluation and indications for ultrasound-assisted lipoplasty. Rohrich RJ, et al. **Clin Plast Surg** 1999 Apr; 26(2):269–73; viii (11 ref.)
Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care [see comments] Douketis JD, et al. **CMAJ** 1999 Feb 23;160(4):513–25 (128 ref.) Comment in: CMAJ 1999 Feb 23;160(4):503–6. Comment in: CMAJ 1999 Jun 29;160(13):1820–1. Comment in: CMAJ 1999 Jun 29;160(13):1821. Comment in: ACP J Club 1999 Jul-Aug;131(1):20.
Salvaging the history, physical examination and doctor-patient relationship in a technological cardiology environment. Clement DL, et al. **J Am Coll Cardiol** 1999 Mar;33(3):892–3 (0 ref.)
What do we know about the reliability and validity of physical examination tests used to examine the upper extremity? [see comments] Marx RG, et al.
J Hand Surg [Am] 1999 Jan;24(1):185–93 (78 ref.) Comment in: J Hand Surg [Am] 1999 Jul;24(4):868–9. Comment in: J Hand Surg [Am] 1999 Jul;24(4):869–70.
The routine use of radiographic spinal displacement analysis: a dissent. Haas M, et al. **J Manipulative Physiol Ther** 1999 May;22(4):254–9 (43 ref.)
Breast health care. A review. McCool WF, et al.
J Nurse Midwifery 1998 Nov-Dec;43(6):406–30 (179 ref.)
Nerve trunk pain: physical diagnosis and treatment. Hall TM, et al. **Man Ther** 1999 May;4(2):63–73 (62 ref.)
Red flags in common pediatric symptoms. Wetzel GV.
MCN Am J Matern Child Nurs 1999 Jan-Feb;24(1):37–44; quiz 45 (19 ref.)
The nutritional dimension of physical assessment. Hammond KA. **Nutrition** 1999 May;15(5):411–9 (17 ref.)
Physical examination of the elbow. Colman WW, et al.
Orthop Clin North Am 1999 Jan;30(1):15–20 (5 ref.)
[Medical assessment in suspected inability to drive a motor vehicle] Hauri-Bionda R, et al.
Schweiz Rundsch Med Prax 1999 Jun 24;88(25-26):1128–33 (20 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Musculoskeletal rehabilitation and sports medicine. 4. Miscellaneous sports medicine topics. Smith J, et al.
Arch Phys Med Rehabil 1999 May;80(5 Suppl 1):S68–89 (246 ref.)
Physical examination and pretreatment testing of the incontinent woman. Julian TM. **Clin Obstet Gynecol** 1998 Sep;41(3):663–71 (10 ref.)
Essentials of a complete physical examination. Swartz MH. **Clin Podiatr Med Surg** 1998 Oct;15(4):569–618, v (2 ref.)
Introduction of a new physical examination procedure for the differentiation of acromioclavicular joint lesions and subacromial impingement. Buchberger DJ.
J Manipulative Physiol Ther 1999 Jun;22(5):316–21 (20 ref.)
Physical and arthroscopic examination techniques of the patellofemoral joint. Nissen CW, et al.
J Orthop Sports Phys Ther 1998 Nov;28(5):277–85 (46 ref.)
The medical evaluation of the sexually abused child: lessons from a decade of research. Atabaki S, et al. **Pediatrics** 1999 Jul;104(1 Pt 2):178–86 (76 ref.)
Approach to the patient. Parsons DP, et al. **Prim Care** 1999 Mar;26(1):15–34 (6 ref.)
The independent medical examination: purpose and process [editorial] Vasudevan SV, et al. **WMJ** 1999 Mar-Apr; 98(2):10–2 (5 ref.)
[Physical diagnosis--signs of lumbosacral irritation (see comments) (published erratum appears in Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1400)] Oosterhuis HJ.
Ned Tijdschr Geneeskd 1999 Mar 20;143(12):617–20 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1393–4. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394–5. **(Dut)**
[Why and how to examine the newborns' hips?] Philippet B, et al. **Rev Med Liege** 1998 Aug;53(8):470–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Facial trauma] Compère JF, et al. **Rev Prat** 1998 Feb 1; 48(3):301–9 (7 ref.) **(Fre)**
["I would like a check-up"] Raetzo MA, et al.
Schweiz Rundsch Med Prax 1999 Apr 8;88(15):669–76 (17 ref.) **(Ger)**
[Clinical examination of accident victims] Echtermeyer V, et al. **Unfallchirurg** 1999 Apr;102(4):305–18 (21 ref.) **(Ger)**

STANDARDS

Revisiting physical diagnosis during the medical residency: it is time for a logbook--and more. Mangione S, et al. **Acad Med** 1999 May;74(5):467–9 (8 ref.)
[Consensus 'diagnosis of short stature in children.' National Organization for Quality Assurance in Hospitals] de Muinck Keizer-Schrama SM. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2519–25 (8 ref.) (Eng. Abstr.) **(Dut)**

VETERINARY

Physical examination of horses with back pain. Martin BB Jr, et al. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):61–70, vi (7 ref.)
Health examinations and clinical diagnostic procedures of ratites. Tully TN Jr.
Vet Clin North Am Food Anim Pract 1998 Nov;14(3):401–20 (12 ref.)
Radiography of orthopedic trauma and fracture repair. Sande R. **Vet Clin North Am Small Anim Pract** 1999 Sep; 29(5):1247–60 (9 ref.)

PHYSICAL EXAMINATION, PREADMISSION see **DIAGNOSTIC TESTS, ROUTINE**

PHYSICAL FITNESS

see related
EXERCISE
Physical fitness and vegetarian diets: is there a relation? Nieman DC. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):570S–575S (81 ref.)
Physical inactivity as a risk factor for cardiovascular disease. Fletcher G. **Am J Med** 1999 Aug 23;107(2A):10S–11S (23 ref.)
Mediating variable framework in physical activity interventions. How are we doing? How might we do better? [published erratum appears in Am J Prev Med 1999 Jul;17(1):98] Baranowski T, et al. **Am J Prev Med** 1998 Nov;15(4):266–97 (95 ref.)
Worksite physical activity interventions. Dishman RK, et al. **Am J Prev Med** 1998 Nov;15(4):344–61 (95 ref.)
Physical activity interventions using mass media, print media, and information technology. Marcus BH, et al.
Am J Prev Med 1998 Nov;15(4):362–78 (68 ref.)
Effects of interventions in health care settings on physical activity or cardiorespiratory fitness. Simons-Morton DG, et al. **Am J Prev Med** 1998 Nov;15(4):413–30 (67 ref.)
Effects of physical activity interventions in youth. Review and synthesis. Stone EJ, et al. **Am J Prev Med** 1998 Nov; 15(4):298–315 (108 ref.)
Effect of spinal cord injury on the heart and cardiovascular fitness. Phillips WT, et al. **Curr Probl Cardiol** 1998 Nov; 23(11):641–716 (246 ref.)
Sympathetic activity and aging: relationship to smoking habits, physical fitness, blood volume, and intracellular signalling. Jensen EW. **Dan Med Bull** 1999 Apr; 46(2):106–17 (135 ref.)
How physically active are American children and what can we do about it? Luepker RV.
Int J Obes Relat Metab Disord 1999 Mar;23 Suppl 2:S12–7 (20 ref.)
Status of the year 2000 health goals for physical activity and fitness. Francis KT. **Phys Ther** 1999 Apr;79(4):405–14 (70 ref.)
Techniques of body composition assessment: a review of laboratory and field methods. Wagner DR, et al.
Res Q Exerc Sport 1999 Jun;70(2):135–49 (114 ref.)
Physical training and exercise-related injuries. Surveillance, research and injury prevention in military populations. Jones BH, et al. **Sports Med** 1999 Feb;27(2):111–25 (61 ref.)
[Diet and fitness in type 2 diabetes] Monnier L, et al.
Rev Prat 1999 Jan 1;49(1):40–5 (20 ref.) (Eng. Abstr.) **(Fre)**
[Are children and adolescents less physically active today than in the past?] Ekeland E, et al.
Tidsskr Nor Laegeforen 1999 Jun 20;119(16):2358–62 (22 ref.) (Eng. Abstr.) **(Nor)**
[Problems in the medical evaluation of the combat fitness of Armed Forces personnel] Zhiliaev EG, et al.
Voen Med Zh 1999 Mar;320(3):56–61 (17 ref.) **(Rus)**
[Current knowledge on muscle training: endurance and strength yield complementary effects] Henriksson J, et al.
Lakartidningen 1999 Jan 6;96(1-2):56–60 (24 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOLOGY

Physical functioning and exercise capacity in patients on dialysis. Johansen KL. **Adv Ren Replace Ther** 1999 Apr; 6(2):141–8 (42 ref.)
Associations between physical activity and susceptibility to cancer: possible mechanisms. Shephard RJ, et al.
Sports Med 1998 Nov;26(5):293–315 (245 ref.)
[Lactate for assessing physical performance, load capacity and monitoring of training] Jeschke D, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Apr; 34(4):234–6 (6 ref.) **(Ger)**
[Physical activity and aging] Kressig R, et al.
Schweiz Med Wochenschr 1998 Aug 4;128(31–32):1181–6 (43 ref.) (Eng. Abstr.) **(Ger)**

PHYSICAL MEDICINE

Measuring quality of life: methodological issues. Dijkers M.
Am J Phys Med Rehabil 1999 May-Jun;78(3):286–300 (98 ref.)
Randomized clinical trials in medical rehabilitation research. Tate DG, et al. **Am J Phys Med Rehabil** 1999 Sep-Oct; 78(5):486–99 (67 ref.)

METHODS

Neural network applications in physical medicine and rehabilitation. Ohno-Machado L, et al.
Am J Phys Med Rehabil 1999 Jul-Aug;78(4):392–8 (38 ref.)

Animal models of neuromuscular diseases: pathophysiology and implications for rehabilitation. Abresch RT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):285–99 (70 ref.)
The role of physiatry in the management of neuromuscular disease. Fowler WM Jr, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):1–8, v (23 ref.)
Clinical approach to the diagnostic evaluation of progressive neuromuscular diseases. McDonald CM. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):9–48 (63 ref.)

ORGANIZATION & ADMINISTRATION

The 31st Walter J. Zeiter Lecture. Issues and challenges for physiatry in the coming decade. DeLisa JA. **Arch Phys Med Rehabil** 1999 Jan;80(1):1–12 (101 ref.)

PHYSICAL STIMULATION

Reinterpreting physical violence: outcome of intense stimulation–seeking behavior [letter] Mawson AR. **Acad Emerg Med** 1999 Aug;6(8):863–5 (12 ref.)
[Stretch-activated Ca(2+)-permeable channel] Sokabe M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1628–35 (39 ref.) **(Jpn)**

ADVERSE EFFECTS

[Round Table: urticaria with a physical cause] Martorell A, et al. **Allergol Immunopathol (Madr)** 1999 Mar–Apr; 27(2):85–96 (39 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Sensory deprivation and chronic pain: a review of the literature. Schofield P, et al. **Disabil Rehabil** 1998 Oct; 20(10):357–66 (75 ref.)

PHYSICAL THERAPY

see related
NATUROPATHY

Pragmatic physical therapy in Parkinson's disease: any scientific basis? Hildick-Smith M. **Adv Neurol** 1999; 80:561–4 (33 ref.)
The role of physical therapy in improving physical functioning of renal patients. Pianta TF. **Adv Ren Replace Ther** 1999 Apr;6(2):149–58 (17 ref.)
Who needs chest physiotherapy? Moving from anecdote to evidence. Wallis C, et al. **Arch Dis Child** 1999 Apr; 80(4):393–7 (49 ref.)
Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Dougados M, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):717–36 (56 ref.)
Treatment for lymphedema of the arm—the Casley-Smith method: a noninvasive method produces continued reduction. Casley-Smith JR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2843–60 (55 ref.)
The effectiveness of predischarge home assessment visits: a systematic review. Patterson CJ, et al. **Clin Rehabil** 1999 Apr;13(2):101–4 (14 ref.)
Exercise and physical therapy in elderly, more severely incapacitated patients in cardiac rehabilitation. Mathes P. **Coron Artery Dis** 1999;10(1):33–6 (43 ref.)
Physiotherapy and bronchial mucus transport. van der Schans CP, et al. **Eur Respir J** 1999 Jun;13(6):1477–86 (121 ref.)
Physiotherapy for the prevention of articular contraction in haemophilia. Buzzard BM. **Haemophilia** 1999 Mar;5 Suppl 1:10–5 (29 ref.)
Physical therapy after hand injuries. Michlovitz S. **Hand Clin** 1999 May;15(2):261–73, viii (33 ref.)
Medical treatment of Parkinson's disease. Fahn S. **J Neurol** 1998 Nov;245(11 Suppl 3):P15–24 (23 ref.)
Nonoperative treatment for patellofemoral pain. Brody LT, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):336–44 (71 ref.)
The biomechanics of the patellofemoral joint. Grelsamer RP, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):286–98 (91 ref.)
Rehabilitation of patellofemoral joint disorders: a critical review. Powers CM. **J Orthop Sports Phys Ther** 1998 Nov; 28(5):345–54 (67 ref.)
Patellofemoral disorders: a classification system and clinical guidelines for nonoperative rehabilitation. Wilk KE, et al. **J Orthop Sports Phys Ther** 1998 Nov;28(5):307–22 (139 ref.)
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):951–4 (12 ref.)
Nerve trunk pain: physical diagnosis and treatment. Hall TM, et al. **Man Ther** 1999 May;4(2):63–73 (62 ref.)
Is there a role for transversus abdominis in lumbo-pelvic stability? Hodges PW. **Man Ther** 1999 May;4(2):74–86 (82 ref.)
Positive expiratory pressure in the physiotherapeutic management of primary ciliary dyskinesia in paediatric age. Gremmo ML, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):255–7 (23 ref.)
Rehabilitation in neuromuscular disorders and thoracic wall deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Aug;53(4):415–8 (26 ref.)
Children undergoing treatment with botulinum toxin: the role of the physical therapist. Leach J. **Muscle Nerve Suppl** 1997; 6:S194–207 (61 ref.)
Physical therapy: exercises and the modalities: when, what, and Why? Nordin M, et al. **Neurol Clin** 1999 Feb; 17(1):75–89 (46 ref.)
Physical and occupational therapy in the treatment of patients with multiple sclerosis. LaBan MM, et al. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):603–14, vii (31 ref.)
Physical therapists' perception of patients' pain and its effect on management. Askew R, et al. **Physiother Res Int** 1998; 3(1):37–57 (28 ref.)
The role of physical therapy and physical modalities in pain management. Minor MA, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):233–48, viii (82 ref.)
Physiotherapy in muscular dystrophy. Kroksmark AK. **Scand J Rehabil Med Suppl** 1999;39:65–8 (11 ref.)
The development of physiotherapeutic intervention with the head injured patient. Spence C. **Ulster Med J** 1998 Jun; 67 Suppl 1:56–62 (21 ref.)
Physical therapy for the equine back. Bromiley MW. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):223–46 (57 ref.)
[Physiotherapeutic possibilities in the treatment of postpolio syndrome] Bocker B, et al. **Dtsch Med Wochenschr** 1999 Mar 19;124(11):327–31 (24 ref.) **(Ger)**
[Management and after-care of extensor tendon injuries of the hand] Partecke BD, et al. **Unfallchirurg** 1998 Nov; 101(11):807–12 (18 ref.) (Eng. Abstr.) **(Ger)**
[Diabetes mellitus and physical medicine] Doering TJ, et al. **Z Arztl Fortbild Qualitatssich** 1998 Sep;92(7):485–90 (15 ref.) (Eng. Abstr.) **(Ger)**
[Physical modalities for arthritis] Shimada T. **Ryumachi** 1998 Aug;38(4):631–9 (21 ref.) **(Jpn)**
[Is exercise therapy and manipulation effective in low back pain?] Brox JI, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2042–50 (75 ref.) (Eng. Abstr.) **(Nor)**
[Physiotherapy as manual therapy] Torstensen TA, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2059–63 (57 ref.) (Eng. Abstr.) **(Nor)**
[The modulating effect of physical factors during their action on immunocompetent organs] Babov KD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jan–Feb;(1):41–4 (56 ref.) **(Rus)**
[Physiotherapy in the rehabilitation of patients with chronic gastroduodenitis] Filimonov RM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Jul–Aug; (4):48–50 (23 ref.) **(Rus)**
[The combined use of antibiotics, immunomodulators and physiotherapy in urogenital infections in men] Titova TM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jan–Feb; (1):45–7 (49 ref.) **(Rus)**
[Hemo-physiotherapy: its basis and the outlook for its use and study] Ulashchik VS. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 May–Jun;(3):3–9 (42 ref.) (Eng. Abstr.) **(Rus)**
[Prescribed exercise can help the patient to change his habits] Hellénius ML, et al. **Lakartidningen** 1999 Jul 28; 96(30–31):3343–6 (34 ref.) **(Swe)**

ADVERSE EFFECTS

[Supplementary history and occupational dermatologic evaluation of medical bath workers, masseurs, and physical therapists] Wessbecher R, et al. **Hautarzt** 1998 Dec; 49(12):912–9 (64 ref.) (Eng. Abstr.) **(Ger)**

CONTRAINDICATIONS

[The effect of physical factors on the action of other therapeutic means (the problem of therapeutic interference)] Ulashchik VS. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 May–Jun; (3):46–9 (62 ref.) **(Rus)**

EDUCATION

The Vodder School: the Vodder method. Kasseroller RG. **Cancer** 1998 Dec 15;83(12 Suppl American):2840–2 (8 ref.)
Complete decongestive physiotherapy and the Lerner Lymphedema Services Academy of Lymphatic Studies (the Lerner School). Lerner R. **Cancer** 1998 Dec 15;83(12 Suppl American):2861–3 (13 ref.)

INSTRUMENTATION

[Physical therapy in prevention and treatment of osteoporosis] Häuselmann HJ, et al. **Ther Umsch** 1998 Nov; 55(11):724–30 (18 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Rehabilitation in children with juvenile chronic arthritis. Häfner R, et al. **Baillieres Clin Rheumatol** 1998 May; 12(2):329–61 (19 ref.)
The Vodder School: the Vodder method. Kasseroller RG. **Cancer** 1998 Dec 15;83(12 Suppl American):2840–2 (8 ref.)
Complete decongestive physiotherapy and the Lerner Lymphedema Services Academy of Lymphatic Studies (the Lerner School). Lerner R. **Cancer** 1998 Dec 15;83(12 Suppl American):2861–3 (13 ref.)
American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Rockson SG, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2882–5 (8 ref.)
Physical and occupational therapy. Case-Smith J, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):323–45 (72 ref.)
Neuropsychology and the relearning of motor skills following stroke. Hochstenbach J, et al. **Int J Rehabil Res** 1999 Mar;22(1):11–9 (57 ref.)
The radioulnar joints and forearm axis: therapist's commentary. Contesti LA. **J Hand Ther** 1999 Apr–Jun; 12(2):85–91 (6 ref.)
The carpus: therapist's commentary. Feinberg NR. **J Hand Ther** 1999 Apr–Jun;12(2):108–10 (16 ref.)
Treatment of congenital differences of the upper extremity: therapist's commentary. Fuller M. **J Hand Ther** 1999 Apr–Jun;12(2):174–7 (13 ref.)
Arthroplasty of the hand and wrist: therapist's commentary [comment] Michlovitz S. **J Hand Ther** 1999 Apr–Jun; 12(2):133–4 (8 ref.) Comment on: J Hand Ther 1999 Apr–Jun;12(2):123–32.
Bone and joint injury in the hand: therapist's commentary. Russell CR. **J Hand Ther** 1999 Apr–Jun;12(2):121–2 (3 ref.)
Treatment of flexor tendon injuries: therapist's commentary. Steelman P. **J Hand Ther** 1999 Apr–Jun;12(2):149–51 (12 ref.)
Vascular disorders of the hand: therapist's commentary. Talley M. **J Hand Ther** 1999 Apr–Jun;12(2):160–3 (42 ref.)
Management of fractures of the distal radius: therapist's commentary. Weinstock TB. **J Hand Ther** 1999 Apr–Jun; 12(2):99–102 (9 ref.)
Thoracic outlet syndrome. Rayan GM. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):440–51 (55 ref.)
Physical therapist management of lymphedema following treatment for breast cancer: a critical review of its effectiveness. Megens A, et al. **Phys Ther** 1998 Dec; 78(12):1302–11 (39 ref.)
Maximizing functional capacity. Pulmonary rehabilitation and adjunctive measures. Resnikoff PM, et al. **Respir Care Clin N Am** 1998 Sep;4(3):475–92 (91 ref.)
[Oscillating physical therapy in bronchial diseases—rheologic and anti-inflammatory effect] App EM, et al. **Pneumologie** 1999 Jul;53(7):348–59 (73 ref.) **(Ger)**

PHYSICALLY CHALLENGED see **DISABLED PERSONS**

PHYSICALLY HANDICAPPED see **DISABLED PERSONS**

PHYSICIAN ASSISTANTS

Description of the role of nonphysician practitioners in radiation oncology. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):163–9 (17 ref.)
Non-physician practitioners in radiation oncology: advanced practice nurses and physician assistants. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):255–63 (14 ref.)

ORGANIZATION & ADMINISTRATION

A challenge for clinical nurses: a new nursing role [see comments] Balogh D, et al. **Heart Lung** 1998 Nov–Dec; 27(6):355–9 (11 ref.) Comment in: Heart Lung 1999 May–Jun;28(3):226.

PHYSICIAN-ASSISTED SUICIDE see **SUICIDE, ASSISTED**

PHYSICIAN EXECUTIVES

LEGISLATION & JURISPRUDENCE

Potential liabilities of medical directors for actions of EMTs. Hall SA. **Prehosp Emerg Care** 1998 Jan–Mar;2(1):76–80 (43 ref.)

PSYCHOLOGY

A job-satisfaction measure for internal medicine residency program directors. Beasley BW, et al. **Acad Med** 1999 Mar; 74(3):263–70 (14 ref.)

PHYSICIAN-HOSPITAL ORGANIZATIONS see **HOSPITAL-PHYSICIAN JOINT VENTURES**

PHYSICIAN-HOSPITAL RELATIONS see **HOSPITAL-PHYSICIAN RELATIONS**

PHYSICIAN IMPAIRMENT

Impaired doctors. The modern approach of medical boards. Breen KJ, et al. **Aust Fam Physician** 1998 Nov; 27(11):1005–8 (0 ref.)

PHYSICIAN INCENTIVE PLANS

ECONOMICS

Physicians' financial incentives in five dimensions: a conceptual framework for HMO managers. Magnus SA.

PHYSICIAN INCENTIVE PLANS

Health Care Manage Rev 1999 Winter;24(1):57–72 (70 ref.)

ORGANIZATION & ADMINISTRATION

The utility of decision support, clinical guidelines, and financial incentives as tools to achieve improved clinical performance. Goldfarb S. **Jt Comm J Qual Improv** 1999 Mar;25(3):137–44 (19 ref.)

PHYSICIAN-NURSE RELATIONS

A conceptual model of collaborative nurse-physician interactions: the management of traditional influences and personal tendencies. Corser WD. **Sch Inq Nurs Pract** 1998 Winter;12(4):325–41; discussion 343–6 (113 ref.)

PHYSICIAN-PATIENT RELATIONS

see related
TRUTH DISCLOSURE

Toward creating physician-healers: fostering medical students' self-awareness, personal growth, and well-being. Novack DH, et al. **Acad Med** 1999 May;74(5):516–20 (51 ref.)

Strategic risk management: reducing malpractice claims through more effective patient-doctor communication. Virshup BB, et al. **Am J Med Qual** 1999 Jul–Aug; 14(4):153–9 (26 ref.)

Improving adherence to hormone replacement therapy with effective patient-physician communication. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):337–40 (15 ref.)

Discussing palliative care with patients. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians–American Society of Internal Medicine. Lo B, et al. **Ann Intern Med** 1999 May 4;130(9):744–9 (27 ref.)

Are physicians aware of what patients know about what physicians know? [editorial] Sabbioni ME, et al. **Ann Oncol** 1999 Jan;10(1):11–2 (8 ref.)

Somatization reconsidered: incorporating the patient's experience of illness [see comments] Epstein RM, et al. **Arch Intern Med** 1999 Feb 8;159(3):215–22 (86 ref.) Comment in: Arch Intern Med 1999 Aug 9–23;159(15):1813–4.

Strategies for dealing with men in general practice. Burkitt G. **Aust Fam Physician** 1999 Aug;28(8):773–4 (4 ref.)

Patients' preferences for participation in clinical decision making: a review of published surveys. Benbassat J, et al. **Behav Med** 1998 Summer;24(2):81–8 (53 ref.)

Breaking bad news. 3: Encouraging the adoption of best practices. Campbell EM, et al. **Behav Med** 1998 Summer; 24(2):73–80 (47 ref.)

Breaking bad news. 1: Current best advice for clinicians. Girgis A, et al. **Behav Med** 1998 Summer;24(2):53–9 (42 ref.)

Breaking bad news. 2: What evidence is available to guide clinicians? Walsh RA, et al. **Behav Med** 1998 Summer; 24(2):61–72 (65 ref.)

Doctor-patient relationships in primary care. Doctor, help! My child has cancer. **BMJ** 1999 Aug 28;319(7209):554–6 (0 ref.)

Narrative based medicine: stories we hear and stories we tell: analysing talk in clinical practice. Elwyn G, et al. **BMJ** 1999 Jan 16;318(7177):186–8 (31 ref.)

Narrative based medicine: why study narrative? Greenhalgh T, et al. **BMJ** 1999 Jan 2;318(7175):48–50 (18 ref.)

Narrative based medicine: a narrative approach to mental health in general practice. Launer J. **BMJ** 1999 Jan 9; 318(7176):117–9 (21 ref.)

The rise of doctor-patient working groups. Williamson C. **BMJ** 1998 Nov 14;317(7169):1374–7 (31 ref.)

Use of formal and informal care among people with prolonged fatigue: a review of the literature. Elliott H. **Br J Gen Pract** 1999 Feb;49(439):131–4 (62 ref.)

Evidence on patient-doctor communication. Stewart M, et al. **Cancer Prev Control** 1999 Feb;3(1):25–30 (67 ref.)

Failure in communication. The common denominator. Webb MS. **Clin Plast Surg** 1999 Jan;26(1):41–51, vi (48 ref.)

Mental retardation and decision making: balancing autonomy and protection. Van Hoof TJ, et al. **Conn Med** 1998 Aug; 62(8):455–60 (23 ref.)

Clinician/patient interaction: communicating the benefits and risks of oral contraceptives. Davis A, et al. **Contraception** 1999 Jan;59(1 Suppl):39S–42S (22 ref.)

How do we know? Reflections on qualitative research in diabetes [editorial; comment] Anderson RM, et al. **Diabetes Care** 1998 Sep;21(9):1387–8 (7 ref.) Comment on: Diabetes Care 1998 Sep;21(9):1391–6.

The general approach to the difficult patient. Adams J, et al. **Emerg Med Clin North Am** 1998 Nov;16(4):689–700, v (23 ref.)

Communication and conflict resolution in emergency medicine. O'Mara K. **Emerg Med Clin North Am** 1999 May; 17(2):451–9, xii (36 ref.)

The difficult patient. Simon JR, et al. **Emerg Med Clin North Am** 1999 May;17(2):353–70, x (22 ref.)

Medical ethics. The patient-doctor relationship. Lachowsky M. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):81–3 (5 ref.)

Thoughts on the patient-doctor relationship in obstetrics and gynecology. Ludwig H. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):85–91 (59 ref.)

Clinical and cultural issues in caring for deaf people. Barnett S. **Fam Med** 1999 Jan;31(1):17–22 (38 ref.)

A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Kenny T, et al. **Fam Pract** 1998 Oct;15(5):471–9 (96 ref.)

Doctor-patient communication and patient satisfaction: a review. Williams S, et al. **Fam Pract** 1998 Oct;15(5):480–92 (44 ref.)

Doctors' diagnoses and patients' perceptions. Lessons from chronic fatigue syndrome [editorial] Sharpe M. **Gen Hosp Psychiatry** 1998 Nov;20(6):335–8 (27 ref.)

Professional competence in medicine. Southgate L. **Hosp Med** 1999 Mar;60(3):203–5 (17 ref.)

Salvaging the history, physical examination and doctor-patient relationship in a technological cardiology environment. Clement DL, et al. **J Am Coll Cardiol** 1999 Mar;33(3):892–3 (0 ref.)

Practitioner review: communicating with hospitalised children: review and application of research pertaining to children's understanding of health and illness. Rushforth H. **J Child Psychol Psychiatry** 1999 Jul;40(5):683–91 (55 ref.)

Emotions, ethics, and decisions in primary care. Connelly J. **J Clin Ethics** 1998 Fall;9(3):225–34 (36 ref.)

Improving physicians' relationships with patients. Clark W, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S45–50 (46 ref.)

The doctor-patient relationship: challenges, opportunities, and strategies. Dorr Goold S, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S26–33 (51 ref.)

Time and the patient-physician relationship. Dugdale DC, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S34–40 (43 ref.)

Differences in clinical communication by gender. Elderkin-Thompson V, et al. **J Gen Intern Med** 1999 Feb; 14(2):112–21 (116 ref.)

Defining educational priorities in managed care: a symposium overview. Kerr EA, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S1–5 (31 ref.)

Culturally competent professionals in therapeutic alliances enhance patient compliance [editorial] Langer N. **J Health Care Poor Underserved** 1999 Feb;10(1):19–26 (22 ref.)

The functions and limitations of trust in the provision of medical care [see comments] Mechanic D. **J Health Polit Policy Law** 1998 Aug;23(4):661–86 (53 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687–95.

The scope for the involvement of patients in their consultations with health professionals: rights, responsibilities and preferences of patients. Buetow S. **J Med Ethics** 1998 Aug;24(4):243–7 (53 ref.)

Yes, male physicians should care for adolescent females. Hewitt G, et al. **J Pediatr Adolesc Gynecol** 1999 May; 12(2):100–2 (9 ref.)

Why physician gender matters in shaping the physician-patient relationship. Roter DL, et al. **J Womens Health** 1998 Nov;7(9):1093–7 (24 ref.)

The hospital doctor in legislation and medical deontology: tension between profession and institution. Schutyser K. **Med Law** 1998;17(4):519–44 (57 ref.)

Discussing disease progression and end-of-life decisions. Baile WF, et al. **Oncology (Huntingt)** 1999 Jul; 13(7):1021–31; discussion 1031–6, 1038 (57 ref.)

Approach to the patient. Parsons DP, et al. **Prim Care** 1999 Mar;26(1):15–34 (6 ref.)

Substance use disorders. Difficulties in diagnoses. Ross SM, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):803–28 (37 ref.)

Therapist-patient sex. From boundary violations to sexual misconduct. Simon RI. **Psychiatr Clin North Am** 1999 Mar; 22(1):31–47 (54 ref.)

Cosmetic surgery: surgical tools--psychosocial goals. Grossbart TA, et al. **Semin Cutan Med Surg** 1999 Jun; 18(2):101–11 (32 ref.)

Euthanasia and physician-assisted suicide. Gittelman DK. **South Med J** 1999 Apr;92(4):369–74 (29 ref.)

Ethical considerations in psychotherapeutic systems. Bergsma J, et al. **Theor Med Bioeth** 1998 Aug;19(4):371–81 (21 ref.)

Whose consent is it anyway? A poststructuralist framing of the person in medical decision-making. Marta J. **Theor Med Bioeth** 1998 Aug;19(4):353–70 (33 ref.)

Respect for patients should dominate health care decisions [comment] Alpers A. **West J Med** 1999 May;170(5):291–2 (11 ref.) Comment on: West J Med 1999 May;170(5):287–90.

Treating the developmentally disabled. Doostan D, et al. **West J Med** 1999 Aug;171(2):92–6 (13 ref.)

Medical futility [editorial] Weijer C. **West J Med** 1999 May; 170(5):254 (6 ref.)

[Diagnostic disclosure. Psychological impact and practical aspects] Baillet F, et al. **Encephale** 1998 Dec;24 Spec No 2:35–41 (19 ref.) **(Fre)**

[Patient information and medical responsibility] Chartier Y. **Prog Urol** 1998 Sep;8(4):487–90; discussion 490–1 (15 ref.) (Eng. Abstr.) **(Fre)**

[Is there an essence of medicine?] Weber JC. **Rev Med Interne** 1998 Dec;19(12):924–7 (15 ref.) (Eng. Abstr.) **(Fre)**

[Violence our medical trauma in specialized multidisciplinary consultation] Albrecht E, et al. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):280–4 (4 ref.) (Eng. Abstr.) **(Fre)**

[Informing the patient--but how? Ethics and theory of patient information] Maio G. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jul; 34(7):396–401 (27 ref.) (Eng. Abstr.) **(Ger)**

[Current status of cancer therapy. 5. Informing patients the true nature of their illnesses and palliative treatment] Kashiwagi T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1772–6 (14 ref.) **(Jpn)**

[Patient rights and the physician-patient relationship] Førde R. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1467–9 (30 ref.) (Eng. Abstr.) **(Nor)**

[Justice--the most demanding of virtues] Gulbrandsen P. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1149–53 (29 ref.) (Eng. Abstr.) **(Nor)**

["The consultation lab"--training clinical communication] Larsen JH, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10; 119(1):52–5 (18 ref.) (Eng. Abstr.) **(Nor)**

[Wisdom--knowledge, the patient and the physician] Vestbø E. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1146–8 (17 ref.) (Eng. Abstr.) **(Nor)**

[Chemical tests during a real time physician-patient interaction--the concept and practical problems resulting from its realization] Naskalski JW. **Przegl Lek** 1998; 55(7–8):388–92 (23 ref.) (Eng. Abstr.) **(Pol)**

[Difficulties in the physician-patient relationship in somaticizers (I). Patient expectations] Garcia-Campayo J, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):102–5 (37 ref.) **(Spa)**

[The human language of medicine. Physical expression of empathy added to diagnosis promotes understanding] Rudebeck CE. **Lakartidningen** 1998 Oct 7;95(41):4500, 4503–4, 4507 (20 ref.) (Eng. Abstr.) **(Swe)**

PHYSICIAN REFUSAL TO TREAT see **REFUSAL TO TREAT**

PHYSICIAN SHORTAGE AREA see **MEDICALLY UNDERSERVED AREA**

PHYSICIANS

How can physicians keep up-to-date? Laine C, et al. **Annu Rev Med** 1999;50:99–110 (65 ref.)

A review of the incorporation of complementary and alternative medicine by mainstream physicians. Astin JA, et al. **Arch Intern Med** 1998 Nov 23;158(21):2303–10 (57 ref.)

Predictors of success in medicine. Reede JY. **Clin Orthop** 1999 May;(362):72–7 (64 ref.)

Prescription to over-the-counter switches: the physician perspective. Byrns PJ. **Clin Ther** 1998;20 Suppl C:C118–23 (19 ref.)

Who cares? Who cures? The ongoing debate in the provision of health care. Baumann AO, et al. **J Adv Nurs** 1998 Nov; 28(5):1040–5 (24 ref.)

Nutrient Intake Report: a coordination of patient dietary assessment between physicians and registered dietitians. Olendzki BC, et al. **J Am Diet Assoc** 1998 Oct; 98(10):1159–62 (20 ref.)

A surgeon's response to the intersex controversy. Schober JM. **J Clin Ethics** 1998 Winter;9(4):393–7 (12 ref.)

Clinical documentation: the handheld computer as a survival tool. Wofford MM, et al. **MD Comput** 1998 Nov-Dec; 15(6):352–4, 356, 358 (30 ref.)

American medical residency programs: an analysis of New York's "Bell" regulations and the training of physicians. Tobias M. **Med Health R I** 1998 Sep;81(9):284–8 (19 ref.)

[Internet for physicians: a tool for today and tomorrow] Boyer C, et al. **Rev Med Suisse Romande** 1999 Feb; 119(2):137–44 (14 ref.) (Eng. Abstr.) **(Fre)**

[Is there a physician on board? (see comments)] Andersen HT. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3630–2 (6 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1998 Nov 20;118(28):4416. **(Nor)**

[Without shame, no moral. How physicians could commit murder] Riksen KI. **Tidsskr Nor Laegeforen** 1999 Mar 20; 119(8):1096–9 (22 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Truth and consequences. Foster GS. **Acad Med** 1998 Dec; 73(12):1226–7 (1 ref.)

Legal implications of clinical practice guidelines [editorial; comment] Dwyer P. **Med J Aust** 1998 Sep 21;169(6):292–3 (12 ref.) Comment on: Med J Aust 1998 Sep 21;169(6):330–3.

ORGANIZATION & ADMINISTRATION

Physician unionization. The impact on the medical profession. Phan C. **J Leg Med** 1999 Mar;20(1):115–40 (203 ref.)

PSYCHOLOGY

The doctor's troubled marriage. Harari E. **Aust Fam Physician** 1998 Nov;27(11):999–1004 (16 ref.)

Barriers to the doctor as patient role. A cultural construct. Rogers T. **Aust Fam Physician** 1998 Nov;27(11):1009–13 (21 ref.)

European life-support questionnaire [editorial; comment] Leonard C, et al. **Crit Care Med** 1999 Aug;27(8):1686–7

(9 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1626–33.
The psychology of human error [see comments] Green R. **Eur J Anaesthesiol** 1999 Mar;16(3):148–55 (59 ref.) Comment in: Eur J Anaesthesiol 1999 Mar;16(3):147.
Bioethics of the refusal of blood by Jehovah's Witnesses: Part 1. Should bioethical deliberation consider dissidents' views? [published erratum appears in J Med Ethics 1998 Dec;24(6):375] Muramoto O. **J Med Ethics** 1998 Aug; 24(4):223–30 (40 ref.)
One size does not fit all: questions to answer before intervening to change physician behavior. Poses RM. **Jt Comm J Qual Improv** 1999 Sep;25(9):486–95 (78 ref.)
Legal implications of clinical practice guidelines [editorial; comment] Dwyer P. **Med J Aust** 1998 Sep 21;169(6):292–3 (12 ref.) Comment on: Med J Aust 1998 Sep 21;169(6):330–3.
Act first and look up the law afterward?: medical malpractice and the ethics of defensive medicine. De Ville K. **Theor Med Bioeth** 1998 Dec;19(6):569–89 (96 ref.)
[The Emperor's New Clothes syndrome. Description of a new epidemic] Born JD. **Rev Med Liege** 1998 Jul; 53(7):393–8 (9 ref.) (Eng. Abstr.) **(Fre)**
[Bioethics of medical practitioner] Dukov LG, et al. **Klin Med (Mosk)** 1998;76(8):46–8 (8 ref.) **(Rus)**
[Debaters in Läkartidningen do not agree with the students about active euthanasia] Ahvenainen J, et al. **Lakartidningen** 1999 Apr 7;96(14):1731–4 (47 ref.) **(Swe)**

STANDARDS

Professionalism reconsidered. Priorities for physicians. Halvorsen JG. **Arch Fam Med** 1999 Mar–Apr;8(2):173–6 (37 ref.)

STATISTICS & NUMERICAL DATA

Violence towards doctors: prevalence and effects. Zahid MA, et al. **Hosp Med** 1999 Jun;60(6):414–8 (18 ref.)

SUPPLY & DISTRIBUTION

Impact of minority physicians on health care. Thurmond VB, et al. **South Med J** 1998 Nov;91(11):1009–13 (25 ref.)

TRENDS

[The struggle with the ego: the assessment center in the selection of physicians–in–chief] Fritz T. **Chirurg** 1999 Apr; 70(4):493–6 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSICIANS' ASSISTANTS see **PHYSICIAN ASSISTANTS**

PHYSICIANS' EXTENDERS see **PHYSICIAN ASSISTANTS**

PHYSICIANS, FAMILY

Successful immunotherapy. A partnership between consultant and general practitioner. Katelaris CH. **Aust Fam Physician** 1998 Aug;27(8):687–92 (9 ref.)
Intravascular radiographic contrast media: issues for family physicians. Hash RB. **J Am Board Fam Pract** 1999 Jan–Feb; 12(1):32–42 (76 ref.)
The interaction between family physicians and palliative care consultants in the delivery of palliative care: clinical and educational issues. Brenneis C, et al. **J Palliat Care** 1998 Autumn;14(3):58–61 (21 ref.)
[Diagnosis and differential diagnosis of bronchial asthma and chronic obstructive bronchitis as see by a general practitioner] Rakov AL, et al. **Klin Med (Mosk)** 1999; 77(1):54–7 (0 ref.) **(Rus)**

EDUCATION

Sending a policy signal: state legislatures, medical schools, and primary care mandates. Weissert CS, et al. **J Health Polit Policy Law** 1998 Oct;23(5):743–70 (39 ref.)

PSYCHOLOGY

Databases and evidence–based medicine in general practice [editorial; comment] [see comments] Van der Weyden MB. **Med J Aust** 1999 Jan 18;170(2):52–3 (14 ref.) Comment on: Med J Aust 1999 Jan 18;170(2):56–8. Comment in: Med J Aust 1999 Apr 19;170(8):393. Comment in: Med J Aust 1999 Apr 19;170(8):393–4.
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point–of–view of general physicians] Samuelson M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:147–52 (42 ref.) **(Fre)**

STANDARDS

Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. Hecht FM, et al. **Ann Intern Med** 1999 Jul 20;131(2):136–43 (63 ref.)
Evaluating without fear. Kaprielian VS, et al. **Fam Med** 1999 Mar;31(3):155–6 (0 ref.)

SUPPLY & DISTRIBUTION

Sending a policy signal: state legislatures, medical schools, and primary care mandates. Weissert CS, et al. **J Health Polit Policy Law** 1998 Oct;23(5):743–70 (39 ref.)

PHYSICIANS, JUNIOR see **MEDICAL STAFF, HOSPITAL**

PHYSICIANS' OFFICES

[White coat hypertension] Soma J, et al. **Tidsskr Nor Laegeforen** 1999 Feb 20;119(5):667–70 (55 ref.) (Eng. Abstr.) **(Nor)**

STANDARDS

Disinfection of tonometers and contact lenses in the office setting: are current techniques adequate? Smith CA, et al. **Am J Ophthalmol** 1999 Jan;127(1):77–84 (58 ref.)

PHYSICIAN'S PRACTICE PATTERNS

Practice parameters for the management of colonic cancer I: surgical issues. Recommendations of the Colorectal Surgical Society of Australia. Moore J, et al. **Aust N Z J Surg** 1999 Jun;69(6):415–21 (93 ref.)
Spots and clots – leave them or treat them? Why and how to treat. Jensen DM. **Can J Gastroenterol** 1999 Jun; 13(5):413–5 (9 ref.)
The use of psychotropic medication in preschoolers: some recent developments. Minde K. **Can J Psychiatry** 1998 Aug;43(6):571–5 (22 ref.)
Using state and federal claims data to evaluate the patterns and costs of cancer care. Desch CE, et al. **Cancer Treat Res** 1998;97:53–69 (48 ref.)
Breast cancer practice patterns at VA hospitals: implications for future research. Hynes DM, et al. **Cancer Treat Res** 1998;97:149–58 (28 ref.)
Ambulatory obstetric management. Cohen AW. **Clin Obstet Gynecol** 1998 Sep;41(3):481–90 (18 ref.)
Failure to practice evidence–based medicine: why do physicians not treat patients with heart failure with angiotensin–converting enzyme inhibitors? McMurray JJ. **Eur Heart J** 1998 Oct;19 Suppl L:L15–21 (30 ref.)
Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice. Cohn JN. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S38–40 (14 ref.)
The small polyp at flexible sigmoidoscopy: an historical perspective on why practices still vary. Rex DK. **J Clin Gastroenterol** 1999 Jan;28(1):19–22 (27 ref.)
Physician–family partnerships: the adaptive practice model [see comments] Feldman HM, et al. **J Dev Behav Pediatr** 1999 Apr;20(2):111–6 (29 ref.) Comment in: J Dev Behav Pediatr 1999 Apr;20(2):117–9. Comment in: J Dev Behav Pediatr 1999 Apr;20(2):120–2. Comment in: J Dev Behav Pediatr 1999 Apr;20(2):123–4.
Mandatory practice self–appraisal: moving towards outcomes based continuing education. Donen N. **J Eval Clin Pract** 1999 Aug;5(3):297–303 (49 ref.)
The patient–provider relationship: opportunities as well as problems. Lo B. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S41–4 (5 ref.)
BRCA–associated cancer risk: molecular biology and clinical practice. van Golen K, et al. **J Lab Clin Med** 1999 Jul; 134(1):11–8 (80 ref.)
Clinical practices in the management of new–onset, uncomplicated, low back workers' compensation disability claims. Tacci JA, et al. **J Occup Environ Med** 1999 May; 41(5):397–404 (37 ref.)
Herbalism in Minnesota. What should physicians know? Plotnikoff GA, et al. **Minn Med** 1999 May;82(5):12–26 (0 ref.)
Quality of life assessment in clinical practice. Cramer JA. **Neurology** 1999;53(5 Suppl 2):S49–52 (18 ref.)
[Lumbar puncture headache. Routines of Danish hospital departments compared with recommendations found in the literature] Winge K, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2368–72 (20 ref.) (Eng. Abstr.) **(Dan)**
[How to detect, diagnose and survey hepatitis C? Biological tests used by the physician in current practice (editorial)] Doffoël M. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):387–9 (7 ref.) **(Fre)**
[Delivery methods for infants of birthweight less than 2500 grams. Description of practices in France. The Obstetricians Sentinel Network A.U.D.I.P.O.G.] Mamelle N. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:269–74 (7 ref.) **(Fre)**
[Does continuing medical education improve the way physicians conduct their practice?] Durieux P, et al. **Presse Med** 1999 Mar 6;28(9):468–72 (35 ref.) (Eng. Abstr.) **(Fre)**
[Gynecologic oncologists and their practice in the U.S.A.] Tsukamoto N. **Gan To Kagaku Ryoho** 1999 Jan;26(1):69–75 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Factors affecting drug prescriptions by the primary care physician] Abánades Herranz JC, et al. **Aten Primaria** 1998 Oct 15;22(6):391–8 (41 ref.) **(Spa)**

LEGISLATION & JURISPRUDENCE

The impact of clinical guidelines and clinical pathways on medical practice: effectiveness and medico–legal aspects. Cheah TS. **Ann Acad Med Singapore** 1998 Jul;27(4):533–9 (37 ref.)
Liability in prescribing choice: the example of the antidepressants [see comments] Beerworth EE, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):560–6 (66 ref.) Comment in: Aust N Z J Psychiatry 1999 Apr;33(2):281–2.
[Practice guidelines for medical treatment from the perspective of health law] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2480–4 (19 ref.) (Eng. Abstr.) **(Dut)**

ORGANIZATION & ADMINISTRATION

The doctor–patient relationship: challenges, opportunities, and strategies. Dorr Goold S, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S26–33 (51 ref.)
Rationale, principles, and educational approaches of organizational transformation. Suchman AL, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S51–7 (18 ref.)

STANDARDS

Science or show business [editorial] MacAuley D. **Br J Sports Med** 1999 Jun;33(3):147–8 (11 ref.)
Ethical and pragmatic issues in the use of psychotropic agents in young children. Jensen PS. **Can J Psychiatry** 1998 Aug; 43(6):585–8 (13 ref.)
The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators. McAlister FA, et al. **J Am Geriatr Soc** 1999 Jul;47(7):811–8 (74 ref.)
Time and the patient–physician relationship. Dugdale DC, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S34–40 (43 ref.)
Clinical practice patterns in implantable rhythm management device therapy: new players and new norms. Saksena S. **Pacing Clin Electrophysiol** 1999 May;22(5):814–5 (11 ref.)
[Practice guidelines for medical treatment from the perspective of health law] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2480–4 (19 ref.) (Eng. Abstr.) **(Dut)**

STATISTICS & NUMERICAL DATA

Implementing preventive services: to what extent can we change provider performance in ambulatory care? A review of the screening, immunization, and counseling literature. Anderson LA, et al. **Ann Behav Med** 1998 Summer;20(3):161–7 (65 ref.)
Management of uterine leiomyosarcoma in Australia. Gard GB, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):93–8 (17 ref.)
Antibiotic–resistant Streptococcus pneumoniae. Implications for medical practice [see comments] Wang EE, et al. **Can Fam Physician** 1998 Sep;44:1881–8 (72 ref.) Comment in: Can Fam Physician 1998 Sep;44:1769–73, 1780–4. Comment in: Can Fam Physician 1998 Nov;44:2375–6.
Incorporating preventive care recommendations into clinical practice: how do we bridge the gap? [editorial; comment] Douketis JD. **CMAJ** 1999 Apr 20;160(8):1171–2 (19 ref.) Comment on: CMAJ 1999 Apr 20;160(8):1137–40.
Methicillin–resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Monnet DL. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):552–9 (100 ref.)
Medication use in nursing homes for elderly people. Furniss L, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):433–9 (61 ref.)
Variation by specialty in the treatment of urinary tract infection in women. Wigton RS, et al. **J Gen Intern Med** 1999 Aug;14(8):491–4 (11 ref.)
Psychotropic drug prescribing: first the good news [editorial; comment] Keks NA, et al. **Med J Aust** 1999 Apr 5; 170(7):293–4 (12 ref.) Comment on: Med J Aust 1999 Apr 5;170(7):299–301.
Medical practice variations: changing the theoretical approach. Westert GP, et al. **Scand J Public Health** 1999 Sep;27(3):173–80 (35 ref.)
[Overprescribing of antibiotics outside the hospital] Sternon J, et al. **Rev Med Brux** 1999 Feb;20(1):43–7 (29 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

The future of allergy practice: a different perspective from another academician [editorial] Slavin RG. **Allergy Asthma Proc** 1999 Jul–Aug;20(4):225–7 (7 ref.)
Concluding thoughts—looking forward. Clancy CM, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S63–4 (14 ref.)
The impact of HIV on a fertility problems clinic. Hargreave TB, et al. **J Reprod Immunol** 1998 Dec;41(1–2):261–70 (21 ref.)
Psychotropic drug prescribing: first the good news [editorial; comment] Keks NA, et al. **Med J Aust** 1999 Apr 5; 170(7):293–4 (12 ref.) Comment on: Med J Aust 1999 Apr 5;170(7):299–301.

PHYSICIAN'S ROLE

Prevention of osteoporotic fractures—should orthopedic surgeons care? Obrant KJ. **Acta Orthop Scand** 1998 Aug; 69(4):333–8 (39 ref.)
Alcohol, health, and the heart: implications for clinicians. Chick J. **Alcohol Alcohol** 1998 Nov–Dec;33(6):576–91 (135 ref.)
Cardiovascular risk profiling in blacks: don't forget the lipids [editorial] Kountz DS, et al. **Am Fam Physician** 1998 Nov 1;58(7):1541–2 (9 ref.)
Home health care [see comments] Montauk SL.

Am Fam Physician 1998 Nov 1;58(7):1608–14 (9 ref.) Comment in: Am Fam Physician 1999 Jul;60(1):53–4.

The obstetrician–gynecologist's role in the practical management of polycystic ovary syndrome. Berga SL. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 2):S109–S113 (28 ref.)

Motor vehicle safety: current concepts and challenges for emergency physicians. Peterson TD, et al. **Ann Emerg Med** 1999 Sep;34(3):384–93 (28 ref.)

Poverty and ill health: physicians can, and should, make a difference. McCally M, et al. **Ann Intern Med** 1998 Nov 1;129(9):726–33 (57 ref.)

Recent advances in the management of cerebrovascular disease: the diminishing role of the surgeon? Stacey R, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):86–9 (15 ref.)

Think HIV: why physicians should lower their threshold for HIV testing. Freedberg KA, et al. **Arch Intern Med** 1999 Sep 27;159(17):1994–2000 (69 ref.)

Role of the primary care physician in problems of substance abuse. Weaver MF, et al. **Arch Intern Med** 1999 May 10; 159(9):913–24 (47 ref.)

Musculoskeletal rehabilitation and sports medicine. 4. Miscellaneous sports medicine topics. Smith J, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S68–89 (246 ref.)

Modern radiotherapy. Does the GP have a role? MacLeod C, et al. **Aust Fam Physician** 1999 Feb;28(2):145–50 (39 ref.)

The role of the psychologist in crisis/hostage negotiations. Hatcher C, et al. **Behav Sci Law** 1998 Autumn;16(4):455–72 (72 ref.)

Special perspective an immodest proposal: should treating mental health professionals be barred from testifying about their patients? Shuman DW, et al. **Behav Sci Law** 1998 Autumn;16(4):509–23 (38 ref.)

The role of the psychiatrist in organ transplantation. Klapheke MM. **Bull Menninger Clin** 1999 Winter; 63(1):13–39 (60 ref.)

Taking on diabetes. Family doctors on the front lines of the battle against diabetes [editorial; comment] Harris SB, et al. **Can Fam Physician** 1998 Nov;44:2345–9, 2356–60 (17 ref.) Comment on: Can Fam Physician 1998 Nov;44 :2465–6, 2469–79. **(Eng, Fre)**

Update in genetics: genetic eye diseases and the ophthalmologist. MacDonald IM. **Can J Ophthalmol** 1999 Apr;34(2):69–73 (10 ref.)

Decision-making and the role of surrogacy in withdrawal or withholding of therapy in neonates. Steinberg A. **Clin Perinatol** 1998 Sep;25(3):779–90, xii (42 ref.)

Good Samaritan acts. Daniels S. **Emerg Med Clin North Am** 1999 May;17(2):491–504, xiii (22 ref.)

Law and ethics in emergency medicine. Derse AR. **Emerg Med Clin North Am** 1999 May;17(2):307–25, ix (58 ref.)

Principles of biomedical ethics. Iserson KV. **Emerg Med Clin North Am** 1999 May;17(2):283–306, ix (35 ref.)

Ethical issues of managed care. Larkin GL. **Emerg Med Clin North Am** 1999 May;17(2):397–415 (88 ref.)

Informed consent in the emergency department. Moskop JC. **Emerg Med Clin North Am** 1999 May;17(2):327–40, ix–x (19 ref.)

Advance directives. Sanders AB. **Emerg Med Clin North Am** 1999 May;17(2):519–26, xiii (9 ref.)

Emergency physicians' role in end-of-life care. Schears RM. **Emerg Med Clin North Am** 1999 May;17(2):539–59, xiv (111 ref.)

The difficult patient. Simon JR, et al. **Emerg Med Clin North Am** 1999 May;17(2):353–70, x (22 ref.)

What can we generalize from research on patient education and clinical health promotion to physician counseling on diet? Green LW. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S9–18 (92 ref.)

How to improve the impact of nutrition guidance by general physicians: public health versus individual patient? Worsley A. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S101–7 (56 ref.)

Elder abuse and neglect: the emergency medicine perspective. Allison EJ, et al. **Eur J Emerg Med** 1998 Sep; 5(3):355–63 (32 ref.)

Violence against women: the physician's role. Schmuel E, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 80(2):239–45 (20 ref.)

A systematic review of the literature exploring the role of primary care in genetic services. Emery J, et al. **Fam Pract** 1999 Aug;16(4):426–45 (65 ref.)

Parents and their child's fever: do as I say, not as I do? [editorial; comment] Kai J. **Fam Pract** 1998 Dec;15(6):505–6 (14 ref.) Comment on: Fam Pract 1998 Dec;15(6):513–8.

What is left of professionalism after managed care? Sullivan WM. **Hastings Cent Rep** 1999 Mar–Apr;29(2):7–13 (12 ref.)

ACOG committee opinion. Ethical issues related to expert testimony by obstetricians and gynecologists. Number 217, April 1999 (replaces number 56, October 1987). Committee on Ethics. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jun;65(3):321–2 (3 ref.)

Physicians can make a difference with smokers: evidence-based clinical approaches. Presentation given during the Symposium on Smoking Cessation at the 29th World Conference of the IUATLD/UICTMR and Global Congress on Lung Health, Bangkok, Thailand, 23–26 November 1998. International Union Against Tuberculosis and Lung Disease. Richmond RL. **Int J Tuberc Lung Dis** 1999 Feb;3(2):100–12 (120 ref.)

A multidisciplinary approach to obesity management: the physician's role and team care alternatives. Frank A. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S44–8 (10 ref.)

On and off the playing field: ethics in medicine [editorial] Young RC Jr, et al. **J Health Care Poor Underserved** 1999 May;10(2):178–85 (28 ref.)

The role of the hypertension specialist [see comments] Beevers DG. **J Hum Hypertens** 1998 Oct;12(10):659–61 (16 ref.) Comment in: J Hum Hypertens 1999 Feb;13(2):151–2.

Alternative medicine: what is the physician's role? Altshuler LH. **J Okla State Med Assoc** 1999 May;92(5):219–26 (43 ref.)

The role and education of doctors in the delivery of health care. Chantler C. **Lancet** 1999 Apr 3;353(9159):1178–81 (17 ref.)

Choice and representation in health care [see comments] Emanuel EJ. **Med Care Res Rev** 1999;56 Suppl 1:113–40 (14 ref.) Comment in: Med Care Res Rev 1999 ;56 Suppl 1:141–4.

The physician's role in preventing alcohol and drug abuse. Dube C. **Med Health R I** 1999 Mar;82(3):95–8 (21 ref.)

Introduction to notification, deposition, and court testimony: A primer for the defendant physician. Bounds JA. **Neurol Clin** 1999 May;17(2):335–43 (6 ref.)

Physician role change in managed care: a frontline report. Christian JH. **Occup Med** 1998 Oct–Dec;13(4):851–68, v (0 ref.)

The role of the pediatrician in hearing loss. From detection to connection. Finitzo T, et al. **Pediatr Clin North Am** 1999 Feb;46(1):15–34, ix–x (25 ref.)

Screening, early identification, and office-based intervention with children and youth living in substance-abusing families. Werner MJ, et al. **Pediatrics** 1999 May;103(5 Pt 2):1099–112 (53 ref.)

The role of physiatry in the management of neuromuscular disease. Fowler WM Jr, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):1–8, v (23 ref.)

Companion animal issues and the physician. Hoff GL, et al. **South Med J** 1999 Jul;92(7):651–9 (78 ref.)

Role of the surgeon in managing hypercholesterolemia. Buchwald H. **Surgery** 1999 May;125(5):465–7 (13 ref.)

Denied worker's compensation claims: what physicians can and cannot do [editorial] Drury DL, et al. **WMJ** 1998 Dec; 97(11):20–2 (10 ref.)

[Principles of medical liability and practice in medical imaging] Thibierge M, et al. **J Radiol** 1999 Jul;80(7):701–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Is there an essence of medicine?] Weber JC. **Rev Med Interne** 1998 Dec;19(12):924–7 (15 ref.) (Eng. Abstr.) **(Fre)**

[The provoking dimension of pain. From somatoform pain disorder to a phenomenological approach to illness] Célis-Gennart M. **Rev Med Suisse Romande** 1999 Apr; 119(4):273–80 (17 ref.) **(Fre)**

[The practitioner and reduction of risks] Leckie M. **Rev Med Suisse Romande** 1998 Sep;118(9):739–42 (12 ref.) **(Fre)**

[Anxiety of physicians about addiction therapy] Scholz H. **Wien Med Wochenschr** 1998;148(6):149–51 (5 ref.) (Eng. Abstr.) **(Ger)**

[Adolescents and suicide. Some comments on the role of the pediatrician in researching the motivations for suicidal behaviors] Franchini F, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):251–3 (14 ref.) (Eng. Abstr.) **(Ita)**

[Justice—the most demanding of virtues] Gulbrandsen P. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1149–53 (29 ref.) (Eng. Abstr.) **(Nor)**

[Physicians cannot... A poster on reality orientation in health care (see comments)] Holmen J. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3168–71 (15 ref.) Comment in: Tidsskr Nor Laegeforen 1999 Mar 10;119(7):1000–1. **(Nor)**

[Role of pediatricians in the prevention of adult hypertension] Lagomarsino E. **Rev Med Chil** 1999 Mar;127(3):349–57 (43 ref.) (Eng. Abstr.) **(Spa)**

PHYSICIANS, WOMEN

PSYCHOLOGY

Why physician gender matters in shaping the physician-patient relationship. Roter DL, et al. **J Womens Health** 1998 Nov;7(9):1093–7 (24 ref.)

PHYSICS

Endovascular brachytherapy: physics and technology. Balter S. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):292–8 (0 ref.)

Basic physics for ultrasound-assisted lipoplasty. Zocchi ML. **Clin Plast Surg** 1999 Apr;26(2):209–20; vii (0 ref.)

PHYSIOGNOMY

see related
FACIAL EXPRESSION

PHYSIOLOGIC AVAILABILITY see **BIOLOGICAL AVAILABILITY**

PHYSIOLOGY

Endocrine function and emergency contraception: physiology and society. Anderson M. **Am J Physiol** 1998 Jun;274(6 Pt 2):S46–52 (29 ref.)

1998 ISEK Congress Keynote Lecture: The use of electromyography in applied physiology. International Society of Electrophysiology and Kinesiology. Moritani T, et al. **J Electromyogr Kinesiol** 1998 Dec;8(6):363–81 (100 ref.)

The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621–44 (63 ref.)

HISTORY

"The Queen has been dreadfully shocked": aspects of teaching experimental physiology using animals in Britain, 1876–1986. Tansey EM. **Am J Physiol** 1998 Jun;274(6 Pt 2):S18–33 (26 ref.)

METHODS

Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. Civelli O, et al. **Crit Rev Neurobiol** 1998;12(3):163–76 (104 ref.)

Body composition: overview. Forbes GB. **J Nutr** 1999 Jan; 129(1S Suppl):270S–272S (8 ref.)

[Analysis of physiological function by antisense oligonucleotide system] Takeuchi T, et al. **Nippon Seirigaku Zasshi** 1998;60(10):383–99 (17 ref.) **(Jpn)**

[Use of academician P.K.Anokhin's creative heritage for analysis of mechanisms responsible for homeostasis formation under microgravity] Grigor'ev AI, et al. **Vestn Ross Akad Med Nauk** 1999;(6):11–5 (21 ref.) (Eng. Abstr.) **(Rus)**

[Theory of functional systems and integrative physiology] Sudakov KV. **Vestn Ross Akad Med Nauk** 1999;(6):5–10 (40 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

[Ethic aspects of conducting physiological-hygienic and psychological studies on human subjects as applied to the activities in extreme environments] Genin AM, et al. **Aviakosm Ekolog Med** 1998;32(6):50–5 (4 ref.) (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Fundamental concepts in statistics: elucidation and illustration. Curran-Everett D, et al. **J Appl Physiol** 1998 Sep;85(3):775–86 (51 ref.)

TRENDS

Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Boyce BF, et al. **Lab Invest** 1999 Feb;79(2):83–94 (131 ref.)

[The present situation of physiology in cellular–molecular trends] Fu W, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):285–8 (7 ref.) **(Chi)**

PHYSIOTHERAPY see **PHYSICAL THERAPY**

PHYTAGGLUTININS see **LECTINS**

PHYTANIC ACID

METABOLISM

The metabolism of phytanic acid and pristanic acid in man: a review. Verhoeven NM, et al. **J Inherit Metab Dis** 1998 Oct;21(7):697–728 (173 ref.)

6-PHYTASE

Phytase: sources, preparation and exploitation. Dvořáková J. **Folia Microbiol (Praha)** 1998;43(4):323–38 (200 ref.)

PHYTOCHROME

GENETICS

[Phytochrome-like photoreceptor systems in cyanobacteria] Tretyn A. **Postepy Biochem** 1998;44(2):113–7 (14 ref.) **(Pol)**

METABOLISM

The system of phytochromes: photobiophysics and photobiochemistry in vivo. Sineshchekov VA. **Membr Cell Biol** 1998;12(5):691–720 (110 ref.)

Ca2+ and intracellular signalling in plant cells: a role in phytochrome transduction. Volotovski ID. **Membr Cell Biol** 1998;12(5):721–42 (75 ref.)

PHYSIOLOGY

Photomophogenesis: Phytochrome takes a partner! Whitelam GC, et al. **Curr Biol** 1999 Mar 25;9(6):R225–7 (16 ref.)

The phytochrome family: dissection of functional roles and

signalling pathways among family members. Quail PH. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1399–403 (41 ref.)

Calcium-dependent signal transduction pathways in plants--phytochrome mechanism of action as an example. Tretyn A. **Pol J Pharmacol** 1999 Mar–Apr;51(2):145–51 (45 ref.)

RADIATION EFFECTS

Phytochromes and photomorphogenesis in Arabidopsis. Whitelam GC, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1445–53 (62 ref.)

PHYTOHORMONES see **PLANT GROWTH REGULATORS**

PHYTOMENADIONE see **PHYTONADIONE**

PHYTOMITOGENS see **LECTINS**

PHYTONADIONE

ADVERSE EFFECTS

Oral versus intramuscular phytomenadione: safety and efficacy compared. von Kries R. **Drug Saf** 1999 Jul; 21(1):1–6 (33 ref.)

THERAPEUTIC USE

Oral versus intramuscular phytomenadione: safety and efficacy compared. von Kries R. **Drug Saf** 1999 Jul; 21(1):1–6 (33 ref.)

PHYTOPHAGINEAE see **PLANT VIRUSES**

PHYTOREOVIRUS see **REOVIRIDAE**

PHYTOSTEROLS

CHEMISTRY

[Steroidal glycoalkaloids from the Solanaceae family] Zimowski J. **Postepy Biochem** 1998;44(3):254–62 (72 ref.) **(Pol)**

METABOLISM

Enzymology of phytosterol transformations. Nes WD, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):81–93 (40 ref.)

PHYTOTHERAPY see **MEDICINE, HERBAL**

PI-3 KINASE see **1-PHOSPHATIDYLINOSITOL 3-KINASE**

PIA MATER

BLOOD SUPPLY

Transumbilical embolization of a congenital dural arteriovenous fistula at the torcular herophili in a neonate. Case report. Komiyama M, et al. **J Neurosurg** 1999 May; 90(5):964–9 (40 ref.)

PATHOLOGY

Management of recurrent pilocytic astrocytoma with leptomeningeal dissemination in childhood. Tamura M, et al. **Childs Nerv Syst** 1998 Nov;14(11):617–22 (19 ref.)

PIAL VEIN see **CEREBRAL VEINS**

PICA

COMPLICATIONS

[Pica in Germany--amylophagia as the etiology of iron deficiency anemia] Menge H, et al. **Z Gastroenterol** 1998 Aug;36(8):635–40 (27 ref.) (Eng. Abstr.) **(Ger)**

PICHIA

A transphyletic anti-infectious control strategy based on the killer phenomenon. Conti S, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):151–61 (61 ref.)

Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. Séguy N, et al. **FEMS Immunol Med Microbiol** 1998 Sep; 22(1–2):145–9 (27 ref.)

PICIBANIL

THERAPEUTIC USE

The past, the present and future of the OK-432 therapy for patients with malignant effusions. Katano M, et al. **Anticancer Res** 1998 Sep–Oct;18(5D):3917–25 (35 ref.)

PICKS DISEASE OF BRAIN see **DEMENTIA**

PICK'S DISEASE OF HEART see **PERICARDITIS, CONSTRICTIVE**

PICODNAVIRUSES see **PARVOVIRIDAE**

PICOLINIC ACIDS

THERAPEUTIC USE

Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives. Cesura AM, et al. **Adv Neurol** 1999;80:521–8 (42 ref.)

High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. McCarty MF. **Med Hypotheses** 1999 May;52(5):401–6 (75 ref.)

PICORNAVIRIDAE

CHEMISTRY

Picornaviruses: epitopes, canyons, and pockets. Smith TJ, et al. **Adv Virus Res** 1999;52:1–23 (71 ref.)

ENZYMOLOGY

The structures of picornaviral proteinases. Seipelt J, et al. **Virus Res** 1999 Aug;62(2):159–68 (60 ref.)

GENETICS

Paradoxes of the replication of picornaviral genomes. Agol VI, et al. **Virus Res** 1999 Aug;62(2):129–47 (170 ref.)

Molecular detection and typing of human picornaviruses. Santti J, et al. **Virus Res** 1999 Aug;62(2):177–83 (36 ref.)

[Genome organization of insect picorna-like viruses] Bando H, et al. **Uirusu** 1998 Jun;48(1):89–96 (41 ref.) **(Jpn)**

IMMUNOLOGY

Picornaviruses: epitopes, canyons, and pockets. Smith TJ, et al. **Adv Virus Res** 1999;52:1–23 (71 ref.)

METABOLISM

Paradoxes of the replication of picornaviral genomes. Agol VI, et al. **Virus Res** 1999 Aug;62(2):129–47 (170 ref.)

PHYSIOLOGY

Intracellular determinants of picornavirus replication. Andino R, et al. **Trends Microbiol** 1999 Feb;7(2):76–82 (61 ref.)

PICORNAVIRIDAE INFECTIONS

Rhinoviruses: important respiratory pathogens. Pitkäranta A, et al. **Ann Med** 1998 Dec;30(6):529–37 (79 ref.)

[Rhinovirus pneumonia] Kasai T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):90–2 (14 ref.) **(Jpn)**

COMPLICATIONS

The role of viral and atypical bacterial pathogens in asthma pathogenesis. Johnston SL. **Pediatr Pulmonol Suppl** 1999; 18:141–3 (13 ref.)

Asthma, viruses, and nitric oxide. Sanders SP. **Proc Soc Exp Biol Med** 1999 Mar;220(3):123–32 (162 ref.)

DRUG THERAPY

Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections. Wang QM. **Prog Drug Res** 1999;52:197–219 (100 ref.)

VIROLOGY

Association of rhinovirus infections with asthma. Gern JE, et al. **Clin Microbiol Rev** 1999 Jan;12(1):9–18 (139 ref.)

Molecular detection and typing of human picornaviruses. Santti J, et al. **Virus Res** 1999 Aug;62(2):177–83 (36 ref.)

PICORNAVIRUS INFECTIONS see **PICORNAVIRIDAE INFECTIONS**

PICTURE ARCHIVING AND COMMUNICATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

PICTURE ARCHIVING, RADIOLOGIC see **RADIOLOGY INFORMATION SYSTEMS**

PIEBALD DOLPHINS see **DOLPHINS**

PIEBALDISM

see related
WAARDENBURG'S SYNDROME

PIG SKIN DRESSINGS see **BIOLOGICAL DRESSINGS**

PIG-TAILED MONKEY see **MACACA NEMESTRINA**

PIGEON BREEDER'S LUNG see **BIRD FANCIER'S LUNG**

PIGMENT EPITHELIUM OF EYE

Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium. Beermann F, et al. **Pigment Cell Res** 1999 Apr;12(2):71–80 (71 ref.)

EMBRYOLOGY

Morphogenesis of the retinal pigment epithelium: toward understanding retinal degenerative diseases. Marmorstein AD, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:1–12 (46 ref.)

METABOLISM

Binding of drugs to eye melanin is not predictive of ocular toxicity. Leblanc B, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):124–32 (120 ref.)

PHYSIOLOGY

Standardization notice: EOG standard reapproved. Electro-oculogram. Marmor MF. **Doc Ophthalmol** 1998; 95(1):91–2 (5 ref.)

The retinal pigment epithelium as a developmental regulator of the neural retina. Jeffery G. **Eye** 1998;12 (Pt 3b):499–503 (32 ref.)

Senescence of the retinal pigmented epithelium [comment] Hjelmeland LM. **Invest Ophthalmol Vis Sci** 1999 Jan; 40(1):1–2 (15 ref.) Comment on: Invest Ophthalmol Vis Sci 1999 Jan;40(1):197–202.

Photoreceptor "retinoid pumps" in health and disease. Bok D. **Neuron** 1999 Jul;23(3):412–4 (11 ref.)

PHYSIOPATHOLOGY

Matrix and the retinal pigment epithelium in proliferative retinal disease. Hiscott P, et al. **Prog Retin Eye Res** 1999 Mar;18(2):167–90 (140 ref.)

TRANSPLANTATION

Immunological problems of transplantation into the subretinal space. Enzmann V, et al. **Acta Anat (Basel)** 1998; 162(2–3):178–83 (51 ref.)

PIGMENTARY RETINOPATHY see **RETINITIS PIGMENTOSA**

PIGMENTATION

see related
SKIN PIGMENTATION

Novel coloured flowers. Mol J, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):198–201 (24 ref.)

Melanosis of the uterine cervix: a report of two cases and discussion of pigmented cervical lesions. Yilmaz AG, et al. **Int J Gynecol Pathol** 1999 Jan;18(1):73–6 (15 ref.)

GENETICS

Human pigmentation genetics: the difference is only skin deep. Sturm RA, et al. **Bioessays** 1998 Sep;20(9):712–21 (84 ref.)

Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Oetting WS, et al. **Hum Mutat** 1999;13(2):99–115 (98 ref.)

Expanded (CAG)n, (CGG)n and (GAA)n trinucleotide repeat microsatellites, and mutant purine synthesis and pigmentation genes cause schizophrenia and autism. Fischer KM. **Med Hypotheses** 1998 Sep;51(3):223–33 (89 ref.)

PIGMENTATION DISORDERS

Genodermatosis with reticulate, patchy and mottled pigmentation of the neck--a clue to rare dermatologic disorders. Itin PH, et al. **Dermatology** 1998;197(3):281–90 (133 ref.)

Reticulate, patchy and mottled pigmentation of the neck. Acquired forms. Lautenschlager S, et al. **Dermatology** 1998; 197(3):291–6 (63 ref.)

[Phacomatosis] Takeshita K. **No To Shinkei** 1999 Jan; 51(1):5–9 (20 ref.) **(Jpn)**

CHEMICALLY INDUCED

Oral and systemic effects of prolonged minocycline therapy. Patel K, et al. **Br Dent J** 1998 Dec 12–26;185(11–12):560–2 (19 ref.)

COMPLICATIONS

Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease. Tsuruta D, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):35–8 (17 ref.)

DIAGNOSIS

[Color and form changes in the iris] Wollensak J. **Klin Monatsbl Augenheilkd** 1999 May;214(5):266–9 (0 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Skin manifestations of mitochondrial DNA syndromes: case report and review. Flynn MK, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):819–23 (33 ref.)

PIGMENTATION DISORDERS

GENETICS

Hypomelanosis of Ito: no entity, but a cutaneous sign of mosaicism. Küster W, et al. **Am J Med Genet** 1999 Aug 6;85(4):346–50 (50 ref.)

Multi-organellar disorders of pigmentation: tied up in traffic. Spritz RA. **Clin Genet** 1999 May;55(5):309–17 (113 ref.)

Pigmentary mosaicism in hypomelanosis of Ito. Further evidence for functional disomy of Xp. Fritz B, et al. **Hum Genet** 1998 Oct;103(4):441–9 (51 ref.)

Multi-organellar disorders of pigmentation: intracellular traffic jams in mammals, flies and yeast. Spritz RA. **Trends Genet** 1999 Sep;15(9):337–40 (39 ref.)

METABOLISM

Multi-organellar disorders of pigmentation: intracellular traffic jams in mammals, flies and yeast. Spritz RA. **Trends Genet** 1999 Sep;15(9):337–40 (39 ref.)

PATHOLOGY

Hypomelanosis of Ito: no entity, but a cutaneous sign of mosaicism. Küster W, et al. **Am J Med Genet** 1999 Aug 6;85(4):346–50 (50 ref.)

Erythema dyschromicum perstans: report of a new case and critical review of the literature. Combemale P, et al. **J Dermatol** 1998 Nov;25(11):747–53 (68 ref.)

RADIOTHERAPY

Laser treatment of pigmented lesions in children. Carpo BG, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):233–43 (59 ref.)

SURGERY

Q-switched ruby laser treatment of tattoos and benign pigmented skin lesions: a critical review. Raulin C, et al. **Ann Plast Surg** 1998 Nov;41(5):555–65 (66 ref.)

THERAPY

[Laser therapy in dermatology] St Lautenschlager. **Ther Umsch** 1998 Aug;55(8):522–8 (22 ref.) (Eng. Abstr.) **(Ger)**

PIGMENTS

PHYSIOLOGY

The eyes of deep-sea fish. I: Lens pigmentation, tapeta and visual pigments. Douglas RH, et al. **Prog Retin Eye Res** 1998 Oct;17(4):597–636 (178 ref.)

PIGMY KILLER WHALE see **DOLPHINS**

PIGS see **SWINE**

PILAR CYST see **EPIDERMAL CYST**

PILI, BACTERIAL see **FIMBRIAE, BACTERIAL**

PILI, COMMON see **FIMBRIAE, BACTERIAL**

PILI, SEX

see related
CONJUGATION, GENETIC

PILOCARPINE

ADMINISTRATION & DOSAGE

Sjögren's syndrome: a critical review of clinical management. Bell M, et al. **J Rheumatol** 1999 Sep;26(9):2051–61 (31 ref.)

THERAPEUTIC USE

The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Nusair S, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):360–7 (24 ref.)

[Pilocarpine--new use for an old drug] Tishler M. **Harefuah** 1998 Aug;135(3–4):150–2 (25 ref.) **(Heb)**

PILOMATRIXOMA

DIAGNOSIS

[Pilomatrix carcinoma in an unusual location. Case report and review of the literature] Haferkamp B, et al. **Hautarzt** 1999 May;50(5):355–9 (31 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Multiple pilomatrixomata and myotonic dystrophy: a familial association. Geh JL, et al. **Br J Plast Surg** 1999 Mar; 52(2):143–5 (17 ref.)

PATHOLOGY

Fine needle aspiration (FNA) cytology of pilomatrixoma: report of 14 cases and review of the literature. Viero RM, et al. **Cytopathology** 1999 Aug;10(4):263–9 (20 ref.)

Pilomatricoma in elderly individuals. Behnke N, et al. **Dermatology** 1998;197(4):391–3 (23 ref.)

Malignant pilomatricoma: a case report. Waxtein L, et al. **Int J Dermatol** 1998 Jul;37(7):538–40 (14 ref.)

SECONDARY

Pilomatrix carcinoma with multiple metastases: report of a case and review of the literature. Bremnes RM, et al. **Eur J Cancer** 1999 Mar;35(3):433–7 (44 ref.)

SURGERY

Pilomatrixoma of the head and neck in children: a study of 38 cases and a review of the literature. Duflo S, et al. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1239–42 (18 ref.)

PILONIDAL CYST see **PILONIDAL SINUS**

PILONIDAL SINUS

Recurrent squamous-cell carcinoma arising in sacrococcygeal pilonidal sinus tract: report of a case and review of the literature. Abboud B, et al. **Dis Colon Rectum** 1999 Apr;42(4):525–8 (22 ref.)

Anorectal miscellany: pilonidal disease, anal cancer, Bowen's and Paget's diseases, foreign bodies, and hidradenitis suppurativa. Billingham RP. **Prim Care** 1999 Mar; 26(1):171–7 (29 ref.)

PATHOLOGY

Fine-needle aspiration cytology of metastatic squamous-cell carcinoma arising in a pilonidal sinus, with literature review. Williamson JD, et al. **Diagn Cytopathol** 1999 Jun; 20(6):367–70 (20 ref.)

SURGERY

[Sacrococcygeal cyst or "pilonidal sinus"] Cortese M. **Minerva Chir** 1998 May;53(5):457–64 (32 ref.) (Eng. Abstr.) **(Ita)**

PILOT WHALES see **DOLPHINS**

PINACIDIL

PHARMACOLOGY

Cardiovascular ATP-sensitive K+ channel as a new molecular target for development of antihypertensive drugs. Wang H. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep; 19(5):397–402 (27 ref.)

PINDOLOL

PHARMACOLOGY

Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants? Puzantian T, et al. **Pharmacotherapy** 1999 Feb;19(2):205–12 (12 ref.)

THERAPEUTIC USE

Pindolol augmentation of antidepressant therapy [published erratum appears in Br J Psychiatry 1998 Nov;173:443] [see comments] McAskill R, et al. **Br J Psychiatry** 1998 Sep; 173:203–8 (19 ref.) Comment in: Br J Psychiatry 1998 Dec;173:536–7.

PINEAL BODY

Extraneural metastasis of intracranial germinoma with syncytiotrophoblastic giant cells--case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38(9):574–7 (16 ref.)

Intracranial germ cell tumour (embryonal carcinoma with teratoma) with complex karyotype including isochromosome 12p. Losi L, et al. **Virchows Arch** 1998 Dec; 433(6):571–4 (18 ref.)

[Extraneural metastasis of pineal germinoma through a ventriculoperitoneal shunt, following histological change] Uchino M, et al. **No Shinkei Geka** 1999 Mar;27(3):269–74 (23 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Synaptic-like microvesicles in mammalian pinealocytes. Redecker P. **Int Rev Cytol** 1999;191:201–55 (285 ref.)

DRUG EFFECTS

Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. Debeljuk L, et al. **Peptides** 1999; 20(2):285–99 (139 ref.)

ENZYMOLOGY

Molecular rhythms in the pineal gland. Li X, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):648–51 (24 ref.)

Melatonin synthesis pathway: circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Bernard M, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):325–34 (44 ref.)

INNERVATION

Vipergic innervation of the mammalian pineal gland. Cozzi B. **Microsc Res Tech** 1999 Aug 15-Sep 1;46(4–5):257–64 (109 ref.)

Peptidergic peripheral nervous systems in the mammalian pineal gland. Matsushima S, et al. **Microsc Res Tech** 1999 Aug 15-Sep 1;46(4–5):265–80 (77 ref.)

Cholinergic innervation and function in the mammalian pineal gland. Phansuwan-Pujito P, et al. **Microsc Res Tech** 1999 Aug 15-Sep 1;46(4–5):281–95 (115 ref.)

Trigeminal innervation of the mammalian pineal gland. Reuss S. **Microsc Res Tech** 1999 Aug 15-Sep 1;46(4–5):305–9 (43 ref.)

METABOLISM

The pineal gland and melatonin: molecular and pharmacologic regulation. Borjigin J, et al. **Annu Rev Pharmacol Toxicol** 1999;39:53–65 (79 ref.)

Extrapineal melatonin and exogenous serotonin in seasonal affective disorder. Partonen T. **Med Hypotheses** 1998 Nov; 51(5):441–2 (5 ref.)

[Cascade of biochemical events triggered by stimulation of adrenergic receptors in the rat pineal gland--from cell membrane to nucleus] Zawilska JB, et al. **Postepy Hig Med Dosw** 1999;53(2):233–46 (53 ref.) (Eng. Abstr.) **(Pol)**

[Magnetosensitivity of the epiphysis] Temur'iants NA, et al. **Biofizika** 1998 Sep-Oct;43(5):761–5 (66 ref.) (Eng. Abstr.) **(Rus)**

[Extrapineal melatonin: its place and role in the neuroendocrine regulation of homeostasis] Kvetnoi IM, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):364–70 (60 ref.) **(Rus)**

PATHOLOGY

Trilateral retinoblastoma: is the location of the intracranial tumor important? [see comments] Paulino AC. **Cancer** 1999 Jul 1;86(1):135–41 (45 ref.) Comment in: Cancer 1999 Jul 1;86(1):3–5.

Pineal region tumours in childhood. A 30-year experience. Drummond KJ, et al. **Childs Nerv Syst** 1999 Mar; 15(2–3):119–26; discussion 127 (23 ref.)

Epidermoid cysts of the pineal region. MacKay CI, et al. **Childs Nerv Syst** 1999 Apr;15(4):170–8 (47 ref.)

Melanotic progonoma of the brain: a case report and review. Rickert CH, et al. **Childs Nerv Syst** 1998 Aug;14(8):389–93 (36 ref.)

Comparative histology of pineal calcification. Vigh B, et al. **Histol Histopathol** 1998 Jul;13(3):851–70 (136 ref.)

PHYSIOLOGY

Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Reiter RJ, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:410–24 (77 ref.)

Cross-talk between the pineal gland and immune system. Poon AM, et al. **Chin Med J (Engl)** 1998 Jan;111(1):7–11 (70 ref.)

Melatonin's role in vertebrate circadian rhythms. Cassone VM. **Chronobiol Int** 1998 Sep;15(5):457–73 (86 ref.)

Melatonin. Pineal gland hormone--a brief review. Patel JC. **Indian J Med Sci** 1998 Dec;52(12):567–8 (0 ref.)

The Cartesian clock metaphor for pineal gland operation pervades the origin of modern chronobiology. Barrera-Mera B, et al. **Neurosci Biobehav Rev** 1998; 23(1):1–4 (35 ref.)

Cellular circadian clocks in the pineal. Falcón J. **Prog Neurobiol** 1999 Jun;58(2):121–62 (391 ref.)

Cholinergic signal transduction cascades in rat pinealocytes: functional and ontogenetic aspects. Schomerus C, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):305–14 (43 ref.)

RADIOGRAPHY

Epidermoid cysts of the pineal region. MacKay CI, et al. **Childs Nerv Syst** 1999 Apr;15(4):170–8 (47 ref.)

PINEAL GLAND see **PINEAL BODY**

PINEALOCYTOMA see **PINEALOMA**

PINEALOMA

SECONDARY

Extraneural metastasis of intracranial germinoma with syncytiotrophoblastic giant cells--case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38(9):574–7 (16 ref.)

[Extraneural metastasis of pineal germinoma through a ventriculoperitoneal shunt, following histological change] Uchino M, et al. **No Shinkei Geka** 1999 Mar;27(3):269–74 (23 ref.) (Eng. Abstr.) **(Jpn)**

PINEOBLASTOMA see **PINEALOMA**

PINEOCYTOMA see **PINEALOMA**

PINNIPEDIA

PARASITOLOGY

The impact of parasites on marine mammals: a review. Raga JA, et al. **Parassitologia** 1997 Dec;39(4):293–6 (36 ref.)

PIPECOLIC ACIDS

CHEMICAL SYNTHESIS

Asymmetric syntheses of pipecolic acid and derivatives. Couty F. **Amino Acids** 1999;16(3-4):297-320 (69 ref.)

PIPERACILLIN

PHARMACOLOGY

Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Perry CM, et al. **Drugs** 1999 May;57(5):805-43 (167 ref.)

PIPERAZINES

Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Lode H, et al. **Clin Ther** 1999 Jan;21(1):61-74; discussion 1-2 (36 ref.)

[Sildenafil] Sperling H, et al. **Dtsch Med Wochenschr** 1999 Feb 12;124(6):151-3 (0 ref.) **(Ger)**

ADMINISTRATION & DOSAGE

New treatment options for erectile dysfunction. McMahon CG. **Aust Fam Physician** 1999 Aug;28(8):783-7, 789-90 (10 ref.)

ADVERSE EFFECTS

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Goldenberg MM. **Clin Ther** 1998 Nov-Dec;20(6):1033-48 (52 ref.)

Erectile dysfunction and sildenafil. Billner KL. **Nurse Pract** 1998 Nov;23(11):111 (0 ref.)

[Sildenafil (Viagra) in erectile dysfunction. Effective treatment with noteworthy side effects] Rolf C, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1356-61 (40 ref.) **(Ger)**

CHEMISTRY

Catalytic inhibitors of DNA topoisomerase II. Andoh T, et al. **Biochim Biophys Acta** 1998 Oct 1;1400(1-3):155-71 (108 ref.)

CONTRAINDICATIONS

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. Cheitlin MD, et al. **J Am Coll Cardiol** 1999 Jan;33(1):273-82 (33 ref.)

[Sildenafil (Viagra). Tolerance, contraindications, drug interactions] Sperling H, et al. **Urologe A** 1999 Mar; 38(2):124-7 (3 ref.) (Eng. Abstr.) **(Ger)**

[A new agent against impotence. Contraindicated in reduced renal and hepatic function, in angina and with simultaneously used nitroglycerin preparations] Hedelin H. **Lakartidningen** 1998 Oct 14;95(42):4558-60 (13 ref.) **(Swe)**

METABOLISM

Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Chouinard G, et al. **Cell Mol Neurobiol** 1999 Aug;19(4):533-52 (90 ref.)

PHARMACOLOGY

Overall cardiovascular profile of sildenafil citrate. Zusman RM, et al. **Am J Cardiol** 1999 Mar 4;83(5A):35C-44C (33 ref.)

Sildenafil (Viagra) and ophthalmology [editorial] Marmor MF. **Arch Ophthalmol** 1999 Apr;117(4):518-9 (9 ref.)

Novel benztropine [3a-(diphenylmethoxy)tropane] analogs as probes for the dopamine transporter. Newman AH, et al. **Curr Med Chem** 1998 Aug;5(4):305-19 (55 ref.)

Viagra: what every physician should know. Kloner RA. **Ear Nose Throat J** 1998 Sep;77(9):783-6 (19 ref.)

Molecular mechanisms of the effects of sildenafil (VIAGRA). Glossmann H, et al. **Exp Gerontol** 1999 Jun;34(3):305-18 (55 ref.)

Pharmacology of sildenafil citrate. Umrani DN, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):160-4 (15 ref.)

Cyclic GMP phosphodiesterase-5: target of sildenafil. Corbin JD, et al. **J Biol Chem** 1999 May 14;274(20):13729-32 (70 ref.)

[Phosphodiesterase 5--the enzyme inhibited by sildenafil (Viagra)] Sandberg M, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):945-9 (31 ref.) (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

Newer pharmacologic alternatives for erectile dysfunction. Viera AJ, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1159-66, 1169, 1172 (23 ref.)

Cardiovascular effects of sildenafil citrate and recommendations for its use. Kloner RA, et al. **Am J Cardiol** 1999 Sep 9;84(5B):11N-17N (21 ref.)

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Cheitlin MD, et al. **Circulation** 1999 Jan 5-12;99(1):168-77 (33 ref.)

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Goldenberg MM. **Clin Ther** 1998 Nov-Dec;20(6):1033-48 (52 ref.)

Use of oral sildenafil (Viagra) in the treatment of erectile dysfunction. Licht MR. **Compr Ther** 1999 Feb;25(2):90-4 (13 ref.)

Opportunities for the treatment of erectile dysfunction by modulation of the NO axis--alternatives to sildenafil citrate. de Mey C. **Curr Med Res Opin** 1998;14(4):187-202 (133 ref.)

Sildenafil: a revolutionary therapy? [editorial] Marshall SM. **Diabet Med** 1998 Nov;15(11):897-9 (14 ref.)

Urapidil. A reappraisal of its use in the management of hypertension. Dooley M, et al. **Drugs** 1998 Nov; 56(5):929-55 (52 ref.)

Sildenafil: a review of its use in erectile dysfunction. Langtry HD, et al. **Drugs** 1999 Jun;57(6):967-89 (80 ref.)

Vitamin V: the sildenafil craze. Kuritzky L. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):163-5 (3 ref.)

Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. Shen WW, et al. **J Reprod Med** 1999 Jun;44(6):535-42 (61 ref.)

Viagra--after one year. Steers WD. **Urology** 1999 Jul; 54(1):12-7 (42 ref.)

[Sildenafil (Viagra) for the treatment of erectile disorder (see comments)] Meuleman EJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2337-41 (31 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2332-3. Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2333-6. **(Dut)**

[Drug of the month. Sildenafil (Viagra)] Andrianne R. **Rev Med Liege** 1999 Jan;54(1):58-61 (8 ref.) (Eng. Abstr.) **(Fre)**

[Sildenafil (Viagra) in erectile dysfunction. Effective treatment with noteworthy side effects] Rolf C, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1356-61 (40 ref.) **(Ger)**

[Erectile dysfunction--problem solved with sildenafil (Viagra)?] Hofer C, et al. **Internist (Berl)** 1998 Dec; 39(12):1232-6 (14 ref.) **(Ger)**

[Sildenafil (Viagra). Hormonal properties, indications and legal problems] Ullrich T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):233-45 (84 ref.) **(Ger)**

[Urology is more than Viagra. Potpourri of new developments in urology] Hobi C, et al. **Schweiz Med Wochenschr** 1998 Dec 26;128(51-52):2047-51 (3 ref.) **(Ger)**

[Protective effect of oxatomide in infantile bronchial asthma. Double-blind study vs placebo] Giorgi PL, et al. **Minerva Pediatr** 1998 Jul-Aug;50(7-8):339-46 (22 ref.) (Eng. Abstr.) **(Ita)**

[Sildenafil and erectile dysfunction] Menárguez Puche JF, et al. **Aten Primaria** 1998 Oct 15;22(6):379-86 (30 ref.) **(Spa)**

PIPERIDINES

Postoperative pain management after intraoperative remifentanil. Albrecht S, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S40-5 (26 ref.)

Inpatient experience with remifentanil. Camu F, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S15-21 (18 ref.)

Ambulatory anesthesia experience with remifentanil. Peacock JE, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S22-7 (6 ref.)

Remifentanil as an analgesic adjunct in local/regional anesthesia and in monitored anesthesia care. Servin F, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S28-32 (15 ref.)

Enzymatic and chemical cleavage methods. Taylor GR. **Electrophoresis** 1999 Jun;20(6):1125-30 (32 ref.)

[Remifentanil in pediatric surgery] Ferrero F, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):58-9 (13 ref.) **(Ita)**

[Discovery and development of donepezil hydrochloride for the treatment of Alzheimer's disease] Sugimoto H, et al. **Yakugaku Zasshi** 1999 Feb;119(2):101-13 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Remifentanyl. Indications in anesthesia] Torres LM, et al. **Rev Esp Anestesiol Reanim** 1999 Feb;46(2):75-80 (47 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

A review of the cardiac systemic side-effects of antihistamines: ebastine. Moss AJ, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:200-5 (14 ref.)

The non-cardiac systemic side-effects of antihistamines: ebastine. Roberts DJ, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:151-5 (16 ref.)

CLASSIFICATION

Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). Kodama I, et al. **Jpn Circ J** 1999 Jan;63(1):1-12 (126 ref.)

METABOLISM

Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Shire D, et al. **Life Sci** 1999; 65(6-7):627-35 (35 ref.)

PHARMACOKINETICS

A review of the pharmacokinetics and pharmacodynamics of remifentanil. Glass PS, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S7-14 (29 ref.)

Pharmacokinetics of raloxifene and its clinical application. Hochner-Celnikier D. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):23-9 (59 ref.)

[Second generation topical antihistaminics] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May;6(35):277-80 (59 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Raloxifene: a selective estrogen receptor modulator [see comments] Scott JA, et al. **Am Fam Physician** 1999 Sep 15;60(4):1131-9 (27 ref.) Comment in: Am Fam Physician 1999 Sep 15;60(4):1092, 1095.

A review of the pharmacokinetics and pharmacodynamics of remifentanil. Glass PS, et al. **Anesth Analg** 1999 Oct;89(4 Suppl):S7-14 (29 ref.)

Experience with remifentanil in neurosurgical patients. Warner DS. **Anesth Analg** 1999 Oct;89(4 Suppl):S33-9 (22 ref.)

Sibrafiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):225-30; discussion 231-2 (9 ref.)

Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Malaisse WJ. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:21-9 (34 ref.)

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Mijatovic V, et al. **Gynecol Endocrinol** 1999 Apr; 13(2):130-44 (129 ref.)

Raloxifene, a new selective estrogen receptor modulator. Goldfrank D, et al. **J Clin Pharmacol** 1999 Aug; 39(8):767-74 (67 ref.)

Multiple mechanisms of action: the pharmacological profile of budipine. Eltze M. **J Neural Transm Suppl** 1999; 56:83-105 (102 ref.)

An estrogen receptor basis for raloxifene action in bone. Bryant HU, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):37-44 (34 ref.)

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. Labrie F, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):51-84 (224 ref.)

Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). Kodama I, et al. **Jpn Circ J** 1999 Jan;63(1):1-12 (126 ref.)

Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167-74 (50 ref.)

[Remifentanil, a new opioid analgesic] Amo K. **Masui** 1998 Dec;47 Suppl:S93-100 (19 ref.) **(Jpn)**

THERAPEUTIC USE

Raloxifene: a selective estrogen receptor modulator [see comments] Scott JA, et al. **Am Fam Physician** 1999 Sep 15;60(4):1131-9 (27 ref.) Comment in: Am Fam Physician 1999 Sep 15;60(4):1092, 1095.

Educational considerations for the clinical introduction and use of remifentanil. Reves JG. **Anesth Analg** 1999 Oct;89(4 Suppl):S4-6 (6 ref.)

An overview of remifentanil. Rosow CE. **Anesth Analg** 1999 Oct;89(4 Suppl):S1-3 (15 ref.)

Clinical effects of raloxifene hydrochloride in women. Khovidhunkit W, et al. **Ann Intern Med** 1999 Mar 2; 130(5):431-9 (86 ref.)

Naratriptan: an alternative for migraine. Dulli DA. **Ann Pharmacother** 1999 Jun;33(6):704-11 (39 ref.)

Is the placebo control obsolete in a world after donepezil and vitamin E? [see comments] Karlawish JH, et al. **Arch Neurol** 1998 Nov;55(11):1420-4 (35 ref.) Comment in: Arch Neurol 1998 Nov;55(11):1396-8.

Antihistamines in severe/chronic rhinitis. Bousquet J. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:49-53 (23 ref.)

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Rogers SL. **Dement Geriatr Cogn Disord** 1998;9 Suppl 3:29-42 (67 ref.)

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs. Owens DR. **Diabet Med** 1998;15 Suppl 4:S28-36 (16 ref.)

Donepezil update. **Drug Ther Bull** 1998 Aug;36(8):60-1 (9 ref.)

Sibrafiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):225-30; discussion 231-2 (9 ref.)

Repaglinide [published erratum appears in Drugs Aging 1999 Jul;15(1):28] Balfour JA, et al. **Drugs Aging** 1998 Aug; 13(2):173-80 (32 ref.)

Tamoxifen, raloxifene, and the prevention of breast cancer. Jordan VC, et al. **Endocr Rev** 1999 Jun;20(3):253-78 (264 ref.)

Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Owens DR. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:30-7 (39 ref.)

Clinical efficacy of raloxifene in postmenopausal women. Agnusdei D. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul; 85(1):43-6 (25 ref.)

Clinical benefits of a new piperidine-class AChE inhibitor. Doody RS. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl

PIPERIDINES

2:S69–77 (29 ref.)
Clinical profile of donepezil in the treatment of Alzheimer's disease. Doody RS. **Gerontology** 1999;45 Suppl 1:23–32 (62 ref.)
Prevention of breast cancer in high-risk women. Kardinal CG, et al. **J La State Med Soc** 1999 Apr;151(4):198–201 (6 ref.)
Clinical efficacy of budipine in Parkinson's disease. Przuntek H, et al. **J Neural Transm Suppl** 1999;56:75–82 (27 ref.)
Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. Barrett-Connor E, et al. **J Womens Health** 1998 Sep;7(7):839–47 (61 ref.)
Effect of raloxifene on the endometrium: will this be the ultimate key to its utilization? [editorial; comment] Goldstein SR. **Menopause** 1999 Fall;6(3):183–5 (17 ref.) Comment on: Menopause 1999 Fall;6(3):188–95.
New frontiers in the management of obstructive sleep apnoea syndrome. Krieger J. **Monaldi Arch Chest Dis** 1998 Oct; 53(5):515–9 (29 ref.)
Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Guay DR. **Pharmacotherapy** 1998 Nov-Dec;18(6):1195–204 (35 ref.)
What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Shadlen MF, et al. **Postgrad Med** 1999 Jan;105(1):109–18 (25 ref.)
Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene. Jordan VC. **Recent Results Cancer Res** 1998;152:265–76 (56 ref.)
[Syndrome X] Kotake H, et al. **Nippon Rinsho** 1999 Mar; 57(3):622–6 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA Azanza JR, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):109–18 (43 ref.) **(Spa)**

PIRACETAM

PHARMACOLOGY

Piracetam and platelets--a review of laboratory and clinical data. Evers S, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:44–8 (20 ref.)
Piracetam: novelty in a unique mode of action. Müller WE, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:2–9 (59 ref.)

THERAPEUTIC USE

Piracetam in the treatment of cortical myoclonus. Genton P, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:49–53 (28 ref.)
The role of piracetam in the treatment of acute and chronic aphasia. Huber W. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:38–43 (46 ref.)
The effectiveness of piracetam in vertigo. Oosterveld WJ. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:54–60 (23 ref.)

PIRENZEPINE

ANALOGS & DERIVATIVES

Olanzapine: a basic science update. Bymaster F, et al. **Br J Psychiatry Suppl** 1999;(37):36–40 (18 ref.)
Olanzapine: preclinical pharmacology and recent findings. Moore NA. **Br J Psychiatry Suppl** 1999;(37):41–4 (10 ref.)
Review of recent clinical studies with olanzapine. Tollefson GD, et al. **Br J Psychiatry Suppl** 1999;(37):30–5 (22 ref.)
Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans. Kassahun K, et al. **Drug Metab Dispos** 1998 Sep;26(9):848–55 (11 ref.)
Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience. Wrighton SA, et al. **Drug Metab Rev** 1999 Feb;31(1):15–28 (13 ref.)
Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Kasper S. **Int Clin Psychopharmacol** 1998 Nov;13(6):253–62 (51 ref.)
Management of acute mania. Tohen M, et al. **J Clin Psychiatry** 1999;60 Suppl 5:31–4; discussion 35–6 (39 ref.)
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Meltzer HY, et al. **Schizophr Bull** 1999;25(2):233–55 (115 ref.)
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Revicki DA. **Schizophr Res** 1999 Mar 1;35 Suppl:S101–9 (31 ref.)
[Use of novel agents in the treatment of schizophrenia and a look to the future] Keks NA. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Jun; 18(3):97–101 (4 ref.) **(Jpn)**
[Olanzapine: preclinical pharmacology and recent findings] Moore N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Jun;18(3):91–5 (13 ref.) **(Jpn)**
[Neuroleptic malignant syndrome associated with olanzapine (letter)] García López MM, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (8 ref.) **(Spa)**

PIROPLASMOSIS see **BABESIOSIS**

PIROXICAM

ADVERSE EFFECTS

[Photosensitivity induced by piroxicam] Varela P, et al. **Acta Med Port** 1998 Nov;11(11):997–1001 (19 ref.) (Eng. Abstr.) **(Por)**

PHARMACOLOGY

Stimulation of apoptosis by sulindac and piroxicam. Waddell WR. **Clin Sci (Colch)** 1998 Sep;95(3):385–8 (34 ref.)

PIT AND FISSURE SEALANTS

THERAPEUTIC USE

[Inter-dentist variability in the provision of fissure sealants] Galarneau C, et al. **J Can Dent Assoc** 1998 Nov; 64(10):718–25 (40 ref.) (Eng. Abstr.) **(Fre)**

PITCH DISCRIMINATION

PHYSIOLOGY

Is the target-to-target interval a critical determinant of P3 amplitude? Gonsalvez CJ, et al. **Psychophysiology** 1999 Sep; 36(5):643–54 (45 ref.)

PITCH PERCEPTION

DRUG EFFECTS

Reversible pitch perception deficit due to carbamazepine. Kashihara K, et al. **Intern Med** 1998 Sep;37(9):774–5 (8 ref.)

PITHECINAE see **CEBIDAE**

PITUITARY ADENOMA, PROLACTIN-SECRETING see **PROLACTINOMA**

PITUITARY-ADRENAL SYSTEM

[Liver and endocrine system. Part II: pituitary-gonadal axis and adrenal gland activity disturbances] Marek B, et al. **Wiad Lek** 1998;51(7-8):352–9 (23 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Oxidant anti-oxidant imbalance and effects of ethanol. Rivier C. **Front Biosci** 1999 Jun 1;4:D514–9 (59 ref.)
Measures of hypothalamic-pituitary-adrenal function in patients with asthma treated with inhaled glucocorticoids: clinical and research implications. Wolthers OD, et al. **J Asthma** 1999 Sep;36(6):477–86 (119 ref.)
Epiphenomenal, causal, or correlational--more on the mechanism(s) of action of antidepressants [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1998 Aug;18(4):265–7 (26 ref.)

IMMUNOLOGY

Mechanisms mediating the influence of alcohol on the hypothalamic-pituitary-adrenal axis responses to immune and nonimmune signals. Ogilvie K, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):243S–247S (31 ref.)
Hypophyseal-pituitary-adrenal axis in autoimmune and rheumatic diseases. Athreya BH, et al. **Immunol Res** 1998; 18(2):93–102 (56 ref.)
Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature. Chrousos GP, et al. **Neuroimmunomodulation** 1998 Nov-Dec;5(6):288–308 (70 ref.)
Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Chrousos GP, et al. **Neuroimmunomodulation** 1998 Nov-Dec;5(6):277–87 (61 ref.)
[Liver and endocrine system. Part I: pituitary-thyroid axis activity disorders] Marek B, et al. **Wiad Lek** 1998; 51(5-6):271–6 (23 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Individual variation in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Lenczowski MJ, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:139–47 (52 ref.)
Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Krysiak R, et al. **Eur J Endocrinol** 1999 Feb;140(2):130–6 (65 ref.)
Hypothalamus-pituitary-adrenal activity during human sleep: a coordinating role for the limbic hippocampal system. Born J, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):153–63 (81 ref.)
Endocrine changes in critically ill patients. Van den Berghe G. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:77–81 (28 ref.)
Review: Central non-glucocorticoid inhibitors of the hypothalamo-pituitary-adrenal axis. Jessop DS. **J Endocrinol** 1999 Feb;160(2):169–80 (139 ref.)
Alterations in the hypothalamic pituitary adrenal axis during pregnancy and the placental clock that determines the length of parturition. Smith R. **J Reprod Immunol** 1998 Aug;39(1-2):215–20 (16 ref.)
Modeling the involvement of the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes in autoimmune and stress-related rheumatic syndromes in women. Crofford LJ, et al. **J Womens Health** 1999 Mar;8(2):203–15 (58 ref.)
The roles of steroidogenic factor 1 in endocrine development and function. Parker KL. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):15–20 (36 ref.)
Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Nussdorfer GG, et al. **Peptides** 1998;19(8):1443–67 (346 ref.)
Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Turnbull AV, et al. **Physiol Rev** 1999 Jan;79(1):1–71 (1004 ref.)
Corticosteroid hormones and neuronal vulnerability: towards identification of candidate vulnerability genes. Vreugdenhil E, et al. **Prog Brain Res** 1998;117:9–22 (92 ref.)
Stress and the developing limbic-hypothalamic-pituitary-adrenal axis. Vázquez DM. **Psychoneuroendocrinology** 1998 Oct;23(7):663–700 (110 ref.)
[Glucocorticoid resistance syndrome and hypothalamo-pituitary-adrenal axis] Arai K. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):396–401 (36 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Differential effects of psychological and immunological challenge on the hypothalamo-pituitary-adrenal axis function in adjuvant-induced arthritis. Harbuz MS, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:43–52 (28 ref.)
The neurobiology of social phobia. Bell CJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S11–8 (53 ref.)
The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Scott LV, et al. **Funct Neurol** 1999 Jan-Mar;14(1):3–11 (59 ref.)
Perturbations of the hypothalamic-pituitary-adrenal axis and the metabolic syndrome in ageing. Björntorp P, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:121–3 (14 ref.)
Nitric oxide in the stress axis. López-Figueroa MO, et al. **Histol Histopathol** 1998 Oct;13(4):1243–52 (90 ref.)
Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits. Raber J. **Mol Neurobiol** 1998 Aug;18(1):1–22 (246 ref.)
The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. Crofford LJ. **Z Rheumatol** 1998;57 Suppl 2:67–71 (32 ref.)
[Neuroendocrine disorders cause stress-related disease. "Civilization syndrome" is a growing health problem] Björntorp P, et al. **Lakartidningen** 1999 Feb 24;96(8):893–6 (21 ref.) (Eng. Abstr.) **(Swe)**

PITUITARY APOPLEXY

CHEMICALLY INDUCED

Pituitary apoplexy induced by a combined anterior pituitary test: case report and literature review. Otsuka F, et al. **Endocr J** 1998 Jun;45(3):393–8 (29 ref.)

PITUITARY DISEASES

Pituitary diseases in pregnancy. Molitch ME. **Semin Perinatol** 1998 Dec;22(6):457–70 (91 ref.)

DIAGNOSIS

Pituitary disease. Pullan P. **Aust Fam Physician** 1999 May; 28(5):455–61 (13 ref.)
Clinical usefulness of the low dose ACTH test [see comments] Patel L, et al. **J Endocrinol Invest** 1999 May; 22(5):401–4 (19 ref.) Comment in: J Endocrinol Invest 1999 Jun;22(6):492–5.
Imaging of sellar and parasellar pathology. FitzPatrick M, et al. **Radiol Clin North Am** 1999 Jan;37(1):101–21, x (80 ref.)

METABOLISM

A review of endocrine changes in anorexia nervosa. Støving RK, et al. **J Psychiatr Res** 1999 Mar-Apr;33(2):139–52 (219 ref.)

PATHOLOGY

Current approaches to imaging of the sellar region and pituitary. Naidich MJ, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):45–79, vi (106 ref.)

PHYSIOPATHOLOGY

Neurology of the pituitary gland. Anderson JR, et al. **J Neurol Neurosurg Psychiatry** 1999 Jun;66(6):703–21 (152 ref.)

SURGERY

Pituitary surgery. Laws ER Jr, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):119–31 (38 ref.)

THERAPY

Pituitary disease. Pullan P. **Aust Fam Physician** 1999 May; 28(5):455–61 (13 ref.)

PITUITARY FUNCTION TESTS

ADVERSE EFFECTS

Pituitary apoplexy induced by a combined anterior pituitary test: case report and literature review. Otsuka F, et al. **Endocr J** 1998 Jun;45(3):393–8 (29 ref.)

PITUITARY GLAND

Pharyngeal pituitary: development, malformation, and tumorigenesis. Hori A, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):262–72 (38 ref.)

Immunohistochemical survey of migration of human anterior pituitary cells in developmental, pathological, and clinical aspects: a review. Hori A, et al. **Microsc Res Tech** 1999 Jul 1;46(1):59–68 (73 ref.)

CYTOLOGY

Electrophysiological studies of neurohypophysial neurons and peptides. Pittman QJ, et al. **Prog Brain Res** 1998; 119:311–20 (57 ref.)

DRUG EFFECTS

Assisted reproduction–in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin–releasing hormone analogues. Barbieri RL, et al. **Endocr Rev** 1999 Jun;20(3):249–52 (27 ref.)

EMBRYOLOGY

POU domain factors in neural development. Schonemann MD, et al. **Adv Exp Med Biol** 1998;449:39–53 (128 ref.)

Morphogenesis of the hypothalamus and hypophysis: their association, dissociation and reassociation before and after "Rathke". Kawamura K, et al. **Arch Histol Cytol** 1998 Aug; 61(3):189–98 (49 ref.)

Anterior pituitary development and Pit-1/GHF-1 transcription factor. de la Hoya M, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1059–66 (39 ref.)

Central integrative role of oestrogen in the regulation of placental steroidogenic maturation and the development of the fetal pituitary-adrenocortical axis in the baboon. Pepe GJ, et al. **Hum Reprod Update** 1998 Jul–Aug; 4(4):406–19 (127 ref.)

A model for the development of the hypothalamic–pituitary axis: transcribing the hypophysis. Kioussi C, et al. **Mech Dev** 1999 Mar;81(1–2):23–35 (82 ref.)

Early steps in pituitary organogenesis. Sheng HZ, et al. **Trends Genet** 1999 Jun;15(6):236–40 (36 ref.)

ENZYMOLOGY

[Pituitary adenylate cyclase-activating polypeptide] Gonzalez BJ, et al. **Ann Endocrinol (Paris)** 1998 Dec; 59(5):364–405 (454 ref.) (Eng. Abstr.) **(Fre)**

[High activity of deoxyribonuclease I identified in human pituitary gland—structure and function] Yasuda T. **Nippon Hoigaku Zasshi** 1998 Oct;52(5):295–300 (12 ref.) (Eng. Abstr.) **(Jpn)**

GROWTH & DEVELOPMENT

The PTX family of homeodomain transcription factors during pituitary developments. Drouin J, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):31–6 (16 ref.)

IMMUNOLOGY

Prolactin, a pituitary hormone that modifies immune responses. Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico [editorial; comment] [see comments] Walker SE, et al. **Lupus** 1998;7(6):371–5 (70 ref.) Comment on: Lupus 1998 ;7(6):420–7. Comment in: Lupus 1999;8(30:251.

METABOLISM

Growth hormone heterogeneity in human pituitary and plasma. Baumann G. **Horm Res** 1999;51 Suppl 1:2–6 (22 ref.)

Vitamin A functions in the regulation of the dopaminergic system in the brain and pituitary gland. Wolf G. **Nutr Rev** 1998 Dec;56(12):354–5 (12 ref.)

PATHOLOGY

Sheehan's syndrome of more than 30 years' duration: an endocrine and MRI study of 6 cases. Otsuka F, et al. **Endocr J** 1998 Aug;45(4):451–8 (27 ref.)

Current approaches to imaging of the sellar region and pituitary. Naidich MJ, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):45–79, vi (106 ref.)

Histologically proven lymphocytic hypophysitis: spontaneous resolution and subsequent pregnancy. Gagneja H, et al. **Mayo Clin Proc** 1999 Feb;74(2):150–4 (29 ref.)

PHYSIOLOGY

Development and organization of the hypophysiotropic hypothalamus driving the pituitary-gonadal axis in the rhesus monkey. Plant TM, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):60–6 (43 ref.)

Growth hormone–releasing peptide (GHRP). Bowers CY. **Cell Mol Life Sci** 1998 Dec;54(12):1316–29 (62 ref.)

Anterior pituitary development and Pit-1/GHF-1 transcription factor. de la Hoya M, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1059–66 (39 ref.)

Regulation of B and T cell development by anterior pituitary hormones. Foster M, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1076–82 (55 ref.)

Growth hormone: a paracrine growth factor in embryonic development? Harvey S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):305–15 (103 ref.)

The role of cytokines in the normal and neoplastic pituitary. Tsagarakis S, et al. **Crit Rev Oncol Hematol** 1998 Aug; 28(2):73–90 (183 ref.)

The brain–pituitary–adipocyte axis: role of leptin in modulating neuroendocrine function. Barb CR. **J Anim Sci** 1999 May;77(5):1249–57 (75 ref.)

Fertility and infertility: genetic contributions from the hypothalamic–pituitary–gonadal axis. Achermann JC, et al. **Mol Endocrinol** 1999 Jun;13(6):812–8 (19 ref.)

The thymus–pituitary axis and its changes during aging. Goya RG, et al. **Neuroimmunomodulation** 1999 Jan–Apr; 6(1–2):137–42 (87 ref.)

Neurohypophyseal peptides and social recognition in rats. Popik P, et al. **Prog Brain Res** 1998;119:415–36 (167 ref.)

Effects of pituitary hormones on the prostate. Reiter E, et al. **Prostate** 1999 Feb 1;38(2):159–65 (69 ref.)

PHYSIOPATHOLOGY

Insights into hypothalamic–pituitary dysfunction in polycystic ovary syndrome. Hall JE, et al. **J Endocrinol Invest** 1998 Oct;21(9):602–11 (67 ref.)

Is the hypothalamic–pituitary–adrenal axis really hyperactivated in visceral obesity? [comment] Kopelman PG. **J Endocrinol Invest** 1999 Jan;22(1):76–9 (17 ref.) Comment on: J Endocrinol Invest 1998 Apr;21(4):268–71.

Neurology of the pituitary gland. Anderson JR, et al. **J Neurol Neurosurg Psychiatry** 1999 Jun;66(6):703–21 (152 ref.)

SECRETION

Patch clamp study on mechanism of adenosine-induced inhibitory effects in frog pituitary melanotrophs. Mei YA, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep;17(5):385–9 (30 ref.)

SURGERY

Stereotactic radiosurgery—the role of charged particles. Levy RP, et al. **Acta Oncol** 1999;38(2):165–9 (21 ref.)

Pituitary surgery. Laws ER Jr, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):119–31 (38 ref.)

ULTRASTRUCTURE

[Cellular mechanism of growth hormone secretion by hypothalamic peptides] Kato M. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):402–4 (21 ref.) **(Jpn)**

PITUITARY GLAND, ANTERIOR

CYTOLOGY

Cell and molecular biology of the pars tuberalis of the pituitary. Wittkowski W, et al. **Int Rev Cytol** 1999; 185:157–94 (150 ref.)

Immunohistochemical survey of migration of human anterior pituitary cells in developmental, pathological, and clinical aspects: a review. Hori A, et al. **Microsc Res Tech** 1999 Jul 1;46(1):59–68 (73 ref.)

DRUG EFFECTS

Effects of substance P on cellular signalling systems in the rat anterior pituitary. Mau SE. **Dan Med Bull** 1999 Feb; 46(1):35–56 (243 ref.)

Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland. Evans JJ. **Endocr Rev** 1999 Feb; 20(1):46–67 (322 ref.)

EMBRYOLOGY

The role of POU domain proteins in the regulation of mammalian pituitary and nervous system development. McEvilly RJ, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 63:223–55 (138 ref.)

IMMUNOLOGY

Pituitary function in the acute phase response in domestic farm animals: cytokines, prostaglandins, and secretion of ACTH. Abraham EJ, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):389–96 (34 ref.)

METABOLISM

Regulation and role of intrapituitary IL-6 production by folliculostellate cells. Renner U, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):353–62 (59 ref.)

Differential management of Ca2+ oscillations by anterior pituitary cells: a comparative overview. Kwiecien R, et al. **Neuroendocrinology** 1998 Sep;68(3):135–51 (106 ref.)

PHYSIOLOGY

Galanin in normal and hyperplastic anterior pituitary cells. From pituitary tumor cell lines to transgenic mice. Hyde JF, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:48–55 (31 ref.)

Effects of substance P on cellular signalling systems in the rat anterior pituitary. Mau SE. **Dan Med Bull** 1999 Feb; 46(1):35–56 (243 ref.)

Pituitary apoplexy induced by a combined anterior pituitary test: case report and literature review. Otsuka F, et al. **Endocr J** 1998 Jun;45(3):393–8 (29 ref.)

Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland. Evans JJ. **Endocr Rev** 1999 Feb; 20(1):46–67 (322 ref.)

Does the CRH binding protein shield the anterior pituitary from placental CRH? Thomson M. **Endocrine** 1998 Dec; 9(3):221–6 (46 ref.)

Cell and molecular biology of the pars tuberalis of the pituitary. Wittkowski W, et al. **Int Rev Cytol** 1999; 185:157–94 (150 ref.)

PHYSIOPATHOLOGY

Pathophysiological role of the cytokine network in the anterior pituitary gland. Arzt E, et al. **Front Neuroendocrinol** 1999 Jan;20(1):71–95 (178 ref.)

Anterior pituitary response to stress: time-related changes and adaptation. Marti O, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):241–60 (230 ref.)

SECRETION

Ageing and growth hormone status. Toogood AA, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):281–96 (81 ref.)

Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility? Chappel S. **Clin Endocrinol (Oxf)** 1999 May; 50(5):547–56 (113 ref.)

Inhibitory effect of melatonin on GnRH-induced LH release. Vanecek J. **Rev Reprod** 1999 May;4(2):67–72 (53 ref.)

PITUITARY GLAND, POSTERIOR

METABOLISM

Hypothalamic transcription factors and the regulation of the hypothalamo–neurohypophysial system. Burbach JP, et al. **Adv Exp Med Biol** 1998;449:29–37 (59 ref.)

Evidence for diverse pathways of hypophysiotropic hormone transport in mammals. Anthony EL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):365–74 (34 ref.)

Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. de Wied D. **Eur J Pharmacol** 1999 Jun 30;375(1–3):1–11 (85 ref.)

Astroglial modulation of neurotransmitter/peptide release from the neurohypophysis: present status. Hatton GI. **J Chem Neuroanat** 1999 May;16(3):203–21 (147 ref.)

PHYSIOLOGY

Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Postina R, et al. **Adv Exp Med Biol** 1998;449:371–85 (27 ref.)

Membrane excitability in the neurohypophysis. Wilke RA, et al. **Adv Exp Med Biol** 1998;449:193–200 (28 ref.)

Evidence for diverse pathways of hypophysiotropic hormone transport in mammals. Anthony EL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):365–74 (34 ref.)

Astroglial modulation of neurotransmitter/peptide release from the neurohypophysis: present status. Hatton GI. **J Chem Neuroanat** 1999 May;16(3):203–21 (147 ref.)

Unique evolution of neurohypophysial hormones in cartilaginous fishes: possible implications for urea-based osmoregulation. Acher R, et al. **J Exp Zool** 1999 Oct 1; 284(5):475–84 (60 ref.)

PITUITARY GONADOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

PITUITARY GROWTH HORMONE see **SOMATOTROPIN**

PITUITARY GROWTH HORMONES, RECOMBINANT see **SOMATOTROPINS, RECOMBINANT**

PITUITARY HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE**

PITUITARY HORMONE-REGULATING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

PITUITARY HORMONE RELEASE INHIBITING HORMONES

see related
RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE

PITUITARY HORMONE-RELEASING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

PITUITARY HORMONE-RELEASING HORMONES

see related
RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE

PITUITARY HORMONES

see related
HYPOPITUITARISM
RECEPTORS, PITUITARY HORMONE

BLOOD

Histologically proven lymphocytic hypophysitis: spontaneous resolution and subsequent pregnancy. Gagneja H, et al. **Mayo Clin Proc** 1999 Feb;74(2):150–4 (29 ref.)

CHEMICAL SYNTHESIS

Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives. Deghenghi R. **J Endocrinol Invest** 1998 Dec;21(11):787–93 (47 ref.)

DEFICIENCY

Rarity of PIT1 involvement in children from Russia with combined pituitary hormone deficiency. Fofanova OV, et al. **Am J Med Genet** 1998 Jun 5;77(5):360–5 (31 ref.)

PHYSIOLOGY

Unique evolution of neurohypophysial hormones in cartilaginous fishes: possible implications for urea-based osmoregulation. Acher R, et al. **J Exp Zool** 1999 Oct 1; 284(5):475–84 (60 ref.)

THERAPEUTIC USE

Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives. Deghenghi R. **J Endocrinol Invest** 1998 Dec;21(11):787–93 (47 ref.)

PITUITARY HORMONES, ANTERIOR

METABOLISM

Alcohol ingestion, hormonal changes, and the skin. Shulman A, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):405–9 (46 ref.)

PHYSIOLOGY

Effects of pituitary hormones on the prostate. Reiter E, et al. **Prostate** 1999 Feb 1;38(2):159–65 (69 ref.)

PITUITARY HORMONES, POSTERIOR

GENETICS

Hypothalamic transcription factors and the regulation of the hypothalamo-neurohypophysial system. Burbach JP, et al. **Adv Exp Med Biol** 1998;449:29–37 (59 ref.)

METABOLISM

Evidence for diverse pathways of hypophysiotropic hormone transport in mammals. Anthony EL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):365–74 (34 ref.)

PHYSIOLOGY

Evidence for diverse pathways of hypophysiotropic hormone transport in mammals. Anthony EL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):365–74 (34 ref.)

[Hormones of the posterior region of the hypophyseal gland] Mirčić GM, et al. **Srp Arh Celok Lek** 1998 Mar–Apr; 126(3–4):111–8 (63 ref.) (Eng. Abstr.) **(Sec)**

PITUITARY NEOPLASMS

Malignant prolactinoma: case report and review of the literature. Popadić A, et al. **Surg Neurol** 1999 Jan; 51(1):47–54; discussion 54–5 (29 ref.)

[Prolactin--a hormone with many effects] Werner S, et al. **Lakartidningen** 1999 Mar 10;96(10):1171–4 (37 ref.) **(Swe)**

CHEMICALLY INDUCED

Three cases of a hitherto unrecognized pituitary tumour: it is caused by maternal exposure to unidentified factor(s) during pregnancy? [letter] Horvath E, et al. **Clin Endocrinol (Oxf)** 1998 Oct;49(4):547–8 (4 ref.)

COMPLICATIONS

Hyperprolactinaemia and pituitary adenomas in adolescence. Dissaneevate P, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug;11(4):531–41 (60 ref.)

[Diabetes insipidus and adipsic hypernatremia in a patient with a craniopharyngioma] Macias Batista A, et al. **An Med Interna** 1999 Feb;16(2):87–8 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosis and treatment of prolactinomas. Molitch ME. **Adv Intern Med** 1999;44:117–53 (179 ref.)

Diagnosis and therapy for pituitary tumors. Veznedaroglu E, et al. **Curr Opin Oncol** 1999 Jan;11(1):27–31 (59 ref.)

Differential diagnosis of sellar masses. Freda PU, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):81–117, vi (165 ref.)

Receptor imaging in the diagnosis and treatment of pituitary tumors. Kwekkeboom DJ, et al. **J Endocrinol Invest** 1999 Jan;22(1):80–8 (63 ref.)

Unusual MRI finding of multiple adenomas in the pituitary gland: a case report and review of the literature. Cannavò S, et al. **Magn Reson Imaging** 1999 May;17(4):633–6 (13 ref.)

Juvenile symptomatic Rathke's cleft cyst--case report. Tanaka T, et al. **Neurol Med Chir (Tokyo)** 1998 Sep; 38(9):578–81 (19 ref.)

Imaging of sellar and parasellar pathology. FitzPatrick M, et al. **Radiol Clin North Am** 1999 Jan;37(1):101–21, x (80 ref.)

[Treatment of pituitary adenoma] Chanson P. **Presse Med** 1998 Dec 12;27(39):2077–87 (113 ref.) (Eng. Abstr.) **(Fre)**

[The syndrome of inappropriate TSH secretion of neoplastic origin (NIST)] Grzywa M, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):101–3 (36 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Treatment of prolactinomas. Colao A, et al. **Ann Med** 1998 Oct;30(5):452–9 (78 ref.)

Medical treatment of prolactinomas. Molitch ME. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):143–69, vii (169 ref.)

Medical therapy for gonadotroph and thyrotroph tumors. Shomali ME, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):223–40, viii (103 ref.)

[Medical treatment of secretory hypophyseal adenomas] Thomopoulos P. **Neurochirurgie** 1998 Dec;44(5):309–11 (11 ref.) (Eng. Abstr.) **(Fre)**

[Advances in pharmacological treatment of pituitary adenomas] Morales Pérez FM, et al. **An Med Interna** 1998 Sep;15(9):490–500 (145 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Pharyngeal pituitary: development, malformation, and tumorigenesis. Hori A, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):262–72 (38 ref.)

EPIDEMIOLOGY

[Is there an age- and gender-related occurrence of pituitary adenomas?] Mindermann T. **Schweiz Rundsch Med Prax** 1999 Jun 24;88(25–26):1134–6 (10 ref.) **(Ger)**

ETIOLOGY

The cytogenesis and pathogenesis of pituitary adenomas. Asa SL, et al. **Endocr Rev** 1998 Dec;19(6):798–827 (365 ref.)

Pathogenesis of pituitary tumors. Melmed S. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):1–12, v (59 ref.)

[The syndrome of inappropriate TSH secretion of neoplastic origin (NIST)] Grzywa M, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):101–3 (36 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Molecular pathogenesis of pituitary adenomas: a review. Shuhardja AS, et al. **Acta Neurochir (Wien)** 1999; 141(7):729–36 (108 ref.)

The molecular pathogenesis of corticotroph tumors. Dahia PL, et al. **Endocr Rev** 1999 Apr;20(2):136–55 (291 ref.)

G protein abnormalities in pituitary adenomas. Spada A, et al. **Mol Cell Endocrinol** 1998 Jul 25;142(1–2):1–14 (97 ref.)

[Expression of a novel transcript for the TRH receptor in human pituitary adenomas] Yamada M, et al. **Nippon Rinsho** 1999 Mar;57(3):737–45 (20 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The role of cytokines in the normal and neoplastic pituitary. Tsagarakis S, et al. **Crit Rev Oncol Hematol** 1998 Aug; 28(2):73–90 (183 ref.)

PATHOLOGY

The cytogenesis and pathogenesis of pituitary adenomas. Asa SL, et al. **Endocr Rev** 1998 Dec;19(6):798–827 (365 ref.)

The pathology of pituitary tumors. Asa SL. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):13–43, v–vi (156 ref.)

Progression of a Nelson's adenoma to pituitary carcinoma; a case report and review of the literature [published erratum appears in J Endocrinol Invest 1999 Jul–Aug;22(7):582] Kemink SA, et al. **J Endocrinol Invest** 1999 Jan;22(1):70–5 (43 ref.)

Immunohistochemical survey of migration of human anterior pituitary cells in developmental, pathological, and clinical aspects: a review. Hori A, et al. **Microsc Res Tech** 1999 Jul 1;46(1):59–68 (73 ref.)

Immature teratoma originating from the pituitary gland: case report. Nishioka H, et al. **Neurosurgery** 1999 Mar; 44(3):644–7; discussion 647–8 (12 ref.)

Aggressive pituitary tumors. Blevins LS Jr, et al. **Oncology (Huntingt)** 1998 Sep;12(9):1307–12, 1315; discussion 1315–8 (77 ref.)

Oncocytic and granular cell neoplasms of the central nervous system and pituitary gland. Giangaspero F, et al. **Semin Diagn Pathol** 1999 May;16(2):91–7 (31 ref.)

PHYSIOPATHOLOGY

Apoptosis in human primary brain tumours. Leaver HA, et al. **Br J Neurosurg** 1998 Dec;12(6):539–46 (58 ref.)

The role of cytokines in the normal and neoplastic pituitary. Tsagarakis S, et al. **Crit Rev Oncol Hematol** 1998 Aug; 28(2):73–90 (183 ref.)

RADIOTHERAPY

Role of gamma knife therapy in the management of pituitary tumors. Jackson IM, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):133–42 (26 ref.)

SECRETION

Current medical approach to thyroid stimulating hormone-secreting pituitary adenomas [editorial; comment] Demura R. **Intern Med** 1998 Dec;37(12):999–1000 (12 ref.) Comment on: Intern Med 1998 Dec;37(12):1027–30.

Pituitary macroadenoma and Cushing's disease in pediatric patients: patient report and review of the literature. Damiani D, et al. **J Pediatr Endocrinol Metab** 1998 Sep–Oct;11(5):665–9 (18 ref.)

[Thyrotropin-producing hypophyseal adenomas] Calvo Romero JM, et al. **Rev Clin Esp** 1999 May;199(5):285–7 (13 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Treatment of prolactinomas. Colao A, et al. **Ann Med** 1998 Oct;30(5):452–9 (78 ref.)

Primary transsphenoidal microsurgery in the treatment of craniopharyngiomas. Norris JS, et al. **Br J Neurosurg** 1998 Aug;12(4):305–12 (35 ref.)

The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Lissett CA, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):653–7 (16 ref.)

Role of gamma knife therapy in the management of pituitary tumors. Jackson IM, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):133–42 (26 ref.)

Radiosurgery for pituitary tumors and craniopharyngiomas. Laws ER Jr, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):327–36 (61 ref.)

[The place of radiosurgery in the treatment of hypophyseal adenoma] Nataf F, et al. **Neurochirurgie** 1998 Dec; 44(5):339–43 (21 ref.) (Eng. Abstr.) **(Fre)**

[Neurosurgical management of extracerebral tumors] Antoniadis G, et al. **Rontgenpraxis** 1998;51(8–9):304–10 (26 ref.) **(Ger)**

THERAPY

Diagnosis and therapy for pituitary tumors. Veznedaroglu E, et al. **Curr Opin Oncol** 1999 Jan;11(1):27–31 (59 ref.)

Receptor imaging in the diagnosis and treatment of pituitary tumors. Kwekkeboom DJ, et al. **J Endocrinol Invest** 1999 Jan;22(1):80–8 (63 ref.)

Gene therapy strategies for the treatment of pituitary tumours. Castro MG. **J Mol Endocrinol** 1999 Feb; 22(1):9–18 (88 ref.)

[Treatment of pituitary tumors] Valtonen S, et al. **Duodecim** 1995;111(21):2013–9 (35 ref.) **(Fin)**

VETERINARY

Tumors of the central nervous system. Paradis MR. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):543–61, vii (52 ref.)

PITUITRIN see **PITUITARY HORMONES, POSTERIOR**

PITYRIASIS RUBRA PILARIS

Pityriasis rubra pilaris. Albert MR, et al. **Int J Dermatol** 1999 Jan;38(1):1–11 (157 ref.)

PITYRIASIS VERSICOLOR see **TINEA VERSICOLOR**

PITYROSPORUM see **MALASSEZIA**

PKC see **PROTEIN KINASE C**

PKC(ALPHA) see **PROTEIN KINASE C**

PKC(BETA) see **PROTEIN KINASE C**

PKC(GAMMA) see **PROTEIN KINASE C**

PL 104-191 see **HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT**

PLACEBO EFFECT

Placebos, drug effects, and study design: a clinician's guide. Quitkin FM. **Am J Psychiatry** 1999 Jun;156(6):829-36 (72 ref.)

Placebo--efficacy and adverse effects in controlled clinical trials. Weihrauch TR, et al. **Arzneimittelforschung** 1999 May;49(5):385-93 (38 ref.)

The placebo response in Parkinson's disease. Parkinson Study Group. Shetty N, et al. **Clin Neuropharmacol** 1999 Jul-Aug; 22(4):207-12 (33 ref.)

Psychoneuroimmunology, the placebo effect and chiropractic [see comments] Morgan LG.
J Manipulative Physiol Ther 1998 Sep;21(7):484-91 (47 ref.)
Comment in: J Manipulative Physiol Ther 1999 Mar-Apr;22(3):180-1.

Is placebo analgesia mediated by endogenous opioids? A systematic review. ter Riet G, et al. **Pain** 1998 Jun; 76(3):273-5 (12 ref.)

The placebo effect. Margo CE. **Surv Ophthalmol** 1999 Jul-Aug;44(1):31-44 (180 ref.)

Towards a risk-benefit evaluation of placebos. Ernst E. **Wien Med Wochenschr** 1998;148(20):461-3 (35 ref.)

[Placebo effect in clinical trials] Weihrauch TR.
Med Klin 1999 Mar 15;94(3):173-81 (37 ref.) (Eng. Abstr.) **(Ger)**

[Is homeopathy more than a placebo?] Brockow T, et al. **Schweiz Rundsch Med Prax** 1998 Dec 3;87(49):1687-94 (31 ref.) (Eng. Abstr.) **(Ger)**

[The mechanisms of the placebo effect] Lapin IP, et al. **Eksp Klin Farmakol** 1999 May-Jun;62(3):75-9 (40 ref.) (Eng. Abstr.) **(Rus)**

PLACEBOS

Alternatives to placebo-controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. European College of Neuropsychopharmacology. Montgomery SA.
Eur Neuropsychopharmacol 1999 Mar;9(3):265-9 (4 ref.)

The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Montgomery SA.
Eur Neuropsychopharmacol 1999 Mar;9(3):271-6 (10 ref.)

AZT trials and tribulations. Crouch RA, et al.
Hastings Cent Rep 1998 Nov-Dec;28(6):26-34 (32 ref.)

Commentary: the use of placebos in psychiatric research [comment] Forester BP. **Int J Psychiatry Med** 1999; 29(1):91-5 (9 ref.) Comment on: Int J Psychiatry Med 1999 ;29(1):97-105. Comment on: Int J Psychiatry Med 1999 ;29(1):107-17.

ADMINISTRATION & DOSAGE

Placebos, drug effects, and study design: a clinician's guide. Quitkin FM. **Am J Psychiatry** 1999 Jun;156(6):829-36 (72 ref.)

ADVERSE EFFECTS

Placebo--efficacy and adverse effects in controlled clinical trials. Weihrauch TR, et al. **Arzneimittelforschung** 1999 May;49(5):385-93 (38 ref.)

PHARMACOLOGY

The ethics of using placebo in hypertension clinical trials [editorial] Weber MA. **J Hypertens** 1999 Jan;17(1):5-8 (15 ref.)

STANDARDS

The placebo effect: mocking or mirroring medicine? Biller N. **Perspect Biol Med** 1999 Spring;42(3):398-401 (11 ref.)

THERAPEUTIC USE

Clinical trials in Alzheimer disease: debate on the use of placebo controls. Kawas CH, et al.
Alzheimer Dis Assoc Disord 1999 Jul-Sep;13(3):124-9 (28 ref.)

Are randomized control trial outcomes influenced by the inclusion of a placebo group?: a systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment. Rochon PA, et al. **J Clin Epidemiol** 1999 Feb; 52(2):113-22 (34 ref.)

Placebo-controlled studies in rheumatoid arthritis: ethical issues [see comments] Stein CM, et al. **Lancet** 1999 Jan 30;353(9150):400-3 (37 ref.) Comment in: Lancet 1999 Apr 3;353(9159):1186.

PLACENTA

see related
MATERNAL-FETAL EXCHANGE
UTEROPLACENTAL CIRCULATION

ABNORMALITIES

Experimental models used to measure direct and indirect ethanol teratogenicity. Shibley IA Jr, et al.
Alcohol Alcohol 1999 Mar-Apr;34(2):125-40 (140 ref.)

The consequences of monochorionic placentation. Denbow ML, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):37-51 (77 ref.)

Sonographically detected fetal and placental abnormalities associated with trisomy 16 confined to the placenta. A case report and review of the literature. Astner A, et al.
Prenat Diagn 1998 Dec;18(12):1308-15 (31 ref.)

ANATOMY & HISTOLOGY

Structure, function, and evolution of the oviducts of squamate reptiles, with special reference to viviparity and placentation. Blackburn DG. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):560-617 (314 ref.)

BLOOD SUPPLY

Uteroplacental vascular involvement in recurrent spontaneous abortion. Torry DS, et al.
Curr Opin Obstet Gynecol 1998 Oct;10(5):379-82 (33 ref.)

Venous return in the fetal-placental cardiovascular system. Moll W. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun; 84(2):133-7 (13 ref.)

Vasa previa: an avoidable obstetric tragedy. Oyelese KO, et al. **Obstet Gynecol Surv** 1999 Feb;54(2):138-45 (58 ref.)

[The potentials of dopplerometry in studying fetal-placental circulation] Kuz'mina IIu. **Lik Sprava** 1998 Aug;(6):24-7 (16 ref.) **(Ukr)**

DRUG EFFECTS

Evaluation of the placenta: suggestions for a greater role in developmental toxicology. Maranghi F, et al.
Adv Exp Med Biol 1998;444:129-36 (23 ref.)

[Effect of smoking on the feto-placental unit] Habek D.
Lijec Vjesn 1998 Jul-Aug;120(7-8):215-9 (46 ref.) (Eng. Abstr.) **(Scr)**

ENZYMOLOGY

Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Burton PJ, et al. **Biol Reprod** 1999 Feb;60(2):234-40 (98 ref.)

Physiological roles of placental proteases in feto-placental homeostasis. Mizutani S. **Nagoya J Med Sci** 1998 Oct; 61(3-4):85-95 (73 ref.)

Expression of 11 beta-hydroxysteroid dehydrogenase in early pregnancy: implications in human trophoblast-endometrial interactions. Arcuri F, et al. **Semin Reprod Endocrinol** 1999; 17(1):53-61 (63 ref.)

GROWTH & DEVELOPMENT

Evidence for an association between birth weight and blood pressure. Hindmarsh PC, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):66-9 (24 ref.)

IMMUNOLOGY

HLA expression at the maternal-fetal interface. Hutter H, et al. **Dev Immunol** 1998;6(3-4):197-204 (57 ref.)

Placental HLA-G protein expression in vivo: where and what for? Le Bouteiller P, et al. **Hum Reprod Update** 1999 May-Jun;5(3):223-33 (101 ref.)

The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces. Guller S, et al.
Semin Reprod Endocrinol 1999;17(1):39-44 (53 ref.)

METABOLISM

Placental corticotropin-releasing hormone: function and regulation. Majzoub JA, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S242-6 (41 ref.)

Placenta growth factor: potential role in pregnancy. Torry DS, et al. **Am J Reprod Immunol** 1999 Jan;41(1):79-85 (64 ref.)

Controlling drug delivery across the placenta. Audus KL. **Eur J Pharm Sci** 1999 Jul;8(3):161-5 (38 ref.)

Pregnancy maintenance and the regulation of placental progesterone biosynthesis in the baboon. Henson MC.
Hum Reprod Update 1998 Jul-Aug;4(4):389-405 (92 ref.)

Central integrative role of oestrogen in the regulation of placental steroidogenic maturation and the development of the fetal pituitary-adrenocortical axis in the baboon. Pepe GJ, et al. **Hum Reprod Update** 1998 Jul-Aug; 4(4):406-19 (127 ref.)

Corticotropin-releasing hormone signals adversity in both the placenta and the brain: regulation by glucocorticoids and allostatic overload. Schulkin J. **J Endocrinol** 1999 Jun; 161(3):349-56 (108 ref.)

The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. Linzer DI, et al. **Mol Endocrinol** 1999 Jun;13(6):837-40 (16 ref.)

Mechanisms of drug transfer across the human placenta. van der Aa EM, et al. **Pharm World Sci** 1998 Aug;20(4):139-48 (139 ref.)

Placental biogenic amine transporters: in vivo function, regulation and pathobiological significance. Nguyen TT, et al. **Placenta** 1999 Jan;20(1):3-11 (108 ref.)

PATHOLOGY

Placental pathology in antiphospholipid syndrome. Levy RA, et al. **Lupus** 1998;7 Suppl 2:S81-5 (21 ref.)

PHYSIOLOGY

Maternal endocrine adaptations to placental hormones in humans. Evain-Brion D. **Acta Paediatr Suppl** 1999 Feb; 88(428):12-6 (46 ref.)

The placenta and its significance in neonatal outcome. Lewis SH, et al. **Adv Pediatr** 1998;45:223-66 (29 ref.)

Corticotropin-releasing hormone and the fetoplacental clock: an Australian perspective. Smith R.
Am J Obstet Gynecol 1999 Jan;180(1 Pt 3):S269-71 (23 ref.)

Formation of the placenta and extraembryonic membranes. Cross JC. **Ann N Y Acad Sci** 1998 Oct 23;857:23-32 (59 ref.)

Confined placental mosaicism and intrauterine fetal growth. Lestou VS, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F223-6 (30 ref.)

Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Miller WL. **Clin Perinatol** 1998 Dec;25(4):799-817, v (104 ref.)

Nutrition of the fetus and the premature infant. Battaglia FC, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B70-4 (42 ref.)

Does the CRH binding protein shield the anterior pituitary from placental CRH? Thomson M. **Endocrine** 1998 Dec; 9(3):221-6 (46 ref.)

The origin and future of placental bed research. Pijnenborg R. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec; 81(2):185-90 (36 ref.)

Paracrine regulation of human placenta: control of hormonogenesis. Petraglia F, et al. **J Reprod Immunol** 1998 Aug;39(1-2):221-33 (46 ref.)

Alterations in the hypothalamic pituitary adrenal axis during pregnancy and the placental clock that determines the length of parturition. Smith R. **J Reprod Immunol** 1998 Aug;39(1-2):215-20 (16 ref.)

Putative role of placental corticotropin-releasing factor in the mechanisms of human parturition. Reis FM, et al.
J Soc Gynecol Investig 1999 May-Jun;6(3):109-19 (106 ref.)

Fetal growth and placental function. Bauer MK, et al.
Mol Cell Endocrinol 1998 May 25;140(1-2):115-20 (41 ref.)

The IGF system during fetal-placental development of the mouse. van Kleffens M, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):129-35 (59 ref.)

Central integrative role of oestrogen in modulating the communication between the placenta and fetus that results in primate fecal-placental development. Albrecht ED, et al. **Placenta** 1999 Mar-Apr;20(2-3):129-39 (128 ref.)

Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Shiverick KT, et al. **Placenta** 1999 May; 20(4):265-72 (103 ref.)

The influence of maternal nutrient restriction in early to mid-pregnancy on placental and fetal development in sheep. Heasman L, et al. **Proc Nutr Soc** 1999 May; 58(2):283-8 (37 ref.)

Dynamics of immunoglobulins at the feto-maternal interface. Saji F, et al. **Rev Reprod** 1999 May;4(2):81-9 (85 ref.)

Transplacental transfer of radionuclides. A review. von Zallinger C, et al. **Zentralbl Veterinarmed A** 1998 Dec; 45(10):581-90 (45 ref.)

[Renin-angiotensin-aldosterone system in the reproductive system] Tanaka M, et al. **Nippon Rinsho** 1999 May; 57(5):1060-4 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Pre-eclampsia: a disorder of placental mitochondria? Widschwendter M, et al. **Mol Med Today** 1998 Jul; 4(7):286-91 (45 ref.)

VIROLOGY

Transmission of HIV to the placenta, fetus and mother and implications of gametic infection. Douglas GC, et al.
J Reprod Immunol 1998 Dec;41(1-2):321-9 (48 ref.)

PLACENTA ACCRETA

THERAPY

[MRI evaluation of placenta accreta treated by embolization. Apropos of a case. Review of the literature] Lemercier E, et al. **J Radiol** 1999 Apr;80(4):383-7 (26 ref.) (Eng. Abstr.) **(Fre)**

PLACENTA DISEASES

PATHOLOGY

A case of intraplacental choriocarcinoma associated with placental hemangioma. Aonahata M, et al. **Pathol Int** 1998 Nov;48(11):897-901 (21 ref.)

Recent trends in chorangiomas, especially those of multiple and recurrent chorangiomas. Benirschke K.
Pediatr Dev Pathol 1999 May-Jun;2(3):264-9 (33 ref.)

PLACENTA DISEASES

ULTRASONOGRAPHY

Vasa previa: an avoidable obstetric tragedy. Oyelese KO, et al. **Obstet Gynecol Surv** 1999 Feb;54(2):138–45 (58 ref.)

PLACENTA PRAEVIA

THERAPY

Placenta previa, placenta abruptio. Baron F, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):527–32 (40 ref.)

PLACENTAL ANTICOAGULANT PROTEIN I see **ANNEXIN V**

PLACENTAL ANTICOAGULANT PROTEINS see **ANNEXINS**

PLACENTAL EXTRACTS

ADVERSE EFFECTS

Premature sexual development in children following the use of estrogen- or placenta-containing hair products. Tiwary CM. **Clin Pediatr (Phila)** 1998 Dec;37(12):733–9 (29 ref.)

PLACENTAL HORMONES

PHYSIOLOGY

Physiological role of human placental growth hormone. Alsat E, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):121–7 (36 ref.)

PLACENTAL LACTOGEN

see related
RECEPTORS, SOMATOTROPIN

METABOLISM

The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. Linzer DI, et al. **Mol Endocrinol** 1999 Jun;13(6):837–40 (16 ref.)

PLACENTAL PROTEINS see **PREGNANCY PROTEINS**

PLACENTAL-SITE TROPHOBLASTIC TUMOR see **TROPHOBLASTIC TUMOR, PLACENTAL SITE**

PLACENTAL VILLI see **CHORIONIC VILLI**

PLACENTATION

The influence of the maternal uterine immune response on placentation in human subjects. King A, et al. **Proc Nutr Soc** 1999 Feb;58(1):69–73 (36 ref.)

IMMUNOLOGY

[Immunologic and tumor biology aspects of placentation in humans] Marzusch K, et al. **Zentralbl Gynakol** 1999; 121(4):206–13 (99 ref.) (Eng. Abstr.) **(Ger)**

PLACENTOMA, NORMAL see **PLACENTA**

PLACENTOME see **PLACENTA**

PLAGUE

Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections. Smego RA, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):1–15 (183 ref.)

[Plague] Yanagihara I, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):119–22 (9 ref.) **(Jpn)**

EPIDEMIOLOGY

Plague. Titball RW, et al. **Br Med Bull** 1998;54(3):625–33 (16 ref.)

Infectious disease. Return of the plagues. Raoult D. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV18 (5 ref.)

PLANARIANS

PHYSIOLOGY

The use of planarians to dissect the molecular basis of metazoan regeneration. Alvarado AS, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):413–20 (39 ref.)

PLANETS

see related
EXTRATERRESTRIAL ENVIRONMENT

Interiors of giant planets inside and outside the solar system. Guillot T. **Science** 1999 Oct 1;286(5437):72–7 (58 ref.)

PLANKTON

see related
EUTROPHICATION

RADIATION EFFECTS

The impact of UVB radiation on marine plankton. Davidson AT. **Mutat Res** 1998 Nov 9;422(1):119–29 (116 ref.)

PLANNED PARENTHOOD see **FAMILY PLANNING**

PLANNING, HEALTH AND WELFARE see **HEALTH PLANNING**

PLANNING, HEALTH FACILITY see **HEALTH FACILITY PLANNING**

PLANNING TECHNIQUES

see related
HEALTH PLANNING

PLANT AGGLUTININS see **LECTINS**

PLANT COMPONENTS

CHEMISTRY

Strategies for bioengineering the development and metabolism of glandular tissues in plants. McCaskill D, et al. **Nat Biotechnol** 1999 Jan;17(1):31–6 (85 ref.)

GROWTH & DEVELOPMENT

Petal and stamen development. Irish VF. **Curr Top Dev Biol** 1999;41:133–61 (141 ref.)

Patterning the flower. Irish VF. **Dev Biol** 1999 May 15; 209(2):211–20 (99 ref.)

PHYSIOLOGY

Phloem transport: Are you chaperoned? Crawford KM, et al. **Curr Biol** 1999 Apr 22;9(8):R281–5 (23 ref.)

Strategies for bioengineering the development and metabolism of glandular tissues in plants. McCaskill D, et al. **Nat Biotechnol** 1999 Jan;17(1):31–6 (85 ref.)

Signaling in pollen-pistil interactions [see comments] Gaude T, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):139–47 (73 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.

PLANT DISEASES

Biocontrol of plant disease: a (gram-) positive perspective. Emmert EA, et al. **FEMS Microbiol Lett** 1999 Feb 1; 171(1):1–9 (47 ref.)

Introduction to classical crossprotection. Fraser RS. **Methods Mol Biol** 1998;81:13–24 (70 ref.)

Phytooxylipins and plant defense reactions. Blée E. **Prog Lipid Res** 1998 May;37(1):33–72 (361 ref.)

GENETICS

The hypersensitive response. A programmed cell death associated with plant resistance. Pontier D, et al. **C R Acad Sci III** 1998 Sep;321(9):721–34 (174 ref.)

Functional analysis of plant disease resistance genes and their downstream effectors. Martin GB. **Curr Opin Plant Biol** 1999 Aug;2(4):273–9 (51 ref.)

Clusters of resistance genes in plants evolve by divergent selection and a birth-and-death process. Michelmore RW, et al. **Genome Res** 1998 Nov;8(11):1113–30 (105 ref.)

Characterization of plant nematode genes: identifying targets for a transgenic defence. Lilley CJ, et al. **Parasitology** 1999; 118 Suppl:S63–72 (70 ref.)

MICROBIOLOGY

Fungi in forestry--significance and research in Hungary. Szabó I. **Acta Microbiol Immunol Hung** 1999; 46(2–3):245–52 (25 ref.)

Current research on phytopathogenic fungi: an overview. Virányi F. **Acta Microbiol Immunol Hung** 1999; 46(2–3):253–7 (36 ref.)

Gene-for-gene interactions: bacterial avirulence proteins specify plant disease resistance. Bonas U, et al. **Curr Opin Microbiol** 1999 Feb;2(1):94–8 (59 ref.)

Avirulence and resistance genes in the Cladosporium fulvum-tomato interaction. de Wit PJ, et al. **Curr Opin Microbiol** 1999 Aug;2(4):368–73 (49 ref.)

Infection-related development in the rice blast fungus Magnaporthe grisea. Hamer JE, et al. **Curr Opin Microbiol** 1998 Dec;1(6):693–7 (39 ref.)

Use of molecular cytology to study the structure and biology of phytopathogenic and mycorrhizal fungi. Hardham AR, et al. **Fungal Genet Biol** 1998 Jun–Jul;24(1–2):252–84 (286 ref.)

PARASITOLOGY

Phytomonas and other trypanosomatid parasites of plants and fruit. Camargo EP. **Adv Parasitol** 1999;42:29–112 (340 ref.)

VIROLOGY

Some results of 50 years of research on the resistance to plum pox virus. Kegler H, et al. **Acta Virol** 1998 Sep; 42(4):200–15 (270 ref.)

Viroids and the nature of viroid diseases. Diener TO. **Arch Virol Suppl** 1999;15:203–20 (89 ref.)

Gene silencing: plants and viruses fight it out. Smyth DR. **Curr Biol** 1999 Feb 11;9(3):R100–2 (17 ref.)

Fast forward genetics based on virus-induced gene silencing. Baulcombe DC. **Curr Opin Plant Biol** 1999 Apr;2(2):109–13 (49 ref.)

Mechanisms of arthropod transmission of plant and animal viruses. Gray SM, et al. **Microbiol Mol Biol Rev** 1999 Mar; 63(1):128–48 (168 ref.)

Tobacco mosaic virus virulence and avirulence. Dawson WO. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):645–51 (61 ref.)

Recognition and receptors in virus transmission by arthropods. van den Heuvel JF, et al. **Trends Microbiol** 1999 Feb;7(2):71–6 (59 ref.)

PLANT DNA see **DNA, PLANT**

PLANT EMBRYOS see **SEEDS**

PLANT EPIDERMIS

PHYSIOLOGY

Perspective: phloem transport of viruses and macromolecules – what goes in must come out. Santa Cruz S. **Trends Microbiol** 1999 Jun;7(6):237–41 (44 ref.)

PLANT EXTRACTS

Novel chemicals from plants via bioengineering. An overview. Kolodziejczyk PP, et al. **Adv Exp Med Biol** 1999; 464:1–4 (5 ref.)

ADVERSE EFFECTS

Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Ernst E, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):589–94 (40 ref.)

CHEMISTRY

Chemistry and pharmacology of Monimiaceae: a special focus on Siparuna and Mollinedia. Leitão GG, et al. **J Ethnopharmacol** 1999 May;65(2):87–102 (61 ref.)

ISOLATION & PURIFICATION

Recent progress in biotechnology of Mexican medicinal plants. Villarreal ML, et al. **Adv Exp Med Biol** 1999; 464:221–33 (22 ref.)

METABOLISM

Modern drug development from traditional medicinal plants using radioligand receptor-binding assays. Misra R. **Med Res Rev** 1998 Nov;18(6):383–402 (37 ref.)

PHARMACOLOGY

Kava: Piper methysticum. Pepping J. **Am J Health Syst Pharm** 1999 May 15;56(10):957–8, 960 (27 ref.)

Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions [see comments] Miller LG. **Arch Intern Med** 1998 Nov 9; 158(20):2200–11 (171 ref.) Comment in: Arch Intern Med 1999 May 24;159(10):1142–3.

The DINs and don'ts of herbal/natural preparations. Mishkin S. **Can J Gastroenterol** 1999 May;13(4):335–7 (14 ref.)

Stilbene compounds: from the grapevine to wine. Bavaresco L, et al. **Drugs Exp Clin Res** 1999;25(2–3):57–63 (56 ref.)

Cardioprotection of red wine: role of polyphenolic antioxidants. Das DK, et al. **Drugs Exp Clin Res** 1999; 25(2–3):115–20 (25 ref.)

Flavonoids: old and new aspects of a class of natural therapeutic drugs. Di Carlo G, et al. **Life Sci** 1999; 65(4):337–53 (102 ref.)

Tuberculosis: a search for novel therapy starting with natural products. Mitscher LA, et al. **Med Res Rev** 1998 Nov; 18(6):363–74 (19 ref.)

Assay of inducible form of nitric oxide synthase activity: effect of flavonoids and plant extracts. Kobuchi H, et al. **Methods Enzymol** 1999;301:504–13 (30 ref.)

The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Nathan P. **Mol Psychiatry** 1999 Jul;4(4):333–8 (68 ref.)

Recent advances in the fight against leishmaniasis with natural products. Akendengue B, et al. **Parasite** 1999 Mar; 6(1):3–8 (26 ref.)

Pharmacology and chemotaxonomy of Diospyros. Mallavadhani UV, et al. **Phytochemistry** 1998 Oct; 49(4):901–51 (271 ref.)

Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Rege NN, et al. **Phytother Res** 1999 Jun;13(4):275–91 (90 ref.)

Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. Dashwood RH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):239–43 (28 ref.)

Mechanistic findings of green tea as cancer preventive for humans. Fujiki H, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):225–8 (14 ref.)

Mechanism of cancer chemopreventive activity of green Tea. Mukhtar H, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):234–8 (31 ref.)

Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Rice-Evans C. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):262–6 (21 ref.)
Tea and health: the underlying mechanisms. Weisburger JH. **Proc Soc Exp Biol Med** 1999 Apr;220(4):271–5 (42 ref.)
[Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000] Clostre F. **Ann Pharm Fr** 1999 Jul;57 Suppl 1:1S8–88 (295 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Black cohosh: Cimicifuga racemosa. Pepping J. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1400–2 (21 ref.)
Echinacea. Pepping J. **Am J Health Syst Pharm** 1999 Jan 15;56(2):121–2 (10 ref.)
Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Mashour NH, et al. **Arch Intern Med** 1998 Nov 9;158(20):2225–34 (125 ref.)
Feverfew as a preventive treatment for migraine: a systematic review. Vogler BK, et al. **Cephalalgia** 1998 Dec; 18(10):704–8 (30 ref.)
Utilization of natural products for treatment of blood diseases. Miles DH, et al. **Curr Med Chem** 1998 Dec; 5(6):421–40 (65 ref.)
Natural products as angiogenesis inhibitors. Paper DH. **Planta Med** 1998 Dec;64(8):686–95 (124 ref.)
The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Chung FL. **Proc Soc Exp Biol Med** 1999 Apr;220(4):244–8 (28 ref.)
Preclinical efficacy studies of green and black tea extracts. Steele VE, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):210–2 (5 ref.)
Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Lowe FC, et al. **Prostate** 1998 Nov 1;37(3):187–93 (32 ref.)
[Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000] Clostre F. **Ann Pharm Fr** 1999 Jul;57 Suppl 1:1S8–88 (295 ref.) (Eng. Abstr.) **(Fre)**
[Adaptogens as agents for prophylactic oncology] Bocharova OA. **Vestn Ross Akad Med Nauk** 1999;(5):49–53 (76 ref.) (Eng. Abstr.) **(Rus)**

PLANT EXTRACTS, CHINESE see **DRUGS, CHINESE HERBAL**

PLANT GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, PLANT**

PLANT GENES see **GENES, PLANT**

PLANT GENOME see **GENOME, PLANT**

PLANT GROWTH REGULATORS

METABOLISM

Plants embrace a stepchild: the discovery of peptide growth regulators. Franssen HJ. **Curr Opin Plant Biol** 1998 Oct; 1(5):384–7 (37 ref.)
ABA signal transduction. Grill E, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):412–8 (69 ref.)
Jasmonate and salicylate as global signals for defense gene expression. Reymond P, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):404–11 (76 ref.)
Ethylene gas: perception, signaling and response. Solano R, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):393–8 (52 ref.)

PHYSIOLOGY

Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Setchell KD. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1333S–1346S (226 ref.)
Radically novel prostaglandins in animals and plants: the isoprostanes. Mueller MJ. **Chem Biol** 1998 Dec; 5(12):R323–33 (90 ref.)
Receptors and signalling components of plant hormones. Iten M, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):41–58 (71 ref.)
Plant hormone perception and action: a role for G-protein signal transduction? Hooley R. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1425–30 (55 ref.)

PLANT HORMONES see **PLANT GROWTH REGULATORS**

PLANT LEAVES

CYTOLOGY

Cellular differentiation in the leaf. Langdale JA. **Curr Opin Cell Biol** 1998 Dec;10(6):734–8 (43 ref.)

GROWTH & DEVELOPMENT

The specification of leaf identity during shoot development. Kerstetter RA, et al. **Annu Rev Cell Dev Biol** 1998; 14:373–98 (122 ref.)
Axioms and axes in leaf formation? Hudson A. **Curr Opin Plant Biol** 1999 Feb;2(1):56–60 (44 ref.)
The formation of leaves. Tsiantis M, et al. **Curr Opin Plant Biol** 1998 Feb;1(1):43–8 (51 ref.)
Development of the leaf epidermis. Becraft PW. **Curr Top Dev Biol** 1999;45:1–40 (154 ref.)
Genetic, molecular, and morphological analysis of compound leaf development. Goliber T, et al. **Curr Top Dev Biol** 1999; 43:259–90 (100 ref.)

PHYSIOLOGY

Plant development: the making of a leaf. Christensen S, et al. **Curr Biol** 1998 Sep 10;8(18):R643–5 (9 ref.)
The evolutionary basis of leaf senescence: method to the madness? Bleecker AB. **Curr Opin Plant Biol** 1998 Feb; 1(1):73–8 (19 ref.)

PLANT OILS

Production of novel oils in plants. Murphy DJ. **Curr Opin Biotechnol** 1999 Apr;10(2):175–80 (45 ref.)
Antioxidant and other activities of phenolics in olives/olive oil, typical components of the Mediterranean diet. Galli C, et al. **Lipids** 1999;34 Suppl:S23–6 (14 ref.)
Movements towards tailor-made fats. Gunstone FD. **Prog Lipid Res** 1998 Nov;37(5):277–305 (89 ref.)
Risk of developing lung cancer in relation to exposure to fumes from Chinese-style cooking. Zhong L, et al. **Scand J Work Environ Health** 1999 Aug;25(4):309–16 (35 ref.)

ADMINISTRATION & DOSAGE

Plant sources of vitamin A and human nutrition: red palm oil does the job. Solomons NW. **Nutr Rev** 1998 Oct; 56(10):309–11 (12 ref.)

ADVERSE EFFECTS

Tea tree oil allergy: what is the offending agent? Report of three cases of tea tree oil allergy and review of the literature. Rubel DM, et al. **Australas J Dermatol** 1998 Nov; 39(4):244–7 (9 ref.)

ANALYSIS

Tea tree oil allergy: what is the offending agent? Report of three cases of tea tree oil allergy and review of the literature. Rubel DM, et al. **Australas J Dermatol** 1998 Nov; 39(4):244–7 (9 ref.)

CHEMISTRY

Impact of processing on formation of trans fatty acids. King JM, et al. **Adv Exp Med Biol** 1999;459:51–65 (52 ref.)
Manipulation of plant oil composition for the production of valuable chemicals. Progress, problems, and prospects. Murphy DJ. **Adv Exp Med Biol** 1999;464:21–35 (30 ref.)
Impact of high-temperature food processing on fats and oils. Warner K. **Adv Exp Med Biol** 1999;459:67–77 (25 ref.)

METABOLISM

Recent developments in biochemistry of the plant lipoxygenase pathway. Grechkin A. **Prog Lipid Res** 1998 Nov;37(5):317–52 (277 ref.)

PHARMACOLOGY

[Gamma-oryzanol: an important component in rice brain oil] Scavariello EM, et al. **Arch Latinoam Nutr** 1998 Mar; 48(1):7–12 (30 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Efficacy and safety of tea tree oil as a topical antimicrobial agent. Carson CF, et al. **J Hosp Infect** 1998 Nov; 40(3):175–8 (30 ref.)
[Sea buckthorn and sea buckthorn oils--recent developments in China and central Asia] Aitzetmüller K, et al. **Nahrung** 1999 Aug;43(4):228–32 (25 ref.) (Eng. Abstr.) **(Ger)**

PLANT PHOTORECEPTORS see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT PHOTOSYNTHETIC PROTEIN COMPLEXES see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT PHOTOSYNTHETIC REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT PHYSIOLOGY

Flavonoids and arbuscular-mycorrhizal fungi. Vierheilig H, et al. **Adv Exp Med Biol** 1998;439:9–33 (72 ref.)
Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Jabs T. **Biochem Pharmacol** 1999 Feb 1;57(3):231–45 (161 ref.)
The plant Golgi apparatus. Dupree P, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):259–70 (84 ref.)
Plant responses to metal toxicity. Briat JF, et al. **C R Acad Sci III** 1999 Jan;322(1):43–54 (130 ref.)
Structure and functions of the vascular cambium. Lachaud S, et al. **C R Acad Sci III** 1999 Aug;322(8):633–50 (177 ref.)
Intercellular connections are developmentally controlled to help move molecules through the plant [comment] Pickard BG, et al. **Cell** 1999 Jul 9;98(1):5–8 (12 ref.) Comment on: Cell 1999 Jun 11;97(6):743–54.
Light perception in higher plants. Batschauer A. **Cell Mol Life Sci** 1999 Feb;55(2):153–66 (165 ref.)
MAP kinases in plant signal transduction. Jonak C, et al. **Cell Mol Life Sci** 1999 Feb;55(2):204–13 (40 ref.)
Ultradian rhythms in Desmodium. Engelmann W, et al. **Chronobiol Int** 1998 Jul;15(4):293–307 (80 ref.)
Gene silencing: plants and viruses fight it out. Smyth DR. **Curr Biol** 1999 Feb 11;9(3):R100–2 (17 ref.)
Novel coloured flowers. Mol J, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):198–201 (24 ref.)
Seeing the world in red and blue: insight into plant vision and photoreceptors. Ahmad M. **Curr Opin Plant Biol** 1999 Jun;2(3):230–5 (43 ref.)
Plant stress adaptations--making metabolism move. Bohnert HJ, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):267–74 (56 ref.)
Biochemical dissection of photorespiration. Douce R, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):214–22 (58 ref.)
Molecular determinants of sink strength. Herbers K, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):207–16 (58 ref.)
Resistance response physiology and signal transduction. Scheel D. **Curr Opin Plant Biol** 1998 Aug;1(4):305–10 (67 ref.)
Plant-insect interactions. Stotz HU, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):268–72 (50 ref.)
The mating game: pollination and fertilization in flowering plants. Wilhelmi LK, et al. **Curr Opin Plant Biol** 1999 Feb; 2(1):18–22 (53 ref.)
Parasitic plant responses to host plant signals: a model for subterranean plant-plant interactions. Yoder JI. **Curr Opin Plant Biol** 1999 Feb;2(1):65–70 (51 ref.)
Plant graviperception and gravitropism: a newcomer's view. Ranjeva R, et al. **FASEB J** 1999;13 Suppl:S135–41 (67 ref.)
Statoliths motions in gravity-perceiving plant cells: does actomyosin counteract gravity? Volkmann D, et al. **FASEB J** 1999;13 Suppl:S143–7 (51 ref.)
Spontaneous ultraweak bioluminescence in plants: origin, mechanisms and properties. Radotić K, et al. **Gen Physiol Biophys** 1998 Dec;17(4):289–308 (105 ref.)
Plant pathogenesis-related proteins: molecular mechanisms of gene expression and protein function. Kitajima S, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):1–8 (61 ref.)
Ionic channels of the vacuolar membrane of higher plants. Tikhonova LI. **Membr Cell Biol** 1998;12(3):301–18 (117 ref.)
The plant cell cycle in context. Fowler MR, et al. **Mol Biotechnol** 1998 Oct;10(2):123–53 (308 ref.)
Jasmonates: key players in the plant defence. Beale MH, et al. **Nat Prod Rep** 1998 Dec;15(6):533–48 (150 ref.)
Oligopeptide signalling and the action of systemin. Schaller A. **Plant Mol Biol** 1999 Jul;40(5):763–9 (17 ref.)
Photoreceptors of higher plants. Batschauer A. **Planta** 1998 Nov;206(4):479–92 (166 ref.)
Calcium-dependent signal transduction pathways in plants--phytochrome mechanism of action as an example. Tretyn A. **Pol J Pharmacol** 1999 Mar-Apr;51(2):145–51 (45 ref.)
How plants learn [comment] Trewavas A. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4216–8 (23 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4718–23.
Signalling in light-controlled development [see comments] Deng XW, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):121–9 (71 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.
Signalling in cell type specification [see comments] Dolan L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):149–56 (33 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.
A molecular basis for auxin action [see comments] Leyser O, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):131–7 (35 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.
An introduction to ALS-inhibiting herbicides. Whitcomb CE. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):231–9 (114 ref.)
[Plant defense-related proteins as latex allergens] Yagami T. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):46–62 (121 ref.) (Eng. Abstr.) **(Jpn)**
[Early events occurring during light signal transduction in plants] Hasunuma K, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1443–52 (50 ref.) **(Jpn)**
[Oligosaccharides as the elicitor signal for the activation of defense system in plants] Shibuya N, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2531–9 (58 ref.) **(Jpn)**

PLANT POISONING

Microalgal blooms: a global issue with negative impact in Chile. Lagos N. **Biol Res** 1998;31(4):375–86 (54 ref.)

DIAGNOSIS

Pyrrolizidine alkaloid plants, metabolism and toxicity. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):95–116 (155 ref.)

ETIOLOGY

[The hunter hunted (editorial++; comment)] Garrido

PLANT POISONING

Morales P. **Med Clin (Barc)** 1999 Feb 6;112(4):140-2 (49 ref.) Comment on: Med Clin (Barc) 1999 Feb 6;112(4):143-6. **(Spa)**

VETERINARY

Lupines, poison-hemlock and Nicotiana spp: toxicity and teratogenicity in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):117-34 (88 ref.)

Locoweeds: effects on reproduction in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):53-62 (49 ref.)

Larkspur (Delphinium spp.) poisoning in livestock. Pfister JA, et al. **J Nat Toxins** 1999 Feb;8(1):81-94 (76 ref.)

Locoweed grazing. Ralphs MH, et al. **J Nat Toxins** 1999 Feb;8(1):47-51 (42 ref.)

Biochemistry of hemlock (Conium maculatum L.) alkaloids and their acute and chronic toxicity in livestock. A review. López TA, et al. **Toxicon** 1999 Jun;37(6):841-65 (96 ref.)

PLANT PROTEINS

Plant lectins - more than just tools for glycoscientists: occurrence, structure, and possible functions of plant lectins. Rüdiger H. **Acta Anat (Basel)** 1998;161(1-4):130-52 (381 ref.)

Molecular strategies to improve the nutritional quality of legume proteins. de Lumen BO, et al. **Adv Exp Med Biol** 1999;464:117-26 (30 ref.)

[Plant defense-related proteins as latex allergens] Yagami T. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):46-62 (121 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Genetically modified food: a danger or a benefit for atopics? Ebner C. **Curr Probl Dermatol** 1999;28:81-7 (11 ref.)

In vitro screening of food peptides toxic for coeliac and other gluten-sensitive patients: a review. Silano M, et al. **Toxicology** 1999 Feb 15;132(2-3):99-110 (98 ref.)

ANALYSIS

2-D electrophoresis of plant proteins. Tsugita A, et al. **Methods Mol Biol** 1999;112:95-7 (6 ref.)

BIOSYNTHESIS

Molecular strategies to improve the nutritional quality of legume proteins. de Lumen BO, et al. **Adv Exp Med Biol** 1999;464:117-26 (30 ref.)

Molecular farming of industrial proteins from transgenic maize. Hood EE, et al. **Adv Exp Med Biol** 1999;464:127-47 (40 ref.)

Mevalonate biosynthesis in plants. Bach TJ, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):107-22 (90 ref.)

Isoprenoid biosynthesis in plants: carbon partitioning within the cytoplasmic pathway. Newman JD, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):95-106 (80 ref.)

CHEMISTRY

A model for early events in the assembly pathway of cyanobacterial phycobilisomes. Anderson LK, et al. **Mol Microbiol** 1998 Nov;30(3):467-74 (45 ref.)

Bioactive antinutritional peptides derived from cereal prolamins: a review. Silano M, et al. **Nahrung** 1999 Jun; 43(3):175-84 (127 ref.)

The ethylene-receptor family from Arabidopsis: structure and function. Bleecker AB, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1405-12 (42 ref.)

Zinc-finger proteins: the classical zinc finger emerges in contemporary plant science. Takatsuji H. **Plant Mol Biol** 1999 Apr;39(6):1073-8 (13 ref.)

DIAGNOSTIC USE

Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Brinck U, et al. **Acta Anat (Basel)** 1998;161(1-4):219-33 (90 ref.)

GENETICS

Molecular strategies to improve the nutritional quality of legume proteins. de Lumen BO, et al. **Adv Exp Med Biol** 1999;464:117-26 (30 ref.)

An update on allergens. Parietaria pollen allergens. Colombo P, et al. **Allergy** 1998 Oct;53(10):917-21 (31 ref.)

Structure and function of proteins controlling strain-specific pathogen resistance in plants. Ellis J, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):288-93 (46 ref.)

Self-incompatibility and other pollen-pistil interactions. McCormick S. **Curr Opin Plant Biol** 1998 Feb;1(1):18-25 (43 ref.)

Proteomics for genetic and physiological studies in plants. Thiellement H, et al. **Electrophoresis** 1999 Jul; 20(10):2013-26 (119 ref.)

Plant pathogenesis-related proteins: molecular mechanisms of gene expression and protein function. Kitajima S, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):1-8 (61 ref.)

Transcription signals of mitochondrial and nuclear genes for mitochondrial proteins in dicot plants. Brennicke A, et al. **J Hered** 1999 May-Jun;90(3):345-50 (34 ref.)

Sequence analyses and phylogenetic characterization of the ZIP family of metal ion transport proteins. Eng BH, et al. **J Membr Biol** 1998 Nov 1;166(1):1-7 (24 ref.)

Interactions between tobacco mosaic virus and the tobacco N gene. Erickson FL, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):653-8 (41 ref.)

Plant disease-resistance proteins and the gene-for-gene concept. Van der Biezen EA, et al. **Trends Biochem Sci** 1998 Dec;23(12):454-6 (25 ref.)

Evolution of a conserved protein module from Archaea to plants. Shutov AD, et al. **Trends Genet** 1999 Sep; 15(9):348-9 (18 ref.)

IMMUNOLOGY

Peanut allergens. Burks W, et al. **Allergy** 1998 Aug; 53(8):725-30 (33 ref.)

The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Valenta R, et al. **Clin Exp Allergy** 1999 Jul;29(7):896-904 (68 ref.)

ISOLATION & PURIFICATION

Plant defense peptides. García-Olmedo F, et al. **Biopolymers** 1998;47(6):479-91 (148 ref.)

METABOLISM

Membrane proteins involved in pollen-pistil interactions. Giranton JL, et al. **Biochimie** 1999 Jun;81(6):675-80 (46 ref.)

Protein retention and localization in the endoplasmic reticulum and the golgi apparatus. Gomord V, et al. **Biochimie** 1999 Jun;81(6):607-18 (109 ref.)

Involvement of plasma membrane proteins in plant defense responses. Analysis of the cryptogein signal transduction in tobacco. Lebrun-Garcia A, et al. **Biochimie** 1999 Jun; 81(6):663-8 (52 ref.)

Beyond plant lectin histochemistry: preparation and application of markers to visualize the cellular capacity for protein-carbohydrate recognition. Gabius HJ, et al. **Biotech Histochem** 1998 Sep;73(5):263-77 (79 ref.)

Structure and function of metal chelators produced by plants: the case for organic acids, amino acids, phytin, and metallothioneins. Rauser WE. **Cell Biochem Biophys** 1999; 31(1):19-48 (174 ref.)

Enzymology of phytosterol transformations. Nes WD, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):81-93 (40 ref.)

Ethylene signalling: redundant receptors all have their say. Theologis A. **Curr Biol** 1998 Dec 3;8(24):R875-8 (16 ref.)

Connections between virus movement, macromolecular signaling and assimilate allocation. Lucas WJ, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):192-7 (51 ref.)

Regulation of cytosolic enzymes in primary metabolism by reversible protein phosphorylation. MacKintosh C. **Curr Opin Plant Biol** 1998 Jun;1(3):224-9 (37 ref.)

Protein transport within the plant cell endomembrane system: an update. Matsuoka K, et al. **Curr Opin Plant Biol** 1998 Dec;1(6):463-9 (68 ref.)

Protein phosphorylation and redox sensing in chloroplast thylakoids. Vener AV, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):217-23 (48 ref.)

Plant pathogenesis-related proteins: molecular mechanisms of gene expression and protein function. Kitajima S, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):1-8 (61 ref.)

Proteins for transport of water and mineral nutrients across the membranes of plant cells. Chrispeels MJ, et al. **Plant Cell** 1999 Apr;11(4):661-76 (113 ref.)

Protein import and routing systems of chloroplasts. Keegstra K, et al. **Plant Cell** 1999 Apr;11(4):557-70 (106 ref.)

The specificity of vesicle trafficking: coat proteins and SNAREs. Sanderfoot AA, et al. **Plant Cell** 1999 Apr; 11(4):629-42 (108 ref.)

News in chloroplast protein import. Caliebe A, et al. **Plant Mol Biol** 1999 Mar;39(4):641-5 (14 ref.)

Protein targeting to the nuclear pore. What can we learn from plants? Smith HM, et al. **Plant Physiol** 1999 Apr; 119(4):1157-64 (43 ref.)

Protein translocation into and across the bacterial plasma membrane and the plant thylakoid membrane. Dalbey RE, et al. **Trends Biochem Sci** 1999 Jan;24(1):17-22 (53 ref.)

Protein import into chloroplasts. Chen X, et al. **Trends Cell Biol** 1999 Jun;9(6):222-7 (48 ref.)

Making sense of the COP9 signalosome. A regulatory protein complex conserved from Arabidopsis to human. Wei N, et al. **Trends Genet** 1999 Mar;15(3):98-103 (41 ref.)

[Adaptation of thylakoid membranes to environmental light conditions] Romanowska E. **Postepy Biochem** 1999; 45(1):58-65 (75 ref.) **(Pol)**

PHARMACOLOGY

Estrogens and atherosclerosis: phytoestrogens and selective estrogen receptor modulators. St Clair RW. **Curr Opin Lipidol** 1998 Oct;9(5):457-63 (101 ref.)

Bioactive antinutritional peptides derived from cereal prolamins: a review. Silano M, et al. **Nahrung** 1999 Jun; 43(3):175-84 (127 ref.)

PHYSIOLOGY

Systemin: a polypeptide signal for plant defensive genes. Ryan CA, et al. **Annu Rev Cell Dev Biol** 1998;14:1-17 (77 ref.)

Recent advances on proteins of plant terminal membranes. Grignon C. **Biochimie** 1999 Jun;81(6):577-96 (170 ref.)

Photomorphogenesis: Phytochrome takes a partner! Whitelam GC, et al. **Curr Biol** 1999 Mar 25;9(6):R225-7 (16 ref.)

14-3-3 proteins: eukaryotic regulatory proteins with many functions. Finnie C, et al. **Plant Mol Biol** 1999 Jul; 40(4):545-54 (78 ref.)

Oligopeptide signalling and the action of systemin. Schaller A. **Plant Mol Biol** 1999 Jul;40(5):763-9 (17 ref.)

Cell wall loosening by expansins. Cosgrove DJ. **Plant Physiol** 1998 Oct;118(2):333-9 (32 ref.)

The role of COP1 in repression of Arabidopsis photomorphogenic development. Osterlund MT, et al. **Trends Cell Biol** 1999 Mar;9(3):113-8 (37 ref.)

Perspective: phloem transport of viruses and macromolecules - what goes in must come out. Santa Cruz S. **Trends Microbiol** 1999 Jun;7(6):237-41 (44 ref.)

PLANT RNA see **RNA, PLANT**

PLANT ROOTS

CHEMISTRY

Chemicals from roots, hairy roots, and their application. Canto-Canché B, et al. **Adv Exp Med Biol** 1999;464:235-75 (410 ref.)

GROWTH & DEVELOPMENT

Root development: new meanings for root canals? Scheres B, et al. **Curr Opin Plant Biol** 1998 Feb;1(1):32-6 (28 ref.)

METABOLISM

Plant 'hairy root' culture. Shanks JV, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):151-5 (52 ref.)

MICROBIOLOGY

Extracellular polysaccharides and polysaccharide-containing biopolymers from Azospirillum species: properties and the possible role in interaction with plant roots. Skvortsov IM, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):223-9 (47 ref.)

Use of molecular cytology to study the structure and biology of phytopathogenic and mycorrhizal fungi. Hardham AR, et al. **Fungal Genet Biol** 1998 Jun-Jul;24(1-2):252-84 (286 ref.)

PHYSIOLOGY

Statoliths motions in gravity-perceiving plant cells: does actomyosin counteract gravity? Volkmann D, et al. **FASEB J** 1999;13 Suppl:S143-7 (51 ref.)

PLANT SHOOTS

CYTOLOGY

Cellular differentiation in the shoot epidermis. Martin C, et al. **Curr Opin Plant Biol** 1998 Dec;1(6):511-9 (54 ref.)

GROWTH & DEVELOPMENT

Reevaluating concepts of apical dominance and the control of axillary bud outgrowth. Napoli CA, et al. **Curr Top Dev Biol** 1999;44:127-69 (140 ref.)

PLANT STEMS

GROWTH & DEVELOPMENT

The specification of leaf identity during shoot development. Kerstetter RA, et al. **Annu Rev Cell Dev Biol** 1998; 14:373-98 (122 ref.)

PLANT STEROLS see **PHYTOSTEROLS**

PLANT STRUCTURAL GENES see **GENES, STRUCTURAL, PLANT**

PLANT STRUCTURES see **PLANT COMPONENTS**

PLANT VIRUSES

Potential benefits of the transgenic control of plant viruses in the United Kingdom. Barker I, et al. **Methods Mol Biol** 1998;81:557-66 (26 ref.)

Introduction to plant virology. Hillman BI. **Methods Mol Biol** 1998;81:3-12 (26 ref.)

CLASSIFICATION

Developments in plant virus taxonomy since the publication of the 6th ICTV Report. International Committee on Taxonomy of Viruses. Mayo MA. **Arch Virol** 1999; 144(8):1659-66 (9 ref.)

GENETICS

Viruses and gene silencing in plants. Baulcombe D. **Arch Virol Suppl** 1999;15:189-201 (50 ref.)

Luteovirus-associated viruses and subviral RNAs. Falk BW, et al. **Curr Top Microbiol Immunol** 1999;239:159-75 (45 ref.)

Replication, recombination, and symptom-modulation properties of the satellite RNAs of turnip crinkle virus. Simon AE. **Curr Top Microbiol Immunol** 1999;239:19-36

(49 ref.)
Encapsidated circular viroid-like satellite RNAs (virusoids) of plants. Symons RH, et al.
Curr Top Microbiol Immunol 1999;239:81–105 (73 ref.)
Defective and defective interfering RNAs of monopartite plus-strand RNA plant viruses. White KA, et al.
Curr Top Microbiol Immunol 1999;239:1–17 (66 ref.)
Recombination in RNA viruses and in virus-resistant transgenic plants. Aaziz R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1339–46 (85 ref.)

METABOLISM

Viroids with hammerhead ribozymes: some unique structural and functional aspects with respect to other members of the group. Flores R, et al. **Biol Chem** 1999 Jul–Aug; 380(7–8):849–54 (36 ref.)
Endogenous changes in citokinin activity in systemically virus-infected plants. Pennazio S, et al. **New Microbiol** 1998 Oct;21(4):419–26 (62 ref.)

PATHOGENICITY

Viruses and gene silencing in plants. Baulcombe D.
Arch Virol Suppl 1999;15:189–201 (50 ref.)
Recognition and receptors in virus transmission by arthropods. van den Heuvel JF, et al. **Trends Microbiol** 1999 Feb;7(2):71–6 (59 ref.)

PHYSIOLOGY

Gene silencing: plants and viruses fight it out. Smyth DR. **Curr Biol** 1999 Feb 11;9(3):R100–2 (17 ref.)
Fast forward genetics based on virus-induced gene silencing. Baulcombe DC. **Curr Opin Plant Biol** 1999 Apr;2(2):109–13 (49 ref.)
Connections between virus movement, macromolecular signaling and assimilate allocation. Lucas WJ, et al.
Curr Opin Plant Biol 1999 Jun;2(3):192–7 (51 ref.)
Perspective: phloem transport of viruses and macromolecules – what goes in must come out. Santa Cruz S.
Trends Microbiol 1999 Jun;7(6):237–41 (44 ref.)

PLANT ZYGOTES see **SEEDS**

PLANTANISTIDAE see **DOLPHINS**

PLANTAR PRINTS see **DERMATOGLYPHICS**

PLANTAR ULCER see **FOOT ULCER**

PLANTARIS MUSCLE see **MUSCLE, SKELETAL**

PLANTS

see related
HERBICIDES
POLLEN
SEEDS

Use of plant cell cultures in biotechnology. Mühlbach HP. **Biotechnol Annu Rev** 1998;4:113–76 (254 ref.)
Plastid evolution: origins, diversity, trends. Douglas SE.
Curr Opin Genet Dev 1998 Dec;8(6):655–61 (73 ref.)
Plants showing antiplasmodial activity—from crude extracts to isolated compounds. Sharma P, et al.
Indian J Malariol 1998 Jun;35(2):57–110 (134 ref.)

ADVERSE EFFECTS

Phytophotodermatitis. Bowers AG. **Am J Contact Dermat** 1999 Jun;10(2):89–93 (20 ref.)
The language of plants. McGovern TW.
Am J Contact Dermat 1999 Mar;10(1):45–7 (2 ref.)
Phytodermatitis. Sasseville D. **J Cutan Med Surg** 1999 Jul; 3(5):263–79 (58 ref.)
Phytoestrogens and human health effects: weighing up the current evidence. Humfrey CD. **Nat Toxins** 1998;6(2):51–9 (76 ref.)

CHEMISTRY

Bioactive agents from natural sources: trends in discovery and application. Grabley S, et al.
Adv Biochem Eng Biotechnol 1999;64:101–54 (360 ref.)
Insect cytochromes P450: diversity, insecticide resistance and tolerance to plant toxins. Scott JG, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Nov;121(1–3):147–55 (74 ref.)
Inhibition of cholesterol absorption by plant sterols for mass intervention. Ikeda I, et al. **Curr Opin Lipidol** 1998 Dec; 9(6):527–31 (42 ref.)
Regulation of cholesterol metabolism by dietary plant sterols. Miettinen TA, et al. **Curr Opin Lipidol** 1999 Feb;10(1):9–14 (54 ref.)
A 20(th) century roller coaster ride: a short account of lignification. Lewis NG. **Curr Opin Plant Biol** 1999 Apr; 2(2):153–62 (55 ref.)
Bioactive phytochemicals with emphasis on dietary practices. Krishnaswamy K, et al. **Indian J Med Res** 1998 Nov; 108:167–81 (56 ref.)
Starch granules: structure and biosynthesis. Buléon A, et al. **Int J Biol Macromol** 1998 Aug;23(2):85–112 (211 ref.)
Anticancer drug design based on plant-derived natural products. Lee KH. **J Biomed Sci** 1999 Jul–Aug;6(4):236–50 (68 ref.)
Oligosaccharide signaling of plant cells. Etzler ME.
J Cell Biochem Suppl 1998;30–31:123–8 (35 ref.)
Prospecting for potentially new pharmaceuticals from natural sources. Pandey RC. **Med Res Rev** 1998 Sep;18(5):333–46 (21 ref.)
Optimal nutrition: fibre and phytochemicals. Rowland I.
Proc Nutr Soc 1999 May;58(2):415–9 (22 ref.)
Structure and function analysis of Pseudomonas plant cell wall hydrolases. Hazlewood GP, et al.
Prog Nucleic Acid Res Mol Biol 1998;61:211–41 (81 ref.)
A tale of dwarfs and drugs: brassinosteroids to the rescue. Altmann T. **Trends Genet** 1998 Dec;14(12):490–5 (53 ref.)
[Steroidal glycoalkaloids from the Solanaceae family] Zimowski J. **Postepy Biochem** 1998;44(3):254–62 (72 ref.) **(Pol)**
[Polysaccharides of flower plants: structure and physiological activity] Ovodov IuS. **Bioorg Khim** 1998 Jul;24(7):483–501 (230 ref.) (Eng. Abstr.) **(Rus)**
[Mechanism of the antistressor and antiradiation action of plant phenol compounds] Baraboi VA, et al.
Ukr Biokhim Zh 1998 Nov–Dec;70(6):13–23 (82 ref.) (Eng. Abstr.) **(Rus)**
[Plant metallothioneins] Ruchko MV, et al.
Ukr Biokhim Zh 1998 Nov–Dec;70(6):24–34 (63 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

The language of plants. McGovern TW.
Am J Contact Dermat 1999 Mar;10(1):45–7 (2 ref.)
A revised six-kingdom system of life. Cavalier-Smith T.
Biol Rev Camb Philos Soc 1998 Aug;73(3):203–66 (262 ref.)
Mass migration of a group I intron: promiscuity on a grand scale [comment] Gray MW. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14003–5 (20 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14244–9.

CYTOLOGY

Structure and functions of the vascular cambium. Lachaud S, et al. **C R Acad Sci III** 1999 Aug;322(8):633–50 (177 ref.)
The retinoblastoma pathway in plant cell cycle and development. Gutierrez C. **Curr Opin Plant Biol** 1998 Dec; 1(6):492–7 (46 ref.)
Cytokinesis in flowering plants: cellular process and developmental integration. Heese M, et al.
Curr Opin Plant Biol 1998 Dec;1(6):486–91 (46 ref.)
Probing plant cell structure and function with viral movement proteins. Lazarowitz SG.
Curr Opin Plant Biol 1999 Aug;2(4):332–8 (50 ref.)
Meiosis: vive la difference! Shaw P, et al.
Curr Opin Plant Biol 1998 Dec;1(6):458–62 (37 ref.)
Oligosaccharide signaling of plant cells. Etzler ME.
J Cell Biochem Suppl 1998;30–31:123–8 (35 ref.)
Separation of plant membranes by electromigration techniques. Canut H, et al.
J Chromatogr B Biomed Sci Appl 1999 Feb 5; 722(1–2):121–39 (88 ref.)
Methods for studying cell division in higher plants. Vos IW, et al. **Methods Cell Biol** 1999;61:413–37 (73 ref.)
An introduction to plant-cell culture. Pointers to success. Hall RD. **Methods Mol Biol** 1999;111:1–18 (11 ref.)
Confocal microscopy of plant cells. Wymer CL, et al.
Methods Mol Biol 1999;122:103–30 (35 ref.)
Signal transduction and ion channels in guard cells. MacRobbie EA. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1475–88 (87 ref.)

DRUG EFFECTS

Plant responses to metal toxicity. Briat JF, et al.
C R Acad Sci III 1999 Jan;322(1):43–54 (130 ref.)
Herbicide resistance and supersensitivity in photosystem II. Oettmeier W. **Cell Mol Life Sci** 1999 Aug 15;55(10):1255–77 (141 ref.)

EMBRYOLOGY

Is the shoot a root with a view? Benfey PN.
Curr Opin Plant Biol 1999 Feb;2(1):39–43 (28 ref.)
Signaling in plant embryogenesis. Harada JJ.
Curr Opin Plant Biol 1999 Feb;2(1):23–7 (40 ref.)
Shoot meristem formation and maintenance. Lenhard M, et al. **Curr Opin Plant Biol** 1999 Feb;2(1):44–50 (45 ref.)
Signalling in plant embryos during the establishment of the polar axis [see comments] Vroemen C, et al.
Semin Cell Dev Biol 1999 Apr;10(2):157–64 (55 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.

ENZYMOLOGY

Plant subtilisins. Bogacheva AM. **Biochemistry (Mosc)** 1999 Mar;64(3):287–93 (20 ref.)
Molecular and biochemical properties and physiological roles of plant phospholipase D. Pappan K, et al.
Biochim Biophys Acta 1999 Jul 30;1439(2):151–66 (102 ref.)
Light receptor kinases in plants! Fankhauser C, et al.
Curr Biol 1999 Feb 25;9(4):R123–6 (25 ref.)
Plant desaturases: harvesting the fat of the land [see comments] Napier JA, et al. **Curr Opin Plant Biol** 1999 Apr;2(2):123–7 (30 ref.) Comment in: Curr Opin Plant Biol 1999 Apr;2(2):121–2.
H+-proton-pumping inorganic pyrophosphatase: a tightly membrane-bound family. Baltscheffsky M, et al.
FEBS Lett 1999 Jun 11;452(3):121–7 (64 ref.)
H+ -PPases: a tightly membrane-bound family. Baltscheffsky M, et al. **FEBS Lett** 1999 Sep 3;457(3):527–33 (64 ref.)
Plant MAP kinase kinase kinases structure, classification and evolution. Jouannic S, et al. **Gene** 1999 Jun 11;233(1–2):1–11 (58 ref.)
Inhibitors of plant copper amine oxidases. Padiglia A, et al.
J Enzyme Inhib 1998 Aug;13(5):311–25 (37 ref.)
Hairy plant polysaccharides: a close shave with microbial esterases. Williamson G, et al. **Microbiology** 1998 Aug;144 (Pt 8):2011–23 (84 ref.)
Protein phosphatase 2C (PP2C) function in higher plants. Rodriguez PL. **Plant Mol Biol** 1998 Dec;38(6):919–27 (68 ref.)

GENETICS

The specification of leaf identity during shoot development. Kerstetter RA, et al. **Annu Rev Cell Dev Biol** 1998; 14:373–98 (122 ref.)
Systemin: a polypeptide signal for plant defensive genes. Ryan CA, et al. **Annu Rev Cell Dev Biol** 1998;14:1–17 (77 ref.)
Homeoboxes in plant development. Chan RL, et al.
Biochim Biophys Acta 1998 Oct 23;1442(1):1–19 (98 ref.)
Assembly of the VirB transport complex for DNA transfer from Agrobacterium tumefaciens to plant cells. Zupan JR, et al. **Curr Opin Microbiol** 1998 Dec;1(6):649–55 (50 ref.)
Recent advances in brassinosteroid molecular genetics. Altmann T. **Curr Opin Plant Biol** 1998 Oct;1(5):378–83 (33 ref.)
Genome studies and molecular evolution. Commonalities, contrasts, continuity and change in plant genomes [editorial] Bevan M, et al. **Curr Opin Plant Biol** 1998 Apr; 1(2):101–2 (0 ref.)
Plant biotechnology. Bright S. **Curr Opin Plant Biol** 1998 Apr;1(2):159–60 (12 ref.)
Plant cytogenetics at the dawn of the 21st century. Gill BS, et al. **Curr Opin Plant Biol** 1998 Apr;1(2):109–15 (53 ref.)
Sex determination in plants. Juarez C, et al.
Curr Opin Plant Biol 1998 Feb;1(1):68–72 (39 ref.)
Who's related to whom? Recent results from molecular systematic studies. Kellogg EA. **Curr Opin Plant Biol** 1998 Apr;1(2):149–58 (85 ref.)
To pair or not to pair: chromosome pairing and evolution. Moore G. **Curr Opin Plant Biol** 1998 Apr;1(2):116–22 (56 ref.)
Genetic recombination in plants. Schnable PS, et al.
Curr Opin Plant Biol 1998 Apr;1(2):123–9 (69 ref.)
Sugar regulation of gene expression in plants. Smeekens S.
Curr Opin Plant Biol 1998 Jun;1(3):230–4 (45 ref.)
Genetic, molecular, and morphological analysis of compound leaf development. Goliber T, et al. **Curr Top Dev Biol** 1999; 43:259–90 (100 ref.)
Proteomics for genetic and physiological studies in plants. Thiellement H, et al. **Electrophoresis** 1999 Jul; 20(10):2013–26 (119 ref.)
Dorsoventral patterning in plants. Sessions A, et al.
Genes Dev 1999 May 1;13(9):1051–4 (38 ref.)
Clusters of resistance genes in plants evolve by divergent selection and a birth-and-death process. Michelmore RW, et al. **Genome Res** 1998 Nov;8(11):1113–30 (105 ref.)
Organellar RNA polymerases of higher plants. Hess WR, et al. **Int Rev Cytol** 1999;190:1–59 (284 ref.)
Cellular and molecular mechanisms of sexual incompatibility in plants and fungi. Hiscock SJ, et al. **Int Rev Cytol** 1999; 193:165–295 (756 ref.)
Animal and plant cell technology: a critical evaluation of the technology/society interface. Spier RE.
J Biotechnol 1998 Oct 27;65(2–3):111–25 (35 ref.)
RNA editing site recognition in higher plant mitochondria. Mulligan RM, et al. **J Hered** 1999 May–Jun;90(3):338–44 (65 ref.)
Plant transformation via protoplast electroporation. Bates GW. **Methods Mol Biol** 1999;111:359–66 (18 ref.)
Agrobacterium-mediated transformation of Petunia leaf disks. van der Meer IM. **Methods Mol Biol** 1999;111:327–34 (13 ref.)
Nuclear organization and chromosome segregation. Franklin AE, et al. **Plant Cell** 1999 Apr;11(4):523–34 (80 ref.)
Isovariant dynamics expand and buffer the responses of complex systems: the diverse plant actin gene family. Meagher RB, et al. **Plant Cell** 1999 Jun;11(6):995–1006 (122 ref.)
Transcriptional regulation in plants: the importance of combinatorial control. Singh KB. **Plant Physiol** 1998 Dec; 118(4):1111–20 (67 ref.)
Mass migration of a group I intron: promiscuity on a grand scale [comment] Gray MW. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14003–5 (20 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14244–9.
Gene discovery and product development for grain quality traits. Mazur B, et al. **Science** 1999 Jul 16;285(5426):372–5 (33 ref.)
Plant functional genomics. Somerville C, et al. **Science** 1999 Jul 16;285(5426):380–3 (36 ref.)
Plant disease-resistance proteins and the gene-for-gene concept. Van der Biezen EA, et al. **Trends Biochem Sci** 1998 Dec;23(12):454–6 (25 ref.)
The small, the large and the wild: the value of comparison in plant genomics. Bevan M, et al. **Trends Genet** 1999 Jun; 15(6):211–4 (32 ref.)

PLANTS

Do unintended antisense transcripts contribute to sense cosuppression in plants? [letter; comment] Jorgensen RA, et al. **Trends Genet** 1999 Jan;15(1):11–2 (14 ref.) Comment on: Trends Genet 1998 Jul;14(7):255–8.

[Preservation of strains of Ipomoea nil] Nitasaka E. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):171–4 (13 ref.) **(Jpn)**

[Plant resistance genes and their role during infection] Krzymowska M. **Postepy Biochem** 1998;44(4):318–25 (45 ref.) **(Pol)**

GROWTH & DEVELOPMENT

The specification of leaf identity during shoot development. Kerstetter RA, et al. **Annu Rev Cell Dev Biol** 1998; 14:373–98 (122 ref.)

Cell ablation studies in plant development. Berger F. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):711–9 (24 ref.)

Plant development: the making of a leaf. Christensen S, et al. **Curr Biol** 1998 Sep 10;8(18):R643–5 (9 ref.)

The evolution of plant development. Baum DA. **Curr Opin Plant Biol** 1998 Feb;1(1):79–86 (70 ref.)

Growth and development: growing up green. Hake S, et al. **Curr Opin Plant Biol** 1998 Feb;1(1):9–11 (21 ref.)

The molecular and genetic control of ovule development. Schneitz K. **Curr Opin Plant Biol** 1999 Feb;2(1):13–7 (49 ref.)

Nitrate regulation of metabolism and growth. Stitt M. **Curr Opin Plant Biol** 1999 Jun;2(3):178–86 (79 ref.)

Signaling tip growth in plants. Yang Z. **Curr Opin Plant Biol** 1998 Dec;1(6):525–30 (54 ref.)

Genetic, molecular, and morphological analysis of compound leaf development. Goliber T, et al. **Curr Top Dev Biol** 1999; 43:259–90 (100 ref.)

Digging out roots: pattern formation, cell division, and morphogenesis in plants. Scheres B, et al. **Curr Top Dev Biol** 1999;45:207–47 (141 ref.)

Patterning the flower. Irish VF. **Dev Biol** 1999 May 15; 209(2):211–20 (99 ref.)

Dorsoventral patterning in plants. Sessions A, et al. **Genes Dev** 1999 May 1;13(9):1051–4 (38 ref.)

Guard cell protoplasts. Isolation, culture, and regeneration of plants. Boorse G, et al. **Methods Mol Biol** 1999; 111:243–57 (27 ref.)

Spore-derived axenic cultures of ferns as a method of propagation. Ford MV, et al. **Methods Mol Biol** 1999; 111:159–68 (33 ref.)

Noncryogenic, long-term germplasm storage. Golmirzaie A, et al. **Methods Mol Biol** 1999;111:95–101 (12 ref.)

In vitro propagation of succulent plants. Gratton J, et al. **Methods Mol Biol** 1999;111:135–40 (4 ref.)

Meristem-tip culture for propagation and virus elimination. Grout BW. **Methods Mol Biol** 1999;111:115–25 (20 ref.)

Clonal propagation of woody species. Harry IS, et al. **Methods Mol Biol** 1999;111:149–57 (33 ref.)

Micropropagation of flower bulbs. Lily and narcissus. Langens-Gerrits MM, et al. **Methods Mol Biol** 1999; 111:141–7 (17 ref.)

Clonal propagation of orchids. Tisserat B, et al. **Methods Mol Biol** 1999;111:127–34 (20 ref.)

Signalling of abscisic acid to regulate plant growth. Himmelbach A, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1439–44 (77 ref.)

IMMUNOLOGY

Role of active oxygen species and NO in plant defence responses. Bolwell GP. **Curr Opin Plant Biol** 1999 Aug; 2(4):287–94 (72 ref.)

Early events in host-pathogen interactions. Grant M, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):312–9 (63 ref.)

Genetically engineered plant allergens with reduced anaphylactic activity. Singh MB, et al. **Int Arch Allergy Immunol** 1999 Jun;119(2):75–85 (81 ref.)

[Plant resistance genes and their role during infection] Krzymowska M. **Postepy Biochem** 1998;44(4):318–25 (45 ref.) **(Pol)**

METABOLISM

Production of food related colorants by culture of plant cells. The case of betalains. Jiménez-Aparicio A, et al. **Adv Exp Med Biol** 1999;464:195–210 (80 ref.)

Monoterpenes in essential oils. Biosynthesis and properties. Loza-Tavera H. **Adv Exp Med Biol** 1999;464:49–62 (63 ref.)

The ethylene gas signal transduction pathway: a molecular perspective. Johnson PR, et al. **Annu Rev Genet** 1998; 32:227–54 (124 ref.)

Modelling lipid metabolism in plants: a slippery problem? Harwood JL, et al. **Biochem Soc Trans** 1999 Feb; 27(2):285–9 (20 ref.)

Membrane trafficking in higher plant cells: GFP and antibodies, partners for probing the secretory pathway. Satiat-Jeunemaitre B, et al. **Biochimie** 1999 Jun; 81(6):597–605 (40 ref.)

Sulfur metabolism in higher plants: potential for phytoremediation. Ernst WH. **Biodegradation** 1998; 9(3–4):311–8 (86 ref.)

Beyond plant lectin histochemistry: preparation and application of markers to visualize the cellular capacity for protein-carbohydrate recognition. Gabius HJ, et al. **Biotech Histochem** 1998 Sep;73(5):263–77 (79 ref.)

Structure and function of metal chelators produced by plants: the case for organic acids, amino acids, phytin, and metallothioneins. Rauser WE. **Cell Biochem Biophys** 1999; 31(1):19–48 (174 ref.)

The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Eisenreich W, et al. **Chem Biol** 1998 Sep;5(9):R221–33 (81 ref.)

Tracing steroid synthesis in plants. Groeneveld HW. **Crit Rev Biochem Mol Biol** 1999;34(2):59–69 (49 ref.)

Plant natural products: the molecular genetic basis of biosynthetic diversity. Dixon RA. **Curr Opin Biotechnol** 1999 Apr;10(2):192–7 (48 ref.)

Production of novel oils in plants. Murphy DJ. **Curr Opin Biotechnol** 1999 Apr;10(2):175–80 (45 ref.)

Production of new polymeric compounds in plants. Poirier Y. **Curr Opin Biotechnol** 1999 Apr;10(2):181–5 (30 ref.)

Plant sulfur metabolism—the reduction of sulfate to sulfite. Bick JA, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):240–4 (37 ref.)

Plant stress adaptations—making metabolism move. Bohnert HJ, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):267–74 (56 ref.)

Sugar transporters in plant biology. Bush DR. **Curr Opin Plant Biol** 1999 Jun;2(3):187–91 (32 ref.)

Nitrate transport: a key step in nitrate assimilation. Daniel-Vedele F, et al. **Curr Opin Plant Biol** 1998 Jun; 1(3):235–9 (37 ref.)

Glutathione-mediated detoxification systems in plants. Dixon DP, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):258–66 (51 ref.)

SA, JA, ethylene, and disease resistance in plants. Dong X. **Curr Opin Plant Biol** 1998 Aug;1(4):316–23 (67 ref.)

Biochemical dissection of photorespiration. Douce R, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):214–22 (58 ref.)

Zeroing in on zinc uptake in yeast and plants. Guerinot ML, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):244–9 (49 ref.)

Genetic dissection of R gene signal transduction pathways. Innes RW. **Curr Opin Plant Biol** 1998 Aug;1(4):299–304 (41 ref.)

Manipulating flux through plant metabolic pathways. Kinney AJ. **Curr Opin Plant Biol** 1998 Apr;1(2):173–8 (21 ref.)

Plasma membrane transport in context – making sense out of complexity. Maathuis FJ, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):236–43 (45 ref.)

Regulated nuclear targeting. Nagatani A. **Curr Opin Plant Biol** 1998 Dec;1(6):470–4 (46 ref.)

Redundancy as a way of life – IAA metabolism. Normanly J, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):207–13 (62 ref.)

Metabolic engineering of plants for osmotic stress resistance [see comments] Nuccio ML, et al. **Curr Opin Plant Biol** 1999 Apr;2(2):128–34 (48 ref.) Comment in: Curr Opin Plant Biol 1999 Apr;2(2):121–2.

Source-sink regulation by sugar and stress. Roitsch T. **Curr Opin Plant Biol** 1999 Jun;2(3):198–206 (74 ref.)

Making starch. Smith AM. **Curr Opin Plant Biol** 1999 Jun; 2(3):223–9 (48 ref.)

Nitrate regulation of metabolism and growth. Stitt M. **Curr Opin Plant Biol** 1999 Jun;2(3):178–86 (79 ref.)

Ca2+ signalling in plant cells: the big network! Trewavas AJ, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):428–33 (55 ref.)

The alphabet soup of plant intracellular signalling: enter cyclic nucleotides. Walden R. **Curr Opin Plant Biol** 1998 Oct;1(5):419–23 (39 ref.)

Phenylpropanoid biosynthesis and its regulation. Weisshaar B, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):251–7 (64 ref.)

Plant expression systems for the production of vaccines. Ma JK, et al. **Curr Top Microbiol Immunol** 1999;236:275–92 (45 ref.)

Phosphoinositide kinases and the synthesis of polyphosphoinositides in higher plant cells. Drøbak BK, et al. **Int Rev Cytol** 1999;189:95–130 (127 ref.)

Mechanisms of regulation and interplastid localization of chlorophyll biosynthesis. Averina NG. **Membr Cell Biol** 1998;12(5):627–43 (105 ref.)

The final stage of chlorophyll biosynthesis and formation of reaction centres of photosystems. Litvin FF, et al. **Membr Cell Biol** 1998;12(5):609–26 (124 ref.)

The system of phytochromes: photobiophysics and photobiochemistry in vivo. Sineshchekov VA. **Membr Cell Biol** 1998;12(5):691–720 (110 ref.)

Free radicals in primary photobiological processes. Vladimirov YA. **Membr Cell Biol** 1998;12(5):645–63 (64 ref.)

Ca2+ and intracellular signalling in plant cells: a role in phytochrome transduction. Volotovski ID. **Membr Cell Biol** 1998;12(5):721–42 (75 ref.)

Alkaloid accumulation in Catharanthus roseus suspension cultures. Scragg AH. **Methods Mol Biol** 1999;111:393–402 (20 ref.)

Endogenous changes in citokinin activity in systemically virus-infected plants. Pennazio S, et al. **New Microbiol** 1998 Oct;21(4):419–26 (62 ref.)

Signalling of abscisic acid to regulate plant growth. Himmelbach A, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1439–44 (77 ref.)

Signal transduction and ion channels in guard cells. MacRobbie EA. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1475–88 (87 ref.)

Protein prenylation in plants: old friends and new targets. Rodríguez-Concepción M, et al. **Plant Mol Biol** 1999 Mar; 39(5):865–70 (32 ref.)

Protein targeting to the nuclear pore. What can we learn from plants? Smith HM, et al. **Plant Physiol** 1999 Apr; 119(4):1157–64 (43 ref.)

Calcium-dependent signal transduction pathways in plants—phytochrome mechanism of action as an example. Tretyn A. **Pol J Pharmacol** 1999 Mar-Apr;51(2):145–51 (45 ref.)

Phytooxylipins and plant defense reactions. Blée E. **Prog Lipid Res** 1998 May;37(1):33–72 (361 ref.)

Lipid trafficking in plant cells. Moreau P, et al. **Prog Lipid Res** 1998 Dec;37(6):371–91 (171 ref.)

Lipid metabolism during plant senescence. Thompson JE, et al. **Prog Lipid Res** 1998 Jul-Aug;37(2–3):119–41 (183 ref.)

Cyclic condensed metaphosphates in plants and the possible correlations between inorganic polyphosphates and other compounds. Niemeyer R. **Prog Mol Subcell Biol** 1999; 23:83–100 (51 ref.)

[Signal transmission in plant cells; plasma membrane receptors] Barańska J. **Postepy Biochem** 1998;44(3):201–8 (38 ref.) **(Pol)**

[Cyanogenesis in plants] Siegień I. **Postepy Biochem** 1998; 44(4):325–33 (90 ref.) **(Pol)**

[Steroidal glycoalkaloids from the Solanaceae family] Zimowski J. **Postepy Biochem** 1998;44(3):254–62 (72 ref.) **(Pol)**

MICROBIOLOGY

Fungal symbioses. Jakucs E. **Acta Microbiol Immunol Hung** 1999;46(2–3):193–5 (13 ref.)

Mutagenesis via insertional- or restriction enzyme-mediated-integration (REMI) as a tool to tag pathogenicity related genes in plant pathogenic fungi. Maier FJ, et al. **Biol Chem** 1999 Jul-Aug;380(7–8):855–64 (52 ref.)

Determinants of pathogenicity and avirulence in plant pathogenic bacteria. Collmer A. **Curr Opin Plant Biol** 1998 Aug;1(4):329–35 (52 ref.)

Structure and function of proteins controlling strain-specific pathogen resistance in plants. Ellis J, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):288–93 (46 ref.)

Fungal pathogenicity. Knogge W. **Curr Opin Plant Biol** 1998 Aug;1(4):324–8 (49 ref.)

Transcriptional control of plant genes responsive to pathogens. Rushton PJ, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):311–5 (47 ref.)

Transgenic approaches to microbial disease resistance in crop plants. Salmeron JM, et al. **Curr Opin Plant Biol** 1998 Aug; 1(4):347–52 (59 ref.)

Fungal avirulence genes: structure and possible functions. Laugé R, et al. **Fungal Genet Biol** 1998 Aug;24(3):285–97 (80 ref.)

Antimicrobial phytoprotectants and fungal pathogens: a commentary. Osbourn AE. **Fungal Genet Biol** 1999 Apr; 26(3):163–8 (50 ref.)

Plant pathogenesis-related proteins: molecular mechanisms of gene expression and protein function. Kitajima S, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):1–8 (61 ref.)

Pseudomonas syringae phytotoxins: mode of action, regulation, and biosynthesis by peptide and polyketide synthetases. Bender CL, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):266–92 (297 ref.)

Hairy plant polysaccharides: a close shave with microbial esterases. Williamson G, et al. **Microbiology** 1998 Aug;144 (Pt 8):2011–23 (84 ref.)

Plant disease-resistance proteins and the gene-for-gene concept. Van der Biezen EA, et al. **Trends Biochem Sci** 1998 Dec;23(12):454–6 (25 ref.)

[Biochemical and molecular basis of symbiotic plant and microbe interactions] Jakubowska A, et al. **Postepy Biochem** 1998;44(1):72–82 (104 ref.) **(Pol)**

PARASITOLOGY

Biological nitrogen fixation and future challenges of agriculture. The endophytic connection. Sánchez F, et al. **Adv Exp Med Biol** 1999;464:107–15 (69 ref.)

Plant nematode resistance genes. Williamson VM. **Curr Opin Plant Biol** 1999 Aug;2(4):327–31 (51 ref.)

Parasitic plant responses to host plant signals: a model for subterranean plant-plant interactions. Yoder JI. **Curr Opin Plant Biol** 1999 Feb;2(1):65–70 (51 ref.)

POISONING

Ponderosa pine and broom snakeweed: poisonous plants that affect livestock. Gardner DR, et al. **J Nat Toxins** 1999 Feb;8(1):27–34 (53 ref.)

RADIATION EFFECTS

Signalling in light-controlled development [see comments] Deng XW, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):121–9 (71 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.

TOXICITY

Larkspur (Delphinium spp.) poisoning in livestock. Pfister JA, et al. **J Nat Toxins** 1999 Feb;8(1):81–94 (76 ref.)

The pathogenesis and toxicokinetics of locoweed (Astragalus and Oxytropis spp.) poisoning in livestock. Stegelmeier BL,

et al. **J Nat Toxins** 1999 Feb;8(1):35–45 (81 ref.)

ULTRASTRUCTURE

Ionic channels of the vacuolar membrane of higher plants. Tikhonova LI. **Membr Cell Biol** 1998;12(3):301–18 (117 ref.)

Nuclear organization and chromosome segregation. Franklin AE, et al. **Plant Cell** 1999 Apr;11(4):523–34 (80 ref.)

VIROLOGY

Tomato spotted wilt virus in ornamental plants, vegetables and weeds in the Czech Republic. Mertelik J, et al. **Acta Virol** 1998 Nov;42(5):347–51 (27 ref.)

Gene silencing: plants and viruses fight it out. Smyth DR. **Curr Biol** 1999 Feb 11;9(3):R100–2 (17 ref.)

Viral invasion and host defense: strategies and counter-strategies. Carrington JC, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):336–41 (62 ref.)

Introduction to classical crossprotection. Fraser RS. **Methods Mol Biol** 1998;81:13–24 (70 ref.)

Introduction to plant virology. Hillman BI. **Methods Mol Biol** 1998;81:3–12 (26 ref.)

History of coat protein-mediated protection. Miller ED, et al. **Methods Mol Biol** 1998;81:25–38 (87 ref.)

Mechanisms of arthropod transmission of plant and animal viruses. Gray SM, et al. **Microbiol Mol Biol Rev** 1999 Mar; 63(1):128–48 (168 ref.)

[Tobacco mosaic virus] Okada Y. **Uirusu** 1998 Jun; 48(1):97–102 (20 ref.) **(Jpn)**

PLANTS, EDIBLE

Products from plant biotechnology. Fuchs RL, et al. **Allergy** 1998;53(46 Suppl):93–7 (10 ref.)

Plant-based diets and bone health: nutritional implications. Anderson JJ. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):539S–542S (17 ref.)

Health aspects of fish and n-3 polyunsaturated fatty acids from plant and marine origin. de Deckere EA, et al. **Eur J Clin Nutr** 1998 Oct;52(10):749–53 (58 ref.)

Antioxidant and other activities of phenolics in olives/olive oil, typical components of the Mediterranean diet. Galli C, et al. **Lipids** 1999;34 Suppl:S23–6 (14 ref.)

Animal- and plant-food-based diets and iron status: benefits and costs. Hambraeus L. **Proc Nutr Soc** 1999 May; 58(2):235–42 (40 ref.)

The nutritional value of plant-based diets in relation to human amino acid and protein requirements. Millward DJ. **Proc Nutr Soc** 1999 May;58(2):249–60 (59 ref.)

Animal v. plant foods in human diets and health: is the historical record unequivocal? Nestle M. **Proc Nutr Soc** 1999 May;58(2):211–8 (87 ref.)

The nutritional adequacy of plant-based diets. Sanders TA. **Proc Nutr Soc** 1999 May;58(2):265–9 (37 ref.)

ADVERSE EFFECTS

Genetically modified food: a danger or a benefit for atopics? Ebner C. **Curr Probl Dermatol** 1999;28:81–7 (11 ref.)

CHEMISTRY

The role of dietary fats in plant-based diets. Coulston AM. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):512S–515S (32 ref.)

Genetic engineering of plant lipids. Broun P, et al. **Annu Rev Nutr** 1999;19:197–216 (105 ref.)

Safety assessment and potential health benefits of food components based on selected scientific criteria. ILSI North America Technical Committee on Food Components for Health Promotion. **Crit Rev Food Sci Nutr** 1999 May;39(3):203–316 (627 ref.)

Antioxidant actions of plant foods: use of oxidative DNA damage as a tool for studying antioxidant efficacy. Aruoma OI. **Free Radic Res** 1999 Jun;30(6):419–27 (40 ref.)

Effect of dietary phytochemicals on cancer development (review) Waladkhani AR, et al. **Int J Mol Med** 1998 Apr; 1(4):747–53 (81 ref.)

Characteristics and occurrence of phenolic phytochemicals. King A, et al. **J Am Diet Assoc** 1999 Feb;99(2):213–8 (42 ref.)

Phytochemicals: biochemistry and physiology. Introduction. Hasler CM, et al. **J Nutr** 1999 Mar;129(3):756S–757S (8 ref.)

[Microbial and enzymatic extraction of pectin. A review] Contreras-Esquivel JC, et al. **Arch Latinoam Nutr** 1997 Sep;47(3):208–16 (98 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Recent developments in biochemistry of the plant lipoxygenase pathway. Grechkin A. **Prog Lipid Res** 1998 Nov;37(5):317–52 (277 ref.)

GENETICS

Genetic engineering of plant lipids. Broun P, et al. **Annu Rev Nutr** 1999;19:197–216 (105 ref.)

Plant cell walls as targets for biotechnology. Chapple C, et al. **Curr Opin Plant Biol** 1998 Apr;1(2):179–85 (52 ref.)

Nutritional genomics: manipulating plant micronutrients to improve human health. DellaPenna D. **Science** 1999 Jul 16;285(5426):375–9 (42 ref.)

Novel and transgenic food crops: overview of scientific versus public perception. Ruibal-Mendieta NL, et al. **Transgenic Res** 1998 Sep;7(5):379–86 (32 ref.)

IMMUNOLOGY

Plant-food and seafood allergens--an overview. Breiteneder H. **Allergy** 1998;53(46 Suppl):31–4 (21 ref.)

METABOLISM

Betalains. Their accumulation and release in vitro. Hunter CS, et al. **Methods Mol Biol** 1999;111:403–10 (20 ref.)

THERAPEUTIC USE

Studies on some edible and medicinal plants of Mesoamerica. Kinghorn AD, et al. **Proc West Pharmacol Soc** 1998; 41:253–8 (37 ref.)

PLANTS, MEDICINAL

see related
ALKALOIDS
ETHNOBOTANY
PLANT EXTRACTS

Recent progress in biotechnology of Mexican medicinal plants. Villarreal ML, et al. **Adv Exp Med Biol** 1999; 464:221–33 (22 ref.)

Herbal 'health' products: what family physicians need to know [see comments] [published erratum appears in Am Fam Physician 1999 Feb 1;59(3):540] Zink T, et al. **Am Fam Physician** 1998 Oct 1;58(5):1133–40 (37 ref.) Comment in: Am Fam Physician 1998 Oct 1;58(5):1064–5.

Medicinal plants used for treating female diseases in Malaysia--a review. Ling SK, et al. **Am J Chin Med** 1998; 26(2):211–22 (18 ref.)

Echinacea. Pepping J. **Am J Health Syst Pharm** 1999 Jan 15;56(2):121–2 (10 ref.)

Neuropharmacology of St. John's Wort (Hypericum). Bennett DA Jr, et al. **Ann Pharmacother** 1998 Nov; 32(11):1201–8 (38 ref.)

A review of 12 commonly used medicinal herbs. O'Hara M, et al. **Arch Fam Med** 1998 Nov–Dec;7(6):523–36 (112 ref.)

Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Packer L, et al. **Free Radic Biol Med** 1999 Sep;27(5–6):704–24 (130 ref.)

Uncaria tomentosa (Willd.) D.C.: cat's claw, uña de gato, or savéntaro. Reinhard KH. **J Altern Complement Med** 1999 Apr;5(2):143–51 (36 ref.)

Activity and biological effects of neem products against arthropods of medical and veterinary importance. Mulla MS, et al. **J Am Mosq Control Assoc** 1999 Jun;15(2):133–52 (122 ref.)

Indigenous patterns of conserving biodiversity: pharmacologic implications. Etkin NL. **J Ethnopharmacol** 1998 Dec;63(3):233–45 (48 ref.)

Medical ethnobotany of the Zapotecs of the Isthmus-Sierra (Oaxaca, Mexico): documentation and assessment of indigenous uses [published erratum appears in J Ethnopharmacol 1999 Mar;64(3):289–90] Frei B, et al. **J Ethnopharmacol** 1998 Sep;62(2):149–65 (48 ref.)

Uncaria tomentosa (Willd.) DC.--ethnomedicinal use and new pharmacological, toxicological and botanical results. Keplinger K, et al. **J Ethnopharmacol** 1999 Jan;64(1):23–34 (60 ref.)

Herbalism in Minnesota. What should physicians know? Plotnikoff GA, et al. **Minn Med** 1999 May;82(5):12–26 (0 ref.)

Review, critique, and guidelines for the use of herbs and homeopathy. Glisson J, et al. **Nurse Pract** 1999 Apr; 24(4):44–6, 53, 60 passim; quiz 68–9 (73 ref.)

HIV reverse transcriptase inhibitors of natural origin. Matthée G, et al. **Planta Med** 1999 Aug;65(6):493–506 (137 ref.)

Ethnopharmacology and ethnobotany along the US-Mexican border: potential problems with cross-cultural "borrowings". Huxtable RJ. **Proc West Pharmacol Soc** 1998; 41:259–64 (60 ref.)

Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Lowe FC, et al. **Prostate** 1998 Nov 1;37(3):187–93 (32 ref.)

Nontraditional treatments for localized prostate cancer: ten rules to know before talking to my patients. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):64–9 (52 ref.)

[Medicinal plants of Nepal. A gift of the gods from the land of Shangri-La] Bielenberg J. **Pharm Unserer Zeit** 1998 Nov;27(6):272–7 (12 ref.) **(Ger)**

[The utilization and safety of medicinal plants and crude drugs] Satake M. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):13–29 (43 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Assessing the risks and benefits of herbal medicine: an overview of scientific evidence. Barrett B, et al. **Altern Ther Health Med** 1999 Jul;5(4):40–9 (118 ref.)

Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. McPartland JM, et al. **Altern Ther Health Med** 1999 Jul;5(4):57–62 (100 ref.)

Herbal remedies: adverse effects and drug interactions. Cupp MJ. **Am Fam Physician** 1999 Mar 1;59(5):1239–45 (31 ref.)

Compositae dermatitis. Gordon LA. **Australas J Dermatol** 1999 Aug;40(3):123–8; quiz 129–30 (30 ref.)

Tea tree oil allergy: what is the offending agent? Report of three cases of tea tree oil allergy and review of the literature. Rubel DM, et al. **Australas J Dermatol** 1998 Nov; 39(4):244–7 (9 ref.)

Herbs and the childbearing woman. Guidelines for midwives. Belew C. **J Nurse Midwifery** 1999 May-Jun;44(3):231–52 (103 ref.)

Safety and quality concerns related to the use of herbal therapies. Chaffin JA. **Minn Med** 1999 May;82(5):45–8 (20 ref.)

The hazards of psychotropic herbs. Tinsley JA. **Minn Med** 1999 May;82(5):29–31 (16 ref.)

The toxicology of African herbal remedies. Stewart MJ, et al. **Ther Drug Monit** 1998 Oct;20(5):510–6 (117 ref.)

[Herbal remedies and nephrotoxicity] Nortier J, et al. **Rev Med Brux** 1999 Feb;20(1):9–14 (36 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Annonaceous acetogenins: recent progress. Alali FQ, et al. **J Nat Prod** 1999 Mar;62(3):504–40 (138 ref.)

Antiviral activity of lignans. Charlton JL. **J Nat Prod** 1998 Nov;61(11):1447–51 (27 ref.)

Hallucinogenic drugs and plants in psychotherapy and shamanism. Metzner R. **J Psychoactive Drugs** 1998 Oct-Dec;30(4):333–41 (46 ref.)

Psychoactive plants and ethnopsychiatric medicines of the Matsigenka. Shepard GH Jr. **J Psychoactive Drugs** 1998 Oct-Dec;30(4):321–32 (57 ref.)

Modern drug development from traditional medicinal plants using radioligand receptor-binding assays. Misra R. **Med Res Rev** 1998 Nov;18(6):383–402 (37 ref.)

Recent advances on bioactive natural products from Chinese medicinal plants. Qin GW, et al. **Med Res Rev** 1998 Nov; 18(6):375–82 (22 ref.)

Antiplatelet agents isolated from medicinal plants. Teng CM, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):211–25 (68 ref.)

Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Gong X, et al. **Trends Pharmacol Sci** 1999 May;20(5):191–6 (38 ref.)

[A trip to the past: quinine and quinine alkaloids. I. The isolation of quinine alkaloids and clarification of its chemistry] Eiden F. **Pharm Unserer Zeit** 1998 Nov; 27(6):257–71 (53 ref.) **(Ger)**

[Studies on caffeic acid derivatives in medicinal plants] Agata I. **Yakugaku Zasshi** 1999 Apr;119(4):237–48 (40 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Pharmacology and chemotaxonomy of Diospyros. Mallavadhani UV, et al. **Phytochemistry** 1998 Oct; 49(4):901–51 (271 ref.)

[The ecological, taxonomic and biotechnology aspects of research on bacteria and higher plants that produce biologically active substances] Smirnov VV. **Mikrobiol Z** 1998 Sep-Oct;60(5):3–18 (87 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Directing anthraquinone accumulation via manipulation of Morinda suspension cultures. Hagendoorn MJ, et al. **Methods Mol Biol** 1999;111:383–91 (9 ref.)

Enzymatic oxidations in the biosynthesis of complex alkaloids. Chou WM, et al. **Plant J** 1998 Aug;15(3):289–300 (73 ref.)

THERAPEUTIC USE

Phytotherapeutic approaches to common dermatologic conditions. Brown DJ, et al. **Arch Dermatol** 1998 Nov; 134(11):1401–4 (39 ref.)

Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions [see comments] Miller LG. **Arch Intern Med** 1998 Nov 9; 158(20):2200–11 (171 ref.) Comment in: Arch Intern Med 1999 May 24;159(10):1142–3.

Herbal remedies. How much do you know? Myerscough M. **Aust Fam Physician** 1998 Nov;27(11):1037–40 (33 ref.)

Medicinal herbs: a primer for primary care. Hadley SK, et al. **Hosp Pract (Off Ed)** 1999 Jun 15;34(6):105–6, 109–12, 115–6 passim (12 ref.)

Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. Perry EK, et al. **J Altern Complement Med** 1998 Winter; 4(4):419–28 (49 ref.)

Echinacea for upper respiratory infection. Barrett B, et al. **J Fam Pract** 1999 Aug;48(8):628–35 (71 ref.)

Efficacy and safety of tea tree oil as a topical antimicrobial agent. Carson CF, et al. **J Hosp Infect** 1998 Nov; 40(3):175–8 (30 ref.)

The use of Japanese herbal medicine in the treatment of medically unexplained physical symptoms [editorial] Mizushima H, et al. **J Psychosom Res** 1999 Jun;46(6):531–5 (11 ref.)

Natural options for menopause. Norling S. **Minn Med** 1999 May;82(5):42–4 (6 ref.)

The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Nathan P. **Mol Psychiatry** 1999 Jul;4(4):333–8 (68 ref.)

PLANTS, MEDICINAL

Past and present herbs used to treat cancer: medicine, magic, or poison? Montbriand MJ. **Oncol Nurs Forum** 1999 Jan-Feb;26(1):49-60; quiz 61-2 (53 ref.)
Studies on some edible and medicinal plants of Mesoamerica. Kinghorn AD, et al. **Proc West Pharmacol Soc** 1998; 41:253-8 (37 ref.)
[Herbs for atopic dermatitis: phytotherapy of the sorcerer's apprentice or a fake and culpable mascarade] Piérard GE, et al. **Rev Med Liege** 1999 Jun;54(6):539-40 (22 ref.) (Eng. Abstr.) **(Fre)**

PLANTS, TOXIC

see related
PLANT POISONING

CHEMISTRY

Plant toxins. Betz JM. **J AOAC Int** 1999 May-Jun; 82(3):781-4 (61 ref.)

POISONING

[Plant toxicity-coriamyrtin, anisatin, cicutoxin] Fujii M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):682-4 (8 ref.) **(Jpn)**

TOXICITY

Bracken carcinogens in the human diet. Shahin M, et al. **Mutat Res** 1999 Jul 15;443(1-2):69-79 (117 ref.)

PLANTS, TRANSGENIC

Prospects for the metabolic engineering of bioactive flavonoids and related phenylpropanoid compounds. Dixon RA, et al. **Adv Exp Med Biol** 1998;439:55-66 (56 ref.)
Novel chemicals from plants via bioengineering. An overview. Kolodziejczyk PP, et al. **Adv Exp Med Biol** 1999; 464:1-4 (5 ref.)
Manipulation of plant oil composition for the production of valuable chemicals. Progress, problems, and prospects. Murphy DJ. **Adv Exp Med Biol** 1999;464:21-35 (30 ref.)
Public reactions and scientific responses to transgenic crops. Dale PJ. **Curr Opin Biotechnol** 1999 Apr;10(2):203-8 (45 ref.)
Controlling gene expression in transgenics. Gallie DR. **Curr Opin Plant Biol** 1998 Apr;1(2):166-72 (55 ref.)
Position effects and epigenetic silencing of plant transgenes. Matzke AJ, et al. **Curr Opin Plant Biol** 1998 Apr;1(2):142-8 (56 ref.)
Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Cramer CL, et al. **Curr Top Microbiol Immunol** 1999;240:95-118 (80 ref.)
Particle bombardment mediated transformation. Finer JJ, et al. **Curr Top Microbiol Immunol** 1999;240:59-80 (110 ref.)
Overview: the many uses and applications of transgenic plants. Hammond J. **Curr Top Microbiol Immunol** 1999; 240:1-19 (100 ref.)
Lessons in gene transfer to plants by a gifted microbe. Hansen G, et al. **Curr Top Microbiol Immunol** 1999;240:21-57 (200 ref.)
Transgenic plants as edible vaccines. Richter L, et al. **Curr Top Microbiol Immunol** 1999;240:159-76 (60 ref.)
Feasibility of antibody production in plants for human therapeutic use. Russell DA. **Curr Top Microbiol Immunol** 1999;240:119-38 (80 ref.)
Potential benefits of the transgenic control of plant viruses in the United Kingdom. Barker I, et al. **Methods Mol Biol** 1998;81:557-66 (26 ref.)
Characterization of plant nematode genes: identifying targets for a transgenic defence. Lilley CJ, et al. **Parasitology** 1999; 118 Suppl:S63-72 (70 ref.)
Transgenic plants for tropical regions: some considerations about their development and their transfer to the small farmer. Herrera-Estrella L. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5978-81 (26 ref.)
Perspective: edible vaccines--a concept coming of age. Mor TS, et al. **Trends Microbiol** 1998 Nov;6(11):449-53 (36 ref.)

ADVERSE EFFECTS

Genetically modified food: a danger or a benefit for atopics? Ebner C. **Curr Probl Dermatol** 1999;28:81-7 (11 ref.)

ENZYMOLOGY

Challenges in understanding RLK function. Lease K, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):388-92 (27 ref.)

GENETICS

Molecular farming of recombinant antibodies in plants. Fischer R, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):825-39 (124 ref.)
Production of new/modified proteins in transgenic plants. Herbers K, et al. **Curr Opin Biotechnol** 1999 Apr; 10(2):163-8 (50 ref.)
Plant-based production of xenogenic proteins. Hood EE, et al. **Curr Opin Biotechnol** 1999 Aug;10(4):382-6 (25 ref.)
Transgene-induced gene silencing in plants. Vaucheret H, et al. **Plant J** 1998 Dec;16(6):651-9 (67 ref.)
Production of antibodies in transgenic plants. Larrick JW, et al. **Res Immunol** 1998 Jul-Aug;149(6):603-8 (40 ref.)
Horizontal gene transfers in the environment: natural transformation as a putative process for gene transfers between transgenic plants and microorganisms. Bertolla F, et al. **Res Microbiol** 1999 Jul-Aug;150(6):375-84 (81 ref.)
[Genetic transformation of plants, recombination processes, and gene expression regulation in transgenic plants] Kurochkina SD, et al. **Mol Gen Mikrobiol Virusol** 1998; (4):3-12 (131 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Improvements in human health through production of human milk proteins in transgenic food plants. Arakawa T, et al. **Adv Exp Med Biol** 1999;464:149-59 (50 ref.)
Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Arakawa T, et al. **Adv Exp Med Biol** 1999;464:161-78 (70 ref.)
Molecular farming of industrial proteins from transgenic maize. Hood EE, et al. **Adv Exp Med Biol** 1999;464:127-47 (40 ref.)
Autoantigens produced in plants for oral tolerance therapy of autoimmune diseases. Ma S, et al. **Adv Exp Med Biol** 1999;464:179-94 (44 ref.)
Production of recombinant blood factors in transgenic plants. Theisen M. **Adv Exp Med Biol** 1999;464:211-20 (18 ref.)
Novel insights in the control of tetrapyrrole metabolism of higher plants. Grimm B. **Curr Opin Plant Biol** 1998 Jun; 1(3):245-50 (39 ref.)
The metabolic effects of native and transgenic hemoglobins on plants. Bülow L, et al. **Trends Biotechnol** 1999 Jan; 17(1):21-4 (49 ref.)

PARASITOLOGY

Potential side effects of insect-resistant transgenic plants on arthropod natural enemies. Schuler TH, et al. **Trends Biotechnol** 1999 May;17(5):210-6 (77 ref.)

PHYSIOLOGY

Tandem constructs: preventing the rise of superweeds. Gressel J. **Trends Biotechnol** 1999 Sep;17(9):361-6 (62 ref.)

VIROLOGY

Viruses and gene silencing in plants. Baulcombe D. **Arch Virol Suppl** 1999;15:189-201 (50 ref.)
Recombination in RNA viruses and in virus-resistant transgenic plants. Aaziz R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1339-46 (85 ref.)

PLAQUE THERAPY, RADIOISOTOPE see **BRACHYTHERAPY**

PLASMA

Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Foster PR. **Transfus Med** 1999 Mar; 9(1):3-14 (60 ref.)
Factors determining quality of plasma. Myllylä G. **Vox Sang** 1998;74 Suppl 2:507-11 (11 ref.)
[The potentials of current transfusion hematology for component therapy with thrombocytes, granulocytes, plasma and plasma factors in obstetrics and gynecology] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(4):50-2 (25 ref.) **(Bul)**
[Physician liability and patient information related to blood and plasma product safety] Bock RW. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):501-3 (0 ref.) **(Ger)**
[Blood and plasma product safety from viewpoint of the surgeon] Kussmann J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):495-7 (18 ref.) **(Ger)**
[The anesthesiologic view of blood and plasma product safety] Mehrkens HH. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):492-5 (16 ref.) **(Ger)**
[Hemostasis and transfusion aspects of blood and plasma product safety] Seyfert UT, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):488-92 (7 ref.) **(Ger)**
[Blood and plasma product safety from the viewpoint of public health officials] Willkommen H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):497-500 (15 ref.) **(Ger)**

METABOLISM

Plasma contact activation: a revised hypothesis. Schmaier AH. **Biol Res** 1998;31(3):251-62 (55 ref.)
[Serum antioxidative activity] Klebanov GI, et al. **Vestn Ross Akad Med Nauk** 1999;(2):15-22 (46 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Biesert L, et al. **Vox Sang** 1998;74 Suppl 1:207-12 (12 ref.)
Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Horowitz B, et al. **Vox Sang** 1998;74 Suppl 1:203-6 (22 ref.)
Virus inactivation of fresh plasma. Mohr H. **Vox Sang** 1998; 74 Suppl 2:171-2 (12 ref.)
[Virologic aspects of blood and plasma product safety] Gärtner BC, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):486-8 (12 ref.) **(Ger)**

PLASMA CELL ANTIGENS PC-1 see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

PLASMA CELL DYSCRASIAS see **PARAPROTEINEMIAS**

PLASMA CELL GRANULOMA see **GRANULOMA, PLASMA CELL**

PLASMA CELL GRANULOMA, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PLASMA CELL LEUKEMIA see **LEUKEMIA, PLASMACYTIC**

PLASMA CELL TUMOR see **PLASMACYTOMA**

PLASMA CELLS

CYTOLOGY

Long-lived plasma cells survive independent of antigen. Manz RA, et al. **Curr Top Microbiol Immunol** 1999; 246:71-4; discussion 74-5 (2 ref.)

IMMUNOLOGY

Long-lived plasma cells survive independent of antigen. Manz RA, et al. **Curr Top Microbiol Immunol** 1999; 246:71-4; discussion 74-5 (2 ref.)

PATHOLOGY

Plasma cell mucositis: a review and case report. Smith ME, et al. **J Oral Pathol Med** 1999 Apr;28(4):183-6 (11 ref.)
Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS. Bartl R, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):158-68 (84 ref.)

PHYSIOLOGY

B cell memory and the long-lived plasma cell. McHeyzer-Williams MG, et al. **Curr Opin Immunol** 1999 Apr;11(2):172-9 (75 ref.)

PLASMA EXCHANGE

Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management. Mahalati K, et al. **J Clin Apheresis** 1999; 14(1):1-8 (65 ref.)
Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome [editorial] Hughes RA. **Ther Apher** 1997 May;1(2):129-30 (14 ref.)
Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis. Kaplan AA. **Ther Apher** 1997 Aug;1(3):255-9 (47 ref.)
Therapeutic apheresis in neurological disorders. Khatri BO. **Ther Apher** 1999 May;3(2):161-71 (127 ref.)
Plasma exchange in Rasmussen's encephalitis. Palcoux JB, et al. **Ther Apher** 1997 Feb;1(1):79-82 (18 ref.)
[Treatment of Guillain-Barré syndrome in adults: role of plasma exchange] Raphael JC, et al. **Rev Med Interne** 1998 Jan;19(1):60-8 (39 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic plasma exchange] Castellá Cahiz MD. **Sangre (Barc)** 1999 Feb;44(1):76-9 (17 ref.) **(Spa)**

ADVERSE EFFECTS

PCR testing of plasma pools: from concept to reality. Flanagan P, et al. **Transfus Med Rev** 1999 Jul;13(3):164-76 (40 ref.)
Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Biesert L, et al. **Vox Sang** 1998;74 Suppl 1:207-12 (12 ref.)
Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Horowitz B, et al. **Vox Sang** 1998;74 Suppl 1:203-6 (22 ref.)

METHODS

Treatment of thrombotic thrombocytopenic purpura with the cryosupernatant fraction of plasma: a case report and review of the literature. Ellis J, et al. **Am J Med Sci** 1999 Sep;318(3):190-3 (31 ref.)
[Therapeutic plasma exchanges with cyclophosphamide in the treatment of rapidly progressing glomerulonephritis] Wańkowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov; 5(29):304-6 (14 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

PCR testing of plasma pools: from concept to reality. Flanagan P, et al. **Transfus Med Rev** 1999 Jul;13(3):164-76 (40 ref.)

PLASMA FLOW, RENAL, EFFECTIVE see **RENAL PLASMA FLOW, EFFECTIVE**

PLASMA MEMBRANE see **CELL MEMBRANE**

PLASMA PROKALLIKREIN see **PREKALLIKREIN**

PLASMA PROTEINS see **BLOOD PROTEINS**

PLASMA SUBSTITUTES

see related
BLOOD SUBSTITUTES

[Replenishment of circulating blood volume by the use of colloid solutions] Franke R. **Anesteziol Reanimatol** 1999 May-Jun;(3):70-6 (30 ref.) **(Rus)**

[A new hydroxyethyl starch for volume replacement: Elohes 6%] Medel J, et al. **Rev Esp Anestesiol Reanim** 1998 Nov; 45(9):389-96 (68 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

An international view of hydroxyethyl starches. Treib J, et al. **Intensive Care Med** 1999 Mar;25(3):258-68 (82 ref.)

STANDARDS

Risks of virus transmission associated with animal sera or substitutes and methods of control. Eloit M. **Dev Biol Stand** 1999;99:9-16 (10 ref.)

Serum and serum substitutes: virus safety by inactivation or removal. Willkommen H, et al. **Dev Biol Stand** 1999; 99:131-8 (18 ref.)

THERAPEUTIC USE

Concerns with defining appropriate uses of albumin by meta-analysis. Erstad BL. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1451-4 (31 ref.)

Hypertonic saline resuscitation. Rocha e Silva M. **Medicina (B Aires)** 1998;58(4):393-402 (186 ref.)

Hydroxyethyl starch: pharmaceutical and clinical profile. Boldt J. **Minerva Anestesiol** 1999 May;65(5):305-9 (25 ref.)

Circulatory effects of whole blood, packed red cells, albumin, starch, and crystalloids in resuscitation of shock and acute critical illness. Shoemaker WC, et al. **Vox Sang** 1998;74 Suppl 2:69-74 (17 ref.)

[Hemoglobin solutions: volume replacement or oxygen therapy?] Standl T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):699-714 (152 ref.) (Eng. Abstr.) **(Ger)**

PLASMA THROMBOPLASTIN ANTECEDENT see **FACTOR XI**

PLASMA THROMBOPLASTIN COMPONENT see **FACTOR IX**

PLASMA TRANSGLUTAMINASE see **PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE**

PLASMA VOLUME

PHYSIOLOGY

The influence of exercise-induced plasma volume changes on the interpretation of biochemical parameters used for monitoring exercise, training and sport. Kargotich S, et al. **Sports Med** 1998 Aug;26(2):101-17 (123 ref.)

PLASMA VOLUME EXPANDERS see **PLASMA SUBSTITUTES**

PLASMACYTES see **PLASMA CELLS**

PLASMACYTIC LEUKEMIA see **LEUKEMIA, PLASMACYTIC**

PLASMACYTOMA

Falcotentorial plasmacytoma. Case report. Vaicys C, et al. **J Neurosurg** 1999 Jul;91(1):132-5 (17 ref.)

[Solitary plasmacytoma of bone] Togawa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):417-8 (6 ref.) **(Jpn)**

[Extramedullary plasmacytoma] Togawa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):419-21 (5 ref.) **(Jpn)**

COMPLICATIONS

Solitary plasmacytoma of the skull base presenting with unilateral sensorineural hearing loss. Vijaya-Sekaran S, et al. **J Laryngol Otol** 1999 Feb;113(2):164-6 (13 ref.)

Extramedullary plasmacytoma in a patient with AIDS: report of a case and review of the literature. Vallisa D, et al. **Tumori** 1998 Jul-Aug;84(4):511-4 (27 ref.)

DIAGNOSIS

Solitary plasmacytoma of the skull: a case report. Tanaka M, et al. **Jpn J Clin Oncol** 1998 Oct;28(10):626-30 (35 ref.)

Solitary plasmacytoma in the thoracic spine. Two case reports. Takahashi T, et al. **Neurosurg Rev** 1998; 21(2-3):121-5 (13 ref.)

[Primary extramedullary plasmacytoma of the duodenum] Gianom D, et al. **Swiss Surg** 1999;5(1):6-10 (21 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Cytokine network imbalances in plasmacytoma-regressor mice. Sagi-Assif O, et al. **Curr Top Microbiol Immunol** 1999;246:395-401 (30 ref.)

PATHOLOGY

Pulmonary plasmacytomas: a clinicopathologic and immunohistochemical study of five cases. Koss MN, et al. **Ann Diagn Pathol** 1998 Feb;2(1):1-11 (37 ref.)

Plasmacytoma of the ovary: a case report and literature review. Emery JD, et al. **Gynecol Oncol** 1999 Apr; 73(1):151-4 (18 ref.)

Solitary plasmocytoma of bone in an adolescent. Bertoni-Salateo R, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):574-6 (14 ref.)

[Refractory multiple myeloma preceded by extramedullary plasmacytoma of lymph node--a case report and review of the literature] Ise M, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):505-10 (19 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Inhibition of pristane-induced peritoneal plasmacytoma formation. Potter M, et al. **Curr Top Microbiol Immunol** 1999;246:351-61; discussion 361-2 (48 ref.)

RADIOGRAPHY

Plasmacytoma of the breast: mammographic and sonographic findings. Coll D, et al. **AJR Am J Roentgenol** 1999 Oct; 173(4):1135, 1136 (4 ref.)

Solitary plasmocytoma of bone in an adolescent. Bertoni-Salateo R, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):574-6 (14 ref.)

ULTRASONOGRAPHY

Plasmacytoma of the breast: mammographic and sonographic findings. Coll D, et al. **AJR Am J Roentgenol** 1999 Oct; 173(4):1135, 1136 (4 ref.)

VIROLOGY

Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Adamson SR. **Dev Biol Stand** 1998;93:89-96 (18 ref.)

PLASMACYTOMA GROWTH FACTOR see **INTERLEUKIN-6**

PLASMALOGENS

BIOSYNTHESIS

Biosynthesis and possible biological functions of plasmalogens. Lee TC. **Biochim Biophys Acta** 1998 Nov 2;1394(2-3):129-45 (83 ref.)

METABOLISM

Determination of plasmalogen-selective phospholipase A2 activity by radiochemical and fluorometric assay procedures. Farooqui AA, et al. **Methods Mol Biol** 1999; 109:39-47 (15 ref.)

PHYSIOLOGY

Biosynthesis and possible biological functions of plasmalogens. Lee TC. **Biochim Biophys Acta** 1998 Nov 2;1394(2-3):129-45 (83 ref.)

The biological significance of plasmalogens in defense against oxidative damage. Brosche T, et al. **Exp Gerontol** 1998 Aug; 33(5):363-9 (37 ref.)

PLASMAPHERESIS

Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Thiery J, et al. **Curr Opin Lipidol** 1998 Dec;9(6):521-6 (45 ref.)

Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Jindal KK. **Kidney Int Suppl** 1999 Jun;70:S33-40 (27 ref.)

Therapeutic apheresis for renal diseases [editorial] Harada T, et al. **Ther Apher** 1998 Aug;2(3):193-8 (31 ref.)

Therapeutic apheresis for renal disorders. Kaplan AA. **Ther Apher** 1999 Feb;3(1):25-30 (83 ref.)

Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column [editorial] Kojima S, et al. **Ther Apher** 1997 Nov;1(4):309-13 (16 ref.)

Plasmapheresis in collagen vascular diseases. Lewis EJ. **Ther Apher** 1999 May;3(2):172-7 (58 ref.)

Therapeutic apheresis in malignancy [editorial] Nand S. **Ther Apher** 1997 Feb;1(1):29-32 (25 ref.)

Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenström's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Siami GA, et al. **Ther Apher** 1999 Feb;3(1):8-19 (110 ref.)

Present status of apheresis technologies: Part 2. Membrane plasma fractionator [editorial] Sueoka A. **Ther Apher** 1997 May;1(2):135-46 (19 ref.)

Theoretical background of effect mechanism by extracorporeal immunomodulation. Tani T, et al. **Ther Apher** 1997 Aug;1(3):219-23 (15 ref.)

A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Yamada H, et al. **Ther Apher** 1998 May;2(2):153-6 (14 ref.)

[Plaque stabilization by LDL apheresis?] Schuff-Werner P, et al. **Herz** 1999 Feb;24(1):57-61 (20 ref.) (Eng. Abstr.) **(Ger)**

[Plasmapheresis for collagen diseases] Tsuda H, et al. **Nippon Rinsho** 1999 Feb;57(2):445-8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The use of therapeutic plasmapheresis in the combined therapy of a female patient with idiopathic hemochromatosis] Krivosheev AB, et al. **Anesteziol Reanimatol** 1998 Jul-Aug;(4):50-2 (10 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome. Stegmayr B. **Clin Chem Lab Med** 1999 Mar;37(3):327-32 (73 ref.)

Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis. Stefanutti C, et al. **Clin Ter** 1998 May-Jun;149(3):231-3 (20 ref.)

Application of bioaffinity technology in therapeutic extracorporeal plasmapheresis and large-scale fractionation of human plasma. Burnouf T, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 11;715(1):65-80 (98 ref.)

PLASMIDS

see related
EXTRACHROMOSOMAL INHERITANCE

Extrachromosomal genetic elements in fungi. Kevei F, et al. **Acta Microbiol Immunol Hung** 1999;46(2-3):279-87 (37 ref.)

DNA vaccines for viral diseases. Donnelly JJ, et al. **Braz J Med Biol Res** 1999 Feb;32(2):215-22 (25 ref.)

Demonstration of extrachromosomal elements. Voelker LL, et al. **Methods Mol Biol** 1998;104:239-46 (8 ref.)

Engineering of bacterial ribosomes: replacement of all seven Escherichia coli rRNA operons by a single plasmid-encoded operon [see comments] Nomura M. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1820-2 (25 ref.) Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1971-6.

GENETICS

Conjugation in gram-positive bacteria and kinetics of plasmid transfer. Andrup L. **APMIS Suppl** 1998;84:47-55 (53 ref.)

Broad-host-range plasmids and their role in gene transfer in nature. Valla S. **APMIS Suppl** 1998;84:19-24 (13 ref.)

Application of lipids and plasmid design for gene delivery to mammalian cells. Scherman D, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):480-5 (59 ref.)

Plasmids of corynebacteria. Deb JK, et al. **FEMS Microbiol Lett** 1999 Jun 1;175(1):11-20 (50 ref.)

Proteic toxin-antitoxin, bacterial plasmid addiction systems and their evolution with special reference to the pas system of pTF-FC2. Rawlings DE. **FEMS Microbiol Lett** 1999 Jul 15;176(2):269-77 (46 ref.)

Genome evolution within the alpha Proteobacteria: why do some bacteria not possess plasmids and others exhibit more than one different chromosome? Moreno E. **FEMS Microbiol Rev** 1998 Oct;22(4):255-75 (159 ref.)

Bacterial plasmids: replication of extrachromosomal genetic elements encoding resistance to antimicrobial compounds. Actis LA, et al. **Front Biosci** 1999 Jan 1;4:D43-62 (226 ref.)

Regulatory implications of protein assemblies at the gamma origin of plasmid R6K - a review. Filutowicz M, et al. **Gene** 1998 Nov 26;223(1-2):195-204 (90 ref.)

The virulence plasmid of Yersinia, an antihost genome. Cornelis GR, et al. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1315-52 (395 ref.)

The plasmid prophage N15: a linear DNA with covalently closed ends. Rybchin VN, et al. **Mol Microbiol** 1999 Sep; 33(5):895-903 (40 ref.)

Timing, self-control and a sense of direction are the secrets of multicopy plasmid stability. Summers D. **Mol Microbiol** 1998 Sep;29(5):1137-45 (48 ref.)

Replication of plasmids during bacterial response to amino acid starvation. Wegrzyn G. **Plasmid** 1999 Jan;41(1):1-16 (82 ref.)

Kissing and RNA stability in antisense control of plasmid replication. Gerhart E, et al. **Trends Biochem Sci** 1998 Dec; 23(12):451-4 (33 ref.)

Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. Prazeres DM, et al. **Trends Biotechnol** 1999 Apr;17(4):169-74 (30 ref.)

Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? Bauernfeind A, et al. **Yonsei Med J** 1998 Dec;39(6):520-5 (23 ref.)

[Regulation of bacteriophage lambda and lambda plasmid DNA replication] Węgrzyn A, et al. **Postepy Biochem** 1999; 45(1):5-11 (59 ref.) **(Pol)**

PLASMIDS

ISOLATION & PURIFICATION

Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. Prazeres DM, et al. **Trends Biotechnol** 1999 Apr;17(4):169–74 (30 ref.)

METABOLISM

Applications of oriP plasmids and their mode of replication. Mackey D, et al. **Methods Enzymol** 1999;306:308–28 (121 ref.)

PHYSIOLOGY

Termination of DNA replication of bacterial and plasmid chromosomes. Bussiere DE, et al. **Mol Microbiol** 1999 Mar; 31(6):1611–8 (42 ref.)

Participation of host gene functions in plasmid postsegregational killing: how and why. Touati E. **Res Microbiol** 1997 Nov;148(8):645–7 (11 ref.)

Contrasting lifestyles of rolling-circle phages and plasmids. Novick RP. **Trends Biochem Sci** 1998 Nov;23(11):434–8 (24 ref.)

PLASMIN

BIOSYNTHESIS

Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? Christ G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):277–85 (95 ref.)

METABOLISM

Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review). Shen GX. **Int J Mol Med** 1998 Feb;1(2):399–408 (170 ref.)

[Fibrinolytic substances formation by cancer. Pathogenetic sequelae] Uszyński M. **Ginekol Pol** 1999 Feb;70(2):105–11 (18 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Proteolytic control of growth factor availability. Rifkin DB, et al. **APMIS** 1999 Jan;107(1):80–5 (52 ref.)

PLASMINOGEN

DEFICIENCY

Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Carmeliet P, et al. **Thromb Res** 1998 Sep 15;91(6):255–85 (254 ref.)

[Congenital hypoplasminogenemia and dysplasminogenemia (type I and type II congenital plasminogen deficiency)] Shigekiyo T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):9–10 (14 ref.) **(Jpn)**

GENETICS

[Molecular patho-biochemistry and genetic diagnosis for plasminogen-apolipoprotein (a) gene family related to atherosclerosis and thrombosis] Ichinose A. **Rinsho Byori** 1998 Dec;46(12):1210–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Plasminogen activation in human leukemia and in normal hematopoietic cells. Mustjoki S, et al. **APMIS** 1999 Jan; 107(1):144–9 (59 ref.)

[The clinical prospects for the study of the plasminogen activation system in breast cancer] Gershtein ES, et al. **Vestn Ross Akad Med Nauk** 1999;(8):58–61 (53 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Cao Y. **Prog Mol Subcell Biol** 1998;20:161–76 (67 ref.)

THERAPEUTIC USE

Therapeutic potentials of angiostatin in the treatment of cancer. Cao Y. **Haematologica** 1999 Jul;84(7):643–50 (45 ref.)

Regulating angiogenesis: a new therapeutic strategy. Gibaldi M. **J Clin Pharmacol** 1998 Oct;38(10):898–903 (23 ref.)

[Antiangiogenic therapy] Toi M. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2003–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

PLASMINOGEN ACTIVATOR INHIBITOR 1

[Plasminogen activator inhibitor-1 in thrombotic disease] Niiya K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):24–7 (15 ref.) **(Jpn)**

ANALYSIS

Clinical relevance of the urokinase plasminogen activator system in breast cancer. Look MP, et al. **APMIS** 1999 Jan; 107(1):150–9 (50 ref.)

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Stephens RW, et al. **Breast Cancer Res Treat** 1998;52(1–3):99–111 (45 ref.)

BIOSYNTHESIS

A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Yamamoto K, et al. **Int J Hematol** 1998 Dec;68(4):371–85 (152 ref.)

BLOOD

Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Cesari M, et al. **Arterioscler Thromb Vasc Biol** 1999 Jun;19(6):1378–86 (108 ref.)

Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? Christ G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):277–85 (95 ref.)

The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Salat C, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):25–32 (29 ref.)

Predictive value of fibrinolytic factors in coronary heart disease. Wiman B. **Scand J Clin Lab Invest Suppl** 1999; 230:23–31 (50 ref.)

[Fibrinolysis in ischemic cardiopathy: the role of plasminogen activator inhibitor 1] Cesari M, et al. **Cardiologia** 1999 Jan; 44(1):25–32 (89 ref.) **(Ita)**

[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions] Galajda P, et al. **Vnitr Lek** 1998 Feb;44(2):111–4 (38 ref.) (Eng. Abstr.) **(Slo)**

DEFICIENCY

[Plasminogen activator inhibitor deficiency] Mimuro J. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):494–7 (9 ref.) **(Jpn)**

METABOLISM

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox [editorial] Sobel BE. **Circulation** 1999 May 18;99(19):2496–8 (41 ref.)

Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review). Shen GX. **Int J Mol Med** 1998 Feb;1(2):399–408 (170 ref.)

[Evidence of a renin receptor on human mesangial cells: effects on PAI1 and cGMP] Nguyen G, et al. **Nephrologie** 1998;19(7):411–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[The role of PAI-1 in thrombotic events] Orbe J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):63–9 (115 ref.) **(Spa)**

PHYSIOLOGY

Regulation of cell adhesion by PAI-1. Loskutoff DJ, et al. **APMIS** 1999 Jan;107(1):54–61 (56 ref.)

A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Yamamoto K, et al. **Int J Hematol** 1998 Dec;68(4):371–85 (152 ref.)

Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. Vaughan DE. **J Investig Med** 1998 Oct;46(8):370–6 (85 ref.)

PLASMINOGEN ACTIVATOR INHIBITOR 2

ANALYSIS

Clinical relevance of the urokinase plasminogen activator system in breast cancer. Look MP, et al. **APMIS** 1999 Jan; 107(1):150–9 (50 ref.)

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Stephens RW, et al. **Breast Cancer Res Treat** 1998;52(1–3):99–111 (45 ref.)

BLOOD

Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Astedt B, et al. **Semin Thromb Hemost** 1998;24(5):431–5 (72 ref.)

PLASMINOGEN ACTIVATOR, TISSUE-TYPE see **TISSUE PLASMINOGEN ACTIVATOR**

PLASMINOGEN ACTIVATOR, UROKINASE-TYPE see **UROKINASE**

PLASMINOGEN ACTIVATORS

The role of the plasminogen activation system in cancer. Carroll VA, et al. **Semin Thromb Hemost** 1999;25(2):183–97 (327 ref.)

ADMINISTRATION & DOSAGE

Prehospital thrombolytic treatment of massive pulmonary embolism with reteplase during cardiopulmonary resuscitation. Kuisma M, et al. **Resuscitation** 1998 Jul; 38(1):47–50 (10 ref.)

BIOSYNTHESIS

New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile. Maksimenko AV. **Ann N Y Acad Sci** 1998 Dec 13;864:96–105 (50 ref.)

GENETICS

Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer [editorial] Del Rosso M, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):389–93 (56 ref.)

IMMUNOLOGY

Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. Cuzner ML, et al. **J Neuroimmunol** 1999 Feb 1;94(1–2):1–14 (111 ref.)

METABOLISM

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox [editorial] Sobel BE. **Circulation** 1999 May 18;99(19):2496–8 (41 ref.)

Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Mohanam S, et al. **Front Biosci** 1999 Feb 15;4:D178–87 (113 ref.)

[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer] Herszényi L, et al. **Orv Hetil** 1999 Aug 15;140(33):1833–6 (48 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOKINETICS

Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective. Martin U, et al. **Clin Pharmacokinet** 1999 Apr;36(4):265–76 (57 ref.)

PHYSIOLOGY

Plasminogen activation in human leukemia and in normal hematopoietic cells. Mustjoki S, et al. **APMIS** 1999 Jan; 107(1):144–9 (59 ref.)

Proteolytic control of growth factor availability. Rifkin DB, et al. **APMIS** 1999 Jan;107(1):80–5 (52 ref.)

Regulation of the plasminogen activator system in the ovary. Liu YX. **Biol Signals Recept** 1999 May–Jun;8(3):160–77 (113 ref.)

[Involvement of urokinase and its receptor in the remodeling of normal and pathological tissue] Tkachuk VA, et al. **Vestn Ross Akad Med Nauk** 1998;(8):36–41 (61 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice? Weber JJ, et al. **Am J Health Syst Pharm** 1998 Nov 15; 55(22):2414–6 (16 ref.)

Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Wooster MB, et al. **Ann Pharmacother** 1999 Mar;33(3):318–24 (17 ref.)

New plasminogen activators: a clinical review. Ross AM. **Clin Cardiol** 1999 Mar;22(3):165–71 (54 ref.)

[Thrombolytic therapy] Matsuda T. **Nippon Rinsho** 1998 Oct; 56(10):2577–81 (20 ref.) (Eng. Abstr.) **(Jpn)**

PLASMODIUM

see related

ANTIMALARIALS

Malaria: existing methods of vector control and molecular entomology. Curtis CF, et al. **Br Med Bull** 1998; 54(2):311–25 (61 ref.)

A historical review of the F-1 strain of Anopheles freeborni as a host and vector for studies of malaria. Collins WE, et al. **J Am Mosq Control Assoc** 1999 Jun;15(2):117–27 (165 ref.)

CLASSIFICATION

[The relationship of the susceptibility of mosquitoes to the causative agents of malaria to their taxonomic position and the geographical origin of the interacting organisms] Rasnitsyn SP. **Parazitologiia** 1998 Nov–Dec;32(6):495–500 (21 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Bisquinoline antimalarials: their role in malaria chemotherapy. Raynes K. **Int J Parasitol** 1999 Mar; 29(3):367–79 (90 ref.)

Challenges in the development of antimalarial drugs with causal prophylactic activity. Chulay JD. **Trans R Soc Trop Med Hyg** 1998 Nov–Dec;92(6):577–9 (25 ref.)

GENETICS

Waves of malarial var-iations. Wahlgren M, et al. **Cell** 1999 Mar 5;96(5):603–6 (15 ref.)

The evolution of multiple drug resistance in malaria parasites. Mackinnon MJ, et al. **Trans R Soc Trop Med Hyg** 1998 Mar–Apr;92(2):188–95 (33 ref.)

METABOLISM

Intracellular trafficking in Plasmodium-infected erythrocytes. Haldar K. **Curr Opin Microbiol** 1998 Aug; 1(4):466–71 (44 ref.)

PATHOGENICITY

Adhesive proteins of the malaria parasite. Coppel RL, et al. **Curr Opin Microbiol** 1998 Aug;1(4):472–81 (84 ref.)
Protein trafficking in malaria-infected erythrocytes. Foley M, et al. **Int J Parasitol** 1998 Nov;28(11):1671–80 (69 ref.)
[The relationship of the susceptibility of mosquitoes to the causative agents of malaria to their taxonomic position and the geographical origin of the interacting organisms] Rasnitsyn SP. **Parazitologiia** 1998 Nov–Dec;32(6):495–500 (21 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Multispecies Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1999 Feb;85(1):12–8 (76 ref.)
Periodic infectivity of Plasmodium gametocytes to the vector. A review. Gautret P, et al. **Parasite** 1999 Jun; 6(2):103–11 (69 ref.)

PLASMODIUM BERGHEI

DRUG EFFECTS

Plants showing antiplasmodial activity—from crude extracts to isolated compounds. Sharma P, et al. **Indian J Malariol** 1998 Jun;35(2):57–110 (134 ref.)

PLASMODIUM FALCIPARUM

New insights into the epidemiology of malaria relevant for disease control. Snow RW, et al. **Br Med Bull** 1998; 54(2):293–309 (50 ref.)
[Molecular analysis of Plasmodium falciparum infections in man] Mercereau-Puijalon O. **Transfus Clin Biol** 1999 Feb; 6(1):44–56 (35 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Malaria prevention in travelers. Juckett G. **Am Fam Physician** 1999 May 1;59(9):2523–30, 2535–6 (13 ref.)
Plants showing antiplasmodial activity—from crude extracts to isolated compounds. Sharma P, et al. **Indian J Malariol** 1998 Jun;35(2):57–110 (134 ref.)
The treatment of chloroquine-resistant malaria. van Vugt M, et al. **Trop Doct** 1999 Jul;29(3):176–9 (23 ref.)

GENETICS

Antigenic variation in Plasmodium falciparum: mechanisms and consequences. Newbold CI. **Curr Opin Microbiol** 1999 Aug;2(4):420–5 (67 ref.)
Genome projects, genetic analysis, and the changing landscape of malaria research. Wellems TE, et al. **Curr Opin Microbiol** 1999 Aug;2(4):415–9 (58 ref.)
Control of gene expression in Plasmodium falciparum. Horrocks P, et al. **Mol Biochem Parasitol** 1998 Sep 15; 95(2):171–81 (91 ref.)
From genomics to vaccines: malaria as a model system [comment] Hoffman SL, et al. **Nat Med** 1998 Dec; 4(12):1351–3 (12 ref.) Comment on: Nat Med 1998 Dec;4(12):1360–2.
Genetic structure and dynamics of Plasmodium falciparum infections in the Kilombero region of Tanzania. Babiker HA, et al. **Trans R Soc Trop Med Hyg** 1999 Feb;93 Suppl 1:11–4 (29 ref.)

IMMUNOLOGY

Vaccines against the blood stages of falciparum malaria. Miller LH, et al. **Adv Exp Med Biol** 1998;452:193–205 (45 ref.)
Malaria vaccines [comment] Holder AA. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1167–9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1615–20.

ISOLATION & PURIFICATION

Malaria miscellany. Isaäcson M. **J Travel Med** 1999 Jun; 6(2):155–7 (9 ref.)

METABOLISM

Metabolic changes of the malaria parasite during the transition from the human to the mosquito host. Lang-Unnasch N, et al. **Annu Rev Microbiol** 1998; 52:561–90 (165 ref.)
Intracellular trafficking in Plasmodium-infected erythrocytes. Haldar K. **Curr Opin Microbiol** 1998 Aug; 1(4):466–71 (44 ref.)
[Plasmodium falciparum and chondroitin-4-sulfate: the new key couple in sequestration] Pouvelle B, et al. **Med Trop (Mars)** 1998;58(2):187–98 (125 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Multispecies Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1999 Feb;85(1):12–8 (76 ref.)

PLASMODIUM FALCIPARUM MALARIA see **MALARIA, FALCIPARUM**

PLASMODIUM INFECTIONS see **MALARIA**

PLASMODIUM MALARIAE

PHYSIOLOGY

Multispecies Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1999 Feb;85(1):12–8 (76 ref.)

PLASMODIUM VIVAX

PHYSIOLOGY

Multispecies Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1999 Feb;85(1):12–8 (76 ref.)

PLASMODIUM VIVAX MALARIA see **MALARIA, VIVAX**

PLASMOSOME see **CELL NUCLEOLUS**

PLASTER CASTS see **CASTS, SURGICAL**

PLASTIC CASTS see **CASTS, SURGICAL**

PLASTIC SURGERY see **SURGERY, PLASTIC**

PLASTICITY, NEURONAL see **NEURONAL PLASTICITY**

PLASTICS

Which stents do we need? The case for plastic stents. Seitz U, et al. **Endoscopy** 1998 Nov;30(9):A242–6 (42 ref.)
Recent advances in polyhydroxyalkanoate production by bacterial fermentation: mini-review. Lee SY, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1–3):31–6 (46 ref.)
Polyhydroxybutyrate: plastic made and degraded by microorganisms. Hankermeyer CR, et al. **Rev Environ Contam Toxicol** 1999;159:1–24 (37 ref.)

PLASTIDS

Plastid evolution: origins, diversity, trends. Douglas SE. **Curr Opin Genet Dev** 1998 Dec;8(6):655–61 (73 ref.)
Plastid division: evidence for a prokaryotically derived mechanism. Osteryoung KW, et al. **Curr Opin Plant Biol** 1998 Dec;1(6):475–9 (41 ref.)

DRUG EFFECTS

Apicomplexan plastids as drug targets. McFadden GI, et al. **Trends Microbiol** 1999 Aug;7(8):328–33 (44 ref.)

GENETICS

Plastids and protein targeting. McFadden GI. **J Eukaryot Microbiol** 1999 Jul-Aug;46(4):339–46 (100 ref.)

METABOLISM

Metabolite transporters in plastids. Flügge UI. **Curr Opin Plant Biol** 1998 Jun;1(3):201–6 (49 ref.)
Plastids and protein targeting. McFadden GI. **J Eukaryot Microbiol** 1999 Jul-Aug;46(4):339–46 (100 ref.)
Mechanisms of regulation and interplastid localization of chlorophyll biosynthesis. Averina NG. **Membr Cell Biol** 1998;12(5):627–43 (105 ref.)

PHYSIOLOGY

Do plastid envelope membranes play a role in the expression of the plastid genome? Sato N, et al. **Biochimie** 1999 Jun; 81(6):619–29 (72 ref.)
Origin, targeting, and function of the apicomplexan plastid. Roos DS, et al. **Curr Opin Microbiol** 1999 Aug;2(4):426–32 (80 ref.)

PLATANISTA see **DOLPHINS**

PLATANNA see **XENOPUS LAEVIS**

PLATELET ACTIVATING FACTOR

[Platelet-activating factor (PAF) receptor-related pathophysiology] Ishii S, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1068–74 (16 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The potential role of therapeutic cytokine manipulation in acute pancreatitis. Denham W, et al. **Surg Clin North Am** 1999 Aug;79(4):767–81 (79 ref.)

BIOSYNTHESIS

Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis. Johnson CD. **Dig Surg** 1999;16(2):93–101 (85 ref.)

METABOLISM

Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions. Weber C, et al. **Clin Chem Lab Med** 1999 Mar;37(3):243–51 (88 ref.)

PHYSIOLOGY

Potential role of platelet activating factor in acute renal failure. López-Novoa JM. **Kidney Int** 1999 May; 55(5):1672–82 (105 ref.)
The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Bazan NG. **Prog Brain Res** 1998; 118:281–91 (42 ref.)
The potential role of therapeutic cytokine manipulation in acute pancreatitis. Denham W, et al. **Surg Clin North Am** 1999 Aug;79(4):767–81 (79 ref.)
Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. Izzo AA, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):403–5 (28 ref.)

PLATELET ACTIVATION

Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles. Igarashi Y, et al. **Acta Biochim Pol** 1998;45(2):299–309 (29 ref.)
The platelet in cardiopulmonary bypass. Weerasinghe A, et al. **Ann Thorac Surg** 1998 Dec;66(6):2145–52 (77 ref.)
Different activation states of GP IIb/IIIa complexes in platelets. Nurden AT, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S67–70 (30 ref.)
Overview of platelet physiology and laboratory evaluation of platelet function. Rodgers GM. **Clin Obstet Gynecol** 1999 Jun;42(2):349–59 (19 ref.)
Platelet microparticles: a wide-angle perspective. Horstman LL, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):111–42 (411 ref.)
Platelet dense granules: structure, function and implications for haemostasis. McNicol A, et al. **Thromb Res** 1999 Jul 1;95(1):1–18 (153 ref.)
[Vascular disease and cellular activation: exploration of cell adhesion phenotype by quantitative flow cytometry] Latger V, et al. **J Mal Vasc** 1999 Feb;24(1):11–8 (59 ref.) (Eng. Abstr.) **(Fre)**
[Neutrophil adherence-inhibiting factor, AIF, is released from lysosomes of activated platelets] Iwabuchi K, et al. **Seikagaku** 1999 May;71(5):353–8 (19 ref.) **(Jpn)**

DRUG EFFECTS

Effect of ethanol on platelet function. Rubin R. **Alcohol Clin Exp Res** 1999 Jun;23(6):1114–8 (58 ref.)
Laboratory markers of platelet activation and their clinical significance. Michelson AD, et al. **Curr Opin Hematol** 1999 Sep;6(5):342–8 (60 ref.)
Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms. Puri RN. **Int J Biochem Cell Biol** 1998 Oct;30(10):1107–22 (152 ref.)
[The pharmacological regulation of thrombocyte activity] Dukhanin AS, et al. **Eksp Klin Farmakol** 1998 Jul-Aug; 61(4):66–71 (47 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Inhibitory and activating human antiplatelet antibodies. Deckmyn H, et al. **Baillieres Clin Haematol** 1998 Jun; 11(2):343–59 (86 ref.)
Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Joseph JE, et al. **Lupus** 1998;7 Suppl 2:S48–51 (35 ref.)

PHYSIOLOGY

Thrombin interaction with platelet GpIb: structural mapping and effects on platelet activation (review). De Cristofaro R, et al. **Int J Mol Med** 1999 Apr;3(4):363–71 (78 ref.)
Sodium-hydrogen exchange and platelet function. Rosskopf D. **J Thromb Thrombolysis** 1999 Jul;8(1):15–24 (128 ref.)
Platelet activation and its detection during the preparation of platelets for transfusion. Rinder HM, et al. **Transfus Med Rev** 1998 Oct;12(4):271–87 (77 ref.)
[Platelet activation] Oda A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1863–9 (12 ref.) **(Jpn)**

PLATELET ADHESIVENESS

see related
PLATELET MEMBRANE GLYCOPROTEINS

PLATELET AGGREGATION

see related
PLATELET MEMBRANE GLYCOPROTEINS

Primary haemostasis: sticky fingers cement the relationship. Clemetson KJ. **Curr Biol** 1999 Feb 11;9(3):R110–2 (9 ref.)
Patient stratification and its predictive value for cardiac events. Topol E. **Eur Heart J** 1998 Sep;19 Suppl K:K5–7 (14 ref.)
Nitric oxide and platelet aggregation. Riddell DR, et al. **Vitam Horm** 1999;57:25–48 (113 ref.)
[Montreal platelet syndrome] Shimasaki AK. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):316–9 (14 ref.) **(Jpn)**

DRUG EFFECTS

Effects of smoking on prostacyclin formation and platelet

aggregation in users of oral contraceptives. Roy S. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 2):S364–8 (10 ref.)

Monitoring platelet GPIIb/IIIa antagonist therapy. Coller BS. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S81–6 (40 ref.)

IIb/IIIa inhibitors in acute myocardial infarction. Montalescot G. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S71–5 (41 ref.)

Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. Calverley DC, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1231–49, vi (122 ref.)

Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. Halpern MJ, et al. **J Int Med Res** 1998 Aug–Sep;26(4):171–80 (53 ref.)

Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology. Gibson CM, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):287–302 (63 ref.)

Discovery and pharmacological evaluation of new platelet glycoprotein gpIIb/IIIa antagonists. Merlos M, et al. **Methods Find Exp Clin Pharmacol** 1998 Dec;20(10):869–80 (79 ref.)

Rationale for the combination of anti-aggregating drugs. Herman AG. **Thromb Res** 1998 Sep 15;92(1 Suppl 1):S17–21 (11 ref.)

[Anti-integrins--new platelet function inhibitors for therapy and prevention of acute coronary syndrome] Schrör K. **Wien Klin Wochenschr** 1999 Feb 12;111(3):90–7 (55 ref.) (Eng. Abstr.) **(Ger)**

[Inhibition of thrombocyte aggregation after heart valve replacement] von Schacky C. **Z Kardiol** 1998;87 Suppl 4:46–55 (64 ref.) (Eng. Abstr.) **(Ger)**

[Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation] Pastorova VE, et al. **Usp Fiziol Nauk** 1999 Apr–Jun;30(2):80–91 (66 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[Antiphospholipid-protein antibodies. Effects on the endothelium-platelet interaction] Forastiero RR, et al. **Sangre (Barc)** 1999 Jun;44(3):223–30 (85 ref.) **(Spa)**

PHYSIOLOGY

Nitric oxide in atherosclerosis: vascular protector or villain? Dusting GJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S34–41 (65 ref.)

Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Kunapuli SP. **Trends Pharmacol Sci** 1998 Oct;19(10):391–4 (56 ref.)

[High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy] Isaka N, et al. **Nippon Rinsho** 1998 Oct;56(10):2624–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

PLATELET AGGREGATION INHIBITORS

Fibrin-fibrinogen and dethrombosis. Muhlestein JB. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S59–62 (24 ref.)

New antithrombotic agents. Weitz JI, et al. **Chest** 1998 Nov; 114(5 Suppl):715S–727S (140 ref.)

Platelet GPIIb-IIIa blockers [see comments] Topol EJ, et al. **Lancet** 1999 Jan 16;353(9148):227–31 (48 ref.) Comment in: Lancet 1999 Apr 3;353(9159):1185.

Viper venom disintegrins and related molecules. McLane MA, et al. **Proc Soc Exp Biol Med** 1998 Nov;219(2):109–19 (103 ref.)

ADMINISTRATION & DOSAGE

Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Kereiakes DJ. **Am Heart J** 1999 Jul;138(1 Pt 2):S39–46 (25 ref.)

Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. Cantor WJ, et al. **Cardiol Rev** 1999 Jul–Aug; 7(4):232–44 (75 ref.)

Therapeutic inhibition of platelet function in stroke. Harker LA. **Cerebrovasc Dis** 1998;8 Suppl 5:8–18 (83 ref.)

Antithrombotic drugs: insights from cardiology. Meyer BJ. **Cerebrovasc Dis** 1998;8 Suppl 5:19–27 (45 ref.)

Cardiologists and their war on platelets [editorial] Ferrari R, et al. **Eur Heart J** 1999 Apr;20(8):557–8 (4 ref.)

Antiproliferative stent coatings: Taxol and related compounds. Herdeg C, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):197–9 (26 ref.)

Rationale for the combination of anti-aggregating drugs. Herman AG. **Thromb Res** 1998 Sep 15;92(1 Suppl 1):S17–21 (11 ref.)

[Anti-integrins--new platelet function inhibitors for therapy and prevention of acute coronary syndrome] Schrör K. **Wien Klin Wochenschr** 1999 Feb 12;111(3):90–7 (55 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Jubelirer SJ, et al. **Am J Hematol** 1999 Jul;61(3):205–8 (11 ref.)

Ticlopidine-induced phenytoin toxicity. Klaassen SL. **Ann Pharmacother** 1998 Dec;32(12):1295–8 (18 ref.)

Hepatotoxicity due to ticlopidine [letter] Martínez Pérez-Balsa A, et al. **Ann Pharmacother** 1998 Nov; 32(11):1250–1 (17 ref.)

Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature [see comments] Chen DK, et al. **Arch Intern Med** 1999 Feb 8;159(3):311–4 (26 ref.) Comment in: Arch Intern Med 1999 Jul 26;159(14):1624.

Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Madan M, et al. **Curr Opin Hematol** 1999 Sep;6(5):334–41 (25 ref.)

Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature. Iqbal M, et al. **Dig Dis Sci** 1998 Oct;43(10):2223–6 (33 ref.)

Thrombotic thrombocytopenic purpura associated with ticlopidine therapy. Leavey SF, et al. **J Am Soc Nephrol** 1997 Apr;8(4):689–93 (26 ref.)

Anticoagulant therapy, anti-platelet agents and gastrointestinal endoscopy. Miller AM, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):109–13 (43 ref.)

Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. Boysen G. **J Intern Med** 1999 Sep;246(3):239–45 (16 ref.)

Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Urmey WF, et al. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6 Suppl 2):146–51 (16 ref.)

[The risk of hemorrhage in long-term use of aspirin and triflusal] Alvarez Sabin J, et al. **Rev Neurol** 1998 Dec; 27(160):951–5 (43 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Economic issues in glycoprotein IIb/IIIa receptor therapy. Hillegass WB, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S24–32 (28 ref.)

ISOLATION & PURIFICATION

Antiplatelet agents isolated from medicinal plants. Teng CM, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):211–25 (68 ref.)

PHARMACOLOGY

Potential non-glycoprotein IIb/IIIa effects of abciximab. Coller BS. **Am Heart J** 1999 Jul;138(1 Pt 2):S1–5 (50 ref.)

Pharmacological remodeling of the thrombus architecture. Collet JP, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S49–53 (32 ref.)

The effects of diadenosine polyphosphates on the cardiovascular system. Flores NA, et al. **Cardiovasc Res** 1999 Apr;42(1):15–26 (82 ref.)

Clopidogrel: a new antiplatelet agent. Feret B. **Conn Med** 1999 Jun;63(6):331–3 (7 ref.)

Pharmacology of the intravenous platelet receptor glycoprotein IIb–IIIa antagonists. Kleiman NS. **Coron Artery Dis** 1998;9(9):603–16 (104 ref.)

Thrombin inhibitor design. Sanderson PE, et al. **Curr Med Chem** 1998 Aug;5(4):289–304 (94 ref.)

A risk-benefit assessment of abciximab in angioplasty. Kleiman NS. **Drug Saf** 1999 Jan;20(1):43–57 (77 ref.)

Lamifiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):215–21; discussion 222–3 (14 ref.)

Sibrafiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):225–30; discussion 231–2 (9 ref.)

Cilostazol. Sorkin EM, et al. **Drugs Aging** 1999 Jan; 14(1):63–71; discussion 72–3 (35 ref.)

Wine and polyphenols related to platelet aggregation and atherothrombosis. Ruf JC. **Drugs Exp Clin Res** 1999; 25(2–3):125–31 (49 ref.)

Antiplatelet agents and the role of clopidogrel in the prevention of secondary atherosclerotic events. Jackson A, et al. **Med Health R I** 1999 Aug;82(8):297–9 (18 ref.)

Piracetam and platelets--a review of laboratory and clinical data. Evers S, et al. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:44–8 (20 ref.)

Antiplatelet agents isolated from medicinal plants. Teng CM, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):211–25 (68 ref.)

Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? Patrono C. **Thromb Res** 1998 Sep 15;92(1 Suppl 1):S7–12 (40 ref.)

Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Schrör K. **Vasc Med** 1998; 3(3):247–51 (49 ref.)

[Antagonists of glycoprotein IIb/IIIa as new antiplatelet agents] Petrusewicz J. **Przegl Lek** 1998;55(2):64–7 (27 ref.) (Eng. Abstr.) **(Pol)**

[Clopidogrel] Castillo J. **Neurologia** 1998 Nov;13(9):431–5 (25 ref.) **(Spa)**

THERAPEUTIC USE

Antithrombotic therapy in acute coronary syndromes. Sabatine MS, et al. **Acta Cardiol** 1999 Feb;54(1):3–29 (196 ref.)

Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Colombo A, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):153–7 (37 ref.)

Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Dangas G, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S16–23 (40 ref.)

IIb/IIIa receptor blockade in acute myocardial infarction. Ferguson JJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):164–70 (24 ref.)

Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. Ferrario M, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):121–5 (45 ref.)

Relation between inhibition of platelet aggregation and clinical outcomes. Harrington RA, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S43–50 (39 ref.)

Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH. **Am Heart J** 1999 Apr;137(4 Pt 2):S9–S13 (23 ref.)

Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Kleiman NS, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S32–42 (84 ref.)

The future of antithrombotic and antiplatelet therapy for ischemic heart disease. Topol EJ. **Am Heart J** 1998 Oct; 136(4 Pt 2 Su):S66–8 (12 ref.)

Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM. **Am J Cardiol** 1998 Oct 22;82(8B):36P–42P (24 ref.)

Effects of aspirin on endothelial dysfunction in atherosclerosis. Quyyumi AA. **Am J Cardiol** 1998 Nov 19; 82(10A):31S–33S (11 ref.)

Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)

Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Chong PH. **Am J Health Syst Pharm** 1998 Nov 15;55(22):2363–86 (117 ref.)

Atherosclerosis: a unifying disorder with diverse manifestations. Gonzalez ER, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19 Suppl 1):S4–7 (18 ref.)

Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease. Harbison JW. **Am J Health Syst Pharm** 1998 Oct 1;55(19 Suppl 1):S17–20 (20 ref.)

Management of peripheral arterial disease. Hilleman DE. **Am J Health Syst Pharm** 1998 Oct 1;55(19 Suppl 1):S21–7 (69 ref.)

Anagrelide, a selective thrombocytopenic agent. Oertel MD. **Am J Health Syst Pharm** 1998 Oct 1;55(19):1979–86 (24 ref.)

Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. Tisdale JE. **Am J Health Syst Pharm** 1998 Oct 1;55(19 Suppl 1):S8–16 (47 ref.)

Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Subbarao VD, et al. **Am J Med Sci** 1999 Aug;318(2):107–14 (37 ref.)

Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB, et al. **Ann Emerg Med** 1998 Dec;32(6):712–22 (40 ref.)

Interaction of ACE inhibitors and aspirin in patients with congestive heart failure. Song KH, et al. **Ann Pharmacother** 1999 Mar;33(3):375–7 (20 ref.)

The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Stringer KA. **Ann Pharmacother** 1999 Jun;33(6):712–22 (53 ref.)

IIb/IIIa inhibitors in acute myocardial infarction. Montalescot G. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S71–5 (41 ref.)

Evidence based cardiology: Prevention of ischaemic stroke. Barnett HJ, et al. **BMJ** 1999 Jun 5;318(7197):1539–43 (45 ref.)

Adjuvant medical therapy in peripheral bypass surgery. Watson HR, et al. **Br J Surg** 1999 Aug;86(8):981–91 (58 ref.)

Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: are we doing enough? Xhignesse M, et al. **Can J Cardiol** 1999 Feb;15(2):185–9 (32 ref.)

Antiplatelet therapy for treatment of acute coronary syndromes. Mazur W, et al. **Cardiol Clin** 1999 May; 17(2):345–57, ix (84 ref.)

Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Patrono C, et al. **Chest** 1998 Nov;114(5 Suppl):470S–488S (183 ref.)

Glycoprotein IIb/IIIa integrin blockade. Madan M, et al. **Circulation** 1998 Dec 8;98(23):2629–35 (41 ref.)

Frontiers in interventional cardiology. Topol EJ, et al. **Circulation** 1998 Oct 27;98(17):1802–20 (198 ref.)

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV37–43 (57 ref.)

Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV30–6 (31 ref.)

Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects [see comments] Mehta JL. **Clin Cardiol** 1998 Dec;21(12):879–84 (61 ref.) Comment in: Clin Cardiol 1999 Jun;22(6):A27.

Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for

drug selection. Zusman RM, et al. **Clin Cardiol** 1999 Sep; 22(9):559–73 (86 ref.)
Clopidogrel: a new antiplatelet agent. Feret B. **Conn Med** 1999 Jun;63(6):331–3 (7 ref.)
Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Bates ER. **Curr Opin Cardiol** 1998 Jul;13(4):274–9 (21 ref.)
Laboratory markers of platelet activation and their clinical significance. Michelson AD, et al. **Curr Opin Hematol** 1999 Sep;6(5):342–8 (60 ref.)
Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis. Johnson CD. **Dig Surg** 1999;16(2):93–101 (85 ref.)
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH, et al. **Drugs** 1998 Dec;56(6):965–76 (29 ref.)
Abciximab. An updated review of its use in ischaemic heart disease [published erratum appears in Drugs 1999 Jan;57(1):91] Foster RH, et al. **Drugs** 1998 Oct;56(4):629–65 (163 ref.)
Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Goa KL, et al. **Drugs** 1999 Mar; 57(3):439–62 (74 ref.)
Tirofiban. A review of its use in acute coronary syndromes. McClellan KJ, et al. **Drugs** 1998 Dec;56(6):1067–80 (29 ref.)
Aspirin and heparin in acute ischaemic stroke in older patients. Gubitz GJ, et al. **Drugs Aging** 1999 Jul;15(1):29–36 (33 ref.)
Treatment options in unstable angina: a clinical update. Fox KA, et al. **Eur Heart J** 1998 Sep;19 Suppl K:K8–10 (4 ref.)
Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB, et al. **Eur J Emerg Med** 1998 Dec;5(4):391–402 (40 ref.)
New antithrombotic and antiplatelet treatment. Neuhaus KL. **Heart** 1999 Sep;82 Suppl 1:I8–111 (22 ref.)
Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. Calverley DC, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1231–49, vi (122 ref.)
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes. Ramanathan A, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:45–56 (56 ref.)
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. Folts JD, et al. **J Am Coll Cardiol** 1999 Feb;33(2):295–303 (87 ref.)
Clopidogrel: secondary prevention of vascular ischaemic events. Misson J, et al. **J Clin Pharm Ther** 1998 Apr; 23(2):91–5 (17 ref.)
The platelet in acute coronary syndromes: defining the pivotal role of platelet glycoprotein IIb/IIIa receptor blockade. Jesse RL. **J Emerg Med** 1999 May-Jun; 17(3):575–80 (24 ref.)
Overview of the use of glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Joseph A. **J Emerg Med** 1999 May-Jun;17(3):567–73 (30 ref.)
Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. Kaplan AL, et al. **J Emerg Med** 1999 May-Jun;17(3):589–95 (24 ref.)
Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. Roe MT, et al. **J Emerg Med** 1999 May-Jun;17(3):581–8 (49 ref.)
Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success [see comments] Chalmers J. **J Hypertens** 1998 Oct;16(10):1403–5 (16 ref.) Comment in: J Hypertens 1998 Oct;16(10):1401–2.
Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. Halpern MJ, et al. **J Int Med Res** 1998 Aug-Sep;26(4):171–80 (53 ref.)
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology. Gibson CM, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):287–302 (63 ref.)
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. Hudson MP, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):241–5 (21 ref.)
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999. McCullough PA, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):233–9 (28 ref.)
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. Roe MT, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):247–57 (49 ref.)
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. Steinhubl SR, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):227–31 (22 ref.)
Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. Vorchheimer DA, et al. **JAMA** 1999 Apr 21;281(15):1407–14 (64 ref.)
Antiplatelet drugs. Baker RI, et al. **Med J Aust** 1999 Apr 19;170(8):379–82 (42 ref.)
Using clopidogrel bisulfate: a new antiplatelet drug [news] Pfister SM. **Nurse Pract** 1999 Sep;24(9):100–1, 105–8, 110 (12 ref.)
Clopidogrel: the future choice for preventing platelet activation during coronary stenting? Gurbel PA, et al. **Pharmacol Res** 1999 Aug;40(2):107–11 (53 ref.)
Platelets, aspirin, and cardiovascular disease. Elwood PC, et al. **Postgrad Med J** 1998 Oct;74(876):587–91 (68 ref.)
Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. Garg RK, et al. **Prog Cardiovasc Dis** 1998 Nov-Dec;41(3):225–36 (76 ref.)
Aspirin: benefit and risk in thromboprophylaxis. Dickinson JP, et al. **QJM** 1998 Aug;91(8):523–38 (125 ref.)
The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures. Dangas G, et al. **Rev Port Cardiol** 1999 Feb;18 Suppl 1:I49–53 (28 ref.)
Antiplatelet drugs in secondary prevention after acute myocardial infarction. Thizon-de-Gaulle I. **Rev Port Cardiol** 1998 Dec;17(12):993–7 (12 ref.)
Antiplatelet therapy for secondary stroke prevention [see comments] Forbes CD. **Scott Med J** 1999 Apr;44(2):54–9 (26 ref.) Comment in: Scott Med J 1999 Apr;44(2):39–40.
Strategies to prevent further cerebral ischaemic episodes. MacWalter RS. **Scott Med J** 1997 Oct;42(5):135 (11 ref.)
Treatment of essential thrombocythemia with anagrelide. Silverstein MN, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 2):23–5 (28 ref.)
Antithrombotic stent coatings: hirudin/iloprost combination. Alt E, et al. **Semin Interv Cardiol** 1998 Sep-Dec; 3(3–4):177–83 (40 ref.)
Safety of the use of IIb/IIIa receptor blockers with or without the use of other anticoagulants. Ferguson JJ, et al. **Semin Interv Cardiol** 1999 Jun;4(2):97–102 (24 ref.)
Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty. Mathew TP, et al. **Semin Interv Cardiol** 1999 Jun;4(2):67–75 (60 ref.)
Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Neumann FJ, et al. **Semin Interv Cardiol** 1998 Jun;3(2):81–90 (96 ref.)
The evolution of oral antiplatelet therapy. Timmis SB, et al. **Semin Interv Cardiol** 1999 Jun;4(2):89–95 (53 ref.)
Results of IIb/IIIa receptor blockade in patients with unstable angina. Vahanian A, et al. **Semin Interv Cardiol** 1999 Jun;4(2):61–6 (36 ref.)
IIb/IIIa Receptor Blockers. Preface. van den Brand M, et al. **Semin Interv Cardiol** 1999 Jun;4(2):59–60 (0 ref.)
The use of platelet glycoprotein IIb/IIIa receptor antagonists during the acute phase of myocardial infarction. van den Brand M, et al. **Semin Interv Cardiol** 1999 Jun;4(2):85–8 (28 ref.)
Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease. van der Wieken LR. **Semin Interv Cardiol** 1999 Jun;4(2):77–83 (25 ref.)
Antiplatelet agents and stroke prevention. Dyken ML. **Semin Neurol** 1998;18(4):441–50 (75 ref.)
Antiplatelet therapy in acute cerebral ischemia. Bednar MM, et al. **Stroke** 1999 Apr;30(4):887–93 (96 ref.)
Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Gorelick PB, et al. **Stroke** 1999 Aug;30(8):1716–21 (47 ref.)
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Creager MA. **Vasc Med** 1998; 3(3):257–60 (8 ref.)
[Management of a suspicion of heparin-induced thrombopenia] Samama CM. **Presse Med** 1998 Jun;27 Suppl 2:18–21 (10 ref.) (Eng. Abstr.) **(Fre)**
[Anti-platelet agents in peripheral vascular surgery] Van Damme H, et al. **Rev Med Liege** 1999 Feb;54(2):109–17 (47 ref.) (Eng. Abstr.) **(Fre)**
[Antiplatelet drugs for prevention of cerebral ischemic accidents] Crassard I, et al. **Rev Neurol (Paris)** 1999 Sep; 155(8):531–41 (52 ref.) (Eng. Abstr.) **(Fre)**
[New antiplatelet agents] Beer JH. **Schweiz Rundsch Med Prax** 1999 May 6;88(19):853–60 (45 ref.) (Eng. Abstr.) **(Ger)**
[Antithrombotic therapy in chronic coronary syndromes--value of thrombocyte aggregation inhibition, anticoagulation and chronic thrombolysis] Leschke M, et al. **Z Kardiol** 1998;87 Suppl 2:145–51 (33 ref.) (Eng. Abstr.) **(Ger)**
[Clinical use of glycoprotein IIb/IIIa inhibitors] Simonetti I, et al. **Ann Ital Med Int** 1998 Jul-Sep;13(3):163–8 (20 ref.) (Eng. Abstr.) **(Ita)**
[Reflections on GPIIb/IIIA inhibitors ... and all around ... (editorial; comment)] Neri Serneri GG. **G Ital Cardiol** 1999 Apr;29(4):467–71 (47 ref.) Comment on: G Ital Cardiol 1999 Mar;29(3):312–4. **(Ita)**
[Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency] Cappelli R, et al. **Minerva Cardioangiol** 1999 Mar;47(3):81–8 (30 ref.) (Eng. Abstr.) **(Ita)**
[Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct (editorial)] Di Pasquale G, et al. **Recenti Prog Med** 1998 Oct;89(10):514–9 (26 ref.) (Eng. Abstr.) **(Ita)**
[Thrombolytic, antiplatelet and anticoagulant therapy for thrombotic disorders] Homma S, et al. **Nippon Rinsho** 1999 Jul;57(7):1561–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy] Isaka N, et al. **Nippon Rinsho** 1998 Oct;56(10):2624–9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention] Kakuta T, et al. **Nippon Rinsho** 1998 Oct;56(10):2630–4 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Antiplatelet therapy in elderly] Matsuda T. **Nippon Ronen Igakkai Zasshi** 1998 Oct;35(10):703–12 (92 ref.) **(Jpn)**
[Inhibitors of platelet receptor GP IIb-IIIa--new possibilities of treatment for atherosclerosis complications] Gosk-Bierska I, et al. **Pol Arch Med Wewn** 1998 Jun; 99(6):497–506 (50 ref.) **(Pol)**
[Ticlid: clinical effectiveness and significance in combined conservative treatment of chronic obliterating diseases of lower limb arteries] Koskin VM, et al. **Ter Arkh** 1998; 70(9):89–91 (22 ref.) **(Rus)**
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke] Warlow C. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(2):47–50 (0 ref.) **(Rus)**
[Platelet activation and inhibition. Old and new platelet antiaggregants] López Bescós L, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:67–75 (49 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney. Levin S, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):38–43 (0 ref.)

PLATELET ALLOANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET ALPHA-GRANULE MEMBRANE PROTEIN see **P-SELECTIN**

PLATELET ANTAGONISTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET ANTIAGGREGANTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET COUNT

Reticulated platelet counts in the assessment of thrombocytopenic disorders. Saxon BR, et al. **Acta Paediatr Suppl** 1998 Jun;424:65–70 (39 ref.)
Thrombopoietin: its role from early hematopoiesis to platelet production. Wendling F. **Haematologica** 1999 Feb; 84(2):158–66 (138 ref.)
[Preeclampsia not (yet) predictable from the blood platelet count] Lazarov R, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):10–3 (22 ref.) (Eng. Abstr.) **(Dut)**

PLATELET-DERIVED GROWTH FACTOR

see related
RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

DRUG EFFECTS

Anti-atherosclerotic action of vascular D1 receptors. Yasunari K, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S36–40 (54 ref.)

PHARMACOLOGY

Mitogenic effect of PDGF-AA on cardiac fibroblasts. Simm A, et al. **Basic Res Cardiol** 1998;93 Suppl 3:40–3 (27 ref.)
Control of apoptosis of cardiovascular fibroblasts: a novel drug target. Rupp H, et al. **Herz** 1999 May;24(3):225–31 (43 ref.)

PHYSIOLOGY

Physiology and clinical applications of platelet growth factors. Harker LA. **Curr Opin Hematol** 1999 May; 6(3):127–34 (66 ref.)
Role of platelet-derived growth factors in angiogenesis and alveogenesis. Lindahl P, et al. **Curr Top Pathol** 1999; 93:27–33 (34 ref.)
Regulation of platelet-derived growth factor signaling by activated p21Ras. Stice LL, et al. **Front Biosci** 1999 Jan 15;4:D72–86 (113 ref.)

THERAPEUTIC USE

Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. LeGrand EK. **Am J Surg** 1998 Aug;176(2A Suppl):48S–54S (48 ref.)

TOXICITY

A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB). Knight EV, et al. **Am J Surg** 1998 Aug; 176(2A Suppl):55S–60S (7 ref.)

PLATELET-DERIVED GROWTH FACTOR RECEPTORS see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

PLATELET ENDOTHELIAL CELL ADHESION MOLECULE-1 see **ANTIGENS, CD31**

PLATELET FUNCTION TESTS

INSTRUMENTATION

Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Rand ML, et al. **Semin Thromb Hemost** 1998;24(6):523-9 (38 ref.)

METHODS

Progress in point-of-care laboratory testing for assessing platelet function. Berkowitz SD, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S51-65 (40 ref.)

Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Rand ML, et al. **Semin Thromb Hemost** 1998;24(6):523-9 (38 ref.)

PLATELET GLYCOPROTEIN GPIB-IX COMPLEX

GENETICS

Platelet glycoprotein polymorphism and risk for coronary heart disease. Wu KK, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S63-5 (14 ref.)

Genetic polymorphisms and risk of coronary artery disease. Murata M, et al. **Semin Thromb Hemost** 1998;24(3):245-50 (45 ref.)

METABOLISM

Adhesion-dependent signalling and the initiation of haemostasis and thrombosis. Andrews RK, et al. **Histol Histopathol** 1998 Jul;13(3):837-44 (70 ref.)

Thrombin interaction with platelet GpIb: structural mapping and effects on platelet activation (review). De Cristofaro R, et al. **Int J Mol Med** 1999 Apr;3(4):363-71 (78 ref.)

PHYSIOLOGY

[Coronary thrombosis and cell adhesion molecules] Ikeda H, et al. **Nippon Rinsho** 1999 Jul;57(7):1502-7 (21 ref.) (Eng. Abstr.) **(Jpn)**

PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX

see related
THROMBASTHENIA

Overview of the use of glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Joseph A. **J Emerg Med** 1999 May-Jun;17(3):567-73 (30 ref.)

Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. Kaplan AL, et al. **J Emerg Med** 1999 May-Jun;17(3):589-95 (24 ref.)

Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. Roe MT, et al. **J Emerg Med** 1999 May-Jun;17(3):581-8 (49 ref.)

ANTAGONISTS & INHIBITORS

Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Colombo A, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):153-7 (37 ref.)

Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Dangas G, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S16-23 (40 ref.)

IIb/IIIa receptor blockade in acute myocardial infarction. Ferguson JJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):164-70 (24 ref.)

Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. Ferrario M, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):121-5 (45 ref.)

Economic issues in glycoprotein IIb/IIIa receptor therapy. Hillegass WB, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S24-32 (28 ref.)

Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Kereiakes DJ. **Am Heart J** 1999 Jul;138(1 Pt 2):S39-46 (25 ref.)

Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Kleiman NS, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S32-42 (84 ref.)

Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM. **Am J Cardiol** 1998 Oct 22;82(8B):36P-42P (24 ref.)

Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Chong PH. **Am J Health Syst Pharm** 1998 Nov 15;55(22):2363-86 (117 ref.)

Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Subbarao VD, et al. **Am J Med Sci** 1999 Aug;318(2):107-14 (37 ref.)

Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB, et al. **Ann Emerg Med** 1998 Dec;32(6):712-22 (40 ref.)

Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Gibson CM. **Ann Intern Med** 1999 May 18;130(10):841-7 (33 ref.)

The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Stringer KA. **Ann Pharmacother** 1999 Jun;33(6):712-22 (53 ref.)

Monitoring platelet GPIIb/IIIa antagonist therapy. Coller BS. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S81-6 (40 ref.)

IIb/IIIa inhibitors in acute myocardial infarction. Montalescot G. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S71-5 (41 ref.)

Glycoprotein IIb/IIIa integrin blockade. Madan M, et al. **Circulation** 1998 Dec 8;98(23):2629-35 (41 ref.)

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Scarborough RM, et al. **Circulation** 1999 Jul 27; 100(4):437-44 (72 ref.)

Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV30-6 (31 ref.)

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV37-43 (57 ref.)

Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists. Kleiman NS. **Coron Artery Dis** 1998;9(9):603-16 (104 ref.)

Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Bates ER. **Curr Opin Cardiol** 1998 Jul;13(4):274-9 (21 ref.)

Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Madan M, et al. **Curr Opin Hematol** 1999 Sep;6(5):334-41 (25 ref.)

Laboratory markers of platelet activation and their clinical significance. Michelson AD, et al. **Curr Opin Hematol** 1999 Sep;6(5):342-8 (60 ref.)

Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH, et al. **Drugs** 1998 Dec;56(6):965-76 (29 ref.)

Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Ronner E, et al. **Eur Heart J** 1998 Nov; 19(11):1608-16 (86 ref.)

Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB, et al. **Eur J Emerg Med** 1998 Dec;5(4):391-402 (40 ref.)

Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes. Ramanathan A, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:45-56 (56 ref.)

GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction. Salame M, et al. **Int J Cardiol** 1999 Jun 1;69(3):231-6 (22 ref.)

Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology. Gibson CM, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):287-302 (63 ref.)

Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. Hudson MP, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):241-5 (21 ref.)

Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. Roe MT, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):247-57 (49 ref.)

Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. Vorchheimer DA, et al. **JAMA** 1999 Apr 21;281(15):1407-14 (64 ref.)

Platelet GPIIb-IIIa blockers [see comments] Topol EJ, et al. **Lancet** 1999 Jan 16;353(9148):227-31 (48 ref.) Comment in: Lancet 1999 Apr 3;353(9159):1185.

Discovery and pharmacological evaluation of new platelet glycoprotein gpIIb/IIIa antagonists. Merlos M, et al. **Methods Find Exp Clin Pharmacol** 1998 Dec;20(10):869-80 (79 ref.)

The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures. Dangas G, et al. **Rev Port Cardiol** 1999 Feb;18 Suppl 1:I49-53 (28 ref.)

Safety of the use of IIb/IIIa receptor blockers with or without the use of other anticoagulants. Ferguson JJ, et al. **Semin Interv Cardiol** 1999 Jun;4(2):97-102 (24 ref.)

Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents. Gershlick AH. **Semin Interv Cardiol** 1998 Sep-Dec;3(3-4):185-90 (26 ref.)

Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty. Mathew TP, et al. **Semin Interv Cardiol** 1999 Jun;4(2):67-75 (60 ref.)

Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Neumann FJ, et al. **Semin Interv Cardiol** 1998 Jun;3(2):81-90 (96 ref.)

Results of IIb/IIIa receptor blockade in patients with unstable angina. Vahanian A, et al. **Semin Interv Cardiol** 1999 Jun;4(2):61-6 (36 ref.)

IIb/IIIa Receptor Blockers. Preface. van den Brand M, et al. **Semin Interv Cardiol** 1999 Jun;4(2):59-60 (0 ref.)

The use of platelet glycoprotein IIb/IIIa receptor antagonists during the acute phase of myocardial infarction. van den Brand M, et al. **Semin Interv Cardiol** 1999 Jun;4(2):85-8 (28 ref.)

Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease. van der Wieken LR. **Semin Interv Cardiol** 1999 Jun;4(2):77-83 (25 ref.)

Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney. Levin S, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):38-43 (0 ref.)

[Clinical use of glycoprotein IIb/IIIa inhibitors] Simonetti I, et al. **Ann Ital Med Int** 1998 Jul-Sep;13(3):163-8 (20 ref.) (Eng. Abstr.) **(Ita)**

[Reflections on GPIIb/IIIA inhibitors ... and all around ... (editorial; comment)] Neri Serneri GG. **G Ital Cardiol** 1999 Apr;29(4):467-71 (47 ref.) Comment on: G Ital Cardiol 1999 Mar;29(3):312-4. **(Ita)**

[Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention] Kakuta T, et al. **Nippon Rinsho** 1998 Oct;56(10):2630-4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Glycoprotein (GP) IIb/IIIa platelet inhibitors in acute ischemic syndrome and percutaneous coronary intervention] Caramori PR, et al. **Arq Bras Cardiol** 1998 Nov;71(5):725-34 (114 ref.) **(Por)**

GENETICS

Platelet glycoprotein polymorphism and risk for coronary heart disease. Wu KK, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S63-5 (14 ref.)

IMMUNOLOGY

T cell immunobiology of alloimmune thrombocytopenias. Gorski J, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):269-75 (33 ref.)

METABOLISM

Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Kleiman NS, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S32-42 (84 ref.)

PHYSIOLOGY

Different activation states of GP IIb/IIIa complexes in platelets. Nurden AT, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S67-70 (30 ref.)

The platelet in acute coronary syndromes: defining the pivotal role of platelet glycoprotein IIb/IIIa receptor blockade. Jesse RL. **J Emerg Med** 1999 May-Jun; 17(3):575-80 (24 ref.)

[Coronary thrombosis and cell adhesion molecules] Ikeda H, et al. **Nippon Rinsho** 1999 Jul;57(7):1502-7 (21 ref.) (Eng. Abstr.) **(Jpn)**

PLATELET GLYCOPROTEIN IV see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN IB see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIB see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIA see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIB see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN V see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IX see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEINS

Platelet proteins as autoantibody targets in idiopathic thrombocytopenic purpura. Wadenvik H, et al. **Acta Paediatr Suppl** 1998 Jun;424:26-36 (113 ref.)

ANALYSIS

Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Joseph JE, et al. **Lupus** 1998;7 Suppl 2:S48-51 (35 ref.)

ANTAGONISTS & INHIBITORS

[Inhibitors of platelet receptor GP IIb-IIIa--new possibilities of treatment for atherosclerosis complications] Gosk-Bierska I, et al. **Pol Arch Med Wewn** 1998 Jun; 99(6):497-506 (50 ref.) **(Pol)**

CLASSIFICATION

[Platelet alloantigenic systems] Hallé L. **Transfus Clin Biol** 1998 Oct;5(5):362-5 (6 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[Variant type von Willebrand disease with defective binding to factor VIII] Shima M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):430-3 (7 ref.) **(Jpn)**

IMMUNOLOGY

Human platelet-specific alloantigens: update. Santoso S, et al. **Vox Sang** 1998;74 Suppl 2:249-53 (40 ref.)

PHYSIOLOGY

Role of the beta3 integrin subunit in human primary

melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression [comment] Seftor RE. **Am J Pathol** 1998 Nov;153(5):1347–51 (78 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1435–42.

PLATELET NUMBER see **PLATELET COUNT**

PLATELET-SPECIFIC ANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET STORAGE POOL DEFICIENCY

[Alpha-storage pool disease (Gray platelet syndrome)] Isshiki I, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):350–1 (9 ref.) **(Jpn)**

[Delta-storage pool disease] Isshiki I, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):352–3 (3 ref.) **(Jpn)**

PLATELET TRANSFORMING GROWTH FACTOR see **TRANSFORMING GROWTH FACTOR BETA**

PLATELET TRANSFUSION

Trigger factors for prophylactic platelet transfusion. Ancliff PJ, et al. **Blood Rev** 1998 Dec;12(4):234–8 (23 ref.)

Consensus conference on platelet transfusion. Final statement. Contreras M. **Blood Rev** 1998 Dec;12(4):239–40 (0 ref.)

Indications for therapeutic platelet transfusions. Hunt BJ. **Blood Rev** 1998 Dec;12(4):227–33 (65 ref.)

Hematopoietic supportive care. Hester J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2666–70 (27 ref.)

Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions. Sandler SG. **Haematologia (Budap)** 1998;29(1):1–11 (46 ref.)

Risks, costs, and alternatives to platelet transfusions. Webb IJ, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):71–84 (69 ref.)

The efficacy of synthetic media in the storage of human platelets for transfusion. Murphy S. **Transfus Med Rev** 1999 Jul;13(3):153–63 (51 ref.)

Platelet growth factors: potential impact on transfusion medicine. Kuter DJ, et al. **Transfusion** 1999 Mar; 39(3):321–32 (60 ref.)

Use of HLA- and HPA—matched platelets in alloimmunized patients. Kekomäki R. **Vox Sang** 1998;74 Suppl 2:359–63 (47 ref.)

[Treatment of thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999;77(7):56–9 (0 ref.) **(Rus)**

[Alternatives to platelet transfusion] Mazzara R, et al. **Sangre (Barc)** 1998 Aug;43(4):331–8 (64 ref.) **(Spa)**

ADVERSE EFFECTS

Diagnosis and treatment of patients refractory to platelet transfusions. Contreras M. **Blood Rev** 1998 Dec; 12(4):215–21 (69 ref.)

How should the safety and efficacy of platelet transfusions be assured? Williamson LM. **Blood Rev** 1998 Dec; 12(4):203–14 (104 ref.)

Clinical aspects and typing of platelet alloantigens. Kroll H, et al. **Vox Sang** 1998;74 Suppl 2:345–54 (120 ref.)

Prevention and management of platelet transfusion refractoriness. Novotny VM. **Vox Sang** 1999;76(1):1–13 (109 ref.)

[Refractoriness to platelet transfusion] Tsurumi H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):332–4 (8 ref.) **(Jpn)**

INSTRUMENTATION

Platelet activation and its detection during the preparation of platelets for transfusion. Rinder HM, et al. **Transfus Med Rev** 1998 Oct;12(4):271–87 (77 ref.)

METHODS

In vitro and in vivo properties of various types of platelets. Rebulla P. **Vox Sang** 1998;74 Suppl 2:217–22 (45 ref.)

[The potentials of current transfusion hematology for component therapy with thrombocytes, granulocytes, plasma and plasma factors in obstetrics and gynecology] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(4):50–2 (25 ref.) **(Bul)**

STANDARDS

The ideal platelet prescription. Murphy WG. **Blood Rev** 1998 Dec;12(4):222–6 (44 ref.)

How should the safety and efficacy of platelet transfusions be assured? Williamson LM. **Blood Rev** 1998 Dec; 12(4):203–14 (104 ref.)

Consensus conference on platelet transfusion: final statement. Contreras M. **Vox Sang** 1998;75(2):173–4 (0 ref.)

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates. Corash L. **Vox Sang** 1998;74 Suppl 2:173–6 (45 ref.)

Storage and quality assessment of platelets. Holme S. **Vox Sang** 1998;74 Suppl 2:207–16 (0 ref.)

Quality assurance and standards for red cells and platelets. Sweeney J. **Vox Sang** 1998;74 Suppl 2:201–5 (5 ref.)

UTILIZATION

The rational use of platelet transfusions in children. Cahill MR, et al. **Semin Thromb Hemost** 1998;24(6):567–75 (95 ref.)

Thrombopoietins and thrombopoiesis: a clinical perspective. Kuter DJ. **Vox Sang** 1998;74 Suppl 2:75–85 (43 ref.)

PLATELETPHERESIS

STANDARDS

[Leukodepletion of labile blood products] Vignon D. **Ann Pharm Fr** 1999 Jan;57(1):61–7 (31 ref.) (Eng. Abstr.) **(Fre)**

PLATELETS see **BLOOD PLATELETS**

PLATINUM

see related
ORGANOPLATINUM COMPOUNDS

PLATINUM COMPOUNDS

ADVERSE EFFECTS

Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Hausheer FH, et al. **Semin Oncol** 1998 Oct;25(5):584–99 (56 ref.)

THERAPEUTIC USE

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Lebwohl D, et al. **Eur J Cancer** 1998 Sep;34(10):1522–34 (132 ref.)

Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? Ruckdeschel JC, et al. **Eur J Cancer** 1998 Dec;34(13):1993–9 (74 ref.)

PLATINUM COMPOUNDS, INORGANIC see **PLATINUM COMPOUNDS**

PLATINUM DIAMMINODICHLORIDE see **CISPLATIN**

PLATYBASIA

see related
ARNOLD-CHIARI DEFORMITY

SURGERY

Transmaxillary anterior decompressions in patients with severe basilar impression. Bhangoo RS, et al. **Clin Orthop** 1999 Feb;(359):115–25 (69 ref.)

PLATYPUS

Field biology of the platypus (Ornithorhynchus anatinus): historical and current perspectives. Grant TR, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1081–91 (88 ref.)

Platypus research 1798–1998. Griffiths M. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1059–61 (19 ref.)

Disease conditions and subclinical infections of the platypus (Ornithorhynchus anatinus). Munday BL, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1093–9 (24 ref.)

EMBRYOLOGY

Early development and embryology of the platypus. Hughes RL, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1101–14 (19 ref.)

GROWTH & DEVELOPMENT

The development of the external features of the platypus (Ornithorhynchus anatinus). Manger PR, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1115–25 (24 ref.)

PHYSIOLOGY

Electroreception in monotremes. Pettigrew JD. **J Exp Biol** 1999 May;202 (Pt 10):1447–54 (30 ref.)

Some related aspects of platypus electroreception: temporal integration behaviour, electroreceptive thresholds and directionality of the bill acting as an antenna. Fjällbrant TT, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1211–9 (19 ref.)

The sensory world of the platypus. Pettigrew JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1199–210 (38 ref.)

PLATYRRHINA see **CEBIDAE**

PLAY AND PLAYTHINGS

Laser pointers: toys, nuisances, or significant eye hazards? Yolton RL, et al. **J Am Optom Assoc** 1999 May;70(5):285–9 (15 ref.)

Play, creativity, and adaptive functioning: implications for play interventions. Russ SW. **J Clin Child Psychol** 1998 Dec;27(4):469–80 (98 ref.)

Using puppetry in a coordinated school health program. Synovitz LB. **J Sch Health** 1999 Apr;69(4):145–7 (46 ref.)

PSYCHOLOGY

Diagnostic play interview. Its role in comprehensive psychiatric evaluation. Close N. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):239–55 (13 ref.)

Play fighting of rats in comparative perspective: a schema for neurobehavioral analyses. Pellis SM, et al. **Neurosci Biobehav Rev** 1998;23(1):87–101 (114 ref.)

PLEASURE-PAIN PRINCIPLE

[Anhedonia—a general nosology surmounting correlate of a dysfunctional dopaminergic reward system?] Heinz A. **Nervenarzt** 1999 May;70(5):391–8 (94 ref.) (Eng. Abstr.) **(Ger)**

PLEOCYTOSIS see **LEUKOCYTOSIS**

PLETHYSMOGRAPHY, IMPEDANCE

Bioimpedance and the estimation of net fluid balance in critical care patients: problems and possibilities [editorial; comment] Zarowitz BJ, et al. **Crit Care Med** 1999 Aug; 27(8):1655–7 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1472–7.

PLETHYSMOGRAPHY, IMPEDANCE, TRANSTHORACIC see **CARDIOGRAPHY, IMPEDANCE**

PLETHYSMOGRAPHY, WHOLE BODY

STANDARDS

On the barometric method for measurements of ventilation, and its use in small animals [comment] Mortola JP, et al. **Can J Physiol Pharmacol** 1998 Oct-Nov;76(10–11):937–44 (30 ref.) Comment on: Can J Physiol Pharmacol 1998 Oct-Nov;76(10–11):945–51.

PLEURA

ANATOMY & HISTOLOGY

[Advances in the study on the mechanism of pleural effusion] Miu L, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Dec; 20(6):364–6 (16 ref.) **(Chi)**

ENZYMOLOGY

[Matrix metalloproteases and their inhibitors in the pleura] Eickelberg O, et al. **Pneumologie** 1998 Sep;52(9):526–30 (33 ref.) **(Ger)**

SURGERY

Techniques of pneumonectomy. Pleural pneumonectomy. Sugarbaker DJ, et al. **Chest Surg Clin N Am** 1999 May; 9(2):379–92, xi (53 ref.)

[The use of the pleural tent in superior lobectomies] Solli P, et al. **Acta Biomed Ateneo Parmense** 1996;67(5–6):173–6 (8 ref.) (Eng. Abstr.) **(Ita)**

PLEURAL CAVITY see **PLEURA**

PLEURAL DISEASES

Pleural space infections: microbiology and antimicrobial therapy. Everts RJ, et al. **Semin Respir Infect** 1999 Mar; 14(1):18–30 (67 ref.)

CHEMICALLY INDUCED

Drugs and the pleura. Morelock SY, et al. **Chest** 1999 Jul; 116(1):212–21 (117 ref.)

DIAGNOSIS

Pleuropulmonary blastoma in an adult: an initial case report. Hill DA, et al. **Cancer** 1999 Jun 1;85(11):2368–74 (33 ref.)

Imaging techniques for pleural space infections. Levin DL, et al. **Semin Respir Infect** 1999 Mar;14(1):31–8 (23 ref.)

[Pleural plaque fibrosis: a clinical case] Iovino F, et al. **Ann Ital Chir** 1999 Mar-Apr;70(2):273–6 (16 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Pleural complications in the intensive care unit. Strange C. **Clin Chest Med** 1999 Jun;20(2):317–27 (84 ref.)

ETIOLOGY

Early complications. Esophagopleural fistula. Massard G, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):617–31, ix (44 ref.)

Respiratory complications in mixed connective tissue disease. Prakash UB. **Clin Chest Med** 1998 Dec;19(4):733–46, ix (75 ref.)

Traumatic thoracobiliary fistula: report of a case successfully managed conservatively, with an overview of current diagnostic and therapeutic options. Sheik-Gafoor MH, et

al. **J Trauma** 1998 Oct;45(4):819–21 (16 ref.)
A thoracic complication of hereditary multiple exostoses in an adult. Nick JA, et al. **Respir Med** 1999 Mar;93(3):217–9 (22 ref.)
[Non-malignant asbestos-related diseases] Ameille J, et al. **Rev Mal Respir** 1998 Sep;15(4):479–87 (99 ref.) (Eng. Abstr.) **(Fre)**
[A colopleural fistula as the clinical presentation of colonic adenocarcinoma (letter)] Domingo-Morera JA, et al. **Arch Bronconeumol** 1999 Jan;35(1):52–3 (6 ref.) **(Spa)**

IMMUNOLOGY

Pulmonary manifestations of systemic lupus erythematosus. Murin S, et al. **Clin Chest Med** 1998 Dec;19(4):641–65, viii (209 ref.)
Radiologic manifestations of the systemic autoimmune diseases. Primack SL, et al. **Clin Chest Med** 1998 Dec; 19(4):573–86, vii (68 ref.)
Pulmonary manifestations of rheumatoid arthritis. Tanoue LT. **Clin Chest Med** 1998 Dec;19(4):667–85, viii (150 ref.)

MICROBIOLOGY

[Pleuropulmonary manifestations of salmonellosis] Hovette P, et al. **Med Trop (Mars)** 1998;58(4):403–7 (67 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Video-assisted thoracoscopy for pleural disease. Ronson RS, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):919–32, x (49 ref.)

THERAPY

Recent advances in the management of pleural sepsis: what is the evidence? Lim TK. **Respirology** 1999 Sep;4(3):207–12 (44 ref.)

PLEURAL EFFUSION

CLASSIFICATION

The definitions and epidemiology of pleural space infection. Strange C, et al. **Semin Respir Infect** 1999 Mar;14(1):3–8 (31 ref.)

COMPLICATIONS

Hepatic hydrothorax: pathogenesis, diagnosis, and management. Lazaridis KN, et al. **Am J Med** 1999 Sep; 107(3):262–7 (39 ref.)

DIAGNOSIS

Useful tests on the pleural fluid in the management of patients with pleural effusions [editorial] Light RW. **Curr Opin Pulm Med** 1999 Jul;5(4):245–9 (33 ref.)
Diagnosis of tuberculous pleural effusion. Aggarwal AN, et al. **Indian J Chest Dis Allied Sci** 1999 Apr–Jun;41(2):89–100 (83 ref.)
Pseudochylothorax. Report of 2 cases and review of the literature. Garcia-Zamalloa A, et al. **Medicine (Baltimore)** 1999 May;78(3):200–7 (34 ref.)
Evaluating pleural effusions. How should you go about finding the cause? Rubins JB, et al. **Postgrad Med** 1999 May 1;105(5):39–42, 45–8 (23 ref.)
Indications for draining a parapneumonic effusion: an evidence-based approach. Heffner JE. **Semin Respir Infect** 1999 Mar;14(1):48–58 (57 ref.)
[Pleural effusion in cancer patients:pathophysiology, diagnosis and treatment] Wcisło G, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):33–6 (44 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Streptokinase and urokinase for the treatment of pleural effusions and empyemas. Barletta JF. **Ann Pharmacother** 1999 Apr;33(4):495–8 (24 ref.)
Fibrinolytics in the treatment of parapneumonic effusions. Bouros D, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):258–63 (42 ref.)
Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Sahn SA. **Thorax** 1998 Aug;53 Suppl 2:S65–72 (65 ref.)
[Current value of intrapleural fibrinolysis in the treatment of exudative fibrinous pleural effusions in pleural empyema and hemothorax] Kemper P, et al. **Pneumologie** 1999 Aug; 53(8):373–84 (96 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Isolated pleural effusion in severe ovarian hyperstimulation: A case report. Gregory WT, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1468–71 (17 ref.)
Diagnosis of tuberculous pleural effusion. Aggarwal AN, et al. **Indian J Chest Dis Allied Sci** 1999 Apr–Jun;41(2):89–100 (83 ref.)
Pseudochylothorax. Report of 2 cases and review of the literature. Garcia-Zamalloa A, et al. **Medicine (Baltimore)** 1999 May;78(3):200–7 (34 ref.)
Evaluating pleural effusions. How should you go about finding the cause? Rubins JB, et al. **Postgrad Med** 1999 May 1;105(5):39–42, 45–8 (23 ref.)
The definitions and epidemiology of pleural space infection. Strange C, et al. **Semin Respir Infect** 1999 Mar;14(1):3–8 (31 ref.)
Always remember chylothorax. Pérez J, et al. **South Med J** 1999 Aug;92(8):833–5 (31 ref.)
[Advances in the study on the mechanism of pleural effusion] Miu L, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Dec; 20(6):364–6 (16 ref.) **(Chi)**
[Primary pulmonary cryptococcosis with pleural effusion] Matsunaga K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug;36(8):708–12 (16 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Diagnostic problems in serous effusions. Bedrossian CW. **Diagn Cytopathol** 1998 Aug;19(2):131–7 (16 ref.)
[Parapneumonic pleural effusion, pleural empyema: medical and surgical aspects] Gugger M, et al. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):556–62 (26 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Pathophysiology of pleural space infections. Antony VB, et al. **Semin Respir Infect** 1999 Mar;14(1):9–17 (34 ref.)

SURGERY

Practical management of pleural effusions. When and how should fluid accumulations be drained? Colice GL, et al. **Postgrad Med** 1999 Jun;105(7):67–70, 73–7 (27 ref.)
[Parapneumonic pleural effusion, pleural empyema: medical and surgical aspects] Gugger M, et al. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):556–62 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Utility of fibrinolytic agents for draining intrapleural infections. Bouros D, et al. **Semin Respir Infect** 1999 Mar; 14(1):39–47 (39 ref.)
Indications for draining a parapneumonic effusion: an evidence-based approach. Heffner JE. **Semin Respir Infect** 1999 Mar;14(1):48–58 (57 ref.)
[Pleuro-peritoneal Denver shunt in treatment of chronic pleurisy] Boudard C, et al. **Ann Chir** 1998;52(2):192–6 (15 ref.) (Eng. Abstr.) **(Fre)**
[Pleural effusion in cancer patients:pathophysiology, diagnosis and treatment] Wcisło G, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):33–6 (44 ref.) (Eng. Abstr.) **(Pol)**

PLEURAL EFFUSION, MALIGNANT

The past, the present and future of the OK-432 therapy for patients with malignant effusions. Katano M, et al. **Anticancer Res** 1998 Sep-Oct;18(5D):3917–25 (35 ref.)

ETIOLOGY

[Surgical treatment of pulmonary metastases from digestive organs and management of malignant pleural effusions] Ogawa J. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):216–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Treatment of malignant pleural effusions. Erasmus JJ, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):250–5 (55 ref.)
[Pleuro-peritoneal Denver shunt in treatment of chronic pleurisy] Boudard C, et al. **Ann Chir** 1998;52(2):192–6 (15 ref.) (Eng. Abstr.) **(Fre)**

PLEURAL ENDOSCOPY see **THORACOSCOPY**

PLEURAL NEOPLASMS

Primary angiosarcomas of the chest wall and pleura. Alexiou C, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):523–6 (13 ref.)
Localized fibrous tumours of the pleura: 15 new cases and review of the literature. Suter M, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):453–9 (33 ref.)
Malignant mesothelioma of the pleural space. Grondin SC, et al. **Oncology (Huntingt)** 1999 Jul;13(7):919–26; discussion 926, 931–2 (45 ref.)
[Report of 2 cases of pleural recurrences of surgically treated bronchogenic carcinoids. Diagnostic and therapeutic problems] Bonnette P, et al. **Rev Mal Respir** 1999 Feb; 16(1):85–8 (14 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. Murthy SS, et al. **J Cell Physiol** 1999 Aug;180(2):150–7 (66 ref.)

DIAGNOSIS

In search of a positive immunohistochemical marker for mesothelioma: an update. Ordóñez NG. **Adv Anat Pathol** 1998 Jan;5(1):53–60 (56 ref.)
Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Ordóñez NG. **Am J Clin Pathol** 1999 Jul;112(1):75–89 (144 ref.)
Pleural mesothelioma. Astoul P. **Curr Opin Pulm Med** 1999 Jul;5(4):259–68 (81 ref.)
Malignant pleural mesothelioma [see comments] Boutin C, et al. **Eur Respir J** 1998 Oct;12(4):972–81 (113 ref.) Comment in: Eur Respir J 1999 Mar;13(3):706.
[Pleural mesothelioma. A case report] Della Vittoria Scarpati M, et al. **Recenti Prog Med** 1999 Jun;90(6):327–30 (18 ref.) (Eng. Abstr.) **(Ita)**
[Modern approach to malignant pleural mesothelioma. 1) Pretherapeutic evaluation] Dagović A, et al. **Srp Arh Celok Lek** 1998 Jul–Aug;126(7–8):290–4 (19 ref.) (Eng. Abstr.) **(Scc)**

EPIDEMIOLOGY

New molecular and epidemiological issues in mesothelioma: role of SV40. Carbone M, et al. **J Cell Physiol** 1999 Aug; 180(2):167–72 (34 ref.)

ETIOLOGY

Mechanism for the development of pyothorax-associated lymphoma. Kanno H, et al. **Pathol Int** 1998 Sep; 48(9):653–64 (87 ref.)
Malignant pleural mesothelioma: a problematic review. Moskal TL, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):5–12 (62 ref.)
[Asbestos exposure and pleuropulmonary cancer] Begin R. **Rev Mal Respir** 1998 Dec;15(6):723–30 (41 ref.) (Eng. Abstr.) **(Fre)**
[Chemical and physical characteristics and toxicology of man-made mineral fibers] Foà V, et al. **Med Lav** 1999 Jan–Feb;90(1):10–52 (100 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. Rizzo P, et al. **Dev Biol Stand** 1998;94:33–40 (19 ref.)

PATHOLOGY

[Pleural mesotheliomas. Current knowledge] Evrard C, et al. **Ann Chir** 1999;53(4):314–23 (45 ref.) (Eng. Abstr.) **(Fre)**
[Visceral pleura lipoma: a previously undescribed localization and review of the literature on pleural lipomas] Naccarato AG, et al. **Pathologica** 1998 Jun;90(3):298–301 (18 ref.) (Eng. Abstr.) **(Ita)**
[Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation] Okamoto T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug;36(8):696–701 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Morphological aspects of verification of pleural neoplasms in one's life time] Fominykh IV, et al. **Arkh Patol** 1998 Jul–Aug;60(4):71–4 (37 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Pedunculated solitary fibrous tumor of the interlobar fissure: a wandering chest mass. Karabulut N, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):476–7 (8 ref.)
[Malignant pleural mesothelioma with an unusual radiologic manifestation] Jover-Sáenz A, et al. **An Med Interna** 1999 Jul;16(7):354–6 (22 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Indications for pneumonectomy. Extrapleural pneumonectomy. Rusch VW. **Chest Surg Clin N Am** 1999 May;9(2):327–38, x (42 ref.)
Thoracoscopy and video-assisted thoracic surgery. Yim AP. **Curr Opin Pulm Med** 1999 Jul;5(4):256–8 (24 ref.)
[Treatment strategy in pleural mesothelioma] Schirren J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:498–506 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Advances in the treatment of malignant pleural mesothelioma. Sterman DH, et al. **Chest** 1999 Aug; 116(2):504–20 (146 ref.)
Pleural mesothelioma. Astoul P. **Curr Opin Pulm Med** 1999 Jul;5(4):259–68 (81 ref.)
Malignant pleural mesothelioma [see comments] Boutin C, et al. **Eur Respir J** 1998 Oct;12(4):972–81 (113 ref.) Comment in: Eur Respir J 1999 Mar;13(3):706.
[Therapy of malignant pleural mesothelioma--a permanent dilemma] von Bültzingslöwen F, et al. **Pneumologie** 1999 May;53(5):266–75 (103 ref.) (Eng. Abstr.) **(Ger)**
[Gene therapy in cancers of the lung and pleura] Wiewrodt R, et al. **Pneumologie** 1999 Mar;53(3):176–84 (64 ref.) **(Ger)**
[Malignant pleural mesothelioma. II. Modern therapeutic concepts] Dagović A, et al. **Srp Arh Celok Lek** 1998 Nov-Dec;126(11–12):472–7 (31 ref.) (Eng. Abstr.) **(Scc)**

VIROLOGY

Detection of SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases. Galateau-Salle F, et al. **Dev Biol Stand** 1998;94:147–52 (28 ref.)
Further validation of SV40-like DNA in human pleural mesotheliomas. Pass H, et al. **Dev Biol Stand** 1998;94:143–5 (6 ref.)
SV40 expression in human neoplastic and non-neoplastic

tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Procopio A, et al. **Dev Biol Stand** 1998;94:361–7 (16 ref.)

PLEURAL RUB see **RESPIRATORY SOUNDS**

PLEURISY

DIAGNOSIS

[Purulent pleurisy and empyema. With the exception of pleural tuberculosis] Jébrak G, et al. **Presse Med** 1998 Nov 28;27(37):1924–31 (73 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[Bacterial pleurisy] Matsushima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):428–30 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Pathophysiology of pleural space infections. Antony VB, et al. **Semin Respir Infect** 1999 Mar;14(1):9–17 (34 ref.)

THERAPY

[Pleuro-peritoneal Denver shunt in treatment of chronic pleurisy] Boudard C, et al. **Ann Chir** 1998;52(2):192–6 (15 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

[Viral pleuritis] Shimokata K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):77–9 (15 ref.) **(Jpn)**

PLEURISY, TUBERCULOUS see **TUBERCULOSIS, PLEURAL**

PLEURODYNIA, EPIDEMIC

[Epidemic pleurodynia] Kaji M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):147–8 (5 ref.) **(Jpn)**

PLEUROPNEUMONIA, CONTAGIOUS

MICROBIOLOGY

PCR and RFLP methods for the specific detection and identification of Mycoplasma mycoides subsp. mycoides SC. Bashiruddin JB. **Methods Mol Biol** 1998;104:167–78 (16 ref.)

PLEUROPNEUMONIA-LIKE ORGANISMS see **MYCOPLASMA**

PLEXUS COELIACUS see **CELIAC PLEXUS**

PLOIDIES

Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. Qian J, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):373–80 (59 ref.)

The impact of ancestral tetraploidy on antibody heterogeneity in salmonid fishes. Hordvik I. **Immunol Rev** 1998 Dec;166:153–7 (28 ref.)

PLUGS, SURGICAL see **SURGICAL INSTRUMENTS**

PLUM POX VIRUS

PATHOGENICITY

Some results of 50 years of research on the resistance to plum pox virus. Kegler H, et al. **Acta Virol** 1998 Sep; 42(4):200–15 (270 ref.)

PLUMBING see **SANITARY ENGINEERING**

PLUMMER-VINSON SYNDROME

DIAGNOSIS

Plummer–Vinson syndrome--a rare presentation in a child. Mansell NJ, et al. **J Laryngol Otol** 1999 May;113(5):475–6 (16 ref.)

ETIOLOGY

[Disorders caused by mutations of the thyrotropin receptor] Kosugi S. **Nippon Rinsho** 1998 Jul;56(7):1856–60 (21 ref.) (Eng. Abstr.) **(Jpn)**

PLURALISM see **CULTURAL DIVERSITY**

PLUTONIUM

Review of historical monitoring data on Techa River contamination. Vorobiova MI, et al. **Health Phys** 1999 Jun; 76(6):605–18 (35 ref.)

PMMA see **POLYMETHYL METHACRYLATE**

PMN ELASTASE see **LEUKOCYTE ELASTASE**

PNEUMATIC SUITS see **G SUITS**

PNEUMATOSIS CYSTOIDES INTESTINALIS

[Pneumatosis cystoides intestinalis] Grasland A, et al. **Presse Med** 1998 Nov 14;27(35):1804–12 (69 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Pneumatosis intestinalis with Clostridium difficile colitis as a cause of acute abdomen after lung transplantation. Schenk P, et al. **Dig Dis Sci** 1998 Nov;43(11):2455–8 (17 ref.)

[Pneumoretroperitoneum due to pneumatosis cystoides intestinalis. An etiopathogenetic and clinico–diagnostic assessment. A clinical case report] Gullà N, et al. **Minerva Chir** 1998 Sep;53(9):757–65 (43 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Pneumatosis cystoides intestinalis: confirmation of diagnosis by endoscopic puncture a review of pathogenesis, associated disease and therapy and a new theory of cyst formation. Höer J, et al. **Endoscopy** 1998 Nov;30(9):793–9 (83 ref.)

[Primary pneumatosis intestinalis: its clinical significance, radiologic and endoscopic findings (letter)] Rodriguez Jiménez I, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):155–6 (6 ref.) **(Spa)**

ETIOLOGY

[Involvement of the small intestine in systemic scleroderma] Marie I, et al. **Rev Med Interne** 1999 Jun;20(6):504–13 (86 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Pneumatosis intestinalis: an accidental finding in a patient after kidney transplantation (letter)] López A, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):318–9 (7 ref.) **(Spa)**

PNEUMOCEPHALUS

ETIOLOGY

Pneumocephalus after shunting for hydrocephalus. Villarejo F, et al. **Childs Nerv Syst** 1998 Jul;14(7):333–7 (25 ref.)

Idiopathic CSF rhinorrhoea presenting with tension pneumocephalus and hemiparesis. Hogg RP, et al. **J Laryngol Otol** 1998 Jul;112(7):654–6 (24 ref.)

Pneumocephalus following inadvertent intrathecal puncture during epidural anesthesia: a case report and review of the literature. Sherer DM, et al. **J Matern Fetal Med** 1999 May–Jun;8(3):138–40 (16 ref.)

Spontaneous otogenic pneumocephalus. Case report and review of the literature. Dowd GC, et al. **J Neurosurg** 1998 Dec;89(6):1036–9 (19 ref.)

Incidence and management of tension pneumocephalus after anterior craniofacial resection: case reports and review of the literature. Clevens RA, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):579–83 (18 ref.)

Atraumatic pneumocephalus: a case report and review of the literature. Babl FE, et al. **Pediatr Emerg Care** 1999 Apr;15(2):106–9 (30 ref.)

RADIOGRAPHY

Pneumocephalus complicating general anaesthesia in a nine-year-old child. Hatcher IS, et al. **Paediatr Anaesth** 1999;9(3):265–7 (7 ref.)

SURGERY

Traumatic subdural pneumocephalus causing rise in intracranial pressure in the early phase of head trauma: report of two cases. Oge K, et al. **Acta Neurochir (Wien)** 1998;140(7):655–8 (13 ref.)

Spontaneous otogenic pneumocephalus. Case report and review of the literature. Dowd GC, et al. **J Neurosurg** 1998 Dec;89(6):1036–9 (19 ref.)

PNEUMOCOCCAL INFECTIONS

Unusual manifestations of invasive pneumococcal infection. Taylor SN, et al. **Am J Med** 1999 Jul 26;107(1A):12S–27S (286 ref.)

Streptococcus pneumoniae peritonitis secondary to a tubo-ovarian abscess. Abalde M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):671–3 (6 ref.)

Pneumococcal arthritis in the wrist and ankle. A case report and short review of the literature. Levi N, et al. **Panminerva Med** 1999 Jun;41(2):171–4 (53 ref.)

[Septic arthritis caused by S. pneumoniae. Report of 2 cases with unusual location] Ruiz Martin JM, et al. **Rev Clin Esp** 1998 Sep;198(9):596–7 (13 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Acute bacterial infections and HIV disease. Gilks CF. **Br Med Bull** 1998;54(2):383–93 (48 ref.)

Mycotic aneurysm of the suprarenal aorta due to Streptococcus pneumoniae: case report and literature review. Lussier N, et al. **Can J Surg** 1999 Aug;42(4):302–4 (18 ref.)

Pneumococcal polyarticular septic arthritis in a patient with rheumatoid arthritis. Lohse A, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):344–6 (13 ref.)

DIAGNOSIS

Pneumococcal peritonitis in previously healthy adults: case report and review. Hemsley C, et al. **Clin Infect Dis** 1998 Aug;27(2):376–9 (40 ref.)

Molecular techniques for the diagnosis of respiratory bacterial infection. Gillespie S. **Curr Opin Pulm Med** 1999 May;5(3):174–8 (35 ref.)

[Septic oligoarthritis due to Streptococcus pneumoniae (letter)] García García JC, et al. **Rev Clin Esp** 1999 Jul; 199(7):478 (7 ref.) **(Spa)**

DRUG THERAPY

Strategies in the treatment of penicillin-resistant Streptococcus pneumoniae. Lund BC, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19):1987–94 (76 ref.)

Therapy for pneumococcal infection at the millennium: doubts and certainties. Ball P. **Am J Med** 1999 Jul 26; 107(1A):77S–85S (97 ref.)

Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Jacobs MR. **Am J Med** 1999 May 3; 106(5A):19S–25S; discussion 48S–52S (52 ref.)

Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice [see comments] Wang EE, et al. **Can Fam Physician** 1998 Sep;44:1881–8 (72 ref.) Comment in: Can Fam Physician 1998 Sep;44:1769–73, 1780–4. Comment in: Can Fam Physician 1998 Nov;44:2375–6.

beta-lactam-resistant Streptococcus pneumoniae: epidemiology and evolutionary mechanism. Hakenbeck R. **Chemotherapy** 1999 Mar–Apr;45(2):83–94 (102 ref.)

Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Kaplan SL, et al. **Clin Microbiol Rev** 1998 Oct;11(4):628–44 (148 ref.)

Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem. Klugman KP, et al. **Drugs** 1999 Jul;58(1):1–4 (29 ref.)

Multi-resistant pneumococci in children in day-care centres [comment] Allen KD. **J Infect** 1998 Jul;37(1):5–8 (24 ref.) Comment on: J Infect 1998 Jul;37(1):9–14.

Impact of antibiotic resistance on chemotherapy for pneumococcal infections. Pallares R, et al. **Microb Drug Resist** 1998 Winter;4(4):339–47 (92 ref.)

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group [published erratum appears in Pediatr Infect Dis J 1999 Apr;18(4):341] [see comments] Dowell SF, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):1–9 (59 ref.) Comment in: Pediatr Infect Dis J 1999 Jun;18(6):571–2.

Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update. Jacobs MR. **Pediatr Infect Dis J** 1998 Oct;17(10):947–52 (30 ref.)

EPIDEMIOLOGY

Pneumococcal pericarditis since 1980 [letter; comment] Go C, et al. **Clin Infect Dis** 1998 Nov;27(5):1338–40 (13 ref.) Comment on: Clin Infect Dis 1998 Mar;26(3):762–3.

Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Ghaffar F, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):638–46 (100 ref.)

The epidemiology of pneumococcal infection in children in the developing world. Greenwood B. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):777–85 (55 ref.)

Addressing emerging infections. The partnership between public health and primary care physicians. Danila RN, et al. **Postgrad Med** 1999 Aug;106(2):90–2, 97–8, 103–5 (15 ref.)

ETIOLOGY

[Recurrent spontaneous bacterial peritonitis due to encapsulated microorganisms (Haemophilus influenzae and Streptococcus pneumoniae) in a patient with liver cirrhosis (letter)] Salavert M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):30–1 (10 ref.) **(Spa)**

IMMUNOLOGY

Immunization and protection in pneumococcal otitis media studied in a rat model. Prellner K, et al. **Microb Drug Resist** 1999 Spring;5(1):73–82 (37 ref.)

[Conjugated pneumococcal vaccines] Reinert P. **Arch Pediatr** 1999;6 Suppl 3:643s–646s (25 ref.) **(Fre)**

MICROBIOLOGY

Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice [see comments] Wang EE, et al. **Can Fam Physician** 1998 Sep;44:1881–8 (72 ref.) Comment in: Can Fam Physician 1998 Sep;44:1769–73, 1780–4. Comment in: Can Fam Physician 1998 Nov;44:2375–6.

Molecular and cellular biology of pneumococcal infection.

Tuomanen E. **Curr Opin Microbiol** 1999 Feb;2(1):35–9 (37 ref.)
Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Ghaffar F, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):638–46 (100 ref.)

PREVENTION & CONTROL

Pneumococcal vaccines: history, current status, and future directions. Butler JC, et al. **Am J Med** 1999 Jul 26; 107(1A):69S–76S (72 ref.)
Typing of Streptococcus pneumoniae: past, present, and future. Henrichsen J. **Am J Med** 1999 Jul 26; 107(1A):50S–54S (32 ref.)
Preventing pneumococcal disease: a Canadian consensus conference. 16–18 February 1998. **Can Commun Dis Rep** 1999 Feb 15;25(4):25–35 (0 ref.) **(Eng, Fre)**
Preventing pneumococcal disease. Thomas R. **Can Fam Physician** 1998 Oct;44:2180–1, 2184–5 (7 ref.) **(Eng, Fre)**
The place of pneumococcal vaccination. **Drug Ther Bull** 1998 Oct;36(10):73–6 (43 ref.)
Immunization and protection in pneumococcal otitis media studied in a rat model. Prellner K, et al. **Microb Drug Resist** 1999 Spring;5(1):73–82 (37 ref.)
Maternal immunization [editorial] Combs BG, et al. **P N G Med J** 1997 Jun;40(2):63–8 (44 ref.)
Pneumococcal conjugate vaccines. Eskola J, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):543–51 (59 ref.)
The burden of pneumococcal disease: the role of conjugate vaccines. Poland GA. **Vaccine** 1999 Mar 26; 17(13–14):1674–9 (26 ref.)
Use of vaccine in the era of antimicrobial resistance: need of effective pneumococcal vaccines. Sohn YM. **Yonsei Med J** 1998 Dec;39(6):611–8 (46 ref.)
[Pneumococcal vaccine] Flø RW, et al. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3799–802 (39 ref.) (Eng. Abstr.) **(Nor)**
[The elderly should be vaccinated against pneumococci] Ortqvist A, et al. **Lakartidningen** 1999 Mar 17;96(11):1305–8 (35 ref.) (Eng. Abstr.) **(Swe)**

TRANSMISSION

Multi-resistant pneumococci in children in day-care centres [comment] Allen KD. **J Infect** 1998 Jul;37(1):5–8 (24 ref.) Comment on: J Infect 1998 Jul;37(1):9–14.

PNEUMOCOCCUS see **STREPTOCOCCUS PNEUMONIAE**

PNEUMOCONIOSIS

[Yesterday's and today's pneumoconiosis] De Vuyst P. **Rev Prat** 1998 Jun 15;48(12):1324–6 (12 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Metals that cause sarcoidosis. Newman LS. **Semin Respir Infect** 1998 Sep;13(3):212–20 (88 ref.)

PATHOLOGY

[Pulmonary fibrosis caused by inhalation: silicosis] Ortuño Pacheco G. **Rev Med Univ Navarra** 1998 Oct–Dec; 42(4):208–19 (11 ref.) (Eng. Abstr.) **(Spa)**

PNEUMOCYSTIS CARINII

CLASSIFICATION

Typing methods to approach Pneumocystis carinii genetic heterogeneity. Hauser PM, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):27–35 (46 ref.)
Taxonomy, genetic organization, and life cycle of Pneumocystis carinii. Cushion MT. **Semin Respir Infect** 1998 Dec;13(4):304–12 (65 ref.)

GENETICS

Typing methods to approach Pneumocystis carinii genetic heterogeneity. Hauser PM, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):27–35 (46 ref.)
The genome of Pneumocystis carinii. Stringer JR, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):15–26 (100 ref.)
Taxonomy, genetic organization, and life cycle of Pneumocystis carinii. Cushion MT. **Semin Respir Infect** 1998 Dec;13(4):304–12 (65 ref.)

GROWTH & DEVELOPMENT

Current in vitro culture systems for Pneumocystis. Atzori C, et al. **FEMS Immunol Med Microbiol** 1998 Sep; 22(1–2):169–72 (17 ref.)

IMMUNOLOGY

Immunological features of Pneumocystis carinii infection in humans. Walzer PD. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):149–55 (138 ref.)
Immune responses to naturally acquired Pneumocystis carinii in gene disruption mutant mice. Hanano R, et al. **Res Immunol** 1998 May–Jun;149(4–5):429–35; discussion 514 (40 ref.)
Lymphocytes in host defense against Pneumocystis carinii. Beck JM, et al. **Semin Respir Infect** 1998 Dec;13(4):330–8 (62 ref.)
Antigenic characterization of Pneumocystis carinii. Gigliotti F, et al. **Semin Respir Infect** 1998 Dec;13(4):313–22 (52 ref.)
Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Limper AH. **Semin Respir Infect** 1998 Dec;13(4):339–47 (77 ref.)

ISOLATION & PURIFICATION

Morphological and ultrastructural methods for Pneumocystis. Dei-Cas E, et al. **FEMS Immunol Med Microbiol** 1998 Sep; 22(1–2):185–9 (15 ref.)
Detection of Pneumocystis carinii DNA in blood specimens from human immunodeficiency virus-infected patients by nested PCR. Rabodonirina M, et al. **J Clin Microbiol** 1999 Jan;37(1):127–31 (23 ref.)
Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii. Hughes WT. **Semin Respir Infect** 1998 Dec;13(4):283–8 (33 ref.)
Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Thomas CF Jr, et al. **Semin Respir Infect** 1998 Dec;13(4):289–95 (34 ref.)

PATHOGENICITY

Pneumocystis carinii: the art and science of survival in the hostile environment of the alveolar spaces. Martin WJ 2nd. **Semin Respir Infect** 1998 Dec;13(4):348–52 (17 ref.)
Pneumocystis carinii interactions with respiratory epithelium. Pottratz ST. **Semin Respir Infect** 1998 Dec;13(4):323–9 (35 ref.)
Animal pneumocystosis: a model for man. Ceré N, et al. **Vet Res** 1999 Jan–Feb;30(1):1–26 (209 ref.)

PHYSIOLOGY

The major surface antigen of Pneumocystis carinii. Nakamura Y. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):67–74 (69 ref.)
Alveolar macrophage interactions with Pneumocystis carinii. Vassallo R, et al. **J Lab Clin Med** 1999 Jun;133(6):535–40 (35 ref.)
Genetics, metabolism and host specificity of Pneumocystis carinii. Wakefield AE, et al. **Med Mycol** 1998;36 Suppl 1:183–93 (90 ref.)

ULTRASTRUCTURE

Morphological and ultrastructural methods for Pneumocystis. Dei-Cas E, et al. **FEMS Immunol Med Microbiol** 1998 Sep; 22(1–2):185–9 (15 ref.)
Pneumocystis carinii interactions with respiratory epithelium. Pottratz ST. **Semin Respir Infect** 1998 Dec;13(4):323–9 (35 ref.)

PNEUMOCYSTIS CARINII INFECTIONS

DIAGNOSIS

[Pneumocystosis: progress in diagnosis and treatment] Ulewicz-Filipowicz J, et al. **Pol Merkuriusz Lek** 1999 May; 6(35):286–90 (37 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Pneumocystosis: progress in diagnosis and treatment] Ulewicz-Filipowicz J, et al. **Pol Merkuriusz Lek** 1999 May; 6(35):286–90 (37 ref.) (Eng. Abstr.) **(Pol)**

PNEUMOCYSTIS CARINII PNEUMONIA see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMOGASTRIC NERVE see **VAGUS NERVE**

PNEUMOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PNEUMOMEDIASTINUM see **MEDIASTINAL EMPHYSEMA**

PNEUMONECTOMY

Surgical treatment of chronic obstructive pulmonary disease. Payne DK, et al. **Am J Med Sci** 1999 Aug;318(2):89–95 (53 ref.)
Anomalous systemic arterial supply to normal basal segments of the left lower lobe. Yamanaka A, et al. **Ann Thorac Surg** 1999 Aug;68(2):332–8 (20 ref.)
Imaging of patients with severe emphysema considered for lung volume reduction surgery. Cleverley JR, et al. **Br J Radiol** 1999 Mar;72(855):227–35 (58 ref.)
Lung volume reduction for emphysema and the Canadian Lung Volume Reduction Surgery (CLVR) Project. Miller JD, et al. **Can Respir J** 1999 Jan–Feb;6(1):26–32 (45 ref.)
Follow-up of patients with completely resected lung cancer [editorial; comment] Downey RJ. **Chest** 1999 Jun; 115(6):1487–8 (9 ref.) Comment on: Chest 1999 Jun;115(6):1494–9.
The postpneumonectomy state [see comments] Kopec SE, et al. **Chest** 1998 Oct;114(4):1158–84 (198 ref.) Comment in: Chest 1999 Apr;115(4):1214.
Indications for pneumonectomy. Pneumonectomy for benign disease. Conlan AA, et al. **Chest Surg Clin N Am** 1999 May;9(2):311–26 (53 ref.)
Postpneumonectomy pulmonary edema. Deslauriers J, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):611–31, ix (46 ref.)
Indications for pneumonectomy. Pneumonectomy for malignant disease. James TW, et al. **Chest Surg Clin N Am** 1999 May;9(2):291–309, ix (61 ref.)
Postoperative care and monitoring. Naunheim KS. **Chest Surg Clin N Am** 1999 Aug;9(3):501–13 (35 ref.)
Indications for pneumonectomy. Extrapleural pneumonectomy. Rusch VW. **Chest Surg Clin N Am** 1999 May;9(2):327–38, x (42 ref.)
Late-stage emphysema: when medical therapy fails. Dasgupta A, et al. **Cleve Clin J Med** 1999 Jul–Aug; 66(7):415–7, 421–5 (41 ref.)
Physiological basis of improvement after lung volume reduction surgery for severe emphysema: where are we? [see comments] Marchand E, et al. **Eur Respir J** 1999 Mar; 13(3):686–96 (99 ref.) Comment in: Eur Respir J 1999 Mar;13(3):480–1.
Surgical lung volume reduction for severe pulmonary emphysema--a new review series [editorial; comment] Russi EW, et al. **Eur Respir J** 1999 Mar;13(3):480–1 (11 ref.) Comment on: Eur Respir J 1999 Mar;13(3):686–96.
Functional and morphological heterogeneity of emphysema and its implication for selection of patients for lung volume reduction surgery. Russi EW, et al. **Eur Respir J** 1999 Jul; 14(1):230–6 (48 ref.)
Short- and long-term functional results after lung volume reduction surgery for severe emphysema. Teschler H, et al. **Eur Respir J** 1999 May;13(5):1170–6 (44 ref.)
Left postpneumonectomy syndrome successfully treated with endobronchial stent. Nakamura Y, et al. **Intern Med** 1998 Oct;37(10):880–3 (12 ref.)
Lung volume reduction surgery for pulmonary emphysema [editorial; comment] Yoshida M. **Intern Med** 1999 Feb; 38(2):79 (10 ref.) Comment on: Intern Med 1999 Feb;38(2):119–25.
Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):518–28 (41 ref.)
Lung-reduction surgery: 5 years on. Cooper JD, et al. **Lancet** 1999 Apr;353 Suppl 1:SI26–7 (19 ref.)
Pulmonary rehabilitation and lung volume reduction surgery in the treatment of patients with chronic obstructive pulmonary disease. Celli BR. **Monaldi Arch Chest Dis** 1998 Aug;53(4):471–9 (78 ref.)
Breathing in patients with bullous emphysema: why lung volume reduction may work. Pride NB. **Monaldi Arch Chest Dis** 1998 Aug;53(4):483–5 (17 ref.)
Evidence-based aspects of lung volume reduction surgery. Zannini P, et al. **Monaldi Arch Chest Dis** 1998 Dec; 53(6):709–13 (29 ref.)
Lung volume reduction surgery. Geddes DM. **Thorax** 1999 Aug;54 Suppl 2:S14–8 (18 ref.)
[Lung volume reduction surgery. A new surgical therapeutic possibility for patients with emphysema] Stentoft P, et al. **Ugeskr Laeger** 1999 Feb 22;161(8):1095–9 (25 ref.) (Eng. Abstr.) **(Dan)**
[Anesthesia in lung volume reduction] Grundmann U, et al. **Anaesthesist** 1999 Feb;48(2):121–8 (29 ref.) **(Ger)**
[Risk assessment of patients before lung surgery] Schulz C, et al. **Chirurg** 1999 Jun;70(6):664–73 (64 ref.) (Eng. Abstr.) **(Ger)**
[Surgical lung volume reduction—an option for treating severe pulmonary emphysema] Russi EW, et al. **Ther Umsch** 1999 Mar;56(3):157–60 (5 ref.) (Eng. Abstr.) **(Ger)**
[The surgical physiopathology of essential pulmonary emphysema and volume-reduction intervention] Nazari S. **Minerva Chir** 1998 Nov;53(11):899–918 (36 ref.) (Eng. Abstr.) **(Ita)**
[Volume reduction surgery for the treatment of pulmonary edema] Yoshida M, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):82–8 (5 ref.) **(Jpn)**
[Pulmonary hyperinflation. The functional and clinico-radiological criteria, mechanisms and surgery to reduce lung volume in severe emphysema] Spânu V, et al. **Pneumoftiziologia** 1998 Jan–Mar;47(1):29–35 (5 ref.) **(Rum)**
[Stridor in a female patient who underwent pneumonectomy. A postpneumonectomy syndrome] Jiménez Castro D, et al. **Rev Clin Esp** 1999 May;199(5):323–4 (8 ref.) **(Spa)**
[Volume-reduction surgery for pulmonary edema] Jiménez Castro D, et al. **Rev Clin Esp** 1999 Jul;199(7):449–55 (75 ref.) **(Spa)**

ADVERSE EFFECTS

Early complications. Cardiac complications. Asamura H. **Chest Surg Clin N Am** 1999 Aug;9(3):527–41, vii–viii (25 ref.)
Early complications. Recurrent nerve palsy. Carew JF, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):597–608, viii–ix (20 ref.)
Late results. Daly BD. **Chest Surg Clin N Am** 1999 Aug; 9(3):675–93, x (93 ref.)

Assessment of operative risk for pneumonectomy. Ferguson MK. **Chest Surg Clin N Am** 1999 May;9(2):339–51 (100 ref.)
Morbidity and mortality after pneumonectomy. Klemperer J, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):515–25, vii (64 ref.)
Physiologic consequences of pneumonectomy. Long-term consequences of pneumonectomy done in children. Lezama-del Valle Valle P, et al. **Chest Surg Clin N Am** 1999 May;9(2):485–95, xiii (36 ref.)
Early complications. Esophagopleural fistula. Massard G, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):617–31, ix (44 ref.)
Late complications. Postpneumonectomy syndrome. Mehran RJ, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):655–73, x (32 ref.)
Physiologic consequences of pneumonectomy. Consequences on the pulmonary function. Reed CE. **Chest Surg Clin N Am** 1999 May;9(2):449–57, xii (37 ref.)
Physiologic consequences of pneumonectomy. Consequences on the esophageal function. Suen HC, et al. **Chest Surg Clin N Am** 1999 May;9(2):475–83, xiii (12 ref.)
Physiologic consequences of pneumonectomy. Consequences on the pulmonary function. Tronc F, et al. **Chest Surg Clin N Am** 1999 May;9(2):459–73, xii–xiii (70 ref.)
Early complications. Chylothorax. Vallières E, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):609–16, ix (30 ref.)
Late complications. Late respiratory failure. Wihlm JM, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):633–54, ix–x (79 ref.)
Early complications. Respiratory failure. Zwischenberger JB, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):543–64, viii (142 ref.)
[Supraventricular arrhythmia after pneumonectomy. Apropos of 100 cases and review of the literature] Douchet MP, et al. **Ann Cardiol Angeiol (Paris)** 1998 May; 47(5):323–7 (30 ref.) (Eng. Abstr.) **(Fre)**
[Etiology and treatment of bronchial fistula after pneumonectomy] Zieliński M. **Pneumonol Alergol Pol** 1998; 66(9–10):487–92 (24 ref.) (Eng. Abstr.) **(Pol)**
[A complication after lung resection due to a patent foramen ovale] Kuksinskii VE, et al. **Vestn Khir Im I I Grek** 1999; 158(1):65–6 (7 ref.) **(Rus)**

HISTORY

A history of pneumonectomy. Fell SC. **Chest Surg Clin N Am** 1999 May;9(2):267–90, ix (51 ref.)

METHODS

Techniques of pneumonectomy. Sleeve pneumonectomy. Dartevelle P, et al. **Chest Surg Clin N Am** 1999 May; 9(2):407–17, xi (11 ref.)
Techniques of pneumonectomy. Drainage after pneumonectomy. Deslauriers J, et al. **Chest Surg Clin N Am** 1999 May;9(2):437–48, xii (21 ref.)
Video-assisted thoracic surgery for lung volume reduction surgery. Fischel RJ, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):789–807, viii (41 ref.)
The current status of video-assisted thoracic surgery lobectomy. McKenna RJ Jr. **Chest Surg Clin N Am** 1998 Nov;8(4):775–85, viii; discussion 787–8 (27 ref.)
Techniques of pneumonectomy. Pneumonectomy through an empyema. Odell JA, et al. **Chest Surg Clin N Am** 1999 May;9(2):369–78, x–xi (16 ref.)
Techniques of pneumonectomy. Standard pneumonectomy. Rice TW. **Chest Surg Clin N Am** 1999 May;9(2):353–68, x (08 ref.)
Techniques of pneumonectomy. Video-assisted thoracic surgery pneumonectomy. Roviaro G, et al. **Chest Surg Clin N Am** 1999 May;9(2):419–36, xi–xii (17 ref.)
Techniques of pneumonectomy. Pleural pneumonectomy. Sugarbaker DJ, et al. **Chest Surg Clin N Am** 1999 May; 9(2):379–92, xi (53 ref.)
Techniques of pneumonectomy. Completion pneumonectomy. Tronc F, et al. **Chest Surg Clin N Am** 1999 May;9(2):393–405, xi (23 ref.)
Surgical aspects and techniques of lung volume reduction surgery for severe emphysema. Klepetko W. **Eur Respir J** 1999 Apr;13(4):919–25 (42 ref.)
Surgical approaches to advanced emphysema. Edelman JD, et al. **Respir Care Clin N Am** 1998 Sep;4(3):513–39, x (98 ref.)
German Thoracic Research Scholarship 1996: lung volume reduction for endstage pulmonary emphysema at the Washington University of St. Louis. Moersig W. **Thorac Cardiovasc Surg** 1998 Jun;46(3):176–80 (28 ref.)
Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema. Young J, et al. **Thorax** 1999 Sep; 54(9):779–89 (54 ref.)
[Value and limits of surgery in stage IIIB non-small-cell bronchial cancers] Grunenwald D. **Cancer Radiother** 1998 Sep–Oct;2(5):568–73 (30 ref.) (Eng. Abstr.) **(Fre)**
[The use of the pleural tent in superior lobectomies] Solli P, et al. **Acta Biomed Ateneo Parmense** 1996;67(5–6):173–6 (8 ref.) (Eng. Abstr.) **(Ita)**
[Lung volume reduction--surgical alternative to the treatment of severe diffuse pulmonary emphysema?] Losso LC, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):246–52 (34 ref.) **(Por)**

MORTALITY

Assessment of operative risk for pneumonectomy. Ferguson MK. **Chest Surg Clin N Am** 1999 May;9(2):339–51 (100 ref.)
[Results of surgical treatment of T3 lung carcinoma according to the combined resection of involved organs] Shirakusa T, et al. **Kyobu Geka** 1998 Oct;51(11):949–53 (13 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Assessing new technology, another chapter: lung volume reduction surgery/recombinant human growth hormone [editorial; comment] Slonim AD, et al. **Crit Care Med** 1999 Aug;27(8):1687–8 (15 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634–8.

PNEUMONIA

Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Muder RR. **Am J Med** 1998 Oct;105(4):319–30 (134 ref.)
Pneumonia, tuberculosis, and urinary tract infections in pregnancy. Riley LE. **Curr Clin Top Infect Dis** 1999; 19:181–97 (112 ref.)
Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Auble TE, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):741–59, x (36 ref.)
Hospital-acquired pneumonia: epidemiology, etiology, and treatment. McEachern R, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):761–79, x (81 ref.)
Community-acquired pneumonia: epidemiology, etiology, treatment. Marrie TJ. **Infect Dis Clin North Am** 1998 Sep; 12(3):723–40 (70 ref.)
Community acquired pneumonia. Finch R. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):328–32 (13 ref.)
Community-acquired pneumonia "State-of-the-art". Bohte R, et al. **Neth J Med** 1998 Nov;53(5):214–23 (104 ref.)
[Hospital-acquired pneumonia] Goto H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):404–6 (5 ref.) **(Jpn)**
[Community-acquired pneumonia] Tomiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):400–3 (6 ref.) **(Jpn)**
[Nosocomial pneumonia in intensive care units (review of the literature)] Gel'fand BR, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):38–46 (90 ref.) **(Rus)**

CHEMICALLY INDUCED

Ozone-induced lung inflammation and mucosal barrier disruption: toxicology, mechanisms, and implications. Bhalla DK. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar;2(1):31–86 (103 ref.)
[Drug-induced pneumonitis] Kondo A. **Kekkaku** 1999 Jan; 74(1):33–41 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Isoniazid-induced pneumonitis] Hatakeyama S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):448–52 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Pneumonia in the patient with HIV infection. Bartlett JG. **Infect Dis Clin North Am** 1998 Sep;12(3):807–20, xi (26 ref.)
Rapidly growing mycobacterial lung infection in association with esophageal disorders [see comments] Hadjiliadis D, et al. **Mayo Clin Proc** 1999 Jan;74(1):45–51 (25 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):744–5.
Fibrinolytics in the treatment of parapneumonic effusions. Bouros D, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):258–63 (42 ref.)
[Medium and long-term sequelae of community-acquired pneumonia in children] Deschildre A. **Arch Pediatr** 1998; 5 Suppl 1:45s–48s (19 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The diagnosis and treatment challenges in nosocomial pneumonia. Baughman RP, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):131–9 (26 ref.)
Controversies on diagnosis and prevention of ventilator-associated pneumonia. Bonten MJ. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):199–204 (38 ref.)
Invasive diagnostic techniques for pneumonia: protected specimen brush, bronchoalveolar lavage, and lung biopsy methods. Torres A, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):701–22 (112 ref.)
Diagnosis of ventilator-associated pneumonia. Flanagan PG. **J Hosp Infect** 1999 Feb;41(2):87–99 (84 ref.)
Community-acquired pneumonia: diagnosis and treatment. Sinaniotis CA. **Pediatr Pulmonol Suppl** 1999;18:144–5 (11 ref.)
Assessment of severity of community-acquired pneumonia. Boersma WG. **Semin Respir Infect** 1999 Jun;14(2):103–14 (64 ref.)
[Diagnostic and treatment of community-acquired pneumonia in the adult. Recommendations for clinical practice. By the "Practice guidelines for community-acquired pneumonia" Work Group] **Rev Med Suisse Romande** 1999 May;119(5):403–27 (121 ref.) **(Fre)**
[Pneumonia as a nosocomial infection] Otto T. **Pneumonol Alergol Pol** 1997;65(11–12):837–42 (32 ref.) **(Pol)**
[Invasive diagnostic technics in pneumonia] Aspa FJ, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:41–9 (64 ref.) **(Spa)**
[Non-invasive technics in the diagnosis of pneumonia] Bello S, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:31–40 (60 ref.) **(Spa)**
[Differential diagnosis of pneumonia] Roig Cutillas J, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:3–10 (103 ref.) **(Spa)**

DRUG THERAPY

Antimicrobial switch therapy. Bui K, et al. **Conn Med** 1998 Nov;62(11):665–8 (11 ref.)
The diagnosis and treatment challenges in nosocomial pneumonia. Baughman RP, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):131–9 (26 ref.)
Antibiotic resistance and therapeutic options in lower respiratory tract infections. Bouza E. **Int J Antimicrob Agents** 1999 Mar;11 Suppl 1:S3–6; discussion S31–2 (32 ref.)
Antibiotic therapy of childhood pneumonia. Schaad UB. **Pediatr Pulmonol Suppl** 1999;18:146–9 (14 ref.)
[Systemic antibiotics in routine practice: ENT and lower respiratory tract infections. National Agency for Accreditation and Evaluation of Health (ANAES)] **Rev Pneumol Clin** 1999 Jun;55(3):127–54 (115 ref.) **(Fre)**
[Treatment of community-acquired pneumonia] Dorca J, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:50–6 (38 ref.) **(Spa)**
[Treatment of nosocomial pneumonia] Molinos L, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:57–62 (35 ref.) **(Spa)**

EPIDEMIOLOGY

[Epidemiology of community-acquired pneumonia in children. Current data] Marguet C, et al. **Arch Pediatr** 1998; 5 Suppl 1:9s–13s (26 ref.) (Eng. Abstr.) **(Fre)**
[Community pneumonia. Epidemiology. Risk factors and prognosis] Alfageme Michavila I, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:17–24 (37 ref.) **(Spa)**

ETIOLOGY

Mechanisms of lung injury after bone marrow transplantation. Folz RJ. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1097–9 (20 ref.)
Myelodysplasia presenting with pulmonary manifestations associated with neutrophilic dermatosis. Peters FP, et al. **Ann Hematol** 1998 Sep;77(3):135–8 (20 ref.)
Postoperative pneumonia. Ferdinand B, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):529–39, viii (48 ref.)
Toward an understanding of idiopathic pneumonia syndrome after bone marrow transplantation [editorial; comment] Wiedermann HP. **Crit Care Med** 1999 Sep;27(9):2040–1 (8 ref.) Comment on: Crit Care Med 1999 Sep;27(9):1800–6.
Pneumonia in the compromised host including cancer patients and transplant patients. Collin BA, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):781–805, xi (160 ref.)
Nursing home-acquired pneumonia. Medina-Walpole AM, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1005–15 (102 ref.)
Community-acquired pneumonia: definition, epidemiology, and outcome. Ewig S. **Semin Respir Infect** 1999 Jun; 14(2):94–102 (60 ref.)
[The solitary echinococcal cyst--a rare cause of a round pulmonary focus] Gessner C, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):891–5 (15 ref.) (Eng. Abstr.) **(Ger)**
[Growth factors in the process of inflammation and fibrosis in the lung] Matsuse T. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):413–20 (49 ref.) (Eng. Abstr.) **(Jpn)**
[Severe community-acquired pneumonia. An update] Blanquer Olivas J. **Arch Bronconeumol** 1999 May;35 Suppl 3:65–9 (35 ref.) **(Spa)**
[Torpid pneumonia secondary to the aspiration of a phonation prosthesis (letter)] García Gasalla M, et al. **Rev Clin Esp** 1999 Jul;199(7):481–2 (10 ref.) **(Spa)**

IMMUNOLOGY

The function of cell adhesion molecules in lung inflammation: more questions than answers. DeLisser HM, et al. **Am J Respir Cell Mol Biol** 1998 Oct;19(4):533–6 (53 ref.)
Inflammation in severe pneumonia: act locally, not globally [editorial; comment] Niederman MS, et al. **Crit Care Med** 1999 Sep;27(9):2030–2 (9 ref.) Comment on: Crit Care Med 1999 Sep;27(9):1745–53.
Role of cytokines in pulmonary antimicrobial host defense. Mehrad B, et al. **Immunol Res** 1999;20(1):15–27 (115 ref.)
[Severe community-acquired pneumonia in immunocompetent children] Fayon M, et al. **Arch Pediatr** 1998;5 Suppl 1:49s–56s (46 ref.) (Eng. Abstr.) **(Fre)**
[Inflammatory response in pneumonia] Montón C, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:11–6 (35 ref.) **(Spa)**

PNEUMONIA

MICROBIOLOGY

A question of balance [editorial; comment] Nelson S. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1365–7 (15 ref.) Comment on: Am J Respir Crit Care Med 1999 May;159(5 Pt 1):1377–82.

Endemic fungal pneumonia in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1999 Jan;14(1):1–8 (52 ref.)

Opportunistic fungal pneumonia. Connolly JE Jr, et al. **J Thorac Imaging** 1999 Jan;14(1):51–62 (60 ref.)

Rapidly growing mycobacterial lung infection in association with esophageal disorders [see comments] Hadjiliadis D, et al. **Mayo Clin Proc** 1999 Jan;74(1):45–51 (25 ref.) Comment in: Mayo Clin Proc 1999 Jul;74(7):744–5.

Nocardia farcinica pneumonia in chronic granulomatous disease. Shetty AK, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):961–4 (36 ref.)

PARASITOLOGY

Acanthamoebiasis in Korea: two new cases with clinical cases review. Im K, et al. **Yonsei Med J** 1998 Oct;39(5):478–84 (15 ref.)

PATHOLOGY

The concept of organizing pneumonia. Cordier JF. **Curr Top Pathol** 1999;93:149–56 (44 ref.)

Histopathology of ventilator-associated pneumonia (VAP) and its clinical implications. Torres A, et al. **Infection** 1999 Jan–Feb;27(1):71–6 (28 ref.)

Airway epithelial cells as regulators of airway inflammation (Review). Takizawa H. **Int J Mol Med** 1998 Feb; 1(2):367–78 (107 ref.)

Ozone-induced lung inflammation and mucosal barrier disruption: toxicology, mechanisms, and implications. Bhalla DK. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar;2(1):31–86 (103 ref.)

[Parapneumonic pleural effusion, pleural empyema: medical and surgical aspects] Gugger M, et al. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):556–62 (26 ref.) (Eng. Abstr.) **(Ger)**

[Pneumonia: what's new?] Täuber MG. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):563–9 (23 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Effect of pneumonia in childhood on adult lung function. Johnston ID. **J Pediatr** 1999 Aug;135(2 Pt 2):33–7 (48 ref.)

Severe community-acquired pneumonia: how to assess illness severity. Ewig S, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):250–4 (26 ref.)

[Medium and long-term sequelae of community-acquired pneumonia in children] Deschildre A. **Arch Pediatr** 1998; 5 Suppl 1:45s–48s (19 ref.) (Eng. Abstr.) **(Fre)**

[Severe community-acquired pneumonia in immunocompetent children] Fayon M, et al. **Arch Pediatr** 1998;5 Suppl 1:49s–56s (46 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Potential interventions for the prevention of childhood pneumonia in developing countries: improving nutrition. Victora CG, et al. **Am J Clin Nutr** 1999 Sep;70(3):309–20 (99 ref.)

Controversies on diagnosis and prevention of ventilator-associated pneumonia. Bonten MJ. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):199–204 (38 ref.)

The prevention of ventilator-associated pneumonia [see comments] Kollef MH. **N Engl J Med** 1999 Feb 25; 340(8):627–34 (53 ref.) Comment in: N Engl J Med 1999 Jul 22;341(4):293–4.

RADIOGRAPHY

Maximizing the usefulness of imaging in children with community-acquired pneumonia. Donnelly LF. **AJR Am J Roentgenol** 1999 Feb;172(2):505–12 (63 ref.)

[Evolution and radiologic surveillance on community-acquired pneumonia in children] Monroc M, et al. **Arch Pediatr** 1998;5 Suppl 1:37s–44s (18 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of the respiratory complications of neuromuscular diseases in the pediatric intensive care unit. Birnkrant DJ, et al. **J Child Neurol** 1999 Mar;14(3):139–43 (13 ref.)

[Non-antibiotic treatments for community-acquired pneumonia in children] Dubus JC. **Arch Pediatr** 1998;5 Suppl 1:62s–66s (36 ref.) (Eng. Abstr.) **(Fre)**

[First seminar on the improvement of pediatric pneumonia. Conclusions and perspectives] Dutau G. **Arch Pediatr** 1998; 5 Suppl 1:67s–69s (10 ref.) **(Fre)**

[Diagnostic and treatment of community-acquired pneumonia in the adult. Recommendations for clinical practice. By the "Practice guidelines for community-acquired pneumonia" Work Group] **Rev Med Suisse Romande** 1999 May;119(5):403–27 (121 ref.) **(Fre)**

VETERINARY

Bovine pneumonia. Its radiographic appearance. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):301–58, vi–vii (0 ref.)

PNEUMONIA, ASPIRATION

DIAGNOSIS

[Mendelson syndrome in infancy and childhood] Baum WF, et al. **Pneumologie** 1998 Oct;52(10):556–9 (21 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Body position and pneumonia [editorial; comment] deBoisblanc BP. **Crit Care Med** 1999 Apr;27(4):678–9 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):745–8.

PREVENTION & CONTROL

Preoperative fasting in children. Splinter WM, et al. **Anesth Analg** 1999 Jul;89(1):80–9 (114 ref.)

PNEUMONIA, BACTERIAL

Community-acquired pneumonia [see comments] Brown PD, et al. **Lancet** 1998 Oct 17;352(9136):1295–302 (80 ref.) Comment in: Lancet 1998 Dec 19–26;352(9145):2019. Comment in: Lancet 1999 May 1;353(9163):1528–9.

[Respiratory manifestations of leptospirosis. A retrospective study of 91 cases (1978–1984)] Courtin JP, et al. **Rev Pneumol Clin** 1998 Dec;54(6):382–92 (98 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary anthrax] Debord T, et al. **Rev Pneumol Clin** 1998 Dec;54(6):377–81 (22 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary melioidosis] Perret JL, et al. **Rev Pneumol Clin** 1998 Dec;54(6):365–72 (65 ref.) (Eng. Abstr.) **(Fre)**

[Streptococcal pneumonia] Hashiguchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):350–3 (12 ref.) **(Jpn)**

[Chlamydia pneumoniae pneumonia] Kishimoto T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):236–40 (10 ref.) **(Jpn)**

[Anaerobic pneumonia] Kobayashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):392–5 (11 ref.) **(Jpn)**

[Xanthomonas maltophilia pneumonia] Maruyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):389–91 (7 ref.) **(Jpn)**

[Francisella pneumonia] Masuda G. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):387–8 (3 ref.) **(Jpn)**

[Branhamella pneumonia] Miura H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):362–5 (12 ref.) **(Jpn)**

[Pasteurella multocida pneumonia] Miyashita T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):384–6 (15 ref.) **(Jpn)**

[Chlamydia trachomatis pneumonia] Motai Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):230–2 (7 ref.) **(Jpn)**

[Serratia marcescens pneumonia] Nakamura J, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):381–3 (9 ref.) **(Jpn)**

[Haemophilus influenzae pneumonia] Okimoto N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):377–80 (12 ref.) **(Jpn)**

[Klebsiella pneumoniae pneumonia] Sugiyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):366–8 (11 ref.) **(Jpn)**

[Pseudomonas aeruginosa pneumonia] Watanabe K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):371–3 (14 ref.) **(Jpn)**

[Escherichia coli pneumonia] Watanabe K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):374–6 (13 ref.) **(Jpn)**

[Bacillus cereus pneumonia] Watanabe K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):360–1 (11 ref.) **(Jpn)**

COMPLICATIONS

Suppurative Acinetobacter baumanii thyroiditis with bacteremic pneumonia: case report and review. Yu EH, et al. **Clin Infect Dis** 1998 Nov;27(5):1286–90 (74 ref.)

[Virus bacteria interactions in acute viral pneumonia in infancy: clinical and therapeutic consequences] Brouard J, et al. **Arch Pediatr** 1998;5 Suppl 1:22s–25s (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Emergency department management of pneumonia. Talan DA, et al. **Can Respir J** 1999 Jan–Feb;6 Suppl A:10A–4A (35 ref.)

Community-acquired pneumonia. Cassiere HA, et al. **Dis Mon** 1998 Nov;44(11):613–75 (120 ref.)

Value of noninvasive studies in community-acquired pneumonia. Plouffe JF, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):689–99, ix (47 ref.)

Lower respiratory tract infection and pneumonia in the community. Macfarlane J. **Semin Respir Infect** 1999 Jun; 14(2):151–62 (77 ref.)

In-hospital management of adults who have community-acquired pneumonia. Ortqvist A. **Semin Respir Infect** 1999 Jun;14(2):135–50 (84 ref.)

Childhood community-acquired pneumonia. Ruuskanen O, et al. **Semin Respir Infect** 1999 Jun;14(2):163–72 (56 ref.)

Community-acquired pneumonia in the elderly. Torres A, et al. **Semin Respir Infect** 1999 Jun;14(2):173–83 (61 ref.)

[Ventilator-associated pneumonia; controversies with respect to diagnosis, pathogenesis, therapy and prevention] Bonten MJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):726–30 (24 ref.) (Eng. Abstr.) **(Dut)**

[Neonatal pneumonia] Albertini M. **Arch Pediatr** 1998;5 Suppl 1:57s–61s (11 ref.) (Eng. Abstr.) **(Fre)**

[Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia in children] Iniguez JL. **Arch Pediatr** 1998;5 Suppl 1:18s–21s (24 ref.) (Eng. Abstr.) **(Fre)**

[Investigations for etiologic causes in community-acquired pneumonia in children (besides imagery) Le Roux P. **Arch Pediatr** 1998;5 Suppl 1:28s–32s (26 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary infection in the emphysematous bulla due to Mycobacterium szulgai diagnosed by percutaneus needle aspiration] Inoue Y, et al. **Kansenshogaku Zasshi** 1998 Nov; 72(11):1236–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Difficulties in diagnosis of specific pneumonia: clinical and pathomorphological confrontation] Lewek S, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):325–7 (15 ref.) (Eng. Abstr.) **(Pol)**

[Diagnosis and treatment of pneumonia] Sil'vestrov VP. **Ter Arkh** 1998;70(9):45–9 (11 ref.) **(Rus)**

[Bordetella bronchiseptica pneumonia and the acquired immunodeficiency syndrome (letter)] Abad A, et al. **Rev Clin Esp** 1999 May;199(5):330–1 (10 ref.) **(Spa)**

[Chlamydia pneumoniae and other Chlamydia species in community-acquired pneumonia] Ruiz Carmona M, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 1:30–4 (45 ref.) **(Spa)**

DRUG THERAPY

Intravenous azithromycin. Garey KW, et al. **Ann Pharmacother** 1999 Feb;33(2):218–28 (60 ref.)

Levofloxacin in the treatment of community acquired pneumonia. File TM Jr. **Can Respir J** 1999 Jan–Feb;6 Suppl A:35A–9A (8 ref.)

Nosocomial pneumonia in the ICU--year 2000 and beyond. Bowton DL. **Chest** 1999 Mar;115(3 Suppl):28S–33S (26 ref.)

Overview of resistance in the 1990s. File TM Jr. **Chest** 1999 Mar;115(3 Suppl):3S–8S (32 ref.)

New intervention strategies for reducing antibiotic resistance. Yates RR. **Chest** 1999 Mar;115(3 Suppl):24S–27S (21 ref.)

Outpatient parenteral antibiotic therapy in the management of community-acquired lower respiratory infections. Brown RB. **Infect Dis Clin North Am** 1998 Dec; 12(4):921–33, vii (53 ref.)

Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods. Low DE. **Infect Dis Clin North Am** 1998 Sep;12(3):613–30, viii (124 ref.)

A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Finch RG. **Int J Antimicrob Agents** 1999 Jun;12(1):5–17 (84 ref.)

[First seminar on the improvement of pediatric pneumonia. Conclusions and perspectives] Dutau G. **Arch Pediatr** 1998; 5 Suppl 1:67s–69s (10 ref.) **(Fre)**

[Empirical antibiotic therapy for nosocomial pneumonia acquired in assisted ventilation] Charbonneau P. **Presse Med** 1998 Sep 12;27(26):1362–4 (5 ref.) **(Fre)**

[What is reliable in antibiotic therapy of inflammatory bronchopulmonary diseases?] Koehler U, et al. **Internist (Berl)** 1998 Dec;39(12):1264–72 (28 ref.) **(Ger)**

[Recommendations for therapy of community-acquired pneumonia. German Society of Pneumology] Schaberg T, et al. **Pneumologie** 1998 Aug;52(8):450–62 (109 ref.) **(Ger)**

[Trends in the treatment of pneumonia] Grassi V, et al. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):373–9 (10 ref.) **(Ita)**

[Diagnosis and treatment of pneumonia] Sil'vestrov VP. **Ter Arkh** 1998;70(9):45–9 (11 ref.) **(Rus)**

[The place of the new quinolones in the guidelines on the treatment of community-acquired pneumonia] Dorca J. **Arch Bronconeumol** 1999 May;35 Suppl 3:77–80 (23 ref.) **(Spa)**

[Initial empirical antibiotic treatment of community-acquired pneumonia] Frias J, et al. **Rev Esp Quimioter** 1998 Sep; 11(3):255–61 (12 ref.) **(Spa)**

ENZYMOLOGY

The protease-antiprotease battle in the cystic fibrosis lung. Balfour-Lynn IM. **J R Soc Med** 1999;92 Suppl 37:23–30 (65 ref.)

EPIDEMIOLOGY

Pyogenic lung infections. Mwandumba HC, et al. **Curr Opin Pulm Med** 1999 May;5(3):151–6 (71 ref.)

Health care quality improvement in Rhode Island: community acquired pneumonia. Jagminas L, et al. **Med Health R I** 1998 Dec;81(12):412–4 (19 ref.)

[Nosocomial pneumonia: epidemiology, risk factors, and prognosis] Rodríguez de Castro F, et al.

Arch Bronconeumol 1998 Nov;34 Suppl 2:25–30 (50 ref.) **(Spa)**

[Pneumonia in the elderly] Zalacain R, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:63–7 (41 ref.) **(Spa)**

ETIOLOGY

Staphylococcus aureus infections in trauma patients [editorial; comment] Sheagren JN. **Crit Care Med** 1999 Apr; 27(4):692–3 (8 ref.) Comment on: Crit Care Med 1999 Apr;27(4):798–801.

The effects of dental disease on systemic disease. DeBowes LJ. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1057–62 (16 ref.)

[Miliary pneumonia after the intravesical BCG therapy of a superficial urothelial carcinoma of the bladder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Aug 27; 124(34–35):993–7 (21 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Role of leukotrienes in antimicrobial host defense of the lung. Peters-Golden M, et al. **Clin Rev Allergy Immunol** 1999 Spring–Summer;17(1–2):261–9 (34 ref.)

Role of leukotrienes in antimicrobial defense of the lung. Peters-Golden M, et al. **J Lab Clin Med** 1998 Oct; 132(4):251–7 (42 ref.)

Bacterial pneumonia in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1998 Oct;13(4):261–70 (81 ref.)

The role of cytokines in bacterial pneumonia: an inflammatory balancing act. Moore TA, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):297–305 (81 ref.)

The lung in the immunocompromised patient. Infectious complications Part 1. Baughman RP. **Respiration** 1999; 66(2):95–109 (179 ref.)

MICROBIOLOGY

Role of 'atypical' pneumonia pathogens in respiratory tract infections. Tan JS. **Can Respir J** 1999 Jan–Feb;6 Suppl A:15A–9A (32 ref.)

Role of leukotrienes in antimicrobial host defense of the lung. Peters-Golden M, et al. **Clin Rev Allergy Immunol** 1999 Spring–Summer;17(1–2):261–9 (34 ref.)

Corynebacterium pseudodiphtheriticum: an easily missed respiratory pathogen in HIV-infected patients. Gutiérrez-Rodero F, et al. **Diagn Microbiol Infect Dis** 1999 Apr;33(4):209–16 (36 ref.)

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. File TM Jr, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):569–92, vii (127 ref.)

Microbial etiology and bacterial resistance. Manresa F, et al. **Semin Respir Infect** 1999 Jun;14(2):115–27 (71 ref.)

Microbiological investigations. Salo P, et al. **Semin Respir Infect** 1999 Jun;14(2):128–34 (57 ref.)

[Current microbiologic problems. Pulmonary infection by Streptococcus pneumoniae. Current physiopathological aspects] Bédos JP, et al. **Presse Med** 1999 Feb 27; 28(8):442–9 (84 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Mortality as an outcome in hospital-acquired pneumonia. Rello J, et al. **Infect Control Hosp Epidemiol** 1998 Oct; 19(10):795–7 (24 ref.)

PATHOLOGY

The role of cytokines in bacterial pneumonia: an inflammatory balancing act. Moore TA, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):297–305 (81 ref.)

PHYSIOPATHOLOGY

[Virus bacteria interactions in acute viral pneumonia in infancy: clinical and therapeutic consequences] Brouard J, et al. **Arch Pediatr** 1998;5 Suppl 1:22s–25s (16 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

A randomised trial of a Haemophilus influenzae type b conjugate vaccine in a developing country for the prevention of pneumonia—ethical considerations [comment] Mulholland K, et al. **Int J Tuberc Lung Dis** 1999 Sep;3(9):749–55 (22 ref.) Comment on: Int J Tuberc Lung Dis 1999 Sep;3(9):745–6.

RADIOGRAPHY

Radiologic findings: pulmonary infections after bone marrow transplantation. Choi YH, et al. **J Thorac Imaging** 1999 Jul;14(3):201–6 (9 ref.)

Bacterial pneumonia in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1998 Oct;13(4):261–70 (81 ref.)

THERAPY

Emergency department management of pneumonia. Talan DA, et al. **Can Respir J** 1999 Jan–Feb;6 Suppl A:10A–4A (35 ref.)

Health care quality improvement in Rhode Island: community acquired pneumonia. Jagminas L, et al. **Med Health R I** 1998 Dec;81(12):412–4 (19 ref.)

Managing community-acquired pneumonia. Factors to consider in outpatient care. Farber MO. **Postgrad Med** 1999 Apr;105(4):106–14 (51 ref.)

Severe pneumonia. When and why to hospitalize. Kohler RB. **Postgrad Med** 1999 Apr;105(4):117–24 (19 ref.)

[Ventilator-associated pneumonia; controversies with respect to diagnosis, pathogenesis, therapy and prevention] Bonten MJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):726–30 (24 ref.) (Eng. Abstr.) **(Dut)**

[New spectra of resistance of the main bacteria of the respiratory tract] Mariani-Kurkdjian P, et al. **Arch Pediatr** 1998;5 Suppl 1:14s–17s (12 ref.) (Eng. Abstr.) **(Fre)**

[Non-glucose carbohydrates in the parenteral nutrition of patients with systemic inflammatory response syndrome] López Martínez J, et al. **Nutr Hosp** 1999 Mar–Apr; 14(2):71–80 (35 ref.) (Eng. Abstr.) **(Spa)**

PNEUMONIA, EOSINOPHILIC see **PULMONARY EOSINOPHILIA**

PNEUMONIA, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONIA, INTERSTITIAL PLASMA CELL see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMONIA, LIPID

CHEMICALLY INDUCED

Kerosene-induced severe acute respiratory failure in near drowning: reports on four cases and review of the literature. Segev D, et al. **Crit Care Med** 1999 Aug; 27(8):1437–40 (14 ref.)

[Exogenous lipoid pneumonia induced by inhalation of insecticide] Yokohori N, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):583–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

PNEUMONIA, LOBAR see **PNEUMONIA, PNEUMOCOCCAL**

PNEUMONIA, MYCOPLASMA

[Mycoplasma pneumonia] Saito A. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):241–3 (14 ref.) **(Jpn)**

DIAGNOSIS

Mycoplasma pneumoniae respiratory infection. Cimolai N. **Pediatr Rev** 1998 Oct;19(10):327–31; quiz 32 (6 ref.)

[Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia in children] Iniguez JL. **Arch Pediatr** 1998;5 Suppl 1:18s–21s (24 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Role of 'atypical' pneumonia pathogens in respiratory tract infections. Tan JS. **Can Respir J** 1999 Jan–Feb;6 Suppl A:15A–9A (32 ref.)

'Atypical pneumonia'. Why this term may be better left unsaid. Sarosi GA. **Postgrad Med** 1999 Apr;105(4):131–2, 135–8 (20 ref.)

[Mycoplasma pneumoniae pneumopathy. 10 cases] Lesobre V, et al. **Presse Med** 1999 Jan 16;28(2):59–66 (56 ref.) (Eng. Abstr.) **(Fre)**

[Microbiology of atypical community-acquired pneumonia. Clinical needs and contribution of new antibiotics] García-Rodríguez JA, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:22–30; discussion 47–52 (75 ref.) **(Spa)**

PNEUMONIA, PNEUMOCOCCAL

[Clinical aspects of pneumococcal pneumonia] Léophonte P. **Presse Med** 1998 May;27 Suppl 1:17–20 (44 ref.) **(Fre)**

[Pneumococcal pneumonia] Kuroki M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):343–5 (11 ref.) **(Jpn)**

DRUG THERAPY

Treatment of pneumococcal pneumonia: the case for penicillin G. Bryan CS. **Am J Med** 1999 Jul 26; 107(1A):63S–68S (73 ref.)

ECONOMICS

[Economic evaluations of pneumococcal vaccination. A critical analysis] Beutels P. **Presse Med** 1998 May;27 Suppl 1:33–8 (22 ref.) **(Fre)**

EPIDEMIOLOGY

The epidemiology of pneumococcal infection in children in the developing world. Greenwood B. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):777–85 (55 ref.)

Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Butler JC, et al. **Vaccine** 1998 Nov;16(18):1693–7 (56 ref.)

[Severe community-acquired bacterial pneumonia from Streptococcus pneumonia in HIV-infected patients: epidemiology and prognostic features of mortality] Mégarbane B, et al. **Pathol Biol (Paris)** 1999 May; 47(5):422–9 (63 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pneumococcal pneumonia in alcoholism and HIV infection. Gentry MJ. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):201S–203S (29 ref.)

[Where are we with purpura fulminans? (editorial)] Huault G. **Arch Pediatr** 1998 Oct;5(10):1061–4 (24 ref.) **(Fre)**

[Economic evaluations of pneumococcal vaccination. A critical analysis] Beutels P. **Presse Med** 1998 May;27 Suppl 1:33–8 (22 ref.) **(Fre)**

PATHOLOGY

Necrotizing pneumococcal pneumonia in childhood. McCarthy VP, et al. **Pediatr Pulmonol** 1999 Sep; 28(3):217–21 (19 ref.)

PREVENTION & CONTROL

Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Briles DE, et al. **Clin Microbiol Rev** 1998 Oct; 11(4):645–57 (147 ref.)

Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Nguyen-Van-Tam JS, et al. **Semin Respir Infect** 1999 Jun;14(2):184–95 (116 ref.)

Pneumococcal disease in sub-Saharan Africa: could currently available vaccines avert a crisis? Gordon SB, et al. **Trop Doct** 1999 Jan;29(1):5–7 (20 ref.)

[The elderly should be vaccinated against pneumococci] Ortqvist A, et al. **Lakartidningen** 1999 Mar 17;96(11):1305–8 (35 ref.) (Eng. Abstr.) **(Swe)**

PNEUMONIA, PNEUMOCYSTIS CARINII

Animal models of pneumocystosis. Dei-Cas E, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):163–8 (36 ref.)

[Pneumocystis carinii pneumonia] Ajisawa A. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):409–11 (5 ref.) **(Jpn)**

[Pneumocystis carinii pneumonia in AIDS. New concepts for an old problem] Bottaro E. **Medicina (B Aires)** 1999; 59(2):187–94 (99 ref.) (Eng. Abstr.) **(Spa)**

[Pneumocystis carinii is still a dangerous opportunist. The infection is continuously a threat to immunocompromised patients] Olsson M, et al. **Lakartidningen** 1999 Jan 27; 96(4):328–31 (60 ref.) (Eng. Abstr.) **(Swe)**

CHEMICALLY INDUCED

[Pneumocystis carinii pneumonia in an immunocompetent patient after paraquat spraying (letter)] Lillo A, et al. **An Med Interna** 1999 Jul;16(7):381 (9 ref.) **(Spa)**

COMPLICATIONS

Two cases of idiopathic CD4+ T-lymphocytopenia in elderly patients. Matsuyama W, et al. **Intern Med** 1998 Oct; 37(10):891–5 (28 ref.)

DIAGNOSIS

Pneumocystis carinii infection in human immunodeficiency virus-positive patients. Looney WJ, et al. **Br J Biomed Sci** 1999;56(1):39–48 (86 ref.)

Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Thomas CF Jr, et al. **Semin Respir Infect** 1998 Dec;13(4):289–95 (34 ref.)

[Pneumocystis carinii pneumonia and HIV infection: diagnosis and treatment] González-García J, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:36–44 (60 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Hyperkalemic renal tubular acidosis induced by trimethoprim/sulfamethoxazole in an AIDS patient. Sheehan MT, et al. **Clin Nephrol** 1998 Sep;50(3):188–93 (39 ref.)

Evaluation of drug efficacy by using animal models or in vitro systems. Brun Pascaud M, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1–2):173–9 (55 ref.)

Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. Séguy N, et al. **FEMS Immunol Med Microbiol** 1998 Sep; 22(1–2):145–9 (27 ref.)

Treatment and prophylaxis of Pneumocystis carinii pneumonia. Castro M. **Semin Respir Infect** 1998 Dec; 13(4):296–303 (65 ref.)

[Pneumocystis carinii pneumonia and HIV infection: diagnosis and treatment] González-García J, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:36–44 (60 ref.) (Eng. Abstr.) **(Spa)**

PNEUMONIA, PNEUMOCYSTIS CARINII

EPIDEMIOLOGY

Pneumocystis: the 'carrier state': epidemiology and transmission of human pneumocystosis. Latouche S, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):81-6 (59 ref.)

Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii. Hughes WT. **Semin Respir Infect** 1998 Dec;13(4):283-8 (33 ref.)

IMMUNOLOGY

Alcohol and host defense against pulmonary infection with Pneumocystis carinii. Shellito JE. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):208S-211S (40 ref.)

Immunological features of Pneumocystis carinii infection in humans. Walzer PD. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):149-55 (138 ref.)

Response to Pneumocystis infection in an immunocompetent host. Rajagopalan-Levasseur P, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):107-21 (71 ref.)

Pneumocystis carinii pneumonia in a child receiving ACTH for infantile spasms. Dunagan DP, et al. **Pediatr Pulmonol** 1999 Apr;27(4):286-9 (17 ref.)

Immune responses to naturally acquired Pneumocystis carinii in gene disruption mutant mice. Hanano R, et al. **Res Immunol** 1998 May-Jun;149(4-5):429-35; discussion 514 (40 ref.)

Lymphocytes in host defense against Pneumocystis carinii. Beck JM, et al. **Semin Respir Infect** 1998 Dec;13(4):330-8 (62 ref.)

Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Limper AH. **Semin Respir Infect** 1998 Dec;13(4):339-47 (77 ref.)

Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Thomas CF Jr, et al. **Semin Respir Infect** 1998 Dec;13(4):289-95 (34 ref.)

MICROBIOLOGY

The Pneumocystis carinii major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. Benfield TL, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):129-34 (48 ref.)

Detection of Pneumocystis carinii DNA in blood specimens from human immunodeficiency virus-infected patients by nested PCR. Rabodonirina M, et al. **J Clin Microbiol** 1999 Jan;37(1):127-31 (23 ref.)

Genetics, metabolism and host specificity of Pneumocystis carinii. Wakefield AE, et al. **Med Mycol** 1998;36 Suppl 1:183-93 (90 ref.)

Pneumocystis carinii: the art and science of survival in the hostile environment of the alveolar spaces. Martin WJ 2nd. **Semin Respir Infect** 1998 Dec;13(4):348-52 (17 ref.)

PATHOLOGY

[Pneumonia caused by granulomatous Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome] Tanaka Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug; 36(8):690-5 (13 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Clinical aspects of Pneumocystis carinii pneumonia in HIV-infected patients: 1997. Miller R. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):103-5 (13 ref.)

Pneumocystosis pathophysiology. Prévost MC, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):123-8 (48 ref.)

Animal pneumocystosis: a model for man. Ceré N, et al. **Vet Res** 1999 Jan-Feb;30(1):1-26 (209 ref.)

PREVENTION & CONTROL

Treatment and prophylaxis of Pneumocystis carinii pneumonia. Castro M. **Semin Respir Infect** 1998 Dec; 13(4):296-303 (65 ref.)

RADIOGRAPHY

The changing face of Pneumocystis carinii pneumonia in AIDS patients. Boiselle PM, et al. **AJR Am J Roentgenol** 1999 May;172(5):1301-9 (48 ref.)

Viral and Pneumocystis carinii infections of the lung in the immunocompromised host. McGuinness G, et al. **J Thorac Imaging** 1999 Jan;14(1):25-36 (46 ref.)

THERAPY

Modalities of ventilation in patients with human immunodeficiency virus infection. Gachot B, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):540-2 (28 ref.)

TRANSMISSION

Pneumocystis: the 'carrier state': epidemiology and transmission of human pneumocystosis. Latouche S, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):81-6 (59 ref.)

Animal pneumocystosis: a model for man. Ceré N, et al. **Vet Res** 1999 Jan-Feb;30(1):1-26 (209 ref.)

PNEUMONIA, PRIMARY ATYPICAL see **PNEUMONIA, MYCOPLASMA**

PNEUMONIA, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONIA, STAPHYLOCOCCAL

[Staphylococcal pneumonia] Yamamoto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):346-9 (13 ref.) **(Jpn)**

PREVENTION & CONTROL

MRSA in cystic fibrosis. London, 16 June 1997. **J Hosp Infect** 1998 Nov;40(3):179-91 (17 ref.)

PNEUMONIA, VIRAL

[Adenoviral pneumonia] Akizawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):93-5 (9 ref.) **(Jpn)**

[Varicella pneumonia] Higashiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):96-8 (11 ref.) **(Jpn)**

[Rhinovirus pneumonia] Kasai T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):90-2 (14 ref.) **(Jpn)**

[Measles pneumonia] Seki M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):99-101 (15 ref.) **(Jpn)**

[Cytomegalovirus pneumonia] Suzuki H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):87-9 (12 ref.) **(Jpn)**

[Influenza virus pneumonia] Yamada M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):83-6 (15 ref.) **(Jpn)**

COMPLICATIONS

[Virus bacteria interactions in acute viral pneumonia in infancy: clinical and therapeutic consequences] Brouard J, et al. **Arch Pediatr** 1998;5 Suppl 1:22s-25s (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Chickenpox pneumonia: case report and literature review. Nee PA, et al. **J Accid Emerg Med** 1999 Mar;16(2):147-50 (28 ref.)

[Neonatal pneumonia] Albertini M. **Arch Pediatr** 1998;5 Suppl 1:57s-61s (11 ref.) (Eng. Abstr.) **(Fre)**

[Investigations for etiologic causes in community-acquired pneumonia in children (besides imagery) Le Roux P. **Arch Pediatr** 1998;5 Suppl 1:28s-32s (26 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness? Dominguez KD, et al. **Ann Pharmacother** 1999 Jun;33(6):739-41 (19 ref.)

EPIDEMIOLOGY

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. Han LL, et al. **J Infect Dis** 1999 Jan;179(1):25-30 (39 ref.)

ETIOLOGY

Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: case report and review of the literature. Breathnach O, et al. **Ann Oncol** 1999 Apr;10(4):461-5 (28 ref.)

IMMUNOLOGY

The lung in the immunocompromised patient. Infectious complications Part 1. Baughman RP. **Respiration** 1999; 66(2):95-109 (179 ref.)

PHYSIOPATHOLOGY

[Virus bacteria interactions in acute viral pneumonia in infancy: clinical and therapeutic consequences] Brouard J, et al. **Arch Pediatr** 1998;5 Suppl 1:22s-25s (16 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Nguyen-Van-Tam JS, et al. **Semin Respir Infect** 1999 Jun;14(2):184-95 (116 ref.)

RADIOGRAPHY

Radiologic findings: pulmonary infections after bone marrow transplantation. Choi YH, et al. **J Thorac Imaging** 1999 Jul;14(3):201-6 (9 ref.)

Viral and Pneumocystis carinii infections of the lung in the immunocompromised host. McGuinness G, et al. **J Thorac Imaging** 1999 Jan;14(1):25-36 (46 ref.)

THERAPY

Chickenpox pneumonia: case report and literature review. Nee PA, et al. **J Accid Emerg Med** 1999 Mar;16(2):147-50 (28 ref.)

VIROLOGY

[Case of varicella-zoster pneumonia with bronchioalveolar lavage confirmed by the detection of VZV DNA in the bronchial washing by the polymerase chain reaction] Saito S, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):346-50 (12 ref.) (Eng. Abstr.) **(Jpn)**

PNEUMONIC PLAGUE see **PLAGUE**

PNEUMONITIS see **PNEUMONIA**

PNEUMONITIS, HYPERSENSITIVITY see **ALVEOLITIS, EXTRINSIC ALLERGIC**

PNEUMONITIS, HYPERSENSITIVITY, AVIAN see **BIRD FANCIER'S LUNG**

PNEUMONITIS, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONITIS, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PNEUMOPERICARDIUM

ETIOLOGY

Pneumopericardium and pneumoperitoneum after penetrating chest injury. Rashid MA, et al. **Eur J Surg** 1999 Mar;165(3):278-9 (8 ref.)

PNEUMOPERITONEUM

[Usefulness of the trans-umbilical incision in laparoscopic surgery] Weber Sánchez A, et al. **Ginecol Obstet Mex** 1998 Dec;66:503-6 (25 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Laparoscopic surgery during the second trimester of pregnancy: indications, technique, and fetal repercussions. Report of nine cases and review the literature] Batallan A, et al. **Ann Chir** 1999;53(4):285-90 (36 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pneumopericardium and pneumoperitoneum after penetrating chest injury. Rashid MA, et al. **Eur J Surg** 1999 Mar;165(3):278-9 (8 ref.)

Generalized peritonitis with pneumoperitoneum caused by the spontaneous perforation of pyometra without malignancy: report of a case. Inui A, et al. **Surg Today** 1999;29(9):935-8 (15 ref.)

[Pneumoperitoneum with systemic sclerosis] Nakajima A, et al. **Ryumachi** 1998 Dec;38(6):825-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Percutaneous drainage of emphysematous cholecystitis associated with pneumoperitoneum. Zeebregts CJ, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):771-4 (16 ref.)

PNEUMOPERITONEUM, ARTIFICIAL

Pneumoperitoneum in the cancer patient: advantages and pitfalls. Greene FL. **Semin Surg Oncol** 1998 Oct-Nov; 15(3):151-4 (24 ref.)

CO(2) pneumoperitoneum: what we know and what we need to know. Holthausen UH, et al. **World J Surg** 1999 Aug; 23(8):794-800 (40 ref.)

ADVERSE EFFECTS

Pneumoperitoneum--physiology and nursing interventions [published erratum appears in AORN J 1999 Jan;69(1):21] Steuer K. **AORN J** 1998 Sep;68(3):412-25; quiz 426, 429-32 (54 ref.)

The pneumoperitoneum and its role in tumor seeding. Reymond MA, et al. **Dig Surg** 1998;15(2):105-9 (48 ref.)

[Cardiorespiratory effects of laparoscopic surgery] Bazin JE. **Presse Med** 1998 Mar 7;27(9):388-93 (60 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Pneumoperitoneum--physiology and nursing interventions [published erratum appears in AORN J 1999 Jan;69(1):21] Steuer K. **AORN J** 1998 Sep;68(3):412-25; quiz 426, 429-32 (54 ref.)

PNEUMORETROPERITONEUM see **RETROPNEUMOPERITONEUM**

PNEUMOTHORAX

COMPLICATIONS

Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and

review of the literature. Jansen TL, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):733-5 (21 ref.)
Left postpneumonectomy syndrome successfully treated with endobronchial stent. Nakamura Y, et al. **Intern Med** 1998 Oct;37(10):880-3 (12 ref.)

DIAGNOSIS

Tension pneumothorax. Barton ED. **Curr Opin Pulm Med** 1999 Jul;5(4):269-74 (24 ref.)
[Recurrent spontaneous pneumothorax as the earliest indication of the pulmonary metastasis of a synovial sarcoma?] Bode F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):318-20 (10 ref.) **(Ger)**

EPIDEMIOLOGY

Pleural complications in the intensive care unit. Strange C. **Clin Chest Med** 1999 Jun;20(2):317-27 (84 ref.)

ETIOLOGY

Tension pneumothorax secondary to grass head aspiration. Newson TP, et al. **Pediatr Emerg Care** 1998 Aug; 14(4):287-9 (12 ref.)
[A case of intestinal endometriosis with bilateral pneumothorax] Kirii H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):38-44 (17 ref.) **(Jpn)**

SURGERY

Tension pneumothorax. Barton ED. **Curr Opin Pulm Med** 1999 Jul;5(4):269-74 (24 ref.)

POACEAE see **GRASSES**

POCKET, PERIODONTAL see **PERIODONTAL POCKET**

PODIATRY

see related
FOOT DISEASES

Neurologic differential diagnosis in podiatry. Khella SL. **Clin Podiatr Med Surg** 1999 Jan;16(1):49-66, vi (34 ref.)

INSTRUMENTATION

Sensory examination. Comparison of instruments. Song J, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):29-48, v-vi (73 ref.)
Pneumatic ankle tourniquets: physiological factors related to minimal arterial occlusion pressure. Massey KA, et al. **J Foot Ankle Surg** 1999 Jul-Aug;38(4):256-63; discussion 306-7 (42 ref.)

METHODS

The neurologic examination of the podiatric patient. Spadone SJ. **Clin Podiatr Med Surg** 1999 Jan;16(1):1-17, v (10 ref.)
Preoperative assessment of the transplant patient. Morgan CB, et al. **J Foot Ankle Surg** 1998 Jul-Aug;37(4):350-4 (30 ref.)

STANDARDS

Hammer toe syndrome. American College of Foot and Ankle Surgeons. **J Foot Ankle Surg** 1999 Mar-Apr;38(2):166-78 (86 ref.)

POEMS SYNDROME

[Recent advance in neuroimmunology] Arimura K, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):993-6 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Crow-Fukase syndrome] Hitoshi S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):496-9 (14 ref.) **(Jpn)**

DIAGNOSIS

[Bilateral optic disk edema in polyneuropathy, organomegaly, endocrinopathy, monoclonal proteins and skin changes (POEMS syndrome)] Barry JC, et al. **Klin Monatsbl Augenheilkd** 1999 Jul;215(1):59-63 (24 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Papillary edema and the POEMS syndrome] Gatinel D, et al. **J Fr Ophtalmol** 1998 Feb;21(2):133-41 (39 ref.) (Eng. Abstr.) **(Fre)**

POETRY

Writing poetry: a way of knowing nursing. Holmes V, et al. **J Adv Nurs** 1998 Dec;28(6):1191-4 (11 ref.)

POIKILODERMA CONGENITALE

PATHOLOGY

Congenital poikiloderma with unusual hypopigmentation and acral blistering at birth. Ogunbiyi AO, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):54-8 (11 ref.)

POINT MUTATION

see related
MUTATION, MISSENSE

Rhodopsin mutations as the cause of retinal degeneration. Classification of degeneration phenotypes in the model system Drosophila melanogaster. Bentrop J. **Acta Anat (Basel)** 1998;162(2-3):85-94 (50 ref.)
Factor VLeiden: death and DNA [editorial; comment] Florell SR, et al. **Am J Clin Pathol** 1999 Mar;111(3):302-3 (8 ref.) Comment on: Am J Clin Pathol 1999 Mar;111(3):413-7.
Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role. Göthert M, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:26-30 (20 ref.)
Copper, zinc superoxide dismutase (SOD1) and its role in neuronal function and disease with particular relevance to motor neurone disease/amyotrophic lateral sclerosis. de Belleroche J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):476-80 (36 ref.)
Congenital deficiencies and abnormalities of prothrombin. Girolami A, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):557-69 (84 ref.)
Clinical implications of G-CSF receptor mutations. Tidow N, et al. **Crit Rev Oncol Hematol** 1998 Jun;28(1):1-6 (23 ref.)
Mucinous cystadenocarcinoma of the spleen presenting a point mutation of the Kirsten-ras oncogene at codon 12. Hirota M, et al. **Dig Dis Sci** 1999 Apr;44(4):768-74 (16 ref.)
Transition mutations at CpG dinucleotides are the most frequent in vivo spontaneous single-based substitution mutation in the human HPRT gene. O'Neill JP, et al. **Environ Mol Mutagen** 1998;32(2):188-91 (15 ref.)
A patient homozygous for mutation 20210A in the prothrombin gene with venous thrombosis and transient ischemic attacks of thrombotic origin [letter] González Ordóñez AJ, et al. **Haematologica** 1998 Nov;83(11):1050-1 (9 ref.)
Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Kimura W, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):532-9 (83 ref.)
Arginine in the beginning of the 1A rod domain of the keratin 10 gene is the hot spot for the mutation in epidermolytic hyperkeratosis. Yang JM, et al. **J Dermatol Sci** 1999 Feb; 19(2):126-33 (35 ref.)
A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. Bhatti MT, et al. **J Neuroophthalmol** 1999 Mar;19(1):28-33 (27 ref.)
Somatic hypermutation and B-cell malignancies. Spencer JO, et al. **J Pathol** 1999 Jan;187(2):158-63 (54 ref.)
Alterations in gonadal steroidogenesis in individuals expressing a common genetic variant of luteinizing hormone. Huhtaniemi IT, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):281-5 (26 ref.)
Update on hereditary hemochromatosis and the HFE gene. Brandhagen DJ, et al. **Mayo Clin Proc** 1999 Sep; 74(9):917-21 (25 ref.)
Transthyretin Tyr77 familial amyloid polyneuropathy: a clinicopathological study of a large kindred. Blanco-Jerez CR, et al. **Muscle Nerve** 1998 Nov;21(11):1478-85 (25 ref.)
Principal causes of hot spots for cytosine to thymine mutations at sites of cytosine methylation in growing cells. A model, its experimental support and implications. Lutsenko E, et al. **Mutat Res** 1999 Jul;437(1):11-20 (66 ref.)
CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others [editorial; comment] Tournier-Lasserve E. **Neurology** 1999 Jul 13;53(1):3-4 (14 ref.) Comment on: Neurology 1999 Jul 13;53(1):26-33. Comment on: Neurology 1999 Jul 13;53(1):34-7. Comment on: Neurology 1999 Jul 13;53(1):38-43.
Congenital hypomyelinating neuropathy: two patients with long-term follow-up. Phillips JP, et al. **Pediatr Neurol** 1999 Mar;20(3):226-32 (28 ref.)
Neurodegenerative Alzheimer-like pathology in PDAPP 717V-->F transgenic mice. Chen KS, et al. **Prog Brain Res** 1998;117:327-34 (37 ref.)
Gene specific therapy for cardiac disease: the case of long QT syndrome. Priori SG. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III27-38 (41 ref.)
Epidemiology of factor V Leiden: clinical implications. De Stefano V, et al. **Semin Thromb Hemost** 1998;24(4):367-79 (140 ref.)
Factor V:Q506 mutation-resistance to activated protein C (APC): clinical implications with respect to family screening. Middeldorp S, et al. **Semin Thromb Hemost** 1998; 24(4):363-6 (30 ref.)
Molecular biology and pathophysiology of APC resistance: current insights and clinical implications. Rosing J, et al. **Semin Thromb Hemost** 1998;24(4):329-35 (45 ref.)
Hereditary pancreatitis. Gene defects and their implications. Gates LK Jr, et al. **Surg Clin North Am** 1999 Aug; 79(4):711-22, vii-viii (22 ref.)
[Function of p16 gene and correlation of p16 with human cancer] Sun M, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):265-7 (10 ref.) **(Chi)**
[Presenilins as a marker of Alzheimer's disease] Scheper W, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1247-52 (40 ref.) (Eng. Abstr.) **(Dut)**
[The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease] Spiering W, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1445-50 (39 ref.) (Eng. Abstr.) **(Dut)**
[p53 and hematologic malignancies] Preudhomme C, et al. **Pathol Biol (Paris)** 1997 Dec;45(10):898-908 (128 ref.) (Eng. Abstr.) **(Fre)**
[A familial case of proliferative diabetic retinopathy associated with a mutation in the mitochondrial gene] Kuze M, et al. **Nippon Ganka Gakkai Zasshi** 1998 Nov; 102(11):739-45 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of Helicobacter pylori 23S rRNA gene mutation associated with clarithromycin resistance and its clinical applicability] Maeda S, et al. **Nippon Rinsho** 1999 Jan; 57(1):87-92 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Constitutively activating mutations in the luteinizing hormone receptor gene in cases of male-limited precocious puberty] Yano K, et al. **Nippon Rinsho** 1998 Jul; 56(7):1843-7 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Comparison of clinical pictures of mitochondrial encephalomyopathy with tRNA(Leu(UUR)) mutation in 3243 with that in 3254] Mitsuoka T, et al. **No To Shinkei** 1998 Dec;50(12):1089-92 (8 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

From gels to chips: "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms. Syvänen AC. **Hum Mutat** 1999;13(1):1-10 (75 ref.)
Genetic models for non insulin dependent diabetes mellitus in rodents. Kim JH, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):325-45 (62 ref.)
An introduction to molecular biology: gene structure, expression, and mutation. Achan V. **Pediatr Cardiol** 1999 Mar-Apr;20(2):94-6 (4 ref.)
[Molecular-genetic characteristics of mutations in dystrophin gene and clinical symptoms in Duchenne muscular dystrophy] Lisiecka D, et al. **Neurol Neurochir Pol** 1998 Sep-Oct;32(5):1069-79 (20 ref.) (Eng. Abstr.) **(Pol)**
[Clinical and genetic implications of dynamic mutations in neuropediatric practice] Benitez J. **Rev Neurol** 1999 Jan 1-15;28(1):60-3 (8 ref.) (Eng. Abstr.) **(Spa)**
[Studies of pathogenicity and characterization of molecular phenotype caused by mutations in human mitochondrial DNA] Bornstein B, et al. **Rev Neurol** 1998 Apr;26 Suppl 1:S36-43 (55 ref.) (Eng. Abstr.) **(Spa)**

POINT-OF-CARE SYSTEMS

Progress in point-of-care laboratory testing for assessing platelet function. Berkowitz SD, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S51-65 (40 ref.)
Emergency medicine resident education: making a case for training residents to perform and interpret bedside sonographic examinations. Sankoff J, et al. **Ann Emerg Med** 1999 Jul;34(1):105-8 (28 ref.)
Point-of-care testing: the views of the working group of the Dutch Association of Clinical Chemistry. Janssen HW, et al. **Clin Chem Lab Med** 1999 Jun;37(6):675-80 (18 ref.)
Cardiac markers: point of care testing. Hudson MP, et al. **Clin Chim Acta** 1999 Jun 30;284(2):223-37 (45 ref.)
Point of care testing informatics. The critical care-hospital interface. Halpern NA, et al. **Crit Care Clin** 1999 Jul; 15(3):577-91, vi-vii (34 ref.)
Computerized protocols and bedside decision support. Morris AH. **Crit Care Clin** 1999 Jul;15(3):523-45, vi (90 ref.)

ORGANIZATION & ADMINISTRATION

Point-of-care laboratory testing in critical care. Harvey MA. **Am J Crit Care** 1999 Mar;8(2):72-83; quiz 84-5 (81 ref.)
Clinical documentation: the handheld computer as a survival tool. Wofford MM, et al. **MD Comput** 1998 Nov-Dec; 15(6):352-4, 356, 358 (30 ref.)

STANDARDS

[Chemical tests during a real time physician-patient interaction--the concept and practical problems resulting from its realization] Naskalski JW. **Przegl Lek** 1998; 55(7-8):388-92 (23 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

Science, medicine, and the future. Near patient microbiological tests. Borriello SP. **BMJ** 1999 Jul 31; 319(7205):298-301 (12 ref.)
[Point-of-care-testing--the intensive care laboratory] Müller MM, et al. **Anaesthesist** 1999 Jan;48(1):3-8 (14 ref.) (Eng. Abstr.) **(Ger)**

POINT OF CARE TECHNOLOGY see **POINT-OF-CARE SYSTEMS**

POINT OF SERVICE REGULATIONS see **PATIENT FREEDOM OF CHOICE LAWS**

POISON CONTROL CENTERS

Chlorpyrifos: a ten-year US poison center exposure experience. Kingston RL, et al. **Vet Hum Toxicol** 1999 Apr; 41(2):87-92 (16 ref.)

POISONING

see related
ANTIDOTES

Delayed toxidromes. Bosse GM, et al. **J Emerg Med** 1999 Jul-Aug;17(4):679-90 (121 ref.)

COMPLICATIONS

Acute hepatitis due to poisoning. Geubel AP, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):468-9 (7 ref.)

DIAGNOSIS

Recovery from prolonged metabolic acidosis due to accidental ethylene glycol poisoning. Wisse B, et al. **Am J Kidney Dis** 1999 Feb;33(2):E4 (79 ref.)

Heavy metal poisoning and its laboratory investigation. Baldwin DR, et al. **Ann Clin Biochem** 1999 May;36 (Pt 3):267-300 (179 ref.)

Environmental poisoning: presentation and management. Moore MR, et al. **Ther Drug Monit** 1998 Oct;20(5):502-9 (41 ref.)

Laboratory support for the poisoned patient. Watson ID. **Ther Drug Monit** 1998 Oct;20(5):490-7 (27 ref.)

DRUG THERAPY

Activated charcoal supercedes ipecac as gastric decontaminant. Fountain JS, et al. **N Z Med J** 1998 Oct 23;111(1076):402-4 (29 ref.)

[Specific drug therapy of acute poisoning] Ostapenko IuN. **Anesteziol Reanimatol** 1998 Nov-Dec;(6):68-71 (5 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Acute poisoning from pesticides: human and economic costs] Garcia JE. **Rev Panam Salud Publica** 1998 Dec;4(6):383-7 (65 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Ponderosa pine and broom snakeweed: poisonous plants that affect livestock. Gardner DR, et al. **J Nat Toxins** 1999 Feb;8(1):27-34 (53 ref.)

Childhood poisoning: the scope for prevention. Chan TY. **Vet Hum Toxicol** 1998 Dec;40(6):361-3 (27 ref.)

THERAPY

Gastrointestinal decontamination in acute toxic ingestions. Lheureux P, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec; 61(4):461-7 (69 ref.)

The toxicology of silver nitrate. Humphreys SD, et al. **Adverse Drug React Toxicol Rev** 1998 Jun-Sep; 17(2-3):115-43 (91 ref.)

Gastric decontamination--a view for the millennium. Bateman DN. **J Accid Emerg Med** 1999 Mar;16(2):84-6 (9 ref.)

Environmental poisoning: presentation and management. Moore MR, et al. **Ther Drug Monit** 1998 Oct;20(5):502-9 (41 ref.)

Practical management of the poisoned patient. Proudfoot A. **Ther Drug Monit** 1998 Oct;20(5):498-501 (0 ref.)

[Accidental ingestion of cigarettes by children] Hulzebos CV, et al. **Ned Tijdschr Geneeskd** 1998 Nov 21;142(47):2569-71 (14 ref.) (Eng. Abstr.) **(Dut)**

[Methods of poison elimination--controversies and actual views about their use] Groszek B, et al. **Przegl Lek** 1999; 56(6):442-9 (32 ref.) (Eng. Abstr.) **(Pol)**

[Current principles of detoxification therapy in acute poisoning] Luzhnikov EA. **Anesteziol Reanimatol** 1998 Nov-Dec;(6):4-6 (5 ref.) **(Rus)**

[Use of apheresis procedures in the treatment of patients with hemobiologic disorders] Balint B, et al. **Vojnosanit Pregl** 1999 Jan-Feb;56(1):45-55 (66 ref.) **(Scc)**

VETERINARY

Toxic and metabolic causes of seizures. O'Brien D. **Clin Tech Small Anim Pract** 1998 Aug;13(3):159-66 (53 ref.)

Ponderosa pine and broom snakeweed: poisonous plants that affect livestock. Gardner DR, et al. **J Nat Toxins** 1999 Feb;8(1):27-34 (53 ref.)

The pathogenesis and toxicokinetics of locoweed (Astragalus and Oxytropis spp.) poisoning in livestock. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):35-45 (81 ref.)

An overview of ivermectin toxicosis. Roder JD, et al. **Vet Hum Toxicol** 1998 Dec;40(6):369-70 (8 ref.)

POISONS

Botulinum toxin: potent poison, potent medicine. Simpson LL. **Hosp Pract (Off Ed)** 1999 Apr 15;34(4):87-91; quiz 163 (10 ref.)

ADVERSE EFFECTS

Acute hepatitis due to poisoning. Geubel AP, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):468-9 (7 ref.)

ANALYSIS

Forensic science. Brettell TA, et al. **Anal Chem** 1999 Jun 15;71(12):235R-255R (782 ref.)

BLOOD

Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose. Siff JE, et al. **Ann Emerg Med** 1999 Jan;33(1):73-6 (21 ref.)

POL III see **DNA POLYMERASE III**

POLAR BEARS see **BEARS**

POLAR RECOMBINATION see **GENE CONVERSION**

POLAR REGIONS see **COLD CLIMATE**

POLARITY OF DEVELOPMENT see **BODY PATTERNING**

POLARIZATION, FLUORESCENCE see **FLUORESCENCE POLARIZATION**

POLARIZATION MICROSCOPY see **MICROSCOPY, POLARIZATION**

POLARON see **GENE CONVERSION**

POLICE

Toxicologic evaluation of pepper spray as a possible weapon for the Dutch police force: risk assessment and efficacy. Busker RW, et al. **Am J Forensic Med Pathol** 1998 Dec; 19(4):309-16 (38 ref.)

Suicide and violence risk in law enforcement: practical guidelines for risk assessment, prevention, and intervention. Mohandie K, et al. **Behav Sci Law** 1999;17(3):357-76 (56 ref.)

Police officer attitudes and use of discretion in situations involving the mentally ill. The need to narrow the focus. Patch PC, et al. **Int J Law Psychiatry** 1999 Jan-Feb; 22(1):23-35 (56 ref.)

Factors associated with excited delirium deaths in police custody. Ross DL. **Mod Pathol** 1998 Nov;11(11):1127-37 (47 ref.)

POLICY COMPLIANCE see **GUIDELINE ADHERENCE**

POLICY MAKING

see related
HEALTH POLICY
PUBLIC POLICY

The HIV/AIDS epidemic in eastern Europe: recent patterns and trends and their implications for policy-making [editorial] Dehne KL, et al. **AIDS** 1999 May 7;13(7):741-9 (38 ref.)

Dumpers, rips, and other hazards for the environmental surfer [editorial] Langley J. **Inj Prev** 1999 Jun;5(2):84 (4 ref.)

Evidence-based policy-making in the NHS: exploring the interface between research and the commissioning process. Harries U, et al. **J Public Health Med** 1999 Mar;21(1):29-36 (16 ref.)

Critical review: synthesis and recommendations for research, education, and policy [comment] Kivett VR. **J Women Aging** 1998;10(4):81-90 (17 ref.) Comment on: J Women Aging 1998 ;10(4):7-24. Comment on: J Women Aging 1998 ;10(4):25-39. Comment on: J Women Aging 1998 ;10(4):41-65. Comment on: J Women Aging 1998 ;10(4):67-80.

Contraceptive introduction reconsidered: a new methodology for policy and program development. Simmons R, et al. **J Womens Health** 1999 Mar;8(2):163-73 (12 ref.)

Mortality among people with mental retardation living in the United States: research review and policy application. Hayden MF. **Ment Retard** 1998 Oct;36(5):345-59 (42 ref.)

Occupational hygiene science and its application in occupational health policy, at home and abroad. Vincent JH. **Occup Med (Lond)** 1999 Jan;49(1):27-35 (22 ref.)

Developing a pesticide policy for individuals with multiple chemical sensitivity: considerations for institutions. Brown AE. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):432-7 (13 ref.)

POLIO see **POLIOMYELITIS**

POLIODYSTROPHIA CEREBRI see **CEREBRAL SCLEROSIS, DIFFUSE**

POLIOMYELITIS

see related
POSTPOLIOMYELITIS SYNDROME

[Poliomyelitis and polio-like paralysis] Kurashige T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):111-4 (12 ref.) **(Jpn)**

HISTORY

Milestones in early poliomyelitis research (1840 to 1949). Eggers HJ. **J Virol** 1999 Jun;73(6):4533-5 (29 ref.)

PREVENTION & CONTROL

Poliovirus vaccine options. Zimmerman RK, et al. **Am Fam Physician** 1999 Jan 1;59(1):113-8, 125-6 (17 ref.)

Poliovirus immunizations. What goes around, comes around. Soto NE, et al. **Infect Dis Clin North Am** 1999 Mar; 13(1):265-78, ix (73 ref.)

Poliomyelitis as a paradigm for investment in and success of vaccination programs. Ogra PL. **Pediatr Infect Dis J** 1999 Jan;18(1):10-5 (32 ref.)

Ending polio immunization: when and how are we sure that the needle is out of the haystack? Kimman TG, et al. **Vaccine** 1999 Feb 26;17(7-8):624-7 (22 ref.)

Poliomyelitis eradication. Dowdle WR, et al. **Virus Res** 1999 Aug;62(2):185-92 (27 ref.)

VIROLOGY

Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans. Friedrich F. **Acta Virol** 1998 Jun; 42(3):187-94 (175 ref.)

Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Pelletier I, et al. **Cell Mol Life Sci** 1998 Dec; 54(12):1385-402 (107 ref.)

[Viral infection of the central nervous system: from experimental model to human application] Monteyne P. **Ann Fr Anesth Reanim** 1999 May;18(5):550-3 (23 ref.) (Eng. Abstr.) **(Fre)**

POLIOVIRUS VACCINE

ADMINISTRATION & DOSAGE

Poliovirus vaccine options. Zimmerman RK, et al. **Am Fam Physician** 1999 Jan 1;59(1):113-8, 125-6 (17 ref.)

Poliovirus immunizations. What goes around, comes around. Soto NE, et al. **Infect Dis Clin North Am** 1999 Mar; 13(1):265-78, ix (73 ref.)

Poliomyelitis as a paradigm for investment in and success of vaccination programs. Ogra PL. **Pediatr Infect Dis J** 1999 Jan;18(1):10-5 (32 ref.)

CHEMISTRY

Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Hilleman MR. **Dev Biol Stand** 1998;94:183-90 (16 ref.)

Examination of poliovaccines for the presence of SV40 sequences. Sangar DV, et al. **Dev Biol Stand** 1998;94:221-5 (10 ref.)

Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer--a review of the epidemiological evidence. Strickler HD, et al. **Dev Biol Stand** 1998;94:235-44 (26 ref.)

POLIOVIRUS VACCINE, ORAL

ADMINISTRATION & DOSAGE

Poliovirus immunizations. What goes around, comes around. Soto NE, et al. **Infect Dis Clin North Am** 1999 Mar; 13(1):265-78, ix (73 ref.)

ADVERSE EFFECTS

Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans. Friedrich F. **Acta Virol** 1998 Jun; 42(3):187-94 (175 ref.)

Ending polio immunization: when and how are we sure that the needle is out of the haystack? Kimman TG, et al. **Vaccine** 1999 Feb 26;17(7-8):624-7 (22 ref.)

STANDARDS

Product quality control testing for the oral polio vaccine. Brock B, et al. **Dev Biol Stand** 1998;94:217-9 (1 ref.)

THERAPEUTIC USE

Ending polio immunization: when and how are we sure that the needle is out of the haystack? Kimman TG, et al. **Vaccine** 1999 Feb 26;17(7-8):624-7 (22 ref.)

POLIOVIRUSES

Ending polio immunization: when and how are we sure that the needle is out of the haystack? Kimman TG, et al. **Vaccine** 1999 Feb 26;17(7-8):624-7 (22 ref.)

PHYSIOLOGY

Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Pelletier I, et al. **Cell Mol Life Sci** 1998 Dec; 54(12):1385-402 (107 ref.)

POLIOVIRUSES, HUMAN 1-3

GENETICS

Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans. Friedrich F. **Acta Virol** 1998 Jun; 42(3):187-94 (175 ref.)

Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. Solecki D, et al. **J Mol Recognit** 1998 Winter;11(1-6):2-9 (53 ref.)

GROWTH & DEVELOPMENT

Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans. Friedrich F. **Acta Virol** 1998 Jun; 42(3):187–94 (175 ref.)

PATHOGENICITY

Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. Solecki D, et al. **J Mol Recognit** 1998 Winter;11(1–6):2–9 (53 ref.)

POLIOVIRUSES, MURINE see **THEILER MURINE ENCEPHALOMYELITIS VIRUS**

POLISHES, DENTAL see **DENTIFRICES**

POLITEF see **POLYTETRAFLUOROETHYLENE**

POLITICAL ACTIVITY see **POLITICS**

POLITICS

Economic sanctions as human rights violations: reconciling political and public health imperatives [comment] Marks SP. **Am J Public Health** 1999 Oct;89(10):1509–13 (60 ref.) Comment on: Am J Public Health 1999 Oct;89(10):1499–504.

Normalising the crisis in Africa. Bradbury M. **Disasters** 1998 Dec;22(4):328–38 (21 ref.)

Burma: the political economy of violence. Brown C. **Disasters** 1999 Sep;23(3):234–56 (55 ref.)

Waiting for peace: perspectives from action-oriented research on the humanitarian impasse in the Caucasus. Hansen G, et al. **Disasters** 1999 Sep;23(3):257–70 (0 ref.)

Depolarising the 'broadened' and 'back-to-basics' relief models. Jackson S, et al. **Disasters** 1999 Jun;23(2):93–114 (31 ref.)

Aid and violence, with special reference to Sierra Leone. Keen D. **Disasters** 1998 Dec;22(4):318–27 (33 ref.)

The death of humanitarianism?: an anatomy of the attack. Macrae J. **Disasters** 1998 Dec;22(4):309–17 (13 ref.)

Neoliberalism revised? A critical account of World Bank conceptions of good governance and market friendly intervention. Kiely R. **Int J Health Serv** 1998;28(4):683–702 (65 ref.)

Neoliberalism, "globalization," unemployment, inequalities, and the welfare state. Navarro V. **Int J Health Serv** 1998; 28(4):607–82 (91 ref.)

The political economy of the welfare state in developed capitalist countries. Navarro V. **Int J Health Serv** 1999; 29(1):1–50 (36 ref.)

New labour and the third way in the British National Health Service. Powell M. **Int J Health Serv** 1999;29(2):353–70 (82 ref.)

The benefit-risk politics of vaccination against hepatitis B virus [comment] Degos F. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):392–4 (17 ref.) Comment on: Ital J Gastroenterol Hepatol 1999 Jun-Jul;31(5):388–91.

Social and political dis-ease. Frankford DM. **J Health Polit Policy Law** 1999 Feb;24(1):181–96 (19 ref.)

The missing millions: organized labor, business, and the defeat of Clinton's Health Security Act. Gottschalk M. **J Health Polit Policy Law** 1999 Jun;24(3):489–529 (176 ref.)

The Oregon Health Plan and the political paradox of rationing: what advocates and critics have claimed and what Oregon did. Jacobs L, et al. **J Health Polit Policy Law** 1999 Feb;24(1):161–80 (19 ref.)

Social movements as catalysts for policy change: the case of smoking and guns. Nathanson CA. **J Health Polit Policy Law** 1999 Jun;24(3):421–88 (146 ref.)

An introduction to consumer politics. Epstein M, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Aug;36(8):40–9 (13 ref.)

Stochastic game theory: for playing games, not just for doing theory. Goeree JK, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10564–7 (36 ref.)

[Current responsibilities of health care research and political counseling] Wismar M. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):691–5 (15 ref.) (Eng. Abstr.) **(Ger)**

POLLEN

see related
ALLERGENS
HAY FEVER

The mating game: pollination and fertilization in flowering plants. Wilhelmi LK, et al. **Curr Opin Plant Biol** 1999 Feb; 2(1):18–22 (53 ref.)

[Japanese cedar pollen allergen standardization: analysis of major allergens] Sakaguchi M. **Arerugi** 1998 Dec; 47(12):1233–6 (14 ref.) **(Jpn)**

ADVERSE EFFECTS

Process and current status of the epidemiologic studies on cedar pollinosis in Japan. Tanihara S, et al. **J Epidemiol** 1999 Feb;9(1):20–6 (59 ref.)

[Inter-relationship between allergenic pollens and air pollution] Peltre G. **Allerg Immunol (Paris)** 1998 Dec; 30(10):324–6 (1 ref.) (Eng. Abstr.) **(Fre)**

[The role of aeroallergens monitoring in the allergological practice] Rapiejko P, et al. **Otolaryngol Pol** 1997;51 Suppl 25:217–9 (5 ref.) (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

Microspore embryogenesis and in vitro pollen maturation in tobacco. Touraev A, et al. **Methods Mol Biol** 1999; 111:281–91 (26 ref.)

IMMUNOLOGY

Latex antigens: identification and use in clinical and experimental studies, including crossreactivity with food and pollen allergens. Nel A, et al. **Ann Allergy Asthma Immunol** 1998 Nov;81(5 Pt 1):388–96; quiz 397–8 (60 ref.)

Grass pollen: trends and predictions [editorial] Burr ML. **Clin Exp Allergy** 1999 Jun;29(6):735–8 (26 ref.)

Allergy to Parietaria officinalis pollen. Cvitanović S. **Croat Med J** 1999 Mar;40(1):42–8 (51 ref.)

In situ localization of pollen allergens by immunogold electron microscopy: allergens at unexpected sites. Grote M. **Int Arch Allergy Immunol** 1999 Jan;118(1):1–6 (43 ref.)

METABOLISM

An update on allergens. Parietaria pollen allergens. Colombo P, et al. **Allergy** 1998 Oct;53(10):917–21 (31 ref.)

PHYSIOLOGY

Membrane proteins involved in pollen-pistil interactions. Giranton JL, et al. **Biochimie** 1999 Jun;81(6):675–80 (46 ref.)

Self-incompatibility and other pollen-pistil interactions. McCormick S. **Curr Opin Plant Biol** 1998 Feb;1(1):18–25 (43 ref.)

Signaling in pollen-pistil interactions [see comments] Gaude T, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):139–47 (73 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.

POLONIUM

ANALYSIS

Dating human skeletal remains: investigating the viability of measuring the equilibrium between 210Po and 210Pb as a means of estimating the post-mortem interval. Swift B. **Forensic Sci Int** 1998 Nov 30;98(1–2):119–26 (29 ref.)

POLY A

BIOSYNTHESIS

Polyadenylation and degradation of mRNA in the chloroplast. Schuster G, et al. **Plant Physiol** 1999 Aug; 120(4):937–44 (33 ref.)

METABOLISM

mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. Minvielle-Sebastia L, et al. **Curr Opin Cell Biol** 1999 Jun; 11(3):352–7 (52 ref.)

POLY(A)+ MRNA see **RNA, MESSENGER**

POLY(A)+ RNA see **RNA, MESSENGER**

POLY(A) TAIL see **RNA, MESSENGER**

POLY ADP RIBOSE POLYMERASE see **NAD+ ADP-RIBOSYLTRANSFERASE**

POLY(ADP-RIBOSE) SYNTHASE see **NAD+ ADP-RIBOSYLTRANSFERASE**

POLY(LACTIDE-CO-GLYCOSIDE) see **POLYGLACTIN 910**

POLYACRYLAMIDE GEL ELECTROPHORESIS see **ELECTROPHORESIS, POLYACRYLAMIDE GEL**

POLYACRYLAMIDE GEL ELECTROPHORESIS, TWO-DIMENSIONAL see **ELECTROPHORESIS, GEL, TWO-DIMENSIONAL**

POLYADENYLIC ACIDS see **POLY A**

POLYALKENOATE CEMENTS see **GLASS IONOMER CEMENTS**

POLYAMIDES see **NYLONS**

POLYAMINES

[Statement on polyamines] Dandrifosse G, et al. **Rev Med Liege** 1999 Mar;54(3):175–83 (29 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Histamine, polyamines, and cancer. Medina MA, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1341–4 (42 ref.)

Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Shantz LM, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):107–22 (113 ref.)

Polyamine metabolism as target for cancer chemoprevention (review). Seiler N, et al. **Int J Oncol** 1998 Nov; 13(5):993–1006 (202 ref.)

The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Bernstein HG, et al. **Prog Neurobiol** 1999 Apr;57(5):485–505 (185 ref.)

[Importance of the polyamines: review of the literature] Farriol M, et al. **Nutr Hosp** 1999 May-Jun;14(3):101–13 (117 ref.) (Eng. Abstr.) **(Spa)**

POLYAMINES, BIOGENIC see **BIOGENIC POLYAMINES**

POLYANGIACEAE see **MYXOCOCCALES**

POLYANGIUM see **MYXOCOCCALES**

POLYARTERITIS NODOSA

Cutaneous polyarteritis nodosa: a case report and literature review. Khoo BP, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):868–72 (33 ref.)

[Polyarteritis nodosa] Murakami M, et al. **Nippon Rinsho** 1999 Feb;57(2):349–54 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Periarteritis nodosa, polyarteritis nodosa] Ohno I, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):115–8 (14 ref.) **(Jpn)**

COMPLICATIONS

Reversible bilateral hydronephrosis without obstruction in hepatitis B-associated polyarteritis nodosa. Casserly LF, et al. **Am J Kidney Dis** 1999 Sep;34(3):e11 (29 ref.)

Acute pancreatitis as a complication of polyarteritis nodosa. Flaherty J, et al. **Int J Pancreatol** 1999 Feb;25(1):53–7 (24 ref.)

Perforation of the sigmoid colon with ischemic change due to polyarteritis nodosa. Okada M, et al. **J Gastroenterol** 1999 Jun;34(3):400–4 (12 ref.)

Polyarteritis with symptomatic intracerebral aneurysms at initial presentation. Munn EJ, et al. **J Rheumatol** 1998 Oct; 25(10):2022–5 (18 ref.)

Simultaneous bilateral perirenal hematomas developing spontaneously in a patient with polyarteritis nodosa. Yonou H, et al. **J Urol** 1999 Aug;162(2):483 (3 ref.)

DIAGNOSIS

Uncommon features of polyarteritis nodosa: psychosis and angio-oedema. Fernandes SR, et al. **Clin Rheumatol** 1998; 17(4):353–6 (16 ref.)

[Gastric necrosis due to vasculitis in an HIV+ patient (letter)] Alcántara Gijón F, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):152–3 (6 ref.) **(Spa)**

THERAPY

Treatment of polyarteritis nodosa and microscopic polyangiitis. Guillevin L, et al. **Arthritis Rheum** 1998 Dec; 41(12):2100–5 (49 ref.)

Treatment of classic polyarteritis nodosa in 1999 [editorial] Guillevin L. **Nephrol Dial Transplant** 1999 Sep;14(9):2077–9 (19 ref.)

VIROLOGY

[Periarteritis nodosa induced by hepatitis B virus] Mouthon L. **Pathol Biol (Paris)** 1999 Mar;47(3):237–44 (68 ref.) (Eng. Abstr.) **(Fre)**

POLYARTHRALGIA see **ARTHRALGIA**

POLYARTHRITIS see **ARTHRITIS**

POLYBROMINATED BIPHENYLS

ADVERSE EFFECTS

PBBs, PCBs, and dioxins in food animals, their public health implications. Headrick ML, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):109–31, ix-x (43 ref.)

CHEMISTRY

Polychlorinated biphenyls, polybrominated biphenyls, and dioxin reduction during processing/cooking food. Zabik ME, et al. **Adv Exp Med Biol** 1999;459:213–31 (35 ref.)

POLYBROMOBIPHENYL COMPOUNDS see **POLYBROMINATED BIPHENYLS**

POLYCHEMOTHERAPY see **DRUG THERAPY, COMBINATION**

POLYCHLORINATED BIPHENYLS

ADVERSE EFFECTS

Neurodevelopmental, immunological and endocrinological indices of perinatal human exposure to PCBs and dioxins. Weisglas-Kuperus N. **Chemosphere** 1998 Oct-Nov; 37(9–12):1845–53 (55 ref.)

POLYCHLORINATED BIPHENYLS

Polychlorinated biphenyls and human health. Carpenter DO. **Int J Occup Med Environ Health** 1998;11(4):291–303 (86 ref.)
Environmental chemicals and child development [editorial; comment] Dietrich KN. **J Pediatr** 1999 Jan;134(1):7–9 (18 ref.) Comment on: J Pediatr 1999 Jan;134(1):33–41.
PBBs, PCBs, and dioxins in food animals, their public health implications. Headrick ML, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):109–31, ix–x (43 ref.)

ANALYSIS

Recent developments in the high-resolution gas chromatography of polychlorinated biphenyls. Cochran JW, et al. **J Chromatogr A** 1999 May 28;843(1–2):323–68 (231 ref.)
Organochlorine residues and elemental contaminants in U.S. freshwater fish, 1976–1986: National Contaminant Biomonitoring Program. Schmitt CJ, et al. **Rev Environ Contam Toxicol** 1999;162:43–104 (160 ref.)

CHEMISTRY

Polychlorinated biphenyls, polybrominated biphenyls, and dioxin reduction during processing/cooking food. Zabik ME, et al. **Adv Exp Med Biol** 1999;459:213–31 (35 ref.)

METABOLISM

(Bio)remediation of polychlorinated biphenyls (PCBs): problems, perspectives and solutions. Robinson GK. **Biochem Soc Trans** 1998 Nov;26(4):686–90 (22 ref.)

TOXICITY

Behavioural effects of endocrine disrupting chemicals on laboratory rodents: statistical methodologies and an application concerning developmental PCB exposure. Puopolo M, et al. **Chemosphere** 1999 Oct;39(8):1259–71 (47 ref.)
Dioxin-like and non-dioxin-like toxic effects of polychlorinated biphenyls (PCBs): implications for risk assessment. Giesy JP, et al. **Crit Rev Toxicol** 1998 Nov; 28(6):511–69 (286 ref.)
Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Van den Berg M, et al. **Environ Health Perspect** 1998 Dec;106(12):775–92 (225 ref.)
The neurotoxicity of polychlorinated biphenyls. Tilson HA, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):517–25 (77 ref.)

POLYCHLOROBIPHENYL COMPOUNDS see **POLYCHLORINATED BIPHENYLS**

POLYCHLOROPRENE see **NEOPRENE**

POLYCHONDRITIS, CHRONIC ATROPHIC see **POLYCHONDRITIS, RELAPSING**

POLYCHONDRITIS, RELAPSING

COMPLICATIONS

Pulmonary manifestations of ankylosing spondylitis and relapsing polychondritis. Lee-Chiong TL Jr. **Clin Chest Med** 1998 Dec;19(4):747–57, ix (89 ref.)

DIAGNOSIS

Relapsing polychondritis. Miyasaka LS, et al. **Rev Paul Med** 1998 Jan–Feb;116(1):1637–42 (24 ref.)

POLYCYCLIC COMPOUNDS see **POLYCYCLIC HYDROCARBONS**

POLYCYCLIC HYDROCARBONS

Balkan endemic nephropathy: a need for novel aetiological approaches. Stefanović V. **QJM** 1998 Jul;91(7):457–63 (45 ref.)

ADVERSE EFFECTS

[Information on a new occupational disease: "Lung cancer caused by polycyclic aromatic hydrocarbons with evidence of the effect of a cumulative dose of at least 100 benzo(a)pyrene years ([microgram/m3] • years)] Praml G, et al. **Pneumologie** 1998 Dec;52(12):684–6 (20 ref.) **(Ger)**

ANALYSIS

Polycyclic aromatic hydrocarbons in the diet. Phillips DH. **Mutat Res** 1999 Jul 15;443(1–2):139–47 (52 ref.)

TOXICITY

Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Collins JF, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):45–54 (73 ref.)

POLYCYCLIC HYDROCARBONS, AROMATIC

ADVERSE EFFECTS

Tobacco smoke carcinogens and lung cancer. Hecht SS. **J Natl Cancer Inst** 1999 Jul 21;91(14):1194–210 (249 ref.)

ANALYSIS

Urinary 1-hydroxypyrene and other PAH metabolites as biomarkers of exposure to environmental PAH in air particulate matter. Strickland P, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):191–9 (53 ref.)

CHEMISTRY

Explorations of molecular structure–property relationships. Seybold PG. **SAR QSAR Environ Res** 1999;10(2–3):101–15 (32 ref.)

METABOLISM

Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Penning TM, et al. **Chem Res Toxicol** 1999 Jan;12(1):1–18 (140 ref.)

PHARMACOLOGY

Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. Bock KW, et al. **Drug Metab Rev** 1999 May;31(2):411–22 (44 ref.)
Molecular studies on the toxifying effects by genetically engineered cytochromes P450. Doehmer J, et al. **Drug Metab Rev** 1999 May;31(2):423–35 (16 ref.)

TOXICITY

DNA reactions, mutagenic action and stealth properties of polycyclic aromatic hydrocarbon carcinogens (review). Dipple A, et al. **Int J Oncol** 1999 Jan;14(1):103–11 (81 ref.)
Polycyclic aromatic hydrocarbons: correlations between DNA adducts and ras oncogene mutations. Ross JA, et al. **Mutat Res** 1999 Mar 8;424(1–2):155–66 (59 ref.)
Explorations of molecular structure–property relationships. Seybold PG. **SAR QSAR Environ Res** 1999;10(2–3):101–15 (32 ref.)
[The toxicology and prevention of the risks of occupational exposure to aromatic polycyclic hydrocarbons. II. Toxicology. Exposure assessment. Environmental and biological monitoring] Apostoli P, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):137–51 (54 ref.) (Eng. Abstr.) **(Ita)**
[The toxicology and prevention of the risks of occupational exposure to aromatic polycyclic hydrocarbons. III. The effects: epidemiological evidence, early effects. Individual hypersusceptibility. Health surveillance] Porru S, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):152–63 (60 ref.) (Eng. Abstr.) **(Ita)**

POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC**

POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT see **KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT**

POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE see **KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE**

POLYCYSTIC OVARY SYNDROME

see related
HYPERANDROGENISM

Polycystic ovary syndrome. Kahn JA, et al. **Adolesc Med** 1999 Jun;10(2):321–36 (79 ref.)
Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Guzick D. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 2):S89–S93 (20 ref.)
Polycystic ovary syndrome. Taylor AE. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):877–902, ix (130 ref.)
Insulin and polycystic ovary syndrome: a new look at an old subject. Ciampelli M, et al. **Gynecol Endocrinol** 1998 Aug;12(4):277–92 (127 ref.)
New routes in the polycystic ovary syndrome labyrinth: a way out? Moghetti P, et al. **J Endocrinol Invest** 1998 Oct; 21(9):648–55 (59 ref.)
Polycystic ovary syndrome: clinical perspectives and management. Futterweit W. **Obstet Gynecol Surv** 1999 Jun; 54(6):403–13 (91 ref.)
Diagnosing and treating polycystic ovary syndrome. Hagan P, et al. **Practitioner** 1998 Feb;242(1583):98–100, 103, 105–6 (9 ref.)

COMPLICATIONS

Cardiovascular consequences of polycystic ovary syndrome. Amowitz LL, et al. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):439–58, viii (99 ref.)
The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Solomon CG. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):247–63 (76 ref.)
Polycystic ovary syndrome and hyperandrogenism as a risk factor for cardiovascular disease. Martikainen H, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):133–7 (14 ref.)
Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Ibáñez L, et al. **J Endocrinol Invest** 1998 Oct; 21(9):558–66 (88 ref.)
The diagnosis and treatment of hirsutism. de Berker D. **Practitioner** 1999 Jun;243(1599):493–8, 501 (3 ref.)
[Polycystic ovaries: when to suspect the diagnosis?] Chardonnens D, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):459–61 (19 ref.) **(Fre)**

DIAGNOSIS

Polycystic ovary syndrome: current and future treatment paradigms. Legro RS. **Am J Obstet Gynecol** 1998 Dec; 179(6 Pt 2):S101–S108 (77 ref.)
Diagnosis of polycystic ovary syndrome. Chang RJ, et al. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):397–408, vii (29 ref.)
[The polycystic ovary syndrome--its diagnosis and the therapeutic approach] Tanchev S, et al. **Akush Ginekol (Sofiia)** 1998;37(1):50–3 (20 ref.) **(Bul)**
[Polycystic ovaries: when to suspect the diagnosis?] Chardonnens D, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):459–61 (19 ref.) **(Fre)**
[Polycystic ovary syndrome--only relevant in reproductive medicine?] Heim SC, et al. **Ther Umsch** 1999 May; 56(5):271–5 (18 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Ehrmann DA. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):423–38, viii (55 ref.)
Antiandrogen treatment of polycystic ovary syndrome. Rittmaster RS. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):409–21 (46 ref.)
The feasibility of long-term treatment of polycystic ovary syndrome with GnRH-agonists. Berga SL. **J Endocrinol Invest** 1998 Oct;21(9):630–1 (7 ref.)
How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome? Diamanti-Kandarakis E. **J Endocrinol Invest** 1998 Oct; 21(9):623–9 (58 ref.)
Estrogen–progestagen therapy in the management of the polycystic ovary syndrome. Marshall JC. **J Endocrinol Invest** 1998 Oct;21(9):618–22 (31 ref.)

EPIDEMIOLOGY

The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Solomon CG. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):247–63 (76 ref.)
Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Carmina E, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1897–9 (23 ref.)

ETIOLOGY

The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies. Barnes RB. **J Endocrinol Invest** 1998 Oct;21(9):567–79 (94 ref.)
Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome. Carmina E, et al. **J Endocrinol Invest** 1998 Oct;21(9):580–8 (56 ref.)
Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? Ehrmann DA. **J Endocrinol Invest** 1998 Oct;21(9):632–5 (36 ref.)
Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma. Toscano V. **J Endocrinol Invest** 1998 Oct;21(9):546–50 (47 ref.)
Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. Gordon CM. **Pediatr Clin North Am** 1999 Jun;46(3):519–43 (118 ref.)

GENETICS

Genetic abnormalities in polycystic ovary syndrome. Franks S, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):131–3 (13 ref.)
Polycystic ovary syndrome. Phenotype to genotype. Legro RS. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):379–96 (45 ref.)
Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? Holte J. **J Endocrinol Invest** 1998 Oct;21(9):589–601 (101 ref.)
Genetics of polycystic ovary syndrome. Franks S, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):123–8 (51 ref.)
Molecular mysteries of polycystic ovary syndrome. Strauss JF 3rd, et al. **Mol Endocrinol** 1999 Jun;13(6):800–5 (46 ref.)
Phenotype and genotype in polycystic ovary syndrome. Legro RS, et al. **Recent Prog Horm Res** 1998;53:217–56 (189 ref.)

METABOLISM

Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. Taylor AE. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 2):S94–S100

(65 ref.)
Role of cytochrome P450c17 in polycystic ovary syndrome. Qin KN, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):111-21 (116 ref.)
Molecular mysteries of polycystic ovary syndrome. Strauss JF 3rd, et al. **Mol Endocrinol** 1999 Jun;13(6):800-5 (46 ref.)

PATHOLOGY

Polysystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles? Homburg R, et al. **J Endocrinol Invest** 1998 Oct;21(9):552-7 (43 ref.)

PHYSIOPATHOLOGY

Insulin action in the polycystic ovary syndrome. Dunaif A. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):341-59 (57 ref.)
Insulin action in the normal and polycystic ovary. Franks S, et al. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):361-78 (46 ref.)
Growth factor action on ovarian function in polycystic ovary syndrome. Giudice LC. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):325-39, vi (117 ref.)
Neuroendocrine aspects of polycystic ovary syndrome. Marshall JC, et al. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):295-324 (88 ref.)
Ovarian and adrenal function in polycystic ovary syndrome. Rosenfield RL. **Endocrinol Metab Clin North Am** 1999 Jun; 28(2):265-93 (139 ref.)
Involvement of growth factors in the pathophysiology of polycystic ovary syndrome. Homburg R. **Gynecol Endocrinol** 1998 Dec;12(6):391-7 (43 ref.)
Hyperandrogenic anovulation (the polycystic ovary syndrome)--back to the ovary? Ben-Shlomo I, et al. **Hum Reprod Update** 1998 May-Jun;4(3):296-300 (39 ref.)
Leptin, polycystic ovaries and polycystic ovary syndrome. Jacobs HS, et al. **Hum Reprod Update** 1999 Mar-Apr; 5(2):166-71 (70 ref.)
Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. Hall JE, et al. **J Endocrinol Invest** 1998 Oct;21(9):602-11 (67 ref.)
Role of GnRH drive in the pathophysiology of polycystic ovary syndrome. Leondires MP, et al. **J Endocrinol Invest** 1998 Jul-Aug;21(7):476-85 (78 ref.)
Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis. Franks S, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):269-72 (27 ref.)
Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Legro RS. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):103-10 (54 ref.)
Polycystic ovaries: question of definition [comment] Mason H. **Ultrasound Obstet Gynecol** 1998 Sep;12(3):154-5 (19 ref.) Comment on: Ultrasound Obstet Gynecol 1998 Sep;12(3):180-7.
[Physiopathology of polycystic ovary syndrome] Dewailly D. **Ann Endocrinol (Paris)** 1999 Jul;60(2):123-30 (31 ref.) (Eng. Abstr.) **(Fre)**
[Polycystic ovary syndrome: from physiopathology to therapy] Pugeat M. **Ann Endocrinol (Paris)** 1998 Nov; 59(4):305-9 (16 ref.) **(Fre)**
[The role of insulin-like growth-factor binding proteins in normal and polycystic ovaries] Vasiljević M, et al. **Srp Arh Celok Lek** 1998 Nov-Dec;126(11-12):488-94 (22 ref.) (Eng. Abstr.) **(Scc)**
[Insulin resistance in polycystic ovary syndrome] Aquino Carlos P, et al. **Ginecol Obstet Mex** 1998 Nov;66:446-51 (18 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. Apter D. **J Endocrinol Invest** 1998 Oct; 21(9):613-7 (30 ref.)

SURGERY

[Surgical options in the treatment of polycystic ovary syndrome] Zornoza A, et al. **Rev Med Univ Navarra** 1997 Oct-Dec;41(4):230-6 (38 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The obstetrician-gynecologist's role in the practical management of polycystic ovary syndrome. Berga SL. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 2):S109-S113 (28 ref.)
Treatment in polycystic ovarian syndrome (PCOS) with emphasis on ovarian electrocautery. Gjønnaess H. **Ginekol Pol** 1998 Dec;69(12):855-8 (16 ref.)
How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome? Cortet-Rudelli C, et al. **J Endocrinol Invest** 1998 Oct;21(9):636-40 (38 ref.)
Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma. Toscano V. **J Endocrinol Invest** 1998 Oct;21(9):546-50 (47 ref.)
Polycystic ovary syndrome: a new direction in treatment. Kidson W. **Med J Aust** 1998 Nov 16;169(10):537-40 (44 ref.)
[Polycystic ovary syndrome: from physiopathology to therapy] Pugeat M. **Ann Endocrinol (Paris)** 1998 Nov; 59(4):305-9 (16 ref.) **(Fre)**

ULTRASONOGRAPHY

The role of ovarian volume in reproductive medicine. Lass A, et al. **Hum Reprod Update** 1999 May-Jun;5(3):256-66 (118 ref.)

POLYCYTHEMIA

GENETICS

Molecular basis for polycythemia. Prchal JF, et al. **Curr Opin Hematol** 1999 Mar;6(2):100-9 (96 ref.)

POLYCYTHEMIA VERA

[Vaquez disease. Diagnosis, course, treatment] Bauters F. **Rev Prat** 1998 Sep 1;48(13):1483-9 (4 ref.) **(Fre)**

COMPLICATIONS

Budd-Chiari syndrome complicating restorative proctocolectomy for ulcerative colitis: report of a case. Whiteford MH, et al. **Dis Colon Rectum** 1999 Sep; 42(9):1220-4 (15 ref.)
Acute lymphoid leukemia following polycythemia vera. Camós M, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):395-8 (20 ref.)

DIAGNOSIS

Transition of polycythemia vera to chronic neutrophilic leukemia. Higuchi T, et al. **Leuk Lymphoma** 1999 Mar; 33(1-2):203-6 (21 ref.)
Diagnosing polycythemia vera: a paradigm shift. Tefferi A. **Mayo Clin Proc** 1999 Feb;74(2):159-62 (10 ref.)
Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency? [editorial] Lindstedt G, et al. **Scand J Clin Lab Invest** 1998 Oct;58(6):441-58 (97 ref.)
Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Murphy S. **Semin Hematol** 1999 Jan;36(1 Suppl 2):9-13 (35 ref.)

DRUG THERAPY

Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Gilbert HS. **Semin Hematol** 1999 Jan;36(1 Suppl 2):19-22 (32 ref.)

PATHOLOGY

Apoptosis and polycythemia vera. Fernández-Luna JL. **Curr Opin Hematol** 1999 Mar;6(2):94-9 (52 ref.)

POLYDACTYLY

Polydactyly of the foot. Overview with case presentations. Kleanthous JK, et al. **J Am Podiatr Med Assoc** 1998 Oct; 88(10):493-9 (49 ref.)

POLYDEOXYRIBONUCLEOTIDE LIGASES see **DNA LIGASES**

POLYDEOXYRIBONUCLEOTIDE SYNTHETASES see **DNA LIGASES**

POLYDIMETHYLSILOXANES see **DIMETHYLPOLYSILOXANES**

POLYDNAVIRIDAE

[Relationship between parasotoid wasps and polydnaviruses] Hayakawa Y. **Uirusu** 1998 Jun;48(1):67-72 (27 ref.) **(Jpn)**

POLYDYSTROPHIC DWARFISM see **MUCOPOLYSACCHARIDOSIS VI**

POLYENDOCRINOPATHIES, AUTOIMMUNE

[Autoimmune polyglandular syndrome] Inaba M. **Nippon Rinsho** 1999 Aug;57(8):1888-93 (11 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Cloning of the APECED gene provides new insight into human autoimmunity. Aaltonen J, et al. **Ann Med** 1999 Apr;31(2):111-6 (41 ref.)
Autoimmune polyglandular syndromes. Obermayer-Straub P, et al. **Baillieres Clin Gastroenterol** 1998 Jun; 12(2):293-315 (103 ref.)
Gene defect behind APECED: a new clue to autoimmunity. Björses P, et al. **Hum Mol Genet** 1998;7(10):1547-53 (53 ref.)

IMMUNOLOGY

Cloning of the APECED gene provides new insight into human autoimmunity. Aaltonen J, et al. **Ann Med** 1999 Apr;31(2):111-6 (41 ref.)
Gene defect behind APECED: a new clue to autoimmunity. Björses P, et al. **Hum Mol Genet** 1998;7(10):1547-53 (53 ref.)

POLYERGIN see **TRANSFORMING GROWTH FACTOR BETA**

POLYESTERS

Impregnated polyester arterial prostheses: performance and prospects. Chakfé N, et al. **Ann Vasc Surg** 1999 Sep; 13(5):509-23 (157 ref.)
Production of new polymeric compounds in plants. Poirier Y. **Curr Opin Biotechnol** 1999 Apr;10(2):181-5 (30 ref.)
Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Jain R, et al. **Drug Dev Ind Pharm** 1998 Aug;24(8):703-27 (2457 ref.)

CHEMISTRY

Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers. Abe H, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):185-92 (52 ref.)
Detection, synthesis, structure, and function of oligo(3-hydroxyalkanoates): contributions by synthetic organic chemists. Seebach D, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):217-36 (121 ref.)
Chemical composition distribution of bacterial copolyesters. Yoshie N, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):193-200 (54 ref.)

METABOLISM

Microbial degradation of polyurethane, polyester polyurethanes and polyether polyurethanes. Nakajima-Kambe T, et al. **Appl Microbiol Biotechnol** 1999 Feb;51(2):134-40 (90 ref.)
Photosynthetic accumulation of poly-(hydroxybutyrate) by cyanobacteria--the metabolism and potential for CO2 recycling. Asada Y, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):37-42 (21 ref.)
Microbial inclusions with special reference to PHA inclusions and intracellular boundary envelopes. Fuller RC. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):21-9 (66 ref.)
Recent advances in polyhydroxyalkanoate production by bacterial fermentation: mini-review. Lee SY, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):31-6 (46 ref.)
Biochemical and genetic analysis of PHA synthases and other proteins required for PHA synthesis. Rehm BH, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):3-19 (74 ref.)
Detection, synthesis, structure, and function of oligo(3-hydroxyalkanoates): contributions by synthetic organic chemists. Seebach D, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):217-36 (121 ref.)
Chemical composition distribution of bacterial copolyesters. Yoshie N, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):193-200 (54 ref.)
Polyhydroxyalkanoates, biopolyesters from renewable resources: physiological and engineering aspects. Braunegg G, et al. **J Biotechnol** 1998 Oct 27;65(2-3):127-61 (240 ref.)
Metabolic engineering of poly(3-hydroxyalkanoates): from DNA to plastic. Madison LL, et al. **Microbiol Mol Biol Rev** 1999 Mar;63(1):21-53 (303 ref.)
Polyphosphate/poly-(R)-3-hydroxybutyrate) ion channels in cell membranes. Reusch RN. **Prog Mol Subcell Biol** 1999; 23:151-82 (101 ref.)
Polyhydroxybutyrate: plastic made and degraded by microorganisms. Hankermeyer CR, et al. **Rev Environ Contam Toxicol** 1999;159:1-24 (37 ref.)
Bacterial and other biological systems for polyester production. Steinbüchel A, et al. **Trends Biotechnol** 1998 Oct;16(10):419-27 (76 ref.)

PHARMACOKINETICS

Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers. Abe H, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):185-92 (52 ref.)

THERAPEUTIC USE

Laboratory and field evaluation of biodegradable polyesters for sustained release of isometamidium and ethidium. Geerts S, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr; 94(2):211-4 (17 ref.)

POLYETHYLENE GLYCOLS

[Clinico-laboratory effectiveness of modern ointments with a polyethylene glycol base in the treatment of purulent wounds] Blatun LA, et al. **Antibiot Khimioter** 1999; 44(7):25-31 (12 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Apr;13 Suppl 1:S14-8 (23 ref.)
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14-8 (23 ref.)

POLYETHYLENE TEREPHTHALATES

Structural failure of Dacron arterial grafts. Nunn DB.

POLYETHYLENE TEREPHTHALATES

Semin Vasc Surg 1999 Mar;12(1):83–91 (85 ref.)

ADVERSE EFFECTS

Extrusion and granuloma formation with mersilene mesh brow suspension. Mutlu FM, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):47–51 (17 ref.)

THERAPEUTIC USE

Giant prosthetic reinforcement of the visceral sac. The Stoppa groin hernia repair. Wantz GE. **Surg Clin North Am** 1998 Dec;78(6):1075–87 (16 ref.)

POLYETHYLENES

Late failure of the polyethylene liner fixation in an uncemented total hip arthroplasty. Louwerse RT, et al. **J Arthroplasty** 1999 Apr;14(3):391–6 (16 ref.)

Alloplastic sternal replacement in malignant sternal tumors. Case report and review of the literature. Meyer M, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):853–7 (42 ref.)

ADVERSE EFFECTS

Intrapelvic cyst formation after hip arthroplasty with a carbon fibre-reinforced polyethylene socket. Korkala O, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):113–5 (8 ref.)

THERAPEUTIC USE

Mesh plug repair and groin hernia surgery. Robbins AW, et al. **Surg Clin North Am** 1998 Dec;78(6):1007–23, vi–vii (54 ref.)

[The use of prosthetic materials placed intraperitoneally in the repair of large defects of the abdominal wall, reflections on a limited case series] Miro AG, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):277–81; discussion 281–2 (30 ref.) (Eng. Abstr.) **(Ita)**

POLYGALACTURONASE

BIOSYNTHESIS

Production of pectic enzymes in yeasts. Blanco P, et al. **FEMS Microbiol Lett** 1999 Jun 1;175(1):1–9 (36 ref.)

POLYGENIC INHERITANCE

see related

QUANTITATIVE TRAIT

Genetics of type II diabetes. Permutt MA, et al. **Recent Prog Horm Res** 1998;53:201–16 (67 ref.)

GENETICS

Introduction to the post-Human Genome Project era, a target for interactions between polygenic and/or multiphenotypical components in cancer control in South America. Iscovich J. **Cad Saude Publica** 1998;14 Suppl 3:15–23 (28 ref.)

POLYGLACTIN 910

[Tissue engineered cartilage and its clinical use] Liu Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Sep;11(5):305–8 (22 ref.) **(Chi)**

POLYGLANDULAR TYPE I AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLANDULAR TYPE II AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLUCOSES see **GLUCANS**

POLYGLYCOLIC ACID

Orthopaedic applications for PLA-PGA biodegradable polymers. Athanasiou KA, et al. **Arthroscopy** 1998 Oct;14(7):726–37 (95 ref.)

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Lima KM, et al. **Braz J Med Biol Res** 1999 Feb;32(2):171–80 (63 ref.)

Something new in the field of PLA/GA bioresorbable polymers? Vert M, et al. **J Controlled Release** 1998 Apr 30;53(1–3):85–92 (16 ref.)

[Absorbable materials and their uses in surgery] Zhao X, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jul;11(4):253–5 (24 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov–Dec; 15(6):699–713 (28 ref.)

CHEMISTRY

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov–Dec; 15(6):699–713 (28 ref.)

POLYGLYCOLIDE see **POLYGLYCOLIC ACID**

POLYISOCYANATES see **POLYURETHANES**

POLYISOPRENYL PHOSPHATES

BIOSYNTHESIS

Isoprenoid biosynthesis in plants: carbon partitioning within the cytoplasmic pathway. Newman JD, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):95–106 (80 ref.)

METABOLISM

Biotransformation of monoterpenes, bile acids, and other isoprenoids in anaerobic ecosystems. Hylemon PB, et al. **FEMS Microbiol Rev** 1998 Dec;22(5):475–88 (75 ref.)

POLYKARYOCYTES see **GIANT CELLS**

POLYMENORRHEA see **MENSTRUATION DISORDERS**

POLYMERASE CHAIN REACTION

see related

SEQUENCE TAGGED SITES

Polymerase chain reaction: a new chapter in critical care diagnosis [editorial; comment] Teba L. **Crit Care Med** 1999 May;27(5):860–1 (15 ref.) Comment on: Crit Care Med 1999 May;27(5):937–40.

Primer mixture enhances PCR detection of Mycoplasma/Acholeplasma contaminants in cell cultures [letter] Tang J, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan;35(1):1–3 (16 ref.)

Polymerase chain reaction approaches for the detection of Neospora caninum and Toxoplasma gondii. Ellis JT. **Int J Parasitol** 1998 Jul;28(7):1053–60 (67 ref.)

Evaluation of new method for diagnosis of opportunistic fungal infection. Hashimoto A, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):187–92 (17 ref.)

Advances in the identification of Dirofilaria repens and Dirofilaria immitis by a PCR-based approach. Favia G, et al. **Parassitologia** 1997 Dec;39(4):401–2 (14 ref.)

Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Wells D, et al. **Prenat Diagn** 1998 Dec;18(13):1389–401 (78 ref.)

The role of rapid diagnostic tests for tuberculosis in Singapore. Lim TK. **Singapore Med J** 1999 Apr; 40(4):298–302 (33 ref.)

PCR-based approaches to adduct analysis. Pfeifer GP, et al. **Toxicol Lett** 1998 Dec 28;102–103:447–51 (26 ref.)

[Molecular biologic screening test (PCR) for fragile X syndrome] Kovács E, et al. **Orv Hetil** 1998 Dec 27; 139(52):3121–3 (22 ref.) (Eng. Abstr.) **(Hun)**

[Case of varicella-zoster pneumonia with bronchioalveolar lavage confirmed by the detection of VZV DNA in the bronchial washing by the polymerase chain reaction] Saito S, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):346–50 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Educational symposium: DNA diagnosis of malignancies; strategies and applications of PCR-mediated DNA diagnosis in a case of hemophilia B] Kojima T. **Rinsho Byori** 1998 Sep;46(9):861–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[PCR in the diagnosis of focal cerebral lesions in HIV infected patients] Pujol-Riqué M, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):29–35 (82 ref.) **(Spa)**

INSTRUMENTATION

Automation of the polymerase chain reaction. Part I. Prospects and problems. Clewley JP. **Commun Dis Public Health** 1999 Jan;2(1):71–2 (3 ref.)

METHODS

The polymerase chain reaction in the detection of micrometastases and circulating tumor cells: present status and future potential. Ghossein RA, et al. **Anat Pathol** 1998; 3:233–51 (105 ref.)

Genetic methods for assessing antimicrobial resistance. Cockerill FR 3rd. **Antimicrob Agents Chemother** 1999 Feb; 43(2):199–212 (84 ref.)

Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Faderl S, et al. **Blood** 1999 May 1;93(9):2755–9 (42 ref.)

Advances in approaches to DNA-based diagnostics. Whitcombe D, et al. **Curr Opin Biotechnol** 1998 Dec; 9(6):602–8 (51 ref.)

The evolving role of direct amplification tests in diagnosing osteoarticular infections caused by mycobacteria and fungi. Harrington JT. **Curr Opin Rheumatol** 1999 Jul;11(4):289–92 (29 ref.)

Techniques for quantification of cytokine mRNAs. Benveniste O, et al. **Cytokines Cell Mol Ther** 1998 Sep; 4(3):207–14 (50 ref.)

Use of the polymerase chain reaction in the evaluation of cutaneous T-cell infiltrates. Kohler S, et al. **Dermatol Clin** 1999 Jul;17(3):657–66, x (33 ref.)

Consideration of PCR methods for the detection of SV40 in tissue and DNA specimens. Lednicky JA, et al. **Dev Biol Stand** 1998;94:155–64 (17 ref.)

A broad spectrum PCR method for the détection of polyomaviruses and avoidance of contamination by cloning vectors. Völter C, et al. **Dev Biol Stand** 1998;94:137–42 (15 ref.)

Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management. Bowen EF. **Drugs** 1999 May;57(5):735–41 (24 ref.)

Polymerase chain reaction-single strand conformation polymorphism or how to detect reliably and efficiently each sequence variation in many samples and many genes. Jaeckel S, et al. **Electrophoresis** 1998 Dec;19(18):3055–61 (68 ref.)

Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Kutach LS, et al. **Electrophoresis** 1999 Jun;20(6):1204–10 (45 ref.)

Applications of constant denaturant capillary electrophoresis/high-fidelity polymerase chain reaction to human genetic analysis. Li-Sucholeiki XC, et al. **Electrophoresis** 1999 Jun;20(6):1224–32 (32 ref.)

Flow cytometry in situ polymerase chain reaction as an innovative approach to HIV-1 proviral DNA detection. Gibellini D, et al. **Eur J Histochem** 1998;42(2):137–41 (16 ref.)

In-situ polymerase chain reaction: foundation of the technology and today's options. Long AA. **Eur J Histochem** 1998;42(2):101–9 (56 ref.)

"Real-time" polymerase chain reaction [editorial; comment] Oldach D. **Gastroenterology** 1999 Mar;116(3):763–4 (13 ref.) Comment on: Gastroenterology 1999 Mar;116(3):636–42.

The use of molecular technologies for the detection of enteroviral ribonucleic acid in myocarditis. Micevski V. **J Cardiovasc Nurs** 1999 Jul;13(4):78–90 (31 ref.)

Principles and applications of methods for DNA-based typing of microbial organisms. Olive DM, et al. **J Clin Microbiol** 1999 Jun;37(6):1661–9 (93 ref.)

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Schultze JL, et al. **J Mol Med** 1999 Feb;77(2):259–65 (34 ref.)

Simple sequence-length polymorphism analysis. Liao EC, et al. **Methods Cell Biol** 1999;60:181–3 (2 ref.)

PCR and RFLP methods for the specific detection and identification of Mycoplasma mycoides subsp. mycoides SC. Bashiruddin JB. **Methods Mol Biol** 1998;104:167–78 (16 ref.)

PCR methodology applied to genetic studies of lipoprotein metabolism and atherosclerosis. Cole SA, et al. **Methods Mol Biol** 1998;110:1–34 (70 ref.)

Characterization of mycoplasmas by PCR and sequence analysis with universal 16S rDNA primers. Johansson KE, et al. **Methods Mol Biol** 1998;104:145–65 (41 ref.)

Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Karge WH 3rd, et al. **Methods Mol Biol** 1998;110:43–61 (9 ref.)

Preparation of single-stranded antisense cDNA probes by asymmetric PCR. Millican DS, et al. **Methods Mol Biol** 1998;105:337–50 (8 ref.)

Application of polymerase chain reaction for the discovery of new adhesion molecule family members. Woodard AS, et al. **Methods Mol Biol** 1999;96:65–76 (16 ref.)

Molecular assessment of tumour stage and disease recurrence using PCR-based assays. Bustin SA, et al. **Mol Med Today** 1998 Sep;4(9):389–96 (52 ref.)

Demystified ... the polymerase chain reaction. Baumforth KR, et al. **Mol Pathol** 1999 Feb;52(1):1–10 (42 ref.)

Electronic PCR: bridging the gap between genome mapping and genome sequencing. Schuler GD. **Trends Biotechnol** 1998 Nov;16(11):456–9 (16 ref.)

STANDARDS

PCR testing of plasma pools: from concept to reality. Flanagan P, et al. **Transfus Med Rev** 1999 Jul;13(3):164–76 (40 ref.)

TRENDS

The polymerase chain reaction in the detection of micrometastases and circulating tumor cells: present status and future potential. Ghossein RA, et al. **Anat Pathol** 1998; 3:233–51 (105 ref.)

VETERINARY

PCR-based technology in veterinary parasitology. Gasser RB. **Vet Parasitol** 1999 Aug 1;84(3–4):229–58 (231 ref.)

POLYMERASE CHAIN REACTION, REVERSE TRANSCRIPTASE see **REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION**

POLYMERS

see related

MACROMOLECULAR SYSTEMS

Self organization in synthetic polymeric systems. Pojman JA. **Ann N Y Acad Sci** 1999 Jun 30;879:194–214 (61 ref.)

Orthopaedic applications for PLA-PGA biodegradable polymers. Athanasiou KA, et al. **Arthroscopy** 1998 Oct; 14(7):726–37 (95 ref.)

Molecularly imprinted polymers in chemical and biological sensing. Haupt K, et al. **Biochem Soc Trans** 1999 Feb;

27(2):344–50 (45 ref.)
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Lima KM, et al. **Braz J Med Biol Res** 1999 Feb;32(2):171–80 (63 ref.)
Bioerodible polymers for ocular drug delivery. Deshpande AA, et al. **Crit Rev Ther Drug Carrier Syst** 1998; 15(4):381–420 (220 ref.)
Diblock copolymer nanoparticles for drug delivery. Kwon GS. **Crit Rev Ther Drug Carrier Syst** 1998;15(5):481–512 (93 ref.)
Polymeric supports for solid phase synthesis. Labadie JW. **Curr Opin Chem Biol** 1998 Jun;2(3):346–52 (53 ref.)
Bioabsorbable polymers for implantable therapeutic systems. Sinha VR, et al. **Drug Dev Ind Pharm** 1998 Dec; 24(12):1129–38 (89 ref.)
Adhesion of polymeric films to pharmaceutical solids. Felton LA, et al. **Eur J Pharm Biopharm** 1999 Jan;47(1):3–14 (69 ref.)
Basic aspects of the pathogenesis of staphylococcal polymer-associated infections. von Eiff C, et al. **Infection** 1999;27 Suppl 1:S7–10 (55 ref.)
Polymer concepts in tissue engineering. Peter SJ, et al. **J Biomed Mater Res** 1998 Winter;43(4):422–7 (21 ref.)
Something new in the field of PLA/GA bioresorbable polymers? Vert M, et al. **J Controlled Release** 1998 Apr 30;53(1–3):85–92 (16 ref.)
Vertical Pt–C replication for TEM, a revolution in imaging non-periodic macromolecules, biological gels and low-density polymer networks. Ruben GC. **Micron** 1998 Oct;29(5):359–96 (93 ref.)
Biomimicry 1: PC. Cumberland DC, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):149–50 (11 ref.)
Synthetic polymers. van Beusekom HM, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):145–8 (37 ref.)
[Current status and trends of guided tissue regeneration materials] Zhang Q, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):365–8 (28 ref.) **(Chi)**
[Absorbable materials and their uses in surgery] Zhao X, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jul;11(4):253–5 (24 ref.) **(Chi)**
[A new hydroxyethyl starch for volume replacement: Elohes 6%] Medel J, et al. **Rev Esp Anestesiol Reanim** 1998 Nov; 45(9):389–96 (68 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov–Dec; 15(6):699–713 (28 ref.)

ADVERSE EFFECTS

Problems encountered for food safety with polymer packages: chemical exchange, recycling. Vergnaud JM. **Adv Colloid Interface Sci** 1998 Nov 13;78(3):267–97 (37 ref.)
Current diagnostic methods for diisocyanate induced occupational asthma. Bernstein DI, et al. **Am J Ind Med** 1999 Oct;36(4):459–68 (35 ref.)

ANALYSIS

Surface characterization of polymers for medical devices. Werner C, et al. **Int J Artif Organs** 1999 Mar;22(3):160–76 (104 ref.)
Analysis of tea polyphenols. Beecher GR, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):267–70 (31 ref.)

CHEMICAL SYNTHESIS

Enzymatic synthesis and modification of polymers in nonaqueous solvents. Akkara JA, et al. **Trends Biotechnol** 1999 Feb;17(2):67–73 (38 ref.)

CHEMISTRY

Problems encountered for food safety with polymer packages: chemical exchange, recycling. Vergnaud JM. **Adv Colloid Interface Sci** 1998 Nov 13;78(3):267–97 (37 ref.)
Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. Hellerstein MK, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1146–70 (40 ref.)
Hydrophobically driven attachments of synthetic polymers onto surfaces of biological interest: lipid bilayers and globular proteins. Tribet C. **Biochimie** 1998 May–Jun; 80(5–6):461–73 (65 ref.)
Adhesion of mammalian cells to polymer surfaces: from physical chemistry of surfaces to selective adhesion on defined patterns. Dewez JL, et al. **Biomaterials** 1998 Aug; 19(16):1441–5 (17 ref.)
Molecular rotors as fluorescent probes for biological studies. Viriot ML, et al. **Clin Hemorheol Microcirc** 1998 Oct; 19(2):151–60 (25 ref.)
Applications of dendrimers in bio-organic chemistry. Kim Y, et al. **Curr Opin Chem Biol** 1998 Dec;2(6):733–42 (53 ref.)
Interfacial adsorption of polymers and surfactants: implications for the properties of disperse systems of pharmaceutical interest. Duro R, et al. **Drug Dev Ind Pharm** 1999 Jul;25(7):817–29 (146 ref.)
Polymeric micelles – a new generation of colloidal drug carriers. Jones M, et al. **Eur J Pharm Biopharm** 1999 Sep; 48(2):101–11 (102 ref.)
Polymer-grafted starch microparticles for oral and nasal immunization. McDermott MR, et al. **Immunol Cell Biol** 1998 Jun;76(3):256–62 (52 ref.)
Dynamic mechanical analysis of polymeric systems of pharmaceutical and biomedical significance. Jones DS. **Int J Pharm** 1999 Mar 15;179(2):167–78 (40 ref.)
Polymer concepts in tissue engineering. Peter SJ, et al. **J Biomed Mater Res** 1998 Winter;43(4):422–7 (21 ref.)
Counterion condensation revisited. Manning GS, et al. **J Biomol Struct Dyn** 1998 Oct;16(2):461–76 (39 ref.)
Separation and sensing based on molecular recognition using molecularly imprinted polymers. Takeuchi T, et al. **J Chromatogr B Biomed Sci Appl** 1999 May 14;728(1):1–20 (145 ref.)
Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov–Dec; 15(6):699–713 (28 ref.)
Alternative polymer supports for organic chemistry. Bergbreiter DE. **Med Res Rev** 1999 Sep;19(5):439–50 (47 ref.)
Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Bravo L. **Nutr Rev** 1998 Nov; 56(11):317–33 (149 ref.)
Soluble self-assembled block copolymers for drug delivery. Kwon GS, et al. **Pharm Res** 1999 May;16(5):597–600 (36 ref.)
Polymers in dentistry. Deb S. **Proc Inst Mech Eng [H]** 1998; 212(6):453–64 (78 ref.)
Enzymatic synthesis and modification of polymers in nonaqueous solvents. Akkara JA, et al. **Trends Biotechnol** 1999 Feb;17(2):67–73 (38 ref.)
Smart[1] polymers and what they could do in biotechnology and medicine. Galaev IY, et al. **Trends Biotechnol** 1999 Aug;17(8):335–40 (77 ref.)

DIAGNOSTIC USE

Polymer diagnostics: the next generation of image contrast agents. Perkins AC. **J Drug Target** 1998;6(2):79–84 (22 ref.)

METABOLISM

Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. Hellerstein MK, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1146–70 (40 ref.)
Polymer hydrolysis in a cold climate. Cummings SP, et al. **Extremophiles** 1999 May;3(2):81–7 (44 ref.)
Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Bravo L. **Nutr Rev** 1998 Nov; 56(11):317–33 (149 ref.)
Antioxidant capacity and polyphenolic components of teas: implications for altering in vivo antioxidant status. Prior RL, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):255–61 (40 ref.)
Smart[1] polymers and what they could do in biotechnology and medicine. Galaev IY, et al. **Trends Biotechnol** 1999 Aug;17(8):335–40 (77 ref.)
Plastic antibodies: developments and applications. Haupt K, et al. **Trends Biotechnol** 1998 Nov;16(11):468–75 (49 ref.)

PHARMACOKINETICS

Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention [editorial; comment] Muggia FM. **Clin Cancer Res** 1999 Jan;5(1):7–8 (9 ref.) Comment on: Clin Cancer Res 1999 Jan;5(1):83–94.
Colonic drug targeting. Kinget R, et al. **J Drug Target** 1998; 6(2):129–49 (150 ref.)
Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Yang CS, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):213–7 (31 ref.)

PHARMACOLOGY

Cellular camouflage: fooling the immune system with polymers. Scott MD, et al. **Curr Pharm Des** 1998 Dec; 4(6):423–38 (59 ref.)
Cardioprotection of red wine: role of polyphenolic antioxidants. Das DK, et al. **Drugs Exp Clin Res** 1999; 25(2–3):115–20 (25 ref.)
Wine and polyphenols related to platelet aggregation and atherothrombosis. Ruf JC. **Drugs Exp Clin Res** 1999; 25(2–3):125–31 (49 ref.)
Antimutagenic and anticarcinogenic activity of tea polyphenols. Kuroda Y, et al. **Mutat Res** 1999 Jan; 436(1):69–97 (131 ref.)
Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Rice-Evans C. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):262–6 (21 ref.)
Tea and health: the underlying mechanisms. Weisburger JH. **Proc Soc Exp Biol Med** 1999 Apr;220(4):271–5 (42 ref.)

THERAPEUTIC USE

Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Lin JK, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):911–5 (28 ref.)
Prevention of oral diseases by polyphenols (review). Sakagami H, et al. **In Vivo** 1999 Mar–Apr;13(2):155–71 (179 ref.)
Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. Halpern MJ, et al. **J Int Med Res** 1998 Aug–Sep;26(4):171–80 (53 ref.)
Green tea polyphenols and cancer: biologic mechanisms and practical implications. Ahmad N, et al. **Nutr Rev** 1999 Mar; 57(3):78–83 (41 ref.)

POLYMETHYL METHACRYLATE

Continuous hemodialfiltration using PMMA membrane: clinical efficacy and its mechanisms. Moriyama K, et al. **Contrib Nephrol** 1999;125:222–32 (21 ref.)
[Materials for intraocular implants. I. Polymethylmethacrylate intraocular implants and surface modifications] Werner LP, et al. **J Fr Ophtalmol** 1998 Aug–Sep;21(7):515–24 (75 ref.) **(Fre)**

ADVERSE EFFECTS

Panniculitis induced by collagen and plexiglas microsphere injections used for aesthetic treatment. Biasi D, et al. **Clin Rheumatol** 1999;18(4):328–9 (15 ref.)
Skin ulceration from tibial cement extrusion: case report and literature review. Ward WG, et al. **J Arthroplasty** 1998 Oct;13(7):826–9 (9 ref.)

CHEMISTRY

Nitric oxide production with PMMA membrane. Amore A, et al. **Contrib Nephrol** 1999;125:182–96 (72 ref.)
Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes. Buoncristiani U, et al. **Contrib Nephrol** 1999;125:133–58 (72 ref.)
Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes. Campistol JM, et al. **Contrib Nephrol** 1999;125:76–85 (42 ref.)
Pyrogen transfer across PMMA membranes. Cappelli G, et al. **Contrib Nephrol** 1999;125:233–9 (41 ref.)
Effects of PMMA membrane on hepatocyte growth factor release. Dal Canton A. **Contrib Nephrol** 1999;125:197–204 (21 ref.)
Structural and functional characteristics of currently available PMMA dialyzers. Ghezzi PM, et al. **Contrib Nephrol** 1999;125:25–40 (18 ref.)
Biocompatibility of PMMA membranes in acute and chronic patients with renal failure. Manzoni C, et al. **Contrib Nephrol** 1999;125:65–75 (28 ref.)
Polymethylmethacrylate: from polymer to dialyzer. Sugaya H, et al. **Contrib Nephrol** 1999;125:1–8 (8 ref.)
Polymethylmethacrylate: one biomaterial for a series of membrane. Takeyama T, et al. **Contrib Nephrol** 1999; 125:9–24 (27 ref.)
The reinforcement of dentures. Jagger DC, et al. **J Oral Rehabil** 1999 Mar;26(3):185–94 (73 ref.)

PHARMACOLOGY

Review of the biological response to a novel bone cement containing poly(ethyl methacrylate) and n-butyl methacrylate. Revell PA, et al. **Biomaterials** 1998 Sep; 19(17):1579–86 (24 ref.)

THERAPEUTIC USE

Impaction morcellized allografting and cement. Slooff TJ, et al. **Instr Course Lect** 1999;48:79–89 (40 ref.)

POLYMETHYLMETHACRYLATE see **POLYMETHYL METHACRYLATE**

POLYMORPHIC EPITHELIAL MUCIN see **CA-15-3 ANTIGEN**

POLYMORPHISM (GENETICS)

Gene-environment interaction in late-onset Alzheimer disease: the role of apolipoprotein-epsilon4. Mayeux R. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 3:S10–5 (73 ref.)
Culturally competent drug administration. Kudzma EC. **Am J Nurs** 1999 Aug;99(8):46–51; quiz 52 (18 ref.)
Gene organization and plasticity of the beta-lactam genes in different filamentous fungi. Gutiérrez S, et al. **Antonie Van Leeuwenhoek** 1999 Jan–Feb;75(1–2):81–94 (90 ref.)
Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Santoro SA. **Blood** 1999 Jun 1;93(11):3575–7 (32 ref.)
Platelet glycoprotein polymorphism and risk for coronary heart disease. Wu KK, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S63–5 (14 ref.)
The role of APOE polymorphisms in late-onset dementias. Corder EH, et al. **Cell Mol Life Sci** 1998 Sep;54(9):928–34 (65 ref.)
Polymorphisms of coagulation factor genes--a review. Ferrer-Antunes C. **Clin Chem Lab Med** 1998 Dec; 36(12):897–906 (110 ref.)
Promoter polymorphisms predisposing to the development of asthma and atopy. Rosenwasser LJ, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:13–5; discussion 26–8 (30 ref.)
Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Wormhoudt LW, et al. **Crit Rev Toxicol** 1999 Jan; 29(1):59–124 (545 ref.)

POLYMORPHISM (GENETICS)

Nitric oxide synthase gene polymorphism and its influence on cardiovascular disease. Soma M, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):83–7 (43 ref.)

Genetic aspects of osteoporosis. Ferrari S, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):294–300 (69 ref.)

Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Nebert DW, et al. **Drug Metab Rev** 1999 May;31(2):467–87 (72 ref.)

Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Touw DJ. **Drug Metabol Drug Interact** 1997;14(2):55–82 (89 ref.)

Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Kutach LS, et al. **Electrophoresis** 1999 Jun;20(6):1204–10 (45 ref.)

Meat, metabolic genotypes and risk for colorectal cancer. Roberts-Thomson IC, et al. **Eur J Cancer Prev** 1999 Jul; 8(3):207–11 (19 ref.)

The essence of SNPs. Brookes AJ. **Gene** 1999 Jul 8; 234(2):177–86 (73 ref.)

Advances in carrier detection in haemophilia. Goodeve AC. **Haemophilia** 1998 Jul;4(4):358–64 (44 ref.)

Single nucleotide polymorphism hunting in cyberspace. Gu Z, et al. **Hum Mutat** 1998;12(4):221–5 (22 ref.)

Genomics and hypertension: concepts, potentials, and opportunities. Pratt RE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):238–47 (73 ref.)

Relevance of pheno- and genotyping in clinical drug development. Zühlsdorf MT. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):607–12 (15 ref.)

Association between beta3-adrenoreceptor polymorphism with obesity and diabetes in Japan. Yoshida T, et al. **Intern Med** 1999 Feb;38(2):207–9 (21 ref.)

DNA polymorphisms of genetic diseases in Italy. Piazza A. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):1–7 (36 ref.)

SNPing away at innate immunity [comment] Chanock SJ, et al. **J Clin Invest** 1999 Aug;104(4):369–70 (21 ref.) Comment on: J Clin Invest 1999 Aug;104(4):431–7.

Polymorphic DNA markers in the genome of parasitic nematodes. Roos MH, et al. **J Helminthol** 1998 Dec; 72(4):291–4 (38 ref.)

Mitochondrial DNA analysis: polymorphisms and pathogenicity. Chinnery PF, et al. **J Med Genet** 1999 Jul; 36(7):505–10 (65 ref.)

Gene polymorphism of the renin-angiotensin system and progression of diabetic nephropathy. Orisio S. **J Nephrol** 1999 Jan–Feb;12(1):9–17 (104 ref.)

Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. Bailey LB, et al. **J Nutr** 1999 May; 129(5):919–22 (41 ref.)

MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. Chen J, et al. **J Nutr** 1999 Feb; 129(2S Suppl):560S–564S (30 ref.)

Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. White PC, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):409–12 (31 ref.)

Simple sequence-length polymorphism analysis. Liao EC, et al. **Methods Cell Biol** 1999;60:181–3 (2 ref.)

Mutations and polymorphisms in gonadotropin genes. Huhtaniemi I, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1–2):89–94 (39 ref.)

The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. López-Larrea C, et al. **Mol Med Today** 1998 Dec;4(12):540–9 (49 ref.)

Drug metabolism polymorphisms as modulators of cancer susceptibility. Taningher M, et al. **Mutat Res** 1999 May; 436(3):227–61 (170 ref.)

How about vitamin D receptor polymorphisms? Pols HA, et al. **Osteoporos Int** 1998;8 Suppl 2:S20–3 (28 ref.)

Wild mice as a source of genetic polymorphism. Guénet JL. **Pathol Biol (Paris)** 1998 Nov;46(9):685–8 (7 ref.) **(Eng, Fre)**

The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Uhl GR, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7752–5 (31 ref.)

Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Hengstler JG, et al. **Recent Results Cancer Res** 1998; 154:47–85 (178 ref.)

Genetic polymorphisms and risk of coronary artery disease. Murata M, et al. **Semin Thromb Hemost** 1998;24(3):245–50 (45 ref.)

Polymorphisms in xenobiotic conjugation and disease predisposition. Brockmöller J, et al. **Toxicol Lett** 1998 Dec 28;102–103:173–83 (64 ref.)

Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Daly AK, et al. **Toxicol Lett** 1998 Dec 28; 102–103:143–7 (24 ref.)

Functional consequences of polymorphism of xenobiotic metabolising enzymes. Ingelman-Sundberg M. **Toxicol Lett** 1998 Dec 28;102–103:155–60 (17 ref.)

Polymorphic CYP genes and disease predisposition--what have the studies shown so far? Watanabe M. **Toxicol Lett** 1998 Dec 28;102–103:167–71 (17 ref.)

Symposium overview: the role of genetic polymorphism and repair deficiencies in environmental disease. Hulla JE, et al. **Toxicol Sci** 1999 Feb;47(2):135–43 (87 ref.)

Cytokine gene polymorphisms and relevance to forms of rejection. Hutchinson IV, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):734–6 (17 ref.)

Cytokine genotypes in allograft rejection: guidelines for immunosuppression. Hutchinson IV, et al. **Transplant Proc** 1998 Dec;30(8):3991–2 (11 ref.)

DNA chips: promising toys have become powerful tools. Gerhold D, et al. **Trends Biochem Sci** 1999 May; 24(5):168–73 (28 ref.)

Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Smith G, et al. **Xenobiotica** 1998 Dec;28(12):1129–65 (232 ref.)

[Polymorphism of the renin-angiotensin-aldosterone system: molecular and epidemiogenetic aspects] Soubrier F. **Nephrologie** 1998;19(7):377–84 (67 ref.) (Eng. Abstr.) **(Fre)**

[Genetic polymorphisms in the renin-angiotensin system] Jeunemaitre X. **Therapie** 1998 May–Jun;53(3):271–7 (50 ref.) (Eng. Abstr.) **(Fre)**

[Polymorphisms--genetic risk factors for coronary heart disease?] Ortlepp JR, et al. **Dtsch Med Wochenschr** 1999 May 14;124(19):600–8 (49 ref.) **(Ger)**

[Use of studies on genome polymorphism in follow up after allogenic bone marrow transplantation] Páldi-Haris P, et al. **Orv Hetil** 1998 Dec 20;139(51):3075–8 (15 ref.) (Eng. Abstr.) **(Hun)**

[Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes] Ozawa S. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):69–81 (126 ref.) (Eng. Abstr.) **(Jpn)**

[Linkage disequilibrium between the Machado-Joseph disease and intragenic polymorphisms] Ichikawa Y. **Nippon Rinsho** 1999 Apr;57(4):832–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Gene loci and polymorphisms of angiotensin II receptor] Katsuya T, et al. **Nippon Rinsho** 1999 May;57(5):1020–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic polymorphisms as risk factors for coronary artery disease] Yoneya K, et al. **Nippon Rinsho** 1998 Oct; 56(10):2509–14 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic factors in the development of atherosclerosis] Nakajima T, et al. **Nippon Ronen Igakkai Zasshi** 1999 Apr; 36(4):229–33 (23 ref.) **(Jpn)**

[Genetic polymorphism of the CYP2C subfamily] Chiba K. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):15–21 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese] Yokoi T, et al. **Nippon Yakurigaku Zasshi** 1998 Jul; 112(1):5–14 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Polymorphism of protein systems and individual predisposition to broncho-pulmonary occupational diseases (literature review)] Kuz'mina LP. **Med Tr Prom Ekol** 1999; (5):28–31 (25 ref.) **(Rus)**

[Polymorphism of the genes of steroidogenesis and risk of malignant tumor development] Berstein LM, et al. **Vopr Onkol** 1999;45(3):213–8 (34 ref.) **(Rus)**

[The poly(hetero)morphic forms of pathogenic bacteria in infectious pathology] Vysotskii VV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar–Apr; (2):100–4 (42 ref.) **(Rus)**

GENETICS

The beta-adrenoceptor. Johnson M. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S146–53 (60 ref.)

Angiotensin-converting enzyme gene polymorphism: is there a link to nephropathy in patients with type 1 diabetes? Martin JK, et al. **Ann Pharmacother** 1999 Apr;33(4):474–9 (33 ref.)

The study of genetic polymorphisms related to serotonin in Alzheimer's disease: a new perspective in a heterogenic disorder. Oliveira JR, et al. **Braz J Med Biol Res** 1999 Apr;32(4):463–7 (40 ref.)

Genetic polymorphism and their contribution to cancer susceptibility. Conforti-Froes N, et al. **Cad Saude Publica** 1998;14 Suppl 3:7–13 (41 ref.)

Is the A1166C polymorphism of the angiotensin II type 1 receptor involved in cardiovascular disease? van Geel PP, et al. **Eur Heart J** 1998 Jul;19 Suppl G:G13–7 (31 ref.)

Pluripotent PPARgamma polymorphisms. Berg JP. **Eur J Endocrinol** 1999 Apr;140(4):293–5 (17 ref.)

Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Oetting WS, et al. **Hum Mutat** 1999;13(2):99–115 (98 ref.)

Polymorphisms, genomic imprinting and cancer susceptibility. Pulford DJ, et al. **Mutat Res** 1999 Jan; 436(1):59–67 (79 ref.)

Genetic polymorphisms in Parkinson's disease. Checkoway H, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):635–43 (95 ref.)

Concise review of the cytochrome P450s and their roles in toxicology. Omiecinski CJ, et al. **Toxicol Sci** 1999 Apr; 48(2):151–6 (35 ref.)

Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Büscher R, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):94–9 (30 ref.)

[The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease] Spiering W, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1445–50 (39 ref.) (Eng. Abstr.) **(Dut)**

[The genetic polymorphism of somatotropin] Balatskiĭ VN, et al. **Tsitol Genet** 1998 Mar–Apr;32(2):92–104 (77 ref.) (Eng. Abstr.) **(Rus)**

[Genetic polymorphisms of the renin-angiotensin system and essential hypertension] Fernández-Llama P, et al. **Med Clin (Barc)** 1999 May 1;112(15):561–4 (35 ref.) (Eng. Abstr.) **(Spa)**

[Enzymatic polymorphisms and pulmonary cancer] Ladero JM, et al. **Med Clin (Barc)** 1998 Oct 17;111(12):465–70 (89 ref.) **(Spa)**

IMMUNOLOGY

Major histocompatibility complex class II polymorphisms in primates. Bontrop RE, et al. **Immunol Rev** 1999 Feb; 167:339–50 (50 ref.)

Monomorphism and polymorphism at Mhc DRB loci in domestic and wild ruminants. Mikko S, et al. **Immunol Rev** 1999 Feb;167:169–78 (60 ref.)

Effect of gene conversion on polymorphic patterns at major histocompatibility complex loci. Ohta T. **Immunol Rev** 1999 Feb;167:319–25 (25 ref.)

Antigenic diversity and gene polymorphisms in Haemophilus influenzae. Gilsdorf JR. **Infect Immun** 1998 Nov; 66(11):5053–9 (91 ref.)

POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

see related
DNA FINGERPRINTING
MUTATION

Terminal restriction fragment length polymorphism (T-RFLP): an emerging method for characterizing diversity among homologous populations of amplification products. Marsh TL. **Curr Opin Microbiol** 1999 Jun; 2(3):323–7 (33 ref.)

PCR and RFLP methods for the specific detection and identification of Mycoplasma mycoides subsp. mycoides SC. Bashiruddin JB. **Methods Mol Biol** 1998;104:167–78 (16 ref.)

POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL

Polymerase chain reaction-single strand conformation polymorphism or how to detect reliably and efficiently each sequence variation in many samples and many genes. Jaeckel S, et al. **Electrophoresis** 1998 Dec;19(18):3055–61 (68 ref.)

Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Kutach LS, et al. **Electrophoresis** 1999 Jun;20(6):1204–10 (45 ref.)

Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Nataraj AJ, et al. **Electrophoresis** 1999 Jun;20(6):1177–85 (69 ref.)

Gene mapping in zebrafish using single-strand conformation polymorphism analysis. Foernzler D, et al. **Methods Cell Biol** 1999;60:185–93 (13 ref.)

POLYMORPHONUCLEAR LEUKOCYTE ELASTASE see **LEUKOCYTE ELASTASE**

POLYMORPHONUCLEAR LEUKOCYTES see **NEUTROPHILS**

POLYMYALGIA RHEUMATICA

see related
TEMPORAL ARTERITIS

Polymyalgia rheumatica: a disorder of extraarticular synovial structures? [editorial] Salvarani C, et al. **J Rheumatol** 1999 Mar;26(3):517–21 (33 ref.)

[Polymyalgia rheumatica] Nishikai M. **Nippon Rinsho** 1999 Feb;57(2):370–3 (17 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Bronchiolitis obliterans organizing pneumonia associated with polymyalgia rheumatica. Stey C, et al. **Eur Respir J** 1999 Apr;13(4):926–9 (33 ref.)

DIAGNOSIS

Diagnostic approach in a patient presenting with polymyalgia [editorial] Gonzalez-Gay MA, et al. **Clin Exp Rheumatol** 1999 May–Jun;17(3):276–8 (29 ref.)

DRUG THERAPY

Epidemiology and optimal management of polymyalgia rheumatica. Labbe P, et al. **Drugs Aging** 1998 Aug;

13(2):109–18 (73 ref.)

EPIDEMIOLOGY

Epidemiology and optimal management of polymyalgia rheumatica. Labbe P, et al. **Drugs Aging** 1998 Aug; 13(2):109–18 (73 ref.)

POLYMYOSITIS

The lung in polymyositis. Schwarz MI. **Clin Chest Med** 1998 Dec;19(4):701–12, viii (88 ref.)

Scleromyositis: a scleroderma/polymyositis overlap syndrome [editorial] Jablonska S, et al. **Clin Rheumatol** 1998;17(6):465–7 (25 ref.)

[Polymyositis and dermatomyositis] Yamasaki M, et al. **Nippon Rinsho** 1999 Feb;57(2):339–43 (13 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Acute sympathetic hyperfunction in overlapping syndromes of systemic lupus erythematosus and polymyositis. Nakajima A, et al. **J Rheumatol** 1998 Aug;25(8):1638–41 (12 ref.)

DIAGNOSIS

Dermatomyositis, polymyositis and inclusion body myositis: current concepts [editorial] Illa I, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):13–6 (33 ref.)

ETIOLOGY

Myositis and malignancy: is there a true association? Brown H, et al. **Hosp Med** 1999 Jan;60(1):51–3 (10 ref.)

Thymoma-associated dermatomyositis and polymyositis [editorial; comment] Nagasawa K. **Intern Med** 1999 Feb; 38(2):81–2 (10 ref.) Comment on: Intern Med 1999 Feb;38(2):155–9.

GENETICS

Molecular immunology and genetics of inflammatory muscle diseases. Dalakas MC. **Arch Neurol** 1998 Dec; 55(12):1509–12 (22 ref.)

IMMUNOLOGY

Molecular immunology and genetics of inflammatory muscle diseases. Dalakas MC. **Arch Neurol** 1998 Dec; 55(12):1509–12 (22 ref.)

PATHOLOGY

[Focal myositis: report of a case in pediatric age and review of the literature] Lorenzo-Sanz G, et al. **Rev Neurol** 1998 Sep;27(157):505–8 (28 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Extramuscular manifestations in idiopathic inflammatory myopathies. Spiera R, et al. **Curr Opin Rheumatol** 1998 Nov;10(6):556–61 (52 ref.)

THERAPY

Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Dalakas MC. **Neurology** 1998 Dec;51(6 Suppl 5):S37–45 (30 ref.)

POLYMYXIN B

THERAPEUTIC USE

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Evans ME, et al. **Ann Pharmacother** 1999 Sep;33(9):960–7 (102 ref.)

Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Segal-Maurer S, et al. **Clin Infect Dis** 1999 May; 28(5):1134–8 (36 ref.)

Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application [editorial] Shoji H, et al. **Ther Apher** 1998 Feb;2(1):3–12 (58 ref.)

POLYMYXIN E see **COLISTIN**

POLYNEURITIS

DIAGNOSIS

[Autonomic disorders in polyneuropathies] Hilz MJ, et al. **Med Klin** 1998 Sep 15;93(9):533–40 (103 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Polyneuropathies of pregnancy. Clinical neurophysiological, and anatomo-pathological study apropos of 38 cases collected at the Neurology Clinic of the the Fann University Hospital Center] Thiam A, et al. **Dakar Med** 1996;41(1):47–54 (20 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Plasma cell dyscrasia associated with polyneuropathy and endocrinological abnormality (Takatsuki disease)] Hata H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):472–5 (13 ref.) **(Jpn)**

PATHOLOGY

Autoimmune inflammatory neuropathy. Hadden RD, et al. **J R Coll Physicians Lond** 1999 May-Jun;33(3):219–24 (18 ref.)

PHYSIOPATHOLOGY

Electrophysiologic recovery after vitamin E-deficient neuropathy. Ko HY, et al. **Arch Phys Med Rehabil** 1999 Aug;80(8):964–7 (28 ref.)

POLYNUCLEAR AROMATIC HYDROCARBONS see **POLYCYCLIC HYDROCARBONS, AROMATIC**

POLYNUCLEOTIDE VACCINES see **VACCINES, DNA**

POLYOMAVIRUS

Bovine polyomavirus, a frequent contaminant of calf sera. van der Noordaa J, et al. **Dev Biol Stand** 1999;99:45–7 (10 ref.)

Post-transplantation polyomavirus infections. Boubenider S, et al. **J Nephrol** 1999 Jan-Feb;12(1):24–9 (44 ref.)

ISOLATION & PURIFICATION

A broad spectrum PCR method for the detection of polyomaviruses and avoidance of contamination by cloning vectors. Völter C, et al. **Dev Biol Stand** 1998;94:137–42 (15 ref.)

PATHOGENICITY

Polyomaviruses and human tumors: a brief review of current concepts and interpretations. Lednicky JA, et al. **Front Biosci** 1999 Feb 15;4:D153–64 (168 ref.)

PHYSIOLOGY

Polyomaviruses and human tumors: a brief review of current concepts and interpretations. Lednicky JA, et al. **Front Biosci** 1999 Feb 15;4:D153–64 (168 ref.)

POLYOMAVIRUS HOMINIS 1

ISOLATION & PURIFICATION

Host range analysis of simian virus 40, BK virus and chimaeric SV40/BKV: relative expression of large T-antigen and Vp1 in infected and transformed cells. O'Neill FJ, et al. **Dev Biol Stand** 1998;94:191–205 (33 ref.)

PATHOGENICITY

Molecular biology and pathogenesis of human polyomavirus infections. Dörries K. **Dev Biol Stand** 1998;94:71–9 (24 ref.)

BK virus as a potential co-factor in human cancer. Harris KF, et al. **Dev Biol Stand** 1998;94:81–91 (53 ref.)

POLYOMAVIRUS HOMINIS 2

[Advances in the diagnosis and treatment of infections caused by herpesvirus and JC virus] Arribas JR, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:11–9 (38 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The human polyomavirus, JCV, and neurological diseases (review). Gordon J, et al. **Int J Mol Med** 1998 Apr; 1(4):647–55 (75 ref.)

Convicting a human tumor virus: guilt by association? Blaho JA, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7619–21 (31 ref.)

IMMUNOLOGY

[Disturbance of the normal cell cycle by T antigens of SV40 viruses and JC cause some tumors] Kryńska B, et al. **Postepy Hig Med Dosw** 1998;52(3):237–57 (78 ref.) (Eng. Abstr.) **(Pol)**

PATHOGENICITY

Molecular biology and pathogenesis of human polyomavirus infections. Dörries K. **Dev Biol Stand** 1998;94:71–9 (24 ref.)

Oncogenic potential of human neurotropic papovavirus, JCV, in CNS. Gordon J, et al. **Dev Biol Stand** 1998; 94:93–101 (26 ref.)

Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. Jensen PN, et al. **J Leukoc Biol** 1999 Apr;65(4):428–38 (99 ref.)

POLYOMAVIRUS LARGE T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS MACACAE

New molecular and epidemiological issues in mesothelioma: role of SV40. Carbone M, et al. **J Cell Physiol** 1999 Aug; 180(2):167–72 (34 ref.)

GENETICS

Detection of authentic SV40 DNA sequences in human brain and bone tumours. Butel JS, et al. **Dev Biol Stand** 1998; 94:23–32 (15 ref.)

SV40 DNA sequences in mesotheliomas. Gibbs AR, et al. **Dev Biol Stand** 1998;94:41–5 (8 ref.)

Simian virus 40 footprints in normal human tissues, brain and bone tumours of different histotypes. Martini F, et al. **Dev Biol Stand** 1998;94:55–66 (30 ref.)

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. Rizzo P, et al. **Dev Biol Stand** 1998;94:33–40 (19 ref.)

Search for SV40 in human mesotheliomas. Shah KV. **Dev Biol Stand** 1998;94:67–8 (5 ref.)

Simian virus 40 DNA sequences in human brain and bone tumours. Wang J, et al. **Dev Biol Stand** 1998;94:13–21 (27 ref.)

Cell and molecular biology of simian virus 40: implications for human infections and disease. Butel JS, et al. **J Natl Cancer Inst** 1999 Jan 20;91(2):119–34 (134 ref.)

Gene delivery to the liver using simian virus 40-derived vectors. Strayer DS, et al. **Semin Liver Dis** 1999;19(1):71–81 (51 ref.)

IMMUNOLOGY

[Disturbance of the normal cell cycle by T antigens of SV40 viruses and JC cause some tumors] Kryńska B, et al. **Postepy Hig Med Dosw** 1998;52(3):237–57 (78 ref.) (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

Detection of SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases. Galateau-Salle F, et al. **Dev Biol Stand** 1998;94:147–52 (28 ref.)

Detection of SV40 sequences in human mesothelioma. Griffiths DJ, et al. **Dev Biol Stand** 1998;94:127–36 (20 ref.)

Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Hilleman MR. **Dev Biol Stand** 1998;94:183–90 (16 ref.)

Consideration of PCR methods for the detection of SV40 in tissue and DNA specimens. Lednicky JA, et al. **Dev Biol Stand** 1998;94:155–64 (17 ref.)

SV40 in adenovirus vaccines and adenovirus-SV40 recombinants. Lewis AM Jr. **Dev Biol Stand** 1998;94:207–16 (17 ref.)

Host range analysis of simian virus 40, BK virus and chimaeric SV40/BKV: relative expression of large T-antigen and Vp1 in infected and transformed cells. O'Neill FJ, et al. **Dev Biol Stand** 1998;94:191–205 (33 ref.)

Further validation of SV40-like DNA in human pleural mesotheliomas. Pass H, et al. **Dev Biol Stand** 1998;94:143–5 (6 ref.)

SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Procopio A, et al. **Dev Biol Stand** 1998;94:361–7 (16 ref.)

Examination of poliovaccines for the presence of SV40 sequences. Sangar DV, et al. **Dev Biol Stand** 1998;94:221–5 (10 ref.)

Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer--a review of the epidemiological evidence. Strickler HD, et al. **Dev Biol Stand** 1998;94:235–44 (26 ref.)

METABOLISM

The role of the J domain of SV40 large T in cellular transformation. DeCaprio JA. **Biologicals** 1999 Mar; 27(1):23–8 (36 ref.)

Simian virus 40 infection via MHC class I molecules and caveolae. Norkin LC. **Immunol Rev** 1999 Apr;168:13–22 (55 ref.)

Exploitation of major histocompatibility complex class I molecules and caveolae by simian virus 40. Parton RG, et al. **Immunol Rev** 1999 Apr;168:23–31 (70 ref.)

PATHOGENICITY

Experimental tumour induction by SV40 transformed cells. Cook JL, et al. **Dev Biol Stand** 1998;94:303–9 (15 ref.)

Introduction to simian virus 40: getting by with more than a little help from its host cell. Fanning E. **Dev Biol Stand** 1998;94:3–8 (22 ref.)

Molecular chaperone function of the SV40 large T antigen. Pipas JM. **Dev Biol Stand** 1998;94:313–9 (16 ref.)

SV40 infections in simians and humans. Shah KV. **Dev Biol Stand** 1998;94:9–12 (12 ref.)

SV40 as an oncogenic virus and possible human pathogen. Weiss R, et al. **Dev Biol Stand** 1998;94:355–60, 369–82 (0 ref.)

PHYSIOLOGY

SV40 as a putative human commensal. Levine A, et al. **Dev Biol Stand** 1998;94:245–69 (32 ref.)

SV40-Mediated immortalization. Jha KK, et al. **Exp Cell Res** 1998 Nov 25;245(1):1–7 (49 ref.)

POLYOMAVIRUS MIDDLE T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS SMALL T ANTIGENS

POLYOMAVIRUS SMALL T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS T PROTEINS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS TRANSFORMING ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS TUMOR ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOXYETHYLENES see **POLYETHYLENE GLYCOLS**

POLYPENTOSE SULFATE see **PENTOSAN SULFURIC POLYESTER**

POLYPEPTIDES see **PEPTIDES**

POLYPHARMACY

see related
DRUG THERAPY, COMBINATION

Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. Tanaka E.
J Clin Pharm Ther 1999 Apr;24(2):87–92 (51 ref.)

POLYPHOSPHATES

ANALYSIS

Definitive enzymatic assays in polyphosphate analysis. Ault-Riché D, et al. **Prog Mol Subcell Biol** 1999;23:241–52 (25 ref.)

Methods for investigation of inorganic polyphosphates and polyphosphate-metabolizing enzymes. Lorenz B, et al.
Prog Mol Subcell Biol 1999;23:217–39 (93 ref.)

METABOLISM

Study of polyphosphate metabolism in intact cells by 31-P nuclear magnetic resonance spectroscopy. Chen KY.
Prog Mol Subcell Biol 1999;23:253–73 (49 ref.)

From polyphosphates to bisphosphonates and their role in bone and calcium metabolism. Fleisch H.
Prog Mol Subcell Biol 1999;23:197–216 (95 ref.)

Polyphosphate-accumulating bacteria and enhanced biological phosphorus removal. Kortstee GJ, et al.
Prog Mol Subcell Biol 1999;23:275–97 (69 ref.)

Metabolism and function of polyphosphates in bacteria and yeast. Kulaev IS, et al. **Prog Mol Subcell Biol** 1999;23:27–43 (78 ref.)

Cyclic condensed metaphosphates in plants and the possible correlations between inorganic polyphosphates and other compounds. Niemeyer R. **Prog Mol Subcell Biol** 1999; 23:83–100 (51 ref.)

Inorganic polyphosphate regulates responses of Escherichia coli to nutritional stringencies, environmental stresses and survival in the stationary phase. Rao NN, et al.
Prog Mol Subcell Biol 1999;23:183–95 (34 ref.)

Polyphosphate/poly-(R)-3-hydroxybutyrate) ion channels in cell membranes. Reusch RN. **Prog Mol Subcell Biol** 1999; 23:151–82 (101 ref.)

Inorganic polyphosphate in eukaryotes: enzymes, metabolism and function. Schröder HC, et al.
Prog Mol Subcell Biol 1999;23:45–81 (158 ref.)

POLYPHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOL PHOSPHATES**

POLYPLOIDY

Eukaryote genome duplication - where's the evidence? Skrabanek L, et al. **Curr Opin Genet Dev** 1998 Dec; 8(6):694–700 (60 ref.)

Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Ludwig M, et al. **Hum Reprod** 1998 Aug;13(8):2082–7 (34 ref.)

POLYPORACEAE

GROWTH & DEVELOPMENT

[Advances in the study on the biological characteristics of Grifola umbellata (Pers. ex Fr.) Pilat] Guo S, et al.
Chung Kuo Chung Yao Tsa Chih 1996 Sep;21(9):515–7 (20 ref.) **(Chi)**

POLYPOSIS COLI, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPOSIS SYNDROME, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPROPYLENES

THERAPEUTIC USE

Mesh plug repair and groin hernia surgery. Robbins AW, et al. **Surg Clin North Am** 1998 Dec;78(6):1007–23, vi–vii (54 ref.)

[The use of prosthetic materials placed intraperitoneally in the repair of large defects of the abdominal wall, reflections on a limited case series] Miro AG, et al. **Ann Ital Chir** 1999 Mar-Apr;70(2):277–81; discussion 281–2 (30 ref.) (Eng. Abstr.) **(Ita)**

POLYPROTEINS see **PROTEINS**

POLYPS

Gastric polyps. Debongnie JC. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):187–9 (14 ref.)

CHEMICALLY INDUCED

Tamoxifen-induced endometrial polyp. A case report and review of the literature. Nomikos IN, et al.
Eur J Gynaecol Oncol 1998;19(5):476–8 (13 ref.)

COMPLICATIONS

Hyperplastic gastric polyp causing progressive gastric outlet obstruction. Dean PG, et al. **Mayo Clin Proc** 1998 Oct; 73(10):964–7 (17 ref.)

Polypoid dysplasias in ulcerative colitis and sporadic adenomas: genetic approach to the differential diagnosis (review). Fogt F, et al. **Oncol Rep** 1999 Jul-Aug;6(4):721–5 (26 ref.)

[Gastric polypoid angioma: a rare cause of bleeding in the elderly. Report of a case and review of the literature] Pelizzari E, et al. **Minerva Chir** 1998 May;53(5):405–10 (18 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Unusual gastric polyp showing submucosal proliferation of glands: case report and literature review. Itoh K, et al. **J Gastroenterol** 1998 Oct;33(5):720–3 (23 ref.)

[A rare case of a variant cervical polyp in adolescence] Vasileva P, et al. **Akush Ginekol (Sofiia)** 1998;37(3):56–8 (9 ref.) (Eng. Abstr.) **(Bul)**

[A fibroepithelial myxoid polyp of the renal pelvis in a patient with horseshoe kidneys. Apropos a case] Camacho Garcia C, et al. **Actas Urol Esp** 1999 Jul-Aug;23(7):609–12 (8 ref.) (Eng. Abstr.) **(Spa)**

[Fibroepithelial polyps of the upper urinary tract: their diagnostic evaluation and treatment in pediatrics] Mora Durbán MJ, et al. **Arch Esp Urol** 1999 Jan-Feb;52(1):61–7 (38 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Tamoxifen-associated polyps (basalomas) arising in multiple endometriotic foci: A case report and review of the literature. Schlesinger C, et al. **Gynecol Oncol** 1999 May; 73(2):305–11 (34 ref.)

PATHOLOGY

Gastric polypoid lesions--illustrative cases and literature review. Lau CF, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2559–64 (36 ref.)

Benign fibroepithelial polyps of the renal pelvis. Nowak MA, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):850–2 (22 ref.)

Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases. Thurberg BL, et al. **Hum Pathol** 1999 Jul;30(7):745–52 (37 ref.)

Giant fibrovascular polyp of the esophagus. Belafsky P, et al. **South Med J** 1999 Apr;92(4):428–31 (20 ref.)

SURGERY

[Polypectomy of the digestive tract] Gallo Reynoso S.
Rev Gastroenterol Mex 1998 Oct-Dec;63(4 Suppl 1):S74–9 (30 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Evaluation of polyps by endoscopic ultrasonography (eus): implication for endotherapy. Gillard V.
Acta Gastroenterol Belg 1999 Apr-Jun;62(2):196–9 (32 ref.)

POLYRADICULITIS

VIROLOGY

Cytomegalovirus polyradiculopathy in patients with AIDS. Anders HJ, et al. **Clin Infect Dis** 1998 Aug;27(2):345–52 (100 ref.)

POLYRADICULONEURITIS

see related
MILLER FISHER SYNDROME

[Guillain-Barré syndrome: from the original description to the modern concepts] Raphael JC, et al.
Ann Med Interne (Paris) 1999 Jan;150(1):33–41 (25 ref.) (Eng. Abstr.) **(Fre)**

[Subacute idiopathic demyelinating polyradiculoneuropathy (SIDP)] Hattori N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):475–7 (9 ref.) **(Jpn)**

[Guillain-Barré syndrome] Koga M, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):464–9 (14 ref.) **(Jpn)**

[Chronic inflammatory demyelinating polyneuropathy (CIDP)] Tanaka H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):479–82 (15 ref.) **(Jpn)**

COMPLICATIONS

Ulcerative colitis and acquired demyelinating neuropathy (Guillain-Barré syndrome) [letter] Roca B, et al.
Neth J Med 1999 Mar;54(3):129–30 (8 ref.)

DIAGNOSIS

Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants. Terryberry JW, et al.
Clin Rev Allergy Immunol 1998 Fall;16(3):265–73 (73 ref.)

Guillain-Barré syndrome: recent advances. Hadden RD, et al. **Hosp Med** 1998 Jan;59(1):55–60 (17 ref.)

[A case of pharyngeal-cervical-branchial variant of Guillain-Barré syndrome with IgG anti-GT1a antibody] Nagano K, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):333–5 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Bilateral peripheral facial paralysis and Guillain-Barré syndrome] Garcia Callejo FJ, et al.
Acta Otorrinolaringol Esp 1998 Oct;49(7):561–8 (95 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

IGIV in neurology--evidence and recommendations. Bril V, et al. **Can J Neurol Sci** 1999 May;26(2):139–52 (92 ref.)

EPIDEMIOLOGY

[Polyneuropathies of pregnancy. Clinical neurophysiological, and anatomo-pathological study apropos of 38 cases collected at the Neurology Clinic of the the Fann University Hospital Center] Thiam A, et al. **Dakar Med** 1996;41(1):47–54 (20 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Guillain-Barre syndrome following malaria. Kanjalkar M, et al. **J Infect** 1999 Jan;38(1):48–50 (14 ref.)

Polyradiculopathy in sarcoidosis. Koffman B, et al.
Muscle Nerve 1999 May;22(5):608–13 (38 ref.)

[A case of measles encephaloneuropathy in a pregnant women] Haraguchi T, et al. **No To Shinkei** 1998 Aug; 50(8):761–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[A case of recurrent Guillain-Barré syndrome with myocarditis] Okuma Y, et al. **No To Shinkei** 1999 Mar; 51(3):241–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies] Kusunoki S.
Rinsho Shinkeigaku 1999 Jan;39(1):93–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Campylobacter jejuni enteritis and Guillain-Barré syndrome] Yuki N. **Rinsho Shinkeigaku** 1999 Jan;39(1):17–8 (2 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies [editorial] Hartung HP, et al. **Curr Opin Neurol** 1998 Oct;11(5):497–513 (133 ref.)

[Autoimmune nervous dysfunctions] Kusunoki S.
Nippon Naika Gakkai Zasshi 1999 May 10;88(5):826–31 (5 ref.) **(Jpn)**

MICROBIOLOGY

Update on acute and chronic inflammatory polyneuropathy. Ouvrier R. **J Child Neurol** 1999 Jan;14(1):53–7 (29 ref.)

Guillain-Barré syndrome and Campylobacter infection [letter] Isaäcson M. **J Travel Med** 1998 Sep;5(3):160 (3 ref.)

PATHOLOGY

Autoimmune inflammatory neuropathy. Hadden RD, et al. **J R Coll Physicians Lond** 1999 May-Jun;33(3):219–24 (18 ref.)

PHYSIOPATHOLOGY

Demyelinating inflammatory neuropathies, including Guillain-Barré syndrome [published erratum appears in Curr Opin Neurol 1998 Dec;11(6):739] Steck AJ, et al. **Curr Opin Neurol** 1998 Aug;11(4):311–8 (73 ref.)

Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Trojaborg W. **Electroencephalogr Clin Neurophysiol** 1998 Nov;107(5):303–16 (117 ref.)

[Dysautonomia in Guillain-Barré syndrome] Pfeiffer G.
Nervenarzt 1999 Feb;70(2):136–48 (83 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of Guillain-Barré syndrome with intravenous immunoglobulin. Sater RA, et al. **Neurology** 1998 Dec;51(6 Suppl 5):S9–15 (97 ref.)

Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome [editorial] Hughes RA.
Ther Apher 1997 May;1(2):129–30 (14 ref.)

[Treatment of Guillain-Barré syndrome in adults: role of plasma exchange] Raphael JC, et al. **Rev Med Interne** 1998 Jan;19(1):60–8 (39 ref.) (Eng. Abstr.) **(Fre)**

[Guillain-Barré syndrome in the adult: therapeutic aspects] Raphael JC, et al. **Schweiz Med Wochenschr** 1998 Sep 26;

128(39):1453-61 (39 ref.) (Eng. Abstr.) **(Fre)**

POLYSACCHARIDE-LYASES

CHEMISTRY

alpha-1,4-glucan lyases producing 1,5-anhydro-D-fructose from starch and glycogen have sequence similarity to alpha-glucosidases. Yu S, et al. **Biochim Biophys Acta** 1999 Aug 17;1433(1-2):1-15 (106 ref.)

Structure and evolution of parallel beta-helix proteins. Jenkins J, et al. **J Struct Biol** 1998;122(1-2):236-46 (44 ref.)

POLYSACCHARIDES

Heteropolysaccharides from lactic acid bacteria. De Vuyst L, et al. **FEMS Microbiol Rev** 1999 Apr;23(2):153-77 (145 ref.)

[Frontiers and applications of glycotechnology and glycobiology--introduction] Irimura T, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2602-3 (0 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Three-dimensional power Doppler imaging of the fallopian tube. Sladkevicius P. **Ultrasound Obstet Gynecol** 1999 Apr; 13(4):287 (2 ref.)

ANALYSIS

Glycobiology and proteomics: is mass spectrometry the Holy Grail? Packer NH, et al. **Electrophoresis** 1998 Aug; 19(11):1872-82 (62 ref.)

CHEMISTRY

On the molecular characteristics, compositional properties, and structural-functional mechanisms of maltodextrins: a review. Chronakis IS. **Crit Rev Food Sci Nutr** 1998 Oct; 38(7):599-637 (136 ref.)

Structure and technofunctional properties of protein-polysaccharide complexes: a review. Schmitt C, et al. **Crit Rev Food Sci Nutr** 1998 Nov;38(8):689-753 (238 ref.)

Hairy plant polysaccharides: a close shave with microbial esterases. Williamson G, et al. **Microbiology** 1998 Aug;144 (Pt 8):2011-23 (84 ref.)

Glycoproteins: glycan presentation and protein-fold stability. Wormald MR, et al. **Structure Fold Des** 1999 Jul 15; 7(7):R155-60 (35 ref.)

[Polysaccharides of flower plants: structure and physiological activity] Ovodov IuS. **Bioorg Khim** 1998 Jul;24(7):483-501 (230 ref.) (Eng. Abstr.) **(Rus)**

[Radiochemistry of polysaccharides (review)] Sharpatyĭ VA. **Radiats Biol Radioecol** 1999 Jan-Feb;39(1):156-61 (36 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Applications of lectins and neoglycoconjugates in histology and pathology. Danguy A, et al. **Acta Anat (Basel)** 1998; 161(1-4):206-18 (106 ref.)

Portohepatic vascular pathology and liver disease: diagnosis and monitoring. Bolondi L, et al. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S41-52 (41 ref.)

Diagnosis of renal artery stenosis and renovascular hypertension. Karasch T, et al. **Eur J Ultrasound** 1998 Jul; 7 Suppl 3:S27-39 (60 ref.)

Investigation of peripheral arterial disease--the expanding role of echo-enhanced color flow doppler and duplex sonography. Langholz J. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S53-61 (25 ref.)

Echo-enhanced ultrasound for diagnosis and management in stroke patients. Ringelstein EB. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S3-15 (57 ref.)

Carotid artery stenosis--where do we go from here? Strandness DE, et al. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S17-26 (29 ref.)

IMMUNOLOGY

[A new vaccine concept: polysaccharide conjugate vaccines] Moreau M. **Ann Pharm Fr** 1999 May;57(3):223-31 (22 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Simultaneous bioconversion of cellulose and hemicellulose to ethanol. Chandrakant P, et al. **Crit Rev Biotechnol** 1998; 18(4):295-331 (190 ref.)

Novel forms of protein glycosylation. Vliegenthart JF, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):565-71 (38 ref.)

Production of ginseng and its bioactive components in plant cell culture: current technological and applied aspects. Wu J, et al. **J Biotechnol** 1999 Feb 19;68(2-3):89-99 (56 ref.)

Structure and function analysis of Pseudomonas plant cell wall hydrolases. Hazlewood GP, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:211-41 (81 ref.)

The cellulosome concept as an efficient microbial strategy for the degradation of insoluble polysaccharides. Shoham Y, et al. **Trends Microbiol** 1999 Jul;7(7):275-81 (66 ref.)

[VIP36 recognizes high-mannose type glycans in relation to apical membrane traffic] Yamashita K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2455-63 (41 ref.) **(Jpn)**

PHARMACOLOGY

[Polysaccharides of flower plants: structure and physiological activity] Ovodov IuS. **Bioorg Khim** 1998 Jul;24(7):483-501 (230 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Role of lectins (and rhizobial exopolysaccharides) in legume nodulation. Hirsch AM. **Curr Opin Plant Biol** 1999 Aug; 2(4):320-6 (53 ref.)

Glycans in post-Golgi apical targeting: sorting signals or structural props? Rodriguez-Boulan E, et al. **Trends Cell Biol** 1999 Aug;9(8):291-4 (45 ref.)

RADIATION EFFECTS

[Radiochemistry of polysaccharides (review)] Sharpatyĭ VA. **Radiats Biol Radioecol** 1999 Jan-Feb;39(1):156-61 (36 ref.) (Eng. Abstr.) **(Rus)**

POLYSACCHARIDES, BACTERIAL

BIOSYNTHESIS

Xanthan gum biosynthesis and application: a biochemical/genetic perspective. Becker A, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):145-52 (65 ref.)

Genetic organization of the regions associated with surface polysaccharide synthesis in Vibrio cholerae O1, O139 and Vibrio anguillarum O1 and O2: a review. Stroeher UH, et al. **Gene** 1998 Nov 26;223(1-2):269-82 (61 ref.)

CHEMISTRY

Structure and conformation of complex carbohydrates of glycoproteins, glycolipids, and bacterial polysaccharides. Bush CA, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:269-93 (150 ref.)

Extracellular polysaccharides and polysaccharide-containing biopolymers from Azospirillum species: properties and the possible role in interaction with plant roots. Skvortsov IM, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):223-9 (47 ref.)

GENETICS

Genetic organization of the regions associated with surface polysaccharide synthesis in Vibrio cholerae O1, O139 and Vibrio anguillarum O1 and O2: a review. Stroeher UH, et al. **Gene** 1998 Nov 26;223(1-2):269-82 (61 ref.)

IMMUNOLOGY

Conjugated polysaccharide vaccines. Ahmad H, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):113-33, vii (133 ref.)

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S117-22 (19 ref.)

Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Wasserman RL, et al. **Pediatr Infect Dis J** 1999 Feb; 18(2):157-63 (37 ref.)

PHYSIOLOGY

Extracellular polysaccharides and polysaccharide-containing biopolymers from Azospirillum species: properties and the possible role in interaction with plant roots. Skvortsov IM, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):223-9 (47 ref.)

Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Heinrichs DE, et al. **Mol Microbiol** 1998 Oct;30(2):221-32 (33 ref.)

Structure, assembly and regulation of expression of capsules in Escherichia coli. Whitfield C, et al. **Mol Microbiol** 1999 Mar;31(5):1307-19 (52 ref.)

THERAPEUTIC USE

Group B streptococcus. Schuchat A. **Lancet** 1999 Jan 2; 353(9146):51-6 (33 ref.)

POLYSOMNOGRAPHY

Sleep studies. Current techniques and future trends. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):195-210 (25 ref.)

Diagnostic techniques in obstructive sleep apnea. George CF. **Prog Cardiovasc Dis** 1999 Mar-Apr;41(5):355-66 (78 ref.)

[Prematurity and sudden infant death syndrome. Polysomnography in question] Lequien P, et al. **Arch Pediatr** 1999 Jun;6(6):683-5 (16 ref.) (Eng. Abstr.) **(Fre)**

[Measurement of respiratory effort (esophageal pressure) and estimation of resistance of the upper airway in polysomnography: indications, limitations and results] Loiodice C, et al. **Neurophysiol Clin** 1998 Dec;28(6):507-20 (29 ref.) (Eng. Abstr.) **(Fre)**

[Polysomnographic screening of infants at risk for SIDS] Hirsch A, et al. **Orv Hetil** 1999 Jan 10;140(2):67-72 (49 ref.) (Eng. Abstr.) **(Hun)**

POLYTEF see **POLYTETRAFLUOROETHYLENE**

POLYTETRAFLUOROETHYLENE

Reconstruction of the temporomandibular joint using calvarial bone after a failed Teflon-Proplast implant. Lee JJ, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):457-61 (14 ref.)

[Current status and trends of guided tissue regeneration materials] Zhang Q, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):365-8 (28 ref.) **(Chi)**

[Composite fluorine polymer-containing sorbents for isolation and purification of biopolymers] Kapustin DV, et al. **Bioorg Khim** 1998 Nov;24(11):868-76 (23 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Injection therapy for stress incontinence in women. Su TH, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(3):200-6 (77 ref.)

THERAPEUTIC USE

[The use of prosthetic materials placed intraperitoneally in the repair of large defects of the abdominal wall, reflections on a limited case series] Miro AG, et al. **Ann Ital Chir** 1999 Mar-Apr;70(2):277-81; discussion 281-2 (30 ref.) (Eng. Abstr.) **(Ita)**

POLYURETHANES

A new technology of microdispersed silver in polyurethane induces antimicrobial activity in central venous catheters. Guggenbichler JP, et al. **Infection** 1999;27 Suppl 1:S16-23 (49 ref.)

Biomedical applications of polyurethanes: a review of past promises, present realities, and a vibrant future. Zdrahala RJ, et al. **J Biomater Appl** 1999 Jul;14(1):67-90 (63 ref.)

METABOLISM

Microbial degradation of polyurethane, polyester polyurethanes and polyether polyurethanes. Nakajima-Kambe T, et al. **Appl Microbiol Biotechnol** 1999 Feb;51(2):134-40 (90 ref.)

Synthesis of cholesterol esterase by monocyte-derived macrophages: a potential role in the biodegradation of poly(urethane)s. Labow RS, et al. **J Biomater Appl** 1999 Jan;13(3):187-205 (75 ref.)

POLYURIA

[Polyuropolydipsic syndromes] Fouqueray B, et al. **Presse Med** 1998 Oct 10;27(30):1545-53 (67 ref.) (Eng. Abstr.) **(Fre)**

POLYVINYLPYRROLIDONE IODINE see **POVIDONE-IODINE**

POLYVINYLS

Long-term follow-up of a sponge breast implant and review of the literature. Glatt BS, et al. **Ann Plast Surg** 1999 Feb; 42(2):196-201 (18 ref.)

Polyvinyl siloxane impression materials: an update on clinical use. Mandikos MN. **Aust Dent J** 1998 Dec;43(6):428-34 (48 ref.)

POMC see **PRO-OPIOMELANOCORTIN**

POMPE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE II**

PONS

[Brown-Vialetto-Van Laere syndrome: a case with anti-ganglioside GM1 antibodies and literature review] Sztajzel R, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):51-4 (10 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Parallel circuits for emotional coping behaviour: new pieces in the puzzle [comment] Bernard JF, et al. **J Comp Neurol** 1998 Nov 30;401(4):429-36 (130 ref.) Comment on: J Comp Neurol 1998 Nov 30;401(4):437-54. Comment on: J Comp Neurol 1998 Nov 30;401(4):455-79. Comment on: J Comp Neurol 1998 Nov 30;401(4):480-505.

INJURIES

Frontal syndrome as a consequence of lesions in the pedunculopontine tegmental nucleus: a short theoretical review. Winn P. **Brain Res Bull** 1998 Dec;47(6):551-63 (141 ref.)

PATHOLOGY

Voiding and MRI analysis of the brain. Sakakibara R, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(3):192-9 (47 ref.)

PHYSIOLOGY

Brain activation during micturition [editorial; comment] Fowler CJ. **Brain** 1998 Nov;121 (Pt 11):2031-2 (11 ref.) Comment on: Brain 1998 Nov;121 (Pt 11):2033-42.

PONS

The parabrachial nucleus and conditioned taste aversion. Reilly S. **Brain Res Bull** 1999 Feb;48(3):239–54 (170 ref.)
Vasopressin in the locus coeruleus and dorsal pontine tegmentum affects posture and vestibulospinal reflexes. Pompeiano O. **Prog Brain Res** 1998;119:537–54 (65 ref.)
Synaptic excitation in the dorsal nucleus of the lateral lemniscus. Wu SH. **Prog Neurobiol** 1999 Feb;57(3):357–75 (106 ref.)
Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions. Valentino RJ, et al. **Trends Pharmacol Sci** 1999 Jun;20(6):253–60 (79 ref.)

PHYSIOPATHOLOGY

Frontal syndrome as a consequence of lesions in the pedunculopontine tegmental nucleus: a short theoretical review. Winn P. **Brain Res Bull** 1998 Dec;47(6):551–63 (141 ref.)

PONSINOMYCIN see **MIOCAMYCIN**

PONTIC see **DENTURE, PARTIAL, FIXED**

PONTINE MYELINOLYSIS, CENTRAL see **MYELINOLYSIS, CENTRAL PONTINE**

PONTOPORIA see **DOLPHINS**

PONTOPORIIDAE see **DOLPHINS**

PONV see **POSTOPERATIVE NAUSEA AND VOMITING**

POPLITEAL ARTERY

Popliteal pseudoaneurysm caused by an adjacent osteochondroma: a case report and review of the literature. Wiater JM, et al. **Am J Orthop** 1999 Jul;28(7):412–6 (32 ref.)
Spontaneous popliteal artery dissection: a case report and review of the literature. Rabkin DG, et al. **J Vasc Surg** 1999 Apr;29(4):737–40 (10 ref.)

ABNORMALITIES

Popliteal artery entrapment syndrome. Stager A, et al. **Sports Med** 1999 Jul;28(1):61–70 (49 ref.)

SURGERY

Iliac to popliteal artery bypass through the iliac wing: An alternative extracavitary route for management of complex groin injuries. Donayre CE, et al. **Ann Vasc Surg** 1999 Mar; 13(2):209–15 (23 ref.)
Minimally invasive in situ bypass. Rosenthal D, et al. **Surg Clin North Am** 1999 Jun;79(3):645–52, x (07 ref.)

POPLITEAL CYST

DIAGNOSIS

Ganglia of the posterior cruciate ligament. A report of three cases and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998;57(3):165–8 (8 ref.)
Tibial neuroma presenting as a Baker cyst. A case report. DeLuca PF, et al. **J Bone Joint Surg Am** 1999 Jun; 81(6):856–8 (10 ref.)

EPIDEMIOLOGY

Prevalence of popliteal cysts in children. A sonographic study and review of the literature. Seil R, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):73–5 (20 ref.)

SURGERY

Ganglia of the posterior cruciate ligament. A report of three cases and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998;57(3):165–8 (8 ref.)
[Baker's cyst--current surgical status. Overview and personal results (see comments)] Burger C, et al. **Chirurg** 1998 Nov; 69(11):1224–9 (24 ref.) (Eng. Abstr.) Comment in: Chirurg 1999 Feb;70(2):217. **(Ger)**

ULTRASONOGRAPHY

Prevalence of popliteal cysts in children. A sonographic study and review of the literature. Seil R, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):73–5 (20 ref.)

POPLITEAL VEIN

Popliteal vein aneurysm as a source of recurrent pulmonary embolism. Cairols MA, et al. **Eur J Vasc Endovasc Surg** 1999 Aug;18(2):171–3 (10 ref.)
Deep venous thrombosis: recent advances and optimal investigation with US. Fraser JD, et al. **Radiology** 1999 Apr;211(1):9–24 (118 ref.)

POPULATION-BASED PLANNING see **COMMUNITY HEALTH PLANNING**

POPULATION CONTROL

see related
ABORTION, LEGAL
CONTRACEPTION
FAMILY PLANNING
STERILIZATION, SEXUAL

METHODS

Barriers to uptake and use of modern methods of contraception in developing countries. Konje JC, et al. **Int J Gynaecol Obstet** 1999 Jun;65(3):287–94 (25 ref.)

POPULATION DENSITY

see related
CROWDING
SOCIAL ISOLATION

POPULATION DISTRIBUTION see **DEMOGRAPHY**

POPULATION DYNAMICS

see related
GENETICS, POPULATION

Assessing the impact of disease vectors on animal populations. Canals M, et al. **Acta Biotheor** 1998–99; 46(4):337–45 (29 ref.)
Who are "the homeless"? Reconsidering the stability and composition of the homeless population. Phelan JC, et al. **Am J Public Health** 1999 Sep;89(9):1334–8 (36 ref.)
The changing elderly population and future health care needs. Mechanic D. **J Urban Health** 1999 Mar;76(1):24–38 (21 ref.)
The transition to agricultural sustainability. Ruttan VW. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5960–7 (66 ref.)
Dispersal, gene flow, and population structure. Bohonak AJ. **Q Rev Biol** 1999 Mar;74(1):21–45 (121 ref.)
Shaken not stirred: on permanence in ecological communities. Jansen VA, et al. **Theor Popul Biol** 1998 Dec;54(3):195–201 (48 ref.)
Baby Boomers likely to go out with a bang. Kennedy M. **WMJ** 1998 Dec;97(11):24–7 (0 ref.)

POPULATION EXPLOSION see **POPULATION GROWTH**

POPULATION GROWTH

Current status of reproductive behaviour in Africa. Bambra CS. **Hum Reprod Update** 1999 Jan–Feb;5(1):1–20 (158 ref.)
From pre-hispanic to future conservation alternatives: lessons from Mexico. Gómez-Pompa A, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5982–6 (41 ref.)

POPULATION SURVEILLANCE

Selected global health care activities of the Hospital Infections Program, Centers for Disease Control and Prevention. Manangan LP, et al. **Am J Infect Control** 1999 Jun;27(3):270–4 (8 ref.)
Public health surveillance for hereditary hemochromatosis. Wetterhall SF, et al. **Ann Intern Med** 1998 Dec 1; 129(11):980–6 (58 ref.)
Preventing pneumococcal disease: a Canadian consensus conference. 16–18 February 1998. **Can Commun Dis Rep** 1999 Feb 15;25(4):25–35 (0 ref.) **(Eng, Fre)**
Global control and Leishmania HIV co-infection. Desjeux P. **Clin Dermatol** 1999 May–Jun;17(3):317–25 (13 ref.)
Ten years of the SWORD project. Surveillance of Work-related and Occupational Respiratory Disease [see comments] Ross DJ. **Clin Exp Allergy** 1999 Jun;29(6):750–3 (23 ref.) Comment in: Clin Exp Allergy 1999 Jun;29(6):725–8.
The global impact of HIV infection and disease. Nicoll A, et al. **Commun Dis Public Health** 1999 Jun;2(2):85–95 (54 ref.)
Cytogenetic effects of ethylene oxide, with an emphasis on population monitoring. Preston RJ. **Crit Rev Toxicol** 1999 May;29(3):263–82 (68 ref.)
The application of population pharmacokinetics to the drug development process. Jackson KA, et al. **Drug Dev Ind Pharm** 1998 Dec;24(12):1155–62 (56 ref.)
Improvement of surveillance programs for sexually transmitted infections and related conditions. Mårdh PA. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):136–46 (26 ref.)
Limitations of current surveillance programs for sexually transmitted infections and allied conditions affecting reproductive health care. Mårdh PA. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):147–54 (11 ref.)
Cancer screening in the elderly. van Dongen JA. **Eur J Surg Oncol** 1998 Oct;24(5):367–9 (15 ref.)
Maternal mortality in the developing world: many unanswered questions. Rizvi JH, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):149–51 (24 ref.)
Population-based research assessing the effectiveness of trauma systems [see comments] Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S59–66 (32 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S67–8.
Federal surveillance of veterinary drugs and chemical residues (with recent data). Paige JC, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):45–61, viii (6 ref.)
[Surveillance of multiresistant bacteria: justification, role of the laboratory, indicators, and recent French data] Marty L, et al. **Pathol Biol (Paris)** 1998 Apr;46(4):217–26 (20 ref.) (Eng. Abstr.) **(Fre)**
[Colorectal cancer: prevention and screening] Tariciotti G, et al. **Ann Ital Med Int** 1998 Oct–Dec;13(4):217–26 (64 ref.) (Eng. Abstr.) **(Ita)**
[The toxicology and prevention of the risks of occupational exposure to aromatic polycyclic hydrocarbons. III. The effects: epidemiological evidence, early effects. Individual hypersusceptibility. Health surveillance] Porru S, et al. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):152–63 (60 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Colorectal cancer: risk factors and recommendations for early detection [see comments] Read TE, et al. **Am Fam Physician** 1999 Jun;59(11):3083–92 (46 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2979–80.
Alcohol intake assessment: the sober facts. Feunekes GI, et al. **Am J Epidemiol** 1999 Jul 1;150(1):105–12 (41 ref.)
Use of national data systems for firearm-related injury surveillance. Annest JL, et al. **Am J Prev Med** 1998 Oct; 15(3 Suppl):17–30 (31 ref.)
Why firearm injury surveillance? Frattaroli S, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):2–5 (17 ref.)
Firearm injury surveillance at the local level from data to action. Kellermann AL, et al. **Am J Prev Med** 1998 Oct; 15(3 Suppl):109–12 (25 ref.)
Prospects and challenges in implementing firearm-related injury surveillance in the United States. Not a flash in the pan. Koo D, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):120–4 (36 ref.)
Firearm-related injury surveillance. An overview of progress and the challenges ahead. Mercy JA, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):6–16 (41 ref.)
Fatal firearm-related injury surveillance in Maryland. Wiersema B, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):46–56 (4 ref.)
A world behaving badly: the global challenge for behavioral surveillance [editorial] McQueen DV. **Am J Public Health** 1999 Sep;89(9):1312–4 (26 ref.)
Surveillance and prevention of hepatitis B virus transmission [comment] Smith N, et al. **Am J Public Health** 1999 Jan; 89(1):11–3 (23 ref.) Comment on: Am J Public Health 1999 Jan;89(1):14–8. Comment on: Am J Public Health 1999 Jan;89(1):19–24.
Alcohol-related injuries: Do we really need more proof? [editorial; comment] Hargarten SW. **Ann Emerg Med** 1999 Jun;33(6):699–701 (9 ref.) Comment on: Ann Emerg Med 1999 Jun;33(6):659–68.
Rapid assessment methodology: its origins, development and use by the United Nations International Drug Control Programme [editorial] **Bull Narc** 1996;48(1-2):1–10 (40 ref.)
Perspectives on epidemiologic surveillance in the 21st century [see comments] Choi BC. **Chronic Dis Can** 1998; 19(4):145–51 (36 ref.) Comment in: Chronic Dis Can 1998 ;19(4):143–4.
Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)
Occupational cancer research in the Nordic countries. Kjaerheim K. **Environ Health Perspect** 1999 May;107 Suppl 2:233–8 (113 ref.)
Case-case comparisons to study causation of common infectious diseases. McCarthy N, et al. **Int J Epidemiol** 1999 Aug;28(4):764–8 (24 ref.)
Surveillance and occupational health. Fine LJ. **Int J Occup Environ Health** 1999 Jan–Mar;5(1):26–9 (19 ref.)
Medical surveillance of animal handlers. McMurry FG, et al. **Occup Med** 1999 Apr–Jun;14(2):317–36 (78 ref.)
Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. **World Health Organ Tech Rep Ser** 1998;881:I–VI, 1–114 (8 ref.)
[The potentials and prospects for the use of computer systems for the surveillance of hospital bacterial infections] Men'shikov DD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar–Apr; (2):104–7 (47 ref.) **(Rus)**

PORCELAIN see **DENTAL PORCELAIN**

PORCINE HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS see **CORONAVIRUS**

PORCINE INFLUENZA A VIRUS see **INFLUENZA A VIRUS, PORCINE**

PORCINE INFLUENZA VIRUS TYPE A see **INFLUENZA A VIRUS, PORCINE**

PORCINE XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

PORCINE XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

PORCUPINES see **RODENTIA**

PORE PROTEINS see **PORINS**

PORFIMER see **DIHEMATOPORPHYRIN ETHER**

PORIFERA

Evolution of metazoan collagens. Garrone R.
Prog Mol Subcell Biol 1998;21:119–39 (136 ref.)

CHEMISTRY

The discovery and development of marine compounds with pharmaceutical potential. Munro MH, et al.
J Biotechnol 1999 Apr 30;70(1–3):15–25 (23 ref.)
Marine spongean cytotoxins. Kobayashi M, et al.
J Nat Toxins 1999 Jun;8(2):249–58 (31 ref.)
[Marine natural products influencing larval settlement and metamorphosis of marine sessile organisms] Tsukamoto S.
Yakugaku Zasshi 1999 Jul;119(7):457–71 (45 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Evolution of early Metazoa: phylogenetic status of the Hexactinellida within the phylum of Porifera (sponges). Müller WE, et al. **Prog Mol Subcell Biol** 1998;21:141–56 (49 ref.)

GENETICS

Towards an understanding of the molecular basis of immune responses in sponges: the marine demosponge Geodia cydonium as a model. Müller WE, et al.
Microsc Res Tech 1999 Feb 15;44(4):219–36 (80 ref.)
Structure and evolution of genes encoding polyubiquitin in marine sponges. Gamulin V, et al.
Prog Mol Subcell Biol 1998;21:157–81 (73 ref.)

IMMUNOLOGY

Towards an understanding of the molecular basis of immune responses in sponges: the marine demosponge Geodia cydonium as a model. Müller WE, et al.
Microsc Res Tech 1999 Feb 15;44(4):219–36 (80 ref.)

PHYSIOLOGY

Cell adhesion and histocompatibility in sponges. Fernàndez-Busquets X, et al. **Microsc Res Tech** 1999 Feb 15;44(4):204–18 (160 ref.)
Dissociated cells of the calcareous sponge clathrina: a model for investigating cell adhesion and cell motility in vitro. Gaino E, et al. **Microsc Res Tech** 1999 Feb 15;44(4):279–92 (125 ref.)
Molecular self-recognition and adhesion via proteoglycan to proteoglycan interactions as a pathway to multicellularity: atomic force microscopy and color coded bead measurements in sponges. Misevic GN.
Microsc Res Tech 1999 Feb 15;44(4):304–9 (40 ref.)
Sponges (Porifera) molecular model systems to study cellular differentiation in Metazoa. Müller WE, et al.
Prog Mol Subcell Biol 1998;21:71–95 (104 ref.)

PORINS

CHEMISTRY

Molecular dynamics simulations of membranes with embedded proteins and peptides: porin, alamethicin and influenza virus M2. Sansom MS, et al.
Biochem Soc Trans 1998 Aug;26(3):438–43 (27 ref.)

IMMUNOLOGY

[Some aspects of the study of gonorrhea vaccine] He F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul; 32(4):248–50 (20 ref.) **(Chi)**

METABOLISM

Mechanisms of solute transport through outer membrane porins: burning down the house. Klebba PE, et al.
Curr Opin Microbiol 1998 Apr;1(2):238–47 (86 ref.)
Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Nir S, et al.
Mol Membr Biol 1999 Jan–Mar;16(1):95–101 (36 ref.)

PHYSIOLOGY

The mitochondrial permeability transition pore and its role in cell death. Crompton M. **Biochem J** 1999 Jul 15;341 (Pt 2):233–49 (208 ref.)
Characterization of the yeast mitochondria unselective channel: a counterpart to the mammalian permeability transition pore? Manon S, et al. **J Bioenerg Biomembr** 1998 Oct;30(5):419–29 (57 ref.)

PORNOGRAPHY see **EROTICA**

POROKERATOSIS

DIAGNOSIS

[Porokeratosis Mibelli gigantea: case report and literature review] Götz A, et al. **Hautarzt** 1999 Jun;50(6):435–8 (45 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Porokeratosis and immunosuppression. Kanitakis J, et al.
Eur J Dermatol 1998 Oct–Nov;8(7):459–65 (88 ref.)

PATHOLOGY

Vulvar porokeratosis: case report and review of the literature. Robinson JB, et al. **Int J Gynecol Pathol** 1999 Apr; 18(2):169–73 (34 ref.)

POROKERATOSIS PALMARIS ET PLANTARIS DISSEMINATA see **POROKERATOSIS**

PORPHOBILINOGEN AMMONIA-LYASE see **HYDROXYMETHYLBILANE SYNTHASE**

PORPHOBILINOGEN DEAMINASE see **HYDROXYMETHYLBILANE SYNTHASE**

PORPHOBILINOGEN SYNTHASE

CHEMISTRY

Structure and mechanism of enzymes involved in the assembly of the tetrapyrrole macrocycle.
Shoolingin-Jordan PM. **Biochem Soc Trans** 1998 Aug; 26(3):326–36 (43 ref.)

METABOLISM

Structure and mechanism of enzymes involved in the assembly of the tetrapyrrole macrocycle.
Shoolingin-Jordan PM. **Biochem Soc Trans** 1998 Aug; 26(3):326–36 (43 ref.)

PORPHYRIA

see related
HYDROXYMETHYLBILANE SYNTHASE

The porphyrias. Nordmann Y, et al. **J Hepatol** 1999;30 Suppl 1:12–6 (10 ref.)
[Porphyrins and porphyrias] Bogard C, et al.
Ann Biol Clin (Paris) 1998 Jul;56 Spec No:11–22 (43 ref.) **(Fre)**

CHEMICALLY INDUCED

Pseudoporphyria induced by propionic acid derivatives. Al-Khenaizan S, et al. **J Cutan Med Surg** 1999 Jan; 3(3):162–6 (29 ref.)

ENZYMOLOGY

Porphyrias. Scarlett YV, et al. **J Clin Gastroenterol** 1998 Oct; 27(3):192–8 (16 ref.)

ETIOLOGY

[Extrahepatic manifestations of hepatitis C virus] Tohme A, et al. **J Med Liban** 1998 Mar–Apr;46(2):84–8 (58 ref.) **(Fre)**
[Disorders of porphyrin metabolism. 2: Diagnosis and therapy] Van de Velde R, et al. **Fortschr Med** 1998 Aug 20;116(22–23):44–6 (14 ref.) **(Ger)**

GENETICS

The genetic bases of the porphyrias. Frank J, et al.
Skin Pharmacol Appl Skin Physiol 1998 Nov–Dec; 11(6):297–309 (100 ref.)

METABOLISM

The photodynamic and non-photodynamic actions of porphyrins. Afonso SG, et al. **Braz J Med Biol Res** 1999 Mar;32(3):255–66 (56 ref.)

PATHOLOGY

The acute porphyrias. Gordon N. **Brain Dev** 1999 Sep; 21(6):373–7 (20 ref.)

PHYSIOPATHOLOGY

The porphyrias. Nordmann Y, et al. **J Hepatol** 1999;30 Suppl 1:12–6 (10 ref.)

THERAPY

The porphyrias. Nordmann Y, et al. **J Hepatol** 1999;30 Suppl 1:12–6 (10 ref.)

PORPHYRIA, ACUTE INTERMITTENT

Acute intermittent porphyria: mutation analysis and identification of gene carriers in a German kindred by PCR-DGGE analysis. Petrides PE.
Skin Pharmacol Appl Skin Physiol 1998 Nov–Dec; 11(6):374–80 (24 ref.)

DIAGNOSIS

[Perplexing acute or chronic somatic or psychiatric symptoms: possibly due to porphyria] Schattenberg AV, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1801–4 (17 ref.) (Eng. Abstr.) **(Dut)**

PORPHYRIA CUTANEA TARDA

CHEMICALLY INDUCED

Nonsteroidal anti-inflammatory-induced pseudoporphyria: is there an alternative drug? Checketts SR, et al. **Cutis** 1999 Apr;63(4):223–5 (30 ref.)

DIAGNOSIS

Porphyria cutanea tarda. Don't forget to look at the urine. Rich MW. **Postgrad Med** 1999 Apr;105(4):208–10, 213–4 (9 ref.)
[Porphyria cutanea tarda] Fritsch C, et al. **Hautarzt** 1998 Nov;49(11):870–82; quiz 882 (89 ref.) **(Ger)**

ETIOLOGY

Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature. Huang WS, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar; 22(1):111–6 (20 ref.)
Alcohol intake and porphyria cutanea tarda. Elder GH.
Clin Dermatol 1999 Jul–Aug;17(4):431–6 (55 ref.)
Iron overload in porphyria cutanea tarda. Sampietro M, et al. **Haematologica** 1999 Mar;84(3):248–53 (65 ref.)

PATHOLOGY

Porphyria cutanea tarda. Fritsch C, et al.
Skin Pharmacol Appl Skin Physiol 1998 Nov–Dec; 11(6):321–35 (86 ref.)

URINE

Porphyria cutanea tarda. Don't forget to look at the urine. Rich MW. **Postgrad Med** 1999 Apr;105(4):208–10, 213–4 (9 ref.)

PORPHYRIA, ERYTHROHEPATIC

COMPLICATIONS

Erythropoietic protoporphyria with fatal liver failure. Ishibashi A, et al. **J Gastroenterol** 1999 Jun;34(3):405–9 (17 ref.)

GENETICS

Clinical implications of the molecular biology of erythropoietic protoporphyria. Todd DJ.
J Eur Acad Dermatol Venereol 1998 Nov;11(3):207–13 (83 ref.)

SURGERY

[Severe liver failure in erythropoietic protoporphyria. A report of a case treated by liver transplantation] Jiménez-Sáenz M, et al. **Med Clin (Barc)** 1999 Jul 10; 113(5):176–9 (20 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Erythropoietic protoporphyria with fatal liver failure. Ishibashi A, et al. **J Gastroenterol** 1999 Jun;34(3):405–9 (17 ref.)

PORPHYRIA, HEPATIC

Variegate porphyria: past, present and future. Frank J, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov–Dec; 11(6):310–20 (73 ref.)
[Hepatic porphyria] Nordmann Y, et al. **Rev Med Interne** 1999 Apr;20(4):333–40 (22 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Hepatic porphyrias and alcohol] Doss MO, et al.
Med Klin 1999 Jun 15;94(6):314–28 (116 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

[Acute hepatic porphyrias] Nordmann Y.
Rev Med Interne 1998;19 Suppl 3:358S–360S (6 ref.) **(Fre)**

PORPHYRIA, VARIEGATE see **PORPHYRIA, HEPATIC**

PORPHYRINOGENS

ADVERSE EFFECTS

Porphyria cutanea tarda. Fritsch C, et al.
Skin Pharmacol Appl Skin Physiol 1998 Nov–Dec; 11(6):321–35 (86 ref.)

PORPHYRINS

[Porphyrins and porphyrias] Bogard C, et al.
Ann Biol Clin (Paris) 1998 Jul;56 Spec No:11–22 (43 ref.) **(Fre)**

CHEMISTRY

Photodynamic diagnosis and therapy in dermatology. Fritsch C, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov–Dec; 11(6):358–73 (74 ref.)

PORPHYRINS

METABOLISM

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Fritsch C, et al. **Br J Cancer** 1999 Mar;79(9-10):1603-8 (36 ref.)

Photochemically driven models of oxygenases based on the use of iron porphyrins. Maldotti A, et al. **J Biol Inorg Chem** 1999 Apr;4(2):154-61 (61 ref.)

PHARMACOLOGY

The photodynamic and non-photodynamic actions of porphyrins. Afonso SG, et al. **Braz J Med Biol Res** 1999 Mar;32(3):255-66 (56 ref.)

RADIATION EFFECTS

The photodynamic and non-photodynamic actions of porphyrins. Afonso SG, et al. **Braz J Med Biol Res** 1999 Mar;32(3):255-66 (56 ref.)

PORPHYROMONAS

Infected cardiac myxoma. Case report and literature review. Revankar SG, et al. **Medicine (Baltimore)** 1998 Sep; 77(5):337-44 (74 ref.)

PORPHYROMONAS GINGIVALIS

[The application of a transponson, Tn4351, to an oral anaerobe, Porphyromonas gingivalis] Hayashi J, et al. **Nippon Saikingaku Zasshi** 1998 Aug;53(3):509-18 (12 ref.) **(Jpn)**

ENZYMOLOGY

Role of gingipains R in the pathogenesis of Porphyromonas gingivalis-mediated periodontal disease. Genco CA, et al. **Clin Infect Dis** 1999 Mar;28(3):456-65 (67 ref.)

ISOLATION & PURIFICATION

Porphyromonas gingivalis in an edentulous proband. A case-report. Danser MM, et al. **J Clin Periodontol** 1998 Nov;25(11 Pt 1):933-6 (21 ref.)

METABOLISM

Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Lamont RJ, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1244-63 (285 ref.)

PATHOGENICITY

Role of gingipains R in the pathogenesis of Porphyromonas gingivalis-mediated periodontal disease. Genco CA, et al. **Clin Infect Dis** 1999 Mar;28(3):456-65 (67 ref.)

Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Lamont RJ, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1244-63 (285 ref.)

[Study on stimulatory mechanism of inflammatory bone resorption induced by Porphyromonas gingivalis] Hanazawa S. **Nippon Saikingaku Zasshi** 1998 Nov; 53(4):571-86 (66 ref.) **(Jpn)**

PHYSIOLOGY

Animal models for Porphyromonas gingivalis-mediated periodontal disease. Genco CA, et al. **Trends Microbiol** 1998 Nov;6(11):444-9 (35 ref.)

PORT-WINE STAIN

PATHOLOGY

Phacomatosis pigmentovascularis type IIb associated with Sturge-Weber syndrome and pyogenic granuloma. Hagiwara K, et al. **J Dermatol** 1998 Nov;25(11):721-9 (26 ref.)

RADIOTHERAPY

Port-wine stains unresponsive to pulsed dye laser: explanations and solutions. Lanigan SW. **Br J Dermatol** 1998 Aug;139(2):173-7 (39 ref.)

SURGERY

Possible hazards of cryogen use with pulsed dye laser. A case report and summary. White JM, et al. **Dermatol Surg** 1999 Mar;25(3):250-2; discussion 252-3 (1 ref.)

THERAPY

Review of modern techniques in detecting port-wine stain response to laser therapy. Le KV, et al. **Dermatol Surg** 1999 Feb;25(2):127-32 (34 ref.)

PORTACAVAL SHUNT, SURGICAL

METHODS

Budd-Chiari syndrome caused by Behçet's disease: treatment by side-to-side portacaval shunt. Orloff LA, et al. **J Am Coll Surg** 1999 Apr;188(4):396-407 (65 ref.)

PORTAL SYSTEM

see related
LIVER CIRCULATION
PORTOGRAPHY

Portal venous magnetic resonance angiography. A review. Stafford-Johnson DB, et al. **Invest Radiol** 1998 Sep; 33(9):628-36 (42 ref.)

ABNORMALITIES

Patent ductus venosus. Nagano K, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):285-8 (23 ref.)

DRUG EFFECTS

Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Piscaglia F, et al. **Ultrasound Med Biol** 1999 Jul;25(6):923-32 (90 ref.)

PATHOLOGY

Contrast-enhanced three-dimensional MR portography. Okumura A, et al. **Radiographics** 1999 Jul-Aug; 19(4):973-87 (24 ref.)

[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172-4 (0 ref.) **(Ger)**

PHYSIOPATHOLOGY

Portal hemodynamics in chronic liver disease. Nagral A, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):78-83 (73 ref.)

RADIOGRAPHY

[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172-4 (0 ref.) **(Ger)**

ULTRASONOGRAPHY

Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Piscaglia F, et al. **Ultrasound Med Biol** 1999 Jul;25(6):923-32 (90 ref.)

PORTAL VEIN

see related
PORTOGRAPHY

Portal vein thrombosis in paroxysmal nocturnal haemoglobinuria. Tomizuka H, et al. **Acta Haematol** 1999; 101(3):149-52 (20 ref.)

Portal vein thrombosis associated with antiphospholipid syndrome: a case report. Ishida H, et al. **Eur J Ultrasound** 1998 Sep;8(1):39-42 (10 ref.)

Diffuse bile duct carcinoma treated by major hepatectomy and pancreatoduodenectomy with the aid of pre-operative portal vein embolization. Report of two cases. Chijiiwa K, et al. **Hepatogastroenterology** 1999 May-Jun; 46(27):1634-8 (13 ref.)

Hepatic aneurysm and portal vein thrombosis in a patient with lupus erythematosus on dialysis. Huang JW, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):753-6 (12 ref.)

Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Gates J, et al. **Radiographics** 1999 Mar-Apr;19(2):399-414 (7 ref.)

[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature] Crétel E, et al. **Rev Med Interne** 1999 Jul;20(7):602-6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Thrombosis of the portal vein] Calabrese L, et al. **Acta Biomed Ateneo Parmense** 1998;69(1-2):37-45 (19 ref.) (Eng. Abstr.) **(Ita)**

[A case of gas occurrence in the venous hepato-portal area after blunt trauma of the abdomen] Torriero F, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):118-20 (6 ref.) **(Ita)**

ABNORMALITIES

Congenital intrahepatic portosystemic shunt. Florio F, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):421-4 (11 ref.)

Preduodenal portal vein in the adult. Ooshima I, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):455-8 (21 ref.)

Baller-Gerold syndrome associated with congenital portal venous malformation. Savarirayan R, et al. **J Med Genet** 1998 Sep;35(9):767-9 (28 ref.)

Congenital absence of the portal vein in a boy. Kohda E, et al. **Pediatr Radiol** 1999 Apr;29(4):235-7 (17 ref.)

Absence of bifurcation of the portal vein [letter; comment] McNulty JG, et al. **Radiology** 1999 May;211(2):589-90 (10 ref.) Comment on: Radiology 1998 Jun;207(3):723-8.

INJURIES

[Stent migration with perforation of the portal vein after transjugular intrahepatic portosystemic shunt (TIPS) with a self-expanding stent] Adamus R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):174-6 (0 ref.) **(Ger)**

PATHOLOGY

[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971-5 (18 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Portal hypertension and variceal bleeding: shunt in concomitant or general prehepatic block] Hirner A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:443-50 (25 ref.) (Eng. Abstr.) **(Ger)**

[Recanalization of an extensive fresh portal vein thrombosis by transjugular intrahepatic portosystemic stent-shunt (TIPS)] Vogl T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):163-5 (10 ref.) **(Ger)**

[Is pancreaticoduodenectomy with portal vein resection indicated in patients with ductal pancreatic carcinoma?] Böttger T. **Zentralbl Chir** 1999;124(3):220-5 (24 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Duplex ultrasound of the liver and portal vein system] Mohr HH, et al. **Med Klin** 1998 Nov 15;93(11):669-77 (72 ref.) (Eng. Abstr.) **(Ger)**

PORTASYSTEMIC SHUNT, SURGICAL

A practical guide to the management of oesophageal varices. McCormack G, et al. **Drugs** 1999 Mar;57(3):327-35 (37 ref.)

Surgical treatment of Budd-Chiari syndrome [editorial; comment] Chawla Y, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):57-9 (29 ref.) Comment on: Indian J Gastroenterol 1999 Apr-Jun;18(2):60-2.

[Portal hypertension and variceal bleeding: shunt in concomitant or general prehepatic block] Hirner A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:443-50 (25 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Shunt versus transplantation. Langnas AN. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S105-7 (12 ref.)

PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC

Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt. Azoulay D, et al. **Clin Nephrol** 1998 Aug;50(2):118-22 (29 ref.)

An unusual cause of early TIPS dysfunction [letter] Amitrano L, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):428 (12 ref.)

Role of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension in pediatric patients. Heyman MB, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep; 29(3):240-9 (44 ref.)

Current status of transjugular intrahepatic portosystemic shunts. Patel NH, et al. **Postgrad Med J** 1998 Dec; 74(878):716-20 (62 ref.)

[Recanalization of an extensive fresh portal vein thrombosis by transjugular intrahepatic portosystemic stent-shunt (TIPS)] Vogl T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):163-5 (10 ref.) **(Ger)**

[Our experience with Transjugular Intrahepatic Portosystemic Shunt (TIPS)] Péter M, et al. **Orv Hetil** 1999 Aug 15;140(33):1827-31 (31 ref.) (Eng. Abstr.) **(Hun)**

[Intrahepatic portocaval shunt as a new method for treating and prevention of bleeding from esophageal varices in portal hypertension] Wróblewski T, et al. **Przegl Lek** 1998; 55(9):469-74 (19 ref.) (Eng. Abstr.) **(Pol)**

[Transjugular intrahepatic portosystemic shunt in treatment of portal hypertension] Tarazov PG. **Khirurgiia (Mosk)** 1999;(7):64-9 (80 ref.) **(Rus)**

ADVERSE EFFECTS

Helical CT angiography of transjugular intrahepatic portosystemic shunts. Chopra S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):25-35 (21 ref.)

[Stent migration with perforation of the portal vein after transjugular intrahepatic portosystemic shunt (TIPS) with a self-expanding stent] Adamus R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):174-6 (0 ref.) **(Ger)**

METHODS

Transjugular intrahepatic portosystemic stent-shunt (TIPSS): technique and indications. Kauffmann GW, et al. **Eur Radiol** 1999;9(4):685-92 (18 ref.)

Further experiments are necessary to determine whether transjugular intrahepatic portosystemic shunt is the definitive treatment for refractory hepatic hydrothorax [editorial; comment] Mitamura K. **J Gastroenterol** 1999 Feb;34(1):154-6 (18 ref.) Comment on: J Gastroenterol 1999 Feb;34(1):128-31.

PORTOENTEROSTOMY, HEPATIC

Biliary atresia: pathogenesis and treatment. Bates MD, et al. **Semin Liver Dis** 1998;18(3):281-93 (106 ref.)

METHODS

Biliary atresia--surgical management and treatment options as they relate to outcome. Ryckman FC, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S24-33 (47 ref.)

PORTOGRAPHY

METHODS

Contrast-enhanced three-dimensional MR portography. Okumura A, et al. **Radiographics** 1999 Jul-Aug; 19(4):973-87 (24 ref.)

PORTOSYSTEMIC ENCEPHALOPATHY see **HEPATIC ENCEPHALOPATHY**

PORTOSYSTEMIC SHUNT, SURGICAL see **PORTASYSTEMIC SHUNT, SURGICAL**

PORTOSYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC see **PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC**

PORTUGUESE MAN-OF-WAR see **JELLYFISH**

POSITION DESCRIPTION see **JOB DESCRIPTION**

POSITIVE END-EXPIRATORY PRESSURE see **POSITIVE-PRESSURE RESPIRATION**

POSITIVE-PRESSURE RESPIRATION

Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. **Chest** 1999 Aug;116(2):521-34 (63 ref.)

The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. [see comments] Pang D, et al. **Chest** 1998 Oct;114(4):1185-92 (23 ref.) Comment in: ACP J Club 1999 May-Jun;130(3):58.

PEEP: blood gas cosmetics or a therapy for ARDS? [editorial; comment] Pesenti A, et al. **Crit Care Med** 1999 Feb;27(2):253-4 (17 ref.) Comment on: Crit Care Med 1999 Feb;27(2):380-4.

Pulmonary mechanics and graphics during positive pressure ventilation. Hess DR, et al. **Int Anesthesiol Clin** 1999 Summer;37(3):15-34 (75 ref.)

Noninvasive positive pressure ventilation for acute respiratory failure. Hess DR. **Int Anesthesiol Clin** 1999 Summer;37(3):85-102 (50 ref.)

Noninvasive pressure support ventilation in acute respiratory failure. Brochard L. **Monaldi Arch Chest Dis** 1998 Aug; 53(4):486-7 (20 ref.)

CPAP therapy: outcomes and patient use. Douglas NJ, et al. **Thorax** 1998 Oct;53 Suppl 3:S47-8 (20 ref.)

Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Naughton MT. **Thorax** 1998 Oct;53 Suppl 3:S37-40 (40 ref.)

[For or against the early use of nasal continuous positive pressure and exogenous surfactant in hyaline membrane disease. Physiopathologic arguments] Storme L, et al. **Arch Pediatr** 1999 May;6(5):549-55 (60 ref.) (Eng. Abstr.) **(Fre)**

[Use of non-invasive positive pressure ventilation for cardiogenic pulmonary edema in emergency care units (editorial; comment)] Brochard L. **Presse Med** 1998 Jun 20;27(22):1105-7 (10 ref.) (Eng. Abstr.) Comment on: Presse Med 1998 Jun 20;27(22):1089-94. **(Fre)**

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Schweiz Med Wochenschr** 1999 Jul 13; 129(27-28):1013-24 (45 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Tidal volume, PaCO2, and lung injury [editorial; comment] Gregory GA, et al. **Crit Care Med** 1998 Oct;26(10):1632-3 (16 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1690-7.

The answer is (gently) blowing in the wind? [editorial; comment] Marelich GP, et al. **Crit Care Med** 1999 Apr; 27(4):687-8 (9 ref.) Comment on: Crit Care Med 1999 Apr;27(4):779-83.

Neurohormonal responses during positive pressure mechanical ventilation. Frazier SK. **Heart Lung** 1999 May-Jun;28(3):149-65; quiz 166-7 (58 ref.)

ECONOMICS

Auto-CPAP: an effective and low-cost procedure in the management of OSAS? [editorial; comment] Lévy P, et al. **Eur Respir J** 1998 Oct;12(4):753-5 (19 ref.) Comment on: Eur Respir J 1998 Oct;12(4):759-63.

INSTRUMENTATION

Auto-CPAP: an effective and low-cost procedure in the management of OSAS? [editorial; comment] Lévy P, et al. **Eur Respir J** 1998 Oct;12(4):753-5 (19 ref.) Comment on: Eur Respir J 1998 Oct;12(4):759-63.

Noninvasive positive pressure ventilation in acute respiratory failure. Mehta S. **Intensive Care Med** 1998 Oct; 24(10):1113-4 (4 ref.)

Experience with new autotitrating nasal continuous positive airway pressure machines. Becker HF. **Monaldi Arch Chest Dis** 1998 Oct;53(5):582-5 (9 ref.)

Autocontinuous positive airway pressure in the diagnosis and treatment of obstructive sleep apnoea. Braghiroli A, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):621-4 (20 ref.)

Intelligent CPAP systems: clinical experience. Teschler H, et al. **Thorax** 1998 Oct;53 Suppl 3:S49-54 (34 ref.)

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Ther Umsch** 1999 Mar;56(3):147-50 (8 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Continuous distending pressure. Morley C. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F152-6 (73 ref.)

Early nasal continuous positive airway pressure and minimal handling in the treatment of very-low-birth-weight infants. Kamper J. **Biol Neonate** 1999 Jun;76 Suppl 1:22-8 (34 ref.)

N-CPAP in the prevention of recurrent intubations and hospitalizations in a patient with refractory congestive heart failure. Parmar MS, et al. **Can J Cardiol** 1998 Nov; 14(11):1405-8 (22 ref.)

Tidal volume, positive end-expiratory pressure, and mortality in acute respiratory distress syndrome [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1661-3 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1492-8.

Tidal volume, PaCO2, and lung injury [editorial; comment] Gregory GA, et al. **Crit Care Med** 1998 Oct;26(10):1632-3 (16 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1690-7.

Inspiratory flow rate: more may not be better [editorial; comment] Jubran A. **Crit Care Med** 1999 Apr;27(4):670-1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):715-22.

The answer is (gently) blowing in the wind? [editorial; comment] Marelich GP, et al. **Crit Care Med** 1999 Apr; 27(4):687-8 (9 ref.) Comment on: Crit Care Med 1999 Apr;27(4):779-83.

Moon phases and ocean tides: the relationship between the inspiratory-expiratory phases of mechanical ventilation and right ventricular function [editorial; comment] Popovich MJ. **Crit Care Med** 1999 May;27(5):864-5 (14 ref.) Comment on: Crit Care Med 1999 May;27(5):953-8.

Noninvasive positive pressure ventilation in acute respiratory failure. Mehta S. **Intensive Care Med** 1998 Oct; 24(10):1113-4 (4 ref.)

Positive expiratory pressure in the physiotherapeutic management of primary ciliary dyskinesia in paediatric age. Gremmo ML, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):255-7 (23 ref.)

How to improve compliance to nasal continuous positive airway pressure in sleep apnoea syndrome. Rodenstein D. **Monaldi Arch Chest Dis** 1998 Oct;53(5):586-8 (15 ref.)

Modalities of ventilation in neuromuscular disorders and thoracic deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):552-5 (10 ref.)

[Sleep apnea and non-invasive positive-pressure respiration] Oi M. **Nippon Naika Gakkai Zasshi** 1998 Oct 10; 87(10):2100-6 (22 ref.) **(Jpn)**

[Effective nasal CPAP therapy for heavy snoring and paradoxical respiration during sleep in a case of multiple system atrophy] Miyamoto M, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1059-63 (14 ref.) (Eng. Abstr.) **(Jpn)**

POSITIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

POSITRON-EMISSION TOMOGRAPHY see **TOMOGRAPHY, EMISSION-COMPUTED**

POSITRONS see **ELECTRONS**

POST AND CORE TECHNIQUE

Factors affecting retention of post systems: a literature review. Stockton LW. **J Prosthet Dent** 1999 Apr; 81(4):380-5 (96 ref.)

POSTAGE STAMPS see **PHILATELY**

POST-BASIC NURSING EDUCATION see **EDUCATION, NURSING, CONTINUING**

POSTCIBAL PERIOD see **POSTPRANDIAL PERIOD**

POSTCOITAL CONTRACEPTIVES see **CONTRACEPTIVES, POSTCOITAL**

POSTENCEPHALITIC PARKINSONISM see **PARKINSON DISEASE, POSTENCEPHALITIC**

POSTERIOR CERVICAL SYMPATHETIC SYNDROME see **SPINAL OSTEOPHYTOSIS**

POSTERIOR CRUCIATE LIGAMENT

see related

ANTERIOR CRUCIATE LIGAMENT

Ganglia of the posterior cruciate ligament. A report of three cases and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998;57(3):165-8 (8 ref.)

INJURIES

Posterior cruciate ligament injuries. St Pierre P, et al. **Clin Sports Med** 1999 Jan;18(1):199-221, vii (62 ref.)

The posterior cruciate ligament injured knee: principles of evaluation and treatment. Miller MD, et al. **Instr Course Lect** 1999;48:199-207 (58 ref.)

[Injuries of the knee ligaments. II. Surgical therapy of anterior and posterior knee instability] Lobenhoffer P. **Chirurg** 1999 Mar;70(3):326-38 (0 ref.) **(Ger)**

[The upper ankle joint. Biomechanics and functional anatomy] Seiler H. **Orthopade** 1999 Jun;28(6):460-8 (62 ref.) (Eng. Abstr.) **(Ger)**

[Combined anterior cruciate ligament and posterior cruciate ligament injury--technique and results of simultaneous arthroscopic reconstruction] Martinek V, et al. **Zentralbl Chir** 1998;123(9):1027-32 (21 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Role of the posterior cruciate ligament in total knee arthroplasty. Pagnano MW, et al. **J Am Acad Orthop Surg** 1998 May-Jun;6(3):176-87 (51 ref.)

POSTERIOR LONGITUDINAL LIGAMENT see **LONGITUDINAL LIGAMENTS**

POSTERIOR VITREOUS DETACHMENT see **VITREOUS DETACHMENT**

POSTGRADUATE NURSING EDUCATION see **EDUCATION, NURSING, GRADUATE**

POST-INFARCTION HEART RUPTURE see **HEART RUPTURE, POST-INFARCTION**

POSTMARKETING PRODUCT SURVEILLANCE see **PRODUCT SURVEILLANCE, POSTMARKETING**

POSTMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY see **ESTROGEN REPLACEMENT THERAPY**

POSTMENOPAUSAL OSTEOPOROSIS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSE

Primary prevention of coronary heart disease in postmenopausal women. Denke MA. **Am J Med** 1999 Aug 23;107(2A):48S-50S (18 ref.)

Improving adherence to hormone replacement therapy with effective patient-physician communication. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):337-40 (15 ref.)

Selective estrogen receptor modulators: Women's panacea for the next millennium? Spencer CP, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):763-70 (120 ref.)

Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Mustafa IA, et al. **Ann Surg** 1998 Nov; 228(5):638-51 (115 ref.)

Cardiovascular changes and cardiac morbidity of menopause. Effects of hormone replacement therapy. Bassan R. **Arq Bras Cardiol** 1999 Jan;72(1):85-98 (89 ref.) **(Eng, Por)**

Postmenopausal hormone use for cardioprotection: what we know and what we must learn. Wenger NK. **Curr Opin Cardiol** 1999 Jul;14(4):292-7 (23 ref.)

Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Lamb HM, et al. **Drugs** 1998 Dec;56(6):1125-40 (54 ref.)

Clinical efficacy of raloxifene in postmenopausal women. Agnusdei D. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul; 85(1):43-6 (25 ref.)

The therapeutic use of androgens in women. Davis SR. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):177-84 (66 ref.)

Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. Barrett-Connor E, et al. **J Womens Health** 1998 Sep;7(7):839-47 (61 ref.)

Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health. Curtis MG. **J Womens Health** 1999 Apr;8(3):321-33 (151 ref.)

Chemicals and menopause: effects on age at menopause and on health status in the postmenopausal period. Silbergeld EK, et al. **J Womens Health** 1999 Mar;8(2):227-34 (68 ref.)

Hormone replacement therapy in women treated for gynaecological malignancy. Burger CW, et al. **Maturitas** 1999 Jun 21;32(2):69-76 (34 ref.)

POSTMENOPAUSE

Cardiovascular disease in postmenopausal women. Samsioe G. **Maturitas** 1998 Sep 20;30(1):11–8 (38 ref.)

Estrogen replacement therapy in women with a history of breast cancer. Seifert M, et al. **Maturitas** 1999 Jun 21; 32(2):63–8 (40 ref.)

Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. van der Mooren MJ, et al. **Maturitas** 1998 Sep 20;30(1):27–36 (94 ref.)

Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women. Fitzpatrick LA. **Mayo Clin Proc** 1999 Jun;74(6):601–7 (22 ref.)

Tibolone and the serum lipid/lipoprotein profile: does this have a role in cardiovascular protection in postmenopausal women? [editorial; comment] Ginsburg J, et al. **Menopause** 1999 Summer;6(2):87–9 (34 ref.) Comment on: Menopause 1999 Summer;6(2):92–97. Comment on: Menopause 1999 Summer;6(2):98–104.

Development of a new prevention maintenance therapy for postmenopausal women. Jordan VC. **Recent Results Cancer Res** 1999;151:96–109 (51 ref.)

Evaluation of postmenopausal endometrium [editorial] Parsons AK. **Ultrasound Obstet Gynecol** 1998 Nov; 12(5):295–300 (52 ref.)

Primary hyperparathyroidism of postmenopausal women. Prospective population-based case-control analysis on prevalence, clinical findings and treatment. Minireview based on a doctoral thesis. Lundgren E. **Ups J Med Sci** 1999;104(2):87–130 (338 ref.)

[Role of diagnostic hysteroscopy in the exploration of postmenopausal metrorrhagia] Roger V, et al. **Presse Med** 1998 Sep 5;27(25):1294–5 (6 ref.) (Eng. Abstr.) **(Fre)**

[Burning mouth syndrome] Fraikin N, et al. **Rev Med Liege** 1999 Jun;54(6):548–52 (20 ref.) (Eng. Abstr.) **(Fre)**

[Effects of 17beta-estradiol on peripheral and coronary vasomotor function in postmenopausal women] Macquin-Mavier I, et al. **Therapie** 1999 May–Jun; 54(3):353–5 (15 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Moderate alcohol consumption and estrogen levels in postmenopausal women: a review. Purohit V. **Alcohol Clin Exp Res** 1998 Aug;22(5):994–7 (22 ref.)

Do estrogens reduce glycemic levels? [editorial; comment] Wilson PW. **Diabetes Care** 1998 Oct;21(10):1585–6 (30 ref.) Comment on: Diabetes Care 1998 Oct;21(10):1589–95.

DRUG EFFECTS

Cardioprotective effects of postmenopausal hormone treatment. Espeland MA. **Am J Cardiol** 1998 Nov 19; 82(10A):37S–39S (13 ref.)

Androgen cotherapy in menopause: evolving benefits and challenges. Bachmann GA. **Am J Obstet Gynecol** 1999 Mar; 180(3 Pt 2):308–11 (42 ref.)

Alternatives to the use of estrogen in postmenopausal women. Pinkerton JV, et al. **Endocr Rev** 1999 Jun;20(3):308–20 (128 ref.)

Estradiol-releasing vaginal ring delivery system for urogenital atrophy. Experience over the past decade. Bachmann G. **J Reprod Med** 1998 Nov;43(11):991–8 (25 ref.)

Androgen treatment in women. Davis SR. **Med J Aust** 1999 Jun 7;170(11):545–9 (44 ref.)

[The versatility of estrogens is taken advantage of in the treatment of postmenopause] Zárate-Treviño A. **Gac Med Mex** 1999 May–Jun;135(3):341–4 (8 ref.) **(Spa)**

ETHNOLOGY

Hormone replacement therapy for African American women: missed opportunities for effective intervention. Nicholson WK, et al. **Menopause** 1999 Summer;6(2):147–55 (105 ref.)

METABOLISM

Vasomotor flushes in menopausal women. Bachmann GA. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):312–6 (26 ref.)

Role of androgens in surgical menopause. Gelfand MM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):325–7 (10 ref.)

PHYSIOLOGY

Estradiol-releasing vaginal ring delivery system for urogenital atrophy. Experience over the past decade. Bachmann G. **J Reprod Med** 1998 Nov;43(11):991–8 (25 ref.)

Postmenopausal estrogen therapy and selected (less-often-considered) disease outcomes. Barrett-Connor E. **Menopause** 1999 Spring;6(1):14–20 (68 ref.)

[The role of estrogens in hormonal regulation of lipid metabolism in women] Szafran H, et al. **Przegl Lek** 1998; 55(5):266–70 (31 ref.) (Eng. Abstr.) **(Pol)**

[Postmenopausal arterial hypertension and cardiovascular risk] Artigao R. **Rev Esp Cardiol** 1998;51 Suppl 4:36–43 (37 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Psychosexual effects of menopause: role of androgens. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):319–24 (29 ref.)

Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Burt VK, et al. **Harv Rev Psychiatry** 1998 Sep–Oct;6(3):121–32 (55 ref.)

Cognitive assessment for postmenopausal women and general assessment of their mental health. Sherwin BB. **Psychopharmacol Bull** 1998;34(3):323–6 (28 ref.)

POSTMORTEM CHANGES

Procurement, interpretation, and value of postmortem cultures. Roberts FJ. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):821–7 (35 ref.)

Indoor postmortem animal interference by carnivores and rodents: report of two cases and review of the literature. Tsokos M, et al. **Int J Legal Med** 1999;112(2):115–9 (30 ref.)

POSTNATAL CARE

Early postpartum discharge. Brumfield CG. **Clin Obstet Gynecol** 1998 Sep;41(3):611–25 (57 ref.)

METHODS

What does postnatal care do for women's health? [see comments] MacArthur C. **Lancet** 1999 Jan 30; 353(9150):343–4 (11 ref.) Comment in: Lancet 1999 May 1;353(9163):1532.

STANDARDS

Are we providing adequate postnatal services? Cooke M, et al. **Aust N Z J Public Health** 1999 Apr;23(2):210–2 (16 ref.)

TRENDS

What does postnatal care do for women's health? [see comments] MacArthur C. **Lancet** 1999 Jan 30; 353(9150):343–4 (11 ref.) Comment in: Lancet 1999 May 1;353(9163):1532.

POSTNATAL DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTOPERATIVE CARE

Warfarin prophylaxis after total knee arthroplasty. Lieberman JR. **Am J Knee Surg** 1999 Winter;12(1):49–53 (22 ref.)

Current clinical concepts in perioperative anticoagulation. Hewitt RL, et al. **Am Surg** 1999 Mar;65(3):270–3 (15 ref.)

Postoperative ventilatory management. Price JA, et al. **Chest** 1999 May;115(5 Suppl):130S–137S (44 ref.)

Cardiac management in the ICU. Ramsay JG. **Chest** 1999 May;115(5 Suppl):138S–144S (36 ref.)

Postoperative care and monitoring. Naunheim KS. **Chest Surg Clin N Am** 1999 Aug;9(3):501–13 (35 ref.)

Postoperative urinary drainage. Young SB, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):735–43 (7 ref.)

The role of nutrition before and after transplantation [editorial; comment] Allard JP. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):313–4 (5 ref.) Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):315–21. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):323–7. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):329–33.

Glutamine in the support of patients following bone marrow transplantation [see comments] Wilmore DW, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):323–7 (34 ref.) Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.

Appropriate follow-up of orthopaedic oncology patients. Letson GD, et al. **Instr Course Lect** 1999;48:603–6 (10 ref.)

The Sixth John M. Kinney International Awards for Nutrition and Metabolism . "Glutamine-enhanced bacterial killing by neutrophils from postoperative patients": background [see comments] Furukawa S. **Nutrition** 1999 Jun;15(6):439–42 (37 ref.) Comment in: Nutrition 1999 Jun;15(6):443.

Perioperative red cell transfusion: evidence, guidelines and practice. McClelland B. **Vox Sang** 1998;74 Suppl 2:3–10 (20 ref.)

[Role of non-steroidal anti-inflammatory agents in the perioperative period. Usefulness and limitations] Derrier M, et al. **Ann Fr Anesth Reanim** 1997;16(5):498–520 (98 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative management of the coronary patient] Metzler H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Mar;34(3):175–7 (9 ref.) **(Ger)**

[Management of the anterior cruciate ligament rupture: indications, choice of procedure, timing, concomitant and after-care] Wentzensen A, et al. **Zentralbl Chir** 1998; 123(9):970–80 (50 ref.) (Eng. Abstr.) **(Ger)**

[Home mechanical ventilation as a treatment of the sequelae of tuberculosis surgery] Prats Soro E, et al. **An Med Interna** 1999 Jan;16(1):35–7 (12 ref.) (Eng. Abstr.) **(Spa)**

[Postcystectomy radiotherapy in bladder cancer] Salina Ramos J, et al. **Arch Esp Urol** 1999 Jul–Aug;52(6):595–7 (18 ref.) (Eng. Abstr.) **(Spa)**

[Pre-postoperative neuropsychological evaluation in the surgical treatment of epilepsy] Campo P, et al. **Rev Neurol** 1998 Oct;27(158):616–25 (127 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Aspiration of gauze pressure-pack following a dental extraction: a case report. Villasenor A. **Pediatr Dent** 1999 Mar–Apr;21(2):135–6 (6 ref.)

[Miliary pneumonia after the intravesical BCG therapy of a superficial urothelial carcinoma of the bladder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Aug 27; 124(34–35):993–7 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Split-thickness skin graft donor site care: a quantitative synthesis of the research. Rakel BA, et al. **Appl Nurs Res** 1998 Nov;11(4):174–82 (29 ref.)

Nutrition management in the ICU. Chan S, et al. **Chest** 1999 May;115(5 Suppl):145S–148S (23 ref.)

Management of patients after cardiac surgery. Morris DC, et al. **Curr Probl Cardiol** 1999 Apr;24(4):161–228 (131 ref.)

Tranexamic acid: a review of its use in surgery and other indications. Dunn CJ, et al. **Drugs** 1999 Jun;57(6):1005–32 (132 ref.)

Functional criteria for mandibular implant placement post resection and reconstruction for cancer. Marunick MT, et al. **J Prosthet Dent** 1999 Jul;82(1):107–13 (50 ref.)

Electrophysiological follow-up of tetralogy of fallot. Friedli B. **Pediatr Cardiol** 1999 Sep–Oct;20(5):326–30 (49 ref.)

Head positioning compliance with spectacles after gas retinopexy. Boucher MC, et al. **Retina** 1999;19(2):177–8 (0 ref.)

Preoperative and postoperative skin care with laser resurfacing. Hrabovsky SL. **Semin Ophthalmol** 1998 Sep; 13(3):115–22 (32 ref.)

[Anesthesia and postoperative recovery for parathyroid gland surgery] Roland E. **Ann Chir** 1999;53(2):150–61 (48 ref.) (Eng. Abstr.) **(Fre)**

[Radiation and concomitant chemotherapy after surgery for breast cancer: Arcosein study] Calais G. **Cancer Radiother** 1998 Sep–Oct;2(5):469–74 (31 ref.) (Eng. Abstr.) **(Fre)**

[Nasogastric tubes after elective abdominal surgery is not justified] Gouzi JL, et al. **J Chir (Paris)** 1998 Dec; 135(6):273–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Echo-doppler surveillance of revascularization of the legs in asymptomatic postoperative patients. Why? With what rhythm? How much time? How?] Mellière D, et al. **J Mal Vasc** 1999 Jun;24(3):233–8 (20 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative treatment after ear surgery] Schmelzer A, et al. **Laryngorhinootologie** 1999 Feb;78(2):103–6 (10 ref.) (Eng. Abstr.) **(Ger)**

[The strategy and current potentials of parenteral feeding in surgery] Kostiuchenko AL. **Vestn Khir Im I I Grek** 1998; 157(4):116–20 (9 ref.) (Eng. Abstr.) **(Rus)**

NURSING

Cerebral vascular accident after cardiac surgery: its impact on nursing care. Lindsay M. **Prog Cardiovasc Nurs** 1999 Spring;14(2):47–52 (25 ref.)

STANDARDS

[Locoregional radiotherapy after mastectomy and chemotherapy for breast cancer: prolonged survival and better local tumor control (see comments] Struikmans H, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):71–3 (8 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):73–5. **(Dut)**

TRENDS

Vascular surveillance after peripheral artery interventions. Bizzini Pezzetta G, et al. **Schweiz Med Wochenschr** 1999 Mar 13;129(10):413–9 (26 ref.)

POSTOPERATIVE COMPLICATIONS

Post-transplantation hypoglycaemia in type 1 diabetic pancreas allograft recipients. Osei K. **Acta Diabetol** 1998 Dec;35(4):176–82 (29 ref.)

Pediatric liver transplantation. Dhawan A, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):525–9 (31 ref.)

Complications of surgery in HIV-infected patients [editorial] Rose DN, et al. **AIDS** 1998 Dec 3;12(17):2243–51 (119 ref.)

The alcohol patient and surgery. Tønnesen H. **Alcohol Alcohol** 1999 Mar–Apr;34(2):148–52 (34 ref.)

Acute pancreatitis after gynecologic and obstetric surgery. Ramsey PS, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):542–6 (15 ref.)

Flap complications of lamellar refractive surgery [editorial; comment] Gimbel HV. **Am J Ophthalmol** 1999 Feb; 127(2):202–4 (6 ref.) Comment on: Am J Ophthalmol 1999 Feb;127(2):129–36.

Unusual presentation of hemoptysis in a 78-year-old with previous Nissen fundoplication. Bavry AA, et al. **Am Surg** 1998 Dec;64(12):1223–5 (18 ref.)

Heterotopic ossification of soft tissue: a review with emphasis on ossification within abdominal surgical scars. Gaffey MJ, et al. **Anat Pathol** 1998;3:195–208 (52 ref.)

Treatment and prognosis of post-transplant lymphoproliferative disease. Mamzer-Bruneel MF, et al. **Ann Transplant** 1997;2(4):42–8 (72 ref.)

Clinicopathologic features of posttransplant lymphoproliferative disorders. Nalesnik MA.

Ann Transplant 1997;2(4):33–40 (113 ref.)
Overview of the problem of cancer in organ transplant recipients. Penn I. **Ann Transplant** 1997;2(4):5–6 (0 ref.)
Etiology and pathogenesis of posttransplant tumors: new insights into viral oncogenesis. el-Sabrout R, et al. **Ann Transplant** 1997;2(4):67–9 (45 ref.)
Kaposi's sarcoma in renal transplant recipients. Shaheen FA, et al. **Ann Transplant** 1997;2(4):49–58 (218 ref.)
Ano-genital neoplasia in renal transplant patients. Sillman FH, et al. **Ann Transplant** 1997;2(4):59–66 (51 ref.)
Deep venous thrombosis and pulmonary embolism: diagnosis, prophylaxis, and treatment. Alexander P, et al. **Ann Vasc Surg** 1999 May;13(3):318–27 (48 ref.)
Severe postoperative laryngeal oedema causing total airway obstruction immediately on extubation. Dark A, et al. **Br J Anaesth** 1999 Apr;82(4):644–6 (14 ref.)
Postoperative cognitive deficit in the elderly surgical patient [see comments] Dodds C, et al. **Br J Anaesth** 1998 Sep; 81(3):449–62 (89 ref.) Comment in: Br J Anaesth 1999 Feb;82(2):307–8.
Myocardial ischaemia in anaemic patients. Wahr JA. **Br J Anaesth** 1998 Dec;81 Suppl 1:10–5 (31 ref.)
Evaluation of prosthetic valve function and associated complications. Barbetseas J, et al. **Cardiol Clin** 1998 Aug; 16(3):505–30 (148 ref.)
Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Lafont A, et al. **Cardiovasc Res** 1998 Jul;39(1):50–9 (136 ref.)
Fatal postoperative pulmonary edema: pathogenesis and literature review [see comments] Arieff AI. **Chest** 1999 May;115(5):1371–7 (45 ref.) Comment in: Chest 1999 May;115(5):1224–6.
The postpneumonectomy state [see comments] Kopec SE, et al. **Chest** 1998 Oct;114(4):1158–84 (198 ref.) Comment in: Chest 1999 Apr;115(4):1214.
Postpneumonectomy pulmonary edema. Deslauriers J, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):611–31, ix (46 ref.)
Complications after video-assisted thoracic surgery. Downey RJ. **Chest Surg Clin N Am** 1998 Nov;8(4):907–17, x (52 ref.)
Neurologic complications in thoracic surgery. Feins RH. **Chest Surg Clin N Am** 1998 Aug;8(3):633–43 (26 ref.)
Postoperative pneumonia. Ferdinand B, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):529–39, viii (48 ref.)
Myocardial ischemia and infarction postthoracotomy. Herrington CS, et al. **Chest Surg Clin N Am** 1998 Aug; 8(3):495–502, vii (24 ref.)
Gastrointestinal complications postthoracotomy and postvagotomy. Kokoska ER, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):645–61 (47 ref.)
Postoperative atelectasis. Massard G, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):503–28, viii (75 ref.)
Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death. Humphries JO. **Clin Cardiol** 1998 Oct; 21(10):711–8 (95 ref.)
Acute hyponatremia in the perioperative period: insights into its pathophysiology and recommendations for management. Gowrishankar M, et al. **Clin Nephrol** 1998 Dec;50(6):352–60 (60 ref.)
Safety issues in ultrasound-assisted large-volume lipoplasty. Gilliland MD, et al. **Clin Plast Surg** 1999 Apr;26(2):317–35; x (86 ref.)
Insulin resistance: a marker of surgical stress. Thorell A, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):69–78 (68 ref.)
Update on lung transplantation in children. Gaynor JW, et al. **Curr Opin Pediatr** 1998 Jun;10(3):256–61 (15 ref.)
Heterotopic bone formation after joint replacement. Nilsson OS, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):127–31 (39 ref.)
Port site recurrences after laparoscopic surgery. A review. Schaeff B, et al. **Dig Surg** 1998;15(2):124–34 (95 ref.)
Comparison of adhesion formation in open and laparoscopic surgery. Schäfer M, et al. **Dig Surg** 1998;15(2):148–52 (48 ref.)
Complications of endoscopic sphincterotomy. Freeman ML. **Endoscopy** 1998 Nov;30(9):A216–20 (36 ref.)
Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation. Haagsma EB. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):639–42 (14 ref.)
Hypoglossal nerve injury as a complication of anterior surgery to the upper cervical spine. Sengupta DK, et al. **Eur Spine J** 1999;8(1):78–80 (10 ref.)
Multisystem organ failure secondary to increased intraabdominal pressure. Sugerman HJ, et al. **Infection** 1999 Jan-Feb;27(1):61–6 (33 ref.)
Complications of shoulder surgery. Gill TJ, et al. **Instr Course Lect** 1999;48:359–74 (81 ref.)
Renal failure in the recipients of nonrenal solid organ transplants. Wilkinson AH, et al. **J Am Soc Nephrol** 1999 May;10(5):1136–44 (70 ref.)
Bilateral intraosseous cystic formation in the talus: a complication of subtalar arthroeresis. Rockett AK, et al. **J Foot Ankle Surg** 1998 Sep-Oct;37(5):421–5 (14 ref.)
Bilateral sudden sensorineural hearing loss following non-otologic surgery. de la Cruz M, et al. **J Laryngol Otol** 1998 Aug;112(8):769–71 (16 ref.)
Herpes simplex encephalitis after brain surgery: case report and review of the literature. Spuler A, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):239–42 (29 ref.)
Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. Ghika J, et al. **J Neurosurg** 1999 Aug;91(2):313–21 (114 ref.)
Bilateral vocal cord paralysis following anterior cervical discectomy and fusion. Case report. Manski TJ, et al. **J Neurosurg** 1998 Nov;89(5):839–43 (97 ref.)
Erectile dysfunction induced by orthopedic trauma managed with a fracture table: a case report and review of the literature. Chan PT, et al. **J Trauma** 1999 Jul;47(1):183–5 (22 ref.)
The role of lipids in transplant vascular disease. McDonald PC, et al. **Lab Invest** 1998 Oct;78(10):1187–201 (125 ref.)
Complications of liver transplantation: a perioperative perspective. Merritt WT. **Liver Transpl Surg** 1999 Jul; 5(4):342–4 (11 ref.)
Lung transplantation. Arcasoy SM, et al. **N Engl J Med** 1999 Apr 8;340(14):1081–91 (100 ref.)
Concomitant parvovirus B19 and cytomegalovirus infections after living-related renal transplantation. Keung YK, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):469–71 (26 ref.)
Deep-seated fungal infection in surgery. Tsunoda T, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):203–9 (31 ref.)
Frey's syndrome following submandibular gland excision: an unusual postoperative complication. Teague A, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec; 60(6):346–8 (30 ref.)
Fractures of the patella after total knee replacement. Bourne RB. **Orthop Clin North Am** 1999 Apr;30(2):287–91 (16 ref.)
Classification of the hip. Brady OH, et al. **Orthop Clin North Am** 1999 Apr;30(2):215–20 (26 ref.)
Periprosthetic fractures of the acetabulum. Callaghan JJ, et al. **Orthop Clin North Am** 1999 Apr;30(2):221–34 (25 ref.)
Periprosthetic fractures of the humerus and scapula: management and prevention. Cameron B, et al. **Orthop Clin North Am** 1999 Apr;30(2):305–18 (28 ref.)
Knee: role and results of allografts. McAuley JP, et al. **Orthop Clin North Am** 1999 Apr;30(2):293–303 (54 ref.)
Periprosthetic fractures of the femur complicating total knee arthroplasty. Rorabeck CH, et al. **Orthop Clin North Am** 1999 Apr;30(2):265–77 (41 ref.)
Total knee arthroplasty: periprosthetic tibial fractures. Stuart MJ, et al. **Orthop Clin North Am** 1999 Apr;30(2):279–86 (7 ref.)
Fractures of the femur after hip replacement: the Oregon experience. Tower SS, et al. **Orthop Clin North Am** 1999 Apr;30(2):235–47 (21 ref.)
Incidence and management of tension pneumocephalus after anterior craniofacial resection: case reports and review of the literature. Clevens RA, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):579–83 (18 ref.)
Cancers after stem cell transplantation in children: a cost of cure? Ship AM, et al. **Pediatr Transplant** 1997 Nov; 1(2):104–10 (38 ref.)
Critical care issues in cervical cancer management. Mirhashemi R, et al. **Semin Surg Oncol** 1999 Apr-May; 16(3):267–74 (48 ref.)
Early complications after orthotopic liver transplantation. Mazariegos GV, et al. **Surg Clin North Am** 1999 Feb; 79(1):109–29 (103 ref.)
Dysfunctional filtering blebs. Azuara-Blanco A, et al. **Surv Ophthalmol** 1998 Sep-Oct;43(2):93–126 (291 ref.)
Immunologic and nonimmunologic risk factors of chronic rejection. Fellström B, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1304–5 (20 ref.)
Role of infections, pathogenesis, and management in lung transplantation. Frost AE. **Transplant Proc** 1999 Feb-Mar; 31(1-2):175–7 (17 ref.)
Lymphoproliferative disease in children. Harmon WE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1268–9 (22 ref.)
Hepatitis C virus infection and renal transplantation. Morales JM. **Transplant Proc** 1999 Sep;31(6):2221–4 (32 ref.)
Patterns of malignancies following renal transplantation. Sheil AG. **Transplant Proc** 1999 Feb-Mar;31(1-2):1263–5 (30 ref.)
Problems of suprapubic prostatectomy. Schweitzer FA. **Trop Doct** 1999 Apr;29(2):113–5 (8 ref.)
[Paraplegia secondary to surgery of the abdominal aorta] Clavert P, et al. **J Mal Vasc** 1999 Jun;24(3):229–32 (11 ref.) (Eng. Abstr.) **(Fre)**
[Postoperative thromboembolic disease. Prevention, diagnosis, treatment] Paquin S, et al. **Presse Med** 1998 Mar 7;27(9):407–15 (68 ref.) (Eng. Abstr.) **(Fre)**
[Sudden hearing loss complicating general surgery: report of a case and review of the literature] Maione A. **Acta Otorhinolaryngol Ital** 1998 Jun;18(3):172–5 (10 ref.) (Eng. Abstr.) **(Ita)**
[Myelodysplastic syndrome (RAEB in T) developed in a renal allograft recipient] Shiraishi J, et al. **Rinsho Ketsueki** 1998 Aug;39(8):600–5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Thromboembolic complications, venous hemodynamics and lower extremities in laparoscopic operations] Starkov IuG, et al. **Khirurgiia (Mosk)** 1999;(8):63–7 (68 ref.) **(Rus)**
[Neurological complications of aortic artery surgery] Carrascal Y, et al. **Rev Neurol** 1998 Nov;27(159):854–61 (89 ref.) (Eng. Abstr.) **(Spa)**
[Diagnosis, treatment, prevention and prognostication of suppurative-septic complications in abdominal surgery] Ohonovs'kiĭ VK. **Klin Khir** 1999;(7):48–51 (45 ref.) **(Ukr)**

CHEMICALLY INDUCED

Adverse effects of medications commonly administered to thoracic surgical patients. Weill D, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):681–702, x (27 ref.)
[Paraffinoma--a rare complication following endonasal surgery] Bachor E, et al. **Laryngorhinootologie** 1999 Jun; 78(6):307–12 (31 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Classification of periprosthetic fractures complicating total knee arthroplasty. Rorabeck CH, et al. **Orthop Clin North Am** 1999 Apr;30(2):209–14 (18 ref.)

DIAGNOSIS

Virtues and drawbacks of titanium alloy aneurysm clips. Steiger HJ, et al. **Acta Neurochir Suppl (Wien)** 1999;72:81–8 (18 ref.)
Sudden profound hypoxaemia in the intensive care unit--a case report. Singh K, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):597–600 (14 ref.)
Permanent cardiac pacemakers: issues relevant to the emergency physician, Part I. Cardall TY, et al. **J Emerg Med** 1999 May-Jun;17(3):479–89 (33 ref.)
Complications of angioma surgery--personal experience in 191 patients with cerebral angiomas. Hassler W, et al. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:238–44 (32 ref.)
Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567–83 (56 ref.)
Tympanostomy tubes: types, indications, techniques, and complications. Morris MS. **Otolaryngol Clin North Am** 1999 Jun;32(3):385–90 (21 ref.)
Imaging techniques for evaluation of postoperative orthopedic infections. Seabold JE, et al. **Q J Nucl Med** 1999 Mar;43(1):21–8 (34 ref.)
Preoperative and postoperative MRI of congenital heart disease. Hubbard AM, et al. **Semin Roentgenol** 1998 Jul; 33(3):218–27 (57 ref.)
Diagnosis and management of venous thrombosis in the surgical patient. Jackson MR. **Semin Thromb Hemost** 1998; 24 Suppl 1:67–76 (44 ref.)
Imaging of abdominal aortic aneurysms after endoluminal repair. Golzarian J, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):16–24 (34 ref.)
[Risk assessment of patients before lung surgery] Schulz C, et al. **Chirurg** 1999 Jun;70(6):664–73 (64 ref.) (Eng. Abstr.) **(Ger)**
[Soft tissue operations in neuromuscular foot deformities] Döderlein L. **Orthopade** 1999 Feb;28(2):151–8 (15 ref.) (Eng. Abstr.) **(Ger)**
[Post-therapeutic lymphedema of the arm--possibilities and limits of diagnosis and therapy] Döller W. **Wien Med Wochenschr** 1999;149(2-4):101–4 (33 ref.) (Eng. Abstr.) **(Ger)**
[Pharmacological treatment of restenosis after coronary angioplasty and bypass grafting] Halawa B. **Pol Merkuriusz Lek** 1998 Jun;4(24):335–8 (31 ref.) (Eng. Abstr.) **(Pol)**
[The excessive cerebrospinal fluid drainage syndrome as a complication of the surgical treatment of hydrocephalus] Shkarubo AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):37–9; discussion 40 (14 ref.) (Eng. Abstr.) **(Rus)**
[The superior vena cava syndrome as a manifestation of aortic dissection following aortic valve replacement (letter)] Vericat MC, et al. **An Med Interna** 1999 Jan;16(1):48–9 (10 ref.) **(Spa)**
[Hyperlipidemia following heart transplantation. Pathogenic mechanisms and treatment] Zambrana García JL, et al. **Med Clin (Barc)** 1999 Mar 6;112(8):303–7 (96 ref.) **(Spa)**
[Stridor in a female patient who underwent pneumonectomy. A postpneumonectomy syndrome] Jiménez Castro D, et al. **Rev Clin Esp** 1999 May;199(5):323–4 (8 ref.) **(Spa)**

DIET THERAPY

[Guidelines of GASL for nutrition in liver diseases and liver transplantation] Plauth M, et al. **Z Gastroenterol** 1999 Apr; 37(4):301–12 (154 ref.) **(Ger)**

DRUG THERAPY

Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report. Ejaz AA, et al. **Angiology** 1999 Apr;50(4):327–30 (7 ref.)
Epoetin alfa. A bloodless approach for the treatment of perioperative anemia. Faris PM, et al. **Clin Orthop** 1998 Dec;(357):60–7 (37 ref.)
Management of postoperative chylothorax with nitric oxide: a critical review [editorial; comment] Mavroudis C. **Crit Care Med** 1999 May;27(5):877 (4 ref.) Comment on: Crit Care Med 1999 May;27(5):1022–4.
Pouchitis: pathophysiology and treatment. Kühbacher T, et al. **Int J Colorectal Dis** 1998;13(5-6):196–207 (199 ref.)
Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. Carrier M, et al. **J Heart Lung Transplant** 1999 Jul;18(7):664–7 (9 ref.)

Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature. Bungard TJ, et al. **Pharmacotherapy** 1999 Apr;19(4):416–23 (26 ref.)
Perioperative hypertension. Goldberg ME, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):911–4 (30 ref.)
[Antibiotic therapy in surgery] Zimmerli W. **Chirurg** 1998 Dec;69(12):1392–8 (10 ref.) **(Ger)**
[Thrombosis of prosthetic heart valves: diagnosis and management] Horstkotte D, et al. **Z Kardiol** 1998;87 Suppl 4:20–32 (69 ref.) (Eng. Abstr.) **(Ger)**
[Glucose-insulin-potassium (GIK) in the reduction of acute myocardial ischemia after an aortocoronary bypass intervention] Dainese L, et al. **G Ital Cardiol** 1999 May; 29(5):575–9; discussion 580–2 (46 ref.) **(Ita)**
[A survival case of fulminant pneumococcal meningitis as overwhelming postsplenectomy infection (OPSI) syndrome] Yamashita S, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1054–8 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Empirical antimicrobial chemoprophylaxis and chemotherapy of infections in surgical patients] Kostiuchenko AL. **Anesteziol Reanimatol** 1999 Mar–Apr; (2):45–8 (9 ref.) (Eng. Abstr.) **(Rus)**
[Use of ciprofloxacin in the treatment and prevention of surgical infections] Iakovlev VP. **Antibiot Khimioter** 1999; 44(7):38–44 (90 ref.) **(Rus)**
[The use of macrolide antibiotics in the treatment of postop intestinal paresis] Skomarovskii AA, et al. **Klin Khir** 1999; (1):55–6 (7 ref.) **(Rus)**

EPIDEMIOLOGY

Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984–1996. Weiss BM, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1643–53 (177 ref.)
Skin cancers in organ transplant recipients. Euvrard S, et al. **Ann Transplant** 1997;2(4):28–32 (53 ref.)
Frey's syndrome after carotid endarterectomy. Mehta M, et al. **Ann Vasc Surg** 1999 Mar;13(2):232–4 (9 ref.)
Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Veness MJ, et al. **Cancer** 1999 Apr 15;85(8):1758–64 (21 ref.)
Aggressive treatment of 119 open fracture wounds. DeLong WG Jr, et al. **J Trauma** 1999 Jun;46(6):1049–54 (25 ref.)
Preoperative pulmonary evaluation. Smetana GW. **N Engl J Med** 1999 Mar 25;340(12):937–44 (69 ref.)
Epidemiology: hip and knee. Berry DJ. **Orthop Clin North Am** 1999 Apr;30(2):183–90 (56 ref.)
Long-term metabolic complications. Legendre C. **Transplant Proc** 1999 Feb–Mar;31(1–2):1278–9 (15 ref.)
[Complications of tubal sterilization by minilaparotomy under local anesthesia] Cisse CT, et al. **Dakar Med** 1997; 42(2):96–8 (15 ref.) (Eng. Abstr.) **(Fre)**
[Complications of thyroid surgery, apropos of 104 thyroidectomies at the Ougadougou University Hospital Center] Ouoba K, et al. **Dakar Med** 1998;43(1):122–5 (13 ref.) (Eng. Abstr.) **(Fre)**
[Incidence of thromboembolism after heart valve replacement: modifying factors] Burckhardt D, et al. **Z Kardiol** 1998;87 Suppl 4:33–6 (11 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Superior mesenteric artery syndrome after segmental instrumentation: a biomechanical analysis. Vitale MG, et al. **Am J Orthop** 1999 Aug;28(8):461–7 (27 ref.)
Otolaryngologic complications of the anterior approach to the cervical spine. Winslow CP, et al. **Am J Otolaryngol** 1999 Jan–Feb;20(1):16–27 (64 ref.)
Complications of primary repair of colon injury: literature review of 2,964 cases. Curran TJ, et al. **Am J Surg** 1999 Jan;177(1):42–7 (64 ref.)
Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report. Ejaz AA, et al. **Angiology** 1999 Apr;50(4):327–30 (7 ref.)
Anterior ischemic optic neuropathy: a complication after extracorporal circulation. Busch T, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):354–8 (30 ref.)
Central nervous system effects of cardiopulmonary bypass. Taylor KM. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S20–4; discussion S25–8 (11 ref.)
Fracture of the axis after dome-like cervical laminoplasty. Ito H, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):106–8 (3 ref.)
Intrapelvic cyst formation after hip arthroplasty with a carbon fibre-reinforced polyethylene socket. Korkala O, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):113–5 (8 ref.)
ABC of sexual health: a woman's sexual life after an operation. de Marquiegui A, et al. **BMJ** 1999 Jan 16; 318(7177):178–81 (0 ref.)
Preoperative alcoholism and postoperative morbidity. Tonnesen H, et al. **Br J Surg** 1999 Jul;86(7):869–74 (53 ref.)
Upper cervical spine trauma: outcome assessment. Alexander JT, et al. **Clin Neurosurg** 1997;44:305–13 (37 ref.)
Low-grade gliomas: in search of evidence-based treatment. Bernstein M. **Clin Neurosurg** 1997;44:315–30 (45 ref.)
Outcomes assessment for pallidotomy. Cosgrove GR, et al. **Clin Neurosurg** 1997;44:385–99 (18 ref.)
Outcome analysis in lumbar spine: instabilities/degenerative disease. Fessler RG. **Clin Neurosurg** 1997;44:297–303 (12 ref.)
Outcome after microvascular decompression for typical trigeminal neuralgia, hemifacial spasm, tinnitus, disabling positional vertigo, and glossopharyngeal neuralgia (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997; 44:331–83 (119 ref.)
Analysis of outcome in carotid endarterectomy trials. Mayberg MR. **Clin Neurosurg** 1997;44:423–37 (32 ref.)
Analysis of outcome: temporal lobe resection. Pilcher WH, et al. **Clin Neurosurg** 1997;44:401–21 (50 ref.)
Obesity as a factor in penetrating keratoplasty. Johansen TR, et al. **Cornea** 1999 Jan;18(1):12–8 (10 ref.)
Postsurgical pemphigus [letter] Micali G, et al. **Dermatology** 1998;197(2):192–3 (14 ref.)
Pneumatosis intestinalis with Clostridium difficile colitis as a cause of acute abdomen after lung transplantation. Schenk P, et al. **Dig Dis Sci** 1998 Nov;43(11):2455–8 (17 ref.)
Three cases of tuberculosis after heart transplantation in Spain. Muñoz RM, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):801–6 (15 ref.)
Posterior hernia of the rectum after coccygectomy. Garcia FJ, et al. **Eur J Surg** 1998 Oct;164(10):793–4 (3 ref.)
Venous intravasation of Gastrografin: a serious but underestimated complication. Glauser T, et al. **Eur J Surg** 1999 Mar;165(3):274–7 (25 ref.)
Type IV thoraco-abdominal aortic aneurysm complicated by an aorto-enteric fistula due to previous infrarenal aortic graft. Karacagil S, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):268–70 (9 ref.)
Late endoleak after endovascular therapy for abdominal aortic aneurysm. Schurink GW, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):448–50 (9 ref.)
Isolated compartment syndrome of the hand after brachial embolectomy. Whatling PJ, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):446–7 (5 ref.)
The role of the gut in major surgical postoperative morbidity. Chieveley-Williams S, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):81–110 (133 ref.)
Postoperative textilomas: review of 14 cases. Fernandez Lobato R, et al. **Int Surg** 1998 Jan–Mar;83(1):63–6 (25 ref.)
Left postpneumonectomy syndrome successfully treated with endobronchial stent. Nakamura Y, et al. **Intern Med** 1998 Oct;37(10):880–3 (12 ref.)
Aortic thrombosis after acetabular revision of a total hip arthroplasty. Leung AG, et al. **J Arthroplasty** 1998 Dec; 13(8):961–5 (19 ref.)
Constrictive pericarditis after surgical closure of atrial septal defect in a child. Kim BJ, et al. **J Korean Med Sci** 1998 Dec;13(6):658–61 (15 ref.)
Cerebral fat embolism from cardiopulmonary bypass. Brown WR, et al. **J Neuropathol Exp Neurol** 1999 Feb;58(2):109–19 (101 ref.)
Bilateral cervicofacial, axillary, and anterior mediastinal emphysema: a rare complication of third molar extraction. Capes JO, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):996–9 (12 ref.)
Stress fracture of the tibia: an unusual complication of reconstructive surgery of the mandible. Westesson PL, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):70–4 (21 ref.)
Massive prostatic bleeding after transurethral resection of the prostate in a patient with a congenital pelvic arteriovenous malformation. Touyama H, et al. **J Urol** 1998 Nov;160(5):1803 (3 ref.)
Bone tunnel enlargement after anterior cruciate ligament reconstruction: fact or fiction? Höher J, et al. **Knee Surg Sports Traumatol Arthrosc** 1998;6(4):231–40 (41 ref.)
Electrophysiological follow-up of tetralogy of fallot. Friedli B. **Pediatr Cardiol** 1999 Sep–Oct;20(5):326–30 (49 ref.)
Cochlear implant and traumatic lesions secondary to electrode insertion. Rossi G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(5):317–22 (25 ref.)
Complications of groin hernia surgery. Bendavid R. **Surg Clin North Am** 1998 Dec;78(6):1089–103 (79 ref.)
Surgical stress response: does endoscopic surgery confer an advantage? Kehlet H. **World J Surg** 1999 Aug;23(8):801–7 (55 ref.)
Second step: testing-outcome measurements. Lorenz W, et al. **World J Surg** 1999 Aug;23(8):768–80 (112 ref.)
[Sclerosing cholangitis after the surgical treatment of hepatic echinococcosis] Tasev V. **Khirurgiia (Sofiia)** 1998; 51(1):47–50 (35 ref.) (Eng. Abstr.) **(Bul)**
[Mild intraoperative hypothermia. Another risk factor for postoperative complications] Rosenberg J, et al. **Ugeskr Laeger** 1999 May 17;161(20):2935–8 (29 ref.) (Eng. Abstr.) **(Dan)**
[Postoperative ptosis: etiopathogenesis, clinical analysis, and therapeutic management. Apropos of a series of 43 cases] Baggio E, et al. **J Fr Ophtalmol** 1998 May;21(5):361–73 (15 ref.) (Eng. Abstr.) **(Fre)**
[New data on recurrence rate of Crohn disease] Post S. **Chirurg** 1998 Sep;69(9):903–7 (44 ref.) (Eng. Abstr.) **(Ger)**
[Loop enterostomy] Rosen HR, et al. **Chirurg** 1999 Jun; 70(6):650–5 (38 ref.) (Eng. Abstr.) **(Ger)**
[Ulcerative colitis--late functional results of ileoanal pouch anastomosis] Schumpelick V, et al. **Chirurg** 1998 Oct; 69(10):1013–9 (75 ref.) (Eng. Abstr.) **(Ger)**
[Microsurgical lumbar intervertebral disk operation. Technique and complications] Merk H, et al. **Orthopade** 1999 Jul;28(7):593–7 (21 ref.) (Eng. Abstr.) **(Ger)**
[Perioperative management of patients with arterial hypertension] Filipovic M, et al. **Ther Umsch** 1999 Jan; 56(1):37–42 (25 ref.) (Eng. Abstr.) **(Ger)**
[Evaluation of surgical risk in patients with COPD] Stucki A, et al. **Ther Umsch** 1999 Mar;56(3):151–6 (17 ref.) (Eng. Abstr.) **(Ger)**
[Complications in trauma surgery] Piltz S, et al. **Unfallchirurg** 1998 Nov;101(11):856–65 (18 ref.) **(Ger)**
[Complications and results of peri-aortocoval lymphadenectomy in gynecology] Schlicht E, et al. **Zentralbl Gynakol** 1998;120(9):425–36 (51 ref.) (Eng. Abstr.) **(Ger)**
[A complication after lung resection due to a patent foramen ovale] Kuksinskii VE, et al. **Vestn Khir Im I I Grek** 1999; 158(1):65–6 (7 ref.) **(Rus)**
[The negative sequelae of surgical treatment in postoperative ventral hernias. The prognostic possibilities and prophylactic means] Maistrenko NA, et al. **Vestn Khir Im I I Grek** 1998;157(4):130–6 (72 ref.) **(Rus)**
[The excessive drainage syndrome as a complication in the surgical treatment of hydrocephalus in children] Lubnin AIu, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar;(1):31–5 (82 ref.) (Eng. Abstr.) **(Rus)**
[The cerebral hyperperfusion syndrome after a carotid endarterectomy operation (a case report and review of the literature)] Lubnin AIu, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct–Dec; (4):40–5 (41 ref.) (Eng. Abstr.) **(Rus)**
[Mixed cryoglobulinemia due to hepatitis C viral infection in a post-liver transplant patient (letter)] López Hidalgo JL, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):117–8 (10 ref.) **(Spa)**
[Postoperative complications in malnourished patients: economic impact and predictive value of some nutritional indicators] Farré Rovira R, et al. **Nutr Hosp** 1998 Sep–Oct; 13(5):233–9 (38 ref.) (Eng. Abstr.) **(Spa)**
[Seromas after the surgical treatment of breast cancer] Savran VV, et al. **Lik Sprava** 1999 Jan–Feb;(1):19–23 (42 ref.) **(Ukr)**

IMMUNOLOGY

Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications. Sietses C, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):250–8 (85 ref.)

METABOLISM

Metabolic consequences of continent urinary diversion. Mills RD, et al. **J Urol** 1999 Apr;161(4):1057–66 (129 ref.)
The metabolic needs of critically ill children and neonates. Shew SB, et al. **Semin Pediatr Surg** 1999 Aug;8(3):131–9 (88 ref.)

MICROBIOLOGY

Listeria infection after liver transplantation: report of a case and review of the literature. Limaye AP, et al. **Am J Gastroenterol** 1998 Oct;93(10):1942–4 (23 ref.)
Overview of quinolones in the treatment and prevention of surgical infection. Weigelt JA. **Am J Surg** 1998 Dec;176(6A Suppl):4S–7S (40 ref.)
Clinical significance of Candida species isolated from cerebrospinal fluid following neurosurgery. Geers TA, et al. **Clin Infect Dis** 1999 May;28(5):1139–47 (27 ref.)

MORTALITY

Meningioma surgery in the elderly: a case-control study assessing morbidity and mortality. Black P, et al. **Acta Neurochir (Wien)** 1998;140(10):1013–6; discussion 1016–7 (12 ref.)
Changing practice of coronary bypass surgery and its impact on early risk and long-term survival. Katz NM, et al. **Curr Opin Cardiol** 1998 Nov;13(6):465–75 (37 ref.)
[Arterial myocardial revascularization in the 9th decade of life. Personal results and review of the literature] Mortasawi A, et al. **Herz** 1999 Apr;24(2):158–70 (130 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Disseminated intravascular coagulation. Gobel BH. **Semin Oncol Nurs** 1999 Aug;15(3):174–82 (40 ref.)

PATHOLOGY

Acute nonoliguric renal failure after renal transplantation. de Fijter JW, et al. **Am J Kidney Dis** 1999 Jan;33(1):166–9 (13 ref.)
Uretero-arterial fistula: a case report and review of the literature. Camps JI, et al. **Bol Asoc Med P R** 1998 Apr–Jun;90(4–6):82–4 (11 ref.)
Splenic peliosis: a rare complication following liver transplantation. Raghavan R, et al. **Dig Dis Sci** 1999 Jun; 44(6):1128–31 (24 ref.)
The anatomical basis of sciatica secondary to herniated lumbar disc: a review. Spencer DL. **Neurol Res** 1999;21 Suppl 1:S33–6 (41 ref.)
The neuropathology of organ transplantation: comparison and contrast in 500 patients. Martinez AJ. **Pathol Res Pract** 1998;194(7):473–86 (96 ref.)

PHYSIOPATHOLOGY

The physiology of ileo-anal pouch function. Levitt MD, et al. **Am J Surg** 1998 Oct;176(4):384-9 (78 ref.)

Acute failure of the transplanted kidney--pathophysiology, diagnosis and prevention. Więcek A, et al. **Ann Transplant** 1996;1(4):5-9 (86 ref.)

Erythropoietic response to acute and chronic anaemia: focus on postoperative anaemia. van Iperen CE, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:2-5 (44 ref.)

Perioperative factors influencing surgical morbidity: what the anesthesiologist needs to know. Carli F. **Can J Anaesth** 1999 May;46(5 Pt 2):R70-9 (21 ref.) **(Eng, Fre)**

Cardiac arrhythmias. Amar D. **Chest Surg Clin N Am** 1998 Aug;8(3):479-93, vii (43 ref.)

Pain management and pulmonary dysfunction. Desai PM. **Crit Care Clin** 1999 Jan;15(1):151-66, vii (48 ref.)

The stress response of critical illness. Epstein J, et al. **Crit Care Clin** 1999 Jan;15(1):17-33, v (56 ref.)

The role of the gut in major surgical postoperative morbidity. Chieveley-Williams S, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):81-110 (133 ref.)

Renal preservation in the perioperative period. Urzua J, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):111-23 (32 ref.)

Pouchitis: pathophysiology and treatment. Kühbacher T, et al. **Int J Colorectal Dis** 1998;13(5-6):196-207 (199 ref.)

MRI for physiology and function in congenital heart disease: functional assessment of the heart preoperatively and postoperatively. Fogel MA, et al. **Semin Roentgenol** 1998 Jul;33(3):239-51 (71 ref.)

On the mechanism of transient postoperative deficit of cranial nerves. Menovsky T, et al. **Surg Neurol** 1999 Feb; 51(2):223-6 (28 ref.)

Surgery and the respiratory muscles. Siafakas NM, et al. **Thorax** 1999 May;54(5):458-65 (111 ref.)

[Stoma physiology] Stern J, et al. **Chirurg** 1999 Jun; 70(6):627-34 (35 ref.) (Eng. Abstr.) **(Ger)**

[The physiology of intestinal pouches] Teixeira FV, et al. **Chirurg** 1999 May;70(5):513-9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Secondary diabetes in pancreatic carcinoma and after pancreatectomy: pathophysiology, therapeutic peculiarities and prognosis] Pfeffer F, et al. **Z Gastroenterol** 1999 Jun; Suppl 1:10-4 (36 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanical aspects of load-bearing capacity after total endoprosthesis replacement of the hip joint. An evaluation of current knowledge and review of the literature] Wirtz DC, et al. **Z Orthop Ihre Grenzgeb** 1998 Jul-Aug; 136(4):310-6 (69 ref.) (Eng. Abstr.) **(Ger)**

[The use of macrolide antibiotics in the treatment of postop intestinal paresis] Skomarovskii AA, et al. **Klin Khir** 1999; (1):55-6 (7 ref.) **(Rus)**

[Intestinal ischemia after abdominal aorta surgery. A dreaded complication surveyed by a combination of different methods] Björck M, et al. **Lakartidningen** 1999 Sep 1; 96(35):3659-62 (17 ref.) (Eng. Abstr.) **(Swe)**

PREVENTION & CONTROL

Alcohol withdrawal in the surgical patient: prevention and treatment. Spies CD, et al. **Anesth Analg** 1999 Apr; 88(4):946-54 (86 ref.)

Preoperative fasting in children. Splinter WM, et al. **Anesth Analg** 1999 Jul;89(1):80-9 (114 ref.)

Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous? Nurmohamed MT, et al. **Ann Rheum Dis** 1999 Jul;58(7):392-5 (38 ref.)

Prevention of venous thromboembolism in general surgery. Kakkar VV, et al. **Baillieres Clin Haematol** 1998 Sep; 11(3):605-19 (56 ref.)

Results of the Gil Vernet procedure in preventing contralateral reflux in unilateral ureteric reflux. Liard A, et al. **BJU Int** 1999 Apr;83(6):658-61 (19 ref.)

Graduated compression stockings in the prevention of venous thromboembolism. Agu O, et al. **Br J Surg** 1999 Aug; 86(8):992-1004 (135 ref.)

Preoperative cardiac preparation. Belzberg H, et al. **Chest** 1999 May;115(5 Suppl):82S-95S (158 ref.)

Assessing and modifying the risk of postoperative pulmonary complications. Doyle RL. **Chest** 1999 May;115(5 Suppl):77S-81S (43 ref.)

Age related risk and prevention of postoperative complications. Beltrami V. **Clin Ter** 1998 Nov-Dec; 149(6):435-8 (6 ref.)

Benefits of leukocyte-reduced blood transfusions in surgical patients. Jensen LS. **Curr Opin Hematol** 1998 Nov; 5(6):376-80 (31 ref.)

The role of octreotide in the prevention of complications following pancreatic resection. Berberat PO, et al. **Digestion** 1999;60 Suppl 2:15-22 (28 ref.)

Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. van Gorp EC, et al. **Drugs Aging** 1998 Aug;13(2):145-57 (94 ref.)

The use of spacers to prevent postoperative middle meatal adhesions. Yanagisawa E, et al. **Ear Nose Throat J** 1999 Aug;78(8):530-2 (3 ref.)

Renal preservation in the perioperative period. Urzua J, et al. **Int Anesthesiol Clin** 1999 Spring;37(2):111-23 (32 ref.)

A review of the impact of pre-operative education on recovery from surgery. Shuldham C. **Int J Nurs Stud** 1999 Apr;36(2):171-7 (20 ref.)

Use of postoperative steroids to reduce pain and inflammation. Fleischli JW, et al. **J Foot Ankle Surg** 1999 May-Jun;38(3):232-7 (31 ref.)

Diamond-like carbon coating and plasma or glow discharge treatment of mechanical heart valves. Tran HS, et al. **J Invest Surg** 1999 May-Jun;12(3):133-40 (50 ref.)

Minimizing complications in neck dissection. Talmi YP. **J Laryngol Otol** 1999 Feb;113(2):101-13 (92 ref.)

Prophylactic and therapeutic use of antibiotics in pelvic surgery. Price SA, et al. **J Surg Oncol** 1999 Aug;71(4):261-8 (17 ref.)

Prevention of renal function loss after non-renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire? [editorial] Broekroelofs J, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1841-3 (13 ref.)

Prophylaxis of cytomegalovirus infection in renal transplantation [editorial] Kuypers DR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3012-6 (12 ref.)

Prevention of peridural fibrosis: current methodologies. Geisler FH. **Neurol Res** 1999;21 Suppl 1:S9-22 (93 ref.)

Use of ADCON in neurosurgery: preclinical review. Lo H, et al. **Neurol Res** 1999;21 Suppl 1:S27-32 (21 ref.)

A major review of antimetabolites in glaucoma therapy. Loon SC, et al. **Ophthalmologica** 1999;213(4):234-45 (117 ref.)

The prevention of periprosthetic fractures in total hip and knee arthroplasty. Haddad FS, et al. **Orthop Clin North Am** 1999 Apr;30(2):191-207 (84 ref.)

Recognition and management of preoperative risk. Nierman E, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):585-622 (150 ref.)

Perioperative management of selected problems in patients with rheumatic diseases. Shaw M, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):623-38, ix (58 ref.)

Antibiotic prophylaxis in surgery: summary of a Swedish-Norwegian Consensus Conference. **Scand J Infect Dis** 1998;30(6):547-57 (83 ref.)

Diagnosis and management of venous thrombosis in the surgical patient. Jackson MR. **Semin Thromb Hemost** 1998; 24 Suppl 1:67-76 (44 ref.)

[Advance in the study of restoration of sensation in skin flaps] Kuang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):94-6 (25 ref.) **(Chi)**

[The effect of tobacco smoking on risks in connection in anesthesia and surgery. Development of complications and the preventive effect of smoking cessation] Møller AM, et al. **Ugeskr Laeger** 1999 Jul 26;161(30):4273-6 (27 ref.) (Eng. Abstr.) **(Dan)**

[Rules of preoperative antibiotic prophylaxis prescription] Martin C, et al. **Presse Med** 1998 Mar 7;27(9):416-26 (18 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of Crohn disease recurrence] Schölmerich J. **Chirurg** 1998 Sep;69(9):908-14 (41 ref.) (Eng. Abstr.) **(Ger)**

[New approaches in surgery--visceral surgery in the tension field between trauma from surgical access and radicality] Siewert JR, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:53-60 (13 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in surgery, after hemorrhagic complications and in pregnancy] Gohlke-Bärwolf C. **Z Kardiol** 1998;87 Suppl 4:56-62 (41 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in patients with heart valve replacement in pregnancy] Harenberg J. **Z Kardiol** 1998;87 Suppl 4:63-7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Molecular mechanisms and indicators of thrombogenesis after heart valve replacement] Scharf RE, et al. **Z Kardiol** 1998;87 Suppl 4:7-19 (46 ref.) (Eng. Abstr.) **(Ger)**

[Intensity of oral anticoagulant therapy after heart valve replacement] Stenzinger W. **Z Kardiol** 1998;87 Suppl 4:37-41 (12 ref.) (Eng. Abstr.) **(Ger)**

[Inhibition of thrombocyte aggregation after heart valve replacement] von Schacky C. **Z Kardiol** 1998;87 Suppl 4:46-55 (64 ref.) (Eng. Abstr.) **(Ger)**

[Guidelines for prevention of thrombosis in orthopedics] Pauschert R, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep-Oct; 136(5):471-9 (62 ref.) (Eng. Abstr.) **(Ger)**

[Consequences of perioperative hypothermia] Berti M, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):42-5 (25 ref.) **(Ita)**

[The prevention of adhesions in surgery. A clinical review and experimental contribution] Palmieri B, et al. **Minerva Chir** 1998 Nov;53(11):953-62 (28 ref.) (Eng. Abstr.) **(Ita)**

[The concept of the clinical use of serotonin adipinate in treating surgical patients] Fedorov VD, et al. **Vestn Khir Im I I Grek** 1998;157(3):15-9 (24 ref.) (Eng. Abstr.) **(Rus)**

[Cerebral complications are not rare after heart surgery. Difficult to avoid in older and seriously ill patients] Ahlgren E, et al. **Lakartidningen** 1998 Sep 30; 95(40):4318-20 (15 ref.) **(Swe)**

[The prevention of thromboembolic complications in neurosurgery] Polishchuk MIe, et al. **Klin Khir** 1998; (9-10):76-9 (22 ref.) **(Ukr)**

PSYCHOLOGY

[Postoperative delirium: risk factors, prophylaxis and treatment (see comments)] Gallinat J, et al. **Anaesthesist** 1999 Aug;48(8):507-18 (113 ref.) (Eng. Abstr.) Comment in: Anaesthesist 1999 Aug;48(8):505-6. **(Ger)**

RADIOGRAPHY

Imaging of cardiac transplantation complications. Knisely BL, et al. **Radiographics** 1999 Mar-Apr;19(2):321-39; discussion 340-1 (41 ref.)

[Stent migration with perforation of the portal vein after transjugular intrahepatic portosystemic shunt (TIPS) with a self-expanding stent] Adamus R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):174-6 (0 ref.) **(Ger)**

[The diagnostic contribution of computed tomography in a case of volvulus of the small intestine after an ileoanal anastomosis] Catalano O. **Minerva Chir** 1998 Sep; 53(9):747-50 (14 ref.) (Eng. Abstr.) **(Ita)**

[Pneumatosis intestinalis: an accidental finding in a patient after kidney transplantation (letter)] López A, et al. **Gastroenterol Hepatol** 1999 Jun-Jul;22(6):318-9 (7 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Diagnostic imaging modalities for delayed renal graft function: a review. el-Maghraby TA, et al. **Nucl Med Commun** 1998 Oct;19(10):915-36 (156 ref.)

RADIOTHERAPY

Radiation therapy for heterotopic ossification. Lo TC. **Semin Radiat Oncol** 1999 Apr;9(2):163-70 (72 ref.)

REHABILITATION

Arthroplasty of the hand and wrist: therapist's commentary [comment] Michlovitz S. **J Hand Ther** 1999 Apr-Jun; 12(2):133-4 (8 ref.) Comment on: J Hand Ther 1999 Apr-Jun;12(2):123-32.

[Postoperative patient management. Perioperative myocardial infarct] Fellahi JL, et al. **Presse Med** 1999 Jan 30;28(4):187-94 (51 ref.) (Eng. Abstr.) **(Fre)**

[Management and after-care of extensor tendon injuries of the hand] Partecke BD, et al. **Unfallchirurg** 1998 Nov; 101(11):807-12 (18 ref.) (Eng. Abstr.) **(Ger)**

[Management of the anterior cruciate ligament rupture: indications, choice of procedure, timing, concomitant and after-care] Wentzensen A, et al. **Zentralbl Chir** 1998; 123(9):970-80 (50 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Recurrent intracranial neurenteric cysts. Chaynes P, et al. **Acta Neurochir (Wien)** 1998;140(9):905-11 (33 ref.)

Left ventricular free wall rupture following mitral valve replacement. Yoshida K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):336-9 (12 ref.)

Recurrent gallstone ileus: underestimated. Doogue MP, et al. **Aust N Z J Surg** 1998 Nov;68(11):755-6 (32 ref.)

Complications after hallux valgus surgery. Richardson EG. **Instr Course Lect** 1999;48:331-42 (75 ref.)

Ossification of transverse ligament of the atlas associated with atlanto-axial dislocation--case report. Hayashi T, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):425-8 (18 ref.)

The treatment of periprosthetic fractures of the femur using cortical onlay allograft struts. Brady OH, et al. **Orthop Clin North Am** 1999 Apr;30(2):249-57 (20 ref.)

[Results of artificial sphincter in a case of sphincter incontinence in the multiple surgery patient] Leduc F, et al. **Acta Urol Belg** 1998 Dec;66(4):9-13 (15 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative management. Critical care in intra-abdominal infection after surgical intervention] Montravers P, et al. **Presse Med** 1999 Jan 30;28(4):196-202 (51 ref.) (Eng. Abstr.) **(Fre)**

[Typical complications and their control after restorative proctocolectomy] Buhr HJ, et al. **Chirurg** 1998 Oct; 69(10):1035-44 (45 ref.) (Eng. Abstr.) **(Ger)**

[Permanent stomata] Falkenberg B, et al. **Chirurg** 1999 Jun; 70(6):643-9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Minimally invasive surgery and Crohn disease] Hildebrandt U, et al. **Chirurg** 1998 Sep;69(9):915-21 (23 ref.) (Eng. Abstr.) **(Ger)**

[Osteotomy of the proximal femur for correction of post-traumatic changes] Strecker W, et al. **Chirurg** 1998 Nov;69(11):1153-60 (28 ref.) (Eng. Abstr.) **(Ger)**

[Repeat interventions after decompression of the carpal tunnel] Wulle C. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:641-6 (12 ref.) (Eng. Abstr.) **(Ger)**

[Osteotomies of the mid- and back-foot in recurrent club foot] Dierauer S, et al. **Orthopade** 1999 Feb;28(2):117-24 (38 ref.) (Eng. Abstr.) **(Ger)**

[Artificial hip replacement in young patients with hip dysplasia--long-term outcome after 10 years] Porsch M, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):548-53 (36 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative ileus--early, late or no surgery at all?] Decurtins M, et al. **Zentralbl Chir** 1998;123(12):1355-9 (32 ref.) (Eng. Abstr.) **(Ger)**

[Golden standard: patellar tendon-plasty--technique and management of postoperative complications] Lobenhoffer P. **Zentralbl Chir** 1998;123(9):981-93 (61 ref.) (Eng. Abstr.) **(Ger)**

[Revision surgery in failed anterior cruciate ligament-plasty]

POSTOPERATIVE COMPLICATIONS

Oettl GM, et al. **Zentralbl Chir** 1998;123(9):1033–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Ischemic colitis and mesenteric ischemia after abdominal aortic reconstruction] Würsten HU, et al. **Zentralbl Chir** 1998;123(12):1418–21 (24 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Alcohol withdrawal in the surgical patient: prevention and treatment. Spies CD, et al. **Anesth Analg** 1999 Apr; 88(4):946–54 (86 ref.)

Selective review of key perioperative renal–electrolyte disturbances in chronic renal failure patients. Yee J, et al. **Chest** 1999 May;115(5 Suppl):149S–157S (40 ref.)

Mechanical ventilation for respiratory failure postthoracotomy. D'Arsigny C, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):585–610 (124 ref.)

LASIK: management of common complications. Laser in situ keratomileusis. Wilson SE. **Cornea** 1998 Sep;17(5):459–67 (14 ref.)

Ventilation in the trauma and surgical patient. Battistella FD. **Crit Care Clin** 1998 Oct;14(4):731–42 (61 ref.)

Endovascular repair of iliac aneurysms following aortoiliac surgery. Vraux H, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):442–5 (9 ref.)

Endoscopic management of major bile leaks complicating hepatic resections for hepatocellular carcinoma. Lau JY, et al. **Gastrointest Endosc** 1999 Jul;50(1):99–101 (10 ref.)

Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. Tung BY, et al. **Gastrointest Endosc** 1999 May;49(5):647–51 (18 ref.)

Endourological treatment of ureteroenteric strictures: efficacy of Acucise endoureterotomy. Lin DW, et al. **J Urol** 1999 Sep;162(3 Pt 1):696–8 (20 ref.)

Endobronchial stents: primary and adjuvant therapy for endobronchial airway obstruction. Sonett JR. **Md Med J** 1998 Nov;47(5):260–3 (10 ref.)

Surgical management of chylous fistula after retroperitoneal lymph node dissection. Haukaas SA, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):71–2 (6 ref.)

Challenge of supportive surgical care in pediatric oncology. Dillon PW. **Semin Surg Oncol** 1999 Mar;16(2):193–9 (68 ref.)

Control of intraocular pressure after trabeculectomy. Haynes WL, et al. **Surv Ophthalmol** 1999 Jan–Feb;43(4):345–55 (82 ref.)

The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Flach AJ. **Trans Am Ophthalmol Soc** 1998;96:557–634 (379 ref.)

[The total knee prosthesis: indications and complications] Hamelynck KJ. **Ned Tijdschr Geneeskd** 1998 Sep 12; 142(37):2030–4 (30 ref.) (Eng. Abstr.) **(Dut)**

[Complications related to surgery in ulcerative colitis, pouchitis, special sequelae—internal medicine viewpoint] Zeitz M. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:154–9 (15 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of Crohn disease in internal medicine: postoperative recurrence and fistulas] Volk–Zeiher BA, et al. **Schweiz Rundsch Med Prax** 1998 Nov 26;87(48):1657–60 (18 ref.) (Eng. Abstr.) **(Ger)**

[Intensive care medicine in surgery. General principles and special surgical intensive care medicine (1)] Hartl WH, et al. **Zentralbl Chir** 1999;124(7):W63–74 (0 ref.) **(Ger)**

[The critically ill septic surgical patient] Greenberg R, et al. **Harefuah** 1998 Sep;135(5–6):229–35 (54 ref.) **(Heb)**

[Present-day concepts concerning immunoprophylaxis and immunotherapy of surgical infections] Pinegin BV, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):61–7 (35 ref.) **(Rus)**

[Home mechanical ventilation as a treatment of the sequelae of tuberculosis surgery] Prats Soro E, et al. **An Med Interna** 1999 Jan;16(1):35–7 (12 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Post-transplantation polyomavirus infections. Boubenider S, et al. **J Nephrol** 1999 Jan–Feb;12(1):24–9 (44 ref.)

Viral hepatitis in renal transplantation. Vathsala A. **Transplant Proc** 1999 Feb–Mar;31(1–2):337–9 (22 ref.)

POSTOPERATIVE HEMORRHAGE

DIAGNOSIS

[Diagnosis and treatment of early bleedings after open–heart surgery] Shevchenko IuL, et al. **Khirurgiia (Mosk)** 1999; (8):28–36 (59 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

[Diagnosis and treatment of early bleedings after open–heart surgery] Shevchenko IuL, et al. **Khirurgiia (Mosk)** 1999; (8):28–36 (59 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Multiple postoperative intracerebral haematomas remote from the site of craniotomy. Rapanà A, et al. **Br J Neurosurg** 1998 Aug;12(4):364–8 (32 ref.)

[Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation] Madei W, et al. **Dtsch Med Wochenschr** 1999 Apr 23; 124(16):487–90 (16 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Despotis GJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):84–104 (208 ref.)

Safety of adrenal vein ligation during endoscopic adrenalectomy: a technical note. Pietrabissa A, et al. **Surg Endosc** 1999 Mar;13(3):298–302 (23 ref.)

POSTOPERATIVE NAUSEA AND VOMITING

NURSING

The management of post–operative nausea and vomiting. Thompson HJ. **J Adv Nurs** 1999 May;29(5):1130–6 (17 ref.)

PHYSIOPATHOLOGY

[Postoperative nausea and emesis: mechanisms and treatment] Unkel W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Sep; 33(9):533–44 (104 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery [see comments] **Am J Health Syst Pharm** 1999 Apr 15;56(8):729–64 (423 ref.) Comment in: Am J Health Syst Pharm 1999 Apr 15;56(8):728.

The management of post–operative nausea and vomiting. Thompson HJ. **J Adv Nurs** 1999 May;29(5):1130–6 (17 ref.)

[Antiemetic effect of propofol] Borgeat A, et al. **Anaesthesist** 1998 Nov;47(11):918–24 (54 ref.) (Eng. Abstr.) **(Ger)**

[Acupuncture in prevention of postoperative nausea and vomiting] Schlager A. **Wien Med Wochenschr** 1998; 148(19):454–6 (31 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Has the use of meta–analysis enhanced our understanding of therapies for postoperative nausea and vomiting? [editorial; comment] White PF, et al. **Anesth Analg** 1999 Jun;88(6):1200–2 (28 ref.) Comment on: Anesth Analg 1999 Jun;88(6):1354–61. Comment on: Anesth Analg 1999 Jun;88(6):1362–9. Comment on: Anesth Analg 1999 Jun;88(6):1370–9.

[Postoperative nausea and emesis: mechanisms and treatment] Unkel W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Sep; 33(9):533–44 (104 ref.) (Eng. Abstr.) **(Ger)**

POSTOPERATIVE WOUND INFECTION see **SURGICAL WOUND INFECTION**

POSTOVULATORY PHASE see **LUTEAL PHASE**

POSTPARTUM DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTPARTUM HEMORRHAGE

Peripartum hemorrhage. Alamia V Jr, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):385–98 (63 ref.)

[Postpartum hemorrhage] Aflak N, et al. **Rev Prat** 1999 Jan 15;49(2):155–9 (28 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Diagnostic and therapeutic management of postpartum hemorrhage] Gaubert P, et al. **Contracept Fertil Sex** 1999 May;27(5):335–44 (40 ref.) **(Fre)**

[Postpartum hemorrhage. Diagnosis and treatment fundamentals] Toffani V, et al. **Rev Prat** 1998 May 15; 48(10):1155–7 (0 ref.) **(Fre)**

EPIDEMIOLOGY

[Intrapartum hemorrhages in the maternity ward of the Yalgado Ouédraogo University Hospital Center of Ouagadougou, Burkina Faso] Lankoandé J, et al. **Dakar Med** 1998;43(1):57–9 (6 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Postpartum hemorrhage and arterial embolization. Mason BA. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):475–9 (17 ref.)

[Diagnostic and therapeutic management of postpartum hemorrhage] Gaubert P, et al. **Contracept Fertil Sex** 1999 May;27(5):335–44 (40 ref.) **(Fre)**

[Postpartum hemorrhage. Diagnosis and treatment fundamentals] Toffani V, et al. **Rev Prat** 1998 May 15; 48(10):1155–7 (0 ref.) **(Fre)**

POSTPARTUM PERIOD see **PUERPERIUM**

POSTPHLEBITIC DISEASE see **POSTPHLEBITIC SYNDROME**

POSTPHLEBITIC SYNDROME

ULTRASONOGRAPHY

[Place of duplex sonography in the differential diagnosis of deep vein thrombosis] Habscheid W. **Dtsch Med Wochenschr** 1998 Oct 2;123(40):1185–90 (51 ref.) **(Ger)**

POSTPHLEBITIC ULCER see **POSTPHLEBITIC SYNDROME**

POSTPOLIOMYELITIS MUSCULAR ATROPHY see **POSTPOLIOMYELITIS SYNDROME**

POSTPOLIOMYELITIS SYNDROME

The reappearance of polio. Postpolio syndrome. Tillett SG, et al. **J Am Podiatr Med Assoc** 1999 Apr;89(4):183–7 (7 ref.)

[Post–polio syndrome] Nagashima T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):356–9 (15 ref.) **(Jpn)**

THERAPY

[Physiotherapeutic possibilities in the treatment of postpolio syndrome] Bocker B, et al. **Dtsch Med Wochenschr** 1999 Mar 19;124(11):327–31 (24 ref.) **(Ger)**

POSTPRANDIAL PERIOD

Postprandial dyslipidaemia in a nutshell: food for thought. Watts GF, et al. **Aust N Z J Med** 1998 Dec;28(6):816–23 (62 ref.)

The postprandial state and risk of cardiovascular disease. Lefebvre PJ, et al. **Diabet Med** 1998;15 Suppl 4:S63–8 (52 ref.)

Drug therapy of postprandial hyperglycaemia. Mooradian AD, et al. **Drugs** 1999 Jan;57(1):19–29 (95 ref.)

Long–chain n–3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Roche HM, et al. **Lipids** 1999;34 Suppl:S259–65 (68 ref.)

PHYSIOLOGY

The influence of exercise on postprandial triacylglycerol metabolism. Hardman AE. **Atherosclerosis** 1998 Dec;141 Suppl 1:S93–100 (88 ref.)

Glucose metabolism and the postprandial state. Lefebvre PJ, et al. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:1–6 (38 ref.)

Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Ursini F, et al. **Free Radic Biol Med** 1998 Jul 15;25(2):250–2 (15 ref.)

POST-REGISTRATION NURSING EDUCATION see **EDUCATION, NURSING, CONTINUING**

POST-TRANSCRIPTIONAL RNA MODIFICATION see **RNA PROCESSING, POST-TRANSCRIPTIONAL**

POST-TRANSLATIONAL ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

POST-TRANSLATIONAL PROTEIN MODIFICATION see **PROTEIN PROCESSING, POST-TRANSLATIONAL**

POST-TRAUMATIC NEOPLASMS see **NEOPLASMS, POST-TRAUMATIC**

POST-TRAUMATIC STRESS DISORDERS see **STRESS DISORDERS, POST-TRAUMATIC**

POSTURE

see related
HYPOTENSION, ORTHOSTATIC
KINESICS

Idiopathic orthostatic intolerance and postural tachycardia syndromes. Jacob G, et al. **Am J Med Sci** 1999 Feb; 317(2):88–101 (74 ref.)

Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS). Low PA, et al. **Am J Med Sci** 1999 Feb;317(2):124–33 (80 ref.)

The epidemic of orthostatic tachycardia and orthostatic intolerance. Robertson D. **Am J Med Sci** 1999 Feb; 317(2):75–7 (12 ref.)

The importance of orthostatic intolerance in the chronic fatigue syndrome. Schondorf R, et al. **Am J Med Sci** 1999 Feb;317(2):117–23 (87 ref.)

Orthostatic intolerance. A historical introduction to the pathophysiological mechanisms. Streeten DH. **Am J Med Sci** 1999 Feb;317(2):78–87 (55 ref.)

Side sleeping position and bed sharing in the sudden infant death syndrome. Scragg RK, et al. **Ann Med** 1998 Aug; 30(4):345–9 (41 ref.)

Analysis of the forces and position required for direct laryngoscopic exposure of the anterior vocal folds. Hochman H, et al. **Ann Otol Rhinol Laryngol** 1999 Aug; 108(8):715–24 (38 ref.)

Positioning for ultrasound–assisted lipoplasty. Nahai F. **Clin Plast Surg** 1999 Apr;26(2):235–43 (2 ref.)

Body position and pneumonia [editorial; comment] deBoisblanc BP. **Crit Care Med** 1999 Apr;27(4):678–9 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):745–8.
Visual–vestibular control of posture and gait: physiological mechanisms and disorders. Bronstein AM, et al. **Curr Opin Neurol** 1999 Feb;12(1):5–11 (62 ref.)
Current techniques for assessing physical exposure to work-related musculoskeletal risks, with emphasis on posture-based methods. Li G, et al. **Ergonomics** 1999 May; 42(5):674–95 (147 ref.)
Branching out in locomotion: the mechanics of perch use in birds and primates. Bonser RH. **J Exp Biol** 1999 Jun; 202 (Pt 11):1459–63 (35 ref.)
A review of biomechanics of the central nervous system--part II: spinal cord strains from postural loads. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 Jun; 22(5):322–32 (49 ref.)
Nerve trunk pain: physical diagnosis and treatment. Hall TM, et al. **Man Ther** 1999 May;4(2):63–73 (62 ref.)
Common patterns of clinical motor dysfunction. Mayer NH, et al. **Muscle Nerve Suppl** 1997;6:S21–35 (13 ref.)
Treatment for positional vertigo [see comments] Hornibrook J. **N Z Med J** 1998 Sep 11;111(1073):331–2 (28 ref.) Comment in: N Z Med J 1998 Sep 11;111(1073):349.
Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. Grubb BP, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):798–810 (77 ref.)
Acute respiratory distress syndrome. Patient position and motion strategies. Force TR, et al. **Respir Care Clin N Am** 1998 Dec;4(4):665–77, viii (31 ref.)
Head positioning compliance with spectacles after gas retinopexy. Boucher MC, et al. **Retina** 1999;19(2):177–8 (0 ref.)
The importance of an intact abdominal musculature mechanism in maintaining spinal sagittal balance. Case illustration in prune-belly syndrome. Lam KS, et al. **Spine** 1999 Apr 1;24(7):719–22 (16 ref.)
[An update on the diagnosis and treatment of autonomic nervous system dysfunctional syndromes with orthostatic intolerance] Grubb BP, et al. **G Ital Cardiol** 1999 Mar; 29(3):323–32 (41 ref.) **(Ita)**
[Orthostatic intolerance. A review and clinical case] Freitas J, et al. **Rev Port Cardiol** 1998 Sep;17(9):715–20 (5 ref.) (Eng. Abstr.) **(Por)**
[Diagnosis and therapeutic options in benign paroxysmal positional vertigo] Suzuki AR, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):106–17 (42 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Postural disorders and dentofacial morphology. Huggare J. **Acta Odontol Scand** 1998 Dec;56(6):383–6 (39 ref.)
The interaction of otolith and proprioceptive information in the perception of verticality. The effects of labyrinthine and CNS disease. Bronstein AM. **Ann N Y Acad Sci** 1999 May 28;871:324–33 (25 ref.)
Set-up error & organ motion uncertainty: a review. Booth JT, et al. **Australas Phys Eng Sci Med** 1999 Jun;22(2):29–47 (84 ref.)
The cerebellum and postural sensorimotor learning in mice and rats. Caston J, et al. **Behav Brain Res** 1998 Sep; 95(1):17–22 (45 ref.)
The sitting position in neurosurgery: a critical appraisal. Porter JM, et al. **Br J Anaesth** 1999 Jan;82(1):117–28 (84 ref.)
Role of gravity in the development of posture and locomotion in the neonatal rat. Clarac F, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):35–43 (49 ref.)
Body orientation and control of coordinated movements in microgravity. Massion J, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):83–91 (48 ref.)
Interaction of vestibular, somatosensory and visual signals for postural control and motion perception under terrestrial and microgravity conditions--a conceptual model. Mergner T, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):118–35 (67 ref.)
Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Reschke MF, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):102–17 (189 ref.)
Post-spaceflight orthostatic intolerance: possible relationship to microgravity-induced plasticity in the vestibular system. Yates BJ, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):73–82 (61 ref.)
New assistive technology for passive standing. Gear AJ, et al. **J Burn Care Rehabil** 1999 Mar–Apr;20(2):164–9 (14 ref.)
A review of biomechanics of the central nervous system--Part I: spinal canal deformations resulting from changes in posture. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 May;22(4):227–34 (67 ref.)
A review of biomechanics of the central nervous system--Part III: spinal cord stresses from postural loads and their neurologic effects. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 Jul–Aug;22(6):399–410 (84 ref.)
Vasopressin in the locus coeruleus and dorsal pontine tegmentum affects posture and vestibulospinal reflexes. Pompeiano O. **Prog Brain Res** 1998;119:537–54 (65 ref.)
[Thromboembolic syndrome from prolonged sitting and flights of long duration: experience of the Emergency Medical Service of the Paris Airports] Clérel M, et al. **Bull Acad Natl Med** 1999;183(5):985–97; discussion 997–1001 (34 ref.) (Eng. Abstr.) **(Fre)**
[Is spinal anesthesia for operations in the prone or jackknife position suitable?] Standl T, et al. **Anaesthesist** 1999 Apr; 48(4):242–50 (49 ref.) (Eng. Abstr.) **(Ger)**

POSTVIRAL FATIGUE SYNDROME see **FATIGUE SYNDROME, CHRONIC**

POTASSIUM

see related
HYPERKALEMIA
HYPOKALEMIA

ADMINISTRATION & DOSAGE

The effects of potassium, magnesium, calcium, and fiber on risk of stroke. Suter PM. **Nutr Rev** 1999 Mar;57(3):84–8 (35 ref.)

METABOLISM

Cell volume-regulated cation channels. Wehner F. **Contrib Nephrol** 1998;123:8–20 (79 ref.)
Effects of electromagnetic fields on membrane ion transport of cultured cells. Ikehara T, et al. **J Med Invest** 1998 Aug; 45(1–4):47–56 (52 ref.)
Inward rectifier renal potassium channel (ROMK), the low-conductance channels for potassium secretion. Bhandari S, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3019–23 (52 ref.)
K+ currents of glomus cells and chemosensory functions of carotid body. Donnelly DF. **Respir Physiol** 1999 Apr 1;115(2):151–60 (52 ref.)
Regulation of potassium transport in the maturing kidney. Satlin LM. **Semin Nephrol** 1999 Mar;19(2):155–65 (63 ref.)
[Towards the crystal structure of potassium channels: the pore structure for selective permeation of K ions] Oiki S. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):1990–7 (24 ref.) **(Jpn)**
[The mechanisms of Na+, K(+)-ATPase in renal tubular epithelium] Beltowski J. **Postepy Biochem** 1998; 44(4):282–91 (159 ref.) **(Pol)**

PHYSIOLOGY

Galanin activates an inwardly rectifying potassium conductance and inhibits a voltage-dependent calcium conductance in mudpuppy parasympathetic neurons. Parsons RL, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:156–69 (34 ref.)
A necessary role for cell shrinkage in apoptosis. Bortner CD, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1549–59 (68 ref.)
On the viability of a physiological system. Regulation of potassium by aldosterone. Auberlet JM, et al. **C R Acad Sci III** 1998 Oct;321(10):797–803 (20 ref.)
Luminal signal in tubuloglomerular feedback: what about potassium? Vallon V, et al. **Kidney Int Suppl** 1998 Sep; 67:S177–9 (11 ref.)
Potassium and anaesthesia. Reddy VG. **Singapore Med J** 1998 Nov;39(11):511–6 (56 ref.)

URINE

Urinary potassium and the overactive bladder. Hohlbrugger G. **BJU Int** 1999 Mar;83 Suppl 2:22–8 (31 ref.)

POTASSIUM CHANNELS

see related
NA(+)-K(+)-EXCHANGING ATPASE

Cardiovascular ATP-sensitive K+ channel as a new molecular target for development of antihypertensive drugs. Wang H. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep; 19(5):397–402 (27 ref.)
New frontiers of cardioprotection. Terzic A. **Clin Pharmacol Ther** 1999 Aug;66(2):105–9 (41 ref.)
Molecular biology of adenosine triphosphate-sensitive potassium channels. Aguilar-Bryan L, et al. **Endocr Rev** 1999 Apr;20(2):101–35 (375 ref.)
X-ray crystallographic structures of gramicidin and their relation to the Streptomyces lividans potassium channel structure. Wallace BA. **Novartis Found Symp** 1999; 225:23–32; discussion 33–7 (31 ref.)

AGONISTS

Pharmacology of voltage-gated and calcium-activated potassium channels. Kaczorowski GJ, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):448–58 (87 ref.)
Recent advances in antihypertensive therapy. Quadri L, et al. **Curr Pharm Des** 1998 Dec;4(6):489–512 (194 ref.)
Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. Shotts RH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):706–7 (5 ref.)

ANTAGONISTS & INHIBITORS

5-HT4 receptors: long-term blockade of K+ channels and effects on olfactory memory. Bockaert J, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):217–21 (33 ref.)
Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Taglialatela M, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:182–9 (38 ref.)
Scorpion toxins as tools for studying potassium channels. Garcia ML, et al. **Methods Enzymol** 1999;294:624–39 (37 ref.)

CHEMISTRY

Unlocking family secrets: K+ channel transmembrane domains. Clapham DE. **Cell** 1999 May 28;97(5):547–50 (22 ref.)
Chemical basis for alkali cation selectivity in potassium-channel proteins. Moczydlowski E. **Chem Biol** 1998 Nov;5(11):R291–301 (49 ref.)
Ion channels: structure of a molecular brake. Sansom MS. **Curr Biol** 1999 Mar 11;9(5):R173–5 (9 ref.)
The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. Miki T, et al. **J Mol Endocrinol** 1999 Apr;22(2):113–23 (68 ref.)
Towards the three-dimensional structure of voltage-gated potassium channels. Choe S, et al. **Trends Biochem Sci** 1999 Sep;24(9):345–9 (54 ref.)
[Towards the crystal structure of potassium channels: the pore structure for selective permeation of K ions] Oiki S. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):1990–7 (24 ref.) **(Jpn)**

CLASSIFICATION

Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line. Miller TR, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):179–85 (27 ref.)

DRUG EFFECTS

The warm-up phenomenon and ischaemic preconditioning: an uncertain relationship [editorial; comment] Cohen MV, et al. **Eur Heart J** 1999 Feb;20(3):167–8 (9 ref.) Comment on: Eur Heart J 1999 Feb;20(3):196–202. Comment on: Eur Heart J 1999 Feb;20(3):203–10.
Alcohol modulation of calcium-activated potassium channels. Dopico AM, et al. **Neurochem Int** 1999 Aug; 35(2):103–6 (31 ref.)
KATP channel openers for the treatment of airways hyperreactivity. Buchheit KH, et al. **Pulm Pharmacol Ther** 1999;12(2):103–5 (7 ref.)
Baseline K+ channels as targets of general anesthetics: studies of the action of volatile anesthetics on TOK1. Yost CS, et al. **Toxicol Lett** 1998 Nov 23;100–101:293–300 (21 ref.)
Mitochondria: a new target for K channel openers? Szewczyk A, et al. **Trends Pharmacol Sci** 1999 Apr;20(4):157–61 (55 ref.)

GENETICS

Behavioral and electrophysiological analysis of Ca-activated K-channel transgenes in Drosophila. Atkinson NS, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:296–305 (33 ref.)
Differential expression and targeting of K+ channel genes in the lobster pyloric central pattern generator. Baro DJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:281–95 (53 ref.)
Molecular diversity of K+ channels. Coetzee WA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:233–85 (144 ref.)
Involvement of genes encoding a K+ channel (ether a go-go) and a Na+ channel (smellblind) in Drosophila olfaction. Dubin AE, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:212–22 (28 ref.)
Functional and molecular aspects of voltage-gated K+ channel beta subunits. Pongs O, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:344–55 (34 ref.)
Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Sanguinetti MC. **Ann N Y Acad Sci** 1999 Apr 30;868:406–13 (55 ref.)
Benign familial neonatal epilepsy with mutations in two potassium channel genes. Leppert M, et al. **Curr Opin Neurol** 1999 Apr;12(2):143–7 (36 ref.)
Molecular genetics of long-QT syndrome. Wattanasirichaigoon D, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):628–34 (58 ref.)
Ion channels and the genetic contribution to epilepsy. Ryan SG. **J Child Neurol** 1999 Jan;14(1):58–66 (68 ref.)
When, where, and how much? Expression of the Kv3.1 potassium channel in high-frequency firing neurons. Gan L, et al. **J Neurobiol** 1998 Oct;37(1):69–79 (44 ref.)
Dynamic regulation of K+ channel gene expression in differentiated cells. Levitan ES, et al. **J Neurobiol** 1998 Oct;37(1):60–8 (50 ref.)
Ion channel activity drives ion channel expression. Ribera AB. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):645 (8 ref.)
G protein regulation of potassium ion channels. Yamada M, et al. **Pharmacol Rev** 1998 Dec;50(4):723–60 (248 ref.)
The pathophysiological and molecular basis of Bartter's and Gitelman's syndromes. Bhandari S. **Postgrad Med J** 1999 Jul;75(885):391–6 (65 ref.)
Gene defects in idiopathic epilepsy. Steinlein OK. **Rev Neurol (Paris)** 1999 Jul;155(6–7):450–3 (18 ref.)

METABOLISM

G protein gated potassium channels. Sui JL, et al. **Adv Second Messenger Phosphoprotein Res** 1999;33:179–201 (122 ref.)

POTASSIUM CHANNELS

Behavioral and electrophysiological analysis of Ca-activated K-channel transgenes in Drosophila. Atkinson NS, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:296–305 (33 ref.)
Small-conductance calcium-activated potassium channels. Bond CT, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:370–8 (52 ref.)
Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Gross GJ, et al. **Circ Res** 1999 May 14;84(9):973–9 (53 ref.)
Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Waldron GJ, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):180–4 (39 ref.)
Recent advances on renal inward rectifier K+ channels. Huang CL. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):503–8 (56 ref.)
ATP dependent K+ channel: a novel therapeutic target in unstable angina [editorial; comment] Dana A, et al. **Eur Heart J** 1999 Jan;20(1):2–5 (21 ref.) Comment on: Eur Heart J 1999 Jan;20(1):51–7.
Regulation of the ROMK potassium channel in the kidney. Wald H. **Exp Nephrol** 1999 May–Jun;7(3):201–6 (28 ref.)
Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. Baines CP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):741–54 (111 ref.)
The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. Miki T, et al. **J Mol Endocrinol** 1999 Apr;22(2):113–23 (68 ref.)
Role of cell–cell interactions in the developmental regulation of Ca2+-activated K+ currents in vertebrate neurons. Dryer SE. **J Neurobiol** 1998 Oct;37(1):23–36 (65 ref.)
Regulation of voltage-gated K+ channel expression in the developing mammalian myocardium. Nerbonne JM. **J Neurobiol** 1998 Oct;37(1):37–59 (178 ref.)
Inward rectifier renal potassium channel (ROMK), the low-conductance channels for potassium secretion. Bhandari S, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3019–23 (52 ref.)
Potassium channels: some assembly required. Papazian DM. **Neuron** 1999 May;23(1):7–10 (20 ref.)
K+ and Ca2+ channel activity and cytosolic [Ca2+] in oxygen-sensing tissues. López-Barneo J, et al. **Respir Physiol** 1999 Apr 1;115(2):215–27 (60 ref.)
Towards the three-dimensional structure of voltage-gated potassium channels. Choe S, et al. **Trends Biochem Sci** 1999 Sep;24(9):345–9 (54 ref.)
Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Alkon DL, et al. **Trends Neurosci** 1998 Dec;21(12):529–37 (97 ref.)
[The function of voltage-gated potassium canals in T-lymphocytes under physiological and pathologic conditions] Teisseyre A. **Postepy Hig Med Dosw** 1999; 53(2):383–97 (42 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Ca2+ channels, ryanodine receptors and Ca(2+)-activated K+ channels: a functional unit for regulating arterial tone. Jaggar JH, et al. **Acta Physiol Scand** 1998 Dec; 164(4):577–87 (69 ref.)
K+ channel modulation in arterial smooth muscle. Standen NB, et al. **Acta Physiol Scand** 1998 Dec;164(4):549–57 (60 ref.)
Potassium channels: basic aspects, functional roles, and medical significance. Yost CS. **Anesthesiology** 1999 Apr; 90(4):1186–203 (107 ref.)
Galanin activates an inwardly rectifying potassium conductance and inhibits a voltage-dependent calcium conductance in mudpuppy parasympathetic neurons. Parsons RL, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:156–69 (34 ref.)
ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Seino S. **Annu Rev Physiol** 1999;61:337–62 (133 ref.)
Unlocking family secrets: K+ channel transmembrane domains. Clapham DE. **Cell** 1999 May 28;97(5):547–50 (22 ref.)
Cell volume-regulated cation channels. Wehner F. **Contrib Nephrol** 1998;123:8–20 (79 ref.)
Ion channels: structure of a molecular brake. Sansom MS. **Curr Biol** 1999 Mar 11;9(5):R173–5 (9 ref.)
Potassium ion channels and human disease: phenotypes to drug targets? Curran ME. **Curr Opin Biotechnol** 1998 Dec; 9(6):565–72 (97 ref.)
The bacterial K+ channel structure and its implications for neuronal channels. Yellen G. **Curr Opin Neurobiol** 1999 Jun;9(3):267–73 (52 ref.)
Voltage-gated potassium channels: from hyperexcitability to excitement. Pongs O. **FEBS Lett** 1999 Jun 4;452(1–2):31–5 (40 ref.)
Oxygen-sensing potassium currents in pulmonary artery. McCulloch KM, et al. **Gen Pharmacol** 1999 Apr; 32(4):403–11 (54 ref.)
Beta-cell ion channels: keys to endodermal excitability. Philipson LH. **Horm Metab Res** 1999 Aug;31(8):455–61 (90 ref.)
Potassium-current oscillation of rat megakaryocytes: As a model system for drug evaluation (Review). Uneyama C, et al. **Int J Mol Med** 1999 Aug;4(2):163–9 (36 ref.)
Role of potassium channels in regulation of cerebral vascular tone. Faraci FM, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1047–63 (209 ref.)
Evolutionary link between prokaryotic and eukaryotic K+ channels. Derst C, et al. **J Exp Biol** 1998 Oct;201 (Pt 20):2791–9 (55 ref.)
Shedding light on voltage-dependent gating. Perozo E. **J Gen Physiol** 1998 Oct;112(4):373–6 (21 ref.)
Development of electrical excitability in embryonic neurons: mechanisms and roles. Spitzer NC, et al. **J Neurobiol** 1998 Oct;37(1):190–7 (86 ref.)
Potassium currents and excitability in second-order auditory and vestibular neurons. Peusner KD, et al. **J Neurosci Res** 1998 Sep 1;53(5):511–20 (76 ref.)
ATP-sensitive potassium channels: structures, functions, and pathophysiology. Inagaki N, et al. **Jpn J Physiol** 1998 Dec; 48(6):397–412 (162 ref.)
Potassium channels and regulation of the microcirculation. Jackson WF. **Microcirculation** 1998;5(2–3):85–90 (25 ref.)
The intracellular potassium and chloride channels: properties, pharmacology and function (review). Szewczyk A. **Mol Membr Biol** 1998 Apr–Jun;15(2):49–58 (117 ref.)
Modulation of ion channels: a "current" view of AKAPs. Fraser ID, et al. **Neuron** 1999 Jul;23(3):423–6 (20 ref.)
G protein regulation of potassium ion channels. Yamada M, et al. **Pharmacol Rev** 1998 Dec;50(4):723–60 (248 ref.)
Spatial distribution of NA+ and K+ channels in spinal dorsal horn neurones: role of the soma, axon and dendrites in spike generation. Safronov BV. **Prog Neurobiol** 1999 Oct; 59(3):217–41 (125 ref.)
The IKs channel: coassembly of IsK (minK) and KvLQT1 proteins. Suessbrich H, et al. **Rev Physiol Biochem Pharmacol** 1999;137:191–226 (147 ref.)
Correlating structure and function in ATP-sensitive K+ channels. Ashcroft FM, et al. **Trends Neurosci** 1998 Jul; 21(7):288–94 (48 ref.)
[ATP-sensitive K+ channels of the cardiovascular system] Kurachi Y. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:32P–35P (15 ref.) (Eng. Abstr.) **(Jpn)**

POTASSIUM COMPOUNDS

ADVERSE EFFECTS

[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

POTASSIUM DEFICIENCY

see related
HYPOKALEMIA

POTASSIUM, DIETARY

ADVERSE EFFECTS

What is the role of dietary sodium and potassium in hypertension and target organ injury? He J, et al. **Am J Med Sci** 1999 Mar;317(3):152–9 (50 ref.)

PHARMACOLOGY

Relationship between urinary calcium and net acid excretion as determined by dietary protein and potassium: a review. Lemann J Jr. **Nephron** 1999;81 Suppl 1:18–25 (29 ref.)

POTASSIUM GLUTAMATE see **GLUTAMATES**

POTASSIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

POTATOES

CHEMISTRY

Postharvest changes in glycoalkaloid content of potatoes. Friedman M, et al. **Adv Exp Med Biol** 1999;459:121–43 (124 ref.)

GROWTH & DEVELOPMENT

Callus initiation, maintenance, and shoot induction in potato. Monitoring of spontaneous genetic variability in vitro and in vivo. Curry RF, et al. **Methods Mol Biol** 1999;111:31–42 (27 ref.)
Microprotoplast-mediated chromosome transfer (MMCT) for the direct production of monosomic addition lines. Ramulu KS, et al. **Methods Mol Biol** 1999;111:227–42 (27 ref.)

POTT'S DISEASE see **TUBERCULOSIS, SPINAL**

POUCHITIS

DRUG THERAPY

Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Sandborn WJ, et al. **Inflamm Bowel Dis** 1999 Feb;5(1):33–9 (34 ref.)
Pouchitis: pathophysiology and treatment. Kühbacher T, et al. **Int J Colorectal Dis** 1998;13(5–6):196–207 (199 ref.)

PHYSIOPATHOLOGY

Pouchitis: pathophysiology and treatment. Kühbacher T, et al. **Int J Colorectal Dis** 1998;13(5–6):196–207 (199 ref.)

THERAPY

[Complications related to surgery in ulcerative colitis, pouchitis, special sequelae--internal medicine viewpoint] Zeitz M. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:154–9 (15 ref.) (Eng. Abstr.) **(Ger)**

POULTRY

Functional properties of myosin isoforms in avian muscle. Bandman E. **Poult Sci** 1999 May;78(5):729–34 (79 ref.)
Mechanical harvesting of broilers. Lacy MP, et al. **Poult Sci** 1998 Dec;77(12):1794–7 (18 ref.)
Extracellular modifications to muscle collagen: implications for meat quality. McCormick RJ. **Poult Sci** 1999 May; 78(5):785–91 (30 ref.)
Influence of growth factors on poultry myogenic satellite cells. McFarland DC. **Poult Sci** 1999 May;78(5):747–58 (139 ref.)
Poultry welfare in North America: opportunities and challenges. Mench JA, et al. **Poult Sci** 1998 Dec; 77(12):1763–5 (6 ref.)
Reducing phosphorus runoff and improving poultry production with alum. Moore PA Jr, et al. **Poult Sci** 1999 May;78(5):692–8 (26 ref.)
Management and utilization of poultry wastes. Williams CM, et al. **Rev Environ Contam Toxicol** 1999;162:105–57 (338 ref.)

GROWTH & DEVELOPMENT

Absence of growth hormone-induced avian muscle growth in vivo. Vasilatos-Younken R. **Poult Sci** 1999 May; 78(5):759–68 (108 ref.)
The role of the extracellular matrix in skeletal muscle development. Velleman SG. **Poult Sci** 1999 May; 78(5):778–84 (47 ref.)

IMMUNOLOGY

Introduction to poultry vaccines and immunity. Sharma JM. **Adv Vet Med** 1999;41:481–94 (62 ref.)

METABOLISM

[Metabolic insights and nutrition of poultry] Decuypere E, et al. **Tijdschr Diergeneeskd** 1999 Jan 15;124(2):47–51 (9 ref.) (Eng. Abstr.) **(Dut)**

MICROBIOLOGY

Novel detection techniques for human pathogens that contaminate poultry. Mandrell RE, et al. **Curr Opin Biotechnol** 1999 Jun;10(3):273–8 (32 ref.)
Food-borne antibiotic-resistant Campylobacter infections. **Nutr Rev** 1999 Jul;57(7):224–7 (5 ref.)

PHYSIOLOGY

Temporal control of feeding behaviour and its association with gastrointestinal function. Savory CJ. **J Exp Zool** 1999 Mar–Apr 1;283(4–5):339–47 (83 ref.)
Behavior and behavioral needs. Duncan IJ. **Poult Sci** 1998 Dec;77(12):1766–72 (66 ref.)
Health and husbandry considerations of induced molting. Ruszler PL. **Poult Sci** 1998 Dec;77(12):1789–93 (32 ref.)

POULTRY DISEASES

Physiological stress and welfare of broiler chickens in transit: solutions not problems! Mitchell MA, et al. **Poult Sci** 1998 Dec;77(12):1803–14 (59 ref.)

DIAGNOSIS

Chicken anemia virus. Rosenberger JK, et al. **Poult Sci** 1998 Aug;77(8):1190–2 (7 ref.)

DIET THERAPY

Dietary modulation of avian coccidiosis. Allen PC, et al. **Int J Parasitol** 1998 Jul;28(7):1131–40 (55 ref.)

DRUG THERAPY

Evaluation of the efficacy of anticoccidial drugs against Eimeria species in the fowl. Chapman HD. **Int J Parasitol** 1998 Jul;28(7):1141–4 (12 ref.)

EPIDEMIOLOGY

Epidemiological aspects of the use of live anticoccidial vaccines for chickens. Williams RB. **Int J Parasitol** 1998 Jul;28(7):1089–98 (42 ref.)
Infectious bursal disease and hemorrhagic enteritis. Saif YM. **Poult Sci** 1998 Aug;77(8):1186–9 (29 ref.)
[Aortic rupture in poultry: a review] van Veen L. **Tijdschr Diergeneeskd** 1999 Apr 15;124(8):244–7 (38 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Pathogenesis of enteric diseases. Hoerr FJ. **Poult Sci** 1998 Aug;77(8):1150–5 (51 ref.)
Rapid growth problems: ascites and skeletal deformities in broilers. Julian RJ. **Poult Sci** 1998 Dec;77(12):1773–80 (36 ref.)
The problem of broken bones during the handling of laying hens--a review. Knowles TG, et al. **Poult Sci** 1998 Dec; 77(12):1798–802 (36 ref.)
Amyloid arthropathy in chickens. Landman WJ. **Vet Q** 1999 Jun;21(3):78–82 (67 ref.)
[Metabolic insights and nutrition of poultry] Decuypere E, et al. **Tijdschr Diergeneeskd** 1999 Jan 15;124(2):47–51 (9 ref.) (Eng. Abstr.) **(Dut)**

GENETICS

Impact of genetics on disease resistance. Lamont SJ. **Poult Sci** 1998 Aug;77(8):1111–8 (96 ref.)

IMMUNOLOGY

In ovo vaccination technology. Ricks CA, et al. **Adv Vet Med** 1999;41:495–515 (51 ref.)
Introduction to poultry vaccines and immunity. Sharma JM. **Adv Vet Med** 1999;41:481–94 (62 ref.)
Immune and endocrine regulation of food intake in sick animals. Johnson RW. **Domest Anim Endocrinol** 1998 Sep; 15(5):309–19 (81 ref.)
Role of T lymphocytes and cytokines in coccidiosis. Lillehoj HS. **Int J Parasitol** 1998 Jul;28(7):1071–81 (90 ref.)
Genetic analysis of the essential components of the immunoprotective response to infection with Eimeria vermiformis. Smith AL, et al. **Int J Parasitol** 1998 Jul; 28(7):1061–9 (54 ref.)
Nutritional modulation of resistance to infectious diseases. Klasing KC. **Poult Sci** 1998 Aug;77(8):1119–25 (55 ref.)
Impact of genetics on disease resistance. Lamont SJ. **Poult Sci** 1998 Aug;77(8):1111–8 (96 ref.)
Understanding immunology in disease development and control. Qureshi MA, et al. **Poult Sci** 1998 Aug; 77(8):1126–9 (37 ref.)

MICROBIOLOGY

Bacterial respiratory disease of poultry. Glisson JR. **Poult Sci** 1998 Aug;77(8):1139–42 (10 ref.)
Mycoplasmas in the etiology of multifactorial respiratory disease. Kleven SH. **Poult Sci** 1998 Aug;77(8):1146–9 (61 ref.)
Bacterial enteritides of poultry. Porter RE Jr. **Poult Sci** 1998 Aug;77(8):1159–65 (57 ref.)
Avian pathogenic Escherichia coli (APEC). Dho-Moulin M, et al. **Vet Res** 1999 Mar–Jun;30(2–3):299–316 (117 ref.)

PARASITOLOGY

Important parasites in poultry production systems. Ruff MD. **Vet Parasitol** 1999 Aug 1;84(3–4):337–47 (57 ref.)

PHYSIOPATHOLOGY

Relationship of structure and function of the avian respiratory system to disease susceptibility. Fedde MR. **Poult Sci** 1998 Aug;77(8):1130–8 (51 ref.)
Pathogenesis of enteric diseases. Hoerr FJ. **Poult Sci** 1998 Aug;77(8):1150–5 (51 ref.)
Intestinal protozoa important to poultry. McDougald LR. **Poult Sci** 1998 Aug;77(8):1156–8 (5 ref.)

PREVENTION & CONTROL

Control of avian encephalomyelitis: a historical account. Calnek BW. **Avian Dis** 1998 Oct–Dec;42(4):632–47 (59 ref.)
The early history of infectious bronchitis. Fabricant J. **Avian Dis** 1998 Oct–Dec;42(4):648–50 (24 ref.)
Use of live oocyst vaccines in the control of avian coccidiosis: experimental studies and field trials. Danforth HD. **Int J Parasitol** 1998 Jul;28(7):1099–109 (17 ref.)
Progress on developing a recombinant coccidiosis vaccine. Jenkins MC. **Int J Parasitol** 1998 Jul;28(7):1111–9 (105 ref.)
Progress in recombinant vaccine development against coccidiosis. A review and prospects into the next millennium. Vermeulen AN. **Int J Parasitol** 1998 Jul; 28(7):1121–30 (39 ref.)
Use of competitive exclusion in food animals. Nisbet DJ. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1744–6 (14 ref.)
Poultry industry strategies for control of immunosuppressive diseases. Fussell LW. **Poult Sci** 1998 Aug;77(8):1193–6 (25 ref.)
Vaccination for control of Salmonella in poultry. Zhang-Barber L, et al. **Vaccine** 1999 Jun 4; 17(20–21):2538–45 (79 ref.)
The poultry red mite Dermanyssus gallinae (De Geer, 1778): current situation and future prospects for control. Chauve C. **Vet Parasitol** 1998 Nov 16;79(3):239–45 (24 ref.)

VIROLOGY

Virus infections of the gastrointestinal tract of poultry. Guy JS. **Poult Sci** 1998 Aug;77(8):1166–75 (69 ref.)
Retrovirus-induced disease in poultry. Payne LN. **Poult Sci** 1998 Aug;77(8):1204–12 (58 ref.)
Viral diseases of the respiratory system. Villegas P. **Poult Sci** 1998 Aug;77(8):1143–5 (24 ref.)

POULTRY PRODUCTS

MICROBIOLOGY

Food-borne antibiotic-resistant Campylobacter infections. **Nutr Rev** 1999 Jul;57(7):224–7 (5 ref.)

POVERTY

Ethics and allocation of health resources--the influence of poverty on health. Taipale V. **Acta Oncol** 1999;38(1):51–5 (50 ref.)
The hospital emergency department as a social welfare institution. Gordon JA. **Ann Emerg Med** 1999 Mar; 33(3):321–5 (45 ref.)
Poverty and ill health: physicians can, and should, make a difference. McCally M, et al. **Ann Intern Med** 1998 Nov 1;129(9):726–33 (57 ref.)
Head Start, nutrition, and problems of poverty in childhood [editorial] Karp RJ. **J Am Coll Nutr** 1999 Apr;18(2):100–1 (21 ref.)
Improving prenatal care services for low-income African American women and infants [editorial] Sanders-Phillips K, et al. **J Health Care Poor Underserved** 1998 Feb; 9(1):14–29 (96 ref.)
Economic determinants and dietary consequences of food insecurity in the United States. Rose D. **J Nutr** 1999 Feb; 129(2S Suppl):517S–520S (11 ref.)
Opportunities to improve health care for low-income adolescents. Collins KS, et al. **J Urban Health** 1998 Dec; 75(4):660–76 (14 ref.)
Medicaid's impact on access to and utilization of health care services among racial and ethnic minority children. Hall AG. **J Urban Health** 1998 Dec;75(4):677–92 (25 ref.)
What role can public health institutions play in drug development for the poor? A case study of artesunate. Gomes M, et al. **Med Trop (Mars)** 1998;58(3 Suppl):97–100 (10 ref.)
Women, welfare, and work: one view of the debate. Schroeder C, et al. **Nurs Outlook** 1998 Sep–Oct; 46(5):226–32 (34 ref.)
Health and quality of life within Colonias settlements along the United States and Mexico border. Davidhizar R, et al. **Public Health Nurs** 1999 Aug;16(4):301–6 (18 ref.)
Medicaid managed care: the challenge of providing care to low-income women. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):57S–67S (32 ref.)
[Chronic lead poisoning in children today. A pathology of poverty and social exclusion] Sinnaeve O, et al. **Arch Pediatr** 1999 Jul;6(7):762–7 (37 ref.) (Eng. Abstr.) **(Fre)**
[Re-emergence of tuberculosis and socioeconomic uncertainty] Poinsignon Y, et al. **Rev Med Interne** 1998 Sep;19(9):649–57 (39 ref.) (Eng. Abstr.) **(Fre)**
[Tropical medicine and the pathology of poverty. New paradigms in international health policy] Stefanini A. **Ann Ig** 1998 Sep–Dec;10(5–6):387–93 (28 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

The stress of being a poor child in America. Garbarino J. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):105–19, ix (23 ref.)

STATISTICS & NUMERICAL DATA

Maternal mortality in Nigeria: the real issues. Harrison KA. **Afr J Reprod Health** 1997 Mar;1(1):7–13 (8 ref.)
The effects of poverty and ageing on the increase in tuberculosis. Davies PD. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):168–71 (12 ref.)

TRENDS

The Asian currency crisis and public health: poverty and health revisited [editorial] Binns C, et al. **Asia Pac J Public Health** 1998;10(1):1–4 (17 ref.)

POVIDONE-IODINE

ADVERSE EFFECTS

Induction of a critical elevation of povidone-iodine absorption in the treatment of a burn patient: report of a case. Aiba M, et al. **Surg Today** 1999;29(2):157–9 (10 ref.)
[Hyperthyroidism due to the improper use of povidone-iodine] Pagliaricci S, et al. **Ann Ital Med Int** 1999 Apr–Jun;14(2):124–6 (10 ref.) (Eng. Abstr.) **(Ita)**

POWER (PSYCHOLOGY)

see related
SOCIAL CONTROL, INFORMAL

A concept analysis on the process of empowerment. Ellis-Stoll CC, et al. **ANS Adv Nurs Sci** 1998 Dec; 21(2):62–8 (35 ref.)
Autonomy, power, and control in palliative care. Scott PA. **Camb Q Healthc Ethics** 1999 Spring;8(2):139–47 (35 ref.)
The authority of the clinical ethicist. Casarett DJ, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):6–11 (19 ref.)
A concept analysis of empowerment: its relationship to mental health nursing. Ryles SM. **J Adv Nurs** 1999 Mar; 29(3):600–7 (86 ref.)

POWER, PERSONAL see **POWER (PSYCHOLOGY)**

POWER PLANTS

Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Nikiforov YE, et al. **Adv Anat Pathol** 1999 Mar;6(2):78–91 (44 ref.)
Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl. Pisarchik AV, et al. **Thyroid** 1998 Nov;8(11):1003–8 (39 ref.)
[Management of 29 children with thyroid cancer following the Chernobyl accident] Aurengo A, et al. **Bull Acad Natl Med** 1998;182(5):955–76; discussion 976–9 (77 ref.) (Eng. Abstr.) **(Fre)**
[Biological capabilities of the thymus of human fetus during normal development and during constant exposure to small doses of radiation after the accident at the Chernobyl power plant] Khlystova ZS, et al. **Arkh Patol** 1998 Sep–Oct;60(5):74–9 (41 ref.) (Eng. Abstr.) **(Rus)**
[The involvement of the upper digestive tract and psychosomatic disorders in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Svintsitskii AS, et al. **Lik Sprava** 1998 Oct–Nov;(7):39–42 (44 ref.) **(Rus)**
[Role of emotional stress in development of somatic injuries in liquidators of the Chernobyl power plant accident irradiated with small doses] Moroz BB, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):97–105 (41 ref.) (Eng. Abstr.) **(Rus)**
[The function of the digestive system organs in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station (a review of the literature)] Tkachyshyn VS. **Lik Sprava** 1999 Mar; (2):32–5 (47 ref.) (Eng. Abstr.) **(Ukr)**

POWER, PROFESSIONAL see **POWER (PSYCHOLOGY)**

POWER, SOCIAL see **POWER (PSYCHOLOGY)**

POWER SOURCES

see related
BIOELECTRIC ENERGY SOURCES

Possible mechanisms by which electric fields from power lines might affect airborne particles harmful to health [see comments] Swanson J, et al. **J Radiol Prot** 1999 Sep; 19(3):213–29 (73 ref.) Comment in: J Radiol Prot 1999 Sep;19(3):199–200.

POWER SOURCES, BIOELECTRIC see **BIOELECTRIC ENERGY SOURCES**

POWER SUPPLIES see **POWER SOURCES**

POXVIRIDAE

GENETICS

Tumor necrosis factor receptors encoded by poxviruses. Cunnion KM. **Mol Genet Metab** 1999 Aug;67(4):278–82 (48 ref.)

IMMUNOLOGY

Viral modulation of the host response via crmA/SPI-2 expression. Turner S, et al. **Immunol Cell Biol** 1999 Jun; 77(3):236–41 (88 ref.)

POXVIRIDAE INFECTIONS

DIAGNOSIS

Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections. Mayers DL. **Dermatol Clin** 1999 Jan;17(1):29–40, vii–viii (69 ref.)

EPIDEMIOLOGY

Re-emergence of monkeypox in Africa: a review of the past six years. Heymann DL, et al. **Br Med Bull** 1998; 54(3):693–702 (9 ref.)

THERAPY

Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections. Mayers DL. **Dermatol Clin** 1999 Jan;17(1):29–40, vii–viii (69 ref.)

VETERINARY

Swinepox virus as a vaccine vector for swine pathogens. Tripathy DN. **Adv Vet Med** 1999;41:463–80 (45 ref.)

POXVIRUS AVIUM see **AVIPOXVIRUS**

POXVIRUS INFECTIONS see **POXVIRIDAE INFECTIONS**

POXVIRUS MYXOMATIS see **MYXOMA VIRUS**

POXVIRUS OFFICINALE see **VACCINIA VIRUS**

POXVIRUS VARIOLAE see **VARIOLA VIRUS**

PP60(V-SRC) see **ONCOGENE PROTEIN PP60(V-SRC)**

PP2B see **CALCINEURIN**

PPIASE see **PEPTIDYLPROLYL ISOMERASE**

PPLO see **MYCOPLASMA**

PRACTICE GUIDELINES

The cost of implementing the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines. Wish J, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):67–74 (34 ref.)

Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas? Carruthers SG. **Am Heart J** 1999 Sep; 138(3 Pt 2):256–60 (27 ref.)

Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. **Am J Cardiol** 1999 Jan 21;83(2A):1A–38A (404 ref.)

National guidelines needed to manage rhinitis and prevent complications. Rachelefsky GS. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):296–305 (126 ref.)

National recommendations for the pharmacological treatment of hypertension: should they be revised? [comment] Moser M. **Arch Intern Med** 1999 Jul 12;159(13):1403–6 (23 ref.) Comment on: Arch Intern Med 1997 Nov 24;157(21):2413–46.

New evidence, new guidelines [editorial; comment] Shepherd J. **Atherosclerosis** 1998 Oct;140(2):197–8 (9 ref.) Comment on: Atherosclerosis 1998 Oct;140(2):199–270.

Management of choroid plexus cysts in the mid–trimester fetus. Choong S, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):7–11 (20 ref.)

Review. Guidelines for the urological screening and initial management of lower urinary tract dysfunction in children with anorectal malformations—the ARGUS protocol. Boemers TM, et al. **BJU Int** 1999 Apr;83(6):662–71 (24 ref.)

Clinical guidelines: using clinical guidelines. Feder G, et al. **BMJ** 1999 Mar 13;318(7185):728–30 (25 ref.)

Clinical guidelines–the hidden costs. Haycox A, et al. **BMJ** 1999 Feb 6;318(7180):391–3 (14 ref.)

Clinical guidelines: developing guidelines. Shekelle PG, et al. **BMJ** 1999 Feb 27;318(7183):593–6 (17 ref.)

Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. Woolf SH, et al. **BMJ** 1999 Feb 20; 318(7182):527–30 (16 ref.)

Taking on diabetes. Family doctors on the front lines of the battle against diabetes [editorial; comment] Harris SB, et al. **Can Fam Physician** 1998 Nov;44:2345–9, 2356–60 (17 ref.) Comment on: Can Fam Physician 1998 Nov;44 :2465–6, 2469–79. **(Eng, Fre)**

Guidelines for using insulin lispro. Toth EL, et al. **Can Fam Physician** 1998 Nov;44:2444–9 (42 ref.)

Development and implementation of asthma guidelines. FitzGerald JM. **Can Respir J** 1998 Jul–Aug;5 Suppl A:85A–8A (34 ref.)

Role of evidence–based medicine and clinical practice guidelines in treatment decisions. Pearson KC. **Clin Ther** 1998;20 Suppl C:C80–5 (21 ref.)

Incorporating preventive care recommendations into clinical practice: how do we bridge the gap? [editorial; comment] Douketis JD. **CMAJ** 1999 Apr 20;160(8):1171–2 (19 ref.) Comment on: CMAJ 1999 Apr 20;160(8):1137–40.

Clinical practice guidelines: questions family physicians should ask themselves. Worrall G. **Compr Ther** 1999 Jan; 25(1):46–9 (26 ref.)

Humanitarianism, pluralism and ombudsmen: do the pieces fit? Christoplos I. **Disasters** 1999 Jun;23(2):125–38 (21 ref.)

Current guidelines for the treatment of patients with rheumatic fever. Thatai D, et al. **Drugs** 1999 Apr; 57(4):545–55 (93 ref.)

Screening for colorectal cancer in Germany: guidelines and reality [editorial] Neuhaus H. **Endoscopy** 1999 Aug; 31(6):468–70 (10 ref.)

Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced [editorial; comment] Pyörälä K, et al. **Eur Heart J** 1998 Oct;19(10):1413–5 (14 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1434–503.

Guidelines—Do we need them! [editorial; comment] Shepherd J. **Eur Heart J** 1998 Oct;19(10):1419 (4 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1531–7.

Objectives of guidelines on heart failure. Tavazzi L. **Eur Heart J** 1998 Oct;19 Suppl L:L33–5 (16 ref.)

Guidelines for anti–emetic therapy: acute emesis. Fauser AA, et al. **Eur J Cancer** 1999 Mar;35(3):361–70 (94 ref.)

The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Bjerklund Johansen TE, et al. **Eur Urol** 1998 Dec;34(6):457–66 (47 ref.)

A review of research in the United Kingdom to evaluate the implementation of clinical guidelines in general practice. Dowie R. **Fam Pract** 1998 Oct;15(5):462–70 (34 ref.)

Organizational tactics for the successful assimilation of medical practice guidelines. Sonnad SS. **Health Care Manage Rev** 1998 Summer;23(3):30–7 (15 ref.)

Specific issues related to developing, disseminating, and implementing pediatric practice guidelines for physicians, patients, families, and other stakeholders. Bauchner H, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1161–77 (51 ref.)

Clinical practice guidelines in the management of gynecologic malignancies. Winn RJ, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):63–75, viii (53 ref.)

Evidence–based guidelines for early stroke management. Pushpangadan M, et al. **Hosp Med** 1999 Feb;60(2):105–14 (98 ref.)

Practice guidelines for community–based parenteral anti–infective therapy. Williams DN, et al. **Infect Dis Clin North Am** 1998 Dec;12(4):1009–21, viii–ix (40 ref.)

Evaluation of the spine utilizing the AMA Guides to the Evaluation of Permanent Impairment, 4th edition. Haralson RH 3rd. **Instr Course Lect** 1999;48:451–61 (3 ref.)

Drawing up clinical guidelines. McGovern MC, et al. **Int J Clin Pract** 1999 Mar;53(2):118–21 (11 ref.)

Evidence of self–report bias in assessing adherence to guidelines. Adams AS, et al. **Int J Qual Health Care** 1999 Jun;11(3):187–92 (28 ref.)

Deriving treatment recommendations from evidence within randomized trials. The role and limitation of meta–analysis. Freemantle N, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):304–15 (46 ref.)

Clinical guidelines in nursing, midwifery and the therapies: a systematic review. Thomas LH, et al. **J Adv Nurs** 1999 Jul;30(1):40–50 (40 ref.)

Practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder. **J Am Acad Child Adolesc Psychiatry** 1998 Oct;37(10 Suppl):4S–26S (210 ref.)

Treatment of AIDS and HIV–related conditions—1999 [see comments] Goldschmidt RH, et al. **J Am Board Fam Pract** 1999 Jan–Feb;12(1):71–94 (46 ref.) Comment in: J Am Board Fam Pract 1999 Jan–Feb;12(1):97–9.

Guidelines for surgical standby for coronary angioplasty: should they be changed? [editorial; comment] Angelini P. **J Am Coll Cardiol** 1999 Apr;33(5):1266–8 (13 ref.) Comment on: J Am Coll Cardiol 1999 Apr;33(5):1257–65.

Computer–based guideline implementation systems: a systematic review of functionality and effectiveness. Shiffman RN, et al. **J Am Med Inform Assoc** 1999 Mar–Apr;6(2):104–14 (37 ref.)

Quality medical management of the geriatric population using practice guidelines, physician–managed home health services, and continuous quality–improvement management strategies. Reaves LA, et al. **J Am Osteopath Assoc** 1999 May;99(5):265–9 (32 ref.)

Clinical practice guidelines in end–stage renal disease: a strategy for implementation. Kliger AS, et al. **J Am Soc Nephrol** 1999 Apr;10(4):872–7 (18 ref.)

Consensus statement on the diagnosis of multiple system atrophy. Gilman S, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):189–92 (26 ref.)

Standards of care and standard form contracts: distinguishing patient rights and consumer rights in managed care. Mariner WK. **J Contemp Health Law Policy** 1998 Fall; 15(1):1–55 (0 ref.)

Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations. Nevarre DR, et al. **J Endovasc Surg** 1998 Aug;5(3):282–91 (47 ref.)

Improving clinical outcome in bacteremia. Herchline T, et al. **J Eval Clin Pract** 1998 Aug;4(3):191–5 (22 ref.)

Practice guidelines and tort reform: the legal system confronts the technocratic wish. Matthews JR. **J Health Polit Policy Law** 1999 Apr;24(2):275–304 (40 ref.)

Infection control—evidence into practice. Jenner EA, et al. **J Hosp Infect** 1999 Jun;42(2):91–104 (46 ref.)

Guidelines for arterial hypertension: the echocardiography controversy [comment] de Simone G. **J Hypertens** 1999 Jun;17(6):735–6 (10 ref.) Comment on: J Hypertens 1999 Jun;17(6):817–24.

Consensus conference. Colorectal cancer: prevention, screening and management. Daher M. **J Med Liban** 1998 Sep–Oct;46(5):268–79 (0 ref.) **(Eng, Fre)**

Adapting guidelines to Lebanese clinical practice. Hamadeh G, et al. **J Med Liban** 1998 Sep–Oct;46(5):261–7 (50 ref.)

Older adults living with chronic pain: an opportunity for improvement. Ebener MK. **J Nurs Care Qual** 1999 Apr; 13(4):1–7 (22 ref.)

A practical approach to managing community dwellers with Alzheimer's disease. Winn PA. **J Okla State Med Assoc** 1999 Mar;92(3):116–20 (14 ref.)

A primer on clinical management guidelines in neonatology. Bowen FW. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S10–2 (36 ref.)

A review of guidelines for the discharge of premature infants: opportunities for improving cost effectiveness. Merritt TA, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S27–37 (79 ref.)

Assisted suicide and nursing: possibly compatible? White BC. **J Prof Nurs** 1999 May–Jun;15(3):151–9 (52 ref.)

Motor neuron disease and its management. Parton MJ, et al. **J R Coll Physicians Lond** 1999 May–Jun;33(3):212–8 (12 ref.)

Who should decide how effective cervical cancer screening will be? [editorial] Austin RM. **J Reprod Med** 1999 Apr; 44(4):317–20 (11 ref.)

Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association [see comments] Gorelick PB, et al. **JAMA** 1999 Mar 24–31;281(12):1112–20 (128 ref.) Comment in: ACP J Club 1999 Sep–Oct;131(2):30–1.

The utility of decision support, clinical guidelines, and financial incentives as tools to achieve improved clinical performance. Goldfarb S. **Jt Comm J Qual Improv** 1999 Mar;25(3):137–44 (19 ref.)

One size does not fit all: questions to answer before intervening to change physician behavior. Poses RM. **Jt Comm J Qual Improv** 1999 Sep;25(9):486–95 (78 ref.)

The performance of doctors: the new professionalism [see comments] Irvine D. **Lancet** 1999 Apr 3;353(9159):1174–7 (30 ref.) Comment in: Lancet 1999 Jul 10;354(9173):165.

Legal implications of clinical practice guidelines [editorial; comment] Dwyer P. **Med J Aust** 1998 Sep 21;169(6):292–3 (12 ref.) Comment on: Med J Aust 1998 Sep 21;169(6):330–3.

Clinical pathways [editorial; comment] [see comments] Kitchiner DJ, et al. **Med J Aust** 1999 Jan 18;170(2):54–5 (12 ref.) Comment on: Med J Aust 1999 Jan 18;170(2):59–62. Comment in: Med J Aust 1999 Jun 7;170(11):568.

ICH–harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Müller L, et al. **Mutat Res** 1999 May;436(3):195–225 (46 ref.)

Perils, pitfalls, and accomplishments of guidelines for treatment of back problems. Bigos SJ. **Neurol Clin** 1999 Feb;17(1):179–92 (5 ref.)

Rule–makers who establish infection control standards. Yost AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):527–33 (18 ref.)

Theory construction based on standards of care: a proposed theory of the peaceful end of life. Ruland CM, et al. **Nurs Outlook** 1998 Jul–Aug;46(4):169–75 (19 ref.)

Occupational medicine practice guidelines. Bruckman RZ, et al. **Occup Med** 1998 Oct–Dec;13(4):679–91 (19 ref.)

Progress toward guidelines for the management of fatigue. Cella D, et al. **Oncology (Huntingt)** 1998 Nov; 12(11A):369–77 (53 ref.)

Demonstrating oncology provider value: data, guidelines, and the law. Gosfield AG. **Oncology (Huntingt)** 1998 Nov; 12(11A):157–61 (14 ref.)

Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. Payne R. **Oncology (Huntingt)** 1998 Nov;12(11A):169–75 (45 ref.)

Incorporating new modalities into practice guidelines: platelet growth factors. Rubenstein EB, et al. **Oncology (Huntingt)** 1998 Nov;12(11A):381–6 (15 ref.)

Guidelines for screening for diabetic retinopathy revisited [editorial; comment] Klein R. **Ophthalmic Epidemiol** 1999 Mar;6(1):1–4 (20 ref.) Comment on: Ophthalmic Epidemiol 1999 Mar;6(1):61–72.

Radiographic assessment of hip and knee osteoarthritis. Recommendations: recommended guidelines. Vignon E, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):434–6 (15 ref.)

Recommended immunization practices for pediatric renal transplant recipients. Neu AM, et al. **Pediatr Transplant** 1998 Nov;2(4):263–9 (44 ref.)

Is 'routine' laboratory testing a thing of the past? Current recommendations regarding screening [see comments] Tabas GH, et al. **Postgrad Med** 1999 Mar;105(3):213–20; quiz 227 (19 ref.) Comment in: Postgrad Med 1999 Jun;105(7):36.

Selected drug complications and treatment conflicts in the presence of coexistent diseases. Vassilopoulos D, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):745–77, x (232 ref.)

Evidence based approach to practice guides and decision thresholds for cardiac markers. Christenson RH, et al. **Scand J Clin Lab Invest Suppl** 1999;230:90–102 (28 ref.)

Standards of treatment in chronic hepatitis C. Gish RG. **Semin Liver Dis** 1999;19 Suppl 1:35–47 (187 ref.)

The utility of peak flow measurements in guiding asthma management—what is the evidence? [editorial] Chee CB. **Singapore Med J** 1998 Nov;39(11):476–7 (11 ref.)

Principles of medical decision making. Lurie JD, et al. **Spine** 1999 Mar 1;24(5):493–8 (20 ref.)

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Hurley CK, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):394–406 (88 ref.)

[Practice guidelines for medical treatment from the perspective of health law] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2480–4 (19 ref.) (Eng. Abstr.) **(Dut)**

[Therapeutic choices for cancer of the rectum: discussion and update of the consensus conference] de Calan L, et al. **J Chir (Paris)** 1998 May;135(2):51–6 (44 ref.) (Eng. Abstr.) **(Fre)**

[Guidelines for the therapy of heart failure: importance of the treatment individualization] Ceia F. **Rev Port Cardiol** 1999 Apr;18(4):439–45 (26 ref.) (Eng. Abstr.) **(Por)**

[The place of the new quinolones in the guidelines on the treatment of community–acquired pneumonia] Dorca J. **Arch Bronconeumol** 1999 May;35 Suppl 3:77–80 (23 ref.) **(Spa)**

STANDARDS

Effect of pharmaceutical services on adherence to criteria–for–use guidelines in the operating room. Higgins

B, et al. **Am J Health Syst Pharm** 1999 May 15; 56(10):977–82 (7 ref.)
Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Schulberg HC, et al. **Arch Gen Psychiatry** 1998 Dec;55(12):1121–7 (77 ref.)
A novel method of guideline development for the diagnosis and management of mild to moderate hypertension. Adams JL, et al. **Br J Gen Pract** 1999 Mar;49(440):175–9 (22 ref.)
1998 revision of the Canadian Asthma Consensus Guidelines. Asthma Consensus Conference Editorial Committee [editorial] Boulet LP, et al. **Can Respir J** 1999 May–Jun; 6(3):231–2 (19 ref.)
Colorectal cancer screening: making sense of the different guidelines. Burke CA, et al. **Cleve Clin J Med** 1999 May; 66(5):303–11 (45 ref.)
Practice guidelines [editorial] Junginger T, et al. **G Chir** 1999 Apr;20(4):141–7 (33 ref.)
A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. Harvey RJ. **Int J Geriatr Psychiatry** 1999 Apr;14(4):249–56 (18 ref.)
Rational 'DOTS plus' for the control of MDR–TB. Espinal MA, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):561–3 (18 ref.)
Tuberculosis control and directly observed therapy from the public health/human rights perspective. Hurtig AK, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):553–60 (62 ref.)
Anxiety and its treatment in the elderly. Krasucki C, et al. **Int Psychogeriatr** 1999 Mar;11(1):25–45 (114 ref.)
Using outcomes to improve quality of research and quality of care. Deyo RA. **J Am Board Fam Pract** 1998 Nov–Dec; 11(6):465–73 (53 ref.)
Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. Jassal SV, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1697–708 (87 ref.)
Best clinical practice: guidelines for managing major depression in primary medical care. Schulberg HC, et al. **J Clin Psychiatry** 1999;60 Suppl 7:19–26; discussion 27–8 (70 ref.)
Practice guidelines for practicing doctors [editorial; comment] Weiss KB. **J Gen Intern Med** 1998 Oct; 13(10):714–5 (8 ref.) Comment on: J Gen Intern Med 1998 Oct;13(10):659–63.
JNC–VI: a view from the United Kingdom. Beevers DG, et al. **J Hum Hypertens** 1998 Sep;12(9):649–51 (16 ref.)
European brain death codes: a comparison of national guidelines. Haupt WF, et al. **J Neurol** 1999 Jun;246(6):432–7 (32 ref.)
Evidence–based medicine: is translating evidence into practice a solution to the cost–quality challenges facing medicine? Larson EB. **Jt Comm J Qual Improv** 1999 Sep; 25(9):480–5 (15 ref.)
Clinical practice guidelines before the law: sword or shield? [see comments] Pelly JE, et al. **Med J Aust** 1998 Sep 21; 169(6):330–3 (9 ref.) Comment in: Med J Aust 1998 Sep 21;169(6):292–3.
Therapist–patient sex. From boundary violations to sexual misconduct. Simon RI. **Psychiatr Clin North Am** 1999 Mar; 22(1):31–47 (54 ref.)
How to judge practice guidelines. Weingarten S. **West J Med** 1999 Jun;170(6):352 (6 ref.)
[Why not standard practice guidelines in Japan?] Nakajima T. **Gan To Kagaku Ryoho** 1999 Apr;26(5):597–601 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Practice guidelines in western countries] Sasako M, et al. **Gan To Kagaku Ryoho** 1999 Apr;26(5):602–8 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Development of cancer treatment practice guidelines in Japan: advantages and disadvantages] Yamaguchi T, et al. **Gan To Kagaku Ryoho** 1999 Apr;26(5):609–13 (6 ref.) (Eng. Abstr.) **(Jpn)**

PRACTICE MANAGEMENT, DENTAL

ECONOMICS

Dentists and their practices. Brown LJ, et al. **J Am Dent Assoc** 1998 Dec;129(12):1692–9 (18 ref.)

STATISTICS & NUMERICAL DATA

Dentists and their practices. Brown LJ, et al. **J Am Dent Assoc** 1998 Dec;129(12):1692–9 (18 ref.)

PRACTICE MANAGEMENT, MEDICAL

The business of medicine: physicians head back to school. Weatherford L. **Mich Med** 1999 Jan;98(1):33–5 (0 ref.)

ECONOMICS

Methods of reducing the financial risk of physicians under capitation. Anderson GF, et al. **Arch Fam Med** 1999 Mar–Apr;8(2):149–55 (33 ref.)
Economic analysis and general practice. Beilby J, et al. **Aust Fam Physician** 1998 Oct;27(10):905–6 (12 ref.)
Capitation payment rates and implications for the general pediatrician. Anderson GF, et al. **Curr Opin Pediatr** 1998 Oct;10(5):480–5 (32 ref.)

LEGISLATION & JURISPRUDENCE

Dealing with "excluded providers": contracts that can bring trouble to physicians. Padgett PT. **J Ky Med Assoc** 1998 Nov;96(11):457–8 (8 ref.)
Judicial diagnosis. Antitrust and physicians. Wishik J. **Med Health R I** 1999 Apr;82(4):140–1 (14 ref.)

TRENDS

The future of gastroenterology in the era of managed care. Ganz RA. **J Clin Gastroenterol** 1999 Mar;28(2):117–24 (34 ref.)

PRACTICE PATTERNS, DENTAL see **DENTIST'S PRACTICE PATTERNS**

PRACTICE PATTERNS, PROFESSIONAL see **PHYSICIAN'S PRACTICE PATTERNS**

PRACTICE VALUATION AND PURCHASE

see related
OWNERSHIP

PRAD1 PROTEIN see **CYCLIN D1**

PRADER–WILLI SYNDROME

Prader–Willi syndrome. Couper R. **J Paediatr Child Health** 1999 Aug;35(4):331–4 (42 ref.)

GENETICS

Imprinting in Angelman and Prader–Willi syndromes. Jiang Y, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):334–42 (72 ref.)
Prader–Willi and Angelman syndromes: update on genetic mechanisms and diagnostic complexities. Khan NL, et al. **Curr Opin Neurol** 1999 Apr;12(2):149–54 (60 ref.)
[Genomic imprinting and hereditary diseases] Orstavik KH. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):835–8 (23 ref.) (Eng. Abstr.) **(Nor)**

PRAOMYS see **MURIDAE**

PRASTERONE

Dehydroepiandrosterone and sport. Corrigan AB. **Med J Aust** 1999 Aug 16;171(4):206–8 (48 ref.)

ADMINISTRATION & DOSAGE

Hormone replacement for disabilities and diseases of aging. Dwivedi RN. **J Indian Med Assoc** 1998 May;96(5):139–40 (6 ref.)

BIOSYNTHESIS

Early steps in androgen biosynthesis: from cholesterol to DHEA. Miller WL. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):67–81 (104 ref.)

METABOLISM

DHEA and DHEA–S: a review. Kroboth PD, et al. **J Clin Pharmacol** 1999 Apr;39(4):327–48 (151 ref.)

PHYSIOLOGY

Is there a case for DHEA replacement? Nippoldt TB, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):507–20 (87 ref.)

SECRETION

[Dehydroepiandrosterone, reticular area of adrenal cortex and resistance to stress and disease] Obut TA. **Vestn Ross Akad Med Nauk** 1998;(10):18–22 (52 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

DHEA: panacea or snake oil? Sirrs SM, et al. **Can Fam Physician** 1999 Jul;45:1723–8 (35 ref.)
Dehydroepiandrosterone (DHEA) for serious disease, a possibility? [editorial; comment] Lahita RG. **Lupus** 1999; 8(3):169–70 (11 ref.) Comment on: Lupus 1999 ;8(3):181–7.
The role of dehydroepiandrosterone in diabetes mellitus. Wellman M, et al. **Pharmacotherapy** 1999 May;19(5):582–91 (47 ref.)
Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Robinzon B, et al. **Rheumatology (Oxford)** 1999 Jun;38(6):488–95 (111 ref.)

PRAVASTATIN

THERAPEUTIC USE

Statin therapy for prevention of coronary artery disease with average cholesterol levels [editorial] Gambhir DS. **Indian Heart J** 1999 Jan–Feb;51(1):19–20, 105 (6 ref.)
Does cholesterol lowering prevent stroke? Henry RY, et al. **J Clin Pharm Ther** 1998 Oct;23(5):337–44 (30 ref.)
[Are there differences in various statins?] Otto C, et al. **Internist (Berl)** 1998 Sep;39(9):987–93 (42 ref.) **(Ger)**
[The impact HMG–CoA reductase inhibitors on the modification of the natural history of coronary artery disease] Kaiser SE, et al. **Arq Bras Cardiol** 1998 Aug; 71(2):153–62 (75 ref.) **(Por)**
[Statins (HMG–CoA reductase inhibitors), cholesterol and stroke] Marta–Moreno J, et al. **Rev Neurol** 1998 Nov; 27(159):827–30 (28 ref.) (Eng. Abstr.) **(Spa)**

PRAWNS see **SHRIMP**

PRAYER see **RELIGION**

PRAYER HEALING see **MENTAL HEALING**

PRAZIQUANTEL

THERAPEUTIC USE

Therapeutic and operational profiles of metrifonate and praziquantel in Schistosoma haematobium infection. Feldmeier H, et al. **Arzneimittelforschung** 1999 Jul; 49(7):557–65 (81 ref.)
Taeniasis and cysticercosis. Cook GC. **J R Soc Med** 1998 Oct;91(10):534–5 (19 ref.)
Community–wide treatment of schistosomiasis with praziquantel. Webbe G. **Trop Doct** 1999 Jul;29(3):172–6 (28 ref.)

PREALBUMIN

ANALYSIS

[Chemical analysis of clinical materials using mass spectrometry] Shimizu A, et al. **Rinsho Byori** 1999 Feb; Suppl 109:116–25 (16 ref.) **(Jpn)**

GENETICS

Evolution of thyroid hormone distribution. Schreiber G, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):728–32 (25 ref.)
Transthyretin Tyr77 familial amyloid polyneuropathy: a clinicopathological study of a large kindred. Blanco–Jerez CR, et al. **Muscle Nerve** 1998 Nov;21(11):1478–85 (25 ref.)
[Hereditary amyloid cardiomyopathy related to a mutation at transthyretin protein number 111. A clinical, genetic and echocardiographic study of an affected Danish family] Svendsen IH, et al. **Ugeskr Laeger** 1999 Sep 6; 161(36):4995–9 (20 ref.) (Eng. Abstr.) **(Dan)**

PREANESTHETIC MEDICATION

Clonidine in paediatric anaesthesia. Nishina K, et al. **Paediatr Anaesth** 1999;9(3):187–202 (143 ref.)
[Oral premedication with clonidine as an alternative in dental practice. The effects on the pain threshold, blood pressure and salivary flow] Fanini D, et al. **Minerva Stomatol** 1998 Sep;47(9):453–64 (57 ref.) (Eng. Abstr.) **(Ita)**
[Choice of drugs for general anesthesia in patients with arrhythmia] Men'shikh MS. **Anesteziol Reanimatol** 1999 May–Jun;(3):18–22 (74 ref.) **(Rus)**

METHODS

Premedication, preparation, and surveillance. Lazzaroni M, et al. **Endoscopy** 1999 Jan;31(1):2–8 (50 ref.)

PREBETA–LIPOPROTEINS see **LIPOPROTEINS, VLDL**

PRECANCEROUS CONDITIONS

Precursors to pulmonary neoplasia. Colby TV, et al. **Adv Anat Pathol** 1998 Jul;5(4):205–15 (72 ref.)
Aspects of malignant progression of vulvar epithelial disorders [editorial] Kagie MJ. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):1–3 (13 ref.)
Malignancy and aneuploidy: prevention and early detection. Kirschner B. **Inflamm Bowel Dis** 1998 Aug;4(3):216–20 (25 ref.)
A review of the recent literature regarding malignant transformation of oral lichen planus. van der Meij EH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):307–10 (35 ref.)

CHEMICALLY INDUCED

Short– and intermediate–term carcinogenicity testing––a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay. Enzmann H, et al. **Food Chem Toxicol** 1998 Nov;36(11):979–95 (184 ref.)
Chemically induced preneoplastic lesions in rodents as indicators of carcinogenic activity. Williams GM. **IARC Sci Publ** 1999;(146):185–202 (216 ref.)

DIAGNOSIS

Premalignant breast lesions: role for biological markers in predicting progression to cancer. Stoll BA. **Eur J Cancer** 1999 May;35(5):693–7 (70 ref.)
Clinical evolution of prostatic intraepithelial neoplasia. Zlotta AR, et al. **Eur Urol** 1999;35(5–6):498–503 (33 ref.)
The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec;48(6):663–8 (70 ref.)
How do we assess the value of surveillance techniques in ulcerative colitis? Bernstein CN. **J Gastrointest Surg** 1998 Jul–Aug;2(4):318–21 (22 ref.)

PRECANCEROUS CONDITIONS

[Carcinoma in chronic inflammatory bowel diseases] von Herbay A. **Internist (Berl)** 1998 Oct;39(10):1024–9 (51 ref.) **(Ger)**

[Cerebral ischemia as initial manifestation of neoplastic low-malignancy changes. 2 case reports and review of the literatures] Jahn K, et al. **Nervenarzt** 1999 Apr;70(4):342–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Early diagnosis of bronchial carcinoma. Technical endoscopic progress--a step toward new screening concepts?] Häussinger K, et al. **Pneumologie** 1999 Feb; 53(2):77–82 (35 ref.) (Eng. Abstr.) **(Ger)**

[Colorectal carcinoma. Prevention and early detection] Seidensticker F, et al. **Urologe A** 1998 Jul;37(4):W431–9 (60 ref.) **(Ger)**

[A case of disseminated intravascular coagulation--a paraneoplastic manifestation of a borderline ovarian tumor] Bălănescu I, et al. **Chirurgia (Bucur)** 1998 Sep–Oct; 93(5):331–41 (13 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis. Boone CW, et al. **Cancer Surv** 1998; 32:133–47 (40 ref.)

[Topical photodynamic therapy in dermatology] Grob M, et al. **Ther Umsch** 1998 Aug;55(8):529–32 (11 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[The current concepts of papillomavirus infection and its role in the pathogenesis of pretumorous and tumorous processes of the cervix uteri] Lakatosh VP, et al. **Lik Sprava** 1999 Mar;(2):22–31 (83 ref.) **(Ukr)**

GENETICS

Skin precancer. Brash DE, et al. **Cancer Surv** 1998;32:69–113 (232 ref.)

Precancer of the prostate. Busch PC, et al. **Cancer Surv** 1998; 32:149–79 (163 ref.)

Molecular alterations in bladder cancer. Cordon-Cardo C. **Cancer Surv** 1998;32:115–31 (87 ref.)

Molecular precursor lesions in oesophageal cancer. Montesano R, et al. **Cancer Surv** 1998;32:53–68 (77 ref.)

The transition from hyperplasia to invasive carcinoma of the breast. Lakhani SR. **J Pathol** 1999 Feb;187(3):272–8 (82 ref.)

[From dysplasia to cancer: cytologic, histopathologic and molecular aspects] Vignaud JM. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S107–11 (18 ref.) **(Fre)**

MICROBIOLOGY

[Relation between Helicobacter pylori and stomach cancers] Guo F, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr; 36(4):276–8 (20 ref.) **(Chi)**

PATHOLOGY

Diagnostic terminology in fine-needle aspiration biopsy of the breast: redefining the term "atypia" [editorial; comment] Masood S. **Cancer** 1999 Feb 25;87(1):1–4 (25 ref.) Comment on: Cancer 1999 Feb 25;87(1):19–24.

Gliomas. Collins VP. **Cancer Surv** 1998;32:37–51 (81 ref.)

Cell biology of precancer. Pontén J. **Cancer Surv** 1998; 32:5–35 (125 ref.)

Precancer of the human cervix. Pontén J, et al. **Cancer Surv** 1998;32:201–29 (94 ref.)

The dynamics of early intestinal tumour proliferation: to be or not to be. Shibata D. **Cancer Surv** 1998;32:181–200 (56 ref.)

Anaplastic nodules in an ovarian mucinous tumor. Case report and literature review. Hellemans H, et al. **Eur J Gynaecol Oncol** 1998;19(6):529–33 (19 ref.)

Tissue architecture analysis in prostate cancer and its precursors: An innovative approach to computerized histometry. Bartels PH, et al. **Eur Urol** 1999;35(5–6):484–91 (8 ref.)

Polyps as biomarkers for colorectal neoplasia. Tobi M. **Front Biosci** 1999 Mar 15;4:D329–38 (95 ref.)

Gastric precancerous lesions: heading for an international consensus. Genta RM, et al. **Gut** 1999 Jul;45 Suppl 1:I5–8 (38 ref.)

Chemically induced preneoplastic lesions in rodents as indicators of carcinogenic activity. Williams GM. **IARC Sci Publ** 1999;(146):185–202 (216 ref.)

Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. Palefsky JM. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S42–8 (28 ref.)

Risk of cancer in ulcerative colitis. Ekbom A. **J Gastrointest Surg** 1998 Jul–Aug;2(4):312–3 (14 ref.)

Biology of colorectal cancer in ulcerative colitis. Lashner BA, et al. **J Gastrointest Surg** 1998 Jul–Aug;2(4):307–11 (65 ref.)

How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis? Riddell RH. **J Gastrointest Surg** 1998 Jul–Aug;2(4):314–7 (14 ref.)

Recognising and treating. Premalignant skin conditions. Khorshid SM, et al. **Practitioner** 1998 Apr;242(1585):270–2, 275, 277 (6 ref.)

Cell proliferation and its evaluation in the colorectal mucosa: effect of ethanol. Seitz HK, et al. **Z Gastroenterol** 1998 Aug;36(8):645–55 (82 ref.)

[Hepatocyte dysplasia: pre- or peri-neoplastic lesion?] Scoazec JY. **Gastroenterol Clin Biol** 1999 Apr;23(4):433–7 (39 ref.) **(Fre)**

[From dysplasia to cancer: cytologic, histopathologic and molecular aspects] Vignaud JM. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S107–11 (18 ref.) **(Fre)**

[Cirrhosis of the liver as a precancerous condition] Maier KP. **Schweiz Rundsch Med Prax** 1998 Oct 28;87(44):1462–5 (11 ref.) (Eng. Abstr.) **(Ger)**

[Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast] Nizze H, et al. **Zentralbl Chir** 1998;123 Suppl 5:14–8 (46 ref.) (Eng. Abstr.) **(Ger)**

[Regularities of corneal tissue correlation and their biological significance for regeneration and pre-tumor growth] Beliaev VS. **Vestn Oftalmol** 1999 Mar–Apr;115(2):15–21 (28 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Chemoprevention of head and neck and lung (pre)cancer. de Vries N, et al. **Recent Results Cancer Res** 1999;151:13–25 (47 ref.)

[Practice-relevant intestinal diseases: prevention of colon carcinoma] Seidensticker F, et al. **Schweiz Rundsch Med Prax** 1998 Nov 26;87(48):1649–51 (22 ref.) (Eng. Abstr.) **(Ger)**

[Correlation between dietary vitamin A consumption and onset of precancerous lesions in the oral cavity] Cianfriglia F, et al. **Minerva Stomatol** 1998 Jul–Aug;47(7–8):325–43 (32 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Haag S, et al. **Gastrointest Endosc** 1999 Aug;50(2):229–40 (118 ref.)

[Benign tumors of the liver: primum non nocere] Chiche L. **Ann Chir** 1998;52(1):64–7 (10 ref.) **(Fre)**

[Malignant transformation in ulcerative colitis and surgical implications] Herfarth C, et al. **Chirurg** 1998 Oct; 69(10):1020–7 (57 ref.) (Eng. Abstr.) **(Ger)**

[Barrett carcinoma as a tumor entity with special therapy consequences] Fuchs KH. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:295–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Barrett and stomach carcinoma: surgical guidelines] Hölscher AH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:304–11 (22 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. Palefsky JM. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S42–8 (28 ref.)

PRECAUTIONS, UNIVERSAL see **UNIVERSAL PRECAUTIONS**

PRECIPITIN TESTS

Immunodetection of lipoprotein lipase: antibody production, immunoprecipitation, and western blotting techniques. Doolittle MH, et al. **Methods Mol Biol** 1999;109:215–37 (16 ref.)

METHODS

Immunoprecipitation of nitrotyrosine-containing proteins. MacMillan-Crow LA, et al. **Methods Enzymol** 1999; 301:135–45 (16 ref.)

Detergent solubilization and immunoprecipitation of native NMDA receptors. Wenthold RJ, et al. **Methods Mol Biol** 1999;128:113–9 (11 ref.)

PRECONCEPTION CARE

see related

PRENATAL CARE

Prepregnancy genetic testing for age-related aneuploidies by polar body analysis. Verlinsky Y, et al. **Genet Test** 1997–98; 1(4):231–5 (13 ref.)

Preconception care. An integral part of primary care for women. Reynolds HD. **J Nurse Midwifery** 1998 Nov–Dec; 43(6):445–58 (69 ref.)

LEGISLATION & JURISPRUDENCE

Medicolegal issues in fertility regulation. Gupta S, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):818–26 (63 ref.)

PRECURSOR RNA see **RNA PRECURSORS**

PREDATORY BEHAVIOR

Killer kangaroos and other murderous marsupials. Wroe S. **Sci Am** 1999 May;280(5):68–74 (3 ref.)

Shaken not stirred: on permanence in ecological communities. Jansen VA, et al. **Theor Popul Biol** 1998 Dec;54(3):195–201 (48 ref.)

PHYSIOLOGY

Rattlesnake hunting behavior: correlations between plasticity of predatory performance and neuroanatomy. Kardong KV, et al. **Brain Behav Evol** 1999;53(1):20–8 (83 ref.)

Forebrain and midbrain structures involved in prey-catching behaviour of toads: stimulus-response mediating circuits and their modulating loops. Ewert JP, et al. **Eur J Morphol** 1999 Apr;37(2–3):172–6 (18 ref.)

PREDIABETIC STATE

PREVENTION & CONTROL

Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Holman RR. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S21–5 (18 ref.)

PREDICTIVE VALUE OF TESTS

Evaluation of diagnostic tests without gold standards. Hui SL, et al. **Stat Methods Med Res** 1998 Dec;7(4):354–70 (34 ref.)

Correcting for verification bias in studies of a diagnostic test's accuracy. Zhou XH. **Stat Methods Med Res** 1998 Dec; 7(4):337–53 (43 ref.)

PREDISPOSING FACTORS see **CAUSALITY**

PREDNISOLONE

[Corticosteroid resistant idiopathic thrombocytopenic purpura] Murai K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):299–302 (11 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

[A case report of steroid-responsive progressive encephalomyelitis with rigidity showing muscle stiffness limited to the upper body] Matsuno S, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):680–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Myelodysplastic syndrome (RAEB in T) developed in a renal allograft recipient] Shiraishi J, et al. **Rinsho Ketsueki** 1998 Aug;39(8):600–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Corticosteroid purpura] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):403–4 (7 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

New corticosteroids for the treatment of ocular inflammation [editorial; comment] Whitcup SM, et al. **Am J Ophthalmol** 1999 May;127(5):597–9 (9 ref.) Comment on: Am J Ophthalmol 1999 May;127(5):537–44.

THERAPEUTIC USE

Glucocorticosteroids in the management of rheumatoid arthritis. Laan RF, et al. **Rheumatology (Oxford)** 1999 Jan; 38(1):6–12 (49 ref.)

PREDNISONE

ADMINISTRATION & DOSAGE

Metastatic Crohn's disease: remission induced by mesalamine and prednisone. Gilson MR, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):476–9 (15 ref.)

ADVERSE EFFECTS

Mortality associated with concurrent strongyloidosis and cytomegalovirus infection in a patient on steroid therapy. Wang BY, et al. **Mt Sinai J Med** 1999 Mar;66(2):128–32 (35 ref.)

A steroid-induced acute psychosis in a child with asthma. Dawson KL, et al. **Pediatr Pulmonol** 1998 Nov;26(5):362–4 (11 ref.)

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

[Frequent occurrence of diabetes mellitus after corticosteroid treatment in mixed cryoglobulinemia. An HCV-related complication?] Marson P, et al. **Minerva Med** 1998 Jul–Aug;89(7–8):277–81 (42 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid-dependent rheumatoid arthritis. Kotha P, et al. **Clin Cardiol** 1998 Nov;21(11):853–6 (22 ref.)

Drug therapy in the management of type 1 autoimmune hepatitis. Czaja AJ. **Drugs** 1999 Jan;57(1):49–68 (152 ref.)

Management of minimal lesion glomerulonephritis: evidence-based recommendations. Bargman JM. **Kidney Int Suppl** 1999 Jun;70:S3–16 (78 ref.)

Management of focal segmental glomerulosclerosis: evidence-based recommendations. Burgess E. **Kidney Int Suppl** 1999 Jun;70:S26–32 (36 ref.)

Management of IgA nephropathy: evidence-based recommendations. Nolin L, et al. **Kidney Int Suppl** 1999 Jun;70:S56–62 (56 ref.)

Treatment of acute interstitial nephritis. Reddy S, et al. **Ren Fail** 1998 Nov;20(6):829–38 (24 ref.)
[Hepatic inflammatory pseudotumor: apropos a case with a response to steroid treatment] Fernández de la Puebla Giménez RA, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):14–7 (20 ref.) (Eng. Abstr.) **(Spa)**

PRE-ECLAMPSIA

Current concepts in preeclampsia. Patrick T, et al. **MCN Am J Matern Child Nurs** 1999 Jul–Aug; 24(4):193–200; quiz 201 (44 ref.)
Animal models of preeclampsia. Podjarny E, et al. **Semin Perinatol** 1999 Feb;23(1):2–13 (113 ref.)
Counseling for women with preeclampsia or eclampsia. Witlin AG. **Semin Perinatol** 1999 Feb;23(1):91–8 (30 ref.)
[Arterial hypertension in pregnancy] Ivanović-Krstić B, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):178–82 (26 ref.) **(Scc)**
[Pre-eclampsia-eclampsia: a deferred medical problem] López-Llera M, et al. **Gac Med Mex** 1999 Jul–Aug; 135(4):397–405 (31 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. Hayman R, et al. **J Soc Gynecol Investig** 1999 Jan–Feb;6(1):3–10 (70 ref.)
Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Astedt B, et al. **Semin Thromb Hemost** 1998;24(5):431–5 (72 ref.)
[Preeclampsia not (yet) predictable from the blood platelet count] Lazarov R, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):10–3 (22 ref.) (Eng. Abstr.) **(Dut)**

COMPLICATIONS

Pregnancy in SLE. Petri M. **Baillieres Clin Rheumatol** 1998 Aug;12(3):449–76 (105 ref.)
Magnesium sulfate therapy in preeclampsia and eclampsia. Witlin AG, et al. **Obstet Gynecol** 1998 Nov;92(5):883–9 (42 ref.)

DIAGNOSIS

Imitators of preeclampsia and eclampsia. Egerman RS, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):551–62 (65 ref.)
Management of pre-eclampsia and haemolysis, elevated liver enzymes, and low platelets syndrome. Anumba DO, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):149–56 (84 ref.)
Ambulatory blood pressure monitoring in pregnancy. Walker SP, et al. **Obstet Gynecol Surv** 1998 Oct;53(10):636–44 (56 ref.)
Prediction of preeclampsia. Myatt L, et al. **Semin Perinatol** 1999 Feb;23(1):45–57 (93 ref.)
[Preeclampsia not (yet) predictable from the blood platelet count] Lazarov R, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):10–3 (22 ref.) (Eng. Abstr.) **(Dut)**
[Prediction of preeclampsia:new hypotheses, new approaches] Müller HM, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(4):222–31 (81 ref.) (Eng. Abstr.) **(Ger)**
[The role of endothelium in normal pregnancy and pregnancy complicated by preeclampsia] Bielecki M, et al. **Ginekol Pol** 1999 Mar;70(3):113–9 (31 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Low-dose aspirin therapy in the treatment of preeclampsia [letter] Christian R. **Nurse Pract** 1999 Mar;24(3):138–9 (8 ref.)

EPIDEMIOLOGY

Risk factors for preeclampsia. Dekker GA. **Clin Obstet Gynecol** 1999 Sep;42(3):422–35 (53 ref.)

ETIOLOGY

Etiology and pathogenesis of preeclampsia: current concepts. Dekker GA, et al. **Am J Obstet Gynecol** 1998 Nov; 179(5):1359–75 (237 ref.)
Preeclampsia: an excessive maternal inflammatory response to pregnancy. Redman CW, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):499–506 (75 ref.)
Insulin resistance and preeclampsia. Berkowitz KM. **Clin Perinatol** 1998 Dec;25(4):873–85 (51 ref.)
Obstetrics. Preterm birth and pre-eclampsia--bad news and good news. Roberts JM, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV22 (5 ref.)
Pre-eclampsia: a disorder of placental mitochondria? Widschwendter M, et al. **Mol Med Today** 1998 Jul; 4(7):286–91 (45 ref.)

GENETICS

Influence of human leukocyte antigen and tumour necrosis factor genes on the development of pre-eclampsia. Kilpatrick DC. **Hum Reprod Update** 1999 Mar–Apr; 5(2):94–102 (98 ref.)
Genomic imprinting, development and disease--is pre-eclampsia caused by a maternally imprinted gene? Graves JA. **Reprod Fertil Dev** 1998;10(1):23–9 (40 ref.)
New insights into the genetics of preeclampsia. Morgan T, et al. **Semin Perinatol** 1999 Feb;23(1):14–23 (84 ref.)

IMMUNOLOGY

Pregnancy in SLE. Petri M. **Baillieres Clin Rheumatol** 1998 Aug;12(3):449–76 (105 ref.)
The immunology of preeclampsia. Dekker GA, et al. **Semin Perinatol** 1999 Feb;23(1):24–33 (104 ref.)

METABOLISM

Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Pettersson A, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):808–13 (25 ref.)
Insulin resistance and preeclampsia. Berkowitz KM. **Clin Perinatol** 1998 Dec;25(4):873–85 (51 ref.)

PATHOLOGY

Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. Zhou Y, et al. **J Reprod Immunol** 1998 Aug;39(1–2):197–213 (16 ref.)

PHYSIOPATHOLOGY

Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. Hayman R, et al. **J Soc Gynecol Investig** 1999 Jan–Feb;6(1):3–10 (70 ref.)
Pre-eclampsia: a disorder of placental mitochondria? Widschwendter M, et al. **Mol Med Today** 1998 Jul; 4(7):286–91 (45 ref.)
Vascular reactivity in preeclampsia. Vedernikov Y, et al. **Semin Perinatol** 1999 Feb;23(1):34–44 (98 ref.)

PREVENTION & CONTROL

Prevention of preeclampsia: a big disappointment. Sibai BM. **Am J Obstet Gynecol** 1998 Nov;179(5):1275–8 (32 ref.)
Prevention of preeclampsia: is it possible? Norwitz ER, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):436–54 (100 ref.)
Prevention of preeclampsia. Mattar F, et al. **Semin Perinatol** 1999 Feb;23(1):58–64 (67 ref.)

THERAPY

Management of mild preeclampsia. Barton JR, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):455–69 (46 ref.)
Expectant management of severe preeclampsia remote from term. Friedman SA, et al. **Clin Obstet Gynecol** 1999 Sep; 42(3):470–8 (23 ref.)
Management of acute severe hypertension and encephalopathy. Mabie WC. **Clin Obstet Gynecol** 1999 Sep; 42(3):519–31 (73 ref.)
Management of pre-eclampsia and haemolysis, elevated liver enzymes, and low platelets syndrome. Anumba DO, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):149–56 (84 ref.)
Management of complicated preeclampsia. Van Hook JW. **Semin Perinatol** 1999 Feb;23(1):79–90 (91 ref.)
[Severe maternal and fetal situations during delivery] Chauvet MP, et al. **Rev Prat** 1999 Jan 15;49(2):151–4 (15 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Transcranial and orbital Doppler ultrasound in normal pregnancy and preeclampsia. Belfort MA, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):479–506 (57 ref.)
Imaging of subcapsular hepatic and renal hematomas in pregnancy complicated by preeclampsia and the HELLP syndrome. Chan AD, et al. **J Clin Ultrasound** 1999 Jan; 27(1):35–40 (28 ref.)

PREENING see **GROOMING**

PRE-EXCITATION, MAHAIM-TYPE

DIAGNOSIS

Mahaim tachycardias. Aliot E, et al. **Eur Heart J** 1998 May; 19 Suppl E:E25–31, E52–3 (31 ref.)

PRE-EXCITATION SYNDROMES

ULTRASONOGRAPHY

[Echocardiography in the localization of the anomalous pathway in ventricular pre-excitation. Technics, usefulness and limits] Mele D, et al. **G Ital Cardiol** 1999 Jun; 29(6):730–8 (65 ref.) **(Ita)**

PREFRONTAL CORTEX

DRUG EFFECTS

Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Ahlenius S. **Pharmacol Toxicol** 1999 May;84(5):193–6 (39 ref.)

METABOLISM

Prefrontal cortical-amygdalar metabolism in major depression. Drevets WC. **Ann N Y Acad Sci** 1999 Jun 29; 877:614–37 (139 ref.)

PHYSIOLOGY

Neural aspects of anticipatory behavior. Brunia CH. **Acta Psychol (Amst)** 1999 Apr;101(2–3):213–42 (92 ref.)
Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Knight RT, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):159–78 (115 ref.)
Prefrontal cortical networks related to visceral function and mood. Price JL. **Ann N Y Acad Sci** 1999 Jun 29;877:383–96 (46 ref.)
From perception to action: temporal integrative functions of prefrontal and parietal neurons. Quintana J, et al. **Cereb Cortex** 1999 Apr–May;9(3):213–21 (52 ref.)
Perseveration, inhibition and the prefrontal cortex: a new look. Hauser MD. **Curr Opin Neurobiol** 1999 Apr; 9(2):214–22 (37 ref.)
Phonology, semantics, and the role of the left inferior prefrontal cortex [editorial] Fiez JA. **Hum Brain Mapp** 1997;5(2):79–83 (39 ref.)
EEG correlates of the response to ECT: a possible antidepressant role of brain-derived neurotrophic factor. Krystal AD, et al. **J ECT** 1999 Mar;15(1):27–38 (73 ref.)
Functions of the prefrontal cortex in the human brain. Paik E. **J Korean Med Sci** 1998 Dec;13(6):569–81 (74 ref.)
The prefrontal cortex: complex neural properties for complex behavior. Miller EK. **Neuron** 1999 Jan;22(1):15–7 (20 ref.)
The role of prefrontal cortex in working memory: examining the contents of consciousness. Courtney SM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1819–28 (59 ref.)
Cognitive and motivational operations in primate prefrontal neurons. Watanabe M. **Rev Neurosci** 1998;9(4):225–41 (133 ref.)

PHYSIOPATHOLOGY

The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Marek GJ, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1118–27 (85 ref.)
Negative symptoms in schizophrenia: neurobiological models and treatment response. Goff DC, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):59–77 (208 ref.)
Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Yang CR, et al. **Neuropsychopharmacology** 1999 Aug;21(2):161–94 (369 ref.)

PREGNADIENEDIOLS

THERAPEUTIC USE

Mometasone furoate. A review of its intranasal use in allergic rhinitis. Onrust SV, et al. **Drugs** 1998 Oct;56(4):725–45 (71 ref.)

PREGNANCY

see related
PRENATAL CARE
PSEUDOPREGNANCY

ABC of sexual health: sexual problems associated with infertility, pregnancy, and ageing. Read J. **BMJ** 1999 Feb 27;318(7183):587–9 (0 ref.)
Dietary vitamin A and teratogenic risk: European Teratology Society discussion paper. Dolk HM, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):31–6 (52 ref.)
Preventing the high-risk sexual behavior of adolescents: focus on HIV/AIDS transmission, unintended pregnancy, or both? Whaley AL. **J Adolesc Health** 1999 Jun; 24(6):376–82 (49 ref.)
Herbs and the childbearing woman. Guidelines for midwives. Belew C. **J Nurse Midwifery** 1999 May–Jun;44(3):231–52 (103 ref.)
Working with childhood sexual abuse survivors during pregnancy, labor, and birth. Heritage C. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):671–7 (17 ref.)
Migraine in pregnancy. Aubé M. **Neurology** 1999;53(4 Suppl 1):S26–8 (16 ref.)
Domestic violence in the pregnant patient: obstetric and behavioral interventions. Mayer L, et al. **Obstet Gynecol Surv** 1998 Oct;53(10):627–35 (65 ref.)
Administered radionuclides in pregnancy. Adelstein SJ. **Teratology** 1999 Apr;59(4):236–9 (10 ref.)
[Group therapy and smoking cessation] Møller AM, et al. **Ugeskr Laeger** 1999 Sep 6;161(36):4987–8 (8 ref.) (Eng. Abstr.) **(Dan)**
[Collection of autologous blood during pregnancy and fetal safety. Computer analysis of fetal heart rate] Rech F, et al. **Minerva Ginecol** 1998 Jul–Aug;50(7–8):313–9 (33 ref.) (Eng. Abstr.) **(Ita)**
[Spontaneous and assisted reproduction-associated heterotopic pregnancy. The clinical characteristics] Barrón Vallejo J, et al. **Ginecol Obstet Mex** 1999 Jul;67:291–4 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Concentrations of essential trace elements in maternal serum and the effect on birth weight and newborn body mass index in sub-arctic and arctic populations of Norway and

Russia. Odland JO, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):605–14 (44 ref.)
A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Hadley AG. **Vox Sang** 1998;74 Suppl 2:375–83 (79 ref.)

DRUG EFFECTS

[Pregnancy in an acromegalic patient treated with lanreotide and bromocryptin (letter)] Sánchez R, et al. **Med Clin (Barc)** 1999 Jul 10;113(5):198 (4 ref.) **(Spa)**

GENETICS

Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. Clark DA, et al. **Am J Reprod Immunol** 1999 Jan;41(1):5–22 (165 ref.)

IMMUNOLOGY

Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. Clark DA, et al. **Am J Reprod Immunol** 1999 Jan;41(1):5–22 (165 ref.)
Immunology understood through pregnancy [editorial] Voisin GA. **Am J Reprod Immunol** 1998 Sep;40(3):124–9 (21 ref.)
Immunotolerant functions of HLA-G. Carosella ED, et al. **Cell Mol Life Sci** 1999 Mar;55(3):327–33 (42 ref.)
The maternal immune system in health and disease. Iwatani Y, et al. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):453–8 (50 ref.)
Microchimerism and the pathogenesis of systemic sclerosis. Nelson JL. **Curr Opin Rheumatol** 1998 Nov;10(6):564–71 (63 ref.)
The major histocompatibility complex: an important factor in every stage of pregnancy from preimplantation to birth? Part I. Christiansen OB. **Hum Reprod Update** 1999 Mar–Apr;5(2):91–3 (8 ref.)
Human uterine lymphocytes. King A, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):480–5 (49 ref.)
Fetomaternal HLA differences and the onset and course of rheumatoid arthritis. Hazes JM. **Rev Rhum Engl Ed** 1998 Nov;65(11):611–3 (27 ref.)
HLA-G and pregnancy. Le Bouteiller P. **Rev Rhum Engl Ed** 1998 Nov;65(11):608–10 (21 ref.)
Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Amino N, et al. **Thyroid** 1999 Jul;9(7):705–13 (50 ref.)
The thyroid immunology of the postpartum period. Davies TF. **Thyroid** 1999 Jul;9(7):675–84 (66 ref.)
The immunology of pregnancy. Weetman AP. **Thyroid** 1999 Jul;9(7):643–6 (28 ref.)

METABOLISM

Saliva as a fluid for measurement of estriol levels. Voss HF. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S226–31 (34 ref.)
Adaptation of maternal lipid flux to pregnancy: research needs. Neville MC. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S120–3 (16 ref.)
Advance in the study of inhibin, activin and follistatin production in pregnant women. Qu J, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):141–8 (88 ref.)
Dietary calcium and mineral/vitamin supplementation: a controversial problem. Celotti F, et al. **J Int Med Res** 1999 Jan–Feb;27(1):1–14 (79 ref.)
[Nitric oxide as a regulator of hemodynamic changes in pregnancy] Genoveva Durán-Reyes MO, et al. **Ginecol Obstet Mex** 1999 Jan;67:29–36 (35 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Maternal endocrine adaptations to placental hormones in humans. Evain-Brion D. **Acta Paediatr Suppl** 1999 Feb;88(428):12–6 (46 ref.)
Placenta growth factor: potential role in pregnancy. Torry DS, et al. **Am J Reprod Immunol** 1999 Jan;41(1):79–85 (64 ref.)
Role of pelvic ultrasonography in evaluation of symptomatic first-trimester pregnancy. Dart RG. **Ann Emerg Med** 1999 Mar;33(3):310–20 (38 ref.)
The kallikrein-kinin system along the different stages of gestation: experimental and clinical findings. Valdés G, et al. **Biol Res** 1998;31(3):235–41 (49 ref.)
Growth, development and differentiation: a functional food science approach. Koletzko B, et al. **Br J Nutr** 1998 Aug; 80 Suppl 1:S5–45 (417 ref.)
Acid-base regulation and control of ventilation in human pregnancy. Wolfe LA, et al. **Can J Physiol Pharmacol** 1998 Sep;76(9):815–27 (116 ref.)
Transcranial and orbital Doppler ultrasound in normal pregnancy and preeclampsia. Belfort MA, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):479–506 (57 ref.)
Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Miller WL. **Clin Perinatol** 1998 Dec;25(4):799–817, v (104 ref.)
Pain management in the critically ill obstetric patient. Jayasinghe C, et al. **Crit Care Clin** 1999 Jan;15(1):201–28, viii (73 ref.)
Does the CRH binding protein shield the anterior pituitary from placental CRH? Thomson M. **Endocrine** 1998 Dec; 9(3):221–6 (46 ref.)
Pregnancy and lactation in relation to range of acceptable carbohydrate and fat intake. Catalano PM. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S124–31; discussion S131–5 (45 ref.)
Embryo-maternal interactions at the implantation site: a delicate equilibrium. Duc-Goiran P, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):85–100 (109 ref.)
Insulin in obstetrics: a main parameter in the management of pregnancy. Ciampelli M, et al. **Hum Reprod Update** 1998 Nov–Dec;4(6):904–14 (133 ref.)
Control and assessment of the uterus and cervix during pregnancy and labour. Garfield RE, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):673–95 (87 ref.)
Inhibins and activins in human ovulation, conception and pregnancy. Lockwood GM, et al. **Hum Reprod Update** 1998 May–Jun;4(3):284–95 (111 ref.)
Changes in the cervical extracellular matrix during pregnancy and parturition. Winkler M, et al. **J Perinat Med** 1999;27(1):45–60 (56 ref.)
Alterations in the hypothalamic pituitary adrenal axis during pregnancy and the placental clock that determines the length of parturition. Smith R. **J Reprod Immunol** 1998 Aug;39(1–2):215–20 (16 ref.)
The influence of sex hormones on obesity across the female life span. Lovejoy JC. **J Womens Health** 1998 Dec; 7(10):1247–56 (53 ref.)
Pregnancy-induced alterations in renal function. Schobel HP. **Kidney Blood Press Res** 1998;21(2–4):274–6 (15 ref.)
The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. Linzer DI, et al. **Mol Endocrinol** 1999 Jun;13(6):837–40 (16 ref.)
Regulation of uterine smooth muscle function during gestation. Riemer RK, et al. **Pediatr Res** 1998 Nov; 44(5):615–27 (146 ref.)
Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Shiverick KT, et al. **Placenta** 1999 May; 20(4):265–72 (103 ref.)
Heart disease during pregnancy. Which cardiovascular changes are normal or transient? Villablanca AC. **Postgrad Med** 1998 Oct;104(4):183–4, 187–92 (10 ref.)
Dynamics of immunoglobulins at the feto-maternal interface. Saji F, et al. **Rev Reprod** 1999 May;4(2):81–9 (85 ref.)
Tolerance of the fetus by the maternal immune system. Current concepts. Kanellopoulos-Langevin C. **Rev Rhum Engl Ed** 1998 Nov;65(11):603–7 (28 ref.)
The relationship of pregnancy, hormones, and melanoma. Grin CM, et al. **Semin Cutan Med Surg** 1998 Sep; 17(3):167–71 (44 ref.)
Glomerular filtration rate in normal and abnormal pregnancies. Baylis C. **Semin Nephrol** 1999 Mar;19(2):133–9 (55 ref.)
What happens to the normal thyroid during pregnancy? Glinoer D. **Thyroid** 1999 Jul;9(7):631–5 (15 ref.)
[Physiological and sensorial determinism of maternal behavior in mammals] Lévy F. **Contracept Fertil Sex** 1998 Oct;26(10):718–27 (78 ref.) (Eng. Abstr.) **(Fre)**
[The cervix uteri in pregnancy] Aubard Y, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27(8):755–64 (51 ref.) (Eng. Abstr.) **(Fre)**
[Combined aspects of pregnancy and tumor immunology] Koldovsky U. **Zentralbl Gynakol** 1999;121(4):185–9 (23 ref.) **(Ger)**
[Melatonin and its role the circadian function] Nowak JZ, et al. **Postepy Hig Med Dosw** 1999;53(3):445–71 (98 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Fear of childbirth and psychosomatic support. A follow up of 72 women. Sjögren B. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):819–25 (24 ref.)
Pharmacologic treatment of depression in women: PMS, pregnancy, and the postpartum period. Cohen LS. **Depress Anxiety** 1998;8 Suppl 1:18–26 (102 ref.)
Methods used to detect drug abuse in pregnancy: a brief review. Strano-Rossi S. **Drug Alcohol Depend** 1999 Feb 1;53(3):257–71 (98 ref.)
Unconscious pregnancy fantasies as an underlying dynamism in panic disorder. Milrod B. **J Am Psychoanal Assoc** 1998; 46(3):673–90 (24 ref.)
Available instruments for research on prenatal attachment and adaptation to pregnancy. Beck CT. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):25–32 (47 ref.)
Evaluation of mental health and depression during pregnancy: position paper. Hendrick V, et al. **Psychopharmacol Bull** 1998;34(3):297–9 (20 ref.)
Perinatal mood disorders: position paper. Steiner M. **Psychopharmacol Bull** 1998;34(3):301–6 (72 ref.)
Mental disorders associated with childbearing: report of the Biennial Meeting of the Marcé Society. Stuart S, et al. **Psychopharmacol Bull** 1998;34(3):333–8 (19 ref.)
Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA. **Thyroid** 1999 Jul;9(7):691–7 (51 ref.)

RADIATION EFFECTS

Pregnancy and in-flight cosmic radiation [see comments] Geeze DS. **Aviat Space Environ Med** 1998 Nov; 69(11):1061–4 (23 ref.) Comment in: Aviat Space Environ Med 1999 May;70(5):533.
[The risks of exposure to ionizing radiation during pregnancy and of the exposure of the gonads before conception] Moreno García M, et al. **Rev Clin Esp** 1999 Jul;199(7):442–8 (81 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Daily demands during pregnancy, gestational age, and birthweight: reviewing physical and psychological demands in employment and non-employment contexts. Woo GM. **Ann Behav Med** 1998 Fall;19(4):385–98 (73 ref.)
Methods for obtaining valid data on time to pregnancy among men and women. Joffe M. **Scand J Work Environ Health** 1999;25 Suppl 1:8–9 (6 ref.)
Analysis of time-to-pregnancy data. Keiding N. **Scand J Work Environ Health** 1999;25 Suppl 1:10–1 (10 ref.)

PREGNANCY, ADOLESCENT see **PREGNANCY IN ADOLESCENCE**

PREGNANCY, ANIMAL

see related
ANIMALS, NEWBORN

[Effect of variation of the dietary fat content in rats during gestation on the fatty acid profile in maternal and fetal plasma] Amusquivar E, et al. **Nutr Hosp** 1999 May–Jun; 14(3):114–9 (34 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunology understood through pregnancy [editorial] Voisin GA. **Am J Reprod Immunol** 1998 Sep;40(3):124–9 (21 ref.)

PHYSIOLOGY

Endocrinology of the ovarian cycle and pregnancy in the Asian (Elephas maximus) and African (Loxodonta africana) elephant. Hodges JK. **Anim Reprod Sci** 1998 Oct; 53(1–4):3–18 (49 ref.)
IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Martal JL, et al. **Biochimie** 1998 Aug–Sep;80(8–9):755–77 (236 ref.)
The kallikrein-kinin system along the different stages of gestation: experimental and clinical findings. Valdés G, et al. **Biol Res** 1998;31(3):235–41 (49 ref.)
Control and assessment of the uterus and cervix during pregnancy and labour. Garfield RE, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):673–95 (87 ref.)
Electrophysiological effects of oxytocin within the bed nuclei of the stria terminalis: influence of reproductive stage and ovarian steroids. Wakerley JB, et al. **Prog Brain Res** 1998; 119:321–34 (57 ref.)

PREGNANCY-ASSOCIATED ALPHA-PLASMA PROTEIN

ANALYSIS

First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: a happy union? Thilaganathan B. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):229–30 (23 ref.)

PREGNANCY COMPLICATIONS

see related
PREGNANCY, PROLONGED

Prevention of alcohol abuse-related birth effects--I. Public education efforts. Abel EL. **Alcohol Alcohol** 1998 Jul–Aug; 33(4):411–6 (45 ref.)
Pregnancy in chronic renal insufficiency and end-stage renal disease. Hou S. **Am J Kidney Dis** 1999 Feb;33(2):235–52 (83 ref.)
Stress-associated preterm delivery: the role of corticotropin-releasing hormone. Lockwood CJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S264–6 (18 ref.)
Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272–4 (50 ref.)
Neonatal peroneal neurapraxia: a report of two cases and review of the literature. Godley DR. **Am J Orthop** 1998 Dec;27(12):803–4 (11 ref.)
Pregnancies in women with Turner's syndrome. Hovatta O. **Ann Med** 1999 Apr;31(2):106–10 (46 ref.)
Pregnancy and malignant neoplasms of the head and neck. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):991–8 (82 ref.)
Thyroid disease and pregnancy. Mortimer RH. **Aust N Z J Med** 1998 Oct;28(5):647–53 (57 ref.)
The Barker hypothesis. An analysis. Wilson J. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):1–7 (36 ref.)
Syphilis in pregnancy. Sheffield JS, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):97–106; quiz 174–5 (35 ref.)
Perinatal effects of prenatal drug exposure. Neonatal aspects.

Bauer CR. **Clin Perinatol** 1999 Mar;26(1):87–106 (181 ref.)
Early development of infants exposed to drugs prenatally. Eyler FD, et al. **Clin Perinatol** 1999 Mar;26(1):107–50, vii (146 ref.)
Adolescent pregnancy and substance use. Flanagan P, et al. **Clin Perinatol** 1999 Mar;26(1):185–200 (68 ref.)
Treatment strategies for drug–exposed neonates. Kandall SR. **Clin Perinatol** 1999 Mar;26(1):231–43 (68 ref.)
Prenatal drug exposure and child outcome. Past, present, future. Smeriglio VL, et al. **Clin Perinatol** 1999 Mar; 26(1):1–16 (61 ref.)
Prenatal cocaine exposure, child development, and the compromising effects of cumulative risk. Tronick EZ, et al. **Clin Perinatol** 1999 Mar;26(1):151–71 (104 ref.)
Impact of addictive and harmful substances on fetal brain development. Ferriero DM, et al. **Curr Opin Neurol** 1999 Apr;12(2):161–6 (54 ref.)
Unexplained elevated maternal serum alpha–fetoprotein: what is the appropriate follow–up? Wilkins–Haug L. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):469–74 (24 ref.)
Hyperthyroidism: multiple possibilities in the female patient. Daniels GH. **Int J Fertil Womens Med** 1999 Jan–Feb; 44(1):6–11 (22 ref.)
Primary hyperparathyroidism and acute pancreatitis during pregnancy. Report of a case and a review of the English and Japanese literature. Kondo Y, et al. **Int J Pancreatol** 1998 Aug;24(1):43–7 (24 ref.)
The posthumous gift of life: the world according to Kane. Shuster E. **J Contemp Health Law Policy** 1999 Spring; 15(2):401–23 (91 ref.)
Cholestasis of pregnancy. McDonald JA. **J Gastroenterol Hepatol** 1999 Jun;14(6):515–8 (31 ref.)
ENT issues in pregnancy. Lippincott LH, et al. **J La State Med Soc** 1999 Jul;151(7):350–4 (13 ref.)
Maternal phenylketonuria: a new cause for concern. Kirby RB. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):227–34 (19 ref.)
Substance abuse: infant and childhood outcomes. D'Apolito K. **J Pediatr Nurs** 1998 Oct;13(5):307–16 (92 ref.)
Recurrent pregnancy loss. An update. Ansari AH, et al. **J Reprod Med** 1998 Sep;43(9):806–14 (95 ref.)
Pregnancy during dialysis: case report and management guidelines [see comments] Giatras I, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3266–72 (36 ref.) Comment in: Nephrol Dial Transplant 1998 Dec;13(12):3005–7.
Maternal shunt dependency: implications for obstetric care, neurosurgical management, and pregnancy outcomes and a review of selected literature. Bradley NK, et al. **Neurosurgery** 1998 Sep;43(3):448–60; discussion 460–1 (15 ref.)
Pregnancy in women with spinal cord injuries. Atterbury JL, et al. **Nurs Clin North Am** 1998 Dec;33(4):603–13 (52 ref.)
Biomedical and feminist perspectives on low back pain during pregnancy. DeJoseph JF, et al. **Nurs Clin North Am** 1998 Dec;33(4):713–24 (31 ref.)
High maternal body weight and pregnancy outcome. de Groot LC. **Nutr Rev** 1999 Feb;57(2):62–4 (15 ref.)
Asthma and reproductive medicine. Terr AI. **Obstet Gynecol Surv** 1998 Nov;53(11):699–707 (54 ref.)
Thyroid disease in pregnancy. Drake WM, et al. **Postgrad Med J** 1998 Oct;74(876):583–6 (22 ref.)
Obesity and reproductive disorders: a review. Norman RJ, et al. **Reprod Fertil Dev** 1998;10(1):55–63 (62 ref.)
1998 update on pregnancy in lupus patients. New horizons, new hopes. Wechsler B, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):619–24 (66 ref.)
Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Bennedsen BE. **Schizophr Res** 1998 Sep 7;33(1–2):1–26 (230 ref.)
Dermatoses of pregnancy. Shornick JK. **Semin Cutan Med Surg** 1998 Sep;17(3):172–81 (55 ref.)
Congenital adrenal hyperplasia in pregnancy. Garner PR. **Semin Perinatol** 1998 Dec;22(6):446–56 (73 ref.)
Parathyroid disorders of pregnancy. Mestman JH. **Semin Perinatol** 1998 Dec;22(6):485–96 (76 ref.)
Pituitary diseases in pregnancy. Molitch ME. **Semin Perinatol** 1998 Dec;22(6):457–70 (91 ref.)
Thyroid hyperfunction during pregnancy. Glinoer D. **Thyroid** 1998 Sep;8(9):859–64 (20 ref.)
Thyroid hormone and intellectual development: a clinician's view. Lazarus JH. **Thyroid** 1999 Jul;9(7):659–60 (12 ref.)
[Cushing's syndrome and pregnancy: a case report and review of the literature] Atallah D, et al. **Contracept Fertil Sex** 1999 Jan;27(1):61–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy intrahepatic cholestasis] Bacq Y, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep;22(8–9):705–13 (74 ref.) **(Fre)**
[Pregnancy and acute disseminated lupus erythematosus] Wechsler B, et al. **Rev Prat** 1998 Mar 15;48(6):632–6 (26 ref.) (Eng. Abstr.) **(Fre)**
[Antiretroviral therapy in pregnant women with HIV] Niemiec KT, et al. **Ginekol Pol** 1998 Nov;69(11):820–6 (34 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

Histologically proven lymphocytic hypophysitis: spontaneous resolution and subsequent pregnancy. Gagneja H, et al. **Mayo Clin Proc** 1999 Feb;74(2):150–4 (29 ref.)

CHEMICALLY INDUCED

Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Lewis DP, et al. **Ann Pharmacother** 1998 Sep;32(9):947–61 (85 ref.)
Workshop report. Health risks of drinking water chlorination by–products: report of an expert working group. Mills CJ, et al. **Chronic Dis Can** 1998;19(3):91–102 (52 ref.)
Valproic acid use in psychiatry: issues in treating women of reproductive age. Kennedy D, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):223–8 (49 ref.)
A mechanistic–based approach for assessing chemical hazards to parturition. Loch–Caruso R. **J Womens Health** 1999 Mar;8(2):235–48 (96 ref.)
[Pregnancy and smoking: significance of the problem and health–service based prevention] Castellanos E, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):670–4 (76 ref.) **(Spa)**

DIAGNOSIS

Review article: The management of inflammatory bowel disease during pregnancy. Subhani JM, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1039–53 (127 ref.)
Liver disease in pregnancy. Hunt CM, et al. **Am Fam Physician** 1999 Feb 15;59(4):829–36 (37 ref.)
Clinical features and management of 87 patients with pemphigoid gestationis. Jenkins RE, et al. **Clin Exp Dermatol** 1999 Jul;24(4):255–9 (14 ref.)
Endocrine analytes in multiple–marker screening. Lambert–Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963–81, vii (95 ref.)
Diagnosis and management of maternal and fetal thyroid disorders. Mestman JH. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):167–75 (60 ref.)
Violence during pregnancy. Datner EM, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):645–56, vi (62 ref.)
Reflex sympathetic dystrophy in pregnancy: nine cases and a review of the literature. Poncelet C, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):55–63 (33 ref.)
Pregnancy in Parkinson's disease: a review of the literature and a case report [letter; comment] Benito–León J, et al. **Mov Disord** 1999 Jan;14(1):194 (6 ref.) Comment on: Mov Disord 1998 Jan;13(1):34–8.
Systemic lupus erythematosus and pregnancy. Zarcone R, et al. **Panminerva Med** 1998 Dec;40(4):319–28 (71 ref.)
Obstetric MR imaging. Levine D, et al. **Radiology** 1999 Jun; 211(3):609–17 (73 ref.)
Antiphospholipids and pregnancy––a review. Yap C, et al. **Singapore Med J** 1998 Jul;39(7):331–4 (30 ref.)
Maternal hypothyroidism: recognition and management. Brent GA. **Thyroid** 1999 Jul;9(7):661–5 (29 ref.)
Nodular thyroid disease diagnosed during pregnancy: how and when to treat. Hay ID. **Thyroid** 1999 Jul;9(7):667–70 (30 ref.)
Hyperthyroidism in pregnancy: diagnosis and treatment. Masiukiewicz US, et al. **Thyroid** 1999 Jul;9(7):647–52 (62 ref.)
[Human chorionic gonadotropin, its degradation products and possibilities of their use] Hrehorčák M, et al. **Ceska Gynekol** 1999 Apr;64(2):108–13 (62 ref.) **(Cze)**
[Trauma during pregnancy] Siebenga J, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1144–8 (59 ref.) (Eng. Abstr.) **(Dut)**
[Multiple sclerosis and pregnancy: clinical issues] Confavreux C, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):186–91 (35 ref.) (Eng. Abstr.) **(Fre)**
[Glaucoma and pregnancy––review of the literature with a case report] Cursiefen C, et al. **Klin Monatsbl Augenheilkd** 1998 Sep;213(3):126–31 (58 ref.) (Eng. Abstr.) **(Ger)**
[Acute fatty liver of pregnancy (AFLP) as a rare and severecomplication and differential diagnostic problem in the last trimester] Fleckenstein G, et al. **Z Geburtshilfe Neonatol** 1998 Nov–Dec;202(6):240–6 (42 ref.) (Eng. Abstr.) **(Ger)**
[Pregnancy and hyperthyroidism] Sax B, et al. **Z Geburtshilfe Neonatol** 1999 Jan–Feb;203(1):29–35 (32 ref.) (Eng. Abstr.) **(Ger)**
[Pregnancy–induced algodystrophy] Perka C, et al. **Z Rheumatol** 1998 Dec;57(6):399–408 (74 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis and treatment of autoimmune thyroid disease (ATD) complicated by pregnancy] Momotani N. **Nippon Rinsho** 1999 Aug;57(8):1866–72 (25 ref.) (Eng. Abstr.) **(Jpn)**
[The role of endothelium in normal pregnancy and pregnancy complicated by preeclampsia] Bielecki M, et al. **Ginekol Pol** 1999 Mar;70(3):113–9 (31 ref.) (Eng. Abstr.) **(Pol)**
[Hypothyroidism coexisting with pregnancy] Milczek T, et al. **Ginekol Pol** 1998 Dec;69(12):1093–6 (9 ref.) (Eng. Abstr.) **(Pol)**
[Maternal PKU syndrome as an obstetric problem: literature review and own clinical experience] Rogowiecka E, et al. **Ginekol Pol** 1998 Dec;69(12):1007–15 (18 ref.) (Eng. Abstr.) **(Pol)**
[Pregnancy in women with multiple sclerosis (MS): a report of 2 cases] Starnawski M, et al. **Ginekol Pol** 1998 Dec; 69(12):1032–4 (9 ref.) (Eng. Abstr.) **(Pol)**
[Management and diagnostics in blunt abdominal trauma in pregnancy] Turczynowski W, et al. **Przegl Lek** 1998; 55(6):328–33 (12 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Fortnightly review: drug treatment during pregnancy [see comments] Rubin P. **BMJ** 1998 Nov 28;317(7171):1503–6 (29 ref.) Comment in: BMJ 1999 May 8;318(7193):1286.
Outpatient management of asthma during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):555–63 (26 ref.)
Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Armenti VT, et al. **Drug Saf** 1998 Sep;19(3):219–32 (70 ref.)
Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus. McGrath C, et al. **Drug Saf** 1999 Feb;20(2):171–86 (114 ref.)
Treating allergic rhinitis in pregnancy. Safety considerations. Mazzotta P, et al. **Drug Saf** 1999 Apr;20(4):361–75 (54 ref.)
Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Ostensen M, et al. **Drug Saf** 1998 Nov;19(5):389–410 (264 ref.)
Migraine in pregnancy: what are the safest treatment options? Pfaffenrath V, et al. **Drug Saf** 1998 Nov;19(5):383–8 (52 ref.)
Treatment of epilepsy in pregnancy [published erratum appears in Drugs 1999 Jun;57(6):870] Nulman I, et al. **Drugs** 1999 Apr;57(4):535–44 (75 ref.)
Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Berwaerts J, et al. **Gynecol Endocrinol** 1999 Jun;13(3):175–82 (49 ref.)
Medication use during the perinatal period [see comments] Briggs GG. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec; 38(6):717–26; quiz 726–7 (97 ref.) Comment in: J Am Pharm Assoc (Wash) 1999 Mar–Apr;39(2):119.
Update on treatment of rheumatoid arthritis. Schuna AA. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec;38(6):728–35; quiz 735–7 (20 ref.)
Pharmacologic treatment of depression during pregnancy. Wisner KL, et al. **JAMA** 1999 Oct 6;282(13):1264–9 (48 ref.)
Asthma and pregnancy. Schatz M. **Lancet** 1999 Apr 10; 353(9160):1202–4 (17 ref.)
Treatment of antiphospholipid syndrome in pregnancy. Cowchock S. **Lupus** 1998;7 Suppl 2:S95–7 (15 ref.)
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Khamashta MA. **Lupus** 1998; 7 Suppl 2:S162–5 (48 ref.)
Psychotropic medications in pregnant women: treatment dilemmas. Austin MP, et al. **Med J Aust** 1998 Oct 19; 169(8):428–31 (41 ref.)
Selective serotonin reuptake inhibitors in pregnancy and lactation. Gupta S, et al. **Obstet Gynecol Surv** 1998 Dec; 53(12):733–6 (17 ref.)
Graves' Disease during pregnancy––results of antithyroid drug therapy. Dwarakanath CS, et al. **Singapore Med J** 1999 Feb;40(2):70–3 (12 ref.)
[Ursodeoxycholic acid: prospect for treatment of gravidic cholestasis? Report of 3 cases] Calmelet P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):617–21 (25 ref.) (Eng. Abstr.) **(Fre)**
[Epilepsy and pregnancy] Hösli I, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):90–5 (50 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Demographic and psychosocial characteristics of substance–abusing pregnant women. Hans SL. **Clin Perinatol** 1999 Mar;26(1):55–74 (131 ref.)
Dead mothers and injured wives: the social context of maternal morbidity and mortality among the Hausa of northern Nigeria. Wall LL. **Stud Fam Plann** 1998 Dec; 29(4):341–59 (128 ref.)
[Polyneuropathies of pregnancy. Clinical neurophysiological, and anatomo–pathological study apropos of 38 cases collected at the Neurology Clinic of the the Fann University Hospital Center] Thiam A, et al. **Dakar Med** 1996;41(1):47–54 (20 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy and delivery in western Africa. High risk motherhood] Prual A. **Sante Publique** 1999 Jun; 11(2):155–65 (126 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Grandmultiparity. Is it a perinatal risk? Samueloff A, et al. **Clin Perinatol** 1998 Sep;25(3):529–38 (39 ref.)
Pruritus in pregnancy and obstetric cholestasis. Clark TJ, et al. **Hosp Med** 1999 Apr;60(4):254–60 (22 ref.)
Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Ludwig M, et al. **Hum Reprod** 1998 Aug;13(8):2082–7 (34 ref.)
Long–term effects of delayed parenthood. Tarin JJ, et al. **Hum Reprod** 1998 Sep;13(9):2371–6 (106 ref.)
Interrelationships between asthma and pregnancy: a literature review. Schatz M. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S330–6 (43 ref.)
Ballet dancers––pregnancy outcomes. Barry S. **J R Soc Health** 1998 Dec;118(6):360–2 (10 ref.)
Pregnancy outcome in long–term survivors of childhood cancer. Blatt J. **Med Pediatr Oncol** 1999 Jul;33(1):29–33

(32 ref.)
Shift work and reproductive health. Nurminen T.
Scand J Work Environ Health 1998;24 Suppl 3:28–34 (27 ref.)
Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Strauss AW, et al. **Semin Perinatol** 1999 Apr;23(2):100–12 (55 ref.)
[Laparoscopic surgery during the second trimester of pregnancy: indications, technique, and fetal repercussions. Report of nine cases and review the literature] Batallan A, et al. **Ann Chir** 1999;53(4):285–90 (36 ref.) (Eng. Abstr.) **(Fre)**
[Pelvic trauma and pregnancy. Literature review and case report] Occelli B, et al. **Contracept Fertil Sex** 1998 Dec; 26(12):869–75 (42 ref.) (Eng. Abstr.) **(Fre)**
[Systemic autoimmune diseases during pregnancy: a practical approach] Ruiz-Irastorza G, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):785–97 (190 ref.) **(Spa)**

IMMUNOLOGY

Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Chowdhury MM, et al. **Br J Dermatol** 1998 Sep; 139(3):500–3 (23 ref.)
The maternal immune system in health and disease. Iwatani Y, et al. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):453–8 (50 ref.)
Pregnancy in lupus. Meng C, et al. **Curr Opin Rheumatol** 1999 Sep;11(5):348–51 (19 ref.)
Antiphospholipid antibodies in obstetrics: new complexities and sites of action. Caruso A, et al.
Hum Reprod Update 1999 May-Jun;5(3):267–76 (105 ref.)
Pregnancy loss and antiphospholipid antibodies. Lockshin MD. **Lupus** 1998;7 Suppl 2:S86–9 (51 ref.)
Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Amino N, et al.
Thyroid 1999 Jul;9(7):705–13 (50 ref.)
The thyroid immunology of the postpartum period. Davies TF. **Thyroid** 1999 Jul;9(7):675–84 (66 ref.)

METABOLISM

Endocrine analytes in multiple-marker screening.
Lambert-Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963–81, vii (95 ref.)

MICROBIOLOGY

Hypothesis on the role of sub-clinical bacteria of the endometrium (bacteria endometrialis) in gynaecological and obstetric enigmas. Viniker DA.
Hum Reprod Update 1999 Jul-Aug;5(4):373–85 (135 ref.)

NURSING

Identification and management of pregnancy-related low back pain. Perkins J, et al. **J Nurse Midwifery** 1998 Sep-Oct;43(5):331–40 (39 ref.)
Systemic lupus erythematosus: perinatal and neonatal implications. Classen SR, et al.
J Obstet Gynecol Neonatal Nurs 1998 Sep-Oct; 27(5):493–500 (20 ref.)
Acute renal failure in pregnancy. Poole JH, et al.
MCN Am J Matern Child Nurs 1999 Mar-Apr;24(2):66–72; quiz 73 (23 ref.)

PATHOLOGY

Placental pathology in antiphospholipid syndrome. Levy RA, et al. **Lupus** 1998;7 Suppl 2:S81–5 (21 ref.)

PHYSIOPATHOLOGY

Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ostensen M.
Ann N Y Acad Sci 1999 Jun 22;876:131–43; discussion 144 (95 ref.)
Maternal and obstetric effects of prenatal drug exposure. Bishai R, et al. **Clin Perinatol** 1999 Mar;26(1):75–86, vii (65 ref.)
Abnormal Doppler velocities in the umbilical artery [editorial] Karsdorp VH.
Eur J Obstet Gynecol Reprod Biol 1998 Oct;80(2):129–31 (11 ref.)
Migraine in pregnancy. Aubé M. **Neurology** 1999;53(4 Suppl 1):S26–8 (16 ref.)
Course and treatment of myasthenia gravis during pregnancy. Batocchi AP, et al. **Neurology** 1999 Feb;52(3):447–52 (40 ref.)
Multiple sclerosis potpourri. Paroxysmal symptoms, seizures, fatigue, pregnancy, and more. Taylor RS.
Phys Med Rehabil Clin N Am 1998 Aug;9(3):551–9, vi (31 ref.)
Glomerular filtration rate in normal and abnormal pregnancies. Baylis C. **Semin Nephrol** 1999 Mar;19(2):133–9 (55 ref.)
Decidual and vascular pathophysiology in pregnancy compromise. Starzyk KA, et al.
Semin Reprod Endocrinol 1999;17(1):63–72 (113 ref.)
Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans. Graham JM Jr, et al. **Teratology** 1998 Nov;58(5):209–21 (130 ref.)
What happens to the normal thyroid during pregnancy? Glinoer D. **Thyroid** 1999 Jul;9(7):631–5 (15 ref.)
[Angiogenesis in gynecology and obstetrics] Obermair A, et al. **Wien Klin Wochenschr** 1999 Apr 9;111(7):262–77 (131 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prevention of alcohol abuse-related birth effects--II. Targeting and pricing. Abel EL. **Alcohol Alcohol** 1998 Jul-Aug;33(4):417–20 (30 ref.)
Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Lewis DP, et al. **Ann Pharmacother** 1998 Sep;32(9):947–61 (85 ref.)
Essential fatty acids in relation to pregnancy complications and fetal development. Sattar N, et al.
Br J Obstet Gynaecol 1998 Dec;105(12):1248–55 (26 ref.)
Ambulatory obstetric management. Cohen AW.
Clin Obstet Gynecol 1998 Sep;41(3):481–90 (18 ref.)
The role of antibiotic therapy in the prevention of prematurity. Mazor M, et al. **Clin Perinatol** 1998 Sep; 25(3):659–85, x (147 ref.)
Physical abuse during pregnancy: a significant threat to maternal and child health [editorial; comment] MacMillan HL. **CMAJ** 1999 Apr 6;160(7):1022–3 (11 ref.) Comment on: CMAJ 1999 Apr 6;160(7):1007–11.
Preconception care. An integral part of primary care for women. Reynolds HD. **J Nurse Midwifery** 1998 Nov-Dec; 43(6):445–58 (69 ref.)
Medical aspects of pregnancy. Thacker HL.
J Womens Health 1999 Apr;8(3):335–46 (20 ref.)
Management issues for women with epilepsy: a review of the literature. Zahn CA, et al. **Neurology** 1998 Oct; 51(4):949–56 (83 ref.)
Preventive dentistry during pregnancy [letter] Holder R, et al. **Nurse Pract** 1999 Feb;24(2):21–4 (15 ref.)
[Management of pregnant women and newborns in high-risk pregnancies] Grandjean H, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:21–36 (102 ref.) **(Fre)**
[Pregnancy and scuba diving: what precautions?] Morales M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May; 28(2):118–23 (22 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy and delivery in western Africa. High risk motherhood] Prual A. **Sante Publique** 1999 Jun; 11(2):155–65 (126 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy and delivery in western Africa. Towards a lower risk motherhood?] Prual A. **Sante Publique** 1999 Jun; 11(2):167–91 (126 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy and smoking: significance of the problem and health-service based prevention] Castellanos E, et al.
Med Clin (Barc) 1998 Nov 21;111(17):670–4 (76 ref.) **(Spa)**

PSYCHOLOGY

Trichotillomania resulting in a trichobezoar: a case report. Stone KD, et al. **J La State Med Soc** 1998 Oct; 150(10):478–81 (14 ref.)
Interpersonal violence and the pregnant homeless woman. Robrecht LC, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec;27(6):684–91 (32 ref.)
The impact of pregnancy and puerperium on panic disorder: a review. Hertzberg T, et al.
J Psychosom Obstet Gynaecol 1999 Jun;20(2):59–64 (23 ref.)
Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA.
Thyroid 1999 Jul;9(7):691–7 (51 ref.)

RADIOGRAPHY

Safety of radiographic imaging during pregnancy. Toppenberg KS, et al. **Am Fam Physician** 1999 Apr 1; 59(7):1813–8, 1820 (18 ref.)

REHABILITATION

The methadone-maintained pregnancy. Kandall SR, et al. **Clin Perinatol** 1999 Mar;26(1):173–83 (63 ref.)
Methadone in the management of narcotic addiction in pregnancy [editorial] Archie C.
Curr Opin Obstet Gynecol 1998 Dec;10(6):435–40 (25 ref.)
A review of recent findings on substance abuse treatment for pregnant women. Howell EM, et al.
J Subst Abuse Treat 1999 Apr;16(3):195–219 (128 ref.)

SURGERY

Hyperparathyroidism and pregnancy. Kort KC, et al.
Am J Surg 1999 Jan;177(1):66–8 (27 ref.)
Laparoscopy during pregnancy: a literature review. Nezhat FR, et al. **J Soc Laparoendosc Surg** 1997 Jan-Mar; 1(1):17–27 (106 ref.)
Laparoscopic cholecystectomy during pregnancy: a case series and review of the literature. Graham G, et al.
Obstet Gynecol Surv 1998 Sep;53(9):566–74 (44 ref.)
Management of pelvic abscess during pregnancy: a case and review of the literature. Sherer DM, et al.
Obstet Gynecol Surv 1999 Oct;54(10):655–62 (72 ref.)
Pregnancy: A contraindication? Holthausen UH, et al.
World J Surg 1999 Aug;23(8):856–62 (72 ref.)
[Laparoscopic surgery and pregnancy] Slim K, et al.
J Chir (Paris) 1998 Dec;135(6):261–6 (53 ref.) (Eng. Abstr.) **(Fre)**
[Appendicitis in pregnancy] Retzke U, et al.
Zentralbl Chir 1998;123 Suppl 4:61–5 (16 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Review article: The management of inflammatory bowel disease during pregnancy. Subhani JM, et al.
Aliment Pharmacol Ther 1998 Nov;12(11):1039–53 (127 ref.)
Clinical uses of intravenous immunoglobulin in pregnancy. Clark AL. **Clin Obstet Gynecol** 1999 Jun;42(2):368–80 (97 ref.)
Diagnosis and management of maternal and fetal thyroid disorders. Mestman JH. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):167–75 (60 ref.)
Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options? Broussard CN, et al. **Drug Saf** 1998 Oct;19(4):325–37 (70 ref.)
Violence during pregnancy. Datner EM, et al.
Emerg Med Clin North Am 1999 Aug;17(3):645–56, vi (62 ref.)
Obstetric and gynecologic care of women with epilepsy. El-Sayed YY. **Epilepsia** 1998;39 Suppl 8:S17–25 (87 ref.)
Neurologic care of pregnant women with epilepsy. Zahn C.
Epilepsia 1998;39 Suppl 8:S26–31 (66 ref.)
Pregnancy in chronic dialysis: a review and analysis of the literature. Chan WS, et al. **Int J Artif Organs** 1998 May; 21(5):259–68 (82 ref.)
Advances in perinatal medical care--from our experience. Sakamoto S, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S107–14 (9 ref.)
Identification and management of pregnancy-related low back pain. Perkins J, et al. **J Nurse Midwifery** 1998 Sep-Oct;43(5):331–40 (39 ref.)
The pregnant addict: treat or prosecute? Implications for midwifery management. Stephany TM.
J Nurse Midwifery 1999 Mar-Apr;44(2):154–6 (27 ref.)
Alternative therapies for nausea and vomiting of pregnancy. Zeidenstein L. **J Nurse Midwifery** 1998 Sep-Oct; 43(5):392–3 (0 ref.)
Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Gordon C, et al. **Lupus** 1998; 7(7):429–33 (52 ref.)
Wegener's granulomatosis in pregnancy--the therapeutic dilemma. Harber MA, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1789–91 (33 ref.)
Pregnancy and end-stage renal disease--past experience and new insights [editorial; comment] Levy DP, et al.
Nephrol Dial Transplant 1998 Dec;13(12):3005–7 (11 ref.) Comment on: Nephrol Dial Transplant 1998 Dec;13(12):3266–72.
Trauma in the obstetric patient. Stone IK.
Obstet Gynecol Clin North Am 1999 Sep;26(3):459–67, viii (21 ref.)
The course and management of bipolar disorder during pregnancy. Viguera AC, et al. **Psychopharmacol Bull** 1998; 34(3):339–46 (83 ref.)
Maternal hypothyroidism: recognition and management. Brent GA. **Thyroid** 1999 Jul;9(7):661–5 (29 ref.)
Nodular thyroid disease diagnosed during pregnancy: how and when to treat. Hay ID. **Thyroid** 1999 Jul;9(7):667–70 (30 ref.)
Hyperthyroidism in pregnancy: diagnosis and treatment. Masiukiewicz US, et al. **Thyroid** 1999 Jul;9(7):647–52 (62 ref.)
[Current obstetrical management of antiphospholipid antibody syndrome: review of the literature apropos of 20 cases] Denis E, et al. **Contracept Fertil Sex** 1998 Sep; 26(9):613–20 (55 ref.) **(Fre)**
[Diagnosis and treatment of autoimmune thyroid disease (ATD) complicated by pregnancy] Momotani N.
Nippon Rinsho 1999 Aug;57(8):1866–72 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Amnioinfusion or not during labor? Better documentation and more trials can answer the question] Wallin G.
Lakartidningen 1999 Mar 3;96(9):1017–9 (30 ref.) (Eng. Abstr.) **(Swe)**

ULTRASONOGRAPHY

Ultrasonographic screening for fetal chromosomal abnormalities in early pregnancy. Taipale P, et al.
Acta Obstet Gynecol Scand 1999 Aug;78(7):563–72 (88 ref.)
Prenatal diagnosis of complicated abdominal wall defects. Fogata ML, et al. **Curr Probl Diagn Radiol** 1999 Jul-Aug; 28(4):101–28 (98 ref.)
A growing role for ultrasound. Booker M. **Practitioner** 1998 Apr;242(1585):297–9 (0 ref.)
The role of color Doppler ultrasonography in obstetrics. Abrahim-Zadeh R, et al. **Semin Roentgenol** 1998 Oct; 33(4):351–9 (29 ref.)
Emergency obstetrical ultrasonography. Doubilet PM, et al.
Semin Roentgenol 1998 Oct;33(4):339–50 (45 ref.)

VIROLOGY

Perinatal hepatitis B: update & recommendations. Corrarino JE. **MCN Am J Matern Child Nurs** 1998 Sep-Oct; 23(5):246–52; quiz 253 (23 ref.)

PREGNANCY COMPLICATIONS, CARDIOVASCULAR

Pregnancy-induced hypertension and insulin resistance: evidence for a connection. Innes KE, et al. **Acta Obstet Gynecol Scand** 1999 Apr;78(4):263–84 (359 ref.)

Cerebral arteriovenous malformation in pregnancy: presentation and neurologic, obstetric, and ethical significance. Finnerty JJ, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):296–303 (21 ref.)

Crack-cocaine-associated aortic dissection in early pregnancy--a case report. Madu EC, et al. **Angiology** 1999 Feb;50(2):163–8 (11 ref.)

Chronic hypertension in pregnancy. Haddad B, et al. **Ann Med** 1999 Aug;31(4):246–52 (47 ref.)

The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. McColl MD, et al. **Br J Obstet Gynaecol** 1999 Aug;106(8):756–66 (106 ref.)

Valvular heart disease in pregnancy. A contemporary perspective. Teerlink JR, et al. **Cardiol Clin** 1998 Aug; 16(3):573–98, x (142 ref.)

Pregnancy-induced severe left ventricular systolic dysfunction in a patient with hypertrophic cardiomyopathy. Kazimuddin M, et al. **Clin Cardiol** 1998 Nov;21(11):848–50 (8 ref.)

Postpartum hemorrhage and arterial embolization. Mason BA. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):475–9 (17 ref.)

Hypertrophic cardiomyopathy and pregnancy. Piacenza JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep; 80(1):17–23 (24 ref.)

The special case of venous thromboembolism in pregnancy. Greer IA. **Haemostasis** 1998;28 Suppl 3:22–34 (45 ref.)

Pregnancy and the heart. Williams D. **Hosp Med** 1999 Feb; 60(2):100–4 (18 ref.)

Thrombosis in pregnancy: maternal and fetal issues [see comments] Greer IA. **Lancet** 1999 Apr 10; 353(9160):1258–65 (61 ref.) Comment in: Lancet 1999 Jul 10;354(9173):162–3.

Overview of common obstetric bleeding disorders. Carter S. **Nurse Pract** 1999 Mar;24(3):50–1, 54, 57–8 passim (29 ref.)

Peripartum cardiomyopathy: a review of the literature. Heider AL, et al. **Obstet Gynecol Surv** 1999 Aug; 54(8):526–31 (34 ref.)

Heart disease during pregnancy. Which cardiovascular changes reflect disease? [see comments] Villablanca AC. **Postgrad Med** 1998 Nov;104(5):149–56 (17 ref.) Comment in: Postgrad Med 1999 Feb;105(2):33–4.

Acquired thrombophilia in pregnancy. Ballem P. **Semin Thromb Hemost** 1998;24 Suppl 1:41–7 (41 ref.)

Inherited thrombophilia and pregnancy: the obstetric perspective. Bonnar J, et al. **Semin Thromb Hemost** 1998; 24 Suppl 1:49–53 (21 ref.)

[Arterial hypertension in pregnancy] Ivanović-Krstić B, et al. **Srp Arh Celok Lek** 1999 May-Jun;127(5–6):178–82 (26 ref.) **(Scc)**

[Arterial hypertension and pregnancy: diagnostic criteria and therapeutic approach] Palma Gámiz JL. **Rev Esp Cardiol** 1998;51 Suppl 4:50–8 (34 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Astedt B, et al. **Semin Thromb Hemost** 1998;24(5):431–5 (72 ref.)

Relevance of markers of hemostasis activation in obstetrics/gynecology and pediatrics. Dati F, et al. **Semin Thromb Hemost** 1998;24(5):443–8 (42 ref.)

CHEMICALLY INDUCED

Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. Onuigbo M, et al. **South Med J** 1998 Dec;91(12):1153–5 (17 ref.)

DIAGNOSIS

Myocardial infarction during pregnancy and postpartum: a review. Patti G, et al. **G Ital Cardiol** 1999 Mar;29(3):333–8 (54 ref.)

Moyamoya disease and pregnancy: case report and review of the literature. Komiyama M, et al. **Neurosurgery** 1998 Aug;43(2):360–8; discussion 368–9 (64 ref.)

Ambulatory blood pressure monitoring in pregnancy. Walker SP, et al. **Obstet Gynecol Surv** 1998 Oct;53(10):636–44 (56 ref.)

[Hypertensive syndromes in pregnancy. Diagnosis and therapy] Mounier-Vehier C, et al. **Presse Med** 1999 Apr 24;28(16):886–91 (42 ref.) (Eng. Abstr.) **(Fre)**

[Heart valve disease in women in the reproductive age] Zuber M, et al. **Ther Umsch** 1998 Dec;55(12):762–6 (38 ref.) (Eng. Abstr.) **(Ger)**

[Pregnancy in mothers with congenital heart defects. An overview] Schmaltz AA, et al. **Z Geburtshilfe Neonatol** 1999 May-Jun;203(3):101–9 (68 ref.) (Eng. Abstr.) **(Ger)**

[Deep venous thrombosis in pregnant women] Hervig T, et al. **Tidsskr Nor Laegeforen** 1998 Oct 30;118(26):4093–7 (29 ref.) (Eng. Abstr.) **(Nor)**

[Dilated myocardiopathy and pregnancy. Report of 3 cases and review of the literature] Villanueva González MA, et al. **Ginecol Obstet Mex** 1999 Apr;67:173–5 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Safety of antiarrhythmics during pregnancy: case report and review of the literature. Fagih B, et al. **Can J Cardiol** 1999 Jan;15(1):113–7 (30 ref.)

Treatment of cardiac arrhythmias during pregnancy: safety considerations. Joglar JA, et al. **Drug Saf** 1999 Jan; 20(1):85–94 (70 ref.)

Anticoagulant treatment during pregnancy: an update. Dizon-Townson D, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:55–62 (80 ref.)

Safety of low-molecular-weight heparin in pregnancy: a systematic review. Sanson BJ, et al. **Thromb Haemost** 1999 May;81(5):668–72 (33 ref.)

[Current conception of arterial hypertension treatment in pregnancy] Eliseev OM. **Ter Arkh** 1998;70(9):29–35 (0 ref.) **(Rus)**

ETIOLOGY

Cigarette smoking and pregnancy II: vascular effects. Salafia C, et al. **Placenta** 1999 May;20(4):273–9 (89 ref.)

Endocrine causes of hypertension in pregnancy--when to start looking for zebras. Keely E. **Semin Perinatol** 1998 Dec;22(6):471–84 (98 ref.)

NURSING

Being prepared for a pregnant code blue [see comments] Fillion DN. **MCN Am J Matern Child Nurs** 1998 Sep-Oct; 23(5):240–5 (15 ref.) Comment in: MCN Am J Matern Child Nurs 1999 Jan-Feb;24(1):53.

PHYSIOPATHOLOGY

Hypertension in women with gestational diabetes. Roberts R. **Diabetes Care** 1998 Aug;21 Suppl 2:B27–32 (42 ref.)

Hypertension in pregnancy: a potential window into long-term cardiovascular risk in women. Seely EW. **J Clin Endocrinol Metab** 1999 Jun;84(6):1858–61 (27 ref.)

Heart disease during pregnancy. Which cardiovascular changes are normal or transient? Villablanca AC. **Postgrad Med** 1998 Oct;104(4):183–4, 187–92 (10 ref.)

PREVENTION & CONTROL

Dietary salt restriction in pregnancy an outmoded practice [comment] Churchill D. **J Hum Hypertens** 1999 Mar; 13(3):157–8 (9 ref.) Comment on: J Hum Hypertens 1999 Mar;13(3):159–66.

Calcium supplementation in pregnancy to prevent pregnancy induced hypertension (PIH). Yabes-Almirante C. **J Perinat Med** 1998;26(5):347–53 (39 ref.)

Low molecular weight heparin use during pregnancy: issues of safety and practicality. Chan WS, et al. **Obstet Gynecol Surv** 1999 Oct;54(10):649–54 (38 ref.)

SURGERY

Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984–1996. Weiss BM, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1643–53 (177 ref.)

[Subarachnoid hemorrhage and pregnancy] Rossi A, et al. **Minerva Anestesiol** 1998 Apr;64(4):189–91 (3 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Pregnancy in women with diabetes and ischaemic heart disease. Bagg W, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):99–102 (22 ref.)

Fortnightly review: management of hypertension in pregnancy. Magee LA, et al. **BMJ** 1999 May 15; 318(7194):1332–6 (49 ref.)

Outcome of pregnancy in women with congenital heart disease. Schmaltz AA, et al. **Cardiol Young** 1999 Jan; 9(1):88–96 (68 ref.)

Management of acute severe hypertension and encephalopathy. Mabie WC. **Clin Obstet Gynecol** 1999 Sep; 42(3):519–31 (73 ref.)

Hypertension. Witlin AG, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):533–44 (25 ref.)

Management of peripartum hemorrhage. Skye DV. **WMJ** 1998 Dec;97(11):43–6 (3 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of left ventricular aneurysm: a report of three cases and a review [see comments] Matias A, et al. **Cardiol Young** 1999 Mar;9(2):175–84 (22 ref.) Comment in: Cardiol Young 1999 Mar;9(2):123–6.

Vasa previa: an avoidable obstetric tragedy. Oyelese KO, et al. **Obstet Gynecol Surv** 1999 Feb;54(2):138–45 (58 ref.)

PREGNANCY COMPLICATIONS, HEMATOLOGIC

Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Diav-Citrin O, et al. **Am J Hematol** 1999 Feb;60(2):148–50 (21 ref.)

Immune thrombocytopenic purpura in pregnancy. Christiaens GC. **Baillieres Clin Haematol** 1998 Jun; 11(2):373–80 (34 ref.)

Inherited bleeding disorders in obstetrics and gynaecology. Economides DL, et al. **Br J Obstet Gynaecol** 1999 Jan; 106(1):5–13 (87 ref.)

Gestational thrombocytopenia. Shehata N, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):327–34 (22 ref.)

Twin-twin transfusion syndrome: the challenge of etiology-based management decisions. Filkins KA, et al. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):441–6 (63 ref.)

Management of pregnancy in carriers of haemophilia. Giangrande PL. **Haemophilia** 1998 Nov;4(6):779–84 (23 ref.)

Peripartum hemorrhage. Alamia V Jr, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):385–98 (63 ref.)

[Leukocytosis in pregnancy] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):23–4 (5 ref.) **(Jpn)**

DIAGNOSIS

Diagnosis and management of thrombotic microangiopathies during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):360–7 (32 ref.)

Review of autoimmune thrombocytopenia: pathogenesis, diagnosis, and management in pregnancy. Johnson JR, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):317–26 (16 ref.)

Diagnosis of deep venous thrombosis and pulmonary embolism in pregnancy. Macklon NS. **Curr Opin Pulm Med** 1999 Jul;5(4):233–7 (40 ref.)

Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: four cases and a review. Sheikh RA, et al. **J Clin Gastroenterol** 1999 Jun;28(4):323–8 (37 ref.)

[Anemia in pregnancy] Huch R. **Schweiz Rundsch Med Prax** 1999 Jan 28;88(5):157–63 (15 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Use of antithrombotic agents during pregnancy. Ginsberg JS, et al. **Chest** 1998 Nov;114(5 Suppl):524S–530S (57 ref.)

Anticoagulation. Brown HL, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):545–54 (49 ref.)

Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism [editorial] Grendys EC Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):71–9 (75 ref.)

Treatment and prevention of venous thromboembolic disease in pregnancy. Valentine KA. **Curr Opin Pulm Med** 1999 Jul;5(4):238–43 (60 ref.)

EPIDEMIOLOGY

Risk factors for venous thromboembolism in pregnancy. McColl MD, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):227–32 (49 ref.)

PATHOLOGY

Death due to thrombotic thrombocytopenic purpura in pregnancy: case report with review of thrombotic microangiopathies of pregnancy. Kemp WL, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):189–98 (30 ref.)

PHYSIOPATHOLOGY

Pathophysiology of renal fluid retention. Schrier RW, et al. **Kidney Int Suppl** 1998 Sep;67:S127–32 (62 ref.)

PREVENTION & CONTROL

Use of antithrombotic agents during pregnancy. Ginsberg JS, et al. **Chest** 1998 Nov;114(5 Suppl):524S–530S (57 ref.)

[Anticoagulation in surgery, after hemorrhagic complications and in pregnancy] Gohlke-Bärwolf C. **Z Kardiol** 1998;87 Suppl 4:56–62 (41 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in patients with heart valve replacement in pregnancy] Harenberg J. **Z Kardiol** 1998;87 Suppl 4:63–7 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diagnosis and management of thrombotic microangiopathies during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):360–7 (32 ref.)

Congenital disorders of platelet function. Fausett B, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):390–405 (34 ref.)

Review of autoimmune thrombocytopenia: pathogenesis, diagnosis, and management in pregnancy. Johnson JR, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):317–26 (16 ref.)

Transfusional transmitted viruses in pregnancy. Eleftheriou A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:901–14 (65 ref.)

[Obstetric treatment of hemophilia carriers] Aguilar C, et al. **Sangre (Barc)** 1998 Oct;43(5):399–405 (71 ref.) **(Spa)**

PREGNANCY COMPLICATIONS, INFECTIOUS

Viral hepatitis and pregnancy. Michielsen PP, et al. **Acta Gastroenterol Belg** 1999 Jan-Mar;62(1):21–9 (101 ref.)

Timing and mechanism of perinatal human immunodeficiency virus-1 infection. Phuapradit W. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):293–7 (46 ref.)

Perinatal consequences of hepatitis C. Eriksen NL.

Clin Obstet Gynecol 1999 Mar;42(1):121–33; quiz 174–5 (85 ref.)
TORCH testing in HIV-infected women. Helfgott A. **Clin Obstet Gynecol** 1999 Mar;42(1):149–62; quiz 174–5 (69 ref.)
Parvovirus infection. Rodis JF. **Clin Obstet Gynecol** 1999 Mar;42(1):107–20; quiz 174–5 (38 ref.)
Prevention of perinatal herpes: prophylactic antiviral therapy? Scott LL. **Clin Obstet Gynecol** 1999 Mar; 42(1):134–48; quiz 174–5 (53 ref.)
Hodgkin's lymphoma in a pregnant patient with acquired immunodeficiency syndrome. Okechukwu CN, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):410–1 (6 ref.)
Pneumonia, tuberculosis, and urinary tract infections in pregnancy. Riley LE. **Curr Clin Top Infect Dis** 1999; 19:181–97 (112 ref.)
Fetal cells from maternal blood: purpose, biological questions, technical challenges. Bohmer RM. **Intervirology** 1998;41(4–5):226–31 (14 ref.)
Transmission of cervical cancer-associated human papilloma viruses from mother to child. Cason J, et al. **Intervirology** 1998;41(4–5):213–8 (44 ref.)
Hepatitis B maternal-fetal transmission in Southern Europe. Papaevangelou G, et al. **Intervirology** 1998;41(4–5):197–200 (16 ref.)
Role of periodontitis in systemic health: spontaneous preterm birth. Offenbacher S, et al. **J Dent Educ** 1998 Oct; 62(10):852–8 (20 ref.)
Foodborne infections during pregnancy. Smith JL. **J Food Prot** 1999 Jul;62(7):818–29 (132 ref.)
Update on vertical HIV transmission. Groginsky E, et al. **J Reprod Med** 1998 Aug;43(8):637–46 (72 ref.)
Successful pregnancy in an adolescent with perinatally acquired human immunodeficiency virus. Crane S, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):711 (2 ref.)
Listeriosis during pregnancy. Silver HM. **Obstet Gynecol Surv** 1998 Dec;53(12):737–40 (26 ref.)
Cytomegalovirus infection. Brown HL, et al. **Semin Perinatol** 1998 Aug;22(4):260–6 (36 ref.)
Perinatal infectious disease. Introduction. Duff P. **Semin Perinatol** 1998 Aug;22(4):241 (78 ref.)
Hepatitis in pregnancy. Duff P. **Semin Perinatol** 1998 Aug; 22(4):277–83 (35 ref.)
Syphilis. Hollier LM, et al. **Semin Perinatol** 1998 Aug; 22(4):323–31 (58 ref.)
Pathophysiology, diagnosis, and management of intraamniotic infection. Riggs JW, et al. **Semin Perinatol** 1998 Aug;22(4):251–9 (73 ref.)
[Progresses in the study of perinatology in China, 1997] Bian X. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):924–5 (0 ref.) **(Chi)**
[Neurological complications of HIV-1 infection in an infant born to a seropositive mother] Tardieu M. **Rev Neurol (Paris)** 1998 Dec;154(12):850–5 (24 ref.) **(Fre)**
[Infectious diseases during pregnancy. Prevention, diagnosis and fetal risks] Luton D, et al. **Rev Prat** 1999 Jan 1; 49(1):89–106 (5 ref.) **(Fre)**
[A case of measles encephaloneuropathy in a pregnant women] Haraguchi T, et al. **No To Shinkei** 1998 Aug; 50(8):761–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Perinatal infection with the human immunodeficiency virus] Milošević S. **Med Pregl** 1998 Jul–Aug;51(7–8):325–8 (8 ref.) (Eng. Abstr.) **(Scr)**

DIAGNOSIS

Legal considerations in screening pregnant women for human immunodeficiency virus. Grimes RM, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):259–64 (24 ref.)
Q fever during pregnancy: a public health problem in southern France. Stein A, et al. **Clin Infect Dis** 1998 Sep; 27(3):592–6 (24 ref.)
The diagnosis of intrauterine infection in women with preterm premature rupture of the membranes (PPROM). Greig PC. **Clin Obstet Gynecol** 1998 Dec;41(4):849–63 (48 ref.)
Diagnosis of perinatal TORCH infections. Newton ER. **Clin Obstet Gynecol** 1999 Mar;42(1):59–70; quiz 174–5 (32 ref.)
Genital herpes complicating pregnancy. Brown ZA. **Dermatol Clin** 1998 Oct;16(4):805–10, xiv (24 ref.)
ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov;63(2):195–202 (24 ref.)
Human immunodeficiency virus and hepatitis B virus infection in pregnancy: diagnostic potential of viral genome detection. Berger A, et al. **Intervirology** 1998;41(4–5):201–7 (38 ref.)
Herpes simplex virus infection in pregnancy: diagnosis and significance. Desselberger U. **Intervirology** 1998; 41(4–5):185–90 (30 ref.)
Cytomegalovirus infection in pregnancy: a still complicated diagnostic problem. Lazzarotto T, et al. **Intervirology** 1998; 41(4–5):149–57 (63 ref.)
Antenatal screening for HIV in the UK: what is to be done? [editorial] [see comments] Nicoll A. **J Med Screen** 1998; 5(4):170–1 (31 ref.) Comment in: J Med Screen 1999;6(2):111–2.
Congenital and perinatal tuberculosis: discussion of difficult issues in diagnosis and management. Hageman JR. **J Perinatol** 1998 Sep–Oct;18(5):389–94 (31 ref.)
Serious group A streptococcal infection around delivery. Udagawa H, et al. **Obstet Gynecol** 1999 Jul;94(1):153–7 (22 ref.)
Broadsheet. Number 50: Diagnosis of human cytomegalovirus infection and disease. Rawlinson WD. **Pathology** 1999 May;31(2):109–15 (33 ref.)
Bacterial vaginosis: association with adverse pregnancy outcome. Kimberlin DF, et al. **Semin Perinatol** 1998 Aug; 22(4):242–50 (73 ref.)
In utero varicella-zoster infections. Derrick CW Jr, et al. **South Med J** 1998 Nov;91(11):1064–6 (15 ref.)
Screening of pregnant women for hepatitis B. Boxall E. **Vaccine** 1998 Nov;16 Suppl:S30–3 (13 ref.)
[Can one predict the prognosis of HIV infection?] Furrer H, et al. **Schweiz Rundsch Med Prax** 1998 Oct 7; 87(41):1361–7 (42 ref.) **(Ger)**

DRUG THERAPY

A review of the role of trials of the use of antibiotics in women with preterm labor and intact membranes. Chaim W, et al. **Arch Gynecol Obstet** 1998;261(4):167–72 (21 ref.)
Antifungal therapy during pregnancy. King CT, et al. **Clin Infect Dis** 1998 Nov;27(5):1151–60 (106 ref.)
Perinatal cytomegalovirus and toxoplasmosis: challenges of antepartum therapy. Piper JM, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):81–96; quiz 174–5 (74 ref.)
AZT trials and tribulations. Crouch RA, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):26–34 (32 ref.)
Science in the service of healing. Grady C. **Hastings Cent Rep** 1998 Nov–Dec;28(6):34–8 (19 ref.)
Zidovudine. Sperling R. **Infect Dis Obstet Gynecol** 1998; 6(5):197–203 (27 ref.)
Antiviral therapy for genital herpes in nonpregnant and pregnant women. Baker DA. **Int J Fertil Womens Med** 1998 Sep–Oct;43(5):243–8 (22 ref.)
HIV infection and pregnancy. de Ruiter A, et al. **Int J STD AIDS** 1998 Nov;9(11):647–54; quiz 655 (34 ref.)
Use of combination antiretroviral therapy in pregnant women with HIV disease. Newshan G, et al. **MCN Am J Matern Child Nurs** 1998 Nov–Dec; 23(6):307–12; quiz 313 (22 ref.)
Antimicrobial prevention of early-onset group B streptococcal sepsis: estimates of risk reduction based on a critical literature review. Benitz WE, et al. **Pediatrics** 1999 Jun;103(6):e78 (112 ref.)
British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). Taylor GP, et al. **Sex Transm Infect** 1999 Apr;75(2):90–7 (55 ref.)
[Management of VZV infections. Short text of the 11th consensus conference on anti-infectious therapies] **Presse Med** 1998 Jul 4–11;27(24):1231–6 (0 ref.) **(Fre)**
[Reducing perinatal transmission by antiretroviral therapy] Schmied B. **Wien Med Wochenschr** 1998;148(23–24):550–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Antibiotic treatment in preterm labor with intact membranes] Chaim W, et al. **Harefuah** 1998 Aug; 135(3–4):130–4 (31 ref.) **(Heb)**

ECONOMICS

How to assess an article on economic evaluation. Sculpher M, et al. **Sex Transm Infect** 1998 Jun;74(3):223–7 (22 ref.)

EPIDEMIOLOGY

HIV infections in obstetrics and gynaecology. Mola G. **P N G Med J** 1996 Sep;39(3):190–5 (8 ref.)
Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Benitz WE, et al. **Pediatrics** 1999 Jun;103(6):e77 (165 ref.)
The megalovirus [editorial] Ville Y. **Ultrasound Obstet Gynecol** 1998 Sep;12(3):151–3 (18 ref.)
[Chickenpox in pregnancy] Berrebi A, et al. **Arch Pediatr** 1998 Jan;5(1):79–83 (32 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pregnancy and leprosy: a comprehensive literature review. Lockwood DN, et al. **Int J Lepr Other Mycobact Dis** 1999 Mar;67(1):6–12 (21 ref.)

NURSING

Clostridium difficile-associated disease. Implications for midwifery practice. Alef K. **J Nurse Midwifery** 1999 Jan–Feb;44(1):19–29 (132 ref.)
Current issues in the midwifery management of women living with HIV/AIDS. MacLaren A, et al. **J Nurse Midwifery** 1998 Nov–Dec;43(6):502–25 (156 ref.)

PHYSIOPATHOLOGY

Sepsis in obstetric and gynecologic patients. Faro S. **Curr Clin Top Infect Dis** 1999;19:60–82 (124 ref.)
Bacterial vaginosis: association with adverse pregnancy outcome. Kimberlin DF, et al. **Semin Perinatol** 1998 Aug; 22(4):242–50 (73 ref.)

PREVENTION & CONTROL

Congenital rubella syndrome. How can we do better? Bar-Oz B, et al. **Can Fam Physician** 1999 Aug;45:1865–9 (18 ref.)
Clostridium difficile-associated disease. Implications for midwifery practice. Alef K. **J Nurse Midwifery** 1999 Jan–Feb;44(1):19–29 (132 ref.)
Immunizations in pregnancy. A public health perspective. Hackley BK. **J Nurse Midwifery** 1999 Mar–Apr; 44(2):106–17 (37 ref.)
Management of cervical cerclage after preterm premature rupture of membranes. O'Connor S, et al. **Obstet Gynecol Surv** 1999 Jun;54(6):391–4 (14 ref.)
Infection control practices and the pregnant health care worker. Mirza A, et al. **Pediatr Infect Dis J** 1999 Jan; 18(1):18–22 (51 ref.)
Health and cost-benefits of chlamydia screening in young women. Mangione-Smith R, et al. **Sex Transm Dis** 1999 Jul;26(6):309–16 (83 ref.)
[Vertical HIV-I-transmission. I. Risk and prevention in pregnancy (see comments)] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12;142(50):2720–4 (27 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2720–4. **(Dut)**
[Antiretroviral therapy and prevention of maternal-fetal transmission of HIV-1. Current and future strategies] Monpoux F, et al. **Arch Pediatr** 1999 May;6(5):556–65 (70 ref.) (Eng. Abstr.) **(Fre)**
[The threat of premature labor: new aspects for management] Wertz JP, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1998;135(1):51–8 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Pyelonephritis. Wing DA. **Clin Obstet Gynecol** 1998 Sep; 41(3):515–26 (38 ref.)
ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov;63(2):195–202 (24 ref.)
HIV: mother to child transmission, current knowledge and on-going studies. Giaquinto C, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S161–5 (22 ref.)
Congenital and perinatal tuberculosis: discussion of difficult issues in diagnosis and management. Hageman JR. **J Perinatol** 1998 Sep–Oct;18(5):389–94 (31 ref.)
[Current position on the care of HIV-seropositive pregnancies] Funke AM. **Zentralbl Gynakol** 1999; 121(1):33–4 (14 ref.) (Eng. Abstr.) **(Ger)**
[Fluconazole administration during pregnancy] Albukrek D, et al. **Harefuah** 1998 Sep;135(5–6):243–6 (19 ref.) **(Heb)**

VETERINARY

Effects of stress on leukocyte trafficking and immune responses: implications for vaccination. Kehrli ME, et al. **Adv Vet Med** 1999;41:61–81 (108 ref.)

VIROLOGY

Main viral diseases with in utero transmission of pathogen during pregnancy: epidemiology, pathological features and outcome. Shlyakhov E, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):875–82 (115 ref.)
The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Brocklehurst P, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):836–48 (58 ref.)
Parvovirus B19 infection in pregnancy. Eis-Hübinger AM, et al. **Intervirology** 1998;41(4–5):178–84 (59 ref.)
Current issues in the midwifery management of women living with HIV/AIDS. MacLaren A, et al. **J Nurse Midwifery** 1998 Nov–Dec;43(6):502–25 (156 ref.)
Transfusional transmitted viruses in pregnancy. Eleftheriou A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:901–14 (65 ref.)
Herpes simplex hepatitis in pregnancy: a case report and review of the literature. Kang AH, et al. **Obstet Gynecol Surv** 1999 Jul;54(7):463–8 (36 ref.)
Varicella in pregnancy. Chapman SJ. **Semin Perinatol** 1998 Aug;22(4):339–46 (39 ref.)
Parvovirus B19 infections in pregnancy. Markenson GR, et al. **Semin Perinatol** 1998 Aug;22(4):309–17 (60 ref.)
Human immunodeficiency virus infection in pregnancy. Minkoff HL. **Semin Perinatol** 1998 Aug;22(4):293–308 (112 ref.)
Herpes simplex virus. Riley LE. **Semin Perinatol** 1998 Aug; 22(4):284–92 (75 ref.)
Rubella and rubeola. Rosa C. **Semin Perinatol** 1998 Aug; 22(4):318–22 (14 ref.)
Screening of pregnant women for hepatitis B. Boxall E. **Vaccine** 1998 Nov;16 Suppl:S30–3 (13 ref.)
[Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment] Villegas Castrejón H, et al. **Ginecol Obstet Mex** 1999 May;67:196–206 (35 ref.) (Eng. Abstr.) **(Spa)**

PREGNANCY COMPLICATIONS, NEOPLASTIC

Hodgkin's lymphoma in a pregnant patient with acquired immunodeficiency syndrome. Okechukwu CN, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):410–1 (6 ref.)
Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. MacKie RM. **Curr Opin Oncol** 1999 Mar;11(2):129–31 (15 ref.)

Myocardial infarction and death after caesarean section in a woman with protein S deficiency and undiagnosed phaeochromocytoma. Zangrillo A, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):268–70 (9 ref.)

Clear cell carcinoma arising in extragonadal endometriosis in a Caeserean section scar during pregnancy [letter] Gücer F, et al. **Gynecol Oncol** 1999 May;73(2):337 (4 ref.)

The relationship of pregnancy, hormones, and melanoma. Grin CM, et al. **Semin Cutan Med Surg** 1998 Sep; 17(3):167–71 (44 ref.)

DIAGNOSIS

Renal cell carcinoma with hypercalcemia complicating a pregnancy: case report and review of the literature. Usta IM, et al. **Eur J Gynaecol Oncol** 1998;19(6):584–7 (27 ref.)

Prenatal diagnosis of congenital neuroblastoma. Analysis of 4 cases and review of the literature. Heling KS, et al. **Fetal Diagn Ther** 1999 Jan–Feb;14(1):47–52 (28 ref.)

Neuroendocrine small cell uterine cervix cancer in pregnancy: long-term survival following combined therapy. Balderston KD, et al. **Gynecol Oncol** 1998 Oct; 71(1):128–32 (16 ref.)

Uterine malignant leiomyoblastoma (epithelioid leiomyosarcoma) during pregnancy. Bekkers RL, et al. **Gynecol Oncol** 1999 Mar;72(3):433–6 (14 ref.)

Endometrial carcinoma associated with pregnancy: A report of three cases and review of the literature. Vaccarello L, et al. **Gynecol Oncol** 1999 Jul;74(1):118–22 (24 ref.)

Choriocarcinoma co-existent with an intact pregnancy: case report and review of the literature. Steigrad SJ, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):197–203 (30 ref.)

[The course of pregnancy, labor and the postpartum period in a woman with a myomatous node of the uterus who gave birth to twins] Istatkov M, et al. **Akush Ginekol (Sofiia)** 1998;37(4):56–8 (6 ref.) **(Bul)**

[Pheochromocytoma associated with pregnancy. Report of 2 cases and review of the literature] Castaigne V, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):622–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Colorectal cancer in pregnancy. A case report] Colecchia G, et al. **G Chir** 1999 Apr;20(4):159–61 (15 ref.) (Eng. Abstr.) **(Ita)**

[Bladder leiomyoma during pregnancy] Núñez Mora C, et al. **Arch Esp Urol** 1999 Jun;52(5):510–3 (14 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Elit L, et al. **Gynecol Oncol** 1999 Jan;72(1):123–7 (29 ref.)

EPIDEMIOLOGY

[Melanoma in pregnancy (see comments)] de Wit AC, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19;142(38):2087–90 (29 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2073–5. **(Dut)**

PATHOLOGY

Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature. Duska LR, et al. **Eur J Gynaecol Oncol** 1998;19(5):441–3 (10 ref.)

A case of intraplacental choriocarcinoma associated with placental hemangioma. Aonahata M, et al. **Pathol Int** 1998 Nov;48(11):897–901 (21 ref.)

A tumorous type of pulmonary rhabdomyomatous dysplasia [see comments] Ramaswamy A, et al. **Pathol Res Pract** 1998;194(9):639–42 (15 ref.) Comment in: Pathol Res Pract 1999;195(3):199–200.

[Cavernous hemangioma of the umbilical cord] Nawroth F, et al. **Zentralbl Gynakol** 1998;120(9):458–61 (17 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Are pancreatic tumors hormone dependent?: A case report of unusual, rapidly growing pancreatic tumor during pregnancy, its possible relationship to female sex hormones, and review of the literature. Ganepola GA, et al. **Am Surg** 1999 Feb;65(2):105–11 (18 ref.)

PREVENTION & CONTROL

[Breast screening in women considering pregnancy] Chiechi LM. **Minerva Ginecol** 1999 Mar;51(3):77–81 (31 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Recurrent myxoma of the left ventricle. Case report and review of the literature. Bortolotti U, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):233–5 (8 ref.)

Melanoma during pregnancy: a case report and review of the literature. Teplitzky S, et al. **J La State Med Soc** 1998 Nov;150(11):539–43 (19 ref.)

Laparoscopic removal of a right adrenal pheochromocytoma in a pregnant woman. Demeure MJ, et al. **J Laparoendosc Adv Surg Tech A** 1998 Oct;8(5):315–9 (16 ref.)

THERAPY

Relapse of acute lymphoblastic leukemia in pregnancy: survival following chemoirradiation and autologous transfer of interleukin-2-activated stem cells. Tewari K, et al. **Gynecol Oncol** 1999 Jul;74(1):143–6 (20 ref.)

Burkitt lymphoma in pregnancy. Barnes MN, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):675–8 (7 ref.)

Management of cervical cancer in pregnancy. Method MW, et al. **Semin Surg Oncol** 1999 Apr–May;16(3):251–60 (57 ref.)

Carcinoma of the breast during pregnancy: a review and update on treatment options. Bernik SF, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):45–9 (50 ref.)

PREGNANCY COMPLICATIONS, PARASITIC

Toxoplasmosis. Beazley DM, et al. **Semin Perinatol** 1998 Aug; 22(4):332–8 (42 ref.)

[Pregnancy and malaria. Study of 143 cases in French Guyana] Carles G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27(8):798–805 (34 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Parasitic infections in pregnancy and congenital protozoan infections. Part I.: Protozoan infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):55–62 (44 ref.) (Eng. Abstr.) **(Ger)**

[Parasitic infections in pregnancy and congenital parasitoses. II. Helminth infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 May–Jun;203(3):128–33 (32 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Parasitic infections in pregnancy and congenital protozoan infections. Part I.: Protozoan infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):55–62 (44 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Mother–child pass in Austria and primary toxoplasmosis infections in pregnant women. Moese JR, et al. **Cent Eur J Public Health** 1998 Nov;6(4):261–4 (9 ref.)

IMMUNOLOGY

Mother–child pass in Austria and primary toxoplasmosis infections in pregnant women. Moese JR, et al. **Cent Eur J Public Health** 1998 Nov;6(4):261–4 (9 ref.)

PREVENTION & CONTROL

Mother–child pass in Austria and primary toxoplasmosis infections in pregnant women. Moese JR, et al. **Cent Eur J Public Health** 1998 Nov;6(4):261–4 (9 ref.)

Mefloquine for malaria chemoprophylaxis 1992–1998: a review. Schlagenhauf P. **J Travel Med** 1999 Jun;6(2):122–33 (96 ref.)

VETERINARY

[Diagnosis and epidemiology of Neospora caninum-associated abortions in cattle] Conraths FJ, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 May; 27(3):145–53 (99 ref.) (Eng. Abstr.) **(Ger)**

PREGNANCY, ECTOPIC

CHEMICALLY INDUCED

Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Kessel E. **Adv Contracept** 1998 Jun;14(2):81–90 (37 ref.)

DIAGNOSIS

Early diagnosis of ectopic pregnancy and treatment with methotrexate. Fylstra DL. **J S C Med Assoc** 1999 Feb; 95(2):59–63 (32 ref.)

[Spontaneous and assisted reproduction-associated heterotopic pregnancy. The clinical characteristics] Barrón Vallejo J, et al. **Ginecol Obstet Mex** 1999 Jul;67:291–4 (16 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Medical management of ectopic pregnancy. Buster JE, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):23–30; quiz 55–6 (33 ref.)

Ultrasound-guided injection of ectopic pregnancy. Natofsky JG, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):39–47; quiz 55–6 (31 ref.)

Surgical and medical management of tubal and non-tubal ectopic pregnancies. Yao M, et al. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):371–4 (36 ref.)

Medical management of interstitial ectopic pregnancy: a case report and literature review. Fisch JD, et al. **Hum Reprod** 1998 Jul;13(7):1981–6 (25 ref.)

Prognostic factors for an unsatisfactory primary methotrexate treatment of cervical pregnancy: a quantitative review. Hung TH, et al. **Hum Reprod** 1998 Sep;13(9):2636–42 (45 ref.)

Early diagnosis of ectopic pregnancy and treatment with methotrexate. Fylstra DL. **J S C Med Assoc** 1999 Feb; 95(2):59–63 (32 ref.)

EPIDEMIOLOGY

Incidence and risk factors for ectopic pregnancy. Pisarska MD, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):2–8; quiz 55–6 (37 ref.)

ETIOLOGY

[Etiology of ectopic pregnancy] Zhang H, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):476–8 (18 ref.) **(Chi)**

SURGERY

Surgical management of ectopic pregnancy. Tulandi T, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):31–8; quiz 55–6 (21 ref.)

Surgical and medical management of tubal and non-tubal ectopic pregnancies. Yao M, et al. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):371–4 (36 ref.)

Laparoscopic management of ectopic pregnancy. Ghosh S, et al. **Semin Laparosc Surg** 1999 Jun;6(2):68–72 (23 ref.)

[Cornual pregnancy. Its laparoscopic management and a case report] Cortés Algara A, et al. **Ginecol Obstet Mex** 1999 Jul;67:300–1 (6 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Current treatment of ectopic pregnancy. Mäkinen J. **Ann Med** 1999 Jun;31(3):197–201 (30 ref.)

Expectant management of ectopic pregnancy. Cohen MA, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):48–54; quiz 55–6 (22 ref.)

Conservative medical and surgical management of interstitial ectopic pregnancy. Lau S, et al. **Fertil Steril** 1999 Aug; 72(2):207–15 (54 ref.)

ULTRASONOGRAPHY

Role of pelvic ultrasonography in evaluation of symptomatic first-trimester pregnancy. Dart RG. **Ann Emerg Med** 1999 Mar;33(3):310–20 (38 ref.)

PREGNANCY, FIRST TRIMESTER see **PREGNANCY TRIMESTER, FIRST**

PREGNANCY, HIGH-RISK

see related
PREGNANCY COMPLICATIONS

Outcome of pregnancy in women with congenital heart disease. Schmaltz AA, et al. **Cardiol Young** 1999 Jan; 9(1):88–96 (68 ref.)

Psychosocial impact of high-risk pregnancy: hospital and home care. Heaman M. **Clin Obstet Gynecol** 1998 Sep; 41(3):626–39 (52 ref.)

Antepartum testing. Miller DA. **Clin Obstet Gynecol** 1998 Sep;41(3):647–53 (42 ref.)

High risk pregnancy outcome by route of delivery. Ben Shachar I, et al. **Curr Opin Obstet Gynecol** 1998 Dec; 10(6):447–52 (40 ref.)

Personal costs associated with high-risk prenatal care attendance. Stringer M. **J Health Care Poor Underserved** 1998 Aug;9(3):222–35 (38 ref.)

Pregnancy in women with spinal cord injuries. Atterbury JL, et al. **Nurs Clin North Am** 1998 Dec;33(4):603–13 (52 ref.)

Routine use of ultrasound during pregnancy. Lowe SW, et al. **Nurse Pract** 1998 Oct;23(10):60, 63–6, 71 (15 ref.)

1998 update on pregnancy in lupus patients. New horizons, new hopes. Wechsler B, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):619–24 (66 ref.)

[Management of pregnant women and newborns in high-risk pregnancies] Grandjean H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:21–36 (102 ref.) **(Fre)**

[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:94–103 (40 ref.) **(Fre)**

[Severe maternal and fetal situations during delivery] Chauvet MP, et al. **Rev Prat** 1999 Jan 15;49(2):151–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy and delivery in western Africa. High risk motherhood] Prual A. **Sante Publique** 1999 Jun; 11(2):155–65 (126 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy and delivery in western Africa. Towards a lower risk motherhood?] Prual A. **Sante Publique** 1999 Jun; 11(2):167–91 (126 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antiphospholipid antibodies in obstetrics: new complexities and sites of action. Caruso A, et al. **Hum Reprod Update** 1999 May–Jun;5(3):267–76 (105 ref.)

PREGNANCY IN ADOLESCENCE

Adolescent pregnancy and substance use. Flanagan P, et al. **Clin Perinatol** 1999 Mar;26(1):185–200 (68 ref.)

Teenage childbearing is not so bad after all...or is it? A review of the new literature. Hoffman SD. **Fam Plann Perspect** 1998 Sep–Oct;30(5):236–9, 243 (0 ref.)

PREGNANCY IN ADOLESCENCE

The risk of teen mothers having low birth weight babies: implications of recent medical research for school health personnel. Roth J, et al. **J Sch Health** 1998 Sep;68(7):271–5 (40 ref.)

Health-related problems in a vulnerable population: pregnant teens and adolescent mothers. Lesser J, et al. **Nurs Clin North Am** 1999 Jun;34(2):289–99 (48 ref.)

Pregnancy in the adolescent patient. Screening, diagnosis, and initial management. Polaneczky M, et al. **Pediatr Clin North Am** 1999 Aug;46(4):649–70, x (62 ref.)

PREVENTION & CONTROL

An update on contraception for adolescents. Brooks TL, et al. **Adolesc Med** 1999 Jun;10(2):211–9, v (37 ref.)

Teen pregnancy prevention: do any programs work? Card JJ. **Annu Rev Public Health** 1999;20:257–85 (83 ref.)

Pregnancy during adolescence: wanted vs. unwanted. Pinto e Silva JL. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S151–6 (14 ref.)

Sex education in school: preventing unwanted pregnancy in adolescents. Saito MI. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S157–60 (17 ref.)

Pregnancy prevention using emergency contraception: efficacy, attitudes, and limitations to use. Schein AB. **J Pediatr Adolesc Gynecol** 1999 Feb;12(1):3–9 (29 ref.)

Reflections on two decades of research on teen sexual behavior and pregnancy. Kirby D. **J Sch Health** 1999 Mar; 69(3):89–94 (43 ref.)

PSYCHOLOGY

Sexually transmitted diseases, unintended pregnancy, and adolescent health promotion. Santelli JS, et al. **Adolesc Med** 1999 Feb;10(1):87–108, vi (180 ref.)

PREGNANCY IN DIABETES

see related
DIABETES, GESTATIONAL

Pregnancy performance and outcomes associated with diabetic nephropathy. Reece EA, et al. **Am J Perinatol** 1998 Jul;15(7):413–21 (26 ref.)

What is the significance of macrosomia? Schwartz R, et al. **Diabetes Care** 1999 Jul;22(7):1201–5 (43 ref.)

[Diabetic retinopathy and pregnancy] Ben Mehidi A, et al. **J Fr Ophtalmol** 1999 May;22(5):602–10 (83 ref.) **(Fre)**

[Pregnancy in diabetic women] Zghal A, et al. **Tunis Med** 1998 Jun–Jul;76(6–7):173–8 (26 ref.) **(Fre)**

[Pathogenesis and management of gestational diabetes mellitus] Sanaka M. **Nippon Rinsho** 1999 Mar;57(3):627–31 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Pregnancies complicated by diabetic proliferative retinopathy. Lauszus FF, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):814–8 (22 ref.)

Pregnancy in women with diabetes and ischaemic heart disease. Bagg W, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):99–102 (22 ref.)

The effect of pregnancy on the natural history of diabetic retinopathy and nephropathy. Star J, et al. **Clin Perinatol** 1998 Dec;25(4):887–916 (86 ref.)

Diabetic embryopathy. Kousseff BG. **Curr Opin Pediatr** 1999 Aug;11(4):348–52 (31 ref.)

[Diabetes and pregnancy. Part II: obstetrical aspects] Atallah D, et al. **J Med Liban** 1998 Sep–Oct;46(5):280–3 (33 ref.) **(Fre)**

EMBRYOLOGY

Endocrine and metabolism [editorial] Root AW. **Curr Opin Pediatr** 1999 Aug;11(4):329–32 (12 ref.)

EPIDEMIOLOGY

[Diabetes and pregnancy in Mexico] Forsbach G, et al. **Rev Invest Clin** 1998 May–Jun;50(3):227–31 (37 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Diabetic embryopathy. Kousseff BG. **Curr Opin Pediatr** 1999 Aug;11(4):348–52 (31 ref.)

METABOLISM

[Diabetes and pregnancy. I. Metabolic aspects] Atallah C, et al. **J Med Liban** 1998 Jul–Aug;46(4):199–205 (20 ref.) **(Fre)**

PHYSIOPATHOLOGY

How to improve prognosis in type 1 diabetic pregnancy. Old problems, new concepts. Hadden DR. **Diabetes Care** 1999 Mar;22 Suppl 2:B104–8 (36 ref.)

Growth factors and the regulation of fetal growth. Hill DJ, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B60–9 (109 ref.)

Diabetic ketoacidosis in pregnancy. Ramin KD. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):481–8, viii (52 ref.)

PREVENTION & CONTROL

[Diabetes and pregnancy. Part II: obstetrical aspects] Atallah D, et al. **J Med Liban** 1998 Sep–Oct;46(5):280–3 (33 ref.) **(Fre)**

THERAPY

Clinical and scientific results in perinatal care of pregnancy complicated by insulin dependent diabetes mellitus in Croatia. Djelmiš J. **Acta Med Croatica** 1998;52(3):147–53 (21 ref.)

Pregnancy in women with diabetes and ischaemic heart disease. Bagg W, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):99–102 (22 ref.)

Ambulatory care of the pregnant woman with diabetes. Homko CJ, et al. **Clin Obstet Gynecol** 1998 Sep; 41(3):584–96 (21 ref.)

Diabetic ketoacidosis in pregnancy. Ramin KD. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):481–8, viii (52 ref.)

Assessment and management of pregnancy complicated by pregestational diabetes mellitus. Wiznitzer A, et al. **Pediatr Ann** 1999 Sep;28(9):605–13 (44 ref.)

PREGNANCY MAINTENANCE

Pregnancy maintenance and the regulation of placental progesterone biosynthesis in the baboon. Henson MC. **Hum Reprod Update** 1998 Jul–Aug;4(4):389–405 (92 ref.)

Achieving and maintaining pregnancy after age 40. Corson SL. **Int J Fertil Womens Med** 1998 Sep–Oct;43(5):249–56 (15 ref.)

[Discordant fetal growth in multiple pregnancy: intervention should be based on chorionicity] van Heteren CF, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1017–21 (13 ref.) (Eng. Abstr.) **(Dut)**

PREGNANCY, MOLAR see **HYDATIDIFORM MOLE**

PREGNANCY, MULTIPLE

see related
PREGNANCY REDUCTION, MULTIFETAL

Strategies to prevent multiple pregnancies in assisted conception programmes. Child TJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):131–46 (52 ref.)

Prediction of preterm labour in multiple pregnancies. Chuileannáin FN, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):53–66 (78 ref.)

Prevention of preterm birth in multiple pregnancy. Crowther CA. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):67–75 (50 ref.)

The consequences of monochorionic placentation. Denbow ML, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):37–51 (77 ref.)

Multifetal pregnancy reduction. Evans MI, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):147–59 (27 ref.)

Doppler ultrasound in multiple pregnancies. Giles WB. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):77–89 (81 ref.)

Obstetric management of high-order multiple pregnancies. Newman RB. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):109–29 (84 ref.)

Adverse outcome after multiple pregnancy. Petterson B, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):1–17 (77 ref.)

Screening for fetal abnormalities in multiple pregnancies. Sebire NJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):19–36 (67 ref.)

ABC of labour care: unusual presentations and positions and multiple pregnancy. Chamberlain G, et al. **BMJ** 1999 May 1;318(7192):1192–4 (0 ref.)

Ambulatory management of multiple gestation. Gall SA. **Clin Obstet Gynecol** 1998 Sep;41(3):564–83 (104 ref.)

Twin pregnancy. Al-Kouatly HB, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):125–9 (31 ref.)

Chorionic villus sampling in multiple pregnancies. Appelman Z, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul; 85(1):97–9 (14 ref.)

How to avoid multiple pregnancies in assisted reproduction. Cohen J. **Hum Reprod** 1998 Jun;13 Suppl 3:197–214; discussion 215–8 (44 ref.)

Embryo transfer and multiple gestation. How many transfers are too many? Geva E, et al. **Hum Reprod** 1998 Nov; 13(11):2988–9 (22 ref.)

ACOG educational bulletin. Special problems of multiple gestation. Number 253, November 1998 (Replaces Number 131, August 1989). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Mar; 64(3):323–33 (65 ref.)

Should multifetal pregnancy reduction be used for prevention of preterm deliveries in triplet or higher order multiple pregnancies? Papiernik E, et al. **J Perinat Med** 1998; 26(5):365–70 (22 ref.)

Delayed interval delivery in multiple gestations. Platt JS, et al. **Obstet Gynecol Surv** 1999 May;54(5):343–8 (40 ref.)

First trimester ultrasonography of multiple gestations: a review. Sherer DM. **Obstet Gynecol Surv** 1998 Nov; 53(11):715–26 (114 ref.)

Early prenatal diagnosis of cord entanglement in monoamniotic multiple pregnancies [see comments] Arabin B, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):181–6 (24 ref.) Comment in: Ultrasound Obstet Gynecol 1999 Mar;13(3):157–60.

[The course of pregnancy, labor and the postpartum period in a woman with a myomatous node of the uterus who gave birth to twins] Istatkov M, et al. **Akush Ginekol (Sofiia)** 1998;37(4):56–8 (6 ref.) **(Bul)**

[Discordant fetal growth in multiple pregnancy: intervention should be based on chorionicity] van Heteren CF, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1017–21 (13 ref.) (Eng. Abstr.) **(Dut)**

[Arguments in favor of a relation between the organization of perinatal care and the optimal management of prematurity and multiple pregnancies] Truffert P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:85–93 (37 ref.) **(Fre)**

PHYSIOLOGY

The endocrinology of dizygotic twinning in the human. Lambalk CB, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):97–102 (26 ref.)

STATISTICS & NUMERICAL DATA

The epidemiology of multiple births. Bortolus R, et al. **Hum Reprod Update** 1999 Mar–Apr;5(2):179–87 (62 ref.)

Iatrogenic multiple birth, multiple pregnancy and assisted reproductive technologies. Keith L, et al. **Int J Gynaecol Obstet** 1999 Jan;64(1):11–25 (48 ref.)

PREGNANCY OUTCOME

The placenta and its significance in neonatal outcome. Lewis SH, et al. **Adv Pediatr** 1998;45:223–66 (29 ref.)

Safety of radiographic imaging during pregnancy. Toppenberg KS, et al. **Am Fam Physician** 1999 Apr 1; 59(7):1813–8, 1820 (18 ref.)

Pregnancy performance and outcomes associated with diabetic nephropathy. Reece EA, et al. **Am J Perinatol** 1998 Jul;15(7):413–21 (26 ref.)

Drug and environmental factors associated with adverse pregnancy outcomes. Part III: Folic acid: pharmacology, therapeutic recommendations, and economics. Lewis DP, et al. **Ann Pharmacother** 1998 Oct;32(10):1087–95 (119 ref.)

Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Lewis DP, et al. **Ann Pharmacother** 1998 Sep;32(9):947–61 (85 ref.)

The retained twin/triplet following a preterm delivery--an analysis of the literature. Trivedi AN, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):461–5 (26 ref.)

Adverse outcome after multiple pregnancy. Petterson B, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):1–17 (77 ref.)

Intrapartum umbilical artery Doppler velocimetry as a predictor of adverse perinatal outcome: a systematic review. Farrell T, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):783–92 (58 ref.)

Prenatal diagnosis of left ventricular aneurysm: a report of three cases and a review [see comments] Matias A, et al. **Cardiol Young** 1999 Mar;9(2):175–84 (22 ref.) Comment in: Cardiol Young 1999 Mar;9(2):123–6.

Outcome of pregnancy in women with congenital heart disease. Schmaltz AA, et al. **Cardiol Young** 1999 Jan; 9(1):88–96 (68 ref.)

Ethical issues surrounding resuscitation. Boyle RJ, et al. **Clin Perinatol** 1999 Sep;26(3):779–92 (73 ref.)

Grandmultiparity. Is it a perinatal risk? Samueloff A, et al. **Clin Perinatol** 1998 Sep;25(3):529–38 (39 ref.)

Prenatal drug exposure and child outcome. Past, present, future. Smeriglio VL, et al. **Clin Perinatol** 1999 Mar; 26(1):1–16 (61 ref.)

High risk pregnancy outcome by route of delivery. Ben Shachar I, et al. **Curr Opin Obstet Gynecol** 1998 Dec; 10(6):447–52 (40 ref.)

Unexplained elevated maternal serum alpha-fetoprotein: what is the appropriate follow-up? Wilkins-Haug L. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):469–74 (24 ref.)

Risk factors for venous thromboembolism in pregnancy. McColl MD, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):227–32 (49 ref.)

How to improve prognosis in type 1 diabetic pregnancy. Old problems, new concepts. Hadden DR. **Diabetes Care** 1999 Mar;22 Suppl 2:B104–8 (36 ref.)

Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature. Duska LR, et al. **Eur J Gynaecol Oncol** 1998;19(5):441–3 (10 ref.)

Renal cell carcinoma with hypercalcemia complicating a pregnancy: case report and review of the literature. Usta IM, et al. **Eur J Gynaecol Oncol** 1998;19(6):584–7 (27 ref.)

Triptorelin acetate administration in early pregnancy: case reports and review of the literature. Chardonnens D, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):143–9 (71 ref.)

Omphalocele delivery enigma: the best mode of delivery still remains dubious. Lurie S, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):19–22 (24 ref.)

Acardiac twins: pathophysiology, diagnosis, outcome and treatment. Six cases and review of the literature. Søgaard K, et al. **Fetal Diagn Ther** 1999 Jan–Feb;14(1):53–9 (34 ref.)

Studies of HLA, fertility and mate choice in a human isolate. Ober C. **Hum Reprod Update** 1999 Mar–Apr;5(2):103–7 (39 ref.)

Immunity to heat shock proteins and pregnancy outcome.

Witkin SS. **Infect Dis Obstet Gynecol** 1999;7(1-2):35-8 (20 ref.)
Appropriate technology: antenatal care. Lumbiganon P. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S91-5 (29 ref.)
Advances in perinatal medical care--from our experience. Sakamoto S, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S107-14 (9 ref.)
Ballet dancers--pregnancy outcomes. Barry S. **J R Soc Health** 1998 Dec;118(6):360-2 (10 ref.)
Laparoscopy during pregnancy: a literature review. Nezhat FR, et al. **J Soc Laparoendosc Surg** 1997 Jan-Mar; 1(1):17-27 (106 ref.)
Asthma and pregnancy. Schatz M. **Lancet** 1999 Apr 10; 353(9160):1202-4 (17 ref.)
Psychotropic medications in pregnant women: treatment dilemmas. Austin MP, et al. **Med J Aust** 1998 Oct 19; 169(8):428-31 (41 ref.)
Pregnancy outcome in long-term survivors of childhood cancer. Blatt J. **Med Pediatr Oncol** 1999 Jul;33(1):29-33 (32 ref.)
High maternal body weight and pregnancy outcome. de Groot LC. **Nutr Rev** 1999 Feb;57(2):62-4 (15 ref.)
Successful pregnancy in an adolescent with perinatally acquired human immunodeficiency virus. Crane S, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):711 (2 ref.)
Laparoscopic cholecystectomy during pregnancy: a case series and review of the literature. Graham G, et al. **Obstet Gynecol Surv** 1998 Sep;53(9):566-74 (44 ref.)
Who should provide routine antenatal care for low-risk women, and how often? A systematic review of randomised controlled trials. WHO Antenatal Care Trial Research Group. Khan-Neelofur D, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:7-26 (24 ref.)
1998 update on pregnancy in lupus patients. New horizons, new hopes. Wechsler B, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):619-24 (66 ref.)
Perinatal infectious disease. Introduction. Duff P. **Semin Perinatol** 1998 Aug;22(4):241 (78 ref.)
Intrauterine effects of ultrasound: animal studies. Jensh RP, et al. **Teratology** 1999 Apr;59(4):240-51 (140 ref.)
The megalovirus [editorial] Ville Y. **Ultrasound Obstet Gynecol** 1998 Sep;12(3):151-3 (18 ref.)
[Pregnancy and malaria. Study of 143 cases in French Guyana] Carles G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27(8):798-805 (34 ref.) (Eng. Abstr.) **(Fre)**
[Gestational diabetes: prognostic significance for the infant] Géronooz I, et al. **Rev Med Liege** 1999 Jun;54(6):517-21 (16 ref.) (Eng. Abstr.) **(Fre)**
[Training and sports competition during pregnancy and after childbirth. Physical training is beneficial for mother and child] Henriksson-Larsén K. **Lakartidningen** 1999 Apr 28; 96(17):2097-100 (46 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. Weiss BM, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1643-53 (177 ref.)
Disinfection by-products and adverse pregnancy outcomes: what is the agent and how should it be measured? [editorial; comment] Swan SH, et al. **Epidemiology** 1998 Sep; 9(5):479-81 (13 ref.) Comment on: Epidemiology 1998 Sep;9(5):484-9.
Methodological issues in the study of rare exposures and rare outcomes in perinatal epidemiology. Bracken MB. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S354-5 (7 ref.)

PREGNANCY, PROLONGED

Sweeping of the membranes to prevent post-term pregnancy and to induce labour: a systematic review. Boulvain M, et al. **Br J Obstet Gynaecol** 1999 May;106(5):481-5 (21 ref.)
Epidemiology of cesarean sections: prolonged pregnancy. Scollo P. **Clin Exp Obstet Gynecol** 1999;26(1):22-6 (25 ref.)
[Overdue term of pregnancy: current concepts] Gaudet R, et al. **Contracept Fertil Sex** 1999 May;27(5):329-34 (40 ref.) **(Fre)**

PREGNANCY PROTEINS

Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Persico MG, et al. **Curr Top Microbiol Immunol** 1999;237:31-40 (33 ref.)
Trophoblast interferons. Roberts RM, et al. **Placenta** 1999 May;20(4):259-64 (60 ref.)

ANALYSIS

[Usefulness of selected circulating biochemical markers in diagnosis and monitoring of endometriosis] Wieczorek J, et al. **Ginekol Pol** 1999 Mar;70(3):161-5 (41 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

Early pregnancy factor: an extracellular chaperonin 10 homologue. Morton H. **Immunol Cell Biol** 1998 Dec; 76(6):483-96 (133 ref.)

METABOLISM

The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. Linzer DI, et al. **Mol Endocrinol** 1999 Jun;13(6):837-40 (16 ref.)

PHYSIOLOGY

Placenta growth factor: potential role in pregnancy. Torry DS, et al. **Am J Reprod Immunol** 1999 Jan;41(1):79-85 (64 ref.)
IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Martal JL, et al. **Biochimie** 1998 Aug-Sep;80(8-9):755-77 (236 ref.)
Glycodelins: biological activity in reproduction and differentiation. Seppälä M. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):261-3 (15 ref.)
Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Seppälä M, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:262-9; discussion 270 (39 ref.)

PREGNANCY REDUCTION, MULTIFETAL

First-trimester multifetal pregnancy reduction: evaluation of technical aspects and risks from 2,756 cases in the literature. Dechaud H, et al. **Fetal Diagn Ther** 1998 Sep-Oct; 13(5):261-5 (35 ref.)
Should multifetal pregnancy reduction be used for prevention of preterm deliveries in triplet or higher order multiple pregnancies? Papiernik E, et al. **J Perinat Med** 1998; 26(5):365-70 (22 ref.)

METHODS

Multifetal pregnancy reduction. Evans MI, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):147-59 (27 ref.)

PREGNANCY, TEENAGE see **PREGNANCY IN ADOLESCENCE**

PREGNANCY, THIRD TRIMESTER see **PREGNANCY TRIMESTER, THIRD**

PREGNANCY TRIMESTER, FIRST

Current progress in early pregnancy investigation. Polliotti BM. **Early Pregnancy** 1997 Sep;3(3):228-41 (49 ref.)

PREGNANCY TRIMESTER, THIRD

PHYSIOLOGY

[Maternal elimination diet during pregnancy and lactation, and the development of allergies in infants] Oldak E. **Pol Merkuriusz Lek** 1998 Dec;5(30):387-9 (29 ref.) (Eng. Abstr.) **(Pol)**

PREGNANCY, TUBAL

DRUG THERAPY

The effectiveness of non-surgical management of early interstitial pregnancy: a report of ten cases and review of the literature. Hafner T, et al. **Ultrasound Obstet Gynecol** 1999 Feb;13(2):131-6 (30 ref.)

THERAPY

Expectant management of ectopic pregnancy. Cohen MA, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):48-54; quiz 55-6 (22 ref.)

ULTRASONOGRAPHY

Three-dimensional power Doppler imaging of the fallopian tube. Sladkevicius P. **Ultrasound Obstet Gynecol** 1999 Apr; 13(4):287 (2 ref.)

PREGNANCY, UNWANTED

Pregnancy during adolescence: wanted vs. unwanted. Pinto e Silva JL. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S151-6 (14 ref.)
Sex education in school: preventing unwanted pregnancy in adolescents. Saito MI. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S157-60 (17 ref.)
Unintended pregnancy. Consequences and solutions for a worldwide problem. Klima CS. **J Nurse Midwifery** 1998 Nov-Dec;43(6):483-91 (39 ref.)
Prevention and medical management of unwanted pregnancy: the physician's role. Kothari S. **J Womens Health** 1999 Jan-Feb;8(1):59-64 (22 ref.)
Managed care and unintended pregnancy: testing the limits of prevention. Gonen JS. **Womens Health Issues** 1999 Mar-Apr;9(2 Suppl):26S-35S (24 ref.)

PREGNANOLONE

BIOSYNTHESIS

Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Guidotti A, et al. **Biol Psychiatry** 1998 Nov 1;44(9):865-73 (42 ref.)

PREGNATRIENES

PHARMACOLOGY

The effect of 21-aminosteroids on endotoxin-induced TNF-alpha release [editorial; comment] Kimura RE, et al. **Crit Care Med** 1999 Jun;27(6):1058-9 (7 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1164-7.

THERAPEUTIC USE

Schemes against ischemia; solutions for reperfusion (injury)? [editorial; comment] Barie PS. **Crit Care Med** 1999 Apr; 27(4):684-5 (11 ref.) Comment on: Crit Care Med 1999 Apr;27(4):764-70.
The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage. Dorsch NW. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:156-60 (13 ref.)
[Indications for steroid and tirilazad treatment in patients with subarachnoid hemorrhage] Tommasino C, et al. **Minerva Anestesiol** 1998 May;64(5):225-7 (12 ref.) (Eng. Abstr.) **(Ita)**

PREGNENOLONE

BIOSYNTHESIS

Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Miller WL. **Clin Perinatol** 1998 Dec;25(4):799-817, v (104 ref.)

PREHOSPITAL EMERGENCY CARE see **EMERGENCY MEDICAL SERVICES**

PREIMPLANTATION DIAGNOSIS

see related
PREIMPLANTATION PHASE
PRENATAL DIAGNOSIS

Screening oocytes and preimplantation embryos for aneuploidy. Handyside AH, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):301-5 (28 ref.)
Genetics, age, and infertility. Nasseri A, et al. **Maturitas** 1998 Oct 12;30(2):189-92 (21 ref.)

TRENDS

The future of preimplantation genetic diagnosis. Handyside AH, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:249-55 (22 ref.)

PREIMPLANTATION GENETIC DIAGNOSIS see **PREIMPLANTATION DIAGNOSIS**

PREIMPLANTATION PHASE

see related
PREIMPLANTATION DIAGNOSIS

Reflections on the culture of the preimplantation embryo. Biggers JD. **Int J Dev Biol** 1998;42(7 Spec No):879-84 (75 ref.)
Calcium signaling in human preimplantation development: a review. Tesarik J. **J Assist Reprod Genet** 1999 Apr; 16(4):216-20 (26 ref.)
Non-disclosure preimplantation genetic diagnosis for Huntington's disease: practical and ethical dilemmas. Braude PR, et al. **Prenat Diagn** 1998 Dec;18(13):1422-6 (17 ref.)
Clinical evaluation of preimplantation genetic diagnosis. Handyside AH. **Prenat Diagn** 1998 Dec;18(13):1345-8 (16 ref.)
The expression of genes in human preimplantation embryos. Pergament E, et al. **Prenat Diagn** 1998 Dec;18(13):1366-73 (55 ref.)
Chromosome translocations: segregation modes and strategies for preimplantation genetic diagnosis [see comments] Scriven PN, et al. **Prenat Diagn** 1998 Dec; 18(13):1437-49 (31 ref.) Comment in: Prenat Diagn 1998 Dec;18(13):1343-4.
Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Wells D, et al. **Prenat Diagn** 1998 Dec;18(13):1389-401 (78 ref.)

IMMUNOLOGY

A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and feto-maternal interactions. Fernandez N, et al. **Hum Reprod Update** 1999 May-Jun;5(3):234-48 (154 ref.)

PREJUDICE

An analysis of genetic discrimination legislation proposed by the 105th congress. Colby JA. **Am J Law Med** 1998;

PREJUDICE

24(4):443–80 (0 ref.)
Protecting genetic privacy by permitting employer access only to job-related employee medical information: analysis of a unique Minnesota law. Rothstein MA, et al. **Am J Law Med** 1998;24(4):399–416 (0 ref.)
Colonizing images and diagnostic labels: oppressive mechanisms for African American women's health. Taylor JY. **ANS Adv Nurs Sci** 1999 Mar;21(3):32–45 (58 ref.)
Stewardship of the aged: meeting the ethical challenge of ageism. In honor of Joseph Fletcher. Thomasma DC. **Camb Q Healthc Ethics** 1999 Spring;8(2):148–59 (38 ref.)
Racial variation in cancer care: a case study of prostate cancer. Horner RD. **Cancer Treat Res** 1998;97:99–114 (56 ref.)
Sex or body size? Selection of dialysis type revisited [editorial; comment] Levin A. **CMAJ** 1999 Mar 23; 160(6):828–9 (10 ref.) Comment on: CMAJ 1999 Mar 23;160(6):818–9.
U.S. Senate Bill 422: the Genetic Confidentiality and Nondiscrimination Act of 1997. Berman JJ, et al. **Diagn Mol Pathol** 1998 Aug;7(4):192–6 (3 ref.)
Embodying inequality: a review of concepts, measures, and methods for studying health consequences of discrimination. Krieger N. **Int J Health Serv** 1999; 29(2):295–352 (338 ref.)
Homophobia: an evolutionary analysis of the concept as applied to nursing. Richmond JP, et al. **J Adv Nurs** 1998 Aug;28(2):362–9 (95 ref.)
Asymptomatic HIV under the ADA: the invisible, yet legitimate disability. Davis CS. **J Contemp Health Law Policy** 1998 Fall;15(1):357–400 (0 ref.)
Broad statutory language is not ambiguous: the Americans with Disabilities Act applies in state prisons. Hoppe SB. **J Contemp Health Law Policy** 1998 Fall;15(1):275–305 (0 ref.)
Culture and systems of oppression in abused women's lives. Phillips DS. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):678–83 (16 ref.)
The dark side of nursing: impact of stigmatizing responses on patients. Corley MC, et al. **Sch Inq Nurs Pract** 1998 Summer;12(2):99–118; discussion 119–22 (83 ref.)
The primary care of elder mistreatment. Hirsch CH, et al. **West J Med** 1999 Jun;170(6):353–8 (25 ref.)
[Schizophrenia--an illness and its treatment reflected in public attitude] Schöny W. **Wien Med Wochenschr** 1998; 148(11–12):284–8 (18 ref.) (Eng. Abstr.) **(Ger)**

PREKALLIKREIN

see related
COAGULANTS

DEFICIENCY

[Prekallikrein deficiency (Fletcher trait)] Isobe J. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):468–70 (16 ref.) **(Jpn)**

PRELEUKEMIA

VIROLOGY

Possible retroviral origin of prion disease: could prion disease be reconsidered as a preleukemia syndrome? Labat ML. **Biomed Pharmacother** 1999;53(1):47–53 (60 ref.)

PREMATURE AGING see **AGING, PREMATURE**

PREMATURE VENTRICULAR BEATS see **VENTRICULAR PREMATURE COMPLEXES**

PREMATURE VENTRICULAR CONTRACTIONS see **VENTRICULAR PREMATURE COMPLEXES**

PREMEDICATION

see related
ANTIBIOTIC PROPHYLAXIS
PREANESTHETIC MEDICATION
Liquid perfluorochemical priming before surfactant therapy: this time the egg really does precede the chicken [editorial; comment] Baumgart S, et al. **Crit Care Med** 1999 Sep; 27(9):2053–4 (15 ref.) Comment on: Crit Care Med 1999 Sep;27(9):1916–22.
[Use of clonidine for perioperative therapy] Fidziańska-Długosz E. **Przegl Lek** 1998;55(5):284–7 (34 ref.) (Eng. Abstr.) **(Pol)**
[Present-day concepts concerning immunoprophylaxis and immunotherapy of surgical infections] Pinegin BV, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):61–7 (35 ref.) **(Rus)**

METHODS

Premedication, preparation, and surveillance. Lazzaroni M, et al. **Endoscopy** 1999 Jan;31(1):2–8 (50 ref.)

PREMEDICATION, ANTIBIOTIC see **ANTIBIOTIC PROPHYLAXIS**

PREMENOPAUSE

Oral contraceptive use during the perimenopausal years. Van Winter JT, et al. **Am Fam Physician** 1998 Oct 15; 58(6):1373–7, 1381–2 (22 ref.)
Hilus cell tumour of the ovary in a virilized, premenopausal woman. Case report and review of hyperandrogenism of ovarian origin. Moore A, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):75–8 (16 ref.)
Perimenopausal weight gain and progression of breast cancer precursors. Stoll BA. **Cancer Detect Prev** 1999;23(1):31–6 (67 ref.)
Management of perimenopause: focus on alternative therapies. Thacker HL, et al. **Cleve Clin J Med** 1999 Apr; 66(4):213–8 (9 ref.)
Helping women through the perimenopause. Overton C, et al. **Practitioner** 1999 Jun;243(1599):502–8 (9 ref.)

DRUG EFFECTS

Natural menopause and ovarian toxicity associated with breast cancer therapy. Knobf MT. **Oncol Nurs Forum** 1998 Oct;25(9):1519–30; quiz 1531–2 (131 ref.)
[Psychic effects of an adjuvant hormone replacement therapy in premenopausal patients: influence on the quality of life] Springer-Kremser M. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):109–11 (8 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The impact of age on reproductive potential: lessons learned from oocyte donation. Sauer MV. **Maturitas** 1998 Oct 12; 30(2):221–5 (23 ref.)

PSYCHOLOGY

Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Burt VK, et al. **Harv Rev Psychiatry** 1998 Sep–Oct;6(3):121–32 (55 ref.)
Clinical evaluation in studies of perimenopausal women: position paper. Schmidt PJ, et al. **Psychopharmacol Bull** 1998;34(3):309–11 (19 ref.)

PREMENSTRUAL SYNDROME

[Modern aspects of the premenstrual syndrome] Dragojević-Dikić S. **Srp Arh Celok Lek** 1998 Jul–Aug; 126(7–8):304–8 (23 ref.) (Eng. Abstr.) **(Scc)**

DIAGNOSIS

Premenstrual syndrome: diagnosis and intervention. Ugarriza DN, et al. **Nurse Pract** 1998 Sep;23(9):40, 45, 49–52 passim (63 ref.)
Premenstrual syndrome. Pearlstein T, et al. **Psychiatr Clin North Am** 1998 Sep;21(3):577–90 (90 ref.)

DRUG THERAPY

Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. Wyatt KM, et al. **BMJ** 1999 May 22;318(7195):1375–81 (52 ref.)
The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Romano S, et al. **Clin Ther** 1999 Apr; 21(4):615–33; discussion 613 (67 ref.)
Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Eriksson E. **Int Clin Psychopharmacol** 1999 May;14 Suppl 2:S27–33 (36 ref.)
Androgen treatment in women. Davis SR. **Med J Aust** 1999 Jun 7;170(11):545–9 (44 ref.)
Micronized progesterone: a new option for women's health care. Wetzel W. **Nurse Pract** 1999 May;24(5):62–6, 71, 75–6 (29 ref.)

ETIOLOGY

Premenstrual syndrome, neuroactive steroids and the brain. Sundström I, et al. **Gynecol Endocrinol** 1999 Jun; 13(3):206–20 (160 ref.)

PHYSIOPATHOLOGY

Premenstrual syndromes: closing the 20th century chapters. Halbreich U. **Curr Opin Obstet Gynecol** 1999 Jun; 11(3):265–70 (121 ref.)
Premenstrual syndrome, neuroactive steroids and the brain. Sundström I, et al. **Gynecol Endocrinol** 1999 Jun; 13(3):206–20 (160 ref.)

PSYCHOLOGY

Pharmacologic treatment of depression in women: PMS, pregnancy, and the postpartum period. Cohen LS. **Depress Anxiety** 1998;8 Suppl 1:18–26 (102 ref.)
Premenstrual syndromes. Freeman EW, et al. **Psychopharmacol Bull** 1998;34(3):291–5 (38 ref.)
Mood disorders and the reproductive cycle: affective disorders during the menopause and premenstrual dysphoric disorder. Haynes P, et al. **Psychopharmacol Bull** 1998;34(3):313–8 (57 ref.)

THERAPY

Premenstrual syndrome: diagnosis and intervention. Ugarriza DN, et al. **Nurse Pract** 1998 Sep;23(9):40, 45, 49–52 passim (63 ref.)

PREMENSTRUAL TENSION see **PREMENSTRUAL SYNDROME**

PRENATAL CARE

Adverse effects of prenatal glucocorticoid treatment in the preterm infant. Rubaltelli FF, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:35–8 (25 ref.)
ABC of labour care: place of birth. Zander L, et al. **BMJ** 1999 Mar 13;318(7185):721–3 (0 ref.)
Mother–child pass in Austria and primary toxoplasmosis infections in pregnant women. Moese JR, et al. **Cent Eur J Public Health** 1998 Nov;6(4):261–4 (9 ref.)
Psychosocial impact of high-risk pregnancy: hospital and home care. Heaman M. **Clin Obstet Gynecol** 1998 Sep; 41(3):626–39 (52 ref.)
Unexplained elevated maternal serum alpha-fetoprotein: what is the appropriate follow-up? Wilkins-Haug L. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):469–74 (24 ref.)
ACOG educational bulletin. Special problems of multiple gestation. Number 253, November 1998 (Replaces Number 131, August 1989). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Mar; 64(3):323–33 (65 ref.)
Medication use during the perinatal period [see comments] Briggs GG. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec; 38(6):717–26; quiz 726–7 (97 ref.) Comment in: J Am Pharm Assoc (Wash) 1999 Mar–Apr;39(2):119.
Homeopathic remedies in prenatal care. Brennan P. **J Nurse Midwifery** 1999 May–Jun;44(3):291–9 (20 ref.)
Technology and family-centered perinatal care: conflict or synergy? Gordin P, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):401–8 (28 ref.)
Fetal surgery: exploring the challenges in nursing care. Howell LJ, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):427–32 (17 ref.)
Bedside musical care: applications in pregnancy, childbirth, and neonatal care. Olson SL. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):569–75 (33 ref.)
Prenatal diagnosis of bladder exstrophy: what counseling? Cacciari A, et al. **J Urol** 1999 Jan;161(1):259–61; discussion 262 (32 ref.)
Medical aspects of pregnancy. Thacker HL. **J Womens Health** 1999 Apr;8(3):335–46 (20 ref.)
Maternal shunt dependency: implications for obstetric care, neurosurgical management, and pregnancy outcomes and a review of selected literature. Bradley NK, et al. **Neurosurgery** 1998 Sep;43(3):448–60; discussion 460–1 (15 ref.)
Key developments in obstetrics. Hurley P. **Practitioner** 1998 Feb;242(1583):110, 113 (6 ref.)
Antenatal glucocorticoid, magnesium exposure, and the prevention of brain injury of prematurity. Perlman JM. **Semin Pediatr Neurol** 1998 Sep;5(3):202–10 (89 ref.)
[Consensus conference on prenatal care, delivery, and the newborn. Paris, France, 2–3 December 1998. Proceedings] **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:1–317 (0 ref.) **(Fre)**
[Prenatal protection. Regulations. Perinatal mortality. Epidemiology] Kremp O. **Rev Prat** 1998 Jun 1; 48(11):1233–8 (0 ref.) **(Fre)**
[Prenatal medicine--guarantee of a health child? Janus-head Medical advances] Hepp H. **Zentralbl Gynakol** 1999;121 Suppl 1:4–15 (35 ref.) **(Ger)**

ECONOMICS

Economics of antenatal prophylaxis. Cairns JA. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:19–22 (12 ref.)
Personal costs associated with high-risk prenatal care attendance. Stringer M. **J Health Care Poor Underserved** 1998 Aug;9(3):222–35 (38 ref.)

LEGISLATION & JURISPRUDENCE

[Current prenatal care with reference to state of the art knowledge] Vogt HP. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1654–66 (42 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Obstetric management of high-order multiple pregnancies. Newman RB. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):109–29 (84 ref.)
ABC of labour care: obstetric emergencies. Chamberlain G, et al. **BMJ** 1999 May 15;318(7194):1342–5 (5 ref.)
ABC of labour care: unusual presentations and positions and multiple pregnancy. Chamberlain G, et al. **BMJ** 1999 May 1;318(7192):1192–4 (0 ref.)
ABC of labour care: labour in special circumstances. Chamberlain G, et al. **BMJ** 1999 Apr 24;318(7191):1124–7 (0 ref.)
ABC of labour care: physiology and management of normal labour. Steer P, et al. **BMJ** 1999 Mar 20;318(7186):793–6 (0 ref.)
ABC of labour care: assessment of mother and fetus in labour. Steer P. **BMJ** 1999 Mar 27;318(7187):858–61 (0 ref.)
Antenatal corticosteroids in preterm premature rupture of membranes. Chen B, et al. **Clin Obstet Gynecol** 1998 Dec;

41(4):832–41 (40 ref.)
Ambulatory obstetric management. Cohen AW.
Clin Obstet Gynecol 1998 Sep;41(3):481–90 (18 ref.)
Ambulatory obstetrical care: strategies to reduce telephone liability. Phelan JP. **Clin Obstet Gynecol** 1998 Sep; 41(3):640–6 (22 ref.)
Endocrine analytes in multiple-marker screening. Lambert-Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963–81, vii (95 ref.)
Appropriate technology: antenatal care. Lumbiganon P. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S91–5 (29 ref.)
Assessment and management of pregnancy complicated by pregestational diabetes mellitus. Wiznitzer A, et al. **Pediatr Ann** 1999 Sep;28(9):605–13 (44 ref.)
Graves' Disease during pregnancy--results of antithyroid drug therapy. Dwarakanath CS, et al. **Singapore Med J** 1999 Feb;40(2):70–3 (12 ref.)
[Management of pregnant women and newborns in low-risk pregnancies. Evaluation of the literature] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:8–20 (52 ref.) **(Fre)**
[Management of pregnant women and newborns in high-risk pregnancies] Grandjean H, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:21–36 (102 ref.) **(Fre)**
[Obstetric treatment of hemophilia carriers] Aguilar C, et al. **Sangre (Barc)** 1998 Oct;43(5):399–405 (71 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Psychosocial support or active management of labour or both to improve the outcome of labour. Arulkumaran S, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):617–9 (17 ref.)
Who should provide routine antenatal care for low-risk women, and how often? A systematic review of randomised controlled trials. WHO Antenatal Care Trial Research Group. Khan-Neelofur D, et al.
Paediatr Perinat Epidemiol 1998 Oct;12 Suppl 2:7–26 (24 ref.)

STANDARDS

Available instruments for research on prenatal attachment and adaptation to pregnancy. Beck CT.
MCN Am J Matern Child Nurs 1999 Jan–Feb;24(1):25–32 (47 ref.)

UTILIZATION

Improving prenatal care services for low-income African American women and infants [editorial] Sanders-Phillips K, et al. **J Health Care Poor Underserved** 1998 Feb; 9(1):14–29 (96 ref.)

PRENATAL DIAGNOSIS

see related
GENETIC COUNSELING
PREIMPLANTATION DIAGNOSIS

Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses [letter] Bradley LA, et al.
Am J Med Genet 1999 Feb 12;82(4):355–8 (23 ref.)
Undiagnosed maternal phenylketonuria: the need for prenatal selective screening or case finding. Hanley WB, et al.
Am J Obstet Gynecol 1999 Apr;180(4):986–94 (25 ref.)
What should be the role of public health in newborn screening and prenatal diagnosis? Clayton EW.
Am J Prev Med 1999 Feb;16(2):111–5 (20 ref.)
Who should be offered prenatal diagnosis? The 35-year-old question. Kuppermann M, et al. **Am J Public Health** 1999 Feb;89(2):160–3 (31 ref.)
Intrauterine fetal diagnosis for hematologic and other congenital disorders. Kramer K, et al. **Clin Lab Med** 1999 Mar;19(1):239–53, vii–viii (98 ref.)
Fetal uropathy. Johnson MP, et al.
Curr Opin Obstet Gynecol 1999 Apr;11(2):185–94 (40 ref.)
Twin pregnancy. Al-Kouatly HB, et al.
Curr Opin Obstet Gynecol 1999 Apr;11(2):125–9 (31 ref.)
Perinatal management of fetal malformations amenable to surgical correction. Milner R, et al.
Curr Opin Obstet Gynecol 1999 Apr;11(2):177–83 (38 ref.)
Prenatal diagnosis of haemophilia. Ljung RC.
Haemophilia 1999 Mar;5(2):84–7 (17 ref.)
Carrier testing and prenatal diagnosis of haemophilia--utilisation and psychological consequences. Tedgård U. **Haemophilia** 1998 Jul;4(4):365–9 (29 ref.)
Parvovirus B19 infection in pregnancy. Eis-Hübinger AM, et al. **Intervirology** 1998;41(4–5):178–84 (59 ref.)
Fetal oxygenation, assessment of fetal well-being, and obstetric management of the pregnant patient with asthma. Cousins L. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S343–9 (32 ref.)
Prenatal diagnosis as a test for genodermatoses: its past, present and future. Shimizu H, et al. **J Dermatol Sci** 1999 Jan;19(1):1–8 (57 ref.)
Natural history of Down's syndrome: a brief review for those involved in antenatal screening. Noble J. **J Med Screen** 1998;5(4):172–7 (40 ref.)
Fetal surgery: exploring the challenges in nursing care. Howell LJ, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):427–32 (17 ref.)
Prenatal screening with evaluated high risk scores. Papiernik E, et al. **J Perinat Med** 1999;27(1):21–5 (6 ref.)
Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. Carlson AD, et al.
J Steroid Biochem Mol Biol 1999 Apr–Jun;69(1–6):19–29 (23 ref.)
Urinary analyte screening: a noninvasive detection method for Down syndrome? Canick JA, et al.
Mol Med Today 1999 Feb;5(2):68–73 (29 ref.)
Ethical considerations in prenatal surgical consultation [see comments] Caniano DA, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):303–9 (21 ref.) Comment in: Pediatr Surg Int 1999 Jul;15(5–6):301–2.
Prenatally diagnosed cystic neuroblastoma. Hamada Y, et al. **Pediatr Surg Int** 1999;15(1):71–4 (19 ref.)
Partial moles: from postnatal to prenatal diagnosis. Jauniaux E. **Placenta** 1999 Jul–Aug;20(5–6):379–88 (60 ref.)
Prenatal diagnosis of Smith-Lemli-Opitz syndrome in a pregnancy with low maternal serum oestriol and a sex-reversed fetus. Bick DP, et al. **Prenat Diagn** 1999 Jan; 19(1):68–71 (16 ref.)
Prenatal detection of a 1p36 deletion in a fetus with multiple malformations and a review of the literature. Faivre L, et al. **Prenat Diagn** 1999 Jan;19(1):49–53 (20 ref.)
Prenatal diagnosis of an 8p23.1 deletion in a fetus with a diaphragmatic hernia and review of the literature. Faivre L, et al. **Prenat Diagn** 1998 Oct;18(10):1055–60 (24 ref.)
Prenatal diagnosis of a satellited non-acrocentric chromosome derived from a maternal translocation (10;13)(p13;p12) and review of literature. Faivre L, et al. **Prenat Diagn** 1999 Mar;19(3):282–6 (16 ref.)
Prenatal detection of extra structurally abnormal chromosomes (ESACs): new cases and a review of the literature. Hastings RJ, et al. **Prenat Diagn** 1999 May; 19(5):436–45 (48 ref.)
Tuberous sclerosis with intracardiac rhabdomyoma in a fetus with trisomy 21: case report and review of literature. Krapp M, et al. **Prenat Diagn** 1999 Jul;19(7):610–3 (26 ref.)
Prenatal diagnosis of Canavan disease. Matalon R, et al.
Prenat Diagn 1999 Jul;19(7):669–70 (8 ref.)
Prenatal diagnosis of Friedreich ataxia. Pandolfo M, et al.
Prenat Diagn 1998 Aug;18(8):831–3 (15 ref.)
Magnetic resonance imaging of the fetal brain. Bilaniuk LT.
Semin Roentgenol 1999 Jan;34(1):48–61 (32 ref.)
Prenatal magnetic resonance imaging of fetal anomalies. Hubbard AM, et al. **Semin Roentgenol** 1999 Jan;34(1):41–7 (42 ref.)
Screening programmes for foetomaternal alloimmune thrombocytopenia. Williamson LM. **Vox Sang** 1998;74 Suppl 2:385–9 (32 ref.)
[Human chorionic gonadotropin, its degradation products and possibilities of their use] Hrehorčák M, et al.
Ceska Gynekol 1999 Apr;64(2):108–13 (62 ref.) **(Cze)**
[Cleft lip and palate--prenatal diagnosis and counseling] Hrušková H, et al. **Ceska Gynekol** 1998 Oct;63(5):382–7 (32 ref.) (Eng. Abstr.) **(Cze)**
[Unusual behavior of serum markers in risk evaluation for trisomy 21] Guibaud S, et al. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):439–44 (31 ref.) (Eng. Abstr.) **(Fre)**
[Prenatal diagnosis of chylothorax] Dendale J, et al.
Arch Pediatr 1999 Aug;6(8):867–71 (33 ref.) (Eng. Abstr.) **(Fre)**
[Nuclear magnetic resonance brain imaging in the prenatal period] Girard N, et al. **Arch Pediatr** 1998;5 Suppl 2:171s–174s (27 ref.) **(Fre)**
[Prenatal diagnosis and outcome of patients with spina bifida] Gressens P, et al. **Arch Pediatr** 1998 Sep;5(9):1004–8 (10 ref.) (Eng. Abstr.) **(Fre)**
[Treatment and decision tree in ante- and perinatal neurologic pathology] Marret S, et al. **Arch Pediatr** 1998; 5 Suppl 2:174s–179s (21 ref.) **(Fre)**
[Contributions and expectations of molecular genetics in perinatal neurologic diagnosis] Mathieu M. **Arch Pediatr** 1998;5 Suppl 2:179s–181s (15 ref.) **(Fre)**
[Ethical problems within the context of genetic counseling and diagnosis] Murken J. **Internist (Berl)** 1999 Mar; 40(3):286–93 (14 ref.) **(Ger)**
[Prenatal diagnosis and therapy of feto-fetal transfusion syndrome] Mielke G, et al. **Z Geburtshilfe Neonatol** 1998 Jul–Aug;202(4):141–8 (87 ref.) (Eng. Abstr.) **(Ger)**
[Prenatal medicine--guarantee of a health child? Janus-head Medical advances] Hepp H. **Zentralbl Gynakol** 1999;121 Suppl 1:4–15 (35 ref.) **(Ger)**
[The antenatal diagnosis of cystic adenomatoid malformation of the lung. Apropos 2 cases] Tabuenca Guitart Y, et al. **An Esp Pediatr** 1998 Dec;49(6):631–4 (15 ref.) **(Spa)**

INSTRUMENTATION

Nurse versus machine: slaves or masters of technology? Buus-Frank M. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):433–41 (42 ref.)

METHODS

Management of choroid plexus cysts in the mid-trimester fetus. Choong S, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):7–11 (20 ref.)
Screening for fetal abnormalities in multiple pregnancies. Sebire NJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):19–36 (67 ref.)
Prenatal typing of fetal DNA in cases of potential alloimmune haemolytic disease of the newborn: clinical benefit outweighs disadvantage. Shields JA. **Br J Biomed Sci** 1999; 56(1):49–55 (31 ref.)
Fetal cells in the maternal circulation: feasibility for prenatal diagnosis. Bianchi DW. **Br J Haematol** 1999 Jun; 105(3):574–83 (126 ref.)
Prenatal screening for chromosome abnormalities. Chitty L. **Br Med Bull** 1998;54(4):839–56 (90 ref.)
Prenatal diagnosis on fetal cells from maternal blood: approaches and perspectives [editorial] Oosterwijk JC.
Eur J Obstet Gynecol Reprod Biol 1999 Feb;82(2):169–70 (15 ref.)
Variability of adjustments to indices in determining patient risk in biochemical screening. Brooks K, et al.
Fetal Diagn Ther 1999 Jan–Feb;14(1):41–6 (45 ref.)
Diagnosis and management of intrauterine growth retardation. Lepercq J, et al. **Horm Res** 1998;49 Suppl 2:14–9 (53 ref.)
Prenatal screening for Down syndrome. Ogle RF, et al.
Hosp Med 1998 Aug;59(8):632–6 (22 ref.)
Fetal cells from maternal blood: purpose, biological questions, technical challenges. Bohmer RM.
Intervirology 1998;41(4–5):226–31 (14 ref.)
Ultrafast fetal MR images of intracranial teratoma. Peng SS, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):318–9 (8 ref.)
What's new in perinatology. Chescheir NC, et al.
Pediatr Rev 1999 Feb;20(2):57–63 (11 ref.)
Clinical evaluation of preimplantation genetic diagnosis. Handyside AH. **Prenat Diagn** 1998 Dec;18(13):1345–8 (16 ref.)
Recent advances in molecular and molecular cytogenetic techniques have enabled the diagnosis of some inherited diseases from a single cell [editorial; comment] Harper J, et al. **Prenat Diagn** 1998 Dec;18(13):1343–4 (14 ref.) Comment on: Prenat Diagn 1998 Dec;18(13):1437–49.
Chromosome translocations: segregation modes and strategies for preimplantation genetic diagnosis [see comments] Scriven PN, et al. **Prenat Diagn** 1998 Dec; 18(13):1437–49 (31 ref.) Comment in: Prenat Diagn 1998 Dec;18(13):1343–4.
Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Wells D, et al.
Prenat Diagn 1998 Dec;18(13):1389–401 (78 ref.)
Antenatal genotyping of the blood groups of the fetus. Avent ND. **Vox Sang** 1998;74 Suppl 2:365–74 (74 ref.)
[Discordant fetal growth in multiple pregnancy: intervention should be based on chorionicity] van Heteren CF, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1017–21 (13 ref.) (Eng. Abstr.) **(Dut)**
[Fetal trisomy 21 risk evaluation by measurement of maternal serum markers] Dhondt JL. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):471–5 (11 ref.) **(Fre)**
[Fetal cells in the maternal blood: a step towards non-invasive prenatal diagnosis? Review of the literature] Houfflin-Debarge V, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Sep;27(5):483–93 (83 ref.) (Eng. Abstr.) **(Fre)**
[Genetic counseling and prenatal diagnosis in mitochondrial diseases] Klopstock T, et al. **Nervenarzt** 1999 Jun; 70(6):504–8 (21 ref.) (Eng. Abstr.) **(Ger)**
[The prenatal diagnosis of hydronephrosis, when and why to operate?] González R, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):575–9 (18 ref.) (Eng. Abstr.) **(Spa)**
[The prenatal diagnosis of hydronephrosis: when and why NOT to operate?] Koff SA. **Arch Esp Urol** 1998 Jul–Aug; 51(6):569–74 (18 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Technology and family-centered perinatal care: conflict or synergy? Gordin P, et al.
J Obstet Gynecol Neonatal Nurs 1999 Jul–Aug;28(4):401–8 (28 ref.)

TRENDS

Screening for aneuploidy. Evans MI, et al.
Curr Opin Obstet Gynecol 1999 Apr;11(2):115–8 (34 ref.)
Gestational diabetes mellitus: controversies and current opinions. Khandelwal M, et al.
Curr Opin Obstet Gynecol 1999 Apr;11(2):157–65 (75 ref.)
Perinatal testing. Testing times for pregnant women. Dezateux C, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV24 (5 ref.)

PRENATAL DIAGNOSIS, ULTRASONIC see
ULTRASONOGRAPHY, PRENATAL

PRENATAL EXPOSURE DELAYED EFFECTS

see related
MATERNAL EXPOSURE
PATERNAL EXPOSURE

Prenatal exposure to ionizing radiation: sources, effects and regulatory aspects. Fattibene P, et al. **Acta Paediatr** 1999 Jul;88(7):693–702 (58 ref.)
Potential mechanisms of metabolic imprinting that lead to chronic disease. Waterland RA, et al. **Am J Clin Nutr** 1999 Feb;69(2):179–97 (13 ref.)
The Barker hypothesis. An analysis. Wilson J.
Aust N Z J Obstet Gynaecol 1999 Feb;39(1):1–7 (36 ref.)
Fetal origins of adult disease--the hypothesis revisited. Lucas A, et al. **BMJ** 1999 Jul 24;319(7204):245–9 (55 ref.)
Prenatal factors and adult mental and physical health [see

comments] Susser EB, et al. **Can J Psychiatry** 1999 May; 44(4):326–34 (79 ref.) Comment in: Can J Psychiatry 1999 May;44(4):325.
Perinatal effects of prenatal drug exposure. Neonatal aspects. Bauer CR. **Clin Perinatol** 1999 Mar;26(1):87–106 (181 ref.)
Early development of infants exposed to drugs prenatally. Eyler FD, et al. **Clin Perinatol** 1999 Mar;26(1):107–50, vii (146 ref.)
Treatment strategies for drug-exposed neonates. Kandall SR. **Clin Perinatol** 1999 Mar;26(1):231–43 (68 ref.)
Physiologic programming of the fetus. Seckl JR. **Clin Perinatol** 1998 Dec;25(4):939–62, vii (171 ref.)
Prenatal drug exposure and child outcome. Past, present, future. Smeriglio VL, et al. **Clin Perinatol** 1999 Mar; 26(1):1–16 (61 ref.)
Prenatal cocaine exposure, child development, and the compromising effects of cumulative risk. Tronick EZ, et al. **Clin Perinatol** 1999 Mar;26(1):151–71 (104 ref.)
Impact of addictive and harmful substances on fetal brain development. Ferriero DM, et al. **Curr Opin Neurol** 1999 Apr;12(2):161–6 (54 ref.)
Birth weight and the future development of diabetes. A review of the evidence. Phillips DI. **Diabetes Care** 1998 Aug;21 Suppl 2:B150–5 (41 ref.)
Prenatal effects of drugs of abuse on brain development. Levitt P. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):109–25 (224 ref.)
Methods used to detect drug abuse in pregnancy: a brief review. Strano-Rossi S. **Drug Alcohol Depend** 1999 Feb 1;53(3):257–71 (98 ref.)
Annotation: the psychological development and welfare of children of opiate and cocaine users: review and research needs. Hogan DM. **J Child Psychol Psychiatry** 1998 Jul; 39(5):609–20 (70 ref.)
Environmental chemicals and child development [editorial; comment] Dietrich KN. **J Pediatr** 1999 Jan;134(1):7–9 (18 ref.) Comment on: J Pediatr 1999 Jan;134(1):33–41.
Early antecedents of adult health. Susser E, et al. **J Urban Health** 1998 Jun;75(2):236–41 (12 ref.)
The influence of maternal diet on breast cancer risk among female offspring. Hilakivi-Clarke L, et al. **Nutrition** 1999 May;15(5):392–401 (148 ref.)
Prenatal oestrogens and breast cancer. Lumey LH. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):361–5 (34 ref.)
Prenatal exposures and childhood cancer. Bolande RP. **Pediatr Dev Pathol** 1999 May–Jun;2(3):208–14 (74 ref.)
Perinatal determinants of adult cardiovascular disease and cancer. Signorello LB, et al. **Scand J Soc Med** 1998 Sep; 26(3):161–5 (57 ref.)
Childhood and adult cancer after intrauterine exposure to ionizing radiation. Boice JD Jr, et al. **Teratology** 1999 Apr; 59(4):227–33 (60 ref.)
Intrauterine effects of ultrasound: animal studies. Jensh RP, et al. **Teratology** 1999 Apr;59(4):240–51 (140 ref.)
Cognitive function and prenatal exposure to ionizing radiation. Schull WJ, et al. **Teratology** 1999 Apr;59(4):222–6 (35 ref.)
Radioiodine and pregnancy. Gorman CA. **Thyroid** 1999 Jul; 9(7):721–6 (45 ref.)
Thyroid hormone and intellectual development: a clinician's view. Lazarus JH. **Thyroid** 1999 Jul;9(7):659–60 (12 ref.)
[Vertical HIV-1-transmission. I. Risk and prevention in pregnancy (see comments)] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12;142(50):2720–4 (27 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2720–4. **(Dut)**
[Intrauterine nutrition] Henriksen T, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3162–5 (36 ref.) (Eng. Abstr.) **(Nor)**

PRENEOPLASTIC CONDITIONS see **PRECANCEROUS CONDITIONS**

PRENIDATION PHASE see **PREIMPLANTATION PHASE**

PREOPERATIVE CARE

Current clinical concepts in perioperative anticoagulation. Hewitt RL, et al. **Am Surg** 1999 Mar;65(3):270–3 (15 ref.)
Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy [see comments] Povoski SP, et al. **Ann Surg** 1999 Aug;230(2):131–42 (54 ref.) Comment in: Ann Surg 1999 Aug;230(2):143–4.
Preoperative alcoholism and postoperative morbidity. Tonnesen H, et al. **Br J Surg** 1999 Jul;86(7):869–74 (53 ref.)
Preoperative assessment of pulmonary risk. Ferguson MK. **Chest** 1999 May;115(5 Suppl):58S–63S (59 ref.)
Preoperative cardiac risk assessment. Hollenberg SM. **Chest** 1999 May;115(5 Suppl):51S–57S (27 ref.)
Preoperative issues in clinical nutrition. McClave SA, et al. **Chest** 1999 May;115(5 Suppl):64S–70S (50 ref.)
Preparation of high-risk patients for major thoracic surgery. Bisson A, et al. **Chest Surg Clin N Am** 1998 Aug; 8(3):541–55, viii (58 ref.)
Presurgical strategies and epilepsy surgery in children: comparison of literature and personal experiences. Munari C, et al. **Childs Nerv Syst** 1999 Apr;15(4):149–57 (63 ref.)
The role of nutrition before and after transplantation [editorial; comment] Allard JP. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):313–4 (5 ref.) Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):315–21. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):323–7. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):329–33.
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Miller AR, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):624–33 (63 ref.)
Acetabular bone loss during revision total hip replacement: preoperative investigation and planning. Campbell DG, et al. **Instr Course Lect** 1999;48:43–56 (60 ref.)
Planning for revision total knee arthroplasty. Rand JA. **Instr Course Lect** 1999;48:161–6 (17 ref.)
Preoperative pulmonary evaluation. Smetana GW. **N Engl J Med** 1999 Mar 25;340(12):937–44 (69 ref.)
Endovascular therapy of brain AVMs prior to radiosurgery. Henkes H, et al. **Neurol Res** 1998 Sep;20(6):479–92 (29 ref.)
Perioperative management of selected problems in patients with rheumatic diseases. Shaw M, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):623–38, ix (58 ref.)
The role of arterial embolization in renal cell carcinoma. Kalman D, et al. **Scand J Urol Nephrol** 1999 Jun; 33(3):162–70 (64 ref.)
Preanesthetic evaluation of children with anterior mediastinal masses. Shamberger RC. **Semin Pediatr Surg** 1999 May; 8(2):61–8 (31 ref.)
[Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(1):55–7 (20 ref.) **(Bul)**
[Role of non-steroidal anti-inflammatory agents in the perioperative period. Usefulness and limitations] Derrier M, et al. **Ann Fr Anesth Reanim** 1997;16(5):498–520 (98 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative management of patients with high-risk cardiovascular conditions] Broustet JP, et al. **Arch Mal Coeur Vaiss** 1998 Aug;91 Spec No 4:7–16; discussion 29–30 (39 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative skin preparation in abdominal surgery] Duron JJ, et al. **J Chir (Paris)** 1998 Nov;135(5):207–11 (31 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative assessment of primary varicose veins] Pfyffer M. **Schweiz Med Wochenschr** 1998 Nov 7;128(45):1772–80 (50 ref.) (Eng. Abstr.) **(Ger)**
[Position of internal medicine in the preoperative evaluation of circulatory functions] Fujii T. **Masui** 1998 Dec;47 Suppl:S142–8 (12 ref.) **(Jpn)**
[Evaluation criteria in anesthesiology--with special reference to ischemic heart disease] Ishihara S. **Masui** 1998 Dec;47 Suppl:S149–54 (19 ref.) **(Jpn)**
[Pre-operative radiotherapy, conventional or accelerated, for invasive bladder cancer. Objectives and radiation modalities. Results and complications] López Torrecilla J, et al. **Arch Esp Urol** 1999 Jul–Aug;52(6):586–94 (27 ref.) (Eng. Abstr.) **(Spa)**
[Pre-postoperative neuropsychological evaluation in the surgical treatment of epilepsy] Campo P, et al. **Rev Neurol** 1998 Oct;27(158):616–25 (127 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost-effective preoperative evaluation and testing. Fischer SP. **Chest** 1999 May;115(5 Suppl):96S–100S (41 ref.)

METHODS

Management of preoperative anaemia. Mercuriali F, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:56–61 (39 ref.)
Nutritional support and aging in preoperative nutrition. Nourhashemi F, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):87–92 (36 ref.)
Ultrasonographic appearance of fallopian tube carcinoma. Ekici E, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):325–9 (24 ref.)
Spatiotemporal EEG analysis and distributed source estimation in presurgical epilepsy evaluation. Michel CM, et al. **J Clin Neurophysiol** 1999 May;16(3):239–66 (67 ref.)
Surgical considerations in preoperative chemotherapy of breast cancer. Margolese RG. **Recent Results Cancer Res** 1998;152:193–201 (14 ref.)
Preoperative and postoperative skin care with laser resurfacing. Hrabovsky SL. **Semin Ophthalmol** 1998 Sep; 13(3):115–22 (32 ref.)
[Surgical treatment of gastroesophageal reflux: preoperative evaluation] Tack J. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S130–3 (36 ref.) **(Fre)**
[Adult fecal incontinence due to anal sphincter lesions: which preoperative preparations? Which surgical solutions?] Lehur PA, et al. **J Chir (Paris)** 1998 May;135(2):83–9 (30 ref.) (Eng. Abstr.) **(Fre)**
[Staging of exocrine pancreatic cancer] Sauvanet A, et al. **J Chir (Paris)** 1998 Feb;135(1):10–6 (31 ref.) (Eng. Abstr.) **(Fre)**
[Meigs' syndrome: is it possible to make a preoperative diagnosis?] Rouzier R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):517–22 (38 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative management of subjects at risk. Asthmatic patients] Dureuil B, et al. **Presse Med** 1998 Mar 7; 27(9):437–42 (31 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative management of subjects at risk. Diabetic patients] Raucoules-Aimé M, et al. **Presse Med** 1998 Mar 7;27(9):444–51 (61 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative management of subjects at risk. Obese patients] Servin F. **Presse Med** 1998 Mar 7;27(9):452–4 (20 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic and pretherapeutic management of breast cancer] Serin D, et al. **Rev Prat** 1998 Jan 1;48(1):36–43 (43 ref.) (Eng. Abstr.) **(Fre)**
[The feasibility of preoperative autologous blood donation in children] Dada A, et al. **Klin Padiatr** 1999 Mar–Apr; 211(2):57–60 (23 ref.) (Eng. Abstr.) **(Ger)**
[The advantage of preparing the colon with Fortrans for diagnostic explorations or surgical interventions] Palade R, et al. **Chirurgia (Bucur)** 1998 May–Jun;93(3):189–93 (14 ref.) **(Rum)**

NURSING

A review of the impact of pre-operative education on recovery from surgery. Shuldham C. **Int J Nurs Stud** 1999 Apr;36(2):171–7 (20 ref.)
Pre-operative education--a review of the research design. Shuldham C. **Int J Nurs Stud** 1999 Apr;36(2):179–87 (61 ref.)

PSYCHOLOGY

Cosmetic surgery: surgical tools--psychosocial goals. Grossbart TA, et al. **Semin Cutan Med Surg** 1999 Jun; 18(2):101–11 (32 ref.)

STANDARDS

Pre-operative assessment of cardiac risk for non-cardiac surgery [see comments] Turner M, et al. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):545–7 (14 ref.) Comment in: J R Coll Physicians Lond 1999 Mar–Apr;33(2):192.

PREOPTIC AREA

PHYSIOLOGY

Integration of chemosensory and hormonal input in the male Syrian hamster brain. Wood RI. **Ann N Y Acad Sci** 1998 Nov 30;855:362–72 (20 ref.)
Role of the medial preoptic area/anterior hypothalamus in the control of masculine sexual behavior. Paredes RG, et al. **Annu Rev Sex Res** 1997;8:68–101 (176 ref.)
Control of REM sleep: an aspect of the regulation of physiological homeostasis. Zamboni G, et al. **Arch Ital Biol** 1999 Aug;137(4):249–62 (43 ref.)
Gonadal steroid-dependent neuronal circuitries in avian limbic and preoptic regions. Panzica GC, et al. **Eur J Morphol** 1999 Apr;37(2–3):112–6 (21 ref.)

PREOVULATORY PHASE see **FOLLICULAR PHASE**

PREPAID GROUP HEALTH ORGANIZATIONS see **HEALTH MAINTENANCE ORGANIZATIONS**

PREPAID HEALTH PLANS

ORGANIZATION & ADMINISTRATION

Rural health prepayment schemes in China: towards a more active role for government. Bloom G, et al. **Soc Sci Med** 1999 Apr;48(7):951–60 (36 ref.)

PREPROSTHETIC ORAL SURGICAL PROCEDURES see **ORAL SURGICAL PROCEDURES, PREPROSTHETIC**

PRESBYCUSIS

Hearing loss with aging: presbycusis. Cohn ES. **Clin Geriatr Med** 1999 Feb;15(1):145–61, viii (39 ref.)

DIAGNOSIS

[Presbycusis] Ottaviani F. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):77–9 (23 ref.) (Eng. Abstr.) **(Ita)**

PRESBYOPIA

CLASSIFICATION

Explaining presbyopia to patients [editorial] [see comments] Shabany RY, et al. **Optom Vis Sci** 1998 Sep;75(9):627–8 (7 ref.) Comment in: Optom Vis Sci 1999 Feb;76(2):81.

PHYSIOPATHOLOGY

[Role of ciliary muscle in ocular physiology and disease] Nesterov AP, et al. **Vestn Oftalmol** 1999 Mar–Apr; 115(2):13–5 (10 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Monovision and LASIK. Hom MM. **J Am Optom Assoc** 1999 Feb;70(2):117–22 (35 ref.)

PRESBYTIS see **CERCOPITHECIDAE**

PRESCRIPTION INSURANCE see **INSURANCE, PHARMACEUTICAL SERVICES**

PRESCRIPTIONS, DRUG

Direct-to-consumer prescription drug advertising. Terzian TV. **Am J Law Med** 1999;25(1):149–67 (0 ref.)
Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications [editorial] Collier J. **Br J Clin Pharmacol** 1999 Jul;48(1):5–8 (9 ref.)
Prescription-event monitoring--recent progress and future horizons. Mann RD. **Br J Clin Pharmacol** 1998 Sep; 46(3):195–201 (17 ref.)
Are there special considerations in the prescription of serotonin reuptake inhibitors for women? Stewart DE. **Can J Psychiatry** 1998 Nov;43(9):900–4 (28 ref.)
Prescription to over-the-counter switches: the physician perspective. Byrns PJ. **Clin Ther** 1998;20 Suppl C:C118–23 (19 ref.)
Prescription to over-the-counter switch: a regulatory perspective. Juhl RP. **Clin Ther** 1998;20 Suppl C:C111–7 (1 ref.)
American Pharmaceutical Association review of literature on prescription to over-the-counter drug switches. Schulke DG. **Clin Ther** 1998;20 Suppl C:C124–33 (14 ref.)
Changing prescribing in the light of tolerability concerns: how is this best achieved? de Vries CS, et al. **Drug Saf** 1999 Sep;21(3):153–60 (66 ref.)
Should emergency contraceptive pills be available without prescription? Ellertson C, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):226–9, 232 (48 ref.)
Emergency contraceptive pills: what does the law say about prescribing, dispensing, repackaging, and advertising? [see comments] Jones BS. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):233–7 (71 ref.) Comment in: J Am Med Womens Assoc 1999 Spring;54(2):101–2.
Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):32–5 (11 ref.)
Keeping up with current drug approvals [see comments] Kupecz D. **Nurse Pract** 1999 Feb;24(2):44–8, 54, 56–7; quiz 58–9 (0 ref.) Comment in: Nurse Pract 1999 May;24(5):20.
[French National Institute for observation of prescriptions and consumption of medicines. Prescription and consumption of antibiotics in ambulatory care] Bouvenot G. **Bull Acad Natl Med** 1999;183(3):601–9; discussion 609–13 (14 ref.) (Eng. Abstr.) **(Fre)**
[Rules of preoperative antibiotic prophylaxis prescription] Martin C, et al. **Presse Med** 1998 Mar 7;27(9):416–26 (18 ref.) (Eng. Abstr.) **(Fre)**
[Prescription and use of antibiotics in ambulatory care. Drug Agency] **Rev Pneumol Clin** 1999 Apr;55(2):65–74 (14 ref.) (Eng. Abstr.) **(Fre)**
[New distribution forms for pharmaceuticals--a logistic perspective] Grund J, et al. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4237–40 (24 ref.) (Eng. Abstr.) **(Nor)**
[Factors affecting drug prescriptions by the primary care physician] Abanades Herranz JC, et al. **Aten Primaria** 1998 Oct 15;22(6):391–8 (41 ref.) **(Spa)**
[Is the medical prescription of heroin a treatment option for heroin addiction? The PEPSA Team (The Experimental Program of Narcotic Prescription in Andalucía (editorial)] Zunzunegui MV. **Med Clin (Barc)** 1999 Sep 4;113(6):219–21 (30 ref.) **(Spa)**

ECONOMICS

[Prescriptions and consumption of venotonic drugs in France (à propos of the report of the French National Institute for prescriptions and consumption of drugs)] Bouvenot G. **Bull Acad Natl Med** 1999;183(5):865–75; discussion 875–8 (19 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Nurse prescribing: radicalism or tokenism? McCartney W, et al. **J Adv Nurs** 1999 Feb;29(2):348–54 (22 ref.)
A rheumatologist's verdict on the safety of chloroquine versus hydroxychloroquine. Liability in off-label prescribing [editorial] [see comments] Houpt JB. **J Rheumatol** 1999 Sep;26(9):1864–6 (16 ref.) Comment in: J Rheumatol 1999 Sep;26(9):1868.
Prescription data as a tool in pharmacotherapy audit (II). The development of an instrument. de Vries CS, et al. **Pharm World Sci** 1999 Apr;21(2):85–90 (24 ref.)

STATISTICS & NUMERICAL DATA

The "prescription-to-OTC switch" movement. Its effects on antifungal vaginitis preparations. Lipsky MS, et al. **Arch Fam Med** 1999 Jul-Aug;8(4):297–300 (27 ref.)
Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics [editorial; comment] Conly J. **Can Fam Physician** 1998 Sep;44:1769–73, 1780–4 (30 ref.) Comment on: Can Fam Physician 1998 Sep;44 :1881–8. **(Eng, Fre)**
Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice [see comments] Wang EE, et al. **Can Fam Physician** 1998 Sep;44:1881–8 (72 ref.) Comment in: Can Fam Physician 1998 Sep;44:1769–73, 1780–4. Comment in: Can Fam Physician 1998 Nov;44:2375–6.
Medication use in nursing homes for elderly people. Furniss L, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):433–9 (61 ref.)
Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May;38(5):557–65 (46 ref.)
Psychotropic drug prescribing: first the good news [editorial; comment] Keks NA, et al. **Med J Aust** 1999 Apr 5; 170(7):293–4 (12 ref.) Comment on: Med J Aust 1999 Apr 5;170(7):299–301.
Prescription data as a tool in pharmacotherapy audit (I). General considerations. de Vries CS, et al. **Pharm World Sci** 1999 Apr;21(2):80–4 (41 ref.)
[Overprescribing of antibiotics outside the hospital] Sternon J, et al. **Rev Med Brux** 1999 Feb;20(1):43–7 (29 ref.) (Eng. Abstr.) **(Fre)**

PRESCRIPTIONS, NON-DRUG

Mathematical models for prescription and delivery in peritoneal dialysis. Amici G. **Nephrol Dial Transplant** 1998; 13 Suppl 6:120–4 (48 ref.)
[Idiopathic calcium lithiasis. Practical guide for dietary measures prescriptions (published erratum appears in Presse Med 1998 Mar 7;27(9):415)] Achard JM, et al. **Presse Med** 1998 Feb 7;27(5):230–7 (19 ref.) (Eng. Abstr.) **(Fre)**

PRESENTATION, BREECH see **BREECH PRESENTATION**

PRESENTATION, FETAL see **LABOR PRESENTATION**

PRESERVATION, BIOLOGICAL

see related
FIXATIVES

PRESERVATION, FOOD see **FOOD PRESERVATION**

PRESERVATIVES, PHARMACEUTICAL

see related
ANTIOXIDANTS

ADVERSE EFFECTS

An update of the risk assessment for methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) with focus on rinse-off products. Fewings J, et al. **Contact Dermatitis** 1999 Jul;41(1):1–13 (97 ref.)
Bronchoconstrictor additives in bronchodilator solutions. Asmus MJ, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 2):S53–60 (49 ref.)
[Preservatives in nebulizer solutions: risks without benefit] Hanquin JM. **J Pharm Belg** 1999 Mar-Apr;54(2):38–43 (0 ref.) **(Fre)**

PRESSORECEPTORS

see related
BAROREFLEX

PHYSIOLOGY

Physiology and pathophysiology of baroreceptor function and neuro-hormonal abnormalities in heart failure. Kirchheim HR, et al. **Basic Res Cardiol** 1998;93 Suppl 1:1–22 (192 ref.)

PHYSIOPATHOLOGY

Baroreflex control of sympathetic activity in experimental hypertension. Irigoyen MC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1213–20 (49 ref.)
[Baroreceptor regulation in chronic heart failure] Chaban TI. **Lik Sprava** 1999 Apr-May;(3):20–4 (34 ref.) **(Ukr)**

PRESSURE

see related
BLOOD PRESSURE
MANOMETRY

Mechanisms of gene expression controlled by pressure in deep-sea microorganisms. Nakasone K, et al. **Extremophiles** 1998 Aug;2(3):149–54 (13 ref.)
[Slow pressure waves during intracranial hypertension] Lemaire JJ. **Ann Fr Anesth Reanim** 1997;16(4):394–8 (41 ref.) (Eng. Abstr.) **(Fre)**

PRESSURE SORE see **DECUBITUS ULCER**

PRESSURE SUITS see **G SUITS**

PRESSURE ULCER see **DECUBITUS ULCER**

PRESYNAPTIC RECEPTORS see **RECEPTORS, PRESYNAPTIC**

PRESYNAPTIC TERMINALS

METABOLISM

Presynaptic ionotropic receptors and the control of transmitter release. MacDermott AB, et al. **Annu Rev Neurosci** 1999;22:443–85 (216 ref.)
Interactions between the presynaptic alpha2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Schlicker E, et al. **Brain Res Bull** 1998 Sep 15;47(2):129–32 (45 ref.)
Interactions between presynaptic calcium channels and proteins implicated in synaptic vesicle trafficking and exocytosis. Seagar M, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):347–56 (58 ref.)
Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. Garzón M, et al. **J Comp Neurol** 1999 Jul 26;410(2):197–210 (108 ref.)
The hypothesis of an ambient level of acetylcholine in the central nervous system. Descarries L. **J Physiol Paris** 1998 Jun-Aug;92(3-4):215–20 (49 ref.)
Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Somogyi GT, et al. **Life Sci** 1999;64(6-7):411–8 (50 ref.)
Ion channels in presynaptic nerve terminals and control of transmitter release. Meir A, et al. **Physiol Rev** 1999 Jul; 79(3):1019–88 (1014 ref.)
Neuroprotective strategies: voltage-gated Na+-channel down-modulation versus presynaptic glutamate release inhibition. Obrenovitch TP. **Rev Neurosci** 1998 Jul-Dec; 9(3):203–11 (74 ref.)

PHYSIOLOGY

Presynaptic imidazoline receptors. New developments in characterization and classification. Göthert M, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:171–84 (21 ref.)
Formation of lamina-specific synaptic connections. Sanes JR, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):79–87 (68 ref.)
Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. Sheng ZH, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):335–45 (80 ref.)
A lie detector test for presynaptic capacitance measurements [comment] Matthews G. **Neuron** 1998 Nov;21(5):940–1 (9 ref.) Comment on: Neuron 1998 Nov;21(5):1177–88.
Presynaptic modulation of glutamate release. Nicholls DG. **Prog Brain Res** 1998;116:15–22 (52 ref.)
Calcium transients and neurotransmitter release at an identified synapse. Fossier P, et al. **Trends Neurosci** 1999 Apr;22(4):161–6 (68 ref.)
[A presynaptic Ca(2+)-binding protein--synaptotagmin] Qiang M, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):268–70 (10 ref.) **(Chi)**

PRETEEN PREGNANCY see **PREGNANCY IN ADOLESCENCE**

PREVALENCE

Critical appraisal of the health research literature: prevalence or incidence of a health problem. Loney PL, et al. **Chronic Dis Can** 1998;19(4):170–6 (27 ref.)

PREVENTION, PRIMARY see **PRIMARY PREVENTION**

PREVENTIVE DENTISTRY

Preventive dentistry during pregnancy [letter] Holder R, et al. **Nurse Pract** 1999 Feb;24(2):21–4 (15 ref.)

PREVENTIVE HEALTH SERVICES

see related
HEALTH PROMOTION
IMMUNIZATION

Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S–759S (37 ref.)
The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S–754S (78 ref.)
Use of preventive health care services by patients with obesity. Zayat EN, et al. **Obes Res** 1999 Mar;7(2):223–6 (22 ref.)
Accelerated Campaign to Enhance STD Services (ACCESS) for youth: successes, challenges, and lessons learned. DeLisle S, et al. **Sex Transm Dis** 1999 Apr;26(4 Suppl):S28–41; discussion S42–3 (11 ref.)
[Prevention and research on prevention seen from a perspective of health policy] Iversen L. **Ugeskr Laeger** 1998 Nov 16;160(47):6795–9 (11 ref.) **(Dan)**
[HIV prevention for migrant prostitutes] Nitschke-Ozbay H. **Zentralbl Gynakol** 1999;121(1):36–41 (5 ref.) (Eng. Abstr.) **(Ger)**
[Moderation--a virtue of necessity] Nylenna M. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1154–7 (33 ref.) (Eng. Abstr.) **(Nor)**
[Do computerized reminders to the patients affect the preventive work in general practice?] Steen M, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):42–4 (35 ref.) (Eng. Abstr.) **(Nor)**
[Alcohol abuse prevention in health care services: screening methods and motivational counseling] Andréasson S, et al. **Lakartidningen** 1999 Mar 31;96(13):1594–8 (11 ref.) (Eng. Abstr.) **(Swe)**
[How can primary health care influence patients' alcohol drinking habits. "Simple intervention" results in a new

therapeutic perspective] Dahl G, et al. **Lakartidningen** 1998 Oct 21;95(43):4726–30 (43 ref.) (Eng. Abstr.) **(Swe)**

LEGISLATION & JURISPRUDENCE

The complex realities of primary prevention for HIV infection in a "just do it" world. Bradley-Springer LA. **Nurs Clin North Am** 1999 Mar;34(1):49–70 (90 ref.)

ORGANIZATION & ADMINISTRATION

Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Habicht JP, et al. **Int J Epidemiol** 1999 Feb;28(1):10–8 (20 ref.)

Implementing breast and cervical cancer prevention programs among the Houma Indians of southern Louisiana: cultural and ethical considerations. Coughlin SS. **J Health Care Poor Underserved** 1998 Feb;9(1):30–41 (44 ref.)

STANDARDS

Interventions to improve the delivery of preventive services in primary care. Hulscher ME, et al. **Am J Public Health** 1999 May;89(5):737–46 (83 ref.)

Sharing responsibility for the public's health. Stoto MA. **Public Health Rep** 1999 May-Jun;114(3):231–5 (8 ref.)

STATISTICS & NUMERICAL DATA

An ounce of prevention ... what are the returns? Second edition, 1999. Messonnier ML, et al. **Am J Prev Med** 1999 Apr;16(3):248–63 (90 ref.)

UTILIZATION

Implementing preventive services: to what extent can we change provider performance in ambulatory care? A review of the screening, immunization, and counseling literature. Anderson LA, et al. **Ann Behav Med** 1998 Summer;20(3):161–7 (65 ref.)

Breast screening practices among Russian immigrant women in Israel. Remennick LI. **Women Health** 1999;28(4):29–51 (36 ref.)

PREVENTIVE MEDICINE

see related

HEALTH PROMOTION

Cross-cultural issues in prevention, health promotion, and risk reduction in adolescence. Bell DL, et al. **Adolesc Med** 1999 Feb;10(1):57–69, vi (55 ref.)

Coronary heart disease. At the interface of molecular genetics and preventive medicine. Ellsworth DL, et al. **Am J Prev Med** 1999 Feb;16(2):122–33 (87 ref.)

Safety assessment and potential health benefits of food components based on selected scientific criteria. ILSI North America Technical Committee on Food Components for Health Promotion. **Crit Rev Food Sci Nutr** 1999 May;39(3):203–316 (627 ref.)

Simple, sensible preventive measures for managed care settings. Waltzer KB. **Geriatrics** 1998 Oct;53(10):65–8, 75–7, 81; quiz 82 (29 ref.)

Health counseling in adolescent preventive visits: effectiveness, current practices, and quality measurement. Hedberg VA, et al. **J Adolesc Health** 1998 Dec; 23(6):344–53 (82 ref.)

Yoga: intuition, preventive medicine, and treatment. Collins C. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct; 27(5):563–8 (33 ref.)

[The use of biological markers for the study and prevention of chronic degenerative diseases. 3. Biomarkers in public health and preventive medicine] Donato F, et al. **Ann Ig** 1998 Sep–Dec;10(5–6):361–71 (41 ref.) (Eng. Abstr.) **(Ita)**

[Primary preventive medicine and laboratory medicine] Hashizume N, et al. **Rinsho Byori** 1999 Feb;47(2):101–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Alternatives for myocardial protection: adenosine-enhanced ischemic preconditioning. McCully JD, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:295–305 (60 ref.)

Meditation for prevention of disease. Subramanian P. **Indian J Med Sci** 1998 Mar;52(3):114–8 (0 ref.)

Prevention of diseases an Ayurvedic approach. Upadyay RL. **Indian J Med Sci** 1998 Mar;52(3):119–24 (0 ref.)

ORGANIZATION & ADMINISTRATION

Carrying out the Medicine/Public Health Initiative: the roles of preventive medicine and community-responsive care. Cashman SB, et al. **Acad Med** 1999 May;74(5):473–83 (54 ref.)

Principles of practice for academic/practice/community research partnerships. Baker EA, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):86–93 (23 ref.)

Community/practice/academic partnerships in public health. Clark NM. **Am J Prev Med** 1999 Apr;16(3 Suppl):18–9 (8 ref.)

The intersection of genetics, public health, and preventive medicine. Coughlin SS. **Am J Prev Med** 1999 Feb; 16(2):89–90 (14 ref.)

Research linkages between academia and public health practice. Building a prevention research agenda. Lane DS. **Am J Prev Med** 1999 Apr;16(3 Suppl):7–9 (7 ref.)

Using case research to enhance linkages between academia and public health practice. Liang AP, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):12–3 (11 ref.)

It's about time. The medicine/public health initiative. Nickens H. **Am J Prev Med** 1999 Apr;16(3 Suppl):20–1 (3 ref.)

Prevention research centers. The academic and community partnership. Riley PL, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):5–6 (4 ref.)

STANDARDS

Measuring the impact of prevention research on public health practice. Brownson RC, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):72–9 (69 ref.)

PREVENTIVE PSYCHIATRY

METHODS

A public mental health approach to the postdisaster treatment of children and adolescents. Pynoos RS, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):195–210, x (21 ref.)

PRIAPISM

[Priapism] Hora M, et al. **Cas Lek Cesk** 1999 Mar 1; 138(5):131–5 (43 ref.) (Eng. Abstr.) **(Cze)**

DIAGNOSIS

[Partial priapism. Case report and review of the literature of diagnostic and therapeutic measures] Schneede P, et al. **Urologe A** 1999 Mar;38(2):179–83 (8 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Posttraumatic priapism in a 6-year-old boy: a case report] Iwata K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):679–82 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Successful multidisciplinary treatment for bladder cancer with priapism. A case report] Kitsukawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):788–91 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Priapism secondary to a bilateral abscess of the corpora cavernosa] Fernández Duran AM, et al. **Actas Urol Esp** 1999 Jan;23(1):64–6 (10 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Posttraumatic priapism in a 6-year-old boy: a case report] Iwata K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):679–82 (20 ref.) (Eng. Abstr.) **(Jpn)**

PRILOCAINE

ADMINISTRATION & DOSAGE

[Pharma clinics. How I treat...or preventing pain with "patches"] Piérard GE. **Rev Med Liege** 1998 Oct; 53(10):586–7 (19 ref.) (Eng. Abstr.) **(Fre)**

PRIMACLONE see **PRIMIDONE**

PRIMAQUINE

ADVERSE EFFECTS

[Primaquine and travelers from the Arab world. A report and recommendations] Menéndez Capote R, et al. **Rev Cubana Med Trop** 1995;47(3):221–3 (11 ref.) (Eng. Abstr.) **(Spa)**

PRIMARY CARE see **PRIMARY HEALTH CARE**

PRIMARY CARE PHYSICIANS see **PHYSICIANS, FAMILY**

PRIMARY HEALTH CARE

Using DSM-IV primary care version: a guide to psychiatric diagnosis in primary care. Pingitore D, et al. **Am Fam Physician** 1998 Oct 15;58(6):1347–52 (23 ref.)

Primary care of international adoptees [see comments] [published erratum appears in Am Fam Physician 1999 May 1;59(9):2435] Quarles CS, et al. **Am Fam Physician** 1998 Dec;58(9):2025–32, 2039–40 (16 ref.) Comment in: Am Fam Physician 1998 Dec;58(9):1958, 1960, 1963.

Screening for hemochromatosis in primary care settings. McDonnell SM, et al. **Ann Intern Med** 1998 Dec 1; 129(11):962–70 (48 ref.)

Primary health care. McElmurry BJ, et al. **Annu Rev Nurs Res** 1999;17:241–68 (165 ref.)

Role of the primary care physician in problems of substance abuse. Weaver MF, et al. **Arch Intern Med** 1999 May 10; 159(9):913–24 (47 ref.)

Challenges facing primary care mental health in Australia. Holmwood C. **Aust Fam Physician** 1998 Aug;27(8):716–9 (28 ref.)

Clinical pharmacy in primary care. Hawksworth GM, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):415–20 (78 ref.)

GP referrals to adult psychological services: a research agenda for promoting needs-led practice through the involvement of mental health clinicians. Ross H, et al. **Br J Med Psychol** 1999 Mar;72 (Pt 1):75–91 (87 ref.)

Working with the primary care physician. Schowalter JE, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul; 7(3):599–613 (39 ref.)

Prevention of asthma in genetically predisposed children in primary care--from clinical efficacy to a feasible intervention programme. Schönberger HJ, et al. **Clin Exp Allergy** 1998 Nov;28(11):1325–31 (86 ref.)

Primary care for women: the role of the obstetrician-gynecologist. Brown CV. **Clin Obstet Gynecol** 1999 Jun;42(2):306–13 (20 ref.)

Integrating health and mental health services in schools: psychologists collaborating with primary care providers. Kubiszyn T. **Clin Psychol Rev** 1999 Mar;19(2):179–98 (104 ref.)

The at-risk foot: the role of the primary care team in achieving St Vincent targets for reducing amputation. Gadsby R, et al. **Diabet Med** 1998 Nov;15 Suppl 3:S61–4 (25 ref.)

A primary-care-led diabetes service: strengths, weaknesses, opportunities and threats [editorial] Greenhalgh T. **Diabet Med** 1998 Nov;15 Suppl 3:S7–9 (26 ref.)

Contributing to improved health through new knowledge: primary care teams and the unanswered questions [editorial] Kinmonth AL. **Diabet Med** 1998 Nov;15 Suppl 3:S10–3 (23 ref.)

Doing research in general practice: advice for the uninitiated. Pierce M. **Diabet Med** 1998 Nov;15 Suppl 3:S25–8 (7 ref.)

Anxiety in primary care depression: how does it lead to poor outcomes and what can we do about it? [editorial; comment] Roy-Byrne P. **Gen Hosp Psychiatry** 1999 May-Jun;21(3):151–3 (27 ref.) Comment on: Gen Hosp Psychiatry 1999 May-Jun;21(3):158–67.

Carotid occlusive disease: primary care of patients with or without symptoms. Eugene JR, et al. **Geriatrics** 1999 May; 54(5):24–6, 29–30, 33 passim (48 ref.)

Chronic pain: primary care treatment of the older patient. Leland JY. **Geriatrics** 1999 Jan;54(1):23–8, 33–4, 37 (26 ref.)

Antibiotic troubleshooting in primary care. Czachor JS. **Hosp Pract (Off Ed)** 1999 May 15;34(5):95–101 (13 ref.)

The overactive bladder: an overview for primary care health providers. Wein AJ, et al. **Int J Fertil Womens Med** 1999 Mar-Apr;44(2):56–66 (29 ref.)

Mental health problems in primary care: a research agenda. Klinkman MS, et al. **Int J Psychiatry Med** 1998; 28(4):361–74 (68 ref.)

Promoting adolescent mental health in primary care: a review of the literature. Walker Z, et al. **J Adolesc** 1998 Oct; 21(5):621–34 (104 ref.)

Health counseling in adolescent preventive visits: effectiveness, current practices, and quality measurement. Hedberg VA, et al. **J Adolesc Health** 1998 Dec; 23(6):344–53 (82 ref.)

A multidisciplinary approach to obesity management: the physician's role and team care alternatives. Frank A. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S44–8 (10 ref.)

A model for chronic care of obesity through dietary treatment. Nonas CA. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S16–22 (39 ref.)

The basis for using the Internet to support the information needs of primary care. Westberg EE, et al. **J Am Med Inform Assoc** 1999 Jan-Feb;6(1):6–25 (365 ref.)

The management of anxious depression in primary care. Goldberg D. **J Clin Psychiatry** 1999;60 Suppl 7:39–42; discussion 43–4 (27 ref.)

Primary care issues related to the treatment of depression in elderly patients. Montano CB. **J Clin Psychiatry** 1999; 60 Suppl 20:45–51 (106 ref.)

Panic disorder: the ultimate anxiety. Sansone RA, et al. **J Womens Health** 1998 Oct;7(8):983–9 (69 ref.)

Low back pain. Evaluation and management in the primary care setting. Rosomoff HL, et al. **Med Clin North Am** 1999 May;83(3):643–62 (24 ref.)

Treating depressed older adults in primary care: narrowing the gap between efficacy and effectiveness. Unützer J, et al. **Milbank Q** 1999;77(2):225–56, 174 (138 ref.)

Primary care and case management of persons with HIV/AIDS. Kirton CA, et al. **Nurs Clin North Am** 1999 Mar;34(1):71–94 (27 ref.)

Prevention of child abuse and neglect in the primary care setting. Nester CB. **Nurse Pract** 1998 Sep;23(9):61–2, 67–70, 73 (21 ref.)

Community analysis for health planning: strategies for primary care practitioners. Reece SM. **Nurse Pract** 1998 Oct;23(10):46, 49, 53–6 passim (23 ref.)

Pediatric epilepsy: primary care treatment and health care management. Valente MB, et al. **Nurse Pract** 1998 Nov; 23(11):38, 43–4, 47 passim (32 ref.)

Focus on primary care diagnosis and management of headache in women. Marcus DA. **Obstet Gynecol Surv** 1999 Jun;54(6):395–402 (53 ref.)

A report from the Second International Forum for Primary Care Research on Low Back Pain. Reexamining priorities. Borkan JM, et al. **Spine** 1998 Sep 15;23(18):1992–6 (8 ref.)

Diagnosis and management of dementia in primary care at an early stage: the need for a new concept and an adapted procedure. De Lepeleire J, et al. **Theor Med Bioeth** 1999 Jun;20(3):215–28 (72 ref.)

[Psychotropic drugs and primary care] Cuché H.

Ann Pharm Fr 1998;56(2):83–9 (7 ref.) (Eng. Abstr.) **(Fre)**

[Primary health care in Thailand with community participation special reference to Japanese assistance] Rakue Y, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun; 45(6):578–85 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical guidelines for primary health care] Holmen J, et al. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1794–7 (31 ref.) **(Nor)**

[Certain issues in the utilization of pancreatic enzyme preparations in therapeutic practice] Rapoport SI, et al. **Klin Med (Mosk)** 1998;76(11):52–4 (33 ref.) **(Rus)**

[Diarrhea syndrome in the practice of internal medicine physicians] Sheptulin AA. **Klin Med (Mosk)** 1998; 76(11):54–9 (9 ref.) **(Rus)**

[Factors affecting drug prescriptions by the primary care physician] Abánades Herranz JC, et al. **Aten Primaria** 1998 Oct 15;22(6):391–8 (41 ref.) **(Spa)**

[How can primary health care influence patients' alcohol drinking habits. "Simple intervention" results in a new therapeutic perspective] Dahl G, et al. **Lakartidningen** 1998 Oct 21;95(43):4726–30 (43 ref.) (Eng. Abstr.) **(Swe)**

CLASSIFICATION

Does the VA provide "primary" primary care? [editorial; comment] Petersen LA, et al. **J Gen Intern Med** 1999 May; 14(5):318–9 (17 ref.) Comment on: J Gen Intern Med 1999 May;14(5):274–80.

ECONOMICS

[Capitation fixed payment for primary care: a possible alternative to the traditional fee-for-service--part 2] Roland M. **Rev Med Brux** 1999 Feb;20(1):35–41 (56 ref.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Wisconsin statutes regarding HIV testing in primary care: frequent questions and answers. Vergeront JM, et al. **WMJ** 1998 Dec;97(11):47–51 (1 ref.)

METHODS

Women battering in primary care practice. Naumann P, et al. **Fam Pract** 1999 Aug;16(4):343–52 (79 ref.)

DepRelief: training programme for primary care. Philp I. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S55–7 (8 ref.)

Improved therapies for HIV infection and AIDS--implications for primary care [editorial; comment] Goldbaum GM, et al. **J Am Board Fam Pract** 1999 Jan–Feb; 12(1):97–9 (11 ref.) Comment on: J Am Board Fam Pract 1999 Jan–Feb;12(1):71–94.

Does the VA provide "primary" primary care? [editorial; comment] Petersen LA, et al. **J Gen Intern Med** 1999 May; 14(5):318–9 (17 ref.) Comment on: J Gen Intern Med 1999 May;14(5):274–80.

Pesticides primer for the primary care physician. Musharrafieh U, et al. **J Med Liban** 1998 Nov–Dec; 46(6):321–7 (21 ref.)

Posttraumatic stress disorder in children: implications for assessment, prevention, and referral in primary care. Pfefferbaum B, et al. **J Okla State Med Assoc** 1999 Jul; 92(7):309–15 (67 ref.)

Viral hepatitis: primary care diagnosis and management. Alexander IM. **Nurse Pract** 1998 Oct;23(10):13–4, 17–20, 25–6 passim; quiz 44–5 (66 ref.)

Managing alcohol-related problems in the primary care setting. Martin AC, et al. **Nurse Pract** 1999 Aug;24(8):14, 16–8, 21, 25–6, 28, 38–9; quiz (34 ref.)

Pediatric dermatologic surgery for the primary care pediatrician. Babich D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1437–53 (47 ref.)

Pediatric stomas, tubes, and appliances. Borkowski S. **Pediatr Clin North Am** 1998 Dec;45(6):1419–35 (18 ref.)

Care of the surgical intensive care nursery graduate. The primary care pediatrician's perspective. Brown RL, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1327–52 (60 ref.)

Approaches to recognition and management of childhood psychiatric disorders in pediatric primary care. Cassidy LJ, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1037–52 (46 ref.)

Pediatric and adolescent gynecology for the primary care pediatrician. Craighill MC. **Pediatr Clin North Am** 1998 Dec;45(6):1659–88 (28 ref.)

Common pediatric dental problems. Creighton PR. **Pediatr Clin North Am** 1998 Dec;45(6):1579–60 (21 ref.)

Vascular anomalies. A primer for pediatricians. Fishman SJ, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1455–77 (28 ref.)

Management and long-term complications of pediatric cancer. Grossi M. **Pediatr Clin North Am** 1998 Dec; 45(6):1637–58 (213 ref.)

Care of the pediatric solid organ transplant recipient. The primary care perspective. Kosmach B, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1395–418 (85 ref.)

Adolescent and pediatric sports injuries. Ryu RK, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1601–35, x (48 ref.)

Patients with alcohol problems in primary care: understanding their resistance and motivating change. Botelho RJ, et al. **Prim Care** 1999 Jun;26(2):279–98 (50 ref.)

A:ttention-deficit/hyperactivity disorder and associated childhood disorders. Dunne JE. **Prim Care** 1999 Jun; 26(2):349–72 (17 ref.)

The psychotic patient. Hilty DM, et al. **Prim Care** 1999 Jun; 26(2):327–48 (27 ref.)

Beyond the Folstein: dementia in primary care. Howarth DF, et al. **Prim Care** 1999 Jun;26(2):299–314 (12 ref.)

Anxiety disorders. Leaman TL. **Prim Care** 1999 Jun; 26(2):197–210 (35 ref.)

Personality disorders in primary care. Paré MF, et al. **Prim Care** 1999 Jun;26(2):243–78 (66 ref.)

Depression. Rakel RE. **Prim Care** 1999 Jun;26(2):211–24 (27 ref.)

The somatizing patient. Servan-Schreiber D, et al. **Prim Care** 1999 Jun;26(2):225–42 (38 ref.)

Domestic violence. Stringham P. **Prim Care** 1999 Jun; 26(2):373–84 (13 ref.)

Behavioral medicine. Vogel ME, et al. **Prim Care** 1999 Jun; 26(2):385–400 (9 ref.)

Factitious disorders. Wise MG, et al. **Prim Care** 1999 Jun; 26(2):315–26 (56 ref.)

[Problem drinking] Huas D, et al. **Rev Prat** 1999 Feb 15; 49(4):379–82 (22 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Carrying out the Medicine/Public Health Initiative: the roles of preventive medicine and community-responsive care. Cashman SB, et al. **Acad Med** 1999 May;74(5):473–83 (54 ref.)

Meeting primary oral health care needs of HIV-infected women [editorial; comment] Zabos GP. **Am J Public Health** 1999 Jun;89(6):818–9 (7 ref.) Comment on: Am J Public Health 1999 Jun;89(6):834–9.

Collaboration between GPs and nurse practitioners. The overseas experience and lessons for Australia. Whitecross L. **Aust Fam Physician** 1999 Apr;28(4):349–53 (40 ref.)

Screening in general practice and primary care. Robson J. **Br Med Bull** 1998;54(4):961–82 (95 ref.)

The organization of successful diabetes management in primary care. Tasker PR. **Diabet Med** 1998 Nov;15 Suppl 3:S58–60 (6 ref.)

Breaking the barriers for improved glycaemic control: primary care and secondary care interface. Williams R. **Diabet Med** 1998;15 Suppl 4:S37–40 (22 ref.)

Primary health care in the eastern Mediterranean region before and after Alma-Ata. Abdullatif AA. **East Mediterr Health J** 1998;4 Suppl:S85–102 (18 ref.)

Structural issues and policy in the primary care management of depression. Magruder KM, et al. **J Clin Psychiatry** 1999; 60 Suppl 7:45–51; discussion 52–3 (23 ref.)

Tensions in setting health care priorities for South Africa's children. Landman WA, et al. **J Med Ethics** 1998 Aug; 24(4):268–73 (30 ref.)

Primary care and pain medicine. A community solution to the public health problem of chronic pain. Gallagher RM. **Med Clin North Am** 1999 May;83(3):555–83, v (91 ref.)

Collaborative care in the United Kingdom. Jenkins GC. **Prim Care** 1999 Jun;26(2):411–22 (41 ref.)

Models of collaboration. Lorenz AD, et al. **Prim Care** 1999 Jun;26(2):401–10 (14 ref.)

Health plans and purchasers: managing women's primary care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):15S–25S (36 ref.)

Women's primary care in managed care: clinical and provider issues. Gonen JS. **Womens Health Issues** 1999 Mar–Apr; 9(2 Suppl):5S–14S (46 ref.)

[Volunteerism and the reorientation of health services] Tomás Sancho A, et al. **Aten Primaria** 1998 Oct 31;22(7):450–6 (62 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Asthma--a problem of health care delivery. Is it time for a new paradigm? Weinberger M. **Allergy Asthma Proc** 1999 Jan–Feb;20(1):57–65 (64 ref.)

Interventions to improve the delivery of preventive services in primary care. Hulscher ME, et al. **Am J Public Health** 1999 May;89(5):737–46 (83 ref.)

Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Schulberg HC, et al. **Arch Gen Psychiatry** 1998 Dec;55(12):1121–7 (77 ref.)

Refugees and primary care: tackling the inequalities [see comments] Jones D, et al. **BMJ** 1998 Nov 21; 317(7170):1444–6 (25 ref.) Comment in: BMJ 1999 Mar 6;318(7184):671.

Performance indicators for primary care groups: an evidence based approach [see comments] McColl A, et al. **BMJ** 1998 Nov 14;317(7169):1354–60 (43 ref.) Comment in: BMJ 1999 Mar 20;318(7186):803; discussion 804–5. Comment in: BMJ 1999 Mar 20;318(7186):803–4; discussion 804–5. Comment in: BMJ 1999 Mar 20;318(7186):804–5.

Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. Calabrese LH. **J Am Osteopath Assoc** 1999 Jun;99(6):313–21 (46 ref.)

Emotions, ethics, and decisions in primary care. Connelly J. **J Clin Ethics** 1998 Fall;9(3):225–34 (36 ref.)

Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. Ballenger JC, et al. **J Clin Psychiatry** 1999;60 Suppl 7:54–61 (29 ref.)

Best clinical practice: guidelines for managing major depression in primary medical care. Schulberg HC, et al. **J Clin Psychiatry** 1999;60 Suppl 7:19–26; discussion 27–8 (70 ref.)

Depression in the community: physician and patient perspective. Tylee A. **J Clin Psychiatry** 1999;60 Suppl 7:12–6; discussion 17–8 (53 ref.)

Challenges in evaluating primary health care for teenagers. Research Sub-Committee of the Adolescent Working Party of the Royal College of General Practitioners, London, UK. Jacobson LD, et al. **J Eval Clin Pract** 1998 Aug; 4(3):183–9 (36 ref.)

Immunization performance measurement in a changing immunization environment. Rodewald L, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):889–97 (79 ref.)

Issues at the interface between primary and secondary care in the management of common respiratory disease. 3: Providing better asthma care: what is there left to do? Neville RG, et al. **Thorax** 1999 Sep;54(9):813–7 (32 ref.)

The primary care of elder mistreatment. Hirsch CH, et al. **West J Med** 1999 Jun;170(6):353–8 (25 ref.)

Meeting the challenge of early identification of HIV infection in primary care. Vergeront JM, et al. **WMJ** 1998 Dec; 97(11):52–61 (6 ref.)

[Management of mental health and primary care. Development and evaluation of a training program based on the PLISSIT approach] Vauth R, et al. **Nervenarzt** 1999 Jan;70(1):54–63 (32 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Comparison of dermatologic diagnoses by primary care practitioners and dermatologists. A review of the literature. Federman DG, et al. **Arch Fam Med** 1999 Mar–Apr; 8(2):170–2 (14 ref.)

Solar retinopathy in a hospital-based primary care clinic. Stokkermans TJ, et al. **J Am Optom Assoc** 1998 Oct; 69(10):625–36 (75 ref.)

Comorbidity in primary care: presentation and consequences. Wittchen HU, et al. **J Clin Psychiatry** 1999;60 Suppl 7:29–36; discussion 37–8 (37 ref.)

TRENDS

Incorporating palliative care into primary care education. National Consensus Conference on Medical Education for Care Near the End of Life. Block SD, et al. **J Gen Intern Med** 1998 Nov;13(11):768–73 (28 ref.)

UTILIZATION

Medically unexplained symptoms in primary care. Katon WJ, et al. **J Clin Psychiatry** 1998;59 Suppl 20:15–21 (54 ref.)

PRIMARY NURSING CARE

Preconception care. An integral part of primary care for women. Reynolds HD. **J Nurse Midwifery** 1998 Nov–Dec; 43(6):445–58 (69 ref.)

PRIMARY PREVENTION

Social, community, and preventive interventions. Reppucci ND, et al. **Annu Rev Psychol** 1999;50:387–418 (192 ref.)

Stroke: how large a public health problem, and how can the neurologist help? Hankey GJ. **Arch Neurol** 1999 Jun; 56(6):748–54 (36 ref.)

Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension [see comments] Staessen JA, et al. **Eur Heart J** 1999 Jan; 20(1):11–24 (113 ref.) Comment in: Eur Heart J 1999 Jan;20(1):5–6.

Austrian Committee for Injury Prevention in Childhood. Purtscher K, et al. **Inj Prev** 1998 Sep;4(3):236–7 (3 ref.)

The complex realities of primary prevention for HIV infection in a "just do it" world. Bradley-Springer LA. **Nurs Clin North Am** 1999 Mar;34(1):49–70 (90 ref.)

[Prevention of cutaneous melanoma] van der Rhee HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1356–9 (24 ref.) (Eng. Abstr.) **(Dut)**

[Medicine seized by the principle of precaution] David G. **Bull Acad Natl Med** 1998;182(6):1219–28; discussion 1228–30 (15 ref.) (Eng. Abstr.) **(Fre)**

[The successes and failures in the primary prevention of coronary disease] Clara JG, et al. **Rev Port Cardiol** 1999 Jul–Aug;18(7–8):729–32 (16 ref.) (Eng. Abstr.) **(Por)**

[Justification of a prevention policy of perinatal disease by group B streptococci (GBS). Recommendations] Andreu A, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):138–40 (8 ref.) **(Spa)**

[Prevention--illusion or hope for the future?] Allander E. **Lakartidningen** 1999 Feb 10;96(6):620–2 (29 ref.) **(Swe)**

[Prescribed exercise can help the patient to change his habits] Hellénius ML, et al. **Lakartidningen** 1999 Jul 28; 96(30–31):3343–6 (34 ref.) **(Swe)**

ECONOMICS

[Primary and secondary prevention of coronary heart disease: what can we afford?] Kübler W, et al. **Z Kardiol** 1999 Feb; 88(2):85–9 (13 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Preventing unsafe abortion in Nigeria. Okonofua F. **Afr J Reprod Health** 1997 Mar;1(1):25–36 (31 ref.)

PRIMARY PREVENTION

The role of mechanical and other adjuncts. Westrich GH. **Am J Knee Surg** 1999 Winter;12(1):64–71 (92 ref.)
Putting prevention into practice: just do it [editorial] Litt J. **Aust Fam Physician** 1999 Jan;28 Suppl 1:S1–2 (15 ref.)
Disability in older adults. 2: Physical activity as prevention. Carlson JE, et al. **Behav Med** 1999 Winter;24(4):157–68 (78 ref.)
Is primary prevention of asthma possible? Becker AB. **Can Respir J** 1998 Jul–Aug;5 Suppl A:45A–9A (32 ref.)
Of resilience, vulnerability, and a woman who never lived. Allen JR. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):53–71, viii (177 ref.)
Risk factors: assessment and preventive measures. Wild RA. **Clin Obstet Gynecol** 1998 Dec;41(4):966–75 (12 ref.)
Incorporating preventive care recommendations into clinical practice: how do we bridge the gap? [editorial; comment] Douketis JD. **CMAJ** 1999 Apr 20;160(8):1171–2 (19 ref.) Comment on: CMAJ 1999 Apr 20;160(8):1137–40.
Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations. Malm HM. **Hastings Cent Rep** 1999 Jan–Feb;29(1):26–37 (55 ref.)
Malignancy and aneuploidy: prevention and early detection. Kirschner B. **Inflamm Bowel Dis** 1998 Aug;4(3):216–20 (25 ref.)
Current approach to STD management in women. Amaral E. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S183–9 (28 ref.)
Posttraumatic stress disorder in children: implications for assessment, prevention, and referral in primary care. Pfefferbaum B, et al. **J Okla State Med Assoc** 1999 Jul; 92(7):309–15 (67 ref.)
Prevention: are we really reaching today's teens? Muscari ME. **MCN Am J Matern Child Nurs** 1999 Mar–Apr; 24(2):87–91 (7 ref.)
Vascular dementia: diagnosis, management and possible prevention. Sachdev PS, et al. **Med J Aust** 1999 Jan 18; 170(2):81–5 (25 ref.)
Prevention of work-related disability. Feldstein A, et al. **Occup Med** 1998 Oct–Dec;13(4):841–50, v (13 ref.)
Can birth defects be prevented? [editorial] Dryden R. **P N G Med J** 1997 Mar;40(1):1–3 (12 ref.)
AIDS and the community. Farmer E. **P N G Med J** 1996 Sep;39(3):214–7 (6 ref.)
Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253–62 (34 ref.)
Strategies to prevent further cerebral ischaemic episodes. MacWalter RS. **Scott Med J** 1997 Oct;42(5):135 (11 ref.)
Emphasizing and promoting overall health and nontraditional treatments after a prostate cancer diagnosis. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):119–24 (95 ref.)
Pathophysiology, prevention, and management of prosthetic infections in hernia surgery. Deysine M. **Surg Clin North Am** 1998 Dec;78(6):1105–15, viii (26 ref.)
Childhood poisoning: the scope for prevention. Chan TY. **Vet Hum Toxicol** 1998 Dec;40(6):361–3 (27 ref.)
Diabetic foot ulcers: A framework for prevention and care. Boulton AJ, et al. **Wound Repair Regen** 1999 Jan–Feb; 7(1):7–16 (78 ref.)
[Delivery methods for infants weighing less than 2500 grams. Which particular preventative modalities should be proposed for natural delivery?] Verspyck E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:311–3 (13 ref.) **(Fre)**
[Malaria prophylaxis] Bouchaud O, et al. **Rev Prat** 1998 Feb 1;48(3):279–86 (28 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of skin cancers] Grob JJ, et al. **Rev Prat** 1999 Apr 15;49(8):838–42 (17 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of cerebral ischemic vascular accidents] Jaillard A, et al. **Rev Prat** 1998 Jan 15;48(2):165–70 (38 ref.) (Eng. Abstr.) **(Fre)**
[Infectious diseases during pregnancy. Prevention, diagnosis and fetal risks] Luton D, et al. **Rev Prat** 1999 Jan 1; 49(1):89–106 (5 ref.) **(Fre)**
[Prevention using folic acid--a good method for reduction of neural tube defects in Poland] Lech M. **Przegl Lek** 1998; 55(6):334–6 (22 ref.) (Eng. Abstr.) **(Pol)**

ORGANIZATION & ADMINISTRATION

Childhood lead poisoning: the promise and abandonment of primary prevention [see comments] Needleman HL. **Am J Public Health** 1998 Dec;88(12):1871–7 (38 ref.) Comment in: Am J Public Health 1998 Dec;88(12):1759–60. Comment in: Am J Public Health 1999 Jul;89(7):1126–31.
Reducing the burden of injury. Rivara FP. **Inj Prev** 1999 Jun;5(2):85–6 (7 ref.)
Some theoretical remarks regarding the integration of somatic and psychosocial risk factors of coronary artery disease in preventive programmes in occupational medicine. Schmahl FW. **Int J Occup Med Environ Health** 1998;11(4):285–9 (12 ref.)
Policy options for prevention: the case of alcohol. Toomey TL, et al. **J Public Health Policy** 1999;20(2):192–213 (81 ref.)
The role of prevention in workers' compensation managed care arrangements. Dembe AE, et al. **Occup Med** 1998 Oct–Dec;13(4):663–77, iii (48 ref.)
Health promotion for people with disabilities: the emerging paradigm shift from disability prevention to prevention of secondary conditions. Rimmer JH. **Phys Ther** 1999 May; 79(5):495–502 (39 ref.)
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of decision-makers. An example currently in place: the prenatal network for child abuse prevention] Hermange MT. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:237–46 (15 ref.) **(Fre)**

TRENDS

[Therapeutics of the future for allergy] Sibille G. **Allerg Immunol (Paris)** 1999 Apr;31(4):120–1 (4 ref.) (Eng. Abstr.) **(Fre)**
[The primary prevention of cholesterol biliary lithiasis: the present and future] Encinas Sotillos A, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):22–7 (63 ref.) **(Spa)**

PRIMARY TOOTH see **TOOTH, DECIDUOUS**

PRIMATE IMMUNODEFICIENCY VIRUSES see **LENTIVIRUSES, PRIMATE**

PRIMATES

Cryopreservation of non-human primate sperm: priorities for future research. Morrell JM, et al. **Anim Reprod Sci** 1998 Oct;53(1–4):43–63 (66 ref.)
Nutritional characteristics of wild primate foods: do the diets of our closest living relatives have lessons for us? Milton K. **Nutrition** 1999 Jun;15(6):488–98 (114 ref.)

ANATOMY & HISTOLOGY

Functional morphology of the trabecular meshwork in primate eyes. Lütjen-Drecoll E. **Prog Retin Eye Res** 1999 Jan;18(1):91–119 (136 ref.)

CLASSIFICATION

A test of Archonta monophyly and the phylogenetic utility of the mitochondrial gene 12S rRNA. McNiff BE, et al. **Am J Phys Anthropol** 1998 Nov;107(3):225–41 (78 ref.)

GENETICS

Major histocompatibility complex class II polymorphisms in primates. Bontrop RE, et al. **Immunol Rev** 1999 Feb; 167:339–50 (50 ref.)
Molecular clock and recombination in primate Mhc genes. Satta Y, et al. **Immunol Rev** 1999 Feb;167:367–79 (79 ref.)

IMMUNOLOGY

Major histocompatibility complex class II polymorphisms in primates. Bontrop RE, et al. **Immunol Rev** 1999 Feb; 167:339–50 (50 ref.)
Molecular clock and recombination in primate Mhc genes. Satta Y, et al. **Immunol Rev** 1999 Feb;167:367–79 (79 ref.)

METABOLISM

Lipoprotein and cholesterol metabolism in diet-induced coronary artery atherosclerosis in primates. Role of cholesterol and fatty acids. Rudel LL, et al. **Prog Lipid Res** 1998 Dec;37(6):353–70 (101 ref.)

PHYSIOLOGY

Evolution of human growth prolongation. Leigh SR, et al. **Am J Phys Anthropol** 1998 Nov;107(3):331–50 (84 ref.)
The concept of the ventral striatum in nonhuman primates. Haber SN, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:33–48 (55 ref.)
Stepping in nonhuman primates with a complete spinal cord transection: old and new data, and implications for humans. Vilensky JA, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:528–30 (15 ref.)
Theory of mind in nonhuman primates. Heyes CM. **Behav Brain Sci** 1998 Feb;21(1):101–14; discussion 115–48 (275 ref.)
Auditory processing in primate cerebral cortex. Kaas JH, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):164–70 (82 ref.)
Cortical processing of complex sounds. Rauschecker JP. **Curr Opin Neurobiol** 1998 Aug;8(4):516–21 (53 ref.)
The organization of the cortical motor system: new concepts. Rizzolatti G, et al. **Electroencephalogr Clin Neurophysiol** 1998 Apr;106(4):283–96 (104 ref.)
Calorie restriction in primates: will it work and how will we know? Roth GS, et al. **J Am Geriatr Soc** 1999 Jul; 47(7):896–903 (40 ref.)
Branching out in locomotion: the mechanics of perch use in birds and primates. Bonser RH. **J Exp Biol** 1999 Jun; 202 (Pt 11):1459–63 (35 ref.)
Molecular mechanism of embryo-endometrial adhesion in primates: a future task for implantation biologists. Ghosh D, et al. **Mol Hum Reprod** 1998 Aug;4(8):733–5 (33 ref.)
Reward prediction in primate basal ganglia and frontal cortex. Schultz W, et al. **Neuropharmacology** 1998 Apr–May;37(4–5):421–9 (30 ref.)
Vision for perception and vision for action in the primate brain. Goodale MA. **Novartis Found Symp** 1998;218:21–34; discussion 34–9 (47 ref.)
Response properties of spinal interneurons in awake, behaving primates. Fetz EE. **Pain** 1999 Aug;Suppl 6:S55–60 (37 ref.)
Functional morphology of the trabecular meshwork in primate eyes. Lütjen-Drecoll E. **Prog Retin Eye Res** 1999 Jan;18(1):91–119 (136 ref.)
Cognitive and motivational operations in primate prefrontal neurons. Watanabe M. **Rev Neurosci** 1998;9(4):225–41 (133 ref.)
Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Bergman H, et al. **Trends Neurosci** 1998 Jan;21(1):32–8 (58 ref.)

PSYCHOLOGY

Theory of mind in nonhuman primates. Heyes CM. **Behav Brain Sci** 1998 Feb;21(1):101–14; discussion 115–48 (275 ref.)
Primate socioecology: new insights from males. Kappeler PM. **Naturwissenschaften** 1999 Jan;86(1):18–29 (147 ref.)
Reward prediction in primate basal ganglia and frontal cortex. Schultz W, et al. **Neuropharmacology** 1998 Apr–May;37(4–5):421–9 (30 ref.)
Social influences on endocrine activity in guinea pigs, with comparisons to findings in nonhuman primates. Hennessy MB. **Neurosci Biobehav Rev** 1999 May;23(5):687–98 (102 ref.)
Generic aspects of primate attachments: parents, offspring and mates. Mason WA, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):765–78 (97 ref.)
Levels of selection, altruism, and primate behavior. Bradley BJ. **Q Rev Biol** 1999 Jun;74(2):171–94 (94 ref.)

PRIMED IN SITU LABELING

METHODS

The use of arbitrarily primed polymerase chain reaction in cancer research. Navarro JM, et al. **Electrophoresis** 1999 Feb;20(2):283–90 (34 ref.)

PRIMIDONE

ADVERSE EFFECTS

A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor. Louis ED. **Arch Neurol** 1999 Jul;56(7):807–8 (18 ref.)

PRIMIPARITY see **PARITY**

PRIMITIVE GUT see **GASTRULA**

PRIMITIVE STREAK see **GASTRULA**

PRINCIPLE-BASED ETHICS see **ETHICS**

PRINDOLOL see **PINDOLOL**

PRINS see **PRIMED IN SITU LABELING**

PRINZMETAL'S ANGINA see **ANGINA PECTORIS, VARIANT**

PRION DISEASES

The prionoses and other conformational disorders. Wisniewski T, et al. **Amyloid** 1998 Sep;5(3):212–24 (107 ref.)
Transmissible spongiform encephalopathies. Liemann S, et al. **Biochem Biophys Res Commun** 1998 Sep 18; 250(2):187–93 (90 ref.)
Prions and prion diseases of the central nervous system. Tyler KL. **Curr Clin Top Infect Dis** 1999;19:226–51 (267 ref.)
Prion diseases. Aguzzi A, et al. **Haemophilia** 1998 Jul; 4(4):619–27 (81 ref.)
The spongiform encephalopathies: prion diseases. Mocsny N. **J Neurosci Nurs** 1998 Oct;30(5):302–6 (36 ref.)
Prion diseases in man. Ironside JW. **J Pathol** 1998 Nov; 186(3):227–34 (85 ref.)
Prions. Prusiner SB. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13363–83 (347 ref.)
[Prion diseases in pediatrics] Sol-Caubel I, et al. **Arch Pediatr** 1999 Mar;6(3):293–301 (36 ref.) (Eng. Abstr.) **(Fre)**
[The new research frontier on prion disease (editorial)] Aguzzi A, et al. **Pathologica** 1998 Dec;90(6):743–52 (83 ref.) **(Ita)**
[Iatrogenic prion disease] Kuroda Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):230–3 (12 ref.) **(Jpn)**
[Subacute spongiform encephalopathy] Mizutani T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):211–3 (5 ref.) **(Jpn)**
[Fatal familial insomnia] Shinohara Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):226–9 (12 ref.) **(Jpn)**
[Prionoses--neurodegenerative diseases caused by prions, offectious proteinaceous molecules] Ferenčik M, et al. **Bratisl Lek Listy** 1998 Aug–Sep;99(8–9):486–98 (76 ref.) (Eng. Abstr.) **(Slo)**

CEREBROSPINAL FLUID

Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. Weller RO. **J Neuropathol Exp Neurol** 1998 Oct;57(10):885–94 (89 ref.)

CLASSIFICATION

[Diseases transmitted by non-conventional agents ("prions"): nosology and diagnosis] Hauw JJ, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):131-7 (62 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Unconventional transmissible agents, or prions] Bodaghi B, et al. **J Fr Ophtalmol** 1998 Jan;21(1):51-69 (193 ref.) **(Fre)**

[Clinical presentations of spongiform encephalopathies in humans] Szczudlik A, et al. **Przegl Lek** 1999;56(4):324-6 (24 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. Soto C. **J Mol Med** 1999 May; 77(5):412-8 (74 ref.)

[Spongiform encephalopathies: a second chance for GABAergic agonists] Vamvakidès A. **Ann Pharm Fr** 1998; 56(1):26-30 (42 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Prion infections in Creutzfeldt-Jakob disease and its variants. Parker JC Jr, et al. **Ann Clin Lab Sci** 1999 Apr-Jun; 29(2):112-7 (33 ref.)

Pathologic conformations of prion proteins. Cohen FE, et al. **Annu Rev Biochem** 1998;67:793-819 (139 ref.)

Agents that cause transmissible subacute spongiform encephalopathies. Dormont D. **Biomed Pharmacother** 1999; 53(1):3-8 (58 ref.)

Cellular biology of prion diseases. Harris DA. **Clin Microbiol Rev** 1999 Jul;12(3):429-44 (186 ref.)

Transmissible spongiform encephalopathies: transmission, mechanism of disease, and persistence. Foster J, et al. **Curr Opin Microbiol** 1998 Aug;1(4):442-7 (52 ref.)

[The non-conventional transmissible agents at the origin of transmissible subacute spongiform encephalopathies] Dormont D. **Therapie** 1998 Mar-Apr;53(2):93-100 (50 ref.) (Eng. Abstr.) **(Fre)**

[Conformation and neurotoxicity: relationship between Alzheimer's disease and prion disease] Kawahara M. **Seikagaku** 1998 Dec;70(12):1422-6 (14 ref.) **(Jpn)**

[Prion disease and brain amyloidosis] Rukosuev VS, et al. **Arkh Patol** 1999 Mar-Apr;61(2):50-5 (49 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Prion infections in Creutzfeldt-Jakob disease and its variants. Parker JC Jr, et al. **Ann Clin Lab Sci** 1999 Apr-Jun; 29(2):112-7 (33 ref.)

The three-dimensional structure of prion protein: implications for prion disease. Baldwin MA, et al. **Biochem Soc Trans** 1998 Aug;26(3):481-6 (64 ref.)

Transgenic and knockout mice in research on prion diseases. Raeber AJ, et al. **Brain Pathol** 1998 Oct;8(4):715-33 (147 ref.)

Molecular genetics of transmissible spongiform encephalopathies. Weissmann C. **J Biol Chem** 1999 Jan 1; 274(1):3-6 (50 ref.)

The prion diseases: Creutzfeldt-Jakob, Gerstmann-Sträussler-Scheinker, and related disorders. Mastrianni JA. **J Geriatr Psychiatry Neurol** 1998 Summer; 11(2):78-97 (210 ref.)

The genetics of prions--a contradiction in terms? Aguzzi A, et al. **Lancet** 1999 Jul;354 Suppl 1:SI22-5 (45 ref.)

An inherited prion disease with a PrP P105L mutation: clinicopathologic and PrP heterogeneity. Yamada M, et al. **Neurology** 1999 Jul 13;53(1):181-8 (31 ref.)

Molecular studies of prion diseases. Safar J, et al. **Prog Brain Res** 1998;117:421-34 (90 ref.)

[Fatal familial insomnia] Delisle MB, et al. **Clin Exp Pathol** 1999;47(3-4):176-80 (40 ref.) (Eng. Abstr.) **(Fre)**

[Molecular bases of prion diseases] Pokrovskiĭ VI, et al. **Vestn Ross Akad Med Nauk** 1998;(10):45-55 (31 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

1755 and all that: a historical primer of transmissible spongiform encephalopathy. Brown P, et al. **BMJ** 1998 Dec 19-26;317(7174):1688-92 (20 ref.)

IMMUNOLOGY

Prion diseases and the immune system [editorial] Aucouturier P, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):75-8 (26 ref.)

Prions, new molecular forms of biological information. Dormont D. **Res Immunol** 1998 Sep-Oct;149(7-8):711-7 (64 ref.)

METABOLISM

Prion protein and species barriers in the transmissible spongiform encephalopathies. Priola SA. **Biomed Pharmacother** 1999;53(1):27-33 (55 ref.)

Abnormalities in stress proteins in prion diseases. Tatzelt J, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):721-9 (37 ref.)

Conformational changes and disease--serpins, prions and Alzheimer's. Carrell RW, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):799-809 (59 ref.)

NURSING

Prion diseases--an evidence-based protocol for infection control. Steelman VM. **AORN J** 1999 May;69(5):946-54, 956-67 passim; quiz 968-76 (94 ref.)

PATHOLOGY

Clinical aspects of human spongiform encephalopathies, with the exception of iatrogenic forms. Brandel JP. **Biomed Pharmacother** 1999;53(1):14-8 (18 ref.)

Neuropathology of prion diseases. Mikol J. **Biomed Pharmacother** 1999;53(1):19-26 (58 ref.)

Transgenic and knockout mice in research on prion diseases. Raeber AJ, et al. **Brain Pathol** 1998 Oct;8(4):715-33 (147 ref.)

The evolution of views on the nosological position of transmissible spongiform encephalopathies. Liberski PP, et al. **Folia Neuropathol** 1997;35(4):214-25 (111 ref.)

The use of monoclonal antibodies in human prion disease. Bodemer W. **Naturwissenschaften** 1999 May;86(5):212-20 (45 ref.)

[A process of programmed cell death as a mechanisms of neuronal death in prion diseases] Chrétien F, et al. **Clin Exp Pathol** 1999;47(3-4):181-91 (89 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Impaired motor coordination in mice lacking prion protein. Katamine S, et al. **Cell Mol Neurobiol** 1998 Dec; 18(6):731-42 (56 ref.)

Cellular biology of prion diseases. Harris DA. **Clin Microbiol Rev** 1999 Jul;12(3):429-44 (186 ref.)

Physical bioenergetics of degradation-resistant proteins in diseases and aging. Axelsson S. **Med Hypotheses** 1998 Jul; 51(1):47-51 (20 ref.)

[Biology of non-conventional transmissible agents or prions] Dormont D. **Rev Neurol (Paris)** 1998 Feb;154(2):142-51 (126 ref.) (Eng. Abstr.) **(Fre)**

[Familial fatal insomnia: a human prion disease which opens the door to a greater understanding of the thalamus] Barriga F, et al. **Rev Med Univ Navarra** 1997 Oct-Dec; 41(4):224-8 (24 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Prion diseases--an evidence-based protocol for infection control. Steelman VM. **AORN J** 1999 May;69(5):946-54, 956-67 passim; quiz 968-76 (94 ref.)

Inactivation of prions in daily medical practice. Darbord JC. **Biomed Pharmacother** 1999;53(1):34-8 (24 ref.)

Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Yap PL, et al. **Vox Sang** 1998;74 Suppl 2:131-4 (8 ref.)

TRANSMISSION

The human prion diseases. A review with special emphasis on new variant CJD and comments on surveillance. Keohane C. **Clin Exp Pathol** 1999;47(3-4):125-32 (30 ref.)

Risk of prion disease transmission from ocular donor tissue transplantation. Hogan RN, et al. **Cornea** 1999 Jan; 18(1):2-11 (49 ref.)

Transmissible spongiform encephalopathies: transmission, mechanism of disease, and persistence. Foster J, et al. **Curr Opin Microbiol** 1998 Aug;1(4):442-7 (52 ref.)

Transmission of spongiform encephalopathy through biological products. Brown P. **Dev Biol Stand** 1998;93:73-8 (16 ref.)

Transmissible spongiform encephalopathy agents and animal sera. Dormont D. **Dev Biol Stand** 1999;99:25-34 (51 ref.)

A dual pathway for the transmission of spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1998 Jul;51(1):17-22 (45 ref.)

The spatial dynamics of prion disease. Payne RJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2341-6 (34 ref.)

[Anesthesia and non-conventional transmissible agents (or prion diseases)] Estèbe JP. **Ann Fr Anesth Reanim** 1997; 16(8):955-63 (61 ref.) (Eng. Abstr.) **(Fre)**

[Spongiform encephalopathies] Pastoret PP. **Bull Soc Sci Med Grand Duche Luxemb** 1998;135(1):25-38 (43 ref.) (Eng. Abstr.) **(Fre)**

[Biology of non-conventional transmissible agents or prions] Dormont D. **Rev Neurol (Paris)** 1998 Feb;154(2):142-51 (126 ref.) (Eng. Abstr.) **(Fre)**

[Diseases transmitted by non-conventional agents ("prions"): nosology and diagnosis] Hauw JJ, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):131-7 (62 ref.) (Eng. Abstr.) **(Fre)**

[Nosocomial infections implying viruses and unconventional transmissible agents] Zandotti C, et al. **Rev Prat** 1998 Sep 15;48(14):1563-8 (31 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Possible retroviral origin of prion disease: could prion disease be reconsidered as a preleukemia syndrome? Labat ML. **Biomed Pharmacother** 1999;53(1):47-53 (60 ref.)

PRION PROTEINS see **PRIONS**

PRIONS

Transmissible spongiform encephalopathies. Liemann S, et al. **Biochem Biophys Res Commun** 1998 Sep 18; 250(2):187-93 (90 ref.)

Prions of yeast and fungi. Proteins as genetic material. Wickner RB, et al. **J Biol Chem** 1999 Jan 8;274(2):555-8 (40 ref.)

Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Yap PL, et al. **Vox Sang** 1998;74 Suppl 2:131-4 (8 ref.)

[Diseases transmitted by non-conventional agents ("prions"): nosology and diagnosis] Hauw JJ, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):131-7 (62 ref.) (Eng. Abstr.) **(Fre)**

[Nosocomial infections implying viruses and unconventional transmissible agents] Zandotti C, et al. **Rev Prat** 1998 Sep 15;48(14):1563-8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Prion terminology] Makarov VV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr; (2):96-9 (11 ref.) **(Rus)**

[Prionoses--neurodegenerative diseases caused by prions, offectious proteinaceous molecules] Ferenčik M, et al. **Bratisl Lek Listy** 1998 Aug-Sep;99(8-9):486-98 (76 ref.) (Eng. Abstr.) **(Slo)**

[A review of the current research on prions. The evidence suggests the possibility of transmission of the mad cow disease to humans] Grandien M, et al. **Lakartidningen** 1998 Nov 25;95(48):5499-500, 5503-5 (35 ref.) (Eng. Abstr.) **(Swe)**

ANALYSIS

The use of monoclonal antibodies in human prion disease. Bodemer W. **Naturwissenschaften** 1999 May;86(5):212-20 (45 ref.)

ANTAGONISTS & INHIBITORS

Inactivation of prions in daily medical practice. Darbord JC. **Biomed Pharmacother** 1999;53(1):34-8 (24 ref.)

BLOOD

Transmissible spongiform encephalopathy agents and animal sera. Dormont D. **Dev Biol Stand** 1999;99:25-34 (51 ref.)

CHEMISTRY

The prionoses and other conformational disorders. Wisniewski T, et al. **Amyloid** 1998 Sep;5(3):212-24 (107 ref.)

Pathologic conformations of prion proteins. Cohen FE, et al. **Annu Rev Biochem** 1998;67:793-819 (139 ref.)

The three-dimensional structure of prion protein: implications for prion disease. Baldwin MA, et al. **Biochem Soc Trans** 1998 Aug;26(3):481-6 (64 ref.)

Conformational changes and disease--serpins, prions and Alzheimer's. Carrell RW, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):799-809 (59 ref.)

Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. Soto C. **J Mol Med** 1999 May; 77(5):412-8 (74 ref.)

Physical bioenergetics of degradation-resistant proteins in diseases and aging. Axelsson S. **Med Hypotheses** 1998 Jul; 51(1):47-51 (20 ref.)

Molecular studies of prion diseases. Safar J, et al. **Prog Brain Res** 1998;117:421-34 (90 ref.)

GENETICS

The three-dimensional structure of prion protein: implications for prion disease. Baldwin MA, et al. **Biochem Soc Trans** 1998 Aug;26(3):481-6 (64 ref.)

The yeast [PSI+] prion: making sense of nonsense. Liebman SW, et al. **J Biol Chem** 1999 Jan 15;274(3):1181-4 (60 ref.)

The genetics of prions--a contradiction in terms? Aguzzi A, et al. **Lancet** 1999 Jul;354 Suppl 1:SI22-5 (45 ref.)

An inherited prion disease with a PrP P105L mutation: clinicopathologic and PrP heterogeneity. Yamada M, et al. **Neurology** 1999 Jul 13;53(1):181-8 (31 ref.)

Molecular studies of prion diseases. Safar J, et al. **Prog Brain Res** 1998;117:421-34 (90 ref.)

[Gerstmann-Straüssler-Scheinker syndrome] Tranchant C, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):152-7 (47 ref.) (Eng. Abstr.) **(Fre)**

[Prions and their characteristics in light of recent tests] Szostek S, et al. **Przegl Lek** 1999;56(4):321-3 (19 ref.) (Eng. Abstr.) **(Pol)**

[Molecular bases of prion diseases] Pokrovskiĭ VI, et al. **Vestn Ross Akad Med Nauk** 1998;(10):45-55 (31 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Prions, new molecular forms of biological information. Dormont D. **Res Immunol** 1998 Sep-Oct;149(7-8):711-7 (64 ref.)

METABOLISM

Prion protein and species barriers in the transmissible spongiform encephalopathies. Priola SA. **Biomed Pharmacother** 1999;53(1):27-33 (55 ref.)

Abnormalities in stress proteins in prion diseases. Tatzelt J,

PRIONS

et al. **Cell Mol Neurobiol** 1998 Dec;18(6):721-9 (37 ref.)
Prions and prion diseases of the central nervous system. Tyler KL. **Curr Clin Top Infect Dis** 1999;19:226-51 (267 ref.)
Physical bioenergetics of degradation-resistant proteins in diseases and aging. Axelsson S. **Med Hypotheses** 1998 Jul; 51(1):47-51 (20 ref.)

PATHOGENICITY

[About prions...] Prévot M, et al. **Ann Chir Plast Esthet** 1996 Dec;41(6):676-83 (9 ref.) (Eng. Abstr.) **(Fre)**
[Unconventional transmissible agents, or prions] Bodaghi B, et al. **J Fr Ophtalmol** 1998 Jan;21(1):51-69 (193 ref.) **(Fre)**
[Prions and their characteristics in light of recent tests] Szostek S, et al. **Przegl Lek** 1999;56(4):321-3 (19 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Impaired motor coordination in mice lacking prion protein. Katamine S, et al. **Cell Mol Neurobiol** 1998 Dec; 18(6):731-42 (56 ref.)
Cellular biology of prion diseases. Harris DA. **Clin Microbiol Rev** 1999 Jul;12(3):429-44 (186 ref.)
Prion diseases. Aguzzi A, et al. **Haemophilia** 1998 Jul; 4(4):619-27 (81 ref.)
A dual pathway for the transmission of spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1998 Jul;51(1):17-22 (45 ref.)
Prion proteins as memory molecules: an hypothesis. Tompa P, et al. **Neuroscience** 1998 Oct;86(4):1037-43 (58 ref.)
Prions. Prusiner SB. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13363-83 (347 ref.)
Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Rieger R, et al. **Transfus Clin Biol** 1999 Feb;6(1):7-16 (65 ref.)
[Biology of non-conventional transmissible agents or prions] Dormont D. **Rev Neurol (Paris)** 1998 Feb;154(2):142-51 (126 ref.) (Eng. Abstr.) **(Fre)**
[On some controversies concerning "prions"] Marcinkowski T. **Pol Merkuriusz Lek** 1998 Sep;5(27):187-90 (16 ref.) **(Pol)**

PRIORITIES, HEALTH see **HEALTH PRIORITIES**

PRISONERS

Novel antipsychotic agents and their implications for forensic psychiatry. Pinals DA, et al. **J Am Acad Psychiatry Law** 1999;27(1):7-22 (92 ref.)
HIV infection in U.S. correctional systems: its effect on the community. Leh SK. **J Community Health Nurs** 1999; 16(1):53-63 (18 ref.)
Drug abusers who die during arrest or in custody. Karch SB, et al. **J R Soc Med** 1999 Mar;92(3):110-3 (40 ref.)
Drug abuse and incarcerated women. A research review. Henderson DJ. **J Subst Abuse Treat** 1998 Nov-Dec; 15(6):579-87 (100 ref.)
The ethics of organ transplantation reconsidered: paid organ donation and the use of executed prisoners as donors [see comments] Cameron JS, et al. **Kidney Int** 1999 Feb; 55(2):724-32 (45 ref.) Comment in: Kidney Int 1999 Feb;55(2):733.

LEGISLATION & JURISPRUDENCE

Broad statutory language is not ambiguous: the Americans with Disabilities Act applies in state prisons. Hoppe SB. **J Contemp Health Law Policy** 1998 Fall;15(1):275-305 (0 ref.)
Forensic psychiatry. A chill wind blows. Farnham F, et al. **Lancet** 1998 Dec 19-26;352 Suppl 4:SIV12 (5 ref.)
The "mad" vs. the "bad" revisited: managing predatory behavior. Tucker W. **Psychiatr Q** 1999 Fall;70(3):221-30 (12 ref.)

PSYCHOLOGY

The role of the psychologist in crisis/hostage negotiations. Hatcher C, et al. **Behav Sci Law** 1998 Autumn;16(4):455-72 (72 ref.)
Differences in anxiety between first-time and multiple-time inmates: a multicultural perspective. Reinhardt V, et al. **J Am Acad Psychiatry Law** 1998;26(3):375-82 (35 ref.)
The management of opiate addicts in police custody. Davison SE, et al. **Med Sci Law** 1999 Apr;39(2):153-60 (31 ref.)
The aggressive patient/inmate: beyond denial. Maier GJ. **Psychiatr Q** 1999 Fall;70(3):199-208 (33 ref.)
Describing and evaluating jail diversion services for persons with serious mental illness. Draine J, et al. **Psychiatr Serv** 1999 Jan;50(1):56-61 (25 ref.)

PRISONER'S DILEMMA see **GAME THEORY**

PRISONS

Controlling tobacco use within prisons [letter] Awofeso N. **Int J Tuberc Lung Dis** 1999 Jun;3(6):547-8 (9 ref.)
Effective HIV/AIDS strategies, policies and programs for the correctional centre system. Munro D. **P N G Med J** 1996 Sep;39(3):230-3 (0 ref.)

LEGISLATION & JURISPRUDENCE

Describing and evaluating jail diversion services for persons with serious mental illness. Draine J, et al. **Psychiatr Serv** 1999 Jan;50(1):56-61 (25 ref.)

ORGANIZATION & ADMINISTRATION

HIV infection in U.S. correctional systems: its effect on the community. Leh SK. **J Community Health Nurs** 1999; 16(1):53-63 (18 ref.)

STATISTICS & NUMERICAL DATA

Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Portaels F, et al. **Int J Tuberc Lung Dis** 1999 Jul; 3(7):582-8 (42 ref.)

PRISTINAMYCIN see **VIRGINIAMYCIN**

PRIVACY

see related
CONFIDENTIALITY
PERSONAL SPACE
SELF DISCLOSURE

Driving toward guiding principles: a goal for privacy, confidentiality, and security of health information. Buckovich SA, et al. **J Am Med Inform Assoc** 1999 Mar-Apr;6(2):122-33 (20 ref.)
[Privacy in intensive care] Buzzi F. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):37-41 (0 ref.) **(Ita)**

LEGISLATION & JURISPRUDENCE

An analysis of genetic discrimination legislation proposed by the 105th congress. Colby JA. **Am J Law Med** 1998; 24(4):443-80 (0 ref.)
Protecting genetic privacy by permitting employer access only to job-related employee medical information: analysis of a unique Minnesota law. Rothstein MA, et al. **Am J Law Med** 1998;24(4):399-416 (0 ref.)
Health services research and personal health information: privacy concerns, new legislation and beyond [editorial] [see comments] Willison DJ. **CMAJ** 1998 Dec 1; 159(11):1378-80 (25 ref.) Comment in: CMAJ 1999 Apr 6;160(7):988.
U.S. Senate Bill 422: the Genetic Confidentiality and Nondiscrimination Act of 1997. Berman JJ, et al. **Diagn Mol Pathol** 1998 Aug;7(4):192-6 (3 ref.)
Medical records. Enhancing privacy, preserving the common good. Etzioni A. **Hastings Cent Rep** 1999 Mar-Apr; 29(2):14-23 (53 ref.)

PRIVACY ACT see **PRIVACY**

PRIVACY OF PATIENT DATA see **CONFIDENTIALITY**

PRIVACY OF SPACE see **PERSONAL SPACE**

PRIVATE ENTERPRISE see **PRIVATE SECTOR**

PRIVATE HOSPITALS see **HOSPITALS, PRIVATE**

PRIVATE PRACTICE

[Perinatal care: advantages and disadvantages of network functioning . Analysis and point-of-view of private clinic pediatricians] Buisson G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:165-75 (18 ref.) **(Fre)**
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic obstetricians] Crézé B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:117-20 (3 ref.) **(Fre)**
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of private clinic anesthetists] Fillette D. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:186-8 (8 ref.) **(Fre)**

PRIVATE SECTOR

The World Bank and world health. Healthcare strategy. Abbasi K. **BMJ** 1999 Apr 3;318(7188):933-6 (4 ref.)
Outcomes and effectiveness research in the private sector. Mendelson DN, et al. **Health Aff (Millwood)** 1998 Sep-Oct; 17(5):75-90 (19 ref.)
Viewpoint: management of malaria--working with the private sector. Brugha R, et al. **Trop Med Int Health** 1999 May;4(5):402-6 (40 ref.)

LEGISLATION & JURISPRUDENCE

Preventive law by corporate professional team players: liability and responsibility in the work of company doctors. Draper E. **J Contemp Health Law Policy** 1999 Spring; 15(2):525-607 (99 ref.)

STATISTICS & NUMERICAL DATA

Health impact of occupational risks in the informal sector in Zimbabwe. Loewenson RH. **Int J Occup Environ Health** 1998 Oct-Dec;4(4):264-74 (31 ref.)

PRIVATIZATION

The Mexican Social Security counterreform: pensions for profit. Laurell AC. **Int J Health Serv** 1999;29(2):371-91 (48 ref.)

ORGANIZATION & ADMINISTRATION

Privatization and the rise and fall of the public mental health safety net. Schnapp WB, et al. **Adm Policy Ment Health** 1999 Jan;26(3):221-5 (9 ref.)
The functions and limitations of trust in the provision of medical care [see comments] Mechanic D. **J Health Polit Policy Law** 1998 Aug;23(4):661-86 (53 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687-95.
Privatisation of teaching hospitals. Brooks PM. **Med J Aust** 1999 Apr 5;170(7):321-2 (17 ref.)

PRIVILEGED COMMUNICATION see **CONFIDENTIALITY**

PRL-SECRETING PITUITARY ADENOMA see **PROLACTINOMA**

PROACCELERIN see **FACTOR V**

PROALBUMIN see **PREALBUMIN**

PROBABILISTIC MODELS see **MODELS, STATISTICAL**

PROBABILITY

The rationale for early diagnosis of cancer--the example of breast cancer. Tubiana M, et al. **Acta Oncol** 1999; 38(3):295-303 (48 ref.)
Field performance measurements of half-facepiece respirators: developing probability estimates to evaluate the adequacy of an APF of 10. Myers WR, et al. **Am Ind Hyg Assoc J** 1998 Nov;59(11):796-801 (19 ref.)
Diagnostic criteria for Parkinson disease. Gelb DJ, et al. **Arch Neurol** 1999 Jan;56(1):33-9 (71 ref.)
Glaucoma care in Olmsted County, Minnesota, 1965-1980: filtering surgery and vision outcomes [editorial; comment] Gaasterland DE. **Arch Ophthalmol** 1999 Sep;117(9):1236-7 (17 ref.) Comment on: Arch Ophthalmol 1999 Sep;117(9):1211-5.
Survival probabilities (the Kaplan-Meier method). Bland JM, et al. **BMJ** 1998 Dec 5;317(7172):1572 (3 ref.)
Rational diagnosis of pulmonary embolism (RADIA PE) in symptomatic outpatients with suspected PE: an improved strategy to exclude or diagnose venous thromboembolism by the sequential use of a clinical model, rapid ELISA D-dimer test, perfusion lung scan, ultrasonography, spiral CT, and pulmonary angiography. Michiels JJ. **Semin Thromb Hemost** 1998;24(4):413-8 (28 ref.)
Probabilities and health risks: a qualitative approach. Heyman B, et al. **Soc Sci Med** 1998 Nov;47(9):1295-306 (48 ref.)
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Gooley TA, et al. **Stat Med** 1999 Mar 30;18(6):695-706 (20 ref.)

PROBIOTICS

Probiotics or microbes against microbes. Zivković R. **Acta Med Croatica** 1999;53(1):23-8 (35 ref.)
Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Collins MD, et al. **Am J Clin Nutr** 1999 May;69(5):1052S-1057S (66 ref.)
Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? Macfarlane GT, et al. **BMJ** 1999 Apr 10;318(7189):999-1003 (48 ref.)
Health benefits of probiotics. Goldin BR. **Br J Nutr** 1998 Oct;80(4):S203-7 (24 ref.)
Prebiotics and synbiotics: concepts and nutritional properties. Roberfroid MB. **Br J Nutr** 1998 Oct;80(4):S197-202 (38 ref.)
Effects of probiotics and prebiotics on blood lipids. Taylor GR, et al. **Br J Nutr** 1998 Oct;80(4):S225-30 (35 ref.)
Conventional and molecular methods for understanding probiotic bacteria functionality in gastrointestinal tracts. Ricke SC, et al. **Crit Rev Microbiol** 1999;25(1):19-38 (149 ref.)
[Probiotics, prebiotics and probiotic products. Current status] Sheveleva SA. **Vopr Pitan** 1999;68(2):32-40 (87 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Demonstration of safety of probiotics -- a review. Salminen S, et al. **Int J Food Microbiol** 1998 Oct 20;44(1-2):93-106 (96 ref.)

CHEMICAL SYNTHESIS

Selection and design of probiotics. Klaenhammer TR, et al. **Int J Food Microbiol** 1999 Sep 15;50(1-2):45-57 (71 ref.)

METABOLISM

Probiotic spectra of lactic acid bacteria (LAB). Naidu AS, et al. **Crit Rev Food Sci Nutr** 1999 Jan;39(1):13-126 (490

ref.)
[The ecological, taxonomic and biotechnology aspects of research on bacteria and higher plants that produce biologically active substances] Smirnov VV. **Mikrobiol Z** 1998 Sep–Oct;60(5):3–18 (87 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Lewis SJ, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):807–22 (144 ref.)
Review of probiotics available to modify gastrointestinal flora. Gismondo MR, et al. **Int J Antimicrob Agents** 1999 Aug;12(4):287–92 (39 ref.)
Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. Reddy BS. **J Nutr** 1999 Jul;129(7 Suppl):1478S–82S (41 ref.)
Use of probiotics in childhood gastrointestinal disorders. Vanderhoof JA, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):323–32 (121 ref.)
Probiotics in the new millennium. Vaughan EE, et al. **Nahrung** 1999 Jun;43(3):148–53 (76 ref.)
[Probiotics and their therapeutic properties] Ochmański W, et al. **Przegl Lek** 1999;56(3):211–5 (11 ref.) (Eng. Abstr.) **(Pol)**
[Immunostimulating action of lactobacteria used as the basis of probiotic preparations] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep–Oct;(5):107–12 (57 ref.) **(Rus)**

PROBLEM-BASED LEARNING

Do we all mean the same thing by "problem-based learning"? A review of the concepts and a formulation of the ground rules. Maudsley G. **Acad Med** 1999 Feb;74(2):178–85 (59 ref.)
A core curriculum in the evaluative sciences for diagnostic imaging [editorial] Stolberg HO, et al. **Can Assoc Radiol J** 1998 Oct;49(5):295–306 (66 ref.)
The challenge for basic science education in problem-based medical curricula [see comments] Sweeney G. **Clin Invest Med** 1999 Feb;22(1):15–22 (19 ref.) Comment in: Clin Invest Med 1999 Feb;22(1):23–4.
[Problem-based teaching and learning. An opportunity for medical psychology, psychosomatic medicine and psychotherapy?] Köhle K, et al. **Psychother Psychosom Med Psychol** 1999 May;49(5):171–5 (13 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[The introduction of new teaching methods in medical studies or student-focused teaching: application to the initial training in hepatogastroenterology] Tran A, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):851–4 (21 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Problem-based learning in medical education [editorial] [see comments] Dwinnell BG, et al. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):15–6, 21 (7 ref.) Comment in: Hosp Pract (Off Ed) 1999 Apr 15;34(4):62.

STANDARDS

Critical thinking as an outcome of nursing education. What is it? Why is it important to nursing practice? Daly WM. **J Adv Nurs** 1998 Aug;28(2):323–31 (55 ref.)

PROBLEM SOLVING

see related
DECISION MAKING

Exploring the etiology of content specificity: factors influencing analogic transfer and problem solving. Eva KW, et al. **Acad Med** 1998 Oct;73(10 Suppl):S1–5 (45 ref.)
Problem-solving for better health: literature as a resource. Akhigbe F. **Afr J Med Med Sci** 1997 Sep–Dec; 26(3–4):205–8 (21 ref.)
Psychological changes accompanying and mediating stress-management training for essential hypertension. García-Vera MP, et al. **Appl Psychophysiol Biofeedback** 1998 Sep;23(3):159–78 (47 ref.)
Catching the wave: understanding the concept of critical thinking. Boychuk Duchscher JE. **J Adv Nurs** 1999 Mar; 29(3):577–83 (46 ref.)
'Non-barking dogs and other odd species': identifying anomaly in witness testimony. Shepherd E. **Med Sci Law** 1999 Apr;39(2):138–45 (4 ref.)
Problem solving and suicidal behavior. Pollock LR, et al. **Suicide Life Threat Behav** 1998 Winter;28(4):375–87 (75 ref.)
[Clinical reasoning—the diagnostic and therapeutic decision process] Réa-Neto A. **Rev Assoc Med Bras** 1998 Oct–Dec; 44(4):301–11 (27 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

A neuropsychological theory of positive affect and its influence on cognition. Ashby FG, et al. **Psychol Rev** 1999 Jul;106(3):529–50 (230 ref.)

PROBUCOL

PHARMACOLOGY

Probucol suppresses ICAM-1 expression in rat mesangial cells: possible role of IL-1. Sugiura T, et al. **Kidney Int Suppl** 1999 Jul;71:S167–70 (10 ref.)

THERAPEUTIC USE

[Anti-atherogenic drugs] Kanaki T, et al. **Nippon Rinsho** 1998 Oct;56(10):2635–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

PROCAINAMIDE

ADVERSE EFFECTS

Procainamide-induced psychosis: a case report and review of the literature. Bizjak ED, et al. **Ann Pharmacother** 1999 Sep;33(9):948–51 (27 ref.)

THERAPEUTIC USE

Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death. Humphries JO. **Clin Cardiol** 1998 Oct; 21(10):711–8 (95 ref.)

PROCAINE

ADVERSE EFFECTS

[Complications at anesthesia in tonsillectomy] Protasevich GS. **Vestn Otorinolaringol** 1999;(3):57–60 (89 ref.) **(Rus)**

PROCAINE AMIDE see **PROCAINAMIDE**

PROCESS ASSESSMENT (HEALTH CARE)

METHODS

Including the family perspective in sensory integration outcomes research. Cohn ES, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):540–6 (63 ref.)

ORGANIZATION & ADMINISTRATION

[The quality audit in a blood transfusion center] Hergon E. **Transfus Clin Biol** 1998 Dec;5(6):422–30 (12 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Health-care performance measurement systems and the ACHS Care Evaluation Program. Australian Council on Healthcare Standards. Collopy BT. **J Qual Clin Pract** 1998 Sep;18(3):171–6 (6 ref.)

PROCOLLAGEN

GENETICS

Ehlers-Danlos syndrome type VII: clinical features and molecular defects. Giunta C, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):225–38 (46 ref.)

PROCOLLAGEN-PROLINE DIOXYGENASE

see related
PROTEIN DISULFIDE-ISOMERASE

PROCONVERTIN see **FACTOR VII**

PROCTITIS

[Chlamydia trachomatis proctitis] Kusugami K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):43–5 (11 ref.) **(Jpn)**

DRUG THERAPY

Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Rompalo AM. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S84–90 (95 ref.)

PHYSIOPATHOLOGY

Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Zimmermann FB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:85–9 (32 ref.)

THERAPY

Treatment of radiation proctitis with hyperbaric oxygen: what is the optimal number of HBO treatments? Carl UM, et al. **Strahlenther Onkol** 1998 Sep;174(9):482–3 (11 ref.)
[Non-surgical treatment of chronic radiation proctitis] de Parades V, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep; 22(8–9):688–96 (88 ref.) **(Fre)**

PROCTOCOLECTOMY, RESTORATIVE

see related
POUCHITIS

Misconceptions about the colonic J-pouch: what the accumulating data show. Dennett ER, et al. **Dis Colon Rectum** 1999 Jun;42(6):804–11 (47 ref.)
Budd-Chiari syndrome complicating restorative proctocolectomy for ulcerative colitis: report of a case. Whiteford MH, et al. **Dis Colon Rectum** 1999 Sep; 42(9):1220–4 (15 ref.)
Pouchitis: pathophysiology and treatment. Kühbacher T, et al. **Int J Colorectal Dis** 1998;13(5–6):196–207 (199 ref.)
Anastomotic integrity and function: role of the colonic J-pouch. Wexner SD, et al. **Semin Surg Oncol** 1998 Sep; 15(2):91–100 (98 ref.)
[What is new in the surgical treatment of rectal cancer?] Dousset B, et al. **J Chir (Paris)** 1999 Mar;136(1):35–40 (45 ref.) (Eng. Abstr.) **(Fre)**
[Typical complications and their control after restorative proctocolectomy] Buhr HJ, et al. **Chirurg** 1998 Oct; 69(10):1035–44 (45 ref.) (Eng. Abstr.) **(Ger)**
[Primary sclerosing cholangitis—an ulcerative colitis-associated illness with surgical consequences] Heuschen G, et al. **Chirurg** 1998 Oct;69(10):1028–34 (67 ref.) (Eng. Abstr.) **(Ger)**
[Quality of life after proctocolectomy for ulcerative colitis] Heuschen UA, et al. **Chirurg** 1998 Oct;69(10):1045–51 (54 ref.) (Eng. Abstr.) **(Ger)**
[Ulcerative colitis—late functional results of ileoanal pouch anastomosis] Schumpelick V, et al. **Chirurg** 1998 Oct; 69(10):1013–9 (75 ref.) (Eng. Abstr.) **(Ger)**
[Indications for restorative rectal resection in carcinoma—complete vs. partial and local resection] Farthmann EH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:454–8 (20 ref.) (Eng. Abstr.) **(Ger)**
[Indications for restorative proctocolectomy in systemic colorectal diseases (ulcerative colitis and familial adenomatous polyposis coli)] Senninger N, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:468–71 (7 ref.) (Eng. Abstr.) **(Ger)**
[The diagnostic contribution of computed tomography in a case of volvulus of the small intestine after an ileoanal anastomosis] Catalano O. **Minerva Chir** 1998 Sep; 53(9):747–50 (14 ref.) (Eng. Abstr.) **(Ita)**
[Ileoanal reservoir: new concepts and current results] Muñoz-Juárez M, et al. **Rev Gastroenterol Mex** 1998 Jan–Mar;63(1):45–9 (34 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

The physiology of ileo-anal pouch function. Levitt MD, et al. **Am J Surg** 1998 Oct;176(4):384–9 (78 ref.)

INSTRUMENTATION

[Surgical treatment of hemorrhagic proctocolitis] Mariani P, et al. **J Chir (Paris)** 1999 Mar;136(1):10–4 (32 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Surgical treatment of ulcerative colitis and familiar adenomatous polyposis: recent developments (see comments)] van Laarhoven CJ, et al. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):662–6 (29 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 10;143(28):1490; discussion 1491. **(Dut)**
[Colonic pouch] Schumpelick V, et al. **Chirurg** 1999 May; 70(5):543–51 (50 ref.) (Eng. Abstr.) **(Ger)**
[The physiology of intestinal pouches] Teixeira FV, et al. **Chirurg** 1999 May;70(5):513–9 (29 ref.) (Eng. Abstr.) **(Ger)**

PROCTOCOLITIS

DRUG THERAPY

Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Rompalo AM. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S84–90 (95 ref.)

PROCTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

PROCTOCOLITIS, ULCERATIVE see **COLITIS, ULCERATIVE**

PROCTOLOGY see **COLORECTAL SURGERY**

PROCTOSIGMOIDITIS see **PROCTOCOLITIS**

PROCTOSIGMOIDOSCOPY see **SIGMOIDOSCOPY**

PROCYONIDAE see **CARNIVORA**

PRODRUGS

Design of intramolecularly activated prodrugs. Testa B, et al. **Drug Metab Rev** 1998 Nov;30(4):787–807 (31 ref.)
Glutathione therapy: from prodrugs to genes. Anderson ME, et al. **Semin Liver Dis** 1998;18(4):415–24 (84 ref.)

PRODRUGS

[Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?] Matsuda A, et al. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):1981-9 (12 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Syrigos KN, et al. **Anticancer Res** 1999 Jan-Feb; 19(1A):605-13 (77 ref.)

Prodrug approaches to the improved delivery of peptide drugs. Wang W, et al. **Curr Pharm Des** 1999 Apr; 5(4):265-87 (168 ref.)

[Pancreatic lipase drug delivery with glyceride-containing prodrugs] Scriba GK. **Pharm Unserer Zeit** 1999 Mar; 28(2):87-94 (23 ref.) **(Ger)**

CHEMICAL SYNTHESIS

Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs. Xia Z, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):286-94 (43 ref.)

A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Naka T, et al. **Curr Pharm Des** 1999 Jun;5(6):453-72 (38 ref.)

METABOLISM

Current issues in the enzymology of mitomycin C metabolic activation. Spanswick VJ, et al. **Gen Pharmacol** 1998 Oct; 31(4):539-44 (58 ref.)

PHARMACOKINETICS

Prodrug approaches to the improved delivery of peptide drugs. Wang W, et al. **Curr Pharm Des** 1999 Apr; 5(4):265-87 (168 ref.)

The use of esters as prodrugs for oral delivery of beta-lactam antibiotics. Mizen L, et al. **Pharm Biotechnol** 1998; 11:345-65 (60 ref.)

Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341-3 (7 ref.)

PHARMACOLOGY

Famciclovir. Discovery and development of a novel antiherpesvirus agent. Jarvest RL, et al. **Pharm Biotechnol** 1998;11:313-43 (93 ref.)

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Capizzi RL. **Semin Oncol** 1999 Apr;26(2 Suppl 7):3-21 (99 ref.)

[Propacetamol: from basic action to clinical utilization] Viel E, et al. **Ann Fr Anesth Reanim** 1999 Mar;18(3):332-40 (43 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Genetic prodrug activation therapy for pancreatic cancer. Rigg AS, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:319-25 (26 ref.)

Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs. Xia Z, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):286-94 (43 ref.)

Tolerability of a modern antihypertensive agent: candesartan cilexetil. Andersson OK. **Basic Res Cardiol** 1998;93 Suppl 2:54-8 (29 ref.)

Advances in the treatment of herpesvirus infection: the role of famciclovir. Tyring SK. **Clin Ther** 1998 Jul-Aug; 20(4):661-70 (45 ref.)

Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Pouillart PR. **Life Sci** 1998;63(20):1739-60 (225 ref.)

Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Gregoire V, et al. **Oncol Rep** 1999 Sep-Oct; 6(5):949-57 (61 ref.)

[Propacetamol: from basic action to clinical utilization] Viel E, et al. **Ann Fr Anesth Reanim** 1999 Mar;18(3):332-40 (43 ref.) (Eng. Abstr.) **(Fre)**

PRODUCT CONTAINERS see **PRODUCT PACKAGING**

PRODUCT LABELING, DRUG see **DRUG LABELING**

PRODUCT LABELING, FOOD see **FOOD LABELING**

PRODUCT PACKAGING

Compostable packaging materials--test methods and limit values for biodegradation. Pagga U. **Appl Microbiol Biotechnol** 1999 Feb;51(2):125-33 (35 ref.)

PRODUCT SURVEILLANCE, POSTMARKETING

Prescription-event monitoring--recent progress and future horizons. Mann RD. **Br J Clin Pharmacol** 1998 Sep; 46(3):195-201 (17 ref.)

Postmarketing drug surveillance: an epidemiologic approach. Hennessy S. **Clin Ther** 1998;20 Suppl C:C32-9 (37 ref.)

[Pharmacovigilance: education and continuing updating. The role of university institutes] Mariani L. **Clin Ter** 1998 May-Jun;149(3):219-25 (15 ref.) (Eng. Abstr.) **(Ita)**

METHODS

An introduction to analytical methods for the postmarketing surveillance of veterinary vaccines. Siev D. **Adv Vet Med** 1999;41:749-74 (26 ref.)

Safety monitoring of new anti-malarials in immediate post-marketing phase. Edwards IR. **Med Trop (Mars)** 1998; 58(3 Suppl):93-6 (11 ref.)

STANDARDS

Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT. **Stat Med** 1998 Aug 15-30;17(15-16):1851-8; discussion 1859-62 (6 ref.)

PRODUCTIVITY see **EFFICIENCY**

PRODUCTIVITY, ORGANIZATIONAL see **EFFICIENCY, ORGANIZATIONAL**

PROENZYMES see **ENZYME PRECURSORS**

PROERYTHROBLASTS see **ERYTHROBLASTS**

PROFESSIONAL AUTONOMY

The ramifications of regulatory reform. Moyers PA. **Am J Occup Ther** 1998 Oct;52(9):702-8 (28 ref.)

Evolving competence in the practitioner role. Youngstrom MJ. **Am J Occup Ther** 1998 Oct;52(9):716-20 (10 ref.)

Morally autonomous practice? Scott PA. **ANS Adv Nurs Sci** 1998 Dec;21(2):69-79 (20 ref.)

Evidence-based nursing: a stereotyped view of quantitative and experimental research could work against professional autonomy and authority. Bonell C. **J Adv Nurs** 1999 Jul; 30(1):18-23 (40 ref.)

A concept analysis of autonomy. Keenan J. **J Adv Nurs** 1999 Mar;29(3):556-62 (25 ref.)

Nurse prescribing: radicalism or tokenism? McCartney W, et al. **J Adv Nurs** 1999 Feb;29(2):348-54 (22 ref.)

Professional nurse autonomy: concept analysis and application to nursing education. Wade GH. **J Adv Nurs** 1999 Aug;30(2):310-8 (61 ref.)

Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):32-5 (11 ref.)

Maintaining professional integrity in the midst of interdisciplinary collaboration. Lindeke LL, et al. **Nurs Outlook** 1998 Sep-Oct;46(5):213-8 (25 ref.)

Interdisciplinary team: the nursing perspective is essential. McCloskey JC, et al. **Nurs Outlook** 1998 Jul-Aug; 46(4):157-63 (33 ref.)

More expanded scope: operational EMS [editorial; comment] Bogucki MS. **Prehosp Emerg Care** 1998 Oct-Dec; 2(4):330-3 (23 ref.) Comment on: Prehosp Emerg Care 1998 Oct-Dec;2(4):280-4.

When and why can an environmental epidemiologist legitimately refuse to undertake survey requested by public authorities (or other representatives of the population) on the ground that the proposal is insufficiently justified? [editorial] Terracini B. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):201-3 (10 ref.)

ReVisions in knowledge development: a passion for substance. Meleis AI. **Sch Inq Nurs Pract** 1998 Spring; 12(1):65-77; discussion 79-94 (26 ref.)

PROFESSIONAL COMPETENCE

Professionalism in emergency medicine. Finkel MA, et al. **Emerg Med Clin North Am** 1999 May;17(2):443-50 (19 ref.)

The nature of philosophy of science, theory and knowledge relating to nursing and professionalism. Rutty JE. **J Adv Nurs** 1998 Aug;28(2):243-50 (63 ref.)

STANDARDS

Competence in scientific inquiry and research. Abreu BC, et al. **Am J Occup Ther** 1998 Oct;52(9):751-9 (61 ref.)

Transitional portfolios: orchestrating our professional competence. Crist P, et al. **Am J Occup Ther** 1998 Oct; 52(9):729-36 (24 ref.)

Competence and the occupational therapy entrepreneur. Foto M. **Am J Occup Ther** 1998 Oct;52(9):765-9 (8 ref.)

Management competencies required of administrative and clinical practitioners in the new millennium. Schell BA, et al. **Am J Occup Ther** 1998 Oct;52(9):744-50 (31 ref.)

The performance of doctors: the new professionalism [see comments] Irvine D. **Lancet** 1999 Apr 3;353(9159):1174-7 (30 ref.) Comment in: Lancet 1999 Jul 10;354(9173):165.

PROFESSIONAL-FAMILY RELATIONS

The doctor's troubled marriage. Harari E. **Aust Fam Physician** 1998 Nov;27(11):999-1004 (16 ref.)

Parent's participation and perspectives regarding clinical judgment and clinical guideline development. Pachter LM. **Curr Opin Pediatr** 1998 Oct;10(5):476-9 (12 ref.)

Learning to listen: serendipitous outcomes of a research training experience. Chambers-Evans J, et al. **J Adv Nurs** 1999 Jun;29(6):1421-6 (12 ref.)

Ethics consultants: could they do better? Howe EG. **J Clin Ethics** 1999 Spring;10(1):13-25 (23 ref.)

Physician-family partnerships: the adaptive practice model [see comments] Feldman HM, et al. **J Dev Behav Pediatr** 1999 Apr;20(2):111-6 (29 ref.) Comment in: J Dev Behav Pediatr 1999 Apr;20(2):117-9. Comment in: J Dev Behav Pediatr 1999 Apr;20(2):120-2. Comment in: J Dev Behav Pediatr 1999 Apr;20(2):123-4.

Treating the developmentally disabled. Doostan D, et al. **West J Med** 1999 Aug;171(2):92-6 (13 ref.)

PROFESSIONAL LIABILITY see **LIABILITY, LEGAL**

PROFESSIONAL-PATIENT RELATIONS

see related
TRUTH DISCLOSURE

Communication and interpretation of risk. Eiser JR. **Br Med Bull** 1998;54(4):779-90 (27 ref.)

Allegations of sexual abuse in an intensive care unit. Hansen-Flaschen J, et al. **Crit Care Med** 1999 Feb; 27(2):437-40 (32 ref.)

Possible allegations of sexual abuse in an intensive care unit: an editorial [editorial] Mohindra V, et al. **Crit Care Med** 1999 Feb;27(2):268-9 (10 ref.)

Events in the life of the therapist: the effect on transference and countertransference. Gold JH. **Harv Rev Psychiatry** 1999 Jan-Feb;6(5):263-9 (51 ref.)

Talisman or taboo: the controversy of the suicide-prevention contract. Miller MC, et al. **Harv Rev Psychiatry** 1998 Jul-Aug;6(2):78-87 (64 ref.)

The management of embarrassment and sexuality in health care. Meerabeau L. **J Adv Nurs** 1999 Jun;29(6):1507-13 (55 ref.)

Building community: developing skills for interprofessional health professions education and relationship-centered care. NLN Appointed Interdisciplinary Health Education Panel. Walker PH, et al. **J Allied Health** 1998 Fall; 27(3):173-8 (14 ref.)

The patient-provider relationship: opportunities as well as problems. Lo B. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S41-4 (5 ref.)

Caring for elderly patients who have paranoia. Davidhizar R, et al. **Radiol Technol** 1999 May-Jun;70(5):461-4 (18 ref.)

PROFESSIONAL PRACTICE

see related
PRACTICE MANAGEMENT, DENTAL
PRACTICE MANAGEMENT, MEDICAL

How to improve transfusion medicine. A treating physician's perspective. Alving B, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):492-5 (26 ref.)

Clinical guidelines: using clinical guidelines. Feder G, et al. **BMJ** 1999 Mar 13;318(7185):728-30 (25 ref.)

Identifying appropriate tasks for the preregistration year: modified Delphi technique. Stewart J, et al. **BMJ** 1999 Jul 24;319(7204):224-9 (19 ref.)

Latex allergy in neurosurgical practice. Mazagri R, et al. **Childs Nerv Syst** 1999 Aug;15(8):404-7 (45 ref.)

Integrative thinking: the essence of good medical education and practice. Rosch PJ. **Integr Physiol Behav Sci** 1998 Apr-Jun;33(2):141-50 (8 ref.)

Evidence-based nursing: a stereotyped view of quantitative and experimental research could work against professional autonomy and authority. Bonell C. **J Adv Nurs** 1999 Jul; 30(1):18-23 (40 ref.)

Evolution and current status of direct-entry midwifery education, regulation, and practice in the United States, with examples from Washington State [see comments] Myers-Ciecko JA. **J Nurse Midwifery** 1999 Jul-Aug; 44(4):384-93 (58 ref.) Comment in: J Nurse Midwifery 1999 Jul-Aug;44(4):337-40.

Preserving midwifery practice in a managed care environment [see comments] Williams DR. **J Nurse Midwifery** 1999 Jul-Aug;44(4):375-83 (54 ref.) Comment in: J Nurse Midwifery 1999 Jul-Aug;44(4):337-40.

The role of science in medicine. Nordin I. **Theor Med Bioeth** 1999 Jun;20(3):229-44 (18 ref.)

ECONOMICS

How should we pay doctors? A systematic review of salary payments and their effect on doctor behaviour. Gosden T, et al. **QJM** 1999 Jan;92(1):47-55 (44 ref.)

ORGANIZATION & ADMINISTRATION

Description of the role of nonphysician practitioners in

radiation oncology. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):163–9 (17 ref.)

STANDARDS

Uniting practice and theory in an occupational framework. 1998 Eleanor Clarke Slagle Lecture. Fisher AG. **Am J Occup Ther** 1998 Jul–Aug;52(7):509–21 (68 ref.)

Professionalism reconsidered. Priorities for physicians. Halvorsen JG. **Arch Fam Med** 1999 Mar–Apr;8(2):173–6 (37 ref.)

What is left of professionalism after managed care? Sullivan WM. **Hastings Cent Rep** 1999 Mar–Apr;29(2):7–13 (12 ref.)

STATISTICS & NUMERICAL DATA

Risks and benefits of the practice of anesthesiology. Duncan PG. **Can J Anaesth** 1999 May;46(5 Pt 2):R131–44 (33 ref.) **(Eng, Fre)**

Perioperative red cell transfusion: evidence, guidelines and practice. McClelland B. **Vox Sang** 1998;74 Suppl 2:3–10 (20 ref.)

TRENDS

The future of allergy practice: an academician's perspective. Rich RR. **Allergy Asthma Proc** 1998 Sep–Oct;19(5):295–9 (11 ref.)

Computers in ophthalmology practice. Rajeev B. **Indian J Ophthalmol** 1998 Sep;46(3):163–8 (2 ref.)

PROFESSIONAL STAFF COMMITTEES

see related
UTILIZATION REVIEW

The new biotech world order. Cahill LS. **Hastings Cent Rep** 1999 Mar–Apr;29(2):45–8 (9 ref.)

Managing the informed consent process in large multicenter projects. Mark BA, et al. **Nurs Res** 1999 Mar–Apr; 48(2):114–7 (10 ref.)

Reviewing credentials and granting privileges. Peterson JL. **Tex Med** 1998 Nov;94(11):91–9 (13 ref.)

The transfusion medicine consultant and hospital transfusion committee. Popovsky MA. **Vox Sang** 1998;74 Suppl 2:391–3 (6 ref.)

PROFIBRINOLYSIN see **PLASMINOGEN**

PROGASTRICSIN see **PEPSINOGEN C**

PROGENITOR CELLS see **STEM CELLS**

PROGENITOR CELLS, ERYTHROPOIETIC see **ERYTHROID PROGENITOR CELLS**

PROGENITOR CELLS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

PROGERIA, ADULT see **WERNER SYNDROME**

PROGESTATIONAL HORMONE ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTATIONAL HORMONES

Progestin-only oral contraception: a comprehensive review. McCann MF, et al. **Contraception** 1994 Dec;50(6 Suppl 1):S1–195 (532 ref.)

ADMINISTRATION & DOSAGE

[Hormone replacement therapy and endometrial cancer] Concin H, et al. **Gynakol Geburtshilfliche Rundsch** 1998; 38(2):93–5 (19 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Update on androgenicity. Thorneycroft IH. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 2):288–94 (27 ref.)

Progestins and coronary heart disease [comment] Cano A. **Hum Reprod Update** 1999 May–Jun;5(3):189–90 (11 ref.) Comment on: Hum Reprod Update 1999 May–Jun;5(3):191–9. Comment on: Hum Reprod Update 1999 May–Jun;5(3):200–4. Comment on: Hum Reprod Update 1999 May–Jun;5(3):205–9.

Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. Colditz GA. **J Womens Health** 1999 Apr; 8(3):347–57 (85 ref.)

CONTRAINDICATIONS

[Hormone replacement therapy and endometrial cancer] Concin H, et al. **Gynakol Geburtshilfliche Rundsch** 1998; 38(2):93–5 (19 ref.) (Eng. Abstr.) **(Ger)**

[Hormonal replacement therapy in patients with cervical and ovarian cancers] Urdl W. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):89–92 (27 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Hyder SM, et al. **Mol Endocrinol** 1999 Jun;13(6):806–11 (60 ref.)

Nuclear matrix and steroid hormone action. Barrett TJ, et al. **Vitam Horm** 1999;55:127–63 (217 ref.)

PHARMACOLOGY

Effects of sex steroids on proliferation in normal mammary tissue. Söderqvist G. **Ann Med** 1998 Dec;30(6):511–24 (104 ref.)

The differential effects of oestrogens and progestins on vascular tone [see comments] Sarrel PM. **Hum Reprod Update** 1999 May–Jun;5(3):205–9 (52 ref.) Comment in: Hum Reprod Update 1999 May–Jun;5(3):189–90.

Effects of progestins on cardiovascular diseases: the haemostatic system [see comments] Winkler UH. **Hum Reprod Update** 1999 May–Jun;5(3):200–4 (51 ref.) Comment in: Hum Reprod Update 1999 May–Jun;5(3):189–90.

Effects of estrogens, progestins, and androgens on coronary vasomotion and atherosclerosis. Clarkson TB. **J Reprod Med** 1998 Aug;43(8 Suppl):741–5 (34 ref.)

[Vascular effects of gestagens--biochemistry versus epidemiology] Kuhl H. **Zentralbl Gynakol** 1999; 121(2):67–78 (99 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Spitz IM, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):584–93 (71 ref.)

THERAPEUTIC USE

Other medical management of uterine fibroids. Eldar-Geva T, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun; 12(2):269–88 (76 ref.)

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Mijatovic V, et al. **Gynecol Endocrinol** 1999 Apr; 13(2):130–44 (129 ref.)

Effects of progestogens on thrombosis and atherosclerosis [see comments] Badimon L, et al. **Hum Reprod Update** 1999 May–Jun;5(3):191–9 (110 ref.) Comment in: Hum Reprod Update 1999 May–Jun;5(3):189–90.

Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. Barrett-Connor E, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1848–53 (38 ref.)

Estrogen–progestagen therapy in the management of the polycystic ovary syndrome. Marshall JC. **J Endocrinol Invest** 1998 Oct;21(9):618–22 (31 ref.)

Progestins in the menopause. Sitruk-Ware R. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):185–93 (61 ref.)

A critical European view of the HERS trial. Lauritzen C. **Maturitas** 1998 Nov 30;31(1):15–9 (28 ref.)

PROGESTATIONAL HORMONES, SYNTHETIC

see related
ANTINEOPLASTIC AGENTS, HORMONAL
CONTRACEPTIVE AGENTS, FEMALE
CONTRACEPTIVES, ORAL, SYNTHETIC

Oral micronized progesterone. de Lignières B. **Clin Ther** 1999 Jan;21(1):41–60; discussion 1–2 (86 ref.)

Uniqueness of oral contraceptive progestins. Carr BR. **Contraception** 1998 Sep;58(3 Suppl):23S–27S; quiz 67S (25 ref.)

Research, introduction, and use: advancing from Norplant. Harrison PF, et al. **Contraception** 1998 Dec;58(6):323–34 (15 ref.)

Research on mifepristone and levonorgestrel in comparison with the Yuzpe regimen. von Hertzen H. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):222–4, 232 (20 ref.)

[Gestagens have become of great clinical value. Disadvantages are irregular bleeding and bad temper] Landgren BM. **Lakartidningen** 1999 Mar 31;96(13):1578–81 (27 ref.) **(Swe)**

ADVERSE EFFECTS

Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty. Maling TJ. **N Z Med J** 1999 Aug 27;112(1094):305–7 (30 ref.)

THERAPEUTIC USE

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Mantovani G, et al. **Crit Rev Oncog** 1998; 9(2):99–106 (36 ref.)

The heart and estrogen/progestin replacement study (HERS). Speroff L. **Maturitas** 1998 Nov 30;31(1):9–14 (38 ref.)

The use of long-acting contraceptives in adolescents. Harel Z, et al. **Pediatr Clin North Am** 1999 Aug;46(4):719–32 (77 ref.)

PROGESTERONE

see related
RECEPTORS, PROGESTERONE

Oral micronized progesterone. de Lignières B. **Clin Ther** 1999 Jan;21(1):41–60; discussion 1–2 (86 ref.)

Potential benefits of estrogens and progestogens on breast cancer. Schneider HP, et al. **Int J Fertil Womens Med** 1998 Nov–Dec;43(6):278–85 (41 ref.)

ADMINISTRATION & DOSAGE

Micronized progesterone: clinical indications and comparison with current treatments. Fitzpatrick LA, et al. **Fertil Steril** 1999 Sep;72(3):389–97 (74 ref.)

Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Cicinelli E, et al. **Hum Reprod Update** 1999 Jul–Aug; 5(4):365–72 (43 ref.)

Micronized progesterone: a new therapeutic option. Langer RD. **Int J Fertil Womens Med** 1999 Mar–Apr;44(2):67–73 (21 ref.)

Uses of progesterone in clinical practice. Warren MP, et al. **Int J Fertil Womens Med** 1999 Mar–Apr;44(2):96–103 (19 ref.)

ADVERSE EFFECTS

Do exogenous oestrogens and progesterone influence asthma? Forbes L. **Thorax** 1999 Mar;54(3):265–7 (34 ref.)

ANTAGONISTS & INHIBITORS

Contraceptive use of antiprogestin. Bygdeman M, et al. **Eur J Contracept Reprod Health Care** 1999 Jun;4(2):103–7 (24 ref.)

BIOSYNTHESIS

Pregnancy maintenance and the regulation of placental progesterone biosynthesis in the baboon. Henson MC. **Hum Reprod Update** 1998 Jul–Aug;4(4):389–405 (92 ref.)

Central integrative role of oestrogen in the regulation of placental steroidogenic maturation and the development of the fetal pituitary–adrenocortical axis in the baboon. Pepe GJ, et al. **Hum Reprod Update** 1998 Jul–Aug; 4(4):406–19 (127 ref.)

Progesterone as a neurosteroid: synthesis and actions in rat glial cells. Jung-Testas I, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):97–107 (34 ref.)

IMMUNOLOGY

Regulation of uterine immune function by progesterone--lessons from the sheep. Hansen PJ. **J Reprod Immunol** 1998 Oct;40(1):63–79 (61 ref.)

METABOLISM

Progesterone receptors in gastric leiomyosarcoma [letter] Munoz E. **Eur J Surg** 1998 Oct;164(10):796 (5 ref.)

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone [see comments] Risch HA. **J Natl Cancer Inst** 1998 Dec 2;90(23):1774–86 (237 ref.) Comment in: J Natl Cancer Inst 1999 Apr 7;91(7):650–1.

Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Lange CA, et al. **Mol Endocrinol** 1999 Jun;13(6):829–36 (39 ref.)

PHARMACOKINETICS

Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Cicinelli E, et al. **Hum Reprod Update** 1999 Jul–Aug; 5(4):365–72 (43 ref.)

PHARMACOLOGY

The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1999 Jul; 42(1):44–8 (47 ref.)

Dynamics of steroid regulation of GnRH secretion during the oestrus cycle of the ewe. Caraty A, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):68–78 (45 ref.)

Effects of progesterone on human spermatozoa: clinical implications. Forti G, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):107–10 (31 ref.)

Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Mustafa IA, et al. **Ann Surg** 1998 Nov; 228(5):638–51 (115 ref.)

Hormonal effects on the brain. Woolley CS, et al. **Epilepsia** 1998;39 Suppl 8:S2–8 (45 ref.)

Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implications. Baldi E, et al. **Front Biosci** 1998 Nov 1;3:D1051–9 (86 ref.)

The hormonal control of endometrial receptivity: estrogen (E2) and progesterone. de Ziegler D, et al. **J Reprod Immunol** 1998 Aug;39(1–2):149–66 (32 ref.)

Electrophysiological effects of oxytocin within the bed nuclei of the stria terminalis: influence of reproductive stage and ovarian steroids. Wakerley JB, et al. **Prog Brain Res** 1998; 119:321–34 (57 ref.)

PROGESTERONE

PHYSIOLOGY

Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Mustafa IA, et al. **Ann Surg** 1998 Nov; 228(5):638–51 (115 ref.)

Hormonal effects on epilepsy in women. Klein P, et al. **Epilepsia** 1998;39 Suppl 8:S9–16 (92 ref.)

Progesterone signaling and mammary gland morphogenesis. Shyamala G. **J Mammary Gland Biol Neoplasia** 1999 Jan; 4(1):89–104 (72 ref.)

Progesterone as a neurosteroid: synthesis and actions in rat glial cells. Jung-Testas I, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):97–107 (34 ref.)

Ovarian steroids and serotonin neural function. Bethea CL, et al. **Mol Neurobiol** 1998 Oct;18(2):87–123 (269 ref.)

Vasopressin, gonadal steroids and social recognition. Dantzer R. **Prog Brain Res** 1998;119:409–14 (23 ref.)

Extragenomic actions of progesterone in human sperm and progesterone metabolites in human platelets. Blackmore PF. **Steroids** 1999 Jan–Feb;64(1–2):149–56 (71 ref.)

Progesterone induces meiotic division in the amphibian oocyte by releasing lipid second messengers from the plasma membrane. Morrill GA, et al. **Steroids** 1999 Jan–Feb;64(1–2):157–67 (45 ref.)

[Epidemiologic considerations on the significance of hormones in carcinogenesis] Obermair A, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):73–9 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Micronized progesterone: a new option for women's health care. Wetzel W. **Nurse Pract** 1999 May;24(5):62–6, 71, 75–6 (29 ref.)

PROGESTERONE RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTIN ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTIN RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTINS see **PROGESTATIONAL HORMONES**

PROGESTINS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTOGENS see **PROGESTATIONAL HORMONES**

PROGESTOGENS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGLUMIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PROGNATHISM

COMPLICATIONS

Changes in airway and hyoid position in response to mandibular protrusion in subjects with obstructive sleep apnoea (OSA). Battagel JM, et al. **Eur J Orthod** 1999 Aug; 21(4):363–76 (46 ref.)

PROGNOSIS

Some elements of prognosis in terminal cancer. Lamont EB, et al. **Oncology (Huntingt)** 1999 Aug;13(8):1165–70; discussion 1172–4, 1179–80 (48 ref.)

PROGNOSTIC NUTRITIONAL INDEX (PNI) see **NUTRITION ASSESSMENT**

PROGONOMA, MELANOTIC see **NEUROECTODERMAL TUMOR, MELANOTIC**

PROGRAM DEVELOPMENT

Clinical guidelines: developing guidelines. Shekelle PG, et al. **BMJ** 1999 Feb 27;318(7183):593–6 (17 ref.)

Workshop report: research, policy and program planning on sun protective behaviours. Ashbury FD, et al. **Cancer Prev Control** 1998 Jun;2(3):129–32 (12 ref.)

Use of brief interventions to treat individuals with drinking problems. Finfgeld DL. **J Psychosoc Nurs Ment Health Serv** 1999 Apr;37(4):23–30 (12 ref.)

Contraceptive introduction reconsidered: a new methodology for policy and program development. Simmons R, et al. **J Womens Health** 1999 Mar;8(2):163–73 (12 ref.)

[Management of mental health and primary care. Development and evaluation of a training program based on the PLISSIT approach] Vauth R, et al. **Nervenarzt** 1999 Jan;70(1):54–63 (32 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Prospects and challenges in implementing firearm-related injury surveillance in the United States. Not a flash in the pan. Koo D, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):120–4 (36 ref.)

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms. Breton JJ. **Can J Psychiatry** 1999 Apr;44(3):227–34 (76 ref.)

An interactive approach to training teams and developing programs. Corrigan PW, et al. **New Dir Ment Health Serv** 1998 Fall;(79):3–12 (34 ref.)

A systems approach to developing staff training. Giffort DW. **New Dir Ment Health Serv** 1998 Fall;(79):25–33 (23 ref.)

Developing health insurance in transitional Asia. Ensor T. **Soc Sci Med** 1999 Apr;48(7):871–9 (25 ref.)

[Vaccine strategies for the general practitioner. I. Apropos of a research-action] Limme C, et al. **Rev Med Liege** 1998 Sep;53(9):541–52 (14 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Comprehensive multidisciplinary programs for the management of patients with congestive heart failure [see comments] Philbin EF. **J Gen Intern Med** 1999 Feb; 14(2):130–5 (44 ref.) Comment in: J Gen Intern Med 1999 Feb;14(2):138–40.

PROGRAM EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

PROGRAM EVALUATION

A multidimensional evaluation of fire fighter training for hazardous materials response: first results from the IAFF Program. Cohen A. **Am J Ind Med** 1998 Oct;34(4):331–41 (12 ref.)

Issues underlying the evaluation of screening programmes. Peckham CS, et al. **Br Med Bull** 1998;54(4):767–78 (41 ref.)

Issues to consider in the evaluation of speech and language therapy for preschool children. Roulstone S, et al. **Child Care Health Dev** 1999 Mar;25(2):141–55 (31 ref.)

Home visiting: recent program evaluations--analysis and recommendations. Gomby DS, et al. **Future Child** 1999 Spring-Summer;9(1):4–26, 195–223 (19 ref.)

Skin cancer prevention for children: a critical review. Buller DB, et al. **Health Educ Behav** 1999 Jun;26(3):317–43 (52 ref.)

Introduction to the Academic Symposium to Evaluate Evidence Regarding the Efficacy of Trauma Systems. Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S3–7 (10 ref.)

Monitoring clinical trials. Sharples K, et al. **N Z Med J** 1998 Aug 28;111(1072):322–5 (22 ref.)

How to assess an article on economic evaluation. Sculpher M, et al. **Sex Transm Infect** 1998 Jun;74(3):223–7 (22 ref.)

Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Bresee JS, et al. **Vaccine** 1999 May 4; 17(18):2207–22 (148 ref.)

[Evaluation of new programs to prevent tuberculosis infection. I. Chemoprophylaxis] Prados C, et al. **An Med Interna** 1998 Dec;15(12):664–8 (35 ref.) (Eng. Abstr.) **(Spa)**

[An evaluation of new prevention programs for tuberculous infection. II. BCG vaccination] Prados C, et al. **An Med Interna** 1999 Jan;16(1):38–40 (11 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Glasgow RE, et al. **Am J Public Health** 1999 Sep;89(9):1322–7 (88 ref.)

Evaluation of early childhood programs. Schweinhart LJ. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):395–407, viii–ix (44 ref.)

Using benefit-cost analysis to assess child abuse prevention and intervention programs. Plotnick RD, et al. **Child Welfare** 1999 May-Jun;78(3):381–407 (33 ref.)

Promotion of evaluation as a strategy towards an effective substance prevention. Ostaszewski K. **Eur Addict Res** 1998 Sep;4(3):128–33 (33 ref.)

The health of children. Szilagyi PG, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1001–39 (97 ref.)

Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Habicht JP, et al. **Int J Epidemiol** 1999 Feb;28(1):10–8 (20 ref.)

Student evaluations of dental faculty and courses. Jasinevicius TR, et al. **J Dent Educ** 1998 Dec;62(12):957–63 (46 ref.)

Challenges in evaluating primary health care for teenagers. Research Sub-Committee of the Adolescent Working Party of the Royal College of General Practitioners, London, UK. Jacobson LD, et al. **J Eval Clin Pract** 1998 Aug; 4(3):183–9 (36 ref.)

Outcomes assessment: implications for nursing education. Thompson C, et al. **J Prof Nurs** 1999 May-Jun;15(3):170–8 (24 ref.)

Reflections on two decades of research on teen sexual behavior and pregnancy. Kirby D. **J Sch Health** 1999 Mar; 69(3):89–94 (43 ref.)

[Parents judgement concerning family work of a child psychiatric ward] Romberg A. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec;47(10):773–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[The monitoring, evaluation and programming of mental health departments. A regional system of indicators. The Evaluation Center, the QUALI DSM Project, the Lazio region] **Epidemiol Psichiatr Soc** 1998 Sep-Dec;7(3 Suppl):1–39 (0 ref.) **(Ita)**

[Multilevel automatic monitoring system for epidemiological tuberculous process in the north-western region, project and implementation] Nechaeva NE, et al. **Probl Tuberk** 1999;(3):10–4 (6 ref.) (Eng. Abstr.) **(Rus)**

TRENDS

Programs promoting timely sequential antimicrobial therapy: an American perspective. Drew RH. **J Infect** 1998 Jul;37 Suppl 1:3–9 (58 ref.)

[Parent-infant-program "Menschenskind"--concept and outcomes of the first three years] Barth R. **Prax Kinderpsychol Kinderpsychiatr** 1999 Mar;48(3):178–91 (47 ref.) (Eng. Abstr.) **(Ger)**

PROGRAM EVALUATION, NURSING see **NURSING EVALUATION RESEARCH**

PROGRAMMABLE IMPLANTABLE INSULIN PUMP see **INSULIN INFUSION SYSTEMS**

PROGRAMMABLE IMPLANTABLE MEDICATION SYSTEMS see **INFUSION PUMPS, IMPLANTABLE**

PROGRAMMED INSTRUCTION, COMPUTERIZED see **COMPUTER-ASSISTED INSTRUCTION**

PROGRANULOCYTIC LEUKEMIA see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PROGRESSIVE LENTICULAR DEGENERATION see **HEPATOLENTICULAR DEGENERATION**

PROGRESSIVE MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

PROGRESSIVE PATIENT CARE

ORGANIZATION & ADMINISTRATION

Functional assessment for transitions in patient acuity and care. Barad MB. **Nurs Clin North Am** 1999 Sep; 34(3):607–20 (13 ref.)

PROGUANIL see **CHLOROGUANIDE**

PROINSULIN

BLOOD

Assays for insulin, proinsulin(s) and C-peptide. Clark PM. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):541–64 (161 ref.)

GENETICS

(Pro)insulin and insulin-like growth factor I complementary expression and roles in early development. Alarcón C, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):13–7 (27 ref.)

PROJECTIONS AND PREDICTIONS see **FORECASTING**

PROKARYOTIC CELLS

Initiation of translation in prokaryotes and eukaryotes. Kozak M. **Gene** 1999 Jul 8;234(2):187–208 (260 ref.)

CLASSIFICATION

The origin of eukaryotes: the difference between prokaryotic and eukaryotic cells. Vellai T, et al. **Proc R Soc Lond B Biol Sci** 1999 Aug 7;266(1428):1571–7 (63 ref.)

CYTOLOGY

[Molecular regulation of sigma factor and anti-sigma factor in prokaryote differentiation] Tan H. **Wei Sheng Wu Hsueh Pao** 1997 Jun;37(3):234–6 (5 ref.) **(Chi)**

METABOLISM

Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Ahmad SI, et al. **Annu Rev Microbiol** 1998; 52:591–625 (226 ref.)

Thiamin biosynthesis in prokaryotes. Begley TP, et al. **Arch Microbiol** 1999 Apr;171(5):293–300 (55 ref.)

Molecular mechanisms of cytochrome c biogenesis: three distinct systems. Kranz R, et al. **Mol Microbiol** 1998 Jul; 29(2):383–96 (114 ref.)

[Phosphatidylserine in Prokaryota and Eukaryota. Decarboxylation, synthesis and transport] Dygas A. **Postepy Biochem** 1998;44(4):292–8 (66 ref.) **(Pol)**

PHYSIOLOGY

Diversity of prokaryotic chromosomal proteins and the origin of the nucleosome. Sandman K, et al. **Cell Mol Life Sci** 1998 Dec;54(12):1350–64 (145 ref.)

Life among the primitives: protein O-phosphatases in

prokaryotes. Kennelly PJ, et al. **Front Biosci** 1999 Mar 15; 4:D372–85 (138 ref.)
Evolutionary link between prokaryotic and eukaryotic K+ channels. Derst C, et al. **J Exp Biol** 1998 Oct;201 (Pt 20):2791–9 (55 ref.)

PROLACTIN

see related
HYPERPROLACTINEMIA
RECEPTORS, PROLACTIN

[Prolactin--a hormone with many effects] Werner S, et al. **Lakartidningen** 1999 Mar 10;96(10):1171–4 (37 ref.) **(Swe)**

BLOOD

Peripheral biomarkers and exposure to manganese. Smargiassi A, et al. **Neurotoxicology** 1999 Apr–Jun;20(2–3):401–6 (37 ref.)

GENETICS

Marker genes of decidualization: activation of the decidual prolactin gene. Telgmann R, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):472–9 (41 ref.)

IMMUNOLOGY

Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu-Lee L, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1067–75 (103 ref.)
Immunological aspects of human growth hormone and prolactin. Hattori N, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):371–5 (11 ref.)
[The role of prolactin in immunological processes (editorial)] Hrycek A. **Wiad Lek** 1998;51(5–6):226–33 (78 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Control of luteinizing hormone and prolactin secretion in birds. Sharp PJ, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):275–82 (88 ref.)
Beta cell proliferation and growth factors. Nielsen JH, et al. **J Mol Med** 1999 Jan;77(1):62–6 (49 ref.)

PHYSIOLOGY

Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Chikanza IC. **Ann N Y Acad Sci** 1999 Jun 22;876:119–30 (82 ref.)
Prolactin and prolactin-like polypeptides in rheumatoid arthritis. Neidhart M, et al. **Biomed Pharmacother** 1999 Jun; 53(5–6):218–22 (44 ref.)
A role for growth hormone and prolactin in leukaemia and lymphoma? Hooghe R, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1095–101 (85 ref.)
Prolactin, growth hormone and the immune system in humans. Velkeniers B, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1102–8 (75 ref.)
Role of prolactin and growth hormone on thymus physiology. De Mello-Coelho V, et al. **Dev Immunol** 1998; 6(3–4):317–23 (45 ref.)
Prolactin receptor antagonists. Kuo CB, et al. **Endocrine** 1998 Oct;9(2):121–31 (84 ref.)
The fetal adrenal and the maturation of the growth hormone and prolactin axes [editorial] Freemark M. **Endocrinology** 1999 May;140(5):1963–5 (41 ref.)
Elasmobranch color change: A short review and novel data on hormone regulation. Visconti MA, et al. **J Exp Zool** 1999 Oct 1;284(5):485–91 (54 ref.)
Prolactin and mammary gland development. Horseman ND. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):79–88 (63 ref.)
Prolactin, a pituitary hormone that modifies immune responses. Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico [editorial; comment] [see comments] Walker SE, et al. **Lupus** 1998;7(6):371–5 (70 ref.) Comment on: Lupus 1998 ;7(6):420–7. Comment in: Lupus 1999;8(30:251.
Should prolactin be reconsidered as a therapeutic target in human breast cancer? Goffin V, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):79–87 (71 ref.)
The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. Linzer DI, et al. **Mol Endocrinol** 1999 Jun;13(6):837–40 (16 ref.)
Prolactin: the forgotten hormone of human breast cancer. Vonderhaar BK. **Pharmacol Ther** 1998 Aug;79(2):169–78 (104 ref.)
Prolactin and antipsychotic medications: mechanism of action. Petty RG. **Schizophr Res** 1999 Mar 1;35 Suppl:S67–73 (21 ref.)
Prolactin and its receptor in human endometrium. Tseng L, et al. **Semin Reprod Endocrinol** 1999;17(1):23–7 (19 ref.)

THERAPEUTIC USE

Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Woody MA, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):69–80 (101 ref.)

PROLACTIN-PRODUCING PITUITARY ADENOMA see **PROLACTINOMA**

PROLACTIN RECEPTORS see **RECEPTORS, PROLACTIN**

PROLACTINOMA

see related
HYPERPROLACTINEMIA

Malignant prolactinoma: case report and review of the literature. Popadić A, et al. **Surg Neurol** 1999 Jan; 51(1):47–54; discussion 54–5 (29 ref.)
[Prolactin--a hormone with many effects] Werner S, et al. **Lakartidningen** 1999 Mar 10;96(10):1171–4 (37 ref.) **(Swe)**

DIAGNOSIS

Diagnosis and treatment of prolactinomas. Molitch ME. **Adv Intern Med** 1999;44:117–53 (179 ref.)
[Treatment of pituitary adenoma] Chanson P. **Presse Med** 1998 Dec 12;27(39):2077–87 (113 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of prolactinomas. Colao A, et al. **Ann Med** 1998 Oct;30(5):452–9 (78 ref.)
Medical treatment of prolactinomas. Molitch ME. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):143–69, vii (169 ref.)

SURGERY

Treatment of prolactinomas. Colao A, et al. **Ann Med** 1998 Oct;30(5):452–9 (78 ref.)
[Neurosurgical management of extracerebral tumors] Antoniadis G, et al. **Rontgenpraxis** 1998;51(8–9):304–10 (26 ref.) **(Ger)**

PROLAPSED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

PROLIFERATING CELL NUCLEAR ANTIGEN

CHEMISTRY

PCNA, a multifunctional ring on DNA. Tsurimoto T. **Biochim Biophys Acta** 1998 Nov 26;1443(1–2):23–39 (138 ref.)

METABOLISM

PCNA, a multifunctional ring on DNA. Tsurimoto T. **Biochim Biophys Acta** 1998 Nov 26;1443(1–2):23–39 (138 ref.)
Chromatin replication: Finding the right connection. Krude T. **Curr Biol** 1999 Jun 3;9(11):R394–6 (15 ref.)
Detection of chromatin-bound PCNA in mammalian cells and its use to study DNA excision repair. Miura M. **J Radiat Res (Tokyo)** 1999 Mar;40(1):1–12 (56 ref.)

PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

PROLONGED-ACTION PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

PROLYL ISOMERASE see **PEPTIDYLPROLYL ISOMERASE**

PROLYMPHOCYTIC LEUKEMIA see **LEUKEMIA, PROLYMPHOCYTIC**

PROM (PREGNANCY) see **FETAL MEMBRANES, PREMATURE RUPTURE**

PROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PROMOTER REGIONS (GENETICS)

see related
GENES, REPORTER

Regulation of expression of surfactant protein-A. Mendelson CR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):132–49 (59 ref.)
Artificial promoters for metabolic optimization. Jensen PR, et al. **Biotechnol Bioeng** 1998 Apr 20–May 5;58(2–3):191–5 (17 ref.)
Association of hepatic nuclear factor-4 in the apolipoprotein B promoter: a preliminary report. Novák EM, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1405–8 (15 ref.)
Promoter polymorphisms predisposing to the development of asthma and atopy. Rosenwasser LJ, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:13–5; discussion 26–8 (30 ref.)
The DPE, a conserved downstream core promoter element that is functionally analogous to the TATA box. Burke TW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:75–82 (37 ref.)
Transcription regulation, initiation, and "DNA scrunching" by T7 RNA polymerase. Cheetham GM, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:263–7 (29 ref.)
Ten years of TFIIH. Coin F, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:105–10 (72 ref.)
Cooperative assembly of RNA polymerase II transcription complexes. Ellwood K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:253–61 (36 ref.)
Strength and regulation without transcription factors: lessons from bacterial rRNA promoters. Gourse RL, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:131–9 (63 ref.)
The functional and regulatory roles of sigma factors in transcription. Gross CA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:141–55 (98 ref.)
Promoter-associated pausing in promoter architecture and postinitiation transcriptional regulation. Lis J. **Cold Spring Harb Symp Quant Biol** 1998;63:347–56 (59 ref.)
Functional analysis of TFIID components. Shen WC, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:219–27 (115 ref.)
The initiator element: a paradigm for core promoter heterogeneity within metazoan protein-coding genes. Smale ST, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:21–31 (50 ref.)
Regulation of SRF activity by Rho family GTPases. Treisman R, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:643–51 (44 ref.)
Polarity of transcription on Pol II and archaeal promoters: where is the "one-way sign" and how is it read? Tsai FT, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:53–61 (25 ref.)
The biology of eukaryotic promoter prediction--a review. Pedersen AG, et al. **Comput Chem** 1999 Jun 15; 23(3–4):191–207 (188 ref.)
Regulatory targets in the RNA polymerase II holoenzyme. Parvin JD, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):565–70 (58 ref.)
Expression systems and physiological control of promoter activity in bacteria. Cases I, et al. **Curr Opin Microbiol** 1998 Jun;1(3):303–10 (71 ref.)
Transcriptional regulation of mammalian cytochrome c oxidase genes. Grossman LI, et al. **Electrophoresis** 1998 Jun;19(8–9):1254–9 (41 ref.)
Models for prediction and recognition of eukaryotic promoters. Werner T. **Mamm Genome** 1999 Feb; 10(2):168–75 (66 ref.)
Mycobacterial promoters. Mulder MA, et al. **Tuber Lung Dis** 1997;78(5–6):211–23 (117 ref.)
A core promoter hairpin is essential for subgenomic RNA synthesis in alfalfa mosaic alfamovirus and is conserved in other Bromoviridae. Jaspars EM. **Virus Genes** 1998; 17(3):233–42 (62 ref.)

GENETICS

Application of exogenously regulatable promoter systems to transgenic models for the study of aging. Morgan WW, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jan;54(1):B30–40; discussion B41–2 (68 ref.)
The GnRH promoter: target of transcription factors, hormones, and signaling pathways. Nelson SB, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):151–5 (22 ref.)
The DNA methylation paradox. Jones PA. **Trends Genet** 1999 Jan;15(1):34–7 (33 ref.)

PHYSIOLOGY

Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. Lian JB, et al. **J Cell Biochem Suppl** 1998;30–31:62–72 (91 ref.)

PROMOTION OF HEALTH see **HEALTH PROMOTION**

PROMYELOCYTES see **GRANULOCYTES**

PROMYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PRONATION

Pronation in runners. Implications for injuries. Hintermann B, et al. **Sports Med** 1998 Sep;26(3):169–76 (65 ref.)

PRONE POSITION

Prone ventilation--it's time. Tobin A, et al. **Anaesth Intensive Care** 1999 Apr;27(2):194–201 (55 ref.)
Prone positioning in acute lung injury. Dries DJ. **J Trauma** 1998 Oct;45(4):849–52 (23 ref.)

PHYSIOLOGY

Prone position in acute respiratory distress syndrome: turning over an old idea [editorial; comment] Trottier SJ. **Crit Care Med** 1998 Dec;26(12):1934–5 (20 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1977–85.
[Is spinal anesthesia for operations in the prone or jackknife position suitable?] Standl T, et al. **Anaesthesist** 1999 Apr; 48(4):242–50 (49 ref.) (Eng. Abstr.) **(Ger)**

PRONORMOBLASTS see **ERYTHROBLASTS**

PRO-OPIOCORTIN see **PRO-OPIOMELANOCORTIN**

PRO-OPIOMELANOCORTIN

PRO-OPIOMELANOCORTIN

GENETICS

A new family of growth and differentiation factors derived from the N-terminal domain of proopiomelanocortin (N-POMC). Denef C, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Jun;119(3):317-24 (67 ref.)

METABOLISM

Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. de Wied D. **Eur J Pharmacol** 1999 Jun 30;375(1-3):1-11 (85 ref.)

Can high maternal melatonin concentrations be responsible for inducing fetal pathologies, and can melatonin participate in immunohormonal homeostasis by determining prohormone convertase activity?--Hypothesis and facts. Ciesla W. **Med Hypotheses** 1998 Oct;51(4):269-80 (100 ref.)

PHYSIOLOGY

A new family of growth and differentiation factors derived from the N-terminal domain of proopiomelanocortin (N-POMC). Denef C, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Jun;119(3):317-24 (67 ref.)

PROPAFENONE

ADMINISTRATION & DOSAGE

The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation. Capucci A, et al. **Curr Opin Cardiol** 1999 Jan; 14(1):4-8 (19 ref.)

THERAPEUTIC USE

Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. Rae AP. **Am J Cardiol** 1998 Oct 16; 82(8A):59N-65N (55 ref.)

PROPANE

ANALOGS & DERIVATIVES

1,2-Dibromo-3-chloropropane.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:479-500 (97 ref.)

Exporting DBCP and other banned pesticides: consideration of ethical issues. Lowry LK, et al.
Int J Occup Environ Health 1999 Apr-Jun;5(2):135-41 (14 ref.)

The toxicology of 1,2-dibromo-3-chloropropane (DBCP): a brief review. Teitelbaum DT.
Int J Occup Environ Health 1999 Apr-Jun;5(2):122-6 (27 ref.)

PROPANEDIAL see **MALONDIALDEHYDE**

PROPANEDIOL DEHYDRATASE

GENETICS

Biochemistry of coenzyme B12-dependent glycerol and diol dehydratases and organization of the encoding genes. Daniel R, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):553-66 (61 ref.)

METABOLISM

Biochemistry of coenzyme B12-dependent glycerol and diol dehydratases and organization of the encoding genes. Daniel R, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):553-66 (61 ref.)

1,2-PROPANEDIOL see **PROPYLENE GLYCOL**

PROPANEDIOLS see **PROPYLENE GLYCOLS**

PROPANOLAMINES

THERAPEUTIC USE

Carvedilol: the new role of beta blockers in congestive heart failure. Vanderhoff BT, et al. **Am Fam Physician** 1998 Nov 1;58(7):1627-34, 1641-2 (38 ref.)

Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Fowler MB.
Eur Heart J 1998 Dec;19 Suppl P:P17-25 (27 ref.)

Carvedilol [see comments] Frishman WH. **N Engl J Med** 1998 Dec 10;339(24):1759-65 (77 ref.) Comment in: N Engl J Med 1999 May 6;340(18):1443-4.

Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes. Moreno AJ, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II63-77 (100 ref.)

PROPENE POLYMERS see **POLYPROPYLENES**

PROPENYLACRYLIC ACID see **SORBIC ACID**

PROPERDIN

PHYSIOLOGY

Does properdin crosslink the cellular and the humoral immune response? Schwaeble WJ, et al. **Immunol Today** 1999 Jan;20(1):17-21 (44 ref.)

PROPERDIN PATHWAY see **COMPLEMENT PATHWAY, ALTERNATIVE**

PROPHAGE EXCISION see **VIRUS ACTIVATION**

PROPHAGE INDUCTION see **VIRUS ACTIVATION**

PROPHAGE INTEGRATION see **LYSOGENY**

PROPHASE

PHYSIOLOGY

Ras family proteins: new players involved in the diplotene arrest of Xenopus oocytes. Jessus C, et al. **Biol Cell** 1998 Nov;90(8):573-83 (78 ref.)

Dynamics of meiotic prophase I during spermatogenesis: from pairing to division [see comments] Cobb J, et al.
Semin Cell Dev Biol 1998 Aug;9(4):445-50 (31 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

PROPIONIBACTERIUM ACNES

Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes-treated rats. Toshima K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S51-4 (19 ref.)

[Endocarditis of the native aortic valve due to Propionibacterium acnes (letter)] Jiménez-Navarro MF, et al. **Rev Clin Esp** 1999 May;199(5):331 (7 ref.) **(Spa)**

PATHOGENICITY

[Propionibacterium acnes infectious endocarditis] Durupt S, et al. **Presse Med** 1998 Nov 21;27(36):1839-41 (21 ref.) (Eng. Abstr.) **(Fre)**

PROPIONIC ACIDS

ADVERSE EFFECTS

Pseudoporphyria induced by propionic acid derivatives. Al-Khenaizan S, et al. **J Cutan Med Surg** 1999 Jan; 3(3):162-6 (29 ref.)

CHEMISTRY

Marine polypropionates. Davies-Coleman MT, et al.
Nat Prod Rep 1998 Oct;15(5):477-93 (149 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of oxaprozin. Davies NM.
Clin Pharmacokinet 1998 Dec;35(6):425-36 (44 ref.)

THERAPEUTIC USE

Thyroid hormone and thyroid hormone analogues in the treatment of heart failure. Spooner PH, et al.
Coron Artery Dis 1999 Sep;10(6):395-9 (33 ref.)

TOXICITY

3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Alexi T, et al. **Neuroreport** 1998 Aug 3;9(11):R57-64 (72 ref.)

PROPITOCAINE see **PRILOCAINE**

PROPLAST

Reconstruction of the temporomandibular joint using calvarial bone after a failed Teflon-Proplast implant. Lee JJ, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):457-61 (14 ref.)

PROPOFOL

Propofol in the endoscopy suite: an anesthesiologist's perspective [editorial; comment] Graber RG.
Gastrointest Endosc 1999 Jun;49(6):803-6 (15 ref.) Comment on: Gastrointest Endosc 1999 Jun;49(6):677-83.

Use of propofol and sevoflurane in moyamoya disease--case reports and literature review. Khan-Ghori SN, et al.
Middle East J Anesthesiol 1999 Feb;15(1):73-83 (39 ref.)

Propofol anesthesia for outpatient oral and maxillofacial surgery. Cillo JE Jr.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 May;87(5):530-8 (58 ref.)

Propofol anesthesia. Short CE, et al.
Vet Clin North Am Small Anim Pract 1999 May; 29(3):747-78 (217 ref.)

[Antiemetic effect of propofol] Borgeat A, et al.
Anaesthesist 1998 Nov;47(11):918-24 (54 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Propofol: application in veterinary sedation and anesthesia. Glowaski MM, et al. **Clin Tech Small Anim Pract** 1999 Feb;14(1):1-9 (37 ref.)

The use of propofol infusions in paediatric anaesthesia: a practical guide. McFarlan CS, et al. **Paediatr Anaesth** 1999; 9(3):209-16 (30 ref.)

ADVERSE EFFECTS

Lactic acidemia and bradyarrhythmia in a child sedated with propofol [see comments] Cray SH, et al. **Crit Care Med** 1998 Dec;26(12):2087-92 (31 ref.) Comment in: Crit Care Med 1998 Dec;26(12):1959-60.

Propofol toxicity in critically ill pediatric patients: show us the proof [editorial; comment] Susla GM.
Crit Care Med 1998 Dec;26(12):1959-60 (15 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2087-92.

Propofol-infusion syndrome in children [see comments] Hatch DJ. **Lancet** 1999 Apr 3;353(9159):1117-8 (12 ref.) Comment in: Lancet 1999 Jun 12;353(9169):2074-5.

Propofol infusion syndrome in children. Bray RJ.
Paediatr Anaesth 1998;8(6):491-9 (59 ref.)

THERAPEUTIC USE

Role of propofol in refractory status epilepticus. Brown LA, et al. **Ann Pharmacother** 1998 Oct;32(10):1053-9 (33 ref.)

[Antiemetic effect of propofol] Borgeat A, et al.
Anaesthesist 1998 Nov;47(11):918-24 (54 ref.) (Eng. Abstr.) **(Ger)**

PROPORTIONAL HAZARDS MODELS

Time-dependent covariates in the Cox proportional-hazards regression model. Fisher LD, et al.
Annu Rev Public Health 1999;20:145-57 (13 ref.)

PROPOXYPHENE

THERAPEUTIC USE

Co-proxamol or paracetamol for acute pain?
Drug Ther Bull 1998 Oct;36(10):80 (4 ref.)

D-PROPOXYPHENE see **PROPOXYPHENE**

PROPRANOLOL

ADVERSE EFFECTS

A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor. Louis ED. **Arch Neurol** 1999 Jul;56(7):807-8 (18 ref.)

PHARMACOLOGY

Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report. Tokudome T, et al.
Angiology 1999 Apr;50(4):331-5 (8 ref.)

THERAPEUTIC USE

[The role of nitrogen oxide in migraine attack] Stępień A.
Neurol Neurochir Pol 1999 Mar-Apr;33(2):435-44 (20 ref.) (Eng. Abstr.) **(Pol)**

PROPRIOCEPTION

Muscle rehabilitation in haemophilia. Beeton K, et al.
Haemophilia 1998 Jul;4(4):532-7 (33 ref.)

Proprioceptive training in haemophilia. Buzzard BM.
Haemophilia 1998 Jul;4(4):528-31 (14 ref.)

Proprioceptive impairment in knee osteoarthritis. Sharma L.
Rheum Dis Clin North Am 1999 May;25(2):299-314, vi (59 ref.)

PHYSIOLOGY

The interaction of otolith and proprioceptive information in the perception of verticality. The effects of labyrinthine and CNS disease. Bronstein AM. **Ann N Y Acad Sci** 1999 May 28;871:324-33 (25 ref.)

The continuing debate about CNS control of proprioception [comment] Prochazka A, et al. **J Physiol (Lond)** 1998 Dec 1;513 (Pt 2):315 (10 ref.) Comment on: J Physiol (Lond) 1998 Dec 1;513 (Pt 2):621-8.

Functional roles of the proprioceptive system in the control of goal-directed movement. Park S, et al.
Percept Mot Skills 1999 Apr;88(2):631-47 (60 ref.)

Extraocular muscle proprioceptors and proprioception. Ruskell GL. **Prog Retin Eye Res** 1999 May;18(3):269-91 (129 ref.)

[New trends in the treatment of sports injuries. Shortest possible immobilization. Teach the control of posture and movement] Norlin R, et al. **Lakartidningen** 1998 Sep 23; 95(39):4248-9 (17 ref.) **(Swe)**

PROPTOSIS see **EXOPHTHALMOS**

PROPYLENE GLYCOL

TOXICITY

A review of the comparative mammalian toxicity of ethylene glycol and propylene glycol. LaKind JS, et al. **Crit Rev Toxicol** 1999 Jul;29(4):331-65 (121 ref.)

PROPYLENE GLYCOLS

CHEMISTRY

Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Brown WM, et al. **Crit Rev Neurobiol** 1998;12(3):205-22 (190 ref.)

THERAPEUTIC USE

Preclinical evaluation of a new immunosuppressive agent, FTY720. Troncoso P, et al. **Clin Biochem** 1998 Jul; 31(5):369-73 (21 ref.)

Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Brown WM, et al. **Crit Rev Neurobiol** 1998;12(3):205-22 (190 ref.)

Felbamate in epilepsy therapy: evaluating the risks. Pellock JM. **Drug Saf** 1999 Sep;21(3):225-39 (85 ref.)

PROPYLENE POLYMERS see **POLYPROPYLENES**

PROPYLTHIOURACIL

6-n-Propylthiouracil: a genetic marker for taste, with implications for food preference and dietary habits. Tepper BJ. **Am J Hum Genet** 1998 Nov;63(5):1271-6 (29 ref.)

ADVERSE EFFECTS

Propylthiouracil-induced severe hepatitis: a case report and review of the literature. Ichiki Y, et al. **J Gastroenterol** 1998 Oct;33(5):747-50 (24 ref.)

Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. Pillinger M, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):124-9 (31 ref.)

[A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves' disease] Kawasaki Y, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):612-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

PROSENCEPHALON

What basal forebrain lesions cause amnesia? [editorial; comment] Mayes AR. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):140 (5 ref.) Comment on: J Neurol Neurosurg Psychiatry 1999 Aug;67(2):163-8.

ANATOMY & HISTOLOGY

Some introductory notes on the organization of the forebrain in tetrapods. ten Donkelaar HJ. **Eur J Morphol** 1999 Apr; 37(2-3):73-80 (52 ref.)

The chemoarchitecture of the forebrain of lampreys: evolutionary implications by comparisons with gnathostomes. Weigle C, et al. **Eur J Morphol** 1999 Apr; 37(2-3):122-5 (17 ref.)

CYTOLOGY

The subependymal layer in rodents: a site of structural plasticity and cell migration in the adult mammalian brain. Peretto P, et al. **Brain Res Bull** 1999 Jul 1;49(4):221-43 (184 ref.)

Neuroblasts of the postnatal mammalian forebrain: their phenotype and fate. Luskin MB. **J Neurobiol** 1998 Aug; 36(2):221-33 (87 ref.)

DRUG EFFECTS

Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Mattson MP, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):737-53 (99 ref.)

The behavioral functions of the cholinergic basal forebrain: lessons from 192 IgG-saporin. Wrenn CC, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):595-602 (69 ref.)

EMBRYOLOGY

Getting a-head of the organizer: anterior-posterior patterning of the forebrain. Brewster R, et al. **Bioessays** 1999 Aug;21(8):631-6 (36 ref.)

METABOLISM

The chemoarchitecture of the forebrain of lampreys: evolutionary implications by comparisons with gnathostomes. Weigle C, et al. **Eur J Morphol** 1999 Apr; 37(2-3):122-5 (17 ref.)

The acetylcholine, GABA, glutamate triangle in the rat forebrain. Pepeu G, et al. **J Physiol Paris** 1998 Oct-Dec; 92(5-6):351-5 (51 ref.)

PHYSIOLOGY

The interstitial nucleus of the posterior limb of the anterior commissure: a novel layer of the central division of extended amygdala. Alheid GF, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:645-54 (60 ref.)

The concepts of the ventral striatopallidal system and extended amygdala. de Olmos JS, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:1-32 (100 ref.)

Functions of the amygdala and related forebrain areas in attention and cognition. Gallagher M, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:397-411 (38 ref.)

Functional and anatomical relationships among the amygdala, basal forebrain, ventral striatum, and cortex.An integrative discussion. Gray TS. **Ann N Y Acad Sci** 1999 Jun 29; 877:439-44 (14 ref.)

Regulation of neurotransmitter interactions in the ventral striatum. McGinty JF. **Ann N Y Acad Sci** 1999 Jun 29; 877:129-39 (54 ref.)

Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Sarter M, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:368-82 (73 ref.)

The basal forebrain corticopetal system revisited. Zaborszky L, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:339-67 (130 ref.)

Cognitive functions of the basal forebrain. Baxter MG, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):178-83 (62 ref.)

Forebrain and midbrain structures involved in prey-catching behaviour of toads: stimulus-response mediating circuits and their modulating loops. Ewert JP, et al. **Eur J Morphol** 1999 Apr;37(2-3):172-6 (18 ref.)

Forebrain pathways mediating stress-induced hormone secretion. Van de Kar LD, et al. **Front Neuroendocrinol** 1999 Jan;20(1):1-48 (380 ref.)

Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Gibbs RB, et al. **Horm Behav** 1998 Oct;34(2):98-111 (117 ref.)

Immunolesion of the cholinergic basal forebrain: effects on functional properties of hippocampal and septal neurons. Bassant MH, et al. **Int J Dev Neurosci** 1998 Nov-Dec; 16(7-8):613-32 (109 ref.)

The effects of neonatal basal forebrain lesions on cognition: towards understanding the developmental role of the cholinergic basal forebrain. Berger-Sweeney J. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):603-12 (59 ref.)

The neural mechanisms underlying cholinergic cell death within the basal forebrain. Wenk GL, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):729-35 (97 ref.)

Pacemaker neurons of the forebrain medical septal area and theta rhythm of the hippocampus. Vinogradova OS, et al. **Membr Cell Biol** 1998;11(6):715-25 (27 ref.)

Forebrain mechanisms of nociception and pain: analysis through imaging. Casey KL. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7668-74 (88 ref.)

The role of basal forebrain neurons in tonic and phasic activation of the cerebral cortex. Détári L, et al. **Prog Neurobiol** 1999 Jun;58(3):249-77 (196 ref.)

Maps versus clusters: different representations of auditory space in the midbrain and forebrain. Cohen YE, et al. **Trends Neurosci** 1999 Mar;22(3):128-35 (113 ref.)

[The role of the striatum in the evolution of the mammalian forebrain] Tolkunov BF. **Zh Evol Biokhim Fiziol** 1998 Jul-Aug;34(4):392-400 (43 ref.) **(Rus)**

PHYSIOPATHOLOGY

Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential. Mufson EJ, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:291-304 (73 ref.)

Anxiety and cardiovascular reactivity: the basal forebrain cholinergic link. Berntson GG, et al. **Behav Brain Res** 1998 Aug;94(2):225-48 (280 ref.)

PROSPECTIVE STUDIES

Exposure measurement in cohort studies: the challenges of prospective data collection. White E, et al. **Epidemiol Rev** 1998;20(1):43-56 (94 ref.)

Simulation studies: a new method of prospective technology assessment and design. Kumbruck C, et al. **Qual Life Res** 1999;8(1-2):161-70 (10 ref.)

PROSTACYCLIN see **EPOPROSTENOL**

PROSTAGLANDIN ANALOGS see **PROSTAGLANDINS, SYNTHETIC**

PROSTAGLANDIN ANTAGONISTS

see related
CYCLOOXYGENASE INHIBITORS

PROSTAGLANDIN D2

GENETICS

Prostaglandin D2 and sleep--a molecular genetic approach. Hayaishi O. **J Sleep Res** 1999 Jun;8 Suppl 1:60-4 (24 ref.)

PHYSIOLOGY

Prostaglandin D2 and sleep regulation. Urade Y, et al. **Biochim Biophys Acta** 1999 Jan 4;1436(3):606-15 (111 ref.)

[Sleep-promoting substances] Fujitani Y, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):811-6 (53 ref.) **(Jpn)**

[Molecular and neuroanatomical mechanisms of sleep-wakefulness regulation by prostaglandins D2 and E2] Onoe H. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):343-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

PROSTAGLANDIN E RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PROSTAGLANDIN E1 see **ALPROSTADIL**

PROSTAGLANDIN E2 see **DINOPROSTONE**

PROSTAGLANDIN E2ALPHA see **DINOPROSTONE**

PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE

Celecoxib, a COX-2--specific inhibitor: the clinical data. Fort J. **Am J Orthop** 1999 Mar;28(3 Suppl):13-8 (14 ref.)

Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. O'Banion MK. **Crit Rev Neurobiol** 1999; 13(1):45-82 (354 ref.)

Cyclooxygenase-2 as a therapeutic target. Mitchell JA, et al. **Inflamm Res** 1998 Oct;47 Suppl 2:S88-92 (22 ref.)

Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? Wallace JL, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S28-34 (37 ref.)

[Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers] Ohara M, et al. **Masui** 1998 Nov;47(11):1325-32 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Current topics in the regulation of prostanoids--3. Prostanoid synthases and prostanoid receptors] Ohara M, et al. **Masui** 1999 Jan;48(1):42-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of COX-1 and COX-2 and gastrointestinal diseases] Tsujii M, et al. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2114-21 (15 ref.) **(Jpn)**

[Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2] Tada Y, et al. **Nippon Rinsho** 1999 Feb;57(2):419-24 (23 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. Marnett LJ, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):482-90 (61 ref.)

Cyclooxygenase-1 and -2 isoenzymes. Hla T, et al. **Int J Biochem Cell Biol** 1999 May;31(5):551-7 (43 ref.)

Cyclooxygenase-2 inhibitors in tumorigenesis (part I). Taketo MM. **J Natl Cancer Inst** 1998 Oct 21;90(20):1529-36 (98 ref.)

Carbocations in the synthesis of prostaglandins by the cyclooxygenase of PGH synthase? A radical departure! Dean AM, et al. **Protein Sci** 1999 May;8(5):1087-98 (94 ref.)

DEFICIENCY

[Platelet cyclooxygenase deficiency] Fuse I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):369-71 (7 ref.) **(Jpn)**

DRUG EFFECTS

COX-1 and COX-2 inhibition: current status and future perspective. Greyn J, et al. **Acta Anaesthesiol Belg** 1998; 49(3):175-83 (39 ref.)

The clinical potential of cyclooxygenase-2-specific inhibitors. Lipsky PE. **Am J Med** 1999 May 31; 106(5B):51S-57S (51 ref.)

The cyclooxygenase-2 inhibitors: safety and effectiveness. Kaplan-Machlis B, et al. **Ann Pharmacother** 1999 Sep; 33(9):979-88 (59 ref.)

COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs [editorial] Schachna L, et al. **Med J Aust** 1999 Aug 16;171(4):175-6 (20 ref.)

4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Talley JJ, et al. **Med Res Rev** 1999 May;19(3):199-208 (29 ref.)

Overview of nimesulide. Bennett A. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:1-3 (19 ref.)

Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Bjarnason I, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:24-32 (87 ref.)

Molecular model of the interaction between nimesulide and human cyclooxygenase-2. Garcia-Nieto R, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:14-8 (26 ref.)

Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rainsford KD. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:4-10 (22 ref.)

The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Shah AA, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:19-23 (47 ref.)

[New NSAIDS: COX-1, COX-2, what about them?] Peretz A. **Rev Med Brux** 1998 Sep;19(4):A399-402 (14 ref.) (Eng. Abstr.) **(Fre)**

PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE

GENETICS

Molecular model of the interaction between nimesulide and human cyclooxygenase-2. Garcia-Nieto R, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:14-8 (26 ref.)

Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels. Hauck W, et al. **Semin Perinatol** 1999 Jun;23(3):250-60 (92 ref.)

METABOLISM

Role and regulation of cyclooxygenase-2 during inflammation. Simon LS. **Am J Med** 1999 May 31; 106(5B):37S-42S (14 ref.)

The prevention of colorectal cancer by aspirin use. Giovannucci E. **Biomed Pharmacother** 1999 Aug; 53(7):303-8 (53 ref.)

The COX-1/COX-2 balance in asthma. Pang L, et al. **Clin Exp Allergy** 1998 Sep;28(9):1050-8 (75 ref.)

Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. Goodwin DC, et al. **FASEB J** 1999 Jul; 13(10):1121-36 (104 ref.)

Cyclooxygenase-dependent signalling: molecular events and consequences. Versteeg HH, et al. **FEBS Lett** 1999 Feb 19;445(1):1-5 (58 ref.)

Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Katori M, et al. **Inflamm Res** 1998 Oct;47 Suppl 2:S107-11 (25 ref.)

Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Pairet M, et al. **Inflamm Res** 1998 Oct;47 Suppl 2:S93-101 (65 ref.)

Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J, et al. **Inflamm Res** 1999 May;48(5):247-54 (97 ref.)

Cyclo-oxygenase-2 in vascular smooth muscle. Bishop-Bailey D, et al. **Int J Mol Med** 1999 Jan;3(1):41-8 (70 ref.)

Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Chiarugi V, et al. **Int J Mol Med** 1998 Dec; 2(6):715-9 (35 ref.)

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. Marnett LJ, et al. **J Biol Chem** 1999 Aug 13;274(33):22903-6 (58 ref.)

Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. Sakamoto C. **J Gastroenterol** 1998 Oct; 33(5):618-24 (68 ref.)

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). Taketo MM. **J Natl Cancer Inst** 1998 Nov 4;90(21):1609-20 (146 ref.)

Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. Pasinetti GM. **J Neurosci Res** 1998 Oct 1;54(1):1-6 (57 ref.)

Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS. **J Rheumatol** 1999 Apr;26 Suppl 56:31-6 (19 ref.)

Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? Lipsky PE. **J Rheumatol** 1999 Apr;26 Suppl 56:25-30 (88 ref.)

Free-radical and cyclooxygenase-catalyzed lipid peroxidation in membranes of blood cells under UV irradiation. Roshchupkin DI, et al. **Membr Cell Biol** 1998; 12(2):279-86 (14 ref.)

Cox-2-selective inhibitors: the new super aspirins. DeWitt DL. **Mol Pharmacol** 1999 Apr;55(4):625-31 (35 ref.)

COX-2 in synovial tissues. Crofford LJ. **Osteoarthritis Cartilage** 1999 Jul;7(4):406-8 (18 ref.)

Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis. Needleman P, et al. **Osteoarthritis Cartilage** 1999 Jul;7(4):367-70 (28 ref.)

Selective cyclooxygenase-2 inhibitors. Golden BD, et al. **Rheum Dis Clin North Am** 1999 May;25(2):359-78 (145 ref.)

COX-1, COX-2: so what? [editorial] Emery P. **Scand J Rheumatol** 1999;28(1):6-9 (16 ref.)

Selective COX-2 inhibitors: is the water becoming muddy? Wallace JL. **Trends Pharmacol Sci** 1999 Jan;20(1):4-6 (28 ref.)

[Non-steroidal anti-inflammatory agents (NSAID's) with lesser side effects by selective inhibition of cyclo-oxygenase-2] Bijlsma JW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1;142(31):1762-5 (20 ref.) (Eng. Abstr.) **(Dut)**

[COX-1 and COX-2: functions and pharmacological effects] Hinz B, et al. **Pharm Unserer Zeit** 1999 Jan;28(1):21-9 (80 ref.) **(Ger)**

[Colon cancer and cyclooxygenase] Oshima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec;95(12):1327-32 (29 ref.) **(Jpn)**

[Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology] Ledro Cano D, et al. **Rev Esp Enferm Dig** 1999 Apr;91(4):305-9 (27 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Cyclooxygenases and cyclooxygenase inhibitors: is a new class of drugs in the making? Berenbaum F. **Rev Rhum Engl Ed** 1998 Nov;65(11):634-40 (56 ref.)

PHYSIOLOGY

Role of cyclooxygenase-1 and -2 in health and disease. Lipsky PE. **Am J Orthop** 1999 Mar;28(3 Suppl):8-12 (29 ref.)

Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Amin AR, et al. **Curr Opin Rheumatol** 1999 May;11(3):202-9 (58 ref.)

Cyclooxygenase-1 and -2 isoenzymes. Hla T, et al. **Int J Biochem Cell Biol** 1999 May;31(5):551-7 (43 ref.)

Roles of COX-1 and COX-2 [letter; comment] McCormack K. **J Rheumatol** 1998 Nov;25(11):2279-81 (13 ref.) Comment on: J Rheumatol 1997 Feb;24(2):243-5. Comment on: J Rheumatol 1997 Feb;24(2):246-8.

The role of COX-2 produced by cartilage in arthritis. Abramson SB. **Osteoarthritis Cartilage** 1999 Jul;7(4):380-1 (16 ref.)

The advent of highly selective inhibitors of cyclooxygenase--a review. Cryer B, et al. **Prostaglandins Other Lipid Mediat** 1998 Aug; 56(5-6):341-61 (102 ref.)

Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS. **Scand J Rheumatol Suppl** 1999;109:31-7 (19 ref.)

COX-2: separating myth from reality. McKenna F. **Scand J Rheumatol Suppl** 1999;109:19-29 (57 ref.)

[Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances] Hinz B, et al. **Wien Klin Wochenschr** 1999 Feb 12;111(3):103-12 (91 ref.) (Eng. Abstr.) **(Ger)**

[Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity] Dammann HG. **Z Gastroenterol** 1999 Jan; 37(1):45-58 (129 ref.) (Eng. Abstr.) **(Ger)**

[Functional coupling between phospholipase A2 and cyclooxygenase] Murakami M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1146-56 (38 ref.) **(Jpn)**

PROSTAGLANDIN ENDOPEROXIDE SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN ENDOPEROXIDE SYNTHETASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN F ANALOGS see **PROSTAGLANDINS F, SYNTHETIC**

PROSTAGLANDIN F2 see **DINOPROST**

PROSTAGLANDIN F2ALPHA see **DINOPROST**

PROSTAGLANDIN H SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN I2 see **EPOPROSTENOL**

PROSTAGLANDIN RECEPTORS see **RECEPTORS, PROSTAGLANDIN**

PROSTAGLANDIN SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN SYNTHESIS ANTAGONISTS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN X see **EPOPROSTENOL**

PROSTAGLANDINS

see related
RECEPTORS, PROSTAGLANDIN

ADMINISTRATION & DOSAGE

Anticoagulation with prostaglandins during extracorporeal circulation. Kozek-Langenecker SA. **Wien Klin Wochenschr** 1999 Feb 26;111(4):129-40 (124 ref.)

ADVERSE EFFECTS

Adverse events associated with commonly used glaucoma drugs. Vogel R, et al. **Int Ophthalmol Clin** 1999 Spring; 39(2):107-24 (82 ref.)

ANALYSIS

Measurement of lipid peroxidation. Moore K, et al. **Free Radic Res** 1998 Jun;28(6):659-71 (671 ref.)

Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. Tsikas D. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9;717(1-2):201-45 (304 ref.)

Extraction and measurements of prostanoids and leukotrienes by radioimmunoassays. Battistini B, et al. **Methods Mol Biol** 1998;105:187-99 (10 ref.)

Measurements of prostanoids, leukotrienes, and isoprostanes by enzyme immunoassays. Battistini B, et al. **Methods Mol Biol** 1998;105:201-7 (5 ref.)

BIOSYNTHESIS

Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions. Levi G, et al. **Biochimie** 1998 Nov;80(11):899-904 (49 ref.)

Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. Goodwin DC, et al. **FASEB J** 1999 Jul; 13(10):1121-36 (104 ref.)

Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. Lawson JA, et al. **J Biol Chem** 1999 Aug 27;274(35):24441-4 (69 ref.)

Key enzymes of prostaglandin biosynthesis and metabolism. Coordinate regulation of expression by cytokines in gestational tissues: a review. Hansen WR, et al. **Prostaglandins Other Lipid Mediat** 1999 Jun;57(4):243-57 (128 ref.)

Carbocations in the synthesis of prostaglandins by the cyclooxygenase of PGH synthase? A radical departure! Dean AM, et al. **Protein Sci** 1999 May;8(5):1087-98 (94 ref.)

[Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers] Ohara M, et al. **Masui** 1998 Nov;47(11):1325-32 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Current topics in the regulation of prostanoids--3. Prostanoid synthases and prostanoid receptors] Ohara M, et al. **Masui** 1999 Jan;48(1):42-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Measurement of lipid peroxidation. Moore K, et al. **Free Radic Res** 1998 Jun;28(6):659-71 (671 ref.)

The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. Liu T, et al. **J Biomed Sci** 1999 Jul-Aug;6(4):226-35 (45 ref.)

Carbocations in the synthesis of prostaglandins by the cyclooxygenase of PGH synthase? A radical departure! Dean AM, et al. **Protein Sci** 1999 May;8(5):1087-98 (94 ref.)

METABOLISM

Role of non-nitric oxide non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. Resende AC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1229-35 (58 ref.)

Prostaglandin--a pluralistic hormone embracing divergent signal properties [editorial] Sack S. **Cardiovasc Res** 1998 Dec;40(3):438-9 (20 ref.)

Matrix metalloproteinases, prostaglandins and endothelins: paracrine regulators of implantation. Cameron IT. **Gynecol Endocrinol** 1998 Dec;12(6):415-9 (38 ref.)

The isoprostanes: unique bioactive products of lipid peroxidation. An overview. Liu TZ, et al. **J Biomed Sci** 1998 Nov-Dec;5(6):415-20 (27 ref.)

Prostaglandins in macula densa function. Harris RC, et al. **Kidney Int Suppl** 1998 Sep;67:S49-52 (40 ref.)

Novel eicosanoids. Isoprostanes and related compounds. Roberts LJ 2nd, et al. **Methods Mol Biol** 1999;120:257-85 (98 ref.)

Prostaglandins as putative neurotoxins in Alzheimer's disease. Prasad KN, et al. **Proc Soc Exp Biol Med** 1998 Nov; 219(2):120-5 (82 ref.)

The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Khan MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar; 60(3):169-74 (83 ref.)

[Current topics in the regulation of prostanoids--4. The feedback regulation by PPAR-gamma] Ohara M, et al. **Masui** 1999 Feb;48(2):146-51 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Current topics in the regulation of prostanoids--2. The interaction with cytokines and nitric oxide] Ohara M, et al. **Masui** 1998 Dec;47(12):1471-7 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Establishment of microanalysis of prostaglandin metabolites by GC/MS and its clinical application] Mizugaki M. **Yakugaku Zasshi** 1999 Jan;119(1):61-80 (39 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Weber AA, et al. **Basic Res Cardiol** 1998;93 Suppl 3:54-7 (20 ref.)

Radically novel prostaglandins in animals and plants: the isoprostanes. Mueller MJ. **Chem Biol** 1998 Dec; 5(12):R323-33 (90 ref.)

Prostaglandins in the stomach: an update. Arakawa T, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S1-11 (42 ref.)

Histamine and prostaglandins in schizophrenia: revisited. Heleniak E, et al. **Med Hypotheses** 1999 Jan;52(1):37-42 (59 ref.)

COX-2 in synovial tissues. Crofford LJ. **Osteoarthritis Cartilage** 1999 Jul;7(4):406-8 (18 ref.)

Prostaglandins and bone: physiology and pathophysiology. Raisz LG. **Osteoarthritis Cartilage** 1999 Jul;7(4):419-21 (24 ref.)

Role of prostaglandins in the urinary bladder: an update. Khan MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Dec; 59(6):415-22 (115 ref.)

[Physiopathological and therapeutic study of collagen diseases based on results of clinical tests--role of prostaglandins] Sano H. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2438-45 (13 ref.) **(Jpn)**
[The role of prostaglandins in allergic inflammation] Rašković S, et al. **Srp Arh Celok Lek** 1998 Sep-Oct; 126(9-10):388-93 (33 ref.) (Eng. Abstr.) **(Scc)**

PROSTAGLANDINS D

METABOLISM

New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts. Roberts LJ 2nd, et al. **FASEB J** 1999 Jul; 13(10):1157-68 (40 ref.)

PROSTAGLANDINS E

METABOLISM

New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts. Roberts LJ 2nd, et al. **FASEB J** 1999 Jul; 13(10):1157-68 (40 ref.)

PROSTAGLANDINS F

PHYSIOLOGY

Peptide growth factors in amphibian embryogenesis: intersection of modern molecular approaches with traditional inductive interaction paradigms. Asashima M, et al. **Int J Dev Biol** 1999 Jan;43(1):1-10 (107 ref.)

PROSTAGLANDINS F, SYNTHETIC

THERAPEUTIC USE

A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Eisenberg DL, et al. **Drug Saf** 1999 Jun; 20(6):505-14 (58 ref.)
Prostaglandin analogues in the treatment of glaucoma. Lindén C, et al. **Drugs Aging** 1999 May;14(5):387-98 (108 ref.)

PROSTAGLANDINS, SYNTHETIC

THERAPEUTIC USE

Topical therapies for glaucoma: what family physicians need to know. Lewis PR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1871-9, 1882 (30 ref.)
Prostaglandin analogues in the treatment of glaucoma. Lindén C, et al. **Drugs Aging** 1999 May;14(5):387-98 (108 ref.)

PROSTANOIC ACIDS

CHEMISTRY

The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. Liu T, et al. **J Biomed Sci** 1999 Jul-Aug;6(4):226-35 (45 ref.)

PROSTATE

see related
PROSTATECTOMY

Estrogen receptor-beta: implications for the prostate gland. Chang WY, et al. **Prostate** 1999 Jul 1;40(2):115-24 (63 ref.)
[Embryologic hypotheses of prostatic ectopy: apropos of a case] Colombel M, et al. **Prog Urol** 1998 Sep;8(4):573-7 (28 ref.) (Eng. Abstr.) **(Fre)**
[Prostasomes enhance sperm capacity. Prostatic components, or antibodies against them, may be used in in vitro fertilization, as contraceptive agents and for the diagnosis of cancer] Ronquist G, et al. **Lakartidningen** 1998 Oct 21; 95(43):4724-5 (16 ref.) (Eng. Abstr.) **(Swe)**

BLOOD SUPPLY

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Moul JW. **Eur Urol** 1999;35(5-6):399-407 (67 ref.)

CHEMISTRY

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Rittenhouse HG, et al. **Crit Rev Clin Lab Sci** 1998 Aug;35(4):275-368 (457 ref.)

CYTOLOGY

Analytical molecular pathology of epithelial-stromal interactions in the normal and neoplastic prostate. Bonkhoff H. **Anal Quant Cytol Histol** 1998 Oct;20(5):437-42 (36 ref.)
Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies. O'Connor KC. **Pharm Res** 1999 Apr;16(4):486-93 (60 ref.)

DRUG EFFECTS

Potential adverse effects of long-term testosterone therapy. Rolf C, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):521-34 (66 ref.)
Preclinical pharmacology of alpha1-adrenoceptor antagonists. Martin DJ. **Eur Urol** 1999;36 Suppl 1:35-41; discussion 65 (23 ref.)

GROWTH & DEVELOPMENT

Molecular biology of prostate development and prostate cancer. Sciavolino PJ, et al. **Ann Med** 1998 Aug; 30(4):357-68 (136 ref.)

METABOLISM

Role of p27 in prostate carcinogenesis. Macri E, et al. **Cancer Metastasis Rev** 1998-99;17(4):337-44 (70 ref.)
Molecular action of androgen in the normal and neoplastic prostate. Kokontis JM, et al. **Vitam Horm** 1999;55:219-307 (560 ref.)

PATHOLOGY

Analytical molecular pathology of epithelial-stromal interactions in the normal and neoplastic prostate. Bonkhoff H. **Anal Quant Cytol Histol** 1998 Oct;20(5):437-42 (36 ref.)
Automated histometry in quantitative prostate pathology. Hamilton PW, et al. **Anal Quant Cytol Histol** 1998 Oct; 20(5):443-60 (48 ref.)
Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Relationship to pathologic parameters, volume and spatial distribution of carcinoma of the prostate. Sakr WA, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):417-23 (43 ref.)
Considerations regarding prostate biopsies. Beerlage HP, et al. **Eur Urol** 1998 Oct;34(4):303-12 (94 ref.)
Broadsheet number 45: thin core biopsy of prostate. The Royal College of Pathologists of Australia. Delahunt B, et al. **Pathology** 1998 Aug;30(3):247-56 (80 ref.)
Prostate biopsy interpretation. Current concepts, 1999. Iczkowski KA, et al. **Urol Clin North Am** 1999 Aug; 26(3):435-52 (139 ref.)
Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Sakr WA, et al. **Urol Clin North Am** 1999 Aug;26(3):453-63, v (62 ref.)
[Transrectal biopsies of prostate and infection. Antibiotherapy or antibioprophylaxis?] Lobel B. **Prog Urol** 1998 Sep;8(4):578 (3 ref.) **(Fre)**
[Value of biopsies in staging of prostatic cancer before radical prostatectomy] Salomon L, et al. **Prog Urol** 1998 Dec; 8(6):969-76 (93 ref.) (Eng. Abstr.) **(Fre)**
[The advance of ultrasound guided prostate biopsy--comparison between 4 quadrant and 6 sextant biopsy] Ishitoya S, et al. **Nippon Rinsho** 1998 Aug; 56(8):2056-61 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Signal transduction pathways associated with alpha1-adrenoceptor subtypes in cells and tissues including human prostate. Marshall I, et al. **Eur Urol** 1999;36 Suppl 1:42-7; discussion 65 (23 ref.)
Prostate stroma: physiology. Farnsworth WE. **Prostate** 1999 Jan 1;38(1):60-72 (105 ref.)
[Autonomic nervous system and prostatic physiology. Specific features of the alpha-adrenergic system] Mottet N, et al. **Prog Urol** 1999 Feb;9(1):26-36 (78 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Prostate specific antigen: an opinion on its value to the radiologist. Clements R. **Eur Radiol** 1999;9(3):529-35 (41 ref.)

RADIONUCLIDE IMAGING

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA, et al. **Prostate** 1998 Dec 1;37(4):261-9 (29 ref.)

PROSTATE CANCER see **PROSTATIC NEOPLASMS**

PROSTATE-SPECIFIC ANTIGEN

see related
PROSTATIC NEOPLASMS

Prostate specific antigen: an opinion on its value to the radiologist. Clements R. **Eur Radiol** 1999;9(3):529-35 (41 ref.)
[Regulation of prostate gland-specific gene expression] Ueyama H, et al. **Seikagaku** 1999 Mar;71(3):210-4 (17 ref.) **(Jpn)**

ANALYSIS

Prostate-specific antigen (PSA) in women. Yu H, et al. **J La State Med Soc** 1999 Apr;151(4):209-13 (54 ref.)
[Markers of prostatic carcinoma] Safařík L. **Cas Lek Cesk** 1998 Aug 31;137(17):525-7 (22 ref.) (Eng. Abstr.) **(Cze)**

BLOOD

PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases [see comments] Barry MJ. **Ann Oncol** 1998 Dec;9(12):1279-82 (20 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.
PSA screening for prostate cancer: the current controversy [see comments] de Koning HJ, et al. **Ann Oncol** 1998 Dec; 9(12):1293-6 (19 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.
Screening for prostate cancer [see comments] Neal DE, et al. **Ann Oncol** 1998 Dec;9(12):1289-92 (30 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.
PSA screening--current controversy [see comments] Svetec D, et al. **Ann Oncol** 1998 Dec;9(12):1283-8 (42 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.
Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2799-801 (40 ref.)
Prostate cancer and PSA screening. Mameghan H. **Aust Fam Physician** 1999 Aug;28(8):777-81 (11 ref.)
Prostate cancer screening: promise and peril--a review. Godley PA. **Cancer Detect Prev** 1999;23(4):316-24 (97 ref.)
Prostate-specific antigen and new related markers for prostate cancer. Daher R, et al. **Clin Chem Lab Med** 1998 Sep;36(9):671-81 (139 ref.)
Prostate cancer: 4. Screening. Meyer F, et al. **CMAJ** 1998 Oct 20;159(8):968-72 (22 ref.)
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. **Eur J Cancer** 1999 Feb;35(2):262-71 (12 ref.)
The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials. Crawford ED. **Eur Urol** 1999;35(5-6):511-4 (14 ref.)
Chemoprevention of prostate cancer: concepts and strategies. Kelloff GJ, et al. **Eur Urol** 1999;35(5-6):342-50 (37 ref.)
Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Valicenti RK, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1; 42(3):501-6 (22 ref.)
The use of percent free PSA for early detection of prostate cancer. Potter SR, et al. **J Androl** 1999 Jul-Aug; 20(4):449-53 (31 ref.)
Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: a preliminary report. Loughlin KR, et al. **J Surg Oncol** 1999 Jan;70(1):49-53 (21 ref.)
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. Epstein JI, et al. **J Urol** 1998 Dec;160(6 Pt 2):2407-11 (26 ref.)
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. Polascik TJ, et al. **J Urol** 1999 Aug;162(2):293-306 (141 ref.)
Rising PSA after local therapy failure: immediate vs deferred treatment. Moul JW. **Oncology (Huntingt)** 1999 Jul; 13(7):985-90, 993; discussion 993-5, 999 (33 ref.)
The management of PSA failure after radical radiotherapy for localized prostate cancer. Parker CC, et al. **Radiother Oncol** 1998 Nov;49(2):103-10 (39 ref.)
Prostate-specific antigen. Stenman UH, et al. **Semin Cancer Biol** 1999 Apr;9(2):83-93 (103 ref.)
Race and serum prostate-specific antigen levels: current status and future directions. Abdalla I, et al. **Semin Urol Oncol** 1998 Nov;16(4):207-13 (55 ref.)
Hormonal manipulation for rising PSA after radical prostatectomy. Bhayani SB, et al. **Semin Urol Oncol** 1999 Aug;17(3):148-53 (45 ref.)
The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy. de la Taille A, et al. **Semin Urol Oncol** 1998 Aug;16(3):137-44 (74 ref.)
How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Jhaveri FM, et al. **Semin Urol Oncol** 1999 Aug;17(3):130-4 (37 ref.)
The role of dietary manipulation in biochemical recurrence of prostate cancer after radical prostatectomy. Lee CT, et al. **Semin Urol Oncol** 1999 Aug;17(3):154-63 (79 ref.)
The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Pannek J, et al. **Semin Urol Oncol** 1998 Aug;16(3):100-5 (40 ref.)
The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Ravery V. **Semin Urol Oncol** 1999 Aug;17(3):127-9 (15 ref.)
Observation/delayed treatment for rising PSA after radical prostatectomy: pros and cons. Ruffion A, et al. **Semin Urol Oncol** 1999 Aug;17(3):135-40 (64 ref.)
Rising PSAs after primary therapy: active or passive intervention. Slovin SF, et al. **Semin Urol Oncol** 1999 Aug; 17(3):164-73 (54 ref.)
Radiation therapy for a rising PSA level after radical prostatectomy. Tiguert R, et al. **Semin Urol Oncol** 1999 Aug;17(3):141-7 (35 ref.)
Prostate-specific antigen and other markers of therapeutic response. Carducci MA, et al. **Urol Clin North Am** 1999 May;26(2):291-302, viii (83 ref.)
Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Kim J, et al. **Urol Clin North Am** 1999 May;26(2):281-90 (92 ref.)
Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties

are clinically significant. Bassler TJ Jr, et al. **Urology** 1998 Dec;52(6):1064–9 (54 ref.)
[Limitations on the interpretation of prostate-specific antigen serum levels] Sciarra A, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):105–12 (27 ref.) (Eng. Abstr.) **(Ita)**
[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer] Akino H, et al. **Nippon Rinsho** 1998 Aug;56(8):2003–5 (14 ref.) (Eng. Abstr.) **(Jpn)**
[The significance and limitation of prostate specific antigen in the mass screening for prostate cancer] Imai K, et al. **Nippon Rinsho** 1998 Aug;56(8):1994–7 (7 ref.) (Eng. Abstr.) **(Jpn)**
[The clinical value of prostate-specific antigen velocity as a method for prostate cancer detection] Ito K, et al. **Nippon Rinsho** 1998 Aug;56(8):2021–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[The efficacy of PSA density for the early detection of prostate cancer] Kanehara H, et al. **Nippon Rinsho** 1998 Aug;56(8):2012–5 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Standardization of PSA assays] Kuriyama M. **Nippon Rinsho** 1998 Aug;56(8):1998–2002 (11 ref.) (Eng. Abstr.) **(Jpn)**
[PSATZ (prostate specific antigen adjusted for the transition zone volume)] Maeda H, et al. **Nippon Rinsho** 1998 Aug;56(8):2016–20 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Percent free prostate-specific antigen: a marker for detection of prostate cancer] Miyanaga N, et al. **Nippon Rinsho** 1998 Aug;56(8):2006–11 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status] Nakata S, et al. **Nippon Rinsho** 1998 Aug;56(8):2026–30 (16 ref.) (Eng. Abstr.) **(Jpn)**
[The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer] Saito Y. **Nippon Rinsho** 1998 Aug;56(8):1989–93 (13 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review). Willis RA, et al. **Int J Mol Med** 1998 Feb;1(2):379–86 (59 ref.)

METABOLISM

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Rittenhouse HG, et al. **Crit Rev Clin Lab Sci** 1998 Aug;35(4):275–368 (457 ref.)
["Prostatic" kallikreins, sex hormones and insulin-like growth factors: complex of male and female regulatory elements in health and carcinogenesis] Zezerov EG, et al. **Vestn Ross Akad Med Nauk** 1999;(3):49–56 (63 ref.) (Eng. Abstr.) **(Rus)**

PROSTATECTOMY

Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Valicenti RK, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1; 42(3):501–6 (22 ref.)
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. Obek C, et al. **J Urol** 1999 Feb;161(2):494–8; discussion 498–9 (20 ref.)
Massive prostatic bleeding after transurethral resection of the prostate in a patient with a congenital pelvic arteriovenous malformation. Touyama H, et al. **J Urol** 1998 Nov;160(5):1803 (3 ref.)
ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA, et al. **Prostate** 1998 Dec 1;37(4):261–9 (29 ref.)
Hormonal manipulation for rising PSA after radical prostatectomy. Bhayani SB, et al. **Semin Urol Oncol** 1999 Aug;17(3):148–53 (45 ref.)
The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy. de la Taille A, et al. **Semin Urol Oncol** 1998 Aug;16(3):137–44 (74 ref.)
How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Jhaveri FM, et al. **Semin Urol Oncol** 1999 Aug;17(3):130–4 (37 ref.)
The role of dietary manipulation in biochemical recurrence of prostate cancer after radical prostatectomy. Lee CT, et al. **Semin Urol Oncol** 1999 Aug;17(3):154–63 (79 ref.)
The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Ravery V. **Semin Urol Oncol** 1999 Aug;17(3):127–9 (15 ref.)
Observation/delayed treatment for rising PSA after radical prostatectomy: pros and cons. Ruffion A, et al. **Semin Urol Oncol** 1999 Aug;17(3):135–40 (64 ref.)
Rising PSAs after primary therapy: active or passive intervention. Slovin SF, et al. **Semin Urol Oncol** 1999 Aug; 17(3):164–73 (54 ref.)
Radiation therapy for a rising PSA level after radical prostatectomy. Tiguert R, et al. **Semin Urol Oncol** 1999 Aug;17(3):141–7 (35 ref.)
Problems of suprapubic prostatectomy. Schweitzer FA. **Trop Doct** 1999 Apr;29(2):113–5 (8 ref.)
Patient-reported complications after cryoablation therapy for prostate cancer. Badalament RA, et al. **Urology** 1999 Aug; 54(2):295–300 (18 ref.)
Treatment outcome after radical prostatectomy is not adversely affected by a pre-existing penile prosthesis. Tiguert R, et al. **Urology** 1998 Dec;52(6):1030–3 (16 ref.)
Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Vicini FA, et al. **Urology** 1999 Jul;54(1):111–7 (39 ref.)
[Value of biopsies in staging of prostatic cancer before radical prostatectomy] Salomon L, et al. **Prog Urol** 1998 Dec; 8(6):969–76 (93 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

BPH and sexuality. Zlotta AR, et al. **Eur Urol** 1999;36 Suppl 1:107–12 (37 ref.)
Have complication rates decreased after treatment for localized prostate cancer? Thompson IM, et al. **J Urol** 1999 Jul;162(1):107–12 (12 ref.)

HISTORY

A century of prostatic surgery. Shackley D. **BJU Int** 1999 May;83(7):776–82 (17 ref.)

METHODS

Is transurethral resection of the prostate still justified? Madersbacher S, et al. **BJU Int** 1999 Feb;83(3):227–37 (79 ref.)
Prostate cancer: 6. Surgical treatment of localized disease. Goldenberg SL, et al. **CMAJ** 1998 Nov 17;159(10):1265–71 (25 ref.)
Side-firing Neodymium:YAG laser prostatectomy. Costello AJ, et al. **Eur Urol** 1999 Feb;35(2):138–46 (68 ref.)
Holmium laser resection of the prostate. Le Duc A, et al. **Eur Urol** 1999 Feb;35(2):155–60 (32 ref.)
Interstitial laser therapy of benign prostatic hyperplasia. Muschter R, et al. **Eur Urol** 1999 Feb;35(2):147–54 (62 ref.)
Thick loop transurethral resection of the prostate. Perlmutter AP, et al. **Eur Urol** 1999 Feb;35(2):161–5 (8 ref.)
Electrosurgery: VaporTrode. Weiner DM, et al. **Eur Urol** 1999 Feb;35(2):166–72 (27 ref.)
[Radical prostatectomy: improving urinary incontinence (editorial)] Rodriguez-Rubio Cortadellas FI, et al. **Actas Urol Esp** 1998 Sep;22(8):629–41 (54 ref.) **(Spa)**

PROSTATECTOMY, RETROPUBIC see **PROSTATECTOMY**

PROSTATECTOMY, SUPRAPUBIC see **PROSTATECTOMY**

PROSTATECTOMY, TRANSURETHRAL see **PROSTATECTOMY**

PROSTATIC ADENOMA see **PROSTATIC HYPERPLASIA**

PROSTATIC DISEASES

Cryptococcal prostatic abscess in an immunocompromised patient: a case report and review of the literature. Yip SK, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):873–6 (28 ref.)
Phytoestrogens and diseases of the prostate gland. Griffiths K, et al. **Baillieres Clin Endocrinol Metab** 1998 Dec; 12(4):625–47 (107 ref.)
Prostate and sexuality: An overview. Burger B, et al. **Eur Urol** 1999;35(3):177–84 (44 ref.)
[Prostatic abscess] Miyazaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):231–2 (7 ref.) **(Jpn)**

COMPLICATIONS

[Prostatic cancer with cystic formation: a case report] Kubo M, et al. **Hinyokika Kiyo** 1998 Dec;44(12):883–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

A century of prostatic surgery. Shackley D. **BJU Int** 1999 May;83(7):776–82 (17 ref.)

PROSTATIC HYPERPLASIA

Benign changes in the prostate with ageing. Diokno AC. **Br J Urol** 1998 Dec;82 Suppl 1:44–6 (13 ref.)
Benign prostatic hyperplasia (the aging prostate). Medina JJ, et al. **Med Clin North Am** 1999 Sep;83(5):1213–29 (44 ref.)
Benign prostatic hyperplasia: an overview. Ziada A, et al. **Urology** 1999 Mar;53(3 Suppl 3a):1–6 (51 ref.)
Quality-of-life aspects in urology – benign prostatic hyperplasia. MacDonagh R, et al. **World J Urol** 1999 Aug; 17(4):199–204 (41 ref.)
[Medical-economic models of benign prostatic hypertrophy] Le Pen C, et al. **Prog Urol** 1998 Dec;8(6):961–8 (23 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Hypertension in the elderly with coexisting benign prostatic hyperplasia. Maruenda J, et al. **Urology** 1999 Mar;53(3 Suppl 3a):7–12; discussion 12–3, 41–2 (40 ref.)
[Dysuria and prostatic adenoma: information provided by uroflowmetry] Grise P, et al. **Prog Urol** 1999 Feb; 9(1):146–50 (32 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

'Appropriateness of referral to urologists': can it be defined for symptoms of benign prostatic obstruction and used as a quality measure? Elwyn G, et al. **BJU Int** 1999 Feb; 83(3):238–42 (19 ref.)
Office evaluation of men with lower urinary tract symptoms. Jepsen JV, et al. **Urol Clin North Am** 1998 Nov; 25(4):545–54, vii (76 ref.)
[Contribution of pressure-flow relationship studies in the evaluation of benign hypertrophy of the prostate] Haab F. **Prog Urol** 1999 Feb;9(1):151–5 (24 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. Wilt TJ, et al. **BJU Int** 1999 Jun;83(9):976–83 (32 ref.)
Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension. Altwein JE. **Br J Hosp Med** 1998 Dec 10;58(11):592–4 (31 ref.)
Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Cooper KL, et al. **Drugs** 1999 Jan; 57(1):9–17 (38 ref.)
Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Wilde MI, et al. **Drugs** 1999 Apr;57(4):557–81 (012 ref.)
Medical therapy and quality of life. Chapple CR. **Eur Urol** 1998;34 Suppl 2:10–7; discussion 46 (63 ref.)
Clinical experience in Europe with uroselective alpha1-antagonists. Debruyne FM, et al. **Eur Urol** 1999;36 Suppl 1:54–8; discussion 65 (36 ref.)
Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH. de Mey C. **Eur Urol** 1998;34 Suppl 2:18–28; discusion 47 (87 ref.)
Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being [published erratum appears in Eur Urol 1998 Dec;34(6):527] de Mey C. **Eur Urol** 1998;34 Suppl 2:18–28; discussion 47 (87 ref.)
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer. Habib FK, et al. **Eur Urol** 1999; 35(5–6):439–42 (9 ref.)
Clinical pharmacology of alpha1-adrenoceptor antagonists. Kirby RS. **Eur Urol** 1999;36 Suppl 1:48–53; discussion 65 (37 ref.)
Adrenoceptor pharmacology: urogenital applications. Ruffolo RR Jr, et al. **Eur Urol** 1999;36 Suppl 1:17–22 (57 ref.)
Medical management of benign prostatic hyperplasia. Chacon A, et al. **Geriatr Nephrol Urol** 1999;9(1):39–48 (75 ref.)
Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Kirby RS. **Int J Clin Pract** 1998 Sep;52(6):402–7 (44 ref.)
Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Lowe FC, et al. **Prostate** 1998 Nov 1;37(3):187–93 (32 ref.)
Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Bostwick DG, et al. **Urol Clin North Am** 1999 Aug; 26(3):465–79 (129 ref.)
Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Rhodes PR, et al. **Urology** 1999 Jun;53(6):1090–8 (30 ref.)
Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Tewari A, et al. **Urology** 1999 Mar;53(3 Suppl 3a):14–20; discussion 41–2 (88 ref.)
Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin. Boehm S, et al. **Wien Klin Wochenschr** 1998 Dec 11; 110(23):817–23 (51 ref.)
[Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach] Jolliet P, et al. **Therapie** 1998 Jan–Feb;53(1):61–6 (28 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer. Habib FK, et al. **Eur Urol** 1999; 35(5–6):439–42 (9 ref.)

EPIDEMIOLOGY

Population-based studies of the epidemiology of benign prostatic hyperplasia. Girman CJ. **Br J Urol** 1998 Dec;82 Suppl 1:34–43 (111 ref.)

ETIOLOGY

Diet, micronutrients, and the prostate gland. Thomas JA. **Nutr Rev** 1999 Apr;57(4):95–103 (101 ref.)

METABOLISM

Transforming growth factor-beta in benign and malignant prostate. Lee C, et al. **Prostate** 1999 Jun 1;39(4):285–90 (50 ref.)

PATHOLOGY

Stem cell features of benign and malignant prostate epithelial cells. De Marzo AM, et al. **J Urol** 1998 Dec;160(6 Pt 2):2381–92 (148 ref.)

New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. De Marzo AM, et al. **Urology** 1999 Mar;53(3 Suppl 3a):29–39; discussion 39–42 (122 ref.)

PHYSIOPATHOLOGY

Towards a noninvasive urodynamic diagnosis of infravesical obstruction. Van Mastrigt R, et al. **BJU Int** 1999 Jul; 84(2):195–203 (34 ref.)

alpha1- and alpha2-adrenoceptors in BPH. Takeda M, et al. **Eur Urol** 1999;36 Suppl 1:31–4; discussion 65 (23 ref.)

The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Steers WD, et al. **Exp Physiol** 1999 Jan;84(1):137–47 (55 ref.)

[Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach] Jolliet P, et al. **Therapie** 1998 Jan-Feb;53(1):61–6 (28 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Steers WD, et al. **Exp Physiol** 1999 Jan;84(1):137–47 (55 ref.)

RADIOTHERAPY

Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Bostwick DG, et al. **Urol Clin North Am** 1999 Aug; 26(3):465–79 (129 ref.)

SURGERY

Is transurethral resection of the prostate still justified? Madersbacher S, et al. **BJU Int** 1999 Feb;83(3):227–37 (79 ref.)

Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Chapple CR, et al. **Eur Urol** 1999 Feb;35(2):119–28 (29 ref.)

Side-firing Neodymium:YAG laser prostatectomy. Costello AJ, et al. **Eur Urol** 1999 Feb;35(2):138–46 (68 ref.)

Holmium laser resection of the prostate. Le Duc A, et al. **Eur Urol** 1999 Feb;35(2):155–60 (32 ref.)

Interstitial laser therapy of benign prostatic hyperplasia. Muschter R, et al. **Eur Urol** 1999 Feb;35(2):147–54 (62 ref.)

Thick loop transurethral resection of the prostate. Perlmutter AP, et al. **Eur Urol** 1999 Feb;35(2):161–5 (8 ref.)

Electrosurgery: VaporTrode. Weiner DM, et al. **Eur Urol** 1999 Feb;35(2):166–72 (27 ref.)

Massive prostatic bleeding after transurethral resection of the prostate in a patient with a congenital pelvic arteriovenous malformation. Touyama H, et al. **J Urol** 1998 Nov;160(5):1803 (3 ref.)

[Giant prostatic hypertrophy: a case report] Yonou H, et al. **Hinyokika Kiyo** 1999 May;45(5):375–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

High intensity focused ultrasound in benign prostatic hyperplasia. Hegarty NJ, et al. **Eur J Ultrasound** 1999 Mar; 9(1):55–60 (27 ref.)

Transurethral microwave thermotherapy. Lynch JH, et al. **Eur Urol** 1999 Feb;35(2):129–37 (36 ref.)

BPH and sexuality. Zlotta AR, et al. **Eur Urol** 1999;36 Suppl 1:107–12 (37 ref.)

Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia. Djavan B, et al. **Tech Urol** 1999 Mar; 5(1):12–20 (93 ref.)

The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. Holtgrewe HL. **Urol Clin North Am** 1998 Nov;25(4):555–69, vii (90 ref.)

Office treatment of benign prostatic hyperplasia. Ramsey EW. **Urol Clin North Am** 1998 Nov;25(4):571–80 (46 ref.)

Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? Djavan B, et al. **Urology** 1998 Dec;52(6):935–47 (100 ref.)

Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Lowe FC, et al. **Urology** 1999 Apr; 53(4):671–8 (55 ref.)

[New therapeutic trends in benign hypertrophy of the prostate (editorial)] Chatelain C. **Chirurgie** 1999 Jun; 124(3):223–31 (34 ref.) **(Fre)**

[Benign prostatic hyperplasia: variability in practice and guide to action based on scientific evidence] Baile A, et al. **Aten Primaria** 1999 Feb 28;23(3):142–50 (27 ref.) **(Spa)**

[Research and development called for thermotherapy of prostatic hyperplasia] Hallin A. **Lakartidningen** 1999 Aug 25;96(34):3520–2 (30 ref.) (Eng. Abstr.) **(Swe)**

PROSTATIC HYPERTROPHY see **PROSTATIC HYPERPLASIA**

PROSTATIC HYPERTROPHY, BENIGN see **PROSTATIC HYPERPLASIA**

PROSTATIC INTRAEPITHELIAL NEOPLASIA

GENETICS

Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. Qian J, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):373–80 (59 ref.)

PATHOLOGY

Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Relationship to pathologic parameters, volume and spatial distribution of carcinoma of the prostate. Sakr WA, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):417–23 (43 ref.)

PROSTATIC NEOPLASMS

see related
PROSTATE-SPECIFIC ANTIGEN

Prostate cancer--the snowball is rolling. Ruutu M, et al. **Ann Chir Gynaecol** 1999;88(1):5–8 (31 ref.)

Recent advances in early prostatic cancer. Gorgoulis VG, et al. **Anticancer Res** 1999 May-Jun;19(3B):2327–48 (334 ref.)

Diagnosis and management of early prostate cancer. Report of a British association of urological surgeons working party. Dearnaley dP, et al. **BJU Int** 1999 Jan;83(1):18–33 (62 ref.)

Malignant changes in the prostate with ageing. Dunsmuir WD, et al. **Br J Urol** 1998 Dec;82 Suppl 1:47–58 (129 ref.)

Prostate cancer: 2. Natural history. Nam RK, et al. **CMAJ** 1998 Sep 22;159(6):685–91 (47 ref.)

Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. López-Otín C, et al. **Endocr Rev** 1998 Aug;19(4):365–96 (410 ref.)

Prostate cancer in the elderly. Kirk D. **Eur J Surg Oncol** 1998 Oct;24(5):379–83 (40 ref.)

Prostate cancer. Hahnfeld LE, et al. **Med Clin North Am** 1999 Sep;83(5):1231–45, vi (84 ref.)

Tumor progression, micrometastasis, and genetic instability tracked with histochemical marker genes. Culp LA, et al. **Prog Histochem Cytochem** 1998;33(3-4):XI–XV, 329–48 (35 ref.)

Prostate cancer and black men. Brawley OW. **Semin Urol Oncol** 1998 Nov;16(4):184–6 (25 ref.)

Examining health-related quality of life in men treated for prostate cancer. Litwin MS. **World J Urol** 1999 Aug; 17(4):205–10 (58 ref.)

[Adenocarcinoma of the prostate] Dvořáček J. **Cas Lek Cesk** 1998 Aug 31;137(17):515–21 (70 ref.) (Eng. Abstr.) **(Cze)**

[Prostate cancer] Uchida K, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(1):76–82 (40 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Insulin-like growth factors and prostate cancer. Pollak M, et al. **Cancer Metastasis Rev** 1998-99;17(4):383–90 (44 ref.)

Prostate specific antigen: an opinion on its value to the radiologist. Clements R. **Eur Radiol** 1999;9(3):529–35 (41 ref.)

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. Epstein JI, et al. **J Urol** 1998 Dec;160(6 Pt 2):2407–11 (26 ref.)

Prostate specific antigen: a decade of discovery--what we have learned and where we are going. Polascik TJ, et al. **J Urol** 1999 Aug;162(2):293–306 (141 ref.)

Prostate-specific antigen. Stenman UH, et al. **Semin Cancer Biol** 1999 Apr;9(2):83–93 (103 ref.)

The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy. de la Taille A, et al. **Semin Urol Oncol** 1998 Aug;16(3):137–44 (74 ref.)

The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Pannek J, et al. **Semin Urol Oncol** 1998 Aug;16(3):100–5 (40 ref.)

The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Ravery V. **Semin Urol Oncol** 1999 Aug;17(3):127–9 (15 ref.)

[Limitations on the interpretation of prostate-specific antigen serum levels] Sciarra A, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):105–12 (27 ref.) (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Microvessel density in prostate cancer: prognostic and therapeutic utility. Bostwick DG, et al. **Semin Urol Oncol** 1998 Aug;16(3):118–23 (32 ref.)

Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Rubin MA, et al. **Urology** 1999 Mar;53(3):542–7 (26 ref.)

CLASSIFICATION

The pathologist as optimist: cancer grade deflation in prostatic needle biopsies [editorial] Iczkowski KA, et al. **Am J Surg Pathol** 1998 Oct;22(10):1169–70 (6 ref.)

[Histological classification of prostatic cancer] Sakamoto A, et al. **Nippon Rinsho** 1998 Aug;56(8):1959–62 (14 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Prostatic cancer with cystic formation: a case report] Kubo M, et al. **Hinyokika Kiyo** 1998 Dec;44(12):883–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[The therapeutic modalities of bone pain in prostate cancer] Cózar JM, et al. **Actas Urol Esp** 1999 May;23(5):464–70 (24 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Screening for prostate cancer--more questions than answers [see comments] Rietbergen JB, et al. **Acta Oncol** 1998; 37(6):515–32 (179 ref.) Comment in: Acta Oncol 1998 ;37(6):513–4.

The pathologist as optimist: cancer grade deflation in prostatic needle biopsies [editorial] Iczkowski KA, et al. **Am J Surg Pathol** 1998 Oct;22(10):1169–70 (6 ref.)

Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. Bostwick DG. **Anal Quant Cytol Histol** 1998 Oct;20(5):323–42 (216 ref.)

Minimal criteria for the diagnosis of prostate cancer on needle biopsy. Bostwick DG, et al. **Ann Diagn Pathol** 1997 Dec; 1(2):104–29 (213 ref.)

PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases [see comments] Barry MJ. **Ann Oncol** 1998 Dec;9(12):1279–82 (20 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263–4.

PSA screening for prostate cancer: the current controversy [see comments] de Koning HJ, et al. **Ann Oncol** 1998 Dec; 9(12):1293–6 (19 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263–4.

Screening for prostate cancer [see comments] Neal DE, et al. **Ann Oncol** 1998 Dec;9(12):1289–92 (30 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263–4.

PSA screening--current controversy [see comments] Svetec D, et al. **Ann Oncol** 1998 Dec;9(12):1283–8 (42 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263–4.

Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. Woolf SH, et al. **Annu Rev Med** 1999;50:207–21 (61 ref.)

Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2799–801 (40 ref.)

Prostate cancer and PSA screening. Mameghan H. **Aust Fam Physician** 1999 Aug;28(8):777–81 (11 ref.)

Screening for prostate cancer: the current position. Moss SM, et al. **Br Med Bull** 1998;54(4):791–805 (54 ref.)

Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Murphy GP, et al. **Cancer** 1998 Dec 1;83(11):2259–69 (78 ref.)

Prognostic markers in localized prostate cancer: from microscopes to molecules. Harding MA, et al. **Cancer Metastasis Rev** 1998-99;17(4):429–37 (64 ref.)

Prostate-specific antigen and new related markers for prostate cancer. Daher R, et al. **Clin Chem Lab Med** 1998 Sep;36(9):671–81 (139 ref.)

Prostate cancer screening: waiting for Godot [editorial; comment] Iscoe NA. **CMAJ** 1998 Dec 1;159(11):1375–7 (18 ref.) Comment on: CMAJ 1998 Dec 1;159(11):1368–72.

Prostate cancer: 5. Diagnostic tools for early detection [see comments] Karakiewicz PI, et al. **CMAJ** 1998 Nov 3; 159(9):1139–46 (43 ref.) Comment in: CMAJ 1999 Jul 13;161(1):20.

Prostate cancer: 4. Screening. Meyer F, et al. **CMAJ** 1998 Oct 20;159(8):968–72 (22 ref.)

Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. **Eur J Cancer** 1999 Feb;35(2):262–71 (12 ref.)

The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials. Crawford ED. **Eur Urol** 1999;35(5–6):511–4 (14 ref.)

Chemoprevention of prostate cancer: concepts and strategies. Kelloff GJ, et al. **Eur Urol** 1999;35(5–6):342–50 (37 ref.)

Molecular diagnostics and therapy of prostate cancer: new avenues. Schalken J. **Eur Urol** 1998;34 Suppl 3:3–6 (13 ref.)

Clinical evolution of prostatic intraepithelial neoplasia. Zlotta AR, et al. **Eur Urol** 1999;35(5–6):498–503 (33 ref.)

The use of percent free PSA for early detection of prostate cancer. Potter SR, et al. **J Androl** 1999 Jul-Aug; 20(4):449–53 (31 ref.)

Malignant peripheral nerve sheath tumor of the prostate: a rare manifestion of neurofibromatosis type 1. Rames RA, et al. **J Urol** 1999 Jul;162(1):165–6 (3 ref.)

The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. Rietbergen JB, et al. **J Urol** 1999 Apr;161(4):1192–8 (23 ref.)

Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications. Gerard MJ, et al.

Oncol Nurs Forum 1998 Oct;25(9):1561–9 (63 ref.)
Broadsheet number 45: thin core biopsy of prostate. The Royal College of Pathologists of Australia. Delahunt B, et al. **Pathology** 1998 Aug;30(3):247–56 (80 ref.)
Citrate in the diagnosis of prostate cancer. Costello LC, et al. **Prostate** 1999 Feb 15;38(3):237–45 (34 ref.)
Emphasizing and promoting overall health and nontraditional treatments after a prostate cancer diagnosis. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):119–24 (95 ref.)
Prognostic indicators in hormone refractory prostate cancer. George DJ, et al. **Urol Clin North Am** 1999 May; 26(2):303–10, viii (53 ref.)
Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Kim J, et al. **Urol Clin North Am** 1999 May;26(2):281–90 (92 ref.)
Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Ornstein DK, et al. **Urol Clin North Am** 1998 Nov;25(4):591–601 (94 ref.)
Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy. Partin AW, et al. **Urol Clin North Am** 1998 Nov;25(4):581–9, viii (68 ref.)
Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Bassler TJ Jr, et al. **Urology** 1998 Dec;52(6):1064–9 (54 ref.)
Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Bogers HA, et al. **Urology** 1999 Jul;54(1):97–104 (34 ref.)
Differential diagnosis of glandular proliferations in the prostate. A conventional and immunohistochemical approach. Helpap B. **Virchows Arch** 1998 Nov; 433(5):397–405 (58 ref.)
[Markers of prostatic carcinoma] Safařik L. **Cas Lek Cesk** 1998 Aug 31;137(17):525–7 (22 ref.) (Eng. Abstr.) **(Cze)**
[Place of surveillance in the treatment of localized prostate cancer] Ravery V, et al. **Prog Urol** 1999 Apr;9(2):225–30; discussion 229–30 (29 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of advanced prostate cancer] Leisinger HJ, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):507–11 (9 ref.) **(Fre)**
[A case of synchronous triple primary cancers of prostate, kidney and bladder] Harima M, et al. **Hinyokika Kiyo** 1998 Sep;44(9):675–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Leiomyosarcoma of the prostate: report of two cases] Iida K, et al. **Hinyokika Kiyo** 1998 Oct;44(10):739–42 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer] Akino H, et al. **Nippon Rinsho** 1998 Aug;56(8):2003–5 (14 ref.) (Eng. Abstr.) **(Jpn)**
[The significance and limitation of prostate specific antigen in the mass screening for prostate cancer] Imai K, et al. **Nippon Rinsho** 1998 Aug;56(8):1994–7 (7 ref.) (Eng. Abstr.) **(Jpn)**
[The clinical value of prostate-specific antigen velocity as a method for prostate cancer detection] Ito K, et al. **Nippon Rinsho** 1998 Aug;56(8):2021–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[The efficacy of PSA density for the early detection of prostate cancer] Kanehara H, et al. **Nippon Rinsho** 1998 Aug;56(8):2012–5 (11 ref.) (Eng. Abstr.) **(Jpn)**
[PSATZ (prostate specific antigen adjusted for the transition zone volume)] Maeda H, et al. **Nippon Rinsho** 1998 Aug; 56(8):2016–20 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Percent free prostate-specific antigen: a marker for detection of prostate cancer] Miyanaga N, et al. **Nippon Rinsho** 1998 Aug;56(8):2006–11 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status] Nakata S, et al. **Nippon Rinsho** 1998 Aug;56(8):2026–30 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical role of magnetic resonance imaging (MRI) of prostatic cancer] Nasu Y, et al. **Nippon Rinsho** 1998 Aug; 56(8):2042–5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer] Saito Y. **Nippon Rinsho** 1998 Aug;56(8):1989–93 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Prostatic mass screening program and its technology] Watanabe H, et al. **Nippon Rinsho** 1998 Aug;56(8):1974–7 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Current aspects of the diagnosis and treatment of prostatic cancer] Petrov SB, et al. **Vestn Khir Im I I Grek** 1998; 157(5):44–8 (15 ref.) (Eng. Abstr.) **(Rus)**
[Prostatic rhabdomyosarcoma in adults] Muñoz Vélez D, et al. **Arch Esp Urol** 1998 Nov;51(9):883–8 (21 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Bostwick DG. **Anat Pathol** 1998;3:1–16 (84 ref.)
The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium. Mikkola A, et al. **Ann Chir Gynaecol** 1999;88(1):18–21 (37 ref.)
MMP inhibition in prostate cancer. Lokeshwar BL. **Ann N Y Acad Sci** 1999 Jun 30;878:271–89 (71 ref.)
Neoadjuvant hormonal therapy in carcinoma of the prostate. Lee HH, et al. **BJU Int** 1999 Mar;83(4):438–48 (81 ref.)
Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review. Westin P, et al. **Cancer Detect Prev** 1998;22(5):476–84 (114 ref.)
Vitamin D and prostate cancer: biologic interactions and clinical potentials. Miller GJ. **Cancer Metastasis Rev** 1998–99;17(4):353–60 (56 ref.)
Hormone resistance in prostate cancer. Pilat MJ, et al. **Cancer Metastasis Rev** 1998–99;17(4):373–81 (71 ref.)
Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Sokoloff MH, et al. **Cancer Metastasis Rev** 1998–99; 17(4):307–15 (64 ref.)
Systemic treatment for prostate cancer. Dowling AJ, et al. **Cancer Treat Rev** 1998 Aug;24(4):283–301 (183 ref.)
Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Njar VC, et al. **Curr Pharm Des** 1999 Mar;5(3):163–80 (165 ref.)
The treatment of advanced prostate cancer with ketoconazole: safety issues. Bok RA, et al. **Drug Saf** 1999 May;20(5):451–8 (38 ref.)
Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Bosland MC. **Eur Urol** 1999; 35(5–6):459–63 (17 ref.)
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer. Habib FK, et al. **Eur Urol** 1999; 35(5–6):439–42 (9 ref.)
Antiandrogens as monotherapy for prostate cancer. Schröder FH. **Eur Urol** 1998;34 Suppl 3:12–7 (21 ref.)
Arguments against the long-term use of combined androgen blockade. Studer UE, et al. **Eur Urol** 1998;34 Suppl 3:29–32 (24 ref.)
Arguments for the long-term use of combined androgen blockade. Wajsman Z. **Eur Urol** 1998;34 Suppl 3:25–8 (13 ref.)
Androgen deprivation for prostatic carcinoma: a rationale for choosing components. Fourcade RO, et al. **Int J Urol** 1998 Jul;5(4):303–11 (78 ref.)
Current status of androgen suppression and radiotherapy for patients with prostate cancer. Roach M 3rd. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):239–45 (47 ref.)
Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Quella SK, et al. **J Urol** 1999 Jul;162(1):98–102 (15 ref.)
A new look at an old option in the treatment of early-stage prostate cancer: hormone therapy as an alternative to watchful waiting. Yang FE, et al. **Med Hypotheses** 1998 Sep;51(3):243–51 (66 ref.)
Bicalutamide dosages used in the treatment of prostate cancer. Kolvenbag GJ, et al. **Prostate** 1999 Apr 1; 39(1):47–53 (29 ref.)
Chemotherapy in advanced prostate cancer. Beedassy A, et al. **Semin Oncol** 1999 Aug;26(4):428–38 (50 ref.)
Overcoming bcl-2- and p53-mediated resistance in prostate cancer. DiPaola RS, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):112–6 (30 ref.)
Paclitaxel in the treatment of hormone-refractory prostate cancer. Smith DC, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):109–11 (13 ref.)
Hormonal manipulation for rising PSA after radical prostatectomy. Bhayani SB, et al. **Semin Urol Oncol** 1999 Aug;17(3):148–53 (45 ref.)
Vitamin D in the prevention and treatment of prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1999 May;17(2):77–84 (51 ref.)
Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Bostwick DG, et al. **Urol Clin North Am** 1999 Aug; 26(3):465–79 (129 ref.)
Differentiating agents and nontoxic therapies. Myers CE. **Urol Clin North Am** 1999 May;26(2):341–51, ix (50 ref.)
Chemotherapy for hormone refractory prostate cancer. Smith DC. **Urol Clin North Am** 1999 May;26(2):323–31 (64 ref.)
[Conformal radiotherapy] Hubert J, et al. **Prog Urol** 1999 Jun;9(3):544–51 (35 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy in hormone refractory prostatic carcinoma] Biedermann B, et al. **Dtsch Med Wochenschr** 1999 Jul 16; 124(28–29):874–9 (55 ref.) **(Ger)**
[Lymph node positive prostate carcinoma. A case for primary hormone therapy] Altwein JE. **Urologe A** 1999 Jul; 38(4):337–43 (41 ref.) (Eng. Abstr.) **(Ger)**
[Progress in oral anti-cancer drug therapy for urological cancer] Tsukamoto S, et al. **Gan To Kagaku Ryoho** 1999 Feb;26(3):308–14 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Antiandrogen withdrawal syndrome] Akimoto S. **Nippon Rinsho** 1998 Aug;56(8):2135–9 (22 ref.) (Eng. Abstr.) **(Jpn)**
[High-dose intravenous diethylstilbestrol diphosphate therapy for hormone refractory prostate cancer] Honda M, et al. **Nippon Rinsho** 1998 Aug;56(8):2145–9 (18 ref.) **(Jpn)**
[Reevaluation and potential therapeutic effects of estrogen therapy to prostate cancer patients] Kato M, et al. **Nippon Rinsho** 1998 Aug;56(8):2140–4 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer] Kawai K, et al. **Nippon Rinsho** 1998 Aug;56(8):2108–13 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy for hormone-refractory prostate cancer] Tsushima T. **Nippon Rinsho** 1998 Aug;56(8):2167–72 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Monotherapy with antiandrogens for prostatic cancer] Sander S. **Tidsskr Nor Laegeforen** 1999 Apr 20; 119(10):1451–3 (20 ref.) (Eng. Abstr.) **(Nor)**
[Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate] Matveev BP, et al. **Vopr Onkol** 1998;44(5):537–40 (10 ref.) (Eng. Abstr.) **(Rus)**
[Early versus late hormonal treatment in advanced prostate cancer (editorial)] Allepuz Losa C, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):557–64 (35 ref.) **(Spa)**

ENZYMOLOGY

MMP inhibition in prostate cancer. Lokeshwar BL. **Ann N Y Acad Sci** 1999 Jun 30;878:271–89 (71 ref.)
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer. Habib FK, et al. **Eur Urol** 1999; 35(5–6):439–42 (9 ref.)

EPIDEMIOLOGY

Advances in prostate cancer. Small EJ. **Curr Opin Oncol** 1999 May;11(3):226–35 (73 ref.)
Molecular genetics and epidemiology of prostate carcinoma. Ruijter E, et al. **Endocr Rev** 1999 Feb;20(1):22–45 (312 ref.)
Epidemiology of prostate cancer chemoprevention. Boyle P, et al. **Eur Urol** 1999;35(5–6):370–6 (34 ref.)
Diet and its preventive role in prostatic disease. Denis L, et al. **Eur Urol** 1999;35(5–6):377–87 (87 ref.)
Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Ekman P. **Eur Urol** 1999; 35(5–6):362–9 (84 ref.)
Vitamin D and prostate cancer risk. Peehl DM. **Eur Urol** 1999;35(5–6):392–4 (22 ref.)
Dietary carotenoids and certain cancers, heart disease, and age-related macular degeneration: a review of recent research. Cooper DA, et al. **Nutr Rev** 1999 Jul;57(7):201–14 (120 ref.)
The rising incidence of breast cancer in women and prostate cancer in men. Dietary influences: a possible preventive role for nature's sex hormone modifiers – the phytoestrogens (review). Stephens FO. **Oncol Rep** 1999 Jul–Aug;6(4):865–70 (93 ref.)
What causes prostate cancer? A brief summary of the epidemiology. Chan JM, et al. **Semin Cancer Biol** 1998 Aug; 8(4):263–73 (180 ref.)
The epidemiology of prostate cancer part I: descriptive epidemiology. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov;16(4):187–92 (46 ref.)
Prostate cancer research and the National Cancer Institute. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):235–40 (26 ref.)
An estimate of prostate cancer prevalence for a demographically similar workforce population. Westra CS, et al. **W V Med J** 1999 May–Jun;95(3):116–22 (14 ref.)
[Epidemiology and clinical features of prostate cancer in Japan] Kakehi Y. **Nippon Rinsho** 1998 Aug;56(8):1969–73 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Urologic neoplasms in patients with renal transplantation. Experience and review of the literature] Hermida Gutiérrez JF, et al. **Actas Urol Esp** 1998 Nov–Dec;22(10):818–27 (75 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Is race an independent prognostic factor for survival from prostate cancer? Roach M 3rd. **J Natl Med Assoc** 1998 Nov;90(11 Suppl):S713–9 (58 ref.)
Race and serum prostate-specific antigen levels: current status and future directions. Abdalla I, et al. **Semin Urol Oncol** 1998 Nov;16(4):207–13 (55 ref.)
Prostate cancer treatment outcome in blacks and whites: a summary of the literature. Alexander GA, et al. **Semin Urol Oncol** 1998 Nov;16(4):232–4 (16 ref.)
Prostate cancer in the African American: is this a different disease? Powell IJ. **Semin Urol Oncol** 1998 Nov;16(4):221–6 (40 ref.)
Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Sakr WA, et al. **Semin Urol Oncol** 1998 Nov;16(4):214–20 (49 ref.)

ETIOLOGY

Diet, androgens, oxidative stress and prostate cancer susceptibility. Fleshner NE, et al. **Cancer Metastasis Rev** 1998–99;17(4):325–30 (75 ref.)
Prostate cancer: 3. Individual risk factors [see comments] Gallagher RP, et al. **CMAJ** 1998 Oct 6;159(7):807–13 (79 ref.) Comment in: CMAJ 1999 Apr 6;160(7):983; discussion 983–4.
Dietary fat and prostate cancer progression and survival. Fradet Y, et al. **Eur Urol** 1999;35(5–6):388–91 (10 ref.)
Dietary fat and prostate cancer: current status. Kolonel LN, et al. **J Natl Cancer Inst** 1999 Mar 3;91(5):414–28 (190 ref.)
New aspects on prostate cancer: hereditary form, developmental estrogenization and differentiation therapy. Sciarra A, et al. **Minerva Urol Nefrol** 1998 Sep;50(3):185–90 (35 ref.)

Dietary fat and carcinogenesis. Woutersen RA, et al. **Mutat Res** 1999 Jul 15;443(1-2):111-27 (183 ref.)
Diet, micronutrients, and the prostate gland. Thomas JA. **Nutr Rev** 1999 Apr;57(4):95-103 (101 ref.)
Growing evidence that several human cancers may originate in utero. Ekbom A. **Semin Cancer Biol** 1998 Aug; 8(4):237-44 (76 ref.)
The epidemiology of prostate cancer part II: the risk factors. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):193-201 (123 ref.)

GENETICS

Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. Qian J, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):373-80 (59 ref.)
Molecular biology of prostate development and prostate cancer. Sciavolino PJ, et al. **Ann Med** 1998 Aug; 30(4):357-68 (136 ref.)
The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Kantoff P, et al. **Biochim Biophys Acta** 1998 Nov 26;1378(3):C1-5 (25 ref.)
Genetic epidemiology of prostate cancer. Narod S. **Biochim Biophys Acta** 1999 Jan 29;1423(1):F1-13 (62 ref.)
The cellular and molecular basis of prostate cancer. Foster CS, et al. **BJU Int** 1999 Jan;83(2):171-94 (203 ref.)
Chromosomal basis of adenocarcinoma of the prostate. Verma RS, et al. **Cancer Invest** 1999;17(6):441-7 (124 ref.)
Stem cell genes in androgen-independent prostate cancer. Bui M, et al. **Cancer Metastasis Rev** 1998-99;17(4):391-9 (60 ref.)
Epigenetic mechanisms for progression of prostate cancer. Rennie PS, et al. **Cancer Metastasis Rev** 1998-99; 17(4):401-9 (76 ref.)
Metastasis-related genes in prostate cancer: the role of caveolin-1. Thompson TC. **Cancer Metastasis Rev** 1998-99; 17(4):439-42 (18 ref.)
Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Ross RK, et al. **Cancer Res** 1998 Oct 15;58(20):4497-504 (62 ref.)
Precancer of the prostate. Busch PC, et al. **Cancer Surv** 1998; 32:149-79 (163 ref.)
Molecular genetics and epidemiology of prostate carcinoma. Ruijter E, et al. **Endocr Rev** 1999 Feb;20(1):22-45 (312 ref.)
Changes in gene expression and targets for therapy. Bussemakers MJ. **Eur Urol** 1999;35(5-6):408-12 (28 ref.)
Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Ekman P. **Eur Urol** 1999; 35(5-6):362-9 (84 ref.)
Molecular biology of progression of prostate cancer. Nupponen N, et al. **Eur Urol** 1999;35(5-6):351-4 (15 ref.)
Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Qian J, et al. **Eur Urol** 1999;35(5-6):479-83 (35 ref.)
Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Ross RK, et al. **Eur Urol** 1999;35(5-6):355-61 (38 ref.)
GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes. Reichardt JK. **Front Biosci** 1999 Jul 15;4:D596-600 (40 ref.)
The androgen receptor: genetic considerations in the development and treatment of prostate cancer. Cude KJ, et al. **J Mol Med** 1999 May;77(5):419-26 (81 ref.)
Molecular genetics of prostate cancer: clinical applications. Morton RA Jr, et al. **J Natl Med Assoc** 1998 Nov;90(11 Suppl):S728-31 (44 ref.)
The genetics of cancer--a 3D model. Cole KA, et al. **Nat Genet** 1999 Jan;21(1 Suppl):38-41 (47 ref.)
Mouse models of prostate cancer. Sharma P, et al. **Oncogene** 1999 Sep 20;18(38):5349-55 (78 ref.)
Chromosome 10 alterations in prostate adenocarcinoma (review). Ittmann MM. **Oncol Rep** 1998 Nov-Dec; 5(6):1329-35 (51 ref.)
Chromosomal clues to the development of prostate tumors. Brothman AR, et al. **Prostate** 1999 Mar 1;38(4):303-12 (86 ref.)
Use of a yeast assay to detect functional alterations in p53 in prostate cancer: review and future directions. deVere White RW, et al. **Prostate** 1999 Oct 1;41(2):134-42 (69 ref.)
Metastasis-related genes in prostate cancer. Bangma CH, et al. **Semin Oncol** 1999 Aug;26(4):422-7 (35 ref.)
Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Bruckheimer EM, et al. **Semin Oncol** 1999 Aug;26(4):382-98 (241 ref.)
Overcoming bcl-2- and p53-mediated resistance in prostate cancer. DiPaola RS, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):112-6 (30 ref.)
Hereditary prostate cancer in African-American families. Cooney KA. **Semin Urol Oncol** 1998 Nov;16(4):202-6 (23 ref.)
Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines. König JJ, et al. **Urol Res** 1999;27(1):3-8 (19 ref.)
Adenosquamous carcinoma of the prostate: case report with DNA analysis, immunohistochemistry, and literature review. Bassler TJ Jr, et al. **Urology** 1999 Apr;53(4):832-4 (14 ref.)

IMMUNOLOGY

Neuroendocrine and immune mediators in prostate cancer progression. Hoosein NM. **Front Biosci** 1998 Dec 15; 3:D1274-9 (50 ref.)
Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: a preliminary report. Loughlin KR, et al. **J Surg Oncol** 1999 Jan;70(1):49-53 (21 ref.)

METABOLISM

Trefoil peptides and surgical disease. Longman RJ, et al. **Br J Surg** 1999 Jun;86(6):740-8 (69 ref.)
Stem cell genes in androgen-independent prostate cancer. Bui M, et al. **Cancer Metastasis Rev** 1998-99;17(4):391-9 (60 ref.)
Mechanistic concepts in androgen-dependence of prostate cancer. Craft N, et al. **Cancer Metastasis Rev** 1998-99; 17(4):421-7 (53 ref.)
Diet, androgens, oxidative stress and prostate cancer susceptibility. Fleshner NE, et al. **Cancer Metastasis Rev** 1998-99;17(4):325-30 (75 ref.)
Peptide growth factors and prostate cancer: new models, new opportunities. Foster BA, et al. **Cancer Metastasis Rev** 1998-99;17(4):317-24 (55 ref.)
Prognostic markers in localized prostate cancer: from microscopes to molecules. Harding MA, et al. **Cancer Metastasis Rev** 1998-99;17(4):429-37 (64 ref.)
Role of p27 in prostate carcinogenesis. Macri E, et al. **Cancer Metastasis Rev** 1998-99;17(4):337-44 (70 ref.)
Vitamin D and prostate cancer: biologic interactions and clinical potentials. Miller GJ. **Cancer Metastasis Rev** 1998-99;17(4):353-60 (56 ref.)
Metastasis-related genes in prostate cancer: the role of caveolin-1. Thompson TC. **Cancer Metastasis Rev** 1998-99; 17(4):439-42 (18 ref.)
Growth factor network disruption in prostate cancer progression. Ware JL. **Cancer Metastasis Rev** 1998-99; 17(4):443-7 (39 ref.)
Dietary fat and prostate cancer: current status. Kolonel LN, et al. **J Natl Cancer Inst** 1999 Mar 3;91(5):414-28 (190 ref.)
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Koeneman KS, et al. **Prostate** 1999 Jun 1;39(4):246-61 (153 ref.)
Transforming growth factor-beta in benign and malignant prostate. Lee C, et al. **Prostate** 1999 Jun 1;39(4):285-90 (50 ref.)
Markers of androgen-independent progression of prostatic carcinoma. Daliani D, et al. **Semin Oncol** 1999 Aug; 26(4):399-406 (112 ref.)
The role of the androgen receptor in the development and progression of prostate cancer. Jenster G. **Semin Oncol** 1999 Aug;26(4):407-21 (173 ref.)
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Sweat SD, et al. **Urology** 1998 Oct;52(4):637-40 (24 ref.)
Molecular action of androgen in the normal and neoplastic prostate. Kokontis JM, et al. **Vitam Horm** 1999;55:219-307 (560 ref.)
["Prostatic" kallikreins, sex hormones and insulin-like growth factors: complex of male and female regulatory elements in health and carcinogenesis] Zezerov EG, et al. **Vestn Ross Akad Med Nauk** 1999;(3):49-56 (63 ref.) (Eng. Abstr.) **(Rus)**

MORTALITY

Dietary fat and prostate cancer progression and survival. Fradet Y, et al. **Eur Urol** 1999;35(5-6):388-91 (10 ref.)

PATHOLOGY

Atypical prostatic stromal lesions. Cohen MB. **Adv Anat Pathol** 1998 Nov;5(6):359-66 (13 ref.)
Analytical molecular pathology of epithelial-stromal interactions in the normal and neoplastic prostate. Bonkhoff H. **Anal Quant Cytol Histol** 1998 Oct;20(5):437-42 (36 ref.)
Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. Bostwick DG. **Anal Quant Cytol Histol** 1998 Oct;20(5):323-42 (216 ref.)
Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Magi-Galluzzi C, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):343-50 (73 ref.)
Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Relationship to pathologic parameters, volume and spatial distribution of carcinoma of the prostate. Sakr WA, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):417-23 (43 ref.)
Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Bostwick DG. **Anat Pathol** 1998;3:1-16 (84 ref.)
The cellular and molecular basis of prostate cancer. Foster CS, et al. **BJU Int** 1999 Jan;83(2):171-94 (203 ref.)
Prognostic factors in prostate and testis cancer. Van Brussel JP, et al. **BJU Int** 1999 May;83(8):910-6; quiz 916-7 (64 ref.)
Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review. Westin P, et al. **Cancer Detect Prev** 1998;22(5):476-84 (114 ref.)
The role of cell motility in prostate cancer. Banyard J, et al. **Cancer Metastasis Rev** 1998-99;17(4):449-58 (72 ref.)
Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Lange PH, et al. **Cancer Metastasis Rev** 1998-99;17(4):331-6 (46 ref.)
Model systems of prostate cancer: uses and limitations. Navone NM, et al. **Cancer Metastasis Rev** 1998-99; 17(4):361-71 (73 ref.)
What might a stromal response mean to prostate cancer progression? Rowley DR. **Cancer Metastasis Rev** 1998-99; 17(4):411-9 (79 ref.)
Prostate cancer: 9. Treatment of advanced disease. Gleave ME, et al. **CMAJ** 1999 Jan 26;160(2):225-32 (33 ref.)
Tissue architecture analysis in prostate cancer and its precursors: An innovative approach to computerized histometry. Bartels PH, et al. **Eur Urol** 1999;35(5-6):484-91 (8 ref.)
Considerations regarding prostate biopsies. Beerlage HP, et al. **Eur Urol** 1998 Oct;34(4):303-12 (94 ref.)
Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention. Bostwick DG, et al. **Eur Urol** 1999;35(5-6):492-5 (21 ref.)
Subtle morphological and molecular changes in normal-looking epithelium in prostates with prostatic intraepithelial neoplasia or cancer. Montironi R, et al. **Eur Urol** 1999;35(5-6):468-73 (33 ref.)
PIN I-III: when should we interfere? Newling D. **Eur Urol** 1999;35(5-6):504-7 (9 ref.)
High-grade prostatic intraepithelial neoplasia in dogs. Waters DJ. **Eur Urol** 1999;35(5-6):456-8 (21 ref.)
Metastatic prostate carcinoma to the foot with magnetic resonance imaging and pathologic correlation. Schwartz ED, et al. **Foot Ankle Int** 1998 Sep;19(9):594-7 (14 ref.)
Neuroendocrine and immune mediators in prostate cancer progression. Hoosein NM. **Front Biosci** 1998 Dec 15; 3:D1274-9 (50 ref.)
Stem cell features of benign and malignant prostate epithelial cells. De Marzo AM, et al. **J Urol** 1998 Dec;160(6 Pt 2):2381-92 (148 ref.)
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. Epstein JI, et al. **J Urol** 1998 Dec;160(6 Pt 2):2407-11 (26 ref.)
Prostatic paraganglioma: 5-year followup. Jimenez RE, et al. **J Urol** 1999 Jun;161(6):1909-10 (4 ref.)
Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. Kindrick AV, et al. **J Urol** 1998 Dec;160(6 Pt 1):2102-6 (15 ref.)
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. Obek C, et al. **J Urol** 1999 Feb;161(2):494-8; discussion 498-9 (20 ref.)
Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. Rodriguez LV, et al. **J Urol** 1998 Dec;160(6 Pt 1):2115-20 (39 ref.)
Metastatic adenocarcinoma of the prostate to the choroid with loss of visual acuity as a presenting symptom [see comments] Wiegel T, et al. **J Urol** 1998 Dec;160(6 Pt 1):2158-9 (4 ref.) Comment in: J Urol 1999 Sep;162(3 Pt 1):809.
The genetics of cancer--a 3D model. Cole KA, et al. **Nat Genet** 1999 Jan;21(1 Suppl):38-41 (47 ref.)
E-cadherin and associated molecules in the invasion and progression of prostate cancer. Davies G, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1567-76 (134 ref.)
Molecular staging of prostate cancer: dream or reality? de la Taille A, et al. **Oncology (Huntingt)** 1999 Feb; 13(2):187-94; discussion 194-8, 204-5 pas (61 ref.)
Prostatic signet-ring cell carcinoma: case report and literature review. Kuroda N, et al. **Pathol Int** 1999 May; 49(5):457-61 (25 ref.)
Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies. O'Connor KC. **Pharm Res** 1999 Apr;16(4):486-93 (60 ref.)
Neuroendocrine differentiation in prostatic carcinoma. Abrahamsson PA. **Prostate** 1999 May;39(2):135-48 (159 ref.)
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Koeneman KS, et al. **Prostate** 1999 Jun 1;39(4):246-61 (153 ref.)
Metastasis-related genes in prostate cancer. Bangma CH, et al. **Semin Oncol** 1999 Aug;26(4):422-7 (35 ref.)
The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. Epstein JI. **Semin Urol Oncol** 1998 Aug;16(3):124-8 (17 ref.)
How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Jhaveri FM, et al. **Semin Urol Oncol** 1999 Aug;17(3):130-4 (37 ref.)
The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Manyak MJ, et al. **Semin Urol Oncol** 1998 Aug;16(3):145-52 (37 ref.)
Prostate cancer in the African American: is this a different disease? Powell IJ. **Semin Urol Oncol** 1998 Nov;16(4):221-6 (40 ref.)
Observation/delayed treatment for rising PSA after radical prostatectomy: pros and cons. Ruffion A, et al. **Semin Urol Oncol** 1999 Aug;17(3):135-40 (64 ref.)
Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Sakr WA, et al. **Semin Urol Oncol** 1998 Nov;16(4):214-20 (49 ref.)
The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Veltri

RW, et al. **Semin Urol Oncol** 1998 Aug;16(3):106–17 (69 ref.)

Local and systemic radiation for palliation of metastatic disease. Friedland J. **Urol Clin North Am** 1999 May; 26(2):391–402, x (57 ref.)

Prostate biopsy interpretation. Current concepts, 1999. Iczkowski KA, et al. **Urol Clin North Am** 1999 Aug; 26(3):435–52 (139 ref.)

Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Sakr WA, et al. **Urol Clin North Am** 1999 Aug;26(3):453–63, v (62 ref.)

Multiple pulmonary metastasis of prostatic carcinoma with little or no bone or lymph node metastasis. Report of two cases and review of the literature. Kume H, et al. **Urol Int** 1999;62(1):44–7 (9 ref.)

Adenosquamous carcinoma of the prostate: case report with DNA analysis, immunohistochemistry, and literature review. Bassler TJ Jr, et al. **Urology** 1999 Apr;53(4):832–4 (14 ref.)

Clinically unsuspected and undetected (clinical stage t0) prostate cancer diagnosed on random needle biopsy. Corica FA, et al. **Urology** 1999 Mar;53(3):557–60 (29 ref.)

New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. De Marzo AM, et al. **Urology** 1999 Mar;53(3 Suppl 3a):29–39; discussion 39–42 (122 ref.)

Review of staging modalities in clinically localized prostate cancer. Perrotti M, et al. **Urology** 1999 Aug;54(2):208–14 (58 ref.)

Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Rubin MA, et al. **Urology** 1999 Mar;53(3):542–7 (26 ref.)

[Palliative treatment of bone metastases with bone-seeking radionuclides (see comments)] De Klerk JM, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2618–22 (21 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 23;143(4):224. **(Dut)**

[Clinical stage T3 prostate cancer: natural history, therapeutic choices and their results] Peneau M, et al. **Prog Urol** 1998 Dec;8(6):977–93 (148 ref.) (Eng. Abstr.) **(Fre)**

[Value of biopsies in staging of prostatic cancer before radical prostatectomy] Salomon L, et al. **Prog Urol** 1998 Dec; 8(6):969–76 (93 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of organ-confined prostate cancer by systematic biopsy under guidance of TRUS] Gohji K, et al. **Nippon Rinsho** 1998 Aug;56(8):2062–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume] Hachiya T, et al. **Nippon Rinsho** 1998 Aug;56(8):2157–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The advance of ultrasound guided prostate biopsy--comparison between 4 quadrant and 6 sextant biopsy] Ishitoya S, et al. **Nippon Rinsho** 1998 Aug; 56(8):2056–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical staging and management of prostate cancer] Maeda O, et al. **Nippon Rinsho** 1998 Aug;56(8):1984–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical staging of prostate cancer] Okada K, et al. **Nippon Rinsho** 1998 Aug;56(8):1963–8 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Histological classification of prostatic cancer] Sakamoto A, et al. **Nippon Rinsho** 1998 Aug;56(8):1959–62 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Left supraclavicular adenopathy with a neuroendocrine pattern of unknown cause: prostatic carcinoma metastasis] Fernández Borrell A, et al. **Actas Urol Esp** 1999 Jul–Aug; 23(7):603–8 (22 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Moul JW. **Eur Urol** 1999;35(5–6):399–407 (67 ref.)

The role of stromal cells in prostate cancer development and progression. Condon MS, et al. **In Vivo** 1999 Jan–Feb; 13(1):61–5 (37 ref.)

Growth hormone and prostate cancer: guilty by association? Grimberg A, et al. **J Endocrinol Invest** 1999;22(5 Suppl):64–73 (71 ref.)

E-cadherin and associated molecules in the invasion and progression of prostate cancer. Davies G, et al. **Oncol Rep** 1998 Nov–Dec;5(6):1567–76 (134 ref.)

The biology of hormone refractory prostate cancer. Why does it develop? Isaacs JT. **Urol Clin North Am** 1999 May; 26(2):263–73 (38 ref.)

[Development and progression of prostate cancer in relation with androgen dependency] Shimazaki J. **Nippon Rinsho** 1998 Aug;56(8):1953–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Legumes and soybeans: overview of their nutritional profiles and health effects. Messina MJ. **Am J Clin Nutr** 1999 Sep; 70(3 Suppl):439S–450S (188 ref.)

Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis [see comments] Giovannucci E. **Cancer Causes Control** 1998 Dec;9(6):567–82 (122 ref.) Comment in: Cancer Causes Control 1998 Dec;9(6):541–3.

Prostate cancer screening: promise and peril--a review. Godley PA. **Cancer Detect Prev** 1999;23(4):316–24 (97 ref.)

Prostate cancer: 4. Screening. Meyer F, et al. **CMAJ** 1998 Oct 20;159(8):968–72 (22 ref.)

Epidemiology of prostate cancer chemoprevention. Boyle P, et al. **Eur Urol** 1999;35(5–6):370–6 (34 ref.)

The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials. Crawford ED. **Eur Urol** 1999;35(5–6):511–4 (14 ref.)

Diet and its preventive role in prostatic disease. Denis L, et al. **Eur Urol** 1999;35(5–6):377–87 (87 ref.)

Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Griffiths K, et al. **Eur Urol** 1999;35(5–6):443–55 (78 ref.)

Chemoprevention of prostate cancer: concepts and strategies. Kelloff GJ, et al. **Eur Urol** 1999;35(5–6):342–50 (37 ref.)

Mechanism of androgen receptor activation and possible implications for chemoprevention trials. Klocker H, et al. **Eur Urol** 1999;35(5–6):413–9 (28 ref.)

Lipoxygenase inhibition in prostate cancer. Myers CE, et al. **Eur Urol** 1999;35(5–6):395–8 (3 ref.)

Vitamin D and prostate cancer risk. Peehl DM. **Eur Urol** 1999;35(5–6):392–4 (22 ref.)

New agents for chemoprevention of prostate cancer. Sporn MB. **Eur Urol** 1999;35(5–6):420–3 (9 ref.)

Statistical considerations of chemoprevention clinical trials in prostate cancer. Sylvester R, et al. **Eur Urol** 1999; 35(5–6):519–22 (5 ref.)

Practical aspects of clinical trials on chemoprevention of prostate cancer. van der Meijden AP. **Eur Urol** 1999; 35(5–6):515–8 (14 ref.)

Chemoprevention of urological cancer. Kamat AM, et al. **J Urol** 1999 Jun;161(6):1748–60 (152 ref.)

Vitamin D and prostate cancer. Blutt SE, et al. **Proc Soc Exp Biol Med** 1999 Jun;221(2):89–98 (143 ref.)

Race and serum prostate-specific antigen levels: current status and future directions. Abdalla I, et al. **Semin Urol Oncol** 1998 Nov;16(4):207–13 (55 ref.)

The epidemiology of prostate cancer part I: descriptive epidemiology. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov;16(4):187–92 (46 ref.)

Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Coker KH. **Semin Urol Oncol** 1999 May;17(2):111–8 (30 ref.)

Prostate cancer chemoprevention by green tea. Gupta S, et al. **Semin Urol Oncol** 1999 May;17(2):70–6 (82 ref.)

Vitamin D in the prevention and treatment of prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1999 May;17(2):77–84 (51 ref.)

The role of dietary manipulation in biochemical recurrence of prostate cancer after radical prostatectomy. Lee CT, et al. **Semin Urol Oncol** 1999 Aug;17(3):154–63 (79 ref.)

Vitamin E, alpha- and gamma-tocopherol, and prostate cancer. Moyad MA, et al. **Semin Urol Oncol** 1999 May; 17(2):85–90 (74 ref.)

Soy, disease prevention, and prostate cancer. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):97–102 (110 ref.)

Selenium and prostate cancer prevention. Nelson MA, et al. **Semin Urol Oncol** 1999 May;17(2):91–6 (34 ref.)

Nutrition and prostate cancer. Yip I, et al. **Urol Clin North Am** 1999 May;26(2):403–11, x (94 ref.)

An estimate of prostate cancer prevalence for a demographically similar workforce population. Westra CS, et al. **W V Med J** 1999 May–Jun;95(3):116–22 (14 ref.)

PSYCHOLOGY

Prostate cancer: 13. Whose prostate is it anyway? The view from the other side of the examining table. Gray RE, et al. **CMAJ** 1999 Mar 23;160(6):833–6 (16 ref.)

Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Coker KH. **Semin Urol Oncol** 1999 May;17(2):111–8 (30 ref.)

RADIOGRAPHY

Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. Kindrick AV, et al. **J Urol** 1998 Dec;160(6 Pt 1):2102–6 (15 ref.)

RADIONUCLIDE IMAGING

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA, et al. **Prostate** 1998 Dec 1;37(4):261–9 (29 ref.)

[Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer] Oyama N, et al. **Nippon Rinsho** 1998 Aug;56(8):2052–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Prostate cancer: 7. Radiation therapy for localized disease. Warde P, et al. **CMAJ** 1998 Dec 1;159(11):1381–8 (33 ref.)

High dose rate brachytherapy in the treatment of prostate cancer. Rodriguez RR, et al. **Hematol Oncol Clin North Am** 1999 Jun;13(3):503–23 (27 ref.)

Permanent radioactive seed implantation in the treatment of prostate cancer. Stock RG, et al. **Hematol Oncol Clin North Am** 1999 Jun;13(3):489–501 (54 ref.)

Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high dose rate prostate brachytherapy implants. Kini VR, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):571–8 (34 ref.)

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Nag S, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 1;44(4):789–99 (132 ref.)

Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Valicenti RK, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1; 42(3):501–6 (22 ref.)

A comprehensive review of prostate cancer brachytherapy: defining an optimal technique. Vicini FA, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):483–91 (97 ref.)

Current status of androgen suppression and radiotherapy for patients with prostate cancer. Roach M 3rd. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):239–45 (47 ref.)

Have complication rates decreased after treatment for localized prostate cancer? Thompson IM, et al. **J Urol** 1999 Jul;162(1):107–12 (12 ref.)

Does pelvic irradiation play a role in the management of prostate cancer? Stock RG, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1467–72; discussion 1472, 1475–6 (47 ref.)

Brachytherapy boost techniques for locally advanced prostate cancer. Vicini FA, et al. **Oncology (Huntingt)** 1999 Apr;13(4):491–9, 503; discussion 503–6, 509 (77 ref.)

Update on the treatment of prostate cancer with external beam irradiation. Horwitz EM, et al. **Prostate** 1998 Nov 1;37(3):195–206 (51 ref.)

The management of PSA failure after radical radiotherapy for localized prostate cancer. Parker CC, et al. **Radiother Oncol** 1998 Nov;49(2):103–10 (39 ref.)

Radiation therapy for a rising PSA level after radical prostatectomy. Tiguert R, et al. **Semin Urol Oncol** 1999 Aug;17(3):141–7 (35 ref.)

Minimal requirements in prostate cancer irradiation: a consensus document by the AIRO Lombardia Cooperative Group. Valdagni R, et al. **Tumori** 1999 Mar–Apr; 85(2):143–8 (56 ref.)

Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Bostwick DG, et al. **Urol Clin North Am** 1999 Aug; 26(3):465–79 (129 ref.)

Patient-reported complications after cryoablation therapy for prostate cancer. Badalament RA, et al. **Urology** 1999 Aug; 54(2):295–300 (18 ref.)

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Vicini FA, et al. **Urology** 1999 Jul;54(1):111–7 (39 ref.)

[Current studies of combined radiotherapy-hormone therapy in localized and locally advanced prostatic cancers] Bolla M, et al. **Cancer Radiother** 1998 Dec;2(6):783–6 (16 ref.) (Eng. Abstr.) **(Fre)**

[Interstitial radiotherapy and prostate cancer. Analysis of the literature. Subcommittee of Prostate Cancer of C.C.A.F.U.] Peneau M. **Prog Urol** 1999 Jun;9(3):440–51 (66 ref.) (Eng. Abstr.) **(Fre)**

[Lymph node positive prostate carcinoma. A case for radiotherapy] Steiner U, et al. **Urologe A** 1999 Jul; 38(4):349–52 (26 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Hormonal ablation therapy for metastatic prostatic carcinoma: a review. Leewansangtong S, et al. **J Med Assoc Thai** 1999 Feb;82(2):192–205 (116 ref.)

SURGERY

Prostate cancer: 6. Surgical treatment of localized disease. Goldenberg SL, et al. **CMAJ** 1998 Nov 17;159(10):1265–71 (25 ref.)

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Moul JW. **Eur Urol** 1999;35(5–6):399–407 (67 ref.)

Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Valicenti RK, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1; 42(3):501–6 (22 ref.)

Have complication rates decreased after treatment for localized prostate cancer? Thompson IM, et al. **J Urol** 1999 Jul;162(1):107–12 (12 ref.)

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA, et al. **Prostate** 1998 Dec 1;37(4):261–9 (29 ref.)

The management of PSA failure after radical radiotherapy for localized prostate cancer. Parker CC, et al. **Radiother Oncol** 1998 Nov;49(2):103–10 (39 ref.)

Hormonal manipulation for rising PSA after radical prostatectomy. Bhayani SB, et al. **Semin Urol Oncol** 1999 Aug;17(3):148–53 (45 ref.)

How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Jhaveri FM, et al. **Semin Urol Oncol** 1999 Aug;17(3):130–4 (37 ref.)

The role of dietary manipulation in biochemical recurrence of prostate cancer after radical prostatectomy. Lee CT, et al. **Semin Urol Oncol** 1999 Aug;17(3):154–63 (79 ref.)

The significance of recurrent PSA after radical

prostatectomy: benign versus malignant sources. Ravery V. **Semin Urol Oncol** 1999 Aug;17(3):127–9 (15 ref.)
Observation/delayed treatment for rising PSA after radical prostatectomy: pros and cons. Ruffion A, et al. **Semin Urol Oncol** 1999 Aug;17(3):135–40 (64 ref.)
Rising PSAs after primary therapy: active or passive intervention. Slovin SF, et al. **Semin Urol Oncol** 1999 Aug; 17(3):164–73 (54 ref.)
Radiation therapy for a rising PSA level after radical prostatectomy. Tiguert R, et al. **Semin Urol Oncol** 1999 Aug;17(3):141–7 (35 ref.)
Patient-reported complications after cryoablation therapy for prostate cancer. Badalament RA, et al. **Urology** 1999 Aug; 54(2):295–300 (18 ref.)
Treatment outcome after radical prostatectomy is not adversely affected by a pre-existing penile prosthesis. Tiguert R, et al. **Urology** 1998 Dec;52(6):1030–3 (16 ref.)
Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Vicini FA, et al. **Urology** 1999 Jul;54(1):111–7 (39 ref.)
[Treatment of localized carcinoma of the prostate] Jarolim J, et al. **Cas Lek Cesk** 1998 Aug 31;137(17):528–31 (28 ref.) (Eng. Abstr.) **(Cze)**

THERAPY

Prostate cancer and PSA screening. Mameghan H. **Aust Fam Physician** 1999 Aug;28(8):777–81 (11 ref.)
Endocrine treatment of prostate cancer – recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. Schröder FH. **BJU Int** 1999 Jan;83(2):161–70 (00 ref.)
Prospects of immunotherapy for the treatment of prostate carcinoma--a review. Hillman GG, et al. **Cancer Detect Prev** 1999;23(4):333–42 (51 ref.)
Treatment options in androgen-independent prostate cancer. Lara PN Jr, et al. **Cancer Invest** 1999;17(2):137–44 (72 ref.)
Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Gjertsen BT, et al. **Cancer Metastasis Rev** 1998–99;17(4):345–51 (62 ref.)
Racial variation in cancer care: a case study of prostate cancer. Horner RD. **Cancer Treat Res** 1998;97:99–114 (56 ref.)
Prostate cancer: 13. Whose prostate is it anyway? The view from the other side of the examining table. Gray RE, et al. **CMAJ** 1999 Mar 23;160(6):833–6 (16 ref.)
Prostate cancer: 11. Alternative approaches and the future of treatment. Trachtenberg J, et al. **CMAJ** 1999 Feb 23; 160(4):528–34 (25 ref.)
Advances in prostate cancer. Small EJ. **Curr Opin Oncol** 1999 May;11(3):226–35 (73 ref.)
Therapeutic options in locally defined or advanced prostate cancer. Altwein JE. **Eur Urol** 1999;35 Suppl 1:9–15; discussion 16 (42 ref.)
Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention. Bostwick DG, et al. **Eur Urol** 1999;35(5–6):492–5 (21 ref.)
Changes in gene expression and targets for therapy. Bussemakers MJ. **Eur Urol** 1999;35(5–6):408–12 (28 ref.)
Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Gleave M, et al. **Eur Urol** 1998;34 Suppl 3:37–41 (18 ref.)
Orchidectomy and oestrogen therapy revisited. Iversen P. **Eur Urol** 1998;34 Suppl 3:7–11 (31 ref.)
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Kelly WK. **Eur Urol** 1998;34 Suppl 3:18–23 (33 ref.)
PIN I–III: when should we interfere? Newling D. **Eur Urol** 1999;35(5–6):504–7 (9 ref.)
Molecular diagnostics and therapy of prostate cancer: new avenues. Schalken J. **Eur Urol** 1998;34 Suppl 3:3–6 (13 ref.)
Refined testing and targeted therapy lead new fight against prostate cancer [interview by Wayne Kuznar] Catalona WJ. **Geriatrics** 1999 Sep;54(9):49–54; quiz 57 (11 ref.)
A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review). Willis RA, et al. **Int J Mol Med** 1998 Feb;1(2):379–86 (59 ref.)
Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. Berlyn KA, et al. **J Biotechnol** 1999 Aug 20;73(2–3):155–79 (78 ref.)
Treatment of prostate cancer. Henry RY, et al. **J Clin Pharm Ther** 1999 Apr;24(2):93–102 (50 ref.)
Hormonal ablation therapy for metastatic prostatic carcinoma: a review. Leewansangtong S, et al. **J Med Assoc Thai** 1999 Feb;82(2):192–205 (116 ref.)
Statistical considerations when assessing outcomes following treatment for prostate cancer. Albertsen PC, et al. **J Urol** 1999 Aug;162(2):439–44 (20 ref.)
Prospects for gene therapy in human prostate cancer. Ficazzola MA, et al. **Mol Med Today** 1998 Nov; 4(11):494–504 (50 ref.)
Rising PSA after local therapy failure: immediate vs deferred treatment. Moul JW. **Oncology (Huntingt)** 1999 Jul; 13(7):985–90, 993; discussion 993–5, 999 (33 ref.)
Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies. O'Connor KC. **Pharm Res** 1999 Apr;16(4):486–93 (60 ref.)
Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours. Lümmen G, et al. **Pharmacol Res** 1998 Sep;38(3):151–64 (70 ref.)
Future prospects in prostate cancer. Hegarty NJ, et al. **Prostate** 1999 Sep 1;40(4):261–8 (82 ref.)
Defeating prostate cancer: crucial directions for research--excerpt from the report of the Prostate Cancer Progress Review Group. Tindall DJ, et al. **Prostate** 1999 Feb 1;38(2):166–71 (0 ref.)
Immunologic approaches to the treatment of prostate cancer. Harris DT, et al. **Semin Oncol** 1999 Aug;26(4):439–47 (47 ref.)
Gene therapy for prostate cancer. Hrouda D, et al. **Semin Oncol** 1999 Aug;26(4):455–71 (166 ref.)
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center. Slovin SF, et al. **Semin Oncol** 1999 Aug; 26(4):448–54 (31 ref.)
Prostate cancer treatment outcome in blacks and whites: a summary of the literature. Alexander GA, et al. **Semin Urol Oncol** 1998 Nov;16(4):232–4 (16 ref.)
Traditional Chinese medicine, acupuncture, and other alternative medicines for prostate cancer: an introduction and the need for more research. Moyad MA, et al. **Semin Urol Oncol** 1999 May;17(2):103–10 (72 ref.)
Emphasizing and promoting overall health and nontraditional treatments after a prostate cancer diagnosis. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):119–24 (95 ref.)
Nontraditional treatments for localized prostate cancer: ten rules to know before talking to my patients. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):64–9 (52 ref.)
Rising PSAs after primary therapy: active or passive intervention. Slovin SF, et al. **Semin Urol Oncol** 1999 Aug; 17(3):164–73 (54 ref.)
Prostate-specific antigen and other markers of therapeutic response. Carducci MA, et al. **Urol Clin North Am** 1999 May;26(2):291–302, viii (83 ref.)
Supportive care, pain management, and quality of life in advanced prostate cancer. Esper P, et al. **Urol Clin North Am** 1999 May;26(2):375–89 (74 ref.)
Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Kim J, et al. **Urol Clin North Am** 1999 May;26(2):281–90 (92 ref.)
Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Ornstein DK, et al. **Urol Clin North Am** 1998 Nov;25(4):591–601 (94 ref.)
Gene therapy for prostate cancer. New perspectives on an old problem. Palapattu GS, et al. **Urol Clin North Am** 1999 May;26(2):353–63, ix (75 ref.)
Secondary hormonal manipulations in hormone refractory prostate cancer. Reese DM, et al. **Urol Clin North Am** 1999 May;26(2):311–21, viii (72 ref.)
Treatment options for early prostate cancer. Kirby R. **Urology** 1998 Dec;52(6):948–62 (192 ref.)
[Hormone therapy in advanced and generalized carcinoma of the prostate] Vachalovský V, et al. **Cas Lek Cesk** 1998 Aug 31;137(17):532–6 (39 ref.) (Eng. Abstr.) **(Cze)**
[Localized or metastatic cancer of the prostate: review of new treatment modalities] Deniaud-Alexandre E, et al. **Bull Cancer** 1998 Sep;(1 Suppl):40–50 (99 ref.) (Eng. Abstr.) **(Fre)**
[Clinical stage T3 prostate cancer: natural history, therapeutic choices and their results] Peneau M, et al. **Prog Urol** 1998 Dec;8(6):977–93 (148 ref.) (Eng. Abstr.) **(Fre)**
[Place of surveillance in the treatment of localized prostate cancer] Ravery V, et al. **Prog Urol** 1999 Apr;9(2):225–30; discussion 229–30 (29 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of advanced prostate cancer] Leisinger HJ, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):507–11 (9 ref.) **(Fre)**
[Evolution of treatments for prostatic cancer] Aso Y. **Nippon Rinsho** 1998 Aug;56(8):1978–83 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Application and limitation of neoadjuvant hormonal therapy for prostate cancer] Demura T, et al. **Nippon Rinsho** 1998 Aug;56(8):2150–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Radiation therapy with neoadjuvant hormonal therapy for prostate cancer confined to pelvis] Furuya Y, et al. **Nippon Rinsho** 1998 Aug;56(8):2181–4 (11 ref.) (Eng. Abstr.) **(Jpn)**
[A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume] Hachiya T, et al. **Nippon Rinsho** 1998 Aug;56(8):2157–61 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical or medical castration with LH-RH analogue for prostatic cancer] Kameyama S, et al. **Nippon Rinsho** 1998 Aug;56(8):2114–8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Usefulness of initial chemoendocrine therapy for advanced prostate cancer] Kanetake H, et al. **Nippon Rinsho** 1998 Aug;56(8):2173–6 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical staging and management of prostate cancer] Maeda O, et al. **Nippon Rinsho** 1998 Aug;56(8):1984–8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Total androgen blockade--concept, theory, method and clinical application] Ozono S, et al. **Nippon Rinsho** 1998 Aug;56(8):2129–34 (27 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

EUS and EUS-guided fine-needle aspiration for the diagnosis of rectal linitis plastica secondary to prostate carcinoma. Bhutani MS. **Gastrointest Endosc** 1999 Jul; 50(1):117–9 (13 ref.)
Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high dose rate prostate brachytherapy implants. Kini VR, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):571–8 (34 ref.)
[Progress of clinical application for prostatic ultrasound] Nakagawa S, et al. **Nippon Rinsho** 1998 Aug;56(8):2031–5 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Efficacy of transrectal ultrasonography in staging prostate cancer] Soh S, et al. **Nippon Rinsho** 1998 Aug;56(8):2036–41 (18 ref.) (Eng. Abstr.) **(Jpn)**

PROSTATISM see **PROSTATIC HYPERPLASIA**

PROSTATITIS

Prostatitis and urinary tract infection in men: what's new; what's true? Lipsky BA. **Am J Med** 1999 Mar;106(3):327–34 (76 ref.)
Prostatitis [editorial] Feit RM, et al. **Sex Transm Dis** 1978 Apr-Jun;5(2):78–80 (32 ref.)
[Prostatitis syndrome] Kawahara M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):537–40 (13 ref.) **(Jpn)**

DIAGNOSIS

Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Nickel JC, et al. **Urology** 1999 Aug;54(2):229–33 (14 ref.)

DRUG THERAPY

The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Bjerklund Johansen TE, et al. **Eur Urol** 1998 Dec;34(6):457–66 (47 ref.)

ETIOLOGY

Prostatitis. Domingue GJ Sr, et al. **Clin Microbiol Rev** 1998 Oct;11(4):604–13 (73 ref.)
[Nonbacterial prostatitis] Arakawa S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):226–30 (17 ref.) **(Jpn)**

MICROBIOLOGY

[Cryptococcal prostatitis] Fuse H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):364–6 (15 ref.) **(Jpn)**

PATHOLOGY

[Granulomatous prostatitis. Review of 22 cases] Rodríguez Martínez JJ, et al. **Actas Urol Esp** 1998 Jul-Aug; 22(7):575–80 (13 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Prostatitis unplugged? Prostatic massage revisited. Nickel JC, et al. **Tech Urol** 1999 Mar;5(1):1–7 (19 ref.)
Effective office management of chronic prostatitis. Nickel JC. **Urol Clin North Am** 1998 Nov;25(4):677–84 (34 ref.)
Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Nickel JC, et al. **Urology** 1999 Aug;54(2):229–33 (14 ref.)

PROSTHESES AND IMPLANTS

Composite technology in load-bearing orthopaedic implants. Evans SL, et al. **Biomaterials** 1998 Aug;19(15):1329–42 (84 ref.)
Biomaterials: a forecast for the future. Hench LL. **Biomaterials** 1998 Aug;19(16):1419–23 (22 ref.)
The war against junk science: the use of expert panels in complex medical-legal scientific litigation. Price JM, et al. **Biomaterials** 1998 Aug;19(16):1425–32 (28 ref.)
Hemispherectomy complications in the light of craniocerebral disproportion: review of the literature and rationale for a filling-reduction cranioplasty. Sorano V, et al. **Childs Nerv Syst** 1998 Sep;14(9):440–7 (63 ref.)
Practical biomechanical considerations for spine implant testing. Margulies JY, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):347–64 (66 ref.)
Use of the Maxwell-Brancheau arthroereisis implant for the correction of posterior tibial tendon dysfunction. Maxwell JR, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):479–89 (20 ref.)
Radiology of intervertebral cages in spinal surgery. Hanley SD, et al. **Clin Radiol** 1999 Apr;54(4):201–6 (7 ref.)
Radiopaque polymeric materials for medical applications. Current aspects of biomaterial research. Mottu F, et al. **Invest Radiol** 1999 May;34(5):323–35 (134 ref.)
Implant fixation by bone ingrowth. Kienapfel H, et al. **J Arthroplasty** 1999 Apr;14(3):355–68 (146 ref.)
The effects of the surface topography of micromachined titanium substrata on cell behavior in vitro and in vivo. Brunette DM, et al. **J Biomech Eng** 1999 Feb;121(1):49–57 (56 ref.)
Prosthesis-bone interface. Plenk H Jr. **J Biomed Mater Res** 1998 Winter;43(4):350–5 (38 ref.)
Performance of subcutaneously implanted glucose sensors: a review. Gerritsen M, et al. **J Invest Surg** 1998 May-Jun; 11(3):163–74 (83 ref.)
Hemifacial microsomia and treatment options for auricular

PROSTHESES AND IMPLANTS

replacement: A review of the literature. Wang RR, et al. **J Prosthet Dent** 1999 Aug;82(2):197-204 (118 ref.)
Bone-graft substitutes. Van Heest A, et al. **Lancet** 1999 Apr; 353 Suppl 1:SI28-9 (8 ref.)
Performance of subcutaneously implanted glucose sensors for continuous monitoring. Gerritsen M, et al. **Neth J Med** 1999 Apr;54(4):167-79 (103 ref.)
Alternatives to spinal fusion. Kostuik JP. **Orthop Clin North Am** 1998 Oct;29(4):701-15 (37 ref.)
Carriers that concentrate native bone morphogenetic protein in vivo. De Groot J. **Tissue Eng** 1998 Winter;4(4):337-41 (27 ref.)
[Tissue engineered cartilage and its clinical use] Liu Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Sep;11(5):305-8 (22 ref.) **(Chi)**
[Current status of the study of tissue engineering] Zhang C, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 May;11(3):164-7 (23 ref.) **(Chi)**
[Microrough surface and its bio-effects of metallic biomaterials (I)--microrough surface of metallic biomaterials] Wen X, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):77-80, 86 (25 ref.) (Eng. Abstr.) **(Chi)**
[Microrough surface and its bio-effects of metallic biomaterials (II)--bio-effects of microrough surface of metallic biomaterials] Wen X. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Jun; 14(2):164-9 (25 ref.) (Eng. Abstr.) **(Chi)**
[An overview on research and application of intelligent materials in modern medicine] Zhang L, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):68-72 (10 ref.) (Eng. Abstr.) **(Chi)**
[Soft tissue augmentation for treatment of wrinkles and scars of the face] Streit M, et al. **Ther Umsch** 1999 Apr; 56(4):212-8 (11 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

The ligament augmentation device: an historical perspective. Kumar K, et al. **Arthroscopy** 1999 May;15(4):422-32 (49 ref.)

STANDARDS

Applications of computer modelling for the design of orthopaedic, dental and cardiovascular biomaterials. Vander Sloten J, et al. **Proc Inst Mech Eng [H]** 1998; 212(6):489-500 (90 ref.)
Voluntary guidance for the development of tissue-engineered products. Omstead DR, et al. **Tissue Eng** 1998 Fall; 4(3):239-66 (55 ref.)

TRENDS

[The current prospects for tracheal prostheses (editorial)] Beltrami V. **G Chir** 1998 Oct;19(10):373-6 (11 ref.) **(Ita)**

PROSTHESIS see **PROSTHESES AND IMPLANTS**

PROSTHESIS, DENTAL see **DENTAL PROSTHESIS**

PROSTHESIS DESIGN

see related
DENTURE DESIGN

Impregnated polyester arterial prostheses: performance and prospects. Chakfé N, et al. **Ann Vasc Surg** 1999 Sep; 13(5):509-23 (157 ref.)
Socket considerations for the patient with a transtibial amputation. Fergason J, et al. **Clin Orthop** 1999 Apr; (361):76-84 (23 ref.)
Modern prosthetic knee mechanisms. Michael JW. **Clin Orthop** 1999 Apr;(361):39-47 (32 ref.)
Strength requirements for internal and external prostheses. Paul JP. **J Biomech** 1999 Apr;32(4):381-93 (53 ref.)

PROSTHESIS FAILURE

see related
DENTAL RESTORATION FAILURE

A new technique for removing noncemented acetabular components in revision total hip arthroplasty. Markovich GD, et al. **Am J Orthop** 1999 Jan;28(1):35-7 (10 ref.)
Long-term results of cemented femoral stems with roughened precoated surfaces. Harris WH. **Clin Orthop** 1998 Oct;(355):137-43 (32 ref.)
Porosity reduction in acrylic cement is clinically irrelevant. Ling RS, et al. **Clin Orthop** 1998 Oct;(355):249-53 (31 ref.)
A review of the complications and results of implantation of the AMS artificial urinary sphincter. Hajivassiliou CA. **Eur Urol** 1999 Jan;35(1):36-44 (124 ref.)
Bird nest deformity of a self-expanding esophageal stent and a technique of removal. Berg JC. **Gastrointest Endosc** 1999 Jul;50(1):108-10 (6 ref.)
Bone loss with revision total knee arthroplasty: defect classification and alternatives for reconstruction. Engh GA, et al. **Instr Course Lect** 1999;48:167-75 (22 ref.)
A new classification system for the management of acetabular osteolysis after total hip arthroplasty. Rubash HE, et al. **Instr Course Lect** 1999;48:37-42 (42 ref.)
Late failure of the polyethylene liner fixation in an uncemented total hip arthroplasty. Louwerse RT, et al. **J Arthroplasty** 1999 Apr;14(3):391-6 (16 ref.)
Catastrophic failure of a cemented, collarless, polished, tapered cobalt-chromium femoral stem used with impaction bone-grafting. A report of two cases. Jazrawi LM, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):844-7 (22 ref.)
Pathology of silicone leakage from breast implants. van Diest PJ, et al. **J Clin Pathol** 1998 Jul;51(7):493-7 (35 ref.)
[The total knee prosthesis: indications and complications] Hamelynck KJ. **Ned Tijdschr Geneeskd** 1998 Sep 12; 142(37):2030-4 (30 ref.) (Eng. Abstr.) **(Dut)**
[The causes of failure for hip and knee arthroplasties] Huiskes R. **Ned Tijdschr Geneeskd** 1998 Sep 12;142(37):2035-40 (9 ref.) (Eng. Abstr.) **(Dut)**
[Surgical techniques used in the revision of hip prostheses] Slooff TJ, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20; 142(25):1438-45 (10 ref.) (Eng. Abstr.) **(Dut)**
[Prevention and management of dysfunction of prosthetic heart valves] Körfer R, et al. **Herz** 1998 Nov;23(7):448-52 (6 ref.) (Eng. Abstr.) **(Ger)**
[Pharmacological treatment of restenosis after coronary angioplasty and bypass grafting] Halawa B. **Pol Merkuriusz Lek** 1998 Jun;4(24):335-8 (31 ref.) (Eng. Abstr.) **(Pol)**
[Rare causes of the dysfunction of mechanical bicuspid heart valves] Novikov VK, et al. **Vestn Khir Im I I Grek** 1998; 157(3):60-4 (36 ref.) (Eng. Abstr.) **(Rus)**
[Pseudoaneurysm of the mitral-aortic fibrosa secondary to the partial detachment of a mechanical aortic prosthesis] Delgado C, et al. **Rev Esp Cardiol** 1999 May;52(5):348-50 (7 ref.) (Eng. Abstr.) **(Spa)**
[Salvaged femoral heads banked for re-use. Excellent bone replacement in revision of prosthetic surgery] Aspenberg P. **Lakartidningen** 1999 Feb 24;96(8):870-4 (39 ref.) (Eng. Abstr.) **(Swe)**

PROSTHESIS FITTING

Fitting contact lenses in eyes with filtering blebs. Grohe RM, et al. **J Glaucoma** 1998 Dec;7(6):439-45 (52 ref.)

PROSTHESIS IMPLANTATION

Percutaneous implants in the temporal bone for securing a bone conductor: surgical methods and results. van der Pouw CT, et al. **Ann Otol Rhinol Laryngol** 1999 Jun; 108(6):532-6 (18 ref.)
Innovations in keratoprosthesis: proved and unproved. Yaghouti F, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):27-36 (40 ref.)
Hemifacial microsomia and treatment options for auricular replacement: A review of the literature. Wang RR, et al. **J Prosthet Dent** 1999 Aug;82(2):197-204 (118 ref.)
Advanced techniques in liposuction. Johnson DS, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):139-48 (26 ref.)
Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease. van der Wieken LR. **Semin Interv Cardiol** 1999 Jun;4(2):77-83 (25 ref.)
[Modern techniques of restoration of locomotion in paralyzed persons] Rabischong P. **Bull Acad Natl Med** 1999; 183(3):531-7; discussion 538-9 (49 ref.) (Eng. Abstr.) **(Fre)**
[Controversies regarding silicone implants in plastic surgery. Evaluation of arguments based on criteria of evidence-based medicine] Sohn W. **Fortschr Med** 1998 Sep 30;116(27):18-20, 22 (16 ref.) **(Ger)**
[Insufficiency of the anal sphincter--attempt at anorectal reconstruction] Bruch HP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:482-7 (16 ref.) (Eng. Abstr.) **(Ger)**
[Amputation and prosthetics. 2: Amputation of the foot and its orthopedic management] Wetz HH, et al. **Orthopade** 1998 Nov;27(11):779-92 (45 ref.) **(Ger)**
[Augmentation techniques: are they out?] Kiefer H, et al. **Zentralbl Chir** 1998;123(9):1002-13 (86 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

A review of the complications and results of implantation of the AMS artificial urinary sphincter. Hajivassiliou CA. **Eur Urol** 1999 Jan;35(1):36-44 (124 ref.)
[PTA stent implantation in the carotid artery: dangerous experiment or the treatment of the future? (editorial)] Minar E, et al. **Wien Klin Wochenschr** 1999 Jul 9;111(13):495-500 (32 ref.) **(Ger)**

INSTRUMENTATION

The development of biliary drainage and stenting. Wurbs D. **Endoscopy** 1998 Nov;30(9):A202-6 (36 ref.)
Alloplastic sternal replacement in malignant sternal tumors. Case report and review of the literature. Meyer M, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):853-7 (42 ref.)
Biomaterials in Urology II: future usage and management. Reid G, et al. **J Endourol** 1999 Feb;13(1):1-7 (73 ref.)

METHODS

Simultaneous transcatheter valvuloplasty and Amplatzer septal occlusion for pulmonary valvar stenosis and secundum atrial septal defect. Yip WC, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):578-81 (11 ref.)
Practical biomechanical considerations for spine implant testing. Margulies JY, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):347-64 (66 ref.)
Airway stents. Mehta AC, et al. **Clin Chest Med** 1999 Mar; 20(1):139-51 (68 ref.)
Self-expandable metal stents for malignant gastric outlet obstruction: a modified technique. Venu RP, et al. **Endoscopy** 1998 Aug;30(6):553-8 (18 ref.)
The use of endoprostheses in biliary fistula of hydatid cyst. de Aretxabala X, et al. **Gastrointest Endosc** 1999 Jun; 49(6):797-9 (20 ref.)
The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation [editorial] Parsonnet V, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):695-7 (17 ref.)
[Silastic implants and reconstruction of the orbital floor: review of twenty year's experience] Laxenaire A, et al. **Ann Chir Plast Esthet** 1996 Dec;41(6):631-8 (23 ref.) (Eng. Abstr.) **(Fre)**
[Percutaneous closure of an interatrial communication with the Amplatzer device. The first case in Mexico] Zabal C, et al. **Arch Inst Cardiol Mex** 1998 Mar-Apr;68(2):147-52 (20 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Guidelines of the French Society of Digestive Endoscopy (SFED): esophageal prosthesis. Greff M. **Endoscopy** 1998 Oct;30(8):737-9 (11 ref.)
Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. Greenfield LJ, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1013-9 (97 ref.)

TRENDS

Current status and critical reflections on implantable hearing aids. Hüttenbrink KB. **Am J Otol** 1999 Jul;20(4):409-15 (21 ref.)
Complications and lessons learned from 10 years of expandable gastrointestinal prostheses. Kozarek RA. **Dig Dis** 1999;17(1):14-22 (35 ref.)

PROSTHESIS LOOSENING see **PROSTHESIS FAILURE**

PROSTHESIS-RELATED INFECTIONS

see related
BIOFILMS

Pathophysiology, prevention, and management of prosthetic infections in hernia surgery. Deysine M. **Surg Clin North Am** 1998 Dec;78(6):1105-15, viii (26 ref.)

DIAGNOSIS

An unusual vascular graft infection by Aspergillus--a case report and literature review. Fuster RG, et al. **Angiology** 1999 Feb;50(2):169-73 (14 ref.)
Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Hanssen AD, et al. **Instr Course Lect** 1999;48:111-22 (141 ref.)
Imaging techniques for evaluation of postoperative orthopedic infections. Seabold JE, et al. **Q J Nucl Med** 1999 Mar;43(1):21-8 (34 ref.)
[Propionibacterium acnes infectious endocarditis] Durupt S, et al. **Presse Med** 1998 Nov 21;27(36):1839-41 (21 ref.) (Eng. Abstr.) **(Fre)**
[Aortoiliac graft infection as a diagnostic and treatment problem] Gutowski P. **Ann Acad Med Stetin** 1998;Suppl 41:1-72 (143 ref.) (Eng. Abstr.) **(Pol)**
[Natural-valve endocarditis in patients wearing pacemakers] Climent Payá V, et al. **Rev Clin Esp** 1999 Jan;199(1):28-30 (9 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Bladder augmentation: does it predispose to prosthetic infection of simultaneously placed artificial genitourinary sphincters or in situ ventriculoperitoneal shunts? Furness PD 3rd, et al. **BJU Int** 1999 Jul;84(1):25-9 (18 ref.)
Thrombosis of a mitral valve prosthesis resulting from Staphylococcus epidermidis endocarditis. Costa GM, et al. **Cardiologia** 1999 Jul;44(7):675-8 (12 ref.)
Infection of endovascular stents: an uncommon but important complication. Latham JA, et al. **Cardiovasc Surg** 1999 Mar; 7(2):179-82 (15 ref.)
Efficacy of silver-coated medical devices. Schierholz JM, et al. **J Hosp Infect** 1998 Dec;40(4):257-62 (51 ref.)
[Infectious endocarditis of prosthetic valves due to Staphylococcus capitis: a new case] Domínguez Rodríguez A, et al. **Rev Esp Cardiol** 1999 Apr;52(4):277-8 (7 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Mycoplasma infections of aneurysms or vascular grafts. Fenollar F, et al. **Clin Infect Dis** 1999 Mar;28(3):694-5 (10 ref.)
Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia. Munter RG, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):353-6 (18 ref.)
[Mitral valve prosthetic endocarditis due to Hafnia alvei (letter)] Gallego Page JC, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):199 (10 ref.) **(Spa)**

PREVENTION & CONTROL

Efficacy of silver-coated medical devices. Schierholz JM, et al. **J Hosp Infect** 1998 Dec;40(4):257-62 (51 ref.)
[Prevention and treatment of infections in orthopedic surgery. The role of antibiotic-loaded cements] Manfredi R, et al. **Recenti Prog Med** 1999 Jul-Aug;90(7-8):425-9 (45 ref.) **(Ita)**

THERAPY

Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Hanssen AD, et al. **Instr Course Lect** 1999;48:111-22 (141 ref.)
[Aortoiliac graft infection as a diagnostic and treatment problem] Gutowski P. **Ann Acad Med Stetin** 1998;Suppl 41:1-72 (143 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

[Chronic bacterial endocarditis on the electrical catheter in a pacemaker wearer: a clinical case report] Perrone C, et al. **G Ital Cardiol** 1999 May;29(5):558-61 (21 ref.) (Eng. Abstr.) **(Ita)**

PROSTHODONTICS

see related
ORAL SURGICAL PROCEDURES, PREPROSTHETIC

Annual review of selected dental literature: report of the Committee on Scientific Investigation of the American Academy of Restorative Dentistry. Allen EP, et al. **J Prosthet Dent** 1999 Jul;82(1):27-66 (309 ref.)
[Variants in the use of CAD/CAM systems in orthodontic dentistry] Riakhovskiĭ AN, et al. **Stomatologiia (Mosk)** 1999;78(4):56-9 (32 ref.) **(Rus)**

PROSTITUTION

Evaluating outreach clinics [comment] Davidson EA. **Sex Transm Infect** 1999 Jun;75(3):198-9 (11 ref.) Comment on: Sex Transm Infect 1999 Jun;75(3):195-7.
A novel approach to outcome evaluation [see comments] Horn CK, et al. **Sex Transm Infect** 1999 Jun;75(3):195-7 (6 ref.) Comment in: Sex Transm Infect 1999 Jun;75(3):146-7. Comment in: Sex Transm Infect 1999 Jun;75(3):198-9.

STATISTICS & NUMERICAL DATA

[HIV prevention for migrant prostitutes] Nitschke-Ozbay H. **Zentralbl Gynakol** 1999;121(1):36-41 (5 ref.) (Eng. Abstr.) **(Ger)**

PROTAMINE SULFATE see **PROTAMINES**

PROTAMINES

CHEMISTRY

Are there molecules of nucleoprotamine? Raukas E, et al. **Bioessays** 1999 May;21(5):440-8 (68 ref.)

PROTEASE ANTAGONISTS see **PROTEASE INHIBITORS**

PROTEASE INHIBITORS

ADMINISTRATION & DOSAGE

Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin. Yew WW, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):126-9 (15 ref.)

ADVERSE EFFECTS

A review of protease inhibitor-induced hyperglycemia. Kaufman MB, et al. **Pharmacotherapy** 1999 Jan;19(1):114-7 (17 ref.)
[Lipodystrophy--an adverse effect of protease inhibitors used against HIV infection? Concern about negative delayed effects of this break-through] Morfeldt L, et al. **Lakartidningen** 1998 Oct 14;95(42):4616-7 (16 ref.) **(Swe)**

CHEMICAL SYNTHESIS

The next generation of MMP inhibitors. Design and synthesis. De B, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:40-60 (19 ref.)
Discovery of protease inhibitors using targeted libraries. Whittaker M. **Curr Opin Chem Biol** 1998 Jun;2(3):386-96 (45 ref.)

CHEMISTRY

Discovery of protease inhibitors using targeted libraries. Whittaker M. **Curr Opin Chem Biol** 1998 Jun;2(3):386-96 (45 ref.)

METABOLISM

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. Arthur MJ, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S33-8 (59 ref.)
[Antiproteases in the pathogenesis of neoplastic diseases] Dąbrowska M. **Przegl Lek** 1998;55(9):475-9 (65 ref.) (Eng. Abstr.) **(Pol)**
[Brain proteinase activity and the mobilization of endogenous proteolytic inhibitors as factors in the development of the functional state of the body] Gurin VN, et al. **Fiziol Cheloveka** 1999 Jan-Feb;25(1):71-7 (36 ref.) **(Rus)**

PHARMACOLOGY

Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Woessner JF Jr. **Ann N Y Acad Sci** 1999 Jun 30;878:388-403 (111 ref.)
Regulation of neurotrophic functions: proteinase inhibitors. Fumagalli L, et al. **Ital J Anat Embryol** 1999 Apr-Jun; 104(2):53-88 (110 ref.)
Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton. Shimazawa R, et al. **J Enzyme Inhib** 1999;14(4):259-75 (67 ref.)
An overview of proteinase inhibitors. Hibbetts K, et al. **J Vet Intern Med** 1999 Jul-Aug;13(4):302-8 (91 ref.)
Human immunodeficiency virus protease inhibitors. Rana KZ, et al. **Pharmacotherapy** 1999 Jan;19(1):35-59 (205 ref.)
Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections. Wang QM. **Prog Drug Res** 1999;52:197-219 (100 ref.)
Role of proteases in implantation. Salamonsen LA. **Rev Reprod** 1999 Jan;4(1):11-22 (98 ref.)
Proteasome inhibitors: valuable new tools for cell biologists. Lee DH, et al. **Trends Cell Biol** 1998 Oct;8(10):397-403 (49 ref.)
[Recent challenges and progress in AIDS therapy--emergence of drug resistant HIV-1 variants] Mitsuya H. **Rinsho Ketsueki** 1999 Apr;40(4):249-54 (20 ref.) **(Jpn)**

THERAPEUTIC USE

Preclinical and clinical studies of MMP inhibitors in cancer. Drummond AH, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:228-35 (24 ref.)
Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Greenwald RA. **Ann N Y Acad Sci** 1999 Jun 30;878:413-9 (6 ref.)
Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications. Leff RL. **Ann N Y Acad Sci** 1999 Jun 30;878:201-7 (12 ref.)
MMP inhibition in prostate cancer. Lokeshwar BL. **Ann N Y Acad Sci** 1999 Jun 30;878:271-89 (71 ref.)
Clinical studies with matrix metalloproteinase inhibitors. Brown PD. **APMIS** 1999 Jan;107(1):174-80 (41 ref.)
Matrix metalloproteinase inhibitors. Brown PD. **Breast Cancer Res Treat** 1998;52(1-3):125-36 (59 ref.)
Protease inhibitors as antiviral agents. Patick AK, et al. **Clin Microbiol Rev** 1998 Oct;11(4):614-27 (169 ref.)
Matrix metalloproteinases. Johnson LL, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):466-71 (51 ref.)
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Holst JJ, et al. **Diabetes** 1998 Nov;47(11):1663-70 (82 ref.)
Molecular chemotherapy for breast cancer. Patterson A, et al. **Drugs Aging** 1999 Feb;14(2):75-90 (188 ref.)
Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age. Hoegl L, et al. **Pharmazie** 1999 May;54(5):319-29 (65 ref.)
[Synthetic protease inhibitors for human acute pancreatitis] Otani T. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov; 95(11):1205-11 (24 ref.) **(Jpn)**
[Antiproteases in the pathogenesis of neoplastic diseases] Dąbrowska M. **Przegl Lek** 1998;55(9):475-9 (65 ref.) (Eng. Abstr.) **(Pol)**

PROTECTIVE AGENTS

ADMINISTRATION & DOSAGE

Dosing considerations with amifostine: a review of the literature and clinical experience. Dorr RT, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):108-19 (42 ref.)

CHEMISTRY

Past and present scenario of hepatoprotectants. Ram VJ, et al. **Curr Med Chem** 1999 Mar;6(3):217-54 (302 ref.)

PHARMACOLOGY

Protection by amifostine of cyclophosphamide-induced myelosuppression. Alberts DS. **Semin Oncol** 1999 Apr;26(2 Suppl 7):37-40 (11 ref.)
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Capizzi RL. **Semin Oncol** 1999 Apr;26(2 Suppl 7):3-21 (99 ref.)
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Capizzi RL. **Semin Oncol** 1999 Apr;26(2 Suppl 7):72-81 (68 ref.)
Neurologic protection by amifostine. DiPaola RS, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):82-8 (41 ref.)

THERAPEUTIC USE

The role of folic acid in oral clefting. Hartridge T, et al. **Br J Orthod** 1999 Jun;26(2):115-20 (42 ref.)
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links M, et al. **Drugs** 1999 Mar; 57(3):293-308 (94 ref.)
Future directions in gynecologic cancer. Alberts DS. **Semin Oncol** 1999 Apr;26(2 Suppl 7):125-8 (13 ref.)
Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Balzarotti M, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):66-71 (32 ref.)
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. Budd GT, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):41-50 (41 ref.)
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. List AF. **Semin Oncol** 1999 Apr;26(2 Suppl 7):61-5 (30 ref.)
Amifostine and combined-modality therapeutic approaches. Mehta MP. **Semin Oncol** 1999 Apr;26(2 Suppl 7):95-101 (32 ref.)
Future directions in non-small cell lung cancer. Schiller JH. **Semin Oncol** 1999 Apr;26(2 Suppl 7):120-4 (38 ref.)
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Selvaggi G, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):51-60 (85 ref.)
[Anticancer chemotherapy. Prevention of toxicity] Chvetzoff G, et al. **Presse Med** 1998 Dec 12;27(39):2106-12 (44 ref.) (Eng. Abstr.) **(Fre)**
[Anticancer chemotherapy. Prevention of complications] Paule B, et al. **Presse Med** 1998 Dec 12;27(39):2113-9 (79 ref.) (Eng. Abstr.) **(Fre)**

PROTECTIVE CLOTHING

ADVERSE EFFECTS

Heat stress and protective clothing: an emerging approach from the United States. Bernard TE. **Ann Occup Hyg** 1999 Jul;43(5):321-7 (22 ref.)
Development of a draft British standard: the assessment of heat strain for workers wearing personal protective equipment. Hanson MA. **Ann Occup Hyg** 1999 Jul; 43(5):309-19 (38 ref.)
Heat balance when wearing protective clothing. Havenith G. **Ann Occup Hyg** 1999 Jul;43(5):289-96 (11 ref.)
Clothing evaporative heat resistance--proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339-46 (17 ref.) Comment in: Ann Occup Hyg 1999 Jul;43(5):347-52.
The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353-6 (15 ref.)
International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297-308 (28 ref.)

STANDARDS

Clothing evaporative heat resistance--proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339-46 (17 ref.) Comment in: Ann Occup Hyg 1999 Jul;43(5):347-52.
The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353-6 (15 ref.)

PROTECTIVE DEVICES

Toxicologic evaluation of pepper spray as a possible weapon for the Dutch police force: risk assessment and efficacy. Busker RW, et al. **Am J Forensic Med Pathol** 1998 Dec; 19(4):309-16 (38 ref.)

STANDARDS

Austrian Committee for Injury Prevention in Childhood. Purtscher K, et al. **Inj Prev** 1998 Sep;4(3):236-7 (3 ref.)

PROTECTIVE GLOVES see **GLOVES, PROTECTIVE**

PROTEIN A see **STAPHYLOCOCCAL PROTEIN A**

PROTEIN AA see **AMYLOID PROTEIN AA**

PROTEIN ARGININE METHYLTRANSFERASE see **PROTEIN-ARGININE N-METHYLTRANSFERASE**

PROTEIN-ARGININE N-METHYLTRANSFERASE

METABOLISM

RNA and protein interactions modulated by protein arginine methylation. Gary JD, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:65-131 (250 ref.)

PROTEIN BINDING

see related
BINDING SITES
CARRIER PROTEINS
METALLOPROTEINS

PROTEIN BINDING

RADIOLIGAND ASSAY
THYROXINE-BINDING PROTEINS

NMR for the design of functional mimetics of protein-protein interactions: one key is in the building of bridges. Song J, et al. **Biochem Cell Biol** 1998;76(2-3):177-88 (67 ref.)
'In vivo' models of hapten generation. Bolzacchini E, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:83-6 (11 ref.)
Integrin associated proteins. Hemler ME. **Curr Opin Cell Biol** 1998 Oct;10(5):578-85 (87 ref.)
Protein folding via binding and vice versa. Tsai CJ, et al. **Fold Des** 1998;3(4):R71-80 (90 ref.)
High-performance frontal analysis for drug-protein binding study. Shibukawa A, et al. **J Pharm Biomed Anal** 1999 Jan; 18(6):1047-55 (30 ref.)
Peptide modulators of protein-protein interactions in intracellular signaling. Souroujon MC, et al. **Nat Biotechnol** 1998 Oct;16(10):919-24 (50 ref.)

PROTEIN-BINDING RADIOASSAY see **RADIOLIGAND ASSAY**

PROTEIN-BOUND IODINE TEST see **THYROID FUNCTION TESTS**

PROTEIN C

GENETICS

Inherited combined deficiency of proteins C and S [letter] Ozbek N, et al. **Eur J Haematol** 1999 Aug;63(2):138-9 (7 ref.)

METABOLISM

Lupus anticoagulants, thrombosis and the protein C system. Esmon NL, et al. **Haematologica** 1999 May;84(5):446-51 (32 ref.)

PHYSIOLOGY

Blood coagulation. Mann KG. **Alcohol Clin Exp Res** 1999 Jun;23(6):1111-3 (11 ref.)
Inflammation, sepsis, and coagulation. Esmon CT, et al. **Haematologica** 1999 Mar;84(3):254-9 (24 ref.)
Regulation and functions of the protein C anticoagulant pathway. Esmon CT, et al. **Haematologica** 1999 Apr; 84(4):363-8 (42 ref.)
The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: pathomechanisms and new tools for assessing its clinical relevance. Kraus M. **Semin Thromb Hemost** 1998;24(4):337-54 (142 ref.)

PROTEIN C DEFICIENCY

see related
ACTIVATED PROTEIN C RESISTANCE

COMPLICATIONS

Mesenteric venous thrombosis associated with protein C deficiency. Mitani M, et al. **J Gastroenterol** 1999 Jun; 34(3):387-9 (17 ref.)
[The role of protein C in the pathogenesis of stroke] Wojczal J, et al. **Neurol Neurochir Pol** 1998 Mar-Apr;32(2):379-85 (21 ref.) (Eng. Abstr.) **(Pol)**

CONGENITAL

[Congenital protein C deficiency and abnormality] Saito H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):11-4 (10 ref.) **(Jpn)**

DIAGNOSIS

Mesenteric venous thrombosis associated with protein C deficiency. Mitani M, et al. **J Gastroenterol** 1999 Jun; 34(3):387-9 (17 ref.)

GENETICS

Inherited combined deficiency of proteins C and S [letter] Ozbek N, et al. **Eur J Haematol** 1999 Aug;63(2):138-9 (7 ref.)
[Screening methods in genetic diagnosis of hereditary protein C deficiency] David M, et al. **Orv Hetil** 1999 Jan 17; 140(3):125-32 (44 ref.) (Eng. Abstr.) **(Hun)**

PROTEIN-CALORIE MALNUTRITION see **PROTEIN-ENERGY MALNUTRITION**

PROTEIN CDKN2 see **PROTEIN P16**

PROTEIN CONFORMATION

see related
MACROMOLECULAR SYSTEMS

Molecular structure of the two-dimensional hexon crystalline array and of adenovirus capsid. Adám E, et al. **Acta Microbiol Immunol Hung** 1998;45(3-4):305-10 (13 ref.)
Linear and rotary molecular motors. Kinosita K Jr. **Adv Exp Med Biol** 1998;453:5-13; discussion 13-4 (34 ref.)
HIV-1 integrase: structural organization, conformational changes, and catalysis. Asante-Appiah E, et al. **Adv Virus Res** 1999;52:351-69 (67 ref.)
Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity. Wlodawer A. **Adv Virus Res** 1999;52:335-50 (48 ref.)
Active site flexibility in enzyme catalysis. Tsou CL. **Ann N Y Acad Sci** 1998 Dec 13;864:1-8 (35 ref.)
The lysosomal cysteine proteases. McGrath ME. **Annu Rev Biophys Biomol Struct** 1999;28:181-204 (112 ref.)
New perceptions of transcription factor properties from NMR. Bagby S, et al. **Biochem Cell Biol** 1998; 76(2-3):368-78 (85 ref.)
Solid-state NMR studies of proteins: the view from static 2H NMR experiments. Siminovitch DJ. **Biochem Cell Biol** 1998;76(2-3):411-22 (74 ref.)
A change-in-hand mechanism for S100 signalling. Smith SP, et al. **Biochem Cell Biol** 1998;76(2-3):324-33 (69 ref.)
NMR structural studies on antifreeze proteins. Sönnichsen FD, et al. **Biochem Cell Biol** 1998;76(2-3):284-93 (41 ref.)
The structure and function of HPr. Waygood EB. **Biochem Cell Biol** 1998;76(2-3):359-67 (53 ref.)
Molecular mechanisms of calmodulin's functional versatility. Zhang M, et al. **Biochem Cell Biol** 1998;76(2-3):313-23 (74 ref.)
How cytidylyltransferase uses an amphipathic helix to sense membrane phospholipid composition. Cornell RB. **Biochem Soc Trans** 1998 Aug;26(3):539-44 (38 ref.)
Vibrational circular dichroism spectroscopy of selected oligopeptide conformations. Keiderling TA, et al. **Bioorg Med Chem** 1999 Jan;7(1):133-41 (42 ref.)
Progress in the design of DNA sequence-specific lexitropsins. Walker WL, et al. **Biopolymers** 1997;44(4):323-34 (44 ref.)
Ribosomal mechanics, antibiotics, and GTP hydrolysis [comment] Porse BT, et al. **Cell** 1999 May 14;97(4):423-6 (16 ref.) Comment on: Cell 1999 May 14;97(4):491-502.
Cataract as a conformational disease--the Maillard reaction, alpha-crystallin and chemotherapy. Crabbe MJ. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1047-50 (30 ref.)
Structural view of adherin-mediated cell-cell adhesion. Alattia JR, et al. **Cell Mol Life Sci** 1999 Mar;55(3):359-67 (37 ref.)
Structural properties of matrix metalloproteinases. Bode W, et al. **Cell Mol Life Sci** 1999 Apr;55(4):639-52 (89 ref.)
Identifying the conformational state of bi-liganded haemoglobin. Marden MC, et al. **Cell Mol Life Sci** 1998 Dec;54(12):1365-84 (99 ref.)
A thermodynamic analysis of the contribution of hydroxyproline to the structural stability of the collagen triple helix. Burjanadze TV, et al. **Connect Tissue Res** 1997; 36(4):347-65 (92 ref.)
Ion channels: structure of a molecular brake. Sansom MS. **Curr Biol** 1999 Mar 11;9(5):R173-5 (9 ref.)
NMR structure determination of proteins and protein complexes larger than 20 kDa. Clore GM, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):564-70 (51 ref.)
Targeting growth factor and cytokine receptors with recombinant peptide libraries. Dower WJ. **Curr Opin Chem Biol** 1998 Jun;2(3):328-34 (35 ref.)
Two-dimensional mass spectrometry of biomolecules at the subfemtomole level. McLafferty FW, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):571-8 (51 ref.)
Combinatorial transcription factors. Wolberger C. **Curr Opin Genet Dev** 1998 Oct;8(5):552-9 (54 ref.)
Computer search algorithms in protein modification and design. Desjarlais JR, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):471-5 (40 ref.)
Biomolecules interactions and competitions by non-immobilised ligand interaction assay by circular dichroism. Siligardi G, et al. **Enantiomer** 1998;3(2):77-87 (26 ref.)
Structural aspects of collectins and receptors for collectins. Hansen S, et al. **Immunobiology** 1998 Aug;199(2):165-89 (136 ref.)
Ficolins and the fibrinogen-like domain. Lu J, et al. **Immunobiology** 1998 Aug;199(2):190-9 (36 ref.)
Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Braden BC, et al. **Immunol Rev** 1998 Jun; 163:45-57 (44 ref.)
CD2 and the nature of protein interactions mediating cell-cell recognition. Davis SJ, et al. **Immunol Rev** 1998 Jun; 163:217-36 (102 ref.)
Comparison of the conformations of two intact monoclonal antibodies with hinges. Harris LJ, et al. **Immunol Rev** 1998 Jun;163:35-43 (32 ref.)
IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Jefferis R, et al. **Immunol Rev** 1998 Jun; 163:59-76 (93 ref.)
Recognition surfaces of MHC class I. Jones EY, et al. **Immunol Rev** 1998 Jun;163:121-8 (45 ref.)
Structure-function studies of T-cell receptor-superantigen interactions. Li H, et al. **Immunol Rev** 1998 Jun;163:177-86 (52 ref.)
Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. O'Callaghan CA, et al. **Immunol Rev** 1998 Jun;163:129-38 (49 ref.)
Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Tzartos SJ, et al. **Immunol Rev** 1998 Jun; 163:89-120 (239 ref.)
Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Wang J, et al. **Immunol Rev** 1998 Jun;163:197-215 (104 ref.)
The C-type lectin superfamily in the immune system. Weis WI, et al. **Immunol Rev** 1998 Jun;163:19-34 (73 ref.)
Conformational changes of contractile proteins and their role in muscle contraction. Borovikov YS. **Int Rev Cytol** 1999; 189:267-301 (150 ref.)
Analytical techniques and computer algorithms combined for the rapid characterization of structural peptide and protein features. Caporale C. **J Pept Res** 1998 Nov;52(5):421-9 (52 ref.)
Allosteric nicotinic receptors, human pathologies. Léna C, et al. **J Physiol Paris** 1998 Apr;92(2):63-74 (112 ref.)
100,000 protein structures for the biologist [see comments] Sali A. **Nat Struct Biol** 1998 Dec;5(12):1029-32 (3 ref.) Comment in: Nat Struct Biol 1998 Dec;5(12):1019-20.
Folding and binding cascades: shifts in energy landscapes [comment] Tsai CJ, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9970-2 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10118-22.
Matrix metalloproteases: variations on a theme. Borkakoti N. **Prog Biophys Mol Biol** 1998;70(1):73-94 (76 ref.)
Stability and folding of domain proteins. Jaenicke R. **Prog Biophys Mol Biol** 1999;71(2):155-241 (400 ref.)
Molecular modelling of the 5-hydroxytryptamine receptors. Wishart G, et al. **Receptors Channels** 1999;6(4):317-35 (127 ref.)
The interleukin-11/receptor complex: rational design of agonists/antagonists and immunoassays potentially useful in human therapy. Jacques Y, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):737-40 (13 ref.)
A new decoration for nitric oxide synthase - a Zn(Cys)4 site. Ludwig ML, et al. **Structure** 1999 Apr 15;7(4):R73-9 (35 ref.)
ATP synthase: two motors, two fuels. Oster G, et al. **Structure** 1999 Apr 15;7(4):R67-72 (25 ref.)
A close family resemblance: the importance of structure in understanding cytochromes P450. Peterson JA, et al. **Structure** 1998 Sep 15;6(9):1079-85 (28 ref.)
CAMPASS: a database of structurally aligned protein superfamilies. Sowdhamini R, et al. **Structure** 1998 Sep 15; 6(9):1087-94 (50 ref.)
High energy exchange: proteins that make or break phosphoramidate bonds. Robinson VL, et al. **Structure Fold Des** 1999 Mar 15;7(3):R47-53 (24 ref.)
Courageous science: structural studies of bluetongue virus core. Rossmann MG, et al. **Structure Fold Des** 1999 Mar 15;7(3):R43-6 (31 ref.)
Clathrin: anatomy of a coat protein. Smith CJ, et al. **Trends Cell Biol** 1999 Sep;9(9):335-8 (32 ref.)
[New aspects is stable-isotope-assisted NMR techniques: application to be structural analysis of larger complexes between proteins and nucleic acids] Ohki S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):574-81 (56 ref.) **(Jpn)**
[Synchrotron radiation and biological crystallography] Tomizaki T, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar; 44(4 Suppl):566-73 (6 ref.) **(Jpn)**

PROTEIN CONFORMATION, ALPHA-HELICAL see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN CONFORMATION, BETA-SHEET see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN CONFORMATION, BETA-STRAND see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN DENATURATION

PHYSIOLOGY

Time-temperature equivalence of heat-induced changes in cells and proteins. Wright NT, et al. **J Biomech Eng** 1998 Feb;120(1):22-6 (29 ref.)

PROTEIN DISULFIDE ISOMERASE see **PROTEIN DISULFIDE-ISOMERASE**

PROTEIN DISULFIDE-ISOMERASE

METABOLISM

Protein disulfide isomerase assists protein folding as both an isomerase and a chaperone. Wang CC. **Ann N Y Acad Sci** 1998 Dec 13;864:9-13 (27 ref.)
The protein disulphide-isomerase family: unravelling a string of folds. Ferrari DM, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):1-10 (174 ref.)

PROTEIN-ENERGY MALNUTRITION

[Modification of the nutritional septicemic risk (RSN) by means of perioperative transfusion] Larrea J, et al. **Nutr Hosp** 1998 Sep-Oct;13(5):210-4 (35 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Low levels of plasma proteins: malnutrition or inflammation? Johnson AM. **Clin Chem Lab Med** 1999 Feb;37(2):91-6 (55

ref.)

COMPLICATIONS

[Malnutrition at the beginning of life: long-term effects] Rolland-Cachera MF. **Arch Pediatr** 1998;5 Suppl 2:209s-211s (21 ref.) **(Fre)**

[Malnutrition and osteoporosis] Rizzoli R, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I31-7 (60 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Sensitive measures of nutritional status in children in hospital and in the field. Motil KJ. **Int J Cancer Suppl** 1998;11:2-9 (27 ref.)

[A tool for nutritional anamnesis of elderly patients] Lauque S, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I45-54 (37 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

[Oral nutrition therapy in malnutrition] Eisenbart E, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I64-8 (26 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Administration of growth hormone to catabolic patients. Hinds CJ. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:71-5 (49 ref.)

EPIDEMIOLOGY

Protein-energy malnutrition in older subjects. Morley JE. **Proc Nutr Soc** 1998 Nov;57(4):587-92 (75 ref.)

ETIOLOGY

Protein-energy malnutrition in dialysis patients. Bistrian BR, et al. **Am J Kidney Dis** 1999 Jan;33(1):172-5 (37 ref.)

Sensitive measures of nutritional status in children in hospital and in the field. Motil KJ. **Int J Cancer Suppl** 1998;11:2-9 (27 ref.)

Pathophysiology of protein-energy wasting in chronic renal failure. Kopple JD. **J Nutr** 1999 Jan;129(1S Suppl):247S-251S (48 ref.)

[What should be done in weight loss of unknown origin?] Schwenk A. **Med Klin** 1998 Dec 15;93(12):719-25 (57 ref.) (Eng. Abstr.) **(Ger)**

[Causes of protein-calorie malnutrition] Thomas DR. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I38-44 (55 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The influence of the diet on the maturation of the immune system. Hughes DA. **Allergy** 1998;53(46 Suppl):26-8 (19 ref.)

The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition. Hug DH, et al. **J Photochem Photobiol B** 1998 Jul 10; 44(2):117-23 (81 ref.)

METABOLISM

The effect of under- and overnutrition on essential fatty acid metabolism in childhood. Decsi T, et al. **Eur J Clin Nutr** 1998 Aug;52(8):541-8 (54 ref.)

Adaptation to low energy intakes: the responses and limits to low intakes in infants, children and adults. Shetty PS. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S14-33 (151 ref.)

MORTALITY

Does nutritional intervention in protein-energy malnutrition improve morbidity or mortality? Koretz RL. **J Ren Nutr** 1999 Jul;9(3):119-21 (17 ref.)

PHYSIOPATHOLOGY

Adaptation to low energy intakes: the responses and limits to low intakes in infants, children and adults. Shetty PS. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S14-33 (151 ref.)

Pathophysiology of protein-energy wasting in chronic renal failure. Kopple JD. **J Nutr** 1999 Jan;129(1S Suppl):247S-251S (48 ref.)

PREVENTION & CONTROL

[Preventive nutritional services for the elderly] Millen BE. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I80-8 (85 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Kopple JD. **Am J Kidney Dis** 1999 Jan;33(1):180-5 (53 ref.)

Enteral nutrition in intensive care patients: a practical approach. Jolliet P, et al. **Clin Nutr** 1999 Feb;18(1):47-56 (82 ref.)

Does nutritional intervention in protein-energy malnutrition improve morbidity or mortality? Koretz RL. **J Ren Nutr** 1999 Jul;9(3):119-21 (17 ref.)

[Parenteral feeding in malnutrition] Jordan A, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I69-74 (23 ref.) (Eng. Abstr.) **(Ger)**

PROTEIN ENGINEERING

Engineering of selective TIMPs. Nagase H, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:1-11 (32 ref.)

Surface plasmon resonance biosensors as a tool in antibody engineering. Alfthan K. **Biosens Bioelectron** 1998 Sep 15; 13(6):653-63 (93 ref.)

Protein structure prediction and design. Morea V, et al. **Biotechnol Annu Rev** 1998;4:177-214 (160 ref.)

Peptide ligation and its application to protein engineering. Cotton GJ, et al. **Chem Biol** 1999 Sep;6(9):R247-56 (76 ref.)

Scratching the (cell) surface: cytokine engineering for improved ligand/receptor trafficking dynamics. Lauffenburger DA, et al. **Chem Biol** 1998 Oct; 5(10):R257-63 (58 ref.)

Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Reiter Y, et al. **Clin Cancer Res** 1996 Feb; 2(2):245-52 (62 ref.)

Genomics and the discovery of new drug targets. Jones DA, et al. **Curr Opin Chem Biol** 1999 Feb;3(1):71-6 (44 ref.)

Functionalization of designed folded polypeptides. Baltzer L. **Curr Opin Struct Biol** 1998 Aug;8(4):466-70 (34 ref.)

Redesigning small molecule-protein interfaces. Clackson T. **Curr Opin Struct Biol** 1998 Aug;8(4):451-8 (33 ref.)

Antibody engineering. Dall'Acqua W, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):443-50 (69 ref.)

Computer search algorithms in protein modification and design. Desjarlais JR, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):471-5 (40 ref.)

The design of protein-based catalysts using semisynthetic methods. Distefano MD, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):459-65 (53 ref.)

Evolutionary approaches to protein engineering. Steipe B. **Curr Top Microbiol Immunol** 1999;243:55-86 (143 ref.)

Can we improve on nature? "Super molecules" of factor VIII. Kaufman RJ, et al. **Haemophilia** 1998 Jul;4(4):370-9 (96 ref.)

Protein engineering with nonstandard amino acids. Steward LE, et al. **Methods Mol Biol** 1998;77:325-54 (37 ref.)

Pharmacokinetics and biodistribution of genetically-engineered antibodies. Colcher D, et al. **Q J Nucl Med** 1998 Dec;42(4):225-41 (164 ref.)

The emerging impact of phage display technology in thrombosis and haemostasis. Arza B, et al. **Thromb Haemost** 1998 Sep;80(3):354-65 (159 ref.)

Elastic molecular machines in metabolism and soft-tissue restoration. Urry DW. **Trends Biotechnol** 1999 Jun; 17(6):249-57 (31 ref.)

[Action of hydrostatic pressure on proteins: emergence of high pressure biotechnology, potential pharmaceutical and medical applications] Masson P. **Ann Pharm Fr** 1999 Jan; 57(1):49-55 (47 ref.) (Eng. Abstr.) **(Fre)**

[Evolutionary molecular engineering of proteins] Nemoto N, et al. **Seikagaku** 1998 Oct;70(10):1251-61 (72 ref.) **(Jpn)**

METHODS

Fighting nerve agent chemical weapons with enzyme technology. LeJeune KE, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:153-70 (38 ref.)

A toolbox of recombinant lipases for industrial applications. Schmidt-Dannert C, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:14-22 (27 ref.)

Protein disulfide isomerase assists protein folding as both an isomerase and a chaperone. Wang CC. **Ann N Y Acad Sci** 1998 Dec 13;864:9-13 (27 ref.)

Heterologous expression of G-protein-coupled receptors: human opioid receptors under scrutiny. Stanasila L, et al. **Biochimie** 1998 May-Jun;80(5-6):563-71 (78 ref.)

tRNA-mediated protein engineering. Rothschild KJ, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):64-70 (46 ref.)

Design and discovery of protein dimerizers. Clemons PA. **Curr Opin Chem Biol** 1999 Feb;3(1):112-5 (28 ref.)

Molecular remodeling of complement regulatory proteins for xenotransplantation. Seya T, et al. **Immunopharmacology** 1999 May;42(1-3):75-80 (52 ref.)

Complementarity-determining region (CDR) implantation: a theme of recombination. Söderlind E, et al. **Immunotechnology** 1999 Mar;4(3-4):279-85 (25 ref.)

Prokaryotic gene fusion expression systems and their use in structural and functional studies of proteins. Sheibani N. **Prep Biochem Biotechnol** 1999 Feb;29(1):77-90 (24 ref.)

Patch engineering: a general approach for creating proteins that have new binding activities. Smith G. **Trends Biochem Sci** 1998 Dec;23(12):457-60 (41 ref.)

Genetic optimization of recombinant glycoprotein production by mammalian cells. Fussenegger M, et al. **Trends Biotechnol** 1999 Jan;17(1):35-42 (121 ref.)

Applying neural networks as software sensors for enzyme engineering. Linko S, et al. **Trends Biotechnol** 1999 Apr; 17(4):155-62 (56 ref.)

[Peptide synthesis aiming at elucidation and creation of protein functions] Futaki S. **Yakugaku Zasshi** 1998 Nov; 118(11):493-510 (46 ref.) (Eng. Abstr.) **(Jpn)**

PROTEIN FOLDING

see related

PROTEIN CONFORMATION

Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Paulson HL. **Am J Hum Genet** 1999 Feb;64(2):339-45 (37 ref.)

Protein disulfide isomerase assists protein folding as both an isomerase and a chaperone. Wang CC. **Ann N Y Acad Sci** 1998 Dec 13;864:9-13 (27 ref.)

Structure and function in GroEL-mediated protein folding. Sigler PB, et al. **Annu Rev Biochem** 1998;67:581-608 (83 ref.)

Membrane protein folding and stability: physical principles. White SH, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:319-65 (188 ref.)

Fast events in protein folding: the time evolution of primary processes. Callender RH, et al. **Annu Rev Phys Chem** 1998; 49:173-202 (130 ref.)

How similar are P450s and what can their differences teach us? Graham SE, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):24-9 (38 ref.)

The protein disulphide-isomerase family: unravelling a string of folds. Ferrari DM, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):1-10 (174 ref.)

Interferon-gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al. **Biochimie** 1998 Aug-Sep;80(8-9):729-37 (49 ref.)

Elementary steps in protein folding. Bieri O, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):923-9 (64 ref.)

Protein structure prediction and design. Morea V, et al. **Biotechnol Annu Rev** 1998;4:177-214 (160 ref.)

From computer simulations to human disease: emerging themes in protein folding. Radford SE, et al. **Cell** 1999 Apr 30;97(3):291-8 (42 ref.)

Biological activity and pathological implications of misfolded proteins. Bellotti V, et al. **Cell Mol Life Sci** 1999 Jun; 55(6-7):977-91 (112 ref.)

Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Göthel SF, et al. **Cell Mol Life Sci** 1999 Mar;55(3):423-36 (96 ref.)

Regulation of p53 protein function through alterations in protein-folding pathways. Hupp TR. **Cell Mol Life Sci** 1999 Jan;55(1):88-95 (77 ref.)

Chimeras of human lysozyme and alpha-lactalbumin: an interesting tool for studying partially folded states during protein folding. Van Dael H. **Cell Mol Life Sci** 1998 Nov; 54(11):1217-30 (104 ref.)

Molecular chaperones: pathways and networks. Ellis RJ. **Curr Biol** 1999 Feb 25;9(4):R137-9 (12 ref.)

Oxidative stress: Protein folding with a novel redox switch. Ruddock LW, et al. **Curr Biol** 1999 Jun 3;9(11):R400-2 (11 ref.)

Molecular chaperones: small heat shock proteins in the limelight. van den IJssel P, et al. **Curr Biol** 1999 Feb 11; 9(3):R103-5 (13 ref.)

Advances in refolding of proteins produced in E. coli. Lilie H, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):497-501 (39 ref.)

Manipulation of single molecules in biology. Wang MD. **Curr Opin Biotechnol** 1999 Feb;10(1):81-6 (60 ref.)

Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579-84 (57 ref.)

Matching theory and experiment in protein folding. Alm E, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):189-96 (69 ref.)

Functionalization of designed folded polypeptides. Baltzer L. **Curr Opin Struct Biol** 1998 Aug;8(4):466-70 (34 ref.)

Membrane protein folding. Booth PJ, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):115-21 (64 ref.)

The fundamentals of protein folding: bringing together theory and experiment. Dobson CM, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):92-101 (86 ref.)

Principles of protein folding in the cellular environment. Ellis RJ, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):102-10 (66 ref.)

New Monte Carlo algorithms for protein folding. Hansmann UH, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):177-83 (84 ref.)

Designing potential energy functions for protein folding. Hao MH, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):184-8 (40 ref.)

Co-translational folding. Hardesty B, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):111-4 (26 ref.)

Deciphering the timescales and mechanisms of protein folding using minimal off-lattice models. Thirumalai D, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):197-207 (91 ref.)

Quality control: from molecules to organelles. Luzikov VN. **FEBS Lett** 1999 Apr 9;448(2-3):201-5 (63 ref.)

How do small single-domain proteins fold? Jackson SE. **Fold Des** 1998;3(4):R81-91 (88 ref.)

Ubiquitin superfolds: intrinsic and attachable regulators of cellular activities? Mayer RJ, et al. **Fold Des** 1998; 3(5):R97-9 (35 ref.)

Folding nucleus: specific or multiple? Insights from lattice models and experiments. Shakhnovich EI. **Fold Des** 1998; 3(6):R108-11; discussion R107 (31 ref.)

Fishing for folding nuclei in lattice models and proteins. Thirumalai D, et al. **Fold Des** 1998;3(6):R112-8; discussion R107 (27 ref.)

Protein folding via binding and vice versa. Tsai CJ, et al. **Fold Des** 1998;3(4):R71-80 (90 ref.)

On the path to the heat shock response: destabilization and formation of partially folded protein intermediates, a consequence of protein thiol modification. Freeman ML, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):737-45 (102

ref.)
The cellular response to protein misfolding in the endoplasmic reticulum. Welihinda AA, et al. **Gene Expr** 1999;7(4–6):293–300 (51 ref.)
The archaeal molecular chaperone machine: peculiarities and paradoxes. Macario AJ, et al. **Genetics** 1999 Aug; 152(4):1277–83 (56 ref.)
Protein misfolding and degradation in genetic diseases. Bross P, et al. **Hum Mutat** 1999;14(3):186–98 (66 ref.)
Supercoiled protein motifs: the collagen triple-helix and the alpha-helical coiled coil. Beck K, et al. **J Struct Biol** 1998; 122(1–2):17–29 (83 ref.)
Nuclear lamins: their structure, assembly, and interactions. Stuurman N, et al. **J Struct Biol** 1998;122(1–2):42–66 (186 ref.)
GroEL/GroES: structure and function of a two-stroke folding machine. Xu Z, et al. **J Struct Biol** 1998 Dec 15; 124(2–3):129–41 (63 ref.)
Misfolded proteins in the endoplasmic reticulum. Perlmutter DH. **Lab Invest** 1999 Jun;79(6):623–38 (150 ref.)
Folding of secretory and membrane proteins. Kuznetsov G, et al. **N Engl J Med** 1998 Dec 3;339(23):1688–95 (69 ref.)
Peroxin puzzles and folded freight: peroxisomal protein import in review. Crookes WJ, et al. **Naturwissenschaften** 1999 Feb;86(2):51–61 (126 ref.)
A tail of protein folding. Villafañe RJ, et al. **P R Health Sci J** 1999 Jun;18(2):105–15 (82 ref.)
Chaperone-mediated protein folding. Fink AL. **Physiol Rev** 1999 Apr;79(2):425–49 (274 ref.)
Searching for "downhill scenarios" in protein folding [comment] Eaton WA. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5897–9 (40 ref.) Comment on: Proc Natl Acad Sci U S A 1999 May 25;96(11):6031–6.
Chaperone rings in protein folding and degradation. Horwich AL, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28; 96(20):11033–40 (80 ref.)
Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease [comment] Lansbury PT Jr. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3342–4 (37 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3590–4.
Folding and binding cascades: shifts in energy landscapes [comment] Tsai CJ, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9970–2 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10118–22.
Stability and folding of domain proteins. Jaenicke R. **Prog Biophys Mol Biol** 1999;71(2):155–241 (400 ref.)
Polymer principles and protein folding. Dill KA. **Protein Sci** 1999 Jun;8(6):1166–80 (103 ref.)
The hydrogen exchange core and protein folding. Li R, et al. **Protein Sci** 1999 Aug;8(8):1571–90 (127 ref.)
Folding funnels, binding funnels, and protein function. Tsai CJ, et al. **Protein Sci** 1999 Jun;8(6):1181–90 (67 ref.)
Review of the fourth Johns Hopkins protein folding meeting. Pappu RV. **Proteins** 1999 Aug 15;36(3):263–9 (42 ref.)
Two crystal structures of N-acetyltransferases reveal a new fold for CoA-dependent enzymes. Modis Y, et al. **Structure** 1998 Nov 15;6(11):1345–50 (3 ref.)
There's a right way and a wrong way: in vivo and in vitro folding, misfolding and subunit assembly of the P22 tailspike. Betts S, et al. **Structure Fold Des** 1999 Jun 15; 7(6):R131–9 (44 ref.)
Glycoproteins: glycan presentation and protein-fold stability. Wormald MR, et al. **Structure Fold Des** 1999 Jul 15; 7(7):R155–60 (35 ref.)
Protein folding in a specialized compartment: the endoplasmic reticulum. Zapun A, et al. **Structure Fold Des** 1999 Aug 15;7(8):R173–82 (88 ref.)
Is protein folding hierarchic? II. Folding intermediates and transition states [published erratum appears in Trends Biochem Sci 1999 May;24(5):185] Baldwin RL, et al. **Trends Biochem Sci** 1999 Feb;24(2):77–83 (49 ref.)
Is protein folding hierarchic? I. Local structure and peptide folding. Baldwin RL, et al. **Trends Biochem Sci** 1999 Jan; 24(1):26–33 (46 ref.)
Protein misfolding, evolution and disease. Dobson CM. **Trends Biochem Sci** 1999 Sep;24(9):329–32 (35 ref.)
Hsp90's secrets unfold: new insights from structural and functional studies. Caplan AJ. **Trends Cell Biol** 1999 Jul; 9(7):262–8 (66 ref.)
Following the leader: bacterial protein export through the Sec pathway. Economou A. **Trends Microbiol** 1999 Aug; 7(8):315–20 (51 ref.)
[Analysis of the unfolded protein response: an intracellular signaling pathway from the endoplasmic reticulum to the nucleus] Mori K. **Seikagaku** 1998 Jul;70(7):505–15 (42 ref.) **(Jpn)**
[Direct promotion of polypeptide folding by asnglycans] Yamaguchi H. **Seikagaku** 1999 Mar;71(3):201–5 (9 ref.) **(Jpn)**

PROTEIN FOLDING, GLOBULAR see **PROTEIN FOLDING**

PROTEIN-FREE MEDIA see **CULTURE MEDIA, SERUM-FREE**

PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE

ANALYSIS

CD34 and factor XIIIa-positive microvascular dendritic cells and the family of fibrohistiocytic mesenchymal tumors [letter; comment] Silverman JS, et al. **Am J Dermatopathol** 1998 Oct;20(5):533–6 (39 ref.) Comment on: Am J Dermatopathol 1996 Jun;18(3):283–8. Comment on: Am J Dermatopathol 1998 Jun;20(3):317–22.

DEFICIENCY

[Deficiency of A or B subunit for coagulation factor XIII] Souri M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):464–7 (14 ref.) **(Jpn)**

IMMUNOLOGY

Identification of the autoantigen of celiac disease. Schuppan D, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:121–6 (21 ref.)
[Tissue transglutaminase as autoantigen in endemic sprue. New aspects in diagnosis and etiopathogenesis] Riecken EO, et al. **Dtsch Med Wochenschr** 1998 Nov 27; 123(48):1454–60 (75 ref.) **(Ger)**

METABOLISM

The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Schalkwijk J, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):569–77 (70 ref.)
Solid-phase ELISA for tissue transglutaminase, an endomysial target for possible serological diagnosis of celiac disease. Freeman HJ. **Can J Gastroenterol** 1998 Jul-Aug;12(5):323–4 (0 ref.)
Transglutaminase-catalyzed protein cross-linking in the molecular program of apoptosis and its relationship to neuronal processes. Fesus L. **Cell Mol Neurobiol** 1998 Dec; 18(6):683–94 (68 ref.)
Tissue transglutaminase: an enzyme with a split personality. Chen JS, et al. **Int J Biochem Cell Biol** 1999 Aug; 31(8):817–36 (156 ref.)
Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. Cooper AJ, et al. **J Neurochem** 1999 Mar;72(3):889–99 (98 ref.)

PHYSIOLOGY

"Tissue" transglutaminase and apoptosis. Autuori F, et al. **Adv Biochem Eng Biotechnol** 1998;62:129–36 (63 ref.)

PROTEIN GLYCOSYLATION see **GLYCOSYLATION**

PROTEIN I see **SYNAPSINS**

PROTEIN III see **SYNAPSINS**

PROTEIN ISOFORMS

ANALYSIS

Multiple isoforms of thyroid hormone receptor: an analysis of their relative contribution in mediating thyroid hormone action. Murata Y. **Nagoya J Med Sci** 1998 Oct; 61(3–4):103–15 (55 ref.)

BIOSYNTHESIS

Differentially expressed GABAA-receptor subunits result in structurally and functionally receptor assemblies following excitatory afferent synaptic transmission. Grayson DR, et al. **Perspect Dev Neurobiol** 1998;5(2–3):193–205 (72 ref.)

BLOOD

[Limitations on the interpretation of prostate-specific antigen serum levels] Sciarra A, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):105–12 (27 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Differentially expressed GABAA-receptor subunits result in structurally and functionally receptor assemblies following excitatory afferent synaptic transmission. Grayson DR, et al. **Perspect Dev Neurobiol** 1998;5(2–3):193–205 (72 ref.)

CLASSIFICATION

The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Hevers W, et al. **Mol Neurobiol** 1998 Aug; 18(1):35–86 (428 ref.)

GENETICS

Isoform sorting and the creation of intracellular compartments. Gunning P, et al. **Annu Rev Cell Dev Biol** 1998;14:339–72 (166 ref.)
Genetically modified animals in pharmacological research: future trends. Rudolph U, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):327–37 (87 ref.)
Early diagnosis and the clinical genetics of Alzheimer's disease. Lovestone S. **J Neurol** 1999 Feb;246(2):69–72 (24 ref.)
Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Nathan CA, et al. **Laryngoscope** 1999 Aug;109(8):1253–8 (18 ref.)
A big gene linked to small eyes encodes multiple Mitf isoforms: many promoters make light work. Yasumoto K, et al. **Pigment Cell Res** 1998 Dec;11(6):329–36 (45 ref.)

IMMUNOLOGY

HLA-G: a tolerance molecule from the major histocompatibility complex. Carosella ED, et al. **Immunol Today** 1999 Feb;20(2):60–2 (22 ref.)

METABOLISM

Post-translational modifications of beta subunits of voltage-dependent calcium channels. Chien AJ, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):377–86 (42 ref.)
Determinants of circulating insulin-like growth factor-I. Hall K, et al. **J Endocrinol Invest** 1999;22(5 Suppl):48–57 (58 ref.)
Why adult mammalian intrafusal and extrafusal fibers contain different myosin heavy-chain isoforms. Walro JM, et al. **Trends Neurosci** 1999 Apr;22(4):180–4 (49 ref.)

PHYSIOLOGY

Photomophogenesis: Phytochrome takes a partner! Whitelam GC, et al. **Curr Biol** 1999 Mar 25;9(6):R225–7 (16 ref.)
Na+-dependent phosphate cotransporters: the NaPi protein families. Werner A, et al. **J Exp Biol** 1998 Dec;201 (Pt 23):3135–42 (61 ref.)
GABAA-receptor subtypes in developing brain. Actors or spectators? Paysan J, et al. **Perspect Dev Neurobiol** 1998; 5(2–3):179–92 (59 ref.)
[Cadherins, the development and regeneration of the neuromuscular axis] Mege RM, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):796–801 (58 ref.) (Eng. Abstr.) **(Fre)**

PROTEIN ISOPRENYLATION

Rapid identification of cysteine-linked isoprenyl groups by metabolic labeling with [3H]farnesol and [3H]geranylgeraniol. Andres DA, et al. **Methods Mol Biol** 1999;116:107–23 (29 ref.)
Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. A useful tool for studying protein prenylation. Corsini A, et al. **Methods Mol Biol** 1999;116:125–44 (37 ref.)
Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. Dudler T, et al. **Methods Mol Biol** 1999;116:161–76 (19 ref.)
Protein prenylation in plants: old friends and new targets. Rodríguez-Concepción M, et al. **Plant Mol Biol** 1999 Mar; 39(5):865–70 (32 ref.)

PROTEIN KINASE A see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

PROTEIN KINASE C

[Structural biology of protein kinase C] Ohno S. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):404–11 (15 ref.) **(Jpn)**

ANALYSIS

Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy. Wang J, et al. **Can J Cardiol** 1999 Jun;15(6):683–90 (50 ref.)
Second messenger pathways in the honeybee brain: immunohistochemistry of protein kinase A and protein kinase C. Müller U. **Microsc Res Tech** 1999 May 1; 45(3):165–73 (57 ref.)

ANTAGONISTS & INHIBITORS

Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Grant S, et al. **Clin Cancer Res** 1996 Dec;2(12):1915–20 (79 ref.)
Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Goekjian PG, et al. **Curr Med Chem** 1999 Sep;6(9):877–903 (182 ref.)
Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Pindur U, et al. **Curr Med Chem** 1999 Jan;6(1):29–69 (79 ref.)
Flavonoids and the inhibition of PKC and PI 3-kinase. Gamet-Payrastre L, et al. **Gen Pharmacol** 1999 Mar; 32(3):279–86 (51 ref.)
Analogs of staurosporine: potential anticancer drugs? Gescher A. **Gen Pharmacol** 1998 Nov;31(5):721–8 (65 ref.)
Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Csukai M, et al. **Pharmacol Res** 1999 Apr;39(4):253–9 (44 ref.)
[PKC 412] Lansiaux A, et al. **Bull Cancer** 1999 Jul-Aug; 86(7–8):614–7 (25 ref.) **(Fre)**

CHEMISTRY

Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Newton

AC, et al. **Biochim Biophys Acta** 1998 Aug 21; 1376(2):155–72 (131 ref.)
Protein kinase C delta. Gschwendt M. **Eur J Biochem** 1999 Feb;259(3):555–64 (138 ref.)
Modular PH and C2 domains in membrane attachment and other functions. Katan M, et al. **FEBS Lett** 1999 Jun 4; 452(1–2):36–40 (61 ref.)
[Structure and function of PKN] Mukai H, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1659–65 (39 ref.) **(Jpn)**

GENETICS

Transcriptional control of the galanin gene. Tissue-specific expression and induction by NGF, protein kinase C, and estrogen. Rökaeus A, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:1–13 (37 ref.)
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji HK, et al. **J Clin Psychiatry** 1999;60 Suppl 2:27–39; discussion 40–1, 113–6 (138 ref.)
Genetic analysis of the role of protein kinase C signaling pathways in behaviors by direct gene transfer with HSV-1 vectors. Geller AI. **Rev Neurosci** 1999;10(1):1–13 (106 ref.)

METABOLISM

Critical targets of protein kinase C in differentiation of tumour cells. Watters DJ, et al. **Biochem Pharmacol** 1999 Aug 1;58(3):383–8 (63 ref.)
Molecular mechanisms of diabetic complications. Aleksandrovski YA. **Biochemistry (Mosc)** 1998 Nov; 63(11):1249–57 (137 ref.)
The sevenfold way of PKC regulation. Liu WS, et al. **Cell Signal** 1998 Sep;10(8):529–42 (171 ref.)
Protein kinases C: potential targets for intervention in diabetic nephropathy. Murphy M, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):563–70 (63 ref.)
Phosphorylation-dependent protein kinase D activation. Waldron RT, et al. **Electrophoresis** 1999 Feb;20(2):382–90 (54 ref.)
Multiple biological responses activated by nuclear protein kinase C. Martelli AM, et al. **J Cell Biochem** 1999 Sep 15;74(4):499–521 (169 ref.)
Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. Kagnoff MF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S444–7 (11 ref.)
Protein kinase C in normal and pathologic myocardial states. Cain BS, et al. **J Surg Res** 1999 Feb;81(2):249–59 (166 ref.)
Subspecies-specific targeting mechanism of protein kinase C. Shirai Y, et al. **Jpn J Pharmacol** 1998 Dec;78(4):411–7 (30 ref.)
Multiple mechanisms involving protein phosphorylation are linked to desensitization of muscarinic receptors. Hosey MM, et al. **Life Sci** 1995;56(11–12):951–5 (23 ref.)
Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity. Hilakivi-Clarke L, et al. **Mol Cell Biochem** 1998 Nov; 188(1–2):5–12 (82 ref.)
The protein kinase C-mediated MAP kinase pathway involved in the maintenance of cellular integrity in Saccharomyces cerevisiae. Heinisch JJ, et al. **Mol Microbiol** 1999 May;32(4):671–80 (64 ref.)
The regulation of neurotransmitter secretion by protein kinase C. Vaughan PF, et al. **Mol Neurobiol** 1998 Oct; 18(2):125–55 (237 ref.)
Protein kinase C--a potential modifier of carotid body function. Faff L, et al. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):172–7 (69 ref.)
Genetic analysis of the role of protein kinase C signaling pathways in behaviors by direct gene transfer with HSV-1 vectors. Geller AI. **Rev Neurosci** 1999;10(1):1–13 (106 ref.)
General anesthetic effects on protein kinase C. Hemmings HC Jr. **Toxicol Lett** 1998 Nov 23;100–101:89–95 (32 ref.)
Ca2+-calmodulin and protein kinase Cs: a hypothetical synthesis of their conflicting convergences on shared substrate domains. Chakravarthy B, et al. **Trends Neurosci** 1999 Jan;22(1):12–6 (38 ref.)

PHYSIOLOGY

PKC-dependent signalling mechanisms in differentiated smooth muscle. Morgan KG, et al. **Acta Physiol Scand** 1998 Dec;164(4):495–505 (112 ref.)
Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Blakely RD, et al. **Biol Psychiatry** 1998 Aug 1;44(3):169–78 (65 ref.)
Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Simkhovich BZ, et al. **Cardiovasc Res** 1998 Oct;40(1):9–22 (115 ref.)
T-cell signal transduction and the role of protein kinase C. Wilkinson SE, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1122–44 (168 ref.)
Signal transduction by protein kinase C in mammalian cells. Kanashiro CA, et al. **Clin Exp Pharmacol Physiol** 1998 Dec; 25(12):974–85 (89 ref.)
Signaling through protein kinase C. Toker A. **Front Biosci** 1998 Nov 1;3:D1134–47 (125 ref.)
The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Park JY, et al. **Perit Dial Int** 1999;19 Suppl 2:S222–7 (29 ref.)
Protein kinase C and IP3 in photoresponses of functionally intact rod outer segments: constraints about their role. Jindrová H, et al. **Physiol Res** 1998;47(4):285–90 (39 ref.)
1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2. Boyan BD, et al. **Steroids** 1999 Jan–Feb;64(1–2):129–36 (63 ref.)
[Structure and function of PKN] Mukai H, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1659–65 (39 ref.) **(Jpn)**

PROTEIN KINASE C(ALPHA) see **PROTEIN KINASE C**

PROTEIN KINASE C(BETA) see **PROTEIN KINASE C**

PROTEIN KINASE C(GAMMA) see **PROTEIN KINASE C**

PROTEIN KINASE PKR see **EIF-2 KINASE**

PROTEIN KINASE, RNA ACTIVATED see **EIF-2 KINASE**

PROTEIN KINASES

[Cofilin phosphorylation and regulation of actin cytoskeletal reorganization by LIM-kinase] Mizuno K. **Seikagaku** 1999 May;71(5):345–50 (21 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Haq R, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):233–9 (57 ref.)
The development and therapeutic potential of protein kinase inhibitors. Cohen P. **Curr Opin Chem Biol** 1999 Aug; 3(4):459–65 (45 ref.)
Bioprobes for investigating mammalian cell cycle control. Osada H. **J Antibiot (Tokyo)** 1998 Nov;51(11):973–82 (62 ref.)
[New anticancer molecules: drugs for tomorrow?] Lavelle F. **Bull Cancer** 1999 Jan;86(1):91–5 (31 ref.) **(Fre)**

BLOOD

Tyrosine kinases in neutrophils. Berton G. **Curr Opin Hematol** 1999 Jan;6(1):51–8 (68 ref.)

CHEMISTRY

Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. Gross SD, et al. **Cell Signal** 1998 Nov;10(10):699–711 (93 ref.)
Atomic force microscopy and other scanning probe microscopies [published erratum appears in Curr Opin Chem Biol 1998 Dec;2(6):767] Hansma HG, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):579–84 (57 ref.)
LIM-kinase1. Stanyon CA, et al. **Int J Biochem Cell Biol** 1999 Mar–Apr;31(3–4):389–94 (16 ref.)
Comparison of human COP9 signalsome and 26S proteasome lid1. Henke W, et al. **Mol Biol Rep** 1999 Apr;26(1–2):29–34 (20 ref.)
Structure and mechanism of action of the histone acetyltransferase Gcn5 and similarity to other N-acetyltransferases [comment] Sternglanz R, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8807–8 (22 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):8931–6.
High energy exchange: proteins that make or break phosphoramidate bonds. Robinson VL, et al. **Structure Fold Des** 1999 Mar 15;7(3):R47–53 (24 ref.)

GENETICS

JNK, cytoskeletal regulator and stress response kinase? A Drosophila perspective. Goberdhan DC, et al. **Bioessays** 1998 Dec;20(12):1009–19 (83 ref.)
Casein kinase I: spatial organization and positioning of a multifuncional protein kinase family. Gross SD, et al. **Cell Signal** 1998 Nov;10(10):699–711 (93 ref.)
The genetics and molecular biology of the titin/connectin-like proteins of invertebrates. Benian GM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:235–68 (119 ref.)
The titin cDNA sequence and partial genomic sequences: insights into the molecular genetics, cell biology and physiology of the titin filament system. Kolmerer B, et al. **Rev Physiol Biochem Pharmacol** 1999;138:19–55 (82 ref.)

METABOLISM

Surface protein phosphorylation by ecto-protein kinases. Role in neuronal development and synaptic plasticity. Ehrlich YH, et al. **Adv Exp Med Biol** 1998;446:51–71 (85 ref.)
Influence of phospholipids and sequential kinase activities on tau in vitro. Shea TB, et al. **Adv Exp Med Biol** 1998; 446:181–201 (84 ref.)
The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Hardie DG, et al. **Annu Rev Biochem** 1998;67:821–55 (151 ref.)
Roles of the AMP-activated/SNF1 protein kinase family in the response to cellular stress. Hardie DG. **Biochem Soc Symp** 1999;64:13–27 (75 ref.)
Protein kinase cascades in intracellular signalling by interleukin-1 and tumour necrosis factor. Saklatvala J, et al. **Biochem Soc Symp** 1999;64:63–77 (65 ref.)
A novel protein kinase target for the lipid second messenger phosphatidic acid. McPhail LC, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):277–90 (208 ref.)
JNK, cytoskeletal regulator and stress response kinase? A Drosophila perspective. Goberdhan DC, et al. **Bioessays** 1998 Dec;20(12):1009–19 (83 ref.)
The stress-activated protein kinase pathways. Tibbles LA, et al. **Cell Mol Life Sci** 1999 Aug 15;55(10):1230–54 (373 ref.)
Histidine kinases and two-component signal transduction systems. Pirrung MC. **Chem Biol** 1999 Jun;6(6):R167–75 (60 ref.)
Activation of protein kinases upon volume changes: role in cellular homeostasis. Shrode LD, et al. **Contrib Nephrol** 1998;123:79–93 (83 ref.)
Light receptor kinases in plants! Fankhauser C, et al. **Curr Biol** 1999 Feb 25;9(4):R123–6 (25 ref.)
Protein modification: docking sites for kinases. Holland PM, et al. **Curr Biol** 1999 May 6;9(9):R329–31 (28 ref.)
Signal transduction: Gyrating protein kinases. Stock J. **Curr Biol** 1999 May 20;9(10):R364–7 (29 ref.)
Two-component signal transduction systems in eukaryotic microorganisms. Loomis WF, et al. **Curr Opin Microbiol** 1998 Dec;1(6):643–8 (37 ref.)
The sigmaE and Cpx regulatory pathways: overlapping but distinct envelope stress responses. Raivio TL, et al. **Curr Opin Microbiol** 1999 Apr;2(2):159–65 (52 ref.)
Challenges in understanding RLK function. Lease K, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):388–92 (27 ref.)
The protein kinase ABC's of signal transduction as targets for drug development. Glazer RI. **Curr Pharm Des** 1998 Jun;4(3):277–90 (207 ref.)
Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic beta-cells. Jones PM, et al. **Endocr Rev** 1998 Aug;19(4):429–61 (361 ref.)
Polo-like kinases: a team that plays throughout mitosis. Glover DM, et al. **Genes Dev** 1998 Dec 15;12(24):3777–87 (72 ref.)
Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. Baines CP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):741–54 (111 ref.)
Organization of kinases, phosphatases, and receptor signaling complexes. Schillace RV, et al. **J Clin Invest** 1999 Mar; 103(6):761–5 (27 ref.)
Comparison of human COP9 signalsome and 26S proteasome lid1. Henke W, et al. **Mol Biol Rep** 1999 Apr;26(1–2):29–34 (20 ref.)
Regulation of neuronal plasticity in the central nervous system by phosphorylation and dephosphorylation. Tokuda M, et al. **Mol Neurobiol** 1998 Winter;17(1–3):137–56 (131 ref.)
Signaling by dual specificity kinases. Dhanasekaran N, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1447–55 (117 ref.)
Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Widmann C, et al. **Physiol Rev** 1999 Jan;79(1):143–80 (409 ref.)
Abnormalities of protein kinases in neurodegenerative diseases. Wagey RT, et al. **Prog Drug Res** 1998;51:133–83 (248 ref.)
Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Klann E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):359–76 (94 ref.)
Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Becker W, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:1–17 (41 ref.)
Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression. Eigenthaler M, et al. **Rev Physiol Biochem Pharmacol** 1999;135:173–209 (151 ref.)
Structure and function of cGMP-dependent protein kinases. Pfeifer A, et al. **Rev Physiol Biochem Pharmacol** 1999; 135:105–49 (201 ref.)
Possible regulation of intermediate filament proteins by Rho-binding kinases. Matsuzawa K, et al. **Subcell Biochem** 1998;31:423–35 (39 ref.)
Dealing with energy demand: the AMP-activated protein kinase. Kemp BE, et al. **Trends Biochem Sci** 1999 Jan; 24(1):22–5 (44 ref.)
Regulation of protein kinase cascades by protein phosphatase 2A. Millward TA, et al. **Trends Biochem Sci** 1999 May; 24(5):186–91 (89 ref.)
Kinase-phosphatase competition regulates Bacillus subtilis development. Perego M. **Trends Microbiol** 1998 Sep; 6(9):366–70 (43 ref.)
[Reversible phosphorylation of catalytic subunit of monovalent cation-transporting ATPases by protein kinases and phosphatases] Kaya S. **Seikagaku** 1999 May; 71(5):341–5 (15 ref.) **(Jpn)**

PHYSIOLOGY

Receptor-mediated signaling pathways: potential targets of modulation by dietary fatty acids. Hwang D, et al. **Am J Clin Nutr** 1999 Oct;70(4):545–56 (82 ref.)
Cytokines, Jaks, Stats, health and disease. Brown MP. **Aust N Z J Med** 1999 Feb;29(1):73–8 (49 ref.)
Signal perception and transduction: the role of protein

PROTEIN KINASES

kinases. Schenk PW, et al. **Biochim Biophys Acta** 1999 Feb 4;1449(1):1–24 (174 ref.)
Protein kinases: which one is the memory molecule? Micheau J, et al. **Cell Mol Life Sci** 1999 Apr;55(4):534–48 (128 ref.)
RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198–200 (12 ref.)
Muscle assembly: a titanic achievement? Gregorio CC, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):18–25 (54 ref.)
Pathophysiological implications of the structural organization of the excitatory synapse. Cattabeni F, et al.
Eur J Pharmacol 1999 Jun 30;375(1–3):339–47 (72 ref.)
Protein kinases in control of the centrosome cycle. Mayor T, et al. **FEBS Lett** 1999 Jun 4;452(1–2):92–5 (48 ref.)
Control of sarcomeric assembly: the flow of information on titin. Gautel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 138:97–137 (173 ref.)
The physiological role of titin in striated muscle. Horowits R. **Rev Physiol Biochem Pharmacol** 1999;138:57–96 (108 ref.)
[Mitogen-activated protein kinase involved in intracellular signal transduction] Li TC, et al.
Sheng Li Ko Hsueh Chin Chan 1996 Jul;27(3):258–60 (10 ref.) **(Chi)**

PROTEIN-LOSING ENTEROPATHIES

ETIOLOGY

[Exudative enteropathy in disseminated lupus erythematosus. Report of 3 cases and review of the literature] Viallard JF, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):485–91 (24 ref.) (Eng. Abstr.) **(Fre)**

PROTEIN METHYLASE I see **PROTEIN-ARGININE N-METHYLTRANSFERASE**

PROTEIN METHYLASES see **PROTEIN METHYLTRANSFERASES**

PROTEIN METHYLTRANSFERASE I see **PROTEIN-ARGININE N-METHYLTRANSFERASE**

PROTEIN METHYLTRANSFERASES

DEFICIENCY

[Characterization of protein isoaspartyl methyltransferase (PIMT)-deficient mice] Shirasawa T. **Seikagaku** 1999 Feb; 71(2):134–40 (11 ref.) **(Jpn)**

METABOLISM

D-amino acids in aging erythrocytes. Ingrosso D, et al. **EXS** 1998;85:119–41 (95 ref.)

PROTEIN MTS1 see **PROTEIN P16**

PROTEIN NMR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

PROTEIN P16

GENETICS

Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma. Bullock GJ, et al. **Am J Surg** 1999 Jan;177(1):15–8 (39 ref.)
For better or worse? Telomerase inhibition and cancer. de Lange T, et al. **Cell** 1999 Aug 6;98(3):273–5 (21 ref.)
The INK4A/ARF locus and its two gene products. Sharpless NE, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):22–30 (81 ref.)
The INK4 family of cell cycle inhibitors in cancer. Roussel MF. **Oncogene** 1999 Sep 20;18(38):5311–7 (72 ref.)
[Inhibitors of cyclins/CDK of the 9p21 chromosomal region and malignant hemopathies] Quesnel B. **Bull Cancer** 1998 Sep;85(9):747–54 (43 ref.) (Eng. Abstr.) **(Fre)**
[Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer] Eres N, et al. **Med Clin (Barc)** 1998 Nov 7; 111(15):592–6 (22 ref.) **(Spa)**

METABOLISM

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. Pavletich NP. **J Mol Biol** 1999 Apr 16; 287(5):821–8 (33 ref.)
The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Chin L, et al.
Trends Biochem Sci 1998 Aug;23(8):291–6 (50 ref.)

PROTEIN P16INK4 see **PROTEIN P16**

PROTEIN P34CDC2

PHYSIOLOGY

Regulating the onset of mitosis. Ohi R, et al.
Curr Opin Cell Biol 1999 Apr;11(2):267–73 (65 ref.)

PROTEIN P53

The challenge of p53: linking biochemistry, biology, and patient management. Bray SE, et al. **Stem Cells** 1998; 16(4):248–60 (121 ref.)

ANALYSIS

Prognostic and predictive value of p53 and p21 in breast cancer. Elledge RM, et al. **Breast Cancer Res Treat** 1998; 52(1–3):79–98 (125 ref.)
Positive staining for p53 and expression of c-erbB-2 in endosalpinx hyperplasia: analysis of 48 cases and review of literature. Rabczyński JK, et al. **Neoplasma** 1999; 46(1):31–4 (17 ref.)

BIOSYNTHESIS

p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Hainaut P, et al. **Pathol Biol (Paris)** 1997 Dec;45(10):833–44 (80 ref.)

CHEMISTRY

The DNA binding regulatory domain of p53: see the C. Wolkowicz R, et al. **Pathol Biol (Paris)** 1997 Dec; 45(10):785–96 (137 ref.)
The p53 tumor suppressor gene: structure, function and mechanism of action. Choisy-Rossi C, et al.
Results Probl Cell Differ 1999;23:145–72 (240 ref.)

GENETICS

Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Roemer K. **Biol Chem** 1999 Jul-Aug; 380(7–8):879–87 (86 ref.)
p53 and p53-regulated genes in bladder cancer [see comments] Keegan PE, et al. **Br J Urol** 1998 Nov; 82(5):710–20 (77 ref.) Comment in: BJU Int 1999 Mar;83(4):529–30.
Mechanisms of p53-mediated apoptosis. Bates S, et al.
Cell Mol Life Sci 1999 Jan;55(1):28–37 (104 ref.)
p53 in embryonic development: maintaining a fine balance. Choi J, et al. **Cell Mol Life Sci** 1999 Jan;55(1):38–47 (63 ref.)
Functions of the MDM2 oncoprotein. Freedman DA, et al. **Cell Mol Life Sci** 1999 Jan;55(1):96–107 (79 ref.)
The dual role model for p53 in maintaining genomic integrity. Janus F, et al. **Cell Mol Life Sci** 1999 Jan;55(1):12–27 (176 ref.)
Introduction: p53--the first twenty years. Oren M, et al.
Cell Mol Life Sci 1999 Jan;55(1):9–11 (19 ref.)
Mechanisms of p53-mediated apoptosis. Ding HF, et al.
Crit Rev Oncog 1998;9(1):83–98 (172 ref.)
p53: prospects for cancer gene therapy. Soddu S, et al.
Cytokines Cell Mol Ther 1998 Sep;4(3):177–85 (66 ref.)
Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. Feitelson MA.
J Hepatobiliary Pancreat Surg 1998;5(4):367–74 (111 ref.)
Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. Ananthaswamy HN, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):52–6 (71 ref.)
The p53 tumor suppressor gene: structure, function and mechanism of action. Choisy-Rossi C, et al.
Results Probl Cell Differ 1999;23:145–72 (240 ref.)
Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Nickells RW. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S151–61 (94 ref.)
[Protein p53 in gastric carcinoma: clinical use of cancer research on neoplasms (editorial)] Starzyńska T.
Pol Merkuriusz Lek 1999 Feb;6(32):61–4 (30 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Comparative anticancer effects of vaccination and dietary factors on experimentally-induced cancers. Zusman I.
In Vivo 1998 Nov-Dec;12(6):675–89 (186 ref.)

METABOLISM

Induction of type I PACAP receptor expression by the new zinc finger protein Zac1 and p53. Hoffmann A, et al.
Ann N Y Acad Sci 1998 Dec 11;865:49–58 (29 ref.)
Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. Kramer DL, et al. **Biochem Soc Trans** 1998 Nov; 26(4):609–14 (25 ref.)
Cancer therapy based on p53. McCormick F.
Cancer J Sci Am 1999 May-Jun;5(3):139–44 (31 ref.)
Signaling to p53: breaking the MDM2-p53 circuit. Prives C. **Cell** 1998 Oct 2;95(1):5–8 (24 ref.)
Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Grilli M, et al. **Cell Death Differ** 1999 Jan;6(1):22–7 (77 ref.)
Regulation of p53 protein function through alterations in protein-folding pathways. Hupp TR. **Cell Mol Life Sci** 1999 Jan;55(1):88–95 (77 ref.)
Covalent and noncovalent modifiers of the p53 protein. Jayaraman L, et al. **Cell Mol Life Sci** 1999 Jan;55(1):76–87 (132 ref.)
Mechanisms of p53-mediated apoptosis. Ding HF, et al.
Crit Rev Oncog 1998;9(1):83–98 (172 ref.)
New developments in the multi-site phosphorylation and integration of stress signalling at p53. Meek DW.
Int J Radiat Biol 1998 Dec;74(6):729–37 (84 ref.)
The emerging p53 gene family. Kaelin WG Jr.
J Natl Cancer Inst 1999 Apr 7;91(7):594–8 (86 ref.)
Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Salvat C, et al. **Mol Biol Rep** 1999 Apr;26(1–2):45–51 (37 ref.)
p53 and the CNS: tumors and developmental abnormalities. Fulci G, et al. **Mol Neurobiol** 1999 Feb;19(1):61–77 (121 ref.)
Could p53 be a target for therapeutic suppression? Komarova EA, et al. **Semin Cancer Biol** 1998;8(5):389–400 (92 ref.)
Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Peller S.
Semin Cancer Biol 1998;8(5):379–87 (95 ref.)

PHYSIOLOGY

p53-oriented cancer therapies: current progress. Gallagher WM, et al. **Ann Oncol** 1999 Feb;10(2):139–50 (144 ref.)
Mechanisms of p53-induced apoptosis. Bennett MR.
Biochem Pharmacol 1999 Oct 1;58(7):1089–95 (80 ref.)
Exploiting the p53 pathway for cancer diagnosis and therapy. Lane DP. **Br J Cancer** 1999 Jul;80 Suppl 1:1–5 (25 ref.)
The p53 tumour suppressor gene. Steele RJ, et al.
Br J Surg 1998 Nov;85(11):1460–7 (87 ref.)
p53 in life and death. Shimamura A, et al.
Clin Cancer Res 1996 Mar;2(3):435–40 (56 ref.)
Negative control elements of the cell cycle in human tumors. Adams PD, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):791–7 (66 ref.)
HIF-1alpha and p53 promote hypoxia-induced delayed neuronal death in models of CNS ischemia. Halterman MW, et al. **Exp Neurol** 1999 Sep;159(1):65–72 (65 ref.)
The complexity of p53 modulation: emerging patterns from divergent signals. Giaccia AJ, et al. **Genes Dev** 1998 Oct 1;12(19):2973–83 (109 ref.)
Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Baas IO, et al. **Histol Histopathol** 1999 Jan;14(1):279–84 (53 ref.)
p53 and cancer therapy: a double-edged sword [comment] McGill G, et al. **J Clin Invest** 1999 Aug;104(3):223–5 (20 ref.) Comment on: J Clin Invest 1999 Aug;104(3):263–9.
The p53 pathway. Prives C, et al. **J Pathol** 1999 Jan; 187(1):112–26 (156 ref.)
The p53 paradox in the pathogenesis of tumor progression. Holden RJ, et al. **Med Hypotheses** 1999 May;52(5):483–5 (26 ref.)
Functional regulative pathways for p53, a protein of basic importance for the integrity of the cell genome. Chiarugi V, et al. **Mol Genet Metab** 1999 Jun;67(2):93–9 (45 ref.)
The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Basu A, et al.
Mol Hum Reprod 1998 Dec;4(12):1099–109 (127 ref.)
Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Amundson SA, et al.
Oncogene 1998 Dec 24;17(25):3287–99 (212 ref.)
Post-translational modification of p53 and the integration of stress signals. Meek DW. **Pathol Biol (Paris)** 1997 Dec; 45(10):804–14 (96 ref.)
Regulation of p53 downstream genes. el-Deiry WS.
Semin Cancer Biol 1998;8(5):345–57 (97 ref.)
p53 and apoptosis. Gottlieb TM, et al. **Semin Cancer Biol** 1998;8(5):359–68 (122 ref.)
Mouse models dissect the role of p53 in cancer and development. Lozano G, et al. **Semin Cancer Biol** 1998; 8(5):337–44 (56 ref.)
p53-dependent cell cycle control: response to genotoxic stress. Schwartz D, et al. **Semin Cancer Biol** 1998; 8(5):325–36 (172 ref.)
Reactivation of mutant p53: a new strategy for cancer therapy. Selivanova G, et al. **Semin Cancer Biol** 1998; 8(5):369–78 (70 ref.)
Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. Choisy-Rossi C, et al. **Toxicol Lett** 1998 Dec 28; 102–103:491–6 (39 ref.)
[Cell cycle regulation after exposure to ionizing radiation] Teyssier F, et al. **Bull Cancer** 1999 Apr;86(4):345–57 (106 ref.) (Eng. Abstr.) **(Fre)**
[The tumor suppressor p53: "guardian of our genomes"] Deppert W. **Med Monatsschr Pharm** 1999 Jun;22(6):166–73 (9 ref.) **(Ger)**

RADIATION EFFECTS

Ultraviolet radiation-induced p53 responses in the epidermis are differentiation-dependent. Tron VA, et al.
J Cutan Med Surg 1999 Jul;3(5):280–3 (43 ref.)

PROTEIN PHOSPHATASE-2B see **CALCINEURIN**

PROTEIN PHOSPHATASES see **PHOSPHOPROTEIN PHOSPHATASE**

PROTEIN PRECURSORS

see related
ENZYME PRECURSORS

ANALYSIS

Procalcitonin in pediatrics: overview and challenge. Chiesa C, et al. **Infection** 1998 Jul-Aug;26(4):236–41 (32 ref.)

BIOSYNTHESIS

Neuroregulation of ProTRH biosynthesis and processing. Nillni EA. **Endocrine** 1999 Jun;10(3):185–99 (208 ref.)
Thymic expression of the pancreatic endocrine hormones. Throsby M, et al. **Neuroimmunomodulation** 1999 Jan–Apr; 6(1–2):108–14 (48 ref.)
An autopsy case of hepatoid carcinoma of the ovary with PIVKA-II production: immunohistochemical study and literature review. Senzaki H, et al. **Pathol Int** 1999 Feb; 49(2):164–9 (22 ref.)

BLOOD

Procalcitonin--a new indicator for bacterial infections. Steinbach G, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):164–7 (36 ref.)
[Procalcitonin: a new marker of bacterial infection. Importance and prospects (editorial)] Bohuon C, et al. **Arch Pediatr** 1999 Feb;6(2):141–4 (23 ref.) **(Fre)**

CHEMISTRY

Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. Deshpande V, et al. **Biochim Biophys Acta** 1999 Mar 19;1430(2):157–78 (226 ref.)
The dermaseptin precursors: a protein family with a common preproregion and a variable C-terminal antimicrobial domain. Amiche M, et al. **FEBS Lett** 1999 Aug 13; 456(3):352–6 (53 ref.)

GENETICS

[Post-translational maturation of proglucagon: variations in tissues and regulation pathways] Bataille D, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:127–40 (45 ref.) **(Fre)**

METABOLISM

Pre-mRNP particles: From gene to nuclear pore. Daneholt B. **Curr Biol** 1999 Jun 3;9(11):R412–5 (19 ref.)
Expression of trichohyalin in skin disorders. Manabe M, et al. **Exp Dermatol** 1999 Aug;8(4):312 (5 ref.)
Protein secretion and possible roles for multiple signal peptidases for precursor processing in bacilli. Bron S, et al. **J Biotechnol** 1998 Sep 17;64(1):3–13 (21 ref.)
Glutamine, as a precursor of glutathione, and oxidative stress. Amores-Sánchez MI, et al. **Mol Genet Metab** 1999 Jun; 67(2):100–5 (47 ref.)
Ilial transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Mason EE. **Obes Surg** 1999 Jun; 9(3):223–8 (35 ref.)
[Processing of mitochondrial protein precursors] Ito A. **Seikagaku** 1998 Dec;70(12):1401–12 (96 ref.) **(Jpn)**

PHYSIOLOGY

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Nauck MA. **Acta Diabetol** 1998 Oct;35(3):117–29 (166 ref.)
Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Brotchie JM, et al. **Adv Neurol** 1998; 78:41–52 (34 ref.)
Is there appetite after GLP-1 and PACAP? Christophe J. **Ann N Y Acad Sci** 1998 Dec 11;865:323–35 (88 ref.)
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)
Pleiotropic changes controlled by the pre-T-cell receptor. von Boehmer H, et al. **Curr Opin Immunol** 1999 Apr; 11(2):135–42 (68 ref.)
Is glucagon-like peptide 1 an incretin hormone? Nauck MA. **Diabetologia** 1999 Mar;42(3):373–9 (67 ref.)
Multiple roles for trichohyalin in the inner root sheath. Steinert PM, et al. **Exp Dermatol** 1999 Aug;8(4):331–2 (10 ref.)
Chloroplast precursor protein translocon. May T, et al. **FEBS Lett** 1999 Jun 4;452(1–2):52–6 (53 ref.)
Thymic expression of neuroendocrine self-peptide precursors: role in T cell survival and self-tolerance. Geenen V, et al. **J Neuroendocrinol** 1998 Nov;10(11):811–22 (137 ref.)
The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Hildt E, et al. **Recent Results Cancer Res** 1998;154:315–29 (50 ref.)
Is Ps4 (prepro-TRH [160–169]) more than an enhancer for thyrotropin-releasing hormone? Pekary AE. **Thyroid** 1998 Oct;8(10):963–8 (41 ref.)
Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Rieger R, et al. **Transfus Clin Biol** 1999 Feb;6(1):7–16 (65 ref.)

SECRETION

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Burcelin R, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:277–85 (42 ref.)

THERAPEUTIC USE

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Nauck MA. **Acta Diabetol** 1998 Oct;35(3):117–29 (166 ref.)
On the treatment of diabetes mellitus with glucagon-like peptide-1. Holst JJ, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:336–43 (37 ref.)
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)

URINE

[Urinary tract infection and biological markers: C-reactive protein, interleukins and procalcitonin] Gendrel D. **Arch Pediatr** 1998;5 Suppl 3:269S–273S (21 ref.) (Eng. Abstr.) **(Fre)**

PROTEIN PRENYLATION see **PROTEIN ISOPRENYLATION**

PROTEIN PROCESSING, POST-TRANSLATIONAL

Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Riordan JR. **Am J Hum Genet** 1999 Jun; 64(6):1499–504 (39 ref.)
The ubiquitin system. Hershko A, et al. **Annu Rev Biochem** 1998;67:425–79 (298 ref.)
Swinging arms in multifunctional enzymes and the specificity of post-translational modification. Perham RN, et al. **Biochem Soc Trans** 1998 Aug;26(3):299–303 (47 ref.)
Characterization of beta-secretase. Stephens DJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):500–4 (21 ref.)
Structure, processing and properties of surfactant protein A. McCormack FX. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):109–31 (191 ref.)
Synthesis, processing and secretion of surfactant proteins B and C. Weaver TE. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):173–9 (42 ref.)
Protein glycosylation in development and disease. Dennis JW, et al. **Bioessays** 1999 May;21(5):412–21 (80 ref.)
Nitrosative and oxidative modulation of iron regulatory proteins. Bouton C. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1043–53 (102 ref.)
S-nitrosylation of proteins. Broillet MC. **Cell Mol Life Sci** 1999 Jul;55(8–9):1036–42 (57 ref.)
Phosphorylation of RNA polymerase II C-terminal domain (CTD): a new control for heat shock gene expression? Dubois MF, et al. **Cell Stress Chaperones** 1998 Sep; 3(3):147–51 (52 ref.)
The polymorphism of acetylcholinesterase: post-translational processing, quaternary associations and localization. Massoulié J, et al. **Chem Biol Interact** 1999 May 14; 119–120:29–42 (59 ref.)
Activation of protein kinases upon volume changes: role in cellular homeostasis. Shrode LD, et al. **Contrib Nephrol** 1998;123:79–93 (83 ref.)
Protein N-glycosylation: molecular genetics and functional significance. Kukuruzinska MA, et al. **Crit Rev Oral Biol Med** 1998;9(4):415–48 (332 ref.)
Intracellular signalling: PDK1--a kinase at the hub of things. Belham C, et al. **Curr Biol** 1999 Feb 11;9(3):R93–6 (21 ref.)
Protein modification: docking sites for kinases. Holland PM, et al. **Curr Biol** 1999 May 6;9(9):R329–31 (28 ref.)
RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198–200 (12 ref.)
Modifying secretion and post-translational processing in insect cells. Ailor E, et al. **Curr Opin Biotechnol** 1999 Apr; 10(2):142–5 (44 ref.)
Co- and posttranslational modifications and functions of Marburg virus proteins. Becker S, et al. **Curr Top Microbiol Immunol** 1999;235:23–34 (53 ref.)
Isolation and identification of naturally modified C-C chemokines MCP-1, MCP-2 and RANTES: effects of posttranslational modifications on receptor usage, chemotactic and anti-HIV-1 activity. Proost P, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):73–5 (17 ref.)
Post-translationally modified neuropeptides from Conus venoms. Craig AG, et al. **Eur J Biochem** 1999 Sep; 264(2):271–5 (46 ref.)
Biosynthesis of D-amino acid-containing peptides: exploring the role of peptide isomerases. Volkmann RA, et al. **EXS** 1998;85:87–105 (65 ref.)
Post-translational modifications of beta subunits of voltage-dependent calcium channels. Chien AJ, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):377–86 (42 ref.)
Protein secretion and possible roles for multiple signal peptidases for precursor processing in bacilli. Bron S, et al. **J Biotechnol** 1998 Sep 17;64(1):3–13 (21 ref.)
Molecular mechanisms for the regulation of the expression and function of muscarinic acetylcholine receptors. Hamilton SE, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3–4):275–8 (15 ref.)
Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, and posttranslational levels. Kühn H, et al. **Lipids** 1999;34 Suppl:S273–9 (34 ref.)
Age-related chemical modification of the skeletal muscle sarcoplasmic reticulum Ca-ATPase of the rat. Schöneich C, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):221–31 (69 ref.)
Evidence for age-related deamidation reactions in erythrocyte p55 and glycophorins C and D: implications for signal transduction involving tumour-suppressor proteins in higher eukaryotes. Lofthouse JT. **Med Hypotheses** 1998 Oct;51(4):321–4 (14 ref.)
The measurement of processivity errors in protein synthesis. Dong H. **Methods Mol Biol** 1998;77:33–42 (13 ref.)
Preparation and assay of myristoyl-CoA:protein N-myristoyltransferase. Raju RV, et al. **Methods Mol Biol** 1999;116:193–211 (31 ref.)
Thiazole and oxazole peptides: biosynthesis and molecular machinery. Roy RS, et al. **Nat Prod Rep** 1999 Apr; 16(2):249–63 (124 ref.)
Potassium channels: some assembly required. Papazian DM. **Neuron** 1999 May;23(1):7–10 (20 ref.)
Post-translational modification of p53 and the integration of stress signals. Meek DW. **Pathol Biol (Paris)** 1997 Dec; 45(10):804–14 (96 ref.)
Vasopressin processing defects in the Brattleboro rat: implications for hereditary central diabetes insipidus in humans? Kim JK, et al. **Proc Assoc Am Physicians** 1998 Sep-Oct;110(5):380–6 (42 ref.)
Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7723–30 (83 ref.)
Histone acetyltransferase complexes [see comments] Grant PA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):169–77 (95 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.
Histone deacetylases: complex transducers of nuclear signals [see comments] Johnson CA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):179–88 (80 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.
Histone acetylation in signal transduction by growth regulatory signals [see comments] Magnaghi-Jaulin L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):197–203 (105 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.
High energy exchange: proteins that make or break phosphoramidate bonds. Robinson VL, et al. **Structure Fold Des** 1999 Mar 15;7(3):R47–53 (24 ref.)
The enzymatic biotinylation of proteins: a post-translational modification of exceptional specificity. Chapman-Smith A, et al. **Trends Biochem Sci** 1999 Sep;24(9):359–63 (32 ref.)
[Molecular signals in protein sorting in epithelial cells: implication of the transmembrane domain and the post-translational process] Ait Slimane T, et al. **J Soc Biol** 1999;193(2):125–30 (53 ref.) (Eng. Abstr.) **(Fre)**
[Post-translational maturation of proglucagon: variations in tissues and regulation pathways] Bataille D, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:127–40 (45 ref.) **(Fre)**

PHYSIOLOGY

Organization and regulation of mitogen-activated protein kinase signaling pathways. Garrington TP, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):211–8 (58 ref.)
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Leevers SJ, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):219–25 (54 ref.)
Post-translational processing of insulin-like growth factors. Duguay SJ. **Horm Metab Res** 1999 Feb-Mar;31(2–3):43–9 (63 ref.)

PROTEIN-RESTRICTED DIET see **DIET, PROTEIN-RESTRICTED**

PROTEIN S

GENETICS

Inherited combined deficiency of proteins C and S [letter] Ozbek N, et al. **Eur J Haematol** 1999 Aug;63(2):138–9 (7 ref.)

PROTEIN S DEFICIENCY

[Inherited protein S deficiency] Suzuki K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):15–9 (12 ref.) **(Jpn)**

COMPLICATIONS

Myocardial infarction and death after caesarean section in a woman with protein S deficiency and undiagnosed phaeochromocytoma. Zangrillo A, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):268–70 (9 ref.)
Mesenteric venous thrombosis in protein S deficiency: case report and literature review. Lau LL, et al. **Ulster Med J** 1999 May;68(1):33–5 (10 ref.)

GENETICS

Inherited combined deficiency of proteins C and S [letter] Ozbek N, et al. **Eur J Haematol** 1999 Aug;63(2):138–9 (7 ref.)

PROTEIN-SERINE-THREONINE KINASES

[Protein kinase PKN] Mukai H, et al. **Seikagaku** 1998 Nov; 70(11):1335–9 (16 ref.) **(Jpn)**

CHEMISTRY

Plant MAP kinase kinase kinases structure, classification and

evolution. Jouannic S, et al. **Gene** 1999 Jun 11;233(1-2):1-11 (58 ref.)
Phosphatidylinositol phosphate kinase: a link between protein kinase and glutathione synthase folds. Grishin NV. **J Mol Biol** 1999 Aug 13;291(2):239-47 (31 ref.)
Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Greenwald J, et al. **Nat Struct Biol** 1999 Jan;6(1):18-22 (29 ref.)

GENETICS

The serine, threonine, and/or tyrosine-specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait. Shi L, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):229-53 (98 ref.)
Molecular surface sequence analysis of several E. coli enzymes and implications for existence of casein kinase-2 bacterial predecessor. Torshin I. **Front Biosci** 1999 Apr 1;4:D394-407 (51 ref.)
Murine protein kinase CK2: gene and oncogene. Xu X, et al. **Mol Cell Biochem** 1999 Jan;191(1-2):65-74 (53 ref.)
[Effect on gene expression of the expanded CTG repeat on 3'-untranslated region of myotonic dystrophy (DM) protein kinase] Furuya H, et al. **Nippon Rinsho** 1999 Apr; 57(4):932-6 (20 ref.) (Eng. Abstr.) **(Jpn)**
[DM pathogenesis and expansion of CTG trinucleotide repeat within 3' untranslated region of DMPK gene] Takahashi N, et al. **Nippon Rinsho** 1999 Apr;57(4):937-42 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

G protein-coupled receptor kinases. Pitcher JA, et al. **Annu Rev Biochem** 1998;67:653-92 (255 ref.)
DNA-dependent protein kinase and related proteins. Smith GC, et al. **Biochem Soc Symp** 1999;64:91-104 (69 ref.)
Regulation of the DNA-dependent protein kinase (DNA-PK) activity in eukaryotic cells. Muller C, et al. **Biochimie** 1999 Jan-Feb;81(1-2):117-25 (95 ref.)
Cellular response to DNA damage. Link between p53 and DNA-PK. Salles-Passador I, et al. **C R Acad Sci III** 1999 Feb-Mar;322(2-3):113-20 (103 ref.)
Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? Bokoch GM. **Cell Death Differ** 1998 Aug;5(8):637-45 (82 ref.)
Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Ben-Levy R, et al. **Curr Biol** 1998 Sep 24;8(19):1049-57 (42 ref.)
Serine/threonine protein kinases and phosphatases in filamentious fungi. Dickman MB, et al. **Fungal Genet Biol** 1999 Mar;26(2):99-117 (65 ref.)
The DNA-dependent protein kinase. Smith GC, et al. **Genes Dev** 1999 Apr 15;13(8):916-34 (234 ref.)
Integrin-linked kinase and associated proteins (review). Huang Y, et al. **Int J Mol Med** 1999 Jun;3(6):563-72 (153 ref.)
Signaling by the germinal center kinase family of protein kinases. Kyriakis JM. **J Biol Chem** 1999 Feb 26; 274(9):5259-62 (55 ref.)
Promiscuous subunit interactions: a possible mechanism for the regulation of protein kinase CK2. Allende CC, et al. **J Cell Biochem Suppl** 1998;30-31:129-36 (37 ref.)
Insulin signal transduction through protein kinase cascades. Avruch J. **Mol Cell Biochem** 1998 May;182(1-2):31-48 (211 ref.)
Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. Zandi E, et al. **Mol Cell Biol** 1999 Jul;19(7):4547-51 (48 ref.)
Signaling by dual specificity kinases. Dhanasekaran N, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1447-55 (117 ref.)
Stress-activated kinases regulate protein stability. Fuchs SY, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1483-90 (87 ref.)
Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Widmann C, et al. **Physiol Rev** 1999 Jan;79(1):143-80 (409 ref.)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Cantley LC, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4240-5 (76 ref.)
Rac and Cdc42 effectors. Boettner B, et al. **Prog Mol Subcell Biol** 1999;22:135-58 (129 ref.)
p21-activated protein kinase: a crucial component of morphological signaling? Daniels RH, et al. **Trends Biochem Sci** 1999 Sep;24(9):350-5 (50 ref.)
First the CDKs, now the DDKs. Johnston LH, et al. **Trends Cell Biol** 1999 Jul;9(7):249-52 (30 ref.)

PHYSIOLOGY

AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Winder WW, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E1-10 (91 ref.)
Rho-associated kinase: involvement in the cytoskeleton regulation. Redowicz MJ. **Arch Biochem Biophys** 1999 Apr 1;364(1):122-4 (17 ref.)
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Coffer PJ, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):1-13 (129 ref.)
DNA-dependent protein kinase gets a break: its role in repairing DNA and maintaining genomic integrity. Featherstone C, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:14-9 (62 ref.)
The cdk-activating kinase (CAK): from yeast to mammals. Kaldis P. **Cell Mol Life Sci** 1999 Feb;55(2):284-96 (149 ref.)
Intracellular signalling: PDK1--a kinase at the hub of things. Belham C, et al. **Curr Biol** 1999 Feb 11;9(3):R93-6 (21 ref.)
Polo-like kinases: positive regulators of cell division from start to finish. Nigg EA. **Curr Opin Cell Biol** 1998 Dec; 10(6):776-83 (66 ref.)
HIV-1 Tat: coping with negative elongation factors. Garber ME, et al. **Curr Opin Immunol** 1999 Aug;11(4):460-5 (40 ref.)
Protein kinase CK2 and its role in cellular proliferation, development and pathology. Guerra B, et al. **Electrophoresis** 1999 Feb;20(2):391-408 (171 ref.)
The TAO of MEKK. Schlesinger TK, et al. **Front Biosci** 1998 Nov 15;3:D1181-6 (50 ref.)
Integrin-linked kinase and associated proteins (review). Huang Y, et al. **Int J Mol Med** 1999 Jun;3(6):563-72 (153 ref.)
Promiscuous subunit interactions: a possible mechanism for the regulation of protein kinase CK2. Allende CC, et al. **J Cell Biochem Suppl** 1998;30-31:129-36 (37 ref.)
Ku, a DNA repair protein with multiple cellular functions? Featherstone C, et al. **Mutat Res** 1999 May 14;434(1):3-15 (93 ref.)
Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Terada Y, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:45-7 (7 ref.)
Roles of PAK family kinases. Manser E, et al. **Prog Mol Subcell Biol** 1999;22:115-33 (95 ref.)
Pak to the future [see comments] Bagrodia S, et al. **Trends Cell Biol** 1999 Sep;9(9):350-5 (55 ref.) Comment in: Trends Cell Biol 1999 Sep;9(9):355.
Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Dedhar S, et al. **Trends Cell Biol** 1999 Aug;9(8):319-23 (38 ref.)
[DNA-dependent protein kinase (DNA-PK), a key enzyme in the re-ligation of double-stranded DNA breaks] Hennequin C, et al. **Cancer Radiother** 1999 Jul-Aug; 3(4):289-95 (62 ref.) (Eng. Abstr.) **(Fre)**
[Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration] Ishiguro K. **Rinsho Byori** 1998 Oct; 46(10):1003-7 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction through receptor serine/threonine kinases and its regulation] Tsuchida K. **Seikagaku** 1998 Dec;70(12):1430-5 (14 ref.) **(Jpn)**

PROTEIN SPLICING

Putting protein splicing to work. Gimble FS. **Chem Biol** 1998 Oct;5(10):R251-6 (19 ref.)

PHYSIOLOGY

A natural example of protein trans-splicing. Perler FB. **Trends Biochem Sci** 1999 Jun;24(6):209-11 (27 ref.)

PROTEIN STRUCTURE

Remarks about protein structure precision [published erratum appears in Acta Crystallogr D Biol Crystallogr 1999 May;55(5):1108] Cruickshank DW. **Acta Crystallogr D Biol Crystallogr** 1999 Mar;55 (Pt 3):583-601 (61 ref.)
Databases in protein crystallography. Kleywegt GJ, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Nov 1;54(1 (Pt 6)):1119-31 (78 ref.)
Expanding the model: anisotropic displacement parameters in protein structure refinement. Merritt EA. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1109-17 (44 ref.)
Design of protein function by physical perturbation method. Kidokoro S. **Adv Biophys** 1998;35:121-43 (18 ref.)
Nitroxide spin-spin interactions: applications to protein structure and dynamics. Hustedt EJ, et al. **Annu Rev Biophys Biomol Struct** 1999;28:129-53 (71 ref.)
Towards structural genomics for transmembrane proteins. Jones DT, et al. **Biochem Soc Trans** 1998 Aug;26(3):429-38 (35 ref.)
Presenilins--in search of functionality. Karran EH, et al. **Biochem Soc Trans** 1998 Aug;26(3):491-6 (48 ref.)
Binding of bee venom and human group IIa phospholipases A2 to membranes: a minor role for electrostatics. Lin Y, et al. **Biochem Soc Trans** 1998 Aug;26(3):341-5 (30 ref.)
Are there molecules of nucleoprotamine? Raukas E, et al. **Bioessays** 1999 May;21(5):440-8 (68 ref.)
Contemporary approaches to protein structure classification. Swindells MB, et al. **Bioessays** 1998 Nov;20(11):884-91 (53 ref.)
The Ca2+ pumps and the Na+/Ca2+ exchangers. Guerini D. **Biometals** 1998 Dec;11(4):319-30 (116 ref.)
Structures of EF-hand Ca(2+)-binding proteins: diversity in the organization, packing and response to Ca2+ binding. Nelson MR, et al. **Biometals** 1998 Dec;11(4):297-318 (98 ref.)
Src homology-2 domains: structure, mechanisms, and drug discovery. Sawyer TK. **Biopolymers** 1998;47(3):243-61 (44 ref.)
Predicting structures for genome proteins. Fischer D, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):208-11 (22 ref.)
Analytical techniques used to study the degradation of proteins and peptides: physical instability. Reubsaet JL, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):979-84 (44 ref.)
Structural genomics: beyond the human genome project. Burley SK, et al. **Nat Genet** 1999 Oct;23(2):151-7 (21 ref.)
Protein dynamics and photon echoes. Fleming GR. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15161-2 (13 ref.)
The structure of iron-sulfur proteins. Sticht H, et al. **Prog Biophys Mol Biol** 1998;70(2):95-136 (296 ref.)
Alpha-crystallin as a molecular chaperone. Derham BK, et al. **Prog Retin Eye Res** 1999 Jul;18(4):463-509 (306 ref.)
Structure calculation of biological macromolecules from NMR data. Güntert P. **Q Rev Biophys** 1998 May; 31(2):145-237 (218 ref.)
Global optimization of clusters, crystals, and biomolecules. Wales DJ, et al. **Science** 1999 Aug 27;285(5432):1368-72 (63 ref.)

PROTEIN STRUCTURE, PRIMARY see **AMINO ACID SEQUENCE**

PROTEIN STRUCTURE, QUATERNARY see **PROTEIN CONFORMATION**

PROTEIN STRUCTURE, SECONDARY

Structural aspects of transmembrane alpha-helices. von Heijne G. **Acta Physiol Scand Suppl** 1998 Aug;643:17-9 (6 ref.)
Structure-mutation analysis of the ATPase site of Dictyostelium discoideum myosin II. Sasaki N, et al. **Adv Biophys** 1998;35:1-24 (25 ref.)
A putative alpha-helical G beta gamma-coupling domain in the second intracellular loop of the 5-HT1A receptor. Albert PR, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:146-61 (72 ref.)
Solution structure comparison of the VIP/PACAP family of peptides by NMR spectroscopy. Wray V, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:37-44 (17 ref.)
How similar are P450s and what can their differences teach us? Graham SE, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):24-9 (38 ref.)
The pyrroloquinoline quinone (PQQ)-containing quinoprotein dehydrogenases. Anthony C. **Biochem Soc Trans** 1998 Aug;26(3):413-7 (30 ref.)
Studies on the structure of a transmembrane region and a cytoplasmic loop of the human red cell anion exchanger (band 3, AE1). Chambers EJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):516-20 (40 ref.)
How cytidylyltransferase uses an amphipathic helix to sense membrane phospholipid composition. Cornell RB. **Biochem Soc Trans** 1998 Aug;26(3):539-44 (38 ref.)
Helical structure and dynamics in membrane polypeptides. Dempsey CE, et al. **Biochem Soc Trans** 1998 Aug; 26(3):444-50 (37 ref.)
Structural bases for the catalytic mechanism of [NiFe] hydrogenases. Garcin E, et al. **Biochem Soc Trans** 1998 Aug;26(3):396-401 (22 ref.)
The membrane-integral domain of succinate:quinone oxidoreductases--a secretive haem-containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408-13 (33 ref.)
The effects of phospholipid structure on the function of a calcium pump. Lee AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):359-65 (28 ref.)
Swinging arms in multifunctional enzymes and the specificity of post-translational modification. Perham RN, et al. **Biochem Soc Trans** 1998 Aug;26(3):299-303 (47 ref.)
Mechanistic aspects of energy coupling in the Escherichia coli mannitol phosphotransferase system: a domain approach. Robillard GT, et al. **Biochem Soc Trans** 1998 Aug;26(3):532-8 (15 ref.)
Modelling the packing of transmembrane helices: application to aquaporin-1. Sansom MS, et al. **Biochem Soc Trans** 1998 Aug;26(3):509-15 (30 ref.)
Molecular dynamics simulations of membranes with embedded proteins and peptides: porin, alamethicin and influenza virus M2. Sansom MS, et al. **Biochem Soc Trans** 1998 Aug;26(3):438-43 (27 ref.)
Structure and mechanism of enzymes involved in the assembly of the tetrapyrrole macrocycle. Shoolingin-Jordan PM. **Biochem Soc Trans** 1998 Aug; 26(3):326-36 (43 ref.)
Three-dimensional models of glutamate receptors. Sutcliffe MJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):450-8 (50 ref.)
Structure of the G-protein-coupled receptor, rhodopsin: a domain approach. Yeagle PL, et al. **Biochem Soc Trans** 1998 Aug;26(3):520-31 (70 ref.)
New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Heizmann CW, et al. **Biometals** 1998 Dec;11(4):383-97 (160 ref.)
Classification and evolution of EF-hand proteins. Kawasaki H, et al. **Biometals** 1998 Dec;11(4):277-95 (75 ref.)
Annexins. Seaton BA, et al. **Biometals** 1998 Dec; 11(4):399-404 (54 ref.)
Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Oren Z, et al. **Biopolymers** 1998; 47(6):451-63 (152 ref.)

DNA recognition by beta-sheets. Tateno M, et al. **Biopolymers** 1997;44(4):335-59 (44 ref.)
DNA recognition and nucleosome organization. Travers A, et al. **Biopolymers** 1997;44(4):423-33 (70 ref.)
Minimal model systems for beta sheet secondary structure in proteins. Gellman SH. **Curr Opin Chem Biol** 1998 Dec; 2(6):717-25 (45 ref.)
Secondary structure and protein deamidation. Xie M, et al. **J Pharm Sci** 1999 Jan;88(1):8-13 (31 ref.)
Congenital myasthenic syndromes: experiments of nature. Engel AG, et al. **J Physiol Paris** 1998 Apr;92(2):113-7 (25 ref.)
Scanning mutagenesis of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor. Hulme EC, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):269-74 (15 ref.)
Allosteric nicotinic receptors, human pathologies. Léna C, et al. **J Physiol Paris** 1998 Apr;92(2):63-74 (112 ref.)
Supercoiled protein motifs: the collagen triple-helix and the alpha-helical coiled coil. Beck K, et al. **J Struct Biol** 1998; 122(1-2):17-29 (83 ref.)
GroEL/GroES: structure and function of a two-stroke folding machine. Xu Z, et al. **J Struct Biol** 1998 Dec 15; 124(2-3):129-41 (63 ref.)
The structure of iron-sulfur proteins. Sticht H, et al. **Prog Biophys Mol Biol** 1998;70(2):95-136 (296 ref.)
Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. O'Reilly EK, et al. **Virology** 1998 Dec 20;252(2):287-303 (80 ref.)

PROTEIN STRUCTURE, TERTIARY

The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Beamer LJ, et al. **Biochem Pharmacol** 1999 Feb 1; 57(3):225-9 (34 ref.)
The modular nature of apoptotic signaling proteins. Hofmann K. **Cell Mol Life Sci** 1999 Jul;55(8-9):1113-28 (108 ref.)
Scanning mutagenesis of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor. Hulme EC, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):269-74 (15 ref.)
Acetylcholinesterase: C-terminal domains, molecular forms and functional localization. Massoulié J, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):183-90 (59 ref.)
Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Bustin M. **Mol Cell Biol** 1999 Aug;19(8):5237-46 (130 ref.)
The DNA binding regulatory domain of p53: see the C. Wolkowicz R, et al. **Pathol Biol (Paris)** 1997 Dec; 45(10):785-96 (137 ref.)

PROTEIN SYNTHESIS ANTAGONISTS see **PROTEIN SYNTHESIS INHIBITORS**

PROTEIN SYNTHESIS INHIBITORS

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP, et al. **Toxicol Pathol** 1999 Jan-Feb; 27(1):95-100 (35 ref.)

ADVERSE EFFECTS

Lack of evidence for systemic toxicity following topical chloramphenicol use. Walker S, et al. **Eye** 1998;12 (Pt 5):875-9 (38 ref.)

PROTEIN TP53 see **PROTEIN P53**

PROTEIN-TYROSINE KINASE

see related
ONCOGENE PROTEIN PP60(V-SRC)
SRC HOMOLOGY DOMAINS

[Bruton's tyrosine kinase: what's known now] Kawakami T, et al. **Seikagaku** 1998 Oct;70(10):1262-6 (15 ref.) **(Jpn)**
[Protein kinase PKN] Mukai H, et al. **Seikagaku** 1998 Nov; 70(11):1335-9 (16 ref.) **(Jpn)**
[Non-receptor protein tyrosine kinase CAK beta/PYK2] Sasaki T, et al. **Tanpakushitsu Kakusan Koso** 1999 Feb; 44(2):112-22 (32 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Kim H, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1418S-1425S (102 ref.)
Tyrosine kinase inhibitors in chronic myeloid leukemia. Sawyers CL, et al. **Cancer J Sci Am** 1999 Mar-Apr; 5(2):63-9 (66 ref.)
The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Bridges AJ. **Curr Med Chem** 1999 Sep;6(9):825-43 (122 ref.)
Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Ruggeri BA, et al. **Curr Med Chem** 1999 Sep;6(9):845-57 (104 ref.)
The structure-based design of ATP-site directed protein kinase inhibitors. Toledo LM, et al. **Curr Med Chem** 1999 Sep;6(9):775-805 (158 ref.)

CHEMISTRY

Protein tyrosine kinases: structure, substrate specificity, and drug discovery. al-Obeidi FA, et al. **Biopolymers** 1998; 47(3):197-223 (198 ref.)
Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Girault JA, et al. **Mol Med** 1998 Dec;4(12):751-69 (137 ref.)
Regulation of antigen receptor function by protein tyrosine kinases. Bubeck-Wardenburg J, et al. **Prog Biophys Mol Biol** 1999;71(3-4):373-92 (126 ref.)
Recognition and regulation of primary-sequence motifs by signaling modular domains. Songyang Z. **Prog Biophys Mol Biol** 1999;71(3-4):359-72 (93 ref.)
The N-termini of FAK and JAKs contain divergent band 4.1 domains. Girault JA, et al. **Trends Biochem Sci** 1999 Feb;24(2):54-7 (25 ref.)

GENETICS

The serine, threonine, and/or tyrosine-specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait. Shi L, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):229-53 (98 ref.)
Signaling through focal adhesion kinase. Schlaepfer DD, et al. **Prog Biophys Mol Biol** 1999;71(3-4):435-78 (249 ref.)
ZAP-70 and defects of T-cell receptor signaling. Elder ME. **Semin Hematol** 1998 Oct;35(4):310-20 (62 ref.)

METABOLISM

Analysis of transmembrane signalling and T cell defects associated with idiopathic thrombocytopenic purpura (ITP). Lazarus AH, et al. **Acta Paediatr Suppl** 1998 Jun; 424:21-5 (29 ref.)
Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset [published erratum appears in Adv Anat Pathol 1998 Nov;5(6):399] Chan JK. **Adv Anat Pathol** 1998 Sep;5(5):281-313 (83 ref.)
Protein tyrosine kinases: structure, substrate specificity, and drug discovery. al-Obeidi FA, et al. **Biopolymers** 1998; 47(3):197-223 (198 ref.)
Protein tyrosine kinase-mediated pathways in G protein-coupled receptor signaling. Dikic I, et al. **Cell Biochem Biophys** 1999;30(3):369-87 (84 ref.)
Bruton's tyrosine kinase controls a sustained calcium signal essential for B lineage development and function. Rawlings DJ. **Clin Immunol** 1999 Jun;91(3):243-53 (116 ref.)
STAT structure and function in signaling. Hoey T, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):582-7 (51 ref.)
Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma. Hsueh RC, et al. **Curr Top Microbiol Immunol** 1999; 246:299-304; discussion 305 (14 ref.)
Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. Inagami T, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S57-61 (23 ref.)
Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. Darnell JE Jr. **J Interferon Cytokine Res** 1998 Aug;18(8):549-54 (64 ref.)
Functions of Bruton's tyrosine kinase in mast and B cells. Kawakami Y, et al. **J Leukoc Biol** 1999 Mar;65(3):286-90 (46 ref.)
Integrin signaling: tyrosine phosphorylation events in focal adhesions. Vuori K. **J Membr Biol** 1998 Oct 1;165(3):191-9 (125 ref.)
Regulation of megakaryocytopoiesis and platelet production by tyrosine kinases and tyrosine phosphatases. Avraham H, et al. **Methods** 1999 Mar;17(3):250-64 (131 ref.)
Induction of intracellular signals through binding of adhesive molecules. Activation of p125FAK tyrosine phosphorylation. Venturino M, et al. **Methods Mol Biol** 1999;96:191-8 (12 ref.)
Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Girault JA, et al. **Mol Med** 1998 Dec;4(12):751-69 (137 ref.)
Signaling by dual specificity kinases. Dhanasekaran N, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1447-55 (117 ref.)
Antigen receptor signaling: integration of protein tyrosine kinase functions. Tamir I, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1353-64 (203 ref.)
Regulation of antigen receptor function by protein tyrosine kinases. Bubeck-Wardenburg J, et al. **Prog Biophys Mol Biol** 1999;71(3-4):373-92 (126 ref.)
Signaling through focal adhesion kinase. Schlaepfer DD, et al. **Prog Biophys Mol Biol** 1999;71(3-4):435-78 (249 ref.)
The STAT family of proteins in cytokine signaling. Shuai K. **Prog Biophys Mol Biol** 1999;71(3-4):405-22 (117 ref.)
Recognition and regulation of primary-sequence motifs by signaling modular domains. Songyang Z. **Prog Biophys Mol Biol** 1999;71(3-4):359-72 (93 ref.)
Down-modulation of IL-2-triggered JAK3-STAT5 signaling following CD4-ligand binding. Lowry RP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):820-1 (16 ref.)
FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? Girault JA, et al. **Trends Neurosci** 1999 Jun;22(6):257-63 (100 ref.)
[Tyrosine kinases of the Src family, enzymes with multiple functions: from the growth of fibroblasts to the migration of epithelial cells] Roche S. **C R Seances Soc Biol Fil** 1998; 192(2):357-65 (18 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Potential roles for focal adhesion kinase in development. Ridyard MS, et al. **Anat Embryol (Berl)** 1999 Jan;199(1):1-7 (89 ref.)
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Coffer PJ, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):1-13 (129 ref.)
Negative regulation of the JAK/STAT pathway. Starr R, et al. **Bioessays** 1999 Jan;21(1):47-52 (44 ref.)
Conspiracy theory: RAS and RAF do not act alone. Sternberg PW, et al. **Cell** 1998 Nov 13;95(4):447-50 (17 ref.)
Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Luttrell LM, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):177-83 (56 ref.)
The CIS family: negative regulators of JAK-STAT signaling. Yoshimura A. **Cytokine Growth Factor Rev** 1998 Sep-Dec; 9(3-4):197-204 (46 ref.)
Tyrosine kinase substrates in interleukin-2 signaling. Gesbert F, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):33-40 (70 ref.)
Focal adhesion kinase in integrin-mediated signaling. Cary LA, et al. **Front Biosci** 1999 Jan 15;4:D102-13 (142 ref.)
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Kornberg LJ. **Head Neck** 1998 Dec;20(8):745-52 (52 ref.)
Receptor-operated calcium influx mediated by protein tyrosine kinase pathways. Tsunoda Y. **J Recept Signal Transduct Res** 1998 Jul-Nov; 18(4-6):281-310 (126 ref.)
Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kamanna VS, et al. **Kidney Int Suppl** 1999 Jul;71:S70-5 (23 ref.)
Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection. Mahlmann S, et al. **Leukemia** 1998 Dec; 12(12):1858-65 (77 ref.)
The CIS/JAB family: novel negative regulators of JAK signaling pathways. Yoshimura A. **Leukemia** 1998 Dec; 12(12):1851-7 (47 ref.)
Janus kinases and their role in growth and disease. Aringer M, et al. **Life Sci** 1999;64(24):2173-86 (111 ref.)
Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Terada Y, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:45-7 (7 ref.)
Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Carter-Su C, et al. **Recent Prog Horm Res** 1998;53:61-82; discussion 82-3 (78 ref.)
Signalling of Bruton's tyrosine kinase, Btk. Mohamed AJ, et al. **Scand J Immunol** 1999 Feb;49(2):113-8 (63 ref.)
ZAP-70 and defects of T-cell receptor signaling. Elder ME. **Semin Hematol** 1998 Oct;35(4):310-20 (62 ref.)
Signalling through the JAK-STAT pathway in the developing brain. Cattaneo E, et al. **Trends Neurosci** 1999 Aug;22(8):365-9 (82 ref.)
[Recent progresses in the JAK-STAT signaling pathways] Nakajima K. **Nippon Rinsho** 1998 Jul;56(7):1763-72 (55 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of B cell receptor signaling through tyrosine kinases and phosphatases] Takata M, et al. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):655-67 (43 ref.) **(Jpn)**

PROTEIN TYROSINE KINASE P56(LCK) see **LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK)**

PROTEIN-TYROSINE-PHOSPHATASE

CHEMISTRY

Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Burke TR Jr, et al. **Biopolymers** 1998; 47(3):225-41 (190 ref.)

GENETICS

Protein tyrosine phosphatases: counting the trees in the forest. Hooft van Huijsduijnen R. **Gene** 1998 Dec 28;225(1-2):1-8 (46 ref.)
[X-linked recessive myotubular myopathy with a splice-site mutation in the myotubularin gene] Watanabe T, et al. **No To Hattatsu** 1998 Nov;30(6):523-7 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway. Cornall RJ, et al. **Curr Top Microbiol Immunol** 1999;244:57-68 (67 ref.)
Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Leslie RD, et al. **Diabetologia** 1999 Jan;42(1):3-14 (105 ref.)

METABOLISM

Protein tyrosine dephosphorylation and the maintenance of cell adhesions in the pancreas. Schnekenburger J, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:157-65 (31 ref.)
Protein-tyrosine phosphatases: structure, mechanism, and

inhibitor discovery. Burke TR Jr, et al. **Biopolymers** 1998; 47(3):225–41 (190 ref.)
How to extinguish lymphocyte activation. immunotyrosine-based inhibition motif (ITIM)-bearing molecules a solution? Blery M, et al. **Clin Chem Lab Med** 1999 Mar;37(3):187–91 (54 ref.)
Receptor tyrosine phosphatases: the worm clears the picture. Zinn K. **Curr Biol** 1998 Oct 8;8(20):R725–6 (9 ref.)
Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Denu JM, et al. **Curr Opin Chem Biol** 1998 Oct; 2(5):633–41 (58 ref.)
The regulation of antigen-receptor signaling by protein tyrosine phosphatases: a hole in the story. Thomas ML. **Curr Opin Immunol** 1999 Jun;11(3):270–6 (59 ref.)
Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation. Siminovitch KA, et al. **Curr Top Microbiol Immunol** 1999;246:291–7; discussion 298 (39 ref.)
Negative signaling in health and disease. Coggeshall KM. **Immunol Res** 1999;19(1):47–64 (165 ref.)
Protein tyrosine phosphatases as negative regulators of mitogenic signaling. Chernoff J. **J Cell Physiol** 1999 Aug; 180(2):173–81 (94 ref.)
Regulation of megakaryocytopoiesis and platelet production by tyrosine kinases and tyrosine phosphatases. Avraham H, et al. **Methods** 1999 Mar;17(3):250–64 (131 ref.)
Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Wishart MJ, et al. **Trends Biochem Sci** 1998 Aug;23(8):301–6 (47 ref.)

PHYSIOLOGY

The insulin receptor substrate 1 associates with phosphotyrosine phosphatase SHPTP2 in liver and muscle of rats. Lima MH, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1409–13 (17 ref.)
Immune signalling: SHP-2 docks at multiple ports. Huyer G, et al. **Curr Biol** 1999 Feb 25;9(4):R129–32 (11 ref.)
Mitogen-activated protein kinase phosphatase: a negative regulator of the mitogen-activated protein kinase cascade. Haneda M, et al. **Eur J Pharmacol** 1999 Jan 15;365(1):1–7 (71 ref.)
Lymphocyte activation: the coming of the protein tyrosine phosphatases. Mustelin T, et al. **Front Biosci** 1998 Nov 1; 3:D1060–96 (473 ref.)
Protein-tyrosine phosphatases in development. den Hertog J. **Mech Dev** 1999 Jul;85(1–2):3–14 (117 ref.)
Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Byon JC, et al. **Mol Cell Biochem** 1998 May;182(1–2):101–8 (51 ref.)
Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action. Drake PG, et al. **Mol Cell Biochem** 1998 May;182(1–2):79–89 (87 ref.)
Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Goldstein BJ, et al. **Mol Cell Biochem** 1998 May;182(1–2):91–9 (74 ref.)

PROTEINASE INHIBITORS see **PROTEASE INHIBITORS**

PROTEINASES see **PEPTIDE PEPTIDOHYDROLASES**

PROTEINS

see related
AMINO ACID SEQUENCE
BLOOD PROTEINS
PROTEIN CONFORMATION

Human salivary histatins: promising anti-fungal therapeutic agents. Tsai H, et al. **Crit Rev Oral Biol Med** 1998; 9(4):480–97 (118 ref.)
Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Adamson SR. **Dev Biol Stand** 1998;93:89–96 (18 ref.)
Residual host cell protein from continuous cell lines. Effect on the safety of protein pharmaceuticals. Lupker JH. **Dev Biol Stand** 1998;93:61–4 (19 ref.)
Mining protein data from two-dimensional gels: tools for systematic post-planned analyses. Oh JM, et al. **Electrophoresis** 1999 Apr-May;20(4–5):766–74 (16 ref.)
Genomes and proteomes: towards a multidimensional view of biology. Williams KL. **Electrophoresis** 1999 Apr-May; 20(4–5):678–88 (86 ref.)
IAP family proteins--suppressors of apoptosis. Deveraux QL, et al. **Genes Dev** 1999 Feb 1;13(3):239–52 (99 ref.)
Leptin resistance in obese humans: does it exist and what does it mean? Arch JR, et al. **Int J Obes Relat Metab Disord** 1998 Dec;22(12):1159–63 (42 ref.)
Proteolytic processing in the secretory pathway. Zhou A, et al. **J Biol Chem** 1999 Jul 23;274(30):20745–8 (111 ref.)
The leptin era: new insight into the mechanisms of body weight homeostasis. Hoppin AG, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):250–64 (164 ref.)
[Guanine nucleotide-exchange proteins (GEP) for ADP-ribosylation factors (ARF)] Morinaga N, et al. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):587–98 (52 ref.) **(Jpn)**
[Congenital histidine-rich glycoprotein deficiency] Shigekiyo T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):491–3 (12 ref.) **(Jpn)**
[Regulation of prostate gland-specific gene expression] Ueyama H, et al. **Seikagaku** 1999 Mar;71(3):210–4 (17 ref.) **(Jpn)**
[Ribosome recycling factor (RRF): a factor which disassemble the post-termination complex and reduces translational error] Kaji A, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):831–44 (48 ref.) **(Jpn)**
[Protein-RNA molecular mimicry] Nakamura Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1421–32 (45 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Use of vitamin B12 conjugates to deliver protein drugs by the oral route. Russell-Jones GJ. **Crit Rev Ther Drug Carrier Syst** 1998;15(6):557–86 (73 ref.)
Encapsulation of proteins for improved delivery. Putney SD. **Curr Opin Chem Biol** 1998 Aug;2(4):548–52 (24 ref.)
Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov-Dec; 15(6):699–713 (28 ref.)
Novel approaches for oral delivery of macromolecules. Fasano A. **J Pharm Sci** 1998 Nov;87(11):1351–6 (53 ref.)
Transdermal iontophoresis. Part II: Peptide and protein delivery. Pillai O, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr;21(3):229–40 (119 ref.)
Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Banga AK, et al. **Trends Biotechnol** 1998 Oct;16(10):408–12 (35 ref.)

ANALYSIS

Pharmaceuticals and related drugs. Gilpin RK, et al. **Anal Chem** 1999 Jun 15;71(12):217R–233R (562 ref.)
Separation and analysis of peptides and proteins. Larive CK, et al. **Anal Chem** 1999 Jun 15;71(12):389R–423R (80 ref.)
Colorimetric protein assay techniques. Sapan CV, et al. **Biotechnol Appl Biochem** 1999 Apr;29 (Pt 2):99–108 (145 ref.)
In vitro selection methods for screening of peptide and protein libraries. Hanes J, et al. **Curr Top Microbiol Immunol** 1999;243:107–22 (38 ref.)
Safety of biological products prepared from mammalian cell culture. Host-cell proteins. **Dev Biol Stand** 1998;93:139–40 (0 ref.)
Proteome and proteomics: new technologies, new concepts, and new words. Anderson NL, et al. **Electrophoresis** 1998 Aug;19(11):1853–61 (41 ref.)
Theory and practice of isoelectric focusing of interacting systems. Cann JR. **Electrophoresis** 1998 Jul;19(10):1577–85 (42 ref.)
High sensitivity analysis of proteins and peptides by capillary electrophoresis-tandem mass spectrometry: recent developments in technology and applications. Figeys D, et al. **Electrophoresis** 1998 May;19(6):885–92 (126 ref.)
Proteome analysis: biological assay or data archive? Haynes PA, et al. **Electrophoresis** 1998 Aug;19(11):1862–71 (50 ref.)
Advances in protein solubilisation for two-dimensional electrophoresis. Herbert B. **Electrophoresis** 1999 Apr-May; 20(4–5):660–3 (21 ref.)
Glycobiology and proteomics: is mass spectrometry the Holy Grail? Packer NH, et al. **Electrophoresis** 1998 Aug; 19(11):1872–82 (62 ref.)
Proteomics and automation. Quadroni M, et al. **Electrophoresis** 1999 Apr-May;20(4–5):664–77 (108 ref.)
The Australian Proteome Analysis Facility (APAF): assembling large scale proteomics through integration and automation. Walsh BJ, et al. **Electrophoresis** 1998 Aug; 19(11):1883–90 (31 ref.)
Capillary electrophoresis of peptides and proteins in acidic, isoelectric buffers: recent developments. Righetti PG, et al. **J Biochem Biophys Methods** 1999 Jul 28;40(1–2):1–15 (29 ref.)
Flow cytometric analysis and FACS sorting of cells based on GFP accumulation. Galbraith DW, et al. **Methods Cell Biol** 1999;58:315–41 (63 ref.)
Analysis of protein and gene expression. Jowett T. **Methods Cell Biol** 1999;59:63–85 (8 ref.)
Measurement and significance of free and protein-bound 3-nitrotyrosine, 3-chlorotyrosine, and free 3-nitro-4-hydroxyphenylacetic acid in biologic samples: a high-performance liquid chromatography method using electrochemical detection. Crow JP. **Methods Enzymol** 1999;301:151–60 (28 ref.)
Gel electrofocusing method for studying protein S-nitrosylation. Ji Y, et al. **Methods Enzymol** 1999; 301:145–51 (15 ref.)
Immunoprecipitation of nitrotyrosine-containing proteins. MacMillan-Crow LA, et al. **Methods Enzymol** 1999; 301:135–45 (16 ref.)
Constructing a 2-D database for the World Wide Web. Appel RD, et al. **Methods Mol Biol** 1999;112:411–6 (4 ref.)
Computer analysis of 2-D images. Appel RD, et al. **Methods Mol Biol** 1999;112:363–81 (12 ref.)
2-D databases on the World Wide Web. Appel RD, et al. **Methods Mol Biol** 1999;112:383–91 (11 ref.)
Identification of proteins by matrix-assisted laser desorption/ionization mass spectrometry using peptide and fragment ion masses. Courchesne PL, et al. **Methods Mol Biol** 1999;112:487–511 (28 ref.)
Electroblotting of proteins from 2-D polyacrylamide gels. Dunn MJ. **Methods Mol Biol** 1999;112:313–8 (16 ref.)
Detection of total proteins on western blots of 2-D polyacrylamide gels. Dunn MJ. **Methods Mol Biol** 1999; 112:319–29 (11 ref.)
Characterizing proteins from 2-DE gels by internal sequence analysis of peptide fragments. Strategies for microsample handling. Erdjument-Bromage H, et al. **Methods Mol Biol** 1999;112:467–72 (10 ref.)
2-D protein gel electrophoresis. An overview. Fichmann J, et al. **Methods Mol Biol** 1999;112:1–7 (13 ref.)
Advantages of immobilized pH gradients. Fichmann J. **Methods Mol Biol** 1999;112:173–4 (4 ref.)
Casting immobilized pH gradients (IPGs). Gianazza E. **Methods Mol Biol** 1999;112:175–88 (24 ref.)
Analytical IPG-Dalt. Görg A, et al. **Methods Mol Biol** 1999; 112:189–95 (15 ref.)
IPG-Dalt of very alkaline proteins. Görg A. **Methods Mol Biol** 1999;112:197–209 (22 ref.)
2-D diagonal gel electrophoresis. Goverman J. **Methods Mol Biol** 1999;112:265–70 (3 ref.)
Absolute quantitation of 2-D protein spots. Gygi SP, et al. **Methods Mol Biol** 1999;112:417–21 (10 ref.)
Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. Jensen ON, et al. **Methods Mol Biol** 1999;112:513–30 (56 ref.)
Peptide sequencing of 2-DE gel-isolated proteins by nanoelectrospray tandem mass spectrometry. Jensen ON, et al. **Methods Mol Biol** 1999;112:571–88 (34 ref.)
Nonreducing 2-D polyacrylamide gel electrophoresis. Ji H, et al. **Methods Mol Biol** 1999;112:255–63 (20 ref.)
N-terminal amino acid sequencing of 2-DE spots. Kamo M, et al. **Methods Mol Biol** 1999;112:461–6 (5 ref.)
Large-gel 2-D electrophoresis. Klose J. **Methods Mol Biol** 1999;112:147–72 (17 ref.)
Fractionated extraction of total tissue proteins from mouse and human for 2-D electrophoresis. Klose J. **Methods Mol Biol** 1999;112:67–85 (3 ref.)
Double-label analysis. Lee KH, et al. **Methods Mol Biol** 1999; 112:291–5 (3 ref.)
Comparing 2-D electrophoretic gels across Internet databases. Lemkin PF. **Methods Mol Biol** 1999;112:393–410 (24 ref.)
Autoradiography of 2-D gels. Link AJ. **Methods Mol Biol** 1999;112:285–90 (8 ref.)
Internal standards for 2-D. Link AJ. **Methods Mol Biol** 1999; 112:281–4 (2 ref.)
Measuring the radioactivity of 2-D protein extracts. Link AJ, et al. **Methods Mol Biol** 1999;112:105–7 (1 ref.)
2-D electrophoresis using carrier ampholytes in the first dimension (IEF). Lopez MF. **Methods Mol Biol** 1999; 112:111–27 (12 ref.)
Nonequilibrium pH gel electrophoresis (NEPHGE). Lopez MF. **Methods Mol Biol** 1999;112:129–31 (3 ref.)
Immunoaffinity identification of 2-DE separated proteins. Magi B, et al. **Methods Mol Biol** 1999;112:431–43 (52 ref.)
Staining of preparative 2-D gels. Coomassie blue and imidazole-zinc negative staining. Matsui NM, et al. **Methods Mol Biol** 1999;112:307–11 (10 ref.)
Obtaining molecular weights of proteins and their cleavage products by directly combining gel electrophoresis with mass spectrometry. Ogorzalek Loo RR, et al. **Methods Mol Biol** 1999;112:473–85 (31 ref.)
Conjugation of colloidal gold to proteins. Oliver C. **Methods Mol Biol** 1999;115:331–4 (8 ref.)
Protein detection using reversible metal chelate stains. Patton WF, et al. **Methods Mol Biol** 1999;112:331–9 (23 ref.)
Image acquisition in 2-D electrophoresis. Patton WF, et al. **Methods Mol Biol** 1999;112:353–62 (11 ref.)
Silver staining of 2-D electrophoresis gels. Rabilloud T. **Methods Mol Biol** 1999;112:297–305 (12 ref.)
Solubilization of proteins in 2-D electrophoresis. An outline. Rabilloud T. **Methods Mol Biol** 1999;112:9–19 (33 ref.)
Quantifying protein in 2-D PAGE solubilization buffers. Ramagli LS. **Methods Mol Biol** 1999;112:99–103 (10 ref.)
In-gel sample rehydration of immobilized pH gradient. Sanchez JC, et al. **Methods Mol Biol** 1999;112:221–5 (3 ref.)
High-resolution, IPG-based, mini two-dimensional gel electrophoresis. Sanchez JC, et al. **Methods Mol Biol** 1999; 112:227–33 (6 ref.)
High-resolution, 2-D protein electrophoresis using nondedicated equipment. Sarmiento M. **Methods Mol Biol** 1999;112:133–45 (11 ref.)
Solubilization and assay of cellular and tissue protein. Shaw CE. **Methods Mol Biol** 1998;105:287–93 (2 ref.)
Western immunoblot analysis. Shaw CE, et al. **Methods Mol Biol** 1998;105:295–306 (4 ref.)
Casting and running vertical slab-gel electrophoresis for 2D-PAGE. Walsh BJ, et al. **Methods Mol Biol** 1999; 112:245–53 (2 ref.)
Protein identification and analysis tools in the ExPASy server. Wilkins MR, et al. **Methods Mol Biol** 1999; 112:531–52 (16 ref.)
Automated protein identification using microcolumn liquid chromatography-tandem mass spectrometry. Yates JR 3rd, et al. **Methods Mol Biol** 1999;112:553–69 (17 ref.)
Immunohistochemistry and immunocytochemistry. Zheng J. **Methods Mol Biol** 1998;105:307–14 (6 ref.)
[A case of adenosquamous pancreatic cancer with high serum level of parathyroid related protein in which both primary

and liver metastatic lesions showed remarkable cystic changes] Hyodo N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):181–8 (13 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):81–4 (51 ref.) **(Rus)**

BIOSYNTHESIS

Possible evolution of factors involved in protein biosynthesis. Nyborg J. **Acta Biochim Pol** 1998;45(4):883–94 (40 ref.)

Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? [comment] Laurén J, et al. **Am J Pathol** 1998 Nov;153(5):1333–9 (79 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1459–66.

Proteins expressed by pancreatic duct cells and their relatives. Hollingsworth MA. **Ann N Y Acad Sci** 1999 Jun 30; 880:38–49 (72 ref.)

The genomic tag hypothesis: modern viruses as molecular fossils of ancient strategies for genomic replication, and clues regarding the origin of protein synthesis. Weiner AM, et al. **Biol Bull** 1999 Jun;196(3):327–8; discussion 329–30 (5 ref.)

Transgenic bioreactors. Jänne J, et al. **Biotechnol Annu Rev** 1998;4:55–74 (86 ref.)

Regulatory signals in messenger RNA: determinants of nutrient-gene interaction and metabolic compartmentation [see comments] Hesketh JE, et al. **Br J Nutr** 1998 Oct; 80(4):307–21 (114 ref.) Comment in: Br J Nutr 1998 Oct;80(4):305–6.

Epithelial antimicrobial peptides: review and significance for oral applications. Weinberg A, et al. **Crit Rev Oral Biol Med** 1998;9(4):399–414 (94 ref.)

Combinatorial protein design by in vitro recombination. Giver L, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):335–8 (26 ref.)

Replication-induced protein synthesis and its importance to proteomics. Humphery-Smith I. **Electrophoresis** 1999 Apr-May;20(4–5):653–9 (50 ref.)

Translational control: the cancer connection. Clemens MJ, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):1–23 (165 ref.)

Uncoupling protein-2 (UCP2) and uncoupling protein-3 (UCP3) expression in adipose tissue and skeletal muscle in humans. Langin D, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S64–7 (36 ref.)

Alkaline phosphatase, defensin gene expression and effect of myeloid cell growth factors in normal and leukemic cells. Tsuruta T, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):237–47 (115 ref.)

The measurement of processivity errors in protein synthesis. Dong H. **Methods Mol Biol** 1998;77:33–42 (13 ref.)

In vitro engineering using acyl-derivatized tRNAs. Odom OW, et al. **Methods Mol Biol** 1998;77:93–103 (14 ref.)

A fractionated reticulocyte lysate system for studies on protein synthesis initiation factors. Rau M, et al. **Methods Mol Biol** 1998;77:211–26 (24 ref.)

Permeabilized mammalian cells as a system for protein synthesis. Stapulionis R, et al. **Methods Mol Biol** 1998; 77:23–31 (23 ref.)

A biosynthetic approach for the incorporation of unnatural amino acids into proteins. Thorson JS, et al. **Methods Mol Biol** 1998;77:43–73 (84 ref.)

The measurement of missense errors during in vivo protein synthesis. Violand BN, et al. **Methods Mol Biol** 1998; 77:143–51 (33 ref.)

The protein synthetic response to feeding: a fundamental question revisited [editorial; comment] Emery P. **Nutrition** 1999 Mar;15(3):241–2 (9 ref.) Comment on: Nutrition 1999 Mar;15(3):200–7.

Leptin production in human adipose tissue. Coppack SW, et al. **Proc Nutr Soc** 1998 Aug;57(3):461–70 (89 ref.)

Regulation of leptin production: a dominant role for the sympathetic nervous system? Trayhurn P, et al. **Proc Nutr Soc** 1998 Aug;57(3):413–9 (70 ref.)

Regulation of protein biogenesis at the endoplasmic reticulum membrane. Hegde RS, et al. **Trends Cell Biol** 1999 Apr; 9(4):132–7 (61 ref.)

Recent advances in understanding the pathogenesis of Huntington's disease. Reddy PH, et al. **Trends Neurosci** 1999 Jun;22(6):248–55 (70 ref.)

[Ribosome recycling factor (RRF): a factor which disassemble the post-termination complex and reduces translational error] Kaji A, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):831–44 (48 ref.) **(Jpn)**

[Large-scale protein preparation using the cell-free synthesis] Kigawa T, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar; 44(4 Suppl):598–605 (21 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Design and discovery of protein dimerizers. Clemons PA. **Curr Opin Chem Biol** 1999 Feb;3(1):112–5 (28 ref.)

The design of protein-based catalysts using semisynthetic methods. Distefano MD, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):459–65 (53 ref.)

[Photo-activatable caged peptides and proteins] Tatsu Y, et al. **Seikagaku** 1999 Mar;71(3):197–201 (15 ref.) **(Jpn)**

CHEMISTRY

Comparative studies of protein crystallization by vapour-diffusion and microbatch techniques. Chayen NE. **Acta Crystallogr D Biol Crystallogr** 1998 Jan 1;54 (Pt 1):8–15 (54 ref.)

Design of protein function by physical perturbation method. Kidokoro S. **Adv Biophys** 1998;35:121–43 (18 ref.)

The important contribution of high precision mass spectrometric methods in the study of the structure-function relationship of proteins and enzymes. Devreese B, et al. **Analyst** 1998 Dec;123(12):2457–61 (38 ref.)

Relevance of the protein-lipid interaction on the functioning of the bacterial reaction center. Agostiano A, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:215–9 (10 ref.)

Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitrone and vitamin E. Butterfield DA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:448–62 (61 ref.)

Protein disulfide isomerase assists protein folding as both an isomerase and a chaperone. Wang CC. **Ann N Y Acad Sci** 1998 Dec 13;864:9–13 (27 ref.)

Solid-state nuclear magnetic resonance investigation of protein and polypeptide structure. Fu R, et al. **Annu Rev Biophys Biomol Struct** 1999;28:235–68 (113 ref.)

Nitroxide spin-spin interactions: applications to protein structure and dynamics. Hustedt EJ, et al. **Annu Rev Biophys Biomol Struct** 1999;28:129–53 (71 ref.)

Raman spectroscopy of protein and nucleic acid assemblies. Thomas GJ Jr. **Annu Rev Biophys Biomol Struct** 1999; 28:1–27 (97 ref.)

Fast events in protein folding: the time evolution of primary processes. Callender RH, et al. **Annu Rev Phys Chem** 1998; 49:173–202 (130 ref.)

RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Borden KL. **Biochem Cell Biol** 1998; 76(2–3):351–8 (44 ref.)

Theoretical calculations of acid-dissociation constants of proteins. Juffer AH. **Biochem Cell Biol** 1998; 76(2–3):198–209 (88 ref.)

Protein dynamics from NMR. Kay LE. **Biochem Cell Biol** 1998;76(2–3):145–52 (60 ref.)

NMR for the design of functional mimetics of protein-protein interactions: one key is in the building of bridges. Song J, et al. **Biochem Cell Biol** 1998;76(2–3):177–88 (67 ref.)

Protein chemical shift analysis: a practical guide. Wishart DS, et al. **Biochem Cell Biol** 1998;76(2–3):153–63 (57 ref.)

Electron transfer and coupled processes in protein film voltammetry. Armstrong FA. **Biochem Soc Trans** 1999 Feb; 27(2):206–10 (25 ref.)

Use of density increment in assessing protein aggregation under unusual conditions. Butler PJ. **Biochem Soc Trans** 1998 Nov;26(4):749–53 (15 ref.)

Analytical band centrifugation of proteins and protein complexes. Lebowitz J, et al. **Biochem Soc Trans** 1998 Nov; 26(4):745–9 (15 ref.)

Possibilities of the method of step-by-step complication of ligand structure in studies of protein--nucleic acid interactions: mechanisms of functioning of some replication, repair, topoisomerization, and restriction enzymes. Bugreev DV, et al. **Biochemistry (Mosc)** 1999 Mar;64(3):237–49 (72 ref.)

MARCKS, membranes, and calmodulin: kinetics of their interaction. Arbuzova A, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):369–79 (81 ref.)

Import of proteins into peroxisomes. Hettema EH, et al. **Biochim Biophys Acta** 1999 Aug 12;1451(1):17–34 (121 ref.)

Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Resh MD. **Biochim Biophys Acta** 1999 Aug 12;1451(1):1–16 (138 ref.)

The reactions of copper proteins with nitric oxide. Torres J, et al. **Biochim Biophys Acta** 1999 May 5;1411(2–3):310–22 (60 ref.)

Femtosecond processes in proteins. Vos MH, et al. **Biochim Biophys Acta** 1999 Apr 21;1411(1):1–20 (174 ref.)

Hydrophobically driven attachments of synthetic polymers onto surfaces of biological interest: lipid bilayers and globular proteins. Tribet C. **Biochimie** 1998 May-Jun; 80(5–6):461–73 (65 ref.)

Solid-state NMR for the study of membrane systems: the use of anisotropic interactions. Warschawski DE, et al. **Biochimie** 1998 May-Jun;80(5–6):437–50 (91 ref.)

Contemporary approaches to protein structure classification. Swindells MB, et al. **Bioessays** 1998 Nov;20(11):884–91 (53 ref.)

Molecules to maps: tools for visualization and interaction in support of computational biology. Kraemer ET, et al. **Bioinformatics** 1998;14(9):764–71 (25 ref.)

Classification and evolution of EF-hand proteins. Kawasaki H, et al. **Biometals** 1998 Dec;11(4):277–95 (75 ref.)

Polycomplexes--potential for bioseparation. Izumrudov VA, et al. **Bioseparation** 1998–99;7(4–5):207–20 (45 ref.)

Protein structure prediction and design. Morea V, et al. **Biotechnol Annu Rev** 1998;4:177–214 (160 ref.)

A FLASH of insight into cellular chemistry: genetically encoded labels for protein visualization in vivo. Luebke KJ. **Chem Biol** 1998 Dec;5(12):R317–22 (24 ref.)

Combinatorial libraries: studies in molecular recognition. Nestler HP, et al. **Comb Chem High Throughput Screen** 1998 Oct;1(3):113–26 (129 ref.)

Structure and technofunctional properties of protein-polysaccharide complexes: a review. Schmitt C, et al. **Crit Rev Food Sci Nutr** 1998 Nov;38(8):689–753 (238 ref.)

Molecular chaperones: pathways and networks. Ellis RJ. **Curr Biol** 1999 Feb 25;9(4):R137–9 (12 ref.)

Atomic force microscopy: a forceful way with single molecules. Engel A, et al. **Curr Biol** 1999 Feb 25; 9(4):R133–6 (20 ref.)

Bioanalytic applications of mass spectrometry. Costello CE. **Curr Opin Biotechnol** 1999 Feb;10(1):22–8 (60 ref.)

In silico design for protein stabilization. Dahiyat BI. **Curr Opin Biotechnol** 1999 Aug;10(4):387–90 (25 ref.)

NMR screening in drug discovery. Moore JM. **Curr Opin Biotechnol** 1999 Feb;10(1):54–8 (24 ref.)

NMR structure determination of proteins and protein complexes larger than 20 kDa. Clore GM, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):564–70 (51 ref.)

Mussel byssus and biomolecular materials. Deming TJ. **Curr Opin Chem Biol** 1999 Feb;3(1):100–5 (42 ref.)

Combinatorial protein design by in vitro recombination. Giver L, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):335–8 (26 ref.)

Hydrophobic core packing and protein design. Lazar GA, et al. **Curr Opin Chem Biol** 1998 Dec;2(6):675–9 (62 ref.)

Thermodynamic analysis of biomolecules: a volumetric approach. Chalikian TV, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):657–64 (60 ref.)

Protein families in multicellular organisms. Copley RR, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):408–15 (61 ref.)

From protein sequence to function. Danchin A. **Curr Opin Struct Biol** 1999 Jun;9(3):363–7 (64 ref.)

Protein dynamics simulations from nanoseconds to microseconds. Doniach S, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):157–63 (42 ref.)

New approaches to structure determination by NMR spectroscopy. Dötsch V, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):619–23 (37 ref.)

Predicting structures for genome proteins. Fischer D, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):208–11 (22 ref.)

Topological characteristics of helical repeat proteins. Groves MR, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):383–9 (31 ref.)

Co-translational folding. Hardesty B, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):111–4 (26 ref.)

Recent advances in site-directed spin labeling of proteins. Hubbell WL, et al. **Curr Opin Struct Biol** 1998 Oct; 8(5):649–56 (35 ref.)

The stability of proteins in extreme environments. Jaenicke R, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):738–48 (98 ref.)

Investigating protein dynamics in collective coordinate space. Kitao A, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):164–9 (64 ref.)

Theory and simulation. Can theory challenge experiment? [editorial] Koehl P, et al. **Curr Opin Struct Biol** 1999 Apr; 9(2):155–6 (6 ref.)

Validation of protein models derived from experiment. Laskowski RA, et al. **Curr Opin Struct Biol** 1998 Oct; 8(5):631–9 (55 ref.)

Messages from ultrahigh resolution crystal structures. Longhi S, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):730–7 (50 ref.)

From protein structure to function. Orengo CA, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):374–82 (68 ref.)

Disassembly of intact multiprotein complexes in the gas phase. Rostom AA, et al. **Curr Opin Struct Biol** 1999 Feb; 9(1):135–41 (29 ref.)

Progress in protein structure prediction: assessment of CASP3. Sternberg MJ, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):368–73 (34 ref.)

Macromolecular structure determination by electron microscopy: new advances and recent results. Stowell MH, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):595–600 (42 ref.)

Advances in structural genomics. Teichmann SA, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):390–9 (57 ref.)

Cobalt proteins. Kobayashi M, et al. **Eur J Biochem** 1999 Apr;261(1):1–9 (60 ref.)

Folding nucleus: specific or multiple? Insights from lattice models and experiments. Shakhnovich EI. **Fold Des** 1998; 3(6):R108–11; discussion R107 (31 ref.)

Fishing for folding nuclei in lattice models and proteins. Thirumalai D, et al. **Fold Des** 1998;3(6):R112–8; discussion R107 (27 ref.)

Human beta-defensin-2. Schröder JM, et al. **Int J Biochem Cell Biol** 1999 Jun;31(6):645–51 (15 ref.)

Peptide and protein identification by matrix-assisted laser desorption ionization (MALDI) and MALDI-post-source decay time-of-flight mass spectrometry. Chaurand P, et al. **J Am Soc Mass Spectrom** 1999 Feb;10(2):91–103 (67 ref.)

Selenocysteine-containing proteins in mammals. Gladyshev VN, et al. **J Biomed Sci** 1999 May-Jun;6(3):151–60 (104 ref.)

Hydrolysis and amino acid composition of proteins. Fountoulakis M, et al. **J Chromatogr A** 1998 Nov 27; 826(2):109–34 (246 ref.)

Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function. Turková J. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5;722(1–2):11–31 (78 ref.)

Prediction of binding constants of protein ligands: a fast

method for the prioritization of hits obtained from de novo design or 3D database search programs. Böhm HJ. **J Comput Aided Mol Des** 1998 Jul;12(4):309–23 (132 ref.)

A method for determining B1 field inhomogeneity. Are the biases assumed in heteronuclear relaxation experiments usually underestimated? Guenneugues M, et al. **J Magn Reson** 1999 Jan;136(1):118–26 (25 ref.)

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. Crotts G, et al. **J Microencapsul** 1998 Nov–Dec; 15(6):699–713 (28 ref.)

Self-organizing neural networks bridge the biomolecular resolution gap. Wriggers W, et al. **J Mol Biol** 1998 Dec 18;284(5):1247–54 (47 ref.)

Analytical techniques and computer algorithms combined for the rapid characterization of structural peptide and protein features. Caporale C. **J Pept Res** 1998 Nov;52(5):421–9 (52 ref.)

Solid-state chemical stability of proteins and peptides. Lai MC, et al. **J Pharm Sci** 1999 May;88(5):489–500 (81 ref.)

Molecular crowding: analysis of effects of high concentrations of inert cosolutes on biochemical equilibria and rates in terms of volume exclusion. Minton AP. **Methods Enzymol** 1998;295:127–49 (41 ref.)

Characterization of NAD:arginine ADP-ribosyltransferases. Moss J, et al. **Mol Cell Biochem** 1999 Mar;193(1–2):109–13 (19 ref.)

Natural covalent complexes of nucleic acids and proteins: some comments on practice and theoryon the path from well-known complexes to new ones. Drygin YF. **Nucleic Acids Res** 1998 Nov 1;26(21):4791–6 (88 ref.)

Predicting protein decomposition: the case of aspartic-acid racemization kinetics. Collins MJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jan 29; 354(1379):51–64 (99 ref.)

Borrowing to make ends meet [comment] Clardy J. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1826–7 (11 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1953–8.

Searching for "downhill scenarios" in protein folding [comment] Eaton WA. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5897–9 (40 ref.) Comment on: Proc Natl Acad Sci U S A 1999 May 25;96(11):6031–6.

Protein dynamics and photon echoes. Fleming GR. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15161–2 (13 ref.)

Folding and binding cascades: shifts in energy landscapes [comment] Tsai CJ, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9970–2 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10118–22.

Cooperative charge fluctuations by migrating protons in globular proteins. Careri G. **Prog Biophys Mol Biol** 1998; 70(3):223–49 (103 ref.)

Ab initio characterization of building units in peptides and proteins. Császár AG, et al. **Prog Biophys Mol Biol** 1999; 71(2):243–309 (300 ref.)

Genome-based structural biology. Frishman D, et al. **Prog Biophys Mol Biol** 1999;72(1):1–17 (78 ref.)

Future directions for combining molecular and continuum models in protein simulations. Huber GA. **Prog Biophys Mol Biol** 1998;69(2–3):483–96 (99 ref.)

Applications of mass spectrometry to signal transduction. Resing KA, et al. **Prog Biophys Mol Biol** 1999; 71(3–4):501–23 (166 ref.)

RNA and protein interactions modulated by protein arginine methylation. Gary JD, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:65–131 (250 ref.)

Folding funnels, binding funnels, and protein function. Tsai CJ, et al. **Protein Sci** 1999 Jun;8(6):1181–90 (67 ref.)

High-precision measurement of hydrogen bond lengths in proteins by nuclear magnetic resonance methods. Harris TK, et al. **Proteins** 1999 May 15;35(3):275–82 (54 ref.)

Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Buck M. **Q Rev Biophys** 1998 Aug;31(3):297–355 (263 ref.)

Structure calculation of biological macromolecules from NMR data. Güntert P. **Q Rev Biophys** 1998 May; 31(2):145–237 (218 ref.)

Illuminating single molecules in condensed matter. Moerner WE, et al. **Science** 1999 Mar 12;283(5408):1670–6 (75 ref.)

Fluorescence spectroscopy of single biomolecules. Weiss S. **Science** 1999 Mar 12;283(5408):1676–83 (87 ref.)

The art of matchmaking: sequence alignment methods and their structural implications. Smith TF. **Structure Fold Des** 1999 Jan 15;7(1):R7–R12 (41 ref.)

Computational protein design. Street AG, et al. **Structure Fold Des** 1999 May;7(5):R105–9 (58 ref.)

Protein crystals and their evil twins. Yeates TO, et al. **Structure Fold Des** 1999 Feb 15;7(2):R25–9 (21 ref.)

GEFs: structural basis for their activation of small GTP-binding proteins. Cherfils J, et al. **Trends Biochem Sci** 1999 Aug;24(8):306–11 (34 ref.)

The WD repeat: a common architecture for diverse functions. Smith TF, et al. **Trends Biochem Sci** 1999 May;24(5):181–5 (40 ref.)

Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Whitmarsh AJ, et al. **Trends Biochem Sci** 1998 Dec;23(12):481–5 (33 ref.)

Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Wishart MJ, et al. **Trends Biochem Sci** 1998 Aug;23(8):301–6 (47 ref.)

Chemoselective ligation reactions with proteins, oligosaccharides and cells. Lemieux GA, et al. **Trends Biotechnol** 1998 Dec;16(12):506–13 (74 ref.)

Beyond proteins. Robson B. **Trends Biotechnol** 1999 Aug; 17(8):311–5 (22 ref.)

[Structural genomics: approach of structure biology towards genome analysis] Nakamura H. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):590–7 (51 ref.) **(Jpn)**

[What determines the characteristics of the intrinsic UV-fluorescence of proteins? Analysis of the properties of the microenvironment and features of the localization of their tryptophan residues] Kuznetsova IM, et al. **Tsitologiia** 1998;40(8–9):747–62 (45 ref.) (Eng. Abstr.) **(Rus)**

[Protein and peptide construction for delivery of oligonucleotides and DNA into the cell] Pozmogova GE, et al. **Vopr Med Khim** 1998 Jul–Aug;44(4):331–7 (46 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Contemporary approaches to protein structure classification. Swindells MB, et al. **Bioessays** 1998 Nov;20(11):884–91 (53 ref.)

DIAGNOSTIC USE

Radiolabelled antimicrobial peptides for imaging of infections: a review. Nibbering PH, et al. **Nucl Med Commun** 1998 Dec;19(12):1117–21 (27 ref.)

DRUG EFFECTS

Can growth hormone counteract the effects of glucocorticoids on protein metabolism? Beaufrère B. **Acta Paediatr Suppl** 1999 Feb;88(428):97–9 (24 ref.)

Developmental pathways: Sonic hedgehog-Patched-GLI. Walterhouse DO, et al. **Environ Health Perspect** 1999 Mar; 107(3):167–71 (65 ref.)

The role of insulin and other hormones in the regulation of amino acid and protein metabolism in humans. Miers WR, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2–4):235–53 (86 ref.)

What is the significance of increases in background levels of carcinogen-derived protein and DNA adducts? Some considerations for incremental risk assessment. Farmer PB, et al. **Mutat Res** 1999 Mar 8;424(1–2):275–86 (88 ref.)

GENETICS

Phage display of proteins. Kościelska K, et al. **Acta Biochim Pol** 1998;45(3):705–20 (71 ref.)

Leptin and the genetics of obesity. Clément K. **Acta Paediatr Suppl** 1999 Feb;88(428):51–7 (49 ref.)

Cloning of the familial Mediterranean fever gene: expectations for learning about the pathogenesis of amyloid A amyloidosis. Pras M. **Adv Nephrol Necker Hosp** 1998; 28:343–54 (25 ref.)

Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Jones AC, et al. **Am J Hum Genet** 1999 May; 64(5):1305–15 (47 ref.)

Learning from the slime mold: Dictyostelium and human disease. Saxe CL. **Am J Hum Genet** 1999 Jul;65(1):25–30 (26 ref.)

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Weiss B, et al. **Am J Med Genet** 1999 Mar 26; 89(1):14–22 (103 ref.)

Ataxia-telangiectasia, ATM and genomic stability: maintaining a delicate balance. Two international workshops on ataxia-telangiectasia, related disorders and the ATM protein. Shiloh Y. **Biochim Biophys Acta** 1998 Oct 14;1378(2):R11–8 (32 ref.)

Genetics of Parkinson's disease. Mizuno Y, et al. **Biomed Pharmacother** 1999 Apr;53(3):109–16 (67 ref.)

Classification and evolution of EF-hand proteins. Kawasaki H, et al. **Biometals** 1998 Dec;11(4):277–95 (75 ref.)

Understanding the molecular basis of Wiskott-Aldrich syndrome. Abo A. **Cell Mol Life Sci** 1998 Oct; 54(10):1145–53 (73 ref.)

Proteome in perspective. Hochstrasser DF. **Clin Chem Lab Med** 1998 Nov;36(11):825–36 (105 ref.)

Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Meyn MS. **Clin Genet** 1999 May;55(5):289–304 (181 ref.)

Protein evolution by molecular breeding. Minshull J, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):284–90 (42 ref.)

The INK4A/ARF locus and its two gene products. Sharpless NE, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):22–30 (81 ref.)

Characterization of the Wiskott-Aldrich syndrome protein and its role in the disease. Nonoyama S, et al. **Curr Opin Immunol** 1998 Aug;10(4):407–12 (46 ref.)

Protein families in multicellular organisms. Copley RR, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):408–15 (61 ref.)

Predicting structures for genome proteins. Fischer D, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):208–11 (22 ref.)

Co-translational folding. Hardesty B, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):111–4 (26 ref.)

Advances in structural genomics. Teichmann SA, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):390–9 (57 ref.)

ATM and lymphoid malignancies; use of oriented peptide libraries to identify novel substrates of ATM critical in downstream signaling pathways. Rathbun GA, et al. **Curr Top Microbiol Immunol** 1999;246:267–73; discussion 274 (25 ref.)

Proteomics in human disease: cancer, heart and infectious diseases. Jungblut PR, et al. **Electrophoresis** 1999 Jul; 20(10):2100–10 (66 ref.)

Tuberous sclerosis-related gene expression in normal and dysplastic brain. Vinters HV, et al. **Epilepsy Res** 1998 Sep; 32(1–2):12–23 (51 ref.)

Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. Panteleyev AA, et al. **Exp Dermatol** 1998 Oct;7(5):249–67 (138 ref.)

ATM: from gene to function. Rotman G, et al. **Hum Mol Genet** 1998;7(10):1555–63 (109 ref.)

Protein misfolding and degradation in genetic diseases. Bross P, et al. **Hum Mutat** 1999;14(3):186–98 (66 ref.)

The protein truncation test: A review. Den Dunnen JT, et al. **Hum Mutat** 1999;14(2):95–102 (51 ref.)

Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5. Mole SE, et al. **Hum Mutat** 1999;14(3):199–215 (81 ref.)

ATM: the product of the gene mutated in ataxia-telangiectasia. Lavin MF. **Int J Biochem Cell Biol** 1999 Jul;31(7):735–40 (36 ref.)

Using EC and ES cell culture to study early development: recent observations on Indian hedgehog and Bmps. Grabel L, et al. **Int J Dev Biol** 1998;42(7 Spec No):917–25 (67 ref.)

Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related? Wang NM, et al. **Int J Mol Med** 1999 May;3(5):491–5 (54 ref.)

Thyroid hormone and other regulators of uncoupling proteins. Reitman ML, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S56–9 (36 ref.)

Brain distribution of UCP2 mRNA: in situ hybridization histochemistry studies. Richard D, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S53–5 (11 ref.)

Uncoupling protein-2 (UCP2): molecular and genetic studies. Ricquier D. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S38–42 (42 ref.)

Molecular and genetic aspects of the UCPs: view from the chair. Stock MJ. **Int J Obes Relat Metab Disord** 1999 Jun; 23 Suppl 6:S51–2 (6 ref.)

Genetics of uncoupling proteins in humans. Warden C. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S46–8 (14 ref.)

Proteome analysis. I. Gene products are where the biological action is. Lopez MF. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5;722(1–2):191–202 (94 ref.)

Proteome analysis. II. Protein subcellular redistribution: linking physiology to genomics via the proteome and separation technologies involved. Patton WF. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1–2):203–23 (138 ref.)

Genes involved in animal models of obesity and anorexia. Schalling M, et al. **J Intern Med** 1999 Jun;245(6):613–9 (49 ref.)

Predicting function: from genes to genomes and back. Bork P, et al. **J Mol Biol** 1998 Nov 6;283(4):707–25 (155 ref.)

Phenotypic variability in PKD1: the family as a starting point [editorial; comment] Guay-Woodford LM. **Kidney Int** 1999 Jul;56(1):344–6 (19 ref.) Comment on: Kidney Int 1999 Jul;56(1):34–40.

Alkaline phosphatase, defensin gene expression and effect of myeloid cell growth factors in normal and leukemic cells. Tsuruta T, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):237–47 (115 ref.)

GFP biofluorescence: imaging gene expression and protein dynamics in living cells. Design considerations for a fluorescence imaging laboratory. Goodwin PC. **Methods Cell Biol** 1999;58:343–67 (33 ref.)

Protein phylogenies and signature sequences: A reappraisal of evolutionary relationships among archaebacteria, eubacteria, and eukaryotes. Gupta RS. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1435–91 (264 ref.)

Characterization of NAD:arginine ADP-ribosyltransferases. Moss J, et al. **Mol Cell Biochem** 1999 Mar;193(1–2):109–13 (19 ref.)

Wiskott-Aldrich syndrome: a gene, a multifunctional protein and the beginnings of an explanation. Kirchhausen T. **Mol Med Today** 1998 Jul;4(7):300–4 (30 ref.)

Niemann-Pick C disease: cholesterol handling gone awry. Morris JA, et al. **Mol Med Today** 1998 Dec;4(12):525–31 (49 ref.)

The von Hippel-Lindau tumour suppressor protein: new perspectives. Ohh M, et al. **Mol Med Today** 1999 Jun; 5(6):257–63 (45 ref.)

Molecular studies of leptin: implications for renal disease. Stenvinkel P, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1103–12 (101 ref.)

The role of ATM in DNA damage responses and cancer. Canman CE, et al. **Oncogene** 1998 Dec 24;17(25):3301–8 (142 ref.)

From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'. Sudol M. **Oncogene** 1998 Sep 17;17(11 Reviews):1469–74 (64 ref.)

FHITness and cancer. Druck T, et al. **Oncol Res** 1998; 10(7):341–5 (27 ref.)

ob gene mutations and human obesity. Farooqi S, et al. **Proc Nutr Soc** 1998 Aug;57(3):471–5 (26 ref.)

Genome-based structural biology. Frishman D, et al.

Prog Biophys Mol Biol 1999;72(1):1-17 (78 ref.)
The ataxia telangiectasia gene in familial and sporadic cancer. Yuille MA, et al. **Recent Results Cancer Res** 1998; 154:156-73 (70 ref.)
Moonlighting proteins. Jeffery CJ. **Trends Biochem Sci** 1999 Jan;24(1):8-11 (28 ref.)
Forty years under the central dogma [see comments] Thieffry D, et al. **Trends Biochem Sci** 1998 Aug;23(8):312-6 (36 ref.) Comment in: Trends Biochem Sci 1998 Dec;23(12):468.
The VHL tumour-suppressor gene paradigm. Kaelin WG Jr, et al. **Trends Genet** 1998 Oct;14(10):423-6 (47 ref.)
[Activating mutations of the parathyroid hormone and parathyroid hormone related peptide] David L. **Arch Pediatr** 1998;5 Suppl 4:385S-389S (22 ref.) (Eng. Abstr.) **(Fre)**
[Genetics of Parkinson disease] Brassat D, et al. **Rev Med Interne** 1999 Aug;20(8):709-14 (37 ref.) (Eng. Abstr.) **(Fre)**
[New knowledge about obesity--news for obese patients?] Geyer G. **Acta Med Austriaca** 1998;25(4-5):117-25 (63 ref.) (Eng. Abstr.) **(Ger)**
[New insights in the molecular genetics and pathophysiology of hereditary ataxias] Bürk K, et al. **Nervenarzt** 1999 Jun; 70(6):491-5 (39 ref.) (Eng. Abstr.) **(Ger)**
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin). Additional report: Physiological regulation of ob gene expression] Kawakami Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1817-20 (12 ref.) **(Jpn)**
[Cloning of Parkin gene and its function] Shimizu N, et al. **No To Shinkei** 1999 Jun;51(6):487-91 (18 ref.) **(Jpn)**
[A Parkin gene (PARK 2) and Parkinson's disease] Matsumine H. **Rinsho Shinkeigaku** 1999 Jan;39(1):9-12 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Evolutionary molecular engineering of proteins] Nemoto N, et al. **Seikagaku** 1998 Oct;70(10):1251-61 (72 ref.) **(Jpn)**
[Fukutin, a novel protein product responsible for Fukuyama-type congenital muscular dystrophy] Toda T. **Seikagaku** 1999 Jan;71(1):55-61 (15 ref.) **(Jpn)**
[Proteomics in pharmaceutical industry] Blackstock WP, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2214-21 (46 ref.) **(Jpn)**

IMMUNOLOGY

ATM in lymphoid development and tumorigenesis. Xu Y. **Adv Immunol** 1999;72:179-89 (58 ref.)
Immune reactivity to proteins biotransformed by alcohol metabolites. Klassen LW, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):204S-207S (15 ref.)
Protein modification by thermal processing. Davis PJ, et al. **Allergy** 1998;53(46 Suppl):102-5 (22 ref.)
Integration of T cell receptor-dependent signaling pathways by adapter proteins. Clements JL, et al. **Annu Rev Immunol** 1999;17:89-108 (105 ref.)
Degradation of cell proteins and the generation of MHC class I-presented peptides. Rock KL, et al. **Annu Rev Immunol** 1999;17:739-79 (211 ref.)
The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Snapper SB, et al. **Annu Rev Immunol** 1999;17:905-29 (169 ref.)
The role of the proteasome system and the proteasome activator PA28 complex in the cellular immune response. Kloetzel PM, et al. **Biol Chem** 1999 Mar;380(3):293-7 (43 ref.)
Cancer-testis antigens: targets for cancer immunotherapy [comment] Chen YT, et al. **Cancer J Sci Am** 1999 Jan-Feb; 5(1):16-7 (11 ref.) Comment on: Cancer J Sci Am 1999 Jan-Feb;5(1):20-5.
Epithelial antimicrobial peptides: review and significance for oral applications. Weinberg A, et al. **Crit Rev Oral Biol Med** 1998;9(4):399-414 (94 ref.)
C1q-binding proteins and C1q receptors. Nicholson-Weller A, et al. **Curr Opin Immunol** 1999 Feb;11(1):42-6 (47 ref.)
Interferon-inducible Mx proteins in fish. Leong JC, et al. **Immunol Rev** 1998 Dec;166:349-63 (103 ref.)
The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Tanaka K, et al. **Immunol Rev** 1998 Jun;163:161-76 (127 ref.)
Human seminal plasma protein allergy: a diagnosis rarely considered. Ludman BG. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):359-63 (18 ref.)

ISOLATION & PURIFICATION

New methods of protein purification. Expanded bed chromatography. Galaev IY. **Biochemistry (Mosc)** 1998 Jun;63(6):619-24 (28 ref.)
New methods of protein purification. Displacement chromatography. Galaev IY. **Biochemistry (Mosc)** 1998 Nov;63(11):1258-65 (41 ref.)
Additional possible tools for identification of proteins on one- or two-dimensional electrophoresis. Tsugita A, et al. **Electrophoresis** 1998 May;19(6):928-38 (30 ref.)
Electromigration for separations of protein complexes. Tulp A, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1-2):141-51 (55 ref.)
Chromatin structure and analysis of mechanisms of activators and repressors. Simpson RT. **Methods** 1998 Aug; 15(4):283-94 (61 ref.)
Methods for in situ localization of proteins and DNA in the centromere-kinetochore complex. Van Hooser A, et al. **Methods Cell Biol** 1999;61:57-80 (54 ref.)

METABOLISM

Neuroendocrine regulation of food intake. Seeley RJ, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):58-61 (37 ref.)
Protein glycosylation: implications for in vivo functions and therapeutic applications. Bhatia PK, et al. **Adv Biochem Eng Biotechnol** 1999;64:155-201 (276 ref.)
Design of protein function by physical perturbation method. Kidokoro S. **Adv Biophys** 1998;35:121-43 (18 ref.)
Protein and amino acid metabolism in human muscle. Wagenmakers AJ. **Adv Exp Med Biol** 1998;441:307-19 (39 ref.)
Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Witko-Sarsat V, et al. **Adv Nephrol Necker Hosp** 1998; 28:321-41 (80 ref.)
IV. Paneth cell antimicrobial peptides and the biology of the mucosal barrier. Ouellette AJ. **Am J Physiol** 1999 Aug; 277(2 Pt 1):G257-61 (32 ref.)
Lung epithelium-specific proteins: characteristics and potential applications as markers. Hermans C, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):646-78 (469 ref.)
Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitrone and vitamin E. Butterfield DA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:448-62 (61 ref.)
Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Bonifacino JS, et al. **Annu Rev Cell Dev Biol** 1998;14:19-57 (164 ref.)
Degradation of cell proteins and the generation of MHC class I-presented peptides. Rock KL, et al. **Annu Rev Immunol** 1999;17:739-79 (211 ref.)
Responsiveness of selenoproteins to dietary selenium. Allan CB, et al. **Annu Rev Nutr** 1999;19:1-16 (50 ref.)
P62 and the sequestosome, a novel mechanism for protein metabolism. Shin J. **Arch Pharm Res** 1998 Dec;21(6):629-33 (35 ref.)
Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Suzuki F. **Biochem Biophys Res Commun** 1999 May 27;259(1):1-7 (46 ref.)
The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Schalkwijk J, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):569-77 (70 ref.)
Ras, superoxide and signal transduction. Irani K, et al. **Biochem Pharmacol** 1998 May 1;55(9):1339-46 (90 ref.)
Electron transfer and coupled processes in protein film voltammetry. Armstrong FA. **Biochem Soc Trans** 1999 Feb; 27(2):206-10 (25 ref.)
Antizyme modifications affecting polyamine homoeostasis. Mitchell JL, et al. **Biochem Soc Trans** 1998 Nov;26(4):591-5 (29 ref.)
Possibilities of the method of step-by-step complication of ligand structure in studies of protein--nucleic acid interactions: mechanisms of functioning of some replication, repair, topoisomerization, and restriction enzymes. Bugreev DV, et al. **Biochemistry (Mosc)** 1999 Mar;64(3):237-49 (72 ref.)
Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Buday L. **Biochim Biophys Acta** 1999 Jul 6;1422(2):187-204 (246 ref.)
Signalling functions of protein palmitoylation. Dunphy JT, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):245-61 (109 ref.)
Protein sorting in the Golgi complex. Füllekrug J, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):77-84 (59 ref.)
Protein translocation into mitochondria. Káldi K, et al. **Biofactors** 1998;8(3-4):221-4 (6 ref.)
Lymphocyte antigen receptor signal integration and regulation by the SHC adaptor. Baldari CT, et al. **Biol Chem** 1999 Feb;380(2):129-34 (42 ref.)
Protein translocation: how Hsp70 pulls it off. Pilon M, et al. **Cell** 1999 Jun 11;97(6):679-82 (19 ref.)
Invasion of the nucleotide snatchers: structural insights into the mechanism of G protein GEFs. Sprang SR, et al. **Cell** 1998 Oct 16;95(2):155-8 (20 ref.)
The Rho GTPases in macrophage motility and chemotaxis. Jones GE, et al. **Cell Adhes Commun** 1998;6(2-3):237-45 (40 ref.)
Expression, regulation, and function of the SPR family of proteins. A review. Tesfaigzi J, et al. **Cell Biochem Biophys** 1999;30(2):243-65 (47 ref.)
Nitric oxide: a radical molecule in quest of free radicals in proteins. Guittet O, et al. **Cell Mol Life Sci** 1999 Jul; 55(8-9):1054-67 (75 ref.)
The Grb7 family of signalling proteins. Daly RJ. **Cell Signal** 1998 Oct;10(9):613-8 (49 ref.)
Regulatory role of SH3 domain-mediated protein-protein interactions in synaptic vesicle endocytosis. McPherson PS. **Cell Signal** 1999 Apr;11(4):229-38 (127 ref.)
Putting protein splicing to work. Gimble FS. **Chem Biol** 1998 Oct;5(10):R251-6 (19 ref.)
Parathyroid hormone-related protein in lower vertebrates. Danks JA, et al. **Clin Exp Pharmacol Physiol** 1998 Sep; 25(9):750-2 (17 ref.)
Combinatorial libraries: studies in molecular recognition. Nestler HP, et al. **Comb Chem High Throughput Screen** 1998 Oct;1(3):113-26 (129 ref.)
Actin polymerization: Where the WASP stings. Bi E, et al. **Curr Biol** 1999 Mar 11;9(5):R160-3 (17 ref.)
Molecular chaperones: pathways and networks. Ellis RJ. **Curr Biol** 1999 Feb 25;9(4):R137-9 (12 ref.)
Protein regulation: tag wrestling with relatives of ubiquitin. Hodges M, et al. **Curr Biol** 1998 Oct 22;8(21):R749-52 (25 ref.)
Transport pathways of macromolecules between the nucleus and the cytoplasm. Adam SA. **Curr Opin Cell Biol** 1999 Jun;11(3):402-6 (41 ref.)
Mechanisms of protein sorting and coat assembly: insights from the clathrin-coated vesicle pathway. Le Borgne R, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):499-503 (61 ref.)
Delivery of proteins and organelles to the vacuole from the cytoplasm. Scott SV, et al. **Curr Opin Cell Biol** 1998 Aug; 10(4):523-9 (53 ref.)
Noninvasive intracellular delivery of functional peptides and proteins. Hawiger J. **Curr Opin Chem Biol** 1999 Feb; 3(1):89-94 (31 ref.)
Nutrient regulation of gene and protein expression [editorial; comment] Clarke SD. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):287-9 (9 ref.) Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):297-301. Comment on: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):303-6.
Discrepancy between muscle and whole body protein turnover. Deutz NE, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):29-32 (12 ref.)
Amino acids and proteins--new definitions and requirements, hormonal interactions, methodological advances and pitfalls [editorial] Fürst P, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):5-8 (17 ref.)
Of flux and flooding: the advantages and problems of different isotopic methods for quantifying protein turnover in vivo: I. Methods based on the dilution of a tracer. Reeds PJ, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan; 2(1):23-8 (48 ref.)
Inter-organ protein and carbohydrate metabolic relationships during sepsis: necessary evils or uncanny coincidences? Vary TC. **Curr Opin Clin Nutr Metab Care** 1999 May; 2(3):235-42 (64 ref.)
Deterrents to the successful clinical use of growth factors that enhance protein anabolism. Wilmore DW. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):15-21 (45 ref.)
New players and puzzles in the Hedgehog signaling pathway. Johnston RL, et al. **Curr Opin Genet Dev** 1998 Aug; 8(4):450-6 (77 ref.)
Leptin and the onset of puberty [editorial] Edmonds DK. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):361-3 (27 ref.)
Three molecular determinants of malignant conversion and their potential as therapeutic targets [published erratum appears in Curr Opin Oncol 1999 Mar;11(2):145] Dome JS, et al. **Curr Opin Oncol** 1999 Jan;11(1):58-67 (112 ref.)
Redesigning small molecule-protein interfaces. Clackson T. **Curr Opin Struct Biol** 1998 Aug;8(4):451-8 (33 ref.)
Novel forms of protein glycosylation. Vliegenthart JF, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):565-71 (38 ref.)
The two hybrid toolbox. Kolanus W. **Curr Top Microbiol Immunol** 1999;243:37-54 (69 ref.)
Antigen sequence- and library-based mapping of linear and discontinuous protein-protein-interaction sites by spot synthesis. Reineke U, et al. **Curr Top Microbiol Immunol** 1999;243:23-36 (49 ref.)
Eph receptors and ephrins: effectors of morphogenesis. Holder N, et al. **Development** 1999 May;126(10):2033-44 (104 ref.)
Protein and nitrogen metabolism in gestational diabetes. Kalhan SC. **Diabetes Care** 1998 Aug;21 Suppl 2:B75-8 (17 ref.)
The measurement of ubiquitin and ubiquitinated proteins. Mimnaugh EG, et al. **Electrophoresis** 1999 Feb;20(2):418-28 (99 ref.)
The ubiquitin-proteasome pathway: on protein death and cell life. Ciechanover A. **EMBO J** 1998 Dec 15;17(24):7151-60 (75 ref.)
Protein hormone storage in secretory granules: mechanisms for concentration and sorting. Dannies PS. **Endocr Rev** 1999 Feb;20(1):3-21 (200 ref.)
Leptin and cardiac cachexia: marker or mediator? [editorial; comment] Cleland JG, et al. **Eur Heart J** 1998 Oct; 19(10):1421-2 (15 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1547-51.
Adaptation of protein metabolism in relation to limits to high dietary protein intake. Garlick PJ, et al. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S34-43 (77 ref.)
D-amino acid hydrolysing enzymes. Yamada R, et al. **EXS** 1998;85:145-55 (35 ref.)
Aldehyde-protein adducts in the liver as a result of ethanol-induced oxidative stress. Niemelä O. **Front Biosci** 1999 Jun 1;4:D506-13 (90 ref.)
Contributions of molecular motor enzymes to vesicle-based protein transport in gastrointestinal epithelial cells. McNiven MA, et al. **Gastroenterology** 1999 Feb; 116(2):438-51 (133 ref.)
The proteasome: a protein-destroying machine. Tanaka K, et al. **Genes Cells** 1998 Aug;3(8):499-510 (80 ref.)
Protein misfolding and degradation in genetic diseases. Bross P, et al. **Hum Mutat** 1999;14(3):186-98 (66 ref.)
Obesity and increased contractile activity influence the

protein content of UCP2 in human skeletal muscle. Simoneau JA, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S68–71 (28 ref.)

Mitochondrial proteins at unexpected cellular locations: export of proteins from mitochondria from an evolutionary perspective. Soltys BJ, et al. **Int Rev Cytol** 2000;194:133–96 (265 ref.)

Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis. Takeuchi T, et al. **Int Rev Immunol** 1998;17(5–6):365–81 (69 ref.)

The regulation of obese (ob) gene expression by intracellular fatty acid concentration in adipocytes. Kawakami Y, et al. **Intern Med** 1999 Feb;38(2):213–5 (6 ref.)

Clinical implication of leptin, the obese gene product. Ogawa Y, et al. **Intern Med** 1999 Feb;38(2):210–2 (15 ref.)

Protein transport from the endoplasmic reticulum to the Golgi apparatus. Hong W. **J Cell Sci** 1998 Oct;111 (Pt 19):2831–9 (123 ref.)

Clinical review 107: Role of gonadal steroids in the sexual dimorphisms in body composition and circulating concentrations of leptin. Rosenbaum M, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1784–9 (94 ref.)

Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. Böhm HJ. **J Comput Aided Mol Des** 1998 Jul;12(4):309–23 (132 ref.)

Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. Bequette BJ, et al. **J Dairy Sci** 1998 Sep;81(9):2540–59 (116 ref.)

An evaluation of postabsorptive protein and amino acid metabolism in the lactating dairy cow. Hanigan MD, et al. **J Dairy Sci** 1998 Dec;81(12):3385–401 (84 ref.)

Plastids and protein targeting. McFadden GI. **J Eukaryot Microbiol** 1999 Jul–Aug;46(4):339–46 (100 ref.)

Leptin and its potential role in human obesity. Lönnqvist F, et al. **J Intern Med** 1999 Jun;245(6):643–52 (66 ref.)

Contributions of studies on uncoupling proteins to research on metabolic diseases. Ricquier D, et al. **J Intern Med** 1999 Jun;245(6):637–42 (27 ref.)

Amino acid metabolism, substrate availability and the control of protein dynamics in the human kidney. Garibotto G, et al. **J Nephrol** 1999 Jul–Aug;12(4):203–11 (55 ref.)

Molecular biology of biotin attachment to proteins. Chapman-Smith A, et al. **J Nutr** 1999 Feb;129(2S Suppl):477S–484S (58 ref.)

Analytical techniques used to study the degradation of proteins and peptides: physical instability. Reubsaet JL, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):979–84 (44 ref.)

Analytical techniques used to study the degradation of proteins and peptides: chemical instability. Reubsaet JL, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):955–78 (96 ref.)

Secondary structure and protein deamidation. Xie M, et al. **J Pharm Sci** 1999 Jan;88(1):8–13 (31 ref.)

Protein metabolism in critical illness: methodologies and their problems underlying in kinetic studies using isotope tracers in vivo. Sakurai Y. **Keio J Med** 1999 Jun;48(2):69–78 (100 ref.)

Carbonylated proteins in aging and exercise: immunoblot approaches. Goto S, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):245–53 (54 ref.)

Receptors for proteins modified by advanced glycation endproducts (AGE)--their functional role in atherosclerosis. Sano H, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):333–46 (58 ref.)

Visualizing protein interactions in living cells using digitized GFP imaging and FRET microscopy. Periasamy A, et al. **Methods Cell Biol** 1999;58:293–314 (98 ref.)

Synchronous real-time reporting of multiple cellular events. Plautz JD, et al. **Methods Cell Biol** 1999;58:283–91 (19 ref.)

Metabolic labeling of protein-derived lipid thioesters in palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:213–9 (10 ref.)

Fatty acid analysis of protein-derived lipid thioesters isolated from palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:221–8 (4 ref.)

Gel retardation and UV-crosslinking assays to detect specific RNA-protein interactions in the 5' or 3' UTRs of translationally regulated mRNAs. Walker J, et al. **Methods Mol Biol** 1998;77:365–78 (30 ref.)

The proteasome-dependent proteolytic system. Tanahashi N, et al. **Mol Biol Rep** 1999 Apr;26(1–2):3–9 (36 ref.)

Visualizing protein-protein interactions in the nucleus of the living cell. Day RN, et al. **Mol Endocrinol** 1999 Apr; 13(4):517–26 (63 ref.)

Isolation of the Ca2+ releasing component(s) of mammalian sperm extracts: the search continues. Fissore RA, et al. **Mol Hum Reprod** 1999 Mar;5(3):189–92 (57 ref.)

Wiskott-Aldrich syndrome: a gene, a multifunctional protein and the beginnings of an explanation. Kirchhausen T. **Mol Med Today** 1998 Jul;4(7):300–4 (30 ref.)

The role of agouti-related protein in regulating body weight. Wilson BD, et al. **Mol Med Today** 1999 Jun;5(6):250–6 (50 ref.)

The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways. Mort JS, et al. **Mol Pathol** 1999 Feb;52(1):11–8 (43 ref.)

Pathophysiology of progressive nephropathies. Remuzzi G, et al. **N Engl J Med** 1998 Nov 12;339(20):1448–56 (95 ref.)

Peroxin puzzles and folded freight: peroxisomal protein import in review. Crookes WJ, et al. **Naturwissenschaften** 1999 Feb;86(2):51–61 (126 ref.)

Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. McCann SM, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):193–202 (55 ref.)

Protein metabolism in alcoholism: effects on specific tissues and the whole body. Preedy VR, et al. **Nutrition** 1999 Jul–Aug;15(7–8):604–8 (50 ref.)

Human uncoupling proteins and obesity. Schrauwen P, et al. **Obes Res** 1999 Jan;7(1):97–105 (51 ref.)

Stress-activated kinases regulate protein stability. Fuchs SY, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1483–90 (87 ref.)

From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'. Sudol M. **Oncogene** 1998 Sep 17;17(11 Reviews):1469–74 (64 ref.)

Chaperone rings in protein folding and degradation. Horwich AL, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28; 96(20):11033–40 (80 ref.)

Effects of leptin on mitochondrial 'proton leak' and uncoupling proteins: implications for mammalian energy metabolism. Porter RK, et al. **Proc Nutr Soc** 1998 Aug; 57(3):455–60 (86 ref.)

RNA and protein interactions modulated by protein arginine methylation. Gary JD, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:65–131 (250 ref.)

Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Kettle AJ, et al. **Redox Rep** 1997 Oct–Dec;3(5–6):257–8 (17 ref.)

Protein sorting by directed maturation of Golgi compartments. Allan BB, et al. **Science** 1999 Jul 2; 285(5424):63–6 (68 ref.)

Protein interaction methods--toward an endgame. Mendelsohn AR, et al. **Science** 1999 Jun 18; 284(5422):1948–50 (44 ref.)

GEFs: structural basis for their activation of small GTP-binding proteins. Cherfils J, et al. **Trends Biochem Sci** 1999 Aug;24(8):306–11 (34 ref.)

The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Chin L, et al. **Trends Biochem Sci** 1998 Aug;23(8):291–6 (50 ref.)

How regulated protein translocation can produce switch-like responses. Ferrell JE Jr. **Trends Biochem Sci** 1998 Dec; 23(12):461–5 (37 ref.)

Retrograde protein translocation: ERADication of secretory proteins in health and disease. Plemper RK, et al. **Trends Biochem Sci** 1999 Jul;24(7):266–70 (44 ref.)

The WD repeat: a common architecture for diverse functions. Smith TF, et al. **Trends Biochem Sci** 1999 May;24(5):181–5 (40 ref.)

Tripeptidyl peptidases: enzymes that count. Tomkinson B. **Trends Biochem Sci** 1999 Sep;24(9):355–9 (31 ref.)

Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Whitmarsh AJ, et al. **Trends Biochem Sci** 1998 Dec;23(12):481–5 (33 ref.)

Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Wishart MJ, et al. **Trends Biochem Sci** 1998 Aug;23(8):301–6 (47 ref.)

Prospects for drug screening using the reverse two-hybrid system. Vidal M, et al. **Trends Biotechnol** 1999 Sep; 17(9):374–81 (57 ref.)

Proteasome inhibitors: valuable new tools for cell biologists. Lee DH, et al. **Trends Cell Biol** 1998 Oct;8(10):397–403 (49 ref.)

Nuclear migration, nucleokinesis and lissencephaly. Morris NR, et al. **Trends Cell Biol** 1998 Dec;8(12):467–70 (37 ref.)

Waltzing with WASP [see comments] Ramesh N, et al. **Trends Cell Biol** 1999 Jan;9(1):15–9 (58 ref.) Comment in: Trends Cell Biol 1999 Jun;9(6):211–2.

Old and new pathways of protein export in chloroplasts and bacteria. Settles AM, et al. **Trends Cell Biol** 1998 Dec; 8(12):494–501 (67 ref.)

Photobleaching GFP reveals protein dynamics inside live cells. White J, et al. **Trends Cell Biol** 1999 Feb;9(2):61–5 (29 ref.)

Postoperative protein sparing. Wilmore DW. **World J Surg** 1999 Jun;23(6):545–52 (49 ref.)

[Cachexia in cancer: disturbances in the protein and aminoacid metabolism] de Blaauw I, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3;143(27):1408–13 (60 ref.) (Eng. Abstr.) **(Dut)**

[The significance of leptin for the pathogenesis of diabetes mellitus type 2. Direct effects on endocrine pancreas] Seufert J. **Internist (Berl)** 1999 Aug;40(8):894–7 (00 ref.) **(Ger)**

[Human diseases associated with ubiquitin/proteasome proteolytic system] Anan T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):776–86 (45 ref.) **(Jpn)**

[Molecular mechanism of ubiquitin proteasome-regulated quality control in the endoplasmic reticulum] Tokunaga F. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):766–75 (67 ref.) **(Jpn)**

[Intracellular proteolysis] Staszczak M, et al. **Postepy Biochem** 1999;45(1):32–41 (95 ref.) **(Pol)**

[Studying intestinal maturation in newborn infants by means of stable isotopes] Sáenz de Pipaón M, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):77–82 (59 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. Marttin E, et al. **J Drug Target** 1998; 6(1):17–36 (98 ref.)

PHARMACOLOGY

Leptin sensitive neurons in the hypothalamus. Baskin DG, et al. **Horm Metab Res** 1999 May;31(5):345–50 (83 ref.)

Utilization of genetically altered animals in the pharmaceutical industry. Rudmann DG, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):111–4 (51 ref.)

[Use of snake venom proteins in medicine] Stocker K. **Schweiz Med Wochenschr** 1999 Feb 13;129(6):205–16 (51 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Host proteins in retroviral cDNA integration. Bushman FD. **Adv Virus Res** 1999;52:301–17 (81 ref.)

Multiple ATM-dependent pathways: an explanation for pleiotropy [editorial] Brown KD, et al. **Am J Hum Genet** 1999 Jan;64(1):46–50 (35 ref.)

The role of leptin in human obesity and disease: a review of current evidence. Mantzoros CS. **Ann Intern Med** 1999 Apr 20;130(8):671–80 (160 ref.)

Endogenous salivary inhibitors of human immunodeficiency virus. Shugars DC, et al. **Arch Oral Biol** 1999 Jun; 44(6):445–53 (68 ref.)

Interaction between body composition, leptin and growth hormone status. Casanueva FF, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):297–314 (96 ref.)

Orphan selenoproteins. Burk RF, et al. **Bioessays** 1999 Mar; 21(3):231–7 (67 ref.)

To fear or not to fear: what was the question? A potential role for Ras-GRF in memory. Finkbeiner S, et al. **Bioessays** 1998 Sep;20(9):691–5 (27 ref.)

Melanocortin receptors and antagonists regulate pigmentation and body weight. Jordan SA, et al. **Bioessays** 1998 Aug;20(8):603–6 (27 ref.)

Leptin's actions on the reproductive axis: perspectives and mechanisms. Cunningham MJ, et al. **Biol Reprod** 1999 Feb; 60(2):216–22 (123 ref.)

Physiological perspectives on leptin as a regulator of reproduction: role in timing puberty. Foster DL, et al. **Biol Reprod** 1999 Feb;60(2):205–15 (69 ref.)

Multiple phosphorylation sites and quaternary organization of guanine-nucleotide exchange complex of elongation factor-1 (EF-1betagammadelta/ValRS) control the various functions of EF-1alpha. Minella O, et al. **Biosci Rep** 1998 Jun;18(3):119–27 (41 ref.)

Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Jüppner H. **Bone** 1999 Jul;25(1):87–90 (61 ref.)

Leptin and reproduction: is it a critical link between adipose tissue, nutrition, and reproduction? Thong FS, et al. **Can J Appl Physiol** 1999 Aug;24(4):317–36 (101 ref.)

Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Ganther HE. **Carcinogenesis** 1999 Sep;20(9):1657–66 (86 ref.)

Hedgehog and Spitz: making a match between photoreceptor axons and their targets. Salecker I, et al. **Cell** 1998 Nov 25;95(5):587–90 (18 ref.)

Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein. Robert M, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):944–60 (95 ref.)

Recruitment of proteins to modulate protein-protein interactions. Liu JO. **Chem Biol** 1999 Aug;6(8):R213–5 (18 ref.)

Leptin and the thyroid--a puzzle with missing pieces [comment] Korbonits M. **Clin Endocrinol (Oxf)** 1998 Nov; 49(5):569–72 (29 ref.) Comment on: Clin Endocrinol (Oxf) 1998 Nov;49(5):583–8.

Leptin: in search of role(s) in human physiology and pathophysiology. Mantzoros CS, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):551–67 (202 ref.)

Leptin: physiology and pathophysiology. Frühbeck G, et al. **Clin Physiol** 1998 Sep;18(5):399–419 (155 ref.)

Parathyroid hormone-related peptide (PTHrP) and parathyroid hormone (PTH)/PTHrP receptor. Lanske B, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3–4):297–320 (107 ref.)

Going for the GAP. McCormick F. **Curr Biol** 1998 Sep 24; 8(19):R673–4 (5 ref.)

Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Pepicelli CV, et al. **Curr Biol** 1998 Sep 24;8(19):1083–6 (18 ref.)

Light-activated proteins. Curley K, et al. **Curr Opin Chem Biol** 1999 Feb;3(1):84–8 (19 ref.)

Mussel byssus and biomolecular materials. Deming TJ. **Curr Opin Chem Biol** 1999 Feb;3(1):100–5 (42 ref.)

Recent advances in our understanding of Wiskott-Aldrich syndrome. Sullivan KE. **Curr Opin Hematol** 1999 Jan; 6(1):8–14 (50 ref.)

Characterization of the Wiskott-Aldrich syndrome protein and its role in the disease. Nonoyama S, et al. **Curr Opin Immunol** 1998 Aug;10(4):407–12 (46 ref.)

Leptin, the hypothalamus and the regulation of adiposity. Harrold JA, et al. **Curr Opin Lipidol** 1998 Aug;9(4):295–9 (30 ref.)

The role of the PHEX gene (PEX) in families with X-linked hypophosphataemic rickets. Rowe PS.
Curr Opin Nephrol Hypertens 1998 Jul;7(4):367-76 (108 ref.)
From protein sequence to function. Danchin A.
Curr Opin Struct Biol 1999 Jun;9(3):363-7 (64 ref.)
From protein structure to function. Orengo CA, et al.
Curr Opin Struct Biol 1999 Jun;9(3):374-82 (68 ref.)
The angiopoietins: Yin and Yang in angiogenesis. Davis S, et al. **Curr Top Microbiol Immunol** 1999;237:173-85 (42 ref.)
Does leptin regulate insulin secretion? Poitout V, et al.
Diabetes Metab 1998 Sep;24(4):321-6 (35 ref.)
Nutritional regulation of leptin in humans. Coleman RA, et al. **Diabetologia** 1999 Jun;42(6):639-46 (80 ref.)
Leptin and its receptors: regulators of whole-body energy homeostasis. Houseknecht KL, et al.
Domest Anim Endocrinol 1998 Nov;15(6):457-75 (166 ref.)
Hypothalamic control of gonadotropin secretion by LHRH, FSHRF, NO, cytokines, and leptin. McCann SM, et al.
Domest Anim Endocrinol 1998 Sep;15(5):333-44 (53 ref.)
Parathyroid hormone-related protein in cardiovascular development and blood pressure regulation [editorial; comment] Massfelder T, et al. **Endocrinology** 1999 Apr; 140(4):1507-10 (27 ref.) Comment on: Endocrinology 1999 Apr;140(4):1815-25.
Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium [see comments] Hiemstra PS, et al.
Eur Respir J 1998 Nov;12(5):1200-8 (103 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250-1.
Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. Panteleyev AA, et al.
Exp Dermatol 1998 Oct;7(5):249-67 (138 ref.)
Parathyroid hormone-related protein: roles in the glomerulus. Bosch RJ, et al. **Exp Nephrol** 1999 May-Jun; 7(3):212-6 (15 ref.)
Tumor surveillance via the ARF-p53 pathway. Sherr CJ.
Genes Dev 1998 Oct 1;12(19):2984-91 (81 ref.)
Trefoil peptides. Wong WM, et al. **Gut** 1999 Jun;44(6):890-5 (88 ref.)
Is there a role for leptin in human reproduction? Macut D, et al. **Gynecol Endocrinol** 1998 Oct;12(5):321-6 (58 ref.)
ATM: from gene to function. Rotman G, et al.
Hum Mol Genet 1998;7(10):1555-63 (109 ref.)
Leptin, polycystic ovaries and polycystic ovary syndrome. Jacobs HS, et al. **Hum Reprod Update** 1999 Mar-Apr; 5(2):166-71 (70 ref.)
Leptin in human reproduction. Messinis IE, et al.
Hum Reprod Update 1999 Jan-Feb;5(1):52-63 (111 ref.)
State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Mark AL, et al. **Hypertension** 1999 Jan;33(1 Pt 2):537-41 (40 ref.)
Leptin. Prolo P, et al. **Int J Biochem Cell Biol** 1998 Dec; 30(12):1285-90 (18 ref.)
Abnormal cortical development; towards elucidation of the LIS1 gene product function (review). Reiner O, et al.
Int J Mol Med 1998 May;1(5):849-53 (74 ref.)
UCP1, UCP2 and UCP3: are they true uncouplers of respiration? Bouillaud F.
Int J Obes Relat Metab Disord 1999 Jun;23 Suppl 6:S19-23 (30 ref.)
The physiological role of the novel uncoupling proteins: view from the chair. Silva JE.
Int J Obes Relat Metab Disord 1999 Jun;23 Suppl 6:S72-4 (14 ref.)
Leptin: fundamental aspects. Trayhurn P, et al.
Int J Obes Relat Metab Disord 1999 Feb;23 Suppl 1:22-8 (83 ref.)
Clinical endocrinology of human leptin. Van Gaal LF, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:29-36 (55 ref.)
The diverse role of selenium within selenoproteins: a review. Holben DH, et al. **J Am Diet Assoc** 1999 Jul;99(7):836-43 (117 ref.)
The brain-pituitary-adipocyte axis: role of leptin in modulating neuroendocrine function. Barb CR.
J Anim Sci 1999 May;77(5):1249-57 (75 ref.)
Molecular bases for the recognition of tyrosine-based sorting signals. Bonifacino JS, et al. **J Cell Biol** 1999 May 31; 145(5):923-6 (42 ref.)
Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431-5 (33 ref.)
Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development. Dunbar ME, et al.
J Mammary Gland Biol Neoplasia 1999 Jan;4(1):21-34 (69 ref.)
Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. Dallongeville J, et al. **J Med Chem** 1998 Dec 31; 41(27):5337-52 (216 ref.)
Leptin: physiological actions. Marti A, et al.
J Physiol Biochem 1999 Mar;55(1):43-9 (49 ref.)
Melanocortin and leptin signaling systems: central regulation of catabolic energy balance. Fisher SL, et al.
J Recept Signal Transduct Res 1999 Jan-Jul;19(1-4):203-16 (34 ref.)
Leptin in renal failure. Mantzoros CS. **J Ren Nutr** 1999 Jul; 9(3):122-5 (45 ref.)
Nitration modifying function of proteins, hormones and neurotransmitters. Nakaki T, et al. **Jpn J Pharmacol** 1999 Feb;79(2):125-9 (53 ref.)
A role for leptin in glomerulosclerosis? [editorial; comment] Ballermann BJ. **Kidney Int** 1999 Sep;56(3):1154-5 (9 ref.) Comment on: Kidney Int 1999 Sep;56(3):860-72.
Induction of islet cell neogenesis in the adult pancreas: the partial duct obstruction model. Rosenberg L.
Microsc Res Tech 1998 Nov 15;43(4):337-46 (75 ref.)
A role for leptin in hemopoieses? Gainsford T, et al.
Mol Biotechnol 1999 Apr;11(2):149-58 (91 ref.)
Metabolic control of sexual function and growth: role of neuropeptide Y and leptin. Aubert ML, et al.
Mol Cell Endocrinol 1998 May 25;140(1-2):107-13 (32 ref.)
Use of two-hybrid methodology for identifying proteins of interest in endocrinology. Pirson I, et al.
Mol Cell Endocrinol 1999 May 25;151(1-2):137-41 (42 ref.)
On the search for the sperm oscillogen. Swann K, et al.
Mol Hum Reprod 1998 Nov;4(11):1010-2 (31 ref.)
Human developmental disorders and the Sonic hedgehog pathway. Ming JE, et al. **Mol Med Today** 1998 Aug; 4(8):343-9 (49 ref.)
Unraveling the central nervous system pathways underlying responses to leptin. Elmquist JK, et al. **Nat Neurosci** 1998 Oct;1(6):445-50 (107 ref.)
Leptin and the regulation of body weight in mammals. Friedman JM, et al. **Nature** 1998 Oct 22;395(6704):763-70 (109 ref.)
Molecular studies of leptin: implications for renal disease. Stenvinkel P, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1103-12 (101 ref.)
Upsetting the balance: VGF and the regulation of body weight [comment] Altshuler D, et al. **Neuron** 1999 Jul; 23(3):415-7 (9 ref.) Comment on: Neuron 1999 Jul;23(3):537-48.
From lesions to leptin: hypothalamic control of food intake and body weight. Elmquist JK, et al. **Neuron** 1999 Feb; 22(2):221-32 (133 ref.)
Leptin (OB protein) and meal size [editorial] Flynn MC, et al. **Nutrition** 1999 Jun;15(6):508-9 (15 ref.)
The role of ATM in DNA damage responses and cancer. Canman CE, et al. **Oncogene** 1998 Dec 24;17(25):3301-8 (142 ref.)
The inhibitors of apoptosis (IAPs) and their emerging role in cancer. LaCasse EC, et al. **Oncogene** 1998 Dec 24; 17(25):3247-59 (122 ref.)
Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Levy-Strumpf N, et al. **Oncogene** 1998 Dec 24; 17(25):3331-40 (33 ref.)
Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Badet J.
Pathol Biol (Paris) 1999 Apr;47(4):345-51 (57 ref.)
The role of the polycystins in kidney development. van Adelsberg JS. **Pediatr Nephrol** 1999 Jun;13(5):454-9 (48 ref.)
Regulation of body weight in humans. Jéquier E, et al.
Physiol Rev 1999 Apr;79(2):451-80 (286 ref.)
14-3-3 proteins: eukaryotic regulatory proteins with many functions. Finnie C, et al. **Plant Mol Biol** 1999 Jul; 40(4):545-54 (78 ref.)
Leptin: energy regulation and beyond to a hormone with pan-physiological function. Andrews JF. **Proc Nutr Soc** 1998 Aug;57(3):409-11 (16 ref.)
Human and clinical perspectives on leptin. Blum WF, et al.
Proc Nutr Soc 1998 Aug;57(3):477-85 (78 ref.)
Overview: neurobiology of OB protein (leptin). Campfield LA, et al. **Proc Nutr Soc** 1998 Aug;57(3):429-40 (70 ref.)
Peripheral metabolic actions of leptin. Cawthorne MA, et al. **Proc Nutr Soc** 1998 Aug;57(3):449-53 (33 ref.)
Leptin and reproduction. Hoggard N, et al.
Proc Nutr Soc 1998 Aug;57(3):421-7 (38 ref.)
Effects of leptin on mitochondrial 'proton leak' and uncoupling proteins: implications for mammalian energy metabolism. Porter RK, et al. **Proc Nutr Soc** 1998 Aug; 57(3):455-60 (86 ref.)
The MONA LISA hypothesis in the time of leptin. Bray GA, et al. **Recent Prog Horm Res** 1998;53:95-117; discussion 117-8 (122 ref.)
Functional analysis of the PTH/PTHrP network of ligands and receptors. Kronenberg HM, et al.
Recent Prog Horm Res 1998;53:283-301; discussion 301-3 (38 ref.)
Parathyroid hormone-related protein in the pancreatic islet and the cardiovascular system. Vasavada RC, et al.
Recent Prog Horm Res 1998;53:305-38; discussion 338-40 (68 ref.)
The IAP family of apoptotic regulators. Eiben LJ, et al.
Results Probl Cell Differ 1998;24:91-104 (54 ref.)
Leptin and reproduction. Clarke IJ, et al. **Rev Reprod** 1999 Jan;4(1):48-55 (74 ref.)
The specification of neuronal identity by graded Sonic Hedgehog signalling. Briscoe J, et al.
Semin Cell Dev Biol 1999 Jun;10(3):353-62 (60 ref.)
"Spot 14" protein: a metabolic integrator in normal and neoplastic cells. Cunningham BA, et al. **Thyroid** 1998 Sep; 8(9):815-25 (89 ref.)
Moonlighting proteins. Jeffery CJ. **Trends Biochem Sci** 1999 Jan;24(1):8-11 (28 ref.)
RGS proteins: more than just GAPs for heterotrimeric G proteins. De Vries L, et al. **Trends Cell Biol** 1999 Apr; 9(4):138-44 (67 ref.)
Endocytosis proteins and cancer: a potential link? Floyd S, et al. **Trends Cell Biol** 1998 Aug;8(8):299-301 (35 ref.)
Emerging roles for SH2/PTB-containing Shc adaptor proteins in the developing mammalian brain. Cattaneo E, et al. **Trends Neurosci** 1998 Nov;21(11):476-81 (65 ref.)
Feeding and body-weight regulation by hypothalamic neuropeptides--mediation of the actions of leptin. Inui A.
Trends Neurosci 1999 Feb;22(2):62-7 (83 ref.)
Emerging roles for RGS proteins in cell signalling. Hepler JR. **Trends Pharmacol Sci** 1999 Sep;20(9):376-82 (84 ref.)
[From Claude Bernard to the regulatory system between the hypothalamus and the periphery: implications for homeostasis of body weight and obesity] Jeanrenaud B, et al. **C R Seances Soc Biol Fil** 1998;192(5):829-41 (48 ref.) (Eng. Abstr.) **(Fre)**
[Molecular mechanisms of fertilization: the re-opening of the search for oscillin] Tesarik J. **Contracept Fertil Sex** 1998 Oct;26(10):693-5 (30 ref.) **(Fre)**
[Leptin and puberty in humans: hypothesis of the critical adipose mass revisited] Issad T, et al. **Diabetes Metab** 1998 Sep;24(4):376-8 (13 ref.) **(Fre)**
[Leptin implications in reproduction endocrinology] Pralong FP. **Rev Med Suisse Romande** 1999 Jun;119(6):463-7 (12 ref.) **(Fre)**
[Obesity and leptin] Hauner H. **Dtsch Med Wochenschr** 1998 Oct 30;123(44):1315-6 (7 ref.) **(Ger)**
[Leptin--new knowledge on the pathogenesis of obesity] Spitzweg C, et al. **Med Klin** 1998 Aug 15;93(8):478-85 (106 ref.) (Eng. Abstr.) **(Ger)**
[Possible pathophysiologic, diagnostic and therapeutic implications of new findings on leptin secretion within the scope of anorexia nervosa] Wewetzer C, et al.
Z Kinder Jugendpsychiatr Psychother 1998 Dec; 26(4):244-52 (55 ref.) (Eng. Abstr.) **(Ger)**
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin). Additional report: Physiological regulation of ob gene expression] Kawakami Y, et al.
Nippon Naika Gakkai Zasshi 1998 Sep 10;87(9):1817-20 (12 ref.) **(Jpn)**
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin)] Ogawa Y, et al.
Nippon Naika Gakkai Zasshi 1998 Sep 10;87(9):1811-6 (16 ref.) **(Jpn)**
[The function of spinocerebellar ataxia type 2 (SCA2) gene product, ataxin-2 and the mechanism of pathogenesis for SCA2] Sanpei K. **Nippon Rinsho** 1999 Apr;57(4):822-4 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of G protein-mediated signaling pathways by RGS proteins] Kozasa T. **Seikagaku** 1998 Dec; 70(12):1418-22 (21 ref.) **(Jpn)**
[Evidence for a Ras/Ral signaling cascade] Urano T.
Seikagaku 1998 Sep;70(9):1181-3 (15 ref.) **(Jpn)**
[Regulation of protein function by lipid modifications] Fukada Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1319-20 (0 ref.) **(Jpn)**
[Regulation of protein functions by fatty acid acylation and isoprenylation] Hagiwara K, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1337-45 (71 ref.) **(Jpn)**
[Leptin--a fatty tissue hormone with many functions] Reseland JE, et al. **Tidsskr Nor Laegeforen** 1999 May 30; 119(14):2024-7 (54 ref.) (Eng. Abstr.) **(Nor)**
[Leptin and human reproduction] Macut D, et al.
Med Pregl 1998 Sep-Oct;51(9-10):410-4 (55 ref.) (Eng. Abstr.) **(Scr)**
[Leptin and puberty] Puigdevall Gallego V, et al.
An Esp Pediatr 1998 Dec;49(6):561-7 (95 ref.) **(Spa)**

SECRETION

Protein and lipid sorting from the trans-Golgi network to secretory granules-recent developments. Thiele C, et al.
Semin Cell Dev Biol 1998 Oct;9(5):511-6 (57 ref.)
[Body weight regulation in anorexia nervosa with special attention to leptin secretion] Hebebrand J, et al.
Nervenarzt 1999 Jan;70(1):31-40 (78 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Internal standards for 2-D. Link AJ. **Methods Mol Biol** 1999; 112:281-4 (2 ref.)

THERAPEUTIC USE

Parathyroid hormone and parathyroid hormone-related protein: model systems for the development of an osteoporosis therapy. Mierke DF, et al.
Curr Pharm Des 1999 Jan;5(1):21-36 (177 ref.)
Host defence (cationic) peptides: what is their future clinical potential? Hancock RE. **Drugs** 1999 Apr;57(4):469-73 (21 ref.)
Anticatabolic and anabolic strategies in critical illness: a review of current treatment modalities. Chang DW, et al.
Shock 1998 Sep;10(3):155-60 (77 ref.)

TOXICITY

Safety evaluation of peptides and proteins. Wong LC.
Chung Kuo Yao Li Hsueh Pao 1998 Mar;19(2):175-81 (12 ref.)
Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system. Capen CC. **Toxicol Lett** 1998 Dec 28;102-103:405-9 (7 ref.)

PROTEINS, ACUTE-PHASE

PROTEINS, ACUTE-PHASE see **ACUTE-PHASE PROTEINS**

PROTEINS, DIETARY see **DIETARY PROTEINS**

PROTEINS, IMMEDIATE-EARLY see **IMMEDIATE-EARLY PROTEINS**

PROTEINS, RIBOSOMAL see **RIBOSOMAL PROTEINS**

PROTEINURIA

Evaluating proteinuria in children [published erratum appears in Am Fam Physician 1999 Feb 1;59(3):540] Loghman-Adham M. **Am Fam Physician** 1998 Oct 1; 58(5):1145-52, 1158-9 (26 ref.)

Pheromone signalling in the mouse: role of urinary proteins and vomeronasal organ. Cavaggioni A, et al. **Arch Ital Biol** 1999 May;137(2-3):193-200 (52 ref.)

Clinical analysis of human urinary proteins using high resolution electrophoretic methods. Marshall T, et al. **Electrophoresis** 1998 Jul;19(10):1752-70 (184 ref.)

Preparation and solubilization of body fluids for 2-D. Sanchez JC, et al. **Methods Mol Biol** 1999;112:87-93 (21 ref.)

[Proteinuria] Burtsev VI, et al. **Klin Med (Mosk)** 1998; 76(8):48-52 (0 ref.) **(Rus)**

CHEMICALLY INDUCED

Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy [see comments] Shah M, et al. **Cancer** 1998 Nov 1;83(9):1938-46 (53 ref.) Comment in: Cancer 1999 Jun 15;85(12):2669-70.

COMPLICATIONS

Nephrotoxicity of increased glomerular protein traffic. Abbate M, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):304-12 (78 ref.)

[Mechanism of the development of tubulo-interstitial nephropathies caused by proteinuria] Saito T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1480-5 (7 ref.) **(Jpn)**

DIAGNOSIS

Electrophoretic analysis of Bence Jones proteinuria. Marshall T, et al. **Electrophoresis** 1999 Jun;20(7):1307-24 (156 ref.)

DIET THERAPY

Effects of soy protein on renal function and proteinuria in patients with type 2 diabetes. Anderson JW, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1347S-1353S (46 ref.)

DRUG THERAPY

Therapeutic concepts of proteinuria and intra-glomerular hypertension. Woo KT. **Singapore Med J** 1998 Jun; 39(6):271-2 (8 ref.)

ETIOLOGY

Nephrotic range proteinuria and hematuria in a white bisexual male. Paueksakon P, et al. **Am J Kidney Dis** 1999 Mar;33(3):607-12 (27 ref.)

[Proteinuria] Naujoks H, et al. **Internist (Berl)** 1998 Sep; 39(9):955-67; quiz 967 (11 ref.) **(Ger)**

GENETICS

Chemokines and renal inflammation in proteinuric disorders: searching for the inciting stimulus [editorial; comment] Crisman JM, et al. **J Lab Clin Med** 1999 Jan;133(1):13-4 (13 ref.) Comment on: J Lab Clin Med 1999 Jan;133(1):41-7.

PATHOLOGY

Proteinuria as a mediator of tubulointerstitial injury. Abbate M, et al. **Kidney Blood Press Res** 1999;22(1-2):37-46 (101 ref.)

Chronic interstitial damage in proteinuria. Does complement mediate tubulointerstitial injury? Sheerin NS, et al. **Kidney Blood Press Res** 1999;22(1-2):47-52 (57 ref.)

PHYSIOPATHOLOGY

Physiopathology of proteinuria and laboratory diagnostic strategy based on single protein analysis. Guder WG, et al. **Clin Chem Lab Med** 1998 Dec;36(12):935-9 (25 ref.)

Proteinuria as a mediator of tubulointerstitial injury. Abbate M, et al. **Kidney Blood Press Res** 1999;22(1-2):37-46 (101 ref.)

Endothelial function in proteinuric renal disease. Joles JA, et al. **Kidney Int Suppl** 1999 Jul;71:S57-61 (28 ref.)

URINE

Dry chemistry urinalysis of pathological proteinuria [see comments] Kutter D. **Clin Chem Lab Med** 1998 Dec; 36(12):929-33 (21 ref.) Comment in: Clin Chem Lab Med 1998 Dec;36(12):907.

A comparison of analytic procedures for measurement of fractional dextran clearances [see comments] Hemmelder MH, et al. **J Lab Clin Med** 1998 Nov;132(5):390-403 (57 ref.) Comment in: J Lab Clin Med 1998 Nov;132(5):360-2.

Assessment of glomerular size-selective function with fractional clearance of neutral dextran [editorial; comment] Remuzzi A, et al. **J Lab Clin Med** 1998 Nov;132(5):360-2 (27 ref.) Comment on: J Lab Clin Med 1998 Nov;132(5):390-403.

Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Weir MR. **Miner Electrolyte Metab** 1998;24(6):438-45 (56 ref.)

PROTEINURIA-EDEMA-HYPERTENSION GESTOSIS see **GESTOSIS, EPH**

PROTELES see **CARNIVORA**

PROTEOCHONDROITIN SULFATES

CHEMISTRY

Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. Watanabe H, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):687-93 (62 ref.)

GENETICS

BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Gary SC, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):576-81 (31 ref.)

PHYSIOLOGY

Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. Watanabe H, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):687-93 (62 ref.)

PROTEOGLYCANS

Hyaluronan and proteoglycans in ovarian follicles. Salustri A, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):293-301 (79 ref.)

ANALYSIS

A survey of methodological challenges for glycosaminoglycan/proteoglycan analysis and structural characterization by capillary electrophoresis. Karamanos NK, et al. **Electrophoresis** 1998 Nov;19(15):2561-71 (63 ref.)

BIOSYNTHESIS

Protein O-mannosylation. Strahl-Bolsinger S, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):297-307 (98 ref.)

CHEMISTRY

Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. Watanabe H, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):687-93 (62 ref.)

Proteoglycans: master regulators of molecular encounter? Lander AD. **Matrix Biol** 1998 Nov;17(7):465-72 (39 ref.)

GENETICS

Genetic analysis of functions for cell surface proteoglycans [see comments] Selleck S. **Matrix Biol** 1998 Nov; 17(7):473-6 (30 ref.) Comment in: Matrix Biol 1998 Nov;17(7):461-3.

Transcriptional and posttranscriptional regulation of proteoglycan gene expression. Iozzo RV, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:19-53 (134 ref.)

Transcriptional regulation of Syndecan-1 expression by growth factors. Jaakkola P, et al. **Prog Nucleic Acid Res Mol Biol** 1999;63:109-38 (130 ref.)

Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family. Schwartz NB, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 62:177-225 (151 ref.)

[Hyaluronan aggregating proteoglycans] Bobiński R, et al. **Postepy Biochem** 1998;44(3):245-51 (75 ref.) **(Pol)**

[Small interstitial proteoglycans--genetic differences and similarities] Bobiński R, et al. **Postepy Biochem** 1998; 44(1):64-71 (76 ref.) **(Pol)**

ISOLATION & PURIFICATION

Isolation and separation of proteoglycans. Savolainen H. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1-2):255-62 (69 ref.)

METABOLISM

Overgrowth syndromes and the regulation of signaling complexes by proteoglycans. Selleck SB. **Am J Hum Genet** 1999 Feb;64(2):372-7 (30 ref.)

Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Camejo G, et al. **Atherosclerosis** 1998 Aug;139(2):205-22 (131 ref.)

Proteoglycans at the bone-implant interface. Klinger MM, et al. **Crit Rev Oral Biol Med** 1998;9(4):449-63 (107 ref.)

Molecular interactions of the syndecan core proteins. Rapraeger AC, et al. **Curr Opin Cell Biol** 1998 Oct; 10(5):620-8 (63 ref.)

The syndecans, tuners of transmembrane signaling. Zimmermann P, et al. **FASEB J** 1999;13 Suppl:S91-S100 (79 ref.)

Ribonuclease-gold labels proteoglycan-containing cytoplasmic granules and ribonucleic acid-containing organelles--a survey. Dvorak AM, et al. **Histol Histopathol** 1999 Apr;14(2):597-626 (166 ref.)

Proteoglycans: master regulators of molecular encounter? Lander AD. **Matrix Biol** 1998 Nov;17(7):465-72 (39 ref.)

Measurements of proteoglycan-lipoprotein interaction by gel mobility shift assay. Hurt-Camejo E, et al. **Methods Mol Biol** 1998;110:267-79 (23 ref.)

Molecular self-recognition and adhesion via proteoglycan to proteoglycan interactions as a pathway to multicellularity: atomic force microscopy and color coded bead measurements in sponges. Misevic GN. **Microsc Res Tech** 1999 Feb 15;44(4):304-9 (40 ref.)

[Hyaluronan aggregating proteoglycans] Bobiński R, et al. **Postepy Biochem** 1998;44(3):245-51 (75 ref.) **(Pol)**

PHARMACOLOGY

The role of the extracellular matrix in skeletal muscle development. Velleman SG. **Poult Sci** 1999 May; 78(5):778-84 (47 ref.)

PHYSIOLOGY

Matrix proteoglycans: from molecular design to cellular function. Iozzo RV. **Annu Rev Biochem** 1998;67:609-52 (285 ref.)

Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Ständer M, et al. **Cell Tissue Res** 1999 May;296(2):221-7 (48 ref.)

Hyaluronan and proteoglycans in ovarian follicles. Salustri A, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):293-301 (79 ref.)

Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. Watanabe H, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):687-93 (62 ref.)

The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. Iozzo RV. **J Biol Chem** 1999 Jul 2;274(27):18843-6 (52 ref.)

Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Dhodapkar MV, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):35-43 (53 ref.)

Syndecan proteoglycans and cell adhesion [see comments] Woods A, et al. **Matrix Biol** 1998 Nov;17(7):477-83 (49 ref.) Comment in: Matrix Biol 1998 Nov;17(7):461-3.

Syndecan-3 in limb skeletal development. Kosher RA. **Microsc Res Tech** 1998 Oct 15;43(2):123-30 (97 ref.)

What is the role of decorin in diabetic kidney disease? Mogyorósi A, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1078-81 (27 ref.)

Experimental and human liver fibrogenesis. Kovalszky I, et al. **Scand J Gastroenterol Suppl** 1998;228:51-5 (25 ref.)

[Regulation of cell proliferation by proteoglycans] Yanagishita M. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2589-93 (24 ref.) **(Jpn)**

PROTEOLIPID PROTEIN, MYELIN see **MYELIN PROTEOLIPID PROTEIN**

PROTEOLIPIDS

see related
LIPOPROTEINS

Chromatographic approaches to liposomes, proteoliposomes and biomembrane vesicles. Lundahl P, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1-2):103-20 (147 ref.)

BIOSYNTHESIS

Regulation of surfactant protein gene transcription. Whitsett JA, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):303-11 (50 ref.)

CHEMISTRY

Structure and properties of surfactant protein B. Hawgood S, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):150-60 (53 ref.)

Structure and properties of surfactant protein C. Johansson J. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):161-72 (41 ref.)

Structure, processing and properties of surfactant protein A. McCormack FX. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):109-31 (191 ref.)

Functional roles and structural analysis of lung collectins SP-A and SP-D. Kuroki Y, et al. **Biol Neonate** 1999 Jun; 76 Suppl 1:19-21 (4 ref.)

Use of knockout mice to study surfactant protein structure and function. Weaver TE, et al. **Biol Neonate** 1999 Jun;76 Suppl 1:15-8 (10 ref.)

Structure of the ductin channel. Finbow ME, et al. **Biosci Rep** 1998 Dec;18(6):287-97 (33 ref.)

GENETICS

Genetics of the hydrophilic surfactant proteins A and D. Floros J, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):312-22 (53 ref.)

Regulation of expression of surfactant protein-A. Mendelson CR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):132-49 (59 ref.)

Genetics of the hydrophobic surfactant proteins. Nogee LM. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):323-33 (43 ref.)

IMMUNOLOGY

Surfactant protein A (SP-A) gene targeted mice. Korfhagen TR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):296-302 (46 ref.)
Membrane receptors for soluble defense collagens. Tenner AJ. **Curr Opin Immunol** 1999 Feb;11(1):34-41 (79 ref.)

ISOLATION & PURIFICATION

Surfactant proteins A and D: disease markers. Kuroki Y, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):334-45 (47 ref.)

METABOLISM

Interactions of surfactant protein A with pathogens. Haagsman HP. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):264-77 (73 ref.)
Surfactant protein metabolism in vivo. Ikegami M, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):218-25 (41 ref.)
Structure, processing and properties of surfactant protein A. McCormack FX. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):109-31 (191 ref.)
Interfacial properties of surfactant proteins. Pérez-Gil J, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):203-17 (70 ref.)
Interactions of surfactant protein A with epithelial cells and phagocytes. Tino MJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):241-63 (112 ref.)
Synthesis, processing and secretion of surfactant proteins B and C. Weaver TE. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):173-9 (42 ref.)

PHYSIOLOGY

Structure and properties of surfactant protein B. Hawgood S, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):150-60 (53 ref.)
Functional roles and structural analysis of lung collectins SP-A and SP-D. Kuroki Y, et al. **Biol Neonate** 1999 Jun; 76 Suppl 1:19-21 (4 ref.)
Use of knockout mice to study surfactant protein structure and function. Weaver TE, et al. **Biol Neonate** 1999 Jun;76 Suppl 1:15-8 (10 ref.)
Structure of the ductin channel. Finbow ME, et al. **Biosci Rep** 1998 Dec;18(6):287-97 (33 ref.)
Functional roles of the lung surfactant proteins SP-A and SP-D in innate immunity. Reid KB. **Immunobiology** 1998 Aug;199(2):200-7 (44 ref.)
Regulation and function of pulmonary surfactant protein B. Pryhuber GS. **Mol Genet Metab** 1998 Aug;64(4):217-28 (86 ref.)

SECRETION

Regulatory mechanisms of surfactant secretion. Mason RJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):226-40 (99 ref.)

PROTEOLYTIC ENZYMES see **PEPTIDE HYDROLASES**

PROTESTANTISM see **CHRISTIANITY**

PROTEUS

IMMUNOLOGY

[Common antigenicity of lipopolysaccharides between Rickettsiae and Proteus in the Weil-Felix test] Amano K. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):599-610 (43 ref.) **(Jpn)**

PROTEUS INFECTIONS

COMPLICATIONS

Rheumatoid arthritis, fasting, diet and bacteria: myths and enthusiasm [editorial] Nenonen MT. **Clin Rheumatol** 1998; 17(4):269-70 (17 ref.)

PROTEUS MIRABILIS

PATHOGENICITY

Rheumatoid arthritis, fasting, diet and bacteria: myths and enthusiasm [editorial] Nenonen MT. **Clin Rheumatol** 1998; 17(4):269-70 (17 ref.)

PROTEUS SYNDROME

DIAGNOSIS

Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Biesecker LG, et al. **Am J Med Genet** 1999 Jun 11;84(5):389-95 (35 ref.)

GENETICS

Elattoproteus syndrome: delineation of an inverse form of Proteus syndrome. Happle R. **Am J Med Genet** 1999 May 7;84(1):25-8 (25 ref.)

PROTHROMBIN

see related
COAGULANTS

BIOSYNTHESIS

An autopsy case of hepatoid carcinoma of the ovary with PIVKA-II production: immunohistochemical study and literature review. Senzaki H, et al. **Pathol Int** 1999 Feb; 49(2):164-9 (22 ref.)

GENETICS

Congenital deficiencies and abnormalities of prothrombin. Girolami A, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):557-69 (84 ref.)
The prothrombin 20210 G to A variation and thrombosis. Bertina RM. **Curr Opin Hematol** 1998 Sep;5(5):339-42 (34 ref.)
A patient homozygous for mutation 20210A in the prothrombin gene with venous thrombosis and transient ischemic attacks of thrombotic origin [letter] González Ordóñez AJ, et al. **Haematologica** 1998 Nov;83(11):1050-1 (9 ref.)
The prothrombin gene variant 20210A in venous and arterial thromboembolism [see comments] Vicente V, et al. **Haematologica** 1999 Apr;84(4):356-62 (78 ref.) Comment in: Haematologica 1999 Apr;84(4):290.

IMMUNOLOGY

Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Galli M, et al. **Blood** 1999 Apr 1;93(7):2149-57 (82 ref.)
Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. de Groot PG, et al. **Lupus** 1998;7 Suppl 2:S32-6 (36 ref.)
Prothrombin as cofactor for antiphospholipids. Galli M, et al. **Lupus** 1998;7 Suppl 2:S37-40 (30 ref.)
Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Rauch J. **Lupus** 1998;7 Suppl 2:S29-31 (20 ref.)

PHYSIOLOGY

The biology of prothrombin. Degen SJ, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):203-24 (98 ref.)

PROTHROMBIN DEFICIENCY see **HYPOPROTHROMBINEMIAS**

PROTHROMBIN TIME

Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Kitchen S, et al. **Semin Thromb Hemost** 1999;25(1):17-25 (62 ref.)
[Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time] Kagawa K, et al. **Rinsho Byori** 1999 May;47(5):431-7 (11 ref.) (Eng. Abstr.) **(Jpn)**

PROTIRELIN

see related
RECEPTORS, THYROTROPIN-RELEASING HORMONE

Orexis, anorexia, and thyrotropin-releasing hormone. Karydis I, et al. **Thyroid** 1998 Oct;8(10):947-50 (38 ref.)
A heuristic model of mental depression derived from basic and applied research on thyrotropin-releasing hormone. Sattin A. **Thyroid** 1998 Oct;8(10):957-62 (67 ref.)

ANALOGS & DERIVATIVES

Modulation of mammalian sperm function by fertilization promoting peptide (FPP). Fraser LR. **Andrologia** 1998 Aug-Sep;30(4-5):241-7 (33 ref.)
Role of fertilization promoting peptide (FPP) in modulating mammalian sperm function. Fraser LR. **Front Biosci** 1998 Dec 1;3:D1187-91 (34 ref.)
The modulation of sperm function by fertilization promoting peptide. Fraser LR. **Hum Reprod** 1998 Dec;13 Suppl 4:1-10 (32 ref.)
Fertilization promoting peptide: an important regulator of sperm function in vivo? Fraser LR. **Rev Reprod** 1998 Sep; 3(3):151-4 (32 ref.)

BIOSYNTHESIS

Neuroregulation of ProTRH biosynthesis and processing. Nillni EA. **Endocrine** 1999 Jun;10(3):185-99 (208 ref.)

DIAGNOSTIC USE

The clinical impact of the thyrotropin-releasing hormone test. Faglia G. **Thyroid** 1998 Oct;8(10):903-8 (47 ref.)

GENETICS

Physiological and pathophysiological aspects of thyrotropin-releasing hormone gene expression in the human hypothalamus. Fliers E, et al. **Thyroid** 1998 Oct; 8(10):921-8 (45 ref.)
The thyrotropin-releasing hormone gene 1998: cloning, characterization, and transcriptional regulation in the central nervous system, heart, and testis. Wilber JF, et al. **Thyroid** 1998 Oct;8(10):897-901 (14 ref.)

METABOLISM

Thyrotropin releasing hormone (TRH), the TRH-receptor and the TRH-degrading ectoenzyme: three elements of a peptidergic signalling system. Bauer K, et al. **Results Probl Cell Differ** 1999;26:13-42 (140 ref.)
The thyrotropin-releasing hormone-degrading ectoenzyme: the third element of the thyrotropin-releasing hormone-signaling system. Heuer H, et al. **Thyroid** 1998 Oct;8(10):915-20 (28 ref.)
Limited proteolysis and physiological regulation: an example from thyrotropin-releasing hormone metabolism. Prasad C. **Thyroid** 1998 Oct;8(10):969-75 (90 ref.)

PHARMACOLOGY

The role of TRH and related peptides in the mechanism of action of ECT. Sattin A. **J ECT** 1999 Mar;15(1):76-92 (103 ref.)
The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Lazarus JH. **Thyroid** 1998 Oct;8(10):909-13 (52 ref.)

PHYSIOLOGY

TRH inactivation in the extracellular compartment: role of pyroglutamyl peptidase II. Charli JL, et al. **Neurobiology (Bp)** 1998;6(1):45-57 (65 ref.)
Is Ps4 (prepro-TRH [160-169]) more than an enhancer for thyrotropin-releasing hormone? Pekary AE. **Thyroid** 1998 Oct;8(10):963-8 (41 ref.)
Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Persani L. **Thyroid** 1998 Oct;8(10):941-6 (45 ref.)

PROTIRELIN RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

PROTO-ONCOGENE PROTEIN FMS see **RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR**

PROTO-ONCOGENE PROTEIN P21(RAS)

GENETICS

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Weiss B, et al. **Am J Med Genet** 1999 Mar 26; 89(1):14-22 (103 ref.)
Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Mitsumori K, et al. **Toxicol Pathol** 1998 Jul-Aug;26(4):520-31 (50 ref.)

PHYSIOLOGY

Going for the GAP. McCormick F. **Curr Biol** 1998 Sep 24; 8(19):R673-4 (5 ref.)
Regulation of platelet-derived growth factor signaling by activated p21Ras. Stice LL, et al. **Front Biosci** 1999 Jan 15;4:D72-86 (113 ref.)
Modulation of the immune response and tumor growth by activated Ras. Weijzen S, et al. **Leukemia** 1999 Apr; 13(4):502-13 (107 ref.)
Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. Dudler T, et al. **Methods Mol Biol** 1999;116:161-76 (19 ref.)

PROTO-ONCOGENE PROTEIN P185(NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENE PROTEINS

[Structure and dynamics of the transcription factor, Myb, in DNA-sequence recognition] Ogata K. **Seikagaku** 1998 Oct;70(10):1233-50 (44 ref.) **(Jpn)**
[Interaction of transcription factor PU. 1 with coactivator CBP] Yamamoto H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1389-95 (35 ref.) **(Jpn)**

ANALYSIS

RET protooncogene analysis in the diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type II. Matias-Guiu X. **Adv Anat Pathol** 1998 May;5(3):196-201 (19 ref.)
The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Gullick WJ, et al. **Breast Cancer Res Treat** 1998;52(1-3):43-53 (46 ref.)
Thrombopoietin receptor in acute myeloid leukemia. Wetzler M, et al. **Leuk Res** 1999 Feb;23(2):191-4 (33 ref.)

CHEMISTRY

Cbl: complex formation and functional implications. Liu YC, et al. **Cell Signal** 1998 Jun;10(6):377-85 (120 ref.)
Fyn, a Src family tyrosine kinase. Resh MD. **Int J Biochem Cell Biol** 1998 Nov;30(11):1159-62 (15 ref.)

GENETICS

Specificity within the ets family of transcription factors.

Graves BJ, et al. **Adv Cancer Res** 1998;75:1-55 (236 ref.)
RET proto-oncogene: role in kidney development and molecular pathology. Salomon R, et al. **Adv Nephrol Necker Hosp** 1998;28:401-17 (50 ref.)
The Tpr protein: linking structure and function in the nuclear interior? Paddy MR. **Am J Hum Genet** 1998 Aug; 63(2):305-10 (34 ref.)
The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Oliveira C, et al. **Am J Pathol** 1998 Oct;153(4):1211-9 (44 ref.)
Mechanisms of Wnt signaling in development. Wodarz A, et al. **Annu Rev Cell Dev Biol** 1998;14:59-88 (147 ref.)
Different mutations of the RET gene cause different human tumoral diseases. Santoro M, et al. **Biochimie** 1999 Apr; 81(4):397-402 (57 ref.)
Cell cycle control in the Drosophila wing. Milán M. **Bioessays** 1998 Dec;20(12):969-71 (19 ref.)
Exploiting the p53 pathway for cancer diagnosis and therapy. Lane DP. **Br J Cancer** 1999 Jul;80 Suppl 1:1-5 (25 ref.)
The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Ponder BA. **Cancer Res** 1999 Apr 1;59(7 Suppl):1736s-1741s; discussion 1742s (78 ref.)
Functions of the MDM2 oncoprotein. Freedman DA, et al. **Cell Mol Life Sci** 1999 Jan;55(1):96-107 (79 ref.)
The c-Fes family of protein-tyrosine kinases. Smithgall TE, et al. **Crit Rev Oncog** 1998;9(1):43-62 (131 ref.)
RET proto-oncogene in the development of human cancer. Eng C. **J Clin Oncol** 1999 Jan;17(1):380-93 (127 ref.)
Myb-transformed hematopoietic cells as a model for monocyte differentiation into dendritic cells and macrophages. Banyer JL, et al. **J Leukoc Biol** 1999 Aug; 66(2):217-23 (82 ref.)
A ret transgenic mouse model of thyroid carcinogenesis. Capen C, et al. **Lab Anim Sci** 1998 Dec;48(6):580-3 (3 ref.)
GDNF family neurotrophic factor signaling: four masters, one servant? Airaksinen MS, et al. **Mol Cell Neurosci** 1999 May;13(5):313-25 (117 ref.)
Mdm2: the ups and downs. Juven-Gershon T, et al. **Mol Med** 1999 Feb;5(2):71-83 (110 ref.)
Effects of differentiation on the transcriptional regulation of the FGF-4 gene: critical roles played by a distal enhancer. Lamb KA, et al. **Mol Reprod Dev** 1998 Oct;51(2):218-24 (57 ref.)
Myb targeted therapeutics for the treatment of human malignancies. Gewirtz AM. **Oncogene** 1999 May 13; 18(19):3056-62 (73 ref.)
Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Pierotti MA, et al. **Recent Results Cancer Res** 1998;154:237-47 (47 ref.)
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Rabes HM, et al. **Recent Results Cancer Res** 1998;154:248-64 (92 ref.)
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M, et al. **Recent Results Cancer Res** 1998; 154:229-36 (22 ref.)
Genetic aspects of Hirschsprung's disease. Kusafuka T, et al. **Semin Pediatr Surg** 1998 Aug;7(3):148-55 (97 ref.)
Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Kebebew E, et al. **Thyroid** 1999 Feb;9(2):127-31 (17 ref.)
Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl. Pisarchik AV, et al. **Thyroid** 1998 Nov;8(11):1003-8 (39 ref.)
[Genes and genetics in Hirschsprung's disease] Maas SM, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1352-6 (24 ref.) (Eng. Abstr.) **(Dut)**
[Mdm2, p53 and the cell cycle: when well enough is best left alone] Maréchal V. **Pathol Biol (Paris)** 1997 Dec; 45(10):824-32 (70 ref.) (Eng. Abstr.) **(Fre)**
[Primary splenic lymphoma with t(3;14)(q27;q32) chromosomal abnormality and rearrangement of BCL-6 gene] Yata K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):587-92 (14 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Lupher ML Jr, et al. **Immunol Today** 1999 Aug;20(8):375-82 (62 ref.)

METABOLISM

Mechanisms of Wnt signaling in development. Wodarz A, et al. **Annu Rev Cell Dev Biol** 1998;14:59-88 (147 ref.)
Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Grilli M, et al. **Biochem Pharmacol** 1999 Jan 1;57(1):1-7 (60 ref.)
Specification of neuronal connectivity: ETS marks the spot [comment] Ghosh A, et al. **Cell** 1998 Oct 30;95(3):303-6 (17 ref.) Comment on: Cell 1998 Oct 30;95(3):393-407.
Signaling to p53: breaking the MDM2-p53 circuit. Prives C. **Cell** 1998 Oct 2;95(1):5-8 (24 ref.)
The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Oikawa T, et al. **Cell Death Differ** 1999 Jul; 6(7):599-608 (161 ref.)
Autoinhibition as a transcriptional regulatory mechanism. Graves BJ, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:621-9 (60 ref.)
The c-Fes family of protein-tyrosine kinases. Smithgall TE, et al. **Crit Rev Oncog** 1998;9(1):43-62 (131 ref.)
Wnt signalling: pathway or network? Arias AM, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):447-54 (82 ref.)
Extracellular modulation of the Hedgehog, Wnt and TGF-beta signalling pathways during embryonic development. Capdevila J, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):427-33 (91 ref.)
Propagation and localization of Wnt signaling. Gumbiner BM. **Curr Opin Genet Dev** 1998 Aug;8(4):430-5 (43 ref.)
Wnt signaling and dorso-ventral axis specification in vertebrates. Sokol SY. **Curr Opin Genet Dev** 1999 Aug; 9(4):405-10 (73 ref.)
The CCN family of angiogenic regulators: the integrin connection. Lau LF, et al. **Exp Cell Res** 1999 Apr 10; 248(1):44-57 (101 ref.)
A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Maniatis T. **Genes Dev** 1999 Mar 1;13(5):505-10 (38 ref.)
Regulation of protein kinase B. Meier R, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1-4):121-8 (29 ref.)
Mdm2: the ups and downs. Juven-Gershon T, et al. **Mol Med** 1999 Feb;5(2):71-83 (110 ref.)
Expression of bcl-2 and bax in glomerular disease. Yoshimura A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:55-7 (8 ref.)
Interactions between growth factors and gap junctional communication in developing systems. Warner A. **Novartis Found Symp** 1999;219:60-72; discussion 72-5 (24 ref.)
Myb binding proteins: regulators and cohorts in transformation. Ness SA. **Oncogene** 1999 May 13; 18(19):3039-46 (62 ref.)
The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Cohen P. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1382):485-95 (83 ref.)
The DH protein family, exchange factors for Rho-like GTPases. Stam JC, et al. **Prog Mol Subcell Biol** 1999; 22:51-83 (187 ref.)
Signalling at a distance: transport of Wingless in the embryonic epidermis of Drosophila. Pfeiffer S, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):303-9 (55 ref.)
NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Foo SY, et al. **Trends Genet** 1999 Jun; 15(6):229-35 (50 ref.)
[The role of APC in colonic cancerogenesis: zeroing in on Myc] Jeanteur P. **Bull Cancer** 1998 Nov;85(11):925-8 (31 ref.) (Eng. Abstr.) **(Fre)**
[Transcription factors of the Ets family and morphogenesis of the vascular tree] Mattot V, et al. **J Soc Biol** 1999; 193(2):147-53 (68 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Myb and oncogenesis. Ganter B, et al. **Adv Cancer Res** 1999; 76:21-60 (289 ref.)
Thrombopoietin and its receptor: structure, function and role in the regulation of platelet production. von dem Borne AE, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):409-26 (111 ref.)
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Coffer PJ, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):1-13 (129 ref.)
Cbl: complex formation and functional implications. Liu YC, et al. **Cell Signal** 1998 Jun;10(6):377-85 (120 ref.)
Lymphocyte signalling: a coordinating role for Vav? Cantrell D. **Curr Biol** 1998 Jul 16;8(15):R535-8 (15 ref.)
Cell death: shadow baxing. Silke J, et al. **Curr Biol** 1998 Jul 16;8(15):R528-31 (22 ref.)
Cellular mechanisms of wingless/Wnt signal transduction. Dierick H, et al. **Curr Top Dev Biol** 1999;43:153-90 (166 ref.)
FLT3: receptor and ligand. Biology and potential clinical application. Shurin MR, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):37-48 (104 ref.)
Thrombopoietin and its receptor. Wendling F, et al. **Eur Cytokine Netw** 1998 Sep;9(3):221-31 (139 ref.)
c-Cbl: a regulator of T cell receptor-mediated signalling. Thien CB, et al. **Immunol Cell Biol** 1998 Oct;76(5):473-82 (90 ref.)
Thymocyte selection in Vav and IRF-1 gene-deficient mice. Penninger JM, et al. **Immunol Rev** 1998 Oct;165:149-66 (213 ref.)
Fyn, a Src family tyrosine kinase. Resh MD. **Int J Biochem Cell Biol** 1998 Nov;30(11):1159-62 (15 ref.)
Physiological signals and oncogenesis mediated through Crk family adapter proteins. Feller SM, et al. **J Cell Physiol** 1998 Dec;177(4):535-52 (229 ref.)
Functional roles of thrombopoietin-c-mpl system in essential thrombocythemia. Matsumura I, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):351-8 (57 ref.)
The role of the MPL receptor in myeloproliferative disorders. Kaushansky K. **Leukemia** 1998 Sep;12 Suppl 1:S47-50 (26 ref.)
Trks: signal transduction and intracellular pathways. Klesse LJ, et al. **Microsc Res Tech** 1999 May 15-Jun 1; 45(4-5):210-6 (73 ref.)
The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Basu A, et al. **Mol Hum Reprod** 1998 Dec;4(12):1099-109 (127 ref.)
Signal transduction by the receptor tyrosine kinase Ret. van Weering DH, et al. **Recent Results Cancer Res** 1998; 154:271-81 (40 ref.)
WNT targets. Repression and activation. Nusse R. **Trends Genet** 1999 Jan;15(1):1-3 (25 ref.)
[Physiological function of BCL-3] Fujita T, et al. **Seikagaku** 1999 Feb;71(2):115-8 (7 ref.) **(Jpn)**

PROTO-ONCOGENE PROTEINS C-ABL

see related
FUSION PROTEINS, BCR-ABL

METABOLISM

Determination of cell fate by c-Abl activation in the response to DNA damage. Kharbanda S, et al. **Oncogene** 1998 Dec 24;17(25):3309-18 (177 ref.)

PHYSIOLOGY

Cycling, stressed-out and nervous: cellular functions of c-Abl. Van Etten RA. **Trends Cell Biol** 1999 May; 9(5):179-86 (62 ref.)

PROTO-ONCOGENE PROTEINS C-BCL-1 see **CYCLIN D1**

PROTO-ONCOGENE PROTEINS C-BCL-2

BCL-2--general considerations. Moldoveanu E, et al. **Haematologia (Budap)** 1998;29(3):167-80 (91 ref.)
[Structural biology of apoptosis proteins: recent advances in structural analysis of TNF-related, Fas-related, Bcl-2 family and caspase family proteins] Aritomi M, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):395-403 (25 ref.) **(Jpn)**

BIOSYNTHESIS

BCL2 overexpression in diffuse large B-cell lymphoma. Monni O, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):45-52 (60 ref.)

CHEMISTRY

Bcl-2 family proteins as ion-channels. Schendel SL, et al. **Cell Death Differ** 1998 May;5(5):372-80 (59 ref.)

GENETICS

The Bcl-2 protein family. O'Connor L, et al. **Results Probl Cell Differ** 1999;23:173-207 (278 ref.)

IMMUNOLOGY

Regulation of B cell apoptosis by Bcl-2 and Bcl-XL and its role in the development of autoimmune diseases (Review). López-Hoyos M, et al. **Int J Mol Med** 1998 Feb;1(2):475-83 (116 ref.)

METABOLISM

BCL-2 family members and the mitochondria in apoptosis. Gross A, et al. **Genes Dev** 1999 Aug 1;13(15):1899-911 (122 ref.)
Intracellular mechanisms of ovarian cell apoptosis. Hsu SY, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):21-5 (23 ref.)
Expression of bcl-2 and bax in glomerular disease. Yoshimura A, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:55-7 (8 ref.)

PHYSIOLOGY

Recent progress on the regulation of apoptosis by Bcl-2 family members. Minn AJ, et al. **Adv Immunol** 1998; 70:245-79 (156 ref.)
Why do mature CNS neurons of mammals fail to re-establish connections following injury--functions of bcl-2 [see comments] Chen DF, et al. **Cell Death Differ** 1998 Oct; 5(10):816-22 (51 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803-4.
Bcl-2 family members in the development and degenerative pathologies of the nervous system [see comments] Sadoul R. **Cell Death Differ** 1998 Oct;5(10):805-15 (101 ref.) Comment in: Cell Death Differ 1998 Oct;5(10):803-4.
Cell death: shadow baxing. Silke J, et al. **Curr Biol** 1998 Jul 16;8(15):R528-31 (22 ref.)
Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Tsujimoto Y. **Genes Cells** 1998 Nov; 3(11):697-707 (75 ref.)
The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Basu A, et al. **Mol Hum Reprod** 1998 Dec;4(12):1099-109 (127 ref.)
Bcl-2 family proteins. Reed JC. **Oncogene** 1998 Dec 24; 17(25):3225-36 (156 ref.)
Regulation of apoptosis: involvement of Bcl-2-related proteins. Motyl T. **Reprod Nutr Dev** 1999 Jan-Feb; 39(1):49-59 (50 ref.)
Prevention of neuronal cell death by Bcl-2. Tsujimoto Y.

Results Probl Cell Differ 1998;24:137-55 (103 ref.)
Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Kelekar A, et al. **Trends Cell Biol** 1998 Aug; 8(8):324-30 (62 ref.)

PROTO-ONCOGENE PROTEINS C-ERBA see **RECEPTORS, THYROID HORMONE**

PROTO-ONCOGENE PROTEINS C-ERBB-1 see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

PROTO-ONCOGENE PROTEINS C-ERBB-2

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Goldenberg MM. **Clin Ther** 1999 Feb;21(2):309-18 (28 ref.)

ANALYSIS

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. De Placido S, et al.
Breast Cancer Res Treat 1998;52(1-3):55-64 (38 ref.)
The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Gullick WJ, et al. **Breast Cancer Res Treat** 1998;52(1-3):43-53 (46 ref.)
HER-2/neu as a predictive marker of response to breast cancer therapy. Pegram MD, et al.
Breast Cancer Res Treat 1998;52(1-3):65-77 (39 ref.)
Positive staining for p53 and expression of c-erbB-2 in endosalpinx hyperplasia: analysis of 48 cases and review of literature. Rabczyński JK, et al. **Neoplasma** 1999; 46(1):31-4 (17 ref.)
The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Ross JS, et al.
Semin Cancer Biol 1999 Apr;9(2):125-38 (124 ref.)

BIOSYNTHESIS

HER-2/neu (c-erb-B2) gene and protein in breast cancer. Ross JS, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S53-67 (149 ref.)
c-erbB-2 expression in primary breast cancer. Tagliabue E, et al. **Int J Biol Markers** 1999 Jan-Mar;14(1):16-26 (90 ref.)

BLOOD

c-erbB-2 in serum of patients with breast cancer. Harris L, et al. **Int J Biol Markers** 1999 Jan-Mar;14(1):8-15 (23 ref.)

GENETICS

The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Yu D, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):195-202 (98 ref.)

IMMUNOLOGY

Novel approaches in development for the treatment of pancreatic cancer. Butera J, et al. **Front Biosci** 1998 Nov 1;3:E226-9 (45 ref.)
Biological therapies for breast carcinoma: concepts for improvement in survival. Borden EC, et al.
Semin Oncol 1999 Aug;26(4 Suppl 12):28-40 (118 ref.)
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Shak S.
Semin Oncol 1999 Aug;26(4 Suppl 12):71-7 (21 ref.)
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Sliwkowski MX, et al.
Semin Oncol 1999 Aug;26(4 Suppl 12):60-70 (75 ref.)
[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?] Beuzeboc P, et al.
Bull Cancer 1999 Jun;86(6):544-9 (40 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

HER-2/neu testing comes of age [editorial; comment] Wisecarver JL. **Am J Clin Pathol** 1999 Mar;111(3):299-301 (12 ref.) Comment on: Am J Clin Pathol 1999 Mar;111(3):311-6.

PHYSIOLOGY

Basic science of HER-2/neu: a review. Hung MC, et al. **Semin Oncol** 1999 Aug;26(4 Suppl 12):51-9 (102 ref.)
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Ross JS, et al. **Stem Cells** 1998;16(6):413-28 (125 ref.)

THERAPEUTIC USE

First MAb approved for treatment of metastatic breast cancer. Brenner TL, et al. **J Am Pharm Assoc (Wash)** 1999 Mar-Apr;39(2):236-8 (12 ref.)

PROTO-ONCOGENE PROTEINS C-FOS

see related
TRANSCRIPTION FACTOR AP-1

METABOLISM

C-fos expression in the rat nucleus basalis upon excitotoxic lesion with quisqualic acid: a study in adult and aged animals. Giovannelli L, et al. **J Neural Transm** 1998; 105(8-9):935-48 (29 ref.)
Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Salvat C, et al. **Mol Biol Rep** 1999 Apr;26(1-2):45-51 (37 ref.)

PHYSIOLOGY

DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Nestler EJ, et al. **Brain Res** 1999 Jul 17;835(1):10-7 (38 ref.)
c-Fos as a transcription factor: a stressful (re)view from a functional map. Kovács KJ. **Neurochem Int** 1998 Oct; 33(4):287-97 (118 ref.)

PROTO-ONCOGENE PROTEINS C-JUN

see related
TRANSCRIPTION FACTOR AP-1

BIOSYNTHESIS

Role of NGF in axotomy-induced c-Jun expression in medial septal cholinergic neurons. Haas CA, et al.
Int J Dev Neurosci 1998 Nov-Dec;16(7-8):691-703 (103 ref.)

GENETICS

Signal transduction during liver regeneration. Brenner DA. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S93-5 (11 ref.)

METABOLISM

Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Salvat C, et al. **Mol Biol Rep** 1999 Apr;26(1-2):45-51 (37 ref.)

PROTO-ONCOGENE PROTEINS C-KIT

BIOSYNTHESIS

Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Yoshida H, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):321-32 (56 ref.)

GENETICS

Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. Kitamura Y, et al. **Ann Chir Gynaecol** 1998;87(4):282-6 (33 ref.)

PHYSIOLOGY

Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Chan JK. **Adv Anat Pathol** 1999 Jan;6(1):19-40 (112 ref.)

PROTO-ONCOGENE PROTEINS C-MET

BIOSYNTHESIS

[Hepatocyte growth factor is an important signal exchanger between mesenchyme and epithelia during development] Guo SH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):249-51 (8 ref.) **(Chi)**

METABOLISM

Cross-talk between CD44 and c-Met in B cells. Taher TE, et al. **Curr Top Microbiol Immunol** 1999;246:31-7; discussion 38 (26 ref.)
Interactions between scatter factors and their receptors: hints for therapeutic applications. Trusolino L, et al.
FASEB J 1998 Oct;12(13):1267-80 (152 ref.)
Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Moriyama T, et al. **Int J Mol Med** 1999 May;3(5):531-6 (66 ref.)
Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Seidel C, et al. **Med Oncol** 1998 Sep; 15(3):145-53 (72 ref.)
[Elevated expression of met protein in papillary carcinoma of the thyroid facilitates tumor cell invasiveness] Scarpino S, et al. **Pathologica** 1998 Dec;90(6):818-20 (8 ref.) **(Ita)**

PHYSIOLOGY

The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Børset M, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):249-56 (60 ref.)
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Birchmeier C, et al. **Trends Cell Biol** 1998 Oct;8(10):404-10 (60 ref.)

PROTO-ONCOGENE PROTEINS C-MOS

see related
PROTEIN-SERINE-THREONINE KINASES

PROTO-ONCOGENE PROTEINS C-MYC

ANTAGONISTS & INHIBITORS

Repression by the Mad(Mxi1)-Sin3 complex. Schreiber-Agus N, et al. **Bioessays** 1998 Oct;20(10):808-18 (86 ref.)

GENETICS

Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc. Thompson EB, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):453-61 (32 ref.)
c-Myc target genes involved in cell growth, apoptosis, and metabolism. Dang CV. **Mol Cell Biol** 1999 Jan;19(1):1-11 (206 ref.)

METABOLISM

c-Myc target genes involved in cell growth, apoptosis, and metabolism. Dang CV. **Mol Cell Biol** 1999 Jan;19(1):1-11 (206 ref.)
The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Lüscher B, et al. **Oncogene** 1999 May 13;18(19):2955-66 (110 ref.)
New Myc-interacting proteins: a second Myc network emerges. Sakamuro D, et al. **Oncogene** 1999 May 13; 18(19):2942-54 (150 ref.)

PHYSIOLOGY

P62 and the sequestosome, a novel mechanism for protein metabolism. Shin J. **Arch Pharm Res** 1998 Dec;21(6):629-33 (35 ref.)
Target genes and cellular regulators of the Myc transcription complex. Peters MA, et al.
Crit Rev Eukaryot Gene Expr 1998;8(3-4):277-96 (225 ref.)
Myc-mediated transformation: the repression connection. Claassen GF, et al. **Oncogene** 1999 May 13;18(19):2925-33 (103 ref.)
The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Cole MD, et al. **Oncogene** 1999 May 13;18(19):2916-24 (85 ref.)
The proto-oncogene c-myc and apoptosis. Hoffman B, et al. **Oncogene** 1998 Dec 24;17(25):3351-7 (93 ref.)
Mysterious liaisons: the relationship between c-Myc and the cell cycle. Obaya AJ, et al. **Oncogene** 1999 May 13; 18(19):2934-41 (119 ref.)
Mechanisms of apoptosis by c-Myc. Prendergast GC.
Oncogene 1999 May 13;18(19):2967-87 (315 ref.)
The role of c-myc in cellular growth control. Schmidt EV. **Oncogene** 1999 May 13;18(19):2988-96 (106 ref.)

PROTO-ONCOGENE PROTEINS C-RAF

GENETICS

Cell cycle targets of Ras/Raf signalling. Kerkhoff E, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1457-62 (82 ref.)

METABOLISM

Cell cycle targets of Ras/Raf signalling. Kerkhoff E, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1457-62 (82 ref.)

PROTO-ONCOGENE PROTEINS HER-2 see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENES

Proto-oncogenes, unlike 'harmless' genes, tend to be dispersed in the human genome: selection against out-of-register recombination? [editorial] Ahmed S, et al. **Biol Chem** 1999 Jan;380(1):3-5 (12 ref.)
A ret transgenic mouse model of thyroid carcinogenesis. Capen C, et al. **Lab Anim Sci** 1998 Dec;48(6):580-3 (3 ref.)
BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. Gaidano G, et al.
Leuk Lymphoma 1998 Sep;31(1-2):39-46 (50 ref.)
Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Pierotti MA, et al. **Recent Results Cancer Res** 1998;154:237-47 (47 ref.)
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Rabes HM, et al.
Recent Results Cancer Res 1998;154:248-64 (92 ref.)
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M, et al. **Recent Results Cancer Res** 1998; 154:229-36 (22 ref.)
[Mdm2, p53 and the cell cycle: when well enough is best left alone] Maréchal V. **Pathol Biol (Paris)** 1997 Dec; 45(10):824-32 (70 ref.) (Eng. Abstr.) **(Fre)**

PROTO-ONCOGENES

GENETICS

Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. Kitamura Y, et al. **Ann Chir Gynaecol** 1998;87(4):282-6 (33 ref.)
Clinical implications of molecular abnormalities in lung cancer. Dziadziuszko R, et al. **Cancer Treat Rev** 1998 Oct; 24(5):317-30 (154 ref.)
Chronic retroviruses and oncogenesis. Patarca R. **Crit Rev Oncog** 1998;9(2):151-98 (375 ref.)
Mutations and altered expression of the human cancer genes: what they tell us about causes. Devereux TR, et al. **IARC Sci Publ** 1999;(146):19-42 (188 ref.)
Translational control of growth factor and proto-oncogene expression. Willis AE. **Int J Biochem Cell Biol** 1999 Jan; 31(1):73-86 (77 ref.)

PHYSIOLOGY

RET proto-oncogene: role in kidney development and molecular pathology. Salomon R, et al. **Adv Nephrol Necker Hosp** 1998;28:401-17 (50 ref.)

PROTOCOL COMPLIANCE see **GUIDELINE ADHERENCE**

PROTOCOL-DIRECTED THERAPY, COMPUTER-ASSISTED see **THERAPY, COMPUTER-ASSISTED**

PROTOCOL DRUG THERAPY, COMPUTER-ASSISTED see **DRUG THERAPY, COMPUTER-ASSISTED**

PROTOCOLLAGEN see **PROCOLLAGEN**

PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

PROTOHEME see **HEME**

PROTON-MOTIVE FORCE

see related
PROTON PUMP

PHYSIOLOGY

The significance and mechanism of mitochondrial proton conductance. Brand MD, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S4-11 (60 ref.)

PROTON PUMP

see related
H(+)-TRANSPORTING ATP SYNTHASE

[Crystal structure and proton pump mechanism of bacteriorhodopsin] Mogi T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):51-7 (21 ref.) **(Jpn)**

ADVERSE EFFECTS

Short-term side effects during H. pylori eradication therapy. Dumonceau JM. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):348-9 (11 ref.)

ANTAGONISTS & INHIBITORS

The search for optimal Helicobacter pylori eradication regimen: a mid 1997 update. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):344-7 (30 ref.)
Review article: drug interactions with agents used to treat acid-related diseases. Humphries TJ, et al. **Aliment Pharmacol Ther** 1999 Aug;13 Suppl 3:18-26 (69 ref.)
Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Ishizaki T, et al. **Aliment Pharmacol Ther** 1999 Aug;13 Suppl 3:27-36 (46 ref.)
Review article: the pharmacokinetics of rabeprazole in health and disease. Swan SK, et al. **Aliment Pharmacol Ther** 1999 Aug;13 Suppl 3:11-7 (38 ref.)
Review article: the pharmacology of rabeprazole. Williams MP, et al. **Aliment Pharmacol Ther** 1999 Aug;13 Suppl 3:3-10 (49 ref.)
Proton-pump inhibitors in acid-related diseases [see comments] Berardi RR, et al. **Am J Health Syst Pharm** 1998 Nov 1;55(21):2289-98 (60 ref.) Comment in: Am J Health Syst Pharm 1998 Nov 1;55(21):2249.
Considerations for long-term use of proton-pump inhibitors [see comments] Garnett WR. **Am J Health Syst Pharm** 1998 Nov 1;55(21):2268-79 (166 ref.) Comment in: Am J Health Syst Pharm 1998 Nov 1;55(21):2249.
Importance of pH control in the management of GERD. Hunt RH. **Arch Intern Med** 1999 Apr 12;159(7):649-57 (75 ref.)
Acid suppression therapy. Tavenor T. **Can J Gastroenterol** 1998 Jul-Aug;12(5):320-1 (0 ref.)
Possibilities and shortcomings of maintenance therapy in gastroesophageal reflux disease. Tytgat GN. **Dig Surg** 1999; 16(1):1-6 (20 ref.)
Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Richardson P, et al. **Drugs** 1998 Sep;56(3):307-35 (28 ref.)
Treat or investigate? Galmiche JP. **Eur J Gastroenterol Hepatol** 1999 Jun;11 Suppl 1:S11-5 (9 ref.)
Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. Lazzaroni M, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S73-8 (39 ref.)
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. Dattilo M, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S163-9 (55 ref.)
Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. Israel DM, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):568-79 (129 ref.)
Gastro-oesophageal reflux disease. de Carle DJ. **Med J Aust** 1998 Nov 16;169(10):549-54 (30 ref.)
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Kromer W, et al. **Pharmacology** 1999 Aug;59(2):57-77 (165 ref.)
Proton pump inhibitors. Grover JK, et al. **Trop Gastroenterol** 1999 Jan-Mar;20(1):16-28 (182 ref.)
[Mechanism of proton pump inhibitors in the treatment of Holicobacter pylori-associated ulcers] Huang J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):488-91 (20 ref.) **(Chi)**
[Medical treatment of gastroesophageal reflux with proton pump inhibitors] Vallot T, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S97-109 (93 ref.) **(Fre)**
[The treatment strategy of H. pylori infection and the new triple therapy] Hoshiya S, et al. **Nippon Rinsho** 1999 Jan; 57(1):121-6 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication] Kanayama S. **Nippon Rinsho** 1999 Jan;57(1):153-6 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Recent progress in the drug therapy for gastrointestinal bleeding] Nakajima S, et al. **Nippon Rinsho** 1998 Sep; 56(9):2291-6 (21 ref.) (Eng. Abstr.) **(Jpn)**
[The role and significance of acid suppressive drugs in the eradication of H. pylori] Yakabi K, et al. **Nippon Rinsho** 1999 Jan;57(1):53-60 (29 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Biosynthesis and regulation of the yeast vacuolar H+-ATPase. Kane PM. **J Bioenerg Biomembr** 1999 Feb; 31(1):49-56 (32 ref.)

CHEMISTRY

Cooperative coupling and role of heme a in the proton pump of heme-copper oxidases. Papa S, et al. **Biochimie** 1998 Oct;80(10):821-36 (62 ref.)
Assembly of the yeast vacuolar proton-translocating ATPase. Graham LA, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):39-47 (32 ref.)
The structure of the vacuolar ATPase in Neurospora crassa. Margolles-Clark E, et al. **J Bioenerg Biomembr** 1999 Feb; 31(1):29-37 (51 ref.)

METABOLISM

Proton translocation by bacteriorhodopsin and heme-copper oxidases. Wikström M. **Curr Opin Struct Biol** 1998 Aug; 8(4):480-8 (68 ref.)
Vacuolar and plasma membrane proton-adenosinetriphosphatases. Nelson N, et al. **Physiol Rev** 1999 Apr;79(2):361-85 (233 ref.)

PHYSIOLOGY

Structure and properties of the clathrin-coated vesicle and yeast vacuolar V-ATPases. Forgac M. **J Bioenerg Biomembr** 1999 Feb;31(1):57-65 (48 ref.)
Introduction: V-ATPases 1992-1998. Kane PM. **J Bioenerg Biomembr** 1999 Feb;31(1):3-5 (16 ref.)

PROTON-TRANSLOCATING ATPASE COMPLEX see **H(+)-TRANSPORTING ATP SYNTHASE**

PROTONS

Proton translocation by bacteriorhodopsin and heme-copper oxidases. Wikström M. **Curr Opin Struct Biol** 1998 Aug; 8(4):480-8 (68 ref.)
The mechanism of proton transport mediated by mitochondrial uncoupling proteins. Garlid KD, et al. **FEBS Lett** 1998 Oct 30;438(1-2):10-4 (34 ref.)
Neutron, proton, and photonuclear cross-sections for radiation therapy and radiation protection. Chadwick MB. **Radiat Environ Biophys** 1998 Dec;37(4):235-42 (39 ref.)
[Conformational radiotherapy for bladder cancer: limits to precision and potential advantages of the utilization of proton beams] Miralbell R. **Arch Esp Urol** 1999 Jul-Aug; 52(6):684-91 (6 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Potential gains using high-energy protons for therapy of malignant tumours. Glimelius B, et al. **Acta Oncol** 1999; 38(2):137-45 (44 ref.)
Proton therapy for tumors of the skull base. Munzenrider JE, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:57-63 (46 ref.)

PROTOPLASM see **CYTOPLASM**

PROTOPLASTS

METABOLISM

Use of cell wall-less bacteria (L-forms) for efficient expression and secretion of heterologous gene products. Gumpert J, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):506-9 (19 ref.)

PROTOPORPHYRIA, ERYTHROPOIETIC see **PORPHYRIA, ERYTHROHEPATIC**

PROTOPORPHYRINS

BLOOD

Erythrocyte zinc protoporphyrin. Braun J. **Kidney Int Suppl** 1999 Mar;69:S57-60 (21 ref.)

PROTOSTELIOMYCETES see **MYXOMYCETES**

PROTOTHECA

Disseminated cutaneous protothecosis in an immunocompromised host: a case report and literature review. Wirth FA, et al. **Cutis** 1999 Mar;63(3):185-8 (48 ref.)

ISOLATION & PURIFICATION

[Endocarditis due to an alga of the genus Prototheca sp. A saprophyte of water and of tree sap?] Buendia A, et al. **Arch Inst Cardiol Mex** 1998 Jul-Aug;68(4):333-6 (11 ref.) (Eng. Abstr.) **(Spa)**

PROTOZOA

see related
ANTIPROTOZOAL AGENTS

CLASSIFICATION

A revised six-kingdom system of life. Cavalier-Smith T. **Biol Rev Camb Philos Soc** 1998 Aug;73(3):203-66 (262 ref.)

DRUG EFFECTS

Why metronidazole is active against both bacteria and parasites. Samuelson J. **Antimicrob Agents Chemother** 1999 Jul;43(7):1533-41 (102 ref.)
Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates. Corash L. **Vox Sang** 1998;74 Suppl 2:173-6 (45 ref.)

ENZYMOLOGY

Proteases of protozoan parasites. Rosenthal PJ. **Adv Parasitol** 1999;43:105-59 (270 ref.)
DNA topoisomerases: a new twist for antiparasitic chemotherapy? Nenortas EC, et al. **Biochim Biophys Acta** 1998 Oct 1;1400(1-3):349-54 (51 ref.)
Cytochrome P450 in parasitic protozoa and helminths. Barrett J. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):181-3 (30 ref.)
Keto-acid oxidoreductases in the anaerobic protozoa. Upcroft JA, et al. **J Eukaryot Microbiol** 1999 Jul-Aug; 46(4):447-9 (20 ref.)

GENETICS

Replication origins in metazoan chromosomes: fact or fiction? DePamphilis ML. **Bioessays** 1999 Jan;21(1):5-16 (97 ref.)

GROWTH & DEVELOPMENT

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Corash L. **Transfus Med Rev** 1999 Jan;13(1):18-30 (92 ref.)

METABOLISM

Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes. Tiede A, et al. **Biol Chem** 1999 May;380(5):503-23 (169 ref.)
Microbial glycoconjugates. Mengeling BJ, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):572-7 (45 ref.)
Plastids and protein targeting. McFadden GI. **J Eukaryot Microbiol** 1999 Jul-Aug;46(4):339-46 (100 ref.)

MICROBIOLOGY

Invasion of protozoa by Legionella pneumophila and its role in bacterial ecology and pathogenesis. Abu Kwaik Y, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3127-33 (49 ref.)
Intracellular bacteria in protozoa. Görtz HD, et al. **Naturwissenschaften** 1998 Aug;85(8):359-68 (93 ref.)
Unexplored reservoirs of pathogenic bacteria: protozoa and biofilms. Brown MR, et al. **Trends Microbiol** 1999 Jan; 7(1):46-50 (53 ref.)

PROTOZOAN ANTIGENS see **ANTIGENS, PROTOZOAN**

PROTOZOAN DNA see **DNA, PROTOZOAN**

PROTOZOAN GENES see **GENES, PROTOZOAN**

PROTOZOAN GENOME see **GENOME, PROTOZOAN**

PROTOZOAN INFECTIONS

see related
ANTIPROTOZOAL AGENTS

COMPLICATIONS

Eosinophilia in the returning traveler. Wolfe MS. **Med Clin North Am** 1999 Jul;83(4):1019–32, vii (52 ref.)

DIAGNOSIS

[Infectious esophagitis] Arenas Miravé JI, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):302–8 (65 ref.) **(Spa)**

DRUG THERAPY

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Lamp KC, et al. **Clin Pharmacokinet** 1999 May;36(5):353–73 (130 ref.)

ETIOLOGY

Transfusion-transmitted diseases: risks, prevention and perspectives. Moor AC, et al. **Eur J Haematol** 1999 Jan; 62(1):1–18 (183 ref.)

METABOLISM

The role of iron in protozoan and fungal infectious diseases. Weinberg ED. **J Eukaryot Microbiol** 1999 May–Jun; 46(3):231–8 (100 ref.)

PARASITOLOGY

Proteases of protozoan parasites. Rosenthal PJ. **Adv Parasitol** 1999;43:105–59 (270 ref.)

PREVENTION & CONTROL

Parasitic infections in pregnancy and congenital protozoan infections. Part I.: Protozoan infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):55–62 (44 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Parasitic infections in pregnancy and congenital protozoan infections. Part I.: Protozoan infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):55–62 (44 ref.) (Eng. Abstr.) **(Ger)**

PROTOZOAN INFECTIONS, ANIMAL

Whirling disease: re-emergence among wild trout. Hedrick RP, et al. **Immunol Rev** 1998 Dec;166:365–76 (54 ref.)

DIAGNOSIS

Recent advances in the diagnosis in livestock of Cryptosporidium, Toxoplasma, Giardia and other protozoa of veterinary importance. Taylor MA, et al. **Res Vet Sci** 1998 Nov–Dec;65(3):183–93 (140 ref.)

PROTOZOAN PROTEINS

GENETICS

Waves of malarial var-iations. Wahlgren M, et al. **Cell** 1999 Mar 5;96(5):603–6 (15 ref.)

METABOLISM

Adhesive proteins of the malaria parasite. Coppel RL, et al. **Curr Opin Microbiol** 1998 Aug;1(4):472–81 (84 ref.)

Calcium regulation of the actin-myosin interaction of Physarum polycephalum. Nakamura A, et al. **Int Rev Cytol** 1999;191:53–98 (142 ref.)

Location of the binding site of the mannose-specific lectin comitin on F-actin. Fulgenzi G, et al. **J Mol Biol** 1998 Dec 18;284(5):1255–63 (38 ref.)

SECRETION

Surface coats and secretory trafficking in African trypanosomes. Bangs JD. **Curr Opin Microbiol** 1998 Aug; 1(4):448–54 (63 ref.)

PROTOZOAN RNA see **RNA, PROTOZOAN**

PROTOZOAN STRUCTURAL GENES see **GENES, STRUCTURAL, PROTOZOAN**

PROTOZOAN VACCINES

Immunization and diagnosis in bovine reproductive tract infections. Corbeil LB. **Adv Vet Med** 1999;41:217–39 (108 ref.)

Recent trends in vaccine development and immunization. Jaffe CL. **Clin Dermatol** 1999 May–Jun;17(3):339–44 (54 ref.)

Host-pathogen interaction in amebiasis and progress in vaccine development. Huston CD, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):601–14 (143 ref.)

Use of live oocyst vaccines in the control of avian coccidiosis: experimental studies and field trials. Danforth HD. **Int J Parasitol** 1998 Jul;28(7):1099–109 (17 ref.)

Progress on developing a recombinant coccidiosis vaccine. Jenkins MC. **Int J Parasitol** 1998 Jul;28(7):1111–9 (105 ref.)

Progress in recombinant vaccine development against coccidiosis. A review and prospects into the next millennium. Vermeulen AN. **Int J Parasitol** 1998 Jul; 28(7):1121–30 (39 ref.)

Epidemiological aspects of the use of live anticoccidial vaccines for chickens. Williams RB. **Int J Parasitol** 1998 Jul;28(7):1089–98 (42 ref.)

PROVIDENCIA

ENZYMOLOGY

The chromosomal 2'-N-acetyltransferase of Providencia stuartii: physiological functions and genetic regulation. Macinga DR, et al. **Front Biosci** 1999 Feb 1;4:D132–40 (61 ref.)

PROVINCIAL GOVERNMENT see **STATE GOVERNMENT**

PROVIRUS INTEGRATION see **VIRUS INTEGRATION**

PROVIRUSES

see related
ENDOGENOUS RETROVIRUSES
MUTAGENESIS, INSERTIONAL
VIRUS INTEGRATION

The regional integration of retroviral sequences into the mosaic genomes of mammals. Rynditch AV, et al. **Gene** 1998 Nov 5;222(1):1–16 (160 ref.)

GENETICS

Endogenous proviruses. Friedlander A, et al. **Crit Rev Oncog** 1999;10(1–2):129–59 (311 ref.)

PROVOCATION TESTS, BRONCHIAL see **BRONCHIAL PROVOCATION TESTS**

PROVOCATION TESTS, NASAL see **NASAL PROVOCATION TESTS**

PROXEMICS see **SPATIAL BEHAVIOR**

PROXIMAL RENAL TUBULAR ACIDOSIS see **ACIDOSIS, RENAL TUBULAR**

PROXIMAL RENAL TUBULAR DYSFUNCTION see **FANCONI SYNDROME**

PROXY

see related
THIRD-PARTY CONSENT

Surrogate decision making for genetic testing for Alzheimer disease. Eaton ML. **Genet Test** 1999;3(1):93–7 (16 ref.)

PRP PROTEINS see **PRIONS**

PRPC PROTEINS

CHEMISTRY

Trafficking of the cellular isoform of the prion protein. Lehmann S, et al. **Biomed Pharmacother** 1999;53(1):39–46 (47 ref.)

PHYSIOLOGY

Impaired motor coordination in mice lacking prion protein. Katamine S, et al. **Cell Mol Neurobiol** 1998 Dec; 18(6):731–42 (56 ref.)

PRPSC PROTEINS

ANALYSIS

The immunodetection of the abnormal isoform of prion protein. Yokoyama T. **Histochem J** 1999 Apr;31(4):209–12 (48 ref.)

TOXICITY

Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death. Schröder HC, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):683–8 (30 ref.)

PRUNE BELLY SYNDROME

COMPLICATIONS

The importance of an intact abdominal musculature mechanism in maintaining spinal sagittal balance. Case illustration in prune-belly syndrome. Lam KS, et al. **Spine** 1999 Apr 1;24(7):719–22 (16 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of prune belly syndrome at 12 weeks of pregnancy: case report and review of the literature. Hoshino T, et al. **Ultrasound Obstet Gynecol** 1998 Nov; 12(5):362–6 (20 ref.)

PRURIGO

ETIOLOGY

[A case of non-icteric bile duct carcinoma associated with prurigo chronica multiforme] Kokawa A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Mar;96(3):300–4 (11 ref.) **(Jpn)**

PRURITUS

Pruritus in children. Leung AK, et al. **J R Soc Health** 1998 Oct;118(5):280–6 (25 ref.)

Uraemic pruritus. Schwartz IF, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):834–9 (82 ref.)

COMPLICATIONS

Itching and the atopic skin. Koblenzer CS. **J Allergy Clin Immunol** 1999 Sep;104(3 Pt 2):S109–13 (39 ref.)

DIAGNOSIS

Bullous pemphigoid presenting as generalized pruritus: observations in six patients. Alonso-Llamazares J, et al. **Int J Dermatol** 1998 Jul;37(7):508–14 (14 ref.)

DRUG THERAPY

Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Terra SG, et al. **Ann Pharmacother** 1998 Nov;32(11):1228–30 (29 ref.)

Respiratory chain complex in deficiency with pruritus: a novel vitamin responsive clinical feature. Mowat D, et al. **J Pediatr** 1999 Mar;134(3):352–4 (13 ref.)

[Antihistaminics. II] Reider N, et al. **Hautarzt** 1998 Sep; 49(9):734–42; quiz 472 (0 ref.) **(Ger)**

ETIOLOGY

Rare syndromes in Hodgkin's disease. Cavalli F. **Ann Oncol** 1998;9 Suppl 5:S109–13 (26 ref.)

The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Jones EA, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):623–31 (32 ref.)

The pruritus of cholestasis. Jones EA, et al. **Hepatology** 1999 Apr;29(4):1003–6 (40 ref.)

Pruritus in pregnancy and obstetric cholestasis. Clark TJ, et al. **Hosp Med** 1999 Apr;60(4):254–60 (22 ref.)

Pruritus in the elderly. Gupta A. **Practitioner** 1999 Mar; 243(1596):203–7 (5 ref.)

PHYSIOPATHOLOGY

The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Jones EA, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):623–31 (32 ref.)

THERAPY

The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Jones EA, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):623–31 (32 ref.)

The pruritus of cholestasis. Jones EA, et al. **Hepatology** 1999 Apr;29(4):1003–6 (40 ref.)

PSDA see **PATIENT SELF-DETERMINATION ACT**

PSEUDALLESCHERIA

[Allescheriasis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):384–6 (14 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Pulmonary scedosporiosis. Severo LC, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul–Aug;40(4):241–3 (19 ref.)

PSEUDARTHROSIS

CONGENITAL

[Congenital pseudoarthrosis of the clavicle: review of literature and a case report] Malawski S, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):341–5 (14 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Pseudarthrosis of the capitate. Rico AA, et al. **J Hand Surg [Br]** 1999 Jun;24(3):382–4 (11 ref.)

Symptomatic pseudarthrosis of the acromion: report of a case and review of the literature. Dounchis JS, et al. **J Orthop Trauma** 1999 Jan;13(1):63–6 (24 ref.)

Ununited humeral diaphyses. Jupiter JB, et al. **J Shoulder Elbow Surg** 1998 Nov–Dec;7(6):644–53 (84 ref.)

[Congenital pseudoarthrosis of the clavicle: review of literature and a case report] Malawski S, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):341–5 (14 ref.)

PSEUDARTHROSIS

(Eng. Abstr.) **(Pol)**

THERAPY

[Electrically enhanced damaged tissues healing. Part I: direct current in bone healing] Franek A, et al. **Pol Merkuriusz Lek** 1999 May;6(35):294–6 (17 ref.) (Eng. Abstr.) **(Pol)**

PSEUDO-OBSTRUCTION, COLONIC see **COLONIC PSEUDO-OBSTRUCTION**

PSEUDO-OBSTRUCTION, INTESTINAL see **INTESTINAL PSEUDO-OBSTRUCTION**

PSEUDOANEURYSM see **ANEURYSM, FALSE**

PSEUDOAPHAKIA see **CATARACT**

PSEUDOBULBAR PARALYSIS see **PARALYSIS**

PSEUDOCYESIS see **PSEUDOPREGNANCY**

PSEUDODEMENTIA see **FACTITIOUS DISORDERS**

PSEUDOEXFOLIATION SYNDROME see **EXFOLIATION SYNDROME**

PSEUDOGENES

GENETICS

Amplification of a pseudogene cassette underlies euchromatic variation of 16p at the cytogenetic level. Barber JC, et al. **Hum Genet** 1999 Mar;104(3):211–8 (29 ref.)

PSEUDOGOUT see **CHONDROCALCINOSIS**

PSEUDOHERMAPHRODITISM

DIAGNOSIS

US and MRI in a case of persistent Müllerian duct syndrome. Di Cesare E, et al. **Pediatr Radiol** 1998 Nov;28(11):865–7 (4 ref.)

ENZYMOLOGY

Natural potent androgens: lessons from human genetic models. Zhu YS, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):83–113 (170 ref.)

PSEUDOHYPOALDOSTERONISM

ETIOLOGY

[Transient pseudohypoaldosteronism secondary to congenital malformation pathology of the urinary tract (valves of the posterior urethra): a report of a case with elements of a physiopathological nature] Parisi G, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):289–93 (32 ref.) (Eng. Abstr.) **(Ita)**

PSEUDOHYPOPARATHYROIDISM

CLASSIFICATION

[Pseudohypoparathyroidism and the concept of hormonal resistance. Types Ib and II] Vlaeminck-Guillem V, et al. **Presse Med** 1999 Sep 11;28(26):1442–7 (142 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Pseudohypoparathyroidism in a pediatric patient (letter)] Giménez Llort A, et al. **An Esp Pediatr** 1999 Jun;50(6):635–6 (10 ref.) **(Spa)**

GENETICS

The expanding spectrum of G protein diseases. Farfel Z, et al. **N Engl J Med** 1999 Apr 1;340(13):1012–20 (54 ref.)

PSEUDOLYMPHOMA

[Cutaneous pseudolymphoma] Kura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):338–40 (5 ref.) **(Jpn)**

ETIOLOGY

Lymphoid hyperplasia of the stomach caused by Helicobacter pylori: upper gastrointestinal findings. Lee EY, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):362–3 (8 ref.)

PATHOLOGY

Microscopic mimicry of lymphomas: diagnostic pitfalls. Banks PM. **Mod Pathol** 1999 Feb;12(2):116–24 (19 ref.)

VIROLOGY

Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Wagner M, et al. **Clin Infect Dis** 1998 Nov;27(5):1299–308 (112 ref.)

[Lymphoid hyperplasia associated with human immunodeficiency virus and Epstein-Barr virus; relationship with lymphomatous pathology] Raphaël M, et al. **Ann Pathol** 1998 Oct;18(4):325–30 (61 ref.) **(Fre)**

PSEUDOMONAS

GENETICS

Development of a recombinant interleukin-4–Pseudomonas exotoxin for therapy of glioblastoma. Puri RK. **Toxicol Pathol** 1999 Jan–Feb;27(1):53–7 (28 ref.)

METABOLISM

Rhamnose lipids--biosynthesis, microbial production and application potential. Lang S, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):22–32 (116 ref.)

Pseudomonas syringae phytotoxins: mode of action, regulation, and biosynthesis by peptide and polyketide synthetases. Bender CL, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):266–92 (297 ref.)

PSEUDOMONAS AERUGINOSA

CHEMISTRY

BR96 sFv–PE40 immunotoxin: nonclinical safety assessment. Haggerty HG, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):87–94 (17 ref.)

CLASSIFICATION

[The use of molecular biology in the modeling of Pseudomonas aeruginosa strains recovered from nosocomial infections] Fiett J, et al. **Przegl Epidemiol** 1998;52(4):427–40 (18 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Hancock RE. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S93–9 (60 ref.)

Quorum sensing: a novel target for anti-infective therapy. Finch RG, et al. **J Antimicrob Chemother** 1998 Nov;42(5):569–71 (18 ref.)

[Current microbiological problems. Antibiotic resistance and therapeutic problems raised by Pseudomonas aeruginosa] Bert F, et al. **Presse Med** 1999 Feb 27;28(8):451–8 (61 ref.) (Eng. Abstr.) **(Fre)**

[Mechanisms of resistance in Pseudomonas aeruginosa] Cercenado Mansilla E, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:10–6 (67 ref.) **(Spa)**

[Active drugs against Pseudomonas aeruginosa and their clinical usefulness] Gobernado M. **Rev Clin Esp** 1998 Sep;198 Suppl 2:51–61 (161 ref.) **(Spa)**

ENZYMOLOGY

GSP-dependent protein secretion in gram-negative bacteria: the Xcp system of Pseudomonas aeruginosa. Filloux A, et al. **FEMS Microbiol Rev** 1998 Sep;22(3):177–98 (155 ref.)

IMMUNOLOGY

[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][von Specht BU. **Zentralbl Chir** 1999;124(4):298–302 (23 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Further insights into early acquisition of Pseudomonas aeruginosa [editorial; comment] Saiman L, et al. **Pediatr Pulmonol** 1998 Aug;26(2):79–80 (7 ref.) Comment on: Pediatr Pulmonol 1998 Aug;26(2):81–8.

[The use of molecular biology in the modeling of Pseudomonas aeruginosa strains recovered from nosocomial infections] Fiett J, et al. **Przegl Epidemiol** 1998;52(4):427–40 (18 ref.) (Eng. Abstr.) **(Pol)**

[Hospital infections caused by Pseudomonas aeruginosa. Spread and clinical importance of antibiotic resistance] Sidorenko SV, et al. **Antibiot Khimioter** 1999;44(3):25–34 (68 ref.) **(Rus)**

PATHOGENICITY

Quorum sensing: a novel target for anti-infective therapy. Finch RG, et al. **J Antimicrob Chemother** 1998 Nov;42(5):569–71 (18 ref.)

[General characteristics of Pseudomonas and other related bacteria. Pathogenic ability of Pseudomonas aeruginosa] Cisterna Cancer R. **Rev Clin Esp** 1998 Sep;198 Suppl 2:3–9 (22 ref.) **(Spa)**

PHYSIOLOGY

Cell-to-cell signaling and Pseudomonas aeruginosa infections. Van Delden C, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):551–60 (82 ref.)

PSEUDOMONAS CEPACIA see **BURKHOLDERIA CEPACIA**

PSEUDOMONAS FLUORESCENS

ENZYMOLOGY

Structure and function analysis of Pseudomonas plant cell wall hydrolases. Hazlewood GP, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:211–41 (81 ref.)

PSEUDOMONAS INFECTIONS

[Sepsis by Pseudomonas aeruginosa] Inamatsu T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):266–9 (10 ref.) **(Jpn)**

[Multi-drug resistant Pseudomonas aeruginosa infection] Tomono K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):198–201 (10 ref.) **(Jpn)**

[Pseudomonas aeruginosa pneumonia] Watanabe K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):371–3 (14 ref.) **(Jpn)**

[Other infections caused by Pseudomonas aeruginosa] Bouza Santiago E, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:30–6 (86 ref.) **(Spa)**

[Skin and soft-tissue infections caused by Pseudomonas aeruginosa] Cainzos Fernández M. **Rev Clin Esp** 1998 Sep;198 Suppl 2:21–4 (21 ref.) **(Spa)**

[Bacteremia, endocarditis and meningitis caused by Pseudomonas aeruginosa] Cisneros Herreros JM, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:25–9 (49 ref.) **(Spa)**

[General characteristics of Pseudomonas and other related bacteria. Pathogenic ability of Pseudomonas aeruginosa] Cisterna Cancer R. **Rev Clin Esp** 1998 Sep;198 Suppl 2:3–9 (22 ref.) **(Spa)**

[Respiratory tract infections by Pseudomonas aeruginosa in patients under intubation] Rello J, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:17–20 (31 ref.) **(Spa)**

COMPLICATIONS

Cutaneous manifestations due to Pseudomonas infection. Silvestre JF, et al. **Int J Dermatol** 1999 Jun;38(6):419–31 (76 ref.)

[Prevention and treatment of infections in patients with neutropenia and fever: the role of Pseudomonas aeruginosa] Jiménez Martínez C, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:44–50 (32 ref.) **(Spa)**

[Pseudomonas aeruginosa as a pathogen in patients with human immunodeficiency virus infection] Vidal Marsal F, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:37–43 (36 ref.) **(Spa)**

DIAGNOSIS

[Non-bacteremic ecthyma gangrenosum in a patient with human immunodeficiency virus infection (letter)] Tornero C, et al. **Rev Clin Esp** 1999 May;199(5):332–3 (10 ref.) **(Spa)**

DRUG THERAPY

[Hospital infections caused by Pseudomonas aeruginosa. Spread and clinical importance of antibiotic resistance] Sidorenko SV, et al. **Antibiot Khimioter** 1999;44(3):25–34 (68 ref.) **(Rus)**

[Active drugs against Pseudomonas aeruginosa and their clinical usefulness] Gobernado M. **Rev Clin Esp** 1998 Sep;198 Suppl 2:51–61 (161 ref.) **(Spa)**

ETIOLOGY

Ear-piercing techniques as a cause of auricular chondritis. More DR, et al. **Pediatr Emerg Care** 1999 Jun;15(3):189–92 (13 ref.)

[Infection in burn patients: the problems of pathogenesis, prevention and treatment] Alekseev AA, et al. **Khirurgiia (Mosk)** 1999;(6):4–9 (14 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Further insights into early acquisition of Pseudomonas aeruginosa [editorial; comment] Saiman L, et al. **Pediatr Pulmonol** 1998 Aug;26(2):79–80 (7 ref.) Comment on: Pediatr Pulmonol 1998 Aug;26(2):81–8.

[Current microbiological problems. Antibiotic resistance and therapeutic problems raised by Pseudomonas aeruginosa] Bert F, et al. **Presse Med** 1999 Feb 27;28(8):451–8 (61 ref.) (Eng. Abstr.) **(Fre)**

[The use of molecular biology in the modeling of Pseudomonas aeruginosa strains recovered from nosocomial infections] Fiett J, et al. **Przegl Epidemiol** 1998;52(4):427–40 (18 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

[Prevention and treatment of infections in patients with neutropenia and fever: the role of Pseudomonas aeruginosa] Jiménez Martínez C, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:44–50 (32 ref.) **(Spa)**

PSEUDOMONAS PHAGE PHI 6 see **BACTERIOPHAGE PHI 6**

PSEUDOMONAS PSEUDOMALLEI see **BURKHOLDERIA PSEUDOMALLEI**

PSEUDOMONAS PUTIDA

GENETICS

Transcriptional activation of the catechol and chlorocatechol operons: variations on a theme. McFall SM, et al. **Gene** 1998 Nov 26;223(1-2):257-67 (41 ref.)

PSEUDOMONAS PYOCYANEA see **PSEUDOMONAS AERUGINOSA**

PSEUDOMONIC ACID see **MUPIROCIN**

PSEUDOMYXOMA PERITONEI

Pseudomyxoma peritonei [see comments] Hinson FL, et al. **Br J Surg** 1998 Oct;85(10):1332-9 (86 ref.) Comment in: Br J Surg 1999 Jun;86(6):842.

PSEUDONEUROTIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPELADE see **ALOPECIA**

PSEUDOPHAKIA

COMPLICATIONS

Endocapsular hematoma: report of a case following glaucoma surgery in a pseudophakic eye. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):389-93 (22 ref.)

PSEUDOPOLYARTHRITIS, RHIZOMELIC see **POLYMYALGIA RHEUMATICA**

PSEUDOPREGNANCY

A little pregnant, or not at all? Grossl NA. **Pharos** 1999 Spring;62(2):16-9 (24 ref.)

PSEUDOPROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PSEUDOPSYCHOPATHIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPSYCHOSIS see **FACTITIOUS DISORDERS**

PSEUDORABIES

IMMUNOLOGY

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447-61 (60 ref.)

PHYSIOPATHOLOGY

Practical considerations for the use of pseudorabies virus in transneuronal studies of neural circuitry. Card JP. **Neurosci Biobehav Rev** 1998 Oct;22(6):685-94 (46 ref.)

VIROLOGY

Life beyond eradication: veterinary viruses in basic science. Enquist LW. **Arch Virol Suppl** 1999;15:87-109 (67 ref.)

PSEUDORABIES VIRUS see **HERPESVIRUS 1, SUID**

PSEUDORCA see **DOLPHINS**

PSEUDOSCLEROSIS see **HEPATOLENTICULAR DEGENERATION**

PSEUDOTUBERCULOSIS, PASTEURELLA see **YERSINIA PSEUDOTUBERCULOSIS INFECTIONS**

PSEUDOTUMOR CEREBRI

COMPLICATIONS

[A rare cause of peracute vision loss: pseudotumor cerebri. Case report of course with recurrence after decompression of the optic nerve] Heckmann JG, et al. **Nervenarzt** 1998 Aug;69(8):702-6 (43 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Pseudotumor cerebri and leukoencephalopathy in childhood lupus. Chaves-Carballo E, et al. **Lupus** 1999;8(1):81-4 (26 ref.)

SURGERY

[The central nervous system and the lymphatic system. Lymphatic drainage of the cerebrospinal fluid] Kiwic G, et al. **Neurol Neurochir Pol** 1998 May-Jun;32(3):633-41 (20 ref.) (Eng. Abstr.) **(Pol)**

PSEUDOTUMOR, INFLAMMATORY see **GRANULOMA, PLASMA CELL**

PSEUDOTUMOR, INFLAMMATORY, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PSEUDOURIDINE

ANALYSIS

Mapping of pseudouridine residues in RNA to nucleotide resolution. Bakin AV, et al. **Methods Mol Biol** 1998; 77:297-309 (24 ref.)

PSEUDOXANTHOMA ELASTICUM

GENETICS

Pseudoxanthoma elasticum: an update. Sherer DW, et al. **Dermatology** 1999;199(1):3-7 (53 ref.)

PATHOLOGY

Pseudoxanthoma elasticum: an update. Sherer DW, et al. **Dermatology** 1999;199(1):3-7 (53 ref.)

PSITTACOSIS see **ORNITHOSIS**

PSITTACOSIS-LYMPHOGRANULOMA GROUP see **CHLAMYDIA**

PSOAS ABSCESS

ETIOLOGY

[Psoas abscess with mediastinal extension secondary to rectal perforation (letter; comment)] Jiménez Almonacid P, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):149-50 (6 ref.) Comment on: Rev Esp Enferm Dig 1995 Nov;87(11):830-1. **(Spa)**

MICROBIOLOGY

[Endocarditis manifesting as a spondylodiscitis and psoas abscess] Berger A, et al. **Rev Med Suisse Romande** 1999 Jan;119(1):55-7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Psoas abscess caused Actinomyces israelii (letter)] Pérez AF, et al. **Enferm Infecc Microbiol Clin** 1998 Jun-Jul; 16(6):289-90 (9 ref.) **(Spa)**

PSOAS MUSCLES

Difficulties in estimating muscle forces from muscle cross-sectional area. An example using the psoas major muscle. Gatton ML, et al. **Spine** 1999 Jul 15;24(14):1487-93 (26 ref.)

[Ureteral reimplantation on psoas bladder: long-term results] el Kahder K, et al. **Acta Urol Belg** 1998 Dec;66(4):15-20 (24 ref.) (Eng. Abstr.) **(Fre)**

PSORALEN ULTRAVIOLET A THERAPY see **PUVA THERAPY**

PSORALENS

see related
COUMARINS

ADVERSE EFFECTS

Phytophotodermatitis. Bowers AG. **Am J Contact Dermat** 1999 Jun;10(2):89-93 (20 ref.)

Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? Lindelöf B. **Drug Saf** 1999 Apr;20(4):289-97 (115 ref.)

THERAPEUTIC USE

[Photo oxidative reactions of psoralens and their role in therapy of dermatoses] Potapenko Ala, et al. **Vestn Ross Akad Med Nauk** 1999;(2):32-8 (35 ref.) (Eng. Abstr.) **(Rus)**

PSORIASIS

[Progresses in the study of dermatology and venereology in China, 1997] Zhu T. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):942-3 (0 ref.) **(Chi)**

CLASSIFICATION

[Psoriasis. Rheumatologic manifestations] Grasland A, et al. **Presse Med** 1999 Jun 26;28(23):1251-8 (92 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

IgA nephropathy in psoriasis. Ahuja TS, et al. **Am J Nephrol** 1998;18(5):425-9 (26 ref.)

Is psoriasis a neuroimmunologic disease? Farber EM, et al. **Int J Dermatol** 1999 Jan;38(1):12-5 (35 ref.)

Renal abnormalities in psoriatic patients: a review [editorial] Heuvels J, et al. **Nephron** 1999;82(1):1-6 (42 ref.)

DIAGNOSIS

[Psoriasis of the nails] Duhard-Brohan E. **Ann Dermatol Venereol** 1999 May;126(5):445-9 (17 ref.) **(Fre)**

[Amicrobial intertriginous pustulosis in autoimmune diseases--a new entity?] Hoch O, et al. **Hautarzt** 1998 Aug; 49(8):634-40 (26 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Topical psoriasis therapy. Federman DG, et al. **Am Fam Physician** 1999 Feb 15;59(4):957-62, 964 (26 ref.)

Use of hydroxyurea in psoriasis. Smith CH. **Clin Exp Dermatol** 1999 Jan;24(1):2-6 (33 ref.)

Pharmacologic profile of tazarotene. Duvic M. **Cutis** 1998 Feb;61(2 Suppl):22-6 (26 ref.)

Old wine in new bottles: the revival of anthralin. Harris DR. **Cutis** 1998 Oct;62(4):201-3 (21 ref.)

How and where tazarotene might fit into the current therapeutic armamentarium: an expert opinion. Koo JY. **Cutis** 1998 Feb;61(2 Suppl):36-7 (0 ref.)

Clinical efficacy and safety of tazarotene: optimizing clinical results. Lebwohl M. **Cutis** 1998 Feb;61(2 Suppl):27-9 (6 ref.)

The management of psoriasis-tazarotene: the bottom line. Weinstein GD. **Cutis** 1998 Feb;61(2 Suppl):38-9 (0 ref.)

Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? Lindelöf B. **Drug Saf** 1999 Apr;20(4):289-97 (115 ref.)

5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. McNeely W, et al. **Drugs** 1998 Oct;56(4):667-90 (80 ref.)

The role of salicylic acid in the treatment of psoriasis. Lebwohl M. **Int J Dermatol** 1999 Jan;38(1):16-24 (60 ref.)

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. Koo J. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S25-8 (21 ref.)

Tazarotene in combination with phototherapy. Koo JY. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S144-8 (29 ref.)

Tazarotene in combination with topical corticosteroids. Lebwohl M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S139-43 (15 ref.)

Acitretin in combination with UVB or PUVA. Lebwohl M. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S22-4 (10 ref.)

Acitretin: optimal dosing strategies. Ling MR. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S13-7 (11 ref.)

Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. Saurat JH. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S2-6 (20 ref.)

Strategy for treatment of psoriasis: systemic treatments. Dubertret L. **J Dermatol** 1998 Dec;25(12):788-92 (0 ref.)

Malignant melanoma in patients treated for psoriasis with PUVA. Stern RS. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):37-8 (6 ref.)

EPIDEMIOLOGY

A review of the epidemiology of psoriasis vulgaris in the community. Plunkett A, et al. **Australas J Dermatol** 1998 Nov;39(4):225-32 (71 ref.)

ETIOLOGY

Insights into the pathogenesis of psoriasis and psoriatic arthritis. Espinoza LR, et al. **Am J Med Sci** 1998 Oct; 316(4):271-6 (66 ref.)

Cigarette smoking and psoriasis. Naldi L. **Clin Dermatol** 1998 Sep-Oct;16(5):571-4 (24 ref.)

Alcohol intake and psoriasis. Wolf R, et al. **Clin Dermatol** 1999 Jul-Aug;17(4):423-30 (109 ref.)

Which T cells cause psoriasis? Prinz JC. **Clin Exp Dermatol** 1999 Jul;24(4):291-5 (34 ref.)

Pathogenesis of psoriasis. Barker JN. **J Dermatol** 1998 Dec; 25(12):778-81 (19 ref.)

Animal models of psoriasis - what can we learn from them? Schön MP. **J Invest Dermatol** 1999 Apr;112(4):405-10 (60 ref.)

[Psoriasis. Pathogenesis] Ortonne N, et al. **Presse Med** 1999 Jun 26;28(23):1259-65 (56 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The immunologic and genetic basis of psoriasis. Nickoloff BJ. **Arch Dermatol** 1999 Sep;135(9):1104-10 (76 ref.)

Genetics of psoriasis. Henseler T. **Arch Dermatol Res** 1998 Sep;290(9):463-76 (133 ref.)

Pathogenesis and genetics of psoriasis. Menter A. **Cutis** 1998 Feb;61(2 Suppl):8-10 (20 ref.)

The genetics of psoriasis: a complex disorder of the skin and immune system. Bhalerao J, et al. **Hum Mol Genet** 1998; 7(10):1537-45 (128 ref.)

IMMUNOLOGY

The immunologic and genetic basis of psoriasis. Nickoloff BJ. **Arch Dermatol** 1999 Sep;135(9):1104-10 (76 ref.)

The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. Leung DY, et al. **Br J Dermatol** 1998 Dec;139 Suppl 53:17-29 (91 ref.)

Pathogenesis and genetics of psoriasis. Menter A. **Cutis** 1998 Feb;61(2 Suppl):8-10 (20 ref.)

Immunopathogenesis of psoriasis: news in an old concept. Guilhou J. **Dermatology** 1998;197(4):310-2 (30 ref.)

Psoriasis as a T cell-mediated autoimmune disease. Barker JN. **Hosp Med** 1998 Jul;59(7):530-3 (25 ref.)

The genetics of psoriasis: a complex disorder of the skin and immune system. Bhalerao J, et al. **Hum Mol Genet** 1998; 7(10):1537-45 (128 ref.)

The pathogenesis of psoriasis: immunological facts and speculations. Bos JD, et al. **Immunol Today** 1999 Jan; 20(1):40-6 (57 ref.)

PSORIASIS

METABOLISM

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Fritsch C, et al. **Br J Cancer** 1999 Mar;79(9-10):1603-8 (36 ref.)

Cytokines in psoriasis. Bonifati C, et al. **Int J Dermatol** 1999 Apr;38(4):241-51 (119 ref.)

The pathogenesis of psoriasis and the mechanism of action of tazarotene. Duvic M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S129-33 (27 ref.)

Pharmacokinetics and safety review of tazarotene. Marks R. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S134-8 (27 ref.)

[The metabolic disorders and the validation of the possible use of the tesigraphic study method in psoriasis] Baranova OA. **Lik Sprava** 1999 Mar;(2):18-22 (20 ref.) **(Ukr)**

PATHOLOGY

The pathogenesis of psoriasis and the mechanism of action of tazarotene. Duvic M, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S129-33 (27 ref.)

Renal abnormalities in psoriatic patients: a review [editorial] Heuvels J, et al. **Nephron** 1999;82(1):1-6 (42 ref.)

Unusual skin presentations of psoriasis. Chu A. **Practitioner** 1998 Apr;242(1585):282-6 (0 ref.)

PHYSIOPATHOLOGY

[Psoriasis in childhood] Fond L, et al. **Arch Pediatr** 1999 Jun;6(6):669-74 (15 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Quality of life measures in psoriasis: a critical appraisal of their quality. Ashcroft DM, et al. **J Clin Pharm Ther** 1998 Oct;23(5):391-8 (48 ref.)

RADIOGRAPHY

[Spondarthritis hyperostotica pustulo-psoriatica: nosologic study with clinical and radiologic presentation in relation to the SAPHO syndrome] Schilling F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Dec;169(6):576-84 (38 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Acitretin in combination with UVB or PUVA. Lebwohl M. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S22-4 (10 ref.)

THERAPY

Efficacy and safety of treatment modalities for psoriasis. Tristani-Firouzi P, et al. **Cutis** 1998 Feb;61(2 Suppl):11-21 (69 ref.)

Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Molin L. **Dermatology** 1999;198(4):375-81 (31 ref.)

Novel therapeutic approaches to psoriasis. Griffiths CE. **Hosp Med** 1998 Jul;59(7):539-42 (23 ref.)

Dead-Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost-effectiveness. Shani J, et al. **Int J Dermatol** 1999 Apr;38(4):252-62 (67 ref.)

Duration of remission of psoriasis therapies. Koo J, et al. **J Am Acad Dermatol** 1999 Jul;41(1):51-9 (49 ref.)

Acitretin combination therapy. Roenigk HH Jr. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S18-21 (14 ref.)

[Psoriasis in childhood] Fond L, et al. **Arch Pediatr** 1999 Jun;6(6):669-74 (15 ref.) (Eng. Abstr.) **(Fre)**

[Psoriasis therapy today] Itin PH, et al. **Ther Umsch** 1998 Aug;55(8):484-91 (13 ref.) (Eng. Abstr.) **(Ger)**

PSORIASIS, ARTHRITIC see **ARTHRITIS, PSORIATIC**

PSORIASIS ARTHROPATHICA see **ARTHRITIS, PSORIATIC**

PSYCHEDELIC AGENTS see **HALLUCINOGENS**

PSYCHIATRIC DEPARTMENT, HOSPITAL

[Parents judgement concerning family work of a child psychiatric ward] Romberg A. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec;47(10):773-8 (15 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The use of videoconferencing for telepsychiatry in Finland. Mielonen ML, et al. **J Telemed Telecare** 1998;4(3):125-31 (21 ref.)

Reorganizing departments of psychiatry, hospitals, and medical centers for the 21st century. Schreter RK. **Psychiatr Serv** 1998 Nov;49(11):1429-33 (51 ref.)

TRENDS

[Integrative painting therapy. A therapeutic concept for psychiatric inpatients at the University clinic in Graz] Steinbauer M, et al. **Wien Klin Wochenschr** 1999 Jul 9; 111(13):525-32 (21 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

Systematic review of the effectiveness of planned short hospital stays for mental health care. Johnstone P, et al. **BMJ** 1999 May 22;318(7195):1387-90 (27 ref.)

PSYCHIATRIC NURSING

Can paternalism be justified in mental health care? Breeze J. **J Adv Nurs** 1998 Aug;28(2):260-5 (40 ref.)

Issues of non-compliance in mental health. Lowry DA. **J Adv Nurs** 1998 Aug;28(2):280-7 (51 ref.)

Patterns of mental health care among Mexican Americans. Bechtel GA, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Nov;36(11):20-7 (28 ref.)

Current understanding of violence and aggression: assessment and treatment. Littrell KH, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Dec;36(12):18-24 (40 ref.)

A nursing-centered treatment team in inpatient medical psychiatry. Norton JW, et al. **J Psychosoc Nurs Ment Health Serv** 1999 Apr;37(4):39-41 (0 ref.)

EDUCATION

Potential for violence toward psychiatric nursing students: risk reduction techniques. Echternacht MR. **J Psychosoc Nurs Ment Health Serv** 1999 Mar;37(3):36-9 (9 ref.)

METHODS

The Heideggerian view of person: a perspective conducive to the therapeutic encounter. Orbanic SD. **Arch Psychiatr Nurs** 1999 Jun;13(3):137-44 (19 ref.)

A concept analysis of empowerment: its relationship to mental health nursing. Ryles SM. **J Adv Nurs** 1999 Mar; 29(3):600-7 (86 ref.)

Restraints and the elderly with mental illness: ethical issues and moral reasoning [see comments] Dawkins VH. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):22-7 (12 ref.) Comment in: J Psychosoc Nurs Ment Health Serv 1998 Dec;36(12):6.

ORGANIZATION & ADMINISTRATION

The psychiatric clinical nurse specialist/nurse practitioner: an example of a combined role [comment] Cukr PL, et al. **Arch Psychiatr Nurs** 1998 Dec;12(6):311-8 (34 ref.) Comment on: Arch Psychiatr Nurs 1997 Feb;11(1):2-12.

Psychiatric nurse practitioner versus clinical nurse specialist: moving from debate to action on the future of advanced psychiatric nursing. McCabe S, et al. **Arch Psychiatr Nurs** 1999 Jun;13(3):111-6 (9 ref.)

Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):32-5 (11 ref.)

TRENDS

Advantages and disadvantages of collaborative research: a university and behavioral health care provider's experience. Jones SL, et al. **Arch Psychiatr Nurs** 1998 Oct;12(5):241-6 (30 ref.)

PSYCHIATRIC STATUS RATING SCALES

Reflections on the clinical utility of the ICD-10 and DSM-IV classifications and their diagnostic criteria. Bertelsen A. **Aust N Z J Psychiatry** 1999 Apr;33(2):166-73 (21 ref.)

The nature of psychiatric classification: issues beyond ICD-10 and DSM-IV. Jablensky A. **Aust N Z J Psychiatry** 1999 Apr;33(2):137-44 (40 ref.)

Development and testing of a new hostility scale. Arthur HM, et al. **Can J Cardiol** 1999 May;15(5):539-44 (30 ref.)

An investigation of anxious thought in patients with DSM-IV agoraphobia/panic disorder: rationale and design. Compton A. **J Am Psychoanal Assoc** 1998;46(3):691-721 (105 ref.)

The Delirium Rating Scale. Its use in consultation-liaison research. Trzepacz PT. **Psychosomatics** 1999 May-Jun; 40(3):193-204 (35 ref.)

[The mini-mental state examination in screening of cognitive dysfunction and dementia] Lomholt RK, et al. **Ugeskr Laeger** 1998 Dec 7;160(50):7251-4 (20 ref.) (Eng. Abstr.) **(Dan)**

[The use of screening tools in psychiatry of the elderly person] Copeland JR, et al. **Rev Med Suisse Romande** 1999 Apr;119(4):323-8 (39 ref.) **(Fre)**

STANDARDS

Psychopathology: description and classification. Nathan PE, et al. **Annu Rev Psychol** 1999;50:79-107 (162 ref.)

Do personality disorders exist? On the validity of the concept and its cognitive-behavioral formulation and treatment. Arntz A. **Behav Res Ther** 1999 Jul;37 Suppl 1:S97-134 (109 ref.)

The convergent validity of the Phobia Origins Questionnaire (POQ): a review of the evidence. Menzies RG, et al. **Behav Res Ther** 1998 Nov;36(11):1081-9 (42 ref.)

Antisocial personality disorder and psychopathy: diagnostic dilemmas in classifying patterns of antisocial behavior in sentencing evaluations. Cunningham MD, et al. **Behav Sci Law** 1998 Summer;16(3):333-51 (94 ref.)

Rating scales for mania: is self-rating reliable? Altman E. **J Affect Disord** 1998 Sep;50(2-3):283-6 (12 ref.)

The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Dittrich A. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:80-4 (17 ref.)

Recognizing comorbid personality disorder can help manage and treat the "untreatable". Benjamin LS, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):775-89, vi (23 ref.)

Nosology and epidemiology of addictive disorders and their comorbidity. Bucholz KK. **Psychiatr Clin North Am** 1999 Jun;22(2):221-40 (28 ref.)

STATISTICS & NUMERICAL DATA

DSM-IV and beyond: what is generalized anxiety disorder? Barlow DH, et al. **Acta Psychiatr Scand Suppl** 1998; 393:23-9 (38 ref.)

Instruments for assessment of auditory hallucinations. Frederick JA, et al. **Arch Psychiatr Nurs** 1998 Oct; 12(5):255-63 (24 ref.)

Computer interviews for depression management. Greist JH. **J Clin Psychiatry** 1998;59 Suppl 16:20-4; discussion 40-2 (21 ref.)

The chronological assessment of suicide events: a practical interviewing strategy for the elicitation of suicidal ideation. Shea SC. **J Clin Psychiatry** 1998;59 Suppl 20:58-72 (10 ref.)

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Sheehan DV, et al. **J Clin Psychiatry** 1998;59 Suppl 20:22-33;quiz 34-57 (25 ref.)

Progress of ICD-10 (F) family in Japan: research, field trials and publications. Takada K, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S341-3 (15 ref.)

Measurement reliability and agreement in psychiatry. Shrout PE. **Stat Methods Med Res** 1998 Sep;7(3):301-17 (77 ref.)

PSYCHIATRY

Sport psychiatry. Macleod AD. **Aust N Z J Psychiatry** 1998 Dec;32(6):860-6 (66 ref.)

From consultation-liaison psychiatry to psychosocial advocacy: maintaining psychiatry's scope. Smith GC. **Aust N Z J Psychiatry** 1998 Dec;32(6):753-61; discussion 762-6 (75 ref.)

Randomised controlled trials in psychiatry: important but poorly accepted. Andrews G. **BMJ** 1999 Aug 28; 319(7209):562-4 (19 ref.)

The role of the psychiatrist in organ transplantation. Klapheke MM. **Bull Menninger Clin** 1999 Winter; 63(1):13-39 (60 ref.)

The psychiatric consultant in professional team sports. Calhoun JW, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):791-802 (18 ref.)

A developmental and psychoeducational approach to reducing conflict and abuse in little league and youth sports. The sport psychiatrist's role. Kamm RL. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):891-918 (44 ref.)

Comprehending role conflicts in the coaching of children, adolescents, and young adults. Transference, countertransference, and achievement by proxy distortion paradigms. Ogilvie BC, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):879-90 (31 ref.)

The use of natural remedies in psychiatry: a commentary. Mischoulon D, et al. **Harv Rev Psychiatry** 1999 Jan-Feb; 6(5):279-83 (42 ref.)

Commentary: the use of placebos in psychiatric research [comment] Forester BP. **Int J Psychiatry Med** 1999; 29(1):91-5 (9 ref.) Comment on: Int J Psychiatry Med 1999 ;29(1):97-105. Comment on: Int J Psychiatry Med 1999 ;29(1):107-17.

Recent advances in evolutionary psychology and psychiatry. Bacciagaluppi M. **J Am Acad Psychoanal** 1998 Spring; 26(1):5-13 (30 ref.)

Clinical relevance of contemporary cultural psychiatry. Alarcón RD, et al. **J Nerv Ment Dis** 1999 Aug; 187(8):465-71 (69 ref.)

Possible roles for mismatch negativity in neuropsychiatry. Gené-Cos N, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1999 Jan; 12(1):17-27 (101 ref.)

Physician-assisted suicide in psychiatry: developments in The Netherlands. Schoevers RA, et al. **Psychiatr Serv** 1998 Nov; 49(11):1475-80 (54 ref.)

Quality of life in psychiatry as an ethical duty: from the clinical to the societal perspective. Kilian R, et al. **Psychopathology** 1999 May-Jun;32(3):127-34 (28 ref.)

[Sex differences relating to psychiatric treatment] Godfroid IO. **Can J Psychiatry** 1999 May;44(4):362-7 (61 ref.) (Eng. Abstr.) **(Fre)**

[Genetic epidemiology and psychiatry (I): scope and limitations of familial studies. Case of panic disorder] Gorwood P, et al. **Encephale** 1999 Jan-Feb;25(1):21-9 (47 ref.) (Eng. Abstr.) **(Fre)**

[How do we utilize our knowledge of psychiatry?] Magnussen F, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;

118(23):3659–62 (5 ref.) **(Nor)**
[Neuronal death is basic problem of neurology and psychiatry] Zavalishin IA, et al. **Vestn Ross Akad Med Nauk** 1999;(1):28–33 (45 ref.) (Eng. Abstr.) **(Rus)**

ECONOMICS

[Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature] Frasch K, et al. **Nervenarzt** 1999 May; 70(5):387–90 (27 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

The United States Supreme Court and psychiatry in the 1990s. Ciccone JR. **Psychiatr Clin North Am** 1999 Mar; 22(1):197–211 (24 ref.)
The Russian concept of schizophrenia: a review of the literature. Lavretsky H. **Schizophr Bull** 1998;24(4):537–57 (166 ref.)

LEGISLATION & JURISPRUDENCE

The clinician's duty to protect third parties. Felthous AR. **Psychiatr Clin North Am** 1999 Mar;22(1):49–60 (67 ref.)
Therapist–patient sex. From boundary violations to sexual misconduct. Simon RI. **Psychiatr Clin North Am** 1999 Mar; 22(1):31–47 (54 ref.)
Managed care, liability, and ERISA. Stone AA. **Psychiatr Clin North Am** 1999 Mar;22(1):17–29 (40 ref.)
The right to refuse psychiatric treatment. Wettstein RM. **Psychiatr Clin North Am** 1999 Mar;22(1):173–82, viii (15 ref.)

METHODS

Limitations of the symptom-oriented approach to psychiatric research. Mojtabai R, et al. **Br J Psychiatry** 1998 Sep; 173:198–202 (37 ref.)
Assessment and management of antipsychotic-induced adverse events. Cortese L, et al. **Can J Psychiatry** 1998 Sep;43 Suppl 1:15S–20S (44 ref.)
Telepsychiatry in South Australia. Hawker F, et al. **J Telemed Telecare** 1998;4(4):187–94 (15 ref.)
Methodological issues of human experimental research with hallucinogens. Gouzoulis-Mayfrank E, et al. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:114–8 (20 ref.)
Power spectral analysis of heart rate variability in psychiatry. Cohen H, et al. **Psychother Psychosom** 1999 Mar–Apr; 68(2):59–66 (55 ref.)
Clinical trials in psychiatry: background and statistical perspective. Johnson T. **Stat Methods Med Res** 1998 Sep; 7(3):209–34 (118 ref.)
[Diagnostic imaging techniques in psychiatry] Hulshoff Pol HE, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17; 142(42):2285–90 (35 ref.) (Eng. Abstr.) **(Dut)**
[Methodology of psychiatric case histories] Scherbaum N, et al. **Fortschr Neurol Psychiatr** 1999 May;67(5):229–36 (44 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The impact of managed care on psychiatry. Domino ME, et al. **Adm Policy Ment Health** 1998 Nov;26(2):149–57 (34 ref.)
Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):32–5 (11 ref.)

STANDARDS

The diagnosis of depression in disorder. van Praag HM. **Aust N Z J Psychiatry** 1998 Dec;32(6):767–72; discussion 773–7 (18 ref.)
Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21–33 (281 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.
Chirality and drugs used in psychiatry: nice to know or need to know? Lane RM, et al. **Cell Mol Neurobiol** 1999 Jun; 19(3):355–72 (134 ref.)

TRENDS

Gene transfer to the brain: emerging therapeutic strategy in psychiatry? Lesch KP. **Biol Psychiatry** 1999 Feb 1; 45(3):247–53 (44 ref.)
Sharing the responsibilities: the roles of the government. Gjerris A. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S7–9 (9 ref.)
Sharing the responsibility for improved care: the example of the Lundbeck International Psychiatric Institute. Joubert AF. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S41–8 (21 ref.)
Sexual predators. Zonana HV, et al. **Psychiatr Clin North Am** 1999 Mar;22(1):109–27, vii (68 ref.)
[Communication on the Internet. Possibilities and risks of the Internet for psychiatry] Seemann O, et al. **Fortschr Neurol Psychiatr** 1998 Nov;66(11):483–6 (34 ref.) (Eng. Abstr.) **(Ger)**
[Psychiatry and psychotherapy on the internet. Current overview] Seemann O, et al. **Nervenarzt** 1999 Jan; 70(1):76–80 (17 ref.) (Eng. Abstr.) **(Ger)**
[Occupational psychiatry: major stages and prospects of development (review of literature)] Beliaeva GG. **Med Tr Prom Ekol** 1999;(7):33–7 (37 ref.) **(Rus)**

PSYCHIATRY, BIOLOGICAL see **BIOLOGICAL PSYCHIATRY**

PSYCHIATRY, COMMUNITY see **COMMUNITY PSYCHIATRY**

PSYCHIATRY, GERIATRIC see **GERIATRIC PSYCHIATRY**

PSYCHICAL RESEARCH see **PARAPSYCHOLOGY**

PSYCHOACTIVE AGENTS see **PSYCHOTROPIC DRUGS**

PSYCHOANALYSIS

Psychoanalysis and cognitive-evolutionary psychology: an attempt at integration. Migone P, et al. **Int J Psychoanal** 1998 Dec;79 (Pt 6):1071–95 (116 ref.)
Kleinian guilt, determinism, and free will: implications for clinical theory and treatment. Goodman G. **J Am Acad Psychoanal** 1998 Spring;26(1):137–63 (52 ref.)

EDUCATION

Meaning and metaphor in psychoanalytic education. Gargiulo GJ. **Psychoanal Rev** 1998 Jun;85(3):413–22 (8 ref.)

HISTORY

Ego autonomy and the healthy personality: psychodynamics, cognitive style, and clinical applications. Miller L. **Psychoanal Rev** 1998 Jun;85(3):423–48 (88 ref.)
Freud's treatment of the "Rat Man": a polemic with his critics. Schwartz C. **Psychoanal Rev** 1998 Jun;85(3):373–97 (38 ref.)

METHODS

First loves and prime adventures: adolescent expressions in adult analyses. Kulish N. **Psychoanal Q** 1998 Oct; 67(4):539–65 (30 ref.)

TRENDS

Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. Kandel ER. **Am J Psychiatry** 1999 Apr;156(4):505–24 (136 ref.)
Psychoanalytic contributions to the study of gender issues. Barbieri NB. **Can J Psychiatry** 1999 Feb;44(1):72–6 (53 ref.)
Countertransference past and present: a review of the concept. Jacobs TJ. **Int J Psychoanal** 1999 Jun;80 (Pt 3):575–94 (98 ref.)
[Psychoanalysis, psychoanalytic psychotherapy and supportive psychotherapy: current controversies] Kernberg OF. **Psychother Psychosom Med Psychol** 1999 Mar–Apr; 49(3–4):90–9 (31 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOANALYTIC INTERPRETATION

Mohawks and combat boots: the schizoid dilemma of punks. McAllister MJ. **Bull Menninger Clin** 1999 Winter; 63(1):89–102 (25 ref.)
Moving ahead: integrating influences of affective processes for development and for psychoanalysis. Emde RN. **Int J Psychoanal** 1999 Apr;80 (Pt 2):317–39 (198 ref.)
Whose consent is it anyway? A poststructuralist framing of the person in medical decision-making. Marta J. **Theor Med Bioeth** 1998 Aug;19(4):353–70 (33 ref.)

PSYCHOANALYTIC THEORY

Recent advances in evolutionary psychology and psychiatry. Bacciagaluppi M. **J Am Acad Psychoanal** 1998 Spring; 26(1):5–13 (30 ref.)
The distinction between needs and wishes: implications for psychoanalytic theory and technique. Akhtar S. **J Am Psychoanal Assoc** 1999;47(1):113–51 (152 ref.)
An investigation of anxious thought in patients with DSM-IV agoraphobia/panic disorder: rationale and design. Compton A. **J Am Psychoanal Assoc** 1998;46(3):691–721 (105 ref.)
Female homosexuality: classical psychoanalytic theory reconsidered [see comments] Downey JI, et al. **J Am Psychoanal Assoc** 1998;46(2):471–506 (100 ref.) Comment in: J Am Psychoanal Assoc 1998 ;46(2):361–3.
Unconscious pregnancy fantasies as an underlying dynamism in panic disorder. Milrod B. **J Am Psychoanal Assoc** 1998; 46(3):673–90 (24 ref.)
The enigmatic dimension of sexual experience: the "otherness" of sexuality and primal seduction. Stein R. **Psychoanal Q** 1998 Oct;67(4):594–625 (54 ref.)
[How can psychodynamic diagnosis in childhood and adolescence be operationalized?] Schulte-Markwort M, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug; 26(3):211–20 (53 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOANALYTIC THERAPY

Process and outcome in mental health care delivery: a model approach to treatment evaluation. Fonagy P. **Bull Menninger Clin** 1999 Summer;63(3):288–304 (75 ref.)
The "ideologic" view of transference. Biancoli R. **J Am Acad Psychoanal** 1998 Spring;26(1):15–28 (50 ref.)
Creativity in the psychoanalytic process. Chessick RD. **J Am Acad Psychoanal** 1998 Summer;26(2):209–22 (42 ref.)
The distinction between needs and wishes: implications for psychoanalytic theory and technique. Akhtar S. **J Am Psychoanal Assoc** 1999;47(1):113–51 (152 ref.)
Contributions of psychoanalysis to the understanding and treatment of depression. Blatt SJ. **J Am Psychoanal Assoc** 1998;46(3):722–52 (100 ref.)
[Intuitive dialogue--a way out of emotional blockages with defocusing imagination] Drees A. **Wien Med Wochenschr** 1998;148(6):166–70 (19 ref.) (Eng. Abstr.) **(Ger)**
[How can psychodynamic diagnosis in childhood and adolescence be operationalized?] Schulte-Markwort M, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug; 26(3):211–20 (53 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Psychodynamic-supportive group therapy model for elderly Holocaust survivors. Müller U, et al. **Int J Group Psychother** 1998 Oct;48(4):461–75 (41 ref.)
Memory and therapeutic action [editorial] Fonagy P. **Int J Psychoanal** 1999 Apr;80 (Pt 2):215–23 (70 ref.)

TRENDS

[Psychoanalysis, psychoanalytic psychotherapy and supportive psychotherapy: current controversies] Kernberg OF. **Psychother Psychosom Med Psychol** 1999 Mar–Apr; 49(3–4):90–9 (31 ref.) (Eng. Abstr.) **(Ger)**

PSYCHODIDAE

What's eating you? Sand flies. (Diptera: Psychodidae, Phlebotominae: Lutzomyia, Phlebotomus). Elston DM. **Cutis** 1998 Oct;62(4):164 (4 ref.)

PSYCHODINAE see **PSYCHODIDAE**

PSYCHOGENETICS see **GENETICS, BEHAVIORAL**

PSYCHOGERIATRICS see **GERIATRIC PSYCHIATRY**

PSYCHOIMMUNOLOGY see **PSYCHONEUROIMMUNOLOGY**

PSYCHOLINGUISTICS

see related
LANGUAGE DEVELOPMENT

Influences on infant speech processing: toward a new synthesis. Werker JF, et al. **Annu Rev Psychol** 1999; 50:509–35 (126 ref.)
On the nature of left hemisphere specialization for signed language. Corina DP. **Brain Lang** 1999 Sep;69(2):230–40 (34 ref.)
On processing lexical meanings in aphasia and Alzheimer's disease: some (re)considerations. Hillert D. **Brain Lang** 1999 Sep;69(2):95–118 (121 ref.)
Rethinking innateness [see comments] Rispoli M. **J Child Lang** 1999 Feb;26(1):217–25 (13 ref.) Comment in: J Child Lang 1999 Feb;26(1):242–5. Comment in: J Child Lang 1999 Feb;26(1):248–53. Comment in: J Child Lang 1999 Feb;26(1):253–60.
Subordinate-level object classification reexamined. Biederman I, et al. **Psychol Res** 1999;62(2–3):131–53 (79 ref.)
Visual and mental exploration of visuo-spatial configurations: behavioral and neuroimaging approaches. Cocude M, et al. **Psychol Res** 1999;62(2–3):93–106 (57 ref.)
From objects to names: a cognitive neuroscience approach. Humphreys GW, et al. **Psychol Res** 1999;62(2–3):118–30 (56 ref.)

PSYCHOLOGICAL TESTS

A case for the usefulness of laboratory social stressors. Linden W, et al. **Ann Behav Med** 1998 Fall;20(4):310–6 (57 ref.)
Developmental assessment. Its role in comprehensive psychiatric assessment of young children. Gilliam WS. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):225–38 (27 ref.)
Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing. Beatty WW. **Mult Scler** 1999 Aug;5(4):239–43 (51 ref.)
Manganese neurotoxicity in industrial exposures: proof of effects, critical exposure level, and sensitive tests. Iregren A. **Neurotoxicology** 1999 Apr–Jun;20(2–3):315–23 (27 ref.)

STANDARDS

Statistical adequacy of the Abel Assessment for Interest in Paraphilias. Fischer L, et al. **Sex Abuse** 1999 Jul; 11(3):195–205 (23 ref.)
Assessment of juvenile sexual offenders: reliability and validity of the Abel Assessment for Interest in Paraphilias. Smith G, et al. **Sex Abuse** 1999 Jul;11(3):207–16 (20 ref.)
[Ethic aspects of conducting physiological-hygienic and psychological studies on human subjects as applied to the activities in extreme environments] Genin AM, et al.

PSYCHOLOGICAL TESTS

Aviakosm Ekolog Med 1998;32(6):50–5 (4 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGICAL THEORY

Theoretical perspectives on female sexual behaviour in Africa: a review and conceptual model. Djamba YK. **Afr J Reprod Health** 1997 Sep;1(2):67–78 (57 ref.)

Object relations theory and short-term dynamic psychotherapy: findings from the Quality of Object Relations Scale. Piper WE, et al. **Clin Psychol Rev** 1999 Sep;19(6):669–85 (69 ref.)

Strengthening domestic violence theories: intersections of race, class, sexual orientation, and gender. Bograd M. **J Marital Fam Ther** 1999 Jun;25(3):275–89 (92 ref.)

Approaching psychotherapy of the personality disorders from the Millon perspective. Dorr D. **J Pers Assess** 1999 Jun;72(3):407–25 (35 ref.)

[Personality and endogeneity in psychopathology] Ramos Gorostiza P. **Actas Esp Psiquiatr** 1999 May–Jun; 27(3):167–75 (24 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

A new conceptual paradigm from genetics and psychobiology for the science of mental health. Cloninger CR. **Aust N Z J Psychiatry** 1999 Apr;33(2):174–86 (31 ref.)

Processing capacity defined by relational complexity: implications for comparative, developmental, and cognitive psychology. Halford GS, et al. **Behav Brain Sci** 1998 Dec; 21(6):803–31; discussion 831–64 (243 ref.)

Psychoanalysis and cognitive–evolutionary psychology: an attempt at integration. Migone P, et al. **Int J Psychoanal** 1998 Dec;79 (Pt 6):1071–95 (116 ref.)

Behavioral economics: reunifying psychology and economics. Camerer C. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10575–7 (23 ref.)

EDUCATION

[Problem-based teaching and learning. An opportunity for medical psychology, psychosomatic medicine and psychotherapy?] Köhle K, et al. **Psychother Psychosom Med Psychol** 1999 May;49(5):171–5 (13 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

Proceedings of the 6th conference on the neurobiology of learning and memory. Brain and memory: from genes to behavior. Some historical background of topics in this conference. Rosenzweig MR. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):3–13 (70 ref.)

STANDARDS

[The evolution of ethical standards in the practice of psychology: a reflection on the APA Code of Ethics] Sabourin M. **Shinrigaku Kenkyu** 1999 Apr;70(1):51–64 (38 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

The art of assessment in psychology: ethics, expertise, and validity. Cates JA. **J Clin Psychol** 1999 May;55(5):631–41 (64 ref.)

Human nature and the nature of reality: conceptual challenges from consciousness research. Grof S. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):343–57 (33 ref.)

The psychology in psychoneuroendocrinology. Ursin H. **Psychoneuroendocrinology** 1998 Aug;23(6):555–70 (83 ref.)

PSYCHOLOGY, CLINICAL

[Contribution of the clinical psychologists to rehabilitation of children with craniofacial abnormalities] Sarimski K. **Psychother Psychosom Med Psychol** 1998 Dec; 48(12):475–82 (30 ref.) (Eng. Abstr.) **(Ger)**

MANPOWER

Integrating health and mental health services in schools: psychologists collaborating with primary care providers. Kubiszyn T. **Clin Psychol Rev** 1999 Mar;19(2):179–98 (104 ref.)

The role of the clinical psychologist in gynecological cancer. Rieger E, et al. **J Psychosom Res** 1998 Sep;45(3):201–14 (88 ref.)

ORGANIZATION & ADMINISTRATION

Collaborative care in the United Kingdom. Jenkins GC. **Prim Care** 1999 Jun;26(2):411–22 (41 ref.)

PSYCHOLOGY, COMPARATIVE

Neuroethology of spatial learning: the birds and the bees. Capaldi EA, et al. **Annu Rev Psychol** 1999;50:651–82 (216 ref.)

TRENDS

Single-gene influences on brain and behavior. Wahlsten D. **Annu Rev Psychol** 1999;50:599–624 (103 ref.)

PSYCHOLOGY, CRIMINAL see **CRIMINAL PSYCHOLOGY**

PSYCHOLOGY, HEALTH see **BEHAVIORAL MEDICINE**

PSYCHOLOGY, INDUSTRIAL

see related
HUMAN ENGINEERING

Occupational health psychology: historical roots and future directions. Quick JC. **Health Psychol** 1999 Jan;18(1):82–8 (47 ref.)

ORGANIZATION & ADMINISTRATION

Occupational health psychology: an emerging discipline. Sauter SL, et al. **Ind Health** 1999 Apr;37(2):199–211 (90 ref.)

PSYCHOLOGY, PASTORAL see **PASTORAL CARE**

PSYCHOLOGY, PHYSIOLOGICAL see **PSYCHOPHYSIOLOGY**

PSYCHOLOGY, SCHIZOPHRENIC see **SCHIZOPHRENIC PSYCHOLOGY**

PSYCHOLOGY, SELF see **SELF PSYCHOLOGY**

PSYCHOLOGY, SOCIAL

Assessing threats of targeted group violence: contributions from social psychology. Pynchon MR, et al. **Behav Sci Law** 1999;17(3):339–55 (52 ref.)

Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease. Systematic review of prospective cohort studies. Hemingway H, et al. **BMJ** 1999 May 29;318(7196):1460–7 (31 ref.)

A theoretical analysis of Carper's ways of knowing using a model of social cognition. Stein KF, et al. **Sch Inq Nurs Pract** 1998 Spring;12(1):43–60; discussion 61–4 (58 ref.)

PSYCHOMETRICS

Evidence of self-report bias in assessing adherence to guidelines. Adams AS, et al. **Int J Qual Health Care** 1999 Jun;11(3):187–92 (28 ref.)

METHODS

Collaboration and teamwork in assessment for early intervention. Bagnato SJ, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):347–63 (16 ref.)

Culturally sensitive assessment. Edwards CP, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):409–24, ix (46 ref.)

Developmental assessment. Its role in comprehensive psychiatric assessment of young children. Gilliam WS. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):225–38 (27 ref.)

Assessing communication in children with psychiatric and communication disorders. Kennedy MD. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):113–35, vii (90 ref.)

Assessment of caregiver–child interaction in the context of a preschool psychiatric evaluation. Keren M, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):281–96 (55 ref.)

Handicap questionnaires: what do they assess? [see comments] Cardol M, et al. **Disabil Rehabil** 1999 Mar; 21(3):97–105 (46 ref.) Comment in: Disabil Rehabil 1999 Mar;21(3):106–7; discussion 108–9.

A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Brazier J, et al. **Health Econ** 1999 Feb;8(1):41–51 (51 ref.)

MMPI, MMPI-2 and PTSD: overview of scores, scales, and profiles. Lyons JA, et al. **J Trauma Stress** 1999 Jan; 12(1):175–83 (22 ref.)

A review of research instruments for use during the postpartum period. Beck CT. **MCN Am J Matern Child Nurs** 1998 Sep–Oct;23(5):254–61 (56 ref.)

Quality of life assessment in clinical practice. Cramer JA. **Neurology** 1999;53(5 Suppl 2):S49–52 (18 ref.)

The Delirium Rating Scale. Its use in consultation-liaison research. Trzepacz PT. **Psychosomatics** 1999 May–Jun; 40(3):193–204 (35 ref.)

A review of health-related quality-of-life concepts and measures for Parkinson's disease. Damiano AM, et al. **Qual Life Res** 1999 May;8(3):235–43 (30 ref.)

STANDARDS

Methodological issues in evaluating Rorschach validity: a comment on Burns and Viglione (1996), Weiner (1996), and Ganellen (1996). Wood JM, et al. **Assessment** 1999 Jun; 6(2):115–29 (79 ref.)

STATISTICS & NUMERICAL DATA

A tutorial on creating logfiles for event-driven applications. Breinholt G, et al. **Behav Res Methods Instrum Comput** 1999 Aug;31(3):410–5 (13 ref.)

The use of multivariate statistical methods in psychiatry. Everitt BS, et al. **Stat Methods Med Res** 1998 Sep; 7(3):253–77 (89 ref.)

Measurement reliability and agreement in psychiatry. Shrout PE. **Stat Methods Med Res** 1998 Sep;7(3):301–17 (77 ref.)

PSYCHOMOTOR AGITATION

[Recent progress in akathisia] Horiguchi J, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Feb; 19(1):1–9 (94 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Bispectral Index: better information for sedation in the intensive care unit? [editorial; comment] Shapiro BA. **Crit Care Med** 1999 Aug;27(8):1663–4 (20 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1499–1504.

[State of agitation. Diagnostic guidance and procedures in emergencies along with drug dosage recommendations] Haffen E, et al. **Rev Prat** 1998 May 15;48(10):1123–7 (0 ref.) **(Fre)**

DRUG THERAPY

Bispectral Index: better information for sedation in the intensive care unit? [editorial; comment] Shapiro BA. **Crit Care Med** 1999 Aug;27(8):1663–4 (20 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1499–1504.

The role of typical and atypical antipsychotic medications in the management of agitation and aggression. Buckley PF. **J Clin Psychiatry** 1999;60 Suppl 10:52–60 (83 ref.)

Phenomenology and treatment of agitation. Schatzberg AF, et al. **J Clin Psychiatry** 1999;60 Suppl 15:17–20 (17 ref.)

Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. Verma SD, et al. **J Clin Psychiatry** 1998;59 Suppl 19:50–5 (32 ref.)

[Value of tiapride for agitation in the elderly. Review of published studies] Roger M, et al. **Encephale** 1998 Sep–Oct; 24(5):462–8 (61 ref.) (Eng. Abstr.) **(Fre)**

[State of agitation. Diagnostic guidance and procedures in emergencies along with drug dosage recommendations] Haffen E, et al. **Rev Prat** 1998 May 15;48(10):1123–7 (0 ref.) **(Fre)**

[Midazolam (Dormicum) in terminal anxiety and agitation. The last choice alternative in palliative care] Jakobsson M, et al. **Lakartidningen** 1999 Apr 28;96(17):2079–81 (9 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

[Motor signs of depression] Lemke MR. **Nervenarzt** 1999 Jul; 70(7):600–12 (145 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Behavioral approaches for reducing agitation in residents of long-term-care facilities: critical review and suggestions for future research. Landreville P, et al. **Int Psychogeriatr** 1998 Dec;10(4):397–419 (56 ref.)

Treatment of agitation in dementia. Tariot PN. **J Clin Psychiatry** 1999;60 Suppl 8:11–20 (42 ref.)

PSYCHOMOTOR DISORDERS

ETIOLOGY

Mania, pseudomania, depression, and pseudodepression resulting from focal unilateral cortical lesions. Braun CM, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1999 Jan; 12(1):35–51 (163 ref.)

[Dynamic course of neurological syndromes in very young children with the history of intrauterine growth retardation] Burtsev EM, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(9):9–11 (12 ref.) (Eng. Abstr.) **(Rus)**

[The course of psychomotor development in different encephalic malformations] Roche MC. **Rev Neurol** 1999 Jan 16–31;28(2):130–5 (45 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Do systems theory models promote understanding of disorders of sensorimotor function in neurology?] Glasauer S, et al. **Nervenarzt** 1998 Oct;69(10):919–23 (18 ref.) **(Ger)**

PSYCHOLOGY

Schizophrenia--a disorder of the corollary discharge systems that integrate the motor systems of thought with the sensory systems of consciousness. Feinberg I, et al. **Br J Psychiatry** 1999 Mar;174:196–204 (62 ref.)

[Motor signs of depression] Lemke MR. **Nervenarzt** 1999 Jul; 70(7):600–12 (145 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOMOTOR PERFORMANCE

Attention and executive deficits in Alzheimer's disease. A critical review. Perry RJ, et al. **Brain** 1999 Mar;122 (Pt 3):383–404 (190 ref.)

The objects of action and perception. Goodale MA, et al. **Cognition** 1998 Jul;67(1–2):181–207 (100 ref.)

Neuropsychology and the relearning of motor skills following stroke. Hochstenbach J, et al. **Int J Rehabil Res** 1999 Mar;22(1):11–9 (57 ref.)

[Work shifts, sleep and biological rhythms] Gaspar S, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):239–45 (13 ref.)

(Por)

[Pre-postoperative neuropsychological evaluation in the surgical treatment of epilepsy] Campo P, et al. **Rev Neurol** 1998 Oct;27(158):616–25 (127 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Hindmarch I, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:133–42 (42 ref.)

Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Kay GG, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:147–50 (19 ref.)

[Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function] Horga de la Parte JF. **Rev Neurol** 1999 Mar 1–15; 28(5):499–504 (31 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Development of perception in action in healthy and at-risk children. van der Meer AL, et al. **Acta Paediatr Suppl** 1999 May;88(429):29–36 (36 ref.)

Motor skills in motor disorders: measuring performance changes in tracking and other perceptual-motor tasks. Flowers KA. **Adv Neurol** 1999;80:41–8 (36 ref.)

Neural selection and control of visually guided eye movements. Schall JD, et al. **Annu Rev Neurosci** 1999; 22:241–59 (86 ref.)

Resonance behaviors and mirror neurons. Rizzolatti G, et al. **Arch Ital Biol** 1999 May;137(2–3):85–100 (43 ref.)

Major review: ocular sighting dominance: a review and a study of athletic proficiency and eye-hand dominance in a collegiate baseball team [see comments] Portal JM, et al. **Binocul Vis Strabismus Q** 1998 Summer-Winter;13(2 2nd Qtr):125–32 (12 ref.) Comment in: Binocul Vis Strabismus Q 1998 Fall;13(3 3rd Qtr):165–6.

The importance of boron nutrition for brain and psychological function. Penland JG. **Biol Trace Elem Res** 1998 Winter;66(1–3):299–317 (39 ref.)

Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Crawley JN. **Brain Res** 1999 Jul 17;835(1):18–26 (77 ref.)

Problems of sensorimotor coordination in weightlessness. Bock O. **Brain Res Brain Res Res Rev** 1998 Nov;28(1–2):155–60 (48 ref.)

Reference frames and internal models for visuo-manual coordination: what can we learn from microgravity experiments? McIntyre J, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):143–54 (77 ref.)

Interaction of vestibular, somatosensory and visual signals for postural control and motion perception under terrestrial and microgravity conditions--a conceptual model. Mergner T, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):118–35 (67 ref.)

From perception to action: temporal integrative functions of prefrontal and parietal neurons. Quintana J, et al. **Cereb Cortex** 1999 Apr-May;9(3):213–21 (52 ref.)

Active vision: visual activity in everyday life. Findlay J. **Curr Biol** 1998 Sep 10;8(18):R640–2 (12 ref.)

Visuomotor transformations: early cortical mechanisms of reaching. Caminiti R, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):753–61 (71 ref.)

Working in a moving environment. Wertheim AH. **Ergonomics** 1998 Dec;41(12):1845–58 (70 ref.)

Early motor influences on visuomotor transformations for reaching: a positive image of optic ataxia. Battaglia Mayer A, et al. **Exp Brain Res** 1998 Nov;123(1–2):172–89 (104 ref.)

Role of the hippocampal system in conditional motor learning: mapping antecedents to action. Wise SP, et al. **Hippocampus** 1999;9(2):101–17 (112 ref.)

The handshaking model of brain function: notes toward a theory. Lauter JL. **Med Hypotheses** 1999 May;52(5):435–45 (34 ref.)

A new view on grasping [see comments] Smeets JB, et al. **Motor Control** 1999 Jul;3(3):237–71 (86 ref.) Comment in: Motor Control 1999 Jul;3(3):272–5; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):276–9; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):280–4; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):285–8; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):289–97; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):298–301; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):302–6; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):307–11; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):312–5; discussion 316–25.

Differential roles of the frontal cortex, basal ganglia, and cerebellum in visuomotor sequence learning. Hikosaka O, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1–2):137–49 (18 ref.)

Posterior parietal areas specialized for eye movements (LIP) and reach (PRR) using a common coordinate frame. Andersen RA, et al. **Novartis Found Symp** 1998;218:109–22; discussion 122–8, 171–5 (32 ref.)

Online visual control of the arm. Georgopoulos AP. **Novartis Found Symp** 1998;218:147–64; discussion 164–70 (42 ref.)

Cerebellum and the sensory guidance of movement. Glickstein M. **Novartis Found Symp** 1998;218:252–66; discussion 266–71, 332–3 (56 ref.)

Vision for perception and vision for action in the primate brain. Goodale MA. **Novartis Found Symp** 1998;218:21–34; discussion 34–9 (47 ref.)

Grasping an object: one movement, several components. Jeannerod M, et al. **Novartis Found Symp** 1998;218:5–16; discussion 16–20 (41 ref.)

Internal models for motor control. Kawato M, et al. **Novartis Found Symp** 1998;218:291–304; discussion 304–7 (35 ref.)

The cerebellum, predictive control and motor coordination. Miall RC. **Novartis Found Symp** 1998;218:272–84; discussion 284–90 (35 ref.)

How do visual instructions influence the motor system? Passingham RE, et al. **Novartis Found Symp** 1998; 218:129–41; discussion 141–6 (52 ref.)

Cross-modal links in spatial attention. Driver J, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Aug 29; 353(1373):1319–31 (58 ref.)

14C-deoxyglucose mapping of the monkey brain during reaching to visual targets. Savaki HE, et al. **Prog Neurobiol** 1999 Aug;58(6):473–540 (600 ref.)

Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Flyckt L, et al. **Psychiatry Res** 1999 May 31;86(2):113–29 (50 ref.)

The contribution of the anterior cingulate cortex to executive processes in cognition. Carter CS, et al. **Rev Neurosci** 1999; 10(1):49–57 (62 ref.)

[Procedural learning in aphasic patients] Arroyo-Anlló EM, et al. **Rev Neurol** 1998 Dec;27(160):926–32 (51 ref.) (Eng. Abstr.) **(Spa)**

PSYCHONEUROIMMUNOLOGY

see related
NEUROIMMUNOMODULATION

Psychoneuroimmunology: the final hurdle. Overmier JB, et al. **Integr Physiol Behav Sci** 1998 Apr-Jun;33(2):137–40 (26 ref.)

Stress and HIV disease progression: psychoneuroimmunological framework. Robinson FP, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):21–31 (56 ref.)

Psychoneuroimmunology, the placebo effect and chiropractic [see comments] Morgan LG. **J Manipulative Physiol Ther** 1998 Sep;21(7):484–91 (47 ref.) Comment in: J Manipulative Physiol Ther 1999 Mar-Apr;22(3):180–1.

[Psychoimmunology: a model in question] Vuitton DA. **Rev Med Interne** 1998;19 Suppl 3:343S–346S (12 ref.) **(Fre)**

[From neuropeptides and cytokines to psychotherapy. Skin diseases between psychoneuroimmunology research and psychosomatic treatment] Niemeier V, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:14–8 (45 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The measurement of stress-related immune dysfunction in psychoneuroimmunology. Vedhara K, et al. **Neurosci Biobehav Rev** 1999 May;23(5):699–715 (85 ref.)

TRENDS

Health psychology: mapping biobehavioral contributions to health and illness. Baum A, et al. **Annu Rev Psychol** 1999; 50:137–63 (208 ref.)

Psychoneuroimmunology update. Kemeny ME, et al. **Semin Gastrointest Dis** 1999 Jan;10(1):20–9 (95 ref.)

PSYCHONEUROSES see **NEUROTIC DISORDERS**

PSYCHOPATHIC PERSONALITY see **ANTISOCIAL PERSONALITY DISORDER**

PSYCHOPATHOLOGY

CLASSIFICATION

Psychopathology: description and classification. Nathan PE, et al. **Annu Rev Psychol** 1999;50:79–107 (162 ref.)

PSYCHOPHARMACEUTICALS see **PSYCHOTROPIC DRUGS**

PSYCHOPHARMACOLOGY

see related
PSYCHOTROPIC DRUGS

The challenges of psychopharmacogenetics. Catalano M. **Am J Hum Genet** 1999 Sep;65(3):606–10 (35 ref.)

Time-dependent sensitization--possible implications for clinical psychopharmacology. Antelman SM, et al. **Behav Pharmacol** 1997 Nov;8(6–7):505–14; discussion 515–22 (61 ref.)

Psychopharmacology and the human condition [see comments] Charlton BG. **J R Soc Med** 1998 Nov; 91(11):599–601 (11 ref.) Comment in: J R Soc Med 1999 Feb;92(2):101–2. Comment in: J R Soc Med 1999 Mar;92(3):156. Comment in: J R Soc Med 1999 May;92(5):269–70.

A new algorithm for treating schizophrenia. Pearsall R, et al. **Psychopharmacol Bull** 1998;34(3):349–53 (27 ref.)

Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). Trivedi MH, et al. **Psychopharmacol Bull** 1998;34(3):355–9 (7 ref.)

ORGANIZATION & ADMINISTRATION

Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):32–5 (11 ref.)

TRENDS

Psychopharmacology of affective disorders in the 21st century. Nemeroff CB. **Biol Psychiatry** 1998 Oct 1; 44(7):517–25 (24 ref.)

The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Holsboer F. **J Psychiatr Res** 1999 May-Jun;33(3):181–214 (163 ref.)

Psychopharmacotherapy in children and adults with intellectual disability. Santosh PJ, et al. **Lancet** 1999 Jul 17;354(9174):233–42 (82 ref.)

Neuropsychopharmacology at the new millennium: new industry directions. Tallman JF. **Neuropsychopharmacology** 1999 Feb;20(2):99–105 (27 ref.)

The future of pediatric psychopharmacology. Walkup JT, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1265–78 (30 ref.)

New vistas in immunopsychopharmacology. Herman ZS. **Pol J Pharmacol** 1998 Nov-Dec;50(6):377–86 (108 ref.)

[From gene to behavior, a new method for elaboration of new psychotropic agents] Costentin J. **Ann Pharm Fr** 1998; 56(2):60–7 (49 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOPHYSICS

Pain: an unpleasant topic. Fields HL. **Pain** 1999 Aug;Suppl 6:S61–9 (48 ref.)

PSYCHOPHYSIOLOGIC DISORDERS

Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. Mann SJ. **Arch Intern Med** 1999 Apr 12; 159(7):670–4 (14 ref.)

Psychogenic nonepileptic seizures: theoretic and clinical considerations. Sirven JI, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Oct; 11(4):225–35 (75 ref.)

[The provoking dimension of pain. From somatoform pain disorder to a phenomenological approach to illness] Célis-Gennart M. **Rev Med Suisse Romande** 1999 Apr; 119(4):273–80 (17 ref.) **(Fre)**

[Psychosomatic aspects of chronic low back pain] Bach M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):802–6 (10 ref.) **(Ger)**

[Psychosomatic disorders (clinical picture, epidemiology, therapy and models of health services] Smulevich AB, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(4):4–16 (124 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Some theoretical remarks regarding the integration of somatic and psychosocial risk factors of coronary artery disease in preventive programmes in occupational medicine. Schmahl FW. **Int J Occup Med Environ Health** 1998;11(4):285–9 (12 ref.)

DIAGNOSIS

Psychological aspects of rosacea. Garnis-Jones S. **J Cutan Med Surg** 1998 Jun;2 Suppl 4:S4–16–9 (16 ref.)

[Somatization in general practice] Jørgensen CK, et al. **Ugeskr Laeger** 1998 Oct 5;160(41):5919–23 (37 ref.) (Eng. Abstr.) **(Dan)**

[Diagnosis of functional heart complaints from the psychosomatic viewpoint] Langkafel M, et al. **Herz** 1999 Apr;24(2):107–13 (20 ref.) (Eng. Abstr.) **(Ger)**

[From psychosomatic disorder to autoimmune disease--50 years urticaria and Quincke edema] Wyss M. **Schweiz Rundsch Med Prax** 1998 Sep 30;87(40):1325–9 (25 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiology of psychosomatic symptoms and subjective health evaluation among secondary school students] Pikó B. **Orv Hetil** 1999 Jun 6;140(23):1297–304 (40 ref.) (Eng. Abstr.) **(Hun)**

[A role of psychosomatic cycles in genesis of psychosomatic diseases] Korkina MV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):30–2 (11 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Migration and pain. Need for epidemiologic research] Moser J. **Rev Med Suisse Romande** 1999 Apr;119(4):265–7 (11 ref.) **(Fre)**

PSYCHOPHYSIOLOGIC DISORDERS

ETIOLOGY

Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218–28 (36 ref.)

[The involvement of the upper digestive tract and psychosomatic disorders in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Svintsitskii AS, et al. **Lik Sprava** 1998 Oct–Nov;(7):39–42 (44 ref.) **(Rus)**

[Neuroendocrine disorders cause stress-related disease. "Civilization syndrome" is a growing health problem] Björntorp P, et al. **Lakartidningen** 1999 Feb 24;96(8):893–6 (21 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Psychological aspects of rosacea. Garnis-Jones S. **J Cutan Med Surg** 1998 Jun;2 Suppl 4:S4–16–9 (16 ref.)

Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218–28 (36 ref.)

Irritable bowel syndrome and recurrent abdominal pain. A comparative review. Burke P, et al. **Psychosomatics** 1999 Jul–Aug;40(4):277–85 (86 ref.)

[Approach of psychology to health] Bruchon-Schweitzer M, et al. **Encephale** 1998 Dec;24 Spec No 2:2–14 (53 ref.) **(Fre)**

[Iatrogenic psychopathology and cancerology] Ronson A, et al. **Encephale** 1998 Dec;24 Spec No 2:15–24 (63 ref.) **(Fre)**

[Measure of negative life events before onset of cancer] Saltel P, et al. **Encephale** 1998 Dec;24 Spec No 2:42–9 (19 ref.) **(Fre)**

[Migration and pain. Need for epidemiologic research] Moser J. **Rev Med Suisse Romande** 1999 Apr;119(4):265–7 (11 ref.) **(Fre)**

[A role of psychosomatic cycles in genesis of psychosomatic diseases] Korkina MV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):30–2 (11 ref.) (Eng. Abstr.) **(Rus)**

REHABILITATION

[Homeopathy--possibilities and limits] Halter K. **Schweiz Rundsch Med Prax** 1998 Aug 5;87(31–32):969–74 (0 ref.) **(Ger)**

THERAPY

The use of Japanese herbal medicine in the treatment of medically unexplained physical symptoms [editorial] Mizushima H, et al. **J Psychosom Res** 1999 Jun;46(6):531–5 (11 ref.)

[Inexplicable medial symptoms and somatization] Cathébras P. **Rev Med Interne** 1998;19 Suppl 3:335S–338S (16 ref.) **(Fre)**

[The psychosomatic approach in 1998] Consoli SM. **Rev Med Interne** 1998;19 Suppl 3:331S–334S (16 ref.) **(Fre)**

[Geriatric psychosomatic disorders and psychotherapy of the elderly. Current concept and approaches to treatment] Heuft G. **Psychother Psychosom Med Psychol** 1998 Jul; 48(7):232–42 (130 ref.) (Eng. Abstr.) **(Ger)**

[Clinical hypnosis. Current status of theory and empirical aspects] Revenstorf D. **Psychother Psychosom Med Psychol** 1999 Jan;49(1):5–13 (68 ref.) (Eng. Abstr.) **(Ger)**

[Free from stress by autogenic therapy. Relaxation technique yielding peace of mind and self-insight] Broms C. **Lakartidningen** 1999 Feb 10;96(6):588–92 (20 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOPHYSIOLOGY

see related
PSYCHOSOMATIC MEDICINE

Health psychology: mapping biobehavioral contributions to health and illness. Baum A, et al. **Annu Rev Psychol** 1999; 50:137–63 (208 ref.)

Single-gene influences on brain and behavior. Wahlsten D. **Annu Rev Psychol** 1999;50:599–624 (103 ref.)

The body is the shadow of the soul. Hassed C. **Aust Fam Physician** 1999 Jun;28(6):613–4 (11 ref.)

Mind-body therapy in the management and prevention of coronary disease. Pandya DP, et al. **Compr Ther** 1999 May; 25(5):283–93 (142 ref.)

Visual perception: mind and brain see eye to eye. Moore C, et al. **Curr Biol** 1999 Jan 28;9(2):R74–6 (8 ref.)

Recent advances in evolutionary psychology and psychiatry. Bacciagaluppi M. **J Am Acad Psychoanal** 1998 Spring; 26(1):5–13 (30 ref.)

Biological aspects of near-death experiences. Greyson B. **Perspect Biol Med** 1998 Autumn;42(1):14–32 (82 ref.)

Models of collaboration. Lorenz AD, et al. **Prim Care** 1999 Jun;26(2):401–10 (14 ref.)

The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621–44 (63 ref.)

[The provoking dimension of pain. From somatoform pain disorder to a phenomenological approach to illness] Célis-Gennart M. **Rev Med Suisse Romande** 1999 Apr; 119(4):273–80 (17 ref.) **(Fre)**

TRENDS

Making the case for psychophysiology during the era of molecular biology. Anderson NB, et al. **Psychophysiology** 1999 Jan;36(1):1–13 (99 ref.)

PSYCHOSES see **PSYCHOTIC DISORDERS**

PSYCHOSES, AFFECTIVE see **AFFECTIVE DISORDERS, PSYCHOTIC**

PSYCHOSES, ALCOHOLIC

ETIOLOGY

B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Cook CC, et al. **Alcohol Alcohol** 1998 Jul–Aug;33(4):317–36 (127 ref.)

THERAPY

B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Cook CC, et al. **Alcohol Alcohol** 1998 Jul–Aug;33(4):317–36 (127 ref.)

PSYCHOSES, DRUG see **PSYCHOSES, SUBSTANCE-INDUCED**

PSYCHOSES, PARANOID see **PARANOID DISORDERS**

PSYCHOSES, SUBSTANCE-INDUCED

New antiepileptic drugs and psychopathology. Trimble MR. **Neuropsychobiology** 1998 Oct;38(3):149–51 (15 ref.)

DIAGNOSIS

Anabolic-androgenic steroid abuse and psychopathology. Porcerelli JH, et al. **Psychiatr Clin North Am** 1998 Dec; 21(4):829–33 (23 ref.)

ETIOLOGY

Procainamide-induced psychosis: a case report and review of the literature. Bizjak ED, et al. **Ann Pharmacother** 1999 Sep;33(9):948–51 (27 ref.)

Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Jiang HK, et al. **Clin Rheumatol** 1999;18(4):339–45 (33 ref.)

Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Wolters EC. **Neurology** 1999;52(7 Suppl 3):S10–3 (26 ref.)

A steroid-induced acute psychosis in a child with asthma. Dawson KL, et al. **Pediatr Pulmonol** 1998 Nov;26(5):362–4 (11 ref.)

Anabolic-androgenic steroid abuse and psychopathology. Porcerelli JH, et al. **Psychiatr Clin North Am** 1998 Dec; 21(4):829–33 (23 ref.)

A brief review of moonshine use [letter] Montgomery R, et al. **Psychiatr Serv** 1999 Aug;50(8):1088 (5 ref.)

[Psychiatric side effects of non-steroidal anti-inflammatory agents] Defromont L, et al. **Encephale** 1999 Jan–Feb; 25(1):11–5 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Schizophrenia – A disturbance of signal interaction between the entorhinal cortex and the dentate gyrus? The contribution of experimental dibenamine psychosis to the pathogenesis of schizophrenia: A hypothesis. Arnold OH. **Neuropsychobiology** 1999;40(1):21–32 (54 ref.)

PSYCHOSES, TOXIC see **PSYCHOSES, SUBSTANCE-INDUCED**

PSYCHOSES, TRAUMATIC see **DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS**

PSYCHOSEXUAL DEVELOPMENT

Abnormal sexual development and psychosexual issues. Hines M. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):173–89 (69 ref.)

First loves and prime adventures: adolescent expressions in adult analyses. Kulish N. **Psychoanal Q** 1998 Oct; 67(4):539–65 (30 ref.)

PSYCHOSEXUAL DISORDERS see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

PSYCHOSEXUAL DYSFUNCTIONS see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

PSYCHOSIS, BRIEF REACTIVE see **PSYCHOTIC DISORDERS**

PSYCHOSIS, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

PSYCHOSIS, MANIC-DEPRESSIVE see **BIPOLAR DISORDER**

PSYCHOSOCIAL DEPRIVATION

Psychosocial aspects of stress, health and safety on North Sea installations. Parkes KR. **Scand J Work Environ Health** 1998 Oct;24(5):321–33 (84 ref.)

PSYCHOSOCIAL SUPPORT SYSTEMS see **SOCIAL SUPPORT**

PSYCHOSOMATIC DISORDERS see **PSYCHOPHYSIOLOGIC DISORDERS**

PSYCHOSOMATIC MEDICINE

see related
PSYCHOPHYSIOLOGIC DISORDERS
PSYCHOPHYSIOLOGY

Mind-body medicine. Practical applications in dermatology. Bilkis MR, et al. **Arch Dermatol** 1998 Nov;134(11):1437–41 (13 ref.)

[Inexplicable medial symptoms and somatization] Cathébras P. **Rev Med Interne** 1998;19 Suppl 3:335S–338S (16 ref.) **(Fre)**

[From neuropeptides and cytokines to psychotherapy. Skin diseases between psychoneuroimmunology research and psychosomatic treatment] Niemeier V, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:14–8 (45 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

[Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature] Frasch K, et al. **Nervenarzt** 1999 May; 70(5):387–90 (27 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

[Problem-based teaching and learning. An opportunity for medical psychology, psychosomatic medicine and psychotherapy?] Köhle K, et al. **Psychother Psychosom Med Psychol** 1999 May;49(5):171–5 (13 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

An historical and critical review of the articles on blood pressure published in Psychosomatic Medicine between 1939 and 1997. Engel BT. **Psychosom Med** 1998 Nov–Dec; 60(6):682–96 (208 ref.)

Praise be to psychosomatic medicine [editorial] Weiner H. **Psychosom Med** 1999 May–Jun;61(3):259–62 (15 ref.)

TRENDS

[The psychosomatic approach in 1998] Consoli SM. **Rev Med Interne** 1998;19 Suppl 3:331S–334S (16 ref.) **(Fre)**

[The subjective element in transplantation medicine. The importance of psychosocial indicators in transplantation and their effect on the quality of life] Johann B, et al. **Zentralbl Chir** 1999;124(2):84–9 (23 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSURGERY

Analysis of outcome: temporal lobe resection. Pilcher WH, et al. **Clin Neurosurg** 1997;44:401–21 (50 ref.)

[A case of glioblastoma manifesting 49 years after lobotomy] Fukushima H, et al. **No To Shinkei** 1998 Aug;50(8):755–60 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Is capsulotomy in obsessive-compulsive syndromes an unnecessary therapeutic method? Good results with drug therapy and behavior therapy] Bejerot S. **Lakartidningen** 1998 Nov 4;95(45):5003–5 (17 ref.) **(Swe)**

[Capsulotomy as a last way out as far as no other alternative is available] Edman G, et al. **Lakartidningen** 1998 Nov 4; 95(45):5008–12 (20 ref.) **(Swe)**

HISTORY

Therapeutic effectiveness and social context: the case of lobotomy in a California state hospital, 1947–1954. Braslow J. **West J Med** 1999 May;170(5):293–6 (31 ref.)

INSTRUMENTATION

Surgical techniques in temporal lobe epilepsy. Olivier A. **Clin Neurosurg** 1997;44:211–41 (72 ref.)

PSYCHOTHERAPEUTIC PROCESSES

Thought-starting: a review of new developments. de Silva P. **Behav Res Ther** 1999 Jul;37 Suppl 1:S175–80 (22 ref.)

First loves and prime adventures: adolescent expressions in adult analyses. Kulish N. **Psychoanal Q** 1998 Oct; 67(4):539–65 (30 ref.)

PSYCHOTHERAPY

The efficacy of psychotherapy in non-bipolar depression: a review [see comments] Balslev Jørgensen M, et al. **Acta Psychiatr Scand** 1998 Jul;98(1):1–13 (108 ref.) Comment in: Acta Psychiatr Scand 1999 May;99(5):394–6.

Effectiveness of psychotherapy for personality disorders. Perry JC, et al. **Am J Psychiatry** 1999 Sep;156(9):1312–21 (42 ref.)

An integrated treatment algorithm for pharmacotherapy and

psychotherapy. Kisely SR, et al.
Aust N Z J Psychiatry 1999 Apr;33(2):207–16 (49 ref.)
New directions in treatment research of anorexia and bulimia nervosa. Kaye W, et al. **Biol Psychiatry** 1999 May 15; 45(10):1285–92 (72 ref.)
Integrating psychological therapies: processes of meaning transformation. Brewin CR, et al. **Br J Med Psychol** 1999 Jun;72 (Pt 2):143–57 (74 ref.)
Psychotherapeutic work with people with dementia: a review of the literature. Cheston R. **Br J Med Psychol** 1998 Sep; 71 (Pt 3):211–31 (75 ref.)
Some risk factors in the psychotherapy of children and families: well-established techniques that can put some clients at risk. Mordock JB. **Child Psychiatry Hum Dev** 1999 Spring;29(3):229–44 (60 ref.)
Alliance and technique in short-term dynamic therapy. Crits-Christoph P, et al. **Clin Psychol Rev** 1999 Sep; 19(6):687–704 (66 ref.)
The phenomenon of envy in theory and therapy. Urlić I, et al. **Coll Antropol** 1998 Jun;22(1):203–19 (18 ref.)
The management of anxious depression in primary care. Goldberg D. **J Clin Psychiatry** 1999;60 Suppl 7:39–42; discussion 43–4 (27 ref.)
Best clinical practice: guidelines for managing major depression in primary medical care. Schulberg HC, et al. **J Clin Psychiatry** 1999;60 Suppl 7:19–26; discussion 27–8 (70 ref.)
Psychosocial and pharmacological treatment of eating disorders: a review of research findings. Peterson CB, et al. **J Clin Psychol** 1999 Jun;55(6):685–97 (23 ref.)
Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer [see comments] McQuaid EL, et al.
J Pediatr Psychol 1999 Aug;24(4):305–28 (63 ref.)
Comment in: J Pediatr Psychol 1999 Aug;24(4):333–4.
A review of transpersonal theory and its application to the practice of psychotherapy. Kasprow MC, et al.
J Psychother Pract Res 1999 Winter;8(1):12–23 (89 ref.)
Some neurobiological aspects of psychotherapy. A review. Liggan DY, et al. **J Psychother Pract Res** 1999 Spring; 8(2):103–14 (137 ref.)
Sequential consequences of therapists' interventions. Milbrath C, et al. **J Psychother Pract Res** 1999 Winter;8(1):40–54 (63 ref.)
Pets and health. Brasić JR. **Psychol Rep** 1998 Dec;83(3 Pt 1):1011–24 (100 ref.)
Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Twillman RK, et al. **Psychooncology** 1998 Jul–Aug; 7(4):285–90 (13 ref.)
Executive function disorders: rehabilitation challenges and strategies. Mateer CA. **Semin Clin Neuropsychiatry** 1999 Jan;4(1):50–9 (53 ref.)
The relevance of problems and models to treatment outcome: a comparative study of two agencies. Keene J, et al.
Subst Use Misuse 1999 Aug;34(10):1347–69 (30 ref.)
Ethical considerations in psychotherapeutic systems. Bergsma J, et al. **Theor Med Bioeth** 1998 Aug;19(4):371–81 (21 ref.)
[Sex differences relating to psychiatric treatment] Godfroid IO. **Can J Psychiatry** 1999 May;44(4):362–7 (61 ref.) (Eng. Abstr.) **(Fre)**
[Psychological principles in the treatment of tinnitus patients] Greimel KV, et al. **HNO** 1999 Feb;47(2):130–4 (20 ref.) **(Ger)**
[Geriatric psychosomatic disorders and psychotherapy of the elderly. Current concept and approaches to treatment] Heuft G. **Psychother Psychosom Med Psychol** 1998 Jul; 48(7):232–42 (130 ref.) (Eng. Abstr.) **(Ger)**
[Psycho-oncologic interventions--critical review] Larbig W. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):381–9 (75 ref.) (Eng. Abstr.) **(Ger)**
[Integration of drug therapy and psychotherapy concepts in treatment of depression] Scholz H, et al.
Wien Med Wochenschr 1998;148(15–16):364–9 (10 ref.) (Eng. Abstr.) **(Ger)**
["Now tell me, what is your orientation to religion?"--Therapeutic attitude and management as an expression of religious faith] Schuierer E.
Wien Med Wochenschr 1998;148(6):158–62 (17 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

[Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature] Frasch K, et al. **Nervenarzt** 1999 May; 70(5):387–90 (27 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

Issues in teaching and learning time-limited psychodynamic psychotherapy. Binder JL. **Clin Psychol Rev** 1999 Sep; 19(6):705–19 (67 ref.)
[Problem-based teaching and learning. An opportunity for medical psychology, psychosomatic medicine and psychotherapy?] Köhle K, et al.
Psychother Psychosom Med Psychol 1999 May;49(5):171–5 (13 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

Countertransference. Hinshelwood RD. **Int J Psychoanal** 1999 Aug;80 (Pt 4):797–818 (104 ref.)

LEGISLATION & JURISPRUDENCE

Malpractice in psychotherapy. An overview. Slovenko R. **Psychiatr Clin North Am** 1999 Mar;22(1):1–15, v (63 ref.)

METHODS

Substance abuse treatment for people with schizophrenia. Bellack AS, et al. **Addict Behav** 1998 Nov–Dec; 23(6):749–66 (94 ref.)
The Heideggerian view of person: a perspective conducive to the therapeutic encounter. Orbanic SD.
Arch Psychiatr Nurs 1999 Jun;13(3):137–44 (19 ref.)
Psychotherapy for severe personality disorder: exploring the limits of evidence based purchasing [see comments] Kisely S. **BMJ** 1999 May 22;318(7195):1410–2 (25 ref.) Comment in: BMJ 1999 May 22;318(7195):1412.
Psychological treatment of depression in children and adolescents. A review of treatment research. Harrington R, et al. **Br J Psychiatry** 1998 Oct;173:291–8 (81 ref.)
Interaction of pharmacological and psychological treatments of anxiety. Lader MH, et al. **Br J Psychiatry Suppl** 1998; (34):42–8 (43 ref.)
The psychotherapist and the adolescent athlete. Begel D. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):867–77 (19 ref.)
Empirical foundations for writing in prevention and psychotherapy: mental and physical health outcomes. Esterling BA, et al. **Clin Psychol Rev** 1999 Jan;19(1):79–96 (76 ref.)
Psychotherapy for male sexual dysfunction: a review. O'Donohue WT, et al. **Clin Psychol Rev** 1999 Aug; 19(5):591–630 (91 ref.)
Object relations theory and short-term dynamic psychotherapy: findings from the Quality of Object Relations Scale. Piper WE, et al. **Clin Psychol Rev** 1999 Sep;19(6):669–85 (69 ref.)
Effectiveness of psychotherapy. Ritvo RZ, et al.
Curr Opin Pediatr 1999 Aug;11(4):323–7 (44 ref.)
The king is dead; long live the king: narrative therapy and practicing what we preach. Doan RE. **Fam Process** 1998 Fall;37(3):379–85 (11 ref.)
Health visiting as therapy: a phenomenological perspective. Cody A. **J Adv Nurs** 1999 Jan;29(1):119–27 (68 ref.)
Treatment of schizophrenia in childhood and adolescence. Clark AF, et al. **J Child Psychol Psychiatry** 1998 Nov; 39(8):1071–81 (97 ref.)
The treatment of the long-term sequelae of child abuse. Stevenson J. **J Child Psychol Psychiatry** 1999 Jan; 40(1):89–111 (146 ref.)
Treatment of patients with functional esophageal symptoms: is there a role for a psychotherapeutic approach? [editorial; comment] Ringel Y, et al. **J Clin Gastroenterol** 1999 Apr; 28(3):189–93 (43 ref.) Comment on: J Clin Gastroenterol 1999 Apr;28(3):228–32.
End piece: reflections on the treatment of anger. DiGiuseppe R. **J Clin Psychol** 1999 Mar;55(3):365–79 (33 ref.)
Research review on anger in psychotherapy. Mayne TJ, et al. **J Clin Psychol** 1999 Mar;55(3):353–63 (15 ref.)
Approaching psychotherapy of the personality disorders from the Millon perspective. Dorr D. **J Pers Assess** 1999 Jun;72(3):407–25 (35 ref.)
Brief early psychological interventions following trauma: a systematic review of the literature. Rose S, et al.
J Trauma Stress 1998 Oct;11(4):697–710 (45 ref.)
Recognizing comorbid personality disorder can help manage and treat the "untreatable". Benjamin LS, et al.
Psychiatr Clin North Am 1998 Dec;21(4):775–89, vi (23 ref.)
Gender differences in substance use disorders. Brady KT, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):241–52 (51 ref.)
Theoretical and treatment issues of personality disorders in individualistic and collectivistic societies. Kim HA.
Psychiatry Clin Neurosci 1998 Dec;52 Suppl:S242–5 (12 ref.)
Common myths and misconceptions in the treatment of addicted women. **Rep Group Adv Psychiatry** 1998; (142):137–56 (53 ref.)
[Behavioral psychotherapy: possibilities in the framework of general medicine] Leclerc V. **Presse Med** 1998 Dec 19; 27(40):2179–84 (55 ref.) (Eng. Abstr.) **(Fre)**
[Disorder-specific psychotherapy in child and adolescent psychiatry] Warnke A, et al.
Z Kinder Jugendpsychiatr Psychother 1998 Aug; 26(3):197–210 (30 ref.) **(Ger)**

STANDARDS

Individual psychotherapy outcome and process research: challenges leading to greater turmoil or a positive transition? Kopta SM, et al. **Annu Rev Psychol** 1999; 50:441–69 (208 ref.)
The dissemination of empirically supported treatments: a view to the future. Barlow DH, et al. **Behav Res Ther** 1999 Jul;37 Suppl 1:S147–62 (70 ref.)
Routine monitoring of the effectiveness of child psychotherapy. Weiss B. **J Child Psychol Psychiatry** 1998 Oct;39(7):943–50 (43 ref.)
Toward an ethical standard for coerced mental health treatment: least restrictive or most therapeutic? Olsen DP. **J Clin Ethics** 1998 Fall;9(3):235–46 (36 ref.)
Empirically supported treatments in pediatric psychology: recurrent pediatric headache [see comments] Holden EW, et al. **J Pediatr Psychol** 1999 Apr;24(2):91–109 (67 ref.)
Comment in: J Pediatr Psychol 1999 Apr;24(2):110.
Comment in: J Pediatr Psychol 1999 Apr;24(2):111–2.
Comment in: J Pediatr Psychol 1999 Apr;24(2):113–4.
Empirically supported treatments in pediatric psychology: procedure-related pain [see comments] Powers SW.
J Pediatr Psychol 1999 Apr;24(2):131–45 (32 ref.)
Comment in: J Pediatr Psychol 1999 Apr;24(2):147–9.
Comment in: J Pediatr Psychol 1999 Apr;24(2):150–2.
Comment in: J Pediatr Psychol 1999 Apr;24(2):153–4.
Empirically supported treatments in pediatric psychology: disease-related pain [see comments] Walco GA, et al.
J Pediatr Psychol 1999 Apr;24(2):155–67; discussion 168–71 (58 ref.) Comment in: J Pediatr Psychol 1999 Apr;24(2):172–4.
Therapist-patient sex. From boundary violations to sexual misconduct. Simon RI. **Psychiatr Clin North Am** 1999 Mar; 22(1):31–47 (54 ref.)

STATISTICS & NUMERICAL DATA

Why are empirically supported treatments for bulimia nervosa underutilized and what can we do about it? Arnow BA. **J Clin Psychol** 1999 Jun;55(6):769–79 (18 ref.)

TRENDS

Individual psychotherapy outcome and process research: challenges leading to greater turmoil or a positive transition? Kopta SM, et al. **Annu Rev Psychol** 1999; 50:441–69 (208 ref.)
The dissemination of empirically supported treatments: a view to the future. Barlow DH, et al. **Behav Res Ther** 1999 Jul;37 Suppl 1:S147–62 (70 ref.)
[Psychiatry and psychotherapy on the internet. Current overview] Seemann O, et al. **Nervenarzt** 1999 Jan; 70(1):76–80 (17 ref.) (Eng. Abstr.) **(Ger)**
[Psychoanalysis, psychoanalytic psychotherapy and supportive psychotherapy: current controversies] Kernberg OF. **Psychother Psychosom Med Psychol** 1999 Mar–Apr; 49(3–4):90–9 (31 ref.) (Eng. Abstr.) **(Ger)**
["Integrated psychotherapy": a new clinical challenge] Barolin GS. **Wien Med Wochenschr** 1998;148(15–16):344–51 (37 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOTHERAPY, BRIEF

EDUCATION

Recommendations for the future of training in brief dynamic psychotherapy. Levenson H, et al. **J Clin Psychol** 1999 Apr;55(4):385–91 (20 ref.)

METHODS

A relational approach to group therapy for women with bulimia nervosa: moving from understanding to action. Tantillo M. **Int J Group Psychother** 1998 Oct;48(4):477–98 (61 ref.)
Minimal interventions for problem drinkers: a review of the literature. Watson HE. **J Adv Nurs** 1999 Aug;30(2):513–9 (39 ref.)
Brief therapy in college counseling and mental health [see comments] Cooper S, et al. **J Am Coll Health** 1999 Jul; 48(1):21–8 (47 ref.) Comment in: J Am Coll Health 1999 Jul;48(1):3–6.

PSYCHOTHERAPY, COGNITIVE see **COGNITIVE THERAPY**

PSYCHOTHERAPY, GROUP

Envy in the group-therapy process. Dubner MA.
Int J Group Psychother 1998 Oct;48(4):519–31 (26 ref.)
[Group therapy and smoking cessation] Møller AM, et al.
Ugeskr Laeger 1999 Sep 6;161(36):4987–8 (8 ref.) (Eng. Abstr.) **(Dan)**
[Intuitive dialogue--a way out of emotional blockages with defocusing imagination] Drees A.
Wien Med Wochenschr 1998;148(6):166–70 (19 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

Course design: an integration of didactic and experiential approaches to graduate training of group therapy. Feiner SE. **Int J Group Psychother** 1998 Oct;48(4):439–60 (37 ref.)

METHODS

Psychodynamic-supportive group therapy model for elderly Holocaust survivors. Müller U, et al.
Int J Group Psychother 1998 Oct;48(4):461–75 (41 ref.)
A relational approach to group therapy for women with bulimia nervosa: moving from understanding to action. Tantillo M. **Int J Group Psychother** 1998 Oct;48(4):477–98 (61 ref.)
Group therapy in the cancer setting. Fawzy FI, et al.
J Psychosom Res 1998 Sep;45(3):191–200 (24 ref.)

ORGANIZATION & ADMINISTRATION

An invitation to join in difficulty: realizing the deeper promise of group psychotherapy. Hawkins DM.
Int J Group Psychother 1998 Oct;48(4):423–38 (17 ref.)

PSYCHOTIC DISORDERS

Psychiatric aspects of alcohol misuse. Dunn N, et al. **Hosp Med** 1999 Mar;60(3):169–72 (24 ref.)
Case series: catatonic syndrome in young people. Cohen D, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Aug; 38(8):1040–6 (38 ref.)
[Creative experience and psychotic experience] Borgna E. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):412–8 (29 ref.) **(Ita)**

COMPLICATIONS

Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Schlozman SC. **J Clin Psychiatry** 1998 Dec;59(12):681–6 (22 ref.)
Psychosis and peri-ictal confusional states. Lancman M. **Neurology** 1999;53(5 Suppl 2):S33–8 (87 ref.)

DIAGNOSIS

Uncommon features of polyarteritis nodosa: psychosis and angio-oedema. Fernandes SR, et al. **Clin Rheumatol** 1998; 17(4):353–6 (16 ref.)
Late-life psychosis: making the diagnosis and controlling symptoms. Brown FW. **Geriatrics** 1998 Dec;53(12):26–8, 37–8, 41–2 (6 ref.)
Psychoses in the elderly: a spectrum of disorders. Targum SD, et al. **J Clin Psychiatry** 1999;60 Suppl 8:4–10 (46 ref.)
The psychotic patient. Hilty DM, et al. **Prim Care** 1999 Jun; 26(2):327–48 (27 ref.)
Frequently missed diagnoses in adolescent psychiatry. Berenson CK. **Psychiatr Clin North Am** 1998 Dec; 21(4):917–26, viii (37 ref.)
The detection of malingered psychosis. Resnick PJ. **Psychiatr Clin North Am** 1999 Mar;22(1):159–72 (62 ref.)
Atypical psychosis. Smith ML. **Psychiatr Clin North Am** 1998 Dec;21(4):895–904 (20 ref.)
Morphological brain imaging studies on major psychoses. Okazaki Y. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S215–8 (23 ref.)

DRUG THERAPY

Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Levinson DF, et al. **Am J Psychiatry** 1999 Aug;156(8):1138–48 (64 ref.)
Novel antipsychotics and patient care in state hospitals. Buckley PF. **Ann Pharmacother** 1998 Sep;32(9):906–14 (72 ref.)
The clinical use of plasma clozapine levels. Bell R, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):567–74 (54 ref.)
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Kroeze WK, et al. **Biol Psychiatry** 1998 Dec 1; 44(11):1128–42 (162 ref.)
The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Marek GJ, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1118–27 (85 ref.)
Assessment and management of antipsychotic-induced adverse events. Cortese L, et al. **Can J Psychiatry** 1998 Sep;43 Suppl 1:15S–20S (44 ref.)
Antipsychotics in children and adolescents. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May; 38(5):537–45 (87 ref.)
Legal and ethical considerations in the treatment of psychosis. Fitzgerald WL Jr. **J Clin Psychiatry** 1999;60 Suppl 19:59–65; discussion 66 (11 ref.)
Formulary decisions and health economics. Glazer WM. **J Clin Psychiatry** 1998;59 Suppl 19:23–9 (31 ref.)
Management of psychotic aspects of Parkinson's disease. Juncos JL. **J Clin Psychiatry** 1999;60 Suppl 8:42–53 (161 ref.)
An overview of the treatment of schizoaffective disorder. McElroy SL, et al. **J Clin Psychiatry** 1999;60 Suppl 5:16–21; discussion 22 (68 ref.)
The efficacy, safety, and tolerability of antipsychotics in the elderly. Maixner SM, et al. **J Clin Psychiatry** 1999;60 Suppl 8:29–41 (140 ref.)
Pharmacologic management of psychosis in dementia. Schneider LS. **J Clin Psychiatry** 1999;60 Suppl 8:54–60 (48 ref.)
Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. Ghaemi SN, et al. **J Clin Psychopharmacol** 1999 Aug; 19(4):354–61 (72 ref.)
The role of serotonin in antipsychotic drug action. Meltzer HY. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):106S–115S (82 ref.)
Atypical antipsychotics in older adults. Chan YC, et al. **Pharmacotherapy** 1999 Jul;19(7):811–22 (89 ref.)
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Letterman L, et al. **Pharmacotherapy** 1999 May; 19(5):565–72 (32 ref.)
Schizoaffective disorder: role of atypical antipsychotics. Keck PE Jr, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S5–12 (60 ref.)
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Volavka J, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S23–33 (62 ref.)
[Two new antidepressants: mirtazapine and venlafaxine] Birkenhäger TK, et al. **Ned Tijdschr Geneeskd** 1999 May 1;143(18):934–7 (26 ref.) (Eng. Abstr.) **(Dut)**
[New psychotropic drugs--is only the price new?] Woggon B. **Schweiz Rundsch Med Prax** 1999 Apr 29;88(18):819–25 (3 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Complications of severe mental illness related to alcohol and drug use disorders. Drake RE, et al. **Recent Dev Alcohol** 1998;14:285–99 (127 ref.)

ETIOLOGY

Psychosis and hallucinations in Parkinson's disease. Godwin-Austen RB. **Adv Neurol** 1999;80:401–2 (9 ref.)
Atypical psychosis. Smith ML. **Psychiatr Clin North Am** 1998 Dec;21(4):895–904 (20 ref.)
Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247–61 (81 ref.)
Psychiatric disorders related to solvent-exposure. Trabert W. **Zentralbl Hyg Umweltmed** 1999 Aug;202(2–4):121–6 (13 ref.)
[Schizo-affective psychosis manifested in adolescence] Kaleda VG. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998; 98(9):12–6 (29 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies. Epstein J, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:562–74 (97 ref.)
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Kroeze WK, et al. **Biol Psychiatry** 1998 Dec 1; 44(11):1128–42 (162 ref.)
GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Keverne EB. **Brain Res Bull** 1999 Mar 15;48(5):467–73 (71 ref.)
The role of brain insulin in the neurophysiology of serious mental disorders: review. Holden RJ. **Med Hypotheses** 1999 Mar;52(3):193–200 (64 ref.)
Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA. **Thyroid** 1999 Jul;9(7):691–7 (51 ref.)

PSYCHOLOGY

Insight in psychosis: an elusive target. McGorry PD, et al. **Compr Psychiatry** 1999 Mar–Apr;40(2):131–42 (108 ref.)
Which characteristics of schizophrenia predate psychosis? Davies N, et al. **J Psychiatr Res** 1998 May–Aug; 32(3–4):121–31 (134 ref.)
Social interpersonal dimensions of the psychoses. Lindsay JS. **Med Hypotheses** 1999 Apr;52(4):335–47 (28 ref.)
Depression, psychosis, and dementia: impact on the family. Ellgring JH. **Neurology** 1999;52(7 Suppl 3):S17–20 (9 ref.)
Psychosis and peri-ictal confusional states. Lancman M. **Neurology** 1999;53(5 Suppl 2):S33–8 (87 ref.)
Psychosis: impact on the patient and family. Melamed E, et al. **Neurology** 1999;52(7 Suppl 3):S14–6 (2 ref.)
When symptoms of psychosis drive serious violence. Taylor PJ. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S47–54 (24 ref.)
[Psychosis, language and literature] Maier T. **Nervenarzt** 1999 May;70(5):438–43 (35 ref.) (Eng. Abstr.) **(Ger)**
[Schizo-affective psychosis manifested in adolescence] Kaleda VG. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998; 98(9):12–6 (29 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Cognitive-behavioural therapy for psychosis: a status report. Norman RM, et al. **Can J Psychiatry** 1999 Apr;44(3):245–52 (69 ref.)
Late-life psychosis: making the diagnosis and controlling symptoms. Brown FW. **Geriatrics** 1998 Dec;53(12):26–8, 37–8, 41–2 (6 ref.)
Treatment of psychiatric aspects of alcohol misuse. Naik PC, et al. **Hosp Med** 1999 Mar;60(3):173–7 (27 ref.)
Management of chronic psychotic ambulatory outpatients. Petty RG. **J Clin Psychiatry** 1998;59 Suppl 19:30–5 (32 ref.)
The psychotic patient. Hilty DM, et al. **Prim Care** 1999 Jun; 26(2):327–48 (27 ref.)

PSYCHOTOMIMETIC AGENTS see **HALLUCINOGENS**

PSYCHOTROPIC DRUGS

Psychotropic drugs used in anesthesia practice: abuse liability and epidemiology of abuse. Zacny JP, et al. **Anesthesiology** 1999 Jan;90(1):269–88 (309 ref.)
The use of psychotropic medication in preschoolers: some recent developments. Minde K. **Can J Psychiatry** 1998 Aug;43(6):571–5 (22 ref.)
Drug prohibition and public health: 25 years of evidence [see comments] Drucker E. **Public Health Rep** 1999 Jan–Feb;114(1):14–29 (55 ref.) Comment in: Public Health Rep 1999 Mar–Apr;114(2):99–100.
[The consumption of psychotropics in France and some european countries] Legrain M, et al. **Ann Pharm Fr** 1998; 56(2):67–75 (23 ref.) (Eng. Abstr.) **(Fre)**
[Role of science in the formulation of social policy on drugs] Kalant H. **C R Seances Soc Biol Fil** 1998;192(5):905–15 (29 ref.) (Eng. Abstr.) **(Fre)**
[Detection of drugs of abuse] von Meyer L. **Internist (Berl)** 1999 Jun;40(6):601–4 (14 ref.) **(Ger)**

ADMINISTRATION & DOSAGE

The treatment of social phobia: a critical assessment. Stravynski A, et al. **Acta Psychiatr Scand** 1998 Sep; 98(3):171–81 (68 ref.)
Use of herbal medicine for treating psychiatric disorders in Japan. Kanba S, et al. **Psychiatry Clin Neurosci** 1998 Dec; 52 Suppl:S331–3 (4 ref.)
Nonenteral routes of administration for psychiatric medications. A literature review. Thompson D, et al. **Psychosomatics** 1999 May–Jun;40(3):185–92 (51 ref.)

ADVERSE EFFECTS

Use of psychotropic medications in breast-feeding women: acute and prophylactic treatment. Austin MP, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):778–84 (40 ref.)
Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management. Clayton DO, et al. **Drug Saf** 1998 Oct;19(4):299–312 (109 ref.)
Drug-induced cognitive impairment in the elderly. Moore AR, et al. **Drugs Aging** 1999 Jul;15(1):15–28 (123 ref.)
Psychotropics and sexuality. Demyttenaere K, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S35–41 (72 ref.)
Psychotropic medications in pregnant women: treatment dilemmas. Austin MP, et al. **Med J Aust** 1998 Oct 19; 169(8):428–31 (41 ref.)
The influence of drugs upon testimony. Lader M. **Med Sci Law** 1999 Apr;39(2):99–105 (9 ref.)
The hazards of psychotropic herbs. Tinsley JA. **Minn Med** 1999 May;82(5):29–31 (16 ref.)
Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Alldredge BK. **Neurology** 1999;53(5 Suppl 2):S68–75 (73 ref.)
Management of and counseling for psychotropic drug-induced sexual dysfunction. Gutierrez MA, et al. **Pharmacotherapy** 1999 Jul;19(7):823–31 (57 ref.)
Preventing problems from psychoactive substance use. Room R. **Proc Assoc Am Physicians** 1999 Mar–Apr;111(2):141–7 (30 ref.)
Hematologic side effects of psychotropics. Oyesanmi O, et al. **Psychosomatics** 1999 Sep–Oct;40(5):414–21 (52 ref.)
Aquaporin-2 as a biomarker of distal renal tubular function using lithium as an experimental model. Sisson D, et al. **Ren Fail** 1999 May–Jul;21(3–4):331–6 (35 ref.)
[Psychotropic drugs and accidental falls in the elderly] Weyerer S, et al. **Fortschr Med** 1998 Nov 20;116(32):29–31 (18 ref.) **(Ger)**
[Principles of withdrawal from illicit drugs during inpatient therapy] Singer W, et al. **Internist (Berl)** 1999 Jun; 40(6):634–9 (21 ref.) **(Ger)**
[Psychotropic drugs and automobile driving ability of elderly patients] Püllen R. **Versicherungsmedizin** 1999 Jun 1; 51(2):71–4 (14 ref.) (Eng. Abstr.) **(Ger)**
[Drug interactions of methadone with CNS-active agents] Moreno Brea MR, et al. **Actas Esp Psiquiatr** 1999 Mar–Apr; 27(2):103–10 (61 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Chirality and drugs used in psychiatry: nice to know or need to know? Lane RM, et al. **Cell Mol Neurobiol** 1999 Jun; 19(3):355–72 (134 ref.)

HISTORY

[Society before and after the introduction of psychotropic drugs in therapeutic use] Juillet P. **Ann Pharm Fr** 1998; 56(2):49–54 (8 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Impact of delta-9-tetrahydrocannabinol and its metabolites on the immune system] Masset D, et al. **Acta Clin Belg Suppl** 1999;1:39–43 (20 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions. Kalash GR. **Psychooncology** 1998 Jul–Aug;7(4):307–20 (21 ref.)

PHARMACOKINETICS

Polymorphic cytochromes P450 and drugs used in psychiatry. Coutts RT, et al. **Cell Mol Neurobiol** 1999 Jun; 19(3):325–54 (153 ref.)
Chirality and drugs used in psychiatry: nice to know or need to know? Lane RM, et al. **Cell Mol Neurobiol** 1999 Jun; 19(3):355–72 (134 ref.)
Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Thürmann PA, et al. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):586–90 (37 ref.)
Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. Yoshida K, et al. **J Psychopharmacol** 1999;13(1):64–80 (115 ref.)

Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Alldredge BK. **Neurology** 1999;53(5 Suppl 2):S68–75 (73 ref.)
Drug–drug interactions in pediatric psychopharmacology. Ten Eick AP, et al. **Pediatr Clin North Am** 1998 Oct; 45(5):1233–64, x–xi (179 ref.)
Child and adolescent psychopharmacology. Important developmental issues. Tosyali MC, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1021–35, vii (90 ref.)
[Significance of hepatic cytochrome P450 enzymes for psychopharmacology] Normann C, et al. **Nervenarzt** 1998 Nov;69(11):944–55 (146 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Time–dependent sensitization––possible implications for clinical psychopharmacology. Antelman SM, et al. **Behav Pharmacol** 1997 Nov;8(6–7):505–14; discussion 515–22 (61 ref.)
Pediatric psychopharmacology and the interaction between drugs and the developing brain. Vitiello B. **Can J Psychiatry** 1998 Aug;43(6):582–4 (21 ref.)
Effects of psychotropic medications on pancreatic function: a review. Cerulli TR, et al. **Harv Rev Psychiatry** 1999 May–Jun;7(1):54–60 (76 ref.)
Psychotropics and sexuality. Demyttenaere K, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S35–41 (72 ref.)
Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Thürmann PA, et al. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):586–90 (37 ref.)
Psychoactive drug use and progression of HIV infection. Des Jarlais DC. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):272–4 (9 ref.)
Heart medications: indications and interactions in stress testing. Duncan BH, et al. **J Nucl Cardiol** 1999 May–Jun; 6(3):357–61 (26 ref.)
Developmental pharmacodynamics: implications for child and adolescent psychopharmacology. Carrey N, et al. **J Psychiatry Neurosci** 1998 Nov;23(5):274–6 (16 ref.)
The application of a computerized measurement of the content analysis of natural language to the assessment of the effects of psychoactive drugs. Gottschalk LA. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):133–8 (67 ref.)
Drug–drug interactions in pediatric psychopharmacology. Ten Eick AP, et al. **Pediatr Clin North Am** 1998 Oct; 45(5):1233–64, x–xi (179 ref.)
Child and adolescent psychopharmacology. Important developmental issues. Tosyali MC, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1021–35, vii (90 ref.)
Voltage–operated calcium channels: characteristics and their role in the mechanism of action of psychotropic drugs. Antkiewicz–Michaluk L. **Pol J Pharmacol** 1999 Mar–Apr; 51(2):179–86 (71 ref.)
Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Tzschentke TM. **Prog Neurobiol** 1998 Dec;56(6):613–72 (700 ref.)
Volume transmission in the CNS and its relevance for neuropsychopharmacology. Zoli M, et al. **Trends Pharmacol Sci** 1999 Apr;20(4):142–50 (119 ref.)
[Behavioral and neurochemical methods in research on new psychotropics] Boulu R. **Ann Pharm Fr** 1998;56(2):54–9 (28 ref.) (Eng. Abstr.) **(Fre)**
[From gene to behavior, a new method for elaboration of new psychotropic agents] Costentin J. **Ann Pharm Fr** 1998; 56(2):60–7 (49 ref.) (Eng. Abstr.) **(Fre)**
[Psychotropic drugs and behavior] Lôo H, et al. **Ann Pharm Fr** 1998;56(2):75–82 (8 ref.) (Eng. Abstr.) **(Fre)**
[Calcium antagonistic actions of drugs used in treatment of affective disorders] Langosch JM, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66(12):570–9 (92 ref.) (Eng. Abstr.) **(Ger)**
[Pharmacology of drugs of abuse] Haen E, et al. **Internist (Berl)** 1999 Jun;40(6):605–10 (7 ref.) **(Ger)**
[Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology] Bespalov AIu, et al. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):39–53 (174 ref.) (Eng. Abstr.) **(Rus)**
[Adamantane derivatives enhancing body's resistance to emergencies] Morozov IS, et al. **Vestn Ross Akad Med Nauk** 1999;(3):28–32 (25 ref.) (Eng. Abstr.) **(Rus)**

POISONING

Hepatotoxicity of psychotropic drugs. Selim K, et al. **Hepatology** 1999 May;29(5):1347–51 (69 ref.)

STANDARDS

The use of psychotropic medication in preschoolers: indications, safety, and efficacy. Greenhill LL. **Can J Psychiatry** 1998 Aug;43(6):576–81 (55 ref.)

THERAPEUTIC USE

Use of psychotropic medications in breast–feeding women: acute and prophylactic treatment. Austin MP, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):778–84 (40 ref.)
Ethical and pragmatic issues in the use of psychotropic agents in young children. Jensen PS. **Can J Psychiatry** 1998 Aug; 43(6):585–8 (13 ref.)
Review of current treatment in panic disorder. den Boer JA, et al. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S25–30 (51 ref.)
The role of drug therapy in social phobia. Lydiard RB. **J Affect Disord** 1998 Sep;50 Suppl 1:S35–9 (35 ref.)
Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May;38(5):557–65 (46 ref.)
Gender differences in the epidemiology and treatment of anxiety disorders. Pigott TA. **J Clin Psychiatry** 1999;60 Suppl 18:4–15 (146 ref.)
Psychotropic medication management in persons with co–occurring psychiatric and substance use disorders. Sowers W, et al. **J Psychoactive Drugs** 1999 Jan–Mar; 31(1):59–70 (57 ref.)
Psychopharmacotherapy in children and adults with intellectual disability. Santosh PJ, et al. **Lancet** 1999 Jul 17;354(9174):233–42 (82 ref.)
Psychotropic drug prescribing: first the good news [editorial; comment] Keks NA, et al. **Med J Aust** 1999 Apr 5; 170(7):293–4 (12 ref.) Comment on: Med J Aust 1999 Apr 5;170(7):299–301.
Attention–deficit disorder. A paradigm for psychotropic medication intervention in pediatrics. Block SL. **Pediatr Clin North Am** 1998 Oct;45(5):1053–83 (87 ref.)
Transcultural psychopharmacology: present and future. Pi EH. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S185–7 (36 ref.)
Psychotropic adjuvant analgesics for pain in cancer and AIDS. Breitbart W. **Psychooncology** 1998 Jul–Aug; 7(4):333–45 (118 ref.)
The uses of psychotropics in symptom management in advanced cancer. Bruera E, et al. **Psychooncology** 1998 Jul–Aug;7(4):346–58 (105 ref.)
Exploratory studies: implications for drug development in Alzheimer's disease. Cutler NR, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S131–6 (32 ref.)
Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Gasior M, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):107–12 (60 ref.)
[Psychotropic drugs and primary care] Cuché H. **Ann Pharm Fr** 1998;56(2):83–9 (7 ref.) (Eng. Abstr.) **(Fre)**
[Society before and after the introduction of psychotropic drugs in therapeutic use] Juillet P. **Ann Pharm Fr** 1998; 56(2):49–54 (8 ref.) (Eng. Abstr.) **(Fre)**
[Sex differences relating to psychiatric treatment] Godfroid IO. **Can J Psychiatry** 1999 May;44(4):362–7 (61 ref.) (Eng. Abstr.) **(Fre)**
[Calcium antagonistic actions of drugs used in treatment of affective disorders] Langosch JM, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66(12):570–9 (92 ref.) (Eng. Abstr.) **(Ger)**
[Drug substitution from the legal viewpoint] Joachimski J. **Internist (Berl)** 1999 Jun;40(6):640–4 (0 ref.) **(Ger)**
[Abnormal behavior and adaptation problems in dogs and cats and their pharmacologic control] Jöchle W. **Tierarztl Prax Ausg K Kleintiere Heimtiere** 1998 Nov; 26(6):410–21 (62 ref.) (Eng. Abstr.) **(Ger)**
[Psychopharmacotherapy of behavioral disorders in patients with dementia] Stoppe G, et al. **Z Gerontol Geriatr** 1999 Jun;32(3):153–8 (42 ref.) (Eng. Abstr.) **(Ger)**

PSYLLIDS see **HEMIPTERA**

PSYLLOIDEA see **HEMIPTERA**

PTA DEFICIENCY see **FACTOR XI DEFICIENCY**

PTC see **FACTOR IX**

PTCA see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

PTDINS see **PHOSPHATIDYLINOSITOLS**

PTDINS 3–KINASE see **1–PHOSPHATIDYLINOSITOL 3–KINASE**

PTDINS 4–KINASE see **1–PHOSPHATIDYLINOSITOL 4–KINASE**

PTERIDINES

CHEMISTRY

A structural comparison of molybdenum cofactor–containing enzymes. Kisker C, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):503–21 (73 ref.)

METABOLISM

Dimethylsulphoxide reductase from purple phototrophic bacteria: structures and mechanism(s). McEwan AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):390–6 (34 ref.)
Regulation of pteridine–requiring enzymes by the cofactor tetrahydrobiopterin. Nagatsu T, et al. **Mol Neurobiol** 1999 Feb;19(1):79–96 (88 ref.)

PTERINS

PHARMACOLOGY

PT523 and other aminopterin analogs with a hemiphthaloyl–L–ornithine side chain: exceptionally tight–binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Rosowsky A. **Curr Med Chem** 1999 Apr;6(4):329–52 (30 ref.)

PTEROYLGLUTAMIC ACID see **FOLIC ACID**

PTERYGIUM

RADIOTHERAPY

Postoperative irradiation of pterygium with 90Sr eye applicator. Fukushima S, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):597–600 (15 ref.)

SURGERY

Current options in pterygium management. Hoffman RS, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):15–26 (45 ref.)

THERAPY

Treatment of pterygium [editorial; comment] Hirst LW. **Aust N Z J Ophthalmol** 1998 Nov;26(4):269–70 (7 ref.) Comment on: Aust N Z J Ophthalmol 1998 Nov;26(4):291–6.

PTERYGOID MUSCLES

ANATOMY & HISTOLOGY

Mechanical advantage of area of origin for the external pterygoid muscle in two murid rodents, Apodemus speciosus and Clethrionomys rufocanus. Satoh K. **J Morphol** 1999 Apr;240(1):1–14 (48 ref.)

INJURIES

Myositis ossificans traumatica of the medial pterygoid muscle. Takahashi K, et al. **J Oral Maxillofac Surg** 1999 Apr; 57(4):451–6 (24 ref.)

PTILOCERCUS see **TUPAIIDAE**

PTOSIS, EYELID see **BLEPHAROPTOSIS**

PTPASE see **PROTEIN–TYROSINE–PHOSPHATASE**

PTSD see **STRESS DISORDERS, POST–TRAUMATIC**

PUBERTY

Disorders of puberty. Blondell RD, et al. **Am Fam Physician** 1999 Jul;60(1):209–18, 223–4 (25 ref.)
Obstetric and gynecologic care of women with epilepsy. El–Sayed YY. **Epilepsia** 1998;39 Suppl 8:S17–25 (87 ref.)
The prepubertal testis: a quiescent or a silently active organ? Rey R. **Histol Histopathol** 1999 Jul;14(3):991–1000 (66 ref.)

DRUG EFFECTS

Management of recombinant human growth hormone therapy at puberty. Albers N. **Horm Res** 1998;49 Suppl 2:58–61 (13 ref.)

GENETICS

Mutations in human gonadotropin genes and their physiologic significance in puberty and reproduction. Layman LC. **Fertil Steril** 1999 Feb;71(2):201–18 (77 ref.)

METABOLISM

Leptin and the onset of puberty [editorial] Edmonds DK. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):361–3 (27 ref.)

PHYSIOLOGY

Adipose tissue as an endocrine organ regulating growth, puberty, and other physiological functions. Pankov YA. **Biochemistry (Mosc)** 1999 Jun;64(6):601–9 (41 ref.)
Physiological perspectives on leptin as a regulator of reproduction: role in timing puberty. Foster DL, et al. **Biol Reprod** 1999 Feb;60(2):205–15 (69 ref.)
Is there a role for leptin in human reproduction? Macut D, et al. **Gynecol Endocrinol** 1998 Oct;12(5):321–6 (58 ref.)
Puberty: when it comes too soon guidelines for the evaluation of sexual precocity. Clark PA. **J Ky Med Assoc** 1998 Nov; 96(11):440–7 (13 ref.)
Glial–neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids. Ojeda SR, et al. **J Neurobiol** 1999 Sep 15;40(4):528–40 (95 ref.)
Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Kaplowitz PB, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):936–41 (27 ref.)
[Leptin and puberty in humans: hypothesis of the critical

PUBERTY

adipose mass revisited] Issad T, et al. **Diabetes Metab** 1998 Sep;24(4):376–8 (13 ref.) **(Fre)**

[Leptin implications in reproduction endocrinology] Pralong FP. **Rev Med Suisse Romande** 1999 Jun;119(6):463–7 (12 ref.) **(Fre)**

[Leptin and puberty] Puigdevall Gallego V, et al. **An Esp Pediatr** 1998 Dec;49(6):561–7 (95 ref.) **(Spa)**

PSYCHOLOGY

The vulnerable transition: puberty and the development of eating pathology and negative mood. Graber JA, et al. **Womens Health Issues** 1999 Mar–Apr;9(2):107–14 (47 ref.)

PUBERTY, DELAYED

Amenorrhea in the athlete. Gidwani GP. **Adolesc Med** 1999 Jun;10(2):275–90, vii (24 ref.)

DIAGNOSIS

Disorders of puberty. Blondell RD, et al. **Am Fam Physician** 1999 Jul;60(1):209–18, 223–4 (25 ref.)

[Delayed puberty (in a boy)] Conte-Devolx B, et al. **Ann Endocrinol (Paris)** 1998 Dec;59(5):417–23 (14 ref.) **(Fre)**

DRUG THERAPY

Androgen replacement in children with constitutional delay of puberty: the case for aggressive therapy. Houchin LD, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):427–40 (65 ref.)

THERAPY

[Delayed puberty (in a boy)] Conte-Devolx B, et al. **Ann Endocrinol (Paris)** 1998 Dec;59(5):417–23 (14 ref.) **(Fre)**

PUBERTY, PRECOCIOUS

COMPLICATIONS

Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Ibáñez L, et al. **J Endocrinol Invest** 1998 Oct; 21(9):558–66 (88 ref.)

DIAGNOSIS

Disorders of puberty. Blondell RD, et al. **Am Fam Physician** 1999 Jul;60(1):209–18, 223–4 (25 ref.)

Precocious puberty: who has it? Who should be treated? [editorial; comment] Klein KO. **J Clin Endocrinol Metab** 1999 Feb;84(2):411–4 (12 ref.) Comment on: J Clin Endocrinol Metab 1999 Feb;84(2):415–23.

Puberty: when it comes too soon guidelines for the evaluation of sexual precocity. Clark PA. **J Ky Med Assoc** 1998 Nov; 96(11):440–7 (13 ref.)

Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Kaplowitz PB, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):936–41 (27 ref.)

DRUG THERAPY

Combined use of growth hormone and gonadotropin-releasing hormone analogues in precocious puberty: theoretic and practical considerations. Walvoord EC, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1010–4 (38 ref.)

ETIOLOGY

[Constitutively activating mutations in the luteinizing hormone receptor gene in cases of male-limited precocious puberty] Yano K, et al. **Nippon Rinsho** 1998 Jul; 56(7):1843–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Precocious puberty secondary to tuberculous meningitis] Buño Soto M, et al. **An Esp Pediatr** 1998 Dec;49(6):635–7 (9 ref.) **(Spa)**

GENETICS

[Activating mutations of the gonadotrophin receptors] Beck-Peccoz P, et al. **Arch Pediatr** 1998;5 Suppl 4:380S–384S (17 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Gonadotropin independent precocious puberty. Low LC, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug;11(4):497–507 (75 ref.)

THERAPY

Precocious puberty: who has it? Who should be treated? [editorial; comment] Klein KO. **J Clin Endocrinol Metab** 1999 Feb;84(2):411–4 (12 ref.) Comment on: J Clin Endocrinol Metab 1999 Feb;84(2):415–23.

Puberty: when it comes too soon guidelines for the evaluation of sexual precocity. Clark PA. **J Ky Med Assoc** 1998 Nov; 96(11):440–7 (13 ref.)

PUBIC SYMPHYSIS

Osteitis pubis: a diagnosis for the family physician. Andrews SK, et al. **J Am Board Fam Pract** 1998 Jul–Aug;11(4):291–5 (16 ref.)

PUBLIC ADVOCACY see **CONSUMER ADVOCACY**

PUBLIC ASSISTANCE

see related
SOCIAL WELFARE

LEGISLATION & JURISPRUDENCE

Assessing the effects of welfare reform policies on reproductive and infant health [see comments] Wise P, et al. **Am J Public Health** 1999 Oct;89(10):1514–21 (79 ref.) Comment in: Am J Public Health 1999 Oct;89(10):1476–8. Comment in: Am J Public Health 1999 Oct;89(10):1479–82.

PUBLIC DOMAIN see **PUBLIC SECTOR**

PUBLIC ENTERPRISE see **PUBLIC SECTOR**

PUBLIC HEALTH

see related
SOCIAL MEDICINE
ZOONOSES

Carrying out the Medicine/Public Health Initiative: the roles of preventive medicine and community-responsive care. Cashman SB, et al. **Acad Med** 1999 May;74(5):473–83 (54 ref.)

Academic health centers can bridge the gulf between medicine and public health. Williams JF, et al. **Acad Med** 1999 May;74(5):484–7 (4 ref.)

Epidemiology of type 1 (insulin-dependent) diabetes mellitus: public health implications in the Middle East. Green A. **Acta Paediatr Suppl** 1999 Jan;88(427):8–10 (5 ref.)

Host genes and infectious diseases. HIV, other pathogens, and a public health perspective. McNicholl JM, et al. **Am J Prev Med** 1999 Feb;16(2):141–54 (131 ref.)

Frequency of policy recommendations in epidemiologic publications. Jackson LW, et al. **Am J Public Health** 1999 Aug;89(8):1206–11 (53 ref.)

A tale of 3 tails [editorial] McKinlay JB, et al. **Am J Public Health** 1999 Mar;89(3):295–8 (26 ref.)

A world behaving badly: the global challenge for behavioral surveillance [editorial] McQueen DV. **Am J Public Health** 1999 Sep;89(9):1312–4 (26 ref.)

Economic sanctions as human rights violations: reconciling political and public health imperatives [comment] Marks SP. **Am J Public Health** 1999 Oct;89(10):1509–13 (60 ref.) Comment on: Am J Public Health 1999 Oct;89(10):1499–504.

The global burden of mental disorders [see comments] Ustün TB. **Am J Public Health** 1999 Sep;89(9):1315–8 (24 ref.) Comment in: Am J Public Health 1999 Sep;89(9):1309–11.

A call for caution in the interpretation of the observed smaller relative importance of risk factors in the elderly [editorial; comment] Howard G, et al. **Ann Epidemiol** 1998 Oct; 8(7):411–4 (13 ref.) Comment on: Ann Epidemiol 1998 Oct;8(7):415–21.

Obesity: a major global public health problem. Khan LK, et al. **Annu Rev Nutr** 1999;19:xiii–xvii (29 ref.)

Why literacy matters. Links between reading ability and health. Lee PP. **Arch Ophthalmol** 1999 Jan;117(1):100–3 (28 ref.)

Climate change and human health in Europe. Kovats RS, et al. **BMJ** 1999 Jun 19;318(7199):1682–5 (32 ref.)

Can we deworm this wormy world? Bundy DA, et al. **Br Med Bull** 1998;54(2):421–32 (43 ref.)

Impacts of global environmental change on future health and health care in tropical countries. McMichael AJ, et al. **Br Med Bull** 1998;54(2):475–88 (51 ref.)

Cutaneous leishmaniasis: strategies for prevention. Ashford RW. **Clin Dermatol** 1999 May–Jun;17(3):327–32 (9 ref.)

The medical threat of biological weapons. Atlas RM. **Crit Rev Microbiol** 1998;24(3):157–68 (17 ref.)

Human health and chemical mixtures: an overview. Carpenter DO, et al. **Environ Health Perspect** 1998 Dec; 106 Suppl 6:1263–70 (69 ref.)

Public health challenges posed by chemical mixtures. Hansen H, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1271–80 (71 ref.)

How to improve the impact of nutrition guidance by general physicians: public health versus individual patient? Worsley A. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S101–7 (56 ref.)

Legal abortion in Denmark during the past 25 years: aspects of public health and ethics. Goldstein H. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):155–9 (11 ref.)

What are the health risks? The medical consequences of obesity and its health risks. James WP. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:1–6 (17 ref.)

Societal and personal costs of obesity. Seidell JC. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:7–9 (15 ref.)

Compendium of chlamydiosis (psittacosis) control, 1999. Psittacosis Compendium Committee, National Association of State Public Health Veterinarians. Johnston WB, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):640–6 (10 ref.)

Immunizations in pregnancy. A public health perspective. Hackley BK. **J Nurse Midwifery** 1999 Mar–Apr; 44(2):106–17 (37 ref.)

Quality of public health information: lessons from the field. Bialek R. **J Urban Health** 1998 Dec;75(4):853–63 (9 ref.)

Meeting information needs in health policy and public health: priorities for the National Library of Medicine and The National Network of Libraries of Medicine. Humphreys BL. **J Urban Health** 1998 Dec;75(4):878–83 (4 ref.)

Strategies for addressing priority information problems in health policy and public health. Lasker RD. **J Urban Health** 1998 Dec;75(4):888–95 (0 ref.)

Challenges to accessing useful information in health policy and public health: an introduction to a national forum held at the New York Academy of Medicine, March 23, 1998. Lasker RD. **J Urban Health** 1998 Dec;75(4):779–84 (0 ref.)

The retrieval problem for health policy and public health: knowledge bases and search engines. Lynch C. **J Urban Health** 1998 Dec;75(4):794–806 (0 ref.)

Information needs in public health and health policy: results of recent studies. O'Carroll PW, et al. **J Urban Health** 1998 Dec;75(4):785–93 (3 ref.)

Information resources for public health practice. Rambo N. **J Urban Health** 1998 Dec;75(4):807–25 (8 ref.)

Meeting information needs in health policy and public health: roles for the Centers for Disease Control and Prevention. Ross D. **J Urban Health** 1998 Dec;75(4):884–7 (2 ref.)

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. Inglesby TV, et al. **JAMA** 1999 May 12;281(18):1735–45 (73 ref.)

Rapid assessment, injecting drug use, and public health. Rhodes T, et al. **Lancet** 1999 Jul 3;354(9172):65–8 (32 ref.)

Risky business: health risk assessment and public health policy on environmental carcinogens. Sim MR, et al. **Med J Aust** 1999 Apr 19;170(8):372–4 (15 ref.)

Public health impact of carotid endarterectomy. Chaturvedi S. **Neuroepidemiology** 1999;18(1):15–21 (28 ref.)

Varicella: the vaccine and the public health debate. Niederhauser VP. **Nurse Pract** 1999 Mar;24(3):74–6, 79, 83–4 passim (54 ref.)

European politicians need epidemiologists. O'Brien SJ, et al. **Public Health** 1998 Sep;112(5):287–8 (17 ref.)

The indoor air we breathe. Oliver LC, et al. **Public Health Rep** 1998 Sep–Oct;113(5):398–409 (23 ref.)

Constructing violence as a public health problem. Winett LB. **Public Health Rep** 1998 Nov–Dec;113(6):498–507 (25 ref.)

The nutrient–toxin dosage continuum in human evolution and modern health. Gerber LM, et al. **Q Rev Biol** 1999 Sep;74(3):273–89 (82 ref.)

Traffic-related air pollutants: exposure of road users and populations living near busy roads. van Wijnen JH, et al. **Rev Environ Health** 1998 Jan–Jun;13(1–2):1–25 (51 ref.)

The looming threat of bioterrorism. Henderson DA. **Science** 1999 Feb 26;283(5406):1279–82 (24 ref.)

Social capital and health: implications for public health and epidemiology. Lomas J. **Soc Sci Med** 1998 Nov; 47(9):1181–8 (40 ref.)

How unhealthy is migrating? [editorial; comment] Junghanss T. **Trop Med Int Health** 1998 Dec;3(12):933–4 (10 ref.) Comment on: Trop Med Int Health 1998 Dec;3(12):936–44.

Applying medical anthropology in the control of infectious disease [see comments] Manderson L. **Trop Med Int Health** 1998 Dec;3(12):1020–7 (60 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):993–5.

Society and public health: crisis and rebirth. Mann JM. **West J Med** 1998 Aug;169(2):118–21 (4 ref.)

World trade: bringing health into the picture. Kinnon CM. **World Health Forum** 1998;19(4):397–406 (13 ref.)

[French National Institute for observation of prescriptions and consumption of medicines. Prescription and consumption of antibiotics in ambulatory care] Bouvenot G. **Bull Acad Natl Med** 1999;183(3):601–9; discussion 609–13 (14 ref.) (Eng. Abstr.) **(Fre)**

[The requisite internationalization of the campaign against smoking] Dubois G. **Bull Acad Natl Med** 1998; 182(5):939–50; discussion 951–3 (61 ref.) (Eng. Abstr.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of public health physicians] Lombrail P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:191–6 (29 ref.) **(Fre)**

[Safe motherhood: is the initiative an orphan?] Weil O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jun; 28(3):205–10 (21 ref.) (Eng. Abstr.) **(Fre)**

[Burkina Faso--a multitude of public health emergencies] Niakara A, et al. **Med Trop (Mars)** 1998;58(3):235–9 (11 ref.) **(Fre)**

[Epidemiology and public health. Pursuing the clarification effort (editorial)] Ducimetière P. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):105–8 (15 ref.) **(Fre)**

[Why has menopause become a public health problem?] Rozenbaum H. **Therapie** 1998 Jan–Feb;53(1):49–59 (47 ref.) (Eng. Abstr.) **(Fre)**

[Blood and plasma product safety from the viewpoint of public health officials] Willkommen H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):497–500 (15 ref.) **(Ger)**

[Neonatal hearing screening--consequences for public health policy] Henke KD, et al. **Gesundheitswesen** 1999 Feb; 61(2):86–92 (51 ref.) (Eng. Abstr.) **(Ger)**

[Feeding of milk from cows with diseased udders to calves from the viewpoint of public health] Hässig M. **Schweiz Arch Tierheilkd** 1999;141(3):125–9 (0 ref.) (Eng. Abstr.) **(Ger)**

[The use of biological markers for the study and prevention of chronic degenerative diseases. 3. Biomarkers in public health and preventive medicine] Donato F, et al. **Ann Ig** 1998 Sep–Dec;10(5–6):361–71 (41 ref.) (Eng. Abstr.) **(Ita)**

[Construction and its characteristic on the concept of a 'health culture'] Takizawa T. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):398–406 (42 ref.) (Eng. Abstr.) **(Jpn)**

[Public health work in connection with a new international airport] Smith A, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3656–8 (7 ref.) (Eng. Abstr.) **(Nor)**

[Food, ecology and public health--over all boundaries?] Westin S. **Tidsskr Nor Laegeforen** 1998 Sep 20; 118(22):3483–7 (21 ref.) **(Nor)**

[Metrological aspects of the study of physical characteristics of the air on the objects in the vicinity of the habitat] Meshcheriakov AIu. **Med Tekh** 1999 Jan–Feb;(1):43–6 (8 ref.) (Eng. Abstr.) **(Rus)**

[Antibiotic treatment in animals has repercussions in humans.] Torres C, et al. **Rev Esp Quimioter** 1998 Mar;11(1):29–35 (75 ref.) **(Spa)**

[Risk of chemical disaster as a public health problem] Castro Delgado R, et al. **Rev Esp Salud Publica** 1998 Nov–Dec; 72(6):481–500 (33 ref.) (Eng. Abstr.) **(Spa)**

EDUCATION

Creating training opportunities for public health practitioners. Greene D, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):80–5 (18 ref.)

Linking public health education and practice: the Australian experience. Rotem A, et al. **Asia Pac J Public Health** 1998; 10(1):17–20 (10 ref.)

Teaching social inequalities in health: barriers and opportunities. Muntaner C. **Scand J Public Health** 1999 Sep;27(3):161–5 (58 ref.)

LEGISLATION & JURISPRUDENCE

Burden of proof: judging science and protecting public health in (and out of) the courtroom [see comments] Annas GJ. **Am J Public Health** 1999 Apr;89(4):490–3 (32 ref.) Comment in: Am J Public Health 1999 Apr;89(4):487–9.

Lobbying and advocacy for the public's health: what are the limits for nonprofit organizations? Vernick JS. **Am J Public Health** 1999 Sep;89(9):1425–9 (31 ref.)

Xenotransplantation and public health: identifying the legal issues. Florencio PS, et al. **Can J Public Health** 1999 Jul–Aug;90(4):282–4 (32 ref.)

[The new law concerning public health services in North Rhine- Westphalia--essentials and perspectives in dentistry] Wolf M, et al. **Gesundheitswesen** 1999 May; 61(5):260–2 (6 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The state of health and provision of health care in Hong Kong. Morley AP, et al. **Hosp Med** 1998 Jun;59(6):457–60 (19 ref.)

Improving health outcomes--a review of case studies from English health authorities. McColl A, et al. **J Public Health Med** 1998 Sep;20(3):302–11 (24 ref.)

Applications of the case/multicase SAR method to environmental and public health situations. Rosenkranz HS, et al. **SAR QSAR Environ Res** 1999;10(2–3):263–76 (34 ref.)

STANDARDS

The quality of medical information on the Internet. A new public health concern [editorial] McLeod SD. **Arch Ophthalmol** 1998 Dec;116(12):1663–5 (19 ref.)

Tuberculosis control and directly observed therapy from the public health/human rights perspective. Hurtig AK, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):553–60 (62 ref.)

Racial bias in federal nutrition policy, Part I: The public health implications of variations in lactase persistence. Bertron P, et al. **J Natl Med Assoc** 1999 Mar;91(3):151–7 (52 ref.)

The healthy city. Taggart SC. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):568–71 (6 ref.)

[Paradigm as a methodological approach to analyzing Russia's public health system] Shchepin OP, et al. **Vestn Ross Akad Med Nauk** 1998;(10):38–41 (5 ref.) (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Lessons from 12 years of comparative risk projects. Jones K, et al. **Annu Rev Public Health** 1999;20:159–72 (34 ref.)

The social environment and health: a discussion of the epidemiologic literature. Yen IH, et al. **Annu Rev Public Health** 1999;20:287–308 (127 ref.)

Violence as a public health emergency. Scott JL. **Emerg Med Clin North Am** 1999 Aug;17(3):567–73, v (17 ref.)

Violence in America: a public health crisis--domestic violence. Sisley A, et al. **J Trauma** 1999 Jun;46(6):1105–12; discussion 1112–3 (70 ref.)

Medicaid managed care and public health data. Rutherford GW, et al. **Public Health Rep** 1999 May–Jun;114(3):225–30 (25 ref.)

TRENDS

The shape of our river. Healton CG. **Am J Prev Med** 1999 Apr;16(3 Suppl):1–4 (6 ref.)

Mind matters: the importance of mental disorders in public health's 21st century mission [editorial; comment] Neugebauer R. **Am J Public Health** 1999 Sep;89(9):1309–11 (30 ref.) Comment on: Am J Public Health 1999 Sep;89(9):1315–8.

Public health in the twentieth century: advances and challenges. Fielding JE. **Annu Rev Public Health** 1999; 20:xiii–xxx (42 ref.)

Health education's contributions to public health in the twentieth century: a glimpse through health promotion's rear-view mirror. Green LW. **Annu Rev Public Health** 1999;20:67–88 (125 ref.)

A future for epidemiology? Schwartz S, et al. **Annu Rev Public Health** 1999;20:15–33 (85 ref.)

The Asian currency crisis and public health: poverty and health revisited [editorial] Binns C, et al. **Asia Pac J Public Health** 1998;10(1):1–4 (17 ref.)

Public health issues for the 21st century [editorial] Baum F. **Aust N Z J Public Health** 1999 Apr;23(2):115–6 (13 ref.)

Divisions of population health: quantum leap forward or rearranging the deckchairs? Sainsbury P. **Aust N Z J Public Health** 1999 Apr;23(2):119–25 (30 ref.)

Safe drinking water: a public health challenge. Wigle DT. **Chronic Dis Can** 1998;19(3):103–7 (36 ref.)

Environment, health, and gender in Latin America: trends and research issues. Wasserman E. **Environ Res** 1999 Apr; 80(3):253–73 (103 ref.)

The use of public health approaches in mental health programmes. Sartorius N. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S1–5 (3 ref.)

A public health perspective on the evaluation of subsistence food safety. Egeland GM, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:572–5 (23 ref.)

Migration and health in the European Union [see comments] Carballo M, et al. **Trop Med Int Health** 1998 Dec; 3(12):936–44 (79 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):933–4.

[Perspectives in public health care for refugees in Germany] Herrmann M. **Gesundheitswesen** 1999 Jun;61(6):312–8 (39 ref.) (Eng. Abstr.) **(Ger)**

[Strengthening the patients' position--a new challenge to public health] Jäger H. **Gesundheitswesen** 1999 Jun; 61(6):269–73 (43 ref.) (Eng. Abstr.) **(Ger)**

[Social work in public health service as reflected by selected studies--a description of current status] Reinicke P. **Gesundheitswesen** 1999 Apr;61(4):197–202 (19 ref.) (Eng. Abstr.) **(Ger)**

[Present-day global public health] Vartanian FE. **Vestn Ross Akad Med Nauk** 1999;(2):61–4 (9 ref.) **(Rus)**

PUBLIC HEALTH ADMINISTRATION

see related

COMMUNITY HEALTH SERVICES

Privatization and the rise and fall of the public mental health safety net. Schnapp WB, et al. **Adm Policy Ment Health** 1999 Jan;26(3):221–5 (9 ref.)

Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98–101 (10 ref.)

Assurance opportunities for local health departments. Reid WM, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):128–33 (18 ref.)

Immunization registries in the United States: implications for the practice of public health in a changing health care system. Wood D, et al. **Annu Rev Public Health** 1999; 20:231–55 (81 ref.)

Linking public health education and practice: the Australian experience. Rotem A, et al. **Asia Pac J Public Health** 1998; 10(1):17–20 (10 ref.)

Addressing emerging infections. The partnership between public health and primary care physicians. Danila RN, et al. **Postgrad Med** 1999 Aug;106(2):90–2, 97–8, 103–5 (15 ref.)

[Development of NIHS Information and Computing Infrastructure (NICI)] Nakata K, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):92–100 (7 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

The public health workforce: key to public health infrastructure [editorial] Gebbie KM. **Am J Public Health** 1999 May;89(5):660–1 (8 ref.)

The skills of public health and their development in the UK. Dalziel M. **Hosp Med** 1998 Sep;59(9):723–5 (5 ref.)

STANDARDS

Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Habicht JP, et al. **Int J Epidemiol** 1999 Feb;28(1):10–8 (20 ref.)

HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Sullivan G, et al. **Psychiatr Serv** 1999 May;50(5):648–52 (44 ref.)

Sharing responsibility for the public's health. Stoto MA. **Public Health Rep** 1999 May–Jun;114(3):231–5 (8 ref.)

[Paradigm as a methodological approach to analyzing Russia's public health system] Shchepin OP, et al. **Vestn Ross Akad Med Nauk** 1998;(10):38–41 (5 ref.) (Eng. Abstr.) **(Rus)**

PUBLIC HEALTH DENTISTRY

Uses of oral health related quality of life measures in Public Health. Weintraub JA. **Community Dent Health** 1998 Mar; 15(1):8–12 (24 ref.)

PUBLIC HEALTH NURSING

Latex sensitivity: a public health care challenge. Bartlett J. **J Community Health Nurs** 1998;15(4):193–204 (37 ref.)

ORGANIZATION & ADMINISTRATION

Health and quality of life within Colonias settlements along the United States and Mexico border. Davidhizar R, et al. **Public Health Nurs** 1999 Aug;16(4):301–6 (18 ref.)

Public health nursing in Japan: new opportunities for health promotion. Murashima S, et al. **Public Health Nurs** 1999 Apr;16(2):133–9 (16 ref.)

PUBLIC HEALTH PRACTICE

Principles of practice for academic/practice/community research partnerships. Baker EA, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):86–93 (23 ref.)

Measuring the impact of prevention research on public health practice. Brownson RC, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):72–9 (69 ref.)

Community/practice/academic partnerships in public health. Clark NM. **Am J Prev Med** 1999 Apr;16(3 Suppl):18–9 (8 ref.)

What should be the role of public health in newborn screening and prenatal diagnosis? Clayton EW. **Am J Prev Med** 1999 Feb;16(2):111–5 (20 ref.)

Screening for hemochromatosis. A public health perspective. Cogswell ME, et al. **Am J Prev Med** 1999 Feb;16(2):134–40 (73 ref.)

The intersection of genetics, public health, and preventive medicine. Coughlin SS. **Am J Prev Med** 1999 Feb; 16(2):89–90 (14 ref.)

BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Coughlin SS, et al. **Am J Prev Med** 1999 Feb;16(2):91–8 (64 ref.)

Public health perspectives on testing for colorectal cancer susceptibility genes. Coughlin SS, et al. **Am J Prev Med** 1999 Feb;16(2):99–104 (42 ref.)

Research linkages between academia and public health practice. Building a prevention research agenda. Lane DS. **Am J Prev Med** 1999 Apr;16(3 Suppl):7–9 (7 ref.)

Using case research to enhance linkages between academia and public health practice. Liang AP, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):12–3 (11 ref.)

It's about time. The medicine/public health initiative. Nickens H. **Am J Prev Med** 1999 Apr;16(3 Suppl):20–1 (3 ref.)

Preventing morbidity and mortality from sickle cell disease. A public health perspective. Olney RS. **Am J Prev Med** 1999 Feb;16(2):116–21 (64 ref.)

Prevention research centers. The academic and community partnership. Riley PL, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):5–6 (4 ref.)

Public health and brownfields: reviving the past to protect the future [editorial; comment] Greenberg M, et al. **Am J Public Health** 1998 Dec;88(12):1759–60 (12 ref.) Comment on: Am J Public Health 1998 Dec;88(12):1762–6. Comment on: Am J Public Health 1998 Dec;88(12):1834–6. Comment on: Am J Public Health 1998 Dec;88(12):1837–9. Comment on: Am J Public Health 1998 Dec;88(12):1840–5. Comment on: Am J Public Health 1998 Dec;88(12):1871–7.

Community-level interventions are needed to prevent new HIV infections [editorial; comment] Kelly JA. **Am J Public Health** 1999 Mar;89(3):299–301 (20 ref.) Comment on: Am J Public Health 1999 Mar;89(3):336–45.

Childhood lead poisoning: the promise and abandonment of primary prevention [see comments] Needleman HL. **Am J Public Health** 1998 Dec;88(12):1871–7 (38 ref.) Comment in: Am J Public Health 1998 Dec;88(12):1759–60. Comment in: Am J Public Health 1999 Jul;89(7):1126–31.

Protecting children from lead poisoning and building healthy communities [editorial] Ryan D, et al. **Am J Public Health** 1999 Jun;89(6):822–4 (25 ref.)

Promoting the health and well-being of future generations [editorial] Schneider D, et al. **Am J Public Health** 1999 Feb;89(2):155–7 (34 ref.)

Linking public health education and practice: the Australian experience. Rotem A, et al. **Asia Pac J Public Health** 1998; 10(1):17–20 (10 ref.)

Cultural sensitivity in public health: defined and demystified. Resnicow K, et al. **Ethn Dis** 1999 Winter;9(1):10–21 (98 ref.)

What role can public health institutions play in drug development for the poor? A case study of artesunate. Gomes M, et al. **Med Trop (Mars)** 1998;58(3 Suppl):97–100 (10 ref.)

ECONOMICS

An expensive policy: the impact of inadequate funding for substance abuse treatment [editorial] Amaro H.

PUBLIC HEALTH PRACTICE

Am J Public Health 1999 May;89(5):657–9 (32 ref.)

STANDARDS

The public health workforce: key to public health infrastructure [editorial] Gebbie KM. **Am J Public Health** 1999 May;89(5):660–1 (8 ref.)

Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Glasgow RE, et al. **Am J Public Health** 1999 Sep;89(9):1322–7 (88 ref.)

Prevention of sexually transmitted diseases: the need for social and behavioral science expertise in public health departments [editorial; comment] Van Devanter N. **Am J Public Health** 1999 Jun;89(6):815–8 (38 ref.) Comment on: Am J Public Health 1999 Jun;89(6):899–902.

Evidence-based public health practice. Glasziou P, et al. **Aust N Z J Public Health** 1999 Aug;23(4):436–40 (13 ref.)

PUBLIC HEALTH SERVICE (U.S.) see **UNITED STATES PUBLIC HEALTH SERVICE**

PUBLIC HEALTH SURVEILLANCE see **POPULATION SURVEILLANCE**

PUBLIC LAW 93-406 see **EMPLOYEE RETIREMENT INCOME SECURITY ACT**

PUBLIC LAW 93-579 see **PRIVACY**

PUBLIC LAW 101-508 see **PATIENT SELF-DETERMINATION ACT**

PUBLIC LAW 104-191 see **HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT**

PUBLIC OPINION

see related
ATTITUDE TO HEALTH

Analysis of factors for the prediction of the response to xenotransplantation. Daar AS. **Ann N Y Acad Sci** 1998 Dec 30;862:222–33 (45 ref.)

Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. Woolf SH, et al. **Annu Rev Med** 1999;50:207–21 (61 ref.)

Public reactions and scientific responses to transgenic crops. Dale PJ. **Curr Opin Biotechnol** 1999 Apr;10(2):203–8 (45 ref.)

Public trust and accountability for clinical performance: lessons from the national press reportage of the Bristol hearing [see comments] Davies HT, et al. **J Eval Clin Pract** 1999 Aug;5(3):335–42 (28 ref.) Comment in: J Eval Clin Pract 1999 Aug;5(3):343–6.

Legal decisions and public opinion informing the debate on assisted suicide. Zimbelman J. **J Prof Nurs** 1999 May-Jun; 15(3):146–50 (30 ref.)

[Schizophrenia--an illness and its treatment reflected in public attitude] Schöny W. **Wien Med Wochenschr** 1998; 148(11–12):284–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Medical research on patients' experiences--structured questionnaires result in worthless answers] Kirkengen AL. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3449–52 (20 ref.) (Eng. Abstr.) **(Nor)**

PUBLIC POLICY

Prevention of alcohol abuse-related birth effects--II. Targeting and pricing. Abel EL. **Alcohol Alcohol** 1998 Jul-Aug;33(4):417–20 (30 ref.)

The pharmacist and assisted suicide. Veatch RM. **Am J Health Syst Pharm** 1999 Feb 1;56(3):260–6 (29 ref.)

American College of Preventive Medicine public policy statement. Folic acid fortification of grain products in the U.S. to prevent neural tube defects. Bentley JR, et al. **Am J Prev Med** 1999 Apr;16(3):264–7 (40 ref.)

Environmental and policy interventions to promote physical activity. Sallis JF, et al. **Am J Prev Med** 1998 Nov; 15(4):379–97 (73 ref.)

Economic sanctions as human rights violations: reconciling political and public health imperatives [comment] Marks SP. **Am J Public Health** 1999 Oct;89(10):1509–13 (60 ref.) Comment on: Am J Public Health 1999 Oct;89(10):1499–504.

Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. Woolf SH, et al. **Annu Rev Med** 1999;50:207–21 (61 ref.)

A different route to health: implications of transport policies. Dora C. **BMJ** 1999 Jun 19;318(7199):1686–9 (37 ref.)

Physician-assisted death: can philosophical bioethics aid social policy? Kuczewski MG. **Camb Q Healthc Ethics** 1998 Fall;7(4):339–47 (19 ref.)

Drug policies and harms: a conceptual framework. Longshore D, et al. **Eur Addict Res** 1998 Dec;4(4):172–82 (41 ref.)

Disability theory and public policy: implications for critical gerontology. Kennedy J, et al. **Int J Health Serv** 1998; 28(4):757–76 (73 ref.)

Multiple chemical sensitivities: the social construction of an illness. Lax MB. **Int J Health Serv** 1998;28(4):725–45 (55 ref.)

Neoliberalism, "globalization," unemployment, inequalities, and the welfare state. Navarro V. **Int J Health Serv** 1998; 28(4):607–82 (91 ref.)

The political economy of the welfare state in developed capitalist countries. Navarro V. **Int J Health Serv** 1999; 29(1):1–50 (36 ref.)

The export of pesticides: shipments from U.S. ports, 1995–1996. Smith C, et al. **Int J Occup Environ Health** 1999 Apr-Jun;5(2):141–50 (45 ref.)

The tuberculosis crisis: the deadly consequence of immigration policies and welfare reform. Johns KA, et al. **J Contemp Health Law Policy** 1998 Fall;15(1):101–30 (0 ref.)

Empirical research on the insanity defense and attempted reforms: evidence toward informed policy. Borum R, et al. **Law Hum Behav** 1999 Jun;23(3):375–93 (71 ref.)

Rethinking the early childcare agenda [see comments] Cook PS. **Med J Aust** 1999 Jan 4;170(1):29–31 (36 ref.) Comment in: Med J Aust 1999 Aug 2;171(3):166–7.

Low-level chemical sensitivity: implications for research and social policy. Ashford NA. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):421–7 (27 ref.)

[Role of science in the formulation of social policy on drugs] Kalant H. **C R Seances Soc Biol Fil** 1998;192(5):905–15 (29 ref.) (Eng. Abstr.) **(Fre)**

[Social work with the elderly--current orientation and strategies] Zeman P. **Z Gerontol Geriatr** 1998 Oct; 31(5):313–8 (34 ref.) (Eng. Abstr.) **(Ger)**

PUBLIC SECTOR

The World Bank and world health. Healthcare strategy. Abbasi K. **BMJ** 1999 Apr 3;318(7188):933–6 (4 ref.)

Public land and natural resource issues confronting animal scientists and livestock producers. Vavra M. **J Anim Sci** 1998 Sep;76(9):2340–5 (25 ref.)

The role of the public sector in the development and implementation of animal health policies. Ekboir JM. **Prev Vet Med** 1999 May 31;40(2):101–15 (25 ref.)

ORGANIZATION & ADMINISTRATION

Ten dimensions of public-sector managed care [see comments] Hoge MA, et al. **Psychiatr Serv** 1999 Jan; 50(1):51–5 (27 ref.) Comment in: Psychiatr Serv 1999 Jan;50(1):7.

STATISTICS & NUMERICAL DATA

Health impact of occupational risks in the informal sector in Zimbabwe. Loewenson RH. **Int J Occup Environ Health** 1998 Oct-Dec;4(4):264–74 (31 ref.)

PUBLIC SPEAKING see **SPEECH**

PUBLICATIONS

What nutrition knowledge and skills do primary care physicians need to have, and how should this be communicated? Truswell AS. **Eur J Clin Nutr** 1999 May; 53 Suppl 2:S67–71 (26 ref.)

STANDARDS

[Significance of bibliographic state standards for scientific publications] Klyk TV. **Vestn Ross Akad Med Nauk** 1999; (1):57–60 (2 ref.) (Eng. Abstr.) **(Rus)**

PUBLISHING

see related
PERIODICALS

Publish or perish--and bankrupt the medical library while we're at it. Halperin EC. **Acad Med** 1999 May;74(5):470–2 (19 ref.)

Get your book published. Banks M. **BMJ** 1998 Dec 19–26; 317(7174):1715–8 (3 ref.)

Critical appraisal of the health research literature: prevalence or incidence of a health problem. Loney PL, et al. **Chronic Dis Can** 1998;19(4):170–6 (27 ref.)

Publishing the results of factor analysis: interpretation and presentation. Watson R. **J Adv Nurs** 1998 Dec;28(6):1361–3 (21 ref.)

Medical advice editorials: transferring medical science into clinical practice [editorial] Gross A, et al. **J Lab Clin Med** 1999 Sep;134(3):185–9 (19 ref.)

Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. **Med Educ** 1999 Jan;33(1):66–78 (00 ref.)

Nursing e-journals: are current models using the web's potential? Murray PJ, et al. **Medinfo** 1998;9 Pt 1:135–9 (9 ref.)

Electronic publishing--a challenge in medical information exchange. Kayser K, et al. **Pathologica** 1998 Jun;90(3):321–4 (25 ref.)

Progress of ICD-10 (F) family in Japan: research, field trials and publications. Takada K, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S341–3 (15 ref.)

[Publications] Skjaerback CB. **Ugeskr Laeger** 1999 Aug 16; 161(33):4644–6 (0 ref.) **(Dan)**

[Preparing a manuscript for publication in a scientific journal] Claes L, et al. **Unfallchirurg** 1999 May;102(5):377–83 (6 ref.) (Eng. Abstr.) **(Ger)**

[The publication in biomedical journals of clinical trial protocols: a new way to improve research quality (editorial)] Bosch X. **Rev Esp Cardiol** 1999 May; 52(5):359–61 (29 ref.) **(Spa)**

HISTORY

An historical and critical review of the articles on blood pressure published in Psychosomatic Medicine between 1939 and 1997. Engel BT. **Psychosom Med** 1998 Nov-Dec; 60(6):682–96 (208 ref.)

Praise be to psychosomatic medicine [editorial] Weiner H. **Psychosom Med** 1999 May-Jun;61(3):259–62 (15 ref.)

ORGANIZATION & ADMINISTRATION

Authorship: "Law" and order. Gaeta TJ. **Acad Emerg Med** 1999 Apr;6(4):297–301 (19 ref.)

Surgical Internet at a glance: volume IX. Allen J. **Am J Surg** 1999 Mar;177(3):183 (0 ref.)

Electronic publishing and nursing research. Sparks SM. **Nurs Res** 1999 Jan-Feb;48(1):50–4 (3 ref.)

STANDARDS

Reviewers, authors, and editors: balance of power. Bressler NM. **Arch Ophthalmol** 1999 Apr;117(4):524–6 (13 ref.)

It's as simple as black and white! Race and ethnicity as categorical variables [editorial] Hammerschmidt DE. **J Lab Clin Med** 1999 Jan;133(1):10–2 (8 ref.)

Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. **J Vasc Surg** 1999 Sep;30(3):573–9 (97 ref.)

[How to improve the statistical quality of articles presented to biomedical journals: a checklist for authors] Mora i Ripoll R. **Med Clin (Barc)** 1999 Jul 3;113(4):138–49 (144 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Sociodemographic factors in Health Psychology research: 12 years in review. Park TL, et al. **Health Psychol** 1998 Jul;17(4):381–3 (10 ref.)

Nursing research in Finland from 1958 to 1995. Leino-Kilpi H, et al. **Image J Nurs Sch** 1998;30(4):363–7 (27 ref.)

Productivity of SCI Korean medical papers: 1996–1997. Lee CS. **J Korean Med Sci** 1999 Aug;14(4):351–8 (20 ref.)

Logistic regression models in obstetrics and gynecology literature. Khan KS, et al. **Obstet Gynecol** 1999 Jun; 93(6):1014–20 (21 ref.)

[Evaluation of research--reality and illusions] Sawicki W. **Postepy Hig Med Dosw** 1998;52(3):297–305 (11 ref.) (Eng. Abstr.) **(Pol)**

[Nutrition surveys of Spanish school-age children: analysis of the period 1984–1994] Gorgojo L, et al. **Med Clin (Barc)** 1999 Mar 20;112(10):368–74 (55 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

Nursing research in Finland from 1958 to 1995. Leino-Kilpi H, et al. **Image J Nurs Sch** 1998;30(4):363–7 (27 ref.)

PUBLISHING, ELECTRONIC see **PUBLISHING**

PUERICULTURE see **CHILD CARE**

PUERPERAL DISORDERS

Peripartum cardiomyopathy: a review of the literature. Heider AL, et al. **Obstet Gynecol Surv** 1999 Aug; 54(8):526–31 (34 ref.)

Postpartum thyroiditis. Terry AJ, et al. **Semin Perinatol** 1998 Dec;22(6):497–502 (40 ref.)

[Mastitis puerperalis] Kano T. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):185–7 (7 ref.) **(Jpn)**

DIAGNOSIS

A case of peripartum eosinophilic myocarditis. Pearce CB, et al. **Can J Cardiol** 1999 Apr;15(4):465–8 (26 ref.)

Myocardial infarction during pregnancy and postpartum: a review. Patti G, et al. **G Ital Cardiol** 1999 Mar;29(3):333–8 (54 ref.)

Spontaneous coronary artery dissection. Case report and literature review. Elming H, et al. **Scand Cardiovasc J** 1999; 33(3):175–9 (39 ref.)

[The course of pregnancy, labor and the postpartum period in a woman with a myomatous node of the uterus who gave birth to twins] Istatkov M, et al. **Akush Ginekol (Sofiia)** 1998;37(4):56–8 (6 ref.) **(Bul)**

[Puerperal thrombophlebitis of the ovarian vein revealed by renal colic] Sappey O, et al. **Prog Urol** 1999 Apr;9(2):313–8 (20 ref.) (Eng. Abstr.) **(Fre)**

[From a diagnostic test to discovery of a new syndrome] Amino N. **Rinsho Byori** 1999 Feb;Suppl 109:103–10 (16 ref.) **(Jpn)**

[The HELLP syndrome: a potentially severe complication of pre-eclampsia in the immediate puerperium (letter)] Martinez Diaz de Argandoña C, et al. **Rev Clin Esp** 1999 Apr;199(4):255–6 (10 ref.) **(Spa)**

[Spontaneous postpartum coronary dissection] Alcalá López J, et al. **Rev Esp Cardiol** 1998 Oct;51(10):844–6 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Use of psychotropic medications in breast-feeding women: acute and prophylactic treatment. Austin MP, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):778-84 (40 ref.)

ETIOLOGY

[Pelvic and perineal sequelae of delivery] Fatton B, et al. **Rev Prat** 1999 Jan 15;49(2):160-6 (29 ref.) (Eng. Abstr.) **(Fre)**

[Postpartum autoimmune thyroid syndrome] Hidaka Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1775-8 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The thyroid immunology of the postpartum period. Davies TF. **Thyroid** 1999 Jul;9(7):675-84 (66 ref.)

PHYSIOPATHOLOGY

Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Amino N, et al. **Thyroid** 1999 Jul;9(7):705-13 (50 ref.)

Postpartum depression and thyroid antibody status. Harris B. **Thyroid** 1999 Jul;9(7):699-703 (42 ref.)

Clinical manifestations of postpartum thyroid disease. Lazarus JH. **Thyroid** 1999 Jul;9(7):685-9 (34 ref.)

Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA. **Thyroid** 1999 Jul;9(7):691-7 (51 ref.)

PREVENTION & CONTROL

Use of psychotropic medications in breast-feeding women: acute and prophylactic treatment. Austin MP, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):778-84 (40 ref.)

PSYCHOLOGY

The impact of pregnancy and puerperium on panic disorder: a review. Hertzberg T, et al. **J Psychosom Obstet Gynaecol** 1999 Jun;20(2):59-64 (23 ref.)

Postpartum depression and thyroid antibody status. Harris B. **Thyroid** 1999 Jul;9(7):699-703 (42 ref.)

Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA. **Thyroid** 1999 Jul;9(7):691-7 (51 ref.)

RADIOGRAPHY

Postpartum complications in the abdomen and pelvis: CT evaluation. Urban BA, et al. **Crit Rev Diagn Imaging** 1999 Apr;40(1):1-21 (8 ref.)

THERAPY

[Different organizational modalities in perinatal care of intra-uterine growth retardation, malformations, maternal-fetal pathology, high-risk delivery, postpartum complications] Sagot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:94-103 (40 ref.) **(Fre)**

VETERINARY

[Postpartum anestrus in dairy cattle--a review] Opsomer G, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):30-5 (34 ref.) (Eng. Abstr.) **(Ger)**

PUERPERAL INFECTION

[Puerperal endometritis and parametritis] Sugimura M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):188-91 (8 ref.) **(Jpn)**

PUERPERIUM

Early postpartum discharge. Brumfield CG. **Clin Obstet Gynecol** 1998 Sep;41(3):611-25 (57 ref.)

Therapeutic controversy: Screening for postpartum thyroiditis. Amino N, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1813-21 (92 ref.)

Dissections after childbirth. Gasecki AP, et al. **J Neurol** 1999 Aug;246(8):712-5 (22 ref.)

Working with childhood sexual abuse survivors during pregnancy, labor, and birth. Heritage C. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec; 27(6):671-7 (17 ref.)

IMMUNOLOGY

The thyroid immunology of the postpartum period. Davies TF. **Thyroid** 1999 Jul;9(7):675-84 (66 ref.)

PHYSIOLOGY

Relationship between overfeeding and overconditioning in the dry period and the problems of high producing dairy cows during the postparturient period. Rukkwamsuk T, et al. **Vet Q** 1999 Jun;21(3):71-7 (125 ref.)

[Physiological and sensorial determinism of maternal behavior in mammals] Lévy F. **Contracept Fertil Sex** 1998 Oct;26(10):718-27 (78 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Pharmacologic treatment of depression in women: PMS, pregnancy, and the postpartum period. Cohen LS. **Depress Anxiety** 1998;8 Suppl 1:18-26 (102 ref.)

Brain N-acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. Poland RE, et al. **J Psychiatr Res** 1999 Jan-Feb;33(1):41-51 (126 ref.)

A review of research instruments for use during the postpartum period. Beck CT. **MCN Am J Matern Child Nurs** 1998 Sep-Oct;23(5):254-61 (56 ref.)

Perinatal mood disorders: position paper. Steiner M. **Psychopharmacol Bull** 1998;34(3):301-6 (72 ref.)

PUERTO RICANS see **HISPANIC AMERICANS**

PULMONARY ALVEOLAR PROTEINOSIS

METABOLISM

Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Reed JA, et al. **Proc Assoc Am Physicians** 1998 Jul-Aug;110(4):321-32 (56 ref.)

PHYSIOPATHOLOGY

The clinical characteristics of pulmonary alveolar proteinosis: experience at Seoul National University Hospital, and review of the literature. Kim G, et al. **J Korean Med Sci** 1999 Apr;14(2):159-64 (21 ref.)

PULMONARY ALVEOLI

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099-104 (13 ref.)

Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium. Berthiaume Y, et al. **Thorax** 1999 Feb;54(2):150-60 (154 ref.)

ABNORMALITIES

Perilobular pulmonary opacities: high-resolution CT findings and pathologic correlation. Johkoh T, et al. **J Thorac Imaging** 1999 Jul;14(3):172-7 (10 ref.)

ANATOMY & HISTOLOGY

The alveolar surface network: a new anatomy and its physiological significance. Scarpelli EM. **Anat Rec** 1998 Aug;251(4):491-527 (125 ref.)

BLOOD SUPPLY

[Neonatal hypoxemia due to misaligned pulmonary vessels with alveolar capillary dysplasia] Liet JM, et al. **Arch Pediatr** 1998 Jan;5(1):27-30 (13 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Alveolar fluid clearance in developing lungs and its role in neonatal transition. Jain L. **Clin Perinatol** 1999 Sep; 26(3):585-99 (88 ref.)

Role of platelet-derived growth factors in angiogenesis and alveogenesis. Lindahl P, et al. **Curr Top Pathol** 1999; 93:27-33 (34 ref.)

IMMUNOLOGY

Pneumocystis carinii: the art and science of survival in the hostile environment of the alveolar spaces. Martin WJ 2nd. **Semin Respir Infect** 1998 Dec;13(4):348-52 (17 ref.)

METABOLISM

Sodium channels in alveolar epithelial cells: molecular characterization, biophysical properties, and physiological significance. Matalon S, et al. **Annu Rev Physiol** 1999; 61:627-61 (188 ref.)

Surfactant protein metabolism in vivo. Ikegami M, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):218-25 (41 ref.)

Interactions of surfactant protein A with epithelial cells and phagocytes. Tino MJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):241-63 (112 ref.)

Iron metabolism in the lower respiratory tract. Mateos F, et al. **Thorax** 1998 Jul;53(7):594-600 (67 ref.)

MICROBIOLOGY

Pneumocystis carinii: the art and science of survival in the hostile environment of the alveolar spaces. Martin WJ 2nd. **Semin Respir Infect** 1998 Dec;13(4):348-52 (17 ref.)

PHYSIOLOGY

The alveolar surface network: a new anatomy and its physiological significance. Scarpelli EM. **Anat Rec** 1998 Aug;251(4):491-527 (125 ref.)

Pulmonary surfactant: functions and molecular composition. Goerke J. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):79-89 (80 ref.)

Formation and structure of surface films: captive bubble surfactometry. Schürch S, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):180-202 (56 ref.)

Ventilation-perfusion MR imaging of the lung. Hatabu H, et al. **Magn Reson Imaging Clin N Am** 1999 May; 7(2):379-92, x (47 ref.)

PULMONARY ARTERY

Pulmonary artery catheterization in anaesthesia and intensive care. Gómez CM, et al. **Br J Anaesth** 1998 Dec; 81(6):945-56 (192 ref.)

Mycotic pulmonary arterial aneurysms in an intravenous drug user. McLean L, et al. **Can Respir J** 1998 Jul-Aug; 5(4):307-11 (13 ref.)

Contrast-enhanced magnetic resonance angiography of the pulmonary vasculature. A review. Kauczor HU. **Invest Radiol** 1998 Sep;33(9):606-17 (65 ref.)

Ruptured mycotic pulmonary artery aneurysm: an unusual complication of right-sided endocarditis. Benveniste O, et al. **Scand J Infect Dis** 1998;30(6):626-9 (20 ref.)

[A successful surgical repair of mitral stenosis and regurgitation with pulmonary arteriovenous fistula] Inoue T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):757-61 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary artery aneurysm. A case report] Palma Nieto JC, et al. **Rev Esp Cardiol** 1999 Feb;52(2):148-50 (8 ref.) (Eng. Abstr.) **(Spa)**

[An intimal sarcoma of the pulmonary artery. An immunohistochemical study] Pérez del Río MJ, et al. **Rev Esp Cardiol** 1998 Oct;51(10):850-2 (8 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Origin of the circumflex coronary artery from the pulmonary artery in infants. Alexi-Meskishvili V, et al. **Ann Thorac Surg** 1998 Oct;66(4):1406-9 (9 ref.)

Aortic arch and pulmonary artery anomalies in children. Weinberg PM, et al. **Semin Roentgenol** 1998 Jul; 33(3):262-80 (35 ref.)

Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Shovlin CL, et al. **Thorax** 1999 Aug;54(8):714-29 (193 ref.)

[Anomalous origin of the left pulmonary artery (Sling): a case report and review of the literature] Loureiro M, et al. **Rev Port Cardiol** 1998 Oct;17(10):811-5 (25 ref.) (Eng. Abstr.) **(Por)**

[An anomalous origin of the left coronary artery in the right pulmonary artery with interventricular communication] Cabrera A, et al. **Rev Esp Cardiol** 1999 Apr;52(4):279-80 (8 ref.) (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

The real fate of pulmonary arteries after bidirectional superior cavopulmonary anastomosis: is there a need for concern? [see comments] Slavik Z, et al. **Cardiol Young** 1999 Jan;9(1):6-10 (28 ref.) Comment in: Cardiol Young 1999 Jan;9(1):2-3.

IMMUNOLOGY

Takayasu's arteritis: a cell-mediated large-vessel vasculitis. Rizzi R, et al. **Int J Clin Lab Res** 1999;29(1):8-13 (61 ref.)

METABOLISM

Ion channels in the pulmonary vasculature. Reeve HL, et al. **Pulm Pharmacol Ther** 1997 Oct-Dec;10(5-6):243-52 (99 ref.)

PATHOLOGY

Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Botney MD. **Am J Respir Crit Care Med** 1999 Feb;159(2):361-4 (35 ref.)

Magnetic resonance pulmonary angiography. Wielopolski PA. **Coron Artery Dis** 1999 May;10(3):157-75 (108 ref.)

Takayasu's arteritis involving proximal pulmonary arteries and mimicking thromboembolic disease. Haque U, et al. **J Rheumatol** 1999 Feb;26(2):450-3 (15 ref.)

Case report of a patient with an intimal sarcoma of the pulmonary trunk presenting as a pulmonary embolism. Weijmer MC, et al. **Neth J Med** 1999 Aug;55(2):80-3 (7 ref.)

PHYSIOLOGY

Oxygen-sensing potassium currents in pulmonary artery. McCulloch KM, et al. **Gen Pharmacol** 1999 Apr; 32(4):403-11 (54 ref.)

Complex flow patterns in the great vessels: a review. Bogren HG, et al. **Int J Card Imaging** 1999 Apr;15(2):105-13 (48 ref.)

PHYSIOPATHOLOGY

Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Voelkel NF, et al. **Pulm Pharmacol Ther** 1997 Oct-Dec;10(5-6):231-41 (104 ref.)

[Acute pulmonary heart disease caused by pulmonary artery embolism] Heintzen MP, et al. **Internist (Berl)** 1999 Jul;

PULMONARY ARTERY

40(7):710–21 (42 ref.) **(Ger)**

RADIOGRAPHY

Optimization of contrast delivery for pulmonary CT angiography. Yankelevitz DF, et al. **Clin Imaging** 1998 Nov–Dec;22(6):398–403 (13 ref.)

Hughes–Stovin syndrome: a case report and review of the literature. Riantawan P, et al. **J Med Assoc Thai** 1999 Mar; 82(3):312–6 (7 ref.)

Spiral computed tomographic scanning and magnetic resonance angiography for the diagnosis of pulmonary embolism. Grenier PA, et al. **Thorax** 1998 Aug;53 Suppl 2:S25–31 (43 ref.)

SURGERY

Pulmonary thromboendarterectomy: an advance in the treatment of chronic thromboembolic pulmonary hypertension. McKane CL. **Heart Lung** 1998 Sep–Oct; 27(5):293–6 (11 ref.)

Outcome after pulmonary thromboendarterectomy. Archibald CJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):164–71 (31 ref.)

Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension. Auger WR, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):179–90 (42 ref.)

ULTRASONOGRAPHY

In vivo tomographic assessment of the heart and blood vessels with intravascular ultrasound. Görge G, et al. **Basic Res Cardiol** 1998 Aug;93(4):219–40 (186 ref.)

PULMONARY ATRESIA

DIAGNOSIS

Evaluation and management of pulmonary atresia with intact ventricular septum. Bichell DP. **Curr Opin Cardiol** 1999 Jan;14(1):60–6 (62 ref.)

SURGERY

Evaluation and management of pulmonary atresia with intact ventricular septum. Bichell DP. **Curr Opin Cardiol** 1999 Jan;14(1):60–6 (62 ref.)

PULMONARY BLASTOMA

DIAGNOSIS

Pleuropulmonary blastoma in an adult: an initial case report. Hill DA, et al. **Cancer** 1999 Jun 1;85(11):2368–74 (33 ref.)

MORTALITY

Pleuropulmonary blastoma: long-term survival and literature review. Romeo C, et al. **Med Pediatr Oncol** 1999 Oct; 33(4):372–6 (34 ref.)

PULMONARY CIRCULATION

see related
VENTILATION–PERFUSION RATIO

The real fate of pulmonary arteries after bidirectional superior cavopulmonary anastomosis: is there a need for concern? [see comments] Slavik Z, et al. **Cardiol Young** 1999 Jan;9(1):6–10 (28 ref.) Comment in: Cardiol Young 1999 Jan;9(1):2–3.

Cyanotic congenital heart disease with increased pulmonary blood flow. Grifka RG. **Pediatr Clin North Am** 1999 Apr; 46(2):405–25 (65 ref.)

Cyanotic congenital heart disease with decreased pulmonary blood flow in children. Waldman JD, et al. **Pediatr Clin North Am** 1999 Apr;46(2):385–404 (15 ref.)

Imaging of lung vascularization and perfusion in children. Mani TM, et al. **Pediatr Pulmonol Suppl** 1999;18:198–200 (2 ref.)

[Vasomotor control of the pulmonary circulation] Shirai M. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):235–48 (87 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Low-dose inhaled nitric oxide and oxygenation in pediatric hypoxic respiratory failure. Wrong bullet, wrong target [editorial; comment] Tibby S, et al. **Crit Care Med** 1999 May;27(5):871–2 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):989–96.

PHYSIOLOGY

Neutrophil rheology and transit through capillaries and sinusoids [editorial; comment] Doerschuk CM. **Am J Respir Crit Care Med** 1999 Jun;159(6):1693–5 (16 ref.) Comment on: Am J Respir Crit Care Med 1999 Jun;159(6):1696–702.

Structure, strength, failure, and remodeling of the pulmonary blood-gas barrier. West JB, et al. **Annu Rev Physiol** 1999; 61:543–72 (91 ref.)

Control of the pulmonary circulation in the fetus and during the transitional period to air breathing. Heymann MA. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):127–32 (55 ref.)

Nitric oxide and endothelin-1 in coronary and pulmonary circulation. Rubino A, et al. **Int Rev Cytol** 1999;189:59–93 (185 ref.)

Cellular responses to hypoxia in the pulmonary circulation. Brij SO, et al. **Thorax** 1998 Dec;53(12):1075–9 (49 ref.)

[Physiology and physiopathology of the pulmonary circulation] Olschewski H, et al. **Internist (Berl)** 1999 Jul; 40(7):696–709 (30 ref.) **(Ger)**

[Circulatory dynamics based on physiopathology of respiratory insufficiency] Nagasaka Y. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):18–23 (7 ref.) **(Jpn)**

[Mechanical extracorporeal circulation. Artificial heart. Percutaneous cardiopulmonary circulation. Part II] Ostrowska G. **Pol Merkuriusz Lek** 1999 Mar;6(33):146–51 (53 ref.) (Eng. Abstr.) **(Pol)**

PULMONARY COIN LESION see **COIN LESION, PULMONARY**

PULMONARY DIFFUSING CAPACITY

PHYSIOLOGY

Gas exchange: large surface and thin barrier determine pulmonary diffusing capacity. Weibel ER. **Minerva Anestesiol** 1999 Jun;65(6):377–82 (19 ref.)

PULMONARY DISEASE (SPECIALTY)

[Pathophysiological and pathomorphological aspects of pulmonology] Uglov FG. **Vestn Ross Akad Med Nauk** 1998;(10):36–8 (2 ref.) (Eng. Abstr.) **(Rus)**

[The Internet for pneumologists and thoracic surgeons: an interactive fantasy (editorial)] Moreno Balsalobre R, et al. **Arch Bronconeumol** 1999 Jan;35(1):1–4 (19 ref.) **(Spa)**

EDUCATION

[Training of high-skilled researchers at the Saint-Petersburg Research Institute of Phtisiopulmonology in 1994–1998] Vinogradova TI. **Probl Tuberk** 1999;(3):50–2 (0 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Of shadows and wind. Callahan CW. **Pediatr Pulmonol** 1998 Aug;26(2):145–6 (4 ref.)

TRENDS

Recent changes: pulmonary medicine. Roche N. **BMJ** 1999 Jan 16;318(7177):171–6 (48 ref.)

[Pneumology] Seeger W. **Internist (Berl)** 1999 Apr; 40(4):391–400 (19 ref.) **(Ger)**

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE see **LUNG DISEASES, OBSTRUCTIVE**

PULMONARY DISEASES see **LUNG DISEASES**

PULMONARY EDEMA

Environmental pulmonary edema: an update. Cordasco EM Sr, et al. **Rev Environ Health** 1998 Jan–Jun;13(1–2):27–57 (215 ref.)

[Acute hemodynamic pulmonary edema (cardiogenic or overload)] Michard F, et al. **Rev Prat** 1999 Feb 15; 49(4):415–8 (4 ref.) **(Fre)**

CHEMICALLY INDUCED

Vinorelbine-related acute cardiopulmonary toxicity. Karminsky N, et al. **Cancer Chemother Pharmacol** 1999; 43(2):180–2 (11 ref.)

[Severe flecainide acetate poisoning. Apropos of a case] Maury P, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):273–7 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Diagnostic imaging in intensive care. Techniques, indications, diagnostic signs--II] Bankier A, et al. **Internist (Berl)** 1999 Mar;40(3):W294–304 (18 ref.) **(Ger)**

ETIOLOGY

Transfusion-related acute lung injury. Kopko PM, et al. **Br J Haematol** 1999 May;105(2):322–9 (48 ref.)

Fatal postoperative pulmonary edema: pathogenesis and literature review [see comments] Arieff AI. **Chest** 1999 May;115(5):1371–7 (45 ref.) Comment in: Chest 1999 May;115(5):1224–6.

Postpneumonectomy pulmonary edema. Deslauriers J, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):611–31, ix (46 ref.)

Altitude-related illness in children. Carpenter TC, et al. **Curr Probl Pediatr** 1998 Jul;28(6):177–98 (70 ref.)

Non-cardiogenic pulmonary oedema in vascular surgery. Pararajasingam R, et al. **Eur J Vasc Endovasc Surg** 1999 Feb;17(2):93–105 (154 ref.)

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099–104 (13 ref.)

High altitude pulmonary edema. Bärtsch P. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S23–7 (59 ref.)

Transfusion-related acute lung injury. Silliman CC. **Transfus Med Rev** 1999 Jul;13(3):177–86 (50 ref.)

[Lung damage due to mechanical ventilation] Plötz FB, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):133–6 (33 ref.) (Eng. Abstr.) **(Dut)**

[Radiographic diagnosis of cardiogenic pulmonary edema] Matsuyama S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 May; 59(6):223–30 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary edema--from etiology to treatment] Kawakami Y. **Nippon Naika Gakkai Zasshi** 1999 Feb 20;88 Suppl:69–73 (13 ref.) **(Jpn)**

MORTALITY

The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. [see comments] Pang D, et al. **Chest** 1998 Oct;114(4):1185–92 (23 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):58.

PATHOLOGY

Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium. Berthiaume Y, et al. **Thorax** 1999 Feb;54(2):150–60 (154 ref.)

[Pathology of diseases responsible for the development of respiratory insufficiency] Nagai A. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):45–50 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

High altitude maladies: recent trends in medical management. Selvamurthy W, et al. **Int J Biometeorol** 1998 Dec; 42(2):61–4 (57 ref.)

The pathophysiology of high altitude pulmonary edema. Grissom CK, et al. **Wilderness Environ Med** 1999 Summer; 10(2):88–92 (32 ref.)

RADIOGRAPHY

[Radiographic diagnosis of cardiogenic pulmonary edema] Matsuyama S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 May; 59(6):223–30 (14 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Volume reduction surgery for the treatment of pulmonary edema] Yoshida M, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):82–8 (5 ref.) **(Jpn)**

[Volume-reduction surgery for pulmonary edema] Jiménez Castro D, et al. **Rev Clin Esp** 1999 Jul;199(7):449–55 (75 ref.) **(Spa)**

THERAPY

The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. [see comments] Pang D, et al. **Chest** 1998 Oct;114(4):1185–92 (23 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):58.

[Use of non-invasive positive pressure ventilation for cardiogenic pulmonary edema in emergency care units (editorial; comment)] Brochard L. **Presse Med** 1998 Jun 20;27(22):1105–7 (10 ref.) (Eng. Abstr.) Comment on: Presse Med 1998 Jun 20;27(22):1089–94. **(Fre)**

PULMONARY EMBOLISM

Deep venous thrombosis and pulmonary embolism: diagnosis, prophylaxis, and treatment. Alexander P, et al. **Ann Vasc Surg** 1999 May;13(3):318–27 (48 ref.)

BLOOD

[Does D-dimer determination allow the exclusion of pulmonary embolism?] Bounameaux H. **Rev Pneumol Clin** 1998 Jul;54(3):144–8 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg? [editorial] Flegel KM. **CMAJ** 1999 Apr 20;160(8):1181–2 (28 ref.)

Chronic thromboembolic pulmonary hypertension. Lang IM. **Indian Heart J** 1999 Jan–Feb;51(1):27–30 (17 ref.)

Adnexal torsion and pulmonary embolism: case report and review of the literature. McGovern PG, et al. **Obstet Gynecol Surv** 1999 Sep;54(9):601–8 (130 ref.)

[Acute pulmonary heart disease caused by pulmonary artery embolism] Heintzen MP, et al. **Internist (Berl)** 1999 Jul; 40(7):710–21 (42 ref.) **(Ger)**

[Severe venous thrombosis in pulmonary embolism: physiopathological aspects] Mercuro G, et al. **Cardiologia** 1998 Jun;43 Suppl 1:53–7 (34 ref.) **(Ita)**

[Prevention of severe venous thrombosis in pulmonary embolism] Palareti G. **Cardiologia** 1998 Jun;43 Suppl 1:65–8 (16 ref.) **(Ita)**

DIAGNOSIS

Idiopathic pulmonary vein thrombosis: detection by CT and MR imaging. Selvidge SD, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1639–41 (10 ref.)

Modern management of pulmonary embolism. Tai NR, et

al. **Br J Surg** 1999 Jul;86(7):853–68 (145 ref.)
Pulmonary embolism: opinions and facts [editorial; comment] Pistolesi M. **Cardiologia** 1999 Aug;44(8):743–5 (19 ref.) Comment on: Cardiologia 1999 Aug;44(8):735–41.
Venous thromboembolism in the intensive care unit. Legere BM, et al. **Clin Chest Med** 1999 Jun;20(2):367–84, ix (116 ref.)
Diagnosis of pulmonary embolism. Raskob GE, et al. **Curr Opin Hematol** 1999 Sep;6(5):280–4 (23 ref.)
Diagnosis of deep venous thrombosis and pulmonary embolism in pregnancy. Macklon NS. **Curr Opin Pulm Med** 1999 Jul;5(4):233–7 (40 ref.)
The role of newer diagnostic techniques in the diagnosis of pulmonary embolism. Stein PD, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):212–5 (43 ref.)
Spiral CT and pulmonary embolism: is the emperor still unclothed? Lally JF, et al. **Del Med J** 1999 May;71(5):221–3 (5 ref.)
Update on diagnostic strategies of pulmonary embolism. Kauczor HU, et al. **Eur Radiol** 1999;9(2):262–75 (109 ref.)
Non-invasive imaging of the great vessels of the chest. Marchal G, et al. **Eur Radiol** 1998;8(7):1099–105 (56 ref.)
Pulmonary embolism presenting as syncope: case report and review of the literature. Koutkia P, et al. **Heart Lung** 1999 Sep–Oct;28(5):342–7 (19 ref.)
Takayasu's arteritis involving proximal pulmonary arteries and mimicking thromboembolic disease. Haque U, et al. **J Rheumatol** 1999 Feb;26(2):450–3 (15 ref.)
Evaluation of pulmonary emboli: current concepts. Abbott GF. **Med Health R I** 1999 Jun;82(6):194–7 (17 ref.)
The place of D-dimer testing in an integrated approach of patients suspected of pulmonary embolism. de Moerloose P, et al. **Semin Thromb Hemost** 1998;24(4):409–12 (26 ref.)
Rapid D-dimer assays to exclude deep venous thrombosis and pulmonary embolism: current status and new developments. Janssen MC, et al. **Semin Thromb Hemost** 1998;24(4):393–400 (46 ref.)
Rational diagnosis of pulmonary embolism (RADIA PE) in symptomatic outpatients with suspected PE: an improved strategy to exclude or diagnose venous thromboembolism by the sequential use of a clinical model, rapid ELISA D-dimer test, perfusion lung scan, ultrasonography, spiral CT, and pulmonary angiography. Michiels JJ. **Semin Thromb Hemost** 1998;24(4):413–8 (28 ref.)
Spiral computed tomographic scanning and magnetic resonance angiography for the diagnosis of pulmonary embolism. Grenier PA, et al. **Thorax** 1998 Aug;53 Suppl 2:S25–31 (43 ref.)
Rapid D-dimer testing as an adjunct to clinical findings in excluding pulmonary embolism. Lennox AF, et al. **Thorax** 1999 Aug;54 Suppl 2:S33–6 (26 ref.)
[Diagnostic imaging of acute pulmonary embolism: critical analysis of the 1997 literature] Amiel M, et al. **J Radiol** 1998 Jan;79(1):13–9 (49 ref.) (Eng. Abstr.) **(Fre)**
[Does a universal strategy of acute pulmonary embolism diagnosis exist today?] Coulomb M, et al. **J Radiol** 1998 Jun;79(6):515–28 (121 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis of pulmonary embolism: value of imaging] Marceau A, et al. **Presse Med** 1998 Jun 6;27(20):974–6 (10 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis of pulmonary embolism] Noseda A, et al. **Rev Med Brux** 1999 Jun;20(3):147–52 (30 ref.) (Eng. Abstr.) **(Fre)**
[Does D-dimer determination allow the exclusion of pulmonary embolism?] Bounameaux H. **Rev Pneumol Clin** 1998 Jul;54(3):144–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Current diagnostic strategy in pulmonary embolism] Henrot P, et al. **Rev Prat** 1998 Jan 15;48(2):124–8 (23 ref.) **(Fre)**
[Diagnosis of pulmonary embolism] Burghuber OC. **Acta Med Austriaca** 1999;26(2):47–51 (23 ref.) (Eng. Abstr.) **(Ger)**
[Incidence of pulmonary embolism in venous thrombosis] Mostbeck A. **Wien Med Wochenschr** 1999;149(2–4):72–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis and treatment of pulmonary thromboembolism] Shirato K, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1892–6 (15 ref.) **(Jpn)**
[Campylobacter fetus sepsis, pulmonary thromboembolism and an occult neoplasm (letter)] Conde Martel A, et al. **An Med Interna** 1999 Feb;16(2):103 (7 ref.) **(Spa)**
[Current and future diagnostic strategies in venous thromboembolic disease] Gabriel Botella F, et al. **An Med Interna** 1999 Aug;16(8):427–33 (58 ref.) (Eng. Abstr.) **(Spa)**
[A hydatid cyst in the vena cava inferior and right atrium with venous flow obstruction and pulmonary dissemination] Caballero J, et al. **Rev Esp Cardiol** 1999 Apr; 52(4):281–4 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Thrombolytic therapy for venous thrombosis and pulmonary embolism. Gallus AS. **Baillieres Clin Haematol** 1998 Sep; 11(3):663–73 (65 ref.)
Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Arcasoy SM, et al. **Chest** 1999 Jun;115(6):1695–707 (102 ref.)
Thrombolytic therapy for venous thromboembolism. Elliott G. **Curr Opin Hematol** 1999 Sep;6(5):304–8 (35 ref.)
Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism [editorial] Grendys EC Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):71–9 (75 ref.)
Disorders of pulmonary circulation [editorial; comment] Pineo GF, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):209–11 (24 ref.) Comment on: Curr Opin Pulm Med 1999 Jul;5(4):216–21.
Heparin and low molecular weight heparin for treatment of acute pulmonary embolism [see comments] Raskob GE. **Curr Opin Pulm Med** 1999 Jul;5(4):216–21 (34 ref.) Comment in: Curr Opin Pulm Med 1999 Jul;5(4):209.
Treatment and prevention of venous thromboembolic disease in pregnancy. Valentine KA. **Curr Opin Pulm Med** 1999 Jul;5(4):238–43 (60 ref.)
New perspectives for treatment of pulmonary embolism. Simonneau G. **Haemostasis** 1998;28 Suppl 3:95–9 (9 ref.)
Low molecular weight heparins: current use and indications [see comments] Quader MA, et al. **J Am Coll Surg** 1998 Dec;187(6):641–58 (95 ref.) Comment in: J Am Coll Surg 1999 Jul;189(1):141–2.
[A different focus on the current status of thrombolysis in pulmonary thromboembolism] Jerjes Sánchez C, et al. **Arch Inst Cardiol Mex** 1998 Mar–Apr;68(2):166–80 (90 ref.) **(Spa)**

EPIDEMIOLOGY

The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Lewis MA. **Am J Obstet Gynecol** 1998 Oct; 179(4):1086–97 (85 ref.)
Venous thromboembolism in the intensive care unit. Legere BM, et al. **Clin Chest Med** 1999 Jun;20(2):367–84, ix (116 ref.)

ETIOLOGY

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Oger E, et al. **Drugs Aging** 1999 Jan;14(1):55–61 (38 ref.)
Popliteal vein aneurysm as a source of recurrent pulmonary embolism. Cairols MA, et al. **Eur J Vasc Endovasc Surg** 1999 Aug;18(2):171–3 (10 ref.)
Paradoxical cerebral embolism complicating a major orthopaedic operation. A report of two cases. Della Valle CJ, et al. **J Bone Joint Surg Am** 1999 Jan;81(1):108–10 (20 ref.)
Thrombosis in pregnancy: maternal and fetal issues [see comments] Greer IA. **Lancet** 1999 Apr 10; 353(9160):1258–65 (61 ref.) Comment in: Lancet 1999 Jul 10;354(9173):162–3.
Case report of a patient with an intimal sarcoma of the pulmonary trunk presenting as a pulmonary embolism. Weijmer MC, et al. **Neth J Med** 1999 Aug;55(2):80–3 (7 ref.)
Peripherally inserted central venous catheter fracture and embolization to the lung. Kossoff EH, et al. **Pediatr Emerg Care** 1998 Dec;14(6):403–5 (11 ref.)
Ruptured mycotic pulmonary artery aneurysm: an unusual complication of right-sided endocarditis. Benveniste O, et al. **Scand J Infect Dis** 1998;30(6):626–9 (20 ref.)
[Pulmonary embolism. Risk factors of venous thromboembolic disease] Gagnadoux F, et al. **Presse Med** 1998 May 2–9;27(17):814–8 (29 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetics and pulmonary medicine. 4. Pulmonary embolism. Laffan M. **Thorax** 1998 Aug;53(8):698–702 (50 ref.)

NURSING

Pulmonary embolism presenting as syncope: case report and review of the literature. Koutkia P, et al. **Heart Lung** 1999 Sep–Oct;28(5):342–7 (19 ref.)

PHYSIOPATHOLOGY

[Severe venous thrombosis in pulmonary embolism: physiopathological aspects] Mercuro G, et al. **Cardiologia** 1998 Jun;43 Suppl 1:53–7 (34 ref.) **(Ita)**

PREVENTION & CONTROL

The role of aspirin for thromboembolic disease in total joint arthroplasty. Lotke PA. **Am J Knee Surg** 1999 Winter; 12(1):61–3 (15 ref.)
When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg? [editorial] Flegel KM. **CMAJ** 1999 Apr 20;160(8):1181–2 (28 ref.)
Prevention of venous thromboembolism. Rosen SF, et al. **Curr Opin Hematol** 1999 Sep;6(5):285–90 (28 ref.)
Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism [editorial] Grendys EC Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):71–9 (75 ref.)
Prevention of venous thrombosis after elective hip surgery [see comments] Turpie AG, et al. **Orthopedics** 1998 Dec; 21(12):1275–81 (45 ref.) Comment in: Orthopedics 1999 May;22(5):476–7.
Deep vein thrombosis and pulmonary embolism prophylaxis in joint replacement surgery. Merli GJ. **Rheum Dis Clin North Am** 1999 Aug;25(3):639–56, ix (91 ref.)
[Guidelines for prevention of thrombosis in orthopedics] Pauschert R, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct; 136(5):471–9 (62 ref.) (Eng. Abstr.) **(Ger)**
[The caval filter in prevention of pulmonary embolism] Fiorani P, et al. **Cardiologia** 1998 Jun;43 Suppl 1:79–82 (18 ref.) **(Ita)**
[Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism] Kirienko AI, et al. **Ter Arkh** 1998;70(11):78–80 (25 ref.) **(Rus)**

RADIOGRAPHY

Role of spiral computed tomography in the diagnosis of pulmonary embolism in the emergency department. Holbert JM, et al. **Ann Emerg Med** 1999 May;33(5):520–8 (47 ref.)
Spiral CT of pulmonary embolism: diagnostic approach, interpretive pitfalls and current indications. Remy-Jardin M, et al. **Eur Radiol** 1998;8(8):1376–90 (63 ref.)
[Spiral CT in pulmonary embolism] Coche E, et al. **J Belge Radiol** 1998 Aug;81(4):199–203 (20 ref.) (Eng. Abstr.) **(Fre)**
[Pulmonary embolism. The role of computed tomography angiography] Ghossain M, et al. **Presse Med** 1998 May 2–9;27(17):819–27 (38 ref.) (Eng. Abstr.) **(Fre)**
[Role of angiographic scanning in the diagnostic strategy for pulmonary embolism] Perrier A. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S61–2 (11 ref.) **(Fre)**
[Value and limits of spiral computerized tomography angiography in diagnosis of pulmonary embolism] Remy J, et al. **Rev Pneumol Clin** 1998 Sep;54(4):196–204 (13 ref.) **(Fre)**
[Value of spiral computer tomography for the diagnosis of acute pulmonary embolism] Rademaker J, et al. **Dtsch Med Wochenschr** 1999 Feb 12;124(6):153–7 (40 ref.) **(Ger)**
[Spiral computed tomography--solution to diagnostic problems in pulmonary embolism?] Tylen U, et al. **Lakartidningen** 1999 Jun 2;96(22):2712–7 (40 ref.) (Eng. Abstr.) **(Swe)**

RADIONUCLIDE IMAGING

Quantifying the value of diagnostic tests. Lloyd JJ, et al. **Nucl Med Commun** 1998 Oct;19(10):999–1004 (7 ref.)

SURGERY

Pulmonary thromboendarterectomy: an advance in the treatment of chronic thromboembolic pulmonary hypertension. McKane CL. **Heart Lung** 1998 Sep–Oct; 27(5):293–6 (11 ref.)
Outcome after pulmonary thromboendarterectomy. Archibald CJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):164–71 (31 ref.)
Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension. Auger WR, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):179–90 (42 ref.)

THERAPY

Treatment of pulmonary thromboembolism. Goldhaber SZ. **Intern Med** 1999 Aug;38(8):620–5 (42 ref.)
Prehospital thrombolytic treatment of massive pulmonary embolism with reteplase during cardiopulmonary resuscitation. Kuisma M, et al. **Resuscitation** 1998 Jul; 38(1):47–50 (10 ref.)
[Treatment of venous thromboembolic disease in the elderly] el Kouri D, et al. **J Mal Vasc** 1999 Jun;24(3):183–8 (37 ref.) (Eng. Abstr.) **(Fre)**
[Pulmonary embolism. Current aspects of treatment] Girard P. **Presse Med** 1998 May 2–9;27(17):829–35 (46 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of pulmonary embolism] Palla A, et al. **Cardiologia** 1998 Jun;43 Suppl 1:73–7 (23 ref.) **(Ita)**
[Diagnosis and treatment of pulmonary thromboembolism] Shirato K, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1892–6 (15 ref.) **(Jpn)**
[Fibrinolytic treatment of pulmonary embolism] Tomkowski WZ. **Pneumonol Alergol Pol** 1997;65(11–12):849–53 (15 ref.) **(Pol)**

ULTRASONOGRAPHY

The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Kearon C, et al. **Ann Intern Med** 1998 Dec 15; 129(12):1044–9 (56 ref.)
[Transthoracic sonography in the diagnosis of pulmonary embolism] Mathis G. **Acta Med Austriaca** 1999;26(2):52–6 (36 ref.) (Eng. Abstr.) **(Ger)**
[A right atrial thrombus in transit: its echocardiographic diagnosis 72 hours before a pulmonary embolism] Valenzuela Garcia LF, et al. **Rev Esp Cardiol** 1999 Jan; 52(1):59–62 (7 ref.) (Eng. Abstr.) **(Spa)**

PULMONARY EMPHYSEMA

COMPLICATIONS

[Pulmonary infection in the emphysematous bulla due to Mycobacterium szulgai diagnosed by percutaneus needle aspiration] Inoue Y, et al. **Kansenshogaku Zasshi** 1998 Nov; 72(11):1236–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY EMPHYSEMA

DIAGNOSIS

[Magnetic resonance tomography with inhalation of polarized noble gases: new perspectives in functional imaging diagnosis of emphysema] Kauczor HU, et al. **Pneumologie** 1998 Oct;52(10):563–7 (22 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Segmental bronchial atresia--a case report and a literature review. Ouzidane L, et al. **Eur J Pediatr Surg** 1999 Feb; 9(1):49–52 (16 ref.)

PATHOLOGY

Proteinase–antiproteinase imbalance in the pathogenesis of emphysema: the role of metalloproteinases in lung damage. Pardo A, et al. **Histol Histopathol** 1999 Jan;14(1):227–33 (76 ref.)

PHYSIOPATHOLOGY

Functional and morphological heterogeneity of emphysema and its implication for selection of patients for lung volume reduction surgery. Russi EW, et al. **Eur Respir J** 1999 Jul; 14(1):230–6 (48 ref.)

[The surgical physiopathology of essential pulmonary emphysema and volume–reduction intervention] Nazari S. **Minerva Chir** 1998 Nov;53(11):899–918 (36 ref.) (Eng. Abstr.) **(Ita)**

[Pulmonary hyperinflation. The functional and clinico–radiological criteria, mechanisms and surgery to reduce lung volume in severe emphysema] Spânu V, et al. **Pneumoftiziologia** 1998 Jan–Mar;47(1):29–35 (5 ref.) **(Rum)**

RADIOGRAPHY

Imaging of patients with severe emphysema considered for lung volume reduction surgery. Cleverley JR, et al. **Br J Radiol** 1999 Mar;72(855):227–35 (58 ref.)

Functional and morphological heterogeneity of emphysema and its implication for selection of patients for lung volume reduction surgery. Russi EW, et al. **Eur Respir J** 1999 Jul; 14(1):230–6 (48 ref.)

SURGERY

Lung volume reduction for emphysema and the Canadian Lung Volume Reduction Surgery (CLVR) Project. Miller JD, et al. **Can Respir J** 1999 Jan–Feb;6(1):26–32 (45 ref.)

Video–assisted thoracic surgery for lung volume reduction surgery. Fischel RJ, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):789–807, viii (41 ref.)

Late–stage emphysema: when medical therapy fails. Dasgupta A, et al. **Cleve Clin J Med** 1999 Jul–Aug; 66(7):415–7, 421–5 (41 ref.)

Surgical aspects and techniques of lung volume reduction surgery for severe emphysema. Klepetko W. **Eur Respir J** 1999 Apr;13(4):919–25 (42 ref.)

Physiological basis of improvement after lung volume reduction surgery for severe emphysema: where are we? [see comments] Marchand E, et al. **Eur Respir J** 1999 Mar; 13(3):686–96 (99 ref.) Comment in: Eur Respir J 1999 Mar;13(3):480–1.

Surgical lung volume reduction for severe pulmonary emphysema--a new review series [editorial; comment] Russi EW, et al. **Eur Respir J** 1999 Mar;13(3):480–1 (11 ref.) Comment on: Eur Respir J 1999 Mar;13(3):686–96.

Short– and long–term functional results after lung volume reduction surgery for severe emphysema. Teschler H, et al. **Eur Respir J** 1999 May;13(5):1170–6 (44 ref.)

Bullectomy for chronic obstructive pulmonary disease. Oo AY, et al. **Hosp Med** 1998 Oct;59(10):793–6 (14 ref.)

Lung volume reduction surgery for pulmonary emphysema [editorial; comment] Yoshida M. **Intern Med** 1999 Feb; 38(2):79 (10 ref.) Comment on: Intern Med 1999 Feb;38(2):119–25.

Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):518–28 (41 ref.)

Breathing in patients with bullous emphysema: why lung volume reduction may work. Pride NB. **Monaldi Arch Chest Dis** 1998 Aug;53(4):483–5 (17 ref.)

Surgical approaches to advanced emphysema. Edelman JD, et al. **Respir Care Clin N Am** 1998 Sep;4(3):513–39, x (98 ref.)

German Thoracic Research Scholarship 1996: lung volume reduction for endstage pulmonary emphysema at the Washington University of St. Louis. Moersig W. **Thorac Cardiovasc Surg** 1998 Jun;46(3):176–80 (28 ref.)

Lung volume reduction surgery. Geddes DM. **Thorax** 1999 Aug;54 Suppl 2:S14–8 (18 ref.)

[Lung volume reduction surgery. A new surgical therapeutic possibility for patients with emphysema] Stentoft P, et al. **Ugeskr Laeger** 1999 Feb 22;161(8):1095–9 (25 ref.) (Eng. Abstr.) **(Dan)**

[Anesthesia in lung volume reduction] Grundmann U, et al. **Anaesthesist** 1999 Feb;48(2):121–8 (29 ref.) **(Ger)**

[Surgical lung volume reduction--an option for treating severe pulmonary emphysema] Russi EW, et al. **Ther Umsch** 1999 Mar;56(3):157–60 (5 ref.) (Eng. Abstr.) **(Ger)**

[Lung transplantation in advanced pulmonary emphysema] Speich R, et al. **Ther Umsch** 1999 Mar;56(3):161–5 (4 ref.) (Eng. Abstr.) **(Ger)**

[The surgical physiopathology of essential pulmonary emphysema and volume–reduction intervention] Nazari S. **Minerva Chir** 1998 Nov;53(11):899–918 (36 ref.) (Eng. Abstr.) **(Ita)**

[Lung volume reduction--surgical alternative to the treatment of severe diffuse pulmonary emphysema?] Losso LC, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):246–52 (34 ref.) **(Por)**

PULMONARY EOSINOPHILIA

[Parasitic eosinophilic lungs] Vaylet F, et al. **Rev Pneumol Clin** 1998 Dec;54(6):329–39 (73 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary eosinophilia with asthma] Sebata K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):104–6 (15 ref.) **(Jpn)**

[Prolonged pulmonary eosinophilia] Yano H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):101–3 (15 ref.) **(Jpn)**

[Löffler's syndrome] Yano H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):98–100 (15 ref.) **(Jpn)**

CHEMICALLY INDUCED

Mesalazine–induced eosinophilic pneumonia. Tanigawa K, et al. **Respiration** 1999;66(1):69–72 (18 ref.)

DIAGNOSIS

A 57–year–old woman with pulmonary infiltrates and eosinophilia. Lobo A, et al. **Cleve Clin J Med** 1999 Jun; 66(6):335–9 (4 ref.)

[The eosinophilic lung] Miltgen J, et al. **Med Trop (Mars)** 1998;58(4 Suppl):447–53 (62 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[The eosinophilic lung] Miltgen J, et al. **Med Trop (Mars)** 1998;58(4 Suppl):447–53 (62 ref.) (Eng. Abstr.) **(Fre)**

[Chronic eosinophilic pneumonia associated with rheumatoid arthritis] Saito T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Apr;37(4):291–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis: current concepts [see comments] Ryu JH, et al. **Mayo Clin Proc** 1998 Nov; 73(11):1085–101 (127 ref.) Comment in: Mayo Clin Proc 1999 May;74(5):533–4.

CHEMICALLY INDUCED

Cellular and molecular mechanisms of asbestos–induced fibrosis. Robledo R, et al. **J Cell Physiol** 1999 Aug; 180(2):158–66 (99 ref.)

DIAGNOSIS

Idiopathic pulmonary fibrosis: prognostic indicators [editorial] Chhabra SK. **Indian J Chest Dis Allied Sci** 1998 Jul–Sep;40(3):159–61 (16 ref.)

[Pleural plaque fibrosis: a clinical case] Iovino F, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):273–6 (16 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Pharmacologic therapy of idiopathic pulmonary fibrosis. Egan J. **J Heart Lung Transplant** 1998 Nov;17(11):1039–44 (31 ref.)

[Current status of the treatment of idiopathic pulmonary fibrosis (editorial)] Agusti C, et al. **Arch Bronconeumol** 1998 Dec;34(11):517–9 (32 ref.) **(Spa)**

ETIOLOGY

Transforming growth factor–beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Gauldie J, et al. **Curr Top Pathol** 1999;93:35–45 (38 ref.)

Oxidant–induced lung injury in anticancer therapy. Beinert T, et al. **Eur J Med Res** 1999 Feb 25;4(2):43–53 (113 ref.)

The role of eosinophils in pulmonary fibrosis (Review). Gharaee–Kermani M, et al. **Int J Mol Med** 1998 Jan; 1(1):43–53 (133 ref.)

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099–104 (13 ref.)

Pulmonary toxicity of chemotherapy and G/GM–CSF: a report of five cases. Couderc LJ, et al. **Respir Med** 1999 Jan;93(1):65–8 (16 ref.)

The molecular basis of asbestos induced lung injury. Kamp DW, et al. **Thorax** 1999 Jul;54(7):638–52 (193 ref.)

In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many? Turner–Warwick M. **Thorax** 1998 Aug;53 Suppl 2:S3–9 (61 ref.)

[Growth factors in the process of inflammation and fibrosis in the lung] Matsuse T. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):413–20 (49 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[The lung as an immunologic organ] Ziesche R, et al. **Wien Klin Wochenschr Suppl** 1999;1:1–5 (34 ref.) (Eng. Abstr.) **(Ger)**

[Giant cell interstitial pneumonia] Barzó P, et al. **Orv Hetil** 1998 Dec 20;139(51):3079–83 (43 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Cell adhesion molecules and pulmonary fibrosis. Paine R 3rd, et al. **Am J Med** 1999 Sep;107(3):268–79 (81 ref.)

Role of transcription factors in inflammatory lung diseases. Rahman I, et al. **Thorax** 1998 Jul;53(7):601–12 (119 ref.)

PATHOLOGY

Airway remodeling: potential contributions of subepithelial fibrosis and airway smooth muscle hypertrophy/hyperplasia to airway narrowing in asthma. Bento AM, et al. **Allergy Asthma Proc** 1998 Nov–Dec; 19(6):353–8 (46 ref.)

Erdheim–Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Egan AJ, et al. **Am J Surg Pathol** 1999 Jan; 23(1):17–26 (24 ref.)

The myofibroblast as an inflammatory cell in pulmonary fibrosis. Phan SH, et al. **Curr Top Pathol** 1999;93:173–82 (57 ref.)

Dynamic interactions between lung fibroblasts and leukocytes: implications for fibrotic lung disease. Hogaboam CM, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):313–20 (57 ref.)

[The roles of apoptosis in lung injury and fibrosis] Kuwano K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Sep; 36(9):739–44 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Pathophysiology and respiratory therapy of chronic respiratory insufficiency in chronic pulmonary fibrosis] Fabel H. **Wien Klin Wochenschr Suppl** 1999;1:6–10 (6 ref.) **(Ger)**

RADIOGRAPHY

Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis. Wells A. **Thorax** 1998 Dec;53(12):1080–7 (67 ref.)

PULMONARY FUNCTION TESTS see **RESPIRATORY FUNCTION TESTS**

PULMONARY GAS EXCHANGE

Gas exchange in acute respiratory failure. Hedenstierna G, et al. **Minerva Anestesiol** 1999 Jun;65(6):383–7 (23 ref.)

Intravascular gas exchange. Keogh BF, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):38–42 (18 ref.)

PHYSIOLOGY

Support of gas exchange in the delivery room and beyond: how do we avoid hurting the baby we seek to save? Clark RH. **Clin Perinatol** 1999 Sep;26(3):669–81, vii–viii (68 ref.)

Gas exchange: large surface and thin barrier determine pulmonary diffusing capacity. Weibel ER. **Minerva Anestesiol** 1999 Jun;65(6):377–82 (19 ref.)

Biotransport in the human respiratory system. Elad D. **Technol Health Care** 1999;7(4):271–84 (68 ref.)

[Respiration and aging] Guenard H. **Rev Mal Respir** 1998 Dec;15(6):713–21 (86 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary diagnosis with model aerosols. II: Aerosol bolus dispersion--a marker for convection gas transport. Basic principles and initial clinical results] Kohlhäufl M, et al. **Pneumologie** 1999 Jan;53(1):50–6 (42 ref.) **(Ger)**

PULMONARY HEART DISEASE

DIAGNOSIS

[Chronic pulmonary heart disease. Epidemiology, physiopathology and clinical aspects] Orth M, et al. **Internist (Berl)** 1999 Jul;40(7):722–8 (49 ref.) **(Ger)**

[Diagnosis of chronic pulmonary heart disease] Perings C, et al. **Internist (Berl)** 1999 Jul;40(7):729–38 (49 ref.) **(Ger)**

EPIDEMIOLOGY

[Chronic pulmonary heart disease. Epidemiology, physiopathology and clinical aspects] Orth M, et al. **Internist (Berl)** 1999 Jul;40(7):722–8 (49 ref.) **(Ger)**

ETIOLOGY

[Acute pulmonary heart disease caused by pulmonary artery embolism] Heintzen MP, et al. **Internist (Berl)** 1999 Jul; 40(7):710–21 (42 ref.) **(Ger)**

[Pulmonary artery hypertension and obstructive sleep apnea. Pathophysiology and clinical relevance] Steiner S, et al. **Internist (Berl)** 1999 Jul;40(7):739–46 (61 ref.) **(Ger)**

SURGERY

Technical aspects of adult lung transplantation. Meyers BF,

et al. **Semin Thorac Cardiovasc Surg** 1998 Jul;10(3):213–20 (14 ref.)

THERAPY

[Long-term oxygen inhalation therapy and home artificial respiration for chronic pulmonary heart disease] Köhler D, et al. **Internist (Berl)** 1999 Jul;40(7):756–63 (62 ref.) **(Ger)**

PULMONARY INFARCTION see **PULMONARY EMBOLISM**

PULMONARY MACROPHAGES see **MACROPHAGES, ALVEOLAR**

PULMONARY MEDICINE see **PULMONARY DISEASE (SPECIALTY)**

PULMONARY NEOPLASMS see **LUNG NEOPLASMS**

PULMONARY NODULE, SOLITARY see **COIN LESION, PULMONARY**

PULMONARY SARCOIDOSIS see **SARCOIDOSIS, PULMONARY**

PULMONARY SEQUESTRATION see **BRONCHOPULMONARY SEQUESTRATION**

PULMONARY STENOSIS see **PULMONARY VALVE STENOSIS**

PULMONARY SURFACTANTS

Cytokines, pulmonary surfactant and consequences of intrauterine infection. Hallman M. **Biol Neonate** 1999 Jun; 76 Suppl 1:2–9 (52 ref.)

[The pulmonary surfactant system: physiology, pathologies associated with its alteration and exogenous administration as therapeutic and diagnostic agent] Calmanovici G, et al. **Acta Physiol Pharmacol Ther Latinoam** 1998;48(4):175–90 (72 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Liquid perfluorochemical priming before surfactant therapy: this time the egg really does precede the chicken [editorial; comment] Baumgart S, et al. **Crit Care Med** 1999 Sep; 27(9):2053–4 (15 ref.) Comment on: Crit Care Med 1999 Sep;27(9):1916–22.

BIOSYNTHESIS

Regulation of surfactant protein gene transcription. Whitsett JA, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):303–11 (50 ref.)

BLOOD

Partitioning lung and plasma proteins: circulating surfactant proteins as biomarkers of alveolocapillary permeability. Doyle IR, et al. **Clin Exp Pharmacol Physiol** 1999 Mar; 26(3):185–97 (110 ref.)

CHEMISTRY

Structure and properties of surfactant protein B. Hawgood S, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):150–60 (53 ref.)

Structure and properties of surfactant protein C. Johansson J. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):161–72 (41 ref.)

Structure, processing and properties of surfactant protein A. McCormack FX. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):109–31 (191 ref.)

Functional roles and structural analysis of lung collectins SP-A and SP-D. Kuroki Y, et al. **Biol Neonate** 1999 Jun; 76 Suppl 1:19–21 (4 ref.)

Use of knockout mice to study surfactant protein structure and function. Weaver TE, et al. **Biol Neonate** 1999 Jun;76 Suppl 1:15–8 (10 ref.)

DEFICIENCY

Primary surfactant deficiency [letter; comment] McCabe AJ, et al. **Crit Care Med** 1999 Jun;27(6):1219–21 (19 ref.) Comment on: Crit Care Med 1998 Mar;26(3):573–80.

Functional pulmonary surfactant deficiency and neonatal respiratory disorders. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:175–7 (8 ref.)

[Relation between pulmonary surfactants and asthma] Mu Y, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Oct;20(5):318–20 (15 ref.) **(Chi)**

DRUG EFFECTS

Effect of air pollutants on the pulmonary surfactant system. Müller B, et al. **Eur J Clin Invest** 1998 Sep;28(9):762–77 (179 ref.)

GENETICS

Genetics of the hydrophilic surfactant proteins A and D. Floros J, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):312–22 (53 ref.)

Regulation of expression of surfactant protein-A. Mendelson CR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):132–49 (59 ref.)

Genetics of the hydrophobic surfactant proteins. Nogee LM. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):323–33 (43 ref.)

IMMUNOLOGY

Structure, biologic properties, and expression of surfactant protein D (SP-D). Crouch EC. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):278–89 (72 ref.)

Surfactant protein A (SP-A) gene targeted mice. Korfhagen TR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):296–302 (46 ref.)

Interactions of surfactant protein D with pathogens, allergens and phagocytes. Reid KB. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):290–5 (34 ref.)

Lung surfactant proteins involved in innate immunity. Eggleton P, et al. **Curr Opin Immunol** 1999 Feb;11(1):28–33 (36 ref.)

Membrane receptors for soluble defense collagens. Tenner AJ. **Curr Opin Immunol** 1999 Feb;11(1):34–41 (79 ref.)

ISOLATION & PURIFICATION

Surfactant proteins A and D: disease markers. Kuroki Y, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):334–45 (47 ref.)

METABOLISM

Interactions of surfactant protein A with pathogens. Haagsman HP. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):264–77 (73 ref.)

Surfactant protein metabolism in vivo. Ikegami M, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):218–25 (41 ref.)

Structure, processing and properties of surfactant protein A. McCormack FX. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):109–31 (191 ref.)

Interfacial properties of surfactant proteins. Pérez-Gil J, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):203–17 (70 ref.)

Interactions of surfactant protein A with epithelial cells and phagocytes. Tino MJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):241–63 (112 ref.)

Synthesis, processing and secretion of surfactant proteins B and C. Weaver TE. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):173–9 (42 ref.)

Effect of air pollutants on the pulmonary surfactant system. Müller B, et al. **Eur J Clin Invest** 1998 Sep;28(9):762–77 (179 ref.)

Surfactant and acute lung injury. Jobe AH, et al. **Proc Assoc Am Physicians** 1998 Nov-Dec;110(6):489–95 (53 ref.)

PHYSIOLOGY

The alveolar surface network: a new anatomy and its physiological significance. Scarpelli EM. **Anat Rec** 1998 Aug;251(4):491–527 (125 ref.)

Pulmonary surfactant: functions and molecular composition. Goerke J. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):79–89 (80 ref.)

Structure and properties of surfactant protein B. Hawgood S, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):150–60 (53 ref.)

Formation and structure of surface films: captive bubble surfactometry. Schürch S, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):180–202 (56 ref.)

The role of lipids in pulmonary surfactant. Veldhuizen R, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):90–108 (80 ref.)

Functional roles and structural analysis of lung collectins SP-A and SP-D. Kuroki Y, et al. **Biol Neonate** 1999 Jun; 76 Suppl 1:19–21 (4 ref.)

Use of knockout mice to study surfactant protein structure and function. Weaver TE, et al. **Biol Neonate** 1999 Jun;76 Suppl 1:15–8 (10 ref.)

Respiratory mechanics and surfactant in the acute respiratory distress syndrome. Bersten AD, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):955–63 (76 ref.)

Evolution of surface activity related functions of vertebrate pulmonary surfactant. Daniels CB, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):716–21 (40 ref.)

Pulmonary surfactant in health and human lung diseases: state of the art. Griese M. **Eur Respir J** 1999 Jun;13(6):1455–76 (216 ref.)

Functional roles of the lung surfactant proteins SP-A and SP-D in innate immunity. Reid KB. **Immunobiology** 1998 Aug;199(2):200–7 (44 ref.)

Regulation and function of pulmonary surfactant protein B. Pryhuber GS. **Mol Genet Metab** 1998 Aug;64(4):217–28 (86 ref.)

Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Reed JA, et al. **Proc Assoc Am Physicians** 1998 Jul-Aug;110(4):321–32 (56 ref.)

The lipids of pulmonary surfactant: dynamics and interactions with proteins. Batenburg JJ, et al. **Prog Lipid Res** 1998 Sep;37(4):235–76 (462 ref.)

SECRETION

Regulatory mechanisms of surfactant secretion. Mason RJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):226–40 (99 ref.)

THERAPEUTIC USE

Principles of surfactant replacement. Robertson B, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):346–61 (72 ref.)

Surfactant lavage for the management of severe meconium aspiration syndrome. Lam BC. **Biol Neonate** 1999 Jun;76 Suppl 1:10–4 (37 ref.)

Is there a role for surfactant replacement therapy in adult pulmonary dysfunction? [editorial; comment] Warren WH. **Crit Care Med** 1998 Oct;26(10):1626–7 (18 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1660–2.

Surfactant replacement therapy. Yu V. **Indian Pediatr** 1998 Nov;35(11):1081–96 (126 ref.)

[For or against the early use of nasal continuous positive pressure and exogenous surfactant in hyaline membrane disease. Physiopathologic arguments] Storme L, et al. **Arch Pediatr** 1999 May;6(5):549–55 (60 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY SURGICAL PROCEDURES

Staging and surgery for non-small cell lung cancer (NSCLC). Alpard SK, et al. **Surg Oncol** 1998 Jul-Aug;7(1–2):25–43 (103 ref.)

PULMONARY THROMBOEMBOLISM see **PULMONARY EMBOLISM**

PULMONARY VALVE

Coagulase-negative staphylococcus endocarditis restricted to the normal pulmonic valve in a patient with end-stage renal disease: case report and review. Hussain KM, et al. **Clin Infect Dis** 1998 Dec;27(6):1550–2 (10 ref.)

TRANSPLANTATION

Aortic allografts and pulmonary autografts for replacement of the aortic valve and aortic root. Kouchoukos NT. **Ann Thorac Surg** 1999 Jun;67(6):1846–8; discussion 1853–6 (13 ref.)

Invited commentary on the Ross procedure. Oury JH. **J Card Surg** 1998 May;13(3):171–2 (3 ref.)

Options for right ventricular outflow tract reconstruction. Ross DN. **J Card Surg** 1998 May;13(3):186–9 (24 ref.)

PULMONARY VALVE ATRESIA see **PULMONARY ATRESIA**

PULMONARY VALVE STENOSIS

PHYSIOPATHOLOGY

Exercise testing in children with pulmonary valvar stenosis. Steinberger J, et al. **Pediatr Cardiol** 1999 Jan-Feb; 20(1):27–31; discussion 32 (17 ref.)

THERAPY

Simultaneous transcatheter valvuloplasty and Amplatzer septal occlusion for pulmonary valvar stenosis and secundum atrial septal defect. Yip WC, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):578–81 (11 ref.)

Long-term follow-up results after balloon dilatation of pulmonic stenosis, aortic stenosis, and coarctation of the aorta: a review. Rao PS. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):59–74 (58 ref.)

[Treatment of valve diseases] Stauffer JC. **Rev Med Suisse Romande** 1999 May;119(5):361–6 (12 ref.) **(Fre)**

PULMONARY VEINS

Contrast-enhanced magnetic resonance angiography of the pulmonary vasculature. A review. Kauczor HU. **Invest Radiol** 1998 Sep;33(9):606–17 (65 ref.)

[A successful surgical repair of mitral stenosis and regurgitation with pulmonary arteriovenous fistula] Inoue T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):757–61 (13 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Cyanotic congenital heart disease with increased pulmonary blood flow. Grifka RG. **Pediatr Clin North Am** 1999 Apr; 46(2):405–25 (65 ref.)

Cyanotic congenital heart disease with decreased pulmonary blood flow in children. Waldman JD, et al. **Pediatr Clin North Am** 1999 Apr;46(2):385–404 (15 ref.)

Meandering right pulmonary vein: a case of scimitar variant. Salazar-Mena J, et al. **Pediatr Radiol** 1999 Aug; 29(8):578–80 (9 ref.)

Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Shovlin CL, et al. **Thorax** 1999 Aug;54(8):714–29 (193 ref.)

[Neonatal hypoxemia due to misaligned pulmonary vessels

PULMONARY VEINS

with alveolar capillary dysplasia] Liet JM, et al. **Arch Pediatr** 1998 Jan;5(1):27-30 (13 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Ion channels in the pulmonary vasculature. Reeve HL, et al. **Pulm Pharmacol Ther** 1997 Oct-Dec;10(5-6):243-52 (99 ref.)

PATHOLOGY

Idiopathic pulmonary vein thrombosis: detection by CT and MR imaging. Selvidge SD, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1639-41 (10 ref.)

Magnetic resonance pulmonary angiography. Wielopolski PA. **Coron Artery Dis** 1999 May;10(3):157-75 (108 ref.)

[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172-4 (0 ref.) **(Ger)**

[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971-5 (18 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Pulmonary venous flow analysis after cardioversion [editorial; comment] Brecker SJ. **Eur Heart J** 1999 Mar; 20(5):323-4 (7 ref.) Comment on: Eur Heart J 1999 Mar;20(5):375-85.

RADIOGRAPHY

Idiopathic pulmonary vein thrombosis: detection by CT and MR imaging. Selvidge SD, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1639-41 (10 ref.)

Meandering right pulmonary vein: a case of scimitar variant. Salazar-Mena J, et al. **Pediatr Radiol** 1999 Aug; 29(8):578-80 (9 ref.)

[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172-4 (0 ref.) **(Ger)**

ULTRASONOGRAPHY

Predictive value of pulmonary venous flow patterns in detecting mitral regurgitation and left ventricular abnormalities. Hynes MS, et al. **Can J Cardiol** 1999 Jun; 15(6):665-70 (24 ref.)

PULMONARY VENO-OCCLUSIVE DISEASE

PHYSIOPATHOLOGY

Pulmonary veno-occlusive disease. Veeraraghavan S, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):310-3 (33 ref.)

PULMONARY VENTILATION

Inspiratory flow rate: more may not be better [editorial; comment] Jubran A. **Crit Care Med** 1999 Apr;27(4):670-1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):715-22.

Prone position in acute respiratory distress syndrome: turning over an old idea [editorial; comment] Trottier SJ. **Crit Care Med** 1998 Dec;26(12):1934-5 (20 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1977-85.

Assessing the effect of deep inhalation on airway calibre: a novel approach to lung function in bronchial asthma and COPD. Pellegrino R, et al. **Eur Respir J** 1998 Nov; 12(5):1219-27 (87 ref.)

DRUG EFFECTS

Pharmacological modulators of respiratory control. Casaburi R. **Monaldi Arch Chest Dis** 1998 Jun;53(3):287-93 (99 ref.)

PHYSIOLOGY

On the barometric method for measurements of ventilation, and its use in small animals [comment] Mortola JP, et al. **Can J Physiol Pharmacol** 1998 Oct-Nov;76(10-11):937-44 (30 ref.) Comment on: Can J Physiol Pharmacol 1998 Oct-Nov;76(10-11):945-51.

Methods and clinical significance of studying chemical drives. De Backer WA. **Respir Physiol** 1998 Oct; 114(1):75-81 (41 ref.)

Time domains of the hypoxic ventilatory response. Powell FL, et al. **Respir Physiol** 1998 May;112(2):123-34 (45 ref.)

PULMONIC PLAGUE see **PLAGUE**

PULMONOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PULP CANAL see **DENTAL PULP CAVITY**

PULP CAPPING see **DENTAL PULP CAPPING**

PULP CHAMBER see **DENTAL PULP CAVITY**

PULPITIS

ULTRASONOGRAPHY

[Dental pulp diseases. Ultramicroscopic studies] Conversini A, et al. **Minerva Stomatol** 1998 Dec;47(12):631-48 (445 ref.) (Eng. Abstr.) **(Ita)**

PULPOTOMY

ADVERSE EFFECTS

Odontogenic cysts related to pulpotomized deciduous molars: clinical features and treatment outcome. Lustig JP, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):499-503 (15 ref.)

PULSATILE FLOW

Molecular and cellular changes in vein grafts: influence of pulsatile stretch. Powell JT, et al. **Curr Opin Cardiol** 1998 Nov;13(6):453-8 (27 ref.)

PHYSIOLOGY

Physiology of nonpulsatile circulation: acute versus chronic support. Jett GK. **ASAIO J** 1999 May-Jun;45(3):119-22 (41 ref.)

Arterial pressure, vascular input impedance, and resistance as determinants of pulsatile blood flow in the umbilical artery. Adamson SL. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):119-25 (24 ref.)

PULSE

Positive association between resting pulse and cancer incidence in current and former smokers. Cerhan JR, et al. **Ann Epidemiol** 1999 Jan;9(1):34-44 (31 ref.)

Right-sided pulsus alternans in diastolic left ventricular dysfunction [see comments] Ilia R, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):336-9 (10 ref.) Comment in: Catheter Cardiovasc Interv 1999 Jul;47(3):340.

Takayasu arteritis--beyond pulselessness. Numano F, et al. **Intern Med** 1999 Mar;38(3):226-32 (41 ref.)

Pulse wave analysis and arterial stiffness. Wilkinson IB, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S33-7 (35 ref.)

Influence of arterial pulse and reflective waves on systolic blood pressure and cardiac function. London GM, et al. **J Hypertens Suppl** 1999 Jun;17(2):S3-6 (13 ref.)

Hypertension corner. Wide pulse pressure: diagnostic, prognostic and therapeutic implications [editorial] Birbari AE. **J Med Liban** 1998 Nov-Dec;46(6):303-5 (22 ref.)

Pulse transit time: an appraisal of potential clinical applications. Smith RP, et al. **Thorax** 1999 May;54(5):452-7 (27 ref.)

PULSE OXIMETRY see **OXIMETRY**

PULSED DYE LASER LITHOTRIPSY see **LITHOTRIPSY, LASER**

PULSELESS DISEASE see **TAKAYASU'S ARTERITIS**

PUMPING, INTRA-AORTIC BALLOON see **INTRA-AORTIC BALLOON PUMPING**

PUMPS, HEART-ASSIST see **HEART-ASSIST DEVICES**

PUMPS, INFUSION see **INFUSION PUMPS**

PUNCTURE BIOPSY see **BIOPSY, NEEDLE**

PUNCTURES

see related
PARACENTESIS

The pneumoperitoneum and its role in tumor seeding. Reymond MA, et al. **Dig Surg** 1998;15(2):105-9 (48 ref.)

Pneumatosis cystoides intestinalis: confirmation of diagnosis by endoscopic puncture a review of pathogenesis, associated disease and therapy and a new theory of cyst formation. Höer J, et al. **Endoscopy** 1998 Nov;30(9):793-9 (83 ref.)

The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation [editorial] Parsonnet V, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):695-7 (17 ref.)

[Puncture, catheterization and drainage. 1] Straubel U, et al. **Zentralbl Chir** 1998;123(8):955-65 (0 ref.) **(Ger)**

ADVERSE EFFECTS

Tongue piercing and associated tooth fracture. Botchway C, et al. **J Can Dent Assoc** 1998 Dec;64(11):803-5 (9 ref.)

Body piercing medical concerns with cutting-edge fashion. Koenig LM, et al. **J Gen Intern Med** 1999 Jun;14(6):379-85 (77 ref.)

INSTRUMENTATION

[Puncture, catheterization and drainage. 2] Straubel U, et al. **Zentralbl Chir** 1998;123(9):1043-53 (22 ref.) **(Ger)**

METHODS

[Endosonography-guided puncture: useful or dangerous?] Napoléon B. **Gastroenterol Clin Biol** 1999 May;23(5):459-62 (20 ref.) **(Fre)**

PUPIL

see related
MIOTICS
REFLEX, PUPILLARY

PUPIL NURSES see **STUDENTS, NURSING**

PUPILLARY FUNCTIONS, ABNORMAL

DIAGNOSIS

Neuro-ophthalmology of pupillary function--practical guidelines. Wilhelm H. **J Neurol** 1998 Sep;245(9):573-83 (70 ref.)

PUPPET CHILDREN see **ANGELMAN SYNDROME**

PUPPETS see **PLAY AND PLAYTHINGS**

PURE RED-CELL APLASIA see **RED-CELL APLASIA, PURE**

PURGATIVES see **CATHARTICS**

PURINE-NUCLEOSIDE PHOSPHORYLASE

DEFICIENCY

[PNP deficiency] Sato T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):228-31 (16 ref.) **(Jpn)**

PURINE NUCLEOTIDES

METABOLISM

Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Hatse S, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):539-55 (177 ref.)

Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleotide synthesis: studies with ribose, adenine, inosine, and orotic acid in rats. Zimmer HG. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:179-87 (41 ref.)

PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS

DIAGNOSIS

[New neurometabolic disorders: indicative clinical signs] Garcia-Silva MT. **Rev Neurol** 1999 Jan 1-15;28(1):4-11 (33 ref.) (Eng. Abstr.) **(Spa)**

PURINE RECEPTORS see **RECEPTORS, PURINERGIC**

PURINERGIC P1 RECEPTORS see **RECEPTORS, PURINERGIC P1**

PURINERGIC P2 RECEPTORS see **RECEPTORS, PURINERGIC P2**

PURINERGIC RECEPTORS see **RECEPTORS, PURINERGIC**

PURINES

ADMINISTRATION & DOSAGE

Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Lennard L. **Ther Drug Monit** 1998 Oct;20(5):527-31 (33 ref.)

ANALYSIS

The answer is (gently) blowing in the wind? [editorial; comment] Marelich GP, et al. **Crit Care Med** 1999 Apr; 27(4):687-8 (9 ref.) Comment on: Crit Care Med 1999 Apr;27(4):779-83.

BIOSYNTHESIS

Expanded (CAG)n, (CGG)n and (GAA)n trinucleotide repeat microsatellites, and mutant purine synthesis and pigmentation genes cause schizophrenia and autism. Fischer KM. **Med Hypotheses** 1998 Sep;51(3):223-33 (89 ref.)

METABOLISM

Receptors for purines and pyrimidines. Ralevic V, et al. **Pharmacol Rev** 1998 Sep;50(3):413-92 (1009 ref.)

PHARMACOLOGY

Purines, a new class of agonists in salivary glands? Dehaye JP, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S39–43 (23 ref.)

Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Lennard L. **Ther Drug Monit** 1998 Oct;20(5):527–31 (33 ref.)

PURINOCEPTORS see **RECEPTORS, PURINERGIC**

PURKINJE CELLS

CHEMISTRY

The cells and molecules that make a cerebellum. Goldowitz D, et al. **Trends Neurosci** 1998 Sep;21(9):375–82 (88 ref.)

CYTOLOGY

The cells and molecules that make a cerebellum. Goldowitz D, et al. **Trends Neurosci** 1998 Sep;21(9):375–82 (88 ref.)

METABOLISM

Neurosteroids in the cerebellar Purkinje neuron and their actions (review). Tsutsui K, et al. **Int J Mol Med** 1999 Jul;4(1):49–56 (60 ref.)

PHYSIOLOGY

Cellular mechanisms of cerebellar LTD. Daniel H, et al. **Trends Neurosci** 1998 Sep;21(9):401–7 (63 ref.)

PURKINJE FIBERS

DRUG EFFECTS

Pharmacological stress testing of the His–Purkinje system in patients with bifascicular block. Englund A, et al. **Pacing Clin Electrophysiol** 1998 Oct;21(10):1979–87 (73 ref.)

PURPLE MEMBRANE

see related
BACTERIORHODOPSIN

PURPURA

[Autoerythrocyte sensitization (Gardner–Diamond syndrome)] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):400–2 (5 ref.) **(Jpn)**

[Purpura simplex] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):416–7 (2 ref.) **(Jpn)**

[Scurvy, Möller–Barlow disease] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):405–7 (8 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Drug-induced purpura] Kikuta A, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):412–5 (12 ref.) **(Jpn)**

[Corticosteroid purpura] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):403–4 (7 ref.) **(Jpn)**

ETIOLOGY

Autoerythrocyte sensitization (psychogenic purpura): a case report and review of the literature. Anderson JE, et al. **Pediatr Emerg Care** 1999 Feb;15(1):47–8 (4 ref.)

[Infection and vascular purpura] Levesque H, et al. **J Mal Vasc** 1999 Jun;24(3):177–82 (30 ref.) (Eng. Abstr.) **(Fre)**

[Senile purpura] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):418–9 (1 ref.) **(Jpn)**

[DNA autosensitivity] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):397–9 (6 ref.) **(Jpn)**

PATHOLOGY

Splenic peliosis: a rare complication following liver transplantation. Raghavan R, et al. **Dig Dis Sci** 1999 Jun;44(6):1128–31 (24 ref.)

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. Cather JC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):858–63 (54 ref.)

PURPURA FULMINANS see **PURPURA, SCHOENLEIN–HENOCH**

PURPURA HEMORRHAGICA see **PURPURA, SCHOENLEIN–HENOCH**

PURPURA, HYPERGLOBULINEMIC

[Hypergammaglobulinemic purpura] Ito M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):531–3 (13 ref.) **(Jpn)**

PURPURA, NONTHROMBOCYTOPENIC see **PURPURA, SCHOENLEIN–HENOCH**

PURPURA, SCHOENLEIN–HENOCH

Infectious purpura fulminans: diagnosis and treatment. Smith OP, et al. **Br J Haematol** 1999 Feb;104(2):202–7 (50 ref.)

[Henoch–Schönlein purpura] Kikuta A, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):408–11 (16 ref.) **(Jpn)**

COMPLICATIONS

Henoch–Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Rieu P, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):151–9 (48 ref.)

Intra-abdominal manifestations of Henoch–Schönlein purpura. Choong CK, et al. **J Paediatr Child Health** 1998 Oct;34(5):405–9 (75 ref.)

Henoch–Schönlein purpura and pulmonary hemorrhage: a report and literature review. Vats KR, et al. **Pediatr Nephrol** 1999 Aug;13(6):530–4 (23 ref.)

Colo–colic intussusception in Henoch–Schönlein purpura. Choong CK, et al. **Pediatr Surg Int** 1998 Dec;14(3):173–4 (25 ref.)

[Multiple amputations due to sepsis: however, functional rehabilitation is possible] Hacking HG, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1073–7 (11 ref.) (Eng. Abstr.) **(Dut)**

DIAGNOSIS

Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch–Schönlein purpura. Szer IS. **Cleve Clin J Med** 1999 May;66(5):312–7 (16 ref.)

ETIOLOGY

Purpura fulminans associated with Streptococcus pneumoniae infection in a child. Cnota JF, et al. **Pediatr Emerg Care** 1999 Jun;15(3):187–8 (17 ref.)

PHYSIOPATHOLOGY

[Where are we with purpura fulminans? (editorial)] Huault G. **Arch Pediatr** 1998 Oct;5(10):1061–4 (24 ref.) **(Fre)**

THERAPY

Henoch–Schönlein purpura. Tizard EJ. **Arch Dis Child** 1999 Apr;80(4):380–3 (34 ref.)

Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch–Schönlein purpura. Szer IS. **Cleve Clin J Med** 1999 May;66(5):312–7 (16 ref.)

PURPURA, THROMBOCYTOPENIC

[Neonatal alloimmune thrombocytopenic purpura (NAITP)] Matsuzaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):303–6 (15 ref.) **(Jpn)**

BLOOD

Reticulated platelet counts in the assessment of thrombocytopenic disorders. Saxon BR, et al. **Acta Paediatr Suppl** 1998 Jun;424:65–70 (39 ref.)

Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura. Moake JL, et al. **J Clin Apheresis** 1998;13(3):126–32 (28 ref.)

CONGENITAL

The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Bussel J, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):391–408 (36 ref.)

DIAGNOSIS

[Idiopathic thrombocytopenic purpura in adults: diagnostic and therapeutic problems] Urasiński I. **Pol Arch Med Wewn** 1998 Jul;100(1):82–8 (36 ref.) **(Pol)**

IMMUNOLOGY

The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Bussel J, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):391–408 (36 ref.)

THERAPY

Immune ablation and stem cell transplantation for severe Evans syndrome and refractory thrombocytopenic purpura. Marmont AM. **Bone Marrow Transplant** 1999 Jun;23(12):1215–6 (26 ref.)

[Idiopathic thrombocytopenic purpura in adults: diagnostic and therapeutic problems] Urasiński I. **Pol Arch Med Wewn** 1998 Jul;100(1):82–8 (36 ref.) **(Pol)**

PURPURA, THROMBOCYTOPENIC, AUTOIMMUNE see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

PURPURA, THROMBOCYTOPENIC, IDIOPATHIC

Immune thrombocytopenic purpura in pregnancy. Christiaens GC. **Baillieres Clin Haematol** 1998 Jun;11(2):373–80 (34 ref.)

Immune thrombocytopenic purpura in adults: clinical aspects. Gillis S, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):361–72 (77 ref.)

Immune-mediated thrombocytopenias: basic and immunological aspects. Porcelijn L, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):331–41 (36 ref.)

Acute autoimmune thrombocytopenia. Sutor AH, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):381–9 (40 ref.)

Immune thrombocytopenic purpura ITP. Imbach P, et al. **Vox Sang** 1998;74 Suppl 2:309–14 (64 ref.)

[Acute idiopathic thrombocytopenic purpura] Ando Y. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):284–6 (5 ref.) **(Jpn)**

[Idiopathic thrombocytopenic purpura in childhood] Miyata H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):293–8 (16 ref.) **(Jpn)**

[Corticosteroid resistant idiopathic thrombocytopenic purpura] Murai K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):299–302 (11 ref.) **(Jpn)**

[Chronic idiopathic thrombocytopenic purpura] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):289–92 (19 ref.) **(Jpn)**

BLOOD

Chronic immune thrombocytopenic purpura in childhood. Kühne T, et al. **Semin Thromb Hemost** 1998;24(6):549–53 (50 ref.)

Acute immune thrombocytopenia in childhood. Are we treating the platelet count? Sutor AH. **Semin Thromb Hemost** 1998;24(6):545–8 (42 ref.)

CHEMICALLY INDUCED

Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Glynne P, et al. **Am J Kidney Dis** 1999 Jan;33(1):133–7 (22 ref.)

Drug-induced immune thrombocytopenia: an overview of pathogenesis. Aster RH. **Semin Hematol** 1999 Jan;36(1 Suppl 1):2–6 (38 ref.)

COMPLICATIONS

Idiopathic thrombocytopenic purpura associated with breast cancer: a case report and review of the current literature. Porrata LF, et al. **Am J Clin Oncol** 1999 Aug;22(4):411–3 (5 ref.)

Idiopathic thrombocytopenic purpura preceding malignant lymphoma: report of one case. Lin WC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 Jan–Feb;40(1):39–42 (17 ref.)

Massive intracranial bleeding requiring emergency splenectomy in a patient with CMV-associated thrombocytopenia. Gural A, et al. **Haemostasis** 1998 Sep–Oct;28(5):250–5 (16 ref.)

[A case of mitral valve replacement combined with idiopathic thrombocytopenic purpura (ITP)] Goshima M, et al. **Kyobu Geka** 1999 Jul;52(7):573–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Two cases of autoimmune thrombocytopenic purpura associated with antiphospholipid antibodies. Moccia F. **Ann Ital Med Int** 1999 Apr–Jun;14(2):114–7 (29 ref.)

Idiopathic thrombocytopenic purpura: guidance amid uncertainty. Lichtin A. **Cleve Clin J Med** 1998 Nov–Dec;65(10):510–4 (7 ref.)

DRUG THERAPY

Immune thrombocytopenic purpura: why treat? [editorial; comment] Nugent DJ. **J Pediatr** 1999 Jan;134(1):3–4 (15 ref.) Comment on: J Pediatr 1999 Jan;134(1):21–6.

ETIOLOGY

Drug-induced immune thrombocytopenia: an overview of pathogenesis. Aster RH. **Semin Hematol** 1999 Jan;36(1 Suppl 1):2–6 (38 ref.)

[Autoimmune thrombocytopenia following syngeneic peripheral blood stem cell transplantation] Nishio M, et al. **Rinsho Ketsueki** 1998 Aug;39(8):580–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Cytokines in idiopathic thrombocytopenic purpura (ITP). Andersson J. **Acta Paediatr Suppl** 1998 Jun;424:61–4 (23 ref.)

Role of complement in immune or idiopathic thrombocytopenic purpura. Hed J. **Acta Paediatr Suppl** 1998 Jun;424:37–40 (20 ref.)

Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP). Hedlund–Treutiger I, et al. **Acta Paediatr Suppl** 1998 Jun;424:46–50 (35 ref.)

Analysis of transmembrane signalling and T cell defects associated with idiopathic thrombocytopenic purpura (ITP). Lazarus AH, et al. **Acta Paediatr Suppl** 1998 Jun;424:21–5 (29 ref.)

Platelet function in autoimmune (idiopathic) thrombocytopenic purpura. Rand ML, et al. **Acta Paediatr Suppl** 1998 Jun;424:57–60 (40 ref.)

Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Semple JW. **Acta Paediatr Suppl** 1998 Jun;424:41–5 (48 ref.)

Platelet proteins as autoantibody targets in idiopathic thrombocytopenic purpura. Wadenvik H, et al.

Acta Paediatr Suppl 1998 Jun;424:26–36 (113 ref.)
Measurement of platelet antibodies: where do we stand? Winiarski J. **Acta Paediatr Suppl** 1998 Jun;424:51–3 (11 ref.)
Mechanisms in childhood idiopathic thrombocytopenic purpura (ITP). Winiarski J. **Acta Paediatr Suppl** 1998 Jun; 424:54–6 (22 ref.)

THERAPY

Current management issues of childhood and adult immune thrombocytopenic purpura (ITP). Kühne T, et al. **Acta Paediatr Suppl** 1998 Jun;424:75–81 (74 ref.)
Idiopathic thrombocytopenic purpura: guidance amid uncertainty. Lichtin A. **Cleve Clin J Med** 1998 Nov–Dec; 65(10):510–4 (7 ref.)
Clinical uses of intravenous immunoglobulin in pregnancy. Clark AL. **Clin Obstet Gynecol** 1999 Jun;42(2):368–80 (97 ref.)
Acute immune thrombocytopenia in childhood. Are we treating the platelet count? Sutor AH. **Semin Thromb Hemost** 1998;24(6):545–8 (42 ref.)
[Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects] Böcher A, et al. **Med Klin** 1998 Dec 15;93(12):707–18 (144 ref.) (Eng. Abstr.) **(Ger)**

PURPURA, THROMBOPENIC see **PURPURA, THROMBOCYTOPENIC**

PURPURA, THROMBOTIC THROMBOCYTOPENIC

Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Eldor A. **Baillieres Clin Haematol** 1998 Jun;11(2):475–95 (115 ref.)
[Thrombotic thrombocytopenic purpura] Ieko M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):40–2 (15 ref.) **(Jpn)**

CHEMICALLY INDUCED

Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature [see comments] Chen DK, et al. **Arch Intern Med** 1999 Feb 8;159(3):311–4 (26 ref.) Comment in: Arch Intern Med 1999 Jul 26;159(14):1624.
Thrombotic thrombocytopenic purpura associated with ticlopidine therapy. Leavey SF, et al. **J Am Soc Nephrol** 1997 Apr;8(4):689–93 (26 ref.)
Ticlopidine-induced thrombotic thrombocytopenic purpura. Muszkat M, et al. **Pharmacotherapy** 1998 Nov–Dec; 18(6):1352–5 (22 ref.)

COMPLICATIONS

Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Sutor GC, et al. **Infection** 1999 Jan–Feb; 27(1):12–5 (45 ref.)

DIAGNOSIS

Diagnosis and management of thrombotic microangiopathies during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):360–7 (32 ref.)
Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: diagnosis and management. George JN, et al. **J Clin Apheresis** 1998;13(3):120–5 (33 ref.)
Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Musio F, et al. **Semin Arthritis Rheum** 1998 Aug;28(1):1–19 (71 ref.)

EPIDEMIOLOGY

Thrombotic thrombocytopenia purpura: a single institution experience. Ramanan AS, et al. **J Clin Apheresis** 1999; 14(1):9–13 (11 ref.)

ETIOLOGY

Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Gordon LI, et al. **Semin Thromb Hemost** 1999;25(2):217–21 (82 ref.)
[Thrombotic microangiopathy in hematopoietic stem cell transplantation] Miwa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):611–8 (19 ref.) **(Jpn)**

IMMUNOLOGY

Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects. Porta C, et al. **Haematologica** 1999 Mar;84(3):260–9 (107 ref.)
[Gastrointestinal cancer-associated antigen (GICA) and intravascular hemolysis. Report of 2 cases and review of the literature] Bianconcini G, et al. **Minerva Med** 1999 Mar; 90(3):73–9 (98 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Death due to thrombotic thrombocytopenic purpura in pregnancy: case report with review of thrombotic microangiopathies of pregnancy. Kemp WL, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):189–98 (30 ref.)
Thrombotic microangiopathy: a challenge with uncertain outcome. Kulzer P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2154–60 (29 ref.)

PHYSIOPATHOLOGY

Pathophysiology and management of thrombotic microangiopathies. Ruggenenti P, et al. **J Nephrol** 1998 Nov–Dec;11(6):300–10 (58 ref.)
Thrombotic microangiopathy: a challenge with uncertain outcome. Kulzer P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2154–60 (29 ref.)

THERAPY

Treatment of thrombotic thrombocytopenic purpura with the cryosupernatant fraction of plasma: a case report and review of the literature. Ellis J, et al. **Am J Med Sci** 1999 Sep;318(3):190–3 (31 ref.)
Diagnosis and management of thrombotic microangiopathies during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):360–7 (32 ref.)
Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: diagnosis and management. George JN, et al. **J Clin Apheresis** 1998;13(3):120–5 (33 ref.)
Apheresis and the thrombotic thrombocytopenic purpura syndrome: current advances in diagnosis, pathophysiology, and management. Brailey LL, et al. **Ther Apher** 1999 Feb; 3(1):20–4 (37 ref.)

PURPURA, THROMBOTIC THROMBOPENIC see **PURPURA, THROMBOTIC THROMBOCYTOPENIC**

PURSUIT, SACCADIC see **SACCADES**

PUSTULANTS see **IRRITANTS**

PUSTULAR DERMATOSIS, SUBCORNEAL see **SKIN DISEASES, VESICULOBULLOUS**

PUSTULAR PSORIASIS OF PALMS AND SOLES see **PSORIASIS**

PUSTULOSIS OF PALMS AND SOLES see **PSORIASIS**

PUSTULOSIS PALMARIS ET PLANTARIS see **PSORIASIS**

PUTAMEN

DRUG EFFECTS

[Motor neuropathy, putamen necrosis and optic nerve atrophy after acute methanol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1998 Dec;154(12):862–5 (12 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Intracerebral Whipple's disease diagnosed by stereotactic biopsy: a case report and review of the literature. Mendel E, et al. **Neurosurgery** 1999 Jan;44(1):203–9 (32 ref.)

RADIOGRAPHY

[Motor neuropathy, putamen necrosis and optic nerve atrophy after acute methanol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1998 Dec;154(12):862–5 (12 ref.) (Eng. Abstr.) **(Fre)**

PUUMALA VIRUS see **HANTAVIRUS**

PUVA THERAPY

Subcorneal pustular dermatosis treated with PUVA therapy. A case report and review of the literature. Bauwens M, et al. **Dermatology** 1999;198(2):203–5 (18 ref.)
Immunomodulation induced by psoralen plus ultraviolet A radiation. Aubin F, et al. **Eur J Dermatol** 1998 Apr–May; 8(3):212–3 (29 ref.)
Acitretin in combination with UVB or PUVA. Lebwohl M. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S22–4 (10 ref.)
Strategy for treatment of psoriasis: systemic treatments. Dubertret L. **J Dermatol** 1998 Dec;25(12):788–92 (0 ref.)
Modulation of cytokine production by 8-methoxypsoralen and UVA. Tokura Y. **J Dermatol Sci** 1999 Feb;19(2):114–22 (56 ref.)
Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Redding SW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):183–7 (28 ref.)
HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)

ADVERSE EFFECTS

Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? Lindelöf B. **Drug Saf** 1999 Apr;20(4):289–97 (115 ref.)
Improving the safety profile of long-term PUVA therapy [editorial; comment] Hobbs J, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):496–7 (20 ref.) Comment on: J Am Acad Dermatol 1999 Sep;41(3 Pt 1):408–13.
Malignant melanoma in patients treated for psoriasis with PUVA. Stern RS. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):37–8 (6 ref.)

METHODS

Efficacy and safety of treatment modalities for psoriasis. Tristani-Firouzi P, et al. **Cutis** 1998 Feb;61(2 Suppl):11–21 (69 ref.)

TRENDS

PUVA therapy: current concerns in Japan. Danno K. **J Dermatol Sci** 1999 Feb;19(2):89–105 (138 ref.)

PVP-IODINE see **POVIDONE-IODINE**

PYELOGRAPHY see **UROGRAPHY**

PYELONEPHRITIS

see related
KIDNEY FAILURE, CHRONIC

[Acute-chronic pyelonephritis] Kaneko S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):514–8 (16 ref.) **(Jpn)**
[Emphysematous pyelonephritis] Yuri T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):519–22 (14 ref.) **(Jpn)**

DIAGNOSIS

[Emphysematous pyelonephritis: apropos of 4 cases] Rocher L, et al. **J Radiol** 1999 Mar;80(3):297–302 (15 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Antibiotic treatment of acute pyelonephritis in the child] Bégué P. **Arch Pediatr** 1998;5 Suppl 3:296S–301S (29 ref.) (Eng. Abstr.) **(Fre)**
[Antibiotic therapy of acute pyelonephritis: which treatment to offer?] Gaudelus J. **Arch Pediatr** 1999;6 Suppl 2:403s–405s (10 ref.) **(Fre)**
[Current role of aminoglycosides in the treatment of acute pyelonephritis] Caron F. **Prog Urol** 1998 Dec;8(6):1077–9 (6 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Etiology and therapy of chronic pyelonephritis] Nihei H, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1305–10 (5 ref.) **(Jpn)**

PATHOLOGY

[Parenchymatous cicatrix and urinary tract infection: physiopathology and clinical implications] Cochat P, et al. **Arch Pediatr** 1998;5 Suppl 3:290S–295S (48 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

[Role of DMSA scintigraphy in managing pediatric pyelonephritis] Girardin E, et al. **Arch Pediatr** 1998;5 Suppl 3:285S–289S (15 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Pyelonephritis. Wing DA. **Clin Obstet Gynecol** 1998 Sep; 41(3):515–26 (38 ref.)

ULTRASONOGRAPHY

[Ultrasonic methods in the diagnosis and treatment of pyelonephritis] Petrov DA, et al. **Urol Nefrol (Mosk)** 1998 Sep–Oct;(5):48–51 (98 ref.) **(Rus)**

PYELONEPHRITIS, XANTHOGRANULOMATOUS

Xanthogranulomatous pyelonephritis. Gregg CR, et al. **Curr Clin Top Infect Dis** 1999;19:287–304 (63 ref.)

PYGATHRIX see **CERCOPITHECIDAE**

PYGMY RIGHT WHALE see **WHALES**

PYGMY SPERM WHALE see **WHALES**

PYKNOLEPSY see **EPILEPSY, ABSENCE**

PYLORIC GLANDS see **GASTRIC MUCOSA**

PYLORIC STENOSIS

SURGERY

Laparoscopic pyloromyotomy. Downey EC Jr. **Semin Pediatr Surg** 1998 Nov;7(4):220–4 (18 ref.)

ULTRASONOGRAPHY

Emergency abdominal ultrasound in children: current concepts. Mendelson KL. **Med Health R I** 1999 Jun; 82(6):198–201 (22 ref.)

PYLORUS

see related
GASTRIC EMPTYING

ABNORMALITIES

[Double pylorus. Description of two new cases and survey of the literature] Tola M, et al. **Minerva Chir** 1998 Oct; 53(10):801–5 (44 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Laparoscopic pyloromyotomy. Downey EC Jr. **Semin Pediatr Surg** 1998 Nov;7(4):220–4 (18 ref.)

PYODERMA

[Ecthyma vulgare, ecthyma gangrenosum, chancriform pyoderma] Yamamoto Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):579–81 (6 ref.) **(Jpn)**

DIAGNOSIS

Pyodermatitis–pyostomatitis vegetans: report of a case and review of the literature. Soriano ML, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):322–6 (35 ref.)

PYODERMA GANGRENOSUM

Pyoderma gangrenosum affecting the foot. A case report. Archer JV, et al. **J Am Podiatr Med Assoc** 1999 Mar; 89(3):141–2 (8 ref.)

Pyoderma gangrenosum involving the foot. A case report. Kashefsky H, et al. **J Am Podiatr Med Assoc** 1999 Mar; 89(3):137–40 (9 ref.)

[Ecthyma vulgare, ecthyma gangrenosum, chancriform pyoderma] Yamamoto Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):579–81 (6 ref.) **(Jpn)**

DIAGNOSIS

[Pyoderma gangrenosum with an atypical location and a rapid response to cyclosporin A] Ferrer Rios T, et al. **Gastroenterol Hepatol** 1999 May;22(5):227–9 (16 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Pyoderma gangrenosum with an atypical location and a rapid response to cyclosporin A] Ferrer Rios T, et al. **Gastroenterol Hepatol** 1999 May;22(5):227–9 (16 ref.) (Eng. Abstr.) **(Spa)**

PYONEPHROSIS see **PYELONEPHRITIS**

PYORRHEA ALVEOLARIS see **PERIODONTAL DISEASES**

PYOTHORAX see **EMPYEMA, PLEURAL**

PYRAMIDAL CELLS

PHYSIOLOGY

Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Andrade R. **Ann N Y Acad Sci** 1998 Dec 15;861:190–203 (81 ref.)

PYRAMIDAL TRACTS

[A case of hereditary motor and sensory neuropathy with pyramidal tract sign, optic nerve atrophy and mental retardation] Adachi T, et al. **Rinsho Shinkeigaku** 1998 Dec; 38(12):1037–41 (15 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

Role of L1 in neural development: what the knockouts tell us. Kamiguchi H, et al. **Mol Cell Neurosci** 1998 Sep; 12(1–2):48–55 (54 ref.)

GROWTH & DEVELOPMENT

Axon guidance of outgrowing corticospinal fibres in the rat. Joosten EA, et al. **J Anat** 1999 Jan;194 (Pt 1):15–32 (99 ref.)

PHYSIOLOGY

Motor areas on the medial wall of the hemisphere. Strick PL, et al. **Novartis Found Symp** 1998;218:64–75; discussion 75–80, 104–8 (42 ref.)

PHYSIOPATHOLOGY

Surgical monitoring of motor pathways [see comments] Burke D, et al. **J Clin Neurophysiol** 1998 May;15(3):194–205 (75 ref.) Comment in: J Clin Neurophysiol 1998 May;15(3):181–2.

PYRAZINAMIDE

ADMINISTRATION & DOSAGE

[Short-course chemotherapy of tuberculosis with pyrazinamide] Asai S, et al. **Nippon Rinsho** 1998 Dec; 56(12):3087–90 (9 ref.) (Eng. Abstr.) **(Jpn)**

PYRAZINES

PHARMACOLOGY

Chemopreventive effects of 2-(allylthio)pyrazine. Kim ND, et al. **Arch Pharm Res** 1999 Apr;22(2):99–107 (65 ref.)

Development of cancer chemopreventive agents: oltipraz as a paradigm. Kensler TW, et al. **Chem Res Toxicol** 1999 Feb;12(2):113–26 (113 ref.)

Antiproliferative, differentiating and apoptotic effects elicited by imidazo[1,2–a]pyrazine derivatives. Zurbonsen K, et al. **Gen Pharmacol** 1999 Jan;32(1):135–41 (31 ref.)

[Status quo of experimental and clinical studies in retarding kidney damage of chronic nephropathy by ligustrazine] Cao WF, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 May; 17(5):314–5 (22 ref.) **(Chi)**

PYRAZINOPYRIMIDINES see **PTERIDINES**

PYRAZOLES

METABOLISM

Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Shire D, et al. **Life Sci** 1999; 65(6–7):627–35 (35 ref.)

PYRENES

ANALYSIS

Urinary 1-hydroxypyrene and other PAH metabolites as biomarkers of exposure to environmental PAH in air particulate matter. Strickland P, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):191–9 (53 ref.)

PYRETHRINS

Can anything be done to maintain the effectiveness of pyrethroid-impregnated bednets against malaria vectors? Curtis CF, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Oct 29;353(1376):1769–75 (46 ref.)

ADVERSE EFFECTS

Urticaria due to airborne permethrin exposure. Fuortes L. **Vet Hum Toxicol** 1999 Apr;41(2):92–3 (16 ref.)

PYRETHRUM

see related
PYRETHRINS

PYREXIA see **FEVER**

PYRIDINES

ADVERSE EFFECTS

The safety and tolerability of zolpidem--an update. Darcourt G, et al. **J Psychopharmacol** 1999;13(1):81–93 (150 ref.)

CHEMISTRY

Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Thaisrivongs S, et al. **Biopolymers** 1999;51(1):51–8 (50 ref.)

METABOLISM

Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Chouinard G, et al. **Cell Mol Neurobiol** 1999 Aug;19(4):533–52 (90 ref.)

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6–7):511–8 (17 ref.)

PHARMACOKINETICS

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Mück W. **Drugs** 1998;56 Suppl 1:15–23; discussion 33 (49 ref.)

PHARMACOLOGY

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Mück W. **Drugs** 1998;56 Suppl 1:15–23; discussion 33 (49 ref.)

Cicletanine: new insights into its pharmacological actions. Kalinowski L, et al. **Gen Pharmacol** 1999 Jul;33(1):7–16 (67 ref.)

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. Decker MW, et al. **J Physiol Paris** 1998 Jun–Aug;92(3–4):221–4 (17 ref.)

Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Rush CR. **Pharmacol Biochem Behav** 1998 Nov;61(3):253–69 (154 ref.)

[Epibatidine. An old work principle rediscovered] Hecker T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):226–32 (41 ref.) **(Ger)**

THERAPEUTIC USE

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. Bischoff H, et al. **Atherosclerosis** 1998 Sep;139 Suppl 1:S7–13 (22 ref.)

Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety. Stein E. **Atherosclerosis** 1998 Sep;139 Suppl 1:S15–22 (25 ref.)

Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin. Leiter LA, et al. **Can J Cardiol** 1999 May;15(5):545–55 (38 ref.)

Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC Jr. **J Hypertens Suppl** 1999 Feb; 17(1):S37–43 (49 ref.)

[Changes in sedative therapy?] Shnädelbach S. **Med Monatsschr Pharm** 1998 Dec;21(12):391–2 (7 ref.) **(Ger)**

PYRIDINIUM COMPOUNDS

Monitoring secretory membrane with FM1-43 fluorescence. Cochilla AJ, et al. **Annu Rev Neurosci** 1999;22:1–10 (76 ref.)

METABOLISM

Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. Castagnoli N Jr, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):31–8 (40 ref.)

PYRIDINONES see **PYRIDONES**

PYRIDONES

CHEMICAL SYNTHESIS

The 2-pyridone antibacterial agents: 8-position modifications. Fung AK, et al. **Curr Pharm Des** 1999 Jul; 5(7):515–43 (21 ref.)

THERAPEUTIC USE

[Iron chelation in 1998] de Montalembert M. **Transfus Clin Biol** 1998 Oct;5(5):353–6 (7 ref.) (Eng. Abstr.) **(Fre)**

PYRIDOXAL

ANALOGS & DERIVATIVES

Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs [letter; comment] Richardson DR, et al. **J Lab Clin Med** 1998 Oct; 132(4):351–2 (8 ref.) Comment on: J Lab Clin Med 1998 Apr;131(4):290–1.

Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Richardson DR. **Leuk Lymphoma** 1998 Sep;31(1–2):47–60 (73 ref.)

PYRIDOXAL PHOSPHATE

ANALOGS & DERIVATIVES

Unexpected MR–T1 enhancement of endocrine liver metastases with mangafodipir. Mathieu D, et al. **J Magn Reson Imaging** 1999 Aug;10(2):193–5 (15 ref.)

METABOLISM

Update on interconversions of vitamin B-6 with its coenzyme. McCormick DB, et al. **J Nutr** 1999 Feb; 129(2):325–7 (33 ref.)

PYRIDOXAMINE

METABOLISM

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Khalifah RG, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):251–8 (65 ref.)

PYRIDOXINE

Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine. Powers HJ. **Proc Nutr Soc** 1999 May;58(2):435–40 (47 ref.)

CHEMISTRY

Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Mason RP. **Curr Med Chem** 1999 Jun;6(6):481–99 (175 ref.)

METABOLISM

Structure, evolution and action of vitamin B6-dependent enzymes. Jansonius JN. **Curr Opin Struct Biol** 1998 Dec; 8(6):759–69 (59 ref.)

Update on interconversions of vitamin B-6 with its coenzyme. McCormick DB, et al. **J Nutr** 1999 Feb; 129(2):325–7 (33 ref.)

Hypertension, calcium channel and pyridoxine (vitamin B6).

PYRIDOXINE

Dakshinamurti K, et al. **Mol Cell Biochem** 1998 Nov; 188(1-2):137-48 (68 ref.)

PHYSIOLOGY

B vitamins and homocysteine in cardiovascular disease and aging. Wilcken DE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:361-70 (29 ref.)

THERAPEUTIC USE

Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. Wyatt KM, et al. **BMJ** 1999 May 22;318(7195):1375-81 (52 ref.)

Non-nutritional uses of vitamin B6. Bender DA. **Br J Nutr** 1999 Jan;81(1):7-20 (174 ref.)

Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness [editorial] Marangella M. **Nephrol Dial Transplant** 1999 Feb; 14(2):301-3 (13 ref.)

PYRIDOXINE DEFICIENCY

see related
ANEMIA, SIDEROBLASTIC

METABOLISM

Hypertension, calcium channel and pyridoxine (vitamin B6). Dakshinamurti K, et al. **Mol Cell Biochem** 1998 Nov; 188(1-2):137-48 (68 ref.)

PYRIMETHAMINE

THERAPEUTIC USE

[Empirical anti-toxoplasma therapy in cerebral AIDS and Chagas disease. Presentation of 2 cases, review of the literature and proposal of an algorithm] Montero A, et al. **Medicina (B Aires)** 1998;58(5 Pt 1):504-6 (19 ref.) (Eng. Abstr.) **(Spa)**

PYRIMIDINE DIMERS

Base excision repair of cyclobutane pyrimidine dimers. Lloyd RS. **Mutat Res** 1998 Sep 11;408(3):159-70 (118 ref.)

The initiation of DNA base excision repair of dipyrimidine photoproducts. Lloyd RS. **Prog Nucleic Acid Res Mol Biol** 1999;62:155-75 (109 ref.)

METABOLISM

Roles of the DNA mismatch repair and nucleotide excision repair proteins during meiosis. Kirkpatrick DT. **Cell Mol Life Sci** 1999 Mar;55(3):437-49 (112 ref.)

PYRIMIDINE NUCLEOTIDES

METABOLISM

Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Hatse S, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):539-55 (177 ref.)

Basis of pyrimidine nucleotide metabolism in the myocardium. Rossi A, et al. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:171-7 (47 ref.)

Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleotide synthesis: studies with ribose, adenine, inosine, and orotic acid in rats. Zimmer HG. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:179-87 (41 ref.)

PYRIMIDINES

BIOSYNTHESIS

Regulation of the Bacillus subtilis pyrimidine biosynthetic operon by transcriptional attenuation: control of gene expression by an mRNA-binding protein. Switzer RL, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:329-67 (82 ref.)

METABOLISM

Receptors for purines and pyrimidines. Ralevic V, et al. **Pharmacol Rev** 1998 Sep;50(3):413-92 (1009 ref.)

THERAPEUTIC USE

Developments in fluoropyrimidine therapy for gastrointestinal cancer. Van Cutsem E, et al. **Curr Opin Oncol** 1999 Jul;11(4):312-7 (44 ref.)

PYROCATECHOLS see **CATECHOLS**

PYROCOCCUS

GENETICS

Archaeon Pyrococcus kodakaraensis KOD1: application and evolution. Fujiwara S, et al. **Biotechnol Annu Rev** 1998; 4:259-84 (85 ref.)

ISOLATION & PURIFICATION

Archaeon Pyrococcus kodakaraensis KOD1: application and evolution. Fujiwara S, et al. **Biotechnol Annu Rev** 1998; 4:259-84 (85 ref.)

PYROCOCCUS FURIOSUS

METABOLISM

Sugar utilization and its control in hyperthermophiles. de Vos WM, et al. **Extremophiles** 1998 Aug;2(3):201-5 (23 ref.)

PYROGENS

Afferent pathways of pyrogen signaling. Blatteis CM, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:95-107 (87 ref.)

Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Dinarello CA. **Ann N Y Acad Sci** 1998 Sep 29;856:1-11 (84 ref.)

BLOOD

Sudden infant death syndrome: hypothalamic failure to sense elevated blood pyrogens. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):569-75 (69 ref.)

METABOLISM

Pyrogen transfer across PMMA membranes. Cappelli G, et al. **Contrib Nephrol** 1999;125:233-9 (41 ref.)

PHYSIOLOGY

Cytokines as endogenous pyrogens. Dinarello CA. **J Infect Dis** 1999 Mar;179 Suppl 2:S294-304 (116 ref.)

TOXICITY

Tolerance to pyrogens. Zeisberger E, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:116-31 (54 ref.)

PYROGLUTAMATE AMINOPEPTIDASE see **PYROGLUTAMYL-PEPTIDASE I**

PYROGLUTAMYL-PEPTIDASE I

PHYSIOLOGY

Pyroglutamyl peptidase: an overview of the three known enzymatic forms. Cummins PM, et al. **Biochim Biophys Acta** 1998 Dec 8;1429(1):1-17 (181 ref.)

PYRONES

CHEMISTRY

Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Thaisrivongs S, et al. **Biopolymers** 1999;51(1):51-8 (50 ref.)

Kojic acid--a new leading molecule for a preparation of compounds with an anti-neoplastic potential. Novotný L, et al. **Neoplasma** 1999;46(2):89-92 (30 ref.)

PHARMACOLOGY

Kojic acid--a new leading molecule for a preparation of compounds with an anti-neoplastic potential. Novotný L, et al. **Neoplasma** 1999;46(2):89-92 (30 ref.)

PYROPHOSPHATASES

Inorganic polyphosphate: a molecule of many functions. Kornberg A. **Prog Mol Subcell Biol** 1999;23:1-18 (60 ref.)

CHEMISTRY

H+-proton-pumping inorganic pyrophosphatase: a tightly membrane-bound family. Baltscheffsky M, et al. **FEBS Lett** 1999 Jun 11;452(3):121-7 (64 ref.)

METABOLISM

H+-proton-pumping inorganic pyrophosphatase: a tightly membrane-bound family. Baltscheffsky M, et al. **FEBS Lett** 1999 Jun 11;452(3):121-7 (64 ref.)

H+ -PPases: a tightly membrane-bound family. Baltscheffsky M, et al. **FEBS Lett** 1999 Sep 3;457(3):527-33 (64 ref.)

Cytoplasmic inorganic pyrophosphatase. Baykov AA, et al. **Prog Mol Subcell Biol** 1999;23:127-50 (97 ref.)

PYROPHOSPHATES see **DIPHOSPHATES**

PYROSIS see **HEARTBURN**

PYRROLES

[Atorvastatin . A new generation of hypolipemic agents?] Azanza JR, et al. **Rev Med Univ Navarra** 1998 Jan-Mar; 42(1):51-5 (35 ref.) **(Spa)**

METABOLISM

Structure and mechanism of enzymes involved in the assembly of the tetrapyrrole macrocycle. Shoolingin-Jordan PM. **Biochem Soc Trans** 1998 Aug; 26(3):326-36 (43 ref.)

Novel insights in the control of tetrapyrrole metabolism of higher plants. Grimm B. **Curr Opin Plant Biol** 1998 Jun; 1(3):245-50 (39 ref.)

PHARMACOLOGY

Cannabimimetic indoles, pyrroles and indenes. Huffman JW. **Curr Med Chem** 1999 Aug;6(8):705-20 (49 ref.)

THERAPEUTIC USE

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Malinowski JM. **Am J Health Syst Pharm** 1998 Nov 1;55(21):2253-67; quiz 2302-3 (90 ref.)

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS, et al. **Ann Pharmacother** 1998 Oct;32(10):1030-43 (99 ref.)

PYRROLIDINES

PHARMACOLOGY

Muscarinic antagonists in development for disorders of smooth muscle function. Wallis RM, et al. **Life Sci** 1999; 64(6-7):395-401 (19 ref.)

PYRROLIDINONES

PHARMACOLOGY

[Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways] Yoshii M, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:41P-43P (5 ref.) (Eng. Abstr.) **(Jpn)**

PYRROLIDONECARBOXYLATE PEPTIDASE see **PYROGLUTAMYL-PEPTIDASE I**

PYRROLIDONES see **PYRROLIDINONES**

PYRROLIDONYL PEPTIDASE see **PYROGLUTAMYL-PEPTIDASE I**

PYRROLIZIDINE ALKALOIDS

CHEMISTRY

Pyrrolizidine alkaloids in human diet. Prakash AS, et al. **Mutat Res** 1999 Jul 15;443(1-2):53-67 (126 ref.)

TOXICITY

Pyrrolizidine alkaloid plants, metabolism and toxicity. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):95-116 (155 ref.)

Pyrrolizidine alkaloids in human diet. Prakash AS, et al. **Mutat Res** 1999 Jul 15;443(1-2):53-67 (126 ref.)

PYRUVALDEHYDE

METABOLISM

Methylglyoxal production in bacteria: suicide or survival? Ferguson GP, et al. **Arch Microbiol** 1998 Oct;170(4):209-18 (50 ref.)

On the promine/retine theory of cell division: now and then. Kalapos MP. **Biochim Biophys Acta** 1999 Jan 4;1426(1):1-16 (149 ref.)

Protective mechanisms against toxic electrophiles in Escherischia coli. Ferguson GP. **Trends Microbiol** 1999 Jun;7(6):242-7 (23 ref.)

[Participation of glyoxalases and methylglyoxal in diabetic complication development] Piskorska D, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):342-4 (20 ref.) (Eng. Abstr.) **(Pol)**

PYRUVATE see **PYRUVIC ACID**

PYRUVATE DEHYDROGENASE COMPLEX

CHEMISTRY

Swinging arms in multifunctional enzymes and the specificity of post-translational modification. Perham RN, et al. **Biochem Soc Trans** 1998 Aug;26(3):299-303 (47 ref.)

IMMUNOLOGY

Antigen peptide analog: induction of T cell anergy in primary biliary cirrhosis. Ishibashi H, et al. **Intern Med** 1999 Feb; 38(2):173-5 (12 ref.)

[New therapeutic strategy for autoimmune diseases. 1) An antigenic peptide analog] Ishibashi H, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1735-40 (9 ref.) **(Jpn)**

METABOLISM

Pyruvate dehydrogenase complex activation status and acetyl group availability as a site of interchange between anaerobic and oxidative metabolism during intense exercise. Greenhaff PL, et al. **Adv Exp Med Biol** 1998;441:287-98 (51 ref.)

Swinging arms in multifunctional enzymes and the specificity of post-translational modification. Perham RN, et al. **Biochem Soc Trans** 1998 Aug;26(3):299-303 (47 ref.)

PYRUVATE KINASE

see related
ANEMIA, HEMOLYTIC

Structure, function and regulation of pyruvate carboxylase. Jitrapakdee S, et al. **Biochem J** 1999 May 15;340 (Pt 1):1–16 (231 ref.)

DEFICIENCY

The molecular basis of disorders of red cell enzymes. McMullin MF. **J Clin Pathol** 1999 Apr;52(4):241–4 (19 ref.)

GENETICS

Regulation of pyruvate kinase M gene expression. Yamada K, et al. **Biochem Biophys Res Commun** 1999 Mar 16; 256(2):257–62 (63 ref.)

Hematologically important mutations: red cell pyruvate kinase (2nd update). Baronciani L, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):273–9 (41 ref.)

The molecular basis of disorders of red cell enzymes. McMullin MF. **J Clin Pathol** 1999 Apr;52(4):241–4 (19 ref.)

METABOLISM

A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate. McCarty MF. **Med Hypotheses** 1999 Feb;52(2):89–93 (41 ref.)

PYRUVATES

PHARMACOLOGY

Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling' the oxidation of fatty acids. McCarty MF, et al. **Med Hypotheses** 1999 May; 52(5):407–16 (97 ref.)

PYRUVIC ACID

THERAPEUTIC USE

Pyruvate: beyond the marketing hype. Sukala WR. **Int J Sport Nutr** 1998 Sep;8(3):241–9 (36 ref.)

PYTHIUM

Penicilliosis marneffei and pythiosis: emerging tropical diseases. Kaufman L. **Mycopathologia** 1998;143(1):3–7 (28 ref.)

PYURIA

CHEMICALLY INDUCED

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Perazella MA, et al. **Clin Nephrol** 1998 Sep;50(3):194–6 (8 ref.)

PYY PEPTIDE see **PEPTIDE YY**

Q FEVER

[Chronic Q fever] Oda H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):252–4 (11 ref.) **(Jpn)**

[Acute Q fever] Ohnishi K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):249–51 (16 ref.) **(Jpn)**

DIAGNOSIS

Q fever during pregnancy: a public health problem in southern France. Stein A, et al. **Clin Infect Dis** 1998 Sep; 27(3):592–6 (24 ref.)

[Coxiella burnetii endocarditis. A report of the first case diagnosed in Mexico] Sahagún Sánchez G, et al. **Arch Inst Cardiol Mex** 1998 Jul–Aug;68(4):322–7 (26 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Q fever in Bulgaria and Slovakia. Serbezov VS, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):388–94 (40 ref.)

Advances in the understanding of Coxiella burnetii infection in Japan. Hirai K, et al. **J Vet Med Sci** 1998 Jul;60(7):781–90 (81 ref.)

MICROBIOLOGY

Developmental biology of Coxiella burnettii. Heinzen RA, et al. **Trends Microbiol** 1999 Apr;7(4):149–54 (32 ref.)

VETERINARY

Advances in the understanding of Coxiella burnetii infection in Japan. Hirai K, et al. **J Vet Med Sci** 1998 Jul;60(7):781–90 (81 ref.)

QALY see **QUALITY-ADJUSTED LIFE YEARS**

QIGONG see **BREATHING EXERCISES**

QUACKERY

[Herbs for atopic dermatitis: phytotherapy of the sorcerer's apprentice or a fake and culpable mascarade] Piérard GE, et al. **Rev Med Liege** 1999 Jun;54(6):539–40 (22 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

[Unconventional diagnostic and therapeutic methods in environmental medicine] Oepen I. **Gesundheitswesen** 1998 Jul;60(7):420–30 (64 ref.) (Eng. Abstr.) **(Ger)**

QUADRIGEMINAL PLATE see **CORPORA QUADRIGEMINA**

QUADRIPLEGIA

Moral dilemmas of tetraplegia; the 'locked-in' syndrome, the persistent vegetative state and brain death. Firsching R. **Spinal Cord** 1998 Nov;36(11):741–3 (17 ref.)

CHEMICALLY INDUCED

[Renal tubular acidosis with severe hypokalemic tetraparesis after ibuprofen intake] Gaul C, et al. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):483–6 (15 ref.) (Eng. Abstr.) **(Ger)**

[Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease] Uno S, et al. **Rinsho Ketsueki** 1999 May;40(5):414–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

MR appearance of an intracranial dural arteriovenous fistula leading to cervical myelopathy. Hähnel S, et al. **Neurology** 1998 Oct;51(4):1131–5 (10 ref.)

SURGERY

[Surgical management of tetraplegia [see comments] Bühren V, et al. **Unfallchirurg** 1999 Jan;102(1):2–12 (37 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1999 Jan;102(1):1. **(Ger)**

QUALITY-ADJUSTED LIFE YEARS

Economic Notes: opportunity cost. Palmer S, et al. **BMJ** 1999 Jun 5;318(7197):1551–2 (9 ref.)

Economic evaluation of cancer treatments: a review of the methods. Brown J. **Clin Oncol (R Coll Radiol)** 1999; 11(2):78–83 (42 ref.)

A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Brazier J, et al. **Health Econ** 1999 Feb;8(1):41–51 (51 ref.)

A review of the use of health status measures in economic evaluation. Brazier J, et al. **Health Technol Assess** 1999; 3(9):i–iv, 1–164 (1135 ref.)

The value of utility: assumptions underlying preferences and quality adjusted life years [editorial] [see comments] Guillemin F. **J Rheumatol** 1999 Sep;26(9):1861–3 (20 ref.) Comment in: J Rheumatol 1999 Sep;26(9):1859–60.

QUALITY ASSESSMENT, HEALTH CARE see **QUALITY ASSURANCE, HEALTH CARE**

QUALITY ASSURANCE, HEALTH CARE

The role of the health care team in the implementation of the National Kidney Foundation-Dialysis Outcomes Quality Initiative: a case study. Callahan MB, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):42–51 (34 ref.)

An overview of the National Kidney Foundation-Dialysis Outcomes Quality Initiative Implementation. Eknoyan G, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):3–6 (14 ref.)

Access to quality cancer care: consensus statement of the American Federation of Clinical Oncologic Societies. Edwards MJ. **Ann Surg Oncol** 1998 Oct–Nov;5(7):657–9 (0 ref.)

Optimizing the cost-effectiveness of quality assurance in transfusion medicine. AuBuchon JP. **Arch Pathol Lab Med** 1999 Jul;123(7):603–6 (12 ref.)

Performance improvement in transfusion medicine. What do nurses need and want? Mancini ME. **Arch Pathol Lab Med** 1999 Jun;123(6):496–502 (14 ref.)

Quality assurance in screening programmes. Gray JA, et al. **Br Med Bull** 1998;54(4):983–92 (5 ref.)

Damage pattern as a function of radiation quality and other factors. Burkart W, et al. **C R Acad Sci III** 1999 Feb–Mar; 322(2–3):89–101 (18 ref.)

Towards quality assurance of postgraduate training in radiology. Needham G. **Clin Radiol** 1999 Mar;54(3):140–3 (9 ref.)

Assessing the quality of psychiatric care: research methods and application in clinical practice. Dickey B, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):88–96 (67 ref.)

Assessing the performance of community systems for children. DuPlessis HM, et al. **Health Serv Res** 1998 Oct; 33(4 Pt 2):1111–42 (84 ref.)

Current issues in mammographic breast cancer screening. Rickard MT. **Hosp Med** 1999 May;60(5):325–8 (25 ref.)

Internal quality control and external quality assurance in the IVF laboratory. Matson PL. **Hum Reprod** 1998 Dec;13 Suppl 4:156–65 (50 ref.)

Good medical practice in antipsychotic pharmacotherapy. Peuskens J. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S35–41 (32 ref.)

Should UK emergency physicians undertake diagnostic ultrasound examinations? Robinson NA, et al. **J Accid Emerg Med** 1999 Jul;16(4):248–9 (21 ref.)

Infective endocarditis: how well are we managing our patients? [editorial; comment] Muhlestein JB. **J Am Coll Cardiol** 1999 Mar;33(3):794–5 (7 ref.) Comment on: J Am Coll Cardiol 1999 Mar;33(3):788–93.

Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? Morton DL, et al. **J Am Coll Surg** 1999 Aug; 189(2):214–23 (93 ref.)

Quality assurance in the dental profession [see comments] Brothwell DJ. **J Can Dent Assoc** 1998 Nov;64(10):726–31 (37 ref.) Comment in: J Can Dent Assoc 1999 Feb;65(2):80–1.

Strategies to improve diabetes care delivery. Peterson KA, et al. **J Fam Pract** 1998 Nov;47(5 Suppl):S55–62 (43 ref.)

American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning. Fraass B, et al. **Med Phys** 1998 Oct;25(10):1773–829 (81 ref.)

The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)

Administrative data for quality improvement. Schwartz RM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):291–301 (30 ref.)

Quality assurance in mammography: artifact analysis. Hogge JP, et al. **Radiographics** 1999 Mar–Apr;19(2):503–22 (15 ref.)

Quality control and artifacts in mammography. Newman J. **Radiol Technol** 1998 Sep–Oct;70(1):61–76; quiz 77–80 (27 ref.)

Improving the use of therapeutic drug monitoring. Bates DW. **Ther Drug Monit** 1998 Oct;20(5):550–5 (26 ref.)

[From quality circles to evidence-based clinical practice--a status article on quality development. I. Concepts, methods and strategies] Kjaergaard J, et al. **Ugeskr Laeger** 1998 Nov 9;160(46):6638–43 (31 ref.) (Eng. Abstr.) **(Dan)**

[From quality circles to evidence-based clinical practice--a status article on quality development. III. Responsibility and tasks] Knudsen JL, et al. **Ugeskr Laeger** 1998 Nov 23;160(48):6945–50 (34 ref.) **(Dan)**

[Documentation. A prerequisite for quality management] Krämer KL. **Orthopade** 1999 Mar;28(3):191–200 (59 ref.) (Eng. Abstr.) **(Ger)**

[MRI follow-up in multiple sclerosis. A guideline for quality assurance] Gass A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):581–6 (51 ref.) (Eng. Abstr.) **(Ger)**

[Quality measures in interventional radiology] Heuser L. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):131–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Quality aspects in internal medicine--from anamnesis to meta-analysis] Battegay M, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24;87(51–52):1785–92 (22 ref.) (Eng. Abstr.) **(Ger)**

[Dealing with errors in medicine] Schoenenberger RA, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24; 87(51–52):1793–7 (23 ref.) (Eng. Abstr.) **(Ger)**

[Systematic scientific quality improvement in surgical specialties. The AQS mode] Rageth JC, et al. **Swiss Surg** 1999;5(2):62–72 (23 ref.) (Eng. Abstr.) **(Ger)**

[Management of polytrauma patients in an international comparison] Oestern HJ. **Unfallchirurg** 1999 Feb; 102(2):80–91 (60 ref.) (Eng. Abstr.) **(Ger)**

[Recommendations for clinicopathologic quality standards in gastroenterology and hepatology. Consensus report of the Austrian Society of Gastroenterology ahd Hepatology and the Austrian Society of Pathology] Wrba F, et al. **Z Gastroenterol** 1998 Oct;36(10):917–23 (5 ref.) **(Ger)**

[Quality recommendations of the German Society of Rheumatology. Basis for further responsibilities] Keitel W. **Z Rheumatol** 1998 Oct;57(5):355–7 (17 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance under professional law and law relating to health services physicians and doctors] Ratzel R. **Zentralbl Gynakol** 1998;120(12):581–3 (8 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance and risk management in gynecology and obstetrics] Ulsenheimer K. **Zentralbl Gynakol** 1998; 120(12):593–7 (4 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance of department administration] Lichtenberg SM, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):983–6 (10 ref.) **(Nor)**

[Quality development in health care--time for strategic choices! Open account challenging but inevitable] Calltorp J. **Lakartidningen** 1999 May 26;96(21):2566–8 (17 ref.) **(Swe)**

[Better assessment of the patients results in better nursing home care. A new system for development of geriatric care is being introduced] Ljunggren G. **Lakartidningen** 1998 Nov 4;95(45):4997–5000 (27 ref.) **(Swe)**

[Quality assurance of the quality work! Poor basic data can totally twist the results] Nilsson G, et al. **Lakartidningen** 1999 Feb 3;96(5):494–7 (16 ref.) **(Swe)**

[Health care safety should be focused on prevention. Lessons to be learned from aviation, nuclear power plants and

offshore industries] Odegård S. **Lakartidningen** 1999 Jun 23;96(25):3068–73 (19 ref.) (Eng. Abstr.) **(Swe)**

[Quality registries are a gold-mine of information that should be better used. Knowledge of improvement is acquired by means of special projects] Sachs MA, et al. **Lakartidningen** 1999 May 19;96(20):2438–40 (16 ref.) **(Swe)**

[Follow up of pediatric care is a good resource of knowledge that can be even better] Sjögren LH, et al. **Lakartidningen** 1999 Mar 10;96(10):1201–5 (10 ref.) **(Swe)**

CLASSIFICATION

Scoring systems in the measurement of performance of ICUs. Miranda DR. **Intensive Care Med** 1999 Apr;25(4):418–9 (4 ref.)

ECONOMICS

The cost of implementing the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines. Wish J, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):67–74 (34 ref.)

Getting the incentives right for children. Glied S. **Health Serv Res** 1998 Oct;33(4 Pt 2):1143–60 (35 ref.)

[Quality assurance for rational diagnosis and therapy in dermatology] Korting HC, et al. **Hautarzt** 1998 Oct; 49(10):755–61 (19 ref.) (Eng. Abstr.) **(Ger)**

[Economic evaluation within the scope of clinical studies] Walshe R, et al. **Internist (Berl)** 1998 Sep;39(9):943–54 (72 ref.) **(Ger)**

LEGISLATION & JURISPRUDENCE

The 1997 amendments to the IDEA: improving the quality of special education for children with disabilities. Annino P. **Ment Phys Disabil Law Rep** 1999 Jan–Feb;23(1):125–8 (53 ref.)

[Indicators for quality evaluation of inpatient patient care in an ENT clinic (see comments)] Streppel M, et al. **HNO** 1998 Oct;46(10):864–9 (15 ref.) (Eng. Abstr.) Comment in: HNO 1998 Oct;46(10):840–1. **(Ger)**

[Current prenatal care with reference to state of the art knowledge] Vogt HP. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1654–66 (42 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Practical guide to measuring adequacy of dialysis. Blake PG. **Adv Ren Replace Ther** 1999 Jan;6(1):80–4 (12 ref.)

Beyond screening: improving the quality of treatment for depression. Wang P. **Harv Rev Psychiatry** 1999 Sep–Oct; 7(3):177–82 (31 ref.)

Overview of issues in improving quality of care for children. McGlynn EA, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):977–1000 (69 ref.)

Assessing the quality of healthcare provided to children. Mangione-Smith R, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1059–90 (80 ref.)

Methodological challenges for measuring quality of care at the end of life. Fowler FJ Jr, et al. **J Pain Symptom Manage** 1999 Feb;17(2):114–9 (7 ref.)

For every numerator, you need a denominator: a simple statement but key to measuring the quality of care of the "dying". Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):109–13 (9 ref.)

Is health care ready for Six Sigma quality? Chassin MR. **Milbank Q** 1998;76(4):565–91, 510 (62 ref.)

GMP in blood collection and processing. Wagstaff W. **Vox Sang** 1998;74 Suppl 2:513–21 (4 ref.)

Quality of care for women: where are we now and where are we headed? McGlynn EA. **Womens Health Issues** 1999 Mar–Apr;9(2):65–80; discussion 93–106 (22 ref.)

ORGANIZATION & ADMINISTRATION

The "new VA": a national laboratory for health care quality management. Kizer KW. **Am J Med Qual** 1999 Jan–Feb; 14(1):3–20 (108 ref.)

Assurance opportunities for local health departments. Reid WM, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):128–33 (18 ref.)

The Safe Motherhood Initiative: why has it stalled? Maine D, et al. **Am J Public Health** 1999 Apr;89(4):480–2 (18 ref.)

The rise of doctor-patient working groups. Williamson C. **BMJ** 1998 Nov 14;317(7169):1374–7 (31 ref.)

Using outcomes to improve quality of research and quality of care. Deyo RA. **J Am Board Fam Pract** 1998 Nov–Dec; 11(6):465–73 (53 ref.)

Managing the clinic wait: an important quality of care challenge. Rondeau KV. **J Nurs Care Qual** 1998 Dec; 13(2):11–20 (24 ref.)

The uses of comparative information in perinatal care. Gagnon DE. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S6–9 (5 ref.)

Total quality management in behavioral health care. Sluyter GV. **New Dir Ment Health Serv** 1998 Fall;(79):35–43 (29 ref.)

Ethics perspectives on end-of-life care. Tilden VP. **Nurs Outlook** 1999 Jul–Aug;47(4):162–7 (88 ref.)

Towards quality of care in child health programmes: a challenge for the partnership in health and social sciences. Kanani S. **Soc Sci Med** 1998 Nov;47(9):1223–30 (16 ref.)

Haemovigilance: concept, Europe and UK initiatives. McClelland B, et al. **Vox Sang** 1998;74 Suppl 2:431–9 (5 ref.)

Blood collection and the labile blood components: what should the regulators ask for? Maniatis A, et al. **Vox Sang** 1998;74 Suppl 2:523–5 (6 ref.)

Hemovigilance in the United States of America. Menitove JE. **Vox Sang** 1998;74 Suppl 2:447–55 (68 ref.)

The French haemovigilance system. Noel L, et al. **Vox Sang** 1998;74 Suppl 2:441–5 (0 ref.)

Quality assurance and standards for red cells and platelets. Sweeney J. **Vox Sang** 1998;74 Suppl 2:201–5 (5 ref.)

[Arguments in favor of a relation between the organization of perinatal care and the optimal management of prematurity and multiple pregnancies] Truffert P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:85–93 (37 ref.) **(Fre)**

[The quality audit in a blood transfusion center] Hergon E. **Transfus Clin Biol** 1998 Dec;5(6):422–30 (12 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Joint Commission on Accreditation of Healthcare Organizations' expectations for transfusion medicine in health care organizations. Belanger AC. **Arch Pathol Lab Med** 1999 Jun;123(6):472–4 (3 ref.)

An overview of state efforts to improve transfusion medicine. The New York state model. Linden JV, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):482–5 (10 ref.)

Polish approach to the quality assurance system in occupational health services. Indulski JA, et al. **Int J Occup Med Environ Health** 1998;11(3):209–15 (7 ref.)

Scoring systems in the measurement of performance of ICUs. Miranda DR. **Intensive Care Med** 1999 Apr;25(4):418–9 (4 ref.)

Accreditation by the National Committee on Quality Assurance (NCQA): a description. Bell D, et al. **J Okla State Med Assoc** 1999 May;92(5):234–7 (13 ref.)

Health-care performance measurement systems and the ACHS Care Evaluation Program. Australian Council on Healthcare Standards. Collopy BT. **J Qual Clin Pract** 1998 Sep;18(3):171–6 (6 ref.)

Quality and its measurement. Wilson LL. **J Qual Clin Pract** 1998 Sep;18(3):163–70 (6 ref.)

The role of peer review in internal quality assurance in cytopathology. Zardawi IM, et al. **Pathology** 1998 Aug; 30(3):309–13 (11 ref.)

Quality in women's health: taking the measure of managed care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):79S–88S (16 ref.)

New approach to assessing clinical quality of care for women: the QA Tool system. McGlynn EA, et al. **Womens Health Issues** 1999 Jul–Aug;9(4):184–92 (9 ref.)

[Patients also desire standard therapies] Tanabe I. **Gan To Kagaku Ryoho** 1999 Apr;26(5):614–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Quality of health care for people with developmental disabilities: the challenge of managed care. Walsh KK, et al. **Ment Retard** 1999 Feb;37(1):1–15 (60 ref.)

[Evidence-based medicine] Antes G. **Internist (Berl)** 1998 Sep;39(9):899–908 (61 ref.) **(Ger)**

[Radioiodine therapy of Graves' disease--quality assurance and radiation protection] Reiners C. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:61–6 (40 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance of scientific information and databanks] Schweim HG, et al. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):723–8 (34 ref.) (Eng. Abstr.) **(Ger)**

QUALITY CIRCLES see **MANAGEMENT QUALITY CIRCLES**

QUALITY CONTROL

see related
REFERENCE STANDARDS
TOTAL QUALITY MANAGEMENT

Is automatic disinfection between each endoscopy mandatory? Société Royale Belge de Gastro-entérologie. Glupczynski Y, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):422–30 (61 ref.)

Association for Molecular Pathology statement. Recommendations for in-house development and operation of molecular diagnostic tests. **Am J Clin Pathol** 1999 Apr; 111(4):449–63 (14 ref.)

Evidence on peer review-scientific quality control or smokescreen? [see comments] Goldbeck-Wood S. **BMJ** 1999 Jan 2;318(7175):44–5 (21 ref.) Comment in: BMJ 1999 Jan 2;318(7175):4–5.

Quality control of bovine serum used for vaccine production. Mareschal JC. **Dev Biol Stand** 1999;99:61–8 (6 ref.)

Internal quality control and external quality assurance in the IVF laboratory. Matson PL. **Hum Reprod** 1998 Dec;13 Suppl 4:156–65 (50 ref.)

Rethinking the early childcare agenda [see comments] Cook PS. **Med J Aust** 1999 Jan 4;170(1):29–31 (36 ref.) Comment in: Med J Aust 1999 Aug 2;171(3):166–7.

Analytical methods for quality control of combinatorial libraries. Fitch WL. **Mol Divers** 1998–99;4(1):39–45 (57 ref.)

Safe practices in parenteral nutrition compounding--an international consensus? Allwood MC. **Nutrition** 1999 May; 15(5):409–10 (5 ref.)

Manipulating meat quality and composition. Wood JD, et al. **Proc Nutr Soc** 1999 May;58(2):363–70 (42 ref.)

A general guide for conducting in-process inspections. Massari C. **Qual Assur** 1998 Apr–Jun;6(2):97–105 (2 ref.)

[Quality assurance based on civil and penal law] Bock RW. **Zentralbl Gynakol** 1998;120(12):584–7 (13 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance by experts] Ulsenheimer K. **Zentralbl Gynakol** 1998;120(12):588–92 (13 ref.) (Eng. Abstr.) **(Ger)**

[Quality control in anesthesia. A new frontier] Varrassi G, et al. **Minerva Anestesiol** 1999 Mar;65(3):95–100 (15 ref.) (Eng. Abstr.) **(Ita)**

[Concept of quality assurance and its practice] Hosogaya S, et al. **Rinsho Byori** 1999 Feb;Suppl 109:72–80 (21 ref.) **(Jpn)**

[Quality assurance of the quality work! Poor basic data can totally twist the results] Nilsson G, et al. **Lakartidningen** 1999 Feb 3;96(5):494–7 (16 ref.) **(Swe)**

QUALITY INDICATORS see **QUALITY INDICATORS, HEALTH CARE**

QUALITY INDICATORS, HEALTH CARE

Predicting rehospitalization after bypass surgery: can we do it? Should we care? [editorial; comment] Kiefe C. **Med Care** 1999 Jul;37(7):621–4 (16 ref.) Comment on: Med Care 1999 Jul;37(7):625–36.

Research evidence on the validity of risk-adjusted mortality rate as a measure of hospital quality of care [published erratum appears in Med Care Res Rev 1999 Mar;56(1):118] Thomas JW, et al. **Med Care Res Rev** 1998 Dec; 55(4):371–404 (67 ref.)

Performance measurement in workers' compensation managed care organizations. Greenberg EL, et al. **Occup Med** 1998 Oct–Dec;13(4):755–72, iv (28 ref.)

Performance measures in occupational medicine: a tool to manage quality. Rudolph L. **Occup Med** 1998 Oct–Dec; 13(4):747–53, iv (28 ref.)

Vital records for quality improvement. Gould JB. **Pediatrics** 1999 Jan;103(1 Suppl E):278–90 (39 ref.)

Quality indicators in spinal cord injury care: a Swedish collaborative project. The Swedish Spinal Cord Injury Council 1998. Levi R, et al. **Scand J Rehabil Med Suppl** 1998;38:1–80 (26 ref.)

The ethics of attribution: the case of health care outcome indicators. Russell E. **Soc Sci Med** 1998 Nov;47(9):1161–9 (75 ref.)

LEGISLATION & JURISPRUDENCE

[Indicators for quality evaluation of inpatient patient care in an ENT clinic (see comments)] Streppel M, et al. **HNO** 1998 Oct;46(10):864–9 (15 ref.) (Eng. Abstr.) Comment in: HNO 1998 Oct;46(10):840–1. **(Ger)**

ORGANIZATION & ADMINISTRATION

Performance indicators for primary care groups: an evidence based approach [see comments] McColl A, et al. **BMJ** 1998 Nov 14;317(7169):1354–60 (43 ref.) Comment in: BMJ 1999 Mar 20;318(7186):803; discussion 804–5. Comment in: BMJ 1999 Mar 20;318(7186):803–4; discussion 804–5. Comment in: BMJ 1999 Mar 20;318(7186):804–5.

[The monitoring, evaluation and programming of mental health departments. A regional system of indicators. The Evaluation Center, the QUALI DSM Project, the Lazio region] **Epidemiol Psichiatr Soc** 1998 Sep–Dec;7(3 Suppl):1–39 (0 ref.) **(Ita)**

STATISTICS & NUMERICAL DATA

Is health care ready for Six Sigma quality? Chassin MR. **Milbank Q** 1998;76(4):565–91, 510 (62 ref.)

QUALITY OF HEALTH CARE

see related
PROFESSIONAL STAFF COMMITTEES

Defining quality of care for children and adolescents with type 1 diabetes. Daneman D, et al. **Acta Paediatr Suppl** 1998 Oct;425:11–9 (45 ref.)

The health of children. Szilagyi PG, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1001–39 (97 ref.)

A review of the quality of trauma protocols on the Internet. Branfoot T, et al. **Injury** 1999 Jan;30(1):1–7 (11 ref.)

Satisfaction with palliative care: what should we be aware of? Fakhoury WK. **Int J Nurs Stud** 1998 Jun;35(3):171–6 (68 ref.)

Using outcomes to improve quality of research and quality of care. Deyo RA. **J Am Board Fam Pract** 1998 Nov–Dec; 11(6):465–73 (53 ref.)

The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators. McAlister FA, et al. **J Am Geriatr Soc** 1999 Jul;47(7):811–8 (74 ref.)

The University HealthSystems Consortium: a bureaucracy designed to smother academic excellence [editorial] Edlich

RF, et al. **J Emerg Med** 1998 Nov-Dec;16(6):893-4 (5 ref.)
Challenges in evaluating primary health care for teenagers. Research Sub-Committee of the Adolescent Working Party of the Royal College of General Practitioners, London, UK. Jacobson LD, et al. **J Eval Clin Pract** 1998 Aug; 4(3):183-9 (36 ref.)
Managed care and quality of care [editorial; comment] Krumholz HM. **J Gen Intern Med** 1999 Feb;14(2):136-7 (5 ref.) Comment on: J Gen Intern Med 1999 Feb;14(2):73-81.
Protecting patient welfare in managed care: six safeguards [see comments] Emanuel EJ, et al. **J Health Polit Policy Law** 1998 Aug;23(4):635-59 (71 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687-95.
The functions and limitations of trust in the provision of medical care [see comments] Mechanic D. **J Health Polit Policy Law** 1998 Aug;23(4):661-86 (53 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687-95.
Review of studies that compare the quality of cardiovascular care in HMO versus non-HMO settings. Seidman JJ, et al. **Med Care** 1998 Dec;36(12):1607-25 (51 ref.)
Community health centers: promise and performance. Dievler A, et al. **Med Care Res Rev** 1998 Dec;55(4):405-31 (54 ref.)
Health care quality improvement in Rhode Island: community acquired pneumonia. Jagminas L, et al. **Med Health R I** 1998 Dec;81(12):412-4 (19 ref.)
Health care quality improvement in Rhode Island: congestive heart failure. Westrick W. **Med Health R I** 1998 Sep; 81(9):300-1 (10 ref.)
Quality in healthcare in the United Kingdom: lessons for Australia [see comments] Duggan JM. **Med J Aust** 1999 Feb 1;170(3):121-4 (16 ref.) Comment in: Med J Aust 1999 May 17;170(10):507. Comment in: Med J Aust 1999 May 17;170(10):507-8. Comment in: Med J Aust 1999 May 17;170(10):508. Comment in: Med J Aust 1999 May 17;170(10):508-9.
Qualitative research: a path to better healthcare. Peat JK, et al. **Med J Aust** 1998 Sep 21;169(6):327-9 (20 ref.)
Occupational health practice in New Zealand [see comments] Gorman D, et al. **N Z Med J** 1999 Mar 12;112(1083):79-82 (18 ref.) Comment in: N Z Med J 1999 Apr 23;112(1086):147.
Rethinking geriatric nursing. Fulmer T, et al. **Nurs Clin North Am** 1998 Sep;33(3):387-94 (3 ref.)
How I address quality and teamwork issues in the occupational health department. Addley K. **Occup Med (Lond)** 1998 May;48(4):273-8 (6 ref.)
Issues in the psychiatric treatment of African Americans. Baker FM, et al. **Psychiatr Serv** 1999 Mar;50(3):362-8 (66 ref.)
Complaints against nurses: a reflection of 'the new managerialism' and consumerism in health care? Beardwood B, et al. **Soc Sci Med** 1999 Feb;48(3):363-74 (57 ref.)
[Evaluation of patient satisfaction in health facilities. Review of the literature] Labarère J, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):175-84 (82 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

The cost of treating hypertension: can we keep it under control without compromising the level of care? Moser M. **Am J Hypertens** 1998 Aug;11(8 Pt 2):120S-127S; discussion 135S-137S (29 ref.)
The impact of financial incentives on quality of health care. Dudley RA, et al. **Milbank Q** 1998;76(4):649-86, 511 (71 ref.)
Increased competition and the quality of health care. Sisk JE. **Milbank Q** 1998;76(4):687-707, 512 (44 ref.)

ORGANIZATION & ADMINISTRATION

[Results of questionnaire to 56 medical institutions about clinical trials of cancer chemotherapy] Kurihara M, et al. **Gan To Kagaku Ryoho** 1999 Jun;26(7):916-25 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Paradigm as a methodological approach to analyzing Russia's public health system] Shchepin OP, et al. **Vestn Ross Akad Med Nauk** 1998;(10):38-41 (5 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Optimizing disease management at a health care system level: the rationale and methods of the improving cardiovascular outcomes in Nova Scotia (ICONS) study. Cox JL. **Can J Cardiol** 1999 Jul;15(7):787-96 (64 ref.)
Grappling with intensive care unit quality--does the readmission rate tell us anything? [editorial; comment] Angus DC. **Crit Care Med** 1998 Nov;26(11):1779-80 (12 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1834-41.
Quality improvement of gastrointestinal endoscopy: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1999 Jun;49(6):842-4 (6 ref.)
The concept of quality of life of dying persons in the context of health care. Stewart AL, et al. **J Pain Symptom Manage** 1999 Feb;17(2):93-108 (75 ref.)
Research agenda for developing measures to examine quality of care and quality of life of patients diagnosed with life-limiting illness. Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):75-82 (29 ref.)
Quality of care for women: where are we now and where are we headed? McGlynn EA. **Womens Health Issues** 1999 Mar-Apr;9(2):65-80; discussion 93-106 (22 ref.)

STATISTICS & NUMERICAL DATA

How good is the quality of health care in the United States? Schuster MA, et al. **Milbank Q** 1998;76(4):517-63, 509 (75 ref.)
Immunization performance measurement in a changing immunization environment. Rodewald L, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):889-97 (79 ref.)

TRENDS

Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Inouye SK, et al. **Am J Med** 1999 May;106(5):565-73 (103 ref.)
Managed care and the quality of children's health services. Bergman DA, et al. **Future Child** 1998 Summer-Fall; 8(2):60-75 (62 ref.)
A report card on continuous quality improvement [see comments] Blumenthal D, et al. **Milbank Q** 1998; 76(4):625-48, 511 (29 ref.) Comment in: Milbank Q 1998 ;76(4):749-53. Comment in: Milbank Q 1998 ;76(4):755-7.
The role of regulation in quality improvement [see comments] Brennan TA. **Milbank Q** 1998;76(4):709-31, 512 (49 ref.) Comment in: Milbank Q 1998 ;76(4):745-7.
Assessing the impact of continuous quality improvement on clinical practice: what it will take to accelerate progress [see comments] Shortell SM, et al. **Milbank Q** 1998; 76(4):593-624, 510 (106 ref.) Comment in: Milbank Q 1998 ;76(4):755-7.
Quality of care for women: where are we now and where are we headed? McGlynn EA. **Womens Health Issues** 1999 Mar-Apr;9(2):65-80; discussion 93-106 (22 ref.)

QUALITY OF LIFE

see related
LIFE STYLE
SICKNESS IMPACT PROFILE

Peer relationships and quality of life. Bukowski WM, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):108-9 (10 ref.)
Modern insulin therapy in children and adolescents. Dahl-Jørgensen K. **Acta Paediatr Suppl** 1999 Jan; 88(427):25-30 (42 ref.)
Methodological considerations in the assessment of health-related quality of life in children. Erling A. **Acta Paediatr Suppl** 1999 Feb;88(428):106-7 (3 ref.)
Present and future perspectives on children with type 1 diabetes. Kordonouri O, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):43-6 (32 ref.)
Health-related quality of life in intersexuality. Meyer-Bahlburg HF. **Acta Paediatr Suppl** 1999 Feb; 88(428):114-5 (14 ref.)
Self-reported functional status: an important predictor of health outcomes among end-stage renal disease patients. Curtin RB, et al. **Adv Ren Replace Ther** 1999 Apr; 6(2):133-40 (46 ref.)
Physical functioning: definitions, measurement, and expectations. Painter P, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):110-23 (56 ref.)
The role of physical therapy in improving physical functioning of renal patients. Pianta TF. **Adv Ren Replace Ther** 1999 Apr;6(2):149-58 (17 ref.)
Exercise and a cycle of life: help us help ourselves. Stewart P. **Adv Ren Replace Ther** 1999 Apr;6(2):184-6 (0 ref.)
Health-related quality of life: a primer for gastroenterologists. Eisen GM, et al. **Am J Gastroenterol** 1999 Aug;94(8):2017-21 (17 ref.)
Assessing patient wellness: new perspectives on quality of life and compliance. Williams GH. **Am J Hypertens** 1998 Nov;11(11 Pt 2):186S-191S (27 ref.)
Measuring quality of life: methodological issues. Dijkers M. **Am J Phys Med Rehabil** 1999 May-Jun;78(3):286-300 (98 ref.)
The burden of diabetic foot ulcers. Reiber GE, et al. **Am J Surg** 1998 Aug;176(2A Suppl):5S-10S (40 ref.)
Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group. Flechtner H, et al. **Ann Oncol** 1998;9 Suppl 5:S147-54 (52 ref.)
Hodgkin's disease: quality of life in future trials. Kaasa S, et al. **Ann Oncol** 1998;9 Suppl 5:137-45 (63 ref.)
Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. McLeod RS. **Ann Oncol** 1999;10 Suppl 4:281-4 (21 ref.)
Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Roukos DH. **Ann Surg Oncol** 1999 Jan-Feb;6(1):46-56 (86 ref.)
Cost, quality of life and outcome measures in ovarian cancer. Abbas FM, et al. **Anticancer Drugs** 1998 Nov;9(10):859-67 (86 ref.)
Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Patnaik A, et al. **Anticancer Drugs** 1998 Nov;9(10):869-78 (47 ref.)
Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. Kobelt G, et al. **BJU Int** 1999 Apr;83(6):583-90 (30 ref.)
Reporting on quality of life in randomised controlled trials: bibliographic study [published erratum appears in BMJ 1998 Nov 14;317(7169):1353] [see comments] Sanders C, et al. **BMJ** 1998 Oct 31;317(7167):1191-4 (22 ref.) Comment in: BMJ 1999 Apr 24;318(7191):1142.
The Laing Essay 1998: Ethical issues in burn care. Young AE. **Burns** 1999 May;25(3):193-206 (55 ref.)
Effect of asthma on quality of life. Juniper EF. **Can Respir J** 1998 Jul-Aug;5 Suppl A:77A-84A (48 ref.)
Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Passik SD, et al. **Cancer** 1998 Dec 15;83(12 Suppl American):2817-20 (12 ref.)
Psychological aspects of ovarian cancer. Hamilton AB. **Cancer Invest** 1999;17(5):335-41 (39 ref.)
Psychosocial concerns and quality of life in breast cancer survivors. Leedham B, et al. **Cancer Invest** 1999;17(5):342-8 (79 ref.)
Quality of life research: clinical applications. Reifel JL, et al. **Cancer Treat Res** 1998;97:1-12 (36 ref.)
Quality of life in tube-fed patients with diabetes mellitus. Gallagher-Allred C, et al. **Clin Nutr** 1998 Sep;17 Suppl 2:60-2 (15 ref.)
Using oral quality of life measures in geriatric dentistry. Jones JA. **Community Dent Health** 1998 Mar;15(1):13-8 (27 ref.)
Uses of oral health related quality of life measures in Public Health. Weintraub JA. **Community Dent Health** 1998 Mar; 15(1):8-12 (24 ref.)
The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. Bomalaski JJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):11-5 (37 ref.)
Measuring health-related quality of life in patients with upper gastrointestinal disease. Moyer CA, et al. **Dig Dis** 1998 Sep-Oct;16(5):315-24 (47 ref.)
Heart failure treatments: issues of safety versus issues of quality of life. Feenstra J, et al. **Drug Saf** 1999 Jan;20(1):1-7 (32 ref.)
Review of available instruments and methods for assessing quality of life in anti-anginal trials. Bliven BD, et al. **Drugs Aging** 1998 Oct;13(4):311-20 (49 ref.)
Drugs, heart failure and quality of life: what are we achieving? What should we be trying to achieve? Doba N, et al. **Drugs Aging** 1999 Mar;14(3):153-63 (46 ref.)
The role of quality of life in functional gastrointestinal disorders: regulatory issues. Bergmann JF, et al. **Eur J Surg Suppl** 1998;(583):87-91 (14 ref.)
Problems in measurement of quality of life in dyspepsia trials. Veldhuyzen van Zanten S. **Eur J Surg Suppl** 1998; (583):77-80 (20 ref.)
Quality of life in different gastrointestinal conditions. Wiklund IK, et al. **Eur J Surg Suppl** 1998;(582):56-61 (52 ref.)
Quality-of-life assessment in children and adolescents with asthma. Rutishauser C, et al. **Eur Respir J** 1998 Aug; 12(2):486-94 (72 ref.)
Medical therapy and quality of life. Chapple CR. **Eur Urol** 1998;34 Suppl 2:10-7; discussion 46 (63 ref.)
Quality of life in chronic illness. Lawton MP. **Gerontology** 1999 Jul-Aug;45(4):181-3 (2 ref.)
Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Bossuyt PM, et al. **Haemostasis** 1998;28 Suppl 3:100-7 (14 ref.)
Health-related quality of life evaluations of gastric and pancreatic cancer. Schmier J, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1998-2004 (42 ref.)
Perianal disease, growth failure, and quality of life. Colletti RB. **Inflamm Bowel Dis** 1998 Aug;4(3):214-6 (35 ref.)
Quality of life and social issues in older depressed patients. Warner JP. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S19-24 (36 ref.)
Life control and health. Pietilä AM. **Int J Circumpolar Health** 1998 Jul;57(2-3):211-7 (51 ref.)
The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. Wimo A, et al. **Int J Geriatr Psychiatry** 1999 May;14(5):338-47 (92 ref.)
A review of quality of life assessment in oral cancer. Rogers SN, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):99-117 (118 ref.)
Long-term functional and psychological problems in whiplash associated disorders. Söderlund A, et al. **Int J Rehabil Res** 1999 Jun;22(2):77-84 (47 ref.)
Conceptualization and measurement of quality of life as an outcome variable for health care intervention and research. Anderson KL, et al. **J Adv Nurs** 1999 Feb;29(2):298-306 (58 ref.)
The impact of asthma on health-related quality of life. Schmier JK, et al. **J Asthma** 1998;35(7):585-97 (81 ref.)
New assistive technology for passive standing. Gear AJ, et al. **J Burn Care Rehabil** 1999 Mar-Apr;20(2):164-9 (14 ref.)
Quality of life in patients with atrial fibrillation. Jung W, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S177-86 (49 ref.)
Assessing quality of life in clinical research: from where have we come and where are we going? Wood-Dauphinee S. **J Clin Epidemiol** 1999 Apr;52(4):355-63 (108 ref.)

QUALITY OF LIFE

For the sake of the children: destigmatizing intersexuality. Preves SE. **J Clin Ethics** 1998 Winter;9(4):411–20 (24 ref.)

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson GD, et al. **J Clin Psychiatry** 1999;60 Suppl 5:23–9; discussion 30 (45 ref.)

The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients. Deijen JB, et al. **J Endocrinol Invest** 1999;22(5 Suppl):127–36 (54 ref.)

Two hot topics in the field of GH therapy: quality of life in hypopituitary adults, and clinical implications of the somatopause. Report from an interactive discussion. Jørgensen JO. **J Endocrinol Invest** 1999;22(5 Suppl):150–6 (26 ref.)

The use of self-rating questionnaires as a quantitative measure of quality of life in adult growth hormone deficiency. Murray RD, et al. **J Endocrinol Invest** 1999;22(5 Suppl):118–26 (37 ref.)

How should quality of life be measured? Lara-Muñoz C, et al. **J Investig Med** 1999 Jan;47(1):17–24 (99 ref.)

Quality of life in patients with rhinosinusitis. Durr DG, et al. **J Otolaryngol** 1999 Apr;28(2):108–11 (33 ref.)

Assessment of quality of life in the younger child: the use of an animated computer program. Büller H. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S53–5 (11 ref.)

Quality of life in inflammatory bowel disease: background and definitions. Ferry GD. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S15–8 (28 ref.)

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. Irvine EJ. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S23–7 (14 ref.)

Potential uses for quality-of-life measures in childhood inflammatory bowel disease. Koot HM, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S56–61 (20 ref.)

Measurement of quality of life in surgery. Camilleri-Brennan J, et al. **J R Coll Surg Edinb** 1999 Aug;44(4):252–9 (59 ref.)

The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. Ortiz Z, et al. **J Rheumatol** 1999 Jan; 26(1):210–6 (26 ref.)

Quality of life research in patients with rectal cancer: traditional approaches versus a problem-solving oriented perspective. Koller M, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):427–36 (59 ref.)

Quality of life in clinical trials: assessment and utility with special reference to rHuEPO. Brandberg Y. **Med Oncol** 1998 Aug;15 Suppl 1:S8–12 (30 ref.)

Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Osterborg A. **Med Oncol** 1998 Aug;15 Suppl 1:S47–9 (21 ref.)

Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Thomas ML. **Med Oncol** 1998 Aug;15 Suppl 1:S13–8 (34 ref.)

Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Thomas ML. **Med Oncol** 1998 Aug; 15 Suppl 1:S3–7 (31 ref.)

Measures of functional status and quality of life in chronic obstructive pulmonary disease. Cullen DL. **Monaldi Arch Chest Dis** 1999 Apr;54(2):183–5 (16 ref.)

Assessment and relief of dyspnoea. Mahler DA. **Monaldi Arch Chest Dis** 1998 Aug;53(4):466–70 (45 ref.)

Recent developments in the assessment of quality of life in multiple sclerosis (MS). Fischer JS, et al. **Mult Scler** 1999 Aug;5(4):251–9 (52 ref.)

CAPD to improve quality of life in patients with refractory heart failure. Elhalel-Dranitzki M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3041–2 (16 ref.)

Quality of life assessment in clinical practice. Cramer JA. **Neurology** 1999;53(5 Suppl 2):S49–52 (18 ref.)

Urinary incontinence among elderly persons who live at home: a literature review. Steeman E, et al. **Nurs Clin North Am** 1998 Sep;33(3):441–55 (63 ref.)

Theory construction based on standards of care: a proposed theory of the peaceful end of life. Ruland CM, et al. **Nurs Outlook** 1998 Jul-Aug;46(4):169–75 (19 ref.)

Quality of life issues: parenteral nutrition to small bowel transplantation--a review. Brook G. **Nutrition** 1998 Oct; 14(10):813–6 (24 ref.)

Physical and psychosocial correlates of head and neck cancer: a review of the literature. De Boer MF, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):427–36 (81 ref.)

The impact of different models of specialist palliative care on patients' quality of life: a systematic literature review. Salisbury C, et al. **Palliat Med** 1999 Jan;13(1):3–17 (97 ref.)

Managing the lifestyle of the child with epilepsy. Parker C. **Pediatr Ann** 1999 Apr;28(4):254–9 (10 ref.)

Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. Hack M. **Pediatrics** 1999 Jan;103(1 Suppl E):319–28 (110 ref.)

Neuropathy and quality of life in diabetic continuous ambulatory peritoneal dialysis patients. Apostolou T, et al. **Perit Dial Int** 1999;19 Suppl 2:S242–7 (42 ref.)

Effects of ACE inhibitor therapy on quality of life in patients with heart failure. Wolfel EE. **Pharmacotherapy** 1998 Nov-Dec;18(6):1323–34 (43 ref.)

Quality of life. Issues for persons with neuromuscular diseases. Abresch RT, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):233–48 (29 ref.)

Quality of life in psychiatry as an ethical duty: from the clinical to the societal perspective. Kilian R, et al. **Psychopathology** 1999 May-Jun;32(3):127–34 (28 ref.)

Health and quality of life within Colonias settlements along the United States and Mexico border. Davidhizar R, et al. **Public Health Nurs** 1999 Aug;16(4):301–6 (18 ref.)

A review of health-related quality-of-life concepts and measures for Parkinson's disease. Damiano AM, et al. **Qual Life Res** 1999 May;8(3):235–43 (30 ref.)

Quality of life in alcohol-dependent subjects--a review. Foster JH, et al. **Qual Life Res** 1999 May;8(3):255–61 (68 ref.)

Quality of life assessment in the adjuvant setting: is it relevant? International Breast Cancer Study Group. Gelber RD, et al. **Recent Results Cancer Res** 1998;152:373–89 (23 ref.)

Quality of life assessment in the International Breast Cancer Study Group: past, present, and future. Hürny C, et al. **Recent Results Cancer Res** 1998;152:390–5 (27 ref.)

Quality of life after cardiopulmonary resuscitation. de Vos R. **Resuscitation** 1997 Nov;35(3):231–6 (60 ref.)

Quantifying quality of life: overcoming an apparent paradox to meet an urgent need [editorial] Pouchot J. **Rev Rhum Engl Ed** 1998 Dec;65(12):741–4 (18 ref.)

Quality of life in patients with ankylosing spondylitis. Ward MM. **Rheum Dis Clin North Am** 1998 Nov;24(4):815–27, x (60 ref.)

Quality of life after intensive care. Niskanen M. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1474–7 (23 ref.)

Quality of life assessments in dermatology. Finlay AY. **Semin Cutan Med Surg** 1998 Dec;17(4):291–6 (54 ref.)

Quality of life issues in the management of ovarian cancer. Fish LS, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 1):32–9 (13 ref.)

Lymphomas: long-term sequelae and survivorship issues. Fernsler J, et al. **Semin Oncol Nurs** 1998 Nov;14(4):321–8 (82 ref.)

Issues in quality of life assessment during cancer therapy. Scott CB. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):5–9 (21 ref.)

Psychosocial outcome assessments for use in cardiac rehabilitation service evaluation: a 10-year systematic review. McGee HM, et al. **Soc Sci Med** 1999 May; 48(10):1373–93 (88 ref.)

Assessment of dyspnea in advanced cancer patients [see comments] Mancini I, et al. **Support Care Cancer** 1999 Jul; 7(4):229–32 (15 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):215–6.

Surgical treatment of chronic pancreatitis and quality of life after operation. Izbicki JR, et al. **Surg Clin North Am** 1999 Aug;79(4):913–44 (92 ref.)

Using quality-of-life instruments to assess surgical outcomes. Velanovich V. **Surgery** 1999 Jul;126(1):1–4 (13 ref.)

Supportive care, pain management, and quality of life in advanced prostate cancer. Esper P, et al. **Urol Clin North Am** 1999 May;26(2):375–89 (74 ref.)

Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Rhodes PR, et al. **Urology** 1999 Jun;53(6):1090–8 (30 ref.)

Baby Boomers likely to go out with a bang. Kennedy M. **WMJ** 1998 Dec;97(11):24–7 (0 ref.)

Health-related quality-of-life studies in urology: conceptual and methodological considerations. Browne JP. **World J Urol** 1999 Aug;17(4):193–8 (31 ref.)

Mental health, psychosocial functioning, and quality of life in patients with bladder exstrophy and epispadias - an overview. Diseth TH, et al. **World J Urol** 1999 Aug; 17(4):239–48 (66 ref.)

Quality-of-life issues in the treatment of testicular cancer. Heidenreich A, et al. **World J Urol** 1999 Aug;17(4):230–8 (40 ref.)

Examining health-related quality of life in men treated for prostate cancer. Litwin MS. **World J Urol** 1999 Aug; 17(4):205–10 (58 ref.)

Quality-of-life aspects in urology - benign prostatic hyperplasia. MacDonagh R, et al. **World J Urol** 1999 Aug; 17(4):199–204 (41 ref.)

When the bladder is gone: quality of life following different types of urinary diversion. Månsson A, et al. **World J Urol** 1999 Aug;17(4):211–8 (34 ref.)

The impact of urinary incontinence on the quality of life of women. Swithinbank LV, et al. **World J Urol** 1999 Aug; 17(4):225–9 (51 ref.)

Quality-of-life assessment in bladder cancer. van der Veen JH, et al. **World J Urol** 1999 Aug;17(4):219–24 (25 ref.)

[Evaluation of the impact of peripheral obliterative arteriopathy on quality of life] Marquis P. **Drugs** 1998;56 Suppl 3:25–35 (39 ref.) (Eng. Abstr.) **(Fre)**

[Socioeconomic and quality of life repercussions of arterial hypertension] Selke B, et al. **Drugs** 1998;56 Suppl 2:45–53 (38 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of symptoms of gastroesophageal reflux and their impact on quality of life] Amouretti M. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S45–9 (33 ref.) **(Fre)**

[Quality of life in patients with colorectal cancer] Conroy T, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):489–501 (77 ref.) **(Fre)**

[Evaluation of gastroesophageal reflux symptoms and their impact on the quality of life] Evrard S. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S214–20 (58 ref.) **(Fre)**

[Quality of life of patients treated for terminal chronic renal failure] Patte D. **Presse Med** 1998 Oct 3;27(29):1499–505 (58 ref.) **(Fre)**

[Evaluation of the quality of life in children and adolescents] Siméoni MC, et al. **Presse Med** 1999 May 22–29; 28(19):1033–9 (49 ref.) (Eng. Abstr.) **(Fre)**

[Quality of life after proctocolectomy for ulcerative colitis] Heuschen UA, et al. **Chirurg** 1998 Oct;69(10):1045–51 (54 ref.) (Eng. Abstr.) **(Ger)**

[Psychic effects of an adjuvant hormone replacement therapy in premenopausal patients: influence on the quality of life] Springer-Kremser M. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):109–11 (8 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonological rehabilitation. An integral therapeutic concept for the improvement of management capability and quality of life] Petro W, et al. **Internist (Berl)** 1999 Jul;40(7):772–8 (7 ref.) **(Ger)**

[Functional capacity (dyspnea) and quality of life in patients with chronic obstructive lung disease (COPD): instruments of assessment and methodological aspects] Hütter BO, et al. **Pneumologie** 1999 Mar;53(3):133–42 (81 ref.) (Eng. Abstr.) **(Ger)**

[Illness specific data collection on quality of life of patients with asthma and chronic obstructive bronchitis] Mühlig S, et al. **Rehabilitation (Stuttg)** 1998 Aug; 37(3):XXV–XXXVIII (140 ref.) (Eng. Abstr.) **(Ger)**

[Hormone replacement therapy after treatment of breast carcinoma] Birkhäuser M. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1675–89 (88 ref.) (Eng. Abstr.) **(Ger)**

[Quality of life in urologic oncology] Biermann CW, et al. **Urologe A** 1999 Mar;38(2):W189–200 (64 ref.) **(Ger)**

[Quality of life and cytokines in oncological therapy] Leitgeb C. **Wien Med Wochenschr** 1998;148(18):424–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[To what extent is it possible to integrated quality of life as a normative, subjective evaluation into scientific medicine?] Meran JG, et al. **Wien Med Wochenschr** 1998; 148(18):414–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Assessing the quality of life of children and adolescents with psychiatric disorders--a review] Mattejat F, et al. **Z Kinder Jugendpsychiatr Psychother** 1998 Aug; 26(3):183–96 (45 ref.) **(Ger)**

[Quality of life following liver transplantation in childhood] Roll C, et al. **Zentralbl Chir** 1999;124(2):79–83 (14 ref.) (Eng. Abstr.) **(Ger)**

[[Assessment of quality of life of patients with brain tumors] Tucha O, et al. **Zentralbl Neurochir** 1998;59(4):263–8 (32 ref.) (Eng. Abstr.) **(Ger)**

[Recent advances of supportive therapy for cancer patients] Ariyoshi Y. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:60–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Progress in palliative medicine] Ishitani K. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:70–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Significance and problems of quality-of-life assessment in clinical trials] Shimozuma K, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):183–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Quality of life of patients with cardiovascular diseases] Fujii J. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2530–5 (16 ref.) **(Jpn)**

[Use of the quality of life concept in medical research--useful or useless?] Wyller TB. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4247–51 (41 ref.) **(Nor)**

[Environment and health--studies using biomarkers] Wicherek S, et al. **Folia Med Cracov** 1997;38(3-4):133–44 (20 ref.) (Eng. Abstr.) **(Pol)**

[Examining the quality of life in patients with proliferative diseases of the hemopoietic system] Wichary R, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):513–8 (32 ref.) **(Pol)**

[Evaluation of quality of life in patients after stroke] Brola W, et al. **Pol Merkuriusz Lek** 1999 Jun;6(36):332–5 (22 ref.) (Eng. Abstr.) **(Pol)**

[Examination of the quality of life in post stroke patients] Brola W, et al. **Przegl Lek** 1999;56(2):152–6 (26 ref.) (Eng. Abstr.) **(Pol)**

[Quality of patient's life: effects of bronchial asthma and allergic rhinitis] Chuchalin AG, et al. **Ter Arkh** 1998; 70(9):53–7 (31 ref.) **(Rus)**

[Quality of life of oncologic patients] Ionova TI, et al. **Vopr Onkol** 1998;44(6):749–52 (38 ref.) **(Rus)**

[Evaluation of the quality of life in patients with HIV and AIDS infection] Badia X, et al. **Med Clin (Barc)** 1999 May 29;112(19):739–44 (65 ref.) **(Spa)**

[AIDS: more and better life? (editorial; comment)] Castilla J. **Med Clin (Barc)** 1999 Jul 10;113(5):171–2 (18 ref.) Comment on: Med Clin (Barc) 1999 Jul 10;113(5):169–70. **(Spa)**

[Migraine and quality of life] Lainez Andrés JM. **Neurologia** 1998 Oct;13 Suppl 2:1–8 (44 ref.) (Eng. Abstr.) **(Spa)**

[Quality of life and dementia] Pascual-Millán LF. **Rev Neurol** 1998 Apr;26(152):582–4 (25 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults? Chrisoulidou A, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):261-79 (52 ref.)

Quality of life and diabetes. Rubin RR, et al. **Diabetes Metab Res Rev** 1999 May-Jun;15(3):205-18 (115 ref.)

The relationship between stress and migraine. Fanciullacci C, et al. **Funct Neurol** 1998 Jul-Sep;13(3):215-23 (51 ref.)

The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? Healy D, et al. **J Affect Disord** 1998 Dec; 51(3):313-22 (57 ref.)

Quality of life measures in psoriasis: a critical appraisal of their quality. Ashcroft DM, et al. **J Clin Pharm Ther** 1998 Oct;23(5):391-8 (48 ref.)

Methodological challenges for measuring quality of care at the end of life. Fowler FJ Jr, et al. **J Pain Symptom Manage** 1999 Feb;17(2):114-9 (7 ref.)

The concept of quality of life of dying persons in the context of health care. Stewart AL, et al. **J Pain Symptom Manage** 1999 Feb;17(2):93-108 (75 ref.)

For every numerator, you need a denominator: a simple statement but key to measuring the quality of care of the "dying". Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):109-13 (9 ref.)

[Development of QOL questionnaires in Japan] Kobayashi K. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):189-95 (18 ref.) (Eng. Abstr.) **(Jpn)**

QUANTITATIVE TRAIT

see related

POLYGENIC INHERITANCE

Affected sib-pair methods for detecting linkage to dichotomous traits: review of the methodology. Holmans P. **Hum Biol** 1998 Dec;70(6):1025-40 (75 ref.)

Identifying candidate genes for blood pressure quantitative trait loci using differential gene expression and a panel of congenic strains. Cicila GT, et al. **Hypertens Res** 1998 Dec; 21(4):289-96 (39 ref.)

Genetic models for non insulin dependent diabetes mellitus in rodents. Kim JH, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):325-45 (62 ref.)

Strategies to utilize marker-quantitative trait loci associations. Haley CS, et al. **J Dairy Sci** 1998 Sep;81 Suppl 2:85-97 (48 ref.)

Methods of analysis and resources available for genetic trait mapping. Ott J. **J Hered** 1999 Jan-Feb;90(1):68-70 (15 ref.)

Recent progress toward the identification of genes related to risk for alcoholism. Buck KJ. **Mamm Genome** 1998 Dec; 9(12):927-8 (7 ref.)

Towards the cloning of genes underlying murine QTLs. Rikke BA, et al. **Mamm Genome** 1998 Dec;9(12):963-8 (98 ref.)

Quantitative genetics of energy balance--lessons from animal models. Pomp D, et al. **Obes Res** 1999 Jan;7(1):106-10 (36 ref.)

On the origin of species by means of assortative mating. Kondrashov AS, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2273-8 (25 ref.)

From complex traits to complex alleles. Phillips PC. **Trends Genet** 1999 Jan;15(1):6-8 (19 ref.)

QUANTUM THEORY

Quantal analysis and long-term potentiation. Korn H, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):125-30 (48 ref.)

Quantal analysis of synaptic processes in the neocortex. Thomson AM. **C R Acad Sci III** 1998 Feb-Mar; 321(2-3):131-3 (16 ref.)

Unification of the quantum and classical theories of methyl NMR. Clough S. **Solid State Nucl Magn Reson** 1999 Jul; 14(2):73-9 (16 ref.)

QUARANTINE

Catching patients: tuberculosis and detention in the 1990s. Lerner BH. **Chest** 1999 Jan;115(1):236-41 (47 ref.)

VETERINARY

Rodent quarantine programs: purpose, principles, and practice. Rehg JE, et al. **Lab Anim Sci** 1998 Oct; 48(5):438-47 (54 ref.)

QUERCETIN

PHARMACOKINETICS

Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Graefe EU, et al. **Int J Clin Pharmacol Ther** 1999 May;37(5):219-33 (72 ref.)

QUESTIONNAIRES

The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Yoshida EM. **Can J Gastroenterol** 1999 Jan-Feb;13(1):65-73 (47 ref.)

Handicap questionnaires: what do they assess? [see comments] Cardol M, et al. **Disabil Rehabil** 1999 Mar; 21(3):97-105 (46 ref.) Comment in: Disabil Rehabil 1999 Mar;21(3):106-7; discussion 108-9.

Psychosocial aspects of acne vulgaris. Layton AM. **J Cutan Med Surg** 1998 May;2 Suppl 3:19-23 (17 ref.)

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. Irvine EJ. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S23-7 (14 ref.)

Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: overview. Keller SD, et al. **Med Care** 1999 May;37(5 Suppl):MS1-9 (77 ref.)

Neonatal intensive care: satisfaction measured from a parent's perspective. Conner JM, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):336-49 (67 ref.)

Perceptions of psychosocial adjustment to aphasia: applications of the Code--Müller Protocols. Code C, et al. **Semin Speech Lang** 1999;20(1):51-62; quiz 63 (30 ref.)

Measurement of pain. Katz J, et al. **Surg Clin North Am** 1999 Apr;79(2):231-52 (111 ref.)

Patient-reported complications after cryoablation therapy for prostate cancer. Badalament RA, et al. **Urology** 1999 Aug; 54(2):295-300 (18 ref.)

[Evaluation of symptoms of gastroesophageal reflux and their impact on quality of life] Amouretti M. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S45-9 (33 ref.) **(Fre)**

[Evaluation of patient satisfaction in health facilities. Review of the literature] Labarère J, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):175-84 (82 ref.) (Eng. Abstr.) **(Fre)**

[Detection and diagnosis of alcoholism] Gache P. **Rev Prat** 1999 Feb 15;49(4):375-8 (21 ref.) (Eng. Abstr.) **(Fre)**

[Development of QOL questionnaires in Japan] Kobayashi K. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):189-95 (18 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Alcohol intake assessment: the sober facts. Feunekes GI, et al. **Am J Epidemiol** 1999 Jul 1;150(1):105-12 (41 ref.)

Measuring quality of life: methodological issues. Dijkers M. **Am J Phys Med Rehabil** 1999 May-Jun;78(3):286-300 (98 ref.)

Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group. Flechtner H, et al. **Ann Oncol** 1998;9 Suppl 5:S147-54 (52 ref.)

Hodgkin's disease: quality of life in future trials. Kaasa S, et al. **Ann Oncol** 1998;9 Suppl 5:137-45 (63 ref.)

The role of quality of life in functional gastrointestinal disorders: regulatory issues. Bergmann JF, et al. **Eur J Surg Suppl** 1998;(583):87-91 (14 ref.)

Applying the results of self-report measures to individual patients: an example using the Roland-Morris Questionnaire. Stratford PW, et al. **J Orthop Sports Phys Ther** 1999 Apr;29(4):232-9 (34 ref.)

Statistical adequacy of the Abel Assessment for Interest in Paraphilias. Fischer L, et al. **Sex Abuse** 1999 Jul; 11(3):195-205 (23 ref.)

Assessment of juvenile sexual offenders: reliability and validity of the Abel Assessment for Interest in Paraphilias. Smith G, et al. **Sex Abuse** 1999 Jul;11(3):207-16 (20 ref.)

[Retrospective estimation methods of pesticide occupational exposure] Baldi I, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):165-74 (75 ref.) (Eng. Abstr.) **(Fre)**

QUETELET'S INDEX see **BODY MASS INDEX**

QUEUING THEORY see **SYSTEMS THEORY**

QUICK TEST see **PROTHROMBIN TIME**

QUINACRINE

ADVERSE EFFECTS

Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Kessel E. **Adv Contracept** 1998 Jun;14(2):81-90 (37 ref.)

QUINAZOLINES

THERAPEUTIC USE

Anagrelide, a selective thrombocytopenic agent. Oertel MD. **Am J Health Syst Pharm** 1998 Oct 1;55(19):1979-86 (24 ref.)

Treatment of essential thrombocythemia with anagrelide. Silverstein MN, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 2):23-5 (28 ref.)

QUINCKE'S EDEMA see **ANGIONEUROTIC EDEMA**

QUINIDINE

THERAPEUTIC USE

Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death. Humphries JO. **Clin Cardiol** 1998 Oct; 21(10):711-8 (95 ref.)

QUININE

ADMINISTRATION & DOSAGE

[Intramuscular injections in Sub-saharan African children, apropos of a frequently misunderstood pathology: the complications related to intramuscular quinine injections] Barennes H. **Bull Soc Pathol Exot** 1999 Feb;92(1):33-7 (43 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Ototoxicity. Tange RA. **Adverse Drug React Toxicol Rev** 1998 Jun-Sep;17(2-3):75-89 (79 ref.)

Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Glynne P, et al. **Am J Kidney Dis** 1999 Jan;33(1):133-7 (22 ref.)

ANALYSIS

[A trip to the past: quinine and quinine alkaloids. 1. The isolation of quinine alkaloids and clarification of its chemistry] Eiden F. **Pharm Unserer Zeit** 1998 Nov; 27(6):257-71 (53 ref.) **(Ger)**

HISTORY

[A trip to the past: quinine and quinine alkaloids. 1. The isolation of quinine alkaloids and clarification of its chemistry] Eiden F. **Pharm Unserer Zeit** 1998 Nov; 27(6):257-71 (53 ref.) **(Ger)**

QUINOLINES

ADMINISTRATION & DOSAGE

[Targeted immunotherapy for malignant tumors] Turuo T. **Rinsho Ketsueki** 1999 Jun;40(6):476-9 (7 ref.) **(Jpn)**

CHEMISTRY

Nonpeptide antagonists for kinin receptors. Altamura M, et al. **Regul Pept** 1999 Mar 17;80(1-2):13-26 (94 ref.)

PHARMACOLOGY

Bisquinoline antimalarials: their role in malaria chemotherapy. Raynes K. **Int J Parasitol** 1999 Mar; 29(3):367-79 (90 ref.)

THERAPEUTIC USE

Antileukotrienes and asthma: alternative or adjunct to inhaled steroids? Kavuru MS, et al. **Cleve Clin J Med** 1998 Nov-Dec;65(10):519-26 (25 ref.)

Montelukast and zafirlukast in asthma. **Drug Ther Bull** 1998 Sep;36(9):65-8 (13 ref.)

Montelukast. Markham A, et al. **Drugs** 1998 Aug;56(2):251-6; discussion 257 (26 ref.)

Leukotriene-receptor antagonists. Lipworth BJ. **Lancet** 1999 Jan 2;353(9146):57-62 (49 ref.)

Role of leukotrienes and leukotriene receptor antagonists in asthma. Jones TR, et al. **Pulm Pharmacol Ther** 1999; 12(2):107-10 (30 ref.)

TOXICITY

DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Schut HA, et al. **Carcinogenesis** 1999 Mar;20(3):353-68 (300 ref.)

QUINOLINONES see **QUINOLONES**

QUINOLONE ANTI-INFECTIVE AGENTS see **ANTI-INFECTIVE AGENTS, QUINOLONE**

QUINOLONES

see related

ANTI-INFECTIVE AGENTS, QUINOLONE

Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Lode H, et al. **Clin Ther** 1999 Jan;21(1):61-74; discussion 1-2 (36 ref.)

Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs. Tokura Y. **J Dermatol Sci** 1998 Sep;18(1):1-10 (43 ref.)

METABOLISM

The biochemistry, physiology and genetics of PQQ and PQQ-containing enzymes. Goodwin PM, et al. **Adv Microb Physiol** 1998;40:1-80 (221 ref.)

The pyrroloquinoline quinone (PQQ)-containing quinoprotein dehydrogenases. Anthony C. **Biochem Soc Trans** 1998 Aug;26(3):413-7 (30 ref.)

PHARMACOKINETICS

[Comparative pharmacokinetics of lomefloxacin and other fluoroquinolones] Iakovlev VP. **Antibiot Khimioter** 1998; 43(10):46-52 (85 ref.) **(Rus)**

QUINOLONES

PHARMACOLOGY

Recent advances in the discovery and development of quinolones and analogs as antitumor agents. Xia Y, et al. **Curr Med Chem** 1999 Mar;6(3):179–94 (63 ref.)

Pyrroloquinoline quinone: a novel vitamin? Bishop A, et al. **Nutr Rev** 1998 Oct;56(10):287–93 (52 ref.)

THERAPEUTIC USE

Clinical applications of quinolones. Hooper DC. **Biochim Biophys Acta** 1998 Oct 1;1400(1–3):45–61 (188 ref.)

Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin. Nord CE. **Infection** 1999 May–Jun;27(3):166–72 (77 ref.)

[Difluoroquinolone lomefloxacin (Maxaquin): its role among fluoroquinolones, possibilities and prospectives] Padeiskaia EN. **Antibiot Khimioter** 1998;43(10):4–9 (23 ref.) **(Rus)**

[Has the moment arrived for quinolones in the treatment of respiratory infections?] Gomis M, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:1–7; discussion 47–52 (20 ref.) **(Spa)**

QUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

QUINONES

CuI–semiquinone radical species in plant copper–amine oxidases. Medda R, et al. **FEBS Lett** 1999 Jun 18; 453(1–2):1–5 (32 ref.)

METABOLISM

The biochemistry, physiology and genetics of PQQ and PQQ–containing enzymes. Goodwin PM, et al. **Adv Microb Physiol** 1998;40:1–80 (221 ref.)

The pyrroloquinoline quinone (PQQ)–containing quinoprotein dehydrogenases. Anthony C. **Biochem Soc Trans** 1998 Aug;26(3):413–7 (30 ref.)

Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o–quinones. Penning TM, et al. **Chem Res Toxicol** 1999 Jan;12(1):1–18 (140 ref.)

PHARMACOLOGY

Pyrroloquinoline quinone: a novel vitamin? Bishop A, et al. **Nutr Rev** 1998 Oct;56(10):287–93 (52 ref.)

TOXICITY

Role of quinoids in estrogen carcinogenesis. Bolton JL, et al. **Chem Res Toxicol** 1998 Oct;11(10):1113–27 (150 ref.)

QUINOXALINES

PHARMACOLOGY

Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans [editorial; comment] Kaufman PF. **Arch Ophthalmol** 1999 May;117(5):673–4 (25 ref.) Comment on: Arch Ophthalmol 1999 May;117(5):586–91.

QUINPIROLE

PHARMACOLOGY

Role of dopamine systems in obsessive–compulsive disorder (OCD): implications from a novel psychostimulant–induced animal model. Szechtman H, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):55–61 (35 ref.)

QUINUCLIDINES

METABOLISM

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6–7):511–8 (17 ref.)

QUISQUALATE RECEPTORS see **RECEPTORS, AMPA**

QUISQUALIC ACID

PHARMACOLOGY

C–fos expression in the rat nucleus basalis upon excitotoxic lesion with quisqualic acid: a study in adult and aged animals. Giovannelli L, et al. **J Neural Transm** 1998; 105(8–9):935–48 (29 ref.)

QUOKKAS see **KANGAROOS**

R FACTORS

GENETICS

Mobile drug resistance genes among fish bacteria. Sørum H. **APMIS Suppl** 1998;84:74–6 (10 ref.)

R GENE PRODUCTS see **GENE PRODUCTS, VPR**

R PLASMIDS see **R FACTORS**

RABBIT AORTA CONTRACTING SUBSTANCE see **THROMBOXANE A2**

RABBITPOX VIRUS see **VACCINIA VIRUS**

RABBITS

[Dental problems in rabbits and rodents. I. Anatomy, physiology, symptomatology, diagnosis] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1;123(23):698–706 (30 ref.) (Eng. Abstr.) **(Dut)**

[Dental problems in rabbits and rodents. II. Dental treatment] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1; 123(23):707–13 (30 ref.) (Eng. Abstr.) **(Dut)**

[Eye diseases in dwarf rabbits. 2. Diseases of the cornea, intraocular and retrobulbar disorders, and neoplasms] Wagner F, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):345–50 (33 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Transgenic rabbit models for biomedical research: current status, basic methods and future perspectives. Fan J, et al. **Pathol Int** 1999 Jul;49(7):583–94 (93 ref.)

PHYSIOLOGY

Sedation and anesthesia of pet rabbits. Borkowski R, et al. **Clin Tech Small Anim Pract** 1999 Feb;14(1):44–9 (21 ref.)

RABIES

[Rabies] Rikitomi N. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):142–4 (31 ref.) **(Jpn)**

EPIDEMIOLOGY

Epidemiology and control of fox rabies in Europe. Pastoret PP, et al. **Vaccine** 1999 Mar 26;17(13–14):1750–4 (35 ref.)

IMMUNOLOGY

Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Mackowiak M, et al. **Adv Vet Med** 1999;41:571–83 (18 ref.)

NURSING

Preventing human rabies before and after exposure. Garcia R. **Nurse Pract** 1999 Apr;24(4):91–2, 95–7, 101–2 passim (32 ref.)

PREVENTION & CONTROL

CDC issues revised guidelines for the prevention of human rabies. Rose VL. **Am Fam Physician** 1999 Apr 1; 59(7):2007–8, 2013–4 (00 ref.)

Current recommendations for the prophylaxis and treatment of rabies. Dreesen DW, et al. **Drugs** 1998 Nov;56(5):801–9 (15 ref.)

Rabies vaccine. Developments employing molecular biology methods. Paolazzi CC, et al. **Mol Biotechnol** 1999 Apr; 11(2):137–47 (47 ref.)

Preventing human rabies before and after exposure. Garcia R. **Nurse Pract** 1999 Apr;24(4):91–2, 95–7, 101–2 passim (32 ref.)

Rabies—risk of exposure and current trends in prevention of human cases. Haupt W. **Vaccine** 1999 Mar 26; 17(13–14):1742–9 (18 ref.)

[The current epizootic situation of prospects for eradicating rabies] Selimov MA. **Vopr Virusol** 1998 Sep–Oct; 43(5):196–8 (20 ref.) **(Rus)**

THERAPY

Current recommendations for the prophylaxis and treatment of rabies. Dreesen DW, et al. **Drugs** 1998 Nov;56(5):801–9 (15 ref.)

TRANSMISSION

Rabies prophylaxis following the feeding of a rabid pony. Feder HM, et al. **Clin Pediatr (Phila)** 1998 Aug; 37(8):477–81 (38 ref.)

VIROLOGY

Rabies vaccine. Developments employing molecular biology methods. Paolazzi CC, et al. **Mol Biotechnol** 1999 Apr; 11(2):137–47 (47 ref.)

RABIES VACCINE

Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Mackowiak M, et al. **Adv Vet Med** 1999;41:571–83 (18 ref.)

Preventing human rabies before and after exposure. Garcia R. **Nurse Pract** 1999 Apr;24(4):91–2, 95–7, 101–2 passim (32 ref.)

ADMINISTRATION & DOSAGE

CDC issues revised guidelines for the prevention of human rabies. Rose VL. **Am Fam Physician** 1999 Apr 1; 59(7):2007–8, 2013–4 (00 ref.)

GENETICS

Rabies vaccine. Developments employing molecular biology methods. Paolazzi CC, et al. **Mol Biotechnol** 1999 Apr; 11(2):137–47 (47 ref.)

RABIES VIRUS

PHYSIOLOGY

Rabies virus–induced membrane fusion. Gaudin Y, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):21–31 (88 ref.)

RACCOON DOGS see **CARNIVORA**

RACE see **RACIAL STOCKS**

RACE RELATIONS

see related
CIVIL RIGHTS

RACHITIS see **RICKETS**

RACIAL STOCKS

Racial differences in skin function. Berardesca E. **Acta Derm Venereol Suppl (Stockh)** 1994;185:44–6 (10 ref.)

Understanding ethnic differences in energy balance: can we get there from here? [editorial; comment] Kumanyika SK. **Am J Clin Nutr** 1999 Jul;70(1):1–2 (10 ref.) Comment on: Am J Clin Nutr 1999 Jul;70(1):13–20.

Theories of race, ethnicity and culture [see comments] Pfeffer N. **BMJ** 1998 Nov 14;317(7169):1381–4 (18 ref.) Comment in: BMJ 1999 Jun 19;318(7199):1696.

Racial variation in cancer care: a case study of prostate cancer. Horner RD. **Cancer Treat Res** 1998;97:99–114 (56 ref.)

Race, ethnicity and disasters in the United States: a review of the literature. Fothergill A, et al. **Disasters** 1999 Jun; 23(2):156–73 (69 ref.)

It's as simple as black and white! Race and ethnicity as categorical variables [editorial] Hammerschmidt DE. **J Lab Clin Med** 1999 Jan;133(1):10–2 (8 ref.)

Strengthening domestic violence theories: intersections of race, class, sexual orientation, and gender. Bograd M. **J Marital Fam Ther** 1999 Jun;25(3):275–89 (92 ref.)

Ethnic and racial factors in cobalamin metabolism and its disorders. Carmel R. **Semin Hematol** 1999 Jan;36(1):88–100 (103 ref.)

The epidemiology of prostate cancer part I: descriptive epidemiology. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov;16(4):187–92 (46 ref.)

The epidemiology of prostate cancer part II: the risk factors. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):193–201 (123 ref.)

GENETICS

Culturally competent drug administration. Kudzma EC. **Am J Nurs** 1999 Aug;99(8):46–51; quiz 52 (18 ref.)

Ethnic differences in drug disposition and response. Wood AJ. **Ther Drug Monit** 1998 Oct;20(5):525–6 (11 ref.)

RACISM see **PREJUDICE**

RACQUET SPORTS

INJURIES

Baseball/lacrosse injuries. Casazza BA, et al. **Phys Med Rehabil Clin N Am** 1999 Feb;10(1):141–57, vii (31 ref.)

RACQUETBALL see **RACQUET SPORTS**

RADIAL ARTERY

Vascular biology of the radial artery. Chester AH, et al. **Curr Opin Cardiol** 1998 Nov;13(6):447–52 (37 ref.)

Acute presentation of bilateral radial artery pseudoaneurysms following arterial cannulation. Edwards DP, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):456–7 (5 ref.)

PHYSIOLOGY

Pulse wave analysis and arterial stiffness. Wilkinson IB, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S33–7 (35 ref.)

SURGERY

The return of the radial artery in CABG. Reger TB, et al. **Am J Nurs** 1999 Sep;99(9):26–30; quiz 31 (6 ref.)

Vascular disorders of the hand: surgeons' perspective. Levin LS, et al. **J Hand Ther** 1999 Apr–Jun;12(2):152–9 (14 ref.)

TRANSPLANTATION

A standard of care for radial artery grafting. Hayes EC, et al. **Am J Crit Care** 1998 Nov;7(6):429–35 (23 ref.)

Severe spasm of a radial artery coronary bypass graft during coronary intervention. Kulkarni NM, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):331–5 (18 ref.)

RADIAL KERATOTOMY see **KERATOTOMY, RADIAL**

RADIAL NERVE

Uncommon nerve compression syndromes of the upper extremity. Lubahn JD, et al. **J Am Acad Orthop Surg** 1998 Nov–Dec;6(6):378–86 (38 ref.)
Radial neuropathy. Carlson N, et al. **Neurol Clin** 1999 Aug; 17(3):499–523, vi (100 ref.)

PATHOLOGY

Malignant granular cell tumor: report of a case and review of the literature. Sonobe H, et al. **Pathol Res Pract** 1998; 194(7):507–13; discussion 515–6 (50 ref.)

PHYSIOPATHOLOGY

Disputed radial tunnel syndrome. Rosenbaum R. **Muscle Nerve** 1999 Jul;22(7):960–7 (46 ref.)

RADIATION

see related
NUCLEAR WARFARE

RADIATION ACCIDENTS see **ACCIDENTS, RADIATION**

RADIATION BIOLOGY see **RADIOBIOLOGY**

RADIATION DOSAGE

see related
DOSE-RESPONSE RELATIONSHIP, RADIATION
RADIOTHERAPY DOSAGE

Use of the concept of energy imparted in diagnostic radiology. Carlsson GA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):39–62 (100 ref.)
Patient dosimetry measurement methods. Faulkner K, et al. **Appl Radiat Isot** 1999 Jan;50(1):113–23 (38 ref.)
Radiation dose in interventional fluoroscopic procedures. Geise RA, et al. **Appl Radiat Isot** 1999 Jan;50(1):173–84 (61 ref.)
Impact of new digital X- and gamma ray imaging systems upon patient doses. Speller R, et al. **Appl Radiat Isot** 1999 Jan;50(1):153–63 (52 ref.)
Radiation dosimetry in nuclear medicine. Stabin MG, et al. **Appl Radiat Isot** 1999 Jan;50(1):73–87 (84 ref.)
Neutron RBE values and their relationship to judgements in radiological protection. Edwards AA. **J Radiol Prot** 1999 Jun;19(2):93–105 (56 ref.)
Administered radionuclides in pregnancy. Adelstein SJ. **Teratology** 1999 Apr;59(4):236–9 (10 ref.)
Changing perspectives on the genetic doubling dose of ionizing radiation for humans, mice, and Drosophila. Neel JV. **Teratology** 1999 Apr;59(4):216–21 (35 ref.)
[X-ray examinations in Norway--optimized use of radiation and radiation protection] Olerud HM. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1322–5 (21 ref.) **(Nor)**
[Control of effective doses in x-ray studies] Stavitskii RV, et al. **Med Tekh** 1999 Mar–Apr;(2):39–44 (41 ref.) (Eng. Abstr.) **(Rus)**
[Small doses and synergistic interaction of environmental factors] Petin VG, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):113–26 (36 ref.) (Eng. Abstr.) **(Rus)**
[Biological effects of low level ionizing radiation (the threshold of effects and radiosensitivity/radioreactivity of biological structures with different level of organization)] Rozhdestvenskii LM. **Radiats Biol Radioecol** 1999 Jan–Feb; 39(1):127–44 (46 ref.) (Eng. Abstr.) **(Rus)**

RADIATION DOSIMETRY see **RADIOMETRY**

RADIATION EFFECTS

Behavioral evaluation of microwave irradiation. D'Andrea JA. **Bioelectromagnetics** 1999;Suppl 4:64–74 (50 ref.)
Genetic susceptibility to radiation effects: possible implication for medical ionising radiation exposures. Sharp C, et al. **Eur J Nucl Med** 1999 Apr;26(4):425–8 (11 ref.)
Optimized radiation therapy based on radiobiological objectives. Brahme A. **Semin Radiat Oncol** 1999 Jan; 9(1):35–47 (41 ref.)
The physiologic response of domestic animals to ionizing radiation: a review. von Zallinger C, et al. **Vet Radiol Ultrasound** 1998 Nov–Dec;39(6):495–503 (49 ref.)
[Biological effects of low level ionizing radiation (the threshold of effects and radiosensitivity/radioreactivity of biological structures with different level of organization)] Rozhdestvenskii LM. **Radiats Biol Radioecol** 1999 Jan–Feb; 39(1):127–44 (46 ref.) (Eng. Abstr.) **(Rus)**

RADIATION-INDUCED DERMATITIS see **RADIODERMATITIS**

RADIATION INJURIES

see related
ACCIDENTS, RADIATION

Damage pattern as a function of radiation quality and other factors. Burkart W, et al. **C R Acad Sci III** 1999 Feb–Mar; 322(2–3):89–101 (18 ref.)
Radiation injuries. Reeves GI. **Crit Care Clin** 1999 Apr; 15(2):457–73 (38 ref.)
Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. Kaplan BM, et al. **J Interv Card Electrophysiol** 1997 Nov;1(3):175–88 (88 ref.)
Effects of small doses of ionising radiation [see comments] Doll R. **J Radiol Prot** 1998 Sep;18(3):163–74 (70 ref.) Comment in: J Radiol Prot 1999 Mar;19(1):63–5.
Risks from ionising radiation: deterministic effects. Edwards AA, et al. **J Radiol Prot** 1998 Sep;18(3):175–83 (5 ref.)
A possible link between neural tube defects and ultraviolet light exposure. Jablonski NG. **Med Hypotheses** 1999 Jun; 52(6):581–2 (11 ref.)
Imaging changes after radiosurgery for vascular malformations, functional targets, and tumors. Kihlström L, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):167–80 (45 ref.)
Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Brent RL. **Teratology** 1999 Apr;59(4):182–204 (125 ref.)
[Radiation nephritis] Harada T, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1463–6 (5 ref.) **(Jpn)**

COMPLICATIONS

Chylothorax from radiation-induced mediastinal fibrosis [letter] Lee YC, et al. **Aust N Z J Med** 1998 Oct;28(5):667–8 (7 ref.)
Collagen vascular diseases and radiation therapy: a critical review. De Naeyer B, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 15;44(5):975–80 (17 ref.)
A-bomb survivors: reassessment of the radiation hazard. Stewart AM, et al. **Med Confl Surviv** 1999 Jan–Mar; 15(1):47–56 (14 ref.)
[Nuclear risk and thyroid neoplasms in infancy] Calbo L, et al. **Chir Ital** 1997;49(4–5):27–9 (20 ref.) (Eng. Abstr.) **(Ita)**
[The involvement of the upper digestive tract and psychosomatic disorders in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Svintsitskii AS, et al. **Lik Sprava** 1998 Oct–Nov;(7):39–42 (44 ref.) **(Rus)**
[Role of emotional stress in development of somatic injuries in liquidators of the Chernobyl power plant accident irradiated with small doses] Moroz BB, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):97–105 (41 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Skeletal complications in pediatric oncology patients. Roebuck DJ. **Radiographics** 1999 Jul–Aug;19(4):873–85 (50 ref.)
[Tumor and individual radiosensitivity. An introduction] Cosset JM, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):523–9 (50 ref.) (Eng. Abstr.) **(Fre)**
[A clinical study of chronic actinic enteropathy] Napolitano L, et al. **G Chir** 1999 Apr;20(4):165–8 (20 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[Pilocarpine--new use for an old drug] Tishler M. **Harefuah** 1998 Aug;135(3–4):150–2 (25 ref.) **(Heb)**

EPIDEMIOLOGY

Biological effects of electromagnetic fields and radiation [see comments] Sienkiewicz Z. **J Radiol Prot** 1998 Sep; 18(3):185–93 (34 ref.) Comment in: J Radiol Prot 1998 Sep;18(3):161–2.
Have complication rates decreased after treatment for localized prostate cancer? Thompson IM, et al. **J Urol** 1999 Jul;162(1):107–12 (12 ref.)
Clinical impact of predictive assays for acute and late radiation morbidity. Budach W, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:20–4 (30 ref.)
Pharmacological management of acute radiation morbidity. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:62–5 (43 ref.)
The impact of acute radiation morbidity on therapeutic outcome [editorial] Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:1–3 (24 ref.)
[Is there an increased risk of leukemia, brain tumors or breast cancer after exposure to high-frequency radiation? Review of methods and results of epidemiologic studies] Blettner M, et al. **Med Klin** 1999 Mar 15;94(3):150–8 (41 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Safety of radiographic imaging during pregnancy. Toppenberg KS, et al. **Am Fam Physician** 1999 Apr 1; 59(7):1813–8, 1820 (18 ref.)
Radiofrequency (RF) sickness in the Lilienfeld Study: an effect of modulated microwaves? Johnson Liakouris AG. **Arch Environ Health** 1998 May–Jun;53(3):236–8 (27 ref.)
Light exposure is not associated with retinopathy of prematurity. Mills MD. **Arch Ophthalmol** 1998 Nov; 116(11):1517–8 (18 ref.)
Pulmonary complications of cancer therapy. Wesselius LJ. **Compr Ther** 1999 May;25(5):272–7 (20 ref.)
Radiation myelopathy. Rampling R, et al. **Curr Opin Neurol** 1998 Dec;11(6):627–32 (69 ref.)
Oxidant-induced lung injury in anticancer therapy. Beinert T, et al. **Eur J Med Res** 1999 Feb 25;4(2):43–53 (113 ref.)
Cerebral radionecrosis following the treatment of parotid tumours: a case report and review of the literature. Coghlan KM, et al. **Int J Oral Maxillofac Surg** 1999 Feb;28(1):50–2 (22 ref.)
Retinal phototoxicity. Solley WA, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):1–12 (55 ref.)
Laser injuries of the eye. Thach AB. **Int Ophthalmol Clin** 1999 Spring;39(2):13–27 (93 ref.)
Solar retinopathy in a hospital-based primary care clinic. Stokkermans TJ, et al. **J Am Optom Assoc** 1998 Oct; 69(10):625–36 (75 ref.)
Slipped capital femoral epiphysis associated with radiation therapy. Loder RT, et al. **J Pediatr Orthop** 1998 Sep–Oct; 18(5):630–6 (25 ref.)
Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Micali G, et al. **Pharmacotherapy** 1999 Feb;19(2):223–7 (39 ref.)
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Taylor SE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):14–26 (154 ref.)
Altered fractionation: limited by mucosal reactions? Kaanders JH, et al. **Radiother Oncol** 1999 Mar;50(3):247–60 (89 ref.)
Optical radiation hazards of welding arcs. Tenkate TD. **Rev Environ Health** 1998 Jul–Sep;13(3):131–46 (99 ref.)
Biological effects of amplitude-modulated radiofrequency radiation [see comments] Juutilainen J, et al. **Scand J Work Environ Health** 1998 Aug;24(4):245–54 (64 ref.) Comment in: Scand J Work Environ Health 1998 Aug;24(4):241–3.
Radiobiological models of normal tissue reactions. Dörr W. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:4–7 (16 ref.)
[Tumor and individual radiosensitivity. An introduction] Cosset JM, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):523–9 (50 ref.) (Eng. Abstr.) **(Fre)**
[Disorders of endocrine function after brain tumor therapy in childhood] Marx M, et al. **Strahlenther Onkol** 1999 Jul; 175(7):305–8 (30 ref.) (Eng. Abstr.) **(Ger)**
[Molecular mechanisms of major radiobiological sequels of the effect of ionizing radiation on mammals] Mazurik VK, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):89–96 (53 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Mechanisms and implications of genomic instability and other delayed effects of ionizing radiation exposure. Mothersill C, et al. **Mutagenesis** 1998 Sep;13(5):421–6 (59 ref.)

MORTALITY

A-bomb survivors: reassessment of the radiation hazard. Stewart AM, et al. **Med Confl Surviv** 1999 Jan–Mar; 15(1):47–56 (14 ref.)

PHYSIOPATHOLOGY

Factors of importance for implantation and problems after treatment for childhood cancer. Critchley HO. **Med Pediatr Oncol** 1999 Jul;33(1):9–14 (41 ref.)
Pharmacological protection of the gonads. Howell SJ, et al. **Med Pediatr Oncol** 1999 Jul;33(1):41–5 (48 ref.)
Reproductive physiology and treatment-related loss of sex hormone production. Sklar C. **Med Pediatr Oncol** 1999 Jul; 33(1):2–8 (63 ref.)
Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Classen J, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:82–4 (29 ref.)
The role of cytokines in the development of normal-tissue reactions after radiotherapy. Herskind C, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:12–5 (37 ref.)
Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Zimmermann FB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:85–9 (32 ref.)

PREVENTION & CONTROL

Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Henriksson R, et al. **Acta Oncol** 1999;38(2):159–64 (37 ref.)
Ultraviolet radiation screening compounds. Cockell CS, et al. **Biol Rev Camb Philos Soc** 1999 Aug;74(3):311–45 (232 ref.)
An overview of radiation safety regulatory recommendations and requirements. Balter S. **Catheter Cardiovasc Interv** 1999 Aug;47(4):469–74 (15 ref.)
Detecting the health risks of radiation. Stewart A. **Med Confl Surviv** 1999 Apr–Jun;15(2):138–48 (7 ref.)
Clinical status and optimal use of amifostine. Capizzi RL. **Oncology (Huntingt)** 1999 Jan;13(1):47–59; discussion 63, 67 (90 ref.)
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Taylor SE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):14–26 (154 ref.)
Radiation safety considerations for diagnostic radiology personnel. Brateman L. **Radiographics** 1999 Jul–Aug; 19(4):1037–55 (33 ref.)
Minimizing occupational exposure. Shymko MJ. **Radiol Technol** 1998 Sep–Oct;70(1):89–90 (3 ref.)

RADIATION INJURIES

Individual skin care during radiation therapy. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:74–7 (19 ref.)

[Radiation exposure during thoracic radiography at the intensive care unit. Dose accumulation and risk of radiation-induced cancer in long-term therapy] Leppek R, et al. **Radiologe** 1998 Sep;38(9):730–6 (42 ref.) (Eng. Abstr.) **(Ger)**

[Radiation hazards in interventional radiology] Widmark A, et al. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4543–5 (14 ref.) **(Nor)**

REHABILITATION

[Current problems of chemical radiation protection of organisms] Kudriashov IuB, et al. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):197–211 (98 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

[Duodeno-caval fistula: a rare cause of upper gastrointestinal hemorrhage] Runkel N, et al. **Chirurg** 1998 Aug;69(8):883–6 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Modern therapy of chronic wounds with respect to radiation. Frank J, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:69–73 (26 ref.)

Management of radiation injuries of vulva and vagina. Fraunholz IB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:90–2 (29 ref.)

The treatment of late radiation effects with hyperbaric oxygenation (HBO). Plafki C, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:66–8 (30 ref.)

Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. Zimmermann FB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:78–81 (30 ref.)

Pharmacological management of acute radiation morbidity. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:62–5 (43 ref.)

[Non-surgical treatment of chronic radiation proctitis] de Parades V, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep; 22(8–9):688–96 (88 ref.) **(Fre)**

[Patient treatment in radiation accidents] Tanum G, et al. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1446–50 (21 ref.) (Eng. Abstr.) **(Nor)**

VETERINARY

An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors. Adams WM, et al. **Vet Radiol Ultrasound** 1998 Sep–Oct;39(5):475–81 (23 ref.)

The physiologic response of domestic animals to ionizing radiation: a review. von Zallinger C, et al. **Vet Radiol Ultrasound** 1998 Nov–Dec;39(6):495–503 (49 ref.)

[Chronic damage in domestic animals after ionizing radiation (review)] von Zallinger C, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov–Dec; 111(11–12):457–63 (45 ref.) (Eng. Abstr.) **(Ger)**

RADIATION INJURIES, EXPERIMENTAL

DRUG THERAPY

[Experimental substantiation of the use of cytokines in acute radiation disease] Rogacheva SA. **Radiats Biol Radioecol** 1998 Nov–Dec;38(6):854–73 (203 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Chromosomes in the assessment of the effects of low levels of genotoxic agents. Leonard Sagan BELLE Award. Biological Effects of Low Level Exposure. Wolff S. **Hum Exp Toxicol** 1998 Nov;17(11):625–32 (39 ref.)

Modelling radiation-induced biological lesions: from initial energy depositions to chromosome aberrations. Ottolenghi A, et al. **Radiat Environ Biophys** 1999 May;38(1):1–13 (76 ref.)

PHYSIOPATHOLOGY

Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Quarmby S, et al. **Int J Cancer** 1999 Jul 30;82(3):385–95 (101 ref.)

RADIATION, IONIZING

Research of the adaptive response induced by low-dose radiation: where have we been and where should we go? Cai L. **Hum Exp Toxicol** 1999 Jul;18(7):419–25 (52 ref.)

The role of adaptive responses following exposure to ionizing radiation. Feinendegen LE. **Hum Exp Toxicol** 1999 Jul; 18(7):426–32 (37 ref.)

Radioadaptive response: responses to the five questions. Ikushima T. **Hum Exp Toxicol** 1999 Jul;18(7):433–5 (15 ref.)

Adaptive response and its relationship to hormesis and low dose cancer risk estimation. Olivieri G. **Hum Exp Toxicol** 1999 Jul;18(7):440–2 (21 ref.)

The adaptive response to ionizing radiation: low dose effects unpredictable from high dose experiments. Rigaud O. **Hum Exp Toxicol** 1999 Jul;18(7):443–6 (20 ref.)

Perspectives on the adaptive response from studies on the response to low radiation doses (or to cisplatin) in mammalian cells. Skov KA. **Hum Exp Toxicol** 1999 Jul; 18(7):447–51 (36 ref.)

Radiation-induced genomic instability. Little JB. **Int J Radiat Biol** 1998 Dec;74(6):663–71 (26 ref.)

Ionizing radiation and genetic risks IX. Estimates of the frequencies of mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective. Sankaranarayanan K. **Mutat Res** 1998 Sep;411(2):129–78 (285 ref.)

Ionizing radiation and genetic risks. X. The potential "disease phenotypes" of radiation-induced genetic damage in humans: perspectives from human molecular biology and radiation genetics. Sankaranarayanan K. **Mutat Res** 1999 Aug 11;429(1):45–83 (266 ref.)

Childhood and adult cancer after intrauterine exposure to ionizing radiation. Boice JD Jr, et al. **Teratology** 1999 Apr; 59(4):227–33 (60 ref.)

Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Brent RL. **Teratology** 1999 Apr;59(4):182–204 (125 ref.)

Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. Byrne J. **Teratology** 1999 Apr; 59(4):210–5 (30 ref.)

Changing perspectives on the genetic doubling dose of ionizing radiation for humans, mice, and Drosophila. Neel JV. **Teratology** 1999 Apr;59(4):216–21 (35 ref.)

Cognitive function and prenatal exposure to ionizing radiation. Schull WJ, et al. **Teratology** 1999 Apr;59(4):222–6 (35 ref.)

The physiologic response of domestic animals to ionizing radiation: a review. von Zallinger C, et al. **Vet Radiol Ultrasound** 1998 Nov–Dec;39(6):495–503 (49 ref.)

[A new possibility for enhancing natural immunity: a radiation-detoxified endotoxin] Bertók L. **Orv Hetil** 1999 Apr 11;140(15):819–27 (50 ref.) (Eng. Abstr.) **(Hun)**

RADIATION MONITORING

INSTRUMENTATION

Intracoronary brachytherapy in the Cath Lab. Physics dosimetry, technology and safety considerations. Waksman R. **Herz** 1998 Sep;23(6):401–6 (18 ref.)

Radiation detectors in nuclear medicine. Ranger NT. **Radiographics** 1999 Mar–Apr;19(2):481–502 (6 ref.)

RADIATION, NONIONIZING

[Mechanism of radiobiological effects of low intensity nonionizing electromagnetic radiation] Kudriashov IuB, et al. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):79–83 (22 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Brent RL. **Teratology** 1999 Apr;59(4):182–204 (125 ref.)

RADIATION ONCOLOGY

MANPOWER

Non-physician practitioners in radiation oncology: advanced practice nurses and physician assistants. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):255–63 (14 ref.)

Description of the role of nonphysician practitioners in radiation oncology. Kelvin JF, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):163–9 (17 ref.)

RADIATION PNEUMONITIS

DIAGNOSIS

[Pulmonary damage after radiotherapy for breast cancer] de Fijter WM, et al. **Ned Tijdschr Geneeskd** 1999 Apr 17; 143(16):833–6 (13 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Oxidant-induced lung injury in anticancer therapy. Beinert T, et al. **Eur J Med Res** 1999 Feb 25;4(2):43–53 (113 ref.)

[Pulmonary damage after radiotherapy for breast cancer] de Fijter WM, et al. **Ned Tijdschr Geneeskd** 1999 Apr 17; 143(16):833–6 (13 ref.) (Eng. Abstr.) **(Dut)**

RADIATION PROTECTION

Prenatal exposure to ionizing radiation: sources, effects and regulatory aspects. Fattibene P, et al. **Acta Paediatr** 1999 Jul;88(7):693–702 (58 ref.)

Dosimetry for optimisation of patient protection in computed tomography. Jessen KA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):165–72 (27 ref.)

Endovascular brachytherapy—treatment planning and radiation protection. Quast U, et al. **Herz** 1998 Sep; 23(6):337–46 (57 ref.)

Risks from ionising radiation: deterministic effects. Edwards AA, et al. **J Radiol Prot** 1998 Sep;18(3):175–83 (5 ref.)

Biological effects of electromagnetic fields and radiation [see comments] Sienkiewicz Z. **J Radiol Prot** 1998 Sep; 18(3):185–93 (34 ref.) Comment in: J Radiol Prot 1998 Sep;18(3):161–2.

Protection against solar ultraviolet radiation. Gies PH, et al. **Mutat Res** 1998 Nov 9;422(1):15–22 (37 ref.)

Radiation safety considerations for diagnostic radiology personnel. Brateman L. **Radiographics** 1999 Jul–Aug; 19(4):1037–55 (33 ref.)

Minimizing occupational exposure. Shymko MJ. **Radiol Technol** 1998 Sep–Oct;70(1):89–90 (3 ref.)

Metallothionein in radiation exposure: its induction and protective role. Cai L, et al. **Toxicology** 1999 Feb 15; 132(2–3):85–98 (102 ref.)

[X-ray examinations in Norway—optimized use of radiation and radiation protection] Olerud HM. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1322–5 (21 ref.) **(Nor)**

[Possible modification of radiation injury using radio frequency electromagnetic radiation] Aminova EM, et al. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):345–8 (32 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Radiation safety. Shymko M, et al. **AORN J** 1998 Oct; 68(4):596–602; quiz 603–4, 606, 609–10 (35 ref.)

Patients leaving hospital after administration of radioactive substances. Working Party of the Radiation Protection Committee of the British Institute of Radiology. **Br J Radiol** 1999 Feb;72(854):121–5 (12 ref.)

Radiation safety for health care workers in the bronchoscopy suite. Jain P, et al. **Clin Chest Med** 1999 Mar;20(1):33–8, ix–x (25 ref.)

Effective presentation of radiation safety training—risk communication: an important function of radiation safety training. Johnson RH Jr. **Health Phys** 1999 Feb;76(2 Suppl):S10–5 (7 ref.)

[Can we optimize radioprotection for medical workers?] Aubert B, et al. **J Radiol** 1998 Apr;79(4):307–12 (17 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

An overview of radiation safety regulatory recommendations and requirements. Balter S. **Catheter Cardiovasc Interv** 1999 Aug;47(4):469–74 (15 ref.)

Prudent management of minors with occupational exposures to hazardous agents: the radiation protection "standard of care". Emery RJ, et al. **Inj Prev** 1998 Sep;4(3):232–5 (28 ref.)

Neutron RBE values and their relationship to judgements in radiological protection. Edwards AA. **J Radiol Prot** 1999 Jun;19(2):93–105 (56 ref.)

[Safety of laser use] Mierczyk Z, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):211–7 (14 ref.) (Eng. Abstr.) **(Pol)**

RADIATION-PROTECTIVE AGENTS

Ultraviolet radiation screening compounds. Cockell CS, et al. **Biol Rev Camb Philos Soc** 1999 Aug;74(3):311–45 (232 ref.)

CLASSIFICATION

[Classification of radiation protective agents as a basis of modern radiation pharmacology] Vasin MV. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):212–22 (149 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links M, et al. **Drugs** 1999 Mar; 57(3):293–308 (94 ref.)

PHARMACOLOGY

Chemopreventive effects of 2-(allylthio)pyrazine. Kim ND, et al. **Arch Pharm Res** 1999 Apr;22(2):99–107 (65 ref.)

Radioprotective effects of amifostine. Wasserman T. **Semin Oncol** 1999 Apr;26(2 Suppl 7):89–94 (29 ref.)

Radioprotectants: pharmacology and clinical applications of amifostine. Dorr RT. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):10–3 (20 ref.)

Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Castiglione F, et al. **Tumori** 1999 Mar–Apr;85(2):85–91 (72 ref.)

[Classification of radiation protective agents as a basis of modern radiation pharmacology] Vasin MV. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):212–22 (149 ref.) (Eng. Abstr.) **(Rus)**

[Mechanism of the antistressor and antiradiation action of plant phenol compounds] Baraboĭ VA, et al. **Ukr Biokhim Zh** 1998 Nov–Dec;70(6):13–23 (82 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Aspects on reducing gastrointestinal adverse effects

associated with radiotherapy. Henriksson R, et al. **Acta Oncol** 1999;38(2):159–64 (37 ref.)
The sulfhydryl containing compounds WR–2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Hospers GA, et al. **Br J Cancer** 1999 May;80(5–6):629–38 (81 ref.)
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links M, et al. **Drugs** 1999 Mar; 57(3):293–308 (94 ref.)
Clinical status and optimal use of amifostine. Capizzi RL. **Oncology (Huntingt)** 1999 Jan;13(1):47–59; discussion 63, 67 (90 ref.)
Future development of amifostine as a radioprotectant. Werner-Wasik M. **Semin Oncol** 1999 Apr;26(2 Suppl 7):129–34 (28 ref.)
Future directions in toxicity prevention. Brizel DM. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):17–20 (14 ref.)
Radiation-induced toxicities: the role of radioprotectants. Curran WJ. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):2–4 (14 ref.)
Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine. Mehta MP. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):14–6 (11 ref.)
Toxicity antagonists in head and neck cancer. Trotti A. **Semin Radiat Oncol** 1998 Oct;8(4):282–91 (83 ref.)
Pharmacological management of acute radiation morbidity. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:62–5 (43 ref.)
[Current problems of chemical radiation protection of organisms] Kudriashov IuB, et al. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):197–211 (98 ref.) (Eng. Abstr.) **(Rus)**

RADIATION SENSITIVITY see **RADIATION TOLERANCE**

RADIATION-SENSITIZING AGENTS

[Navelbine (vinorelbine): a review of its antitumor activity and toxicity in clinical studies] Niitani H. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1495–507 (66 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Continuous radiosensitizing chemotherapy] Hennequin C, et al. **Pathol Biol (Paris)** 1999 Mar;47(3):279–81 (12 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Radiosensitization and apoptosis. Muschel RJ, et al. **Oncogene** 1998 Dec 24;17(25):3359–63 (100 ref.)
Camptothecin radiation sensitization: mechanisms, schedules, and timing. Rich TA, et al. **Oncology (Huntingt)** 1998 Aug; 12(8 Suppl 6):114–20 (55 ref.)
Combination of taxanes with radiation: preclinical studies. Milas L, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):12–26 (83 ref.)

THERAPEUTIC USE

Docetaxel in head and neck cancer: a review. Colevas AD, et al. **Am J Clin Oncol** 1998 Oct;21(5):482–6 (28 ref.)
Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Saunders M, et al. **Br J Cancer Suppl** 1996 Jul;27:S271–8 (48 ref.)
Taxanes as radiosensitizers for head and neck cancer. Herscher LL, et al. **Curr Opin Oncol** 1999 May;11(3):183–6 (22 ref.)
Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Gregoire V, et al. **Oncol Rep** 1999 Sep–Oct; 6(5):949–57 (61 ref.)
Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. King TC, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):4–11 (58 ref.)
[Current studies of combined radiotherapy-hormone therapy in localized and locally advanced prostatic cancers] Bolla M, et al. **Cancer Radiother** 1998 Dec;2(6):783–6 (16 ref.) (Eng. Abstr.) **(Fre)**
[Adjuvant chemoradiotherapy of cancers of the rectum] Bosset JF, et al. **Cancer Radiother** 1998 Dec;2(6):703–7 (40 ref.) (Eng. Abstr.) **(Fre)**
[Clinical evaluation of concomitant chemoradiotherapy and practical recommendations] Bosset JF, et al. **Cancer Radiother** 1998 Dec;2(6):665–7 (13 ref.) (Eng. Abstr.) **(Fre)**
[Biological principles of chemoradiotherapy] Bourhis J, et al. **Cancer Radiother** 1998 Dec;2(6):657–62 (41 ref.) (Eng. Abstr.) **(Fre)**
[Chemoradiotherapy of carcinomas of the upper aerodigestive tract] Bourhis J, et al. **Cancer Radiother** 1998 Dec;2(6):679–88 (70 ref.) (Eng. Abstr.) **(Fre)**
[Concomitant chemoradiotherapy of cancer of the esophagus] Calais G. **Cancer Radiother** 1998 Dec;2(6):689–95 (42 ref.) (Eng. Abstr.) **(Fre)**
[Chemoradiotherapy: history and state of the art] Cosset JM. **Cancer Radiother** 1998 Dec;2(6):653–6 (19 ref.) (Eng. Abstr.) **(Fre)**
[Respective roles of radiotherapy and chemotherapy in adjuvant treatment of cancer of the breast: theoretical importance and feasibility of chemoradiotherapy] Freyer G, et al. **Cancer Radiother** 1998 Dec;2(6):723–31 (49 ref.) (Eng. Abstr.) **(Fre)**
[Chemoradiotherapy in treatment of cancer of the anal canal] Gérard JP. **Cancer Radiother** 1998 Dec;2(6):708–12 (35 ref.) (Eng. Abstr.) **(Fre)**
[Local control of the primary tumor. Necessary step in control of cancer (published erratum appears in Cancer Radiother 1999 Jan–Feb;3(1):85)] Gérard JP, et al. **Cancer Radiother** 1998 Dec;2(6):668–71 (13 ref.) (Eng. Abstr.) **(Fre)**
[Combined chemoradiotherapy of tumors in the child (published erratum appears in Cancer Radiother 1999 Jan–Feb;3(1):85)] Habrand JL, et al. **Cancer Radiother** 1998 Dec;2(6):752–9 (70 ref.) (Eng. Abstr.) **(Fre)**
[Concomitant chemoradiotherapy and malignant glial tumors in the adult] Honnorat J. **Cancer Radiother** 1998 Dec; 2(6):672–8 (46 ref.) (Eng. Abstr.) **(Fre)**
[Concomitant chemoradiotherapy of infiltrating cancers of the bladder] Housset M. **Cancer Radiother** 1998 Dec; 2(6):713–7 (36 ref.) (Eng. Abstr.) **(Fre)**
[Radiation sensitizing agents for hypoxic cells: past, present and future] Lartigau E. **Cancer Radiother** 1998 Dec; 2(6):775–80 (57 ref.) (Eng. Abstr.) **(Fre)**
[Chemoradiotherapy in cancers of the uterine cervix] Maingon P, et al. **Cancer Radiother** 1998 Dec;2(6):718–22 (40 ref.) (Eng. Abstr.) **(Fre)**
[Concomitant chemoradiotherapy in the therapeutic strategy of adenocarcinoma of the exocrine pancreas and stomach] Mornex F, et al. **Cancer Radiother** 1998 Dec;2(6):696–702 (48 ref.) (Eng. Abstr.) **(Fre)**
[Radiochemotherapy and radiosensitization for locally advanced non-small-cell bronchial cancer] Quoix E, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):590–9 (58 ref.) (Eng. Abstr.) **(Fre)**
[Contribution of radiation biology to the development of radiation therapy] Shibamoto Y. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1242–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION SICKNESS see **RADIATION INJURIES**

RADIATION SYNDROME see **RADIATION INJURIES**

RADIATION TOLERANCE

see related
RADIATION-PROTECTIVE AGENTS
RADIATION-SENSITIZING AGENTS

Adaptive response and induced resistance. Joiner MC, et al. **C R Acad Sci III** 1999 Feb–Mar;322(2–3):167–75 (57 ref.)
Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Smith BD, et al. **Radiat Oncol Investig** 1999; 7(3):125–44 (134 ref.)
Clinical impact of predictive assays for acute and late radiation morbidity. Budach W, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:20–4 (30 ref.)
[Tumor and individual radiosensitivity. An introduction] Cosset JM, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):523–9 (50 ref.) (Eng. Abstr.) **(Fre)**
[Tumor radiosensitivity tests: state of assays in 1998] Girinsky T, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):530–3 (24 ref.) (Eng. Abstr.) **(Fre)**
[Radiotherapy of the elderly patient. Radiotherapy tolerance and results in older patients] Geinitz H, et al. **Strahlenther Onkol** 1999 Mar;175(3):119–27 (46 ref.) (Eng. Abstr.) **(Ger)**
[Biological effects of low level ionizing radiation (the threshold of effects and radiosensitivity/radioreactivity of biological structures with different level of organization)] Rozhdestvenskii LM. **Radiats Biol Radioecol** 1999 Jan–Feb; 39(1):127–44 (46 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[Photosensitivity induced by piroxicam] Varela P, et al. **Acta Med Port** 1998 Nov;11(11):997–1001 (19 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Radiation, DNA damage and cancer. Hall J, et al. **Mol Med Today** 1999 Apr;5(4):157–64 (61 ref.)

PHYSIOLOGY

Radiosensitivity and the cell cycle. Bernhard EJ, et al. **Cancer J Sci Am** 1999 Jul–Aug;5(4):194–204 (145 ref.)
The role of adaptive responses following exposure to ionizing radiation. Feinendegen LE. **Hum Exp Toxicol** 1999 Jul; 18(7):426–32 (37 ref.)
[The factors of individual sensitivity to ultraviolet radiation] Strzhizhovskiĭ AD. **Usp Fiziol Nauk** 1998 Jul–Sep; 29(3):130–43 (96 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Research of the adaptive response induced by low-dose radiation: where have we been and where should we go? Cai L. **Hum Exp Toxicol** 1999 Jul;18(7):419–25 (52 ref.)
Radioadaptive response: responses to the five questions. Ikushima T. **Hum Exp Toxicol** 1999 Jul;18(7):433–5 (15 ref.)
Adaptive response and its relationship to hormesis and low dose cancer risk estimation. Olivieri G. **Hum Exp Toxicol** 1999 Jul;18(7):440–2 (21 ref.)
The adaptive response to ionizing radiation: low dose effects unpredictable from high dose experiments. Rigaud O. **Hum Exp Toxicol** 1999 Jul;18(7):443–6 (20 ref.)
Perspectives on the adaptive response from studies on the response to low radiation doses (or to cisplatin) in mammalian cells. Skov KA. **Hum Exp Toxicol** 1999 Jul; 18(7):447–51 (36 ref.)

RADIATION, VISIBLE see **LIGHT**

RADIATION, WHOLE-BODY see **WHOLE-BODY IRRADIATION**

RADICAL NECK DISSECTION

METHODS

Selective lateral neck dissection for laryngeal cancer with limited metastatic disease: is it indicated? Ferlito A, et al. **J Laryngol Otol** 1998 Nov;112(11):1031–3 (19 ref.)
Minimizing complications in neck dissection. Talmi YP. **J Laryngol Otol** 1999 Feb;113(2):101–13 (92 ref.)
Surgical management of the neck in squamous cell carcinoma of the floor of the mouth. Zupi A, et al. **Oral Oncol** 1998 Nov;34(6):472–5 (12 ref.)
Use of apron flap incision for neck dissection. Yii NW, et al. **Plast Reconstr Surg** 1999 May;103(6):1655–60 (24 ref.)

RADICULAR CYST

PATHOLOGY

Odontogenic cysts related to pulpotomized deciduous molars: clinical features and treatment outcome. Lustig JP, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):499–503 (15 ref.)

RADICULITIS

[Radiculomyelopathy due to genital herpes simplex virus infection (Elsberg syndrome)] Kido M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):52–4 (15 ref.) **(Jpn)**

COMPLICATIONS

[Myeloradiculitis] Shoji H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):49–51 (10 ref.) **(Jpn)**

DIAGNOSIS

Chronic neck syndromes: an update. Pawl RP. **Compr Ther** 1999 May;25(5):278–82 (32 ref.)
[Physical diagnosis--signs of lumbosacral irritation (see comments) (published erratum appears in Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1400)] Oosterhuis HJ. **Ned Tijdschr Geneeskd** 1999 Mar 20;143(12):617–20 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1393–4. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394–5. **(Dut)**

ETIOLOGY

[Radicular and pseudo-radicular pain syndrome] Knutti O, et al. **Ther Umsch** 1998 Oct;55(10):601–12 (29 ref.) (Eng. Abstr.) **(Ger)**

RADIO WAVES

Radiofrequency (RF) sickness in the Lilienfeld Study: an effect of modulated microwaves? Johnson Liakouris AG. **Arch Environ Health** 1998 May–Jun;53(3):236–8 (27 ref.)
[Possible modification of radiation injury using radio frequency electromagnetic radiation] Aminova EM, et al. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):345–8 (32 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Biomedical concerns in wireless communications. Stuchly MA. **Crit Rev Biomed Eng** 1998;26(1–2):117–51 (115 ref.)
Safety aspects of radiofrequency power deposition in magnetic resonance. Schaefer DJ. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):775–89 (47 ref.)
Cell phones and cancer: what is the evidence for a connection? Moulder JE, et al. **Radiat Res** 1999 May; 151(5):513–31 (75 ref.)
Biological effects of amplitude-modulated radiofrequency radiation [see comments] Juutilainen J, et al. **Scand J Work Environ Health** 1998 Aug;24(4):245–54 (64 ref.) Comment in: Scand J Work Environ Health 1998 Aug;24(4):241–3.
Intrauterine effects in animals exposed to radiofrequency and microwave fields. O'Connor ME. **Teratology** 1999 Apr; 59(4):287–91 (60 ref.)

RADIOACTIVE ISOTOPES see **RADIOISOTOPES**

RADIOACTIVE POLLUTANTS

ADVERSE EFFECTS

[The interactions of functional systems at the homeostatic

RADIOACTIVE POLLUTANTS

level in normal children and adolescents and in a radioecologically unfavorable environment] Glazachev OS, et al. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):73-92 (81 ref.) (Eng. Abstr.) **(Rus)**

RADIOACTIVE TRACERS

Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Vogel JS, et al. **Adv Exp Med Biol** 1998;445:397-410 (41 ref.)

Fundamentals of tracer kinetics for radiologists. Peters AM. **Br J Radiol** 1998 Nov;71(851):1116-29 (26 ref.)

RADIOACTIVE WASTE

Sites in the United States contaminated with radioactivity. Wolbarst AB, et al. **Health Phys** 1999 Sep;77(3):247-60 (47 ref.)

RADIOAUTOGRAPHY see **AUTORADIOGRAPHY**

RADIOBIOLOGY

see related
NUCLEAR MEDICINE

Radiation biology and treatment options in radiation oncology. Withers HR. **Cancer Res** 1999 Apr 1;59(7 Suppl):1676s-1684s (70 ref.)

The radiobiology and physics of brachytherapy. Crownover RL, et al. **Hematol Oncol Clin North Am** 1999 Jun; 13(3):477-87 (5 ref.)

Review of photon interaction cross section data in the medical and biological context. Hubbell JH. **Phys Med Biol** 1999 Jan;44(1):R1-22 (157 ref.)

International radiobiology archives of long-term animal studies: structure, possible uses and potential extension. Gerber GB, et al. **Radiat Environ Biophys** 1999 Jul; 38(2):75-9 (6 ref.)

Heavy-ion radiobiology: new approaches to delineate mechanisms underlying enhanced biological effectiveness. Blakely EA, et al. **Radiat Res** 1998 Nov;150(5 Suppl):S126-45 (264 ref.)

Development of primary tissue culture techniques for use in radiobiology. Mothersill C. **Radiat Res** 1998 Nov;150(5 Suppl):S121-5 (58 ref.)

[The anthropic principle in biology and radiobiology] Akif'ev AP, et al. **Radiats Biol Radioecol** 1999 Jan-Feb;39(1):5-9 (21 ref.) (Eng. Abstr.) **(Rus)**

[Small doses and synergistic interaction of environmental factors] Petin VG, et al. **Radiats Biol Radioecol** 1999 Jan-Feb;39(1):113-26 (36 ref.) (Eng. Abstr.) **(Rus)**

METHODS

DNA damage and repair in individual cells: applications of the comet assay in radiobiology. Olive PL. **Int J Radiat Biol** 1999 Apr;75(4):395-405 (85 ref.)

Applications of amorphous track models in radiation biology. Cucinotta FA, et al. **Radiat Environ Biophys** 1999 Jul; 38(2):81-92 (78 ref.)

Modelling radiation-induced biological lesions: from initial energy depositions to chromosome aberrations. Ottolenghi A, et al. **Radiat Environ Biophys** 1999 May;38(1):1-13 (76 ref.)

RADIOCHEMISTRY

METHODS

Determination of plasmalogen-selective phospholipase A2 activity by radiochemical and fluorometric assay procedures. Farooqui AA, et al. **Methods Mol Biol** 1999; 109:39-47 (15 ref.)

RADIODERMATITIS

EPIDEMIOLOGY

The CHART regimen and morbidity. Dische S, et al. **Acta Oncol** 1999;38(2):147-52 (12 ref.)

ETIOLOGY

Chronic radiodermatitis following cardiac catheterisation: a report of two cases and a brief review of the literature. Dehen L, et al. **Heart** 1999 Mar;81(3):308-12 (22 ref.)

Atypical acute reaction associated with radiotherapy: a case report. Akmansu M, et al. **Radiat Med** 1998 Sep-Oct; 16(5):379-82 (11 ref.)

[Photo-aging] Paredes BE, et al. **Ther Umsch** 1999 Apr; 56(4):188-93 (23 ref.) (Eng. Abstr.) **(Ger)**

[Radiotherapy-induced pemphigus] Correia MP, et al. **Acta Med Port** 1998 Jun;11(6):581-3 (15 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Individual skin care during radiation therapy. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:74-7 (19 ref.)

[Prevention of ultraviolet ray damage: external and internal sunscreens] Grundmann JU, et al. **Ther Umsch** 1999 Apr; 56(4):225-32 (48 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHIC FILM see **X-RAY FILM**

RADIOGRAPHIC IMAGE ENHANCEMENT

Impact of new digital X- and gamma ray imaging systems upon patient doses. Speller R, et al. **Appl Radiat Isot** 1999 Jan;50(1):153-63 (52 ref.)

Filmless cardiac imaging: motion or commotion? Vastenaeken GD. **Int J Card Imaging** 1998;14 Suppl 1:19-22 (0 ref.)

Algorithms for radiological image registration and their clinical application. Hawkes DJ. **J Anat** 1998 Oct;193 (Pt 3):347-61 (49 ref.)

Digital medical image management. Furlow B. **Radiol Technol** 1999 May-Jun;70(5):434-45; quiz 446-8 (31 ref.)

METHODS

Replacement of cinefilm with a digital archive and review network. Cusma JT, et al. **Int J Card Imaging** 1998 Oct; 14(5):293-300 (10 ref.)

The status of the GE approach to the digital catheterization laboratory. Herro PJ. **Int J Card Imaging** 1998 Oct; 14(5):329-33 (0 ref.)

The Camtronics experience with the filmless digital catheterization laboratory. Kapp MA, et al. **Int J Card Imaging** 1998 Oct;14(5):343-8 (3 ref.)

The effect of DICOM on QCA and clinical trials. Reiber JH, et al. **Int J Card Imaging** 1998;14 Suppl 1:7-12 (17 ref.)

Digital networking and archiving with ACOM T.O.P. Saalfrank W. **Int J Card Imaging** 1998 Oct;14(5):323-7 (0 ref.)

Integration of haemodynamic and electrocardiographic waveform data with DICOM images. Solomon HP. **Int J Card Imaging** 1998 Oct;14(5):301-6 (11 ref.)

Integrated image storage solution for the Cath department. Weterings RA. **Int J Card Imaging** 1998 Oct;14(5):349-56 (8 ref.)

Application of the advanced communications technology satellite to teleradiology and real-time compressed ultrasound video telemedicine. Stewart BK, et al. **J Digit Imaging** 1999 May;12(2):68-76 (12 ref.)

Do acute lesions of Wernicke's encephalopathy show contrast enhancement? Report of three cases and review of the literature. Mascalchi M, et al. **Neuroradiology** 1999 Apr;41(4):249-54 (20 ref.)

Principles of digital radiography with large-area, electronically readable detectors: a review of the basics. Chotas HG, et al. **Radiology** 1999 Mar;210(3):595-9 (21 ref.)

[Quantitative angiography: update for peripheral vascular applications] Beregi JP, et al. **J Radiol** 1999 Aug; 80(8):835-41 (26 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Clinical importance of the DICOM structured reporting standard. Bidgood WD Jr. **Int J Card Imaging** 1998 Oct; 14(5):307-15 (22 ref.)

The DICOM review stations: are they truly different? Goedhart B, et al. **Int J Card Imaging** 1998 Oct; 14(5):317-22 (7 ref.)

The Kodak approach to digital cardiovascular imaging laboratories. Pelanek GA. **Int J Card Imaging** 1998 Oct; 14(5):335-42 (2 ref.)

TRENDS

The digital cardiac network: today and the future. Katz S. **Int J Card Imaging** 1998;14 Suppl 1:23-5 (2 ref.)

Digital image in cardiology now and for the future. Okano A. **Int J Card Imaging** 1998;14 Suppl 1:13-5 (0 ref.)

Advances in three-dimensional diagnostic radiology. ter Haar Romeny BM, et al. **J Anat** 1998 Oct;193 (Pt 3):363-71 (20 ref.)

RADIOGRAPHIC PHANTOMS see **PHANTOMS, IMAGING**

RADIOGRAPHY

see related
CONTRAST MEDIA
EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS
TECHNOLOGY, RADIOLOGIC

Use of the concept of energy imparted in diagnostic radiology. Carlsson GA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):39-62 (100 ref.)

Characteristics of radiation detectors for diagnostic radiology. DeWerd LA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):125-36 (52 ref.)

Measurement of image quality in diagnostic radiology. Martin CJ, et al. **Appl Radiat Isot** 1999 Jan;50(1):21-38 (72 ref.)

Diagnostic medical exposures in the U.K. Shrimpton PC, et al. **Appl Radiat Isot** 1999 Jan;50(1):261-9 (55 ref.)

ADVERSE EFFECTS

Somatic effects in nuclear medicine and radiology. Overbeek FJ, et al. **Appl Radiat Isot** 1999 Jan;50(1):63-72 (48 ref.)

[Control of effective doses in x-ray studies] Stavitskiĭ RV, et al. **Med Tekh** 1999 Mar-Apr;(2):39-44 (41 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Humanity and radiation: the good, the bad, and the unusual. Holcomb WF. **Mil Med** 1999 Jul;164(7):520-5 (37 ref.)

STANDARDS

Performance assessment of patient dosimetry services and X-ray quality assurance instruments used in diagnostic radiology. Green S, et al. **Appl Radiat Isot** 1999 Jan; 50(1):137-52 (23 ref.)

[Radiological expertise and diagnosis. I. Theoretical advances] Raufaste E, et al. **J Radiol** 1998 Mar;79(3):227-34 (41 ref.) (Eng. Abstr.) **(Fre)**

[The Emperor's New Clothes syndrome. Description of a new epidemic] Born JD. **Rev Med Liege** 1998 Jul; 53(7):393-8 (9 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

[X-ray examinations in Norway--optimized use of radiation and radiation protection] Olerud HM. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1322-5 (21 ref.) **(Nor)**

TRENDS

Scoliosis circa 2000: radiologic imaging perspective. I. Diagnosis and pretreatment evaluation. Oestreich AE, et al. **Skeletal Radiol** 1998 Nov;27(11):591-605 (75 ref.)

RADIOGRAPHY, ABDOMINAL

Radiology versus endoscopy of the small bowel. Lewis BS. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):13-27 (56 ref.)

Plain films and cross-sectional imaging for acute abdominal pain: unresolved issues. Baker SR. **Semin Ultrasound CT MR** 1999 Apr;20(2):142-7 (24 ref.)

Unenhanced CT of abdominal and pelvic hemorrhage. Katz DS, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):94-107 (56 ref.)

[Hemoperitoneum as the form of presentation of hepatocellular carcinoma. The contribution of computed tomography to the diagnosis] da Fonseca CR, et al. **Acta Med Port** 1999 Apr-Jun;12(4-6):223-6 (15 ref.) (Eng. Abstr.) **(Por)**

METHODS

Percutaneous radiologic placement of peritoneal dialysis catheters. Savader SJ. **J Vasc Interv Radiol** 1999 Mar; 10(3):249-56 (28 ref.)

Advances in abdominal interventional radiology. Dondelinger RF. **Lancet** 1999 Apr;353 Suppl 1:SI15-8 (11 ref.)

Helical CT applications in the thorax and abdomen. Rappaport DC. **Postgrad Med** 1998 Nov;104(5):105-8, 113-4 (19 ref.)

RADIOGRAPHY, DENTAL

An update on dental imaging [see comments] Whaites E, et al. **Br Dent J** 1998 Aug 22;185(4):166-72 (17 ref.) Comment in: Br Dent J 1998 Dec 12-26;185(11-12):558-9.

INSTRUMENTATION

[Dental CT: image quality and radiation exposure in relation to scan parameters] Schorn C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):137-44 (24 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Oral-dental radiographic examination technique. Eisner ER. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1063-87, v (20 ref.)

RADIOGRAPHY, INTERVENTIONAL

Radiologic evaluation and management of malfunctioning long-term central vein catheters. Kidney DD, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1251-7 (40 ref.)

Laparoscopic ultrasonography versus operative cholangiography during laparoscopic cholecystectomy: review of the literature and a comparison with open intraoperative ultrasonography. Machi J, et al. **J Am Coll Surg** 1999 Apr;188(4):360-7 (32 ref.)

Interventional radiology of the liver and pancreas. Newman J. **Radiol Technol** 1999 Jul-Aug;70(6):513-30; quiz 531-3 (25 ref.)

[Computed tomography-guided diagnostic puncture in abdominal pathology] de Mey J, et al. **J Radiol** 1999 Jan; 80(1):11-6 (33 ref.) (Eng. Abstr.) **(Fre)**

[Effects on vasomotor tone and hemostatic function of radiologic contrast media used during invasive cardiological procedures] De Caterina R, et al. **G Ital Cardiol** 1999 Sep;29(9):1047-52 (40 ref.) (Eng. Abstr.) **(Ita)**

[Progress in interventional radiology (IVR) in emergency medicine] Nishimaki H, et al. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):435-42 (27 ref.)

(Eng. Abstr.) **(Jpn)**
[Interventional radiology for recurrent cancer] Uchida H, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):220–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

An improved reversal technique from retrograde to antegrade femoral artery cannulation. Hartnell G. **Cardiovasc Intervent Radiol** 1998 Nov–Dec;21(6):512–3 (5 ref.)
Case presentations of neuroradiologic interventions for acute cerebrovascular disease. Bader MK. **J Cardiovasc Nurs** 1998 Oct;13(1):1–16 (26 ref.)
Interventional cardiac catheterization. Pihkala J, et al. **Pediatr Clin North Am** 1999 Apr;46(2):441–64 (181 ref.)
[Superior vena cava endoprostheses] Lacombe P, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S157–61 (22 ref.) **(Fre)**
[Interventional catheterization in pediatric cardiology] Massin M. **Rev Med Liege** 1999 Jan;54(1):22–7 (11 ref.) (Eng. Abstr.) **(Fre)**
[A coated stent as alternative therapy for stopping a tumor-induced arrosive hemorrhage] Steudel A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):324–6 (10 ref.) **(Ger)**
[Interventional radiology for the peripheral vascular occlusive disease] Kurata T, et al. **Nippon Rinsho** 1999 Jul; 57(7):1577–82 (13 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Interventional neuroradiology. Recent developments and anaesthesiologic aspects. Luginbühl M, et al. **Minerva Anestesiol** 1999 Jun;65(6):445–54 (80 ref.)

RADIOGRAPHY, PANORAMIC

[Image deformation resulting from panoramic zonography of different facial cranial regions] Arzhantsev AP, et al. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):36–8 (0 ref.) **(Rus)**

RADIOGRAPHY, THORACIC

Spiral CT: thoracic applications. Padhani AR. **Eur J Radiol** 1998 Aug;28(1):2–17 (77 ref.)
Normal chest radiograph and lung function do not necessarily mean normal lungs [editorial; comment] Shimura S. **Intern Med** 1998 Nov;37(11):901–2 (10 ref.) Comment on: Intern Med 1998 Nov;37(11):922–6.
Chest radiography: potential and limitations. Schaefer-Prokop C. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):10–1 (14 ref.)
[Significance and role of radiation studies in complex diagnosis of exogenous allergic alveolitis] Dmitrieva LI, et al. **Probl Tuberk** 1998;(6):40–4 (0 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

[Radiation exposure during thoracic radiography at the intensive care unit. Dose accumulation and risk of radiation-induced cancer in long-term therapy] Leppek R, et al. **Radiologe** 1998 Sep;38(9):730–6 (42 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

To chest x-rays and beyond!! [editorial; comment] Helfaer M. **Crit Care Med** 1999 Aug;27(8):1676–7 (18 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1588–93.

METHODS

Thoracic foreign bodies in adults. Kavanagh PV, et al. **Clin Radiol** 1999 Jun;54(6):353–60 (17 ref.)
Helical CT applications in the thorax and abdomen. Rappaport DC. **Postgrad Med** 1998 Nov;104(5):105–8, 113–4 (19 ref.)
The ribs: anatomic and radiologic considerations. Kurihara Y, et al. **Radiographics** 1999 Jan–Feb;19(1):105–19; quiz 151–2 (16 ref.)
Three-dimensional CT angiography of the thorax: clinical applications. Kawamoto S, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):425–38 (46 ref.)

RADIOIMMUNOASSAY

Development and review of radioimmunoassay of 12-S-hydroxyheptadecatrienoic acid. John H, et al. **Prostaglandins Other Lipid Mediat** 1998 Jun;56(2–3):53–76 (117 ref.)

METHODS

[The progress and methodologic problems of in vitro radioassay] Ikekubo K. **Kaku Igaku** 1998 Jul;35(6):357–66 (27 ref.) (Eng. Abstr.) **(Jpn)**

RADIOIMMUNOCONJUGATES see **IMMUNOCONJUGATES**

RADIOIMMUNODETECTION

Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies. Mariani G. **Ann Oncol** 1999;10 Suppl 4:37–40 (36 ref.)
A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging. Moffat FL Jr, et al. **Cancer Invest** 1999;17(5):322–34 (61 ref.)
Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L, et al. **Nucl Med Commun** 1999 Aug;20(8):689–96 (26 ref.)
Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation. Roselli M, et al. **Semin Surg Oncol** 1998 Dec;15(4):254–62 (49 ref.)
Novel diagnostic and therapeutic strategies with genetically engineered human antibodies. Ouwehand WH, et al. **Vox Sang** 1998;74 Suppl 2:223–32 (53 ref.)
[Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies] Oriuchi N. **Gan To Kagaku Ryoho** 1999 May;26(6):762–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Intraoperative probes and imaging probes. Hoffman EJ, et al. **Eur J Nucl Med** 1999 Aug;26(8):913–35 (159 ref.)
Clinical applications of gamma-detection probes – radioguided surgery. Schneebaum S, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S26–35 (68 ref.)
Radioimmunoguided surgery for colorectal carcinoma. Filez L, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):691–700 (78 ref.)

METHODS

Breast cancer imaging with radiolabeled antibodies. Goldenberg DM, et al. **Semin Nucl Med** 1999 Jan; 29(1):41–8 (72 ref.)
The radioimmunoguided surgery (RIGS) system as a diagnostic tool. Bakalakos EA, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):129–44 (37 ref.)
[Diagnostic techniques for bronchial cancer. New scintigraphic techniques (immunoscintigraphy and positron-emission tomography)] Vaylet F, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S78–82 (24 ref.) **(Fre)**

RADIOIMMUNOIMAGING see **RADIOIMMUNODETECTION**

RADIOIMMUNOSCINTIGRAPHY see **RADIOIMMUNODETECTION**

RADIOIMMUNOTHERAPY

Radioimmunotherapy with alpha-emitting nuclides. McDevitt MR, et al. **Eur J Nucl Med** 1998 Sep; 25(9):1341–51 (68 ref.)
[Radioimmunotherapy of lymphomas and leukemias] Rain JD, et al. **Pathol Biol (Paris)** 1998 May;46(5):341–5 (14 ref.) (Eng. Abstr.) **(Fre)**
[Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies] Oriuchi N. **Gan To Kagaku Ryoho** 1999 May;26(6):762–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Iznaga-Escobar N. **Nucl Med Biol** 1998 Jul;25(5):441–7 (58 ref.)
Improving monoclonal antibody pharmacokinetics via chemical modification. Sharifi J, et al. **Q J Nucl Med** 1998 Dec;42(4):242–9 (31 ref.)

TRENDS

Radioimmunotherapy of hematological cancer: problems and progress. Jurcic JG, et al. **Clin Cancer Res** 1995 Dec; 1(12):1439–46 (69 ref.)

RADIOISOTOPE BRACHYTHERAPY see **BRACHYTHERAPY**

RADIOISOTOPE DILUTION TECHNIQUE

Of flux and flooding: the advantages and problems of different isotopic methods for quantifying protein turnover in vivo: I. Methods based on the dilution of a tracer. Reeds PJ, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan; 2(1):23–8 (48 ref.)

RADIOISOTOPE RENOGRAPHY

Renographic indices for evaluation of changes in graft function. El-Maghraby TA, et al. **Eur J Nucl Med** 1998 Nov;25(11):1575–86 (79 ref.)
Quantitative scintigraphic parameters for the assessment of renal transplant patients. el Maghraby TA, et al. **Eur J Radiol** 1998 Oct;28(3):256–69 (74 ref.)
[Radioisotopic studies in the diagnosis of obstructive uropathy] Testa HJ. **Rev Esp Med Nucl** 1999 Jun; 18(3):214–24 (43 ref.) **(Spa)**

METHODS

Interventions in renal scintirenography. Fine EJ. **Semin Nucl Med** 1999 Apr;29(2):128–45 (78 ref.)
Radionuclide renography: a personal approach. Taylor A. **Semin Nucl Med** 1999 Apr;29(2):102–27 (104 ref.)

STANDARDS

Quality assurance in renography: a review. Cosgriff PS. **Nucl Med Commun** 1998 Jul;19(7):711–6 (50 ref.)
Report of the Radionuclides in Nephrourology Committee for evaluation of transplanted kidney (review of techniques). Dubovsky EV, et al. **Semin Nucl Med** 1999 Apr;29(2):175–88 (43 ref.)
Consensus on renal cortical scintigraphy in children with urinary tract infection. Scientific Committee of Radionuclides in Nephrourology. Piepsz A, et al. **Semin Nucl Med** 1999 Apr;29(2):160–74 (125 ref.)
Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International Consensus Committee from the Scientific Committee of Radionuclides in Nephrourology. Prigent A, et al. **Semin Nucl Med** 1999 Apr;29(2):146–59 (112 ref.)

RADIOISOTOPE SCANNING see **RADIONUCLIDE IMAGING**

RADIOISOTOPE TELETHERAPY

Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Khan DC, et al. **Cancer Invest** 1999;17(2):110–3 (24 ref.)

RADIOISOTOPES

see related
ISOTOPE LABELING
ISOTOPES

Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia. Krasikova RN, et al. **Eur J Nucl Med** 1999 Jul;26(7):774–88 (125 ref.)

DIAGNOSTIC USE

Diagnostic medical exposures in the U.K. Shrimpton PC, et al. **Appl Radiat Isot** 1999 Jan;50(1):261–9 (55 ref.)
[The significance of radioisotopic methods in internal diseases diagnosis] Rogulski B, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):44–6 (10 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Transplacental transfer of radionuclides. A review. von Zallinger C, et al. **Zentralbl Veterinarmed A** 1998 Dec; 45(10):581–90 (45 ref.)

THERAPEUTIC USE

Radiation dosimetry in nuclear medicine. Stabin MG, et al. **Appl Radiat Isot** 1999 Jan;50(1):73–87 (84 ref.)
Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. Mertens WC, et al. **CA Cancer J Clin** 1998 Nov–Dec;48(6):361–74, 321 (89 ref.)

RADIOLIGAND ASSAY

METHODS

Solubilized muscarinic acetylcholine receptors from the rat myocardium: pharmacological and hydrodynamic characterization. Berrie CP, et al. **Methods Mol Biol** 1999; 106:73–87 (9 ref.)
[3H]-GABA binding to GABAA and GABAB sites on rat brain crude synaptic membranes. Bruton R, et al. **Methods Mol Biol** 1999;106:27–35 (16 ref.)
Radioligand binding to solubilized 5-HT3 receptors. Fletcher S, et al. **Methods Mol Biol** 1999;106:49–71 (29 ref.)
Characterization of imidazoline receptors by radioligand binding. Hudson AL, et al. **Methods Mol Biol** 1999; 106:37–47 (12 ref.)
Definition of receptors in radioligand-binding experiments. Keen M. **Methods Mol Biol** 1999;106:187–96 (19 ref.)
Radioligand binding in intact cells. Koenig JA. **Methods Mol Biol** 1999;106:89–98 (18 ref.)
Measurement of agonist-stimulated [35S]GTP gamma S binding to cell membranes. Lazareno S. **Methods Mol Biol** 1999;106:231–45 (43 ref.)
Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation. Hume SP, et al. **Nucl Med Biol** 1998 Nov;25(8):729–32 (43 ref.)

STATISTICS & NUMERICAL DATA

Methods and data analyses in radioligand-receptor binding: unnecessary transformations may cause biased results. Nowak G. **Pol J Pharmacol** 1998 Mar–Apr;50(2):101–5 (10 ref.)

RADIOLOGIC HEALTH

Humanity and radiation: the good, the bad, and the unusual. Holcomb WF. **Mil Med** 1999 Jul;164(7):520–5 (37 ref.)

RADIOLOGIC PHANTOMS see **PHANTOMS, IMAGING**

RADIOLOGIC PHYSICS see **HEALTH PHYSICS**

RADIOLOGY

Forensic radiology. Kahana T, et al. **Br J Radiol** 1999 Feb; 72(854):129–33 (24 ref.)

Turf battles in radiology: how to avoid/how to fight/how to win. Schnyder P, et al. **Eur Radiol** 1999;9(4):741–8 (37 ref.)

World Wide Web and Internet: applications for radiologists. Wunderbaldinger P, et al. **Eur Radiol** 1999;9(6):1170–82 (50 ref.)

[The neuro-radiologist's approach to the diagnosis and treatment of diseases of the nervous system (editorial)] Solé-Llenas J. **Rev Neurol** 1999 Apr 1–15;28(7):708–10 (13 ref.) **(Spa)**

EDUCATION

A core curriculum in the evaluative sciences for diagnostic imaging [editorial] Stolberg HO, et al. **Can Assoc Radiol J** 1998 Oct;49(5):295–306 (66 ref.)

Towards quality assurance of postgraduate training in radiology. Needham G. **Clin Radiol** 1999 Mar;54(3):140–3 (9 ref.)

Focused abdominal sonogram for trauma: the learning curve of nonradiologist clinicians in detecting hemoperitoneum. Shackford SR, et al. **J Trauma** 1999 Apr;46(4):553–62; discussion 562–4 (40 ref.)

[Radiological expertise and diagnosis. I. Theoretical advances] Raufaste E, et al. **J Radiol** 1998 Mar;79(3):227–34 (41 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

[Principles of medical liability and practice in medical imaging] Thibierge M, et al. **J Radiol** 1999 Jul;80(7):701–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Rights and responsibilities of the radiologist in determining indications and applying radiologic procedures] Schunk K. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):7–15 (29 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[New non-ionic monomeric and dimeric contrasting agents in radiology] Sviridov NK. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):56–7 (25 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

The radical revolution of radiology. Nauert RC. **J Health Care Finance** 1998 Winter;25(2):9–19 (0 ref.)

STANDARDS

Minimizing occupational exposure. Shymko MJ. **Radiol Technol** 1998 Sep–Oct;70(1):89–90 (3 ref.)

TRENDS

The radical revolution of radiology. Nauert RC. **J Health Care Finance** 1998 Winter;25(2):9–19 (0 ref.)

Research in pediatric radiology: preparing for our future. Strife JL, et al. **Pediatr Radiol** 1998 Aug;28(8):563–8 (13 ref.)

RADIOLOGY DEPARTMENT, HOSPITAL

STANDARDS

The radiology department and nosocomial infections. Shagam JY. **Radiol Technol** 1999 May–Jun;70(5):418–30; quiz 431–3 (6 ref.)

RADIOLOGY, DIAGNOSTIC X-RAY see **RADIOGRAPHY**

RADIOLOGY INFORMATION SYSTEMS

Increasing spiral CT benefits with postprocessing applications. Kirchgeorg MA, et al. **Eur J Radiol** 1998 Aug; 28(1):39–54 (81 ref.)

PACS: the silent revolution. Bick U, et al. **Eur Radiol** 1999; 9(6):1152–60 (71 ref.)

Integrating HIS-RIS-PACS: the Freiburg experience. Kotter E, et al. **Eur Radiol** 1998;8(9):1707–18 (47 ref.)

Replacement of cinefilm with a digital archive and review network. Cusma JT, et al. **Int J Card Imaging** 1998 Oct; 14(5):293–300 (10 ref.)

The status of the GE approach to the digital catheterization laboratory. Herro PJ. **Int J Card Imaging** 1998 Oct; 14(5):329–33 (0 ref.)

Integrated image storage solution for the Cath department. Weterings RA. **Int J Card Imaging** 1998 Oct;14(5):349–56 (8 ref.)

Digital medical image management. Furlow B. **Radiol Technol** 1999 May–Jun;70(5):434–45; quiz 446–8 (31 ref.)

[Clinical computer applications in the radiology department] Ando Y. **Rinsho Byori** 1999 Feb;47(2):111–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

The Camtronics experience with the filmless digital catheterization laboratory. Kapp MA, et al. **Int J Card Imaging** 1998 Oct;14(5):343–8 (3 ref.)

Digital networking and archiving with ACOM T.O.P. Saalfrank W. **Int J Card Imaging** 1998 Oct;14(5):323–7 (0 ref.)

STANDARDS

Clinical importance of the DICOM structured reporting standard. Bidgood WD Jr. **Int J Card Imaging** 1998 Oct; 14(5):307–15 (22 ref.)

The DICOM review stations: are they truly different? Goedhart B, et al. **Int J Card Imaging** 1998 Oct; 14(5):317–22 (7 ref.)

The Kodak approach to digital cardiovascular imaging laboratories. Pelanek GA. **Int J Card Imaging** 1998 Oct; 14(5):335–42 (2 ref.)

TRENDS

Digital image in cardiology now and for the future. Okano A. **Int J Card Imaging** 1998;14 Suppl 1:13–5 (0 ref.)

RADIOLOGY, INTERVENTIONAL

Interventional neuroradiology. Nakstad PH. **Acta Radiol** 1999 Jul;40(4):344–59 (148 ref.)

The interventional neuroradiological treatment of intracranial aneurysms. Guglielmi G. **Adv Tech Stand Neurosurg** 1998; 24:215–60 (79 ref.)

Interventional magnetic resonance: realistic prospect or wishful thinking? Günther RW, et al. **Cardiovasc Intervent Radiol** 1999 May–Jun;22(3):187–95 (61 ref.)

Radiological management of oesophageal strictures. Cowling MG, et al. **Hosp Med** 1998 Sep;59(9):693–7 (17 ref.)

Percutaneous radiologic placement of peritoneal dialysis catheters. Savader SJ. **J Vasc Interv Radiol** 1999 Mar; 10(3):249–56 (28 ref.)

Brain biopsy using high-field strength interventional magnetic resonance imaging. Hall WA, et al. **Neurosurgery** 1999 Apr;44(4):807–13; discussion 813–4 (11 ref.)

Interventional procedures for congenital heart disease. Mandell VS. **Radiol Clin North Am** 1999 Mar;37(2):439–61, vii (98 ref.)

[Progresses in the study of radiology in China, 1997] Zhang X. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):926–7 (0 ref.) **(Chi)**

[Quality measures in interventional radiology] Heuser L. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):131–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Interventional radiology—an option in minimally invasive therapy] Mutze S, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):238–44 (24 ref.) (Eng. Abstr.) **(Ger)**

[Radiation hazards in interventional radiology] Widmark A, et al. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4543–5 (14 ref.) **(Nor)**

METHODS

Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Palma LD. **Br J Radiol** 1998 Aug;71(848):808–18 (73 ref.)

The radioimmunoguided surgery (RIGS) system as a diagnostic tool. Bakalakos EA, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):129–44 (37 ref.)

[Arterial embolization: present role of an old method of interventional radiology in the treatment of hemorrhages] Florio F, et al. **Radiol Med (Torino)** 1999 Mar;97(3):107–15 (28 ref.) **(Ita)**

STANDARDS

Plea for a "surgical conscience" in the interventional radiology suite. Joffre F, et al. **Cardiovasc Intervent Radiol** 1998 Nov–Dec;21(6):445–7 (15 ref.)

Surgical face masks: are they mandatory for interventional endovascular procedures? Taylor PR, et al. **Cardiovasc Intervent Radiol** 1998 Nov–Dec;21(6):448–9 (22 ref.)

RADIOLOGY, THERAPEUTIC see **RADIATION ONCOLOGY**

RADIOMETRY

Breast dosimetry. Dance DR, et al. **Appl Radiat Isot** 1999 Jan;50(1):185–203 (77 ref.)

Radiation dose in interventional fluoroscopic procedures. Geise RA, et al. **Appl Radiat Isot** 1999 Jan;50(1):173–84 (61 ref.)

Dosimetry for optimisation of patient protection in computed tomography. Jessen KA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):165–72 (27 ref.)

Radiation dosimetry in nuclear medicine. Stabin MG, et al. **Appl Radiat Isot** 1999 Jan;50(1):73–87 (84 ref.)

[Radiation exposure and computed tomography] Trigaux JP, et al. **Rev Mal Respir** 1999 Apr;16(2):127–36 (21 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Characteristics of radiation detectors for diagnostic radiology. DeWerd LA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):125–36 (52 ref.)

Performance assessment of patient dosimetry services and X-ray quality assurance instruments used in diagnostic radiology. Green S, et al. **Appl Radiat Isot** 1999 Jan; 50(1):137–52 (23 ref.)

Impact of new digital X- and gamma ray imaging systems upon patient doses. Speller R, et al. **Appl Radiat Isot** 1999 Jan;50(1):153–63 (52 ref.)

METHODS

Industrial hygiene chemistry: keeping pace with rapid change in the workplace. Draper WM, et al. **Anal Chem** 1999 Jun 15;71(12):33R–60R (657 ref.)

Patient dosimetry measurement methods. Faulkner K, et al. **Appl Radiat Isot** 1999 Jan;50(1):113–23 (38 ref.)

Biomedical concerns in wireless communications. Stuchly MA. **Crit Rev Biomed Eng** 1998;26(1-2):117–51 (115 ref.)

NMR microscopy of trabecular bone and its role in skeletal dosimetry. Jokisch DW, et al. **Health Phys** 1998 Dec; 75(6):584–96 (90 ref.)

Assays for pancreatic triglyceride lipase and colipase. Lowe ME. **Methods Mol Biol** 1999;109:59–70 (31 ref.)

[Methodical approaches for establishing the values of spatial non-uniformity radiation coefficients for generalized dose calculation to evaluate immediate radiobiological effects] Shafirkin AV. **Aviakosm Ekolog Med** 1999;33(1):50–6 (36 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Performance assessment of patient dosimetry services and X-ray quality assurance instruments used in diagnostic radiology. Green S, et al. **Appl Radiat Isot** 1999 Jan; 50(1):137–52 (23 ref.)

In vivo dosimetry during external photon beam radiotherapy. Essers M, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):245–59 (126 ref.)

Radiation interactions and internal dosimetry in nuclear medicine. Simpkin DJ. **Radiographics** 1999 Jan–Feb; 19(1):155–67; quiz 153–4 (15 ref.)

RADIONUCLIDE ANGIOGRAPHY, GATED see **GATED BLOOD-POOL IMAGING**

RADIONUCLIDE IMAGING

see related
GAMMA CAMERAS
SCINTILLATION COUNTING

Imaging gene expression: principles and assays. Gambhir SS, et al. **J Nucl Cardiol** 1999 Mar–Apr;6(2):219–33 (70 ref.)

Relevance of accurate Monte Carlo modeling in nuclear medical imaging. Zaidi H. **Med Phys** 1999 Apr; 26(4):574–608 (288 ref.)

Dying a thousand deaths. Radionuclide imaging of apoptosis. Blankenberg F, et al. **Q J Nucl Med** 1999 Jun;43(2):170–6 (50 ref.)

Polypeptides from phage display. A superior source of in vivo imaging agents. Ladner RC. **Q J Nucl Med** 1999 Jun; 43(2):119–24 (44 ref.)

ADVERSE EFFECTS

Somatic effects in nuclear medicine and radiology. Overbeek FJ, et al. **Appl Radiat Isot** 1999 Jan;50(1):63–72 (48 ref.)

INSTRUMENTATION

Intraoperative probes and imaging probes. Hoffman EJ, et al. **Eur J Nucl Med** 1999 Aug;26(8):913–35 (159 ref.)

Radio-imaging for quantitative autoradiography in biology. Charon Y, et al. **Nucl Med Biol** 1998 Nov;25(8):699–704 (26 ref.)

METHODS

Liposomes for scintigraphic imaging: optimization of in vivo behavior. Boerman OC, et al. **Q J Nucl Med** 1998 Dec; 42(4):271–9 (70 ref.)

TRENDS

[Progress of nuclear oncology] Endo K. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1261–8 (3 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE TOMOGRAPHY, COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED**

RADIONUCLIDE TOMOGRAPHY, SINGLE-PHOTON EMISSION-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

RADIONUCLIDE VENTRICULOGRAPHY

Choosing the appropriate stress modality. A clinical cardiologist's perspective. Crawford MH. **Cardiol Clin** 1999 Aug;17(3):597–606, x (28 ref.)

RADIONUCLIDE VENTRICULOGRAPHY, GATED see **GATED BLOOD-POOL IMAGING**

RADIONUCLIDES see **RADIOISOTOPES**

RADIOPAQUE MEDIA see **CONTRAST MEDIA**

RADIOPHARMACEUTICALS

Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia. Krasikova RN, et al. **Eur J Nucl Med** 1999 Jul;26(7):774–88 (125 ref.)

PET and drug research and development. Fowler JS, et al. **J Nucl Med** 1999 Jul;40(7):1154–63 (102 ref.)

Radiopharmaceuticals in PET imaging. Duncan K. **J Nucl Med Technol** 1998 Dec;26(4):228–34; quiz 242 (17 ref.)

ADMINISTRATION & DOSAGE

Radiation interactions and internal dosimetry in nuclear medicine. Simpkin DJ. **Radiographics** 1999 Jan–Feb; 19(1):155–67; quiz 153–4 (15 ref.)

Administered radionuclides in pregnancy. Adelstein SJ. **Teratology** 1999 Apr;59(4):236–9 (10 ref.)

ADVERSE EFFECTS

Exposure of critical groups to nuclear medicine patients. Mountford PJ, et al. **Appl Radiat Isot** 1999 Jan;50(1):89–111 (99 ref.)

ANALYSIS

In vivo radiolabel quantification in small-animal models. Ploux L, et al. **Nucl Med Biol** 1998 Nov;25(8):737–42 (37 ref.)

CHEMICAL SYNTHESIS

Compounds labelled with short-lived beta(+)-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. Långström B, et al. **Acta Chem Scand** 1999 Sep;53(9):651–69 (76 ref.)

CHEMISTRY

Polypeptides from phage display. A superior source of in vivo imaging agents. Ladner RC. **Q J Nucl Med** 1999 Jun; 43(2):119–24 (44 ref.)

DIAGNOSTIC USE

18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Rose DM, et al. **Ann Surg** 1999 May;229(5):729–37; discussion 737–8 (42 ref.)

Radionuclide scanning in parathyroid diseases. Pattou F, et al. **Br J Surg** 1998 Dec;85(12):1605–16 (130 ref.)

Technetium Tc 99m sestamibi myocardial perfusion imaging: current role for evaluation of prognosis. Mandalapu BP, et al. **Chest** 1999 Jun;115(6):1684–94 (77 ref.)

Role of PET FDG in the management of head and neck squamous cell cancer. Wong WL, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):361–6 (41 ref.)

Nuclear medicine procedures in lung cancer. Chiti A, et al. **Eur J Nucl Med** 1999 May;26(5):533–55 (194 ref.)

Radiopharmaceuticals in sentinel lymph-node detection – an overview. Wilhelm AJ, et al. **Eur J Nucl Med** 1999 Apr; 26(4 Suppl):S36–42 (50 ref.)

99m-Tc-tetrofosmin scintigraphy and breast cancer. Berghammer P, et al. **Gynecol Oncol** 1999 Apr;73(1):87–90 (16 ref.)

18F-labeled 2-deoxy-2-fluoro-D-glucose positron-emission tomography scans for the localization of the epileptogenic foci. Hotta SS. **Health Technol Assess (Rockv)** 1998 Jul; (12):i–vi, 1–17 (71 ref.)

Radionuclide imaging probes for expressed proteins. Fischman AJ. **J Nucl Cardiol** 1999 Jul–Aug;6(4):438–48 (58 ref.)

18-Fluorodeoxyglucose imaging in oncology. Harolds JA. **J Okla State Med Assoc** 1999 Sep;92(9):457–61 (36 ref.)

Radiopharmaceuticals for sentinel node detection. Frier M. **Nucl Med Commun** 1999 Apr;20(4):306–8 (12 ref.)

Radiolabelled antimicrobial peptides for imaging of infections: a review. Nibbering PH, et al. **Nucl Med Commun** 1998 Dec;19(12):1117–21 (27 ref.)

The role of FDG PET in the clinical management of head and neck cancer. Stokkel MP, et al. **Oral Oncol** 1998 Nov; 34(6):466–71 (63 ref.)

Non-invasive diagnosis of acute heart- or lung-transplant rejection using radiolabeled annexin V. Blankenberg FG, et al. **Pediatr Radiol** 1999 May;29(5):299–305 (53 ref.)

Liposomes for scintigraphic imaging: optimization of in vivo behavior. Boerman OC, et al. **Q J Nucl Med** 1998 Dec; 42(4):271–9 (70 ref.)

Clinical imaging of multidrug resistance in cancer. Del Vecchio S, et al. **Q J Nucl Med** 1999 Jun;43(2):125–31 (47 ref.)

Clinical applications of radiolabeled blood elements in inflammatory bowel disease. Martin-Comin J, et al. **Q J Nucl Med** 1999 Mar;43(1):74–82 (74 ref.)

The clinical role of nuclear medicine in rheumatoid arthritis patients. A comparison with other diagnostic imaging modalities. Vos K, et al. **Q J Nucl Med** 1999 Mar; 43(1):38–45 (74 ref.)

Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals. Weiner RE, et al. **Q J Nucl Med** 1999 Mar;43(1):2–8 (49 ref.)

Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Shreve PD, et al. **Radiographics** 1999 Jan–Feb;19(1):61–77; quiz 150–1 (39 ref.)

Benign causes of 18-FDG uptake on whole body imaging. Bakheet SM, et al. **Semin Nucl Med** 1998 Oct;28(4):352–8 (67 ref.)

Skeletal metastases from breast cancer: imaging with nuclear medicine. Cook GJ, et al. **Semin Nucl Med** 1999 Jan; 29(1):69–79 (61 ref.)

Fatty acids for myocardial imaging. Corbett JR. **Semin Nucl Med** 1999 Jul;29(3):237–58 (89 ref.)

Breast cancer imaging with radiolabeled antibodies. Goldenberg DM, et al. **Semin Nucl Med** 1999 Jan; 29(1):41–8 (72 ref.)

18-FDG imaging in breast cancer. Hoh CK, et al. **Semin Nucl Med** 1999 Jan;29(1):49–56 (35 ref.)

Technetium-99m labeled myocardial perfusion imaging agents. Jain D. **Semin Nucl Med** 1999 Jul;29(3):221–36 (103 ref.)

The current role of infarct avid imaging. Khaw BA. **Semin Nucl Med** 1999 Jul;29(3):259–70 (59 ref.)

The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Taillefer R. **Semin Nucl Med** 1999 Jan;29(1):16–40 (133 ref.)

Relevance of positron emission tomography (PET) in oncology. Weber WA, et al. **Strahlenther Onkol** 1999 Aug; 175(8):356–73 (168 ref.)

Detection of residual and recurrent thyroid cancer by radionuclide imaging. Maxon HR. **Thyroid** 1999 May; 9(5):443–6 (11 ref.)

Diagnosis and staging of pancreatic cancer by positron emission tomography. Berberat P, et al. **World J Surg** 1999 Sep;23(9):882–7 (54 ref.)

[Use of radiopharmaceuticals, radiation burden and radiation risks in examination procedures in nuclear medicine] Hušák V, et al. **Cas Lek Cesk** 1999 May 24;138(11):323–8 (21 ref.) (Eng. Abstr.) **(Cze)**

[Nuclear oncology update] Maublant J, et al. **Bull Cancer** 1999 Jan;86(1):57–64 (66 ref.) **(Fre)**

[Tumor imaging using 201Tl chloride and 67Ga citrate in nucleomedical surveys] Togawa T, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):749–55 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Nuclear oncology with monoclonal antibodies and peptides] Hosono M. **Kaku Igaku** 1998 Oct;35(8):681–7 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical significance of 123I-BMIPP myocardial SPECT] Yamazaki J. **Kaku Igaku** 1998 Jul;35(6):367–73 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation. Hume SP, et al. **Nucl Med Biol** 1998 Nov;25(8):729–32 (43 ref.)

PHARMACOKINETICS

Effects of genetic engineering on the pharmacokinetics of antibodies. Colcher D, et al. **Q J Nucl Med** 1999 Jun; 43(2):132–9 (38 ref.)

The influence of stereoisomerism on the pharmacokinetics of Tc radiopharmaceuticals. Hansen L, et al. **Q J Nucl Med** 1998 Dec;42(4):280–93 (69 ref.)

Transplacental transfer of radionuclides. A review. von Zallinger C, et al. **Zentralbl Veterinarmed A** 1998 Dec; 45(10):581–90 (45 ref.)

THERAPEUTIC USE

Postoperative irradiation of pterygium with 90Sr eye applicator. Fukushima S, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):597–600 (15 ref.)

Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique. Roos DE, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):493–5 (12 ref.)

Therapy and nuclear medicine. O'Doherty MJ. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):536–9 (15 ref.)

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Tepmongkol S, et al. **Med Pediatr Oncol** 1999 Jun;32(6):427–31; discussion 432 (63 ref.)

Radiolabelled somatostatins: towards the magic bullet? [editorial] Buscombe JR, et al. **Nucl Med Commun** 1999 Apr;20(4):299–301 (22 ref.)

Guidelines for the use of radio-iodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Paloyan E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):665–80 (37 ref.)

[Palliative treatment of bone metastases with bone-seeking radionuclides (see comments)] De Klerk JM, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2618–22 (21 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 23;143(4):224. **(Dut)**

TOXICITY

Preclinical evaluation of radiopharmaceutical toxicological prerequisites. Marzin D. **Nucl Med Biol** 1998 Nov; 25(8):733–6 (10 ref.)

RADIOPROTECTIVE AGENTS see **RADIATION-PROTECTIVE AGENTS**

RADIORECEPTOR ASSAY see **RADIOLIGAND ASSAY**

RADIOSENSITIVITY see **RADIATION TOLERANCE**

RADIOSENSITIZING AGENTS see **RADIATION-SENSITIZING AGENTS**

RADIOSURGERY

Stereotactic radiosurgery--the role of charged particles. Levy RP, et al. **Acta Oncol** 1999;38(2):165–9 (21 ref.)

Radiosurgery for the treatment of brain metastases in renal cell carcinoma. Becker G, et al. **Anticancer Res** 1999 Mar–Apr;19(2C):1611–7 (36 ref.)

Stereotactic radiosurgery for acoustic neuroma: a Canadian perspective [see comments] Ross IB, et al. **Can J Neurol Sci** 1998 Nov;25(4):310–4 (20 ref.) Comment in: Can J Neurol Sci 1999 May;26(2):154–5.

Role of radiosurgery in the management of central nervous system metastases. Loeffler JS, et al. **Cancer Chemother Pharmacol** 1999;43 Suppl:S11–4 (18 ref.)

The case for radiosurgery. Alexander E 3rd, et al. **Clin Neurosurg** 1999;45:32–40 (53 ref.)

Radiosurgery versus surgery for arteriovenous malformations: the case for radiosurgery. Friedman WA. **Clin Neurosurg** 1999;45:18–20 (16 ref.)

Surgical treatment of brain metastases. Sawaya R. **Clin Neurosurg** 1999;45:41–7 (34 ref.)

Novel radiation technologies for malignant gliomas. Shafman TD, et al. **Curr Opin Oncol** 1999 May;11(3):147–51 (39 ref.)

Role of gamma knife therapy in the management of pituitary tumors. Jackson IM, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):133–42 (26 ref.)

Clinical applications of gamma-detection probes - radioguided surgery. Schneebaum S, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S26–35 (68 ref.)

Small photon field dosimetry for stereotactic radiosurgery. Duggan DM, et al. **Med Dosim** 1998 Fall;23(3):153–9 (50 ref.)

Image processing in stereotactic planning: volume visualization and image registration. Pelizzari CA. **Med Dosim** 1998 Fall;23(3):137–45 (39 ref.)

Endovascular therapy of brain AVMs prior to radiosurgery. Henkes H, et al. **Neurol Res** 1998 Sep;20(6):479–92 (29 ref.)

[The treatment of intracranial arteriovenous malformations] Hernesniemi J. **Duodecim** 1995;111(21):2039–46 (39 ref.) **(Fin)**

ADVERSE EFFECTS

Imaging changes after radiosurgery for vascular malformations, functional targets, and tumors. Kihlström L, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):167–80 (45 ref.)

INSTRUMENTATION

The Brain Bench: virtual tools for stereotactic frame neurosurgery. Serra L, et al. **Med Image Anal** 1997 Sep; 1(4):317–29 (28 ref.)

METHODS

Fractionated stereotactic radiotherapy: rationale and methods. Solberg TD, et al. **Med Dosim** 1998 Fall; 23(3):209–19 (69 ref.)

Comprehensive management of arteriovenous malformations. de Oliveira E, et al. **Neurol Res** 1998 Dec;20(8):673–83 (1 ref.)

The role of radiosurgery for glial neoplasms. Alexander E 3rd, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):351–8 (66 ref.)

Radiosurgery for brain metastases. Boyd TS, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):337–50 (53 ref.)

Dose selection in stereotactic radiosurgery. Flickinger JC, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):271–80 (25 ref.)

Linear accelerator radiosurgery in brain tumor management. Foote KD, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):203–42 (175 ref.)

Radiosurgery of angiographically occult vascular malformations. Kida Y, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):291–303 (25 ref.)

Stereotactic radiosurgery for meningiomas. Kondziolka D, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):317–25 (21 ref.)

The radiobiology of radiosurgery. Kondziolka D, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):157–66 (48 ref.)

RADIOSURGERY

Radiosurgery for pituitary tumors and craniopharyngiomas. Laws ER Jr, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):327–36 (61 ref.)

Stereotactic radiosurgery for arteriovenous malformations. Pollock BE. **Neurosurg Clin N Am** 1999 Apr;10(2):281–90 (34 ref.)

Extracranial stereotactic radiosurgery: applications for the spine and beyond. Takacs I, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):257–70 (54 ref.)

Gamma Knife radiosurgery: technology, applications, and future directions. Yamamoto M. **Neurosurg Clin N Am** 1999 Apr;10(2):181–202 (160 ref.)

[Stereotactic radiotherapy of central nervous system tumors] Jääskeläinen J, et al. **Duodecim** 1995;111(21):2028–37 (20 ref.) **(Fin)**

[The place of radiosurgery in the treatment of hypophyseal adenoma] Nataf F, et al. **Neurochirurgie** 1998 Dec; 44(5):339–43 (21 ref.) (Eng. Abstr.) **(Fre)**

[Stereotactic one-time irradiation (radiosurgery). The methods, indications and results] Debus J, et al. **Strahlenther Onkol** 1999 Feb;175(2):47–56 (66 ref.) (Eng. Abstr.) **(Ger)**

Noval radiosurgical technique of cuts and hemostasis in otorhinolaryngology] Pogosov VS, et al. **Vestn Otorinolaringol** 1999;(4):40–1 (6 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

The treatment of movement disorders using Gamma Knife stereotactic radiosurgery. Duma CM, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):379–89 (41 ref.)

Can hearing improve after acoustic tumor radiosurgery? Niranjan A, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):305–15 (27 ref.)

Radiosurgery for trigeminal neuralgia and epilepsy. Régis J, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):359–77 (86 ref.)

TRENDS

Functional radiosurgery. Kondziolka D. **Neurosurgery** 1999 Jan;44(1):12–20; discussion 20–2 (48 ref.)

Vestibular schwannoma management in the next century: a radiosurgical perspective. Pollock BE, et al. **Neurosurgery** 1998 Sep;43(3):475–81; discussion 481–3 (48 ref.)

RADIOTHERAPY

When to consider radiation therapy for your patient. Tisdale BA. **Am Fam Physician** 1999 Mar 1;59(5):1177–84 (24 ref.)

Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia. Krasikova RN, et al. **Eur J Nucl Med** 1999 Jul;26(7):774–88 (125 ref.)

Radionuclide therapy. Chatal JF, et al. **Lancet** 1999 Sep 11; 354(9182):931–5 (21 ref.)

[Radiotherapy of the elderly patient. Radiotherapy tolerance and results in older patients] Geinitz H, et al. **Strahlenther Onkol** 1999 Mar;175(3):119–27 (46 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery [see comments] **Am J Health Syst Pharm** 1999 Apr 15;56(8):729–64 (423 ref.) Comment in: Am J Health Syst Pharm 1999 Apr 15;56(8):728.

Treatment-related chronic myelogenous leukemia. Waller CF, et al. **Ann Hematol** 1999 Aug;78(8):341–54 (125 ref.)

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). **Ann Oncol** 1998 Aug;9(8):811–9 (103 ref.)

Long-term toxicity of the treatment of Hodgkin's disease. Armitage JO. **Ann Oncol** 1998;9 Suppl 5:S133–6 (28 ref.)

Radiotherapy in early stage Hodgkin's disease: principles and results of recent clinical trials. Noordijk EM. **Ann Oncol** 1998;9 Suppl 5:S63–5 (15 ref.)

Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Hoekman K, et al. **Drugs** 1999 Feb;57(2):133–55 (213 ref.)

Gonadal damage from chemotherapy and radiotherapy. Howell S, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):927–43 (94 ref.)

Oxidant-induced lung injury in anticancer therapy. Beinert T, et al. **Eur J Med Res** 1999 Feb 25;4(2):43–53 (113 ref.)

Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. Antley CA, et al. **J Cutan Pathol** 1999 Jan;26(1):48–50 (11 ref.)

Neurological complications of radiotherapy and chemotherapy. Keime-Guibert F, et al. **J Neurol** 1998 Nov; 245(11):695–708 (85 ref.)

Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. Esik O, et al. **J Neurol Sci** 1999 Feb 1; 163(1):39–43 (15 ref.)

Radiation-induced esophageal carcinoma 30 years after mediastinal irradiation: case report and review of the literature. Micke O, et al. **Jpn J Clin Oncol** 1999 Mar; 29(3):164–70 (43 ref.)

Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14–8 (23 ref.)

Atypical acute reaction associated with radiotherapy: a case report. Akmansu M, et al. **Radiat Med** 1998 Sep–Oct; 16(5):379–82 (11 ref.)

Future directions in toxicity prevention. Brizel DM. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):17–20 (14 ref.)

Radiation-induced toxicities: the role of radioprotectants. Curran WJ. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):2–4 (14 ref.)

Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine. Mehta MP. **Semin Radiat Oncol** 1998 Oct;8(4 Suppl 1):14–6 (11 ref.)

Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Egeler RM, et al. **Semin Urol Oncol** 1999 Feb;17(1):55–61 (35 ref.)

Clinical impact of predictive assays for acute and late radiation morbidity. Budach W, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:20–4 (30 ref.)

Treatment of radiation proctitis with hyperbaric oxygen: what is the optimal number of HBO treatments? Carl UM, et al. **Strahlenther Onkol** 1998 Sep;174(9):482–3 (11 ref.)

Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Classen J, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:82–4 (29 ref.)

DNA-repair, cell killing and normal tissue damage. Dahm-Daphi J, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:8–11 (30 ref.)

Radiobiological models of normal tissue reactions. Dörr W. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:4–7 (16 ref.)

Radiotherapy-induced emesis. An overview. Feyer P, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:56–61 (36 ref.)

Modern therapy of chronic wounds with respect to radiation. Frank J, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:69–73 (26 ref.)

Management of radiation injuries of vulva and vagina. Fraunholz IB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:90–2 (29 ref.)

The role of cytokines in the development of normal-tissue reactions after radiotherapy. Herskind C, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:12–5 (37 ref.)

The treatment of late radiation effects with hyperbaric oxygenation (HBO). Plafki C, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:66–8 (30 ref.)

Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Zimmermann FB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:85–9 (32 ref.)

Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. Zimmermann FB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:78–81 (30 ref.)

Pharmacological management of acute radiation morbidity. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:62–5 (43 ref.)

Individual skin care during radiation therapy. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:74–7 (19 ref.)

The impact of acute radiation morbidity on therapeutic outcome [editorial] Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:1–3 (24 ref.)

Prevention and management of oral infections in cancer patients [see comments] Heimdahl A. **Support Care Cancer** 1999 Jul;7(4):224–8 (19 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):217–8.

Oral infection [editorial; comment] Peterson DE. **Support Care Cancer** 1999 Jul;7(4):217–8 (8 ref.) Comment on: Support Care Cancer 1999 Jul;7(4):224–8. Comment on: Support Care Cancer 1999 Jul;7(4):244–52.

[Pulmonary damage after radiotherapy for breast cancer] de Fijter WM, et al. **Ned Tijdschr Geneeskd** 1999 Apr 17; 143(16):833–6 (13 ref.) (Eng. Abstr.) **(Dut)**

[Late sequelae of oncologic treatment in children] Heikens J, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2191–5 (49 ref.) (Eng. Abstr.) **(Dut)**

[D-xylose test of resorption as a method to determine radiation side effects in the small intestine] Köst S, et al. **Strahlenther Onkol** 1998 Sep;174(9):462–7 (33 ref.) (Eng. Abstr.) **(Ger)**

[A clinical study of chronic actinic enteropathy] Napolitano L, et al. **G Chir** 1999 Apr;20(4):165–8 (20 ref.) (Eng. Abstr.) **(Ita)**

[Radiation myelopathy] Arakawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):438–41 (15 ref.) **(Jpn)**

[Radiation necrosis] Yamada T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):434–7 (12 ref.) **(Jpn)**

[Radiotherapy-induced pemphigus] Correia MP, et al. **Acta Med Port** 1998 Jun;11(6):581–3 (15 ref.) (Eng. Abstr.) **(Por)**

[Radiation therapy and cardiac pacemakers] Serafim P, et al. **Rev Port Cardiol** 1999 May;18(5):503–5 (7 ref.) (Eng. Abstr.) **(Por)**

CONTRAINDICATIONS

Collagen vascular diseases and radiation therapy: a critical review. De Naeyer B, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 15;44(5):975–80 (17 ref.)

[Sources of interference for cardiac pacemakers. Technical improvements of pacemakers--risks in the medical realm] Wilke A, et al. **Fortschr Med** 1998 Aug 20;116(22–23):27–31 (9 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

[History of radiotherapy for cancer] Okawa T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:15–22 (31 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Neutron, proton, and photonuclear cross-sections for radiation therapy and radiation protection. Chadwick MB. **Radiat Environ Biophys** 1998 Dec;37(4):235–42 (39 ref.)

METHODS

Radiation therapy as a component of high-dose salvage strategies in Hodgkin's disease. Hoppe RT. **Ann Oncol** 1998;9 Suppl 5:S87–90 (14 ref.)

Future strategies in external radiation therapy of renal cell carcinoma. Kortmann RD, et al. **Anticancer Res** 1999 Mar–Apr;19(2C):1601–3 (11 ref.)

Set-up error & organ motion uncertainty: a review. Booth JT, et al. **Australas Phys Eng Sci Med** 1999 Jun;22(2):29–47 (84 ref.)

Intraoperatic electron beam irradiation in pancreatic cancer. Willett CG, et al. **Front Biosci** 1998 Nov 15;3:E207–13 (33 ref.)

The effect of beam divergence on target coverage. Bentel GC, et al. **Med Dosim** 1999 Summer;24(2):99–113 (11 ref.)

[Re-irradiation with hyperthermia in patients with recurrent breast cancer] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):80–4 (23 ref.) (Eng. Abstr.) **(Dut)**

[Treatment of pituitary tumors] Valtonen S, et al. **Duodecim** 1995;111(21):2013–9 (35 ref.) **(Fin)**

[Radiotherapy update] Daly-Schveitzer N. **Bull Cancer** 1999 Jan;86(1):71–6 (59 ref.) **(Fre)**

STANDARDS

[Guideline 'Radiotherapy in non-small-cell lung carcinoma. Working Group, National Organization for Quality Assurance in Hospitals, Netherlands (see comments)] Festen J. **Ned Tijdschr Geneeskd** 1998 Oct 10; 142(41):2248–51 (32 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Dec 19;142(15):2809–10. **(Dut)**

TRENDS

Modern aspects of radiation therapy for glial tumours of the brain. Rampling R. **Forum (Genova)** 1998 Jul–Sep; 8(3):289–301 (107 ref.)

[Development of radiotherapy--history and future prospects] Okawa T. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1269–74 (24 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY, ADJUVANT

Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Bijker N, et al. **Cancer** 1999 Apr 15; 85(8):1773–81 (42 ref.)

ADVERSE EFFECTS

Postmastectomy radiotherapy: toxicities and techniques to reduce them. Hardenbergh PH, et al. **Semin Radiat Oncol** 1999 Jul;9(3):259–68 (42 ref.)

ECONOMICS

Is the use of radiation therapy after mastectomy cost-effective? Hayman JA, et al. **Semin Radiat Oncol** 1999 Jul;9(3):287–91 (11 ref.)

METHODS

Postmastectomy radiotherapy: toxicities and techniques to reduce them. Hardenbergh PH, et al. **Semin Radiat Oncol** 1999 Jul;9(3):259–68 (42 ref.)

[Locoregional radiotherapy after mastectomy and chemotherapy for breast cancer: prolonged survival and better local tumor control (see comments)] Struikmans H, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):71–3 (8 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):73–5. **(Dut)**

[Hyperthermia in combination with radiotherapy (see comments)] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):76–80 (21 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):75–8. **(Dut)**

RADIOTHERAPY, COMPUTER-ASSISTED

see related
RADIOTHERAPY, CONFORMAL

RADIOTHERAPY, CONFORMAL

see related
RADIOTHERAPY DOSAGE
RADIOTHERAPY PLANNING, COMPUTER-ASSISTED

Potential gains using high-energy protons for therapy of malignant tumours. Glimelius B, et al. **Acta Oncol** 1999; 38(2):137-45 (44 ref.)
Conformal radiotherapy: a clinical review. Read G. **Clin Oncol (R Coll Radiol)** 1998;10(5):288-96 (87 ref.)
External beam radiotherapy for pelvic node recurrence after curative resection of colon cancer: report of a case. Masaki T, et al. **Jpn J Clin Oncol** 1999 Apr;29(4):229-33 (24 ref.)
Image processing in stereotactic planning: volume visualization and image registration. Pelizzari CA. **Med Dosim** 1998 Fall;23(3):137-45 (39 ref.)
The role of high-LET radiotherapy compared to conformal photon radiotherapy in adenoid cystic carcinoma. Debus J, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:63-5 (12 ref.)
[Conformal radiotherapy] Hubert J, et al. **Prog Urol** 1999 Jun;9(3):544-51 (35 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Target volume definition for three-dimensional conformal radiation therapy of lung cancer. Armstrong JG. **Br J Radiol** 1998 Jun;71(846):587-94 (24 ref.)
Stereotactically guided conformal radiotherapy: a new tool for the treatment of intra-cranial benign tumors [editorial; comment] Kantor G. **Radiother Oncol** 1999 Feb;50(2):143-4 (17 ref.) Comment on: Radiother Oncol 1999 Feb;50(2):145-50.
Optimized planning using physical objectives and constraints. Bortfeld T. **Semin Radiat Oncol** 1999 Jan;9(1):20-34 (63 ref.)
Optimized radiation therapy based on radiobiological objectives. Brahme A. **Semin Radiat Oncol** 1999 Jan; 9(1):35-47 (41 ref.)
Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy. Fraass BA, et al. **Semin Radiat Oncol** 1999 Jan;9(1):60-77 (110 ref.)
Clinical and financial issues for intensity-modulated radiation therapy delivery. Grant W 3rd, et al. **Semin Radiat Oncol** 1999 Jan;9(1):99-107 (17 ref.)
Managing geometric uncertainty in conformal intensity-modulated radiation therapy. Jaffray DA, et al. **Semin Radiat Oncol** 1999 Jan;9(1):4-19 (57 ref.)
Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Verhey LJ. **Semin Radiat Oncol** 1999 Jan;9(1):78-98 (43 ref.)
Proton therapy for tumors of the skull base. Munzenrider JE, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:57-63 (46 ref.)
[Practical determination of volume and doses in conformal radiotherapy] Bey P, et al. **Cancer Radiother** 1998 Sep-Oct; 2(5):615-8 (18 ref.) (Eng. Abstr.) **(Fre)**
[Current status and future prospects of 3D treatment planning in radiation therapy, focusing on IMRT] Nakagawa K, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1248-53 (9 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

In vivo dosimetry during external photon beam radiotherapy. Essers M, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):245-59 (126 ref.)

RADIOTHERAPY DOSAGE

see related
DOSE-RESPONSE RELATIONSHIP, RADIATION
RADIOTHERAPY, CONFORMAL

The effect of beam divergence on target coverage. Bentel GC, et al. **Med Dosim** 1999 Summer;24(2):99-113 (11 ref.)

RADIOTHERAPY DOSE FRACTIONATION see **DOSE FRACTIONATION**

RADIOTHERAPY, HIGH-ENERGY

Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Khan DC, et al. **Cancer Invest** 1999;17(2):110-3 (24 ref.)
Cause-specific versus all-cause survival [editorial; comment] McLean IW, et al. **Ophthalmology** 1998 Nov; 105(11):1989-90 (3 ref.) Comment on: Ophthalmology 1998 Nov;105(11):2035-45.
The role of high-LET radiotherapy compared to conformal photon radiotherapy in adenoid cystic carcinoma. Debus J, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:63-5 (12 ref.)

RADIOTHERAPY, INTERSTITIAL see **BRACHYTHERAPY**

RADIOTHERAPY, INTRACAVITY see **BRACHYTHERAPY**

RADIOTHERAPY, LYMPHATIC see **LYMPHATIC IRRADIATION**

RADIOTHERAPY PLANNING, COMPUTER-ASSISTED

see related
RADIOTHERAPY, CONFORMAL

Image processing in stereotactic planning: volume visualization and image registration. Pelizzari CA. **Med Dosim** 1998 Fall;23(3):137-45 (39 ref.)
Brachytherapy for the next century: use of image-based treatment planning. Martel MK, et al. **Radiat Res** 1998 Nov; 150(5 Suppl):S178-88 (45 ref.)
A horizontal CT system dedicated to heavy-ion beam treatment. Kamada T, et al. **Radiother Oncol** 1999 Feb; 50(2):235-7 (4 ref.)

METHODS

Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high dose rate prostate brachytherapy implants. Kini VR, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):571-8 (34 ref.)
Update on the treatment of prostate cancer with external beam irradiation. Horwitz EM, et al. **Prostate** 1998 Nov 1;37(3):195-206 (51 ref.)

STANDARDS

American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning. Fraass B, et al. **Med Phys** 1998 Oct;25(10):1773-829 (81 ref.)

TRENDS

[Current status and future prospects of 3D treatment planning in radiation therapy, focusing on IMRT] Nakagawa K, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1248-53 (9 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY, SURFACE see **BRACHYTHERAPY**

RADIOTHERAPY, TARGETED see **RADIOTHERAPY**

RADIUM

[Present and future in brachytherapy--from the discovery of radium to the 21st century] Inoue T, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1254-60 (13 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Application of remedy studies to the development of a soil washing pilot plant that uses mineral processing technology: a practical experience. Richardson WS 3rd, et al. **J Hazard Mater** 1999 Apr 23;66(1-2):47-65 (20 ref.)

CHEMISTRY

Application of remedy studies to the development of a soil washing pilot plant that uses mineral processing technology: a practical experience. Richardson WS 3rd, et al. **J Hazard Mater** 1999 Apr 23;66(1-2):47-65 (20 ref.)

RADIUS

ABNORMALITIES

Long first metacarpal in monozygotic twins with probable Baller-Gerold syndrome. Franceschini P, et al. **Am J Med Genet** 1998 Dec 4;80(4):303-8 (26 ref.)
Musculoskeletal manifestations of the Antley-Bixler syndrome. Rumball KM, et al. **J Pediatr Orthop B** 1999 Apr;8(2):139-43 (17 ref.)

RADIUS FRACTURES

[Fractures of the radial head] Luboshitz S, et al. **Harefuah** 1998 Aug;135(3-4):145-9 (44 ref.) **(Heb)**

COMPLICATIONS

Forearm and distal radius fractures in children. Noonan KJ, et al. **J Am Acad Orthop Surg** 1998 May-Jun;6(3):146-56 (43 ref.)
[Combined fractures of the radius and the ulna at the elbow level in the adult. Analysis of 120 cases after more than 1 year] Heim U. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Apr; 84(2):142-53 (24 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Distal radius fractures] Rikli D, et al. **Schweiz Med Wochenschr** 1999 May 22;129(20):776-85 (43 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Management of fractures of the distal radius: therapist's commentary. Weinstock TB. **J Hand Ther** 1999 Apr-Jun; 12(2):99-102 (9 ref.)

SURGERY

Management of fractures of the distal radius: surgeon's perspective. Raskin KB. **J Hand Ther** 1999 Apr-Jun; 12(2):92-8 (11 ref.)
The radioulnar joints and forearm axis: surgeons' perspective. Tang P, et al. **J Hand Ther** 1999 Apr-Jun;12(2):75-84 (40 ref.)
[Combined fractures of the radius and the ulna at the elbow level in the adult. Analysis of 120 cases after more than 1 year] Heim U. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Apr; 84(2):142-53 (24 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The treatment of forearm fractures from penetrating trauma. Kozin SH, et al. **Hand Clin** 1999 May;15(2):221-31, viii (29 ref.)
Fractures of the elbow. Kuntz DG Jr, et al. **Orthop Clin North Am** 1999 Jan;30(1):37-61 (89 ref.)

RADON

ADVERSE EFFECTS

Cohen's paradox [letter] Field RW, et al. **Health Phys** 1999 Sep;77(3):328-9 (21 ref.)

TOXICITY

Mechanistic model predicts a U-shaped relation of radon exposure to lung cancer risk reflected in combined occupational and US residential data [see comments] Bogen KT. **Hum Exp Toxicol** 1998 Dec;17(12):691-6; discussion 701-4, 708-18 (31 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705-7; discussion 716-8.

RAEB see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

RAEM see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

RAF-1 KINASE see **PROTO-ONCOGENE PROTEINS C-RAF**

RAF-1 PROTEIN see **PROTO-ONCOGENE PROTEINS C-RAF**

RAG-1 GENES see **GENES, RAG-1**

RAILLIETINA see **CESTODA**

RAILLIETINIASIS see **CESTODE INFECTIONS**

RAILROADS

An unusual case of railway suicide. Romero Palanco JL, et al. **J Forensic Sci** 1999 Mar;44(2):444-6 (27 ref.)
Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247-61 (81 ref.)

RAJA see **SKATES (FISH)**

RALES see **RESPIRATORY SOUNDS**

RAMAN SPECTROSCOPY see **SPECTRUM ANALYSIS, RAMAN**

RAMIPRIL

ANALOGS & DERIVATIVES

Tight binding influencing the future of pharmacokinetics. Brockmeier D. **Methods Find Exp Clin Pharmacol** 1998 Jul-Aug;20(6):505-16 (0 ref.)

PHARMACOKINETICS

Tight binding influencing the future of pharmacokinetics. Brockmeier D. **Methods Find Exp Clin Pharmacol** 1998 Jul-Aug;20(6):505-16 (0 ref.)

RAMSAY HUNT AURICULAR SYNDROME see **HERPES ZOSTER OTICUS**

RAMSAY HUNT PARALYSIS SYNDROME see **PARKINSON DISEASE**

RANA see **RANIDAE**

RANA CATESBEIANA

GENETICS

Isolation of genes involved in intestinal remodeling during anuran metamorphosis. Amano T. **Wound Repair Regen** 1998 Jul-Aug;6(4):302-13 (80 ref.)

GROWTH & DEVELOPMENT

Differential response of the tail and body epidermis of Rana catesbeiana tadpoles in vitro to the anticancer drug,

RANA CATESBEIANA

cisplatin [letter] Menon J, et al.
In Vitro Cell Dev Biol Anim 1999 Jan;35(1):8–11 (12 ref.)
Thyroid hormone induces a reprogramming of gene expression in the liver of premetamorphic Rana catesbeiana tadpoles. Atkinson BG, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):323–37 (56 ref.)

RANDOM ALLOCATION

Understanding controlled trials. Randomisation methods: concealment. Torgerson DJ, et al. **BMJ** 1999 Aug 7; 319(7206):375–6 (4 ref.)
The role of randomization in clinical studies: myths and beliefs. Abel U, et al. **J Clin Epidemiol** 1999 Jun; 52(6):487–97 (87 ref.)
Stratified randomization for clinical trials. Kernan WN, et al. **J Clin Epidemiol** 1999 Jan;52(1):19–26 (38 ref.)
Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. Avins AL. **J Med Ethics** 1998 Dec;24(6):401–8 (50 ref.)
[Roaming through methodology. III. Randomization at the level of the physicians] van Houwelingen JC.
Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1662–5 (2 ref.) (Eng. Abstr.) **(Dut)**

RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE

see related
DNA FINGERPRINTING
GENETIC MARKERS
Using random amplified polymorphic DNAs in zebrafish genomic analysis. Postlethwait JH, et al.
Methods Cell Biol 1999;60:165–79 (43 ref.)
Characterization of mycoplasmas by RAPD fingerprinting. Rawadi GA. **Methods Mol Biol** 1998;104:179–87 (12 ref.)

RANDOM PEPTIDE LIBRARY see **PEPTIDE LIBRARY**

RANDOMIZATION see **RANDOM ALLOCATION**

RANDOMIZED CONTROLLED TRIALS

Randomized clinical trials in medical rehabilitation research. Tate DG, et al. **Am J Phys Med Rehabil** 1999 Sep–Oct; 78(5):486–99 (67 ref.)
Metaanalytic revision of endpoints [editorial; comment] Gallagher EJ. **Ann Emerg Med** 1999 Jul;34(1):91–5 (44 ref.)
Comment on: Ann Emerg Med 1999 Jul;34(1):8–18.
The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. Williams H, et al. **Arch Dermatol** 1998 Dec; 134(12):1620–6 (43 ref.)
A review of randomised controlled trials published in Archives of Disease in Childhood from 1982–96. Campbell H, et al. **Arch Dis Child** 1998 Aug;79(2):192–7 (00 ref.)
Confidence intervals for the number needed to treat. Altman DG. **BMJ** 1998 Nov 7;317(7168):1309–12 (13 ref.)
Randomised controlled trials in psychiatry: important but poorly accepted. Andrews G. **BMJ** 1999 Aug 28; 319(7209):562–4 (19 ref.)
Contribution of randomised controlled trials to understanding and management of early breast cancer. Baum M, et al. **BMJ** 1999 Aug 28;319(7209):568–71 (37 ref.)
Marketing medicines through randomised controlled trials: the case of interferon. Pieters T. **BMJ** 1998 Oct 31; 317(7167):1231–3 (22 ref.)
Exercise clinical trials in cancer prevention research: a call to action. McTiernan A, et al.
Cancer Epidemiol Biomarkers Prev 1999 Mar;8(3):201–7 (67 ref.)
One year after CAPRIE, IST and ESPS 2. Any changes in concepts? Hankey GJ. **Cerebrovasc Dis** 1998;8 Suppl 5:1–7 (45 ref.)
Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial [editorial] Apstein CS. **Circulation** 1998 Nov 24; 98(21):2223–6 (27 ref.)
The importance of randomized clinical trials and evidence-based medicine: a clinician's perspective. Kennedy HL. **Clin Cardiol** 1999 Jan;22(1):6–12 (70 ref.)
Chinese Herbal Medicine in the treatment of acute respiratory tract infections: review of randomized and controlled clinical trials. Liu C, et al. **Clin Infect Dis** 1999 Feb; 28(2):235–6 (27 ref.)
Randomized clinical trials in interventional cardiology. Holmes DR Jr. **Curr Opin Cardiol** 1998 Sep;13(5):348–54 (11 ref.)
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. **Eur J Cancer** 1999 Feb;35(2):262–71 (12 ref.)
Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eggermont AM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S22–6 (47 ref.)
Science in the service of healing. Grady C.
Hastings Cent Rep 1998 Nov–Dec;28(6):34–8 (19 ref.)
Swan to phoenix: the metamorphosis [editorial] Brandstetter RD, et al. **Heart Lung** 1998 Jul–Aug;27(4):215–7 (21 ref.)
Antiarrhythmic trials: a decade of growth. Kanjwal MY.
Indian Heart J 1998 May–Jun;50(3):277–84 (19 ref.)
Simple sample size calculation for cluster-randomized trials. Hayes RJ, et al. **Int J Epidemiol** 1999 Apr;28(2):319–26 (24 ref.)
Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Ratanatharathorn V, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):1–18 (25 ref.)
Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique. Roos DE, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):493–5 (12 ref.)
Deriving treatment recommendations from evidence within randomized trials. The role and limitation of meta-analysis. Freemantle N, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):304–15 (46 ref.)
Maternal-Fetal Medicine Units (MFMU) studies of inhaled corticosteroids during pregnancy. Dombrowski M, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S356–9 (2 ref.)
Randomized controlled trials of individualized homeopathy: a state-of-the-art review [see comments] Linde K, et al. **J Altern Complement Med** 1998 Winter;4(4):371–88 (50 ref.)
Comment in: J Altern Complement Med 1998 Winter;4(4):355–7.
Dietary Approaches to Stop Hypertension: rationale, design, and methods. DASH Collaborative Research Group. Vogt TM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S12–8 (60 ref.)
Stratified randomization for clinical trials. Kernan WN, et al. **J Clin Epidemiol** 1999 Jan;52(1):19–26 (38 ref.)
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women [see comments] Fossati R, et al. **J Clin Oncol** 1998 Oct;16(10):3439–60 (213 ref.) Comment in: J Clin Oncol 1999 May;17(5):1646–7.
Randomizing carotid endarterectomy to carotid stenting? [editorial] Wholey MH. **J Endovasc Surg** 1999 May; 6(2):127–9; discussion 130 (12 ref.)
Antihypertensive treatment and the prevention of dementia: further insights from the Syst-Eur trial [editorial] Hansson L. **J Hypertens** 1999 Mar;17(3):307–8 (8 ref.)
Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. Avins AL. **J Med Ethics** 1998 Dec;24(6):401–8 (50 ref.)
Responsiveness of endpoints in osteoporosis clinical trials--an update. Cranney A, et al. **J Rheumatol** 1999 Jan; 26(1):222–8 (68 ref.)
The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. Ortiz Z, et al. **J Rheumatol** 1999 Jan; 26(1):210–6 (26 ref.)
Brief early psychological interventions following trauma: a systematic review of the literature. Rose S, et al.
J Trauma Stress 1998 Oct;11(4):697–710 (45 ref.)
Reflections on randomised controlled trials in surgery. Baum M. **Lancet** 1999 Apr;353 Suppl 1:SI6–8 (19 ref.)
Can randomised trials inform clinical decisions about individual patients? [see comments] Mant D. **Lancet** 1999 Feb 27;353(9154):743–6 (31 ref.) Comment in: Lancet 1999 May 8;353(9164):1622.
A review of randomized clinical trials in tinnitus. Dobie RA. **Laryngoscope** 1999 Aug;109(8):1202–11 (85 ref.)
CABG and ICD for all patients with hemodynamically significant ventricular arrhythmia and significant coronary artery disease? Do we know enough to decide--or to design a randomized trial? [editorial; comment] Bergfeldt L. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1129–31 (9 ref.) Comment on: Pacing Clin Electrophysiol 1999 Aug;22(8):1132–9.
The importance of randomized clinical trials and evidence-based medicine: a clinician's perspective. Kennedy HL. **Rev Port Cardiol** 1999 May;18(5):471–80 (70 ref.)
Efficacy of epidural steroids in low back pain and sciatica. A critical appraisal by a French Task Force of randomized trials. Critical Analysis Group of the French Society for Rheumatology. Rozenberg S, et al. **Rev Rhum Engl Ed** 1999 Feb;66(2):79–85 (23 ref.)
Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty. Mathew TP, et al.
Semin Interv Cardiol 1999 Jun;4(2):67–75 (60 ref.)
Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Koch GG, et al. **Stat Med** 1998 Aug 15–30;17(15–16):1863–92 (46 ref.)
[Is the randomized controlled trial overvalued as a basis for clinical decision-making? A review with comments] Dahler-Eriksen K, et al. **Ugeskr Laeger** 1998 Dec 14; 160(51):7414–7 (30 ref.) (Eng. Abstr.) **(Dan)**
[Randomization and alternatives] Olsen J, et al.
Ugeskr Laeger 1999 May 3;161(18):2657–60 (25 ref.) (Eng. Abstr.) **(Dan)**
[Chemoprevention of breast cancer by tamoxifen: should we still ask this question?] Sasco AJ.
Rev Epidemiol Sante Publique 1999 Jun;47(3):279–85 (20 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. Hlatky MA. **Am Heart J** 1999 May;137(5):S41–6 (33 ref.)
Analysis and interpretation of cost data in randomised controlled trials: review of published studies [see comments] Barber JA, et al. **BMJ** 1998 Oct 31; 317(7167):1195–200 (34 ref.) Comment in: BMJ 1999 Jun 19;318(7199):1696–7.

HISTORY

A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s. D'Arcy Hart P. **BMJ** 1999 Aug 28;319(7209):572–3 (7 ref.)

LEGISLATION & JURISPRUDENCE

Placebo-controlled studies in rheumatoid arthritis: ethical issues [see comments] Stein CM, et al. **Lancet** 1999 Jan 30;353(9150):400–3 (37 ref.) Comment in: Lancet 1999 Apr 3;353(9159):1186.

METHODS

Number needed to treat: solid science or a path to pernicious rationing? Black HR, et al. **Am J Hypertens** 1998 Aug;11(8 Pt 2):128S–134S; discussion 135S–137S (30 ref.)
Case studies, single-subject research, and N of 1 randomized trials: comparisons and contrasts. Backman CL, et al.
Am J Phys Med Rehabil 1999 Mar–Apr;78(2):170–6 (22 ref.)
Statistics notes. Treatment allocation in controlled trials: why randomise? Altman DG, et al. **BMJ** 1999 May 1; 318(7192):1209 (7 ref.)
Ethical issues in the design and conduct of cluster randomised controlled trials. Edwards SJ, et al. **BMJ** 1999 May 22; 318(7195):1407–9 (5 ref.)
Efficient management of randomised controlled trials: nature or nurture. Farrell B. **BMJ** 1998 Oct 31;317(7167):1236–9 (3 ref.)
Randomisation methods in controlled trials. Roberts C, et al. **BMJ** 1998 Nov 7;317(7168):1301 (2 ref.)
Reporting on quality of life in randomised controlled trials: bibliographic study [published erratum appears in BMJ 1998 Nov 14;317(7169):1353] [see comments] Sanders C, et al. **BMJ** 1998 Oct 31;317(7167):1191–4 (22 ref.)
Comment in: BMJ 1999 Apr 24;318(7191):1142.
Issues to consider in the evaluation of speech and language therapy for preschool children. Roulstone S, et al.
Child Care Health Dev 1999 Mar;25(2):141–55 (31 ref.)
Clinical trials in acute respiratory distress syndrome: what is ARDS? [editorial; comment] Brochard L, et al.
Crit Care Med 1999 Aug;27(8):1657–8 (13 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1478–85.
[Phase III trials in oncology] Imadalou K, et al.
Bull Cancer 1999 Feb;86(2):143–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Methods of controlled clinical studies] Brosteanu O, et al.
Internist (Berl) 1998 Sep;39(9):909–16 (14 ref.) **(Ger)**

STANDARDS

Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army Personnel. O'Malley PG, et al. **Am Heart J** 1999 May; 137(5):932–41 (38 ref.)
The CONSORT statement: will it lead to improved reporting of clinical trials in ophthalmology? Consolidated Standards of Reporting Trials. Hawkins BS. **Arch Ophthalmol** 1999 May;117(5):677–80 (45 ref.)
The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals. Edwards SJ, et al. **BMJ** 1998 Oct 31; 317(7167):1209–12 (47 ref.)
Determining the clinical significance of randomized clinical trials: a review of the efficacy of laser photocoagulation. Sharma S. **Can J Ophthalmol** 1999 Feb;34(1):46–9 (13 ref.)
Ethics and clinical trials. Chassany O, et al.
Fundam Clin Pharmacol 1999;13(4):437–44 (77 ref.)
Choosing between randomised and non-randomised studies: a systematic review. Britton A, et al.
Health Technol Assess 1998;2(13):i–iv, 1–124 (204 ref.)
Ethical issues in the design and conduct of randomised controlled trials. Edwards SJ, et al.
Health Technol Assess 1998 Dec;2(15):i–vi, 1–132 (620 ref.)
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Moher D, et al. **Health Technol Assess** 1999;3(12):i–iv, 1–98 (122 ref.)
The role of randomization in clinical studies: myths and beliefs. Abel U, et al. **J Clin Epidemiol** 1999 Jun; 52(6):487–97 (87 ref.)
How should efficacy be evaluated in randomized clinical trials of treatments for depression? Thase ME.
J Clin Psychiatry 1999;60 Suppl 4:23–31; discussion 32 (34 ref.)
Overviews of respiratory rehabilitation in chronic obstructive pulmonary disease. Lacasse Y, et al.
Monaldi Arch Chest Dis 1999 Apr;54(2):163–7 (33 ref.)
Pacemaker trials: software or hardware randomization? [editorial] Gribbin GM, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1503–7 (37 ref.)
Methodological issues concerning evaluation of treatment for sexual offenders: randomization, treatment dropouts,

untreated controls, and within-treatment studies [see comments] McConaghy N. **Sex Abuse** 1999 Jul; 11(3):183–93 (32 ref.) Comment in: Sex Abuse 1999 Jul;11(3):179–81.
Issues for statisticians in pharmaco-economic evaluations. Grieve AP. **Stat Med** 1998 Aug 15–30;17(15–16):1715–23; discussion 1741–3 (17 ref.)
Therapeutic equivalence investigations: statistical considerations. Röhmel J. **Stat Med** 1998 Aug 15–30; 17(15–16):1703–14 (14 ref.)
Stratification in clinical trials of febrile neutropenia. Elting LS. **Support Care Cancer** 1998 Sep;6(5):457–61 (28 ref.)
[Roaming through methodology. X. The testing of diagnostic procedures] Bossuyt PM, et al. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2345–7 (4 ref.) (Eng. Abstr.) **(Dut)**
[Roaming through the methodology. XIV. The premature ending of a randomized trial] Vandenbroucke JP. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1305–8 (6 ref.) (Eng. Abstr.) **(Dut)**

STATISTICS & NUMERICAL DATA

Advances in clinical trials in the twentieth century. Fisher LD. **Annu Rev Public Health** 1999;20:109–24 (49 ref.)
The adequacy of reporting randomized, controlled trials in the evaluation of antidepressants. Streiner DL, et al. **Can J Psychiatry** 1998 Dec;43(10):1026–30 (33 ref.)
False positive rates of randomized phase II designs. Liu PY, et al. **Control Clin Trials** 1999 Aug;20(4):343–52 (15 ref.)
Randomised controlled trials addressing Australian aboriginal health needs: a systematic review of the literature. Morris PS. **J Paediatr Child Health** 1999 Apr;35(2):130–5 (49 ref.)
The presentation of statistics. Bryant TN. **Pediatr Allergy Immunol** 1998 Aug;9(3):108–15 (16 ref.)
An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Schmid CH, et al. **Stat Med** 1998 Sep 15; 17(17):1923–42 (75 ref.)

TRENDS

Advances in clinical trials in the twentieth century. Fisher LD. **Annu Rev Public Health** 1999;20:109–24 (49 ref.)
Randomised controlled trials in cardiovascular medicine: past achievements, future challenges. Yusuf S. **BMJ** 1999 Aug 28;319(7209):564–8 (29 ref.)

RANGE OF MOTION, ARTICULAR

A commonsense approach to shoulder problems. Steinfeld R, et al. **Mayo Clin Proc** 1999 Aug;74(8):785–94 (15 ref.)
Physical measurements of the lumbar spine. Mooney V. **Phys Med Rehabil Clin N Am** 1998 May;9(2):391–410, viii (72 ref.)

PHYSIOLOGY

Task-dependent reduction of the number of degrees of freedom in sensorimotor systems. Gielen CC, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):136–42 (71 ref.)
Loss of extension after reconstruction of the anterior cruciate ligament. Petsche TS, et al. **J Am Acad Orthop Surg** 1999 Mar–Apr;7(2):119–27 (31 ref.)
Knee joint motion: description and measurement. Bull AM, et al. **Proc Inst Mech Eng [H]** 1998;212(5):357–72 (122 ref.)
[What is the value of biomechanical knowledge for surgery of the hand?] Kummer B, et al. **Handchir Mikrochir Plast Chir** 1998 Jul;30(4):212–8 (34 ref.) (Eng. Abstr.) **(Ger)**

RANIDAE

MICROBIOLOGY

Batrachomyomachia: frogs 1, mice 0. Klein J. **Scand J Immunol** 1999 Jan;49(1):11–3 (9 ref.)

PHYSIOLOGY

Living in the cold: freeze-induced gene responses in freeze-tolerant vertebrates. Storey KB. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):57–63 (45 ref.)

RANITIDINE

ADVERSE EFFECTS

Safety profile of Lansoprazole: the US clinical trial experience. Freston JW, et al. **Drug Saf** 1999 Feb; 20(2):195–205 (22 ref.)

ANALOGS & DERIVATIVES

Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection. Chey WD, et al. **Aliment Pharmacol Ther** 1998 Dec;12(12):1263–7 (16 ref.)

THERAPEUTIC USE

Therapy for ulcers and erosions associated with nonsteroidal anti-inflammatory drugs. Freeman HJ. **Can J Gastroenterol** 1998 Nov–Dec;12(8):537–9 (0 ref.)
Suppression of gastric acid secretion: preventing excess gas [editorial; comment] Heard SO. **Intensive Care Med** 1998 Nov;24(11):1123–5 (26 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1139–43.
[Congenital chloridorrhea: adjuvant therapy with ibuprofen and ranitidine] Martinón-Torres F, et al. **An Esp Pediatr** 1999 Jun;50(6):619–22 (19 ref.) **(Spa)**

RANK-SUM TESTS see **STATISTICS, NONPARAMETRIC**

RANTES

[The role of chemokines such as RANTES in allergic disease] Chihara J. **Rinsho Byori** 1998 Aug;46(8):816–20 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Cytokines, chemokines, RANTES, and eotaxin. Graziano FM, et al. **Allergy Asthma Proc** 1999 May–Jun;20(3):141–6 (38 ref.)

RANVIER'S NODES

METABOLISM

Ion channel redistribution and function during development of the myelinated axon. Vabnick I, et al. **J Neurobiol** 1998 Oct;37(1):80–96 (90 ref.)

RAP GENE PRODUCTS see **GENE PRODUCTS, VPR**

RAPAMYCIN see **SIROLIMUS**

RAPD-PCR see **RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE**

RAPD TECHNIQUE see **RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE**

RAPE

Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. Bamberger JD, et al. **Am J Med** 1999 Mar;106(3):323–6 (22 ref.)
Sexually transmitted diseases in abused children and adolescent and adult victims of rape: review of selected literature. Beck-Sagué CM, et al. **Clin Infect Dis** 1999 Jan; 28 Suppl 1:S74–83 (101 ref.)
ACOG educational bulletin. Adolescent victims of sexual assault. Number 252, October 1998. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Feb;64(2):195–9 (30 ref.)
The management of adult male victims of sexual assault in the GUM clinic: a practical guide. Tomlinson DR, et al. **Int J STD AIDS** 1998 Dec;9(12):720–4; quiz 725 (19 ref.)
Evaluation of the adolescent rape victim. Bechtel K, et al. **Pediatr Clin North Am** 1999 Aug;46(4):809–23, xii (26 ref.)
[Securing evidence after sexual offences is an important task for physicians. Increasing severity of crimes and use of DNA analyses necessitate higher quality standards] Ansell R. **Lakartidningen** 1998 Oct 14;95(42):4626–8, 4630–1 (10 ref.) (Eng. Abstr.) **(Swe)**

DIAGNOSIS

Allegations of sexual abuse by nonverbal autistic people via facilitated communication: testing of validity. Konstantareas MM. **Child Abuse Negl** 1998 Oct; 22(10):1027–41 (46 ref.)
Sexual assault. Linden JA. **Emerg Med Clin North Am** 1999 Aug;17(3):685–97, vii (42 ref.)

LEGISLATION & JURISPRUDENCE

Pornography, rape, and sex crimes in Japan. Diamond M, et al. **Int J Law Psychiatry** 1999 Jan–Feb;22(1):1–22 (102 ref.)
The sensitivity of forensic tests for rape. Ferris LE, et al. **Med Law** 1998;17(3):333–50 (30 ref.)
Changes to Section 2 of Sexual Offences Act 1976. Baird V. **Med Sci Law** 1999 Jul;39(3):198–208 (10 ref.)

PREVENTION & CONTROL

Sexual assault. Linden JA. **Emerg Med Clin North Am** 1999 Aug;17(3):685–97, vii (42 ref.)

PSYCHOLOGY

A review of cognitive factors in the etiology of rape: theories, empirical studies, and implications. Drieschner K, et al. **Clin Psychol Rev** 1999 Jan;19(1):57–77 (70 ref.)

STATISTICS & NUMERICAL DATA

A review of cognitive factors in the etiology of rape: theories, empirical studies, and implications. Drieschner K, et al. **Clin Psychol Rev** 1999 Jan;19(1):57–77 (70 ref.)
Pornography, rape, and sex crimes in Japan. Diamond M, et al. **Int J Law Psychiatry** 1999 Jan–Feb;22(1):1–22 (102 ref.)
Date rape among adolescents and young adults. Rickert VI, et al. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):167–75 (74 ref.)

RAPESEED see **BRASSICA**

RAPHE NUCLEI

PHYSIOLOGY

Electro-oscillographic correlation between dorsal raphe nucleus, neocortex and hippocampus during wakefulness before and after serotoninergic inactivation. Fonoff ET, et al. **Braz J Med Biol Res** 1999 Apr;32(4):469–72 (14 ref.)
Central mechanisms of pain modulation. Mason P. **Curr Opin Neurobiol** 1999 Aug;9(4):436–41 (33 ref.)
Serotonin and stress. Chaouloff F, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):28S–32S (37 ref.)
Sleep and serotonin: an unfinished story. Jouvet M. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):24S–27S (21 ref.)

RAPID EYE MOVEMENTS see **SLEEP, REM**

RARE GASES see **NOBLE GASES**

RAS GENES see **GENES, RAS**

RAS ONCOGENE PROTEIN P21 see **ONCOGENE PROTEIN P21(RAS)**

RAS PROTEINS

ANTAGONISTS & INHIBITORS

Pre-clinical development of farnesyltransferase inhibitors. Lobell RB, et al. **Cancer Metastasis Rev** 1998 Jun; 17(2):203–10 (54 ref.)

CHEMISTRY

[Structures and functions of small GTPase and heterotrimeric G proteins] Saito Y. **Nippon Rinsho** 1998 Jul;56(7):1750–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Lebowitz PF, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1439–45 (76 ref.)

GENETICS

Polycyclic aromatic hydrocarbons: correlations between DNA adducts and ras oncogene mutations. Ross JA, et al. **Mutat Res** 1999 Mar 8;424(1–2):155–66 (59 ref.)
Genetics of RAS signaling in C. elegans. Sternberg PW, et al. **Trends Genet** 1998 Nov;14(11):466–72 (83 ref.)

METABOLISM

Ion channels as physiological effectors for growth factor receptor and Ras/ERK signaling pathways. Rane SG. **Adv Second Messenger Phosphoprotein Res** 1999;33:107–27 (126 ref.)
Ras, superoxide and signal transduction. Irani K, et al. **Biochem Pharmacol** 1998 May 1;55(9):1339–46 (90 ref.)
Modes of interactions between signaling pathways. Jordan JD, et al. **Biochem Pharmacol** 1998 May 1;55(9):1347–52 (35 ref.)
Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Waddick KG, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1411–26 (118 ref.)
Signal transduction via Ras. Wittinghofer A. **Biol Chem** 1998 Aug–Sep;379(8–9):933–7 (14 ref.)
New insights into the interaction of Ras with the plasma membrane [comment] Magee T, et al. **Cell** 1999 Jul 9; 98(1):9–12 (20 ref.) Comment on: Cell 1999 Jul 9;98(1):69–80.
What does insulin do to Ras? Goalstone ML, et al. **Cell Signal** 1998 May;10(5):297–301 (43 ref.)
Apoptosis: Ras to the rescue in the fly eye. McNeill H, et al. **Curr Biol** 1999 Mar 11;9(5):R176–9 (16 ref.)
All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. Bos JL. **EMBO J** 1998 Dec 1;17(23):6776–82 (75 ref.)
ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Rodriguez-Puebla ML, et al. **Mol Carcinog** 1999 Jan;24(1):1–6 (61 ref.)
Insulin regulation of the Ras activation/inactivation cycle. Ceresa BP, et al. **Mol Cell Biochem** 1998 May;182(1–2):23–9 (79 ref.)
Mobile DNA elements: controlling transposition with ATP-dependent molecular switches. Stellwagen AE, et al. **Trends Biochem Sci** 1998 Dec;23(12):486–90 (45 ref.)

PHYSIOLOGY

Points of convergence between Ca2+ and Ras signalling pathways. Gawler DJ. **Biochim Biophys Acta** 1998 Dec 10;1448(2):171–82 (90 ref.)
Rab proteins. Martinez O, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):101–12 (106 ref.)
Ras family proteins: new players involved in the diplotene arrest of Xenopus oocytes. Jessus C, et al. **Biol Cell** 1998 Nov;90(8):573–83 (78 ref.)
Conspiracy theory: RAS and RAF do not act alone. Sternberg PW, et al. **Cell** 1998 Nov 13;95(4):447–50 (17 ref.)
Ras--a versatile cellular switch. Rommel C, et al.

RAS PROTEINS

Curr Opin Genet Dev 1998 Aug;8(4):412–8 (71 ref.)
Ras caught in another affair: the exchange factors for Ral. Wolthuis RM, et al. **Curr Opin Genet Dev** 1999 Feb; 9(1):112–7 (60 ref.)
The role of G proteins in insulin signalling. Rizzo MA, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):167–95 (159 ref.)
Is the Ras–MAPK signalling pathway necessary for long-term memory formation? Orban PC, et al. **Trends Neurosci** 1999 Jan;22(1):38–44 (90 ref.)
[Regulation of endothelial NO production by Rho GTPase] Laufs U, et al. **Med Klin** 1999 Apr 15;94(4):211–8 (36 ref.) (Eng. Abstr.) **(Ger)**
[Structures and functions of small GTPase and heterotrimeric G proteins] Saito Y. **Nippon Rinsho** 1998 Jul;56(7):1750–5 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Evidence for a Ras/Ral signaling cascade] Urano T. **Seikagaku** 1998 Sep;70(9):1181–3 (15 ref.) **(Jpn)**

THERAPEUTIC USE

Mutated Ras peptides as vaccines in immunotherapy of cancer. Gjertsen MK, et al. **Vox Sang** 1998;74 Suppl 2:489–95 (49 ref.)

RAS PROTO-ONCOGENE PROTEIN P21 see **PROTO-ONCOGENE PROTEIN P21(RAS)**

RASH see **EXANTHEMA**

RAT-BITE FEVER

[Rat-bite fever] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):300 (2 ref.) **(Jpn)**

RAT VIRUS see **PARVOVIRUS**

RATE SETTING AND REVIEW

see related
RELATIVE VALUE SCALES

RATIONING, HEALTH CARE see **HEALTH CARE RATIONING**

RATITES

Current ratite therapy. Jensen JM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):485–502, iv (22 ref.)
Jurisprudence for ratite practitioners. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):525–31, vii (2 ref.)
Infectious diseases and parasites of ratites. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):455–83, iv (41 ref.)
United States food and drug laws and ratites as emerging food animals. Spenser EL. **Vet Clin North Am Food Anim Pract** 1998 Nov;14(3):533–40 (26 ref.)
Ratite diagnostic imaging. Williams J. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):421–35, vi (13 ref.)

PHYSIOLOGY

Anesthesia and surgery of ratites. Gilsleider EF. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):503–24, vi–vii (7 ref.)
Ratite reproduction. Hicks–Alldredge K. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):437–53, vi (8 ref.)

SURGERY

Anesthesia and surgery of ratites. Gilsleider EF. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):503–24, vi–vii (7 ref.)

RATS

Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Henry B, et al. **Adv Neurol** 1998;78:53–61 (36 ref.)
Identification of risk factors in rat bite incidents involving humans. Hirschhorn RB, et al. **Pediatrics** 1999 Sep; 104(3):e35 (21 ref.)
Streptobacillus moniliformis infection: 2 cases and a literature review. Hagelskjaer L, et al. **Scand J Infect Dis** 1998; 30(3):309–11 (23 ref.)

METABOLISM

Distribution of calbindin D-28k and parvalbumin neurons and fibers in the rat basal ganglia. Hontanilla B, et al. **Brain Res Bull** 1998 Sep 15;47(2):107–16 (85 ref.)
The acetylcholine, GABA, glutamate triangle in the rat forebrain. Pepeu G, et al. **J Physiol Paris** 1998 Oct–Dec; 92(5–6):351–5 (51 ref.)

PHYSIOLOGY

Interleukin-1 and nociception in the rat. Bianchi M, et al. **J Neurosci Res** 1998 Sep 15;53(6):645–50 (67 ref.)
Analysis of the mechanisms underlying the age-related impairment in long-term potentiation in the rat. Lynch MA. **Rev Neurosci** 1998 Jul–Dec;9(3):169–201 (336 ref.)

RATS, BANDICOOT see **MURIDAE**

RATS, BRATTLEBORO

PHYSIOLOGY

The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Bohus B, et al. **Prog Brain Res** 1998;119:555–73 (112 ref.)

RATS, COTTON see **HESPEROMYINAE**

RATS, INBRED DAHL

GENETICS

In search of hypertension genes in Dahl salt-sensitive rats. Deng AY. **J Hypertens** 1998 Dec;16(12 Pt 1):1707–17 (82 ref.)

RATS, INBRED OLETF

see related
DIABETES MELLITUS, NON-INSULIN-DEPENDENT

RATS, INBRED SHR

PHYSIOLOGY

Cholinergic mechanism and blood pressure regulation in the central nervous system. Kubo T. **Brain Res Bull** 1998 Aug; 46(6):475–81 (67 ref.)
The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Steers WD, et al. **Exp Physiol** 1999 Jan;84(1):137–47 (55 ref.)

PSYCHOLOGY

The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Steers WD, et al. **Exp Physiol** 1999 Jan;84(1):137–47 (55 ref.)

RATS, INBRED STRAINS

Diet and rat strain as factors in nervous system function and influence of confounders. Kacew S, et al. **Biomed Environ Sci** 1998 Sep;11(3):203–17 (84 ref.)
Rodent models of nephropathy associated with type II diabetes. Janssen U, et al. **J Nephrol** 1999 May–Jun; 12(3):159–72 (160 ref.)

GENETICS

A rat model system for predisposition to stomach cancer. Ushijima T, et al. **Prog Exp Tumor Res** 1999;35:120–30 (29 ref.)

RATS, LABORATORY see **RATS**

RATS, MUTANT STRAINS

Abnormal cerebellar output in the genetically dystonic rat. LeDoux MS, et al. **Adv Neurol** 1998;78:63–78 (84 ref.)
Cardiovascular disease in the JCR:LA-cp rat. Russell JC, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):113–26 (44 ref.)

GENETICS

The Royal College of Surgeons rat: an animal model for inherited retinal degeneration with a still unknown genetic defect. Strauss O, et al. **Acta Anat (Basel)** 1998; 162(2–3):101–11 (151 ref.)

RATS, NORWAY see **RATS**

RATS, RICE see **HESPEROMYINAE**

RATS, SPONTANEOUSLY HYPERTENSIVE see **RATS, INBRED SHR**

RATTLESNAKE see **CROTALUS**

RATTUS see **MURIDAE**

RATTUS NORVEGICUS see **RATS**

RAYNAUD'S DISEASE

Raynaud's phenomenon: state of the art 1998 [editorial] Ho M, et al. **Scand J Rheumatol** 1998;27(5):319–22 (37 ref.)

DIAGNOSIS

[Raynaud's phenomena: diagnostic and treatment study] Priollet P. **Rev Prat** 1998 Oct 1;48(15):1659–64 (27 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

The aetiology of Raynaud's phenomenon. Turton EP, et al. **Cardiovasc Surg** 1998 Oct;6(5):431–40 (119 ref.)
[Raynaud's phenomenon and connective tissue diseases] Guilmot JL, et al. **Rev Prat** 1998 Oct 1;48(15):1647–52 (16 ref.) (Eng. Abstr.) **(Fre)**
[Raynaud's phenomena of occupational origin] Hatron PY, et al. **Rev Prat** 1998 Oct 1;48(15):1653–8 (12 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Vascular abnormalities in Raynaud's phenomenon. Khan F. **Scott Med J** 1999 Feb;44(1):4–6 (42 ref.)

THERAPY

[Raynaud's phenomena: diagnostic and treatment study] Priollet P. **Rev Prat** 1998 Oct 1;48(15):1659–64 (27 ref.) (Eng. Abstr.) **(Fre)**

RAZOXANE

ADMINISTRATION & DOSAGE

[Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy] Lopez M. **Clin Ter** 1999 Jan–Feb;150(1):37–49 (82 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Dexrazoxane (ICRF-187). Weiss G, et al. **Gen Pharmacol** 1999 Jan;32(1):155–8 (31 ref.)

THERAPEUTIC USE

Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links M, et al. **Drugs** 1999 Mar; 57(3):293–308 (94 ref.)
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Wiseman LR, et al. **Drugs** 1998 Sep;56(3):385–403 (75 ref.)
Strategies for reduction of anthracycline cardiac toxicity. Speyer J, et al. **Semin Oncol** 1998 Oct;25(5):525–37 (94 ref.)
[Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report] Rhomberg W, et al. **Strahlenther Onkol** 1999 Mar;175(3):102–4 (17 ref.) (Eng. Abstr.) **(Ger)**

RB GENES see **GENES, RETINOBLASTOMA**

RB PROTEIN see **RETINOBLASTOMA PROTEIN**

RDA see **NUTRITION POLICY**

REACTANTS, ACUTE-PHASE see **ACUTE-PHASE PROTEINS**

REACTION, ACUTE-PHASE see **ACUTE-PHASE REACTION**

REACTION CENTER PROTEIN, BACTERIAL see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

REACTION CENTER PROTEIN, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

REACTION TIME

Preparing to react in the absence of uncertainty: I. New perspectives on simple reaction time. Henderson L, et al. **Br J Psychol** 1998 Nov;89 (Pt 4):531–54 (85 ref.)
Gap effect and reaction time distribution: simple vs choice manual responses. Machado-Pinheiro W, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1313–8 (19 ref.)
Temporal inhibition in character identification. Busey TA. **Percept Psychophys** 1998 Nov;60(8):1285–304 (60 ref.)

DRUG EFFECTS

Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors. Sutton MA, et al. **Psychopharmacology (Berl)** 1999 May; 144(2):95–110 (130 ref.)

PHYSIOLOGY

An fMRI study of Stroop word-color interference: evidence for cingulate subregions subserving multiple distributed attentional systems. Peterson BS, et al. **Biol Psychiatry** 1999 May 15;45(10):1237–58 (100 ref.)
Temporal coding as a means of information transfer in the primate visual system. Gawne TJ. **Crit Rev Neurobiol** 1999; 13(1):83–101 (89 ref.)
Average evoked potentials--clinical applications of short latency responses. Tandon OP. **Indian J Physiol Pharmacol** 1998 Apr;42(2):172–88 (49 ref.)
Generators of short latency human somatosensory-evoked potentials recorded over the spine and scalp. Lee EK, et al. **J Clin Neurophysiol** 1998 May;15(3):227–34 (65 ref.)
Reaction time deficits and Parkinson's disease. Gauntlett-Gilbert J, et al. **Neurosci Biobehav Rev** 1998 Oct; 22(6):865–81 (74 ref.)

REACTIVE ATTACHMENT DISORDER

CLASSIFICATION

[Diagnosis of attachment disorders] Brisch KH, et al. **Prax Kinderpsychol Kinderpsychiatr** 1999 Jul-Aug; 48(6):425-37 (38 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Diagnosis of attachment disorders] Brisch KH, et al. **Prax Kinderpsychol Kinderpsychiatr** 1999 Jul-Aug; 48(6):425-37 (38 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Clinical disturbances of attachment in infancy and early childhood. Boris NW, et al. **Curr Opin Pediatr** 1998 Aug; 10(4):365-8 (27 ref.)

PSYCHOLOGY

Clinical disturbances of attachment in infancy and early childhood. Boris NW, et al. **Curr Opin Pediatr** 1998 Aug; 10(4):365-8 (27 ref.)

REACTIVE OXYGEN SPECIES

see related
FREE RADICALS
OXIDATIVE STRESS
PEROXIDES

Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Metodiewa D. **Amino Acids** 1998;14(1-3):181-7 (19 ref.)

Functional food science and defence against reactive oxidative species. Diplock AT, et al. **Br J Nutr** 1998 Aug; 80 Suppl 1:S77-112 (279 ref.)

Detection of active oxygen species in biological systems. Nakano M. **Cell Mol Neurobiol** 1998 Dec;18(6):565-79 (19 ref.)

Role of active oxygen species and NO in plant defence responses. Bolwell GP. **Curr Opin Plant Biol** 1999 Aug; 2(4):287-94 (72 ref.)

Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Grisham MB, et al. **Free Radic Biol Med** 1998 Sep;25(4-5):404-33 (208 ref.)

Reactive oxygen species-induced molecular damage and its application in pathology. Toyokuni S. **Pathol Int** 1999 Feb; 49(2):91-102 (93 ref.)

Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Klann E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):359-76 (94 ref.)

The role of macrophages and reactive oxygen species in experimental hydronephrosis. Ricardo SD, et al. **Semin Nephrol** 1998 Nov;18(6):612-21 (80 ref.)

Oxidation and the spermatozoa. Kim JG, et al. **Semin Reprod Endocrinol** 1998;16(4):235-9 (43 ref.)

Oxygen radicals, antioxidants, and lipid peroxidation. Santanam N, et al. **Semin Reprod Endocrinol** 1998; 16(4):275-80 (51 ref.)

[Oxidative injury and its defense system in vivo] Niwa Y. **Rinsho Byori** 1999 Mar;47(3):189-209 (84 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Oxidative injury in the nervous system. Delanty N, et al. **Acta Neurol Scand** 1998 Sep;98(3):145-53 (90 ref.)

Autoxidation of amyloid precursor protein and formation of reactive oxygen species. Multhaup G, et al. **Adv Exp Med Biol** 1999;448:183-92 (51 ref.)

Mitochondrial free radical production and aging in mammals and birds. Barja G. **Ann N Y Acad Sci** 1998 Nov 20; 854:224-38 (72 ref.)

Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Reiter RJ, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:410-24 (77 ref.)

Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Jabs T. **Biochem Pharmacol** 1999 Feb 1;57(3):231-45 (161 ref.)

Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854-65 (80 ref.)

Regulation of oxidant production in acute lung injury. Sanders KA, et al. **Chest** 1999 Jul;116(1 Suppl):56S-61S (39 ref.)

Antioxidants for hypertension. Kitiyakara C, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):531-8 (61 ref.)

Multiple activated oxygen species in P450 catalysis: contributions To specificity in drug metabolism. Coon MJ, et al. **Drug Metab Dispos** 1998 Dec;26(12):1190-3 (28 ref.)

The P450 catalytic cycle and oxygenation mechanism. Lewis DF, et al. **Drug Metab Rev** 1998 Nov;30(4):739-86 (175 ref.)

The aging paradox: free radical theory of aging. Ashok BT, et al. **Exp Gerontol** 1999 Jun;34(3):293-303 (74 ref.)

Reactive oxygen species and biological aging: a mechanistic approach. Schöneich C. **Exp Gerontol** 1999 Jan;34(1):19-34 (168 ref.)

Transition metal ion-catalyzed oxygen activation during pathogenic processes. Hippeli S, et al. **FEBS Lett** 1999 Jan 22;443(1):1-7 (88 ref.)

Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: an hypothesis. Clément MV, et al. **Free Radic Res** 1999 Apr;30(4):247-52 (44 ref.)

Glutathione S-transferases and prevention of cellular free radical damage. Ketterer B. **Free Radic Res** 1998 Jun; 28(6):647-58 (70 ref.)

Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. Hanson ES, et al. **Gene Expr** 1999;7(4-6):367-76 (100 ref.)

Reactive oxygen metabolites, antioxidants and head and neck cancer. Seidman MD, et al. **Head Neck** 1999 Aug; 21(5):467-79 (479 ref.)

Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. Ruffolo RR Jr, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S22-30 (48 ref.)

Signal transduction by reactive oxygen species in non-phagocytic cells. Finkel T. **J Leukoc Biol** 1999 Mar; 65(3):337-40 (35 ref.)

Redox regulation of signal transduction in cardiac and smooth muscle. Suzuki YJ, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):345-53 (72 ref.)

Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Ginsburg I. **Med Hypotheses** 1998 Oct; 51(4):337-46 (68 ref.)

Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. Mayer AM. **Medicina (B Aires)** 1998;58(4):377-85 (137 ref.)

Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Savolainen KM, et al. **Neurotoxicology** 1998 Aug-Oct; 19(4-5):669-74 (51 ref.)

Reactive oxygen species in male infertility. Review of literature and personal observations. Conte G, et al. **Panminerva Med** 1999 Mar;41(1):45-53 (58 ref.)

Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Reiter RJ, et al. **Proc West Pharmacol Soc** 1998;41:229-36 (156 ref.)

Oxidant mechanisms in gentamicin nephrotoxicity. Walker PD, et al. **Ren Fail** 1999 May-Jul;21(3-4):433-42 (16 ref.)

Roles for NAD(P)H oxidases and reactive oxygen species in vascular oxygen sensing mechanisms. Wolin MS, et al. **Respir Physiol** 1999 Apr 1;115(2):229-38 (55 ref.)

[Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus] Nawroth PP, et al. **Med Klin** 1999 Jan 15;94(1):29-38 (156 ref.) (Eng. Abstr.) **(Ger)**

[Cooperation of membrane proteins and cytosolic proteins in metabolic regulation--involvement of binding of hexokinase to mitochondria in regulation of glucose metabolism and association and complex formation between membrane proteins and cytosolic proteins in regulation of active oxygen production] Ishibashi S. **Yakugaku Zasshi** 1999 Jan;119(1):16-34 (49 ref.) (Eng. Abstr.) **(Jpn)**

[Role of reactive oxygen species in apoptosis] Bartosz G. **Postepy Biochem** 1998;44(1):22-31 (166 ref.) **(Pol)**

[The role of reactive oxygen species in mutagenesis and carcinogenesis processes] Oliński R, et al. **Postepy Biochem** 1999;45(1):50-8 (51 ref.) **(Pol)**

[Oxidation mechanisms and anti-oxidation in HIV infected patients--effect on disease progression] Jaruga P. **Postepy Hig Med Dosw** 1999;53(1):43-54 (79 ref.) (Eng. Abstr.) **(Pol)**

[Antioxidative mechanisms in response to reactive forms of oxygen, apoptosis and differentiation of myogenic cells] Orzechowski A, et al. **Postepy Hig Med Dosw** 1998; 52(4):401-18 (73 ref.) (Eng. Abstr.) **(Pol)**

[The role of the oxygen-binding properties of the blood in maintaining pro-oxidant-antioxidant equilibrium in the body] Zinchuk VV, et al. **Usp Fiziol Nauk** 1999 Jul-Sep; 30(3):38-48 (84 ref.) (Eng. Abstr.) **(Rus)**

[Active oxygen metabolites in provision and control of natural cytotoxic reactions] Cheknev SB. **Vestn Ross Akad Med Nauk** 1999;(2):10-5 (53 ref.) (Eng. Abstr.) **(Rus)**

[Free radical mechanisms of low-intensive laser radiation] Chichuk TV, et al. **Vestn Ross Akad Med Nauk** 1999; (2):27-32 (54 ref.) (Eng. Abstr.) **(Rus)**

[Serum antioxidative activity] Klebanov GI, et al. **Vestn Ross Akad Med Nauk** 1999;(2):15-22 (46 ref.) (Eng. Abstr.) **(Rus)**

[Phagocyte-dependent free oxygen radical mechanisms of autoaggression in pathogenesis of internal diseases] Kogan AKh. **Vestn Ross Akad Med Nauk** 1999;(2):3-10 (47 ref.) **(Rus)**

[Importance of free radicals during the reproduction cycle] Durán Reyes G, et al. **Ginecol Obstet Mex** 1998 Sep; 66:371-6 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine. Aw TY. **Am J Clin Nutr** 1999 Oct;70(4):557-65 (67 ref.)

Oxygen free radical signaling in ischemic preconditioning. Das DK, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:49-65 (107 ref.)

Regulation of gene expression by reactive oxygen. Dalton TP, et al. **Annu Rev Pharmacol Toxicol** 1999;39:67-101 (291 ref.)

Oxidative stress in bacterial meningitis. Koedel U, et al. **Brain Pathol** 1999 Jan;9(1):57-67 (116 ref.)

Demyelination: the role of reactive oxygen and nitrogen species. Smith KJ, et al. **Brain Pathol** 1999 Jan;9(1):69-92 (264 ref.)

Radical species in inflammation and overtraining. Tiidus PM. **Can J Physiol Pharmacol** 1998 May;76(5):533-8 (77 ref.)

Dual role of reactive oxygen species in vascular growth [editorial; comment] Griendling KK, et al. **Circ Res** 1999 Sep 17;85(6):562-3 (14 ref.) Comment on: Circ Res 1999 Sep 17;85(6):524-33.

Antioxidant enzymes and their implications in pathophysiologic processes. Mates JM, et al. **Front Biosci** 1999 Mar 15;4:D339-45 (60 ref.)

Oxidants, antioxidants and alcohol: implications for skeletal and cardiac muscle. Preedy VR, et al. **Front Biosci** 1999 Aug 1;4:e58-66 (70 ref.)

Roles of reactive oxygen species: signaling and regulation of cellular functions. Gamaley IA, et al. **Int Rev Cytol** 1999; 188:203-55 (343 ref.)

Oxygen radical stress in vascular disease: the role of endothelial nitric oxide synthase. Stroes ES, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S14-21 (129 ref.)

Free radicals and reactive oxygen species in programmed cell death. Anderson KM, et al. **Med Hypotheses** 1999 May; 52(5):451-63 (135 ref.)

Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Rösen P, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):103-11 (64 ref.)

Free radicals in disease. Hogg N. **Semin Reprod Endocrinol** 1998;16(4):241-8 (67 ref.)

The role of reactive oxygen species in atherosclerosis. Mügge A. **Z Kardiol** 1998 Nov;87(11):851-64 (81 ref.)

[Microcirculatory hemodynamics in oral tissues with reference to neurogenic response and reactive oxygen species interaction] Okabe E, et al. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):219-25 (43 ref.) (Eng. Abstr.) **(Jpn)**

[The role of oxygen radicals in the physiology and pathology of human sperm] Man'kovs'ka IM, et al. **Fiziol Zh** 1998; 44(5-6):118-25 (37 ref.) (Eng. Abstr.) **(Ukr)**

REACTIVE SITE see **BINDING SITES**

READING

see related
DYSLEXIA, ACQUIRED

Why literacy matters. Links between reading ability and health. Lee PP. **Arch Ophthalmol** 1999 Jan;117(1):100-3 (28 ref.)

An efficient treatment and new criteria for cure of strabismic amblyopia: reading and Bangerter foils. Lang J. **Binocul Vis Strabismus Q** 1999 Spring;14(1):9-10 (6 ref.)

Transcranial magnetic stimulation in study of the visual pathway. Amassian VE, et al. **J Clin Neurophysiol** 1998 Jul;15(4):288-304 (74 ref.)

Dissociation of letter and picture naming resulting from callosal disconnection. Suzuki K, et al. **Neurology** 1998 Nov;51(5):1390-4 (21 ref.)

Neuroanatomy, circuitry and plasticity of word reading. Posner MI, et al. **Neuroreport** 1999 Feb 25;10(3):R12-23 (88 ref.)

Patient understanding of postsurgical instruction forms. Alexander RE. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):153-8 (26 ref.)

Reading skills in hyperlexia: a developmental perspective. Nation K. **Psychol Bull** 1999 May;125(3):338-55 (120 ref.)

Eye movements in reading and information processing: 20 years of research. Rayner K. **Psychol Bull** 1998 Nov; 124(3):372-422 (927 ref.)

Why is learning to read a hard task for some children? Lundberg I. **Scand J Psychol** 1998 Sep;39(3):155-7 (17 ref.)

[100 years research in reading and spelling--what do we know today?] von Suchodoletz W. **Z Kinder Jugendpsychiatr Psychother** 1999 Aug; 27(3):199-206 (70 ref.) **(Ger)**

READING DISABILITY, ACQUIRED see **DYSLEXIA, ACQUIRED**

READING DISABILITY, DEVELOPMENTAL see **DYSLEXIA**

READING DISORDER see **DYSLEXIA**

READING FRAMES

How translational accuracy influences reading frame maintenance. Farabaugh PJ, et al. **EMBO J** 1999 Mar 15; 18(6):1427-34 (55 ref.)

REAGENT KITS, DIAGNOSTIC

Diagnostic tests that are worthwhile for patients with

sexually transmitted bacterial infections in industrialized countries. Taylor-Robinson D, et al. **Int J STD AIDS** 1999 Jan;10(1):1-4 (31 ref.)
Evaluation of commercially available Helicobacter pylori serology kits: a review. Laheij RJ, et al. **J Clin Microbiol** 1998 Oct;36(10):2803-9 (91 ref.)

REAGENT STRIPS

[Urinalysis using dipsticks] Cochat P, et al. **Arch Pediatr** 1998 Jan;5(1):65-70 (16 ref.) (Eng. Abstr.) **(Fre)**

REAGENTS see **INDICATORS AND REAGENTS**

REAL-TIME SYSTEMS see **COMPUTER SYSTEMS**

REALITY TESTING

The biographical component of schizophrenia: a two-faced definition of relationship? Korn H. **Med Hypotheses** 1999 Jun;52(6):539-44 (32 ref.)

REAVEN SYNDROME X see **INSULIN RESISTANCE**

REC A PROTEIN

[Structural biology of RecA and RuvABC proteins involved in homologous DNA recombination] Iwasaki H, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):495-505 (46 ref.) **(Jpn)**

GENETICS

Recombinational DNA repair in bacteria and the RecA protein. Cox MM. **Prog Nucleic Acid Res Mol Biol** 1999; 63:311-66 (342 ref.)

METABOLISM

DNA strand exchange proteins: a biochemical and physical comparison. Bianco PR, et al. **Front Biosci** 1998 Jun 17; 3:D570-603 (307 ref.)
Recombination in phage lambda: one geneticist's historical perspective. Stahl FW. **Gene** 1998 Nov 26;223(1-2):95-102 (77 ref.)

RECA PROTEIN see **REC A PROTEIN**

RECALL

Treatment of childhood memories: theory and practice. Arntz A, et al. **Behav Res Ther** 1999 Aug;37(8):715-40 (31 ref.)
Diagnostic recognition: task constraints, object information, and their interactions. Schyns PG. **Cognition** 1998 Jul; 67(1-2):147-79 (95 ref.)
Image-based object recognition in man, monkey and machine. Tarr MJ, et al. **Cognition** 1998 Jul;67(1-2):1-20 (80 ref.)
A neural network explanation of posttraumatic stress disorder. Tryon WW. **J Anxiety Disord** 1998 Jul-Aug; 12(4):373-85 (45 ref.)
Children's memory for pain. Ornstein PA, et al. **J Dev Behav Pediatr** 1999 Aug;20(4):262-77 (100 ref.)
Rate of forgetting in amnesia: I. Recall and recognition of prose. Isaac CL, et al. **J Exp Psychol Learn Mem Cogn** 1999 Jul;25(4):942-62 (75 ref.)
Obtaining witness statements: the psychology, best practice and proposals for innovation. Milne B, et al. **Med Sci Law** 1999 Apr;39(2):127-38 (49 ref.)
People with mental retardation as witnesses in court: a review. Kebbell MR, et al. **Ment Retard** 1999 Jun; 37(3):179-87 (75 ref.)
Recollections of parental behaviour, adult attachment and mental health: mediating and moderating effects. Gittleman MG, et al. **Psychol Med** 1998 Nov;28(6):1443-55 (46 ref.)
Determinants of positive and negative generation effects in free recall. Steffens MC, et al. **Q J Exp Psychol A** 1998 Nov;51(4):705-33 (62 ref.)
The link between knowledge and remembering in Alzheimer's disease. Bäckman L. **Scand J Psychol** 1998 Sep; 39(3):131-9 (60 ref.)
Interactions of language and memory in deaf children and adults. Marschark M, et al. **Scand J Psychol** 1998 Sep; 39(3):145-8 (26 ref.)
[Personal biography in the aging process and attitude to personal biography in social work with the elderly] Schweppe C. **Z Gerontol Geriatr** 1998 Oct;31(5):325-30 (35 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Neural models of memory. Hasselmo ME, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):184-8 (54 ref.)
The functional neuroanatomy of episodic memory: the role of the frontal lobes, the hippocampal formation, and other areas. Desgranges B, et al. **Neuroimage** 1998 Aug; 8(2):198-213 (120 ref.)
Relating hippocampal circuitry to function: recall of memory sequences by reciprocal dentate-CA3 interactions. Lisman JE. **Neuron** 1999 Feb;22(2):233-42 (78 ref.)
The contralateral organization of visual memory: a theoretical concept and a research tool. Gratton G. **Psychophysiology** 1998 Nov;35(6):638-47 (60 ref.)

RECEIVER OPERATING CHARACTERISTIC see **ROC CURVE**

RECEPTOR AGGREGATION

see related
RECEPTOR CROSS-TALK

RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL

see related
SIGNAL TRANSDUCTION

GENETICS

ZAP-70 and defects of T-cell receptor signaling. Elder ME. **Semin Hematol** 1998 Oct;35(4):310-20 (62 ref.)

IMMUNOLOGY

Function of the CD3 subunits of the pre-TCR and TCR complexes during T cell development. Malissen B, et al. **Adv Immunol** 1999;72:103-48 (198 ref.)

METABOLISM

Defective signal transduction via TCR-CD3 complex in patients with systemic lupus erythematosus. Takeuchi T, et al. **Intern Med** 1999 Feb;38(2):169 (6 ref.)

PHYSIOLOGY

ZAP-70 and defects of T-cell receptor signaling. Elder ME. **Semin Hematol** 1998 Oct;35(4):310-20 (62 ref.)

RECEPTOR, COMPLEMENT 3 see **MACROPHAGE-1 ANTIGEN**

RECEPTOR CROSS-TALK

see related
RECEPTORS, CELL SURFACE
SIGNAL TRANSDUCTION
Signaling and host cell invasion by Trypanosoma cruzi. Burleigh BA, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):461-5 (47 ref.)
Crosstalk between insulin and angiotensin II signalling systems [see comments] Folli F, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):133-9 (21 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111-2.
Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Kato S, et al. **Oncology** 1998 Dec;55 Suppl 1:5-10 (32 ref.)

PHYSIOLOGY

Interactions between effectors linked to serotonin receptors. Berg KA, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:111-20 (24 ref.)
Interactions between the presynaptic alpha2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Schlicker E, et al. **Brain Res Bull** 1998 Sep 15;47(2):129-32 (45 ref.)
Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. McKay LI, et al. **Endocr Rev** 1999 Aug;20(4):435-59 (271 ref.)
Regulation of Smad signalling by protein associations and signalling crosstalk. Zhang Y, et al. **Trends Cell Biol** 1999 Jul;9(7):274-9 (60 ref.)
Hippocampal synapses: do they talk to their neighbours? Rusakov DA, et al. **Trends Neurosci** 1999 Sep;22(9):382-8 (37 ref.)

RECEPTOR-MEDIATED SIGNAL TRANSDUCTION see **SIGNAL TRANSDUCTION**

RECEPTOR PROTEIN-TYROSINE KINASE

see related
PROTO-ONCOGENE PROTEINS C-KIT

ANALYSIS

RET protooncogene analysis in the diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type II. Matias-Guiu X. **Adv Anat Pathol** 1998 May;5(3):196-201 (19 ref.)

BIOSYNTHESIS

Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Yoshida H, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):321-32 (56 ref.)
[Advances in the study of the role of vascular endothelial growth factor and its receptor in tumor angiogenesis and its relation with anti-angiogenesis effect] Bian X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug;26(4):248-50 (15 ref.) **(Chi)**

CHEMISTRY

Structure and function of vascular endothelial growth factor receptor-1 and -2. Shibuya M, et al. **Curr Top Microbiol Immunol** 1999;237:59-83 (92 ref.)
Structural analysis of receptor tyrosine kinases. Hubbard SR. **Prog Biophys Mol Biol** 1999;71(3-4):343-58 (67 ref.)

GENETICS

RET proto-oncogene: role in kidney development and molecular pathology. Salomon R, et al. **Adv Nephrol Necker Hosp** 1998;28:401-17 (50 ref.)
Not Antley-Bixler syndrome [letter; comment] Gripp KW, et al. **Am J Med Genet** 1999 Mar 5;83(1):65-8 (13 ref.) Comment on: Am J Med Genet 1998 May 18;77(3):219-24.
Different mutations of the RET gene cause different human tumoral diseases. Santoro M, et al. **Biochimie** 1999 Apr; 81(4):397-402 (57 ref.)
The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Ponder BA. **Cancer Res** 1999 Apr 1;59(7 Suppl):1736s-1741s; discussion 1742s (78 ref.)
RET proto-oncogene in the development of human cancer. Eng C. **J Clin Oncol** 1999 Jan;17(1):380-93 (127 ref.)
A ret transgenic mouse model of thyroid carcinogenesis. Capen C, et al. **Lab Anim Sci** 1998 Dec;48(6):580-3 (3 ref.)
GDNF family neurotrophic factor signaling: four masters, one servant? Airaksinen MS, et al. **Mol Cell Neurosci** 1999 May;13(5):313-25 (117 ref.)
Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Pierotti MA, et al. **Recent Results Cancer Res** 1998;154:237-47 (47 ref.)
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Rabes HM, et al. **Recent Results Cancer Res** 1998;154:248-64 (92 ref.)
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M, et al. **Recent Results Cancer Res** 1998; 154:229-36 (22 ref.)
Genetic aspects of Hirschsprung's disease. Kusafuka T, et al. **Semin Pediatr Surg** 1998 Aug;7(3):148-55 (97 ref.)
Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Kebebew E, et al. **Thyroid** 1999 Feb;9(2):127-31 (17 ref.)
Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl. Pisarchik AV, et al. **Thyroid** 1998 Nov;8(11):1003-8 (39 ref.)
[Genes and genetics in Hirschsprung's disease] Maas SM, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1352-6 (24 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Witte L, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):155-61 (21 ref.)

METABOLISM

c-Src, receptor tyrosine kinases, and human cancer. Biscardi JS, et al. **Adv Cancer Res** 1999;76:61-119 (488 ref.)
Using green fluorescent protein to understand the mechanisms of G-protein-coupled receptor regulation. Ferguson SS. **Braz J Med Biol Res** 1998 Nov;31(11):1471-7 (50 ref.)
G-protein-linked receptors as tyrosine kinase substrates: new paradigms in signal integration. Malbon CC, et al. **Cell Signal** 1998 Sep;10(8):523-7 (23 ref.)
Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors. Katada T, et al. **Chem Phys Lipids** 1999 Apr; 98(1-2):79-86 (30 ref.)
Eph receptors and ephrins: effectors of morphogenesis. Holder N, et al. **Development** 1999 May;126(10):2033-44 (104 ref.)
Regulation of G-protein-coupled receptor kinase subtypes by calcium sensor proteins. Iacovelli L, et al. **FASEB J** 1999 Jan;13(1):1-8 (43 ref.)
Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases. Daly RJ. **Growth Factors** 1999;16(4):255-63 (70 ref.)
Kinases involved in MSP/RON signaling. Danilkovitch A, et al. **J Leukoc Biol** 1999 Mar;65(3):345-8 (47 ref.)
G-protein coupled receptor kinases as modulators of G-protein signalling. Bünemann M, et al. **J Physiol (Lond)** 1999 May 15;517 (Pt 1):5-23 (186 ref.)
Eph receptors, ephrins, and PDZs gather in neuronal synapses [comment] Hsueh YP, et al. **Neuron** 1998 Dec; 21(6):1227-9 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1453-63.
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Porter AC, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1343-52 (106 ref.)
Adaptor proteins and T-cell antigen receptor signaling. Samelson LE. **Prog Biophys Mol Biol** 1999;71(3-4):393-403 (53 ref.)
Studying signal transduction in neuronal cells: the Trk/NGF system. Kaplan DR. **Prog Brain Res** 1998;117:35-46 (70 ref.)
Eph receptors and ligands in axon pathway choice, target recognition, and synaptogenesis. Lemke G. **Prog Brain Res** 1998;117:171-6 (34 ref.)

[Signal transduction of nerve growth factor (NGF) and its TrkA and p75NTR receptors] Niewiadomska G, et al. **Postepy Biochem** 1999;45(1):21–31 (79 ref.) **(Pol)**

PHYSIOLOGY

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Siemeister G, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):241–8 (70 ref.)

Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Carmeliet P, et al. **Curr Top Microbiol Immunol** 1999;237:133–58 (133 ref.)

Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development. Partanen J, et al. **Curr Top Microbiol Immunol** 1999;237:159–72 (67 ref.)

Structure and function of vascular endothelial growth factor receptor-1 and -2. Shibuya M, et al. **Curr Top Microbiol Immunol** 1999;237:59–83 (92 ref.)

Vascular endothelial growth factor receptor-3. Taipale J, et al. **Curr Top Microbiol Immunol** 1999;237:85–96 (44 ref.)

FLT3: receptor and ligand. Biology and potential clinical application. Shurin MR, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):37–48 (104 ref.)

Vascular endothelial growth factor (VEGF) and its receptors. Neufeld G, et al. **FASEB J** 1999 Jan;13(1):9–22 (182 ref.)

Signal relays in the VEGF system. Ortega N, et al. **Front Biosci** 1999 Feb 1;4:D141–52 (130 ref.)

The Syk family of protein tyrosine kinases in T-cell activation and development. Chu DH, et al. **Immunol Rev** 1998 Oct;165:167–80 (79 ref.)

Heptahelical receptor signaling: beyond the G protein paradigm. Hall RA, et al. **J Cell Biol** 1999 May 31; 145(5):927–32 (66 ref.)

Trks: signal transduction and intracellular pathways. Klesse LJ, et al. **Microsc Res Tech** 1999 May 15–Jun 1; 45(4–5):210–6 (73 ref.)

Eph receptors, ephrins, and PDZs gather in neuronal synapses [comment] Hsueh YP, et al. **Neuron** 1998 Dec; 21(6):1227–9 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1453–63.

Mechanisms involved in development of retinotectal connections: roles of Eph receptor tyrosine kinases, NMDA receptors and nitric oxide. Ernst AF, et al. **Prog Brain Res** 1998;118:115–31 (131 ref.)

Signal transduction by the receptor tyrosine kinase Ret. van Weering DH, et al. **Recent Results Cancer Res** 1998; 154:271–81 (40 ref.)

VEGFs, receptors and angiogenesis. Veikkola T, et al. **Semin Cancer Biol** 1999 Jun;9(3):211–20 (99 ref.)

Emerging roles for SH2/PTB-containing Shc adaptor proteins in the developing mammalian brain. Cattaneo E, et al. **Trends Neurosci** 1998 Nov;21(11):476–81 (65 ref.)

[Receptors and development of endothelial and hematopoietic cells] Eichmann A, et al. **J Soc Biol** 1999; 193(2):155–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of angiogenesis–expression of VEGF receptors] Morita I. **Hum Cell** 1998 Dec;11(4):215–20 (15 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTOR TYROSINE KINASE see **RECEPTOR PROTEIN-TYROSINE KINASE**

RECEPTORS, ACETYLCHOLINE see **RECEPTORS, CHOLINERGIC**

RECEPTORS, ACTH see **RECEPTORS, CORTICOTROPIN**

RECEPTORS, ADENOSINE see **RECEPTORS, PURINERGIC P1**

RECEPTORS, ADP see **RECEPTORS, PURINERGIC P2**

RECEPTORS, ADRENERGIC

BIOSYNTHESIS

[Regulation of expression of adrenergic receptors by steroid hormones] Dygalo NN, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):1115–20 (30 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Büscher R, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):94–9 (30 ref.)

METABOLISM

Molecular basis for the stereoselective interactions of catecholamines with alpha-adrenoceptors. Hieble JP, et al. **Proc West Pharmacol Soc** 1998;41:225–8 (19 ref.)

[Cascade of biochemical events triggered by stimulation of adrenergic receptors in the rat pineal gland--from cell membrane to nucleus] Zawilska JB, et al. **Postepy Hig Med Dosw** 1999;53(2):233–46 (53 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Acute coronary syndromes: "unifying" theory versus adrenergic stress. Baroldi G. **G Ital Cardiol** 1998 Nov; 28(11):1303–16 (24 ref.) **(Eng, Ita)**

Causalgia, pathological pain, and adrenergic receptors. Perl ER. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7664–7 (39 ref.)

RECEPTORS, ADRENERGIC, ALPHA

The functional anatomy of noradrenergic neurons in Parkinson's disease. Soldani P, et al. **Funct Neurol** 1999 Apr–Jun;14(2):97–109 (53 ref.)

PHYSIOLOGY

Adrenergic/cholinergic immunomodulation in the rat model--in vivo veritas? Rinner I, et al. **Dev Immunol** 1998; 6(3–4):245–52 (35 ref.)

[Autonomic nervous system and prostatic physiology. Specific features of the alpha-adrenergic system] Mottet N, et al. **Prog Urol** 1999 Feb;9(1):26–36 (78 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, ADRENERGIC, ALPHA-1

ANTAGONISTS & INHIBITORS

Clinical experience in Europe with uroselective alpha1-antagonists. Debruyne FM, et al. **Eur Urol** 1999;36 Suppl 1:54–8; discussion 65 (36 ref.)

Clinical pharmacology of alpha1-adrenoceptor antagonists. Kirby RS. **Eur Urol** 1999;36 Suppl 1:48–53; discussion 65 (37 ref.)

Preclinical pharmacology of alpha1-adrenoceptor antagonists. Martin DJ. **Eur Urol** 1999;36 Suppl 1:35–41; discussion 65 (23 ref.)

Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parameters. Adkison KK, et al. **Pharm Biotechnol** 1998;11:423–43 (15 ref.)

CLASSIFICATION

Alpha1-adrenoceptor subtypes. Zhong H, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):261–76 (162 ref.)

METABOLISM

Alpha1-adrenergic hypothesis for pulmonary hypertension. Salvi SS. **Chest** 1999 Jun;115(6):1708–19 (106 ref.)

PHYSIOLOGY

Rat renal alpha 1-adrenoceptor subtypes: characterization, function, and regulation. Buscher R, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul;17(4):289–92 (37 ref.)

Subtypes of functional alpha1- and alpha2-adrenoceptors. Docherty JR. **Eur J Pharmacol** 1998 Nov 13;361(1):1–15 (175 ref.)

alpha1-adrenoceptors and bladder function. Andersson K. **Eur Urol** 1999;36 Suppl 1:96–102 (58 ref.)

Modulation of voiding and storage reflexes by activation of alpha1-adrenoceptors. de Groat WC, et al. **Eur Urol** 1999; 36 Suppl 1:68–73 (20 ref.)

Signal transduction pathways associated with alpha1-adrenoceptor subtypes in cells and tissues including human prostate. Marshall I, et al. **Eur Urol** 1999;36 Suppl 1:42–7; discussion 65 (23 ref.)

Pharmacology of alpha-adrenoceptors in male sexual function. Rampin O. **Eur Urol** 1999;36 Suppl 1:103–6 (19 ref.)

Adrenoceptor pharmacology: urogenital applications. Ruffolo RR Jr, et al. **Eur Urol** 1999;36 Suppl 1:17–22 (57 ref.)

Molecular pharmacology of human alpha1-adrenergic receptors: unique features of the alpha 1a-subtype. Schwinn DA, et al. **Eur Urol** 1999;36 Suppl 1:7–10 (22 ref.)

alpha1- and alpha2-adrenoceptors in BPH. Takeda M, et al. **Eur Urol** 1999;36 Suppl 1:31–4; discussion 65 (23 ref.)

[Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach] Jolliet P, et al. **Therapie** 1998 Jan–Feb;53(1):61–6 (28 ref.) (Eng. Abstr.) **(Ita)**

RECEPTORS, ADRENERGIC, ALPHA-2

AGONISTS

alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Khan ZP, et al. **Anaesthesia** 1999 Feb;54(2):146–65 (215 ref.)

Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Newcorn JH, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1099–22, viii (76 ref.)

DRUG EFFECTS

Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. Head GA, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):163–9 (40 ref.)

GENETICS

Alpha 2-adrenergic receptor subtypes: subtle mutation of the alpha 2A-adrenergic receptor in vivo by gene targeting strategies reveals the role of this subtype in multiple physiological settings. MacMillan LB, et al. **Recent Prog Horm Res** 1998;53:25–42 (77 ref.)

PHYSIOLOGY

Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs. Bousquet P, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:272–8 (19 ref.)

Subtypes of functional alpha1- and alpha2-adrenoceptors. Docherty JR. **Eur J Pharmacol** 1998 Nov 13;361(1):1–15 (175 ref.)

alpha1- and alpha2-adrenoceptors in BPH. Takeda M, et al. **Eur Urol** 1999;36 Suppl 1:31–4; discussion 65 (23 ref.)

RECEPTORS, ADRENERGIC, BETA

The beta-adrenoceptor. Johnson M. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S146–53 (60 ref.)

GENETICS

Potential future therapies for heart failure: gene transfer of beta-adrenergic signaling components. Maurice JP, et al. **Coron Artery Dis** 1999 Sep;10(6):401–5 (33 ref.)

Using gene knockout and transgenic techniques to study the physiology and pharmacology of beta3-adrenergic receptors. Lowell BB. **Endocr J** 1998 Apr;45 Suppl:S9–13 (19 ref.)

Association between beta3-adrenoreceptor polymorphism with obesity and diabetes in Japan. Yoshida T, et al. **Intern Med** 1999 Feb;38(2):207–9 (21 ref.)

Adrenoceptor genes in human obesity. Arner P, et al. **J Intern Med** 1999 Jun;245(6):667–72 (49 ref.)

[Obesity and diseases. 5. Molecular mechanism involved in the onset of obesity and overview of its treatment] Yoshida T, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1806–10 (25 ref.) **(Jpn)**

[Beta 3 adrenergic receptor polymorphism and obesity] Yoshida T, et al. **Nippon Rinsho** 1998 Jul;56(7):1871–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

On the presence of a putative fourth beta-adrenoceptor in human adipose tissue [letter; comment] Galitzky J, et al. **Trends Pharmacol Sci** 1998 May;19(5):164–6 (16 ref.) Comment on: Trends Pharmacol Sci 1996 Oct;17(10):373–81.

PHYSIOLOGY

Beta-adrenergic receptors and receptor signaling in heart failure. Post SR, et al. **Annu Rev Pharmacol Toxicol** 1999; 39:343–60 (107 ref.)

Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update. Weyer C, et al. **Diabetes Metab** 1999 Mar;25(1):11–21 (94 ref.)

Using gene knockout and transgenic techniques to study the physiology and pharmacology of beta3-adrenergic receptors. Lowell BB. **Endocr J** 1998 Apr;45 Suppl:S9–13 (19 ref.)

Physiological consequences of beta-adrenergic receptor disruption. Rohrer DK. **J Mol Med** 1998 Oct;76(11):764–72 (72 ref.)

Regulation of beta-adrenoceptor signaling in cardiac function and disease. Dzimiri N. **Pharmacol Rev** 1999 Sep; 51(3):465–501 (357 ref.)

Regulation of beta-adrenergic receptor responsiveness modulation of receptor gene expression. Danner S, et al. **Rev Physiol Biochem Pharmacol** 1999;136:183–223 (192 ref.)

Catecholamine refractoriness and their mechanisms in cardiocirculatory shock and chronic heart failure. Böhm M. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:270–5; discussion 276 (41 ref.)

[Down regulation] Ogawa R. **Masui** 1998 Dec;47 Suppl:S88–92 (6 ref.) **(Jpn)**

RECEPTORS, ADRENERGIC, BETA-2

AGONISTS

Reduction in health care resource utilization associated with extended-release theophylline. Schulz RM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):267–72 (23 ref.)

DRUG EFFECTS

Activation of beta 2-adrenergic receptors and ventricular fibrillation. Billman GE, et al. **Cardiologia** 1998 Aug; 43(8):811–8 (69 ref.)

[Use of delayed-action beta-2 mimetics in the management of chronic obstructive bronchial diseases--for] Muir JF, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S75–6 (10 ref.) **(Fre)**

[Long-acting beta-2-adrenergic agonists in bronchospasm therapy (editorial)] Plusa T. **Pol Merkuriusz Lek** 1999 May; 6(35):227–31 (11 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, ADRENERGIC, BETA-2

GENETICS

Molecular and genetic basis of beta2-adrenergic receptor function. Liggett SB. **J Allergy Clin Immunol** 1999 Aug; 104(2 Pt 2):S42-6 (24 ref.)

METABOLISM

Molecular and genetic basis of beta2-adrenergic receptor function. Liggett SB. **J Allergy Clin Immunol** 1999 Aug; 104(2 Pt 2):S42-6 (24 ref.)

PHYSIOLOGY

Activation of beta 2-adrenergic receptors and ventricular fibrillation. Billman GE, et al. **Cardiologia** 1998 Aug; 43(8):811-8 (69 ref.)

Contrasting properties of albuterol stereoisomers. Page CP, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 2):S31-41 (75 ref.)

RECEPTORS, ADRENOCORTICOTROPIC HORMONE see **RECEPTORS, CORTICOTROPIN**

RECEPTORS, AH see **RECEPTORS, ARYL HYDROCARBON**

RECEPTORS, ALDOSTERONE

METABOLISM

[Aldosterone receptors: new insights in hormonal signal transduction] Rafestin-Oblin ME, et al. **Therapie** 1998 May-Jun;53(3):227-35 (100 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Molecular and cellular determinants of mineralocorticoid selectivity. Farman N. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):45-51 (64 ref.)

RECEPTORS, ALPHA-ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA**

RECEPTORS, ALPHA-1 ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA-1**

RECEPTORS, ALPHA-2 ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA-2**

RECEPTORS, AMINO ACID

PHYSIOLOGY

The organization and regulation of non-NMDA receptors in neurons. Wenthold RJ, et al. **Prog Brain Res** 1998; 116:133-52 (139 ref.)

RECEPTORS, AMPA

ANTAGONISTS & INHIBITORS

[Ionic channel blocking as an approach to investigation of AMPA receptor subtypes] Magazanik LG. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):994-1005 (61 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Crystal clear structure/function relationships for GluRs [comment] Gasic G. **Neuron** 1998 Nov;21(5):938-40 (12 ref.) Comment on: Neuron 1998 Mar;20(3):371-80. Comment on: Neuron 1998 Mar;20(3):381-7. Comment on: Neuron 1998 Mar;20(3):427-44.

DRUG EFFECTS

Neuropharmacology of AMPA and kainate receptors. Bleakman D, et al. **Neuropharmacology** 1998 Oct-Nov; 37(10-11):1187-204 (275 ref.)

GENETICS

AMPA receptors: molecular and functional diversity. Borges K, et al. **Prog Brain Res** 1998;116:153-70 (98 ref.)

METABOLISM

Receptor clustering: activate to accumulate? Kamboj S, et al. **Curr Biol** 1998 Oct 8;8(20):R719-21 (13 ref.)

Food toxins, ampa receptors, and motor neuron diseases. Spencer PS. **Drug Metab Rev** 1999 Aug;31(3):561-87 (99 ref.)

Nomadic AMPA receptors and LTP [comment] Morales M, et al. **Neuron** 1999 Jul;23(3):431-4 (20 ref.) Comment on: Neuron 1998 Aug;21(2):267-70.

Thinking globally, acting locally: AMPA receptor turnover and synaptic strength [comment] Turrigiano GG, et al. **Neuron** 1998 Nov;21(5):933-5 (10 ref.) Comment on: Neuron 1998 Nov;21(5):1067-78.

PHYSIOLOGY

Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Chéramy A, et al. **Amino Acids** 1998;14(1-3):63-8 (25 ref.)

Synaptic transmission: two players team up for a new tune. Jahn R. **Curr Biol** 1998 Nov 19;8(23):R856-8 (18 ref.)

The regulation of AMPA receptor-binding sites. Dev KK, et al. **Mol Neurobiol** 1998 Winter;17(1-3):33-58 (170 ref.)

Crystal clear structure/function relationships for GluRs [comment] Gasic G. **Neuron** 1998 Nov;21(5):938-40 (12 ref.) Comment on: Neuron 1998 Mar;20(3):371-80. Comment on: Neuron 1998 Mar;20(3):381-7. Comment on: Neuron 1998 Mar;20(3):427-44.

AMPA receptors: molecular and functional diversity. Borges K, et al. **Prog Brain Res** 1998;116:153-70 (98 ref.)

[Analysis of molecular basis of neuronal properties using the patch-clamp RT-PCR method] Tsuzuki K. **Nippon Rinsho** 1998 Jul;56(7):1681-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Ca2+ permeation through the ionotropic glutamate receptor] Ozawa S. **Tanpakushitsu Kakusan Koso** 1998 Sep; 43(12 Suppl):1589-95 (29 ref.) **(Jpn)**

RECEPTORS, ANDROGEN

ANALYSIS

[Transcriptional regulation and subcellular localization of mutant androgen receptor in spinal and bulbar muscular atrophy] Miwa S, et al. **Nippon Rinsho** 1999 Apr; 57(4):869-73 (20 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Antiandrogens as environmental endocrine disruptors. Kelce WR, et al. **Reprod Fertil Dev** 1998;10(1):105-11 (65 ref.)

DRUG EFFECTS

Mechanism of androgen receptor activation and possible implications for chemoprevention trials. Klocker H, et al. **Eur Urol** 1999;35(5-6):413-9 (28 ref.)

GENETICS

The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Kantoff P, et al. **Biochim Biophys Acta** 1998 Nov 26;1378(3):C1-5 (25 ref.)

Clinical and molecular aspects of androgen receptor defects. Wieacker PF, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(6):446-53 (52 ref.)

Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. Choong CS, et al. **J Mol Endocrinol** 1998 Dec;21(3):235-57 (211 ref.)

The androgen receptor: genetic considerations in the development and treatment of prostate cancer. Cude KJ, et al. **J Mol Med** 1999 May;77(5):419-26 (81 ref.)

Molecular defects of the androgen receptor. McPhaul MJ. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):315-22 (42 ref.)

Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Yeh S, et al. **Keio J Med** 1999 Jun;48(2):87-92 (40 ref.)

Androgen receptor mutation in Kennedy's disease. Fischbeck KH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29;354(1386):1075-8 (26 ref.)

Androgen receptor transactivation domain and control of spermatogenesis. Yong EL, et al. **Rev Reprod** 1998 Sep; 3(3):141-4 (21 ref.)

[Transcriptional regulation and subcellular localization of mutant androgen receptor in spinal and bulbar muscular atrophy] Miwa S, et al. **Nippon Rinsho** 1999 Apr; 57(4):869-73 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenesis of androgen insensitivity syndrome] Okabe T, et al. **Nippon Rinsho** 1998 Jul;56(7):1881-6 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of expanded CAG trinucleotide repeat in spinal and bulbar muscular atrophy (SBMA)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr;57(4):862-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Physiology and pathophysiology of androgen action. Hiort O, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr; 12(1):115-32 (96 ref.)

Mechanistic concepts in androgen-dependence of prostate cancer. Craft N, et al. **Cancer Metastasis Rev** 1998-99; 17(4):421-7 (53 ref.)

Mechanisms of androgen receptor activation and function. Brinkmann AO, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):307-13 (32 ref.)

Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain. Yong EL, et al. **Mol Cell Endocrinol** 1998 Feb;137(1):41-50 (29 ref.)

The role of the androgen receptor in the development and progression of prostate cancer. Jenster G. **Semin Oncol** 1999 Aug;26(4):407-21 (173 ref.)

Regulation of androgen action. Roy AK, et al. **Vitam Horm** 1999;55:309-52 (224 ref.)

PHYSIOLOGY

Androgen receptor transactivation domain and control of spermatogenesis. Yong EL, et al. **Rev Reprod** 1998 Sep; 3(3):141-4 (21 ref.)

RECEPTORS, ANF see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

RECEPTORS, ANGIOTENSIN

Angiotensin II receptors-antagonists, molecular biology, and signal transduction. Jagadeesh G. **Indian J Exp Biol** 1998 Dec;36(12):1171-94 (223 ref.)

Identification of a novel dual angiotensin II/vasopressin receptor. Ruiz-Opazo N. **Nephrologie** 1998;19(7):417-20 (24 ref.)

ANALYSIS

Localization of angiotensin AT1 and AT2 receptors. Allen AM, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S23-9 (80 ref.)

Concentrations and actions of intraluminal angiotensin II. Navar LG, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S189-95 (55 ref.)

[Kidney] Imanishi K, et al. **Nippon Rinsho** 1999 May; 57(5):1036-41 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Distribution and function of angiotensin receptor subtypes in cardiovascular system] Nakamura Y, et al. **Nippon Rinsho** 1999 May;57(5):1032-5 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Angiotensin receptor in the lung] Noda K. **Nippon Rinsho** 1999 May;57(5):1049-53 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Angiotensin II receptor subtype in human adrenal glands] Tanabe A, et al. **Nippon Rinsho** 1999 May;57(5):1042-8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Distribution and function of angiotensin II receptor subtypes--central nervous system] Tsuchihashi T, et al. **Nippon Rinsho** 1999 May;57(5):1028-31 (8 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Angiotensin II receptor antagonists in the treatment of hypertension. Kaplan NM. **Am Fam Physician** 1999 Sep 15;60(4):1185-90 (16 ref.)

Angiotensin-II receptor antagonists: their place in therapy. Kirk JK. **Am Fam Physician** 1999 Jun;59(11):3140-8 (42 ref.)

Effect of treatment on survival in an animal model of chronic heart failure. Bastien N, et al. **Am J Cardiol** 1998 Nov 19; 82(10A):50S-52S (11 ref.)

How do angiotensin II receptor antagonists affect blood pressure? de Leeuw PW. **Am J Cardiol** 1999 Jul 22; 84(2A):5K-6K (30 ref.)

Pharmacoeconomic issues in antihypertensive therapy. Giles TD. **Am J Cardiol** 1999 Jul 22;84(2A):25K-28K (10 ref.)

Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1-receptor blockade. Mehta JL. **Am J Cardiol** 1998 Nov 19; 82(10A):53S-56S (11 ref.)

Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Meredith PA. **Am J Cardiol** 1999 Jul 22;84(2A):7K-12K (16 ref.)

Safety and efficacy of angiotensin II receptor antagonists. Neutel JM. **Am J Cardiol** 1999 Jul 22;84(2A):13K-17K (13 ref.)

Overview of angiotensin II-receptor antagonists. Pitt B, et al. **Am J Cardiol** 1998 Nov 19;82(10A):47S-49S (12 ref.)

Guidelines for assessing outcomes of antihypertensive treatment. Weber M. **Am J Cardiol** 1999 Jul 22; 84(2A):2K-4K (4 ref.)

Impact of hypertension and antihypertensive treatment on organ damage. Zanchetti A. **Am J Cardiol** 1999 Jul 22; 84(2A):18K-24K (26 ref.)

ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Pylypchuk GB. **Ann Pharmacother** 1998 Oct;32(10):1060-6 (63 ref.)

Angiotensin receptor antagonists and ACE inhibitors. Howes LG, et al. **Aust Fam Physician** 1998 Oct;27(10):914-7, 919-21 (33 ref.)

Pharmacology of angiotensin receptors and AT1 receptor blockers. Chung O, et al. **Basic Res Cardiol** 1998;93 Suppl 2:15-23 (31 ref.)

Role of ACE inhibition or AT1 blockade in the remodeling following myocardial infarction. Holtz J. **Basic Res Cardiol** 1998;93 Suppl 2:92-100 (65 ref.)

AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **Basic Res Cardiol** 1998;93 Suppl 2:85-91 (58 ref.)

Therapeutic advantages of AT1 blockers in hypertension. Kendall MJ. **Basic Res Cardiol** 1998;93 Suppl 2:47-50 (20 ref.)

Clinical efficacy of a new AT1 blocker. Philipp T, et al. **Basic Res Cardiol** 1998;93 Suppl 2:51-3 (20 ref.)

Angiotensin II receptor blockade and renal protection. Sharma AM, et al. **Basic Res Cardiol** 1998;93 Suppl 2:120-4 (51 ref.)

Angiotensin II receptor blockers. Thai H, et al. **Coron Artery Dis** 1999 Sep;10(6):377-81 (36 ref.)

Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Perico N, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):571-8 (62 ref.)

A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Naka T, et al. **Curr Pharm Des** 1999 Jun;5(6):453-72 (38 ref.)

Comparative safety and tolerability of angiotensin II receptor antagonists. Mazzolai L, et al. **Drug Saf** 1999 Jul; 21(1):23-33 (84 ref.)

Telmisartan. McClellan KJ, et al. **Drugs** 1998 Dec;

56(6):1039–44; discussion 1045–6 (22 ref.)
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Willenheimer R, et al. **Eur Heart J** 1999 Jul;20(14):997–1008 (105 ref.)
Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Timmermans PB. **Hypertens Res** 1999 Jul;22(2):147–53 (26 ref.)
Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. Brunner-La Rocca HP, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1163–73 (135 ref.)
Comparative antihypertensive effects of angiotensin II receptor antagonists. Burnier M, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S278–82 (40 ref.)
AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S129–36 (66 ref.)
Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. Mackenzie HS, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S283–6 (43 ref.)
Angiotensin receptor blockers: pharmacology and clinical significance. Mimran A, et al. **J Am Soc Nephroi** 1999 Apr; 10 Suppl 12:S273–7 (48 ref.)
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. Morsing P. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S248–54 (69 ref.)
Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. Navar LG, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S266–72 (65 ref.)
Practical considerations of the pharmacology of angiotensin receptor blockers. McConnaughey MM, et al. **J Clin Pharmacol** 1999 Jun;39(6):547–59 (170 ref.)
Angiotensin II receptor pharmacology and AT1-receptor blockers. Chung O, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S11–20; discussion S33–4 (107 ref.)
Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action. Inada Y, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S75–80 (34 ref.)
Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan. Ogihara T, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S27–31; discussion S33–4 (42 ref.)
ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models. Taal MW, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S51–6; discussion S61 (41 ref.)
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. Birkenhäger WH, et al. **J Hypertens** 1999 Jul;17(7):873–81 (85 ref.)
Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. Brooks DP, et al. **J Hypertens Suppl** 1999 Jun;17(2):S27–32 (63 ref.)
Management of hypertension: the advent of a new angiotensin II receptor antagonist. Hedner T. **J Hypertens Suppl** 1999 Jun;17(2):S21–5 (28 ref.)
Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. Unger T, et al. **J Hypertens Suppl** 1998 Sep;16(7):S3–9 (55 ref.)
The renoprotective effect of antihypertensive drugs. Locatelli F, et al. **J Nephrol** 1998 Nov-Dec;11(6):330–6 (36 ref.)
Angiotensin II receptor antagonists in hypertension. Burnier M, et al. **Kidney Int Suppl** 1998 Dec;68:S107–11 (33 ref.)
Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies. Merlos M, et al. **Methods Find Exp Clin Pharmacol** 1998 Nov;20(9):805–15 (90 ref.)
The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin [editorial; comment] Macdougall IC. **Nephrol Dial Transplant** 1999 Aug; 14(8):1836–41 (28 ref.) Comment on: Nephrol Dial Transplant 1999 Aug;14(8):1912–6. Comment on: Nephrol Dial Transplant 1999 Aug;14(8):2047–9.
Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease? [editorial] McLaughlin K, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):25–8 (30 ref.)
The acute renal effects of angiotensin II receptor blockers [editorial] Veelken R, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1928–9 (13 ref.)
A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Blum RA, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):79S–85S (23 ref.)
The renal profile of eprosartan. Sica DA, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):86S–94S (42 ref.)
Clinical efficacy of eprosartan. Weber M. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):95S–101S (12 ref.)
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Sander GE, et al. **Prog Cardiovasc Dis** 1999 Jan-Feb;41(4):265–300 (241 ref.)
[Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?] Deray G. **Arch Mal Coeur Vaiss** 1999 Jul;92(7):903–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Pharma-clinics. The drug of the month. Candesartan (Atacand)] Kulbertus H. **Rev Med Liege** 1999 Jun; 54(6):557–60 (18 ref.) (Eng. Abstr.) **(Fre)**
[Angiotensin II AT1 receptor antagonists: clinical development and future perspectives] Burnier M, et al. **Therapie** 1998 May-Jun;53(3):279–84 (43 ref.) (Eng. Abstr.) **(Fre)**
[Hypertension therapy and molecular biology--with special reference to renin-angiotensin system] Matsubara H. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):920–7 (23 ref.) **(Jpn)**
[Potential role of angiotensin receptor antagonists in renal protection] Hayashi K, et al. **Nippon Rinsho** 1999 May; 57(5):1164–7 (6 ref.) (Eng. Abstr.) **(Jpn)**
[The effects of angiotensin II receptor antagonists on insulin resistance] Higashiura K, et al. **Nippon Rinsho** 1999 May; 57(5):1182–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Comparison with other antihypertensive drugs, especially with ACEI] Hiwada K. **Nippon Rinsho** 1999 May; 57(5):1187–93 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Pharmacological profiles of candesartan cilexetil (TCV-116)] Inada Y. **Nippon Rinsho** 1999 May; 57(5):1130–6 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Efficacy of angiotensin II receptor antagonists as a novel drug for the treatment of chronic heart failure--in comparison with ACE inhibitors] Kitakaze M, et al. **Nippon Rinsho** 1999 May;57(5):1148–57 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Angiotensin II receptor antagonists as the agents to treat cerebrovascular disease] Kitazono T, et al. **Nippon Rinsho** 1999 May;57(5):1168–75 (21 ref.) **(Jpn)**
[Pathophysiological function of angiotensin II AT1 and AT2 receptors and clinical application of AT1 antagonists] Matsubara H, et al. **Nippon Rinsho** 1998 Jul;56(7):1912–8 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Pharmacological properties and its significance in clinical practice] Nishikibe M, et al. **Nippon Rinsho** 1999 May; 57(5):1124–9 (16 ref.) (Eng. Abstr.) **(Jpn)**
[The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist, for essential hypertension] Rakugi H, et al. **Nippon Rinsho** 1999 May; 57(5):1141–7 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Angiotensin II receptor antagonists: a review of the development and future perspective] Saito I, et al. **Nippon Rinsho** 1999 May;57(5):1015–9 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Vascular remodeling and angiotensin II] Takemoto M, et al. **Nippon Rinsho** 1999 May;57(5):1158–63 (28 ref.) (Eng. Abstr.) **(Jpn)**
[The effects of angiotensin II receptor antagonists on glucose, lipid, and uric acid metabolism in essential hypertensives] Takizawa H, et al. **Nippon Rinsho** 1999 May;57(5):1137–40 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Drug-interactions and adverse effects of losartan potassium, an angiotensin II receptor antagonist] Yoshinaga K. **Nippon Rinsho** 1999 May;57(5):1194–7 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Therapy of arterial hypertension with angiotensin receptor blockers] Nobre FL. **Rev Port Cardiol** 1999 Apr; 18(4):407–12 (23 ref.) (Eng. Abstr.) **(Por)**
[Losartan--a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure] Berezin AE, et al. **Klin Med (Mosk)** 1998;76(7):12–5 (43 ref.) **(Rus)**

BIOSYNTHESIS

Mesangial AT1 receptors: expression, signaling, and regulation. Ardaillou R, et al. **J Am Soc Nephrol** 1999 Jan; 10 Suppl 11:S40–6 (63 ref.)
Angiotensin II and the control of cardiovascular structure. Pratt RE. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S120–8 (96 ref.)
Myocardial angiotensin II receptor expression and ischemia-reperfusion injury. Yang B, et al. **Vasc Med** 1998; 3(2):121–30 (69 ref.)

CHEMISTRY

Several interesting phenotypes of the AT1 receptor produced by site-directed mutagenesis. Conchon S, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S8–14 (43 ref.)
Molecular biology and signaling of angiotensin receptors: an overview. Inagami T. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S2–7 (69 ref.)

CLASSIFICATION

Angiotensin II receptors. Ardaillou R. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S30–9 (105 ref.)

DRUG EFFECTS

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Brooks DP, et al. **Am Heart J** 1999 Sep;138(3 Pt 2):246–51 (53 ref.)
Angiotensin and cerebral blood flow. Saavedra JM, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):553–73 (111 ref.)
Actions of angiotensin II on the renal microvasculature. Arendshorst WJ, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S149–61 (100 ref.)
Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. DiBona GF. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S90–4 (51 ref.)
[Losartan: angiotensin II type 1 receptor antagonist] Piątkowska H, et al. **Wiad Lek** 1999;52(1-2):49–55 (20 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Angiotensin receptors: molecular biology and signalling. Inagami T, et al. **Clin Exp Pharmacol Physiol** 1999 Jul; 26(7):544–9 (53 ref.)
Is the A1166C polymorphism of the angiotensin II type 1 receptor involved in cardiovascular disease? van Geel PP, et al. **Eur Heart J** 1998 Jul;19 Suppl G:G13–7 (31 ref.)
Several interesting phenotypes of the AT1 receptor produced by site-directed mutagenesis. Conchon S, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S8–14 (43 ref.)
[Molecular structure and function of angiotensin ii receptors] Clauser E. **Nephrologie** 1998;19(7):403–10 (53 ref.) (Eng. Abstr.) **(Fre)**
[Gene loci and polymorphisms of angiotensin II receptor] Katsuya T, et al. **Nippon Rinsho** 1999 May;57(5):1020–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Myocardial angiotensin receptors in human hearts. Regitz-Zagrosek V, et al. **Basic Res Cardiol** 1998;93 Suppl 2:37–42 (17 ref.)
Modulation and function of extrarenal angiotensin receptors. Wang DH, et al. **Cell Biochem Biophys** 1999;31(1):1–17 (121 ref.)
Haemorphin peptides may be endogenous ligands for brain angiotensin AT4 receptors. Moeller I, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S68–71 (45 ref.)
Molecular mechanisms of angiotensin II receptor internalization. Hunyady L. **J Am Soc Nephrol** 1999 Jan; 10 Suppl 11:S47–56 (95 ref.)
Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. Inagami T, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S57–61 (23 ref.)
Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. Zhuo J, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2027–37 (102 ref.)
Angiotensin II receptors in the kidney. Chung O, et al. **Kidney Blood Press Res** 1998;21(2-4):245–8 (29 ref.)
Angiotensin II type 1 receptor-modulated signaling pathways in neurons. Richards EM, et al. **Mol Neurobiol** 1999 Feb; 19(1):25–41 (117 ref.)
Angiotensin II--complexities beyond AT1 and AT2 receptors [editorial] Ardaillou R. **Nephrol Dial Transplant** 1998 Dec; 13(12):2988–90 (15 ref.)
Angiotensin II receptors in the human brain. Allen AM, et al. **Regul Pept** 1999 Jan 1;79(1):1–7 (75 ref.)
[Angiotensin II receptors: classification, structure, and signal transduction] Miserey S, et al. **Therapie** 1998 May-Jun; 53(3):205–11 (29 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Biology and functions of renal receptors for angiotensin II and its active fragments. Ardaillou R, et al. **Adv Nephrol Necker Hosp** 1998;28:225–57 (123 ref.)
Pharmacology of angiotensin receptors and AT1 receptor blockers. Chung O, et al. **Basic Res Cardiol** 1998;93 Suppl 2:15–23 (31 ref.)
Interaction between insulin and AT1 receptor. Relevance for hypertension and arteriosclerosis. Nickenig G, et al. **Basic Res Cardiol** 1998;93 Suppl 2:135–9 (26 ref.)
Angiotensin receptors in the nervous system. Allen AM, et al. **Brain Res Bull** 1998 Sep 1;47(1):17–28 (152 ref.)
Modulation and function of extrarenal angiotensin receptors. Wang DH, et al. **Cell Biochem Biophys** 1999;31(1):1–17 (121 ref.)
Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Matsubara H. **Circ Res** 1998 Dec 14-28;83(12):1182–91 (151 ref.)
Angiotensin receptors: molecular biology and signalling. Inagami T, et al. **Clin Exp Pharmacol Physiol** 1999 Jul; 26(7):544–9 (53 ref.)
Stress and brain angiotensin II receptors. Watanabe T, et al. **Crit Rev Neurobiol** 1998;12(4):305–17 (109 ref.)
Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Xoriuchi M, et al. **Hypertens Res** 1999 Jul;22(2):67–74 (70 ref.)
Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Horiuchi M, et al. **Hypertension** 1999 Feb;33(2):613–21 (91 ref.)
Molecular biology and signaling of angiotensin receptors: an overview. Inagami T. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S2–7 (69 ref.)
Regulation of renin secretion by angiotensin II-AT1 receptors. Kurtz A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S162–8 (77 ref.)
Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. Navar LG, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S266–72 (65 ref.)
The renin-angiotensin system and its receptors. Stroth U, et al. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S21–8; discussion S41–3 (115 ref.)
Angiotensin II receptor pharmacology and AT1-receptor blockers. Chung O, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S11–20; discussion S33–4 (107 ref.)
Genetic deletion and overexpression of angiotensin II receptors. Hein L. **J Mol Med** 1998 Oct;76(11):756–63 (82 ref.)
Physiological and pharmacological implications of AT1 versus AT2 receptors. Chung O, et al.

RECEPTORS, ANGIOTENSIN

Kidney Int Suppl 1998 Sep;67:S95–9 (59 ref.)
Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Zhuo J, et al. **Kidney Int Suppl** 1998 Sep;67:S22–8 (29 ref.)
Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis. Zitnay C, et al.
Miner Electrolyte Metab 1998;24(6):362–70 (93 ref.)
The AT2 receptor: fact, fancy and fantasy. de Gasparo M, et al. **Regul Pept** 1999 May 31;81(1–3):11–24 (154 ref.)
Regulation of angiotensin II type 1 (AT1) receptor function. Thomas WG. **Regul Pept** 1999 Jan 1;79(1):9–23 (121 ref.)
[Molecular structure and function of angiotensin ii receptors] Clauser E. **Nephrologie** 1998;19(7):403–10 (53 ref.) (Eng. Abstr.) **(Fre)**
[Functions of AT2 receptors of angiotensin II] Heymes C, et al. **Therapie** 1998 May-Jun;53(3):213–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[Modulations by stimulation of angiotensin II type 1 receptor of gastrointestinal functions] Katsuragi T, et al.
Nippon Rinsho 1999 May;57(5):1054–9 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Structure and function of angiotensin II receptor] Kim S, et al. **Nippon Rinsho** 1999 May;57(5):1065–9 (17 ref.) **(Jpn)**
[Angiotensin II receptor-mediated function unmasked by gene-engineered animals] Matsubara H, et al.
Nippon Rinsho 1999 May;57(5):1084–9 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Pathophysiological function of angiotensin II AT1 and AT2 receptors and clinical application of AT1 antagonists] Matsubara H, et al. **Nippon Rinsho** 1998 Jul;56(7):1912–8 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Intracellular signaling pathways of angiotensin II receptor type 1 involved in the development of cardiovascular diseases] Miyazaki H, et al. **Nippon Rinsho** 1998 Jul; 56(7):1906–11 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction systems of angiotensin II receptors] Takeuchi K. **Nippon Rinsho** 1999 May;57(5):1070–7 (30 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, ANTIGEN

GENETICS

Towards understanding the evolutionary origins and early diversification of rearranging antigen receptors. Rast JP, et al. **Immunol Rev** 1998 Dec;166:79–86 (54 ref.)

IMMUNOLOGY

FcR-mediated inhibition of cell activation and other forms of coinhibition. Anderson CC, et al. **Crit Rev Immunol** 1998; 18(6):525–44 (131 ref.)

METABOLISM

Antigen receptor signaling: integration of protein tyrosine kinase functions. Tamir I, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1353–64 (203 ref.)

PHYSIOLOGY

Regulation of antigen receptor function by protein tyrosine kinases. Bubeck-Wardenburg J, et al.
Prog Biophys Mol Biol 1999;71(3–4):373–92 (126 ref.)

RECEPTORS, ANTIGEN, B-CELL

ANTAGONISTS & INHIBITORS

Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Colombo A, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):153–7 (37 ref.)
IIb/IIIa receptor blockade in acute myocardial infarction. Ferguson JJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):164–70 (24 ref.)
Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. Ferrario M, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):121–5 (45 ref.)

CHEMISTRY

Role of transmembrane domains in the functions of B- and T-cell receptors. Zidovetzki R, et al. **Immunol Lett** 1998 Dec;64(2–3):97–107 (110 ref.)

GENETICS

Genetic analysis of B cell antigen receptor signaling. Kurosaki T. **Annu Rev Immunol** 1999;17:555–92 (182 ref.)
Receptor editing: genetic reprogramming of autoreactive lymphocytes. Retter MW, et al. **Cell Biochem Biophys** 1999; 31(1):81–8 (66 ref.)
V(D)J hypermutation and receptor revision: coloring outside the lines. Kelsoe G. **Curr Opin Immunol** 1999 Feb; 11(1):70–5 (53 ref.)
Alternative splicing of CD79a (Ig alpha) and CD79b (Ig beta) transcripts in human B-CLL cells. Alfarano A, et al.
Curr Top Microbiol Immunol 1999;246:241–6; discussion 247–8 (28 ref.)

IMMUNOLOGY

Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway. Cornall RJ, et al.
Curr Top Microbiol Immunol 1999;244:57–68 (67 ref.)
B cell antigen receptor signalling in the balance of tolerance and immunity. Cornall RJ, et al. **Novartis Found Symp** 1998; 215:21–30; discussion 30–40 (38 ref.)

METABOLISM

Lymphocyte antigen receptor signal integration and regulation by the SHC adaptor. Baldari CT, et al.
Biol Chem 1999 Feb;380(2):129–34 (42 ref.)
Lymphocyte signaling: adapting new adaptors. Rudd CE. **Curr Biol** 1998 Nov 5;8(22):R805–8 (18 ref.)
Signal transduction from the B cell antigen-receptor. Campbell KS. **Curr Opin Immunol** 1999 Jun;11(3):256–64 (74 ref.)
Co-receptors on B lymphocytes. Tsubata T.
Curr Opin Immunol 1999 Jun;11(3):249–55 (58 ref.)
Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma. Hsueh RC, et al. **Curr Top Microbiol Immunol** 1999; 246:299–304; discussion 305 (14 ref.)
The formation and selection of cells expressing preB cell receptors and B cell receptors. ten Boekel E, et al.
Curr Top Microbiol Immunol 1999;246:3–9; discussion 9–10 (38 ref.)

PHYSIOLOGY

B cell development: signal transduction by antigen receptors and their surrogates. Benschop RJ, et al.
Curr Opin Immunol 1999 Apr;11(2):143–51 (87 ref.)
Role of transmembrane domains in the functions of B- and T-cell receptors. Zidovetzki R, et al. **Immunol Lett** 1998 Dec;64(2–3):97–107 (110 ref.)
Molecular dissection of B cell antigen receptor signaling (review). Kurosaki T. **Int J Mol Med** 1998 Mar;1(3):515–27 (115 ref.)
[Regulation of B cell receptor signaling through tyrosine kinases and phosphatases] Takata M, et al.
Tanpakushitsu Kakusan Koso 1999 Apr;44(5):655–67 (43 ref.) **(Jpn)**

RECEPTORS, ANTIGEN, T-CELL

see related
ANTIGENS, CD3
GENE REARRANGEMENT, T-LYMPHOCYTE
GENES, T-CELL RECEPTOR

Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP). Hedlund-Treutiger I, et al.
Acta Paediatr Suppl 1998 Jun;424:46–50 (35 ref.)
Adapter molecules in T cell receptor signaling. Boerth NJ, et al. **Inflamm Bowel Dis** 1999 May;5(2):107–18 (116 ref.)
Chicken CD4, CD8alphabeta, and CD8alphaalpha T cell co-receptor molecules. Luhtala M. **Poult Sci** 1998 Dec; 77(12):1858–73 (122 ref.)
T cell receptors in health and disease. Introduction. Grunewald J, et al. **Springer Semin Immunopathol** 1999; 21(1):1–4 (6 ref.)
[Structural biology of the immune response on cell surface] Kato K, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):325–37 (41 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

T cell receptor antagonism in vivo, at last [comment] Jameson SC. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14001–2 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14332–6.

CHEMISTRY

Structural basis of T cell recognition. Garcia KC, et al.
Annu Rev Immunol 1999;17:369–97 (143 ref.)
Role of transmembrane domains in the functions of B- and T-cell receptors. Zidovetzki R, et al. **Immunol Lett** 1998 Dec;64(2–3):97–107 (110 ref.)

GENETICS

Evolution of immunoglobulin and T-cell receptor gene assembly. Lewis SM. **Ann N Y Acad Sci** 1999 May 18; 870:58–67 (35 ref.)
Evolution of antigen binding receptors. Litman GW, et al.
Annu Rev Immunol 1999;17:109–47 (171 ref.)
Checkpoints for regulation of development and interferon gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):41–2 (10 ref.)
Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases. Hombach A, et al. **Hybridoma** 1999 Feb;18(1):57–61 (10 ref.)
T-cell receptors in ectothermic vertebrates. Charlemagne J, et al. **Immunol Rev** 1998 Dec;166:87–102 (35 ref.)
Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein. Goverman J. **Immunol Rev** 1999 Jun;169:147–59 (111 ref.)
Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems. Ji H, et al. **Immunol Rev** 1999 Jun;169:139–46 (55 ref.)
T cell receptor gene in synovial tissues of rheumatoid arthritis. Cantagrel A, et al. **Int Rev Immunol** 1998; 17(5–6):323–37 (64 ref.)
[Disturbance of signalling pathways for apoptosis in thymic lymphomas from TCR transgenic mice] Strządała L.
Postepy Hig Med Dosw 1999;53(2):345–50 (15 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

T-cell activation and the dynamic world of rafts. Viola A, et al. **APMIS** 1999 Jul;107(7):615–23 (70 ref.)
Formation of peripheral immunoreceptor repertoire for antigens: potential relationship to the pathogenesis of rheumatoid arthritis. Kohsaka H, et al. **Arthritis Rheum** 1998 Nov;41(11):1911–8 (50 ref.)
Targeting the T cell receptor in rheumatoid arthritis [editorial; comment] Kotzin BL, et al. **Arthritis Rheum** 1998 Nov;41(11):1906–10 (30 ref.) Comment on: Arthritis Rheum 1998 Nov;41(11):1919–29.
From TCR engagement to T cell activation: a kinetic view of T cell behavior. Lanzavecchia A, et al. **Cell** 1999 Jan 8;96(1):1–4 (29 ref.)
Positive and negative thymocyte selection. Saito T, et al.
Crit Rev Immunol 1998;18(4):359–70 (89 ref.)
Costimulatory regulation of T cell function. Chambers CA, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):203–10 (81 ref.)
T cell receptor specificity and mimotopes. Sparbier K, et al. **Curr Opin Immunol** 1999 Apr;11(2):214–8 (29 ref.)
Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. Bitton N, et al. **Front Biosci** 1999 Apr 1;4:D386–93 (95 ref.)
T cell response in xenorecognition and xenografts: a review. Brouard S, et al. **Hum Immunol** 1999 Jun;60(6):455–68 (98 ref.)
TCR specificity in infection induced granulomas. Hogan LH, et al. **Immunol Lett** 1999 May 3;68(1):115–20 (36 ref.)
Thymocyte selection: not by TCR alone. Amsen D, et al.
Immunol Rev 1998 Oct;165:209–29 (202 ref.)
Recognition surfaces of MHC class I. Jones EY, et al.
Immunol Rev 1998 Jun;163:121–8 (45 ref.)
A kinetic differentiation model for the action of altered TCR ligands. Lord GM, et al. **Immunol Today** 1999 Jan; 20(1):33–9 (48 ref.)
Molecular basis of drug recognition by specific T-cell receptors. von Greyerz S, et al.
Int Arch Allergy Immunol 1999 Jul;119(3):173–80 (49 ref.)
T cell receptor repertoire in rheumatoid arthritis. Goronzy JJ, et al. **Int Rev Immunol** 1998;17(5–6):339–63 (77 ref.)
Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification. Nishimura Y, et al. **Intern Med** 1998 Oct;37(10):804–17 (96 ref.)
Hypothesis: A recurrent, moderate activation fosters systemic autoimmunity--the apoptotic roles of TCR, IL-2 and Fas ligand. Matsui K, et al. **J Biomed Sci** 1999 Sep-Oct; 6(5):306–13 (57 ref.)
Differential signalling by variant ligands of the T cell receptor and the kinetic model of T cell activation. Madrenas J. **Life Sci** 1999;64(9):717–31 (118 ref.)
Signals that regulate the host response to Mycobacterium tuberculosis. Beyers AD, et al. **Novartis Found Symp** 1998; 217:145–57; discussion 157–9 (40 ref.)
TCR peptide-reactive T cells and peripheral tolerance to myelin basic protein. Kumar V. **Res Immunol** 1998 Nov-Dec;149(9):827–34; discussion 852–4, 855–60 (66 ref.)
The standard model of T-cell receptor function: a critical reassessment. Langman RE, et al. **Scand J Immunol** 1999 Jun;49(6):570–7 (24 ref.)
Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Haks MC, et al.
Semin Immunol 1999 Feb;11(1):23–37 (143 ref.)
Control of early thymocyte development by the pre-T cell receptor complex: A receptor without a ligand? Wiest DL, et al. **Semin Immunol** 1999 Aug;11(4):251–62 (111 ref.)
Involvement of T cells and alterations in T cell receptors in sarcoidosis. Moller DR. **Semin Respir Infect** 1998 Sep; 13(3):174–83 (80 ref.)
Positive and negative signaling pathways. Pratt JC, et al.
Transplant Proc 1999 Feb-Mar;31(1–2):772–4 (23 ref.)

METABOLISM

Integration of T cell receptor-dependent signaling pathways by adapter proteins. Clements JL, et al.
Annu Rev Immunol 1999;17:89–108 (105 ref.)
The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Germain RN, et al. **Annu Rev Immunol** 1999;17:467–522 (271 ref.)
Lymphocyte antigen receptor signal integration and regulation by the SHC adaptor. Baldari CT, et al.
Biol Chem 1999 Feb;380(2):129–34 (42 ref.)
Lymphocyte signaling: adapting new adaptors. Rudd CE. **Curr Biol** 1998 Nov 5;8(22):R805–8 (18 ref.)
The regulation of antigen-receptor signaling by protein tyrosine phosphatases: a hole in the story. Thomas ML.
Curr Opin Immunol 1999 Jun;11(3):270–6 (59 ref.)
Binding energetics of T-cell receptors: correlation with immunological consequences. Manning TC, et al.
Immunol Today 1999 Sep;20(9):417–22 (49 ref.)
Recent developments in lymphocyte activation: linking kinases to downstream signaling events. Clements JL, et al. **J Clin Invest** 1999 Apr;103(7):925–9 (43 ref.)
T cell receptor usage in malignant diseases. Halapi E, et al.

Springer Semin Immunopathol 1999;21(1):19-35 (131 ref.)

PHYSIOLOGY

Cells' perception of position in a concentration gradient. Gurdon JB, et al. **Cell** 1998 Oct 16;95(2):159-62 (21 ref.)
T-cell receptor usage in the intestine. Probert CS, et al. **Chem Immunol** 1998;71:27-39 (43 ref.)
Gamma delta T cells: bodyguards and/or sleepers in the gut. Takahashi I, et al. **Chem Immunol** 1998;71:77-87 (59 ref.)
Signal transduction in T lymphocytes. Peterson EJ, et al. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):107-14 (111 ref.)
T cell antigen-receptor signal transduction. van Leeuwen JE, et al. **Curr Opin Immunol** 1999 Jun;11(3):242-8 (81 ref.)
T cell signaling: effect of age. Pahlavani MA. **Front Biosci** 1998 Nov 1;3:D1120-33 (144 ref.)
c-Cbl: a regulator of T cell receptor-mediated signalling. Thien CB, et al. **Immunol Cell Biol** 1998 Oct;76(5):473-82 (90 ref.)
Role of transmembrane domains in the functions of B- and T-cell receptors. Zidovetzki R, et al. **Immunol Lett** 1998 Dec;64(2-3):97-107 (110 ref.)
Adaptor proteins and T-cell antigen receptor signaling. Samelson LE. **Prog Biophys Mol Biol** 1999;71(3-4):393-403 (53 ref.)
Regulation of naive T cell differentiation by varying the potency of TCR signal transduction. Leitenberg D, et al. **Semin Immunol** 1999 Aug;11(4):283-92 (51 ref.)
T cell receptor-mediated signs and signals governing T cell development. van Oers NS. **Semin Immunol** 1999 Aug;11(4):227-37 (82 ref.)
T cell receptor usage in infectious disease. Callan MF, et al. **Springer Semin Immunopathol** 1999;21(1):37-54 (78 ref.)
T cell receptor usage in autoimmune disease. Moss P, et al. **Springer Semin Immunopathol** 1999;21(1):5-17 (108 ref.)
[T cell receptor and its related molecules in signal transduction] Kobata T, et al. **Nippon Rinsho** 1999 Feb;57(2):273-7 (25 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

HLA-derived peptides as novel immunomodulatory therapeutics. Murphy B, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1346-55 (78 ref.)

RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA

see related
GENES, T-CELL RECEPTOR BETA

Alpha beta/gamma delta lineage commitment in the thymus of normal and genetically manipulated mice. Fehling HJ, et al. **Adv Immunol** 1999;71:1-76 (236 ref.)
The role of the T-cell receptor (TCR) in alpha beta/gamma delta lineage commitment: clues from intracellular TCR staining. MacDonald HR, et al. **Immunol Rev** 1998 Oct;165:87-94 (42 ref.)
Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. von Boehmer H, et al. **Immunol Rev** 1998 Oct;165:111-9 (56 ref.)

CHEMISTRY

Structure-function studies of T-cell receptor-superantigen interactions. Li H, et al. **Immunol Rev** 1998 Jun;163:177-86 (52 ref.)
Glimpses at the recognition of peptide/MHC complexes by T-cell antigen receptors. Mazza G, et al. **Immunol Rev** 1998 Jun;163:187-96 (34 ref.)

GENETICS

Developmental regulation of V(D)J recombination at the TCR alpha/delta locus. Krangel MS, et al. **Immunol Rev** 1998 Oct;165:131-47 (181 ref.)
Accessibility control of variable region gene assembly during T-cell development. Sleckman BP, et al. **Immunol Rev** 1998 Oct;165:121-30 (59 ref.)
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3-15 (84 ref.)

IMMUNOLOGY

Structure-function studies of T-cell receptor-superantigen interactions. Li H, et al. **Immunol Rev** 1998 Jun;163:177-86 (52 ref.)
Using thymus anatomy to dissect T cell repertoire selection. Laufer TM, et al. **Semin Immunol** 1999 Feb;11(1):65-70 (49 ref.)

PHYSIOLOGY

Pleiotropic changes controlled by the pre-T-cell receptor. von Boehmer H, et al. **Curr Opin Immunol** 1999 Apr;11(2):135-42 (68 ref.)
Signals involved in gamma/delta T cell versus alpha/beta T cell lineage commitment. Hayday AC, et al. **Semin Immunol** 1999 Aug;11(4):239-49 (79 ref.)

RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA

Immunoregulatory functions of gamma delta T cells. Born W, et al. **Adv Immunol** 1999;71:77-144 (357 ref.)
Alpha beta/gamma delta lineage commitment in the thymus of normal and genetically manipulated mice. Fehling HJ, et al. **Adv Immunol** 1999;71:1-76 (236 ref.)
The role of the T-cell receptor (TCR) in alpha beta/gamma delta lineage commitment: clues from intracellular TCR staining. MacDonald HR, et al. **Immunol Rev** 1998 Oct;165:87-94 (42 ref.)
Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. von Boehmer H, et al. **Immunol Rev** 1998 Oct;165:111-9 (56 ref.)
[Peripheral gamma delta T-cell lymphoma] Kato R, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):319-22 (15 ref.) **(Jpn)**

BIOSYNTHESIS

Post transplant CD8+ gammadelta T-cell lymphoma associated with human herpes virus-6 infection. Lin WC, et al. **Leuk Lymphoma** 1999 Apr;33(3-4):377-84 (40 ref.)

GENETICS

Advances in molecular hematopathology: T-cell receptor gamma and bcl-2 genes [see comments] Greiner TC. **Am J Pathol** 1999 Jan;154(1):7-9 (28 ref.) Comment in: Am J Pathol 1999 Jan;154(1):67-75. Comment in: Am J Pathol 1999 Jan;154(1):97-103.
Developmental regulation of V(D)J recombination at the TCR alpha/delta locus. Krangel MS, et al. **Immunol Rev** 1998 Oct;165:131-47 (181 ref.)
Accessibility control of variable region gene assembly during T-cell development. Sleckman BP, et al. **Immunol Rev** 1998 Oct;165:121-30 (59 ref.)

IMMUNOLOGY

Innate functions of epithelial gamma delta T cells. Havran WL, et al. **Adv Exp Med Biol** 1998;452:29-35 (42 ref.)
Role of gamma delta T lymphocytes in immune response in humans and mice. Salerno A, et al. **Crit Rev Immunol** 1998;18(4):327-57 (194 ref.)
Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review). Poccia F, et al. **Int J Mol Med** 1998 Feb;1(2):409-13 (62 ref.)
[Regulation of the contact sensitivity reaction by suppression of T gamma delta lymphocytes] Szczepanik M. **Folia Med Cracov** 1998;39(1-2):5-33 (68 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Chang KL, et al. **Adv Anat Pathol** 1998 Jan;5(1):21-9 (22 ref.)
The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1999 Jul;42(1):44-8 (47 ref.)

PHYSIOLOGY

Pleiotropic changes controlled by the pre-T-cell receptor. von Boehmer H, et al. **Curr Opin Immunol** 1999 Apr;11(2):135-42 (68 ref.)
Signals involved in gamma/delta T cell versus alpha/beta T cell lineage commitment. Hayday AC, et al. **Semin Immunol** 1999 Aug;11(4):239-49 (79 ref.)
gamma delta T cells, their T cell receptor usage and role in human diseases. Kabelitz D, et al. **Springer Semin Immunopathol** 1999;21(1):55-75 (196 ref.)

RECEPTORS, ARYL HYDROCARBON

AGONISTS

Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Safe S, et al. **Toxicol Lett** 1998 Dec 28;102-103:343-7 (13 ref.)

DRUG EFFECTS

The Ah receptor: a regulator of the biochemical and toxicological actions of structurally diverse chemicals. Denison MS, et al. **Bull Environ Contam Toxicol** 1998 Nov;61(5):557-68 (45 ref.)
Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses [see comments] Wilson CL, et al. **Toxicol Pathol** 1998 Sep-Oct;26(5):657-71 (200 ref.) Comment in: Toxicol Pathol 1998 Sep-Oct;26(5):672-3.

GENETICS

Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Linder MW, et al. **Drug Metab Rev** 1999 Feb;31(1):247-71 (41 ref.)

METABOLISM

The aryl hydrocarbon receptor: a comparative perspective. Hahn ME. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):23-53 (385 ref.)
The aryl hydrocarbon receptor: studies using the AHR-null mice. Gonzalez FJ, et al. **Drug Metab Dispos** 1998 Dec;26(12):1194-8 (41 ref.)

PHYSIOLOGY

The Ah receptor: a regulator of the biochemical and toxicological actions of structurally diverse chemicals. Denison MS, et al. **Bull Environ Contam Toxicol** 1998 Nov;61(5):557-68 (45 ref.)
Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses [see comments] Wilson CL, et al. **Toxicol Pathol** 1998 Sep-Oct;26(5):657-71 (200 ref.) Comment in: Toxicol Pathol 1998 Sep-Oct;26(5):672-3.

RECEPTORS, ATP see **RECEPTORS, PURINERGIC P2**

RECEPTORS, ATRIAL NATRIURETIC FACTOR

The guanylyl cyclase family of natriuretic peptide receptors. Schulz S, et al. **Vitam Horm** 1999;57:123-51 (99 ref.)

GENETICS

B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Magga J, et al. **Ann Med** 1998 Aug;30 Suppl 1:39-45 (73 ref.)

METABOLISM

B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Magga J, et al. **Ann Med** 1998 Aug;30 Suppl 1:39-45 (73 ref.)

PHYSIOLOGY

Focus on: "G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor" [editorial; comment] Galligan JJ. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1407-8 (14 ref.) Comment on: Am J Physiol 1998 Dec;275(6 Pt 1):C1409-16.
The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. Dessi-Fulgheri P, et al. **J Nephrol** 1998 Nov-Dec;11(6):296-9 (11 ref.)
[Natriuretic peptide receptors and heart failure] Andreassi MG, et al. **Cardiologia** 1999 Mar;44(3):241-8 (75 ref.) **(Ita)**
[Pathophysiological significance of the natriuretic peptide system: receptor subtype as another key factor] Naruse M, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):147-54 (18 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, ATRIOPEPTIN see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

RECEPTORS, BENZODIAZEPINE see **RECEPTORS, GABA-A**

RECEPTORS, BENZODIAZEPINE-GABA see **RECEPTORS, GABA-A**

RECEPTORS, BETA-ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA**

RECEPTORS, BETA-2 ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA-2**

RECEPTORS, BIOGENIC AMINE

PHYSIOLOGY

Regulation of neurotransmitter interactions in the ventral striatum. McGinty JF. **Ann N Y Acad Sci** 1999 Jun 29;877:129-39 (54 ref.)

RECEPTORS, BOMBESIN

PHYSIOLOGY

The influence of the cellular context on receptor function: a necessary consideration for physiologic interpretations of receptor expression studies. Logsdon CD. **Life Sci** 1999;64(6-7):369-74 (38 ref.)

RECEPTORS, BRADYKININ

Kinin receptors. Marceau F, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):385-401 (94 ref.)

AGONISTS

Nonpeptide antagonists for kinin receptors. Altamura M, et al. **Regul Pept** 1999 Mar 17;80(1-2):13-26 (94 ref.)

ANTAGONISTS & INHIBITORS

Nonpeptide antagonists for kinin receptors. Altamura M, et al. **Regul Pept** 1999 Mar 17;80(1-2):13-26 (94 ref.)

RECEPTORS, BRADYKININ

CLASSIFICATION

The B1 receptors for kinins. Marceau F, et al. **Pharmacol Rev** 1998 Sep;50(3):357–86 (241 ref.)

METABOLISM

NMR and CD conformational studies of bradykinin and its agonists and antagonists: application to receptor binding. Kotovych G, et al. **Biochem Cell Biol** 1998;76(2–3):257–66 (88 ref.)

Bradykinin and its receptors in non–mammalian vertebrates. Conlon JM. **Regul Pept** 1999 Feb 5;79(2–3):71–81 (85 ref.)

PHYSIOLOGY

Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Zhuo J, et al. **Kidney Int Suppl** 1998 Sep;67:S22–8 (29 ref.)

RECEPTORS, C3B see **RECEPTORS, COMPLEMENT 3B**

RECEPTORS, C3D see **RECEPTORS, COMPLEMENT 3D**

RECEPTORS, CAERULEIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, CALCITONIN

METABOLISM

RAMPs: accessory proteins for seven transmembrane domain receptors. Foord SM, et al. **Trends Pharmacol Sci** 1999 May;20(5):184–7 (32 ref.)

RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE

METABOLISM

RAMPs: accessory proteins for seven transmembrane domain receptors. Foord SM, et al. **Trends Pharmacol Sci** 1999 May;20(5):184–7 (32 ref.)

RECEPTORS, CALCITRIOL

The vitamin D receptor and the syndrome of hereditary 1,25–dihydroxyvitamin D–resistant rickets. Malloy PJ, et al. **Endocr Rev** 1999 Apr;20(2):156–88 (273 ref.)

GENETICS

Vitamin D resistance. Malloy PJ, et al. **Am J Med** 1999 Mar; 106(3):355–70 (107 ref.)

Molecular mechanism of vitamin D receptor action. Issa LL, et al. **Inflamm Res** 1998 Dec;47(12):451–75 (288 ref.)

Vitamin D receptor polymorphisms as a determinant of bone mass and PTH secretion: from facts to controversies [editorial] Bover J, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1066–8 (14 ref.)

How about vitamin D receptor polymorphisms? Pols HA, et al. **Osteoporos Int** 1998;8 Suppl 2:S20–3 (28 ref.)

[Characterization of ligand–dependent transactivation regions of the human vitamin D receptor] Nakajima S. **Nippon Rinsho** 1998 Jul;56(7):1717–21 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Vitamin D receptor and its abnormality in human diseases] Ozono K. **Nippon Rinsho** 1998 Jul;56(7):1892–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Molecular mechanism of vitamin D receptor action. Issa LL, et al. **Inflamm Res** 1998 Dec;47(12):451–75 (288 ref.)

Receptors for 1alpha,25(OH)2D3: past, present, and future [editorial; comment] Norman AW. **J Bone Miner Res** 1998 Sep;13(9):1360–9 (110 ref.) Comment on: J Bone Miner Res 1998 Sep;13(9):1353–9.

Transcriptional targets of the vitamin D3 receptor–mediating cell cycle arrest and differentiation. Freedman LP. **J Nutr** 1999 Feb;129(2S Suppl):581S–586S (34 ref.)

In vivo function of VDR in gene expression–VDR knock–out mice. Kato S, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):247–51 (23 ref.)

Vitamin D receptors: not just in the nucleus anymore. Fleet JC. **Nutr Rev** 1999 Feb;57(2):60–2 (13 ref.)

[Function and therapeutic potential of the dopamine D3 receptor] Sokoloff P, et al. **C R Seances Soc Biol Fil** 1998; 192(6):1111–25 (35 ref.) (Eng. Abstr.) **(Fre)**

[Molecular mechanisms of fat–soluble vitamins: vitamin receptor knockout mice] Kato S. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1321–35 (74 ref.) **(Jpn)**

RECEPTORS, CALCIUM CHANNEL BLOCKER see **CALCIUM CHANNELS**

RECEPTORS, CCK see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, CCR5

METABOLISM

Chemokine–induced phosphorylation of CC chemokine receptor 5 (CCR5). Olbrich H, et al. **J Leukoc Biol** 1999 Mar;65(3):281–5 (36 ref.)

PHYSIOLOGY

Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Cammack N. **Antivir Chem Chemother** 1999 Mar;10(2):53–62 (94 ref.)

Interference with the signaling capacity of CC chemokine receptor 5 can compromise its role as an HIV–1 entry coreceptor in primary T lymphocytes [comment] Wang JM, et al. **J Exp Med** 1999 Sep 6;190(5):591–5 (40 ref.) Comment on: J Exp Med 1999 Sep 6;190(5):597–605.

RECEPTORS, CD4 see **ANTIGENS, CD4**

RECEPTORS, CELL–ADHESION PROTEIN see **INTEGRINS**

RECEPTORS, CELL SURFACE

Visual pigment: G–protein–coupled receptor for light signals. Shichida Y, et al. **Cell Mol Life Sci** 1998 Dec; 54(12):1299–315 (153 ref.)

Dystroglycan in development and disease. Durbeej M, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):594–601 (71 ref.)

Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. Funaro A, et al. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):54–61 (121 ref.)

Identification of receptor ligands with phage display peptide libraries. Koivunen E, et al. **J Nucl Med** 1999 May; 40(5):883–8 (66 ref.)

The toll of innate immunity on microbial pathogens. Modlin RL, et al. **N Engl J Med** 1999 Jun 10;340(23):1834–5 (5 ref.)

[Recent progress in clinical aspects of receptor research] Imura H. **Nippon Rinsho** 1998 Jul;56(7):1658–66 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress in the molecular biology of receptors and intra–cellular signal transduction] Kaziro Y. **Nippon Rinsho** 1998 Jul;56(7):1651–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

Qualitative and quantitative assessment of relative agonist efficacy. Christopoulos A, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):735–48 (77 ref.)

Binding, gating, affinity and efficacy: the interpretation of structure–activity relationships for agonists and of the effects of mutating receptors. Colquhoun D. **Br J Pharmacol** 1998 Nov;125(5):924–47 (111 ref.)

Melatonin. Mor M, et al. **Curr Med Chem** 1999 Jun; 6(6):501–18 (142 ref.)

The quest for novel bioactive peptides utilizing orphan seven–transmembrane–domain receptors. Hinuma S, et al. **J Mol Med** 1999 Jun;77(6):495–504 (64 ref.)

Partial agonism: mechanisms based on ligand–receptor interactions and on stimulus–response coupling. Pliška V. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):597–629 (33 ref.)

Comprehensive survey of chemical libraries yielding enzyme inhibitors, receptor agonists and antagonists, and other biologically active agents: 1992 through 1997. Dolle RE. **Mol Divers** 1998;3(4):199–233 (81 ref.)

Partial agonists and G protein–coupled receptor desensitization. Clark RB, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):279–86 (63 ref.)

ANALYSIS

Clinical relevance of the urokinase plasminogen activator system in breast cancer. Look MP, et al. **APMIS** 1999 Jan; 107(1):150–9 (50 ref.)

Biosensing with G–protein coupled receptor systems. Lundström I, et al. **Biosens Bioelectron** 1998 Sep 15; 13(6):689–95 (37 ref.)

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Stephens RW, et al. **Breast Cancer Res Treat** 1998;52(1–3):99–111 (45 ref.)

Analysis of binding data. Hulme EC. **Methods Mol Biol** 1999; 106:139–85 (30 ref.)

Definition of receptors in radioligand–binding experiments. Keen M. **Methods Mol Biol** 1999;106:187–96 (19 ref.)

[Evidence of a renin receptor on human mesangial cells: effects on PA11 and cGMP] Nguyen G, et al. **Nephrologie** 1998;19(7):411–6 (8 ref.) (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Colombo A, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):153–7 (37 ref.)

IIb/IIIa receptor blockade in acute myocardial infarction. Ferguson JJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):164–70 (24 ref.)

Low–dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. Ferrario M, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):121–5 (45 ref.)

Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Chong PH. **Am J Health Syst Pharm** 1998 Nov 15;55(22):2363–86 (117 ref.)

[Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention] Kakuta T, et al. **Nippon Rinsho** 1998 Oct;56(10):2630–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Production of G–protein–coupled receptors in yeast. Reiländer H, et al. **Curr Opin Biotechnol** 1998 Oct; 9(5):510–7 (46 ref.)

Extracellular matrix receptors and the differentiation of human megakaryocytes in vitro. Molla A, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):15–23 (46 ref.)

BLOOD

The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. Brünner N, et al. **APMIS** 1999 Jan;107(1):160–7 (62 ref.)

CHEMISTRY

G–protein coupled receptors: conformations and states. Strange PG. **Biochem Pharmacol** 1999 Oct 1;58(7):1081–8 (49 ref.)

Melatonin. Mor M, et al. **Curr Med Chem** 1999 Jun; 6(6):501–18 (142 ref.)

NMR of drugs and ligands bound to membrane receptors. Watts A. **Curr Opin Biotechnol** 1999 Feb;10(1):48–53 (46 ref.)

Generation and screening of synthetic receptor libraries. de Miguel YR, et al. **Curr Opin Chem Biol** 1998 Jun; 2(3):417–21 (30 ref.)

Glycosylation of G–protein–coupled receptors for hormones central to normal reproductive functioning: its occurrence and role. Wheatley M, et al. **Hum Reprod Update** 1999 Jul–Aug;5(4):356–64 (76 ref.)

The modular architecture of leukocyte cell–surface receptors. Campbell ID. **Immunol Rev** 1998 Jun;163:11–8 (53 ref.)

Structural organization of G–protein–coupled receptors. Lomize AL, et al. **J Comput Aided Mol Des** 1999 Jul; 13(4):325–53 (142 ref.)

Structural basis of G protein–coupled receptor function. Schöneberg T, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1–2):181–93 (154 ref.)

Structural features of heterotrimeric G–protein–coupled receptors and their modulatory proteins. LeVine H 3rd. **Mol Neurobiol** 1999 Apr;19(2):111–49 (232 ref.)

Molecular basis of receptor/G–protein–coupling selectivity. Wess J. **Pharmacol Ther** 1998 Dec;80(3):231–64 (345 ref.)

The ethylene–receptor family from Arabidopsis: structure and function. Bleecker AB, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1405–12 (42 ref.)

The structure of the nuclear hormone receptors. Kumar R, et al. **Steroids** 1999 May;64(5):310–9 (80 ref.)

[Structure and function of melatonin receptors] Jockers R, et al. **C R Seances Soc Biol Fil** 1998;192(4):659–67 (12 ref.) (Eng. Abstr.) **(Fre)**

[Structure and function of phospholipase A2 receptor] Arita H. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1025–31 (30 ref.) **(Jpn)**

CLASSIFICATION

The characterization and classification of receptors. Humphrey PP. **J Recept Signal Transduct Res** 1998 Jul–Nov;18(4–6):345–62 (79 ref.)

[Classification of cell–surface receptors based on molecular structures and functions] Yokoyama S, et al. **Nippon Rinsho** 1998 Jul;56(7):1745–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

General anaesthetic actions on ligand–gated ion channels. Krasowski MD, et al. **Cell Mol Life Sci** 1999 Aug 15; 55(10):1278–303 (376 ref.)

Mechanisms of ethanol–induced impairment in asialoglycoprotein receptor expression and function [editorial; comment] Ishii H. **J Gastroenterol** 1998 Dec; 33(6):920–1 (15 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):855–9.

[Hormonal receptors of laryngeal cancer] Kruk–Zagajewska A, et al. **Otolaryngol Pol** 1999;53(1):41–6 (25 ref.) (Eng. Abstr.) **(Pol)**

[Hypoxic bioreductive agents: the possible immune and receptor–mediated mechanisms of antitumor action] Shchepetkin IA. **Eksp Klin Farmakol** 1999 May–Jun; 62(3):67–74 (80 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Will angiotensin converting enzyme genotype, receptor mutation identification, and other miracles of molecular biology permit reduction of NNT? Materson BJ. **Am J Hypertens** 1998 Aug;11(8 Pt 2):138S–142S (40 ref.)

Mammalian expression of transmembrane receptors for pharmaceutical applications. Rhodes AD, et al. **Biochem Soc Trans** 1998 Nov;26(4):699–704 (26 ref.)

Binding, gating, affinity and efficacy: the interpretation of structure–activity relationships for agonists and of the effects of mutating receptors. Colquhoun D. **Br J Pharmacol** 1998 Nov;125(5):924–47 (111 ref.)

A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). Chun J, et al. **Cell Biochem Biophys** 1999;30(2):213–42 (75 ref.)

Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer [editorial] Del Rosso M, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):389–93 (56 ref.)

Expression and recovery of functional G-protein-coupled receptors using baculovirus expression systems. Bouvier M, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):522–7 (48 ref.)

Production of G-protein-coupled receptors in yeast. Reiländer H, et al. **Curr Opin Biotechnol** 1998 Oct; 9(5):510–7 (46 ref.)

Molecular biology and clinical importance of the Ca(2+)-sensing receptor. De Luca F, et al. **Curr Opin Pediatr** 1998 Aug;10(4):435–40 (28 ref.)

Molecular tinkering of G protein-coupled receptors: an evolutionary success. Bockaert J, et al. **EMBO J** 1999 Apr 1;18(7):1723–9 (56 ref.)

Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Cupit LD, et al. **Trends Cardiovasc Med** 1999 Jan–Feb;9(1–2):42–8 (39 ref.)

Why are human G-protein-coupled receptors predominantly intronless? [letter] Gentles AJ, et al. **Trends Genet** 1999 Feb;15(2):47–9 (12 ref.)

Host resistance to infection: genetic control of lipopolysaccharide responsiveness by TOLL-like receptor genes. Qureshi ST, et al. **Trends Genet** 1999 Aug; 15(8):291–4 (24 ref.)

7TM receptors: the splicing on the cake. Kilpatrick GJ, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):294–301 (88 ref.)

[Use of a G-protein-coupled receptor to communicate. An evolutionary success] Bockaert J, et al. **C R Acad Sci III** 1998 Jul;321(7):529–51 (131 ref.) (Eng. Abstr.) **(Fre)**

[Detection of receptor mRNAs using nonradioactive in situ hybridization] Shin M, et al. **Nippon Rinsho** 1998 Jul; 56(7):1667–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Variant type von Willebrand disease with defective binding to factor VIII] Shima M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):430–3 (7 ref.) **(Jpn)**

IMMUNOLOGY

Membrane receptors for soluble defense collagens. Tenner AJ. **Curr Opin Immunol** 1999 Feb;11(1):34–41 (79 ref.)

A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. Gräler MH, et al. **Curr Top Microbiol Immunol** 1999;246:131–6; discussion 137 (31 ref.)

Partial agonists and G protein-coupled receptor desensitization. Clark RB, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):279–86 (63 ref.)

ISOLATION & PURIFICATION

The quest for novel bioactive peptides utilizing orphan seven-transmembrane-domain receptors. Hinuma S, et al. **J Mol Med** 1999 Jun;77(6):495–504 (64 ref.)

METABOLISM

Bacterial lactoferrin receptors. Schryvers AB, et al. **Adv Exp Med Biol** 1998;443:123–33 (31 ref.)

Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Bodenner DL, et al. **Am J Med** 1998 Dec;105(6):524–38 (80 ref.)

G protein-coupled receptor kinases. Pitcher JA, et al. **Annu Rev Biochem** 1998;67:653–92 (255 ref.)

Receptor-mediated endocytosis of cobalamin (vitamin B12). Seetharam B. **Annu Rev Nutr** 1999;19:173–95 (93 ref.)

Desensitization of G-protein-coupled receptors in the cardiovascular system. Bünemann M, et al. **Annu Rev Physiol** 1999;61:169–92 (148 ref.)

Receptor-activated Ca2+ inflow in animal cells: a variety of pathways tailored to meet different intracellular Ca2+ signalling requirements. Barritt GJ. **Biochem J** 1999 Jan 15;337 (Pt 2):153–69 (203 ref.)

Proteinase-activated receptors: a growing family of heptahelical receptors for thrombin, trypsin and tryptase. Déry O, et al. **Biochem Soc Trans** 1999 Feb;27(2):246–54 (50 ref.)

Diversity in the signalling and regulation of G-protein-coupled receptors. Milligan G, et al. **Biochem Soc Trans** 1999 Feb;27(2):149–54 (33 ref.)

Interactions of surfactant protein A with epithelial cells and phagocytes. Tino MJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):241–63 (112 ref.)

Orphan G-protein-coupled receptors: the next generation of drug targets? Wilson S, et al. **Br J Pharmacol** 1998 Dec; 125(7):1387–92 (25 ref.)

Attraction versus repulsion: modular receptors make the difference in axon guidance [comment] Seeger MA, et al. **Cell** 1999 Jun 25;97(7):821–4 (14 ref.) Comment on: Cell 1999 Jun 25;97(7):917–26. Comment on: Cell 1999 Jun 25;97(7):927–41.

Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Thornalley PJ. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1013–23 (70 ref.)

G-protein-linked receptors as tyrosine kinase substrates: new paradigms in signal integration. Malbon CC, et al. **Cell Signal** 1998 Sep;10(8):523–7 (23 ref.)

G protein-coupled receptor signalling in the kidney. Weiss RH. **Cell Signal** 1998 May;10(5):313–20 (82 ref.)

Scratching the (cell) surface: cytokine engineering for improved ligand/receptor trafficking dynamics. Lauffenburger DA, et al. **Chem Biol** 1998 Oct; 5(10):R257–63 (58 ref.)

Melatonin: a chemical photoperiodic signal with clinical significance in humans. Pang SF, et al. **Chin Med J (Engl)** 1998 Mar;111(3):197–203 (69 ref.)

Cytokinin action: two receptors better than one? Estelle M. **Curr Biol** 1998 Jul 16;8(15):R539–41 (9 ref.)

Ethylene signalling: redundant receptors all have their say. Theologis A. **Curr Biol** 1998 Dec 3;8(24):R875–8 (16 ref.)

NMR of drugs and ligands bound to membrane receptors. Watts A. **Curr Opin Biotechnol** 1999 Feb;10(1):48–53 (46 ref.)

Oligosaccharide receptors for bacteria: a view to a kill. Lingwood CA. **Curr Opin Chem Biol** 1998 Dec; 2(6):695–700 (57 ref.)

Abnormal expression and function of hormone receptors in adrenal Cushing's syndrome. Lacroix A, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):835–43 (24 ref.)

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Schally AV, et al. **Eur J Endocrinol** 1999 Jul;141(1):1–14 (102 ref.)

Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Mohanam S, et al. **Front Biosci** 1999 Feb 15;4:D178–87 (113 ref.)

Collagen-platelet interaction: platelet non-integrin receptors. Chiang TM. **Histol Histopathol** 1999 Apr;14(2):579–85 (93 ref.)

Therapeutic strategies targeting proteins that regulate folate and reduced folate transport. Trippett TM, et al. **J Chemother** 1999 Feb;11(1):3–10 (67 ref.)

Organization of kinases, phosphatases, and receptor signaling complexes. Schillace RV, et al. **J Clin Invest** 1999 Mar; 103(6):761–5 (27 ref.)

Kinases involved in MSP/RON signaling. Danilkovitch A, et al. **J Leukoc Biol** 1999 Mar;65(3):345–8 (47 ref.)

Intracellular calcium regulation of channel and receptor expression in the plasmalemma: potential sites of sensitivity along the pathways linking transcription, translation, and insertion. Barish ME. **J Neurobiol** 1998 Oct;37(1):146–57 (101 ref.)

G-protein coupled receptor kinases as modulators of G-protein signalling. Bünemann M, et al. **J Physiol (Lond)** 1999 May 15;517 (Pt 1):5–23 (186 ref.)

Partial agonism: mechanisms based on ligand–receptor interactions and on stimulus–response coupling. Pliška V. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):597–629 (33 ref.)

Sex hormone-binding globulin, its membrane receptor, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells. Fortunati N, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):473–9 (45 ref.)

Receptors for proteins modified by advanced glycation endproducts (AGE)—their functional role in atherosclerosis. Sano H, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):333–46 (58 ref.)

Modern drug development from traditional medicinal plants using radioligand receptor-binding assays. Misra R. **Med Res Rev** 1998 Nov;18(6):383–402 (37 ref.)

Overview of ligand-receptor binding techniques. Qume M. **Methods Mol Biol** 1999;106:3–23 (20 ref.)

Structural basis of G protein–coupled receptor function. Schöneberg T, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1–2):181–93 (154 ref.)

Novel sensing mechanisms and targets for the cAMP-protein kinase A pathway in the yeast Saccharomyces cerevisiae. Thevelein JM, et al. **Mol Microbiol** 1999 Sep;33(5):904–18 (101 ref.)

Endogenous drug-like factors. Mrozikiewicz A. **Pol J Pharmacol** 1998 Nov–Dec;50(6):393–7 (26 ref.)

Structural conservation of Notch receptors and ligands. Fleming RJ. **Semin Cell Dev Biol** 1998 Dec;9(6):599–607 (65 ref.)

The clearance of thrombin–antithrombin and related serpin–enzyme complexes from the circulation: role of various hepatocyte receptors. Wells MJ, et al. **Thromb Haemost** 1999 Mar;81(3):325–37 (179 ref.)

Biological regulation of receptor–hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. Andersen ME, et al. **Toxicol Sci** 1999 Mar;48(1):38–50 (50 ref.)

Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Hicke L. **Trends Cell Biol** 1999 Mar;9(3):107–12 (52 ref.)

HIV-1 attachment: another look. Ugolini S, et al. **Trends Microbiol** 1999 Apr;7(4):144–9 (62 ref.)

G-protein-coupled, extracellular Ca(2+)-sensing receptor: a versatile regulator of diverse cellular functions. Brown EM, et al. **Vitam Horm** 1999;55:1–71 (247 ref.)

[Evidence of a renin receptor on human mesangial cells: effects on PAI1 and cGMP] Nguyen G, et al. **Nephrologie** 1998;19(7):411–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Signaling by melatonin receptors] Petit L, et al. **Therapie** 1998 Sep–Oct;53(5):421–8 (55 ref.) (Eng. Abstr.) **(Fre)**

[Signal transmission in plant cells; plasma membrane receptors] Barańska J. **Postepy Biochem** 1998;44(3):201–8 (38 ref.) **(Pol)**

[The ways of designing new-generation medicinal and biochemical agents by using ligand-receptor interactions for active membrane transport] Iurkevich AM, et al. **Vestn Ross Akad Med Nauk** 1999;(3):3–7 (14 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Structural basis for cytokine hormone–receptor recognition and receptor activation. Kossiakoff AA, et al. **Adv Protein Chem** 1998;52:67–108 (99 ref.)

Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Joseph JA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:268–76 (62 ref.)

Surface receptors and transporters of Trypanosoma brucei. Borst P, et al. **Annu Rev Microbiol** 1998;52:745–78 (144 ref.)

Presynaptic ionotropic receptors and the control of transmitter release. MacDermott AB, et al. **Annu Rev Neurosci** 1999;22:443–85 (216 ref.)

The urokinase receptor. A cell surface, regulated chemokine. Blasi F. **APMIS** 1999 Jan;107(1):96–101 (56 ref.)

Hormones as life regulators in the current molecular endocrinology. Pankov YA. **Biochemistry (Mosc)** 1998 Dec;63(12):1361–73 (125 ref.)

Signal perception and transduction: the role of protein kinases. Schenk PW, et al. **Biochim Biophys Acta** 1999 Feb 4;1449(1):1–24 (174 ref.)

Melatonin receptors and signal transduction mechanisms. Barrett P, et al. **Biol Signals Recept** 1999 Jan–Apr; 8(1–2):6–14 (45 ref.)

Cell death induced in lymphocytes expressing the elastin-laminin receptor by excess agonists: necrosis and apoptosis. Péterszegi G, et al. **Biomed Pharmacother** 1998; 52(9):369–77 (33 ref.)

Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Miyazono K. **Bone** 1999 Jul;25(1):91–3 (39 ref.)

Thrombin and trypsin receptors: the same mechanism of signalling on cellular surfaces. Olejar T, et al. **Bratisl Lek Listy** 1999 Feb;100(2):75–9 (35 ref.)

Protein tyrosine kinase-mediated pathways in G protein-coupled receptor signaling. Dikic I, et al. **Cell Biochem Biophys** 1999;30(3):369–87 (84 ref.)

Enteropathogenic Escherichia coli: a pathogen that inserts its own receptor into host cells. DeVinney R, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):961–76 (122 ref.)

Cell surface receptors, nuclear receptors and ligands that regulate adipose tissue development. Ailhaud G. **Clin Chim Acta** 1999 Aug;286(1–2):181–90 (36 ref.)

Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Chen JD, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):169–90 (130 ref.)

Nuclear hormone receptors and adipogenesis. Gimble JM, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):141–68 (308 ref.)

Apoptosis control by death and decoy receptors. Ashkenazi A, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):255–60 (66 ref.)

Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Luttrell LM, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):177–83 (56 ref.)

Interactions between mitogenic stimuli, or, a thousand and one connections. Schwartz MA, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):197–202 (51 ref.)

The Toll-receptor family and control of innate immunity. Kopp EB, et al. **Curr Opin Immunol** 1999 Feb;11(1):13–8 (48 ref.)

Molecular biology and clinical importance of the Ca(2+)-sensing receptor. De Luca F, et al. **Curr Opin Pediatr** 1998 Aug;10(4):435–40 (28 ref.)

Vascular endothelial growth factor receptor-3. Taipale J, et al. **Curr Top Microbiol Immunol** 1999;237:85–96 (44 ref.)

Mechanisms of aging of the extracellular matrix: role of the elastin-laminin receptor. Robert L. **Gerontology** 1998; 44(6):307–17 (68 ref.)

Growth hormone secretagogues: a pill for growth? Clark RG. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:85–8 (15 ref.)

Growth hormone (GH) secretagogues and neuroendocrine regulation of GH secretion. Dickson SL, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:89–91 (20 ref.)

The growth hormone secretagogue receptor. Korbonits M, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:93–9 (46 ref.)

Inflammation, sepsis, and coagulation. Esmon CT, et al. **Haematologica** 1999 Mar;84(3):254–9 (24 ref.)

Regulation and functions of the protein C anticoagulant pathway. Esmon CT, et al. **Haematologica** 1999 Apr; 84(4):363–8 (42 ref.)

Glycosylation of G-protein-coupled receptors for hormones central to normal reproductive functioning: its occurrence and role. Wheatley M, et al. **Hum Reprod Update** 1999 Jul–Aug;5(4):356–64 (76 ref.)

Structure and function of the extracellular calcium-sensing receptor (Review). Bai M. **Int J Mol Med** 1999 Aug; 4(2):115–25 (98 ref.)

Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and

sphingosine 1-phosphate. An S, et al.
J Cell Biochem Suppl 1998;30-31:147-57 (46 ref.)
Heptahelical receptor signaling: beyond the G protein paradigm. Hall RA, et al. **J Cell Biol** 1999 May 31; 145(5):927-32 (66 ref.)
The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. Ferrero E, et al.
J Leukoc Biol 1999 Feb;65(2):151-61 (77 ref.)
Receptor-operated calcium influx mediated by protein tyrosine kinase pathways. Tsunoda Y.
J Recept Signal Transduct Res 1998 Jul-Nov; 18(4-6):281-310 (126 ref.)
Extracellular matrix receptors and the differentiation of human megakaryocytes in vitro. Molla A, et al.
Leuk Lymphoma 1999 Mar;33(1-2):15-23 (46 ref.)
The generation of nitric oxide by G protein-coupled receptors. Christopoulos A, et al. **Life Sci** 1999;64(1):1-15 (104 ref.)
Intercellular interactions as a basis for the expedient behaviour of multicellular systems. Chailakhyan LM.
Membr Cell Biol 1998;11(6):693-700 (9 ref.)
Structural features of heterotrimeric G-protein-coupled receptors and their modulatory proteins. LeVine H 3rd.
Mol Neurobiol 1999 Apr;19(2):111-49 (232 ref.)
Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors. Pauwels PJ, et al. **Mol Neurobiol** 1998 Winter;17(1-3):109-35 (145 ref.)
Rho as a mediator of G protein-coupled receptor signaling. Seasholtz TM, et al. **Mol Pharmacol** 1999 Jun;55(6):949-56 (98 ref.)
Allosteric receptors after 30 years. Changeux JP, et al.
Neuron 1998 Nov;21(5):959-80 (272 ref.)
Role of the elastin-laminin receptor in the cardiovascular system. Faury G. **Pathol Biol (Paris)** 1998 Sep;46(7):517-26 (84 ref.)
Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Csukai M, et al. **Pharmacol Res** 1999 Apr;39(4):253-9 (44 ref.)
Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):7723-30 (83 ref.)
Modulation of ions channels and membrane receptors activities by mechanical interventions in cardiomyocytes: possible mechanisms for mechanosensitivity. Cazorla O, et al. **Prog Biophys Mol Biol** 1999;71(1):29-58 (143 ref.)
Eph receptors and ligands in axon pathway choice, target recognition, and synaptogenesis. Lemke G.
Prog Brain Res 1998;117:171-6 (34 ref.)
The calcium-sensing receptor (CaR) permits Ca2+ to function as a versatile extracellular first messenger. Brown EM, et al. **Recent Prog Horm Res** 1998;53:257-80; discussion 280-1 (146 ref.)
Notch signaling: cell fate control and signal integration in development. Artavanis-Tsakonas S, et al. **Science** 1999 Apr 30;284(5415):770-6 (92 ref.)
Orphan nuclear receptors: shifting endocrinology into reverse. Kliewer SA, et al. **Science** 1999 Apr 30; 284(5415):757-60 (37 ref.)
A cell's sense of direction. Parent CA, et al. **Science** 1999 Apr 30;284(5415):765-70 (35 ref.)
The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Fraser IP, et al.
Semin Immunol 1998 Oct;10(5):363-72 (94 ref.)
Hepatocyte-directed gene delivery by receptor-mediated endocytosis. Smith RM, et al. **Semin Liver Dis** 1999; 19(1):83-92 (107 ref.)
1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2. Boyan BD, et al. **Steroids** 1999 Jan-Feb;64(1-2):129-36 (63 ref.)
Notch/LIN-12 signaling: transduction by regulated protein slicing. Kimble J, et al. **Trends Biochem Sci** 1998 Sep; 23(9):353-7 (48 ref.)
Agonist-independent regulation of constitutively active G-protein-coupled receptors. Leurs R, et al.
Trends Biochem Sci 1998 Nov;23(11):418-22 (50 ref.)
Integrins take partners: cross-talk between integrins and other membrane receptors. Porter JC, et al.
Trends Cell Biol 1998 Oct;8(10):390-6 (57 ref.)
Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Bellen HJ, et al. **Trends Neurosci** 1998 Oct;21(10):444-9 (48 ref.)
Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. King BF, et al.
Trends Pharmacol Sci 1998 Dec;19(12):506-14 (71 ref.)
Receptors for a growing family of secreted phospholipases A2. Lambeau G, et al. **Trends Pharmacol Sci** 1999 Apr; 20(4):162-70 (92 ref.)
Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Marchese A, et al. **Trends Pharmacol Sci** 1999 Sep;20(9):370-5 (49 ref.)
G protein regulation of adenylate cyclase. Simonds WF.
Trends Pharmacol Sci 1999 Feb;20(2):66-73 (79 ref.)
[Ca2+ receptor in cell membrane] Lou SJ, et al.
Sheng Li Ko Hsueh Chin Chan 1996 Jul;27(3):252-4 (7 ref.) **(Chi)**
[Structure and function of melatonin receptors] Jockers R, et al. **C R Seances Soc Biol Fil** 1998;192(4):659-67 (12 ref.) (Eng. Abstr.) **(Fre)**
[Calcium-sensing receptor and its related diseases] Aida K, et al. **Nippon Rinsho** 1999 Mar;57(3):746-55 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Structure and function of phospholipase A2 receptor] Arita H. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1025-31 (30 ref.) **(Jpn)**
[Involvement of urokinase and its receptor in the remodeling of normal and pathological tissue] Tkachuk VA, et al.
Vestn Ross Akad Med Nauk 1998;(8):36-41 (61 ref.) (Eng. Abstr.) **(Rus)**
[Membrane receptors and their enzymatic mechanisms of action. Associated endocrine diseases] Johnson MC.
Rev Med Chil 1998 Nov;126(11):1384-92 (34 ref.) (Eng. Abstr.) **(Spa)**

RECEPTORS, CGRP see **RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE**

RECEPTORS, CHEMOKINE

Chemokines and chemokine receptors: role in HIV infection. Kalinkovich A, et al. **Immunol Lett** 1999 Jun 1; 68(2-3):281-7 (84 ref.)
[Molecular medicine of chemokine receptors] Hirai K.
Nippon Rinsho 1998 Jul;56(7):1807-12 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Chemokines and Chemokine receptors in collagen diseases] Kawasaki S, et al. **Nippon Rinsho** 1999 Feb;57(2):278-82 (20 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Chemokines and chemokine receptors in allergic diseases. Uguccioni M. **Pediatr Pulmonol Suppl** 1999;18:113-4 (10 ref.)

BIOSYNTHESIS

Regulation of chemokine receptors in mononuclear phagocytes versus dendritic cells and in the amplification of Th1 versus Th2 responses. Mantovani A, et al.
Eur Cytokine Netw 1998 Sep;9(3 Suppl):76-80 (28 ref.)
Regulation of chemokine receptor expression in dendritic cells. Mantovani A, et al. **Res Immunol** 1998 Sep-Oct; 149(7-8):639-41 (19 ref.)

IMMUNOLOGY

Chemokine receptors and chemokines in HIV infection [published erratum appears in J Clin Immunol 1998 Nov;18(6):441] Garzino-Demo A, et al. **J Clin Immunol** 1998 Jul;18(4):243-55 (159 ref.)

METABOLISM

Chemokine receptors as HIV coreceptors: implications and interactions. Rucker J, et al.
AIDS Res Hum Retroviruses 1998 Oct;14 Suppl 3:S241-6 (100 ref.)
Intracellular signalling pathways induced by chemokines in natural killer cells. Maghazachi AA. **Cell Signal** 1999 Jun; 11(6):385-90 (63 ref.)
Recent advances in chemokines and chemokine receptors. Zlotnik A, et al. **Crit Rev Immunol** 1999;19(1):1-47 (198 ref.)
Chemokine receptors in lymphoid organ homeostasis. Jung S, et al. **Curr Opin Immunol** 1999 Jun;11(3):319-25 (53 ref.)
Chemokine receptor trafficking and viral replication. Pelchen-Matthews A, et al. **Immunol Rev** 1999 Apr; 168:33-49 (158 ref.)
Chemokines and chemokine receptors in CNS pathology. Glabinski AR, et al. **J Neurovirol** 1999 Feb;5(1):3-12 (89 ref.)
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. Xia MQ, et al.
J Neurovirol 1999 Feb;5(1):32-41 (106 ref.)
Chemokines, chemokine receptors and renal disease [editorial; comment] Egido J. **Kidney Int** 1999 Jul; 56(1):347-8 (10 ref.) Comment on: Kidney Int 1999 Jul;56(1):52-64.
Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Edinger AL, et al. **Virology** 1999 Aug 1;260(2):211-21 (129 ref.)

PHYSIOLOGY

Role of chemokine receptors in HIV-1 infection and pathogenesis. Ross TM, et al. **Adv Virus Res** 1999;52:233-67 (151 ref.)
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Berger EA, et al.
Annu Rev Immunol 1999;17:657-700 (230 ref.)
Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Locati M, et al.
Annu Rev Med 1999;50:425-40 (78 ref.)
Chemokine receptors in HIV-1 and SIV infection. Choe H.
Arch Pharm Res 1998 Dec;21(6):634-9 (38 ref.)
Chemokine receptors--future therapeutic targets for HIV? Proudfoot AE, et al. **Biochem Pharmacol** 1999 Mar 1; 57(5):451-63 (123 ref.)
T-cell subsets: chemokine receptors guide the way. O'Garra A, et al. **Curr Biol** 1998 Sep 10;8(18):R646-9 (29 ref.)
The role of chemokine receptors in directing traffic of naive, type 1 and type 2 T cells. Sallusto F, et al.
Curr Top Microbiol Immunol 1999;246:123-8; discussion 129 (21 ref.)
Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Broxmeyer HE, et al. **Exp Hematol** 1999 Jul;27(7):1113-23 (147 ref.)
Chemokine receptors and their role in leukocyte activation. Wells TN, et al. **Immunol Lett** 1999 Jan;65(1-2):35-40 (46 ref.)
Chemokine receptors and HIV-1: the fusion of two major research fields. Horuk R. **Immunol Today** 1999 Feb; 20(2):89-94 (51 ref.)
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Sallusto F, et al.
Immunol Today 1998 Dec;19(12):568-74 (89 ref.)
Chemokine receptors and their antagonists in allergic lung disease. Wells TN, et al. **Inflamm Res** 1999 Jul;48(7):353-62 (64 ref.)
Chemokine and chemokine receptor expression in the central nervous system. Hesselgesser J, et al. **J Neurovirol** 1999 Feb;5(1):13-26 (120 ref.)
Potential role for G-protein coupled receptors in HIV-associated nephropathy [editorial; comment] Klotman M. **Kidney Int** 1998 Dec;54(6):2243-4 (10 ref.) Comment on: Kidney Int 1998 Dec;54(6):1945-54.
HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Clapham PR, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):49-55 (58 ref.)
HIV-1 envelope determinants for cell tropism and chemokine receptor use. Hoffman TL, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):57-65 (106 ref.)
Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339-46 (80 ref.)
The role of chemokine receptors in HIV infection. Rowland-Jones S. **Sex Transm Infect** 1999 Jun;75(3):148-51 (40 ref.)
Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Mennicken F, et al. **Trends Pharmacol Sci** 1999 Feb;20(2):73-8 (83 ref.)
Definition, function and pathophysiological significance of chemokine receptors. Wells TN, et al.
Trends Pharmacol Sci 1998 Sep;19(9):376-80 (73 ref.)
[Role of chemokine receptors in T lymphocytes] Utsunomiya I. **Seikagaku** 1998 Oct;70(10):1266-70 (15 ref.) **(Jpn)**

RECEPTORS, CHOLECYSTOKININ

AGONISTS

CCK receptor trafficking: a novel paradigm of travel focus on "regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist" [editorial; comment] del Valle J. **Am J Physiol** 1999 Mar;276(3 Pt 1):C537-8 (20 ref.) Comment on: Am J Physiol 1999 Mar;276(3 Pt 1):C539-47.
Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). de Tullio P, et al.
Curr Med Chem 1999 Jun;6(6):433-55 (201 ref.)
Orally active nonpeptide CCK-A agonists. Sugg EE, et al.
Pharm Biotechnol 1998;11:507-24 (25 ref.)

ANTAGONISTS & INHIBITORS

Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). de Tullio P, et al.
Curr Med Chem 1999 Jun;6(6):433-55 (201 ref.)
CCK receptor antagonists. Dunlop J. **Gen Pharmacol** 1998 Oct;31(4):519-24 (51 ref.)
Discovery of new CCK2 receptor antagonists. A review of pharmacological studies. Part I: Development of potential therapeutic tools for gastrin-related gastrointestinal diseases. Revel L, et al.
Methods Find Exp Clin Pharmacol 1999 Jun;21(5):375-83 (115 ref.)
The anxieties of drug discovery and development. CCK-B receptor antagonists. Lombardo F, et al.
Pharm Biotechnol 1998;11:465-79 (16 ref.)
CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile. Trivedi BK, et al.
Pharm Biotechnol 1998;11:481-505 (51 ref.)
CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Håkanson R, et al.
Regul Pept 1999 Mar 17;80(1-2):1-12 (117 ref.)

CHEMISTRY

CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Noble F, et al.
Prog Neurobiol 1999 Jul;58(4):349-79 (287 ref.)

GENETICS

CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Noble F, et al.
Prog Neurobiol 1999 Jul;58(4):349-79 (287 ref.)

PHYSIOLOGY

CCK receptor trafficking: a novel paradigm of travel focus on "regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist" [editorial;

comment] del Valle J. **Am J Physiol** 1999 Mar;276(3 Pt 1):C537-8 (20 ref.) Comment on: Am J Physiol 1999 Mar;276(3 Pt 1):C539-47.
The influence of the cellular context on receptor function: a necessary consideration for physiologic interpretations of receptor expression studies. Logsdon CD. **Life Sci** 1999; 64(6-7):369-74 (38 ref.)
The cholecystokinin--gastrin family of peptides and their receptors. Rehfeld JF. **Results Probl Cell Differ** 1999; 26:293-321 (170 ref.)
[Receptors for cholecystokinin and gastrin] de Weerth A, et al. **Z Gastroenterol** 1999 May;37(5):389-401 (92 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, CHOLINERGIC

CHEMISTRY

The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Hulme EC, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):247-60 (83 ref.)

DRUG EFFECTS

Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Lemière J, et al. **Acta Neurol Belg** 1999 Jun;99(2):96-106 (113 ref.)
[Blockade of the ion channels of the skeletal muscle acetylcholine receptor] Danilov AF. **Eksp Klin Farmakol** 1998 Nov-Dec;61(6):73-5 (22 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Congenital myasthenic syndromes: experiments of nature. Engel AG, et al. **J Physiol Paris** 1998 Apr;92(2):113-7 (25 ref.)

IMMUNOLOGY

Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Vincent A, et al. **Immunol Rev** 1998 Aug;164:157-68 (87 ref.)
[Myasthenia gravis with electrophysiological features of Lambert-Eaton myasthenic syndrome: usefulness of serum autoantibodies assay and neuromuscular junction biopsy] Matsumoto R, et al. **Rinsho Shinkeigaku** 1999 May; 39(5):531-7 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Adrenergic/cholinergic immunomodulation in the rat model--in vivo veritas? Rinner I, et al. **Dev Immunol** 1998; 6(3-4):245-52 (35 ref.)

RECEPTORS, CHORIONIC GONADOTROPIN see **RECEPTORS, LH**

RECEPTORS, CKR5 see **RECEPTORS, CCR5**

RECEPTORS, COLONY-STIMULATING FACTOR

PHYSIOLOGY

Hemopoietic growth factor receptor abnormalities in leukemia. Alexander WS, et al. **Leuk Res** 1998 Dec; 22(12):1097-111 (134 ref.)

RECEPTORS, COMPLEMENT

CHEMISTRY

The complement regulator C4b-binding protein analyzed by molecular modeling, bioinformatics and computer-aided experimental design. Villoutreix BO, et al. **Immunopharmacology** 1999 May;42(1-3):121-34 (94 ref.)

IMMUNOLOGY

C1q-binding proteins and C1q receptors. Nicholson-Weller A, et al. **Curr Opin Immunol** 1999 Feb;11(1):42-6 (47 ref.)
Measles: immunosuppression, interleukin-12, and complement receptors. Karp CL. **Immunol Rev** 1999 Apr; 168:91-101 (109 ref.)

METABOLISM

Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Sim RB, et al. **Immunobiology** 1998 Aug; 199(2):208-24 (77 ref.)
C1q--how many functions? How many receptors? Eggleton P, et al. **Trends Cell Biol** 1998 Nov;8(11):428-31 (29 ref.)
Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Nataf S, et al. **Trends Neurosci** 1999 Sep; 22(9):397-402 (70 ref.)

PHYSIOLOGY

Structure and function of gC1q-R: a multiligand binding cellular protein. Ghebrehiwet B, et al. **Immunobiology** 1998 Aug;199(2):225-38 (58 ref.)
Platelet receptors for the complement component C1q: implications for hemostasis and thrombosis. Peerschke EI, et al. **Immunobiology** 1998 Aug;199(2):239-49 (47 ref.)
C1q receptors: regulating specific functions of phagocytic cells. Tenner AJ. **Immunobiology** 1998 Aug;199(2):250-64 (70 ref.)
Complement as a promiscuous signal transduction device. Asghar SS, et al. **Lab Invest** 1998 Oct;78(10):1203-25 (157 ref.)

RECEPTORS, COMPLEMENT 3B

METABOLISM

Role of complement receptors CD21/CD35 in B lymphocyte activation and survival. Carroll M. **Curr Top Microbiol Immunol** 1999;246:63-8; discussion 69 (27 ref.)

RECEPTORS, COMPLEMENT 3D

IMMUNOLOGY

Non-structural determinants of immunogenicity and the B cell co-receptors, CD19, CD21, and CD22. Fearon DT. **Adv Exp Med Biol** 1998;452:181-4 (44 ref.)

METABOLISM

Role of complement receptors CD21/CD35 in B lymphocyte activation and survival. Carroll M. **Curr Top Microbiol Immunol** 1999;246:63-8; discussion 69 (27 ref.)
CD21high IgMhigh splenic B cells enriched in the marginal zone: distinct phenotypes and functions. Martin F, et al. **Curr Top Microbiol Immunol** 1999;246:45-50; discussion 51-2 (9 ref.)

PHYSIOLOGY

Functional properties of soluble CD21. Frémeaux-Bacchi V, et al. **Immunopharmacology** 1999 May;42(1-3):31-7 (34 ref.)

RECEPTORS, CORTICOSTEROID see **RECEPTORS, STEROID**

RECEPTORS, CORTICOTROPIN

GENETICS

[ACTH receptor, ACTH receptor anomaly, and familial glucocorticoid deficiency] Fukata J, et al. **Nippon Rinsho** 1998 Jul;56(7):1836-42 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Peptide modulation of fever and inflammation within the brain. Catania A, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:62-8 (54 ref.)
Melanocortin receptors and antagonists regulate pigmentation and body weight. Jordan SA, et al. **Bioessays** 1998 Aug;20(8):603-6 (27 ref.)
Melanocortin receptors: perspectives for novel drugs. Wikberg JE. **Eur J Pharmacol** 1999 Jun 30; 375(1-3):295-310 (130 ref.)
Melanocortin and leptin signaling systems: central regulation of catabolic energy balance. Fisher SL, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1-4):203-16 (34 ref.)

RECEPTORS, CORTICOTROPIN-RELEASING HORMONE

ANTAGONISTS & INHIBITORS

Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. McCarthy JR, et al. **Curr Pharm Des** 1999 May; 5(5):289-315 (183 ref.)
The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Holsboer F. **J Psychiatr Res** 1999 May-Jun;33(3):181-214 (163 ref.)

GENETICS

Stress-axis, coping and dementia: gene-manipulation studies. Heinrichs SC. **Trends Pharmacol Sci** 1999 Aug;20(8):311-5 (51 ref.)

PHYSIOLOGY

Does the CRH binding protein shield the anterior pituitary from placental CRH? Thomson M. **Endocrine** 1998 Dec; 9(3):221-6 (46 ref.)
CRF and CRF receptors. Radulovic J, et al. **Results Probl Cell Differ** 1999;26:67-90 (140 ref.)

RECEPTORS, CR1 see **RECEPTORS, COMPLEMENT 3B**

RECEPTORS, CR2 see **RECEPTORS, COMPLEMENT 3D**

RECEPTORS, CRH see **RECEPTORS, CORTICOTROPIN-RELEASING HORMONE**

RECEPTORS, CXCR4

METABOLISM

CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. Hoxie JA, et al. **J Reprod Immunol** 1998 Dec;41(1-2):197-211 (56 ref.)

PHYSIOLOGY

A CXC chemokine SDF-1/PBSF: a ligand for a HIV coreceptor, CXCR4. Nagasawa T, et al. **Adv Immunol** 1999; 71:211-28 (77 ref.)
Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Cammack N. **Antivir Chem Chemother** 1999 Mar;10(2):53-62 (94 ref.)
The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus. Willett BJ, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):67-72 (47 ref.)

RECEPTORS, CYCLIC AMP

see related
CYCLIC AMP-DEPENDENT PROTEIN KINASES

RECEPTORS, CYTOKINE

[Structure and function of helical cytokines and their cognate receptors] Senda T. **Tanpakushitsu Kakusan Koso** 1999 Mar; 44(4 Suppl):318-24 (35 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Jorgensen C, et al. **Ann Rheum Dis** 1999 Mar;58(3):136-41 (48 ref.)

BIOSYNTHESIS

Altered cytokine (receptor) mRNA expression as a tool in immunotoxicology. Vandebriel RJ, et al. **Toxicology** 1998 Sep 1;130(1):43-67 (225 ref.)

CHEMISTRY

Targeting growth factor and cytokine receptors with recombinant peptide libraries. Dower WJ. **Curr Opin Chem Biol** 1998 Jun;2(3):328-34 (35 ref.)

CLASSIFICATION

[Classification of cytokine receptor superfamily and signal transduction--structural feature and functional property] Tanaka M, et al. **Nippon Rinsho** 1998 Jul;56(7):1784-90 (25 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

Inherited cytokine and cytokine receptor deficiencies in man. Di Santo JP. **Int Rev Immunol** 1998;17(1-4):103-20 (68 ref.)

DRUG EFFECTS

Cytokines and their receptors as therapeutic targets in asthma. Pauwels RA, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:1-5 (45 ref.)

GENETICS

Regulation of expression of chemokine receptor BLR1/CXCR5 during B cell maturation. Pevzner V, et al. **Curr Top Microbiol Immunol** 1999;246:79-84; discussion 85 (18 ref.)
Novel pathways for negative regulation of inflammatory cytokines centered on receptor expression. Mantovani A, et al. **Dev Biol Stand** 1999;97:97-104 (50 ref.)
Rainbow trout cytokine and cytokine receptor genes. Secombes C, et al. **Immunol Rev** 1998 Dec;166:333-40 (34 ref.)
Inherited cytokine and cytokine receptor deficiencies in man. Di Santo JP. **Int Rev Immunol** 1998;17(1-4):103-20 (68 ref.)
[Obesity and diseases. 6. Clinical significance of obesity gene product (leptin)] Ogawa Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1811-6 (16 ref.) **(Jpn)**

IMMUNOLOGY

Soluble cytokine receptors: basic immunology and clinical applications. Fernandez-Botran R. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):165-224 (243 ref.)

METABOLISM

IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Grötzinger J, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):803-13 (77 ref.)
Small molecule cytokine mimetics. Whitty A, et al. **Chem Biol** 1999 Apr;6(4):R107-18 (42 ref.)
The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. Heim MH. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1-4):75-120 (239 ref.)
Cytoplasmic and nuclear cytokine receptor complexes. Mertani HC, et al. **Vitam Horm** 1999;57:79-121 (290 ref.)

PHYSIOLOGY

General mechanisms of cytokine receptor signaling.

RECEPTORS, CYTOKINE

Carpenter LR, et al. **Adv Protein Chem** 1998;52:109–40 (138 ref.)

Cytokines in hematopoiesis: specificity and redundancy in receptor function. Socolovsky M, et al. **Adv Protein Chem** 1998;52:141–98 (254 ref.)

Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production. Goyal RK, et al. **Ann Med** 1999 Jun;31(3):208–16 (75 ref.)

Signaling by the cytokine receptor superfamily. Ihle JN, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:1–9 (50 ref.)

The role of cytokine receptor signaling in lymphocyte development. Baird AM, et al. **Curr Opin Immunol** 1999 Apr;11(2):157–66 (111 ref.)

Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71–6 (55 ref.)

Cytokine pleiotropy and redundancy--gp130 cytokines in human implantation. Sánchez-Cuenca J, et al. **Immunol Today** 1999 Feb;20(2):57–9 (32 ref.)

SOCS: suppressors of cytokine signalling. Starr R, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1081–5 (13 ref.)

Signal transduction through cytokine receptors. Hibi M, et al. **Int Rev Immunol** 1998;17(1–4):75–102 (150 ref.)

Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects. Skoda RC. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):741–72 (163 ref.)

[Interactions of cytokines with their receptors in the regulation of hematopoiesis, clinical and diagnostic applications] Koubek K, et al. **Sb Lek** 1998;99(1):33–51 (54 ref.) (Eng. Abstr.) **(Cze)**

[Analysis of cytokine receptor function by gene manipulation] Taga T. **Nippon Rinsho** 1998 Jul; 56(7):1674–80 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Bone morphogenetic protein (BMP) receptors and signal transduction] Yamashita H, et al. **Nippon Rinsho** 1999 Jan; 57(1):220–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Soluble cytokine receptors: basic immunology and clinical applications. Fernandez-Botran R. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):165–224 (243 ref.)

RECEPTORS, CYTOPLASMIC AND NUCLEAR

see related
TRANSCRIPTION FACTORS

Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. Gonzalez FJ, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1702–9 (77 ref.)

[Current topics in the regulation of prostanoids--4. The feedback regulation by PPAR-gamma] Ohara M, et al. **Masui** 1999 Feb;48(2):146–51 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Lipid metabolism related nuclear receptor--the structure, function, expression and classification of peroxisome proliferation-activated receptor (PPAR)] Kawada T. **Nippon Rinsho** 1998 Jul;56(7):1722–8 (26 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

Melatonin. Mor M, et al. **Curr Med Chem** 1999 Jun; 6(6):501–18 (142 ref.)

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Fruchart JC, et al. **Curr Opin Lipidol** 1999 Jun;10(3):245–57 (99 ref.)

CHEMISTRY

Melatonin. Mor M, et al. **Curr Med Chem** 1999 Jun; 6(6):501–18 (142 ref.)

Generation and screening of synthetic receptor libraries. de Miguel YR, et al. **Curr Opin Chem Biol** 1998 Jun; 2(3):417–21 (30 ref.)

The LXRs: a new class of oxysterol receptors. Peet DJ, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):571–5 (37 ref.)

[Structure and function of melatonin receptors] Jockers R, et al. **C R Seances Soc Biol Fil** 1998;192(4):659–67 (12 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

New developments in the molecular pharmacology of the myo-inositol 1,4,5-trisphosphate receptor. Wilcox RA, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):467–75 (62 ref.)

GENETICS

Expression of nuclear hormone receptors in Escherichia coli. Mossakowska DE. **Curr Opin Biotechnol** 1998 Oct; 9(5):502–5 (29 ref.)

PPARgamma, the ultimate thrifty gene. Auwerx J. **Diabetologia** 1999 Sep;42(9):1033–49 (190 ref.)

Pluripotent PPARgamma polymorphisms. Berg JP. **Eur J Endocrinol** 1999 Apr;140(4):293–5 (17 ref.)

Rhizomelic chondrodysplasia punctata, a peroxisomal biogenesis disorder caused by defects in Pex7p, a peroxisomal protein import receptor: a minireview. Purdue PE, et al. **Neurochem Res** 1999 Apr;24(4):581–6 (43 ref.)

A genetic mutation in PPAR gamma is associated with enhanced fat cell differentiation: implications for human obesity. Freake HC. **Nutr Rev** 1999 May;57(5 Pt 1):154–6 (12 ref.)

METABOLISM

Nuclear receptors, their coactivators and modulation of transcription. Manteuffel-Cymborowska M. **Acta Biochim Pol** 1999;46(1):77–89 (90 ref.)

Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors. Wahli W, et al. **Adv Exp Med Biol** 1999;447:199–209 (40 ref.)

Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Bodenner DL, et al. **Am J Med** 1998 Dec;105(6):524–38 (80 ref.)

Inositol trisphosphate receptors: Ca2+-modulated intracellular Ca2+ channels. Taylor CW. **Biochim Biophys Acta** 1998 Dec 8;1436(1–2):19–33 (162 ref.)

Increasing the complexity of coactivation in nuclear receptor signaling. Freedman LP. **Cell** 1999 Apr 2;97(1):5–8 (22 ref.)

Melatonin: a chemical photoperiodic signal with clinical significance in humans. Pang SF, et al. **Chin Med J (Engl)** 1998 Mar;111(3):197–203 (69 ref.)

Therapeutic potential of selective modulators of nuclear receptor action. Resche-Rigon M, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):501–7 (57 ref.)

The nuclear receptor PPARgamma - bigger than fat. Kliewer SA, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):576–81 (50 ref.)

The LXRs: a new class of oxysterol receptors. Peet DJ, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):571–5 (37 ref.)

Coactivator and corepressor complexes in nuclear receptor function. Xu L, et al. **Curr Opin Genet Dev** 1999 Apr; 9(2):140–7 (57 ref.)

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151–9 (97 ref.)

Nuclear receptor coregulators: cellular and molecular biology. McKenna NJ, et al. **Endocr Rev** 1999 Jun; 20(3):321–44 (216 ref.)

Velcro in the nuclear envelope: LBR and LAPs. Chu A, et al. **FEBS Lett** 1998 Dec 18;441(2):165–9 (43 ref.)

Orphan nuclear receptors--new ligands and new possibilities. Blumberg B, et al. **Genes Dev** 1998 Oct 15;12(20):3149–55 (46 ref.)

Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. McKenna NJ, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):3–12 (92 ref.)

Human Ad4BP/SF-1 and its related nuclear receptor. Nawata H, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun; 69(1–6):323–8 (27 ref.)

Measurement of inositol(1,4,5)trisphosphate using a stereospecific radioreceptor mass assay. Smart D. **Methods Mol Biol** 1999;114:175–83 (11 ref.)

Measurement of Ca2+ flux through Ins(1,4,5)P3 receptor-Ca2+ channels in lipid bilayers ("dip-tip" and "Schindler" methodology). Thrower EC. **Methods Mol Biol** 1999;114:221–33 (19 ref.)

Isolation of the Ca2+ releasing component(s) of mammalian sperm extracts: the search continues. Fissore RA, et al. **Mol Hum Reprod** 1999 Mar;5(3):189–92 (57 ref.)

The role of oxysterols in cholesterol homeostasis. Wolf G. **Nutr Rev** 1999 Jun;57(6):196–8 (10 ref.)

The role of oxidized low-density lipoprotein in the activation of peroxisome proliferator-activated receptor gamma: implications for atherosclerosis. Wolf G. **Nutr Rev** 1999 Mar;57(3):88–91 (11 ref.)

Fatty acids, diacylglycerol, Ins(1,4,5)P3 receptors and Ca2+ influx. Kiselyov K, et al. **Trends Neurosci** 1999 Aug; 22(8):334–7 (57 ref.)

[Signaling by melatonin receptors] Petit L, et al. **Therapie** 1998 Sep–Oct;53(5):421–8 (55 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Waxman DJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):11–23 (128 ref.)

Protein-protein interactions in intracellular Ca2+-release channel function. MacKrill JJ. **Biochem J** 1999 Feb 1;337 (Pt 3):345–61 (220 ref.)

Melatonin receptors and signal transduction mechanisms. Barrett P, et al. **Biol Signals Recept** 1999 Jan–Apr; 8(1–2):6–14 (45 ref.)

Increasing the complexity of coactivation in nuclear receptor signaling. Freedman LP. **Cell** 1999 Apr 2;97(1):5–8 (22 ref.)

Nuclear orphan receptors control cholesterol catabolism. Russell DW. **Cell** 1999 May 28;97(5):539–42 (17 ref.)

Molecular properties of inositol 1,4,5-trisphosphate receptors. Patel S, et al. **Cell Calcium** 1999 Mar; 25(3):247–64 (186 ref.)

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Gelman L, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):932–43 (141 ref.)

Inositol 1,3,4,5-tetrakisphosphate as a second messenger--a special role in neurones? Irvine RF, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):49–57 (50 ref.)

Cell surface receptors, nuclear receptors and ligands that regulate adipose tissue development. Ailhaud G. **Clin Chim Acta** 1999 Aug;286(1–2):181–90 (36 ref.)

Peroxisome proliferator-activated receptors: mediators of a fast food impact on gene regulation. Gelman L, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):307–12 (72 ref.)

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151–9 (97 ref.)

PPARgamma, the ultimate thrifty gene. Auwerx J. **Diabetologia** 1999 Sep;42(9):1033–49 (190 ref.)

PPARgamma: from adipose tissue to the atherosclerotic plaque. Lopez-Liuchi JV, et al. **Eur J Endocrinol** 1998 Oct; 139(4):363–4 (9 ref.)

Chloroplast precursor protein translocon. May T, et al. **FEBS Lett** 1999 Jun 4;452(1–2):52–6 (53 ref.)

A gut check for PPARgamma [editorial; comment] Wu GD, et al. **Gastroenterology** 1998 Nov;115(5):1283–5 (48 ref.) Comment on: Gastroenterology 1998 Nov;115(5):1049–55.

Orphan nuclear receptors--new ligands and new possibilities. Blumberg B, et al. **Genes Dev** 1998 Oct 15;12(20):3149–55 (46 ref.)

Modulating nuclear receptor function: may the phos be with you. Shao D, et al. **J Clin Invest** 1999 Jun;103(12):1617–8 (28 ref.)

Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. Holden PR, et al. **J Mol Endocrinol** 1999 Feb;22(1):1–8 (70 ref.)

Germ cell nuclear factor: an orphan receptor with unexpected properties. Greschik H, et al. **J Mol Med** 1998 Nov–Dec;76(12):800–10 (75 ref.)

Type 1 inositol 1,4,5-trisphosphate receptor knock-out mice: their phenotypes and their meaning in neuroscience and clinical practice. Matsumoto M, et al. **J Mol Med** 1999 May;77(5):406–11 (36 ref.)

Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. Vanden Heuvel JP. **J Nutr** 1999 Feb;129(2S Suppl):575S–580S (60 ref.)

Medical significance of peroxisome proliferator-activated receptors. Vamecq J, et al. **Lancet** 1999 Jul 10; 354(9173):141–8 (55 ref.)

Roles of lipid-activated receptors in the adipogenic action of fatty acids. Grimaldi PA. **Lipids** 1999;34 Suppl:S205–8 (23 ref.)

Dietary polyunsaturated fatty acids and hepatic gene expression. Jump DB, et al. **Lipids** 1999;34 Suppl:S209–12 (25 ref.)

Coactivators and corepressors as mediators of nuclear receptor function: an update. Jenster G. **Mol Cell Endocrinol** 1998 Aug 25;143(1–2):1–7 (68 ref.)

Orphan nuclear receptors: shifting endocrinology into reverse. Kliewer SA, et al. **Science** 1999 Apr 30; 284(5415):757–60 (37 ref.)

Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Hertz R, et al. **Toxicol Lett** 1998 Dec 28;102–103:85–90 (40 ref.)

Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. James NH, et al. **Toxicol Lett** 1998 Dec 28;102–103:91–6 (40 ref.)

Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Vanden Heuvel JP. **Toxicol Sci** 1999 Jan; 47(1):1–8 (72 ref.)

[Structure and function of melatonin receptors] Jockers R, et al. **C R Seances Soc Biol Fil** 1998;192(4):659–67 (12 ref.) (Eng. Abstr.) **(Fre)**

[Nuclear receptors] Milgrom E. **Therapie** 1999 May–Jun; 54(3):327–31 (37 ref.) (Eng. Abstr.) **(Fre)**

[Ca+ metabolism in the sarcoplasmic reticulum and the role of ryanodine and IP3 receptors in the nervous system] Nagata E, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2522–9 (30 ref.) **(Jpn)**

[Endocrine signaling system mediated by nuclear receptors] Umesono K. **Nippon Rinsho** 1998 Jul;56(7):1693–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

[IP3 receptor] Mikoshiba K, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1596–602 (40 ref.) **(Jpn)**

RECEPTORS, DELTA see **RECEPTORS, OPIOID, DELTA**

RECEPTORS, DELTA OPIOID see **RECEPTORS, OPIOID, DELTA**

RECEPTORS, DIAZEPAM see **RECEPTORS, GABA-A**

RECEPTORS, DIIODOTYROSINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, DIOXIN see **RECEPTORS, ARYL HYDROCARBON**

RECEPTORS, DOPAMINE

ANALYSIS

Receptor imaging in the diagnosis and treatment of pituitary tumors. Kwekkeboom DJ, et al. **J Endocrinol Invest** 1999

Jan;22(1):80–8 (63 ref.)

DRUG EFFECTS

Mechanisms of action of anti-psychotic drugs. Strange PG. **Biochem Soc Trans** 1999 Feb;27(2):175–8 (27 ref.)

Ergoline derivatives: receptor affinity and selectivity. Mantegani S, et al. **Farmaco** 1999 May 30;54(5):288–96 (15 ref.)

Pharmacological differentiation of classical and novel antipsychotics. Arnt J. **Int Clin Psychopharmacol** 1998 Mar; 13 Suppl 3:S7–14 (46 ref.)

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington G, et al. **J Clin Psychiatry** 1999;60 Suppl 10:15–9 (50 ref.)

Evolutionary game theory and multiple chemical sensitivity. Newlin DB. **Toxicol Ind Health** 1999 Apr–Jun; 15(3–4):313–22 (56 ref.)

[How do antipsychotics exert their effects on dopamine receptor subtypes?] Inoue A, et al. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):351–61 (46 ref.) (Eng. Abstr.) **(Jpn)**

[Functional role and pharmacological regulation of the dopaminergic system of the brain] Raevskii KS. **Vestn Ross Akad Med Nauk** 1998;(8):19–24 (34 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

New insights into dopaminergic receptor function using antisense and genetically altered animals. Sibley DR. **Annu Rev Pharmacol Toxicol** 1999;39:313–41 (96 ref.)

METABOLISM

Bioisosteric approach in the design of new dopaminergic/serotonergic ligands. Soskić V, et al. **Curr Med Chem** 1998 Dec;5(6):493–512 (102 ref.)

PHYSIOLOGY

New insights into dopaminergic receptor function using antisense and genetically altered animals. Sibley DR. **Annu Rev Pharmacol Toxicol** 1999;39:313–41 (96 ref.)

Role of dopamine in the pathogenesis of hypertension. Jose PA, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr; 26:S10–3 (63 ref.)

N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Adriani W, et al. **Exp Brain Res** 1998 Nov; 123(1–2):52–9 (55 ref.)

Developmental pharmacodynamics: implications for child and adolescent psychopharmacology. Carrey N, et al. **J Psychiatry Neurosci** 1998 Nov;23(5):274–6 (16 ref.)

Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Greengard P, et al. **Neuron** 1999 Jul;23(3):435–47 (89 ref.)

Renal dopamine receptors in health and hypertension. Jose PA, et al. **Pharmacol Ther** 1998 Nov;80(2):149–82 (477 ref.)

Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system. Kostrzewa RM, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):39–47 (84 ref.)

PET measurements of dopaminergic pathways in the brain. Perlmutter JS, et al. **Q J Nucl Med** 1999 Jun;43(2):140–54 (158 ref.)

[Anhedonia--a general nosology surmounting correlate of a dysfunctional dopaminergic reward system?] Heinz A. **Nervenarzt** 1999 May;70(5):391–8 (94 ref.) (Eng. Abstr.) **(Ger)**

[Functional role and pharmacological regulation of the dopaminergic system of the brain] Raevskii KS. **Vestn Ross Akad Med Nauk** 1998;(8):19–24 (34 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, DOPAMINE D1

AGONISTS

Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Ahlenius S. **Pharmacol Toxicol** 1999 May;84(5):193–6 (39 ref.)

DRUG EFFECTS

Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors. Sutton MA, et al. **Psychopharmacology (Berl)** 1999 May; 144(2):95–110 (130 ref.)

METABOLISM

Coupling of D1 and D5 dopamine receptors to multiple G proteins: Implications for understanding the diversity in receptor-G protein coupling. Sidhu A. **Mol Neurobiol** 1998 Apr;16(2):125–34 (52 ref.)

In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters. Bloch B, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):315–9 (44 ref.)

PHYSIOLOGY

Neural substrates of drug craving and relapse in drug addiction. Self DW. **Ann Med** 1998 Aug;30(4):379–89 (93 ref.)

Renal dopamine receptor signaling mechanisms in spontaneously hypertensive and Fischer 344 old rats. Hussain T, et al. **Clin Exp Hypertens** 1999 Jan–Feb; 21(1–2):25–36 (51 ref.)

RECEPTORS, DOPAMINE D2

AGONISTS

Treating and preventing levodopa-induced dyskinesias: current and future strategies. Durif F. **Drugs Aging** 1999 May;14(5):337–45 (49 ref.)

D-3 receptor agonists: combined action neurologic and neuropsychiatric agents [editorial; comment] Cummings JL. **J Neurol Sci** 1999 Feb 1;163(1):2–3 (17 ref.) Comment on: J Neurol Sci 1999 Feb 1;163(1):25–31.

ANTAGONISTS & INHIBITORS

Adverse reactions to antinauseants in common use in the UK. Soukop M. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep; 17(2–3):91–113 (57 ref.)

The discovery of potent and selective dopamine D4 receptor antagonists. Faraci WS, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):535–40 (27 ref.)

DRUG EFFECTS

Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Dixon DA, et al. **Ann Pharmacother** 1999 Apr;33(4):480–8 (94 ref.)

Implications of brain imaging for the management of schizophrenia. Nyberg S, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S15–20 (52 ref.)

GENETICS

Attention deficit hyperactivity disorder: unravelling the molecular genetics [editorial; comment] Thapar A. **Mol Psychiatry** 1998 Sep;3(5):370–2 (13 ref.) Comment on: Mol Psychiatry 1998 Sep;3(5):386–96. Comment on: Mol Psychiatry 1998 Sep;3(5):419–26. Comment on: Mol Psychiatry 1998 Sep;3(5):427–30. Comment on: Mol Psychiatry 1998 Sep;3(5):431–4.

Dopamine D4 receptor gene: novelty or nonsense? Paterson AD, et al. **Neuropsychopharmacology** 1999 Jul;21(1):3–16 (90 ref.)

Vitamin A functions in the regulation of the dopaminergic system in the brain and pituitary gland. Wolf G. **Nutr Rev** 1998 Dec;56(12):354–5 (12 ref.)

Biological research on schizophrenia. Toru M. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S170–2 (28 ref.)

METABOLISM

Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Booij J, et al. **Eur J Nucl Med** 1999 Feb;26(2):171–82 (132 ref.)

Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Wilson JM, et al. **Eur J Pharmacol** 1998 Jun 26;351(3):273–86 (130 ref.)

Application of gene therapy to treat age-related loss of dopamine D2 receptor. Ingram DK, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):793–804 (33 ref.)

PHYSIOLOGY

Neural substrates of drug craving and relapse in drug addiction. Self DW. **Ann Med** 1998 Aug;30(4):379–89 (93 ref.)

D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Joyce JN, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:595–613 (61 ref.)

Agonism and inverse agonism at dopamine D2-like receptors. Strange PG. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr; 26:S3–9 (36 ref.)

RECEPTORS, DRUG

[2-Arachidonoylglycerol: an endogenous cannabinoid receptor agonist] Sugiura T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1104–10 (28 ref.) **(Jpn)**

AGONISTS

alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Khan ZP, et al. **Anaesthesia** 1999 Feb;54(2):146–65 (215 ref.)

Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:420–9 (33 ref.)

ANALYSIS

Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods. Escribá PV, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:8–25 (36 ref.)

Imidazoline binding sites and receptors in cardiovascular tissue. Molderings GJ, et al. **Gen Pharmacol** 1999 Jan; 32(1):17–22 (53 ref.)

Presence and functional regulation of cannabinoid receptors in immune cells. Parolaro D. **Life Sci** 1999;65(6–7):637–44 (63 ref.)

Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Pertwee RG. **Life Sci** 1999;65(6–7):597–605 (54 ref.)

ANTAGONISTS & INHIBITORS

The development of cannabinoid antagonists. Barth F, et al. **Curr Med Chem** 1999 Aug;6(8):745–55 (74 ref.)

CHEMISTRY

Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges. Reggio PH. **Curr Med Chem** 1999 Aug; 6(8):665–83 (141 ref.)

Generation and screening of synthetic receptor libraries. de Miguel YR, et al. **Curr Opin Chem Biol** 1998 Jun; 2(3):417–21 (30 ref.)

Host-guest chemistry: combinatorial receptors. Linton B, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):307–12 (30 ref.)

Methods of screening combinatorial libraries using immobilized or restrained receptors. Woodbury CP Jr, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 2; 725(1):113–37 (111 ref.)

(Extra)thermodynamics of the drug-receptor interaction. Raffa RB. **Life Sci** 1999;65(10):967–80 (29 ref.)

CLASSIFICATION

Presynaptic imidazoline receptors. New developments in characterization and classification. Göthert M, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:171–84 (21 ref.)

DRUG EFFECTS

Pharmacology of cannabinoid receptor ligands. Pertwee RG. **Curr Med Chem** 1999 Aug;6(8):635–64 (171 ref.)

Cannabis and endogenous cannabinoid systems. Childers SR, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):173–87 (165 ref.)

Does a second generation of centrally acting antihypertensive drugs really exist? Feldman J, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):94–7 (42 ref.)

Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. Head GA, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):163–9 (40 ref.)

Approaches to proving there are general anesthetic sites on ligand gated ion channels. Miller KW, et al. **Toxicol Lett** 1998 Nov 23;100–101:139–47 (30 ref.)

Influence of anesthetics on endogenous and recombinantly expressed G protein-coupled receptors in the Xenopus oocyte. Nietgen GW, et al. **Toxicol Lett** 1998 Nov 23; 100–101:319–27 (28 ref.)

A quantitative genetic approach towards volatile anesthetic mechanisms in C. elegans. van Swinderen B, et al. **Toxicol Lett** 1998 Nov 23;100–101:309–17 (21 ref.)

Unifying characteristics of sites of anesthetic action revealed by combined use of anesthetics and non-anesthetics. Xu Y, et al. **Toxicol Lett** 1998 Nov 23;100–101:347–52 (17 ref.)

[Clinical pharmacology of hypotensive drugs acting on central imidazoline receptors] Drzewoski J, et al. **Pol Arch Med Wewn** 1998 Dec;100(6):561–9 (35 ref.) **(Pol)**

GENETICS

Molecular genetics of substance abuse vulnerability: a current approach. Uhl GR. **Neuropsychopharmacology** 1999 Jan; 20(1):3–9 (35 ref.)

Genetic dissection of the molecular target(s) of anesthetics with the gene knockout approach in mice. Homanics GE, et al. **Toxicol Lett** 1998 Nov 23;100–101:301–7 (18 ref.)

A quantitative genetic approach towards volatile anesthetic mechanisms in C. elegans. van Swinderen B, et al. **Toxicol Lett** 1998 Nov 23;100–101:309–17 (21 ref.)

METABOLISM

Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods. Escribá PV, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:8–25 (36 ref.)

Imidazoline receptors and human brain disorders. García-Sevilla JA, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:392–409 (45 ref.)

Imidazoline binding domains on MAO-B. Localization and accessibility. Raddatz R, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:26–31 (17 ref.)

Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Reis DJ, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:65–80 (54 ref.)

Imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts). Farsang C, et al. **Brain Res Bull** 1999 Jul 15;49(5):317–31 (241 ref.)

Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. Reis DJ, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):80–5 (26 ref.)

I1-imidazoline receptors: an update. Bousquet P, et al. **J Hypertens Suppl** 1998 Aug;16(3):S1–5 (55 ref.)

RECEPTORS, DRUG

High blood pressure management: potential benefits of I1 agents. Esler M. **J Hypertens Suppl** 1998 Aug;16(3):S19–24 (47 ref.)
A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. Ueda N, et al. **J Med Invest** 1998 Aug;45(1–4):27–36 (54 ref.)
The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Valk PJ, et al. **Leuk Lymphoma** 1998 Dec; 32(1–2):29–43 (108 ref.)
Signal transduction of eicosanoid CB1 receptor ligands. Howlett AC, et al. **Life Sci** 1999;65(6–7):617–25 (32 ref.)
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Shire D, et al. **Life Sci** 1999; 65(6–7):627–35 (35 ref.)
Characterization of imidazoline receptors by radioligand binding. Hudson AL, et al. **Methods Mol Biol** 1999; 106:37–47 (12 ref.)
Biochemistry of the endogenous ligands of cannabinoid receptors. Di Marzo V, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):386–404 (123 ref.)
The CB1 cannabinoid receptor in the brain. Howlett AC. **Neurobiol Dis** 1998 Dec;5(6 Pt B):405–16 (60 ref.)
The neurobiology of cannabinoid transmission: from anandamide signaling to higher cerebral functions and disease. Navarro M, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):379–85 (48 ref.)
Vanilloid (Capsaicin) receptors and mechanisms. Szallasi A, et al. **Pharmacol Rev** 1999 Jun;51(2):159–212 (598 ref.)
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action [published erratum appears in Trends Neurosci 1999 Feb;22(2):80] Di Marzo V, et al. **Trends Neurosci** 1998 Dec;21(12):521–8 (80 ref.)

PHYSIOLOGY

Participation of imidazoline receptors and alpha(2–)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs. Bousquet P, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:272–8 (19 ref.)
The I1-imidazoline receptor and its cellular signaling pathways. Ernsberger P. **Ann N Y Acad Sci** 1999 Jun 21; 881:35–53 (86 ref.)
Presynaptic imidazoline receptors. New developments in characterization and classification. Göthert M, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:171–84 (21 ref.)
Imidazoline recognition sites and stomach function. Molderings GJ, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:332–43 (56 ref.)
Imidazolines and pancreatic hormone secretion. Morgan NG, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:217–28 (41 ref.)
Novel targets and techniques in imidazoline receptor research. Musgrave IF, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:301–12 (51 ref.)
Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Smyth DD, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:344–57 (72 ref.)
Recent advances in imidazoline receptor research: ligands—localization and isolation—signaling—functional and clinical studies. Head GA, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):74–9 (50 ref.)
Presence and functional regulation of cannabinoid receptors in immune cells. Parolaro D. **Life Sci** 1999;65(6–7):637–44 (63 ref.)
The functional neuroanatomy of brain cannabinoid receptors. Breivogel CS, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):417–31 (120 ref.)
Brain cannabinoid systems as targets for the therapy of neurological disorders. Consroe P. **Neurobiol Dis** 1998 Dec; 5(6 Pt B):534–51 (159 ref.)
Cannabinoid transmission and reward-related events. Gardner EL, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):502–33 (314 ref.)
Role of cannabinoid receptors in memory storage. Hampson RE, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):474–82 (72 ref.)
Cannabinoid transmission and pain perception. Martin BR, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):447–61 (131 ref.)
Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Murphy LL, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):432–46 (126 ref.)
Endogenous cannabinoid signaling. Piomelli D, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):462–73 (79 ref.)
Role of the endogenous cannabinoid system in the regulation of motor activity. Rodríguez de Fonseca F, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):483–501 (130 ref.)
Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. Kaminski NE. **Toxicol Lett** 1998 Dec 28;102–103:59–63 (26 ref.)

RECEPTORS, EICOSANOID

METABOLISM

A 12(S)-HETE receptor in Lewis lung carcinoma cells. Herbertsson H, et al. **Adv Exp Med Biol** 1999;447:193–8 (24 ref.)

RECEPTORS, ENDOGENOUS SUBSTANCES see **RECEPTORS, CELL SURFACE**

RECEPTORS, ENDORPHIN see **RECEPTORS, OPIOID**

RECEPTORS, ENDOTHELIN

ANTAGONISTS & INHIBITORS

Endothelin in hypertension: a role for receptor antagonists? Moreau P. **Cardiovasc Res** 1998 Sep;39(3):534–42 (81 ref.)
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Rabelink TJ, et al. **Cardiovasc Res** 1998 Sep;39(3):543–9 (102 ref.)
Investigations of structural requirements for endothelin antagonism. van der Walle CF, et al. **Curr Med Chem** 1998 Aug;5(4):321–35 (78 ref.)
Endothelin antagonists. Benigni A, et al. **Lancet** 1999 Jan 9;353(9147):133–8 (87 ref.)
Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo JE, et al. **Neurosurgery** 1998 Dec;43(6):1409–17; discussion 1417–8 (95 ref.)
Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Doherty AM, et al. **Pharm Biotechnol** 1998;11:81–112 (126 ref.)
Endothelin receptor antagonists. Elliott JD, et al. **Pharm Biotechnol** 1998;11:113–29 (37 ref.)
Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Kirchengast M, et al. **Proc Soc Exp Biol Med** 1999 Sep;221(4):312–25 (118 ref.)
Blocking of the endothelin system: the development of receptor antagonists. Battistini B, et al. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):97–112 (137 ref.)
Heart failure and endothelin receptor antagonists. Miyauchi T, et al. **Trends Pharmacol Sci** 1999 May;20(5):210–7 (89 ref.)
[Endothelins in chronic cardiac insufficiency] Pousset F. **Arch Mal Coeur Vaiss** 1998 Dec;91(12 Suppl):23–6 (23 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Structural basis of the function of endothelin receptor. Masaki T, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):153–6 (29 ref.)

CLASSIFICATION

Endothelin receptor subtypes: distribution and function in the lung. Goldie RG. **Pulm Pharmacol Ther** 1998 Apr–Jun; 11(2–3):89–95 (103 ref.)

GENETICS

Genetic aspects of Hirschsprung's disease. Kusafuka T, et al. **Semin Pediatr Surg** 1998 Aug;7(3):148–55 (97 ref.)
[Endothelin B receptor system and Hirschsprung disease] Inoue M, et al. **Nippon Rinsho** 1998 Jul;56(7):1876–80 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Endothelin receptor distribution and function in the airways. Henry PJ. **Clin Exp Pharmacol Physiol** 1999 Feb; 26(2):162–7 (51 ref.)
Subcellular mechanisms of endothelin action in vascular system. Masaki T, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):133–8 (38 ref.)

PHYSIOLOGY

Endothelins in health and disease: an overview. Goldie RG. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):145–8 (35 ref.)
Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Zhuo J, et al. **Kidney Int Suppl** 1998 Sep;67:S22–8 (29 ref.)
Structural basis of the function of endothelin receptor. Masaki T, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):153–6 (29 ref.)
Endothelin and the airway mucosa. Baraniuk JN, et al. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):113–23 (102 ref.)
Endothelin-1: an interesting peptide or an important mediator in pulmonary diseases? Hay DW. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):141–6 (75 ref.)
Endothelin-1: a mediator of pulmonary hypertension? MacLean MR. **Pulm Pharmacol Ther** 1998 Apr–Jun; 11(2–3):125–32 (95 ref.)
[Endothelin-1 and cardiovascular diseases] Cracowski JL, et al. **Rev Med Interne** 1999 Jul;20(7):589–96 (58 ref.) (Eng. Abstr.) **(Fre)**
[Endothelin receptor/physiological role] Abe Y, et al. **Nippon Rinsho** 1998 Jul;56(7):1898–905 (49 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, ENDOTHELIUM-DERIVED VASOCONSTRICTOR FACTOR see **RECEPTORS, ENDOTHELIN**

RECEPTORS, ENKEPHALIN see **RECEPTORS, OPIOID**

RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

ANALYSIS

The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Gullick WJ, et al. **Breast Cancer Res Treat** 1998;52(1–3):43–53 (46 ref.)

ANTAGONISTS & INHIBITORS

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Mendelsohn J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2703–7 (48 ref.)
The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Bridges AJ. **Curr Med Chem** 1999 Sep;6(9):825–43 (122 ref.)

IMMUNOLOGY

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Mendelsohn J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2703–7 (48 ref.)
Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Wheeler RH, et al. **Curr Opin Oncol** 1999 May;11(3):187–90 (40 ref.)

METABOLISM

Lymphocyte antigen receptor signal integration and regulation by the SHC adaptor. Baldari CT, et al. **Biol Chem** 1999 Feb;380(2):129–34 (42 ref.)
Twin peaks: Spitz and Argos star in patterning of the Drosophila egg [comment] Stevens L. **Cell** 1998 Oct 30; 95(3):291–4 (16 ref.) Comment on: Cell 1998 Oct 30;95(3):355–64.
Complexity of EGF receptor signalling revealed in Drosophila. Freeman M. **Curr Opin Genet Dev** 1998 Aug; 8(4):407–11 (46 ref.)
EGF receptor signaling in Drosophila oogenesis. Nilson LA, et al. **Curr Top Dev Biol** 1999;44:203–43 (143 ref.)
Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Yamauchi T, et al. **Endocr J** 1998 Apr;45 Suppl:S27–31 (25 ref.)
Take your partners, please—signal diversification by the erbB family of receptor tyrosine kinases. Daly RJ. **Growth Factors** 1999;16(4):255–63 (70 ref.)
EGF receptor. Wells A. **Int J Biochem Cell Biol** 1999 Jun; 31(6):637–43 (15 ref.)
Versatility in signalling: multiple responses to EGF receptor activation during Drosophila oogenesis. Van Buskirk C, et al. **Trends Cell Biol** 1999 Jan;9(1):1–4 (31 ref.)
[Signal transduction mechanisms induced by epidermal growth factor receptor (EGFR) and their role in apoptosis regulation] Oldak M, et al. **Postepy Hig Med Dosw** 1999; 53(2):315–29 (78 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

The epidermal growth factor receptor and its ligand family: their potential role in repair and remodelling in asthma. Davies DE, et al. **Allergy** 1999 Aug;54(8):771–83 (132 ref.)
Multiple functions of the EGF receptor in Drosophila eye development. Dominguez M, et al. **Curr Biol** 1998 Sep 24; 8(19):1039–48 (46 ref.)
Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Hackel PO, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):184–9 (65 ref.)
Multiple positive and negative regulators of signaling by the EGF-receptor. Moghal N, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):190–6 (64 ref.)
Ontogeny of EGF receptors in the human gut. Chailler P, et al. **Front Biosci** 1999 Jan 15;4:D87–101 (193 ref.)
Epidermal growth factor receptor (EGFR) biology and human oral cancer. Todd R, et al. **Histol Histopathol** 1999 Apr;14(2):491–500 (107 ref.)
Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. Carpenter G. **J Cell Biol** 1999 Aug 23;146(4):697–702 (61 ref.)
The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. Tarnawski AS, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S12–20 (63 ref.)
Contributions of the epidermal growth factor receptor to keratinocyte motility. Hudson LG, et al. **Microsc Res Tech** 1998 Dec 1;43(5):444–55 (140 ref.)
[Epidermal growth factor receptors in breast neoplasms: from experiment to the clinical use] Kushlinskii NE, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):485–96 (91 ref.) **(Rus)**

RECEPTORS, EPINEPHRINE see **RECEPTORS, ADRENERGIC**

RECEPTORS, ERYTHROPOIETIN

PHYSIOLOGY

Erythropoietin receptor and hematological disease. McMullin MF, et al. **Am J Hematol** 1999 Jan;60(1):55–60

(71 ref.)
The molecular physiology of erythropoietin and the erythropoietin receptor. Zhu Y, et al. **Curr Opin Hematol** 1994 Mar;1(2):113–8 (39 ref.)
Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Masuda S, et al. **Int J Hematol** 1999 Jul;70(1):1–6 (62 ref.)

RECEPTORS, ESTROGEN

Steroid hormone receptors in breast cancer management. Osborne CK. **Breast Cancer Res Treat** 1998;51(3):227–38 (76 ref.)
Estrogen receptor–beta: implications for the prostate gland. Chang WY, et al. **Prostate** 1999 Jul 1;40(2):115–24 (63 ref.)
Oestrogen receptor beta (ER beta). Saunders PT. **Rev Reprod** 1998 Sep;3(3):164–71 (46 ref.)

AGONISTS

Selective estrogen receptor modulators (SERMs). Grese TA, et al. **Curr Pharm Des** 1998 Feb;4(1):71–92 (183 ref.)
Selective estrogen receptor modulators: clinical spectrum. Cosman F, et al. **Endocr Rev** 1999 Jun;20(3):418–34 (179 ref.)
[Action of SERM and SAS (tibolone) on breast tissue] Gompel A, et al. **Contracept Fertil Sex** 1999 May; 27(5):368–75 (25 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Paraffin section immunocytochemistry and cytosol–based ligand–binding assays for ER and PR detection in breast cancer: the time has come for more objectivity. Goussard J. **Cancer Lett** 1998 Oct 23;132(1–2):61–6 (27 ref.)
[Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast] Nizze H, et al. **Zentralbl Chir** 1998;123 Suppl 5:14–8 (46 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Selective estrogen receptor modulators (SERMs). Grese TA, et al. **Curr Pharm Des** 1998 Feb;4(1):71–92 (183 ref.)
An estrogen receptor basis for raloxifene action in bone. Bryant HU, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):37–44 (34 ref.)
[Action of SERM and SAS (tibolone) on breast tissue] Gompel A, et al. **Contracept Fertil Sex** 1999 May; 27(5):368–75 (25 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Selective estrogen receptor modulators and postmenopausal women's health: the promise for the next millennium [editorial] Agnusdei D. **Aging (Milano)** 1998 Aug; 10(4):269–72 (26 ref.)
Raloxifene: a selective estrogen receptor modulator [see comments] Scott JA, et al. **Am Fam Physician** 1999 Sep 15;60(4):1131–9 (27 ref.) Comment in: Am Fam Physician 1999 Sep 15;60(4):1092, 1095.
Selective estrogen receptor modulators: Women's panacea for the next millennium? Spencer CP, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):763–70 (120 ref.)
Clinical use of selective estrogen receptor modulators. Delmas PD. **Bone** 1999 Jul;25(1):115–8 (31 ref.)
Estrogens and atherosclerosis: phytoestrogens and selective estrogen receptor modulators. St Clair RW. **Curr Opin Lipidol** 1998 Oct;9(5):457–63 (101 ref.)
Clinical pharmacology of selective estrogen receptor modulators. Haynes B, et al. **Drugs Aging** 1999 May; 14(5):323–36 (168 ref.)
Phytoestrogens: the "natural" selective estrogen receptor modulators? Brzezinski A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):47–51 (33 ref.)
Estrogen receptor as a target for the prevention of breast cancer. Jordan VC. **J Lab Clin Med** 1999 May; 133(5):408–14 (44 ref.)
Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health. Curtis MG. **J Womens Health** 1999 Apr;8(3):321–33 (151 ref.)
Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women. Fitzpatrick LA. **Mayo Clin Proc** 1999 Jun;74(6):601–7 (22 ref.)
[Estrogen receptor and selective estrogen receptor modulators (SERMs)] Shioi A, et al. **Nippon Rinsho** 1999 May;57(5):1199–207 (19 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Reproductive phenotypes in the estrogen receptor–alpha knockout mouse. Couse JF, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):143–8 (51 ref.)
Sex with knockout models: behavioral studies of estrogen receptor alpha. Rissman EF, et al. **Brain Res** 1999 Jul 17; 835(1):80–90 (88 ref.)
Methyl–deficient diets, methylated ER genes and breast cancer: an hypothesized association. Zhu K, et al. **Cancer Causes Control** 1998 Dec;9(6):615–20 (58 ref.)
The estrogen receptor family. Warner M, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):249–54 (50 ref.)
Estrogen receptor mutations. Taylor JA, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):61–6 (59 ref.)
Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer. Iwase H, et al. **Oncology** 1998 Dec;55 Suppl 1:11–6 (39 ref.)

METABOLISM

Evidence for plasma membrane–mediated effects of estrogen [editorial] Brubaker KD, et al. **Calcif Tissue Int** 1999 Jun; 64(6):459–62 (57 ref.)
Therapeutic potential of selective estrogen receptor modulators. Gustafsson JA. **Curr Opin Chem Biol** 1998 Aug;2(4):508–11 (27 ref.)
The estrogen receptor family. Warner M, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):249–54 (50 ref.)
Selective estrogen receptor modulators. Weryha G, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):301–6 (49 ref.)
Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Barnes DM, et al. **Eur J Cancer** 1998 Oct;34(11):1677–82 (28 ref.)
Oestrogen receptors – an overview. Enmark E, et al. **J Intern Med** 1999 Aug;246(2):133–8 (29 ref.)
Estrogen receptor immunoreactivity in Schwann–like brain macroglia. Gudiño–Cabrera G, et al. **J Neurobiol** 1999 Sep 15;40(4):458–70 (106 ref.)

PHYSIOLOGY

Sex with knockout models: behavioral studies of estrogen receptor alpha. Rissman EF, et al. **Brain Res** 1999 Jul 17; 835(1):80–90 (88 ref.)
Selective estrogen receptor modulators: a look ahead. Mitlak BH, et al. **Drugs** 1999 May;57(5):653–63 (82 ref.)
Selective estrogen receptor modulators: clinical spectrum. Cosman F, et al. **Endocr Rev** 1999 Jun;20(3):418–34 (179 ref.)
Estrogen receptor null mice: what have we learned and where will they lead us? [published erratum appears in Endocr Rev 1999 Aug;20(4):459] Couse JF, et al. **Endocr Rev** 1999 Jun;20(3):358–417 (511 ref.)
The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Kuiper GG, et al. **Front Neuroendocrinol** 1998 Oct;19(4):253–86 (170 ref.)
Endometrial oestrogen and progesterone receptors and their relationship to sonographic appearance of the endometrium. Ohno Y, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):560–4 (17 ref.)
Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity. Hilakivi–Clarke L, et al. **Mol Cell Biochem** 1998 Nov; 188(1–2):5–12 (82 ref.)
The role of estrogen in folliculogenesis. Drummond AE, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):57–64 (45 ref.)
Estrogen receptor mutations. Taylor JA, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):61–6 (59 ref.)
[Estrogen–induced genes in breast cancer, and their medical importance] Rochefort H. **Bull Acad Natl Med** 1999; 183(5):955–68; discussion 968–71 (29 ref.) (Eng. Abstr.) **(Fre)**
[Effect of estrogens on arterial physiology and mechanisms of their atherosclerosis–protective effect in animals] Arnal JF, et al. **Therapie** 1999 May–Jun;54(3):339–46 (58 ref.) (Eng. Abstr.) **(Fre)**
[Nuclear receptors] Milgrom E. **Therapie** 1999 May–Jun; 54(3):327–31 (37 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, EXCITATORY AMINO ACID see **RECEPTORS, GLUTAMATE**

RECEPTORS, FC

IMMUNOLOGY

FcR–mediated inhibition of cell activation and other forms of coinhibition. Anderson CC, et al. **Crit Rev Immunol** 1998; 18(6):525–44 (131 ref.)
[Fc receptor redux: the role of immunoglobulin receptor (FcR) in glomerulonephritis] Ra C, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1568–76 (19 ref.) **(Jpn)**

RECEPTORS, FC EPSILON see **RECEPTORS, IGE**

RECEPTORS, FC GAMMA see **RECEPTORS, IGG**

RECEPTORS, FGF see **RECEPTORS, FIBROBLAST GROWTH FACTOR**

RECEPTORS, FIBRINOGEN see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

RECEPTORS, FIBROBLAST GROWTH FACTOR

CHEMISTRY

Structure and activation of the large latent transforming growth factor–Beta complex. Nunes I, et al. **J Am Optom Assoc** 1998 Oct;69(10):643–8 (45 ref.)

GENETICS

Not Antley–Bixler syndrome [letter; comment] Gripp KW, et al. **Am J Med Genet** 1999 Mar 5;83(1):65–8 (13 ref.) Comment on: Am J Med Genet 1998 May 18;77(3):219–24.
Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1998 Dec;27(6):451–5 (28 ref.)

METABOLISM

Receptor tyrosine phosphatases: the worm clears the picture. Zinn K. **Curr Biol** 1998 Oct 8;8(20):R725–6 (9 ref.)
Structure and activation of the large latent transforming growth factor–Beta complex. Nunes I, et al. **J Am Optom Assoc** 1998 Oct;69(10):643–8 (45 ref.)

PHYSIOLOGY

How tumor cells make use of CD44. Herrlich P, et al. **Cell Adhes Commun** 1998;6(2–3):141–7 (52 ref.)
Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Xu X, et al. **Cell Tissue Res** 1999 Apr;296(1):33–43 (102 ref.)
Signal transduction by fibroblast growth factor receptors. Klint P, et al. **Front Biosci** 1999 Feb 15;4:D165–77 (123 ref.)
Syndecan–3 in limb skeletal development. Kosher RA. **Microsc Res Tech** 1998 Oct 15;43(2):123–30 (97 ref.)

RECEPTORS, FOLLICLE–STIMULATING HORMONE see **RECEPTORS, FSH**

RECEPTORS, FSH

Gonadotropin receptors. Hai MV, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):89–92 (24 ref.)

AGONISTS

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36–46; discussion 47–51 (47 ref.)

CHEMISTRY

Structure–function relationship of follicle–stimulating hormone and its receptor. Ulloa–Aguirre A, et al. **Hum Reprod Update** 1998 May–Jun;4(3):260–83 (263 ref.)

GENETICS

[Activating mutations of the gonadotrophin receptors] Beck–Peccoz P, et al. **Arch Pediatr** 1998;5 Suppl 4:380S–384S (17 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Inactivating FSH receptor mutations and gonadal dysfunction. Tapanainen JS, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):129–35 (54 ref.)

PHYSIOLOGY

Follicle stimulating hormone and its receptor: future perspectives. Chappel S, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:18–35; discussion 47–51 (77 ref.)
Structure–function relationship of follicle–stimulating hormone and its receptor. Ulloa–Aguirre A, et al. **Hum Reprod Update** 1998 May–Jun;4(3):260–83 (263 ref.)

RECEPTORS, GABA

[GABA receptor chloride ion channel] Hashimoto T. **Nippon Rinsho** 1998 Jul;56(7):1824–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

A new approach to estimate the number, density and variability of receptors at central synapses. Nusser Z. **Eur J Neurosci** 1999 Mar;11(3):745–52 (52 ref.)

DRUG EFFECTS

Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Lancel M. **Sleep** 1999 Feb 1;22(1):33–42 (128 ref.)

PHYSIOLOGY

GABAergic mechanisms that shape the temporal response to odors in moth olfactory projection neurons. Christensen TA, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:475–81 (38 ref.)
Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. Muñoz–Hoyos A, et al. **J Child Neurol** 1998 Oct;13(10):501–9 (112 ref.)
The synaptic pharmacology underlying sensory processing in the superior colliculus. Binns KE. **Prog Neurobiol** 1999 Oct;59(2):129–59 (172 ref.)
[The molecular aspects of the functional heterogeneity of the GABA receptors] Golovko AI, et al. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):29–38 (89 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, GABA-A

[Benzodiazepine receptor imaging in the brain: recent developments and clinical validity] Morimoto K. **Kaku Igaku** 1999 May;36(4):307-13 (35 ref.) (Eng. Abstr.) **(Jpn)**

[GABA receptor chloride ion channel] Hashimoto T. **Nippon Rinsho** 1998 Jul;56(7):1824-9 (13 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Imaging neurochemistry of cerebrovascular disease with PET and SPECT. Hatazawa J, et al. **Q J Nucl Med** 1998 Sep;42(3):193-8 (35 ref.)

Positron emission tomography receptor studies in epilepsy. Duncan JS. **Rev Neurol (Paris)** 1999 Jul;155(6-7):482-8 (50 ref.)

BIOSYNTHESIS

Differentially expressed GABAA-receptor subunits result in structurally and functionally receptor assemblies following excitatory afferent synaptic transmission. Grayson DR, et al. **Perspect Dev Neurobiol** 1998;5(2-3):193-205 (72 ref.)

Developmental expression of cerebellar GABAA-receptor subunit mRNAs. Nature versus nurture. Siegel RE. **Perspect Dev Neurobiol** 1998;5(2-3):207-17 (52 ref.)

CHEMISTRY

Structure and subunit composition of GABA(A) receptors. Sieghart W, et al. **Neurochem Int** 1999 May;34(5):379-85 (71 ref.)

Differentially expressed GABAA-receptor subunits result in structurally and functionally receptor assemblies following excitatory afferent synaptic transmission. Grayson DR, et al. **Perspect Dev Neurobiol** 1998;5(2-3):193-205 (72 ref.)

The molecular mechanism of action of general anesthetics: structural aspects of interactions with GABA(A) receptors. Olsen RW. **Toxicol Lett** 1998 Nov 23;100-101:193-201 (45 ref.)

[Current views on molecular structure of benzodiazepine receptors] Golovko AI, et al. **Vestn Ross Akad Med Nauk** 1999;(7):20-4 (34 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Hevers W, et al. **Mol Neurobiol** 1998 Aug; 18(1):35-86 (428 ref.)

DRUG EFFECTS

Ligands for the benzodiazepine binding site--a survey. Teuber L, et al. **Curr Pharm Des** 1999 May;5(5):317-43 (300 ref.)

Pharmacological and functional implications of developmentally-regulated changes in GABA(A) receptor subunit expression in the cerebellum. Carlson BX, et al. **Eur J Pharmacol** 1998 Jul 3;352(1):1-14 (135 ref.)

Acute effects of ethanol on GABAA and glycine receptor function. Mihic SJ. **Neurochem Int** 1999 Aug;35(2):115-23 (89 ref.)

The GABA-A receptor gene family: new targets for therapeutic intervention. Whiting PJ. **Neurochem Int** 1999 May;34(5):387-90 (38 ref.)

Polychlorocycloalkane insecticide action on GABA-and glycine-dependent chloride flux. Suñol C, et al. **Neurotoxicology** 1998 Aug-Oct;19(4-5):573-80 (54 ref.)

Volatile anesthetics and a volatile convulsant differentially affect GABA(A) receptor-chloride channel complex. Ikemoto Y, et al. **Toxicol Lett** 1998 Nov 23;100-101:225-31 (27 ref.)

The molecular mechanism of action of general anesthetics: structural aspects of interactions with GABA(A) receptors. Olsen RW. **Toxicol Lett** 1998 Nov 23;100-101:193-201 (45 ref.)

General anaesthetics and their effects on GABA(A) receptor desensitization. Orser BA, et al. **Toxicol Lett** 1998 Nov 23;100-101:217-24 (33 ref.)

Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Gasior M, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):107-12 (60 ref.)

[Prevention of recurrent alcoholism with acamprosate. Neurobiological principles and clinical results] Soyka M, et al. **Internist (Berl)** 1999 Mar;40(3):330-6 (27 ref.) **(Ger)**

GENETICS

Molecular and functional diversity of the expanding GABA-A receptor gene family. Whiting PJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:645-53 (46 ref.)

Pharmacologic and therapeutic aspects of the developmentally regulated expression of GABA(A) and GABA(B) receptors: cerebellar granule cells as a model system. Schousboe A. **Neurochem Int** 1999 May;34(5):373-7 (50 ref.)

The GABA-A receptor gene family: new targets for therapeutic intervention. Whiting PJ. **Neurochem Int** 1999 May;34(5):387-90 (38 ref.)

Developmental expression of cerebellar GABAA-receptor subunit mRNAs. Nature versus nurture. Siegel RE. **Perspect Dev Neurobiol** 1998;5(2-3):207-17 (52 ref.)

METABOLISM

Ligands for the benzodiazepine binding site--a survey. Teuber L, et al. **Curr Pharm Des** 1999 May;5(5):317-43 (300 ref.)

[3H]-GABA binding to GABAA and GABAB sites on rat brain crude synaptic membranes. Bruton R, et al. **Methods Mol Biol** 1999;106:27-35 (16 ref.)

Measurement of brain GABA-benzodiazepine receptor levels in vivo using emission tomography. Lingford-Hughes A, et al. **Methods Mol Biol** 1999;106:119-36 (24 ref.)

The role of GABA(A) receptors in the acute and chronic effects of ethanol. Grobin AC, et al. **Psychopharmacology (Berl)** 1998 Sep;139(1-2):2-19 (224 ref.)

[Functional imaging in idiopathic generalized epilepsy] Ryvlin P, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):691-3 (13 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Ethanol, GABA and epilepsy. Brailowsky S, et al. **Arch Med Res** 1999 Jan-Feb;30(1):3-9 (62 ref.)

An update on GABAA receptors. Mehta AK, et al. **Brain Res Brain Res Rev** 1999 Apr;29(2-3):196-217 (370 ref.)

Acute cellular alterations in the hippocampus after status epilepticus. Macdonald RL, et al. **Epilepsia** 1999;40 Suppl 1:S9-20; discussion S21-2 (65 ref.)

Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. Muñoz-Hoyos A, et al. **J Child Neurol** 1998 Oct;13(10):501-9 (112 ref.)

In vitro studies on the role of the peripheral-type benzodiazepine receptor in steroidogenesis. Culty M, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):123-30 (47 ref.)

New perspectives in the functional role of GABA(A) channel heterogeneity. Vicini S. **Mol Neurobiol** 1999 Apr; 19(2):97-110 (79 ref.)

Early developmental modulation of GABAA receptor function. Influence on adaptive responses. Kellogg CK. **Perspect Dev Neurobiol** 1998;5(2-3):219-34 (81 ref.)

GABAA-receptor subtypes in developing brain. Actors or spectators? Paysan J, et al. **Perspect Dev Neurobiol** 1998; 5(2-3):179-92 (59 ref.)

[Pharmacology of the GABA receptor functions in the central nervous systems] Fukuda H, et al. **Yakugaku Zasshi** 1998 Sep;118(9):339-52 (54 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, GABA-B

GENETICS

Pharmacologic and therapeutic aspects of the developmentally regulated expression of GABA(A) and GABA(B) receptors: cerebellar granule cells as a model system. Schousboe A. **Neurochem Int** 1999 May;34(5):373-7 (50 ref.)

METABOLISM

[3H]-GABA binding to GABAA and GABAB sites on rat brain crude synaptic membranes. Bruton R, et al. **Methods Mol Biol** 1999;106:27-35 (16 ref.)

PHYSIOLOGY

GABAB receptors and supraoptic neuronal activity. Pittman QJ, et al. **Adv Exp Med Biol** 1998;449:107-15 (38 ref.)

[Pharmacology of the GABA receptor functions in the central nervous systems] Fukuda H, et al. **Yakugaku Zasshi** 1998 Sep;118(9):339-52 (54 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, GABA-BENZODIAZEPINE see **RECEPTORS, GABA-A**

RECEPTORS, GAMMA-AMINOBUTYRIC ACID see **RECEPTORS, GABA**

RECEPTORS, GASTRIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, GASTRIN-RELEASING PEPTIDE see **RECEPTORS, BOMBESIN**

RECEPTORS, GLUCAGON

see related
GLUCAGON

PHYSIOLOGY

Stimulatory transducing systems in pancreatic islet cells. Emami S, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:118-31 (78 ref.)

RECEPTORS, GLUCOCORTICOID

BIOSYNTHESIS

Glucocorticoid-stimulated gene expression knocked out by knock-in mutation. Berg JP. **Eur J Endocrinol** 1998 Nov; 139(5):479-80 (13 ref.)

DRUG EFFECTS

Epiphenomenal, causal, or correlational--more on the mechanism(s) of action of antidepressants [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1998 Aug;18(4):265-7 (26 ref.)

GENETICS

Genetic dissection of glucocorticoid receptor function in mice. Tronche F, et al. **Curr Opin Genet Dev** 1998 Oct; 8(5):532-8 (49 ref.)

Glucocorticoid-stimulated gene expression knocked out by knock-in mutation. Berg JP. **Eur J Endocrinol** 1998 Nov; 139(5):479-80 (13 ref.)

Mutagenesis of the glucocorticoid receptor in mice. Kellendonk C, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):253-9 (45 ref.)

Stress-axis, coping and dementia: gene-manipulation studies. Heinrichs SC. **Trends Pharmacol Sci** 1999 Aug;20(8):311-5 (51 ref.)

[Familial cortisol resistance and mutations of the glucocorticoid receptor gene] Iida S, et al. **Nippon Rinsho** 1998 Jul;56(7):1887-91 (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The Cre/loxP system--a versatile tool to study glucocorticoid signalling in mice. Reichardt HM, et al. **Biochem Soc Trans** 1999 Feb;27(2):78-83 (22 ref.)

Genetic dissection of glucocorticoid receptor function in mice. Tronche F, et al. **Curr Opin Genet Dev** 1998 Oct; 8(5):532-8 (49 ref.)

Heat shock protein interactions with the glucocorticoid receptor. Bertorelli G, et al. **Pulm Pharmacol Ther** 1998 Feb;11(1):7-12 (57 ref.)

Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Gametchu B, et al. **Steroids** 1999 Jan-Feb;64(1-2):107-19 (47 ref.)

PHYSIOLOGY

Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Miller AH, et al. **Adv Exp Med Biol** 1999; 461:107-16 (33 ref.)

Identification of potential sites of cortisol actions on the reproductive axis in rainbow trout. Teitsma C, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):243-9 (33 ref.)

Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. McKay LI, et al. **Endocr Rev** 1999 Aug;20(4):435-59 (271 ref.)

Glucocorticoid signalling--multiple variations of a common theme. Reichardt HM, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1-2):1-6 (38 ref.)

[Induction of apoptosis in lymphocytes by glucocorticoids: between physiology and pharmacology] Pallardy M, et al. **C R Seances Soc Biol Fil** 1998;192(6):1051-63 (37 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, GLUTAMATE

ANALYSIS

A new approach to estimate the number, density and variability of receptors at central synapses. Nusser Z. **Eur J Neurosci** 1999 Mar;11(3):745-52 (52 ref.)

CHEMISTRY

Three-dimensional models of glutamate receptors. Sutcliffe MJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):450-8 (50 ref.)

DRUG EFFECTS

Glutamate release inhibitors: a critical assessment of their action mechanism. Obrenovitch TP, et al. **Amino Acids** 1998;14(1-3):143-50 (43 ref.)

The activation of glutamate receptors by kainic acid and domoic acid. Hampson DR, et al. **Nat Toxins** 1998; 6(3-4):153-8 (60 ref.)

Ionotropic glutamate receptors as sites of action for ethanol in the brain. Woodward JJ. **Neurochem Int** 1999 Aug; 35(2):107-13 (63 ref.)

Effects of antiepileptic drugs on the activation of glutamate receptors. Taubøll E, et al. **Prog Brain Res** 1998;116:385-93 (63 ref.)

GENETICS

Genetic regulation of glutamate receptor ion channels. Myers SJ, et al. **Annu Rev Pharmacol Toxicol** 1999;39:221-41 (119 ref.)

The lurcher mutation and ionotropic glutamate receptors: contributions to programmed neuronal death in vivo. De Jager PL, et al. **Brain Pathol** 1998 Oct;8(4):795-807 (67 ref.)

METABOLISM

Selectivity in the distribution of glutamate receptors in neurons. Petralia RS, et al. **Cell Biol Int** 1998; 22(9-10):603-8 (36 ref.)
Ionotropic glutamate receptors. Bigge CF.
Curr Opin Chem Biol 1999 Aug;3(4):441-7 (50 ref.)
Determination of membrane topology of glutamate receptors. VanDongen HM, et al. **Methods Mol Biol** 1999;128:155-66 (32 ref.)
Extracellular glutamate diffusion determines the occupancy of glutamate receptors at CA1 synapses in the hippocampus. Kullmann DM, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Feb 28; 354(1381):395-402 (57 ref.)
Anchoring of glutamate receptors at the synapse. Hsueh YP, et al. **Prog Brain Res** 1998;116:123-31 (46 ref.)
Synaptic arrangement of glutamate receptors. Takumi Y, et al. **Prog Brain Res** 1998;116:105-21 (94 ref.)
In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Fedele E, et al.
Prog Neurobiol 1999 May;58(1):89-120 (168 ref.)
Cytoskeletal dynamics in dendritic spines: direct modulation by glutamate receptors? van Rossum D, et al.
Trends Neurosci 1999 Jul;22(7):290-5 (80 ref.)

PHYSIOLOGY

Metabotropic glutamate receptors in the plasticity of excitatory responses in the hippocampus. Clinical impact. Merlin LR. **Adv Exp Med Biol** 1998;446:131-44 (70 ref.)
Functional specificity of ventral striatal compartments in appetitive behaviors. Kelley AE. **Ann N Y Acad Sci** 1999 Jun 29;877:71-90 (115 ref.)
Assembly of signaling machinery at the postsynaptic membrane. Kirsch J. **Curr Opin Neurobiol** 1999 Jun; 9(3):329-35 (61 ref.)
Are glutamate receptors specifically implicated in some forms of memory processes? Ungerer A, et al. **Exp Brain Res** 1998 Nov;123(1-2):45-51 (31 ref.)
The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Cacabelos R, et al. **Int J Geriatr Psychiatry** 1999 Jan; 14(1):3-47 (228 ref.)
Glutamatergic neurotransmission in alcoholism. Tsai G.
J Biomed Sci 1998 Sep-Oct;5(5):309-20 (146 ref.)
Can molecules explain long-term potentiation? Sanes JR, et al. **Nat Neurosci** 1999 Jul;2(7):597-604 (122 ref.)
Modification of glutamate receptor channels: molecular mechanisms and functional consequences. Hatt H.
Naturwissenschaften 1999 Apr;86(4):177-86 (51 ref.)
The glutamate receptor ion channels. Dingledine R, et al.
Pharmacol Rev 1999 Mar;51(1):7-61 (695 ref.)
Glutamate and its receptors in the pathophysiology of brain and spinal cord injuries. Alessandri B, et al.
Prog Brain Res 1998;116:303-30 (180 ref.)
Glutamate receptors in epilepsy. Chapman AG.
Prog Brain Res 1998;116:371-83 (125 ref.)
The synaptic pharmacology underlying sensory processing in the superior colliculus. Binns KE. **Prog Neurobiol** 1999 Oct;59(2):129-59 (172 ref.)
The intact isolated (ex vivo) retina as a model system for the study of excitotoxicity. Romano C, et al.
Prog Retin Eye Res 1998 Oct;17(4):465-83 (124 ref.)
[Calcium channels associated with glutamate receptors] Ogita K, et al. **Nippon Rinsho** 1998 Jul;56(7):1819-23 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Glutamate receptors and brain function] Nakanishi S.
Seikagaku 1998 Sep;70(9):1145-58 (63 ref.) **(Jpn)**

RECEPTORS, GLUTAMATE, METABOTROPIC see **RECEPTORS, METABOTROPIC GLUTAMATE**

RECEPTORS, GLYCINE

AGONISTS

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Krystal JH, et al. **Harv Rev Psychiatry** 1999 Sep-Oct;7(3):125-43 (214 ref.)

DRUG EFFECTS

Acute effects of ethanol on GABAA and glycine receptor function. Mihic SJ. **Neurochem Int** 1999 Aug;35(2):115-23 (89 ref.)
Polychlorocycloalkane insecticide action on GABA-and glycine-dependent chloride flux. Suñol C, et al.
Neurotoxicology 1998 Aug-Oct;19(4-5):573-80 (54 ref.)

METABOLISM

Structure and functions of inhibitory and excitatory glycine receptors. Betz H, et al. **Ann N Y Acad Sci** 1999 Apr 30; 868:667-76 (81 ref.)
Receptor clustering: activate to accumulate? Kamboj S, et al. **Curr Biol** 1998 Oct 8;8(20):R719-21 (13 ref.)

PHYSIOLOGY

The inhibitory glycine receptor: prospects for a therapeutic orphan? Breitinger HG, et al. **Curr Pharm Des** 1998 Aug; 4(4):315-34 (274 ref.)
Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Danysz W, et al. **Pharmacol Rev** 1998 Dec;50(4):597-664 (806 ref.)
Glycine/NMDA receptor and seizure phenomena. Wlaź P.
Pol J Pharmacol 1999 Jan-Feb;51(1):93-100 (25 ref.)

RECEPTORS, GNRH see **RECEPTORS, LHRH**

RECEPTORS, GONADOLIBERIN see **RECEPTORS, LHRH**

RECEPTORS, GONADORELIN see **RECEPTORS, LHRH**

RECEPTORS, GONADOTROPIN

PHYSIOLOGY

Gonadotropin receptors and the control of gonadal steroidogenesis: physiology and pathology. Misrahi M, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):35-66 (170 ref.)

RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR

GENETICS

Clinical implications of G-CSF receptor mutations. Tidow N, et al. **Crit Rev Oncol Hematol** 1998 Jun;28(1):1-6 (23 ref.)

RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

METABOLISM

Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. de Groot RP, et al. **Cell Signal** 1998 Oct;10(9):619-28 (176 ref.)
Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Guthridge MA, et al. **Stem Cells** 1998; 16(5):301-13 (86 ref.)

PHYSIOLOGY

Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Okuda K, et al.
Ann N Y Acad Sci 1999 Apr 30;872:305-12; discussion 312-3 (20 ref.)

RECEPTORS, GROWTH FACTOR

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. Goetzl EJ, et al. **FASEB J** 1998 Dec;12(15):1589-98 (52 ref.)
Growth factor receptors as targets for therapy in pediatric brain tumors. Meuillet EJ, et al. **Pediatr Neurosurg** 1998 Jul;29(1):1-13 (116 ref.)
[Structural biology of growth factors and growth factor receptors] Kohda D. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):338-46 (17 ref.) **(Jpn)**

BIOSYNTHESIS

Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Yoshida H, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):321-32 (56 ref.)
[Advances in the study of the role of vascular endothelial growth factor and its receptor in tumor angiogenesis and its relation with anti-angiogenesis effect] Bian X, et al.
Chung Hua Ping Li Hsueh Tsa Chih 1997 Aug;26(4):248-50 (15 ref.) **(Chi)**

CHEMISTRY

Targeting growth factor and cytokine receptors with recombinant peptide libraries. Dower WJ.
Curr Opin Chem Biol 1998 Jun;2(3):328-34 (35 ref.)
Structure and function of vascular endothelial growth factor receptor-1 and -2. Shibuya M, et al.
Curr Top Microbiol Immunol 1999;237:59-83 (92 ref.)
Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Greenwald J, et al. **Nat Struct Biol** 1999 Jan;6(1):18-22 (29 ref.)

IMMUNOLOGY

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Witte L, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):155-61 (21 ref.)

METABOLISM

Ion channels as physiological effectors for growth factor receptor and Ras/ERK signaling pathways. Rane SG.
Adv Second Messenger Phosphoprotein Res 1999;33:107-27 (126 ref.)
Gene therapy of gliomas: receptor and transcriptional targeting. Spear MA. **Anticancer Res** 1998 Sep-Oct; 18(5A):3223-31 (123 ref.)
Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Bornfeldt KE, et al. **Cell Signal** 1999 Jul;11(7):465-77 (170 ref.)
Growth factors and goitrogenesis. Bidey SP, et al.
J Endocrinol 1999 Mar;160(3):321-32 (123 ref.)

PHYSIOLOGY

Growth factors and their receptors in the olfactory system. Plendl J, et al. **Anat Histol Embryol** 1999 May;28(2):73-9 (78 ref.)
The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Siemeister G, et al.
Cancer Metastasis Rev 1998 Jun;17(2):241-8 (70 ref.)
Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Carmeliet P, et al.
Curr Top Microbiol Immunol 1999;237:133-58 (133 ref.)
Structure and function of vascular endothelial growth factor receptor-1 and -2. Shibuya M, et al.
Curr Top Microbiol Immunol 1999;237:59-83 (92 ref.)
Vascular endothelial growth factor (VEGF) and its receptors. Neufeld G, et al. **FASEB J** 1999 Jan;13(1):9-22 (182 ref.)
Signal relays in the VEGF system. Ortega N, et al.
Front Biosci 1999 Feb 1;4:D141-52 (130 ref.)
VEGFs, receptors and angiogenesis. Veikkola T, et al.
Semin Cancer Biol 1999 Jun;9(3):211-20 (99 ref.)
Growth factors and receptors in allograft arteriosclerosis. Delafontaine P, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):111-4 (41 ref.)
[Neuronal growth factors--neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063-70 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3112-3. **(Dan)**
[Receptors and development of endothelial and hematopoietic cells] Eichmann A, et al. **J Soc Biol** 1999; 193(2):155-7 (31 ref.) (Eng. Abstr.) **(Fre)**
[Regulation of angiogenesis-expression of VEGF receptors] Morita I. **Hum Cell** 1998 Dec;11(4):215-20 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Recent advances in growth factor receptor research] Kanzaki M, et al. **Nippon Rinsho** 1998 Jul;56(7):1791-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, GROWTH HORMONE see **RECEPTORS, SOMATOTROPIN**

RECEPTORS, HEMATOPOIETIC GROWTH FACTORS see **RECEPTORS, COLONY-STIMULATING FACTOR**

RECEPTORS, HISTAMINE

ANALYSIS

Positron emission tomography receptor studies in epilepsy. Duncan JS. **Rev Neurol (Paris)** 1999 Jul;155(6-7):482-8 (50 ref.)

DRUG EFFECTS

Alcohol-histamine interactions. Zimatkin SM, et al.
Alcohol Alcohol 1999 Mar-Apr;34(2):141-7 (50 ref.)

METABOLISM

The fate of released histamine: reception, response and termination. Rangachari PK. **Yale J Biol Med** 1998 May-Aug;71(3-4):173-82 (41 ref.)
[The histamine receptors of the heart] Sergeev PV, et al.
Eksp Klin Farmakol 1999 Jan-Feb;62(1):65-9 (63 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, HISTAMINE H1

CHEMISTRY

Molecular properties and signalling pathways of the histamine H1 receptor. Smit MJ, et al.
Clin Exp Allergy 1999 Jul;29 Suppl 3:19-28 (76 ref.)

DRUG EFFECTS

Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Hattori Y.
Methods Find Exp Clin Pharmacol 1999 Mar;21(2):123-31 (113 ref.)

PHYSIOLOGY

[Ligand recognition and activation mechanism of histamine H1 receptor] Fukui H, et al. **Nippon Yakurigaku Zasshi** 1999 May;113(5):289-97 (13 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, HISTAMINE H2

DRUG EFFECTS

Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Hattori Y.
Methods Find Exp Clin Pharmacol 1999 Mar;21(2):123-31 (113 ref.)

RECEPTORS, HISTAMINE H3

DRUG EFFECTS

Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Passani MB, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):725–33 (96 ref.)

Therapeutic potential of histamine H3 receptor agonists and antagonists. Leurs R, et al. **Trends Pharmacol Sci** 1998 May; 19(5):177–83 (97 ref.)

RECEPTORS, HIV

see related
HIV ENVELOPE PROTEIN GP120

HIV coreceptors. Dimitrov DS, et al. **J Membr Biol** 1998 Nov 15;166(2):75–90 (111 ref.)

ANTAGONISTS & INHIBITORS

Blocking HIV co-receptors by chemokines. Virelizier JL. **Dev Biol Stand** 1999;97:105–9 (15 ref.)

IMMUNOLOGY

HIV entry and tropism. When one receptor is not enough. Berger EA. **Adv Exp Med Biol** 1998;452:151–7 (39 ref.)

METABOLISM

Chemokine receptors as HIV coreceptors: implications and interactions. Rucker J, et al.
AIDS Res Hum Retroviruses 1998 Oct;14 Suppl 3:S241–6 (100 ref.)

Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Edinger AL, et al. **Virology** 1999 Aug 1;260(2):211–21 (129 ref.)

PHYSIOLOGY

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Berger EA, et al.
Annu Rev Immunol 1999;17:657–700 (230 ref.)

Chemokine receptors in HIV-1 and SIV infection. Choe H. **Arch Pharm Res** 1998 Dec;21(6):634–9 (38 ref.)

HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Clapham PR, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):49–55 (58 ref.)

RECEPTORS, HUMAN CHORIONIC GONADOTROPIN see **RECEPTORS, LH**

RECEPTORS, HYALURONAN see **ANTIGENS, CD44**

RECEPTORS, HYPOTHALAMIC RELEASE-INHIBITING HORMONES see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

RECEPTORS, HYPOTHALAMIC RELEASING HORMONES see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

RECEPTORS, IGE

CHEMISTRY

The crystal structure of the human high-affinity IgE receptor (Fc epsilon RI alpha). Garman SC, et al.
Annu Rev Immunol 1999;17:973–6 (15 ref.)

The structural basis of human IgE–Fc receptor interactions. Sayers I, et al. **Clin Exp Allergy** 1999 May;29(5):585–94 (92 ref.)

IMMUNOLOGY

The anti-IgE/anti-FcepsilonRIalpha autoantibody network in allergic and autoimmune diseases. Marone G, et al.
Clin Exp Allergy 1999 Jan;29(1):17–27 (109 ref.)

METABOLISM

The structural basis of human IgE–Fc receptor interactions. Sayers I, et al. **Clin Exp Allergy** 1999 May;29(5):585–94 (92 ref.)

The role of the SRC homology 2-containing inositol 5'-phosphatase in Fc epsilon R1-induced signaling. Huber M, et al. **Curr Top Microbiol Immunol** 1999;244:29–41 (39 ref.)

PHYSIOLOGY

The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Kinet JP. **Annu Rev Immunol** 1999;17:931–72 (249 ref.)

Membrane organization in immunoglobulin E receptor signaling. Sheets ED, et al. **Curr Opin Chem Biol** 1999 Feb; 3(1):95–9 (41 ref.)

A quantitative approach to signal transduction. Metzger H, et al. **Immunol Lett** 1999 May 3;68(1):53–7 (31 ref.)

Parameters determining the stimulatory capacity of the type I Fc epsilon-receptor. Schweitzer-Stenner R, et al.
Immunol Lett 1999 May 3;68(1):59–69 (54 ref.)

Fc epsilon RI on dendritic cells: a receptor, which links IgE mediated allergic reaction and T cell mediated cellular response. Shibaki A. **J Dermatol Sci** 1998 May;20(1):29–38 (90 ref.)

RECEPTORS, IGF-1 see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

RECEPTORS, IGF-II see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

RECEPTORS, IGG

ANALYSIS

CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Scherberich JE, et al. **Clin Chem Lab Med** 1999 Mar; 37(3):209–13 (18 ref.)

BIOSYNTHESIS

Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Moldovan I, et al. **Immunol Lett** 1999 May 3;68(1):125–34 (31 ref.)

BLOOD

Soluble CD16 in plasma cell dyscrasias. Mathiot C, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):467–74 (48 ref.)

GENETICS

Dynamics of immunoglobulins at the feto-maternal interface. Saji F, et al. **Rev Reprod** 1999 May;4(2):81–9 (85 ref.)

METABOLISM

The unexpected complexity of Fc gamma RIIB signal transduction. Cambier JC, et al.
Curr Top Microbiol Immunol 1999;244:43–55 (70 ref.)

Negative regulation of hematopoietic cell activation and proliferation by Fc gamma RIIB. Malbec O, et al.
Curr Top Microbiol Immunol 1999;244:13–27 (84 ref.)

Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Moldovan I, et al. **Immunol Lett** 1999 May 3;68(1):125–34 (31 ref.)

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases [see comments] Yu Z, et al. **N Engl J Med** 1999 Jan 21;340(3):227–8 (9 ref.) Comment in: N Engl J Med 1999 Jul 1;341(1):57–8.

[Signal transmission by Fc gamma receptors] Lisowski J. **Postepy Hig Med Dosw** 1999;53(2):195–203 (43 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Glomerular inflammation: use of genetically deficient mice to elucidate the roles of leukocyte adhesion molecules and Fc-gamma receptors in vivo. Mayadas TN, et al.
Curr Opin Nephrol Hypertens 1999 May;8(3):293–8 (26 ref.)

Soluble CD16 in plasma cell dyscrasias. Mathiot C, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):467–74 (48 ref.)

[Fc gamma receptors in health and disease] Flores-Borja F, et al. **Rev Invest Clin** 1998 Nov–Dec;50(6):529–40 (114 ref.) (Eng. Abstr.) **(Spa)**

RECEPTORS, IL-1 see **RECEPTORS, INTERLEUKIN-1**

RECEPTORS, IL-2 see **RECEPTORS, INTERLEUKIN-2**

RECEPTORS, IL-3 see **RECEPTORS, INTERLEUKIN-3**

RECEPTORS, IL-4 see **RECEPTORS, INTERLEUKIN-4**

RECEPTORS, IL-6 see **RECEPTORS, INTERLEUKIN-6**

RECEPTORS, IL-7 see **RECEPTORS, INTERLEUKIN-7**

RECEPTORS, IMMUNOLOGIC

Regulation of immune responses by inhibitory receptors. Long EO. **Adv Exp Med Biol** 1998;452:19–28 (56 ref.)

[Structure and function of a novel scavenger receptor expressed in human endothelial cells] Adachi H, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1282–6 (24 ref.) **(Jpn)**

[Scavenger receptor class B] Ikemoto M, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1268–76 (49 ref.) **(Jpn)**

[Macrophage scavenger receptor class A] Inoue K, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1261–7 (20 ref.) **(Jpn)**

BIOSYNTHESIS

Cytokine-induced expression of killer inhibitory receptors in human T lymphocytes. Ponte M, et al.
Eur Cytokine Netw 1998 Sep;9(3 Suppl):69–72 (23 ref.)

CHEMISTRY

DAP12: a key accessory protein for relaying signals by natural killer cell receptors. Campbell KS, et al.
Int J Biochem Cell Biol 1999 Jun;31(6):631–6 (17 ref.)

GENETICS

Structure of a human natural killer cell inhibitory receptor. Fan QR, et al. **Transplant Proc** 1999 Jun;31(4):1871–2 (13 ref.)

IMMUNOLOGY

Activating and inhibitory NK cell receptors. Lanier LL.
Adv Exp Med Biol 1998;452:13–8 (57 ref.)

The function of small GTPases in signaling by immune recognition and other leukocyte receptors. Altman A, et al. **Adv Immunol** 1999;72:1–101 (561 ref.)

Inhibitory pathways triggered by ITIM-containing receptors. Bolland S, et al. **Adv Immunol** 1999;72:149–77 (180 ref.)

Interactions of LIRs, a family of immunoreceptors expressed in myeloid and lymphoid cells, with viral and cellular MHC class I antigens. Borges L, et al.
Curr Top Microbiol Immunol 1999;244:123–36 (49 ref.)

Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Braud VM, et al.
Curr Top Microbiol Immunol 1999;244:85–95 (30 ref.)

The enigma of activating isoforms of ITIM-bearing molecules. Cambiaggi A, et al.
Curr Top Microbiol Immunol 1999;244:169–76 (40 ref.)

A novel family of inhibitory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **Curr Top Microbiol Immunol** 1999; 244:115–22 (39 ref.)

Paired immunoglobulin-like receptors of activating and inhibitory types. Kubagawa H, et al.
Curr Top Microbiol Immunol 1999;244:137–49 (24 ref.)

LAIR-1, a widely distributed human ITIM-bearing receptor on hematopoietic cells. Meyaard L.
Curr Top Microbiol Immunol 1999;244:151–7 (37 ref.)

HLA-specific and non-HLA-specific human NK receptors. Moretta A, et al. **Curr Top Microbiol Immunol** 1999; 244:69–84 (84 ref.)

Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Cosman D, et al. **Immunol Rev** 1999 Apr;168:177–85 (71 ref.)

Chemoattractant receptor cross-desensitization. Ali H, et al.
J Biol Chem 1999 Mar 5;274(10):6027–30 (52 ref.)

A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **J Leukoc Biol** 1999 Sep; 66(3):375–81 (61 ref.)

The leukocyte immunoglobulin-like receptors (LIRs): a new family of immune regulators. Fanger NA, et al.
J Leukoc Biol 1999 Aug;66(2):231–6 (65 ref.)

Why so many coinhibitory receptors? Sinclair NR.
Scand J Immunol 1999 Jul;50(1):10–3 (28 ref.)

Human-porcine receptor-ligand compatibility within the immune system: relevance for xenotransplantation. Warrens AN, et al. **Xenotransplantation** 1999 May;6(2):75–8 (20 ref.)

METABOLISM

Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Thornalley PJ.
Cell Mol Biol (Noisy-le-grand) 1998 Nov;44(7):1013–23 (70 ref.)

Scavenger receptors: diverse activities and promiscuous binding of polyanionic ligands. Platt N, et al.
Chem Biol 1998 Aug;5(8):R193–203 (66 ref.)

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Schmidt AM, et al.
Circ Res 1999 Mar 19;84(5):489–97 (89 ref.)

How to extinguish lymphocyte activation, immunotyrosine-based inhibition motif (ITIM)-bearing molecules a solution? Blery M, et al.
Clin Chem Lab Med 1999 Mar;37(3):187–91 (54 ref.)

Scavenger receptors and oxidized low density lipoproteins. Dhaliwal BS, et al. **Clin Chim Acta** 1999 Aug; 286(1–2):191–205 (91 ref.)

Natural killer cell activation and inhibition by receptors for MHC class I. López-Botet M, et al.
Curr Opin Immunol 1999 Jun;11(3):301–7 (75 ref.)

Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. Greaves DR, et al. **Curr Opin Lipidol** 1998 Oct;9(5):425–32 (63 ref.)

Scavenger receptor BI and cholesterol trafficking. Williams DL, et al. **Curr Opin Lipidol** 1999 Aug;10(4):329–39 (97 ref.)

The human natural killer lymphocyte receptors for MHC class I molecules. Bensussan A. **Eur Cytokine Netw** 1998 Dec;9(4):577–83 (73 ref.)

GPI-microdomains: a role in signalling via immunoreceptors. Horejsi V, et al. **Immunol Today** 1999 Aug;20(8):356–61 (51 ref.)

The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Lupher ML Jr, et al.
Immunol Today 1999 Aug;20(8):375–82 (62 ref.)

PHYSIOLOGY

Regulation of immune responses through inhibitory receptors. Long EO. **Annu Rev Immunol** 1999;17:875–904 (160 ref.)

Class A scavenger receptors and the phagocytosis of apoptotic cells. Platt N, et al. **Biochem Soc Trans** 1998 Nov;

26(4):639–44 (27 ref.)
Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Mosser DM, et al. **Curr Opin Immunol** 1999 Aug;11(4):406–11 (34 ref.)
Biology of immunoreceptor tyrosine-based inhibition motif-bearing molecules. Daëron M, et al. **Curr Top Microbiol Immunol** 1999;244:1–12 (78 ref.)
Inhibitory role of murine Ly49 lectin-like receptors on natural killer cells. Salcedo M. **Curr Top Microbiol Immunol** 1999;244:97–105 (45 ref.)
Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15 (161 ref.)
Signal transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an aspect of immunoreceptor function? Horejsí V, et al. **Immunol Lett** 1998 Sep; 63(2):63–73 (185 ref.)
Class A scavenger receptors and the phagocytosis of apoptotic cells. Platt N, et al. **Immunol Lett** 1999 Jan; 65(1–2):15–9 (27 ref.)
A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **J Leukoc Biol** 1999 Sep; 66(3):375–81 (61 ref.)
Recognizing death: the phagocytosis of apoptotic cells. Platt N, et al. **Trends Cell Biol** 1998 Sep;8(9):365–72 (59 ref.)

RECEPTORS, INSULIN

GENETICS

Genetic engineering in mice: impact on insulin signalling and action. Lamothe B, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):193–204 (107 ref.)
Syndromes associated with insulin resistance and acanthosis nigricans. Taylor SI, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):419–39 (76 ref.)
Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. Accili D, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug;12(4):475–85 (62 ref.)
[Insulin receptor abnormality and its clinical aspect] Taira M, et al. **Nippon Rinsho** 1998 Jul;56(7):1866–70 (8 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Syndromes of severe insulin resistance] Araki S. **Nippon Rinsho** 1999 Mar;57(3):617–21 (7 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Hunter SJ, et al. **Am J Med** 1998 Oct;105(4):331–45 (100 ref.)
Insulin-family peptide-receptor interaction at the early stage of vertebrate evolution. Leibush BN, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):57–63 (25 ref.)
Molecular basis of insulin action. Combettes-Souverain M, et al. **Diabetes Metab** 1998 Dec;24(6):477–89 (125 ref.)
Insulin degradation: progress and potential. Duckworth WC, et al. **Endocr Rev** 1998 Oct;19(5):608–24 (237 ref.)
From insulin receptor signalling to Glut 4 translocation abnormalities in obesity and insulin resistance. Le Marchand-Brustel Y, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):217–28 (41 ref.)
Insulin receptor internalization and signalling. Di Guglielmo GM, et al. **Mol Cell Biochem** 1998 May;182(1–2):59–63 (41 ref.)
Binding of SH2 containing proteins to the insulin receptor: a new way for modulating insulin signalling. Liu F, et al. **Mol Cell Biochem** 1998 May;182(1–2):73–8 (42 ref.)

PHYSIOLOGY

Journey beyond immunology. Regulation of receptor internalization by major histocompatibility complex class I (MHC-I) and effect of peptides derived from MHC-I. Stagsted J. **APMIS Suppl** 1998;85:1–40 (553 ref.)
Early steps in insulin action. Dorrestijn J, et al. **Arch Physiol Biochem** 1998 Oct;106(4):269–89 (207 ref.)
The insulin receptor substrate 1 associates with phosphotyrosine phosphatase SHPTP2 in liver and muscle of rats. Lima MH, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1409–13 (17 ref.)
Insulin, insulin-like growth factor-I (IGF-I) and glucagon: the evolution of their receptors. Navarro I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):137–53 (153 ref.)
Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. Unger JW, et al. **Histol Histopathol** 1998 Oct;13(4):1215–24 (74 ref.)
The insulin receptor--a critical link in glucose homeostasis and insulin action. Patti ME, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):89–109 (78 ref.)
The role of G proteins in insulin signalling. Rizzo MA, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):167–95 (159 ref.)
Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. Accili D, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug;12(4):475–85 (62 ref.)
Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action. Drake PG, et al. **Mol Cell Biochem** 1998 May;182(1–2):79–89 (87 ref.)
Role of binding proteins to IRS-1 in insulin signalling. Ogawa W, et al. **Mol Cell Biochem** 1998 May;182(1–2):13–22 (108 ref.)
The IRS-signalling system: a network of docking proteins that mediate insulin action. White MF. **Mol Cell Biochem** 1998 May;182(1–2):3–11 (81 ref.)
GLUT-4, tumor necrosis factor, essential fatty acids and daf-genes and their role in insulin resistance and non-insulin dependent diabetes mellitus. Das UN. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jan; 60(1):13–20 (43 ref.)
The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. White MF. **Recent Prog Horm Res** 1998;53:119–38 (125 ref.)
The insulin receptor and metabolic signaling. Gustafson TA, et al. **Rev Physiol Biochem Pharmacol** 1999;137:71–190 (523 ref.)
[Insulin resistance. Receptor and post-receptor abnormalities] Liguori M, et al. **Minerva Endocrinol** 1998 Jun;23(2):37–52 (81 ref.) (Eng. Abstr.) **(Ita)**

RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I

ANALYSIS

Insulin-like growth factors in human breast cancer. Ellis MJ, et al. **Breast Cancer Res Treat** 1998;52(1–3):175–84 (62 ref.)

GENETICS

Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (review). Resnicoff M. **Int J Mol Med** 1998 May;1(5):883–8 (44 ref.)
Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. Accili D, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug;12(4):475–85 (62 ref.)
Dysregulation of the type 1 IGF receptor as a paradigm in tumor progression [published erratum appears in Mol Cell Endocrinol 1998 Nov 25;146(1–2):213] Werner H. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):1–5 (38 ref.)

METABOLISM

Insulin-like growth factor-I resistance. Jain S, et al. **Endocr Rev** 1998 Oct;19(5):625–46 (206 ref.)

PHYSIOLOGY

The role of growth hormone and insulin-like growth factors in the immune system. van Buul-Offers SC, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1083–94 (160 ref.)
Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Butler AA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep;121(1):19–26 (59 ref.)
Insulin, insulin-like growth factor-I (IGF-I) and glucagon: the evolution of their receptors. Navarro I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):137–53 (153 ref.)
The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. Grothey A, et al. **J Cancer Res Clin Oncol** 1999;125(3–4):166–73 (77 ref.)
Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. Accili D, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug;12(4):475–85 (62 ref.)
Dysregulation of the type 1 IGF receptor as a paradigm in tumor progression [published erratum appears in Mol Cell Endocrinol 1998 Nov 25;146(1–2):213] Werner H. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):1–5 (38 ref.)

RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II

Type-2 IGF receptor: a multi-ligand binding protein. Braulke T. **Horm Metab Res** 1999 Feb–Mar;31(2–3):242–6 (60 ref.)

ANALYSIS

Insulin-like growth factors in human breast cancer. Ellis MJ, et al. **Breast Cancer Res Treat** 1998;52(1–3):175–84 (62 ref.)

GENETICS

The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Oliveira C, et al. **Am J Pathol** 1998 Oct;153(4):1211–9 (44 ref.)

METABOLISM

Insulin-like growth factor-I resistance. Jain S, et al. **Endocr Rev** 1998 Oct;19(5):625–46 (206 ref.)

RECEPTORS, INSULIN-LIKE GROWTH FACTORS see **RECEPTORS, SOMATOMEDIN**

RECEPTORS, INTERFERON

DEFICIENCY

Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Roesler J, et al. **Exp Hematol** 1999 Sep;27(9):1368–74 (23 ref.)
Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Ottenhoff TH, et al. **Immunol Today** 1998 Nov;19(11):491–4 (21 ref.)
Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review). Lamhamedi S, et al. **Int J Mol Med** 1998 Feb;1(2):415–8 (19 ref.)

METABOLISM

Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167–74 (107 ref.)

PHYSIOLOGY

Type I interferons: expression and signalization. Doly J, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1109–21 (136 ref.)
Signaling and signaling dysfunction through the interferon gamma receptor. Rodig S, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):49–53 (25 ref.)
[Anti-viral proteins: from interferon alpha to its receptor] Chieux V, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):283–90 (52 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, INTERLEUKIN

[IL-18 and IL-18 receptor] Kashiwamura S, et al. **Nippon Rinsho** 1998 Jul;56(7):1798–806 (36 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Debinski W. **Crit Rev Oncog** 1998;9(3–4):255–68 (81 ref.)

CHEMISTRY

The interleukin-11/receptor complex: rational design of agonists/antagonists and immunoassays potentially useful in human therapy. Jacques Y, et al. **Res Immunol** 1998 Sep–Oct;149(7–8):737–40 (13 ref.)

DEFICIENCY

Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Ottenhoff TH, et al. **Immunol Today** 1998 Nov;19(11):491–4 (21 ref.)

IMMUNOLOGY

Interleukin-12: a cytokine at the interface of inflammation and immunity. Trinchieri G. **Adv Immunol** 1998;70:83–243 (754 ref.)
The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. He YW, et al. **Crit Rev Immunol** 1998; 18(6):503–24 (159 ref.)
The interleukin-11/receptor complex: rational design of agonists/antagonists and immunoassays potentially useful in human therapy. Jacques Y, et al. **Res Immunol** 1998 Sep–Oct;149(7–8):737–40 (13 ref.)

METABOLISM

Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Guthridge MA, et al. **Stem Cells** 1998; 16(5):301–13 (86 ref.)

PHYSIOLOGY

Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Okuda K, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:305–12; discussion 312–3 (20 ref.)
Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71–6 (55 ref.)
Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Murata T, et al. **Int J Mol Med** 1998 Mar;1(3):551–7 (95 ref.)
Receptors and cytokines involved in allergic TH2 cell responses. de Vries JE, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S492–6 (31 ref.)

RECEPTORS, INTERLEUKIN-1

ANTAGONISTS & INHIBITORS

Arthritis: is the cure in your genes? Herndon JH, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):152-7 (36 ref.)

PHYSIOLOGY

The interleukin 1 receptor: ligand interactions and signal transduction. Auron PE. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):221-37 (91 ref.)

Interleukin-1. Stylianou E, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1075-9 (13 ref.)

Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Watkins LR, et al. **Life Sci** 1999;65(5):449-81 (290 ref.)

RECEPTORS, INTERLEUKIN-2

BIOSYNTHESIS

Dysregulation of interleukin-2 receptor beta and interleukin-2 receptor gamma expression during HIV infection. David D, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):97-101 (38 ref.)

IMMUNOLOGY

The use of antibodies against the IL-2 receptor in transplantation. Waldmann TA, et al. **Curr Opin Immunol** 1998 Oct;10(5):507-12 (66 ref.)

New usage paradigms in antibody therapy: safety of the new agents. Pescovitz MD. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1201-2 (27 ref.)

Immunosuppression through inhibition of interleukin-2/interleukin-2 receptor interaction. Soulillou JP. **Transplant Proc** 1999 Feb-Mar;31(1-2A):49S-51S (23 ref.)

PHYSIOLOGY

Biology of the interleukin-2 receptor. Nelson BH, et al. **Adv Immunol** 1998;70:1-81 (442 ref.)

RECEPTORS, INTERLEUKIN-3

METABOLISM

Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. de Groot RP, et al. **Cell Signal** 1998 Oct;10(9):619-28 (176 ref.)

Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Guthridge MA, et al. **Stem Cells** 1998; 16(5):301-13 (86 ref.)

PHYSIOLOGY

Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Okuda K, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:305-12; discussion 312-3 (20 ref.)

RECEPTORS, INTERLEUKIN-4

GENETICS

[Atopy and interleukin-4 receptor] Izuhara K. **Rinsho Byori** 1999 Jun;47(6):525-30 (7 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Interleukin-4 receptor signalling mechanisms and their biological significance. Nelms K, et al. **Adv Exp Med Biol** 1998;452:37-43 (19 ref.)

PHYSIOLOGY

The IL-4 receptor: signaling mechanisms and biologic functions. Nelms K, et al. **Annu Rev Immunol** 1999; 17:701-38 (183 ref.)

Signal transduction via the interleukin-4 receptor and its correlation with atopy. Izuhara K, et al. **Int J Mol Med** 1999 Jan;3(1):3-10 (107 ref.)

Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Murata T, et al. **Int J Mol Med** 1998 Mar;1(3):551-7 (95 ref.)

Receptors and cytokines involved in allergic TH2 cell responses. de Vries JE, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S492-6 (31 ref.)

RECEPTORS, INTERLEUKIN-6

ANTAGONISTS & INHIBITORS

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Yoshizaki K, et al. **Springer Semin Immunopathol** 1998;20(1-2):247-59 (71 ref.)

BIOSYNTHESIS

Generation and function of the soluble interleukin-6 receptor. Müllberg J, et al. **Biochem Soc Trans** 1999 Feb;27(2):211-9 (66 ref.)

IMMUNOLOGY

[New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition] Nishimoto N, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1745-50 (20 ref.) **(Jpn)**

METABOLISM

Interleukin-6 receptor shedding: a possible role for members of the ADAM family. Croucher PI, et al. **Biochem Soc Trans** 1999 Feb;27(2):224-8 (36 ref.)

PHYSIOLOGY

Generation and function of the soluble interleukin-6 receptor. Müllberg J, et al. **Biochem Soc Trans** 1999 Feb;27(2):211-9 (66 ref.)

Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Peters M, et al. **Blood** 1998 Nov 15;92(10):3495-504 (85 ref.)

RECEPTORS, INTERLEUKIN-7

IMMUNOLOGY

Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Haks MC, et al. **Semin Immunol** 1999 Feb;11(1):23-37 (143 ref.)

RECEPTORS, INTERSTITIAL CELL-STIMULATING HORMONE see **RECEPTORS, LH**

RECEPTORS, INVERTEBRATE PEPTIDE

PHYSIOLOGY

Invertebrate neurohormones and their receptors. Grimmelikhuijzen CJ, et al. **Results Probl Cell Differ** 1999; 26:339-62 (70 ref.)

RECEPTORS, KAINATE see **RECEPTORS, KAINIC ACID**

RECEPTORS, KAINIC ACID

CHEMISTRY

Recent excitement in the ionotropic glutamate receptor field. Ziff EB. **Ann N Y Acad Sci** 1999 Apr 30;868:465-73 (61 ref.)

DRUG EFFECTS

Neuropharmacology of AMPA and kainate receptors. Bleakman D, et al. **Neuropharmacology** 1998 Oct-Nov; 37(10-11):1187-204 (275 ref.)

PHYSIOLOGY

Kainate receptors: subunits, synaptic localization and function. Chittajallu R, et al. **Trends Pharmacol Sci** 1999 Jan;20(1):26-35 (93 ref.)

RECEPTORS, KAPPA see **RECEPTORS, OPIOID, KAPPA**

RECEPTORS, KAPPA OPIOID see **RECEPTORS, OPIOID, KAPPA**

RECEPTORS, LAMININ

ANALYSIS

The 67 kDa laminin receptor as a prognostic factor in human cancer. Ménard S, et al. **Breast Cancer Res Treat** 1998; 52(1-3):137-45 (66 ref.)

PHYSIOLOGY

Cell death induced in lymphocytes expressing the elastin-laminin receptor by excess agonists: necrosis and apoptosis. Péterszegi G, et al. **Biomed Pharmacother** 1998; 52(9):369-77 (33 ref.)

Mechanisms of aging of the extracellular matrix: role of the elastin-laminin receptor. Robert L. **Gerontology** 1998; 44(6):307-17 (68 ref.)

Role of the elastin-laminin receptor in the cardiovascular system. Faury G. **Pathol Biol (Paris)** 1998 Sep;46(7):517-26 (84 ref.)

Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Rieger R, et al. **Transfus Clin Biol** 1999 Feb;6(1):7-16 (65 ref.)

RECEPTORS, LDL

[CD36 as an oxidized LDL receptor] Nozaki S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1306-11 (30 ref.) **(Jpn)**

CHEMISTRY

The VLDL receptor: an LDL receptor relative with eight ligand binding repeats, LR8. Nimpf J, et al. **Atherosclerosis** 1998 Dec;141(2):191-202 (103 ref.)

[Structure and function of a novel scavenger receptor expressed in human endothelial cells] Adachi H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1282-6 (24 ref.) **(Jpn)**

GENETICS

The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism [see comments] Willnow TE. **J Mol Med** 1999 Mar;77(3):306-15 (75 ref.) Comment in: J Mol Med 1999 Mar;77(3):303-4.

The LDL receptor gene family, apolipoprotein B and cholesterol in embryonic development. Herz J, et al. **J Nutr** 1999 Feb;129(2S Suppl):473S-475S (21 ref.)

METABOLISM

The LDL-receptor family. Lactoferrin and lipid metabolism. Huettinger M, et al. **Adv Exp Med Biol** 1998;443:107-11 (20 ref.)

Receptors for oxidized low density lipoprotein. Steinbrecher UP. **Biochim Biophys Acta** 1999 Jan 4;1436(3):279-98 (168 ref.)

Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Gliemann J. **Biol Chem** 1998 Aug-Sep;379(8-9):951-64 (128 ref.)

Receptor-associated protein (RAP): a specialized chaperone for endocytic receptors. Willnow TE. **Biol Chem** 1998 Aug-Sep;379(8-9):1025-31 (54 ref.)

Lipoprotein receptors: signaling functions in the brain? Cooper JA, et al. **Cell** 1999 Jun 11;97(6):671-4 (20 ref.)

PHYSIOLOGY

The mammalian low-density lipoprotein receptor family. Hussain MM, et al. **Annu Rev Nutr** 1999;19:141-72 (206 ref.)

The VLDL receptor: an LDL receptor relative with eight ligand binding repeats, LR8. Nimpf J, et al. **Atherosclerosis** 1998 Dec;141(2):191-202 (103 ref.)

Oocyte growth in the chicken: receptors and more. Schneider WJ, et al. **Biol Chem** 1998 Aug-Sep;379(8-9):965-71 (32 ref.)

LOX-1, a possible clue to the missing link between hypertension and atherogenesis [comment] Kita T. **Circ Res** 1999 May 14;84(9):1113-5 (45 ref.) Comment on: Circ Res 1999 May 14;84(9):1043-9.

[Structure and function of a novel scavenger receptor expressed in human endothelial cells] Adachi H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1282-6 (24 ref.) **(Jpn)**

RECEPTORS, LECTIN see **RECEPTORS, MITOGEN**

RECEPTORS, LEUKOTRIENE

Receptors for cysteinyl-leukotrienes in human cells. Nicosia S, et al. **Adv Exp Med Biol** 1999;447:165-70 (32 ref.)

Leukotriene receptors. Dahlén SE. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):179-91 (82 ref.)

[Leukotriene receptors] Izumi T. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1084-9 (8 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Asthma treatment: antileukotriene drugs. O'Byrne PM. **Can Respir J** 1998 Jul-Aug;5 Suppl A:64A-70A (42 ref.)

Montelukast and zafirlukast in asthma. **Drug Ther Bull** 1998 Sep;36(9):65-8 (13 ref.)

Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma. Devillier P, et al. **Pharmacol Res** 1999 Jul;40(1):15-29 (143 ref.)

Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Devillier P, et al. **Pharmacol Res** 1999 Jul;40(1):3-13 (117 ref.)

Leukotriene antagonism in asthma and rhinitis. Lane SJ. **Respir Med** 1998 Jun;92(6):795-809 (150 ref.)

IMMUNOLOGY

Cysteinyl-leukotrienes and the human lung. Gorenne I, et al. **Adv Exp Med Biol** 1999;447:171-9 (42 ref.)

RECEPTORS, LH

Gonadotropin receptors. Hai MV, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):89-92 (24 ref.)

CHEMISTRY

Structural and molecular studies of human chorionic gonadotropin and its receptor. Lustbader JW, et al. **Recent Prog Horm Res** 1998;53:395-424; discussion 424-5 (61 ref.)

GENETICS

Menstrual disorders and infertility caused by inactivating mutations of the luteinizing hormone receptor gene. Arnhold IJ, et al. **Fertil Steril** 1999 Apr;71(4):597-601 (32

ref.)
[Activating mutations of the gonadotrophin receptors] Beck-Peccoz P, et al. **Arch Pediatr** 1998;5 Suppl 4:380S-384S (17 ref.) (Eng. Abstr.) **(Fre)**
[Constitutively activating mutations in the luteinizing hormone receptor gene in cases of male-limited precocious puberty] Yano K, et al. **Nippon Rinsho** 1998 Jul; 56(7):1843-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Activating and inactivating mutations in LH receptors. Themmen AP, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):137-42 (28 ref.)

PHYSIOLOGY

Gene, interaction, signal generation, signal divergence and signal transduction of the LH/CG receptor. Ryu KS, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S9-20 (60 ref.)

RECEPTORS, LHRH

see related
GONADORELIN
INHIBIN

METABOLISM

Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone. Stanislaus D, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1-2):1-10 (73 ref.)

PHYSIOLOGY

Mechanism of GnRH receptor signaling: from the membrane to the nucleus. Shacham S, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):79-88 (85 ref.)
The tail of the gonadotrophin-releasing hormone receptor: desensitization at, and distal to, G protein-coupled receptors. McArdle CA, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):129-36 (63 ref.)

RECEPTORS, LIPOPOLYSACCHARIDE see **ANTIGENS, CD14**

RECEPTORS, LIPOPROTEIN

[ApoE receptors] Yamamoto T. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1287-93 (24 ref.) **(Jpn)**

ANALYSIS

Cellular assays for lipoprotein receptors. Acton S, et al. **Methods Mol Biol** 1998;110:253-66 (13 ref.)

GENETICS

A candidate high density lipoprotein (HDL) receptor, HB2, with possible multiple functions shows sequence homology with adhesion molecules. Kurata H, et al. **J Atheroscler Thromb** 1998;4(3):112-7 (26 ref.)

METABOLISM

Conversion of chylomicrons into remnants. Hultin M, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S25-9 (25 ref.)
Lipoprotein receptors: signaling functions in the brain? Cooper JA, et al. **Cell** 1999 Jun 11;97(6):671-4 (20 ref.)
Receptor-mediated mechanisms of lipoprotein remnant catabolism. Chappell DA, et al. **Prog Lipid Res** 1998 Dec; 37(6):393-422 (262 ref.)
[Receptor endocytosis of polyenic acids: sensitivity and resistance to atherosclerosis (review of the literature)] Titov VN. **Klin Lab Diagn** 1999 Jan;(1):3-8 (40 ref.) **(Rus)**

PHYSIOLOGY

A candidate high density lipoprotein (HDL) receptor, HB2, with possible multiple functions shows sequence homology with adhesion molecules. Kurata H, et al. **J Atheroscler Thromb** 1998;4(3):112-7 (26 ref.)

RECEPTORS, LOW DENSITY LIPOPROTEIN see **RECEPTORS, LDL**

RECEPTORS, LULIBERIN see **RECEPTORS, LHRH**

RECEPTORS, LUTEINIZING HORMONE see **RECEPTORS, LH**

RECEPTORS, LYMPHOCYTE HOMING

Homing mechanisms of myeloma cells. Van Riet I. **Pathol Biol (Paris)** 1999 Feb;47(2):98-108 (76 ref.)

ANTAGONISTS & INHIBITORS

Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Lin KC, et al. **Curr Opin Chem Biol** 1998 Aug; 2(4):453-7 (22 ref.)

GENETICS

Selective differences in the expression of the homing receptors of helper lymphocyte subsets. Burastero SE, et al. **Clin Immunol Immunopathol** 1998 Nov;89(2):110-6 (54 ref.)

IMMUNOLOGY

Homing mechanisms in the biology of multiple myeloma. Van Camp B, et al. **Verh K Acad Geneeskd Belg** 1998; 60(3):163-94 (117 ref.)

METABOLISM

[Cell cycle-dependent change of the adhesive character of CD34+ progenitor cells and their VLA-4 expression] Yamaguchi M, et al. **Rinsho Byori** 1999 May;47(5):439-46 (30 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Brandtzaeg P, et al. **Immunol Today** 1999 Jun;20(6):267-77 (111 ref.)

RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR

PHYSIOLOGY

The role of CSF-1 in normal and neoplastic breast physiology. Sapi E, et al. **Proc Soc Exp Biol Med** 1999 Jan;220(1):1-8 (79 ref.)

RECEPTORS, MANNOSE-6-PHOSPHATE see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

RECEPTORS, MENOTROPIN see **RECEPTORS, GONADOTROPIN**

RECEPTORS, METABOTROPIC GLUTAMATE

AGONISTS

Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Hölscher C, et al. **Neurosci Biobehav Rev** 1999;23(3):399-410 (125 ref.)

ANTAGONISTS & INHIBITORS

Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Hölscher C, et al. **Neurosci Biobehav Rev** 1999;23(3):399-410 (125 ref.)

CHEMISTRY

New perspectives for the development of selective metabotropic glutamate receptor ligands. Pin JP, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):277-94 (129 ref.)

DRUG EFFECTS

Metabotropic G-protein-coupled glutamate receptors as therapeutic targets. Pellicciari R, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):433-40 (50 ref.)

GENETICS

Heterologous mammalian expression systems for investigating the properties of metabotropic glutamate receptors. Hermans E, et al. **Biochem Soc Trans** 1999 Feb; 27(2):164-70 (59 ref.)

METABOLISM

Heterologous mammalian expression systems for investigating the properties of metabotropic glutamate receptors. Hermans E, et al. **Biochem Soc Trans** 1999 Feb; 27(2):164-70 (59 ref.)

PHYSIOLOGY

Molecular and physiological evidence for glutamate (umami) taste transduction via a G protein-coupled receptor. Chaudhari N, et al. **Ann N Y Acad Sci** 1998 Nov 30; 855:398-406 (32 ref.)
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Anwyl R. **Brain Res Brain Res Rev** 1999 Jan;29(1):83-120 (349 ref.)
Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Bortolotto ZA, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):299-304 (64 ref.)
Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain dopamine. Vezina P, et al. **Neurosci Biobehav Rev** 1999 Mar; 23(4):577-89 (135 ref.)
Metabotropic glutamate receptors and neurodegeneration. Bruno V, et al. **Prog Brain Res** 1998;116:209-21 (98 ref.)
Group I metabotropic glutamate receptors: implications for brain diseases. Bordi F, et al. **Prog Neurobiol** 1999 Sep; 59(1):55-79 (340 ref.)
[Metabotropic glutamate receptor: its ligands and function in the olfactory system] Hayashi Y. **Nippon Yakurigaku Zasshi** 1999 Feb;113(2):73-83 (38 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, N-METHYL-D-ASPARTATE

AGONISTS

Modulation of NMDA receptors by glycine--introduction to some basic aspects and recent developments. Parsons CG, et al. **Amino Acids** 1998;14(1-3):207-16 (87 ref.)

ANALYSIS

In vitro selection of peptides acting on NMDA receptors. Cwirla SE, et al. **Methods Mol Biol** 1999;128:131-41 (4 ref.)
Immunocytochemistry of NMDA receptors. Petralia RS, et al. **Methods Mol Biol** 1999;128:73-92 (59 ref.)
Detergent solubilization and immunoprecipitation of native NMDA receptors. Wenthold RJ, et al. **Methods Mol Biol** 1999;128:113-9 (11 ref.)

ANTAGONISTS & INHIBITORS

GlycineB antagonists as potential therapeutic agents. Previous hopes and present reality. Danysz W, et al. **Amino Acids** 1998;14(1-3):235-9 (13 ref.)
Modulation of NMDA receptors by glycine--introduction to some basic aspects and recent developments. Parsons CG, et al. **Amino Acids** 1998;14(1-3):207-16 (87 ref.)
Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Ebert B, et al. **Biochem Pharmacol** 1998 Sep 1;56(5):553-9 (53 ref.)
Novel targets for therapeutic intervention against ischemic brain injury. Sun A, et al. **Clin Neuropharmacol** 1999 May-Jun;22(3):164-71 (66 ref.)
The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Dannhardt G, et al. **Curr Med Chem** 1998 Aug;5(4):253-63 (58 ref.)
Antagonists selective for NMDA receptors containing the NR2B subunit. Chenard BL, et al. **Curr Pharm Des** 1999 May;5(5):381-404 (113 ref.)
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Krystal JH, et al. **Harv Rev Psychiatry** 1999 Sep-Oct;7(3):125-43 (214 ref.)
Ethanol-induced inhibition of NMDA receptor channels. Wirkner K, et al. **Neurochem Int** 1999 Aug;35(2):153-62 (78 ref.)
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Parsons CG, et al. **Neuropharmacology** 1999 Jun;38(6):735-67 (379 ref.)
Does the noncompetitive NMDA receptor antagonist dizocilpine (MK801) really block behavioural sensitization associated with repeated drug administration? [see comments] Tzschentke TM, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):447-51 (67 ref.) Comment in: Trends Pharmacol Sci 1999 May;20(5):187-8; discussion 189-90. Comment in: Trends Pharmacol Sci 1999 May;20(5):188-9; discussion 189-90.
[Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology] Bespalov AIu, et al. **Usp Fiziol Nauk** 1999 Jan-Mar;30(1):39-53 (174 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Molecular determinants of NMDA receptor pharmacological diversity. Monaghan DT, et al. **Prog Brain Res** 1998; 116:171-90 (119 ref.)

DRUG EFFECTS

Neuronal excitotoxicity: the role of mitochondria. Nicholls DG, et al. **Biofactors** 1998;8(3-4):287-99 (64 ref.)
Antidepressants for the new millennium. Skolnick P. **Eur J Pharmacol** 1999 Jun 30;375(1-3):31-40 (72 ref.)
Subunit- and site-specific pharmacology of the NMDA receptor channel. Yamakura T, et al. **Prog Neurobiol** 1999 Oct;59(3):279-98 (263 ref.)
The role of the NMDA synapse in general anesthesia. Flohr H, et al. **Toxicol Lett** 1998 Nov 23;100-101:23-9 (35 ref.)
[Prevention of recurrent alcoholism with acamprosate. Neurobiological principles and clinical results] Soyka M, et al. **Internist (Berl)** 1999 Mar;40(3):330-6 (27 ref.) **(Ger)**

GENETICS

Molecular biology of the apteronotus NMDA receptor NR1 subunit. Dunn RJ, et al. **J Exp Biol** 1999 May;202 (Pt 10):1319-26 (67 ref.)
Transient expression of functional NMDA receptors in mammalian cells. Chazot PL, et al. **Methods Mol Biol** 1999; 128:33-42 (21 ref.)
Expression of NMDA receptor channel subunit proteins using baculovirus and herpesvirus vectors. Kawamoto S, et al. **Methods Mol Biol** 1999;128:19-32 (40 ref.)
Isolation of receptor clones by expression screening in Xenopus oocytes. Nakamura F, et al. **Methods Mol Biol** 1999;128:1-18 (30 ref.)
Stable expression of human NMDA receptors in cultured mammalian cells. Varney MA, et al. **Methods Mol Biol** 1999;128:43-59 (15 ref.)
Expression of extracellular N-terminal domain of NMDA

receptor in mammalian cells. Whitehorn EA, et al. **Methods Mol Biol** 1999;128:61-72 (10 ref.)

Schizophrenia and N-methyl-D-aspartate receptors: evolutionary adaptations from malfunctioning molecules? Rison RA. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Oct;11(4):236-40 (40 ref.)

Molecular determinants of NMDA receptor pharmacological diversity. Monaghan DT, et al. **Prog Brain Res** 1998; 116:171-90 (119 ref.)

METABOLISM

Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Sonsalla PK, et al. **Amino Acids** 1998;14(1-3):69-74 (13 ref.)

Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Nicoll RA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:515-25 (44 ref.)

Substituted indole-2-carboxylates as potent antagonists of the glycine binding site associated with the NMDA receptor. Micheli F, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):271-8 (36 ref.)

Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse. Nagano T, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):869-75 (74 ref.)

High-throughput functional detection of NMDA receptor activity. Cunningham MD, et al. **Methods Mol Biol** 1999; 128:179-88 (18 ref.)

Engineering the NMDA receptor channel lining. Ferrer-Montiel AV, et al. **Methods Mol Biol** 1999; 128:167-78 (25 ref.)

Redox sensitivity of NMDA receptors. Lipton SA. **Methods Mol Biol** 1999;128:121-30 (9 ref.)

The use of ligand binding in assays of NMDA receptor function. Reynolds IJ, et al. **Methods Mol Biol** 1999; 128:93-102 (25 ref.)

Calmodulin modification of NMDA receptors. Zhang S, et al. **Methods Mol Biol** 1999;128:103-11 (3 ref.)

The subcellular distribution of nitric oxide synthase relative to the NR1 subunit of NMDA receptors in the cerebral cortex. Aoki C, et al. **Prog Brain Res** 1998;118:83-97 (40 ref.)

Redox modulation of the NMDA receptor by NO-related species. Lipton SA, et al. **Prog Brain Res** 1998;118:73-82 (46 ref.)

Modulation of LTP induction by NMDA receptor activation and nitric oxide release. Zorumski CF, et al. **Prog Brain Res** 1998;118:173-82 (58 ref.)

PHYSIOLOGY

Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Chéramy A, et al. **Amino Acids** 1998;14(1-3):63-8 (25 ref.)

Ligands of the NMDA receptor-associated glycine recognition site and motor behavior. Kretschmer BD. **Amino Acids** 1998;14(1-3):227-34 (36 ref.)

The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Loopuijt LD, et al. **Amino Acids** 1998;14(1-3):17-23 (41 ref.)

NMDA receptor-mediated oscillatory properties: potential role in rhythm generation in the mammalian spinal cord. Schmidt BJ, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:189-202 (82 ref.)

Developmental aspects of NMDA receptor function. Vallano ML. **Crit Rev Neurobiol** 1998;12(3):177-204 (293 ref.)

Pathophysiological implications of the structural organization of the excitatory synapse. Cattabeni F, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):339-47 (72 ref.)

Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Moroni F. **Eur J Pharmacol** 1999 Jun 30;375(1-3):87-100 (183 ref.)

N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Adriani W, et al. **Exp Brain Res** 1998 Nov; 123(1-2):52-9 (55 ref.)

N-methyl-D-aspartate (NMDA) receptor: friend or foe? Robichon R, et al. **Indian J Exp Biol** 1998 Oct; 36(10):947-59 (144 ref.)

Orchestration of neuronal migration by activity of ion channels, neurotransmitter receptors, and intracellular Ca2+ fluctuations. Komuro H, et al. **J Neurobiol** 1998 Oct; 37(1):110-30 (129 ref.)

NMDA receptor pharmacology and analysis of patch-clamp recordings. Wright JM, et al. **Methods Mol Biol** 1999; 128:143-53 (16 ref.)

Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging. Yamada K, et al. **Microsc Res Tech** 1998 Oct 1;43(1):68-74 (75 ref.)

Biochemical studies of the structure and function of the N-methyl-D-aspartate subtype of glutamate receptors. Dunah AW, et al. **Mol Neurobiol** 1999 Apr;19(2):151-79 (109 ref.)

Integrated regulation of signal coding and plasticity by NMDA receptors at a central synapse. D'Angelo E, et al. **Neural Plast** 1998 Jul-Sep;6(3):8-16 (38 ref.)

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Jentsch JD, et al. **Neuropsychopharmacology** 1999 Mar;20(3):201-25 (250 ref.)

Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Danysz W, et al. **Pharmacol Rev** 1998 Dec;50(4):597-664 (806 ref.)

The NMDA antagonist model for schizophrenia: promise and pitfalls. Abi-Saab WM, et al. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:104-9 (50 ref.)

Influence of long-lasting administration of neuroleptics on cortical NMDA receptors and phencyclidine-induced deficit in the sensorimotor gating in rats. Ossowska K, et al. **Pol J Pharmacol** 1999 Jan-Feb;51(1):49-53 (41 ref.)

Glycine/NMDA receptor and seizure phenomena. Wlaź P. **Pol J Pharmacol** 1999 Jan-Feb;51(1):98-100 (25 ref.)

Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Yu XM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7697-704 (118 ref.)

Why is the role of nitric oxide in NMDA receptor function and dysfunction so controversial? Aizenman E, et al. **Prog Brain Res** 1998;118:53-71 (106 ref.)

Synaptic plasticity in ischemia: role of NMDA receptors. Crépel V, et al. **Prog Brain Res** 1998;116:273-85 (110 ref.)

Mechanisms involved in development of retinotectal connections: roles of Eph receptor tyrosine kinases, NMDA receptors and nitric oxide. Ernst AF, et al. **Prog Brain Res** 1998;118:115-31 (131 ref.)

Modulation of NMDA receptors. MacDonald JF, et al. **Prog Brain Res** 1998;116:191-208 (133 ref.)

The synaptic pharmacology underlying sensory processing in the superior colliculus. Binns KE. **Prog Neurobiol** 1999 Oct;59(2):129-59 (172 ref.)

Plasticity in the tectum of Xenopus laevis: binocular maps. Udin SB, et al. **Prog Neurobiol** 1999 Oct;59(2):81-106 (162 ref.)

Subunit- and site-specific pharmacology of the NMDA receptor channel. Yamakura T, et al. **Prog Neurobiol** 1999 Oct;59(3):279-98 (263 ref.)

[Ca2+ permeation through the ionotropic glutamate receptor] Ozawa S. **Tanpakushitsu Kakusan Koso** 1998 Sep; 43(12 Suppl):1589-95 (29 ref.) **(Jpn)**

RECEPTORS, MITOGEN

CHEMISTRY

Discoidin domain receptors: structural relations and functional implications. Vogel W. **FASEB J** 1999;13 Suppl:S77-82 (49 ref.)

METABOLISM

Discoidin domain receptors: structural relations and functional implications. Vogel W. **FASEB J** 1999;13 Suppl:S77-82 (49 ref.)

RECEPTORS, MORPHINE see **RECEPTORS, OPIOID, MU**

RECEPTORS, MU see **RECEPTORS, OPIOID, MU**

RECEPTORS, MU OPIOID see **RECEPTORS, OPIOID, MU**

RECEPTORS, MUSCARINIC

Muscarinic receptors and control of airway smooth muscle. Fryer AD, et al. **Am J Respir Crit Care Med** 1998 Nov; 158(5 Pt 3):S154-60 (63 ref.)

ANALYSIS

Muscarinic receptor subtypes involved in hippocampal circuits. Rouse ST, et al. **Life Sci** 1999;64(6-7):501-9 (43 ref.)

Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. van der Zee EA, et al. **Prog Neurobiol** 1999 Aug;58(5):409-71 (620 ref.)

CHEMISTRY

The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Hulme EC, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):247-60 (83 ref.)

Scanning mutagenesis of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor. Hulme EC, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):269-74 (15 ref.)

Structure-function analysis of muscarinic acetylcholine receptors. Kostenis E, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):265-8 (22 ref.)

DRUG EFFECTS

Muscarinic cholinergic receptor signal transduction as a potential target for the developmental neurotoxicity of ethanol. Costa LG, et al. **Biochem Pharmacol** 1999 Apr 1;57(7):721-6 (76 ref.)

Modulation by nicotine on muscarinic receptor-effector systems. Wang H. **Chung Kuo Yao Li Hsueh Pao** 1997 May; 18(3):193-7 (25 ref.)

Positive effects of allosteric modulators on the binding properties and the function of muscarinic acetylcholine receptors. Tuček S, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):241-3 (28 ref.)

Conformational transitions of the nicotinic acetylcholine receptor as a model for anesthetic actions on ligand-gated ion channels: single and sequential mixing stopped-flow fluorescence studies. Raines DE. **Toxicol Lett** 1998 Nov 23;100-101:163-8 (19 ref.)

GENETICS

Repression and activation of muscarinic receptor genes. Buckley NJ, et al. **Life Sci** 1999;64(6-7):495-9 (25 ref.)

Molecular analysis of the regulation of muscarinic receptor expression and function. Hamilton SE, et al. **Life Sci** 1995; 56(11-12):939-43 (10 ref.)

Molecular analysis of the regulation of muscarinic receptor expression and function. Nadler LS, et al. **Life Sci** 1999; 64(6-7):375-9 (18 ref.)

Control elements of muscarinic receptor gene expression. Saffen D, et al. **Life Sci** 1999;64(6-7):479-86 (32 ref.)

METABOLISM

Interaction of viral infections with muscarinic receptors. Jacoby DB, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:59-64 (41 ref.)

Muscarinic receptor ligands and their therapeutic potential. Eglen RM, et al. **Curr Opin Chem Biol** 1999 Aug; 3(4):426-32 (43 ref.)

Muscarinic regulation of Ca2+ signaling in mammalian atrial and ventricular myocardium. Endoh M. **Eur J Pharmacol** 1999 Jun 30;375(1-3):177-96 (104 ref.)

Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Pavía J, et al. **Fundam Clin Pharmacol** 1998;12(5):473-81 (99 ref.)

Muscarinic cholinergic signaling in cardiac myocytes: dynamic targeting of M2AChR to sarcolemmal caveolae and eNOS activation. Feron O, et al. **Life Sci** 1999; 64(6-7):471-7 (24 ref.)

Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Flynn DD, et al. **Life Sci** 1995;56(11-12):869-76 (32 ref.)

Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons. Hille B, et al. **Life Sci** 1995; 56(11-12):989-92 (34 ref.)

Multiple mechanisms involving protein phosphorylation are linked to desensitization of muscarinic receptors. Hosey MM, et al. **Life Sci** 1995;56(11-12):951-5 (23 ref.)

Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists. Jacobson KA, et al. **Life Sci** 1995;56(11-12):823-30 (29 ref.)

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6-7):511-8 (17 ref.)

Development of muscarinic receptors and regulation of secretory responsiveness in rodent sweat glands. Landis SC. **Life Sci** 1999;64(6-7):381-5 (35 ref.)

Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Wess J, et al. **Life Sci** 1995;56(11-12):915-22 (35 ref.)

Solubilized muscarinic acetylcholine receptors from the rat myocardium: pharmacological and hydrodynamic characterization. Berrie CP, et al. **Methods Mol Biol** 1999; 106:73-87 (9 ref.)

In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters. Bloch B, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):315-9 (44 ref.)

PHYSIOLOGY

The ins and outs of caveolar signaling. m2 muscarinic cholinergic receptors and eNOS activation versus neuregulin and ErbB4 signaling in cardiac myocytes. Feron O, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:11-9 (39 ref.)

Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Joseph JA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:268-76 (62 ref.)

Muscarinic receptors in the failing human heart. Giessler C, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):197-202 (70 ref.)

Molecular mechanisms for the regulation of the expression and function of muscarinic acetylcholine receptors. Hamilton SE, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):275-8 (15 ref.)

Some cholinergic themes related to Alzheimer's disease: synaptology of the nucleus basalis, location of m2 receptors, interactions with amyloid metabolism, and perturbations of cortical plasticity. Mesulam MM. **J Physiol Paris** 1998 Jun-Aug;92(3-4):293-8 (56 ref.)

Functional role of M2 muscarinic receptors in the guinea pig ileum. Ehlert FJ, et al. **Life Sci** 1995;56(11-12):965-71 (26 ref.)

Contractile role of M2 and M3 muscarinic receptors in gastrointestinal smooth muscle [published erratum appears in Life Sci 1999;64(26):2535] Ehlert FJ, et al. **Life Sci** 1999; 64(6-7):387-94 (52 ref.)

Muscarinic-mediated analgesia. Eisenach JC. **Life Sci** 1999; 64(6-7):549-54 (29 ref.)

Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Fryer AD, et al. **Life Sci** 1999;64(6-7):449-55 (49 ref.)

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Hegde SS, et al. **Life Sci** 1999;64(6-7):419-28 (60 ref.)

M2 signaling in smooth muscle cells. Kotlikoff MI, et al. **Life Sci** 1999;64(6-7):437-42 (29 ref.)

The influence of the cellular context on receptor function: a necessary consideration for physiologic interpretations of receptor expression studies. Logsdon CD. **Life Sci** 1999; 64(6-7):369-74 (38 ref.)
Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Somogyi GT, et al. **Life Sci** 1999;64(6-7):411-8 (50 ref.)
Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity. Costello RW, et al. **Thorax** 1998 Jul;53(7):613-6 (78 ref.)

RECEPTORS, MUSCIMOL see **RECEPTORS, GABA-A**

RECEPTORS, NARCOTIC see **RECEPTORS, OPIOID**

RECEPTORS, NERVE GROWTH FACTOR

DCC and netrins. Culotti JG, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):609-13 (39 ref.)

CHEMISTRY

[Variability of neurotrophin receptor structures] Ninkina NN, et al. **Mol Biol (Mosk)** 1998 Nov-Dec;32(6):955-63 (100 ref.) **(Rus)**

GENETICS

Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Pierotti MA, et al. **Recent Results Cancer Res** 1998;154:237-47 (47 ref.)

IMMUNOLOGY

Role of 4-1BB in immune responses. Vinay DS, et al. **Semin Immunol** 1998 Dec;10(6):481-9 (43 ref.)

METABOLISM

p75NTR: A study in contrasts [see comments] Barker PA. **Cell Death Differ** 1998 May;5(5):346-56 (140 ref.) Comment in: Cell Death Differ 1998 May;5(5):343-5.
Neurotrophins: the biological paradox of survival factors eliciting apoptosis [see comments] Casaccia-Bonnefil P, et al. **Cell Death Differ** 1998 May;5(5):357-64 (73 ref.) Comment in: Cell Death Differ 1998 May;5(5):343-5.
Role of 4-1BB in immune responses. Vinay DS, et al. **Semin Immunol** 1998 Dec;10(6):481-9 (43 ref.)
[Neurotrophic factors and spinal cord injury. A review] Liu W, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):19-21 (26 ref.) **(Chi)**
[Signal transduction of nerve growth factor (NGF) and its TrkA and p75NTR receptors] Niewiadomska G, et al. **Postepy Biochem** 1999;45(1):21-31 (79 ref.) **(Pol)**

PHYSIOLOGY

p75NTR and the concept of cellular dependence: seeing how the other half die [see comments] Bredesen DE, et al. **Cell Death Differ** 1998 May;5(5):365-71 (39 ref.) Comment in: Cell Death Differ 1998 May;5(5):343-5.
Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Nakagawara A. **Hum Cell** 1998 Sep;11(3):115-24 (46 ref.)
Neuronal life and death decisions functional antagonism between the Trk and p75 neurotrophin receptors. Majdan M, et al. **Int J Dev Neurosci** 1999 Jun;17(3):153-61 (87 ref.)
Trophic interactions between sensory nerves and their targets. Chen WP, et al. **J Biomed Sci** 1999 Mar-Apr; 6(2):79-85 (52 ref.)
p75 neurotrophin receptor as a modulator of survival and death decisions. Casaccia-Bonnefil P, et al. **Microsc Res Tech** 1999 May 15-Jun 1;45(4-5):217-24 (80 ref.)
Trks: signal transduction and intracellular pathways. Klesse LJ, et al. **Microsc Res Tech** 1999 May 15-Jun 1; 45(4-5):210-6 (73 ref.)
Neurotrophin receptors in Alzheimer's disease. Salehi A, et al. **Prog Brain Res** 1998;117:71-89 (142 ref.)
The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Rossner S, et al. **Prog Neurobiol** 1998 Dec; 56(5):541-69 (286 ref.)
Neurotrophins. Lederhaas G. **Reg Anesth Pain Med** 1999 May-Jun;24(3):250-1 (5 ref.)
Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341-3 (7 ref.)
[Neuronal growth factors--neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063-70 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3112-3. **(Dan)**

RECEPTORS, NEU see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

RECEPTORS, NEURAL see **RECEPTORS, SENSORY**

RECEPTORS, NEUROHUMOR see **RECEPTORS, NEUROTRANSMITTER**

RECEPTORS, NEUROKININ-1

PHYSIOLOGY

The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Saria A. **Eur J Pharmacol** 1999 Jun 30;375(1-3):51-60 (116 ref.)

RECEPTORS, NEUROKININ-2

ANTAGONISTS & INHIBITORS

Recent advances in neurokinin receptor antagonists. Gao Z, et al. **Curr Med Chem** 1999 May;6(5):375-88 (63 ref.)

RECEPTORS, NEUROKININ-3

ANTAGONISTS & INHIBITORS

Recent advances in neurokinin receptor antagonists. Gao Z, et al. **Curr Med Chem** 1999 May;6(5):375-88 (63 ref.)

RECEPTORS, NEUROMEDIN B see **RECEPTORS, BOMBESIN**

RECEPTORS, NEUROPEPTIDE

ANTAGONISTS & INHIBITORS

Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Griebel G. **Pharmacol Ther** 1999 Apr;82(1):1-61 (375 ref.)

BIOSYNTHESIS

Regulation of expression of galanin and galanin receptors in dorsal root ganglia and spinal cord after axotomy and inflammation. Zhang X, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:402-13 (50 ref.)

DEFICIENCY

Narcolepsy: a key role for hypocretins (orexins) [comment] Siegel JM. **Cell** 1999 Aug 20;98(4):409-12 (20 ref.) Comment on: Cell 1999 Aug 6;98(3):365-76. Comment on: Cell 1999 Aug 20;98(4):437-51.

GENETICS

Molecular biology and pharmacology of galanin receptors. Branchek T, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:94-107 (83 ref.)
Applications of new genetic approaches to growth hormone-releasing hormone receptor defects. Phillips JA, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:45-9 (14 ref.)
Multiple genes for neuropeptides and their receptors: co-evolution and physiology. Darlison MG, et al. **Trends Neurosci** 1999 Feb;22(2):81-8 (74 ref.)

METABOLISM

Molecular biology and pharmacology of galanin receptors. Branchek T, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:94-107 (83 ref.)
Chemistry and molecular biology of galanin receptor ligands. Langel U, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:86-93 (44 ref.)
Fluorescent ligands for studying neuropeptide receptors by confocal microscopy. Beaudet A, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1479-89 (40 ref.)

PHYSIOLOGY

Gonadal steroid-dependent GAL-IR cells within the medial preoptic nucleus (MPN) and the stimulatory effects of GAL within the MPN on sexual behaviors. Bloch GJ, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:188-205 (88 ref.)
Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Fuxe K, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:274-90 (38 ref.)
Galanin-galanin receptor systems in the hypothalamic paraventricular and supraoptic nuclei. Some recent findings and future challenges. Gundlach AL, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:241-51 (52 ref.)
Galanin inhibits performance on rodent memory tasks. McDonald MP, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:305-22 (59 ref.)
Regulation of galanin in memory pathways. Miller MA. **Ann N Y Acad Sci** 1998 Dec 21;863:323-41 (89 ref.)
Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential. Mufson EJ, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:291-304 (73 ref.)
Galanin in somatosensory function. Wiesenfeld-Hallin Z, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:383-9 (42 ref.)
Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19-26 (35 ref.)
Molecular and cell biology of the growth hormone-releasing hormone receptor. Gaylinn BD. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:37-44 (69 ref.)
Signal transduction of the growth hormone (GH) receptor, and GH-binding protein. Wojcik J, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:51-5 (41 ref.)
Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. Rozengurt E. **J Cell Physiol** 1998 Dec;177(4):507-17 (129 ref.)
Galanin and galanin receptors. Iismaa TP, et al. **Results Probl Cell Differ** 1999;26:257-91 (210 ref.)
Molecular biology of the receptors for somatostatin and cortistatin. Kreienkamp HJ. **Results Probl Cell Differ** 1999; 26:215-37 (110 ref.)

RECEPTORS, NEUROPEPTIDE Y

ANALYSIS

Bioassays for NPY receptors: old and new. Pheng LH, et al. **Regul Pept** 1998 Sep 25;75-76:79-87 (47 ref.)

ANTAGONISTS & INHIBITORS

D-myo inositol 1,2,6, triphosphate (alpha-trinositol, pp56): selective antagonist at neuropeptide Y (NPY) Y-receptors or selective inhibitor of phosphatidylinositol cell signaling? Bell D, et al. **Gen Pharmacol** 1998 Nov;31(5):689-96 (79 ref.)

CLASSIFICATION

Central control of feeding behavior by neuropeptide Y. Zimanyi IA, et al. **Curr Pharm Des** 1998 Aug;4(4):349-66 (196 ref.)

PHYSIOLOGY

Neuropeptide Y feeding receptors: are multiple subtypes involved? Inui A. **Trends Pharmacol Sci** 1999 Feb; 20(2):43-6 (47 ref.)

RECEPTORS, NEUROTENSIN

PHYSIOLOGY

Mechanisms of regulation of neurotensin receptors. Hermans E, et al. **Pharmacol Ther** 1998 Aug;79(2):89-104 (153 ref.)
Neurotensin and neurotensin receptors. Vincent JP, et al. **Trends Pharmacol Sci** 1999 Jul;20(7):302-9 (67 ref.)

RECEPTORS, NEUROTRANSMITTER

[The biological mechanisms underlying alcohol dependence] Alling C. **Lakartidningen** 1999 Jul 14;96(28-29):3248-52 (63 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Roth BL, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):73-85 (152 ref.)
Drug-activation of brain reward pathways. Wise RA. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):13-22 (121 ref.)
Receptor pharmacology of neuroleptics: relation to clinical effects. Richelson E. **J Clin Psychiatry** 1999;60 Suppl 10:5-14 (69 ref.)
Multiple mechanisms of action: the pharmacological profile of budipine. Eltze M. **J Neural Transm Suppl** 1999; 56:83-105 (102 ref.)
Ethanol tolerance and synaptic plasticity. Chandler LJ, et al. **Trends Pharmacol Sci** 1998 Dec;19(12):491-5 (48 ref.)

METABOLISM

Autonomic regulation. i-NANC/e-NANC. Widdicombe JG. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S171-5 (51 ref.)
The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. Robinson MB. **Neurochem Int** 1998 Dec;33(6):479-91 (140 ref.)
Special issues in quantitation of brain receptors and related markers by emission computed tomography. Links JM. **Q J Nucl Med** 1998 Sep;42(3):158-65 (56 ref.)
[Molecular mechanism of the assembly of neurotransmitter receptors and cell adhesion molecules at postsynaptic density] Hata Y. **Seikagaku** 1998 Dec;70(12):1414-8 (16 ref.) **(Jpn)**

PHYSIOLOGY

Interactions between the presynaptic alpha2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Schlicker E, et al. **Brain Res Bull** 1998 Sep 15;47(2):129-32 (45 ref.)
Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Giustina A, et al. **Endocr Rev** 1998 Dec;19(6):717-97 (1103 ref.)
Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit? Satin LS, et al. **Endocrine** 1998 Jun;8(3):213-23 (85 ref.)
Pathophysiological implications of the structural organization of the excitatory synapse. Cattabeni F, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):339-47 (72 ref.)
Neurotransmitter transporters: target for endocrine regulation. Figlewicz DP, et al. **Horm Metab Res** 1999 May;31(5):335-9 (58 ref.)

RECEPTORS, NEUROTRANSMITTER

Inborn errors of neurotransmitter receptors. Surtees R. **J Inherit Metab Dis** 1999 Jun;22(4):374–80 (21 ref.)
Activity and synaptic receptor targeting: the long view. Craig AM. **Neuron** 1998 Sep;21(3):459–62 (20 ref.)
Theoretical aspects of sensory substitution and of neurotransmission-related reorganization in spinal cord injury. Bach-y-Rita P. **Spinal Cord** 1999 Jul;37(7):465–74 (81 ref.)
Pharmacology of pain processing systems. Schadrack J, et al. **Z Rheumatol** 1998;57 Suppl 2:1–4 (22 ref.)
[Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment] Glenthøj BY, et al. **Ugeskr Laeger** 1999 Mar 8; 161(10):1391–8 (40 ref.) (Eng. Abstr.) **(Dan)**

RECEPTORS, NGF see **RECEPTORS, NERVE GROWTH FACTOR**

RECEPTORS, NICOTINIC

BIOSYNTHESIS

Determinants responsible for assembly of the nicotinic acetylcholine receptor. Keller SH, et al. **J Gen Physiol** 1999 Feb;113(2):171–6 (40 ref.)

CHEMISTRY

Heteromeric complexes of alpha 5 and/or alpha 7 subunits. Effects of calcium and potential role in nicotine-induced presynaptic facilitation. Girod R, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:578–90 (81 ref.)
Molecular diversity of neuronal nicotinic acetylcholine receptors. McGehee DS. **Ann N Y Acad Sci** 1999 Apr 30; 868:565–77 (79 ref.)
Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor. Arias HR. **Biochim Biophys Acta** 1998 Aug 21;1376(2):173–220 (343 ref.)
Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Tzartos SJ, et al. **Immunol Rev** 1998 Jun; 163:89–120 (239 ref.)
Allosteric modulation of neuronal nicotinic acetylcholine receptors. Buisson B, et al. **J Physiol Paris** 1998 Apr; 92(2):89–100 (122 ref.)
Toxins selective for subunit interfaces as probes of nicotinic acetylcholine receptor structure. Taylor P, et al. **J Physiol Paris** 1998 Apr;92(2):79–83 (21 ref.)
Molecular basis of the charge selectivity of nicotinic acetylcholine receptor and related ligand-gated ion channels. Corringer PJ, et al. **Novartis Found Symp** 1999; 225:215–24; discussion 224–30 (26 ref.)

CLASSIFICATION

International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Lukas RJ, et al. **Pharmacol Rev** 1999 Jun;51(2):397–401 (35 ref.)

DRUG EFFECTS

Modulation by nicotine on muscarinic receptor-effector systems. Wang H. **Chung Kuo Yao Li Hsueh Pao** 1997 May; 18(3):193–7 (25 ref.)
Neuronal nicotinic acetylcholine receptors: a new target site of ethanol. Narahashi T, et al. **Neurochem Int** 1999 Aug; 35(2):131–41 (124 ref.)
Neuronal nicotinic acetylcholine receptor modulation by general anesthetics. Flood P, et al. **Toxicol Lett** 1998 Nov 23;100–101:149–53 (26 ref.)
Direct interactions of anesthetics and nonanesthetics with the nicotinic acetylcholine receptor pore. Forman SA. **Toxicol Lett** 1998 Nov 23;100–101:169–78 (26 ref.)

GENETICS

New functions for nicotinic acetylcholine receptors? Steinlein O. **Behav Brain Res** 1998 Sep;95(1):31–5 (42 ref.)
Neuronal nicotinic acetylcholine receptors: their properties and alterations in autosomal dominant nocturnal frontal lobe epilepsy. Bertrand D. **Rev Neurol (Paris)** 1999 Jul; 155(6–7):457–62 (30 ref.)
Gene defects in idiopathic epilepsy. Steinlein OK. **Rev Neurol (Paris)** 1999 Jul;155(6–7):450–3 (18 ref.)

METABOLISM

Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Decker MW, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):917–23 (58 ref.)
Allosteric modulation of neuronal nicotinic acetylcholine receptors. Buisson B, et al. **J Physiol Paris** 1998 Apr; 92(2):89–100 (122 ref.)
Toxins selective for subunit interfaces as probes of nicotinic acetylcholine receptor structure. Taylor P, et al. **J Physiol Paris** 1998 Apr;92(2):79–83 (21 ref.)
Nicotinic acetylcholine involvement in cognitive function in animals. Levin ED, et al. **Psychopharmacology (Berl)** 1998 Aug;138(3–4):217–30 (167 ref.)

PHYSIOLOGY

New functions for nicotinic acetylcholine receptors? Steinlein O. **Behav Brain Res** 1998 Sep;95(1):31–5 (42 ref.)
The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. Decker MW, et al. **J Physiol Paris** 1998 Jun–Aug;92(3–4):221–4 (17 ref.)
Allosteric nicotinic receptors, human pathologies. Léna C, et al. **J Physiol Paris** 1998 Apr;92(2):63–74 (112 ref.)
Neuronal nicotinic acetylcholine receptors: their properties and alterations in autosomal dominant nocturnal frontal lobe epilepsy. Bertrand D. **Rev Neurol (Paris)** 1999 Jul; 155(6–7):457–62 (30 ref.)
[Epibatidine. An old work principle rediscovered] Hecker T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):226–32 (41 ref.) **(Ger)**
[Desensitizing function of calcium mobilized by the postsynaptic neuronal-type nicotinic acetylcholine receptors at the neuromuscular junction] Kimura I, et al. **Yakugaku Zasshi** 1999 Jan;119(1):1–15 (55 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, NK-2 see **RECEPTORS, NEUROKININ-2**

RECEPTORS, NK-3 see **RECEPTORS, NEUROKININ-3**

RECEPTORS, NMDA see **RECEPTORS, N-METHYL-D-ASPARTATE**

RECEPTORS, NOREPINEPHRINE see **RECEPTORS, ADRENERGIC**

RECEPTORS, ODORANT

Odorant-binding proteins: expression and function. Steinbrecht RA. **Ann N Y Acad Sci** 1998 Nov 30;855:323–32 (38 ref.)

CHEMISTRY

Odorant-binding proteins: structural aspects. Pelosi P. **Ann N Y Acad Sci** 1998 Nov 30;855:281–93 (82 ref.)

GENETICS

Genome dynamics, evolution, and protein modeling in the olfactory receptor gene superfamily. Sharon D, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:182–93 (29 ref.)
Molecular biology of odorant receptors in vertebrates. Mombaerts P. **Annu Rev Neurosci** 1999;22:487–509 (76 ref.)
Cloning, functional expression and characterization of a human olfactory receptor. Hatt H, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 May;45(3):285–91 (16 ref.)

METABOLISM

Cloning, functional expression and characterization of a human olfactory receptor. Hatt H, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 May;45(3):285–91 (16 ref.)

PHYSIOLOGY

Development of the vertebrate main olfactory system. Lin DM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):74–8 (41 ref.)
Elements of the olfactory signaling pathways in insect antennae. Krieger J, et al. **Invert Neurosci** 1997 Sep–Dec; 3(2–3):137–44 (50 ref.)

RECEPTORS, OPIATE see **RECEPTORS, OPIOID**

RECEPTORS, OPIOID

[Nociceptin and nociceptin receptor] Nishi M, et al. **Seikagaku** 1998 Jul;70(7):548–53 (13 ref.) **(Jpn)**
[Molecular mechanisms of opioidergic antinociception] Satoh M. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1360–8 (27 ref.) **(Jpn)**

AGONISTS

Nociceptin/orphanin FQ. A new opioid, a new analgesic? Taylor F, et al. **Neuroreport** 1998 Aug 24;9(12):R65–70 (43 ref.)

ANALYSIS

Positron emission tomography receptor studies in epilepsy. Duncan JS. **Rev Neurol (Paris)** 1999 Jul;155(6–7):482–8 (50 ref.)

DEFICIENCY

[Behavioral pharmacological characterization of mice lacking the nociceptin receptor] Noda Y, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Apr; 19(2):73–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

The neurobiology of opiate reinforcement. Shippenberg TS, et al. **Crit Rev Neurobiol** 1998;12(4):267–303 (240 ref.)

GENETICS

Targeted mutagenesis of the murine opioid system. Hayward MD, et al. **Results Probl Cell Differ** 1999;26:169–91 (100 ref.)
[The discovery of a novel opioid-receptor-like receptor and its endogenous ligand] Fang Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):210–4 (12 ref.) (Eng. Abstr.) **(Chi)**

METABOLISM

Heterologous expression of G-protein-coupled receptors: human opioid receptors under scrutiny. Stanasila L, et al. **Biochimie** 1998 May–Jun;80(5–6):563–71 (78 ref.)
Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Harrison LM, et al. **Peptides** 1998;19(9):1603–30 (253 ref.)

PHYSIOLOGY

Role of opioid ligands in the irritable bowel syndrome. Corazziari E. **Can J Gastroenterol** 1999 Mar;13 Suppl A:71A–75A (42 ref.)
Opioid receptor signalling mechanisms. Connor M, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):493–9 (77 ref.)
Endogenous opioids: overview and current issues. Akil H, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):127–40 (150 ref.)
Regulation of opioid receptor activities. Law PY, et al. **J Pharmacol Exp Ther** 1999 May;289(2):607–24 (136 ref.)
Endogenous drug-like factors. Mrozikiewicz A. **Pol J Pharmacol** 1998 Nov–Dec;50(6):393–7 (26 ref.)
Nociceptin/orphanin FQ: role in nociceptive information processing. Yamamoto T, et al. **Prog Neurobiol** 1999 Apr; 57(5):527–35 (89 ref.)
Opioids: first lessons from knockout mice. Kieffer BL. **Trends Pharmacol Sci** 1999 Jan;20(1):19–26 (60 ref.)
[Cloning of prepronociceptin has led to the discovery of other biologically active peptides] Costentin J, et al. **C R Seances Soc Biol Fil** 1998;192(6):1099–109 (60 ref.) (Eng. Abstr.) **(Fre)**
[Pain control mechanism involving opioid receptors] Sato M. **Masui** 1998 Dec;47 Suppl:S211–7 (10 ref.) **(Jpn)**
[Behavioral pharmacological characterization of mice lacking the nociceptin receptor] Noda Y, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1999 Apr; 19(2):73–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, OPIOID, DELTA

AGONISTS

Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. Schiller PW, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):573–88 (33 ref.)

ANTAGONISTS & INHIBITORS

Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. Schiller PW, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):573–88 (33 ref.)

PHYSIOLOGY

The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Quock RM, et al. **Pharmacol Rev** 1999 Sep;51(3):503–32 (280 ref.)

RECEPTORS, OPIOID, KAPPA

AGONISTS

Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models. Hiramatsu M, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):595–9 (34 ref.)
U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990. Szmuszkovicz J. **Prog Drug Res** 1999;52:167–95 (74 ref.)
[Effects of newly isolated opioid peptides on G-protein activation: usefulness of [35S] GTP gamma S binding study and its practical application] Narita M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):107–16 (58 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, OPIOID, MU

AGONISTS

[Effects of newly isolated opioid peptides on G-protein activation: usefulness of [35S] GTP gamma S binding study and its practical application] Narita M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):107–16 (58 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Uhl GR, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7752–5 (31 ref.)

RECEPTORS, OPIOID, SIGMA see **RECEPTORS, SIGMA**

RECEPTORS, OXYTOCIN

ANTAGONISTS & INHIBITORS

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

CHEMISTRY

Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Postina R, et al. **Adv Exp Med Biol** 1998;449:371–85 (27 ref.)

Functional architecture of vasopressin/oxytocin receptors. Hibert M, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):589–96 (12 ref.)

GENETICS

The molecular basis of oxytocin and oxytocin receptor gene expression in reproductive tissues. Ivell R, et al. **Adv Exp Med Biol** 1998;449:297–306 (46 ref.)

Bovine endometrial epithelial cells as a model system to study oxytocin receptor regulation. Horn S, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):605–14 (36 ref.)

METABOLISM

Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Postina R, et al. **Adv Exp Med Biol** 1998;449:371–85 (27 ref.)

The brain oxytocin receptor(s)? Verbalis JG. **Front Neuroendocrinol** 1999 Apr;20(2):146–56 (75 ref.)

Bovine endometrial epithelial cells as a model system to study oxytocin receptor regulation. Horn S, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):605–14 (36 ref.)

PHYSIOLOGY

Genomic and non-genomic mechanisms of oxytocin receptor regulation. Zingg HH, et al. **Adv Exp Med Biol** 1998; 449:287–95 (28 ref.)

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Thibonnier M, et al. **Prog Brain Res** 1998;119:147–61 (67 ref.)

The oxytocin receptor. Kimura T, et al. **Results Probl Cell Differ** 1999;26:135–68 (160 ref.)

Neural oxytocinergic systems as genomic targets for hormones and as modulators of hormone-dependent behaviors. Pfaff DW, et al. **Results Probl Cell Differ** 1999; 26:91–105 (75 ref.)

Vasopressin receptors: structural functional relationships and role in neural and endocrine regulation. Schoots O, et al. **Results Probl Cell Differ** 1999;26:107–33 (90 ref.)

RECEPTORS, PAIN see **NOCICEPTORS**

RECEPTORS, PANCREOZYMIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, PARATHYROID HORMONE

GENETICS

Parathyroid hormone (PTH)/PTHrP receptor mutations in human chondrodysplasia [editorial; comment] Nissenson RA. **Endocrinology** 1998 Dec;139(12):4753–5 (21 ref.) Comment on: Endocrinology 1998 Dec;139(12):5255–8.

[Activating mutations of the parathyroid hormone and parathyroid hormone related peptide] David L. **Arch Pediatr** 1998;5 Suppl 4:385S–389S (22 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules [editorial; comment] Goltzman D. **J Bone Miner Res** 1999 Feb;14(2):173–7 (44 ref.) Comment on: J Bone Miner Res 1999 Feb;14(2):163–72.

PHYSIOLOGY

Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Jüppner H. **Bone** 1999 Jul;25(1):87–90 (61 ref.)

Parathyroid hormone-related peptide (PTHrP) and parathyroid hormone (PTH)/PTHrP receptor. Lanske B, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3–4):297–320 (107 ref.)

Regulation of phosphate transport in the renal tubule through parathyroid hormone receptor: unexpected pathways. Silve C, et al. **Exp Nephrol** 1998 Jul–Aug;6(4):282–7 (16 ref.)

RECEPTORS, PDGF see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

RECEPTORS, PEPTIDE

Vasoactive peptide receptors in the rat kidney. Garcia R, et al. **Biol Res** 1998;31(3):217–25 (88 ref.)

The 'chicken and egg' problem of co-evolution of peptides and their cognate receptors: which came first? Darlison MG, et al. **Results Probl Cell Differ** 1999;26:1–11 (33 ref.)

ANALYSIS

Autoradiography of peptide receptors. Wharton J, et al. **Methods Mol Biol** 1999;106:99–118 (48 ref.)

IMMUNOLOGY

Chemoattractant receptor cross-desensitization. Ali H, et al. **J Biol Chem** 1999 Mar 5;274(10):6027–30 (52 ref.)

METABOLISM

Receptor-mediated endocytosis of cobalamin (vitamin B12). Seetharam B. **Annu Rev Nutr** 1999;19:173–95 (93 ref.)

Autoradiographic and immunological techniques to analyse kinin receptor distribution in rat and human tissues. Figueroa CD, et al. **Biol Res** 1998;31(3):175–87 (51 ref.)

Hope, hypothesis, and the inhibin receptor. Does specific inhibin binding suggest there is a specific inhibin receptor? [editorial; comment] Woodruff TK. **Endocrinology** 1999 Jan;140(1):3–5 (16 ref.) Comment on: Endocrinology 1999 Jan;140(1):6–12.

Serpentine receptors and STAT activation: more than one way to twin a STAT. Williams JG. **Trends Biochem Sci** 1999 Sep;24(9):333–4 (15 ref.)

PHYSIOLOGY

Chloroplast precursor protein translocon. May T, et al. **FEBS Lett** 1999 Jun 4;452(1–2):52–6 (53 ref.)

Melanocortin-4 receptor: a novel signalling pathway involved in body weight regulation. Fisher SL, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:54–8 (37 ref.)

RECEPTORS, PEPTIDE, INVERTEBRATE see **RECEPTORS, INVERTEBRATE PEPTIDE**

RECEPTORS, PHEROMONE see **CHEMORECEPTORS**

RECEPTORS, PITUITARY HORMONE

CLASSIFICATION

A critical view of the methods for characterization of the VIP/PACAP receptor subclasses. Robberecht P, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:157–63 (35 ref.)

GENETICS

Induction of type I PACAP receptor expression by the new zinc finger protein Zac1 and p53. Hoffmann A, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:49–58 (29 ref.)

Developmental regulation of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 in rat brain: function of PACAP as a neurotrophic factor. Lindholm D, et al. **Ann N Y Acad Sci** 1998 Dec 11; 865:189–96 (17 ref.)

PHYSIOLOGY

The PACAP ligand/receptor system regulates cerebral cortical neurogenesis. Dicicco-Bloom E, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:274–89 (49 ref.)

Stimulatory transducing systems in pancreatic islet cells. Emami S, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:118–31 (78 ref.)

RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE

GENETICS

Applications of new genetic approaches to growth hormone-releasing hormone receptor defects. Phillips JA, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:45–9 (14 ref.)

PHYSIOLOGY

Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19–26 (35 ref.)

Molecular and cell biology of the growth hormone-releasing hormone receptor. Gaylinn BD. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:37–44 (69 ref.)

Signal transduction of the growth hormone (GH) receptor, and GH-binding protein. Wojcik J, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:51–5 (41 ref.)

RECEPTORS, PITUITARY HORMONE RELEASE INHIBITING HORMONES see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

RECEPTORS, PITUITARY HORMONE-RELEASING HORMONE see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

BIOSYNTHESIS

Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Yoshida H, et al. **Dev Comp Immunol** 1998 May–Jun;22(3):321–32 (56 ref.)

METABOLISM

Signaling networks--do all roads lead to the same genes? [comment] Pawson T, et al. **Cell** 1999 Jun 11;97(6):675–8 (21 ref.) Comment on: Cell 1999 Jun 11;97(6):727–41.

PHYSIOLOGY

Regulation of platelet-derived growth factor signaling by activated p21Ras. Stice LL, et al. **Front Biosci** 1999 Jan 15;4:D72–86 (113 ref.)

Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Rosenkranz S, et al. **Growth Factors** 1999; 16(3):201–16 (120 ref.)

RECEPTORS, PRESYNAPTIC

AGONISTS

Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Feuerstein TJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 May; 359(5):345–59 (23 ref.)

PHYSIOLOGY

Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Chéramy A, et al. **Amino Acids** 1998;14(1–3):63–8 (25 ref.)

RECEPTORS, PROGESTERONE

Steroid hormone receptors in breast cancer management. Osborne CK. **Breast Cancer Res Treat** 1998;51(3):227–38 (76 ref.)

ANALYSIS

Paraffin section immunocytochemistry and cytosol-based ligand-binding assays for ER and PR detection in breast cancer: the time has come for more objectivity. Goussard J. **Cancer Lett** 1998 Oct 23;132(1–2):61–6 (27 ref.)

[Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast] Nizze H, et al. **Zentralbl Chir** 1998;123 Suppl 5:14–8 (46 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

News and views of non-genomic progesterone receptors on spermatozoa. Blackmore PF. **Andrologia** 1998 Aug–Sep; 30(4–5):255–61 (69 ref.)

Progesterone receptors in gastric leiomyosarcoma [letter] Munoz E. **Eur J Surg** 1998 Oct;164(10):796 (5 ref.)

Nongenomic progesterone receptor on human spermatozoa: biochemical aspects and clinical implications. Baldi E, et al. **Steroids** 1999 Jan–Feb;64(1–2):143–8 (53 ref.)

PHYSIOLOGY

Endometrial oestrogen and progesterone receptors and their relationship to sonographic appearance of the endometrium. Ohno Y, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):560–4 (17 ref.)

Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Spitz IM, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):584–93 (71 ref.)

RECEPTORS, PROGESTIN see **RECEPTORS, PROGESTERONE**

RECEPTORS, PROGLUMIDE see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, PROLACTIN

ANTAGONISTS & INHIBITORS

Prolactin receptor antagonists. Kuo CB, et al. **Endocrine** 1998 Oct;9(2):121–31 (84 ref.)

PHYSIOLOGY

Prolactin, growth hormone and the immune system in humans. Velkeniers B, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1102–8 (75 ref.)

Prolactin and its receptor in human endometrium. Tseng L, et al. **Semin Reprod Endocrinol** 1999;17(1):23–7 (19 ref.)

RECEPTORS, PROSTAGLANDIN

[Current topics in the regulation of prostanoids--3. Prostanoid synthases and prostanoid receptors] Ohara M, et al. **Masui** 1999 Jan;48(1):42-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

[Structure and function of prostaglandin receptors] Ichikawa A. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1090-6 (33 ref.) **(Jpn)**

GENETICS

What knockout mice can tell us about parturition. Kimura T, et al. **Rev Reprod** 1999 May;4(2):73-80 (71 ref.)

PHYSIOLOGY

[Structure and function of prostaglandin receptors] Ichikawa A. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1090-6 (33 ref.) **(Jpn)**

RECEPTORS, PROSTAGLANDIN E

[Molecular biology of prostaglandin E receptors--expression of multi-function by PGE receptor subtypes and isoforms] Ichikawa A. **Nippon Rinsho** 1998 Jul;56(7):1813-8 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Regulation of renal function by prostaglandin E receptors. Breyer MD, et al. **Kidney Int Suppl** 1998 Sep;67:S88-94 (74 ref.)

PHYSIOLOGY

Fever: links with an ancient receptor. Dinarello CA, et al. **Curr Biol** 1999 Feb 25;9(4):R147-50 (23 ref.)

RECEPTORS, PROTIRELIN see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

RECEPTORS, PURINERGIC

CHEMISTRY

Purinergic receptors in human blood platelets: chemical modification and cloning investigations. Puri RN, et al. **J Protein Chem** 1998 Jul;17(5):429-51 (167 ref.)

CLASSIFICATION

Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Kunapuli SP. **Trends Pharmacol Sci** 1998 Oct;19(10):391-4 (56 ref.)

DRUG EFFECTS

Adenosine and the nervous system: pharmacological data and therapeutic perspectives. Guieu R, et al. **Gen Pharmacol** 1998 Oct;31(4):553-61 (166 ref.)

PHYSIOLOGY

Connections between P2 purinoceptors and capsaicin-sensitive afferents in the intestine and other tissues. Barthó L, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1-3):203-10 (103 ref.)

Postnatal development of purinoceptors in rat visceral smooth muscle preparations. Hourani SM. **Gen Pharmacol** 1999 Jan;32(1):3-7 (47 ref.)

Extracellular purines and their receptors in immunoregulation. Review of recent advances. Sitkovsky MV. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):351-7 (12 ref.)

[Roles of the cell surface purinergic receptors for extracellular adenosine and ATP in T-cell development and effector functions] Koshiba M. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):263-9 (29 ref.) **(Jpn)**

[Characterization of the facilitatory modulation of adrenergic neurotransmission via prejunctional purinoceptors in rabbit ear artery] Ishii-Nozawa R, et al. **Yakugaku Zasshi** 1999 Jun;119(6):417-28 (47 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, PURINERGIC P1

AGONISTS

Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? [corrected and republished in Eur J Pharmacol 1999 Apr 23;371(1):85-102] Von Lubitz DK. **Eur J Pharmacol** 1999 Jan 15;365(1):9-25 (290 ref.)

Adenosine A3 receptors: novel ligands and paradoxical effects. Jacobson KA. **Trends Pharmacol Sci** 1998 May; 19(5):184-91 (44 ref.)

ANTAGONISTS & INHIBITORS

Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Kuwana Y, et al. **Adv Neurol** 1999; 80:121-3 (13 ref.)

Adenosine receptor antagonists and Parkinson's disease: actions of the A2A receptor in the striatum. Richardson PJ, et al. **Adv Neurol** 1999;80:111-9 (40 ref.)

DRUG EFFECTS

Receptors for purines and pyrimidines. Ralevic V, et al. **Pharmacol Rev** 1998 Sep;50(3):413-92 (1009 ref.)

METABOLISM

Localization of adenosine A2A receptors in brain: therapeutic implications. Augood SJ. **Adv Neurol** 1999;80:105-9 (38 ref.)

Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges [editorial; comment] Auchampach JA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H1113-6 (31 ref.) Comment on: Am J Physiol 1999 Feb;276(2 Pt 2):H341-9.

Adenosine and preconditioning revisited. Miura T, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):92-9 (85 ref.)

Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Fozard JR, et al. **Pulm Pharmacol Ther** 1999;12(2):111-4 (45 ref.)

PHYSIOLOGY

Adenosine receptor antagonists and Parkinson's disease: actions of the A2A receptor in the striatum. Richardson PJ, et al. **Adv Neurol** 1999;80:111-9 (40 ref.)

Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Ribeiro JA. **Eur J Pharmacol** 1999 Jun 30;375(1-3):101-13 (136 ref.)

Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? [corrected and republished article originally printed in Eur J Pharmacol 1999 Jan 15;365(1):9-25] von Lubitz DK. **Eur J Pharmacol** 1999 Apr 23;371(1):85-102 (291 ref.)

Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Roman RM, et al. **Gastroenterology** 1999 Apr;116(4):964-79 (143 ref.)

Purinergic signalling: pathophysiological roles. Abbracchio MP, et al. **Jpn J Pharmacol** 1998 Oct;78(2):113-45 (300 ref.)

Insight into adenosine receptor function using antisense and gene-knockout approaches. Nyce JW. **Trends Pharmacol Sci** 1999 Feb;20(2):79-83 (46 ref.)

RECEPTORS, PURINERGIC P2

[Cardiovascular treatment potentials. P2 receptors important for future drugs] Erlinge D. **Lakartidningen** 1999 May 26; 96(21):2586-9 (21 ref.) (Eng. Abstr.) **(Swe)**

ANTAGONISTS & INHIBITORS

Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Schrör K. **Vasc Med** 1998; 3(3):247-51 (49 ref.)

CLASSIFICATION

P2 receptor subtypes in the cardiovascular system. Kunapuli SP, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):513-23 (181 ref.)

DRUG EFFECTS

Alcohol action on membrane ion channels gated by extracellular ATP (P2X receptors). Weight FF, et al. **Neurochem Int** 1999 Aug;35(2):143-52 (64 ref.)

Receptors for purines and pyrimidines. Ralevic V, et al. **Pharmacol Rev** 1998 Sep;50(3):413-92 (1009 ref.)

METABOLISM

Focus on "multiple functional P2X and P2Y receptors in the luminal and basolateral membranes of pancreatic duct cells" [editorial; comment] Dubyak GR. **Am J Physiol** 1999 Aug; 277(2 Pt 1):C202-4 (21 ref.) Comment on: Am J Physiol 1999 Aug;277(2 Pt 1):C205-15.

Functional and molecular diversity of purinergic ion channel receptors. MacKenzie AB, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:716-29 (97 ref.)

PHYSIOLOGY

Cytolytic P2X purinoceptors. Di Virgilio F, et al. **Cell Death Differ** 1998 Mar;5(3):191-9 (103 ref.)

Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Roman RM, et al. **Gastroenterology** 1999 Apr;116(4):964-79 (143 ref.)

Purinergic signalling: pathophysiological roles. Abbracchio MP, et al. **Jpn J Pharmacol** 1998 Oct;78(2):113-45 (300 ref.)

ATP receptors for the protection of hippocampal functions. Inoue K. **Jpn J Pharmacol** 1998 Dec;78(4):405-10 (43 ref.)

Extracellular ATP: a further modulator in neuroendocrine control of the thymus. Alves LA, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):81-9 (90 ref.)

The functions of ATP receptors in the hippocampus. Inoue K. **Pharmacol Res** 1998 Nov;38(5):323-31 (78 ref.)

Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. King BF, et al. **Trends Pharmacol Sci** 1998 Dec;19(12):506-14 (71 ref.)

[Signal transduction through ATP receptors in brain and the development of new drugs] Inoue K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:36P-40P (15 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, RETINOIC ACID

CHEMISTRY

[Structure of the retinoic acid receptor and its functional analysis using a mutated receptor] Kakizuka A. **Nippon Rinsho** 1998 Jul;56(7):1711-6 (22 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Rational design of receptor-selective retinoids. Chandraratna RA. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S124-8 (21 ref.)

[Adapalene--a new retinoid receptor agonist for the treatment of acne vulgaris] Petersen CS. **Ugeskr Laeger** 1998 Nov 9;160(46):6668-71 (22 ref.) **(Dan)**

GENETICS

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167-215 (605 ref.)

Retinoid-induced apoptosis in normal and neoplastic tissues [see comments] Nagy L, et al. **Cell Death Differ** 1998 Jan; 5(1):11-9 (86 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1-3.

DAX-1, an 'antitestis' gene. Goodfellow PN, et al. **Cell Mol Life Sci** 1999 Jun;55(6-7):857-63 (26 ref.)

METABOLISM

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167-215 (605 ref.)

Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167-74 (107 ref.)

Retinoids and their receptors in skeletal development. Underhill TM, et al. **Microsc Res Tech** 1998 Oct 15; 43(2):137-55 (239 ref.)

Control of retinoid nuclear receptor function and expression. Niles RM. **Subcell Biochem** 1998;30:3-28 (156 ref.)

PHYSIOLOGY

Mammalian sex determination: joining pieces of the genetic puzzle. Jiménez R, et al. **Bioessays** 1998 Sep;20(9):696-9 (24 ref.)

Retinoids: present role and future potential. Evans TR, et al. **Br J Cancer** 1999 Apr;80(1-2):1-8 (120 ref.)

Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors [see comments] Szondy Z, et al. **Cell Death Differ** 1998 Jan; 5(1):4-10 (78 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1-3.

Neutrophil maturation and the role of retinoic acid. Lawson ND, et al. **Exp Hematol** 1999 Sep;27(9):1355-67 (132 ref.)

Retinoids and mammalian development. Morriss-Kay GM, et al. **Int Rev Cytol** 1999;188:73-131 (235 ref.)

Retinoids and their receptors in skeletal development. Underhill TM, et al. **Microsc Res Tech** 1998 Oct 15; 43(2):137-55 (239 ref.)

Retinoid receptors in health and disease: co-regulators and the chromatin connection [see comments] Minucci S, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):215-25 (97 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

[Novel orphan receptor: ROR gamma expressed during adipocyte differentiation] Kurebayashi S, et al. **Nippon Rinsho** 1998 Jul;56(7):1729-33 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanisms of fat-soluble vitamins: vitamin receptor knockout mice] Kato S. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1321-35 (74 ref.) **(Jpn)**

[Current concepts of the structure and functions of retinoid receptors] Uteshev DB, et al. **Eksp Klin Farmakol** 1998 Nov-Dec;61(6):65-72 (80 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

[Current concepts of the structure and functions of retinoid receptors] Uteshev DB, et al. **Eksp Klin Farmakol** 1998 Nov-Dec;61(6):65-72 (80 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, SENSORY

METABOLISM

Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Burns HD, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):388-94 (32 ref.)

Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Stoessl AJ, et al. **Curr Opin Neurol** 1998 Aug;11(4):327-33 (77 ref.)

PHYSIOLOGY

Nerve dependency of developing and mature sensory receptor cells. Fritzsch B, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:14-27 (83 ref.)

Factors controlling hair-cell regeneration/repair in the inner ear. Staecker H, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):480-7 (52 ref.)
Orientation in the dark: brain circuits involved in the perception of electric signals in mormyrid electric fish. von der Emde G. **Eur J Morphol** 1999 Apr;37(2-3):200-5 (21 ref.)
Plasticity of feedback inputs in the apteronotid electrosensory system. Bastian J. **J Exp Biol** 1999 May;202 (Pt 10):1327-37 (41 ref.)
Electroreception in monotremes. Pettigrew JD. **J Exp Biol** 1999 May;202 (Pt 10):1447-54 (30 ref.)
Mechanisms for generating temporal filters in the electrosensory system. Rose GJ, et al. **J Exp Biol** 1999 May;202 (Pt 10):1281-9 (48 ref.)
Some related aspects of platypus electroreception: temporal integration behaviour, electroreceptive thresholds and directionality of the bill acting as an antenna. Fjällbrant TT, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1211-9 (19 ref.)
The sensory world of the platypus. Pettigrew JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1199-210 (38 ref.)
Sensory receptors in monotremes. Proske U, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1187-98 (45 ref.)

PHYSIOPATHOLOGY

Cough, cough receptors, and asthma in children. Chang AB. **Pediatr Pulmonol** 1999 Jul;28(1):59-70 (133 ref.)
Afferent receptors in the airways and cough. Widdicombe JG. **Respir Physiol** 1998 Oct;114(1):5-15 (57 ref.)

RECEPTORS, SEROTONIN

CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back. Paul S. **Br J Psychiatry Suppl** 1999;(37):23-5 (17 ref.)

CHEMISTRY

A putative alpha-helical G beta gamma-coupling domain in the second intracellular loop of the 5-HT1A receptor. Albert PR, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:146-61 (72 ref.)
Molecular modelling of the 5-hydroxytryptamine receptors. Wishart G, et al. **Receptors Channels** 1999;6(4):317-35 (127 ref.)

CLASSIFICATION

The interaction of immunomodulatory muramyl dipeptide with peripheral 5-HT receptors: overview of the current state. Sevcík J, et al. **Int J Immunopharmacol** 1999 Mar; 21(3):227-32 (39 ref.)

DRUG EFFECTS

Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D, et al. **Acta Neurol Belg** 1999 Jun;99(2):85-95 (89 ref.)
Novel therapeutic approaches beyond the serotonin receptor. Duman RS. **Biol Psychiatry** 1998 Sep 1;44(5):324-35 (57 ref.)
Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? Dahlöf CG, et al. **Cephalalgia** 1998 Oct; 18(8):539-45 (73 ref.)
New approaches to rapid onset antidepressants [published erratum appears in Curr Pharm Des 1999 Feb;5(2):139] Briner K, et al. **Curr Pharm Des** 1998 Aug;4(4):291-302 (144 ref.)
Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Marek GJ, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):189-98 (80 ref.)
Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. De Vries P, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):61-74 (176 ref.)
Ergoline derivatives: receptor affinity and selectivity. Mantegani S, et al. **Farmaco** 1999 May 30;54(5):288-96 (15 ref.)
Implications of brain imaging for the management of schizophrenia. Nyberg S, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S15-20 (52 ref.)
The interaction of immunomodulatory muramyl dipeptide with peripheral 5-HT receptors: overview of the current state. Sevcík J, et al. **Int J Immunopharmacol** 1999 Mar; 21(3):227-32 (39 ref.)
Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. Stahl SM. **J Affect Disord** 1998 Dec;51(3):215-35 (131 ref.)
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington G, et al. **J Clin Psychiatry** 1999;60 Suppl 10:15-9 (50 ref.)
Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Passani MB, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):725-33 (96 ref.)
5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic. Lovinger DM. **Neurochem Int** 1999 Aug;35(2):125-30 (52 ref.)
Testosterone and its metabolites modulate 5HT1A and 5HT1B agonist effects on intermale aggression. Simon NG, et al. **Neurosci Biobehav Rev** 1998;23(2):325-36 (104 ref.)
Serotonin in migraine: theories, animal models and emerging therapies. Johnson KW, et al. **Prog Drug Res** 1998; 51:219-44 (123 ref.)
[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity] de Visme PG. **Ugeskr Laeger** 1998 Oct 12;160(42):6088-91 (40 ref.) (Eng. Abstr.) **(Dan)**
[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stepień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341-3 (28 ref.) (Eng. Abstr.) **(Pol)**
[Serotonin both stimulates and inhibits sexual behavior of rats. New possibilities to understand the effects and side-effects of serotonergic drugs] Larsson K, et al. **Lakartidningen** 1999 Jun 9;96(23):2854-6 (22 ref.) **(Swe)**

GENETICS

5-HT4 receptors: gene, transduction and effects on olfactory memory. Bockaert J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:1-15 (61 ref.)
Mouse 5-HT2B receptor-mediated serotonin trophic functions. Choi DS, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:67-73 (20 ref.)
5-HT4 receptors: cloning and expression of new splice variants. Claeysen S, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:49-56 (25 ref.)
Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role. Göthert M, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:26-30 (20 ref.)
Gs protein-coupled serotonin receptors: receptor isoforms and functional differences. Hamblin MW, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:31-7 (25 ref.)
Identification and characterization of RNA editing events within the 5-HT2C receptor. Niswender CM, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:38-48 (34 ref.)
Serotonin receptor variants in disease: new therapeutic opportunities? Peroutka SJ. **Ann N Y Acad Sci** 1998 Dec 15;861:16-25 (21 ref.)
Regulation of levels of 5-HT2A receptor mRNA. Wohlpart KL, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:128-35 (19 ref.)
The human serotonin-7 receptor pseudogene: variation and chromosome location. Nam D, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):214-6 (12 ref.)
Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Murphy DL, et al. **Trends Pharmacol Sci** 1999 Jun;20(6):246-52 (75 ref.)

METABOLISM

A putative alpha-helical G beta gamma-coupling domain in the second intracellular loop of the 5-HT1A receptor. Albert PR, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:146-61 (72 ref.)
Bioisosteric approach in the design of new dopaminergic/serotonergic ligands. Soskić V, et al. **Curr Med Chem** 1998 Dec;5(6):493-512 (102 ref.)
Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Olivier B, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S9-14 (27 ref.)
Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents. Kato S, et al. **Med Res Rev** 1999 Jan; 19(1):25-73 (141 ref.)
Radioligand binding to solubilized 5-HT3 receptors. Fletcher S, et al. **Methods Mol Biol** 1999;106:49-71 (29 ref.)
5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Roth BL, et al. **Pharmacol Ther** 1998 Sep;79(3):231-57 (258 ref.)

PHYSIOLOGY

Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol Suppl** 1996 Mar;1:27-32 (51 ref.)
Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Andrade R. **Ann N Y Acad Sci** 1998 Dec 15;861:190-203 (81 ref.)
Interactions between effectors linked to serotonin receptors. Berg KA, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:111-20 (24 ref.)
Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Berg KA, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:104-10 (13 ref.)
Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Blier P, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:204-16 (51 ref.)
5-HT4 receptors: gene, transduction and effects on olfactory memory. Bockaert J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:1-15 (61 ref.)
Mouse 5-HT2B receptor-mediated serotonin trophic functions. Choi DS, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:67-73 (20 ref.)
5-HT4 receptors: cloning and expression of new splice variants. Claeysen S, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:49-56 (25 ref.)
5-HT1B receptor modulation of prepulse inhibition: recent findings in wild-type and 5-HT1B knockout mice. Dulawa SC, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:79-84 (23 ref.)
Serotonin transporter function in vivo: assessment by chronoamperometry. Frazer A, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:217-29 (48 ref.)
Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Fuxe K, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:274-90 (38 ref.)
Gs protein-coupled serotonin receptors: receptor isoforms and functional differences. Hamblin MW, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:31-7 (25 ref.)
Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Heisler LK, et al. **Ann N Y Acad Sci** 1998 Dec 15; 861:74-8 (30 ref.)
Molecular, cellular and physiological characteristics of 5-HT-moduline, a novel endogenous modulator of 5-HT1B receptor subtype. Massot O, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:174-82 (17 ref.)
The putative 5-ht6 receptor: localization and function. Sleight AJ, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:91-6 (20 ref.)
Activation of the mitogen-activated protein kinase pathway via the 5-HT2A receptor. Watts SW. **Ann N Y Acad Sci** 1998 Dec 15;861:162-8 (20 ref.)
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Kroeze WK, et al. **Biol Psychiatry** 1998 Dec 1; 44(11):1128-42 (162 ref.)
Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Leibowitz SF, et al. **Biol Psychiatry** 1998 Nov 1;44(9):851-64 (166 ref.)
Novel strategies to probe the functions of serotonin receptors. Stark KL, et al. **Biol Psychiatry** 1998 Aug 1;44(3):163-8 (35 ref.)
The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Raymond JR, et al. **Br J Pharmacol** 1999 Aug;127(8):1751-64 (160 ref.)
5-HT4 receptors: long-term blockade of K+ channels and effects on olfactory memory. Bockaert J, et al. **C R Acad Sci III** 1998 Feb-Mar;321(2-3):217-21 (33 ref.)
Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Roth BL, et al. **Crit Rev Neurobiol** 1998;12(4):319-38 (212 ref.)
Serotonin receptor physiology: relation to emesis. Hasler WL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):108S-113S (59 ref.)
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy DL, et al. **J Clin Psychiatry** 1998;59 Suppl 15:4-12 (118 ref.)
Developmental pharmacodynamics: implications for child and adolescent psychopharmacology. Carrey N, et al. **J Psychiatry Neurosci** 1998 Nov;23(5):274-6 (16 ref.)
A review of central 5-HT receptors and their function. Barnes NM, et al. **Neuropharmacology** 1999 Aug; 38(8):1083-152 (650 ref.)
Serotonin and hallucinogens. Aghajanian GK, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):16S-23S (49 ref.)
Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Backstrom JR, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):77S-81S (25 ref.)
Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Blier P, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):91S-98S (58 ref.)
Serotonin and stress. Chaouloff F, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):28S-32S (37 ref.)
Serotonin and hippocampal neurogenesis. Gould E. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):46S-51S (64 ref.)
Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Mann JJ. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):99S-105S (65 ref.)
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Millan MJ, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):61S-67S (37 ref.)
Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Zhuang X, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):52S-60S (67 ref.)
Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system. Kostrzewa RM, et al. **Pol J Pharmacol** 1999 Jan-Feb;51(1):39-47 (84 ref.)
Serotonin receptor knockouts: a moody subject [comment] Julius D. **Proc Natl Acad Sci U S A** 1998 Dec 22; 95(26):15153-4 (17 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14476-81. Comment on: Proc Natl Acad Sci U S A 1998 Dec 8;95(25):15049-54.
Involvement of the 5-HT7 receptor in craniovascular vasodilatation: potential impact in migraine. Terrón JA. **Proc West Pharmacol Soc** 1998;41:247-51 (78 ref.)

RECEPTORS, SEROTONIN

The 5-HT1A receptor and its ligands: structure and function. Olivier B, et al. **Prog Drug Res** 1999;52:103-65 (285 ref.)
Changes in sleep and wakefulness following 5-HT1A ligands given systemically and locally in different brain regions. Bjorvatn B, et al. **Rev Neurosci** 1998;9(4):265-73 (97 ref.)
Paracrine neurotransmission in the CNS: involvement of 5-HT. Bunin MA, et al. **Trends Neurosci** 1999 Sep; 22(9):377-82 (50 ref.)
[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stepień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341-3 (28 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, SIGMA

DRUG EFFECTS

Effects of sigma receptor ligands on conditioned fear stress. Kamei H, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):613-8 (24 ref.)

RECEPTORS, SIGMA OPIOID see **RECEPTORS, SIGMA**

RECEPTORS, SINCALIDE see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, SOMATOMEDIN

BLOOD

Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Rosen CJ. **Clin Chem** 1999 Aug;45(8 Pt 2):1384-90 (75 ref.)

PHYSIOLOGY

The role of the IGF-I receptor in the growth and transformation of mammalian cells. Baserga R, et al. **Cell Prolif** 1994 Feb;27(2):63-71 (48 ref.)

RECEPTORS, SOMATOMEDIN C see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

RECEPTORS, SOMATOSTATIN

see related
SOMATOSTATIN

ANALYSIS

Somatostatin receptor imaging and therapy of pancreatic endocrine tumors. van Eijck CH, et al. **Ann Oncol** 1999; 10 Suppl 4:177-81 (48 ref.)
Receptor imaging in the diagnosis and treatment of pituitary tumors. Kwekkeboom DJ, et al. **J Endocrinol Invest** 1999 Jan;22(1):80-8 (63 ref.)
The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management. Kennedy JW, et al. **Yale J Biol Med** 1997 Sep-Dec;70(5-6):565-75 (33 ref.)
Somatostatin receptor scintigraphy of malignant lymphoma--current status. Serafini AN. **Yale J Biol Med** 1997 Sep-Dec;70(5-6):555-9 (20 ref.)
[Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors] Mure A, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):809-18 (71 ref.) **(Fre)**

DRUG EFFECTS

2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity. Liu S, et al. **Curr Pharm Des** 1999 Apr;5(4):255-63 (59 ref.)

METABOLISM

Somatostatin and its receptor family. Patel YC. **Front Neuroendocrinol** 1999 Jul;20(3):157-98 (233 ref.)
The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management. Kennedy JW, et al. **Yale J Biol Med** 1997 Sep-Dec;70(5-6):565-75 (33 ref.)
Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Reubi JC, et al. **Yale J Biol Med** 1997 Sep-Dec; 70(5-6):471-9 (27 ref.)

PHYSIOLOGY

Somatostatin receptors present knowledge and future directions. Schonbrunn A. **Ann Oncol** 1999;10 Suppl 2:S17-21 (18 ref.)
Molecular biology of the receptors for somatostatin and cortistatin. Kreienkamp HJ. **Results Probl Cell Differ** 1999; 26:215-37 (110 ref.)

RECEPTORS, SOMATOTROPIN

DEFICIENCY

Natural history of growth hormone receptor deficiency. Rosenbloom AL, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):153-6; discussion 157 (19 ref.)
IGF-I deficiency due to GH receptor deficiency. Rosenbloom AL. **Horm Metab Res** 1999 Feb-Mar; 31(2-3):161-71 (72 ref.)

GENETICS

Signal transduction defects in growth hormone insensitivity. Clayton PE, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):174-8; discussion 179 (18 ref.)
Natural history of growth hormone receptor deficiency. Rosenbloom AL, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):153-6; discussion 157 (19 ref.)
Truncated growth hormone receptor isoforms. Ross RJ. **Acta Paediatr Suppl** 1999 Feb;88(428):164-6; discussion 167 (10 ref.)
Partial growth hormone insensitivity--idiopathic short stature is not always idiopathic. Saenger P. **Acta Paediatr Suppl** 1999 Feb;88(428):194-8 (20 ref.)
Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Woods KA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):158-62; discussion 163 (13 ref.)
Alternative processing of growth hormone receptor transcripts. Edens A, et al. **Endocr Rev** 1998 Oct; 19(5):559-82 (131 ref.)
Defects of the growth hormone receptor and their clinical implications. Savage MO, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:57-61 (21 ref.)
[GH receptor gene mutations and growth failure] Kaji H. **Nippon Rinsho** 1998 Jul;56(7):1830-5 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Cytokines in endocrine function. Silva CM, et al. **Adv Protein Chem** 1998;52:199-221 (72 ref.)
The role of growth hormone and insulin-like growth factors in the immune system. van Buul-Offers SC, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1083-94 (160 ref.)
Prolactin, growth hormone and the immune system in humans. Velkeniers B, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1102-8 (75 ref.)
Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Carter-Su C, et al. **Recent Prog Horm Res** 1998;53:61-82; discussion 82-3 (78 ref.)

RECEPTORS, SOMATOTROPIN RELEASE INHIBITING HORMONE see **RECEPTORS, SOMATOSTATIN**

RECEPTORS, SRS-A see **RECEPTORS, LEUKOTRIENE**

RECEPTORS, STEM CELL FACTOR see **PROTO-ONCOGENE PROTEINS C-KIT**

RECEPTORS, STEROID

ANTAGONISTS & INHIBITORS

Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. Takimoto GS, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):45-50 (28 ref.)

GENETICS

The one-to-four rule and paralogues of sex-determining genes. Ohno S. **Cell Mol Life Sci** 1999 Jun;55(6-7):824-30 (19 ref.)
Steroid receptor isoforms: exception or rule? Keightley MC. **Mol Cell Endocrinol** 1998 Feb;137(1):1-5 (51 ref.)

METABOLISM

Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. Ylikomi T, et al. **Crit Rev Biochem Mol Biol** 1998;33(6):437-66 (196 ref.)
Coregulatory proteins in nuclear hormone receptor action. Edwards DP. **Vitam Horm** 1999;55:165-218 (217 ref.)

PHYSIOLOGY

P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Waxman DJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):11-23 (128 ref.)
Regulation of steroid receptor subcellular trafficking. DeFranco DB. **Cell Biochem Biophys** 1999;30(1):1-24 (96 ref.)
Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Chen JD, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):169-90 (130 ref.)
Investigation of steroid receptor function in the budding yeast Saccharomyces cerevisiae. McEwan IJ. **FEMS Microbiol Lett** 1999 Jul 1;176(1):1-9 (35 ref.)
Steroid receptors at the nexus of transcriptional regulation. Barrett TJ, et al. **J Cell Biochem Suppl** 1998;30-31:185-93 (40 ref.)
Symposium: Steroid Hormone Receptor and Nutrient Interactions: Implications for Cancer Prevention. Introduction. Belury MA. **J Nutr** 1999 Feb;129(2S Suppl):569S-570S (4 ref.)
The hsp56 immunophilin component of steroid receptor heterocomplexes: could this be the elusive nuclear localization signal-binding protein? Pratt WB, et al. **J Steroid Biochem Mol Biol** 1993 Sep;46(3):269-79 (74 ref.)
Coactivators and corepressors as mediators of nuclear receptor function: an update. Jenster G. **Mol Cell Endocrinol** 1998 Aug 25;143(1-2):1-7 (68 ref.)
Corticosteroids in the brain. Cellular and molecular actions. Joëls M, et al. **Mol Neurobiol** 1998 Winter;17(1-3):87-108 (139 ref.)
Membrane-initiated steroid actions and the proteins that mediate them. Watson CS, et al. **Proc Soc Exp Biol Med** 1999 Jan;220(1):9-19 (176 ref.)
Orphan nuclear receptors: shifting endocrinology into reverse. Kliewer SA, et al. **Science** 1999 Apr 30; 284(5415):757-60 (37 ref.)
[Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma] Clavière C, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):73-86 (166 ref.) **(Fre)**
[Transcriptional control by steroid receptor] Kato S. **Nippon Rinsho** 1998 Jul;56(7):1699-704 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Functional analysis of nuclear hormone receptors] Nagaya T, et al. **Nippon Rinsho** 1998 Jul;56(7):1688-92 (12 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, STRETCH see **MECHANORECEPTORS**

RECEPTORS, STRETCH, ARTERIAL see **PRESSORECEPTORS**

RECEPTORS, STRETCH, VASCULAR see **PRESSORECEPTORS**

RECEPTORS, SUBSTANCE K see **RECEPTORS, NEUROKININ-2**

RECEPTORS, SUBSTANCE P see **RECEPTORS, NEUROKININ-1**

RECEPTORS, SYNAPTIC see **RECEPTORS, NEUROTRANSMITTER**

RECEPTORS, T-CELL GROWTH FACTOR see **RECEPTORS, INTERLEUKIN-2**

RECEPTORS, TACHYKININ

METABOLISM

In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters. Bloch B, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):315-9 (44 ref.)

RECEPTORS, TETRAGASTRIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, TGF-ALPHA see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, TGF-BETA see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

RECEPTORS, THROMBIN

ANTAGONISTS & INHIBITORS

Therapeutic inhibition of thrombin activities, receptors, and production. Harker LA. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1211-30 (86 ref.)

GENETICS

Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Cupit LD, et al. **Trends Cardiovasc Med** 1999 Jan-Feb;9(1-2):42-8 (39 ref.)

METABOLISM

Proteinase-activated receptors: a growing family of heptahelical receptors for thrombin, trypsin and tryptase. Déry O, et al. **Biochem Soc Trans** 1999 Feb;27(2):246-54 (50 ref.)

PHYSIOLOGY

Thrombin and trypsin receptors: the same mechanism of signalling on cellular surfaces. Olejar T, et al. **Bratisl Lek Listy** 1999 Feb;100(2):75-9 (35 ref.)
How the protease thrombin talks to cells. Coughlin SR. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11023-7 (66 ref.)

RECEPTORS, THROMBOSPONDIN see **ANTIGENS, CD36**

RECEPTORS, THROMBOXANE

PHYSIOLOGY

Thromboxanes: synthase and receptors. Shen RF, et al. **J Biomed Sci** 1998;5(3):153-72 (206 ref.)

RECEPTORS, THROMBOXANE A2 see **RECEPTORS, THROMBOXANE**

RECEPTORS, THYROID HORMONE

see related
THYROID HORMONE RESISTANCE SYNDROME

ANALYSIS

Multiple isoforms of thyroid hormone receptor: an analysis of their relative contribution in mediating thyroid hormone action. Murata Y. **Nagoya J Med Sci** 1998 Oct; 61(3-4):103-15 (55 ref.)

GENETICS

Molecular basis of resistance to thyroid hormone (RTH). Nagaya T, et al. **Endocr J** 1998 Dec;45(6):709-18 (62 ref.)

[Thyroid hormone receptors and the disorders] Nagaya T, et al. **Nippon Rinsho** 1998 Jul;56(7):1861-5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenesis of disorder due to thyroid hormone receptor mutation] Nagaya T, et al. **Rinsho Byori** 1998 Oct; 46(10):1017-22 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Thyroid hormone receptor coactivators and corepressors. Koenig RJ. **Thyroid** 1998 Aug;8(8):703-13 (105 ref.)

PHYSIOLOGY

Molecular and structural biology of thyroid hormone receptors. Apriletti JW, et al.
Clin Exp Pharmacol Physiol Suppl 1998 Nov;25:S2-11 (45 ref.)

Recent advances in understanding thyroid hormone receptor coregulators. Lee H, et al. **J Biomed Sci** 1999 Mar-Apr; 6(2):71-8 (54 ref.)

Role of thyroid hormones and their receptors in peripheral nerve regeneration. Barakat-Walter I. **J Neurobiol** 1999 Sep 15;40(4):541-59 (113 ref.)

Local activation and inactivation of thyroid hormones: the deiodinase family. Köhrle J. **Mol Cell Endocrinol** 1999 May 25;151(1-2):103-19 (152 ref.)

Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. Ribeiro RC, et al. **Recent Prog Horm Res** 1998;53:351-92; discussion 392-4 (190 ref.)

Thyroid hormone regulation of Xenopus laevis metamorphosis: functions of thyroid hormone receptors and roles of extracellular matrix remodeling. Shi YB, et al. **Wound Repair Regen** 1998 Jul-Aug;6(4):314-22 (63 ref.)

[Structure-function relationship of thyroid hormone receptor and analysis of its physiological role by gene targeting] Mitsuhashi T. **Nippon Rinsho** 1998 Jul;56(7):1705-10 (20 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, THYROID STIMULATING HORMONE see **RECEPTORS, THYROTROPIN**

RECEPTORS, THYROLIBERIN see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

RECEPTORS, THYROTROPIN

BLOOD

Thyroid stimulating immunoglobulin (TSI) in Graves' disease. Ochi Y, et al. **Endocr J** 1998 Dec;45(6):701-8 (35 ref.)

[TSH receptor autoantibody: its historical background and interpretation of the data on TSAb, TSBAb and TBII] Saito J, et al. **Nippon Rinsho** 1999 Aug;57(8):1829-33 (25 ref.) **(Jpn)**

GENETICS

Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Derwahl M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S6-9 (41 ref.)

Autosomal dominant nonautoimmune hyperthyroidism. Clinical features-diagnosis-therapy. Führer D, et al.
Exp Clin Endocrinol Diabetes 1998;106 Suppl 4:S10-5 (25 ref.)

Non-autoimmune hyper- and hypothyroidism due to mutations in the thyrotropin receptor gene. Vassart G. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:23-4 (11 ref.)

[Activating mutations of the TSH receptor: a synthesis highlighting certain pediatric aspects] Polak M.
Arch Pediatr 1998;5 Suppl 4:375S-379S (32 ref.) (Eng. Abstr.) **(Fre)**

[Mutations in TSH receptors: pathogenetic significance and clinical relevance] Führer D, et al.
Dtsch Med Wochenschr 1999 May 28;124(21):662-9 (48 ref.) **(Ger)**

[Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism] Derwahl M. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:25-8 (35 ref.) (Eng. Abstr.) **(Ger)**

[Disorders caused by mutations of the thyrotropin receptor] Kosugi S. **Nippon Rinsho** 1998 Jul;56(7):1856-60 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease. Di Cerbo A, et al.
Biochimie 1999 May;81(5):415-24 (118 ref.)

METABOLISM

Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Bodenner DL, et al. **Am J Med** 1998 Dec;105(6):524-38 (80 ref.)

PHYSIOLOGY

Thyrotropin receptor: a role for thyroid tumourigenesis? Russo D, et al. **Forum (Genova)** 1999 Apr-Jun;9(2):166-75 (75 ref.)

RECEPTORS, THYROTROPIN-RELEASING HORMONE

[TRH receptor] Yamada M, et al. **Nippon Rinsho** 1998 Jul; 56(7):1931-7 (45 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Expression of a novel transcript for the TRH receptor in human pituitary adenomas] Yamada M, et al.
Nippon Rinsho 1999 Mar;57(3):737-45 (20 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies [published erratum appears in Endocr Rev 1999 Feb;20(1):100] Rapoport B, et al. **Endocr Rev** 1998 Dec;19(6):673-716 (396 ref.)

METABOLISM

The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies [published erratum appears in Endocr Rev 1999 Feb;20(1):100] Rapoport B, et al. **Endocr Rev** 1998 Dec;19(6):673-716 (396 ref.)

Thyrotropin releasing hormone (TRH), the TRH-receptor and the TRH-degrading ectoenzyme; three elements of a peptidergic signalling system. Bauer K, et al.
Results Probl Cell Differ 1999;26:13-42 (140 ref.)

RECEPTORS, THYROXINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, TRANSFERRIN

see related
CARRIER PROTEINS

BLOOD

[Clinical application of soluble transferrin receptor] Kougo H. **Rinsho Ketsueki** 1999 May;40(5):359-61 (15 ref.) **(Jpn)**

CHEMISTRY

Structure, function and clinical significance of transferrin receptors. Feelders RA, et al. **Clin Chem Lab Med** 1999 Jan;37(1):1-10 (93 ref.)

IMMUNOLOGY

[The erythroblast antigen: a membrane protein bound to the erythroid form of the transferrin receptor?] Fuxon VI, et al. **Ontogenez** 1999 May-Jun;30(3):165-75 (85 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Structure, function and clinical significance of transferrin receptors. Feelders RA, et al. **Clin Chem Lab Med** 1999 Jan;37(1):1-10 (93 ref.)

Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356-8 (15 ref.)

Iron overload: molecular clues to its cause. Kühn LC.
Trends Biochem Sci 1999 May;24(5):164-6 (24 ref.)

PHYSIOLOGY

[The transferrin receptor: its role in iron metabolism and its diagnosis utility] Vernet M. **Ann Biol Clin (Paris)** 1999 Jan-Feb;57(1):9-18 (49 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, TRANSFORMING-GROWTH FACTOR ALPHA see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, TRANSFORMING GROWTH FACTOR BETA

GENETICS

The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Oliveira C, et al. **Am J Pathol** 1998 Oct;153(4):1211-9 (44 ref.)

METABOLISM

TGF-beta activity and expression of its receptors in B-cell chronic lymphocytic leukemia. Lagneaux L, et al.
Leuk Lymphoma 1998 Sep;31(1-2):99-106 (25 ref.)

PHYSIOLOGY

[Receptors and signal transduction for the TGF-beta related factors] Miyazono K. **Nippon Ronen Igakkai Zasshi** 1999 Mar;36(3):162-6 (27 ref.) **(Jpn)**

RECEPTORS, TRH see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

RECEPTORS, TRIIODOTHYRONINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, TRYPTAMINE see **RECEPTORS, SEROTONIN**

RECEPTORS, TUMOR NECROSIS FACTOR

[Fas system in the study of neoplasms] Li H, et al.
Chung Hua Wai Ko Tsa Chih 1997 Jan;35(1):59-62 (25 ref.) **(Chi)**

BLOOD

Tumor necrosis factor receptor expression on inflammatory cells in sepsis [editorial; comment] Opal SM.
Crit Care Med 1999 Feb;27(2):240-1 (10 ref.) Comment on: Crit Care Med 1999 Feb;27(2):319-24.

GENETICS

Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling. Yeh WC, et al.
Immunol Rev 1999 Jun;169:283-302 (183 ref.)

Tumor necrosis factor receptor family members in the immune system [see comments] Gravestein LA, et al.
Semin Immunol 1998 Dec;10(6):423-34 (148 ref.) Comment in: Semin Immunol 1998 Dec;10(6):417-22.

IMMUNOLOGY

Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. O'Connell J, et al. **Dis Esophagus** 1999; 12(2):83-9 (51 ref.)

Signalling by CD95 and TNF receptors: not only life and death. Magnusson C, et al. **Immunol Cell Biol** 1999 Feb; 77(1):41-6 (79 ref.)

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Kollias G, et al.
Immunol Rev 1999 Jun;169:175-94 (198 ref.)

Tumor necrosis factor receptor family members in the immune system [see comments] Gravestein LA, et al.
Semin Immunol 1998 Dec;10(6):423-34 (148 ref.) Comment in: Semin Immunol 1998 Dec;10(6):417-22.

Role of 4-1BB in immune responses. Vinay DS, et al.
Semin Immunol 1998 Dec;10(6):481-9 (43 ref.)

METABOLISM

Tumor necrosis factor receptor and Fas signaling mechanisms. Wallach D, et al. **Annu Rev Immunol** 1999; 17:331-67 (225 ref.)

TNF-related ligands and their receptors. Orlinick JR, et al.
Cell Signal 1998 Sep;10(8):543-51 (129 ref.)

Apoptosis: Silencing the death receptors. Tschopp J, et al.
Curr Biol 1999 May 20;9(10):R381-4 (14 ref.)

Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Kwon B, et al. **Curr Opin Immunol** 1999 Jun;11(3):340-5 (33 ref.)

Activation of caspases by death receptors. Bantel H, et al.
Eur Cytokine Netw 1998 Dec;9(4):681-4 (7 ref.)

Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Kong YY, et al. **Immunol Cell Biol** 1999 Apr; 77(2):188-93 (45 ref.)

Signalling by proteolysis: death receptors induce apoptosis. Muzio M. **Int J Clin Lab Res** 1998;28(3):141-7 (53 ref.)

The role of TNFalpha and TNF receptors in obesity and insulin resistance. Hotamisligil GS. **J Intern Med** 1999 Jun; 245(6):621-5 (37 ref.)

Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? Villunger A, et al. **Oncol Res** 1998; 10(11-12):541-50 (189 ref.)

Role of 4-1BB in immune responses. Vinay DS, et al.
Semin Immunol 1998 Dec;10(6):481-9 (43 ref.)

[Molecular mechanisms of apoptosis induced by activation of membrane receptors from the TNF-R superfamily] Grzelakowska-Sztabert B. **Postepy Biochem** 1998; 44(1):8-21 (162 ref.) **(Pol)**

PHYSIOLOGY

Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Goeddel DV. **Chest** 1999 Jul;116(1

Suppl):69S–73S (37 ref.)
Apoptosis control by death and decoy receptors. Ashkenazi A, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):255–60 (66 ref.)
TRAIL: a molecule with multiple receptors and control mechanisms. Griffith TS, et al. **Curr Opin Immunol** 1998 Oct;10(5):559–63 (25 ref.)
TNF receptor associated factors in cytokine signaling. Wajant H, et al. **Cytokine Growth Factor Rev** 1999 Mar; 10(1):15–26 (114 ref.)
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Suda T, et al. **Endocr Rev** 1999 Jun; 20(3):345–57 (83 ref.)
Death receptors in liver biology and pathobiology. Faubion WA, et al. **Hepatology** 1999 Jan;29(1):1–4 (48 ref.)
The role of Fas and related death receptors in autoimmune and other disease states. Siegel RM, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):729–38 (101 ref.)
Death domain receptors and their role in cell demise. Singh A, et al. **J Interferon Cytokine Res** 1998 Jul;18(7):439–50 (129 ref.)
To die or not to die--the quest of the TRAIL receptors. Degli-Esposti M. **J Leukoc Biol** 1999 May;65(5):535–42 (59 ref.)
Tumor necrosis factor receptors encoded by poxviruses. Cunnion KM. **Mol Genet Metab** 1999 Aug;67(4):278–82 (48 ref.)
Modulation of life and death by the TNF receptor superfamily. Baker SJ, et al. **Oncogene** 1998 Dec 24; 17(25):3261–70 (69 ref.)
The death receptors. Peter ME, et al. **Results Probl Cell Differ** 1999;23:25–63 (280 ref.)

THERAPEUTIC USE

Tumor necrosis factor inhibitors for rheumatoid arthritis. Jones RE, et al. **Bull Rheum Dis** 1999;48(3):1–4 (16 ref.)
Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Goldenberg MM. **Clin Ther** 1999 Jan;21(1):75–87; discussion 1–2 (50 ref.)
Etanercept: a review of its use in rheumatoid arthritis. Jarvis B, et al. **Drugs** 1999 Jun;57(6):945–66 (115 ref.)
Inhibitors of tumor necrosis factor for rheumatoid arthritis. Moreland LW. **J Rheumatol** 1999 May;26 Suppl 57:7–15 (20 ref.)
Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Feldman M, et al. **Transplant Proc** 1998 Dec;30(8):4126–7 (9 ref.)
Treatment advances in rheumatoid arthritis. Arriola ER, et al. **West J Med** 1999 May;170(5):278–81 (16 ref.)

RECEPTORS, UROGASTRONE see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, V1 see **RECEPTORS, VASOPRESSIN**

RECEPTORS, V2 see **RECEPTORS, VASOPRESSIN**

RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE

CLASSIFICATION

A critical view of the methods for characterization of the VIP/PACAP receptor subclasses. Robberecht P, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:157–63 (35 ref.)

PHYSIOLOGY

Stimulatory transducing systems in pancreatic islet cells. Emami S, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:118–31 (78 ref.)
Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Delgado M, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):97–107 (81 ref.)

RECEPTORS, VASOPRESSIN

Identification of a novel dual angiotensin II/vasopressin receptor. Ruiz-Opazo N. **Nephrologie** 1998;19(7):417–20 (24 ref.)

ANTAGONISTS & INHIBITORS

Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Mayinger B, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):157–65 (90 ref.)

CHEMISTRY

Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Postina R, et al. **Adv Exp Med Biol** 1998;449:371–85 (27 ref.)
Functional architecture of vasopressin/oxytocin receptors. Hibert M, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):589–96 (12 ref.)

GENETICS

Nephrogenic diabetes insipidus. Bichet DG. **Am J Med** 1998 Nov;105(5):431–42 (79 ref.)
Vasopressin type-2 receptor and aquaporin-2 water channel mutants in nephrogenic diabetes insipidus. Deen PM, et al. **Am J Med Sci** 1998 Nov;316(5):300–9 (78 ref.)
Mutational analyses of AVPR2 gene in three Japanese families with X-linked nephrogenic diabetes insipidus: two recurrent mutations, R137H and deltaV278, caused by the hypermutability at CpG dinucleotides. Shoji Y, et al. **Hum Mutat** 1998;Suppl 1:S278–83 (27 ref.)
Vasopressin receptor mutations causing nephrogenic diabetes insipidus. Bichet DG, et al. **Proc Assoc Am Physicians** 1998 Sep–Oct;110(5):387–94 (57 ref.)
Nephrogenic diabetes insipidus. Knoers NV, et al. **Semin Nephrol** 1999 Jul;19(4):344–52 (62 ref.)
[Vasopressin type 2 receptor mutations in congenital diabetes insipidus] Tsukaguchi H, et al. **Nippon Rinsho** 1998 Jul; 56(7):1848–55 (21 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Chan PS, et al. **Adv Exp Med Biol** 1998;449:439–43 (14 ref.)
Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Postina R, et al. **Adv Exp Med Biol** 1998;449:371–85 (27 ref.)
Promiscuity and fidelity in receptor–G–protein coupling: cell cycle–dependent coupling of the vasopressin V1 receptor. Kalkbrenner F, et al. **Biochem Soc Trans** 1999 Feb; 27(2):158–63 (38 ref.)
From vasopressin receptor to water channel: intracellular traffic, constraint and by-pass. Laycock JF, et al. **J Endocrinol** 1998 Dec;159(3):361–72 (77 ref.)
Steroid hormone regulation of vasopressinergic neurotransmission in the central nervous system. Watters JJ, et al. **Prog Brain Res** 1998;119:247–61 (60 ref.)

PHYSIOLOGY

Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Grazzini E, et al. **Adv Exp Med Biol** 1998;449:325–34 (26 ref.)
Vasopressin receptors. A historical survey. Jard S. **Adv Exp Med Biol** 1998;449:1–13 (96 ref.)
Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist. Serradeil-Le Gal C. **Adv Exp Med Biol** 1998;449:427–38 (36 ref.)
Vasopressin acting at V1-type receptors produces membrane depolarization in neonatal rat spinal lateral column neurons. Kolaj M, et al. **Prog Brain Res** 1998;119:275–84 (63 ref.)
Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Thibonnier M, et al. **Prog Brain Res** 1998;119:147–61 (67 ref.)
Vasopressin receptors: structural functional relationships and role in neural and endocrine regulation. Schoots O, et al. **Results Probl Cell Differ** 1999;26:107–33 (90 ref.)

RECEPTORS, VIP see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

RECEPTORS, VIRUS

GENETICS

Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. Solecki D, et al. **J Mol Recognit** 1998 Winter;11(1–6):2–9 (53 ref.)

IMMUNOLOGY

Interactions of LIRs, a family of immunoreceptors expressed in myeloid and lymphoid cells, with viral and cellular MHC class I antigens. Borges L, et al. **Curr Top Microbiol Immunol** 1999;244:123–36 (49 ref.)
Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Cosman D, et al. **Immunol Rev** 1999 Apr;168:177–85 (71 ref.)

METABOLISM

FhuA, an Escherichia coli outer membrane protein with a dual function of transporter and channel which mediates the transport of phage DNA. Bonhivers M, et al. **Biochimie** 1998 May–Jun;80(5–6):363–9 (38 ref.)
Simian virus 40 infection via MHC class I molecules and caveolae. Norkin LC. **Immunol Rev** 1999 Apr;168:13–22 (55 ref.)
The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Piguet V, et al. **Immunol Rev** 1999 Apr;168:51–63 (112 ref.)
Recognition and receptors in virus transmission by arthropods. van den Heuvel JF, et al. **Trends Microbiol** 1999 Feb;7(2):71–6 (59 ref.)
Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Edinger AL, et al. **Virology** 1999 Aug 1;260(2):211–21 (129 ref.)

PHYSIOLOGY

P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Waxman DJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):11–23 (128 ref.)
Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Pelletier I, et al. **Cell Mol Life Sci** 1998 Dec; 54(12):1385–402 (107 ref.)
Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. Solecki D, et al. **J Mol Recognit** 1998 Winter;11(1–6):2–9 (53 ref.)
The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus. Willett BJ, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):67–72 (47 ref.)
Xenotropism: the elusive viral receptor finally uncovered [comment] Levy JA. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):802–4 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 2;96(3):927–32.
Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339–46 (80 ref.)

RECEPTORS, VITAMIN D see **RECEPTORS, CALCITRIOL**

RECEPTORS, VITRONECTIN

DRUG EFFECTS

Potential non-glycoprotein IIb/IIIa effects of abciximab. Coller BS. **Am Heart J** 1999 Jul;138(1 Pt 2):S1–5 (50 ref.)

PHYSIOLOGY

Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression [comment] Seftor RE. **Am J Pathol** 1998 Nov;153(5):1347–51 (78 ref.) Comment on: Am J Pathol 1998 Nov;153(5):1435–42.
Role of integrin alpha(v)beta3 in vascular biology. Byzova TV, et al. **Thromb Haemost** 1998 Nov;80(5):726–34 (138 ref.)

RECEPTOSOMES see **ENDOSOMES**

RECIPES see **COOKERY**

RECKLINGHAUSEN'S DISEASE OF NERVE see **NEUROFIBROMATOSIS 1**

RECOGNITION see **MEMORY**

RECOMBINANT DNA see **DNA, RECOMBINANT**

RECOMBINANT DNA VACCINES see **VACCINES, DNA**

RECOMBINANT ERYTHROPOIETIN see **ERYTHROPOIETIN, RECOMBINANT**

RECOMBINANT FUSION PROTEINS

see related
IMMUNOTOXINS

ADMINISTRATION & DOSAGE

A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Agren L, et al. **Immunol Cell Biol** 1998 Jun; 76(3):280–7 (47 ref.)

ANALYSIS

GFP fusions to a microtubule motor protein to visualize meiotic and mitotic spindle dynamics in Drosophila. Endow SA. **Methods Cell Biol** 1999;58:153–63 (21 ref.)
Visualizing protein-protein interactions in the nucleus of the living cell. Day RN, et al. **Mol Endocrinol** 1999 Apr; 13(4):517–26 (63 ref.)

BIOSYNTHESIS

Totally in vitro protein selection using mRNA-protein fusions and ribosome display. Roberts RW. **Curr Opin Chem Biol** 1999 Jun;3(3):268–73 (39 ref.)
Prokaryotic gene fusion expression systems and their use in structural and functional studies of proteins. Sheibani N. **Prep Biochem Biotechnol** 1999 Feb;29(1):77–90 (24 ref.)
Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Schuh JC, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):72–7 (55 ref.)

GENETICS

Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. Frillingos S, et al. **FASEB J** 1998 Oct;12(13):1281–99 (117 ref.)

IMMUNOLOGY

A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Agren L, et al. **Immunol Cell Biol** 1998 Jun; 76(3):280–7 (47 ref.)

PHARMACOLOGY

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):72-7 (55 ref.)

THERAPEUTIC USE

Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Xiang J. **Hum Antibodies** 1999;9(1):23-36 (125 ref.)

Novel diagnostic and therapeutic strategies with genetically engineered human antibodies. Ouwehand WH, et al. **Vox Sang** 1998;74 Suppl 2:223-32 (53 ref.)

RECOMBINANT INTERFERON ALFA-2B see **INTERFERON ALFA-2B**

RECOMBINANT INTERFERON ALFA-2C see **INTERFERON ALFA, RECOMBINANT**

RECOMBINANT-METHIONYL HUMAN GRANULOCYTE COLONY-STIMULATING F see **FILGRASTIM**

RECOMBINANT PITUITARY GROWTH HORMONES see **SOMATOTROPINS, RECOMBINANT**

RECOMBINANT PROTEINS

Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Armitage JO. **Blood** 1998 Dec 15;92(12):4491-508 (187 ref.)

ADMINISTRATION & DOSAGE

The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Chang PL, et al. **Trends Biotechnol** 1999 Feb;17(2):78-83 (41 ref.)

ADVERSE EFFECTS

Genetically modified food: a danger or a benefit for atopics? Ebner C. **Curr Probl Dermatol** 1999;28:81-7 (11 ref.)

The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Sowade B, et al. **Int J Mol Med** 1998 Feb;1(2):303-14 (96 ref.)

ANALYSIS

Electrophoretic methods for process monitoring and the quality assessment of recombinant glycoproteins. Taverna M, et al. **Electrophoresis** 1998 Nov;19(15):2572-94 (186 ref.)

BIOSYNTHESIS

Production of new/modified proteins in transgenic plants. Herbers K, et al. **Curr Opin Biotechnol** 1999 Apr; 10(2):163-8 (50 ref.)

Plant-based production of xenogenic proteins. Hood EE, et al. **Curr Opin Biotechnol** 1999 Aug;10(4):382-6 (25 ref.)

Recent advances in producing and selecting functional proteins by using cell-free translation. Jermutus L, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):534-48 (120 ref.)

Advances in refolding of proteins produced in E. coli. Lilie H, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):497-501 (39 ref.)

Large-scale transient expression in mammalian cells for recombinant protein production. Wurm F, et al. **Curr Opin Biotechnol** 1999 Apr;10(2):156-9 (39 ref.)

Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Cramer CL, et al. **Curr Top Microbiol Immunol** 1999;240:95-118 (80 ref.)

Plant viral vectors based on tobamoviruses. Yusibov V, et al. **Curr Top Microbiol Immunol** 1999;240:81-94 (60 ref.)

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. Liljeqvist S, et al. **J Biotechnol** 1999 Jul 30; 73(1):1-33 (365 ref.)

The next generation of antibodies: production of recombinant antibodies or fragments derived thereof. de Geus B. **Res Immunol** 1998 Jul-Aug;149(6):587-9 (5 ref.)

Production of antibodies in transgenic plants. Larrick JW, et al. **Res Immunol** 1998 Jul-Aug;149(6):603-8 (40 ref.)

Production of recombinant antibodies in the milk of transgenic animals. Young MW, et al. **Res Immunol** 1998 Jul-Aug;149(6):609-10 (4 ref.)

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):72-7 (55 ref.)

Biopharmaceutical production in transgenic livestock. Rudolph NS. **Trends Biotechnol** 1999 Sep;17(9):367-74 (79 ref.)

The biotechnological potential and design of novel carotenoids by gene combination in Escherichia coli. Sandmann G, et al. **Trends Biotechnol** 1999 Jun;17(6):233-7 (42 ref.)

CHEMISTRY

Advances in refolding of proteins produced in E. coli. Lilie H, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):497-501 (39 ref.)

Patch engineering: a general approach for creating proteins that have new binding activities. Smith G. **Trends Biochem Sci** 1998 Dec;23(12):457-60 (41 ref.)

DIAGNOSTIC USE

[Diagnostic and therapeutic value of synthetic or recombinant allergens] Spertini F. **Rev Med Suisse Romande** 1999 Mar;119(3):235-9 (22 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Heterologous expression of G-protein-coupled receptors: human opioid receptors under scrutiny. Stanasila L, et al. **Biochimie** 1998 May-Jun;80(5-6):563-71 (78 ref.)

Use of cell wall-less bacteria (L-forms) for efficient expression and secretion of heterologous gene products. Gumpert J, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):506-9 (19 ref.)

Plant-based production of xenogenic proteins. Hood EE, et al. **Curr Opin Biotechnol** 1999 Aug;10(4):382-6 (25 ref.)

Engineering N-glycosylation pathways in the baculovirus-insect cell system. Jarvis DL, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):528-33 (57 ref.)

Recent advances in producing and selecting functional proteins by using cell-free translation. Jermutus L, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):534-48 (120 ref.)

IMMUNOLOGY

The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Valenta R, et al. **Clin Exp Allergy** 1999 Jul;29(7):896-904 (68 ref.)

METABOLISM

Heterologous expression of G-protein-coupled receptors: human opioid receptors under scrutiny. Stanasila L, et al. **Biochimie** 1998 May-Jun;80(5-6):563-71 (78 ref.)

Engineering N-glycosylation pathways in the baculovirus-insect cell system. Jarvis DL, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):528-33 (57 ref.)

Patch engineering: a general approach for creating proteins that have new binding activities. Smith G. **Trends Biochem Sci** 1998 Dec;23(12):457-60 (41 ref.)

PHARMACOLOGY

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Ryan AM, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):78-86 (75 ref.)

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):72-7 (55 ref.)

STANDARDS

Future prospects for artificial blood. Chang TM. **Trends Biotechnol** 1999 Feb;17(2):61-7 (89 ref.)

THERAPEUTIC USE

Recombinant apolipoproteins for the treatment of vascular diseases. Sirtori CR, et al. **Atherosclerosis** 1999 Jan; 142(1):29-40 (159 ref.)

Recombinant proteins for genetic disease. Russell CS, et al. **Clin Genet** 1999 Jun;55(6):389-94 (34 ref.)

What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins. Balen AH, et al. **Hum Reprod** 1999 Jun; 14(6):1411-7 (59 ref.)

What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone. Bergh C. **Hum Reprod** 1999 Jun;14(6):1418-20 (13 ref.)

Long-term experience with growth hormone treatment in children with chronic renal failure. Schaefer F, et al. **Perit Dial Int** 1999;19 Suppl 2:S467-72 (35 ref.)

[Diagnostic and therapeutic value of synthetic or recombinant allergens] Spertini F. **Rev Med Suisse Romande** 1999 Mar;119(3):235-9 (22 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Ryan AM, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):78-86 (75 ref.)

RECOMBINANT SOMATOTROPINS see **SOMATOTROPINS, RECOMBINANT**

RECOMBINATION-ACTIVATING GENES-1 see **GENES, RAG-1**

RECOMBINATION, GENETIC

RNA recombination in brome mosaic virus, a model plus strand RNA virus. Figlerowicz M, et al. **Acta Biochim Pol** 1998;45(4):847-68 (113 ref.)

Genetic exchange in the trypanosomatidae. Gibson W, et al. **Adv Parasitol** 1999;43:1-46 (150 ref.)

Mice and the role of unequal recombination in gene-family evolution. Schimenti JC. **Am J Hum Genet** 1999 Jan; 64(1):40-5 (42 ref.)

Genome system architecture and natural genetic engineering in evolution. Shapiro JA. **Ann N Y Acad Sci** 1999 May 18;870:23-35 (88 ref.)

Recombination and recombination-dependent DNA replication in bacteriophage T4. Mosig G. **Annu Rev Genet** 1998;32:379-413 (117 ref.)

Transposons as gene haulers. Mahillon J. **APMIS Suppl** 1998; 84:29-36 (10 ref.)

The potential of integrons and connected programmed rearrangements for mediating horizontal gene transfer. Sundström L. **APMIS Suppl** 1998;84:37-42 (50 ref.)

Gene therapy in the central nervous system: the use of recombinant retroviruses. Suhr ST, et al. **Arch Neurol** 1999 Mar;56(3):287-92 (11 ref.)

The role of homologous recombination processes in the repair of severe forms of DNA damage in mammalian cells. Thacker J. **Biochimie** 1999 Jan-Feb;81(1-2):77-85 (95 ref.)

The contribution of homologous recombination in preserving genome integrity in mammalian cells. Thompson LH, et al. **Biochimie** 1999 Jan-Feb;81(1-2):87-105 (249 ref.)

Horizontal gene transfer: pitfalls and promises. Gogarten JP, et al. **Biol Bull** 1999 Jun;196(3):359-61; discussion 361-2 (22 ref.)

Proto-oncogenes, unlike 'harmless' genes, tend to be dispersed in the human genome: selection against out-of-register recombination? [editorial] Ahmed S, et al. **Biol Chem** 1999 Jan;380(1):3-5 (12 ref.)

Prospects for the precise engineering of plant genomes by homologous recombination. Mengiste T, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):749-58 (140 ref.)

Horizontal genetic exchange, evolution, and spread of antibiotic resistance in bacteria. Maiden MC. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S12-20 (56 ref.)

Genetic analysis in fungi using restriction-enzyme-mediated integration. Riggle PJ, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):395-9 (38 ref.)

Genetic recombination in plants. Schnable PS, et al. **Curr Opin Plant Biol** 1998 Apr;1(2):123-9 (69 ref.)

Structure and mechanism in site-specific recombination. Gopaul DN, et al. **Curr Opin Struct Biol** 1999 Feb; 9(1):14-20 (43 ref.)

SV40 in adenovirus vaccines and adenovirus-SV40 recombinants. Lewis AM Jr. **Dev Biol Stand** 1998;94:207-16 (17 ref.)

Human minisatellites, repeat DNA instability and meiotic recombination. Jeffreys AJ, et al. **Electrophoresis** 1999 Jun; 20(8):1665-75 (38 ref.)

Homologous recombination based gene therapy. Lai LW, et al. **Exp Nephrol** 1999 Jan-Feb;7(1):11-4 (15 ref.)

Alzheimer's disease and down syndrome: from meiosis to dementia. Petronis A. **Exp Neurol** 1999 Aug;158(2):403-13 (113 ref.)

DNA strand exchange proteins: a biochemical and physical comparison. Bianco PR, et al. **Front Biosci** 1998 Jun 17; 3:D570-603 (307 ref.)

Recombinogenic targeting: a new approach to genomic analysis--a review. Shashikant CS, et al. **Gene** 1998 Nov 26;223(1-2):9-20 (83 ref.)

Recombination in phage lambda: one geneticist's historical perspective. Stahl FW. **Gene** 1998 Nov 26;223(1-2):95-102 (77 ref.)

Evolution of the mammalian MHC: natural selection, recombination, and convergent evolution. Yeager M, et al. **Immunol Rev** 1999 Feb;167:45-58 (77 ref.)

Transcriptional enhancers and the evolution of the IgH locus. Magor BG, et al. **Immunol Today** 1999 Jan;20(1):13-7 (35 ref.)

Omenn syndrome: a disorder of Rag1 and Rag2 genes. Villa A, et al. **J Clin Immunol** 1999 Mar;19(2):87-97 (70 ref.)

Recombination in RNA viruses and in virus-resistant transgenic plants. Aaziz R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1339-46 (85 ref.)

Asymmetric DDE (D35E)-like sequences in the RAG proteins: implications for V(D)J recombination and retroviral pathogenesis. Dreyfus DH, et al. **Med Hypotheses** 1999 Jun;52(6):545-9 (32 ref.)

Analysis of mammalian cis-regulatory DNA elements by homologous recombination. Fiering S, et al. **Methods Enzymol** 1999;306:42-66 (81 ref.)

Cre recombinase mediated alterations of the mouse genome using embryonic stem cells. Hadjantonakis AK, et al. **Methods Mol Biol** 1999;97:101-22 (42 ref.)

Molecular switches--the ON and OFF of bacterial phase variation. Henderson IR, et al. **Mol Microbiol** 1999 Sep; 33(5):919-32 (76 ref.)

Somatic hypermutation and the three R's: repair, replication and recombination. Harris RS, et al. **Mutat Res** 1999 Mar; 436(2):157-78 (166 ref.)

Analysis of intrachromosomal homologous recombination in mammalian cell, using tandem repeat sequences. Lambert S, et al. **Mutat Res** 1999 Apr 9;433(3):159-68 (72 ref.)

Recombinational DNA repair in bacteria and the RecA protein. Cox MM. **Prog Nucleic Acid Res Mol Biol** 1999; 63:311-66 (342 ref.)

Control of meiotic recombination in Schizosaccharomyces pombe. Fox ME, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:345-78 (132 ref.)

PriA: at the crossroads of DNA replication and recombination. Marians KJ. **Prog Nucleic Acid Res Mol Biol** 1999;63:39-67 (89 ref.)

Phylogenetic classification and the universal tree. Doolittle WF. **Science** 1999 Jun 25;284(5423):2124-9 (43 ref.)

DNA recombination: the replication connection. Haber JE. **Trends Biochem Sci** 1999 Jul;24(7):271-5 (50 ref.)

Selfishness and death: raison d'être of restriction, recombination and mitochondria. Kobayashi I. **Trends Genet** 1998 Sep;14(9):368–74 (34 ref.)
Getting a handle on RNA virus recombination. Miller WA, et al. **Trends Microbiol** 1998 Nov;6(11):421–3 (16 ref.)
Evolution of Helicobacter pylori: the role of recombination. Suerbaum S, et al. **Trends Microbiol** 1999 May;7(5):182–4 (21 ref.)
[Structural biology of RecA and RuvABC proteins involved in homologous DNA recombination] Iwasaki H, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):495–505 (46 ref.) **(Jpn)**
[Genetic transformation of plants, recombination processes, and gene expression regulation in transgenic plants] Kurochkina SD, et al. **Mol Gen Mikrobiol Virusol** 1998; (4):3–12 (131 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Immunoglobulin class switch recombination: will genetics provide new clues to mechanism? Maizels N. **Am J Hum Genet** 1999 May;64(5):1270–5 (42 ref.)
New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Tomasz A. **Am J Med** 1999 Jul 26;107(1A):55S–62S (38 ref.)
Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Pâques F, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):349–404 (575 ref.)

IMMUNOLOGY

Recombination within the human MHC. Carrington M. **Immunol Rev** 1999 Feb;167:245–56 (106 ref.)
Molecular clock and recombination in primate Mhc genes. Satta Y, et al. **Immunol Rev** 1999 Feb;167:367–79 (79 ref.)

RECOMMENDED DIETARY ALLOWANCES see **NUTRITION POLICY**

RECONSTRUCTIVE SURGICAL PROCEDURES

see related
SURGERY, PLASTIC

Meniscal reconstruction. Part II: Outcome, potential complications, and future directions. Maitra RS, et al. **Am J Orthop** 1999 May;28(5):280–6 (85 ref.)
Meniscal reconstruction. Part I: indications, techniques, and graft considerations. Maitra RS, et al. **Am J Orthop** 1999 Apr;28(4):213–8 contd (0 ref.)
The present status of endoscopy. Poindexter BD, et al. **Ann Plast Surg** 1998 Dec;41(6):679–83 (52 ref.)
Hemisphere tomy complications in the light of craniocerebral disproportion: review of the literature and rationale for a filling-reduction cranioplasty. Sorano V, et al. **Childs Nerv Syst** 1998 Sep;14(9):440–7 (63 ref.)
Pudendal neuropathy is predictive of failure following anterior overlapping sphincteroplasty. Gilliland R, et al. **Dis Colon Rectum** 1998 Dec;41(12):1516–22 (46 ref.)
Tracheal resection and reconstruction: a review of 82 patients. Sharpe DA, et al. **Eur J Cardiothorac Surg** 1996; 10(12):1040–5; discussion 1045–6 (23 ref.)
Microvascular reconstruction of the traumatized thumb. Shin AY, et al. **Hand Clin** 1999 May;15(2):347–71 (86 ref.)
The management of bone defects of the forearm after trauma. Stevanovic M, et al. **Hand Clin** 1999 May;15(2):299–318 (31 ref.)
Treatment of composite tissue loss following hand and forearm trauma. Tomaino MM. **Hand Clin** 1999 May; 15(2):319–33, ix (31 ref.)
The use of small intestine in bladder reconstruction. Kashif KM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998; 9(5):275–80 (29 ref.)
Revision anterior cruciate ligament reconstruction surgery. Getelman MH, et al. **J Am Acad Orthop Surg** 1999 May–Jun;7(3):189–98 (30 ref.)
Use of allografts in knee reconstruction: II. Surgical considerations. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):169–75 (29 ref.)
Use of allografts in knee reconstruction: I. Basic science aspects and current status. Shelton WR, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):165–8 (15 ref.)
BoneSource hydroxyapatite cement: a novel biomaterial for craniofacial skeletal tissue engineering and reconstruction. Friedman CD, et al. **J Biomed Mater Res** 1998 Winter; 43(4):428–32 (13 ref.)
Reconstruction of the temporomandibular joint using calvarial bone after a failed Teflon-Proplast implant. Lee JJ, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):457–61 (14 ref.)
Stress fracture of the tibia: an unusual complication of reconstructive surgery of the mandible. Westesson PL, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):70–4 (21 ref.)
Bone tunnel enlargement after anterior cruciate ligament reconstruction: fact or fiction? Höher J, et al. **Knee Surg Sports Traumatol Arthrosc** 1998;6(4):231–40 (41 ref.)
Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients--is reconstruction with a reservoir worthwhile? Liedman B. **Nutrition** 1999 Sep;15(9):677–82 (94 ref.)
Surgical management of vaginal agenesis. Templeman CL, et al. **Obstet Gynecol Surv** 1999 Sep;54(9):583–91 (41 ref.)
Obliteration of the frontal sinus--state of the art and reflections on new materials. Weber R, et al. **Rhinology** 1999 Mar;37(1):1–15 (149 ref.)
Some basic factors essential to autogeneic nonvascularized onlay bone grafting to the craniofacial skeleton. Gordh M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Jun; 33(2):129–46 (134 ref.)
Guidelines in the management of traumatic scars and surgical incisions. Beatty RL, et al. **Semin Ophthalmol** 1998 Sep; 13(3):171–6 (8 ref.)
Reconstruction following total gastrectomy: a review and summary of the randomized prospective clinical trials. Espat NJ, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):65–9 (12 ref.)
Reconstructive rectal surgery. Wheeler JM, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):13–23 (112 ref.)
Venous bypass and valve reconstruction: long-term efficacy. Eklof BG, et al. **Vasc Med** 1998;3(2):157–64 (43 ref.)
Genital skin loss: unified reconstructive approach to a heterogeneous entity. Wessells H. **World J Urol** 1999 Apr; 17(2):107–14 (21 ref.)
[Adipose tissue transplantation and plastic surgery: review of basic research] Wang D, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):61–3 (12 ref.) **(Chi)**
[Uses of artificial implants in the repair and reconstruction of craniomaxillofacial area] Zou L, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jul;11(4):193–5 (20 ref.) **(Chi)**
[Under the epidermis, the dermis, or how to interpret skin cultures?] Echinard C. **Ann Chir Plast Esthet** 1998 Apr; 43(2):197–205 (35 ref.) (Eng. Abstr.) **(Fre)**
[Unusual facial clefts] Stricker M, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):401–41 (153 ref.) (Eng. Abstr.) **(Fre)**
[Update on reconstructive surgery in cancer] Bertrand P, et al. **Bull Cancer** 1999 Jan;86(1):65–9 (18 ref.) **(Fre)**
[Echo-doppler surveillance of revascularization of the legs in asymptomatic postoperative patients. Why? With what rhythm? How much time? How?] Mellière D, et al. **J Mal Vasc** 1999 Jun;24(3):233–8 (20 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Selection of materials for orbital floor reconstruction [see comments] Chowdhury K, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1398–401 (16 ref.) Comment in: Arch Otolaryngol Head Neck Surg 1998 Dec;124(12):1402. Comment in: Arch Otolaryngol Head Neck Surg 1998 Dec;124(12):1402–3.
Loss of extension after reconstruction of the anterior cruciate ligament. Petsche TS, et al. **J Am Acad Orthop Surg** 1999 Mar–Apr;7(2):119–27 (31 ref.)
Anterior cruciate ligament reconstruction and the long-term incidence of gonarthrosis. Gillquist J, et al. **Sports Med** 1999 Mar;27(3):143–56 (132 ref.)

INSTRUMENTATION

The ligament augmentation device: an historical perspective. Kumar K, et al. **Arthroscopy** 1999 May;15(4):422–32 (49 ref.)

METHODS

Intraparietal retrorectus tension-free prosthetic mesh: a simple and effective method of repair of complex ventral hernias via a modified Stoppa technique. Surgical technique. Sakorafas GH, et al. **Acta Chir Belg** 1999 May–Jun;99(3):109–12 (12 ref.)
Articular cartilage lesions of the knee. Mandelbaum BR, et al. **Am J Sports Med** 1998 Nov–Dec;26(6):853–61 (53 ref.)
Arthroscopic knot typing techniques. Nottage WM, et al. **Arthroscopy** 1999 Jul–Aug;15(5):515–21 (12 ref.)
Surgical methods of restoring the prepuce: a critical review. Brandes SB, et al. **BJU Int** 1999 Jan;83 Suppl 1:109–13 (10 ref.)
Surgery of the eyelids. Brady KM, et al. **Clin Plast Surg** 1998 Oct;25(4):579–86, ix (20 ref.)
Adenoid cystic carcinoma of Bartholin's gland: what is the optimal approach? Anaf V, et al. **Eur J Surg Oncol** 1999 Aug;25(4):406–9 (19 ref.)
Platysma myocutaneous flap for intraoral reconstruction: an option in the compromised patient. Berenholz L, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):285–7 (11 ref.)
Anorectal reconstruction--restoring continence after abdominoperineal excision of the anorectum [see comments] Eccersley AJ, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):549–54 (45 ref.) Comment in: Ital J Gastroenterol Hepatol 1999 Apr;31(3):267–8.
Anorectal reconstruction after abdominoperineal excision: a state-of-the-art alternative to a conventional colostomy [letter; comment] Violi V, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):267–8 (9 ref.) Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):549–54.
Spectrum of cartilage grafting in cutaneous reconstructive surgery. Otley CC, et al. **J Am Acad Dermatol** 1998 Dec; 39(6):982–92 (23 ref.)
Distraction osteogenesis of a fibula free flap used for mandibular reconstruction: preliminary report. Siciliano S, et al. **J Craniomaxillofac Surg** 1998 Dec;26(6):386–90 (20 ref.)
Z-plasty closure of the donor defect of the radial forearm free flap. Hui KC, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):19–21 (10 ref.)
Implant reconstruction of the jaws and craniofacial skeleton. Alberto PL. **Mt Sinai J Med** 1998 Oct–Nov;65(5–6):316–21 (12 ref.)
Mutilating injuries to the hand: early amputation or repair and reconstruction. Arellano AO, et al. **Orthopedics** 1999 Jul;22(7):683–4 (18 ref.)
Middle ear reconstructive techniques. Chole RA, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):489–503 (33 ref.)
Flexible approach to tympanomastoidectomy. Kimberley BP, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):585–95 (3 ref.)
Ossiculoplasty. McGee M, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):471–88 (28 ref.)
Canalplasty. Parisier SC, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):457–69 (14 ref.)
Reconstruction of a severe chest and abdominal wall electrical burn injury in a pediatric patient. MacKinnon C, et al. **Plast Reconstr Surg** 1999 May;103(6):1775–7; quiz 1778 (16 ref.)
Subunit principles in midface fractures: the importance of sagittal buttresses, soft-tissue reductions, and sequencing treatment of segmental fractures. Manson PN, et al. **Plast Reconstr Surg** 1999 Apr;103(4):1287–306; quiz 1307 (57 ref.)
Recent advances in soft tissue augmentation. Krauss MC. **Semin Cutan Med Surg** 1999 Jun;18(2):119–28 (71 ref.)
A comparison of graft implantation techniques for hair transplantation. Whitworth JM, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):177–83 (7 ref.)
Preoperative and postoperative skin care with laser resurfacing. Hrabovsky SL. **Semin Ophthalmol** 1998 Sep; 13(3):115–22 (32 ref.)
Reconstructive approaches in soft tissue sarcoma. Langstein HN, et al. **Semin Surg Oncol** 1999 Jul–Aug;17(1):52–65 (27 ref.)
Future perspectives in reconstructive surgery using tissue engineering. Atala A. **Urol Clin North Am** 1999 Feb; 26(1):157–65, ix-x (53 ref.)
Upper ureteral reconstructive surgery. Borhan A, et al. **Urol Clin North Am** 1999 Feb;26(1):175–81, x (35 ref.)
Reconstructive surgery for trauma of the upper urinary tract. Brandes SB, et al. **Urol Clin North Am** 1999 Feb; 26(1):183–99, x (52 ref.)
Complex renal reconstruction. Bretan PN Jr, et al. **Urol Clin North Am** 1999 Feb;26(1):201–17, x (33 ref.)
Vaginal reconstruction. Hensle TW, et al. **Urol Clin North Am** 1999 Feb;26(1):39–47, vii (39 ref.)
Lower ureteral reconstruction. Koo HP, et al. **Urol Clin North Am** 1999 Feb;26(1):167–73, x (29 ref.)
Reconstructive surgery for trauma of the lower urinary tract. Morey AF, et al. **Urol Clin North Am** 1999 Feb;26(1):49–60, viii (36 ref.)
[Craniosynostosis and faciocraniosynostosis] Arnaud E, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):443–80 (69 ref.) (Eng. Abstr.) **(Fre)**
[Maxillo-mandibular + + disharmonies] Raphaël B, et al. **Ann Chir Plast Esthet** 1997 Oct;42(5):481–514 (53 ref.) (Eng. Abstr.) **(Fre)**
[Surgical management of soft tissue sarcomas: principles of resection and reconstructive plastic procedures] Steinau HU, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19; 87(34):1061–5 (17 ref.) (Eng. Abstr.) **(Ger)**
[Surgery of malignant tumors affecting the skull base] Saito K, et al. **No Shinkei Geka** 1999 Jun;27(6):505–14 (21 ref.) **(Jpn)**
[Efficacy and indications for YAG laser optico-reconstructive surgery on the anterior eye segment in children] Arestova NN, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):25–9 (9 ref.) (Eng. Abstr.) **(Rus)**
[Principles of uncomplicated epi- and epimesotympanitis treatment] Melan'in VD, et al. **Vestn Otorinolaringol** 1999; (4):8–10 (3 ref.) (Eng. Abstr.) **(Rus)**
[Plastic repair of a defect in the base of the skull with soft tissues from the orbit after the removal of an extensive esthesioneuroepithelioma] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr–Jun; (2):25–7 (24 ref.) (Eng. Abstr.) **(Rus)**
[The use of the temporal muscle for closing postoperative wounds] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct–Dec; (4):51–4 (22 ref.) (Eng. Abstr.) **(Rus)**
[Vaginal reconstruction in girls and young adults] Hensle TW, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):527–36 (24 ref.) (Eng. Abstr.) **(Spa)**
[Overcoming pitfalls: vesical substitution in women with bladder cancer(editorial)] Martinez-Sagarra JM. **Arch Esp Urol** 1998 Sep;51(7):641–3 (13 ref.) **(Spa)**

TRENDS

Plastic surgery. Kuzon WM Jr. **J Am Coll Surg** 1999 Feb; 188(2):171–7 (57 ref.)
Advanced techniques in liposuction. Johnson DS, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):139–48 (26 ref.)

RECORD LINKAGE, MEDICAL see **MEDICAL RECORD**

LINKAGE

RECORDS

STATISTICS & NUMERICAL DATA

Evaluation of the completeness of cancer case ascertainment in the Seoul male cohort study: application of the capture-recapture method. Kim DS, et al. **J Epidemiol** 1999 Jun;9(3):146-54 (16 ref.)

RECORDS CONTROL see **FORMS AND RECORDS CONTROL**

RECOVERY OF FUNCTION

see related
CONVALESCENCE
REHABILITATION

Recoverability of renal function after relief of chronic partial upper urinary tract obstruction. Shokeir AA, et al. **BJU Int** 1999 Jan;83(1):11-7 (43 ref.)

Recovery from mild head injury. Bernstein DM. **Brain Inj** 1999 Mar;13(3):151-72 (121 ref.)

DRUG EFFECTS

The role of piracetam in the treatment of acute and chronic aphasia. Huber W. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:38-43 (46 ref.)

PHYSIOLOGY

Molecular mechanisms of vestibular compensation in the central vestibular system--review. Kitahara T, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:19-27 (59 ref.)

Synaptic plasticity and the organization of behaviour after early and late brain injury. Kolb B. **Can J Exp Psychol** 1999 Mar;53(1):62-76 (63 ref.)

Imaging recovery from stroke. Weiller C. **Exp Brain Res** 1998 Nov;123(1-2):13-7 (51 ref.)

RECOVERY PERIOD, ANESTHESIA see **ANESTHESIA RECOVERY PERIOD**

RECREATION

Serious waterborne and wilderness infections. Greenberg SB. **Crit Care Clin** 1999 Apr;15(2):387-414 (205 ref.)

[The family, spare-time activities and environmental health risks] Cabut C. **J Pharm Belg** 1999 Mar-Apr;54(2):33-7 (2 ref.) **(Fre)**

RECREATIONAL DRUGS see **STREET DRUGS**

RECRUITMENT (NEUROLOGY)

Orderly recruitment among motoneurons supplying different muscles. Cope TC, et al. **J Physiol Paris** 1999 Jan-Apr; 93(1-2):81-5 (26 ref.)

RECRUITMENT, LOUDNESS

DIAGNOSIS

Disturbances of loudness perception. Phillips DP, et al. **J Am Acad Audiol** 1998 Oct;9(5):371-9; quiz 399 (76 ref.)

RECTAL DISEASES

Condyloma acuminata: a fatal disease? Rhea WG Jr, et al. **Am Surg** 1998 Nov;64(11):1082-7 (39 ref.)

Solitary rectal ulcer syndrome. Vaizey CJ, et al. **Br J Surg** 1998 Dec;85(12):1617-23 (89 ref.)

Anorectal miscellany: pilonidal disease, anal cancer, Bowen's and Paget's diseases, foreign bodies, and hidradenitis suppurativa. Billingham RP. **Prim Care** 1999 Mar; 26(1):171-7 (29 ref.)

[The solitary rectal ulcer today. A review of the literature] Nincheri Kunz M, et al. **Minerva Chir** 1998 Nov; 53(11):919-34 (99 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

[Psoas abscess with mediastinal extension secondary to rectal perforation (letter; comment)] Jiménez Almonacid P, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):149-50 (6 ref.) Comment on: Rev Esp Enferm Dig 1995 Nov;87(11):830-1. **(Spa)**

CONGENITAL

Pediatric rectal and perineal problems. Hendren WH. **Pediatr Clin North Am** 1998 Dec;45(6):1353-72 (23 ref.)

DIAGNOSIS

American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Barnett JL, et al. **Gastroenterology** 1999 Mar;116(3):732-60 (239 ref.)

AGA technical review on anorectal testing techniques. Diamant NE, et al. **Gastroenterology** 1999 Mar; 116(3):735-60 (239 ref.)

Imaging studies of the pelvic floor. Weidner AC, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):825-48, vii (52 ref.)

Pediatric rectal and perineal problems. Hendren WH. **Pediatr Clin North Am** 1998 Dec;45(6):1353-72 (23 ref.)

Approach to the patient. Parsons DP, et al. **Prim Care** 1999 Mar;26(1):15-34 (6 ref.)

Endoluminal MR imaging of the rectum and anus: technique, applications, and pitfalls. Stoker J, et al. **Radiographics** 1999 Mar-Apr;19(2):383-98 (20 ref.)

Endoluminal MR imaging of diseases of the anus and rectum. Stoker J, et al. **Semin Ultrasound CT MR** 1999 Feb; 20(1):47-55 (36 ref.)

[A case of tailgut cyst] Ito F, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):154-9 (22 ref.) **(Jpn)**

ETIOLOGY

Posterior hernia of the rectum after coccygectomy. García FJ, et al. **Eur J Surg** 1998 Oct;164(10):793-4 (3 ref.)

Spontaneous perforation of the rectum with possible stercoral etiology: report of a case and review of the literature. Tokunaga Y, et al. **Surg Today** 1998;28(9):937-9 (11 ref.)

[A strangulated perineal hernia. A rare case of intestinal obstruction] Sciacca P, et al. **Minerva Chir** 1998 Sep; 53(9):739-41 (5 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Juvenile polyp--a premalignant lesion? Cleary K. **Adv Anat Pathol** 1998 Mar;5(2):95-8 (1 ref.)

Anorectal pathology in AIDS. Brar HS, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):913-31 (36 ref.)

[Embryologic hypotheses of prostatic ectopy: apropos of a case] Colombel M, et al. **Prog Urol** 1998 Sep;8(4):573-7 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Internal anal sphincter: advances and insights [see comments] Sangwan YP, et al. **Dis Colon Rectum** 1998 Oct; 41(10):1297-311 (163 ref.) Comment in: Dis Colon Rectum 1999 Jun;42(6):823-4.

SURGERY

How to do it in surgery: transanal endoscopic microsurgery. van Dalen RM, et al. **Br J Hosp Med** 1998 Nov 19-Dec 9;58(10):498-500 (13 ref.)

Internal anal sphincter: advances and insights [see comments] Sangwan YP, et al. **Dis Colon Rectum** 1998 Oct; 41(10):1297-311 (163 ref.) Comment in: Dis Colon Rectum 1999 Jun;42(6):823-4.

Arteriovenous malformation of the rectum: report of a case. Hayakawa H, et al. **Surg Today** 1998;28(11):1182-7 (29 ref.)

[Rectal carcinoma. Optimizing the procedures in an emergency] Hildebrandt U. **Zentralbl Chir** 1999; 124(5):446-50 (27 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diagnostic, pharmacological, surgical and behavioural developments in benign anorectal disease. Kamm MA. **Eur J Surg Suppl** 1998;(582):119-23 (22 ref.)

American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Barnett JL, et al. **Gastroenterology** 1999 Mar;116(3):732-60 (239 ref.)

AGA technical review on anorectal testing techniques. Diamant NE, et al. **Gastroenterology** 1999 Mar; 116(3):735-60 (239 ref.)

Endoscopic management of rectal Dieulafoy-like lesions: a case series and review of literature. Meister TE, et al. **Gastrointest Endosc** 1998 Sep;48(3):302-5 (25 ref.)

Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus. El-Attar SM, et al. **Prim Care** 1999 Mar;26(1):81-100 (32 ref.)

Anorectal abscess and fistula. Hyman N. **Prim Care** 1999 Mar;26(1):69-80 (32 ref.)

RECTAL FISTULA

COMPLICATIONS

Perineal-mound defects. Sharma AK, et al. **Pediatr Surg Int** 1999;15(3-4):227-9 (6 ref.)

CONGENITAL

[Rare anorectal malformations. Intermediate-type anal agenesis with a rectocutaneous fistula] Ghandour HM, et al. **Minerva Chir** 1998 Nov;53(11):935-8 (10 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Rare anorectal malformations. Intermediate-type anal agenesis with a rectocutaneous fistula] Ghandour HM, et al. **Minerva Chir** 1998 Nov;53(11):935-8 (10 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Anterior sacral meningocele associated with a rectal fistula. Case report and review of the literature. Fitzpatrick MO, et al. **J Neurosurg** 1999 Jul;91(1 Suppl):124-7 (26 ref.)

SURGERY

Anorectal abscess and fistula. Hyman N. **Prim Care** 1999 Mar;26(1):69-80 (32 ref.)

[Treatment of anal fistula] Puy-Montbrun T. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B142-7 (38 ref.) **(Fre)**

THERAPY

[Therapy of Crohn disease in internal medicine: postoperative recurrence and fistulas] Volk-Zeiher BA, et al. **Schweiz Rundsch Med Prax** 1998 Nov 26;87(48):1657-60 (18 ref.) (Eng. Abstr.) **(Ger)**

RECTAL GLAND see **SALT GLAND**

RECTAL NEOPLASMS

Dietary factors in human colorectal cancer. Lipkin M, et al. **Annu Rev Nutr** 1999;19:545-86 (330 ref.)

COMPLICATIONS

Splenic metastasis from a rectal tumour: an unusual presentation. Achuthan R, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):139 (4 ref.)

Adenocarcinoma within a rectal duplication cyst: case report and literature review. Michael D, et al. **Ann R Coll Surg Engl** 1999 May;81(3):205-6 (5 ref.)

Myositis and malignancy: is there a true association? Brown H, et al. **Hosp Med** 1999 Jan;60(1):51-3 (10 ref.)

DIAGNOSIS

Preoperative staging of rectal carcinoma. Heriot AG, et al. **Br J Surg** 1999 Jan;86(1):17-28 (151 ref.)

Diffuse cavernous haemangioma of the rectum. Tanaka N, et al. **Eur J Surg** 1999 Mar;165(3):280-3 (18 ref.)

Colorectal surveillance for neoplasia: an overview. Bond JH. **Gastrointest Endosc** 1999 Mar;49(3 Pt 2):S35-40 (28 ref.)

Rectal imaging and cancer. Vining DJ. **Semin Surg Oncol** 1998 Sep;15(2):72-7 (40 ref.)

DRUG THERAPY

Chemoradiation for rectal cancer: current methods. Barrett MW. **Semin Surg Oncol** 1998 Sep;15(2):114-9 (25 ref.)

Induction therapy for rectal carcinoma. Busse PM, et al. **Semin Surg Oncol** 1998 Sep;15(2):120-5 (37 ref.)

[Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer] Wiboltt K, et al. **Ugeskr Laeger** 1999 Jun 21;161(25):3827-32 (36 ref.) (Eng. Abstr.) **(Dan)**

[Progress in the treatment of colorectal cancer] Sasaki T, et al. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:129-38 (56 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment with cytostatic agents should be considered in colorectal cancer. It improves prognosis and quality of life] Larsson PA. **Lakartidningen** 1999 May 12;96(19):2314-6 (15 ref.) **(Swe)**

EPIDEMIOLOGY

Epidemiology of digestive tract cancers in India. V. Large and small bowel. Mohandas KM, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):118-21 (30 ref.)

ETIOLOGY

WHO consensus statement on the role of nutrition in colorectal cancer. Scheppach W, et al. **Eur J Cancer Prev** 1999 Feb;8(1):57-62 (45 ref.)

GENETICS

[The application of molecular technics in the management of colorectal cancer] Laurent-Puig P, et al. **J Chir (Paris)** 1997 Dec;134(7-8):279-82 (21 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The dynamics of early intestinal tumour proliferation: to be or not to be. Shibata D. **Cancer Surv** 1998;32:181-200 (56 ref.)

Small-cell carcinoma of the rectum: report of two cases. Cebrian J, et al. **Dis Colon Rectum** 1999 Feb;42(2):274-7 (22 ref.)

Adenosquamous carcinoma of the rectum showing endocrine-cell differentiation: report of a case. Kono T, et al. **Dis Colon Rectum** 1999 Aug;42(8):1089-92 (8 ref.)

Risk of cancer in ulcerative colitis. Ekbom A. **J Gastrointest Surg** 1998 Jul-Aug;2(4):312-3 (14 ref.)

Biology of colorectal cancer in ulcerative colitis. Lashner BA, et al. **J Gastrointest Surg** 1998 Jul-Aug;2(4):307-11 (65 ref.)

Disseminated intravascular coagulation. Gobel BH. **Semin Oncol Nurs** 1999 Aug;15(3):174-82 (40 ref.)

Prognostic markers in rectal carcinoma. Jessup JM, et al. **Semin Surg Oncol** 1998 Sep;15(2):131-40 (83 ref.)

[Treatment of peritoneal carcinosis of colorectal origin] Dubé P, et al. **J Chir (Paris)** 1997 Nov;134(5-6):233-6 (50 ref.) **(Fre)**

[Surgical treatment of pulmonary metastasis of colorectal cancer. Prognostic survival factors] Baron O, et al. **Presse Med** 1998 May 16;27(18):885-8 (38 ref.) (Eng.

Abstr.) **(Fre)**

[Rectal carcinoma. Optimizing therapy by knowledge of anatomy with special reference to the mesorectum] Konerding MA, et al. **Zentralbl Chir** 1999;124(5):413–7 (15 ref.) (Eng. Abstr.) **(Ger)**

[Histopathologic examination of rectal carcinoma] Wolf HK, et al. **Zentralbl Chir** 1999;124(5):408–12 (35 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Role of endoscopy in the prevention of digestive cancer: application to colorectal cancer. Lambert R. **Endoscopy** 1998 Sep;30(7):628–40 (47 ref.)

RADIONUCLIDE IMAGING

Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation. Roselli M, et al. **Semin Surg Oncol** 1998 Dec;15(4):254–62 (49 ref.)

RADIOTHERAPY

Perioperative radiotherapy in rectal cancer. Glimelius B, et al. **Acta Oncol** 1999;38(1):23–32 (68 ref.)

Radiotherapy in rectal cancer [editorial; comment] Tveit KM. **Acta Oncol** 1999;38(1):5–6 (10 ref.) Comment on: Acta Oncol 1999 ;38(1):7–21. Comment on: Acta Oncol 1999 ;38(1):23–32.

Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Suwinski R, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):943–51 (56 ref.)

Chemoradiation for rectal cancer: current methods. Barrett MW. **Semin Surg Oncol** 1998 Sep;15(2):114–9 (25 ref.)

Induction therapy for rectal carcinoma. Busse PM, et al. **Semin Surg Oncol** 1998 Sep;15(2):120–5 (37 ref.)

[Radiotherapy of cancer of the anal canal. 15 years experience at the Lyon civil hospices and brief review of the literature] Gérard JP, et al. **Ann Chir** 1998;52(1):17–23 (24 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant chemoradiotherapy of cancers of the rectum] Bosset JF, et al. **Cancer Radiother** 1998 Dec;2(6):703–7 (40 ref.) (Eng. Abstr.) **(Fre)**

[Chemoradiotherapy in treatment of cancer of the anal canal] Gérard JP. **Cancer Radiother** 1998 Dec;2(6):708–12 (35 ref.) (Eng. Abstr.) **(Fre)**

[Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?] Fasolini F. **Zentralbl Chir** 1999; 124(5):441–5 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Perioperative radiotherapy in rectal cancer. Glimelius B, et al. **Acta Oncol** 1999;38(1):23–32 (68 ref.)

Mesorectal excision for rectal carcinoma: the new standard? Beart RW Jr. **Adv Surg** 1999;32:193–203 (50 ref.)

The role of surgery and chemoradiation therapy for cancer of the rectum. Paty PB, et al. **Adv Surg** 1999;32:205–23 (111 ref.)

Proctectomy and coloanal anastomosis for rectal cancer. Read TE, et al. **Arch Surg** 1999 Jun;134(6):670–7 (23 ref.)

Pre-operative chemoradiotherapy and total mesorectal excision surgery of rectal cancer: towards the eradication of pelvic failures? Bosset JF, et al. **Aust N Z J Surg** 1999 Sep;69(9):622–4 (32 ref.)

Colorectal carcinoma: is lymphadenectomy useful? Curti G, et al. **Dig Surg** 1998;15(3):193–208 (167 ref.)

Misconceptions about the colonic J-pouch: what the accumulating data show. Dennett ER, et al. **Dis Colon Rectum** 1999 Jun;42(6):804–11 (47 ref.)

Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer: an overview. Ooi BS, et al. **Dis Colon Rectum** 1999 Mar;42(3):403–18 (92 ref.)

Multimodal therapy in rectal cancer. Link KH, et al. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2167–92 (120 ref.)

Anorectal reconstruction--restoring continence after abdominoperineal excision of the anorectum [see comments] Eccersley AJ, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):549–54 (45 ref.) Comment in: Ital J Gastroenterol Hepatol 1999 Apr;31(3):267–8.

Synchronous and metachronous gastric adenocarcinoma: case report and literature review. Gnanalingham KK, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):61–2 (15 ref.)

Actual standards and controversies on operative technique and lymph-node dissection in colorectal cancer. Bruch HP, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):167–75 (89 ref.)

Mesorectal lymph node dissection: is it beneficial? Hohenberger W, et al. **Langenbecks Arch Surg** 1998 Dec; 383(6):402–8 (54 ref.)

Total mesorectal excision in the treatment of rectal cancer: a view from the USA. Goldberg S, et al. **Semin Surg Oncol** 1998 Sep;15(2):87–90 (17 ref.)

Embryology and anatomy of the rectum. Heald RJ, et al. **Semin Surg Oncol** 1998 Sep;15(2):66–71 (9 ref.)

Transanal treatment of rectal cancer: ablative methods and open resection. Kim DG, et al. **Semin Surg Oncol** 1998 Sep;15(2):101–13 (65 ref.)

Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation. Roselli M, et al. **Semin Surg Oncol** 1998 Dec;15(4):254–62 (49 ref.)

Anastomotic integrity and function: role of the colonic J-pouch. Wexner SD, et al. **Semin Surg Oncol** 1998 Sep; 15(2):91–100 (98 ref.)

Mesorectal excision for rectal cancer: a view from Europe. Wiig JN, et al. **Semin Surg Oncol** 1998 Sep;15(2):78–86 (104 ref.)

Reconstructive rectal surgery. Wheeler JM, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):13–23 (112 ref.)

Laparoscopic surgery of the colon and rectum. Tomita H, et al. **World J Surg** 1999 Apr;23(4):397–405 (116 ref.)

[Sphincter-preserving operations in the treatment of carcinoma of the middle and lower third of the rectum] Dimitrov A, et al. **Khirurgiia (Sofiia)** 1998;51(4):44–50 (0 ref.) (Eng. Abstr.) **(Bul)**

[Total excision of the mesorectum and preservation of the genitourinary innervation in surgery of rectal cancer] Tiret E, et al. **Ann Chir** 1999;53(6):507–14 (16 ref.) (Eng. Abstr.) **(Fre)**

[Update on reconstructive surgery in cancer] Bertrand P, et al. **Bull Cancer** 1999 Jan;86(1):65–9 (18 ref.) **(Fre)**

[What is the role of endo-rectal echography in monitoring of patients operated on for rectal cancer? (editorial)] Giovannini M. **Gastroenterol Clin Biol** 1998 Mar; 22(3):266–8 (31 ref.) **(Fre)**

[Therapeutic choices for cancer of the rectum: discussion and update of the consensus conference] de Calan L, et al. **J Chir (Paris)** 1998 May;135(2):51–6 (44 ref.) (Eng. Abstr.) **(Fre)**

[What is new in the surgical treatment of rectal cancer?] Dousset B, et al. **J Chir (Paris)** 1999 Mar;136(1):35–40 (45 ref.) (Eng. Abstr.) **(Fre)**

[Indications for restorative rectal resection in carcinoma--complete vs. partial and local resection] Farthmann EH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:454–8 (20 ref.) (Eng. Abstr.) **(Ger)**

[Rectal carcinoma. Optimizing the procedures in an emergency] Hildebrandt U. **Zentralbl Chir** 1999; 124(5):446–50 (27 ref.) (Eng. Abstr.) **(Ger)**

[Rectal carcinoma. Optimizing therapy by partial or total mesorectum removal] Maurer CA, et al. **Zentralbl Chir** 1999;124(5):428–35 (62 ref.) (Eng. Abstr.) **(Ger)**

[Recent management of metastatic colorectal cancer] Kato T, et al. **Gan To Kagaku Ryoho** 1998 Oct;25(12):1865–72 (40 ref.) (Eng. Abstr.) **(Jpn)**

[Pelvic evisceration in locally advanced cancer of rectum with the ingrowth into urinary bladder] Odariuk TS, et al. **Khirurgiia (Mosk)** 1999;(7):58–63 (73 ref.) **(Rus)**

[Abdomino-anal resection of rectum with hemi-resection of anal canal] Bondar' GV, et al. **Klin Khir** 1998;(6):17–8 (3 ref.) (Eng. Abstr.) **(Rus)**

[Pelvic evisceration (exenteration) for rectal cancer] Timofeev IuM, et al. **Vopr Onkol** 1999;45(3):229–32 (31 ref.) **(Rus)**

[Abdominosacral resection for locoregional recurrence rectal cancer] Meneu JC, et al. **Rev Esp Enferm Dig** 1999 May; 91(5):374–9 (30 ref.) (Eng. Abstr.) **(Spa)**

[Preservation of the anal sphincter in low rectal lesions] Arthur KE, et al. **Rev Med Panama** 1997 Jan;22(1):57–69 (15 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Adjuvant therapy for rectal cancer can no longer be ignored [letter] Barton MB, et al. **Aust N Z J Surg** 1999 Sep; 69(9):619–21 (24 ref.)

Adjuvant combined modality therapy for rectal cancer. Minsky BD. **Cancer Treat Res** 1998;98:153–71 (73 ref.)

Major 20th-century advancements in the management of rectal cancer. Ruo L, et al. **Dis Colon Rectum** 1999 May; 42(5):563–78 (136 ref.)

Is there a standard adjuvant treatment for rectal cancer? Tveit KM, et al. **Eur J Cancer** 1998 Nov;34(12):1827–35 (65 ref.)

Quality of life research in patients with rectal cancer: traditional approaches versus a problem-solving oriented perspective. Koller M, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):427–36 (59 ref.)

Adjuvant radiochemotherapy--what is the patients benefit? Link KH, et al. **Langenbecks Arch Surg** 1998 Dec; 383(6):416–26 (92 ref.)

Adjuvant postoperative combined-modality therapy for rectal cancer. Minsky BD. **Oncology (Huntingt)** 1999 Jul; 13(7 Suppl 3):132–5 (33 ref.)

A dying man asking for a dignified end. Tate P, et al. **Practitioner** 1998 Jul;242(1588):505–8, 510, 515 (0 ref.)

[Curative treatment of rectal cancer] Nordlinger B, et al. **Chirurgie** 1998 Nov;123(5):500–6 (45 ref.) (Eng. Abstr.) **(Fre)**

[Characteristics of anal carcinoma with therapeutic consequences] Hohenberger P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:363–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status (see comments)] Rödel C, et al. **Strahlenther Onkol** 1998 Oct;174(10):497–504 (41 ref.) (Eng. Abstr.) Comment in: Strahlenther Onkol 1999 Mar;175(3):133. **(Ger)**

[Up-to-date approach to the treatment of rectal cancer] Pokrovskii GA, et al. **Khirurgiia (Mosk)** 1998;(9):54–61 (5 ref.) (Eng. Abstr.) **(Rus)**

[Combined radiotherapy and surgery is best against rectal cancer] Påhlman L, et al. **Lakartidningen** 1998 Sep 23; 95(39):4216–20 (30 ref.) (Eng. Abstr.) **(Swe)**

ULTRASONOGRAPHY

Indications for endoscopic ultrasonography in colorectal lesions. Catalano MF. **Endoscopy** 1998 Aug;30 Suppl 1:A79–84 (51 ref.)

[What is the role of endo-rectal echography in monitoring of patients operated on for rectal cancer? (editorial)] Giovannini M. **Gastroenterol Clin Biol** 1998 Mar; 22(3):266–8 (31 ref.) **(Fre)**

[Rectal carcinoma--optimizing therapy by improved preoperative staging? Is endosonography required?] Maier A, et al. **Zentralbl Chir** 1999;124(5):418–21 (21 ref.) (Eng. Abstr.) **(Ger)**

RECTAL PROLAPSE

Rectal prolapse in pediatrics. Siafakas C, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):63–72 (61 ref.)

Rectal prolapse and fecal incontinence. Nagle D. **Prim Care** 1999 Mar;26(1):101–11 (40 ref.)

PHYSIOPATHOLOGY

Pathophysiology of anorectal dysfunction. Toglia MR. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):771–81, vi (63 ref.)

SURGERY

How to do it in surgery: laparoscopic rectopexy. van Dalen RM, et al. **Br J Hosp Med** 1998 Dec 10;58(11):587–8 (10 ref.)

Management of colorectal-anal dysfunction. Ludwig KA. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):923–44, viii (59 ref.)

[Therapeutic approaches to rectal prolapse] Siproudhis L. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B134–41 (69 ref.) **(Fre)**

RECTAL SURGERY (SPECIALTY) see **COLORECTAL SURGERY**

RECTOCELE

DIAGNOSIS

[Genital prolapse. Diagnosis] Jacob D, et al. **Rev Prat** 1998 May 15;48(10):1103–7 (0 ref.) **(Fre)**

RECTOCOLITIS see **PROCTOCOLITIS**

RECTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

RECTOCOLITIS, ULCERATIVE see **COLITIS, ULCERATIVE**

RECTOSIGMOIDITIS see **PROCTOCOLITIS**

RECTUM

ABNORMALITIES

Adenocarcinoma within a rectal duplication cyst: case report and literature review. Michael D, et al. **Ann R Coll Surg Engl** 1999 May;81(3):205–6 (5 ref.)

Accessory perineal scrotum associated with anorectal malformation. Ozcan C, et al. **BJU Int** 1999 Apr; 83(6):729–30 (5 ref.)

Pediatric rectal and perineal problems. Hendren WH. **Pediatr Clin North Am** 1998 Dec;45(6):1353–72 (23 ref.)

[The use of anorectal manometry in the postoperative assessment of continence in congenital anorectal malformations in childhood] Mladenov A. **Khirurgiia (Sofiia)** 1998;51(1):51–9 (15 ref.) (Eng. Abstr.) **(Bul)**

ANATOMY & HISTOLOGY

Embryology and anatomy of the rectum. Heald RJ, et al. **Semin Surg Oncol** 1998 Sep;15(2):66–71 (9 ref.)

EMBRYOLOGY

Fetal defaecation: is it a normal physiological process? Kimble RM, et al. **J Paediatr Child Health** 1999 Apr; 35(2):116–9 (49 ref.)

Embryology and anatomy of the rectum. Heald RJ, et al. **Semin Surg Oncol** 1998 Sep;15(2):66–71 (9 ref.)

INJURIES

Impalement and anorectal injuries in childhood: a retrospective study of 12 cases. Beiler HA, et al. **J Pediatr Surg** 1998 Aug;33(8):1287–91 (11 ref.)

Hydrostatic rectal injury of a jet ski passenger: case report and discussion. Morrison DM, et al. **J Trauma** 1998 Oct; 45(4):816–8 (11 ref.)

Rectal blowout by personal watercraft water jet: case report and review of literature. Philpott JM, et al. **J Trauma** 1999 Aug;47(2):385–8 (48 ref.)

[Traumatic lesions of the anorectum] Roche B, et al. **Swiss Surg** 1998;(5):249–52 (26 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Sessile polypoid gastric heterotopia of rectum: a report of 2 cases and review of the literature. Srinivasan R, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):222–4 (16 ref.)

[Rectal carcinoma. Optimizing therapy by knowledge of anatomy with special reference to the mesorectum] Konerding MA, et al. **Zentralbl Chir** 1999;124(5):413–7 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Barnett JL, et al. **Gastroenterology** 1999 Mar;116(3):732–60 (239 ref.)

AGA technical review on anorectal testing techniques. Diamant NE, et al. **Gastroenterology** 1999 Mar; 116(3):735–60 (239 ref.)

Clinical significance and application of anorectal physiology. Lestár B, et al. **Scand J Gastroenterol Suppl** 1998;228:68–72 (26 ref.)

PHYSIOPATHOLOGY

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Whitehead WE, et al. **Gastroenterology** 1998 Nov;115(5):1263–71 (83 ref.)

[The use of anorectal manometry in the postoperative assessment of continence in congenital anorectal malformations in childhood] Mladenov A. **Khirurgiia (Sofiia)** 1998;51(1):51–9 (15 ref.) (Eng. Abstr.) **(Bul)**

SURGERY

Pre-operative chemoradiotherapy and total mesorectal excision surgery of rectal cancer: towards the eradication of pelvic failures? Bosset JF, et al. **Aust N Z J Surg** 1999 Sep;69(9):622–4 (32 ref.)

Use of the greater omentum in colorectal surgery. O'Leary DP. **Dis Colon Rectum** 1999 Apr;42(4):533–9 (82 ref.)

Anorectal reconstruction--restoring continence after abdominoperineal excision of the anorectum [see comments] Eccersley AJ, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):549–54 (45 ref.) Comment in: Ital J Gastroenterol Hepatol 1999 Apr;31(3):267–8.

Nasogastric tubes and dietary advancement after laparoscopic and open colorectal surgery. Sands DR, et al. **Nutrition** 1999 May;15(5):347–50 (34 ref.)

Laparoscopic surgery of the colon and rectum. Tomita H, et al. **World J Surg** 1999 Apr;23(4):397–405 (116 ref.)

[Sphincter-preserving operations in the treatment of carcinoma of the middle and lower third of the rectum] Dimitrov A, et al. **Khirurgiia (Sofiia)** 1998;51(4):44–50 (0 ref.) (Eng. Abstr.) **(Bul)**

[Surgical treatment of constipation] Hiltunen KM, et al. **Duodecim** 1995;111(20):1955–9 (17 ref.) **(Fin)**

[Total excision of the mesorectum and preservation of the genitourinary innervation in surgery of rectal cancer] Tiret E, et al. **Ann Chir** 1999;53(6):507–14 (16 ref.) (Eng. Abstr.) **(Fre)**

[What is the role of endo-rectal echography in monitoring of patients operated on for rectal cancer? (editorial)] Giovannini M. **Gastroenterol Clin Biol** 1998 Mar; 22(3):266–8 (31 ref.) **(Fre)**

[Rectal carcinoma. Optimizing therapy by partial or total mesorectum removal] Maurer CA, et al. **Zentralbl Chir** 1999;124(5):428–35 (62 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

EUS and EUS-guided fine-needle aspiration for the diagnosis of rectal linitis plastica secondary to prostate carcinoma. Bhutani MS. **Gastrointest Endosc** 1999 Jul; 50(1):117–9 (13 ref.)

[What is the role of endo-rectal echography in monitoring of patients operated on for rectal cancer? (editorial)] Giovannini M. **Gastroenterol Clin Biol** 1998 Mar; 22(3):266–8 (31 ref.) **(Fre)**

RECTUS ABDOMINIS

SURGERY

Intraparietal retrorectus tension-free prosthetic mesh: a simple and effective method of repair of complex ventral hernias via a modified Stoppa technique. Surgical technique. Sakorafas GH, et al. **Acta Chir Belg** 1999 May-Jun;99(3):109–12 (12 ref.)

RECURRENCE

see related
NEOPLASM RECURRENCE, LOCAL

RECURRENT LARYNGEAL NERVE

Bilateral recurrent nerve paralysis associated with multinodular substernal goiter: a case report. Souza JW, et al. **Am Surg** 1999 May;65(5):456–9 (10 ref.)

INJURIES

Recurrent laryngeal nerve injury caused by a laryngeal mask airway. Lowinger D, et al. **Anaesth Intensive Care** 1999 Apr;27(2):202–5 (26 ref.)

RECYCLING see **CONSERVATION OF NATURAL RESOURCES**

RED BLOOD CELL MEMBRANE SIALOGLYCOPROTEIN see **GLYCOPHORIN**

RED BLOOD CELL TRANSFUSION see **ERYTHROCYTE TRANSFUSION**

RED BLOOD CELLS see **ERYTHROCYTES**

RED-CELL APLASIA, PURE

COMPLICATIONS

Multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Hattori K, et al. **Ann Hematol** 1998 Oct;77(4):179–81 (15 ref.)

Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature. Mizobuchi S, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):696–701 (37 ref.)

PHYSIOPATHOLOGY

Aplastic anemia and pure red cell aplasia. Dessypris EN. **Curr Opin Hematol** 1994 Mar;1(2):157–61 (47 ref.)

RED CELL GHOST see **ERYTHROCYTE MEMBRANE**

RED CELL MASS see **ERYTHROCYTE VOLUME**

RED CELL SUBSTITUTES see **BLOOD SUBSTITUTES**

RED CROSS

Organizational changes in Canada. Décary F. **Vox Sang** 1998; 74 Suppl 2:527–9 (3 ref.)

RED MARROW see **BONE MARROW**

RED NUCLEUS

PATHOLOGY

[Dentatorubral-pallidoluysian atrophy (DRPLA: differential diagnosis of progressive myoclonus epilepsy] Naito H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):163–5 (13 ref.) **(Jpn)**

[Dentatorubral-pallidoluysian atrophy (DRPLA: differential diagnosis of chorea)] Tsuji S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):101–3 (10 ref.) **(Jpn)**

[Dentatorubral-pallidoluysian atrophy (DRPLA: Naito-Oyanagi disease)] Tsuji S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):275–9 (17 ref.) **(Jpn)**

PHYSIOLOGY

Construction of a reach-to-grasp. Gibson AR, et al. **Novartis Found Symp** 1998;218:233–45; discussion 245–51 (39 ref.)

RED PEPPER see **CAPSICUM**

REDOX see **OXIDATION-REDUCTION**

REDUCED GRAVITY see **HYPOGRAVITY**

REDUCTASES see **OXIDOREDUCTASES**

REED-STERNBERG CELLS

see related
HODGKIN DISEASE

CYTOLOGY

Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. Küppers R, et al. **Ann Oncol** 1998;9 Suppl 5:S17–20 (36 ref.)

DRUG EFFECTS

Molecular basis of targeted chemotherapy: novel concepts with special reference to the treatment of Hodgkin's disease. Grunicke HH. **Ann Oncol** 1998;9 Suppl 5:S125–8 (29 ref.)

IMMUNOLOGY

The many faces of Hodgkin's disease around the world: what have we learned from its pathology? Harris NL. **Ann Oncol** 1998;9 Suppl 5:S45–56 (112 ref.)

Immune escape mechanisms in Hodgkin's disease. Poppema S, et al. **Ann Oncol** 1998;9 Suppl 5:S21–4 (44 ref.)

PATHOLOGY

Hodgkin's disease: biology and origin of Hodgkin and Reed-Sternberg cells. Stein HS, et al. **Cancer Treat Rev** 1999 Jun;25(3):161–8 (45 ref.)

Identifying the precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease: role of the germinal center in B-cell lymphomagenesis. Küppers R. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S74–9 (47 ref.)

REELER MICE see **MICE, NEUROLOGIC MUTANTS**

REFERENCE BOOKS

see related
TEXTBOOKS

REFERENCE STANDARDS

[Standard chemicals and their use--various materials and enzymes] Kuwa K. **Rinsho Byori** 1999 Feb;Suppl 109:44–62 (24 ref.) **(Jpn)**

REFERRAL AND CONSULTATION

Heart murmurs in pediatric patients: when do you refer? McConnell ME, et al. **Am Fam Physician** 1999 Aug; 60(2):558–65 (06 ref.)

Consultant strategies for the gastroenterologist. Clearfield HR. **Am J Gastroenterol** 1999 Jun;94(6):1453–6 (9 ref.)

From consultation-liaison psychiatry to psychosocial advocacy: maintaining psychiatry's scope. Smith GC. **Aust N Z J Psychiatry** 1998 Dec;32(6):753–61; discussion 762–6 (75 ref.)

GP referrals to adult psychological services: a research agenda for promoting needs-led practice through the involvement of mental health clinicians. Ross H, et al. **Br J Med Psychol** 1999 Mar;72 (Pt 1):75–91 (87 ref.)

Subacute care: which patients benefit? Mistry PR, et al. **Cleve Clin J Med** 1999 Jul-Aug;66(7):443–6 (12 ref.)

Cardiology 7. Stable angina pectoris: treatment and referral options. McTaggart D. **Med J Aust** 1999 Jul 5;171(1):43–9 (18 ref.)

Diagnosis and referral of Wilms' tumor. Pye S. **Nurse Pract** 1999 May;24(5):121–2, 127 (6 ref.)

Consultation with the specialist. Thrombocytopenia. Murphy S, et al. **Pediatr Rev** 1999 Feb;20(2):64–8; quiz 69 (5 ref.)

Ethical considerations in prenatal surgical consultation [see comments] Caniano DA, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):303–9 (21 ref.) Comment in: Pediatr Surg Int 1999 Jul;15(5–6):301–2.

Breast disease: refer or a reassure? Saunders C, et al. **Practitioner** 1998 Mar;242(1584):216–9 (2 ref.)

The Delirium Rating Scale. Its use in consultation-liaison research. Trzepacz PT. **Psychosomatics** 1999 May-Jun; 40(3):193–204 (35 ref.)

How patients use the web for second opinions. Patrick K. **West J Med** 1999 Jun;170(6):332–3 (5 ref.)

[Sedation by non-anesthesiologists should be centralized for considerations of safety (comment)] Lycklama à Nijeholt-Hamstra EW, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1077–9 (8 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1999 May 22;143(21):1098–102. **(Dut)**

[Diabetic retinopathy. When should patients be referred to ophthalmologists for evaluation?] Ducrey N. **Rev Med Suisse Romande** 1998 Nov;118(11):933–5 (7 ref.) **(Fre)**

[Violence our medical trauma in specialized multidisciplinary consultation] Albrecht E, et al. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):280–4 (4 ref.) (Eng. Abstr.) **(Fre)**

["The consultation lab"--training clinical communication] Larsen JH, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10; 119(1):52–5 (18 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

[Rights and responsibilities of the radiologist in determining indications and applying radiologic procedures] Schunk K. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):7–15 (29 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Home health care [see comments] Montauk SL. **Am Fam Physician** 1998 Nov 1;58(7):1608–14 (9 ref.) Comment in: Am Fam Physician 1999 Jul;60(1):53–4.

Principles of generalist-specialist relationships. Pearson SD. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S13–20 (30 ref.)

The scope for the involvement of patients in their consultations with health professionals: rights, responsibilities and preferences of patients. Buetow S. **J Med Ethics** 1998 Aug;24(4):243–7 (53 ref.)

STANDARDS

'Appropriateness of referral to urologists': can it be defined for symptoms of benign prostatic obstruction and used as a quality measure? Elwyn G, et al. **BJU Int** 1999 Feb; 83(3):238–42 (19 ref.)

Moving the conversation forward. Aulisio MP, et al. **J Clin Ethics** 1999 Spring;10(1):49–56 (8 ref.)

Ethics consultants: could they do better? Howe EG.

REFERRAL AND CONSULTATION

J Clin Ethics 1999 Spring;10(1):13–25 (23 ref.)
The application of the Task Force report in rural and frontier settings. Moss AH. **J Clin Ethics** 1999 Spring;10(1):42–8 (11 ref.)
Clinical ethics consultations: some reflections on the report of the SHHV-SBC. Pellegrino ED. **J Clin Ethics** 1999 Spring;10(1):5–12 (4 ref.)
Beyond case consultation: an expanded model for organizational ethics. Pentz RD. **J Clin Ethics** 1999 Spring; 10(1):34–41 (31 ref.)

STATISTICS & NUMERICAL DATA

Depression in the community: physician and patient perspective. Tylee A. **J Clin Psychiatry** 1999;60 Suppl 7:12–6; discussion 17–8 (53 ref.)

UTILIZATION

The good (gatekeeper), the bad (gatekeeper), and the ugly (situation) [editorial; comment] Laine C, et al. **J Gen Intern Med** 1999 May;14(5):320–1 (17 ref.) Comment on: J Gen Intern Med 1999 May;14(5):281–6. Comment on: J Gen Intern Med 1999 May;14(5):287–96.

REFETOFF SYNDROME see **THYROID HORMONE RESISTANCE SYNDROME**

REFLEX

The somatosensory system of the neck and its effects on the central nervous system. Bolton PS. **J Manipulative Physiol Ther** 1998 Oct;21(8):553–63 (84 ref.)

PHYSIOLOGY

Neuronal basis of afferent-evoked enhancement of locomotor activity. McCrea DA. **Ann N Y Acad Sci** 1998 Nov 16; 860:216–25 (38 ref.)
Importance of the blood pressure-heart rate relationship. Folkow B, et al. **Blood Press** 1998 May;7(3):133–8 (30 ref.)
Tapping into spinal circuits to restore motor function. Barbeau H, et al. **Brain Res Brain Res Rev** 1999 Jul; 30(1):27–51 (203 ref.)
Physiologic reflexes and their impact on resuscitation of the newborn. Halbower AC, et al. **Clin Perinatol** 1999 Sep; 26(3):621–7, vi (33 ref.)
Dorsal root potentials and dorsal root reflexes: a double-edged sword. Willis WD Jr. **Exp Brain Res** 1999 Feb;124(4):395–421 (312 ref.)
Controlling the motor neuron. Trimarchi JR, et al. **Int Rev Neurobiol** 1999;43:241–64 (73 ref.)
Role of interneurons in defensive withdrawal reflexes in Aplysia. Cleary LJ, et al. **Learn Mem** 1995 May–Aug; 2(3–4):133–51 (101 ref.)
A neurophysiological approach to brainstem reflexes. Blink reflex. Esteban A. **Neurophysiol Clin** 1999 Feb;29(1):7–38 (162 ref.)
What functions do reflexes serve during human locomotion? Zehr EP, et al. **Prog Neurobiol** 1999 Jun;58(2):185–205 (124 ref.)
[Significance of esophagocardiac reflexes for inducing thoracic pain] Holtmann G, et al. **Herz** 1999 Apr; 24(2):154–7 (23 ref.) (Eng. Abstr.) **(Ger)**

REFLEX, ABNORMAL

Dissociated vertical divergence: a righting reflex gone wrong. Brodsky MC. **Arch Ophthalmol** 1999 Sep; 117(9):1216–22 (50 ref.)

DRUG EFFECTS

Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy. Schwantes U, et al. **Int J Clin Pharmacol Ther** 1999 May; 37(5):209–18 (79 ref.)

PHYSIOLOGY

Incomplete spinal cord injury: neuronal mechanisms of motor recovery and hyperreflexia. Little JW, et al. **Arch Phys Med Rehabil** 1999 May;80(5):587–99 (119 ref.)
Respiratory control during upper airway infection mechanism for prolonged reflex apnoea and sudden infant death with special reference to infant sleep position. Lindgren C. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1–2):97–102 (45 ref.)
Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Yoshimura N. **Prog Neurobiol** 1999 Apr;57(6):583–606 (123 ref.)

REFLEX, BABINSKI

PHYSIOLOGY

[What does the Babinski sign have to offer 100 years after its description?] Barraquer-Bordas L. **Rev Neurol (Paris)** 1998 Jan;154(1):22–7 (39 ref.) (Eng. Abstr.) **(Fre)**

REFLEX, BARORECEPTOR see **BAROREFLEX**

REFLEX, BLINK see **BLINKING**

REFLEX, CONDITIONED see **CONDITIONING, CLASSICAL**

REFLEX, CORNEAL see **BLINKING**

REFLEX, ORBICULARIS OCULI see **BLINKING**

REFLEX, PSYCHOGALVANIC see **GALVANIC SKIN RESPONSE**

REFLEX, PUPILLARY

Dissociated vertical divergence: a righting reflex gone wrong. Brodsky MC. **Arch Ophthalmol** 1999 Sep; 117(9):1216–22 (50 ref.)

REFLEX, STRETCH

PHYSIOLOGY

Tonic stretch reflexes in older able-bodied people. Yeo W, et al. **Electromyogr Clin Neurophysiol** 1998 Jul–Aug; 38(5):273–8 (26 ref.)
Overview of human tremor physiology. Hallett M. **Mov Disord** 1998;13 Suppl 3:43–8 (19 ref.)
Physiology and anatomy of possible oscillators in the central nervous system. Rothwell JC. **Mov Disord** 1998;13 Suppl 3:24–8 (11 ref.)
[Physical diagnostics--tendon reflexes] Stam J. **Ned Tijdschr Geneeskd** 1999 Apr 17;143(16):848–51 (9 ref.) (Eng. Abstr.) **(Dut)**

REFLEX SYMPATHETIC DYSTROPHY

Reflex sympathetic dystrophy: facts and hypotheses. Kurvers HA. **Vasc Med** 1998;3(3):207–14 (79 ref.)

DIAGNOSIS

What is reflex sympathetic dystrophy? Driessens M, et al. **Acta Orthop Belg** 1999 Jun;65(2):202–17 (41 ref.)
Reflex sympathetic dystrophy in pregnancy: nine cases and a review of the literature. Poncelet C, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):55–63 (33 ref.)
[Pregnancy-induced algodystrophy] Perka C, et al. **Z Rheumatol** 1998 Dec;57(6):399–408 (74 ref.) (Eng. Abstr.) **(Ger)**
[Advances in the treatment of algodystrophy] Dzik A. **Pol Merkuriusz Lek** 1998 Sep;5(27):183–4 (10 ref.) (Eng. Abstr.) **(Pol)**
[Diagnosis of reflex sympathetic dystrophy] Bruscas C, et al. **An Med Interna** 1999 Jun;16(6):308–14 (66 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Shoulder-hand syndrome in patients after stroke] Zyluk A, et al. **Neurol Neurochir Pol** 1999 Jan–Feb;33(1):131–42 (18 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Causalgia and reflex sympathetic dystrophy: does the sympathetic nervous system contribute to the generation of pain? Baron R, et al. **Muscle Nerve** 1999 Jun;22(6):678–95 (179 ref.)

REHABILITATION

[Sudeck disease--pathology, clinical aspects and therapy] Schulz RH, et al. **Sportverletz Sportschaden** 1998 Jun; 12(2):79–85 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of reflex sympathetic dystrophy. Viel E, et al. **Ann Med Interne (Paris)** 1999 Apr;150(3):205–10 (55 ref.)
[Advances in the treatment of algodystrophy] Dzik A. **Pol Merkuriusz Lek** 1998 Sep;5(27):183–4 (10 ref.) (Eng. Abstr.) **(Pol)**

REFLEX, TENDON see **REFLEX, STRETCH**

REFLEX THERAPY see **REFLEXOTHERAPY**

REFLEX, VESTIBULO-OCULAR

PHYSIOLOGY

Characteristics of the VOR in response to linear acceleration. Paige GD, et al. **Ann N Y Acad Sci** 1999 May 28;871:123–35 (49 ref.)
Autosomal dominant non-syndromal low-frequency sensorineural hearing impairment linked to chromosome 4p16 (DFNA14): statistical analysis of hearing threshold in relation to age and evaluation of vestibulo-ocular functions. Kunst H, et al. **Audiology** 1999 May–Jun; 38(3):165–73 (32 ref.)
Spatial orientation of the angular vestibulo-ocular reflex. Cohen B, et al. **J Vestib Res** 1999;9(3):163–72 (49 ref.)

REFLEXOLOGY see **MASSAGE**

REFLEXOTHERAPY

[Acupuncture and Vojta therapy in infantile cerebral palsy--a comparison of the effects] Stockert K. **Wien Med Wochenschr** 1998;148(19):434–8 (6 ref.) (Eng. Abstr.) **(Ger)**

REFRACTION, OCULAR

PHYSIOLOGY

The development and maintenance of emmetropia. Brown NP, et al. **Eye** 1999;13 (Pt 1):83–92 (106 ref.)
Modeling human eye aberrations and their compensation for high-resolution retinal imaging. Zhu L, et al. **Optom Vis Sci** 1998 Nov;75(11):827–39 (37 ref.)

REFRACTIVE ERRORS

PHYSIOPATHOLOGY

Observations on the optical effects of a cataract. Campbell C. **J Cataract Refract Surg** 1999 Jul;25(7):995–1003 (3 ref.)

REHABILITATION

Contact lenses after LASIK. Szczotka LB, et al. **J Am Optom Assoc** 1998 Dec;69(12):775–84 (27 ref.)

SURGERY

Flap complications of lamellar refractive surgery [editorial; comment] Gimbel HV. **Am J Ophthalmol** 1999 Feb; 127(2):202–4 (6 ref.) Comment on: Am J Ophthalmol 1999 Feb;127(2):129–36.
Corneal sensation after cataract and refractive surgery. Kohlhaas M. **J Cataract Refract Surg** 1998 Oct; 24(10):1399–409 (48 ref.)
Excimer laser refractive surgery in the pediatric population. Haw WW, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jul–Aug;36(4):173–7; quiz 206–7 (13 ref.)
Could apoptosis change the way we do PRK? [editorial; comment] Krueger RR. **J Refract Surg** 1998 Sep–Oct; 14(5):494–6 (10 ref.) Comment on: J Refract Surg 1998 Sep–Oct;14(5):526–33.
In perspective: eye tracking and autonomous laser radar [comment] Krueger RR. **J Refract Surg** 1999 Mar–Apr; 15(2):145–9 (4 ref.) Comment on: J Refract Surg 1999 Mar–Apr;15(2):137–44.
Barraquer lecture 1998. Why should refractive surgeons be looking beyond the cornea? Werblin TP. **J Refract Surg** 1999 May–Jun;15(3):357–76 (90 ref.)
Advances in refractive surgery. New options expand the scope of corrective procedures. Chaudhry IM, et al. **Postgrad Med** 1999 Sep;106(3):129–31, 135–7 (10 ref.)
Excimer laser ophthalmic surgery: evaluation of a new technology. Infeld DA, et al. **Postgrad Med J** 1998 Sep; 74(875):524–8 (32 ref.)
Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Jester JV, et al. **Prog Retin Eye Res** 1999 May;18(3):311–56 (111 ref.)

REFRACTORY ANEMIA see **ANEMIA, REFRACTORY**

REFRACTORY ANEMIA WITH EXCESS OF BLASTS see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

REFRACTORY PERIOD, NEUROLOGIC

PHYSIOLOGY

Atrial dispersion of refractoriness. Brachmann J, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S35–9 (14 ref.)

REFRIGERATION

see related
HYPOTHERMIA, INDUCED

REFSUM DISEASE, INFANTILE see **PEROXISOMAL DISORDERS**

REFUGEES

Experiences of work among refugees. Pedersen N. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S9–14 (0 ref.)
Refugees and primary care: tackling the inequalities [see comments] Jones D, et al. **BMJ** 1998 Nov 21; 317(7170):1444–6 (25 ref.) Comment in: BMJ 1999 Mar 6;318(7184):671.
Aid and violence, with special reference to Sierra Leone. Keen D. **Disasters** 1998 Dec;22(4):318–27 (33 ref.)
In defence of humanitarianism. Stockton N. **Disasters** 1998 Dec;22(4):352–60 (9 ref.)
Refugee and immigrant health care. Walker PF, et al. **Med Clin North Am** 1999 Jul;83(4):1103–20, viii (53 ref.)
Travelling with "excess baggage": health problems of refugee women in Western Australia. Allotey P. **Women Health** 1998;28(1):63–81 (31 ref.)

[Health situation of refugee children in Münster] Gardemann J, et al. **Gesundheitswesen** 1998 Nov;60(11):686–93 (53 ref.) (Eng. Abstr.) **(Ger)**

[Perspectives in public health care for refugees in Germany] Herrmann M. **Gesundheitswesen** 1999 Jun;61(6):312–8 (39 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Noncitizens and the Supplemental Security Income program. Parrott TM, et al. **Soc Secur Bull** 1998;61(4):3–31 (0 ref.)

PSYCHOLOGY

The mental health and adjustment of immigrant and refugee children. Guarnaccia PJ, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):537–53, viii–ix (52 ref.)

Multiple forms of stress in refugee and immigrant children. Sack WH. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):153–67, ix–x (54 ref.)

The psychosocial effects of torture, mass human rights violations, and refugee trauma: toward an integrated conceptual framework. Silove D. **J Nerv Ment Dis** 1999 Apr;187(4):200–7 (68 ref.)

[Migration and pain. Need for epidemiologic research] Moser J. **Rev Med Suisse Romande** 1999 Apr;119(4):265–7 (11 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Review of social epidemiologic research on migrants' health: findings, methodological cautions, and theoretical perspectives. Friis R, et al. **Scand J Soc Med** 1998 Sep; 26(3):173–80 (58 ref.)

Noncitizens and the Supplemental Security Income program. Parrott TM, et al. **Soc Secur Bull** 1998;61(4):3–31 (0 ref.)

REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

REFUSAL TO TREAT

ABC of intensive care. Withdrawal of treatment. Winter B, et al. **BMJ** 1999 Jul 31;319(7205):306–8 (0 ref.)

Access denied: taking action for medically underserved children. Redlener I. **J Urban Health** 1998 Dec; 75(4):724–31 (2 ref.)

LEGISLATION & JURISPRUDENCE

Bioethics for clinicians: 16. Dealing with demands for inappropriate treatment [see comments] Weijer C, et al. **CMAJ** 1998 Oct 6;159(7):817–21 (39 ref.) Comment in: CMAJ 1999 Feb 9;160(3):309–10.

Health care professionals and treatment of HIV-positive patients. Is there an affirmative duty to treat under common law, the Rehabilitation Act, or the Americans with Disabilities Act? White CC. **J Leg Med** 1999 Mar; 20(1):67–113 (309 ref.)

REFUSE DISPOSAL

Mycological control and surveillance of biological waste and compost. Beffa T, et al. **Med Mycol** 1998;36 Suppl 1:137–45 (31 ref.)

METHODS

Coming to grips with a slippery issue: human waste disposal in cold climates. Meyer-Rochow VB. **Int J Circumpolar Health** 1999 Jan;58(1):57–62 (33 ref.)

REGENERATION

see related
WOUND HEALING

Designing biomaterials to direct biological responses. Healy KE, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:24–35 (31 ref.)

Magnetic resonance imaging of regenerating and dystrophic mouse muscle. McIntosh LM, et al. **Biochem Cell Biol** 1998; 76(2–3):532–41 (61 ref.)

Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Johnsen M, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):667–71 (44 ref.)

The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Basile DP. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):21–30 (135 ref.)

Gastrointestinal mucosal regeneration: role of growth factors. Jones MK, et al. **Front Biosci** 1999 Mar 15;4:D303–9 (79 ref.)

Activin: a novel player in tissue repair processes. Hübner G, et al. **Histol Histopathol** 1999 Jan;14(1):295–304 (61 ref.)

Development and regeneration of the electric organ. Zakon HH, et al. **J Exp Biol** 1999 May;202 (Pt 10):1427–34 (36 ref.)

Neurogenesis, cell death and regeneration in the adult gymnotiform brain. Zupanc GK. **J Exp Biol** 1999 May;202 (Pt 10):1435–46 (111 ref.)

Axolotl/newt. Maden M. **Methods Mol Biol** 1999;97:415–28 (30 ref.)

Use of cultured thymic tissues for the regeneration of the thymus. Jones GV, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):6–22 (132 ref.)

Meniscal regeneration or meniscal transplantation? Messner K. **Scand J Med Sci Sports** 1999 Jun;9(3):162–7 (47 ref.)

Brain, heal thyself. Lowenstein DH, et al. **Science** 1999 Feb 19;283(5405):1126–7 (13 ref.)

Regenerative biology and engineering: strategies for tissue restoration [see comments] Stocum DL. **Wound Repair Regen** 1998 Jul–Aug;6(4):276–90 (116 ref.) Comment in: Wound Repair Regen 1998 Jul–Aug;6(4):273–5.

[The mechanisms of gastrointestinal mucosal injury and repair] Kobayashi K, et al. **Nippon Rinsho** 1998 Sep; 56(9):2215–22 (24 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular mechanisms of cell death and regeneration in acute ischemic renal injury. Padanilam BJ, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):15–9 (30 ref.)

The use of planarians to dissect the molecular basis of metazoan regeneration. Alvarado AS, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):413–20 (39 ref.)

Isolation of genes involved in intestinal remodeling during anuran metamorphosis. Amano T. **Wound Repair Regen** 1998 Jul–Aug;6(4):302–13 (80 ref.)

Expression of sonic hedgehog gene in regenerating newt limbs. Imokawa Y, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):366–70 (22 ref.)

Joint cartilage regeneration by tissue engineering. Sittinger M, et al. **Z Rheumatol** 1999 Jun;58(3):130–5 (21 ref.)

[Homeobox genes: their structure and expression during development and regeneration] Znoiko IIu, et al. **Izv Akad Nauk Ser Biol** 1999 Mar–Apr;(2):133–44 (103 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Regeneration of autotransplanted splenic fragments: basic immunological and clinical relevance [editorial; comment] Pabst R. **Clin Exp Immunol** 1999 Sep;117(3):423–4 (29 ref.) Comment on: Clin Exp Immunol 1999 Sep;117(3):596–604.

[Reparative processes and immunity] Babaeva AG. **Izv Akad Nauk Ser Biol** 1999 May–Jun;(3):261–9 (63 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Neural regulation of myosin gene expression in regenerating skeletal muscle. Schiaffino S, et al. **Acta Physiol Scand** 1998 Jul;163(3):S11–5 (32 ref.)

Factors controlling hair-cell regeneration/repair in the inner ear. Staecker H, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):480–7 (52 ref.)

Regeneration processes in the kidney after acute injury: role of infiltrating cells. Ghielli M, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):502–7 (26 ref.)

The healing and regeneration of articular cartilage. O'Driscoll SW. **J Bone Joint Surg Am** 1998 Dec; 80(12):1795–812 (255 ref.)

A hypothesis for the etiology of interstitial cystitis based upon inhibition of bladder epithelial repair. Keay S, et al. **Med Hypotheses** 1998 Jul;51(1):79–83 (42 ref.)

Growth control in the ontogenetic and regenerating zebrafish fin. Johnson SL, et al. **Methods Cell Biol** 1999;59:301–11 (27 ref.)

Regeneration of skeletal and cardiac muscle in mammals: do nonprimate models resemble human pathology? Borisov AB. **Wound Repair Regen** 1999 Jan–Feb;7(1):26–35 (88 ref.)

Stimulation of regeneration in mammals: pipe dream or realistic goal? Carlson BM. **Wound Repair Regen** 1998 Sep–Oct;6(5):425–33 (50 ref.)

Pattern formation in dissociated limb bud mesenchyme in vitro and in vivo. Ide H, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):398–402 (12 ref.)

Retinoids as endogenous components of the regenerating limb and tail. Maden M. **Wound Repair Regen** 1998 Jul–Aug; 6(4):358–65 (53 ref.)

Role of hair papilla cells on induction and regeneration processes of hair follicles. Matsuzaki T, et al. **Wound Repair Regen** 1998 Nov–Dec;6(6):524–30 (46 ref.)

[Factors involved in the regeneration of the gastrointestinal tract] Matsubara Y, et al. **Nippon Rinsho** 1998 Sep; 56(9):2253–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Pathophysiology in muscle fiber necrosis and regeneration with a particular reference to regenerating process] Nonaka I. **Rinsho Shinkeigaku** 1998 Dec;38(12):997–1000 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Trefoil peptides, cellular repair and progression (editorial)] Soriano A. **Gastroenterol Hepatol** 1999 Apr;22(4):188–90 (19 ref.) **(Spa)**

REGENERATION, GUIDED TISSUE see **GUIDED TISSUE REGENERATION**

REGIONAL BLOOD FLOW

Clinical application of basal regional cerebral blood flow fluctuation measurements by FMRI. Haughton V, et al. **Adv Exp Med Biol** 1998;454:583–90 (53 ref.)

DRUG EFFECTS

Localized paclitaxel delivery. Dhanikula AB, et al. **Int J Pharm** 1999 Jun 25;183(2):85–100 (80 ref.)

REGIONAL HEALTH PLANNING

LEGISLATION & JURISPRUDENCE

Understanding and applying alternative dispute resolution methods in modern medical conflicts. Liang BA. **J Leg Med** 1998 Sep;19(3):397–430 (53 ref.)

REGIONAL MEDICAL PROGRAMS

The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)

[Reduced frequency of resistant pneumococci in Southern Sweden. Community based disease control projects to minimize antibiotic resistance] Ekdahl K, et al. **Lakartidningen** 1999 Jun 16;96(24):2962–5 (39 ref.) (Eng. Abstr.) **(Swe)**

LEGISLATION & JURISPRUDENCE

Dealing with "excluded providers": contracts that can bring trouble to physicians. Padgett PT. **J Ky Med Assoc** 1998 Nov;96(11):457–8 (8 ref.)

ORGANIZATION & ADMINISTRATION

Regionalization of infection prevention and control services in a publicly funded health care system. Wiens RM, et al. **Am J Infect Control** 1998 Aug;26(4):446–8 (5 ref.)

Palliative care in the University Hospital Lausanne: from consultations to an integrated regional program. Mazzocato C, et al. **Support Care Cancer** 1999 Jul;7(4):221–3 (3 ref.)

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of obstetricians of general hospital centers] Dauptain G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:110–6 (13 ref.) **(Fre)**

[Networks in perinatology. The French experience] Dreyfus M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:70–5 (13 ref.) **(Fre)**

[Arguments in favor of a relation between the organization of perinatal care and the optimal management of prematurity and multiple pregnancies] Truffert P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:85–93 (37 ref.) **(Fre)**

STANDARDS

Systematic review of trauma system effectiveness based on registry comparisons [see comments] Jurkovich GJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S46–55 (28 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S56–8.

Systematic review of published evidence regarding trauma system effectiveness. Mann NC, et al. **J Trauma** 1999 Sep; 47(3 Suppl):S25–33 (72 ref.)

Introduction to the Academic Symposium to Evaluate Evidence Regarding the Efficacy of Trauma Systems. Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S3–7 (10 ref.)

Population-based research assessing the effectiveness of trauma systems [see comments] Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S59–66 (32 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S67–8.

STATISTICS & NUMERICAL DATA

Pediatric trauma systems: critical distinctions. Hulka F. **J Trauma** 1999 Sep;47(3 Suppl):S85–9 (28 ref.)

REGIONAL PERFUSION see **PERFUSION, REGIONAL**

REGISTRARS, HOSPITAL see **MEDICAL STAFF, HOSPITAL**

REGISTRIES

The Scandinavian Sarcoma Group Register. Bauer HC, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:41–4 (19 ref.)

Local recurrence after surgery for soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Trovik CS, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:45–6 (16 ref.)

Immunization registries in the United States: implications for the practice of public health in a changing health care system. Wood D, et al. **Annu Rev Public Health** 1999; 20:231–55 (81 ref.)

District diabetes registers: more trouble than they're worth? Elwyn GJ, et al. **Diabet Med** 1998 Nov;15 Suppl 3:S44–8 (33 ref.)

Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)

Occupational cancer research in the Nordic countries. Kjaerheim K. **Environ Health Perspect** 1999 May;107 Suppl 2:233–8 (113 ref.)

Registries and the prevention of colorectal cancer [comment] Young GP, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):19–22 (35 ref.) Comment on: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):10–8.

Systematic review of trauma system effectiveness based on registry comparisons [see comments] Jurkovich GJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S46–55 (28 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S56–8.

What have been the strategies for the registration, positioning

and control of medical information for intramuscular artemether? Helenport JP, et al. **Med Trop (Mars)** 1998;58(3 Suppl):73–6 (22 ref.)
[Secondary prevention of coronary disease in France. Result of the EUROASPIRE study: the Lille register of ischemic cardiopathies] Montaye M, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1211–20 (30 ref.) (Eng. Abstr.) **(Fre)**
[Screening, prediction and prevention of type 1 diabetes. Role of the Belgian Diabetes Registry] Dorchy H. **Rev Med Brux** 1999 Feb;20(1):15–20 (17 ref.) (Eng. Abstr.) **(Fre)**
[Quality registries are a gold-mine of information that should be better used. Knowledge of improvement is acquired by means of special projects] Sachs MA, et al. **Lakartidningen** 1999 May 19;96(20):2438–40 (16 ref.) **(Swe)**

STANDARDS

Canadian Consensus Conference on a National Immunization Records System. **Can Commun Dis Rep** 1998 Sep 1; 24(17):137–40 (0 ref.) **(Eng, Fre)**

STATISTICS & NUMERICAL DATA

Interpretation of population-based cancer survival data. Black RJ, et al. **IARC Sci Publ** 1998;(145):13–7 (11 ref.)
Statistical methods for the analysis of cancer survival data. Black RJ, et al. **IARC Sci Publ** 1998;(145):3–7 (7 ref.)
Hypertension as cause of end-stage renal disease: lessons from international registries. Valderrábano F, et al. **Kidney Int Suppl** 1998 Dec;68:S60–6 (3 ref.)
[Differences in incidence of (violent) traumatic events in the national registration systems, population surveys and studies from family practice; a review of literature] Mol SS, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1308–14 (29 ref.) (Eng. Abstr.) **(Dut)**

REGRESSION ANALYSIS

Identifying efficiently and economically operated hospitals: the prospects and pitfalls of applying frontier regression techniques. Chirikos TN. **J Health Polit Policy Law** 1998 Dec;23(6):879–904 (16 ref.)

REGRESSION DIAGNOSTICS see **REGRESSION ANALYSIS**

REGULATION OF GENE EXPRESSION see **GENE EXPRESSION REGULATION**

REGULATION OF GENE EXPRESSION, ARCHAEAL see **GENE EXPRESSION REGULATION, ARCHAEAL**

REGULATION OF GENE EXPRESSION, BACTERIAL see **GENE EXPRESSION REGULATION, BACTERIAL**

REGULATION OF GENE EXPRESSION, DEVELOPMENTAL see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

REGULATION OF GENE EXPRESSION, EMBRYOLOGIC see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

REGULATION OF GENE EXPRESSION, ENZYMOLOGIC see **GENE EXPRESSION REGULATION, ENZYMOLOGIC**

REGULATION OF GENE EXPRESSION, FUNGAL see **GENE EXPRESSION REGULATION, FUNGAL**

REGULATION OF GENE EXPRESSION, LEUKEMIC see **GENE EXPRESSION REGULATION, LEUKEMIC**

REGULATION OF GENE EXPRESSION, NEOPLASTIC see **GENE EXPRESSION REGULATION, NEOPLASTIC**

REGULATION OF GENE EXPRESSION, PLANT see **GENE EXPRESSION REGULATION, PLANT**

REGULATION OF GENE EXPRESSION, VIRAL see **GENE EXPRESSION REGULATION, VIRAL**

REGULATORY REGIONS, NUCLEIC ACID (GENETICS) see **REGULATORY SEQUENCES, NUCLEIC ACID**

REGULATORY SEQUENCES, NUCLEIC ACID

Cis-regulatory elements controlling basal and inducible VIP gene transcription. Hahm SH, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:10–26 (48 ref.)
Regulation of SRF activity by Rho family GTPases. Treisman R, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:643–51 (44 ref.)
Regulatory elements and expression profiles. Bucher P. **Curr Opin Struct Biol** 1999 Jun;9(3):400–7 (61 ref.)
Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Linder MW, et al. **Drug Metab Rev** 1999 Feb;31(1):247–71 (41 ref.)
Regulatory implications of protein assemblies at the gamma origin of plasmid R6K – a review. Filutowicz M, et al. **Gene** 1998 Nov 26;223(1–2):195–204 (90 ref.)
A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review). Willis RA, et al. **Int J Mol Med** 1998 Feb;1(2):379–86 (59 ref.)
Domains and boundaries in chromosomes. Gerasimova TI, et al. **Results Probl Cell Differ** 1999;25:229–49 (70 ref.)
A new approach for studying gene regulation by distant DNA elements in transgenic mice. Nielsen LB, et al. **Scand J Clin Lab Invest Suppl** 1999;229:33–9 (17 ref.)

GENETICS

[Anatomy of the eukaryotic gene] Acevedo S. **Sangre (Barc)** 1998 Oct;43(5):447–50 (19 ref.) **(Spa)**

REGULON

Regulation in the rpoS regulon of Escherichia coli. Loewen PC, et al. **Can J Microbiol** 1998 Aug;44(8):707–17 (113 ref.)
Identification of a competence regulon in Streptococcus pneumoniae by genomic analysis. Håvarstein LS. **Trends Microbiol** 1998 Aug;6(8):297–9; discussion 299–300 (14 ref.)

GENETICS

Non-specific, general and multiple stress resistance of growth-restricted Bacillus subtilis cells by the expression of the sigmaB regulon. Hecker M, et al. **Mol Microbiol** 1998 Sep;29(5):1129–36 (55 ref.)
[The vir regulon—a new epidemiological marker for Streptococcus pyogenes] Shundi L. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul–Sep; 43(3):195–8 (26 ref.) **(Rum)**

REGURGITATION, GASTRIC see **GASTROESOPHAGEAL REFLUX**

REHABILITATION

see related
DISABILITY EVALUATION
EARLY INTERVENTION (EDUCATION)
RECOVERY OF FUNCTION

Measuring quality of life: methodological issues. Dijkers M. **Am J Phys Med Rehabil** 1999 May–Jun;78(3):286–300 (98 ref.)
Randomized clinical trials in medical rehabilitation research. Tate DG, et al. **Am J Phys Med Rehabil** 1999 Sep–Oct; 78(5):486–99 (67 ref.)
Use of sequential medical trials in rehabilitation research. Tooth L. **Am J Phys Med Rehabil** 1999 Jan–Feb; 78(1):87–97 (18 ref.)
Disability 1986 and beyond: 11 years on. Marks LJ. **Br J Hosp Med** 1998 Nov 19–Dec 9;58(10):489–92 (21 ref.)
Techniques for measurement and assessment of mobility in rehabilitation: a theoretical approach. Bussmann JB, et al. **Clin Rehabil** 1998 Dec;12(6):455–64 (69 ref.)
What does a home mean and when does it cease to be a home? Home as a setting for rehabilitation and care. Tamm M. **Disabil Rehabil** 1999 Feb;21(2):49–55 (33 ref.)
Habilitation and management of auditory processing disorders: overview of selected procedures. Musiek F. **J Am Acad Audiol** 1999 Jun;10(6):329–42 (32 ref.)
Functional status and its uses in rehabilitation medicine. Eastwood EA. **Mt Sinai J Med** 1999 May;66(3):179–87 (23 ref.)
The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)

ECONOMICS

Case-mix in rehabilitation: alternative ways of achieving the same goals [editorial; comment] Wade DT. **Clin Rehabil** 1999 Jun;13(3):183–5 (5 ref.) Comment on: Clin Rehabil 1999 Jun;13(3):253–65.

EDUCATION

Ten years on and more: establishing programmes of rehabilitation education: the New Zealand case. Gregory RJ. **Disabil Rehabil** 1998 Oct;20(10):385–90 (12 ref.)

METHODS

Neural network applications in physical medicine and rehabilitation. Ohno-Machado L, et al. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):392–8 (38 ref.)
Exercise in the rehabilitation of breast cancer survivors. Pinto BM, et al. **Psychooncology** 1999 May–Jun;8(3):191–206 (89 ref.)

NURSING

Rehabilitation, chronic illness and disability: the missing elements in nurse education. Nolan M, et al. **J Adv Nurs** 1999 Apr;29(4):958–66 (52 ref.)

TRENDS

The 31st Walter J. Zeiter Lecture. Issues and challenges for physiatry in the coming decade. DeLisa JA. **Arch Phys Med Rehabil** 1999 Jan;80(1):1–12 (101 ref.)
[The rehabilitation of older people] Meier-Baumgartner HP. **Versicherungsmedizin** 1999 Mar 1;51(1):24–9 (24 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION CENTERS

ORGANIZATION & ADMINISTRATION

Congenital muscular dystrophy. Care of children and families. Eeg-Olofsson KE. **Scand J Rehabil Med Suppl** 1999;39:53–7 (20 ref.)

REHABILITATION CENTERS, DRUG see **SUBSTANCE ABUSE TREATMENT CENTERS**

REHABILITATION OF HEARING IMPAIRED

Hearing impairment, emotions and audiological rehabilitation: a sociological perspective. Danermark BD. **Scand Audiol Suppl** 1998;49:125–31 (32 ref.)
Reflections on evaluative research in audiological rehabilitation. Gagné JP. **Scand Audiol Suppl** 1998;49:69–79 (41 ref.)

REHABILITATION OUTCOME see **TREATMENT OUTCOME**

REHABILITATION, VOCATIONAL

see related
EMPLOYMENT
SHELTERED WORKSHOPS

Purposeful activity for people with enduring mental health problems: reflections from a case study. Mitchell D. **Arch Psychiatr Nurs** 1998 Oct;12(5):282–7 (26 ref.)
[What are the goals of psychiatric rehabilitation, and which have been accomplished?] Priebe S. **Psychiatr Prax** 1999 Apr;26 Suppl 1:S36–40 (17 ref.) **(Ger)**

METHODS

Work dysfunction and addiction. Common roots. Comerford AW. **J Subst Abuse Treat** 1999 Apr;16(3):247–53 (64 ref.)

REHYDRATION see **FLUID THERAPY**

REHYDRATION, ORAL see **FLUID THERAPY**

REHYDRATION SOLUTIONS

ADMINISTRATION & DOSAGE

Subcutaneous fluid administration—better than the intravenous approach? Jain S, et al. **J Hosp Infect** 1999 Apr;41(4):269–72 (13 ref.)
Fluid and electrolyte balance for adults (without a biochemical laboratory). Tovey F. **Trop Doct** 1999 Jan; 29(1):49–53 (0 ref.)

REICHEL'S SYNDROME see **CHONDROMATOSIS, SYNOVIAL**

REIMBURSEMENT, FEE-FOR-SERVICE see **FEE-FOR-SERVICE PLANS**

REIMBURSEMENT, HEALTH INSURANCE see **INSURANCE, HEALTH, REIMBURSEMENT**

REIMBURSEMENT, INCENTIVE

The impact of financial incentives on quality of health care. Dudley RA, et al. **Milbank Q** 1998;76(4):649–86, 511 (71 ref.)

ORGANIZATION & ADMINISTRATION

Getting the incentives right for children. Glied S. **Health Serv Res** 1998 Oct;33(4 Pt 2):1143–60 (35 ref.)
Financial incentives: current realities and challenges for physicians. Gold M. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S6–S12 (17 ref.)
The utility of decision support, clinical guidelines, and financial incentives as tools to achieve improved clinical performance. Goldfarb S. **Jt Comm J Qual Improv** 1999 Mar;25(3):137–44 (19 ref.)

REIMBURSEMENT MECHANISMS

Blended payments. Will they work in general practice? Richards B. **Aust Fam Physician** 1999 Apr;28(4):391–2 (9 ref.)
What do consumers want and need to know in making health care choices? Lubalin JS, et al. **Med Care Res Rev** 1999; 56 Suppl 1:67–102; discussion 103–12 (93 ref.)

ECONOMICS

Medicaid reimbursement and timeliness of payment. Weber RD. **Mich Med** 1999 Jan;98(1):8–9 (0 ref.)
[Comment on the consensus report by medical staff on compensation for ambulatory and inpatient treatment] Hess R. **Chirurg** 1999 Feb;70(2):suppl 35–9 (0 ref.) **(Ger)**

TRENDS

Making Medicaid viable for the 21st century. May D. **Mich Med** 1999 Jan;98(1):14–5 (0 ref.)

REIMPLANTATION see **REPLANTATION**

REINFORCEMENT (PSYCHOLOGY)

Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol Suppl** 1996 Mar; 1:17–25 (36 ref.)

Severe morbid onychophagia: the classification as self-mutilation and a proposed model of maintenance. Wells JH, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):534–45 (79 ref.)

Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. McBride WJ, et al. **Behav Brain Res** 1999 Jun; 101(2):129–52 (142 ref.)

The neurobiology of opiate reinforcement. Shippenberg TS, et al. **Crit Rev Neurobiol** 1998;12(4):267–303 (240 ref.)

The nature of reinforcement in cerebellar learning. Thompson RF, et al. **Neurobiol Learn Mem** 1998 Jul–Sep; 70(1–2):150–76 (110 ref.)

Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Tzschentke TM. **Prog Neurobiol** 1998 Dec;56(6):613–72 (700 ref.)

Is the short-latency dopamine response too short to signal reward error? Redgrave P, et al. **Trends Neurosci** 1999 Apr; 22(4):146–51 (40 ref.)

REINFORCEMENT SCHEDULE

Time and memory: towards a pacemaker-free theory of interval timing [see comments] Staddon JE, et al. **J Exp Anal Behav** 1999 Mar;71(2):215–51 (143 ref.) Comment in: J Exp Anal Behav 1999 Mar;71(2):253–6; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):257–63; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):264–71; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):272–5; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):275–80; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):281–4. Comment in: J Exp Anal Behav 1999 Mar;71(2):284–88. Comment in: J Exp Anal Behav 1999 Mar;71(2):288–91.

REINFORCEMENT, SOCIAL

The social construction of cardiovascular reactivity. Christenfeld N, et al. **Ann Behav Med** 1998 Fall; 20(4):317–25 (53 ref.)

Psychosocial processes underlying the maintenance and persistence of depression: implications for understanding chronic depression. Lara ME, et al. **Clin Psychol Rev** 1999 Aug;19(5):553–70 (120 ref.)

REINFORCING FACTORS see **CAUSALITY**

REITER'S DISEASE

[Recent studies on reactive arthritis] Kobayashi S. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1388–94 (14 ref.) **(Jpn)**

COMPLICATIONS

[Reiter's syndrome and human immunodeficiency virus infection] de Mello e Silva AC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Jul–Aug; 53(4):202–4 (24 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Reiter's syndrome. Diagnosis and clinical features. Amor B. **Rheum Dis Clin North Am** 1998 Nov;24(4):677–95, vii (63 ref.)

IMMUNOLOGY

HLA-B27 and the seronegative spondyloarthropathies. Reveille JD. **Am J Med Sci** 1998 Oct;316(4):239–49 (132 ref.)

REJUVENATION

The role of cosmetic dentistry in restoring a youthful appearance. Morley J. **J Am Dent Assoc** 1999 Aug; 130(8):1166–72 (26 ref.)

REL GENES see **ONCOGENES**

RELAPSING FEVER

[Relapsing fever] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):297 (1 ref.) **(Jpn)**

RELATIVE BIOLOGICAL EFFECTIVENESS

Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Yamada Y, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):99–104 (42 ref.)

Relative biological effectiveness of proton beams in clinical therapy. Gerweck LE, et al. **Radiother Oncol** 1999 Feb; 50(2):135–42 (32 ref.)

RELATIVE RISK see **RISK**

RELATIVE VALUE SCALES

RBRVS (Medicare Resource-Based Relative Value Scale) revisited. Harris-Shapiro J. **J Health Care Finance** 1998 Winter;25(2):49–54 (0 ref.)

RELATIVE-VALUE SCHEDULES see **RELATIVE VALUE SCALES**

RELAXATION TECHNIQUES

Sleep promotion in adults. Floyd JA. **Annu Rev Nurs Res** 1999;17:27–56 (100 ref.)

[Psychophysiology of pain] Kautzsch K. **Ther Umsch** 1999 Aug;56(8):431–4 (3 ref.) (Eng. Abstr.) **(Ger)**

[Free from stress by autogenic therapy. Relaxation technique yielding peace of mind and self-insight] Broms C. **Lakartidningen** 1999 Feb 10;96(6):588–92 (20 ref.) (Eng. Abstr.) **(Swe)**

RELAXATION THERAPY see **RELAXATION TECHNIQUES**

RELAXIN

BLOOD

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837–57, vi (77 ref.)

RELIABILITY AND VALIDITY see **REPRODUCIBILITY OF RESULTS**

RELIEF WORK

Experiences of work among refugees. Pedersen N. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S9–14 (0 ref.)

Selection, training, and support of relief workers: an occupational health issue. McCall M, et al. **BMJ** 1999 Jan 9;318(7176):113–6 (27 ref.)

Food aid in emergencies: a case for wheat? Landman J. **Proc Nutr Soc** 1999 May;58(2):355–61 (53 ref.)

ORGANIZATION & ADMINISTRATION

Understanding the needs of children following large-scale disasters and the role of government. Flynn BW, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):211–27, x (32 ref.)

US government natural disaster assistance: historical analysis and a proposal for the future. Barnett BJ. **Disasters** 1999 Jun;23(2):139–55 (55 ref.)

Normalising the crisis in Africa. Bradbury M. **Disasters** 1998 Dec;22(4):328–38 (21 ref.)

Humanitarianism, pluralism and ombudsmen: do the pieces fit? Christoplos I. **Disasters** 1999 Jun;23(2):125–38 (21 ref.)

Race, ethnicity and disasters in the United States: a review of the literature. Fothergill A, et al. **Disasters** 1999 Jun; 23(2):156–73 (69 ref.)

Waiting for peace: perspectives from action-oriented research on the humanitarian impasse in the Caucasus. Hansen G, et al. **Disasters** 1999 Sep;23(3):257–70 (0 ref.)

Depolarising the 'broadened' and 'back-to-basics' relief models. Jackson S, et al. **Disasters** 1999 Jun;23(2):93–114 (31 ref.)

Aid and violence, with special reference to Sierra Leone. Keen D. **Disasters** 1998 Dec;22(4):318–27 (33 ref.)

Proliferating principles; or how to sup with the devil without getting eaten. Leader N. **Disasters** 1998 Dec;22(4):288–308 (44 ref.)

The death of humanitarianism?: an anatomy of the attack. Macrae J. **Disasters** 1998 Dec;22(4):309–17 (13 ref.)

Military intervention and humanitarian action: trends and issues. Pugh M. **Disasters** 1998 Dec;22(4):339–51 (30 ref.)

In defence of humanitarianism. Stockton N. **Disasters** 1998 Dec;22(4):352–60 (9 ref.)

To South Sudan with operation lifeline Sudan and UNICEF. Taylor-Robinson SD. **J R Coll Physicians Lond** 1999 May-Jun;33(3):276–9 (4 ref.)

The medical department in military operations other than war. Part I. Planning for deployment. Baker MS, et al. **Mil Med** 1999 Aug;164(8):572–9 (22 ref.)

Levels of medical support for United Nations peacekeeping operations. Seet B. **Mil Med** 1999 Jul;164(7):451–6 (24 ref.)

RELIGION

Religious and spiritual case reports on MEDLINE: a systematic analysis of records from 1980 to 1996. Lukoff D, et al. **Altern Ther Health Med** 1999 Jan;5(1):64–70 (68 ref.)

The religion-health connection: evidence, theory, and future directions. Ellison CG, et al. **Health Educ Behav** 1998 Dec; 25(6):700–20 (109 ref.)

Religion and depression: a review of the literature. McCullough ME, et al. **Twin Res** 1999 Jun;2(2):126–36 (86 ref.)

RELIGION AND MEDICINE

Caring for the Islamic patient. McKennis AT. **AORN J** 1999 Jun;69(6):1187–96; quiz 1199–206 (18 ref.)

The view of Jehovah's Witnesses on blood substitutes. Bailey R, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov;26(5–6):571–6 (8 ref.)

Spirituality and health. Hassed C. **Aust Fam Physician** 1999 Apr;28(4):387–8 (7 ref.)

A review of spirituality as applied to nursing. Narayanasamy A. **Int J Nurs Stud** 1999 Apr;36(2):117–25 (38 ref.)

Nutrition and hydration: moral and pastoral reflections. National Conference of Catholic Bishops Committee for Pro-life Activities. **J Contemp Health Law Policy** 1999 Spring;15(2):455–77 (47 ref.)

Integrating Buddhism and HIV prevention in U.S. southeast Asian communities. Loue S, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):100–21 (107 ref.)

Jehovah's witnesses and medicine: an overview of beliefs and issues in their care. Malak J. **J Med Assoc Ga** 1998 Nov; 87(4):322–7 (34 ref.)

Relief of breast engorgement for the Sabbath-observant Jewish woman. Chertok I. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):365–9 (13 ref.)

Articulating the concept of palliative care: philosophical and theological perspectives. Janssens RM, et al. **J Palliat Care** 1999 Summer;15(2):38–44 (29 ref.)

Religion, spirituality, and medicine [see comments] Sloan RP, et al. **Lancet** 1999 Feb 20;353(9153):664–7 (39 ref.) Comment in: Lancet 1999 May 22;353(9166):1803. Comment in: Lancet 1999 May 22;353(9166):1803–4. Comment in: Lancet 1999 May 22;353(9166):1804.

Sharing the pain: response of the churches in Papua New Guinea to the AIDS pandemic. Bouten M. **P N G Med J** 1996 Sep;39(3):220–4 (0 ref.)

The northeast Tennessee Spirituality and End of Life Issues Survey. Ginn DR, et al. **Tenn Med** 1998 Nov;91(11):425–30 (13 ref.)

Recent developments in medical care of Jehovah's Witnesses. Muramoto O. **West J Med** 1999 May;170(5):297–301 (22 ref.)

[Spiritual needs at the end of life] Boubakeur D. **Bull Acad Natl Med** 1999;183(5):929–33 (16 ref.) (Eng. Abstr.) **(Fre)**

[Belief] Kaldestad E. **Tidsskr Nor Laegeforen** 1999 Apr 10; 119(9):1309–12 (10 ref.) (Eng. Abstr.) **(Nor)**

[Spiritual needs of severely ill patients are neglected in health care] Einhorn S. **Lakartidningen** 1999 May 12;96(19):2362–6 (20 ref.) (Eng. Abstr.) **(Swe)**

RELIGION AND PSYCHOLOGY

Research on spirituality and Alcoholics Anonymous. Galanter M. **Alcohol Clin Exp Res** 1999 Apr;23(4):716–9 (32 ref.)

Not just a time-out: change dynamics of prayer for religious couples in conflict situations. Butler MH, et al. **Fam Process** 1998 Winter;37(4):451–78 (70 ref.)

Psychology of religion and adolescents in the United States: past to present. Donelson E. **J Adolesc** 1999 Apr; 22(2):187–204 (158 ref.)

Religion, community service, and identity in American youth. Youniss J, et al. **J Adolesc** 1999 Apr;22(2):243–53 (23 ref.)

Cut from the right wood: spiritual and ethical pluralism in professional nursing practice. Cusveller B. **J Adv Nurs** 1998 Aug;28(2):266–73 (26 ref.)

Transcending the physical: spiritual aspects of pain in patients with HIV and/or cancer. Newshan G. **J Adv Nurs** 1998 Dec;28(6):1236–41 (38 ref.)

Spiritual and religious dimensions of mental illness recovery narratives. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):35–44 (18 ref.)

The place of spirituality and religion in mental health services. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):3–12 (35 ref.)

Research on religion and serious mental illness. Koenig HG, et al. **New Dir Ment Health Serv** 1998 Winter;(80):81–95 (60 ref.)

Recoiling, regrouping, and recovering: first-person accounts of the role of spirituality in the course of serious mental illness. Sullivan WP. **New Dir Ment Health Serv** 1998 Winter;(80):25–33 (29 ref.)

["Now tell me, what is your orientation to religion?"--Therapeutic attitude and management as an expression of religious faith] Schuierer E. **Wien Med Wochenschr** 1998;148(6):158–62 (17 ref.) (Eng. Abstr.) **(Ger)**

[Belief] Kaldestad E. **Tidsskr Nor Laegeforen** 1999 Apr 10; 119(9):1309–12 (10 ref.) (Eng. Abstr.) **(Nor)**

RELIGION AND SEX

Methods of semen collection not based on masturbation or surgical sperm retrieval. Gerris J. **Hum Reprod Update** 1999 May-Jun;5(3):211–5 (20 ref.)

Attitudes towards reproduction in Latin America. Teachings from the use of modern reproductive technologies.

RELIGION AND SEX

Zegers-Hochschild F. **Hum Reprod Update** 1999 Jan-Feb; 5(1):21-5 (5 ref.)
The politics of counter-rejection: gay christians and the church. Yip AK. **J Homosex** 1999;37(2):47-63 (52 ref.)

RELIGIOUS BELIEFS see **RELIGION**

RELIGIOUS ETHICS see **RELIGION**

REMANTADINE see **RIMANTADINE**

REMISSION INDUCTION

METHODS

Acute myeloblastic leukaemia in the elderly: biology, prognostic factors and treatment. Manoharan A. **Int J Hematol** 1998 Oct;68(3):235-43 (48 ref.)
Multiple sclerosis clinical trials: old and new challenges. Noseworthy JH. **Semin Neurol** 1998;18(3):377-88 (100 ref.)

REMISSION, SPONTANEOUS

see related
RECOVERY OF FUNCTION

REMISSION, SPONTANEOUS NEOPLASM see **NEOPLASM REGRESSION, SPONTANEOUS**

REMOTE CONSULTATION

METHODS

Web-based telemicroscopy. Hadida-Hassan M, et al. **J Struct Biol** 1999 Apr-May;125(2-3):235-45 (29 ref.)
Telepsychiatry in South Australia. Hawker F, et al. **J Telemed Telecare** 1998;4(4):187-94 (15 ref.)

REMOTE OPERATIONS (ROBOTICS) see **ROBOTICS**

RENAL AGENTS

PHARMACOLOGY

[Vasopressin: cellular and molecular aspects of its antidiuretic effect] Ivanova LN. **Vestn Ross Akad Med Nauk** 1999; (3):40-5 (74 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Sensitized cells come of age: a new era in renal immunology with important therapeutic implications [editorial; comment] Couser WG. **J Am Soc Nephrol** 1999 Mar; 10(3):664-5 (21 ref.) Comment on: J Am Soc Nephrol 1999 Mar;10(3):499-506.
Desmopressin (DDAVP) in bleeding disorders of childhood. Sutor AH. **Semin Thromb Hemost** 1998;24(6):555-66 (114 ref.)

RENAL ARTERY

Ischemic nephropathy: an important cause of renal disease in the elderly. Buckalew VM Jr. **Geriatr Nephrol Urol** 1998; 8(3):155-9 (16 ref.)
Percutaneous transluminal renal angioplasty of arterial divarication: application of kissing balloon technique. Tamura S, et al. **Radiat Med** 1998 Sep-Oct;16(5):387-9 (6 ref.)
The role of arterial embolization in renal cell carcinoma. Kalman D, et al. **Scand J Urol Nephrol** 1999 Jun; 33(3):162-70 (64 ref.)

PATHOLOGY

Contrast-enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. Bagga H, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1509-11 (7 ref.)
Magnetic resonance angiography of renal arterial stenosis. Grist TM. **Coron Artery Dis** 1999 May;10(3):151-6 (46 ref.)
[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul-Aug;(4):50-9 (101 ref.) **(Rus)**

RADIOGRAPHY

Is there still a place for angiography in the management of renal mass lesions? Roy C, et al. **Eur Radiol** 1999; 9(2):329-35 (23 ref.)
Three-dimensional CT angiography: renal applications. Smith PA, et al. **Semin Ultrasound CT MR** 1998 Oct; 19(5):413-24 (30 ref.)
[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul-Aug;(4):50-9 (101 ref.) **(Rus)**

SURGERY

Stenting of the peripheral, renal and supraaortic arteries and the aorta. Mahler F, et al. **Schweiz Med Wochenschr** 1999 Mar 13;129(10):399-409 (59 ref.)
Vascular reconstruction in urology. Sorcini A, et al. **Urol Clin North Am** 1999 Feb;26(1):219-34, x-xi (31 ref.)

RENAL ARTERY OBSTRUCTION

see related
HYPERTENSION, RENOVASCULAR
Ischemic renal disease. Ismail N, et al. **J Med Liban** 1998 Jan-Feb;46(1):29-35 (50 ref.)

COMPLICATIONS

Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43-55; discussion 55-63 (92 ref.)
Secondary hypertension in the elderly. Januszewicz W, et al. **J Hum Hypertens** 1998 Sep;12(9):603-6 (30 ref.)
[Percutaneous revascularization of renal artery stenosis. Balloon angioplasty vs. stent implantation] Blum U, et al. **Radiologe** 1999 Feb;39(2):135-43 (42 ref.) (Eng. Abstr.) **(Ger)**
[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747-54 (754 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Magnetic resonance angiography of renal arterial stenosis. Grist TM. **Coron Artery Dis** 1999 May;10(3):151-6 (46 ref.)
Imaging and stenting for renal artery stenosis. Dowling RJ, et al. **Hosp Med** 1999 May;60(5):329-36 (49 ref.)
Atherosclerotic renal artery stenosis: is it worth diagnosing? Eardley KS, et al. **J Hum Hypertens** 1999 Apr;13(4):217-20 (33 ref.)
Ischemic nephropathy: diagnosis and treatment. Zuccalà A, et al. **J Nephrol** 1998 Nov-Dec;11(6):318-24 (69 ref.)
Magnetic resonance angiography--the procedure of choice to diagnose renal artery stenosis? [editorial] Olbricht CJ, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1620-2 (30 ref.)

DRUG THERAPY

Treatment of renovascular disease and of renovascular hypertension. Bernini G, et al. **J Nephrol** 1998 Nov-Dec; 11(6):311-7 (35 ref.)

ETIOLOGY

Nephropathy and hypertension as manifestations in a 13-y-old girl with primary antiphospholipid syndrome. Ohtomo Y, et al. **Acta Paediatr** 1998 Aug;87(8):903-7 (44 ref.)
Hypertension in the transplanted patient. Zeier M, et al. **Contrib Nephrol** 1998;124:146-57; discussion 158-65 (86 ref.)
Troubleshooting maldeployed aortic endografts [comment] Kopchok G, et al. **J Endovasc Surg** 1998 Aug;5(3):266-8 (2 ref.) Comment on: J Endovasc Surg 1998 Aug;5(3):261-5.
[Transluminal treatment of abdominal aortic aneurysms. Might one obstruct the renal arteries?] Desgranges P, et al. **J Mal Vasc** 1998 Dec;23(5):385-6 (9 ref.) (Eng. Abstr.) **(Fre)**
[Fibromuscular dysplasia of the renal arteries] Fiquet-Kempf B, et al. **Nephrologie** 1999;20(1):13-8 (29 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[An arterial compression syndrome due to the ligamentum arcuatum mediale of the diaphragm] Rietzler B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):76-8 (8 ref.) **(Ger)**

SURGERY

Management of renovascular disease: a review of renal artery stenting in ten studies. Isles CG, et al. **QJM** 1999 Mar; 92(3):159-67 (39 ref.)
Vascular reconstruction in urology. Sorcini A, et al. **Urol Clin North Am** 1999 Feb;26(1):219-34, x-xi (31 ref.)
[Treatment of renal artery stenosis with intra-arterial stents] Postma CT, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26; 142(39):2132-7 (22 ref.) (Eng. Abstr.) **(Dut)**
[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747-54 (754 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Endovascular stents for renal artery revascularization. Tuttle KR, et al. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):695-701 (49 ref.)
Renal artery stent placement: indications, techniques and clinical results. White CJ, et al. **Indian Heart J** 1998 Oct; 50 Suppl 1:153-60 (43 ref.)
Stents for atherosclerotic renovascular disease. Rees CR. **J Vasc Interv Radiol** 1999 Jun;10(6):689-705 (86 ref.)
Management of the patient with atherosclerotic renal artery stenosis. New information from randomized trials [editorial] Plouin PF, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1623-6 (13 ref.)

ULTRASONOGRAPHY

Diagnosis of renal artery stenosis and renovascular hypertension. Karasch T, et al. **Eur J Ultrasound** 1998 Jul; 7 Suppl 3:S27-39 (60 ref.)

RENAL ARTERY STENOSIS see **RENAL ARTERY OBSTRUCTION**

RENAL BLOOD FLOW see **RENAL CIRCULATION**

RENAL CALCULI see **KIDNEY CALCULI**

RENAL CIRCULATION

Life-threatening hematuria from an arteriovenous fistula complicating an open renal biopsy. Tarif N, et al. **Nephron** 1998 Sep;80(1):66-70 (30 ref.)
[Renal microcirculation] Tamaki T, et al. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):261-7 (22 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. Hall JE, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S258-65 (33 ref.)
Influence of ketanserin on experimental loss of renal blood flow autoregulation. Verbeke M, et al. **Kidney Int Suppl** 1998 Sep;67:S238-41 (25 ref.)
Management of nephrotoxic drugs. Alsina J. **Transplant Proc** 1999 Feb-Mar;31(1-2):1117-9 (36 ref.)

PHYSIOLOGY

Acute interactions between endothelin and nitric oxide in the control of renal haemodynamics. Baylis C. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):253-7 (59 ref.)
Renal perfusion and disease progression. Sensirivatana R, et al. **J Med Assoc Thai** 1999 May;82(5):496-505 (63 ref.)
Shear stress and the endothelium. Ballermann BJ, et al. **Kidney Int Suppl** 1998 Sep;67:S100-8 (91 ref.)
Role of angiotensin in renal vascular development. Gomez RA. **Kidney Int Suppl** 1998 Sep;67:S12-6 (35 ref.)
Characteristics of isolated perfused juxtaglomerular apparatus. Ito S. **Kidney Int Suppl** 1998 Sep;67:S46-8 (12 ref.)
Heterogeneous activation mechanisms in the renal microvasculature. Navar LG, et al. **Kidney Int Suppl** 1998 Sep;67:S17-21 (30 ref.)
Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis. Zitnay C, et al. **Miner Electrolyte Metab** 1998;24(6):362-70 (93 ref.)

RENAL DIALYSIS, HOME see **HEMODIALYSIS, HOME**

RENAL DIALYSIS UNITS, HOSPITAL see **HEMODIALYSIS UNITS, HOSPITAL**

RENAL DISEASE, END-STAGE see **KIDNEY FAILURE, CHRONIC**

RENAL FAILURE see **KIDNEY FAILURE**

RENAL FAILURE, ACUTE see **KIDNEY FAILURE, ACUTE**

RENAL FAILURE, CHRONIC see **KIDNEY FAILURE, CHRONIC**

RENAL FAILURE, END-STAGE see **KIDNEY FAILURE, CHRONIC**

RENAL INSUFFICIENCY see **KIDNEY FAILURE**

RENAL INSUFFICIENCY, ACUTE see **KIDNEY FAILURE, ACUTE**

RENAL INSUFFICIENCY, CHRONIC see **KIDNEY FAILURE, CHRONIC**

RENAL OSTEODYSTROPHY

New insights related to aging and renal osteodystrophy. Hruska KA. **Geriatr Nephrol Urol** 1999;9(1):49-56 (41 ref.)

COMPLICATIONS

[Advances of clinical diagnosis of osteodystrophy complicated by chronic renal failure] Nowak Z. **Pol Merkuriusz Lek** 1998 Nov;5(29):313-6 (30 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

[Renal osteopathy (ROP)] Schulz W. **Internist (Berl)** 1999 Jan;40(1):70-82 (37 ref.) **(Ger)**
[Advances of clinical diagnosis of osteodystrophy complicated by chronic renal failure] Nowak Z. **Pol Merkuriusz Lek** 1998 Nov;5(29):313-6 (30 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Prevention of renal osteodystrophy in predialysis patients. Sanchez CP, et al. **Am J Med Sci** 1999 Jun;317(6):398-404 (59 ref.)

ETIOLOGY

Relative hypoparathyroidism and adynamic bone disease. Mucsi I, et al. **Am J Med Sci** 1999 Jun;317(6):405–9 (44 ref.)
Update on renal osteodystrophy: pathogenesis and clinical management. Sakhaee K, et al. **Am J Med Sci** 1999 Apr; 317(4):251–60 (66 ref.)

METABOLISM

Introduction to renal osteodystrophy: calcium metabolism in health and uremia. Kurokawa K, et al. **Am J Med Sci** 1999 Jun;317(6):355–7 (33 ref.)

PREVENTION & CONTROL

Prevention of renal osteodystrophy in predialysis patients. Sanchez CP, et al. **Am J Med Sci** 1999 Jun;317(6):398–404 (59 ref.)
Prevention of renal osteodystrophy in peritoneal dialysis. Weinreich T. **Kidney Int** 1998 Dec;54(6):2226–33 (64 ref.)

THERAPY

Update on renal osteodystrophy: pathogenesis and clinical management. Sakhaee K, et al. **Am J Med Sci** 1999 Apr; 317(4):251–60 (66 ref.)

RENAL PLASMA FLOW, EFFECTIVE

Technetium-99m-EC and other potential new agents in renal nuclear medicine. Moran JK. **Semin Nucl Med** 1999 Apr; 29(2):91–101 (38 ref.)

RENAL REPLACEMENT THERAPY

see related
KIDNEY
KIDNEY DISEASES

III. Treatment modalities for ESRD patients. **Am J Kidney Dis** 1999 Aug;34(2 Suppl 1):S51–62 (48 ref.)
Past, present and future of end-stage renal disease therapy in the United States. Uribarri J. **Mt Sinai J Med** 1999 Jan; 66(1):14–9 (39 ref.)
Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Pittrow L, et al. **Mycoses** 1999 Apr;42(1–2):17–9 (9 ref.)
Urea rebound and effectively delivered dialysis dose. Alloatti S, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:25–30 (49 ref.)
Renal replacement therapy quantification in acute renal failure. Clark WR, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:86–90 (43 ref.)
Benefits of more frequent dialysis: lower TAC at the same Kt/V. Depner TA. **Nephrol Dial Transplant** 1998;13 Suppl 6:20–4 (15 ref.)
Behaviour of acid–base control with different dialysis schedules. Feriani M. **Nephrol Dial Transplant** 1998;13 Suppl 6:62–5 (21 ref.)
Integrated diet and dialysis programme. Locatelli F, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:132–8 (23 ref.)
The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Macdougall IC, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3030–3 (18 ref.)
Factors influencing dialysis outcome: the dialysis dose in perspective. Mallick NP, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:152–7 (38 ref.)
The haemodialysis system: basic mechanisms of water and solute transport in extracorporeal renal replacement therapies. Ronco C, et al. **Nephrol Dial Transplant** 1998; 13 Suppl 6:3–9 (9 ref.)
Ultrafiltration behaviour with different dialysis schedules. Santoro A, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:55–61 (26 ref.)
[Indications for extra-renal dialysis in terminal chronic renal failure. National Agency for Medical Development and Evaluation. September 1996 (comment)] **Presse Med** 1998 Nov 21;27(36):1847–52 (0 ref.) Comment on: Presse Med 1998 Nov 21;27(36):1853–5. **(Fre)**
[Long-term management of dialysis patients. I. Hypertension and anemia] Schäffer J, et al. **Internist (Berl)** 1999 Jan; 40(1):55–63 (49 ref.) **(Ger)**
[Critical appraisal of treatments in emergency settings] Takahashi H, et al. **Nippon Geka Gakkai Zasshi** 1999 Jul; 100(7):449–54 (32 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Biocompatibility of renal replacement therapy] Schiffl H, et al. **Internist (Berl)** 1999 Jan;40(1):37–48 (98 ref.) **(Ger)**

METHODS

Cell therapy and tissue engineering for renal replacement therapy. Humes HD. **Am J Kidney Dis** 1998 Dec; 32(6):xlii–xliv (11 ref.)
End-stage renal disease (ESRD) and vascular access grafting: a critical review. Szycher M. **J Biomater Appl** 1999 Apr; 13(4):297–350 (125 ref.)
The current place of urea kinetic modelling with respect to different dialysis modalities. Gotch FA. **Nephrol Dial Transplant** 1998;13 Suppl 6:10–4 (10 ref.)
Continuous versus intermittent renal replacement therapy in the treatment of acute renal failure. Ronco C, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:79–85 (36 ref.)
Current and future modalities for functional renal replacement. Amiel GE, et al. **Urol Clin North Am** 1999 Feb;26(1):235–46, xi (131 ref.)
[Indications for and selection of dialysis methods in acute and chronic renal failure including continuous methods] Samtleben W, et al. **Internist (Berl)** 1999 Jan;40(1):3–12 (28 ref.) **(Ger)**

STANDARDS

The role of the health care team in the implementation of the National Kidney Foundation-Dialysis Outcomes Quality Initiative: a case study. Callahan MB, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):42–51 (34 ref.)
An overview of the National Kidney Foundation-Dialysis Outcomes Quality Initiative Implementation. Eknoyan G, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):3–6 (14 ref.)
The cost of implementing the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines. Wish J, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):67–74 (34 ref.)

RENAL TRANSPLANTATION see **KIDNEY TRANSPLANTATION**

RENAL TUBULAR ACIDOSIS, TYPE IV see **HYPOALDOSTERONISM**

RENAL TUBULAR TRANSPORT, INBORN ERRORS

GENETICS

Molecular genetics and clinical phenotype in heritable disorders of tubular Na+ transport. Hildebrandt F. **Kidney Blood Press Res** 1998;21(2–4):217–21 (50 ref.)
Inherited tubular transport disorders. Dell KM, et al. **Semin Nephrol** 1999 Jul;19(4):364–73 (75 ref.)

PHYSIOPATHOLOGY

Molecular pathophysiology of inborn renal Na+ transport defects. Greger R. **Kidney Blood Press Res** 1998; 21(2–4):222–5 (30 ref.)

RENAL VEINS

Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator. Lam KK, et al. **Am J Kidney Dis** 1998 Dec;32(6):1075–9 (27 ref.)

ABNORMALITIES

Left renal vein variations. Satyapal KS, et al. **Surg Radiol Anat** 1999;21(1):77–81 (47 ref.)
Anomalies of the inferior vena cava and renal veins: embryologic and surgical considerations. Mathews R, et al. **Urology** 1999 May;53(5):873–80 (51 ref.)

PATHOLOGY

Contrast-enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. Bagga H, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1509–11 (7 ref.)
Magnetic resonance angiography in nutcracker phenomenon [letter] Kaneko K, et al. **Clin Nephrol** 1999 Apr; 51(4):259–60 (6 ref.)

RADIOGRAPHY

[Nutcracker phenomenon treated with left renal vein transposition: a case report] Ohki T, et al. **Hinyokika Kiyo** 1999 Mar;45(3):183–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Nutcracker phenomenon treated with left renal vein transposition: a case report] Ohki T, et al. **Hinyokika Kiyo** 1999 Mar;45(3):183–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

RENIN

ANTAGONISTS & INHIBITORS

Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. Hollenberg NK. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S239–42 (28 ref.)
Renin inhibitors. Rosenberg SH, et al. **Pharm Biotechnol** 1998;11:7–28 (51 ref.)

BLOOD

Renin-producing adrenal tumor: report of a case. Kawai M, et al. **Surg Today** 1998;28(9):974–8 (26 ref.)

GENETICS

Will angiotensin converting enzyme genotype, receptor mutation identification, and other miracles of molecular biology permit reduction of NNT? Materson BJ. **Am J Hypertens** 1998 Aug;11(8 Pt 2):138S–142S (40 ref.)
[Molecular structure of renin-angiotensin-aldosterone system] Zelechowski M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):202–4 (30 ref.) (Eng. Abstr.) **(Pol)**

HISTORY

The ups and downs of the renin-angiotensin-aldosterone system since Tigerstedt's first discovery of renin. Vallotton MB. **Endocr Res** 1998 Aug–Nov;24(3–4):781–8 (12 ref.)
A memorial to Robert Tiegerstedt: the centennial of renin discovery. Inagami T. **Hypertension** 1998 Dec;32(6):953–7 (44 ref.)

METABOLISM

Control of the renal renin system by local factors. Wagner C, et al. **Kidney Int Suppl** 1998 Sep;67:S78–83 (61 ref.)
[Evidence of a renin receptor on human mesangial cells: effects on PAI1 and cGMP] Nguyen G, et al. **Nephrologie** 1998;19(7):411–6 (8 ref.) (Eng. Abstr.) **(Fre)**
[Molecular structure of renin-angiotensin-aldosterone system] Zelechowski M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):202–4 (30 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Renin system analysis defines the special value of combination antihypertensive therapy using an antirenin agent (CEI) with a long-acting calcium channel blocker (CCB). Laragh JH. **Am J Hypertens** 1998 Oct; 11(10):170S–174S (42 ref.)
Renin-angiotensin systems and reproduction. Vinson GP, et al. **Gynecol Endocrinol** 1999 Feb;13(1):56–70 (195 ref.)
Hypertension-induced end-organ damage : A new transgenic approach to an old problem. Luft FC, et al. **Hypertension** 1999 Jan;33(1 Pt 2):212–8 (76 ref.)
[The role of neurohormonal mechanisms in the etiopathogenesis of essential hypertension] Zyśko D, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):157–61 (29 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Role of nitric oxide in the control of renin secretion. Kurtz A, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):F849–62 (159 ref.)
Regulation of renal renin release. Wagner C, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):437–41 (59 ref.)
Regulation of renin secretion by angiotensin II-AT1 receptors. Kurtz A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S162–8 (77 ref.)
Cellular control of renin secretion. Kurtz A, et al. **J Exp Biol** 1999 Feb;202 (Pt 3):219–25 (59 ref.)

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM see **RENIN-ANGIOTENSIN SYSTEM**

RENIN-ANGIOTENSIN SYSTEM

see related
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Vasoactive peptide receptors in the rat kidney. Garcia R, et al. **Biol Res** 1998;31(3):217–25 (88 ref.)
Examining the renin-angiotensin system one hundred years after its discovery. Bernstein KE. **Nephrologie** 1998; 19(7):391–5 (33 ref.)
Angiotensin-(1–7): a bioactive fragment of the renin-angiotensin system. Ferrario CM, et al. **Regul Pept** 1998 Nov 30;78(1–3):13–8 (67 ref.)
[Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations] Andréjak M, et al. **Therapie** 1998 May–Jun; 53(3):291–300 (60 ref.) (Eng. Abstr.) **(Fre)**
[Renin-angiotensin-aldosterone system and heart failure: therapeutic aspects] Castaigne A, et al. **Therapie** 1998 May–Jun;53(3):285–9 (13 ref.) (Eng. Abstr.) **(Fre)**
[Interaction between the sympathetic and renin-angiotensin system] K-Laflamme A, et al. **Therapie** 1998 May–Jun; 53(3):245–52 (55 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Angiotensin-II receptor antagonists: their place in therapy. Kirk JK. **Am Fam Physician** 1999 Jun;59(11):3140–8 (42 ref.)
Overview of angiotensin II-receptor antagonists. Pitt B, et al. **Am J Cardiol** 1998 Nov 19;82(10A):47S–49S (12 ref.)
Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-aldosterone system [editorial; comment] Pitt B. **Circulation** 1998 Nov 10;98(19):1987–9 (20 ref.) Comment on: Circulation 1998 Nov 10;98(19):2037–42.
Effect of ACE inhibition on myocardial ischaemia. Ferrari R. **Eur Heart J** 1998 Sep;19 Suppl J:J30–5 (40 ref.)
Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. Hollenberg NK. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S239–42 (28 ref.)
AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Jalowy A, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S129–36 (66 ref.)

RENIN-ANGIOTENSIN SYSTEM

Angiotensin II and sympathoactivation in heart failure. Goldsmith SR. **J Card Fail** 1999 Jun;5(2):139–45 (49 ref.)
Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. Unger T, et al. **J Hypertens Suppl** 1998 Sep;16(7):S3–9 (55 ref.)
Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun;21(5):363–74 (113 ref.)

GENETICS

Gene targeting in physiological investigations: studies of the renin–angiotensin system. Coffman TM. **Am J Physiol** 1998 Jun;274(6 Pt 2):F999–1005 (59 ref.)
Genetic variability in the renin–angiotensin system: prevalence of alleles and genotypes. Staessen JA, et al. **J Cardiovasc Risk** 1997 Oct–Dec;4(5–6):401–22 (267 ref.)
Gene polymorphism of the renin–angiotensin system and progression of diabetic nephropathy. Orisio S. **J Nephrol** 1999 Jan–Feb;12(1):9–17 (104 ref.)
Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun;21(5):363–74 (113 ref.)
The TGR(mRen2)27 transgenic rat model of hypertension. Engler S, et al. **Regul Pept** 1998 Oct 16;77(1–3):3–8 (53 ref.)
Renin–angiotensin genes in renal development and the occurrence and progression of renal diseases. Hohenfellner K, et al. **Semin Nephrol** 1999 Mar;19(2):148–54 (50 ref.)
Cardiorenal destiny: the role of genes and environmental factors. Ingelfinger JR, et al. **Semin Nephrol** 1999 Mar; 19(2):201–10 (87 ref.)
[The relationship between genetic polymorphisms and disease, illustrated by the renin–angiotensin–aldosterone system and cardiovascular disease] Spiering W, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1445–50 (39 ref.) (Eng. Abstr.) **(Dut)**
[Experimental genetic modifications in the renin–angiotensin and kallikrein–kinin systems: significance for understanding cardiovascular regulation and study of genetic determinism of human diseases] Meneton P, et al. **Nephrologie** 1998; 19(7):385–9 (20 ref.) (Eng. Abstr.) **(Fre)**
[Polymorphism of the renin–angiotensin–aldosterone system: molecular and epidemiogenetic aspects] Soubrier F. **Nephrologie** 1998;19(7):377–84 (67 ref.) (Eng. Abstr.) **(Fre)**
[Genetic polymorphisms in the renin–angiotensin system] Jeunemaitre X. **Therapie** 1998 May–Jun;53(3):271–7 (50 ref.) (Eng. Abstr.) **(Fre)**
[Angiotensin and arteriosclerosis: an approach from transgenic and knockout mice] Fukamizu A. **Nippon Rinsho** 1999 May;57(5):1176–81 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic polymorphisms of the renin–angiotensin system and essential hypertension] Fernández-Llama P, et al. **Med Clin (Barc)** 1999 May 1;112(15):561–4 (35 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Brooks DP, et al. **Am Heart J** 1999 Sep;138(3 Pt 2):246–51 (53 ref.)
The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Gibbons GH. **Am J Hypertens** 1998 Nov;11(11 Pt 2):177S–181S (25 ref.)
Gene targeting in physiological investigations: studies of the renin–angiotensin system. Coffman TM. **Am J Physiol** 1998 Jun;274(6 Pt 2):F999–1005 (59 ref.)
Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Sun Y, et al. **Ann Med** 1998 Aug; 30 Suppl 1:3–8 (52 ref.)
Hypertension and the renin–angiotensin system—evidence from genetic and transgenic studies. Rothermund L, et al. **Basic Res Cardiol** 1998;93 Suppl 2:1–6 (32 ref.)
Intrauterine programming of hypertension: the role of the renin–angiotensin system. Langley-Evans SC, et al. **Biochem Soc Trans** 1999 Feb;27(2):88–93 (49 ref.)
The renin–angiotensin system in essential hypertension: associations with cardiovascular risk. Allikmets K, et al. **Blood Press** 1999;8(2):70–8 (111 ref.)
Transgenic animal models for the functional analysis of vasoactive peptides. Bader M. **Braz J Med Biol Res** 1998 Sep;31(9):1171–83 (126 ref.)
Bi-directional actions of estrogen on the renin–angiotensin system. Brosnihan KB, et al. **Braz J Med Biol Res** 1999 Apr;32(4):373–81 (72 ref.)
Antihypertensive effects of angiotensin-(1–7). Chappell MC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1205–12 (51 ref.)
Estrogen, natriuretic peptides and the renin–angiotensin system. Kuroski de Bold ML. **Cardiovasc Res** 1999 Mar; 41(3):524–31 (102 ref.)
Modulation and function of extrarenal angiotensin receptors. Wang DH, et al. **Cell Biochem Biophys** 1999;31(1):1–17 (121 ref.)
The cardiac renin–angiotensin system: conceptual, or a regulator of cardiac function? Dostal DE, et al. **Circ Res** 1999 Oct 1;85(7):643–50 (94 ref.)
The renin–angiotensin system and the development of the kidney and adrenal in sheep. Wintour EM, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S97–100 (39 ref.)
The ups and downs of the renin–angiotensin–aldosterone system since Tigerstedt's first discovery of renin. Vallotton MB. **Endocr Res** 1998 Aug–Nov;24(3–4):781–8 (12 ref.)
Fibrinolytic balance, the renin–angiotensin system and atherosclerotic disease. Vaughan DE. **Eur Heart J** 1998 Jul;19 Suppl G:G9–12 (21 ref.)
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Willenheimer R, et al. **Eur Heart J** 1999 Jul;20(14):997–1008 (105 ref.)
Renin–angiotensin systems and reproduction. Vinson GP, et al. **Gynecol Endocrinol** 1999 Feb;13(1):56–70 (195 ref.)
High intensity training and the heart. Montgomery H, et al. **Hosp Med** 1999 Mar;60(3):187–91 (29 ref.)
A memorial to Robert Tiegerstedt: the centennial of renin discovery. Inagami T. **Hypertension** 1998 Dec;32(6):953–7 (44 ref.)
The renin–angiotensin system and vascular fibrinolytic balance. Agirbasli M, et al. **Int J Clin Pract Suppl** 1998 May;94:20–5 (35 ref.)
What have we learned from gene targeting studies for the renin angiotensin system of the kidney? Nishimura H, et al. **Intern Med** 1999 Apr;38(4):315–23 (66 ref.)
Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. Ferrario CM, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1716–22 (73 ref.)
Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. Hall JE, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S258–65 (33 ref.)
The renin–angiotensin system and its receptors. Stroth U, et al. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S21–8; discussion S41–3 (115 ref.)
Renin–angiotensin system in elasmobranch fish: A review. Hazon N, et al. **J Exp Zool** 1999 Oct 1;284(5):526–34 (72 ref.)
Effects of transplantation on the renin angiotensin system (RAS). Farge D, et al. **J Hum Hypertens** 1998 Dec; 12(12):827–32 (47 ref.)
Renin–angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **J Mol Cell Cardiol** 1999 May;31(5):949–70 (156 ref.)
Role of the renin–angiotensin system in disorders of the urinary tract. Brock JW 3rd, et al. **J Urol** 1998 Nov; 160(5):1812–9 (85 ref.)
Differential actions of angiotensin-(1–7) in the kidney. Chappell MC, et al. **Kidney Int Suppl** 1998 Dec;68:S3–6 (26 ref.)
Control of the renal renin system by local factors. Wagner C, et al. **Kidney Int Suppl** 1998 Sep;67:S78–83 (61 ref.)
Antagonism of the renin–angiotensin–aldosterone system and collagen metabolism in cardiac fibroblasts. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr;21(3):215–27 (134 ref.)
Physiologic actions and molecular expression of the renin–angiotensin system in the diabetic rat. Anderson S. **Miner Electrolyte Metab** 1998;24(6):406–11 (45 ref.)
Renin–angiotensin–aldosterone–kinin system influences on diabetic vascular disease and cardiomyopathy. Flack JM, et al. **Miner Electrolyte Metab** 1998;24(6):412–22 (106 ref.)
The renin–angiotensin system in diabetic nephropathy: the endothelial connection. Rabelink TJ, et al. **Miner Electrolyte Metab** 1998;24(6):381–8 (123 ref.)
Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin–angiotensin system. Weir MR. **Miner Electrolyte Metab** 1998;24(6):438–45 (56 ref.)
Interaction of the renal amylin and renin–angiotensin systems in animal models of diabetes and hypertension. Wookey PJ, et al. **Miner Electrolyte Metab** 1998;24(6):389–99 (113 ref.)
The relative roles of circulating and tissue renin–angiotensin systems [editorial] Ardaillou R, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):283–6 (31 ref.)
Angiotensin and aldosterone. Lumbers ER. **Regul Pept** 1999 Apr 30;80(3):91–100 (48 ref.)
[Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?] Deray G. **Arch Mal Coeur Vaiss** 1999 Jul;92(7):903–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Interactions between the renin–angiotensin system, nitric oxide and endothelin] Dussaule JC, et al. **Nephrologie** 1998; 19(7):437–41 (51 ref.) (Eng. Abstr.) **(Fre)**
[Pathophysiology of the renin–angiotensin system] Noda K, et al. **Nippon Rinsho** 1999 May;57(5):1009–14 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Renin–angiotensin–aldosterone system in the reproductive system] Tanaka M, et al. **Nippon Rinsho** 1999 May; 57(5):1060–4 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Vascular endothelial cells and renin–angiotensin system] Rakugi H, et al. **Rinsho Byori** 1998 Nov;46(11):1135–41 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Renal renin–angiotensin system in homeostatic water–electrolyte regulation] Lis GJ. **Przegl Lek** 1999; 56(2):164–8 (30 ref.) (Eng. Abstr.) **(Pol)**

RENIN-SUBSTRATE see **ANGIOTENSINOGEN**

RENNIN see **CHYMOSIN**

RENOGRAPHY see **RADIOISOTOPE RENOGRAPHY**

REOVIRIDAE

[Cytoplasmic polyhedrosis virus and polyhedrin] Mori H, et al. **Uirusu** 1998 Jun;48(1):81–8 (42 ref.) **(Jpn)**

REOVIRUSES, AQUATIC see **REOVIRIDAE**

REPEAT CESAREAN SECTION see **CESAREAN SECTION, REPEAT**

REPERFUSION

Retrograde cerebral perfusion: clinical and experimental aspects. Wong CH, et al. **Perfusion** 1999 Jul;14(4):247–56 (82 ref.)

REPERFUSION INJURY

Ischaemia–reperfusion injury of the liver: treatment in theory and in practice. Tredger JM. **Biofactors** 1998;8(1–2):161–4 (25 ref.)
Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography. Marchal G, et al. **J Cereb Blood Flow Metab** 1999 May;19(5):467–82 (93 ref.)
Postischemic reperfusion injury and allograft arteriosclerosis. Fellström B, et al. **Transplant Proc** 1998 Dec;30(8):4278–80 (36 ref.)
The nature of ischemia/reperfusion injury. Massberg S, et al. **Transplant Proc** 1998 Dec;30(8):4217–23 (82 ref.)
Ischemia reperfusion injury and chronic allograft rejection. Szabo A, et al. **Transplant Proc** 1998 Dec;30(8):4281–4 (59 ref.)

COMPLICATIONS

Postischemic reperfusion injury and allograft dysfunction: is allograft rejection the result of a fateful confusion by the immune system of danger and benefit? Land W. **Transplant Proc** 1999 Feb–Mar;31(1–2):332–6 (20 ref.)

ETIOLOGY

Ischemia and reperfusion injury. The ultimate pathophysiologic paradox. Hammerman C, et al. **Clin Perinatol** 1998 Sep;25(3):757–77 (96 ref.)
Review article: the role of tumor necrosis factor in renal ischemia–reperfusion injury. Donnahoo KK, et al. **J Urol** 1999 Jul;162(1):196–203 (96 ref.)
Ischemia–reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Granger DN. **Microcirculation** 1999 Sep;6(3):167–78 (63 ref.)
Role of cytokines and cytokine-producing cells in reperfusion injury to the liver. Lichtman SN, et al. **Semin Liver Dis** 1999;19(2):171–87 (244 ref.)

IMMUNOLOGY

Endothelial cell adhesion molecules in inflammation and postischemic reperfusion injury. Beekhuizen H, et al. **Transplant Proc** 1998 Dec;30(8):4251–6 (65 ref.)
Postischemic reperfusion injury and cytokines. Land W. **Transplant Proc** 1998 Dec;30(8):4237–8 (14 ref.)
Upregulation of major histocompatibility complex–expression under ischemic conditions in experimental models. Shackleton CR. **Transplant Proc** 1998 Dec;30(8):4264–6 (6 ref.)

METABOLISM

Reoxygenation injury of human brain capillary endothelial cells. Nagashima T, et al. **Cell Mol Neurobiol** 1999 Feb; 19(1):151–61 (66 ref.)
Lipid peroxidation in the reperfusion injury of the liver. Poli G, et al. **Free Radic Res** 1998 Jun;28(6):547–51 (15 ref.)
Invited editorial on "tumor necrosis factor–alpha in ischemia and reperfusion injury in rat lungs". Al-Mehdi AB, et al. **J Appl Physiol** 1998 Dec;85(6):2003–4 (16 ref.)
The many aspects of endothelins in ischemia–reperfusion injury: emergence of a key mediator. Battistini B, et al. **J Invest Surg** 1998 Sep–Oct;11(5):297–313 (151 ref.)
Cytokines and the microcirculation in ischemia and reperfusion. Frangogiannis NG, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2567–76 (48 ref.)
[Neurochemical changes associated with ischemic–reperfusion injury of the CNS] Račay P, et al. **Bratisl Lek Listy** 1998 Jul;99(7):376–85 (165 ref.) (Eng. Abstr.) **(Slo)**

MORTALITY

Cardiogenic shock: a failure in reperfusion. Time for a strategic change? [editorial; comment] Serruys PW, et al. **Eur Heart J** 1999 Jan;20(2):88–9 (10 ref.) Comment on: Eur Heart J 1999 Jan;20(2):128–35.

PATHOLOGY

Mechanisms of cell death in hypoxia/reoxygenation injury. Saikumar P, et al. **Oncogene** 1998 Dec 24;17(25):3341–9 (70 ref.)
[Vascular wall modifications after disruption of the circulation leading to cerebral ischemia] Sercombe R. **Ann Fr Anesth Reanim** 1999 May;18(5):583–7 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Local and systemic consequences of severe ischemia and reperfusion of the skeletal muscle. Physiopathology and prevention. Defraigne JO, et al. **Acta Chir Belg** 1998 Aug; 98(4):176–86 (62 ref.)

The pathophysiology of the acute compartment syndrome. Tollens T, et al. **Acta Chir Belg** 1998 Aug;98(4):171–5 (11 ref.)

Ischemia and reperfusion injury. The ultimate pathophysiologic paradox. Hammerman C, et al. **Clin Perinatol** 1998 Sep;25(3):757–77 (96 ref.)

The role of adhesion molecules and nitric oxide in intestinal and hepatic ischemia/reperfusion. Kubes P. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1458–63 (48 ref.)

Role of microcirculation in hepatic ischemia/reperfusion injury. Menger MD, et al. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1452–7 (78 ref.)

Mechanisms of ischemic preconditioning and clinical implications for multiorgan ischemic–reperfusion injury. Lee HT. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):78–91 (133 ref.)

Ischaemia–reperfusion injury. Implications for the hand surgeon. al-Qattan MM. **J Hand Surg [Br]** 1998 Oct; 23(5):570–3 (37 ref.)

Mechanisms of reperfusion injury after warm ischemia of the liver. Jaeschke H. **J Hepatobiliary Pancreat Surg** 1998; 5(4):402–8 (84 ref.)

Kupffer cell–dependent reperfusion injury in liver transplantation: new clinically relevant use of glycine. Thurman RG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:185–90 (31 ref.)

Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Jean WC, et al. **Neurosurgery** 1998 Dec;43(6):1382–96; discussion 1396–7 (201 ref.)

Microvascular pathophysiology of skeletal muscle ischemia–reperfusion. Durán WN, et al. **Semin Vasc Surg** 1998 Sep;11(3):203–14 (63 ref.)

Mechanism and prevention of ischemia–reperfusion injury. Kurokawa T, et al. **Transplant Proc** 1999 Jun;31(4):1775–6 (5 ref.)

Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor–delta in reperfusion injury of liver transplantation–mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1055–8 (18 ref.)

The purine nucleoside adenosine in retinal ischemia–reperfusion injury. Ghiardi GJ, et al. **Vision Res** 1999 Jul;39(15):2519–35 (81 ref.)

[Progresses in the study of microcirculation in China, 1997] Jin H. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):938–9 (0 ref.) **(Chi)**

[Pathophysiology and clinical aspects of ischemia–reperfusion damage to skeletal muscles] Schellong SM, et al. **Vasa** 1998 Nov;27(4):207–15 (108 ref.) (Eng. Abstr.) **(Ger)**

[Intestinal ischemic reperfusion syndrome: pathophysiology, clinical significance, therapy] Schwarz B, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):539–48 (115 ref.) (Eng. Abstr.) **(Ger)**

[Role of cytokines in hepatic ischemia and reperfusion injury] Suzuki S, et al. **Nippon Geka Gakkai Zasshi** 1999 May; 100(5):325–30 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Interaction between neutrophils and endothelial cells following ischemia/reperfusion] Yamaguchi Y, et al. **Nippon Geka Gakkai Zasshi** 1999 May;100(5):319–24 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Ischemia/reperfusion injury and organ failure] Yasuhara H, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):510–7 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Ischemia–reperfusion liver injury] Turecký L. **Bratisl Lek Listy** 1999 Jan;100(1):36–40 (31 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Local and systemic consequences of severe ischemia and reperfusion of the skeletal muscle. Physiopathology and prevention. Defraigne JO, et al. **Acta Chir Belg** 1998 Aug; 98(4):176–86 (62 ref.)

Ischaemic preconditioning: mechanisms and potential clinical applications. Hawaleshka A, et al. **Can J Anaesth** 1998 Jul; 45(7):670–82 (89 ref.)

Schemes against ischemia; solutions for reperfusion (injury)? [editorial; comment] Barie PS. **Crit Care Med** 1999 Apr; 27(4):684–5 (11 ref.) Comment on: Crit Care Med 1999 Apr;27(4):764–70.

Cardioprotection of red wine: role of polyphenolic antioxidants. Das DK, et al. **Drugs Exp Clin Res** 1999; 25(2–3):115–20 (25 ref.)

Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Calvani M, et al. **Int J Tissue React** 1999; 21(1):1–6 (45 ref.)

Decreasing the cold ischemia time. Abendroth D. **Transplant Proc** 1998 Dec;30(8):4288–90 (42 ref.)

Mechanism and prevention of ischemia–reperfusion injury. Kurokawa T, et al. **Transplant Proc** 1999 Jun;31(4):1775–6 (5 ref.)

[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:72–7 (14 ref.) (Eng. Abstr.) **(Ger)**

REPERFUSION INJURY, MYOCARDIAL see **MYOCARDIAL REPERFUSION INJURY**

REPERFUSION, MYOCARDIAL see **MYOCARDIAL REPERFUSION**

REPETITION STRAIN INJURY see **CUMULATIVE TRAUMA DISORDERS**

REPETITIVE REGION see **REPETITIVE SEQUENCES, NUCLEIC ACID**

REPETITIVE SEQUENCES, AMINO ACID

Topological characteristics of helical repeat proteins. Groves MR, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):383–9 (31 ref.)

The WD repeat: a common architecture for diverse functions. Smith TF, et al. **Trends Biochem Sci** 1999 May;24(5):181–5 (40 ref.)

GENETICS

Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions. Ross CA, et al. **Prog Brain Res** 1998;117:397–419 (160 ref.)

REPETITIVE SEQUENCES, DISPERSED see **INTERSPERSED REPETITIVE SEQUENCES**

REPETITIVE SEQUENCES, INTERSPERSED see **INTERSPERSED REPETITIVE SEQUENCES**

REPETITIVE SEQUENCES, NUCLEIC ACID

see related
MULTIGENE FAMILY

Gene silencing: repeats that count. Selker EU. **Cell** 1999 Apr 16;97(2):157–60 (23 ref.)

Protein binding to simple repetitive sequences depends on DNA secondary structure(s). Mäueler W, et al. **Chromosome Res** 1999;7(3):163–6 (14 ref.)

A comparative approach to physical and linkage mapping of genes on canine chromosomes using gene-associated simple sequence repeat polymorphisms illustrated by studies of dog chromosome 9. Werner P, et al. **J Hered** 1999 Jan–Feb;90(1):39–42 (21 ref.)

Genetic applications of transposons and other repetitive elements in zebrafish. Ivics Z, et al. **Methods Cell Biol** 1999; 60:99–131 (110 ref.)

GENETICS

Transgenic mice in the study of polyglutamine repeat expansion diseases. Bates GP, et al. **Brain Pathol** 1998 Oct; 8(4):699–714 (53 ref.)

Repetitive conundrums of centromere structure and function. Eichler EE. **Hum Mol Genet** 1999 Feb;8(2):151–5 (54 ref.)

PHYSIOLOGY

The role of short sequence repeats in epidemiologic typing. van Belkum A. **Curr Opin Microbiol** 1999 Jun;2(3):306–11 (63 ref.)

REPLACEMENT THERAPY, ESTROGEN see **ESTROGEN REPLACEMENT THERAPY**

REPLACEMENT THERAPY, HORMONE see **HORMONE REPLACEMENT THERAPY**

REPLANTATION

Salmonella infection in total hip replacement--report of successful reimplantation and review of the literature. Chen CM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul; 62(7):472–6 (13 ref.)

Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Schlozman SC. **J Clin Psychiatry** 1998 Dec;59(12):681–6 (22 ref.)

METHODS

Re-implantation of autoclaved bone segments in musculoskeletal tumor surgery. Clinical experience in 9 patients followed for 1.1–8.4 years and review of the literature. Böhm P, et al. **Arch Orthop Trauma Surg** 1998; 118(1–2):57–65 (59 ref.)

REPLICA TECHNIQUES

Vertical Pt–C replication for TEM, a revolution in imaging non-periodic macromolecules, biological gels and low-density polymer networks. Ruben GC. **Micron** 1998 Oct;29(5):359–96 (93 ref.)

REPLICATION ORIGIN

Replication conrol: choreographing replication origins. Diffley JF. **Curr Biol** 1998 Oct 22;8(21):R771–3 (10 ref.)

Regulatory implications of protein assemblies at the gamma origin of plasmid R6K – a review. Filutowicz M, et al. **Gene** 1998 Nov 26;223(1–2):195–204 (90 ref.)

Applications of oriP plasmids and their mode of replication. Mackey D, et al. **Methods Enzymol** 1999;306:308–28 (121 ref.)

DRUG EFFECTS

The 2.2 A structure of a permanganate-sensitive DNA site bound by the Epstein–Barr virus origin binding protein, EBNA1. Bochkarev A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1273–8 (24 ref.)

GENETICS

Replication origins in metazoan chromosomes: fact or fiction? DePamphilis ML. **Bioessays** 1999 Jan;21(1):5–16 (97 ref.)

The regulation of replication origin activation. Donaldson AD, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):62–8 (68 ref.)

PHYSIOLOGY

Initiation of DNA replication in eukaryotes: questioning the origin. Françon P, et al. **FEBS Lett** 1999 Jun 4; 452(1–2):87–91 (62 ref.)

REPLICATION UNIT see **REPLICON**

REPLICATIVE SENESCENCE see **CELL AGING**

REPLICON

[Is the replicon model applicable to higher eukaryotes?] de Recondo AM. **C R Acad Sci III** 1998 Dec;321(12):961–78 (32 ref.) (Eng. Abstr.) **(Fre)**

REPORTER GENES see **GENES, REPORTER**

REPRESSED MEMORY see **REPRESSION**

REPRESSION

Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. Mann SJ. **Arch Intern Med** 1999 Apr 12; 159(7):670–4 (14 ref.)

Thought suppression and psychopathology. Purdon C. **Behav Res Ther** 1999 Nov;37(11):1029–54 (84 ref.)

Memories of childhood sexual abuse: a survey of young adults. Epstein MA, et al. **Child Abuse Negl** 1998 Dec; 22(12):1217–38 (109 ref.)

Traumatic amnesia, repression, and hippocampus injury due to emotional stress, corticosteroids and enkephalins. Joseph R. **Child Psychiatry Hum Dev** 1998 Winter;29(2):169–85 (128 ref.)

Recovered memories of trauma: phenomenology and cognitive mechanisms. Brewin CR, et al. **Clin Psychol Rev** 1998 Dec;18(8):949–70 (98 ref.)

Errors in autobiographical memory. Hyman IE Jr, et al. **Clin Psychol Rev** 1998 Dec;18(8):933–47 (42 ref.)

Memory, amnesia, and the issue of recovered memory: neurobiological aspects. Zola SM. **Clin Psychol Rev** 1998 Dec;18(8):915–32 (77 ref.)

Repression: a mistaken impression? Loftus E, et al. **Dev Psychopathol** 1998 Fall;10(4):781–92 (61 ref.)

False complaints of sexual assault: recovered memories of childhood sexual abuse. Boakes J. **Med Sci Law** 1999 Apr; 39(2):112–20 (9 ref.)

Repressed memories. When are they real? How are they false? Loftus EF, et al. **Psychiatr Clin North Am** 1999 Mar; 22(1):61–70 (29 ref.)

From courtroom to couch. Working with repressed memory and avoiding lawsuits. Scheflin AW, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):847–67, vii (136 ref.)

REPRESSOR MOLECULES see **REPRESSOR PROTEINS**

REPRESSOR PROTEINS

Visualization of large-scale chromatin structure and dynamics using the lac operator/lac repressor reporter system. Belmont AS, et al. **Methods Cell Biol** 1999; 58:203–22 (29 ref.)

GENETICS

Comprehensive mutation analysis of TSC1 and TSC2–and phenotypic correlations in 150 families with tuberous sclerosis. Jones AC, et al. **Am J Hum Genet** 1999 May; 64(5):1305–15 (47 ref.)

Knockout of REST/NRSF shows that the protein is a potent repressor of neuronally expressed genes in non-neural tissues. Jones FS, et al. **Bioessays** 1999 May;21(5):372–6 (26 ref.)

Sex, cell death, and the genome of C. elegans [comment] Hodgkin J. **Cell** 1999 Aug 6;98(3):277–80 (16 ref.) Comment on: Cell 1999 Aug 6;98(3):317–27.

Tuberous sclerosis-related gene expression in normal and

dysplastic brain. Vinters HV, et al. **Epilepsy Res** 1998 Sep; 32(1-2):12-23 (51 ref.)

TSC2 gene mutant (Eker) rat model of a Mendelian dominantly inherited cancer. Hino O, et al. **Prog Exp Tumor Res** 1999;35:95-108 (52 ref.)

METABOLISM

Knockout of REST/NRSF shows that the protein is a potent repressor of neuronally expressed genes in non-neural tissues. Jones FS, et al. **Bioessays** 1999 May;21(5):372-6 (26 ref.)

Transcription regulation by repressosome and by RNA polymerase contact. Adhya S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:1-9 (58 ref.)

The Mad protein family links transcriptional repression to cell differentiation. McArthur GA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:423-33 (100 ref.)

Some repressors of bacterial transcription. Müller-Hill B. **Curr Opin Microbiol** 1998 Apr;1(2):145-51 (51 ref.)

Nuclear receptor coregulators: cellular and molecular biology. McKenna NJ, et al. **Endocr Rev** 1999 Jun; 20(3):321-44 (216 ref.)

PKR, apoptosis and cancer. Jagus R, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):123-38 (192 ref.)

Repression of transcription initiation in bacteria. Rojo F. **J Bacteriol** 1999 May;181(10):2987-91 (68 ref.)

Chromatin structure and analysis of mechanisms of activators and repressors. Simpson RT. **Methods** 1998 Aug; 15(4):283-94 (61 ref.)

Translational control by repressor proteins binding to the 5'UTR of mRNAs. Gray NK. **Methods Mol Biol** 1998; 77:379-97 (42 ref.)

FadR, transcriptional co-ordination of metabolic expediency. Cronan JE Jr, et al. **Mol Microbiol** 1998 Aug;29(4):937-43 (30 ref.)

Chromatin silencing and Arabidopsis development: A role for for polycomb proteins. Preuss D. **Plant Cell** 1999 May; 11(5):765-8 (14 ref.)

Transcriptional coregulators in development. Mannervik M, et al. **Science** 1999 Apr 23;284(5414):606-9 (56 ref.)

Thyroid hormone receptor coactivators and corepressors. Koenig RJ. **Thyroid** 1998 Aug;8(8):703-13 (105 ref.)

PHYSIOLOGY

Repression by the Mad(Mxi1)-Sin3 complex. Schreiber-Agus N, et al. **Bioessays** 1998 Oct;20(10):808-18 (86 ref.)

Regulators and mediators of the p53 tumor suppressor. Cadwell C, et al. **J Cell Biochem Suppl** 1998;30-31:43-9 (41 ref.)

Cellular memory of transcriptional states by Polycomb-group proteins [see comments] Jacobs JJ, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):227-35 (90 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

Suppression mechanisms: themes from variations. Prelich G. **Trends Genet** 1999 Jul;15(7):261-6 (39 ref.)

REPRODUCIBILITY OF RESULTS

Comparison of various cosolvency models for calculating solute solubility in water-cosolvent mixtures. Jouyban-Gharamaleki A, et al. **Int J Pharm** 1999 Jan 15; 177(1):93-101 (35 ref.)

Analysis of clustered data in receiver operating characteristic studies. Beam CA. **Stat Methods Med Res** 1998 Dec; 7(4):324-36 (30 ref.)

Sample size calculations in studies of test accuracy. Obuchowski NA. **Stat Methods Med Res** 1998 Dec; 7(4):371-92 (36 ref.)

REPRODUCTION

Women's reproductive health: some recent developments in occupational epidemiology. Lindbohm ML. **Am J Ind Med** 1999 Jul;36(1):18-24 (51 ref.)

A review of the effects of hazardous waste on reproductive health. Johnson BL. **Am J Obstet Gynecol** 1999 Jul; 181(1):S12-6 (20 ref.)

Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Couse JF, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):143-8 (51 ref.)

Intragonadal regulation of male and female reproduction. Hillier SG. **Ann Endocrinol (Paris)** 1999 Jul;60(2):111-7 (84 ref.)

Mammary gland development, reproductive history, and breast cancer risk. Chodosh LA, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1765-1771s; discussion 1771s-1772s (85 ref.)

Glycodelins: biological activity in reproduction and differentiation. Seppälä M. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):261-3 (15 ref.)

Current status of reproductive behaviour in Africa. Bambra CS. **Hum Reprod Update** 1999 Jan-Feb;5(1):1-20 (158 ref.)

Mini symposium: the role of carbohydrates in reproduction. Introduction. Ivell R. **Hum Reprod Update** 1999 Jul-Aug; 5(4):277-9 (14 ref.)

Ageing and social rank effects on the reproductive system of free-ranging yellow baboons (Papio cynocephalus) at Mikumi National Park, Tanzania. Wasser SK, et al. **Hum Reprod Update** 1998 Jul-Aug;4(4):430-8 (40 ref.)

An elusive role for glycosylation in the structure and function of reproductive hormones. Willey KP. **Hum Reprod Update** 1999 Jul-Aug;5(4):330-55 (154 ref.)

Achieving and maintaining pregnancy after age 40. Corson SL. **Int J Fertil Womens Med** 1998 Sep-Oct;43(5):249-56 (15 ref.)

Ethics, justice and women's health. Cook RJ, et al. **Int J Gynaecol Obstet** 1999 Jan;64(1):81-5 (23 ref.)

Oviductal sperm storage as a reproductive tactic of turtles. Gist DH, et al. **J Exp Zool** 1998 Nov-Dec 1; 282(4-5):526-34 (48 ref.)

Oviduct structure and function and reproductive modes in amphibians. Wake MH, et al. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):477-506 (149 ref.)

Sexually transmitted diseases and reproductive health in women. Burst HV. **J Nurse Midwifery** 1998 Nov-Dec; 43(6):431-44 (71 ref.)

Reproductive health. New perspectives on men's participation. Drennan M. **Popul Rep J** 1998 Oct;(46):1-35 (299 ref.)

Embryo transfer and related technologies in sheep reproduction. Loi P, et al. **Reprod Nutr Dev** 1998 Nov-Dec; 38(6):615-28 (123 ref.)

Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. Byrne J. **Teratology** 1999 Apr; 59(4):210-5 (30 ref.)

Intrauterine effects of ultrasound: human epidemiology. Ziskin MC. **Teratology** 1999 Apr;59(4):252-60 (45 ref.)

Ratite reproduction. Hicks-Alldredge K. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):437-53, vi (8 ref.)

DRUG EFFECTS

An overview of current in vivo test procedures to reproductive toxicology. Nunziata A. **Adv Exp Med Biol** 1998;444:171-83 (0 ref.)

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part I: The reproduction and fertility testing guidelines. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):543-53 (75 ref.)

Reproductive actions of phytoestrogens. Whitten PL, et al. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):667-90 (142 ref.)

The effects of environmental hormones on reproduction. Danzo BJ. **Cell Mol Life Sci** 1998 Nov;54(11):1249-64 (186 ref.)

Neurodevelopmental, immunological and endocrinological indices of perinatal human exposure to PCBs and dioxins. Weisglas-Kuperus N. **Chemosphere** 1998 Oct-Nov; 37(9-12):1845-53 (55 ref.)

Effect of diethylstilbestrol on reproductive function. Goldberg JM, et al. **Fertil Steril** 1999 Jul;72(1):1-7 (60 ref.)

Environmental toxicants and female reproduction [see comments] Sharara FI, et al. **Fertil Steril** 1998 Oct; 70(4):613-22 (100 ref.) Comment in: Fertil Steril 1999 Apr;71(4):775-6.

Occupational risk to male reproduction [editorial; comment] Bonde JP. **Int Arch Occup Environ Health** 1999 May; 72(3):133-4 (17 ref.) Comment on: Int Arch Occup Environ Health 1999 May;72(3):135-41.

Reproductive toxicity of occupational mercury. A review of the literature. Schuurs AH. **J Dent** 1999 May; 27(4):249-56 (101 ref.)

An overview of recent studies on the potential of pulp-mill effluents to alter reproductive parameters in fish. Munkittrick KR, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct-Dec; 1(4):347-71 (92 ref.)

The effects of cannabinoids on the regulation of reproduction. Wenger T, et al. **Life Sci** 1999;65(6-7):695-701 (22 ref.)

Reproductive physiology and treatment-related loss of sex hormone production. Sklar C. **Med Pediatr Oncol** 1999 Jul; 33(1):2-8 (63 ref.)

Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. Debeljuk L, et al. **Peptides** 1999; 20(2):285-99 (139 ref.)

Molinate: rodent reproductive toxicity and its relevance to humans--a review. Wickramaratne GA, et al. **Regul Toxicol Pharmacol** 1998 Apr;27(2):112-8 (17 ref.)

A strategy for assessing the effects of xenobiotics on fish reproduction. Kime DE. **Sci Total Environ** 1999 Jan 12; 225(1-2):3-11 (38 ref.)

[Dioxins: current knowledge about health effects] Wissing M. **Rev Med Brux** 1998 Sep;19(4):A367-71 (24 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin and reproduction in domestic farm animals] Chemineau P, et al. **Therapie** 1998 Sep-Oct;53(5):445-52 (52 ref.) (Eng. Abstr.) **(Fre)**

[Toxicology of reproduction: predictive value of experimental models. Round Table No 1 at Giens XIII] Guittin P, et al. **Therapie** 1998 Jul-Aug;53(4):355-63 (39 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular biology and reproduction. McDonough PG. **Keio J Med** 1999 Mar;48(1):12-21 (13 ref.)

Mitochondrial DNA in mammalian reproduction. Cummins J. **Rev Reprod** 1998 Sep;3(3):172-82 (111 ref.)

Genetics and human reproduction. McLaren A. **Trends Genet** 1998 Oct;14(10):427-31 (37 ref.)

IMMUNOLOGY

Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome [see comments] Kutteh WH, et al. **Am J Reprod Immunol** 1999 Feb; 41(2):133-52 (207 ref.) Comment in: Am J Reprod Immunol 1999 Feb;41(2):113-6.

[Immunology of reproduction] Kulakov VI, et al. **Vestn Ross Akad Med Nauk** 1999;(4):44-8 (12 ref.) (Eng. Abstr.) **(Rus)**

[The mechanisms of the anti-infective protection of the female reproductive tract] Telesheva LF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):85-90 (41 ref.) **(Rus)**

PHYSIOLOGY

Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272-4 (50 ref.)

Reproduction in foxes: current research and future challenges. Farstad W. **Anim Reprod Sci** 1998 Oct; 53(1-4):35-42 (49 ref.)

Chemical signals in the reproduction of Asian (Elephas maximus) and African (Loxodonta africana) elephants. Rasmussen LE, et al. **Anim Reprod Sci** 1998 Oct; 53(1-4):19-34 (92 ref.)

Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Kalra SP, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:236-40 (25 ref.)

The medial extended amygdala in male reproductive behavior. A node in the mammalian social behavior network. Newman SW. **Ann N Y Acad Sci** 1999 Jun 29; 877:242-57 (103 ref.)

Leptin's actions on the reproductive axis: perspectives and mechanisms. Cunningham MJ, et al. **Biol Reprod** 1999 Feb; 60(2):216-22 (123 ref.)

Physiological perspectives on leptin as a regulator of reproduction: role in timing puberty. Foster DL, et al. **Biol Reprod** 1999 Feb;60(2):205-15 (69 ref.)

Human endogenous retroviral sequences: possible roles in reproductive physiopathology. Taruscio D, et al. **Biol Reprod** 1998 Oct;59(4):713-24 (141 ref.)

Leptin and reproduction: is it a critical link between adipose tissue, nutrition, and reproduction? Thong FS, et al. **Can J Appl Physiol** 1999 Aug;24(4):317-36 (101 ref.)

Fish as models for the neuroendocrine regulation of reproduction and growth. Blázquez M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):345-64 (214 ref.)

Developmental effects on intersexual and intrasexual variation in growth and reproduction in a lizard with temperature-dependent sex determination. Crews D, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):229-41 (83 ref.)

Reproduction and love: strategies of the organism's cellular defense system? De Loof A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):167-76 (33 ref.)

Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283-94 (78 ref.)

Identification of potential sites of cortisol actions on the reproductive axis in rainbow trout. Teitsma C, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):243-9 (33 ref.)

Vascular endothelial growth factor in reproductive biology. Lebovic DI, et al. **Curr Opin Obstet Gynecol** 1999 Jun; 11(3):255-60 (54 ref.)

Inhibins: paracrine and endocrine effects in female reproductive function. Petraglia F, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):241-7 (53 ref.)

Wise, winsome, or weird? Mechanisms of sperm storage in female animals. Neubaum DM, et al. **Curr Top Dev Biol** 1999;41:67-97 (156 ref.)

Inhibins, activins and follistatins: a review of complex regulators of the reproductive system. Renier MA, et al. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):129-35 (49 ref.)

Glutathione and glutathione-related enzymes in reproduction. A review. Knapen MF, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):171-84 (136 ref.)

Chemokines and human reproduction. García-Velasco JA, et al. **Fertil Steril** 1999 Jun;71(6):983-93 (101 ref.)

Mutations in human gonadotropin genes and their physiologic significance in puberty and reproduction. Layman LC. **Fertil Steril** 1999 Feb;71(2):201-18 (77 ref.)

Is there a role for leptin in human reproduction? Macut D, et al. **Gynecol Endocrinol** 1998 Oct;12(5):321-6 (58 ref.)

Renin-angiotensin systems and reproduction. Vinson GP, et al. **Gynecol Endocrinol** 1999 Feb;13(1):56-70 (195 ref.)

Cell adhesion and reproduction. An overview. Taga M, et al. **Horm Res** 1998;50 Suppl 2:2-6 (18 ref.)

Utero-ovarian interaction in the regulation of reproductive function. Alexander H, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):550-9 (35 ref.)

Leptin in human reproduction. Messinis IE, et al.

Hum Reprod Update 1999 Jan-Feb;5(1):52-63 (111 ref.)
The check is in the male: male mosquitoes affect female physiology and behavior. Klowden MJ.
J Am Mosq Control Assoc 1999 Jun;15(2):213-20 (92 ref.)
Clinical review 105: Stress and the reproductive cycle. Ferin M. **J Clin Endocrinol Metab** 1999 Jun;84(6):1768-74 (76 ref.)
Reproductive endocrinology of female elasmobranchs: lessons from the little skate (Raja erinacea) and spiny dogfish (Squalus acanthias). Koob TJ, et al.
J Exp Zool 1999 Oct 1;284(5):557-74 (67 ref.)
AIDS and reproductive health. Coggins C, et al.
J Reprod Immunol 1998 Dec;41(1-2):3-15 (51 ref.)
Potential implications of chemokines in reproductive function: an attractive idea. Simón C, et al.
J Reprod Immunol 1998 Jul;38(2):169-93 (134 ref.)
Modeling adverse environmental impacts on the reproductive system. Sussman NB, et al. **J Womens Health** 1999 Mar; 8(2):217-26 (25 ref.)
The role of sex steroids in the oxytocin hormone system. Ivell R, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1-2):95-101 (56 ref.)
Epilepsy in women: the science of why it is special. Morrell MJ. **Neurology** 1999;53(4 Suppl 1):S42-8 (46 ref.)
Leptin and reproduction. Hoggard N, et al.
Proc Nutr Soc 1998 Aug;57(3):421-7 (38 ref.)
The evolutionary antecedents to love. Crews D.
Psychoneuroendocrinology 1998 Nov;23(8):751-64 (20 ref.)
Mood disorders and the reproductive cycle: affective disorders during the menopause and premenstrual dysphoric disorder. Haynes P, et al.
Psychopharmacol Bull 1998;34(3):313-8 (57 ref.)
Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Rubinow DR, et al.
Psychopharmacol Bull 1998;34(3):289-90 (10 ref.)
The AT2 receptor: fact, fancy and fantasy. de Gasparo M, et al. **Regul Pept** 1999 May 31;81(1-3):11-24 (154 ref.)
Melatonin and the seasonal control of reproduction. Malpaux B, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):355-66 (75 ref.)
The oxytocin receptor. Kimura T, et al.
Results Probl Cell Differ 1999;26:135-68 (160 ref.)
[The spermogram and the exigencies of quality] Clavert A, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):334-6 (19 ref.) **(Fre)**
[Natural reproduction and assisted reproduction] Testart J. **Ann Biol Clin (Paris)** 1999 May;57(3):325-9 (28 ref.) **(Fre)**
[Melatonin and reproduction in domestic animals] Chemineau P, et al. **C R Seances Soc Biol Fil** 1998;192(4):669-82 (52 ref.) (Eng. Abstr.) **(Fre)**
[Leptin implications in reproduction endocrinology] Pralong FP. **Rev Med Suisse Romande** 1999 Jun;119(6):463-7 (12 ref.) **(Fre)**
[Leptin and human reproduction] Macut D, et al.
Med Pregl 1998 Sep-Oct;51(9-10):410-4 (55 ref.) (Eng. Abstr.) **(Scr)**
[Importance of free radicals during the reproduction cycle] Durán Reyes G, et al. **Ginecol Obstet Mex** 1998 Sep; 66:371-6 (26 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Reproductive aspects of cancer treatment: an update. Kovacs GT, et al. **Med J Aust** 1999 May 17;170(10):495-7 (19 ref.)
Reproductive physiology and treatment-related loss of sex hormone production. Sklar C. **Med Pediatr Oncol** 1999 Jul; 33(1):2-8 (63 ref.)
Reproductive and teratologic effects of low-frequency electromagnetic fields: a review of in vivo and in vitro studies using animal models. Brent RL. **Teratology** 1999 Apr;59(4):261-86 (170 ref.)
Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Brent RL. **Teratology** 1999 Apr;59(4):182-204 (125 ref.)
Intrauterine effects of ultrasound: animal studies. Jensh RP, et al. **Teratology** 1999 Apr;59(4):240-51 (140 ref.)
Changing perspectives on the genetic doubling dose of ionizing radiation for humans, mice, and Drosophila. Neel JV. **Teratology** 1999 Apr;59(4):216-21 (35 ref.)
Intrauterine effects of electromagnetic fields--(low frequency, mid-frequency RF, and microwave): review of epidemiologic studies. Robert E. **Teratology** 1999 Apr; 59(4):292-8 (75 ref.)

REPRODUCTION, ASEXUAL

see related
CLONING, ORGANISM

PHYSIOLOGY

Cell adhesion in the process of asexual reproduction of tunicates. Kawamura K, et al. **Microsc Res Tech** 1999 Feb 15;44(4):269-78 (70 ref.)

REPRODUCTION TECHNIQUES

New technology and new challenges for assisted reproduction [clinical conference] Falcone T.
Cleve Clin J Med 1999 Feb;66(2):78-82 (8 ref.)
Fertility in perimenopausal women. Cohen MA, et al.
Clin Obstet Gynecol 1998 Dec;41(4):958-65 (32 ref.)
Endometriosis and assisted reproductive technologies. Dokras A, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):687-98 (52 ref.)
Freezing of oocytes. Porcu E. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):297-300 (44 ref.)
Assisted reproduction for testicular failure: management of germ cell maturation arrest. Tesarik J, et al.
Curr Opin Obstet Gynecol 1999 Jun;11(3):283-8 (48 ref.)
Assisted reproductive technology in the United States: 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. **Fertil Steril** 1999 May;71(5):798-807 (03 ref.)
Ovarian markers of implantation potential in assisted reproduction. Gregory L. **Hum Reprod** 1998 Dec;13 Suppl 4:117-32 (38 ref.)
Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART). Quantification of risks as part of informed consent. Kemmann E. **Hum Reprod** 1998 Jul; 13(7):1777 (3 ref.)
The management of genetic origins: secrecy and openness in donor assisted conception in Israel and elsewhere. Landau R. **Hum Reprod** 1998 Nov;13(11):3268-73 (30 ref.)
Assisted reproduction for the treatment of azoospermia. Safran A, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:47-60 (54 ref.)
The application of co-culture in assisted reproduction: 10 years of experience with human embryos. Wiemer KE, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:226-38 (37 ref.)
Hyperactivated motility of human spermatozoa: a review of physiological function and application in assisted reproduction. Kay VJ, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):776-86 (128 ref.)
Iatrogenic multiple birth, multiple pregnancy and assisted reproductive technologies. Keith L, et al.
Int J Gynaecol Obstet 1999 Jan;64(1):11-25 (48 ref.)
Evaluating technologies in reproductive health: case studies of a consumer protection approach. Silver LD, et al.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S75-83 (28 ref.)
Infertility update: use of assisted reproductive technology. Yoshida TM. **J Am Pharm Assoc (Wash)** 1999 Jan-Feb; 39(1):65-72; quiz 103-4 (60 ref.)
Does assisted reproduction make an impact on the identity and self-image of infertile couples? Daniels KR.
J Assist Reprod Genet 1999 Feb;16(2):57-9 (12 ref.)
Does assisted reproduction make an impact on the identity and self-esteem of infertile women during the transition to parenthood? McMahon CA. **J Assist Reprod Genet** 1999 Feb;16(2):59-62 (19 ref.)
Optimizing pure line breeding strategies utilizing reproductive technologies. Meuwissen TH. **J Dairy Sci** 1998 Sep;81 Suppl 2:47-54 (41 ref.)
The commodification of human reproductive materials. Resnik DB. **J Med Ethics** 1998 Dec;24(6):388-93 (21 ref.)
Reproductive technologies 1998: options available for the cancer patient. Pfeifer SM, et al. **Med Pediatr Oncol** 1999 Jul;33(1):34-40 (31 ref.)
Genetic issues in assisted reproductive technology. Ahrens M, et al. **Minn Med** 1998 Oct;81(10):43-7 (15 ref.)
Investigations into the molecular basis of human sperm-egg interactions: what's next? [comment] Benoff S.
Mol Hum Reprod 1998 Oct;4(10):925-8 (85 ref.) Comment on: Mol Hum Reprod 1998 Jun;4(6):523-4. Comment on: Mol Hum Reprod 1998 Jun;4(6):524-5.
Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Lambert A, et al.
Mol Hum Reprod 1998 Jul;4(7):619-29 (116 ref.)
Assisted reproductive techniques--promises and problems. Chew SC, et al. **Singapore Med J** 1999 Apr;40(4):303-9 (87 ref.)
[The potentials for using cocultivation systems in assisted reproductive technologies] Todorov P, et al.
Akush Ginekol (Sofiia) 1998;37(2):43-5 (29 ref.) **(Bul)**
[Natural reproduction and assisted reproduction] Testart J. **Ann Biol Clin (Paris)** 1999 May;57(3):325-9 (28 ref.) **(Fre)**
[Preimplantation genetic diagnosis] Reubinoff BE, et al.
Harefuah 1998 Sep;135(5-6):202-8 (43 ref.) **(Heb)**

ADVERSE EFFECTS

Human assisted conception: a cautionary tale. Lessons from domestic animals. Leese HJ, et al. **Hum Reprod** 1998 Dec; 13 Suppl 4:184-202 (84 ref.)
Severe OHSS: An 'epidemic' caused by doctors. Roest J. **Hum Reprod** 1999 Sep;14(9):2183 (4 ref.)
Long-term effects on women of assisted reproduction. Shelley J, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):36-51 (78 ref.)

LEGISLATION & JURISPRUDENCE

Should the use of assisted reproduction techniques be deregulated? The UK experience: options for change. Johnson MH. **Hum Reprod** 1998 Jul;13(7):1769-76 (18 ref.)
The posthumous gift of life: the world according to Kane. Shuster E. **J Contemp Health Law Policy** 1999 Spring; 15(2):401-23 (91 ref.)
Informed consent issues in assisted reproduction. Reame N. **J Obstet Gynecol Neonatal Nurs** 1999 May-Jun;28(3):331-8 (31 ref.)
[Assisted reproduction. Rules and laws. International comparisons] Cohen J, et al. **Contracept Fertil Sex** 1999 Apr;27(4):I-VII (9 ref.) **(Fre)**

NURSING

Culture, conceptive technology, and nursing. Sandelowski M. **Int J Nurs Stud** 1999 Feb;36(1):13-20 (56 ref.)

PSYCHOLOGY

Attitudes towards reproduction in Latin America. Teachings from the use of modern reproductive technologies. Zegers-Hochschild F. **Hum Reprod Update** 1999 Jan-Feb; 5(1):21-5 (5 ref.)
The management of embarrassment and sexuality in health care. Meerabeau L. **J Adv Nurs** 1999 Jun;29(6):1507-13 (55 ref.)
[Adoption and/or reproductive medicine] Steck B.
Ther Umsch 1999 May;56(5):251-9 (45 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Appropriate technology: antenatal care. Lumbiganon P.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S91-5 (29 ref.)

TRENDS

Are we on the verge of a new era in ART? Felberbaum RE, et al. **Hum Reprod** 1998 Jul;13(7):1778-80 (31 ref.)
Is there a future for spermatid injections? Vanderzwalmen P, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:71-84 (48 ref.)
Recent advances in infertility treatment. Session DR, et al.
Minn Med 1998 Oct;81(10):27-32 (17 ref.)
[Cloning: reproductive medicine or breeding program?] Zülicke F. **Wien Med Wochenschr** 1998;148(20):474-7 (42 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Potential of assisted breeding techniques for the conservation of endangered mammalian species in captivity: a review. Bainbridge DR, et al. **Vet Rec** 1998 Aug 8;143(6):159-68 (137 ref.)

REPRODUCTIVE MEDICINE

see related
REPRODUCTION TECHNIQUES

The reproductive system after childhood cancer. Levitt GA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):946-53 (65 ref.)
Improvement of surveillance programs for sexually transmitted infections and related conditions. Mårdh PA.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):136-46 (26 ref.)
The Internet, intranets and reproductive medicine. Jenkins JM. **Hum Reprod** 1999 Mar;14(3):586-9 (9 ref.)
Acupuncture and acupressure. Applications to women's reproductive health care. Beal MW. **J Nurse Midwifery** 1999 May-Jun;44(3):217-30 (57 ref.)
Modeling adverse environmental impacts on the reproductive system. Sussman NB, et al. **J Womens Health** 1999 Mar; 8(2):217-26 (25 ref.)

LEGISLATION & JURISPRUDENCE

Legal issues in reproductive health care for adolescents. English A, et al. **Adolesc Med** 1999 Jun;10(2):181-94, v (55 ref.)
Human rights and abortion laws. Cook RJ, et al.
Int J Gynaecol Obstet 1999 Apr;65(1):81-7 (50 ref.)

METHODS

Evaluating technologies in reproductive health: case studies of a consumer protection approach. Silver LD, et al.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S75-83 (28 ref.)

ORGANIZATION & ADMINISTRATION

IAMANEH and the new concept of reproductive health. International Association for Maternal and Neonatal Health. Pinotti JA, et al. **Int J Gynaecol Obstet** 1998 Dec; 63 Suppl 1:S3-12 (14 ref.)
When is research participatory? Reflections on a reproductive health project in Brazil. Diaz M, et al.
J Womens Health 1999 Mar;8(2):175-84 (12 ref.)

STANDARDS

Limitations of current surveillance programs for sexually transmitted infections and allied conditions affecting reproductive health care. Mårdh PA.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):147-54 (11 ref.)
The midwife and her functions by level of care. Segovia I. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S61-6 (10 ref.)

TRENDS

Reproductive endocrinology: quo vadis? Scientific, social, ethical and economic challenges. Lunenfeld B, et al.
Gynecol Endocrinol 1998 Dec;12(6):371-9 (24 ref.)

REPTILES

Reptiles as models of contaminant-induced endocrine disruption. Crain DA, et al. **Anim Reprod Sci** 1998 Oct; 53(1–4):77–86 (54 ref.)

The evolution of dinosaurs. Sereno PC. **Science** 1999 Jun 25;284(5423):2137–47 (91 ref.)

METABOLISM

Energetics of free-ranging mammals, reptiles, and birds. Nagy KA, et al. **Annu Rev Nutr** 1999;19:247–77 (173 ref.)

The microsomal mixed function oxidase system of amphibians and reptiles: components, activities and induction. Ertl RP, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Nov;121(1–3):85–105 (108 ref.)

PHYSIOLOGY

Temperature-dependent sex determination and gonadal differentiation in reptiles. Pieau C, et al.
Cell Mol Life Sci 1999 Jun;55(6–7):887–900 (92 ref.)

RESCUE WORK

see related
RELIEF WORK

More expanded scope: operational EMS [editorial; comment] Bogucki MS. **Prehosp Emerg Care** 1998 Oct–Dec; 2(4):330–3 (23 ref.) Comment on: Prehosp Emerg Care 1998 Oct–Dec;2(4):280–4.

METHODS

Rescue and salvage of casualties suffering from the crush syndrome after mass disasters. Better OS. **Mil Med** 1999 May;164(5):366–9 (24 ref.)

RESEARCH

see related
DENTAL RESEARCH
INFORMATION SERVICES
NURSING RESEARCH
SYSTEMS ANALYSIS

Problem-solving for better health: literature as a resource. Akhigbe F. **Afr J Med Med Sci** 1997 Sep–Dec; 26(3–4):205–8 (21 ref.)

Breathing freely: the need for asthma research on gene–environment interactions [editorial] Miller RL.
Am J Public Health 1999 Jun;89(6):819–22 (41 ref.)

Priorities for research in emergency medical services for children: results of a consensus conference [see comments] Seidel JS, et al. **Ann Emerg Med** 1999 Feb;33(2):206–10 (9 ref.) Comment in: Ann Emerg Med 1999 Feb;33(2):214–7.

Life beyond eradication: veterinary viruses in basic science. Enquist LW. **Arch Virol Suppl** 1999;15:87–109 (67 ref.)

North–South research partnerships: the ethics of carrying out research in developing countries. Edejer TT. **BMJ** 1999 Aug 14;319(7207):438–41 (35 ref.)

Translational research: walking the bridge between idea and cure—seventeenth Bruce F. Cain Memorial Award lecture. Chabner BA, et al. **Cancer Res** 1998 Oct 1;58(19):4211–6 (66 ref.)

Genetic research stimulates development of individual treatment. Kluft C. **Cardiologia** 1999 Feb;44(2):119–24 (25 ref.)

The connection between basic research and clinical practice. Bianca M, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:87–91 (24 ref.)

Ultrasound-assisted lipoplasty. Basic science and clinical research. Kenkel JM, et al. **Clin Plast Surg** 1999 Apr; 26(2):221–34; vii (35 ref.)

Advanced laboratory techniques at the Armed Forces Institute of Pathology applicable to diagnosis and research in dermatology. Skelton HG, et al. **Dermatol Clin** 1999 Jan; 17(1):125–34, ix (53 ref.)

Doing research in general practice: advice for the uninitiated. Pierce M. **Diabet Med** 1998 Nov;15 Suppl 3:S25–8 (7 ref.)

Scientific thinking in ophthalmology. Abraham C.
Indian J Ophthalmol 1998 Jun;46(2):105–8 (47 ref.)

The conflict-prone nature of occupational health research and practice. Nemery B. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):35–7 (12 ref.)

Mechanism-based screening: discovery of the next generation of anthelmintics depends upon more basic research. Geary TG, et al. **Int J Parasitol** 1999 Jan;29(1):105–12; discussion 113–4 (40 ref.)

Cause of death in clinical research: time for a reassessment? Lauer MS, et al. **J Am Coll Cardiol** 1999 Sep;34(3):618–20 (17 ref.)

Livestock improvement: art, science, or industry? Harris DL. **J Anim Sci** 1998 Sep;76(9):2294–302 (34 ref.)

Animats: computer-simulated animals in behavioral research. Watts JM. **J Anim Sci** 1998 Oct;76(10):2596–604 (50 ref.)

Understanding and using confidence intervals in clinical research. Visintainer PF, et al. **J Matern Fetal Med** 1998 Jul–Aug;7(4):201–6 (18 ref.)

Selecting subjects for participation in clinical research: one sphere of justice. Weijer C. **J Med Ethics** 1999 Feb; 25(1):31–6 (34 ref.)

Utility and importance of gene knockout animals for nutritional and metabolic research. Hui DY. **J Nutr** 1998 Nov;128(11):2052–7 (63 ref.)

Reflections of thrombosis research in Oklahoma City—1975 to the present. Green R. **J Okla State Med Assoc** 1999 Mar;92(3):131–9 (9 ref.)

Informed consent in school health research: why, how, and making it easy. Ross JG, et al. **J Sch Health** 1999 May; 69(5):171–6 (14 ref.)

Critical review: synthesis and recommendations for research, education, and policy [comment] Kivett VR.
J Women Aging 1998;10(4):81–90 (17 ref.) Comment on: J Women Aging 1998 ;10(4):7–24. Comment on: J Women Aging 1998 ;10(4):25–39. Comment on: J Women Aging 1998 ;10(4):41–65. Comment on: J Women Aging 1998 ;10(4):67–80.

Survey research methods. Calder J. **Med Educ** 1998 Nov; 32(6):638–52 (13 ref.)

In situ transmission electron microscopy employed for studies of effects of ion and electron irradiation on materials. Allen CW, et al. **Microsc Res Tech** 1998 Aug 15;42(4):255–9 (16 ref.)

Applications of telomerase research in the fight against cancer. McKenzie KE, et al. **Mol Med Today** 1999 Mar; 5(3):114–22 (65 ref.)

Recent advances in GABA research. Kardos J.
Neurochem Int 1999 May;34(5):353–8 (86 ref.)

A research programme for testing the biological homology concept. Wagner GP. **Novartis Found Symp** 1999; 222:125–34; discussion 134–40 (50 ref.)

Your research: how to get it on paper and in print [see comments] Griscom NT. **Pediatr Radiol** 1999 Feb; 29(2):81–6 (12 ref.) Comment in: Pediatr Radiol 1999 Feb;29(2):79.

Research in pediatric radiology: preparing for our future. Strife JL, et al. **Pediatr Radiol** 1998 Aug;28(8):563–8 (13 ref.)

Clinical research in medical schools: seizing the opportunity. Meyer RE, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec; 110(6):513–20 (18 ref.)

New understanding in obesity research. James WP, et al. **Proc Nutr Soc** 1999 May;58(2):385–93 (77 ref.)

Australia's role in training and research in tropical medicine. Leggat PA. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):311–5 (22 ref.)

National Institutes of Health (USA): role in tropical medicine research. Western KA.
Southeast Asian J Trop Med Public Health 1998 Jun; 29(2):316–8 (0 ref.)

A report from the Second International Forum for Primary Care Research on Low Back Pain. Reexamining priorities. Borkan JM, et al. **Spine** 1998 Sep 15;23(18):1992–6 (8 ref.)

The role of science in medicine. Nordin I.
Theor Med Bioeth 1999 Jun;20(3):229–44 (18 ref.)

Ions in the fire: recent ion–channel research and approaches to pain therapy. Eglen RM, et al.
Trends Pharmacol Sci 1999 Aug;20(8):337–42 (45 ref.)

[Prevention and research on prevention seen from a perspective of health policy] Iversen L. **Ugeskr Laeger** 1998 Nov 16;160(47):6795–9 (11 ref.) **(Dan)**

[Publications] Skjaerbaek CB. **Ugeskr Laeger** 1999 Aug 16; 161(33):4644–6 (0 ref.) **(Dan)**

[Survey of 50 years of veterinary remedy provision in the Netherlands] van den Bos T. **Tijdschr Diergeneeskd** 1998 Dec 15;123(24):743–8 (31 ref.) (Eng. Abstr.) **(Dut)**

[Cystic fibrosis: a complex disease and a paradigm for biomedical research] Tirouvanziam R. **J Soc Biol** 1999; 193(2):189–209 (180 ref.) (Eng. Abstr.) **(Fre)**

[Acting on clinical trials. Experience of organizations for the fight against AIDS] Barbot J.
Rev Epidemiol Sante Publique 1998 Sep;46(4):305–15 (37 ref.) (Eng. Abstr.) **(Fre)**

[Paradigms and pragmatism] Healy MJ.
Rev Epidemiol Sante Publique 1999 Apr;47(2):185–9 (16 ref.) **(Fre)**

[Migration and pain. Need for epidemiologic research] Moser J. **Rev Med Suisse Romande** 1999 Apr;119(4):265–7 (11 ref.) **(Fre)**

[Autopsy: overlap of teaching and medical research (editorial)] Giarelli L, et al. **Pathologica** 1998 Aug; 90(4):343–50 (14 ref.) **(Ita)**

[Medical research on patients' experiences—structured questionnaires result in worthless answers] Kirkengen AL. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3449–52 (20 ref.) (Eng. Abstr.) **(Nor)**

[Children as medical research subjects] Ruyter KW, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20;119(19):2833–7 (20 ref.) (Eng. Abstr.) **(Nor)**

[Use of the quality of life concept in medical research—useful or useless?] Wyller TB. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4247–51 (41 ref.) **(Nor)**

[Ethic aspects of conducting physiological–hygienic and psychological studies on human subjects as applied to the activities in extreme environments] Genin AM, et al.
Aviakosm Ekolog Med 1998;32(6):50–5 (4 ref.) (Eng. Abstr.) **(Rus)**

[Stable oxygen and carbon isotopes in biological studies] Nazarov NM. **Aviakosm Ekolog Med** 1999;33(1):3–10 (62 ref.) (Eng. Abstr.) **(Rus)**

[Palliative medicine. A new research field with specific demands] Strang P. **Lakartidningen** 1999 Jan 6;96(1–2):26–9 (15 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

The changing landscape for clinical research [published erratum appears in Acad Med 1999 Sep;74(9):950] Heinig SJ, et al. **Acad Med** 1999 Jun;74(6):726–45 (42 ref.)

EDUCATION

The clinician investigator: An endangered species. Roy CC, et al. **Can J Gastroenterol** 1999 May;13(4):339–43 (18 ref.)

The involvement of genome researchers in high school science education. Munn M, et al. **Genome Res** 1999 Jul; 9(7):597–607 (23 ref.)

[Training of high-skilled researchers at the Saint-Petersburg Research Institute of Phtisiopulmonology in 1994–1998] Vinogradova TI. **Probl Tuberk** 1999;(3):50–2 (0 ref.) (Eng. Abstr.) **(Rus)**

[Medical education and research] Ricoy JR, et al.
Med Clin (Barc) 1999 Feb 27;112(7):259–63 (42 ref.) **(Spa)**

HISTORY

"The Queen has been dreadfully shocked": aspects of teaching experimental physiology using animals in Britain, 1876–1986. Tansey EM. **Am J Physiol** 1998 Jun;274(6 Pt 2):S18–33 (26 ref.)

An historical perspective on atherosclerosis research in Germany [editorial] Siegel G. **Atherosclerosis** 1999 May; 144(1):1–6 (45 ref.)

Platypus research 1798–1998. Griffiths M.
Philos Trans R Soc Lond B Biol Sci 1998 Jul 29; 353(1372):1059–61 (19 ref.)

LEGISLATION & JURISPRUDENCE

Waived consent for emergency research. Fost N.
Am J Law Med 1998;24(2–3):163–83 (144 ref.)

Research with children. Glantz LH. **Am J Law Med** 1998; 24(2–3):213–44 (332 ref.)

Do the dead have interests? Policy issues for research after life. Nelkin D, et al. **Am J Law Med** 1998;24(2–3):261–91 (288 ref.)

The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL.
J Health Polit Policy Law 1999 Jun;24(3):531–65 (35 ref.)

METHODS

Patient education and diabetes research: a failure! Going beyond the empirical approaches. Albano MG, et al.
Acta Diabetol 1998 Dec;35(4):207–14 (21 ref.)

Making sense of the results of your research [see comments] Mant A. **Aust Fam Physician** 1998 Aug;27(8):699–701 (2 ref.) Comment in: Aust Fam Physician 1998 Nov;27(11):991. Comment in: Aust Fam Physician 1999 Apr;28(4):311.

Estimating and generalizing with clustered sampling in general practice. Sayer GP. **Aust Fam Physician** 1999 Jan; 28 Suppl 1:S32–4 (8 ref.)

Biomarkers in environmental health research & practice. Links JM, et al. **Drug Chem Toxicol** 1999 Feb;22(1):1–14 (32 ref.)

Qualitative research methods in health technology assessment: a review of the literature. Murphy E, et al. **Health Technol Assess** 1998;2(16):iii–ix, 1–274 (785 ref.)

When is research participatory? Reflections on a reproductive health project in Brazil. Diaz M, et al.
J Womens Health 1999 Mar;8(2):175–84 (12 ref.)

Low-level chemical sensitivity: implications for research and social policy. Ashford NA. **Toxicol Ind Health** 1999 Apr–Jun;15(3–4):421–7 (27 ref.)

[The practice of systematic reviews. III. Evaluation of methodological quality of research studies] Assendelft WJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):714–9 (37 ref.) (Eng. Abstr.) **(Dut)**

[Methods for vascular exploration in man: microcirculation and veins] Carpentier PH. **Therapie** 1999 May–Jun; 54(3):369–74 (30 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Competence in scientific inquiry and research. Abreu BC, et al. **Am J Occup Ther** 1998 Oct;52(9):751–9 (61 ref.)

Research linkages between academia and public health practice. Building a prevention research agenda. Lane DS. **Am J Prev Med** 1999 Apr;16(3 Suppl):7–9 (7 ref.)

Using case research to enhance linkages between academia and public health practice. Liang AP, et al.
Am J Prev Med 1999 Apr;16(3 Suppl):12–3 (11 ref.)

Croatian institute for brain research: bridging the gap from the decade of the brain to the next millenium. Judaš MM.
Croat Med J 1998 Dec;39(4):383–5 (3 ref.)

Research ethics in emergency medicine. Fish SS.
Emerg Med Clin North Am 1999 May;17(2):461–74, xii (21 ref.)

Occupational cancer research in the Nordic countries. Kjaerheim K. **Environ Health Perspect** 1999 May;107 Suppl 2:233–8 (113 ref.)

Research in developing countries: taking "benefit" seriously. Glantz LH, et al. **Hastings Cent Rep** 1998 Nov–Dec; 28(6):38–42 (18 ref.)

The role of information dissemination in sustainability of international partnerships. Delclos GL, et al.
Int J Occup Environ Health 1999 Jul–Sep;5(3):203–8 (14

ref.)
Clinical research in aboriginal health [editorial] Torzillo PJ. **J Paediatr Child Health** 1999 Apr;35(2):123–4 (5 ref.)
Clinical research in surgery: questions but few answers. Beger HG, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):300–5 (55 ref.)
Conceptional and structural conditions for successful clinical research. Troidl H. **Langenbecks Arch Surg** 1998 Oct; 383(5):306–16 (30 ref.)
Priorities for patient-centered research. Feussner JR. **Med Care** 1999 Sep;37(9):843–5 (11 ref.)
Biomedical research: its mission within the French Military Medical Service. Binder P. **Mil Med** 1999 May; 164(5):341–5 (29 ref.)
Gender matters: an integrated model for understanding men's and women's health. Bird CE, et al. **Soc Sci Med** 1999 Mar;48(6):745–55 (51 ref.)
[Need to establish academic research organization for cancer clinical trial and clinical research system having clinical investigators and study coordinators, with special reference to promotion of medical and life science research policy] Shimoyama M. **Gan To Kagaku Ryoho** 1999 Jan;26(2 Suppl):235–46 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of research—reality and illusions] Sawicki W. **Postepy Hig Med Dosw** 1998;52(3):297–305 (11 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Research fundamentals VI: misconduct in biomedical research. Biros MH, et al. **Acad Emerg Med** 1999 Aug; 6(8):840–8 (35 ref.)
Misconduct in clinical research--the Scandinavian experience and actions for prevention. Riis P. **Acta Oncol** 1999;38(1):89–92 (12 ref.)
Research misconduct in clinical research--the American experience and response. Ryan KJ. **Acta Oncol** 1999; 38(1):93–7 (19 ref.)
Impact factors: use and abuse in biomedical research. Coleman R. **Anat Rec** 1999 Apr 15;257(2):54–7 (13 ref.)
Science/industry: problematics of the European cooperative research in the biomaterials/biodevices area. Doddoli R. **Biomaterials** 1998 Aug;19(16):1433–9 (5 ref.)
Culturally competent research: an ethical perspective. Gil EF, et al. **Clin Psychol Rev** 1999 Jan;19(1):45–55 (27 ref.)
Bioethics for clinicians: 17. Conflict of interest in research, education and patient care [see comments] Lemmens T, et al. **CMAJ** 1998 Oct 20;159(8):960–5 (36 ref.) Comment in: CMAJ 1999 Mar 23;160(6):784.
The new biotech world order. Cahill LS. **Hastings Cent Rep** 1999 Mar-Apr;29(2):45–8 (9 ref.)
Research with human embryonic stem cells: ethical considerations. By Geron Ethics Advisory Board. Mendiola MM, et al. **Hastings Cent Rep** 1999 Mar-Apr; 29(2):31–6 (26 ref.)
Maintaining client safety and scientific integrity in research with battered women. Lutz KF. **Image J Nurs Sch** 1999; 31(1):89–93 (40 ref.)
Qigong and hypertension: a critique of research. Mayer M. **J Altern Complement Med** 1999 Aug;5(4):371–82 (90 ref.)
Making progress: does clinical research lead to breakthroughs in basic biomedical sciences? Gershon ES. **Perspect Biol Med** 1998 Autumn;42(1):95–102 (14 ref.)
Consent (assent) for research with pediatric patients. Broome ME. **Semin Oncol Nurs** 1999 May;15(2):96–103 (23 ref.)
The ethical foundation of informed consent in clinical research. McCabe MS. **Semin Oncol Nurs** 1999 May; 15(2):76–80 (18 ref.)
National efforts to improve the informed consent process. Padberg RM, et al. **Semin Oncol Nurs** 1999 May; 15(2):138–44 (16 ref.)
Barriers to informed consent. Taylor HA. **Semin Oncol Nurs** 1999 May;15(2):89–95 (35 ref.)
Two challenges for research ethics: innovative treatment and fetal therapy [comment] Gates E. **Womens Health Issues** 1999 Jul-Aug;9(4):208–10 (14 ref.) Comment on: Womens Health Issues 1999 Jul-Aug;9(4):194–8.
[The practice of systematic reviews. III. Evaluation of methodological quality of research studies] Assendelft WJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):714–9 (37 ref.) (Eng. Abstr.) **(Dut)**
[Microbiological standardization of laboratory animals] Nicklas W. **Berl Munch Tierarztl Wochenschr** 1999 Jun-Jul; 112(6–7):201–10 (23 ref.) (Eng. Abstr.) **(Ger)**
[The impact factor as an assessment criterion of scientific achievements--the right to equal chances] Lehrl S. **Strahlenther Onkol** 1999 Apr;175(4):141–53 (61 ref.) (Eng. Abstr.) **(Ger)**
[The regulation of experiments on animals--ethics, legislation and alternatives] Kopaladze RA. **Usp Fiziol Nauk** 1998 Oct-Dec;29(4):74–92 (115 ref.) (Eng. Abstr.) **(Rus)**
[The publication in biomedical journals of clinical trial protocols: a new way to improve research quality (editorial)] Bosch X. **Rev Esp Cardiol** 1999 May; 52(5):359–61 (29 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Nonselection and nonresponse bias in clinical research [see comments] Roush JK. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1270–3 (21 ref.) Comment in: J Am Vet Med Assoc 1999 Jan 1;214(1):27–8.
Productivity of SCI Korean medical papers: 1996–1997. Lee CS. **J Korean Med Sci** 1999 Aug;14(4):351–8 (20 ref.)
Bibliometric methods for the evaluation of arthritis research. Lewison G, et al. **Rheumatology (Oxford)** 1999 Jan; 38(1):13–20 (28 ref.)
[Testing, estimating, "significance"—concepts and terminology of medical biometry] Koch A, et al. **Med Klin** 1999 Jul 15;94(7):407–13 (4 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

The changing landscape for clinical research [published erratum appears in Acad Med 1999 Sep;74(9):950] Heinig SJ, et al. **Acad Med** 1999 Jun;74(6):726–45 (42 ref.)
Recent progress in mycotoxin research. Varga J, et al. **Acta Microbiol Immunol Hung** 1999;46(2–3):233–43 (65 ref.)
Trends in the content and methodology of Alzheimer caregiving research. Drebing CE. **Alzheimer Dis Assoc Disord** 1999 Apr-Jun;13 Suppl 1:S93–100 (32 ref.)
Future cardiovascular end point studies: where will the research take us? [editorial] LaRosa JC. **Am J Cardiol** 1999 Aug 15;84(4):454–8 (42 ref.)
Breast cancer practice patterns at VA hospitals: implications for future research. Hynes DM, et al. **Cancer Treat Res** 1998;97:149–58 (28 ref.)
The future of clinical cancer research in the next millennium. Freireich EJ. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2563–70 (23 ref.)
Foundations of clinical cancer research: perspective for the 21st century. Hersh EM. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2551–3 (30 ref.)
Research advances in oral mucositis. Peterson DE. **Curr Opin Oncol** 1999 Jul;11(4):261–6 (31 ref.)
Introduction: Epidemiologic research and prevention of occupational cancer in Europe. Boffetta P, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:229–31 (19 ref.)
The National Eye Institute outlines eye research goals. **J Am Optom Assoc** 1999 May;70(5):317–36 (0 ref.)
Assessing quality of life in clinical research: from where have we come and where are we going? Wood-Dauphinee S. **J Clin Epidemiol** 1999 Apr;52(4):355–63 (108 ref.)
The sexual revolution in science: what gender-based research is telling us. Thompson PM, et al. **J Investig Med** 1999 Mar;47(3):106–13 (40 ref.)
Quo vadis? The future of basic research in orthopedics in Japan [editorial] Hirotani H. **J Orthop Sci** 1999;4(1):1–4 (16 ref.)
The contribution of avian models to our understanding of atherosclerosis and their promise for the future. St Clair RW. **Lab Anim Sci** 1998 Dec;48(6):565–8 (36 ref.)
Urinary biomarkers: recommendations of the Joint European/United States Workshop for future research. Finn WF, et al. **Ren Fail** 1999 May-Jul;21(3–4):445–51 (18 ref.)
The promise of a multiple roles paradigm for women's health research [editorial] Repetti RL. **Womens Health** 1998 Winter;4(4):273–80 (32 ref.)
[Scientific and technological innovations in the search for new drugs] Hélène C. **C R Acad Sci III** 1999 Jul; 322(7):529–36 (15 ref.) **(Fre)**
[Progress achieved in the prevention and therapy of Alzheimer's disease] Stähelin HB. **Rev Med Suisse Romande** 1999 Apr;119(4):319–22 (19 ref.) **(Fre)**

RESEARCH, CLINICAL NURSING see **CLINICAL NURSING RESEARCH**

RESEARCH, DENTAL see **DENTAL RESEARCH**

RESEARCH DESIGN

Recent trends and controversies in industry-sponsored clinical trials. Reed CR, et al. **Acad Emerg Med** 1999 Aug; 6(8):833–9 (37 ref.)
Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S–759S (37 ref.)
The controversy of significance testing: misconceptions and alternatives. Glaser DN. **Am J Crit Care** 1999 Sep; 8(5):291–6 (43 ref.)
Number needed to treat: solid science or a path to pernicious rationing? Black HR, et al. **Am J Hypertens** 1998 Aug;11(8 Pt 2):128S–134S; discussion 135S–137S (30 ref.)
Randomized clinical trials in medical rehabilitation research. Tate DG, et al. **Am J Phys Med Rehabil** 1999 Sep-Oct; 78(5):486–99 (67 ref.)
Use of sequential medical trials in rehabilitation research. Tooth L. **Am J Phys Med Rehabil** 1999 Jan-Feb; 78(1):87–97 (18 ref.)
Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al. **Ann Occup Hyg** 1999 Jul;43(5):367–76 (15 ref.)
An emancipatory impulse: a feminist postmodern integrated turning point in nursing research. Glass N, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):43–52 (45 ref.)
Womanism: a methodologic framework for African American women. Taylor JY. **ANS Adv Nurs Sci** 1998 Sep; 21(1):53–64 (60 ref.)
ABC of intensive care: outcome data and scoring systems. Gunning K, et al. **BMJ** 1999 Jul 24;319(7204):241–4 (0 ref.)
Influence of study design on reported mortality and morbidity rates after abdominal aortic aneurysm repair. Blankensteijn JD, et al. **Br J Surg** 1998 Dec;85(12):1624–30 (86 ref.)
Prenatal factors and adult mental and physical health [see comments] Susser EB, et al. **Can J Psychiatry** 1999 May; 44(4):326–34 (79 ref.) Comment in: Can J Psychiatry 1999 May;44(4):325.
Bone repair and enhancement clinical trial design. Spine applications. Boden SD. **Clin Orthop** 1998 Oct;(355 Suppl):S336–46 (48 ref.)
Proper design of clinical trials for the assessment of bone graft substitutes. Cornell CN. **Clin Orthop** 1998 Oct;(355 Suppl):S347–52 (18 ref.)
Population pharmacokinetics. A regulatory perspective. Sun H, et al. **Clin Pharmacokinet** 1999 Jul;37(1):41–58 (60 ref.)
Clinical trials in acute respiratory distress syndrome: what is ARDS? [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1657–8 (13 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1478–85.
A review of research in the United Kingdom to evaluate the implementation of clinical guidelines in general practice. Dowie R. **Fam Pract** 1998 Oct;15(5):462–70 (34 ref.)
Ethical issues in the design and conduct of randomised controlled trials. Edwards SJ, et al. **Health Technol Assess** 1998 Dec;2(15):i–vi, 1–132 (620 ref.)
Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Habicht JP, et al. **Int J Epidemiol** 1999 Feb;28(1):10–8 (20 ref.)
Case-case comparisons to study causation of common infectious diseases. McCarthy N, et al. **Int J Epidemiol** 1999 Aug;28(4):764–8 (24 ref.)
Induction versus Popper: substance versus semantics [letter] Pavesi M. **Int J Epidemiol** 1999 Apr;28(2):360–1 (7 ref.)
Pre-operative education--a review of the research design. Shuldham C. **Int J Nurs Stud** 1999 Apr;36(2):179–87 (61 ref.)
Establishing the credibility of qualitative research findings: the plot thickens. Cutcliffe JR, et al. **J Adv Nurs** 1999 Aug; 30(2):374–80 (43 ref.)
Randomized controlled trials of individualized homeopathy: a state-of-the-art review [see comments] Linde K, et al. **J Altern Complement Med** 1998 Winter;4(4):371–88 (50 ref.) Comment in: J Altern Complement Med 1998 Winter;4(4):355–7.
Dietary Approaches to Stop Hypertension: rationale, design, and methods. DASH Collaborative Research Group. Vogt TM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S12–8 (60 ref.)
Eye Movement Desensitization and Reprocessing: an analysis of specific versus nonspecific treatment factors. Lohr JM, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1–2):185–207 (133 ref.)
Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Calabrese JR, et al. **J Clin Psychiatry** 1999;60 Suppl 5:5–13; discussion 14–5 (42 ref.)
Effect of cognitive rehabilitation on outcomes for persons with traumatic brain injury: A systematic review [see comments] Carney N, et al. **J Head Trauma Rehabil** 1999 Jun;14(3):277–307 (45 ref.) Comment in: J Head Trauma Rehabil 1999 Jun;14(3):308–11; discussion 322–4. Comment in: J Head Trauma Rehabil 1999 Jun;14(3):312–5; discussion 322–4. Comment in: J Head Trauma Rehabil 1999 Jun;14(3):316–21; discussion 322–4.
Special considerations in design of trials with elderly subjects: unexplained weight loss, body composition and energy expenditure. Poehlman ET. **J Nutr** 1999 Jan;129(1S Suppl):260S–263S (25 ref.)
Special considerations in the design of trials involving children. Underwood LE. **J Nutr** 1999 Jan;129(1S Suppl):264S–269S (18 ref.)
Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):518–28 (41 ref.)
Conceptional and structural conditions for successful clinical research. Troidl H. **Langenbecks Arch Surg** 1998 Oct; 383(5):306–16 (30 ref.)
Using single-subject methodology to investigate psychiatric treatments in systemic lupus erythematosus. Iverson GL, et al. **Lupus** 1998;7(5):295–300 (31 ref.)
Quality of life in clinical trials: assessment and utility with special reference to rHuEPO. Brandberg Y. **Med Oncol** 1998 Aug;15 Suppl 1:S8–12 (30 ref.)
Failure to adequately use positive control data leads to poor quality mouse lymphoma data assessments. Moore MM, et al. **Mutagenesis** 1999 May;14(3):261–3 (19 ref.)
Relating clinical study design to basic research. Choh V, et al. **Optom Vis Sci** 1999 Jul;76(7):462–7 (10 ref.)
Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: impact of processing techniques and study methodology. Russell JL, et al. **Orthopedics** 1999 May;22(5):524–31; quiz 532–3 (79 ref.)
Questionnaires: the use and abuse of social survey methods in medical research. Eaden J, et al. **Postgrad Med J** 1999 Jul;75(885):397–400 (36 ref.)
Simulation studies: a new method of prospective technology

assessment and design. Kumbruck C, et al. **Qual Life Res** 1999;8(1-2):161-70 (10 ref.)
Time and qualitative research. Sandelowski M. **Res Nurs Health** 1999 Feb;22(1):79-87 (31 ref.)
Bioaerosols in ambient air particulates: a review and research needs. Monn C, et al. **Rev Environ Health** 1999 Apr-Jun; 14(2):79-89 (56 ref.)
Prostate cancer and black men. Brawley OW. **Semin Urol Oncol** 1998 Nov;16(4):184-6 (25 ref.)
[Roaming through methodology. IV. Causality] van Gijn J, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1;142(31):1765-7 (2 ref.) (Eng. Abstr.) **(Dut)**
[Roaming through methodology. XV. Smoking grandfathers and other selection biases] van Gijn J, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1515-7 (7 ref.) (Eng. Abstr.) **(Dut)**
[Chemoprevention of breast cancer by tamoxifen: should we still ask this question?] Sasco AJ. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):279-85 (20 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Alcohol administration methodology 1994-1995: what researchers do and do not report about subjects and dosing procedures. Breslin FC, et al. **Addict Behav** 1999 Jul-Aug; 24(4):509-20 (108 ref.)
A perspective on the regulation of the evaluation of new antithrombotic drugs. Califf RM. **Am J Cardiol** 1998 Oct 22;82(8B):25P-35P (32 ref.)
Occupational cancer among women: research status and methodologic considerations. Blair A, et al. **Am J Ind Med** 1999 Jul;36(1):6-17 (42 ref.)
Case studies, single-subject research, and N of 1 randomized trials: comparisons and contrasts. Backman CL, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr;78(2):170-6 (22 ref.)
Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Wells KB. **Am J Psychiatry** 1999 Jan;156(1):5-10 (42 ref.)
The emerging importance of genetics in epidemiologic research II. Issues in study design and gene mapping. Ellsworth DL, et al. **Ann Epidemiol** 1999 Feb;9(2):75-90 (54 ref.)
A critical evaluation of the methodology of the literature on medication compliance. Nichol MB, et al. **Ann Pharmacother** 1999 May;33(5):531-40 (72 ref.)
Combining stories and numbers: a methodologic approach for a critical nursing science. Berman H, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):1-15 (51 ref.)
Usage centred research for everyday product design. Kanis H. **Appl Ergon** 1998 Feb;29(1):75-82 (21 ref.)
Methodological issues in evaluating Rorschach validity: a comment on Burns and Viglione (1996), Weiner (1996), and Ganellen (1996). Wood JM, et al. **Assessment** 1999 Jun; 6(2):115-29 (79 ref.)
Outcome measures in multiple sclerosis clinical trials. Andersson PB, et al. **Baillieres Clin Neurol** 1997 Oct; 6(3):409-28 (75 ref.)
Qualitative studies. Their role in medical research. Huston P, et al. **Can Fam Physician** 1998 Nov;44:2453-8 (19 ref.)
Environmental selenium and cancer: risk or protection? [editorial; comment] Clark LC, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):847-8; discussion 851-2 (14 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853-6.
Critical appraisal of the health research literature: prevalence or incidence of a health problem. Loney PL, et al. **Chronic Dis Can** 1998;19(4):170-6 (27 ref.)
Augmented enhancement of in vitro production of inflammatory cytokines...[editorial; comment] Dunn DL. **Crit Care Med** 1999 May;27(5):859-60 (10 ref.) Comment on: Crit Care Med 1999 May;27(5):929-36.
Has high-frequency ventilation been inappropriately discarded in adult acute respiratory distress syndrome? [see comments] Herridge MS, et al. **Crit Care Med** 1998 Dec; 26(12):2073-7 (33 ref.) Comment in: Crit Care Med 1998 Dec;26(12):1955-6.
The sirens' songs of confirmatory sepsis trials: selection bias and sampling error [editorial; comment] Natanson C, et al. **Crit Care Med** 1998 Dec;26(12):1927-31 (19 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1963-71.
Explicit guidelines for qualitative research: a step in the right direction, a defence of the 'soft' option, or a form of sociological imperialism? Chapple A, et al. **Fam Pract** 1998 Dec;15(6):556-61 (34 ref.)
Making Medicaid managed care research relevant. Gold M. **Health Serv Res** 1999 Feb;33(6):1639-50 (13 ref.)
Choosing between randomised and non-randomised studies: a systematic review. Britton A, et al. **Health Technol Assess** 1998;2(13):i-iv, 1-124 (204 ref.)
Swan to phoenix: the metamorphosis [editorial] Brandstetter RD, et al. **Heart Lung** 1998 Jul-Aug;27(4):215-7 (21 ref.)
Objectivity in nursing research: observations and objections. Avis M. **Int J Nurs Stud** 1998 Jun;35(3):141-5 (30 ref.)
The power of the word: some post-structural considerations of qualitative approaches in nursing research. Crowe M. **J Adv Nurs** 1998 Aug;28(2):339-44 (22 ref.)
Collecting and analysing qualitative data: issues raised by the focus group. Sim J. **J Adv Nurs** 1998 Aug;28(2):345-52 (53 ref.)
Does EMDR work? And if so, why?: a critical review of controlled outcome and dismantling research. Cahill SP, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):5-33 (72 ref.)
Summary report: evidence for the effectiveness of rehabilitation for persons with traumatic brain injury. Chesnut RM, et al. **J Head Trauma Rehabil** 1999 Apr; 14(2):176-88 (55 ref.)
Imperialism, research ethics and global health [editorial] [see comments] Benatar SR. **J Med Ethics** 1998 Aug;24(4):221-2 (14 ref.) Comment in: J Med Ethics 1999 Feb;25(1):62.
Empirically supported treatments in pediatric psychology: disease-related pain [see comments] Walco GA, et al. **J Pediatr Psychol** 1999 Apr;24(2):155-67; discussion 168-71 (58 ref.) Comment in: J Pediatr Psychol 1999 Apr;24(2):172-4.
Research based on archived information and samples. Recommendations from the Royal College of Physicians Committee on Ethical Issues in Medicine. **J R Coll Physicians Lond** 1999 May-Jun;33(3):264-6 (15 ref.)
Pooling research results: benefits and limitations of meta-analysis. Ioannidis JP, et al. **Jt Comm J Qual Improv** 1999 Sep;25(9):462-9 (41 ref.)
Assessing "best evidence": issues in grading the quality of studies for systematic reviews. Lohr KN, et al. **Jt Comm J Qual Improv** 1999 Sep;25(9):470-9 (36 ref.)
Basic surgical research. Messmer K. **Langenbecks Arch Surg** 1998 Oct;383(5):297-9 (9 ref.)
Mortality among people with mental retardation living in the United States: research review and policy application. Hayden MF. **Ment Retard** 1998 Oct;36(5):345-59 (42 ref.)
Monitoring clinical trials. Sharples K, et al. **N Z Med J** 1998 Aug 28;111(1072):322-5 (22 ref.)
Methodological issues concerning evaluation of treatment for sexual offenders: randomization, treatment dropouts, untreated controls, and within-treatment studies [see comments] McConaghy N. **Sex Abuse** 1999 Jul; 11(3):183-93 (32 ref.) Comment in: Sex Abuse 1999 Jul;11(3):179-81.
Statistical issues in pharmacoepidemiological case-control studies. Ashby D, et al. **Stat Med** 1998 Aug 15-30; 17(15-16):1839-50; discussion 1859-62 (32 ref.)
The management of interim analyses in drug development. Facey KM, et al. **Stat Med** 1998 Aug 15-30; 17(15-16):1801-9; discussion 1811-2 (28 ref.)
Issues for statisticians in pharmaco-economic evaluations. Grieve AP. **Stat Med** 1998 Aug 15-30;17(15-16):1715-23; discussion 1741-3 (17 ref.)
A framework establishing clear decision criteria for the assessment of drug efficacy. Huster WJ, et al. **Stat Med** 1998 Aug 15-30;17(15-16):1829-38 (23 ref.)
Methodological advances and plans for improving regulatory success for confirmatory studies. Koch GG, et al. **Stat Med** 1998 Aug 15-30;17(15-16):1675-90 (41 ref.)
Providing evidence of efficacy for a new drug. Ruberg S, et al. **Stat Med** 1998 Aug 15-30;17(15-16):1813-23; discussion 1825-7 (11 ref.)
Some controversies in planning and analysing multi-centre trials. Senn S. **Stat Med** 1998 Aug 15-30;17(15-16):1753-65; discussion 1799-800 (8 ref.)
Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Feld R. **Support Care Cancer** 1998 Sep; 6(5):444-8 (14 ref.)
Empiric therapy for the febrile neutropenic patient. Design bias. Schimpff SC. **Support Care Cancer** 1998 Sep; 6(5):449-56 (16 ref.)
[The practice of systematic reviews. III. Evaluation of methodological quality of research studies] Assendelft WJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):714-9 (37 ref.) (Eng. Abstr.) **(Dut)**
[Roaming through the methodology. XIV. The premature ending of a randomized trial] Vandenbroucke JP. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1305-8 (6 ref.) (Eng. Abstr.) **(Dut)**
[Roaming through methodology. XIII. Matching as a rule is not useful] Verbeek AL. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1037-40 (7 ref.) (Eng. Abstr.) **(Dut)**
[Observer variability] Burtin P, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):897-905 (14 ref.) **(Fre)**
[Basic principles of clinical trials--what, how, and why?] Unnebrink K, et al. **Med Klin** 1999 Aug 15;94(8):458-64 (15 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Nursing research in Finland from 1958 to 1995. Leino-Kilpi H, et al. **Image J Nurs Sch** 1998;30(4):363-7 (27 ref.)
Study design and data analysis in clinical and environmental models of nephrotoxicity. Mueller PW. **Ren Fail** 1999 May-Jul;21(3-4):337-40 (6 ref.)

TRENDS

Nursing research in Finland from 1958 to 1995. Leino-Kilpi H, et al. **Image J Nurs Sch** 1998;30(4):363-7 (27 ref.)
Genetics and child psychiatry: I Advances in quantitative and molecular genetics. Rutter M, et al. **J Child Psychol Psychiatry** 1999 Jan;40(1):3-18 (485 ref.)
Science, ethics, and the future of research into maternal infant transmission of HIV-1. Perinatal HIV Intervention Research in Developing Countries Workshop participants [see comments] **Lancet** 1999 Mar 6;353(9155):832-5 (23 ref.) Comment in: Lancet 1999 May 29;353(9167):1878; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1878-9; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879-80; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1880-1.

RESEARCH, HEALTH SERVICES see **HEALTH SERVICES RESEARCH**

RESEARCH INSTITUTES see **ACADEMIES AND INSTITUTES**

RESEARCH MISCONDUCT see **SCIENTIFIC MISCONDUCT**

RESEARCH, NURSING see **NURSING RESEARCH**

RESEARCH, NURSING ADMINISTRATION see **NURSING ADMINISTRATION RESEARCH**

RESEARCH, NURSING EVALUATION see **NURSING EVALUATION RESEARCH**

RESEARCH, NURSING METHODOLOGY see **NURSING METHODOLOGY RESEARCH**

RESEARCH PERSONNEL

The involvement of genome researchers in high school science education. Munn M, et al. **Genome Res** 1999 Jul; 9(7):597-607 (23 ref.)

PSYCHOLOGY

On "being inspired" by Husserl's Phenomenology: reflections on Omery's exposition of phenomenology as a method of nursing research. Porter EJ. **ANS Adv Nurs Sci** 1998 Sep; 21(1):16-28 (53 ref.)

STATISTICS & NUMERICAL DATA

The clinician investigator: An endangered species. Roy CC, et al. **Can J Gastroenterol** 1999 May;13(4):339-43 (18 ref.)

RESEARCH PRIORITIES see **RESEARCH**

RESEARCH PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

RESEARCH SUBJECT RECRUITMENT see **PATIENT SELECTION**

RESEARCH SUPPORT

Funding clinical research: the need for information and longer term strategies. Feneley MR, et al. **Ann R Coll Surg Engl** 1999 May;81(3):145-50 (13 ref.)
How to get a grant funded. Goldblatt D. **BMJ** 1998 Dec 12;317(7173):1647-8 (0 ref.)
Prostate cancer research and the National Cancer Institute. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):235-40 (26 ref.)

ORGANIZATION & ADMINISTRATION

Consumer Assessment of Health Plans Study (CAHPS). Foreword. Crofton C, et al. **Med Care** 1999 Mar;37(3 Suppl):MS1-9 (25 ref.)
Ethics committees: is reform in order? [editorial; comment] [see comments] Loblay RH, et al. **Med J Aust** 1999 Jan 4;170(1):9-10 (16 ref.) Comment on: Med J Aust 1999 Jan 4;170(1):26-8. Comment in: Med J Aust 1999 Jul 5;171(1):51-2.
What role can public health institutions play in drug development for the poor? A case study of artesunate. Gomes M, et al. **Med Trop (Mars)** 1998;58(3 Suppl):97-100 (10 ref.)
The business of science and the science of business in the quest for an AIDS vaccine. Hilleman MR. **Vaccine** 1999 Mar 5;17(9-10):1211-22 (52 ref.)

TRENDS

Recent trends and controversies in industry-sponsored clinical trials. Reed CR, et al. **Acad Emerg Med** 1999 Aug; 6(8):833-9 (37 ref.)
The changing landscape for clinical research [published erratum appears in Acad Med 1999 Sep;74(9):950] Heinig SJ, et al. **Acad Med** 1999 Jun;74(6):726-45 (42 ref.)
FASEB Federal Funding Consensus Conference FY 2000. Executive summary. **Physiologist** 1999 Feb;42(1):1, 3 (0 ref.)

RESEARCHERS see **RESEARCH PERSONNEL**

RESERPINE

ADMINISTRATION & DOSAGE

[Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations] Siepmann M, et al. **Med Klin** 1998 Dec 15;93(12):733-7 (57 ref.) **(Ger)**

RESIDENCE CHARACTERISTICS

AIDS and the community. Farmer E. **P N G Med J** 1996

Sep;39(3):214–7 (6 ref.)

RESIDENCY, DENTAL see **INTERNSHIP AND RESIDENCY**

RESIDENCY, MEDICAL see **INTERNSHIP AND RESIDENCY**

RESIDENTIAL TREATMENT

Soteria and other alternatives to acute psychiatric hospitalization: a personal and professional review. Mosher LR. **J Nerv Ment Dis** 1999 Mar;187(3):142–9 (48 ref.)

RESIDUAL CANCER see **NEOPLASM, RESIDUAL**

RESIDUAL TUMOR see **NEOPLASM, RESIDUAL**

RESIN CEMENTS

CHEMISTRY

Resin-ionomer restorative materials for children: a review [see comments] Hse KM, et al. **Aust Dent J** 1999 Mar; 44(1):1–11 (106 ref.) Comment in: Aust Dent J 1999 Jun;44(2):138.

RESINS

The properties of resin supports and their effects on solid-phase organic synthesis. Yan B. **Comb Chem High Throughput Screen** 1998 Dec;1(4):215–29 (81 ref.)

METABOLISM

Recent advances in understanding resin acid biodegradation: microbial diversity and metabolism. Martin VJ, et al. **Arch Microbiol** 1999 Sep;172(3):131–8 (46 ref.)

RESINS, RESTORATIVE see **DENTAL CEMENTS**

RESINS, SYNTHETIC

CHEMISTRY

Optimization of solid supports for combinatorial chemical synthesis. Mendonca AJ, et al. **Med Res Rev** 1999 Sep; 19(5):451–62 (88 ref.)

RESISTANCE FACTORS see **R FACTORS**

RESISTANCE, NATURAL see **IMMUNITY, NATURAL**

RESISTANT OVARY SYNDROME see **OVARIAN FAILURE, PREMATURE**

RESORTS see **HEALTH RESORTS**

RESOURCE ALLOCATION see **HEALTH CARE RATIONING**

RESOURCE-BASED RELATIVE VALUE SCALE see **RELATIVE VALUE SCALES**

RESPIRATION

see related
APNEA
BREATH TESTS
BREATHING EXERCISES
CELL RESPIRATION
DYSPNEA
OXYGEN CONSUMPTION

The evolution of human speech: the role of enhanced breathing control. MacLarnon AM, et al. **Am J Phys Anthropol** 1999 Jul;109(3):341–63 (160 ref.)

Acid-base regulation and control of ventilation in human pregnancy. Wolfe LA, et al. **Can J Physiol Pharmacol** 1998 Sep;76(9):815–27 (116 ref.)

Short-term rhythms of the cardiorespiratory system and their significance in neonatology. Patzak A. **Chronobiol Int** 1999 May;16(3):249–68 (159 ref.)

Upper airway function and dysfunction in respiration. Pierce RJ, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):1–10 (102 ref.)

Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in chronic heart failure. Do Cheyne and Stokes have an important message for modern-day patients with heart failure? Piepoli MF, et al. **Eur Heart J** 1999 Jul;20(13):946–53 (65 ref.)

Control of the pulmonary circulation in the fetus and during the transitional period to air breathing. Heymann MA. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):127–32 (55 ref.)

Respiratory control during upper airway infection mechanism for prolonged reflex apnoea and sudden infant death with special reference to infant sleep position. Lindgren C. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1–2):97–102 (45 ref.)

The control of breathing with reference to congenital central hypoventilation syndrome. Child F, et al. **J R Soc Med** 1998 Sep;91(9):479–83 (20 ref.)

Control of airway function during and after exercise in asthmatics. Beck KC. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S4–11 (82 ref.)

Breathing in patients with bullous emphysema: why lung volume reduction may work. Pride NB. **Monaldi Arch Chest Dis** 1998 Aug;53(4):483–5 (17 ref.)

Maturation of the mammalian respiratory system. Hilaire G, et al. **Physiol Rev** 1999 Apr;79(2):325–60 (500 ref.)

Neurogenesis of patterns of automatic ventilatory activity. St-John WM. **Prog Neurobiol** 1998 Oct;56(1):97–117 (127 ref.)

Suprapontine control of respiration. Horn EM, et al. **Respir Physiol** 1998 Dec;114(3):201–11 (60 ref.)

Endogenous carbon monoxide in control of respiration. Prabhakar NR. **Respir Physiol** 1998 Oct;114(1):57–64 (46 ref.)

Mechanisms and clinicophysiological implications of the sniff- and gasp-like aspiration reflex. Tomori Z, et al. **Respir Physiol** 1998 Oct;114(1):83–98 (52 ref.)

A reappraisal of mouth-to-mouth ventilation during bystander-initiated cardiopulmonary resuscitation. A statement for healthcare professionals from the Ventilation Working Group of the Basic Life Support and Pediatric Life Support Subcommittees, American Heart Association. Becker LB, et al. **Resuscitation** 1997 Nov;35(3):189–201 (121 ref.)

Exhaled nitric oxide during exercise. Sheel AW, et al. **Sports Med** 1999 Aug;28(2):83–90 (64 ref.)

[Respiration and aging] Guenard H. **Rev Mal Respir** 1998 Dec;15(6):713–21 (86 ref.) (Eng. Abstr.) **(Fre)**

[Effects of female hormones on respiratory and cardiovascular regulation] Tatsumi K. **Nihon Kokyuki Gakkai Zasshi** 1999 May;37(5):359–67 (54 ref.) (Eng. Abstr.) **(Jpn)**

[The present and future of the pulmonary function tests. The relationship between respiratory and non-respiratory function] Kambe M, et al. **Rinsho Byori** 1999 Mar; 47(3):262–7 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Modulating effect of peripheral thermoreceptors on human respiration] Kozyreva TV, et al. **Vestn Ross Akad Med Nauk** 1998;(10):14–8 (25 ref.) (Eng. Abstr.) **(Rus)**

[Maximum respiratory flow on an expedition to the Himalaya] Borderias Clau L. **Arch Bronconeumol** 1999 May;35 Suppl 3:49–54 (26 ref.) **(Spa)**

DRUG EFFECTS

The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Eriksson LI. **Anesth Analg** 1999 Jul;89(1):243–51 (67 ref.)

Pharmacological modulators of respiratory control. Casaburi R. **Monaldi Arch Chest Dis** 1998 Jun;53(3):287–93 (99 ref.)

PHYSIOLOGY

[The current methodological approaches in assessing nasal breathing function] Krotov AIu. **Vestn Otorinolaringol** 1998;(4):51–2 (30 ref.) (Eng. Abstr.) **(Rus)**

RESPIRATION, ARTIFICIAL

see related
VENTILATORS, MECHANICAL

Postoperative ventilatory management. Price JA, et al. **Chest** 1999 May;115(5 Suppl):130S–137S (44 ref.)

Mechanical ventilation for respiratory failure postthoracotomy. D'Arsigny C, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):585–610 (124 ref.)

Adult respiratory failure. Tremblay A, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):557–83, viii–ix (175 ref.)

Paradigm shift in mechanical ventilatory support for acute respiratory distress syndrome: do no harm. Kaminsky DA. **Coron Artery Dis** 1998;9(8):527–33 (41 ref.)

Pharmacologic adjuncts to mechanical ventilation in acute respiratory distress syndrome. Albertson TE, et al. **Crit Care Clin** 1998 Oct;14(4):581–610, v (232 ref.)

Nonsurgical treatment of a severe tracheal rupture after endotracheal intubation. Zettl R, et al. **Crit Care Med** 1999 Mar;27(3):661–3 (9 ref.)

New modes of ventilatory support. Branson RD, et al. **Int Anesthesiol Clin** 1999 Summer;37(3):103–25 (32 ref.)

Cardiopulmonary interactions during mechanical ventilation. Hurford WE. **Int Anesthesiol Clin** 1999 Summer; 37(3):35–46 (52 ref.)

Mechanical ventilation of the patient with severe chronic obstructive pulmonary disease. Gladwin MT, et al. **Intensive Care Med** 1998 Sep;24(9):898–910 (108 ref.)

Prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Matamis D. **Intensive Care Med** 1999 Jan;25(1):118–9 (7 ref.)

Liquid ventilation. Melo J, et al. **Intensive Care Med** 1999 Apr;25(4):420–1 (2 ref.)

Measurement of functional residual capacity in the critically ill. Relevance for the assessment of respiratory mechanics during mechanical ventilation. Rimensberger PC, et al. **Intensive Care Med** 1999 May;25(5):540–2 (3 ref.)

Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective. Borasio GD, et al. **J Neurol** 1998 Aug;245 Suppl 2:S7–12; discussion S29 (19 ref.)

Following the learning curve: the evolution of kinder, gentler neonatal respiratory technology. Lockridge T. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):443–55 (105 ref.)

Early institution of mechanical ventilation. Ambrosino N. **Monaldi Arch Chest Dis** 1998 Jun;53(3):321–3 (19 ref.)

If and when to close tracheostomy. Clini E, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):377–80 (31 ref.)

Noninvasive ventilation in acute exacerbations of chronic obstructive pulmonary disease. Elliott MW. **Monaldi Arch Chest Dis** 1998 Jun;53(3):343–7 (22 ref.)

Is early noninvasive mechanical ventilation of first choice in stable COPD patients with chronic respiratory failure? Patessio A. **Monaldi Arch Chest Dis** 1999 Feb;54(1):83–6 (48 ref.)

Invasive mechanical ventilation in exacerbations of chronic obstructive pulmonary disease. Pingleton SK. **Monaldi Arch Chest Dis** 1998 Jun;53(3):337–42 (44 ref.)

Is early noninvasive ventilation the first choice in stable restrictive patients with chronic respiratory failure? Shneerson J. **Monaldi Arch Chest Dis** 1999 Feb;54(1):87–9 (8 ref.)

Patient-ventilator interactions. Stroetz RW, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):331–6 (22 ref.)

Intraoperative ventilation. Marraro G. **Paediatr Anaesth** 1998; 8(5):373–82 (42 ref.)

Arteriovenous carbon dioxide removal: development and impact on ventilator management and survival during severe respiratory failure. Zwischenberger JB, et al. **Perfusion** 1999 Jul;14(4):299–310 (58 ref.)

Mechanical ventilation: simplifying the terminology. Kapadia F. **Postgrad Med J** 1998 Jun;74(872):330–5 (8 ref.)

Acute respiratory distress syndrome. Liquid ventilation. Anzueto A, et al. **Respir Care Clin N Am** 1998 Dec; 4(4):679–94 (57 ref.)

Acute respiratory distress syndrome: a clinical update. Soubani AO, et al. **South Med J** 1999 May;92(5):450–7 (58 ref.)

Ethical and clinical issues in the use of home non-invasive mechanical ventilation for the palliation of breathlessness in motor neurone disease. Polkey MI, et al. **Thorax** 1999 Apr;54(4):367–71 (43 ref.)

[Techniques and indications for bronchoscopy in the artificially ventilated patient] Dombret MC. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S91–4 (13 ref.) **(Fre)**

[Long-term ventilation at home in adults with neurological diseases] Raphaël JC, et al. **Rev Mal Respir** 1998 Sep; 15(4):495–505 (62 ref.) (Eng. Abstr.) **(Fre)**

[Mask induction and one-lung ventilation with sevoflurane] Janshon GP, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S52–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Weaning from artificial respiration. 2.] Kuhlen R, et al. **Anaesthesist** 1998 Aug;47(8):693–703 (15 ref.) **(Ger)**

[Efficiency and risk of chest physiotherapy in the newborn--review of the literature] Krause MF, et al. **Klin Padiatr** 1999 Jan–Feb;211(1):11–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Schweiz Med Wochenschr** 1999 Jul 13; 129(27–28):1013–24 (45 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysiology and respiratory therapy of chronic respiratory insufficiency in chronic pulmonary fibrosis] Fabel H. **Wien Klin Wochenschr Suppl** 1999;1:6–10 (6 ref.) **(Ger)**

[Ventilatory support in patients with acute disease of the central nervous system] Bugedo G, et al. **Rev Med Chil** 1999 Feb;127(2):211–21 (53 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Lung injury caused by mechanical ventilation. Slutsky AS. **Chest** 1999 Jul;116(1 Suppl):9S–15S (42 ref.)

Pulmonary complications of mechanical ventilation. Sandur S, et al. **Clin Chest Med** 1999 Jun;20(2):223–47 (128 ref.)

Artificial ventilation-acquired sinopathy in the critically ill – the maxillary sinuses revisited. Westergren V. **Clin Exp Allergy** 1999 Mar;29(3):298–305 (52 ref.)

Ventilator-associated sinusitis: a review. Westergren V, et al. **Clin Infect Dis** 1998 Oct;27(4):851–64 (111 ref.)

Acute lobar collapse: adults and infants differ in important ways [editorial; comment] Greene R. **Crit Care Med** 1999 Aug;27(8):1677–9 (21 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1594–7.

Chest wall elastance and acute respiratory failure [editorial; comment] Jardin F. **Crit Care Med** 1999 Aug;27(8):1653–4 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1454–60.

Ventilator-induced lung injury: more studies, more questions [editorial; comment] Kavanagh BP, et al. **Crit Care Med** 1999 Aug;27(8):1669–71 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1533–41.

Intrahospital transport of critically ill children--should we pay attention? [editorial; comment] Venkataraman ST. **Crit Care Med** 1999 Apr;27(4):694–5 (7 ref.) Comment on: Crit Care Med 1999 Apr;27(4):802–6.

Mechanisms initiating lung injury in the preterm. Jobe AH, et al. **Early Hum Dev** 1998 Nov;53(1):81–94 (66 ref.)

Ventilator-associated lung injury. Kacmarek RM. **Int Anesthesiol Clin** 1999 Summer;37(3):47–64 (67 ref.)

Diagnosis of ventilator-associated pneumonia. Flanagan PG. **J Hosp Infect** 1999 Feb;41(2):87–99 (84 ref.)

Does postoperative ventilation have an effect on the integrity of the anastomosis in repaired oesophageal atresia? Beasley SW. **J Paediatr Child Health** 1999 Apr;35(2):120–2 (11 ref.)

Clinical and technical approach to selective decontamination of the digestive tract (SDD). Zandstra DF. **Minerva Anestesiol** 1999 May;65(5):197–201 (44 ref.)
Mechanical ventilation in acute respiratory distress syndrome: evolving concepts. Mehta S, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):647–53 (58 ref.)
Protective ventilatory strategy for ARDS: physiological evaluation of the clinical trials. Ranieri VM, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):644–6 (35 ref.)
Mechanisms of ventilation–induced lung injury: physiological rationale to prevent it. Verbrugge SJ, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):22–37 (158 ref.)
The prevention of ventilator–associated pneumonia [see comments] Kollef MH. **N Engl J Med** 1999 Feb 25; 340(8):627–34 (53 ref.) Comment in: N Engl J Med 1999 Jul 22;341(4):293–4.
[Lung damage due to mechanical ventilation] Plötz FB, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):133–6 (33 ref.) (Eng. Abstr.) **(Dut)**
[Empirical antibiotic therapy for nosocomial pneumonia acquired in assisted ventilation] Charbonneau P. **Presse Med** 1998 Sep 12;27(26):1362–4 (5 ref.) **(Fre)**
[Respiratory tract infections by Pseudomonas aeruginosa in patients under intubation] Rello J, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:17–20 (31 ref.) **(Spa)**

ECONOMICS

Cost/benefit of noninvasive mechanical ventilation. Criner GJ. **Monaldi Arch Chest Dis** 1998 Jun;53(3):358–9 (7 ref.)

INSTRUMENTATION

The art of interface. Tools for administering noninvasive ventilation. Leger SS, et al. **Med Klin** 1999 Apr;94(1 Spec No):35–9 (30 ref.)
Practical applications of monitoring respiratory mechanics in newborn. Migliori C, et al. **Minerva Pediatr** 1999 Mar; 51(3):57–64 (11 ref.) **(Eng, Ita)**
New tools in ventilatory support: high frequency ventilation, nitric oxide, tracheal gas insufflation, non–invasive ventilation. Biarent D. **Pediatr Pulmonol Suppl** 1999; 18:178–81 (25 ref.)
[Anesthesia ventilators (published erratum appears in Ann Fr Anesth Reanim 1998;17(1):90)] Otteni JC, et al. **Ann Fr Anesth Reanim** 1997;16(7):895–907 (31 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Prone ventilation—it's time. Tobin A, et al. **Anaesth Intensive Care** 1999 Apr;27(2):194–201 (55 ref.)
Ventilatory strategies for acute respiratory distress syndrome. Lee KH, et al. **Ann Acad Med Singapore** 1998 May; 27(3):409–13 (37 ref.)
Cardiovascular effects of mechanical ventilation. Shekerdemian L, et al. **Arch Dis Child** 1999 May; 80(5):475–80 (35 ref.)
Liquid ventilation: clinical experiences. Greenspan JS, et al. **Biomed Instrum Technol** 1999 May–Jun;33(3):253–9 (36 ref.)
Liquid ventilation state–of–the–art. Part I. Shaffer TH, et al. **Biomed Instrum Technol** 1999 May–Jun;33(3):251–2 (15 ref.)
ABC of intensive care: respiratory support. Shelly MP, et al. **BMJ** 1999 Jun 19;318(7199):1674–7 (0 ref.)
Liquid ventilation. Day SE, et al. **Clin Perinatol** 1998 Sep; 25(3):711–22 (80 ref.)
Ventilation in the trauma and surgical patient. Battistella FD. **Crit Care Clin** 1998 Oct;14(4):731–42 (61 ref.)
Noninvasive ventilation in neuromuscular disease. Bonekat HW. **Crit Care Clin** 1998 Oct;14(4):775–97 (114 ref.)
Ventilation of patients with asthma and obstructive lung disease. Jain S, et al. **Crit Care Clin** 1998 Oct;14(4):685–705 (85 ref.)
Monitoring patient mechanics during mechanical ventilation. Jubran A. **Crit Care Clin** 1998 Oct;14(4):629–53, vi (112 ref.)
Non–conventional respiratory support modalities applicable in the older child. High frequency ventilation and liquid ventilation. Kallas HJ. **Crit Care Clin** 1998 Oct;14(4):655–83 (245 ref.)
Provision of long–term mechanical ventilation. Scheinhorn DJ, et al. **Crit Care Clin** 1998 Oct;14(4):819–32, viii (68 ref.)
Mechanical ventilation of patients with acute lung injury. Sessler CN. **Crit Care Clin** 1998 Oct;14(4):707–29, vii (119 ref.)
Ventilation in the patient with unilateral lung disease. Thomas AR, et al. **Crit Care Clin** 1998 Oct;14(4):743–73 (115 ref.)
Vasodilators in mechanical ventilation. Zimmerman JL, et al. **Crit Care Clin** 1998 Oct;14(4):611–27 (89 ref.)
Clinical trials in acute respiratory distress syndrome: what is ARDS? [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1657–8 (13 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1478–85.
Chest wall elastance and acute respiratory failure [editorial; comment] Jardin F. **Crit Care Med** 1999 Aug;27(8):1653–4 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1454–60.
Intrahospital transport of critically ill children—should we pay attention? [editorial; comment] Venkataraman ST. **Crit Care Med** 1999 Apr;27(4):694–5 (7 ref.) Comment on: Crit Care Med 1999 Apr;27(4):802–6.
Current status of liquid ventilation. Weis CM, et al. **Curr Opin Pediatr** 1999 Apr;11(2):126–32 (66 ref.)
Recent advances in assisted ventilation for neonatal respiratory distress syndrome. Yu VY. **Indian Pediatr** 1998 Jul;35(7):631–40 (85 ref.)
Sedation for the critically ill. Sydow M, et al. **Intensive Care Med** 1999 Jun;25(6):634–6 (4 ref.)
Noninvasive ventilation. Rabatin JT, et al. **Mayo Clin Proc** 1999 Aug;74(8):817–20 (16 ref.)
One lung ventilation: prospective from an interested observer. Cohen E. **Minerva Anestesiol** 1999 May; 65(5):275–83 (22 ref.)
Proportional assist ventilation. Mancebo J. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):12–5 (8 ref.)
Clinical perspectives of "the open lung concept". Suárez–Sipmann F, et al. **Minerva Anestesiol** 1999 May; 65(5):310–2 (17 ref.)
Negative pressure ventilation. Carrado A, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):488–92 (28 ref.)
Modalities of ventilation in patients with human immunodeficiency virus infection. Gachot B, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):540–2 (28 ref.)
Modalities of ventilation in obesity. Muir JF, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):556–9 (21 ref.)
Is early noninvasive mechanical ventilation of first choice in stable restrictive patients with chronic respiratory failure? Raphaël JC, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):90–7 (95 ref.)
Liquid ventilation: background and clinical trials. Bartlett RH. **Pediatr Pulmonol Suppl** 1999;18:182–3 (4 ref.)
New modes of ventilation: a non–aggression pact. Renolleau S. **Pediatr Pulmonol Suppl** 1999;18:184–7 (15 ref.)
Management of pulmonary complications in neuromuscular disease. Benditt JO. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):167–85 (57 ref.)
Mechanical ventilation of the patient with chronic obstructive pulmonary disease. Hess DR, et al. **Respir Care Clin N Am** 1998 Sep;4(3):439–73 (146 ref.)
A lung–protective approach to ventilating ARDS. Marini JJ. **Respir Care Clin N Am** 1998 Dec;4(4):633–63, viii (133 ref.)
Respiratory failure: current status of experimental therapies. Hirschl RB. **Semin Pediatr Surg** 1999 Aug;8(3):155–70 (177 ref.)
[What are the indications and modalities for mechanical ventilation?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):72–8 (22 ref.) **(Fre)**
[Vasotropic therapy and artificial respiration for pulmonary hypertension] Grimminger F, et al. **Internist (Berl)** 1999 Jul;40(7):747–55 (16 ref.) **(Ger)**
[Long–term oxygen inhalation therapy and home artificial respiration for chronic pulmonary heart disease] Köhler D, et al. **Internist (Berl)** 1999 Jul;40(7):756–63 (62 ref.) **(Ger)**
[Home mechanical ventilation for the treatment of respiratory insufficiency] Kimura K. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):89–93 (10 ref.) **(Jpn)**

STANDARDS

Advances in ventilatory support of the pediatric surgical patient. Hemmila MR, et al. **Curr Opin Pediatr** 1999 Jun; 11(3):241–8 (67 ref.)

TRENDS

Use of high–frequency and nonconventional ventilation for respiratory failure. Donnelly KM, et al. **Curr Opin Pediatr** 1998 Jun;10(3):278–83 (60 ref.)

RESPIRATION, CELL see **CELL RESPIRATION**

RESPIRATION DISORDERS

[Respiratory pathology in the agricultural environment] Dalphin JC. **Rev Prat** 1998 Jun 15;48(12):1313–8 (30 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

[Cardiorespiratory disorders in drug addiction] Kochetkova EA, et al. **Ter Arkh** 1998;70(12):84–7 (81 ref.) **(Rus)**

COMPLICATIONS

Apneustic breathing in children with brainstem damage due to hypoxic–ischemic encephalopathy. Saito Y, et al. **Dev Med Child Neurol** 1999 Aug;41(8):560–7 (37 ref.)

DIAGNOSIS

Surfactant proteins A and D: disease markers. Kuroki Y, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):334–45 (47 ref.)

DRUG THERAPY

Bone loss and glucocorticoid therapy in patients with respiratory disease. Fairney A. **Thorax** 1999 Aug;54 Suppl 2:S52–7 (65 ref.)
The anti–inflammatory effects of macrolides. Wales D, et al. **Thorax** 1999 Aug;54 Suppl 2:S58–62 (48 ref.)

EPIDEMIOLOGY

Ten years of the SWORD project. Surveillance of Work–related and Occupational Respiratory Disease [see comments] Ross DJ. **Clin Exp Allergy** 1999 Jun;29(6):750–3 (23 ref.) Comment in: Clin Exp Allergy 1999 Jun;29(6):725–8.

ETIOLOGY

Assessment of the indoor environment in respiratory allergy. Sarpong SB, et al. **Ear Nose Throat J** 1998 Dec; 77(12):960–4 (30 ref.)
Respiratory aspects of neurological disease. Polkey MI, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):5–15 (170 ref.)

PHYSIOPATHOLOGY

Upper airway function and dysfunction in respiration. Pierce RJ, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):1–10 (102 ref.)

THERAPY

Continuous distending pressure. Morley C. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F152–6 (73 ref.)
Key developments in respiratory disease. Taggart S. **Practitioner** 1998 Mar;242(1584):179–80, 184 (4 ref.)

RESPIRATOR WEANING see **VENTILATOR WEANING**

RESPIRATORS see **VENTILATORS, MECHANICAL**

RESPIRATORS, AIR–PURIFYING see **RESPIRATORY PROTECTIVE DEVICES**

RESPIRATORS, INDUSTRIAL see **RESPIRATORY PROTECTIVE DEVICES**

RESPIRATORS, NEGATIVE–PRESSURE see **VENTILATORS, NEGATIVE–PRESSURE**

RESPIRATORS, PULMONARY, NEGATIVE–PRESSURE see **VENTILATORS, NEGATIVE–PRESSURE**

RESPIRATORY AIRFLOW see **PULMONARY VENTILATION**

RESPIRATORY BURST

see related
GRANULOMATOUS DISEASE, CHRONIC

Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Hampton MB, et al. **Blood** 1998 Nov 1;92(9):3007–17 (165 ref.)

RESPIRATORY CENTER

PHYSIOPATHOLOGY

Role of the respiratory control system in the pathophysiology of hypercapnia. Gardner WN. **Monaldi Arch Chest Dis** 1998 Jun;53(3):281–6 (71 ref.)

RESPIRATORY CHAIN see **ELECTRON TRANSPORT**

RESPIRATORY DISTRESS SYNDROME

DRUG THERAPY

Principles of surfactant replacement. Robertson B, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):346–61 (72 ref.)
Liquid perfluorochemical priming before surfactant therapy: this time the egg really does precede the chicken [editorial; comment] Baumgart S, et al. **Crit Care Med** 1999 Sep; 27(9):2053–4 (15 ref.) Comment on: Crit Care Med 1999 Sep;27(9):1916–22.
Surfactant replacement therapy. Yu V. **Indian Pediatr** 1998 Nov;35(11):1081–96 (126 ref.)
Levels of evidence for the pharmacological effectiveness of prolonged methylprednisolone treatment in unresolving acute respiratory distress syndrome. Meduri GU. **Minerva Anestesiol** 1999 May;65(5):193–6 (12 ref.)

ETIOLOGY

Functional pulmonary surfactant deficiency and neonatal respiratory disorders. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:175–7 (8 ref.)

PHYSIOPATHOLOGY

[The sigh in ARDS (acute respiratory distress syndrome) Pelosi P, et al. **Minerva Anestesiol** 1999 May;65(5):313–7 (16 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Early nasal continuous positive airway pressure and minimal handling in the treatment of very–low–birth–weight infants. Kamper J. **Biol Neonate** 1999 Jun;76 Suppl 1:22–8 (34 ref.)
Recent developments in inhaled nitric oxide therapy of the newborn. Kinsella JP, et al. **Curr Opin Pediatr** 1999 Apr;

11(2):121–5 (33 ref.)
Recent advances in assisted ventilation for neonatal respiratory distress syndrome. Yu VY. **Indian Pediatr** 1998 Jul;35(7):631–40 (85 ref.)
Liquid ventilation. Melo J, et al. **Intensive Care Med** 1999 Apr;25(4):420–1 (2 ref.)
Neonatal respiratory care and infant mortality in emerging countries [editorial; comment] Sola A, et al. **Pediatr Pulmonol** 1999 May;27(5):303–4 (8 ref.) Comment on: Pediatr Pulmonol 1999 May;27(5):305–11. Comment on: Pediatr Pulmonol 1999 May;27(5):312–7.
Acute respiratory distress syndrome: a clinical update. Soubani AO, et al. **South Med J** 1999 May;92(5):450–7 (58 ref.)

RESPIRATORY DISTRESS SYNDROME, ADULT

Acute respiratory distress syndrome: 30 years later. Lesur O, et al. **Can Respir J** 1999 Jan–Feb;6(1):71–86 (130 ref.)
Chemokines in lung injury: Thomas A. Neff Lecture. Strieter RM, et al. **Chest** 1999 Jul;116(1 Suppl):103S–110S (80 ref.)
Cellular alterations in fibroproliferative lung disease. Toews GB. **Chest** 1999 Jul;116(1 Suppl):112S–116S (32 ref.)
ARDS. History, definitions, and physiology. Brown SD. **Respir Care Clin N Am** 1998 Dec;4(4):567–82, vii (21 ref.)
[Acute respiratory distress syndrome] Matějovič M, et al. **Cas Lek Cesk** 1999 Apr 26;138(9):262–7 (37 ref.) (Eng. Abstr.) **(Cze)**

BLOOD

PEEP: blood gas cosmetics or a therapy for ARDS? [editorial; comment] Pesenti A, et al. **Crit Care Med** 1999 Feb;27(2):253–4 (17 ref.) Comment on: Crit Care Med 1999 Feb;27(2):380–4.

COMPLICATIONS

Pulmonary hypertension in acute respiratory distress syndrome. Leeman M. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):146–9 (29 ref.)
Revving the motor of multiple organ dysfunction syndrome. Gut dysfunction in ARDS and multiorgan failure. Taylor DE. **Respir Care Clin N Am** 1998 Dec;4(4):611–31, vii–viii (58 ref.)

DIAGNOSIS

Toward new definitions of acute respiratory distress syndrome [editorial; comment] Abraham E. **Crit Care Med** 1999 Feb;27(2):237–8 (13 ref.) Comment on: Crit Care Med 1999 Feb;27(2):304–12.
[Mendelson syndrome in infancy and childhood] Baum WF, et al. **Pneumologie** 1998 Oct;52(10):556–9 (21 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Pharmacologic adjuncts to mechanical ventilation in acute respiratory distress syndrome. Albertson TE, et al. **Crit Care Clin** 1998 Oct;14(4):581–610, v (232 ref.)
Clinical trials in acute respiratory distress syndrome: what is ARDS? [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1657–8 (13 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1478–85.
Is there a role for surfactant replacement therapy in adult pulmonary dysfunction? [editorial; comment] Warren WH. **Crit Care Med** 1998 Oct;26(10):1626–7 (18 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1660–2.
Nitric oxide in acute hypoxic respiratory failure: from the bench to the bedside and back again [editorial; comment] Bohn D. **J Pediatr** 1999 Apr;134(4):387–9 (29 ref.) Comment on: J Pediatr 1999 Apr;134(4):406–12.
Nitric oxide for ARDS—what is the evidence? Ferreira E, et al. **Pharmacotherapy** 1999 Jan;19(1):60–9 (36 ref.)
Acute respiratory distress syndrome. Inhaled nitric oxide. Hanania NA, et al. **Respir Care Clin N Am** 1998 Dec; 4(4):695–709 (93 ref.)
Systemic pharmacologic therapy of ARDS. Komara JJ Jr, et al. **Respir Care Clin N Am** 1998 Dec;4(4):739–50 (67 ref.)
Corticosteroids in late adult respiratory distress syndrome—towards a better use [editorial; comment] Olivieri D. **Respiration** 1998;65(4):256–7 (13 ref.) Comment on: Respiration 1998 ;65(4):258–64.
[Inhaled nitric oxide: one modality in the treatment of ARDS] Carrillo-Esper R, et al. **Gac Med Mex** 1999 Jul–Aug; 135(4):417–21 (28 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of acute lung injury and ARDS. Hudson LD, et al. **Chest** 1999 Jul;116(1 Suppl):74S–82S (43 ref.)

ETIOLOGY

Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Asimakopoulos G, et al. **Ann Thorac Surg** 1999 Sep;68(3):1107–15 (87 ref.)
Lung cytokines and ARDS: Roger S. Mitchell Lecture. Martin TR. **Chest** 1999 Jul;116(1 Suppl):2S–8S (73 ref.)
Lung injury caused by mechanical ventilation. Slutsky AS. **Chest** 1999 Jul;116(1 Suppl):9S–15S (42 ref.)
Postpneumonectomy pulmonary edema. Deslauriers J, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):611–31, ix (46 ref.)
Targeting the proteolytic arsenal of neutrophils. A promising approach for postpump syndrome and ARDS [editorial; comment] Shah PK. **Circulation** 1999 Jul 27;100(4):333–4 (25 ref.) Comment on: Circulation 1999 Jul 27;100(4):400–6.
Ventilation in the trauma and surgical patient. Battistella FD. **Crit Care Clin** 1998 Oct;14(4):731–42 (61 ref.)
Chest wall elastance and acute respiratory failure [editorial; comment] Jardin F. **Crit Care Med** 1999 Aug;27(8):1653–4 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1454–60.
Ventilator-induced lung injury: more studies, more questions [editorial; comment] Kavanagh BP, et al. **Crit Care Med** 1999 Aug;27(8):1669–71 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1533–41.
The answer is (gently) blowing in the wind? [editorial; comment] Marelich GP, et al. **Crit Care Med** 1999 Apr; 27(4):687–8 (9 ref.) Comment on: Crit Care Med 1999 Apr;27(4):779–83.
Acute lung injury, acute respiratory distress syndrome and inhalation injury: an overview. Kimmel EC, et al. **Drug Chem Toxicol** 1999 Feb;22(1):91–128 (140 ref.)
Non-cardiogenic pulmonary oedema in vascular surgery. Pararajasingam R, et al. **Eur J Vasc Endovasc Surg** 1999 Feb;17(2):93–105 (154 ref.)
Acute lung injury in head trauma patients. Mascia L, et al. **Intensive Care Med** 1998 Oct;24(10):1115–6 (4 ref.)
Phrenic nerve injury following cardiac surgery: a review. Tripp HF, et al. **J Card Surg** 1998 May;13(3):218–23 (29 ref.)
Acute respiratory distress syndrome. Wyncoll DL, et al. **Lancet** 1999 Aug 7;354(9177):497–501 (48 ref.)
[The adult respiratory distress syndrome during the recovery of the neutrophil level after autologous bone marrow transplantation] Lisukov IA, et al. **Ter Arkh** 1998;70(7):78–9 (6 ref.) **(Rus)**
[Respiratory distress syndrome due to hyperleukocytic leukemias] Valdovinos Mahave MC, et al. **An Med Interna** 1999 Jul;16(7):359–60 (8 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Regulation of neutrophil activation in acute lung injury. Downey GP, et al. **Chest** 1999 Jul;116(1 Suppl):46S–54S (59 ref.)

METABOLISM

Adhesion molecules and cellular biomechanical changes in acute lung injury: Giles F. Filley Lecture. Doerschuk CM, et al. **Chest** 1999 Jul;116(1 Suppl):37S–43S (51 ref.)
Regulation of oxidant production in acute lung injury. Sanders KA, et al. **Chest** 1999 Jul;116(1 Suppl):56S–61S (39 ref.)
The answer is (gently) blowing in the wind? [editorial; comment] Marelich GP, et al. **Crit Care Med** 1999 Apr; 27(4):687–8 (9 ref.) Comment on: Crit Care Med 1999 Apr;27(4):779–83.
Adult respiratory distress syndrome – an update. Hasleton PS, et al. **Histopathology** 1999 Apr;34(4):285–94 (77 ref.)
Antioxidant status in patients with acute respiratory distress syndrome [editorial; comment] Koch T. **Intensive Care Med** 1999 Feb;25(2):134–6 (18 ref.) Comment on: Intensive Care Med 1999 Feb;25(2):180–5.
Role of transcription factors in inflammatory lung diseases. Rahman I, et al. **Thorax** 1998 Jul;53(7):601–12 (119 ref.)
[Supranormal oxygen delivery] Katsuya H. **Masui** 1998 Dec; 47 Suppl:S81–7 (16 ref.) **(Jpn)**

MORTALITY

Tidal volume, positive end-expiratory pressure, and mortality in acute respiratory distress syndrome [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1661–3 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1492–8.
Epidemiology in ARDS. Suchyta MR, et al. **Intensive Care Med** 1999 May;25(5):538–9 (3 ref.)

PATHOLOGY

Adult respiratory distress syndrome – an update. Hasleton PS, et al. **Histopathology** 1999 Apr;34(4):285–94 (77 ref.)
Acute respiratory distress syndrome. Cellular biology and pathology. Parsley EL. **Respir Care Clin N Am** 1998 Dec; 4(4):583–609, vii (142 ref.)
[Pathology of diseases responsible for the development of respiratory insufficiency] Nagai A. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):45–50 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Endothelial activation in ARDS. Zimmerman GA, et al. **Chest** 1999 Jul;116(1 Suppl):18S–24S (61 ref.)
Respiratory mechanics and surfactant in the acute respiratory distress syndrome. Bersten AD, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):955–63 (76 ref.)
Chest wall elastance and acute respiratory failure [editorial; comment] Jardin F. **Crit Care Med** 1999 Aug;27(8):1653–4 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1454–60.
Pathophysiology of the acute respiratory distress syndrome. Dennehy KC, et al. **Int Anesthesiol Clin** 1999 Summer; 37(3):1–13 (28 ref.)
Gas exchange in acute respiratory failure. Hedenstierna G, et al. **Minerva Anestesiol** 1999 Jun;65(6):383–7 (23 ref.)
Acute respiratory distress syndrome. Cellular biology and pathology. Parsley EL. **Respir Care Clin N Am** 1998 Dec; 4(4):583–609, vii (142 ref.)

THERAPY

Prone ventilation—it's time. Tobin A, et al. **Anaesth Intensive Care** 1999 Apr;27(2):194–201 (55 ref.)
Ventilatory strategies for acute respiratory distress syndrome. Lee KH, et al. **Ann Acad Med Singapore** 1998 May; 27(3):409–13 (37 ref.)
Targeting the proteolytic arsenal of neutrophils. A promising approach for postpump syndrome and ARDS [editorial; comment] Shah PK. **Circulation** 1999 Jul 27;100(4):333–4 (25 ref.) Comment on: Circulation 1999 Jul 27;100(4):400–6.
Paradigm shift in mechanical ventilatory support for acute respiratory distress syndrome: do no harm. Kaminsky DA. **Coron Artery Dis** 1998;9(8):527–33 (41 ref.)
Pharmacologic adjuncts to mechanical ventilation in acute respiratory distress syndrome. Albertson TE, et al. **Crit Care Clin** 1998 Oct;14(4):581–610, v (232 ref.)
Ventilation in the trauma and surgical patient. Battistella FD. **Crit Care Clin** 1998 Oct;14(4):731–42 (61 ref.)
Non-conventional respiratory support modalities applicable in the older child. High frequency ventilation and liquid ventilation. Kallas HJ. **Crit Care Clin** 1998 Oct;14(4):655–83 (245 ref.)
Mechanical ventilation of patients with acute lung injury. Sessler CN. **Crit Care Clin** 1998 Oct;14(4):707–29, vii (119 ref.)
Tidal volume, positive end-expiratory pressure, and mortality in acute respiratory distress syndrome [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1661–3 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1492–8.
Tidal volume, PaCO2, and lung injury [editorial; comment] Gregory GA, et al. **Crit Care Med** 1998 Oct;26(10):1632–3 (16 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1690–7.
Has high-frequency ventilation been inappropriately discarded in adult acute respiratory distress syndrome? [see comments] Herridge MS, et al. **Crit Care Med** 1998 Dec; 26(12):2073–7 (33 ref.) Comment in: Crit Care Med 1998 Dec;26(12):1955–6.
High-frequency ventilation [editorial; comment] MacIntyre NR. **Crit Care Med** 1998 Dec;26(12):1955–6 (8 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2073–7.
Capnography in critical care: accurate assessment of ARDS therapy? [editorial; comment] Napolitano LM. **Crit Care Med** 1999 May;27(5):862–3 (17 ref.) Comment on: Crit Care Med 1999 May;27(5):946–52.
PEEP: blood gas cosmetics or a therapy for ARDS? [editorial; comment] Pesenti A, et al. **Crit Care Med** 1999 Feb;27(2):253–4 (17 ref.) Comment on: Crit Care Med 1999 Feb;27(2):380–4.
Prone position in acute respiratory distress syndrome: turning over an old idea [editorial; comment] Trottier SJ. **Crit Care Med** 1998 Dec;26(12):1934–5 (20 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1977–85.
Ancillary therapies for acute respiratory distress syndrome. Kwo J, et al. **Int Anesthesiol Clin** 1999 Summer;37(3):65–83 (66 ref.)
Liquid ventilation. Melo J, et al. **Intensive Care Med** 1999 Apr;25(4):420–1 (2 ref.)
Mechanical ventilation in acute respiratory distress syndrome: evolving concepts. Mehta S, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):647–53 (58 ref.)
Protective ventilatory strategy for ARDS: physiological evaluation of the clinical trials. Ranieri VM, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):644–6 (35 ref.)
ARDS, searching for treatment modes or understanding the "rules"? Gattinoni L, et al. **Neth J Med** 1998 Nov; 53(5):212–3 (7 ref.)
Acute respiratory distress syndrome. Liquid ventilation. Anzueto A, et al. **Respir Care Clin N Am** 1998 Dec; 4(4):679–94 (57 ref.)
Acute respiratory distress syndrome. Patient position and motion strategies. Force TR, et al. **Respir Care Clin N Am** 1998 Dec;4(4):665–77, viii (31 ref.)
A lung-protective approach to ventilating ARDS. Marini JJ. **Respir Care Clin N Am** 1998 Dec;4(4):633–63, viii (133 ref.)
Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium. Berthiaume Y, et al. **Thorax** 1999 Feb;54(2):150–60 (154 ref.)
[Recent developments in the treatment of pediatric acute respiratory distress syndrome] Fraisse A, et al. **Arch Pediatr** 1998 Oct;5(10):1107–21 (90 ref.) (Eng. Abstr.) **(Fre)**

RESPIRATORY DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

RESPIRATORY ENTERIC ORPHAN VIRUSES see **REOVIRIDAE**

RESPIRATORY FAILURE see **RESPIRATORY**

RESPIRATORY FAILURE

INSUFFICIENCY

RESPIRATORY FUNCTION TESTS

Allergy to mites: relation to lung function and airway hyperresponsiveness. van der Heide S, et al. **Allergy** 1998; 53(48 Suppl):104–7 (28 ref.)

Normal chest radiograph and lung function do not necessarily mean normal lungs [editorial; comment] Shimura S. **Intern Med** 1998 Nov;37(11):901–2 (10 ref.) Comment on: Intern Med 1998 Nov;37(11):922–6.

Monitoring respiratory muscles. Nava S. **Monaldi Arch Chest Dis** 1998 Dec;53(6):640–3 (26 ref.)

[Evaluation of preoperative functional status in patients with lung cancer] Riedel M, et al. **Cas Lek Cesk** 1999 May 10; 138(10):301–9 (78 ref.) (Eng. Abstr.) **(Cze)**

[Respiratory function tests in pediatric asthma] Chaussain M, et al. **Arch Pediatr** 1998;5 Suppl 2:135s–138s (21 ref.) **(Fre)**

[Functional respiratory testing in mucoviscidosis] Matran R, et al. **Arch Pediatr** 1998;5 Suppl 2:132s–134s (12 ref.) **(Fre)**

[Assessment of functional surgical treatment of patients with bronchial carcinoma] Schulz C, et al. **Pneumologie** 1999 Jul;53(7):337–47 (78 ref.) **(Ger)**

[The present and future of the pulmonary function tests. The relationship between respiratory and non-respiratory function] Kambe M, et al. **Rinsho Byori** 1999 Mar; 47(3):262–7 (4 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Pulmonary diagnosis with model aerosols. II: Aerosol bolus dispersion--a marker for convection gas transport. Basic principles and initial clinical results] Kohlhäufl M, et al. **Pneumologie** 1999 Jan;53(1):50–6 (42 ref.) **(Ger)**

METHODS

Methods of testing lung function in early childhood. Beardsmore CS. **Pediatr Allergy Immunol** 1998;9(11 Suppl):30–6 (56 ref.)

Lung function testing in preschool children. Marchal F, et al. **Pediatr Pulmonol Suppl** 1999;18:21–3 (15 ref.)

Respiratory function testing in early childhood: where have we come from and where are we going? Stocks J. **Pediatr Pulmonol Suppl** 1999;18:24–8 (29 ref.)

Lung function testing in infants. Stocks J. **Pediatr Pulmonol Suppl** 1999;18:14–20 (10 ref.)

[New clinical tests that physicians should know for diagnosis of respiratory system disease] Takizawa H. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1993–8 (9 ref.) **(Jpn)**

RESPIRATORY HYPERSENSITIVITY

CHEMICALLY INDUCED

Chemical respiratory allergy, IgE and the relevance of predictive test methods: a commentary. Kimber I, et al. **Hum Exp Toxicol** 1998 Oct;17(10):537–40 (23 ref.)

COMPLICATIONS

The role of food and inhaled allergens in atopic dermatitis. Grunebaum E, et al. **J Cutan Med Surg** 1999 Feb;3 Suppl 2:S2-24–S2-28 (45 ref.)

From food allergy and atopic dermatitis to respiratory allergy. Kjellman NI, et al. **Pediatr Allergy Immunol** 1998; 9(11 Suppl):13–7 (30 ref.)

[Practical aspects of cross-reaction allergies] Hogendijk S. **Rev Med Suisse Romande** 1999 Mar;119(3):231–4 (11 ref.) **(Fre)**

DIAGNOSIS

Allergic and infectious pediatric sinusitis [see comments] Zacharisen MC, et al. **Pediatr Ann** 1998 Nov;27(11):759–66 (19 ref.) Comment in: Pediatr Ann 1998 Nov;27(11):708.

[Laboratory diagnosis of allergic inflammation] Andrejević S, et al. **Srp Arh Celok Lek** 1998 Nov–Dec; 126(11–12):499–505 (40 ref.) (Eng. Abstr.) **(Scc)**

DRUG THERAPY

Oligonucleotide therapy of allergic asthma. Metzger WJ, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):260–6 (58 ref.)

[Antiallergy drugs and respiratory diseases in children] Donato L, et al. **Arch Pediatr** 1999;6 Suppl 1:98S–104S (12 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of allergic inflammations with steroidal agents] Balaban J, et al. **Srp Arh Celok Lek** 1999 May–Jun; 127(5–6):202–5 (12 ref.) **(Scc)**

[Treatment of allergic inflammation with non-steroidal anti-inflammatory agents] Perić-Popadić A, et al. **Srp Arh Celok Lek** 1999 Mar–Apr;127(3–4):137–41 (25 ref.) **(Scc)**

EPIDEMIOLOGY

Why is allergy increasing?--environmental factors. Davies RJ, et al. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:8–14 (46 ref.)

[Pollution and allergy: the epidemiological data] Dutau H, et al. **Allerg Immunol (Paris)** 1998 Dec;30(10):329–36 (70 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiology of respiratory allergy in children] Pin I, et al. **Arch Pediatr** 1999;6 Suppl 1:6S–13S (65 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Role of viruses in the onset of asthma and allergy: lessons from animal models. Hegele RG. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:78–81 (30 ref.)

Air pollution and respiratory disease in children: what is the clinically relevant impact? Nicolai T. **Pediatr Pulmonol Suppl** 1999;18:9–13 (15 ref.)

[Experimental studies of the effects of atmospheric pollutants] Pauli G, et al. **Allerg Immunol (Paris)** 1998 Dec; 30(10):317–22 (40 ref.) (Eng. Abstr.) **(Fre)**

[Inter-relationship between allergenic pollens and air pollution] Peltre G. **Allerg Immunol (Paris)** 1998 Dec; 30(10):324–6 (1 ref.) (Eng. Abstr.) **(Fre)**

[Pollution and allergy: the contributions of animal and in vitro experimentation] Wallaert B, et al. **Allerg Immunol (Paris)** 1998 Dec;30(10):311–6 (44 ref.) (Eng. Abstr.) **(Fre)**

[Allergens causing respiratory allergy: the aeroallergens] Deschildre A. **Arch Pediatr** 1999;6 Suppl 1:48S–54S (38 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory allergy and environmental pollution in pediatrics] Le Roux P. **Arch Pediatr** 1999;6 Suppl 1:39S–47S (63 ref.) (Eng. Abstr.) **(Fre)**

[Allergologic significance of the epithelium of domestic animals] Wallenstein G. **Pneumologie** 1998 Nov; 52(11):602–7 (79 ref.) **(Ger)**

[Food allergy. Most often conceals an inhalational allergy] Helbling A. **Schweiz Rundsch Med Prax** 1998 Sep 30; 87(40):1309–15 (71 ref.) (Eng. Abstr.) **(Ger)**

[Occupational respiratory allergopathies: environmental monitoring, air allergens, prevention] Previdi M, et al. **Med Lav** 1998 Nov–Dec;89(6):481–98 (68 ref.) (Eng. Abstr.) **(Ita)**

[Animal models of pulmonary allergic disease] Grubek-Jaworska H. **Pneumonol Alergol Pol** 1999; 67(3–4):151–8 (30 ref.) **(Pol)**

IMMUNOLOGY

Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness--a murine model. Hamelmann E, et al. **Allergy** 1999 Apr; 54(4):297–305 (51 ref.)

Allergy to Parietaria officinalis pollen. Cvitanović S. **Croat Med J** 1999 Mar;40(1):42–8 (51 ref.)

Indoor versus outdoor allergens in allergic respiratory disease. Platts-Mills TA, et al. **Curr Opin Immunol** 1998 Dec;10(6):634–9 (52 ref.)

[Practical aspects of cross-reaction allergies] Hogendijk S. **Rev Med Suisse Romande** 1999 Mar;119(3):231–4 (11 ref.) **(Fre)**

PATHOLOGY

Outdoor environmental injury of the airways and development of allergic respiratory diseases. D'Amato G, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):369–74 (57 ref.)

PHYSIOPATHOLOGY

Clinical polymorphism of respiratory allergy. Muñoz-López F. **Allergol Immunopathol (Madr)** 1999 May–Jun; 27(3):169–72 (12 ref.)

The clinical expression of allergy in the lungs. O'Byrne PM, et al. **Allergy** 1999 Jan;54(1):7–14 (53 ref.)

Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Fryer AD, et al. **Life Sci** 1999;64(6–7):449–55 (49 ref.)

PREVENTION & CONTROL

[German Society of Pneumology. Recommendations for prevention of occupational asthma] Baur X, et al. **Pneumologie** 1998 Sep;52(9):504–14 (101 ref.) **(Ger)**

THERAPY

Therapeutic effects of antibodies to interleukin-5. Cuss FM. **Allergy** 1998;53(45 Suppl):89–92 (46 ref.)

Treatment of allergic airways disease with anti-IgE. Holgate ST, et al. **Allergy** 1998;53(45 Suppl):83–8 (62 ref.)

Molecular mechanisms of allergen-specific immunotherapy for atopic diseases. Chiang BL. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Sep–Oct;39(5):293–6 (36 ref.)

Therapy of allergic pulmonary diseases with anti-IgE antibodies. A review. Fick RB. **Pediatr Pulmonol Suppl** 1999;18:115–7 (17 ref.)

RESPIRATORY INSUFFICIENCY

[Engraftment syndrome in hematopoietic stem cell transplantation] Miwa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):595–600 (23 ref.) **(Jpn)**

CHEMICALLY INDUCED

Kerosene-induced severe acute respiratory failure in near drowning: reports on four cases and review of the literature. Segev D, et al. **Crit Care Med** 1999 Aug; 27(8):1437–40 (14 ref.)

DIAGNOSIS

Weaning from mechanical ventilation. Chao DC, et al. **Crit Care Clin** 1998 Oct;14(4):799–817, viii (79 ref.)

[Orthopnea: not always of cardiac origin (see comments)] Oranen BI, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):921–4 (32 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 3;143(27):1443–4. **(Dut)**

[Functional respiratory testing in mucoviscidosis] Matran R, et al. **Arch Pediatr** 1998;5 Suppl 2:132s–134s (12 ref.) **(Fre)**

[Techniques and indications for bronchoscopy in the artificially ventilated patient] Dombret MC. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S91–4 (13 ref.) **(Fre)**

[Mendelson syndrome in infancy and childhood] Baum WF, et al. **Pneumologie** 1998 Oct;52(10):556–9 (21 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of respiratory muscles] Fitting JW. **Schweiz Med Wochenschr** 1998 Aug 15;128(33):1212–6 (10 ref.) (Eng. Abstr.) **(Ger)**

[Approach to diagnosis of respiratory insufficiency] Tatsumi K, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10; 88(1):4–10 (5 ref.) **(Jpn)**

[Acute respiratory failure as the presentation of amyotrophic lateral sclerosis. Apropos a case] Hernández Borge J, et al. **Arch Bronconeumol** 1999 Jan;35(1):48–50 (20 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Low-dose inhaled nitric oxide and oxygenation in pediatric hypoxic respiratory failure. Wrong bullet, wrong target [editorial; comment] Tibby S, et al. **Crit Care Med** 1999 May;27(5):871–2 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):989–96.

Nitric oxide in acute hypoxic respiratory failure: from the bench to the bedside and back again [editorial; comment] Bohn D. **J Pediatr** 1999 Apr;134(4):387–9 (29 ref.) Comment on: J Pediatr 1999 Apr;134(4):406–12.

EPIDEMIOLOGY

[Why are infants prone to respiratory failure?] Hammer J. **Schweiz Rundsch Med Prax** 1999 Jun 3;88(23):1035–7 (11 ref.) **(Ger)**

[Tuberculosis sequelae in Japan] Mori M. **Kekkaku** 1999 Jan; 74(1):1–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Late complications. Late respiratory failure. Wihlm JM, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):633–54, ix-x (79 ref.)

Early complications. Respiratory failure. Zwischenberger JB, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):543–64, viii (142 ref.)

Noninvasive ventilation in neuromuscular disease. Bonekat HW. **Crit Care Clin** 1998 Oct;14(4):775–97 (114 ref.)

Extracorporeal membrane oxygenation--a last-resort therapy for newborns with congenital diaphragmatic hernia or other causes of severe respiratory failure. van der Staak F. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):195–7 (5 ref.)

Left postpneumonectomy syndrome successfully treated with endobronchial stent. Nakamura Y, et al. **Intern Med** 1998 Oct;37(10):880–3 (12 ref.)

Management of pulmonary complications in neuromuscular disease. Benditt JO. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):167–85 (57 ref.)

Life-threatening situations in sarcoidosis. James DG. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):134–9 (13 ref.)

[Acute respiratory insufficiency in children] Duiverman EJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 23;143(4):197–201 (17 ref.) (Eng. Abstr.) **(Dut)**

[Orthopnea: not always of cardiac origin (see comments)] Oranen BI, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):921–4 (32 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 3;143(27):1443–4. **(Dut)**

[Respiratory problems in severe scoliosis] Barois A. **Bull Acad Natl Med** 1999;183(4):721–30 (21 ref.) (Eng. Abstr.) **(Fre)**

[Acute respiratory insufficiency in patients with bronchopulmonary cancer] Mayaud C, et al. **Rev Pneumol Clin** 1998 Sep;54(4):171–9 (56 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory problems after injuries of the cervical spine] Stocker R, et al. **Schweiz Med Wochenschr** 1998 Sep 26; 128(39):1462–6 (13 ref.) (Eng. Abstr.) **(Ger)**

[Myasthenia gravis presenting as isolated respiratory failure] Kishimoto N, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):891–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Etiology and physiopathology of diseases responsible for the development of respiratory insufficiency] Suga M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):37–44 (5 ref.) **(Jpn)**

[Respiratory failure based on pulmonary tuberculosis sequelae and its management] Tsurutani H, et al. **Nippon Rinsho** 1998 Dec;56(12):3190–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Ventilatory support in patients with acute disease of the central nervous system] Bugedo G, et al. **Rev Med Chil** 1999 Feb;127(2):211-21 (53 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY

Reversal of fortune? Respiratory failure after bone marrow transplantation [editorial; comment] Bojko T, et al. **Crit Care Med** 1999 Jun;27(6):1061-2 (17 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1181-6.

NURSING

Following the learning curve: the evolution of kinder, gentler neonatal respiratory technology. Lockridge T. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):443-55 (105 ref.)

PHYSIOPATHOLOGY

Monitoring patient mechanics during mechanical ventilation. Jubran A. **Crit Care Clin** 1998 Oct;14(4):629-53, vi (112 ref.)

Non-invasive ventilation--mechanisms of benefit. Elliott MW. **Med Klin** 1999 Apr;94(1 Spec No):2-6 (18 ref.)

[Pathophysiology and respiratory therapy of chronic respiratory insufficiency in chronic pulmonary fibrosis] Fabel H. **Wien Klin Wochenschr Suppl** 1999;1:6-10 (6 ref.) **(Ger)**

[Sleep and exercise dysfunction in respiratory insufficiency] Akashiba T. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):24-31 (6 ref.) **(Jpn)**

[Pathophysiology of respiratory insufficiency based on the lung function] Kanazawa M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):11-7 (4 ref.) **(Jpn)**

[Circulatory dynamics based on physiopathology of respiratory insufficiency] Nagasaka Y. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):18-23 (7 ref.) **(Jpn)**

[Etiology and physiopathology of acute exacerbation of respiratory insufficiency] Yanai M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):32-6 (4 ref.) **(Jpn)**

REHABILITATION

[Noninvasive ventilation in chronic obstructive lung disease] Laube I, et al. **Ther Umsch** 1999 Mar;56(3):147-50 (8 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of respiratory insufficiency. Comprehensive respiratory rehabilitation] Kida K. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):57-62 (6 ref.) **(Jpn)**

SURGERY

Advances in lung transplantation. Kesten S. **Dis Mon** 1999 Mar;45(3):101-14 (41 ref.)

THERAPY

Intravascular membrane oxygenator and carbon dioxide removal devices: a review of performance and improvements. Zwischenberger JB, et al. **ASAIO J** 1999 Jan-Feb;45(1):41-6 (24 ref.)

Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. **Chest** 1999 Aug;116(2):521-34 (63 ref.)

Mechanical ventilation for respiratory failure postthoracotomy. D'Arsigny C, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):585-610 (124 ref.)

Adult respiratory failure. Tremblay A, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):557-83, viii-ix (175 ref.)

Liquid ventilation. Day SE, et al. **Clin Perinatol** 1998 Sep; 25(3):711-22 (80 ref.)

Noninvasive ventilation in neuromuscular disease. Bonekat HW. **Crit Care Clin** 1998 Oct;14(4):775-97 (114 ref.)

Weaning from mechanical ventilation. Chao DC, et al. **Crit Care Clin** 1998 Oct;14(4):799-817, viii (79 ref.)

Monitoring patient mechanics during mechanical ventilation. Jubran A. **Crit Care Clin** 1998 Oct;14(4):629-53, vi (112 ref.)

Noninvasive management of pediatric neuromuscular ventilatory failure: a viable alternative [editorial; comment] Barnes SD. **Crit Care Med** 1998 Dec;26(12):1952-3 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2061-5.

Use of high-frequency and nonconventional ventilation for respiratory failure. Donnelly KM, et al. **Curr Opin Pediatr** 1998 Jun;10(3):278-83 (60 ref.)

Advances in ventilatory support of the pediatric surgical patient. Hemmila MR, et al. **Curr Opin Pediatr** 1999 Jun; 11(3):241-8 (67 ref.)

Inhaled nitric oxide in the treatment of hypoxemic respiratory failure. Kass LJ, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):284-90 (27 ref.)

Being more positive about negative ventilation? [editorial; comment] Wysocki M. **Eur Respir J** 1998 Sep;12(3):515-6 (19 ref.) Comment on: Eur Respir J 1998 Sep;12(3):519-25.

Noninvasive positive pressure ventilation for acute respiratory failure. Hess DR. **Int Anesthesiol Clin** 1999 Summer;37(3):85-102 (50 ref.)

Noninvasive positive pressure ventilation in acute respiratory failure. Mehta S. **Intensive Care Med** 1998 Oct; 24(10):1113-4 (4 ref.)

Following the learning curve: the evolution of kinder, gentler neonatal respiratory technology. Lockridge T. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):443-55 (105 ref.)

High-frequency ventilation versus conventional ventilation: No winner-but no loser [editorial; comment] Truog WE. **J Pediatr** 1999 Jul;135(1):9-11 (10 ref.) Comment on: J Pediatr 1999 Jul;135(1):39-46.

Noninvasive ventilation. Rabatin JT, et al. **Mayo Clin Proc** 1999 Aug;74(8):817-20 (16 ref.)

Non-invasive ventilation--mechanisms of benefit. Elliott MW. **Med Klin** 1999 Apr;94(1 Spec No):2-6 (18 ref.)

Early institution of mechanical ventilation. Ambrosino N. **Monaldi Arch Chest Dis** 1998 Jun;53(3):321-3 (19 ref.)

Noninvasive pressure support ventilation in acute respiratory failure. Brochard L. **Monaldi Arch Chest Dis** 1998 Aug; 53(4):486-7 (20 ref.)

Negative pressure ventilation. Carrado A, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):488-92 (28 ref.)

Noninvasive ventilation in acute exacerbations of chronic obstructive pulmonary disease. Elliott MW. **Monaldi Arch Chest Dis** 1998 Jun;53(3):343-7 (22 ref.)

Management of respiratory failure in cystic fibrosis. Hodson ME. **Monaldi Arch Chest Dis** 1998 Oct;53(5):537-9 (23 ref.)

Intravascular gas exchange. Keogh BF, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):38-42 (18 ref.)

Modalities of ventilation in obesity. Muir JF, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):556-9 (21 ref.)

Is early noninvasive mechanical ventilation of first choice in stable COPD patients with chronic respiratory failure? Patessio A. **Monaldi Arch Chest Dis** 1999 Feb;54(1):83-6 (48 ref.)

Invasive mechanical ventilation in exacerbations of chronic obstructive pulmonary disease. Pingleton SK. **Monaldi Arch Chest Dis** 1998 Jun;53(3):337-42 (44 ref.)

Is early noninvasive mechanical ventilation of first choice in stable restrictive patients with chronic respiratory failure? Raphaël JC, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):90-7 (95 ref.)

Is early noninvasive ventilation the first choice in stable restrictive patients with chronic respiratory failure? Shneerson J. **Monaldi Arch Chest Dis** 1999 Feb;54(1):87-9 (8 ref.)

Arteriovenous carbon dioxide removal: development and impact on ventilator management and survival during severe respiratory failure. Zwischenberger JB, et al. **Perfusion** 1999 Jul;14(4):299-310 (58 ref.)

Management of pulmonary complications in neuromuscular disease. Benditt JO. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):167-85 (57 ref.)

Respiratory failure: current status of experimental therapies. Hirschl RB. **Semin Pediatr Surg** 1999 Aug;8(3):155-70 (177 ref.)

[Progresses in the study of pediatrics] Chen X, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):899-900 (0 ref.) **(Chi)**

[Instrumental management of chronic respiratory insufficiency: contribution of long-term therapeutic assistance at home] Muir JF, et al. **Bull Acad Natl Med** 1998;182(6):1139-56; discussion 1156-8 (33 ref.) (Eng. Abstr.) **(Fre)**

[Medico-social management of severe respiratory insufficiency. Role of Associations] Voisin C. **Bull Acad Natl Med** 1998;182(6):1159-71; discussion 1172 (25 ref.) (Eng. Abstr.) **(Fre)**

[Techniques and indications for bronchoscopy in the artificially ventilated patient] Dombret MC. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S91-4 (13 ref.) **(Fre)**

[Long-term ventilation at home in adults with neurological diseases] Raphaël JC, et al. **Rev Mal Respir** 1998 Sep; 15(4):495-505 (62 ref.) (Eng. Abstr.) **(Fre)**

[Exercise therapy of respiratory insufficiency] Hirata K, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):70-6 (5 ref.) **(Jpn)**

[Home mechanical ventilation for the treatment of respiratory insufficiency] Kimura K. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):89-93 (10 ref.) **(Jpn)**

[Therapy of respiratory insufficiency. Oxygen inhalation therapy, including home oxygen therapy] Nishimura M. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):51-6 (11 ref.) **(Jpn)**

[Noninvasive positive pressure ventilation (NIPPV) for the treatment of respiratory insufficiency] Oi M, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):77-81 (10 ref.) **(Jpn)**

[Home mechanical ventilation as a treatment of the sequelae of tuberculosis surgery] Prats Soro E, et al. **An Med Interna** 1999 Jan;16(1):35-7 (12 ref.) (Eng. Abstr.) **(Spa)**

[Ventilatory support in patients with acute disease of the central nervous system] Bugedo G, et al. **Rev Med Chil** 1999 Feb;127(2):211-21 (53 ref.) (Eng. Abstr.) **(Spa)**

RESPIRATORY MECHANICS

A critical review of the studies of the effects of simulated or real gastroesophageal reflux on pulmonary function in asthmatic adults. Field SK. **Chest** 1999 Mar;115(3):848-56 (50 ref.)

Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop [see comments] Johnson BD, et al. **Chest** 1999 Aug; 116(2):488-503 (56 ref.) Comment in: Chest 1999 Aug;116(2):277-8.

Monitoring patient mechanics during mechanical ventilation. Jubran A. **Crit Care Clin** 1998 Oct;14(4):629-53, vi (112 ref.)

Pulmonary mechanics and graphics during positive pressure ventilation. Hess DR, et al. **Int Anesthesiol Clin** 1999 Summer;37(3):15-34 (75 ref.)

Mechanical ventilatory constraints in aging, lung disease, and obesity: perspectives and brief review. Babb TG. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S12-22 (44 ref.)

Practical applications of monitoring respiratory mechanics in newborn. Migliori C, et al. **Minerva Pediatr** 1999 Mar; 51(3):57-64 (11 ref.) **(Eng, Ita)**

DRUG EFFECTS

Do sex-related differences exist in the respiratory pharmacology of opioids? Sarton E, et al. **Adv Exp Med Biol** 1998;450:141-5 (15 ref.)

PHYSIOLOGY

Do sex-related differences exist in the respiratory pharmacology of opioids? Sarton E, et al. **Adv Exp Med Biol** 1998;450:141-5 (15 ref.)

Hebbian covariance learning. A nexus for respiratory variability, memory, and optimization? Young DL, et al. **Adv Exp Med Biol** 1998;450:73-83 (41 ref.)

Respiratory mechanics and surfactant in the acute respiratory distress syndrome. Bersten AD, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):955-63 (76 ref.)

Human respiratory muscles: sensations, reflexes and fatiguability. Gandevia SC, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):757-63 (38 ref.)

Moon phases and ocean tides: the relationship between the inspiratory-expiratory phases of mechanical ventilation and right ventricular function [editorial; comment] Popovich MJ. **Crit Care Med** 1999 May;27(5):864-5 (14 ref.) Comment on: Crit Care Med 1999 May;27(5):953-8.

Physiological basis of improvement after lung volume reduction surgery for severe emphysema: where are we? [see comments] Marchand E, et al. **Eur Respir J** 1999 Mar; 13(3):686-96 (99 ref.) Comment in: Eur Respir J 1999 Mar;13(3):480-1.

Measurement of functional residual capacity in the critically ill. Relevance for the assessment of respiratory mechanics during mechanical ventilation. Rimensberger PC, et al. **Intensive Care Med** 1999 May;25(5):540-2 (3 ref.)

Protein kinase C--a potential modifier of carotid body function. Faff L, et al. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):172-7 (69 ref.)

Of shadows and wind. Callahan CW. **Pediatr Pulmonol** 1998 Aug;26(2):145-6 (4 ref.)

The psychobiology of strained breathing and its cardiovascular implications: a functional system review. Fokkema DS. **Psychophysiology** 1999 Mar;36(2):164-75 (165 ref.)

Pathophysiology of chronic obstructive pulmonary disease. Celli BR. **Respir Care Clin N Am** 1998 Sep;4(3):359-70, vii (39 ref.)

[Starling resister and stability of sleep ventilation] Krieger J, et al. **Neurophysiol Clin** 1998 Dec;28(6):493-506 (11 ref.) (Eng. Abstr.) **(Fre)**

[Measurement of respiratory effort (esophageal pressure) and estimation of resistance of the upper airway in polysomnography: indications, limitations and results] Loiodice C, et al. **Neurophysiol Clin** 1998 Dec;28(6):507-20 (29 ref.) (Eng. Abstr.) **(Fre)**

[The sigh in ARDS (acute respiratory distress syndrome) Pelosi P, et al. **Minerva Anestesiol** 1999 May;65(5):313-7 (16 ref.) (Eng. Abstr.) **(Ita)**

RESPIRATORY MUSCLE TRAINING see **BREATHING EXERCISES**

RESPIRATORY MUSCLES

[Evaluation of respiratory muscles] Fitting JW. **Schweiz Med Wochenschr** 1998 Aug 15;128(33):1212-6 (10 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Assessing new technology, another chapter: lung volume reduction surgery/recombinant human growth hormone [editorial; comment] Slonim AD, et al. **Crit Care Med** 1999 Aug;27(8):1687-8 (15 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634-8.

PHYSIOLOGY

Human respiratory muscles: sensations, reflexes and fatiguability. Gandevia SC, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):757-63 (38 ref.)

Sense of effort and dyspnoea. Killian KJ. **Monaldi Arch Chest Dis** 1998 Dec;53(6):654-60 (39 ref.)

RESPIRATORY MUSCLES

Monitoring respiratory muscles. Nava S.
Monaldi Arch Chest Dis 1998 Dec;53(6):640–3 (26 ref.)

PHYSIOPATHOLOGY

Respiratory muscle involvement in multiple sclerosis. Gosselink R, et al. **Eur Respir J** 1999 Feb;13(2):449–54 (49 ref.)
Respiratory muscle function in patients with neuromuscular disorders and cardiopulmonary diseases. Syabbalo N.
Int J Clin Pract 1998 Jul–Aug;52(5):319–29 (129 ref.)
Respiratory muscle function in endocrine diseases. Siafakas NM, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):154–9 (101 ref.)
Respiratory muscles in heart failure. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):150–3 (25 ref.)
Pathophysiology of chronic obstructive pulmonary disease. Celli BR. **Respir Care Clin N Am** 1998 Sep;4(3):359–70, vii (39 ref.)
Surgery and the respiratory muscles. Siafakas NM, et al.
Thorax 1999 May;54(5):458–65 (111 ref.)
[Inspiratory muscle training in patients with chronic obstructive pulmonary disease] Lisboa C, et al.
Rev Med Chil 1998 May;126(5):563–8 (29 ref.) (Eng. Abstr.) **(Spa)**

RESPIRATORY PARALYSIS

DIAGNOSIS

[Evaluation of respiratory muscles] Fitting JW.
Schweiz Med Wochenschr 1998 Aug 15;128(33):1212–6 (10 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Phrenic nerve injury following cardiac surgery: a review. Tripp HF, et al. **J Card Surg** 1998 May;13(3):218–23 (29 ref.)
Diaphragmatic paralysis following minor blunt trauma. Dalshaug GB, et al. **J Trauma** 1999 Aug;47(2):413–5 (15 ref.)

RESPIRATORY PHYSIOLOGY

Determinants and control of breathing during muscular exercise. Whipp BJ, et al. **Br J Sports Med** 1998 Sep; 32(3):199–211 (84 ref.)
Role of the respiratory control system in the pathophysiology of hypercapnia. Gardner WN. **Monaldi Arch Chest Dis** 1998 Jun;53(3):281–6 (71 ref.)
Implications of pathophysiology for management of the obstructive sleep apnoea syndrome. McNicholas WT.
Monaldi Arch Chest Dis 1998 Oct;53(5):524–9 (64 ref.)
Energy balance and intermediate metabolism in chronic lung disease. Muers MF, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):564–73 (51 ref.)
Central control of the cardiovascular and respiratory systems and their interactions in vertebrates. Taylor EW, et al.
Physiol Rev 1999 Jul;79(3):855–916 (673 ref.)
Relationship of structure and function of the avian respiratory system to disease susceptibility. Fedde MR. **Poult Sci** 1998 Aug;77(8):1130–8 (51 ref.)
Endothelin and the airway mucosa. Baraniuk JN, et al.
Pulm Pharmacol Ther 1998 Apr–Jun;11(2–3):113–23 (102 ref.)
Endothelin receptor subtypes: distribution and function in the lung. Goldie RG. **Pulm Pharmacol Ther** 1998 Apr–Jun; 11(2–3):89–95 (103 ref.)
Tachykinins and airway function. Lagente V, et al.
Pulm Pharmacol Ther 1998 Oct–Dec;11(5–6):331–40 (122 ref.)
Nitric oxide and airways. Matera MG.
Pulm Pharmacol Ther 1998 Oct–Dec;11(5–6):341–8 (78 ref.)
Cytokines and airways: recent insights and therapeutic implications. Passalacqua G, et al.
Pulm Pharmacol Ther 1998 Oct–Dec;11(5–6):375–9 (56 ref.)
Modulation of sensory nerve function in the airways. Spina D. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):319–30 (160 ref.)
[Respiratory defence mechanisms. Particular circumstances in healthy and sick children] Donato L. **Arch Pediatr** 1998; 5 Suppl 1:5s–8s (6 ref.) (Eng. Abstr.) **(Fre)**
[Airway myocytes as immune effector cells in the pathogenesis of bronchial asthma. Myocyte culture as an in vitro model] John M, et al. **Pneumologie** 1999 Jun; 53(6):302–6 (40 ref.) **(Ger)**
[The Gaba-ergic system and its importance for regulating respiration] Tarakanov IA, et al. **Fiziol Cheloveka** 1998 Sep–Oct;24(5):116–28 (159 ref.) **(Rus)**

RESPIRATORY PROTECTIVE DEVICES

STANDARDS

Field performance measurements of half-facepiece respirators: developing probability estimates to evaluate the adequacy of an APF of 10. Myers WR, et al.
Am Ind Hyg Assoc J 1998 Nov;59(11):796–801 (19 ref.)

UTILIZATION

Decision model for optimizing respirator protection. Harber P, et al. **J Occup Environ Med** 1999 May;41(5):356–65 (55 ref.)

RESPIRATORY SOUNDS

Neonatal stridor in association with herpes simplex infection of the larynx. Sharp HR, et al. **J Laryngol Otol** 1998 Dec; 112(12):1192–3 (7 ref.)
Recurrent ENT problems and wheezing in infants. Dutau G, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):18–22 (59 ref.)

DIAGNOSIS

[Stridor in a female patient who underwent pneumonectomy. A postpneumonectomy syndrome] Jiménez Castro D, et al. **Rev Clin Esp** 1999 May;199(5):323–4 (8 ref.) **(Spa)**

ETIOLOGY

Goitre presenting as an oropharyngeal mass: an unusual finding in the elderly. Berenholz LP, et al.
J Laryngol Otol 1999 Feb;113(2):170–1 (6 ref.)
An unusual case of stridor due to osteophytes of the cervical spine: (Forestier's disease). Papakostas K, et al.
J Laryngol Otol 1999 Jan;113(1):65–7 (15 ref.)
Immunologic mechanisms of virus-induced wheezing and asthma. Welliver RC. **J Pediatr** 1999 Aug;135(2 Pt 2):14–20 (41 ref.)
Investigation and treatment of chronic stridor in infancy. Landau LI. **Monaldi Arch Chest Dis** 1999 Feb;54(1):18–21 (10 ref.)
The importance of diagnosis of allergy in early wheezing. Trindade JC. **Pediatr Allergy Immunol** 1998;9(11 Suppl):23–9 (50 ref.)

IMMUNOLOGY

Immunologic mechanisms of virus-induced wheezing and asthma. Welliver RC. **J Pediatr** 1999 Aug;135(2 Pt 2):14–20 (41 ref.)

PHYSIOLOGY

Of shadows and wind. Callahan CW. **Pediatr Pulmonol** 1998 Aug;26(2):145–6 (4 ref.)

RESPIRATORY STIMULANTS see **RESPIRATORY SYSTEM AGENTS**

RESPIRATORY SYNCYTIAL VIRUS, BOVINE

IMMUNOLOGY

Contribution of advances in immunology to vaccine development. Morrison WI, et al. **Adv Vet Med** 1999; 41:181–95 (44 ref.)
[Immunobiology of bovine respiratory syncytial virus infections] Schrijver RS. **Tijdschr Diergeneeskd** 1998 Nov 15;123(22):658–62 (29 ref.) (Eng. Abstr.) **(Dut)**

RESPIRATORY SYNCYTIAL VIRUS, HUMAN

[Vaccines against respiratory syncytial virus] Freymuth F, et al. **Arch Pediatr** 1999;6 Suppl 3:650s–654s (26 ref.) **(Fre)**
[Respiratory syncytial virus infection in childhood] Hammer J. **Schweiz Med Wochenschr** 1998 Sep 12;128(37):1366–74 (68 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Domachowske JB, et al. **Clin Microbiol Rev** 1999 Apr;12(2):298–309 (194 ref.)

ISOLATION & PURIFICATION

[Prevention and therapy of bronchiolitis: current status] León León MC, et al. **An Esp Pediatr** 1998 Nov;49(5):451–5 (46 ref.) **(Spa)**

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Respiratory syncytial virus: A continuing culprit and conundrum. Hall CB. **J Pediatr** 1999 Aug;135(2 Pt 2):2–7 (60 ref.)
Respiratory syncytial virus infection. Simoes EA. **Lancet** 1999 Sep 4;354(9181):847–52 (52 ref.)
Respiratory syncytial virus infection in older persons. Falsey AR. **Vaccine** 1998 Nov;16(18):1775–8 (38 ref.)

COMPLICATIONS

Asthma and respiratory syncytial virus infection in infancy: is there a link? Wang SZ, et al. **Clin Exp Allergy** 1998 Aug; 28(8):927–35 (121 ref.)

DIAGNOSIS

[Central apnea in newborns] van Putten MJ, et al.
Ned Tijdschr Geneeskd 1999 Feb 27;143(9):441–4 (17 ref.) (Eng. Abstr.) **(Dut)**
[Respiratory syncytial virus infection in childhood] Hammer J. **Schweiz Med Wochenschr** 1998 Sep 12;128(37):1366–74 (68 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness? Dominguez KD, et al.
Ann Pharmacother 1999 Jun;33(6):739–41 (19 ref.)
[Respiratory syncytial virus infections and ribavirin: the controversy continues (editorial; comment)] Aujard Y.
Arch Pediatr 1998 Feb;5(2):107–10 (24 ref.) Comment on: Arch Pediatr 1998 Feb;5(2):123–31. **(Fre)**

EPIDEMIOLOGY

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. Han LL, et al.
J Infect Dis 1999 Jan;179(1):25–30 (39 ref.)

IMMUNOLOGY

Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Domachowske JB, et al. **Clin Microbiol Rev** 1999 Apr;12(2):298–309 (194 ref.)
Host responses to respiratory virus infection and immunization. Crowe JE Jr.
Curr Top Microbiol Immunol 1999;236:191–214 (235 ref.)
Prevention strategies for respiratory syncytial virus: passive and active immunization. Englund JA. **J Pediatr** 1999 Aug; 135(2 Pt 2):38–44 (66 ref.)
[Vaccines against respiratory syncytial virus] Freymuth F, et al. **Arch Pediatr** 1999;6 Suppl 3:650s–654s (26 ref.) **(Fre)**

PHYSIOPATHOLOGY

Pulmonary function changes in children after respiratory syncytial virus infection in infancy. McBride JT.
J Pediatr 1999 Aug;135(2 Pt 2):28–32 (25 ref.)

PREVENTION & CONTROL

Respiratory syncytial virus (RSV) disease and prospects for its control. Wyde PR. **Antiviral Res** 1998 Aug;39(2):63–79 (200 ref.)
Recent approaches to the management and prevention of respiratory syncytial virus infection. McCarthy CA, et al.
Curr Clin Top Infect Dis 1998;18:1–18 (119 ref.)
Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner? Hussell T, et al. **Curr Opin Microbiol** 1999 Aug; 2(4):410–4 (46 ref.)
Prevention strategies for respiratory syncytial virus: passive and active immunization. Englund JA. **J Pediatr** 1999 Aug; 135(2 Pt 2):38–44 (66 ref.)
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Meissner HC, et al.
Pediatr Infect Dis J 1999 Mar;18(3):223–31 (57 ref.)
[Advances in the study of pediatric infectious diseases] Aristegui Fernández J, et al. **An Esp Pediatr** 1999 May; 50(5):525–30 (59 ref.) **(Spa)**

THERAPY

Management strategies for respiratory syncytial virus infections in infants. Rodriguez WJ. **J Pediatr** 1999 Aug; 135(2 Pt 2):45–50 (37 ref.)

VETERINARY

Contribution of advances in immunology to vaccine development. Morrison WI, et al. **Adv Vet Med** 1999; 41:181–95 (44 ref.)
[Immunobiology of bovine respiratory syncytial virus infections] Schrijver RS. **Tijdschr Diergeneeskd** 1998 Nov 15;123(22):658–62 (29 ref.) (Eng. Abstr.) **(Dut)**

VIROLOGY

[Prevention and therapy of bronchiolitis: current status] León León MC, et al. **An Esp Pediatr** 1998 Nov;49(5):451–5 (46 ref.) **(Spa)**

RESPIRATORY SYNCYTIAL VIRUSES

IMMUNOLOGY

Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner? Hussell T, et al. **Curr Opin Microbiol** 1999 Aug; 2(4):410–4 (46 ref.)
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Meissner HC, et al.
Pediatr Infect Dis J 1999 Mar;18(3):223–31 (57 ref.)

RESPIRATORY SYSTEM

Aspiration of gauze pressure-pack following a dental extraction: a case report. Villasenor A. **Pediatr Dent** 1999 Mar–Apr;21(2):135–6 (6 ref.)

ANATOMY & HISTOLOGY

Biotransport in the human respiratory system. Elad D. **Technol Health Care** 1999;7(4):271–84 (68 ref.)
[Starling resister and stability of sleep ventilation] Krieger J, et al. **Neurophysiol Clin** 1998 Dec;28(6):493–506 (11 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Forkhead transcription factor HFH–4 and respiratory epithelial cell differentiation. Whitsett JA, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):153–4 (17 ref.)
[Airway myocytes as immune effector cells in the pathogenesis of bronchial asthma. Myocyte culture as an in vitro model] John M, et al. **Pneumologie** 1999 Jun; 53(6):302–6 (40 ref.) **(Ger)**

DRUG EFFECTS

Effect of beta–agonists on inflammatory cells. Barnes PJ. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 2):S10–7 (109 ref.)
Bacterial toxins which perturb ciliary function and respiratory epithelium. Dowling RB, et al. **Soc Appl Bacteriol Symp Ser** 1998;27:138S–148S (100 ref.)

IMMUNOLOGY

Allergy in the airway. Sutherland M, et al. **Aust Fam Physician** 1998 Aug;27(8):681–5 (32 ref.)
Functional studies on dendritic cells in the respiratory tract and related mucosal tissues. Holt PG, et al. **J Leukoc Biol** 1999 Aug;66(2):272–5 (43 ref.)
Pulmonary defence mechanisms. Nicod LP. **Respiration** 1999; 66(1):2–11 (75 ref.)
Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Kyd JM, et al. **Vaccine** 1999 Mar 26;17(13–14):1775–81 (49 ref.)

INNERVATION

Autonomic innervation of human airways: structure, function, and pathophysiology in asthma. van der Velden VH, et al. **Neuroimmunomodulation** 1999 May–Jun; 6(3):145–59 (266 ref.)
Neurogenesis of patterns of automatic ventilatory activity. St–John WM. **Prog Neurobiol** 1998 Oct;56(1):97–117 (127 ref.)
Modulation of sensory nerve function in the airways. Spina D. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):319–30 (160 ref.)
[Modulatory mechanisms involved in the parasympathetic excitatory neuro–effector transmission in the airway and gastrointestinal tracts--perspective for a new drug creation] Ito Y. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:28P–31P (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Optimization of the mammalian respiratory system: symmorphosis versus single species adaptation. Jones JH. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):125–38 (58 ref.)
Neuropeptides in atopic dermatitis. Giannetti A. **Curr Probl Dermatol** 1999;28:51–5 (8 ref.)
Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Wise R, et al. **Eur Respir J** 1999 Jul;14(1):221–9 (97 ref.)
Nitric oxide and airways. Matera MG. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):341–8 (78 ref.)

MICROBIOLOGY

Antibiotic resistance in oral/respiratory bacteria. Roberts MC. **Crit Rev Oral Biol Med** 1998;9(4):522–40 (140 ref.)
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Pechere JC, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):405–12 (48 ref.)
Pneumocystis carinii interactions with respiratory epithelium. Pottratz ST. **Semin Respir Infect** 1998 Dec;13(4):323–9 (35 ref.)
[Resistance of respiratory and enteral bacteria to antibiotics] Solórzano–Santos F, et al. **Salud Publica Mex** 1998 Nov–Dec;40(6):510–6 (44 ref.) **(Spa)**

PATHOLOGY

Regulation of airway neurogenic inflammation by neutral endopeptidase [see comments] Di Maria GU, et al. **Eur Respir J** 1998 Dec;12(6):1454–62 (109 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250–1.
Airway structure: a role for confocal microscopy? Goldie RG, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec; 11(5–6):349–54 (68 ref.)
Airways remodelling in asthma. Vignola AM, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):359–67 (148 ref.)
Amyloidosis and the respiratory tract. Gillmore JD, et al. **Thorax** 1999 May;54(5):444–51 (80 ref.)

PHYSIOPATHOLOGY

Pulmonary function changes in children after respiratory syncytial virus infection in infancy. McBride JT. **J Pediatr** 1999 Aug;135(2 Pt 2):28–32 (25 ref.)
[Respiratory defence mechanisms. Particular circumstances in healthy and sick children] Donato L. **Arch Pediatr** 1998; 5 Suppl 1:5s–8s (6 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Evaluation of airways in obstructive pulmonary disease using high–resolution computed tomography. King GG, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):992–1004 (37 ref.)

SECRETION

Airway secretion and asthma [editorial;; comment] Smaldone GC. **Respiration** 1999;66(2):110–1 (4 ref.) Comment on: Respiration 1999 ;66(2):112–8.
Mucin gene expression and mucin secretion in human airway epithelium. Yoon JH, et al. **Rhinology** 1998 Dec; 36(4):146–52 (71 ref.)

VIROLOGY

Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. Kattan M. **J Pediatr** 1999 Aug;135(2 Pt 2):8–13 (38 ref.)

RESPIRATORY SYSTEM ABNORMALITIES

GENETICS

De novo complete trisomy 5p: clinical report and FISH studies. Reichenbach H, et al. **Am J Med Genet** 1999 Aug 27;85(5):447–51 (12 ref.)

VETERINARY

Feline respiratory diseases. Hoskins JD. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):945–58, vii (21 ref.)

RESPIRATORY SYSTEM AGENTS

THERAPEUTIC USE

Pharmacologic adjuncts to mechanical ventilation in acute respiratory distress syndrome. Albertson TE, et al. **Crit Care Clin** 1998 Oct;14(4):581–610, v (232 ref.)

RESPIRATORY THERAPY

see related
BREATHING EXERCISES

Ventilatory care in status asthmaticus. Smyth RJ. **Can Respir J** 1998 Nov–Dec;5(6):485–90 (43 ref.)
Physiotherapy and bronchial mucus transport. van der Schans CP, et al. **Eur Respir J** 1999 Jun;13(6):1477–86 (121 ref.)

METHODS

Contributions of respiratory care practitioners to intensive care: a review. Yu NC, et al. **Ann Acad Med Singapore** 1998 May;27(3):422–5 (21 ref.)
Maximizing functional capacity. Pulmonary rehabilitation and adjunctive measures. Resnikoff PM, et al. **Respir Care Clin N Am** 1998 Sep;4(3):475–92 (91 ref.)
[Inhalation therapy in children younger than 2 years. II. The practice (see comments)] Griffioen RW, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1488–93 (15 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2212–3; discussion 2214–5. **(Dut)**

RESPIRATORY THERAPY DEPARTMENT, HOSPITAL

Infection control in the bronchoscopy suite. A review. Mehta AC, et al. **Clin Chest Med** 1999 Mar;20(1):19–32, ix (114 ref.)

RESPIRATORY TRACT DISEASES

CHEMICALLY INDUCED

All but quiet on the particulate front [editorial; comment] Brunekreef B. **Am J Respir Crit Care Med** 1999 Feb; 159(2):354–6 (16 ref.) Comment on: Am J Respir Crit Care Med 1999 Feb;159(2):365–72. Comment on: Am J Respir Crit Care Med 1999 Feb;159(2):373–82.
Health effects of urban outdoor air pollution in children. Current epidemiological data. Ségala C. **Pediatr Pulmonol Suppl** 1999;18:6–8 (15 ref.)
Toxicological mechanisms underlying oxidant pollutant–induced airway injury. Krishna MT, et al. **Rev Environ Health** 1998 Jan–Jun;13(1–2):59–71 (75 ref.)
Acrolein: a respiratory toxin that suppresses pulmonary host defense. Li L, et al. **Rev Environ Health** 1998 Jan–Jun; 13(1–2):99–108 (75 ref.)

COMPLICATIONS

Sleep in patients with respiratory disease. Lewis DA. **Respir Care Clin N Am** 1999 Sep;5(3):447–60, ix (69 ref.)
[Mitral valve prolapse and respiratory diseases] Korytnikov KI. **Klin Med (Mosk)** 1999;77(4):15–8 (5 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Bronchoalveolar lavage of newborn infants. Kotecha S. **Pediatr Pulmonol Suppl** 1999;18:122–4 (10 ref.)
[New clinical tests that physicians should know for diagnosis of respiratory system disease] Takizawa H. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1993–8 (9 ref.) **(Jpn)**
[Exercise tests and respiratory gas analysis in cardiology. Testing procedure and selected parameters needed for evaluation of cardiopulmonary system function] Podolec P, et al. **Przegl Lek** 1998;55(2):57–63 (18 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Anticholinergic agents. Cazzola M, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):381–92 (96 ref.)
Leukotriene antagonists. Costello JF. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):393–5 (28 ref.)
Cytokines and airways: recent insights and therapeutic implications. Passalacqua G, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):375–9 (56 ref.)
[Therapeutic update 1997–1998 (1). First part] Scheen AJ. **Rev Med Liege** 1998 Aug;53(8):459–66 (28 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation. Koehne P, et al. **Allergy** 1998 Nov;53(11):1023–42 (248 ref.)

EPIDEMIOLOGY

SWORD '97: surveillance of work–related and occupational respiratory disease in the UK. Ross DJ, et al. **Occup Med (Lond)** 1998 Nov;48(8):481–5 (9 ref.)

ETIOLOGY

Noise–induced extra–aural pathology: a review and commentary. Alves–Pereira M. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A7–21 (98 ref.)
Respiratory complications of gastrointestinal diseases. Young MA, et al. **Gastroenterol Clin North Am** 1998 Dec; 27(4):721–46 (115 ref.)
Illness and injury in animal confinement workers. Von Essen S, et al. **Occup Med** 1999 Apr–Jun;14(2):337–50 (69 ref.)
Functional pulmonary surfactant deficiency and neonatal respiratory disorders. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:175–7 (8 ref.)
Health effects of passive smoking–10: Summary of effects of parental smoking on the respiratory health of children and implications for research. Cook DG, et al. **Thorax** 1999 Apr;54(4):357–66 (62 ref.)
[Medium and long–term sequelae of community–acquired pneumonia in children] Deschildre A. **Arch Pediatr** 1998; 5 Suppl 1:45s–48s (19 ref.) (Eng. Abstr.) **(Fre)**
[Diseases associated with organic dusts] Michel O. **Rev Med Brux** 1998 Sep;19(4):A358–62 (20 ref.) (Eng. Abstr.) **(Fre)**
[Endotoxins in the workplace and in the environment] Danuser B, et al. **Schweiz Med Wochenschr** 1999 Mar 27; 129(12):475–83 (56 ref.) (Eng. Abstr.) **(Ger)**
[The role of intercellular adhesion molecule–1 in respiratory disorders] Nagase T. **Nihon Kokyuki Gakkai Zasshi** 1998 Nov;36(11):923–7 (54 ref.) (Eng. Abstr.) **(Jpn)**
[Pediatric diseases associated with passive smoking] Ferris Tortajada J, et al. **An Esp Pediatr** 1998 Oct;49(4):339–47 (83 ref.) **(Spa)**

GENETICS

Case of partial trisomy 2q3 with clinical manifestations of Marshall–Smith syndrome. Seidahmed MZ, et al. **Am J Med Genet** 1999 Jul 16;85(2):185–8 (11 ref.)

PATHOLOGY

Protocol for the examination of specimens removed from patients with carcinomas of the upper aerodigestive tract: carcinomas of the oral cavity including lip and tongue, nasal and paranasal sinuses, pharynx, larynx, salivary glands, hypopharynx, oropharynx, and nasopharynx. Cancer Committee, College of American Pathologists. Min KW, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):222–30 (58 ref.)
Amyloidosis and the respiratory tract. Gillmore JD, et al. **Thorax** 1999 May;54(5):444–51 (80 ref.)

PHYSIOPATHOLOGY

Cytokines and airways: recent insights and therapeutic implications. Passalacqua G, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):375–9 (56 ref.)

PREVENTION & CONTROL

Prevention of respiratory diseases. Thakker H, et al. **Indian J Med Sci** 1998 Feb;52(2):60–5 (3 ref.)

RESPIRATORY TRACT DISEASES

[Respiratory tract diseases and instructions on smoking cessation] Kawakami M. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):362–7 (11 ref.) **(Jpn)**

SURGERY

Thoracoscopic procedures for intrathoracic and pulmonary diseases. Sung SW, et al. **Respirology** 1999 Mar;4(1):19–29 (61 ref.)

THERAPY

Therapeutic benefits of qigong exercises in combination with drugs. Sancier KM. **J Altern Complement Med** 1999 Aug; 5(4):383–9 (38 ref.)

VETERINARY

Relationship of structure and function of the avian respiratory system to disease susceptibility. Fedde MR. **Poult Sci** 1998 Aug;77(8):1130–8 (51 ref.)

Feline respiratory diseases. Hoskins JD. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):945–58, vii (21 ref.)

RESPIRATORY TRACT FISTULA

ETIOLOGY

Early complications. Esophagopleural fistula. Massard G, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):617–31, ix (44 ref.)

Midfacial complications of prolonged cocaine snorting. Villa PD. **J Can Dent Assoc** 1999 Apr;65(4):218–23 (28 ref.)

Traumatic thoracobiliary fistula: report of a case successfully managed conservatively, with an overview of current diagnostic and therapeutic options. Sheik-Gafoor MH, et al. **J Trauma** 1998 Oct;45(4):819–21 (16 ref.)

[A colopleural fistula as the clinical presentation of colonic adenocarcinoma (letter)] Domingo-Morera JA, et al. **Arch Bronconeumol** 1999 Jan;35(1):52–3 (6 ref.) **(Spa)**

RESPIRATORY TRACT INFECTIONS

Opportunistic thoracic infections. Bacteria, viruses, and protozoa. Talbot EA, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):167–92, ix–x (91 ref.)

Host responses to respiratory virus infection and immunization. Crowe JE Jr. **Curr Top Microbiol Immunol** 1999;236:191–214 (235 ref.)

[HIV Infection/AIDS and respiratory tract infections in Japan] Kimura S. **Kekkaku** 1998 Sep;73(9):563–71 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculosis in respiratory system--tracheo-bronchial tuberculosis, pulmonary tuberculosis, tuberculous pleurisy and thoracic empyema] Nagao K. **Nippon Rinsho** 1998 Dec; 56(12):3104–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Acute upper airway infection] Narushima M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):407–9 (12 ref.) **(Jpn)**

[Respiratory tract infections by Pseudomonas aeruginosa in patients under intubation] Rello J, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:17–20 (31 ref.) **(Spa)**

COMPLICATIONS

On eggs and chicken [editorial; comment] de Jongste JC, et al. **Eur Respir J** 1999 Jul;14(1):2–3 (14 ref.) Comment on: Eur Respir J 1999 Jul;14(1):4–11.

Immunologic mechanisms of virus-induced wheezing and asthma. Welliver RC. **J Pediatr** 1999 Aug;135(2 Pt 2):14–20 (41 ref.)

Recurrent ENT problems and wheezing in infants. Dutau G, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):18–22 (59 ref.)

Potential infectious disease complications of upper respiratory tract infections. Gooch WM 3rd. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S79–82 (26 ref.)

[Asthma and infection: risk or prevention?] von Mutius E. **Schweiz Med Wochenschr** 1998 Nov 21;128(47):1833–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Viral respiratory infection in bronchial asthma] Suzuki S. **Arerugi** 1999 Jan;48(1):5–8 (28 ref.) **(Jpn)**

[Infection and chronic obstructive pulmonary disease] Zalacain R. **Arch Bronconeumol** 1998 Oct;34(9):453–62 (118 ref.) **(Spa)**

DIAGNOSIS

Fever without apparent source on clinical examination, lower respiratory infections in children, and other infectious diseases. McCarthy PL, et al. **Curr Opin Pediatr** 1999 Feb; 11(1):89–106 (96 ref.)

Molecular techniques for the diagnosis of respiratory bacterial infection. Gillespie S. **Curr Opin Pulm Med** 1999 May;5(3):174–8 (35 ref.)

Allergic and infectious pediatric sinusitis [see comments] Zacharisen MC, et al. **Pediatr Ann** 1998 Nov;27(11):759–66 (19 ref.) Comment in: Pediatr Ann 1998 Nov;27(11):708.

Lower respiratory tract infection and pneumonia in the community. Macfarlane J. **Semin Respir Infect** 1999 Jun; 14(2):151–62 (77 ref.)

[Laboratory diagnosis of viral infections. 1. Respiratory tract infections] Takeuchi K. **Rinsho Byori** 1998 Nov;Suppl 108:43–58 (22 ref.) **(Jpn)**

[Chlamydia as the agent responsible for infections of the upper respiratory tract in children and adults] Aristegui Fernández J. **Rev Clin Esp** 1998 Sep;198 Suppl 1:19–23 (31 ref.) **(Spa)**

DRUG THERAPY

Appropriate use of antibiotics for URIs in children: Part II. Cough, pharyngitis and the common cold. The Pediatric URI Consensus Team. Dowell SF, et al. **Am Fam Physician** 1998 Oct 15;58(6):1335–42, 1345 (67 ref.)

Antibiotic resistance in community-acquired respiratory tract infections: current issues. Spach DH, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):293–302; quiz 302–3 (87 ref.)

Approaches to antiviral chemotherapy for acute respiratory infections. Shigeta S. **Antivir Chem Chemother** 1998 Mar; 9(2):93–107 (87 ref.)

Respiratory infections in the community. A concise update. Ferguson J. **Aust Fam Physician** 1998 Oct;27(10):883–7 (0 ref.)

Reducing antibiotics for respiratory tract symptoms in primary care: consolidating 'why' and considering 'how' [see comments] Butler CC, et al. **Br J Gen Pract** 1998 Dec; 48(437):1865–70 (105 ref.) Comment in: Br J Gen Pract 1998 Dec;48(437):1815–6. Comment in: Br J Gen Pract 1999 Mar;49(440):237.

Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice [see comments] Wang EE, et al. **Can Fam Physician** 1998 Sep;44:1881–8 (72 ref.) Comment in: Can Fam Physician 1998 Sep;44:1769–73, 1780–4. Comment in: Can Fam Physician 1998 Nov;44:2375–6.

Clinical implications of resistance in the management of respiratory tract infections. Garau J. **Can Respir J** 1999 Jan–Feb;6 Suppl A:23A–6A (25 ref.)

Evolving patterns of resistance to respiratory pathogens in Canada. Hoban DJ, et al. **Can Respir J** 1999 Jan–Feb;6 Suppl A:27A–30A (22 ref.)

Chinese Herbal Medicine in the treatment of acute respiratory tract infections: review of randomized and controlled clinical trials. Liu C, et al. **Clin Infect Dis** 1999 Feb; 28(2):235–6 (27 ref.)

Upper respiratory tract infections. Moore DA, et al. **Curr Opin Pulm Med** 1999 May;5(3):157–63 (63 ref.)

Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Griffith DE. **Drug Saf** 1999 Aug; 21(2):137–52 (60 ref.)

Antibiotic treatment of adults with chest infection in general practice. **Drug Ther Bull** 1998 Sep;36(9):68–72 (34 ref.)

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Langtry HD, et al. **Drugs** 1998 Sep;56(3):487–515 (126 ref.)

What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections? Momméja-Marin H, et al. **Drugs** 1999 Jun;57(6):851–3 (11 ref.)

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Pechère JC, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):405–12 (48 ref.)

Spiramycin renaissance. Rubinstein E, et al. **J Antimicrob Chemother** 1998 Nov;42(5):572–6 (24 ref.)

The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. Carbon C, et al. **J Chemother** 1999 Apr;11(2):107–18 (77 ref.)

Echinacea for upper respiratory infection. Barrett B, et al. **J Fam Pract** 1999 Aug;48(8):628–35 (71 ref.)

Chinese herbal medicines in the treatment of acute respiratory infections: a review of randomised and controlled clinical trials [see comments] Liu C, et al. **Med J Aust** 1998 Dec 7–21;169(11–12):579–82 (36 ref.) Comment in: Med J Aust 1998 Dec 7–21;169(11–12):573–4.

Treatment of upper and lower respiratory tract infections: clinical trials with cefprozil. Aronovitz G. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S83–8 (25 ref.)

When to prescribe in lower respiratory tract infection? Macfarlane J, et al. **Practitioner** 1997 Dec;241(1581):732–4, 737–8 (11 ref.)

[Theoretical basis for the antibiotic therapy of the upper part of the respiratory system] Denys A. **Otolaryngol Pol** 1997; 51 Suppl 25:155–60 (10 ref.) (Eng. Abstr.) **(Pol)**

[Practical implications of bacterial resistance to antibiotics. Attempts to fight it] Denys A. **Otolaryngol Pol** 1997;51 Suppl 25:171–4 (5 ref.) (Eng. Abstr.) **(Pol)**

[Compliance in antibiotic therapy of respiratory tract infections] Karpov OI. **Antibiot Khimioter** 1999;44(8):37–45 (47 ref.) **(Rus)**

[Is trovafloxacin an antibiotic exclusively for the treatment of respiratory infections?] Garau J. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:43–6; discussion 47–52 (24 ref.) **(Spa)**

[Has the moment arrived for quinolones in the treatment of respiratory infections?] Gomis M, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:1–7; discussion 47–52 (20 ref.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of respiratory infectious diseases. Enarson DA, et al. **Curr Opin Pulm Med** 1999 May;5(3):128–35 (142 ref.)

Respiratory diseases among U.S. military personnel: countering emerging threats. Gray GC, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):379–85 (80 ref.)

Regional differences in prevalence and risks of respiratory diseases in children. Cropp GJ. **Pediatr Pulmonol Suppl** 1999;18:37–40 (8 ref.)

ETIOLOGY

Respiratory infectious complications in the intensive care unit. Torres A, et al. **Clin Chest Med** 1999 Jun; 20(2):287–301, viii (67 ref.)

Clinical and technical approach to selective decontamination of the digestive tract (SDD). Zandstra DF. **Minerva Anestesiol** 1999 May;65(5):197–201 (44 ref.)

Regional differences in prevalence and risks of respiratory diseases in children. Cropp GJ. **Pediatr Pulmonol Suppl** 1999;18:37–40 (8 ref.)

[Respiratory involvement in neutropenic patients] Moldovan D, et al. **Pneumoftiziologia** 1998 Jul–Sep;47(3):185–8 (13 ref.) **(Rum)**

GENETICS

Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections. Tümmler B, et al. **Mol Med Today** 1999 Aug;5(8):351–8 (50 ref.)

IMMUNOLOGY

Exercise and resistance to infection. Nieman DC. **Can J Physiol Pharmacol** 1998 May;76(5):573–80 (47 ref.)

Respiratory infections in immunocompromised patients. Barry SM, et al. **Curr Opin Pulm Med** 1999 May; 5(3):168–73 (50 ref.)

Defense mechanisms against infections. Reynolds HY. **Curr Opin Pulm Med** 1999 May;5(3):136–42 (61 ref.)

Sudden infant death syndrome, virus infections and cytokines. Raza MW, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):85–96 (140 ref.)

Inflammatory responses in sudden infant death syndrome -- past and present views. Vege A, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):67–78 (135 ref.)

Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Wasserman RL, et al. **Pediatr Infect Dis J** 1999 Feb; 18(2):157–63 (37 ref.)

METABOLISM

Interaction of viral infections with muscarinic receptors. Jacoby DB, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:59–64 (41 ref.)

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Wise R, et al. **Eur Respir J** 1999 Jul;14(1):221–9 (97 ref.)

MICROBIOLOGY

Moraxella (Branhamella) catarrhalis: clinical, microbiological and immunological features in lower respiratory tract infections. Christensen JJ. **APMIS Suppl** 1999;88:1–36 (249 ref.)

Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice [see comments] Wang EE, et al. **Can Fam Physician** 1998 Sep;44:1881–8 (72 ref.) Comment in: Can Fam Physician 1998 Sep;44:1769–73, 1780–4. Comment in: Can Fam Physician 1998 Nov;44:2375–6.

Antimicrobial resistance in community-acquired respiratory tract pathogens. Lark RL, et al. **Compr Ther** 1999 Jan; 25(1):20–9 (83 ref.)

Upper respiratory tract infections. Moore DA, et al. **Curr Opin Pulm Med** 1999 May;5(3):157–63 (63 ref.)

Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Griffith DE. **Drug Saf** 1999 Aug; 21(2):137–52 (60 ref.)

Susceptibility and resistance emergence studies with macrolides. Retsema JA. **Int J Antimicrob Agents** 1999 Mar; 11 Suppl 1:S15–21; discussion S31–2 (22 ref.)

Role of oral bacteria in respiratory infection. Scannapieco FA. **J Periodontol** 1999 Jul;70(7):793–802 (87 ref.)

Sinusitis [see comments] Wald ER. **Pediatr Ann** 1998 Dec; 27(12):811–8 (30 ref.) Comment in: Pediatr Ann 1999 Mar;28(3):151.

Microbial factors leading to recurrent upper respiratory tract infections. Brook I. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S62–7 (35 ref.)

Microbiology of bacterial respiratory infections. Cappelletty D. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S55–61 (66 ref.)

Update on respiratory infection caused by Bordetella parapertussis. Hoppe JE. **Pediatr Infect Dis J** 1999 Apr; 18(4):375–81 (70 ref.)

Upper respiratory tract infections in family practice. Ruoff G. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S73–8 (33 ref.)

[Bacterial infections in otolaryngology on clinical material study] Murlewska A, et al. **Otolaryngol Pol** 1997;51 Suppl 25:175–8 (10 ref.) (Eng. Abstr.) **(Pol)**

[Other communal respiratory pathogens and new fluoroquinolones] Cantón R, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16 Suppl 2:12–21; discussion 47–52 (107 ref.) **(Spa)**

PHYSIOPATHOLOGY

Mechanisms of asthma exacerbation. Johnston SL. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:181–6; discussion 203–5 (34 ref.)

Role of respiratory infection in onset of asthma and chronic obstructive pulmonary disease. Martinez FD. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:53–8 (42 ref.)

Respiratory control during upper airway infection mechanism for prolonged reflex apnoea and sudden infant death with special reference to infant sleep position. Lindgren C. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1–2):97–102 (45 ref.)

Exposure to nitrogen dioxide (NO2) and respiratory disease risk. Chauhan AJ, et al. **Rev Environ Health** 1998 Jan–Jun; 13(1–2):73–90 (93 ref.)

[Respiratory defence mechanisms. Particular circumstances in healthy and sick children] Donato L. **Arch Pediatr** 1998; 5 Suppl 1:5s–8s (6 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Use of aerosolized antibiotics in patients with cystic fibrosis. Campbell PW 3rd, et al. **Chest** 1999 Sep;116(3):775–88 (47 ref.)

Intranasal antibody prophylaxis for protection against viral disease. Weltzin R, et al. **Clin Microbiol Rev** 1999 Jul; 12(3):383–93 (116 ref.)

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Zeitlin L, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):54–64 (127 ref.)

RADIOGRAPHY

The utility of CT in imaging chest infections in HIV–negative patients. Richenberg J, et al. **Curr Opin Pulm Med** 1999 May;5(3):179–84 (33 ref.)

Trends in pediatric emergency imaging. John SD. **Radiol Clin North Am** 1999 Sep;37(5):995–1034, vi (91 ref.)

[Evolution and radiologic surveillance on community–acquired pneumonia in children] Monroc M, et al. **Arch Pediatr** 1998;5 Suppl 1:37s–44s (18 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

Imported tropical respiratory tract infections. Zuckerman JN. **Curr Opin Pulm Med** 1999 May;5(3):164–7 (20 ref.)

[Respiratory and community infections] Ovetchkine P, et al. **Arch Pediatr** 1999;6 Suppl 3:633s–635s (12 ref.) **(Fre)**

VETERINARY

Properties and functions of feline herpesvirus type 1 glycoproteins. Maeda K, et al. **J Vet Med Sci** 1998 Aug; 60(8):881–8 (97 ref.)

Bacterial respiratory disease of poultry. Glisson JR. **Poult Sci** 1998 Aug;77(8):1139–42 (10 ref.)

Mycoplasmas in the etiology of multifactorial respiratory disease. Kleven SH. **Poult Sci** 1998 Aug;77(8):1146–9 (61 ref.)

Viral diseases of the respiratory system. Villegas P. **Poult Sci** 1998 Aug;77(8):1143–5 (24 ref.)

VIROLOGY

First International Symposium on Influenza and Other Respiratory Viruses: summary and overview: Kapalua, Maui, Hawaii, December 4–6, 1998. Kaiser L, et al. **Antiviral Res** 1999 Jul;42(3):149–75 (94 ref.)

Role of viruses in the onset of asthma and allergy: lessons from animal models. Hegele RG. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:78–81 (30 ref.)

Diagnosis of respiratory viruses in cancer and transplant patients. Englund JA, et al. **Curr Clin Top Infect Dis** 1999; 19:30–59 (121 ref.)

Immunologic mechanisms of virus–induced wheezing and asthma. Welliver RC. **J Pediatr** 1999 Aug;135(2 Pt 2):14–20 (41 ref.)

Respiratory viral infections and the endothelin system. Henry PJ. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):133–40 (81 ref.)

RESPIRATORY TRACT NEOPLASMS

Recurrent respiratory papillomatosis. Murray LN, et al. **J La State Med Soc** 1998 Oct;150(10):456–9 (15 ref.)

[Extramedullary plasmacytoma] Togawa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):419–21 (5 ref.) **(Jpn)**

PATHOLOGY

Variants of squamous cell carcinoma of the upper aerodigestive tract. Wenig BM. **Anat Pathol** 1998;3:17–51 (134 ref.)

Oxyphilic proliferations of the respiratory tract and paranasal sinuses. Ritter JH, et al. **Semin Diagn Pathol** 1999 May; 16(2):105–16 (75 ref.)

PREVENTION & CONTROL

Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Ki Hong W, et al. **Clin Cancer Res** 1995 Jul;1(7):677–86 (64 ref.)

SURGERY

Thoracoscopy in infants and children. Rothenberg SS. **Semin Pediatr Surg** 1998 Nov;7(4):194–201 (27 ref.)

THERAPY

[Interventional bronchoscopic procedures––indications] Schönfeld N, et al. **Dtsch Med Wochenschr** 1999 May 28; 124(21):659–61 (8 ref.) **(Ger)**

VETERINARY

Neoplasia of the respiratory tract. Scarratt WK, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):451–73, v (123 ref.)

RESPONSE, ACUTE-PHASE see **ACUTE-PHASE REACTION**

RESPONSE ELEMENTS

Regulation of expression of surfactant protein–A. Mendelson CR, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2–3):132–49 (59 ref.)

GENETICS

Control elements of muscarinic receptor gene expression. Saffen D, et al. **Life Sci** 1999;64(6–7):479–86 (32 ref.)

Insulin inhibition of glucocorticoid–stimulated gene transcription: requirement for an insulin response element? Pierreux CE, et al. **Mol Cell Endocrinol** 1999 Jan 25; 147(1–2):1–5 (33 ref.)

RESPONSE LATENCY see **REACTION TIME**

RESPONSE TIME see **REACTION TIME**

RESPONSIBILITY, SOCIAL see **SOCIAL RESPONSIBILITY**

REST

see related
BED REST

REST VERTICAL DIMENSION see **VERTICAL DIMENSION**

RESTING PHASE see **INTERPHASE**

RESTING POTENTIALS see **MEMBRANE POTENTIALS**

RESTLESS LEGS

How to help patients with restless legs syndrome. Discerning the indescribable and relaxing the restless. Evidente VG, et al. **Postgrad Med** 1999 Mar;105(3):59–61, 65–6, 73–4 (22 ref.)

[Restless leg syndrome] Winkelmann J, et al. **Med Monatsschr Pharm** 1999 Mar;22(3):67–71 (8 ref.) **(Ger)**

[Restless legs syndrome] Horiguchi J. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):200–2 (6 ref.) **(Jpn)**

[Restless legs. A much neglected syndrome (see comments)] Ulfberg J, et al. **Lakartidningen** 1999 Mar 10;96(10):1183–4, 1187–8 (47 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Jul 14;96(28–29):3238. **(Swe)**

DRUG THERAPY

An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy. Janzen L, et al. **Ann Pharmacother** 1999 Jan;33(1):86–92 (36 ref.)

RESTLESSNESS see **PSYCHOMOTOR AGITATION**

RESTRAINT, PHYSICAL

see related
IMMOBILIZATION
PROTECTIVE DEVICES

Restraints and the elderly with mental illness: ethical issues and moral reasoning [see comments] Dawkins VH. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):22–7 (12 ref.) Comment in: J Psychosoc Nurs Ment Health Serv 1998 Dec;36(12):6.

Restraint and housing of ratites. Raines AM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):387–99, v (1 ref.)

ADVERSE EFFECTS

Reexamination of custody restraint position and positional asphyxia. Chan TC, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):201–5 (31 ref.)

Restraining patients and shoulder dislocations during seizures. DeToledo JC, et al. **J Shoulder Elbow Surg** 1999 Jul–Aug;8(4):300–2 (32 ref.)

Factors associated with excited delirium deaths in police custody. Ross DL. **Mod Pathol** 1998 Nov;11(11):1127–37 (47 ref.)

LEGISLATION & JURISPRUDENCE

Report of the Council on Scientific Affairs. Use of restraints for patients in nursing homes. Council on Scientific Affairs, American Medical Association. Guttman R, et al. **Arch Fam Med** 1999 Mar–Apr;8(2):101–5 (42 ref.)

Physical restraints in the acute care setting: issues and future direction. Frengley JD, et al. **Clin Geriatr Med** 1998 Nov; 14(4):727–43 (59 ref.)

METHODS

Physical restraints in the acute care setting: issues and future direction. Frengley JD, et al. **Clin Geriatr Med** 1998 Nov; 14(4):727–43 (59 ref.)

VETERINARY

Immobilisation of pinniped species. Lynch MJ, et al. **Aust Vet J** 1999 Mar;77(3):181–5 (39 ref.)

RESTRICTION ENDONUCLEASES see **DNA RESTRICTION ENZYMES**

RESTRICTION ENDONUCLEASES, TYPE II see **DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC**

RESTRICTION FRAGMENT LENGTH POLYMORPHISM see **POLYMORPHISM, RESTRICTION FRAGMENT LENGTH**

RESTRICTION MAPPING

METHODS

[The use of molecular biology in the modeling of Pseudomonas aeruginosa strains recovered from nosocomial infections] Fiett J, et al. **Przegl Epidemiol** 1998; 52(4):427–40 (18 ref.) (Eng. Abstr.) **(Pol)**

RESTRICTION-MODIFICATION SYSTEMS see **DNA RESTRICTION-MODIFICATION ENZYMES**

RESUSCITATION

Ethical issues surrounding resuscitation. Boyle RJ, et al. **Clin Perinatol** 1999 Sep;26(3):779–92 (73 ref.)

Medication use in neonatal resuscitation. Burchfield DJ. **Clin Perinatol** 1999 Sep;26(3):683–91 (57 ref.)

Resuscitation of the surgical neonate. Chahine AA, et al. **Clin Perinatol** 1999 Sep;26(3):693–715 (38 ref.)

Physiologic reflexes and their impact on resuscitation of the newborn. Halbower AC, et al. **Clin Perinatol** 1999 Sep; 26(3):621–7, vi (33 ref.)

Intrauterine resuscitation of the compromised fetus. Lindsay MK. **Clin Perinatol** 1999 Sep;26(3):569–84, v (77 ref.)

Delivery room resuscitation of the newborn. Wolkoff LI, et al. **Clin Perinatol** 1999 Sep;26(3):641–58 (45 ref.)

Accidental hypothermia. Hanania NA, et al. **Crit Care Clin** 1999 Apr;15(2):235–49 (53 ref.)

Total splanchnic resuscitation, SIRS, and MODS [editorial; comment] Marik PE. **Crit Care Med** 1999 Feb;27(2):257–8 (43 ref.) Comment on: Crit Care Med 1999 Feb;27(2):394–400.

Ethical issues of resuscitation. Marco CA. **Emerg Med Clin North Am** 1999 May;17(2):527–38, xiii–xiv (96 ref.)

Consensus and controversy over resuscitation of the newborn infant. Soll R. **Lancet** 1999 Jul 3;354(9172):4–5 (13 ref.)

Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Resuscitation** 1999 Feb–Mar;40(2):71–88 (85 ref.)

[The use of curare–like agents in resuscitation] Suppini A, et al. **Ann Fr Anesth Reanim** 1999 Mar;18(3):341–54 (142 ref.) (Eng. Abstr.) **(Fre)**

[Successful resuscitation of a patient with ventricular fibrillation in Bland–White–Garland syndrome in adulthood. A case report] Kreutzer U, et al. **Z Kardiol** 1998 Jul;87(7):560–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Current issues of resuscitation] Negovskiĭ VA, et al. **Anesteziol Reanimatol** 1999 Jan–Feb;(1):6–9 (27 ref.) (Eng. Abstr.) **(Rus)**

[Logic of the development of intensive care in critical states] Riabov GA. **Anesteziol Reanimatol** 1999 Jan–Feb;(1):10–3 (13 ref.) **(Rus)**

METHODS

Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650–1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429–36.

Acadesine during fluid resuscitation from shock and abdominal sepsis [see comments] Melton SM, et al. **Crit Care Med** 1999 Mar;27(3):565–75 (46 ref.) Comment in: Crit Care Med 1999 Mar;27(3):468–9.

Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Eur J Pediatr** 1999 Apr;158(4):345–58 (85 ref.)

An evaluation of the end points of resuscitation. Elliott DC. **J Am Coll Surg** 1998 Nov;187(5):536–47 (84 ref.)

Hypertonic saline resuscitation. Rocha e Silva M. **Medicina (B Aires)** 1998;58(4):393–402 (186 ref.)

RESUSCITATION

[Drowning and near-drowning in children] van der Lely N, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17;142(42):2294–7 (21 ref.) (Eng. Abstr.) **(Dut)**

[Volumetric hemodynamic monitoring] Pittoni G, et al. **Minerva Anestesiol** 1999 Jun;65(6):357–61 (20 ref.) **(Ita)**

[Critical appraisal of treatments in emergency settings] Takahashi H, et al. **Nippon Geka Gakkai Zasshi** 1999 Jul; 100(7):449–54 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Resuscitation of the burned child in critical condition] Sanabria Carretero P, et al. **Rev Esp Anestesiol Reanim** 1998 Aug–Sep;45(7):285–93 (80 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

An advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Pediatrics** 1999 Apr;103(4):e56 (85 ref.)

TRENDS

Future trends in cerebral resuscitation. Safar P. **Minerva Anestesiol** 1999 Mar;65(3):69–73 (20 ref.)

RESUSCITATION DECISIONS see **RESUSCITATION ORDERS**

RESUSCITATION ORDERS

DNR in the OR: a goal-directed approach [see comments] Truog RD, et al. **Anesthesiology** 1999 Jan;90(1):289–95 (20 ref.) Comment in: Anesthesiology 1999 Jan;90(1):3–6.

Do-not-resuscitate orders in the face of patient and family opposition [editorial; comment] Leonard CT, et al. **Crit Care Med** 1999 Jun;27(6):1045–7 (19 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1116–20.

The role of audit in making do not resuscitate decisions. Hayes S, et al. **J Eval Clin Pract** 1999 Aug;5(3):305–12 (30 ref.)

On estimating the causal effects of DNR orders [editorial; comment] McIntosh MW, et al. **Med Care** 1999 Aug; 37(8):722–6 (16 ref.) Comment on: Med Care 1999 Aug;37(8):727–37.

Do patients die because they have DNR orders, or do they have DNR orders because they are going to die? [editorial; comment] Sulmasy DP. **Med Care** 1999 Aug;37(8):719–21 (14 ref.) Comment on: Med Care 1999 Aug;37(8):727–37.

Unexpected return of spontaneous circulation after cessation of resuscitation (Lazarus phenomenon) [see comments] Maleck WH, et al. **Resuscitation** 1998 Oct–Nov; 39(1–2):125–8 (26 ref.) Comment in: Resuscitation 1999 Jun;41(1):87.

A broader look at medical futility. Shelton W. **Theor Med Bioeth** 1998 Aug;19(4):383–400 (18 ref.)

["Meaningless treatment" in terminal care. Importance of declaring do-not-resuscitate orders] Löfmark R, et al. **Lakartidningen** 1998 Oct 21;95(43):4759–61 (20 ref.) (Eng. Abstr.) **(Swe)**

LEGISLATION & JURISPRUDENCE

Do not resuscitate (DNR): analysis of the DNR act. Koehler S, et al. **J Okla State Med Assoc** 1999 Jul;92(7):316–9 (9 ref.)

PSYCHOLOGY

The northeast Tennessee Spirituality and End of Life Issues Survey. Ginn DR, et al. **Tenn Med** 1998 Nov;91(11):425–30 (13 ref.)

RETAINERS, ORTHODONTIC see **ORTHODONTIC RETAINERS**

RETENTION (PSYCHOLOGY)

PHYSIOLOGY

The functional neuroanatomy of episodic memory: the role of the frontal lobes, the hippocampal formation, and other areas. Desgranges B, et al. **Neuroimage** 1998 Aug; 8(2):198–213 (120 ref.)

RETICULAR FORMATION

ANATOMY & HISTOLOGY

The neural substrate for 'learned' and 'nonlearned' activities in birds: a discussion of the organization of bulbar reticular premotor systems with side-lights on the mammalian situation. Dubbeldam JL. **Acta Anat (Basel)** 1998; 163(3):157–72 (84 ref.)

PHYSIOLOGY

Neurology of saccades and smooth pursuit. Gaymard B, et al. **Curr Opin Neurol** 1999 Feb;12(1):13–9 (56 ref.)

Paying attention to the thalamic reticular nucleus. Guillery RW, et al. **Trends Neurosci** 1998 Jan;21(1):28–32 (44 ref.)

RETICULOCYTES

METABOLISM

Hypochromic red blood cells and reticulocytes. Schaefer RM, et al. **Kidney Int Suppl** 1999 Mar;69:S44–8 (19 ref.)

RETICULOENDOTHELIAL SYSTEM

see related
HISTIOCYTES
KUPFFER CELLS
MACROPHAGES
PHAGOCYTES

DRUG EFFECTS

Pentoxifylline--more evidence that it improves host defenses during sepsis [editorial; comment] Reynolds H. **Crit Care Med** 1999 Apr;27(4):681–3 (41 ref.) Comment on: Crit Care Med 1999 Apr;27(4):756–63.

RETICULOENDOTHELIOSIS, LEUKEMIC see **LEUKEMIA, HAIRY CELL**

RETICULOHISTIOCYTOMA see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

RETICULOLYMPHOSARCOMA see **LYMPHOMA**

RETICULOSIS, HISTIOCYTIC MEDULLARY see **HISTIOCYTOSIS, MALIGNANT**

RETICULUM

RADIOGRAPHY

Reticular foreign bodies. Causative or coincidence? Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul; 15(2):397–408 (0 ref.)

RETICULUM-CELL SARCOMA see **LYMPHOMA, LARGE-CELL**

RETINA

see related
ELECTRORETINOGRAPHY

[Implantation of the artificial retina] Yagi T, et al. **Nippon Rinsho** 1999 May;57(5):1208–15 (18 ref.) (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Retinal structure and visual acuity in a polyprotodont marsupial, the fat-tailed dunnart (Sminthopsis crassicaudata). Arrese C, et al. **Brain Behav Evol** 1999; 53(3):111–26 (154 ref.)

Retinal projections and retinal ganglion cell distribution patterns in a sturgeon (Acipenser transmontanus), a non-teleost actinopterygian fish. Ito H, et al. **Brain Behav Evol** 1999;53(3):127–41 (85 ref.)

MR imaging anatomy of the optic pathways. Tamraz JC, et al. **Radiol Clin North Am** 1999 Jan;37(1):1–36, ix (65 ref.)

Optical coherence tomography. Ripandelli G, et al. **Semin Ophthalmol** 1998 Dec;13(4):199–202 (12 ref.)

CYTOLOGY

Neuronal diversity: too many cell types for comfort? Stevens CF. **Curr Biol** 1998 Oct 8;8(20):R708–10 (7 ref.)

Multipotential stem cells and progenitors in the vertebrate retina. Reh TA, et al. **J Neurobiol** 1998 Aug;36(2):206–20 (114 ref.)

Structure determines function of the retina, a neural center. 4. The 'duplex' nature of vision. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):463–74 (88 ref.)

The golden age of retinal cell culture. Seigel GM. **Mol Vis** 1999 Apr 19;5:4 (157 ref.)

Neural retinal cell transplantation: ideal versus reality [editorial] Berson EL, et al. **Ophthalmology** 1999 Mar; 106(3):445–6 (13 ref.)

The eyes of deep-sea fish. II. Functional morphology of the retina. Wagner HJ, et al. **Prog Retin Eye Res** 1998 Oct; 17(4):637–85 (144 ref.)

EMBRYOLOGY

The roles of intrinsic and extrinsic cues and bHLH genes in the determination of retinal cell fates. Cepko CL. **Curr Opin Neurobiol** 1999 Feb;9(1):37–46 (55 ref.)

Eph receptors and ephrins in neural development. O'Leary DD, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):65–73 (74 ref.)

The retinal pigment epithelium as a developmental regulator of the neural retina. Jeffery G. **Eye** 1998;12 (Pt 3b):499–503 (32 ref.)

Development of the retina. Malicki J. **Methods Cell Biol** 1999; 59:273–99 (102 ref.)

ENZYMOLOGY

Melatonin synthesis pathway: circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Bernard M, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):325–34 (44 ref.)

GROWTH & DEVELOPMENT

Genetics of epithelial polarity and pattern in the Drosophila retina. Reifegerste R, et al. **Bioessays** 1999 Apr;21(4):275–85 (63 ref.)

Neurotrophins and other growth factors in the generation of retinal neurons. Frade JM, et al. **Microsc Res Tech** 1999 May 15-Jun 1;45(4–5):243–51 (72 ref.)

GABA as a developmental neurotransmitter in the outer plexiform layer of the vertebrate retina. Redburn-Johnson D. **Perspect Dev Neurobiol** 1998;5(2–3):261–7 (57 ref.)

Mechanisms involved in development of retinotectal connections: roles of Eph receptor tyrosine kinases, NMDA receptors and nitric oxide. Ernst AF, et al. **Prog Brain Res** 1998;118:115–31 (131 ref.)

Apoptosis in developing retinal tissue. Linden R, et al. **Prog Retin Eye Res** 1999 Mar;18(2):133–65 (260 ref.)

IMMUNOLOGY

Immunological problems of transplantation into the subretinal space. Enzmann V, et al. **Acta Anat (Basel)** 1998; 162(2–3):178–83 (51 ref.)

Immune privilege in the retina. Gregerson DS. **Ocul Immunol Inflamm** 1998 Dec;6(4):257–67 (68 ref.)

METABOLISM

Calcium-binding proteins and nitric oxide in retinal function and disease. Müller F, et al. **Acta Anat (Basel)** 1998; 162(2–3):142–50 (109 ref.)

Developmental basis of retinal-specific induction of cancer by RB mutation. Gallie BL, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1731s–1735s (25 ref.)

Glucose transport in brain and retina: implications in the management and complications of diabetes. Kumagai AK. **Diabetes Metab Res Rev** 1999 Jul–Aug;15(4):261–73 (163 ref.)

A hypothesis to explain the reduced blood levels of docosahexaenoic acid in inherited retinal degenerations caused by mutations in genes encoding retina-specific proteins. Anderson RE, et al. **Lipids** 1999;34 Suppl:S235–7 (25 ref.)

Calcium-independent release of neurotransmitter in the retina: a "copernican" viewpoint change. Piccolino M, et al. **Prog Retin Eye Res** 1999 Jan;18(1):1–38 (89 ref.)

[The synthesis and effects of nitric oxide at the retinal level] Cruce M, et al. **Oftalmologia** 1998;42(2):9–12 (12 ref.) (Eng. Abstr.) **(Rum)**

PATHOLOGY

Idiopathic central serous chorioretinopathy. Hussain D, et al. **Indian J Ophthalmol** 1998 Sep;46(3):131–7 (55 ref.)

Biopsy of the retina and the choroid. Arbour JD, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):213–22 (49 ref.)

Peripheral retinal hemorrhages: a literature review and report on thirty-three patients. Tolls DB. **J Am Optom Assoc** 1998 Sep;69(9):563–74 (47 ref.)

Monocular focal retinal lesions induce short-term topographic plasticity in adult cat visual cortex. Calford MB, et al. **Proc R Soc Lond B Biol Sci** 1999 Mar 7; 266(1418):499–507 (37 ref.)

Apoptotic cell death in retinal degenerations. Remé CE, et al. **Prog Retin Eye Res** 1998 Oct;17(4):443–64 (175 ref.)

PHYSIOLOGY

Retinal waves and visual system development. Wong RO. **Annu Rev Neurosci** 1999;22:29–47 (121 ref.)

Modes of interactions between signaling pathways. Jordan JD, et al. **Biochem Pharmacol** 1998 May 1;55(9):1347–52 (35 ref.)

Retinal projections and retinal ganglion cell distribution patterns in a sturgeon (Acipenser transmontanus), a non-teleost actinopterygian fish. Ito H, et al. **Brain Behav Evol** 1999;53(3):127–41 (85 ref.)

Melatonin's role in vertebrate circadian rhythms. Cassone VM. **Chronobiol Int** 1998 Sep;15(5):457–73 (86 ref.)

Keeping an eye on retinal clocks. Herzog ED, et al. **Chronobiol Int** 1999 May;16(3):229–47 (155 ref.)

Retinal processing: amacrine cells keep it short and sweet. Lagnado L. **Curr Biol** 1998 Aug 27;8(17):R598–600 (8 ref.)

Spike timing in the mammalian visual system. Bair W. **Curr Opin Neurobiol** 1999 Aug;9(4):447–53 (49 ref.)

Parallel processing in the mammalian retina: the Proctor Lecture. Boycott B, et al. **Invest Ophthalmol Vis Sci** 1999 Jun;40(7):1313–27 (134 ref.)

Colour processing in the primate retina: recent progress. Martin PR. **J Physiol (Lond)** 1998 Dec 15;513 (Pt 3):631–8 (78 ref.)

Structure determines function of the retina, a neural center. 4. The 'duplex' nature of vision. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):463–74 (88 ref.)

The neural code of the retina. Meister M, et al. **Neuron** 1999 Mar;22(3):435–50 (125 ref.)

GABA as a developmental neurotransmitter in the outer plexiform layer of the vertebrate retina. Redburn-Johnson D. **Perspect Dev Neurobiol** 1998;5(2–3):261–7 (57 ref.)

GABA as a developmental signal in the inner retina and optic nerve. Sandell JH. **Perspect Dev Neurobiol** 1998; 5(2–3):269–78 (137 ref.)

The role of nitric oxide in development of the patch-cluster system and retinocollicular pathways in the rodent superior colliculus. Mize RR, et al. **Prog Brain Res** 1998;118:133–52 (92 ref.)

Endothelium-derived agents in pericyte function/dysfunction. Chakravarthy U, et al. **Prog Retin Eye Res** 1999 Jul;18(4):511–27 (108 ref.)

The intact isolated (ex vivo) retina as a model system for the study of excitotoxicity. Romano C, et al. **Prog Retin Eye Res** 1998 Oct;17(4):465–83 (124 ref.)
Oscillatory potentials in the retina: what do they reveal. Wachtmeister L. **Prog Retin Eye Res** 1998 Oct; 17(4):485–521 (242 ref.)
The eyes of deep-sea fish. II. Functional morphology of the retina. Wagner HJ, et al. **Prog Retin Eye Res** 1998 Oct; 17(4):637–85 (144 ref.)
Early integration of retinal and extra-retinal information: recent results and hypotheses. Sauvan XM. **Rev Neurosci** 1998;9(4):291–9 (35 ref.)
The feedback pathway from horizontal cells to cones. A mini review with a look ahead. Kamermans M, et al. **Vision Res** 1999 Jul;39(15):2449–68 (117 ref.)
[The role of apoptosis in physiology and pathology of the retina] Obuchowska I, et al. **Klin Oczna** 1999;101(2):139–43 (43 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Modeling human eye aberrations and their compensation for high-resolution retinal imaging. Zhu L, et al. **Optom Vis Sci** 1998 Nov;75(11):827–39 (37 ref.)
The electroretinogram in diabetic retinopathy. Tzekov R, et al. **Surv Ophthalmol** 1999 Jul–Aug;44(1):53–60 (106 ref.)
[The prognostic significance of the electrophysiological indices of the retina and optic nerve in patients with opacities of the optical media of the eye] Lariukhina GM, et al. **Vestn Oftalmol** 1998 Sep-Oct;114(5):45–8 (10 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Light exposure is not associated with retinopathy of prematurity. Mills MD. **Arch Ophthalmol** 1998 Nov; 116(11):1517–8 (18 ref.)
Retinal phototoxicity. Solley WA, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):1–12 (55 ref.)
Solar retinopathy in a hospital-based primary care clinic. Stokkermans TJ, et al. **J Am Optom Assoc** 1998 Oct; 69(10):625–36 (75 ref.)
Laser pointers: toys, nuisances, or significant eye hazards? Yolton RL, et al. **J Am Optom Assoc** 1999 May;70(5):285–9 (15 ref.)

SURGERY

Immunological problems of transplantation into the subretinal space. Enzmann V, et al. **Acta Anat (Basel)** 1998; 162(2–3):178–83 (51 ref.)
Surgical management of subretinal hemorrhage. Hochman MA, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):291–301 (45 ref.)

ULTRASONOGRAPHY

Ultrasonic evaluation of the vitreous and retina. Coleman DJ, et al. **Semin Ophthalmol** 1998 Dec;13(4):210–8 (11 ref.)

RETINAL see **RETINALDEHYDE**

RETINAL ANLAGE TUMOR see **NEUROECTODERMAL TUMOR, MELANOTIC**

RETINAL ARTERY

Diagnostic and therapeutic challenges. Schatz H, et al. **Retina** 1998;18(6):551–3 (2 ref.)

ABNORMALITIES

Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Opremcak EM, et al. **Retina** 1999;19(1):1–5 (11 ref.)

DRUG EFFECTS

In vitro studies of the effects of beta-adrenergic drugs on retinal and posterior ciliary microarteries. Hoste AM. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S183–90 (66 ref.)

PHYSIOLOGY

Physiology of perfusion as it relates to the optic nerve head. Orgül S, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S17–26 (144 ref.)

RETINAL ARTERY OCCLUSION

[Small retinal, cochlear, and cerebral infarctions in the young patient, "SICRET" syndrome of Susac syndrome] Mala L, et al. **J Fr Ophtalmol** 1998 May;21(5):375–80 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Systemic lysis therapy in retinal vascular occlusions] Hattenbach LO. **Ophthalmologe** 1998 Aug;95(8):568–75 (47 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Central retinal artery occlusion and optic disc drusen [letter] Farah SG, et al. **Eye** 1998;12 (Pt 3a):480–2 (26 ref.)
The clinico-ophthalmological spectrum of antiphospholipid syndrome. Giorgi D, et al. **Ocul Immunol Inflamm** 1998 Dec;6(4):269–73 (21 ref.)

RETINAL BREAKS see **RETINAL PERFORATIONS**

RETINAL DEGENERATION

BLOOD

A hypothesis to explain the reduced blood levels of docosahexaenoic acid in inherited retinal degenerations caused by mutations in genes encoding retina-specific proteins. Anderson RE, et al. **Lipids** 1999;34 Suppl:S235–7 (25 ref.)

DIAGNOSIS

Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview. Birch DG. **Mol Genet Metab** 1999 Apr;66(4):356–66 (27 ref.)

ETIOLOGY

The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Weleber RG. **Eye** 1998;12 (Pt 3b):580–90 (54 ref.)
Vertebrate photoreceptor cell development and disease. Morrow EM, et al. **Trends Cell Biol** 1998 Sep;8(9):353–8 (68 ref.)
[Senile retinoschisis and schisis-amotio. Pathogenesis, diagnosis, therapy] Clemens S. **Ophthalmologe** 1999 Mar; 96(3):W215–26 (38 ref.) **(Ger)**

GENETICS

Rhodopsin mutations as the cause of retinal degeneration. Classification of degeneration phenotypes in the model system Drosophila melanogaster. Bentrop J. **Acta Anat (Basel)** 1998;162(2–3):85–94 (50 ref.)
The role of the peripherin/RDS gene in retinal dystrophies. Kohl S, et al. **Acta Anat (Basel)** 1998;162(2–3):75–84 (69 ref.)
The Royal College of Surgeons rat: an animal model for inherited retinal degeneration with a still unknown genetic defect. Strauss O, et al. **Acta Anat (Basel)** 1998; 162(2–3):101–11 (151 ref.)
Recent advances in the molecular genetics of hereditary retinal dystrophies with primary involvement of the macula. Weber BH. **Acta Anat (Basel)** 1998;162(2–3):65–74 (93 ref.)
Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus [see comments] Caridi G, et al. **Am J Kidney Dis** 1998 Dec;32(6):1059–62 (12 ref.) Comment in: Am J Kidney Dis 1998 Dec;32(6):1084–5.
Molecular genetics of human retinal dystrophies. Inglehearn CF. **Eye** 1998;12 (Pt 3b):571–9 (114 ref.)
Animal models of human retinal dystrophies. Petersen-Jones SM. **Eye** 1998;12 (Pt 3b):566–70 (53 ref.)
A hypothesis to explain the reduced blood levels of docosahexaenoic acid in inherited retinal degenerations caused by mutations in genes encoding retina-specific proteins. Anderson RE, et al. **Lipids** 1999;34 Suppl:S235–7 (25 ref.)

METABOLISM

Calcium-binding proteins and nitric oxide in retinal function and disease. Müller F, et al. **Acta Anat (Basel)** 1998; 162(2–3):142–50 (109 ref.)
Photoreceptor membrane proteins, phototransduction, and retinal degenerative diseases. The Friedenwald Lecture. Molday RS. **Invest Ophthalmol Vis Sci** 1998 Dec; 39(13):2491–513 (183 ref.)

PATHOLOGY

Apoptotic cell death in retinal degenerations. Remé CE, et al. **Prog Retin Eye Res** 1998 Oct;17(4):443–64 (175 ref.)

PHYSIOPATHOLOGY

Morphogenesis of the retinal pigment epithelium: toward understanding retinal degenerative diseases. Marmorstein AD, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:1–12 (46 ref.)

THERAPY

Stimulus-specific and cell type-specific cascades: emerging principles relating to control of apoptosis in the eye. Wilson SE. **Exp Eye Res** 1999 Sep;69(3):255–66 (99 ref.)
Photoreceptor rescue. Luthert PJ, et al. **Eye** 1998;12 (Pt 3b):591–6 (60 ref.)
Management of hereditary retinal degenerations: present status and future directions. Sharma RK, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):427–44 (254 ref.)

RETINAL DETACHMENT

see related
SCLERAL BUCKLING

DIAGNOSIS

Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119–31, x (64 ref.)

ETIOLOGY

Management of cytomegalovirus-related rhegmatogenous retinal detachments. Baumal CR, et al. **Ophthalmic Surg Lasers** 1998 Nov;29(11):916–25 (60 ref.)
[Senile retinoschisis and schisis-amotio. Pathogenesis, diagnosis, therapy] Clemens S. **Ophthalmologe** 1999 Mar; 96(3):W215–26 (38 ref.) **(Ger)**

SURGERY

Management of cytomegalovirus-related rhegmatogenous retinal detachments. Baumal CR, et al. **Ophthalmic Surg Lasers** 1998 Nov;29(11):916–25 (60 ref.)
Retinal detachment in cytomegalovirus retinitis: should our approach be changed? [editorial; comment] Freeman WR. **Retina** 1999;19(4):271–3 (12 ref.) Comment on: Retina 1999 ;19(4):274–80.
[Retinal detachments and retinal surgery (published erratum appears in Ned Tijdschr Geneeskd 1999 May 8;143(19):1016)] La Heij EC, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):781–5 (16 ref.) (Eng. Abstr.) **(Dut)**
[Liquid perfluorocarbons in vitreo-retinal surgery] Benchekroun O, et al. **J Fr Ophtalmol** 1998 Dec; 21(10):773–81 (54 ref.) **(Fre)**

RETINAL DIALYSES see **RETINAL PERFORATIONS**

RETINAL DISEASES

CHEMICALLY INDUCED

[Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy] Glacet-Bernard A, et al. **Contracept Fertil Sex** 1999 Apr;27(4):285–90 (29 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Diabetic maculopathy caused by disturbances in retinal vasomotion. A new hypothesis. Bek T. **Acta Ophthalmol Scand** 1999 Aug;77(4):376–80 (36 ref.)
Gradual painless visual loss: retinal causes. Elner SG. **Clin Geriatr Med** 1999 Feb;15(1):25–46, v–vi (47 ref.)

DIAGNOSIS

Idiopathic central serous chorioretinopathy. Hussain D, et al. **Indian J Ophthalmol** 1998 Sep;46(3):131–7 (55 ref.)
Detection and prevention of maculopathy associated with antimalarial agents. Easterbrook M. **Int Ophthalmol Clin** 1999 Spring;39(2):49–57 (33 ref.)
Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119–31, x (64 ref.)
Fluorescein and indocyanine green angiography in vascular chorioretinal diseases. Brancato R, et al. **Semin Ophthalmol** 1998 Dec;13(4):189–98 (29 ref.)
Electrophysiological evaluation of the macular cone system: focal electroretinography and visual evoked potentials after photostress. Parisi V, et al. **Semin Ophthalmol** 1998 Dec; 13(4):178–88 (76 ref.)
Optical coherence tomography. Ripandelli G, et al. **Semin Ophthalmol** 1998 Dec;13(4):199–202 (12 ref.)

DRUG THERAPY

Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Osborne NN, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S102–28 (235 ref.)

ETIOLOGY

Rare case of small-cell carcinoma arising from the endometrium with paraneoplastic retinopathy. Sekiguchi I, et al. **Gynecol Oncol** 1998 Dec;71(3):454–7 (9 ref.)
Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy. Giorgi D, et al. **Hum Immunol** 1999 Aug;60(8):688–96 (49 ref.)
Retinal phototoxicity. Solley WA, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):1–12 (55 ref.)
Solar retinopathy in a hospital-based primary care clinic. Stokkermans TJ, et al. **J Am Optom Assoc** 1998 Oct; 69(10):625–36 (75 ref.)
[Viral infectious diseases of the retina] Azumi A, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):336–8 (7 ref.) **(Jpn)**

GENETICS

[Molecular genetics of inherited chorioretinal dystrophy--strategy for identifying disease causing genes] Mashima Y. **Nippon Ganka Gakkai Zasshi** 1999 Mar; 103(3):165–77 (91 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Biopsy of the retina and the choroid. Arbour JD, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):213–22 (49 ref.)
[The role of apoptosis in physiology and pathology of the retina] Obuchowska I, et al. **Klin Oczna** 1999;101(2):139–43 (43 ref.) (Eng. Abstr.) **(Pol)**

RETINAL DISEASES

PHYSIOPATHOLOGY

Photoreceptor "retinoid pumps" in health and disease. Bok D. **Neuron** 1999 Jul;23(3):412–4 (11 ref.)

Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Hayreh SS. **Prog Retin Eye Res** 1999 Mar;18(2):191–221 (168 ref.)

PREVENTION & CONTROL

Detection and prevention of maculopathy associated with antimalarial agents. Easterbrook M. **Int Ophthalmol Clin** 1999 Spring;39(2):49–57 (33 ref.)

[Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy] Glacet-Bernard A, et al. **Contracept Fertil Sex** 1999 Apr;27(4):285–90 (29 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Determining the clinical significance of randomized clinical trials: a review of the efficacy of laser photocoagulation. Sharma S. **Can J Ophthalmol** 1999 Feb;34(1):46–9 (13 ref.)

THERAPY

Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy. Giorgi D, et al. **Hum Immunol** 1999 Aug;60(8):688–96 (49 ref.)

RETINAL DRUSEN

ETIOLOGY

Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Abdelsalam A, et al. **Surv Ophthalmol** 1999 Jul-Aug;44(1):1–29 (148 ref.)

SURGERY

Can laser photocoagulation of eyes with high-risk drusen prevent vision loss from age-related macular degeneration? [editorial; comment] Folk JC, et al. **Ophthalmology** 1999 Jul;106(7):1241–2 (19 ref.) Comment on: Ophthalmology 1999 Jul;106(7):1367–73; discussion 1374.

RETINAL GANGLION CELLS

DRUG EFFECTS

Major biological effects of neurotrophic factors on retinal ganglion cells in mammals. Cui Q, et al. **Biol Signals Recept** 1998 Jul-Aug;7(4):220–6 (63 ref.)

PATHOLOGY

Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Neufeld AH. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S129–35 (54 ref.)

Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Nickells RW. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S151–61 (94 ref.)

PHYSIOLOGY

Retinal projections and retinal ganglion cell distribution patterns in a sturgeon (Acipenser transmontanus), a non-teleost actinopterygian fish. Ito H, et al. **Brain Behav Evol** 1999;53(3):127–41 (85 ref.)

Population coding in the retina. Nirenberg S, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):488–93 (18 ref.)

Eph receptors and ephrins in neural development. O'Leary DD, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):65–73 (74 ref.)

Intrinsic survival mechanisms for retinal ganglion cells. Levin LA. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S12–6 (45 ref.)

Neuronal coupling in the central nervous system: lessons from the retina. Vaney DI. **Novartis Found Symp** 1999; 219:113–25; discussion 125–33 (63 ref.)

Introductory comments on neuroprotection. Kaufman PL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S89–90 (10 ref.)

[Neuronal cell death mechanism in glaucomatous optic neuropathy] Murakami A, et al. **Nippon Ganka Gakkai Zasshi** 1998 Oct;102(10):645–53 (85 ref.) (Eng. Abstr.) **(Jpn)**

RETINAL HEMORRHAGE

DIAGNOSIS

Peripheral retinal hemorrhages: a literature review and report on thirty-three patients. Tolls DB. **J Am Optom Assoc** 1998 Sep;69(9):563–74 (47 ref.)

ETIOLOGY

Peripheral retinal hemorrhages: a literature review and report on thirty-three patients. Tolls DB. **J Am Optom Assoc** 1998 Sep;69(9):563–74 (47 ref.)

Three types of retinal bleeding as a complication of hypotony after trabeculectomy. Suzuki R, et al. **Ophthalmologica** 1999;213(2):135–8 (11 ref.)

SURGERY

Surgical management of subretinal hemorrhage. Hochman MA, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):291–301 (45 ref.)

RETINAL HOLES see **RETINAL PERFORATIONS**

RETINAL NECROSIS SYNDROME, ACUTE

[Viral infectious diseases of the retina] Azumi A, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):336–8 (7 ref.) **(Jpn)**

VIROLOGY

Acute retinal necrosis after neonatal herpes encephalitis [letter; comment] Levinson RD, et al. **Br J Ophthalmol** 1999 Jan;83(1):123–4 (6 ref.) Comment on: Br J Ophthalmol 1997 May;81(5):415–6.

RETINAL NEOPLASMS

see related
RETINOBLASTOMA

Retinoblastoma. Zucker JM, et al. **Eur J Cancer** 1998 Jun; 34(7):1045–8; discussion 1048–9 (40 ref.)

Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium. Beermann F, et al. **Pigment Cell Res** 1999 Apr;12(2):71–80 (71 ref.)

DIAGNOSIS

Retinoblastoma and simulating lesions. Role of CT, MR imaging and use of Gd-DTPA contrast enhancement. Kaufman LM, et al. **Radiol Clin North Am** 1998 Nov; 36(6):1101–17 (63 ref.)

[Leukokoria in a child: emergency and challenge] Balmer A, et al. **Klin Monatsbl Augenheilkd** 1999 May;214(5):332–5 (9 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Topical topic. Use of chemotherapy for retinoblastoma. Pratt CB. **Med Pediatr Oncol** 1998 Dec;31(6):531–3 (28 ref.)

GENETICS

Developmental defects and tumor predisposition in Rb mutant mice. Vooijs M, et al. **Oncogene** 1999 Sep 20; 18(38):5293–303 (137 ref.)

PATHOLOGY

Retinoblastoma in transgenic mice: models of hereditary retinoblastoma. Mills MD, et al. **Surv Ophthalmol** 1999 May-Jun;43(6):508–18 (105 ref.)

[The role of apoptosis in physiology and pathology of the retina] Obuchowska I, et al. **Klin Oczna** 1999;101(2):139–43 (43 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Guy J, et al. **Arch Ophthalmol** 1999 Apr;117(4):471–7 (36 ref.)

Recent developments in the management of retinoblastoma. Shields CL, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jan-Feb;36(1):8–18; quiz 35–6 (64 ref.)

RETINAL PERFORATIONS

DIAGNOSIS

Diagnosis and management of idiopathic macular holes. Saxena S, et al. **Indian J Ophthalmol** 1998 Dec;46(4):185–93 (57 ref.)

ETIOLOGY

Macular hole: a continuing saga [editorial; comment] Fine SL. **Arch Ophthalmol** 1999 Feb;117(2):248–9 (5 ref.) Comment on: Arch Ophthalmol 1999 Feb;117(2):242–6.

SURGERY

Diagnosis and management of idiopathic macular holes. Saxena S, et al. **Indian J Ophthalmol** 1998 Dec;46(4):185–93 (57 ref.)

Surgical management of macular hole. Miller DG, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):261–74 (55 ref.)

RETINAL PIGMENT EPITHELIAL DETACHMENT see **RETINAL DETACHMENT**

RETINAL PIGMENT EPITHELIUM see **PIGMENT EPITHELIUM OF EYE**

RETINAL PIGMENTS

Visual pigment: G-protein-coupled receptor for light signals. Shichida Y, et al. **Cell Mol Life Sci** 1998 Dec; 54(12):1299–315 (153 ref.)

[Diversity of visual pigments and phototransduction systems on the basis of both molecular phylogenetic and functional protein analyses] Terakita A, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):217–25 (35 ref.) **(Jpn)**

CHEMISTRY

How color visual pigments are tuned. Kochendoerfer GG, et al. **Trends Biochem Sci** 1999 Aug;24(8):300–5 (38 ref.)

PHYSIOLOGY

Photopigments and seeing--lessons from natural experiments: the Proctor lecture. Jacobs GH. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2204–16 (99 ref.)

The eyes of deep-sea fish. I: Lens pigmentation, tapeta and visual pigments. Douglas RH, et al. **Prog Retin Eye Res** 1998 Oct;17(4):597–636 (178 ref.)

RADIATION EFFECTS

How color visual pigments are tuned. Kochendoerfer GG, et al. **Trends Biochem Sci** 1999 Aug;24(8):300–5 (38 ref.)

RETINAL S-ANTIGEN see **ARRESTIN**

RETINAL TEARS see **RETINAL PERFORATIONS**

RETINAL VEIN

ABNORMALITIES

Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Opremcak EM, et al. **Retina** 1999;19(1):1–5 (11 ref.)

PHYSIOLOGY

Physiology of perfusion as it relates to the optic nerve head. Orgül S, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S17–26 (144 ref.)

RETINAL VEIN OCCLUSION

[Retinal phlebothrombosis: modern aspects in etiology, pathogenesis, diagnosis and therapy] Malaian AS, et al. **Vestn Oftalmol** 1999 Mar-Apr;115(2):35–40 (97 ref.) **(Rus)**

DRUG THERAPY

[Systemic lysis therapy in retinal vascular occlusions] Hattenbach LO. **Ophthalmologe** 1998 Aug;95(8):568–75 (47 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The clinico-ophthalmological spectrum of antiphospholipid syndrome. Giorgi D, et al. **Ocul Immunol Inflamm** 1998 Dec;6(4):269–73 (21 ref.)

[Fibrinolytic system and a central retinal vein thrombosis] Malukiewicz-Wiśniewska G. **Klin Oczna** 1998;100(3):175–8 (16 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Opremcak EM, et al. **Retina** 1999;19(1):1–5 (11 ref.)

RETINAL VESSELS

see related
FLUORESCEIN ANGIOGRAPHY

Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Hayreh SS. **Prog Retin Eye Res** 1999 Mar;18(2):191–221 (168 ref.)

The purine nucleoside adenosine in retinal ischemia-reperfusion injury. Ghiardi GJ, et al. **Vision Res** 1999 Jul;39(15):2519–35 (81 ref.)

METABOLISM

Structure and activation of the large latent transforming growth factor-Beta complex. Nunes I, et al. **J Am Optom Assoc** 1998 Oct;69(10):643–8 (45 ref.)

PATHOLOGY

Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119–31, x (64 ref.)

PHYSIOLOGY

Regulation of retinal and optic nerve blood flow [see comments] Harris A, et al. **Arch Ophthalmol** 1998 Nov; 116(11):1491–5 (72 ref.) Comment in: Arch Ophthalmol 1999 Jul;116(11):1491–5.

The pecten oculi of the chicken: a model system for vascular differentiation and barrier maturation. Wolburg H, et al. **Int Rev Cytol** 1999;187:111–59 (230 ref.)

Endothelium-derived agents in pericyte function/dysfunction. Chakravarthy U, et al. **Prog Retin Eye Res** 1999 Jul;18(4):511–27 (108 ref.)

PHYSIOPATHOLOGY

Diabetic maculopathy caused by disturbances in retinal vasomotion. A new hypothesis. Bek T. **Acta Ophthalmol Scand** 1999 Aug;77(4):376–80 (36 ref.)

RETINALDEHYDE

CHEMISTRY

The structure and mechanism of the family of retinal proteins from halophilic archaea. Oesterhelt D. **Curr Opin Struct Biol** 1998 Aug;8(4):489–500 (96 ref.)

RETINENE see **RETINALDEHYDE**

RETINITIS

DIAGNOSIS

Leber's idiopathic stellate neuroretinitis: differential diagnosis and approach to management. Casson RJ, et al. **Aust N Z J Ophthalmol** 1999 Feb;27(1):65–9 (21 ref.)

Diffuse unilateral subacute neuroretinitis. Stokkermans TJ. **Optom Vis Sci** 1999 Jul;76(7):444–54 (45 ref.)

THERAPY

Riding on a carousel with IFN-alpha and TNF-alpha [editorial; comment] Zierhut M. **Ocul Immunol Inflamm** 1998 Dec;6(4):209–10 (15 ref.) Comment on: Ocul Immunol Inflamm 1998 Dec;6(4):215–26.

Diffuse unilateral subacute neuroretinitis. Stokkermans TJ. **Optom Vis Sci** 1999 Jul;76(7):444–54 (45 ref.)

RETINITIS, CYTOMEGALOVIRUS see **CYTOMEGALOVIRUS RETINITIS**

RETINITIS PIGMENTOSA

GENETICS

Management of inherited outer retinal dystrophies: present and future. Chong NH, et al. **Br J Ophthalmol** 1999 Jan; 83(1):120–2 (46 ref.)

Update in genetics: genetic eye diseases and the ophthalmologist. MacDonald IM. **Can J Ophthalmol** 1999 Apr;34(2):69–73 (10 ref.)

The cone dystrophies. Simunovic MP, et al. **Eye** 1998;12 (Pt 3b):553–65 (126 ref.)

Retinitis pigmentosa: defined from a molecular point of view. van Soest S, et al. **Surv Ophthalmol** 1999 Jan–Feb; 43(4):321–34 (149 ref.)

PATHOLOGY

Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview. Birch DG. **Mol Genet Metab** 1999 Apr;66(4):356–66 (27 ref.)

SURGERY

Neural retinal cell transplantation: ideal versus reality [editorial] Berson EL, et al. **Ophthalmology** 1999 Mar; 106(3):445–6 (13 ref.)

RETINOBLASTOMA

see related
GENES, RETINOBLASTOMA

Retinoblastoma. Zucker JM, et al. **Eur J Cancer** 1998 Jun; 34(7):1045–8; discussion 1048–9 (40 ref.)

DIAGNOSIS

Tumor markers in retinoblastoma. Mul D, et al. **Med Pediatr Oncol** 1999 Feb;32(2):146–7 (9 ref.)

Retinoblastoma and simulating lesions. Role of CT, MR imaging and use of Gd-DTPA contrast enhancement. Kaufman LM, et al. **Radiol Clin North Am** 1998 Nov; 36(6):1101–17 (63 ref.)

[Leukokoria in a child: emergency and challenge] Balmer A, et al. **Klin Monatsbl Augenheilkd** 1999 May;214(5):332–5 (9 ref.) (Eng. Abstr.) **(Fre)**

[Genetic and molecular diagnostics in retinoblastoma] Lohmann D, et al. **Klin Monatsbl Augenheilkd** 1998 Oct; 213(4):191–6 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Topical topic. Use of chemotherapy for retinoblastoma. Pratt CB. **Med Pediatr Oncol** 1998 Dec;31(6):531–3 (28 ref.)

GENETICS

Developmental defects and tumor predisposition in Rb mutant mice. Vooijs M, et al. **Oncogene** 1999 Sep 20; 18(38):5293–303 (137 ref.)

[Retinoblastoma: importance of genetic counseling] Girardet A, et al. **J Fr Ophtalmol** 1998 Apr;21(4):295–301 (21 ref.) **(Fre)**

[Genetic and molecular diagnostics in retinoblastoma] Lohmann D, et al. **Klin Monatsbl Augenheilkd** 1998 Oct; 213(4):191–6 (25 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Trilateral retinoblastoma: is the location of the intracranial tumor important? [see comments] Paulino AC. **Cancer** 1999 Jul 1;86(1):135–41 (45 ref.) Comment in: Cancer 1999 Jul 1;86(1):3–5.

Retinoblastoma in transgenic mice: models of hereditary retinoblastoma. Mills MD, et al. **Surv Ophthalmol** 1999 May–Jun;43(6):508–18 (105 ref.)

[The role of apoptosis in physiology and pathology of the retina] Obuchowska I, et al. **Klin Oczna** 1999;101(2):139–43 (43 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Recent developments in the management of retinoblastoma. Shields CL, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jan–Feb;36(1):8–18; quiz 35–6 (64 ref.)

RETINOBLASTOMA GENES see **GENES, RETINOBLASTOMA**

RETINOBLASTOMA NUCLEAR PHOSPHOPROTEIN P105-RB see **RETINOBLASTOMA PROTEIN**

RETINOBLASTOMA PROTEIN

ANALYSIS

Expression of cell-cycle regulators during heart development and failure [editorial; comment] Deprez RH, et al. **Eur Heart J** 1999 Apr;20(8):555–7 (7 ref.) Comment on: Eur Heart J 1999 Apr;20(8):604–11.

GENETICS

pRb and E2f-1 in mouse development and tumorigenesis. Macleod K. **Curr Opin Genet Dev** 1999 Feb;9(1):31–9 (64 ref.)

METABOLISM

Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. Kramer DL, et al. **Biochem Soc Trans** 1998 Nov; 26(4):609–14 (25 ref.)

Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Nevins JR. **Cell Growth Differ** 1998 Aug;9(8):585–93 (100 ref.)

The retinoblastoma pathway in plant cell cycle and development. Gutierrez C. **Curr Opin Plant Biol** 1998 Dec; 1(6):492–7 (46 ref.)

PHARMACOLOGY

Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Yeh S, et al. **Keio J Med** 1999 Jun;48(2):87–92 (40 ref.)

PHYSIOLOGY

The cell cycle-regulating transcription factors E2F-RB. Brehm A, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:38–41 (26 ref.)

pRb and the cdks in apoptosis and the cell cycle. Kasten MM, et al. **Cell Death Differ** 1998 Feb;5(2):132–40 (84 ref.)

Negative control elements of the cell cycle in human tumors. Adams PD, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):791–7 (66 ref.)

Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Rubin E, et al. **Front Biosci** 1998 Dec 1;3:D1209–19 (90 ref.)

New perspectives on retinoblastoma family functions in differentiation. Yee AS, et al. **Front Biosci** 1998 Jun 8; 3:D532–47 (100 ref.)

The RB family of cell cycle regulatory factors. Stiegler P, et al. **J Cell Biochem Suppl** 1998;30–31:30–6 (33 ref.)

Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Graña X, et al. **Oncogene** 1998 Dec 24;17(25):3365–83 (193 ref.)

Big brothers are watching: the retinoblastoma family and growth control. Stiegler P, et al. **Prog Mol Subcell Biol** 1998;20:25–42 (107 ref.)

Retinoblastoma protein meets chromatin. Brehm A, et al. **Trends Biochem Sci** 1999 Apr;24(4):142–5 (49 ref.)

RETINOIC ACID see **TRETINOIN**

13-CIS-RETINOIC ACID see **ISOTRETINOIN**

RETINOIC ACID-BINDING PROTEINS see **RECEPTORS, RETINOIC ACID**

RETINOIC ACID RECEPTORS see **RECEPTORS, RETINOIC ACID**

RETINOIDS

Role of retinoids in renal development: pathophysiological implication. Merlet-Bénichou C, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):39–43 (41 ref.)

What are natural retinoids? Vahlquist A. **Dermatology** 1999; 199 Suppl 1:3–11 (84 ref.)

Retinoids and adipose tissues: metabolism, cell differentiation and gene expression. Villarroya F, et al. **Int J Obes Relat Metab Disord** 1999 Jan;23(1):1–6 (47 ref.)

ADMINISTRATION & DOSAGE

Management of Darier's disease. Burge S. **Clin Exp Dermatol** 1999 Mar;24(2):53–6 (25 ref.)

Current research and future developments in retinoids: oral and topical agents. Chandraratna RA. **Cutis** 1998 Feb;61(2 Suppl):40–5 (19 ref.)

ANALYSIS

Retinoids in nonmammalian embryos. Maden M. **Methods Mol Biol** 1999;97:491–509 (41 ref.)

Properties of retinoids. Structure, handling, and preparation. Barua AB, et al. **Mol Biotechnol** 1998 Oct;10(2):167–82 (46 ref.)

CHEMISTRY

Current research and future developments in retinoids: oral and topical agents. Chandraratna RA. **Cutis** 1998 Feb;61(2 Suppl):40–5 (19 ref.)

Properties of retinoids. Structure, handling, and preparation. Barua AB, et al. **Mol Biotechnol** 1998 Oct;10(2):167–82 (46 ref.)

METABOLISM

Function of alcohol dehydrogenase and aldehyde dehydrogenase gene families in retinoid signaling. Duester G. **Adv Exp Med Biol** 1999;463:311–9 (53 ref.)

Vitamin D and retinoids in parathyroid glands (review). Hellman P, et al. **Int J Mol Med** 1999 Apr;3(4):355–61 (79 ref.)

The role of carotenoids and retinoids in gap junctional communication. Stahl W, et al. **Int J Vitam Nutr Res** 1998; 68(6):354–9 (39 ref.)

Retinoids and their receptors in skeletal development. Underhill TM, et al. **Microsc Res Tech** 1998 Oct 15; 43(2):137–55 (239 ref.)

The role of retinoids in developmental mechanisms in embryos. Maden M. **Subcell Biochem** 1998;30:81–111 (138 ref.)

Structure and function of retinoid-binding proteins. Newcomer ME, et al. **Subcell Biochem** 1998;30:53–80 (62 ref.)

Retinoid endocrinology from metabolism to cellular signaling. Vieira AV. **Subcell Biochem** 1998;30:29–51 (148 ref.)

The bioconversion of beta-carotene into retinoids. Wang XD, et al. **Subcell Biochem** 1998;30:159–80 (55 ref.)

Retinoids as endogenous components of the regenerating limb and tail. Maden M. **Wound Repair Regen** 1998 Jul–Aug; 6(4):358–65 (53 ref.)

PHARMACOKINETICS

Future trends: a new generation of retinoids. Chandraratna RA. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S149–52 (11 ref.)

PHARMACOLOGY

Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. James SY, et al. **Gen Pharmacol** 1999 Jan;32(1):143–54 (174 ref.)

Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. Saurat JH. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S2–6 (20 ref.)

Retinoid-mediated signaling pathways in CD38 antigen expression in myeloid leukemia cells. Mehta K, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):441–9 (65 ref.)

Treatment of mice with retinoids in vivo and in vitro. Skeletal staining. Morriss-Kay GM. **Methods Mol Biol** 1999;97:33–9 (15 ref.)

[Retinoids. A new drug group with many possible uses?] Otter K, et al. **Med Monatsschr Pharm** 1999 Jan;22(1):2–7 (15 ref.) **(Ger)**

THERAPEUTIC USE

Retinoids in pancreatic cancer. Riecken EO, et al. **Ann Oncol** 1999;10 Suppl 4:197–200 (35 ref.)

Retinoids: present role and future potential. Evans TR, et al. **Br J Cancer** 1999 Apr;80(1–2):1–8 (120 ref.)

The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Miller WH Jr. **Cancer** 1998 Oct 15;83(8):1471–82 (146 ref.)

Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Ki Hong W, et al. **Clin Cancer Res** 1995 Jul;1(7):677–86 (64 ref.)

Dowling Oration delivered at the Royal College of Physicians, London, Friday 5 June 1998. Retinoids: renaissance and reformation. Griffiths CE. **Clin Exp Dermatol** 1999 Jul;24(4):329–35 (23 ref.)

Retinoids in the chemoprevention of bladder cancer. Sabichi AL, et al. **Curr Opin Oncol** 1998 Sep;10(5):479–84 (33 ref.)

Topical retinoids in the treatment of acne vulgaris. Bershad S, et al. **Cutis** 1999 Aug;64(2 Suppl):8–20; quiz 21–3 (33 ref.)

Acne therapy. White GM. **Dis Mon** 1999 Aug;45(8):301–30 (57 ref.)

Retinoids in chemoprevention. Whelan P. **Eur Urol** 1999; 35(5–6):424–8 (47 ref.)

Retinoids and psoriasis: novel issues in retinoid pharmacology

RETINOIDS

and implications for psoriasis treatment. Saurat JH. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S2–6 (20 ref.)
Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants. Singh DK, et al. **Oncology (Huntingt)** 1998 Nov;12(11):1643–53, 1657–8; discussion 1659–60 (111 ref.)
Chemoprevention in head and neck cancer: basic science and clinical application. Geyer C, et al. **Semin Radiat Oncol** 1998 Oct;8(4):292–301 (60 ref.)
[Prevention of hepatic carcinogenesis by retinoids] Moriwaki H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1548–53 (11 ref.) **(Jpn)**
[Control of thrombosis by retinoids and vitamin D3 derivatives] Koyama T, et al. **Rinsho Ketsueki** 1999 May; 40(5):378–81 (9 ref.) **(Jpn)**
[Acne vulgaris: local and systemic treatment] Kwiecien A, et al. **Pol Merkuriusz Lek** 1999 May;6(35):291–3 (29 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Teratology of retinoids. Collins MD, et al. **Annu Rev Pharmacol Toxicol** 1999;39:399–430 (197 ref.)

RETINOL see **VITAMIN A**

RETINOL-BINDING PROTEINS

CHEMISTRY

Structure and function of retinoid-binding proteins. Newcomer ME, et al. **Subcell Biochem** 1998;30:53–80 (62 ref.)

CLASSIFICATION

Novel classes of fatty acid and retinol binding protein from nematodes. McDermott L, et al. **Mol Cell Biochem** 1999 Feb;192(1–2):69–75 (41 ref.)

METABOLISM

Structure and function of retinoid-binding proteins. Newcomer ME, et al. **Subcell Biochem** 1998;30:53–80 (62 ref.)

RETINOPATHY OF PREMATURITY

Retinopathy of prematurity and associated factors. Simons BD, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):29–48 (96 ref.)
[Retinopathy of prematurity] Nascutzy C, et al. **Oftalmologia** 1998;45(4):85–92 (22 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

[Screening for retinopathy of prematurity: reliability] de la Cruz Bértolo FJ, et al. **An Esp Pediatr** 1999 Feb; 50(2):156–60 (45 ref.) **(Spa)**

ETIOLOGY

Light exposure is not associated with retinopathy of prematurity. Mills MD. **Arch Ophthalmol** 1998 Nov; 116(11):1517–8 (18 ref.)
Effects of premature exposure to light: a credibility struggle. Silverman WA. **Paediatr Perinat Epidemiol** 1999 Apr; 13(2):128–30 (12 ref.)

SURGERY

Surgical advances in retinopathy of prematurity. Andrews AP, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):275–90 (41 ref.)

RETIREMENT

ECONOMICS

Retiring at 55: is it a media-created myth? Lee G. **Can J Gastroenterol** 1999 Jun;13(5):382–4 (2 ref.)
Retirement income security in the United Kingdom. Liu L. **Soc Secur Bull** 1999;62(1):23–46 (87 ref.)
Individual Social Security accounts: issues of administrative feasibility and cost, 1998. Olsen KA, et al. **Soc Secur Bull** 1999;62(1):75–90 (103 ref.)

LEGISLATION & JURISPRUDENCE

Older Americans Act: implications for nursing. Wallace DC, et al. **Nurs Outlook** 1999 Jul–Aug;47(4):181–5 (21 ref.)

STATISTICS & NUMERICAL DATA

Retirement income security in the United Kingdom. Liu L. **Soc Secur Bull** 1999;62(1):23–46 (87 ref.)

TRENDS

Retiring at 55: is it a media-created myth? Lee G. **Can J Gastroenterol** 1999 Jun;13(5):382–4 (2 ref.)
Baby Boomers likely to go out with a bang. Kennedy M. **WMJ** 1998 Dec;97(11):24–7 (0 ref.)

RETIREMENT BENEFITS see **PENSIONS**

RETROBULBAR NEURITIS see **OPTIC NEURITIS**

RETROELEMENTS

see related
DNA TRANSPOSABLE ELEMENTS
MUTAGENESIS, INSERTIONAL

Fidelity of retrotransposon replication. Gabriel A, et al. **Ann N Y Acad Sci** 1999 May 18;870:108–18 (35 ref.)
Human endogenous retroviral sequences: possible roles in reproductive physiopathology. Taruscio D, et al. **Biol Reprod** 1998 Oct;59(4):713–24 (141 ref.)
Control of genes by mammalian retroposons. Tomilin NV. **Int Rev Cytol** 1999;186:1–48 (277 ref.)
[The role of retroposition in the self-regulation of genome processes (do genes program the body and retroposons program genome?)] Bebikhov DV, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):4–14 (77 ref.) **(Rus)**
[Telomeric retrotransposon HeT-A and its role in forming Drosophila telomeres] Danilevskaia ON, et al. **Mol Biol (Mosk)** 1999 Jan–Feb;33(1):38–47 (31 ref.) **(Rus)**
[Retrotransposon-host genome: mechanisms and effects of interaction] Pasiukova EG, et al. **Mol Biol (Mosk)** 1999 Jan–Feb;33(1):26–37 (136 ref.) **(Rus)**

RETROGNATHISM

see related
MANDIBULAR ADVANCEMENT

RETROGRADE OBTURATION

Considerations in the selection of a root-end filling material. Johnson BR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):398–404 (40 ref.)

RETROLENTAL FIBROPLASIA see **RETINOPATHY OF PREMATURITY**

RETROPERITONEAL FIBROSIS

[Idiopathic retroperitoneal fibrosis] Valderrama Rojas M, et al. **Rev Clin Esp** 1999 Apr;199(4):222–6 (28 ref.) **(Spa)**

COMPLICATIONS

Combined idiopathic retroperitoneal and mediastinal fibrosis with pericardial involvement. Klisnick A, et al. **Clin Nephrol** 1999 Jul;52(1):51–5 (31 ref.)
Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. Demko TM, et al. **J Am Soc Nephrol** 1997 Apr;8(4):684–8 (26 ref.)

DIAGNOSIS

Intrinsic common bile duct stricture: an unusual presentation of retroperitoneal fibrosis. Lascarides CE, et al. **Gastrointest Endosc** 1999 Jul;50(1):102–5 (17 ref.)
Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. Demko TM, et al. **J Am Soc Nephrol** 1997 Apr;8(4):684–8 (26 ref.)
Stenosis of the common bile duct due to Ormond's disease: case report and review of the literature. Dejaco C, et al. **J Hepatol** 1999 Jul;31(1):156–9 (19 ref.)
[Chronic periaortitis] Messinetti S, et al. **Ann Ital Chir** 1998 Sep–Oct;69(5):601–11 (86 ref.) (Eng. Abstr.) **(Ita)**
[A 56-year-old man with abdominal pain, intermittent claudication and a retroperitoneal mass] Medina Pérez M, et al. **Arch Esp Urol** 1998 Nov;51(9):935–7 (10 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Idiopathic retroperitoneal fibrosis with bilateral lower ureteric obstruction--a case report with literature review. Koh JS, et al. **Singapore Med J** 1998 Sep;39(9):416–7 (15 ref.)

SURGERY

Idiopathic retroperitoneal fibrosis with bilateral lower ureteric obstruction--a case report with literature review. Koh JS, et al. **Singapore Med J** 1998 Sep;39(9):416–7 (15 ref.)

RETROPERITONEAL NEOPLASMS

Ossifying fibromyxoid tumor of soft parts in a child: a case report. Ijiri R, et al. **J Pediatr Surg** 1999 Aug;34(8):1294–6 (18 ref.)

COMPLICATIONS

Coarctation of the aorta associated with neuroblastoma. Friedman DM, et al. **Pediatr Cardiol** 1998 Nov–Dec; 19(6):480–1 (10 ref.)

DIAGNOSIS

Retroperitoneal ganglioneuroma: report of a case diagnosed by fine-needle aspiration cytology, with review of the literature. Jain M, et al. **Diagn Cytopathol** 1999 Sep; 21(3):194–6 (18 ref.)
Benign retroperitoneal schwannoma mimicking a pancreatic cystic tumor: case report and literature review. Hsiao WC, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2418–20 (9 ref.)
[Retroperitoneal sarcomas: 1. Natural history and preoperative evaluation] Bonvalot S. **J Chir (Paris)** 1999 Mar;136(1):5–9 (17 ref.) (Eng. Abstr.) **(Fre)**
[A case of accessory spleen presenting as retroperitoneal tumor] Kato Y, et al. **Hinyokika Kiyo** 1998 Oct; 44(10):711–4 (20 ref.) (Eng. Abstr.) **(Jpn)**
[A benign retroperitoneal schwannoma: a review of the literature and a report of a new case] Cortés Aránguez I, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):621–4 (15 ref.) (Eng. Abstr.) **(Spa)**
[A retrovesical mass (intestinal duplication)] Marco Pérez LM, et al. **Actas Urol Esp** 1999 May;23(5):440–3 (6 ref.) (Eng. Abstr.) **(Spa)**
[A retroperitoneal cellular schwannoma] Ortiz Rey JA, et al. **Actas Urol Esp** 1999 May;23(5):455–8 (12 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Embryonal rhabdomyosarcoma with only numerical chromosome changes. Case report and review of the literature. Polito P, et al. **Cancer Genet Cytogenet** 1999 Mar; 109(2):161–5 (19 ref.)

PATHOLOGY

A patient with extra-adrenal retroperitoneal paraganglioma and review of the literature. Alp H, et al. **J Pediatr Endocrinol Metab** 1998 Nov–Dec;11(6):763–5 (7 ref.)
A retroperitoneal bronchogenic cyst with malignant change. Sullivan SM, et al. **Pathol Int** 1999 Apr;49(4):338–41 (30 ref.)
Retroperitoneal leiomyosarcoma of a male centenarian. Yokoo H, et al. **Pathol Int** 1998 Dec;48(12):985–8 (15 ref.)
Bone metastases from a paraganglioma. A review of five cases. Razakaboay M, et al. **Rev Rhum Engl Ed** 1999 Feb; 66(2):86–91 (18 ref.)

PHYSIOPATHOLOGY

[Two cases of retroperitoneal functioning paraganglioma] Maruyama T, et al. **Hinyokika Kiyo** 1998 Dec; 44(12):869–73 (12 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Retrorectal carcinoid tumor. Gorski T, et al. **South Med J** 1999 Apr;92(4):417–20 (22 ref.)
Retroperitoneal sarcoma--the continued challenge for surgery and oncology. Herman K, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):77–81 (33 ref.)
[Retroperitoneal sarcomas: 2. Surgical and complementary treatment] Bonvalot S. **J Chir (Paris)** 1999 Jun;136(2):61–6 (17 ref.) (Eng. Abstr.) **(Fre)**
[Surgery of extensive retroperitoneal soft tissue sarcoma] Junginger T. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:388–92 (8 ref.) (Eng. Abstr.) **(Ger)**

RETROPERITONEAL SPACE

Müllerian cysts of the mesentery and retroperitoneum: a case report and literature review. Lee J, et al. **Pathol Int** 1998 Nov;48(11):902–6 (9 ref.)
[Spontaneous ruptures of the kidney and retroperitoneal hematomas in hemorrhagic fever with renal syndrome] Zagidullin IM, et al. **Urol Nefrol (Mosk)** 1998 Nov–Dec; (6):50–3 (56 ref.) **(Rus)**

PATHOLOGY

Laparoscopy and retroperitoneoscopy--novel techniques of which clinical nephrologists should be aware. Rassweiler J, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):313–7 (7 ref.)
Retroperitoneal bronchogenic cyst: report of a case and literature review. Itoh H, et al. **Pathol Int** 1999 Feb; 49(2):152–5 (22 ref.)

RETROPHARYNGEAL ABSCESS

RADIOGRAPHY

Retropharyngeal abscesses: a clinical and radiologic correlation. Boucher C, et al. **J Otolaryngol** 1999 Jun; 28(3):134–7 (13 ref.)

SURGERY

Retropharyngeal abscesses: a clinical and radiologic correlation. Boucher C, et al. **J Otolaryngol** 1999 Jun; 28(3):134–7 (13 ref.)

RETROPNEUMOPERITONEUM

COMPLICATIONS

Fatal carbon dioxide embolism as an unreported complication of retroperitoneoscopy. Blaser A, et al. **Surg Endosc** 1999 Jul;13(7):713–4 (11 ref.)

ETIOLOGY

[Pneumoretroperitoneum due to pneumatosis cystoides intestinalis. An etiopathogenetic and clinico-diagnostic assessment. A clinical case report] Gullà N, et al. **Minerva Chir** 1998 Sep;53(9):757-65 (43 ref.) (Eng. Abstr.) **(Ita)**

RETROPOSONS see **RETROELEMENTS**

RETROSPECTIVE MORAL JUDGMENT see **MORALS**

RETROSPECTIVE STUDIES

Retrospective analyses of large medical databases: what do they tell us? [editorial] Ward RA, et al. **J Am Soc Nephrol** 1999 Feb;10(2):429-32 (19 ref.)

RETROTRANSPOSONS see **RETROELEMENTS**

RETROVIRIDAE

The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Allan JS. **Ann N Y Acad Sci** 1998 Dec 30;862:87-99 (76 ref.)

Endogenous retroviruses: a potential problem for xenotransplantation? Stoye JP, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:67-74 (26 ref.)

Retroviral-fibronectin interactions in transduction of mammalian cells. Williams DA. **Ann N Y Acad Sci** 1999 Apr 30;872:109-13; discussion 113-4 (15 ref.)

Possible retroviral origin of prion disease: could prion disease be reconsidered as a preleukemia syndrome? Labat ML. **Biomed Pharmacother** 1999;53(1):47-53 (60 ref.)

Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction (Review). Dao MA, et al. **Int J Mol Med** 1998 Jan;1(1):257-64 (50 ref.)

Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). Lu L, et al. **J Leukoc Biol** 1999 Aug; 66(2):293-6 (31 ref.)

Retrovirus-mediated insertional mutagenesis in zebrafish. Amsterdam A, et al. **Methods Cell Biol** 1999;60:87-98 (28 ref.)

Gene transfer to the rodent embryo by retroviral vectors. Pavlath GK, et al. **Methods Mol Biol** 1999;97:519-38 (19 ref.)

[Autoimmune diseases and retroviruses] Sugaya T, et al. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2093-9 (13 ref.) **(Jpn)**

[Retroviruses and autoimmune diseases] Fugo K, et al. **Nippon Rinsho** 1999 Feb;57(2):310-5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Gene transfer using virus vectors] Koizumi K, et al. **Nippon Seirigaku Zasshi** 1998;60(7-8):319-30 (36 ref.) **(Jpn)**

CHEMISTRY

Retroviral RNA dimer linkage. Greatorex J, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2877-82 (40 ref.)

DRUG EFFECTS

[Additive effect of marihuana and retrovirus in the anergy of natural killer cells in mice] Ongrádi J, et al. **Orv Hetil** 1999 Jan 10;140(2):81-4 (32 ref.) (Eng. Abstr.) **(Hun)**

ENZYMOLOGY

In vivo analysis of retroviral integrase structure and function. Engelman A. **Adv Virus Res** 1999;52:411-26 (54 ref.)

Substrate recognition by retroviral integrases. Katzman M, et al. **Adv Virus Res** 1999;52:371-95 (125 ref.)

GENETICS

Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Onodera M, et al. **Acta Haematol** 1999;101(2):89-96 (30 ref.)

Host proteins in retroviral cDNA integration. Bushman FD. **Adv Virus Res** 1999;52:301-17 (81 ref.)

Vector development: a major obstacle in human gene therapy [editorial] Jane SM, et al. **Ann Med** 1998 Oct;30(5):413-5 (9 ref.)

Gene therapy in the central nervous system: the use of recombinant retroviruses. Suhr ST, et al. **Arch Neurol** 1999 Mar;56(3):287-92 (11 ref.)

Large-scale processing of recombinant retroviruses for gene therapy. Andreadis ST, et al. **Biotechnol Prog** 1999 Jan-Feb;15(1):1-11 (80 ref.)

Acute retroviruses and oncogenesis. Arbelaez AM, et al. **Crit Rev Oncog** 1999;10(1-2):17-81 (623 ref.)

Chronic retroviruses and oncogenesis. Patarca R. **Crit Rev Oncog** 1998;9(2):151-98 (375 ref.)

Cell targeting by murine retroviral vectors. Karavanas G, et al. **Crit Rev Oncol Hematol** 1998 Jun;28(1):7-30 (203 ref.)

Retroviruses, ascorbate, and mutations, in the evolution of Homo sapiens. Challem JJ, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):130-2 (25 ref.)

Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease. Dawkins R, et al. **Immunol Rev** 1999 Feb;167:275-304 (167 ref.)

Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Hiai H, et al. **Prog Exp Tumor Res** 1999;35:64-77 (32 ref.)

In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors. Sorrentino BP, et al. **Prog Exp Tumor Res** 1999;36:143-61 (47 ref.)

Retroviral vectors for liver-directed gene therapy. Kalpana GV. **Semin Liver Dis** 1999;19(1):27-37 (40 ref.)

Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Rein A, et al. **Trends Biochem Sci** 1998 Aug;23(8):297-301 (54 ref.)

[The retroviral spumaviruses: new data in retrovirology] Saib A. **Bull Acad Natl Med** 1999;183(3):559-68 (13 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunosuppression by retroviruses: implications for xenotransplantation. Denner J. **Ann N Y Acad Sci** 1998 Dec 30;862:75-86 (38 ref.)

ISOLATION & PURIFICATION

[MSRV retrovirus and gliotoxin protein: potential biological markers in multiple sclerosis?] Perron H. **Ann Biol Clin (Paris)** 1998 Jul-Aug;56(4):427-38 (52 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Asymmetric DDE (D35E)-like sequences in the RAG proteins: implications for V(D)J recombination and retroviral pathogenesis. Dreyfus DH, et al. **Med Hypotheses** 1999 Jun;52(6):545-9 (32 ref.)

PHYSIOLOGY

Molecular events in the assembly of retrovirus particles. Sakalian M, et al. **Adv Exp Med Biol** 1998;440:329-39 (33 ref.)

Retroviruses: ancient and modern. Weiss RA, et al. **Arch Virol Suppl** 1999;15:171-7 (30 ref.)

Hypothesis: link between endogenous retroviruses and cardiovascular disease. Bing OH, et al. **J Mol Cell Cardiol** 1998 Jul;30(7):1257-62 (21 ref.)

Beneficial role of human endogenous retroviruses: facts and hypotheses. Larsson E, et al. **Scand J Immunol** 1998 Oct; 48(4):329-38 (123 ref.)

Retroviruses as model systems for the study of nuclear RNA export pathways. Cullen BR. **Virology** 1998 Sep 30; 249(2):203-10 (39 ref.)

RETROVIRIDAE INFECTIONS

COMPLICATIONS

Primate retroviruses and oncogenesis. Sanguineti-Diaz C, et al. **Crit Rev Oncog** 1998;9(3-4):209-53 (471 ref.)

Retrovirus-associated rheumatic syndromes. Herrmann M, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):347-54 (78 ref.)

DRUG THERAPY

Significant interactions with new antiretrovirals and psychotropic drugs. Tseng AL, et al. **Ann Pharmacother** 1999 Apr;33(4):461-73 (83 ref.)

IMMUNOLOGY

Retroviruses and autoimmune endocrine diseases. Coutant R, et al. **Ann Med Interne (Paris)** 1999 Apr;150(3):235-44 (83 ref.)

Immunosuppression by retroviruses: implications for xenotransplantation. Denner J. **Ann N Y Acad Sci** 1998 Dec 30;862:75-86 (38 ref.)

Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Acha-Orbea H, et al. **Immunol Rev** 1999 Apr;168:287-303 (130 ref.)

METABOLISM

Host proteins in retroviral cDNA integration. Bushman FD. **Adv Virus Res** 1999;52:301-17 (81 ref.)

PATHOLOGY

Isolated leptomeningeal Castleman's disease with viral particles in the follicular dendritic cells. Gulati P, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):1026-9 (18 ref.)

PREVENTION & CONTROL

Animal studies of prophylaxis. Black RJ. **Am J Med** 1997 May 19;102(5B):39-44 (19 ref.)

TRANSMISSION

The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Allan JS. **Ann N Y Acad Sci** 1998 Dec 30;862:87-99 (76 ref.)

Endogenous retroviruses: a potential problem for xenotransplantation? Stoye JP, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:67-74 (26 ref.)

Infection in xenotransplantation: a clinical approach. Fishman JA. **Transplant Proc** 1999 Sep;31(6):2225-7 (23 ref.)

VETERINARY

Retroviruses: ancient and modern. Weiss RA, et al. **Arch Virol Suppl** 1999;15:171-7 (30 ref.)

Retrovirus-induced disease in poultry. Payne LN. **Poult Sci** 1998 Aug;77(8):1204-12 (58 ref.)

[Risk of infection causes by viruses in xenotransplantation] von der Helm K, et al. **Zentralbl Chir** 1999;124(7):600-3 (19 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Host proteins in retroviral cDNA integration. Bushman FD. **Adv Virus Res** 1999;52:301-17 (81 ref.)

Retroviruses: ancient and modern. Weiss RA, et al. **Arch Virol Suppl** 1999;15:171-7 (30 ref.)

Possible retroviral origin of prion disease: could prion disease be reconsidered as a preleukemia syndrome? Labat ML. **Biomed Pharmacother** 1999;53(1):47-53 (60 ref.)

RETROVIRIDAE PROTEINS

HIV-1: fifteen proteins and an RNA. Frankel AD, et al. **Annu Rev Biochem** 1998;67:1-25 (134 ref.)

RETROVIRIDAE PROTEINS, ONCOGENIC

PHYSIOLOGY

Myb and oncogenesis. Ganter B, et al. **Adv Cancer Res** 1999; 76:21-60 (289 ref.)

Conspiracy theory: RAS and RAF do not act alone. Sternberg PW, et al. **Cell** 1998 Nov 13;95(4):447-50 (17 ref.)

Physiological signals and oncogenesis mediated through Crk family adapter proteins. Feller SM, et al. **J Cell Physiol** 1998 Dec;177(4):535-52 (229 ref.)

Early growth response factor 1: a pleiotropic mediator of inducible gene expression. Khachigian LM, et al. **J Mol Med** 1998 Aug;76(9):613-6 (34 ref.)

Transformation by v-Myb. Lipsick JS, et al. **Oncogene** 1999 May 13;18(19):3047-55 (145 ref.)

RETROVIRUS INFECTIONS see **RETROVIRIDAE INFECTIONS**

RETROVIRUS-LIKE ELEMENTS see **RETROELEMENTS**

RETROVIRUS PROTEINS see **RETROVIRIDAE PROTEINS**

RETROVIRUSES see **RETROVIRIDAE**

RETROVIRUSES, ENDOGENOUS see **ENDOGENOUS RETROVIRUSES**

RETROVIRUSES TYPE D

ULTRASTRUCTURE

Isolated leptomeningeal Castleman's disease with viral particles in the follicular dendritic cells. Gulati P, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):1026-9 (18 ref.)

RETT SYNDROME

[Contemporary views on Rett's syndrome: clinical, cytogenetic and molecular studies] Vorsanova SG, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(3):61-9 (99 ref.) **(Rus)**

DIAGNOSIS

Male Rett syndrome variant: application of diagnostic criteria. Jan MM, et al. **Pediatr Neurol** 1999 Mar; 20(3):238-40 (13 ref.)

[Rett syndrome as a hodogenesis disorder] Narbona J. **Rev Neurol** 1999 Jan 1-15;28(1):97-101 (51 ref.) (Eng. Abstr.) **(Spa)**

[Atypical forms of Rett's syndrome] Nieto-Barrera M. **Rev Neurol** 1999 Jan 1-15;28(1):101-4 (35 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Rett's syndrome in the Spanish population] Pineda M, et al. **Rev Neurol** 1999 Jan 1-15;28(1):105-9 (16 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

[Rett syndrome as a hodogenesis disorder] Narbona J. **Rev Neurol** 1999 Jan 1-15;28(1):97-101 (51 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Recent insights into hyperventilation from the study of Rett syndrome. Kerr AM, et al. **Arch Dis Child** 1999 Apr; 80(4):384-7 (28 ref.)

REUPTAKE INHIBITORS, NEUROTRANSMITTER see **NEUROTRANSMITTER UPTAKE INHIBITORS**

REV GENE PRODUCTS

REV GENE PRODUCTS see **GENE PRODUCTS, REV**

REV PROTEIN see **GENE PRODUCTS, REV**

REV-RESPONSIVE ELEMENT see **GENES, ENV**

REVERSE IMMUNOBLOTTING see **IMMUNOBLOTTING**

REVERSE TRANSCRIPTASE see **RNA-DIRECTED DNA POLYMERASE**

REVERSE TRANSCRIPTASE, HIV-1 see **HIV-1 REVERSE TRANSCRIPTASE**

REVERSE TRANSCRIPTASE INHIBITORS

ADMINISTRATION & DOSAGE

Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Hilts AE, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2528–33 (38 ref.)

ADVERSE EFFECTS

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial] Brinkman K, et al. **AIDS** 1998 Oct 1;12(14):1735–44 (108 ref.)

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Pollard RB, et al. **Clin Ther** 1998 Nov–Dec;20(6):1071–92 (40 ref.)

Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Moyle GJ, et al. **Drug Saf** 1998 Dec;19(6):481–94 (67 ref.)

CHEMICAL SYNTHESIS

Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate. Adams WJ, et al. **Pharm Biotechnol** 1998;11:285–312 (19 ref.)

CHEMISTRY

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2. Milton J, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2623–8 (11 ref.)

HIV reverse transcriptase inhibitors of natural origin. Matthée G, et al. **Planta Med** 1999 Aug;65(6):493–506 (137 ref.)

ISOLATION & PURIFICATION

HIV reverse transcriptase inhibitors of natural origin. Matthée G, et al. **Planta Med** 1999 Aug;65(6):493–506 (137 ref.)

PHARMACOKINETICS

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Barry M, et al. **Clin Pharmacokinet** 1999 Apr; 36(4):289–304 (101 ref.)

Clinical pharmacokinetics of lamivudine. Johnson MA, et al. **Clin Pharmacokinet** 1999 Jan;36(1):41–66 (70 ref.)

PHARMACOLOGY

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Mayers DL. **Am J Med** 1997 May 19;102(5B):70–5 (55 ref.)

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Balzarini J. **Biochem Pharmacol** 1999 Jul 1;58(1):1–27 (219 ref.)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2. Milton J, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2623–8 (11 ref.)

Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E. **Farmaco** 1999 Jan–Feb;54(1–2):26–45 (157 ref.)

[Recent challenges and progress in AIDS therapy—emergence of drug resistant HIV-1 variants] Mitsuya H. **Rinsho Ketsueki** 1999 Apr;40(4):249–54 (20 ref.) **(Jpn)**

THERAPEUTIC USE

Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee [editorial] **AIDS** 1998 Jul 30;12(11):1259–65 (19 ref.)

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Al-Taie OH, et al. **Ann Hematol** 1999 May;78(5):247–9 (18 ref.)

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E. **Antiviral Res** 1998 Jun;38(3):153–79 (137 ref.)

Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Shafer RW, et al. **Biomed Pharmacother** 1999 Mar; 53(2):73–86 (105 ref.)

AIDS update 1999: viral reservoirs and immune-based therapies. Isada CM, et al. **Cleve Clin J Med** 1999 May; 66(5):267–9 (3 ref.)

Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Simpson DM. **Clin Infect Dis** 1999 Jul;29(1):19–34 (89 ref.)

Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Tavel JA, et al. **Clin Infect Dis** 1999 Mar;28(3):643–76 (99 ref.)

Efavirenz. Adkins JC, et al. **Drugs** 1998 Dec;56(6):1055–64; discussion 1065–6 (34 ref.)

Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Jarvis B, et al. **Drugs** 1999 Jul;58(1):101–41 (279 ref.)

Restoration of the immune system with anti-retroviral therapy. Autran B, et al. **Immunol Lett** 1999 Mar; 66(1–3):207–11 (9 ref.)

HIV and AIDS. Gap between biology and reality in AIDS. Carr A, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV16 (5 ref.)

State of the art: antiretroviral and prophylactic treatments in HIV/AIDS. Porche DJ. **Nurs Clin North Am** 1999 Mar; 34(1):95–112 (37 ref.)

A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection [news] Wolbach J, et al. **Nurse Pract** 1999 Jun;24(6):81–2, 87–90, 92 (27 ref.)

Antiretroviral therapy and medical management of pediatric HIV infection and 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. **Pediatrics** 1998 Oct; 102(4 Pt 2):999–1085 (267 ref.)

[A changed pattern of opportunistic infections and malignancies in HIV-seropositive patients after the introduction of intensive anti-HIV-combination therapy] Borleffs JC, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31; 142(44):2395–9 (16 ref.) (Eng. Abstr.) **(Dut)**

[Nevirapine (Viramune): a new HIV inhibitor] De Wit S, et al. **Rev Med Brux** 1999 Apr;20(2):95–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of ocular viral infections in AIDS patients] Guex-Crosier Y. **Rev Med Suisse Romande** 1998 Nov;118(11):941–7 (15 ref.) (Eng. Abstr.) **(Fre)**

[New management of hepatitis B virus] Sata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):713–7 (14 ref.) **(Jpn)**

[Antiretroviral treatment in 1999: from uncertainty to hopefulness (editorial)] Pujol de la Llave E. **An Med Interna** 1999 May;16(5):215–7 (47 ref.) **(Spa)**

REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION

see related
RNA-DIRECTED DNA POLYMERASE

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Lambrechts AC, et al. **Ann Oncol** 1998 Dec;9(12):1269–76 (60 ref.)

Quantitative RT-PCR: pitfalls and potential. Freeman WM, et al. **Biotechniques** 1999 Jan;26(1):112–22, 124–5 (66 ref.)

Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection? Anguita E, et al. **Haematologica** 1998 Aug;83(8):744–7 (16 ref.)

A tale of two strands: reverse-transcriptase polymerase chain reaction detection of hepatitis C virus replication. Sangar DV, et al. **Hepatology** 1998 Nov;28(5):1173–6 (31 ref.)

[Analysis of molecular basis of neuronal properties using the patch-clamp RT-PCR method] Tsuzuki K. **Nippon Rinsho** 1998 Jul;56(7):1681–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

In situ reverse transcriptase-polymerase chain reaction: an innovative tool for hepatitis C virus RNA detection and localisation, and for quantification of infected cells. Muratori L. **Eur J Histochem** 1998;42(2):133–6 (20 ref.)

Techniques for the measurement of lipoprotein lipase messenger RNA. Ranganathan G, et al. **Methods Mol Biol** 1999;109:329–35 (7 ref.)

In situ RT-PCR and hybridization techniques. Thaker V. **Methods Mol Biol** 1999;115:379–402 (46 ref.)

[Improved RT-PCR: one-step RT-PCR and mRNA selective PCR] Yamamoto J, et al. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):189–93 (6 ref.) **(Jpn)**

STANDARDS

Optimization of a reverse transcription-polymerase chain reaction (RT-PCR) mass assay for low-abundance mRNA. Cale JM, et al. **Methods Mol Biol** 1998;105:351–71 (4 ref.)

REVERSE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

REVIEW LITERATURE

see related
META-ANALYSIS

Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. McManus RJ, et al. **BMJ** 1998 Dec 5;317(7172):1562–3 (5 ref.)

Traditional reviews, meta-analyses and pooled analyses in epidemiology. Blettner M, et al. **Int J Epidemiol** 1999 Feb; 28(1):1–9 (47 ref.)

[The practice of systematic reviews. I. Introduction] Offringa M, et al. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):653–6 (11 ref.) (Eng. Abstr.) **(Dut)**

REWARD

Functional magnetic resonance imaging of brain reward circuitry in the human. Breiter HC, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:523–47 (76 ref.)

Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Everitt BJ, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:412–38 (126 ref.)

What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Berridge KC, et al. **Brain Res Brain Res Rev** 1998 Dec;28(3):309–69 (531 ref.)

Neural systems for behavioral activation and reward. Kalivas PW, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):223–7 (41 ref.)

Drug-activation of brain reward pathways. Wise RA. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):13–22 (121 ref.)

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Green AI, et al. **Harv Rev Psychiatry** 1999 Mar–Apr;6(6):287–96 (94 ref.)

The real and imagined harmful effects of rewards: implications for clinical practice. Reitman D. **J Behav Ther Exp Psychiatry** 1998 Jun;29(2):101–13 (34 ref.)

Cannabinoid transmission and reward-related events. Gardner EL, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):502–33 (314 ref.)

Reward prediction in primate basal ganglia and frontal cortex. Schultz W, et al. **Neuropharmacology** 1998 Apr–May;37(4–5):421–9 (30 ref.)

Opioids, reward and addiction: An encounter of biology, psychology, and medicine. van Ree JM, et al. **Pharmacol Rev** 1999 Jun;51(2):341–96 (740 ref.)

Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Tzschentke TM. **Prog Neurobiol** 1998 Dec;56(6):613–72 (700 ref.)

Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors. Sutton MA, et al. **Psychopharmacology (Berl)** 1999 May; 144(2):95–110 (130 ref.)

[Psychosocial factors at work and cardiovascular diseases: contribution of the Effort-Reward Imbalance model] Niedhammer I, et al. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):398–410 (92 ref.) (Eng. Abstr.) **(Fre)**

REWARMING

Changing temperature management for cardiopulmonary bypass. Cook DJ. **Anesth Analg** 1999 Jun;88(6):1254–71 (166 ref.)

Accidental hypothermia. Hanania NA, et al. **Crit Care Clin** 1999 Apr;15(2):235–49 (53 ref.)

On the accuracy of intra-arterial pressure measurement: the pressure gradient effect [editorial; comment] Hynson JM, et al. **Crit Care Med** 1998 Oct;26(10):1623–4 (15 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1646–9.

[Accidental intraoperative whole-body hypothermia: the mechanisms of its occurrence and of self-warming] Romanov MA. **Anesteziol Reanimatol** 1998 Jul–Aug; (4):65–72 (145 ref.) **(Rus)**

[Can the nervous system functions of mammals be restored during deep cooling without warming? New facts and the evolution of views] Ivanov KP. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):73–89 (68 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Freezing to death—the treatment of accidental hypothermia in the Scottish mountains. Grant P, et al. **Scott Med J** 1998 Apr;43(2):36–7 (4 ref.)

REYE SYNDROME

[Reye's syndrome] Yoshida I. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):120–3 (4 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate] Noda S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):538–41 (15 ref.) **(Jpn)**

DIAGNOSIS

Reye's syndrome: hold the obituary [editorial; comment] Sarnaik AP. **Crit Care Med** 1999 Aug;27(8):1674–6 (19 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1582–7.

EPIDEMIOLOGY

Reye's syndrome: hold the obituary [editorial; comment] Sarnaik AP. **Crit Care Med** 1999 Aug;27(8):1674–6 (19 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1582–7.

RFLP see **POLYMORPHISM, RESTRICTION FRAGMENT LENGTH**

RH FACTORS see **RH-HR BLOOD-GROUP SYSTEM**

RH-HR BLOOD-GROUP SYSTEM

see related
ERYTHROBLASTOSIS, FETAL

Consensus Conference on Anti-D Prophylaxis. Edinburgh, United Kingdom, 8–9 April 1997. Papers and abstracts. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:iv, 1–44 (0 ref.)

ANALYSIS

Antenatal genotyping of the blood groups of the fetus. Avent ND. **Vox Sang** 1998;74 Suppl 2:365–74 (74 ref.)

BLOOD

Prenatal typing of fetal DNA in cases of potential alloimmune haemolytic disease of the newborn: clinical benefit outweighs disadvantage. Shields JA. **Br J Biomed Sci** 1999; 56(1):49–55 (31 ref.)

GENETICS

Rh phenotype prediction by DNA typing and its application to practice. Flegel WA, et al. **Transfus Med** 1998 Dec; 8(4):281–302 (144 ref.)

IMMUNOLOGY

A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Hadley AG. **Vox Sang** 1998;74 Suppl 2:375–83 (79 ref.)

RH IMMUNE GLOBULIN see **RHO(D) IMMUNE GLOBULIN**

RH ISOIMMUNIZATION

see related
ERYTHROBLASTOSIS, FETAL

IMMUNOLOGY

A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Hadley AG. **Vox Sang** 1998;74 Suppl 2:375–83 (79 ref.)

PREVENTION & CONTROL

Consensus Conference on Anti-D Prophylaxis. Edinburgh, United Kingdom, 8–9 April 1997. Papers and abstracts. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:iv, 1–44 (0 ref.)

Economics of antenatal prophylaxis. Cairns JA. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:19–22 (12 ref.)

The prevention of Rh haemolytic disease of the fetus and newborn--general background. Contreras M. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:7–10 (24 ref.)

The scientific basis of antenatal prophylaxis. Urbaniak SJ. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:11–8 (22 ref.)

THERAPY

Rhesus disease: postnatal management and outcome. Greenough A. **Eur J Pediatr** 1999 Sep;158(9):689–93 (58 ref.)

RHABDOID TUMOR

CONGENITAL

Congenital disseminated malignant rhabdoid tumor: a distinct clinicopathologic entity demonstrating abnormalities of chromosome 22q11. White FV, et al. **Am J Surg Pathol** 1999 Mar;23(3):249–56 (52 ref.)

Congenital malignant rhabdoid tumor presenting as a cutaneous nodule: report of 2 cases with review of the literature. Hsueh C, et al. **Arch Pathol Lab Med** 1998 Dec; 122(12):1099–102 (16 ref.)

DIAGNOSIS

Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. Hilden JM, et al. **J Neurooncol** 1998 Dec; 40(3):265–75 (39 ref.)

GENETICS

Congenital disseminated malignant rhabdoid tumor: a distinct clinicopathologic entity demonstrating abnormalities of chromosome 22q11. White FV, et al. **Am J Surg Pathol** 1999 Mar;23(3):249–56 (52 ref.)

PATHOLOGY

Congenital malignant rhabdoid tumor presenting as a cutaneous nodule: report of 2 cases with review of the literature. Hsueh C, et al. **Arch Pathol Lab Med** 1998 Dec; 122(12):1099–102 (16 ref.)

Pathologic quiz case. Extrarenal rhabdoid tumor. Zhou Y, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):853–4 (9 ref.)

Malignant mixed Müllerian tumor with rhabdoid features: a report of two cases and a review of the literature. Baschinsky DY, et al. **Gynecol Oncol** 1999 Apr; 73(1):145–50 (23 ref.)

Malignant rhabdoid tumor of the vulva: case report with cytological, immunohistochemical, ultrastructural and DNA ploidy studies and a review of the literature. Igarashi T, et al. **Pathol Int** 1998 Nov;48(11):887–91 (19 ref.)

THERAPY

Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. Hilden JM, et al. **J Neurooncol** 1998 Dec; 40(3):265–75 (39 ref.)

Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: case report and review. Waldron PE, et al. **J Pediatr Hematol Oncol** 1999 Jan–Feb;21(1):53–7 (28 ref.)

RHABDOMYOLYSIS

Rhabdomyolysis. Visweswaran P, et al. **Crit Care Clin** 1999 Apr;15(2):415–28, ix–x (51 ref.)

COMPLICATIONS

Acute renal failure due to hypokalemic rhabdomyolysis in Gitelman's syndrome. Nishihara G, et al. **Clin Nephrol** 1998 Nov;50(5):330–2 (9 ref.)

Disseminated intravascular coagulation (DIC) and rhabdomyolysis in fulminant varicella infection--case report and review of the literature. Hollenstein U, et al. **Infection** 1998 Sep–Oct;26(5):306–8 (40 ref.)

Acute renal failure in rhabdomyolysis. Guglielminotti J, et al. **Minerva Anestesiol** 1999 May;65(5):250–5 (46 ref.)

[Acute renal failure in rhabdomyolysis] Fernández-Fúnez A. **Rev Clin Esp** 1998 Nov;198(11):758–64 (118 ref.) **(Spa)**

DIAGNOSIS

[Rhabdomyolysis: clinical features, causes, complications and treatment] Szumilak D, et al. **Przegl Lek** 1998;55(5):274–9 (52 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Cocaine-associated rhabdomyolysis and excited delirium: different stages of the same syndrome. Ruttenber AJ, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):120–7 (66 ref.)

Hyponatremia-associated rhabdomyolysis. Trimarchi H, et al. **Nephron** 1999;82(3):274–7 (33 ref.)

[Acute rhabdomyolysis in the child] Hue V, et al. **Arch Pediatr** 1998 Aug;5(8):887–95 (49 ref.) (Eng. Abstr.) **(Fre)**

[A case of severe hypernatremia complicated with rhabdomyolysis] Asahara H, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):301–4 (22 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Fatty acid oxidation defects in muscle. Morris AA, et al. **Curr Opin Neurol** 1998 Oct;11(5):485–90 (50 ref.)

PATHOLOGY

Epidemiology, mechanisms and clinical features of rhabdomyolysis. Bollaert PE, et al. **Minerva Anestesiol** 1999 May;65(5):245–9 (61 ref.)

THERAPY

The management of shock and local injury in traumatic rhabdomyolysis. Nespoli A, et al. **Minerva Anestesiol** 1999 May;65(5):256–62 (36 ref.)

VETERINARY

Review of exertional rhabdomyolysis and a case in a rhesus monkey (Macaca mulatta). Reuter JD, et al. **J Med Primatol** 1998 Dec;27(6):303–9 (29 ref.)

RHABDOMYOMA

COMPLICATIONS

Tuberous sclerosis with intracardiac rhabdomyoma in a fetus with trisomy 21: case report and review of literature. Krapp M, et al. **Prenat Diagn** 1999 Jul;19(7):610–3 (26 ref.)

DIAGNOSIS

[Cardiac tumors. Our experience with 4 cases] Torres Borrego J, et al. **An Esp Pediatr** 1999 Jan;50(1):61–4 (24 ref.) **(Spa)**

PATHOLOGY

A tumorous type of pulmonary rhabdomyomatous dysplasia [see comments] Ramaswamy A, et al. **Pathol Res Pract** 1998;194(9):639–42 (15 ref.) Comment in: Pathol Res Pract 1999;195(3):199–200.

RHABDOMYOSARCOMA

Pediatric genitourinary tumors. Lee HH, et al. **Curr Opin Oncol** 1999 May;11(3):218–25 (57 ref.)

Common musculoskeletal tumors of childhood and adolescence. Arndt CA, et al. **N Engl J Med** 1999 Jul 29; 341(5):342–52 (100 ref.)

[Urogential rhabdomyosarcoma] Wald M, et al. **Harefuah** 1998 Aug;135(3–4):142–4 (13 ref.) **(Heb)**

DIAGNOSIS

The role of radiology in childhood rhabdomyosarcoma. McHugh K, et al. **Clin Radiol** 1999 Jan;54(1):2–10 (46 ref.)

A follow-up of rhabdomyosarcoma of the infratemporal fossa region in adults based on the magnetic resonance imaging findings: case reports. Goto TK, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Nov;86(5):616–25 (20 ref.)

[Standards, options and recommendations (SOR) for clinical care of rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children. Federation of the French Cancer Centers. French Society of Pediatric Oncology (published erratum appears in Bull Cancer 1999 Feb;86(2):232)] Sommelet D, et al. **Bull Cancer** 1998 Dec;85(12):1015–42 (218 ref.) (Eng. Abstr.) **(Fre)**

[Prostatic rhabdomyosarcoma in adults] Muñoz Vélez D, et al. **Arch Esp Urol** 1998 Nov;51(9):883–8 (21 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The role of Pax3 and Pax7 in development and cancer. Mansouri A. **Crit Rev Oncog** 1998;9(2):141–9 (62 ref.)

Rhabdomyosarcoma--working out the pathways. Merlino G, et al. **Oncogene** 1999 Sep 20;18(38):5340–8 (134 ref.)

PATHOLOGY

Laryngeal rhabdomyosarcoma in adults. Ruske DR, et al. **J Laryngol Otol** 1998 Jul;112(7):670–2 (17 ref.)

Rhabdomyosarcoma of the penis in a 15-month-old boy. Antoneli CB, et al. **J Urol** 1998 Dec;160(6 Pt 1):2200–1 (3 ref.)

Rhabdomyosarcoma: an overview. Dagher R, et al. **Oncologist** 1999;4(1):34–44 (80 ref.)

Intergroup Rhabdomyosarcoma Study: update for pathologists. Qualman SJ, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):550–61 (35 ref.)

[Pathology of childhood and adolescent rhabdomyosarcoma] Leuschner I, et al. **Pathologe** 1999 Mar;20(2):87–97 (30 ref.) (Eng. Abstr.) **(Ger)**

[Rhabdomyosarcoma and extraosseous Ewing's sarcoma] Harms D, et al. **Verh Dtsch Ges Pathol** 1998;82:83–98 (71 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Role of radiation therapy in parameningeal rhabdomyosarcoma. Paulino AC. **Cancer Invest** 1999; 17(3):223–30 (40 ref.)

SECONDARY

Clear cell (glycogen-rich) rhabdomyosarcoma presenting as cervical lymphadenopathy. Govender D, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb; 61(1):52–4 (9 ref.)

SURGERY

Risk-based management: current concepts of treating malignant solid tumors of childhood. Grosfeld JL. **J Am Coll Surg** 1999 Oct;189(4):407–25 (93 ref.)

THERAPY

Rhabdomyosarcoma: an overview. Dagher R, et al. **Oncologist** 1999;4(1):34–44 (80 ref.)

[Standards, options and recommendations (SOR) for clinical care of rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children. Federation of the French Cancer Centers. French Society of Pediatric Oncology (published erratum appears in Bull Cancer 1999 Feb;86(2):232)] Sommelet D, et al. **Bull Cancer** 1998 Dec;85(12):1015–42 (218 ref.) (Eng. Abstr.) **(Fre)**

RHABDOMYOSARCOMA, ALVEOLAR

COMPLICATIONS

Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature. Fiegl M, et al. **Ann Hematol** 1999 Jul;78(7):335–8 (18 ref.)

RHABDOMYOSARCOMA, EMBRYONAL

[Paratesticular rhabdomyosarcoma. Report of a case and

review of the literature] Guinda Sevillano C, et al. **Actas Urol Esp** 1998 Sep;22(8):690–4 (17 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Child with mosaic variegated aneuploidy and embryonal rhabdomyosarcoma. Limwongse C, et al. **Am J Med Genet** 1999 Jan 1;82(1):20–4 (24 ref.)

Embryonal rhabdomyosarcoma with only numerical chromosome changes. Case report and review of the literature. Polito P, et al. **Cancer Genet Cytogenet** 1999 Mar; 109(2):161–5 (19 ref.)

PATHOLOGY

Embryonal rhabdomyosarcoma of the nose in an elderly patient, case report and review of the literature. Jund R, et al. **Auris Nasus Larynx** 1998 Dec;25(4):445–50 (25 ref.)

ULTRASONOGRAPHY

Prenatal sonographic features of embryonal rhabdomyosarcoma. Onderoğlu LS, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):210–2 (7 ref.)

RHABDOVIRIDAE INFECTIONS

VETERINARY

Vesicular stomatitis. Letchworth GJ, et al. **Vet J** 1999 May; 157(3):239–60 (267 ref.)

RHAMNOSE

METABOLISM

Rhamnose lipids--biosynthesis, microbial production and application potential. Lang S, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):22–32 (116 ref.)

The metabolism of 6-deoxyhexoses in bacterial and animal cells. Tonetti M, et al. **Biochimie** 1998 Nov;80(11):923–31 (53 ref.)

RHAMNUS

CHEMISTRY

[Sea buckthorn and sea buckthorn oils--recent developments in China and central Asia] Aitzetmüller K, et al. **Nahrung** 1999 Aug;43(4):228–32 (25 ref.) (Eng. Abstr.) **(Ger)**

RHENIUM

DIAGNOSTIC USE

188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Iznaga-Escobar N. **Nucl Med Biol** 1998 Jul;25(5):441–7 (58 ref.)

RHEOGRAPHY see **PLETHYSMOGRAPHY, IMPEDANCE**

RHEOLOGY

Effects of exercise and training on blood rheology. El-Sayed MS. **Sports Med** 1998 Nov;26(5):281–92 (59 ref.)

INSTRUMENTATION

Ultrasonic investigation of blood flow. Fish PJ. **Proc Inst Mech Eng [H]** 1999;213(3):169–80 (28 ref.)

METHODS

Histological methods to determine blood flow distribution with fluorescent microspheres. Luchtel DL, et al. **Biotech Histochem** 1998 Nov;73(6):291–309 (26 ref.)

RHESUS BLOOD-GROUP SYSTEM see **RH-HR BLOOD-GROUP SYSTEM**

RHESUS MONKEY see **MACACA MULATTA**

RHEUMATIC DISEASES

Health services research. Suarez-Almazor ME, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):110–6 (49 ref.)

Developing case definitions for symptom-based conditions: the problem of specificity. Hyams KC. **Epidemiol Rev** 1998; 20(2):148–56 (124 ref.)

The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. Ortiz Z, et al. **J Rheumatol** 1999 Jan; 26(1):210–6 (26 ref.)

Vaccination of the immunosuppressed adult patient with rheumatologic disease. Avery RK. **Rheum Dis Clin North Am** 1999 Aug;25(3):567–84, viii (73 ref.)

[Nomenclature and classification of the rheumatic diseases (editorial)] Shichikawa K. **Ryumachi** 1998 Aug; 38(4):577–80 (8 ref.) **(Jpn)**

COMPLICATIONS

Autoimmune rheumatic diseases and the heart. Hussain S, et al. **Hosp Med** 1999 Feb;60(2):95–9 (23 ref.)

Dyspepsia and heartburn. Ahmad NA, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):703–18, x (106 ref.)

Large artery occlusive disease. Bartholomew JR, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):669–86, ix (48 ref.)

Screening for cancer in the patient with rheumatic disease. Bowles KE, et al. **Rheum Dis Clin North Am** 1999 Aug; 25(3):719–44, x (137 ref.)

Psychological and behavioral approaches to pain management for patients with rheumatic disease. Bradley LA, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):215–32, viii (110 ref.)

Evaluation and treatment of hypertension. Chou CM. **Rheum Dis Clin North Am** 1999 Aug;25(3):521–37 (69 ref.)

Management of lipid disorders. Friedrich CA, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):507–20 (53 ref.)

Detection and management of coronary artery disease in patients with rheumatologic disorders. Ghaffari S. **Rheum Dis Clin North Am** 1999 Aug;25(3):657–68 (42 ref.)

Women's health. Lautenbach GL, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):539–65 (111 ref.)

The use of analgesics in the management of pain in rheumatic diseases. Moreland LW, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):153–91, vii (272 ref.)

Recognition and management of preoperative risk. Nierman E, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):585–622 (150 ref.)

Perioperative management of selected problems in patients with rheumatic diseases. Shaw M, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):623–38, ix (58 ref.)

[Pulmonary hypertension in rheumatic diseases] Manganelli P, et al. **Minerva Med** 1999 Mar;90(3):59–72 (149 ref.) (Eng. Abstr.) **(Ita)**

[The association between autoimmune thyroid diseases and rheumatic diseases: a review] MasukoHongo K, et al. **Nippon Rinsho** 1999 Aug;57(8):1873–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Atherothrombosis in rheumatic diseases: pathogenesis analysis] Nasonov EL. **Ter Arkh** 1998;70(9):92–5 (74 ref.) **(Rus)**

DIAGNOSIS

Immunologic tests in rheumatology. Moder KG. **Ann Allergy Asthma Immunol** 1998 Dec;81(6):539–44, 547; quiz 547–8 (25 ref.)

Autoantibodies and specific serum proteins in the diagnosis of rheumatological disorders. Ismail AA, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):565–78 (115 ref.)

Rheumatic disease and cystic fibrosis. Merkel PA. **Arthritis Rheum** 1999 Aug;42(8):1563–71 (100 ref.)

Enthesiopathy: clinical manifestations, imaging and treatment. Olivieri I, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):665–81 (53 ref.)

Rheumatologic manifestations of HIV-1 and HTLV-1 infections. Vassilopoulos D, et al. **Cleve Clin J Med** 1998 Sep;65(8):436–41 (33 ref.)

[Scientific bases of medical examinations of patients with rheumatic diseases] Ivanova MM. **Vestn Ross Akad Med Nauk** 1998;(12):19–22 (36 ref.) (Eng. Abstr.) **(Rus)**

DIET THERAPY

n-6 and n-3 essential fatty acids in rheumatoid arthritis and other rheumatic conditions. Belch JJ, et al. **Proc Nutr Soc** 1998 Nov;57(4):563–9 (39 ref.)

DRUG THERAPY

Can we use steroid hormones to immunomodulate rheumatic diseases? Rheumatoid arthritis as an example. Bijlsma JW. **Ann N Y Acad Sci** 1999 Jun 22;876:366–76; discussion 376–7 (33 ref.)

Enthesiopathy: clinical manifestations, imaging and treatment. Olivieri I, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):665–81 (53 ref.)

Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Singer NG, et al. **Curr Opin Rheumatol** 1999 May;11(3):173–8 (21 ref.)

Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Ostensen M, et al. **Drug Saf** 1998 Nov;19(5):389–410 (264 ref.)

Clinically important drug interactions with disease-modifying antirheumatic drugs. Haagsma CJ. **Drugs Aging** 1998 Oct;13(4):281–9 (55 ref.)

Selected drug complications and treatment conflicts in the presence of coexistent diseases. Vassilopoulos D, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):745–77, x (232 ref.)

[Role of corticosteroid therapy in non-malignant diseases] Vignes S, et al. **Rev Med Interne** 1998 Nov;19(11):799–810 (87 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

A résumé of epidemiological surveys of several main rheumatic diseases in China. Zhang N. **Chin Med J (Engl)** 1998 Mar;111(3):195–6 (10 ref.)

Epidemiology of the rheumatic diseases. Rooney BK, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):91–7 (45 ref.)

ETHNOLOGY

Rheumatic disease and the Australian aborigine. Roberts-Thomson RA, et al. **Ann Rheum Dis** 1999 May; 58(5):266–70 (33 ref.)

Rheumatic diseases in North America's indigenous peoples. Peschken CA, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):368–91 (127 ref.)

ETIOLOGY

Rheumatologic manifestations of gastrointestinal disorders. Braun J, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):68–74 (71 ref.)

Rheumatologic features of hematologic disorders. Ehrenfeld M, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):62–7 (42 ref.)

Pathogenesis and mechanisms of inflammation in the childhood rheumatic diseases. Jarvis JN. **Curr Opin Rheumatol** 1998 Sep;10(5):459–67 (91 ref.)

Genetic diseases with rheumatic manifestations in children. Prahalad S, et al. **Curr Opin Rheumatol** 1998 Sep; 10(5):488–93 (38 ref.)

Rheumatologic manifestations of gastrointestinal diseases. Katz JP, et al. **Gastroenterol Clin North Am** 1998 Sep; 27(3):533–62, v (188 ref.)

Modeling the involvement of the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes in autoimmune and stress-related rheumatic syndromes in women. Crofford LJ, et al. **J Womens Health** 1999 Mar;8(2):203–15 (58 ref.)

Assessing the harm of silicone gel-filled breast implants [letter] Shapiro MM. **Nurse Pract** 1999 Mar;24(3):140–1 (20 ref.)

GENETICS

Signal transduction and transcription factors in rheumatic disease. Firestein GS, et al. **Arthritis Rheum** 1999 Apr; 42(4):609–21 (126 ref.)

[Analysis of susceptibility genes to rheumatic diseases] Tsuchiya N, et al. **Nippon Rinsho** 1999 Feb;57(2):323–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic aspects of rheumatic diseases] Miakotkin VA. **Vestn Ross Akad Med Nauk** 1998;(12):39–43 (42 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Adhesion and lymphocyte costimulatory molecules in systemic rheumatic diseases. Sfikakis PP, et al. **Clin Rheumatol** 1999;18(4):317–27 (129 ref.)

Hypophyseal-pituitary-adrenal axis in autoimmune and rheumatic diseases. Athreya BH, et al. **Immunol Res** 1998; 18(2):93–102 (56 ref.)

PHYSIOPATHOLOGY

Signal transduction and transcription factors in rheumatic disease. Firestein GS, et al. **Arthritis Rheum** 1999 Apr; 42(4):609–21 (126 ref.)

Rheumatic disease and cystic fibrosis. Merkel PA. **Arthritis Rheum** 1999 Aug;42(8):1563–71 (100 ref.)

The pathomechanic effects of rheumatic diseases on the pedal joints. Albert SF. **Clin Podiatr Med Surg** 1999 Apr; 16(2):259–70 (9 ref.)

Pathogenesis and mechanisms of inflammation in the childhood rheumatic diseases. Jarvis JN. **Curr Opin Rheumatol** 1998 Sep;10(5):459–67 (91 ref.)

Classification of inflammatory arthritis by enthesitis [see comments] McGonagle D, et al. **Lancet** 1998 Oct 3; 352(9134):1137–40 (43 ref.) Comment in: Lancet 1998 Dec 12;352(9144):1938. Comment in: Lancet 1998 Dec 12;352(9144):1938–9. Comment in: Lancet 1999 May 1;353(9163):1526–7.

PSYCHOLOGY

Depression in the patient with rheumatologic disease. Stoltz CM, et al. **Rheum Dis Clin North Am** 1999 Aug; 25(3):687–702, x (48 ref.)

Psychological factors in chronic rheumatic diseases--a review. The case of rheumatoid arthritis, current research and some problems [see comments] Persson LO, et al. **Scand J Rheumatol** 1999;28(3):137–44 (90 ref.) Comment in: Scand J Rheumatol 1999 ;28(3):131–6.

Psychological distress and rheumatic disease [editorial; comment] Wolfe F. **Scand J Rheumatol** 1999;28(3):131–6 (52 ref.) Comment on: Scand J Rheumatol 1999 ;28(3):137–44.

RADIOGRAPHY

Radiographic manifestations of rheumatic diseases affecting the foot and ankle. Loredo R. **Clin Podiatr Med Surg** 1999 Apr;16(2):215–58, v (39 ref.)

RADIONUCLIDE IMAGING

[Nuclear medicine and rheumatology. Diagnostic and therapeutic integration] Colamussi P, et al. **Radiol Med (Torino)** 1999 Jun;97(6):510–7 (67 ref.) **(Ita)**

RADIOTHERAPY

[Nuclear medicine and rheumatology. Diagnostic and therapeutic integration] Colamussi P, et al. **Radiol Med (Torino)** 1999 Jun;97(6):510–7 (67 ref.) **(Ita)**

REHABILITATION

Bioclimatology and balneology in dermatology: a Dead Sea perspective. Abels DJ, et al. **Clin Dermatol** 1998 Nov–Dec; 16(6):695–8 (15 ref.)

SURGERY

Deep vein thrombosis and pulmonary embolism prophylaxis in joint replacement surgery. Merli GJ. **Rheum Dis Clin North Am** 1999 Aug;25(3):639–56, ix (91 ref.)

THERAPY

Gene therapy for rheumatic diseases. Evans CH, et al. **Arthritis Rheum** 1999 Jan;42(1):1–16 (102 ref.)

Usage of complementary therapies in rheumatology: a systematic review. Ernst E. **Clin Rheumatol** 1998; 17(4):301–5 (31 ref.)

Biologic agents in the treatment of inflammatory rheumatic diseases. Lorenz HM, et al. **Curr Opin Rheumatol** 1999 May;11(3):179–84 (29 ref.)

Hematopoietic stem cell transplantation in rheumatic diseases. Snowden JA, et al. **Curr Opin Rheumatol** 1999 May; 11(3):167–72 (43 ref.)

Stem cell transplantation--a treatment for severe rheumatic diseases?--A review. Jantunen EJ, et al. **Scand J Rheumatol** 1999;28(2):69–74 (47 ref.)

[Rheumatology 1998: are there recent advances?] Frey D, et al. **Schweiz Med Wochenschr** 1998 Dec 26; 128(51–52):2038–42 (4 ref.) **(Ger)**

VIROLOGY

Mechanisms of viral pathogenesis in rheumatic disease. Perl A. **Ann Rheum Dis** 1999 Aug;58(8):454–61 (113 ref.)

Retrovirus-associated rheumatic syndromes. Herrmann M, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):347–54 (78 ref.)

[Epstein-Barr virus and rheumatic disease] Murakami K. **Ryumachi** 1998 Dec;38(6):849–59 (70 ref.) **(Jpn)**

RHEUMATIC FEVER

Rheumatic fever and rheumatic heart disease: an overview. Groves AM. **Trop Doct** 1999 Jul;29(3):129–32 (17 ref.)

[Rheumatic fever] Miyata K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):99–101 (6 ref.) **(Jpn)**

[Sydenham's chorea] Sato H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):104–7 (14 ref.) **(Jpn)**

COMPLICATIONS

PANDAS: the search for environmental triggers of pediatric neuropsychiatric disorders. Lessons from rheumatic fever. Garvey MA, et al. **J Child Neurol** 1998 Sep;13(9):413–23 (123 ref.)

DRUG THERAPY

[Acute rheumatic fever in today's children] Olivier C. **Presse Med** 1998 Jun 27;27(23):1159–67 (51 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

[Acute articular rheumatism in the child in 1997] Olivier C. **Pathol Biol (Paris)** 1998 Dec;46(10):802–12 (52 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[Participation of major histocompatibility system alleles in the susceptibility to rheumatic fever] Vargas-Alarcón G, et al. **Arch Inst Cardiol Mex** 1999 Jan–Feb;69(1):72–9 (54 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

The changing face of rheumatic fever in the 20th century [editorial] Stollerman GH. **J Med Microbiol** 1998 Aug; 47(8):655–7 (30 ref.)

Bacterial infection and related arthritides: what do we really know? Schaeverbeke T, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):1S–2S (11 ref.)

THERAPY

Current guidelines for the treatment of patients with rheumatic fever. Thatai D, et al. **Drugs** 1999 Apr; 57(4):545–55 (93 ref.)

RHEUMATIC HEART DISEASE

Rheumatic fever and rheumatic heart disease: an overview. Groves AM. **Trop Doct** 1999 Jul;29(3):129–32 (17 ref.)

COMPLICATIONS

Acute rheumatic pancarditis associated with poststreptococcal acute glomerulonephritis: a patient report. Kakkera DR, et al. **Clin Pediatr (Phila)** 1998 Sep; 37(9):569–72 (11 ref.)

DIAGNOSIS

[Rheumatic cardiopathy and Chagas disease] Rodriguez-Patiño AE, et al. **Arch Inst Cardiol Mex** 1998 May–Jun;68(3):239–46 (43 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Systematic transesophageal echocardiographic examination in mitral valve repair: the evolution of a discipline into the twenty-first century [editorial; comment] Savage RM, et al. **Anesth Analg** 1999 Jun;88(6):1197–9 (14 ref.) Comment on: Anesth Analg 1999 Jun;88(6):1205–12.

RHEUMATISM see **RHEUMATIC DISEASES**

RHEUMATISM, ARTICULAR, ACUTE see **RHEUMATIC FEVER**

RHEUMATISM, MUSCULAR see **FIBROMYALGIA**

RHEUMATISM, PERI-EXTRA-ARTICULAR see **POLYMYALGIA RHEUMATICA**

RHEUMATOID FACTOR

[Progress in clinical tests and the pathophysiological study of collagen diseases--rheumatoid factor] Ozaki S. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2396–401 (5 ref.) **(Jpn)**

RHEUMATOID NODULE

DIAGNOSIS

Rheumatoid nodule of the foot: MRI appearances mimicking an indeterminate soft tissue mass. Sanders TG, et al. **Skeletal Radiol** 1998 Aug;27(8):457–60 (14 ref.)

RHEUMATOID PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

RHEUMATOID SPONDYLITIS see **SPONDYLITIS, ANKYLOSING**

RHEUMATOLOGY

see related
COLLAGEN DISEASES
RHEUMATIC DISEASES

Update in rheumatology. Campbell SM, et al. **Ann Intern Med** 1999 Jan 19;130(2):135–42 (8 ref.)

Usage of complementary therapies in rheumatology: a systematic review. Ernst E. **Clin Rheumatol** 1998; 17(4):301–5 (31 ref.)

[62nd Congress of the American College of Rheumatology, San Diego, 8–12 November 1998] Cherin P. **Rev Med Interne** 1999 Apr;20(4):311–7 (34 ref.) **(Fre)**

[Quality recommendations of the German Society of Rheumatology. Basis for further responsibilities] Keitel W. **Z Rheumatol** 1998 Oct;57(5):355–7 (17 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Does economic evaluation have anything to offer the rheumatologist? [editorial] Hurst NP, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):2–5 (18 ref.)

EDUCATION

Skills development in rheumatology undergraduate and postgraduate curricula. Jerome D, et al. **J Rheumatol** 1999 Feb;26 Suppl 55:38–40 (0 ref.)

INSTRUMENTATION

Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):1003–5 (16 ref.)

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):951–4 (12 ref.)

METHODS

Clinimetric concepts in outcome assessment: the OMERACT filter. Bellamy N. **J Rheumatol** 1999 Apr;26(4):948–50 (19 ref.)

Introduction to reading radiographs by the Scott modification of the Larsen method. Edmonds J, et al. **J Rheumatol** 1999 Mar;26(3):740–2 (12 ref.)

Conceptual issues in scoring radiographic progression in rheumatoid arthritis. Kirwan JR. **J Rheumatol** 1999 Mar; 26(3):720–5 (33 ref.)

How to read radiographs according to the Sharp/van der Heijde method. van der Heijde D. **J Rheumatol** 1999 Mar; 26(3):743–5 (10 ref.)

Methodological issues in radiographic scoring methods in rheumatoid arthritis. van der Heijde D, et al. **J Rheumatol** 1999 Mar;26(3):726–30 (36 ref.)

[Development of studies on problem of infectious arthritis at the Institute of RHeumatology, Russian Academy of Medical Sciences in 1970 to 1990] Agababova ER. **Vestn Ross Akad Med Nauk** 1998;(12):23–6 (41 ref.) (Eng. Abstr.) **(Rus)**

[Scientific bases of medical examinations of patients with rheumatic diseases] Ivanova MM. **Vestn Ross Akad Med Nauk** 1998;(12):19–22 (36 ref.) (Eng. Abstr.) **(Rus)**

[Rheumoorthopedics as an integral part of complex therapy of rheumatic diseases with joint involvement] Pavlov VP. **Vestn Ross Akad Med Nauk** 1998;(12):47–9 (11 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. **Arthritis Rheum** 1999 Apr;42(4):599–608 (123 ref.)

Classification of childhood arthritis: a work in progress. Petty RE. **Baillieres Clin Rheumatol** 1998 May;12(2):181–90 (20 ref.)

TRENDS

Rheumatological arthroscopy or research arthroscopy in rheumatology? [editorial] Ayral X, et al. **Br J Rheumatol** 1998 Oct;37(10):1039–41 (32 ref.)

Therapeutic advances in systemic lupus erythematosus. Godfrey T, et al. **Curr Opin Rheumatol** 1998 Sep; 10(5):435–41 (81 ref.)

1998 update on antiphospholipid antibodies. Petri M. **Curr Opin Rheumatol** 1998 Sep;10(5):426–30 (53 ref.)

The evolution of arthritis antiinflammatory care: where are we today? Simon LS. **J Rheumatol** 1999 Apr;26 Suppl 56:11–7 (76 ref.)

[Rheumatology] Genth E, et al. **Internist (Berl)** 1999 Apr; 40(4):401–6 (21 ref.) **(Ger)**

RHINENCEPHALON see **LIMBIC SYSTEM**

RHINITIS

Allergic rhinitis in childhood. **Allergy** 1999;54 Suppl 55:7–34 (260 ref.)

Rhinitis, sinusitis, and polyposis. Young MC. **Allergy Asthma Proc** 1998 Jul–Aug;19(4):211–8 (37 ref.)

COMPLICATIONS

Allergic rhinitis and rhinosinusitis. Is there a connection between allergy and infection? Ferguson BJ, et al. **Postgrad Med** 1999 Apr;105(4):55–8, 61, 64 (36 ref.)

MR imaging and CT of orbital infections and complications in acute rhinosinusitis. Eustis HS, et al. **Radiol Clin North Am** 1998 Nov;36(6):1165–83, xi (56 ref.)

DIAGNOSIS

The management of postnasal drip. Forer M, et al. **Aust Fam Physician** 1999 Mar;28(3):223–8 (22 ref.)

Rhinosinusitis. Current concepts in evaluation and management. Osguthorpe JD, et al. **Med Clin North Am** 1999 Jan;83(1):27–41, vii–viii (30 ref.)

Diagnosis and management of rhinitis. Weldon D. **Prim Care** 1998 Dec;25(4):831–48 (112 ref.)

[Diagnostic values of nasal mucosa cytology] Miszke A, et al. **Otolaryngol Pol** 1999;53(2):153–6 (11 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Diagnosis and management of rhinitis. Weldon D. **Prim Care** 1998 Dec;25(4):831–48 (112 ref.)

[Decongestants in treatment of nasal obstruction] Bogacka E. **Otolaryngol Pol** 1999;53(3):347–52 (20 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Rhinosinusitis and asthma: epiphenomenon or causal association? de Benedictis FM, et al. **Chest** 1999 Feb; 115(2):550–6 (69 ref.)

ETIOLOGY

Relationships between rhinitis and asthma. Vignola AM, et al. **Allergy** 1998 Sep;53(9):833–9 (83 ref.)

ENT issues in pregnancy. Lippincott LH, et al. **J La State Med Soc** 1999 Jul;151(7):350–4 (13 ref.)

[Environment and nasal hyperreactivity] Lacroix JS. **Rev Med Suisse Romande** 1999 Aug;119(8):619–21 (16 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Mechanisms of mucosal inflammation in the nose and lungs. Kips J. **Allergy** 1999;54 Suppl 50:37–8 (16 ref.)

METABOLISM

The kinin system in rhinitis and asthma. Proud D. **Clin Rev Allergy Immunol** 1998 Winter;16(4):351–64 (83 ref.)

RHINITIS

PHYSIOPATHOLOGY

Occupational and allergic rhinitis: impact on worker productivity and safety. Slavin RG.
Allergy Asthma Proc 1998 Sep-Oct;19(5):277-84 (58 ref.)

SURGERY

[Treatment of nasal obstruction with subtotal inferior turbinectomy in chronic rhinitis: a retrospective study on 50 patients] Faulcon P, et al.
Ann Otolaryngol Chir Cervicofac 1998 Oct;115(4):228-33 (30 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

National guidelines needed to manage rhinitis and prevent complications. Rachelefsky GS.
Ann Allergy Asthma Immunol 1999 Mar;82(3):296-305 (126 ref.)

Current concepts in the management of paediatric rhinosinusitis. Jones NS. **J Laryngol Otol** 1999 Jan; 113(1):1-9 (104 ref.)

RHINITIS, ALLERGIC, NONSEASONAL see **RHINITIS, ALLERGIC, PERENNIAL**

RHINITIS, ALLERGIC, PERENNIAL

Update in allergy and immunology. O'Hollaren MT.
Ann Intern Med 1998 Dec 15;129(12):1036-43 (5 ref.)

BLOOD

Nitric oxide in allergic rhinitis and asthma. Frieri M.
Allergy Asthma Proc 1998 Nov-Dec;19(6):349-51 (42 ref.)

COMPLICATIONS

Pharmacotherapy to prevent the complications of allergic rhinitis. Beckman DB, et al. **Allergy Asthma Proc** 1999 Jul-Aug;20(4):215-23 (81 ref.)

Complications of allergic rhinitis. Settipane RA.
Allergy Asthma Proc 1999 Jul-Aug;20(4):209-13 (39 ref.)

Allergic rhinitis and rhinosinusitis. Is there a connection between allergy and infection? Ferguson BJ, et al.
Postgrad Med 1999 Apr;105(4):55-8, 61, 64 (36 ref.)

DIAGNOSIS

Can we predict atopic disease using perinatal risk factors? [editorial;comment] Bergmann RL, et al.
Clin Exp Allergy 1998 Aug;28(8):905-7 (25 ref.) Comment on: Clin Exp Allergy 1998 Aug;28(8):936-42.

Allergic rhinitis--making the correct diagnosis. Lund V.
Clin Exp Allergy 1998 Dec;28 Suppl 6:25-8 (15 ref.)

Nasal hyperreactivity. Gerth van Wijk RG, et al.
Rhinology 1999 Jun;37(2):50-5 (49 ref.)

DRUG THERAPY

Mechanisms of rhinitis. Baraniuk JN.
Allergy Asthma Proc 1998 Nov-Dec;19(6):343-7 (37 ref.)

Antihistamines in severe/chronic rhinitis. Bousquet J.
Clin Exp Allergy 1998 Dec;28 Suppl 6:49-53 (23 ref.)

Clinical assessment of antihistamines in rhinitis. Scadding GK. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:77-81 (23 ref.)

The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Simon RA.
Clin Rev Allergy Immunol 1999 Spring-Summer; 17(1-2):271-5 (29 ref.)

Advances in the pharmacological treatment of allergic rhinitis. Rusznak C, et al. **Curr Probl Dermatol** 1999; 28:102-18 (29 ref.)

Treating allergic rhinitis in pregnancy. Safety considerations. Mazzotta P, et al. **Drug Saf** 1999 Apr;20(4):361-75 (54 ref.)

Mometasone furoate. A review of its intranasal use in allergic rhinitis. Onrust SV, et al. **Drugs** 1998 Oct;56(4):725-45 (71 ref.)

Pros and cons of the use of antihistamines in managing allergic rhinitis. Day J. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 2):S395-9 (53 ref.)

Use of nasal steroids in managing allergic rhinitis. LaForce C. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S388-94 (90 ref.)

Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. Golden SJ, et al.
J Am Osteopath Assoc 1999 Jul;99(7 Suppl):S7-12 (35 ref.)

[Cromones in the therapy of food-induced allergic rhinitis, pharyngitis and laryngitis] Buczyłko K.
Pol Merkuriusz Lek 1998 Dec;5(30):357-9 (18 ref.) (Eng. Abstr.) **(Pol)**

[Second generation topical antihistaminics] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May;6(35):277-80 (59 ref.) (Eng. Abstr.) **(Pol)**

[Anti-recurrence treatment of polypous rhinosinusitis] Kondrat'ev VA, et al. **Vestn Otorinolaringol** 1999;(4):39 (3 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Changing prevalence of allergic rhinitis and asthma. Sly RM.
Ann Allergy Asthma Immunol 1999 Mar;82(3):233-48; quiz 248-52 (104 ref.)

Asthma and atopy in Western and Eastern communities--current status and open questions [editorial; comment] Nowak D, et al. **Clin Exp Allergy** 1998 Sep; 28(9):1043-6 (34 ref.) Comment on: Clin Exp Allergy 1998 Sep;28(9):1072-80.

ETIOLOGY

The clinical expression of allergy in the nose. van Cauwenberge P, et al. **Allergy** 1999 Feb;54(2):93-102 (82 ref.)

Mechanisms of rhinitis. Baraniuk JN.
Allergy Asthma Proc 1998 Nov-Dec;19(6):343-7 (37 ref.)

Experimental models in rhinitis. Demoly P, et al.
Clin Exp Allergy 1999 Jul;29 Suppl 3:72-6 (17 ref.)

The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Simon RA.
Clin Rev Allergy Immunol 1999 Spring-Summer; 17(1-2):271-5 (29 ref.)

New insights in the pathogenesis of allergic rhinitis. Van Cauwenberge P, et al. **Curr Probl Dermatol** 1999;28:95-101 (35 ref.)

[Cromones in the therapy of food-induced allergic rhinitis, pharyngitis and laryngitis] Buczyłko K.
Pol Merkuriusz Lek 1998 Dec;5(30):357-9 (18 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Hemopoietic mechanisms in allergic airway inflammation. Denburg JA, et al. **Int Arch Allergy Immunol** 1998 Nov; 117(3):155-9 (55 ref.)

Allergic rhinitis. Nash DR. **Pediatr Ann** 1998 Dec; 27(12):799-808 (20 ref.)

PHYSIOPATHOLOGY

Occupational and allergic rhinitis: impact on worker productivity and safety. Slavin RG.
Allergy Asthma Proc 1998 Sep-Oct;19(5):277-84 (58 ref.)

The inflammatory nature of allergic disease. Durham SR.
Clin Exp Allergy 1998 Dec;28 Suppl 6:20-4 (20 ref.)

[The role of eosinophils in nasal hypersensitivity] Okamoto Y. **Arerugi** 1999 Jun;48(6):569-71 (4 ref.) **(Jpn)**

PSYCHOLOGY

[Quality of patient's life: effects of bronchial asthma and allergic rhinitis] Chuchalin AG, et al. **Ter Arkh** 1998; 70(9):53-7 (31 ref.) **(Rus)**

THERAPY

Allergen-specific immunotherapy for allergic rhinitis: a new insight into its clinical efficacy and mechanism. Ohashi Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:178-90 (82 ref.)

Nasal topical immunotherapy [editorial] Muñoz-López F. **Allergol Immunopathol (Madr)** 1999 Jan-Feb;27(1):1-4 (9 ref.) **(Eng, Spa)**

What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis? Ferguson BJ.
Arch Otolaryngol Head Neck Surg 1998 Oct;124(10):1174-8 (19 ref.)

New treatments for allergic rhinitis. Tkachyk SJ.
Can Fam Physician 1999 May;45:1255-60 (22 ref.)

Immunotherapy in allergic rhinitis: a prevention for asthma? Demoly P, et al. **Curr Probl Dermatol** 1999;28:119-23 (20 ref.)

Allergen immunotherapy and avoidance. Fawcett WAIV.
Prim Care 1998 Dec;25(4):869-83 (38 ref.)

How to treat allergic rhinitis. Lee NP, et al.
West J Med 1999 Jul;171(1):31-4 (18 ref.)

RHINITIS, ALLERGIC, SEASONAL see **HAY FEVER**

RHINOPHARYNX see **NASOPHARYNX**

RHINOPHYMA

[On the problem of rhinophyma management] Szmeja Z, et al. **Otolaryngol Pol** 1999;53(1):29-33 (22 ref.) (Eng. Abstr.) **(Pol)**

RHINOPLASTY

[Surgical anatomy of the nose. I] Adant JP, et al.
Ann Chir Plast Esthet 1998 Oct;43(5):499-510 (31 ref.) (Eng. Abstr.) **(Fre)**

[Secondary rhinoplasty for unilateral cleft lip and palate. Review of the literature and 50 clinical cases] Gounot N, et al. **Ann Chir Plast Esthet** 1998 Jun;43(3):240-7 (42 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Stenosis of the nasal vestibule and its treatment. Kotzur A, et al. **Aesthetic Plast Surg** 1999 Mar-Apr;23(2):86-92 (11 ref.)

Principles for correcting the septum in septorhinoplasty: two-point fixation. Jones NS. **J Laryngol Otol** 1999 May; 113(5):405-12 (11 ref.)

Unilateral cleft rhinoplasty: a review. Madorsky SJ, et al. **Otolaryngol Clin North Am** 1999 Aug;32(4):669-82 (43 ref.)

Nasal base surgery. Silver WE, et al.
Otolaryngol Clin North Am 1999 Aug;32(4):653-68 (15 ref.)

[Increasing the length of the columella. Concepts and techniques] Schauss F. **HNO** 1999 Jul;47(7):663-73 (23 ref.) **(Ger)**

[Rhinoplasty] Tschopp AC. **Ther Umsch** 1999 Apr; 56(4):200-5 (13 ref.) (Eng. Abstr.) **(Ger)**

RHINOSCLEROMA

[Some aspects of scleroma problem] Konoval'chikov GD, et al. **Vestn Otorinolaringol** 1999;(4):51-5 (39 ref.) **(Rus)**

COMPLICATIONS

Transglottic scleroma. Keschner D, et al.
Am J Otolaryngol 1998 Nov-Dec;19(6):407-11 (11 ref.)

PATHOLOGY

[Spheno-ethmoidal rhinoscleroma. Report of a case and review of the literature] Evrard I, et al.
Ann Otolaryngol Chir Cervicofac 1998 May;115(2):85-8 (12 ref.) (Eng. Abstr.) **(Fre)**

RHINOSPORIDIOSIS

Disseminated cutaneous rhinosporidiosis. Thappa DM, et al.
J Dermatol 1998 Aug;25(8):527-32 (26 ref.)

RHINOVIRUS

Rhinoviruses: important respiratory pathogens. Pitkäranta A, et al. **Ann Med** 1998 Dec;30(6):529-37 (79 ref.)

Rhinovirus infections: induction and modulation of airways inflammation in asthma. Grünberg K, et al.
Clin Exp Allergy 1999 Jun;29 Suppl 2:65-73 (112 ref.)

The role of viral and atypical bacterial pathogens in asthma pathogenesis. Johnston SL. **Pediatr Pulmonol Suppl** 1999; 18:141-3 (13 ref.)

Asthma, viruses, and nitric oxide. Sanders SP.
Proc Soc Exp Biol Med 1999 Mar;220(3):123-32 (162 ref.)

[Rhinovirus pneumonia] Kasai T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):90-2 (14 ref.) **(Jpn)**

PATHOGENICITY

Association of rhinovirus infections with asthma. Gern JE, et al. **Clin Microbiol Rev** 1999 Jan;12(1):9-18 (139 ref.)

RHIZOBIACEAE

GENETICS

Genes involved in the formation and assembly of rhizobial cytochromes and their role in symbiotic nitrogen fixation. Delgado MJ, et al. **Adv Microb Physiol** 1998;40:191-231 (160 ref.)

RHIZOBIUM

GENETICS

Genes and signal molecules involved in the rhizobia-leguminoseae symbiosis. Bladergroen MR, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):353-9 (61 ref.)

METABOLISM

Regulation of symbiotic root nodule development. Schultze M, et al. **Annu Rev Genet** 1998;32:33-57 (176 ref.)

Biological sensors: More than one way to sense oxygen. Pellequer JL, et al. **Curr Biol** 1999 Jun 3;9(11):R416-8 (12 ref.)

Role of lectins (and rhizobial exopolysaccharides) in legume nodulation. Hirsch AM. **Curr Opin Plant Biol** 1999 Aug; 2(4):320-6 (53 ref.)

PHYSIOLOGY

Carbohydrate determinants of Rhizobium-legume symbioses. Price NP. **Carbohydr Res** 1999 Apr 30;317(1-4):1-9 (89 ref.)

Genealogy of legume-Rhizobium symbioses. Broughton WJ, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):305-11 (50 ref.)

Mass spectrometric analysis of lipo-chitin oligosaccharides--signal molecules mediating the host-specific legume-rhizobium symbiosis. van der Drift KM, et al. **Mass Spectrom Rev** 1998 Mar-Apr;17(2):75-95 (102 ref.)

Acid tolerance in root nodule bacteria. Glenn AR, et al.
Novartis Found Symp 1999;221:112-26; discussion 126-30 (35 ref.)

RHIZOMELIC CHONDRODYSPLASIA PUNCTATA see **CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC**

RHIZOPUS

ENZYMOLOGY

[The roles of chitin synthases and chitinases on the tip growth and the differentiation of filamentous fungi] Horiuchi H, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(15):2182-90 (47 ref.) **(Jpn)**

RHO(D) IMMUNE GLOBULIN

ADMINISTRATION & DOSAGE

The prevention of Rh haemolytic disease of the fetus and newborn--general background. Contreras M. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:7-10 (24 ref.)
The scientific basis of antenatal prophylaxis. Urbaniak SJ. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:11-8 (22 ref.)

ECONOMICS

Economics of antenatal prophylaxis. Cairns JA. **Br J Obstet Gynaecol** 1998 Nov;105 Suppl 18:19-22 (12 ref.)

RHODAMINE 123

see related
P-GLYCOPROTEIN

RHODAMINES

Detection of reactive nitrogen species using 2,7-dichlorodihydrofluorescein and dihydrorhodamine 123. Ischiropoulos H, et al. **Methods Enzymol** 1999;301:367-73 (16 ref.)

RHODNIUS

METABOLISM

Novel nitric oxide-liberating heme proteins from the saliva of bloodsucking insects. Walker FA, et al. **Met Ions Biol Syst** 1999;36:621-63 (189 ref.)

RHODOBACTER

ENZYMOLOGY

Dimethylsulphoxide reductase from purple phototrophic bacteria: structures and mechanism(s). McEwan AG, et al. **Biochem Soc Trans** 1998 Aug;26(3):390-6 (34 ref.)

RHODOBACTER SPHAEROIDES

METABOLISM

Protein engineering of the photoreaction centre from Rhodobacter sphaeroides. Ridge JP, et al. **Biochem Soc Trans** 1998 Aug;26(3):422-7 (41 ref.)

RHODOCOCCUS

The genus Rhodococcus. Bell KS, et al. **J Appl Microbiol** 1998 Aug;85(2):195-210 (189 ref.)

CHEMISTRY

Surface-active lipids in rhodococci. Lang S, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):59-70 (70 ref.)
Cell envelope composition and organisation in the genus Rhodococcus. Sutcliffe IC. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):49-58 (65 ref.)

CLASSIFICATION

Rhodococcal systematics: problems and developments. Goodfellow M, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):3-20 (195 ref.)

ENZYMOLOGY

A self-compartmentalizing protease in Rhodococcus: the 20S proteasome. De Mot R, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):83-7 (25 ref.)

GENETICS

Cloning of genes that have environmental and clinical importance from rhodococci and related bacteria. Dabbs ER. **Antonie Van Leeuwenhoek** 1998 Jul-Oct; 74(1-3):155-67 (50 ref.)
Applied aspects of Rhodococcus genetics. Larkin MJ, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):133-53 (210 ref.)

METABOLISM

Biotransformation of nitriles by rhodococci. Bunch AW. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):89-97 (40 ref.)
Application of whole cell rhodococcal biocatalysts in acrylic polymer manufacture. Hughes J, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):107-18 (50 ref.)
Desulphurisation of benzothiophene and dibenzothiophene by actinomycete organisms belonging to the genus Rhodococcus, and related taxa. Oldfield C, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):119-32 (65 ref.)

RHODOCOCCUS EQUI

Pulmonary malacoplakia associated with Rhodococcus equi infection in patients with AIDS: case report and review. Guerrero MF, et al. **Clin Infect Dis** 1999 Jun;28(6):1334-6 (15 ref.)
Rhodococcus equi infections: clinical features and laboratory diagnosis. Cornish N, et al. **Curr Clin Top Infect Dis** 1999; 19:198-215 (95 ref.)

ISOLATION & PURIFICATION

[Rhodococcus equi--new human threat] Wiercińska-Drapało A, et al. **Pneumonol Alergol Pol** 1998;66(5-6):346-50 (21 ref.) **(Pol)**
[Cerebral abscess caused by Rhodococcus equi in an immunocompetent patient (letter)] Blanco J, et al. **Enferm Infecc Microbiol Clin** 1998 Jun-Jul;16(6):294-5 (10 ref.) **(Spa)**

RHODOPSEUDOMONAS SPHAEROIDES see **RHODOBACTER SPHAEROIDES**

RHODOPSIN

[Structural view of mechanism of photo-signal transduction related with rhodopsin and heterotrimeric G protein] Fujiyoshi Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):347-54 (7 ref.) **(Jpn)**

CHEMISTRY

Structure of the G-protein-coupled receptor, rhodopsin: a domain approach. Yeagle PL, et al. **Biochem Soc Trans** 1998 Aug;26(3):520-31 (70 ref.)
Structure of rhodopsin. Schertler GF. **Eye** 1998;12 (Pt 3b):504-10 (37 ref.)

GENETICS

Rhodopsin mutations as the cause of retinal degeneration. Classification of degeneration phenotypes in the model system Drosophila melanogaster. Bentrop J. **Acta Anat (Basel)** 1998;162(2-3):85-94 (50 ref.)

METABOLISM

Control of rhodopsin activity in vision. Baylor DA, et al. **Eye** 1998;12 (Pt 3b):521-5 (22 ref.)
Post-Golgi trafficking of rhodopsin in retinal photoreceptors. Deretic D. **Eye** 1998;12 (Pt 3b):526-30 (40 ref.)

PHYSIOLOGY

Rhodopsin and phototransduction. Pepe IM. **J Photochem Photobiol B** 1999 Jan;48(1):1-10 (171 ref.)

RHOMBENCEPHALIC SLEEP see **SLEEP, REM**

RHOMBENCEPHALON

EMBRYOLOGY

How to build a vertebrate hindbrain. Lessons from genetics. Schneider-Maunoury S, et al. **C R Acad Sci III** 1998 Oct; 321(10):819-34 (137 ref.)

RHONCHI see **RESPIRATORY SOUNDS**

RHYTHMICITY see **PERIODICITY**

RHYTIDECTOMY see **RHYTIDOPLASTY**

RHYTIDOPLASTY

Cigarette smoking, wound healing, and face-lift. Campanile G, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):575-8 (48 ref.)
Cosmetic use of botulinum A exotoxin for the aging neck. Brandt FS, et al. **Dermatol Surg** 1998 Nov;24(11):1232-4 (9 ref.)

ADVERSE EFFECTS

Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. Ross EV, et al. **J Am Acad Dermatol** 1998 Dec;39(6):975-81 (33 ref.)
[Fasciitis following face lift] Mitz V. **Ann Chir Plast Esthet** 1997 Dec;42(6):603-7; discussion 608 (9 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Erbium: YAG laser--an improved periorbital resurfacing device. Kopelman J. **Semin Ophthalmol** 1998 Sep; 13(3):136-41 (16 ref.)

METHODS

Why does carbon dioxide resurfacing work? A review. Ross EV, et al. **Arch Dermatol** 1999 Apr;135(4):444-54 (98 ref.)
Periorbital rejuvenation: a review of dermatologic treatments. Manaloto RM, et al. **Dermatol Surg** 1999 Jan; 25(1):1-9 (80 ref.)
Fixation techniques for endoscopic browlift. Kennedy BD, et al. **J Oral Maxillofac Surg** 1999 May;57(5):588-94 (24 ref.)
Recent advances in soft tissue augmentation. Krauss MC. **Semin Cutan Med Surg** 1999 Jun;18(2):119-28 (71 ref.)
The transeyelid subperiosteal midface-lift in the unhappy postblepharoplasty patient. Edelstein C, et al. **Semin Ophthalmol** 1998 Sep;13(3):107-14 (13 ref.)
The endoscopic browlift for forehead rejuvenation. Holck DE, et al. **Semin Ophthalmol** 1998 Sep;13(3):149-57 (25 ref.)
[CO2 laser skin resurfacing. Critical analysis of recent literature] Dubois R, et al. **Ann Chir Plast Esthet** 1998 Dec; 43(6):659-63 (22 ref.) (Eng. Abstr.) **(Fre)**
[Conservative cervico-facial facelift. Concept and preliminary results] Gola R. **Ann Chir Plast Esthet** 1997 Feb;42(1):9-20 (27 ref.) (Eng. Abstr.) **(Fre)**
[Face lift--indications, contraindications and operation] Tschopp H. **Ther Umsch** 1999 Apr;56(4):194-9 (9 ref.) (Eng. Abstr.) **(Ger)**

RIBAVIRIN

ADMINISTRATION & DOSAGE

[Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: what is the status today?] Renner EL. **Schweiz Med Wochenschr** 1999 Jan 12;129(1-2):8-10 (6 ref.) **(Ger)**
[Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature] Wedemeyer H, et al. **Z Gastroenterol** 1998 Sep;36(9):819-27 (35 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

The clinical pharmacology of ribavirin. Glue P. **Semin Liver Dis** 1999;19 Suppl 1:17-24 (28 ref.)

THERAPEUTIC USE

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Poynard T, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):431-7 (53 ref.)
Up to date treatment of hepatitis C in adults. Schalm SW, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):397-9 (12 ref.)
Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness? Dominguez KD, et al. **Ann Pharmacother** 1999 Jun;33(6):739-41 (19 ref.)
Combination therapy for chronic hepatitis C: interferon and ribavirin. Christie JM, et al. **Hosp Med** 1999 May; 60(5):357-61 (24 ref.)
Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist [editorial] Fabrizi F, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2079-81 (10 ref.)
Two options for hepatitis C treatment. **Pa Med** 1999 Apr; 102(4):22-3 (9 ref.)
Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Davis GL. **Semin Liver Dis** 1999;19 Suppl 1:49-55 (46 ref.)
Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Dieterich DT, et al. **Semin Liver Dis** 1999;19 Suppl 1:87-94 (63 ref.)
Standards of treatment in chronic hepatitis C. Gish RG. **Semin Liver Dis** 1999;19 Suppl 1:35-47 (187 ref.)
[Respiratory syncytial virus infections and ribavirin: the controversy continues (editorial; comment)] Aujard Y. **Arch Pediatr** 1998 Feb;5(2):107-10 (24 ref.) Comment on: Arch Pediatr 1998 Feb;5(2):123-31. **(Fre)**
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)] Delwaide J. **Rev Med Liege** 1998 Aug;53(8):467-9 (17 ref.) (Eng. Abstr.) **(Fre)**
[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C] Zeuzem S. **Dtsch Med Wochenschr** 1999 May 21;124(20):636-42 (42 ref.) **(Ger)**

RIBOFLAVIN

Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine. Powers HJ. **Proc Nutr Soc** 1999 May;58(2):435-40 (47 ref.)

RIBOFLAVIN DEFICIENCY

METABOLISM

Riboflavin metabolism--relevance to human nutrition. Lakshmi AV. **Indian J Med Res** 1998 Nov;108:182-90 (75 ref.)

RIBONUCLEASE A see **RIBONUCLEASE, PANCREATIC**

RIBONUCLEASE, PANCREATIC

ANTAGONISTS & INHIBITORS

[Angiogenin-induced angiogenesis as a target in the therapy of tumors] Komolova GS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):81-4 (51 ref.) **(Rus)**

RIBONUCLEASES

Human ribonucleases. Vlassov AV. **Biochemistry (Mosc)** 1998 Dec;63(12):1349–60 (127 ref.)

Ribonuclease–gold labels proteoglycan–containing cytoplasmic granules and ribonucleic acid–containing organelles––a survey. Dvorak AM, et al. **Histol Histopathol** 1999 Apr;14(2):597–626 (166 ref.)

CHEMISTRY

Structure–function relationships of acid ribonucleases: lysosomal, vacuolar, and periplasmic enzymes. Irie M. **Pharmacol Ther** 1999 Feb;81(2):77–89 (114 ref.)

GENETICS

Function, mechanism and regulation of bacterial ribonucleases. Nicholson AW. **FEMS Microbiol Rev** 1999 Jun;23(3):371–90 (148 ref.)

METABOLISM

Enzymatic and chemical cleavage methods. Taylor GR. **Electrophoresis** 1999 Jun;20(6):1125–30 (32 ref.)

Function, mechanism and regulation of bacterial ribonucleases. Nicholson AW. **FEMS Microbiol Rev** 1999 Jun;23(3):371–90 (148 ref.)

PHYSIOLOGY

Structure–function relationships of acid ribonucleases: lysosomal, vacuolar, and periplasmic enzymes. Irie M. **Pharmacol Ther** 1999 Feb;81(2):77–89 (114 ref.)

RIBONUCLEIC ACID see **RNA**

RIBONUCLEOPROTEIN PARTICLES, VAULT see **VAULT RIBONUCLEOPROTEIN PARTICLES**

RIBONUCLEOPROTEINS

Analysis of B-cell epitopes of the Ro/SS-A autoantigen. Wahren-Herlenius M, et al. **Immunol Today** 1999 May; 20(5):234–40 (57 ref.)

[Calbindin D28K and calreticulin] Kuwano R. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1675–80 (43 ref.) **(Jpn)**

CHEMISTRY

Recent advances in protein methylation: enzymatic methylation of nucleic acid binding proteins. Kim S, et al. **Amino Acids** 1998;15(4):291–306 (58 ref.)

Calreticulin, a multifunctional Ca2+ binding chaperone of the endoplasmic reticulum. Michalak M, et al. **Biochem Cell Biol** 1998;76(5):779–85 (51 ref.)

IMMUNOLOGY

Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Scofield RH, et al. **Arthritis Rheum** 1999 Feb;42(2):199–209 (94 ref.)

[Progress in clinical tests and the pathophysiological study of collagen diseases––anti-ribonucleoprotein antibodies] Mimori T. **Nippon Naika Gakkai Zasshi** 1998 Dec 10; 87(12):2414–20 (4 ref.) **(Jpn)**

[Autoantibodies and analysis of target antigens] Mimori T. **Nippon Rinsho** 1999 Feb;57(2):316–22 (4 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Recent advances in protein methylation: enzymatic methylation of nucleic acid binding proteins. Kim S, et al. **Amino Acids** 1998;15(4):291–306 (58 ref.)

Pre-mRNP particles: From gene to nuclear pore. Daneholt B. **Curr Biol** 1999 Jun 3;9(11):R412–5 (19 ref.)

Lectins as chaperones in glycoprotein folding. Trombetta ES, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):587–92 (48 ref.)

Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Sim RB, et al. **Immunobiology** 1998 Aug; 199(2):208–24 (77 ref.)

Functions of SR and Tra2 proteins in pre-mRNA splicing regulation. Tacke R, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):59–63 (29 ref.)

PHYSIOLOGY

Calreticulin, a multifunctional Ca2+ binding chaperone of the endoplasmic reticulum. Michalak M, et al. **Biochem Cell Biol** 1998;76(5):779–85 (51 ref.)

hnRNP complexes: composition, structure, and function. Krecic AM, et al. **Curr Opin Cell Biol** 1999 Jun; 11(3):363–71 (62 ref.)

mRNA surveillance in eukaryotes: kinetic proofreading of proper translation termination as assessed by mRNP domain organization? Hilleren P, et al. **RNA** 1999 Jun; 5(6):711–9 (67 ref.)

Pathophysiological roles of calreticulin in autoimmune disease. Eggleton P, et al. **Scand J Immunol** 1999 May; 49(5):466–73 (77 ref.)

Cytoplasmic regulatory functions of the KH-domain proteins hnRNPs K and E1/E2. Ostareck-Lederer A, et al. **Trends Biochem Sci** 1998 Nov;23(11):409–11 (36 ref.)

RIBONUCLEOPROTEINS, SMALL NUCLEAR

CHEMISTRY

Structure and assembly of the spliceosomal small nuclear ribonucleoprotein particles. Kambach C, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):222–30 (64 ref.)

METABOLISM

Guided tours: from precursor snoRNA to functional snoRNP. Weinstein LB, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):378–84 (56 ref.)

Birth of the snoRNPs: the evolution of the modification-guide snoRNAs. Lafontaine DL, et al. **Trends Biochem Sci** 1998 Oct;23(10):383–8 (50 ref.)

RIBONUCLEOPROTEINS, SMALL, U1

PHYSIOLOGY

Transcriptional regulation: SWItching circuitry. Wade PA, et al. **Curr Biol** 1999 Mar 25;9(6):R221–4 (12 ref.)

RIBONUCLEOPROTEINS, SMALL, U3 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

RIBONUCLEOPROTEINS, SMALL, U7 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

RIBONUCLEOSIDE PHOSPHATES see **RIBONUCLEOTIDES**

RIBONUCLEOSIDES

PHARMACOLOGY

Mizoribine and mycophenolate mofetil. Ishikawa H. **Curr Med Chem** 1999 Jul;6(7):575–97 (82 ref.)

THERAPEUTIC USE

Acadesine during fluid resuscitation from shock and abdominal sepsis [see comments] Melton SM, et al. **Crit Care Med** 1999 Mar;27(3):565–75 (46 ref.) Comment in: Crit Care Med 1999 Mar;27(3):468–9.

RIBONUCLEOTIDE REDUCTASES

ANTAGONISTS & INHIBITORS

Mechanism-based inhibition of ribonucleotide reductases: new mechanistic considerations and promising biological applications. Robins MJ. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):779–93 (36 ref.)

GENETICS

Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung. Schreiber G, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):1109–15 (43 ref.)

METABOLISM

Ribonucleotide reductases. Jordan A, et al. **Annu Rev Biochem** 1998;67:71–98 (152 ref.)

The function of adenosylcobalamin in the mechanism of ribonucleoside triphosphate reductase from Lactobacillus leichmannii. Lawrence CC, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):650–5 (33 ref.)

Harnessing free radicals: formation and function of the tyrosyl radical in ribonucleotide reductase. Stubbe J, et al. **Trends Biochem Sci** 1998 Nov;23(11):438–43 (45 ref.)

RIBONUCLEOTIDES

METABOLISM

Novel mechanism for the impairment of cell proliferation in HIV-1 infection. Bofill M, et al. **Immunol Today** 1999 Jun;20(6):258–61 (29 ref.)

RIBOSOMAL DNA see **DNA, RIBOSOMAL**

RIBOSOMAL FRAMESHIFTING see **FRAMESHIFTING, RIBOSOMAL**

RIBOSOMAL PROTEIN S6 KINASE

PHYSIOLOGY

Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Frödin M, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):65–77 (82 ref.)

RIBOSOMAL PROTEINS

CHEMISTRY

Ribosomal mechanics, antibiotics, and GTP hydrolysis [comment] Porse BT, et al. **Cell** 1999 May 14;97(4):423–6 (16 ref.) Comment on: Cell 1999 May 14;97(4):491–502.

METABOLISM

RNA binding strategies of ribosomal proteins. Draper DE, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):381–8 (59 ref.)

PHYSIOLOGY

Involvement of ribosomal proteins in regulating cell growth and apoptosis: translational modulation or recruitment for extraribosomal activity? Naora H. **Immunol Cell Biol** 1999 Jun;77(3):197–205 (74 ref.)

Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Rieger R, et al. **Transfus Clin Biol** 1999 Feb;6(1):7–16 (65 ref.)

RIBOSOMAL RNA see **RNA, RIBOSOMAL**

5S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 5S**

16S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 16S**

23S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 23S**

RIBOSOMES

see related
DNA, RIBOSOMAL
RIBOSOMAL PROTEINS
RNA, RIBOSOMAL

Mutual orientation of tRNAs and interactions between the codon–anticodon duplexes within the ribosome: a stereochemical analysis. Lim VI, et al. **Biol Chem** 1998 Jul; 379(7):773–81 (44 ref.)

Analysis of rRNA function using specialized ribosomes. Brink MF, et al. **Methods Mol Biol** 1998;77:117–28 (11 ref.)

Internal ribosome entry sites tests with circular mRNAs. Chen CY, et al. **Methods Mol Biol** 1998;77:355–63 (15 ref.)

Measurement of ribosomal accuracy and proofreading in E. coli burst systems. Ehrenberg M, et al. **Methods Mol Biol** 1998;77:227–41 (27 ref.)

Heelprinting analysis of in vivo ribosome pause sites. Hollingsworth MJ, et al. **Methods Mol Biol** 1998;77:153–65 (20 ref.)

[Ribosomal abnormalities and human diseases] Kenmochi N. **Seikagaku** 1999 Mar;71(3):205–10 (19 ref.) **(Jpn)**

[Ribosomal structure: RNA–protein and protein–protein interactions] Nikonov SV, et al. **Mol Biol (Mosk)** 1998 Sep–Oct;32(5):773–81 (75 ref.) **(Rus)**

CHEMISTRY

Crystallographic studies on the ribosome, a large macromolecular assembly exhibiting severe nonisomorphism, extreme beam sensitivity and no internal symmetry. Yonath A, et al. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):945–55 (45 ref.)

Structural studies of the translational apparatus. Agrawal RK, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):215–21 (56 ref.)

GENETICS

Dynamics of translation on the ribosome: molecular mechanics of translocation. Rodnina MV, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):317–33 (97 ref.)

Engineering of bacterial ribosomes: replacement of all seven Escherichia coli rRNA operons by a single plasmid-encoded operon [see comments] Nomura M. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1820–2 (25 ref.) Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1971–6.

Internal ribosome entry sites (IRESs): reality and use. Houdebine LM, et al. **Transgenic Res** 1999 Jun;8(3):157–77 (200 ref.)

[Utilization of antisense oligonucleotide strategy in study of exposing and localization of rRNA on surface ribosomal subunits] Sobkiewicz A, et al. **Postepy Biochem** 1998; 44(1):55–63 (43 ref.) **(Pol)**

METABOLISM

Totally in vitro protein selection using mRNA–protein fusions and ribosome display. Roberts RW. **Curr Opin Chem Biol** 1999 Jun;3(3):268–73 (39 ref.)

Functional interaction of yeast elongation factor 3 with yeast ribosomes. Chakraburtty K. **Int J Biochem Cell Biol** 1999 Jan;31(1):163–73 (50 ref.)

Synthesis and site-specific binding of thioated tRNAs to probe ribosome–tRNA interactions. Dabrowski M, et al. **Methods Mol Biol** 1998;77:413–26 (17 ref.)

Chemical and enzymatic probing of antibiotic–ribosome complexes. Rodriguez-Fonseca C, et al. **Methods Mol Biol** 1998;77:311–23 (23 ref.)

Analyses of ribosome distribution during in vitro translation. Wolin SL. **Methods Mol Biol** 1998;77:1–9 (17 ref.)

Internal ribosome entry sites (IRESs): reality and use. Houdebine LM, et al. **Transgenic Res** 1999 Jun;8(3):157–77 (200 ref.)

Ribosome recruitment and scanning: what's new? Pestova TV, et al. **Trends Biochem Sci** 1999 Mar;24(3):85–7 (29 ref.)

PHYSIOLOGY

[Two recent topics in ribosome research] Endo Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2199–205 (22 ref.) **(Jpn)**

ULTRASTRUCTURE

Crystallographic studies on the ribosome, a large macromolecular assembly exhibiting severe nonisomorphism, extreme beam sensitivity and no internal symmetry. Yonath A, et al. **Acta Crystallogr A** 1998 Nov 1;54(1 (Pt 6)):945–55 (45 ref.)

RIBOVIRIN see **RIBAVIRIN**

RIBOZYMES see **RNA, CATALYTIC**

RIBS

see related
TIETZE'S SYNDROME

Primary cervical malignant teratoma with a rib metastasis in an adult: five-year survival after surgery and chemotherapy. A case report with a review of the literature. Als C, et al. **Ann Oncol** 1998 Sep;9(9):1015–22 (51 ref.)

[Tuberculosis of the thoracic wall. Presentation of 4 personal cases and review of the literature] Mathlouthi A, et al. **Rev Pneumol Clin** 1998 Sep;54(4):182–6 (22 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Prenatal ultrasonographic diagnosis of the cerebro–costo–mandibular syndrome: case report and review of the literature. Megier P, et al. **Prenat Diagn** 1998 Dec;18(12):1294–9 (30 ref.)

A thoracic complication of hereditary multiple exostoses in an adult. Nick JA, et al. **Respir Med** 1999 Mar;93(3):217–9 (22 ref.)

[The cerebrocostomandibular syndrome] Cohnen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):160–2 (10 ref.) **(Ger)**

ANATOMY & HISTOLOGY

The ribs: anatomic and radiologic considerations. Kurihara Y, et al. **Radiographics** 1999 Jan–Feb;19(1):105–19; quiz 151–2 (16 ref.)

INJURIES

Posttraumatic fibro–osseous lesion of rib. McDermott MB, et al. **Hum Pathol** 1999 Jul;30(7):770–80 (49 ref.)

PATHOLOGY

Small cell osteogenic sarcoma of the ribs: cytological, immunohistochemical, and ultrastructural study with literature review. Park SH, et al. **Ultrastruct Pathol** 1999 Mar–Apr;23(2):133–40 (19 ref.)

[Gorham disease of the rib with osteolysis followed by bone remodeling. Study with magnetic resonance imaging] Sans N, et al. **Rev Mal Respir** 1999 Feb;16(1):98–101 (14 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

The ribs: anatomic and radiologic considerations. Kurihara Y, et al. **Radiographics** 1999 Jan–Feb;19(1):105–19; quiz 151–2 (16 ref.)

Primary multifocal tuberculous osteomyelitis with involvement of the ribs. Chang DS, et al. **Skeletal Radiol** 1998 Nov;27(11):641–5 (21 ref.)

SURGERY

[Intra–thoracic costal sites of osteogenic exostoses in the child] Cottalorda J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):563–6 (12 ref.) (Eng. Abstr.) **(Fre)**

RICE

The impact of rice pesticides on the aquatic ecosystems of the Sacramento River and Delta (California). Byard JL. **Rev Environ Contam Toxicol** 1999;159:95–110 (32 ref.)

CHEMISTRY

[Gamma–oryzanol: an important component in rice brain oil] Scavariello EM, et al. **Arch Latinoam Nutr** 1998 Mar; 48(1):7–12 (30 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Callus initiation, maintenance, and shoot induction in rice. Blackhall NW, et al. **Methods Mol Biol** 1999;111:19–29 (22 ref.)

GENETICS

Rice as a model for cereal genomics. Goff SA. **Curr Opin Plant Biol** 1999 Apr;2(2):86–9 (38 ref.)

Transformation of rice via PEG–mediated DNA uptake into protoplasts. Datta K, et al. **Methods Mol Biol** 1999; 111:335–47 (19 ref.)

GROWTH & DEVELOPMENT

Transformation of rice via PEG–mediated DNA uptake into protoplasts. Datta K, et al. **Methods Mol Biol** 1999; 111:335–47 (19 ref.)

MICROBIOLOGY

Infection–related development in the rice blast fungus Magnaporthe grisea. Hamer JE, et al. **Curr Opin Microbiol** 1998 Dec;1(6):693–7 (39 ref.)

RICIN

CHEMISTRY

[A novel plant lectin group has homologous structure to ribosome–inactivating protein, ricin] Kaku H. **Seikagaku** 1999 Feb;71(2):124–8 (15 ref.) **(Jpn)**

METABOLISM

Endocytosis and intracellular transport of ricin: recent discoveries. Sandvig K, et al. **FEBS Lett** 1999 Jun 4; 452(1–2):67–70 (54 ref.)

RICINOLEIC ACIDS

METABOLISM

Biosynthesis of ricinoleate in castor oil. McKeon TA, et al. **Adv Exp Med Biol** 1999;464:37–47 (30 ref.)

RICINUS

see related
CASTOR OIL
RICIN

RICKETS

CHEMICALLY INDUCED

Rickets and secondary craniosynostosis associated with long–term antacid use in an infant [letter] [see comments] Shetty AK, et al. **Arch Pediatr Adolesc Med** 1998 Dec; 152(12):1243–5 (19 ref.) Comment in: Arch Pediatr Adolesc Med 1998 Dec;152(12):1168–9.

DIAGNOSIS

[Disease caused by lack of sunlight: rickets and osteomalacia] Wauters IM, et al. **Ned Tijdschr Geneeskd** 1999 Mar 20; 143(12):593–7 (22 ref.) (Eng. Abstr.) **(Dut)**

ENZYMOLOGY

The importance of 25–hydroxyvitamin D3 1 alpha–hydroxylase gene in vitamin D–dependent rickets. Kato S, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):377–83 (61 ref.)

EPIDEMIOLOGY

Vitamin D deficiency rickets in developing countries. Karrar ZA. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S89–92 (36 ref.)

GENETICS

The importance of 25–hydroxyvitamin D3 1 alpha–hydroxylase gene in vitamin D–dependent rickets. Kato S, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):377–83 (61 ref.)

Genetic causes of rickets. Miller WL, et al. **Curr Opin Pediatr** 1999 Aug;11(4):333–9 (40 ref.)

Endocrine and metabolism [editorial] Root AW. **Curr Opin Pediatr** 1999 Aug;11(4):329–32 (12 ref.)

RICKETS, HYPOPHOSPHATEMIC see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETS, RENAL see **RENAL OSTEODYSTROPHY**

RICKETS, VITAMIN D–RESISTANT see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETS, X–LINKED HYPOPHOSPHATEMIC see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETTSIA

CHEMISTRY

Rickettsiae and Chlamydiae: evidence of horizontal gene transfer and gene exchange. Wolf YI, et al. **Trends Genet** 1999 May;15(5):173–5 (15 ref.)

IMMUNOLOGY

[Common antigenicity of lipopolysaccharides between Rickettsiae and Proteus in the Weil–Felix test] Amano K. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):599–610 (43 ref.) **(Jpn)**

RICKETTSIA INFECTIONS

[Sennetsu rickettsiosis] Aoki N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):286–7 (10 ref.) **(Jpn)**

[Queensland tick typhus, and other SFG rickettsiosis] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):270–2 (17 ref.) **(Jpn)**

[African tick–bite fever] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):273–5 (8 ref.) **(Jpn)**

[Spotted fever group rickettsiosis: introduction] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):255–9 (15 ref.) **(Jpn)**

[Japanese spotted fever] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):264–6 (15 ref.) **(Jpn)**

DIAGNOSIS

[Cutaneous signs of Rickettsia and related microorganisms] Duval X, et al. **Rev Med Interne** 1998 Aug;19(8):548–57 (57 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Serological evidence of natural infection of wild rodents (Rattus spp and Tupaia glis) with rickettsiae in Malaysia. Tay ST, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):560–2 (10 ref.)

RICKETTSIA PROWAZEKII

GENETICS

Ancient and recent horizontal transfer events: the origins of mitochondria. Andersson SG, et al. **APMIS Suppl** 1998; 84:5–14 (46 ref.)

The genome of Rickettsia prowazekii and some thoughts on the origin of mitochondria and hydrogenosomes. Müller M, et al. **Bioessays** 1999 May;21(5):377–81 (39 ref.)

RICKETTSIA QUINTANA see **BARTONELLA QUINTANA**

RICKETTSIACEAE

GENETICS

Evolution of Wolbachia pipientis transmission dynamics in insects. McGraw EA, et al. **Trends Microbiol** 1999 Jul; 7(7):297–302 (48 ref.)

PHYSIOLOGY

The diverse habitats of obligate intracellular parasites. Hackstadt T. **Curr Opin Microbiol** 1998 Feb;1(1):82–7 (60 ref.)

Evolution of Wolbachia pipientis transmission dynamics in insects. McGraw EA, et al. **Trends Microbiol** 1999 Jul; 7(7):297–302 (48 ref.)

RICKETTSIACEAE INFECTIONS

[Rickettsialpox] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):267–9 (14 ref.) **(Jpn)**

RICKETTSIALES

CLASSIFICATION

[Rickettsiales—modern findings] Punda–Polić V. **Lijec Vjesn** 1999 Jan–Feb;121(1–2):27–34 (126 ref.) (Eng. Abstr.) **(Scr)**

RICKETTSIALES INFECTIONS

[Rickettsiales—modern findings] Punda–Polić V. **Lijec Vjesn** 1999 Jan–Feb;121(1–2):27–34 (126 ref.) (Eng. Abstr.) **(Scr)**

DRUG THERAPY

[Rickettsioses: their chemoprophylaxis and chemotherapy] Plekhanova TM, et al. **Voen Med Zh** 1998 Sep;319(9):64–8, 95 (34 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[Rickettsioses: their chemoprophylaxis and chemotherapy] Plekhanova TM, et al. **Voen Med Zh** 1998 Sep;319(9):64–8, 95 (34 ref.) (Eng. Abstr.) **(Rus)**

TRANSMISSION

[Rickettsioses: the ecological aspects of the problem] Grabarev PA, et al. **Voen Med Zh** 1998 Aug;319(8):27–34 (32 ref.) **(Rus)**

RICKETTSIALPOX see **RICKETTSIACEAE INFECTIONS**

RIDA see **SCRAPIE**

RIFABUTIN

PHARMACOLOGY

[An antitubercular antibiotic of prolonged action—rifabutin. Antimicrobial spectrum, pharmacodynamic and pharmacokinetic characteristics] Tsybanev AA, et al. **Antibiot Khimioter** 1999;44(8):30–6 (40 ref.) **(Rus)**

RIFAMPICIN see **RIFAMPIN**

RIFAMPIN

ADVERSE EFFECTS

Interaction between ciprofloxacin and rifampin. Temple ME, et al. **Ann Pharmacother** 1999 Jul-Aug;33(7-8):868-70 (24 ref.)

ANALOGS & DERIVATIVES

Rifapentine [published erratum appears in Drugs 1999 Apr;57(4):506] Jarvis B, et al. **Drugs** 1998 Oct;56(4):607-16; discussion 617 (46 ref.)

PHARMACOLOGY

[Molecular basis of rifampin resistance in mycobacterium tuberculosis] Cheng S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Jun; 20(3):183-6 (16 ref.) **(Chi)**

THERAPEUTIC USE

Haemophilic synovitis: is rifampicin an alternative? Caviglia H, et al. **Haemophilia** 1998 Jul;4(4):514-7 (54 ref.)

Treatment of acute and chronic synovitis by non-surgical means. Fernandez-Palazzi F. **Haemophilia** 1998 Jul; 4(4):518-23 (21 ref.)

Uses of rifampin for infections other than tuberculosis. Loeffler AM. **Pediatr Infect Dis J** 1999 Jul;18(7):631-2 (14 ref.)

RIFAMYCINS

[Current status and perspectives on the development of rifamycin derivative antibiotics] Hidaka T. **Kekkaku** 1999 Jan;74(1):53-61 (41 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Burman WJ, et al. **Clin Infect Dis** 1999 Mar;28(3):419-29; quiz 430 (108 ref.)

THERAPEUTIC USE

[Chemotherapeutic agents under study] Kawahara S. **Nippon Rinsho** 1998 Dec;56(12):3096-9 (19 ref.) (Eng. Abstr.) **(Jpn)**

RIFLES see **FIREARMS**

RIFOMYCINS see **RIFAMYCINS**

RIFT VALLEY FEVER

EPIDEMIOLOGY

Disease prevention and preparedness in cases of animal health emergencies in the Middle East. Shimshony A. **Rev Sci Tech** 1999 Apr;18(1):66-75 (22 ref.)

RIGHT HEART BYPASS see **HEART BYPASS, RIGHT**

RIGHT TO DIE

see related
SUICIDE, ASSISTED

Exit association-mediated suicide: toxicologic and forensic aspects. Giroud C, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):40-4 (9 ref.)

A dying man asking for a dignified end. Tate P, et al. **Practitioner** 1998 Jul;242(1588):505-8, 510, 515 (0 ref.)

An analysis of "dignity". Johnson PR. **Theor Med Bioeth** 1998 Aug;19(4):337-52 (35 ref.)

LEGISLATION & JURISPRUDENCE

Preserving end-of-life autonomy: the Patient Self-Determination Act and the Uniform Health Care Decisions Act. Galambos CM. **Health Soc Work** 1998 Nov; 23(4):275-81 (21 ref.)

Suing health care providers for saving lives. Liability for providing unwanted life-sustaining treatment. Rodriguez KF. **J Leg Med** 1999 Mar;20(1):1-66 (331 ref.)

Do not resuscitate (DNR): analysis of the DNR act. Koehler S, et al. **J Okla State Med Assoc** 1999 Jul;92(7):316-9 (9 ref.)

The right to die and physician-assisted suicide: medical, legal, and ethical aspects (Part II). Wecht CH. **Med Law** 1998; 17(4):581-601 (27 ref.)

The northeast Tennessee Spirituality and End of Life Issues Survey. Ginn DR, et al. **Tenn Med** 1998 Nov;91(11):425-30 (13 ref.)

RIGHT TO TREATMENT see **PATIENT ADVOCACY**

RIGHT VENTRICULAR DYSFUNCTION see **VENTRICULAR DYSFUNCTION, RIGHT**

RIGHT VENTRICULAR DYSPLASIA, ARRHYTHMOGENIC see **ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA**

RIGHT VENTRICULAR FUNCTION see **VENTRICULAR FUNCTION, RIGHT**

RIGHT VENTRICULAR HYPERTROPHY see **HYPERTROPHY, RIGHT VENTRICULAR**

RIGHT WHALE see **WHALES**

RIGHT WHALE DOLPHINS see **DOLPHINS**

RIGHT WHALES see **WHALES**

RIGHTSIZING see **PERSONNEL DOWNSIZING**

RILUZOLE

THERAPEUTIC USE

Management of amyotrophic lateral sclerosis with riluzole. Neatherlin JS. **J Neurosci Nurs** 1998 Aug;30(4):257-60 (14 ref.)

[Amyotrophic lateral sclerosis] Iwanowski L. **Neurol Neurochir Pol** 1999 Mar-Apr;33(2):445-50 (38 ref.) (Eng. Abstr.) **(Pol)**

[Riluzole as a treatment for amyotrophic lateral sclerosis] Borrás-Blasco J, et al. **Rev Neurol** 1998 Dec;27(160):1021-7 (47 ref.) (Eng. Abstr.) **(Spa)**

RIMANTADINE

THERAPEUTIC USE

The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Younossi ZM, et al. **Semin Liver Dis** 1999;19 Suppl 1:95-102 (32 ref.)

RINDERPEST

PREVENTION & CONTROL

Disease prevention and preparedness: the Food and Agriculture Organization Emergency Prevention System. Cheneau Y, et al. **Rev Sci Tech** 1999 Apr;18(1):122-34 (16 ref.)

Rinderpest: a case study of animal health emergency management. Mukhopadhyay AK, et al. **Rev Sci Tech** 1999 Apr;18(1):164-78 (23 ref.)

RING CHROMOSOMES

Phenotypic variability in the chromosome 9 ring. Cavaliere ML, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:85-9 (10 ref.)

Ring 2 chromosome: ten-year follow-up report. Lacassie Y, et al. **Am J Med Genet** 1999 Jul 16;85(2):117-22 (14 ref.)

RING CONSTRICTIONS, INTRAUTERINE see **AMNIOTIC BAND SYNDROME**

RINGWORM see **TINEA**

RIOTS

see related
VIOLENCE

RISK

Diet and health risk: risk patterns and disease-specific associations. Marshall JR, et al. **Am J Clin Nutr** 1999 Jun; 69(6):1351S-1356S (21 ref.)

Biological interpretation of relative risk. Lanes SF. **Drug Saf** 1999 Aug;21(2):75-9 (21 ref.)

Effects of misclassification on estimates of relative risk in family history studies. Szatmari P, et al. **Genet Epidemiol** 1999;16(4):368-81 (32 ref.)

Effect of measurement error on epidemiological studies of environmental and occupational exposures. Armstrong BG. **Occup Environ Med** 1998 Oct;55(10):651-6 (7 ref.)

Gender differences in risk perception: theoretical and methodological perspectives. Gustafson PE. **Risk Anal** 1998 Dec;18(6):805-11 (34 ref.)

RISK ADJUSTMENT

Risk adjustment for quality improvement. Richardson D, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):255-65 (76 ref.)

METHODS

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Gooley TA, et al. **Stat Med** 1999 Mar 30;18(6):695-706 (20 ref.)

STATISTICS & NUMERICAL DATA

Research evidence on the validity of risk-adjusted mortality rate as a measure of hospital quality of care [published erratum appears in Med Care Res Rev 1999 Mar;56(1):118] Thomas JW, et al. **Med Care Res Rev** 1998 Dec; 55(4):371-404 (67 ref.)

RISK ASSESSMENT

Alcohol consumption and stroke: benefits and risks. Hillbom M. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):352S-358S (87 ref.)

Risk perception of alcohol consumption. Sjöberg L. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):277S-284S (94 ref.)

An overview of health risks and benefits of alcohol consumption. Thakker KD. **Alcohol Clin Exp Res** 1998 Oct; 22(7 Suppl):285S-298S (131 ref.)

Methods for health risk assessment of chemicals: are they relevant for alcohol? Victorin K, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):270S-276S (26 ref.)

Epidemiology and risk assessment. Samet JM, et al. **Am J Epidemiol** 1998 Nov 15;148(10):929-36 (32 ref.)

Benefits and risks of elimination diets. Arvola T, et al. **Ann Med** 1999 Aug;31(4):293-8 (42 ref.)

Lessons from 12 years of comparative risk projects. Jones K, et al. **Annu Rev Public Health** 1999;20:159-72 (34 ref.)

Observations: Risk, reason, and regulation in contemporary medical devices. Lysaght MJ, et al. **ASAIO J** 1999 May-Jun;45(3):226-8 (18 ref.)

Communication and interpretation of risk. Eiser JR. **Br Med Bull** 1998;54(4):779-90 (27 ref.)

Balancing risks versus benefits in drug therapy decisions. Lasagna L. **Clin Ther** 1998;20 Suppl C:C72-9 (17 ref.)

Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment. van Delft JH, et al. **Crit Rev Toxicol** 1998 Sep;28(5):477-510 (176 ref.)

A review of the studies of the safety of polydextrose in food. Burdock GA, et al. **Food Chem Toxicol** 1999 Feb-Mar; 37(2-3):233-64 (21 ref.)

Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. Falk GW. **Gastrointest Endosc** 1999 Mar;49(3 Pt 2):S29-34 (45 ref.)

Mechanistic model predicts a U-shaped relation of radon exposure to lung cancer risk reflected in combined occupational and US residential data [see comments] Bogen KT. **Hum Exp Toxicol** 1998 Dec;17(12):691-6; discussion 701-4, 708-18 (31 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705-7; discussion 716-8.

A cancer risk model with adaptive repair [see comments] Downs T, et al. **Hum Exp Toxicol** 1998 Dec; 17(12):697-700; discussion 701-4, 711-8 (3 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705-7; discussion 716-8.

U-shaped dose-response curves for carcinogens [comment] Portier CJ, et al. **Hum Exp Toxicol** 1998 Dec;17(12):705-7; discussion 716-8 (10 ref.) Comment on: Hum Exp Toxicol 1998 Dec;17(12):683-90;discussion 701-4, 708-18. Comment on: Hum Exp Toxicol 1998 Dec;17(12):691-6; discussion 701-4, 708-18. Comment on: Hum Exp Toxicol 1998 Dec;17(12):697-700; discussion 701-4, 711-8.

Microbial risk assessment, economics, and food safety. Morales RA. **J Am Vet Med Assoc** 1998 Dec 15; 213(12):1746-9 (8 ref.)

A general framework illustrating an approach to quantitative microbial food safety risk assessment. McNab WB. **J Food Prot** 1998 Sep;61(9):1216-28 (28 ref.)

Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT. **Stat Med** 1998 Aug 15-30;17(15-16):1851-8; discussion 1859-62 (6 ref.)

Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Brent RL. **Teratology** 1999 Apr;59(4):182-204 (125 ref.)

Biochemical and molecular neurotoxicology: relevance to biomarker development, neurotoxicity testing and risk assessment. Costa LG. **Toxicol Lett** 1998 Dec 28; 102-103:417-21 (19 ref.)

Carcinogen risk assessment. Can we harmonise? Di Marco PN, et al. **Toxicol Lett** 1998 Dec 28;102-103:241-6 (16 ref.)

Risk assessment and immunotoxicology. Van Loveren H, et al. **Toxicol Lett** 1998 Dec 28;102-103:261-5 (13 ref.)

[Risk assessment being more important in epidemiological study] Graham JD. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec; 18(6):356-8 (11 ref.) **(Chi)**

METHODS

Development of a draft British standard: the assessment of heat strain for workers wearing personal protective equipment. Hanson MA. **Ann Occup Hyg** 1999 Jul; 43(5):309-19 (38 ref.)

The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353-6 (15 ref.)

Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al. **Ann Occup Hyg** 1999 Jul;43(5):367-76 (15 ref.)

International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297-308 (28 ref.)

Applying the BeSafe method to product safety evaluation. Benedyk R, et al. **Appl Ergon** 1998 Feb;29(1):5-13 (16 ref.)

Threat assessment: defining an approach for evaluating risk of targeted violence. Borum R, et al. **Behav Sci Law** 1999; 17(3):323–37 (52 ref.)
Suicide and violence risk in law enforcement: practical guidelines for risk assessment, prevention, and intervention. Mohandie K, et al. **Behav Sci Law** 1999;17(3):357–76 (56 ref.)
Assessing threats of targeted group violence: contributions from social psychology. Pynchon MR, et al. **Behav Sci Law** 1999;17(3):339–55 (52 ref.)
Risk scoring in surgical patients. Jones HJ, et al. **Br J Surg** 1999 Feb;86(2):149–57 (72 ref.)
Identifying and mapping community vulnerability. Morrow BH. **Disasters** 1999 Mar;23(1):1–18 (126 ref.)
Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment. Haddad S, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1377–84 (31 ref.)
Do measures of externalising behaviour in normal populations predict later outcome?: Implications for targeted interventions to prevent conduct disorder. Bennett KJ, et al. **J Child Psychol Psychiatry** 1998 Nov;39(8):1059–70 (64 ref.)
The use of hematological effects in the development of minimal risk levels. Abadin HG, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):61–6 (34 ref.)
Veterinary drugs no longer need testing for carcinogenicity in rodent bioassays. Galer DM, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):115–23 (53 ref.)
Procedures for calculating benchmark doses for health risk assessment. Gaylor D, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):150–64 (62 ref.)
Uncertainty analysis methods for comparing predictive models and biomarkers: A case study of dietary methyl mercury exposure. Ponce RA, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):96–105 (36 ref.)
Linear extrapolation models of lung cancer risk associated with exposure to environmental tobacco smoke. Rosenbaum WL, et al. **Regul Toxicol Pharmacol** 1998 Oct; 28(2):106–14 (30 ref.)
Aggregate exposures under the Food Quality Protection Act: An approach using chlorpyrifos. Shurdut BA, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):165–77 (65 ref.)
Stimulating research to improve the scientific basis of risk assessment. Conolly RB, et al. **Toxicol Sci** 1999 May; 49(1):1–4 (11 ref.)
[Concept of acceptable risk in space flight medical support system] Petrov VM. **Aviakosm Ekolog Med** 1998; 32(5):46–51 (3 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Development of a draft British standard: the assessment of heat strain for workers wearing personal protective equipment. Hanson MA. **Ann Occup Hyg** 1999 Jul; 43(5):309–19 (38 ref.)
International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297–308 (28 ref.)
Cancer risk assessment of extremely low frequency electric and magnetic fields: a critical review of methodology. McCann J. **Environ Health Perspect** 1998 Nov; 106(11):701–17 (197 ref.)
A procedure for the safety evaluation of flavouring substances. Joint FAO/WHO Expert Committee on Food Additives. Munro IC, et al. **Food Chem Toxicol** 1999 Feb–Mar;37(2–3):207–32 (111 ref.)
Updating of hygiene standards for carbon disulfide based on health risk assessment. Stetkiewicz J, et al. **Int J Occup Med Environ Health** 1998;11(2):129–43 (93 ref.)
Risky business: health risk assessment and public health policy on environmental carcinogens. Sim MR, et al. **Med J Aust** 1999 Apr 19;170(8):372–4 (15 ref.)
Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. O'Neill RT. **Stat Med** 1998 Aug 15–30;17(15–16):1851–8; discussion 1859–62 (6 ref.)

RISK BEHAVIOR see **RISK-TAKING**

RISK-BENEFIT ASSESSMENT see **RISK ASSESSMENT**

RISK MANAGEMENT

Arterial grafting: techniques and conduits [see comments] Barner HB. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S2–5; discussion S25–8 (19 ref.) Comment in: Ann Thorac Surg 1999 Aug;68(2):631–2.
Inflammatory response to cardiopulmonary bypass. Edmunds LH Jr. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S12–6; discussion S25–8 (13 ref.)
The efficacy and safety of aprotinin use in cardiac surgery. Rich JB. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S6–11; discussion S25–8 (20 ref.)
Central nervous system effects of cardiopulmonary bypass. Taylor KM. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S20–4; discussion S25–8 (11 ref.)
Endothelial response to cardiopulmonary bypass surgery. Verrier ED, et al. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S17–9; discussion S25–8 (12 ref.)
Talisman or taboo: the controversy of the suicide-prevention contract. Miller MC, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):78–87 (64 ref.)
Towards the safer use of warfarin I: an overview. Gallus AS. **J Qual Clin Pract** 1999 Mar;19(1):55–9 (22 ref.)
Anticoagulation and neuraxial block: historical perspective, anesthetic implications, and risk management. Horlocker TT, et al. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6 Suppl 2):129–34 (21 ref.)
Risk management lessons from a review of 168 cataract surgery claims. Brick DC. **Surv Ophthalmol** 1999 Jan–Feb; 43(4):356–60 (0 ref.)
[Quality assurance and risk management in gynecology and obstetrics] Ulsenheimer K. **Zentralbl Gynakol** 1998; 120(12):593–7 (4 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Strategic risk management: reducing malpractice claims through more effective patient-doctor communication. Virshup BB, et al. **Am J Med Qual** 1999 Jul–Aug; 14(4):153–9 (26 ref.)
Issues in the management of resistant bacteria in long-term-care facilities. Bradley SF. **Infect Control Hosp Epidemiol** 1999 May;20(5):362–6 (47 ref.)
The assessment and management of risk in adolescents. Sheldrick C. **J Child Psychol Psychiatry** 1999 May; 40(4):507–18 (73 ref.)
Legal issues in neonatal nursing: considerations for staff nurses and advanced practice nurses. Enzman Hagedorn MI, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun; 28(3):320–30 (29 ref.)
Strategies for reducing the risk of malpractice litigation in perinatal nursing. Koniak-Griffin D. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):291–9 (33 ref.)
Fetal surveillance and monitoring legal issues revisited. McRae MJ. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):310–9 (28 ref.)
Professional accountability and legal liability for the team leader and charge nurse. Mahlmeister L. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):300–9 (23 ref.)
An analysis of Australian adverse drug events. Malpass A, et al. **J Qual Clin Pract** 1999 Mar;19(1):27–30 (7 ref.)
The pursuit of effective neuroprotection during infant cardiac surgery. du Plessis AJ, et al. **Semin Pediatr Neurol** 1999 Mar;6(1):55–63 (123 ref.)

ORGANIZATION & ADMINISTRATION

Employer-provider partnerships in advanced managed care: human assets risk management. Comstock ML. **Occup Med** 1998 Oct–Dec;13(4):645–61, iii (28 ref.)
Interactions between science, government and media on selection and testing of donors. Sazama K. **Vox Sang** 1998; 74 Suppl 2:503–6 (24 ref.)
Risk management in blood transfusion services. Whyte G. **Vox Sang** 1998;74 Suppl 2:105–9 (37 ref.)

STANDARDS

A review of infection control practices, risk reduction, and legislative regulations for blood-borne disease: applications for emergency medical services. Rinnert KJ. **Prehosp Emerg Care** 1998 Jan–Mar;2(1):70–5 (40 ref.)

RISK SHARING, FINANCIAL

see related
MANAGED CARE PROGRAMS

Capitation payment rates and implications for the general pediatrician. Anderson GF, et al. **Curr Opin Pediatr** 1998 Oct;10(5):480–5 (32 ref.)

METHODS

Methods of reducing the financial risk of physicians under capitation. Anderson GF, et al. **Arch Fam Med** 1999 Mar–Apr;8(2):149–55 (33 ref.)

RISK-TAKING

Cross-cultural issues in prevention, health promotion, and risk reduction in adolescence. Bell DL, et al. **Adolesc Med** 1999 Feb;10(1):57–69, vi (55 ref.)
Measuring self-efficacy in the context of HIV risk reduction: research challenges and recommendations. Forsyth AD, et al. **Health Psychol** 1998 Nov;17(6):559–68 (91 ref.)
Integrative research review of risk behaviors among adolescents in rural, suburban, and urban areas. Fahs PS, et al. **J Adolesc Health** 1999 Apr;24(4):230–43 (82 ref.)
Preventing the high-risk sexual behavior of adolescents: focus on HIV/AIDS transmission, unintended pregnancy, or both? Whaley AL. **J Adolesc Health** 1999 Jun; 24(6):376–82 (49 ref.)
Impact of lifestyle choices on female infertility. Silva PD, et al. **J Reprod Med** 1999 Mar;44(3):288–96 (121 ref.)

RISPERIDONE

ADMINISTRATION & DOSAGE

Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Kasper S. **Int Clin Psychopharmacol** 1998 Nov;13(6):253–62 (51 ref.)
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Meltzer HY, et al. **Schizophr Bull** 1999;25(2):233–55 (115 ref.)
[Atypical neuroleptics in the child and adolescent] Naja WJ, et al. **Encephale** 1998 Jul–Aug;24(4):378–85 (67 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Revicki DA. **Schizophr Res** 1999 Mar 1;35 Suppl:S101–9 (31 ref.)

THERAPEUTIC USE

Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Kasper S. **Int Clin Psychopharmacol** 1998 Nov;13(6):253–62 (51 ref.)
The Canadian experience with risperidone for the treatment of schizophrenia: an overview. Iskedjian M, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):229–39 (80 ref.)

RISSO'S DOLPHIN see **DOLPHINS**

RITODRINE

ADMINISTRATION & DOSAGE

[Pharmacology of ritodrine] Mangrella M, et al. **Minerva Ginecol** 1999 Jun;51(6):233–44 (52 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Ritodrine-related liver injury. Case reports and review of the literature [see comments] Ceriani R, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):315–7 (8 ref.) Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):318–9.
[Acute hepatitis due to ritodrine (letter)] Castro Fernández M, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (9 ref.) **(Spa)**

RITONAVIR

ADVERSE EFFECTS

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1999 Aug;19(4):293–6 (51 ref.)

PHARMACOKINETICS

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents [published erratum appears in Clin Pharmacokinet 1998 Dec;35(6):473] Hsu A, et al. **Clin Pharmacokinet** 1998 Oct;35(4):275–91 (129 ref.)

RITTER DISEASE see **STAPHYLOCOCCAL SCALDED SKIN SYNDROME**

RIVER BLINDNESS see **ONCHOCERCIASIS, OCULAR**

RIVER DOLPHIN see **DOLPHINS**

RIVER DOLPHINS see **DOLPHINS**

RNA

Evolution of the U-insertion/deletion RNA editing in mitochondria of kinetoplastid protozoa. Simpson L, et al. **Ann N Y Acad Sci** 1999 May 18;870:190–205 (64 ref.)
Aptamers as tools in molecular biology and immunology. Famulok M, et al. **Curr Top Microbiol Immunol** 1999; 243:123–36 (74 ref.)
Primer mixture enhances PCR detection of Mycoplasma/Acholeplasma contaminants in cell cultures [letter] Tang J, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan;35(1):1–3 (16 ref.)
The origin of life--a review of facts and speculations. Orgel LE. **Trends Biochem Sci** 1998 Dec;23(12):491–5 (43 ref.)

ANALYSIS

Molecular biology and reproduction. McDonough PG. **Keio J Med** 1999 Mar;48(1):12–21 (13 ref.)
Preparation of double/single-stranded DNA and RNA molecules for electron microscopy. Hajibagheri MA. **Methods Mol Biol** 1999;117:209–27 (26 ref.)
Different strategies of differential display: areas of application. Matz MV, et al. **Nucleic Acids Res** 1998 Dec 15;26(24):5537–43 (38 ref.)

BIOSYNTHESIS

RNA processing in evolution. The logic of soft-wired genomes. Herbert A, et al. **Ann N Y Acad Sci** 1999 May 18;870:119–32 (45 ref.)
Prebiotic synthesis on minerals: bridging the prebiotic and RNA worlds. Ferris JP. **Biol Bull** 1999 Jun;196(3):311–4 (14 ref.)

RNA

CHEMICAL SYNTHESIS

Continuous-flow cell-free translation, transcription-translation, and replication-translation systems. Ryabova LA, et al. **Methods Mol Biol** 1998; 77:179-93 (31 ref.)

CHEMISTRY

RNA folds: insights from recent crystal structures. Ferré-D'Amaré AR, et al. **Annu Rev Biophys Biomol Struct** 1999;28:57-73 (63 ref.)

Saccharide-RNA recognition. Hermann T, et al. **Biopolymers** 1998;48(2-3):155-65 (80 ref.)

New developments in structure determination of pseudoknots. Hilbers CW, et al. **Biopolymers** 1998; 48(2-3):137-53 (47 ref.)

On the role of magnesium ions in RNA stability. Misra VK, et al. **Biopolymers** 1998;48(2-3):113-35 (142 ref.)

Structure-based and combinatorial search for new RNA-binding drugs. Afshar M, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):59-63 (47 ref.)

Oligonucleotide libraries--variatio delectat. Famulok M, et al. **Curr Opin Chem Biol** 1998 Jun;2(3):320-7 (69 ref.)

RNA-protein complexes. Cusack S. **Curr Opin Struct Biol** 1999 Feb;9(1):66-73 (34 ref.)

A chemogenetic approach to RNA function/structure analysis. Strobel SA. **Curr Opin Struct Biol** 1999 Jun; 9(3):346-52 (36 ref.)

Exposing the kinetic traps in RNA folding. Treiber DK, et al. **Curr Opin Struct Biol** 1999 Jun;9(3):339-45 (47 ref.)

Mapping of pseudouridine residues in RNA to nucleotide resolution. Bakin AV, et al. **Methods Mol Biol** 1998; 77:297-309 (24 ref.)

RNA and protein interactions modulated by protein arginine methylation. Gary JD, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:65-131 (250 ref.)

Chemical etiology of nucleic acid structure. Eschenmoser A. **Science** 1999 Jun 25;284(5423):2118-24 (62 ref.)

New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Darden T, et al. **Structure Fold Des** 1999 Mar 15;7(3):R55-60 (54 ref.)

Kissing and RNA stability in antisense control of plasmid replication. Gerhart E, et al. **Trends Biochem Sci** 1998 Dec; 23(12):451-4 (33 ref.)

[New aspects is stable-isotope-assisted NMR techniques: application to be structural analysis of larger complexes between proteins and nucleic acids] Ohki S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):574-81 (56 ref.) **(Jpn)**

GENETICS

Nucleic acid targeting: therapeutic strategies for the 21st century. Thurston DE. **Br J Cancer** 1999 Jul;80 Suppl 1:65-85 (114 ref.)

Genetics: a touch of elegance with RNAi. Hunter CP. **Curr Biol** 1999 Jun 17;9(12):R440-2 (20 ref.)

Meiosis: MeiRNA hits the spot. Ohno M, et al. **Curr Biol** 1999 Jan 28;9(2):R66-9 (12 ref.)

A chemogenetic approach to RNA function/structure analysis. Strobel SA. **Curr Opin Struct Biol** 1999 Jun; 9(3):346-52 (36 ref.)

Mitochondrial RNA processing and translation: link between mitochondrial mutations and hearing loss? Fischel-Ghodsian N. **Mol Genet Metab** 1998 Oct; 65(2):97-104 (67 ref.)

Gene repair using chimeric RNA/DNA oligonucleotides. Kren BT, et al. **Semin Liver Dis** 1999;19(1):93-104 (44 ref.)

Dynamic diversity and small-molecule evolution: a new paradigm for ligand identification. Klekota B, et al. **Trends Biotechnol** 1999 May;17(5):205-9 (21 ref.)

The origin of the genetic code: amino acids as cofactors in an RNA world. Szathmáry E. **Trends Genet** 1999 Jun; 15(6):223-9 (65 ref.)

IMMUNOLOGY

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. Liljeqvist S, et al. **J Biotechnol** 1999 Jul 30; 73(1):1-33 (365 ref.)

ISOLATION & PURIFICATION

Extraction of cellular and tissue RNA. Millican DS, et al. **Methods Mol Biol** 1998;105:315-24 (6 ref.)

METABOLISM

The destinies and destinations of RNAs. Hazelrigg T. **Cell** 1998 Nov 13;95(4):451-60 (87 ref.)

Rhyme or reason: RNA-arginine interactions and the genetic code. Knight RD, et al. **Chem Biol** 1998 Sep;5(9):R215-20 (23 ref.)

Deciphering RNA recognition: aminoglycoside binding to the hammerhead ribozyme. Tor Y, et al. **Chem Biol** 1998 Nov;5(11):R277-83 (39 ref.)

Structure-based and combinatorial search for new RNA-binding drugs. Afshar M, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):59-63 (47 ref.)

Expression of ribozymes in gene transfer systems to modulate target RNA levels. Welch PJ, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):486-96 (107 ref.)

Transport pathways of macromolecules between the nucleus and the cytoplasm. Adam SA. **Curr Opin Cell Biol** 1999 Jun;11(3):402-6 (41 ref.)

RNA-protein complexes. Cusack S. **Curr Opin Struct Biol** 1999 Feb;9(1):66-73 (34 ref.)

RNA-cytoskeletal associations [see comments] Jansen RP. **FASEB J** 1999 Mar;13(3):455-66 (107 ref.) Comment in: FASEB J 1999 Mar;13(3):419-20.

RNA sorting in Drosophila oocytes and embryos [see comments] Lasko P. **FASEB J** 1999 Mar;13(3):421-33 (110 ref.) Comment in: FASEB J 1999 Mar;13(3):419-20.

RNA sorting in Xenopus oocytes and embryos [see comments] Mowry KL, et al. **FASEB J** 1999 Mar; 13(3):435-45 (98 ref.) Comment in: FASEB J 1999 Mar;13(3):419-20.

Ribonuclease-gold labels proteoglycan-containing cytoplasmic granules and ribonucleic acid-containing organelles--a survey. Dvorak AM, et al. **Histol Histopathol** 1999 Apr;14(2):597-626 (166 ref.)

Y bind RNA for spermatogenesis? Ruggiu M, et al. **Int J Androl** 1999 Feb;22(1):19-27 (73 ref.)

Yeast three-hybrid system to detect and analyze interactions between RNA and protein. Zhang B, et al. **Methods Enzymol** 1999;306:93-113 (19 ref.)

Mitochondrial RNA processing and translation: link between mitochondrial mutations and hearing loss? Fischel-Ghodsian N. **Mol Genet Metab** 1998 Oct; 65(2):97-104 (67 ref.)

Protein-RNA interactions in the regulation of PTH gene expression by calcium and phosphate [editorial] Naveh-Many T, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):811-3 (17 ref.)

Subcellular RNA compartmentalization. Mohr E. **Prog Neurobiol** 1999 Apr;57(5):507-25 (102 ref.)

RNA and protein interactions modulated by protein arginine methylation. Gary JD, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:65-131 (250 ref.)

Kissing and RNA stability in antisense control of plasmid replication. Gerhart E, et al. **Trends Biochem Sci** 1998 Dec; 23(12):451-4 (33 ref.)

[RNA recognition by RNA-binding protein] Katahira M. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):506-17 (31 ref.) **(Jpn)**

PHYSIOLOGY

Myotonic dystrophy: the role of RNA CUG triplet repeats. Timchenko LT. **Am J Hum Genet** 1999 Feb;64(2):360-4 (34 ref.)

The destinies and destinations of RNAs. Hazelrigg T. **Cell** 1998 Nov 13;95(4):451-60 (87 ref.)

Boundaries for an RNA world. Yarus M. **Curr Opin Chem Biol** 1999 Jun;3(3):260-7 (72 ref.)

New insights into the function of noncoding RNA and its potential role in disease pathogenesis. Askew DS, et al. **Histol Histopathol** 1999 Jan;14(1):235-41 (60 ref.)

7S RNA see **RNA, SMALL NUCLEAR**

RNA, ANTISENSE

Using antisense technology to study mitosis. Wordeman L, et al. **Methods Cell Biol** 1999;61:245-66 (100 ref.)

Kissing and RNA stability in antisense control of plasmid replication. Gerhart E, et al. **Trends Biochem Sci** 1998 Dec; 23(12):451-4 (33 ref.)

PHARMACOLOGY

Antisense RNA gene therapy for studying and modulating biological processes. Weiss B, et al. **Cell Mol Life Sci** 1999 Mar;55(3):334-58 (164 ref.)

Antisense strategies: functions and applications in immunology. Varga LV, et al. **Immunol Lett** 1999 Aug 3;69(2):217-24 (45 ref.)

PHYSIOLOGY

Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Kumar M, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1415-34 (342 ref.)

THERAPEUTIC USE

Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (review). Resnicoff M. **Int J Mol Med** 1998 May;1(5):883-8 (44 ref.)

RNA, ARCHAEAL

BIOSYNTHESIS

Archaeal aminoacyl-tRNA synthesis: unique determinants of a universal genetic code? Ibba M, et al. **Biol Bull** 1999 Jun;196(3):335-6; discussion 336-7 (10 ref.)

RNA, BACTERIAL

Small RNAs in Escherichia coli. Wassarman KM, et al. **Trends Microbiol** 1999 Jan;7(1):37-45 (47 ref.)

ANALYSIS

Critical appraisal of molecular biology techniques for detecting bacteria in synovial specimens. Kuipers JG, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):3S-8S (25 ref.)

CHEMISTRY

Mutational analysis of 23S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1999; 41:157-95 (154 ref.)

Comparative sequence analysis of tmRNA. Zwieb C, et al. **Nucleic Acids Res** 1999 May 15;27(10):2063-71 (64 ref.)

GENETICS

Mutational analysis of 23S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1999; 41:157-95 (154 ref.)

Comparative sequence analysis of tmRNA. Zwieb C, et al. **Nucleic Acids Res** 1999 May 15;27(10):2063-71 (64 ref.)

Engineering of bacterial ribosomes: replacement of all seven Escherichia coli rRNA operons by a single plasmid-encoded operon [see comments] Nomura M. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1820-2 (25 ref.) Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1971-6.

Transfer RNAs and pathogenicity islands. Hou YM. **Trends Biochem Sci** 1999 Aug;24(8):295-8 (27 ref.)

PHYSIOLOGY

[A bacterial RNA that functions both as a tRNA and an mRNA] Muto A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1433-42 (30 ref.) **(Jpn)**

RNA-BINDING PROTEINS

[RNA recognition by RNA-binding protein] Katahira M. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):506-17 (31 ref.) **(Jpn)**

[mRNA CAP binding protein] Matsuo H, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):518-29 (44 ref.) **(Jpn)**

CHEMISTRY

RNA recognition by arginine-rich peptide motifs. Weiss MA, et al. **Biopolymers** 1998;48(2-3):167-80 (71 ref.)

RNA-protein complexes. Cusack S. **Curr Opin Struct Biol** 1999 Feb;9(1):66-73 (34 ref.)

Structure and functions of nucleolin. Ginisty H, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):761-72 (179 ref.)

GENETICS

The circadian system of Arabidopsis thaliana: forward and reverse genetic approaches. Staiger D, et al. **Chronobiol Int** 1999 Jan;16(1):1-16 (67 ref.)

Y bind RNA for spermatogenesis? Ruggiu M, et al. **Int J Androl** 1999 Feb;22(1):19-27 (73 ref.)

METABOLISM

Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Rana TM, et al. **Arch Biochem Biophys** 1999 May 15;365(2):175-85 (99 ref.)

The influence of mRNA stability on glucose transporter (GLUT1) gene expression. Qi C, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):265-9 (75 ref.)

Activities of cold-shock domain proteins in translation control. Sommerville J. **Bioessays** 1999 Apr;21(4):319-25 (57 ref.)

Protein-RNA recognition. De Guzman RN, et al. **Biopolymers** 1998;48(2-3):181-95 (52 ref.)

Nitrosative and oxidative modulation of iron regulatory proteins. Bouton C. **Cell Mol Life Sci** 1999 Jul; 55(8-9):1043-53 (102 ref.)

Regulation of endothelial NO synthase mRNA stability: RNA-binding proteins crowd on the 3'-untranslated region [editorial; comment] Bloch KD. **Circ Res** 1999 Oct 1; 85(7):653-5 (10 ref.) Comment on: Circ Res 1999 Oct 1;85(7):588-95.

Meiosis: MeiRNA hits the spot. Ohno M, et al. **Curr Biol** 1999 Jan 28;9(2):R66-9 (12 ref.)

Determinants of SR protein specificity. Tacke R, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):358-62 (42 ref.)

Iron metabolism. Aisen P, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):200-6 (78 ref.)

RNA-protein complexes. Cusack S. **Curr Opin Struct Biol** 1999 Feb;9(1):66-73 (34 ref.)

Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. Hanson ES, et al. **Gene Expr** 1999;7(4-6):367-76 (100 ref.)

PKR, apoptosis and cancer. Jagus R, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):123-38 (192 ref.)

Yeast three-hybrid system to detect and analyze interactions between RNA and protein. Zhang B, et al. **Methods Enzymol** 1999;306:93-113 (19 ref.)

Global regulation by the small RNA-binding protein CsrA and the non-coding RNA molecule CsrB. Romeo T. **Mol Microbiol** 1998 Sep;29(6):1321-30 (53 ref.)

Regulation of the Bacillus subtilis pyrimidine biosynthetic operon by transcriptional attenuation: control of gene expression by an mRNA-binding protein. Switzer RL, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:329-67 (82 ref.)

[Ribosomal structure: RNA-protein and protein-protein

interactions] Nikonov SV, et al. **Mol Biol (Mosk)** 1998 Sep-Oct;32(5):773-81 (75 ref.) **(Rus)**

PHYSIOLOGY

WT1: what has the last decade told us? Little M, et al. **Bioessays** 1999 Mar;21(3):191-202 (87 ref.)
Nuclear orphan receptors control cholesterol catabolism. Russell DW. **Cell** 1999 May 28;97(5):539-42 (17 ref.)
Nucleolin: a multifunctional major nucleolar phosphoprotein. Tuteja R, et al. **Crit Rev Biochem Mol Biol** 1998; 33(6):407-36 (164 ref.)
hnRNP complexes: composition, structure, and function. Krecic AM, et al. **Curr Opin Cell Biol** 1999 Jun; 11(3):363-71 (62 ref.)
Structure and functions of nucleolin. Ginisty H, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):761-72 (179 ref.)
Iron regulatory proteins, iron responsive elements and iron homeostasis. Eisenstein RS, et al. **J Nutr** 1998 Dec; 128(12):2295-8 (27 ref.)
Making proteins at the synapse: activity-regulated translation and CPEB [see comments] Worley P. **Neuron** 1998 Nov; 21(5):936-8 (12 ref.) Comment in: Neuron 1998 Nov;21(5):1129-39.
A superfamily of proteins that contain the cold-shock domain. Graumann PL, et al. **Trends Biochem Sci** 1998 Aug;23(8):286-90 (48 ref.)
Cytoplasmic regulatory functions of the KH-domain proteins hnRNPs K and E1/E2. Ostareck-Lederer A, et al. **Trends Biochem Sci** 1998 Nov;23(11):409-11 (36 ref.)
Gene regulation by Y-box proteins: coupling control of transcription and translation. Matsumoto K, et al. **Trends Cell Biol** 1998 Aug;8(8):318-23 (53 ref.)

RNA CAPS

Nuclear snRNA and nuclear function (discovery of 5' cap structures in RNA). Ro-Choi TS. **Crit Rev Eukaryot Gene Expr** 1999;9(2):107-58 (304 ref.)

METABOLISM

eIF4E activity is regulated at multiple levels. Raught B, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):43-57 (111 ref.)
[mRNA CAP binding protein] Matsuo H, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):518-29 (44 ref.) **(Jpn)**

RNA, CATALYTIC

In vitro selection of nucleic acid enzymes. Kurz M, et al. **Curr Top Microbiol Immunol** 1999;243:137-58 (88 ref.)
Ribozymes: the characteristics and properties of catalytic RNAs. Tanner NK. **FEMS Microbiol Rev** 1999 Jun; 23(3):257-75 (105 ref.)

ADMINISTRATION & DOSAGE

Antisense technologies have a future fighting neurodegenerative diseases. Seidman S, et al. **Antisense Nucleic Acid Drug Dev** 1999 Aug;9(4):333-40 (69 ref.)

CHEMISTRY

Hammerhead ribozyme design and application. Amarzguioui M, et al. **Cell Mol Life Sci** 1998 Nov;54(11):1175-202 (248 ref.)
Structure, folding and catalysis of the small nucleolytic ribozymes. Lilley DM. **Curr Opin Struct Biol** 1999 Jun; 9(3):330-8 (69 ref.)
Recent developments in the hammerhead ribozyme field. Vaish NK, et al. **Nucleic Acids Res** 1998 Dec 1; 26(23):5237-42 (79 ref.)
Designing ribozymes for the inhibition of gene expression. Bramlage B, et al. **Trends Biotechnol** 1998 Oct;16(10):434-8 (59 ref.)

GENETICS

Ribozyme chemogenetics. Strobel SA. **Biopolymers** 1998; 48(1):65-81 (108 ref.)
Expression of ribozymes in gene transfer systems to modulate target RNA levels. Welch PJ, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):486-96 (107 ref.)
Ribozymes as therapeutic tools for genetic disease. Phylactou LA, et al. **Hum Mol Genet** 1998;7(10):1649-53 (54 ref.)
Towards an RNA-based therapy for Marfan syndrome. Kilpatrick MW, et al. **Mol Med Today** 1998 Sep;4(9):376-81 (30 ref.)

METABOLISM

Ribonuclease P: unity and diversity in a tRNA processing ribozyme. Frank DN, et al. **Annu Rev Biochem** 1998; 67:153-80 (157 ref.)
Viroids with hammerhead ribozymes: some unique structural and functional aspects with respect to other members of the group. Flores R, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):849-54 (36 ref.)
Deciphering RNA recognition: aminoglycoside binding to the hammerhead ribozyme. Tor Y, et al. **Chem Biol** 1998 Nov;5(11):R277-83 (39 ref.)
Expression of ribozymes in gene transfer systems to modulate target RNA levels. Welch PJ, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):486-96 (107 ref.)
Nucleic acid enzymes. Carola C, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):274-83 (77 ref.)
DNA enzymes. Sen D, et al. **Curr Opin Chem Biol** 1998 Dec; 2(6):680-7 (52 ref.)
RNA catalysis. Scott WG. **Curr Opin Struct Biol** 1998 Dec; 8(6):720-6 (46 ref.)
Folding and catalysis by the hairpin ribozyme. Lilley DM. **FEBS Lett** 1999 Jun 4;452(1-2):26-30 (33 ref.)
Ribonuclease P: the diversity of a ubiquitous RNA processing enzyme. Schön A. **FEMS Microbiol Rev** 1999 Jun; 23(3):391-406 (128 ref.)
Strategies to express structural and catalytic RNAs in mammalian cells. Thompson JD. **Methods Enzymol** 1999; 306:241-60 (71 ref.)
[New classes of ribozymes isolated by in vitro selection. RNA ligases] Zhenodarova SM, et al. **Mol Biol (Mosk)** 1998 Nov-Dec;32(6):948-54 (23 ref.) **(Rus)**

PHARMACOLOGY

Function and biological applications of catalytic nucleic acids. Gaughan DJ, et al. **Biochim Biophys Acta** 1999 Apr 14;1445(1):1-20 (104 ref.)
Application of preformed hammerhead ribozymes in the gene therapy of cancer (review). Sioud M. **Int J Mol Med** 1999 Apr;3(4):381-4 (384 ref.)
Designing ribozymes for the inhibition of gene expression. Bramlage B, et al. **Trends Biotechnol** 1998 Oct;16(10):434-8 (59 ref.)

PHYSIOLOGY

Function and biological applications of catalytic nucleic acids. Gaughan DJ, et al. **Biochim Biophys Acta** 1999 Apr 14;1445(1):1-20 (104 ref.)
Ribozymes, genomics and therapeutics. Rossi JJ. **Chem Biol** 1999 Feb;6(2):R33-7 (30 ref.)
Boundaries for an RNA world. Yarus M. **Curr Opin Chem Biol** 1999 Jun;3(3):260-7 (72 ref.)

THERAPEUTIC USE

Antisense technologies have a future fighting neurodegenerative diseases. Seidman S, et al. **Antisense Nucleic Acid Drug Dev** 1999 Aug;9(4):333-40 (69 ref.)
Gene therapy: repairing haemoglobin disorders with ribozymes. Weatherall DJ. **Curr Biol** 1998 Sep 24; 8(19):R696-8 (13 ref.)
Ribozymes in gene therapy of HIV-1. Macpherson JL, et al. **Front Biosci** 1999 Jun 1;4:D497-505 (80 ref.)
Ribozymes as therapeutic tools for genetic disease. Phylactou LA, et al. **Hum Mol Genet** 1998;7(10):1649-53 (54 ref.)
Application of preformed hammerhead ribozymes in the gene therapy of cancer (review). Sioud M. **Int J Mol Med** 1999 Apr;3(4):381-4 (384 ref.)
The potential application of ribozymes for the treatment of hematological disorders. James HA. **J Leukoc Biol** 1999 Sep;66(3):361-8 (125 ref.)
[Therapeutic application for leukemia with ribozyme] Matsushita H, et al. **Rinsho Ketsueki** 1998 Aug;39(8):553-64 (63 ref.) **(Jpn)**

RNA, CHLOROPLAST

METABOLISM

Polyadenylation and degradation of mRNA in the chloroplast. Schuster G, et al. **Plant Physiol** 1999 Aug; 120(4):937-44 (33 ref.)

RNA, CHROMOSOMAL see **RNA, NUCLEAR**

RNA-DEPENDENT DNA POLYMERASE see **RNA-DIRECTED DNA POLYMERASE**

RNA-DEPENDENT PROTEIN KINASE see **EIF-2 KINASE**

RNA-DEPENDENT RNA POLYMERASE see **RNA REPLICASE**

RNA-DIRECTED DNA POLYMERASE

DRUG EFFECTS

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2. Milton J, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2623-8 (11 ref.)

METABOLISM

Toeprinting assays. Mapping by blocks to reverse transcriptase primer extension. Ringquist S, et al. **Methods Mol Biol** 1998;77:283-95 (58 ref.)

RNA, DOUBLE-STRANDED

Type I interferon gene expression: differential expression of IFN-A genes induced by viruses and double-stranded RNA. Bragança J, et al. **Biochimie** 1998 Aug-Sep; 80(8-9):673-87 (93 ref.)

GENETICS

RNAi and double-strand RNA. Sharp PA. **Genes Dev** 1999 Jan 15;13(2):139-41 (19 ref.)
The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. Rebouillat D, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):295-308 (108 ref.)
Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Kumar M, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1415-34 (342 ref.)
Precise packaging of the three genomic segments of the double-stranded-RNA bacteriophage phi6. Mindich L. **Microbiol Mol Biol Rev** 1999 Mar;63(1):149-60 (88 ref.)
RNA-triggered gene silencing. Fire A. **Trends Genet** 1999 Sep;15(9):358-63 (50 ref.)

PHYSIOLOGY

Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Kumar M, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1415-34 (342 ref.)

RNA EDITING

Identification and characterization of RNA editing events within the 5-HT2C receptor. Niswender CM, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:38-48 (34 ref.)
Evolution of the U-insertion/deletion RNA editing in mitochondria of kinetoplastid protozoa. Simpson L, et al. **Ann N Y Acad Sci** 1999 May 18;870:190-205 (64 ref.)
Recent advances in mammalian RNA editing. Niswender CM. **Cell Mol Life Sci** 1998 Sep;54(9):946-64 (183 ref.)
RNA editing site recognition in higher plant mitochondria. Mulligan RM, et al. **J Hered** 1999 May-Jun;90(3):338-44 (65 ref.)

GENETICS

RNA editing of a Drosophila sodium channel gene. Hanrahan CJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:51-66 (54 ref.)
Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion. Keller W, et al. **FEBS Lett** 1999 Jun 4;452(1-2):71-6 (44 ref.)
[Mechanisms of nuclear mRNA editing] Kostyrko A, et al. **Postepy Biochem** 1998;44(2):94-101 (53 ref.) **(Pol)**

PHYSIOLOGY

RNA editing. Brennicke A, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):297-316 (56 ref.)

RNA, FUNGAL

In vivo mutational analysis of ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Methods Mol Biol** 1998;77:257-70 (32 ref.)

GENETICS

Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. de la Cruz J, et al. **Trends Biochem Sci** 1999 May;24(5):192-8 (54 ref.)

METABOLISM

Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. de la Cruz J, et al. **Trends Biochem Sci** 1999 May;24(5):192-8 (54 ref.)

PHYSIOLOGY

Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis. Das S, et al. **Front Biosci** 1998 Dec 1;3:D1241-52 (61 ref.)

RNA, GUIDE

see related
RNA EDITING

RNA HELICASES

The protein family of RNA helicases. Lüking A, et al. **Crit Rev Biochem Mol Biol** 1998;33(4):259-96 (202 ref.)

CHEMISTRY

Bacterial helicases. Egelman EH. **J Struct Biol** 1998 Dec 15;124(2-3):123-8 (66 ref.)

METABOLISM

Unraveling the role of helicases in transcription. Eisen A, et al. **Bioessays** 1998 Aug;20(8):634-41 (81 ref.)
Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. de la Cruz J, et al. **Trends Biochem Sci** 1999 May;24(5):192-8 (54 ref.)

RNA, HETEROGENEOUS NUCLEAR

PHYSIOLOGY

Cytoplasmic regulatory functions of the KH-domain proteins hnRNPs K and E1/E2. Ostareck-Lederer A, et al. **Trends Biochem Sci** 1998 Nov;23(11):409-11 (36 ref.)

RNA, MESSENGER

RNA localization in development. Bashirullah A, et al. **Annu Rev Biochem** 1998;67:335–94 (254 ref.)

Identification and characterization of mRNAs differentially expressed in thyroid cells stimulated by a mitogenic treatment. Pirson I, et al. **Biochimie** 1999 Apr;81(4):309–14 (38 ref.)

Control of messenger RNA stability during development. Fontes AM, et al. **Curr Top Dev Biol** 1999;44:171–202 (154 ref.)

Internal ribosome entry sites tests with circular mRNAs. Chen CY, et al. **Methods Mol Biol** 1998;77:355–63 (15 ref.)

[A bacterial RNA that functions both as a tRNA and an mRNA] Muto A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1433–42 (30 ref.) **(Jpn)**

ANALYSIS

Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Nolte FS. **Adv Clin Chem** 1998;33:201–35 (87 ref.)

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Lambrechts AC, et al. **Ann Oncol** 1998 Dec;9(12):1269–76 (60 ref.)

Mucin gene expression in the rat middle ear: an improved method for RNA harvest. Lin J, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):762–8 (36 ref.)

Quantitative RT-PCR: pitfalls and potential. Freeman WM, et al. **Biotechniques** 1999 Jan;26(1):112–22, 124–5 (66 ref.)

Dendritic localization of mRNAs [published erratum appears in Curr Opin Neurobiol 1999 Feb;9(1):142] Kuhl D, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):600–6 (75 ref.)

Techniques for quantification of cytokine mRNAs. Benveniste O, et al. **Cytokines Cell Mol Ther** 1998 Sep; 4(3):207–14 (50 ref.)

Imaging with radiolabeled antisense oligonucleotides for the detection of intracellular messenger RNA and cardiovascular disease. Dewanjee MK, et al. **J Nucl Cardiol** 1999 May–Jun;6(3):345–56 (10 ref.)

mRNA quantitation techniques: considerations for experimental design and application. Reue K. **J Nutr** 1998 Nov;128(11):2038–44 (31 ref.)

Optimization of a reverse transcription–polymerase chain reaction (RT-PCR) mass assay for low-abundance mRNA. Cale JM, et al. **Methods Mol Biol** 1998;105:351–71 (4 ref.)

Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Karge WH 3rd, et al. **Methods Mol Biol** 1998;110:43–61 (9 ref.)

mRNA: detection by in Situ and northern hybridization. Parker RM, et al. **Methods Mol Biol** 1999;106:247–83 (30 ref.)

Techniques for the measurement of lipoprotein lipase messenger RNA. Ranganathan G, et al. **Methods Mol Biol** 1999;109:329–35 (7 ref.)

Differential display of mRNA. Zhang JS, et al. **Mol Biotechnol** 1998 Oct;10(2):155–65 (61 ref.)

Subcellular localization of mRNA in neuronal cells. Contributions of high-resolution in situ hybridization techniques. Martone ME, et al. **Mol Neurobiol** 1998 Dec; 18(3):227–46 (122 ref.)

[Detection of receptor mRNAs using nonradioactive in situ hybridization] Shin M, et al. **Nippon Rinsho** 1998 Jul; 56(7):1667–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular bases of prion diseases] Pokrovskii VI, et al. **Vestn Ross Akad Med Nauk** 1998;(10):45–55 (31 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Transcriptional regulation of smooth muscle contractile apparatus expression. Solway J, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S100–8 (98 ref.)

Totally in vitro protein selection using mRNA–protein fusions and ribosome display. Roberts RW. **Curr Opin Chem Biol** 1999 Jun;3(3):268–73 (39 ref.)

Application of cryopreserved precision-cut liver slices in pharmacotoxicology--principles, literature data and own investigations with special reference to CYP1A1-mRNA induction. Glöckner R, et al. **Exp Toxicol Pathol** 1998 Sep; 50(4–6):440–9 (35 ref.)

Developmental regulation of immunoglobulin mRNA processing and the IgA response: establishing a paradigm. Lebman DA, et al. **Immunol Res** 1999;20(1):43–53 (55 ref.)

Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature. Solves P, et al. **Leuk Res** 1999 Sep;23(9):851–4 (17 ref.)

Cytoplasmic polyadenylation in development and beyond. Richter JD. **Microbiol Mol Biol Rev** 1999 Jun;63(2):446–56 (111 ref.)

Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Zhao J, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):405–45 (518 ref.)

mRNA trafficking and local protein synthesis at the synapse [comment] Schuman EM. **Neuron** 1999 Aug;23(4):645–8 (20 ref.) Comment on: Neuron 1999 Aug;23(4):641–4.

Developmental expression of cerebellar GABAA-receptor subunit mRNAs. Nature versus nurture. Siegel RE. **Perspect Dev Neurobiol** 1998;5(2–3):207–17 (52 ref.)

[Expression af early genes in memory mechanisms] Anokhin KV. **Vestn Ross Akad Med Nauk** 1998;(12):58–61 (33 ref.) **(Rus)**

BLOOD

New prognostic factors in melanoma: mRNA tumour markers. Keilholz U. **Eur J Cancer** 1998 Jul;34 Suppl 3:S37–41 (37 ref.)

DRUG EFFECTS

Gene therapy: repairing haemoglobin disorders with ribozymes. Weatherall DJ. **Curr Biol** 1998 Sep 24; 8(19):R696–8 (13 ref.)

GENETICS

The potential mechanism of induction of inducible nitric oxide synthase mRNA in alveolar macrophages by lipopolysaccharide and its suppression by ethanol, in vivo. Greenberg SS, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):260S–265S (80 ref.)

Should we kill the messenger? The role of the surveillance complex in translation termination and mRNA turnover. Czaplinski K, et al. **Bioessays** 1999 Aug;21(8):685–96 (81 ref.)

The role of the 5' untranslated region of an mRNA in translation regulation during development. van der Velden AW, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):87–106 (102 ref.)

Differences in brain gene expression between sleep and waking as revealed by mRNA differential display and cDNA microarray technology. Cirelli C, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:44–52 (66 ref.)

Making sense of the multiple MAP-2 transcripts and their role in the neuron. Shafit-Zagardo B, et al. **Mol Neurobiol** 1998 Apr;16(2):149–62 (105 ref.)

Degradation of mRNA in Escherichia coli: an old problem with some new twists. Coburn GA, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:55–108 (208 ref.)

The search for trans-acting factors controlling messenger RNA decay. Wilson GM, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:257–91 (146 ref.)

Internal ribosome entry sites (IRESs): reality and use. Houdebine LM, et al. **Transgenic Res** 1999 Jun;8(3):157–77 (200 ref.)

Molecular evolutionary evidence that H19 mRNA is functional. Hurst LD, et al. **Trends Genet** 1999 Apr; 15(4):134–5 (16 ref.)

Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. van Leeuwen FW, et al. **Trends Neurosci** 1998 Aug;21(8):331–5 (48 ref.)

[Mechanisms of nuclear mRNA editing] Kostyrko A, et al. **Postepy Biochem** 1998;44(2):94–101 (53 ref.) **(Pol)**

ISOLATION & PURIFICATION

Size separation and quantification of mRNA by northern analysis. Bird IM. **Methods Mol Biol** 1998;105:325–36 (3 ref.)

METABOLISM

Should we kill the messenger? The role of the surveillance complex in translation termination and mRNA turnover. Czaplinski K, et al. **Bioessays** 1999 Aug;21(8):685–96 (81 ref.)

Regulatory signals in messenger RNA: determinants of nutrient-gene interaction and metabolic compartmentation [see comments] Hesketh JE, et al. **Br J Nutr** 1998 Oct; 80(4):307–21 (114 ref.) Comment in: Br J Nutr 1998 Oct;80(4):305–6.

Motors driving mRNA localization: new insights from in vivo imaging. Arn EA, et al. **Cell** 1998 Oct 16;95(2):151–4 (18 ref.)

A perfect message: RNA surveillance and nonsense-mediated decay. Hentze MW, et al. **Cell** 1999 Feb 5;96(3):307–10 (20 ref.)

Regulation of endothelial NO synthase mRNA stability: RNA-binding proteins crowd on the 3'-untranslated region [editorial; comment] Bloch KD. **Circ Res** 1999 Oct 1; 85(7):653–5 (10 ref.) Comment on: Circ Res 1999 Oct 1;85(7):588–95.

mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. Minvielle-Sebastia L, et al. **Curr Opin Cell Biol** 1999 Jun; 11(3):352–7 (52 ref.)

RNA trafficking in myelinating cells. Carson JH, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):607–12 (44 ref.)

The travels of mRNAs through all cells large and small [see comments] Bassell GJ, et al. **FASEB J** 1999 Mar; 13(3):447–54 (79 ref.) Comment in: FASEB J 1999 Mar;13(3):419–20.

mRNA degradation in bacteria. Rauhut R, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):353–70 (113 ref.)

3'-End processing of pre-mRNA in eukaryotes. Wahle E, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):277–95 (141 ref.)

Control of mRNA turnover as a mechanism of glucose repression in Saccharomyces cerevisiae. Scheffler IE, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1175–93 (113 ref.)

Effects of dietary deprivation, obesity and exercise on UCP3 mRNA levels. Giacobino JP. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S60–3 (20 ref.)

Brain distribution of UCP2 mRNA: in situ hybridization histochemistry studies. Richard D, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S53–5 (11 ref.)

Gel retardation and UV–crosslinking assays to detect specific RNA–protein interactions in the 5' or 3' UTRs of translationally regulated mRNAs. Walker J, et al. **Methods Mol Biol** 1998;77:365–78 (30 ref.)

Polyadenylation and degradation of mRNA in the chloroplast. Schuster G, et al. **Plant Physiol** 1999 Aug; 120(4):937–44 (33 ref.)

Subcellular RNA compartmentalization. Mohr E. **Prog Neurobiol** 1999 Apr;57(5):507–25 (102 ref.)

Regulation of the Bacillus subtilis pyrimidine biosynthetic operon by transcriptional attenuation: control of gene expression by an mRNA-binding protein. Switzer RL, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:329–67 (82 ref.)

mRNA surveillance in eukaryotes: kinetic proofreading of proper translation termination as assessed by mRNP domain organization? Hilleren P, et al. **RNA** 1999 Jun; 5(6):711–9 (67 ref.)

Internal ribosome entry sites (IRESs): reality and use. Houdebine LM, et al. **Transgenic Res** 1999 Jun;8(3):157–77 (200 ref.)

Degrading chloroplast mRNA: the role of polyadenylation. Hayes R, et al. **Trends Biochem Sci** 1999 May;24(5):199–202 (39 ref.)

RNA localization: different zipcodes, same postman? Oleynikov Y, et al. **Trends Cell Biol** 1998 Oct;8(10):381–3 (30 ref.)

mRNA degradation. A tale of poly(A) and multiprotein machines. Carpousis AJ, et al. **Trends Genet** 1999 Jan; 15(1):24–8 (45 ref.)

RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Culbertson MR. **Trends Genet** 1999 Feb;15(2):74–80 (59 ref.)

PHYSIOLOGY

A perfect message: RNA surveillance and nonsense-mediated decay. Hentze MW, et al. **Cell** 1999 Feb 5;96(3):307–10 (20 ref.)

Making sense of the multiple MAP-2 transcripts and their role in the neuron. Shafit-Zagardo B, et al. **Mol Neurobiol** 1998 Apr;16(2):149–62 (105 ref.)

Do unintended antisense transcripts contribute to sense cosuppression in plants? [letter; comment] Jorgensen RA, et al. **Trends Genet** 1999 Jan;15(1):11–2 (14 ref.) Comment on: Trends Genet 1998 Jul;14(7):255–8.

RNA, MESSENGER, EDITING see **RNA EDITING**

RNA, MESSENGER, POLYADENYLATED see **RNA, MESSENGER**

RNA, MESSENGER, PRECURSORS see **RNA PRECURSORS**

RNA, MESSENGER, SPLICING see **RNA SPLICING**

RNA, NEOPLASM

ANALYSIS

Molecular pathology of leukemia and lymphoma. Bagg A, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S76–92 (115 ref.)

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Lambrechts AC, et al. **Ann Oncol** 1998 Dec;9(12):1269–76 (60 ref.)

BLOOD

New prognostic factors in melanoma: mRNA tumour markers. Keilholz U. **Eur J Cancer** 1998 Jul;34 Suppl 3:S37–41 (37 ref.)

RNA, NON-POLYADENYLATED see **RNA**

RNA, NUCLEAR

METABOLISM

Nuclear RNA export in yeast. Strässer K, et al. **FEBS Lett** 1999 Jun 4;452(1–2):77–81 (64 ref.)

Nuclear RNA export. Stutz F, et al. **Genes Dev** 1998 Nov 1;12(21):3303–19 (166 ref.)

RNA NUCLEOTIDYLTRANSFERASES

METABOLISM

New evidence for the genomic tag hypothesis: archaeal CCA-adding enzymes and tDNA substrates. Maizels N, et al. **Biol Bull** 1999 Jun;196(3):331–3; discussion 333–4 (20 ref.)

RNA, PLANT

GENETICS

A comparison of gel-based, nylon filter and microarray techniques to detect differential RNA expression in plants. Baldwin D, et al. **Curr Opin Plant Biol** 1999 Apr; 2(2):96–103 (71 ref.)

METABOLISM

Connections between virus movement, macromolecular signaling and assimilate allocation. Lucas WJ, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):192–7 (51 ref.)

PHYSIOLOGY

Gene silencing: plants and viruses fight it out. Smyth DR. **Curr Biol** 1999 Feb 11;9(3):R100–2 (17 ref.)

Do unintended antisense transcripts contribute to sense cosuppression in plants? [letter; comment] Jorgensen RA, et al. **Trends Genet** 1999 Jan;15(1):11–2 (14 ref.) Comment on: Trends Genet 1998 Jul;14(7):255–8.

RNA, POLYADENYLATED see **RNA, MESSENGER**

RNA POLYMERASE I

METABOLISM

Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Grummt I. **Prog Nucleic Acid Res Mol Biol** 1999;62:109–54 (232 ref.)

Regulation of RNA polymerase I transcription in yeast and vertebrates. Reeder RH. **Prog Nucleic Acid Res Mol Biol** 1999;62:293–327 (212 ref.)

RNA POLYMERASE II

RNA polymerase II holoenzymes and subcomplexes. Myer VE, et al. **J Biol Chem** 1998 Oct 23;273(43):27757–60 (96 ref.)

CHEMISTRY

RNA polymerase–DNA interaction: structures of intermediate, open, and elongation complexes. Ebright RH. **Cold Spring Harb Symp Quant Biol** 1998;63:11–20 (78 ref.)

Protein crystallization on lipid layers and structure determination of the RNA polymerase II transcription initiation complex. Asturias FJ, et al. **J Biol Chem** 1999 Mar 12;274(11):6813–6 (29 ref.)

DNA bending and wrapping around RNA polymerase: a "revolutionary" model describing transcriptional mechanisms. Coulombe B, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):457–78 (169 ref.)

[Function and structural biology of general transcription factors and RNA polymerase II in eukaryotes] Ohkuma Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):438–56 (99 ref.) **(Jpn)**

GENETICS

The role of TAFs in RNA polymerase II transcription. Hahn S. **Cell** 1998 Nov 25;95(5):579–82 (26 ref.)

METABOLISM

Unraveling the role of helicases in transcription. Eisen A, et al. **Bioessays** 1998 Aug;20(8):634–41 (81 ref.)

Recruitment of the RNA polymerase II holoenzyme and its implications in gene regulation. Barberis A, et al. **Biol Chem** 1998 Dec;379(12):1397–405 (82 ref.)

Phosphorylation of RNA polymerase II C-terminal domain (CTD): a new control for heat shock gene expression? Dubois MF, et al. **Cell Stress Chaperones** 1998 Sep; 3(3):147–51 (52 ref.)

RNA polymerase–DNA interaction: structures of intermediate, open, and elongation complexes. Ebright RH. **Cold Spring Harb Symp Quant Biol** 1998;63:11–20 (78 ref.)

Cooperative assembly of RNA polymerase II transcription complexes. Ellwood K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:253–61 (36 ref.)

Activation and the role of reinitiation in the control of transcription by RNA polymerase II. Hahn S. **Cold Spring Harb Symp Quant Biol** 1998;63:181–8 (91 ref.)

Crossing the line between RNA polymerases: transcription of human snRNA genes by RNA polymerases II and III. Henry RW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:111–20 (54 ref.)

Mechanism and regulation of yeast RNA polymerase II transcription. Kornberg RD. **Cold Spring Harb Symp Quant Biol** 1998;63:229–32 (26 ref.)

The transition from initiation to elongation by RNA polymerase II. Luse DS, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:289–300 (34 ref.)

The RNA polymerase II general transcription factors: past, present, and future. Reinberg D, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:83–103 (168 ref.)

Polarity of transcription on Pol II and archaeal promoters: where is the "one-way sign" and how is it read? Tsai FT, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:53–61 (25 ref.)

Fractions to functions: RNA polymerase II thirty years later. Woychik NA. **Cold Spring Harb Symp Quant Biol** 1998; 63:311–7 (97 ref.)

Coupling RNA polymerase II transcription with pre-mRNA processing. Bentley D. **Curr Opin Cell Biol** 1999 Jun; 11(3):347–51 (51 ref.)

Activation of RNA polymerase II transcription. Berk AJ. **Curr Opin Cell Biol** 1999 Jun;11(3):330–5 (51 ref.)

Mechanism and regulation of transcriptional elongation by RNA polymerase II. Reines D, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):342–6 (56 ref.)

RNA polymerase II as a control panel for multiple coactivator complexes. Hampsey M, et al. **Curr Opin Genet Dev** 1999 Apr;9(2):132–9 (79 ref.)

Regulatory targets in the RNA polymerase II holoenzyme. Parvin JD, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):565–70 (58 ref.)

Regulation of c-myc and immunoglobulin kappa gene transcription by promoter-proximal pausing of RNA polymerase II. Schneider EE, et al. **Curr Top Microbiol Immunol** 1999;246:225–31 (32 ref.)

Factors regulating the transcriptional elongation activity of RNA polymerase II. Shilatifard A. **FASEB J** 1998 Nov; 12(14):1437–46 (84 ref.)

[RNA polymerase II] Knoppe DG. **Mol Biol (Mosk)** 1999 Mar–Apr;33(2):156–62 (41 ref.) **(Rus)**

PHYSIOLOGY

Transcription-coupled repair of DNA damage: unanticipated players, unexpected complexities. Leadon SA. **Am J Hum Genet** 1999 May;64(5):1259–63 (39 ref.)

[Function and structural biology of general transcription factors and RNA polymerase II in eukaryotes] Ohkuma Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):438–56 (99 ref.) **(Jpn)**

RNA POLYMERASE III

METABOLISM

The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Chédin S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:381–9 (103 ref.)

Crossing the line between RNA polymerases: transcription of human snRNA genes by RNA polymerases II and III. Henry RW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:111–20 (54 ref.)

Transcription factor IIIB: the architecture of its DNA complex, and its roles in initiation of transcription by RNA polymerase III. Kumar A, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:121–9 (60 ref.)

RNA POLYMERASES see **DNA-DIRECTED RNA POLYMERASE**

RNA PRECURSORS

GENETICS

Flipping the switch to an active spliceosome. Murray HL, et al. **Cell** 1999 Mar 5;96(5):599–602 (14 ref.)

Coupling RNA polymerase II transcription with pre-mRNA processing. Bentley D. **Curr Opin Cell Biol** 1999 Jun; 11(3):347–51 (51 ref.)

Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion. Keller W, et al. **FEBS Lett** 1999 Jun 4;452(1–2):71–6 (44 ref.)

3'-End processing of pre-mRNA in eukaryotes. Wahle E, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):277–95 (141 ref.)

AT-AC pre-mRNA splicing mechanisms and conservation of minor introns in voltage-gated ion channel genes. Wu Q, et al. **Mol Cell Biol** 1999 May;19(5):3225–36 (130 ref.)

The role of alternative pre-mRNA splicing in regulating the structure and function of skeletal protein 4.1. Conboy J. **Proc Soc Exp Biol Med** 1999 Feb;220(2):73–8 (44 ref.)

METABOLISM

Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Lopez AJ. **Annu Rev Genet** 1998;32:279–305 (149 ref.)

RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198–200 (12 ref.)

Nuclear organization of pre-mRNA splicing factors. Sleeman JE, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):372–7 (61 ref.)

Guided tours: from precursor snoRNA to functional snoRNP. Weinstein LB, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):378–84 (56 ref.)

3'-End processing of pre-mRNA in eukaryotes. Wahle E, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):277–95 (141 ref.)

The role of alternative pre-mRNA splicing in regulating the structure and function of skeletal protein 4.1. Conboy J. **Proc Soc Exp Biol Med** 1999 Feb;220(2):73–8 (44 ref.)

Functions of SR and Tra2 proteins in pre-mRNA splicing regulation. Tacke R, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):59–63 (29 ref.)

RNA PROCESSING, POST-TRANSCRIPTIONAL

RNA processing in evolution. The logic of soft-wired genomes. Herbert A, et al. **Ann N Y Acad Sci** 1999 May 18;870:119–32 (45 ref.)

Ribonuclease P: unity and diversity in a tRNA processing ribozyme. Frank DN, et al. **Annu Rev Biochem** 1998; 67:153–80 (157 ref.)

The influence of mRNA stability on glucose transporter (GLUT1) gene expression. Qi C, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):265–9 (75 ref.)

Regulatory signals in messenger RNA: determinants of nutrient-gene interaction and metabolic compartmentation [see comments] Hesketh JE, et al. **Br J Nutr** 1998 Oct; 80(4):307–21 (114 ref.) Comment in: Br J Nutr 1998 Oct;80(4):305–6.

Gene silencing: plants and viruses fight it out. Smyth DR. **Curr Biol** 1999 Feb 11;9(3):R100–2 (17 ref.)

Coupling RNA polymerase II transcription with pre-mRNA processing. Bentley D. **Curr Opin Cell Biol** 1999 Jun; 11(3):347–51 (51 ref.)

mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. Minvielle-Sebastia L, et al. **Curr Opin Cell Biol** 1999 Jun; 11(3):352–7 (52 ref.)

3'-End processing of pre-mRNA in eukaryotes. Wahle E, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):277–95 (141 ref.)

Developmental regulation of immunoglobulin mRNA processing and the IgA response: establishing a paradigm. Lebman DA, et al. **Immunol Res** 1999;20(1):43–53 (55 ref.)

Evolutionary variation of immunoglobulin mu heavy chain RNA processing pathways: origins, effects, and implications. Ross DA, et al. **Immunol Rev** 1998 Dec; 166:143–51 (37 ref.)

Posttranscriptional control of gene expression in yeast. McCarthy JEG. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1492–553 (620 ref.)

RNA processing and the evolution of eukaryotes. Herbert A, et al. **Nat Genet** 1999 Mar;21(3):265–9 (57 ref.)

Polyadenylation and degradation of mRNA in the chloroplast. Schuster G, et al. **Plant Physiol** 1999 Aug; 120(4):937–44 (33 ref.)

Transcriptional and posttranscriptional regulation of proteoglycan gene expression. Iozzo RV, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:19–53 (134 ref.)

RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Culbertson MR. **Trends Genet** 1999 Feb;15(2):74–80 (59 ref.)

GENETICS

Dissecting the mechanisms of posttranscriptional gene silencing: divide and conquer. Grant SR. **Cell** 1999 Feb 5;96(3):303–6 (24 ref.)

PHYSIOLOGY

Post-transcriptional control of gene expression during spermatogenesis. Braun RE. **Semin Cell Dev Biol** 1998 Aug; 9(4):483–9 (50 ref.)

RNA, PROTOZOAN

Evolution of the U-insertion/deletion RNA editing in mitochondria of kinetoplastid protozoa. Simpson L, et al. **Ann N Y Acad Sci** 1999 May 18;870:190–205 (64 ref.)

RNA REPLICASE

CHEMISTRY

Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. O'Reilly EK, et al. **Virology** 1998 Dec 20;252(2):287–303 (80 ref.)

METABOLISM

The arterivirus replicase. The road from RNA to protein(s), and back again. Snijder EJ. **Adv Exp Med Biol** 1998; 440:97–108 (54 ref.)

Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. O'Reilly EK, et al. **Virology** 1998 Dec 20;252(2):287–303 (80 ref.)

RNA, RIBOSOMAL

Analysis of rRNA function using specialized ribosomes. Brink MF, et al. **Methods Mol Biol** 1998;77:117–28 (11 ref.)

Allele-specific priming in the mapping of rRNA. Douthwaite S. **Methods Mol Biol** 1998;77:11–21 (28 ref.)

In vivo mutational analysis of ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Methods Mol Biol** 1998;77:257–70 (32 ref.)

BIOSYNTHESIS

Molecular origins and the null hypothesis: motifs from our maker? Ellington AD. **Biol Bull** 1999 Jun;196(3):315–7; discussion 318–9 (14 ref.)

The nature of the 'nucleolus precursor body' in early preimplantation embryos: a review of fine-structure cytochemical, immunocytochemical and autoradiographic data related to nucleolar function. Fléchon JE, et al. **Zygote** 1998 May;6(2):183–91 (50 ref.)

RNA, RIBOSOMAL

GENETICS

A test of Archonta monophyly and the phylogenetic utility of the mitochondrial gene 12S rRNA. McNiff BE, et al. **Am J Phys Anthropol** 1998 Nov;107(3):225–41 (78 ref.)

Strength and regulation without transcription factors: lessons from bacterial rRNA promoters. Gourse RL, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:131–9 (63 ref.)

Genetic selection of rRNA mutations. Gregory ST, et al. **Methods Mol Biol** 1998;77:271–81 (14 ref.)

Engineering of bacterial ribosomes: replacement of all seven Escherichia coli rRNA operons by a single plasmid-encoded operon [see comments] Nomura M. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1820–2 (25 ref.) Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1971–6.

METABOLISM

RNA binding strategies of ribosomal proteins. Draper DE, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):381–8 (59 ref.)

[Ribosomal structure: RNA–protein and protein–protein interactions] Nikonov SV, et al. **Mol Biol (Mosk)** 1998 Sep–Oct;32(5):773–81 (75 ref.) **(Rus)**

PHYSIOLOGY

[Two recent topics in ribosome research] Endo Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2199–205 (22 ref.) **(Jpn)**

RNA, RIBOSOMAL, PRECURSORS see **RNA PRECURSORS**

RNA, RIBOSOMAL, SELF-SPLICING see **RNA, CATALYTIC**

RNA, RIBOSOMAL, 5S

GENETICS

How do linker histones mediate differential gene expression? Crane-Robinson C. **Bioessays** 1999 May;21(5):367–71 (21 ref.)

RNA, RIBOSOMAL, 16S

GENETICS

Terminal restriction fragment length polymorphism (T-RFLP): an emerging method for characterizing diversity among homologous populations of amplification products. Marsh TL. **Curr Opin Microbiol** 1999 Jun; 2(3):323–7 (33 ref.)

RNA, RIBOSOMAL, 23S

CHEMISTRY

Mutational analysis of 23S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1999; 41:157–95 (154 ref.)

Ribosomal mechanics, antibiotics, and GTP hydrolysis [comment] Porse BT, et al. **Cell** 1999 May 14;97(4):423–6 (16 ref.) Comment on: Cell 1999 May 14;97(4):491–502.

GENETICS

Mutational analysis of 23S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1999; 41:157–95 (154 ref.)

RNA RODENT VIRUSES see **RNA VIRUSES**

RNA, SATELLITE

see related
HELPER VIRUSES
SATELLITE VIRUSES

Encapsidated circular viroid-like satellite RNAs (virusoids) of plants. Symons RH, et al. **Curr Top Microbiol Immunol** 1999;239:81–105 (73 ref.)

CHEMISTRY

Structure and functional relationships of satellite RNAs of cucumber mosaic virus. García-Arenal F, et al. **Curr Top Microbiol Immunol** 1999;239:37–63 (142 ref.)

GENETICS

Large satellite RNA: molecular parasitism or molecular symbiosis. Mayo MA, et al. **Curr Top Microbiol Immunol** 1999;239:65–79 (58 ref.)

Replication, recombination, and symptom-modulation properties of the satellite RNAs of turnip crinkle virus. Simon AE. **Curr Top Microbiol Immunol** 1999;239:19–36 (49 ref.)

PHYSIOLOGY

Structure and functional relationships of satellite RNAs of cucumber mosaic virus. García-Arenal F, et al. **Curr Top Microbiol Immunol** 1999;239:37–63 (142 ref.)

RNA SEQUENCE see **BASE SEQUENCE**

RNA, SMALL NUCLEAR

CLASSIFICATION

[Small nucleolar RNA] Pieńkowska J, et al. **Postepy Biochem** 1998;44(2):102–13 (61 ref.) **(Pol)**

GENETICS

Crossing the line between RNA polymerases: transcription of human snRNA genes by RNA polymerases II and III. Henry RW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:111–20 (54 ref.)

METABOLISM

Nuclear snRNA and nuclear function (discovery of 5' cap structures in RNA). Ro-Choi TS. **Crit Rev Eukaryot Gene Expr** 1999;9(2):107–58 (304 ref.)

Guided tours: from precursor snoRNA to functional snoRNP. Weinstein LB, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):378–84 (56 ref.)

Birth of the snoRNPs: the evolution of the modification-guide snoRNAs. Lafontaine DL, et al. **Trends Biochem Sci** 1998 Oct;23(10):383–8 (50 ref.)

RNA, SMALL NUCLEAR, PRECURSORS see **RNA PRECURSORS**

RNA SPLICING

see related
RNA PRECURSORS
SPLICEOSOMES

Spliceosome assembly: the unwinding role of DEAD-box proteins. Hamm J, et al. **Curr Biol** 1998 Jul 16;8(15):R532–4 (9 ref.)

RNA splicing: more clues from spinal muscular atrophy. Matera AG. **Curr Biol** 1999 Feb 25;9(4):R140–2 (16 ref.)

RNA splicing: What has phosphorylation got to do with it? Misteli T. **Curr Biol** 1999 Mar 25;9(6):R198–200 (12 ref.)

Nuclear organization of pre-mRNA splicing factors. Sleeman JE, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):372–7 (61 ref.)

Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum. O'Neill JP, et al. **Mutat Res** 1998 Nov;411(3):179–214 (98 ref.)

GENETICS

AT–AC pre-mRNA splicing mechanisms and conservation of minor introns in voltage-gated ion channel genes. Wu Q, et al. **Mol Cell Biol** 1999 May;19(5):3225–36 (130 ref.)

PHYSIOLOGY

Flipping the switch to an active spliceosome. Murray HL, et al. **Cell** 1999 Mar 5;96(5):599–602 (14 ref.)

RNA splicing. Newman A. **Curr Biol** 1998 Dec 17–31; 8(25):R903–5 (6 ref.)

[Variable region of the Ca2+/calmodulin-dependent protein kinase II generated by alternative mRNA splicing: its role in the intracellular localization of different isoforms] Yamamoto H, et al. **Seikagaku** 1998 Nov;70(11):1349–54 (16 ref.) **(Jpn)**

RNA SPLICING, ALTERNATIVE see **ALTERNATIVE SPLICING**

RNA SYNTHESIS INHIBITORS see **NUCLEIC ACID SYNTHESIS INHIBITORS**

RNA, TRANSFER

Mutual orientation of tRNAs and interactions between the codon–anticodon duplexes within the ribosome: a stereochemical analysis. Lim VI, et al. **Biol Chem** 1998 Jul; 379(7):773–81 (44 ref.)

tRNA-mediated protein engineering. Rothschild KJ, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):64–70 (46 ref.)

In vitro engineering using synthetic tRNAs with altered anticodons including four-nucleotide anticodons. Kramer G, et al. **Methods Mol Biol** 1998;77:105–16 (22 ref.)

In vitro engineering using acyl-derivatized tRNAs. Odom OW, et al. **Methods Mol Biol** 1998;77:93–103 (14 ref.)

[A bacterial RNA that functions both as a tRNA and an mRNA] Muto A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1433–42 (30 ref.) **(Jpn)**

[Protein–RNA molecular mimicry] Nakamura Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1421–32 (45 ref.) **(Jpn)**

BIOSYNTHESIS

Molecular origins and the null hypothesis: motifs from our maker? Ellington AD. **Biol Bull** 1999 Jun;196(3):315–7; discussion 318–9 (14 ref.)

New evidence for the genomic tag hypothesis: archaeal CCA-adding enzymes and tDNA substrates. Maizels N, et al. **Biol Bull** 1999 Jun;196(3):331–3; discussion 333–4 (20 ref.)

CHEMISTRY

Dimer formation by tRNAs. Kholod NS. **Biochemistry (Mosc)** 1999 Mar;64(3):298–306 (17 ref.)

GENETICS

The trials and travels of tRNA. Wolin SL, et al. **Genes Dev** 1999 Jan 1;13(1):1–10 (76 ref.)

Transfer RNAs and pathogenicity islands. Hou YM. **Trends Biochem Sci** 1999 Aug;24(8):295–8 (27 ref.)

METABOLISM

Ribonuclease P: unity and diversity in a tRNA processing ribozyme. Frank DN, et al. **Annu Rev Biochem** 1998; 67:153–80 (157 ref.)

Transfer RNA biogenesis: A visa to leave the nucleus. Simos G, et al. **Curr Biol** 1999 Apr 8;9(7):R238–41 (12 ref.)

Transfer RNA modification: influence on translational frameshifting and metabolism. Björk GR, et al. **FEBS Lett** 1999 Jun 4;452(1–2):47–51 (41 ref.)

Dynamics of translation on the ribosome: molecular mechanics of translocation. Rodnina MV, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):317–33 (97 ref.)

Synthesis and site-specific binding of thioated tRNAs to probe ribosome–tRNA interactions. Dabrowski M, et al. **Methods Mol Biol** 1998;77:413–26 (17 ref.)

Universal rules and idiosyncratic features in tRNA identity. Giegé R, et al. **Nucleic Acids Res** 1998 Nov 15; 26(22):5017–35 (280 ref.)

PHYSIOLOGY

The genomic tag hypothesis: modern viruses as molecular fossils of ancient strategies for genomic replication, and clues regarding the origin of protein synthesis. Weiner AM, et al. **Biol Bull** 1999 Jun;196(3):327–8; discussion 329–30 (5 ref.)

Back to Camelot: defining the specific role of tRNA in protein synthesis. Weisblum B. **Trends Biochem Sci** 1999 Jun;24(6):247–50 (24 ref.)

RNA, TRANSFER, AMINO ACID-SPECIFIC

GENETICS

Selenocysteine inserting tRNAs: an overview. Commans S, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):335–51 (83 ref.)

METABOLISM

Selenocysteine inserting tRNAs: an overview. Commans S, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):335–51 (83 ref.)

RNA, TRANSFER, AMINO ACYL

BIOSYNTHESIS

Archaeal aminoacyl-tRNA synthesis: unique determinants of a universal genetic code? Ibba M, et al. **Biol Bull** 1999 Jun;196(3):335–6; discussion 336–7 (10 ref.)

tRNA recognition and evolution of determinants in seryl-tRNA synthesis. Lenhard B, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):721–9 (96 ref.)

RNA, TRANSFER, LEU

GENETICS

Maternally inherited mitochondrial cardiomyopathy associated with a C-to-T transition at nucleotide 3303 of mitochondrial DNA in the tRNA(Leu(UUR)) gene. Goldstein JD, et al. **Pediatr Dev Pathol** 1999 Jan–Feb; 2(1):78–85 (14 ref.)

[Comparison of clinical pictures of mitochondrial encephalomyopathy with tRNA(Leu(UUR)) mutation in 3243 with that in 3254] Mitsuoka T, et al. **No To Shinkei** 1998 Dec;50(12):1089–92 (8 ref.) (Eng. Abstr.) **(Jpn)**

RNA, TRANSFER, PRECURSORS see **RNA PRECURSORS**

RNA TUMOR VIRUSES see **RETROVIRIDAE**

RNA, VIRAL

RNA recombination in brome mosaic virus, a model plus strand RNA virus. Figlerowicz M, et al. **Acta Biochim Pol** 1998;45(4):847–68 (113 ref.)

HIV-1: fifteen proteins and an RNA. Frankel AD, et al. **Annu Rev Biochem** 1998;67:1–25 (134 ref.)

Encapsidated circular viroid-like satellite RNAs (virusoids) of plants. Symons RH, et al. **Curr Top Microbiol Immunol** 1999;239:81–105 (73 ref.)

ANALYSIS

In situ reverse transcriptase–polymerase chain reaction: an innovative tool for hepatitis C virus RNA detection and localisation, and for quantification of infected cells. Muratori L. **Eur J Histochem** 1998;42(2):133–6 (20 ref.)

The use of molecular technologies for the detection of enteroviral ribonucleic acid in myocarditis. Micevski V. **J Cardiovasc Nurs** 1999 Jul;13(4):78–90 (31 ref.)

[Prevalence of hepatitis G virus RNA and antibodies to HGV envelope protein (anti-E2) in patients with liver injury in Japan] Matsushita E, et al. **Nippon Rinsho** 1999 Jun;

57(6):1274–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Role of the nonstructural polyproteins in alphavirus RNA synthesis. Sawicki DL, et al. **Adv Exp Med Biol** 1998; 440:187–98 (58 ref.)

Replication of tobacco mosaic virus RNA. Buck KW. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):613–27 (145 ref.)

A core promoter hairpin is essential for subgenomic RNA synthesis in alfalfa mosaic alfamovirus and is conserved in other Bromoviridae. Jaspars EM. **Virus Genes** 1998; 17(3):233–42 (62 ref.)

Paradoxes of the replication of picornaviral genomes. Agol VI, et al. **Virus Res** 1999 Aug;62(2):129–47 (170 ref.)

BLOOD

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. Murray JS, et al. **AIDS** 1999 May 7;13(7):797–804 (24 ref.)

Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Robertson BH, et al. **Biologicals** 1998 Jun;26(2):95–9 (26 ref.)

Measurement of plasma HIV viral load--clinical applications. Churchill D, et al. **J Infect** 1999 May;38(3):147–50 (38 ref.)

HIV-1 viral load testing. Clarke JR, et al. **J Infect** 1999 May; 38(3):141–6 (32 ref.)

Genomic screening for blood-borne viruses in transfusion settings. Lee HH, et al. **Vox Sang** 1998;74 Suppl 2:119–23 (22 ref.)

CHEMISTRY

Adaptive recognition in RNA complexes with peptides and protein modules. Patel DJ. **Curr Opin Struct Biol** 1999 Feb; 9(1):74–87 (59 ref.)

GENETICS

RNA recognition and regulation of HIV-1 gene expression by viral factor Tat. Naryshkin NA, et al. **Biochemistry (Mosc)** 1998 May;63(5):489–503 (98 ref.)

Defective and defective interfering RNAs of monopartite plus-strand RNA plant viruses. White KA, et al. **Curr Top Microbiol Immunol** 1999;239:1–17 (66 ref.)

Processive antitermination. Weisberg RA, et al. **J Bacteriol** 1999 Jan;181(2):359–67 (105 ref.)

Viral RNA and evolved mutational robustness. Wagner A, et al. **J Exp Zool** 1999 Aug 15;285(2):119–27 (54 ref.)

Precise packaging of the three genomic segments of the double-stranded-RNA bacteriophage phi6. Mindich L. **Microbiol Mol Biol Rev** 1999 Mar;63(1):149–60 (88 ref.)

Reverse genetics of negative-strand RNA viruses: closing the circle [comment] Pekosz A, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8804–6 (41 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):9345–50.

[Viral hepatitis: molecular diagnosis] Blum HE. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The arterivirus replicase. The road from RNA to protein(s), and back again. Snijder EJ. **Adv Exp Med Biol** 1998; 440:97–108 (54 ref.)

Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Rana TM, et al. **Arch Biochem Biophys** 1999 May 15;365(2):175–85 (99 ref.)

RNA recognition and regulation of HIV-1 gene expression by viral factor Tat. Naryshkin NA, et al. **Biochemistry (Mosc)** 1998 May;63(5):489–503 (98 ref.)

Adaptive recognition in RNA complexes with peptides and protein modules. Patel DJ. **Curr Opin Struct Biol** 1999 Feb; 9(1):74–87 (59 ref.)

Relationships between proteasomes and viral gene products. Jarrousse AS, et al. **Mol Biol Rep** 1999 Apr;26(1–2):113–7 (54 ref.)

Retroviruses as model systems for the study of nuclear RNA export pathways. Cullen BR. **Virology** 1998 Sep 30; 249(2):203–10 (39 ref.)

PHYSIOLOGY

Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis. Das S, et al. **Front Biosci** 1998 Dec 1;3:D1241–52 (61 ref.)

Virus reconstitution and the proof of the existence of genomic RNA. Fraenkel-Conrat H, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):583–6 (24 ref.)

ULTRASTRUCTURE

Elucidation of the genome organization of tobacco mosaic virus. Zaitlin M. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):587–91 (40 ref.)

RNA VIRUS INFECTIONS

COMPLICATIONS

[Exanthema in childhood. I: Exanthema induced by viral infections] Fölster-Holst R, et al. **Hautarzt** 1999 Jul; 50(7):515–31 (69 ref.) **(Ger)**

IMMUNOLOGY

[Dysfunction of host defence systems caused by virus infection] Fujii N, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):8–18 (35 ref.) **(Jpn)**

TRANSMISSION

Zoonoses and haemorrhagic fever. Mahy BW. **Dev Biol Stand** 1998;93:31–6 (9 ref.)

VIROLOGY

Quasispecies and the implications for virus persistence and escape. Domingo E. **Clin Diagn Virol** 1998 Jul 15; 10(2–3):97–101 (34 ref.)

RNA VIRUSES

Population dynamics in the evolution of RNA viruses. Domingo E, et al. **Adv Exp Med Biol** 1998;440:721–7 (33 ref.)

[Lassa fever: its virological and clinical aspects] Hirabayashi Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):80–4 (23 ref.) **(Jpn)**

ENZYMOLOGY

Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. O'Reilly EK, et al. **Virology** 1998 Dec 20;252(2):287–303 (80 ref.)

GENETICS

Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Conzelmann KK. **Annu Rev Genet** 1998;32:123–62 (186 ref.)

Quasispecies and the implications for virus persistence and escape. Domingo E. **Clin Diagn Virol** 1998 Jul 15; 10(2–3):97–101 (34 ref.)

Defective and defective interfering RNAs of monopartite plus-strand RNA plant viruses. White KA, et al. **Curr Top Microbiol Immunol** 1999;239:1–17 (66 ref.)

Viral RNA and evolved mutational robustness. Wagner A, et al. **J Exp Zool** 1999 Aug 15;285(2):119–27 (54 ref.)

Recombination in RNA viruses and in virus-resistant transgenic plants. Aaziz R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1339–46 (85 ref.)

Virus maturation by budding. Garoff H, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1171–90 (313 ref.)

RNA virus vectors: where are we and where do we need to go? [comment] Palese P. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12750–2 (39 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):12989–94.

Reverse genetics of negative-strand RNA viruses: closing the circle [comment] Pekosz A, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8804–6 (41 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):9345–50.

Getting a handle on RNA virus recombination. Miller WA, et al. **Trends Microbiol** 1998 Nov;6(11):421–3 (16 ref.)

GROWTH & DEVELOPMENT

Virus maturation by budding. Garoff H, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1171–90 (313 ref.)

PHYSIOLOGY

Quasispecies structure and persistence of RNA viruses. Domingo E, et al. **Emerg Infect Dis** 1998 Oct–Dec; 4(4):521–7 (44 ref.)

[Dysfunction of host defence systems caused by virus infection] Fujii N, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):8–18 (35 ref.) **(Jpn)**

RNASE see **RIBONUCLEASES**

RNASE A see **RIBONUCLEASE, PANCREATIC**

RO 15-1788 see **FLUMAZENIL**

ROACH (FISH) see **CYPRINIDAE**

ROBINS see **SONGBIRDS**

ROBOTICS

A sensing system for odor plumes. Nakamoto T, et al. **Anal Chem** 1999 Aug 1;71(15):531A–537A (20 ref.)

Robotics and the future of laparoscopy. Semm K. **JSLS** 1999 Jan–Mar;3(1):87–8 (0 ref.)

Video-assisted and robotic mitral valve surgery: toward an endoscopic surgery. Chitwood WR Jr. **Semin Thorac Cardiovasc Surg** 1999 Jul;11(3):194–205 (39 ref.)

[The Virtual University applied to telesurgery: from tele-education to tele-manipulation] Marescaux J, et al. **Bull Acad Natl Med** 1999;183(3):509–21; discussion 521–2 (10 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

[Progress in molecular medicine: "laser capture microdissection" (see comments)] Bornstein SR, et al. **Med Klin** 1998 Dec 15;93(12):739–43 (29 ref.) (Eng. Abstr.) Comment in: Med Klin 1998 Dec 15;93(12):738. **(Ger)**

METHODS

Evolutionary body building: adaptive physical designs for robots. Funes P, et al. **Artif Life** 1998 Fall;4(4):337–57 (40 ref.)

Online evolution for a self-adapting robotic navigation system using evolvable hardware. Keymeulen D, et al. **Artif Life** 1998 Fall;4(4):359–93 (54 ref.)

Coevolving predator and prey robots: do "arms races" arise in artificial evolution? Nolfi S, et al. **Artif Life** 1998 Fall; 4(4):311–35 (22 ref.)

Biorobotic approaches to the study of motor systems. Beer RD, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):777–82 (54 ref.)

TRENDS

[Neuronavigation. Methods and prospects] Wirtz CR, et al. **Nervenarzt** 1998 Dec;69(12):1029–36 (29 ref.) (Eng. Abstr.) **(Ger)**

ROC ANALYSIS see **ROC CURVE**

ROC CURVE

Analysis of clustered data in receiver operating characteristic studies. Beam CA. **Stat Methods Med Res** 1998 Dec; 7(4):324–36 (30 ref.)

ROCHALIMAEA see **BARTONELLA**

ROCHALIMAEA HENSELAE see **BARTONELLA HENSELAE**

ROCHALIMAEA INFECTIONS see **BARTONELLA INFECTIONS**

ROCHALIMAEA QUINTANA see **BARTONELLA QUINTANA**

ROCKY MOUNTAIN SPOTTED FEVER

Rocky mountain spotted fever. Thorner AR, et al. **Clin Infect Dis** 1998 Dec;27(6):1353–9; quiz 1360 (50 ref.)

[Rocky Mountain spotted fever] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):260–3 (14 ref.) **(Jpn)**

BLOOD

Hemostatic changes in Rocky Mountain spotted fever and Mediterranean spotted fever. Elghetany MT, et al. **Am J Clin Pathol** 1999 Aug;112(2):159–68 (91 ref.)

DIAGNOSIS

Life-threatening rashes: dermatologic signs of four infectious diseases. Drage LA. **Mayo Clin Proc** 1999 Jan;74(1):68–72 (10 ref.)

ROD-CONE DYSTROPHY see **RETINITIS PIGMENTOSA**

ROD MYOPATHY see **NEMALINE MYOPATHY**

ROD OUTER SEGMENTS

PHYSIOLOGY

Protein kinase C and IP3 in photoresponses of functionally intact rod outer segments: constraints about their role. Jindrová H, et al. **Physiol Res** 1998;47(4):285–90 (39 ref.)

ROD PHOTORECEPTORS see **RODS (RETINA)**

RODENT DISEASES

DIAGNOSIS

[Dental problems in rabbits and rodents. I. Anatomy, physiology, symptomatology, diagnosis] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1;123(23):698–706 (30 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Immunology and biochemistry of Hymenolepis diminuta. Andreassen J, et al. **Adv Parasitol** 1999;42:223–75 (250 ref.)

MICROBIOLOGY

Pathology, diagnosis and epidemiology of the rodent Helicobacter infection. Zenner L. **Comp Immunol Microbiol Infect Dis** 1999 Jan;22(1):41–61 (64 ref.)

Rodent quarantine programs: purpose, principles, and

RODENT DISEASES

practice. Rehg JE, et al. **Lab Anim Sci** 1998 Oct; 48(5):438–47 (54 ref.)

PARASITOLOGY

Advances in the life cycle of Toxoplasma gondii. Dubey JP. **Int J Parasitol** 1998 Jul;28(7):1019–24 (38 ref.)

THERAPY

[Dental problems in rabbits and rodents. II. Dental treatment] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1; 123(23):707–13 (30 ref.) (Eng. Abstr.) **(Dut)**

VIROLOGY

Genetics of susceptibility to Theiler's virus infection. Brahic M, et al. **Bioessays** 1998 Aug;20(8):627–33 (56 ref.)

RODENT ULCER see **CARCINOMA, BASAL CELL**

RODENTIA

Making the most of rodent tumour systems in cancer drug discovery. Bibby MC. **Br J Cancer** 1999 Apr; 79(11–12):1633–40 (86 ref.)

Serological evidence of natural infection of wild rodents (Rattus spp and Tupaia glis) with rickettsiae in Malaysia. Tay ST, et al.
Southeast Asian J Trop Med Public Health 1998 Sep; 29(3):560–2 (10 ref.)

ANATOMY & HISTOLOGY

Conservation biology: genes are not enough. Lehman N. **Curr Biol** 1998 Oct 8;8(20):R722–4 (9 ref.)

EMBRYOLOGY

Gene transfer to the rodent embryo by retroviral vectors. Pavlath GK, et al. **Methods Mol Biol** 1999;97:519–38 (19 ref.)

GENETICS

Conservation biology: genes are not enough. Lehman N. **Curr Biol** 1998 Oct 8;8(20):R722–4 (9 ref.)

PHYSIOLOGY

Experience-dependent changes in vibrissae evoked responses in the rodent barrel cortex. Glazewski S.
Acta Neurobiol Exp (Warsz) 1998;58(4):309–20 (70 ref.)

The associative parietal cortex and spatial processing in rodents. Thinus-Blanc C, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):179–83 (45 ref.)

Photic entrainment of circadian rhythms in rodents. Rea MA. **Chronobiol Int** 1998 Sep;15(5):395–423 (227 ref.)

Energy expenditure and efficiency of energy use in rodents: desert and non-desert species. Degen AA.
J Basic Clin Physiol Pharmacol 1998;9(1):29–49 (39 ref.)

Macronutrient-specific dietary selection in rodents and its neural bases. Thibault L, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):457–528 (151 ref.)

[The role of behavioral hyperactivation in the formation of anxiety in rodents] Kaluev AV. **Zh Obshch Biol** 1999 Mar–Apr;60(2):207–12 (32 ref.) (Eng. Abstr.) **(Rus)**

RODS (RETINA)

CYTOLOGY

Birth and death in the retina: more related than we thought? [comment] Zack DJ. **Neuron** 1999 Jul;23(3):411–2 (10 ref.) Comment on: Neuron 1999 Jul;23(3):549–57.

METABOLISM

Control of rhodopsin activity in vision. Baylor DA, et al. **Eye** 1998;12 (Pt 3b):521–5 (22 ref.)

Post-Golgi trafficking of rhodopsin in retinal photoreceptors. Deretic D. **Eye** 1998;12 (Pt 3b):526–30 (40 ref.)

The rod photoreceptor ATP-binding cassette transporter gene, ABCR, and retinal disease: from monogenic to multifactorial. Shroyer NF, et al. **Vision Res** 1999 Jul; 39(15):2537–44 (52 ref.)

PHYSIOLOGY

Molecular basis of dark adaptation in rod photoreceptors. Leibrock CS, et al. **Eye** 1998;12 (Pt 3b):511–20 (36 ref.)

Photoreceptor "retinoid pumps" in health and disease. Bok D. **Neuron** 1999 Jul;23(3):412–4 (11 ref.)

RODS AND CONES see **PHOTORECEPTORS, VERTEBRATE**

ROENTGENOGRAPHY see **RADIOGRAPHY**

ROHYPNOL see **FLUNITRAZEPAM**

ROLE

Comprehending role conflicts in the coaching of children, adolescents, and young adults. Transference, countertransference, and achievement by proxy distortion paradigms. Ogilvie BC, et al.
Child Adolesc Psychiatr Clin N Am 1998 Oct;7(4):879–90 (31 ref.)

The authority of the clinical ethicist. Casarett DJ, et al.
Hastings Cent Rep 1998 Nov–Dec;28(6):6–11 (19 ref.)

The promise of a multiple roles paradigm for women's health research [editorial] Repetti RL. **Womens Health** 1998 Winter;4(4):273–80 (32 ref.)

ROLE CONCEPT see **ROLE**

ROMALEIDAE see **GRASSHOPPERS**

ROMANO-WARD SYNDROME see **LONG QT SYNDROME**

ROOT CANAL see **DENTAL PULP CAVITY**

ROOT CANAL FILLING MATERIALS

Considerations in the selection of a root-end filling material. Johnson BR.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Apr;87(4):398–404 (40 ref.)

THERAPEUTIC USE

Mineral trioxide aggregate: a new material for endodontics. Schwartz RS, et al. **J Am Dent Assoc** 1999 Jul; 130(7):967–75 (33 ref.)

ROOT CANAL SEALANTS see **ROOT CANAL FILLING MATERIALS**

ROOT CANAL THERAPY

Anesthesia for endodontic practice. Saxen MA, et al.
Dent Clin North Am 1999 Apr;43(2):247–61, vi (22 ref.)

METHODS

Mineral trioxide aggregate: a new material for endodontics. Schwartz RS, et al. **J Am Dent Assoc** 1999 Jul; 130(7):967–75 (33 ref.)

Pulp therapy in the primary dentition. Razi RS.
N Y State Dent J 1999 Mar;65(3):18–22 (30 ref.)

VETERINARY

Newer endodontic therapeutic treatment. Anthony JM.
Vet Clin North Am Small Anim Pract 1998 Sep; 28(5):1237–60 (36 ref.)

Endodontic therapy in the veterinary patient. Lyon KF.
Vet Clin North Am Small Anim Pract 1998 Sep; 28(5):1203–36, vii (100 ref.)

RORQUALS see **WHALES**

RORSCHACH TEST

STANDARDS

Methodological issues in evaluating Rorschach validity: a comment on Burns and Viglione (1996), Weiner (1996), and Ganellen (1996). Wood JM, et al. **Assessment** 1999 Jun; 6(2):115–29 (79 ref.)

ROSA see **ROSALES**

ROSACEA see **ACNE ROSACEA**

ROSAI-DORFMAN DISEASE see **HISTIOCYTOSIS, SINUS**

ROSALES

CHEMISTRY

Stilbene compounds: from the grapevine to wine. Bavaresco L, et al. **Drugs Exp Clin Res** 1999;25(2–3):57–63 (56 ref.)

Advances in the study of secondary metabolites occurring in grapes and wines. Di Stefano R.
Drugs Exp Clin Res 1999;25(2–3):53–6 (6 ref.)

VIROLOGY

Some results of 50 years of research on the resistance to plum pox virus. Kegler H, et al. **Acta Virol** 1998 Sep; 42(4):200–15 (270 ref.)

ROSANILINE DYES

ADVERSE EFFECTS

Glenohumeral osteoarthritis following a "color test" during rotator cuff repair. A case report and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998; 57(4):216–8 (12 ref.)

ROSEMARY see **LAMIACEAE**

ROSENTHAL SYNDROME see **FACTOR XI DEFICIENCY**

ROSEOLA INFANTUM see **EXANTHEMA SUBITUM**

ROSIDAE see **ROSALES**

ROTATION

see related
CENTRIFUGATION
GRAVITY, ALTERED

[On the role of technogenic rotating electrical fields in inner and outer ecologic relations (literature review)] Belkin AD.
Med Tr Prom Ekol 1999;(6):27–30 (17 ref.) **(Rus)**

ROTATIONAL ATHERECTOMY see **ATHERECTOMY, CORONARY**

ROTATOR CUFF

see related
SHOULDER IMPINGEMENT SYNDROME

INJURIES

Glenohumeral osteoarthritis following a "color test" during rotator cuff repair. A case report and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998; 57(4):216–8 (12 ref.)

Partial-thickness tears of the rotator cuff: evaluation and management. McConville OR, et al.
J Am Acad Orthop Surg 1999 Jan;7(1):32–43 (37 ref.)

The rotator cuff-deficient arthritic shoulder: diagnosis and surgical management. Zeman CA, et al.
J Am Acad Orthop Surg 1998 Nov–Dec;6(6):337–48 (34 ref.)

Rotator cuff tear arthropathy. Jensen KL, et al.
J Bone Joint Surg Am 1999 Sep;81(9):1312–24 (101 ref.)

Isolated and combined lesions of the axillary nerve. A review of 146 cases. Bonnard C, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):212–7 (25 ref.)

MR imaging of rotator interval, long biceps, and associated injuries in the overhead-throwing athlete. Ho CP.
Magn Reson Imaging Clin N Am 1999 Feb;7(1):23–37 (18 ref.)

INNERVATION

Isolated and combined lesions of the axillary nerve. A review of 146 cases. Bonnard C, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):212–7 (25 ref.)

SURGERY

Glenohumeral osteoarthritis following a "color test" during rotator cuff repair. A case report and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998; 57(4):216–8 (12 ref.)

ULTRASONOGRAPHY

Sonography of the rotator cuff and biceps tendon: technique, normal anatomy, and pathology. Thain LM, et al.
J Clin Ultrasound 1999 Oct;27(8):446–58 (8 ref.)

ROTAVIRUS

[Genome and proteins of rotavirus] Taniguchi K. **Uirusu** 1998 Dec;48(2):137–51 (63 ref.) **(Jpn)**

CLASSIFICATION

Seasonality and diversity of Group A rotaviruses in Europe. Koopmans M, et al. **Acta Paediatr Suppl** 1999 Jan; 88(426):14–9 (37 ref.)

IMMUNOLOGY

First rotavirus vaccine licensed: is there really a need? Glass RI, et al. **Acta Paediatr Suppl** 1999 Jan;88(426):2–8 (47 ref.)

Rotavirus vaccine studies in Europe. Vesikari T.
Acta Paediatr Suppl 1999 Jan;88(426):9–13 (45 ref.)

Rotavirus vaccines: development and use for the prevention of diarrhoeal disease. Vesikari T. **Ann Med** 1999 Feb; 31(1):79–85 (51 ref.)

Tetravalent rotavirus vaccine. Wandstrat TL, et al.
Ann Pharmacother 1999 Jul–Aug;33(7–8):833–9 (26 ref.)

The rotavirus vaccine. Offit PA, et al. **Curr Opin Pediatr** 1999 Feb;11(1):9–13 (39 ref.)

The rotavirus vaccine. Offit PA. **J Clin Virol** 1998 Dec; 11(3):155–9 (31 ref.)

Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Bresee JS, et al. **Vaccine** 1999 May 4; 17(18):2207–22 (148 ref.)

The current status of the rotavirus vaccine. Jacobson RM. **Vaccine** 1999 Mar 26;17(13–14):1690–9 (150 ref.)

[Rotavirus vaccines] Gault E, et al. **Arch Pediatr** 1999;6 Suppl 3:639s–642s (15 ref.) **(Fre)**

[Rotavirus vaccines as a model vaccine against enteric viral infections] Nakagomi O, et al. **Uirusu** 1998 Dec; 48(2):189–200 (68 ref.) **(Jpn)**

[Vaccine against rotavirus] Pérez-Trallero E, et al.
Enferm Infecc Microbiol Clin 1998 Aug–Sep;16(7):334–8 (52 ref.) (Eng. Abstr.) **(Spa)**

ROTAVIRUS INFECTIONS

Rotavirus diarrhea. Belhorn T. **Curr Probl Pediatr** 1999 Aug; 29(7):198–207 (97 ref.)

[Rotavirus infection] Tajima T.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):34–7 (14 ref.)

(Jpn)
[Rotavirus vaccines as a model vaccine against enteric viral infections] Nakagomi O, et al. **Uirusu** 1998 Dec; 48(2):189–200 (68 ref.) (Jpn)

COMPLICATIONS

Encephalopathy associated with haemophagocytic lymphohistiocytosis following rotavirus infection. Takahashi S, et al. **Eur J Pediatr** 1999 Feb;158(2):133–7 (23 ref.)

DIAGNOSIS

Acute gastroenteritis in children. Sturmberg JP, et al. **Aust Fam Physician** 1999 Apr;28(4):329–32 (8 ref.)

DRUG THERAPY

[Progress in the study on the treatment of rotaviral enteritis with traditional Chinese medicine] Xu WC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Aug; 17(8):511–2 (17 ref.) (Chi)

EPIDEMIOLOGY

Seasonality and diversity of Group A rotaviruses in Europe. Koopmans M, et al. **Acta Paediatr Suppl** 1999 Jan; 88(426):14–9 (37 ref.)

Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Cunliffe NA, et al. **Bull World Health Organ** 1998;76(5):525–37 (117 ref.)

IMMUNOLOGY

The immunology of rotavirus infection in the mouse. Rosé J, et al. **Adv Virus Res** 1998;51:203–35 (82 ref.)

Immunity to rotavirus infection in mice. Franco MA, et al. **J Infect Dis** 1999 May;179 Suppl 3:S466–9 (20 ref.)

[Rotavirus vaccines] Gault E, et al. **Arch Pediatr** 1999;6 Suppl 3:639s–642s (15 ref.) (Fre)

PREVENTION & CONTROL

First rotavirus vaccine licensed: is there really a need? Glass RI, et al. **Acta Paediatr Suppl** 1999 Jan;88(426):2–8 (47 ref.)

Rotavirus vaccines: development and use for the prevention of diarrhoeal disease. Vesikari T. **Ann Med** 1999 Feb; 31(1):79–85 (51 ref.)

Tetravalent rotavirus vaccine. Wandstrat TL, et al. **Ann Pharmacother** 1999 Jul–Aug;33(7–8):833–9 (26 ref.)

Vaccination against enteric pathogens: from science to vaccine trials. Lindberg AA. **Curr Opin Microbiol** 1998 Feb;1(1):116–24 (35 ref.)

The rotavirus vaccine. Offit PA, et al. **Curr Opin Pediatr** 1999 Feb;11(1):9–13 (39 ref.)

Rotavirus. Parashar UD, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):561–70 (52 ref.)

The rotavirus vaccine. Offit PA. **J Clin Virol** 1998 Dec; 11(3):155–9 (31 ref.)

[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects] Ivanoff B, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):340–50 (54 ref.) (Eng. Abstr.) (Fre)

[Rotavirus vaccines] Gault E, et al. **Arch Pediatr** 1999;6 Suppl 3:639s–642s (15 ref.) (Fre)

[Vaccine against rotavirus] Pérez-Trallero E, et al. **Enferm Infecc Microbiol Clin** 1998 Aug–Sep;16(7):334–8 (52 ref.) (Eng. Abstr.) (Spa)

[The first rotavirus vaccine approved in the USA and Europe] Svensson L, et al. **Lakartidningen** 1999 Jun 30; 96(26–27):3158–60 (18 ref.) (Eng. Abstr.) (Swe)

THERAPY

Acute gastroenteritis in children. Sturmberg JP, et al. **Aust Fam Physician** 1999 Apr;28(4):329–32 (8 ref.)

VETERINARY

Enteric viral infections of pigs and strategies for induction of mucosal immunity. Saif LJ. **Adv Vet Med** 1999;41:429–46 (54 ref.)

ROTHMUND-THOMSON SYNDROME see **POIKILODERMA CONGENITALE**

ROTOR SYNDROME see **HYPERBILIRUBINEMIA, HEREDITARY**

ROUGET CELLS see **PERICYTES**

ROUGH-TOOTHED DOLPHIN see **DOLPHINS**

ROUGHAGE see **DIETARY FIBER**

ROUND WINDOW

INJURIES

[Round window membrane defect in divers] Böhm F, et al. **Laryngorhinootologie** 1999 Apr;78(4):169–75 (50 ref.) (Eng. Abstr.) (Ger)

ROUS SARCOMA VIRUS see **SARCOMA VIRUSES, AVIAN**

ROUSSY-LEVY SYNDROME see **CHARCOT-MARIE DISEASE**

ROUTINE DIAGNOSTIC TESTS see **DIAGNOSTIC TESTS, ROUTINE**

ROUX-EN-Y ANASTOMOSIS see **ANASTOMOSIS, ROUX-EN-Y**

ROUX-EN-Y DIVERSION see **ANASTOMOSIS, ROUX-EN-Y**

ROUX-EN-Y LOOP see **ANASTOMOSIS, ROUX-EN-Y**

ROXITHROMYCIN

THERAPEUTIC USE

Antibiotics for acute coronary syndromes: are we ready for megatrials? [editorial; comment] Maseri A. **Eur Heart J** 1999 Jan;20(2):89–92 (22 ref.) Comment on: Eur Heart J 1999 Jan;20(2):121–7.

ROYAL FREE DISEASE see **FATIGUE SYNDROME, CHRONIC**

RRNA GENES see **GENES, RRNA**

RRNA OPERON

see related
GENES, RRNA

RRNA PROMOTER see **PROMOTER REGIONS (GENETICS)**

RSH SYNDROME see **SMITH-LEMLI-OPITZ SYNDROME**

RT-PCR see **REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION**

RT7 ANTIGENS see **ANTIGENS, CD45**

RU-486 see **MIFEPRISTONE**

RUBBER ALLERGY see **LATEX ALLERGY**

RUBBER SILICONE see **SILICONE ELASTOMERS**

RUBBER TREE see **EUPHORBIACEAE**

RUBEFACIENTS see **IRRITANTS**

RUBELLA

Rubella and rubeola. Rosa C. **Semin Perinatol** 1998 Aug; 22(4):318–22 (14 ref.)

[Rubella and measles] Kurashige T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):169–72 (15 ref.) (Jpn)

[Acute rubella encephalitis] Matsui M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):31–3 (10 ref.) (Jpn)

[Progressive rubella panencephalitis] Matsui M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):34–7 (15 ref.) (Jpn)

CONGENITAL

Congenital rubella syndrome. How can we do better? Bar-Oz B, et al. **Can Fam Physician** 1999 Aug;45:1865–9 (18 ref.)

PREVENTION & CONTROL

Congenital rubella syndrome. How can we do better? Bar-Oz B, et al. **Can Fam Physician** 1999 Aug;45:1865–9 (18 ref.)

RUBELLA SYNDROME, CONGENITAL

[TORCH syndrome] Hidaka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):85–8 (7 ref.) (Jpn)

[Congenital rubella syndrome] Kadoya R, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):93–6 (15 ref.) (Jpn)

EPIDEMIOLOGY

Rational use of rubella vaccine for prevention of congenital rubella syndrome in the Americas. Hinman AR, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):156–60 (36 ref.)

RUBELLA VACCINE

Immunisation and type 1 diabetes mellitus: is there a link? Hiltunen M, et al. **Drug Saf** 1999 Mar;20(3):207–12 (36 ref.)

ADMINISTRATION & DOSAGE

Rational use of rubella vaccine for prevention of congenital rubella syndrome in the Americas. Hinman AR, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):156–60 (36 ref.)

RUBEOLA see **MEASLES**

RUBIACEAE

Uncaria tomentosa (Willd.) D.C.: cat's claw, uña de gato, or savéntaro. Reinhard KH. **J Altern Complement Med** 1999 Apr;5(2):143–51 (36 ref.)

RUBIDOMYCIN see **DAUNORUBICIN**

RUBOMYCIN see **DAUNORUBICIN**

RUFFINI'S CORPUSCLES see **MECHANORECEPTORS**

RUGBY see **FOOTBALL**

RUMEN

METABOLISM

Modeling ruminal digestibility of carbohydrates and microbial protein flow to the duodenum. Firkins JL, et al. **J Dairy Sci** 1998 Dec;81(12):3350–69 (145 ref.)

Effects of rumen-undegradable protein on dairy cow performance: a 12-year literature review. Santos FA, et al. **J Dairy Sci** 1998 Dec;81(12):3182–213 (128 ref.)

MICROBIOLOGY

Manipulation of ruminal fermentation with organic acids: a review. Martin SA. **J Anim Sci** 1998 Dec;76(12):3123–32 (50 ref.)

Manipulating ruminal fermentation: a microbial ecological perspective. Weimer PJ. **J Anim Sci** 1998 Dec; 76(12):3114–22 (57 ref.)

Different mathematical approaches to estimating microbial protein supply in ruminants. Dijkstra J, et al. **J Dairy Sci** 1998 Dec;81(12):3370–84 (89 ref.)

PHYSIOLOGY

Standardization of in situ techniques for ruminant feedstuff evaluation. Vanzant ES, et al. **J Anim Sci** 1998 Oct; 76(10):2717–29 (68 ref.)

RUMINANTIA see **RUMINANTS**

RUMINANTS

Prospects for vaccines of helminth parasites of grazing ruminants. Smith WD. **Int J Parasitol** 1999 Jan;29(1):17–24 (54 ref.)

Safe handling of large animals. Grandin T. **Occup Med** 1999 Apr–Jun;14(2):195–212 (55 ref.)

GENETICS

Monomorphism and polymorphism at Mhc DRB loci in domestic and wild ruminants. Mikko S, et al. **Immunol Rev** 1999 Feb;167:169–78 (60 ref.)

IMMUNOLOGY

Monomorphism and polymorphism at Mhc DRB loci in domestic and wild ruminants. Mikko S, et al. **Immunol Rev** 1999 Feb;167:169–78 (60 ref.)

METABOLISM

Splanchnic tissue energy use in ruminants that consume forage-based diets ad libitum. Goetsch AL. **J Anim Sci** 1998 Oct;76(10):2737–46 (92 ref.)

Manipulation of ruminal fermentation with organic acids: a review. Martin SA. **J Anim Sci** 1998 Dec;76(12):3123–32 (50 ref.)

Manipulating ruminal fermentation: a microbial ecological perspective. Weimer PJ. **J Anim Sci** 1998 Dec; 76(12):3114–22 (57 ref.)

Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. Bequette BJ, et al. **J Dairy Sci** 1998 Sep;81(9):2540–59 (116 ref.)

Different mathematical approaches to estimating microbial protein supply in ruminants. Dijkstra J, et al. **J Dairy Sci** 1998 Dec;81(12):3370–84 (89 ref.)

PARASITOLOGY

The role of epidemiological knowledge and grazing management for helminth control in small ruminants. Barger IA. **Int J Parasitol** 1999 Jan;29(1):41–7; discussion 49–50 (24 ref.)

Anthelmintic resistance revisited: under-dosing, chemoprophylactic strategies, and mating probabilities. Smith G, et al. **Int J Parasitol** 1999 Jan;29(1):77–91; discussion 93–4 (41 ref.)

International approaches to the concept of integrated control of nematode parasites of livestock. Waller PJ. **Int J Parasitol** 1999 Jan;29(1):155–64; discussion 183–4 (36 ref.)

PHYSIOLOGY

Standardization of in situ techniques for ruminant feedstuff evaluation. Vanzant ES, et al. **J Anim Sci** 1998 Oct; 76(10):2717–29 (68 ref.)

Locoweeds: effects on reproduction in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):53–62 (49 ref.)

Intestinal absorption, blood transport and hepatic and muscle

RUMINANTS

metabolism of fatty acids in preruminant and ruminant animals. Hocquette JF, et al. **Reprod Nutr Dev** 1999 Jan-Feb;39(1):27-48 (122 ref.)

[The role of the forestomachs in the adaptation of the alimentary function in ruminants] Chalyshev AV. **Usp Fiziol Nauk** 1998 Jul-Sep;29(3):92-104 (92 ref.) (Eng. Abstr.) **(Rus)**

RUMINATION DISORDERS see **FEEDING AND EATING DISORDERS OF CHILDHOOD**

RUNAWAY BEHAVIOR

Missing children. Lewit EM, et al. **Future Child** 1998 Summer-Fall;8(2):141-51 (35 ref.)

RUNNING

Aetiology of running-related gastrointestinal dysfunction. How far is the finishing line? Gil SM, et al. **Sports Med** 1998 Dec;26(6):365-78 (163 ref.)

Pronation in runners. Implications for injuries. Hintermann B, et al. **Sports Med** 1998 Sep;26(3):169-76 (65 ref.)

INJURIES

MR imaging of stress reactions, muscle injuries, and other overuse injuries in runners. Bergman AG, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):151-74, ix (114 ref.)

PHYSIOLOGY

Markers of excessive exercise. McKenzie DC. **Can J Appl Physiol** 1999 Feb;24(1):66-73 (36 ref.)

The effects of endurance training on muscle fibre types and enzyme activities. Taylor AW, et al. **Can J Appl Physiol** 1999 Feb;24(1):41-53 (76 ref.)

The coordinated movement of the lumbo-pelvic-hip complex during running: a literature review. Schache AG, et al. **Gait Posture** 1999 Sep;10(1):30-47 (138 ref.)

Use of heart rate monitors by endurance athletes: lessons from triathletes. O'Toole ML, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):181-7 (21 ref.)

RUNT DISEASE see **GRAFT VS HOST DISEASE**

RURAL HEALTH

see related
AGRICULTURAL WORKERS' DISEASES

Clergy perspectives and practices regarding intimate violence: a rural view. Strickland GA, et al. **J Rural Health** 1998 Fall;14(4):305-11 (29 ref.)

STANDARDS

Old, female, and rural. Introduction [editorial] McCulloch BJ. **J Women Aging** 1998;10(4):1-5 (15 ref.)

STATISTICS & NUMERICAL DATA

Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison [see comments] Ng'ang'a LW, et al. **Thorax** 1998 Nov;53(11):919-26 (30 ref.) Comment in: Thorax 1998 Nov;53(11):909-10.

RURAL HEALTH SERVICES

[Primary health care in Thailand with community participation special reference to Japanese assistance] Rakue Y, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun; 45(6):578-85 (11 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Rural health prepayment schemes in China: towards a more active role for government. Bloom G, et al. **Soc Sci Med** 1999 Apr;48(7):951-60 (36 ref.)

ORGANIZATION & ADMINISTRATION

Psychiatric treatment of children and adolescents in rural communities. Myths and realities. Cook AD, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):673-90 (45 ref.)

Health status and access to care among rural minorities. Mueller KJ, et al. **J Health Care Poor Underserved** 1999 May;10(2):230-49 (193 ref.)

Potential effects of managed care organizations in rural communities: a framework. Christianson J. **J Rural Health** 1998 Summer;14(3):169-79 (2 ref.)

Research on managed care organizations in rural communities. Krein S, et al. **J Rural Health** 1998 Summer; 14(3):180-99 (84 ref.)

STATISTICS & NUMERICAL DATA

Dr B. C. Dasgupta Memorial Oration. Rural health services and human resources development in India--an overview. Dutta PK. **Indian J Public Health** 1998 Jul-Sep; 42(3):66-70, 87 (7 ref.)

TRENDS

Do targeted efforts for the rural underserved help kill comprehensive reform? Taylor DH Jr. **J Rural Health** 1999 Winter;15(1):55-60 (27 ref.)

RURAL HOSPITALS see **HOSPITALS, RURAL**

RURAL POPULATION

Aspects of dental health in adult rural population in Poland. Szymańska J, et al. **Ann Agric Environ Med** 1998;5(2):103-8 (32 ref.)

Diet & nutrition situation in rural India. Vijayaraghavan K, et al. **Indian J Med Res** 1998 Nov;108:243-53 (19 ref.)

Epidemiology of obesity: an epidemiological study in rural communities of Hokkaido, Japan. Saitoh S, et al. **Intern Med** 1999 Feb;38(2):195-7 (3 ref.)

STATISTICS & NUMERICAL DATA

Short birth intervals don't kill women: evidence from Matlab, Bangladesh. Ronsmans C, et al. **Stud Fam Plann** 1998 Sep; 29(3):282-90 (34 ref.)

RUSSELL'S VIPER VENOM TIME see **PROTHROMBIN TIME**

RUTABAGA see **BRASSICA**

RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL

CHEMISTRY

Ryanodine receptor isoforms in excitation-contraction coupling. Ogawa Y, et al. **Adv Biophys** 1999;36:27-64 (209 ref.)

Luminal loop of the ryanodine receptor: a pore-forming segment? [comment] Balshaw D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3345-7 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):4164-9.

GENETICS

Genetic analysis of voltage-dependent calcium channels. Fletcher CF, et al. **J Bioenerg Biomembr** 1998 Aug; 30(4):387-98 (88 ref.)

Expression of the ryanodine receptor type 3 in skeletal muscle. A new partner in excitation-contraction coupling? Sorrentino V, et al. **Trends Cardiovasc Med** 1999 Jan-Feb; 9(1-2):54-61 (41 ref.)

METABOLISM

Ryanodine receptor isoforms in excitation-contraction coupling. Ogawa Y, et al. **Adv Biophys** 1999;36:27-64 (209 ref.)

Comparison of properties of Ca2+ release channels between rabbit and frog skeletal muscles. Ogawa Y, et al. **Mol Cell Biochem** 1999 Jan;190(1-2):191-201 (80 ref.)

Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Alkon DL, et al. **Trends Neurosci** 1998 Dec;21(12):529-37 (97 ref.)

PHYSIOLOGY

Ca2+ channels, ryanodine receptors and Ca(2+)-activated K+ channels: a functional unit for regulating arterial tone. Jaggar JH, et al. **Acta Physiol Scand** 1998 Dec; 164(4):577-87 (69 ref.)

Complex interactions between skeletal muscle ryanodine receptor and dihydropyridine receptor proteins. Leong P, et al. **Biochem Cell Biol** 1998;76(5):681-94 (188 ref.)

Protein-protein interactions in intracellular Ca2+-release channel function. MacKrill JJ. **Biochem J** 1999 Feb 1;337 (Pt 3):345-61 (220 ref.)

Role of the ryanodine receptor in ischemic brain damage--localized reduction of ryanodine receptor binding during ischemia in hippocampus CA1. Nozaki H, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):119-31 (74 ref.)

Novel mechanisms of calcium handling by the osteoclast: A review-hypothesis. Zaidi M, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):319-27 (82 ref.)

Luminal loop of the ryanodine receptor: a pore-forming segment? [comment] Balshaw D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3345-7 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):4164-9.

[Ca+ metabolism in the sarcoplasmic reticulum and the role of ryanodine and IP3 receptors in the nervous system] Nagata E, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2522-9 (30 ref.) **(Jpn)**

[Ryanodine receptor] Takeshima H. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1603-9 (50 ref.) **(Jpn)**

RYANODINE RECEPTORS see **RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL**

RYEGRASS see **LOLIUM**

RYR1 see **RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL**

S6 KINASE see **RIBOSOMAL PROTEIN S6 KINASE**

S-ANTIGEN, RETINAL see **ARRESTIN**

S CELLS (INTESTINE) see **ENDOCRINE CELLS OF GUT**

S PHASE

S-phase DNA damage checkpoint in budding yeast. Foiani M, et al. **Biol Chem** 1998 Aug-Sep;379(8-9):1019-23 (25 ref.)

Prognostic and predictive value of thymidine labelling index in breast cancer. Amadori D, et al. **Breast Cancer Res Treat** 1998;51(3):267-81 (70 ref.)

S-phase fraction and breast cancer--a decade of experience. Wenger CR, et al. **Breast Cancer Res Treat** 1998; 51(3):255-65 (84 ref.)

[Replication licensing and S-phase CDK] Mimura S, et al. **Seikagaku** 1999 Apr;71(4):255-68 (63 ref.) **(Jpn)**

GENETICS

S phase and differential DNA replication during Drosophila oogenesis. Royzman I, et al. **Genes Cells** 1998 Dec; 3(12):767-76 (30 ref.)

The S phase: beginning, middle, and end: a perspective. Ford HL, et al. **J Cell Biochem Suppl** 1998;30-31:1-7 (37 ref.)

PHYSIOLOGY

The apparent linkage between centriole replication and the S phase of the cell cycle. Sluder G, et al. **Cell Biol Int** 1998;22(1):3-5 (25 ref.)

The S phase: beginning, middle, and end: a perspective. Ford HL, et al. **J Cell Biochem Suppl** 1998;30-31:1-7 (37 ref.)

SABIN VACCINE see **POLIOVIRUS VACCINE, ORAL**

SABLES see **CARNIVORA**

SACCADES

Gap effect and reaction time distribution: simple vs choice manual responses. Machado-Pinheiro W, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1313-8 (19 ref.)

Treatment of specific phobias with Eye Movement Desensitization and Reprocessing (EMDR): protocol, empirical status, and conceptual issues. De Jongh A, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):69-85 (54 ref.)

Traumatic memories, eye movements, phobia, and panic: a critical note on the proliferation of EMDR. Muris P, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):209-23 (63 ref.)

Eye Movement Desensitization and Reprocessing (EMDR) and the anxiety disorders: clinical and research implications of an integrated psychotherapy treatment. Shapiro F. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):35-67 (130 ref.)

DRUG EFFECTS

Drug therapy of nystagmus and saccadic intrusions. Büttner U, et al. **Adv Otorhinolaryngol** 1999;55:195-227 (165 ref.)

PHYSIOLOGY

Neurology of saccades and smooth pursuit. Gaymard B, et al. **Curr Opin Neurol** 1999 Feb;12(1):13-9 (56 ref.)

Cortical control of saccades. Gaymard B, et al. **Exp Brain Res** 1998 Nov;123(1-2):159-63 (36 ref.)

Gaze shifts in three-dimensional space: A closer look at the superior colliculus [comment] Guitton D. **J Comp Neurol** 1999 Oct 11;413(1):77-82 (52 ref.) Comment on: J Comp Neurol 1999 Oct 11;413(1):68-70.

The antisaccade: a review of basic research and clinical studies. Everling S, et al. **Neuropsychologia** 1998 Sep; 36(9):885-99 (133 ref.)

Eye movements in reading and information processing: 20 years of research. Rayner K. **Psychol Bull** 1998 Nov; 124(3):372-422 (927 ref.)

SACCADIC EYE MOVEMENTS see **SACCADES**

SACCHARIDE-MEDIATED CELL ADHESION MOLECULES see **CELL ADHESION MOLECULES**

SACCHARIN

PHARMACOLOGY

Succinimide and saccharin-based enzyme-activated inhibitors of serine proteases. Martyn DC, et al. **Curr Pharm Des** 1999 Jun;5(6):405-15 (49 ref.)

SACCHAROMYCES CEREVISIAE

[Inositol phospholipid function in yeast] Kagiwada S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1194-9 (21 ref.) **(Jpn)**

CHEMISTRY

The contribution of cell wall proteins to the organization of the yeast cell wall. Kapteyn JC, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):373-83 (81 ref.)

Effect of beta-glucan from oats and yeast on serum lipids. Bell S, et al. **Crit Rev Food Sci Nutr** 1999 Mar;39(2):189-202

(33 ref.)
Analysis of the lipid moiety of GPI anchor in the yeast Saccharomyces cerevisiae. Reggiori F, et al. **Methods Mol Biol** 1999;116:91–105 (22 ref.)
Preparing 2-D protein extracts from yeast. Schieltz DM. **Methods Mol Biol** 1999;112:31–4 (3 ref.)
Comparison of the complete protein sets of worm and yeast: orthology and divergence. Chervitz SA, et al. **Science** 1998 Dec 11;282(5396):2022–8 (44 ref.)

CYTOLOGY

Microbial asymmetric cell division: localization of cell fate determinants. Jacobs C, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):386–91 (46 ref.)
DNA damage checkpoint in budding yeast. Longhese MP, et al. **EMBO J** 1998 Oct 1;17(19):5525–8 (29 ref.)
Preparation of yeast cells for confocal microscopy. Atkin AL. **Methods Mol Biol** 1999;122:131–9 (17 ref.)

ENZYMOLOGY

Stress-activated MAP kinase (mitogen-activated protein kinase) pathways of budding and fission yeasts. Millar JB. **Biochem Soc Symp** 1999;64:49–62 (53 ref.)
Processing glycosidases of Saccharomyces cerevisiae. Herscovics A. **Biochim Biophys Acta** 1999 Jan 6; 1426(2):275–85 (72 ref.)
The oligosaccharyltransferase complex from yeast. Knauer R, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):259–73 (114 ref.)
The KTR and MNN1 mannosyltransferase families of Saccharomyces cerevisiae. Lussier M, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):323–34 (40 ref.)
Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Reid RJ, et al. **Biochim Biophys Acta** 1998 Oct 1;1400(1–3):289–300 (49 ref.)
The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Chédin S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:381–9 (103 ref.)
Structure of the yeast histone acetyltransferase Hat1: insights into substrate specificity and implications for the Gcn5-related N-acetyltransferase superfamily. Dutnall RN, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:501–7 (51 ref.)
Mechanism and regulation of yeast RNA polymerase II transcription. Kornberg RD. **Cold Spring Harb Symp Quant Biol** 1998;63:229–32 (26 ref.)
Progress and variations in two-hybrid and three-hybrid technologies. Drees BL. **Curr Opin Chem Biol** 1999 Feb; 3(1):64–70 (47 ref.)
Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Pearce DA. **Hum Genet** 1999 Jun;104(6):443–8 (54 ref.)
Analysis of eIF-2 alpha kinases in yeast. Dever TE. **Methods Mol Biol** 1998;77:167–78 (16 ref.)
Reconstitution of yeast farnesyltransferase from individually purified subunits. Urano J, et al. **Methods Mol Biol** 1999; 116:145–59 (24 ref.)
MAP kinase pathways in the yeast Saccharomyces cerevisiae. Gustin MC, et al. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1264–300 (527 ref.)
Regulation of Cdc28 cyclin-dependent protein kinase activity during the cell cycle of the yeast Saccharomyces cerevisiae. Mendenhall MD, et al. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1191–243 (642 ref.)
Functional analysis of the proteasome regulatory particle. Glickman MH, et al. **Mol Biol Rep** 1999 Apr;26(1–2):21–8 (44 ref.)
The protein kinase C-mediated MAP kinase pathway involved in the maintenance of cellular integrity in Saccharomyces cerevisiae. Heinisch JJ, et al. **Mol Microbiol** 1999 May;32(4):671–80 (64 ref.)
Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Widmann C, et al. **Physiol Rev** 1999 Jan;79(1):143–80 (409 ref.)
[Mechanism of stress response and gene expression of glyoxalase I in yeast] Inoue Y. **Seikagaku** 1998 Oct; 70(10):1278–83 (18 ref.) **(Jpn)**
[Structure and function of the yeast 26S proteasome] Tohe A. **Seikagaku** 1999 Mar;71(3):173–81 (51 ref.) **(Jpn)**

GENETICS

Sequencing and functional analysis of the yeast genome. Zagulski M, et al. **Acta Biochim Pol** 1998;45(3):627–43 (52 ref.)
The yeast connection to Friedreich ataxia. Knight SA, et al. **Am J Hum Genet** 1999 Feb;64(2):365–71 (32 ref.)
Fidelity of retrotransposon replication. Gabriel A, et al. **Ann N Y Acad Sci** 1999 May 18;870:108–18 (35 ref.)
Mating-type gene switching in Saccharomyces cerevisiae. Haber JE. **Annu Rev Genet** 1998;32:561–99 (226 ref.)
Amyloid fibres of Sup35 support a prion-like mechanism of inheritance in yeast. Lindquist S, et al. **Biochem Soc Trans** 1998 Aug;26(3):486–90 (24 ref.)
ALG gene expression and cell cycle progression. Kukuruzinska MA, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):359–72 (79 ref.)
How do yeast cells sense glucose? Kruckeberg AL, et al. **Bioessays** 1998 Dec;20(12):972–6 (36 ref.)
The yeast genome and clinical genetics. Hieter P. **Clin Genet** 1998 Aug;54(2):113–6 (17 ref.)
The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Chédin S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:381–9 (103 ref.)
Targeting Sir proteins to sites of action: a general mechanism for regulated repression. Cockell M, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:401–12 (59 ref.)
Mechanism and regulation of yeast RNA polymerase II transcription. Kornberg RD. **Cold Spring Harb Symp Quant Biol** 1998;63:229–32 (26 ref.)
Activation and repression mechanisms in yeast. Struhl K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:413–21 (66 ref.)
The SAGA of Spt proteins and transcriptional analysis in yeast: past, present, and future. Winston F, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:553–61 (59 ref.)
Replication conrol: choreographing replication origins. Diffley JF. **Curr Biol** 1998 Oct 22;8(21):R771–3 (10 ref.)
Production of G-protein-coupled receptors in yeast. Reiländer H, et al. **Curr Opin Biotechnol** 1998 Oct; 9(5):510–7 (46 ref.)
Progress and variations in two-hybrid and three-hybrid technologies. Drees BL. **Curr Opin Chem Biol** 1999 Feb; 3(1):64–70 (47 ref.)
Nuclear RNA export in yeast. Strässer K, et al. **FEBS Lett** 1999 Jun 4;452(1–2):77–81 (64 ref.)
Chromatin and transcription in Saccharomyces cerevisiae. Pérez-Martín J. **FEMS Microbiol Rev** 1999 Jul; 23(4):503–23 (155 ref.)
Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Pearce DA. **Hum Genet** 1999 Jun;104(6):443–8 (54 ref.)
Control of mRNA turnover as a mechanism of glucose repression in Saccharomyces cerevisiae. Scheffler IE, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1175–93 (113 ref.)
The petite mutation in yeasts: 50 years on. Chen XJ, et al. **Int Rev Cytol** 2000;194:197–238 (256 ref.)
Prions of yeast and fungi. Proteins as genetic material. Wickner RB, et al. **J Biol Chem** 1999 Jan 8;274(2):555–8 (40 ref.)
Genetic dissection of histone function. Smith MM, et al. **Methods** 1998 Aug;15(4):269–81 (76 ref.)
In vivo mutational analysis of ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Methods Mol Biol** 1998;77:257–70 (32 ref.)
MAP kinase pathways in the yeast Saccharomyces cerevisiae. Gustin MC, et al. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1264–300 (527 ref.)
Posttranscriptional control of gene expression in yeast. McCarthy JEG. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1492–553 (620 ref.)
Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Pâques F, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):349–404 (575 ref.)
FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors. Smardová J. **Neoplasma** 1999; 46(2):80–8 (91 ref.)
Genetic regulation of phospholipid metabolism: yeast as a model eukaryote. Henry SA, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:133–79 (276 ref.)
Regulation of RNA polymerase I transcription in yeast and vertebrates. Reeder RH. **Prog Nucleic Acid Res Mol Biol** 1999;62:293–327 (212 ref.)
Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. de la Cruz J, et al. **Trends Biochem Sci** 1999 May;24(5):192–8 (54 ref.)
The best yeast? Forsburg SL. **Trends Genet** 1999 Sep; 15(9):340–4 (64 ref.)
Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Daum G, et al. **Yeast** 1998 Dec;14(16):1471–510 (310 ref.)
[Biosynthesis and transport of sterols in the yeast Saccharomyces cerevisiae] Soustre I, et al. **C R Seances Soc Biol Fil** 1998;192(5):977–90 (70 ref.) (Eng. Abstr.) **(Fre)**
[Phylogenetic preservation of genetic study stocks of Saccharomyces cerevisiae] Harashima S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):278–82 (28 ref.) **(Jpn)**
[Genetics of yeasts in Institute of Molecular Genetics of the Russian Academy of Sciences (1958–1998). Some results and perspectives] Arman IP, et al. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):48–54 (39 ref.) **(Rus)**

GROWTH & DEVELOPMENT

Role of small G proteins in yeast cell polarization and wall biosynthesis. Cabib E, et al. **Annu Rev Biochem** 1998; 67:307–33 (159 ref.)
Quantification of microbial productivity via multi-angle light scattering and supervised learning. Jones A, et al. **Biotechnol Bioeng** 1998 Jul 20;59(2):131–43 (70 ref.)
Polarity and division site specification in yeast. Palmieri SJ, et al. **Curr Opin Microbiol** 1998 Dec;1(6):678–86 (84 ref.)
Molecular mechanisms of yeast longevity. Jazwinski SM. **Trends Microbiol** 1999 Jun;7(6):247–52 (53 ref.)

IMMUNOLOGY

The utility of ANCA and ASCA in inflammatory bowel disease. Targan SR. **Inflamm Bowel Dis** 1999 Feb;5(1):61–3; discussion 66–7 (7 ref.)

METABOLISM

Cytochemical images of secretion in Saccharomyces cerevisiae and animal cells are different. Vořišek J. **Acta Histochem** 1998 Nov;100(4):419–38 (99 ref.)
Sphingolipid functions in Saccharomyces cerevisiae: comparison to mammals. Dickson RC. **Annu Rev Biochem** 1998;67:27–48 (138 ref.)
Multiple sorting pathways between the late Golgi and the vacuole in yeast. Conibear E, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):211–30 (135 ref.)
Asparagine-linked glycosylation in the yeast Golgi. Dean N. **Biochim Biophys Acta** 1999 Jan 6;1426(2):309–22 (98 ref.)
Yeast sphingolipids. Dickson RC, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):347–57 (99 ref.)
Metabolism and selected functions of sphingolipids in the yeast Saccharomyces cerevisiae. Dickson RC, et al. **Biochim Biophys Acta** 1999 Jun 10;1438(3):305–21 (125 ref.)
Mannosylphosphate transfer to yeast mannan. Jigami Y, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):335–45 (52 ref.)
The Gas1 glycoprotein, a putative wall polymer cross-linker. Popolo L, et al. **Biochim Biophys Acta** 1999 Jan 6; 1426(2):385–400 (77 ref.)
Protein O-mannosylation. Strahl-Bolsinger S, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):297–307 (98 ref.)
Biochemistry and molecular biology of sterol synthesis in Saccharomyces cerevisiae. Lees ND, et al. **Crit Rev Biochem Mol Biol** 1999;34(1):33–47 (96 ref.)
Production of G-protein-coupled receptors in yeast. Reiländer H, et al. **Curr Opin Biotechnol** 1998 Oct; 9(5):510–7 (46 ref.)
Protein traffic in the yeast endocytic and vacuolar protein sorting pathways. Wendland B, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):513–22 (69 ref.)
Signal transduction by MAP kinase cascades in budding yeast. Posas F, et al. **Curr Opin Microbiol** 1998 Apr; 1(2):175–82 (66 ref.)
Cell wall dynamics in yeast. Smits GJ, et al. **Curr Opin Microbiol** 1999 Aug;2(4):348–52 (55 ref.)
Zeroing in on zinc uptake in yeast and plants. Guerinot ML, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):244–9 (49 ref.)
Analysis of intracellular pH in the yeast Saccharomyces cerevisiae under elevated hydrostatic pressure: a study in baro- (piezo-) physiology. Abe F, et al. **Extremophiles** 1998 Aug;2(3):223–8 (35 ref.)
Investigation of steroid receptor function in the budding yeast Saccharomyces cerevisiae. McEwan IJ. **FEMS Microbiol Lett** 1999 Jul 1;176(1):1–9 (35 ref.)
Control of mRNA turnover as a mechanism of glucose repression in Saccharomyces cerevisiae. Scheffler IE, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1175–93 (113 ref.)
Regulation of transition metal transport across the yeast plasma membrane. Radisky D, et al. **J Biol Chem** 1999 Feb 19;274(8):4481–4 (42 ref.)
In vitro assays for studying Saccharomyces cerevisiae kinetochore activity. Severin F, et al. **Methods Cell Biol** 1999;61:145–53 (13 ref.)
Posttranscriptional control of gene expression in yeast. McCarthy JEG. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1492–553 (620 ref.)
Protein targeting to the endoplasmic reticulum in yeast. 1997 Fleming Lecture. Stirling CJ. **Microbiology** 1999 May;145 (Pt 5):991–8 (65 ref.)
Long-chain fatty acid transport in bacteria and yeast. Paradigms for defining the mechanism underlying this protein-mediated process. DiRusso CC, et al. **Mol Cell Biochem** 1999 Feb;192(1–2):41–52 (86 ref.)
A strange calmodulin of yeast. Yazawa M, et al. **Mol Cell Biochem** 1999 Jan;190(1–2):47–54 (46 ref.)
Novel sensing mechanisms and targets for the cAMP-protein kinase A pathway in the yeast Saccharomyces cerevisiae. Thevelein JM, et al. **Mol Microbiol** 1999 Sep;33(5):904–18 (101 ref.)
Genetic regulation of phospholipid metabolism: yeast as a model eukaryote. Henry SA, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:133–79 (276 ref.)
Models for oxygen sensing in yeast: implications for oxygen-regulated gene expression in higher eucaryotes. Poyton RO. **Respir Physiol** 1999 Apr 1;115(2):119–33 (70 ref.)
Feasting, fasting and fermenting. Glucose sensing in yeast and other cells. Johnston M. **Trends Genet** 1999 Jan; 15(1):29–33 (82 ref.)
Starting up yeast glycolysis [see comments] Gonçalves P, et al. **Trends Microbiol** 1998 Aug;6(8):314–9 (31 ref.) Comment in: Trends Microbiol 1998 Dec;6(12):472–3.
Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Daum G, et al. **Yeast** 1998 Dec;14(16):1471–510 (310 ref.)
[Biosynthesis and transport of sterols in the yeast Saccharomyces cerevisiae] Soustre I, et al. **C R Seances Soc Biol Fil** 1998;192(5):977–90 (70 ref.) (Eng. Abstr.) **(Fre)**
[Biosynthesis of triacylglycerol and related intracellular lipid transport in fungi and yeasts] Kamisaka Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1207–12

SACCHAROMYCES CEREVISIAE

(35 ref.) **(Jpn)**

PHYSIOLOGY

Mitochondrial dynamics in yeast. Hermann GJ, et al. **Annu Rev Cell Dev Biol** 1998;14:265–303 (155 ref.)

Aging in Saccharomyces cerevisiae. Sinclair D, et al. **Annu Rev Microbiol** 1998;52:533–60 (137 ref.)

Action at the ends of microtubules. Saunders WS. **Curr Opin Cell Biol** 1999 Feb;11(1):129–33 (35 ref.)

Glucose repression in yeast. Carlson M. **Curr Opin Microbiol** 1999 Apr;2(2):202–7 (55 ref.)

Vicious circles: a mechanism for yeast aging. Defossez PA, et al. **Curr Opin Microbiol** 1998 Dec;1(6):707–11 (45 ref.)

Protein chaperones and the heat shock response in Saccharomyces cerevisiae. Morano KA, et al. **Curr Opin Microbiol** 1998 Apr;1(2):197–203 (44 ref.)

SNAREs and the secretory pathway–lessons from yeast. Pelham HR. **Exp Cell Res** 1999 Feb 25;247(1):1–8 (26 ref.)

Mitochondrial assembly in yeast. Grivell LA, et al. **FEBS Lett** 1999 Jun 4;452(1–2):57–60 (40 ref.)

Stress-activated signalling pathways in yeast. Toone WM, et al. **Genes Cells** 1998 Aug;3(8):485–98 (110 ref.)

Cytoskeletal dynamics in yeast. Carminati JL, et al. **Methods Cell Biol** 1999;58:87–105 (33 ref.)

Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Schaeffer HJ, et al. **Mol Cell Biol** 1999 Apr;19(4):2435–44 (145 ref.)

Electrophysiology in the eukaryotic model cell Saccharomyces cerevisiae. Bertl A, et al. **Pflugers Arch** 1998 Nov;436(6):999–1013 (145 ref.)

Novel pathways, membrane coats and PI kinase regulation in yeast lysosomal trafficking. Burd CG, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):527–33 (77 ref.)

Thermotolerance in Saccharomyces cerevisiae: the Yin and Yang of trehalose. Singer MA, et al. **Trends Biotechnol** 1998 Nov;16(11):460–8 (71 ref.)

New lines of host defense: inhibition of Ty1 retrotransposition by Fus3p and NER/TFIIH. Curcio MJ, et al. **Trends Genet** 1999 Feb;15(2):43–5 (20 ref.)

Oxidative stress responses of the yeast Saccharomyces cerevisiae. Jamieson DJ. **Yeast** 1998 Dec;14(16):1511–27 (155 ref.)

[Sugar chain remodeling through the molecular breeding of yeast saccharomyces cerevisiae] Jigami Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2604–10 (24 ref.) **(Jpn)**

SACCHAROMYCETALES

GENETICS

The molecular biology of Schwanniomyces occidentalis klocker. Wang TT, et al. **Crit Rev Biotechnol** 1999; 19(2):113–43 (172 ref.)

GROWTH & DEVELOPMENT

Cell polarity and morphogenesis in budding yeast. Madden K, et al. **Annu Rev Microbiol** 1998;52:687–744 (333 ref.)

ISOLATION & PURIFICATION

Invasive infections due to Clavispora lusitaniae. Krcmery V Jr, et al. **FEMS Immunol Med Microbiol** 1999 Jan; 23(1):75–8 (6 ref.)

SACRAL PLEXUS see **LUMBOSACRAL PLEXUS**

SACRAL REGION see **SACROCOCCYGEAL REGION**

SACROCOCCYGEAL REGION

Sacrococcygeal teratoma in adults: case reports and a review of the literature. Ng EW, et al. **Cancer** 1999 Oct 1; 86(7):1198–202 (25 ref.)

SACROILIAC JOINT

[Imaging diagnosis in suspected inflammatory rheumatoid axial skeleton diseases (sacroilitis)] Bollow M, et al. **Z Rheumatol** 1999 Apr;58(2):61–70 (40 ref.) (Eng. Abstr.) **(Ger)**

[Septic arthritis caused by S. pneumoniae. Report of 2 cases with unusual location] Ruiz Martin JM, et al. **Rev Clin Esp** 1998 Sep;198(9):596–7 (13 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

The sacroiliac joint. Nothing is sacred. Swezey RL. **Phys Med Rehabil Clin N Am** 1998 May;9(2):515–9, x (31 ref.)

Radiologic diagnosis and pathology of the spondyloarthropathies. Braun J, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):697–735 (178 ref.)

SACRUM

Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)

A physiological approach to the evaluation of lumbosacral spinal stenosis. Kraft GH. **Phys Med Rehabil Clin N Am** 1998 May;9(2):381–9, viii (19 ref.)

[Physical diagnosis--signs of lumbosacral irritation (see comments) (published erratum appears in Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1400)] Oosterhuis HJ. **Ned Tijdschr Geneeskd** 1999 Mar 20;143(12):617–20 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1393–4. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1394–5. **(Dut)**

[Giants schwannoma of the sacrum. Apropos of 3 cases and review of the literature] Anract P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):239–46 (18 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

An unusual case of the complete Currarino triad: case report, discussion of the literature and the embryogenic implications. Gegg CA, et al. **Neurosurgery** 1999 Mar; 44(3):658–62 (17 ref.)

INJURIES

Fracture dislocation of the sacro-coccygeal joint: MRI evaluation [letter] Raissaki MT, et al. **Pediatr Radiol** 1999 Aug;29(8):642–3 (6 ref.)

PATHOLOGY

Anterior sacral meningocele associated with a rectal fistula. Case report and review of the literature. Fitzpatrick MO, et al. **J Neurosurg** 1999 Jul;91(1 Suppl):124–7 (26 ref.)

MR evaluation of stenosis involving the neural foramina, lateral recesses, and central canal of the lumbosacral spine. Jinkins JR. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):493–511, viii (43 ref.)

An unusual case of the complete Currarino triad: case report, discussion of the literature and the embryogenic implications. Gegg CA, et al. **Neurosurgery** 1999 Mar; 44(3):658–62 (17 ref.)

RADIOGRAPHY

[The cauda equina syndrome and a sacral lithic mass] Zambrana García JL, et al. **Rev Clin Esp** 1999 Jul; 199(7):471–2 (7 ref.) **(Spa)**

SURGERY

Long-term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. Spiegel DA, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):848–55 (52 ref.)

Management of degenerative disc disease above an L5-S1 segment requiring arthrodesis. Herkowitz HN, et al. **Spine** 1999 Jun 15;24(12):1268–70 (15 ref.)

[Abdominosacral resection for locoregional recurrence rectal cancer] Meneu JC, et al. **Rev Esp Enferm Dig** 1999 May; 91(5):374–9 (30 ref.) (Eng. Abstr.) **(Spa)**

SADDLEBACK DOLPHIN see **DOLPHINS**

SAETHRE-CHOTZEN SYNDROME see **ACROCEPHALOSYNDACTYLIA**

SAFETY

Protecting the health and safety of working teenagers. Rubenstein H, et al. **Am Fam Physician** 1999 Aug; 60(2):575–80, 587–8 (07 ref.)

Electrosurgical safety. Hutchisson B, et al. **AORN J** 1998 Nov;68(5):830–7; quiz 838–40, 843–4 (4 ref.)

How should the safety and efficacy of platelet transfusions be assured? Williamson LM. **Blood Rev** 1998 Dec; 12(4):203–14 (104 ref.)

Food safety in the 21st century. Käferstein F, et al. **Bull World Health Organ** 1999;77(4):347–51 (15 ref.)

Safety issues of animal products used in serum-free media. Merten OW. **Dev Biol Stand** 1999;99:167–80 (69 ref.)

Maintaining client safety and scientific integrity in research with battered women. Lutz KF. **Image J Nurs Sch** 1999; 31(1):89–93 (40 ref.)

Improving the safety profile of long-term PUVA therapy [editorial; comment] Hobbs J, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):496–7 (20 ref.) Comment on: J Am Acad Dermatol 1999 Sep;41(3 Pt 1):408–13.

Function, flying, and the Age-60 rule [editorial; comment] Odenheimer G. **J Am Geriatr Soc** 1999 Jul;47(7):910–1 (14 ref.) Comment on: J Am Geriatr Soc 1999 Jul;47(7):819–23.

Safety of emergency contraception. Glasier A. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):219–21 (21 ref.)

Handgun safety features: a review for physicians. Milne JS, et al. **J Trauma** 1999 Jul;47(1):145–50 (49 ref.)

Biologic effects of low-level electromagnetic fields: current issues and controversies. Beers GJ, et al. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):749–74 (242 ref.)

Safety aspects of switched gradient fields. Schaefer DJ. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):731–48 (51 ref.)

Safety aspects of radiofrequency power deposition in magnetic resonance. Schaefer DJ. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):775–89 (47 ref.)

MR safety at high magnetic fields. Schenck JF. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):715–30 (128 ref.)

FDA treads delicate line between safety and speed. **Oncology (Huntingt)** 1999 Jan;13(1):16 (0 ref.)

Advising patients about international travel. What they can do to protect their health and safety. Bratton RL. **Postgrad Med** 1999 Jul;106(1):57–64; quiz 143 (14 ref.)

Violence in the emergency department. Managing aggressive patients in a high-stress environment. Kuhn W. **Postgrad Med** 1999 Jan;105(1):143–8, 154 (30 ref.)

The safety of pharmaceutical excipients. de Jong HJ. **Therapie** 1999 Jan-Feb;54(1):11–4 (9 ref.)

[Protection of children in cars: integrating the specifics (editorial)] Floret D. **Arch Pediatr** 1999 Mar;6(3):247–50 (21 ref.) **(Fre)**

[Refractive surgery and flight safety] Draeger J. **Ophthalmologe** 1998 Sep;95(9):639–44 (8 ref.) (Eng. Abstr.) **(Ger)**

[Biological safety problems on the brink of the 21st century] Kalinin IuT, et al. **Vestn Ross Akad Med Nauk** 1999;(8):3–8 (13 ref.) (Eng. Abstr.) **(Rus)**

[Health care safety should be focused on prevention. Lessons to be learned from aviation, nuclear power plants and offshore industries] Odegård S. **Lakartidningen** 1999 Jun 23;96(25):3068–73 (19 ref.) (Eng. Abstr.) **(Swe)**

SAFETY, CONSUMER PRODUCT see **CONSUMER PRODUCT SAFETY**

SAFETY DEVICES see **PROTECTIVE DEVICES**

SAFETY, EQUIPMENT see **EQUIPMENT SAFETY**

SAFETY GLASSES see **EYE PROTECTIVE DEVICES**

SAFETY LENSES see **EYE PROTECTIVE DEVICES**

SAFETY MANAGEMENT

Do workplace interventions prevent low-back disorders? If so, why?: a methodologic commentary. Volinn E. **Ergonomics** 1999 Jan;42(1):258–72 (65 ref.)

Towards integrated hygiene and food safety management systems: the Hygieneomic approach. Armstrong GD. **Int J Food Microbiol** 1999 Sep 15;50(1–2):19–24 (0 ref.)

Nitrobenzene carcinogenicity in animals and human hazard evaluation. Holder JW. **Toxicol Ind Health** 1999 Aug; 15(5):445–57 (117 ref.)

METHODS

Effective presentation of radiation safety training--risk communication: an important function of radiation safety training. Johnson RH Jr. **Health Phys** 1999 Feb;76(2 Suppl):S10–5 (7 ref.)

Potential for violence toward psychiatric nursing students: risk reduction techniques. Echternacht MR. **J Psychosoc Nurs Ment Health Serv** 1999 Mar;37(3):36–9 (9 ref.)

ORGANIZATION & ADMINISTRATION

Motor vehicle safety: current concepts and challenges for emergency physicians. Peterson TD, et al. **Ann Emerg Med** 1999 Sep;34(3):384–93 (28 ref.)

The control of major accident hazards: the land-use planning issue. Christou MD, et al. **J Hazard Mater** 1999 Mar 1; 65(1–2):151–78 (59 ref.)

Precautions against industrial accidents: experience in applying the Seveso II Directive in central and eastern European countries. Kaiser W, et al. **J Hazard Mater** 1999 Mar 1;65(1–2):59–75 (8 ref.)

Application of the Seveso Directive in France. Pineau JP. **J Hazard Mater** 1999 Mar 1;65(1–2):49–57 (7 ref.)

SAFFRON see **LILIACEAE**

SAGE see **LAMIACEAE**

SAIDS see **SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME**

SAIDS VACCINES

IMMUNOLOGY

Live attenuated SIV--a model of a vaccine for AIDS. Almond N, et al. **Immunol Lett** 1999 Mar;66(1–3):167–70 (30 ref.)

SAILORS see **MILITARY PERSONNEL**

SAIMIRI

ANATOMY & HISTOLOGY

The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al. **J Chem Neuroanat** 1999 May;16(3):153–65 (36 ref.)

PHYSIOLOGY

Neuronal control of mammalian vocalization, with special reference to the squirrel monkey. Jürgens U. **Naturwissenschaften** 1998 Aug;85(8):376–88 (53 ref.)

SAIMIRINE HERPESVIRUS 2 see **HERPESVIRUS 2, SAIMIRINE**

SALAAM SEIZURES see **SPASMS, INFANTILE**

SALAMANDERS see **URODELA**

SALAMANDRIDAE

ANATOMY & HISTOLOGY

Survey of the oviduct of salamandrids with special reference to the viviparous species. Greven H. **J Exp Zool** 1998 Nov–Dec 1;282(4–5):507–25 (80 ref.)

PHYSIOLOGY

Survey of the oviduct of salamandrids with special reference to the viviparous species. Greven H. **J Exp Zool** 1998 Nov–Dec 1;282(4–5):507–25 (80 ref.)

Axolotl/newt. Maden M. **Methods Mol Biol** 1999;97:415–28 (30 ref.)

Sodefrin: a novel sex pheromone in a newt. Kikuyama S, et al. **Rev Reprod** 1999 Jan;4(1):1–4 (18 ref.)

SALARIES AND FRINGE BENEFITS

Pension integration and Social Security reform. Slusher C. **Soc Secur Bull** 1998;61(3):20–7 (10 ref.)

ECONOMICS

How should we pay doctors? A systematic review of salary payments and their effect on doctor behaviour. Gosden T, et al. **QJM** 1999 Jan;92(1):47–55 (44 ref.)

SALBUTAMOL see **ALBUTEROL**

SALICYLATES

ADVERSE EFFECTS

[The risk of hemorrhage in long-term use of aspirin and triflusal] Alvarez Sabin J, et al. **Rev Neurol** 1998 Dec; 27(160):951–5 (43 ref.) (Eng. Abstr.) **(Spa)**

POISONING

[Acute poisoning by barbiturates, tranquilizers, tricyclics, paracetamol, salicylates. Diagnosis, treatment] Flesch F, et al. **Rev Prat** 1998 Jun 1;48(11):1257–61 (0 ref.) **(Fre)**

THERAPEUTIC USE

Intriguing gastrointestinal properties of bismuth: a folk remedy brought into the realm of clinical and investigative medicine. Mishkin S. **Can J Gastroenterol** 1998 Nov–Dec; 12(8):569–70 (12 ref.)

SALICYLAZOSULFAPYRIDINE see **SULFASALAZINE**

SALICYLIC ACID

METABOLISM

SA, JA, ethylene, and disease resistance in plants. Dong X. **Curr Opin Plant Biol** 1998 Aug;1(4):316–23 (67 ref.)

Jasmonate and salicylate as global signals for defense gene expression. Reymond P, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):404–11 (76 ref.)

THERAPEUTIC USE

The role of salicylic acid in the treatment of psoriasis. Lebwohl M. **Int J Dermatol** 1999 Jan;38(1):16–24 (60 ref.)

SALIENTIA see **ANURA**

SALINE see **SODIUM CHLORIDE**

SALINE FRAGILITY see **OSMOTIC FRAGILITY**

SALINE SOLUTION, HYPERTONIC

ADMINISTRATION & DOSAGE

[Low-volume infusion therapy with hyperosmolar sodium chloride solutions in the treatment of acute massive blood loss] Tsybuliak GN, et al. **Vestn Khir Im I I Grek** 1999; 158(2):73–6 (31 ref.) **(Rus)**

[Does prehospital hypertonic infusion therapy improve the survival of trauma patients?] Haljamäe H. **Lakartidningen** 1999 Mar 3;96(9):1014–7 (21 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Hypertonic saline resuscitation. Rocha e Silva M. **Medicina (B Aires)** 1998;58(4):393–402 (186 ref.)

SALIVA

CHEMISTRY

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837–57, vi (77 ref.)

Role of epidermal growth factor (EGF) in oesophageal mucosal integrity. Marcinkiewicz M, et al. **Curr Med Res Opin** 1998;14(3):145–53 (69 ref.)

Perspiration versus saliva--basic aspects concerning their use in roadside drug testing. Skopp G, et al. **Int J Legal Med** 1999;112(4):213–21 (74 ref.)

Biochemical markers for preterm labor and birth: what is their role in the care of pregnant women? Moore ML. **MCN Am J Matern Child Nurs** 1999 Mar–Apr;24(2):80–6 (25 ref.)

Saliva composition and exercise. Chicharro JL, et al. **Sports Med** 1998 Jul;26(1):17–27 (103 ref.)

METABOLISM

Saliva as a fluid for measurement of estriol levels. Voss HF. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S226–31 (34 ref.)

Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Liu H, et al. **Clin Pharmacokinet** 1999 Jun;36(6):453–70 (121 ref.)

PHYSIOLOGY

Antimicrobial function of human saliva--how important is it for oral health? Tenovuo J. **Acta Odontol Scand** 1998 Oct;56(5):250–6 (89 ref.)

Saliva and esophageal protection. Kongara KR, et al. **Am J Gastroenterol** 1999 Jun;94(6):1446–52 (49 ref.)

SECRETION

The flow rate and composition of human labial gland saliva. Ferguson DB. **Arch Oral Biol** 1999 May;44 Suppl 1:S11–4 (30 ref.)

Role of epidermal growth factor (EGF) in oesophageal mucosal integrity. Marcinkiewicz M, et al. **Curr Med Res Opin** 1998;14(3):145–53 (69 ref.)

VIROLOGY

Oral transmission of HIV [editorial] Rothenberg RB, et al. **AIDS** 1998 Nov 12;12(16):2095–105 (126 ref.)

Endogenous salivary inhibitors of human immunodeficiency virus. Shugars DC, et al. **Arch Oral Biol** 1999 Jun; 44(6):445–53 (68 ref.)

Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431–5 (33 ref.)

SALIVARY DUCT CALCULI

PATHOLOGY

Parotid sialolithiasis. Bodner L. **J Laryngol Otol** 1999 Mar; 113(3):266–7 (15 ref.)

SALIVARY DUCT STONES see **SALIVARY DUCT CALCULI**

SALIVARY DUCTS

METABOLISM

Control of Na+ transport in salivary duct epithelial cells by cytosolic Cl- and Na+. Cook DI, et al. **Eur J Morphol** 1998 Aug;36 Suppl:67–73 (20 ref.)

PATHOLOGY

Mounting evidence against current histogenetic concepts for salivary gland tumorigenesis. Dardick I. **Eur J Morphol** 1998 Aug;36 Suppl:257–61 (47 ref.)

Malignant tumors of Stensen's duct. Steiner M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):73–7 (24 ref.)

ULTRASTRUCTURE

Comparative ultrastructure of intercalated ducts in major salivary glands: a review. Tandler B, et al. **Anat Rec** 1998 Sep;252(1):64–91 (282 ref.)

SALIVARY GLAND CALCULI

COMPLICATIONS

A megalith of the parotid salivary gland. Kesse WK, et al. **J Laryngol Otol** 1998 Aug;112(8):784–5 (6 ref.)

SALIVARY GLAND DISEASES

DIAGNOSIS

Salivary gland disorders. Neoplastic and nonneoplastic. Rice DH. **Med Clin North Am** 1999 Jan;83(1):197–218, xi (52 ref.)

IMMUNOLOGY

New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Humphreys-Beher MG, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S21–5 (38 ref.)

SALIVARY GLAND NEOPLASMS

DIAGNOSIS

Unusual presentation of a salivary pleomorphic adenoma: a case report and review of the literature. Murphy RJ, et al. **Cutis** 1999 Mar;63(3):167–8 (8 ref.)

Lipomatosis of the minor salivary glands. Saleh HA, et al. **J Laryngol Otol** 1998 Sep;112(9):895–7 (19 ref.)

Salivary gland disorders. Neoplastic and nonneoplastic. Rice DH. **Med Clin North Am** 1999 Jan;83(1):197–218, xi (52 ref.)

EPIDEMIOLOGY

[Salivary gland tumors. Apropos of 48 surgical cases] Ouoba K, et al. **Dakar Med** 1998;43(1):60–4 (17 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Sialoblastoma: clinicopathological/immunohistochemical study. Brandwein M, et al. **Am J Surg Pathol** 1999 Mar; 23(3):342–8 (23 ref.)

Oncocytic mucoepidermoid carcinoma of the salivary glands. Jahan-Parwar B, et al. **Am J Surg Pathol** 1999 May; 23(5):523–9 (47 ref.)

Clear cell neoplasms in salivary glands: clearly a diagnostic challenge. Ellis GL. **Ann Diagn Pathol** 1998 Feb;2(1):61–78 (99 ref.)

Advances in clinical investigations of salivary gland tumorigenesis. el-Naggar AK, et al. **Ann Pathol** 1999 Mar; 19(1):19–22 (39 ref.)

Hybrid carcinomas of salivary glands. Report of 4 cases and review of the literature. Croitoru CM, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):698–702 (11 ref.)

Mounting evidence against current histogenetic concepts for salivary gland tumorigenesis. Dardick I. **Eur J Morphol** 1998 Aug;36 Suppl:257–61 (47 ref.)

Sialadenoma papilliferum of the palate: case report and literature review. Argyres MI, et al. **J Cutan Pathol** 1999 May;26(5):259–62 (34 ref.)

Epithelial-myoepithelial carcinoma of the salivary gland--a low grade malignant neoplasm? Report of two cases and review of the literature. Kasper HU, et al. **Pathol Res Pract** 1999;195(3):189–92 (27 ref.)

Oncocytic and oncocytoid tumors of the salivary glands. Paulino AF, et al. **Semin Diagn Pathol** 1999 May; 16(2):98–104 (31 ref.)

[Basal cell adenocarcinoma of the minor salivary glands of the palate. Case report and review of the literature] Plath T, et al. **Mund Kiefer Gesichtschir** 1998 Sep;2(5):275–8 (22 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

The role of high-LET radiotherapy compared to conformal photon radiotherapy in adenoid cystic carcinoma. Debus J, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:63–5 (12 ref.)

SURGERY

Neck dissection in the treatment of cancer of major salivary glands. Medina JE. **Otolaryngol Clin North Am** 1998 Oct; 31(5):815–22 (21 ref.)

SALIVARY GLAND TUMOR, MIXED see **ADENOMA, PLEOMORPHIC**

SALIVARY GLAND VIRUS DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

SALIVARY GLAND VIRUSES see **CYTOMEGALOVIRUS**

SALIVARY GLANDS

A review of heterotopia and associated salivary gland neoplasms of the head and neck. Ferlito A, et al. **J Laryngol Otol** 1999 Apr;113(4):299–303 (54 ref.)

ABNORMALITIES

Salivary gland aplasia with cleft lip and palate: a case report and review of the literature. Matsuda C, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 May;87(5):594–9 (43 ref.)

ANATOMY & HISTOLOGY

Salivary gland sexual dimorphism: a brief review. Pinkstaff CA. **Eur J Morphol** 1998 Aug;36 Suppl:31–4 (22 ref.)

CHEMISTRY

New insights into the upregulation and function of the salivary Na+-K+-2Cl- cotransporter. Evans RL, et al. **Eur J Morphol** 1998 Aug;36 Suppl:142–6 (14 ref.)

Snare proteins essential for cyclic AMP-regulated exocytosis in salivary glands. Fujita-Yoshigaki J, et al. **Eur J Morphol** 1998 Aug;36 Suppl:46–9 (24 ref.)

SALIVARY GLANDS

CYTOLOGY

Membrane stretch and salivary glands - facts and theories. Zelles T, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S67-71 (42 ref.)

DRUG EFFECTS

Purines, a new class of agonists in salivary glands? Dehaye JP, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S39-43 (23 ref.)

Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Taylor SE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):14-26 (154 ref.)

GROWTH & DEVELOPMENT

HGF controls branched morphogenesis in tubular glands. Maffè A, et al. **Eur J Morphol** 1998 Aug;36 Suppl:74-81 (55 ref.)

METABOLISM

Endogenous salivary inhibitors of human immunodeficiency virus. Shugars DC, et al. **Arch Oral Biol** 1999 Jun; 44(6):445-53 (68 ref.)

Fas (APO-1/CD95)-assisted suicide in NOD exocrine glands [editorial; comment] Elkon KB. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):659-61 (23 ref.) Comment on: Clin Exp Rheumatol 1998 Nov-Dec;16(6):659-61.

New insights into the upregulation and function of the salivary Na+-K+-2Cl- cotransporter. Evans RL, et al. **Eur J Morphol** 1998 Aug;36 Suppl:142-6 (14 ref.)

NMR studies of salivary glands: from energy metabolism to morphology. Seo Y, et al. **Eur J Morphol** 1998 Aug;36 Suppl:98-102 (20 ref.)

PATHOLOGY

Lymphoid complement of the human salivary glands: function and pathology. Ciccone E, et al. **Eur J Morphol** 1998 Aug;36 Suppl:252-6 (13 ref.)

PHYSIOLOGY

Re-engineering the functions of a terminally differentiated epithelial cell in vivo. Baum BJ, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:294-300 (30 ref.)

Lymphoid complement of the human salivary glands: function and pathology. Ciccone E, et al. **Eur J Morphol** 1998 Aug;36 Suppl:252-6 (13 ref.)

Preclinical and biological studies using recombinant adenoviruses encoding aquaporins 1 and 5. Delporte C, et al. **Eur J Morphol** 1998 Aug;36 Suppl:118-22 (17 ref.)

HGF controls branched morphogenesis in tubular glands. Maffè A, et al. **Eur J Morphol** 1998 Aug;36 Suppl:74-81 (55 ref.)

RADIATION EFFECTS

Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Taylor SE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):14-26 (154 ref.)

RADIONUCLIDE IMAGING

NMR studies of salivary glands: from energy metabolism to morphology. Seo Y, et al. **Eur J Morphol** 1998 Aug;36 Suppl:98-102 (20 ref.)

[Radionuclide scan of the salivary glands] Vallejo Casas JA, et al. **Rev Esp Med Nucl** 1998;17(6):450-4 (39 ref.) **(Spa)**

VIROLOGY

SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Furth PA. **Dev Biol Stand** 1998; 94:281-7 (15 ref.)

SALIVARY GLANDS, MINOR

Lipomatosis of the minor salivary glands. Saleh HA, et al. **J Laryngol Otol** 1998 Sep;112(9):895-7 (19 ref.)

Gingival salivary gland choristoma. A case report. Ledesma-Montes C, et al. **J Periodontol** 1998 Oct; 69(10):1164-6 (12 ref.)

ANATOMY & HISTOLOGY

Morphological features of the minor salivary glands. Hand AR, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S3-10 (63 ref.)

PATHOLOGY

[Basal cell adenocarcinoma of the minor salivary glands of the palate. Case report and review of the literature] Plath T, et al. **Mund Kiefer Gesichtschir** 1998 Sep;2(5):275-8 (22 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

The flow rate and composition of human labial gland saliva. Ferguson DB. **Arch Oral Biol** 1999 May;44 Suppl 1:S11-4 (30 ref.)

Ion transport and signalling in human labial glands. Turner RJ, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S15-9 (35 ref.)

SALIVARY PROTEINS

Human salivary histatins: promising anti-fungal therapeutic agents. Tsai H, et al. **Crit Rev Oral Biol Med** 1998; 9(4):480-97 (118 ref.)

PHYSIOLOGY

Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431-5 (33 ref.)

SALIVARY STONES see **SALIVARY GLAND CALCULI**

SALIVATION

see related
XEROSTOMIA

DRUG EFFECTS

Purines, a new class of agonists in salivary glands? Dehaye JP, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S39-43 (23 ref.)

A brief overview of the oral complications in pediatric oncology patients and suggested management strategies. Chin EA. **ASDC J Dent Child** 1998 Nov-Dec;65(6):468-73 (50 ref.)

[Oral premedication with clonidine as an alternative in dental practice. The effects on the pain threshold, blood pressure and salivary flow] Fanini D, et al. **Minerva Stomatol** 1998 Sep;47(9):453-64 (57 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

A brief overview of the oral complications in pediatric oncology patients and suggested management strategies. Chin EA. **ASDC J Dent Child** 1998 Nov-Dec;65(6):468-73 (50 ref.)

SALK VACCINE see **POLIOVIRUS VACCINE**

SALMO GAIRDNERI see **ONCORHYNCHUS MYKISS**

SALMO SALAR

GENETICS

The impact of ancestral tetraploidy on antibody heterogeneity in salmonid fishes. Hordvik I. **Immunol Rev** 1998 Dec;166:153-7 (28 ref.)

IMMUNOLOGY

The impact of ancestral tetraploidy on antibody heterogeneity in salmonid fishes. Hordvik I. **Immunol Rev** 1998 Dec;166:153-7 (28 ref.)

SALMO SALMO see **SALMON**

SALMON

MICROBIOLOGY

Mobile drug resistance genes among fish bacteria. Sørum H. **APMIS Suppl** 1998;84:74-6 (10 ref.)

SALMON, ATLANTIC see **SALMO SALAR**

SALMON, CHINOOK see **SALMON**

SALMON, PINK see **SALMON**

SALMON, SOCKEYE see **SALMON**

SALMONELLA

CLASSIFICATION

An outbreak of extended-spectrum, beta-lactamase-producing Salmonella senftenberg in a burns ward. Revathi G, et al. **J Hosp Infect** 1998 Dec; 40(4):295-302 (36 ref.)

[History of nomenclature of Salmonella species and the legitimate names] Ezaki T. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):629-33 (14 ref.) **(Jpn)**

GENETICS

Molecular basis of the interaction of Salmonella with the intestinal mucosa. Darwin KH, et al. **Clin Microbiol Rev** 1999 Jul;12(3):405-28 (263 ref.)

Statistical methods for the Ames Salmonella assay: a review. Kim BS, et al. **Mutat Res** 1999 Jan;436(1):113-22 (29 ref.)

GROWTH & DEVELOPMENT

Bacterial flagellation and cell division. Aizawa SI, et al. **Genes Cells** 1998 Oct;3(10):625-34 (50 ref.)

IMMUNOLOGY

The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases. Gómez-Duarte OG, et al. **Vaccine** 1999 Mar 26;17(13-14):1667-73 (81 ref.)

PATHOGENICITY

Type III secretion machines and the pathogenesis of enteric infections caused by Yersinia and Salmonella spp. Lee VT, et al. **Immunol Rev** 1999 Apr;168:241-55 (154 ref.)

Interactions of Salmonella with host cells: encounters of the closest kind [comment] Galán JE. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14006-8 (30 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14057-9.

[Pathogenic power of Salmonellae: virulence factors and study models] Millemann Y. **Vet Res** 1998 Sep-Oct; 29(5):385-407 (132 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Interactions of Salmonella with host cells: encounters of the closest kind [comment] Galán JE. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14006-8 (30 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14057-9.

[Pathogenic power of Salmonellae: virulence factors and study models] Millemann Y. **Vet Res** 1998 Sep-Oct; 29(5):385-407 (132 ref.) (Eng. Abstr.) **(Fre)**

SALMONELLA ARIZONAE

[Systemic Salmonella arizonae infections in patients with a deficiency of cell-mediated immunity. A report of 2 cases and a review of the literature] Carfagna P, et al. **Recenti Prog Med** 1998 Dec;89(12):632-6 (25 ref.) (Eng. Abstr.) **(Ita)**

SALMONELLA ENTERICA

PATHOGENICITY

Interaction of Salmonella with host cells through the centisome 63 type III secretion system. Galán JE. **Curr Opin Microbiol** 1999 Feb;2(1):46-50 (32 ref.)

Evolution of host adaptation in Salmonella enterica. Bäumler AJ, et al. **Infect Immun** 1998 Oct;66(10):4579-87 (123 ref.)

PHYSIOLOGY

Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Heinrichs DE, et al. **Mol Microbiol** 1998 Oct;30(2):221-32 (33 ref.)

SALMONELLA ENTERITIDIS

Salmonella infection in total hip replacement--report of successful reimplantation and review of the literature. Chen CM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul; 62(7):472-6 (13 ref.)

Spontaneous non-typhoidal Salmonella peritonitis in patients with serious underlying disorders. de la Fuente-Aguado J, et al. **Infection** 1999 May-Jun;27(3):224-7 (21 ref.)

Salmonella enteritidis infections in the United States. Angulo FJ, et al. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1729-31 (10 ref.)

[Infected aneurysms of the abdominal aorta. Personal case reports] Azzarone M, et al. **Minerva Chir** 1998 Jun; 53(6):535-8 (8 ref.) (Eng. Abstr.) **(Ita)**

[Bleeding infectious enteritis] Mitsuda T, et al. **Nippon Rinsho** 1998 Sep;56(9):2376-81 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Salmonella enteritidis meningitis in adults. Report of 2 cases and review of the literature (letter)] Asensi JM, et al. **Rev Clin Esp** 1998 Sep;198(9):633-4 (10 ref.) **(Spa)**

SALMONELLA FOOD POISONING

EPIDEMIOLOGY

Salmonella enteritidis infections in the United States. Angulo FJ, et al. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1729-31 (10 ref.)

SALMONELLA INFECTIONS

Vertebral osteomyelitis due to salmonellae: report of two cases and review. Santos EM, et al. **Clin Infect Dis** 1998 Aug;27(2):287-95 (86 ref.)

Epidemiologic aspects, control, and importance of multiple-drug resistant Salmonella Typhimurium DT104 in the United States. Akkina JE, et al. **J Am Vet Med Assoc** 1999 Mar 15;214(6):790-8 (46 ref.)

Subdural empyema due to salmonella infection. Jain KC, et al. **Pediatr Neurosurg** 1998 Feb;28(2):89-90 (8 ref.)

[Pleuropulmonary manifestations of salmonellosis] Hovette P, et al. **Med Trop (Mars)** 1998;58(4):403-7 (67 ref.) (Eng. Abstr.) **(Fre)**

[Bleeding infectious enteritis] Mitsuda T, et al. **Nippon Rinsho** 1998 Sep;56(9):2376-81 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Salmonellosis] Sagara H. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):134-7 (11 ref.) **(Jpn)**

[Salmonella enteritidis meningitis in adults. Report of 2 cases and review of the literature (letter)] Asensi JM, et al. **Rev Clin Esp** 1998 Sep;198(9):633-4 (10 ref.) **(Spa)**

CLASSIFICATION

[Nosocomial salmonellosis as an independent nosological form of human infectious pathology] Akimkin VG. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):106-10 (22 ref.) **(Rus)**

COMPLICATIONS

Acute bacterial infections and HIV disease. Gilks CF. **Br Med Bull** 1998;54(2):383-93 (48 ref.)

Salmonella meningitis and its complications in infants. Lee WS, et al. **J Paediatr Child Health** 1999 Aug;35(4):379-82 (23 ref.)

Schistosomiasis and associated infections. Lambertucci JR, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:135-9 (49 ref.)

DIAGNOSIS

[Infected aneurysms of the abdominal aorta. Personal case reports] Azzarone M, et al. **Minerva Chir** 1998 Jun; 53(6):535-8 (8 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Salmonella typhimurium DT104: a virulent and drug-resistant pathogen. Poppe C, et al. **Can Vet J** 1998 Sep;39(9):559-65 (48 ref.)

ETIOLOGY

Salmonella infection in total hip replacement--report of successful reimplantation and review of the literature. Chen CM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul; 62(7):472-6 (13 ref.)

[Systemic Salmonella arizonae infections in patients with a deficiency of cell-mediated immunity. A report of 2 cases and a review of the literature] Carfagna P, et al. **Recenti Prog Med** 1998 Dec;89(12):632-6 (25 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Type III secretion machines and the pathogenesis of enteric infections caused by Yersinia and Salmonella spp. Lee VT, et al. **Immunol Rev** 1999 Apr;168:241-55 (154 ref.)

MICROBIOLOGY

Spontaneous non-typhoidal Salmonella peritonitis in patients with serious underlying disorders. de la Fuente-Aguado J, et al. **Infection** 1999 May-Jun;27(3):224-7 (21 ref.)

An outbreak of extended-spectrum, beta-lactamase-producing Salmonella senftenberg in a burns ward. Revathi G, et al. **J Hosp Infect** 1998 Dec; 40(4):295-302 (36 ref.)

SURGERY

Salmonella mycotic aneurysms: traditional and "alternative" surgical repair with arterial homograft. Locati P, et al. **Minerva Cardioangiol** 1999 Jan-Feb;47(1-2):31-7 (34 ref.) **(Eng, Ita)**

THERAPY

Septic arthritis. Perry CR. **Am J Orthop** 1999 Mar; 28(3):168-78 (93 ref.)

TRANSMISSION

[Animals as sources of infections in humans--salmonellosis] Meyer H. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug; 106(8):344-51 (58 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Aortic valve endocarditis caused by Salmonella species. Pliakos C, et al. **J Clin Ultrasound** 1999 Jan;27(1):45-8 (21 ref.)

SALMONELLA INFECTIONS, ANIMAL

EPIDEMIOLOGY

Salmonella typhimurium DT104: a virulent and drug-resistant pathogen. Poppe C, et al. **Can Vet J** 1998 Sep;39(9):559-65 (48 ref.)

Salmonella Typhimurium DT104 in cattle in Great Britain. Hollinger K, et al. **J Am Vet Med Assoc** 1998 Dec 15; 213(12):1732-3 (6 ref.)

MICROBIOLOGY

Multi-resistant Salmonella Typhimurium DT104--implications for animal industries and the veterinary profession. Crerar SK, et al. **Aust Vet J** 1999 Mar;77(3):170-1 (11 ref.)

PREVENTION & CONTROL

Use of competitive exclusion in food animals. Nisbet DJ. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1744-6 (14 ref.)

Vaccination for control of Salmonella in poultry. Zhang-Barber L, et al. **Vaccine** 1999 Jun 4; 17(20-21):2538-45 (79 ref.)

TRANSMISSION

[Animals as sources of infections in humans--salmonellosis] Meyer H. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug; 106(8):344-51 (58 ref.) (Eng. Abstr.) **(Ger)**

SALMONELLA TYPHI

DRUG EFFECTS

Ciprofloxacin-resistant Salmonella typhi and treatment failure [letter] [see comments] Threlfall EJ, et al. **Lancet** 1999 May 8;353(9164):1590-1 (5 ref.) Comment in: Lancet 1999 Jul 10;354(9173):164.

ISOLATION & PURIFICATION

Subdural empyema due to salmonella infection. Jain KC, et al. **Pediatr Neurosurg** 1998 Feb;28(2):89-90 (8 ref.)

SALMONELLA TYPHIMURIUM

[Poison needles and tails of Salmonella typhimurium: pathogen export apparatus and flagellar motor] Aizawa S. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):1-7 (27 ref.) **(Jpn)**

CLASSIFICATION

Salmonella Typhimurium DT104 in cattle in Great Britain. Hollinger K, et al. **J Am Vet Med Assoc** 1998 Dec 15; 213(12):1732-3 (6 ref.)

DRUG EFFECTS

Epidemiologic aspects, control, and importance of multiple-drug resistant Salmonella Typhimurium DT104 in the United States. Akkina JE, et al. **J Am Vet Med Assoc** 1999 Mar 15;214(6):790-8 (46 ref.)

GENETICS

Identification of carcinogenic substances by means of short-term tests in bacteria. Quillardet P, et al. **IARC Sci Publ** 1999;(146):487-97 (46 ref.)

PATHOGENICITY

Multi-resistant Salmonella Typhimurium DT104--implications for animal industries and the veterinary profession. Crerar SK, et al. **Aust Vet J** 1999 Mar;77(3):170-1 (11 ref.)

Salmonella typhimurium DT104: a virulent and drug-resistant pathogen. Poppe C, et al. **Can Vet J** 1998 Sep;39(9):559-65 (48 ref.)

Enteropathogenic E. coli, Salmonella, and Shigella: masters of host cell cytoskeletal exploitation. Goosney DL, et al. **Emerg Infect Dis** 1999 Mar-Apr;5(2):216-23 (63 ref.)

The relationship between acid stress responses and virulence in Salmonella typhimurium and Listeria monocytogenes. Gahan CG, et al. **Int J Food Microbiol** 1999 Sep 15; 50(1-2):93-100 (38 ref.)

PHYSIOLOGY

The starvation-stress response (SSR) of Salmonella. Spector MP. **Adv Microb Physiol** 1998;40:233-79 (100 ref.)

The relationship between acid stress responses and virulence in Salmonella typhimurium and Listeria monocytogenes. Gahan CG, et al. **Int J Food Microbiol** 1999 Sep 15; 50(1-2):93-100 (38 ref.)

SALMONELLA TYPHOSA see **SALMONELLA TYPHI**

SALMONELLOSIS see **SALMONELLA INFECTIONS**

SALMONIDAE

GENETICS

The salmonid class I MHC: limited diversity in a primitive teleost. Miller KM, et al. **Immunol Rev** 1998 Dec; 166:279-93 (25 ref.)

SALPINGITIS

[Adnexitis (salpingitis, oophoritis)] Matsuoka R, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):215-7 (2 ref.) **(Jpn)**

SALSOLINE ALKALOIDS

METABOLISM

N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease. Naoi M, et al. **Adv Neurol** 1999; 80:259-64 (17 ref.)

SALT GLAND

PHYSIOLOGY

Vertebrate salt glands: short- and long-term regulation of function. Shuttleworth TJ, et al. **J Exp Zool** 1999 Jun 1; 283(7):689-701 (104 ref.)

SALTS

METABOLISM

The renin-angiotensin system and its receptors. Stroth U, et al. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S21-8; discussion S41-3 (115 ref.)

SALVAGE THERAPY

Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Canellos GP. **Ann Oncol** 1998;9 Suppl 5:S91-6 (61 ref.)

Radiation therapy as a component of high-dose salvage strategies in Hodgkin's disease. Hoppe RT. **Ann Oncol** 1998;9 Suppl 5:S87-90 (14 ref.)

Primary refractory Hodgkin's disease. Horning SJ. **Ann Oncol** 1998;9 Suppl 5:S97-101 (20 ref.)

Second-line treatment for primary central nervous system lymphoma. Reni M, et al. **Br J Cancer** 1999 Feb; 79(3-4):530-4 (44 ref.)

Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? Goldberg RM. **Semin Oncol** 1998 Oct;25(5 Suppl 11):21-8 (40 ref.)

Efficacy and toxicity of irinotecan in patients with colorectal cancer. Rothenberg ML. **Semin Oncol** 1998 Oct;25(5 Suppl 11):39-46 (24 ref.)

ECONOMICS

The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. Bomalaski JJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):11-5 (37 ref.)

METHODS

Salvage surgery for recurrent nasopharyngeal cancer. Morton RP. **Clin Otolaryngol** 1998 Oct;23(5):397-402 (43 ref.)

Rescue and salvage of casualties suffering from the crush syndrome after mass disasters. Better OS. **Mil Med** 1999 May;164(5):366-9 (24 ref.)

[Organ-salvaging surgeries in combination with vagotomy for perforative pyloroduodenal ulcer] Chislenko IV. **Klin Khir** 1998;(5):40-2 (25 ref.) **(Rus)**

SAMPLE SIZE

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. Smeeth L, et al. **BMJ** 1999 Jun 5;318(7197):1548-51 (32 ref.)

Statistical methods in epidemiology. II: A commonsense approach to sample size estimation. Rigby AS, et al. **Disabil Rehabil** 1998 Nov;20(11):405-10 (11 ref.)

Simple sample size calculation for cluster-randomized trials. Hayes RJ, et al. **Int J Epidemiol** 1999 Apr;28(2):319-26 (24 ref.)

Sample size calculations in studies of test accuracy. Obuchowski NA. **Stat Methods Med Res** 1998 Dec; 7(4):371-92 (36 ref.)

SAMPLING BIAS see **SELECTION BIAS**

SAMPLING STUDIES

Estimating and generalizing with clustered sampling in general practice. Sayer GP. **Aust Fam Physician** 1999 Jan; 28 Suppl 1:S32-4 (8 ref.)

SAN MIGUEL SEA LION VIRUSES see **CALICIVIRUS**

SAND-DOLLAR see **SEA URCHINS**

SANDFLIES see **PSYCHODIDAE**

SANDHOFF DISEASE

METABOLISM

Glycosphingolipid degradation and animal models of GM2-gangliosidoses. Kolter T, et al. **J Inherit Metab Dis** 1998 Aug;21(5):548-63 (54 ref.)

SANITARY ENGINEERING

METHODS

Coming to grips with a slippery issue: human waste disposal in cold climates. Meyer-Rochow VB. **Int J Circumpolar Health** 1999 Jan;58(1):57-62 (33 ref.)

SAO PAULO TYPHUS see **ROCKY MOUNTAIN SPOTTED FEVER**

SAPHENOUS VEIN

INJURIES

Inadvertent arterial injury during saphenous vein stripping: three cases and therapeutic strategies. Ramsheyi A, et al. **Arch Surg** 1998 Oct;133(10):1120-3 (6 ref.)

SAPHENOUS VEIN

METABOLISM

Molecular and cellular changes in vein grafts: influence of pulsatile stretch. Powell JT, et al. **Curr Opin Cardiol** 1998 Nov;13(6):453–8 (27 ref.)

SURGERY

Inadvertent arterial injury during saphenous vein stripping: three cases and therapeutic strategies. Ramsheyi A, et al. **Arch Surg** 1998 Oct;133(10):1120–3 (6 ref.)

TRANSPLANTATION

Saphenous vein graft ectasia: an unusual late complication of coronary artery bypass surgery. A case report. Sharifi M, et al. **Angiology** 1999 Jun;50(6):497–501 (16 ref.)

Molecular and cellular changes in vein grafts: influence of pulsatile stretch. Powell JT, et al. **Curr Opin Cardiol** 1998 Nov;13(6):453–8 (27 ref.)

Less-invasive saphenous harvest. Iafrati MM. **Surg Clin North Am** 1999 Jun;79(3):623–44 (62 ref.)

Minimally invasive in situ bypass. Rosenthal D, et al. **Surg Clin North Am** 1999 Jun;79(3):645–52, x (07 ref.)

SAPHO SYNDROME see **ACQUIRED HYPEROSTOSIS SYNDROME**

SAPONINS

CHEMISTRY

Relationship between chemical structures and biological activities of triterpenoid saponins from soybean. Yoshiki Y, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2291–9 (60 ref.)

ISOLATION & PURIFICATION

Recent progress in biotechnology of Mexican medicinal plants. Villarreal ML, et al. **Adv Exp Med Biol** 1999; 464:221–33 (22 ref.)

METABOLISM

Production of ginseng and its bioactive components in plant cell culture: current technological and applied aspects. Wu J, et al. **J Biotechnol** 1999 Feb 19;68(2–3):89–99 (56 ref.)

SAQUINAVIR

ADMINISTRATION & DOSAGE

[The new saquinavir formulation SGC (Soft Gel Capsule)] Katlama C. **Presse Med** 1999 Apr 17;28(15):815–8 (24 ref.) **(Fre)**

SARCOIDOSIS

see related
KVEIM TEST

Sarcoidosis: a primary care review. Belfer MH, et al. **Am Fam Physician** 1998 Dec;58(9):2041–50, 2055–6 (10 ref.)

Sarcoidosis: a pediatric perspective. Shetty AK, et al. **Clin Pediatr (Phila)** 1998 Dec;37(12):707–17 (126 ref.)

Update on sarcoidosis. Jones RE, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):83–7 (37 ref.)

Animal models of granulomatous inflammation. Kunkel SL, et al. **Semin Respir Infect** 1998 Sep;13(3):221–8 (56 ref.)

Extrapulmonary sarcoidosis. Lynch JP 3rd, et al. **Semin Respir Infect** 1998 Sep;13(3):229–54 (261 ref.)

[Sarcoidosis–lymphoma syndrome] Nitta M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):323–5 (11 ref.) **(Jpn)**

COMPLICATIONS

Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Hunt J, et al. **Mod Pathol** 1999 Mar;12(3):325–8 (12 ref.)

Polyradiculopathy in sarcoidosis. Koffman B, et al. **Muscle Nerve** 1999 May;22(5):608–13 (38 ref.)

Membranous nephropathy associated with childhood sarcoidosis. Dimitriades C, et al. **Pediatr Nephrol** 1999 Jun; 13(5):444–7 (16 ref.)

Life-threatening situations in sarcoidosis. James DG. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):134–9 (13 ref.)

Peritoneal sarcoidosis: case report and review of the literature. Uthman IW, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):351–4 (21 ref.)

[Otolaryngological manifestations of sarcoidosis. Report of 10 cases and review of the literature] Houliat T, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(1):19–23 (20 ref.) (Eng. Abstr.) **(Fre)**

[Sarcoidosis of the central nervous system] Valeyre D, et al. **Rev Med Interne** 1998 Jun;19(6):409–14 (38 ref.) (Eng. Abstr.) **(Fre)**

[Nervous system diseases associated with sarcoidosis] Iizuka T, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10; 88(5):808–17 (5 ref.) **(Jpn)**

[Symptomatic eye changes during the course of sarcoidosis] Cieślicka E, et al. **Klin Oczna** 1998;100(3):179–83 (28 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Sarcoidosis in children [letter] Shetty AK, et al. **Acta Paediatr** 1999 Feb;88(2):235 (9 ref.)

MR imaging changes of lumbar vertebral sarcoidosis. Fisher AJ, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):354–6 (8 ref.)

A case series of ocular disease as the primary manifestation in sarcoidosis. Sivakumar M, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):560–6 (16 ref.)

Diagnosing the systemic associations of anterior uveitis. Smith JR, et al. **Aust N Z J Ophthalmol** 1998 Nov; 26(4):319–26 (36 ref.)

Renal granulomatous sarcoidosis in childhood: a report of 11 cases and a review of the literature. Coutant R, et al. **Eur J Pediatr** 1999 Feb;158(2):154–9 (35 ref.)

Sarcoidosis of the cauda equina mimicking leptomeningeal malignancy. Abrey LE, et al. **J Neurooncol** 1998 Sep; 39(3):261–5 (11 ref.)

Sarcoidosis presenting as a tumorlike muscular lesion. Case report and review of the literature. Zisman DA, et al. **Medicine (Baltimore)** 1999 Mar;78(2):112–22 (68 ref.)

Diagnostic role of Mantoux test site biopsy in neurosarcoidosis. Mankodi AK, et al. **Neurology** 1998 Oct; 51(4):1216–8 (9 ref.)

Sarcoidosis of the eye, orbit, and central nervous system. Role of MR imaging. Mafee MF, et al. **Radiol Clin North Am** 1999 Jan;37(1):73–87, x (53 ref.)

Whipple's disease presenting as sarcoidosis and valvular heart disease. Wolfert AL, et al. **South Med J** 1999 Aug; 92(8):820–5 (33 ref.)

[Manifestations in the posterior segment during sarcoidosis] Razavi S, et al. **J Fr Ophtalmol** 1999 Feb;22(1):110–21 (97 ref.) **(Fre)**

[Diagnostic-therapeutic procedures in ocular sarcoidosis] Cieślicka E, et al. **Klin Oczna** 1998;100(3):185–8 (28 ref.) (Eng. Abstr.) **(Pol)**

[Sarcoidosis 10 years later (editorial)] Mañá J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):54–5 (21 ref.) **(Spa)**

DRUG THERAPY

Methotrexate for sarcoidosis. Baughman RP. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):147–9 (27 ref.)

A clinical approach to the use of methotrexate for sarcoidosis. Baughman RP, et al. **Thorax** 1999 Aug;54(8):742–6 (61 ref.)

EPIDEMIOLOGY

Ocular sarcoidosis in Kuwait with a review of literature. Hegab SM, et al. **Int Ophthalmol** 1997–98;21(5):255–60 (51 ref.)

ETIOLOGY

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. **Am J Respir Crit Care Med** 1999 Aug; 160(2):736–55 (331 ref.)

Epithelioid cell granulomatosis of the lung: new insights and concepts. Popper HH. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):32–46 (62 ref.)

GENETICS

Genetics of sarcoidosis. Iannuzzi MC. **Monaldi Arch Chest Dis** 1998 Dec;53(6):609–13 (58 ref.)

IMMUNOLOGY

Sarcoidosis: immunopathogenetic concepts and their clinical application. Müller-Quernheim J. **Eur Respir J** 1998 Sep; 12(3):716–38 (305 ref.)

Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Hunt J, et al. **Mod Pathol** 1999 Mar;12(3):325–8 (12 ref.)

Cells and cytokines involved in the pathogenesis of sarcoidosis. Moller DR. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):24–31 (59 ref.)

[Physiopathology of sarcoidosis] Delaporte E, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):845–50 (32 ref.) **(Fre)**

PATHOLOGY

Granulomatous interstitial nephritis in extrapulmonary sarcoidosis. Utaş C, et al. **Clin Nephrol** 1999 Apr; 51(4):252–4 (8 ref.)

Cutaneous sarcoidosis. Wilson NJ, et al. **Postgrad Med J** 1998 Nov;74(877):649–52 (22 ref.)

Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Judson MA, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):75–86 (115 ref.)

PHYSIOPATHOLOGY

[Physiopathology of sarcoidosis] Delaporte E, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):845–50 (32 ref.) **(Fre)**

RADIOGRAPHY

Long-term radiographic follow-up in a patient with osteosclerotic sarcoidosis of the spine and pelvis. Franco M, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):586–90 (17 ref.)

Sarcoidosis and the pancreas. Siavelis HA, et al. **Surgery** 1999 Apr;125(4):456–61 (32 ref.)

SURGERY

Surgical management for instability and paraplegia caused by spinal sarcoidosis. A case report. Tzagarakis GP, et al. **Spine** 1998 Aug 1;23(15):1711–4 (24 ref.)

THERAPY

Sarcoidosis: is therapy effective? Baughman RP, et al. **Semin Respir Infect** 1998 Sep;13(3):255–73 (226 ref.)

[Diagnostic-therapeutic procedures in ocular sarcoidosis] Cieślicka E, et al. **Klin Oczna** 1998;100(3):185–8 (28 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

EUS in gastric sarcoidosis. De Angelis C, et al. **Gastrointest Endosc** 1999 May;49(5):639–41 (18 ref.)

SARCOIDOSIS, PULMONARY

Animal models of granulomatous inflammation. Kunkel SL, et al. **Semin Respir Infect** 1998 Sep;13(3):221–8 (56 ref.)

Epidemiology, demographics, and genetics of sarcoidosis. Rybicki BA, et al. **Semin Respir Infect** 1998 Sep; 13(3):166–73 (67 ref.)

COMPLICATIONS

Localized scleroderma associated with sarcoidosis [letter] Biasi D, et al. **Clin Exp Rheumatol** 1998 Nov-Dec; 16(6):761–2 (17 ref.)

DIAGNOSIS

Diagnostic and therapeutic challenges. Schatz H, et al. **Retina** 1998;18(6):551–3 (2 ref.)

DRUG THERAPY

Oral and inhaled corticosteroids in the treatment of pulmonary sarcoidosis--a critical reappraisal. Milman N. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):150–7 (46 ref.)

ETIOLOGY

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. **Am J Respir Crit Care Med** 1999 Aug; 160(2):736–55 (331 ref.)

Metals that cause sarcoidosis. Newman LS. **Semin Respir Infect** 1998 Sep;13(3):212–20 (88 ref.)

Kveim antigen: what does it tell us about causation of sarcoidosis? Teirstein AS. **Semin Respir Infect** 1998 Sep; 13(3):206–11 (57 ref.)

[Sarcoidosis of the respiratory organs: the problems of etiology and pathogenesis, classification and X-ray diagnosis] Dmitrieva LI, et al. **Vestn Rentgenol Radiol** 1998 Jul-Aug;(4):33–9 (19 ref.) **(Rus)**

GENETICS

T-cell receptor genes in sarcoidosis. Moller DR. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):158–64 (61 ref.)

IMMUNOLOGY

Cytokines in sarcoidosis. Agostini C, et al. **Semin Respir Infect** 1998 Sep;13(3):184–96 (75 ref.)

Involvement of T cells and alterations in T cell receptors in sarcoidosis. Moller DR. **Semin Respir Infect** 1998 Sep; 13(3):174–83 (80 ref.)

MICROBIOLOGY

The role of mycobacteria in the pathogenesis of sarcoidosis. Hance AJ. **Semin Respir Infect** 1998 Sep;13(3):197–205 (80 ref.)

PATHOLOGY

Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Judson MA, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):75–86 (115 ref.)

PHYSIOPATHOLOGY

Clinical courses and prognoses of pulmonary sarcoidosis. Nagai S, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):293–8 (28 ref.)

RADIOGRAPHY

Sarcoidosis: tracking a mystery ailment. Russell C, et al.

Radiol Technol 1999 Jan-Feb;70(3):285-6 (6 ref.)
High resolution computed tomography in sarcoidosis: a clinical perspective. Wells A.
Sarcoidosis Vasc Diffuse Lung Dis 1998 Sep;15(2):140-6 (41 ref.)

SARCOLEMMA

GENETICS

[Sarcoglycanopathies] Colomer J. **Rev Neurol** 1999 Jan 16-31;28(2):150-3 (30 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Regulation of cardiac sarcolemmal Na+/H+ exchanger activity by endogenous ligands. Relevance to ischemia. Avkiran M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:335-45 (77 ref.)
Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Gross GJ, et al. **Circ Res** 1999 May 14;84(9):973-9 (53 ref.)
Caveolar microdomains of the sarcolemma: compartmentation of signaling molecules comes of age [editorial] Ostrom RS, et al. **Circ Res** 1999 May 14; 84(9):1110-2 (25 ref.)

PHYSIOLOGY

Regulation of cardiac sarcolemmal Na+/H+ exchanger activity: potential pathophysiological significance of endogenous mediators and oxidant stress. Avkiran M, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):25-32 (84 ref.)

ULTRASTRUCTURE

Caveolar microdomains of the sarcolemma: compartmentation of signaling molecules comes of age [editorial] Ostrom RS, et al. **Circ Res** 1999 May 14; 84(9):1110-2 (25 ref.)

SARCOLYSINE see **MELPHALAN**

SARCOMA

see related
SARCOMA VIRUSES, AVIAN

Soft tissue sarcomas: integrating primary care recognition with tertiary care center treatment. Rosenthal TC, et al. **Am Fam Physician** 1999 Aug;60(2):567-72 (34 ref.)
Adult soft tissue sarcoma. Mann GB, et al.
Aust N Z J Surg 1999 May;69(5):336-43 (85 ref.)
Soft-tissue sarcomas: an update. de Saint Aubain Somerhausen N, et al. **Eur J Surg Oncol** 1999 Apr; 25(2):215-20 (35 ref.)
The Carney Triad: a lesson in observation, creativity, and perseverance [editorial; comment] Appelman HD.
Mayo Clin Proc 1999 Jun;74(6):638-40 (15 ref.) Comment on: Mayo Clin Proc 1999 Jun;74(6):543-52.
Soft tissue sarcomas of infancy. Palumbo JS, et al.
Semin Perinatol 1999 Aug;23(4):299-309 (61 ref.)

CLASSIFICATION

Histologic grading of adult soft tissue sarcomas. Coindre JM.
Verh Dtsch Ges Pathol 1998;82:59-63 (26 ref.)

DIAGNOSIS

Application of immunocytochemistry in the diagnosis of soft tissue sarcomas: a review and update. Ordóñez NG.
Adv Anat Pathol 1998 Mar;5(2):67-85 (277 ref.)
Follow-up of musculoskeletal tumours. 2. Metastatic disease. Bearcroft PW, et al. **Eur Radiol** 1999;9(2):192-200 (100 ref.)
Spindle cell tumours of the breast: practical approach to diagnosis. Al-Nafussi A. **Histopathology** 1999 Jul; 35(1):1-13 (192 ref.)
Evaluation of soft-tissue tumors. Springfield D.
Instr Course Lect 1999;48:617-9 (1 ref.)
Orthopaedic oncology for the nononcologist orthopaedist: introduction and common errors to avoid. Ward WG Sr.
Instr Course Lect 1999;48:577-86 (10 ref.)
Recent advances in the diagnosis of pediatric soft-tissue tumors. Kilpatrick SE, et al. **Med Pediatr Oncol** 1999 May; 32(5):373-6 (22 ref.)
Case report of a patient with an intimal sarcoma of the pulmonary trunk presenting as a pulmonary embolism. Weijmer MC, et al. **Neth J Med** 1999 Aug;55(2):80-3 (7 ref.)
Prognostic factors in soft tissue sarcoma. Levine EA.
Semin Surg Oncol 1999 Jul-Aug;17(1):23-32 (76 ref.)
Soft tissue sarcomas in children. Pappo AS, et al.
Semin Surg Oncol 1999 Mar;16(2):121-43 (127 ref.)
New diagnostic modalities in soft tissue sarcoma. Singer S.
Semin Surg Oncol 1999 Jul-Aug;17(1):11-22 (78 ref.)
Optimal radiologic imaging of soft tissue sarcomas. Varma DG. **Semin Surg Oncol** 1999 Jul-Aug;17(1):2-10 (56 ref.)
Imaging of soft tissue sarcomas. Heslin MJ, et al.
Surg Oncol Clin N Am 1999 Jan;8(1):91-107 (36 ref.)
[Standards, options and recommendations (SOR) for clinical care of rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children. Federation of the French Cancer Centers. French Society of Pediatric Oncology (published erratum appears in Bull Cancer 1999 Feb;86(2):232)] Sommelet D, et al. **Bull Cancer** 1998 Dec;85(12):1015-42 (218 ref.) (Eng. Abstr.) **(Fre)**
[Retroperitoneal sarcomas: 1. Natural history and preoperative evaluation] Bonvalot S. **J Chir (Paris)** 1999 Mar;136(1):5-9 (17 ref.) (Eng. Abstr.) **(Fre)**
[An intimal sarcoma of the pulmonary artery. An immunohistochemical study] Pérez del Rio MJ, et al.
Rev Esp Cardiol 1998 Oct;51(10):850-2 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Freireich's laws in the treatment of sarcomas. Benjamin RS.
Clin Cancer Res 1997 Dec;3(12 Pt 2):2648-54 (45 ref.)
Should patients with advanced sarcomas be treated with chemotherapy? [see comments] Benjamin RS, et al.
Eur J Cancer 1998 Jun;34(7):958-65 (43 ref.) Comment in: Eur J Cancer 1999 Feb;35(2):327.
The role of chemotherapy in the treatment of adult soft tissue sarcomas. O'Byrne K, et al. **Oncology** 1999;56(1):13-23 (84 ref.)
High-dose chemotherapy in adult sarcomas: no standard yet. Seynaeve C, et al. **Semin Oncol** 1999 Feb;26(1):119-33 (86 ref.)
New chemotherapeutic strategies for soft tissue sarcomas. Patel SR, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):47-51 (31 ref.)
Chemoradiation treatment strategies for localized sarcoma: conventional and investigational approaches. Pisters PW.
Semin Surg Oncol 1999 Jul-Aug;17(1):66-71 (25 ref.)
[Chemotherapy of soft tissue sarcoma in the adult (published erratum appears in Cancer Radiother 1999 Jan-Feb;3(1):85)] Lagarde P, et al. **Cancer Radiother** 1998 Dec;2(6):747-51 (18 ref.) (Eng. Abstr.) **(Fre)**
[Adjuvant chemotherapy in early soft tissue sarcoma and palliative chemotherapy in advanced soft tissue sarcoma in adults] Sauer H. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1066-71 (72 ref.) (Eng. Abstr.) **(Ger)**
[How do we treat refractory soft tissue sarcomas? (editorial)] Colucci G. **Clin Ter** 1998 Sep-Oct;149(5):327-8 (22 ref.) **(Ita)**

EPIDEMIOLOGY

A review of the epidemiology of soft tissue sarcoma. Olsson H. **Acta Orthop Scand Suppl** 1999 Jun;285:8-10 (29 ref.)

ETIOLOGY

Radiation induced sarcoma of the head and neck. Patel SG, et al. **Head Neck** 1999 Jul;21(4):346-54 (56 ref.)

GENETICS

Genetic changes in bone and soft tissue tumors. Mandahl N, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:30-40 (59 ref.)
Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience. Rydholm A, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:50-7 (72 ref.)
Molecular alterations in bone and soft-tissue sarcoma. Bell RS, et al. **Can J Surg** 1999 Aug;42(4):259-66 (45 ref.)
Genetics and the biologic basis of sarcomas. Bennicelli JL, et al. **Curr Opin Oncol** 1999 Jul;11(4):267-74 (65 ref.)
The cytogenetic and molecular characterization of benign and malignant soft tissue tumors. Sreekantaiah C.
Cytogenet Cell Genet 1998;82(1-2):13-29 (277 ref.)
[What is the value of recent molecular biology knowledge for surgical oncologic therapy of soft tissue sarcoma?] Willeke F. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:393-8 (28 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience. Rydholm A, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:50-7 (72 ref.)
Atypical prostatic stromal lesions. Cohen MB.
Adv Anat Pathol 1998 Nov;5(6):359-66 (13 ref.)
Low-grade fibromyxoid sarcoma: clinicopathologic case report with review of the literature. Shidham VB, et al.
Am J Clin Oncol 1999 Apr;22(2):150-5 (17 ref.)
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Fonseca R, et al.
Am J Hematol 1998 Oct;59(2):161-7 (32 ref.)
Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Kilpatrick SE.
Ann Diagn Pathol 1999 Feb;3(1):48-61 (97 ref.)
High-grade endometrial stromal sarcoma in a 10-year-old girl: case report. Wang KC, et al.
Chang Keng I Hsueh Tsa Chih 1998 Sep;21(3):312-7 (20 ref.)
Epithelioid sarcoma of the vulva. Tjalma WA, et al.
Gynecol Oncol 1999 Apr;73(1):160-4 (21 ref.)
Biopsy. Aboulafia AJ. **Instr Course Lect** 1999;48:587-90 (6 ref.)
Phosphorus MR spectroscopy in the treatment of human extremity sarcomas. Sijens PE. **NMR Biomed** 1998 Nov; 11(7):341-53 (73 ref.)
Extranodal follicular dendritic cell sarcoma of the palate. Araújo VC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Feb;87(2):209-14 (30 ref.)
A case of chromophobe renal cell carcinoma with sarcomatoid foci and a small daughter lesion. Kuroda N, et al. **Pathol Int** 1998 Oct;48(10):812-7 (30 ref.)
Epithelioid sarcoma of the penis. Clinicopathologic study of a tumor with myogenic features and review of the literature concerning this unusual location. Corsi A, et al.
Pathol Res Pract 1999;195(6):441-8; discussion 449 (50 ref.)
Histologic grading of adult soft tissue sarcomas. Coindre JM.
Verh Dtsch Ges Pathol 1998;82:59-63 (26 ref.)
[Recommendations for anatamo-pathologic management of soft tissue sarcomas in the adult. Pathologists of the FNCLCC Sarcoma Group (Fédération Nationale des Centres de Lutte Contre le Cancer)] Coindre JM.
Ann Pathol 1998 Dec;18(6):505-11 (24 ref.) (Eng. Abstr.) **(Fre)**
[Histoprognostic grade in adult soft tissue sarcomas. Evaluation method, value and limits] Guillou L, et al.
Ann Pathol 1998 Dec;18(6):473-80 (42 ref.) **(Fre)**
[Clinical experience with uterine sarcoma] Melilli GA, et al.
Minerva Ginecol 1998 Jul-Aug;50(7-8):291-5 (25 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

Is pre-operative radiotherapy superior to postoperative radiotherapy in the treatment of soft tissue sarcoma? Robinson MH, et al. **Eur J Cancer** 1998 Aug;34(9):1309-16 (17 ref.)
Adjuvant brachytherapy in the treatment of soft-tissue sarcomas. Crownover RL, et al.
Hematol Oncol Clin North Am 1999 Jun;13(3):595-607 (40 ref.)
Use of brachytherapy to preserve function in children with soft-tissue sarcomas. Nag S, et al. **Oncology (Huntingt)** 1999 Mar;13(3):361-69; discussion 369-70, 373-4 (32 ref.)
Chemoradiation treatment strategies for localized sarcoma: conventional and investigational approaches. Pisters PW.
Semin Surg Oncol 1999 Jul-Aug;17(1):66-71 (25 ref.)
Contemporary radiotherapy for soft tissue sarcoma. Wylie JP, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):33-46 (91 ref.)
[Late results of radiotherapy of soft tissue sarcoma] Schultze J, et al. **Rontgenpraxis** 1998;51(11):413-9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Radiotherapy of soft tissue sarcomas] Schwarz R, et al.
Schweiz Rundsch Med Prax 1998 Aug 19;87(34):1072-80 (100 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[Surgical management of soft tissue sarcomas: principles of resection and reconstructive plastic procedures] Steinau HU, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19; 87(34):1061-5 (17 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Pulmonary cysts as the sole metastatic manifestation of soft tissue sarcoma: case report and consideration of the pathogenesis. Hasegawa S, et al. **Chest** 1999 Jul; 116(1):263-5 (12 ref.)

SURGERY

Local recurrence after surgery for soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Trovik CS, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:45-6 (16 ref.)
Gastrointestinal sarcoma (GIST)--a review of surgical management. Lehnert T. **Ann Chir Gynaecol** 1998; 87(4):297-305 (64 ref.)
Reconstructive approaches in soft tissue sarcoma. Langstein HN, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):52-65 (27 ref.)
Retroperitoneal sarcoma--the continued challenge for surgery and oncology. Herman K, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):77-81 (33 ref.)
[Cutaneous and subcutaneous sarcomas] Champeau F, et al.
Ann Chir Plast Esthet 1998 Aug;43(4):421-38 (33 ref.) (Eng. Abstr.) **(Fre)**
[Retroperitoneal sarcomas: 2. Surgical and complementary treatment] Bonvalot S. **J Chir (Paris)** 1999 Jun;136(2):61-6 (17 ref.) (Eng. Abstr.) **(Fre)**
[Surgery of extensive retroperitoneal soft tissue sarcoma] Junginger T. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:388-92 (8 ref.) (Eng. Abstr.) **(Ger)**
[Surgical aspects in the multidisciplinary treatment of soft tissue sarcomas] Röhrborn A, et al.
Schweiz Rundsch Med Prax 1998 Aug 19;87(34):1050-60 (50 ref.) (Eng. Abstr.) **(Ger)**
[Surgical management of soft tissue sarcomas: principles of resection and reconstructive plastic procedures] Steinau HU, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19; 87(34):1061-5 (17 ref.) (Eng. Abstr.) **(Ger)**
[Gemcitabine in advanced stage soft tissue sarcoma: a phase II study] Amodio A, et al. **Clin Ter** 1999 Jan-Feb; 150(1):17-20 (25 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

The Scandinavian Sarcoma Group Register. Bauer HC, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:41-4 (19 ref.)
Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. Ham SJ, et al.
Cancer Treat Rev 1998 Dec;24(6):373-91 (319 ref.)
Soft tissue sarcoma in adults. Dirix LY, et al.
Curr Opin Oncol 1999 Jul;11(4):285-95 (66 ref.)
Present knowledge of gynecologic sarcoma management.

Verschraegen CF, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):211-23, x (36 ref.)
Phosphorus MR spectroscopy in the treatment of human extremity sarcomas. Sijens PE. **NMR Biomed** 1998 Nov; 11(7):341-53 (73 ref.)
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Schraffordt Koops H, et al. **Radiother Oncol** 1998 Jul; 48(1):1-4 (19 ref.)
Preclinical experimental therapeutic approaches in soft tissue sarcoma. Hunt KK, et al. **Semin Surg Oncol** 1999 Jul-Aug; 17(1):78-82 (27 ref.)
Immunotherapeutic approaches to sarcoma. Linehan DC, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):72-7 (37 ref.)
Soft tissue sarcomas in children. Pappo AS, et al. **Semin Surg Oncol** 1999 Mar;16(2):121-43 (127 ref.)
[Standards, options and recommendations (SOR) for clinical care of rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children. Federation of the French Cancer Centers. French Society of Pediatric Oncology (published erratum appears in Bull Cancer 1999 Feb;86(2):232)] Sommelet D, et al. **Bull Cancer** 1998 Dec;85(12):1015-42 (218 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Feline vaccine-associated sarcomas. Hendrick MJ. **Cancer Invest** 1999;17(4):273-7 (26 ref.)
Etiology of feline vaccine-associated sarcomas: history and update. Bergman PJ. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1424-5 (5 ref.)
Review of treatment options for vaccine-associated feline sarcoma. Couto CG, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1426-7 (4 ref.)
Feline vaccine-associated sarcomas: current studies on pathogenesis. Hendrick MJ. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1425-6 (5 ref.)

SARCOMA, ALVEOLAR SOFT PART

GENETICS

Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature. Joyama S, et al. **Cancer** 1999 Oct 1;86(7):1246-50 (24 ref.)

PATHOLOGY

Alveolar soft part sarcoma: a review and update. Ordóñez NG. **Adv Anat Pathol** 1999 May;6(3):125-39 (113 ref.)
Alveolar soft-part sarcoma: a review of the pathology and histogenesis. Ordóñez NG, et al. **Ultrastruct Pathol** 1998 Jul-Aug;22(4):275-92 (114 ref.)

SURGERY

Alveolar soft part sarcoma involving the ilium. A case report. Durkin RC, et al. **Clin Orthop** 1999 Feb;(359):197-202 (21 ref.)

SARCOMA, CLEAR CELL

PATHOLOGY

[Clear cell sarcoma of soft tissues. Clinico-pathological and ultrastructural analysis of a case in the head-neck region and a literature review] Bisceglia M, et al. **Pathologica** 1998 Aug;90(4):391-6 (40 ref.) (Eng. Abstr.) **(Ita)**

SARCOMA, ENDOMETRIAL STROMAL

GENETICS

Endometrial stromal sarcoma with clonal complex chromosome abnormalities. Report of a case and review of the literature. Sonobe H, et al. **Cancer Genet Cytogenet** 1999 Jul 1;112(1):34-7 (17 ref.)

SARCOMA, EPITHELIOID see **SARCOMA**

SARCOMA, EWING'S

Common musculoskeletal tumors of childhood and adolescence. Arndt CA, et al. **N Engl J Med** 1999 Jul 29; 341(5):342-52 (100 ref.)

DIAGNOSIS

Diagnosis and tumor response in osteosarcoma and Ewing's sarcoma, according to treatment protocols SSG II, SSG VIII, ISG/SSG I, SSG IV and SSG IX. Holmström T, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:27-9 (0 ref.)
Ewing's sarcoma masquerading as osteomyelitis. Durbin M, et al. **Clin Orthop** 1998 Dec;(357):176-85 (36 ref.)
Pediatric bone tumors. Yaw KM. **Semin Surg Oncol** 1999 Mar;16(2):173-83 (30 ref.)
[Ewing's sarcoma of the soft tissues: apropos of 3 cases and review of the literature] Paoletti H, et al. **J Radiol** 1999 May;80(5):477-82 (26 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Primary orbital Ewing's sarcoma: report of a case and review of the literature. Lam DS, et al. **Eye** 1999;13 (Pt 1):38-42 (21 ref.)

GENETICS

Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Bridge JA, et al. **Am J Surg Pathol** 1999 Feb;23(2):159-65 (30 ref.)
Ewing's sarcoma--a clinical enigma coming into focus. Denny CT. **J Pediatr Hematol Oncol** 1998 Sep-Oct; 20(5):421-5 (64 ref.)

METABOLISM

[Bone tumors and androgen metabolism] Kushlinskiĭ NE, et al. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):14-22 (57 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Ewing's sarcoma of os calcis: case report with a review of literature. Gupta V, et al. **J Foot Ankle Surg** 1999 Jan-Feb; 38(1):61-5; discussion 83 (23 ref.)
Primary extraskeletal Ewing's sarcoma of the external genitalia. Toh KL, et al. **J Urol** 1999 Jul;162(1):159-60 (3 ref.)
[Rhabdomyosarcoma and extraosseous Ewing's sarcoma] Harms D, et al. **Verh Dtsch Ges Pathol** 1998;82:83-98 (71 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Primary orbital Ewing's sarcoma: report of a case and review of the literature. Lam DS, et al. **Eye** 1999;13 (Pt 1):38-42 (21 ref.)

SURGERY

Diagnosis and tumor response in osteosarcoma and Ewing's sarcoma, according to treatment protocols SSG II, SSG VIII, ISG/SSG I, SSG IV and SSG IX. Holmström T, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:27-9 (0 ref.)
Pediatric bone tumors. Yaw KM. **Semin Surg Oncol** 1999 Mar;16(2):173-83 (30 ref.)
[Surgical management of malignant bone tumors in the child. Saint-Etienne Hospital experience, apropos of 17 cases] Cottalorda J, et al. **Ann Chir** 1998;52(1):45-51 (20 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The Ewing family of tumors and the search for the Achilles' heel. Kovar H, et al. **Curr Opin Oncol** 1999 Jul;11(4):275-84 (81 ref.)

SARCOMA, GERMINOBLASTIC see **LYMPHOMA**

SARCOMA, IMMUNOBLASTIC see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

SARCOMA, KAPOSI

AIDS-related malignancies. Smith C, et al. **Ann Med** 1998 Aug;30(4):323-44 (212 ref.)
Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. Reitz MS Jr, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1453-8 (100 ref.)
[Kaposi's disease] Lebbé C. **Rev Prat** 1999 Apr 15;49(8):843-7 (42 ref.) (Eng. Abstr.) **(Fre)**
[HHV8 infection (Kaposi's sarcoma)] Tachikawa N. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):51-4 (6 ref.) **(Jpn)**

COMPLICATIONS

HHV-8 is present in multiple myeloma patients. Berenson JR, et al. **Blood** 1999 May 15;93(10):3157-9; discussion 3164-6 (29 ref.)

DIAGNOSIS

[Laboratory diagnosis of viral infections. 7. Opportunistic infection by herpesviruses (human cytomegalovirus, Epstein-Barr virus, and human herpesvirus 8)] Okuno T. **Rinsho Byori** 1998 Nov;Suppl 108:98-104 (5 ref.) **(Jpn)**

DRUG THERAPY

A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma [published erratum appears in Drug Saf 1999 Jun;20(6):473] Nasti G, et al. **Drug Saf** 1999 May; 20(5):403-25 (92 ref.)

EPIDEMIOLOGY

Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Schulz TF. **Adv Cancer Res** 1999;76:121-60 (172 ref.)
Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Sarid R, et al. **Adv Virus Res** 1999;52:139-232 (395 ref.)
Kaposi's sarcoma. Schwartz RA. **Ann Transplant** 1998; 3(1):5-12 (227 ref.)
Kaposi's sarcoma in renal transplant recipients. Shaheen FA, et al. **Ann Transplant** 1997;2(4):49-58 (218 ref.)
Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 15-year lessons from AIDS. Hermans P. **Biomed Pharmacother** 1998;52(10):440-6 (30 ref.)
Overview of the epidemiology of malignancy in immune deficiency. Mueller N. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S5-10 (23 ref.)
Epidemic Kaposi's sarcoma. Cianfrocca M, et al. **Oncology (Huntingt)** 1998 Sep;12(9):1375-81, 1385; discussion 1385-90 (66 ref.)
[Human herpesvirus 8 (HHV-8): I. Characteristics and epidemiology] Boulanger E. **Ann Biol Clin (Paris)** 1998 Nov-Dec;56(6):643-50 (38 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Kaposi's sarcoma. Schwartz RA. **Ann Transplant** 1998; 3(1):5-12 (227 ref.)
Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment. Mitsuyasu R. **Clin Infect Dis** 1999 Jul;29(1):35-43 (77 ref.)
Kaposi's sarcoma herpesvirus as a new paradigm for virus-induced oncogenesis. Whitby D, et al. **Curr Opin Oncol** 1998 Sep;10(5):405-12 (82 ref.)
Consideration of host-viral interactions in the pathogenesis of Kaposi's sarcoma. Offermann MK. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S58-65 (69 ref.)
Kaposi's sarcoma after renal transplantation [see comments] Francès C. **Nephrol Dial Transplant** 1998 Nov; 13(11):2768-73 (35 ref.) Comment in: Nephrol Dial Transplant 1999 May;14(5):1342-3. Comment in: Nephrol Dial Transplant 1999 May;14(5):1343.
[Kaposi's sarcoma: a sexually transmitted cancer?] Sousa Escandón MA, et al. **Actas Urol Esp** 1999 Feb;23(2):89-94 (34 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Ensoli B, et al. **Crit Rev Oncog** 1998; 9(2):107-24 (130 ref.)

METABOLISM

Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Ensoli B, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):63-83 (215 ref.)

PATHOLOGY

Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'. Logani S, et al. **Am J Surg Pathol** 1999 Jun;23(6):656-61 (11 ref.)
Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Ensoli B, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):63-83 (215 ref.)
The enigmas of Kaposi's sarcoma. Gallo RC. **Science** 1998 Dec 4;282(5395):1837-9 (25 ref.)

THERAPY

The systemic treatment of AIDS-related Kaposi's sarcoma. Schwartsmann G, et al. **Cancer Treat Rev** 1998 Dec; 24(6):415-24 (116 ref.)
Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. McGarvey ME, et al. **Curr Opin Oncol** 1998 Sep; 10(5):413-21 (50 ref.)
Therapy for Kaposi's sarcoma: recent advances and experimental approaches. Yarchoan R. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S66-73 (82 ref.)

VIROLOGY

Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Sarid R, et al. **Adv Virus Res** 1999;52:139-232 (395 ref.)
Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma [comment] Mesri EA. **Blood** 1999 Jun 15;93(12):4031-3 (18 ref.) Comment on: Blood 1999 Jun 15;93(12):4034-43. Comment on: Blood 1999 Jun 15;93(12):4044-58.
Human herpesvirus 8 and its role in the genesis of Kaposi's sarcoma. Ganem D. **Curr Clin Top Infect Dis** 1998; 18:237-51 (86 ref.)
Kaposi's sarcoma: breeding ground of herpesviridae - A tour de force over viral evolution (review). Sinkovics JG, et al. **Int J Oncol** 1999 Apr;14(4):615-46 (300 ref.)
Big but weak: how many pathogenic genes does human herpesvirus-8 need to cause Kaposi's sarcoma? (Review). Sturzl M, et al. **Int J Oncol** 1999 Feb;14(2):287-9 (20 ref.)
The enigmas of Kaposi's sarcoma. Gallo RC. **Science** 1998 Dec 4;282(5395):1837-9 (25 ref.)
The role of HHV-8 in Kaposi's sarcoma. Neipel F, et al. **Semin Cancer Biol** 1999 Jun;9(3):151-64 (82 ref.)
[Human herpesvirus 8 (HHV8). II. Pathogenic role and sensitivity to antiviral drugs] Boulanger E. **Ann Biol Clin (Paris)** 1999 Jan-Feb;57(1):19-28 (48 ref.) (Eng. Abstr.) **(Fre)**

SARCOMA, LYMPHATIC see **LYMPHOMA, DIFFUSE**

SARCOMA, OSTEOGENIC see **OSTEOSARCOMA**

SARCOMA, RETICULUM-CELL see **LYMPHOMA, LARGE-CELL**

SARCOMA, SOFT TISSUE see **SARCOMA**

SARCOMA, SPINDLE CELL see **SARCOMA**

SARCOMA, SYNOVIAL

DIAGNOSIS

Synovial sarcoma of the esophagus simulating achalasia. Bonavina L, et al. **Dis Esophagus** 1998 Oct;11(4):268–71 (17 ref.)

PATHOLOGY

Synovial sarcoma. Fisher C. **Ann Diagn Pathol** 1998 Dec; 2(6):401–21 (179 ref.)

Synovial sarcoma in the parapharyngeal space: case report and review of the literature. Hanada T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):91–4 (24 ref.)

RADIOGRAPHY

Synovial sarcoma in the parapharyngeal space: case report and review of the literature. Hanada T, et al. **Auris Nasus Larynx** 1999 Jan;26(1):91–4 (24 ref.)

SECONDARY

[Recurrent spontaneous pneumothorax as the earliest indication of the pulmonary metastasis of a synovial sarcoma?] Bode F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):318–20 (10 ref.) **(Ger)**

SURGERY

Primary pericardial synovial sarcoma: a case report and literature review. Al-Rajhi N, et al. **J Surg Oncol** 1999 Mar;70(3):194–8 (18 ref.)

SARCOMA VIRUSES, AVIAN

ENZYMOLOGY

Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity. Wlodawer A. **Adv Virus Res** 1999;52:335–50 (48 ref.)

SARCOMERES

GENETICS

Familial hypertrophic cardiomyopathy: a paradigm of the cardiac hypertrophic response to injury. Marian AJ, et al. **Ann Med** 1998 Aug;30 Suppl 1:24–32 (74 ref.)

PHYSIOLOGY

The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? Bennett PM, et al. **Rev Physiol Biochem Pharmacol** 1999;138:203–34 (101 ref.)

Control of sarcomeric assembly: the flow of information on titin. Gautel M, et al. **Rev Physiol Biochem Pharmacol** 1999; 138:97–137 (173 ref.)

ULTRASTRUCTURE

Structure and assembly of the sarcomeric M band. Fürst DO, et al. **Rev Physiol Biochem Pharmacol** 1999;138:163–202 (128 ref.)

SARCOPLASMIC RETICULUM

ENZYMOLOGY

The role of phospholamban and SERCA3 in regulation of smooth muscle-endothelial cell signalling mechanisms: evidence from gene-ablated mice. Paul RJ. **Acta Physiol Scand** 1998 Dec;164(4):589–97 (54 ref.)

Structure-function relationships in the Ca(2+)-binding and translocation domain of SERCA1: physiological correlates in Brody disease. MacLennan DH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:55–67 (52 ref.)

Influence of SR Ca(2+)-ATPase and Na(+)-Ca(2+)-exchanger on the force-frequency relation. Schillinger W, et al. **Basic Res Cardiol** 1998;93 Suppl 1:38–45 (38 ref.)

Sarco/endoplasmic reticulum Ca2+ (SERCA)-pumps: link to heart beats and calcium waves. Misquitta CM, et al. **Cell Calcium** 1999 Apr;25(4):277–90 (126 ref.)

Age-related chemical modification of the skeletal muscle sarcoplasmic reticulum Ca-ATPase of the rat. Schöneich C, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):221–31 (69 ref.)

[Calcium pumps of plasma membrane and sarco(endo)plasmic reticulum] Suzuki H. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1610–21 (146 ref.) **(Jpn)**

METABOLISM

Cryoelectron microscopy of the calcium pump from sarcoplasmic reticulum: two crystal forms reveal two different conformations. Stokes DL, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:35–43 (32 ref.)

Role of transverse tubules (T-tubules) in muscle glucose transport. Dohm GL, et al. **Adv Exp Med Biol** 1998; 441:27–34 (17 ref.)

Sarcoplasmic reticulum Ca(2+) release and muscle fatigue. Favero TG. **J Appl Physiol** 1999 Aug;87(2):471–83 (145 ref.)

[Ca+ metabolism in the sarcoplasmic reticulum and the role of ryanodine and IP3 receptors in the nervous system] Nagata E, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2522–9 (30 ref.) **(Jpn)**

PATHOLOGY

Sarcoplasmic reticulum in vascular cells in hypertension and during proliferation. Lompré AM. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):553–7 (24 ref.)

PHYSIOLOGY

Ca2+ sparks in frog skeletal muscle: generation by one, some, or many SR Ca2+ release channels? Schneider MF. **J Gen Physiol** 1999 Mar;113(3):365–72 (23 ref.)

Role of sarcoplasmic reticulum in the contractile dysfunction during myocardial ischaemia and reperfusion. Kaplán P, et al. **Physiol Res** 1997;46(5):333–9 (59 ref.)

[Cardiac sarcoplasmic reticulum and phospholamban] Tada M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1622–7 (42 ref.) **(Jpn)**

SARCOSOMES see **MITOCHONDRIA, MUSCLE**

SARIN

POISONING

[Sarin poisoning] Sekijima Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):646–9 (9 ref.) **(Jpn)**

SARKOLYSIN see **MELPHALAN**

SASSAFRAS see **LAURACEAE**

SATELLITE COMMUNICATIONS

Application of the advanced communications technology satellite to teleradiology and real-time compressed ultrasound video telemedicine. Stewart BK, et al. **J Digit Imaging** 1999 May;12(2):68–76 (12 ref.)

SATELLITE DNA see **DNA, SATELLITE**

SATELLITE RNA see **RNA, SATELLITE**

SATELLITE TOBACCO MOSAIC VIRUS see **TOBACCO MOSAIC VIRUS SATELLITE**

SATELLITE VIRUSES

see related
HELPER VIRUSES
RNA, SATELLITE

GENETICS

Biology and structure of plant satellite viruses activated by icosahedral helper viruses. Scholthof KB, et al. **Curr Top Microbiol Immunol** 1999;239:123–43 (59 ref.)

ULTRASTRUCTURE

Biology and structure of plant satellite viruses activated by icosahedral helper viruses. Scholthof KB, et al. **Curr Top Microbiol Immunol** 1999;239:123–43 (59 ref.)

SATELLITES, ARTIFICIAL see **SPACECRAFT**

SATELLITES, MAN-MADE see **SPACECRAFT**

SATIATION

Energy density, palatability, and satiety: implications for weight control. Drewnowski A. **Nutr Rev** 1998 Dec; 56(12):347–53 (42 ref.)

PHYSIOLOGY

Intake of fat and carbohydrate: role of energy density. Rolls BJ, et al. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S166–73 (47 ref.)

SATIETY RESPONSE

Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Halford JC, et al. **Pharmacol Biochem Behav** 1998 Oct;61(2):159–68 (73 ref.)

SAVANNA BABOONS see **PAPIO**

SC DISEASE see **HEMOGLOBIN SC DISEASE**

SC1 PROTEIN see **ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE**

SCABIES

The saga of ectoparasitoses: scabies and pediculosis. Parish LC, et al. **Int J Dermatol** 1999 Jun;38(6):432–3 (11 ref.)

Diagnosing and treating scabies. Burgess IF. **Practitioner** 1997 Dec;241(1581):739–43 (9 ref.)

[Scabies] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):518–20 (4 ref.) **(Jpn)**

SCALDED SKIN SYNDROME, NONSTAPHYLOCOCCAL see **EPIDERMAL NECROLYSIS, TOXIC**

SCALDED SKIN SYNDROME, STAPHYLOCOCCAL see **STAPHYLOCOCCAL SCALDED SKIN SYNDROME**

SCALE INSECTS see **HEMIPTERA**

SCALENUS ANTICUS SYNDROME see **THORACIC OUTLET SYNDROME**

SCALP

A rare case of atypical eccrine acrospiroma of the scalp and a literature review. Wilhelmi BJ, et al. **Ann Plast Surg** 1999 May;42(5):568–9 (13 ref.)

Giant malignant eccrine spiradenoma of the scalp. Jamshidi M, et al. **Dermatol Surg** 1999 Jan;25(1):45–8 (20 ref.)

INJURIES

Traumatic alopecia. Whiting DA. **Int J Dermatol** 1999 May; 38 Suppl 1:34–44 (52 ref.)

PATHOLOGY

Adams-Oliver syndrome: autosomal recessive inheritance and new phenotypic-anthropometric findings. Klinger G, et al. **Am J Med Genet** 1998 Sep 23;79(3):197–9 (13 ref.)

Malignant transformation of a giant proliferating trichilemmal tumor of the scalp: patient report and literature review. Markal N, et al. **Ann Plast Surg** 1998 Sep;41(3):314–6 (18 ref.)

Cicatricial pemphigoid rarely involves the scalp. Ball S, et al. **Australas J Dermatol** 1998 Nov;39(4):258–60 (16 ref.)

Specific cutaneous lesions of the scalp in myelodysplastic syndrome with deletion of 20q. Namba Y, et al. **J Dermatol** 1999 Apr;26(4):220–4 (15 ref.)

Intracranial extension of an eccrine porocarcinoma. Case report and review of the literature. Ritter AM, et al. **J Neurosurg** 1999 Jan;90(1):138–40 (13 ref.)

Papillary and follicular thyroid carcinoma metastatic to the skin: a case report and review of the literature. Koller EA, et al. **Thyroid** 1998 Nov;8(11):1045–50 (33 ref.)

SURGERY

Multifocal angiosarcoma of the scalp: a case report and review of the literature. Kacker A, et al. **Ear Nose Throat J** 1999 Apr;78(4):302–5 (14 ref.)

[Case report of epithelioid hemangioendothelioma of the frontal region metastatic to the parotid gland] Schneider B, et al. **Laryngorhinootologie** 1998 Dec;77(12):728–31 (27 ref.) (Eng. Abstr.) **(Ger)**

SCALP DERMATOSES

ETIOLOGY

Hair and scalp conditions. Walkden V. **Practitioner** 1998 Apr; 242(1585):278–81 (4 ref.)

PATHOLOGY

Larva migrans within scalp sebaceous gland. Guimarães LC, et al. **Rev Soc Bras Med Trop** 1999 Mar-Apr;32(2):187–9 (8 ref.)

THERAPY

Evidence based case report: treatment for head lice [see comments] Dawes M, et al. **BMJ** 1999 Feb 6; 318(7180):385–6 (9 ref.) Comment in: BMJ 1999 May 22;318(7195):1422.

SCANNING ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON, SCANNING**

SCANNING FORCE MICROSCOPY see **MICROSCOPY, ATOMIC FORCE**

SCANNING PROBE MICROSCOPY see **MICROSCOPY, ATOMIC FORCE**

SCANNING, RADIOISOTOPE see **RADIONUCLIDE IMAGING**

SCANNING TUNNELING MICROSCOPY see **MICROSCOPY, SCANNING TUNNELING**

SCAPULA

Symptomatic scapulothoracic crepitus and bursitis. Kuhn JE, et al. **J Am Acad Orthop Surg** 1998 Sep–Oct;6(5):267–73 (30 ref.)

Large bursa formation associated with osteochondroma of the scapula: a case report and review of the literature. Okada K, et al. **Jpn J Clin Oncol** 1999 Jul;29(7):356–60 (23 ref.)

[Primary bone tumors and "tumor-like lesions" of the shoulder. Their histopathology and imaging] Link TM, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 May;170(5):507–13 (25 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

An aneurysm involving the axillary artery and its branch vessels in a major league baseball pitcher. A case report and review of the literature. Schneider K, et al. **Am J Sports Med** 1999 May–Jun;27(3):370–5 (23 ref.)

INJURIES

Scapulothoracic dissociation. Lee L, et al. **Am J Orthop** 1998 Oct;27(10):699–702 (31 ref.)

Low-energy scapular body fracture: a case report. McAtee SJ. **Am J Orthop** 1999 Aug;28(8):468–72 (28 ref.)

Periprosthetic fractures of the humerus and scapula: management and prevention. Cameron B, et al. **Orthop Clin North Am** 1999 Apr;30(2):305–18 (28 ref.)

[Isolated coracoid fracture—open reposition and osteosynthesis—report of 3 cases] Spormann C, et al. **Swiss Surg** 1998;(4):198–202 (23 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Uncommon nerve compression syndromes of the upper extremity. Lubahn JD, et al. **J Am Acad Orthop Surg** 1998 Nov–Dec;6(6):378–86 (38 ref.)

SCARLET FEVER

[Scarlet fever] Sunakawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):97–8 (1 ref.) **(Jpn)**

SCARPA'S GANGLION see **VESTIBULAR NERVE**

SCARS see **CICATRIX**

SCARS, HYPERTROPHIC see **CICATRIX, HYPERTROPHIC**

SCATTER FACTOR see **HEPATOCYTE GROWTH FACTOR**

SCATTERING, RADIATION

Absolute and effective cross-sections for low-energy electron-scattering processes within condensed matter. Bass AD, et al. **Radiat Environ Biophys** 1998 Dec; 37(4):243–57 (84 ref.)

SCENEDESMUS see **ALGAE, GREEN**

SCH-13521 see **FLUTAMIDE**

SCHAMBERG'S DISEASE see **PIGMENTATION DISORDERS**

SCHAUMANN'S DISEASE see **SARCOIDOSIS**

SCHEDULES, PATIENT see **APPOINTMENTS AND SCHEDULES**

SCHEIE'S SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

SCHEUERMANN'S DISEASE

Scheuermann's disease. Lowe TG. **Orthop Clin North Am** 1999 Jul;30(3):475–87, ix (37 ref.)

DIAGNOSIS

Scheuermann's kyphosis [see comments] Ali RM, et al. **Curr Opin Pediatr** 1999 Feb;11(1):70–5 (48 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):65–6.

THERAPY

Scheuermann's kyphosis [see comments] Ali RM, et al. **Curr Opin Pediatr** 1999 Feb;11(1):70–5 (48 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):65–6.

SCHILDER'S DISEASE see **ENCEPHALITIS PERIAXIALIS**

SCHISTOSOMA

see related
SCHISTOSOMICIDES

PHYSIOLOGY

Recent studies on the reproductive biology of the schistosomes and their relevance to speciation in the Digenea. Southgate VR, et al. **Int J Parasitol** 1998 Aug; 28(8):1159–72 (83 ref.)

Sex determination and female reproductive development in the genus Schistosoma: a review. Ribeiro-Paes JT, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov–Dec;39(6):337–44 (136 ref.)

SCHISTOSOMA HAEMATOBIUM

Therapeutic and operational profiles of metrifonate and praziquantel in Schistosoma haematobium infection. Feldmeier H, et al. **Arzneimittelforschung** 1999 Jul; 49(7):557–65 (81 ref.)

IMMUNOLOGY

Common features of T cell reactivity in persistent helminth infections: lymphatic filariasis and schistosomiasis. Yazdanbakhsh M. **Immunol Lett** 1999 Jan;65(1–2):109–15 (35 ref.)

SCHISTOSOMA JAPONICUM

CHEMISTRY

Immunolocalization of schistosome proteins. Gobert GN. **Microsc Res Tech** 1998 Aug 1;42(3):176–85 (70 ref.)

ULTRASTRUCTURE

Immunolocalization of schistosome proteins. Gobert GN. **Microsc Res Tech** 1998 Aug 1;42(3):176–85 (70 ref.)

SCHISTOSOMA MANSONI

ENZYMOLOGY

Glutathione S-transferases of 28kDa as major vaccine candidates against schistosomiasis. Riveau G, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:87–94 (41 ref.)

IMMUNOLOGY

The initiation and function of Th2 responses during infection with Schistosoma mansoni. Pearce EJ, et al. **Adv Exp Med Biol** 1998;452:67–73 (30 ref.)

Immune responses to the radiation-attenuated schistosome vaccine: what can we learn from knock-out mice? Wilson RA, et al. **Immunol Lett** 1999 Jan;65(1–2):117–23 (31 ref.)

SCHISTOSOMIASIS

see related
SCHISTOSOMICIDES

Key developments in travel medicine. Chiodini P, et al. **Practitioner** 1998 May;242(1586):342–4, 346 (2 ref.)

[Schistosomiasis] Kojima S. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):156–8 (2 ref.) **(Jpn)**

[Schistosomiasis (intestinal, hepatic, urinary tract)] Ohnishi K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):481–4 (4 ref.) **(Jpn)**

COMPLICATIONS

Relationship between schistosomiasis and bladder cancer. Mostafa MH, et al. **Clin Microbiol Rev** 1999 Jan; 12(1):97–111 (237 ref.)

Schistosomiasis and associated infections. Lambertucci JR, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:135–9 (49 ref.)

DRUG THERAPY

Community-wide treatment of schistosomiasis with praziquantel. Webbe G. **Trop Doct** 1999 Jul;29(3):172–6 (28 ref.)

ECONOMICS

Different approaches to modelling the cost-effectiveness of schistosomiasis control. Guyatt H. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:75–84 (14 ref.)

IMMUNOLOGY

Immunological aspects of human schistosomiasis. Butterworth AE. **Br Med Bull** 1998;54(2):357–68 (40 ref.)

PREVENTION & CONTROL

Schistosomiasis vaccine development: progress and prospects. Bergquist NR. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:95–101 (30 ref.)

Different approaches to modelling the cost-effectiveness of schistosomiasis control. Guyatt H. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:75–84 (14 ref.)

Glutathione S-transferases of 28kDa as major vaccine candidates against schistosomiasis. Riveau G, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:87–94 (41 ref.)

Community-wide treatment of schistosomiasis with praziquantel. Webbe G. **Trop Doct** 1999 Jul;29(3):172–6 (28 ref.)

SCHISTOSOMIASIS HAEMATOBIA

DIAGNOSIS

[Bilharziasis and bladder cancer. A case report] Alvarez Kindelan J, et al. **Actas Urol Esp** 1999 Jan;23(1):60–3 (9 ref.) (Eng. Abstr.) **(Spa)**

[Vesical bilharziasis. A report of a new case] Soler Soler JL, et al. **Arch Esp Urol** 1998 Nov;51(9):937–41 (15 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Common features of T cell reactivity in persistent helminth infections: lymphatic filariasis and schistosomiasis. Yazdanbakhsh M. **Immunol Lett** 1999 Jan;65(1–2):109–15 (35 ref.)

PARASITOLOGY

[Bilharziosis (schistosomiasis) of the bladder. Pathogenesis, therapy and uroprotective measures] Feil G, et al. **Med Monatsschr Pharm** 1999 Jan;22(1):14–8 (25 ref.) **(Ger)**

THERAPY

Therapeutic and operational profiles of metrifonate and praziquantel in Schistosoma haematobium infection. Feldmeier H, et al. **Arzneimittelforschung** 1999 Jul; 49(7):557–65 (81 ref.)

SCHISTOSOMIASIS, INTESTINAL see **SCHISTOSOMIASIS MANSONI**

SCHISTOSOMIASIS JAPONICA

[Cerebral schistosomiasis] Hayashi M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):477–80 (14 ref.) **(Jpn)**

IMMUNOLOGY

[Progresses in the study of tropical diseases and parasitology in China, 1997] Zheng J. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):902–3 (0 ref.) **(Chi)**

SCHISTOSOMIASIS MANSONI

COMPLICATIONS

Genital manifestations of schistosomiasis mansoni in women: important but neglected. Feldmeier H, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:127–33 (41 ref.)

DIAGNOSIS

Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Ferrari TC. **Medicine (Baltimore)** 1999 May;78(3):176–90 (104 ref.)

Ectopic cutaneous schistosomiasis: report of two cases and a review of the literature. Andrade Filho J de S, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul–Aug;40(4):253–7 (15 ref.)

IMMUNOLOGY

The initiation and function of Th2 responses during infection with Schistosoma mansoni. Pearce EJ, et al. **Adv Exp Med Biol** 1998;452:67–73 (30 ref.)

PARASITOLOGY

Histoarchitecture of schistosomal granuloma development and involution: morphogenetic and biomechanical approaches. Lenzi HL, et al. **Mem Inst Oswaldo Cruz** 1998; 93 Suppl 1:141–51 (40 ref.)

PATHOLOGY

[High intensity signal in basal ganglia on T1 weighted images: case report in Manson's Schistosomiasis with portal systemic encephalopathy] Machado Júnior MA, et al. **Arq Neuropsiquiatr** 1999 Jun;57(2A):306–10 (39 ref.) (Eng. Abstr.) **(Por)**

SCHISTOSOMIASIS, URINARY see **SCHISTOSOMIASIS HAEMATOBIA**

SCHISTOSOMICIDES

THERAPEUTIC USE

Community-wide treatment of schistosomiasis with praziquantel. Webbe G. **Trop Doct** 1999 Jul;29(3):172–6 (28 ref.)

SCHIZOAFFECTIVE DISORDER see **PSYCHOTIC DISORDERS**

SCHIZOID PERSONALITY DISORDER

PSYCHOLOGY

Mohawks and combat boots: the schizoid dilemma of punks. McAllister MJ. **Bull Menninger Clin** 1999 Winter; 63(1):89–102 (25 ref.)

SCHIZOMYCETES see **BACTERIA**

SCHIZOPHRENIA

Reduced fertility in schizophrenia: here to stay? Nimgaonkar VL. **Acta Psychiatr Scand** 1998 Nov;98(5):348–53 (56 ref.)

Cognition and neuropathology in schizophrenia. Arnold SE. **Acta Psychiatr Scand Suppl** 1999;395:41–50 (106 ref.)

The concept of target features in schizophrenia research. Tsuang MT, et al. **Acta Psychiatr Scand Suppl** 1999; 395:2–11 (119 ref.)

Precursors to schizophrenia: do biological markers have specificity? [see comments] Tarrant CJ, et al. **Can J Psychiatry** 1999 May;44(4):335–49 (103 ref.) Comment in: Can J Psychiatry 1999 May;44(4):325.

Relationship between panic and schizophrenia. Hofmann SG. **Depress Anxiety** 1999;9(3):101–6 (65 ref.)

Negative symptoms in schizophrenia: neurobiological models and treatment response. Goff DC, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):59–77 (208 ref.)

The natural history and pathophysiology of treatment resistant schizophrenia. Sheitman BB, et al. **J Psychiatr Res** 1998 May–Aug;32(3–4):143–50 (84 ref.)

Schizophrenia. Schultz SK, et al. **Lancet** 1999 Apr 24; 353(9162):1425–30 (42 ref.)

Caffeine and schizophrenia. Hughes JR, et al. **Psychiatr Serv** 1998 Nov;49(11):1415–7 (25 ref.)

The Russian concept of schizophrenia: a review of the literature. Lavretsky H. **Schizophr Bull** 1998;24(4):537–57 (166 ref.)

Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Bennedsen BE. **Schizophr Res** 1998 Sep 7;33(1–2):1–26 (230 ref.)

[Current concept of schizophrenia: state of the art] Tiganov AS. **Vestn Ross Akad Med Nauk** 1999;(1):7–11 (16 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? Strunecká A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul;61(1):1–5 (47 ref.)

CHEMICALLY INDUCED

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Jentsch JD, et al. **Neuropsychopharmacology** 1999 Mar;20(3):201–25 (250 ref.)

Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Sams-Dodd F. **Rev Neurosci** 1999;10(1):59–90 (243 ref.)

CLASSIFICATION

The cycloid type and its differentiation from core schizophrenia: a phenomenological approach. Sigmund D, et al. **Compr Psychiatry** 1999 Jan–Feb;40(1):4–18 (92 ref.)

COMPLICATIONS

Substance abuse treatment for people with schizophrenia. Bellack AS, et al. **Addict Behav** 1998 Nov–Dec; 23(6):749–66 (94 ref.)

Schizophrenia and sudden death: a medical examiner case study. Chute D, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):131–5 (17 ref.)

Cognitive deficit in schizophrenia and its neurochemical basis. Breier A. **Br J Psychiatry Suppl** 1999;(37):16–8 (20 ref.)

Using multidimensional scaling and cluster analysis for understanding information processing and schizophrenia. Catalano JA. **Genet Soc Gen Psychol Monogr** 1999 Aug; 125(3):313–28 (45 ref.)

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Green AI, et al. **Harv Rev Psychiatry** 1999 Mar–Apr;6(6):287–96 (94 ref.)

Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. Duggan L, et al. **J Intellect Disabil Res** 1999 Apr; 43 (Pt 2):94–104 (56 ref.)

Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? Waddington JL, et al. **J Psychiatr Res** 1998 May–Aug;32(3–4):179–89 (151 ref.)

The somatic component of schizophrenia: a dissociation of the goals of visual attention and bifoveal fixation? Korn H. **Med Hypotheses** 1999 Feb;52(2):163–70 (24 ref.)

Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Moberg PJ, et al. **Neuropsychopharmacology** 1999 Sep;21(3):325–40 (90 ref.)

Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Knoll JL 4th, et al. **Schizophr Bull** 1998; 24(3):365–79 (99 ref.)

Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Dixon L. **Schizophr Res** 1999 Mar 1;35 Suppl:S93–100 (36 ref.)

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Krystal JH, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S35–49 (128 ref.)

[Electroencephalography and cognitive processes in schizophrenia] Alfimova MV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):55–8 (57 ref.) **(Rus)**

[Impulse control disorders in schizophrenia in children, adolescents and young people] Golik AN. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(7):63–7 (129 ref.) **(Rus)**

DIAGNOSIS

Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism [see comments] Woods BT. **Am J Psychiatry** 1998 Dec;155(12):1661–70 (108 ref.) Comment in: Am J Psychiatry 1998 Dec;155(12):1657–9.

Triplets with schizophrenia [letter; comment] Torrey EF, et al. **Biol Psychiatry** 1999 Mar 1;45(5):655 (4 ref.) Comment on: Biol Psychiatry 1997 Dec 15;42(12):1186–7.

Late paraphrenia: a variant of schizophrenia manifest in late life or an organic clinical syndrome? A review of recent evidence. Roth M, et al. **Int J Geriatr Psychiatry** 1998 Nov; 13(11):775–84 (60 ref.)

Special feature: childhood personality characteristics of schizophrenia: manifestations of, or risk factors for, the disorder? Ellison Z, et al. **J Personal Disord** 1998 Fall; 12(3):247–61 (69 ref.)

New views on the course and treatment of schizophrenia. Carpenter WT Jr. **J Psychiatr Res** 1998 May–Aug; 32(3–4):191–5 (56 ref.)

Which characteristics of schizophrenia predate psychosis? Davies N, et al. **J Psychiatr Res** 1998 May–Aug; 32(3–4):121–31 (134 ref.)

The profiles of clinical deterioration in schizophrenia. McGlashan TH. **J Psychiatr Res** 1998 May–Aug; 32(3–4):133–41 (56 ref.)

Private and public in the lives of chronic schizophrenic patients. Leferink K. **Psychiatry** 1998 Summer;61(2):147–62 (60 ref.)

Schizophrenia and severe affective illness alternating over time in some patients: a hypothesis. Sigman M. **Psychiatry** 1998 Fall;61(3):262–8 (39 ref.)

Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Flyckt L, et al. **Psychiatry Res** 1999 May 31;86(2):113–29 (50 ref.)

The evaluation of women with schizophrenia. Canuso CM, et al. **Psychopharmacol Bull** 1998;34(3):271–7 (78 ref.)

Outcome of schizophrenia in relation to brain abnormalities. Staal WG, et al. **Schizophr Bull** 1999;25(2):337–48 (80 ref.)

Risk factors for onset and persistence of psychosis. Van Os J, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec; 33(12):596–605 (110 ref.)

[The contribution of functional neuroimaging to the understanding of schizophrenic psychosis] Jeannerod M. **Bull Acad Natl Med** 1999;183(3):477–84; discussion 484–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[Stroop test and schizophrenia] Grapperon J, et al. **Encephale** 1999 Jan–Feb;25(1):50–8 (63 ref.) (Eng. Abstr.) **(Fre)**

[The course of schizophrenic illnesses] Riecher-Rössler A, et al. **Wien Med Wochenschr** 1998;148(11–12):259–65 (36 ref.) (Eng. Abstr.) **(Ger)**

[Schizophrenia--an illness and its treatment reflected in public attitude] Schöny W. **Wien Med Wochenschr** 1998; 148(11–12):284–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Prodromal period of the first episode of schizophrenia] Bogacki P, et al. **Psychiatr Pol** 1998 May–Jun;32(3):239–50 (62 ref.) (Eng. Abstr.) **(Pol)**

[Neuropsychological alteration in schizophrenia and its modification] Penadés R, et al. **Actas Esp Psiquiatr** 1999 May–Jun;27(3):198–208 (101 ref.) (Eng. Abstr.) **(Spa)**

[Biological markers of schizophrenic symptoms: functional neuroimaging] Crespo-Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1998 Sep–Oct;26(5):309–14 (50 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Conventional vs. newer antipsychotics in elderly patients. Jeste DV, et al. **Am J Geriatr Psychiatry** 1999 Winter; 7(1):70–6 (33 ref.)

Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Levinson DF, et al. **Am J Psychiatry** 1999 Aug;156(8):1138–48 (64 ref.)

D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Joyce JN, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:595–613 (61 ref.)

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs. Brown CS, et al. **Ann Pharmacother** 1999 Feb;33(2):210–7 (57 ref.)

Novel antipsychotics and patient care in state hospitals. Buckley PF. **Ann Pharmacother** 1998 Sep;32(9):906–14 (72 ref.)

Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Dixon DA, et al. **Ann Pharmacother** 1999 Apr;33(4):480–8 (94 ref.)

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy [see comments] Markowitz JS, et al. **Ann Pharmacother** 1999 Jan;33(1):73–85 (87 ref.) Comment in: Ann Pharmacother 1999 Jan;33(1):107–8.

Famotidine in the management of schizophrenia. Martinez MC. **Ann Pharmacother** 1999 Jun;33(6):742–7 (14 ref.)

Glycine agonists: what can they teach us about schizophrenia? [comment] Farber NB, et al. **Arch Gen Psychiatry** 1999 Jan;56(1):13–7 (50 ref.) Comment on: Arch Gen Psychiatry 1999 Jan;56(1):21–7. Comment on: Arch Gen Psychiatry 1999 Jan;56(1):29–36.

Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Friedman JI, et al. **Biol Psychiatry** 1999 Jan 1;45(1):1–16 (160 ref.)

Serotonergic basis of antipsychotic drug effects in schizophrenia. Lieberman JA, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1099–117 (213 ref.)

The use of atypical antipsychotics in the management of schizophrenia. Campbell M, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):13–22 (35 ref.)

Olanzapine in the long-term treatment of schizophrenia. Kane J. **Br J Psychiatry Suppl** 1999;(37):26–9 (31 ref.)

An approach to treatment resistance in schizophrenia. Marder SR. **Br J Psychiatry Suppl** 1999;(37):19–22 (21 ref.)

Review of recent clinical studies with olanzapine. Tollefson GD, et al. **Br J Psychiatry Suppl** 1999;(37):30–5 (22 ref.)

Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Lewis R. **Can J Psychiatry** 1998 Aug;43(6):596–604 (57 ref.)

Improving outcome in schizophrenia: the case for early intervention [see comments] Malla AK, et al. **CMAJ** 1999 Mar 23;160(6):843–6 (73 ref.) Comment in: CMAJ 1999 Mar 23;160(6):826–8.

The clinical investigation of medicinal products in the treatment of schizophrenia. **Eur Neuropsychopharmacol** 1998 Aug;8(3):247–52 (0 ref.)

Drug metabolism and atypical antipsychotics. Prior TI, et al. **Eur Neuropsychopharmacol** 1999 Jun;9(4):301–9 (74 ref.)

Choices in antipsychotic therapy in schizophrenia. Frankenburg FR. **Harv Rev Psychiatry** 1999 Jan–Feb; 6(5):241–9 (85 ref.)

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Green AI, et al. **Harv Rev Psychiatry** 1999 Mar–Apr;6(6):287–96 (94 ref.)

Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Barnes TR, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S49–57 (100 ref.)

Critical issues in the treatment of schizophrenia. Gaebel W. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S1–6 (30 ref.)

A review of the safety and tolerability of sertindole. Hale AS. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S65–70 (22 ref.)

Sertindole: a review of clinical efficacy. Kane JM. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S59–63; discussion S63–4 (8 ref.)

How much do novel antipsychotics benefit the patients? Kasper S. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S71–7 (55 ref.)

Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Kasper S. **Int Clin Psychopharmacol** 1998 Nov;13(6):253–62 (51 ref.)

Early detection and intervention in schizophrenia. Linszen DH, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S31–4 (33 ref.)

Novel antipsychotics and negative symptoms. Möller HJ. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S43–7 (21 ref.)

Implications of brain imaging for the management of schizophrenia. Nyberg S, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S15–20 (52 ref.)

Good medical practice in antipsychotic pharmacotherapy. Peuskens J. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S35–41 (32 ref.)

The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Tamminga CA, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S21–6 (45 ref.)

Atypical neuroleptics: autonomy and compliance? Marland GR. **J Adv Nurs** 1999 Mar;29(3):615–22 (47 ref.)

Clozapine: the commitment to patient safety. Alphs LD, et al. **J Clin Psychiatry** 1999;60 Suppl 12:39–42 (22 ref.)

New antipsychotic agents: emerging clinical profiles. Buckley PF. **J Clin Psychiatry** 1999;60 Suppl 1:12–7; discussion 28–30 (57 ref.)

Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. DeQuardo JR. **J Clin Psychiatry** 1998;59 Suppl 19:9–17 (61 ref.)

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Ereshefsky L. **J Clin Psychiatry** 1999;60 Suppl 10:20–30 (90 ref.)

Clozapine: a comparison with other novel antipsychotics. Fleischhacker WW. **J Clin Psychiatry** 1999;60 Suppl 12:30–4 (34 ref.)

Does loxapine have "atypical" properties? Clinical evidence. Glazer WM. **J Clin Psychiatry** 1999;60 Suppl 10:42–6 (38 ref.)

Management strategies for the treatment of schizophrenia. Kane JM. **J Clin Psychiatry** 1999;60 Suppl 12:13–7 (32 ref.)

Some adverse effects of antipsychotics: prevention and treatment. Lader M. **J Clin Psychiatry** 1999;60 Suppl 12:18–21 (34 ref.)

Developing an outcomes-oriented approach for the treatment

of schizophrenia. Lehman AF. **J Clin Psychiatry** 1999;60 Suppl 19:30-5; discussion 36-7 (31 ref.)

Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Lieberman JA. **J Clin Psychiatry** 1999;60 Suppl 12:9-12 (25 ref.)

The effects of clozapine on cognitive functioning in schizophrenia. McGurk SR. **J Clin Psychiatry** 1999;60 Suppl 12:24-9 (31 ref.)

Outcome in schizophrenia: beyond symptom reduction. Meltzer HY. **J Clin Psychiatry** 1999;60 Suppl 3:3-7; discussion 8 (24 ref.)

Optimizing clozapine treatment. Naber D. **J Clin Psychiatry** 1999;60 Suppl 12:35-8 (16 ref.)

Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Neumann PJ. **J Clin Psychiatry** 1999;60 Suppl 3:9-14; discussion 15 (65 ref.)

Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Palmer DD, et al. **J Clin Psychiatry** 1999;60 Suppl 2:100-3; discussion 111-6 (43 ref.)

The evolving definition of treatment resistance. Peuskens J. **J Clin Psychiatry** 1999;60 Suppl 12:4-8 (15 ref.)

Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. Revicki DA. **J Clin Psychiatry** 1999;60 Suppl 1:7-11; discussion 28-30 (22 ref.)

Common treatment goals of antipsychotics: acute treatment. Sharif ZA. **J Clin Psychiatry** 1998;59 Suppl 19:5-8 (14 ref.)

Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Stahl SM. **J Clin Psychiatry** 1999;60 Suppl 10:31-41 (184 ref.)

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson GD, et al. **J Clin Psychiatry** 1999;60 Suppl 5:23-9; discussion 30 (45 ref.)

The effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka J. **J Clin Psychiatry** 1999;60 Suppl 12:43-6 (25 ref.)

Long-term considerations after switching antipsychotics. Weiden PJ, et al. **J Clin Psychiatry** 1998;59 Suppl 19:36-49 (33 ref.)

Critical review of GABA-ergic drugs in the treatment of schizophrenia. Wassef AA, et al. **J Clin Psychopharmacol** 1999 Jun;19(3):222-32 (49 ref.)

New views on the course and treatment of schizophrenia. Carpenter WT Jr. **J Psychiatr Res** 1998 May-Aug; 32(3-4):191-5 (56 ref.)

Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? DeQuardo JR, et al. **J Psychiatr Res** 1998 May-Aug;32(3-4):229-42 (128 ref.)

Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. Jeste DV, et al. **J Psychiatr Res** 1998 May-Aug;32(3-4):201-14 (102 ref.)

New atypical antipsychotic medications. Jibson MD, et al. **J Psychiatr Res** 1998 May-Aug;32(3-4):215-28 (101 ref.)

The effects of early and sustained intervention on the long-term morbidity of schizophrenia. Wyatt RJ, et al. **J Psychiatr Res** 1998 May-Aug;32(3-4):169-77 (86 ref.)

The Canadian experience with risperidone for the treatment of schizophrenia: an overview. Iskedjian M, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):229-39 (80 ref.)

Treatment refractory schizophrenia: how should we proceed? Sharif ZA. **Psychiatr Q** 1998 Winter;69(4):263-81 (44 ref.)

Clinical trials and tribulations: implementation processes in schizophrenia research outcome. Mason SE, et al. **Psychiatry** 1998 Winter;61(4):288-301 (49 ref.)

Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? [editorial] Hawkins KA, et al. **Psychol Med** 1999 Jan;29(1):1-8 (63 ref.)

A new algorithm for treating schizophrenia. Pearsall R, et al. **Psychopharmacol Bull** 1998;34(3):349-53 (27 ref.)

Management of the adverse effects of clozapine. Young CR, et al. **Schizophr Bull** 1998;24(3):381-90 (93 ref.)

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Krystal JH, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S35-49 (128 ref.)

Antipsychotic drugs and relapse prevention. Marder SR. **Schizophr Res** 1999 Mar 1;35 Suppl:S87-92 (26 ref.)

Cognitive improvement in schizophrenia with novel antipsychotic medications. Purdon SE. **Schizophr Res** 1999 Mar 1;35 Suppl:S51-60 (42 ref.)

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Revicki DA. **Schizophr Res** 1999 Mar 1;35 Suppl:S101-9 (31 ref.)

[Success of new treatments for schizophrenics, as shown by the example of modern antipsychotic drugs] Lambert M, et al. **Psychiatr Prax** 1999 Apr;26 Suppl 1:S30-5 (42 ref.) **(Ger)**

[Compliance problems in treatment of schizophrenic patients] Barnas C, et al. **Wien Med Wochenschr** 1998; 148(11-12):281-3 (21 ref.) (Eng. Abstr.) **(Ger)**

[Problems in evaluating new antipsychotic drugs] Fleischhacker WW. **Wien Med Wochenschr** 1998; 148(11-12):266-72 (71 ref.) (Eng. Abstr.) **(Ger)**

[Use of novel agents in the treatment of schizophrenia and a look to the future] Keks NA. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Jun; 18(3):97-101 (4 ref.) **(Jpn)**

[Glycine therapy of schizophrenia; its rationale and a review of clinical trials] Semba J. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Jun; 18(3):71-80 (63 ref.) (Eng. Abstr.) **(Jpn)**

[Benzodiazepines in the treatment of schizophrenia: a review] González-Seijo JC, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1998 Nov-Dec;26(6):371-9 (71 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs. Brown CS, et al. **Ann Pharmacother** 1999 Feb;33(2):210-7 (57 ref.)

Making music out of noise--the cost function approach to evaluation. Knapp M. **Br J Psychiatry Suppl** 1998;(36):7-11 (0 ref.)

Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. Maynard A, et al. **Br J Psychiatry Suppl** 1998;(36):12-8 (52 ref.)

Economics of schizophrenia. Moscarelli M. **Br J Psychiatry Suppl** 1998;(36):4-6 (8 ref.)

Cost-effectiveness of atypical antipsychotics in chronic schizophrenia. Amin S. **Hosp Med** 1999 Jun;60(6):410-3 (21 ref.)

Outcome in schizophrenia: beyond symptom reduction. Meltzer HY. **J Clin Psychiatry** 1999;60 Suppl 3:3-7; discussion 8 (24 ref.)

Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Neumann PJ. **J Clin Psychiatry** 1999;60 Suppl 3:9-14; discussion 15 (65 ref.)

The economic impact of schizophrenia. Rice DP. **J Clin Psychiatry** 1999;60 Suppl 1:4-6; discussion 28-30 (6 ref.)

[The costs of schizophrenia] Rössler W, et al. **Fortschr Neurol Psychiatr** 1998 Nov;66(11):496-504 (63 ref.) (Eng. Abstr.) **(Ger)**

[Economic perspectives in the care and treatment of patients diagnosed with schizophrenia] Percudani M, et al. **Epidemiol Psichiatr Soc** 1998 Sep-Dec;7(3):197-209 (114 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

[Brain isoforms of creatine kinase in health and mental diseases: Alzheimer's disease and schizophrenia] Burbaeva GSh, et al. **Vestn Ross Akad Med Nauk** 1999;(1):20-4 (39 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Dalack GW, et al. **Am J Psychiatry** 1998 Nov;155(11):1490-501 (100 ref.)

The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective. Riecher-Rössler A, et al. **Eur Arch Psychiatry Clin Neurosci** 1998;248(4):189-202 (104 ref.)

Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. Tibbo P, et al. **J Psychiatry Neurosci** 1999 Jan;24(1):15-24 (90 ref.)

At issue: is household crowding a risk factor for schizophrenia and bipolar disorder? Torrey EF, et al. **Schizophr Bull** 1998;24(3):321-4 (38 ref.)

[Schizophrenia and violence: epidemiological, forensic and clinical aspects] Steinert T. **Fortschr Neurol Psychiatr** 1998 Sep;66(9):391-401 (124 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiology of schizophrenic disorders] Hinterhuber H, et al. **Wien Med Wochenschr** 1998;148(11-12):253-8 (74 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Developmental neuropathology and the precursors of schizophrenia. Walker EF, et al. **Acta Psychiatr Scand Suppl** 1999;395:12-9 (31 ref.)

A glutamatergic deficiency model of schizophrenia. Carlsson A, et al. **Br J Psychiatry Suppl** 1999;(37):2-6 (21 ref.)

Prenatal factors and adult mental and physical health [see comments] Susser EB, et al. **Can J Psychiatry** 1999 May; 44(4):326-34 (79 ref.) Comment in: Can J Psychiatry 1999 May;44(4):325.

The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Salem JE, et al. **Clin Psychol Rev** 1998 Nov;18(7):795-819 (201 ref.)

Identifying critical periods of neurodevelopmental risk: the turning point in schizophrenia research. Zornberg GL. **Harv Rev Psychiatry** 1998 Sep-Oct;6(3):171-4 (27 ref.)

Schizophrenia: all in the mind or locked in the brain? Clarke L. **J Adv Nurs** 1998 Aug;28(2):398-404 (50 ref.)

Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? Waddington JL, et al. **J Psychiatr Res** 1998 May-Aug;32(3-4):179-89 (151 ref.)

Histamine and prostaglandins in schizophrenia: revisited. Heleniak E, et al. **Med Hypotheses** 1999 Jan;52(1):37-42 (59 ref.)

GENETICS

Candidate-gene association studies of schizophrenia. O'Donovan MC, et al. **Am J Hum Genet** 1999 Sep; 65(3):587-92 (37 ref.)

Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role. Göthert M, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:26-30 (20 ref.)

Schizophrenia: refining the phenotype, resolving endophenotypes. Lenzenweger MF. **Behav Res Ther** 1999 Mar;37(3):281-95 (80 ref.)

Alternative phenotypes for the complex genetics of schizophrenia. Freedman R, et al. **Biol Psychiatry** 1999 Mar 1;45(5):551-8 (40 ref.)

Triplets with schizophrenia [letter; comment] Torrey EF, et al. **Biol Psychiatry** 1999 Mar 1;45(5):655 (4 ref.) Comment on: Biol Psychiatry 1997 Dec 15;42(12):1186-7.

The etiologic heterogeneity of schizophrenia. Garver DL. **Harv Rev Psychiatry** 1997 Mar-Apr;4(6):317-27 (100 ref.)

Progress on the genetics of schizophrenia [editorial] Bassett AS. **J Psychiatry Neurosci** 1998 Nov;23(5):270-3 (32 ref.)

Expanded (CAG)n, (CGG)n and (GAA)n trinucleotide repeat microsatellites, and mutant purine synthesis and pigmentation genes cause schizophrenia and autism. Fischer KM. **Med Hypotheses** 1998 Sep;51(3):223-33 (89 ref.)

New genetic hypothesis of schizophrenia. Guidry J, et al. **Med Hypotheses** 1999 Jan;52(1):69-75 (66 ref.)

Schizophrenia genetics: expansion of knowledge? [editorial; comment] Ross CA. **Mol Psychiatry** 1999 Jan;4(1):4-5 (14 ref.) Comment on: Mol Psychiatry 1999 Jan;4(1):53-7. Comment on: Mol Psychiatry 1999 Jan;4(1):58-63.

Schizophrenia and N-methyl-D-aspartate receptors: evolutionary adaptations from malfunctioning molecules? Rison RA. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Oct;11(4):236-40 (40 ref.)

Biological research on schizophrenia. Toru M. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S170-2 (28 ref.)

Psychophysiological measures of (dis)inhibition as liability indicators for schizophrenia. Clementz BA. **Psychophysiology** 1998 Nov;35(6):648-68 (250 ref.)

Identifying psychophysiological risk for psychopathology: examples from substance abuse and schizophrenia research. Iacono WG. **Psychophysiology** 1998 Nov;35(6):621-37 (145 ref.)

The ecogenetics of schizophrenia: a review. van Os J, et al. **Schizophr Res** 1998 Jul 27;32(2):127-35 (71 ref.)

[Problem of molecular psychiatry in view of the trinucleotide repeat expansion disease] Ohara K. **Nippon Rinsho** 1999 Apr;57(4):792-5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic factors in the onset of schizophrenia] Zivanović O, et al. **Med Pregl** 1999 Jan-Feb;52(1-2):25-8 (15 ref.) (Eng. Abstr.) **(Scr)**

METABOLISM

In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Kegeles LS, et al. **Biol Psychiatry** 1998 Sep 15;44(6):382-98 (137 ref.)

Olanzapine: a basic science update. Bymaster F, et al. **Br J Psychiatry Suppl** 1999;(37):36-40 (18 ref.)

Glutamatergic aspects of schizophrenia. Tamminga C. **Br J Psychiatry Suppl** 1999;(37):12-5 (15 ref.)

Cholinergic aspects of schizophrenia. Tandon R. **Br J Psychiatry Suppl** 1999;(37):7-11 (11 ref.)

Proton magnetic resonance spectroscopy in schizophrenia. Bertolino A, et al. **Eur J Radiol** 1999 May;30(2):132-41 (55 ref.)

Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Laruelle M. **Q J Nucl Med** 1998 Sep; 42(3):211-21 (84 ref.)

NURSING

Instruments for assessment of auditory hallucinations. Frederick JA, et al. **Arch Psychiatr Nurs** 1998 Oct; 12(5):255-63 (24 ref.)

Atypical neuroleptics: autonomy and compliance? Marland GR. **J Adv Nurs** 1999 Mar;29(3):615-22 (47 ref.)

PATHOLOGY

Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia. Arnold SE, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:762-75 (74 ref.)

Ventromedial temporal lobe pathology in dementia, brain trauma, and schizophrenia. Van Hoesen GW, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:575-94 (96 ref.)

The reduced neuropil hypothesis: a circuit based model of schizophrenia. Selemon LD, et al. **Biol Psychiatry** 1999 Jan 1;45(1):17-25 (91 ref.)

Cell biology of the hippocampal formation in schizophrenia. Weinberger DR. **Biol Psychiatry** 1999 Feb 15;45(4):395-402 (50 ref.)

The neuropathology of schizophrenia. A critical review of the data and their interpretation. Harrison PJ. **Brain** 1999 Apr;122 (Pt 4):593-624 (394 ref.)

Multiple constraint organization in the brain: a theory for schizophrenia. Peled A. **Brain Res Bull** 1999 Jul 1; 49(4):245-50 (40 ref.)

The neuropathology of schizophrenia. Powers RE. **J Neuropathol Exp Neurol** 1999 Jul;58(7):679-90 (98 ref.)

Disturbances of corticogenesis in schizophrenia: morphological findings provide new evidence for the maldevelopmental hypothesis. Kalus P, et al. **Neuropsychobiology** 1999;40(1):1-13 (85 ref.)

PHYSIOPATHOLOGY

Auditory hallucinations: phenomenology, neuropsychology and neuroimaging update. David AS.
Acta Psychiatr Scand Suppl 1999;395:95–104 (112 ref.)

Abnormal neural integration related to cognition in schizophrenia. Dolan RJ, et al.
Acta Psychiatr Scand Suppl 1999;395:58–67 (66 ref.)

Schizophrenia and the disconnection hypothesis. Friston KJ.
Acta Psychiatr Scand Suppl 1999;395:68–79 (49 ref.)

Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Gallhofer B, et al. **Acta Psychiatr Scand Suppl** 1999;395:118–28 (102 ref.)

Transmitter dysfunction during the process of schizophrenia. Glenthøj BY, et al. **Acta Psychiatr Scand Suppl** 1999; 395:105–12 (81 ref.)

Backward masking performance as an indicator of vulnerability to schizophrenia. Green MF, et al.
Acta Psychiatr Scand Suppl 1999;395:34–40 (30 ref.)

From predisposition to psychosis: progression of symptoms in schizophrenia. Parnas J. **Acta Psychiatr Scand Suppl** 1999;395:20–9 (64 ref.)

Abnormal contents of consciousness: the transition from automatic to controlled processing. Gray JA.
Adv Neurol 1998;77:195–208; discussion 208–11 (57 ref.)

Dopamine, serotonin, and schizophrenia. van Veelen NM, et al. **Adv Neurol** 1999;80:425–9 (51 ref.)

Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia. Arnold SE, et al.
Ann N Y Acad Sci 1998 Nov 30;855:762–75 (74 ref.)

Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies. Epstein J, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:562–74 (97 ref.)

D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Joyce JN, et al.
Ann N Y Acad Sci 1999 Jun 29;877:595–613 (61 ref.)

Epilepsy, schizophrenia, and the extended amygdala. Stevens JR. **Ann N Y Acad Sci** 1999 Jun 29;877:548–61 (93 ref.)

Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body Dementia: too much or too little cortical acetylcholine? Sarter M, et al. **Brain Cogn** 1998 Dec; 38(3):297–316 (135 ref.)

An integrated view of pathophysiological models of schizophrenia. Duncan GE, et al.
Brain Res Brain Res Rev 1999 Apr;29(2–3):250–64 (224 ref.)

GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Keverne EB. **Brain Res Bull** 1999 Mar 15;48(5):467–73 (71 ref.)

Cognitive disorders: A question of misattribution. Stein J, et al. **Curr Biol** 1999 May 20;9(10):R374–6 (14 ref.)

Pharmacological differentiation of classical and novel antipsychotics. Arnt J. **Int Clin Psychopharmacol** 1998 Mar; 13 Suppl 3:S7–14 (46 ref.)

Perinatal characteristics and schizophrenia: electrodermal activity as a mediating link in a vulnerability–stress perspective. Hultman CM, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):307–16 (99 ref.)

Insight in severe mental illness: implications for treatment decisions. Husted JR. **J Am Acad Psychiatry Law** 1999; 27(1):33–49 (33 ref.)

Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Lieberman JA.
J Clin Psychiatry 1999;60 Suppl 12:9–12 (25 ref.)

The somatic component of schizophrenia: a dissociation of the goals of visual attention and bifoveal fixation? Korn H. **Med Hypotheses** 1999 Feb;52(2):163–70 (24 ref.)

Schizophrenia – A disturbance of signal interaction between the entorhinal cortex and the dentate gyrus? The contribution of experimental dibenamine psychosis to the pathogenesis of schizophrenia: A hypothesis. Arnold OH. **Neuropsychobiology** 1999;40(1):21–32 (54 ref.)

Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Yang CR, et al. **Neuropsychopharmacology** 1999 Aug;21(2):161–94 (369 ref.)

The NMDA antagonist model for schizophrenia: promise and pitfalls. Abi-Saab WM, et al. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:104–9 (50 ref.)

Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Geyer MA.
Pharmacopsychiatry 1998 Jul;31 Suppl 2:73–9 (47 ref.)

The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Farber NB, et al. **Prog Brain Res** 1998;116:421–37 (60 ref.)

Electroencephalographic findings in functional psychoses: state or trait indicators? Sengoku A, et al.
Psychiatry Clin Neurosci 1998 Aug;52(4):375–81 (91 ref.)

Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Flyckt L, et al. **Psychiatry Res** 1999 May 31;86(2):113–29 (50 ref.)

Identification of neural circuits underlying P300 abnormalities in schizophrenia. O'Donnell BF, et al.
Psychophysiology 1999 May;36(3):388–98 (99 ref.)

Laterality in animals: relevance to schizophrenia. Cowell PE, et al. **Schizophr Bull** 1999;25(1):41–62 (255 ref.)

Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation. Gruzelier JH.
Schizophr Bull 1999;25(1):91–120 (235 ref.)

Laterality in functional brain imaging studies of schizophrenia. Gur RE, et al. **Schizophr Bull** 1999; 25(1):141–56 (87 ref.)

Facial expressions of emotions and schizophrenia: a review. Mandal MK, et al. **Schizophr Bull** 1998;24(3):399–412 (92 ref.)

Structural asymmetries of the human brain and their disturbance in schizophrenia. Petty RG. **Schizophr Bull** 1999;25(1):121–39 (224 ref.)

A review of longitudinal studies of cognitive functions in schizophrenia patients. Rund BR. **Schizophr Bull** 1998; 24(3):425–35 (65 ref.)

Atypical handedness in schizophrenia: some methodological and theoretical issues. Satz P, et al. **Schizophr Bull** 1999; 25(1):63–78 (110 ref.)

Executive function in schizophrenia. Velligan DI, et al.
Semin Clin Neuropsychiatry 1999 Jan;4(1):24–33 (134 ref.)

[Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment] Glenthøj BY, et al. **Ugeskr Laeger** 1999 Mar 8; 161(10):1391–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Psychopathological correlates of dopaminergic dysfunction in alcoholic and schizophrenic patients] Heinz A.
Nervenarzt 1999 May;70(5):399–407 (69 ref.) (Eng. Abstr.) **(Ger)**

[Electroencephalography and cognitive processes in schizophrenia] Alfimova MV, et al.
Zh Nevrol Psikhiatr Im S S Korsakova 1998;98(11):55–8 (57 ref.) **(Rus)**

PREVENTION & CONTROL

The routine use of atypical antipsychotic agents: maintenance treatment. Kinon BJ. **J Clin Psychiatry** 1998;59 Suppl 19:18–22 (34 ref.)

RADIONUCLIDE IMAGING

Brain imaging of affective disorders and schizophrenia. Kishimoto H, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S212–4 (20 ref.)

Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Buchsbaum MS, et al.
Schizophr Bull 1998;24(3):343–64 (165 ref.)

REHABILITATION

Treating substance abuse among patients with schizophrenia. Bellack AS, et al. **Psychiatr Serv** 1999 Jan;50(1):75–80 (57 ref.)

Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Bellack AS, et al.
Schizophr Bull 1999;25(2):257–74 (84 ref.)

Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. Spaulding WD, et al.
Schizophr Bull 1999;25(2):275–89 (65 ref.)

[Long-term treatment of chronic schizophrenia (see comments)] Albers M. **Nervenarzt** 1998 Sep;69(9):737–51 (142 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1999 Mar;70(3):291–2. **(Ger)**

[Rehabilitation in schizophrenia--guidelines for including psychosocial measures] Katschnig H.
Wien Med Wochenschr 1998;148(11–12):273–80 (41 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Early intervention in schizophrenia in the elderly. Burke D, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):809–14 (28 ref.)

Impediments in the treatment of schizophrenic patients. Fleck S. **Conn Med** 1998 Dec;62(12):707–14 (91 ref.)

Using multidimensional scaling and cluster analysis for understanding information processing and schizophrenia. Catalano JA. **Genet Soc Gen Psychol Monogr** 1999 Aug; 125(3):313–28 (45 ref.)

Schizophrenia: improving outcome. Bustillo JR, et al.
Harv Rev Psychiatry 1999 Jan–Feb;6(5):229–40 (72 ref.)

Results of treatment of schizophrenia: is the glass half full or half empty? Kissling W, et al.
Int Clin Psychopharmacol 1999 Jun;14 Suppl 3:S11–4 (9 ref.)

Treatment of schizophrenia in childhood and adolescence. Clark AF, et al. **J Child Psychol Psychiatry** 1998 Nov; 39(8):1071–81 (97 ref.)

Soteria and other alternatives to acute psychiatric hospitalization: a personal and professional review. Mosher LR. **J Nerv Ment Dis** 1999 Mar;187(3):142–9 (48 ref.)

Should schizophrenia be treated as a neurocognitive disorder? Green MF, et al. **Schizophr Bull** 1999;25(2):309–19 (60 ref.)

[Schizophrenia and violence: epidemiological, forensic and clinical aspects] Steinert T. **Fortschr Neurol Psychiatr** 1998 Sep;66(9):391–401 (124 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacologic and cognitive therapy treatment strategies in in persistent negative schizophrenic symptoms] Vauth R, et al. **Fortschr Neurol Psychiatr** 1999 Jun;67(6):261–73 (106 ref.) (Eng. Abstr.) **(Ger)**

[A stimulus barrier model of early onset schizophrenia: an integrative etiological and therapeutic approach] Eggers C. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec; 47(10):740–53 (67 ref.) (Eng. Abstr.) **(Ger)**

[Economic perspectives in the care and treatment of patients diagnosed with schizophrenia] Percudani M, et al.
Epidemiol Psichiatr Soc 1998 Sep–Dec;7(3):197–209 (114 ref.) (Eng. Abstr.) **(Ita)**

SCHIZOPHRENIA, BORDERLINE see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIA, CHILDHOOD

COMPLICATIONS

[Impulse control disorders in schizophrenia in children, adolescents and young people] Golik AN.
Zh Nevrol Psikhiatr Im S S Korsakova 1999;99(7):63–7 (129 ref.) **(Rus)**

DRUG THERAPY

[Atypical neuroleptics in the child and adolescent] Naja WJ, et al. **Encephale** 1998 Jul–Aug;24(4):378–85 (67 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

[Behavior therapy methods in treatment of schizophrenic adolescents] Kienzle N, et al.
Z Kinder Jugendpsychiatr Psychother 1999 Aug; 27(3):189–97 (60 ref.) **(Ger)**

THERAPY

Treatment of schizophrenia in childhood and adolescence. Clark AF, et al. **J Child Psychol Psychiatry** 1998 Nov; 39(8):1071–81 (97 ref.)

SCHIZOPHRENIA, LATENT see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIA, PARANOID

DRUG THERAPY

Asymptomatic pancreatitis associated with clozapine. Bergemann N, et al. **Pharmacopsychiatry** 1999 Mar; 32(2):78–80 (9 ref.)

SCHIZOPHRENIA, PSEUDONEUROTIC see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIC DISORDERS see **SCHIZOPHRENIA**

SCHIZOPHRENIC LANGUAGE

[Psychosis, language and literature] Maier T. **Nervenarzt** 1999 May;70(5):438–43 (35 ref.) (Eng. Abstr.) **(Ger)**

SCHIZOPHRENIC PSYCHOLOGY

Auditory hallucinations: phenomenology, neuropsychology and neuroimaging update. David AS.
Acta Psychiatr Scand Suppl 1999;395:95–104 (112 ref.)

Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Gallhofer B, et al. **Acta Psychiatr Scand Suppl** 1999;395:118–28 (102 ref.)

Backward masking performance as an indicator of vulnerability to schizophrenia. Green MF, et al.
Acta Psychiatr Scand Suppl 1999;395:34–40 (30 ref.)

Developmental neuropathology and the precursors of schizophrenia. Walker EF, et al.
Acta Psychiatr Scand Suppl 1999;395:12–9 (31 ref.)

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Dalack GW, et al.
Am J Psychiatry 1998 Nov;155(11):1490–501 (100 ref.)

Instruments for assessment of auditory hallucinations. Frederick JA, et al. **Arch Psychiatr Nurs** 1998 Oct; 12(5):255–63 (24 ref.)

Schizophrenia: refining the phenotype, resolving endophenotypes. Lenzenweger MF. **Behav Res Ther** 1999 Mar;37(3):281–95 (80 ref.)

Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Friedman JI, et al.
Biol Psychiatry 1999 Jan 1;45(1):1–16 (160 ref.)

Schizophrenia--a disorder of the corollary discharge systems that integrate the motor systems of thought with the sensory systems of consciousness. Feinberg I, et al.
Br J Psychiatry 1999 Mar;174:196–204 (62 ref.)

Family burden of schizophrenia and depressive illness. Specifying the effects of ethnicity, gender and social ecology. Jenkins JH, et al. **Br J Psychiatry** 1999 Jan; 174:31–8 (33 ref.)

Cognitive deficit in schizophrenia and its neurochemical basis. Breier A. **Br J Psychiatry Suppl** 1999;(37):16–8 (20 ref.)

Pharmacological differentiation of classical and novel antipsychotics. Arnt J. **Int Clin Psychopharmacol** 1998 Mar; 13 Suppl 3:S7–14 (46 ref.)

How much do novel antipsychotics benefit the patients? Kasper S. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S71–7 (55 ref.)

Early detection and intervention in schizophrenia. Linszen DH, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S31–4 (33 ref.)

Novel antipsychotics and negative symptoms. Möller HJ.
Int Clin Psychopharmacol 1998 Mar;13 Suppl 3:S43–7 (21 ref.)

Good medical practice in antipsychotic pharmacotherapy. Peuskens J. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl

3:S35–41 (32 ref.)
The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Tamminga CA, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S21–6 (45 ref.)
Schizophrenia: all in the mind or locked in the brain? Clarke L. **J Adv Nurs** 1998 Aug;28(2):398–404 (50 ref.)
Insight in severe mental illness: implications for treatment decisions. Husted JR. **J Am Acad Psychiatry Law** 1999; 27(1):33–49 (33 ref.)
The effects of clozapine on cognitive functioning in schizophrenia. McGurk SR. **J Clin Psychiatry** 1999;60 Suppl 12:24–9 (31 ref.)
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson GD, et al. **J Clin Psychiatry** 1999;60 Suppl 5:23–9; discussion 30 (45 ref.)
Which characteristics of schizophrenia predate psychosis? Davies N, et al. **J Psychiatr Res** 1998 May–Aug; 32(3–4):121–31 (134 ref.)
The profiles of clinical deterioration in schizophrenia. McGlashan TH. **J Psychiatr Res** 1998 May–Aug; 32(3–4):133–41 (56 ref.)
Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? Waddington JL, et al. **J Psychiatr Res** 1998 May–Aug;32(3–4):179–89 (151 ref.)
The biographical component of schizophrenia: a two-faced definition of relationship? Korn H. **Med Hypotheses** 1999 Jun;52(6):539–44 (32 ref.)
Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Geyer MA. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:73–9 (47 ref.)
Treatment refractory schizophrenia: how should we proceed? Sharif ZA. **Psychiatr Q** 1998 Winter;69(4):263–81 (44 ref.)
Private and public in the lives of chronic schizophrenic patients. Leferink K. **Psychiatry** 1998 Summer;61(2):147–62 (60 ref.)
Criminal and violent behavior in schizophrenic patients: an overview. Modestin J. **Psychiatry Clin Neurosci** 1998 Dec; 52(6):547–54 (35 ref.)
Identifying psychophysiological risk for psychopathology: examples from substance abuse and schizophrenia research. Iacono WG. **Psychophysiology** 1998 Nov;35(6):621–37 (145 ref.)
Facial expressions of emotions and schizophrenia: a review. Mandal MK, et al. **Schizophr Bull** 1998;24(3):399–412 (92 ref.)
A review of longitudinal studies of cognitive functions in schizophrenia patients. Rund BR. **Schizophr Bull** 1998; 24(3):425–35 (65 ref.)
[Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment] Glenthøj BY, et al. **Ugeskr Laeger** 1999 Mar 8; 161(10):1391–8 (40 ref.) (Eng. Abstr.) **(Dan)**
[Perception and insight of illness in schizophrenic patients] Böker W. **Fortschr Neurol Psychiatr** 1999 Jun;67(6):237–48 (91 ref.) (Eng. Abstr.) **(Ger)**
[Dissociation and schizophrenia. Schizophrenias--a dissociative nosopoietic construct?] Scharfetter C. **Fortschr Neurol Psychiatr** 1998 Nov;66(11):520–3 (21 ref.) (Eng. Abstr.) **(Ger)**
[Schizophrenia and violence: epidemiological, forensic and clinical aspects] Steinert T. **Fortschr Neurol Psychiatr** 1998 Sep;66(9):391–401 (124 ref.) (Eng. Abstr.) **(Ger)**
[Long-term treatment of chronic schizophrenia (see comments)] Albers M. **Nervenarzt** 1998 Sep;69(9):737–51 (142 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1999 Mar;70(3):291–2. **(Ger)**
[Problems in evaluating new antipsychotic drugs] Fleischhacker WW. **Wien Med Wochenschr** 1998; 148(11–12):266–72 (71 ref.) (Eng. Abstr.) **(Ger)**
[Rehabilitation in schizophrenia--guidelines for including psychosocial measures] Katschnig H. **Wien Med Wochenschr** 1998;148(11–12):273–80 (41 ref.) (Eng. Abstr.) **(Ger)**
[The course of schizophrenic illnesses] Riecher-Rössler A, et al. **Wien Med Wochenschr** 1998;148(11–12):259–65 (36 ref.) (Eng. Abstr.) **(Ger)**
[Schizophrenia--an illness and its treatment reflected in public attitude] Schöny W. **Wien Med Wochenschr** 1998; 148(11–12):284–8 (18 ref.) (Eng. Abstr.) **(Ger)**
[Neuropsychological alteration in schizophrenia and its modification] Penadés R, et al. **Actas Esp Psiquiatr** 1999 May–Jun;27(3):198–208 (101 ref.) (Eng. Abstr.) **(Spa)**

SCHIZOPHRENIFORM DISORDERS see **PSYCHOTIC DISORDERS**

SCHIZOSACCHAROMYCES

CHEMISTRY

Preparation of the fission yeast Schizosaccharomyces pombe for ultrastructural and immunocytochemical study. Hajibagheri MA, et al. **Methods Mol Biol** 1999;117:183–207 (43 ref.)

CYTOLOGY

The fission yeast microtubule cytoskeleton. Hagan IM. **J Cell Sci** 1998 Jun;111 (Pt 12):1603–12 (92 ref.)
GFP fusion proteins as probes for cytology in fission yeast. Sawin KE. **Methods Cell Biol** 1999;58:123–38 (35 ref.)
Control of meiotic recombination in Schizosaccharomyces pombe. Fox ME, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:345–78 (132 ref.)

ENZYMOLOGY

Stress-activated MAP kinase (mitogen-activated protein kinase) pathways of budding and fission yeasts. Millar JB. **Biochem Soc Symp** 1999;64:49–62 (53 ref.)

GENETICS

Genetics, physiology and cytology of yeast-mycelial dimorphism in fission yeasts. Sipiczki M, et al. **Acta Microbiol Immunol Hung** 1999;46(2–3):297–302 (23 ref.)
DNA structure checkpoint pathways in Schizosaccharomyces pombe. Caspari T, et al. **Biochimie** 1999 Jan–Feb;81(1–2):173–81 (65 ref.)
S-phase DNA damage checkpoint in budding yeast. Foiani M, et al. **Biol Chem** 1998 Aug–Sep;379(8–9):1019–23 (25 ref.)
Meiotic telomeres: a matchmaker for homologous chromosomes. Hiraoka Y. **Genes Cells** 1998 Jul;3(7):405–13 (55 ref.)
Genetic control of fission yeast cell wall synthesis: the genes involved in wall biogenesis and their interactions in Schizosaccharomyces pombe. Ishiguro J. **Genes Genet Syst** 1998 Aug;73(4):181–91 (104 ref.)
Control of meiotic recombination in Schizosaccharomyces pombe. Fox ME, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:345–78 (132 ref.)
DNA damage and replication checkpoints in the fission yeast, Schizosaccharomyces pombe. Huberman JA. **Prog Nucleic Acid Res Mol Biol** 1999;62:369–95 (81 ref.)
The best yeast? Forsburg SL. **Trends Genet** 1999 Sep; 15(9):340–4 (64 ref.)
[Phylogenetic preservation of genetic study stocks of Schizosaccharomyces pombe] Shimoda C. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):282–4 (9 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

On growth and form: control of cell morphogenesis in fission yeast. Verde F. **Curr Opin Microbiol** 1998 Dec;1(6):712–8 (54 ref.)
Dynamics of cell wall formation in fission yeast, Schizosaccharomyces pombe. Osumi M, et al. **Fungal Genet Biol** 1998 Jun–Jul;24(1–2):178–206 (98 ref.)

METABOLISM

Genetic regulation of phospholipid metabolism: yeast as a model eukaryote. Henry SA, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:133–79 (276 ref.)

PHYSIOLOGY

Action at the ends of microtubules. Saunders WS. **Curr Opin Cell Biol** 1999 Feb;11(1):129–33 (35 ref.)
Stress-activated signalling pathways in yeast. Toone WM, et al. **Genes Cells** 1998 Aug;3(8):485–98 (110 ref.)
The fission yeast microtubule cytoskeleton. Hagan IM. **J Cell Sci** 1998 Jun;111 (Pt 12):1603–12 (92 ref.)
Fusion of a fission yeast. Davey J. **Yeast** 1998 Dec; 14(16):1529–66 (318 ref.)

ULTRASTRUCTURE

Preparation of the fission yeast Schizosaccharomyces pombe for ultrastructural and immunocytochemical study. Hajibagheri MA, et al. **Methods Mol Biol** 1999;117:183–207 (43 ref.)

SCHIZOTYPAL PERSONALITY DISORDER

ETIOLOGY

Developmental neuropathology and the precursors of schizophrenia. Walker EF, et al. **Acta Psychiatr Scand Suppl** 1999;395:12–9 (31 ref.)

SCHMIDT'S SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

SCHNITZLER SYNDROME

DIAGNOSIS

Schnitzler's syndrome versus adult onset Still's disease [published erratum appears in Eur J Dermatol 1998 Jun;8(4):234] Tomková H, et al. **Eur J Dermatol** 1998 Mar; 8(2):118–21 (20 ref.)
[The Schnitzler syndrome. A case report (letter)] Lozano Gutiérrez F, et al. **Med Clin (Barc)** 1999 Feb 6;112(4):158–9 (10 ref.) **(Spa)**

SCHOENLEIN-HENOCH PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

SCHOOL ADMISSION CRITERIA

Truth and consequences. Foster GS. **Acad Med** 1998 Dec; 73(12):1226–7 (1 ref.)

SCHOOL HEALTH SERVICES

School-based smoking control: a research agenda [see comments] Manske SR, et al. **Cancer Prev Control** 1997 Aug;1(3):196–212 (110 ref.) Comment in: Cancer Prev Control 1997 Aug;1(3):190–1.
Mental health services in schools: utilization, effectiveness, and consent. Evans SW. **Clin Psychol Rev** 1999 Mar; 19(2):165–78 (67 ref.)
School-based approaches for preventing and treating obesity. Story M. **Int J Obes Relat Metab Disord** 1999 Mar;23 Suppl 2:S43–51 (52 ref.)
Defining peer education. Shiner M. **J Adolesc** 1999 Aug; 22(4):555–66 (37 ref.)
Reducing risks and building developmental assets: essential actions for promoting adolescent health. Scales PC. **J Sch Health** 1999 Mar;69(3):113–9 (16 ref.)
Using puppetry in a coordinated school health program. Synovitz LB. **J Sch Health** 1999 Apr;69(4):145–7 (46 ref.)
Bright smiles, shining futures. Yehieli M, et al. **J Sch Health** 1999 Apr;69(4):162–4 (1 ref.)

ECONOMICS

Mental health in schools and system restructuring. Adelman HS, et al. **Clin Psychol Rev** 1999 Mar;19(2):137–63 (102 ref.)
The new child health insurance expansions: how will school-based health centers fit in? Koppelman J, et al. **J Sch Health** 1998 Dec;68(10):441–6 (8 ref.)

ORGANIZATION & ADMINISTRATION

Health promoting schools: issues and future directions for Australia and the Asia Pacific Region. Rowling L, et al. **Asia Pac J Public Health** 1996–97;9:33–7 (41 ref.)
Review of sexuality education in the United States for health professionals working with adolescents. Middleman AB. **Curr Opin Pediatr** 1999 Aug;11(4):283–6 (15 ref.)
Family involvement in expanded school mental health. Bickham NL, et al. **J Sch Health** 1998 Dec;68(10):425–8 (8 ref.)
School-based health centers in the context of education reform. Dryfoos JG. **J Sch Health** 1998 Dec;68(10):404–8 (18 ref.)
Optimizing the roles of school mental health professionals. Flaherty LT, et al. **J Sch Health** 1998 Dec;68(10):420–4 (34 ref.)
School-based health centers and school nurses: cementing the collaboration. Hacker K, et al. **J Sch Health** 1998 Dec; 68(10):409–14 (25 ref.)
Promoting holistic child development: a collaborative school health approach. Haynes NM. **J Sch Health** 1998 Nov; 68(9):381–3 (9 ref.)
Business and faith: key community partnerships for school-based health centers. Juszczak L, et al. **J Sch Health** 1998 Dec;68(10):429–33 (1 ref.)
Interdisciplinary collaborative training for school-based health professionals. Papa PA, et al. **J Sch Health** 1998 Dec;68(10):415–9 (13 ref.)
Managed care, school health programs, and adolescent health services: opportunities for health promotion. Santelli J, et al. **J Sch Health** 1998 Dec;68(10):434–40 (46 ref.)

STANDARDS

Promotion of evaluation as a strategy towards an effective substance prevention. Ostaszewski K. **Eur Addict Res** 1998 Sep;4(3):128–33 (33 ref.)

SUPPLY & DISTRIBUTION

Mental health in schools and system restructuring. Adelman HS, et al. **Clin Psychol Rev** 1999 Mar;19(2):137–63 (102 ref.)
Responding to the mental health needs of Latino children and families through school-based services. Garrison EG, et al. **Clin Psychol Rev** 1999 Mar;19(2):199–219 (98 ref.)
Integrating health and mental health services in schools: psychologists collaborating with primary care providers. Kubiszyn T. **Clin Psychol Rev** 1999 Mar;19(2):179–98 (104 ref.)
Toward collaboration in the growing education-mental health interface. Waxman RP, et al. **Clin Psychol Rev** 1999 Mar;19(2):239–53 (62 ref.)

SCHOOL NURSING

METHODS

The school nurse's role in homeopathic interventions. Selekman J, et al. **J Sch Health** 1998 Oct;68(8):342–5 (7 ref.)

ORGANIZATION & ADMINISTRATION

School nursing: past, present, and future. Hall DM. **Arch Dis Child** 1999 Aug;81(2):181–4 (42 ref.)
School-based health centers and school nurses: cementing the collaboration. Hacker K, et al. **J Sch Health** 1998 Dec;

68(10):409-14 (25 ref.)

SCHOOLS

The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S-754S (78 ref.)

High school genetics education and Alzheimer disease. Horsma HG. **Genet Test** 1999;3(1):147-53 (50 ref.)

Who should be educated? Education strategies: could children educate their parents? Basdevant A, et al. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S10-2; discussion S12-3 (7 ref.)

Mismatch of classroom furniture and student body dimensions: empirical findings and health implications [see comments] Parcells C, et al. **J Adolesc Health** 1999 Apr; 24(4):265-73 (29 ref.) Comment in: J Adolesc Health 1999 Apr;24(4):229.

Informed consent in school health research: why, how, and making it easy. Ross JG, et al. **J Sch Health** 1999 May; 69(5):171-6 (14 ref.)

Emotional and cognitive aspects in adolescence-onset school difficulties. Masi G, et al. **Panminerva Med** 1999 Mar; 41(1):54-8 (21 ref.)

Tinea capitis: recommendations for school attendance. Honig PJ. **Pediatr Infect Dis J** 1999 Feb;18(2):211-4 (23 ref.)

Injuries at school: a review. Haq SM, et al. **Tex Med** 1999 Apr;95(4):62-5 (33 ref.)

SCHOOLS, HEALTH OCCUPATIONS

ORGANIZATION & ADMINISTRATION

Ten years on and more: establishing programmes of rehabilitation education: the New Zealand case. Gregory RJ. **Disabil Rehabil** 1998 Oct;20(10):385-90 (12 ref.)

SCHOOLS, MEDICAL

Clinical research in medical schools: seizing the opportunity. Meyer RE, et al. **Proc Assoc Am Physicians** 1998 Nov-Dec; 110(6):513-20 (18 ref.)

LEGISLATION & JURISPRUDENCE

Truth and consequences. Foster GS. **Acad Med** 1998 Dec; 73(12):1226-7 (1 ref.)

Sending a policy signal: state legislatures, medical schools, and primary care mandates. Weissert CS, et al. **J Health Polit Policy Law** 1998 Oct;23(5):743-70 (39 ref.)

ORGANIZATION & ADMINISTRATION

Undergraduate and postgraduate clinical education in Kobe University School of Medicine. Maruo T. **Kobe J Med Sci** 1997 Dec;43(6):237-42 (0 ref.)

SCHOOLS, NURSERY

see related
CHILD DAY CARE CENTERS

Developmental and psychiatric evaluation in the preschool context. Kaplan MD. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):379-93 (29 ref.)

Evaluation of early childhood programs. Schweinhart LJ. **Child Adolesc Psychiatr Clin N Am** 1999 Apr;8(2):395-407, viii-ix (44 ref.)

Head Start, nutrition, and problems of poverty in childhood [editorial] Karp RJ. **J Am Coll Nutr** 1999 Apr;18(2):100-1 (21 ref.)

SCHOOLS, VETERINARY

HISTORY

[History of control measures against bovine tuberculosis--contributions from the Institute of Microbiology and Contagious Diseases of the Tierärztlichen Hochschule Hannover] Bisping W. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):362-7 (46 ref.) (Eng. Abstr.) **(Ger)**

SCHUELLER-CHRISTIAN DISEASE see **HAND-SCHUELLER-CHRISTIAN SYNDROME**

SCHWALBE'S NUCLEUS see **VESTIBULAR NUCLEI**

SCHWANN CELLS

METABOLISM

Estrogen receptor immunoreactivity in Schwann-like brain macroglia. Gudiño-Cabrera G, et al. **J Neurobiol** 1999 Sep 15;40(4):458-70 (106 ref.)

The Schwann cell at the neuromuscular junction. Koenig J, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):153-5 (15 ref.)

MICROBIOLOGY

How Mycobacterium leprae infects peripheral nerves. Freedman VH, et al. **Lepr Rev** 1999 Jun;70(2):136-9 (13 ref.)

PHYSIOLOGY

The neurobiology of Schwann cells. Mirsky R, et al. **Brain Pathol** 1999 Apr;9(2):293-311 (179 ref.)

Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Frostick SP, et al. **Microsurgery** 1998; 18(7):397-405 (82 ref.)

Schwann cells and their precursors emerge as major regulators of nerve development. Jessen KR, et al. **Trends Neurosci** 1999 Sep;22(9):402-10 (87 ref.)

SECRETION

Peripheral nerve regeneration and neurotrophic factors. Terenghi G. **J Anat** 1999 Jan;194 (Pt 1):1-14 (219 ref.)

TRANSPLANTATION

Transplanting myelin-forming cells into the central nervous system: principles and practice. Franklin RJ, et al. **Methods** 1998 Nov;16(3):311-9 (60 ref.)

SCHWANNOMA see **NEURILEMMOMA**

SCHWANNOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

SCHWANNOMA, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

SCHWARTZ-BARTTER SYNDROME see **INAPPROPRIATE ADH SYNDROME**

SCHWARTZ-JAMPEL SYNDROME see **OSTEOCHONDRODYSPLASIAS**

SCIATIC NERVE

see related
SCIATICA

Sciatic neuropathy. Yuen EC, et al. **Neurol Clin** 1999 Aug; 17(3):617-31, viii (95 ref.)

SCIATICA

DRUG THERAPY

Efficacy of epidural steroids in low back pain and sciatica. A critical appraisal by a French Task Force of randomized trials. Critical Analysis Group of the French Society for Rheumatology. Rozenberg S, et al. **Rev Rhum Engl Ed** 1999 Feb;66(2):79-85 (23 ref.)

ETIOLOGY

[The Maffucci syndrome with axial bone lesions. A rare cause of low back pain] Ribeiro C, et al. **Acta Med Port** 1998 Jun;11(6):559-62 (10 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

The anatomical basis of sciatica secondary to herniated lumbar disc: a review. Spencer DL. **Neurol Res** 1999;21 Suppl 1:S33-6 (41 ref.)

PHYSIOPATHOLOGY

[New information concerning pain caused by herniated disk and sciatica. Exposure to disk tissue sensitizes the nerve roots] Olmarker K, et al. **Lakartidningen** 1998 Dec 2; 95(49):5618-22 (46 ref.) (Eng. Abstr.) **(Swe)**

RADIOGRAPHY

[Radiological imaging in lumbago and sciatica] Dullerud R. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1778-81 (14 ref.) (Eng. Abstr.) **(Nor)**

THERAPY

Sciatica: which intervention? Samanta A, et al. **BMJ** 1999 Jul 31;319(7205):302-3 (6 ref.)

SCID see **SEVERE COMBINED IMMUNODEFICIENCY**

SCID-HU MICE see **MICE, SCID**

SCID MICE see **MICE, SCID**

SCIENCE

Report of the ASHP Task Force on Science: American Society of Health-System Pharmacists. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2519-24 (0 ref.)

Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. Woolf SH, et al. **Annu Rev Med** 1999;50:207-21 (61 ref.)

Science for evil: the scientist's dilemma. Atiyah M. **BMJ** 1999 Aug 14;319(7207):448-9 (1 ref.)

Science, rhetoric, and public discourse in genetic research. Lagay FL. **Camb Q Healthc Ethics** 1999 Spring;8(2):226-37 (33 ref.)

Unitas, Libertas, Caritas: the meaning of science for general practice. de Melker RA. **Fam Pract** 1998 Aug;15(4):369-74 (48 ref.)

Fragmented ethics and "bridge bioethics". Potter VR. **Hastings Cent Rep** 1999 Jan-Feb;29(1):38-40 (17 ref.)

The manipulation of international scientific organizations [editorial] Castleman BI, et al. **Int J Occup Environ Health** 1998 Jan-Mar;4(1):53-5 (17 ref.)

The idea of nursing science. Edwards SD. **J Adv Nurs** 1999 Mar;29(3):563-9 (34 ref.)

The nature of philosophy of science, theory and knowledge relating to nursing and professionalism. Rutty JE. **J Adv Nurs** 1998 Aug;28(2):243-50 (63 ref.)

Clinical jazz: harmonizing clinical experience and evidence-based medicine [see comments] Shaughnessy AF, et al. **J Fam Pract** 1998 Dec;47(6):425-8 (16 ref.) Comment in: J Fam Pract 1999 Apr;48(4):306.

Science, ethics, and the future of research into maternal infant transmission of HIV-1. Perinatal HIV Intervention Research in Developing Countries Workshop participants [see comments] **Lancet** 1999 Mar 6;353(9155):832-5 (23 ref.) Comment in: Lancet 1999 May 29;353(9167):1878; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1878-9; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879-80; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1880-1.

The Nobel Prize and the biomedical paradigm: is it time for a change? Foss L. **Theor Med Bioeth** 1998 Dec;19(6):621-44 (63 ref.)

The role of science in medicine. Nordin I. **Theor Med Bioeth** 1999 Jun;20(3):229-44 (18 ref.)

[Role of science in the formulation of social policy on drugs] Kalant H. **C R Seances Soc Biol Fil** 1998;192(5):905-15 (29 ref.) (Eng. Abstr.) **(Fre)**

[Paradigms and pragmatism] Healy MJ. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):185-9 (16 ref.) **(Fre)**

[Alternative medicine at the crossing of scientific reality and myth] Abramow M. **Rev Med Brux** 1998 Sep;19(4):A301-5 (15 ref.) **(Fre)**

[Women and Science-Helena Rubinstein Awards for Women in Science] Isogai E. **Nippon Saikingaku Zasshi** 1998 Aug; 53(3):531-5 (7 ref.) **(Jpn)**

EDUCATION

A core curriculum in the evaluative sciences for diagnostic imaging [editorial] Stolberg HO, et al. **Can Assoc Radiol J** 1998 Oct;49(5):295-306 (66 ref.)

The challenge for basic science education in problem-based medical curricula [see comments] Sweeney G. **Clin Invest Med** 1999 Feb;22(1):15-22 (19 ref.) Comment in: Clin Invest Med 1999 Feb;22(1):23-4.

LEGISLATION & JURISPRUDENCE

Burden of proof: judging science and protecting public health in (and out of) the courtroom [see comments] Annas GJ. **Am J Public Health** 1999 Apr;89(4):490-3 (32 ref.) Comment in: Am J Public Health 1999 Apr;89(4):487-9.

METHODS

Alternative therapies: abuses of scientific method and challenges to dental research. Brunette DM. **J Prosthet Dent** 1998 Nov;80(5):605-14 (52 ref.)

STANDARDS

Objectivity in nursing research: observations and objections. Avis M. **Int J Nurs Stud** 1998 Jun;35(3):141-5 (30 ref.)

TRENDS

The sexual revolution in science: what gender-based research is telling us. Thompson PM, et al. **J Investig Med** 1999 Mar;47(3):106-13 (40 ref.)

SCIENTIFIC MISCONDUCT

Research fundamentals VI: misconduct in biomedical research. Biros MH, et al. **Acad Emerg Med** 1999 Aug; 6(8):840-8 (35 ref.)

Misconduct in clinical research--the Scandinavian experience and actions for prevention. Riis P. **Acta Oncol** 1999;38(1):89-92 (12 ref.)

Research misconduct in clinical research--the American experience and response. Ryan KJ. **Acta Oncol** 1999; 38(1):93-7 (19 ref.)

Authorship, dissemination of research findings, and related matters. Duncan AM. **Appl Nurs Res** 1999 May;12(2):101-6 (23 ref.)

What is the quality of the reporting of research ethics in publications of nursing home research? Karlawish JH, et al. **J Am Geriatr Soc** 1999 Jan;47(1):76-81 (58 ref.)

Introduction to misconduct in science and scientific duties. Soskolne CL. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:245-51 (18 ref.)

[Don't forget the journals in the fight against research misconduct. Investigation of suspected misconduct should not be conducted by the universities themselves (see comments)] Zetterström R. **Lakartidningen** 1998 Oct 28; 95(44):4864-6 (7 ref.) Comment in: Lakartidningen 1998 Nov 18;95(47):5275. **(Swe)**

SCIENTIFIC MISCONDUCT

LEGISLATION & JURISPRUDENCE

The unending saga of legal controls over scientific misconduct: a clash of cultures needing resolution. Goldner JA. **Am J Law Med** 1998;24(2-3):293-343 (521 ref.)

STATISTICS & NUMERICAL DATA

Fraud in medicine. Coping with fraud. Farthing MJ. **Lancet** 1998 Dec 19-26;352 Suppl 4:SIV11 (5 ref.)

SCIENTIFIC SOCIETIES see **SOCIETIES, SCIENTIFIC**

SCIENTOLOGY see **ALTERNATIVE MEDICINE**

SCINTIGRAPHY see **RADIONUCLIDE IMAGING**

SCINTIGRAPHY, COMPUTED TOMOGRAPHIC see **TOMOGRAPHY, EMISSION-COMPUTED**

SCINTIGRAPHY, EQUILIBRIUM see **GATED BLOOD-POOL IMAGING**

SCINTILLATION CAMERAS see **GAMMA CAMERAS**

SCINTILLATION COUNTING

see related
GAMMA CAMERAS

Intraoperative probes and imaging probes. Hoffman EJ, et al. **Eur J Nucl Med** 1999 Aug;26(8):913-35 (159 ref.)

SCINTIPHOTOGRAPHY see **RADIONUCLIDE IMAGING**

SCISSORS, SURGICAL see **SURGICAL INSTRUMENTS**

SCLERA

see related
LIMBUS CORNEAE
SCLERAL BUCKLING
SCLEROSTOMY

PHYSIOLOGY

Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. Prausnitz MR, et al. **J Pharm Sci** 1998 Dec;87(12):1479-88 (51 ref.)

SURGERY

[Surgical stimulation of uveoscleral discharge in primary glaucoma] Kornilaeva GG. **Vestn Oftalmol** 1999 Jan-Feb; 115(1):34-5 (30 ref.) **(Rus)**

TRANSPLANTATION

Scleral patch graft in the management of necrotizing scleritis. Nguyen QD, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):109-31 (48 ref.)

SCLERAL BUCKLING

METHODS

Surgical advances in retinopathy of prematurity. Andrews AP, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):275-90 (41 ref.)

[Intraocular gases in vitreous and retinal surgery. I: Basic principles] Faude F, et al. **Ophthalmologe** 1999 May; 96(5):W349-58 (66 ref.) **(Ger)**

SCLERAL DISEASES

VIROLOGY

Corneal, anterior segment, and adnexal manifestations of human immunodeficiency virus. Acharya NR, et al. **Int Ophthalmol Clin** 1998 Fall;38(4):161-77 (189 ref.)

SCLERITIS

COMPLICATIONS

An overlap syndrome with features of atypical Cogan syndrome and Wegener's granulomatosis. Gran JT, et al. **Scand J Rheumatol** 1999;28(1):62-4 (12 ref.)

ETIOLOGY

[Episcleritis and brucellosis. Apropos of a case] Bourcier T, et al. **J Fr Ophtalmol** 1998 Feb;21(2):126-7 (4 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Scleral patch graft in the management of necrotizing scleritis. Nguyen QD, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):109-31 (48 ref.)

SCLEROCORNEAL LIMBUS see **LIMBUS CORNEAE**

SCLERODERMA, CIRCUMSCRIBED

[Morphea: classification and management] Salmon-Ehr V, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):283-90 (94 ref.) **(Fre)**

COMPLICATIONS

Localized scleroderma associated with sarcoidosis [letter] Biasi D, et al. **Clin Exp Rheumatol** 1998 Nov-Dec; 16(6):761-2 (17 ref.)

Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Herouy Y, et al. **Int J Mol Med** 1999 May; 3(5):511-5 (25 ref.)

DIAGNOSIS

Morphea and localized scleroderma in children. Vierra E, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):210-25 (105 ref.)

ETIOLOGY

Trauma-induced linear scleroderma. Yamanaka CT, et al. **Cutis** 1999 Jan;63(1):29-32 (36 ref.)

METABOLISM

Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Herouy Y, et al. **Int J Mol Med** 1999 May; 3(5):511-5 (25 ref.)

PATHOLOGY

Trauma-induced linear scleroderma. Yamanaka CT, et al. **Cutis** 1999 Jan;63(1):29-32 (36 ref.)

RADIOTHERAPY

[Ultraviolet A-I phototherapy for skin diseases] Polderman MC, et al. **Ned Tijdschr Geneeskd** 1999 May 1;143(18):931-4 (25 ref.) (Eng. Abstr.) **(Dut)**

THERAPY

Morphea and localized scleroderma in children. Vierra E, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):210-25 (105 ref.)

SCLERODERMA, DIFFUSE see **SCLERODERMA, SYSTEMIC**

SCLERODERMA, LOCALIZED see **SCLERODERMA, CIRCUMSCRIBED**

SCLERODERMA, SYSTEMIC

Scleromyositis: a scleroderma/polymyositis overlap syndrome [editorial] Jablonska S, et al. **Clin Rheumatol** 1998;17(6):465-7 (25 ref.)

[Mixed connective tissue disease and overlap syndrome] Nishimaki T. **Nippon Rinsho** 1999 Feb;57(2):355-9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Systemic sclerosis: different subsets and disease remitting drugs] Ogawa T, et al. **Nippon Rinsho** 1999 Feb;57(2):344-8 (17 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Silica induced scleroderma--clinical and experimental aspects. Haustein UF, et al. **J Rheumatol** 1998 Oct; 25(10):1917-26 (99 ref.)

[Bleomycin-induced PSS-like pseudoscleroderma. Case report and review of the literature] Behrens S, et al. **Hautarzt** 1998 Sep;49(9):725-9 (21 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Manifestations of scleroderma pulmonary disease. Minai OA, et al. **Clin Chest Med** 1998 Dec;19(4):713-31, viii-ix (168 ref.)

Severe urinary bladder involvement in systemic sclerosis. Case report and review of the literature. La Civita L, et al. **Clin Exp Rheumatol** 1998 Sep-Oct;16(5):591-3 (17 ref.)

Advances in the diagnosis and management of scleroderma-related vascular complications. Kerin K, et al. **Compr Ther** 1998 Nov-Dec;24(11-12):574-81 (28 ref.)

Gastrointestinal manifestations of scleroderma. Rose S, et al. **Gastroenterol Clin North Am** 1998 Sep;27(3):563-94 (137 ref.)

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099-104 (13 ref.)

Normotensive scleroderma renal crisis: case report and review of the literature. Haviv YS, et al. **Ren Fail** 1998 Sep;20(5):733-6 (8 ref.)

Multiple stress fractures in a scleroderma patient on methotrexate therapy. Singwe M, et al. **Rev Rhum Engl Ed** 1998 Jul-Sep;65(7-9):508-10 (14 ref.)

[Pneumoperitoneum with systemic sclerosis] Nakajima A, et al. **Ryumachi** 1998 Dec;38(6):825-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A case of systemic lupus erythematosus overlapping with progressive systemic sclerosis accompanied by deposition of AA amyloid in the stomach] Obata T, et al. **Ryumachi** 1998 Dec;38(6):810-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

First report of association of chronic pancreatitis, primary biliary cirrhosis, and systemic sclerosis. Hastier P, et al. **Dig Dis Sci** 1998 Nov;43(11):2426-8 (17 ref.)

Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma). Knupp-Oliveira S, et al. **Scand J Rheumatol** 1999;28(4):260-1 (10 ref.)

Morphea and localized scleroderma in children. Vierra E, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):210-25 (105 ref.)

[Scleroderma renal crisis. 7 cases and review of the literature] Bonnet F, et al. **Ann Med Interne (Paris)** 1998 Sep; 149(5):243-50 (45 ref.) (Eng. Abstr.) **(Fre)**

[Progressive systemic scleroderma--prognosis determining involvement of internal organ systems] Mittag M, et al. **Hautarzt** 1998 Jul;49(7):545-51 (40 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Coagulation factor XIII in scleroderma. Jullien D, et al. **Eur J Dermatol** 1998 Jun;8(4):231-4 (21 ref.)

Therapeutic interventions in systemic sclerosis. van den Hoogen FH. **Neth J Med** 1998 Sep;53(3):137-8 (13 ref.)

EPIDEMIOLOGY

Anti-endothelial cell antibodies in systemic sclerosis. Renaudineau Y, et al. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):156-60 (61 ref.)

ETIOLOGY

Microchimerism and the pathogenesis of systemic sclerosis. Nelson JL. **Curr Opin Rheumatol** 1998 Nov;10(6):564-71 (63 ref.)

The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary? [editorial] Furst DE. **J Mal Vasc** 1999 May;24(2):95-8 (25 ref.)

New perspectives on the etiology of systemic sclerosis. Artlett CM, et al. **Mol Med Today** 1999 Feb;5(2):74-8 (38 ref.)

IMMUNOLOGY

Anti-endothelial cell antibodies in systemic sclerosis. Renaudineau Y, et al. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):156-60 (61 ref.)

Systemic sclerosis: an autoantibody mosaic [editorial] Bunn CC, et al. **Clin Exp Immunol** 1999 Aug;117(2):207-8 (24 ref.)

Systemic sclerosis from autoimmunity to alloimmunity. Famularo G, et al. **South Med J** 1999 May;92(5):472-6 (30 ref.)

METABOLISM

Nitric oxide in systemic sclerosis lung: controversies and expectations [editorial; comment] Rolla G, et al. **Clin Exp Rheumatol** 1998 Sep-Oct;16(5):522-4 (50 ref.) Comment on: Clin Exp Rheumatol 1998 Sep-Oct;16(5):547-52.

Carnitine deficiency in scleroderma [letter] Famularo G, et al. **Immunol Today** 1999 May;20(5):246 (16 ref.)

MORTALITY

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099-104 (13 ref.)

PATHOLOGY

Recurrence of scleroderma in a renal allograft from an identical twin sister. Caplin NJ, et al. **Am J Kidney Dis** 1999 Apr;33(4):e7 (25 ref.)

Is antiendothelial cell antibody the murder weapon in systemic sclerosis? [editorial] Youinou P, et al. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):35-6 (20 ref.)

Biology of the scleroderma fibroblast. Strehlow D, et al. **Curr Opin Rheumatol** 1998 Nov;10(6):572-8 (49 ref.)

PHYSIOPATHOLOGY

Measurement of functional status, self-assessment, and psychological well-being in scleroderma. Merkel PA. **Curr Opin Rheumatol** 1998 Nov;10(6):589-94 (27 ref.)

Pathophysiology of scleroderma: an update. Haustein UF, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):1-8 (64 ref.)

[Involvement of the small intestine in systemic scleroderma] Marie I, et al. **Rev Med Interne** 1999 Jun;20(6):504-13 (86 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Measurement of functional status, self-assessment, and psychological well-being in scleroderma. Merkel PA. **Curr Opin Rheumatol** 1998 Nov;10(6):589-94 (27 ref.)

SURGERY

[Surgical treatment of Thibierge-Weissenbach syndrome and other calcinoses of the hand. Case report and review of the literature] Kauschke T, et al. **Handchir Mikrochir Plast Chir** 1999 Jan;31(1):57-60 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Morphea and localized scleroderma in children. Vierra E, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):210-25 (105 ref.)

SCLEROMA, NASAL see **RHINOSCLEROMA**

SCLEROSIS, DISSEMINATED see **MULTIPLE SCLEROSIS**

SCLEROSIS, HEREDITARY SPINAL see **FRIEDREICH'S ATAXIA**

SCLEROSIS, PROGRESSIVE SYSTEMIC see **SCLERODERMA, SYSTEMIC**

SCLEROSIS, SYSTEMIC see **SCLERODERMA, SYSTEMIC**

SCLEROSTOMY

ADVERSE EFFECTS

Dysfunctional filtering blebs. Azuara-Blanco A, et al. **Surv Ophthalmol** 1998 Sep-Oct;43(2):93-126 (291 ref.)

INSTRUMENTATION

[Trabeculotomy, deep sclerectomy and viscocanalostomy. Non-fistulating microsurgical glaucoma operation ab externo] Schwenn O, et al. **Ophthalmologe** 1998 Dec; 95(12):835-43 (30 ref.) (Eng. Abstr.) **(Ger)**

SCLEROTHERAPY

A practical guide to the management of oesophageal varices. McCormack G, et al. **Drugs** 1999 Mar;57(3):327-35 (37 ref.)

[Choice of hemorrhoids treatment] Vorob'ev GI, et al. **Khirurgiia (Mosk)** 1999;(8):50-5 (43 ref.) **(Rus)**

[Therapeutic endoscopy in portal hypertension. When, how and how far in 1998] Ballesteros Amozurrutia MA. **Rev Gastroenterol Mex** 1998 Oct-Dec;63(4 Suppl 1):S7-20 (77 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Treatment of malignant pleural effusions. Erasmus JJ, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):250-5 (55 ref.)

Endoscopic ligation plus sclerotherapy: two plus two make only three! [editorial; comment] Sarin SK, et al. **Gastrointest Endosc** 1999 Jul;50(1):129-33 (30 ref.)
Comment on: Gastrointest Endosc 1999 Jul;50(1):1-6.
Comment on: Gastrointest Endosc 1999 Jul;50(1):7-12.

Transvenous retrograde nidus sclerotherapy under controlled hypotension (TRENSH): a newly proposed treatment for brain arteriovenous malformations--concepts and rationale. Massoud TF, et al. **Neurosurgery** 1999 Aug;45(2):351-63; discussion 363-5 (82 ref.)

[Endoscopic hemostasis for esophagogastric bleeding: technical assessment and recent advances] Murashima N. **Nippon Rinsho** 1998 Sep;56(9):2276-80 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of bleeding esophago-gastric varices] Oho K, et al. **Nippon Rinsho** 1998 Sep; 56(9):2325-30 (11 ref.) (Eng. Abstr.) **(Jpn)**

SCLEROTINIA see **ASCOMYCOTA**

SCOLIOSIS

Infantile and juvenile scoliosis. Dobbs MB, et al. **Orthop Clin North Am** 1999 Jul;30(3):331-41, vii (63 ref.)

Adolescent idiopathic scoliosis. Roach JW. **Orthop Clin North Am** 1999 Jul;30(3):353-65, vii-viii (44 ref.)

CLASSIFICATION

A concept of idiopathic scoliosis deformities as imperfect torsion(s). Asher MA, et al. **Clin Orthop** 1999 Jul; (364):11-25 (50 ref.)

COMPLICATIONS

Intramedullary spinal teratoma and diastematomyelia. Case report and review of the literature. Hader WJ, et al. **Pediatr Neurosurg** 1999 Mar;30(3):140-5 (19 ref.)

[Respiratory problems in severe scoliosis] Barois A. **Bull Acad Natl Med** 1999;183(4):721-30 (21 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Neuroimaging of scoliosis in childhood. Kim FM, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):195-221 (118 ref.)

EPIDEMIOLOGY

[Idiopathic scoliosis: epidemiology and etiology] Nowakowski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):317-20 (14 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

The treatment of neuromuscular scoliosis. Banta JV, et al. **Instr Course Lect** 1999;48:551-62 (84 ref.)

A genomic approach to scoliosis pathogenesis. Blank RD, et al. **Lupus** 1999;8(5):356-60 (21 ref.)

[Neuromuscular scoliosis] Carstens C. **Orthopade** 1999 Jul; 28(7):622-33 (2 ref.) **(Ger)**

[Idiopathic scoliosis: epidemiology and etiology] Nowakowski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):317-20 (14 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Cause and natural history of adolescent idiopathic scoliosis. Miller NH. **Orthop Clin North Am** 1999 Jul;30(3):343-52, vii (134 ref.)

RADIOGRAPHY

Normalization of the coronal and sagittal profile in idiopathic scoliosis: options of treatment. Bridwell KH. **J Orthop Sci** 1998;3(2):125-34 (16 ref.)

Scoliosis circa 2000: radiologic imaging perspective. I. Diagnosis and pretreatment evaluation. Oestreich AE, et al. **Skeletal Radiol** 1998 Nov;27(11):591-605 (75 ref.)

SURGERY

Superior mesenteric artery syndrome after segmental instrumentation: a biomechanical analysis. Vitale MG, et al. **Am J Orthop** 1999 Aug;28(8):461-7 (27 ref.)

A concept of idiopathic scoliosis deformities as imperfect torsion(s). Asher MA, et al. **Clin Orthop** 1999 Jul; (364):11-25 (50 ref.)

The treatment of neuromuscular scoliosis. Banta JV, et al. **Instr Course Lect** 1999;48:551-62 (84 ref.)

Normalization of the coronal and sagittal profile in idiopathic scoliosis: options of treatment. Bridwell KH. **J Orthop Sci** 1998;3(2):125-34 (16 ref.)

The effects of perioperative blood salvage and autologous blood donation on transfusion requirements in scoliosis surgery. Anand N, et al. **J Spinal Disord** 1998 Dec; 11(6):532-4 (10 ref.)

Scoliosis circa 2000: radiologic imaging perspective. II. Treatment and follow-up. Oestreich AE, et al. **Skeletal Radiol** 1998 Dec;27(12):651-6 (27 ref.)

[Treatment of scoliosis in the adolescent by anterior release and vertebral arthrodesis under thoracoscopy. Preliminary results] Papin P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):231-8 (21 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Bracing (and screening)--yes or no? Dickson RA, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):193-8 (47 ref.)

Modalities of ventilation in neuromuscular disorders and thoracic deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):552-5 (10 ref.)

Management of neuromuscular scoliosis. McCarthy RE. **Orthop Clin North Am** 1999 Jul;30(3):435-49, viii (99 ref.)

[Idiopathic scoliosis: evaluation of the results] Bollini G, et al. **Bull Acad Natl Med** 1999;183(4):757-67; discussion 767-8 (30 ref.) (Eng. Abstr.) **(Fre)**

SCOPOLAMINE

ADVERSE EFFECTS

Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Ebert U, et al. **Eur J Clin Invest** 1998 Nov;28(11):944-9 (65 ref.)

SCOPOLAMINE DERIVATIVES

THERAPEUTIC USE

Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Barnes PJ, et al. **Life Sci** 1995; 56(11-12):853-9 (47 ref.)

Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Disse B, et al. **Life Sci** 1999;64(6-7):457-64 (20 ref.)

SCORBUTUS see **SCURVY**

SCORPION VENOMS

CHEMISTRY

Scorpion toxins specific for Na+-channels. Possani LD, et al. **Eur J Biochem** 1999 Sep;264(2):287-300 (156 ref.)

PHARMACOLOGY

Scorpion toxins as tools for studying potassium channels. Garcia ML, et al. **Methods Enzymol** 1999;294:624-39 (37 ref.)

POISONING

Clinical manifestations and management of scorpion envenomation. Amitai Y. **Public Health Rev** 1998; 26(3):257-63 (25 ref.)

TOXICITY

A new approach to insect-pest control--combination of neurotoxins interacting with voltage sensitive sodium channels to increase selectivity and specificity. Gordon D. **Invert Neurosci** 1997 Sep-Dec;3(2-3):103-16 (55 ref.)

SCRAPIE

see related
PRIONS
PRPSC PROTEINS

Scrapie. Hunter N. **Mol Biotechnol** 1998 Jun;9(3):225-34 (67 ref.)

DIAGNOSIS

The immunodetection of the abnormal isoform of prion protein. Yokoyama T. **Histochem J** 1999 Apr;31(4):209-12 (48 ref.)

EPIDEMIOLOGY

[Epidemiologic aspects of scrapie and BSE including an analysis of risk factors] Schreuder BE. **Tijdschr Diergeneeskd** 1999 Mar 15;124(6):182-4 (0 ref.) (Eng. Abstr.) **(Dut)**

TRANSMISSION

[Animal transmissible subacute spongiform encephalopathies: scrapie in sheep and bovine spongiform encephalopathy] Parodi AL. **Clin Exp Pathol** 1999;47(3-4):133-44 (53 ref.) (Eng. Abstr.) **(Fre)**

SCRAPIE AGENT see **PRPSC PROTEINS**

SCRAPIE AMYLOID PRECURSOR PROTEIN see **PRPC PROTEINS**

SCRAPIE PRP see **PRPSC PROTEINS**

SCREW WORM INFECTION

Case studies of emergency management of screwworm. Reichard R. **Rev Sci Tech** 1999 Apr;18(1):145-63 (38 ref.)

SCROFULA see **TUBERCULOSIS, LYMPH NODE**

SCROFULODERMA see **TUBERCULOSIS, CUTANEOUS**

SCROTUM

Meconium masquerading as a scrotal mass. Han K, et al. **Br J Urol** 1998 Nov;82(5):765-7 (5 ref.)

Acute scrotal pain. Burgher SW. **Emerg Med Clin North Am** 1998 Nov;16(4):781-809, vi (99 ref.)

Paratesticular desmoplastic small round cell tumor: case report and review of the literature. Roganovich J, et al. **J Surg Oncol** 1999 Aug;71(4):269-72 (16 ref.)

Carcinoma en cuirasse of the scrotum: an unusual presentation of lung carcinoma metastatic to the scrotum. Ferguson MA, et al. **J Urol** 1998 Dec;160(6 Pt 1):2154-5 (3 ref.)

Recurrent primary well-differentiated intrascrotal liposarcoma: case report and review of the literature. Kochman A, et al. **Tumori** 1999 Mar-Apr;85(2):135-6 (11 ref.)

[Acute scrotum in the child] Dubois R, et al. **Arch Pediatr** 1998 Aug;5(8):916-22 (14 ref.) (Eng. Abstr.) **(Fre)**

[An apocrine hidrocystoma of the scrotum. A case report] Flessati P, et al. **Minerva Chir** 1999 Jan-Feb;54(1-2):87-9 (7 ref.) (Eng. Abstr.) **(Ita)**

[Cavernous hemangioma of the scrotum: a case report] Awakura Y, et al. **Hinyokika Kiyo** 1998 Oct;44(10):751-3 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Aggressive angiomyxoma in the scrotum: a case report] Ichiyanagi N, et al. **Hinyokika Kiyo** 1999 Jan;45(1):69-72 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Epidermoid cyst of the scrotum: a case report] Sakamoto T, et al. **Hinyokika Kiyo** 1998 Sep;44(9):683-5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A massive hernia of the bladder into the scrotum. A report of a case] Ojea Calvo A, et al. **Actas Urol Esp** 1999 Jan; 23(1):79-82 (7 ref.) (Eng. Abstr.) **(Spa)**

[An intrascrotal epidermoid cyst: apropos a case] Puyol Pallas M, et al. **Actas Urol Esp** 1999 May;23(5):436-9 (18 ref.) (Eng. Abstr.) **(Spa)**

[An epidermal inclusion cyst located in the scrotum. A brief case report] Pellicé i Vilalta C, et al. **Arch Esp Urol** 1999 Jan-Feb;52(1):72-4 (8 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Accessory perineal scrotum associated with anorectal malformation. Ozcan C, et al. **BJU Int** 1999 Apr; 83(6):729-30 (5 ref.)

[Malformations of the scrotum and its contents] Marzotto Caotorta M, et al. **Arch Ital Urol Androl** 1998 Dec; 70(5):251-62 (15 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[Sclerosing lipogranuloma of the scrotum: a case report] Kodama K, et al. **Hinyokika Kiyo** 1999 Mar;45(3):211-4 (16 ref.) (Eng. Abstr.) **(Jpn)**

SCROTUM

[Surgical pathology of the scrotum. An analysis of a series of 56 cases] Redondo Martinez E, et al. **Arch Esp Urol** 1999 Jan-Feb;52(1):11-6 (20 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Scrotal cystocele: US and CT findings in two cases. Casas JD, et al. **Comput Med Imaging Graph** 1998 Jan-Feb; 22(1):53-6 (12 ref.)

SCRUB TYPHUS

[Classic type tsutsugamushi disease] Tachibana N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):288-90 (4 ref.) **(Jpn)**

[New type tsutsugamushi disease] Tachibana N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):291-3 (9 ref.) **(Jpn)**

SCURVY

see related
ASCORBIC ACID DEFICIENCY

[Scurvy, Möller-Barlow disease] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):405-7 (8 ref.) **(Jpn)**

SCYPHOZOA see **JELLYFISH**

SDS-PAGE see **ELECTROPHORESIS, POLYACRYLAMIDE GEL**

SEA ANEMONES

PHYSIOLOGY

A comparison of hair bundle mechanoreceptors in sea anemones and vertebrate systems. Watson GM, et al. **Curr Top Dev Biol** 1999;43:51-84 (75 ref.)

SEA-BLUE HISTIOCYTE SYNDROME

[The syndrome of the sea-blue histiocyte] Kohda K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):571-4 (13 ref.) **(Jpn)**

SEA CUCUMBERS

CHEMISTRY

Toxins from sea cucumbers (holothuroids): chemical structures, properties, taxonomic distribution, biosynthesis and evolution. Stonik VA, et al. **J Nat Toxins** 1999 Jun; 8(2):235-48 (71 ref.)

SEA LION SPUMAVIRUS see **SPUMAVIRUS**

SEA LIONS see **SEALS**

SEA NETTLES see **JELLYFISH**

SEA URCHINS

Imaging sea urchin fertilization. Holy JM. **Methods Mol Biol** 1999;122:153-66 (41 ref.)

EMBRYOLOGY

How to grow a gut: ontogeny of the endoderm in the sea urchin embryo. Wessel GM, et al. **Bioessays** 1999 Jun; 21(6):459-71 (75 ref.)

Cell movements in the sea urchin embryo. Ettensohn CA. **Curr Opin Genet Dev** 1999 Aug;9(4):461-5 (38 ref.)

Studies on heat shock proteins in sea urchin development. Giudice G, et al. **Dev Growth Differ** 1999 Aug;41(4):375-80 (27 ref.)

Regulative development of the sea urchin embryo: signalling cascades and morphogen gradients. Angerer LM, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):327-34 (42 ref.)

GENETICS

Genes and their products in sea urchin development. Giudice G. **Curr Top Dev Biol** 1999;45:41-116 (565 ref.)

GROWTH & DEVELOPMENT

Genes and their products in sea urchin development. Giudice G. **Curr Top Dev Biol** 1999;45:41-116 (565 ref.)

IMMUNOLOGY

Complement systems in invertebrates. The ancient alternative and lectin pathways. Smith LC, et al. **Immunopharmacology** 1999 May;42(1-3):107-20 (64 ref.)

METABOLISM

Studies on heat shock proteins in sea urchin development. Giudice G, et al. **Dev Growth Differ** 1999 Aug;41(4):375-80 (27 ref.)

Matrix and mineral in the sea urchin larval skeleton. Wilt FH. **J Struct Biol** 1999 Jun 30;126(3):216-26 (62 ref.)

PHYSIOLOGY

Using sea urchin gametes for the study of mitosis. Sluder G, et al. **Methods Cell Biol** 1999;61:439-72 (10 ref.)

SEAFOOD

Plant-food and seafood allergens--an overview. Breiteneder H. **Allergy** 1998;53(46 Suppl):31-4 (21 ref.)

Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies. Marckmann P, et al. **Eur J Clin Nutr** 1999 Aug;53(8):585-90 (42 ref.)

Aquatic biotoxins: design and implementation of seafood safety monitoring programs. Park DL, et al. **Rev Environ Contam Toxicol** 1999;161:157-200 (182 ref.)

ANALYSIS

Arsenic speciation in manufactured seafood products. Vélez D, et al. **J Food Prot** 1998 Sep;61(9):1240-5 (60 ref.)

MICROBIOLOGY

[Seafood transmitted diseases] Feldhusen F. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):319-25 (60 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

[Seafood transmitted diseases] Feldhusen F. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):319-25 (60 ref.) (Eng. Abstr.) **(Ger)**

POISONING

Cyanobacterial toxins in Portugal: effects on aquatic animals and risk for human health. Vasconcelos VM. **Braz J Med Biol Res** 1999 Mar;32(3):249-54 (40 ref.)

An overview of the marine food poisoning in Mexico. Sierra-Beltrán AP, et al. **Toxicon** 1998 Nov; 36(11):1493-502 (31 ref.)

A review of selected seafood poisonings. Clark RF, et al. **Undersea Hyperb Med** 1999 Fall;26(3):175-84 (91 ref.)

SEALANTS, ROOT CANAL see **ROOT CANAL FILLING MATERIALS**

SEALANTS, TOOTH see **PIT AND FISSURE SEALANTS**

SEALED CABIN ECOLOGY see **ECOLOGICAL SYSTEMS, CLOSED**

SEALS

PARASITOLOGY

Ecology of host parasite relationships in the Baltic Sea. Zander CD. **Naturwissenschaften** 1998 Sep;85(9):426-36 (38 ref.)

PHYSIOLOGY

Immobilisation of pinniped species. Lynch MJ, et al. **Aust Vet J** 1999 Mar;77(3):181-5 (39 ref.)

Stranded seals: important sentinels. Gulland FM. **J Am Vet Med Assoc** 1999 Apr 15;214(8):1191-2 (5 ref.)

Instrumentation for the remote monitoring of physiological and behavioral variables. Andrews RD. **J Appl Physiol** 1998 Nov;85(5):1974-81 (12 ref.)

VIROLOGY

Morbillivirus infections in aquatic mammals. Kennedy S. **J Comp Pathol** 1998 Oct;119(3):201-25 (106 ref.)

SEARCHING BEHAVIOR see **APPETITIVE BEHAVIOR**

SEASICKNESS see **MOTION SICKNESS**

SEASONAL AFFECTIVE DISORDER

Seasonal affective disorder. Partonen T, et al. **Lancet** 1998 Oct 24;352(9137):1369-74 (50 ref.)

DIAGNOSIS

Cluster headache and periodic affective illness: common chronobiological features. Costa A, et al. **Funct Neurol** 1998 Jul-Sep;13(3):263-72 (47 ref.)

METABOLISM

Extrapineal melatonin and exogenous serotonin in seasonal affective disorder. Partonen T. **Med Hypotheses** 1998 Nov; 51(5):441-2 (5 ref.)

PHYSIOPATHOLOGY

[Seasonal depression] Attar-Levy D. **Therapie** 1998 Sep-Oct; 53(5):489-98 (67 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Seasonal affective disorder and latitude: a review of the literature. Mersch PP, et al. **J Affect Disord** 1999 Apr; 53(1):35-48 (59 ref.)

THERAPY

A turning point for seasonal affective disorder and light therapy research? [comment] Avery DH. **Arch Gen Psychiatry** 1998 Oct;55(10):863-4 (19 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):883-9. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):875-82. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):890-6.

Beginning to see the light [comment] Wirz-Justice A. **Arch Gen Psychiatry** 1998 Oct;55(10):861-2 (20 ref.) Comment on: Arch Gen Psychiatry 1998 Oct;55(10):875-82. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):883-9. Comment on: Arch Gen Psychiatry 1998 Oct;55(10):890-6.

[Phototherapy in the clinic] Pracka D. **Postepy Hig Med Dosw** 1999;53(3):517-23 (26 ref.) (Eng. Abstr.) **(Pol)**

[Winter depression and light therapy] Honory A. **Psychiatr Pol** 1998 Sep-Oct;32(5):605-19 (74 ref.) (Eng. Abstr.) **(Pol)**

SEASONAL MOOD DISORDER see **SEASONAL AFFECTIVE DISORDER**

SEASONS

Seasonality and diversity of Group A rotaviruses in Europe. Koopmans M, et al. **Acta Paediatr Suppl** 1999 Jan; 88(426):14-9 (37 ref.)

Seasonality in live births with congenital heart disease in Malta. Grech V. **Cardiol Young** 1999 Jul;9(4):396-401 (25 ref.)

It's spring, and thoughts turn to...allergies. Metzger H. **Cell** 1999 Apr 30;97(3):287-90 (20 ref.)

Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283-94 (78 ref.)

Regulation of appetite and body weight in seasonal mammals. Mercer JG. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):295-303 (64 ref.)

Seasonal and circadian rhythms in suicide in Cagliari, Italy. Altamura C, et al. **J Affect Disord** 1999 Apr;53(1):77-85 (51 ref.)

Seasonal and weekly rhythms: windows into variability in family socialization experiences in early adolescence. Crouter AC, et al. **New Dir Child Dev** 1998 Winter; (82):69-82 (16 ref.)

Seasonal patterns of idiopathic facial paralysis: a 16-year study. De Diego JI, et al. **Otolaryngol Head Neck Surg** 1999 Feb;120(2):269-71 (29 ref.)

Melatonin and the seasonal control of reproduction. Malpaux B, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):355-66 (75 ref.)

Melatonin mediates seasonal adjustments in immune function. Nelson RJ, et al. **Reprod Nutr Dev** 1999 May-Jun; 39(3):383-98 (148 ref.)

Seasonal variations in vitamin-D status and the incidence of tuberculosis in different countries [letter] Chan TY. **Respiration** 1999;66(2):196 (6 ref.)

Seasonal variation of semen quality and fertility. Levine RJ. **Scand J Work Environ Health** 1999;25 Suppl 1:34-7; discussion 76-8 (22 ref.)

SEAT BELTS

see related
AIR BAGS

ADVERSE EFFECTS

Seat-belt transection of the pararenal vena cava in a 5-year-old child: survival with caval ligation. DeCou JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1074-6 (30 ref.)

Seat belt injury presenting as bilateral abdominal wall herniations in a child. Levine JL, et al. **Pediatr Emerg Care** 1998 Oct;14(5):352-3 (11 ref.)

SEAWATER

see related
GEOLOGIC SEDIMENTS

Effects of estrogenic substances in the aquatic environment. Matthiessen P, et al. **EXS** 1998;86:319-35 (64 ref.)

MICROBIOLOGY

Prochlorococcus, a marine photosynthetic prokaryote of global significance. Partensky F, et al. **Microbiol Mol Biol Rev** 1999 Mar;63(1):106-27 (106 ref.)

Polyunsaturated fatty acids in marine bacteria--a dogma rewritten. Russell NJ, et al. **Microbiology** 1999 Apr;145 (Pt 4):767-79 (80 ref.)

VIROLOGY

Marine viruses and their biogeochemical and ecological effects. Fuhrman JA. **Nature** 1999 Jun 10;399(6736):541-8 (105 ref.)

SEBACEOUS CYST see **EPIDERMAL CYST**

SEBACEOUS GLAND DISEASES

PATHOLOGY

Larva migrans within scalp sebaceous gland. Guimarães LC, et al. **Rev Soc Bras Med Trop** 1999 Mar–Apr;32(2):187–9 (8 ref.)

SEBACEOUS GLAND NEOPLASMS

DIAGNOSIS

[Diseases associated with adnexal tumors. II—Sebaceous tumors, sudoral tumors] Cribier B. **Ann Dermatol Venereol** 1999 May;126(5):455–62 (100 ref.) **(Fre)**

SEBACEOUS GLANDS

PATHOLOGY

The linear naevus sebaceus syndrome. van de Warrenburg BP, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):126–32 (57 ref.)

SEBORRHEA see **DERMATITIS, SEBORRHEIC**

SECOND CRANIAL NERVE see **OPTIC NERVE**

SECOND-GENERATION ANTIDEPRESSIVE AGENTS see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

SECOND MALIGNANCY see **NEOPLASMS, SECOND PRIMARY**

SECOND MESSENGER SYSTEMS

Sphingosine-1-phosphate: extracellular mediator or intracellular second messenger? Hla T, et al. **Biochem Pharmacol** 1999 Jul 15;58(2):201–7 (61 ref.)

A novel protein kinase target for the lipid second messenger phosphatidic acid. McPhail LC, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):277–90 (208 ref.)

Phospholipase D in cellular senescence. Venable ME, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):291–8 (67 ref.)

Cyclic ADP-ribose: a novel Ca2+-mobilising second messenger. Guse AH. **Cell Signal** 1999 May;11(5):309–16 (78 ref.)

Recent advances in the regulation of plant calcium channels: evidence for regulation by G-proteins, the cytoskeleton and second messengers. Thuleau P, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):424–7 (28 ref.)

Role of phospholipases during sperm acrosomal exocytosis. Roldan ER. **Front Biosci** 1998 Nov 1;3:D1109–19 (122 ref.)

Sphingosine 1-phosphate: a prototype of a new class of second messengers. Spiegel S. **J Leukoc Biol** 1999 Mar; 65(3):341–4 (41 ref.)

Autoradiography of enzymes, second messenger systems, and ion channels. Walsh DA, et al. **Methods Mol Biol** 1999; 106:199–214 (36 ref.)

Second messenger pathways in the honeybee brain: immunohistochemistry of protein kinase A and protein kinase C. Müller U. **Microsc Res Tech** 1999 May 1; 45(3):165–73 (57 ref.)

Progesterone induces meiotic division in the amphibian oocyte by releasing lipid second messengers from the plasma membrane. Morrill GA, et al. **Steroids** 1999 Jan–Feb;64(1–2):157–67 (45 ref.)

[Cyclic ADP-ribose as a second messenger—intramembrane signal transduction from receptors to ADP-ribosyl cyclase] Higashida H, et al. **Seikagaku** 1998 Nov;70(11):1326–34 (79 ref.) **(Jpn)**

[Recent development of sphingosin 1-phosphate studies as a second messenger or a second agonist in cell signaling] Igarashi Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1059–66 (43 ref.) **(Jpn)**

PHYSIOLOGY

Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function. Ohanian J, et al. **Acta Physiol Scand** 1998 Dec; 164(4):533–48 (138 ref.)

Regulation of second messengers associated with airway smooth muscle contraction and relaxation. Hakonarson H, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S115–22 (51 ref.)

Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. Ghaemi SN, et al. **Biol Psychiatry** 1999 Jan 15;45(2):137–44 (50 ref.)

The effects of diadenosine polyphosphates on the cardiovascular system. Flores NA, et al. **Cardiovasc Res** 1999 Apr;42(1):15–26 (82 ref.)

Inositol 1,3,4,5-tetrakisphosphate as a second messenger--a special role in neurones? Irvine RF, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):49–57 (50 ref.)

The myogenic response: established facts and attractive hypotheses. Schubert R, et al. **Clin Sci (Colch)** 1999 Apr; 96(4):313–26 (101 ref.)

Dietary lipids: ancestral ligands and regulators of cell signaling pathways [editorial; comment] Zaloga GP. **Crit Care Med** 1999 Aug;27(8):1646–8 (10 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1409–20.

Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Bouscarel B, et al. **Gastroenterology** 1999 Aug; 117(2):433–52 (217 ref.)

Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis. Lennartz MR. **Int J Biochem Cell Biol** 1999 Mar–Apr; 31(3–4):415–30 (108 ref.)

Second messenger systems underlying plasticity at the neuromuscular junction. Hannan F, et al. **Int Rev Neurobiol** 1999;43:119–38 (108 ref.)

Regulation of amyloid precursor protein cleavage. Mills J, et al. **J Neurochem** 1999 Feb;72(2):443–60 (240 ref.)

Neuronal signaling systems and ethanol dependence. Pandey SC. **Mol Neurobiol** 1998 Winter;17(1–3):1–15 (100 ref.)

Second messengers, the substantia gelatinosa and injury-induced persistent pain. Petersen-Zeitz KR, et al. **Pain** 1999 Aug;Suppl 6:S5–12 (87 ref.)

Taking the plunge. Terminal differentiation in Dictyostelium. Thomason P, et al. **Trends Genet** 1999 Jan;15(1):15–9 (53 ref.)

VIP and PACAP: very important in pain? Dickinson T, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):324–9 (77 ref.)

[Role of PI signaling in early development] Kume S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1834–40 (28 ref.) **(Jpn)**

SECOND NEOPLASM see **NEOPLASMS, SECOND PRIMARY**

SECOND OPINION see **REFERRAL AND CONSULTATION**

SECOND PRIMARY NEOPLASMS see **NEOPLASMS, SECOND PRIMARY**

SECRETIN

see related
GASTROINTESTINAL AGENTS

PHYSIOLOGY

[Signalling roles for selectins] Yoshida M. **Seikagaku** 1998 Oct;70(10):1270–4 (16 ref.) **(Jpn)**

SECRETIN CELLS see **ENDOCRINE CELLS OF GUT**

SECRETORY GRANULES see **CYTOPLASMIC GRANULES**

SECRETORY IGA see **IGA, SECRETORY**

SECRETORY PHASE see **MENSTRUAL CYCLE**

SECULARISM see **RELIGION**

SECURITY MEASURES

Violence in the emergency department. Managing aggressive patients in a high-stress environment. Kuhn W. **Postgrad Med** 1999 Jan;105(1):143–8, 154 (30 ref.)

ORGANIZATION & ADMINISTRATION

Violence in the emergency department. Blanchard JC, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):717–31, viii (39 ref.)

SEDATION, CONSCIOUS see **CONSCIOUS SEDATION**

SEDATIVES see **HYPNOTICS AND SEDATIVES**

SEDATIVES, BARBITURATE

PHARMACOKINETICS

Pharmacokinetic alterations after severe head injury. Clinical relevance. Boucher BA, et al. **Clin Pharmacokinet** 1998 Sep; 35(3):209–21 (107 ref.)

Pharmacodynamics and pharmacokinetics of thiopental. Russo H, et al. **Clin Pharmacokinet** 1998 Aug;35(2):95–134 (235 ref.)

PHARMACOLOGY

Phenobarbital-mediated changes in gene expression in the liver. Meyer UA, et al. **Drug Metab Rev** 1999 May; 31(2):365–73 (32 ref.)

POISONING

[Neurotoxicity of sedative-hypnotics, anxiolytics] Murasaki M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):507–14 (25 ref.) **(Jpn)**

THERAPEUTIC USE

Phenobarbital for alcohol withdrawal syndrome. Rodgers JE, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):175–8 (18 ref.)

The amobarbital interview revisited: a review of the literature since 1966. Kavirajan H. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):153–65 (63 ref.)

Tale of two (or three or more) cities [editorial; comment] Gettes LS. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):165–7 (15 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Feb;10(2):154–64.

Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review [see comments] Roberts I, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):729–33 (25 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):66.

SEDATIVES, NONBARBITURATE

ADVERSE EFFECTS

Lactic acidemia and bradyarrhythmia in a child sedated with propofol [see comments] Cray SH, et al. **Crit Care Med** 1998 Dec;26(12):2087–92 (31 ref.) Comment in: Crit Care Med 1998 Dec;26(12):1959–60.

Propofol toxicity in critically ill pediatric patients: show us the proof [editorial; comment] Susla GM. **Crit Care Med** 1998 Dec;26(12):1959–60 (15 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2087–92.

The safety and tolerability of zolpidem—an update. Darcourt G, et al. **J Psychopharmacol** 1999;13(1):81–93 (150 ref.)

Propofol-infusion syndrome in children [see comments] Hatch DJ. **Lancet** 1999 Apr 3;353(9159):1117–8 (12 ref.) Comment in: Lancet 1999 Jun 12;353(9169):2074–5.

Propofol infusion syndrome in children. Bray RJ. **Paediatr Anaesth** 1998;8(6):491–9 (59 ref.)

PHARMACOKINETICS

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1999 Aug;19(4):293–6 (51 ref.)

POISONING

[Neurotoxicity of sedative-hypnotics, anxiolytics] Murasaki M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):507–14 (25 ref.) **(Jpn)**

THERAPEUTIC USE

[Midazolam in sedation in intensive therapy] Braschi A, et al. **Minerva Anestesiol** 1998 Dec;64(12 Suppl 1):7–10 (7 ref.) **(Ita)**

SEDIMENTS, GEOLOGIC see **GEOLOGIC SEDIMENTS**

SEDIMENTS, MARINE see **GEOLOGIC SEDIMENTS**

SEEDLINGS see **PLANTS**

SEEDS

see related
NUTS

Frugivory and seed dispersal by vertebrates in the Oriental (Indomalayan) Region. Corlett RT. **Biol Rev Camb Philos Soc** 1998 Nov;73(4):413–48 (230 ref.)

Signaling in plant embryogenesis. Harada JJ. **Curr Opin Plant Biol** 1999 Feb;2(1):23–7 (40 ref.)

Tension pneumothorax secondary to grass head aspiration. Newson TP, et al. **Pediatr Emerg Care** 1998 Aug; 14(4):287–9 (12 ref.)

ADVERSE EFFECTS

Acute appendicitis in childhood: did mother know best? A pathological analysis of 1409 cases. Byard RW, et al. **Med J Aust** 1998 Dec 7–21;169(11–12):647–8 (15 ref.)

CYTOLOGY

Endosperm development. Berger F. **Curr Opin Plant Biol** 1999 Feb;2(1):28–32 (29 ref.)

GROWTH & DEVELOPMENT

Sugars as signal molecules in plant seed development. Wobus U, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):937–44 (40 ref.)

Seed maturation: genetic programmes and control signals. Wobus U, et al. **Curr Opin Plant Biol** 1999 Feb;2(1):33–8 (49 ref.)

SEER PROGRAM

Prostate cancer research and the National Cancer Institute. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):235–40 (26 ref.)

SEGMENTATION STAGE, OVUM see **CLEAVAGE STAGE, OVUM**

SEGMENTED WORMS see **ANNELIDA**

SEI WHALE see **WHALES**

SEIZURES

Nonepileptic seizures: psychiatric framework, treatment, and outcome. Bowman ES. **Neurology** 1999;53(5 Suppl 2):S84–8

SEIZURES

(41 ref.)
Psychogenic nonepileptic seizures: theoretic and clinical considerations. Sirven JI, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Oct; 11(4):225–35 (75 ref.)

CHEMICALLY INDUCED

Seizures associated with buspirone overdose: case report and literature review. Catalano G, et al. **Clin Neuropharmacol** 1998 Nov–Dec;21(6):347–50 (23 ref.)
[Adverse-effects of theophylline on the central nervous system; clinical characteristics of theophylline-associated seizures] Maegaki Y. **Ryoikibetsu Shokogun Shirizu** 1999; (27 Pt 2):593–6 (19 ref.) **(Jpn)**

CLASSIFICATION

A new epileptic seizure classification based exclusively on ictal semiology [editorial] Lüders H, et al. **Acta Neurol Scand** 1999 Mar;99(3):137–41 (26 ref.)

DIAGNOSIS

Epilepsy update: new medical and surgical treatment options. Arunkumar G, et al. **Cleve Clin J Med** 1998 Nov–Dec; 65(10):527–32, 534–7 (20 ref.)
Automatic detection of seizures and spikes. Gotman J. **J Clin Neurophysiol** 1999 Mar;16(2):130–40 (46 ref.)
Continuous EEG monitoring in the neuroscience intensive care unit and emergency department. Jordan KG. **J Clin Neurophysiol** 1999 Jan;16(1):14–39 (92 ref.)
Pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents. Andriola MR, et al. **Neurology** 1999;53(5 Suppl 2):S89–95 (71 ref.)
Nonepileptic seizures: diagnosis and management. Krumholz A. **Neurology** 1999;53(5 Suppl 2):S76–83 (55 ref.)
Epilepsy and seizures: advances in seizure assessment, treatment, and self-management. Shafer PO. **Nurs Clin North Am** 1999 Sep;34(3):743–59 (36 ref.)
Symptomatic seizures. Evans OB. **Pediatr Ann** 1999 Apr; 28(4):231–7 (13 ref.)
Pseudoseizures. Bowman ES. **Psychiatr Clin North Am** 1998 Sep;21(3):649–57, vii (44 ref.)
Is it possible to anticipate seizure onset by non-linear analysis of intracerebral EEG in human partial epilepsies? Lehnertz K, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):454–6 (29 ref.)
What to do with the first fits. Davidson DL. **Scott Med J** 1999 Feb;44(1):6–8 (19 ref.)

DRUG THERAPY

Benzodiazepines in the home treatment of acute seizures. Akinbi MS, et al. **Ann Pharmacother** 1999 Jan;33(1):99–102 (36 ref.)
Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Rey E, et al. **Clin Pharmacokinet** 1999 Jun;36(6):409–24 (98 ref.)
Management approaches to prolonged seizures and status epilepticus. Bleck TP. **Epilepsia** 1999;40 Suppl 1:S59–63; discussion S64–6 (24 ref.)
Additional modalities for treating acute seizures in children: overview. Bebin EM. **J Child Neurol** 1998 Oct;13 Suppl 1:S23–6; discussion S30–2 (15 ref.)
A review of pharmacodynamics and pharmacokinetics in seizure management. Winkelman C. **J Neurosci Nurs** 1999 Feb;31(1):50–3 (9 ref.)
Nonepileptic seizures: diagnosis and management. Krumholz A. **Neurology** 1999;53(5 Suppl 2):S76–83 (55 ref.)
Treatment of seizures and epilepsy in children and adolescents. Pellock JM. **Neurology** 1998 Nov;51(5 Suppl 4):S8–14 (61 ref.)
Reflections on the treatment of seizures in the elderly population. Rowan AJ. **Neurology** 1998 Nov;51(5 Suppl 4):S28–33 (17 ref.)
Anticonvulsant medications. Russell RJ, et al. **Pediatr Ann** 1999 Apr;28(4):238–45 (22 ref.)
Antiepileptic drugs. Meythaler JM, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):275–300, vii–viii (119 ref.)

ETIOLOGY

Unusual clinical presentation of a meningeal melanocytoma with seizures: case report and review of the literature. Leonardi MA, et al. **Acta Neurochir (Wien)** 1998; 140(6):621–8 (56 ref.)
Seizures in the de-institutionalized patients with early brain injuries. DeToledo JC. **Brain Inj** 1998 Aug;12(8):715–9 (27 ref.)
Evaluation of the patient with seizures: an evidence based approach. Bradford JC, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):203–20, ix–x (94 ref.)
Neurologic complications after coronary artery bypass grafting. Young MA, et al. **J Cardiovasc Nurs** 1998 Oct; 13(1):26–33 (20 ref.)
The long QT syndrome and seizures in childhood. Davis AM, et al. **J Paediatr Child Health** 1998 Oct;34(5):410–1 (15 ref.)
Symptomatic seizures. Evans OB. **Pediatr Ann** 1999 Apr; 28(4):231–7 (13 ref.)
Pediatric manifestations of Hashimoto's encephalopathy. Vasconcellos E, et al. **Pediatr Neurol** 1999 May;20(5):394–8 (21 ref.)
Nitric oxide and the anticonvulsant action of antiepileptic drugs. Czuczwar SJ. **Pol J Pharmacol** 1999 Jan–Feb; 51(1):101–2 (18 ref.)
[Seizures associated with acute subarachnoid hemorrhage. Emergency diagnosis and treatment] Beretta L, et al. **Minerva Anestesiol** 1998 Apr;64(4):131–3 (5 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Heisler LK, et al. **Ann N Y Acad Sci** 1998 Dec 15; 861:74–8 (30 ref.)

METABOLISM

Neuropeptide Y and limbic seizures. Baraban SC. **Rev Neurosci** 1998;9(2):117–28 (94 ref.)

NURSING

Neurologic complications after coronary artery bypass grafting. Young MA, et al. **J Cardiovasc Nurs** 1998 Oct; 13(1):26–33 (20 ref.)

PATHOLOGY

Acute and chronic effects of seizures in the developing brain: experimental models. Jensen FE. **Epilepsia** 1999;40 Suppl 1:S51–8; discussion S64–6 (89 ref.)

PHYSIOPATHOLOGY

Status epilepticus in epileptogenesis. Kapur J. **Curr Opin Neurol** 1999 Apr;12(2):191–5 (31 ref.)
Acute and chronic effects of seizures in the developing brain: lessons from clinical experience. Mizrahi EM. **Epilepsia** 1999;40 Suppl 1:S42–50; discussion S64–6 (80 ref.)
Hormonal effects on the brain. Woolley CS, et al. **Epilepsia** 1998;39 Suppl 8:S2–8 (45 ref.)
Adenosinergic system as an endogenous anticonvulsant mechanism. Gupta YK, et al. **Indian J Physiol Pharmacol** 1997 Oct;41(4):329–43 (111 ref.)
Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. Muñoz-Hoyos A, et al. **J Child Neurol** 1998 Oct;13(10):501–9 (112 ref.)
The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. Sackeim HA. **J ECT** 1999 Mar; 15(1):5–26 (109 ref.)
Seizures in the developing brain: perhaps not so benign after all. Holmes GL, et al. **Neuron** 1998 Dec;21(6):1231–4 (21 ref.)
Multiple sclerosis potpourri. Paroxysmal symptoms, seizures, fatigue, pregnancy, and more. Taylor RS. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):551–9, vi (31 ref.)
Interictal-ictal interactions and limbic seizure generation. Avoli M, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):468–71 (17 ref.)
Is it possible to anticipate seizure onset by non-linear analysis of intracerebral EEG in human partial epilepsies? Lehnertz K, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):454–6 (29 ref.)
Neuropeptide Y and limbic seizures. Baraban SC. **Rev Neurosci** 1998;9(2):117–28 (94 ref.)
Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Vezzani A, et al. **Trends Neurosci** 1999 Jan;22(1):25–30 (65 ref.)
[Limbic ictus as a condition for anxiety attacks] Gallinat J, et al. **Nervenarzt** 1999 Mar;70(3):206–15 (83 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Antiepileptic drugs. Meythaler JM, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):275–300, vii–viii (119 ref.)

THERAPY

Epilepsy emergencies: the first seizure and status epilepticus. Willmore LJ. **Neurology** 1998 Nov;51(5 Suppl 4):S34–8 (25 ref.)
Epilepsy and seizures: advances in seizure assessment, treatment, and self-management. Shafer PO. **Nurs Clin North Am** 1999 Sep;34(3):743–59 (36 ref.)
[Seizures associated with acute subarachnoid hemorrhage. Emergency diagnosis and treatment] Beretta L, et al. **Minerva Anestesiol** 1998 Apr;64(4):131–3 (5 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Seizures as a complication of brain tumors in dogs. Bagley RS, et al. **Clin Tech Small Anim Pract** 1998 Aug; 13(3):179–84 (40 ref.)
Interictal paroxysmal discharges in the electroencephalograms of epileptic dogs. Holliday TA, et al. **Clin Tech Small Anim Pract** 1998 Aug;13(3):132–43 (31 ref.)
Feline epilepsy. Kline KL. **Clin Tech Small Anim Pract** 1998 Aug;13(3):152–8 (34 ref.)
Idiopathic epilepsy. Knowles K. **Clin Tech Small Anim Pract** 1998 Aug;13(3):144–51 (37 ref.)
Seizures: classification, etiologies, and pathophysiology. March PA. **Clin Tech Small Anim Pract** 1998 Aug; 13(3):119–31 (66 ref.)
Toxic and metabolic causes of seizures. O'Brien D. **Clin Tech Small Anim Pract** 1998 Aug;13(3):159–66 (53 ref.)
Antiepileptic drug therapy. Podell M. **Clin Tech Small Anim Pract** 1998 Aug;13(3):185–92 (38 ref.)
Inflammatory diseases of the central nervous system in dogs. Thomas WB. **Clin Tech Small Anim Pract** 1998 Aug; 13(3):167–78 (86 ref.)

VIROLOGY

HIV infection and seizures. Garg RK. **Postgrad Med J** 1999 Jul;75(885):387–90 (22 ref.)

SEIZURES, CONVULSIVE see **CONVULSIONS**

SEIZURES, EPILEPTIC see **EPILEPSY**

SEIZURES, FEBRILE see **CONVULSIONS, FEBRILE**

E-SELECTIN

BLOOD

Nitrite, endothelin and E-selectin plasma levels after arginine infusion in normal and vasculopathic subjects. Ferlito S, et al. **Minerva Cardioangiol** 1998 Dec;46(12):471–7 (38 ref.) **(Eng, Ita)**

L-SELECTIN

METABOLISM

Vascular and non-vascular ligands for L-selectin. Kawashima H, et al. **Cell Adhes Commun** 1998;6(2–3):135–9 (26 ref.)

P-SELECTIN

BLOOD

Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Joseph JE, et al. **Lupus** 1998;7 Suppl 2:S48–51 (35 ref.)

PHYSIOLOGY

The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Yang J, et al. **Thromb Haemost** 1999 Jan;81(1):1–7 (76 ref.)
[Coronary thrombosis and cell adhesion molecules] Ikeda H, et al. **Nippon Rinsho** 1999 Jul;57(7):1502–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

SELECTINS

METABOLISM

Mechanisms that regulate the function of the selectins and their ligands. Vestweber D, et al. **Physiol Rev** 1999 Jan; 79(1):181–213 (386 ref.)

PHYSIOLOGY

Are selectins involved in metastasis? Krause T, et al. **Clin Exp Metastasis** 1999 May;17(3):183–92 (69 ref.)
Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Ebnet K, et al. **Histochem Cell Biol** 1999 Jul;112(1):1–23 (247 ref.)
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed J, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:37–42 (24 ref.)
[Oligosaccharide sulfate inhibitors of selectin-sugar interactions in inflammatory processes] Auge C, et al. **Ann Pharm Fr** 1999 May;57(3):216–22 (12 ref.) (Eng. Abstr.) **(Fre)**
[Selectin and homing of lymphocytes] Kannagi R, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2549–58 (34 ref.) **(Jpn)**

SELECTION (GENETICS)

Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Breivik J, et al. **Adv Cancer Res** 1999;76:187–212 (112 ref.)
Selection for carriers of recessive diseases: a common phenomenon? Zlotogora J. **Am J Med Genet** 1998 Nov 16;80(3):266–8 (19 ref.)
Natural selection at major histocompatibility complex loci of vertebrates. Hughes AL, et al. **Annu Rev Genet** 1998; 32:415–35 (59 ref.)
Antibiotic-selective environments. Baquero F, et al. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S5–11 (28 ref.)
Balancing selection and MHC. Hedrick PW. **Genetica** 1998–99;104(3):207–14 (66 ref.)
The evolution of dominance. Bourguet D. **Heredity** 1999 Jul; 83 (Pt 1):1–4 (40 ref.)
Evolution of the mammalian MHC: natural selection, recombination, and convergent evolution. Yeager M, et al. **Immunol Rev** 1999 Feb;167:45–58 (77 ref.)
Shortcomings of current genetic evaluation systems. Bourdon RM. **J Anim Sci** 1998 Sep;76(9):2308–23 (53 ref.)
The impact of genetic markers on selection. Davis GP, et

al. **J Anim Sci** 1998 Sep;76(9):2331–9 (51 ref.)
Defining multiple-trait objectives for sustainable genetic improvement. Gibson JP, et al. **J Anim Sci** 1998 Sep; 76(9):2303–7 (29 ref.)
HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. Berkhout B. **J Biomed Sci** 1999 Sep–Oct;6(5):298–305 (59 ref.)
Follicle selection in sheep with breed differences in ovulation rate. Baird DT, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):89–95 (28 ref.)
Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Tomlinson I, et al. **Nat Med** 1999 Jan;5(1):11–2 (19 ref.)
Improving animal well-being through genetic selection. Muir WM, et al. **Poult Sci** 1998 Dec;77(12):1781–8 (69 ref.)
Levels of selection, altruism, and primate behavior. Bradley BJ. **Q Rev Biol** 1999 Jun;74(2):171–94 (94 ref.)
Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Breivik J, et al. **Semin Cancer Biol** 1999 Aug;9(4):245–54 (65 ref.)
Tandem constructs: preventing the rise of superweeds. Gressel J. **Trends Biotechnol** 1999 Sep;17(9):361–6 (62 ref.)
Prospects and strategies for genetic improvement of the dairy potential of tropical cattle by selection. Syrstad O, et al. **Trop Anim Health Prod** 1998 Aug;30(4):257–68 (17 ref.)
[The genetics and selection of microorganisms] Matseliukh BP. **Mikrobiol Z** 1998 Sep–Oct;60(5):60–72 (100 ref.) (Eng. Abstr.) **(Ukr)**

SELECTION BIAS

Correcting for verification bias in studies of a diagnostic test's accuracy. Zhou XH. **Stat Methods Med Res** 1998 Dec; 7(4):337–53 (43 ref.)
[Roaming through methodology. XV. Smoking grandfathers and other selection biases] van Gijn J, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1515–7 (7 ref.) (Eng. Abstr.) **(Dut)**

SELECTION CRITERIA see **PATIENT SELECTION**

SELECTIVE MUTISM see **MUTISM**

SELECTIVE PROVIDER RESTRICTIONS see **PATIENT FREEDOM OF CHOICE LAWS**

SELEGILINE

PHARMACOLOGY

Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Kitani K, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:291–306 (36 ref.)

SELENIUM

Functional indicators of iodine and selenium status. Arthur JR. **Proc Nutr Soc** 1999 May;58(2):507–12 (59 ref.)

ADMINISTRATION & DOSAGE

Responsiveness of selenoproteins to dietary selenium. Allan CB, et al. **Annu Rev Nutr** 1999;19:1–16 (50 ref.)
Selenium deficiency and chronic pancreatitis: disease mechanism and potential for therapy. Bowrey DJ, et al. **HPB Surg** 1999;11(4):207–15; discussion 215–6 (41 ref.)

ADVERSE EFFECTS

Environmental selenium and cancer: risk or protection? [editorial; comment] Clark LC, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):847–8; discussion 851–2 (14 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.
False presumptions and continued surprises: how much do we really know about nutritional supplements and cancer risk? [editorial; comment] Kristal AR, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):849–50; discussion 851–2 (12 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.

ANALYSIS

Measurement of selenium in clinical specimens. Sheehan TM, et al. **Ann Clin Biochem** 1999 May;36 (Pt 3):301–15 (107 ref.)
Selenium transport and bioaccumulation in aquatic ecosystems: a proposal for water quality criteria based on hydrological units. Lemly AD. **Ecotoxicol Environ Saf** 1999 Feb;42(2):150–6 (27 ref.)

BLOOD

[Selenium and some antioxidants in blood of patients with chronic renal failure (published erratum appears in Pol Merkuriusz Lek 1998 Dec;5(30):356)] Trafikowska U, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):178–82 (61 ref.) (Eng. Abstr.) **(Pol)**

DEFICIENCY

Selenium deficiency and chronic pancreatitis: disease mechanism and potential for therapy. Bowrey DJ, et al. **HPB Surg** 1999;11(4):207–15; discussion 215–6 (41 ref.)
[Progress in the study of endemic diseases in China, 1997] Wu Z, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):933–4 (0 ref.) **(Chi)**
[Effects of the combined deficiency of selenium and iodine on thyroid function] Miniero R, et al. **Ann Ist Super Sanita** 1998;34(3):349–55 (39 ref.) (Eng. Abstr.) **(Ita)**
[Selenium in health and disease] Inglot AD, et al. **Postepy Hig Med Dosw** 1998;52(3):207–22 (99 ref.) (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

[Active anticarcinogenic chemical components in ordinary garlic and selenium-enriched garlic] Yang W, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):304–6 (21 ref.) **(Chi)**

METABOLISM

The trace element selenium and the thyroid gland. Köhrle J. **Biochimie** 1999 May;81(5):527–33 (81 ref.)
Selenium metabolism in Escherichia coli. Turner RJ, et al. **Biometals** 1998 Sep;11(3):223–7 (31 ref.)
The selenium link: the missing link in our understanding of biochemical trigger reactions? Nyberg-Swenson BE. **Med Hypotheses** 1999 Feb;52(2):125–31 (15 ref.)
Chemopreventive agents: selenium. Combs GF Jr, et al. **Pharmacol Ther** 1998 Sep;79(3):179–92 (179 ref.)
[Selenium in health and disease] Inglot AD, et al. **Postepy Hig Med Dosw** 1998;52(3):207–22 (99 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

False presumptions and continued surprises: how much do we really know about nutritional supplements and cancer risk? [editorial; comment] Kristal AR, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):849–50; discussion 851–2 (12 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.

PHYSIOLOGY

Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Ganther HE. **Carcinogenesis** 1999 Sep;20(9):1657–66 (86 ref.)
The role of copper, molybdenum, selenium, and zinc in nutrition and health. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):673–85 (54 ref.)
Selenium-based antihypertensives. Rationale and potential. May SW, et al. **Drugs** 1998 Dec;56(6):959–64 (38 ref.)
The diverse role of selenium within selenoproteins: a review. Holben DH, et al. **J Am Diet Assoc** 1999 Jul;99(7):836–43 (117 ref.)
[Selenium and the organism] Kvíčala J. **Cas Lek Cesk** 1999 Feb 22;138(4):99–106 (48 ref.) (Eng. Abstr.) **(Cze)**

THERAPEUTIC USE

Lessons from basic research in selenium and cancer prevention. Ip C. **J Nutr** 1998 Nov;128(11):1845–54 (85 ref.)
Chemopreventive agents: selenium. Combs GF Jr, et al. **Pharmacol Ther** 1998 Sep;79(3):179–92 (179 ref.)
Selenium and prostate cancer prevention. Nelson MA, et al. **Semin Urol Oncol** 1999 May;17(2):91–6 (34 ref.)

TOXICITY

Locoweeds: effects on reproduction in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):53–62 (49 ref.)
Selenium. Barceloux DG. **J Toxicol Clin Toxicol** 1999; 37(2):145–72 (224 ref.)

SELENIUM COMPOUNDS

METABOLISM

Defenses against peroxynitrite. Briviba K, et al. **Methods Enzymol** 1999;301:301–11 (26 ref.)

SELENOCYSTEINE

CHEMISTRY

Selenocysteine-containing proteins in mammals. Gladyshev VN, et al. **J Biomed Sci** 1999 May–Jun;6(3):151–60 (104 ref.)

METABOLISM

Selenocysteine inserting tRNAs: an overview. Commans S, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):335–51 (83 ref.)

SELENOMONAS

DRUG EFFECTS

Manipulation of ruminal fermentation with organic acids: a review. Martin SA. **J Anim Sci** 1998 Dec;76(12):3123–32 (50 ref.)

SELENOMONAS RUMINANTIUM see **SELENOMONAS**

SELF see **EGO**

SELF ADMINISTRATION

Patient and family caregiver perspectives. Ferrell BR. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):15–9 (29 ref.)
Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Stafford D, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):169–84 (119 ref.)
The availability of activated charcoal and ipecac for home use. Nordt SP, et al. **Vet Hum Toxicol** 1999 Aug; 41(4):247–8 (10 ref.)

METHODS

Optimizing tuberculosis control in the inner city [editorial; comment] FitzGerald JM. **CMAJ** 1999 Mar 23;160(6):821–2 (14 ref.) Comment on: CMAJ 1999 Mar 23;160(6):789–94. Comment on: CMAJ 1999 Mar 23;160(6):799–802.

STANDARDS

State-of-the-art patient self-management for control of oral anticoagulation. Taborski U, et al. **Semin Thromb Hemost** 1999;25(1):43–7 (18 ref.)

SELF ASSESSMENT (PSYCHOLOGY)

Measurement of functional status, self-assessment, and psychological well-being in scleroderma. Merkel PA. **Curr Opin Rheumatol** 1998 Nov;10(6):589–94 (27 ref.)
Rating scales for mania: is self-rating reliable? Altman E. **J Affect Disord** 1998 Sep;50(2–3):283–6 (12 ref.)
[Epidemiology of psychosomatic symptoms and subjective health evaluation among secondary school students] Pikó B. **Orv Hetil** 1999 Jun 6;140(23):1297–304 (40 ref.) (Eng. Abstr.) **(Hun)**

SELF CARE

Personal responsibility for health? A review of the arguments and the evidence at century's end. Minkler M. **Health Educ Behav** 1999 Feb;26(1):121–40 (118 ref.)
Nursing practice theory of exercise as self-care. Ulbrich SL. **Image J Nurs Sch** 1999;31(1):65–70 (24 ref.)
Self-care agency: the concept and how it is measured. Carter PA. **J Nurs Meas** 1998 Winter;6(2):195–207 (25 ref.)
Encouraging self-help in oesophagitis. Heatley RV. **Practitioner** 1999 Apr;243(1597):261–2, 265–6, 271 passim (0 ref.)
Self-management plans in asthma. Neville R. **Practitioner** 1998 Mar;242(1584):212–5 (20 ref.)
[Home hemodialysis for therapy of late-stage kidney failure] Saito A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1323–8 (9 ref.) **(Jpn)**

METHODS

Epilepsy and seizures: advances in seizure assessment, treatment, and self-management. Shafer PO. **Nurs Clin North Am** 1999 Sep;34(3):743–59 (36 ref.)
Patient education: a tool in the outpatient management of deep vein thrombosis. Haines ST. **Pharmacotherapy** 1998 Nov–Dec;18(6 Pt 3):158S–164S (33 ref.)
[Is self-management practical in bronchial asthma?] Gonon M, et al. **Schweiz Med Wochenschr** 1999 Apr 3; 129(13):519–25 (18 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

A computerized method of identifying potentially preventable heart failure admissions. Thomas V, et al. **J Nurs Care Qual** 1999 Jun;13(5):1–10 (25 ref.)

TRENDS

Evolution of self-care with over-the-counter medications. Soller RW. **Clin Ther** 1998;20 Suppl C:C134–40 (26 ref.)
Home haemodialysis in the 1990s [see comments] Mackenzie P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1944–8 (17 ref.) Comment in: Nephrol Dial Transplant 1999 Jan;14(1):251–2. Comment in: Nephrol Dial Transplant 1999 Apr;14(4):1031–2.

SELF CARE (REHABILITATION) see **ACTIVITIES OF DAILY LIVING**

SELF CONCEPT

see related
BODY IMAGE

Clinical interpretation of "My Secret Life": the emergence of one gay man's authentic identity" [comment] Crepeau EB. **Am J Occup Ther** 1998 Jul–Aug;52(7):570–2 (20 ref.) Comment on: Am J Occup Ther 1998 Jul–Aug;52(7):563–9.
"My secret life": the emergence of one gay man's authentic identity [see comments] Walsh AL, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):563–9 (41 ref.) Comment in: Am J Occup Ther 1998 Jul–Aug;52(7):570–2.
Interpersonal processes: the interplay of cognitive, motivational, and behavioral activities in social interaction. Snyder M, et al. **Annu Rev Psychol** 1999;50:273–303 (138 ref.)
The Heideggerian view of person: a perspective conducive to the therapeutic encounter. Orbanic SD.

SELF CONCEPT

Arch Psychiatr Nurs 1999 Jun;13(3):137–44 (19 ref.)
Calling for the absent male. Edgar D.
Aust Fam Physician 1999 Aug;28(8):797–9 (5 ref.)
Multiple pathways to inflated responsibility beliefs in obsessional problems: possible origins and implications for therapy and research. Salkovskis P, et al.
Behav Res Ther 1999 Nov;37(11):1055–72 (40 ref.)
Brains, minds and selves: changing conceptions of the losses involved in dementia. Cheston R, et al.
Br J Med Psychol 1999 Jun;72 (Pt 2):203–16 (92 ref.)
The stress of being a poor child in America. Garbarino J.
Child Adolesc Psychiatr Clin N Am 1998 Jan;7(1):105–19, ix (23 ref.)
Self-perception and action in infancy. Rochat P.
Exp Brain Res 1998 Nov;123(1–2):102–9 (22 ref.)
The self in self-awareness. Cook SH. **J Adv Nurs** 1999 Jun; 29(6):1292–9 (42 ref.)
Health-within-illness: concept development through research and practice. Moch SD. **J Adv Nurs** 1998 Aug; 28(2):305–10 (38 ref.)
The professional identity of the nurse: concept analysis and development. Ohlén J, et al. **J Adv Nurs** 1998 Oct; 28(4):720–7 (40 ref.)
'Coming out' as a life transition: homosexual identity formation and its implications for health care practice. Taylor B. **J Adv Nurs** 1999 Aug;30(2):520–5 (52 ref.)
Does assisted reproduction make an impact on the identity and self-image of infertile couples? Daniels KR.
J Assist Reprod Genet 1999 Feb;16(2):57–9 (12 ref.)
Does assisted reproduction make an impact on the identity and self-esteem of infertile women during the transition to parenthood? McMahon CA. **J Assist Reprod Genet** 1999 Feb;16(2):59–62 (19 ref.)
Psychosocial aspects of acne vulgaris. Layton AM.
J Cutan Med Surg 1998 May;2 Suppl 3:19–23 (17 ref.)
Identity in political context: lesbian/gay representation in the public sphere. Smith RR, et al. **J Homosex** 1999;37(2):25–45 (86 ref.)
Surviving cancer: the importance of sexual self-concept. Andersen BL. **Med Pediatr Oncol** 1999 Jul;33(1):15–23 (45 ref.)
Self-esteem and health behavior: theoretic and empirical links. Seigley LA. **Nurs Outlook** 1999 Mar–Apr;47(2):74–7 (36 ref.)
Attention, self-regulation and consciousness. Posner MI, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1915–27 (66 ref.)
The perils of outperformance: sensitivity about being the target of a threatening upward comparison. Exline JJ, et al. **Psychol Bull** 1999 May;125(3):307–37 (312 ref.)
Cognitive psychopathology of problem gambling. Toneatto T. **Subst Use Misuse** 1999 Sep;34(11):1593–604 (29 ref.)
[Some relations between pain and identity] Le Breton D.
Rev Med Suisse Romande 1999 Apr;119(4):259–64 (15 ref.) **(Fre)**

SELF-DESTRUCTIVE BEHAVIOR see **SELF-INJURIOUS BEHAVIOR**

SELF DETERMINATION see **FREEDOM**

SELF DISCLOSURE

To speak or not to speak? Self-disclosure with patients. Deering CG. **Am J Nurs** 1999 Jan;99(1 Pt 1):34–8; quiz 39 (12 ref.)
'Coming out' as a life transition: homosexual identity formation and its implications for health care practice. Taylor B. **J Adv Nurs** 1999 Aug;30(2):520–5 (52 ref.)

SELF EFFICACY

Using sports to strengthen resiliency in children. Training heart. Bell CC, et al.
Child Adolesc Psychiatr Clin N Am 1998 Oct;7(4):859–65 (33 ref.)
Measuring self-efficacy in the context of HIV risk reduction: research challenges and recommendations. Forsyth AD, et al. **Health Psychol** 1998 Nov;17(6):559–68 (91 ref.)
Social network ties, self-efficacy, and condom use among women who use crack cocaine: a pilot study. Montoya ID. **Subst Use Misuse** 1998 Aug;33(10):2049–73 (70 ref.)

SELF ESTEEM see **SELF CONCEPT**

SELF-EVALUATION PROGRAMS

Mandatory practice self-appraisal: moving towards outcomes based continuing education. Donen N.
J Eval Clin Pract 1999 Aug;5(3):297–303 (49 ref.)

SELF-EXAMINATION, BREAST see **BREAST SELF-EXAMINATION**

SELF-FERTILIZATION see **INBREEDING**

SELF-HELP DEVICES

New assistive technology for passive standing. Gear AJ, et al. **J Burn Care Rehabil** 1999 Mar–Apr;20(2):164–9 (14 ref.)

SELF-HELP GROUPS

"Nothing about me, without me": participatory action research with self-help/mutual aid organizations for psychiatric consumer/survivors. Nelson G, et al.
Am J Community Psychol 1998 Dec;26(6):881–912 (92 ref.)
[Support groups for patients in the early stage of dementia—usefulness and experiences] Petry H.
Ther Umsch 1999 Feb;56(2):109–13 (11 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Building a support group for parents of children with brain tumors. McGee SJ, et al. **J Neurosci Nurs** 1998 Dec; 30(6):345–9 (7 ref.)
Active listening to cancer patients' stories. ten Kroode HF.
Neth J Med 1998 Aug;53(2):41–52 (4 ref.)

SELF-INJURIOUS BEHAVIOR

DIAGNOSIS

["Self-inflicted injuries"—psychiatric, forensic and insurance aspects (I)] Möllhoff G, et al. **Versicherungsmedizin** 1998 Dec 1;50(6):226–31 (0 ref.) **(Ger)**

PSYCHOLOGY

Childhood sexual and physical abuse and adult self-harm and suicidal behaviour: a literature review [see comments] Santa Mina EE, et al. **Can J Psychiatry** 1998 Oct;43(8):793–800 (52 ref.) Comment in: Can J Psychiatry 1998 Oct;43(8):783.
["Self-inflicted injuries"—psychiatric, forensic and insurance aspects (II)] Möllhoff G, et al. **Versicherungsmedizin** 1999 Mar 1;51(1):30–5 (0 ref.) (Eng. Abstr.) **(Ger)**

SELF-INSTRUCTION PROGRAMS, COMPUTERIZED see **COMPUTER-ASSISTED INSTRUCTION**

SELF MEDICATION

METHODS

[Self-medication in gastroesophageal reflux: role and limits] De Winter B, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S297–301 (27 ref.) **(Fre)**
[Role and limits of self-medication in the therapeutic strategy of gastroesophageal reflux in adults] Poynard T.
Gastroenterol Clin Biol 1999 Jan;23(1 Pt 2):S176–9 (16 ref.) **(Fre)**

SELF-MONITORING, BLOOD GLUCOSE see **BLOOD GLUCOSE SELF-MONITORING**

SELF MUTILATION

Severe morbid onychophagia: the classification as self-mutilation and a proposed model of maintenance. Wells JH, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):534–45 (79 ref.)

COMPLICATIONS

Tongue piercing and associated tooth fracture. Botchway C, et al. **J Can Dent Assoc** 1998 Dec;64(11):803–5 (9 ref.)

ETIOLOGY

Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Schlozman SC.
J Clin Psychiatry 1998 Dec;59(12):681–6 (22 ref.)

PSYCHOLOGY

The functions of self-mutilation. Suyemoto KL.
Clin Psychol Rev 1998 Aug;18(5):531–54 (89 ref.)
Autoenucleation—a culture-specific phenomenon: a case series and review. Shiwach RS. **Compr Psychiatry** 1998 Sep–Oct;39(5):318–22 (39 ref.)

SELF PERCEPTION see **SELF CONCEPT**

SELF PSYCHOLOGY

Countertransference. Hinshelwood RD. **Int J Psychoanal** 1999 Aug;80 (Pt 4):797–818 (104 ref.)
Resilience in child survivors of the Holocaust: toward the concept of resilience. Valent P. **Psychoanal Rev** 1998 Aug; 85(4):517–35 (33 ref.)
[Free from stress by autogenic therapy. Relaxation technique yielding peace of mind and self-insight] Broms C.
Lakartidningen 1999 Feb 10;96(6):588–92 (20 ref.) (Eng. Abstr.) **(Swe)**

SELF TOLERANCE

see related
AUTOIMMUNE DISEASES
CLONAL ANERGY
CLONAL DELETION

Immunological self/nonself discrimination: integration of self vs nonself during cognate T cell interactions with antigen-presenting cells. Mannie MD. **Immunol Res** 1999; 19(1):65–87 (154 ref.)
Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Dighiero G, et al.
Immunol Today 1999 Sep;20(9):423–8 (65 ref.)

IMMUNOLOGY

Linkage of immune self-tolerance with the positive selection of T cells. Rubin RL, et al. **Crit Rev Immunol** 1999; 19(3):199–218 (141 ref.)
Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Hanahan D.
Curr Opin Immunol 1998 Dec;10(6):656–62 (36 ref.)
MHC restriction to T-cell autoaggression: an emerging understanding of IDDM pathogenesis. Choudhuri K, et al. **Diabetes Metab Rev** 1998 Dec;14(4):285–301 (108 ref.)
The presentation of self and allogeneic MHC peptides to T lymphocytes. Benichou G, et al. **Hum Immunol** 1998 Sep; 59(9):540–8 (44 ref.)
The self-nonself discrimination in the context of function. Cohn M. **Theor Med Bioeth** 1998 Sep;19(5):475–84; discussion 485–504 (6 ref.)
Conceptual shifts in immunology: comments on the "two-way paradigm" [comment] Tauber AI.
Theor Med Bioeth 1998 Sep;19(5):457–73 (39 ref.)
Comment on: Theor Med Bioeth 1998 Sep;19(5):441–55.

PHYSIOLOGY

On the intrathymic intercellular transfer of self-determinants. Viret C, et al. **Immunol Today** 1999 Jan;20(1):8–10 (20 ref.)
The thymic repertoire of neuroendocrine-related self antigens: biological role in T-cell selection and pharmacological implications. Geenen V, et al.
Neuroimmunomodulation 1999 Jan–Apr;6(1–2):115–25 (107 ref.)

SELLA TURCICA

Non-neoplastic cystic lesions of the sellar region presentation, diagnosis and management of eight cases and review of the literature. Iqbal J, et al.
Acta Neurochir (Wien) 1999;141(4):389–97; discussion 397–8 (41 ref.)
Extrapituitary parasellar microadenoma in Cushing's disease. Pluta RM, et al. **J Clin Endocrinol Metab** 1999 Aug; 84(8):2912–23 (61 ref.)

PATHOLOGY

Differential diagnosis of sellar masses. Freda PU, et al.
Endocrinol Metab Clin North Am 1999 Mar;28(1):81–117, vi (165 ref.)
Imaging of sellar and parasellar pathology. FitzPatrick M, et al. **Radiol Clin North Am** 1999 Jan;37(1):101–21, x (80 ref.)

SEMANTICS

Cerebral hemispheric mechanisms linking ambiguous word meaning retrieval and creativity. Atchley RA, et al.
Brain Cogn 1999 Aug;40(3):479–99 (79 ref.)
Chronic electrical stimulation of the left ventrointermediate (Vim) thalamic nucleus for the treatment of pharmacotherapy-resistant Parkinson's disease: a differential impact on access to semantic and episodic memory? Tröster AI, et al. **Brain Cogn** 1998 Nov; 38(2):125–49 (120 ref.)
The deterioration of semantic memory in Alzheimer's disease. Salmon DP, et al. **Can J Exp Psychol** 1999 Mar; 53(1):108–17 (56 ref.)
Anatomical spaces: a review [see comments] Newell RL.
Clin Anat 1999;12(1):66–9 (31 ref.) Comment in: Clin Anat 1999 ;12(1):70–1.
Episodic memory: new insights from the study of semantic dementia. Graham KS, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):245–50 (73 ref.)
Semantics, inflammation, cytokines and common sense. Kushner I. **Cytokine Growth Factor Rev** 1998 Sep–Dec; 9(3–4):191–6 (63 ref.)
Developing successful performance appraisals through choosing appropriate words to effectively describe work. Timmreck TC. **Health Care Manage Rev** 1998 Summer; 23(3):48–57 (14 ref.)
Phonology, semantics, and the role of the left inferior prefrontal cortex [editorial] Fiez JA. **Hum Brain Mapp** 1997;5(2):79–83 (39 ref.)
The power of the word: some post-structural considerations of qualitative approaches in nursing research. Crowe M.
J Adv Nurs 1998 Aug;28(2):339–44 (22 ref.)
Neuro-talk: an intervention to enhance communication. Gregory RJ. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):28–31 (10 ref.)
Cognitive integration of language and memory in bilinguals: semantic representation. Francis WS. **Psychol Bull** 1999 Mar;125(2):193–222 (165 ref.)
Assignments of meaning in epidemiology. Little M.
Soc Sci Med 1998 Nov;47(9):1135–45 (31 ref.)

SEMEN

see related
SPERMATOZOA

CHEMISTRY

[The deterioration of the parameters of the human semen:

myth or reality?] Mędraś M, et al. **Ginekol Pol** 1999 Mar; 70(3):155–60 (20 ref.) (Eng. Abstr.) **(Pol)**

[beta–Endorphins and the male reproductive system] Morales Martinez ME, et al. **Ginecol Obstet Mex** 1999 Apr;67:183–7 (33 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunomodulators in human seminal plasma: a vital protection for spermatozoa in the presence of infection? Kelly RW. **Int J Androl** 1999 Feb;22(1):2–12 (121 ref.)

Human seminal plasma protein allergy: a diagnosis rarely considered. Ludman BG.
J Obstet Gynecol Neonatal Nurs 1999 Jul–Aug;28(4):359–63 (18 ref.)

METABOLISM

Antiretroviral–drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Kashuba AD, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1817–26 (141 ref.)

Role of the ionic environment and internal pH on sperm activity. Hamamah S, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:20–30 (62 ref.)

PHYSIOLOGY

Quality assessment of computer–assisted semen analysis (CASA) in the andrology laboratory. Krause W, et al. **Andrologia** 1999 May;31(3):125–9 (23 ref.)

Semen retrieval by penile vibratory stimulation in men with spinal cord injury. Brackett NL. **Hum Reprod Update** 1999 May–Jun;5(3):216–22 (46 ref.)

Methods of semen collection not based on masturbation or surgical sperm retrieval. Gerris J. **Hum Reprod Update** 1999 May–Jun;5(3):211–5 (20 ref.)

Seasonal variation of semen quality and fertility. Levine RJ. **Scand J Work Environ Health** 1999;25 Suppl 1:34–7; discussion 76–8 (22 ref.)

[In vitro assessment of semen for the prediction of fertility] Waberski D, et al.
Tierarztl Prax Ausg G Grosstiere Nutztiere 1999 Feb; 27(1):1–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Analysis of decline in seminal fluid in the Italian population during the past 15 years] Bilotta P, et al.
Minerva Ginecol 1999 Jun;51(6):223–31 (53 ref.) (Eng. Abstr.) **(Ita)**

SEMEN PRESERVATION

Cryopreservation of non–human primate sperm: priorities for future research. Morrell JM, et al. **Anim Reprod Sci** 1998 Oct;53(1–4):43–63 (66 ref.)

The quagmire of postmortem sperm acquisition. Gottenger EE, et al. **J Androl** 1999 Jul–Aug;20(4):458–62 (18 ref.)

The emergence of specialized procedures for the acquisition, processing, and cryopreservation of epididymal and testicular sperm in connection with intracytoplasmic sperm injection. Marmar JL. **J Androl** 1998 Sep–Oct;19(5):517–26 (106 ref.)

The posthumous gift of life: the world according to Kane. Shuster E. **J Contemp Health Law Policy** 1999 Spring; 15(2):401–23 (91 ref.)

Cryopreservation of gametes in young patients with cancer. Schover LR, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct; 20(5):426–8 (19 ref.)

Mouse sperm cryopreservation: a legacy in the making [editorial; comment] Pinkert CA. **Lab Anim Sci** 1998 Jun; 48(3):224 (5 ref.) Comment on: Lab Anim Sci 1998 Jun;48(3):275–81.

METHODS

Collection, storage, and use of zebrafish sperm. Ransom DG, et al. **Methods Cell Biol** 1999;60:365–72 (3 ref.)

Cryopreservation of mouse spermatozoa: double your mouse space. Marschall S, et al. **Trends Genet** 1999 Apr; 15(4):128–31 (20 ref.)

SEMICIRCULAR CANALS

PHYSIOLOGY

An alternative approach to the central processing of canal and otolith signals. Green AM, et al.
Ann N Y Acad Sci 1999 May 28;871:402–5 (8 ref.)

SEMILUNAR CARTILAGES see **MENISCI, TIBIAL**

SEMILUNAR GANGLION see **TRIGEMINAL GANGLION**

SEMINAL PLASMA see **SEMEN**

SEMINAL VESICLES

ABNORMALITIES

[Seminal vesicle cysts (and ejaculatory duct cysts) with ipsilateral renal agenesis. Report of five cases and review of the literature] Gallmetzer J, et al.
Minerva Urol Nefrol 1999 Mar;51(1):27–31 (17 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein. Robert M, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):944–60 (95 ref.)

PATHOLOGY

[Seminal vesicle cysts associated with ipsilateral renal agenesis. Diagnosis, and long–term clinical course] Uder M, et al. **Radiologe** 1998 Sep;38(9):766–73 (43 ref.) (Eng. Abstr.) **(Ger)**

SEMINOMA

Testicular germ cell tumors: molecular understanding and clinical implications. Lutzker SG, et al.
Mol Med Today 1998 Sep;4(9):404–11 (50 ref.)

DRUG THERAPY

[Metastatic pure seminomas of the testicle: role of chemotherapy] Ceccaldi B, et al. **Bull Cancer** 1998 Oct; 85(10):887–91 (36 ref.) (Eng. Abstr.) **(Fre)**

[Bleomycin–induced PSS–like pseudoscleroderma. Case report and review of the literature] Behrens S, et al.
Hautarzt 1998 Sep;49(9):725–9 (21 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Pathogenesis of testicular germ cell tumours. Looijenga LH, et al. **Rev Reprod** 1999 May;4(2):90–100 (78 ref.)

PATHOLOGY

Spermatocytic seminoma: a cytology and histology case report with review of the literature. Saran RK, et al.
Diagn Cytopathol 1999 Apr;20(4):233–6 (18 ref.)

VETERINARY

Treatment of aggressive testicular tumors in four dogs. Dhaliwal RS, et al. **J Am Anim Hosp Assoc** 1999 Jul–Aug; 35(4):311–8 (43 ref.)

SEMIOCHEMICALS see **PHEROMONES**

SEMISYNTHETIC VACCINES see **VACCINES, SYNTHETIC**

SEMLIKI FOREST VIRUS

PATHOGENICITY

The molecular pathogenesis of Semliki Forest virus: a model virus made useful? Atkins GJ, et al. **J Gen Virol** 1999 Sep; 80 (Pt 9):2287–97 (102 ref.)

SENDAI VIRUS see **PARAMYXOVIRUS**

SENECIO

see related
PYRROLIZIDINE ALKALOIDS

SENECIO ALKALOIDS see **PYRROLIZIDINE ALKALOIDS**

SENESCENCE see **AGING**

SENESCENCE, CELLULAR see **CELL AGING**

SENESCENCE, REPLICATIVE see **CELL AGING**

SENILE OSTEOPOROSIS see **OSTEOPOROSIS**

SENILE PLAQUES

see related
AMYLOID BETA–PROTEIN

ENZYMOLOGY

Molecular interactions of acetylcholinesterase with senile plaques. Inestrosa NC, et al. **J Physiol Paris** 1998 Oct–Dec; 92(5–6):341–4 (17 ref.)

GENETICS

Transgenic animals in Alzheimer's disease research. Sturchler–Pierrat C, et al. **Rev Neurosci** 1999;10(1):15–24 (68 ref.)

METABOLISM

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part III: animal model. Chen M. **Front Biosci** 1998 Jun 17;3:A47–51 (42 ref.)

[Mechanism of senile plaque formation in Alzheimer disease] Ohyagi Y. **Fukuoka Igaku Zasshi** 1999 Apr;90(4):113–7 (5 ref.) **(Jpn)**

PATHOLOGY

A new kind of Alzheimer's disease plaque. Baum L, et al.
Adv Anat Pathol 1998 May;5(3):170–4 (11 ref.)

PHYSIOLOGY

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part II: therapeutic rationale. Chen M. **Front Biosci** 1998 Jun 8;3:A32–7 (37 ref.)

SENSATION

see related
PERCEPTION

Neuro–talk: an intervention to enhance communication. Gregory RJ. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):28–31 (10 ref.)

[Disturbance of deep sensation in medial medullary syndrome. Topographical localization of medial lemniscus in the medulla oblongata] Koyano S, et al.
Rinsho Shinkeigaku 1998 Aug;38(8):739–44 (30 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Crawley JN. **Brain Res** 1999 Jul 17;835(1):18–26 (77 ref.)

PHYSIOLOGY

Sensory information and conscious experience. Jasper HH. **Adv Neurol** 1998;77:33–48 (39 ref.)

Brainy mind. Gregory R. **BMJ** 1998 Dec 19–26; 317(7174):1693–5 (15 ref.)

Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Crawley JN. **Brain Res** 1999 Jul 17;835(1):18–26 (77 ref.)

Task–dependent reduction of the number of degrees of freedom in sensorimotor systems. Gielen CC, et al.
Brain Res Brain Res Rev 1998 Nov;28(1–2):136–42 (71 ref.)

Sensory pathways and their modulation in the control of locomotion. Büschges A, et al. **Curr Opin Neurobiol** 1998 Dec;8(6):733–9 (47 ref.)

Experience–dependent changes in function and anatomy of adult barrel cortex. Kossut M. **Exp Brain Res** 1998 Nov; 123(1–2):110–6 (30 ref.)

Neural mechanisms for synthesizing sensory information and producing adaptive behaviors. Stein BE. **Exp Brain Res** 1998 Nov;123(1–2):124–35 (75 ref.)

Gating of the sensory activity within barrel cortex of the awake rat. Wróbel A, et al. **Exp Brain Res** 1998 Nov; 123(1–2):117–23 (39 ref.)

The neurobiology of multimodal sensory integration. Freeman WJ. **Integr Physiol Behav Sci** 1998 Apr–Jun; 33(2):124–9 (36 ref.)

Corneal sensation after cataract and refractive surgery. Kohlhaas M. **J Cataract Refract Surg** 1998 Oct; 24(10):1399–409 (48 ref.)

Sense of effort and dyspnoea. Killian KJ.
Monaldi Arch Chest Dis 1998 Dec;53(6):654–60 (39 ref.)

Endogenous mechanisms of sensory modulation. Dubner R, et al. **Pain** 1999 Aug;Suppl 6:S45–53 (56 ref.)

Hoffman–Tinel sign. The realities. Alfonso MI, et al.
Phys Med Rehabil Clin N Am 1998 Nov;9(4):721–36, v (59 ref.)

Learning–induced physiological plasticity in the thalamo–cortical sensory systems: a critical evaluation of receptive field plasticity, map changes and their potential mechanisms. Edeline JM. **Prog Neurobiol** 1999 Feb; 57(2):165–224 (369 ref.)

Love as sensory stimulation: physiological consequences of its deprivation and expression. Komisaruk BR, et al.
Psychoneuroendocrinology 1998 Nov;23(8):927–44 (58 ref.)

[Physiological and sensorial determinism of maternal behavior in mammals] Lévy F. **Contracept Fertil Sex** 1998 Oct;26(10):718–27 (78 ref.) (Eng. Abstr.) **(Fre)**

[Visceral sensitivity and digestive functional disorders. Clinical significance and therapeutic perspectives] Coffin B, et al. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B109–17 (114 ref.) **(Fre)**

SENSATION DISORDERS

Dimensions of gut dysfunction in irritable bowel syndrome: altered sensory function. Azpiroz F.
Can J Gastroenterol 1999 Mar;13 Suppl A:12A–14A (17 ref.)

Aging and sensory senescence. Nusbaum NJ.
South Med J 1999 Mar;92(3):267–75 (52 ref.)

[Acute sensory neuropathy] Adachi H, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):461–3 (16 ref.) **(Jpn)**

[Lewis–Sumner syndrome] Ogino Y, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):492–5 (12 ref.) **(Jpn)**

[Multifocal motor neuropathy (MMN)] Ozaki I, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):483–6 (13 ref.) **(Jpn)**

[Behavior problems in patients with dementia. The impact on the career life] Garrido R, et al. **Arq Neuropsiquiatr** 1999 Jun;57(2B):427–34 (39 ref.) (Eng. Abstr.) **(Por)**

SENSATION DISORDERS

COMPLICATIONS

Recurrent abdominal pain and the biopsychosocial model of medical practice. Hyams JS, et al. **J Pediatr** 1998 Oct; 133(4):473–8 (53 ref.)

Olfaction and symptoms in the multiple chemical sensitivities syndrome. Ross PM, et al. **Prev Med** 1999 May; 28(5):467–80 (140 ref.)

DIAGNOSIS

Equilibrium and balance in the elderly. Hobeika CP. **Ear Nose Throat J** 1999 Aug;78(8):558–62, 565–6 (53 ref.)

Proximal sensory neuropathies of the Leg. Reid V, et al. **Neurol Clin** 1999 Aug;17(3):655–67, viii (45 ref.)

ETIOLOGY

Reduce risk of inducing spatial disorientation using physiologically compatible ground lighting. Schmidt RT. **Aviat Space Environ Med** 1999 Jun;70(6):598–603 (22 ref.)

PATHOLOGY

Localized hypertrophic neuropathy involving the inferior alveolar nerve. Ethunandan M, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):84–9 (23 ref.)

PHYSIOPATHOLOGY

Balance and aging. Konrad HR, et al. **Laryngoscope** 1999 Sep;109(9):1454–60 (47 ref.)

Multiple sclerosis potpourri. Paroxysmal symptoms, seizures, fatigue, pregnancy, and more. Taylor RS. **Phys Med Rehabil Clin N Am** 1998 Aug;9(3):551–9, vi (31 ref.)

PREVENTION & CONTROL

Reduce risk of inducing spatial disorientation using physiologically compatible ground lighting. Schmidt RT. **Aviat Space Environ Med** 1999 Jun;70(6):598–603 (22 ref.)

[Advance in the study of restoration of sensation in skin flaps] Kuang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):94–6 (25 ref.) **(Chi)**

SENSE ORGANS

see related
RECEPTORS, SENSORY

ANATOMY & HISTOLOGY

The Chievitz juxtaparotid organ. D'Andrea V, et al. **G Chir** 1999 May;20(5):213–7 (37 ref.)

INNERVATION

Nerve dependency of developing and mature sensory receptor cells. Fritzsch B, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:14–27 (83 ref.)

PHYSIOLOGY

Nerve dependency of developing and mature sensory receptor cells. Fritzsch B, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:14–27 (83 ref.)

Elements of the olfactory signaling pathways in insect antennae. Krieger J, et al. **Invert Neurosci** 1997 Sep–Dec; 3(2–3):137–44 (50 ref.)

Theoretical aspects of sensory substitution and of neurotransmission-related reorganization in spinal cord injury. Bach-y-Rita P. **Spinal Cord** 1999 Jul;37(7):465–74 (81 ref.)

SENSITIVITY AND SPECIFICITY

[Sensitivity and specificity revisited: significance of the terms in analytic and diagnostic language] Saah AJ, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):291–4 (26 ref.) (Eng. Abstr.) **(Fre)**

SENSITIVITY, CONTACT see **DERMATITIS, CONTACT**

SENSITIZATION, IMMUNOLOGIC see **IMMUNIZATION**

SENSORY AIDS

Theoretical aspects of sensory substitution and of neurotransmission-related reorganization in spinal cord injury. Bach-y-Rita P. **Spinal Cord** 1999 Jul;37(7):465–74 (81 ref.)

SENSORY AND AUTONOMIC NEUROPATHIES, HEREDITARY see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

SENSORY DEPRIVATION

Reinterpreting physical violence: outcome of intense stimulation-seeking behavior [letter] Mawson AR. **Acad Emerg Med** 1999 Aug;6(8):863–5 (12 ref.)

An efficient treatment and new criteria for cure of strabismic amblyopia: reading and Bangerter foils. Lang J. **Binocul Vis Strabismus Q** 1999 Spring;14(1):9–10 (6 ref.)

Sensory deprivation and chronic pain: a review of the literature. Schofield P, et al. **Disabil Rehabil** 1998 Oct; 20(10):357–66 (75 ref.)

The case for early identification of hearing loss in children. Auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Sininger YS, et al. **Pediatr Clin North Am** 1999 Feb;46(1):1–14 (62 ref.)

PHYSIOLOGY

Love as sensory stimulation: physiological consequences of its deprivation and expression. Komisaruk BR, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):927–44 (58 ref.)

SENSORY GANGLIA see **GANGLIA, SENSORY**

SENSORY MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

SENSORY NEUROPATHY, HEREDITARY see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

SENSORY THRESHOLDS

Reliability of cephalic thermal thresholds in healthy subjects. Becser N, et al. **Cephalalgia** 1998 Oct;18(8):574–82 (45 ref.)

PHYSIOLOGY

Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Arciniegas D, et al. **Brain Inj** 1999 Jan;13(1):1–13 (89 ref.)

Use of image-based information in judgments of surface-reflectance properties. Nishida S, et al. **J Opt Soc Am A Opt Image Sci Vis** 1998 Dec; 15(12):2951–65 (65 ref.)

Technology review: the Neurometer Current Perception Threshold (CPT). AAEM Equipment and Computer Committee. American Association of Electrodiagnostic Medicine. **Muscle Nerve** 1999 Apr;22(4):523–31 (56 ref.)

Nonsynaptic diffusion neurotransmission and some other emerging concepts. Bach-y-Rita P. **Proc West Pharmacol Soc** 1998;41:211–8 (89 ref.)

Theoretical aspects of sensory substitution and of neurotransmission-related reorganization in spinal cord injury. Bach-y-Rita P. **Spinal Cord** 1999 Jul;37(7):465–74 (81 ref.)

SENTINEL HEALTH EVENT see **SENTINEL SURVEILLANCE**

SENTINEL SURVEILLANCE

Weekly Returns Service of the Royal College of General Practitioners. Fleming DM. **Commun Dis Public Health** 1999 Jun;2(2):96–100 (22 ref.)

Approaches to the denominator in practice-based epidemiology: a critical overview. Schlaud M, et al. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:13S–19S (36 ref.)

SWORD '97: surveillance of work-related and occupational respiratory disease in the UK. Ross DJ, et al. **Occup Med (Lond)** 1998 Nov;48(8):481–5 (9 ref.)

Surveillance of hepatitis B: an example of a vaccine preventable disease. Ramsay ME, et al. **Vaccine** 1998 Nov; 16 Suppl:S76–80 (12 ref.)

SEOUL VIRUS see **HANTAVIRUS**

SEPARATION ANXIETY DISORDER see **ANXIETY, SEPARATION**

SEPHAROSE

ANALOGS & DERIVATIVES

Purification of lipases and phospholipases by heparin-sepharose chromatography. Farooqui AA, et al. **Methods Mol Biol** 1999;109:133–43 (40 ref.)

Purification of antibodies using protein A-sepharose and FPLC. Kent UM. **Methods Mol Biol** 1999;115:29–33 (13 ref.)

SEPSIS

Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives. Salomão R, et al. **Infection** 1999 Jan–Feb;27(1):1–11 (165 ref.)

[Diagnosis, treatment, prevention and prognostication of suppurative-septic complications in abdominal surgery] Ohonovs'kii VK. **Klin Khir** 1999;(7):48–51 (45 ref.) **(Ukr)**

BLOOD

Lactate in sepsis and trauma--hindrance or help? Sladen RN. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):237–8 (14 ref.)

Reduction of circulating cholesterol and apolipoprotein levels during sepsis. Fraunberger P, et al. **Clin Chem Lab Med** 1999 Mar;37(3):357–62 (59 ref.)

Deciphering the dark side of free hemoglobin in sepsis [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):685–6 (10 ref.) Comment on: Crit Care Med 1999 Apr;27(4):771–8.

Coagulation and fibrinolysis in sepsis. Thijs GL. **Minerva Anestesiol** 1999 Jan–Feb;65(1–2 Suppl 1):61–4 (37 ref.)

COMPLICATIONS

Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Power DA, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S23–8 (41 ref.)

Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650–1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429–36.

Inflammation, sepsis, and coagulation. Esmon CT, et al. **Haematologica** 1999 Mar;84(3):254–9 (24 ref.)

Antithrombin III and sepsis [editorial; comment] Mammen EF. **Intensive Care Med** 1998 Jul;24(7):649–50 (15 ref.) Comment on: Intensive Care Med 1998 Jul;24(7):663–72.

[Sepsis and organ failure--its pathogenesis and treatment] Hanasawa K, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug; 99(8):523–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Meningococcal sepsis and septic shock: efficient measures and controversial treatments] Casado Flores J, et al. **An Esp Pediatr** 1999 Apr;50(4):346–52 (74 ref.) **(Spa)**

CONGENITAL

Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Goldman S, et al. **Clin Perinatol** 1998 Sep;25(3):699–710 (32 ref.)

DIAGNOSIS

Rapid diagnostic methods in the detection of sepsis. Carlet J. **Infect Dis Clin North Am** 1999 Jun;13(2):483–94, xi (54 ref.)

[Meningococcal sepsis in 3 young men] Diet F, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):424–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Recurrent neonatal sepsis due to Streptococcus B] Casanovas Lax J, et al. **An Esp Pediatr** 1999 Jan;50(1):69–70 (10 ref.) **(Spa)**

[Late neonatal sepsis with meningitis due to meningococcus serogroup C (letter)] Falero Gallego MP, et al. **An Esp Pediatr** 1999 Jun;50(6):639–40 (10 ref.) **(Spa)**

[Sepsis due to azole-resistant Candida albicans in a high-risk premature infant] Martinez Suárez V, et al. **An Esp Pediatr** 1999 Jan;50(1):77–8 (22 ref.) **(Spa)**

[Campylobacter fetus sepsis, pulmonary thromboembolism and an occult neoplasm (letter)] Conde Martel A, et al. **An Med Interna** 1999 Feb;16(2):103 (7 ref.) **(Spa)**

[Streptococcus bovis sepsis, purulent meningitis and colonic diverticulosis (letter)] Fresco Benito FJ, et al. **An Med Interna** 1999 Jul;16(7):383–4 (10 ref.) **(Spa)**

DRUG THERAPY

Myeloid colony-stimulating factors: use in the newborn. Sreenan C, et al. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):984–8 (65 ref.)

Dopexamine: much more than a vasoactive agent [editorial; comment] Bennett ED. **Crit Care Med** 1998 Oct; 26(10):1621–2 (10 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1639–45.

The effects of ibuprofen on eicosanoid synthesis in sepsis [editorial; comment] Fletcher JR. **Crit Care Med** 1999 Apr; 27(4):669–70 (11 ref.) Comment on: Crit Care Med 1999 Apr;27(4):699–707.

Acadesine during fluid resuscitation from shock and abdominal sepsis [see comments] Melton SM, et al. **Crit Care Med** 1999 Mar;27(3):565–75 (46 ref.) Comment in: Crit Care Med 1999 Mar;27(3):468–9.

The sirens' songs of confirmatory sepsis trials: selection bias and sampling error [editorial; comment] Natanson C, et al. **Crit Care Med** 1998 Dec;26(12):1927–31 (19 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1963–71.

Pentoxifylline--more evidence that it improves host defenses during sepsis [editorial; comment] Reynolds H. **Crit Care Med** 1999 Apr;27(4):681–3 (41 ref.) Comment on: Crit Care Med 1999 Apr;27(4):756–63.

ATP and sepsis [editorial; comment] Traber DL. **Crit Care Med** 1999 May;27(5):865–6 (16 ref.) Comment on: Crit Care Med 1999 May;27(5):959–64.

Appraising the potential of pentoxifylline in septic premies [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):695–7 (32 ref.) Comment on: Crit Care Med 1999 Apr;27(4):807–14.

Treatment of sepsis: past and future avenues. Baumgartner JD, et al. **Drugs** 1999 Feb;57(2):127–32 (56 ref.)

Antithrombin replacement in patients with sepsis and septic shock. Giudici D, et al. **Haematologica** 1999 May; 84(5):452–60 (54 ref.)

Why immunomodulatory therapies have not worked in sepsis. Abraham E. **Intensive Care Med** 1999 Jun;25(6):556–66 (108 ref.)

Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. Periti P, et al. **J Chemother** 1998 Dec;10(6):427–48 (126 ref.)

Strategies to rationalize sepsis management--a review of 4 years' experience in Dundee. Nathwani D, et al. **J Infect** 1998 Jul;37 Suppl 1:10-7 (55 ref.)
Therapeutic implications of interleukin-10 in surgical disease. Selzman CH, et al. **Shock** 1998 Nov;10(5):309-18 (156 ref.)
[Role of antiinflammatory and anticoagulant therapy in subacute septic endocarditis] Sumarokov AV, et al. **Ter Arkh** 1998;70(9):49-52 (17 ref.) **(Rus)**
[Antithrombin III in severe sepsis and septic shock] Carrillo-Esper R, et al. **Gac Med Mex** 1999 Jul-Aug; 135(4):443-6 (30 ref.) **(Spa)**
[Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms] Otero AJ, et al. **Rev Cubana Med Trop** 1998;50(1):31-5 (27 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

The epidemiology of bacterial sepsis. Rangel-Frausto MS. **Infect Dis Clin North Am** 1999 Jun;13(2):299-312, vii (55 ref.)

ETIOLOGY

Serious hand sepsis and diabetes mellitus: specific tropical syndrome with western counterparts. Gill GV, et al. **Diabet Med** 1998 Oct;15(10):858-62 (27 ref.)
Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Morrison DC, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):313-40 (121 ref.)
Cytokines and anticytokines in the pathogenesis of sepsis. van der Poll T, et al. **Infect Dis Clin North Am** 1999 Jun; 13(2):413-26, ix (56 ref.)
Nitric oxide, sepsis, and the kidney. Schwartz D, et al. **Semin Nephrol** 1999 May;19(3):272-6 (28 ref.)
Animal models of sepsis and shock: a review and lessons learned. Edwin A Deitch. Shock 9(1):1-11, 1998 [letter; comment] Redl H, et al. **Shock** 1998 Dec;10(6):442-5 (35 ref.) Comment on: Shock 1998 Jan;9(1):1-11.
[Sepsis and the systemic inflammatory response syndrome] Shano VP, et al. **Anesteziol Reanimatol** 1998 Jul-Aug; (4):60-4 (93 ref.) **(Rus)**

IMMUNOLOGY

Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Weiss M, et al. **Blood** 1999 Jan 15;93(2):425-39 (173 ref.)
Dopexamine: much more than a vasoactive agent [editorial; comment] Bennett ED. **Crit Care Med** 1998 Oct; 26(10):1621-2 (10 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1639-45.
Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? [see comments] Opal SM, et al. **Crit Care Med** 1999 Aug;27(8):1608-16 (88 ref.) Comment in: Crit Care Med 1999 Aug;27(8):1682-3.
Pentoxifylline--more evidence that it improves host defenses during sepsis [editorial; comment] Reynolds H. **Crit Care Med** 1999 Apr;27(4):681-3 (41 ref.) Comment on: Crit Care Med 1999 Apr;27(4):756-63.
Nuclear factor kappaB--a new therapeutic approach? [editorial; comment] Böhrer H, et al. **Intensive Care Med** 1998 Nov;24(11):1129-30 (13 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1131-8. Comment on: Intensive Care Med 1998 Nov;24(11):1199-208.

METABOLISM

Endogenous mediators in sepsis and septic shock. Beishuizen A, et al. **Adv Clin Chem** 1998;33:55-131 (464 ref.)
Antithrombin: facts and new hypotheses. Risberg B. **Blood Coagul Fibrinolysis** 1998 Nov;9 Suppl 3:S3-6 (26 ref.)
Nitric oxide production in neonatal and pediatric sepsis [editorial; comment] Carcillo JA. **Crit Care Med** 1999 Jun; 27(6):1063-5 (19 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1187-90.
Pathways of muscle protein breakdown in injury and sepsis. Hasselgren PO. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):155-60 (37 ref.)
Limitations of nutrient intake. The effect of stressors: trauma, sepsis and multiple organ failure. Campbell IT. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S143-7 (56 ref.)
Sepsis as a modulator of adaptation to low and high carbohydrate and low and high fat intakes. Wolfe RR. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S136-42 (52 ref.)
Alterations in intracellular calcium during sepsis. Bhattacharyya J, et al. **Indian J Physiol Pharmacol** 1997 Oct;41(4):344-52 (56 ref.)
Mechanism of impaired oxygen extraction in sepsis. Shunt and the pO2 gap [editorial] Ince C. **Minerva Anestesiol** 1999 Jun;65(6):337-9 (10 ref.)
Role of the ubiquitin-proteasome pathway in sepsis-induced muscle catabolism. Hasselgren PO. **Mol Biol Rep** 1999 Apr; 26(1-2):71-6 (39 ref.)
Regulation of insulin-like growth factor-I in starvation and injury. Thissen JP, et al. **Nutr Rev** 1999 Jun;57(6):167-76 (53 ref.)
From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Tracey KJ, et al. **Shock** 1999 Mar;11(3):224-5 (9 ref.)
Adrenomedullin in sepsis and septic shock [editorial; comment] Wang P. **Shock** 1998 Nov;10(5):383-4 (23 ref.) Comment on: Shock 1998 Jan;9(1):1-11. Comment on: Shock 1998 Aug;10(2):79-89. Comment on: Shock 1998 Aug;10(2):118-22. Comment on: Shock 1998 Oct;10(4):243-7.
[Oxygen delivery in sepsis. After 10 years more questions than answers] Bone HG, et al. **Anaesthesist** 1999 Feb; 48(2):63-79 (138 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? [see comments] Opal SM, et al. **Crit Care Med** 1999 Aug;27(8):1608-16 (88 ref.) Comment in: Crit Care Med 1999 Aug;27(8):1682-3.
Therapy of sepsis: why have we made such little progress? [editorial; comment] Teplick R, et al. **Crit Care Med** 1999 Aug;27(8):1682-3 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1608-16.
Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Sriskandan S, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):397-412 (99 ref.)
Neonatal sepsis caused by Streptococcus pyogenes: resurgence of an old etiology? Greenberg D, et al. **Pediatr Infect Dis J** 1999 May;18(5):479-81 (15 ref.)
[Septic encephalopathy] Bogdanski R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Mar; 34(3):123-30 (39 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

Deciphering the dark side of free hemoglobin in sepsis [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):685-6 (10 ref.) Comment on: Crit Care Med 1999 Apr;27(4):771-8.

NURSING

Sepsis. Shelton BK. **Semin Oncol Nurs** 1999 Aug;15(3):209-21 (105 ref.)

PHYSIOPATHOLOGY

The role of nitric oxide in sepsis--an overview. Kirkebøen KA, et al. **Acta Anaesthesiol Scand** 1999 Mar;43(3):275-88 (143 ref.)
Endogenous mediators in sepsis and septic shock. Beishuizen A, et al. **Adv Clin Chem** 1998;33:55-131 (464 ref.)
Hepatic hemodynamics and cell functions in human and experimental sepsis. Pastor CM, et al. **Anesth Analg** 1999 Aug;89(2):344-52 (94 ref.)
Myocardial dysfunction in sepsis. Piper RD. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):951-4 (36 ref.)
The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Colman RW, et al. **Clin Rev Allergy Immunol** 1998 Winter;16(4):365-84 (44 ref.)
Hemofiltration and left ventricular function in sepsis: mechanisms and clinical implications [editorial; comment] Dhainaut JF, et al. **Crit Care Med** 1999 Mar;27(3):473-4 (13 ref.) Comment on: Crit Care Med 1999 Mar;27(3):588-96.
On the accuracy of intra-arterial pressure measurement: the pressure gradient effect [editorial; comment] Hynson JM, et al. **Crit Care Med** 1998 Oct;26(10):1623-4 (15 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1646-9.
Microcirculatory oxygenation and shunting in sepsis and shock [see comments] Ince C, et al. **Crit Care Med** 1999 Jul;27(7):1369-77 (75 ref.) Comment in: Crit Care Med 1999 Jul;27(7):1400-1.
Doppler "diastology": a new twist to the study of sepsis [editorial; comment] Soble JS. **Crit Care Med** 1998 Nov; 26(11):1777-8 (21 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1829-33.
Sepsis in obstetric and gynecologic patients. Faro S. **Curr Clin Top Infect Dis** 1999;19:60-82 (124 ref.)
Pathophysiology of meningococcal sepsis in children. de Kleijn ED, et al. **Eur J Pediatr** 1998 Nov;157(11):869-80 (143 ref.)
Neutrophil and endothelial cell interactions in sepsis. The role of adhesion molecules. Parent C, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):427-47, x (208 ref.)
Nitric oxide in the pathogenesis of sepsis. Symeonides S, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):449-63, x (83 ref.)
Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock [editorial] Khan RZ, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):814-8 (63 ref.)

PREVENTION & CONTROL

Role of hematopoietic growth factors in non-neutropenic infections and sepsis. Held TK, et al. **Curr Opin Hematol** 1999 May;6(3):176-83 (46 ref.)
Treatment of sepsis: past and future avenues. Baumgartner JD, et al. **Drugs** 1999 Feb;57(2):127-32 (56 ref.)
Sepsis, multi-organ dysfunction syndrome (MODS) and multiple organ failure (MOF). Prevention is better than treatment. Baue AE. **Minerva Anestesiol** 1999 Jul-Aug; 65(7-8):477-80; discussion 481 (10 ref.)
Sepsis and organ dysfunction/failure. An overview. Gullo A. **Minerva Anestesiol** 1999 Jul-Aug;65(7-8):529-40 (80 ref.)
Immunomodulation in sepsis: the role of hemofiltration. Kellum JA. **Minerva Anestesiol** 1999 Jun;65(6):410-8 (58 ref.)
[Ways of correcting immunodeficiency at different stages of burns with the aim of prevention and treatment of sepsis] Nazarov IP, et al. **Anesteziol Reanimatol** 1999 Jan-Feb; (1):63-8 (67 ref.) **(Rus)**

THERAPY

Emerging therapies for sepsis and septic shock. Oh HM. **Ann Acad Med Singapore** 1998 Sep;27(5):738-43 (40 ref.)
Supportive therapy of the sepsis syndrome. Meier-Hellmann A, et al. **Clin Chem Lab Med** 1999 Mar;37(3):333-9 (51 ref.)
Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome. Stegmayr B. **Clin Chem Lab Med** 1999 Mar;37(3):327-32 (73 ref.)
Supplemental immune globulins in sepsis. Werdan K. **Clin Chem Lab Med** 1999 Mar;37(3):341-9 (56 ref.)
Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Goldman S, et al. **Clin Perinatol** 1998 Sep;25(3):699-710 (32 ref.)
Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. **Crit Care Med** 1999 Mar;27(3):639-60 (197 ref.)
Sepsis research: we must change course [see comments] Nasraway SA Jr. **Crit Care Med** 1999 Feb;27(2):427-30 (45 ref.) Comment in: Crit Care Med 1999 Feb;27(2):434-6.
Therapy of sepsis: why have we made such little progress? [editorial; comment] Teplick R, et al. **Crit Care Med** 1999 Aug;27(8):1682-3 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1608-16.
Vaccines and antibodies in the prevention and treatment of sepsis. Bhattacharjee AK, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):355-69, vii (63 ref.)
Current therapy for sepsis. Dellinger RP. **Infect Dis Clin North Am** 1999 Jun;13(2):495-509 (50 ref.)
Clinical trials for severe sepsis. Past failures, and future hopes. Opal SM, et al. **Infect Dis Clin North Am** 1999 Jun; 13(2):285-97, vii (57 ref.)
Severe sepsis trials: why have they failed? [editorial] Dellinger RP. **Minerva Anestesiol** 1999 Jun;65(6):340-5 (36 ref.)
Present and future options in continuous renal replacement therapies of sepsis and MOF. Tetta C, et al. **Minerva Anestesiol** 1999 Jun;65(6):419-26 (63 ref.)
Treating patients with severe sepsis [see comments] Wheeler AP, et al. **N Engl J Med** 1999 Jan 21;340(3):207-14 (90 ref.) Comment in: N Engl J Med 1999 Jul 1;341(1):56; discussion 57. Comment in: N Engl J Med 1999 Jul 1;341(1):56-7.
Recent advances in the management of pleural sepsis: what is the evidence? Lim TK. **Respirology** 1999 Sep;4(3):207-12 (44 ref.)
From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Tracey KJ, et al. **Shock** 1999 Mar;11(3):224-5 (9 ref.)
Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application [editorial] Shoji H, et al. **Ther Apher** 1998 Feb;2(1):3-12 (58 ref.)
[Latest results of intensive care of sepsis, septic shock and multiple organ injuries] Incze F. **Orv Hetil** 1999 Mar 7; 140(10):515-20 (49 ref.) (Eng. Abstr.) **(Hun)**
[Problems and perspective approaches to correction of mediator response in sepsis] Mironov PI, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):54-9 (50 ref.) **(Rus)**
[Meningococcal sepsis and septic shock: efficient measures and controversial treatments] Casado Flores J, et al. **An Esp Pediatr** 1999 Apr;50(4):346-52 (74 ref.) **(Spa)**

ULTRASONOGRAPHY

Doppler "diastology": a new twist to the study of sepsis [editorial; comment] Soble JS. **Crit Care Med** 1998 Nov; 26(11):1777-8 (21 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1829-33.

VETERINARY

The sepsis-coagulant axis: a review. Weiss DJ, et al. **J Vet Intern Med** 1998 Sep-Oct;12(5):317-24 (103 ref.)

SEPSIS SYNDROME

see related
RESPIRATORY DISTRESS SYNDROME, ADULT

Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Asimakopoulos G, et al. **Ann Thorac Surg** 1998 Dec;66(6):2135-44 (89 ref.)
Mechanisms of the systemic inflammatory response. Asimakopoulos G. **Perfusion** 1999 Jul;14(4):269-77 (85 ref.)
[SIRS (systemic inflammatory response syndrome): clinical entity, definitions, and the significance] Kushimoto S, et al. **Nippon Rinsho** 1999 Jan;57(1):227-35 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Systemic inflammatory response syndrome (SIRS)] Aikawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):241-4 (12 ref.) **(Jpn)**

SEPSIS SYNDROME

BLOOD

Tumor necrosis factor receptor expression on inflammatory cells in sepsis [editorial; comment] Opal SM. **Crit Care Med** 1999 Feb;27(2):240–1 (10 ref.) Comment on: Crit Care Med 1999 Feb;27(2):319–24.

COMPLICATIONS

Pancreatitis, cytokines, and SIRS: déjà vu all over again? [editorial; comment] Giroir BP. **Crit Care Med** 1999 Apr; 27(4):680–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):749–55.

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733–40.

Possible role of systemic inflammatory reaction in vascular access thrombosis. Jurado R, et al. **South Med J** 1999 Sep; 92(9):877–81 (56 ref.)

DIAGNOSIS

Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. James JH, et al. **Lancet** 1999 Aug 7; 354(9177):505–8 (47 ref.)

DRUG THERAPY

Total splanchnic resuscitation, SIRS, and MODS [editorial; comment] Marik PE. **Crit Care Med** 1999 Feb;27(2):257–8 (43 ref.) Comment on: Crit Care Med 1999 Feb;27(2):394–400.

Deciphering the oxyradical inflammation Rosetta stone: O2•-NO•, OONO-, polymorphonuclear neutrophils, poly(ADP-ribose) synthetase, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome [editorial; comment] Vaughan D, et al. **Crit Care Med** 1999 Aug;27(8):1666–9 (30 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1517–23. Comment on: Crit Care Med 1999 Aug;27(8):1524–32.

Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy [see comments] Christman JW, et al. **Intensive Care Med** 1998 Nov;24(11):1131–8 (81 ref.) Comment in: Intensive Care Med 1998 Nov;24(11):1129–30.

ETIOLOGY

The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. Peek GJ, et al. **ASAIO J** 1999 Jul–Aug;45(4):250–63 (197 ref.)

The gut as a potential trigger of exercise-induced inflammatory responses. Marshall JC. **Can J Physiol Pharmacol** 1998 May;76(5):479–84 (54 ref.)

Neutrophil signaling alteration: an adverse inflammatory response after burn shock. Sayeed MM. **Medicina (B Aires)** 1998;58(4):386–92 (19 ref.)

Nitric oxide and intestinal barrier failure. Nadler EP, et al. **Semin Pediatr Surg** 1999 Aug;8(3):148–54 (88 ref.)

[Sepsis and the systemic inflammatory response syndrome] Shano VP, et al. **Anesteziol Reanimatol** 1998 Jul–Aug; (4):60–4 (93 ref.) **(Rus)**

IMMUNOLOGY

Inflammatory response to cardiopulmonary bypass. Edmunds LH Jr. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S12–6; discussion S25–8 (13 ref.)

Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Weiss M, et al. **Blood** 1999 Jan 15;93(2):425–39 (173 ref.)

Acute-phase responses and SIRS/MODS: the good, the bad, and the nebulous [editorial; comment] Deutschman CS. **Crit Care Med** 1998 Oct;26(10):1630–1 (22 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1683–9.

Pancreatitis, cytokines, and SIRS: déjà vu all over again? [editorial; comment] Giroir BP. **Crit Care Med** 1999 Apr; 27(4):680–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):749–55.

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.) Comment on: Crit Care Med 1999 Apr;27(4):733–40.

Inflammation in severe pneumonia: act locally, not globally [editorial; comment] Niederman MS, et al. **Crit Care Med** 1999 Sep;27(9):2030–2 (9 ref.) Comment on: Crit Care Med 1999 Sep;27(9):1745–53.

Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy [see comments] Christman JW, et al. **Intensive Care Med** 1998 Nov;24(11):1131–8 (81 ref.) Comment in: Intensive Care Med 1998 Nov;24(11):1129–30.

PATHOLOGY

[Inflammation and plaque instability] Hoffmeister HM, et al. **Z Kardiol** 1998;87 Suppl 2:20–5 (51 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Immunoendocrinology of preterm labor: the link between corticotropin-releasing hormone and inflammation. Dudley DJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S251–6 (62 ref.)

Myocardial dysfunction in sepsis: mechanisms and therapeutic implications. Price S, et al. **Eur Heart J** 1999 May;20(10):715–24 (93 ref.)

Hepatic and splanchnic microvascular responses to inflammation and shock. McCuskey RS. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1464–7 (49 ref.)

PREVENTION & CONTROL

[Preventing the development of secondary infections in severe acute pancreatitis] Gürlich R, et al. **Rozhl Chir** 1999 Feb;78(2):63–7 (24 ref.) (Eng. Abstr.) **(Cze)**

SURGERY

[Surgical management of peritonitis and sepsis] Bruch HP, et al. **Zentralbl Chir** 1999;124(3):176–80 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Hemofiltration for SIRS: bloodletting, twentieth century style? [editorial; comment] Rodby RA. **Crit Care Med** 1998 Dec;26(12):1940–2 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1995–2000.

Hyperbaric oxygen in systemic inflammation ... HBO is not just a movie channel anymore [editorial; comment] Slotman GJ. **Crit Care Med** 1998 Dec;26(12):1932–3 (28 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1972–6.

Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? [see comments] Baue AE, et al. **Shock** 1998 Aug;10(2):79–89 (121 ref.) Comment in: Shock 1998 Nov;10(5):383–4.

Mechanisms of immunomodulatory action of intravenous immunoglobulin in autoimmune and systemic inflammatory diseases [editorial] Vassilev T, et al. **Ther Apher** 1997 Feb; 1(1):38–41 (22 ref.)

[Non-glucose carbohydrates in the parenteral nutrition of patients with systemic inflammatory response syndrome] López Martínez J, et al. **Nutr Hosp** 1999 Mar–Apr; 14(2):71–80 (35 ref.) (Eng. Abstr.) **(Spa)**

SEPTAL NUCLEI

CYTOLOGY

Effects of vasopressin and related peptides on neurons of the rat lateral septum and ventral hippocampus. Urban IJ. **Prog Brain Res** 1998;119:285–310 (168 ref.)

DRUG EFFECTS

Role of NGF in axotomy-induced c-Jun expression in medial septal cholinergic neurons. Haas CA, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7–8):691–703 (103 ref.)

METABOLISM

Coping with stress in rats and mice: differential peptidergic modulation of the amygdala-lateral septum complex. Koolhaas JM, et al. **Prog Brain Res** 1998;119:437–48 (68 ref.)

SEPTICEMIA

see related
ENDOTOXEMIA

DIAGNOSIS

Polymerase chain reaction: a new chapter in critical care diagnosis [editorial; comment] Teba L. **Crit Care Med** 1999 May;27(5):860–1 (15 ref.) Comment on: Crit Care Med 1999 May;27(5):937–40.

[Systemic infection due to implanted leads of a cardiac pacemaker. Apropos of a case and review of the literature] Delpierre S, et al. **Ann Med Interne (Paris)** 1999 Apr; 150(3):265–8 (22 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of sepsis based on the host response] Matsumoto T. **Rinsho Byori** 1999 Jun;47(6):494–500 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Non-culture based laboratory diagnosis of sepsis] Obayashi T. **Rinsho Byori** 1999 Jun;47(6):487–93 (6 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Advances in the treatment of severe refractory diseases. 3) Septicemia] Funada H. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2250–6 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation. Romano V, et al. **Bone Marrow Transplant** 1999 Feb;23(3):271–5 (14 ref.)

ETIOLOGY

Impact of nosocomial infections on outcome: myths and evidence [editorial; comment] Rello J. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):392–4 (15 ref.) Comment on: Infect Control Hosp Epidemiol 1999 Jun;20(6):396–401.

[Infections in granulocytopenic patients] Funada H. **Rinsho Ketsueki** 1999 Mar;40(3):164–7 (9 ref.) **(Jpn)**

MICROBIOLOGY

Neonatal meningitis and septicaemia caused by Burkholderia pseudomallei. Halder D, et al. **Ann Trop Paediatr** 1998 Jun; 18(2):161–4 (9 ref.)

Polymerase chain reaction: a new chapter in critical care diagnosis [editorial; comment] Teba L. **Crit Care Med** 1999 May;27(5):860–1 (15 ref.) Comment on: Crit Care Med 1999 May;27(5):937–40.

Severe sepsis caused by Mobiluncus curtisii subsp. curtisii in a previously healthy female: case report and review. Hill DA, et al. **J Infect** 1998 Sep;37(2):194–6 (10 ref.)

PREVENTION & CONTROL

Role of antimicrobial central venous catheters for the prevention of associated infections. Elliott TS. **J Antimicrob Chemother** 1999 Apr;43(4):441–6 (63 ref.)

[Modification of the nutritional septicemic risk (RSN) by means of perioperative transfusion] Larrea J, et al. **Nutr Hosp** 1998 Sep–Oct;13(5):210–4 (35 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

[The critically ill septic surgical patient] Greenberg R, et al. **Harefuah** 1998 Sep;135(5–6):229–35 (54 ref.) **(Heb)**

[Systemic management of patients under anti-infection treatment] Konishi M, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2234–9 (7 ref.) **(Jpn)**

SEPTUM PELLUCIDUM

ANATOMY & HISTOLOGY

The septal region and memory. von Cramon DY, et al. **Adv Tech Stand Neurosurg** 1998;24:3–40 (162 ref.)

PHYSIOLOGY

Immunolesion of the cholinergic basal forebrain: effects on functional properties of hippocampal and septal neurons. Bassant MH, et al. **Int J Dev Neurosci** 1998 Nov-Dec; 16(7–8):613–32 (109 ref.)

RADIOGRAPHY

[Central neurocytoma: analysis of three cases and review of the literature] Katati MJ, et al. **Rev Neurol** 1999 Apr 1–15; 28(7):713–7 (38 ref.) (Eng. Abstr.) **(Spa)**

SEQUENCE ALIGNMENT

METHODS

Multiple sequence alignment: algorithms and applications. Gotoh O. **Adv Biophys** 1999;36:159–206 (189 ref.)

Hydropathy profile alignment: a tool to search for structural homologues of membrane proteins. Lolkema JS, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):305–22 (39 ref.)

The art of matchmaking: sequence alignment methods and their structural implications. Smith TF. **Structure Fold Des** 1999 Jan 15;7(1):R7–R12 (41 ref.)

SEQUENCE ANALYSIS

METHODS

Genomics and computational molecular biology. Brutlag DL. **Curr Opin Microbiol** 1998 Jun;1(3):340–5 (100 ref.)

Characterizing proteins from 2-DE gels by internal sequence analysis of peptide fragments. Strategies for microsample handling. Erdjument-Bromage H, et al. **Methods Mol Biol** 1999;112:467–72 (10 ref.)

Purification through affinity chromatography and microsequencing. Garlanda C. **Methods Mol Biol** 1999; 96:29–37 (12 ref.)

Peptide sequencing of 2-DE gel-isolated proteins by nanoelectrospray tandem mass spectrometry. Jensen ON, et al. **Methods Mol Biol** 1999;112:571–88 (34 ref.)

N-terminal amino acid sequencing of 2-DE spots. Kamo M, et al. **Methods Mol Biol** 1999;112:461–6 (5 ref.)

STATISTICS & NUMERICAL DATA

Distance measures in terms of substitution processes. Baake E, et al. **Theor Popul Biol** 1999 Apr;55(2):166–75 (31 ref.)

SEQUENCE ANALYSIS, DNA

Ribosomal DNA sequencing as a tool for identification of bacterial pathogens. Kolbert CP, et al. **Curr Opin Microbiol** 1999 Jun;2(3):299–305 (52 ref.)

Data mining parasite genomes: haystack searching with a computer. Lawson D. **Parasitology** 1999;118 Suppl:S15–8 (9 ref.)

Genome sequence of the nematode C. elegans: a platform for investigating biology. The C. elegans Sequencing Consortium [published errata appear in Science 1999 Jan

1;283(5398):35 and 1999 Mar 26;283(5410):2103] **Science** 1998 Dec 11;282(5396):2012–8 (55 ref.)
Arabidopsis thaliana: a model plant for genome analysis. Meinke DW, et al. **Science** 1998 Oct 23;282(5389):662, 679–82 (40 ref.)
[What we can learn from the whole genome sequences of thermophiles] Masui R, et al.
Tanpakushitsu Kakusan Koso 1999 Feb;44(2):165–70 (43 ref.) **(Jpn)**

INSTRUMENTATION

Capillary array electrophoresis DNA sequencing. Kheterpal I, et al. **Anal Chem** 1999 Jan 1;71(1):31A–37A (46 ref.)

METHODS

Clinical analyzers. Microbiology. Mouritsen CL, et al. **Anal Chem** 1999 Jun 15;71(12):366R–372R (79 ref.)
DNA microarray technology: the anticipated impact on the study of human disease. Khan J, et al.
Biochim Biophys Acta 1999 Mar 25;1423(2):M17–28 (20 ref.)
Accessing genomic information: alternatives to PCR. Isaksson A, et al. **Curr Opin Biotechnol** 1999 Feb;10(1):11–5 (33 ref.)
Microbial genome sequencing and pathogenesis. Tang CM, et al. **Curr Opin Microbiol** 1998 Feb;1(1):12–6 (45 ref.)
Differential sequencing with mass spectrometry. Graber JH, et al. **Genet Anal** 1999 Feb;14(5–6):215–9 (24 ref.)
Overview of nucleic acid analysis programs. Lu XJ, et al. **J Biomol Struct Dyn** 1999 Feb;16(4):833–43 (42 ref.)
High throughput analysis of differential gene expression. Carulli JP, et al. **J Cell Biochem Suppl** 1998;30–31:286–96 (33 ref.)
Sequencing microbial genomes--what will it do for microbiology? Jenks PJ. **J Med Microbiol** 1998 May; 47(5):375–82 (43 ref.)
Sequencing of antibodies. Jarrin A, et al.
Methods Mol Biol 1999;96:21–8 (5 ref.)
Characterization of mycoplasmas by PCR and sequence analysis with universal 16S rDNA primers. Johansson KE, et al. **Methods Mol Biol** 1998;104:145–65 (41 ref.)
Functional analysis of cell adhesion molecules. Simmons DL. **Methods Mol Biol** 1999;96:39–63 (25 ref.)
Optical mapping and its potential for large-scale sequencing projects. Aston C, et al. **Trends Biotechnol** 1999 Jul; 17(7):297–302 (26 ref.)
Electronic PCR: bridging the gap between genome mapping and genome sequencing. Schuler GD. **Trends Biotechnol** 1998 Nov;16(11):456–9 (16 ref.)

STANDARDS

Assessing the quality of the DNA sequence from the Human Genome Project. Felsenfeld A, et al. **Genome Res** 1999 Jan;9(1):1–4 (9 ref.)

TRENDS

Status of protozoan genome analysis: trypanosomatids. Blackwell JM, et al. **Parasitology** 1999;118 Suppl:S11–4 (25 ref.)
Helminth genome analysis: the current status of the filarial and schistosome genome projects. Filarial Genome Project. Schistosome Genome Project. Williams SA, et al.
Parasitology 1999;118 Suppl:S19–38 (80 ref.)

SEQUENCE DATA, MOLECULAR see **MOLECULAR SEQUENCE DATA**

SEQUENCE DELETION

A new twist: some patients with Saethre–Chotzen syndrome have a microdeletion syndrome [editorial; comment] Zackai EH, et al. **Am J Hum Genet** 1998 Nov;63(5):1277–81 (33 ref.) Comment on: Am J Hum Genet 1998 Nov;63(5):1282–93.
A novel in-frame deletion mutation in a case of lactate dehydrogenase (LD) H subunit deficiency showing an atypical LD isoenzyme pattern in serum and erythrocytes. Sudo K, et al. **Clin Biochem** 1999 Mar;32(2):137–41 (8 ref.)
5q(–)survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Pedersen B. **Leuk Lymphoma** 1998 Oct;31(3–4):325–34 (49 ref.)
Overview of QTL mapping software and introduction to map manager QT. Manly KF, et al. **Mamm Genome** 1999 Apr; 10(4):327–34 (53 ref.)

SEQUENCE DETERMINATION see **SEQUENCE ANALYSIS**

SEQUENCE DETERMINATION, DNA see **SEQUENCE ANALYSIS, DNA**

SEQUENCE HOMOLOGY

When is homology not homology? Wray GA, et al.
Curr Opin Genet Dev 1998 Dec;8(6):675–80 (47 ref.)

SEQUENCE HOMOLOGY DETERMINATION see **SEQUENCE ALIGNMENT**

SEQUENCE HOMOLOGY, NUCLEIC ACID

see related
SEQUENCE ALIGNMENT

Transvection and other homology effects. Wu CT, et al.
Curr Opin Genet Dev 1999 Apr;9(2):237–46 (123 ref.)
Allelic trans-sensing and imprinting. Páldi A, et al.
Results Probl Cell Differ 1999;25:271–82 (30 ref.)

SEQUENCE TAGGED SITES

Electronic PCR: bridging the gap between genome mapping and genome sequencing. Schuler GD. **Trends Biotechnol** 1998 Nov;16(11):456–9 (16 ref.)

SEQUENCING BY HYBRIDIZATION see **OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS**

SERGENTOMYIA see **PSYCHODIDAE**

SERIAL PASSAGE

Experimental evolution of parasites. Ebert D. **Science** 1998 Nov 20;282(5393):1432–5 (78 ref.)

SERIAL PUBLICATIONS

[Publications] Skjaerbaek CB. **Ugeskr Laeger** 1999 Aug 16; 161(33):4644–6 (0 ref.) **(Dan)**
[Don't forget the journals in the fight against research misconduct. Investigation of suspected misconduct should not be conducted by the universities themselves (see comments)] Zetterström R. **Lakartidningen** 1998 Oct 28; 95(44):4864–6 (7 ref.) Comment in: Lakartidningen 1998 Nov 18;95(47):5275. **(Swe)**

SERINE

DEFICIENCY

Continuing education in neurometabolic disorders--serine deficiency disorders. de Koning TJ, et al.
Neuropediatrics 1999 Feb;30(1):1–4 (14 ref.)

METABOLISM

The anaerobic degradation of L-serine and L-threonine in enterobacteria: networks of pathways and regulatory signals. Sawers G. **Arch Microbiol** 1998 Dec;171(1):1–5 (30 ref.)
Molecular basis for the stereoselective interactions of catecholamines with alpha-adrenoceptors. Hieble JP, et al. **Proc West Pharmacol Soc** 1998;41:225–8 (19 ref.)

SERINE PHOSPHOGLYCERIDES see **PHOSPHATIDYLSERINES**

SERINE PROTEASE INHIBITORS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEASES see **SERINE PROTEINASES**

SERINE PROTEINASE ANTAGONISTS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASE INHIBITORS

see related
SERPINS

Serpins and regulation of cell death. Bird PI.
Results Probl Cell Differ 1998;24:63–89 (130 ref.)

CHEMISTRY

Endoproteinase–protein inhibitor interactions. Bode W, et al. **APMIS** 1999 Jan;107(1):3–10 (40 ref.)
Serine proteinase inhibitors in arthropod immunity. Kanost MR. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):291–301 (74 ref.)

GENETICS

Tissue factor pathway inhibitor gene disruption. Broze GJ Jr. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S89–92 (18 ref.)

METABOLISM

Prolyl endopeptidase inhibitors derived from actinomycetes. Kimura K, et al. **Biosci Biotechnol Biochem** 1997 Oct; 61(10):1754–6 (1 ref.)

PHARMACOLOGY

Hepatitis C virus NS3/4A protease. Kwong AD, et al.
Antiviral Res 1999 Feb;41(1):67–84 (100 ref.)
Coupling of palmitate to ovalbumin inhibits the induction of oral tolerance. Oliveira FM, et al.
Braz J Med Biol Res 1998 Nov;31(11):1421–4 (20 ref.)
Inhibitors of bacterial signal peptidases. Black MT, et al.
Curr Pharm Des 1998 Apr;4(2):133–54 (80 ref.)
Succinimide and saccharin-based enzyme-activated inhibitors of serine proteases. Martyn DC, et al.
Curr Pharm Des 1999 Jun;5(6):405–15 (49 ref.)
Small, noncovalent serine protease inhibitors. Sanderson PE.
Med Res Rev 1999 Mar;19(2):179–97 (103 ref.)
[Role of proteinase inhibitors in the process that provide coupling between body's functional systems] Gurin VN, et al. **Vestn Ross Akad Med Nauk** 1999;(6):25–9 (25 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Chymase: its pathophysiological roles and inhibitors. Fukami H, et al. **Curr Pharm Des** 1998 Dec;4(6):439–53 (73 ref.)
Serine proteinase inhibitors in arthropod immunity. Kanost MR. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):291–301 (74 ref.)
[Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role] Rossi EB, et al.
Medicina (B Aires) 1999;59(1):95–104 (77 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Inhibitors of tryptase for the treatment of mast cell–mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381–96 (122 ref.)
An ataxia telangiectasia model: inefficient cell differentiation and possible reversal by serine protease inhibitors, tumor necrosis factor inhibitors, dexamethasone, and glutathione enhancers. Knittweis J. **Med Hypotheses** 1998 Jul; 51(1):53–7 (88 ref.)

SERINE PROTEINASE INHIBITORS, ENDOGENOUS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASE INHIBITORS, EXOGENOUS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASES

Hepatitis C virus NS3/4A protease. Kwong AD, et al.
Antiviral Res 1998 Dec;40(1–2):1–18 (98 ref.)
Structural features, physiological roles, and biotechnological applications of the membrane proteases of the OmpT bacterial endopeptidase family: a micro-review.
Stathopoulos C. **Membr Cell Biol** 1998;12(1):1–8 (43 ref.)

CHEMISTRY

Structural and energetic determinants of the S1-site specificity in serine proteases. Czapinska H, et al.
Eur J Biochem 1999 Mar;260(3):571–95 (162 ref.)
New insights into the ATP-dependent Clp protease: Escherichia coli and beyond. Porankiewicz J, et al.
Mol Microbiol 1999 May;32(3):449–58 (78 ref.)
Catalytic triads and their relatives. Dodson G, et al.
Trends Biochem Sci 1998 Sep;23(9):347–52 (41 ref.)

DRUG EFFECTS

Inhibitors of tryptase for the treatment of mast cell–mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381–96 (122 ref.)

GENETICS

The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. Ozelius LJ, et al. **Adv Neurol** 1998;78:93–105 (49 ref.)
Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Cupit LD, et al.
Trends Cardiovasc Med 1999 Jan–Feb;9(1–2):42–8 (39 ref.)

IMMUNOLOGY

The importance of serine proteinases as aeroallergens associated with asthma. Shen HD, et al.
Int Arch Allergy Immunol 1999 Aug;119(4):259–64 (40 ref.)

METABOLISM

Hepatitis C virus NS3/4A protease. Kwong AD, et al.
Antiviral Res 1999 Feb;41(1):67–84 (100 ref.)
Proteinase-activated receptors: a growing family of heptahelical receptors for thrombin, trypsin and tryptase. Déry O, et al. **Biochem Soc Trans** 1999 Feb;27(2):246–54 (50 ref.)
Prolyl endopeptidase inhibitors derived from actinomycetes. Kimura K, et al. **Biosci Biotechnol Biochem** 1997 Oct; 61(10):1754–6 (1 ref.)
Combinatorial strategies for the discovery of novel protease specificities. Lien S, et al.
Comb Chem High Throughput Screen 1999 Apr;2(2):73–90 (87 ref.)
Energetic dissection of specificity in serine proteases. Vindigni A. **Comb Chem High Throughput Screen** 1999 Jun; 2(3):139–53 (63 ref.)
Inhibitors of bacterial signal peptidases. Black MT, et al.
Curr Pharm Des 1998 Apr;4(2):133–54 (80 ref.)
Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Bird PI.
Immunol Cell Biol 1999 Feb;77(1):47–57 (96 ref.)
Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Frade R.

SERINE PROTEINASES

Immunopharmacology 1999 May;42(1-3):39-45 (37 ref.)
Protein secretion and possible roles for multiple signal peptidases for precursor processing in bacilli. Bron S, et al. **J Biotechnol** 1998 Sep 17;64(1):3-13 (21 ref.)
New insights into the ATP-dependent Clp protease: Escherichia coli and beyond. Porankiewicz J, et al. **Mol Microbiol** 1999 May;32(3):449-58 (78 ref.)
[Features of the functional organization of glutamylendopeptidase] Demidiuk IV, et al. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):100-5 (23 ref.) **(Rus)**

PHYSIOLOGY

Chymase: its pathophysiological roles and inhibitors. Fukami H, et al. **Curr Pharm Des** 1998 Dec;4(6):439-53 (73 ref.)
Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium [see comments] Hiemstra PS, et al. **Eur Respir J** 1998 Nov;12(5):1200-8 (103 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250-1.
MASP1 (MBL-associated serine protease 1). Matsushita M, et al. **Immunobiology** 1998 Aug;199(2):340-7 (26 ref.)
MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway. Vorup-Jensen T, et al. **Immunobiology** 1998 Aug;199(2):348-57 (36 ref.)
Perforin-dependent nuclear targeting of granzymes: A central role in the nuclear events of granule-exocytosis-mediated apoptosis? Blink EJ, et al. **Immunol Cell Biol** 1999 Jun;77(3):206-15 (101 ref.)
Plasticity-related serine proteases in the brain (review). Yoshida S, et al. **Int J Mol Med** 1999 Apr;3(4):405-9 (55 ref.)
Proteolytic processing in the secretory pathway. Zhou A, et al. **J Biol Chem** 1999 Jul 23;274(30):20745-8 (111 ref.)
[Granzyme B: an essential protease for the inflammatory response] Berthou C, et al. **Pathol Biol (Paris)** 1998 Oct; 46(8):617-24 (35 ref.) (Eng. Abstr.) **(Fre)**
[Role of angiotensin II-forming enzymes, angiotensin-converting enzyme and chymase] Takai S, et al. **Nippon Rinsho** 1999 May;57(5):1078-83 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Angiotensin II formation by chymase in the cardiovascular tissue] Okunishi H. **Nippon Yakurigaku Zasshi** 1998 Sep; 112(3):203-12 (50 ref.) (Eng. Abstr.) **(Jpn)**

SERINE SULFHYDRASE see **CYSTATHIONINE BETA-SYNTHASE**

SERINE-THREONINE PROTEIN KINASES see **PROTEIN-SERINE-THREONINE KINASES**

SERINE-TRNA LIGASE

METABOLISM

tRNA recognition and evolution of determinants in seryl-tRNA synthesis. Lenhard B, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):721-9 (96 ref.)

SERODIAGNOSIS see **SEROLOGIC TESTS**

SEROLOGIC TESTS

Assays to predict the clinical significance of blood group antibodies. Zupańska B. **Curr Opin Hematol** 1998 Nov; 5(6):412-6 (43 ref.)
Serodiagnosis of histoplasmosis, paracoccidioidomycosis and penicilliosis marneffei; current status and future trends. Hamilton AJ. **Med Mycol** 1998 Dec;36(6):351-64 (148 ref.)
Evaluation of serological platelet antibody assays. Kaplan C. **Vox Sang** 1998;74 Suppl 2:355-8 (28 ref.)
[Common antigenicity of lipopolysaccharides between Rickettsiae and Proteus in the Weil-Felix test] Amano K. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):599-610 (43 ref.) **(Jpn)**

METHODS

Microbiological and serological diagnostic tests for Helicobacter pylori: an overview. Glupczynski Y. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):321-6 (44 ref.)
The serodiagnosis of infections caused by Verocytotoxin-producing Escherichia coli. Chart H, et al. **J Appl Microbiol** 1999 May;86(5):731-40 (90 ref.)
[Diagnosis of mycobacterial disease by biochemical and immunological parameters] Yoshikawa M, et al. **Nippon Rinsho** 1998 Dec;56(12):3057-61 (21 ref.) (Eng. Abstr.) **(Jpn)**

SEROTHERAPY see **IMMUNIZATION, PASSIVE**

SEROTONIN

see related
RECEPTORS, SEROTONIN
SEROTONIN AGENTS

ANALOGS & DERIVATIVES

[The concept of the clinical use of serotonin adipinate in treating surgical patients] Fedorov VD, et al. **Vestn Khir Im I I Grek** 1998;157(3):15-9 (24 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

GABA and serotonin immunoreactivity during postembryonic brain development in the beetle Tenebrio molitor. Wegerhoff R. **Microsc Res Tech** 1999 May 1; 45(3):154-64 (55 ref.)

BIOSYNTHESIS

Extrapineal melatonin and exogenous serotonin in seasonal affective disorder. Partonen T. **Med Hypotheses** 1998 Nov; 51(5):441-2 (5 ref.)
NAMS/Solvay Resident Essay Award. Relationship between estrogen, serotonin, and depression. Archer JS. **Menopause** 1999 Spring;6(1):71-8 (49 ref.)

BLOOD

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Blakely RD, et al. **Biol Psychiatry** 1998 Aug 1;44(3):169-78 (65 ref.)

CEREBROSPINAL FLUID

Central nervous system serotonin and personality as variables contributing to excessive alcohol consumption in non-human primates. Higley JD, et al. **Alcohol Alcohol** 1999 May-Jun;34(3):402-18 (152 ref.)
The serotonin transporter and depression. Owens MJ, et al. **Depress Anxiety** 1998;8 Suppl 1:5-12 (68 ref.)

CHEMISTRY

[Serotonin--structure, activity and clinical significance] Zdrojewicz Z, et al. **Postepy Hig Med Dosw** 1998; 52(6):637-54 (76 ref.) (Eng. Abstr.) **(Pol)**

DEFICIENCY

[Male depression--stress reaction combined with serotonin deficiency? (see comments)] Rutz W, et al. **Lakartidningen** 1999 Mar 10;96(10):1177-8 (14 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Jun 9;96(23):2836. **(Swe)**

GENETICS

Specification of dopaminergic and serotonergic neurons in the vertebrate CNS. Hynes M, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):26-36 (85 ref.)

METABOLISM

Serotonin transporter function in vivo: assessment by chronoamperometry. Frazer A, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:217-29 (48 ref.)
Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Lesch KP, et al. **Biol Psychiatry** 1998 Aug 1;44(3):179-92 (75 ref.)
Serotonin, I(f) and human atrial arrhythmia [editorial; comment] Workman AJ, et al. **Cardiovasc Res** 1998 Dec; 40(3):436-7 (12 ref.) Comment on: Cardiovasc Res 1998 Dec;40(3):516-22.
The serotonin transporter and depression. Owens MJ, et al. **Depress Anxiety** 1998;8 Suppl 1:5-12 (68 ref.)
Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Olivier B, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S9-14 (27 ref.)
Thin-layer chromatographic determination of catecholamines, 5-hydroxytryptamine, and their metabolites in biological samples: a review. Alemany G, et al. **J AOAC Int** 1999 Jan-Feb;82(1):17-24 (44 ref.)
Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. Bonhomme N, et al. **J Clin Psychopharmacol** 1998 Dec; 18(6):447-54 (103 ref.)
Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? MacLean MR. **J Lab Clin Med** 1999 Aug;134(2):105-14 (133 ref.)
Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. Carlsson ML. **J Neural Transm** 1998; 105(4-5):525-35 (72 ref.)
Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis. Barkhudaryan N, et al. **Neurochem Res** 1999 Sep;24(9):1169-80 (183 ref.)
Autoregulation of serotonin neurons: role in antidepressant drug action. Piñeyro G, et al. **Pharmacol Rev** 1999 Sep; 51(3):533-91 (787 ref.)
5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Roth BL, et al. **Pharmacol Ther** 1998 Sep;79(3):231-57 (258 ref.)
Serotonin in migraine: theories, animal models and emerging therapies. Johnson KW, et al. **Prog Drug Res** 1998; 51:219-44 (123 ref.)

PHARMACOLOGY

[Serotonin both stimulates and inhibits sexual behavior of rats. New possibilities to understand the effects and side-effects of serotonergic drugs] Larsson K, et al. **Lakartidningen** 1999 Jun 9;96(23):2854-6 (22 ref.) **(Swe)**

PHYSIOLOGY

Anxiety and increased aggression as pacemakers of depression. van Praag HM. **Acta Psychiatr Scand Suppl** 1998;393:81-8 (57 ref.)
Dopamine, serotonin, and schizophrenia. van Veelen NM, et al. **Adv Neurol** 1999;80:425-9 (51 ref.)
The role of serotonin in craving: from basic research to human studies. Ciccocioppo R. **Alcohol Alcohol** 1999 Mar-Apr;34(2):244-53 (105 ref.)
Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Gershon MD. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:15-30 (117 ref.)
Serotonin and the regulation of mammalian circadian rhythmicity. Morin LP. **Ann Med** 1999 Feb;31(1):12-33 (172 ref.)
Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Blier P, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:204-16 (51 ref.)
Mouse 5-HT2B receptor-mediated serotonin trophic functions. Choi DS, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:67-73 (20 ref.)
Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Fuxe K, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:274-90 (38 ref.)
Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Hökfelt T, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:252-63 (48 ref.)
Modulation of acetylcholine and serotonin transmission by galanin. Relationship to spatial and aversive learning. Ogren SO, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:342-63 (77 ref.)
Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Blier P, et al. **Biol Psychiatry** 1998 Sep 1; 44(5):313-23 (61 ref.)
Serotonin and neuropeptides in affiliative behaviors. Insel TR, et al. **Biol Psychiatry** 1998 Aug 1;44(3):207-19 (45 ref.)
Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Joffe H, et al. **Biol Psychiatry** 1998 Nov 1;44(9):798-811 (125 ref.)
Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Kaye W, et al. **Biol Psychiatry** 1998 Nov 1;44(9):825-38 (152 ref.)
Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Leibowitz SF, et al. **Biol Psychiatry** 1998 Nov 1;44(9):851-64 (166 ref.)
Serotonergic basis of antipsychotic drug effects in schizophrenia. Lieberman JA, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1099-117 (213 ref.)
The spectrum of behaviors influenced by serotonin. Lucki I. **Biol Psychiatry** 1998 Aug 1;44(3):151-62 (115 ref.)
The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Marek GJ, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1118-27 (85 ref.)
Development of serotonergic neurons and their projections. Rubenstein JL. **Biol Psychiatry** 1998 Aug 1;44(3):145-50 (40 ref.)
Estrogen-serotonin interactions: implications for affective regulation. Rubinow DR, et al. **Biol Psychiatry** 1998 Nov 1;44(9):839-50 (137 ref.)
Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Staley JK, et al. **Biol Psychiatry** 1998 Oct 1; 44(7):534-49 (148 ref.)
Serotonin and panic. Bell CJ, et al. **Br J Psychiatry** 1998 Jun;172:465-71 (42 ref.)
Role of serotonin in obsessive-compulsive disorder. Baumgarten HG, et al. **Br J Psychiatry Suppl** 1998; (35):13-20 (73 ref.)
Role of serotonin in the immune system and in neuroimmune interactions. Mössner R, et al. **Brain Behav Immun** 1998 Dec;12(4):249-71 (135 ref.)
The study of genetic polymorphisms related to serotonin in Alzheimer's disease: a new perspective in a heterogenic disorder. Oliveira JR, et al. **Braz J Med Biol Res** 1999 Apr;32(4):463-7 (40 ref.)
The role of serotonin in panic, anxiety and depression. Deakin JF. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S1-5 (19 ref.)
Physiology to functionality: the brain and neurotransmitter activity. Racagni G, et al. **Int Clin Psychopharmacol** 1999 May;14 Suppl 1:S3-7 (22 ref.)
Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul;95(1-2):133-40 (58 ref.)
Monoamine dysfunction and the pathophysiology and treatment of depression. Charney DS. **J Clin Psychiatry** 1998;59 Suppl 14:11-4 (22 ref.)
The neurobiology of suicide risk: a review for the clinician. Mann JJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:7-11; discussion 18-20, 113-6 (50 ref.)
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy DL, et al.

J Clin Psychiatry 1998;59 Suppl 15:4–12 (118 ref.)
Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Schatzberg AF. **J Clin Psychiatry** 1998;59 Suppl 14:15–8 (32 ref.)
The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic disturbances. Grubb BP, et al. **J Interv Card Electrophysiol** 1998 Dec;2(4):325–32 (75 ref.)
Developmental pharmacodynamics: implications for child and adolescent psychopharmacology. Carrey N, et al. **J Psychiatry Neurosci** 1998 Nov;23(5):274–6 (16 ref.)
Hallucinogens, serotonin and obsessive–compulsive disorder. Delgado PL, et al. **J Psychoactive Drugs** 1998 Oct–Dec; 30(4):359–66 (63 ref.)
Vitamin D and serotonin in winter. Partonen T. **Med Hypotheses** 1998 Sep;51(3):267–8 (4 ref.)
Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system. Yew DT, et al. **Microsc Res Tech** 1999 Jun 15;45(6):389–400 (123 ref.)
Ovarian steroids and serotonin neural function. Bethea CL, et al. **Mol Neurobiol** 1998 Oct;18(2):87–123 (269 ref.)
Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Schmitz D, et al. **Mol Neurobiol** 1998 Winter;17(1–3):59–72 (85 ref.)
Structural basis of the cholinergic and serotonergic modulation of GABAergic neurons in the hippocampus. Gulyás AI, et al. **Neurochem Int** 1999 May;34(5):359–72 (102 ref.)
Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Reader TA, et al. **Neurochem Int** 1999 Jan;34(1):1–21 (242 ref.)
Serotonin and hallucinogens. Aghajanian GK, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):16S–23S (49 ref.)
Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Azmitia EC. **Neuropsychopharmacology** 1999 Aug; 21(2 Suppl):33S–45S (137 ref.)
Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Backstrom JR, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):77S–81S (25 ref.)
Serotonin and drug-induced therapeutic responses in major depression, obsessive–compulsive and panic disorders. Blier P, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):91S–98S (58 ref.)
Serotonin and stress. Chaouloff F, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):28S–32S (37 ref.)
Serotonin and hippocampal neurogenesis. Gould E. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):46S–51S (64 ref.)
Activity of serotonergic neurons in behaving animals. Jacobs BL, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):9S–15S (26 ref.)
Sleep and serotonin: an unfinished story. Jouvet M. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):24S–27S (21 ref.)
Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Mann JJ. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):99S–105S (65 ref.)
The role of serotonin in antipsychotic drug action. Meltzer HY. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):106S–115S (82 ref.)
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Millan MJ, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):61S–67S (37 ref.)
Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Zhuang X, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):52S–60S (67 ref.)
Serotonin receptor knockouts: a moody subject [comment] Julius D. **Proc Natl Acad Sci U S A** 1998 Dec 22; 95(26):15153–4 (17 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14476–81. Comment on: Proc Natl Acad Sci U S A 1998 Dec 8;95(25):15049–54.
Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Hayreh SS. **Prog Retin Eye Res** 1999 Mar;18(2):191–221 (168 ref.)
Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Meneses A. **Rev Neurosci** 1998;9(4):275–89 (89 ref.)
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Egermayer P, et al. **Thorax** 1999 Feb;54(2):161–8 (186 ref.)
Paracrine neurotransmission in the CNS: involvement of 5-HT. Bunin MA, et al. **Trends Neurosci** 1999 Sep; 22(9):377–82 (50 ref.)
[5HT-moduline an new peptide specifically interactive with the serotonergic system: physiopathologic implications] Fillion G. **Ann Pharm Fr** 1998;56(4):145–7 (7 ref.) (Eng. Abstr.) **(Fre)**
[Heredity and role of serotonin in aggressive impulsive behavior] Staner L, et al. **Encephale** 1998 Jul–Aug; 24(4):355–64 (90 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of depression and sleep disorders. Significance of serotonin and L-tryptophan in pathophysiology and therapy] Riemann D, et al. **Fortschr Med** 1998 Nov 20; 116(32):40–2 (25 ref.) (Eng. Abstr.) **(Ger)**
[The impact of the central serotonin system on alcoholism and therapeutic consequences] Peter H, et al. **Fortschr Neurol Psychiatr** 1998 Oct;66(10):459–65 (50 ref.) (Eng. Abstr.) **(Ger)**
[Impulse control disorders and other serotonin function disorders] Pöldinger W. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1348–55 (33 ref.) (Eng. Abstr.) **(Ger)**
[Serotonin--structure, activity and clinical significance] Zdrojewicz Z, et al. **Postepy Hig Med Dosw** 1998; 52(6):637–54 (76 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol Suppl** 1996 Mar;1:27–32 (51 ref.)

SEROTONIN ACETYLTRANSFERASE see **ARYLAMINE N-ACETYLTRANSFERASE**

SEROTONIN AGENTS

PHARMACOKINETICS

5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Roth BL, et al. **Pharmacol Ther** 1998 Sep;79(3):231–57 (258 ref.)

PHARMACOLOGY

Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy DL, et al. **J Clin Psychiatry** 1998;59 Suppl 15:4–12 (118 ref.)

THERAPEUTIC USE

Methysergide. Silberstein SD. **Cephalalgia** 1998 Sep; 18(7):421–35 (152 ref.)

SEROTONIN AGONISTS

ADMINISTRATION & DOSAGE

[New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses] Dahlöf CG. **Lakartidningen** 1998 Nov 11;95(46):5175, 5178–82, 5184–6 (60 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? Dahlöf CG, et al. **Cephalalgia** 1998 Oct; 18(8):539–45 (73 ref.)
[Safety profile of 311C90 (zolmitriptan)] Morales Asín F. **Neurologia** 1998 Oct;13 Suppl 2:25–30 (13 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Berg KA, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:104–10 (13 ref.)
Electro-oscillographic correlation between dorsal raphe nucleus, neocortex and hippocampus during wakefulness before and after serotoninergic inactivation. Fonoff ET, et al. **Braz J Med Biol Res** 1999 Apr;32(4):469–72 (14 ref.)
Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Backstrom JR, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):77S–81S (25 ref.)
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Millan MJ, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):61S–67S (37 ref.)
Testosterone and its metabolites modulate 5HT1A and 5HT1B agonist effects on intermale aggression. Simon NG, et al. **Neurosci Biobehav Rev** 1998;23(2):325–36 (104 ref.)
Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system. Kostrzewa RM, et al. **Pol J Pharmacol** 1999 Jan–Feb;51(1):39–47 (84 ref.)
The 5-HT1A receptor and its ligands: structure and function. Olivier B, et al. **Prog Drug Res** 1999;52:103–65 (285 ref.)
[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stępień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341–3 (28 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D, et al. **Acta Neurol Belg** 1999 Jun;99(2):85–95 (89 ref.)
Naratriptan: an alternative for migraine. Dulli DA. **Ann Pharmacother** 1999 Jun;33(6):704–11 (39 ref.)
An important drug interaction. Williams CN. **Can J Gastroenterol** 1998 Nov–Dec;12(8):535 (9 ref.)
Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Salonen R, et al. **Cephalalgia** 1999 Jan;19(1):16–9 (16 ref.)
Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen P. **Cephalalgia** 1998 Oct;18(8):532–8 (56 ref.)
Present and future of 5-HT receptor agonists as antimigraine drugs. Pauwels PJ, et al. **Clin Neuropharmacol** 1999 May–Jun;22(3):123–36 (137 ref.)
Current concepts of migraine and its treatment. Dahlöf CG. **Neurologia** 1999 Feb;14(2):67–77 (72 ref.)
A review of central 5-HT receptors and their function. Barnes NM, et al. **Neuropharmacology** 1999 Aug; 38(8):1083–152 (650 ref.)
Serotonin in migraine: theories, animal models and emerging therapies. Johnson KW, et al. **Prog Drug Res** 1998; 51:219–44 (123 ref.)
Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Meneses A. **Rev Neurosci** 1998;9(4):275–89 (89 ref.)
[Anti-migraine treatment: present and future] Schoenen J. **Rev Med Liege** 1999 Feb;54(2):79–86 (52 ref.) (Eng. Abstr.) **(Fre)**
[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stępień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341–3 (28 ref.) (Eng. Abstr.) **(Pol)**
[Clinical efficacy of zolmitriptan in migraine] Leira R, et al. **Neurologia** 1998 Oct;13 Suppl 2:16–24 (20 ref.) (Eng. Abstr.) **(Spa)**
[Mechanism of action of zolmitriptan] Pascual J. **Neurologia** 1998 Oct;13 Suppl 2:9–15 (49 ref.) (Eng. Abstr.) **(Spa)**

SEROTONIN ANTAGONISTS

see related
SEROTONIN UPTAKE INHIBITORS

ADMINISTRATION & DOSAGE

About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. Lehoczky O. **Neoplasma** 1999;46(2):73–9 (50 ref.)

ADVERSE EFFECTS

Adverse reactions to antinauseants in common use in the UK. Soukop M. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep; 17(2–3):91–113 (57 ref.)

PHARMACOLOGY

Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle. Audolfsson G, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:39–47 (16 ref.)
Review article: evaluation of drugs in experimental gut distension models. Pappas TN, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:54–6 (20 ref.)
Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. De Vries P, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):61–74 (176 ref.)
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington G, et al. **J Clin Psychiatry** 1999;60 Suppl 10:15–9 (50 ref.)
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Millan MJ, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):61S–67S (37 ref.)
Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants? Puzantian T, et al. **Pharmacotherapy** 1999 Feb;19(2):205–12 (12 ref.)
The 5-HT1A receptor and its ligands: structure and function. Olivier B, et al. **Prog Drug Res** 1999;52:103–65 (285 ref.)

THERAPEUTIC USE

Review article: clinical pharmacology of alosetron. Gunput MD. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:70–6 (25 ref.)
Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Humphrey PP, et al. **Aliment Pharmacol Ther** 1999 May; 13 Suppl 2:31–8 (70 ref.)
Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Mangel AW, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:77–82 (14 ref.)
Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). **Ann Oncol** 1998 Aug;9(8):811–9 (103 ref.)
Pindolol augmentation of antidepressant therapy [published erratum appears in Br J Psychiatry 1998 Nov;173:443] [see comments] McAskill R, et al. **Br J Psychiatry** 1998 Sep;

SEROTONIN ANTAGONISTS

173:203–8 (19 ref.) Comment in: Br J Psychiatry 1998 Dec;173:536–7.
Antidepressant treatment of the depressed patient with insomnia. Thase ME. **J Clin Psychiatry** 1999;60 Suppl 17:28–31; discussion 46–8 (8 ref.)
Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Passani MB, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):725–33 (96 ref.)
A review of central 5-HT receptors and their function. Barnes NM, et al. **Neuropharmacology** 1999 Aug; 38(8):1083–152 (650 ref.)
Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Meneses A. **Rev Neurosci** 1998;9(4):275–89 (89 ref.)

SEROTONIN BLOCKADERS see **SEROTONIN ANTAGONISTS**

SEROTONIN RECEPTOR AGONISTS see **SEROTONIN AGONISTS**

SEROTONIN RECEPTORS see **RECEPTORS, SEROTONIN**

SEROTONIN REUPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

SEROTONIN SYNDROME

see related
MONOAMINE OXIDASE INHIBITORS
SEROTONIN
SEROTONIN UPTAKE INHIBITORS

Serotonin syndrome: history and risk. Gillman PK. **Fundam Clin Pharmacol** 1998;12(5):482–91 (166 ref.)

DRUG THERAPY

SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. Lane RM. **J Psychopharmacol** 1998;12(2):192–214 (265 ref.)

ETIOLOGY

Treatment of obsessive-compulsive spectrum disorders with SSRIs. Hollander E. **Br J Psychiatry Suppl** 1998;(35):7–12 (50 ref.)

PHYSIOPATHOLOGY

The serotonin syndrome and its treatment. Gillman PK. **J Psychopharmacol** 1999;13(1):100–9 (140 ref.)

THERAPY

The serotonin syndrome and its treatment. Gillman PK. **J Psychopharmacol** 1999;13(1):100–9 (140 ref.)

SEROTONIN UPTAKE INHIBITORS

see related
ADRENERGIC UPTAKE INHIBITORS
ANTIDEPRESSIVE AGENTS, SECOND-GENERATION

Whole human brain autoradiography of serotonin re-uptake inhibitors. Qume M, et al. **Methods Mol Biol** 1999; 106:215–29 (13 ref.)
Citalopram in the treatment of depression and other potential uses in psychiatry. Tan JY, et al. **Pharmacotherapy** 1999 Jun;19(6):675–89 (76 ref.)
[Veterinary drug profile. Clomipramine (Clomicalm)] Pellicaan CH, et al. **Tijdschr Diergeneeskd** 1999 May 15; 124(10):313–5 (14 ref.) **(Dut)**
[Is drug advertising reliable?] Spigset O. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4637–41 (48 ref.) (Eng. Abstr.) **(Nor)**

ADMINISTRATION & DOSAGE

[Indications for the use of serotonin uptake inhibitors in children and adolescents] Thomsen H. **Ugeskr Laeger** 1998 Dec 7;160(50):7285–90 (30 ref.) **(Dan)**
[Is there a relationship between clinical efficacy and antidepressant dosage in major depression?] Corruble E, et al. **Encephale** 1999 Jun;25 Spec No 2:39–43; discussion 44–6 (9 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Management of SSRI-induced sexual dysfunction. Woodrum ST, et al. **Ann Pharmacother** 1998 Nov;32(11):1209–15 (49 ref.)
Are there special considerations in the prescription of serotonin reuptake inhibitors for women? Stewart DE. **Can J Psychiatry** 1998 Nov;43(9):900–4 (28 ref.)
Differences in interactions of SSRIs. Brøsen K. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S45–7 (3 ref.)
Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients. Montgomery SA. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S49–54 (40 ref.)
Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Naranjo CA, et al. **Int Clin Psychopharmacol** 1999 May;14 Suppl 2:S35–47 (120 ref.)
Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Olivier B, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S9–14 (27 ref.)
Selective serotonin reuptake inhibitor-induced sexual dysfunction: clinical and research considerations. Waldinger MD, et al. **Int Clin Psychopharmacol** 1998 Jul; 13 Suppl 6:S27–33 (50 ref.)
The serotonin syndrome and its treatment. Gillman PK. **J Psychopharmacol** 1999;13(1):100–9 (140 ref.)
Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. Goldstein BJ, et al. **J Psychopharmacol** 1998;12(3 Suppl B):S55–87 (370 ref.)
Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. Kirchner V, et al. **J Psychopharmacol** 1998;12(4):396–400 (52 ref.)
SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. Lane RM. **J Psychopharmacol** 1998;12(2):192–214 (265 ref.)
Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. Shen WW, et al. **J Reprod Med** 1999 Jun;44(6):535–42 (61 ref.)
A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. Alcántara AG. **J Sex Marital Ther** 1999 Apr-Jun;25(2):125–9 (34 ref.)
Selective serotonin reuptake inhibitors (SSRIs) and falls in the elderly depressed patient. Mort JR. **S D J Med** 1999 Jun;52(6):201–2 (5 ref.)
[Clinical and toxicologic aspects of the use of Ecstasy (see comments)] Pennings EJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1942–6 (36 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 17;142(42):2321–2. **(Dut)**
[The inappropriate antidiuretic hormone secretion syndrome and citalopram (letter)] Berrocal E, et al. **Med Clin (Barc)** 1999 Jan 23;112(2):78 (9 ref.) **(Spa)**
[Neuroleptic malignant syndrome associated with olanzapine (letter)] García López MM, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (8 ref.) **(Spa)**

CHEMISTRY

New approaches to rapid onset antidepressants [published erratum appears in Curr Pharm Des 1999 Feb;5(2):139] Briner K, et al. **Curr Pharm Des** 1998 Aug;4(4):291–302 (144 ref.)

METABOLISM

Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. DeVane CL. **Cell Mol Neurobiol** 1999 Aug;19(4):443–66 (120 ref.)
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Ingelman-Sundberg M, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):342–9 (79 ref.)

PHARMACOKINETICS

Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Baumann P. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S35–43 (58 ref.)
Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Naranjo CA, et al. **Int Clin Psychopharmacol** 1999 May;14 Suppl 2:S35–47 (120 ref.)

PHARMACOLOGY

Serotonin transporter function in vivo: assessment by chronoamperometry. Frazer A, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:217–29 (48 ref.)
Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Guidotti A, et al. **Biol Psychiatry** 1998 Nov 1;44(9):865–73 (42 ref.)
Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Pacher P, et al. **Curr Med Chem** 1999 Jun;6(6):469–80 (202 ref.)
Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Pacher P, et al. **Curr Med Chem** 1998 Oct; 5(5):381–90 (125 ref.)
Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. Stahl SM. **J Affect Disord** 1998 Dec;51(3):215–35 (131 ref.)
Cardiovascular effects of antidepressant drugs: updated. Glassman AH. **J Clin Psychiatry** 1998;59 Suppl 15:13–8 (33 ref.)
Effects of SSRIs on sexual function: a critical review. Rosen RC, et al. **J Clin Psychopharmacol** 1999 Feb;19(1):67–85 (255 ref.)
Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology. Goodnick PJ, et al. **J Psychopharmacol** 1998;12(3 Suppl B):S5–20 (228 ref.)
Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. Preskorn SH. **J Psychopharmacol** 1998;12(3 Suppl B):S89–97 (59 ref.)
Selective serotonin reuptake inhibitors and neuroendocrine function. Raap DK, et al. **Life Sci** 1999;65(12):1217–35 (228 ref.)
Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants? Puzantian T, et al. **Pharmacotherapy** 1999 Feb;19(2):205–12 (12 ref.)
[Psychopharmacological profile of venlafaxine] Bourin M. **Encephale** 1999 Jun;25 Spec No 2:21–2; discussion 23–5 (7 ref.) (Eng. Abstr.) **(Fre)**
[Differential features of SSRIs] Cervera S. **Rev Med Univ Navarra** 1997 Oct-Dec;41(4):245–57 (95 ref.) (Eng. Abstr.) **(Spa)**

POISONING

SSRI safety in overdose. Barbey JT, et al. **J Clin Psychiatry** 1998;59 Suppl 15:42–8 (36 ref.)

THERAPEUTIC USE

Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Lejoyeux M. **Alcohol Alcohol Suppl** 1996 Mar;1:69–75 (38 ref.)
Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors [editorial] Nair GV, et al. **Am J Cardiol** 1999 Aug 1;84(3):321–3, A8 (30 ref.)
Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Kaye W, et al. **Biol Psychiatry** 1998 Nov 1;44(9):825–38 (152 ref.)
Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Kent JM, et al. **Biol Psychiatry** 1998 Nov 1;44(9):812–24 (115 ref.)
Child and adolescent mood disorders--experience with serotonin-based therapies. Ryan ND, et al. **Biol Psychiatry** 1998 Sep 1;44(5):336–40 (46 ref.)
Serotonin and panic. Bell CJ, et al. **Br J Psychiatry** 1998 Jun;172:465–71 (42 ref.)
Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Delgado PL, et al. **Br J Psychiatry Suppl** 1998;(35):21–5 (30 ref.)
Pharmacotherapy for obsessive-compulsive disorder. Greist JH, et al. **Br J Psychiatry Suppl** 1998;(35):64–70 (92 ref.)
Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Grados M, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jul;8(3):617–34, x (131 ref.)
The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Romano S, et al. **Clin Ther** 1999 Apr; 21(4):615–33; discussion 613 (67 ref.)
SSRIs in the treatment of obsessive-compulsive disorder. Cartwright C, et al. **Depress Anxiety** 1998;8 Suppl 1:105–13 (69 ref.)
Treatment of dysthymic disorder. Dunner DL. **Depress Anxiety** 1998;8 Suppl 1:54–8 (39 ref.)
SSRIs in the treatment of panic disorder. Goddard AW, et al. **Depress Anxiety** 1998;8 Suppl 1:114–20 (54 ref.)
Treatment of geriatric depression. Small GW. **Depress Anxiety** 1998;8 Suppl 1:32–42 (102 ref.)
Ten years of fluoxetine. Stokes PE. **Depress Anxiety** 1998; 8 Suppl 1:1–4 (11 ref.)
Depression: treating the patient with comorbid cardiac disease. Roose SP, et al. **Geriatrics** 1999 Feb;54(2):20–1, 25–6, 29–31 passim (30 ref.)
Fluoxetine: therapeutic and undesirable effects. Cookson J, et al. **Hosp Med** 1998 Aug;59(8):622–6 (27 ref.)
Comorbidity of panic and depression: implications for clinical management. Ballenger JC. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S13–7 (31 ref.)
The issue of comorbidity in the treatment of panic. Dunner DL. **Int Clin Psychopharmacol** 1998 Apr;13 Suppl 4:S19–24 (40 ref.)
Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Eriksson E. **Int Clin Psychopharmacol** 1999 May;14 Suppl 2:S27–33 (36 ref.)
Predicting response: serotonin reuptake inhibition. Mendlewicz J. **Int Clin Psychopharmacol** 1999 May;14 Suppl 1:S17–20 (40 ref.)
Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients. Montgomery SA. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S49–54 (40 ref.)
Beyond depression: citalopram for obsessive-compulsive disorder. Pato MT. **Int Clin Psychopharmacol** 1999 May; 14 Suppl 2:S19–26 (45 ref.)
The clinical relevance of treating social phobia. Lader M. **J Affect Disord** 1998 Sep;50 Suppl 1:S29–34 (30 ref.)
Pharmacotherapy of social anxiety disorder. Davidson JR. **J Clin Psychiatry** 1998;59 Suppl 17:47–53 (27 ref.)
Obsessive-compulsive disorder: diagnosis and treatment. Goodman WK. **J Clin Psychiatry** 1999;60 Suppl 18:27–32 (67 ref.)
SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. Gorman JM, et al. **J Clin Psychiatry** 1999;60 Suppl 4:33–8; discussion 39 (35 ref.)
Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Hirschfeld RM. **J Clin Psychiatry** 1999 May;60(5):326–35 (58 ref.)
Managing aggressive behavior in patients with

obsessive-compulsive disorder and borderline personality disorder. Hollander E. **J Clin Psychiatry** 1999;60 Suppl 15:38-44 (36 ref.)
Update on the diagnosis and treatment of social anxiety disorder. Liebowitz MR. **J Clin Psychiatry** 1999;60 Suppl 18:22-6 (34 ref.)
The use of selective serotonin reuptake inhibitors in eating disorders. Mayer LE, et al. **J Clin Psychiatry** 1998;59 Suppl 15:28-34 (44 ref.)
Treatment of antidepressant nonresponders: augmentation or switch? Nelson JC. **J Clin Psychiatry** 1998;59 Suppl 15:35-41 (83 ref.)
Care of depressed patients with anxiety symptoms. Nutt DJ. **J Clin Psychiatry** 1999;60 Suppl 17:23-7; discussion 46-8 (26 ref.)
A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott TA, et al. **J Clin Psychiatry** 1999 Feb;60(2):101-6 (50 ref.)
Current concepts in the treatment of panic disorder. Sheehan DV. **J Clin Psychiatry** 1999;60 Suppl 18:16-21 (43 ref.)
Mirtazapine versus selective serotonin reuptake inhibitors. Thompson C. **J Clin Psychiatry** 1999;60 Suppl 17:18-22; discussion 46-8 (8 ref.)
Antidepressants and posttraumatic stress disorder. Meek JK, et al. **J La State Med Soc** 1998 Oct;150(10):487-9 (16 ref.)
Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. Amsterdam JD.
J Psychopharmacol 1998;12(3 Suppl B):S99-111 (109 ref.)
Selective serotonin reuptake inhibitors in affective disorders--II. Efficacy and quality of life. Goodnick PJ, et al. **J Psychopharmacol** 1998;12(3 Suppl B):S21-54 (222 ref.)
The analgesic effects of selective serotonin reuptake inhibitors. Smith AJ. **J Psychopharmacol** 1998;12(4):407-13 (40 ref.)
Pharmacological treatment of paraphilias with a focus on antidepressants. Balon R. **J Sex Marital Ther** 1998 Oct-Dec;24(4):241-54 (62 ref.)
Selective serotonin reuptake inhibitors in pregnancy and lactation. Gupta S, et al. **Obstet Gynecol Surv** 1998 Dec; 53(12):733-6 (17 ref.)
Pharmacologic treatment for children and adolescents with anxiety disorders. Birmaher B, et al.
Pediatr Clin North Am 1998 Oct;45(5):1187-204 (102 ref.)
The new antidepressants. Selective serotonin reuptake inhibitors. Labellarte MJ, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1137-55, ix (61 ref.)
Newer antidepressants. Beyond selective serotonin reuptake inhibitor antidepressants. McConville BJ, et al.
Pediatr Clin North Am 1998 Oct;45(5):1157-71 (54 ref.)
Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Ellingrod VL.
Pharmacotherapy 1998 Sep-Oct;18(5):936-60 (98 ref.)
A depressed woman receiving long-term SSRI therapy. Haslam D, et al. **Practitioner** 1999 Jan;243(1594):9-12, 14 (0 ref.)
Antidepressant agents: from tricyclics to serotonin uptake inhibitors. Garattini S, et al. **Psychol Med** 1998 Sep; 28(5):1169-78 (98 ref.)
[Two new antidepressants: mirtazapine and venlafaxine] Birkenhäger TK, et al. **Ned Tijdschr Geneeskd** 1999 May 1;143(18):934-7 (26 ref.) (Eng. Abstr.) **(Dut)**
[The impact of the central serotonin system on alcoholism and therapeutic consequences] Peter H, et al.
Fortschr Neurol Psychiatr 1998 Oct;66(10):459-65 (50 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

[Clinical and toxicologic aspects of the use of Ecstasy (see comments)] Pennings EJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1942-6 (36 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 17;142(42):2321-2. **(Dut)**

SERPENTINE (MINERAL) see **ASBESTOS, SERPENTINE**

SERPENTINE ASBESTOS see **ASBESTOS, SERPENTINE**

SERPIN SUPERFAMILY see **SERPINS**

SERPINS

BLOOD

The clearance of thrombin-antithrombin and related serpin-enzyme complexes from the circulation: role of various hepatocyte receptors. Wells MJ, et al.
Thromb Haemost 1999 Mar;81(3):325-37 (179 ref.)

CHEMISTRY

Conformational changes and disease--serpins, prions and Alzheimer's. Carrell RW, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):799-809 (59 ref.)
Structure-function relationships in serpins: current concepts and controversies. Gils A, et al. **Thromb Haemost** 1998 Oct; 80(4):531-41 (161 ref.)

GENETICS

SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Silverman GA, et al.
Tumour Biol 1998;19(6):480-7 (23 ref.)

METABOLISM

Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Bird PI.
Immunol Cell Biol 1999 Feb;77(1):47-57 (96 ref.)

PHYSIOLOGY

Viral modulation of the host response via crmA/SPI-2 expression. Turner S, et al. **Immunol Cell Biol** 1999 Jun; 77(3):236-41 (88 ref.)
Serpins and regulation of cell death. Bird PI.
Results Probl Cell Differ 1998;24:63-89 (130 ref.)
Structure-function relationships in serpins: current concepts and controversies. Gils A, et al. **Thromb Haemost** 1998 Oct; 80(4):531-41 (161 ref.)
Biological role of SCC antigen. Suminami Y, et al.
Tumour Biol 1998;19(6):488-93 (42 ref.)

SERRATIA

PATHOGENICITY

Serratia odorifera biogroup I: an emerging pathogen. Cook MA, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):505-7 (9 ref.)

PHYSIOLOGY

Surface motility of serratia liquefaciens MG1. Eberl L, et al. **J Bacteriol** 1999 Mar;181(6):1703-12 (96 ref.)

SERRATIA INFECTIONS

[Serratia marcescens pneumonia] Nakamura J, et al.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):381-3 (9 ref.) **(Jpn)**

MICROBIOLOGY

Serratia odorifera biogroup I: an emerging pathogen. Cook MA, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):505-7 (9 ref.)

SERRATIA MARCESCENS

[Serratia marcescens pneumonia] Nakamura J, et al.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):381-3 (9 ref.) **(Jpn)**

GENETICS

Molecular genetics of carbapenem antibiotic biosynthesis. McGowan SJ, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1-2):135-41 (45 ref.)

METABOLISM

Molecular genetics of carbapenem antibiotic biosynthesis. McGowan SJ, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1-2):135-41 (45 ref.)

SERTOLI CELL TUMOR

PATHOLOGY

Sclerosing sertoli cell tumor of the testis--a case report and review of the literature. Gravas S, et al.
Scand J Urol Nephrol 1999 Jun;33(3):197-9 (8 ref.)

VETERINARY

Treatment of aggressive testicular tumors in four dogs. Dhaliwal RS, et al. **J Am Anim Hosp Assoc** 1999 Jul-Aug; 35(4):311-8 (43 ref.)

SERTOLI CELLS

CYTOLOGY

The central role of Sertoli cells in spermatogenesis [see comments] Griswold MD. **Semin Cell Dev Biol** 1998 Aug; 9(4):411-6 (41 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

PHYSIOLOGY

The central role of Sertoli cells in spermatogenesis [see comments] Griswold MD. **Semin Cell Dev Biol** 1998 Aug; 9(4):411-6 (41 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

TRANSPLANTATION

Sertoli cell transplants: their use in the treatment of neurodegenerative disease. Willing AE, et al.
Mol Med Today 1998 Nov;4(11):471-7 (45 ref.)

SERTRALINE

THERAPEUTIC USE

Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors [editorial] Nair GV, et al.
Am J Cardiol 1999 Aug 1;84(3):321-3, A8 (30 ref.)
Pharmacological treatment of paraphilias with a focus on antidepressants. Balon R. **J Sex Marital Ther** 1998 Oct-Dec;24(4):241-54 (62 ref.)

SERUM A RELATED PROTEIN see **AMYLOID PROTEIN SAA**

SERUM ALBUMIN

The development of recombinant human serum albumin. Kobayashi K, et al. **Ther Apher** 1998 Nov;2(4):257-62 (17 ref.)
[Alloalbuminemia] Maruyama Y, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):561-4 (17 ref.) **(Jpn)**

DEFICIENCY

Biological basis of hypoalbuminemia in ESRD. Kaysen GA.
J Am Soc Nephrol 1998 Dec;9(12):2368-76 (91 ref.)
Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients. Kim SB, et al.
Perit Dial Int 1999;19 Suppl 2:S144-9 (59 ref.)
[Congenital analbuminemia] Imaizumi M.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):557-60 (13 ref.) **(Jpn)**
[Acquired hypoalbuminemia] Kato H, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):565-8 (10 ref.) **(Jpn)**
[Friedreich's type of ataxia with hypoalbuminemia and hyperlipidemia (FHH)] Yuasa T.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):215-7 (8 ref.) **(Jpn)**

METABOLISM

[Albumin, transport of saturated fatty acids, and metabolic stress-syndrome (literature review)] Titov VN.
Klin Lab Diagn 1999 Apr;(4):3-11 (93 ref.) **(Rus)**

PHYSIOLOGY

Serum albumin: touchstone or totem? Margarson MP, et al.
Anaesthesia 1998 Aug;53(8):789-803 (108 ref.)
Molecular interactions between albumin and proximal tubular cells. Brunskill NJ. **Exp Nephrol** 1998 Nov-Dec;6(6):491-5 (23 ref.)

SERUM AMYLOID PROTEIN A see **AMYLOID PROTEIN SAA**

SERUM-FREE MEDIA see **CULTURE MEDIA, SERUM-FREE**

SERUM MARKERS see **BIOLOGICAL MARKERS**

SERUM PROTEINS see **BLOOD PROTEINS**

SERUM SICKNESS

CHEMICALLY INDUCED

Serum sickness in a paediatric emergency department: the role of cefaclor [letter] Parshuram CS, et al.
J Paediatr Child Health 1999 Apr;35(2):223-4 (6 ref.)

SERUM THYMIC FACTOR see **THYMIC FACTOR, CIRCULATING**

SERVICE, SOCIAL see **SOCIAL WORK**

SERYL T RNA SYNTHETASE see **SERINE-TRNA LIGASE**

SESAMOID BONES

Disorders of the hallux sesamoid complex: MR features. Karasick D, et al. **Skeletal Radiol** 1998 Aug;27(8):411-8 (30 ref.)

INJURIES

Hallucal sesamoid pain: causes and surgical treatment. Richardson EG. **J Am Acad Orthop Surg** 1999 Jul-Aug; 7(4):270-8 (18 ref.)

SESQUITERPENES

Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine. Patočka J.
Acta Medica (Hradec Kralove) 1998;41(4):155-7 (19 ref.)
Huperzine A (shuangyiping): a promising drug for Alzheimer's disease. Tang XC.
Chung Kuo Yao Li Hsueh Pao 1996 Nov;17(6):481-4 (41 ref.)

ADMINISTRATION & DOSAGE

Intrarectal artemisinin derivatives. Nosten F, et al.
Med Trop (Mars) 1998;58(3 Suppl):63-4 (10 ref.)

ADVERSE EFFECTS

Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Price R, et al.
Am J Trop Med Hyg 1999 Apr;60(4):547-55 (25 ref.)
Factors relating to neurotoxicity of artemisinin antimalarial drugs "listening to arteether". Brewer TG, et al.
Med Trop (Mars) 1998;58(3 Suppl):22-7 (20 ref.)
Neurotoxicity and artemisinin compounds do the

SESQUITERPENES

observations in animals justify limitation of clinical use? Dayan AD. **Med Trop (Mars)** 1998;58(3 Suppl):32–7 (9 ref.)
Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Ribeiro IR, et al. **Med Trop (Mars)** 1998;58(3 Suppl):50–3 (2 ref.)

CHEMICAL SYNTHESIS

Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials. Vroman JA, et al. **Curr Pharm Des** 1999 Feb;5(2):101–38 (133 ref.)

CHEMISTRY

How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Li Y, et al. **Med Trop (Mars)** 1998;58(3 Suppl):9–12 (26 ref.)
The rational use of qinghaosu and its derivatives: what is the future of new compounds? Looareesuwan S, et al. **Med Trop (Mars)** 1998;58(3 Suppl):89–92 (10 ref.)
Positioning, labelling, and medical information control of co-artemether tablets (CPG 56697): a fixed novel combination of artemether and benflumetol. Novartis Co-Artemether International Development Team. Skelton-Stroud P, et al. **Med Trop (Mars)** 1998;58(3 Suppl):77–81 (4 ref.)

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of qinghaosu derivatives: how do they impact on the choice of drug and the dosage regimens? Kyle DE, et al. **Med Trop (Mars)** 1998;58(3 Suppl):38–44 (32 ref.)
Artemisinin antimalarials: mechanisms of action and resistance. Meshnick SR. **Med Trop (Mars)** 1998;58(3 Suppl):13–7 (56 ref.)

THERAPEUTIC USE

Feverfew as a preventive treatment for migraine: a systematic review. Vogler BK, et al. **Cephalalgia** 1998 Dec; 18(10):704–8 (30 ref.)
Therapeutic potential of the anti-angiogenesis drug TNP-470. Gervaz P, et al. **Int J Exp Pathol** 1998 Dec; 79(6):359–62 (30 ref.)
The role of the qinghaosu derivatives in the treatment of severe malaria. Boele van Hensbroek M. **Med Trop (Mars)** 1998;58(3 Suppl):59–60 (10 ref.)
Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use? Dayan AD. **Med Trop (Mars)** 1998;58(3 Suppl):32–7 (9 ref.)
What role can public health institutions play in drug development for the poor? A case study of artesunate. Gomes M, et al. **Med Trop (Mars)** 1998;58(3 Suppl):97–100 (10 ref.)
What have been the strategies for the registration, positioning and control of medical information for intramuscular artemether? Helenport JP, et al. **Med Trop (Mars)** 1998;58(3 Suppl):73–6 (22 ref.)
Pharmacokinetics and pharmacodynamics of qinghaosu derivatives: how do they impact on the choice of drug and the dosage regimens? Kyle DE, et al. **Med Trop (Mars)** 1998;58(3 Suppl):38–44 (32 ref.)
How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Li Y, et al. **Med Trop (Mars)** 1998;58(3 Suppl):9–12 (26 ref.)
The rational use of qinghaosu and its derivatives: what is the future of new compounds? Looareesuwan S, et al. **Med Trop (Mars)** 1998;58(3 Suppl):89–92 (10 ref.)
Treatment of uncomplicated malaria with artemisinin derivatives. A systematic review of randomised controlled trials. McIntosh HM, et al. **Med Trop (Mars)** 1998;58(3 Suppl):57–8 (1 ref.)
Use of artemisinin derivatives for the control of malaria [published erratum appears in Med Trop (Mars) 1998;58(4):368] Nosten F, et al. **Med Trop (Mars)** 1998;58(3 Suppl):45–9 (13 ref.)
Artemisinin and derivatives in the treatment of uncomplicated malaria. White NJ, et al. **Med Trop (Mars)** 1998;58(3 Suppl):54–6 (28 ref.)
Qinghaosu in combinations. White NJ. **Med Trop (Mars)** 1998;58(3 Suppl):85–8 (19 ref.)
Clinical trials referral resource. Clinical trials of MGI-114. Murgo A, et al. **Oncology (Huntingt)** 1999 Feb;13(2):233, 237–8 (13 ref.)
Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. van Agtmael MA, et al. **Trends Pharmacol Sci** 1999 May;20(5):199–205 (110 ref.)
[Current data on major novel antiamalaria drugs: Artemisinin (qinghaosu) derivatives] Ambroise-Thomas P. **Bull Acad Natl Med** 1999;183(4):797–80; discussion 810–3 (60 ref.) (Eng. Abstr.) **(Fre)**
[New antimalarial drugs] Ambroise-Thomas P. **Rev Prat** 1998 Feb 1;48(3):287–90 (21 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma] Konno H, et al. **Nippon Geka Gakkai Zasshi** 1998 Jul;99(7):441–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

SEVENTH CRANIAL NERVE see **FACIAL NERVE**

SEVENTH-DAY ADVENTISTS see **CHRISTIANITY**

SEVERE COMBINED IMMUNODEFICIENCY

[Bare lymphocyte syndrome] Kokawa T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):245–6 (11 ref.) **(Jpn)**
[Adenosine deaminase deficiency] Okawa H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):240–2 (10 ref.) **(Jpn)**
[Reticular dysgenesis] Okawa H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):243–4 (6 ref.) **(Jpn)**
[Severe combined immunodeficiency] Okawa H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):235–9 (12 ref.) **(Jpn)**

ETIOLOGY

[PNP deficiency] Sato T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):228–31 (16 ref.) **(Jpn)**

GENETICS

Interleukin-2 signaling and inherited immunodeficiency. Cacalano NA, et al. **Am J Hum Genet** 1999 Aug; 65(2):287–93 (30 ref.)
The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. DeSandro A, et al. **Am J Hum Genet** 1999 Aug;65(2):279–86 (41 ref.)
Omenn syndrome: a disorder of Rag1 and Rag2 genes. Villa A, et al. **J Clin Immunol** 1999 Mar;19(2):87–97 (70 ref.)
X-linked SCID and other defects of cytokine pathways. Uribe L, et al. **Semin Hematol** 1998 Oct;35(4):299–309 (70 ref.)

IMMUNOLOGY

X-linked SCID and other defects of cytokine pathways. Uribe L, et al. **Semin Hematol** 1998 Oct;35(4):299–309 (70 ref.)

PATHOLOGY

Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71–6 (55 ref.)

THERAPY

Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Onodera M, et al. **Acta Haematol** 1999;101(2):89–96 (30 ref.)

SEVERE COMBINED IMMUNODEFICIENT MICE see **MICE, SCID**

SEVERITY OF ILLNESS INDEX

Review of objective topographic facial nerve evaluation methods. Dulguerov P, et al. **Am J Otol** 1999 Sep; 20(5):672–8 (32 ref.)
Severity of illness scoring systems and performance appraisal. Ridley S. **Anaesthesia** 1998 Dec;53(12):1185–94 (48 ref.)
Severity scoring systems in the modern intensive care unit. Clermont G, et al. **Ann Acad Med Singapore** 1998 May; 27(3):397–403 (44 ref.)
ABC of intensive care: outcome data and scoring systems. Gunning K, et al. **BMJ** 1999 Jul 24;319(7204):241–4 (0 ref.)
Risk scoring in surgical patients. Jones HJ, et al. **Br J Surg** 1999 Feb;86(2):149–57 (72 ref.)
The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Yoshida EM. **Can J Gastroenterol** 1999 Jan-Feb;13(1):65–73 (47 ref.)
Neonatal risk scoring systems. Can they predict mortality and morbidity? Richardson DK, et al. **Clin Perinatol** 1998 Sep;25(3):591–611 (126 ref.)
Severity scoring and outcome assessment. Computerized predictive models and scoring systems. Marik PE, et al. **Crit Care Clin** 1999 Jul;15(3):633–46, viii (67 ref.)
Quantification of organ dysfunction: seeking standardization [editorial; comment] Bernard GR. **Crit Care Med** 1998 Nov; 26(11):1767–8 (19 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1793–800.
Charting the course of critical illness: prognostication and outcome description in the intensive care unit [editorial; comment] Marshall JC. **Crit Care Med** 1999 Apr; 27(4):676–8 (14 ref.) Comment on: Crit Care Med 1999 Apr;27(4):741.
Bispectral Index: better information for sedation in the intensive care unit? [editorial; comment] Shapiro BA. **Crit Care Med** 1999 Aug;27(8):1663–4 (20 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1499–1504.
Sounding the improvement in outcomes in pediatric critical care: are we listening for only what we want to hear? [editorial; comment] Vardis R, et al. **Crit Care Med** 1998 Oct;26(10):1635–6 (12 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1737–43.
The scope for rehabilitation in severely disabled stroke patients. Gladman JR, et al. **Disabil Rehabil** 1998 Oct; 20(10):391–4 (30 ref.)
Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Greenberg PL, et al. **Forum (Genova)** 1999 Jan-Mar;9(1):17–31 (99 ref.)
Management of severe colitis/ileocolitis. Grand RJ. **Inflamm Bowel Dis** 1998 Aug;4(3):225–7 (22 ref.)
Relationship between TISS and costs in intensive care [editorial; comment] Edbrooke D, et al. **Intensive Care Med** 1998 Oct;24(10):995–6 (13 ref.) Comment on: Intensive Care Med 1998 Oct;24(10):1009–17. Comment on: Intensive Care Med 1998 Oct;24(10):1062–9.
Pro: All elective coronary artery bypass grafting patients are American Society of Anesthesiologists' Physical Status IV [see comments] Swamidoss CP, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):225–7 (19 ref.) Comment in: J Cardiothorac Vasc Anesth 1999 Apr;13(2):228–30.
Con: All elective coronary artery bypass grafting patients are not American Society of Anesthesiologists' Physical Status IV [comment] Wiklund RA. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):228–30 (19 ref.) Comment on: J Cardiothorac Vasc Anesth 1999 Apr;13(2):225–7.
Conceptual issues in scoring radiographic progression in rheumatoid arthritis. Kirwan JR. **J Rheumatol** 1999 Mar; 26(3):720–5 (33 ref.)
Comparison of the Dougados Functional Index and the Bath Ankylosing Spondylitis Functional Index. A literature review. Ruof J, et al. **J Rheumatol** 1999 Apr;26(4):955–60 (38 ref.)
Severe community-acquired pneumonia: how to assess illness severity. Ewig S, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):250–4 (26 ref.)
Quantification of impairment in MS: discussion of the scales in use. Amato MP, et al. **Mult Scler** 1999 Aug;5(4):216–9 (17 ref.)
MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Barkhof F. **Mult Scler** 1999 Aug;5(4):283–6 (35 ref.)
Recent developments in the assessment of quality of life in multiple sclerosis (MS). Fischer JS, et al. **Mult Scler** 1999 Aug;5(4):251–9 (52 ref.)
Use of composite scores in the quantification of deterioration in multiple sclerosis. Lienert C, et al. **Mult Scler** 1999 Aug; 5(4):220–2 (8 ref.)
The revision of the International Classification of Impairments, Disabilities and Handicaps and its application in MS. Lux JB, et al. **Mult Scler** 1999 Aug;5(4):291–2 (4 ref.)
Measuring handicap in multiple sclerosis. Thompson AJ. **Mult Scler** 1999 Aug;5(4):260–2 (17 ref.)
Risk adjustment for quality improvement. Richardson D, et al. **Pediatrics** 1999 Jan;103(1 Suppl E):255–65 (76 ref.)
An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Schmid CH, et al. **Stat Med** 1998 Sep 15; 17(17):1923–42 (75 ref.)
Staging of acute pancreatitis. Is it important? McKay CJ, et al. **Surg Clin North Am** 1999 Aug;79(4):733–43 (38 ref.)
[Natural development of non-traumatic osteonecrosis of the hip] Arlet J, et al. **Acta Orthop Belg** 1999;65 Suppl 1:47–50 (15 ref.) **(Fre)**
[Importance of other therapeutic medications administered parenterally in severe acute asthma] Perrotin D. **Ann Fr Anesth Reanim** 1998;17 Suppl 2:44s–47s (10 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of the severity of gastroesophageal reflux: can the spontaneous course and therapeutic response be predicted?] Veyrac M. **Gastroenterol Clin Biol** 1999 Jan; 23(1 Pt 2):S229–36 (58 ref.) **(Fre)**
[Difficult asthmas. Pitfalls and nosological limits] Chanez P, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S48–50 (16 ref.) **(Fre)**
[Severe malaria] Gachot B, et al. **Rev Prat** 1998 Feb 1; 48(3):273–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Severity and pathophysiology of kidney failure] Hishida A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1241–6 (3 ref.) **(Jpn)**

SEWAGE

ADVERSE EFFECTS

Coming to grips with a slippery issue: human waste disposal in cold climates. Meyer-Rochow VB. **Int J Circumpolar Health** 1999 Jan;58(1):57–62 (33 ref.)

MICROBIOLOGY

Microsensors as a tool to determine chemical microgradients and bacterial activity in wastewater biofilms and flocs. Santegoeds CM, et al. **Biodegradation** 1998;9(3-4):159–67 (46 ref.)
Coming to grips with a slippery issue: human waste disposal in cold climates. Meyer-Rochow VB. **Int J Circumpolar Health** 1999 Jan;58(1):57–62 (33 ref.)

SEX

see related
LIBIDO
PSYCHOSEXUAL DEVELOPMENT
RELIGION AND SEX

The sexual revolution in science: what gender-based research is telling us. Thompson PM, et al. **J Investig Med** 1999

Mar;47(3):106–13 (40 ref.)
Gender matters: an integrated model for understanding men's and women's health. Bird CE, et al. **Soc Sci Med** 1999 Mar;48(6):745–55 (51 ref.)
Incorporating gender in the anthropology of infectious diseases [see comments] Vlassoff C, et al. **Trop Med Int Health** 1998 Dec;3(12):1011–9 (45 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):993–5.

SEX ATTRACTANTS

ISOLATION & PURIFICATION

Sodefrin: a novel sex pheromone in a newt. Kikuyama S, et al. **Rev Reprod** 1999 Jan;4(1):1–4 (18 ref.)

PHYSIOLOGY

Chemical signals in the reproduction of Asian (Elephas maximus) and African (Loxodonta africana) elephants. Rasmussen LE, et al. **Anim Reprod Sci** 1998 Oct; 53(1–4):19–34 (92 ref.)
Discrimination of pheromonal cues in fish: emerging parallels with insects. Sorensen PW, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):458–67 (61 ref.)

SEX BEHAVIOR

see related
SEXUAL PARTNERS

Sexually transmitted diseases, unintended pregnancy, and adolescent health promotion. Santelli JS, et al. **Adolesc Med** 1999 Feb;10(1):87–108, vi (180 ref.)
Shedding light on the sexual history. Warner PH, et al. **Am J Nurs** 1999 Jun;99(6):34–40; quiz 41 (11 ref.)
Understanding and promoting sexual and reproductive health behavior: theory and method. Fisher WA, et al. **Annu Rev Sex Res** 1998;9:39–76 (138 ref.)
Sexuality and late modernity. Schmidt G. **Annu Rev Sex Res** 1998;9:224–41 (51 ref.)
Swinging: a review of the literature. Jenks RJ. **Arch Sex Behav** 1998 Oct;27(5):507–21 (36 ref.)
ABC of sexual health: a woman's sexual life after an operation. de Marquiegui A, et al. **BMJ** 1999 Jan 16; 318(7177):178–81 (0 ref.)
Alcohol intake and sexually transmitted diseases. Tüzün B, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):469–78 (130 ref.)
Literature reviews: adolescent medicine. Braverman PK. **Clin Pediatr (Phila)** 1999 Mar;38(3):183–4 (0 ref.)
Allegations of sexual abuse in an intensive care unit. Hansen-Flaschen J, et al. **Crit Care Med** 1999 Feb; 27(2):437–40 (32 ref.)
Possible allegations of sexual abuse in an intensive care unit: an editorial [editorial] Mohindra V, et al. **Crit Care Med** 1999 Feb;27(2):268–9 (10 ref.)
Current status of reproductive behaviour in Africa. Bambra CS. **Hum Reprod Update** 1999 Jan–Feb;5(1):1–20 (158 ref.)
Current approach to STD management in women. Amaral E. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S183–9 (28 ref.)
Changing behavior to prevent STDs/AIDS. Fishbein M. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S175–81 (26 ref.)
Teaching safe sex in school. Short R. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S147–50 (4 ref.)
Strengthening domestic violence theories: intersections of race, class, sexual orientation, and gender. Bograd M. **J Marital Fam Ther** 1999 Jun;25(3):275–89 (92 ref.)
Reflections on two decades of research on teen sexual behavior and pregnancy. Kirby D. **J Sch Health** 1999 Mar; 69(3):89–94 (43 ref.)
Sex and the mature woman. Pariser SF, et al. **J Womens Health** 1998 Sep;7(7):849–59 (38 ref.)
Female genital surgeries: the known, the unknown, and the unknowable. Obermeyer CM. **Med Anthropol Q** 1999 Mar; 13(1):79–106 (85 ref.)
Surviving cancer: the importance of sexual self-concept. Andersen BL. **Med Pediatr Oncol** 1999 Jul;33(1):15–23 (45 ref.)
Children, adolescents, and the media: issues and solutions. Strasburger VC, et al. **Pediatrics** 1999 Jan;103(1):129–39 (156 ref.)
Women HIV sexual risk takers: related behaviors, interpersonal issues, and attitudes. Harlow LL, et al. **Womens Health** 1998 Winter;4(4):407–39 (85 ref.)
[Hormones and sexuality in the young and aging woman] Buvat-Herbaut M. **Contracept Fertil Sex** 1999 Jan; 27(1):17–22 (57 ref.) **(Fre)**
[Questions about sexual ethics related to AIDS] Colpin H. **Contracept Fertil Sex** 1998 Nov;26(11):812–8 (29 ref.) (Eng. Abstr.) **(Fre)**
[Contraception during the first sexual intercourse: a survey concerning 467 female teenagers, 13 to 21 years in the Nantes area] Lemort MF, et al. **Contracept Fertil Sex** 1999 Mar;27(3):197–202 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Pharmacology of alpha-adrenoceptors in male sexual function. Rampin O. **Eur Urol** 1999;36 Suppl 1:103–6 (19 ref.)
Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Olivier B, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S9–14 (27 ref.)
Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents. Levitsky AM, et al. **J Am Geriatr Soc** 1999 Feb;47(2):231–4 (26 ref.)
Alcohol's possible covert role: brain dysfunction, paraphilias, and sexually aggressive behaviors. Williams S. **Sex Abuse** 1999 Apr;11(2):147–58 (54 ref.)

ETHNOLOGY

Theoretical perspectives on female sexual behaviour in Africa: a review and conceptual model. Djamba YK. **Afr J Reprod Health** 1997 Sep;1(2):67–78 (57 ref.)

PHYSIOLOGY

Sexual activity as a trigger for cardiovascular events: what is the risk? Muller JE. **Am J Cardiol** 1999 Sep 9; 84(5B):2N–5N (22 ref.)
Sexual activity and the cardiovascular patient: guidelines. Taylor HA Jr. **Am J Cardiol** 1999 Sep 9;84(5B):6N–10N (19 ref.)
The new heterozygosity theory of mate choice and the MHC. Brown JL. **Genetica** 1998–99;104(3):215–21 (87 ref.)
Love as sensory stimulation: physiological consequences of its deprivation and expression. Komisaruk BR, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):927–44 (58 ref.)
[The regulation of male sexual behavior by the sex hormones] Gladkova AI. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):97–105 (64 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Theoretical perspectives on female sexual behaviour in Africa: a review and conceptual model. Djamba YK. **Afr J Reprod Health** 1997 Sep;1(2):67–78 (57 ref.)
Men's bodies, men's minds: seminal emissions and sexual anxiety in the Middle Ages. Murray J. **Annu Rev Sex Res** 1997;8:1–26 (66 ref.)
Preventing the high-risk sexual behavior of adolescents: focus on HIV/AIDS transmission, unintended pregnancy, or both? Whaley AL. **J Adolesc Health** 1999 Jun; 24(6):376–82 (49 ref.)
Morality and multiplicity: perspectives on the treatment of violence in intimate life. Goldner V. **J Marital Fam Ther** 1999 Jun;25(3):325–36 (24 ref.)
Alcohol's possible covert role: brain dysfunction, paraphilias, and sexually aggressive behaviors. Williams S. **Sex Abuse** 1999 Apr;11(2):147–58 (54 ref.)
[Sexual fantasies and sexual dreams: a sexoanalytical exploration] Crépault C, et al. **Contracept Fertil Sex** 1999 Mar;27(3):231–7 (12 ref.) (Eng. Abstr.) **(Fre)**
[Sexual dissatisfaction and somatic complaints in male infertility] Schilling G, et al. **Psychother Psychosom Med Psychol** 1999 Aug;49(8):256–63 (36 ref.) (Eng. Abstr.) **(Ger)**

SEX BEHAVIOR, ANIMAL

Sexual behaviour: Courting dissatisfaction. O'Kane CJ, et al. **Curr Biol** 1999 Apr 22;9(8):R289–92 (14 ref.)
New perspectives on mate choice and the MHC. Jordan WC, et al. **Heredity** 1998 Sep;81 (Pt 3):239–45 (57 ref.)
New perspectives on mate choice and the MHC. Jordan WC, et al. **Heredity** 1998 Aug;81 (Pt 2):127–33 (55 ref.)
Primate socioecology: new insights from males. Kappeler PM. **Naturwissenschaften** 1999 Jan;86(1):18–29 (147 ref.)
On the origin of species by means of assortative mating. Kondrashov AS, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2273–8 (25 ref.)

DRUG EFFECTS

Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Olivier B, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S9–14 (27 ref.)
[Serotonin both stimulates and inhibits sexual behavior of rats. New possibilities to understand the effects and side-effects of serotonergic drugs] Larsson K, et al. **Lakartidningen** 1999 Jun 9;96(23):2854–6 (22 ref.) **(Swe)**

PHYSIOLOGY

Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Insel TR, et al. **Adv Exp Med Biol** 1998; 449:215–24 (50 ref.)
Gonadal steroid-dependent GAL-IR cells within the medial preoptic nucleus (MPN) and the stimulatory effects of GAL within the MPN on sexual behaviors. Bloch GJ, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:188–205 (88 ref.)
Brain and sexual behavior. Larsson K, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:292–308 (86 ref.)
The medial extended amygdala in male reproductive behavior. A node in the mammalian social behavior network. Newman SW. **Ann N Y Acad Sci** 1999 Jun 29; 877:242–57 (103 ref.)
The Japanese quail as a model system for the investigation of steroid-catecholamine interactions mediating appetitive and consummatory aspects of male sexual behavior. Balthazart J, et al. **Annu Rev Sex Res** 1998;9:96–176 (215 ref.)
Role of the medial preoptic area/anterior hypothalamus in the control of masculine sexual behavior. Paredes RG, et al. **Annu Rev Sex Res** 1997;8:68–101 (176 ref.)
Sexual behavior in same-sexed nonhuman primates: is it relevant to understanding human homosexuality? Wallen K, et al. **Annu Rev Sex Res** 1997;8:195–223 (74 ref.)
Mating vocalizations of female frogs: control and evolutionary mechanisms. Emerson SB, et al. **Brain Behav Evol** 1999;53(4):187–97 (122 ref.)
Sex with knockout models: behavioral studies of estrogen receptor alpha. Rissman EF, et al. **Brain Res** 1999 Jul 17; 835(1):80–90 (88 ref.)
Control of luteinizing hormone and prolactin secretion in birds. Sharp PJ, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):275–82 (88 ref.)
Drosophila conditioned courtship: two ways of testing memory. Kamyshev NG, et al. **Learn Mem** 1999 Jan–Feb; 6(1):1–20 (50 ref.)
Interactions of mating, egg production and death rates in females of the Mediterranean fruit fly, Ceratitis capitata. Chapman T, et al. **Proc R Soc Lond B Biol Sci** 1998 Oct 7;265(1408):1879–94 (145 ref.)
The logic of Ménage à Trois. Enquist M, et al. **Proc R Soc Lond B Biol Sci** 1998 Apr 7;265(1396):609–13 (34 ref.)
Good genes, oxidative stress and condition-dependent sexual signals. von Schantz T, et al. **Proc R Soc Lond B Biol Sci** 1999 Jan 7;266(1414):1–12 (162 ref.)
A peptidergic basis for sexual behavior in mammals. Smock T, et al. **Prog Brain Res** 1998;119:467–81 (113 ref.)
Neural oxytocinergic systems as genomic targets for hormones and as modulators of hormone-dependent behaviors. Pfaff DW, et al. **Results Probl Cell Differ** 1999; 26:91–105 (75 ref.)
Sex determination and female reproductive development in the genus Schistosoma: a review. Ribeiro-Paes JT, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov–Dec;39(6):337–44 (136 ref.)
A neurobehavioral model for rapid actions of corticosterone on sensorimotor integration. Rose JD, et al. **Steroids** 1999 Jan–Feb;64(1–2):92–9 (29 ref.)
[The regulation of male sexual behavior by the sex hormones] Gladkova AI. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):97–105 (64 ref.) (Eng. Abstr.) **(Rus)**

SEX BIAS see **PREJUDICE**

SEX CHARACTERISTICS

Review article: gender-related differences in functional gastrointestinal disorders. Mayer EA, et al. **Aliment Pharmacol Ther** 1999 May;13 Suppl 2:65–9 (44 ref.)
A simple method for visualization of influential landmarks when using euclidean distance matrix analysis. Cole TM 3rd, et al. **Am J Phys Anthropol** 1998 Nov;107(3):273–83 (32 ref.)
Emerging concepts for sexual predilection in the disease systemic lupus erythematosus. Lahita RG. **Ann N Y Acad Sci** 1999 Jun 22;876:64–9; discussion 69–70 (45 ref.)
LHRH and sexual dimorphism. Merchenthaler I. **Ann N Y Acad Sci** 1998 Dec 21;863:175–87 (44 ref.)
Neural plasticity and the development of sex differences. Juraska JM. **Annu Rev Sex Res** 1998;9:20–38 (61 ref.)
Women and heart disease. Maxwell SR. **Basic Res Cardiol** 1998;93 Suppl 2:79–84 (33 ref.)
The structural basis of bone fragility in men. Seeman E. **Bone** 1999 Jul;25(1):143–7 (50 ref.)
Drugs and sex differences: a review of drugs relating to anaesthesia. Ciccone GK, et al. **Br J Anaesth** 1999 Feb; 82(2):255–65 (99 ref.)
Gender and fat metabolism during exercise: a review. Tate CA, et al. **Can J Appl Physiol** 1998 Dec;23(6):570–82 (72 ref.)
Gender differences in sympathetic nervous system regulation. Hinojosa-Laborde C, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):122–6 (50 ref.)
Sex or body size? Selection of dialysis type revisited [editorial; comment] Levin A. **CMAJ** 1999 Mar 23; 160(6):828–9 (10 ref.) Comment on: CMAJ 1999 Mar 23;160(6):818–9.
Human spatial navigation: cognitive maps, sexual dimorphism, and neural substrates. Maguire EA, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):171–7 (76 ref.)
Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine-immunological sexual dimorphism. Gaillard RC, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):345–52 (18 ref.)
Preferences, quantities and concerns: socio-cultural perspectives on the gendered consumption of foods. O'Doherty Jensen K, et al. **Eur J Clin Nutr** 1999 May; 53(5):351–9 (66 ref.)
Oestrogen deficiency in men: where are we today? Faustini-Fustini M, et al. **Eur J Endocrinol** 1999 Feb; 140(2):111–29 (155 ref.)
Salivary gland sexual dimorphism: a brief review. Pinkstaff CA. **Eur J Morphol** 1998 Aug;36 Suppl:31–4 (22 ref.)
Sexual differentiation of the vertebrate brain: principles and mechanisms. Cooke B, et al. **Front Neuroendocrinol** 1998 Oct;19(4):323–62 (222 ref.)
Influence of gender on the pharmacokinetics and

pharmacodynamics of drugs. Thürmann PA, et al. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):586–90 (37 ref.)

Clinical review 107: Role of gonadal steroids in the sexual dimorphisms in body composition and circulating concentrations of leptin. Rosenbaum M, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1784–9 (94 ref.)

Pediatric ethics and the surgical assignment of sex. Kipnis K, et al. **J Clin Ethics** 1998 Winter;9(4):398–410 (56 ref.)

Management of intersex: a shifting paradigm. Wilson BE, et al. **J Clin Ethics** 1998 Winter;9(4):360–9 (32 ref.)

Gender difference in growth hormone response in adults. Johansson AG. **J Endocrinol Invest** 1999;22(5 Suppl):58–60 (22 ref.)

Statistics of sexual size dimorphism. Smith RJ. **J Hum Evol** 1999 Apr;36(4):423–58 (150 ref.)

Genomic imprinting of the X chromosome: a novel mechanism for the evolution of sexual dimorphism. Skuse DH. **J Lab Clin Med** 1999 Jan;133(1):23–32 (47 ref.)

Steroid metabolising enzymes in the determination of brain gender. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):85–96 (64 ref.)

Prenatal stress and glucocorticoid effects on the developing gender-related brain. Reznikov AG, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):109–15 (40 ref.)

The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems. Ambrosio E, et al. **Life Sci** 1999;65(6–7):687–94 (52 ref.)

Osteoporosis: gender differences and similarities. Khosla S, et al. **Lupus** 1999;8(5):393–6 (24 ref.)

Gender differences: the perspective from biology. Lockshin RA. **Lupus** 1999;8(5):361–4 (11 ref.)

Gender and vascular reactivity. Miller VM. **Lupus** 1999; 8(5):409–15 (76 ref.)

Sex-based differences in gene transmission and gene expression. Ostrer H. **Lupus** 1999;8(5):365–9 (63 ref.)

Renal function and renal disease in males or females--vive la petite difference. Zeier M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2195–8 (63 ref.)

Gender differences in substance use disorders. Brady KT, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):241–52 (51 ref.)

Sexually-dimorphic patterns of cortical asymmetry, and the role for sex steroid hormones in determining cortical patterns of lateralization. Wisniewski AB. **Psychoneuroendocrinology** 1998 Jul;23(5):519–47 (130 ref.)

Gender matters: an integrated model for understanding men's and women's health. Bird CE, et al. **Soc Sci Med** 1999 Mar;48(6):745–55 (51 ref.)

SEX CHROMOSOME ABNORMALITIES

Rare sex chromosome aneuploidies in humans: report of six patients with 48,XXYY, 49,XXXXY, and 48,XXXX karyotypes [letter] Cammarata M, et al. **Am J Med Genet** 1999 Jul 2;85(1):86–7 (26 ref.)

De novo duplication xq22–q23 in a girl with short stature and gonadal dysgenesis. Correa-Cerro L, et al. **Ann Genet** 1999;42(1):41–4 (20 ref.)

Genetic abnormalities and male infertility. A comprehensive review. Thielemans BF, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):217–25 (85 ref.)

GENETICS

Random X-inactivation in a girl with duplication Xp11.21–p21.3: report of a patient and review of the literature. Matsuo M, et al. **Am J Med Genet** 1999 Sep 3;86(1):44–50 (50 ref.)

Partial Xp duplication due to a translocation t(X;15) in two male and two female patients: a familial case report and review of the literature. Melaragno MI, et al. **Ann Genet** 1998;41(4):189–94 (27 ref.)

Sex chromosome aneuploidies in sperm of 47,XYY men. Morel F, et al. **Arch Androl** 1999 Jul–Aug;43(1):27–36 (28 ref.)

Advances in Y chromosome mapping. Yen PH. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):275–81 (71 ref.)

Developmental and genetic disorders in spermatogenesis. Diemer T, et al. **Hum Reprod Update** 1999 Mar–Apr; 5(2):120–40 (154 ref.)

Case report of a 22-week fetus with 47,XXX karyotype and multiple lower mesodermal defects. Hoang MP, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):58–61 (17 ref.)

X-linked SCID and other defects of cytokine pathways. Uribe L, et al. **Semin Hematol** 1998 Oct;35(4):299–309 (70 ref.)

[X-chromosomal recessive spinobulbar muscular atrophy (Kennedy type). Description of a family, clinical aspects, molecular genetics, differential diagnosis and therapy] Kuhlenbäumer G, et al. **Nervenarzt** 1998 Aug;69(8):660–5 (19 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Another observation of microphthalmia in an XX male: microphthalmia with linear skin defects syndrome without linear skin lesions. Kono T, et al. **J Hum Genet** 1999; 44(1):63–8 (34 ref.)

SEX CHROMOSOMES

On the origin of sex chromosomes. Lucchesi JC. **Bioessays** 1999 Mar;21(3):188–90 (16 ref.)

GENETICS

Genetic control of gonadal differentiation. Lim HN, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):1–16 (61 ref.)

The origin and evolution of the pseudoautosomal regions of human sex chromosomes. Graves JAM, et al. **Hum Mol Genet** 1998 Dec;7(13):1991–6 (50 ref.)

PHYSIOLOGY

Sex chromosomes and sex-determining genes: insights from marsupials and monotremes. Pask A, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):864–75 (76 ref.)

SEX CORD-STROMAL TUMOR

DIAGNOSIS

Sex cord-stromal and steroid cell tumors of the ovary. Outwater EK, et al. **Radiographics** 1998 Nov–Dec; 18(6):1523–46 (82 ref.)

PATHOLOGY

Testicular fibroma of gonadal stromal origin with minor sex cord elements: clinicopathologic and immunohistochemical study of 2 cases. de Pinieux G, et al. **Arch Pathol Lab Med** 1999 May;123(5):391–4 (12 ref.)

Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature. Duska LR, et al. **Eur J Gynaecol Oncol** 1998;19(5):441–3 (10 ref.)

Classification and pathology of testicular germ cell and sex cord-stromal tumors. Chevilie JC. **Urol Clin North Am** 1999 Aug;26(3):595–609 (110 ref.)

SEX DETERMINATION (GENETICS)

Sexual dimorphism in the neonatal gonad. Hughes IA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):23–30 (54 ref.)

Mammalian sex determination: joining pieces of the genetic puzzle. Jiménez R, et al. **Bioessays** 1998 Sep;20(9):696–9 (24 ref.)

Sex, cell death, and the genome of C. elegans [comment] Hodgkin J. **Cell** 1999 Aug 6;98(3):277–80 (16 ref.) Comment on: Cell 1999 Aug 6;98(3):317–27.

DAX-1, an 'antitestis' gene. Goodfellow PN, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):857–63 (26 ref.)

The one-to-four rule and paralogues of sex-determining genes. Ohno S. **Cell Mol Life Sci** 1999 Jun;55(6–7):824–30 (19 ref.)

Genes essential for early events in gonadal development. Parker KL, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):831–8 (55 ref.)

Sex chromosomes and sex-determining genes: insights from marsupials and monotremes. Pask A, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):864–75 (76 ref.)

Amphibian sex determination and sex reversal. Wallace H, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):901–9 (69 ref.)

Developmental effects on intersexual and intrasexual variation in growth and reproduction in a lizard with temperature-dependent sex determination. Crews D, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):229–41 (83 ref.)

Sex determination in plants. Juarez C, et al. **Curr Opin Plant Biol** 1998 Feb;1(1):68–72 (39 ref.)

Developmental genetics of Caenorhabditis elegans sex determination. Kuwabara PE. **Curr Top Dev Biol** 1999; 41:99–132 (106 ref.)

Mammalian sex determination: a molecular drama. Swain A, et al. **Genes Dev** 1999 Apr 1;13(7):755–67 (87 ref.)

Genes, cells and organs: recent developments in the molecular genetics of mammalian sex determination. Greenfield A. **Mamm Genome** 1998 Sep;9(9):683–7 (47 ref.)

Sex and the single worm: sex determination in the nematode C. elegans. Hansen D, et al. **Mech Dev** 1999 May; 83(1–2):3–15 (103 ref.)

Mammalian sex determination: from gonads to brain. Vilain E, et al. **Mol Genet Metab** 1998 Oct;65(2):74–84 (76 ref.)

Hypothesis: sex determination and germline formation are committed at the pronucleate stage in mammalian embryos. Edwards RG, et al. **Mol Hum Reprod** 1999 Jul;5(7):595–606 (148 ref.)

Recent developments in embryo sexing and its field application. Bredbacka P. **Reprod Nutr Dev** 1998 Nov–Dec; 38(6):605–13 (24 ref.)

Mammalian Y chromosome evolution and the male-specific functions of Y chromosome-borne genes. Delbridge ML, et al. **Rev Reprod** 1999 May;4(2):101–9 (63 ref.)

[Sex determination in mammals: state of the art] Berta P, et al. **Contracept Fertil Sex** 1999 Jun;27(6):423–33 (78 ref.) (Eng. Abstr.) **(Fre)**

[Genes, hormones and the risk factors in the development of the male phenotype] Shishkina GT, et al. **Usp Fiziol Nauk** 1999 Jul–Sep;30(3):49–61 (155 ref.) (Eng. Abstr.) **(Rus)**

SEX DEVIATIONS see **PARAPHILIAS**

SEX DIFFERENCES see **SEX CHARACTERISTICS**

SEX DIFFERENTIATION

The roles of steroidogenic factor 1 in endocrine development and function. Parker KL. **Mol Cell Endocrinol** 1998 May 25;140(1–2):59–63 (25 ref.)

[Function and expression of transcription factors implicated in gonadal differentiation] Morohashi K. **Nippon Rinsho** 1998 Jul;56(7):1739–44 (19 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Sexual differentiation and environmental endocrine disrupters. Toppari J, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):143–56 (67 ref.)

Xenoendocrine disrupters: laboratory studies on male reproductive effects. Gray LE Jr. **Toxicol Lett** 1998 Dec 28;102–103:331–5 (24 ref.)

GENETICS

Abnormalities of gonadal differentiation. Berkovitz GD, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):133–42 (42 ref.)

Physiology and pathophysiology of androgen action. Hiort O, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr; 12(1):115–32 (96 ref.)

Genetic control of gonadal differentiation. Lim HN, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):1–16 (61 ref.)

Embryology and endocrinology of genital development. Rey R, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr; 12(1):17–33 (55 ref.)

Natural potent androgens: lessons from human genetic models. Zhu YS, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):83–113 (170 ref.)

DAX-1, an 'antitestis' gene. Goodfellow PN, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):857–63 (26 ref.)

Temperature-dependent sex determination and gonadal differentiation in reptiles. Pieau C, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):887–900 (92 ref.)

Amphibian sex determination and sex reversal. Wallace H, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):901–9 (69 ref.)

Sexual differentiation: from genes to gender. Migeon CJ, et al. **Horm Res** 1998;50(5):245–51 (42 ref.)

PHYSIOLOGY

A role for ovarian hormones in sexual differentiation of the brain. Fitch RH, et al. **Behav Brain Sci** 1998 Jun; 21(3):311–27; discussion 327–52 (352 ref.)

Sexual differentiation: from genes to gender. Migeon CJ, et al. **Horm Res** 1998;50(5):245–51 (42 ref.)

Development of the cerebral cortex: XV. Sexual differentiation of the central nervous system. Gorski RA. **J Am Acad Child Adolesc Psychiatry** 1999 Mar;38(3):344–6 (7 ref.)

Neuronal cell death during sexual differentiation and lateralisation of vocal communication. Holman SD. **Neurosci Biobehav Rev** 1998 Oct;22(6):725–34 (94 ref.)

SEX DIFFERENTIATION DISORDERS

see related
TRANSSEXUALISM

Disorders of sexual differentiation. Warne GL, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):945–67, x (92 ref.)

Advances and challenges with intersex disorders. Warne GL. **Reprod Fertil Dev** 1998;10(1):79–85 (41 ref.)

EMBRYOLOGY

[Malformations of the scrotum and its contents] Marzotto Caotorta M, et al. **Arch Ital Urol Androl** 1998 Dec; 70(5):251–62 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Inherited disorders in sexual development. Meyers-Wallen VN. **J Hered** 1999 Jan–Feb;90(1):93–5 (19 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of Smith-Lemli-Opitz syndrome in a pregnancy with low maternal serum oestriol and a sex-reversed fetus. Bick DP, et al. **Prenat Diagn** 1999 Jan; 19(1):68–71 (16 ref.)

SEX DIMORPHISM see **SEX CHARACTERISTICS**

SEX DISORDERS

ABC of sexual health: assessing and managing male sexual problems. Gregoire A. **BMJ** 1999 Jan 30;318(7179):315–7 (5 ref.)

Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Berman JR, et al. **Urology** 1999 Sep;54(3):385–91 (26 ref.)

CHEMICALLY INDUCED

Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management. Clayton DO, et al.

Drug Saf 1998 Oct;19(4):299–312 (109 ref.)
Antidepressant-induced sexual dysfunction: review, classification, and suggestions for treatment. Ellison JM. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):177–89 (118 ref.)

DIAGNOSIS

ABC of sexual health: taking a sexual history [see comments] Tomlinson J. **BMJ** 1998 Dec 5;317(7172):1573–6 (0 ref.) Comment in: BMJ 1999 May 8;318(7193):1289.
Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management. Clayton DO, et al. **Drug Saf** 1998 Oct;19(4):299–312 (109 ref.)

DRUG THERAPY

Antidepressant-induced sexual dysfunction: review, classification, and suggestions for treatment. Ellison JM. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):177–89 (118 ref.)
[Painful erections related to sleeping] Menéndez López V, et al. **Actas Urol Esp** 1999 Jun;23(6):539–41 (7 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis. Fowler CJ. **Baillieres Clin Neurol** 1997 Oct;6(3):447–66 (48 ref.)
ABC of sexual health: female sexual problems I: loss of desire–what about the fun? Butcher J. **BMJ** 1999 Jan 2; 318(7175):41–3 (0 ref.)
ABC of sexual health: examination of patients with sexual problems. Dean J. **BMJ** 1998 Dec 12;317(7173):1641–3 (0 ref.)
ABC of sexual health: sexual problems of disabled patients. Glass C, et al. **BMJ** 1999 Feb 20;318(7182):518–21 (0 ref.)
ABC of sexual health: male sexual problems. Gregoire A. **BMJ** 1999 Jan 23;318(7178):245–7 (0 ref.)
ABC of sexual health: sexual problems associated with infertility, pregnancy, and ageing. Read J. **BMJ** 1999 Feb 27;318(7183):587–9 (0 ref.)
A review of the effect of traumatic brain injury on the human sexual response. Aloni R, et al. **Brain Inj** 1999 Apr; 13(4):269–80 (57 ref.)
Sexual dysfunction in uremia. Palmer BF. **J Am Soc Nephrol** 1999 Jun;10(6):1381–8 (33 ref.)
Surviving cancer: the importance of sexual self-concept. Andersen BL. **Med Pediatr Oncol** 1999 Jul;33(1):15–23 (45 ref.)

PHYSIOPATHOLOGY

Ejaculatory dysfunction. Vale J. **BJU Int** 1999 Mar; 83(5):557–63 (46 ref.)

THERAPY

ABC of sexual problems: management of sexual problems [see comments] Ramage M. **BMJ** 1998 Nov 28; 317(7171):1509–12 (0 ref.) Comment in: BMJ 1998 Nov 28;317(7171):1470.
Sexual dysfunction in uremia. Palmer BF. **J Am Soc Nephrol** 1999 Jun;10(6):1381–8 (33 ref.)

SEX EDUCATION

Sexuality and sex education at home and school. Kirby D. **Adolesc Med** 1999 Jun;10(2):195–209, v (76 ref.)
Current approach to STD management in women. Amaral E. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S183–9 (28 ref.)

METHODS

Adolescent abstinence and condom use: are we sure we are really teaching what is safe? Haignere CS, et al. **Health Educ Behav** 1999 Feb;26(1):43–54 (65 ref.)
Teaching safe sex in school. Short R. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S147–50 (4 ref.)
Reflections on two decades of research on teen sexual behavior and pregnancy. Kirby D. **J Sch Health** 1999 Mar; 69(3):89–94 (43 ref.)
Sex education in grade seven students in Papua New Guinea, yes or no? Bouten M. **P N G Med J** 1996 Sep;39(3):225–7 (0 ref.)

ORGANIZATION & ADMINISTRATION

Prevention and intervention of sexually transmitted diseases in adolescents. D'Souza CM, et al. **Curr Opin Pediatr** 1999 Aug;11(4):287–91 (34 ref.)
Review of sexuality education in the United States for health professionals working with adolescents. Middleman AB. **Curr Opin Pediatr** 1999 Aug;11(4):283–6 (15 ref.)
Sex education in school: preventing unwanted pregnancy in adolescents. Saito MI. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S157–60 (17 ref.)

SEX FACTORS

Making use of official statistics in research on gender and health status: recent British data. Dunnell K, et al. **Soc Sci Med** 1999 Jan;48(1):117–27 (26 ref.)

SEX HORMONE-BINDING GLOBULIN

METABOLISM

Sex hormone-binding globulin, its membrane receptor, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells. Fortunati N, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):473–9 (45 ref.)

PHYSIOLOGY

Sex hormone-binding globulin: not only a transport protein. What news is around the corner? Fortunati N. **J Endocrinol Invest** 1999 Mar;22(3):223–34 (114 ref.)
Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. Rosner W, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun; 69(1–6):481–5 (26 ref.)

SEX HORMONES

Psychoneuroendocrine aspects of temporolimbic epilepsy. Part I. Brain, reproductive steroids, and emotions. Herzog AG. **Psychosomatics** 1999 Mar–Apr;40(2):95–101 (82 ref.)
Center for Veterinary Medicine's perspective on the beef hormone case. Leighton JK. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):167–80, x (9 ref.)

BIOSYNTHESIS

The use of computational chemistry in the study of sex steroid biosynthesis. Auchus RJ. **Endocr Res** 1998 Aug–Nov; 24(3–4):541–7 (24 ref.)

IMMUNOLOGY

Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine-immunological sexual dimorphism. Gaillard RC, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):345–52 (18 ref.)

METABOLISM

Alcohol ingestion, hormonal changes, and the skin. Shulman A, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):405–9 (46 ref.)
Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Riman T, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):695–707 (154 ref.)
[The regulation of steroidogenesis by 17 alpha-hydroxylase/17,20-lyase (P450c17)] Katagiri M, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):43–50 (43 ref.) (Eng. Abstr.) **(Jpn)**
["Prostatic" kallikreins, sex hormones and insulin-like growth factors: complex of male and female regulatory elements in health and carcinogenesis] Zezerov EG, et al. **Vestn Ross Akad Med Nauk** 1999;(3):49–56 (63 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effects of steroid hormones on gene expression of glial markers in the central and peripheral nervous system: variations induced by aging. Melcangi RC, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):827–36 (45 ref.)
The influence of sex hormones on obesity across the female life span. Lovejoy JC. **J Womens Health** 1998 Dec; 7(10):1247–56 (53 ref.)
Clinically relevant basic science studies of gender differences and sex hormone effects. McEwen BS, et al. **Psychopharmacol Bull** 1998;34(3):251–9 (91 ref.)
[The Research Encouragement Award. Effects of sex hormones on sexual difference of experimental paracoccidioidomycosis] Sano A, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(1):1–8 (40 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Are pancreatic tumors hormone dependent?: A case report of unusual, rapidly growing pancreatic tumor during pregnancy, its possible relationship to female sex hormones, and review of the literature. Ganepola GA, et al. **Am Surg** 1999 Feb;65(2):105–11 (18 ref.)
Effects of sex steroids on sleep. Empson JA, et al. **Ann Med** 1999 Apr;31(2):141–5 (93 ref.)
Sex hormones and glucocorticoids: interactions with the immune system. Da Silva JA. **Ann N Y Acad Sci** 1999 Jun 22;876:102–17; discussion 117–8 (78 ref.)
Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ostensen M. **Ann N Y Acad Sci** 1999 Jun 22;876:131–43; discussion 144 (95 ref.)
Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Cutolo M, et al. **Ann Rheum Dis** 1998 Oct;57(10):573–7 (67 ref.)
A role for ovarian hormones in sexual differentiation of the brain. Fitch RH, et al. **Behav Brain Sci** 1998 Jun; 21(3):311–27; discussion 327–52 (352 ref.)
Cardiovascular steroid actions: swift swallows or sluggish snails? Christ M, et al. **Cardiovasc Res** 1998 Oct;40(1):34–44 (105 ref.)
Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein. Robert M, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):944–60 (95 ref.)
Sex steroid control of mood, mental state and memory. Fink G, et al. **Clin Exp Pharmacol Physiol** 1998 Oct; 25(10):764–75 (163 ref.)
Sex-steroid actions on neurotransmission. Bicknell RJ. **Curr Opin Neurol** 1998 Dec;11(6):667–71 (40 ref.)
The role of sex hormones in systemic lupus erythematosus. Lahita RG. **Curr Opin Rheumatol** 1999 Sep;11(5):352–6 (29 ref.)
Wellness in women after 40 years of age: the role of sex hormones and pheromones. Cutler WB, et al. **Dis Mon** 1998 Sep;44(9):421–546 (255 ref.)
Steroid hormone-dependent myometrial zonal differentiation in the non-pregnant human uterus. Brosens JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):247–51 (37 ref.)
Hormonal interactions in ovarian cancer. Emons G, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):145–61, ix (103 ref.)
Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Oparil S. **Hypertension** 1999 Jan;33(1 Pt 2):170–6 (56 ref.)
Development of the cerebral cortex: XV. Sexual differentiation of the central nervous system. Gorski RA. **J Am Acad Child Adolesc Psychiatry** 1999 Mar;38(3):344–6 (7 ref.)
Clinical review 107: Role of gonadal steroids in the sexual dimorphisms in body composition and circulating concentrations of leptin. Rosenbaum M, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1784–9 (94 ref.)
Glial-neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids. Ojeda SR, et al. **J Neurobiol** 1999 Sep 15;40(4):528–40 (95 ref.)
Epilepsy in women: the science of why it is special. Morrell MJ. **Neurology** 1999;53(4 Suppl 1):S42–8 (46 ref.)
Clinical application of the vaginal maturation index. McEndree B. **Nurse Pract** 1999 Sep;24(9):48, 51–2, 55–6 (31 ref.)
Genetic and hormonal regulation of murine hepatocarcinogenesis. Chiaverotti T, et al. **Prog Exp Tumor Res** 1999;35:131–42 (52 ref.)
Sexually-dimorphic patterns of cortical asymmetry, and the role for sex steroid hormones in determining cortical patterns of lateralization. Wisniewski AB. **Psychoneuroendocrinology** 1998 Jul;23(5):519–47 (130 ref.)
Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Rubinow DR, et al. **Psychopharmacol Bull** 1998;34(3):289–90 (10 ref.)
Angiotensin II: a reproductive hormone too? Speth RC, et al. **Regul Pept** 1999 Jan 1;79(1):25–40 (151 ref.)
[Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma] Clavière C, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):73–86 (166 ref.) **(Fre)**
[The regulation of male sexual behavior by the sex hormones] Gladkova AI. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):97–105 (64 ref.) (Eng. Abstr.) **(Rus)**
[Genes, hormones and the risk factors in the development of the male phenotype] Shishkina GT, et al. **Usp Fiziol Nauk** 1999 Jul–Sep;30(3):49–61 (155 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Hormonal treatment of endometrial cancer. Quinn MA. **Hematol Oncol Clin North Am** 1999 Feb;13(1):163–87, ix (168 ref.)

SEX MATURATION

Epidermal growth factor tyrosine kinase receptors and the neuroendocrine control of mammalian puberty. Ojeda SR, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):101–6 (49 ref.)

DRUG EFFECTS

Premature sexual development in children following the use of estrogen- or placenta-containing hair products. Tiwary CM. **Clin Pediatr (Phila)** 1998 Dec;37(12):733–9 (29 ref.)

PHYSIOLOGY

Developmental effects on intersexual and intrasexual variation in growth and reproduction in a lizard with temperature-dependent sex determination. Crews D, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):229–41 (83 ref.)
Glial-neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids. Ojeda SR, et al. **J Neurobiol** 1999 Sep 15;40(4):528–40 (95 ref.)
Metabolic control of sexual function and growth: role of neuropeptide Y and leptin. Aubert ML, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):107–13 (32 ref.)
Clinical application of the vaginal maturation index. McEndree B. **Nurse Pract** 1999 Sep;24(9):48, 51–2, 55–6 (31 ref.)
Sex determination and female reproductive development in the genus Schistosoma: a review. Ribeiro-Paes JT, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov–Dec;39(6):337–44

SEX MATURATION

(136 ref.)

SEX OFFENSES

Sexual offender treatment in Europe: an impression of cross-cultural differences. Frenken J. **Sex Abuse** 1999 Jan; 11(1):87–93 (2 ref.)

LEGISLATION & JURISPRUDENCE

What is an 'intact' hymen? A critique of the literature. Goodyear-Smith FA, et al. **Med Sci Law** 1998 Oct; 38(4):289–300 (60 ref.)

Therapist-patient sex. From boundary violations to sexual misconduct. Simon RI. **Psychiatr Clin North Am** 1999 Mar; 22(1):31–47 (54 ref.)

Sexual predators. Zonana HV, et al. **Psychiatr Clin North Am** 1999 Mar;22(1):109–27, vii (68 ref.)

The paraphilias, obsessive compulsive spectrum disorder, and the treatment of sexually deviant behaviour. Bradford JM. **Psychiatr Q** 1999 Fall;70(3):209–19 (44 ref.)

The "mad" vs. the "bad" revisited: managing predatory behavior. Tucker W. **Psychiatr Q** 1999 Fall;70(3):221–30 (12 ref.)

PREVENTION & CONTROL

Understanding sexual and reproductive violence: an overview. Barzelatto J. **Int J Gynaecol Obstet** 1998 Dec; 63 Suppl 1:S13–8 (10 ref.)

Harm reduction or harm facilitation? A reply to Maletzky. Laws DR. **Sex Abuse** 1999 Jul;11(3):233–41 (15 ref.)

Methodological issues concerning evaluation of treatment for sexual offenders: randomization, treatment dropouts, untreated controls, and within-treatment studies [see comments] McConaghy N. **Sex Abuse** 1999 Jul; 11(3):183–93 (32 ref.) Comment in: Sex Abuse 1999 Jul;11(3):179–81.

PSYCHOLOGY

Sexual abuse and the subsequent development of alcohol problems. Moncrieff J, et al. **Alcohol Alcohol** 1998 Nov–Dec;33(6):592–601 (40 ref.)

The aggressive patient/inmate: beyond denial. Maier GJ. **Psychiatr Q** 1999 Fall;70(3):199–208 (33 ref.)

Are sex offenders treatable? A research overview [see comments] Grossman LS, et al. **Psychiatr Serv** 1999 Mar; 50(3):349–61 (98 ref.) Comment in: Psychiatr Serv 1999 Mar;50(3):295.

In defense of the assault cycle: a commentary. Carich MS. **Sex Abuse** 1999 Jul;11(3):249–51 (8 ref.)

SEX ORGANS, ACCESSORY see **GENITALIA**

SEX ORGANS, ACCESSORY, FEMALE see **GENITALIA, FEMALE**

SEX ORGANS, ACCESSORY, MALE see **GENITALIA, MALE**

SEX PHEROMONES see **SEX ATTRACTANTS**

SEX PREFERENCE see **SEX**

SEX REVERSAL, GONADAL

Amphibian sex determination and sex reversal. Wallace H, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):901–9 (69 ref.)

Candidate genes in complete and partial XY sex reversal: mutation analysis of SRY, SRY-related genes and FTZ-F1. Lim HN, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1–2):51–8 (60 ref.)

SEX ROLE see **GENDER IDENTITY**

SEX STEROID-BINDING PROTEIN see **SEX HORMONE-BINDING GLOBULIN**

SEXISM see **PREJUDICE**

SEXOLOGY see **SEX**

SEXTUPLETS see **MULTIPLE BIRTH OFFSPRING**

SEXUAL ABSTINENCE

Abstinence and safer sex HIV risk-reduction interventions for African-American adolescents. Braverman PK. **Clin Pediatr (Phila)** 1999 Mar;38(3):184–7 (0 ref.)

Adolescent abstinence and condom use: are we sure we are really teaching what is safe? Haignere CS, et al. **Health Educ Behav** 1999 Feb;26(1):43–54 (65 ref.)

SEXUAL ABUSE, CHILD see **CHILD ABUSE, SEXUAL**

SEXUAL ABUSE OF CHILD see **CHILD ABUSE, SEXUAL**

SEXUAL AROUSAL DISORDER see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

SEXUAL AVERSION DISORDER see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL

CHEMICALLY INDUCED

The behavioural toxicity of antidepressants: effects on cognition and sexual function. Hindmarch I. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S5–8 (13 ref.)

Selective serotonin reuptake inhibitor-induced sexual dysfunction: clinical and research considerations. Waldinger MD, et al. **Int Clin Psychopharmacol** 1998 Jul; 13 Suppl 6:S27–33 (50 ref.)

Management of sexual side effects of antidepressant therapy. Hirschfeld RM. **J Clin Psychiatry** 1999;60 Suppl 14:27–30; discussion 31–5 (15 ref.)

Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. Shen WW, et al. **J Reprod Med** 1999 Jun;44(6):535–42 (61 ref.)

A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. Alcántara AG. **J Sex Marital Ther** 1999 Apr–Jun;25(2):125–9 (34 ref.)

Problems assessing nonserious adverse drug reactions: antidepressant drug therapy and sexual dysfunction. Michels KB. **Pharmacotherapy** 1999 Apr;19(4):424–9 (43 ref.)

DIAGNOSIS

Does vaginismus exist? A critical review of the literature. Reissing ED, et al. **J Nerv Ment Dis** 1999 May; 187(5):261–74 (110 ref.)

DRUG THERAPY

Management of SSRI-induced sexual dysfunction. Woodrum ST, et al. **Ann Pharmacother** 1998 Nov;32(11):1209–15 (49 ref.)

Care of the sexually active depressed patient. Hirschfeld RM. **J Clin Psychiatry** 1999;60 Suppl 17:32–5; discussion 46–8 (20 ref.)

Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. Shen WW, et al. **J Reprod Med** 1999 Jun;44(6):535–42 (61 ref.)

[Sildenafil (Viagra) for the treatment of erectile disorder (see comments)] Meuleman EJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2337–41 (31 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2332–3. Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2333–6. **(Dut)**

EPIDEMIOLOGY

Care of the sexually active depressed patient. Hirschfeld RM. **J Clin Psychiatry** 1999;60 Suppl 17:32–5; discussion 46–8 (20 ref.)

ETIOLOGY

Sexuality after hypospadias repair. Bracka A. **BJU Int** 1999 Apr;83 Suppl 3:29–33 (21 ref.)

ABC of sexual health: female sexual problems II: sexual pain and sexual fears [see comments] Butcher J. **BMJ** 1999 Jan 9;318(7176):110–2 (0 ref.) Comment in: BMJ 1999 Jun 5;318(7197):1559.

[Sexual dysfunctions in depressed patients] Zięba A, et al. **Psychiatr Pol** 1998 Sep-Oct;32(5):621–8 (38 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. Alcántara AG. **J Sex Marital Ther** 1999 Apr-Jun;25(2):125–9 (34 ref.)

PHYSIOPATHOLOGY

Effects of epilepsy on women's reproductive health. Morrell MJ. **Epilepsia** 1998;39 Suppl 8:S32–7 (61 ref.)

PSYCHOLOGY

Sexual problems in healthy and depressed persons. Angst J. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S1–4 (7 ref.)

THERAPY

Empirically validated treatment for sexual dysfunction. Heiman JR, et al. **Annu Rev Sex Res** 1997;8:148–94 (182 ref.)

Psychotherapy for male sexual dysfunction: a review. O'Donohue WT, et al. **Clin Psychol Rev** 1999 Aug; 19(5):591–630 (91 ref.)

Management of sexual side effects of antidepressant therapy. Hirschfeld RM. **J Clin Psychiatry** 1999;60 Suppl 14:27–30; discussion 31–5 (15 ref.)

SEXUAL HARASSMENT

LEGISLATION & JURISPRUDENCE

Forensic aspects of sexual harassment. Rosman JP, et al. **Psychiatr Clin North Am** 1999 Mar;22(1):129–45 (31 ref.)

PREVENTION & CONTROL

Stalking. An old behavior, a new crime. Meloy JR. **Psychiatr Clin North Am** 1999 Mar;22(1):85–99 (49 ref.)

PSYCHOLOGY

Stalking. An old behavior, a new crime. Meloy JR. **Psychiatr Clin North Am** 1999 Mar;22(1):85–99 (49 ref.)

SEXUAL ORIENTATION see **SEX BEHAVIOR**

SEXUAL PARTNERS

PSYCHOLOGY

Generic aspects of primate attachments: parents, offspring and mates. Mason WA, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):765–78 (97 ref.)

SEXUALITY

see related

PSYCHOSEXUAL DEVELOPMENT

Sexuality and sex education at home and school. Kirby D. **Adolesc Med** 1999 Jun;10(2):195–209, v (76 ref.)

Sexuality, culture, and political economy: recent developments in anthropological and cross-cultural sex research. Parker R, et al. **Annu Rev Sex Res** 1998;9:1–19 (106 ref.)

Diabetes mellitus and female sexuality: a review of 25 years' research [see comments] Enzlin P, et al. **Diabet Med** 1998 Oct;15(10):809–15 (40 ref.) Comment in: Diabet Med 1998 Oct;15(10):807–6.

Prostate and sexuality: An overview. Burger B, et al. **Eur Urol** 1999;35(3):177–84 (44 ref.)

The management of embarrassment and sexuality in health care. Meerabeau L. **J Adv Nurs** 1999 Jun;29(6):1507–13 (55 ref.)

DRUG EFFECTS

Psychotropics and sexuality. Demyttenaere K, et al. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S35–41 (72 ref.)

Effects of SSRIs on sexual function: a critical review. Rosen RC, et al. **J Clin Psychopharmacol** 1999 Feb;19(1):67–85 (255 ref.)

PHYSIOLOGY

The biological basis of female sexuality. Graziottin A. **Int Clin Psychopharmacol** 1998 Jul;13 Suppl 6:S15–22 (36 ref.)

PSYCHOLOGY

The enigmatic dimension of sexual experience: the "otherness" of sexuality and primal seduction. Stein R. **Psychoanal Q** 1998 Oct;67(4):594–625 (54 ref.)

SEXUALLY TRANSMITTED DISEASES

Syndromic management of sexually transmitted diseases. Part 2—The management of genital discharge. Latif AS. **Cent Afr J Med** 1998 Sep;44(9):236–41 (14 ref.)

Sexually transmitted diseases in adolescents: an update. Krowchuk DP. **Compr Ther** 1999 May;25(5):265–71 (44 ref.)

Surveillance of sexually transmitted infections: fit for purpose? [comment] Catchpole MA, et al. **Int J STD AIDS** 1999 Aug;10(8):493–4 (14 ref.) Comment on: Int J STD AIDS 1999 Aug;10(8):554–6.

An overview of sexually transmitted diseases. Part I. Brown TJ, et al. **J Am Acad Dermatol** 1999 Oct;41(4):511–32 (155 ref.)

Adolescents and sexually transmitted diseases. Gevelber MA, et al. **Pediatr Clin North Am** 1999 Aug;46(4):747–66 (69 ref.)

Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus. El-Attar SM, et al. **Prim Care** 1999 Mar;26(1):81–100 (32 ref.)

From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Fleming DT, et al. **Sex Transm Infect** 1999 Feb;75(1):3–17 (81 ref.)

[Progresses in the study of dermatology and venereology in China, 1997] Zhu T. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):942–3 (0 ref.) **(Chi)**

[Molluscum contagiosum (genital)] Honda M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):74–6 (5 ref.) **(Jpn)**

[Hepatitis viruses] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):62–5 (15 ref.) **(Jpn)**

COMPLICATIONS

Alcohol intake and sexually transmitted diseases. Tüzün B, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):469–78 (130 ref.)

Sexually transmitted diseases in HIV-positive patients. Ormond P, et al. **Dermatol Clin** 1998 Oct;16(4):853–7, xvi (52 ref.)

DIAGNOSIS

Sexually transmitted diseases: testing and treating. Rome ES. **Adolesc Med** 1999 Jun;10(2):231–41, vi (40 ref.)

Urethritis and cervicitis. Molodysky E.
Aust Fam Physician 1999 Apr;28(4):333–8 (6 ref.)
Syndromic management of sexually transmitted diseases. Part 1--An overview. Latif AS. **Cent Afr J Med** 1998 Aug; 44(8):210–3 (15 ref.)
Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Rompalo AM. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S84–90 (95 ref.)
Genital ulcers. Evaluation and treatment. Rosen T, et al. **Dermatol Clin** 1998 Oct;16(4):673–85, x (88 ref.)
Etiology of nongonococcal nonchlamydial urethritis. Schwartz MA, et al. **Dermatol Clin** 1998 Oct;16(4):727–33, xi (72 ref.)
The enigmatic cervix. Sweet RL. **Dermatol Clin** 1998 Oct; 16(4):739–45, xii (28 ref.)
Nucleic acid tests for the diagnosis of sexually transmitted diseases. Chernesky MA.
FEMS Immunol Med Microbiol 1999 Jul 15;24(4):437–46 (46 ref.)
Correct samples for diagnostic tests in sexually transmitted diseases: which sample for which test? Stary A.
FEMS Immunol Med Microbiol 1999 Jul 15;24(4):455–9 (30 ref.)
The medical evaluation of the sexually abused child: lessons from a decade of research. Atabaki S, et al. **Pediatrics** 1999 Jul;104(1 Pt 2):178–86 (76 ref.)
Newly available and future laboratory tests for sexually transmitted diseases (STDs) other than HIV. Chernesky M, et al. **Sex Transm Dis** 1999 Apr;26(4 Suppl):S8–11 (13 ref.)
Syndromic management of sexually transmitted diseases: is it rational or scientific? Bosu WK.
Trop Med Int Health 1999 Feb;4(2):114–9 (26 ref.)
[Sexually transmitted diseases: laboratory diagnosis] Corsini V, et al. **Minerva Pediatr** 1998 Jun;50(6):239–42 (6 ref.) **(Ita)**
[Laboratory diagnosis of viral infections. 12. Urogenital diseases and sexually transmitted diseases] Kubota T.
Rinsho Byori 1998 Nov;Suppl 108:128–31 (2 ref.) **(Jpn)**

DRUG THERAPY

Sexually transmitted diseases: testing and treating. Rome ES.
Adolesc Med 1999 Jun;10(2):231–41, vi (40 ref.)
Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Rompalo AM. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S84–90 (95 ref.)
Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Walker CK, et al. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S29–36 (92 ref.)
Urethritis treatment. Erbelding EJ, et al. **Dermatol Clin** 1998 Oct;16(4):735–8, xi–xii (16 ref.)
Issues in the management of sexually transmitted diseases in Papua New Guinea. Passey M. **P N G Med J** 1996 Sep; 39(3):252–60 (14 ref.)
[Optimizing the choice of drugs in sexually transmitted diseases] Khveshchuk PF, et al. **Voen Med Zh** 1999 Mar; 320(3):22–8 (28 ref.) **(Rus)**

ECONOMICS

Cost benefit analysis of sexually transmitted diseases. Bulut A. **FEMS Immunol Med Microbiol** 1999 Jul 15;24(4):461–7 (20 ref.)

EPIDEMIOLOGY

Sexually transmitted diseases in abused children and adolescent and adult victims of rape: review of selected literature. Beck-Sagué CM, et al. **Clin Infect Dis** 1999 Jan; 28 Suppl 1:S74–83 (101 ref.)
Limitations of current surveillance programs for sexually transmitted infections and allied conditions affecting reproductive health care. Mårdh PA.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):147–54 (11 ref.)
Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Cates W Jr. **Sex Transm Dis** 1999 Apr;26(4 Suppl):S2–7 (35 ref.)
Global prevalence and incidence estimates of selected curable STDs. Gerbase AC, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S12–6 (14 ref.)
[Sexually transmitted diseases---past, present and future in China] Zhang J.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1998 Apr; 19(2):118–21 (0 ref.) **(Chi)**

ETHNOLOGY

Latinas and sexually transmitted diseases: implications of recent research for prevention. Suarez ZE, et al.
Soc Work Health Care 1998;28(1):1–19 (61 ref.)

ETIOLOGY

Does circumcision influence sexually transmitted diseases?: a literature review. Van Howe RS. **BJU Int** 1999 Jan;83 Suppl 1:52–62 (104 ref.)
Sexually transmitted organisms in children and child sexual abuse [see comments] Robinson AJ. **Int J STD AIDS** 1998 Sep;9(9):501–10; quiz 510–1 (82 ref.) Comment in: Int J STD AIDS 1999 Mar;10(3):209–10.
Global risk of sexually transmitted diseases. Wang CC, et al. **Med Clin North Am** 1999 Jul;83(4):975–95, vi (78 ref.)

NURSING

Sexually transmitted diseases and reproductive health in women. Burst HV. **J Nurse Midwifery** 1998 Nov–Dec; 43(6):431–44 (71 ref.)

PARASITOLOGY

[Sexually transmitted parasitoses and mycoses] Vahlensieck W. **Fortschr Med** 1999 May 10;117(13):32–5 (42 ref.) **(Ger)**

PHYSIOPATHOLOGY

[Vaginal infections and sexually transmitted diseases] van den Brûle F. **Rev Med Liege** 1999 Apr;54(4):296–302 (25 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of sexually transmitted diseases: the need for social and behavioral science expertise in public health departments [editorial; comment] Van Devanter N.
Am J Public Health 1999 Jun;89(6):815–8 (38 ref.) Comment on: Am J Public Health 1999 Jun;89(6):899–902.
Prevention and intervention of sexually transmitted diseases in adolescents. D'Souza CM, et al. **Curr Opin Pediatr** 1999 Aug;11(4):287–91 (34 ref.)
Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Zeitlin L, et al.
Emerg Infect Dis 1999 Jan–Feb;5(1):54–64 (127 ref.)
Improvement of surveillance programs for sexually transmitted infections and related conditions. Mårdh PA.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):136–46 (26 ref.)
Limitations of current surveillance programs for sexually transmitted infections and allied conditions affecting reproductive health care. Mårdh PA.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):147–54 (11 ref.)
The FemCap: a new contraceptive choice. Shihata AA.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):160–6 (10 ref.)
Changing behavior to prevent STDs/AIDS. Fishbein M.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S175–81 (26 ref.)
Teaching safe sex in school. Short R.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S147–50 (4 ref.)
Syndromic management for sexually transmitted diseases: back to the drawing board. Hudson CP.
Int J STD AIDS 1999 Jul;10(7):423–34 (88 ref.)
Sexually transmitted diseases and reproductive health in women. Burst HV. **J Nurse Midwifery** 1998 Nov–Dec; 43(6):431–44 (71 ref.)
Observations from the CDC. The urgent need for new HIV/STD prevention options for women. Irwin K, et al.
J Womens Health 1998 Nov;7(9):1081–6 (27 ref.)
Accelerated Campaign to Enhance STD Services (ACCESS) for youth: successes, challenges, and lessons learned. DeLisle S, et al. **Sex Transm Dis** 1999 Apr;26(4 Suppl):S28–41; discussion S42–3 (11 ref.)
The use of epidemiologic mass treatment and syndrome management for sexually transmitted disease control. Steen R, et al. **Sex Transm Dis** 1999 Apr;26(4 Suppl):S12–20; discussion S21–2 (93 ref.)
Problems, solutions, and challenges in syndromic management of sexually transmitted diseases. Dallabetta GA, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S1–11 (88 ref.)
Evaluation of behavioural interventions in HIV/STI prevention. Stephenson JM. **Sex Transm Infect** 1999 Feb; 75(1):69–71 (21 ref.)
Latinas and sexually transmitted diseases: implications of recent research for prevention. Suarez ZE, et al.
Soc Work Health Care 1998;28(1):1–19 (61 ref.)
Methods and meanings in anthropological, epidemiological and clinical encounters: the case of sexually transmitted disease and human immunodeficiency virus control and prevention in India [see comments] Lambert H.
Trop Med Int Health 1998 Dec;3(12):1002–10 (38 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):993–5.
Confronting STDs: a challenge for managed care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):36S–46S (25 ref.)

PSYCHOLOGY

Sexually transmitted diseases, unintended pregnancy, and adolescent health promotion. Santelli JS, et al.
Adolesc Med 1999 Feb;10(1):87–108, vi (180 ref.)

THERAPY

Indicators and the measurement of STD case management in developing countries. STD PI6&7 Working Group. Saidel TJ, et al. **AIDS** 1998;12 Suppl 2:S57–65 (30 ref.)
Syndromic management of sexually transmitted diseases. Part 1--An overview. Latif AS. **Cent Afr J Med** 1998 Aug; 44(8):210–3 (15 ref.)
Current approach to STD management in women. Amaral E. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S183–9 (28 ref.)
The use of epidemiologic mass treatment and syndrome management for sexually transmitted disease control. Steen R, et al. **Sex Transm Dis** 1999 Apr;26(4 Suppl):S12–20; discussion S21–2 (93 ref.)
Evaluating outreach clinics [comment] Davidson EA.
Sex Transm Infect 1999 Jun;75(3):198–9 (11 ref.) Comment on: Sex Transm Infect 1999 Jun;75(3):195–7.
A novel approach to outcome evaluation [see comments] Horn CK, et al. **Sex Transm Infect** 1999 Jun;75(3):195–7 (6 ref.) Comment in: Sex Transm Infect 1999 Jun;75(3):146–7. Comment in: Sex Transm Infect 1999 Jun;75(3):198–9.
Syndromic management of sexually transmitted diseases: is it rational or scientific? Bosu WK.
Trop Med Int Health 1999 Feb;4(2):114–9 (26 ref.)
Confronting STDs: a challenge for managed care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):36S–46S (25 ref.)
[Treatment of sexually transmitted diseases] Raudrant D, et al. **Contracept Fertil Sex** 1998 Dec;26(12):830–6 (21 ref.) **(Fre)**
[Gynecological infections in general practice] Lauper U, et al. **Schweiz Rundsch Med Prax** 1999 Apr 1;88(14):633–8 (2 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Gillison ML, et al.
Curr Opin Oncol 1999 May;11(3):191–9 (110 ref.)
Sexually transmitted diseases in sexually abused children: medical and legal implications. Hammerschlag MR.
Sex Transm Infect 1998 Jun;74(3):167–74 (67 ref.)
[Kaposi's sarcoma: a sexually transmitted cancer?] Sousa Escandón MA, et al. **Actas Urol Esp** 1999 Feb;23(2):89–94 (34 ref.) (Eng. Abstr.) **(Spa)**

SEXUALLY TRANSMITTED DISEASES, BACTERIAL

DIAGNOSIS

Pelvic inflammatory disease. From diagnosis to prevention. Paavonen J. **Dermatol Clin** 1998 Oct;16(4):747–56, xii (56 ref.)
Diagnostic tests that are worthwhile for patients with sexually transmitted bacterial infections in industrialized countries. Taylor-Robinson D, et al. **Int J STD AIDS** 1999 Jan;10(1):1–4 (31 ref.)

DRUG THERAPY

Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis, epididymitis and prostatitis. Joly-Guillou ML, et al. **Drugs** 1999 May;57(5):743–50 (31 ref.)
Bacterial sexually transmitted infections: current management strategies. Tariq A, et al. **J Clin Pharm Ther** 1999 Feb; 24(1):53–6 (25 ref.)

ETIOLOGY

[Sexually transmitted diseases produced by Chlamydia trachomatis and their treatment] Perea Pérez EJ.
Rev Clin Esp 1998 Sep;198 Suppl 1:44–50 (38 ref.) **(Spa)**

SEXUALLY TRANSMITTED DISEASES, VIRAL

DRUG THERAPY

[Viral sexually transmitted diseases and their treatments] Parent D, et al. **Rev Med Brux** 1998 Sep;19(4):A185–90 (16 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

HHV-8 and multiple myeloma. Berenson JR, et al.
Pathol Biol (Paris) 1999 Feb;47(2):115–8 (25 ref.)

TRANSMISSION

High risk genital papillomavirus infections are not spread vertically. Dillner J, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):23–9 (63 ref.)
Sexual transmission and prevention of the hepatitis viruses A–E and G. Brook MG. **Sex Transm Infect** 1998 Dec; 74(6):395–8 (61 ref.)
Sexual transmission of hepatitis C virus infection. Rooney G, et al. **Sex Transm Infect** 1998 Dec;74(6):399–404 (77 ref.)

VIROLOGY

[Viral sexually transmitted diseases and their treatments] Parent D, et al. **Rev Med Brux** 1998 Sep;19(4):A185–90 (16 ref.) (Eng. Abstr.) **(Fre)**

SEZARY SYNDROME

Mycosis fungoides and the Sézary syndrome. Kim YH, et al. **Semin Oncol** 1999 Jun;26(3):276–89 (86 ref.)
[Sézary syndrome] Sasaki M, et al.

SEZARY SYNDROME

Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):276–8 (12 ref.) **(Jpn)**

DIAGNOSIS

[The Sézary syndrome] Ferreira F, et al. **Acta Med Port** 1998 Dec;11(12):1135–9 (11 ref.) (Eng. Abstr.) **(Por)**

GENETICS

T-cell receptor gene analysis in the diagnosis of Sézary syndrome. Russell-Jones R, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):254–9 (53 ref.)

SGOT see **ASPARTATE TRANSAMINASE**

SGPT see **ALANINE TRANSAMINASE**

SH DOMAINS see **SRC HOMOLOGY DOMAINS**

SHAMANISM

Hallucinogenic drugs and plants in psychotherapy and shamanism. Metzner R. **J Psychoactive Drugs** 1998 Oct-Dec;30(4):333–41 (46 ref.)

SHARED PARANOID DISORDER

PSYCHOLOGY

[Communicated insanity, folie a deux and shared psychotic disorder. Different concepts and a case from Mallorca] Arenz D, et al. **Fortschr Neurol Psychiatr** 1999 Jun; 67(6):249–55 (31 ref.) (Eng. Abstr.) **(Ger)**

SHARED PSYCHOTIC DISORDER see **SHARED PARANOID DISORDER**

SHARKS

GENETICS

What sharks can tell us about the evolution of MHC genes. Bartl S. **Immunol Rev** 1998 Dec;166:317–31 (99 ref.)
Antibodies of sharks: revolution and evolution. Marchalonis JJ, et al. **Immunol Rev** 1998 Dec;166:103–22 (109 ref.)

IMMUNOLOGY

Shark complement: an assessment. Smith SL. **Immunol Rev** 1998 Dec;166:67–78 (92 ref.)

SHARP SYNDROME see **MIXED CONNECTIVE TISSUE DISEASE**

SHEEHAN'S SYNDROME see **HYPOPITUITARISM**

SHEEP

A review of the road transport of slaughter sheep. Knowles TG. **Vet Rec** 1998 Aug 22;143(8):212–9 (69 ref.)

EMBRYOLOGY

The renin-angiotensin system and the development of the kidney and adrenal in sheep. Wintour EM, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S97–100 (39 ref.)

GENETICS

Duplicate growth hormone genes in sheep and goat. Wallis M, et al. **J Mol Endocrinol** 1998 Aug;21(1):1–5 (28 ref.)

IMMUNOLOGY

Local immune responses in afferent and efferent lymph. Haig DM, et al. **Immunology** 1999 Feb;96(2):155–63 (70 ref.)

PHYSIOLOGY

Dynamics of steroid regulation of GnRH secretion during the oestrus cycle of the ewe. Caraty A, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):68–78 (45 ref.)
Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283–94 (78 ref.)
Follicle selection in sheep with breed differences in ovulation rate. Baird DT, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):89–95 (28 ref.)
Embryo transfer and related technologies in sheep reproduction. Loi P, et al. **Reprod Nutr Dev** 1998 Nov-Dec; 38(6):615–28 (123 ref.)

SHEEP DISEASES

Large offspring syndrome in cattle and sheep. Young LE, et al. **Rev Reprod** 1998 Sep;3(3):155–63 (61 ref.)

CHEMICALLY INDUCED

Diagnosis and treatment of copper toxicosis in ruminants. Auza NJ, et al. **J Am Vet Med Assoc** 1999 Jun 1; 214(11):1624–8 (32 ref.)

DRUG THERAPY

Frontiers in anthelmintic pharmacology. Geary TG, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):275–95 (98 ref.)

EPIDEMIOLOGY

Traumatic myiasis of sheep in Europe: a review. Hall MJ. **Parassitologia** 1997 Dec;39(4):409–13 (50 ref.)
The role of small ruminants in the epidemiology and transmission of foot-and-mouth disease. Barnett PV, et al. **Vet J** 1999 Jul;158(1):6–13 (60 ref.)

IMMUNOLOGY

Mechanisms underlying resistance to nematode infection. Stear MJ, et al. **Int J Parasitol** 1999 Jan;29(1):51–6; discussion 73–5 (14 ref.)

PARASITOLOGY

Inter- and intra-specific variation within the genus Psoroptes (Acari: Psoroptidae). Bates PG. **Vet Parasitol** 1999 Jun 30; 83(3–4):201–17 (105 ref.)
Nutrition-parasite interaction. Coop RL, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):187–204 (95 ref.)

PHYSIOPATHOLOGY

AFA and F17 adhesins produced by pathogenic Escherichia coli strains in domestic animals. Le Bouguénec C, et al. **Vet Res** 1999 Mar-Jun;30(2-3):317–42 (103 ref.)

PREVENTION & CONTROL

A review of the use of a controlled-release formulation of ivermectin in the treatment and prophylaxis of Psoroptes ovis infestations in sheep. Forbes AB, et al. **Vet Parasitol** 1999 Jun 30;83(3–4):319–26 (21 ref.)

TRANSMISSION

Chemo- and thermosensory neurons: structure and function in animal parasitic nematodes. Ashton FT, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):297–316 (49 ref.)

SHELLFISH

see related
CRABS
CRAYFISH
LOBSTERS
MUSSELS
SHRIMP

POISONING

Pfiesteria, "the cell from hell," and other toxic algal nightmares. Morris JG Jr. **Clin Infect Dis** 1999 Jun; 28(6):1191–6; quiz 1197–8 (22 ref.)

SHELTERED WORKSHOPS

see related
EMPLOYMENT, SUPPORTED

Purposeful activity for people with enduring mental health problems: reflections from a case study. Mitchell D. **Arch Psychiatr Nurs** 1998 Oct;12(5):282–7 (26 ref.)

SHEPHERD'S BEAKED WHALE see **WHALES**

SHERMAN ANTITRUST ACT see **ANTITRUST LAWS**

SHIATSU see **ACUPRESSURE**

SHIATZU see **ACUPRESSURE**

SHIGELLA

see related
DYSENTERY, BACILLARY

GENETICS

The Shigella virulence gene regulatory cascade: a paradigm of bacterial gene control mechanisms. Dorman CJ, et al. **Mol Microbiol** 1998 Aug;29(3):677–84 (38 ref.)

PATHOGENICITY

Shigella and Escherichia coli strategies for survival at low pH. Small PL. **Jpn J Med Sci Biol** 1998;51 Suppl:S81–9 (22 ref.)
The Shigella virulence gene regulatory cascade: a paradigm of bacterial gene control mechanisms. Dorman CJ, et al. **Mol Microbiol** 1998 Aug;29(3):677–84 (38 ref.)

PHYSIOLOGY

Mechanism of Shigella entry into epithelial cells. Nhieu GT, et al. **Curr Opin Microbiol** 1999 Feb;2(1):51–5 (23 ref.)

SHIGELLA FLEXNERI

PATHOGENICITY

Molecular bases of epithelial cell invasion by Shigella flexneri. Sansonetti PJ, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):191–7 (50 ref.)
Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri. Sansonetti PJ, et al. **Clin Infect Dis** 1999 Mar;28(3):466–75 (71 ref.)
Enteropathogenic E. coli, Salmonella, and Shigella: masters of host cell cytoskeletal exploitation. Goosney DL, et al. **Emerg Infect Dis** 1999 Mar-Apr;5(2):216–23 (63 ref.)
N-WASP is an important protein for the actin-based motility of Shigella flexneri in the infected epithelial cells. Suzuki T, et al. **Jpn J Med Sci Biol** 1998;51 Suppl:S63–8 (22 ref.)

PHYSIOLOGY

N-WASP is an important protein for the actin-based motility of Shigella flexneri in the infected epithelial cells. Suzuki T, et al. **Jpn J Med Sci Biol** 1998;51 Suppl:S63–8 (22 ref.)

SHIGELLA INFECTIONS see **DYSENTERY, BACILLARY**

SHIGELLA SONNEI

[Septicemia due to Shigella. A case report and review of the literature] Ben Salas C, et al. **Rev Cubana Med Trop** 1995;47(2):131–4 (9 ref.) (Eng. Abstr.) **(Spa)**

SHIKIMIC ACID

METABOLISM

The biosynthesis of shikimate metabolites. Knaggs AR. **Nat Prod Rep** 1999 Aug;16(4):525–60 (73 ref.)
A unique reaction in a common pathway: mechanism and function of chorismate synthase in the shikimate pathway. Macheroux P, et al. **Planta** 1999 Jan;207(3):325–34 (70 ref.)

SHINER see **CYPRINIDAE**

SHINGLES see **HERPES ZOSTER**

SHIPPING FEVER VIRUS see **PARAMYXOVIRUS**

SHIPS

On PMWs and two-stroke engines [editorial] Bell W, et al. **Can Fam Physician** 1998 Sep;44:1775–7, 1787–90 (14 ref.) **(Eng, Fre)**
Legionellosis associated with ships: 1977 to 1997. Rowbotham TJ. **Commun Dis Public Health** 1998 Sep; 1(3):146–51 (32 ref.)

SHOCK

[Shock] Kovačević D, et al. **Med Pregl** 1998 Sep-Oct; 51(9–10):449–55 (16 ref.) (Eng. Abstr.) **(Scr)**

COMPLICATIONS

Neutrophil signaling alteration: an adverse inflammatory response after burn shock. Sayeed MM. **Medicina (B Aires)** 1998;58(4):386–92 (19 ref.)

DRUG THERAPY

[Does prehospital hypertonic infusion therapy improve the survival of trauma patients?] Haljamäe H. **Lakartidningen** 1999 Mar 3;96(9):1014–7 (21 ref.) (Eng. Abstr.) **(Swe)**

ETIOLOGY

Profound circulatory shock following heroin overdose. Remskar M, et al. **Resuscitation** 1998 Jul;38(1):51–3 (6 ref.)
Animal models of sepsis and shock: a review and lessons learned. Edwin A Deitch. Shock 9(1):1–11, 1998 [letter; comment] Redl H, et al. **Shock** 1998 Dec;10(6):442–5 (35 ref.) Comment on: Shock 1998 Jan;9(1):1–11.
[FMRFa and FMRFamide-like peptides (FaRPs) in the pathogenesis of shock] Tiniakov RL, et al. **Usp Fiziol Nauk** 1998 Jul-Sep;29(3):56–65 (62 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Cardiovascular actions of cannabinoids and their generation during shock. Wagner JA, et al. **J Mol Med** 1998 Nov-Dec; 76(12):824–36 (121 ref.)

PHYSIOPATHOLOGY

Nitric oxide and circulatory shock. Rubanyi GM. **Adv Exp Med Biol** 1998;454:165–72 (62 ref.)
Microcirculatory oxygenation and shunting in sepsis and shock [see comments] Ince C, et al. **Crit Care Med** 1999 Jul;27(7):1369–77 (75 ref.) Comment in: Crit Care Med 1999 Jul;27(7):1400–1.
Sudden infant death syndrome and the modulation of neuropeptides released during shock. Reid GM. **Med Hypotheses** 1998 Jul;51(1):23–6 (26 ref.)
[Progresses in the study of microcirculation in China, 1997] Jin H. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):938–9 (0 ref.) **(Chi)**
[Pathophysiology of hemodynamic shock (circulatory failure). Part 2] Kovač Z, et al. **Lijec Vjesn** 1999 Jan-Feb; 121(1-2):34–41 (42 ref.) (Eng. Abstr.) **(Scr)**

THERAPY

An evaluation of the end points of resuscitation. Elliott DC. **J Am Coll Surg** 1998 Nov;187(5):536–47 (84 ref.)
Exploding the albumin myth. Tjoeng MM, et al. **Pharm World Sci** 1999 Feb;21(1):17–20 (31 ref.)
Circulatory effects of whole blood, packed red cells, albumin, starch, and crystalloids in resuscitation of shock and acute critical illness. Shoemaker WC, et al. **Vox Sang** 1998;74 Suppl 2:69–74 (17 ref.)

SHOCK, ANAPHYLACTIC see **ANAPHYLAXIS**

SHOCK, CARDIOGENIC

COMPLICATIONS

The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. [see comments] Pang D, et al. **Chest** 1998 Oct;114(4):1185–92 (23 ref.) Comment in: ACP J Club 1999 May–Jun;130(3):58.

ETIOLOGY

Cardiogenic shock. Hollenberg SM, et al. **Ann Intern Med** 1999 Jul 6;131(1):47–59 (143 ref.)
[Cardiogenic shock] Bertel O, et al. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1428–35 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Catecholamine refractoriness and their mechanisms in cardiocirculatory shock and chronic heart failure. Böhm M. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:270–5; discussion 276 (41 ref.)

PREVENTION & CONTROL

Role of PTCA and mechanical devices in cardiogenic shock. Shawl FA. **Indian Heart J** 1998 Oct;50 Suppl 1:57–61 (50 ref.)

THERAPY

Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction. Santoro GM, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):126–31 (47 ref.)
Cardiogenic shock. Hollenberg SM, et al. **Ann Intern Med** 1999 Jul 6;131(1):47–59 (143 ref.)
Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Davis DR, et al. **Can J Cardiol** 1999 Feb;15(2):193–200 (47 ref.)
Cardiogenic shock: a failure in reperfusion. Time for a strategic change? [editorial; comment] Serruys PW, et al. **Eur Heart J** 1999 Jan;20(2):88–9 (10 ref.) Comment on: Eur Heart J 1999 Jan;20(2):128–35.
Interventional cardiology in the treatment of cardiogenic shock. Nanas JN. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III73–5 (12 ref.)

SHOCK, ENDOTOXIC see **SHOCK, SEPTIC**

SHOCK, HEMORRHAGIC

[Hemorrhagic shock] Vallet B, et al. **Rev Prat** 1999 Jan 15; 49(2):203–7 (0 ref.) **(Fre)**

IMMUNOLOGY

Immunological consequences of trauma and shock. Catania RA, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):120–32 (147 ref.)

METABOLISM

Novel roles of nitric oxide in hemorrhagic shock. Szabó C, et al. **Shock** 1999 Jul;12(1):1–9 (113 ref.)

THERAPY

Acadesine during fluid resuscitation from shock and abdominal sepsis [see comments] Melton SM, et al. **Crit Care Med** 1999 Mar;27(3):565–75 (46 ref.) Comment in: Crit Care Med 1999 Mar;27(3):468–9.
Hypertonic saline resuscitation. Rocha e Silva M. **Medicina (B Aires)** 1998;58(4):393–402 (186 ref.)
[Prehospital and early hospital management of a state of hemorrhagic shock of traumatic origin. 3rd Conference of experts in emergency medicine of the southeastern region] Martin C, et al. **Ann Fr Anesth Reanim** 1997;16(8):1030–6 (0 ref.) **(Fre)**
[Artificial oxygen carriers. Alternatives to homologous blood transfusion?] Habler O, et al. **Zentralbl Chir** 1999; 124(4):260–70 (68 ref.) (Eng. Abstr.) **(Ger)**

SHOCK LUNG see **RESPIRATORY DISTRESS SYNDROME, ADULT**

SHOCK, SEPTIC

Traumatic and septic shock alias post-trauma critical illness. Hardaway RM. **Br J Surg** 1998 Nov;85(11):1473–9 (107 ref.)
[Latest results of intensive care of sepsis, septic shock and multiple organ injuries] Incze F. **Orv Hetil** 1999 Mar 7; 140(10):515–20 (49 ref.) (Eng. Abstr.) **(Hun)**
[Streptococcal toxic shock-like syndrome] Shimizu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):115–8 (9 ref.) **(Jpn)**
[Toxic shock-like syndrome] Shiseki M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):237–40 (12 ref.) **(Jpn)**
[Toxic shock syndrome (TSS)] Totsuka K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):15–9 (6 ref.) **(Jpn)**
[Septic shock] Totsuka K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):248–51 (3 ref.) **(Jpn)**

DIAGNOSIS

Life-threatening rashes: dermatologic signs of four infectious diseases. Drage LA. **Mayo Clin Proc** 1999 Jan;74(1):68–72 (10 ref.)
Another toxic shock syndrome. Streptococcal infection is even more dangerous than the staphylococcal form. Hauser AR. **Postgrad Med** 1998 Dec;104(6):31–4, 39, 43–4 (18 ref.)
["Streptococcal toxic shock-like syndrome"] Broll R, et al. **Chirurg** 1998 Aug;69(8):806–12 (41 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Nitric oxide synthase inhibition in septic shock--a question of the right time, the right drug, and the right model? [editorial; comment] Bone HG. **Crit Care Med** 1998 Dec; 26(12):1945–7 (18 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2021–8.
From mega to more reasonable doses of corticosteroids: a decade to recreate hope [editorial; comment] Carlet J. **Crit Care Med** 1999 Apr;27(4):672–4 (26 ref.) Comment on: Crit Care Med 1999 Apr;27(4):723–32.
Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red [editorial; comment] Cobb JP. **Crit Care Med** 1999 May;27(5):855–6 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):913–22.
Fighting fire with fire [editorial; comment] Kan H, et al. **Crit Care Med** 1998 Oct;26(10):1628–9 (11 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1663–70.
Nitric oxide synthase inhibitors--a mechanism-based treatment of septic shock [editorial; comment] Kilbourn R. **Crit Care Med** 1999 May;27(5):857–8 (13 ref.) Comment on: Crit Care Med 1999 May;27(5):913–22.
An intensivist's dilemma: support of the splanchnic circulation in critical illness [editorial; comment] Marshall JC. **Crit Care Med** 1998 Oct;26(10):1637–8 (20 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1749–58.
Treatment of sepsis: past and future avenues. Baumgartner JD, et al. **Drugs** 1999 Feb;57(2):127–32 (56 ref.)
Antithrombin replacement in patients with sepsis and septic shock. Giudici D, et al. **Haematologica** 1999 May; 84(5):452–60 (54 ref.)
New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Periti P, et al. **Int J Antimicrob Agents** 1999 Jul;12(2):97–105 (74 ref.)
[Toxic shock-like syndrome caused by streptococci (see comments)] van Dissel JT, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1452–5 (33 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 10;143(28):1452–5. **(Dut)**
[Antithrombin III in severe sepsis and septic shock] Carrillo-Esper R, et al. **Gac Med Mex** 1999 Jul–Aug; 135(4):443–6 (30 ref.) **(Spa)**

ENZYMOLOGY

Nitric oxide in septic shock. Titheradge MA. **Biochim Biophys Acta** 1999 May 5;1411(2–3):437–55 (109 ref.)

ETIOLOGY

The flesh-eating bacterium: what's next? Stevens DL. **J Infect Dis** 1999 Mar;179 Suppl 2:S366–74 (96 ref.)
[Meningococcal sepsis and septic shock: efficient measures and controversial treatments] Casado Flores J, et al. **An Esp Pediatr** 1999 Apr;50(4):346–52 (74 ref.) **(Spa)**

GENETICS

The molecular pathogenesis of endotoxic shock and organ failure. Karima R, et al. **Mol Med Today** 1999 Mar; 5(3):123–32 (58 ref.)

IMMUNOLOGY

Antibodies to TNF-alpha: too little, too late? [editorial; comment] Kirschenbaum L, et al. **Crit Care Med** 1998 Oct; 26(10):1625–6 (11 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1650–9.
Molecular basis of host-pathogen interaction in septic shock. Heumann D, et al. **Curr Opin Microbiol** 1998 Feb; 1(1):49–55 (77 ref.)
Endotoxins and endocrine system. Bertók L. **Domest Anim Endocrinol** 1998 Sep;15(5):305–8 (21 ref.)
Structure and function of streptococcal and staphylococcal superantigens in septic shock. Bannan J, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):387–96, ix (69 ref.)
Superantigens in human disease. Bernal A, et al. **J Clin Immunol** 1999 May;19(3):149–57 (83 ref.)
[Bile acids and endotoxins: physico-chemical defense of the body] Bertók L. **Orv Hetil** 1999 Jan 3;140(1):3–8 (38 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Nitric oxide in septic shock: directions for future therapy? Hon WM, et al. **Ann Acad Med Singapore** 1998 May; 27(3):414–21 (70 ref.)
Elevated hypoxanthine in endotoxic shock [editorial; comment] Alston TA. **Crit Care Med** 1999 Apr;27(4):690–1 (12 ref.) Comment on: Crit Care Med 1999 Apr;27(4):790–7.
Adrenomedullin in sepsis and septic shock [editorial; comment] Wang P. **Shock** 1998 Nov;10(5):383–4 (23 ref.) Comment on: Shock 1998 Jan;9(1):1–11. Comment on: Shock 1998 Aug;10(2):79–89. Comment on: Shock 1998 Aug;10(2):118–22. Comment on: Shock 1998 Oct;10(4):243–7.

MICROBIOLOGY

[Toxic shock-like syndrome caused by streptococci (see comments)] van Dissel JT, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1452–5 (33 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 10;143(28):1452–5. **(Dut)**

MORTALITY

Reduced mortality from septic shock--lessons for the future [editorial; comment] Cohen NH. **Crit Care Med** 1998 Dec; 26(12):1956–8 (25 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2078–86.
Has the mortality of septic shock changed with time [see comments] Friedman G, et al. **Crit Care Med** 1998 Dec; 26(12):2078–86 (144 ref.) Comment in: Crit Care Med 1998 Dec;26(12):1956–8.

PATHOLOGY

Alpha1-antitrypsin deficiency and toxic shock: a Japanese autopsy case. Nakade O, et al. **Pathol Int** 1999 Jan; 49(1):79–84 (33 ref.)
[The ultrastructural bases of multiple organ failure in the pathogenesis of endotoxic shock] Bardakhch'ian EA, et al. **Patol Fiziol Eksp Ter** 1999 Jul–Sep;(3):22–5 (39 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Mechanisms and management of myocardial dysfunction in septic shock [editorial; comment] Carpati CM, et al. **Crit Care Med** 1999 Feb;27(2):231–2 (24 ref.) Comment on: Crit Care Med 1999 Feb;27(2):286–92.
Expired nitric oxide and shock in higher order species [editorial; comment] Traber DL. **Crit Care Med** 1999 Feb; 27(2):255–6 (11 ref.) Comment on: Crit Care Med 1999 Feb;27(2):385–93.
Myocardial dysfunction in sepsis: mechanisms and therapeutic implications. Price S, et al. **Eur Heart J** 1999 May;20(10):715–24 (93 ref.)
The molecular pathogenesis of endotoxic shock and organ failure. Karima R, et al. **Mol Med Today** 1999 Mar; 5(3):123–32 (58 ref.)
Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock [editorial] Khan RZ, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):814–8 (63 ref.)
Myocardial dysfunction in sepsis: clinical and experimental investigations. Suffredini AF. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1444–52 (51 ref.)
[Pathogenesis of pancreatogenic sepsis] Runkel N. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:439–42 (6 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. Periti P, et al. **J Chemother** 1998 Dec;10(6):427–48 (126 ref.)

THERAPY

Nitric oxide in septic shock: directions for future therapy? Hon WM, et al. **Ann Acad Med Singapore** 1998 May; 27(3):414–21 (70 ref.)
Emerging therapies for sepsis and septic shock. Oh HM. **Ann Acad Med Singapore** 1998 Sep;27(5):738–43 (40 ref.)
Reduced mortality from septic shock--lessons for the future [editorial; comment] Cohen NH. **Crit Care Med** 1998 Dec; 26(12):1956–8 (25 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2078–86.
Antibodies to TNF-alpha: too little, too late? [editorial; comment] Kirschenbaum L, et al. **Crit Care Med** 1998 Oct; 26(10):1625–6 (11 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1650–9.
Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. Mayer AM. **Medicina (B Aires)** 1998;58(4):377–85 (137 ref.)
Another toxic shock syndrome. Streptococcal infection is even more dangerous than the staphylococcal form. Hauser

SHOCK, SEPTIC

AR. **Postgrad Med** 1998 Dec;104(6):31–4, 39, 43–4 (18 ref.)
[Meningococcal sepsis and septic shock: efficient measures and controversial treatments] Casado Flores J, et al. **An Esp Pediatr** 1999 Apr;50(4):346–52 (74 ref.) **(Spa)**

SHOCK THERAPY see **CONVULSIVE THERAPY**

SHOCK THERAPY, ELECTRIC see **ELECTROCONVULSIVE THERAPY**

SHOCK THERAPY, INSULIN see **CONVULSIVE THERAPY**

SHOCK, TOXIC see **SHOCK, SEPTIC**

SHOCK, TRAUMATIC

Traumatic and septic shock alias post-trauma critical illness. Hardaway RM. **Br J Surg** 1998 Nov;85(11):1473–9 (107 ref.)

DIAGNOSIS

[The course of the traumatic disease in multiple trauma] Sheiko VD. **Klin Khir** 1998;(9–10):70–3; discussion 73–4 (49 ref.) **(Ukr, Rus)**

THERAPY

The management of shock and local injury in traumatic rhabdomyolysis. Nespoli A, et al. **Minerva Anestesiol** 1999 May;65(5):256–62 (36 ref.)

SHOCK WAVES, HIGH-ENERGY see **HIGH-ENERGY SHOCK WAVES**

SHOCKWAVES, ULTRASONIC see **ULTRASONICS**

SHOES

Footwear and postural stability in older people. Menz HB, et al. **J Am Podiatr Med Assoc** 1999 Jul;89(7):346–57 (100 ref.)
Women's shoe wear: an orthopaedist's advice. Frey C, et al. **J Womens Health** 1999 Jan–Feb;8(1):45–9 (14 ref.)
Shoe inserts and orthotics for sport and physical activities. Nigg BM, et al. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S421–8 (61 ref.)
[Technical orthopedic therapy of diabetic foot] Stinus H. **Zentralbl Chir** 1999;124 Suppl 1:65–8 (13 ref.) (Eng. Abstr.) **(Ger)**

SHORT BOWEL SYNDROME

Short bowel syndrome. Booth IW, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):739–73 (142 ref.)
Short bowel syndrome in pediatric patients. Goulet O. **Nutrition** 1998 Oct;14(10):784–7 (58 ref.)

COMPLICATIONS

D-lactic acidosis in short bowel syndrome. Day AS, et al. **N Z Med J** 1999 Jul 23;112(1092):277–8 (13 ref.)

DRUG THERAPY

Small bowel adaptation with growth hormone and glutamine after massive resection of rat's small bowel. Waitzberg DL, et al. **Nutr Hosp** 1999 Mar–Apr;14(2):81–90 (66 ref.)

SURGERY

Short bowel syndrome in patients studied at the National Institute of Pediatrics in Mexico. Care, cost and perspectives [published erratum appears in Arch Med Res 1999 Mar–Apr;30(2):159] Varela-Fascinetto G, et al. **Arch Med Res** 1998 Winter;29(4):337–40 (17 ref.)
[Short bowel syndrome--surgical aspects] Grebeldinger S, et al. **Med Pregl** 1998 Sep–Oct;51(9–10):405–9 (12 ref.) (Eng. Abstr.) **(Ser)**

THERAPY

Management of patients with a short bowel. Nightingale JM. **Nutrition** 1999 Jul–Aug;15(7–8):633–7 (66 ref.)
[Therapy of Crohn disease in internal medicine: short bowel syndrome and toxic megacolon] Forssmann K, et al. **Schweiz Rundsch Med Prax** 1998 Nov 26;87(48):1652–6 (14 ref.) (Eng. Abstr.) **(Ger)**

SHORT INTERSPERSED DNA SEQUENCE ELEMENTS see **SHORT INTERSPERSED NUCLEOTIDE ELEMENTS**

SHORT INTERSPERSED NUCLEOTIDE ELEMENTS

GENETICS

Does SINE evolution preclude Alu function? Schmid CW. **Nucleic Acids Res** 1998 Oct 15;26(20):4541–50 (89 ref.)

SHORT-SNOUTED WHITE-BELLY DOLPHIN see **DOLPHINS**

SHORT-TERM PSYCHOTHERAPY see **PSYCHOTHERAPY, BRIEF**

SHORT WAVES see **RADIO WAVES**

SHOTGUNS see **FIREARMS**

SHOULDER

Brachial plexus palsy: an in utero injury? Gherman RB, et al. **Am J Obstet Gynecol** 1999 May;180(5):1303–7 (52 ref.)
Shoulder dystocia. Gherman RB, et al. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):459–63 (35 ref.)
Isolated and combined lesions of the axillary nerve. A review of 146 cases. Bonnard C, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):212–7 (25 ref.)
Shoulder dystocia. Wagner RK, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):371–83 (49 ref.)
Suprascapular entrapment neuropathy and ganglion cysts about the shoulder. Ferrick MR, et al. **Orthopedics** 1999 Apr;22(4):430–4; discussion 434–5; quiz 436–7 (47 ref.)

ANATOMY & HISTOLOGY

Shoulder sonography. State of the art. Teefey SA, et al. **Radiol Clin North Am** 1999 Jul;37(4):767–85, ix (30 ref.)

INJURIES

Shoulder and elbow injuries and painful syndromes. Kelly AM, et al. **Adolesc Med** 1998 Oct;9(3):569–87, vii (22 ref.)
Musculoskeletal rehabilitation and sports medicine. 2. Shoulder and upper extremity injuries. Ellen MI, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S50–8 (101 ref.)
Shoulder injuries in competitive swimmers. McMaster WC. **Clin Sports Med** 1999 Apr;18(2):349–59, vii (51 ref.)
MR imaging of rotator interval, long biceps, and associated injuries in the overhead-throwing athlete. Ho CP. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):23–37 (18 ref.)
[Paralytic shoulder secondary to post-traumatic peripheral nerve lesions in the adult] Alnot JY. **Acta Orthop Belg** 1999 Mar;65(1):10–22 (50 ref.) (Eng. Abstr.) **(Fre)**
[Clinical examination of the shoulder] König DP, et al. **Sportverletz Sportschaden** 1998 Sep;12(3):94–101 (14 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Axillary nerve injuries in contact sports: recommendations for treatment and rehabilitation. Perlmutter GS, et al. **Sports Med** 1998 Nov;26(5):351–61 (30 ref.)
[Paralytic shoulder secondary to post-traumatic peripheral nerve lesions in the adult] Alnot JY. **Acta Orthop Belg** 1999 Mar;65(1):10–22 (50 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Shoulder sonography. State of the art. Teefey SA, et al. **Radiol Clin North Am** 1999 Jul;37(4):767–85, ix (30 ref.)

SHOULDER DISLOCATION

COMPLICATIONS

Complications of shoulder dislocation. Beeson MS. **Am J Emerg Med** 1999 May;17(3):288–95 (53 ref.)
Irreducible anterior shoulder dislocation with fracture of the greater tuberosity. Ilahi OA. **Am J Orthop** 1998 Aug; 27(8):576–8 (7 ref.)

DIAGNOSIS

Posterior labrocapsular periosteal sleeve avulsion complicating locked posterior shoulder dislocation. Simons P, et al. **Skeletal Radiol** 1998 Oct;27(10):588–90 (5 ref.)

ETIOLOGY

Bilateral anterior shoulder fracture-dislocation. A case report and a review of the literature. Dinopoulos HT, et al. **Int Orthop** 1999;23(2):128–30 (20 ref.)
Restraining patients and shoulder dislocations during seizures. DeToledo JC, et al. **J Shoulder Elbow Surg** 1999 Jul–Aug;8(4):300–2 (32 ref.)
[Management of old neglected posttraumatic acromioclavicular joint instability and arthrosis] Hedtmann A, et al. **Orthopade** 1998 Aug;27(8):556–66 (60 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Intrathoracic dislocation fracture of the head of the humerus] al-Kaar M, et al. **J Radiol** 1998 Jan;79(1):57–9 (6 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Irreducible anterior shoulder dislocation with fracture of the greater tuberosity. Ilahi OA. **Am J Orthop** 1998 Aug; 27(8):576–8 (7 ref.)
[Results of posterior inferior capsular shift in posterior shoulder instability] Jerosch J, et al. **Unfallchirurg** 1998 Oct; 101(10):755–61 (39 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Current concepts in the treatment of anterior shoulder dislocations. Wen DY. **Am J Emerg Med** 1999 Jul; 17(4):401–7 (50 ref.)

SHOULDER FRACTURES

COMPLICATIONS

Irreducible anterior shoulder dislocation with fracture of the greater tuberosity. Ilahi OA. **Am J Orthop** 1998 Aug; 27(8):576–8 (7 ref.)
[Incidence of humeral head osteonecrosis after fracture of the superior end of the humerus] Zygas P. **Acta Orthop Belg** 1999;65 Suppl 1:99–103 (19 ref.) **(Fre)**

ETIOLOGY

Bilateral anterior shoulder fracture-dislocation. A case report and a review of the literature. Dinopoulos HT, et al. **Int Orthop** 1999;23(2):128–30 (20 ref.)

RADIOGRAPHY

[Intrathoracic dislocation fracture of the head of the humerus] al-Kaar M, et al. **J Radiol** 1998 Jan;79(1):57–9 (6 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Irreducible anterior shoulder dislocation with fracture of the greater tuberosity. Ilahi OA. **Am J Orthop** 1998 Aug; 27(8):576–8 (7 ref.)
[Fractures of the proximal humerus] Szyszkowitz R, et al. **Unfallchirurg** 1999 Jun;102(6):422–8 (23 ref.) (Eng. Abstr.) **(Ger)**

SHOULDER-GIRDLE NEUROPATHY see **CERVICO-BRACHIAL NEURALGIA**

SHOULDER-HAND SYNDROME see **REFLEX SYMPATHETIC DYSTROPHY**

SHOULDER IMPINGEMENT SYNDROME

DIAGNOSIS

Rotator cuff tear arthropathy. Jensen KL, et al. **J Bone Joint Surg Am** 1999 Sep;81(9):1312–24 (101 ref.)
Introduction of a new physical examination procedure for the differentiation of acromioclavicular joint lesions and subacromial impingement. Buchberger DJ. **J Manipulative Physiol Ther** 1999 Jun;22(5):316–21 (20 ref.)

SURGERY

Open versus arthroscopic decompression for subacromial impingement. A comprehensive review of the literature from the last 25 years. Checroun AJ, et al. **Bull Hosp Jt Dis** 1998;57(3):145–51 (41 ref.)

SHOULDER JOINT

Shoulder instability in young athletes. Mahaffey BL, et al. **Am Fam Physician** 1999 May 15;59(10):2773–82, 2787 (24 ref.)
Glenohumeral osteoarthritis following a "color test" during rotator cuff repair. A case report and a review of the literature. Nakagawa Y, et al. **Bull Hosp Jt Dis** 1998; 57(4):216–8 (12 ref.)
Osteonecrosis of the humeral head. Loebenberg MI, et al. **Instr Course Lect** 1999;48:349–57 (34 ref.)
Symptomatic scapulothoracic crepitus and bursitis. Kuhn JE, et al. **J Am Acad Orthop Surg** 1998 Sep–Oct;6(5):267–73 (30 ref.)
The rotator cuff-deficient arthritic shoulder: diagnosis and surgical management. Zeman CA, et al. **J Am Acad Orthop Surg** 1998 Nov–Dec;6(6):337–48 (34 ref.)
A ganglion of the spinoglenoid notch. Steinwachs MR, et al. **J Shoulder Elbow Surg** 1998 Sep–Oct;7(5):550–4 (25 ref.)
Pigmented villonodular synovitis of the shoulder: review and case report. Müller LP, et al. **Knee Surg Sports Traumatol Arthrosc** 1999;7(4):249–56 (39 ref.)
Imaging of the painful shoulder. King LJ, et al. **Man Ther** 1999 Feb;4(1):11–8 (45 ref.)
Shoulder instability. Review of current trends in treatment. Norlin R, et al. **Scand J Med Sci Sports** 1998 Dec;8(6):394–7 (14 ref.)
[Shoulder complaints in family practice; a simple approach (see comments)] Winters JC, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1241–4 (16 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32:1832. Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32:1832–3. **(Dut)**
[The mechanical effects of shock waves in extracorporeal shock wave treatment of calcific tendinitis--an in vitro model] Perlick L, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan–Feb;137(1):10–6 (27 ref.) (Eng. Abstr.) **(Ger)**
[Septic arthritis caused by S. pneumoniae. Report of 2 cases with unusual location] Ruiz Martin JM, et al. **Rev Clin Esp** 1998 Sep;198(9):596–7 (13 ref.) (Eng. Abstr.)

(Spa)

INJURIES

Open surgical treatment of anterior glenohumeral instability: an historical perspective and review of the literature. Part I. Rokito AS, et al. **Am J Orthop** 1998 Nov;27(11):723–5 (0 ref.)

PATHOLOGY

Adhesive capsulitis: a sticky issue. Siegel LB, et al. **Am Fam Physician** 1999 Apr 1;59(7):1843–52 (21 ref.)

A commonsense approach to shoulder problems. Steinfeld R, et al. **Mayo Clin Proc** 1999 Aug;74(8):785–94 (15 ref.)

Glenohumeral instability: evaluation using MR arthrography of the shoulder. Shankman S, et al. **Skeletal Radiol** 1999 Jul;28(7):365–82 (35 ref.)

[Useful imaging data before intervention for an unstable shoulder] Dumontier C, et al. **Ann Radiol (Paris)** 1997; 40(3):153–65 (47 ref.) (Eng. Abstr.) (Fre)

[Lesions of the glenoid labrum] Setbon S, et al. **Ann Radiol (Paris)** 1997;40(3):166–75 (24 ref.) (Eng. Abstr.) (Fre)

PHYSIOPATHOLOGY

A commonsense approach to shoulder problems. Steinfeld R, et al. **Mayo Clin Proc** 1999 Aug;74(8):785–94 (15 ref.)

[Arthroscopic shoulder stabilization. Differentiated treatment strategy with Suretac, Fastak, Holmium: YAG-laser and electrosurgery] Imhoff AB, et al. **Orthopade** 1998 Aug; 27(8):518–31 (114 ref.) (Eng. Abstr.) (Ger)

[Radiation therapy in humero-scapular peri-arthropathy. Indication, method, results obtained by authors, review of the literature] Heyd R, et al. **Rontgenpraxis** 1998; 51(11):403–12 (105 ref.) (Ger)

SURGERY

Open surgical treatment of anterior glenohumeral instability: an historical perspective and review of the literature. Part II. Rokito AS, et al. **Am J Orthop** 1998 Dec;27(12):784–90 (60 ref.)

Complications of shoulder surgery. Gill TJ, et al. **Instr Course Lect** 1999;48:359–74 (81 ref.)

Total shoulder arthroplasty — current problems and possible solutions. Skirving AP. **J Orthop Sci** 1999;4(1):42–53 (33 ref.)

Periprosthetic fractures of the humerus and scapula: management and prevention. Cameron B, et al. **Orthop Clin North Am** 1999 Apr;30(2):305–18 (28 ref.)

[Prosthesis of the upper extremity] Rozing PM. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1256–61 (12 ref.) (Eng. Abstr.) (Dut)

[New knowledge of the mysterious "frozen shoulder". Surgical treatment can accelerate the recovery in more serious cases] Ekelund A. **Lakartidningen** 1998 Nov 25; 95(48):5472–4, 5477 (20 ref.) (Eng. Abstr.) (Swe)

SHOULDER PAIN

COMPLICATIONS

Shoulder pain in patients with Parkinson's disease. Vaserman-Lehuédé N, et al. **Rev Rhum Engl Ed** 1999 Apr; 66(4):220–3 (16 ref.)

DIAGNOSIS

Imaging the painful shoulder: an update. Peh WC. **Hosp Med** 1998 Oct;59(10):783–7 (21 ref.)

Introduction of a new physical examination procedure for the differentiation of acromioclavicular joint lesions and subacromial impingement. Buchberger DJ. **J Manipulative Physiol Ther** 1999 Jun;22(5):316–21 (20 ref.)

Imaging of the painful shoulder. King LJ, et al. **Man Ther** 1999 Feb;4(1):11–8 (45 ref.)

[Lesions of the glenoid labrum] Setbon S, et al. **Ann Radiol (Paris)** 1997;40(3):166–75 (24 ref.) (Eng. Abstr.) (Fre)

ETIOLOGY

Shoulder pain in patients with Parkinson's disease. Vaserman-Lehuédé N, et al. **Rev Rhum Engl Ed** 1999 Apr; 66(4):220–3 (16 ref.)

SHREWS, TREE see **TUPAIIDAE**

SHRIMP

CYTOLOGY

Fenestration nodes and the wide submyelinic space form the basis for the unusually fast impulse conduction of shrimp myelinated axons. Xu K, et al. **J Exp Biol** 1999 Aug;202 (Pt 15):1979–89 (35 ref.)

IMMUNOLOGY

B- and T-cell epitopes of tropomyosin, the major shrimp allergen. Subba Rao PV, et al. **Allergy** 1998;53(46 Suppl):44–7 (20 ref.)

SHUTTLE VECTORS see **GENETIC VECTORS**

SHY-DRAGER SYNDROME

[Shy-Drager syndrome (SDS)] Kita K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):258–61 (11 ref.) (Jpn)

SHY-MAGEE SYNDROME see **NEMALINE MYOPATHY**

SH1 DOMAIN see **SRC HOMOLOGY DOMAINS**

SH2 DOMAIN see **SRC HOMOLOGY DOMAINS**

SH3 DOMAIN see **SRC HOMOLOGY DOMAINS**

SIADH see **INAPPROPRIATE ADH SYNDROME**

SIALADENITIS

EPIDEMIOLOGY

Complicated neonatal submandibular suppurative sialadenitis. Bafaqeeh SA. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10; 44(3):267–71 (8 ref.)

PATHOLOGY

Lymphoepithelial cyst with crystalloid formation. Cytologic features of two cases. López-Ríos F, et al. **Acta Cytol** 1999 Mar-Apr;43(2):277–80 (9 ref.)

Parotid sialolithiasis. Bodner L. **J Laryngol Otol** 1999 Mar; 113(3):266–7 (15 ref.)

SURGERY

Frey's syndrome following submandibular gland excision: an unusual postoperative complication. Teague A, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec; 60(6):346–8 (30 ref.)

SIALIC ACID see **N-ACETYLNEURAMINIC ACID**

SIALIC ACIDS

Structure, function and metabolism of sialic acids. Traving C, et al. **Cell Mol Life Sci** 1998 Dec;54(12):1330–49 (143 ref.)

CHEMISTRY

Polysialic acid: three-dimensional structure, biosynthesis and function. Mühlenhoff M, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):558–64 (65 ref.)

METABOLISM

Polysialic acid: three-dimensional structure, biosynthesis and function. Mühlenhoff M, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):558–64 (65 ref.)

Occurrence of sialic acids in healthy humans and different disorders. Sillanaukee P, et al. **Eur J Clin Invest** 1999 May; 29(5):413–25 (123 ref.)

Polysialic acid, a unique glycan that is developmentally regulated by two polysialyltransferases, PST and STX, in the central nervous system: from biosynthesis to function. Nakayama J, et al. **Pathol Int** 1998 Sep;48(9):665–77 (67 ref.)

PHARMACOLOGY

Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Aoki FY, et al. **Clin Pharmacokinet** 1999; 36 Suppl 1:v–ix (24 ref.)

PHYSIOLOGY

Polysialic acid, a unique glycan that is developmentally regulated by two polysialyltransferases, PST and STX, in the central nervous system: from biosynthesis to function. Nakayama J, et al. **Pathol Int** 1998 Sep;48(9):665–77 (67 ref.)

THERAPEUTIC USE

Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Dines GD, et al. **Drug Saf** 1998 Sep;19(3):233–41 (19 ref.)

SIALIDASE see **NEURAMINIDASE**

SIALOGLYCOPEPTIDES see **SIALOGLYCOPROTEINS**

SIALOGLYCOPROTEINS

see related
ASIALOGLYCOPROTEINS

BIOSYNTHESIS

Arthritis: is the cure in your genes? Herndon JH, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):152–7 (36 ref.)

GENETICS

Redox regulation of c-Ha-ras and osteopontin signaling in vascular smooth muscle cells: implications in chemical atherogenesis. Ramos KS. **Annu Rev Pharmacol Toxicol** 1999;39:243–65 (145 ref.)

Arthritis: is the cure in your genes? Herndon JH, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):152–7 (36 ref.)

METABOLISM

Osteopontin in skeletal tissue homeostasis: An emerging picture of the autocrine/paracrine functions of the extracellular matrix [editorial; comment] Gerstenfeld LC. **J Bone Miner Res** 1999 Jun;14(6):850–5 (85 ref.) Comment on: J Bone Miner Res 1999 Jun;14(6):839–49.

PHYSIOLOGY

Osteopontin function in pathology: lessons from osteopontin-deficient mice. Rittling SR, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):103–13 (91 ref.)

The Roman god Janus: a paradigm for the function of CD43. Ostberg JR, et al. **Immunol Today** 1998 Dec;19(12):546–50 (79 ref.)

Osteopontin expression and function: role in bone remodeling. Denhardt DT, et al. **J Cell Biochem Suppl** 1998;30–31:92–102 (65 ref.)

The complex role of osteopontin in renal disease [editorial] Wüthrich RP. **Nephrol Dial Transplant** 1998 Oct; 13(10):2448–50 (45 ref.)

[Integrin signal transduction via FAK in osteoblasts--early differentiation triggered by osteopontin] Nemoto A, et al. **Seikagaku** 1999 Feb;71(2):140–5 (17 ref.) (Jpn)

[Differentiation and function of bone cells induced by bone matrix proteins: osteopontin in bone remodeling] Uemura T, et al. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):143–8 (32 ref.) (Jpn)

THERAPEUTIC USE

Treatment of rheumatoid arthritis with IL-1 inhibitors. Gabay C, et al. **Springer Semin Immunopathol** 1998; 20(1–2):229–46 (90 ref.)

SIALOGLYCOSPHINGOLIPIDS see **GANGLIOSIDES**

SIALOLITHIASIS see **SALIVARY GLAND CALCULI**

SIALOLITHIASIS, DUCTAL see **SALIVARY DUCT CALCULI**

SIALOPROTEINS see **SIALOGLYCOPROTEINS**

SIALYLTRANSFERASES

CHEMISTRY

[Structure and function of GM3 synthase] Ishii A, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2349–57 (52 ref.) (Jpn)

[Sialyltransferase superfamily: structure and function] Tsuji S. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2338–48 (49 ref.) (Jpn)

METABOLISM

Polysialic acid, a unique glycan that is developmentally regulated by two polysialyltransferases, PST and STX, in the central nervous system: from biosynthesis to function. Nakayama J, et al. **Pathol Int** 1998 Sep;48(9):665–77 (67 ref.)

PHYSIOLOGY

[Structure and function of GM3 synthase] Ishii A, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2349–57 (52 ref.) (Jpn)

[Sialyltransferase superfamily: structure and function] Tsuji S. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2338–48 (49 ref.) (Jpn)

SIAMESE TWINS see **TWINS, CONJOINED**

SIB MATING see **INBREEDING**

SIBLING RELATIONS

Bereavement and loss in childhood. Geis HK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):73–85, viii (65 ref.)

Siblings of children with cancer: a review of the literature. Murray JS. **J Pediatr Oncol Nurs** 1999 Jan;16(1):25–34 (20 ref.)

SICCA SYNDROME see **SJOGREN'S SYNDROME**

SICK BUILDING SYNDROME

Developing case definitions for symptom-based conditions: the problem of specificity. Hyams KC. **Epidemiol Rev** 1998; 20(2):148–56 (124 ref.)

ETIOLOGY

[Indoor pollution and health] Kummer J. **Rev Med Brux** 1998 Sep;19(4):A363–6 (7 ref.) (Eng. Abstr.) (Fre)

[Housing and health] Fiedler K. **Gesundheitswesen** 1998 Nov; 60(11):656–60 (5 ref.) (Eng. Abstr.) (Ger)

SICK ROLE

Mechanisms of the behavioural effects of cytokines. Dantzer

SICK ROLE

R, et al. **Adv Exp Med Biol** 1999;461:83–105 (77 ref.)
Health-related quality of life: a primer for gastroenterologists. Eisen GM, et al. **Am J Gastroenterol** 1999 Aug;94(8):2017–21 (17 ref.)
Wandering in dementia. Algase DL. **Annu Rev Nurs Res** 1999;17:185–217 (136 ref.)
Illness as a problem of meaning: moving culture from the classroom to the clinic. McGrath BB. **ANS Adv Nurs Sci** 1998 Dec;21(2):17–29 (40 ref.)
A little lady called Pandora: an exploration of philosophical traditions of humanism and existentialism in nursing ill children. Holyoake DD. **Child Care Health Dev** 1998 Jul; 24(4):325–36 (51 ref.)
Diabetes mellitus and major depressive disorder: an overview of prevalence, complications, and treatment. Carney C. **Depress Anxiety** 1998;7(4):149–57 (70 ref.)
The relationship of hypochondriasis to anxiety disorders [see comments] Noyes R Jr. **Gen Hosp Psychiatry** 1999 Jan–Feb;21(1):8–17 (87 ref.) Comment in: Gen Hosp Psychiatry 1999 Jan–Feb;21(1):5–7.
Practitioner review: long-term consequences of childhood cancer. Eiser C. **J Child Psychol Psychiatry** 1998 Jul; 39(5):621–33 (60 ref.)
Practitioner review: communicating with hospitalised children: review and application of research pertaining to children's understanding of health and illness. Rushforth H. **J Child Psychol Psychiatry** 1999 Jul;40(5):683–91 (55 ref.)
Pets and health. Brasić JR. **Psychol Rep** 1998 Dec;83(3 Pt 1):1011–24 (100 ref.)
Depression in pediatric chronic illness. A diathesis–stress model. Burke P, et al. **Psychosomatics** 1999 Jan–Feb; 40(1):5–17 (102 ref.)
Blindness, fear of sight loss, and suicide. De Leo D, et al. **Psychosomatics** 1999 Jul–Aug;40(4):339–44 (30 ref.)
Concepts of illness in populations as applied to fibromyalgia syndromes: a biopsychosocial perspective. Masi AT. **Z Rheumatol** 1998;57 Suppl 2:31–5 (20 ref.)
[Violence our medical trauma in specialized multidisciplinary consultation] Albrecht E, et al. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):280–4 (4 ref.) (Eng. Abstr.) **(Fre)**
[Coping—status of knowledge in the 90's] Heim E. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):321–37 (150 ref.) (Eng. Abstr.) **(Ger)**
[Psycho-oncologic interventions—critical review] Larbig W. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):381–9 (75 ref.) (Eng. Abstr.) **(Ger)**
[Psychological problems and treatment possibilities in intensive care medicine exemplified by bone marrow transplantation] Schulz-Kindermann F, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):390–7 (55 ref.) (Eng. Abstr.) **(Ger)**
[Melanoma patients: psychosocial stress, coping with illness and social support. A systematic review] Söllner W, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):338–48 (62 ref.) (Eng. Abstr.) **(Ger)**
[Effect pf anti-dementia drugs on the daily routine and attitude of dementia patients] Kurz A. **Z Gerontol Geriatr** 1999 Jun;32(3):167–71 (19 ref.) (Eng. Abstr.) **(Ger)**

SICK SINUS SYNDROME

COMPLICATIONS

Is sinus bradycardia a factor facilitating overt heart failure? Alboni P, et al. **Eur Heart J** 1999 Feb;20(4):252–5 (34 ref.)

MORTALITY

Effect of pacing mode on morbidity and mortality: update of clinical pacing trials. McComb JM, et al. **Am J Cardiol** 1999 Mar 11;83(5B):211D–213D (23 ref.)

PHYSIOPATHOLOGY

Can alteration of dual atrioventricular nodal pathway physiology be related to sinus node dysfunction? [editorial; comment] Sung RJ. **J Cardiovasc Electrophysiol** 1998 May; 9(5):479–80 (12 ref.) Comment on: J Cardiovasc Electrophysiol 1998 May;9(5):470–8.

SICKLE CELL HEMOGLOBIN C DISEASE see **HEMOGLOBIN SC DISEASE**

SICKLE CELL TRAIT

COMPLICATIONS

Renal medullary carcinoma in an adolescent with sickle cell trait. Warren KE, et al. **Pediatrics** 1999 Feb;103(2):E22 (8 ref.)

GENETICS

[Influence of the sickle cell trait heterozygote on energy abilities] Bitanga E, et al. **Pathol Biol (Paris)** 1998 Jan; 46(1):46–52 (50 ref.) (Eng. Abstr.) **(Fre)**

SICKNESS IMPACT PROFILE

Methodological considerations in the assessment of health-related quality of life in children. Erling A. **Acta Paediatr Suppl** 1999 Feb;88(428):106–7 (3 ref.)
Health-related quality of life: a primer for gastroenterologists. Eisen GM, et al. **Am J Gastroenterol** 1999 Aug;94(8):2017–21 (17 ref.)
The impact of asthma on health-related quality of life. Schmier JK, et al. **J Asthma** 1998;35(7):585–97 (81 ref.)
[Evaluation of symptoms of gastroesophageal reflux and their impact on quality of life] Amouretti M. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S45–9 (33 ref.) **(Fre)**

SIDEROPHILIN see **TRANSFERRIN**

SIDEROSIS

see related
HEMOSIDEROSIS

DIAGNOSIS

[Superficial siderosis of the central nervous system] Durieux A, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):201–7 (35 ref.) (Eng. Abstr.) **(Fre)**

SIDS see **SUDDEN INFANT DEATH**

SIGA see **IGA, SECRETORY**

SIGMA ELEMENT see **SIGMA FACTOR**

SIGMA FACTOR

ANTAGONISTS & INHIBITORS

The anti-sigma factors. Hughes KT, et al. **Annu Rev Microbiol** 1998;52:231–86 (282 ref.)
Anti-sigma factors. Helmann JD. **Curr Opin Microbiol** 1999 Apr;2(2):135–41 (54 ref.)
[Molecular regulation of sigma factor and anti-sigma factor in prokaryote differentiation] Tan H. **Wei Sheng Wu Hsueh Pao** 1997 Jun;37(3):234–6 (5 ref.) **(Chi)**

GENETICS

Regulation in the rpoS regulon of Escherichia coli. Loewen PC, et al. **Can J Microbiol** 1998 Aug;44(8):707–17 (113 ref.)
Regulation of the heat-shock response. Yura T, et al. **Curr Opin Microbiol** 1999 Apr;2(2):153–8 (66 ref.)
Non-specific, general and multiple stress resistance of growth-restricted Bacillus subtilis cells by the expression of the sigmaB regulon. Hecker M, et al. **Mol Microbiol** 1998 Sep;29(5):1129–36 (55 ref.)

METABOLISM

Interaction of Escherichia coli sigma 70 with core RNA polymerase. Burgess RR, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:277–87 (99 ref.)
The functional and regulatory roles of sigma factors in transcription. Gross CA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:141–55 (98 ref.)
Summary: three decades after sigma. Losick R. **Cold Spring Harb Symp Quant Biol** 1998;63:653–66 (0 ref.)
Interplay of global regulators and cell physiology in the general stress response of Escherichia coli. Hengge-Aronis R. **Curr Opin Microbiol** 1999 Apr;2(2):148–52 (47 ref.)
The sigmaE and Cpx regulatory pathways: overlapping but distinct envelope stress responses. Raivio TL, et al. **Curr Opin Microbiol** 1999 Apr;2(2):159–65 (52 ref.)

PHYSIOLOGY

Eubacterial sigma-factors. Wösten MM. **FEMS Microbiol Rev** 1998 Sep;22(3):127–50 (206 ref.)
Control of sigma factor activity during Bacillus subtilis sporulation. Kroos L, et al. **Mol Microbiol** 1999 Mar; 31(5):1285–94 (51 ref.)
[Molecular regulation of sigma factor and anti-sigma factor in prokaryote differentiation] Tan H. **Wei Sheng Wu Hsueh Pao** 1997 Jun;37(3):234–6 (5 ref.) **(Chi)**

SIGMA INITIATION FACTOR see **SIGMA FACTOR**

SIGMA RECEPTORS see **RECEPTORS, SIGMA**

SIGMA SUBUNIT see **SIGMA FACTOR**

SIGMODON see **HESPEROMYINAE**

SIGMOID

see related
SIGMOIDOSCOPY

INJURIES

Bowel entrapment within pelvic fractures: a case report and review of the literature. Stubbart JR, et al. **J Orthop Trauma** 1999 Feb;13(2):145–8 (24 ref.)

SIGMOID DISEASES

COMPLICATIONS

Preservation and peeling of the inferior mesenteric artery in the anterior resection for complicated diverticular disease. Messinetti S, et al. **Ann Ital Chir** 1998 Jul–Aug; 69(4):479–82; discussion 482–3 (13 ref.)

DIAGNOSIS

[Encapsulated hematoma of the sigmoid mesocolon. Apropos of an unusual case in Niger] Théry Y, et al. **J Radiol** 1999 Mar;80(3):312–6 (19 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Perforation of the sigmoid colon with ischemic change due to polyarteritis nodosa. Okada M, et al. **J Gastroenterol** 1999 Jun;34(3):400–4 (12 ref.)
Bowel entrapment within pelvic fractures: a case report and review of the literature. Stubbart JR, et al. **J Orthop Trauma** 1999 Feb;13(2):145–8 (24 ref.)

SURGERY

Preservation and peeling of the inferior mesenteric artery in the anterior resection for complicated diverticular disease. Messinetti S, et al. **Ann Ital Chir** 1998 Jul–Aug; 69(4):479–82; discussion 482–3 (13 ref.)
Bowel entrapment within pelvic fractures: a case report and review of the literature. Stubbart JR, et al. **J Orthop Trauma** 1999 Feb;13(2):145–8 (24 ref.)
[Surgical therapy of complicated sigmoid diverticulitis: single stage or multi-stage operation?] Gertsch P, et al. **Zentralbl Chir** 1998;123(12):1386–9 (26 ref.) (Eng. Abstr.) **(Ger)**

SIGMOIDOSCOPES see **ENDOSCOPES**

SIGMOIDOSCOPY

Flexible sigmoidoscopy: screening for colorectal cancer [corrected and republished article originally printed in Am Fam Physician 1999 Jan 15;59(2):313–24, 327–8] Johnson BA. **Am Fam Physician** 1999 Mar 15;59(6):1537–46 (21 ref.)
Flexible sigmoidoscopy: screening for colorectal cancer [see comments] [corrected and republished in Am Fam Physician 1999 Mar 15;59(6):1537–46] Johnson BA. **Am Fam Physician** 1999 Jan 15;59(2):313–24, 327–8 (21 ref.) Comment in: Am Fam Physician 1999 Jan 15;59(2):270, 273.
The small polyp at flexible sigmoidoscopy: an historical perspective on why practices still vary. Rex DK. **J Clin Gastroenterol** 1999 Jan;28(1):19–22 (27 ref.)

METHODS

Flexible sigmoidoscopy. Illuminating the pearls for passage. Davis PW, et al. **Postgrad Med** 1999 Jun;105(7):51–4, 59–60, 62 (5 ref.)

UTILIZATION

Flexible sigmoidoscopy by paramedical personnel [see comments] Schoenfeld P. **J Clin Gastroenterol** 1999 Mar; 28(2):110–6 (40 ref.) Comment in: J Clin Gastroenterol 1999 Mar;28(2):95–6.

SIGN LANGUAGE

Lexidactylophobia: the (irrational) fear of fingerspelling. Grushkin DA. **Am Ann Deaf** 1998 Dec;143(5):404–15 (66 ref.)
On the nature of left hemisphere specialization for signed language. Corina DP. **Brain Lang** 1999 Sep;69(2):230–40 (34 ref.)

SIGNAL DETECTION (PSYCHOLOGY)

Threshold effect in visual perception of geometrical figures. Di Maio V. **Percept Mot Skills** 1998 Aug;87(1):340–2 (9 ref.)

SIGNAL INTERPRETATION, COMPUTER-ASSISTED see **SIGNAL PROCESSING, COMPUTER-ASSISTED**

SIGNAL PATHWAYS see **SIGNAL TRANSDUCTION**

SIGNAL PEPTIDES

see related
NUCLEAR LOCALIZATION SIGNAL

ANALYSIS

Machine learning approaches for the prediction of signal peptides and other protein sorting signals. Nielsen H, et al. **Protein Eng** 1999 Jan;12(1):3–9 (39 ref.)

CHEMISTRY

Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Resh MD. **Biochim Biophys Acta** 1999 Aug 12;1451(1):1–16 (138 ref.)

IMMUNOLOGY

[Production of various antibodies and single chain Fv molecule against signal-transducing proteins] Kurose H, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):59-68 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Inhibitors of bacterial signal peptidases. Black MT, et al. **Curr Pharm Des** 1998 Apr;4(2):133-54 (80 ref.)

PHYSIOLOGY

Modulation of the expression level of human acidic lipases by various signal peptides. Canaan S, et al. **Methods Mol Biol** 1999;109:203-13 (17 ref.)

Signal sequences: more than just greasy peptides. Martoglio B, et al. **Trends Cell Biol** 1998 Oct;8(10):410-5 (60 ref.)

SIGNAL PROCESSING, COMPUTER-ASSISTED

A primer for EEG signal processing in anesthesia [see comments] Rampil IJ. **Anesthesiology** 1998 Oct; 89(4):980-1002 (61 ref.) Comment in: Anesthesiology 1998 Oct;89(4):815-7. Comment in: Anesthesiology 1999 Jun;90(6):1796-8.

Measurement inside the box [editorial; comment] Gibbons KJ. **Crit Care Med** 1999 May;27(5):869-70 (11 ref.) Comment on: Crit Care Med 1999 May;27(5):978-84.

Cardiac output minute to minute with a standard pulmonary artery catheter, without fluid overload? [editorial; comment] Tremper KK. **Crit Care Med** 1999 Aug; 27(8):1665-6 (16 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1505-10.

Signal-averaged electrocardiography. Graham AA, et al. **Health Technol Assess (Rockv)** 1998 May;(11):i-vi, 1-15 (74 ref.)

Signal-processing techniques for cochlear implants. Loizou PC. **IEEE Eng Med Biol Mag** 1999 May-Jun;18(3):34-46 (54 ref.)

ECG pattern recognition and classification using non-linear transformations and neural networks: a review. Maglaveras N, et al. **Int J Med Inf** 1998 Oct-Dec;52(1-3):191-208 (54 ref.)

Digital echocardiographic laboratory: where do we stand? Thomas JD, et al. **J Am Soc Echocardiogr** 1998 Oct; 11(10):978-83 (16 ref.)

Intracranial pressure monitoring by time domain analysis. Penson RP, et al. **J R Soc Health** 1998 Oct;118(5):289-94 (09 ref.)

Video transmission for telemedicine. Squibb NJ. **J Telemed Telecare** 1999;5(1):1-10 (11 ref.)

Power spectral analysis of heart rate variability in psychiatry. Cohen H, et al. **Psychother Psychosom** 1999 Mar-Apr; 68(2):59-66 (55 ref.)

Data compression methods for EEG. Ylöstalo J. **Technol Health Care** 1999;7(4):285-300 (36 ref.)

INSTRUMENTATION

Clinical significance of multiple sensor options: rate response optimization, sensor blending, and trending. Clémenty J, et al. **Am J Cardiol** 1999 Mar 11;83(5B):166D-171D (20 ref.)

Future of bradyarrhythmia therapy systems: automaticity. Jones BR, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):192D-201D (64 ref.)

Taking advantage of sophisticated pacemaker diagnostics. Nowak B. **Am J Cardiol** 1999 Mar 11;83(5B):172D-179D (22 ref.)

How smart should pacemakers Be? Saoudi N, et al. **Am J Cardiol** 1999 Mar 11;83(5B):180D-186D (32 ref.)

[Signal analysis of the hemodynamics of extracorporeal circulation for the evaluation of patient status] Schwarzhaupt A, et al. **Biomed Tech (Berl)** 1999 May; 44(5):120-8 (11 ref.) (Eng. Abstr.) **(Ger)**

[Cardiology update. I: Electrophysiology] Weismüller P, et al. **Med Klin** 1999 Jan 15;94(1):15-28 (173 ref.) **(Ger)**

SIGNAL PROCESSING, DIGITAL see **SIGNAL PROCESSING, COMPUTER-ASSISTED**

SIGNAL RECOGNITION PARTICLE

METABOLISM

New insights into signal recognition and elongation arrest activities of the signal recognition particle. Bui N, et al. **Biol Chem** 1999 Feb;380(2):135-45 (74 ref.)

Protein targeting: getting into the groove. Bernstein HD. **Curr Biol** 1998 Oct 8;8(20):R715-8 (23 ref.)

Protein targeting to the endoplasmic reticulum in yeast. 1997 Fleming Lecture. Stirling CJ. **Microbiology** 1999 May;145 (Pt 5):991-8 (65 ref.)

SIGNAL SEQUENCES see **SIGNAL PEPTIDES**

SIGNAL SEQUENCES, PEPTIDES see **SIGNAL PEPTIDES**

SIGNAL TRANSDUCTION

see related

ION CHANNELS

4-Hydroxy-2,3-nonenal as a signal for cell function and differentiation. Dianzani MU, et al. **Acta Biochim Pol** 1999; 46(1):61-75 (74 ref.)

Differential regulation of signaling pathways for insulin and insulin-like growth factor I. Lopaczynski W. **Acta Biochim Pol** 1999;46(1):51-60 (52 ref.)

Signal transduction in fungi--the role of protein phosphorylation. Fehér Z, et al. **Acta Microbiol Immunol Hung** 1999;46(2-3):269-71 (6 ref.)

Analysis of transmembrane signalling and T cell defects associated with idiopathic thrombocytopenic purpura (ITP). Lazarus AH, et al. **Acta Paediatr Suppl** 1998 Jun; 424:21-5 (29 ref.)

Function of alcohol dehydrogenase and aldehyde dehydrogenase gene families in retinoid signaling. Duester G. **Adv Exp Med Biol** 1999;463:311-9 (53 ref.)

Insulin signaling and glucose transport in insulin resistant skeletal muscle. Special reference to GLUT4 transgenic and GLUT4 knockout mice. Galuska D, et al. **Adv Exp Med Biol** 1998;441:73-85 (67 ref.)

Signal transduction pathways that regulate the fate of B lymphocytes. Craxton A, et al. **Adv Immunol** 1999; 73:79-152 (506 ref.)

Biology of the interleukin-2 receptor. Nelson BH, et al. **Adv Immunol** 1998;70:1-81 (442 ref.)

Insulin signaling in the arterial wall. Hsueh WA, et al. **Am J Cardiol** 1999 Jul 8;84(1A):21J-24J (35 ref.)

Interleukin-2 signaling and inherited immunodeficiency. Cacalano NA, et al. **Am J Hum Genet** 1999 Aug; 65(2):287-93 (30 ref.)

Mechanism of GnRH receptor signaling: from the membrane to the nucleus. Shacham S, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):79-88 (85 ref.)

Afferent pathways of pyrogen signaling. Blatteis CM, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:95-107 (87 ref.)

How cells respond to interferons. Stark GR, et al. **Annu Rev Biochem** 1998;67:227-64 (319 ref.)

Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Martin TF. **Annu Rev Cell Dev Biol** 1998;14:231-64 (198 ref.)

The anaerobic degradation of L-serine and L-threonine in enterobacteria: networks of pathways and regulatory signals. Sawers G. **Arch Microbiol** 1998 Dec;171(1):1-5 (30 ref.)

Cross-talk between angiotensin II and interleukin-6-induced signaling through Stat3 transcription factor. Bhat GJ, et al. **Basic Res Cardiol** 1998;93 Suppl 3:26-9 (20 ref.)

Cell lineages in the embryonic kidney: their inductive interactions and signalling molecules. Sariola H, et al. **Biochem Cell Biol** 1998;76(6):1009-16 (80 ref.)

Extracellular matrix and integrin signalling: the shape of things to come. Boudreau NJ, et al. **Biochem J** 1999 May 1;339 (Pt 3):481-8 (113 ref.)

Genetic engineering in mice: impact on insulin signalling and action. Lamothe B, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):193-204 (107 ref.)

Nongenomic signaling by vitamin D: a new face of Src. Gniadecki R. **Biochem Pharmacol** 1998 Nov 15; 56(10):1273-7 (27 ref.)

Ras, superoxide and signal transduction. Irani K, et al. **Biochem Pharmacol** 1998 May 1;55(9):1339-46 (90 ref.)

Modes of interactions between signaling pathways. Jordan JD, et al. **Biochem Pharmacol** 1998 May 1;55(9):1347-52 (35 ref.)

Signal transduction by the c-Jun N-terminal kinase. Davis RJ. **Biochem Soc Symp** 1999;64:1-12 (77 ref.)

Microtubule involvement in regulating cell contractility and adhesion-dependent signalling: a possible mechanism for polarization of cell motility. Elbaum M, et al. **Biochem Soc Symp** 1999;65:147-72 (197 ref.)

Making the connection: coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signalling modules to extracellular stimuli and biological responses. Kyriakis JM. **Biochem Soc Symp** 1999;64:29-48 (87 ref.)

Phospholipid-binding protein domains. Bottomley MJ, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):165-83 (145 ref.)

Phospholipid signalling in the nucleus. Een DAG uit het leven van de inositide signalering in de nucleus. D'Santos CS, et al. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):201-32 (338 ref.)

Signalling functions of protein palmitoylation. Dunphy JT, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):245-61 (109 ref.)

Signalling sphingomyelinases: which, where, how and why? Levade T, et al. **Biochim Biophys Acta** 1999 Apr 19; 1438(1):1-17 (186 ref.)

The role of ceramide in cell signaling. Perry DK, et al. **Biochim Biophys Acta** 1998 Dec 8;1436(1-2):233-43 (107 ref.)

Signal perception and transduction: the role of protein kinases. Schenk PW, et al. **Biochim Biophys Acta** 1999 Feb 4;1449(1):1-24 (174 ref.)

The versatility of inositol phosphates as cellular signals. Shears SB. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):49-67 (200 ref.)

Structural organization of mammalian lipid phosphate phosphatases: implications for signal transduction. Waggoner DW, et al. **Biochim Biophys Acta** 1999 Jul 30; 1439(2):299-316 (106 ref.)

Involvement of plasma membrane proteins in plant defense responses. Analysis of the cryptogein signal transduction in tobacco. Lebrun-Garcia A, et al. **Biochimie** 1999 Jun; 81(6):663-8 (52 ref.)

IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Martal JL, et al. **Biochimie** 1998 Aug-Sep;80(8-9):755-77 (236 ref.)

Recent advances in the study of nod factor perception and signal transduction. Niebel A, et al. **Biochimie** 1999 Jun; 81(6):669-74 (50 ref.)

Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Pitha PM, et al. **Biochimie** 1998 Aug-Sep;80(8-9):651-8 (50 ref.)

Integrins: alternative splicing as a mechanism to regulate ligand binding and integrin signaling events. de Melker AA, et al. **Bioessays** 1999 Jun;21(6):499-509 (88 ref.)

CaM kinase II as frequency decoder of Ca2+ oscillations. Dupont G, et al. **Bioessays** 1998 Aug;20(8):607-10 (40 ref.)

Chemokines: extracellular messengers for all occasions? Gale LM, et al. **Bioessays** 1999 Jan;21(1):17-28 (98 ref.)

Signaling pathways in phagocytosis. Kwiatkowska K, et al. **Bioessays** 1999 May;21(5):422-31 (92 ref.)

E2F target genes and cell-cycle checkpoint control. Lavia P, et al. **Bioessays** 1999 Mar;21(3):221-30 (71 ref.)

The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events. McCarty JH. **Bioessays** 1998 Nov;20(11):913-21 (71 ref.)

Negative regulation of the JAK/STAT pathway. Starr R, et al. **Bioessays** 1999 Jan;21(1):47-52 (44 ref.)

Copper and signal transduction: platelets as a model to determine the role of copper in stimulus-response coupling. Johnson WT. **Biofactors** 1999;10(1):53-9 (36 ref.)

Lymphocyte antigen receptor signal integration and regulation by the SHC adaptor. Baldari CT, et al. **Biol Chem** 1999 Feb;380(2):129-34 (42 ref.)

Signalling properties of glycosylphosphatidylinositols and their regulated release from membranes in the turnover of glycosylphosphatidylinositol-anchored proteins. Brodbeck U. **Biol Chem** 1998 Aug-Sep;379(8-9):1041-4 (31 ref.)

New insights into signal recognition and elongation arrest activities of the signal recognition particle. Bui N, et al. **Biol Chem** 1999 Feb;380(2):135-45 (74 ref.)

Signal transduction via Ras. Wittinghofer A. **Biol Chem** 1998 Aug-Sep;379(8-9):933-7 (14 ref.)

Sugars as signal molecules in plant seed development. Wobus U, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):937-44 (40 ref.)

Ca2+/calmodulin-dependent protein kinase IV and calcium signaling. Anderson KA, et al. **Biometals** 1998 Dec; 11(4):331-43 (70 ref.)

Nuclear calcium: a key regulator of gene expression. Hardingham GE, et al. **Biometals** 1998 Dec;11(4):345-58 (120 ref.)

Src homology-2 domains: structure, mechanisms, and drug discovery. Sawyer TK. **Biopolymers** 1998;47(3):243-61 (44 ref.)

Biosensing with G-protein coupled receptor systems. Lundström I, et al. **Biosens Bioelectron** 1998 Sep 15; 13(6):689-95 (37 ref.)

Thrombin and trypsin receptors: the same mechanism of signalling on cellular surfaces. Olejar T, et al. **Bratisl Lek Listy** 1999 Feb;100(2):75-9 (35 ref.)

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Siemeister G, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):241-8 (70 ref.)

Cellular and molecular aspects of contractile dysfunction in heart failure. Mittmann C, et al. **Cardiovasc Res** 1998 Aug; 39(2):267-75 (101 ref.)

Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide? Siow RC, et al. **Cardiovasc Res** 1999 Feb;41(2):385-94 (110 ref.)

Ins(1,4,5)P3 and cardiac dysfunction. Woodcock EA, et al. **Cardiovasc Res** 1998 Nov;40(2):251-6 (68 ref.)

Alteration of intracellular Ca2(+)-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats. Zolk O, et al. **Cardiovasc Res** 1998 Jul;39(1):242-56 (144 ref.)

Lipoprotein receptors: signaling functions in the brain? Cooper JA, et al. **Cell** 1999 Jun 11;97(6):671-4 (20 ref.)

Signaling networks--do all roads lead to the same genes? [comment] Pawson T, et al. **Cell** 1999 Jun 11;97(6):675-8 (21 ref.) Comment on: Cell 1999 Jun 11;97(6):727-41.

Signaling to p53: breaking the MDM2-p53 circuit. Prives C. **Cell** 1998 Oct 2;95(1):5-8 (24 ref.)

Adaptors and molecular scaffolds in immune cell signaling. Rudd CE. **Cell** 1999 Jan 8;96(1):5-8 (28 ref.)

Protein tyrosine kinase-mediated pathways in G protein-coupled receptor signaling. Dikic I, et al. **Cell Biochem Biophys** 1999;30(3):369-87 (84 ref.)

Regulatory and spatial aspects of inositol trisphosphate-mediated calcium signals. Horne JH. **Cell Biochem Biophys** 1999;30(2):267-86 (64 ref.)

Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of

apoptotic signal transduction? Bokoch GM. **Cell Death Differ** 1998 Aug;5(8):637–45 (82 ref.)

Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Thornalley PJ. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1013–23 (70 ref.)

Understanding the molecular basis of Wiskott–Aldrich syndrome. Abo A. **Cell Mol Life Sci** 1998 Oct; 54(10):1145–53 (73 ref.)

The modular nature of apoptotic signaling proteins. Hofmann K. **Cell Mol Life Sci** 1999 Jul;55(8–9):1113–28 (108 ref.)

MAP kinases in plant signal transduction. Jonak C, et al. **Cell Mol Life Sci** 1999 Feb;55(2):204–13 (40 ref.)

RdgC/PP5–related phosphatases: novel components in signal transduction. Andreeva AV, et al. **Cell Signal** 1999 Aug; 11(8):555–62 (64 ref.)

Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Bornfeldt KE, et al. **Cell Signal** 1999 Jul;11(7):465–77 (170 ref.)

What does insulin do to Ras? Goalstone ML, et al. **Cell Signal** 1998 May;10(5):297–301 (43 ref.)

Redox regulation of cellular signalling. Kamata H, et al. **Cell Signal** 1999 Jan;11(1):1–14 (270 ref.)

Intracellular signalling pathways induced by chemokines in natural killer cells. Maghazachi AA. **Cell Signal** 1999 Jun; 11(6):385–90 (63 ref.)

Insulin signalling: metabolic pathways and mechanisms for specificity. Nystrom FH, et al. **Cell Signal** 1999 Aug; 11(8):563–74 (162 ref.)

Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Olofsson B. **Cell Signal** 1999 Aug; 11(8):545–54 (81 ref.)

Crowded little caves: structure and function of caveolae. Schlegel A, et al. **Cell Signal** 1998 Jul;10(7):457–63 (62 ref.)

Neuronal ion channel signalling pathways: modulation by angiotensin II. Sumners C, et al. **Cell Signal** 1998 May; 10(5):303–11 (109 ref.)

G protein–coupled receptor signalling in the kidney. Weiss RH. **Cell Signal** 1998 May;10(5):313–20 (82 ref.)

Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Braunewell KH, et al. **Cell Tissue Res** 1999 Jan;295(1):1–12 (129 ref.)

The PIK-related kinases intercept conventional signaling pathways. Kuruvilla FG, et al. **Chem Biol** 1999 May; 6(5):R129–36 (70 ref.)

Mammalian phosphatidylinositol transfer proteins: emerging roles in signal transduction and vesicular traffic. Cockcroft S. **Chem Phys Lipids** 1999 Apr;98(1–2):23–33 (62 ref.)

Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase–related receptors. Katada T, et al. **Chem Phys Lipids** 1999 Apr; 98(1–2):79–86 (30 ref.)

Diacylglycerol kinases in signal transduction. van Blitterswijk WJ, et al. **Chem Phys Lipids** 1999 Apr; 98(1–2):95–108 (77 ref.)

Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Goeddel DV. **Chest** 1999 Jul;116(1 Suppl):69S–73S (37 ref.)

Modulation of drug–induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Grant S, et al. **Clin Cancer Res** 1996 Dec;2(12):1915–20 (79 ref.)

A potential role of an intracellular signaling defect in neutrophil functional abnormalities and promotion of tissue damage in patients with localized juvenile periodontitis. Leino L, et al. **Clin Chem Lab Med** 1999 Mar;37(3):215–22 (85 ref.)

Signal transduction pathways and modulation of gene activity. Weitzman JB, et al. **Clin Chem Lab Med** 1998 Aug;36(8):535–9 (24 ref.)

Angiotensin receptors: molecular biology and signalling. Inagami T, et al. **Clin Exp Pharmacol Physiol** 1999 Jul; 26(7):544–9 (53 ref.)

Signal transduction in T lymphocytes. Peterson EJ, et al. **Clin Exp Rheumatol** 1999 Jan–Feb;17(1):107–14 (111 ref.)

Signaling to chromatin through histone modifications: how clear is the signal? Mizzen C, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:469–81 (109 ref.)

Phage display in proteolysis and signal transduction. Gram H. **Comb Chem High Throughput Screen** 1999 Feb; 2(1):19–28 (61 ref.)

Positive and negative thymocyte selection. Saito T, et al. **Crit Rev Immunol** 1998;18(4):359–70 (89 ref.)

Oncogenes and signal transduction pathways involved in the regulation of Na+ channel expression. Sashihara S, et al. **Crit Rev Oncog** 1998;9(1):19–34 (142 ref.)

Actin polymerization: Where the WASP stings. Bi E, et al. **Curr Biol** 1999 Mar 11;9(5):R160–3 (17 ref.)

Lymphocyte signalling: a coordinating role for Vav? Cantrell D. **Curr Biol** 1998 Jul 16;8(15):R535–8 (15 ref.)

Shoot meristems: Intercellular signals keep the balance. Doerner P. **Curr Biol** 1999 May 20;9(10):R377–80 (18 ref.)

Cytokinin action: two receptors better than one? Estelle M. **Curr Biol** 1998 Jul 16;8(15):R539–41 (9 ref.)

Apoptosis: Ras to the rescue in the fly eye. McNeill H, et al. **Curr Biol** 1999 Mar 11;9(5):R176–9 (16 ref.)

Intracellular signaling: Fleshing out the TGFbeta pathway. Padgett RW. **Curr Biol** 1999 Jun 3;9(11):R408–11 (14 ref.)

Biological sensors: More than one way to sense oxygen. Pellequer JL, et al. **Curr Biol** 1999 Jun 3;9(11):R416–8 (12 ref.)

Imposing specificity by localization: mechanism and evolvability [published erratum appears in Curr Biol 1998 Dec 3;8(24):R897] [see comments] Ptashne M, et al. **Curr Biol** 1998 Nov 5;8(22):R812–22 (36 ref.) Comment in: Curr Biol 1999 Jan 14;9(1):R6–7.

Lymphocyte signaling: adapting new adaptors. Rudd CE. **Curr Biol** 1998 Nov 5;8(22):R805–8 (18 ref.)

Signal transduction: Gyrating protein kinases. Stock J. **Curr Biol** 1999 May 20;9(10):R364–7 (29 ref.)

Differential molecular interactions of beta–catenin and plakoglobin in adhesion, signaling and cancer. Ben–Ze'ev A, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):629–39 (97 ref.)

Extracellular matrix signaling: integration of form and function in normal and malignant cells. Boudreau N, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):640–6 (55 ref.)

Gastric H+/K(+)-ATPase: targeting signals in the regulation of physiologic function. Caplan MJ. **Curr Opin Cell Biol** 1998 Aug;10(4):468–73 (51 ref.)

Wnt signalling: pathway or network? Arias AM, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):447–54 (82 ref.)

Extracellular modulation of the Hedgehog, Wnt and TGF–beta signalling pathways during embryonic development. Capdevila J, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):427–33 (91 ref.)

BMPs, Smads and metalloproteases: extracellular and intracellular modes of negative regulation. Cho KW, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):443–9 (55 ref.)

Complexity of EGF receptor signalling revealed in Drosophila. Freeman M. **Curr Opin Genet Dev** 1998 Aug; 8(4):407–11 (46 ref.)

Propagation and localization of Wnt signaling. Gumbiner BM. **Curr Opin Genet Dev** 1998 Aug;8(4):430–5 (43 ref.)

New players and puzzles in the Hedgehog signaling pathway. Johnston RL, et al. **Curr Opin Genet Dev** 1998 Aug; 8(4):450–6 (77 ref.)

Somitogenesis: segmenting a vertebrate. McGrew MJ, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):487–93 (50 ref.)

Hox proteins meet more partners. Mann RS, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):423–9 (55 ref.)

Roles of the JNK signaling pathway in Drosophila morphogenesis. Noselli S, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):466–72 (75 ref.)

Ras—a versatile cellular switch. Rommel C, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):412–8 (71 ref.)

Wnt signaling and dorso–ventral axis specification in vertebrates. Sokol SY. **Curr Opin Genet Dev** 1999 Aug; 9(4):405–10 (73 ref.)

Specificity in signaling pathways: assembly into multimolecular signaling complexes. Tsunoda S, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):419–22 (39 ref.)

Notch signaling: direct or what? Weinmaster G. **Curr Opin Genet Dev** 1998 Aug;8(4):436–42 (67 ref.)

B cell development: signal transduction by antigen receptors and their surrogates. Benschop RJ, et al. **Curr Opin Immunol** 1999 Apr;11(2):143–51 (87 ref.)

Signal transduction in bacteria: molecular mechanisms of stimulus–response coupling. Goudreau PN, et al. **Curr Opin Microbiol** 1998 Apr;1(2):160–9 (82 ref.)

Two–component signal transduction systems in eukaryotic microorganisms. Loomis WF, et al. **Curr Opin Microbiol** 1998 Dec;1(6):643–8 (37 ref.)

Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL–12 responses. McDowell MA, et al. **Curr Opin Microbiol** 1999 Aug;2(4):438–43 (67 ref.)

Signal transduction by MAP kinase cascades in budding yeast. Posas F, et al. **Curr Opin Microbiol** 1998 Apr; 1(2):175–82 (66 ref.)

Oligosaccharide recognition signals and defence reactions in marine plant–microbe interactions. Potin P, et al. **Curr Opin Microbiol** 1999 Jun;2(3):276–83 (64 ref.)

Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Rozengurt E. **Curr Opin Oncol** 1999 Mar;11(2):116–22 (80 ref.)

Gibberellin signaling. Bethke PC, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):440–6 (66 ref.)

ABA signal transduction. Grill E, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):412–8 (69 ref.)

Signaling in plant embryogenesis. Harada JJ. **Curr Opin Plant Biol** 1999 Feb;2(1):23–7 (40 ref.)

Connections between virus movement, macromolecular signaling and assimilate allocation. Lucas WJ, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):192–7 (51 ref.)

Auxin signaling in Arabidopsis flower development? Nemhauser JL, et al. **Curr Opin Plant Biol** 1998 Dec; 1(6):531–5 (36 ref.)

Cell walls: structures and signals. Pennell R. **Curr Opin Plant Biol** 1998 Dec;1(6):504–10 (50 ref.)

Defence signalling pathways in cereals. Piffanelli P, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):295–300 (46 ref.)

Resistance response physiology and signal transduction. Scheel D. **Curr Opin Plant Biol** 1998 Aug;1(4):305–10 (67 ref.)

Ethylene gas: perception, signaling and response. Solano R, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):393–8 (52 ref.)

The alphabet soup of plant intracellular signalling: enter cyclic nucleotides. Walden R. **Curr Opin Plant Biol** 1998 Oct;1(5):419–23 (39 ref.)

Signaling tip growth in plants. Yang Z. **Curr Opin Plant Biol** 1998 Dec;1(6):525–30 (54 ref.)

Parasitic plant responses to host plant signals: a model for subterranean plant–plant interactions. Yoder JI. **Curr Opin Plant Biol** 1999 Feb;2(1):65–70 (51 ref.)

Signaling and effector pathways. Müller–Ladner U, et al. **Curr Opin Rheumatol** 1999 May;11(3):194–201 (78 ref.)

Fibroblast growth factor signaling regulates growth and morphogenesis at multiple steps during brain development. Vaccarino FM, et al. **Curr Top Dev Biol** 1999;46:179–200 (111 ref.)

The unexpected complexity of Fc gamma RIIB signal transduction. Cambier JC, et al. **Curr Top Microbiol Immunol** 1999;244:43–55 (70 ref.)

The role of the SRC homology 2–containing inositol 5'–phosphatase in Fc epsilon R1–induced signaling. Huber M, et al. **Curr Top Microbiol Immunol** 1999;244:29–41 (39 ref.)

Signal transduction pathways activated during fibroblast contraction of collagen matrices. Grinnell F. **Curr Top Pathol** 1999;93:61–73 (106 ref.)

Mechanisms of cell signaling in immune–mediated inflammation. Bayón Y, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):275–86 (140 ref.)

Eph receptors and ephrins: effectors of morphogenesis. Holder N, et al. **Development** 1999 May;126(10):2033–44 (104 ref.)

All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. Bos JL. **EMBO J** 1998 Dec 1;17(23):6776–82 (75 ref.)

Cell–to–cell signaling and Pseudomonas aeruginosa infections. Van Delden C, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):551–60 (82 ref.)

Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Ghiso JA, et al. **Eur J Biochem** 1999 Jul;263(2):295–304 (118 ref.)

The CCN family of angiogenic regulators: the integrin connection. Lau LF, et al. **Exp Cell Res** 1999 Apr 10; 248(1):44–57 (101 ref.)

Crosstalk between insulin and angiotensin II signalling systems [see comments] Folli F, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):133–9 (21 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111–2.

Insulin signal transduction: possible mechanisms for insulin resistance. Kellerer M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(2):97–106 (93 ref.)

Signal transduction in keratinocytes. Mitev V, et al. **Exp Dermatol** 1999 Apr;8(2):96–108 (83 ref.)

Age–related changes of signal transduction in T cells. Hirokawa K. **Exp Gerontol** 1999 Jan;34(1):7–18 (68 ref.)

Redox signaling: hydrogen peroxide as intracellular messenger. Rhee SG. **Exp Mol Med** 1999 Jun 30;31(2):53–9 (60 ref.)

Mechanotransduction in bone—role of the lacuno–canalicular network. Burger EH, et al. **FASEB J** 1999;13 Suppl:S101–12 (118 ref.)

The syndecans, tuners of transmembrane signaling. Zimmermann P, et al. **FASEB J** 1999;13 Suppl:S91–S100 (79 ref.)

Cyclooxygenase–dependent signalling: molecular events and consequences. Versteeg HH, et al. **FEBS Lett** 1999 Feb 19;445(1):1–5 (58 ref.)

4–Hydroxynonenal and cell signalling. Dianzani MU. **Free Radic Res** 1998 Jun;28(6):553–60 (53 ref.)

Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implications. Baldi E, et al. **Front Biosci** 1998 Nov 1;3:D1051–9 (86 ref.)

Signaling events during male germ cell differentiation: bases and perspectives. Berruti G. **Front Biosci** 1998 Nov 1; 3:D1097–108 (117 ref.)

Focal adhesion kinase in integrin–mediated signaling. Cary LA, et al. **Front Biosci** 1999 Jan 15;4:D102–13 (142 ref.)

Lymphocyte activation: the coming of the protein tyrosine phosphatases. Mustelin T, et al. **Front Biosci** 1998 Nov 1; 3:D1060–96 (473 ref.)

Signal relays in the VEGF system. Ortega N, et al. **Front Biosci** 1999 Feb 1;4:D141–52 (130 ref.)

T cell signaling: effect of age. Pahlavani MA. **Front Biosci** 1998 Nov 1;3:D1120–33 (144 ref.)

Role of PP2A in intracellular signal transduction pathways. Schönthal AH. **Front Biosci** 1998 Dec 15;3:D1262–73 (145 ref.)

Regulation of platelet–derived growth factor signaling by activated p21Ras. Stice LL, et al. **Front Biosci** 1999 Jan 15;4:D72–86 (113 ref.)

Signaling through protein kinase C. Toker A. **Front Biosci** 1998 Nov 1;3:D1134–47 (125 ref.)

Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Alspaugh JA, et al. **Fungal Genet Biol** 1998 Oct;25(1):1–14 (120 ref.)

Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Bouscarel B, et al. **Gastroenterology** 1999 Aug; 117(2):433–52 (217 ref.)

Signaling pathways mediating the response to hypertrophic stress in the heart. Force T, et al. **Gene Expr** 1999; 7(4–6):337–48 (74 ref.)

Stress, superoxide, and signal transduction. Goldschmidt–Clermont PJ, et al. **Gene Expr** 1999;

7(4–6):255–60 (47 ref.)
Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Kyriakis JM. **Gene Expr** 1999; 7(4–6):217–31 (76 ref.)
A G-protein signaling network mediated by an RGS protein. Guan KL, et al. **Genes Dev** 1999 Jul 15;13(14):1763–7 (35 ref.)
Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Kaufman RJ. **Genes Dev** 1999 May 15; 13(10):1211–33 (186 ref.)
New insights in glycosphingolipid function: "glycosignaling domain," a cell surface assembly of glycosphingolipids with signal transducer molecules,involved in cell adhesion coupled with signaling [letter] Hakomori S, et al. **Glycobiology** 1998 Oct;8(10):xi–xix (66 ref.)
Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Rosenkranz S, et al. **Growth Factors** 1999; 16(3):201–16 (120 ref.)
Recent developments in hepatic circulatory physiology. Suematsu M. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1406–8 (23 ref.)
Adhesion-dependent signalling and the initiation of haemostasis and thrombosis. Andrews RK, et al. **Histol Histopathol** 1998 Jul;13(3):837–44 (70 ref.)
Integrin-mediated signal transduction pathways. Cary LA, et al. **Histol Histopathol** 1999 Jul;14(3):1001–9 (144 ref.)
Regulation of tumor cell invasion by extracellular matrix. Crowe DL, et al. **Histol Histopathol** 1999 Apr;14(2):665–71 (79 ref.)
Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex. Grozdanovic Z, et al. **Histol Histopathol** 1999 Jan; 14(1):243–56 (116 ref.)
Cell proliferation and cancer. López-Sáez JF, et al. **Histol Histopathol** 1998 Oct;13(4):1197–214 (109 ref.)
Lipid signaling and cell responses at the nuclear level. Neri LM, et al. **Histol Histopathol** 1999 Jan;14(1):321–35 (157 ref.)
Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. Unger JW, et al. **Histol Histopathol** 1998 Oct;13(4):1215–24 (74 ref.)
T cell signaling: a decision of life and death. Medema JP, et al. **Hum Immunol** 1999 May;60(5):403–11 (97 ref.)
Negative signaling in health and disease. Coggeshall KM. **Immunol Res** 1999;19(1):47–64 (165 ref.)
Small GTPases in lymphocyte biology: Rho proteins take center stage. Henning S, et al. **Immunol Res** 1999; 20(1):29–42 (59 ref.)
Immune cell signaling aberrations in human lupus. Liossis SN, et al. **Immunol Res** 1998 Aug;18(1):27–39 (69 ref.)
Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Cosman D, et al. **Immunol Rev** 1999 Apr;168:177–85 (71 ref.)
Angiotensin II receptors-antagonists, molecular biology, and signal transduction. Jagadeesh G. **Indian J Exp Biol** 1998 Dec;36(12):1171–94 (223 ref.)
Enigmatic relationship of Pleckstrin homology domain with phospholipid breakdown mediated signal transduction. Tyagi MG, et al. **Indian J Exp Biol** 1999 Jan;37(1):1–5 (34 ref.)
Adapter molecules in T cell receptor signaling. Boerth NJ, et al. **Inflamm Bowel Dis** 1999 May;5(2):107–18 (116 ref.)
Epidermal growth factor pathway substrate 15, Eps15. Salcini AE, et al. **Int J Biochem Cell Biol** 1999 Aug; 31(8):805–9 (20 ref.)
FADD/MORT1, a signal transducer that can promote cell death or cell growth. Strasser A, et al. **Int J Biochem Cell Biol** 1999 May;31(5):533–7 (20 ref.)
Gene, interaction, signal generation, signal divergence and signal transduction of the LH/CG receptor. Ryu KS, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S9–20 (60 ref.)
Signal transduction via the interleukin-4 receptor and its correlation with atopy. Izuhara K, et al. **Int J Mol Med** 1999 Jan;3(1):3–10 (107 ref.)
Molecular dissection of B cell antigen receptor signaling (review). Kurosaki T. **Int J Mol Med** 1998 Mar;1(3):515–27 (115 ref.)
Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Murata T, et al. **Int J Mol Med** 1998 Mar;1(3):551–7 (95 ref.)
Signal transduction in arteriosclerosis: mechanical stress-activated MAP kinases in vascular smooth muscle cells (review). Zou Y, et al. **Int J Mol Med** 1998 May; 1(5):827–34 (60 ref.)
Defective signal transduction via TCR-CD3 complex in patients with systemic lupus erythematosus. Takeuchi T, et al. **Intern Med** 1999 Feb;38(2):169 (6 ref.)
Two-component signal transduction in Bacillus subtilis: how one organism sees its world. Fabret C, et al. **J Bacteriol** 1999 Apr;181(7):1975–83 (32 ref.)
Signal transduction of the TGF-beta superfamily by Smad proteins. Kawabata M, et al. **J Biochem (Tokyo)** 1999 Jan; 125(1):9–16 (67 ref.)
Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. Anderson RA, et al. **J Biol Chem** 1999 Apr 9;274(15):9907–10 (65 ref.)
Signaling mechanisms that regulate glucose transport. Czech MP, et al. **J Biol Chem** 1999 Jan 22;274(4):1865–8 (78 ref.)
Signaling by the germinal center kinase family of protein kinases. Kyriakis JM. **J Biol Chem** 1999 Feb 26; 274(9):5259–62 (55 ref.)
The role of phosphatases in inositol signaling reactions. Majerus PW, et al. **J Biol Chem** 1999 Apr 16; 274(16):10669–72 (57 ref.)
Mammalian diacylglycerol kinases, a family of lipid kinases with signaling functions. Topham MK, et al. **J Biol Chem** 1999 Apr 23;274(17):11447–50 (84 ref.)
Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. Zou X, et al. **J Biol Chem** 1999 Jun 25; 274(26):18141–4 (77 ref.)
HIV infection and signal transduction. Bovolenta C, et al. **J Biol Regul Homeost Agents** 1998 Jul-Sep;12(3):63–6 (56 ref.)
Signal transduction pathway for anterior-posterior development in Drosophila. Back KH, et al. **J Biomed Sci** 1999 Sep-Oct;6(5):314–9 (55 ref.)
Molecular bases for the recognition of tyrosine-based sorting signals. Bonifacino JS, et al. **J Cell Biol** 1999 May 31; 145(5):923–6 (42 ref.)
Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. Carpenter G. **J Cell Biol** 1999 Aug 23;146(4):697–702 (61 ref.)
Heptahelical receptor signaling: beyond the G protein paradigm. Hall RA, et al. **J Cell Biol** 1999 May 31; 145(5):927–32 (66 ref.)
Signaling to actin dynamics. Machesky LM, et al. **J Cell Biol** 1999 Jul 26;146(2):267–72 (54 ref.)
The heterogeneity of ER Ca2+ stores has a key role in nonmuscle cell signaling and function. Meldolesi J, et al. **J Cell Biol** 1998 Sep 21;142(6):1395–8 (49 ref.)
The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. Tarnawski AS, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S12–20 (63 ref.)
Recent developments in lymphocyte activation: linking kinases to downstream signaling events. Clements JL, et al. **J Clin Invest** 1999 Apr;103(7):925–9 (43 ref.)
Organization of kinases, phosphatases, and receptor signaling complexes. Schillace RV, et al. **J Clin Invest** 1999 Mar; 103(6):761–5 (27 ref.)
Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. Virkamäki A, et al. **J Clin Invest** 1999 Apr;103(7):931–43 (186 ref.)
Inducible NO synthase: role in cellular signalling. Beck KF, et al. **J Exp Biol** 1999 Mar;202 (Pt 6):645–53 (81 ref.)
Evolution of osmotic stress signaling via MAP kinase cascades. Kütz D, et al. **J Exp Biol** 1998 Nov;201 (Pt 22):3015–21 (37 ref.)
The molecular ZPA. Pearse RV 2nd, et al. **J Exp Zool** 1998 Dec 15;282(6):677–90 (117 ref.)
Kinases involved in MSP/RON signaling. Danilkovitch A, et al. **J Leukoc Biol** 1999 Mar;65(3):345–8 (47 ref.)
Signal transduction by reactive oxygen species in non-phagocytic cells. Finkel T. **J Leukoc Biol** 1999 Mar; 65(3):337–40 (35 ref.)
Integrin signal transduction in myeloid leukocytes. Lowell CA, et al. **J Leukoc Biol** 1999 Mar;65(3):313–20 (94 ref.)
Sphingosine 1-phosphate: a prototype of a new class of second messengers. Spiegel S. **J Leukoc Biol** 1999 Mar; 65(3):341–4 (41 ref.)
Progesterone signaling and mammary gland morphogenesis. Shyamala G. **J Mammary Gland Biol Neoplasia** 1999 Jan; 4(1):89–104 (72 ref.)
Redox regulation of signal transduction in cardiac and smooth muscle. Suzuki YJ, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):345–53 (72 ref.)
The patched signaling pathway in tumorigenesis and development: lessons from animal models. Hahn H, et al. **J Mol Med** 1999 Jun;77(6):459–68 (102 ref.)
Molecular aspects of adrenergic signal transduction in cardiac failure. Hajjar RJ, et al. **J Mol Med** 1998 Oct;76(11):747–55 (65 ref.)
Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. Meinhardt G, et al. **J Mol Med** 1999 Feb; 77(2):282–93 (155 ref.)
Cellular mechanisms of cardiac hypertrophy. Sugden PH, et al. **J Mol Med** 1998 Oct;76(11):725–46 (307 ref.)
Aberrancies in signal transduction and cell cycle related events in Alzheimer's disease. Arendt T, et al. **J Neural Transm Suppl** 1998;54:147–58 (82 ref.)
In vivo molecular signal transduction of peripheral mechanisms of pain. Ueda H. **Jpn J Pharmacol** 1999 Mar; 79(3):263–8 (27 ref.)
Interleukin-10 and Gp130 cytokines in human multiple myeloma. Klein B, et al. **Leuk Lymphoma** 1999 Jun; 34(1–2):63–70 (66 ref.)
Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167–74 (107 ref.)
The generation of nitric oxide by G protein-coupled receptors. Christopoulos A, et al. **Life Sci** 1999;64(1):1–15 (104 ref.)
Muscarinic cholinergic signaling in cardiac myocytes: dynamic targeting of M2AChR to sarcolemmal caveolae and eNOS activation. Feron O, et al. **Life Sci** 1999; 64(6–7):471–7 (24 ref.)
Signal transduction of eicosanoid CB1 receptor ligands. Howlett AC, et al. **Life Sci** 1999;65(6–7):617–25 (32 ref.)
M2 signaling in smooth muscle cells. Kotlikoff MI, et al. **Life Sci** 1999;64(6–7):437–42 (29 ref.)
The influence of the cellular context on receptor function: a necessary consideration for physiologic interpretations of receptor expression studies. Logsdon CD. **Life Sci** 1999; 64(6–7):369–74 (38 ref.)
Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Watkins LR, et al. **Life Sci** 1999;65(5):449–81 (290 ref.)
Sphingolipid metabolism in the regulation of bioactive molecules. Luberto C, et al. **Lipids** 1999;34 Suppl:S5–11 (62 ref.)
Signaling in human lupus T lymphocytes [editorial] Zouali M. **Lupus** 1998;7(8):499–502 (37 ref.)
Dishevelled: at the crossroads of divergent intracellular signaling pathways. Boutros M, et al. **Mech Dev** 1999 May; 83(1–2):27–37 (67 ref.)
Evidence for age-related deamidation reactions in erythrocyte p55 and glycophorins C and D: implications for signal transduction involving tumour-suppressor proteins in higher eukaryotes. Lofthouse JT. **Med Hypotheses** 1998 Oct;51(4):321–4 (14 ref.)
Neutrophil signaling alteration: an adverse inflammatory response after burn shock. Sayeed MM. **Medicina (B Aires)** 1998;58(4):386–92 (19 ref.)
Ca2+ and intracellular signalling in plant cells: a role in phytochrome transduction. Volotovski ID. **Membr Cell Biol** 1998;12(5):721–42 (75 ref.)
Thrombopoietin signal transduction: studies from cell lines and primary cells. Drachman JG, et al. **Methods** 1999 Mar; 17(3):238–49 (80 ref.)
Protein-DNA interactions in interferon-gamma signaling. Park C, et al. **Methods** 1998 Jul;15(3):175–88 (89 ref.)
The identification of signaling molecules by the yeast two-hybrid system. Biffo S, et al. **Methods Mol Biol** 1999; 96:211–20 (7 ref.)
Induction of intracellular signals through binding of adhesive molecules. Activation of p125FAK tyrosine phosphorylation. Venturino M, et al. **Methods Mol Biol** 1999;96:191–8 (12 ref.)
PAS domains: internal sensors of oxygen, redox potential, and light. Taylor BL, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):479–506 (269 ref.)
Comparison of human COP9 signalsome and 26S proteasome lid'. Henke W, et al. **Mol Biol Rep** 1999 Apr;26(1–2):29–34 (20 ref.)
Clostridial toxins: molecular probes of Rho-dependent signaling and apoptosis. Bobak DA. **Mol Cell Biochem** 1999 Mar;193(1–2):37–42 (28 ref.)
Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Ghatpande S, et al. **Mol Cell Biochem** 1999 Jun;196(1–2):93–7 (50 ref.)
Dynamic regulation of intracellular calcium signals through calcium release channels. Iino M. **Mol Cell Biochem** 1999 Jan;190(1–2):185–90 (41 ref.)
Role of acylCoA binding protein in acylCoA transport, metabolism and cell signaling. Knudsen J, et al. **Mol Cell Biochem** 1999 Feb;192(1–2):95–103 (88 ref.)
The IRS-signalling system: a network of docking proteins that mediate insulin action. White MF. **Mol Cell Biochem** 1998 May;182(1–2):3–11 (81 ref.)
Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Schaeffer HJ, et al. **Mol Cell Biol** 1999 Apr;19(4):2435–44 (145 ref.)
Signal transduction involving cyclic AMP-dependent and cyclic AMP-independent mechanisms in the control of steroidogenesis. Cooke BA. **Mol Cell Endocrinol** 1999 May 25;151(1–2):25–35 (100 ref.)
Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Frödin M, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):65–77 (82 ref.)
Local activation and inactivation of thyroid hormones: the deiodinase family. Köhrle J. **Mol Cell Endocrinol** 1999 May 25;151(1–2):103–19 (152 ref.)
The tail of the gonadotrophin-releasing hormone receptor: desensitization at, and distal to, G protein-coupled receptors. McArdle CA, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):129–36 (63 ref.)
Use of two-hybrid methodology for identifying proteins of interest in endocrinology. Pirson I, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):137–41 (42 ref.)
Glucocorticoid signalling--multiple variations of a common theme. Reichardt HM, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1–2):1–6 (38 ref.)
Transcriptional regulation of the StAR gene. Reinhart AJ, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):161–9 (86 ref.)
Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone. Stanislaus D, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1–2):1–10 (73 ref.)
Downstream factors in transforming growth factor-beta family signaling. Visser JA, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1–2):7–17 (113 ref.)
Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Lange CA, et al. **Mol Endocrinol** 1999 Jun;13(6):829–36 (39 ref.)
Cell signaling defects and human disease. Mora-Garcia P, et al. **Mol Genet Metab** 1999 Mar;66(3):143–71 (255 ref.)

Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Girault JA, et al. **Mol Med** 1998 Dec;4(12):751–69 (137 ref.)

Angiotensin II type 1 receptor–modulated signaling pathways in neurons. Richards EM, et al. **Mol Neurobiol** 1999 Feb; 19(1):25–41 (117 ref.)

Rho as a mediator of G protein–coupled receptor signaling. Seasholtz TM, et al. **Mol Pharmacol** 1999 Jun;55(6):949–56 (98 ref.)

Apoptosis and heart failure. Williams RS. **N Engl J Med** 1999 Sep 2;341(10):759–60 (1 ref.)

Going mad with Smads. Zhou S, et al. **N Engl J Med** 1999 Oct 7;341(15):1144–6 (8 ref.)

Peptide modulators of protein–protein interactions in intracellular signaling. Souroujon MC, et al. **Nat Biotechnol** 1998 Oct;16(10):919–24 (50 ref.)

Extracellular ATP: a further modulator in neuroendocrine control of the thymus. Alves LA, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):81–9 (90 ref.)

Galaninergic signalling and adenylate cyclase. Karelson E, et al. **Neuropeptides** 1998 Jun;32(3):197–210 (126 ref.)

Modulation of life and death by the TNF receptor superfamily. Baker SJ, et al. **Oncogene** 1998 Dec 24; 17(25):3261–70 (69 ref.)

Stress signals for apoptosis: ceramide and c-Jun kinase. Basu S, et al. **Oncogene** 1998 Dec 24;17(25):3277–85 (75 ref.)

Increasing complexity of Ras signaling. Campbell SL, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1395–413 (256 ref.)

Regulation of cell proliferation by G proteins. Dhanasekaran N, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1383–94 (139 ref.)

Signaling by dual specificity kinases. Dhanasekaran N, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1447–55 (117 ref.)

Cell signaling: an overview. Dhanasekaran N. **Oncogene** 1998 Sep 17;17(11 Reviews):1329–30 (0 ref.)

Signal transduction pathways that regulate cell survival and cell death. Dragovich T, et al. **Oncogene** 1998 Dec 24; 17(25):3207–13 (62 ref.)

Cell growth control by G protein–coupled receptors: from signal transduction to signal integration. Gutkind JS. **Oncogene** 1998 Sep 17;17(11 Reviews):1331–42 (163 ref.)

Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Jarpe MB, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1475–82 (79 ref.)

Cell cycle targets of Ras/Raf signalling. Kerkhoff E, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1457–62 (82 ref.)

Signaling by integrin receptors. Kumar CC. **Oncogene** 1998 Sep 17;17(11 Reviews):1365–73 (92 ref.)

Genetic analysis of mammalian G-protein signalling. Offermanns S, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1375–81 (66 ref.)

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Porter AC, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1343–52 (106 ref.)

The many faces of Src: multiple functions of a prototypical tyrosine kinase. Schwartzberg PL. **Oncogene** 1998 Sep 17; 17(11 Reviews):1463–8 (65 ref.)

From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'. Sudol M. **Oncogene** 1998 Sep 17;17(11 Reviews):1469–74 (64 ref.)

Antigen receptor signaling: integration of protein tyrosine kinase functions. Tamir I, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1353–64 (203 ref.)

Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? Villunger A, et al. **Oncol Res** 1998; 10(11–12):541–50 (189 ref.)

Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Kato S, et al. **Oncology** 1998 Dec;55 Suppl 1:5–10 (32 ref.)

Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death. Kong AN, et al. **Pharm Res** 1999 Jun;16(6):790–8 (122 ref.)

Regulation of beta-adrenoceptor signaling in cardiac function and disease. Dzimiri N. **Pharmacol Rev** 1999 Sep; 51(3):465–501 (357 ref.)

Oligopeptide signalling and the action of systemin. Schaller A. **Plant Mol Biol** 1999 Jul;40(5):763–9 (17 ref.)

How plants learn [comment] Trewavas A. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4216–8 (23 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4718–23.

Phospholipase A2 (EC 3.1.1.4) and D (EC 3.1.4.4) signalling in lymphocytes. Wakelam MJ, et al. **Proc Nutr Soc** 1998 Nov;57(4):551–4 (22 ref.)

MAP kinase pathways. Cobb MH. **Prog Biophys Mol Biol** 1999;71(3–4):479–500 (205 ref.)

The role of SHIP in growth factor induced signalling. Huber M, et al. **Prog Biophys Mol Biol** 1999;71(3–4):423–34 (72 ref.)

Applications of mass spectrometry to signal transduction. Resing KA, et al. **Prog Biophys Mol Biol** 1999; 71(3–4):501–23 (166 ref.)

Signaling through focal adhesion kinase. Schlaepfer DD, et al. **Prog Biophys Mol Biol** 1999;71(3–4):435–78 (249 ref.)

The STAT family of proteins in cytokine signaling. Shuai K. **Prog Biophys Mol Biol** 1999;71(3–4):405–22 (117 ref.)

Recognition and regulation of primary-sequence motifs by signaling modular domains. Songyang Z. **Prog Biophys Mol Biol** 1999;71(3–4):359–72 (93 ref.)

Studying signal transduction in neuronal cells: the Trk/NGF system. Kaplan DR. **Prog Brain Res** 1998;117:35–46 (70 ref.)

Small GTPases of the Rho family and cell transformation. Fort P. **Prog Mol Subcell Biol** 1999;22:159–81 (146 ref.)

Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation. Pelligrino DA, et al. **Prog Neurobiol** 1998 Oct; 56(1):1–18 (130 ref.)

What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? Strunecká A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul;61(1):1–5 (47 ref.)

Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Fimiani C, et al. **Prostaglandins Other Lipid Mediat** 1999 Jan;57(1):23–34 (86 ref.)

Signal transduction by the receptor tyrosine kinase Ret. van Weering DH, et al. **Recent Results Cancer Res** 1998; 154:271–81 (40 ref.)

Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression. Eigenthaler M, et al. **Rev Physiol Biochem Pharmacol** 1999;135:173–209 (151 ref.)

G protein signalling pathways in myometrium: affecting the balance between contraction and relaxation. Sanborn BM, et al. **Rev Reprod** 1998 Sep;3(3):196–205 (77 ref.)

Notch signaling: cell fate control and signal integration in development. Artavanis-Tsakonas S, et al. **Science** 1999 Apr 30;284(5415):770–6 (92 ref.)

Cryptochromes: blue light receptors for plants and animals. Cashmore AR, et al. **Science** 1999 Apr 30;284(5415):760–5 (50 ref.)

The when and where of floor plate induction. Dodd J, et al. **Science** 1998 Nov 27;282(5394):1654–7 (33 ref.)

Integrin signaling. Giancotti FG, et al. **Science** 1999 Aug 13;285(5430):1028–32 (65 ref.)

Orphan nuclear receptors: shifting endocrinology into reverse. Kliewer SA, et al. **Science** 1999 Apr 30; 284(5415):757–60 (37 ref.)

A cell's sense of direction. Parent CA, et al. **Science** 1999 Apr 30;284(5415):765–70 (35 ref.)

Peptide growth factors and signal transduction. Sidawy AN, et al. **Semin Vasc Surg** 1998 Sep;11(3):149–55 (64 ref.)

Functional roles of STAT family proteins: lessons from knockout mice. Akira S. **Stem Cells** 1999;17(3):138–46 (80 ref.)

Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. Rosner W, et al. **Steroids** 1999 Jan–Feb;64(1–2):100–6 (39 ref.)

The thyrotropin-releasing hormone-degrading ectoenzyme: the third element of the thyrotropin-releasing hormone-signaling system. Heuer H, et al. **Thyroid** 1998 Oct;8(10):915–20 (28 ref.)

Down-modulation of IL-2-triggered JAK3-STAT5 signaling following CD4-ligand binding. Lowry RP, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):820–1 (16 ref.)

How regulated protein translocation can produce switch-like responses. Ferrell JE Jr. **Trends Biochem Sci** 1998 Dec; 23(12):461–5 (37 ref.)

Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Corvera S, et al. **Trends Cell Biol** 1998 Nov;8(11):442–6 (58 ref.)

Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Dedhar S, et al. **Trends Cell Biol** 1999 Aug;9(8):319–23 (38 ref.)

Putting E. coli on a pedestal: a unique system to study signal transduction and the actin cytoskeleton. Goosney DL, et al. **Trends Cell Biol** 1999 Jan;9(1):11–4 (58 ref.)

Signal transduction by a protease cascade. LeMosy EK, et al. **Trends Cell Biol** 1999 Mar;9(3):102–7 (36 ref.)

ECM signalling: orchestrating cell behaviour and misbehaviour. Lukashev ME, et al. **Trends Cell Biol** 1998 Nov;8(11):437–41 (66 ref.)

Glycans in post-Golgi apical targeting: sorting signals or structural props? Rodriguez-Boulan E, et al. **Trends Cell Biol** 1999 Aug;9(8):291–4 (45 ref.)

Versatility in signalling: multiple responses to EGF receptor activation during Drosophila oogenesis. Van Buskirk C, et al. **Trends Cell Biol** 1999 Jan;9(1):1–4 (31 ref.)

Making sense of the COP9 signalosome. A regulatory protein complex conserved from Arabidopsis to human. Wei N, et al. **Trends Genet** 1999 Mar;15(3):98–103 (41 ref.)

Apoptosis: an innate immune response to virus infection. Everett H, et al. **Trends Microbiol** 1999 Apr;7(4):160–5 (57 ref.)

Virus interception of cytokine-regulated pathways. Kalvakolanu DV. **Trends Microbiol** 1999 Apr;7(4):166–71 (57 ref.)

Bordatella pertussis adenylate cyclase: a toxin with multiple talents. Ladant D, et al. **Trends Microbiol** 1999 Apr; 7(4):172–6 (31 ref.)

Signalling pathways in two-component phosphorelay systems. Perraud AL, et al. **Trends Microbiol** 1999 Mar; 7(3):115–20 (38 ref.)

Throwing the switch in bacterial chemotaxis. Silversmith RE, et al. **Trends Microbiol** 1999 Jan;7(1):16–22 (26 ref.)

Emerging roles for RGS proteins in cell signalling. Hepler JR. **Trends Pharmacol Sci** 1999 Sep;20(9):376–82 (84 ref.)

Signaltransduction in vascular endothelium: the role of intracellular calcium and ion channels. Nilius B. **Verh K Acad Geneeskd Belg** 1998;60(3):215–50 (51 ref.)

[Hepatocyte growth factor is an important signal exchanger between mesenchyme and epithelia during development] Guo SH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):249–51 (8 ref.) **(Chi)**

[Mitogen-activated protein kinase involved in intracellular signal transduction] Li TC, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):258–60 (10 ref.) **(Chi)**

[Signal transduction and thyroid pathology: environment and genetics] Pirson I, et al. **C R Seances Soc Biol Fil** 1998; 192(5):847–56 (86 ref.) **(Fre)**

[Angiotensin II receptors: classification, structure, and signal transduction] Miserey S, et al. **Therapie** 1998 May–Jun; 53(3):205–11 (29 ref.) (Eng. Abstr.) **(Fre)**

[Aldosterone receptors: new insights in hormonal signal transduction] Rafestin-Oblin ME, et al. **Therapie** 1998 May–Jun;53(3):227–35 (100 ref.) (Eng. Abstr.) **(Fre)**

[New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition] Nishimoto N, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1745–50 (20 ref.) **(Jpn)**

[Signal transduction of PI3-kinase] Fukui Y. **Nippon Rinsho** 1998 Jul;56(7):1773–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Signal transductions by the MAP kinase cascades] Gotoh I, et al. **Nippon Rinsho** 1998 Jul;56(7):1779–83 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Recent advances in growth factor receptor research] Kanzaki M, et al. **Nippon Rinsho** 1998 Jul;56(7):1791–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Intracellular signaling pathways of angiotensin II receptor type 1 involved in the development of cardiovascular diseases] Miyazaki H, et al. **Nippon Rinsho** 1998 Jul; 56(7):1906–11 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Structures and functions of small GTPase and heterotrimeric G proteins] Saito Y. **Nippon Rinsho** 1998 Jul;56(7):1750–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Classification of cytokine receptor superfamily and signal transduction--structural feature and functional property] Tanaka M, et al. **Nippon Rinsho** 1998 Jul;56(7):1784–90 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Endocrine signaling system mediated by nuclear receptors] Umesono K. **Nippon Rinsho** 1998 Jul;56(7):1693–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Bone morphogenetic protein (BMP) receptors and signal transduction] Yamashita H, et al. **Nippon Rinsho** 1999 Jan; 57(1):220–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Receptors and signal transduction for the TGF-beta related factors] Miyazono K. **Nippon Ronen Igakkai Zasshi** 1999 Mar;36(3):162–6 (27 ref.) **(Jpn)**

[Production of various antibodies and single chain Fv molecule against signal-transducing proteins] Kurose H, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):59–68 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of G protein-mediated signaling pathways by RGS proteins] Kozasa T. **Seikagaku** 1998 Dec; 70(12):1418–22 (21 ref.) **(Jpn)**

[Analysis of the unfolded protein response: an intracellular signaling pathway from the endoplasmic reticulum to the nucleus] Mori K. **Seikagaku** 1998 Jul;70(7):505–15 (42 ref.) **(Jpn)**

[The role of phosphatidylinositol turnover in nuclear] Fukami K. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):969–75 (32 ref.) **(Jpn)**

[Calcium waves as an intercellular signaling] Furuya K. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1547–54 (39 ref.) **(Jpn)**

[Diacylglycerol kinase: molecular diversity and gene expression in central nervous system] Goto K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):976–82 (31 ref.) **(Jpn)**

[Phosphoinositide 3-kinase] Hazeki O. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):961–8 (83 ref.) **(Jpn)**

[Phosphatidic acid phosphatase] Kanoh H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):983–8 (28 ref.) **(Jpn)**

[Glycosphingolipid microdomains/caveolae and signal transduction] Kasahara K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2522–30 (46 ref.) **(Jpn)**

[Roles of phospholipase D in signal transduction] Nakashima S, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):998–1006 (80 ref.) **(Jpn)**

[Role of DARPP-32 in dopamine signal transduction in the striatum] Nishi A. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(15):2172–81 (55 ref.) **(Jpn)**

[Regulation of B cell receptor signaling through tyrosine kinases and phosphatases] Takata M, et al. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):655–67 (43 ref.) **(Jpn)**

[Signal transduction related to sphingosine 1-phosphate] Yatomi Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2510–5 (44 ref.) **(Jpn)**

[The biological mechanisms underlying alcohol dependence] Alling C. **Lakartidningen** 1999 Jul 14;96(28–29):3248–52 (63 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

The intracellular signaling network as a target for ethanol. Hoek JB, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5

Suppl):224S-230S (46 ref.)
Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Haq R, et al. **Cancer Metastasis Rev** 1998 Jun;17(2):233-9 (57 ref.)
The role of corticosteriods in the regulation of vascular tone. Ullian ME. **Cardiovasc Res** 1999 Jan;41(1):55-64 (115 ref.)
Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Goekjian PG, et al. **Curr Med Chem** 1999 Sep;6(9):877-903 (182 ref.)
Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Ruggeri BA, et al. **Curr Med Chem** 1999 Sep;6(9):845-57 (104 ref.)
The protein kinase ABC's of signal transduction as targets for drug development. Glazer RI. **Curr Pharm Des** 1998 Jun;4(3):277-90 (207 ref.)
Effects of substance P on cellular signalling systems in the rat anterior pituitary. Mau SE. **Dan Med Bull** 1999 Feb; 46(1):35-56 (243 ref.)
D-myo inositol 1,2,6, triphosphate (alpha-trinositol, pp56): selective antagonist at neuropeptide Y (NPY) Y-receptors or selective inhibitor of phosphatidylinositol cell signaling? Bell D, et al. **Gen Pharmacol** 1998 Nov;31(5):689-96 (79 ref.)
Interference of eukaryotic signalling pathways by the bacteria Yersinia outer protein YopJ. Spiik AK, et al. **Immunol Lett** 1999 Jun 1;68(2-3):199-203 (44 ref.)
Insulin regulates expression of metabolic genes through divergent signaling pathways. Hall RK, et al. **J Basic Clin Physiol Pharmacol** 1999;10(2):119-33 (47 ref.)
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji HK, et al. **J Clin Psychiatry** 1999;60 Suppl 2:27-39; discussion 40-1, 113-6 (138 ref.)
Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. Darnell JE Jr. **J Interferon Cytokine Res** 1998 Aug;18(8):549-54 (64 ref.)
Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo. Fisher GJ, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):61-8 (48 ref.)
Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Fantus IG, et al. **Mol Cell Biochem** 1998 May;182(1-2):109-19 (89 ref.)
The neurobiology of cannabinoid transmission: from anandamide signaling to higher cerebral functions and disease. Navarro M, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):379-85 (48 ref.)
Activation and injury of endothelial cells by cytokines. Pober JS. **Pathol Biol (Paris)** 1998 Mar;46(3):159-63 (31 ref.)
Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors. Pollack IF, et al. **Pediatr Neurosurg** 1998 Nov;29(5):228-44 (213 ref.)
The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Quock RM, et al. **Pharmacol Rev** 1999 Sep;51(3):503-32 (280 ref.)
Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Yoshizaki K, et al. **Springer Semin Immunopathol** 1998;20(1-2):247-59 (71 ref.)
Cytokines induce airway smooth muscle cell hyperresponsiveness to contractile agonists. Amrani Y, et al. **Thorax** 1998 Aug;53(8):713-6 (47 ref.)
Epigenetic toxicology as toxicant-induced changes in intracellular signalling leading to altered gap junctional intercellular communication. Trosko JE, et al. **Toxicol Lett** 1998 Dec 28;102-103:71-8 (51 ref.)
The nitric oxide-cyclic 3',5'-guanosine monophosphate signal transduction pathway in the mechanism of action of general anesthetics. Vulliemoz Y. **Toxicol Lett** 1998 Nov 23;100-101:103-8 (31 ref.)
Signal-transduction cascades as targets for therapeutic intervention by natural products. Cardenas ME, et al. **Trends Biotechnol** 1998 Oct;16(10):427-33 (71 ref.)
From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling. Morinville A, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):452-60 (89 ref.)
[The effect of NC-1900: its ameliorating effects on impairments of learning and memory in the CA1 neurons and its intracellular signal transduction pathways] Akaike N, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:44P-47P (11 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Signal transduction defects in growth hormone insensitivity. Clayton PE, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):174-8; discussion 179 (18 ref.)
STATs as mediators of cytokine-induced responses. Hoey T, et al. **Adv Immunol** 1999;71:145-62 (113 ref.)
Involvement of genes encoding a K+ channel (ether a go-go) and a Na+ channel (smellblind) in Drosophila olfaction. Dubin AE, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:212-22 (28 ref.)
Signal transduction and transcription factors in rheumatic disease. Firestein GS, et al. **Arthritis Rheum** 1999 Apr; 42(4):609-21 (126 ref.)
JNK, cytoskeletal regulator and stress response kinase? A Drosophila perspective. Goberdhan DC, et al. **Bioessays** 1998 Dec;20(12):1009-19 (83 ref.)
Signalling and gene regulation by urea and NaCl in the renal medulla. Cohen DM. **Clin Exp Pharmacol Physiol** 1999 Jan; 26(1):69-73 (44 ref.)
Genetic dissection of R gene signal transduction pathways. Innes RW. **Curr Opin Plant Biol** 1998 Aug;1(4):299-304 (41 ref.)
Cytokinin signaling. Kakimoto T. **Curr Opin Plant Biol** 1998 Oct;1(5):399-403 (27 ref.)
Genetically modified animals in pharmacological research: future trends. Rudolph U, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):327-37 (87 ref.)
Roles of reactive oxygen species: signaling and regulation of cellular functions. Gamaley IA, et al. **Int Rev Cytol** 1999; 188:203-55 (343 ref.)
Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection. Mahlmann S, et al. **Leukemia** 1998 Dec; 12(12):1858-65 (77 ref.)
The GnRH promoter: target of transcription factors, hormones, and signaling pathways. Nelson SB, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):151-5 (22 ref.)
The taxonomy of developmental control in Caenorhabditis elegans [see comments] Ruvkun G, et al. **Science** 1998 Dec 11;282(5396):2033-41 (51 ref.) Comment in: Science 1998 Dec 11;282(5396):1972-4. Comment in: Science 1999 Jul 9;285(5425):167.

IMMUNOLOGY

Interleukin-4 receptor signalling mechanisms and their biological significance. Nelms K, et al. **Adv Exp Med Biol** 1998;452:37-43 (19 ref.)
The function of small GTPases in signaling by immune recognition and other leukocyte receptors. Altman A, et al. **Adv Immunol** 1999;72:1-101 (561 ref.)
Inhibitory pathways triggered by ITIM-containing receptors. Bolland S, et al. **Adv Immunol** 1999;72:149-77 (180 ref.)
Integrins in the immune system. Shimizu Y, et al. **Adv Immunol** 1999;72:325-80 (456 ref.)
MHC class II and negative regulators of hematopoiesis. Deeg HJ, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):285-91 (46 ref.)
The complexities of CD28 and CTLA-4 signalling: PI3K and beyond. Ward SG. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):69-75 (51 ref.)
Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease. Di Cerbo A, et al. **Biochimie** 1999 May;81(5):415-24 (118 ref.)
Adhesion and signaling mediated by the cytoplasmic tails of leucocyte integrins. van Kooyk Y, et al. **Cell Adhes Commun** 1998;6(2-3):247-54 (72 ref.)
Type I interferons: expression and signalization. Doly J, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1109-21 (136 ref.)
Prolactin, growth hormone and the immune system in humans. Velkeniers B, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1102-8 (75 ref.)
T-cell signal transduction and the role of protein kinase C. Wilkinson SE, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1122-44 (168 ref.)
Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu-Lee L, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1067-75 (103 ref.)
Immune-derived cytokines in the nervous system: epigenetic instructive signals or neuropathogenic mediators? Ensoli F, et al. **Crit Rev Immunol** 1999;19(2):97-116 (211 ref.)
Immune signalling: SHP-2 docks at multiple ports. Huyer G, et al. **Curr Biol** 1999 Feb 25;9(4):R129-32 (11 ref.)
Signal transduction from the B cell antigen-receptor. Campbell KS. **Curr Opin Immunol** 1999 Jun;11(3):256-64 (74 ref.)
T cell antigen-receptor signal transduction. van Leeuwen JE, et al. **Curr Opin Immunol** 1999 Jun;11(3):242-8 (81 ref.)
Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway. Cornall RJ, et al. **Curr Top Microbiol Immunol** 1999;244:57-68 (67 ref.)
The interleukin 1 receptor: ligand interactions and signal transduction. Auron PE. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):221-37 (91 ref.)
Signaling and signaling dysfunction through the interferon gamma receptor. Rodig S, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):49-53 (25 ref.)
Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Heeg K, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):464-9 (54 ref.)
The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Los M, et al. **Immunity** 1999 Jun;10(6):629-39 (87 ref.)
c-Cbl: a regulator of T cell receptor-mediated signalling. Thien CB, et al. **Immunol Cell Biol** 1998 Oct;76(5):473-82 (90 ref.)
A quantitative approach to signal transduction. Metzger H, et al. **Immunol Lett** 1999 May 3;68(1):53-7 (31 ref.)
Parameters determining the stimulatory capacity of the type I Fc epsilon-receptor. Schweitzer-Stenner R, et al. **Immunol Lett** 1999 May 3;68(1):59-69 (54 ref.)
The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. McAdam AJ, et al. **Immunol Rev** 1998 Oct;165:231-47 (96 ref.)
Signal transduction through cytokine receptors. Hibi M, et al. **Int Rev Immunol** 1998;17(1-4):75-102 (150 ref.)
Nuclear factor kappaB--a new therapeutic approach? [editorial; comment] Böhrer H, et al. **Intensive Care Med** 1998 Nov;24(11):1129-30 (13 ref.) Comment on: Intensive Care Med 1998 Nov;24(11):1131-8. Comment on: Intensive Care Med 1998 Nov;24(11):1199-208.
Chemoattractant receptor cross-desensitization. Ali H, et al. **J Biol Chem** 1999 Mar 5;274(10):6027-30 (52 ref.)
Multiple roles for PI 3-kinase in the regulation of PLCgamma activity and Ca2+ mobilization in antigen-stimulated mast cells. Barker SA, et al. **J Leukoc Biol** 1999 Mar;65(3):321-9 (55 ref.)
Retinoid-mediated signaling pathways in CD38 antigen expression in myeloid leukemia cells. Mehta K, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):441-9 (65 ref.)
Differential signalling by variant ligands of the T cell receptor and the kinetic model of T cell activation. Madrenas J. **Life Sci** 1999;64(9):717-31 (118 ref.)
Adaptor proteins and T-cell antigen receptor signaling. Samelson LE. **Prog Biophys Mol Biol** 1999;71(3-4):393-403 (53 ref.)
Checkpoints in antibacterial immunity. Flesch IE, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):693-7 (39 ref.)
Lymphocyte-mediated cytolysis: dual apoptotic mechanisms with overlapping cytoplasmic and nuclear signalling pathways. Trapani JA, et al. **Results Probl Cell Differ** 1999; 23:78-102 (147 ref.)
Signals involved in thymocyte positive and negative selection. Mariathasan S, et al. **Semin Immunol** 1999 Aug; 11(4):263-72 (104 ref.)
Positive and negative signaling pathways. Pratt JC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):772-4 (23 ref.)
[Physiopathological and therapeutic therapy of collagen diseases based on results of clinical tests--disorders of lymphocyte signal transduction] Takeuchi T. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2446-52 (23 ref.) **(Jpn)**
[Antigen peptide/MHC complex as an initiator of a signal for lymphocyte T activation] Kuśnierczyk P. **Postepy Hig Med Dosw** 1999;53(2):331-41 (24 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Signaling pathways for transduction of the initial message of the glycocode into cellular responses. Villalobo A, et al. **Acta Anat (Basel)** 1998;161(1-4):110-29 (162 ref.)
Molecular signals for glial activation: pro- and anti-inflammatory cytokines in the injured brain. Raivich G, et al. **Acta Neurochir Suppl (Wien)** 1999;73:21-30 (87 ref.)
PKC-dependent signalling mechanisms in differentiated smooth muscle. Morgan KG, et al. **Acta Physiol Scand** 1998 Dec;164(4):495-505 (112 ref.)
Inhibitory mechanisms for cross-bridge cycling: the nitric oxide-cGMP signal transduction pathway in smooth muscle relaxation. Murphy RA, et al. **Acta Physiol Scand** 1998 Dec;164(4):373-80 (66 ref.)
The role of phospholamban and SERCA3 in regulation of smooth muscle-endothelial cell signalling mechanisms: evidence from gene-ablated mice. Paul RJ. **Acta Physiol Scand** 1998 Dec;164(4):589-97 (54 ref.)
Insulin signaling and glucose transport in insulin resistant skeletal muscle. Special reference to GLUT4 transgenic and GLUT4 knockout mice. Galuska D, et al. **Adv Exp Med Biol** 1998;441:73-85 (67 ref.)
General mechanisms of cytokine receptor signaling. Carpenter LR, et al. **Adv Protein Chem** 1998;52:109-40 (138 ref.)
Cytokines in endocrine function. Silva CM, et al. **Adv Protein Chem** 1998;52:199-221 (72 ref.)
Receptor-mediated signaling pathways: potential targets of modulation by dietary fatty acids. Hwang D, et al. **Am J Clin Nutr** 1999 Oct;70(4):545-56 (82 ref.)
Specificity in transforming growth factor-beta signaling pathways. Ring CJ, et al. **Am J Hum Genet** 1999 Mar; 64(3):691-7 (37 ref.)
Overgrowth syndromes and the regulation of signaling complexes by proteoglycans. Selleck SB. **Am J Hum Genet** 1999 Feb;64(2):372-7 (30 ref.)
III. Intracellular signaling in response to toxic liver injury. Jones BE, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G874-8 (40 ref.)
Role of plasmalemmal caveolae in signal transduction. Shaul PW, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L843-51 (109 ref.)
The contributions of vestibular signals to the representations of space in the posterior parietal cortex. Andersen RA, et al. **Ann N Y Acad Sci** 1999 May 28;871:282-92 (44 ref.)
Oxygen free radical signaling in ischemic preconditioning. Das DK, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:49-65 (107 ref.)
The I1-imidazoline receptor and its cellular signaling pathways. Ernsberger P. **Ann N Y Acad Sci** 1999 Jun 21; 881:35-53 (86 ref.)
The ins and outs of caveolar signaling. m2 muscarinic cholinergic receptors and eNOS activation versus neuregulin and ErbB4 signaling in cardiac myocytes. Feron O, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:11-9 (39 ref.)
Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Fuxe K, et al.

Ann N Y Acad Sci 1998 Dec 21;863:274–90 (38 ref.)
An alternative approach to the central processing of canal and otolith signals. Green AM, et al.
Ann N Y Acad Sci 1999 May 28;871:402–5 (8 ref.)
Galanin–galanin receptor systems in the hypothalamic paraventricular and supraoptic nuclei. Some recent findings and future challenges. Gundlach AL, et al.
Ann N Y Acad Sci 1998 Dec 21;863:241–51 (52 ref.)
Signaling by the cytokine receptor superfamily. Ihle JN, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:1–9 (50 ref.)
The synaptic framework for chemical signaling in nucleus accumbens. Meredith GE. **Ann N Y Acad Sci** 1999 Jun 29;877:140–56 (84 ref.)
Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. Miyamoto S, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:119–29 (45 ref.)
Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control. Wagner M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:1–10 (36 ref.)
Role of cyclic GMP in olfactory transduction and adaptation. Zufall F, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:199–204 (29 ref.)
Intracellular signaling from the endoplasmic reticulum to the nucleus. Chapman R, et al. **Annu Rev Cell Dev Biol** 1998; 14:459–85 (74 ref.)
The ethylene gas signal transduction pathway: a molecular perspective. Johnson PR, et al. **Annu Rev Genet** 1998; 32:227–54 (124 ref.)
Virocrine transformation: the intersection between viral transforming proteins and cellular signal transduction pathways. DiMaio D, et al. **Annu Rev Microbiol** 1998; 52:397–421 (142 ref.)
Thinking about bacterial populations as multicellular organisms. Shapiro JA. **Annu Rev Microbiol** 1998;52:81–104 (187 ref.)
Beta-adrenergic receptors and receptor signaling in heart failure. Post SR, et al. **Annu Rev Pharmacol Toxicol** 1999; 39:343–60 (107 ref.)
Controversial issues in vertebrate olfactory transduction. Gold GH. **Annu Rev Physiol** 1999;61:857–71 (71 ref.)
Cellular mechanisms of taste transduction. Herness MS, et al. **Annu Rev Physiol** 1999;61:873–900 (175 ref.)
Current topics in signal transduction in bacteria. Hellingwerf KJ, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):211–27 (160 ref.)
Signaling via cAMP in fungi: interconnections with mitogen-activated protein kinase pathways. Kronstad J, et al. **Arch Microbiol** 1998 Nov;170(6):395–404 (66 ref.)
Ion transport and signalling in human labial glands. Turner RJ, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S15–9 (35 ref.)
Signal transduction in wound pharmacology. Kim WJ, et al. **Arch Pharm Res** 1998 Oct;21(5):487–95 (107 ref.)
Early steps in insulin action. Dorrestijn J, et al.
Arch Physiol Biochem 1998 Oct;106(4):269–89 (207 ref.)
Cytokines, Jaks, Stats, health and disease. Brown MP.
Aust N Z J Med 1999 Feb;29(1):73–8 (49 ref.)
Osmotic induction of signaling cascades: role in regulation of cell function. Häussinger D, et al.
Biochem Biophys Res Commun 1999 Feb 24;255(3):551–5 (78 ref.)
Is sperm galactosyltransferase a signaling subunit of a multimeric gamete receptor? Shur BD.
Biochem Biophys Res Commun 1998 Sep 29;250(3):537–43 (79 ref.)
Apoptotic signal transduction: emerging pathways. Wilson MR. **Biochem Cell Biol** 1998;76(4):573–82 (66 ref.)
Signal transduction of stress via ceramide. Mathias S, et al.
Biochem J 1998 Nov 1;335 (Pt 3):465–80 (303 ref.)
Protein kinase cascades in intracellular signalling by interleukin-1 and tumour necrosis factor. Saklatvala J, et al. **Biochem Soc Symp** 1999;64:63–77 (65 ref.)
Hormones as life regulators in the current molecular endocrinology. Pankov YA. **Biochemistry (Mosc)** 1998 Dec;63(12):1361–73 (125 ref.)
Cadherins and tissue formation: integrating adhesion and signaling. Vleminckx K, et al. **Bioessays** 1999 Mar; 21(3):211–20 (55 ref.)
Role of cysteine and glutathione in signal transduction, immunopathology and cachexia. Dröge W, et al.
Biofactors 1998;8(1–2):97–102 (23 ref.)
Melatonin receptors and signal transduction mechanisms. Barrett P, et al. **Biol Signals Recept** 1999 Jan–Apr; 8(1–2):6–14 (45 ref.)
Calcium-binding proteins and development. Beckingham K, et al. **Biometals** 1998 Dec;11(4):359–73 (117 ref.)
Peptide conjugates as tools for the study of biological signal transduction. Eisele F, et al. **Bioorg Med Chem** 1999 Feb; 7(2):193–224 (136 ref.)
Resolving conflicting signals: cross inhibition of cytokine signaling pathways. Begley CG, et al. **Blood** 1999 Mar 1; 93(5):1443–7 (59 ref.)
Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Miyazono K. **Bone** 1999 Jul;25(1):91–3 (39 ref.)
Molecular regulation of tooth development. Thesleff I, et al. **Bone** 1999 Jul;25(1):123–5 (24 ref.)
Smad4 (DPC4)--a potent tumour suppressor? Duff EK, et al. **Br J Cancer** 1998 Dec;78(12):1615–9 (49 ref.)
Signal transduction pathways regulated by the Rho family of small GTPases. Hall A. **Br J Cancer** 1999 Jul;80 Suppl 1:25–7 (17 ref.)
Signal transduction. Sandy JR. **Br J Orthod** 1998 Nov; 25(4):269–74 (31 ref.)
The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Raymond JR, et al.
Br J Pharmacol 1999 Aug;127(8):1751–64 (160 ref.)
The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Bredel M, et al. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):232–49 (257 ref.)
Regulation of cardiovascular collagen synthesis by mechanical load. Bishop JE, et al. **Cardiovasc Res** 1999 Apr;42(1):27–44 (181 ref.)
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Nicoletti A, et al.
Cardiovasc Res 1999 Mar;41(3):532–43 (123 ref.)
Prostaglandin--a pluralistic hormone embracing divergent signal properties [editorial] Sack S. **Cardiovasc Res** 1998 Dec;40(3):438–9 (20 ref.)
Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Crabtree GR. **Cell** 1999 Mar 5;96(5):611–4 (25 ref.)
Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. Edlund T, et al. **Cell** 1999 Jan 22;96(2):211–24 (141 ref.)
Increasing the complexity of coactivation in nuclear receptor signaling. Freedman LP. **Cell** 1999 Apr 2;97(1):5–8 (22 ref.)
Splitting hairs: dissecting roles of signaling systems in epidermal development. Oro AE, et al. **Cell** 1998 Nov 25; 95(5):575–8 (18 ref.)
Conspiracy theory: RAS and RAF do not act alone. Sternberg PW, et al. **Cell** 1998 Nov 13;95(4):447–50 (17 ref.)
Integrin signaling: cytoskeletal complexes, MAP kinase activation, and regulation of gene expression. Danen EH, et al. **Cell Adhes Commun** 1998;6(2–3):217–24 (46 ref.)
Regulation of steroid receptor subcellular trafficking. DeFranco DB. **Cell Biochem Biophys** 1999;30(1):1–24 (96 ref.)
Regulation of Ca2+ release by cAMP-dependent protein kinase. A mechanism for agonist-specific calcium signaling? Bugrim AE. **Cell Calcium** 1999 Mar;25(3):219–26 (56 ref.)
p75NTR and the concept of cellular dependence: seeing how the other half die [see comments] Bredesen DE, et al.
Cell Death Differ 1998 May;5(5):365–71 (39 ref.) Comment in: Cell Death Differ 1998 May;5(5):343–5.
Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors [see comments] Szondy Z, et al. **Cell Death Differ** 1998 Jan; 5(1):4–10 (78 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1–3.
A role for growth hormone and prolactin in leukaemia and lymphoma? Hooghe R, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1095–101 (85 ref.)
The Grb7 family of signalling proteins. Daly RJ.
Cell Signal 1998 Oct;10(9):613–8 (49 ref.)
Phospholipase D: a novel major player in signal transduction. Gomez-Cambronero J, et al. **Cell Signal** 1998 Jun; 10(6):387–97 (161 ref.)
Cbl: complex formation and functional implications. Liu YC, et al. **Cell Signal** 1998 Jun;10(6):377–85 (120 ref.)
G-protein-linked receptors as tyrosine kinase substrates: new paradigms in signal integration. Malbon CC, et al.
Cell Signal 1998 Sep;10(8):523–7 (23 ref.)
Signalling into the T-cell nucleus: NFAT regulation. Masuda ES, et al. **Cell Signal** 1998 Oct;10(9):599–611 (132 ref.)
Diversity and complexity of ceramide signalling in apoptosis. Okazaki T, et al. **Cell Signal** 1998 Nov;10(10):685–92 (91 ref.)
Signalling pathways for cardiac hypertrophy. Yamazaki T, et al. **Cell Signal** 1998 Nov;10(10):693–8 (59 ref.)
Ligand recognition by SH3 and WW domains: the role of N-alkylation in PPII helices. Aghazadeh B, et al.
Chem Biol 1999 Sep;6(9):R241–6 (34 ref.)
Signalling to actin: the Cdc42-N-WASP-Arp2/3 connection. Carlier MF, et al. **Chem Biol** 1999 Sep; 6(9):R235–40 (28 ref.)
Recruitment of proteins to modulate protein–protein interactions. Liu JO. **Chem Biol** 1999 Aug;6(8):R213–5 (18 ref.)
Histidine kinases and two-component signal transduction systems. Pirrung MC. **Chem Biol** 1999 Jun;6(6):R167–75 (60 ref.)
Renal dopamine receptor signaling mechanisms in spontaneously hypertensive and Fischer 344 old rats. Hussain T, et al. **Clin Exp Hypertens** 1999 Jan–Feb; 21(1–2):25–36 (51 ref.)
Signal transduction by protein kinase C in mammalian cells. Kanashiro CA, et al. **Clin Exp Pharmacol Physiol** 1998 Dec; 25(12):974–85 (89 ref.)
Vascular biology of endothelin signal transduction. Neylon CB. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):149–53 (33 ref.)
Neuropharmacologic aspects of apoptosis: significance for neurodegenerative diseases. Michel PP, et al.
Clin Neuropharmacol 1999 May–Jun;22(3):137–50 (296 ref.)
Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Butler AA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep;121(1):19–26 (59 ref.)
Osmoregulation of liver cell function: signalling, osmolytes and cell heterogeneity. Häussinger D. **Contrib Nephrol** 1998;123:185–204 (100 ref.)
Sensors and signal transduction in the activation of cell volume regulatory ion transport systems. Hoffmann EK, et al. **Contrib Nephrol** 1998;123:50–78 (184 ref.)
Intracellular signaling in response to osmotic stress. Kültz D, et al. **Contrib Nephrol** 1998;123:94–109 (70 ref.)
From preadipocyte to adipocyte: differentiation-directed signals of insulin from the cell surface to the nucleus. Sorisky A. **Crit Rev Clin Lab Sci** 1999 Feb;36(1):1–34 (159 ref.)
Intracellular signalling: PDK1--a kinase at the hub of things. Belham C, et al. **Curr Biol** 1999 Feb 11;9(3):R93–6 (21 ref.)
Phosphorelay signalling: new tricks for an ancient pathway. Brown JM, et al. **Curr Biol** 1998 Sep 10;8(18):R662–5 (14 ref.)
Fever: links with an ancient receptor. Dinarello CA, et al. **Curr Biol** 1999 Feb 25;9(4):R147–50 (23 ref.)
Lipid signalling. Downes CP, et al. **Curr Biol** 1998 Dec 3; 8(24):R865–7 (6 ref.)
Going for the GAP. McCormick F. **Curr Biol** 1998 Sep 24; 8(19):R673–4 (5 ref.)
Signal transduction: fast lane to transcriptional activation. Rhodes D, et al. **Curr Biol** 1998 Oct 22;8(21):R765–7 (13 ref.)
Apoptosis control by death and decoy receptors. Ashkenazi A, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):255–60 (66 ref.)
Costimulatory regulation of T cell function. Chambers CA, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):203–10 (81 ref.)
Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Eastman Q, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):233–40 (102 ref.)
Organization and regulation of mitogen-activated protein kinase signaling pathways. Garrington TP, et al.
Curr Opin Cell Biol 1999 Apr;11(2):211–8 (58 ref.)
Microtubules and signal transduction. Gundersen GG, et al.
Curr Opin Cell Biol 1999 Feb;11(1):81–94 (165 ref.)
Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Hackel PO, et al.
Curr Opin Cell Biol 1999 Apr;11(2):184–9 (65 ref.)
Organization and regulation of proteins at synapses [published erratum appears in Curr Opin Cell Biol 1999 Jun;11(3):407–8] Kim JH, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):248–54 (64 ref.)
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Leevers SJ, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):219–25 (54 ref.)
Deciphering the pathways of life and death. Li H, et al.
Curr Opin Cell Biol 1999 Apr;11(2):261–6 (46 ref.)
Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Luttrell LM, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):177–83 (56 ref.)
Multiple signals converging on NF-kappaB. Mercurio F, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):226–32 (50 ref.)
Multiple positive and negative regulators of signaling by the EGF-receptor. Moghal N, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):190–6 (64 ref.)
Bidirectional signaling between the cytoskeleton and integrins. Schoenwaelder SM, et al.
Curr Opin Cell Biol 1999 Apr;11(2):274–86 (156 ref.)
Interactions between mitogenic stimuli, or, a thousand and one connections. Schwartz MA, et al.
Curr Opin Cell Biol 1999 Apr;11(2):197–202 (51 ref.)
Positive feedback interactions between microtubule and actin dynamics during cell motility. Waterman-Storer CM, et al. **Curr Opin Cell Biol** 1999 Feb;11(1):61–7 (58 ref.)
Membrane organization in immunoglobulin E receptor signaling. Sheets ED, et al. **Curr Opin Chem Biol** 1999 Feb; 3(1):95–9 (41 ref.)
Amino acid-dependent signal transduction and insulin sensitivity. Meijer AJ, et al.
Curr Opin Clin Nutr Metab Care 1999 May;2(3):207–11 (31 ref.)
Establishing links between developmental signaling pathways and cell-cycle regulation in Drosophila. Duronio RJ.
Curr Opin Genet Dev 1999 Feb;9(1):81–8 (64 ref.)
Integrins and signal transduction. Dedhar S.
Curr Opin Hematol 1999 Jan;6(1):37–43 (60 ref.)
Signal transduction cascades regulating mating, filamentation, and virulence in Cryptococcus neoformans. Wang P, et al. **Curr Opin Microbiol** 1999 Aug;2(4):358–62 (33 ref.)
Central neural mechanisms for detecting second-order motion. Baker CL Jr. **Curr Opin Neurobiol** 1999 Aug; 9(4):461–6 (56 ref.)
Regulation of back-propagating action potentials in hippocampal neurons. Johnston D, et al.
Curr Opin Neurobiol 1999 Jun;9(3):288–92 (34 ref.)
Assembly of signaling machinery at the postsynaptic membrane. Kirsch J. **Curr Opin Neurobiol** 1999 Jun; 9(3):329–35 (61 ref.)
Who does the hair cell's 'do? Rho GTPases and hair-bundle morphogenesis. Kollmar R. **Curr Opin Neurobiol** 1999 Aug; 9(4):394–8 (40 ref.)
Central mechanisms of pain modulation. Mason P.
Curr Opin Neurobiol 1999 Aug;9(4):436–41 (33 ref.)
Calcium signalling and regulation in olfactory neurons. Menini A. **Curr Opin Neurobiol** 1999 Aug;9(4):419–26 (63 ref.)
Linking extracellular survival signals and the apoptotic machinery. Nuñez G, et al. **Curr Opin Neurobiol** 1998 Oct; 8(5):613–8 (59 ref.)
Mechanisms of stereoscopic vision: the disparity energy model. Ohzawa I. **Curr Opin Neurobiol** 1998 Aug;

8(4):509-15 (30 ref.)
Brain protein serine/threonine phosphatases. Price NE, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):336-42 (68 ref.)
Molecular mechanisms of vertebrate photoreceptor light adaptation. Pugh EN Jr, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):410-8 (61 ref.)
Neural coding of gustatory information. Smith DV, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):427-35 (70 ref.)
Signal transduction underlying growth cone guidance by diffusible factors. Song HJ, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):355-63 (88 ref.)
Effects of estrogen in the CNS. Woolley CS. **Curr Opin Neurobiol** 1999 Jun;9(3):349-54 (44 ref.)
The bacterial K+ channel structure and its implications for neuronal channels. Yellen G. **Curr Opin Neurobiol** 1999 Jun;9(3):267-73 (52 ref.)
Cellular mechanisms of wingless/Wnt signal transduction. Dierick H, et al. **Curr Top Dev Biol** 1999;43:153-90 (166 ref.)
EGF receptor signaling in Drosophila oogenesis. Nilson LA, et al. **Curr Top Dev Biol** 1999;44:203-43 (143 ref.)
Signal transduction by bone morphogenetic proteins. Kawabata M, et al. **Cytokine Growth Factor Rev** 1998 Mar; 9(1):49-61 (119 ref.)
Nuclear import and export of proteins: the molecular basis for intracellular signaling. Sekimoto T, et al. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):205-11 (61 ref.)
TNF receptor associated factors in cytokine signaling. Wajant H, et al. **Cytokine Growth Factor Rev** 1999 Mar; 10(1):15-26 (114 ref.)
The CIS family: negative regulators of JAK-STAT signaling. Yoshimura A. **Cytokine Growth Factor Rev** 1998 Sep-Dec; 9(3-4):197-204 (46 ref.)
Pharmacological modulation of cytokine action and production through signaling pathways. Young PR. **Cytokine Growth Factor Rev** 1998 Sep-Dec;9(3-4):239-57 (171 ref.)
Sympathetic activity and aging: relationship to smoking habits, physical fitness, blood volume, and intracellular signalling. Jensen EW. **Dan Med Bull** 1999 Apr; 46(2):106-17 (135 ref.)
Effects of substance P on cellular signalling systems in the rat anterior pituitary. Mau SE. **Dan Med Bull** 1999 Feb; 46(1):35-56 (243 ref.)
Comparative biology of calcium signaling during fertilization and egg activation in animals. Stricker SA. **Dev Biol** 1999 Jul 15;211(2):157-76 (306 ref.)
Molecular mechanism of growth hormone signalling. Billestrup N, et al. **Endocr J** 1998 Apr;45 Suppl:S41-5 (34 ref.)
GH signalling in pancreatic beta-cells. Sekine N, et al. **Endocr J** 1998 Apr;45 Suppl:S33-40 (36 ref.)
Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. McKay LI, et al. **Endocr Rev** 1999 Aug;20(4):435-59 (271 ref.)
Aspects of novel sites of regulation of the insulin stimulus-secretion coupling in normal and diabetic pancreatic islets. Sjöholm A. **Endocrine** 1998 Aug;9(1):1-13 (226 ref.)
Tyrosine kinase substrates in interleukin-2 signaling. Gesbert F, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):33-40 (70 ref.)
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Besson A, et al. **Eur J Biochem** 1999 Aug; 263(3):605-11 (61 ref.)
The puzzle of hydrodynamic information processing: how are complex water motions analyzed by the lateral line? Mogdans J, et al. **Eur J Morphol** 1999 Apr;37(2-3):195-9 (17 ref.)
Signal transduction pathways associated with alpha1-adrenoceptor subtypes in cells and tissues including human prostate. Marshall I, et al. **Eur Urol** 1999;36 Suppl 1:42-7; discussion 65 (23 ref.)
Cytoskeleton and integrin-mediated adhesion signaling in human CD34+ hemopoietic progenitor cells. Lévesque JP, et al. **Exp Hematol** 1999 Apr;27(4):579-86 (60 ref.)
Vascular endothelial growth factor: how it transmits its signal. Zachary I. **Exp Nephrol** 1998 Nov-Dec;6(6):480-7 (62 ref.)
Growth factor-induced signal transduction in adherent mammalian cells is sensitive to gravity. Boonstra J. **FASEB J** 1999;13 Suppl:S35-42 (77 ref.)
Lipid signaling in CD95-mediated apoptosis. Malisan F, et al. **FEBS Lett** 1999 Jun 4;452(1-2):100-3 (42 ref.)
The complexity of p53 modulation: emerging patterns from divergent signals. Giaccia AJ, et al. **Genes Dev** 1998 Oct 1;12(19):2973-83 (109 ref.)
Intercellular calcium signaling and gap junctional communication in astrocytes. Giaume C, et al. **Glia** 1998 Sep;24(1):50-64 (111 ref.)
Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases. Daly RJ. **Growth Factors** 1999;16(4):255-63 (70 ref.)
Signal transduction of the growth hormone (GH) receptor, and GH-binding protein. Wojcik J, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:51-5 (41 ref.)
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Kornberg LJ. **Head Neck** 1998 Dec;20(8):745-52 (52 ref.)
Variation among cell types in the signaling pathways by which IGF-1 stimulates specific cellular responses. Petley T, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):70-6 (51 ref.)
[Apoptosis-inducing and -preventing signal transduction pathways in cultured cerebellar granule neurons] Ikeuchi T, et al. **Hum Cell** 1998 Sep;11(3):125-40 (88 ref.)
Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Xoriuchi M, et al. **Hypertens Res** 1999 Jul;22(2):67-74 (70 ref.)
Signal transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an aspect of immunoreceptor function? Horejsi V, et al. **Immunol Lett** 1998 Sep; 63(2):63-73 (185 ref.)
A kinetic differentiation model for the action of altered TCR ligands. Lord GM, et al. **Immunol Today** 1999 Jan; 20(1):33-9 (48 ref.)
Cytokine pleiotropy and redundancy--gp130 cytokines in human implantation. Sánchez-Cuenca J, et al. **Immunol Today** 1999 Feb;20(2):57-9 (32 ref.)
Regulation of eosinophil apoptosis: transduction of survival and death signals. Simon H, et al. **Int Arch Allergy Immunol** 1999 Jan;118(1):7-14 (62 ref.)
Signalling by proteolysis: death receptors induce apoptosis. Muzio M. **Int J Clin Lab Res** 1998;28(3):141-7 (53 ref.)
Fibroblast growth factors as multifunctional signaling factors. Szebenyi G, et al. **Int Rev Cytol** 1999;185:45-106 (370 ref.)
Mechanisms of insulin resistance in non-oxidative glucose metabolism: the role of glycogen synthase. Beck-Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):255-79 (39 ref.)
The role of G proteins in insulin signalling. Rizzo MA, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):167-95 (159 ref.)
Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. Baines CP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):741-54 (111 ref.)
Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. An S, et al. **J Cell Biochem Suppl** 1998;30-31:147-57 (46 ref.)
Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. Engel ME, et al. **J Cell Biochem Suppl** 1998;30-31:111-22 (61 ref.)
Oligosaccharide signaling of plant cells. Etzler ME. **J Cell Biochem Suppl** 1998;30-31:123-8 (35 ref.)
In search of cellular control: signal transduction in context. Ingber D. **J Cell Biochem Suppl** 1998;30-31:232-7 (32 ref.)
G-protein regulatory pathways: rocketing into the twenty-first century. Knall C, et al. **J Cell Biochem Suppl** 1998;30-31:137-46 (72 ref.)
A role for cadherins in cellular signaling and differentiation. Knudsen KA, et al. **J Cell Biochem Suppl** 1998; 30-31:168-76 (47 ref.)
Growth factors in the nucleolus? Pederson T. **J Cell Biol** 1998 Oct 19;143(2):279-81 (39 ref.)
Protein tyrosine phosphatases as negative regulators of mitogenic signaling. Chernoff J. **J Cell Physiol** 1999 Aug; 180(2):173-81 (94 ref.)
Physiological signals and oncogenesis mediated through Crk family adapter proteins. Feller SM, et al. **J Cell Physiol** 1998 Dec;177(4):535-52 (229 ref.)
Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. Rozengurt E. **J Cell Physiol** 1998 Dec;177(4):507-17 (129 ref.)
Recent advances in the understanding of interleukin-2 signal transduction. Gesbert F, et al. **J Clin Immunol** 1998 Sep; 18(5):307-20 (123 ref.)
Regulation of growth hormone secretion by signals produced by the adipose tissue. Pombo M, et al. **J Endocrinol Invest** 1999;22(5 Suppl):22-6 (28 ref.)
Signal transduction during liver regeneration. Brenner DA. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S93-5 (11 ref.)
New kid on the block: a role for the Na/Ca exchanger in odor transduction [comment] Dionne VE. **J Gen Physiol** 1998 Nov;112(5):527-8 (5 ref.) Comment on: J Gen Physiol 1998 Nov;112(5):529-35.
Sphingolipids and cell signalling. Fredman P. **J Inherit Metab Dis** 1998 Aug;21(5):472-80 (38 ref.)
The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. Donnelly RP, et al. **J Interferon Cytokine Res** 1999 Jun; 19(6):563-73 (82 ref.)
Death domain receptors and their role in cell demise. Singh A, et al. **J Interferon Cytokine Res** 1998 Jul;18(7):439-50 (129 ref.)
Chemokines: signal lamps for trafficking of T and B cells for development and effector function. Kim CH, et al. **J Leukoc Biol** 1999 Jan;65(1):6-15 (111 ref.)
Modulation of the plasma membrane Ca2+ pump. Penniston JT, et al. **J Membr Biol** 1998 Sep 15;165(2):101-9 (59 ref.)
The insulin signaling pathway. Taha C, et al. **J Membr Biol** 1999 May 1;169(1):1-12 (175 ref.)
Integrin signaling: tyrosine phosphorylation events in focal adhesions. Vuori K. **J Membr Biol** 1998 Oct 1;165(3):191-9 (125 ref.)
Glutathione and signal transduction in the mammalian CNS. Janáky R, et al. **J Neurochem** 1999 Sep;73(3):889-902 (99 ref.)
Recent progress in insulin signal transduction. Hei YJ. **J Pharmacol Toxicol Methods** 1998 Oct;40(3):123-35 (95 ref.)
Regulation of gene expression by trans-synaptic activity: a role for the transcription factor NF-kappa B. Gisiger V. **J Physiol Paris** 1998 Jun-Aug;92(3-4):163-6 (35 ref.)
Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects. Skoda RC. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1-4):741-72 (163 ref.)
Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. Rosner W, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):481-5 (26 ref.)
Intra- and intercellular Ca2+ signaling in paraneurons and other secretory cells. Kanno T. **Jpn J Physiol** 1998 Aug; 48(4):219-27 (73 ref.)
Axoplasmic transport and its signal transduction mechanism. Takenaka T, et al. **Jpn J Physiol** 1998 Dec;48(6):413-20 (20 ref.)
Transforming growth factor beta signal transduction in the kidney. Böttinger EP, et al. **Kidney Blood Press Res** 1998; 21(2-4):259-61 (19 ref.)
Identification of ceramide targets in interleukin-1 and tumor necrosis factor-alpha signaling in mesangial cells. Pfeilschifter J, et al. **Kidney Int Suppl** 1998 Sep;67:S34-9 (34 ref.)
Luminal signal in tubuloglomerular feedback: what about potassium? Vallon V, et al. **Kidney Int Suppl** 1998 Sep; 67:S177-9 (11 ref.)
Complement as a promiscuous signal transduction device. Asghar SS, et al. **Lab Invest** 1998 Oct;78(10):1203-25 (157 ref.)
Recent advances in the molecular basis of TNF signal transduction. Ledgerwood EC, et al. **Lab Invest** 1999 Sep; 79(9):1041-50 (113 ref.)
Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Blalock WL, et al. **Leukemia** 1999 Aug;13(8):1109-66 (871 ref.)
The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Dent P, et al. **Leukemia** 1998 Dec;12(12):1843-50 (114 ref.)
The CIS/JAB family: novel negative regulators of JAK signaling pathways. Yoshimura A. **Leukemia** 1998 Dec; 12(12):1851-7 (47 ref.)
Protein-tyrosine phosphatases in development. den Hertog J. **Mech Dev** 1999 Jul;85(1-2):3-14 (117 ref.)
Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. Dudler T, et al. **Methods Mol Biol** 1999;116:161-76 (19 ref.)
Trks: signal transduction and intracellular pathways. Klesse LJ, et al. **Microsc Res Tech** 1999 May 15-Jun 1; 45(4-5):210-6 (73 ref.)
Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging. Yamada K, et al. **Microsc Res Tech** 1998 Oct 1;43(1):68-74 (75 ref.)
Insulin signal transduction through protein kinase cascades. Avruch J. **Mol Cell Biochem** 1998 May;182(1-2):31-48 (211 ref.)
Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Byon JC, et al. **Mol Cell Biochem** 1998 May;182(1-2):101-8 (51 ref.)
Insulin receptor internalization and signalling. Di Guglielmo GM, et al. **Mol Cell Biochem** 1998 May;182(1-2):59-63 (41 ref.)
Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Goldstein BJ, et al. **Mol Cell Biochem** 1998 May;182(1-2):91-9 (74 ref.)
Binding of SH2 containing proteins to the insulin receptor: a new way for modulating insulin signalling. Liu F, et al. **Mol Cell Biochem** 1998 May;182(1-2):73-8 (42 ref.)
Role of binding proteins to IRS-1 in insulin signalling. Ogawa W, et al. **Mol Cell Biochem** 1998 May;182(1-2):13-22 (108 ref.)
The ubiquitin system in gametogenesis. Baarends WM, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):5-16 (120 ref.)
New insights into adipokinetic hormone signaling. Vroemen SF, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):7-12 (40 ref.)
GDNF family neurotrophic factor signaling: four masters, one servant? Airaksinen MS, et al. **Mol Cell Neurosci** 1999 May;13(5):313-25 (117 ref.)
Neuronal signaling systems and ethanol dependence. Pandey SC. **Mol Neurobiol** 1998 Winter;17(1-3):1-15 (100 ref.)
Hepatocyte growth factor, a versatile signal for developing neurons. Maina F, et al. **Nat Neurosci** 1999 Mar;2(3):213-7 (50 ref.)
New insights into the in vivo function of heterotrimeric G-proteins through gene deletion studies [see comments] Offermanns S. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul;360(1):5-13 (79 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1999 Jul;360(1):3-4.
Regulators of G-protein signalling: a novel protein family involved in timely deactivation and desensitization of signalling via heterotrimeric G proteins [see comments] Wieland T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul; 360(1):14-26 (112 ref.) Comment in: Naunyn Schmiedebergs Arch Pharmacol 1999 Jul;360(1):3-4.

Integrated regulation of signal coding and plasticity by NMDA receptors at a central synapse. D'Angelo E, et al. **Neural Plast** 1998 Jul-Sep;6(3):8-16 (38 ref.)
Endogenous cannabinoid signaling. Piomelli D, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):462-73 (79 ref.)
Molecular mechanisms and putative signalling events controlling utrophin expression in mammalian skeletal muscle fibres. Gramolini AO, et al. **Neuromuscul Disord** 1998 Aug;8(6):351-61 (144 ref.)
Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Impey S, et al. **Neuron** 1999 May; 23(1):11-4 (21 ref.)
Semaphorin signaling: a little less per-plexin. Yu HH, et al. **Neuron** 1999 Jan;22(1):11-4 (20 ref.)
Primitivism and plasticity of pain--implication of polymodal receptors. Kumazawa T. **Neurosci Res** 1998 Sep;32(1):9-31 (218 ref.)
The extracellular matrix, interstitial fluid and ions as a mechanical signal transducer in articular cartilage. Mow VC, et al. **Osteoarthritis Cartilage** 1999 Jan;7(1):41-58 (81 ref.)
Cell signal transduction through the mitogen-activated protein kinase pathway. Schnaper HW. **Pediatr Nephrol** 1998 Nov;12(9):790-5 (9 ref.)
GABAergic cells and signals in CNS development. Barker JL, et al. **Perspect Dev Neurobiol** 1998;5(2-3):305-22 (56 ref.)
GABA as a developmental signal in the inner retina and optic nerve. Sandell JH. **Perspect Dev Neurobiol** 1998; 5(2-3):269-78 (137 ref.)
Signal transduction in the wound response of tomato plants. Bowles D. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1495-510 (148 ref.)
Signalling of abscisic acid to regulate plant growth. Himmelbach A, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1439-44 (77 ref.)
Plant hormone perception and action: a role for G-protein signal transduction? Hooley R. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1425-30 (55 ref.)
Signal transduction and ion channels in guard cells. MacRobbie EA. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1475-88 (87 ref.)
The molecular basis of ethylene signalling in Arabidopsis. Woeste K, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1431-8 (66 ref.)
Signaling mechanisms underlying the vascular myogenic response. Davis MJ, et al. **Physiol Rev** 1999 Apr; 79(2):387-423 (402 ref.)
Signal transduction from the endoplasmic reticulum to the cell nucleus. Pahl HL. **Physiol Rev** 1999 Jul;79(3):683-701 (117 ref.)
Calcium-dependent signal transduction pathways in plants--phytochrome mechanism of action as an example. Tretyn A. **Pol J Pharmacol** 1999 Mar-Apr;51(2):145-51 (45 ref.)
Nitric oxide as a signaling molecule in visual system development. Cramer KS, et al. **Prog Brain Res** 1998; 118:101-14 (109 ref.)
Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Dawson TM, et al. **Prog Brain Res** 1998;118:3-11 (56 ref.)
Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Hawkins RD, et al. **Prog Brain Res** 1998;118:155-72 (137 ref.)
Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Thibonnier M, et al. **Prog Brain Res** 1998;119:147-61 (67 ref.)
Signaling in and regulation of ionizing radiation-induced apoptosis in endothelial cells. Billis W, et al. **Recent Prog Horm Res** 1998;53:85-92; discussion 93 (29 ref.)
Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Carter-Su C, et al. **Recent Prog Horm Res** 1998;53:61-82; discussion 82-3 (78 ref.)
Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Murad F. **Recent Prog Horm Res** 1998;53:43-59; discussion 59-60 (47 ref.)
The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. White MF. **Recent Prog Horm Res** 1998;53:119-38 (125 ref.)
Angiotensin II and nitric oxide: a question of balance. Millatt LJ, et al. **Regul Pept** 1999 May 31;81(1-3):1-10 (83 ref.)
Angiotensin II signal transduction pathways. Sayeski PP, et al. **Regul Pept** 1998 Nov 30;78(1-3):19-29 (93 ref.)
The death receptors. Peter ME, et al. **Results Probl Cell Differ** 1999;23:25-63 (280 ref.)
Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Keller JN, et al. **Rev Neurosci** 1998;9(2):105-16 (100 ref.)
The insulin receptor and metabolic signaling. Gustafson TA, et al. **Rev Physiol Biochem Pharmacol** 1999;137:71-190 (523 ref.)
Transduction and transmission properties of primary nociceptive afferents. Treede RD. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):205-11 (45 ref.)
Regulative development of the sea urchin embryo: signalling cascades and morphogen gradients. Angerer LM, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):327-34 (42 ref.)
Signalling in cell type specification [see comments] Dolan L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):149-56 (33 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117-9.
Intersecting signalling and transcriptional pathways in Drosophila heart specification. Frasch M. **Semin Cell Dev Biol** 1999 Feb;10(1):61-71 (45 ref.)
Signaling in pollen-pistil interactions [see comments] Gaude T, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):139-47 (73 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117-9.
Histone acetyltransferase complexes [see comments] Grant PA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):169-77 (95 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.
Histone deacetylases: complex transducers of nuclear signals [see comments] Johnson CA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):179-88 (80 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.
Morphogen propagation and action: towards molecular models. Kerszberg M. **Semin Cell Dev Biol** 1999 Jun; 10(3):297-302 (30 ref.)
Histone acetylation in signal transduction by growth regulatory signals [see comments] Magnaghi-Jaulin L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):197-203 (105 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.
Modulators of Notch signaling. Panin VM, et al. **Semin Cell Dev Biol** 1998 Dec;9(6):609-17 (83 ref.)
Signalling at a distance: transport of Wingless in the embryonic epidermis of Drosophila. Pfeiffer S, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):303-9 (55 ref.)
MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction [see comments] Thomson S, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):205-14 (77 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.
Signalling in plant embryos during the establishment of the polar axis [see comments] Vroemen C, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):157-64 (55 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117-9.
Rapid effects of 1,25(OH)2 vitamin D3 on signal transduction systems in colonic cells. Sitrin MD, et al. **Steroids** 1999 Jan-Feb;64(1-2):137-42 (21 ref.)
High energy exchange: proteins that make or break phosphoramidate bonds. Robinson VL, et al. **Structure Fold Des** 1999 Mar 15;7(3):R47-53 (24 ref.)
Lipidic signaling and peroxisomal function. Masters C. **Subcell Biochem** 1998;30:437-52 (35 ref.)
The regulation of gene expression in myocardial ischemia. Schaper W. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:277-80; discussion 281 (21 ref.)
Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses [see comments] Wilson CL, et al. **Toxicol Pathol** 1998 Sep-Oct; 26(5):657-71 (200 ref.) Comment in: Toxicol Pathol 1998 Sep-Oct;26(5):672-3.
p21-activated protein kinase: a crucial component of morphological signaling? Daniels RH, et al. **Trends Biochem Sci** 1999 Sep;24(9):350-5 (50 ref.)
Gq signaling in cardiac adaptation and maladaptation. Dorn GW 2nd, et al. **Trends Cardiovasc Med** 1999 Jan-Feb; 9(1-2):26-34 (84 ref.)
RGS proteins: more than just GAPs for heterotrimeric G proteins. De Vries L, et al. **Trends Cell Biol** 1999 Apr; 9(4):138-44 (67 ref.)
Integrin affinity modulation. Hughes PE, et al. **Trends Cell Biol** 1998 Sep;8(9):359-64 (64 ref.)
Integrins take partners: cross-talk between integrins and other membrane receptors. Porter JC, et al. **Trends Cell Biol** 1998 Oct;8(10):390-6 (57 ref.)
Regulation of Smad signalling by protein associations and signalling crosstalk. Zhang Y, et al. **Trends Cell Biol** 1999 Jul;9(7):274-9 (60 ref.)
Feasting, fasting and fermenting. Glucose sensing in yeast and other cells. Johnston M. **Trends Genet** 1999 Jan; 15(1):29-33 (82 ref.)
WNT targets. Repression and activation. Nusse R. **Trends Genet** 1999 Jan;15(1):1-3 (25 ref.)
Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. Tan PB, et al. **Trends Genet** 1999 Apr; 15(4):145-9 (39 ref.)
Signalling through the JAK-STAT pathway in the developing brain. Cattaneo E, et al. **Trends Neurosci** 1999 Aug;22(8):365-9 (82 ref.)
Is the Ras-MAPK signalling pathway necessary for long-term memory formation? Orban PC, et al. **Trends Neurosci** 1999 Jan;22(1):38-44 (90 ref.)
[Electrophysiology and calcium signalling in human bronchial smooth muscle] Marthan R, et al. **Therapie** 1999 Jan-Feb;54(1):79-83 (29 ref.) (Eng. Abstr.) **(Fre)**
[Signaling by melatonin receptors] Petit L, et al. **Therapie** 1998 Sep-Oct;53(5):421-8 (55 ref.) (Eng. Abstr.) **(Fre)**
[The NO/cGMP signal transduction system: a central target for anesthetics? (see comments)] Tonner PH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Feb; 34(2):78-89 (145 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1999 Feb;34(2):77. **(Ger)**
[Signaling molecules involved in induction and early patterning of limb buds] Kawakami Y, et al. **Kaibogaku Zasshi** 1998 Dec;73(6):655-66 (97 ref.) (Eng. Abstr.) **(Jpn)**
[Recent progress in the molecular biology of receptors and intra-cellular signal transduction] Kaziro Y. **Nippon Rinsho** 1998 Jul;56(7):1651-7 (6 ref.) (Eng. Abstr.) **(Jpn)**
[T cell receptor and its related molecules in signal transduction] Kobata T, et al. **Nippon Rinsho** 1999 Feb; 57(2):273-7 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Recent progresses in the JAK-STAT signaling pathways] Nakajima K. **Nippon Rinsho** 1998 Jul;56(7):1763-72 (55 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction systems of angiotensin II receptors] Takeuchi K. **Nippon Rinsho** 1999 May;57(5):1070-7 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction through ATP receptors in brain and the development of new drugs] Inoue K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:36P-40P (15 ref.) (Eng. Abstr.) **(Jpn)**
[Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways] Yoshii M, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:41P-43P (5 ref.) (Eng. Abstr.) **(Jpn)**
[Cellular signal transduction via the neurofibromatosis type 2 tumor suppressor gene product; merlin] Araki N, et al. **Seikagaku** 1999 Feb;71(2):128-34 (18 ref.) **(Jpn)**
[Cyclic ADP-ribose as a second messenger--intramembrane signal transduction from receptors to ADP-ribosyl cyclase] Higashida H, et al. **Seikagaku** 1998 Nov;70(11):1326-34 (79 ref.) **(Jpn)**
[Integrin signal transduction via FAK in osteoblasts--early differentiation triggered by osteopontin] Nemoto A, et al. **Seikagaku** 1999 Feb;71(2):140-5 (17 ref.) **(Jpn)**
[Signal transduction through receptor serine/threonine kinases and its regulation] Tsuchida K. **Seikagaku** 1998 Dec;70(12):1430-5 (14 ref.) **(Jpn)**
[Evidence for a Ras/Ral signaling cascade] Urano T. **Seikagaku** 1998 Sep;70(9):1181-3 (15 ref.) **(Jpn)**
[Signalling roles for selectins] Yoshida M. **Seikagaku** 1998 Oct;70(10):1270-4 (16 ref.) **(Jpn)**
[Cellular recognition through glyco-chain signals involved in differentiation and pathogenesis] Irimura T. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2540-1 (0 ref.) **(Jpn)**
[Phosphatidylinositol kinase: functional roles for PI4-kinase and PIP kinase in signal transduction] Itoh T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):949-60 (80 ref.) **(Jpn)**
[Diciphering mechanisms for glyco-chain signals--introduction] Kawasaki T. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2426-7 (3 ref.) **(Jpn)**
[Structural biology for PH and other domains involved in signal transduction] Koshiba S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):368-79 (76 ref.) **(Jpn)**
[His-Asp phosphotransfer signal transduction] Mizuno T. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):412-20 (16 ref.) **(Jpn)**
[Membrane lipid signaling system participating in intracellular signal transduction--General concept] Nozawa Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):947-8 (12 ref.) **(Jpn)**
[Platelet activation] Oda A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1863-9 (12 ref.) **(Jpn)**
[A signal transducer involved in GalCer expression] Ogura K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2516-21 (21 ref.) **(Jpn)**
[Bioactive glyco-chains and cis-type signalling--introduction] Saito M. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2484-7 (5 ref.) **(Jpn)**
[Multi-photon excitation fluorescence microscopy and its application to the studies of intracellular signal transduction] Sako Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1927-30 (11 ref.) **(Jpn)**
[Oligosaccharides as the elicitor signal for the activation of defense system in plants] Shibuya N, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2531-9 (58 ref.) **(Jpn)**
[Production Mechanisms for glyco-chain signals: recent advances in molecular studies on glyco-chain producing machineries--introduction] Suzuki A. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2335-7 (0 ref.) **(Jpn)**
[Production mechanisms for glyco-chain signals: changes of signaling and functions by sugar remodeling--introduction] Taniguchi N. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2273-4 (0 ref.) **(Jpn)**
[Signal transmission in plant cells; plasma membrane receptors] Barańska J. **Postepy Biochem** 1998;44(3):201-8 (38 ref.) **(Pol)**
[The role of the endosome in insulin signal transmission (published erratum appears in Postepy Biochem 1999;45(1):4)] Bobeszko M, et al. **Postepy Biochem** 1998; 44(3):263-5 (11 ref.) **(Pol)**
[Signalling function of G proteins insensitive to PTX in the cell] Lachowicz A, et al. **Postepy Biochem** 1998;44(2):164-9

(65 ref.) **(Pol)**
[Signal transduction of nerve growth factor (NGF) and its TrkA and p75NTR receptors] Niewiadomska G, et al. **Postepy Biochem** 1999;45(1):21–31 (79 ref.) **(Pol)**
[Cross-talk between signal transduction pathways in the cell-- the role of G proteins in these processes] Barańska J. **Postepy Hig Med Dosw** 1999;53(2):133–46 (29 ref.) (Eng. Abstr.) **(Pol)**
[Signal transmission by Fc gamma receptors] Lisowski J. **Postepy Hig Med Dosw** 1999;53(2):195–203 (43 ref.) (Eng. Abstr.) **(Pol)**
[Does the universal "signal transduction pathway of differentiation" exist? Comparison of different cell differentiation experimental models with differentiation of HL–60 cells in response to 1,25–dihydroxyvitamin D3] Marcinkowska E. **Postepy Hig Med Dosw** 1999; 53(2):305–13 (32 ref.) (Eng. Abstr.) **(Pol)**
[Electric signals as universal mechanisms for fast information transfer between cells. Mechanisms of modulation in physiological and pathological conditions] Mozrzymas JW. **Postepy Hig Med Dosw** 1999;53(2):247–61 (14 ref.) (Eng. Abstr.) **(Pol)**
[Signal transduction mechanisms induced by epidermal growth factor receptor (EGFR) and their role in apoptosis regulation] Ołdak M, et al. **Postepy Hig Med Dosw** 1999; 53(2):315–29 (78 ref.) (Eng. Abstr.) **(Pol)**
[Signal transduction in the cell by phosphoinositide–specific phospholipase C isozymes] Pawełczyk T. **Postepy Hig Med Dosw** 1999;53(2):173–82 (40 ref.) (Eng. Abstr.) **(Pol)**
[Disturbance of signalling pathways for apoptosis in thymic lymphomas from TCR transgenic mice] Strządała L. **Postepy Hig Med Dosw** 1999;53(2):345–50 (15 ref.) (Eng. Abstr.) **(Pol)**
[Impaired signal transduction in T–lymphocytes of the aged] Witkowski JM. **Postepy Hig Med Dosw** 1999;53(2):365–82 (85 ref.) (Eng. Abstr.) **(Pol)**
[The role of nitric oxide in transferring a signal between cells] Turpaev KT. **Mol Biol (Mosk)** 1998 Jul–Aug;32(4):581–91 (105 ref.) **(Rus)**
[Endoplasmic reticulum and mitochondria as elements of mechanism of intracellular signaling in neurons] Kostiuk PG, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):979–84 (14 ref.) (Eng. Abstr.) **(Rus)**
[Proteins of the Stat family: role in cell signalling] Evdonin AL. **Tsitologiia** 1998;40(12):1053–62 (108 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Cellular signal adaptation with damage control at low doses versus the predominance of DNA damage at high doses. Feinendegen LE, et al. **C R Acad Sci III** 1999 Feb–Mar; 322(2–3):245–51 (58 ref.)
Radiation–induced signal transduction. Mechanisms and consequences. Herrlich P, et al. **C R Acad Sci III** 1999 Feb–Mar;322(2–3):121–5 (22 ref.)
Photomophogenesis: Phytochrome takes a partner! Whitelam GC, et al. **Curr Biol** 1999 Mar 25;9(6):R225–7 (16 ref.)
New developments in the multi–site phosphorylation and integration of stress signalling at p53. Meek DW. **Int J Radiat Biol** 1998 Dec;74(6):729–37 (84 ref.)
Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap–1–regulated matrix metalloproteinases that degrade human skin in vivo. Fisher GJ, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):61–8 (48 ref.)
Radiation–induced signal transduction and stress response. Haimovitz–Friedman A. **Radiat Res** 1998 Nov;150(5 Suppl):S102–8 (75 ref.)
Monitoring and signaling of radiation–induced damage in mammalian cells. Szumiel I. **Radiat Res** 1998 Nov;150(5 Suppl):S92–101 (95 ref.)
Signalling in light–controlled development [see comments] Deng XW, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):121–9 (71 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):117–9.

SIGNAL TRANSDUCTION, LIGHT see **PHOTOTRANSDUCTION**

SILIBININ see **SILYMARIN**

SILICA see **SILICON DIOXIDE**

SILICATES

THERAPEUTIC USE

Mineral trioxide aggregate: a new material for endodontics. Schwartz RS, et al. **J Am Dent Assoc** 1999 Jul; 130(7):967–75 (33 ref.)

SILICON

see related
ORGANOSILICON COMPOUNDS

ADVERSE EFFECTS

Al and Si: their speciation, distribution, and toxicity. van Landeghem GF, et al. **Clin Biochem** 1998 Jul;31(5):385–97 (135 ref.)
Silicon and matrix macromolecules: new research opportunities for old diseases from analysis of potential mechanisms of breast implant toxicity. Brawer AE. **Med Hypotheses** 1998 Jul;51(1):27–35 (46 ref.)

ANALYSIS

Silicon assays in women with and without silicone gel breast implants--a review. Peters W, et al. **Ann Plast Surg** 1999 Sep;43(3):324–30 (33 ref.)

IMMUNOLOGY

The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. Shanklin DR, et al. **Immunol Res** 1998; 18(3):125–73 (552 ref.)

PHARMACOKINETICS

Al and Si: their speciation, distribution, and toxicity. van Landeghem GF, et al. **Clin Biochem** 1998 Jul;31(5):385–97 (135 ref.)

SILICON DIOXIDE

Biochemical evolution III: polymerization on organophilic silica–rich surfaces, crystal–chemical modeling, formation of first cells, and geological clues. Smith JV, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3479–85 (57 ref.)
Respirable crystalline silica exposure associated with the installation and removal of RCF and conventional silica–containing refractories in industrial furnaces. Maxim DL, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):44–63 (68 ref.)

ADVERSE EFFECTS

Silica induced scleroderma--clinical and experimental aspects. Haustein UF, et al. **J Rheumatol** 1998 Oct; 25(10):1917–26 (99 ref.)

ANALYSIS

Issues and controversy: the measurement of crystalline silica; review papers on analytical methods. Miles WJ. **Am Ind Hyg Assoc J** 1999 May–Jun;60(3):396–402 (48 ref.)

SILICONE ELASTOMERS

see related
BREAST IMPLANTS

Silicon assays in women with and without silicone gel breast implants--a review. Peters W, et al. **Ann Plast Surg** 1999 Sep;43(3):324–30 (33 ref.)
[Materials for intraocular lenses. II. Silicone intraocular lenses (published erratum appears in J Fr Ophtalmol 1999 May;22(5):613)] Werner LP, et al. **J Fr Ophtalmol** 1999 May;22(4):492–501 (84 ref.) **(Fre)**

ADVERSE EFFECTS

Pathology of silicone leakage from breast implants. van Diest PJ, et al. **J Clin Pathol** 1998 Jul;51(7):493–7 (35 ref.)
Assessing the harm of silicone gel–filled breast implants [letter] Shapiro MM. **Nurse Pract** 1999 Mar;24(3):140–1 (20 ref.)

SILICONE GELS

see related
BREAST IMPLANTS

Imaging breasts with silicone implants. Azavedo E, et al. **Eur Radiol** 1999;9(2):349–55 (60 ref.)
[Controversies regarding silicone implants in plastic surgery. Evaluation of arguments based on criteria of evidence–based medicine] Sohn W. **Fortschr Med** 1998 Sep 30;116(27):18–20, 22 (16 ref.) **(Ger)**

ADVERSE EFFECTS

Ethics, epidemiology, and law: the case of silicone breast implants [comment] Macklin R. **Am J Public Health** 1999 Apr;89(4):487–9 (10 ref.) Comment on: Am J Public Health 1999 Apr;89(4):484–7. Comment on: Am J Public Health 1999 Apr;89(4):490–3.
Silicone breast implants: epidemiological evidence of sequelae [see comments] Stein ZA. **Am J Public Health** 1999 Apr; 89(4):484–7 (17 ref.) Comment in: Am J Public Health 1999 Apr;89(4):487–9.
Cartilaginous metaplasia in the capsule of a Dacron–backed silicone gel breast prosthesis. Kamel M, et al. **Ann Plast Surg** 1999 Feb;42(2):202–6 (25 ref.)
Consensus declaration of EQUAM [letter] Nicolai JP. **Br J Plast Surg** 1999 Jan;52(1):78 (0 ref.)
Assessing the harm of silicone gel–filled breast implants [letter] Shapiro MM. **Nurse Pract** 1999 Mar;24(3):140–1 (20 ref.)
Silicone breast implants: an oncologic perspective. Gerszten K, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1427–33; discussion 1434, 1439–43 (66 ref.)

SILICONE RUBBER see **SILICONE ELASTOMERS**

SILICONES

ADVERSE EFFECTS

The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. Shanklin DR, et al. **Immunol Res** 1998; 18(3):125–73 (552 ref.)

SILICOSIS

DIAGNOSIS

[The main pathogenetic mechanisms in occupational diseases of lungs of dust–related etiology. Part I. From an experiment to a concept] Velichnovskiĭ BT. **Med Tr Prom Ekol** 1998;(10):28–38 (23 ref.) **(Rus)**

ETIOLOGY

[The main pathogenetic mechanisms in occupational diseases of lungs of dust–related etiology. Part I. From an experiment to a concept] Velichnovskiĭ BT. **Med Tr Prom Ekol** 1998;(10):28–38 (23 ref.) **(Rus)**

SILKMOTHS see **SILKWORMS**

SILKWORMS

IMMUNOLOGY

Immune proteins and their gene expression in the silkworm, Bombyx mori. Yamakawa M, et al. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):281–9 (41 ref.)

SILOXANES

Polyvinyl siloxane impression materials: an update on clinical use. Mandikos MN. **Aust Dent J** 1998 Dec;43(6):428–34 (48 ref.)

SILVER

Efficacy of silver–coated medical devices. Schierholz JM, et al. **J Hosp Infect** 1998 Dec;40(4):257–62 (51 ref.)

PHARMACOLOGY

A new technology of microdispersed silver in polyurethane induces antimicrobial activity in central venous catheters. Guggenbichler JP, et al. **Infection** 1999;27 Suppl 1:S16–23 (49 ref.)
Catheter–associated infections in urology: possible use of silver–impregnated catheters and the Erlanger silver catheter. Rösch W, et al. **Infection** 1999;27 Suppl 1:S74–7 (36 ref.)

SILVER NITRATE

ADVERSE EFFECTS

The toxicology of silver nitrate. Humphreys SD, et al. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep; 17(2–3):115–43 (91 ref.)

SILVER NITRATE STAINING see **SILVER STAINING**

SILVER STAINING

METHODS

Silver development in microscopy and bioanalysis: past and present. Newman GR, et al. **J Pathol** 1998 Oct; 186(2):119–25 (136 ref.)
Use of immunogold with silver enhancement. Oliver C. **Methods Mol Biol** 1999;115:241–5 (12 ref.)
Silver staining of 2–D electrophoresis gels. Rabilloud T. **Methods Mol Biol** 1999;112:297–305 (12 ref.)

SILYBIN see **SILYMARIN**

SILYMARIN

PHARMACOLOGY

Silymarin as a potential hypocholesterolaemic drug. Skottová N, et al. **Physiol Res** 1998;47(1):1–7 (61 ref.)

THERAPEUTIC USE

[Silymarin–containing phytopharmaceuticals--biopharmacy as an essential therapeutic quality criterion] Frömming KH, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):VI–XI (20 ref.) **(Ger)**

SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

Pathogenesis of simian immunodeficiency virus infection. Whetter LE, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1557–68 (137 ref.)
Simian immunodeficiency virus as a model of human HIV disease. Geretti AM. **Rev Med Virol** 1999 Jan–Mar; 9(1):57–67 (82 ref.)

SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

IMMUNOLOGY

Simian immunodeficiency virus, infection, alcohol, and host defense. Bagby GJ, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):193S–195S (19 ref.)

The importance of lymphocyte trafficking in regulating blood lymphocyte levels during HIV and SIV infections. Rosenberg YJ, et al. **Semin Immunol** 1999 Apr;11(2):139–54 (113 ref.)

METABOLISM

Chemokine receptors in HIV-1 and SIV infection. Choe H. **Arch Pharm Res** 1998 Dec;21(6):634–9 (38 ref.)

PATHOLOGY

The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. Rausch DM, et al. **J Leukoc Biol** 1999 Apr;65(4):466–74 (74 ref.)

PHYSIOPATHOLOGY

HIV/SIV enteropathy. Zeitz M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:139–48 (48 ref.)

PREVENTION & CONTROL

Candidate vaccines protect macaques against primate immunodeficiency viruses. Stott J, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S265–70 (54 ref.)

Protective immunity induced by live attenuated simian immunodeficiency virus. Johnson RP, et al. **Curr Opin Immunol** 1998 Aug;10(4):436–43 (62 ref.)

VIROLOGY

Localization of Simian immunodeficiency virus-infected cells in the genital tract of male and female Rhesus macaques. Miller CJ. **J Reprod Immunol** 1998 Dec;41(1–2):331–9 (32 ref.)

SIMIAN AIDS see **SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME**

SIMIAN AIDS VACCINES see **SAIDS VACCINES**

SIMIAN FOAMY VIRUSES see **SPUMAVIRUS**

SIMIAN HEMORRHAGIC FEVER VIRUS see **ARTERIVIRUS**

SIMIAN IMMUNODEFICIENCY VIRUSES see **SIV**

SIMIAN LENTIVIRUSES see **SIV**

SIMIAN T-LYMPHOTROPIC VIRUS TYPE I see **STLV**

SIMIAN T-LYMPHOTROPIC VIRUS TYPE III see **SIV**

SIMIAN SARCOMA VIRUS PROTEINS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

SIMIAN VIRUS 40 see **POLYOMAVIRUS MACACAE**

SIMMONDS' DISEASE see **HYPOPITUITARISM**

SIMPLE REPETITIVE SEQUENCE see **MINISATELLITE REPEATS**

SIMPLEXVIRUS

ENZYMOLOGY

Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Blasberg RG, et al. **Q J Nucl Med** 1999 Jun;43(2):163–9 (29 ref.)

GENETICS

Use of herpes simplex virus type 1 for transgene expression within the nervous system. Lachmann RH, et al. **Clin Sci (Colch)** 1999 Jun;96(6):533–41 (57 ref.)

The herpes simplex virus VP16-induced complex: mechanisms of combinatorial transcriptional regulation. Herr W. **Cold Spring Harb Symp Quant Biol** 1998; 63:599–607 (61 ref.)

Engineering herpes simplex virus vectors for CNS applications. Wolfe D, et al. **Exp Neurol** 1999 Sep; 159(1):34–46 (99 ref.)

IMMUNOLOGY

Herpes. Vaccines for HSV. Stanberry LR. **Dermatol Clin** 1998 Oct;16(4):811–6, xiv (27 ref.)

Herpes simplex virus vaccines. Bernstein DI, et al. **Vaccine** 1999 Mar 26;17(13–14):1681–9 (90 ref.)

ISOLATION & PURIFICATION

[Herpes simplex encephalitis (editorial)] Zajkowska JM, et al. **Pol Merkuriusz Lek** 1999 Jun;6(36):297–301 (30 ref.) (Eng. Abstr.) **(Pol)**

PATHOGENICITY

HLA-G and HLA-C at the feto-maternal interface: lessons learned from pathogenic viruses. Schust DJ, et al. **Semin Cancer Biol** 1999 Feb;9(1):37–46 (71 ref.)

PHYSIOLOGY

The role of herpes simplex virus glycoproteins in the virus replication cycle. Rajčáni J, et al. **Acta Virol** 1998 Apr; 42(2):103–18 (195 ref.)

Herpes simplex virus latency and nucleoside analogues. Efstathiou S, et al. **Antiviral Res** 1999 Apr;41(3):85–100 (60 ref.)

Herpes simplex virus as a transneuronal tracer. Norgren RB Jr, et al. **Neurosci Biobehav Rev** 1998 Oct;22(6):695–708 (167 ref.)

Glycoprotein K of herpes simplex virus: a transmembrane protein encoded by the UL53 gene which regulates membrane fusion. Rajčáni J, et al. **Virus Genes** 1999; 18(1):81–90 (63 ref.)

SIMVASTATIN

PHARMACOLOGY

Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Yoshimura A, et al. **Kidney Int Suppl** 1999 Jul;71:S84–7 (7 ref.)

THERAPEUTIC USE

Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Pearson TA. **Am J Cardiol** 1998 Nov 19;82(10A):28S–30S (16 ref.)

Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin. Leiter LA, et al. **Can J Cardiol** 1999 May;15(5):545–55 (38 ref.)

Statin therapy for prevention of coronary artery disease with average cholesterol levels [editorial] Gambhir DS. **Indian Heart J** 1999 Jan–Feb;51(1):19–20, 105 (6 ref.)

Aggressive lipid therapy in the statin era. Farmer JA. **Prog Cardiovasc Dis** 1998 Sep–Oct;41(2):71–94 (67 ref.)

[Are there differences in various statins?] Otto C, et al. **Internist (Berl)** 1998 Sep;39(9):987–93 (42 ref.) **(Ger)**

[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke] Marta-Moreno J, et al. **Rev Neurol** 1998 Nov; 27(159):827–30 (28 ref.) (Eng. Abstr.) **(Spa)**

SIN-10 see **MOLSIDOMINE**

SINANOMYCIN see **NETROPSIN**

SINCALIDE

see related
APPETITE DEPRESSANTS
GASTROINTESTINAL AGENTS

SINCALIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

SINDBIS VIRUS

GENETICS

RNA virus vectors: where are we and where do we need to go? [comment] Palese P. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12750–2 (39 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):12989–94.

SINES see **SHORT INTERSPERSED NUCLEOTIDE ELEMENTS**

SINGLE PARENT

[Child of a single mother] Berthier M, et al. **Arch Pediatr** 1998 Jan;5(1):71–8 (33 ref.) (Eng. Abstr.) **(Fre)**

SINGLE-PARENT FAMILY see **SINGLE PARENT**

SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

SINGLE-STRANDED CONFORMATIONAL POLYMORPHISM see **POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL**

SINGLE-STRANDED DNA see **DNA, SINGLE-STRANDED**

SINGLE-STRANDED DNA BINDING PROTEINS see **DNA-BINDING PROTEINS**

SINOATRIAL NODAL REENTRY TACHYCARDIA see **TACHYCARDIA, SINOATRIAL NODAL REENTRY**

SINOATRIAL NODE

ANATOMY & HISTOLOGY

The architecture of the sinus node, the atrioventricular conduction axis, and the internodal atrial myocardium. Anderson RH, et al. **J Cardiovasc Electrophysiol** 1998 Nov; 9(11):1233–48 (51 ref.)

SINUS ARRHYTHMIA see **ARRHYTHMIA, SINUS**

SINUS OF VALSALVA

ABNORMALITIES

Anomalous left coronary artery arising from right sinus of valsalva could be a minor congenital anomaly--a case report and review of the literature. Abouzied AM, et al. **Angiology** 1999 Feb;50(2):175–8 (21 ref.)

[The single coronary artery arising from the sinus of Valsalva. A rare cause of myocardial ischemia] Gómez-Aldaraví Gutiérrez R, et al. **Rev Esp Cardiol** 1998 Oct;51(10):847–9 (8 ref.) (Eng. Abstr.) **(Spa)**

SINUS THROMBOSIS

DRUG THERAPY

Cerebral venous thrombosis: recurrence with fatal course [letter] van den Berg JS, et al. **J Neurol** 1999 Feb; 246(2):144–6 (11 ref.)

SINUSITIS

Rhinitis, sinusitis, and polyposis. Young MC. **Allergy Asthma Proc** 1998 Jul–Aug;19(4):211–8 (37 ref.)

A focus on acute sinusitis in adults: changes in disease management. Poole MD. **Am J Med** 1999 May 3; 106(5A):38S–47S; discussion 48S–52S (46 ref.)

Quality of life in patients with rhinosinusitis. Durr DG, et al. **J Otolaryngol** 1999 Apr;28(2):108–11 (33 ref.)

[Sinusitis] Takayama M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):289–94 (9 ref.) **(Jpn)**

CHEMICALLY INDUCED

Ammonia exposure: a common cause for sinusitis. A case report and review of the literature. Brautbar N. **Toxicol Ind Health** 1998 Nov–Dec;14(6):891–5 (10 ref.)

COMPLICATIONS

Cystic fibrosis and sinusitis. Isaacson G, et al. **Ear Nose Throat J** 1998 Nov;77(11):886–8 (7 ref.)

Papilloedema secondary to acute purulent sinusitis. Kumar RK, et al. **J Paediatr Child Health** 1999 Aug;35(4):396–8 (11 ref.)

Allergic rhinitis and rhinosinusitis. Is there a connection between allergy and infection? Ferguson BJ, et al. **Postgrad Med** 1999 Apr;105(4):55–8, 61, 64 (36 ref.)

MR imaging and CT of orbital infections and complications in acute rhinosinusitis. Eustis HS, et al. **Radiol Clin North Am** 1998 Nov;36(6):1165–83, xi (56 ref.)

DIAGNOSIS

Acute sinusitis: a cost-effective approach to diagnosis and treatment. Fagnan LJ. **Am Fam Physician** 1998 Nov 15; 58(8):1795–802, 805–6 (46 ref.)

The management of postnasal drip. Forer M, et al. **Aust Fam Physician** 1999 Mar;28(3):223–8 (22 ref.)

Rhinosinusitis. Current concepts in evaluation and management. Osguthorpe JD, et al. **Med Clin North Am** 1999 Jan;83(1):27–41, vii–viii (30 ref.)

The surgical management of chronic sinusitis in children. Lusk RP. **Pediatr Ann** 1998 Dec;27(12):820–7 (47 ref.)

Allergic and infectious pediatric sinusitis [see comments] Zacharisen MC, et al. **Pediatr Ann** 1998 Nov;27(11):759–66 (19 ref.) Comment in: Pediatr Ann 1998 Nov;27(11):708.

A guide to the management of chronic sinusitis. Kennedy V, et al. **Practitioner** 1998 Oct;242(1591):712–7 (8 ref.)

DRUG THERAPY

Pharmacotherapy to prevent the complications of allergic rhinitis. Beckman DB, et al. **Allergy Asthma Proc** 1999 Jul–Aug;20(4):215–23 (81 ref.)

Appropriate use of antibiotics for URIs in children: Part I. Otitis media and acute sinusitis. The Pediatric URI Consensus Team [see comments] Dowell SF, et al. **Am Fam Physician** 1998 Oct 1;58(5):1113–8, 1123 (39 ref.) Comment in: Am Fam Physician 1998 Oct 1;58(5):1066–8.

Acute community acquired bacterial sinusitis: To treat or not to treat. Gwaltney JM Jr. **Can Respir J** 1999 Jan–Feb; 6 Suppl A:46A–50A (18 ref.)

When is it right to prescribe in URTI? Williamson I. **Practitioner** 1997 Dec;241(1581):724–6, 728, 730 (15 ref.)

[Corticotherapy in ENT. Subglottic laryngitis in children, acute sinusitis, naso-sinusal polyposis, sero-mucous otitis] De Corbiere S, et al. **Ann Med Interne (Paris)** 1998 Dec; 149(8):508–11 (16 ref.) (Eng. Abstr.) **(Fre)**

[Anti-recurrence treatment of polypous rhinosinusitis] Kondrat'ev VA, et al. **Vestn Otorinolaringol** 1999;(4):39 (3 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Rhinosinusitis and asthma: epiphenomenon or causal association? de Benedictis FM, et al. **Chest** 1999 Feb; 115(2):550–6 (69 ref.)

The prevalence of allergic rhinosinusitis: a review. Jones NS,

et al. **J Laryngol Otol** 1998 Nov;112(11):1019–30 (173 ref.)

ETIOLOGY

Complications of allergic rhinitis. Settipane RA. **Allergy Asthma Proc** 1999 Jul–Aug;20(4):209–13 (39 ref.)
Ventilator-associated sinusitis: a review. Westergren V, et al. **Clin Infect Dis** 1998 Oct;27(4):851–64 (111 ref.)
Evaluation of the patient with sore throat, earache, and sinusitis: an evidence based approach. Stewart MH, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):153–87, ix (137 ref.)
[Sinusitis in children] Maurer J, et al. **HNO** 1999 Apr; 47(4):301–10 (31 ref.) **(Ger)**

MICROBIOLOGY

Evaluation of the microbiology of chronic maxillary sinusitis. Biel MA, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):942–5 (19 ref.)
Fungal sinusitis. Washburn RG. **Curr Clin Top Infect Dis** 1998;18:60–74 (102 ref.)
Sinusitis [see comments] Wald ER. **Pediatr Ann** 1998 Dec; 27(12):811–8 (30 ref.) Comment in: Pediatr Ann 1999 Mar;28(3):151.
Clinical perspectives on sinusitis and otitis media. Blumer J. **Pediatr Infect Dis J** 1998 Aug;17(8 Suppl):S68–72 (33 ref.)
Difficulties in interpretation of culture results in sinusitis. Verschraegen G, et al. **Rhinology** 1998 Jun;36(2):55–8 (17 ref.)

PREVENTION & CONTROL

National guidelines needed to manage rhinitis and prevent complications. Rachelefsky GS. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):296–305 (126 ref.)

SURGERY

[After care of endonasal pansinus operations] Hörmann K, et al. **HNO** 1998 Dec;46(12):1004–14; quiz 1014 (9 ref.) **(Ger)**
[Selected aspects of endonasal paranasal sinus surgery] Reiss M. **Wien Med Wochenschr** 1998;148(20):469–73 (17 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Acute sinusitis: a cost-effective approach to diagnosis and treatment. Fagnan LJ. **Am Fam Physician** 1998 Nov 15; 58(8):1795–802, 805–6 (46 ref.)
What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis? Ferguson BJ. **Arch Otolaryngol Head Neck Surg** 1998 Oct;124(10):1174–8 (19 ref.)
Current concepts in the management of paediatric rhinosinusitis. Jones NS. **J Laryngol Otol** 1999 Jan; 113(1):1–9 (104 ref.)

SINUSITIS, ETHMOID see **ETHMOID SINUSITIS**

SINUSITIS, FRONTAL see **FRONTAL SINUSITIS**

SINUSITIS, MAXILLARY see **MAXILLARY SINUSITIS**

SINUSITIS, SPHENOID see **SPHENOID SINUSITIS**

SIPHONAPTERA see **FLEAS**

SIPPLE SYNDROME see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

SIPUNCULIDA see **NEMATODA**

SIRENOMELIA see **ECTROMELIA**

SIROGNATHOGRAPHY see **JAW RELATION RECORD**

SIROLIMUS

PHARMACOKINETICS

Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. Soldin SJ. **Clin Biochem** 1998 Jul;31(5):381–4 (27 ref.)
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Trepanier DJ, et al. **Clin Biochem** 1998 Jul;31(5):345–51 (49 ref.)

PHARMACOLOGY

Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN. **Clin Biochem** 1998 Jul;31(5):335–40 (69 ref.)
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Dennis PB, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):49–54 (53 ref.)

THERAPEUTIC USE

Sirolimus, a potent new immunosuppressive drug for organ transplantation. Stepkowski SM. **Ann Transplant** 1996; 1(3):19–25 (71 ref.)
Emerging strategies for the clinical application of rapamycin. Kahan BD. **Clin Biochem** 1998 Jul;31(5):341–4 (22 ref.)
Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN. **Clin Biochem** 1998 Jul;31(5):335–40 (69 ref.)
Rapamycin on trial [editorial] Sacks SH. **Nephrol Dial Transplant** 1999 Sep;14(9):2087–9 (8 ref.)
The potential role of rapamycin in pediatric transplantation as observed from adult studies. Kahan BD. **Pediatr Transplant** 1999 Aug;3(3):175–80 (32 ref.)

SIS GENES see **ONCOGENES**

SISTER CHROMATID EXCHANGE

Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Hagmar L, et al. **Recent Results Cancer Res** 1998;154:177–84 (7 ref.)

DRUG EFFECTS

Chromosomes in the assessment of the effects of low levels of genotoxic agents. Leonard Sagan BELLE Award. Biological Effects of Low Level Exposure. Wolff S. **Hum Exp Toxicol** 1998 Nov;17(11):625–32 (39 ref.)

GENETICS

Chromosomal changes. Preston RJ. **IARC Sci Publ** 1999; (146):395–408 (53 ref.)

SITE-DIRECTED MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

SITE MAPPING, RESTRICTION see **RESTRICTION MAPPING**

SITE-SPECIFIC MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

SITOSTEROLS

ADMINISTRATION & DOSAGE

[Is the Finnish "healthy margarine" food or medicine? Addition of plant sterols can lower cholesterol levels] Wikström AC. **Lakartidningen** 1998 Nov 11;95(46):5146–8 (18 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. Wilt TJ, et al. **BJU Int** 1999 Jun;83(9):976–83 (32 ref.)

SITUATIONAL ETHICS see **ETHICS**

SITUS INVERSUS

COMPLICATIONS

Coronary stenting in patients with situs viscerum inversus. Patti G, et al. **G Ital Cardiol** 1999 Mar;29(3):304–7 (10 ref.)
Orthotopic liver transplantation in patients with biliary atresia and situs inversus. Mattei P, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):104–10 (14 ref.)
[Traditional cholecystectomy in a patient with situs viscerum inversus partialis] Torretta A, et al. **G Chir** 1999 Jun–Jul; 20(6–7):293–5 (12 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Microdeletion of chromosome sub-band 2q37.3 in two patients with abnormal situs viscerum. Reddy KS, et al. **Am J Med Genet** 1999 Jun 11;84(5):460–8 (36 ref.)

ULTRASONOGRAPHY

[Familial heterotaxy syndrome. Case report and review of the international literature] Cesko I, et al. **Orv Hetil** 1998 Nov 15;139(46):2775–8 (45 ref.) (Eng. Abstr.) **(Hun)**

SIV

HIV/SIV enteropathy. Zeitz M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:139–48 (48 ref.)
Pathogenesis of simian immunodeficiency virus infection. Whetter LE, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1557–68 (137 ref.)
Simian immunodeficiency virus as a model of human HIV disease. Geretti AM. **Rev Med Virol** 1999 Jan–Mar; 9(1):57–67 (82 ref.)

IMMUNOLOGY

Simian immunodeficiency virus, infection, alcohol, and host defense. Bagby GJ, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):193S–195S (19 ref.)
Protective immunity induced by live attenuated simian immunodeficiency virus. Johnson RP, et al. **Curr Opin Immunol** 1998 Aug;10(4):436–43 (62 ref.)

ISOLATION & PURIFICATION

Localization of Simian immunodeficiency virus-infected cells in the genital tract of male and female Rhesus macaques. Miller CJ. **J Reprod Immunol** 1998 Dec;41(1–2):331–9 (32 ref.)

PATHOGENICITY

The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. Rausch DM, et al. **J Leukoc Biol** 1999 Apr;65(4):466–74 (74 ref.)

PHYSIOLOGY

Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Edinger AL, et al. **Virology** 1999 Aug 1;260(2):211–21 (129 ref.)

SIV VACCINE see **SAIDS VACCINES**

SIV-1 see **SIV**

SIV-2 see **SIV**

SIXTH CRANIAL NERVE see **ABDUCENS NERVE**

SIXTH DISEASE see **EXANTHEMA SUBITUM**

SIZE PERCEPTION

Threshold effect in visual perception of geometrical figures. Di Maio V. **Percept Mot Skills** 1998 Aug;87(1):340–2 (9 ref.)

SJOGREN'S SYNDROME

see related
KERATOCONJUNCTIVITIS SICCA

Sjögren's syndrome comes of age [editorial] Anaya JM, et al. **Semin Arthritis Rheum** 1999 Jun;28(6):355–9 (29 ref.)
[Sjögren's syndrome] Yoshida S. **Nippon Rinsho** 1999 Feb; 57(2):360–3 (5 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

[Diagnostic criteria of Sjögren syndrome] Ceraulo S, et al. **Minerva Stomatol** 1999 Mar;48(3):79–85 (27 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Androgens and dry eye in Sjögren's syndrome. Sullivan DA, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:312–24 (111 ref.)
Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome. van der Reijden WA, et al. **Ann Rheum Dis** 1999 Aug;58(8):465–74 (115 ref.)
Pulmonary manifestations of Sjögren's syndrome. Cain HC, et al. **Clin Chest Med** 1998 Dec;19(4):687–99, viii (80 ref.)
Outcome assessment in patients with primary Sjögren's syndrome [letter] Oxholm P, et al. **Clin Exp Rheumatol** 1998 Sep–Oct;16(5):627–8 (7 ref.)
Pseudogout attack associated with chronic thyroiditis and Sjögren's syndrome. Hama Y, et al. **Intern Med** 1999 Jan; 38(1):59–62 (18 ref.)
Sjögren's syndrome with acute renal failure. Kwon YJ, et al. **J Korean Med Sci** 1998 Dec;13(6):665–9 (14 ref.)
Bilateral and multicystic major salivary gland disease: a rare presentation of primary Sjögren's syndrome. Ahmad I, et al. **J Laryngol Otol** 1998 Dec;112(12):1196–8 (17 ref.)
Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis. Mariette X. **Leuk Lymphoma** 1999 Mar;33(1–2):93–9 (49 ref.)
Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. Walker RH, et al. **Mov Disord** 1999 Mar;14(2):262–8 (40 ref.)
The diversity of peripheral nervous system disorders in Sjögren's syndrome [editorial; comment] van Dijk GW, et al. **Neth J Med** 1998 Nov;53(5):193–5 (16 ref.) Comment on: Neth J Med 1998 Nov;53(5):196–200.
[Gougerot-Sjögren syndrome. Neurologic complications] Amoura Z, et al. **Presse Med** 1999 Jun 19;28(22):1209–13 (64 ref.) (Eng. Abstr.) **(Fre)**
[Gougerot-Sjögren syndrome and malignant lymphoproliferative syndromes] Grosbois B, et al. **Rev Med Interne** 1998 May;19(5):319–24 (52 ref.) (Eng. Abstr.) **(Fre)**
[Central nervous system symptoms of Gougerot-Sjögren syndrome] Guillevin L. **Rev Med Interne** 1998;19 Suppl 1:35S–38S (10 ref.) **(Fre)**
[Neurologic manifestations of primary Gougerot-Sjögren syndrome] Lafitte C. **Rev Neurol (Paris)** 1998 Oct; 154(10):658–73 (113 ref.) (Eng. Abstr.) **(Fre)**
[Relationship between primary Sjögren's syndrome and autoimmune thyroid disease] Kohriyama K, et al. **Nippon Rinsho** 1999 Aug;57(8):1878–81 (18 ref.) (Eng. Abstr.) **(Jpn)**
[A case of primary Sjögren's syndrome accompanied by transverse myelitis] Kaneko Y, et al. **Ryumachi** 1998 Aug; 38(4):600–4 (13 ref.) (Eng. Abstr.) **(Jpn)**
[MALT lymphoma of the parotid gland associated with Sjögren syndrome. A case report and review of literature] Damborenea Tajada J, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):595–8 (23 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Current issues in the diagnosis and treatment of Sjögren's

syndrome. Fox RI, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):364–71 (88 ref.)
Evolving concepts of diagnosis, pathogenesis, and therapy of Sjögren's syndrome. Fox RI, et al.
Curr Opin Rheumatol 1998 Sep;10(5):446–56 (139 ref.)
Sjögren's syndrome: a critical review of clinical management. Bell M, et al. **J Rheumatol** 1999 Sep;26(9):2051–61 (31 ref.)
[Gougerot–Sjögren syndrome. Diagnostic criteria and therapeutic methods] Kaplan G. **Presse Med** 1999 Jun 19; 28(22):1202–8 (49 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis and treatment of Sjogren's syndrome] Sagawa A. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):490–3 (8 ref.) **(Jpn)**
[A case of primary Sjögren's syndrome with CNS disease mimicking chronic progressive multiple sclerosis] Watanabe S, et al. **Rinsho Shinkeigaku** 1998 Jul; 38(7):658–62 (25 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome. Oxholm P, et al.
Drugs 1998 Sep;56(3):345–53 (35 ref.)
The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Nusair S, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):360–7 (24 ref.)

ETIOLOGY

Evolving concepts of diagnosis, pathogenesis, and therapy of Sjögren's syndrome. Fox RI, et al.
Curr Opin Rheumatol 1998 Sep;10(5):446–56 (139 ref.)
Sjögren's syndrome: pathogenesis. Tabbara K, et al.
Eur J Ophthalmol 1999 Jan–Mar;9(1):1–7 (34 ref.)
An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Humphreys–Beher MG, et al. **Scand J Immunol** 1999 Jan; 49(1):7–10 (31 ref.)

IMMUNOLOGY

New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Humphreys–Beher MG, et al. **Arch Oral Biol** 1999 May;44 Suppl 1:S21–5 (38 ref.)
The role of apoptosis in the initiation of the autoimmune response in Sjögren's syndrome. Humphreys–Beher MG, et al. **Clin Exp Immunol** 1999 Jun;116(3):383–7 (38 ref.)
Sjogren's syndrome. Sumida T. **Intern Med** 1999 Feb; 38(2):165–8 (15 ref.)
An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Humphreys–Beher MG, et al. **Scand J Immunol** 1999 Jan; 49(1):7–10 (31 ref.)
[Clonality of infiltrative T cells in tubular dysfunction caused by Sjogren's syndrome] Murata H, et al.
Nippon Naika Gakkai Zasshi 1999 Aug 10;88(8):1486–91 (5 ref.) **(Jpn)**
[Physiopathology of autoimmune diseases--recent findings. 1) Unique mechanism associated with Sjogren's syndrome] Sumida T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1717–23 (14 ref.) **(Jpn)**

METABOLISM

Fas (APO–1/CD95)–assisted suicide in NOD exocrine glands [editorial; comment] Elkon KB. **Clin Exp Rheumatol** 1998 Nov–Dec;16(6):659–61 (23 ref.) Comment on: Clin Exp Rheumatol 1998 Nov–Dec;16(6):659–61.

PATHOLOGY

The role of apoptosis in the initiation of the autoimmune response in Sjögren's syndrome. Humphreys–Beher MG, et al. **Clin Exp Immunol** 1999 Jun;116(3):383–7 (38 ref.)
Sjögren's syndrome with acute renal failure. Kwon YJ, et al. **J Korean Med Sci** 1998 Dec;13(6):665–9 (14 ref.)

PHYSIOPATHOLOGY

[Central nervous system symptoms of Gougerot–Sjögren syndrome] Guillevin L. **Rev Med Interne** 1998;19 Suppl 1:35S–38S (10 ref.) **(Fre)**

THERAPY

Current issues in the diagnosis and treatment of Sjögren's syndrome. Fox RI, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):364–71 (88 ref.)
It's not the same old lupus or Sjögren's any more: one hundred new insights, approaches, and options since 1990. Wallace DJ, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):321–9 (40 ref.)
Sjögren's syndrome: a critical review of clinical management. Bell M, et al. **J Rheumatol** 1999 Sep;26(9):2051–61 (31 ref.)

VIROLOGY

Sjögren's syndrome and hepatitis C virus. Ramos–Casals M, et al. **Clin Rheumatol** 1999;18(2):93–100 (98 ref.)

SKATEBOARDING see **SKATING**

SKATES (FISH)

Necrotizing fasciitis due to Vibrio alginolyticus following an injury inflicted by a stingray. Ho PL, et al.
Scand J Infect Dis 1998;30(2):192–3 (13 ref.)
[Stingray venom] Yoshikawa S, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):664–7 (9 ref.) **(Jpn)**

PHYSIOLOGY

Reproductive endocrinology of female elasmobranchs: lessons from the little skate (Raja erinacea) and spiny dogfish (Squalus acanthias). Koob TJ, et al.
J Exp Zool 1999 Oct 1;284(5):557–74 (67 ref.)
Elasmobranch color change: A short review and novel data on hormone regulation. Visconti MA, et al. **J Exp Zool** 1999 Oct 1;284(5):485–91 (54 ref.)

SKATING

INJURIES

Figure skating injuries. Bloch RM.
Phys Med Rehabil Clin N Am 1999 Feb;10(1):177–88, viii (54 ref.)

PHYSIOLOGY

Muscle activity in the slalom turn of alpine skiing and in–line skating. Zeglinksi CM, et al. **Int J Sports Med** 1998 Oct; 19(7):447–54 (22 ref.)

SKELETAL AGE MEASUREMENT see **AGE DETERMINATION BY SKELETON**

SKELETAL FIXATION see **FRACTURE FIXATION**

SKELETAL MUSCLE see **MUSCLE, SKELETAL**

SKELETAL MUSCLE RELAXANTS see **NEUROMUSCULAR AGENTS**

SKELETAL MUSCLE VENTRICLE

see related
CARDIOMYOPLASTY
Permanent cardiac assistance from skeletal muscle: a prospect for the new millennium. Salmons S. **Artif Organs** 1999 May; 23(5):380–7 (70 ref.)

SKELETIN see **DESMIN**

SKELETON

see related
BONE AND BONES

SKID ROW ALCOHOLICS see **HOMELESS PERSONS**

SKIING

Snowboarding injuries [published erratum appears in Am Fam Physician 1999 Feb 15;59(4):786] Young CC, et al.
Am Fam Physician 1999 Jan 1;59(1):131–6, 141 (16 ref.)

INJURIES

Skiing injuries. Hunter RE. **Am J Sports Med** 1999 May–Jun; 27(3):381–9 (66 ref.)
Skiing helmets. Rees–Jones A. **Br J Sports Med** 1999 Feb; 33(1):3 (10 ref.)
MR imaging of knee anterior cruciate ligament and associated injuries in skiers. Ho CP, et al.
Magn Reson Imaging Clin N Am 1999 Feb;7(1):117–30 (29 ref.)
Snow skiing. Laskowski ER.
Phys Med Rehabil Clin N Am 1999 Feb;10(1):189–211 (35 ref.)
Injuries in cross–country skiing. Trail markers for diagnosis and treatment. Morris PJ, et al. **Postgrad Med** 1999 Jan; 105(1):89–91, 95–8, 101 (12 ref.)
Alpine ski bindings and injuries. Current findings. Natri A, et al. **Sports Med** 1999 Jul;28(1):35–48 (71 ref.)

PHYSIOLOGY

Muscle activity in the slalom turn of alpine skiing and in–line skating. Zeglinksi CM, et al. **Int J Sports Med** 1998 Oct; 19(7):447–54 (22 ref.)

SKIN

see related
DERMATOLOGIC AGENTS
KERATINOCYTES
Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Venkatraman S, et al. **Biomaterials** 1998 Jul;19(13):1119–36 (32 ref.)
The vital role of the skin in human natural history. Cohn BA. **Int J Dermatol** 1998 Nov;37(11):821–4 (20 ref.)
Assessing the potential of skin electroporation for the delivery of protein– and gene–based drugs. Banga AK, et al. **Trends Biotechnol** 1998 Oct;16(10):408–12 (35 ref.)

ANATOMY & HISTOLOGY

Preservation of human skin structure and function in organ culture. Varani J. **Histol Histopathol** 1998 Jul;13(3):775–83 (53 ref.)
EEMCO guidance for the assessment of skin topography. The European Expert Group on Efficacy Measurement of Cosmetics and other Topical Products. Lévêque JL.
J Eur Acad Dermatol Venereol 1999 Mar;12(2):103–14 (54 ref.)
Direct and non–direct measurement techniques for analysis of skin surface topography. Fischer TW, et al.
Skin Pharmacol Appl Skin Physiol 1999 Jan–Apr; 12(1–2):1–11 (24 ref.)

BLOOD SUPPLY

Recent advances in non–invasive assessment of human skin blood flow. Agache PG, et al.
Acta Derm Venereol Suppl (Stockh) 1994;185:47–51 (29 ref.)
Overview of microcirculatory oxygen measurements and their contribution to our understanding of oxygen delivery to tissue. Johnson PC. **Adv Exp Med Biol** 1998;454:361–5 (19 ref.)
A 12–year–old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paueksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)
A novel approach for studying angiogenesis: a human skin equivalent with a capillary–like network. Black AF, et al. **Cell Biol Toxicol** 1999 Apr;15(2):81–90 (78 ref.)
Cigarette smoking, cutaneous vasculature, and tissue oxygen. Leow YH, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):579–84 (46 ref.)
Alcohol ingestion and the cutaneous vasculature. Wolf R, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):395–403 (135 ref.)
Skin wound healing and ischaemia. Studies on possible interventions. Quirinia A. **Dan Med Bull** 1999 Apr; 46(2):85–105 (178 ref.)
[Transcutaneous oxygen pressure (TcPO2): advantages and limitations] Got I. **Diabetes Metab** 1998 Sep;24(4):379–84 (30 ref.) (Eng. Abstr.) **(Fre)**
[Infection and vascular purpura] Lévesque H, et al.
J Mal Vasc 1999 Jun;24(3):177–82 (30 ref.) (Eng. Abstr.) **(Fre)**
[Skin microcirculation, adherence molecules and inflammatory dermatoses] Henry F, et al.
Rev Med Liege 1998 Aug;53(8):479–82 (15 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Opioid peptides from frog skin. Amiche M, et al. **EXS** 1998; 85:57–71 (48 ref.)
Methods for quantitative determination of drug localized in the skin. Touitou E, et al. **J Controlled Release** 1998 Dec 4;56(1–3):7–21 (51 ref.)
Hereditary skin diseases of anchoring fibrils.
Bruckner–Tuderman L. **J Dermatol Sci** 1999 Jun; 20(2):122–33 (47 ref.)

CYTOLOGY

Immunohistochemistry of normal human skin. Kanitakis J.
Eur J Dermatol 1998 Dec;8(8):539–47 (59 ref.)
Apoptosis and the skin. Teraki Y, et al. **Eur J Dermatol** 1999 Jul–Aug;9(5):413–25; quiz 426 (48 ref.)
The cornified envelope: a model of cell death in the skin. Melino G, et al. **Results Probl Cell Differ** 1998;24:175–212 (118 ref.)

DRUG EFFECTS

Use of topical products for maintaining remission in rosacea [editorial; comment] Wilkin JK. **Arch Dermatol** 1999 Jan; 135(1):79–80 (6 ref.) Comment on: Arch Dermatol 1994 Mar;130(3):359–62. Comment on: Arch Dermatol 1998 Jun;134(6):679–83.
Coenzyme Q10, a cutaneous antioxidant and energizer. Hoppe U, et al. **Biofactors** 1999;9(2–4):371–8 (33 ref.)
Toxicity of middle distillates from dermal exposure. Koschier FJ. **Drug Chem Toxicol** 1999 Feb;22(1):155–64 (17 ref.)
Skin susceptibility to dithranol: contact allergy or irritation? Loffler H, et al. **Eur J Dermatol** 1999 Jan–Feb;9(1):32–4 (23 ref.)
Mucocutaneous reactions to chemotherapy. Susser WS, et al. **J Am Acad Dermatol** 1999 Mar;40(3):367–98; quiz 399–400 (390 ref.)
Skin ulceration from tibial cement extrusion: case report and literature review. Ward WG, et al. **J Arthroplasty** 1998 Oct;13(7):826–9 (9 ref.)
Effect of inhaled beclomethasone dipropionate and budesonide on adrenal function, skin changes and cataract formation. Dluhy RG. **Respir Med** 1998 Jul;92 Suppl B:15–23 (41 ref.)
[Cooling action of topicals--present results and testing methods in vivo and in vitro] Thoma K, et al.
Pharmazie 1998 Dec;53(12):813–9 (24 ref.) (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

Tissue engineering for skin: an update. Eaglstein WH, et al.
J Am Acad Dermatol 1998 Dec;39(6):1007–10 (15 ref.)
The complexity of gene families involved in epithelial differentiation. Keratin genes and the epidermal

differentiation complex. Mischke D. **Subcell Biochem** 1998; 31:71–104 (159 ref.)

IMMUNOLOGY

The clinical expression of allergy in the skin. Ring J, et al. **Allergy** 1999 Mar;54(3):192–7 (36 ref.)

The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Blauvelt A. **Am J Med** 1997 May 19;102(5B):16–20 (31 ref.)

Pathways of antigen traffic from skin allotransplant to recipient lymph nodes--an evolutionarily developed route for initiation of rejection of foreign antigens. Olszewski WL, et al. **Ann Transplant** 1998;3(4):15–20 (38 ref.)

Immune functions of the human skin. Models of in vitro studies using Langerhans cells. Schmitt D. **Cell Biol Toxicol** 1999 Feb;15(1):41–5 (23 ref.)

Immune response to Leishmania infection in human skin. Ghersetich I, et al. **Clin Dermatol** 1999 May–Jun; 17(3):333–8 (39 ref.)

CD8+ cytolytic T lymphocytes and the skin. De Panfilis G. **Exp Dermatol** 1998 Aug;7(4):121–31 (98 ref.)

Psoriasis as a T cell-mediated autoimmune disease. Barker JN. **Hosp Med** 1998 Jul;59(7):530–3 (25 ref.)

Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses. Chin J, et al. **Immunol Cell Biol** 1998 Jun;76(3):245–55 (53 ref.)

Local immune responses in afferent and efferent lymph. Haig DM, et al. **Immunology** 1999 Feb;96(2):155–63 (70 ref.)

Urocanic acid and cutaneous antigen presentation. Lappin MB, et al. **J Photochem Photobiol B** 1998 Jul 10;44(2):112–6 (34 ref.)

No man is an island; no island is an island: does the immune network extend beyond the limits of skin? Rewald E, et al. **Med Hypotheses** 1999 Apr;52(4):325–7 (20 ref.)

Targeting the skin for genetic immunization. Falo LD Jr. **Proc Assoc Am Physicians** 1999 May–Jun;111(3):211–9 (55 ref.)

When to request immunofluorescence: practical hints. Morrison LH. **Semin Cutan Med Surg** 1999 Mar;18(1):36–42 (22 ref.)

[Skin microcirculation, adherence molecules and inflammatory dermatoses] Henry F, et al. **Rev Med Liege** 1998 Aug;53(8):479–82 (15 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Pilcher BK, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:12–24 (34 ref.)

Iatrogenic cutaneous injuries in the neonate. Metzker A, et al. **Arch Dermatol** 1999 Jun;135(6):697–703 (26 ref.)

Skin substitutes in burns. Sheridan RL, et al. **Burns** 1999 Mar; 25(2):97–103 (81 ref.)

A rational approach to the outpatient management of lacerations in pediatric patients. Kanegaye JT. **Curr Probl Pediatr** 1998 Aug;28(7):205–34 (198 ref.)

The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these finding to other dermatologic conditions and wound healing. Smith KJ. **Dermatol Clin** 1999 Jan;17(1):41–60, viii (52 ref.)

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Artuc M, et al. **Exp Dermatol** 1999 Feb;8(1):1–16 (195 ref.)

Lipoatrophia semicircularis--a traumatic panniculitis: report of seven cases and review of the literature. Nagore E, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):879–81 (18 ref.)

The use of Apligraf in acute wounds. Kirsner RS. **J Dermatol** 1998 Dec;25(12):805–11 (39 ref.)

Cutaneous wound healing. Singer AJ, et al. **N Engl J Med** 1999 Sep 2;341(10):738–46 (86 ref.)

Traumatic myiasis of sheep in Europe: a review. Hall MJ. **Parassitologia** 1997 Dec;39(4):409–13 (50 ref.)

INNERVATION

Abdominal wall pain caused by cutaneous nerve entrapment in an adolescent girl taking oral contraceptive pills. Peleg R. **J Adolesc Health** 1999 Jan;24(1):45–7 (13 ref.)

Recent studies of cutaneous nociception in atopic and non-atopic subjects. Heyer GR, et al. **J Dermatol** 1999 Feb; 26(2):77–86 (43 ref.)

Recent advances in neuropharmacology of cutaneous nociceptors. Nakamura A, et al. **Jpn J Pharmacol** 1999 Apr; 79(4):427–31 (29 ref.)

A physiological approach to the evaluation of lumbosacral spinal stenosis. Kraft GH. **Phys Med Rehabil Clin N Am** 1998 May;9(2):381–9, viii (19 ref.)

Efferent functions of C-fiber nociceptors. Sann H, et al. **Z Rheumatol** 1998;57 Suppl 2:8–13 (27 ref.)

[Advance in the study of restoration of sensation in skin flaps] Kuang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):94–6 (25 ref.) **(Chi)**

METABOLISM

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Fritsch C, et al. **Br J Cancer** 1999 Mar;79(9–10):1603–8 (36 ref.)

Smoking and the skin, radically speaking. Wolf R, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):633–9 (72 ref.)

Neuropeptides in atopic dermatitis. Giannetti A. **Curr Probl Dermatol** 1999;28:51–5 (8 ref.)

Percutaneous penetration enhancement and its quantification. Bach M, et al. **Eur J Pharm Biopharm** 1998 Jul;46(1):1–13 (172 ref.)

Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Dooley TP. **Exp Dermatol** 1999 Aug;8(4):328–9 (11 ref.)

Biologic aspects of expression of stably integrated transgenes in cells of the skin in vitro and in vivo. Krueger GG, et al. **Proc Assoc Am Physicians** 1999 May–Jun;111(3):198–205 (48 ref.)

A direct in vivo approach for skin gene therapy. Vogel JC. **Proc Assoc Am Physicians** 1999 May–Jun;111(3):190–7 (27 ref.)

The complexity of gene families involved in epithelial differentiation. Keratin genes and the epidermal differentiation complex. Mischke D. **Subcell Biochem** 1998; 31:71–104 (159 ref.)

MICROBIOLOGY

The role of Malassezia species in the ecology of human skin and as pathogens. Guého E, et al. **Med Mycol** 1998;36 Suppl 1:220–9 (83 ref.)

Dermatophytes and host defence in cutaneous mycoses. Ogawa H, et al. **Med Mycol** 1998;36 Suppl 1:166–73 (60 ref.)

[Hue and cry over pens?] Uhoda I, et al. **Rev Med Liege** 1999 Jan;54(1):37–8 (18 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

Immune response to Leishmania infection in human skin. Ghersetich I, et al. **Clin Dermatol** 1999 May–Jun; 17(3):333–8 (39 ref.)

PATHOLOGY

Atrophic and plaquelike dermatofibrosarcoma protuberans. Davis DA, et al. **Am J Dermatopathol** 1998 Oct; 20(5):498–501 (28 ref.)

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44–8 (36 ref.)

Acquired blaschkolinear dermatoses. Grosshans EM. **Am J Med Genet** 1999 Aug 6;85(4):334–7 (20 ref.)

Hypomelanosis of Ito: no entity, but a cutaneous sign of mosaicism. Küster W, et al. **Am J Med Genet** 1999 Aug 6;85(4):346–50 (50 ref.)

Cytogenetic and molecular evidence for cutaneous mosaicism: the ectodermal origin of Blaschko lines. Moss C. **Am J Med Genet** 1999 Aug 6;85(4):330–3 (22 ref.)

Cutaneous polyarteritis nodosa: a case report and literature review. Khoo BP, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):868–72 (33 ref.)

Use of skin cell cultures for in vitro assessment of corrosion and cutaneous irritancy. Roguet R. **Cell Biol Toxicol** 1999 Feb;15(1):63–75 (81 ref.)

Diagnostic clues to dermatitis artefacta. Joe EK, et al. **Cutis** 1999 Apr;63(4):209–14 (17 ref.)

Keratosis pilaris. Lateef A, et al. **Cutis** 1999 Apr;63(4):205–7 (32 ref.)

Nevus anemicus. Ahkami RN, et al. **Dermatology** 1999; 198(4):327–9 (28 ref.)

Linear cutaneous lupus erythematosus in an adult. Bouzit N, et al. **Dermatology** 1999;199(1):60–2 (8 ref.)

Genodermatosis with reticulate, patchy and mottled pigmentation of the neck--a clue to rare dermatologic disorders. Itin PH, et al. **Dermatology** 1998;197(3):281–90 (133 ref.)

Reticulate, patchy and mottled pigmentation of the neck. Acquired forms. Lautenschlager S, et al. **Dermatology** 1998; 197(3):291–6 (63 ref.)

Granuloma faciale with extrafacial lesions. Roustan G, et al. **Dermatology** 1999;198(1):79–82 (13 ref.)

Twenty-eight cases of juvenile-onset Adamantiades-Behçet disease in Germany. Treudler R, et al. **Dermatology** 1999; 199(1):15–9 (21 ref.)

Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses. Chin J, et al. **Immunol Cell Biol** 1998 Jun;76(3):245–55 (53 ref.)

Xeroderma pigmentosum in black South Africans. Jacyk WK. **Int J Dermatol** 1999 Jul;38(7):511–4 (17 ref.)

Skin problems of musicians. Onder M, et al. **Int J Dermatol** 1999 Mar;38(3):192–5 (10 ref.)

Mid-dermal elastolysis associated with Hashimoto's thyroiditis. Gambichler T, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):245–9 (48 ref.)

"Centripetal flagellate erythema": a cutaneous manifestation associated with dermatomyositis. Nousari HC, et al. **J Rheumatol** 1999 Mar;26(3):692–5 (15 ref.)

Myelodysplastic syndrome and associated skin lesions: a review of the literature. Avivi I, et al. **Leuk Res** 1999 Apr; 23(4):323–30 (97 ref.)

Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Fusenig NE, et al. **Mol Carcinog** 1998 Nov;23(3):144–58 (78 ref.)

Wegener's granulomatosis: case report and literature review. Stein SL, et al. **Pediatr Dermatol** 1998 Sep–Oct;15(5):352–6 (11 ref.)

Cutaneous T cell lymphoma in children. Garzon MC. **Semin Cutan Med Surg** 1999 Sep;18(3):226–32 (47 ref.)

Morphea and localized scleroderma in children. Vierra E, et al. **Semin Cutan Med Surg** 1999 Sep;18(3):210–25 (105 ref.)

[Linear and whorled nevoid hypermelanosis: report of two cases] Claudel P, et al. **Arch Pediatr** 1998 Oct; 5(10):1098–102 (22 ref.) (Eng. Abstr.) **(Fre)**

[Xanthoma disseminatum with marked mucocutaneous involvement] Tietge UJ, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1337–42 (19 ref.) (Eng. Abstr.) **(Ger)**

[The skin biopsy] Weyers W, et al. **Hautarzt** 1999 Feb; 50(2):145–58 (22 ref.) **(Ger)**

PHYSIOPATHOLOGY

The skin and its response to movement. Ryan TJ. **Lymphology** 1998 Sep;31(3):128–9 (4 ref.)

Topographical features of cutaneous tactile hypoesthetic and hyperesthetic abnormalities in chronic pain. Moriwaki K, et al. **Pain** 1999 May;81(1–2):1–6 (43 ref.)

Fibroblast models of neurological disorders: fluorescence measurement studies. Connolly GP. **Trends Pharmacol Sci** 1998 May;19(5):171–7 (36 ref.)

RADIATION EFFECTS

Solar urticaria: the annoying photodermatosis. Roelandts R, et al. **Int J Dermatol** 1999 Jun;38(6):411–8 (123 ref.)

Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. Ananthaswamy HN, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):52–6 (71 ref.)

A new concept of skin-associated lymphoid tissue (SALT): UVB light impaired cutaneous immunity reveals a prominent role for cutaneous nerves. Streilein JW, et al. **Keio J Med** 1999 Mar;48(1):22–7 (33 ref.)

UV-induced mutations and skin cancer: how important is the link? Bridges BA. **Mutat Res** 1998 Nov 9;422(1):23–30 (38 ref.)

Human pigmentation genes and their response to solar UV radiation. Sturm RA. **Mutat Res** 1998 Nov 9;422(1):69–76 (42 ref.)

Individual skin care during radiation therapy. Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:74–7 (19 ref.)

SECRETION

Measurement of histamine release in intact human skin by microdialysis technique. Clinical and experimental findings. Petersen LJ. **Dan Med Bull** 1998 Sep;45(4):383–401 (303 ref.)

SURGERY

Percutaneous tracheostomy: a comprehensive evaluation. Moe KS, et al. **Ann Otol Rhinol Laryngol** 1999 Apr; 108(4):384–91 (37 ref.)

Migration of sterilisation clips: case report and review. AmuO, et al. **Br J Fam Plann** 1999 Apr;25(1):27–8 (14 ref.)

Spectrum of cartilage grafting in cutaneous reconstructive surgery. Otley CC, et al. **J Am Acad Dermatol** 1998 Dec; 39(6):982–92 (23 ref.)

Cutaneous laser resurfacing. Ratner D, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):365–89; quiz 390–2 (314 ref.)

Preoperative and postoperative skin care with laser resurfacing. Hrabovsky SL. **Semin Ophthalmol** 1998 Sep; 13(3):115–22 (32 ref.)

Erbium: YAG laser--an improved periorbital resurfacing device. Kopelman J. **Semin Ophthalmol** 1998 Sep; 13(3):136–41 (16 ref.)

[CO2 laser skin resurfacing. Critical analysis of recent literature] Dubois R, et al. **Ann Chir Plast Esthet** 1998 Dec; 43(6):659–63 (22 ref.) (Eng. Abstr.) **(Fre)**

[Under the epidermis, the dermis, or how to interpret skin cultures?] Echinard C. **Ann Chir Plast Esthet** 1998 Apr; 43(2):197–205 (35 ref.) (Eng. Abstr.) **(Fre)**

[Body contouring by removal of skin and fatty tissue] Erni D, et al. **Ther Umsch** 1999 Apr;56(4):206–11 (3 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

New insights into the immunoultrastructural organization of cutaneous basement membrane zone molecules. Shimizu H. **Exp Dermatol** 1998 Dec;7(6):303–13 (55 ref.)

Granuloma annulare: an elastic tissue disease? Case report and literature review. Hanna WM, et al. **Ultrastruct Pathol** 1999 Jan–Feb;23(1):33–8 (13 ref.)

SKIN ABNORMALITIES

DIAGNOSIS

The diagnosis and treatment of common birthmarks. Brown TJ, et al. **Clin Plast Surg** 1998 Oct;25(4):509–25 (65 ref.)

SKIN ABNORMALITIES

[Atypical constellation of findings in Schimmelpenning-Feuerstein-Mims syndrome--case report and overview] Framme C, et al. **Klin Monatsbl Augenheilkd** 1998 Aug;213(2):97-103 (44 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Neurological involvement in a child with the wrinkly skin syndrome [see comments] Azuri J, et al. **Am J Med Genet** 1999 Jan 1;82(1):31-3 (8 ref.) Comment in: Am J Med Genet 1999 Jul 16;85(2):194.

Elattoproteus syndrome: delineation of an inverse form of Proteus syndrome. Happle R. **Am J Med Genet** 1999 May 7;84(1):25-8 (25 ref.)

Another observation of microphthalmia in an XX male: microphthalmia with linear skin defects syndrome without linear skin lesions. Kono T, et al. **J Hum Genet** 1999; 44(1):63-8 (34 ref.)

PATHOLOGY

Costello syndrome: report and review. van Eeghen AM, et al. **Am J Med Genet** 1999 Jan 15;82(2):187-93 (38 ref.)

Collodion baby concomitant with congenital hypothyroidism: a patient report and review of the literature. Kurtoğlu S, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug;11(4):569-73 (24 ref.)

SKIN ABSORPTION

see related

ADMINISTRATION, CUTANEOUS

The transdermal drug delivery system and transcutaneous absorption. Morimoto Y, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;185:15-7 (7 ref.)

Epicutaneous and transcutaneous immunization using DNA or proteins. Kaiserlian D, et al. **Eur J Dermatol** 1999 Apr-May;9(3):169-76 (35 ref.)

Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. van Hoogdalem EJ. **J Eur Acad Dermatol Venereol** 1998 Sep;11 Suppl 1:S13-9; discussion S28-9 (27 ref.)

Proposal for the assessment of quantitative dermal exposure limits in occupational environments: Part 1. Development of a concept to derive a quantitative dermal occupational exposure limit. Bos PM, et al. **Occup Environ Med** 1998 Dec;55(12):795-804 (48 ref.)

Estimation of dermal absorption using the exponential saturation model. Thongsinthusak T, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):37-43 (17 ref.)

DRUG EFFECTS

Passive enhancement strategies in topical and transdermal drug delivery. Hadgraft J. **Int J Pharm** 1999 Jul 5; 184(1):1-6 (25 ref.)

Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. Marjukka Suhonen T, et al. **J Controlled Release** 1999 May 20; 59(2):149-61 (106 ref.)

[Augmentation of transdermal drug penetration] Préat MV. **Bull Mem Acad R Med Belg** 1998;153(5-6):295-300; discussion 301-2 (9 ref.) (Eng. Abstr.) **(Fre)**

SKIN AGING

Mechanical measurements of skin. Vogel HG. **Acta Derm Venereol Suppl (Stockh)** 1994;185:39-43 (81 ref.)

Botulinum toxin type A injection for the treatment of frown lines. Song KH. **Ann Pharmacother** 1998 Dec;32(12):1365-7 (17 ref.)

Smoker's wrinkles: epidemiological and pathogenic considerations. Francès C. **Clin Dermatol** 1998 Sep-Oct; 16(5):565-70 (49 ref.)

Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region. Wieder JM, et al. **Dermatol Surg** 1998 Nov;24(11):1172-4 (8 ref.)

Aging in epidermal melanocytes: cell cycle genes and melanins. Haddad MM, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):36-40 (58 ref.)

Molecular mechanisms of cutaneous aging: connective tissue alterations in the dermis. Uitto J, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):41-4 (35 ref.)

Aging versus photoaging: postulated mechanisms and effectors. Yaar M, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):47-51 (96 ref.)

Oxidant/antioxidant imbalance in skin aging: environmental and adaptive factors. Mariéthoz E, et al. **Rev Environ Health** 1998 Jul-Sep;13(3):147-68 (133 ref.)

Carbon dioxide laser skin resurfacing. Biesman BS. **Semin Ophthalmol** 1998 Sep;13(3):123-35 (53 ref.)

Preoperative and postoperative skin care with laser resurfacing. Hrabovsky SL. **Semin Ophthalmol** 1998 Sep; 13(3):115-22 (32 ref.)

[CO2 laser skin resurfacing. Critical analysis of recent literature] Dubois R, et al. **Ann Chir Plast Esthet** 1998 Dec; 43(6):659-63 (22 ref.) (Eng. Abstr.) **(Fre)**

[Soft tissue augmentation for treatment of wrinkles and scars of the face] Streit M, et al. **Ther Umsch** 1999 Apr; 56(4):212-8 (11 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Coenzyme Q10, a cutaneous antioxidant and energizer. Hoppe U, et al. **Biofactors** 1999;9(2-4):371-8 (33 ref.)

Dowling Oration delivered at the Royal College of Physicians, London, Friday 5 June 1998. Retinoids: renaissance and reformation. Griffiths CE. **Clin Exp Dermatol** 1999 Jul;24(4):329-35 (23 ref.)

Cosmetic use of botulinum A exotoxin for the aging neck. Brandt FS, et al. **Dermatol Surg** 1998 Nov;24(11):1232-4 (9 ref.)

Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Carruthers A, et al. **Dermatol Surg** 1998 Nov;24(11):1189-94 (11 ref.)

The adjunctive usage of botulinum toxin. Carruthers J, et al. **Dermatol Surg** 1998 Nov;24(11):1244-7 (11 ref.)

Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Edelstein C, et al. **Dermatol Surg** 1998 Nov; 24(11):1208-12 (12 ref.)

Botulinum toxin. The Newport Beach experience. Fulton JE. **Dermatol Surg** 1998 Nov;24(11):1219-24 (8 ref.)

Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Lowe NJ. **Dermatol Surg** 1998 Nov;24(11):1216-8 (15 ref.)

Drug treatment of photoaged skin. Griffiths CE. **Drugs Aging** 1999 Apr;14(4):289-301 (100 ref.)

Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo. Fisher GJ, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):61-8 (48 ref.)

Topical agents used in association with cosmetic surgery. Draelos ZD. **Semin Cutan Med Surg** 1999 Jun;18(2):112-8 (33 ref.)

Cosmetic indications for botulinum A toxin. Foster JA, et al. **Semin Ophthalmol** 1998 Sep;13(3):142-8 (22 ref.)

[Sunscreening creams] Leroy D. **Ann Dermatol Venereol** 1999 Apr;126(4):357-63 (60 ref.) **(Fre)**

PATHOLOGY

EEMCO guidance for the assessment of skin topography. The European Expert Group on Efficacy Measurement of Cosmetics and other Topical Products. Lévêque JL. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):103-14 (54 ref.)

The role of cellular senescence in skin aging. Campisi J. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):1-5 (51 ref.)

Apoptosis: a role in skin aging? Haake AR, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):28-35 (80 ref.)

PHYSIOLOGY

Aging and the epidermal permeability barrier: implications for contact dermatitis. Ghadially R. **Am J Contact Dermat** 1998 Sep;9(3):162-9 (77 ref.)

Skin antioxidants: their role in aging and in oxidative stress--new approaches for their evaluation. Kohen R. **Biomed Pharmacother** 1999 May;53(4):181-92 (76 ref.)

Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo. Fisher GJ, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):61-8 (48 ref.)

RADIATION EFFECTS

The UV-induced SOS response: importance to aging skin. Gilchrest BA. **J Dermatol** 1998 Dec;25(12):775-7 (7 ref.)

[Photo-aging] Paredes BE, et al. **Ther Umsch** 1999 Apr; 56(4):188-93 (23 ref.) (Eng. Abstr.) **(Ger)**

SKIN APPENDAGE DISEASES

Microcystic adnexal carcinoma: collaborative series review and update. Friedman PM, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):225-31 (35 ref.)

COMPLICATIONS

[Diseases associated with adnexal tumors. I--Follicular tumors] Cribier B. **Ann Dermatol Venereol** 1999 Mar; 126(3):270-9 (104 ref.) **(Fre)**

SKIN, ARTIFICIAL

Skin substitutes in burns. Sheridan RL, et al. **Burns** 1999 Mar; 25(2):97-103 (81 ref.)

Tissue engineering and the development of Apligraf, a human skin equivalent. Eaglstein WH, et al. **Cutis** 1998 Jul;62(1 Suppl):1-8 (57 ref.)

Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. Trent JF, et al. **Int J Clin Pract** 1998 Sep; 52(6):408-13 (57 ref.)

Dermagraft in the treatment of diabetic foot ulcers. Bowering CK. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1-29-32 (33 ref.)

Tissue engineering. Sefton MV, et al. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1-18-23 (41 ref.)

Apligraf living skin equivalent for healing venous and chronic wounds. Sibbald RG. **J Cutan Med Surg** 1998 Dec; 3 Suppl 1:S1-24-8 (27 ref.)

Dohi Memorial Lecture. From occlusive to living membranes. Eaglstein WH. **J Dermatol** 1998 Dec; 25(12):766-74 (35 ref.)

Dermagraft treatment of diabetic ulcers. Eaglstein WH. **J Dermatol** 1998 Dec;25(12):803-4 (2 ref.)

Apligraf treatment of venous ulcers and other chronic wounds. Falanga V. **J Dermatol** 1998 Dec;25(12):812-7 (18 ref.)

The use of Apligraf in acute wounds. Kirsner RS. **J Dermatol** 1998 Dec;25(12):805-11 (39 ref.)

Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: clinical and fundamental applications. Auger FA, et al. **Med Biol Eng Comput** 1998 Nov;36(6):801-12 (175 ref.)

Skin substitutes from cultured cells and collagen-GAG polymers. Boyce ST. **Med Biol Eng Comput** 1998 Nov; 36(6):791-800 (101 ref.)

Applications of reconstructed skin models in pharmaco-toxicological trials. Damour O, et al. **Med Biol Eng Comput** 1998 Nov;36(6):825-32 (71 ref.)

Pigmented human skin equivalent--as a model of the mechanisms of control of cell-cell and cell-matrix interactions. Nakazawa K, et al. **Med Biol Eng Comput** 1998 Nov;36(6):813-20 (88 ref.)

Cutaneous wound healing. Singer AJ, et al. **N Engl J Med** 1999 Sep 2;341(10):738-46 (86 ref.)

ADVERSE EFFECTS

Safety evaluation of human living skin equivalents. Nemecek GM, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):101-3 (22 ref.)

SKIN CARE

METHODS

Split-thickness skin graft donor site care: a quantitative synthesis of the research. Rakel BA, et al. **Appl Nurs Res** 1998 Nov;11(4):174-82 (29 ref.)

Neonatal skin: the ideal nursing interface. Lott JW, et al. **J Pediatr Nurs** 1998 Oct;13(5):302-6 (11 ref.)

Topical agents used in association with cosmetic surgery. Draelos ZD. **Semin Cutan Med Surg** 1999 Jun;18(2):112-8 (33 ref.)

Diabetic foot ulcers: A framework for prevention and care. Boulton AJ, et al. **Wound Repair Regen** 1999 Jan-Feb; 7(1):7-16 (78 ref.)

[Fruit acid facial scrubs. Dermatological and esthetic correction with alpha-hydroxy acids (AHA)] Fratila A, et al. **Hautarzt** 1999 Jun;50(6):448-60 (41 ref.) **(Ger)**

NURSING

Neonatal skin care: the scientific basis for practice. Lund C, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May-Jun; 28(3):241-54 (100 ref.)

SKIN DISEASES

see related

DERMATOLOGIC AGENTS

Mechanical measurements of skin. Vogel HG. **Acta Derm Venereol Suppl (Stockh)** 1994;185:39-43 (81 ref.)

Vulvar disorders in adolescents. Fivozinsky KB, et al. **Adolesc Med** 1999 Jun;10(2):305-19, vii (65 ref.)

A lifetime of healthy skin: implications for women. Bergfeld WF. **Int J Fertil Womens Med** 1999 Mar-Apr;44(2):83-95 (49 ref.)

[Cutaneous amyloidosis] Dekio S. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):511-4 (17 ref.) **(Jpn)**

[Cutaneous pseudolymphoma] Kura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):338-40 (5 ref.) **(Jpn)**

CHEMICALLY INDUCED

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44-8 (36 ref.)

Low-molecular-weight heparin-induced skin necrosis. Füreder W, et al. **Ann Hematol** 1998 Sep;77(3):127-30 (28 ref.)

The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these finding to other dermatologic conditions and wound healing. Smith KJ. **Dermatol Clin** 1999 Jan;17(1):41-60, viii (52 ref.)

Striae formation in two HIV-positive persons receiving protease inhibitors. Darvay A, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):467-9 (13 ref.)

Mucocutaneous reactions to chemotherapy. Susser WS, et al. **J Am Acad Dermatol** 1999 Mar;40(3):367-98; quiz 399-400 (390 ref.)

[Cutaneous complications of inhaled corticoids] Guillot B, et al. **Ann Dermatol Venereol** 1998 Dec;125(12):927-30 (30 ref.) **(Fre)**

CLASSIFICATION

Segmental forms of autosomal dominant skin disorders: the puzzle of mosaicism. Itin PH, et al. **Am J Med Genet** 1999 Aug 6;85(4):351-4 (30 ref.)

COMPLICATIONS

Squamous cell carcinoma arising in a cutaneous epidermal cyst: case report and literature review. López-Ríos F, et al. **Am J Dermatopathol** 1999 Apr;21(2):174–7 (25 ref.)
Neurology and the skin. Hurko O, et al.
J Neurol Neurosurg Psychiatry 1999 Apr;66(4):417–30 (115 ref.)
Neutrophilic dermatosis–associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review. Nurre LD, et al. **Pediatr Dermatol** 1999 May–Jun; 16(3):214–6 (9 ref.)
Update on juvenile xanthogranuloma: unusual cutaneous and systemic variants. Chang MW. **Semin Cutan Med Surg** 1999 Sep;18(3):195–205 (104 ref.)
Dermatoses of pregnancy. Shornick JK.
Semin Cutan Med Surg 1998 Sep;17(3):172–81 (55 ref.)
[Diseases associated with adnexal tumors. I--Follicular tumors] Cribier B. **Ann Dermatol Venereol** 1999 Mar; 126(3):270–9 (104 ref.) **(Fre)**

CONGENITAL

The diagnosis and treatment of common birthmarks. Brown TJ, et al. **Clin Plast Surg** 1998 Oct;25(4):509–25 (65 ref.)

DIAGNOSIS

Rosai–Dorfman disease with primary cutaneous manifestations--a case report. Huang HY, et al.
Ann Acad Med Singapore 1998 Jul;27(4):589–93 (16 ref.)
Cutaneous manifestations of biological warfare and related threat agents. McGovern TW, et al. **Arch Dermatol** 1999 Mar;135(3):311–22 (116 ref.)
The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. Williams H, et al. **Arch Dermatol** 1998 Dec; 134(12):1620–6 (43 ref.)
Comparison of dermatologic diagnoses by primary care practitioners and dermatologists. A review of the literature. Federman DG, et al. **Arch Fam Med** 1999 Mar–Apr; 8(2):170–2 (14 ref.)
Skin complications in the intensive care unit. Peerless JR, et al. **Clin Chest Med** 1999 Jun;20(2):453–67, x (95 ref.)
Cutaneous manifestations of cancer. Sabir S, et al.
Curr Opin Oncol 1999 Mar;11(2):139–44 (72 ref.)
Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features. Aftergut K, et al.
Dermatol Clin 1999 Jul;17(3):445–71, vii (188 ref.)
Monoclonal gammopathies and associated skin disorders. Daoud MS, et al. **J Am Acad Dermatol** 1999 Apr; 40(4):507–35; quiz 536–8 (214 ref.)
Skin manifestations of a patient with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS syndrome). Kubota Y, et al.
J Am Acad Dermatol 1999 Sep;41(3 Pt 1):469–73 (8 ref.)
Hemorrhoids: what the dermatologist should know. Orkin BA, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):449–56 (14 ref.)
Skin disease disability: measuring its magnitude. Finlay AY. **Keio J Med** 1998 Sep;47(3):131–4 (35 ref.)
Subcutaneous granuloma annulare: MR imaging features in six children and literature review. Chung S, et al.
Radiology 1999 Mar;210(3):845–9 (15 ref.)
Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Cerroni L, et al.
Semin Cutan Med Surg 1999 Mar;18(1):64–70 (37 ref.)
Update on juvenile xanthogranuloma: unusual cutaneous and systemic variants. Chang MW. **Semin Cutan Med Surg** 1999 Sep;18(3):195–205 (104 ref.)
When to request immunofluorescence: practical hints. Morrison LH. **Semin Cutan Med Surg** 1999 Mar;18(1):36–42 (22 ref.)
[Ultrasound of the lymph nodes and the subcutis in dermatology. Part 1] Blum A, et al. **Hautarzt** 1998 Dec; 49(12):942–9 (34 ref.) **(Ger)**
[The diabetic foot--examination of the skin] Lautenschlager S. **Schweiz Rundsch Med Prax** 1999 Jul 8;88(27–28):1181–5 (24 ref.) (Eng. Abstr.) **(Ger)**
[A case of idiopathic multiple calcinosis cutis] Iannello S, et al. **Minerva Med** 1998 Oct;89(10):379–84 (28 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Traditional Chinese medicine for the treatment of dermatologic disorders. Koo J, et al. **Arch Dermatol** 1998 Nov;134(11):1388–93 (63 ref.)
Tacrolimus: the drug for the turn of the millennium? Ruzicka T, et al. **Arch Dermatol** 1999 May;135(5):574–80 (76 ref.)
Frequency of application of topical corticosteroids: an overview. Lagos BR, et al. **Br J Dermatol** 1998 Nov; 139(5):763–6 (21 ref.)
Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW, et al. **Curr Pharm Des** 1998 Oct; 4(5):367–79 (100 ref.)
Uses of vitamins A, C, and E and related compounds in dermatology: a review. Keller KL, et al.
J Am Acad Dermatol 1998 Oct;39(4 Pt 1):611–25 (200 ref.)
Colchicine in dermatology. Sullivan TP, et al.
J Am Acad Dermatol 1998 Dec;39(6):993–9 (105 ref.)
PUVA therapy: current concerns in Japan. Danno K.
J Dermatol Sci 1999 Feb;19(2):89–105 (138 ref.)
Targeting lurking pathogens in acute traumatic and chronic wounds. Eron LJ. **J Emerg Med** 1999 Jan–Feb;17(1):189–95 (35 ref.)
Dermatology therapy update. Thiers BH.
Med Clin North Am 1998 Nov;82(6):1405–14, vii (61 ref.)
HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)
Ascomycins in dermatology. Paul C, et al.
Semin Cutan Med Surg 1998 Dec;17(4):256–9 (21 ref.)
Thalidomide and its impact in dermatology. Stirling DI.
Semin Cutan Med Surg 1998 Dec;17(4):231–42 (87 ref.)
[Photo oxidative reactions of psoralens and their role in therapy of dermatoses] Potapenko Ala, et al.
Vestn Ross Akad Med Nauk 1999;(2):32–8 (35 ref.) (Eng. Abstr.) **(Rus)**
[New trends in immunodermatology and treatment of skin diseases] Nordlind K, et al. **Lakartidningen** 1999 Feb 24; 96(8):876–81 (28 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

[Quality assurance for rational diagnosis and therapy in dermatology] Korting HC, et al. **Hautarzt** 1998 Oct; 49(10):755–61 (19 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Epidermal enzymes: their role in homeostasis and their relationships with dermatoses. Redoules D, et al.
Skin Pharmacol Appl Skin Physiol 1998;11(4–5):183–92 (69 ref.)

ETHNOLOGY

Diagnosis in racially pigmented skin. Child F.
Practitioner 1998 Apr;242(1585):292–6 (6 ref.)

ETIOLOGY

Food-induced cutaneous adverse reactions. Wüthrich B.
Allergy 1998;53(46 Suppl):131–5 (52 ref.)
Cutaneous T-cell lymphoma presenting as benign dermatoses. Elmer KB, et al. **Am Fam Physician** 1999 May 15;59(10):2809–13 (09 ref.)
Rare syndromes in Hodgkin's disease. Cavalli F.
Ann Oncol 1998;9 Suppl 5:S109–13 (26 ref.)
Cutaneous manifestations of biological warfare and related threat agents. McGovern TW, et al. **Arch Dermatol** 1999 Mar;135(3):311–22 (116 ref.)
Nitric oxide and its implications in skin homeostasis and disease - a review. Bruch-Gerharz D, et al.
Arch Dermatol Res 1998 Dec;290(12):643–51 (79 ref.)
Smoker's wrinkles: epidemiological and pathogenic considerations. Frances C. **Clin Dermatol** 1998 Sep–Oct; 16(5):565–70 (49 ref.)
Alcoholism, malnutrition, vitamin deficiencies, and the skin. Fuchs J. **Clin Dermatol** 1999 Jul–Aug;17(4):457–61 (43 ref.)
Alcohol intake and other skin disorders. Higgins E, et al.
Clin Dermatol 1999 Jul–Aug;17(4):437–41 (55 ref.)
Dermatological manifestations of alcoholic cirrhosis. Ruocco V, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):463–8 (70 ref.)
Alcohol, social behavior disorders, and their cutaneous manifestations. Sanchez MR. **Clin Dermatol** 1999 Jul–Aug; 17(4):479–89 (109 ref.)
Cigarette smoking, hormonal changes, and the skin. Shulman A, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):595–8 (35 ref.)
Smoking and the skin, radically speaking. Wolf R, et al.
Clin Dermatol 1998 Sep–Oct;16(5):633–9 (72 ref.)
Nonorthopaedic problems in the aquatic athlete. Nichols AW. **Clin Sports Med** 1999 Apr;18(2):395–411, viii (40 ref.)
Human immunodeficiency virus disease in the era of HAART: a reevaluation of the mucocutaneous manifestations. Johnson RA. **Curr Clin Top Infect Dis** 1999; 19:252–86 (210 ref.)
Aquatic adversaries: stonefish. Burnett JW. **Cutis** 1998 Dec; 62(6):269–70 (7 ref.)
What's eating you? Centipedes (Chilopoda). Elston DM.
Cutis 1999 Aug;64(2):83 (5 ref.)
Sports-related cutaneous reactions: Part I. Dermatoses due to physical agents [news] Fisher AA. **Cutis** 1999 Mar; 63(3):134–6 (33 ref.)
Sports-related cutaneous reactions: Part II. Allergic contact dermatitis to sports equipment [news] Fisher AA. **Cutis** 1999 Apr;63(4):202–4 (10 ref.)
Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features. Aftergut K, et al.
Dermatol Clin 1999 Jul;17(3):445–71, vii (188 ref.)
Environmental skin diseases and the impact of common dermatoses on medical readiness. Meffert JJ.
Dermatol Clin 1999 Jan;17(1):1–17, vii (143 ref.)
Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. Realdi G, et al. **Dig Dis Sci** 1999 Feb;44(2):229–36 (70 ref.)
Dermatologic manifestations of gastrointestinal disorders. Ward SK, et al. **Gastroenterol Clin North Am** 1998 Sep; 27(3):615–36, vi (77 ref.)
Anetoderma of prematurity in association with electrocardiographic electrodes. Colditz PB, et al.
J Am Acad Dermatol 1999 Sep;41(3 Pt 1):479–81 (9 ref.)
The UV-induced SOS response: importance to aging skin. Gilchrest BA. **J Dermatol** 1998 Dec;25(12):775–7 (7 ref.)
Skin diseases related to abnormality in desmosomes and hemidesmosomes--editorial review [editorial] Hashimoto T. **J Dermatol Sci** 1999 Jun;20(2):81–4 (12 ref.)
Skin lesions in returned travelers. Kain KC.
Med Clin North Am 1999 Jul;83(4):1077–102 (25 ref.)
Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Blanco R, et al. **Medicine (Baltimore)** 1998 Nov;77(6):403–18 (101 ref.)
Allergy, skin and environment. Merk HF, et al.
Zentralbl Hyg Umweltmed 1999 Aug;202(2–4):85–100 (66 ref.)
[The diabetic foot--the view of the dermatologist] Itin PH.
Schweiz Rundsch Med Prax 1999 Jul 8;88(27–28):1186–90 (19 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Segmental forms of autosomal dominant skin disorders: the puzzle of mosaicism. Itin PH, et al. **Am J Med Genet** 1999 Aug 6;85(4):351–4 (30 ref.)
Concept of twin spotting. Koopman RJ.
Am J Med Genet 1999 Aug 6;85(4):355–8 (24 ref.)
Prenatal diagnosis as a test for genodermatoses: its past, present and future. Shimizu H, et al. **J Dermatol Sci** 1999 Jan;19(1):1–8 (57 ref.)

IMMUNOLOGY

The clinical expression of allergy in the skin. Ring J, et al.
Allergy 1999 Mar;54(3):192–7 (36 ref.)
Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. Leigh IM, et al.
J Acquir Immune Defic Syndr 1999 Aug 1;21 Suppl 1:S49–57 (90 ref.)
[From neuropeptides and cytokines to psychotherapy. Skin diseases between psychoneuroimmunology research and psychosomatic treatment] Niemeier V, et al.
Forsch Komplementarmed 1999 Apr;6 Suppl 2:14–8 (45 ref.) (Eng. Abstr.) **(Ger)**
[The role of bacterial superantigens in pathophysiology of the skin] Boehncke WH, et al. **Hautarzt** 1999 Feb;50(2):91–7 (67 ref.) (Eng. Abstr.) **(Ger)**
[Roles of eosinophils in allergic skin diseases] Satoh T.
Arerugi 1999 May;48(5):496–9 (7 ref.) **(Jpn)**
[Neutrophilic dermatosis] Fria Ancona G, et al.
Rev Alerg Mex 1998 Nov–Dec;45(6):159–65 (19 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Expression of trichohyalin in skin disorders. Manabe M, et al. **Exp Dermatol** 1999 Aug;8(4):312 (5 ref.)

PATHOLOGY

Acquired blaschkolinear dermatoses. Grosshans EM.
Am J Med Genet 1999 Aug 6;85(4):334–7 (20 ref.)
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Vergier B, et al.
Am J Surg Pathol 1998 Oct;22(10):1192–202 (47 ref.)
Dermatopathology in Europe: dreams and realities. Kerl H.
Arch Dermatol 1999 Jan;135(1):21–4 (12 ref.)
Multiple cutaneous reticulohistiocytosis [letter] McKenna DB, et al. **Br J Dermatol** 1998 Sep;139(3):544–6 (9 ref.)
Immunohistochemistry in diagnostic dermatopathology. Hudson AR, et al. **Dermatol Clin** 1999 Jul;17(3):667–89, x (303 ref.)
Update on immunoelectron microscopy in diagnostic dermatopathology and cutaneous biology.
Schaumburg-Lever G. **Dermatol Clin** 1999 Jul; 17(3):691–704, x (29 ref.)
Advanced laboratory techniques at the Armed Forces Institute of Pathology applicable to diagnosis and research in dermatology. Skelton HG, et al. **Dermatol Clin** 1999 Jan; 17(1):125–34, ix (53 ref.)
Self-healing juvenile cutaneous mucinosis. Aydingöz IE, et al. **Dermatology** 1999;199(1):57–9 (8 ref.)
Genital variant of folliculosebaceous cystic hamartoma. Bolognia JL, et al. **Dermatology** 1998;197(3):258–60 (17 ref.)
Atypical cutaneous lymphoproliferative disorder in patients with HIV infection. Friedler S, et al. **Int J Dermatol** 1999 Feb;38(2):111–8 (24 ref.)
Eccrine angiomatous hamartoma: report of a case and literature review. Nakatsui TC, et al.
J Am Acad Dermatol 1999 Jul;41(1):109–11 (31 ref.)
Blaschko lines of the face: a step closer to completing the map. Restano L, et al. **J Am Acad Dermatol** 1998 Dec; 39(6):1028–30 (8 ref.)
Cutaneous deposition diseases. Part II. Touart DM, et al.
J Am Acad Dermatol 1998 Oct;39(4 Pt 1):527–44; quiz 545–6 (169 ref.)
A case of nodular cystic fat necrosis: the end stage lesion showing calcification and lipomembranous changes. Oh CW, et al. **J Dermatol** 1998 Sep;25(9):616–21 (13 ref.)
Acquired skin disease of hemidesmosomes. Zillikens D.
J Dermatol Sci 1999 Jun;20(2):134–54 (188 ref.)
Cutaneous ciliated cyst of the right lower leg. Yokozaki H, et al. **Pathol Int** 1999 Apr;49(4):354–7 (24 ref.)
Cutaneous sarcoidosis. Wilson NJ, et al. **Postgrad Med J** 1998 Nov;74(877):649–52 (22 ref.)
Recognising and treating. Premalignant skin conditions. Khorshid SM, et al. **Practitioner** 1998 Apr;242(1585):270–2, 275, 277 (6 ref.)
Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case

Control Etiologic Study of Sarcoidosis. Judson MA, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):75–86 (115 ref.)
[Cutaneous manifestations of graft versus host reaction] Aractingi S, et al. **Ann Dermatol Venereol** 1998 Sep; 125(9):620–7 (51 ref.) **(Fre)**
[Local anesthesia in dermatology] Grognard C. **Ann Dermatol Venereol** 1999 Apr;126(4):369–72 (10 ref.) **(Fre)**
[Palisading granuloma] Vignon-Pennamen MD, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):615–9 (15 ref.) **(Fre)**
[The skin biopsy] Weyers W, et al. **Hautarzt** 1999 Feb; 50(2):145–58 (22 ref.) **(Ger)**
[Multifunctional territories in human pathology] Miranda RN. **Rev Assoc Med Bras** 1998 Oct-Dec;44(4):331–4 (7 ref.) **(Por)**
[Penile cutaneous horn. Report of a case and review of the literature] Garcia Paños JM, et al. **Arch Esp Urol** 1999 Mar; 52(2):173–4 (6 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The benefits of smoking in skin diseases. Wolf R, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):641–7 (107 ref.)
Angiogenesis: potential target for dermatologic intervention. Sauder DN. **J Cutan Med Surg** 1998 Jun;2 Suppl 4:S4–30–2 (22 ref.)
Collagen vascular diseases. Callen JP. **Med Clin North Am** 1998 Nov;82(6):1217–37, v (38 ref.)
[Interleukin-10 in dermatology] Asadullah K, et al. **Hautarzt** 1999 Jan;50(1):12–9 (88 ref.) (Eng. Abstr.) **(Ger)**
[Melatonin in dermatology. Experimental and clinical aspects] Fischer T, et al. **Hautarzt** 1999 Jan;50(1):5–11 (48 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Potentials and limitations of the natural antioxidants RRR-alpha-tocopherol, L-ascorbic acid and beta-carotene in cutaneous photoprotection. Fuchs J. **Free Radic Biol Med** 1998 Nov 1;25(7):848–73 (380 ref.)
Uses of vitamins A, C, and E and related compounds in dermatology: a review. Keller KL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):611–25 (200 ref.)

PSYCHOLOGY

Mind-body medicine. Practical applications in dermatology. Bilkis MR, et al. **Arch Dermatol** 1998 Nov;134(11):1437–41 (13 ref.)
The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin. O'Sullivan RL, et al. **Arch Dermatol** 1998 Nov;134(11):1431–5 (59 ref.)
Cognitive-behavioral techniques. Galassi F. **Clin Dermatol** 1998 Nov-Dec;16(6):715–23 (37 ref.)
Biofeedback in dermatology. Sarti MG. **Clin Dermatol** 1998 Nov-Dec;16(6):711–4 (15 ref.)
Obsessive-compulsive disorders in dermatology. Monti M, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):103–8 (15 ref.)
Quality of life assessments in dermatology. Finlay AY. **Semin Cutan Med Surg** 1998 Dec;17(4):291–6 (54 ref.)
Cosmetics, skin care, and appearance in teenagers. Marcoux D. **Semin Cutan Med Surg** 1999 Sep;18(3):244–9 (31 ref.)
[From neuropeptides and cytokines to psychotherapy. Skin diseases between psychoneuroimmunology research and psychosomatic treatment] Niemeier V, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:14–8 (45 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)
Radiation treatment of benign mesenchymal disease. Suit H, et al. **Semin Radiat Oncol** 1999 Apr;9(2):171–8 (47 ref.)
[Narrow band UVB 311 nm versus broad band UVB. New developments in phototherapy] Degitz K, et al. **Hautarzt** 1998 Oct;49(10):795–806; quiz 806 (15 ref.) **(Ger)**

REHABILITATION

Bioclimatology and balneology in dermatology: a Dead Sea perspective. Abels DJ, et al. **Clin Dermatol** 1998 Nov-Dec; 16(6):695–8 (15 ref.)

SURGERY

Cryosurgery for common skin lesions. Treatment in family physicians' offices. Wetmore SJ. **Can Fam Physician** 1999 Apr;45:964–74 (31 ref.)
Laser therapy and dermatologic surgery. Cunningham BB. **Curr Opin Pediatr** 1998 Aug;10(4):405–10 (40 ref.)
Lasers in the military for cutaneous disease and wound healing. Ross EV, et al. **Dermatol Clin** 1999 Jan; 17(1):135–50, ix (67 ref.)
Cryosurgery in dermatology. Zouboulis CC. **Eur J Dermatol** 1998 Oct-Nov;8(7):466–74 (49 ref.)
Pediatric dermatologic surgery for the primary care pediatrician. Babich D, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1437–53 (47 ref.)
The krypton yellow-green laser for the treatment of facial vascular and pigmented lesions. Patel BC. **Semin Ophthalmol** 1998 Sep;13(3):158–70 (7 ref.)
Genital skin loss: unified reconstructive approach to a heterogeneous entity. Wessells H. **World J Urol** 1999 Apr; 17(2):107–14 (21 ref.)
[Local anesthesia in dermatology] Grognard C. **Ann Dermatol Venereol** 1999 Apr;126(4):369–72 (10 ref.) **(Fre)**

THERAPY

Mind-body medicine. Practical applications in dermatology. Bilkis MR, et al. **Arch Dermatol** 1998 Nov;134(11):1437–41 (13 ref.)
Phytotherapeutic approaches to common dermatologic conditions. Brown DJ, et al. **Arch Dermatol** 1998 Nov; 134(11):1401–4 (39 ref.)
Different modalities of spa therapy for skin diseases at the Dead Sea area. Halevy S, et al. **Arch Dermatol** 1998 Nov; 134(11):1416–20 (51 ref.)
The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. Williams H, et al. **Arch Dermatol** 1998 Dec; 134(12):1620–6 (43 ref.)
Skin complications in the intensive care unit. Peerless JR, et al. **Clin Chest Med** 1999 Jun;20(2):453–67, x (95 ref.)
Hypnosis in dermatology. Bellini MA. **Clin Dermatol** 1998 Nov-Dec;16(6):725–6 (7 ref.)
Cognitive-behavioral techniques. Galassi F. **Clin Dermatol** 1998 Nov-Dec;16(6):715–23 (37 ref.)
Acupuncture in dermatology. Iliev E. **Clin Dermatol** 1998 Nov-Dec;16(6):659–88 (74 ref.)
Biofeedback, cognitive-behavioral methods, hypnosis: "alternative psychotherapy"? Panconesi E, et al. **Clin Dermatol** 1998 Nov-Dec;16(6):709–10 (3 ref.)
Biofeedback in dermatology. Sarti MG. **Clin Dermatol** 1998 Nov-Dec;16(6):711–4 (15 ref.)
Aromatherapy in dermatology. Stevensen CJ. **Clin Dermatol** 1998 Nov-Dec;16(6):689–94 (25 ref.)
High mountain climatotherapy. Tsankov NK. **Clin Dermatol** 1998 Nov-Dec;16(6):699–707 (38 ref.)
The benefits of smoking in skin diseases. Wolf R, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):641–7 (107 ref.)
Practical uses of the interferons in dermatology. Hurd DS, et al. **Int J Dermatol** 1998 Dec;37(12):881–96 (176 ref.)
Gene therapy and dermatology: more than just skin deep. Somani AK, et al. **J Cutan Med Surg** 1999 Jul;3(5):249–59 (119 ref.)
Secondarily infected wounds and dermatoses: a diagnosis and treatment guide. Bikowski J. **J Emerg Med** 1999 Jan-Feb; 17(1):197–206 (46 ref.)
Key developments in dermatology. Groves RW. **Practitioner** 1998 Apr;242(1585):288–90 (8 ref.)
Alternative medicine and dermatology. Buchness MR. **Semin Cutan Med Surg** 1998 Dec;17(4):284–90 (49 ref.)
Perspectives of photodynamic therapy for skin diseases. Colussi VC, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec;11(6):336–46 (78 ref.)
[Regulative therapy: treatment with nonspecific stimulants in dermatology in traditional and modern perspectives] Asefi M, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:9–13 (29 ref.) (Eng. Abstr.) **(Ger)**
[Current status of laser therapy in dermatology] Hellwig S, et al. **Hautarzt** 1998 Sep;49(9):690–704 (154 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic use of lasers in dermatology] Hohenleutner U, et al. **Ther Umsch** 1999 Apr;56(4):170–5 (28 ref.) (Eng. Abstr.) **(Ger)**
[Laser therapy in dermatology] St Lautenschlager. **Ther Umsch** 1998 Aug;55(8):522–8 (22 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound of the lymph nodes and the subcutis in dermatology. Part 1] Blum A, et al. **Hautarzt** 1998 Dec; 49(12):942–9 (34 ref.) **(Ger)**

VETERINARY

Skin disease affecting the conservation of the western swamp tortoise (Pseudemydura umbrina) [see comments] Ladyman JM, et al. **Aust Vet J** 1998 Nov;76(11):743–5 (16 ref.) Comment in: Aust Vet J 1998 Nov;76(11):738.
Diet and skin disease in dogs and cats. Watson TD. **J Nutr** 1998 Dec;128(12 Suppl):2783S–2789S (26 ref.)
Pediatric dermatology. Ackerman L. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):909–20 (8 ref.)

VIROLOGY

Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Wagner M, et al. **Clin Infect Dis** 1998 Nov;27(5):1299–308 (112 ref.)
Manifestations of AIDS in the head and neck. Reisacher WR, et al. **South Med J** 1999 Jul;92(7):684–97 (66 ref.)

SKIN DISEASES, BACTERIAL

Unusual cutaneous infectious and parasitic diseases. Lemons-Estes FM, et al. **Dermatol Clin** 1999 Jan; 17(1):151–85, ix (64 ref.)
[Bacterial cutaneous infections: impetigo, furuncle, erysipelas. Etiology, diagnosis, evolution, treatment] Foulc P, et al. **Rev Prat** 1998 Mar 15;48(6):661–6 (3 ref.) **(Fre)**
[Whitlow and phlegmon of the tendon sheaths. Diagnosis, evolution, treatment] Loy S, et al. **Rev Prat** 1998 Oct 1; 48(15):1723–8 (00 ref.) **(Fre)**
[Skin and soft-tissue infections caused by Pseudomonas aeruginosa] Cainzos Fernández M. **Rev Clin Esp** 1998 Sep; 198 Suppl 2:21–4 (21 ref.) **(Spa)**

DIAGNOSIS

The spectrum of skin, mucosa and other extra-articular manifestations. Angulo J, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):649–64 (76 ref.)
[Cutaneous signs of Rickettsia and related microorganisms] Duval X, et al. **Rev Med Interne** 1998 Aug;19(8):548–57 (57 ref.) (Eng. Abstr.) **(Fre)**
[Meningococcal sepsis in 3 young men] Diet F, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):424–8 (10 ref.) (Eng. Abstr.) **(Ger)**
[Subdermal cellulitis due to E. coli with a fatal evolution (letter)] Martínez-Villalba J, et al. **Rev Clin Esp** 1998 Nov; 198(11):779–81 (8 ref.) **(Spa)**

DRUG THERAPY

Resistance to antibiotics used in dermatological practice. Espersen F. **Br J Dermatol** 1998 Dec;139 Suppl 53:4–8 (27 ref.)
The clinician's choice of antibiotics in the treatment of bacterial skin infection. Veien NK. **Br J Dermatol** 1998 Dec;139 Suppl 53:30–6 (38 ref.)
Efficacy and safety of tea tree oil as a topical antimicrobial agent. Carson CF, et al. **J Hosp Infect** 1998 Nov; 40(3):175–8 (30 ref.)
[Use and adverse reactions of local antibiotics and disinfectants on the skin] Smeenk G, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1140–3 (29 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Bacteria and the skin: clinical practice and therapy update. Thestrup-Pedersen K. **Br J Dermatol** 1998 Dec;139 Suppl 53:1–3 (15 ref.)
Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Ladhani S, et al. **Clin Microbiol Rev** 1999 Apr;12(2):224–42 (290 ref.)
Cutaneous manifestations due to Pseudomonas infection. Silvestre JF, et al. **Int J Dermatol** 1999 Jun;38(6):419–31 (76 ref.)

IMMUNOLOGY

The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. Leung DY, et al. **Br J Dermatol** 1998 Dec;139 Suppl 53:17–29 (91 ref.)
[Superantigens and their importance for inflammatory skin diseases] Olsen JV, et al. **Ugeskr Laeger** 1999 Aug 23; 161(34):4747–50 (40 ref.) (Eng. Abstr.) **(Dan)**

MICROBIOLOGY

Skin bacteriology and the role of Staphylococcus aureus in infection. Noble WC. **Br J Dermatol** 1998 Dec;139 Suppl 53:9–12 (23 ref.)

SKIN DISEASES, BULLOUS see **SKIN DISEASES, VESICULOBULLOUS**

SKIN DISEASES, FUNGAL see **DERMATOMYCOSES**

SKIN DISEASES, GENETIC

Loss of heterozygosity in human skin. Happle R. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):143–64 (265 ref.)

COMPLICATIONS

Gingival lesions in a patient with dermochondrocorneal dystrophy (François syndrome). A case report. Sardella A, et al. **J Clin Periodontol** 1998 Dec;25(12):1047–9 (9 ref.)

GENETICS

Cutaneous mosaicism of lethal mutations. Hamm H. **Am J Med Genet** 1999 Aug 6;85(4):342–5 (20 ref.)
Cytogenetic and molecular evidence for cutaneous mosaicism: the ectodermal origin of Blaschko lines. Moss C. **Am J Med Genet** 1999 Aug 6;85(4):330–3 (22 ref.)
The role of twin studies in the genetics of skin diseases. Bataille V. **Clin Exp Dermatol** 1999 Jul;24(4):286–90 (37 ref.)
Hereditary skin diseases of hemidesmosomes. Jonkman MF. **J Dermatol Sci** 1999 Jun;20(2):103–21 (191 ref.)
Hereditary diseases of desmosomes. McGrath JA. **J Dermatol Sci** 1999 Jun;20(2):85–91 (37 ref.)

PATHOLOGY

Cytogenetic and molecular evidence for cutaneous mosaicism: the ectodermal origin of Blaschko lines. Moss C. **Am J Med Genet** 1999 Aug 6;85(4):330–3 (22 ref.)

THERAPY

[Cutaneous gene therapy--perspectives of gene transfer in keratinocytes] Braun-Falco M, et al. **Hautarzt** 1998 Jul; 49(7):536-44 (55 ref.) (Eng. Abstr.) **(Ger)**

SKIN DISEASES, INFECTIOUS

Disseminated cutaneous rhinosporidiosis. Thappa DM, et al. **J Dermatol** 1998 Aug;25(8):527-32 (26 ref.)

Diagnosing imported rashes and skin lesions. McCarron B. **Practitioner** 1998 May;242(1586):366-8, 371, 374 passim (3 ref.)

DIAGNOSIS

Disseminated cutaneous protothecosis in an immunocompromised host: a case report and literature review. Wirth FA, et al. **Cutis** 1999 Mar;63(3):185-8 (48 ref.)

[Microbiological diagnosis in dermatology. Dermatological days of Paris, 3-6 December 1997] Gangneux JP, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):362-5 (1 ref.) **(Fre)**

DRUG THERAPY

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Langtry HD, et al. **Drugs** 1998 Sep;56(3):487-515 (126 ref.)

Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Deery HG 2nd. **Infect Dis Clin North Am** 1998 Dec;12(4):935-49, vii (50 ref.)

The management of skin and skin structure infections in children, adolescents and adults: a review of empiric antimicrobial therapy. Wilson SE. **Int J Clin Pract** 1998 Sep;52(6):414-7 (15 ref.)

ETIOLOGY

[Infectious cutaneous pathology after organ transplantation] Euvrard S. **Ann Dermatol Venereol** 1998 Dec; 125(12):939-45 (37 ref.) **(Fre)**

SKIN DISEASES, PAPULOSQUAMOUS

ETIOLOGY

Acquired reactive perforating collagenosis with IgA nephropathy. Iwamoto I, et al. **J Dermatol** 1998 Sep; 25(9):597-600 (13 ref.)

PATHOLOGY

Acquired reactive perforating collagenosis with IgA nephropathy. Iwamoto I, et al. **J Dermatol** 1998 Sep; 25(9):597-600 (13 ref.)

SKIN DISEASES, PARASITIC

see related
ECTOPARASITIC INFESTATIONS

Unusual cutaneous infectious and parasitic diseases. Lemons-Estes FM, et al. **Dermatol Clin** 1999 Jan; 17(1):151-85, ix (64 ref.)

[Onchocerciasis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):455-7 (7 ref.) **(Jpn)**

DIAGNOSIS

Ectopic cutaneous schistosomiasis: report of two cases and a review of the literature. Andrade Filho J de S, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):253-7 (15 ref.)

VETERINARY

Traumatic myiasis of sheep in Europe: a review. Hall MJ. **Parassitologia** 1997 Dec;39(4):409-13 (50 ref.)

SKIN DISEASES, STAPHYLOCOCCAL see **STAPHYLOCOCCAL SKIN INFECTIONS**

SKIN DISEASES, VASCULAR

Atrophie blanche. Maessen-Visch MB, et al. **Int J Dermatol** 1999 Mar;38(3):161-72 (136 ref.)

Cutaneous small-vessel vasculitis. Lotti T, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):667-87; quiz 688-90 (218 ref.)

CONGENITAL

[Primary cerebral hemiatrophy associated with other malformations. A case report] Martí Aromir G, et al. **An Esp Pediatr** 1998 Sep;49(3):305-7 (12 ref.) **(Spa)**

DIAGNOSIS

[Mucocutaneous manifestations of dengue] Mahé A, et al. **Presse Med** 1998 Nov 28;27(37):1909-13 (35 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Steroid-responsive pleuropericarditis and livedo reticularis in an unusual case of adult-onset primary hyperoxaluria. Singh S, et al. **Am J Kidney Dis** 1999 Apr;33(4):e5 (36 ref.)

PATHOLOGY

Angiomatosis of skin with local intravascular immunoglobulin deposits, associated with monoclonal gammopathy. A potential cutaneous marker for B-chronic lymphocytic leukemia. A report of unusual case with immunohistochemical and immunofluorescence correlation and review of the literature. Salama SS, et al. **J Cutan Pathol** 1999 Apr;26(4):206-12 (32 ref.)

SKIN DISEASES, VESICULAR see **SKIN DISEASES, VESICULOBULLOUS**

SKIN DISEASES, VESICULOBULLOUS

Intercellular IgA dermatosis. Ongenae KC, et al. **Eur J Dermatol** 1999 Mar;9(2):85-94 (66 ref.)

CHEMICALLY INDUCED

Captopril-triggered linear IgA bullous dermatosis. Friedman IS, et al. **Int J Dermatol** 1998 Aug;37(8):608-12 (20 ref.)

Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Nousari HC, et al. **Medicine (Baltimore)** 1999 Jan;78(1):1-8 (34 ref.)

DIAGNOSIS

[Bullous phototoxic contact dermatitis caused by Ruta graveolens L. (garden rue), Rutaceae. Case report and review of literature] Schempp CM, et al. **Hautarzt** 1999 Jun;50(6):432-4 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Treatment of autoimmune blistering diseases. Glied M, et al. **Dermatol Clin** 1999 Apr;17(2):431-40, x (56 ref.)

Subcorneal pustular dermatosis treated with PUVA therapy. A case report and review of the literature. Bauwens M, et al. **Dermatology** 1999;198(2):203-5 (18 ref.)

ETIOLOGY

Waldenström macroglobulinemia-induced bullous dermatosis. West NY, et al. **Arch Dermatol** 1998 Sep; 134(9):1127-31 (19 ref.)

IMMUNOLOGY

Immunologic bullous diseases: blisters without a precipitating event. Lipp KE, et al. **Geriatrics** 1998 Dec;53(12):43-4, 49-53 (14 ref.)

The blistering diseases. Scott JE, et al. **Med Clin North Am** 1998 Nov;82(6):1239-83 (56 ref.)

[Autoimmune bullous skin diseases] Joly P. **Rev Med Interne** 1999 Jan;20(1):26-38 (67 ref.) (Eng. Abstr.) **(Fre)**

SKIN DISEASES, VIRAL

DIAGNOSIS

[Mucocutaneous manifestations of dengue] Mahé A, et al. **Presse Med** 1998 Nov 28;27(37):1909-13 (35 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

New antiviral agents for dermatologic disease. Carlton S, et al. **Semin Cutan Med Surg** 1998 Dec;17(4):243-55 (77 ref.)

PATHOLOGY

Herpes zoster in a 7-month-old infant: a case report and review. Elmer KB, et al. **Cutis** 1999 Apr;63(4):217-8 (8 ref.)

Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Fazel N, et al. **Dermatol Clin** 1999 Jul;17(3):521-36, viii (138 ref.)

Herpes zoster in seven disparate dermatomes (zoster multiplex): report of a case and review of the literature. Vu AQ, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):868-9 (13 ref.)

SKIN DRUG ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

SKIN ELECTRIC CONDUCTANCE see **GALVANIC SKIN RESPONSE**

SKIN FISTULA see **CUTANEOUS FISTULA**

SKIN NEOPLASMS

Malignant melanoma: a clinical review. Brown TJ, et al. **Cutis** 1999 May;63(5):275-8, 281-4 (66 ref.)

Evaluation and management of nonmelanoma skin cancer. The military perspective. Welch ML, et al. **Dermatol Clin** 1999 Jan;17(1):19-28, vii (36 ref.)

Perianal Bowen's disease and anal intraepithelial neoplasia: review of the literature. Cleary RK, et al. **Dis Colon Rectum** 1999 Jul;42(7):945-51 (48 ref.)

Malignant mesenchymoma arising in an incisional scar of the abdominal wall. Sato N, et al. **Eur J Surg Oncol** 1998 Oct; 24(5):449-50 (10 ref.)

Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Byers HR, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):717-35 (65 ref.)

Public health interventions for melanoma. Prevention, early detection, and education. Koh HK, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):903-28 (126 ref.)

Prognosis in malignant melanoma. Stadelmann WK, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):767-96, vi (92 ref.)

Microcystic adnexal carcinoma: collaborative series review and update. Friedman PM, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):225-31 (35 ref.)

Basal cell carcinoma. Burns T. **Practitioner** 1998 Oct; 242(1591):718 (0 ref.)

Primary cutaneous lymphomas other than mycosis fungoides. Gilliam AC, et al. **Semin Oncol** 1999 Jun;26(3):290-306 (107 ref.)

Mycosis fungoides and the Sézary syndrome. Kim YH, et al. **Semin Oncol** 1999 Jun;26(3):276-89 (86 ref.)

Cutaneous T-cell lymphomas. Samuelson E. **Semin Oncol Nurs** 1998 Nov;14(4):293-301 (55 ref.)

Merkel cell carcinoma: an aggressive neoplasm. Datta CK, et al. **W V Med J** 1999 May-Jun;95(3):127-9 (10 ref.)

[Merkel cell carcinoma: diagnostic and treatment] Voog E, et al. **Bull Cancer** 1999 Jul-Aug;86(7-8):625-30 (51 ref.) (Eng. Abstr.) **(Fre)**

[Melanocytic nevi] Crickx B. **Rev Prat** 1999 Apr 15; 49(8):829-32 (8 ref.) (Eng. Abstr.) **(Fre)**

[Epidermoid carcinoma] Descamps V. **Rev Prat** 1999 Apr 15;49(8):818-23 (14 ref.) (Eng. Abstr.) **(Fre)**

[Melanoma] Dréno B. **Rev Prat** 1999 Apr 15;49(8):833-7 (9 ref.) (Eng. Abstr.) **(Fre)**

[Basal cell carcinoma] Lacour JP. **Rev Prat** 1999 Apr 15; 49(8):824-8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Kaposi's disease] Lebbé C. **Rev Prat** 1999 Apr 15;49(8):843-7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Kasabach-Merrit syndrome] Suzuki S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):513-6 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay. Enzmann H, et al. **Food Chem Toxicol** 1998 Nov;36(11):979-95 (184 ref.)

Genetics of skin tumor promotion. Angel JM, et al. **Prog Exp Tumor Res** 1999;35:143-57 (45 ref.)

CLASSIFICATION

Classification of cutaneous lymphoma: a critical appraisal of recent proposals. Norton AJ. **Am J Dermatopathol** 1999 Jun;21(3):279-87 (54 ref.)

Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Russell-Jones R. **Br J Dermatol** 1998 Dec;139(6):945-9 (25 ref.)

Cutaneous lymphoma. Understanding the new classification schemes. Duncan LM. **Dermatol Clin** 1999 Jul;17(3):569-92 (125 ref.)

Classification and staging of melanoma. Gershenwald JE, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):737-65 (114 ref.)

[Importance of the new classification of primary cutaneous lymphomas elaborated by the EORTC (European Organization for Research and Treatment of Cancer) group] Wechsler J. **Ann Pathol** 1998 Oct;18(4):315-23 (45 ref.) **(Fre)**

[Dermatofibroma. A clinico-pathologic classification scheme] Zelger BG, et al. **Pathologe** 1998 Nov;19(6):412-9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous and subcutaneous soft tissue tumors] Meister P. **Verh Dtsch Ges Pathol** 1998;82:112-20 (36 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous neural neoplasms--an update] Mentzel T. **Verh Dtsch Ges Pathol** 1998;82:309-16 (56 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

The linear naevus sebaceus syndrome. van de Warrenburg BP, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):126-32 (57 ref.)

Clear cell carcinoma arising in extragonadal endometriosis in a Caeserean section scar during pregnancy [letter] Gücer F, et al. **Gynecol Oncol** 1999 May;73(2):337 (4 ref.)

Syringolymphoid hyperplasia and follicular mucinosis in a patient with cutaneous T-cell lymphoma. Tannous Z, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):303-8 (8 ref.)

A case of multiple subungual glomus tumors associated with neurofibromatosis type 1. Okada O, et al. **J Dermatol** 1999 Aug;26(8):535-7 (7 ref.)

[Diseases associated with adnexal tumors. I--Follicular tumors] Cribier B. **Ann Dermatol Venereol** 1999 Mar; 126(3):270-9 (104 ref.) **(Fre)**

[The blue rubber bleb nevus syndrome or Bean's syndrome. A rare cause of digestive hemorrhage] Silva A, et al.

Acta Med Port 1998 Dec;11(12):1131-4 (10 ref.) (Eng. Abstr.) **(Por)**

CONGENITAL

The diagnosis and treatment of common birthmarks. Brown TJ, et al. **Clin Plast Surg** 1998 Oct;25(4):509-25 (65 ref.)

DIAGNOSIS

Basal cell carcinoma of the scrotum. Esquivias Gómez JI, et al. **Australas J Dermatol** 1999 Aug;40(3):141-3 (28 ref.)

Cutaneous manifestations of cancer. Sabir S, et al. **Curr Opin Oncol** 1999 Mar;11(2):139-44 (72 ref.)

The role of screening in the management of skin cancer. Wolfe JT. **Curr Opin Oncol** 1999 Mar;11(2):123-8 (64 ref.)

Moles and melanoma. Chamlin SL, et al. **Curr Opin Pediatr** 1998 Aug;10(4):398-404 (80 ref.)

Melanoma precursors in children. Lefkowitz A, et al. **Cutis** 1999 Jun;63(6):321-4 (41 ref.)

Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Reed JA, et al. **Dermatol Clin** 1999 Jul;17(3):631-43 (108 ref.)

Metastatic basal cell carcinoma presenting as unilateral lymphedema. Christian MM, et al. **Dermatol Surg** 1998 Oct; 24(10):1151-3 (10 ref.)

Epidermal naevus syndrome and hypophosphataemic rickets: description of a patient with central nervous system anomalies and review of the literature. Olivares JL, et al. **Eur J Pediatr** 1999 Feb;158(2):103-7 (19 ref.)

Clinical recognition of melanoma and its precursors. Langley RG, et al. **Hematol Oncol Clin North Am** 1998 Aug; 12(4):699-715, v (62 ref.)

The misdiagnosis of malignant melanoma. Grant-Kels JM, et al. **J Am Acad Dermatol** 1999 Apr;40(4):539-48 (73 ref.)

A case of infantile digital fibromatosis with spontaneous regression. Kawaguchi M, et al. **J Dermatol** 1998 Aug; 25(8):523-6 (9 ref.)

Simultaneous occurrence of segmental odontomaxillary dysplasia and Becker's nevus. Jones AC, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1251-4 (17 ref.)

Merkel cell carcinoma of the cheek: a case report. Quereshy FA, et al. **J Oral Maxillofac Surg** 1999 Aug;57(8):999-1004 (30 ref.)

Skin cancer of the head and neck. Hochman M, et al. **Med Clin North Am** 1999 Jan;83(1):261-82, xii (75 ref.)

Malignant melanoma. Lang PG Jr. **Med Clin North Am** 1998 Nov;82(6):1325-58 (83 ref.)

Benign neoplasms of the skin. Pariser RJ. **Med Clin North Am** 1998 Nov;82(6):1285-307, v-vi (22 ref.)

Nonmelanoma skin cancer. Skidmore RA Jr, et al. **Med Clin North Am** 1998 Nov;82(6):1309-23, vi (55 ref.)

Early detection of cutaneous lymphoma. Abd-el-Baki J, et al. **Oncology (Huntingt)** 1998 Oct;12(10):1521-30; discussion 1532-4 (62 ref.)

Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Cerroni L, et al. **Semin Cutan Med Surg** 1999 Mar;18(1):64-70 (37 ref.)

Photodynamic diagnosis and therapy in dermatology. Fritsch C, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):358-73 (74 ref.)

[Pachydermodactyly: seven new cases] Bardazzi F, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):247-50 (42 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of immunohistochemistry to diagnosis of cutaneous tumors] Kanitakis J, et al. **Ann Dermatol Venereol** 1998 May;125(5):354-69 (143 ref.) **(Fre)**

[Pilomatrix carcinoma in an unusual location. Case report and review of the literature] Haferkamp B, et al. **Hautarzt** 1999 May;50(5):355-9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Spitz nevus and Reed nevus: simulating melanoma in adults] Paredes B, et al. **Pathologe** 1998 Nov;19(6):403-11 (39 ref.) (Eng. Abstr.) **(Ger)**

[The atypical nevus: a risk situation?] Böni R, et al. **Schweiz Med Wochenschr** 1999 Jun 5;129(22):825-32 (74 ref.) (Eng. Abstr.) **(Ger)**

[The Sézary syndrome] Ferreira F, et al. **Acta Med Port** 1998 Dec;11(12):1135-9 (11 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Castro MP, et al. **Cancer** 1999 Mar 1;85(5):1055-9 (40 ref.)

Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. MacKie RM. **Curr Opin Oncol** 1999 Mar;11(2):129-31 (15 ref.)

Current therapy of cutaneous melanoma. Mays SR, et al. **Cutis** 1999 May;63(5):293-8 (52 ref.)

Adjuvant interferon treatment for melanoma. Agarwala SS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):823-33 (24 ref.)

Systemic treatment of metastatic melanoma with chemotherapy. Green RJ, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):863-75, viii (51 ref.)

Vitamin D3 derivatives (deltanoids) in the treatment of tumor cell invasion [editorial; comment] Keski-Oja J. **J Lab Clin Med** 1999 Feb;133(2):95-7 (11 ref.) Comment on: J Lab Clin Med 1999 Feb;133(2):120-8.

[Topical photodynamic therapy in dermatology] Grob M, et al. **Ther Umsch** 1998 Aug;55(8):529-32 (11 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Proteases in cutaneous melanoma. Ferrier CM, et al. **Ann Med** 1998 Oct;30(5):431-42 (86 ref.)

EPIDEMIOLOGY

Skin cancers in organ transplant recipients. Euvrard S, et al. **Ann Transplant** 1997;2(4):28-32 (53 ref.)

Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now? Marks R. **Australas J Dermatol** 1999 Feb;40(1):1-5 (28 ref.)

Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Veness MJ, et al. **Cancer** 1999 Apr 15;85(8):1758-64 (21 ref.)

Incidence, risk factors and prevention of melanoma. MacKie RM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S3-6 (14 ref.)

Issues in the epidemiology of melanoma. Weinstock MA. **Hematol Oncol Clin North Am** 1998 Aug;12(4):681-98 (115 ref.)

Overview of the epidemiology of malignancy in immune deficiency. Mueller N. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S5-10 (23 ref.)

Multiple primary melanomas: analysis of 49 cases. Savoia P, et al. **Melanoma Res** 1998 Aug;8(4):361-6 (24 ref.)

Influence of dietary factors on actinically-induced skin cancer. Black HS. **Mutat Res** 1998 Nov 9;422(1):185-90 (31 ref.)

[Melanoma in pregnancy (see comments)] de Wit AC, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19;142(38):2087-90 (29 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2073-5. **(Dut)**

[Prevention of cutaneous melanoma] van der Rhee HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1356-9 (24 ref.) (Eng. Abstr.) **(Dut)**

[Melanoma of human skin: its epidemiology, etiology and pathogenesis] Korovin SI. **Lik Sprava** 1998 Jun;(4):46-50 (38 ref.) **(Rus)**

ETIOLOGY

Squamous cell carcinoma arising in a cutaneous epidermal cyst: case report and literature review. López-Ríos F, et al. **Am J Dermatopathol** 1999 Apr;21(2):174-7 (25 ref.)

Is the port site really at risk? Biology, mechanisms and prevention: a critical view. Allardyce RA. **Aust N Z J Surg** 1999 Jul;69(7):479-85 (83 ref.)

Cigarette smoking and skin cancer. Merimsky O, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):585-8 (32 ref.)

Alcohol intake-associated skin and mucosal cancer. Merimsky O, et al. **Clin Dermatol** 1999 Jul-Aug; 17(4):447-55 (48 ref.)

Angiosarcoma. A rare secondary malignancy after breast cancer treatment. Autio P, et al. **Eur J Dermatol** 1999 Mar; 9(2):118-21 (26 ref.)

Lymphangiosarcoma of the pubic region: a rare complication arising in congenital non-hereditary lymphedema. Cerri A, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):511-4 (26 ref.)

Relevance of photo-immunosuppression for viral infections (i.e. human papilloma virus). Vermeer BJ, et al. **Eur J Dermatol** 1998 Apr-May;8(3):205-6 (12 ref.)

Melanoma and sun exposure: where are we now? Whiteman DC, et al. **Int J Dermatol** 1999 Jul;38(7):481-9 (99 ref.)

Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. Antley CA, et al. **J Cutan Pathol** 1999 Jan;26(1):48-50 (11 ref.)

Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature. Chuang TY, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):126-32 (42 ref.)

UV-induced mutations and skin cancer: how important is the link? Bridges BA. **Mutat Res** 1998 Nov 9;422(1):23-30 (38 ref.)

The pathogenesis of melanoma induced by ultraviolet radiation. Gilchrest BA, et al. **N Engl J Med** 1999 Apr 29;340(17):1341-8 (94 ref.)

The relationship of pregnancy, hormones, and melanoma. Grin CM, et al. **Semin Cutan Med Surg** 1998 Sep; 17(3):167-71 (44 ref.)

Photochemical genotoxicity and photochemical carcinogenesis--two sides of a coin? Müller L, et al. **Toxicol Lett** 1998 Dec 28;102-103:383-7 (18 ref.)

[Physiopathology of nevi and nevocytes] Grob JJ, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):860-7 (79 ref.) **(Fre)**

[Cancer in patients infected with the human immunodeficiency virus. The unusual aspects] Peyrade F, et al. **Presse Med** 1999 Apr 17;28(15):809-14 (39 ref.) (Eng. Abstr.) **(Fre)**

[Skin cancers and environmental factors] Autier P. **Rev Med Brux** 1998 Sep;19(4):A346-50 (20 ref.) (Eng. Abstr.) **(Fre)**

[Photoprotection, cancer protection and solar protection factor] Heenen M. **Rev Med Brux** 1999 Jun;20(3):143-6 (42 ref.) (Eng. Abstr.) **(Fre)**

[UV-induced immunosuppression and skin cancers] Meunier L, et al. **Rev Med Interne** 1998 Apr;19(4):247-54 (72 ref.) (Eng. Abstr.) **(Fre)**

[Skin carcinogenesis] Soufir N, et al. **Rev Prat** 1999 Apr 15; 49(8):813-7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenesis of malignant melanoma. Molecular biology aspect] Waldmann V, et al. **Hautarzt** 1999 Jun; 50(6):398-405 (62 ref.) (Eng. Abstr.) **(Ger)**

[Risk factors for the development of malignant melanomas] Itin PH. **Ther Umsch** 1999 Jun;56(6):298-301 (18 ref.) (Eng. Abstr.) **(Ger)**

[Photo-aging] Paredes BE, et al. **Ther Umsch** 1999 Apr; 56(4):188-93 (23 ref.) (Eng. Abstr.) **(Ger)**

[Sun and skin] Gelmetti C. **Minerva Pediatr** 1998 Jun; 50(6):283-7 (37 ref.) **(Ita)**

[Melanoma of human skin: its epidemiology, etiology and pathogenesis] Korovin SI. **Lik Sprava** 1998 Jun;(4):46-50 (38 ref.) **(Rus)**

GENETICS

Concept of twin spotting. Koopman RJ. **Am J Med Genet** 1999 Aug 6;85(4):355-8 (24 ref.)

Paradominant inheritance, a hypothesis explaining occasional familial occurrence of sporadic syndromes. Steijlen PM, et al. **Am J Med Genet** 1999 Aug 6;85(4):359-60 (14 ref.)

Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma. Bullock GJ, et al. **Am J Surg** 1999 Jan;177(1):15-8 (39 ref.)

Multiple pilomatrixomata and myotonic dystrophy: a familial association. Geh JL, et al. **Br J Plast Surg** 1999 Mar; 52(2):143-5 (17 ref.)

Skin precancer. Brash DE, et al. **Cancer Surv** 1998;32:69-113 (232 ref.)

The genetics of melanoma: the UK experience. Newton Bishop JA, et al. **Clin Exp Dermatol** 1998 Jul;23(4):158-61 (23 ref.)

Genetic predisposition to skin cancer. Halpern AC, et al. **Curr Opin Oncol** 1999 Mar;11(2):132-8 (49 ref.)

Loss of heterozygosity in human skin. Happle R. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):143-64 (265 ref.)

T-cell receptor gene analysis in the diagnosis of Sézary syndrome. Russell-Jones R, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):254-9 (53 ref.)

Effect of aging on DNA repair and skin carcinogenesis: a minireview of population-based studies. Wei Q. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):19-22 (63 ref.)

Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. Graadt van Roggen JF, et al. **J Pathol** 1998 Sep;186(1):3-7 (43 ref.)

Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Fusenig NE, et al. **Mol Carcinog** 1998 Nov;23(3):144-58 (78 ref.)

ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Rodriguez-Puebla ML, et al. **Mol Carcinog** 1999 Jan;24(1):1-6 (61 ref.)

Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. van Steeg H, et al. **Mol Med Today** 1999 Feb;5(2):86-94 (53 ref.)

Genetics of skin tumor promotion. Angel JM, et al. **Prog Exp Tumor Res** 1999;35:143-57 (45 ref.)

Cancer predisposition in mutant mice defective in the XPC DNA repair gene. Friedberg EC, et al. **Prog Exp Tumor Res** 1999;35:37-52 (45 ref.)

Molecular staging for melanoma and breast cancer. Shivers SC, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):515-26 (41 ref.)

[Microdissection. Use in molecular oncologic dermatology] Böni R, et al. **Hautarzt** 1999 Feb;50(2):98-102 (20 ref.) (Eng. Abstr.) **(Ger)**

[MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma] Bosserhoff AK, et al. **Hautarzt** 1998 Oct;49(10):762-9 (17 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis of malignant melanoma. Molecular biology aspect] Waldmann V, et al. **Hautarzt** 1999 Jun; 50(6):398-405 (62 ref.) (Eng. Abstr.) **(Ger)**

[Cytogenetic aspects of malignant melanoma] Böni R, et al. **Ther Umsch** 1999 Jun;56(6):309-11 (14 ref.) (Eng. Abstr.) **(Ger)**

[Genetic basis of malignant melanoma] Drewa G, et al. **Postepy Hig Med Dosw** 1998;52(4):367-80 (78 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Antitumor immunity at work in a melanoma patient. Coulie PG, et al. **Adv Cancer Res** 1999;76:213-42 (69 ref.)

Cytokines and cutaneous T-cell lymphomas. Asadullah K, et al. **Exp Dermatol** 1998 Dec;7(6):314-20 (64 ref.)

Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB. **Hematol Oncol Clin North Am** 1998 Aug;12(4):877-902, viii (149 ref.)

METABOLISM

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Fritsch C, et al. **Br J Cancer** 1999 Mar;79(9-10):1603-8 (36 ref.)

Upregulation of E2F transcription factors in chemically induced mouse skin tumors. Balasubramanian S, et al. **Int J Oncol** 1999 Aug;15(2):387-90 (25 ref.)

MICROBIOLOGY

[Infection and angiomatous cutaneous lesions] Janier M. **J Mal Vasc** 1999 May;24(2):135–8 (14 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Metastasis to skin. Manning MP. **Semin Oncol Nurs** 1998 Aug;14(3):240–3 (13 ref.)

PATHOLOGY

Naevi spili, Café-au-lait spots and melanocytic naevi aggregated alongside Blaschko's lines, with a review of segmental melanocytic lesions. Langenbach N, et al. **Acta Derm Venereol** 1998 Sep;78(5):378–80 (22 ref.)

Discordance between DNA analysis and the clinical picture in a case of xeroderma pigmentosum [letter] Tessari G, et al. **Acta Derm Venereol** 1999 Jan;79(1):94–5 (4 ref.)

Detection of human papilloma virus type 56 in extragenital Bowen's disease. Uezato H, et al. **Acta Derm Venereol** 1999 Jul;79(4):311–3 (18 ref.)

Tumor progression, early diagnosis and prognosis of melanoma. Elder D. **Acta Oncol** 1999;38(5):535–47 (124 ref.)

Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Beham A, et al. **Adv Anat Pathol** 1998 Sep;5(5):269–80 (91 ref.)

Melan-A, a new melanocytic differentiation marker. Busam KJ, et al. **Adv Anat Pathol** 1999 Jan;6(1):12–8 (27 ref.)

Molecular pathology of malignant melanoma. Slominski A, et al. **Am J Clin Pathol** 1998 Dec;110(6):788–94 (136 ref.)

Subungual malignant melanoma with cartilaginous differentiation. Cachia AR, et al. **Am J Dermatopathol** 1999 Apr;21(2):165–9 (15 ref.)

The melanocyte differentiation pathway in spitz nevi. Cramer SF. **Am J Dermatopathol** 1998 Dec;20(6):555–70 (218 ref.)

Atrophic and plaquelike dermatofibrosarcoma protuberans. Davis DA, et al. **Am J Dermatopathol** 1998 Oct; 20(5):498–501 (28 ref.)

Acrochordons are not a component of the Birt–Hogg–Dubé syndrome: does this syndrome exist? Case reports and review of the literature. De la Torre C, et al. **Am J Dermatopathol** 1999 Aug;21(4):369–74 (65 ref.)

Histopathologic diagnosis of superficial soft tissue tumors, related lesions, and simulators: an algorithmic approach based on colors. Diaz-Cascajo C. **Am J Dermatopathol** 1999 Apr;21(2):193–9 (4 ref.)

Epithelioid cell histiocytoma: a simulant of vascular and melanocytic neoplasms. Glusac EJ, et al. **Am J Dermatopathol** 1999 Feb;21(1):1–7 (23 ref.)

Pigmented squamous cell carcinoma of the skin: report of two cases and review of the literature [published erratum appears in Am J Dermatopathol 1999 Jun;21(3):310] Jurado I, et al. **Am J Dermatopathol** 1998 Dec;20(6):578–81 (11 ref.)

Primary cutaneous adenoid cystic carcinoma with lymph node metastasis [see comments] Kato N, et al. **Am J Dermatopathol** 1998 Dec;20(6):571–7 (43 ref.) Comment in: Am J Dermatopathol 1999 Aug;21(4):400.

Epithelioid hemangioendothelioma presenting in the skin: a clinicopathologic study of eight cases. Quante M, et al. **Am J Dermatopathol** 1998 Dec;20(6):541–6 (33 ref.)

CD34 and factor XIIIa-positive microvascular dendritic cells and the family of fibrohistiocytic mesenchymal tumors [letter; comment] Silverman JS, et al. **Am J Dermatopathol** 1998 Oct;20(5):533–6 (39 ref.) Comment on: Am J Dermatopathol 1996 Jun;18(3):283–8. Comment on: Am J Dermatopathol 1998 Jun;20(3):317–22.

Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature. Te HS, et al. **Am J Gastroenterol** 1999 Jan;94(1):262–6 (40 ref.)

Concept of twin spotting. Koopman RJ. **Am J Med Genet** 1999 Aug 6;85(4):355–8 (24 ref.)

Pancreaticoduodenectomy for melanoma metastatic to the duodenum: a case report and review of the literature. Meyers MO, et al. **Am Surg** 1998 Dec;64(12):1174–6 (15 ref.)

Malignant transformation of a giant proliferating trichilemmal tumor of the scalp: patient report and literature review. Markal N, et al. **Ann Plast Surg** 1998 Sep;41(3):314–6 (18 ref.)

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Congenital malignant rhabdoid tumor presenting as a cutaneous nodule: report of 2 cases with review of the literature. Hsueh C, et al. **Arch Pathol Lab Med** 1998 Dec; 122(12):1099–102 (16 ref.)

Systemic mastocytosis and other mast cell neoplasms. Bain BJ. **Br J Haematol** 1999 Jul;106(1):9–17 (61 ref.)

Cutaneous lesions of metastatic visceral malignancy mimicking pyogenic granuloma. Hager CM, et al. **Cancer Invest** 1999;17(6):385–90 (22 ref.)

Imaging of abdominal manifestations of melanoma. Kamel IR, et al. **Crit Rev Diagn Imaging** 1998 Dec;39(6):447–86 (24 ref.)

Metastatic basal cell carcinoma to the lung. Berti JJ, et al. **Cutis** 1999 Mar;63(3):165–6 (12 ref.)

Amelanotic lentigo maligna melanoma: report of a case and review of the literature. Rocamora V, et al. **Cutis** 1999 Jul;64(1):53–6 (33 ref.)

Fine needle aspiration (FNA) cytology of pilomatrixoma: report of 14 cases and review of the literature. Viero RM, et al. **Cytopathology** 1999 Aug;10(4):263–9 (20 ref.)

Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria. Glusac EJ, et al. **Dermatol Clin** 1999 Jul;17(3):601–14, ix (71 ref.)

Histopathologic and immunohistochemical diagnosis of benign and malignant fibrous and fibrohistiocytic tumors of the skin. Kamino H, et al. **Dermatol Clin** 1999 Jul; 17(3):487–505, vii (53 ref.)

Use of the polymerase chain reaction in the evaluation of cutaneous T-cell infiltrates. Kohler S, et al. **Dermatol Clin** 1999 Jul;17(3):657–66, x (33 ref.)

Selected cutaneous vascular neoplasms. A review. Prieto VG, et al. **Dermatol Clin** 1999 Jul;17(3):507–20, viii (100 ref.)

Morphologic spectrum of cutaneous B-cell lymphomas. Sander CA, et al. **Dermatol Clin** 1999 Jul;17(3):593–9, ix (46 ref.)

Recognition and management of high-risk cutaneous tumors. Schoelch SB, et al. **Dermatol Clin** 1999 Jan;17(1):93–111, viii–ix (104 ref.)

Recent developments in the pathology of melanocytic neoplasia. Shea CR, et al. **Dermatol Clin** 1999 Jul; 17(3):615–30, ix (81 ref.)

Sentinel lymphadenectomy in the management of primary cutaneous malignant melanoma. An update. White WL, et al. **Dermatol Clin** 1999 Jul;17(3):645–55, ix–x (33 ref.)

Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature. Bullen R, et al. **Dermatol Surg** 1998 Oct; 24(10):1105–10 (35 ref.)

Spindle cell lipoma of the scalp: a case report and review. Haas AF, et al. **Dermatol Surg** 1999 Jan;25(1):68–71 (30 ref.)

Linear basal cell carcinoma: report of seventeen cases and review of the presentation and treatment. Lim KK, et al. **Dermatol Surg** 1999 Jan;25(1):63–7 (13 ref.)

Pilomatricoma in elderly individuals. Behnke N, et al. **Dermatology** 1998;197(4):391–3 (23 ref.)

Type 2 segmental manifestation of multiple glomus tumors: A review and reclassification of 5 case reports. Happle R, et al. **Dermatology** 1999;198(3):270–2 (11 ref.)

Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Quaglino P, et al. **Dermatology** 1999;199(1):8–14 (41 ref.)

Pilomatrix carcinoma with multiple metastases: report of a case and review of the literature. Bremnes RM, et al. **Eur J Cancer** 1999 Mar;35(3):433–7 (44 ref.)

Simulators of malignant melanoma of the skin. Cerroni L, et al. **Eur J Dermatol** 1998 Sep;8(6):388–96 (67 ref.)

Granulomatous mycosis fungoides. Telle H, et al. **Eur J Dermatol** 1998 Oct–Nov;8(7):506–10 (29 ref.)

Sentinel lymph node detection and imaging. Keshtgar MRS, et al. **Eur J Nucl Med** 1999 Jan;26(1):57–67 (28 ref.)

The sentinel node procedure in cutaneous melanoma: an overview of 6 years' experience. Statius Muller MG, et al. **Eur J Nucl Med** 1999 Apr;26(4 Suppl):S20–5 (52 ref.)

Intraocular metastases of cutaneous malignant melanoma: a case report and review of the literature. Ramaesh K, et al. **Eye** 1999 Apr;13 (Pt 2):247–50 (24 ref.)

Classification and staging of melanoma. Gershenwald JE, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):737–65 (114 ref.)

Systemic treatment of metastatic melanoma with chemotherapy. Green RJ, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):863–75, viii (51 ref.)

Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Reintgen DS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):807–21, vii (41 ref.)

Cutaneous melanoma: diagnosis and at risk patients. Hall PN, et al. **Hosp Med** 1998 Nov;59(11):866–71 (21 ref.)

Recognition and evaluation of cytological dysplasia in acquired melanocytic nevi. Murphy GF, et al. **Hum Pathol** 1999 May;30(5):506–12 (31 ref.)

Dimensionalities: borderline and intermediate melanocytic neoplasia. Reed RJ. **Hum Pathol** 1999 May;30(5):521–4 (16 ref.)

Malignant pilomatricoma: a case report. Waxtein L, et al. **Int J Dermatol** 1998 Jul;37(7):538–40 (14 ref.)

Sentinel node localisation: A new prospective in the treatment of nodal melanoma metastases. Gennari R, et al. **Int J Oncol** 1999 Jul;15(1):25–32 (36 ref.)

Merkel cell tumor: two cases. Simstein NL, et al. **Int Surg** 1998 Jan–Mar;83(1):60–2 (14 ref.)

Targetoid hemosiderotic hemangioma- a dynamic vascular tumor: report of 3 cases with episodic and cyclic changes and comparison with solitary angiokeratomas. Carlson JA, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):215–24 (51 ref.)

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. Cather JC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):858–63 (54 ref.)

Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. Glass FL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):603–10 (64 ref.)

Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. Tomaszewski MM, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):857–61 (21 ref.)

Basal cell carcinoma: what dentists need to know [see comments] Rishiraj B, et al. **J Am Dent Assoc** 1999 Mar; 130(3):375–80 (28 ref.) Comment in: J Am Dent Assoc 1999 May;130(5):624, 627.

Phacomatosis pigmentovascularis type IIb associated with Sturge-Weber syndrome and pyogenic granuloma. Hagiwara K, et al. **J Dermatol** 1998 Nov;25(11):721–9 (26 ref.)

Adenocarcinoma with signet ring cells of the axilla: two case reports and review of the literature. Kuno Y, et al. **J Dermatol** 1999 Jun;26(6):390–5 (16 ref.)

Osteo-nevus of Nanta: a case report and review of the Japanese literature. Sasaki S, et al. **J Dermatol** 1999 Mar; 26(3):183–8 (32 ref.)

Paget's disease arising near a male areola without an underlying carcinoma. Takeuchi T, et al. **J Dermatol** 1999 Apr;26(4):248–52 (28 ref.)

A case of superficial leiomyosarcoma, and a review of Japanese cases. Wakasugi S, et al. **J Dermatol** 1998 Sep; 25(9):606–11 (16 ref.)

Fibromyxoma of the skin. Watanabe T, et al. **J Dermatol** 1998 Nov;25(11):754–5 (12 ref.)

Mucocutaneous paraneoplastic syndromes (MCPS). A clinical-pathologic review. Silvestris N, et al. **J Exp Clin Cancer Res** 1998 Dec;17(4):453–64 (58 ref.)

Acantholytic squamous cell carcinoma of skin--a case report. Rahman SB, et al. **JPMA J Pak Med Assoc** 1998 Sep; 48(9):283–5 (16 ref.)

Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Fusenig NE, et al. **Mol Carcinog** 1998 Nov;23(3):144–58 (78 ref.)

ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Rodriguez-Puebla ML, et al. **Mol Carcinog** 1999 Jan;24(1):1–6 (61 ref.)

Management of the neck in nonmelanocytic cutaneous carcinomas. Brown RO, et al. **Otolaryngol Clin North Am** 1998 Oct;31(5):841–56 (32 ref.)

Role of interleukin-8 in tumor growth and metastasis of human melanoma. Bar-Eli M. **Pathobiology** 1999;67(1):12–8 (66 ref.)

Melanoma in childhood: review and perspectives. Spatz A, et al. **Pediatr Dev Pathol** 1998 Nov-Dec;1(6):463–74 (122 ref.)

'Is this mole all right'? Jackson A. **Practitioner** 1998 Apr; 242(1585):254–6, 260–2, 264 passim (7 ref.)

Childhood melanoma. Barnhill RL. **Semin Diagn Pathol** 1998 Aug;15(3):189–94 (8 ref.)

Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Carney JA, et al. **Semin Diagn Pathol** 1998 Aug;15(3):216–24 (15 ref.)

Malicious masquerade: myxoid melanoma. Hitchcock MG, et al. **Semin Diagn Pathol** 1998 Aug;15(3):195–202 (56 ref.)

Ancient melanocytic nevus. Kerl H, et al. **Semin Diagn Pathol** 1998 Aug;15(3):210–5 (15 ref.)

Pagetoid melanocytosis: tease or tocsin? Stern JB, et al. **Semin Diagn Pathol** 1998 Aug;15(3):225–9 (16 ref.)

Tumors of the skin composed of large cells with abundant eosinophilic cytoplasm. Suster S. **Semin Diagn Pathol** 1999 May;16(2):162–77 (78 ref.)

Dying dogma: the pathological diagnosis of epidermotropic metastatic malignant melanoma. White WL, et al. **Semin Diagn Pathol** 1998 Aug;15(3):176–88 (72 ref.)

Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Edwards MJ, et al. **Surg Oncol** 1998 Jul-Aug;7(1–2):51–7 (26 ref.)

Lymphoscintigraphy in malignant melanoma and breast cancer. Berman CG, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):401–12, vii (22 ref.)

Radioguided surgery for melanoma. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):413–26, vii (29 ref.)

Lymphatic mapping and sentinel lymph node biopsy for nonmelanoma skin cancers. Pu LL, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):527–39, x (25 ref.)

[Epithelial skin tumors. Anatomo-pathological reminders] Verola O. **Ann Chir Plast Esthet** 1998 Aug;43(4):301–10 (2 ref.) (Eng. Abstr.) **(Fre)**

[Linear and whorled nevoid hypermelanosis: report of two cases] Claudel P, et al. **Arch Pediatr** 1998 Oct; 5(10):1098–102 (22 ref.) (Eng. Abstr.) **(Fre)**

[Benign tumors of the skin and its appendages] Grosshans E. **Rev Prat** 1999 Apr 15;49(8):848–51 (8 ref.) (Eng. Abstr.) **(Fre)**

[Malignant melanoma. Epidemiology, screening, diagnosis, evolution, prognostic clinical and histopathologic criteria] Roudier-Pujol C, et al. **Rev Prat** 1998 Oct 1;48(15):1729–35 (3 ref.) **(Fre)**

[Trichoadenoma of Nikolowski--review of four decades and seven new cases] Reibold R, et al. **Hautarzt** 1998 Dec; 49(12):925–8 (20 ref.) (Eng. Abstr.) **(Ger)**

[The skin biopsy] Weyers W, et al. **Hautarzt** 1999 Feb; 50(2):145–58 (22 ref.) **(Ger)**

[Cutaneous neural neoplasms--an update] Mentzel T. **Pathologe** 1999 Mar;20(2):98–109 (65 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous and subcutaneous soft tissue tumors] Meister P. **Verh Dtsch Ges Pathol** 1998;82:112–20 (36 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous neural neoplasms--an update] Mentzel T.

Verh Dtsch Ges Pathol 1998;82:309–16 (56 ref.) (Eng. Abstr.) **(Ger)**

[A skin lymphoepithelial tumor (skin lymphadenoma)] Baptista AP, et al. **Acta Med Port** 1998 Jun;11(6):555–8 (21 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

[Physiopathology of nevi and nevocytes] Grob JJ, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):860–7 (79 ref.) **(Fre)**

[Angiomas and major tissue dysplasias. Pathogenic origins and management] Hamel-Teillac D. **Arch Pediatr** 1999;6 Suppl 2:299s–302s (22 ref.) **(Fre)**

PREVENTION & CONTROL

Ultraviolet radiation exposure in children: a review of measurement strategies. Creech LL, et al. **Ann Behav Med** 1998 Fall;19(4):399–407 (83 ref.)

Is the port site really at risk? Biology, mechanisms and prevention: a critical view. Allardyce RA. **Aust N Z J Surg** 1999 Jul;69(7):479–85 (83 ref.)

Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now? Marks R. **Australas J Dermatol** 1999 Feb;40(1):1–5 (28 ref.)

Do sunscreens prevent skin cancer? **Drug Ther Bull** 1998 Jul;36(7):49–51 (18 ref.)

Skin cancer prevention for children: a critical review. Buller DB, et al. **Health Educ Behav** 1999 Jun;26(3):317–43 (52 ref.)

Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. Ananthaswamy HN, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):52–6 (71 ref.)

Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. Birt DF, et al. **J Nutr** 1999 Feb;129(2S Suppl):571S–574S (15 ref.)

Clinical implications of the new biology in the development of melanoma vaccines. Hemmila MR, et al. **J Surg Oncol** 1999 Apr;70(4):263–74 (98 ref.)

Melanoma vaccines as a therapeutic option. McGee JM, et al. **South Med J** 1999 Jul;92(7):698–704 (54 ref.)

[Prevention of cutaneous melanoma] van der Rhee HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1356–9 (24 ref.) (Eng. Abstr.) **(Dut)**

[Sunscreening creams] Leroy D. **Ann Dermatol Venereol** 1999 Apr;126(4):357–63 (60 ref.) **(Fre)**

[Photoprotection, cancer protection and solar protection factor] Heenen M. **Rev Med Brux** 1999 Jun;20(3):143–6 (42 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of skin cancers] Grob JJ, et al. **Rev Prat** 1999 Apr 15;49(8):838–42 (17 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of malignant melanoma] Blum A, et al. **Hautarzt** 1998 Nov;49(11):826–34 (54 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of ultraviolet ray damage: external and internal sunscreens] Grundmann JU, et al. **Ther Umsch** 1999 Apr; 56(4):225–32 (48 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Melanoma patients: psychosocial stress, coping with illness and social support. A systematic review] Söllner W, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):338–48 (62 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Sentinel lymph node biopsy using lymphoscintigraphy [see comments] Hader D, et al. **AORN J** 1998 Oct;68(4):572–6, 579–82, 585–8; quiz 589–94 (22 ref.) Comment in: AORN J 1999 Jan;69(1):21.

Use of sentinel node lymphoscintigraphy in malignant melanoma. Yudd AP, et al. **Radiographics** 1999 Mar–Apr; 19(2):343–53; discussion 354–6 (21 ref.)

[Contribution of nuclear medicine to lymphatic mapping and sentinel node identification in oncology] Valdés Olmos RA, et al. **Rev Esp Med Nucl** 1999;18(2):111–21 (48 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature. Bullen R, et al. **Dermatol Surg** 1998 Oct; 24(10):1105–10 (35 ref.)

The evolution of the role of radiation therapy in the management of mucocutaneous malignant melanoma. Cooper JS. **Hematol Oncol Clin North Am** 1998 Aug; 12(4):849–62, vii (58 ref.)

[Radiotherapy and skin tumors] Calitchi E, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):556–65 (64 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Cutaneous lesions of metastatic visceral malignancy mimicking pyogenic granuloma. Hager CM, et al. **Cancer Invest** 1999;17(6):385–90 (22 ref.)

Cutaneous metastatic adenocarcinoma of gallbladder origin: report of a case and review of the literature. Bardaji M, et al. **Hepatogastroenterology** 1998 Jul–Aug;45(22):930–1 (5 ref.)

Metastasis to skin. Manning MP. **Semin Oncol Nurs** 1998 Aug;14(3):240–3 (13 ref.)

Papillary and follicular thyroid carcinoma metastatic to the skin: a case report and review of the literature. Koller EA, et al. **Thyroid** 1998 Nov;8(11):1045–50 (33 ref.)

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237–9 (12 ref.) **(Fre)**

SURGERY

Epidermal nevus syndrome: a review and case report. Losee JE, et al. **Ann Plast Surg** 1999 Aug;43(2):211–4 (9 ref.)

A rare case of atypical eccrine acrospiroma of the scalp and a literature review. Wilhelmi BJ, et al. **Ann Plast Surg** 1999 May;42(5):568–9 (13 ref.)

Basal cell carcinoma of the scrotum. Esquivias Gómez JI, et al. **Australas J Dermatol** 1999 Aug;40(3):141–3 (28 ref.)

Surgical treatment of lentigo maligna and lentigo maligna melanoma. Hill DC, et al. **Australas J Dermatol** 1999 Feb; 40(1):25–30 (16 ref.)

Mohs' micrographic surgery for basal cell carcinoma. Lawrence CM. **Clin Exp Dermatol** 1999 Mar;24(2):130–3 (57 ref.)

Current therapy of cutaneous melanoma. Mays SR, et al. **Cutis** 1999 May;63(5):293–8 (52 ref.)

High-risk nonmelanoma skin cancers. Demetrius RW, et al. **Dermatol Surg** 1998 Dec;24(12):1272–92; quiz 1293–4 (79 ref.)

Spindle cell lipoma of the scalp: a case report and review. Haas AF, et al. **Dermatol Surg** 1999 Jan;25(1):68–71 (30 ref.)

Linear basal cell carcinoma: report of seventeen cases and review of the presentation and treatment. Lim KK, et al. **Dermatol Surg** 1999 Jan;25(1):63–7 (13 ref.)

Multifocal angiosarcoma of the scalp: a case report and review of the literature. Kacker A, et al. **Ear Nose Throat J** 1999 Apr;78(4):302–5 (14 ref.)

Comments on Management of cutaneous melanoma M0: state of the art and trends, Rossi et al., Eur J Cancer 1997, 33, 2302–2312 [letter; comment] Bartoli C, et al. **Eur J Cancer** 1998 Aug;34(9):1467–8 (5 ref.) Comment on: Eur J Cancer 1997 Dec;33(14):2302–12.

The surgical treatment of primary melanoma. McCarthy WH, et al. **Hematol Oncol Clin North Am** 1998 Aug; 12(4):797–805, vi (20 ref.)

Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Reintgen DS, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):807–21, vii (41 ref.)

Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. Glass FL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):603–10 (64 ref.)

Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? Morton DL, et al. **J Am Coll Surg** 1999 Aug; 189(2):214–23 (93 ref.)

The role of elective lymph node dissection in malignant melanoma: who should undergo this nodal staging procedure? Reintgen D. **J Am Coll Surg** 1999 Aug; 189(2):224–32 (22 ref.)

Melanoma during pregnancy: a case report and review of the literature. Teplitzky S, et al. **J La State Med Soc** 1998 Nov;150(11):539–43 (19 ref.)

Melanoma resection margin recommendations, unconventionally based on available facts. Piepkorn M. **Semin Diagn Pathol** 1998 Aug;15(3):230–4 (50 ref.)

Historical perspectives and future applications. Haddad FF, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):391–400, vii (47 ref.)

[Sentinel node--malignant melanoma and primary breast cancer. The significance of sentinel node in the treatment of malignant melanoma and primary breast cancer] Axelsson CK, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2343–7 (40 ref.) (Eng. Abstr.) **(Dan)**

[Cutaneous and subcutaneous sarcomas] Champeau F, et al. **Ann Chir Plast Esthet** 1998 Aug;43(4):421–38 (33 ref.) (Eng. Abstr.) **(Fre)**

[Facial epitheliomas: general considerations, surgical techniques and indications] Martin D, et al. **Ann Chir Plast Esthet** 1998 Aug;43(4):311–64 (142 ref.) (Eng. Abstr.) **(Fre)**

[Sentinel lymphadenectomy in malignant melanoma] Büchels HK, et al. **Chirurg** 1998 Jul;69(7):701–7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Case report of epithelioid hemangioendothelioma of the frontal region metastatic to the parotid gland] Schneider B, et al. **Laryngorhinootologie** 1998 Dec;77(12):728–31 (27 ref.) (Eng. Abstr.) **(Ger)**

[Surgical treatment of malignant melanoma] Bösch U, et al. **Ther Umsch** 1999 Jun;56(6):318–23 (28 ref.) (Eng. Abstr.) **(Ger)**

[Merkel-cell carcinoma. A report of 3 clinical cases] Del Rio P, et al. **Minerva Chir** 1999 Mar;54(3):179–83 (14 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Moles and melanoma. Chamlin SL, et al. **Curr Opin Pediatr** 1998 Aug;10(4):398–404 (80 ref.)

Recognition and management of high-risk cutaneous tumors. Schoelch SB, et al. **Dermatol Clin** 1999 Jan;17(1):93–111, viii–ix (104 ref.)

Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eggermont AM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S22–6 (47 ref.)

Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB. **Hematol Oncol Clin North Am** 1998 Aug;12(4):877–902, viii (149 ref.)

Vaccines and other adjuvant therapies for melanoma. Wolchok JD, et al. **Hematol Oncol Clin North Am** 1998 Aug;12(4):835–48, vii (67 ref.)

Therapeutic trends in cutaneous melanoma. Hall PN, et al. **Hosp Med** 1999 Jan;60(1):39–43 (22 ref.)

Immune and gene therapy for melanoma, and the immunobiology of melanoma. Smith KJ, et al. **Int J Dermatol** 1999 Jul;38(7):490–508 (123 ref.)

[Palliative care for cancer patients with refractory ulcerating malignant skin tumors and skin metastases] van Leeuwen BL, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):561–4 (11 ref.) (Eng. Abstr.) **(Dut)**

[Angiomas and major tissue dysplasias. Pathogenic origins and management] Hamel-Teillac D. **Arch Pediatr** 1999;6 Suppl 2:299s–302s (22 ref.) **(Fre)**

[Managing cutaneous melanoma] Thomas L, et al. **Cancer Radiother** 1998 Dec;2(6):732–46 (256 ref.) (Eng. Abstr.) **(Fre)**

[Is interleukin 2 useful in oncology?] Négrier S. **Rev Prat** 1998 Feb 1;48(3):237–9 (12 ref.) **(Fre)**

[Current status of laser therapy in dermatology] Hellwig S, et al. **Hautarzt** 1998 Sep;49(9):690–704 (154 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of cutaneous melanoma] Dummer R, et al. **Ther Umsch** 1998 Aug;55(8):509–14 (13 ref.) (Eng. Abstr.) **(Ger)**

[Systemic therapy of metastatic melanoma] Dummer R, et al. **Ther Umsch** 1999 Jun;56(6):330–3 (8 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of non-melanocytic skin tumors] Hafner J. **Ther Umsch** 1998 Aug;55(8):515–21 (8 ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant therapy of malignant melanoma] Hauschild A, et al. **Ther Umsch** 1999 Jun;56(6):324–9 (26 ref.) (Eng. Abstr.) **(Ger)**

[Therapeutic use of lasers in dermatology] Hohenleutner U, et al. **Ther Umsch** 1999 Apr;56(4):170–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Laser therapy in dermatology] St Lautenschlager. **Ther Umsch** 1998 Aug;55(8):522–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Skin cancer melanoma] Ishihara K. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:173–84 (23 ref.) (Eng. Abstr.) **(Jpn)**

[The treatment of malignant melanoblastoma of the skin] Korovin SI. **Lik Sprava** 1998 Jul–Aug;(5):41–6 (43 ref.) **(Rus)**

VETERINARY

The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Modiano JF, et al. **J Vet Intern Med** 1999 May–Jun;13(3):163–74 (138 ref.)

Equine sarcoids. Goodrich L, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):607–23, vii (86 ref.)

Dermatologic tumors (excluding sarcoids). Johnson PJ. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):625–58, viii (218 ref.)

Intralesional and topical chemotherapy and immunotherapy. Théon AP. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):659–71, viii (35 ref.)

VIROLOGY

Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Wagner M, et al. **Clin Infect Dis** 1998 Nov;27(5):1299–308 (112 ref.)

Human papillomavirus and the development of non-melanoma skin cancer. Harwood CA, et al. **J Clin Pathol** 1999 Apr;52(4):249–53 (51 ref.)

SKIN PHYSIOLOGY

Racial differences in skin function. Berardesca E. **Acta Derm Venereol Suppl (Stockh)** 1994;185:44–6 (10 ref.)

Measurement of skin pH. Dikstein S, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;185:18–20 (20 ref.)

Skin hydration: recent advances. Ozawa T, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;185:26–8 (6 ref.)

Bioengineering and the skin: from standard error to standard operating procedure. Serup J. **Acta Derm Venereol Suppl (Stockh)** 1994;185:5–8 (15 ref.)

Quantitative measurements of water concentration of the stratum corneum In vivo by high-frequency current. Tagami H. **Acta Derm Venereol Suppl (Stockh)** 1994; 185:29–33 (23 ref.)

Measurement and analysis of skin electrical impedance. Yamamoto Y. **Acta Derm Venereol Suppl (Stockh)** 1994; 185:34–8 (15 ref.)

The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin. O'Sullivan RL, et al. **Arch Dermatol** 1998 Nov;134(11):1431–5 (59 ref.)

Nitric oxide and its implications in skin homeostasis and disease - a review. Bruch-Gerharz D, et al.

Arch Dermatol Res 1998 Dec;290(12):643–51 (79 ref.)
Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Benita S.
Biomed Pharmacother 1999 May;53(4):193–206 (68 ref.)
Skin antioxidants: their role in aging and in oxidative stress--new approaches for their evaluation. Kohen R.
Biomed Pharmacother 1999 May;53(4):181–92 (76 ref.)
Preservation of human skin structure and function in organ culture. Varani J. **Histol Histopathol** 1998 Jul;13(3):775–83 (53 ref.)
The vital role of the skin in human natural history. Cohn BA. **Int J Dermatol** 1998 Nov;37(11):821–4 (20 ref.)
Neonatal skin: the ideal nursing interface. Lott JW, et al. **J Pediatr Nurs** 1998 Oct;13(5):302–6 (11 ref.)
The skin and its response to movement. Ryan TJ. **Lymphology** 1998 Sep;31(3):128–9 (4 ref.)
No man is an island; no island is an island: does the immune network extend beyond the limits of skin? Rewald E, et al. **Med Hypotheses** 1999 Apr;52(4):325–7 (20 ref.)
Studies on the biological activity of the dermal regeneration template. Yannas IV. **Wound Repair Regen** 1998 Nov–Dec; 6(6):518–23 (42 ref.)

DRUG EFFECTS

Direct and non-direct measurement techniques for analysis of skin surface topography. Fischer TW, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Jan–Apr; 12(1–2):1–11 (24 ref.)

SKIN PIGMENTATION

Multiple factors in the evolution of animal coloration. Cloudsley-Thompson JL. **Naturwissenschaften** 1999 Mar; 86(3):123–32 (78 ref.)
Diagnosis in racially pigmented skin. Child F. **Practitioner** 1998 Apr;242(1585):292–6 (6 ref.)

DRUG EFFECTS

Topical agents used in association with cosmetic surgery. Draelos ZD. **Semin Cutan Med Surg** 1999 Jun;18(2):112–8 (33 ref.)

PHYSIOLOGY

Elasmobranch color change: A short review and novel data on hormone regulation. Visconti MA, et al. **J Exp Zool** 1999 Oct 1;284(5):485–91 (54 ref.)
Does alpha-MSH have a role in regulating skin pigmentation in humans? Thody AJ, et al. **Pigment Cell Res** 1998 Oct; 11(5):265–74 (85 ref.)

RADIATION EFFECTS

Pigmented human skin equivalent--as a model of the mechanisms of control of cell–cell and cell–matrix interactions. Nakazawa K, et al. **Med Biol Eng Comput** 1998 Nov;36(6):813–20 (88 ref.)
Human pigmentation genes and their response to solar UV radiation. Sturm RA. **Mutat Res** 1998 Nov 9;422(1):69–76 (42 ref.)

SKIN RASH see **EXANTHEMA**

SKIN SUBSTITUTES see **SKIN, ARTIFICIAL**

SKIN TEMPERATURE

A minireview of studies conducted in japan using finger–skin temperature during cold–stress tests for the diagnosis of hand–arm vibration syndrome. Harada N, et al. **Int Arch Occup Environ Health** 1999 Aug;72(5):330–4 (54 ref.)

SKIN TESTS

[Skin tests for general anesthetics] Le Sellin J. **Allerg Immunol (Paris)** 1998 Sep;30(7):231–3 (2 ref.) (Eng. Abstr.) **(Fre)**

SKIN TRANSPLANTATION

see related
SURGICAL FLAPS

Pathways of antigen traffic from skin allotransplant to recipient lymph nodes--an evolutionarily developed route for initiation of rejection of foreign antigens. Olszewski WL, et al. **Ann Transplant** 1998;3(4):15–20 (38 ref.)
Split-thickness skin graft donor site care: a quantitative synthesis of the research. Rakel BA, et al. **Appl Nurs Res** 1998 Nov;11(4):174–82 (29 ref.)
A systematic review of autologous transplantation methods in vitiligo. Njoo MD, et al. **Arch Dermatol** 1998 Dec; 134(12):1543–9 (59 ref.)
Pre-confluent keratinocyte grafting: the future for cultured skin replacements? [editorial] Harris PA, et al. **Burns** 1998 Nov;24(7):591–3 (15 ref.)
The logic of follicular unit transplantation. Bernstein RM, et al. **Dermatol Clin** 1999 Apr;17(2):277–95, viii; discussion 296 (28 ref.)
Creating a hairline. Pomerantz MA. **Dermatol Clin** 1999 Apr; 17(2):271–5, vii; discussion 276 (9 ref.)
Methodology of follicular unit hair transplantation. Stough D, et al. **Dermatol Clin** 1999 Apr;17(2):297–306, viii (7 ref.)
Cultivation and transplantation of epidermal keratinocytes. Terskikh VV, et al. **Int Rev Cytol** 1999;188:41–72 (154 ref.)
Apligraf treatment of venous ulcers and other chronic wounds. Falanga V. **J Dermatol** 1998 Dec;25(12):812–7 (18 ref.)
The use of Apligraf in acute wounds. Kirsner RS. **J Dermatol** 1998 Dec;25(12):805–11 (39 ref.)
Management of burns: skin cover. Antia NH, et al. **Trop Doct** 1999 Apr;29(2):66–9 (0 ref.)
Skin grafting in difficult situations. James J. **Trop Doct** 1999 Jan;29(1):41–2 (2 ref.)

METHODS

New forms of skin grafting: from the laboratory to the clinic. Freedlander E. **Hosp Med** 1998 Jun;59(6):484–7 (18 ref.)
Dermagraft in the treatment of diabetic foot ulcers. Bowering CK. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1–29–32 (33 ref.)
Apligraf living skin equivalent for healing venous and chronic wounds. Sibbald RG. **J Cutan Med Surg** 1998 Dec; 3 Suppl 1:S1–24–8 (27 ref.)
Dermagraft treatment of diabetic ulcers. Eaglstein WH. **J Dermatol** 1998 Dec;25(12):803–4 (2 ref.)

TRENDS

Tissue engineering for skin: an update. Eaglstein WH, et al. **J Am Acad Dermatol** 1998 Dec;39(6):1007–10 (15 ref.)

SKIN TUBERCULOSIS see **TUBERCULOSIS, CUTANEOUS**

SKIN ULCER

DIAGNOSIS

Genital ulcers. Evaluation and treatment. Rosen T, et al. **Dermatol Clin** 1998 Oct;16(4):673–85, x (88 ref.)
Lymphocutaneous syndrome. A review of non-sporothrix causes. Smego RA Jr, et al. **Medicine (Baltimore)** 1999 Jan; 78(1):38–63 (261 ref.)

DRUG THERAPY

Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. LeGrand EK. **Am J Surg** 1998 Aug;176(2A Suppl):48S–54S (48 ref.)
Metastatic Crohn's disease: remission induced by mesalamine and prednisone. Gilson MR, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):476–9 (15 ref.)

MICROBIOLOGY

Mycobacterium ulcerans--a mini-review [editorial] Johnson PD, et al. **J Med Microbiol** 1999 Jun;48(6):511–3 (21 ref.)
Lymphocutaneous syndrome. A review of non-sporothrix causes. Smego RA Jr, et al. **Medicine (Baltimore)** 1999 Jan; 78(1):38–63 (261 ref.)

THERAPY

The debridement of chronic wounds: a systematic review. Bradley M, et al. **Health Technol Assess (Rockv)** 1999;3(17 Pt 1):iii–iv, 1–78 (62 ref.)
[Palliative care for cancer patients with refractory ulcerating malignant skin tumors and skin metastases] van Leeuwen BL, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):561–4 (11 ref.) (Eng. Abstr.) **(Dut)**

SKIN WRINKLING see **SKIN AGING**

SKULL

see related
CEPHALOMETRY
CRANIOTOMY
INTRACRANIAL PRESSURE

Transcranial cortical magnetic stimulation of lower-lip mimetic muscles: effect of coil position on motor evoked potentials. Rödel R, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 May–Jun; 61(3):119–25 (26 ref.)
[Assymetric skull? Early correct diagnosis is a must! Positional skull deformities can be avoided (see comments)] Lauritzen C, et al. **Lakartidningen** 1999 Mar 24; 96(12):1447–53 (10 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Mar 24;96(12):1404–5. **(Swe)**

ABNORMALITIES

Hemispherectomy complications in the light of craniocerebral disproportion: review of the literature and rationale for a filling-reduction cranioplasty. Sorano V, et al. **Childs Nerv Syst** 1998 Sep;14(9):440–7 (63 ref.)

ANATOMY & HISTOLOGY

Craniofacial anatomy and otitis media [letter] Kemaloğlu YK. **Am J Otol** 1999 Jul;20(4):556–8 (26 ref.)
[The coronal approach in maxillofacial surgery. Notes on the surgical anatomy] Salgarelli A, et al. **Minerva Chir** 1998 Jun;53(6):567–73 (19 ref.) (Eng. Abstr.) **(Ita)**
[Recommendations are not changed--let infants sleep in supine position. Surgical specialists' contribution to population studies would be of value] Sedin G. **Lakartidningen** 1999 May 12;96(19):2357–8 (16 ref.) **(Swe)**

BLOOD SUPPLY

Sinus pericranii. Report of a case and review of the literature. Buxton N, et al. **Pediatr Neurosurg** 1999 Feb;30(2):96–9 (42 ref.)

CHEMISTRY

Glycoconjugate expression and cartilage development of the cranial skeleton. Zschäbitz A. **Acta Anat (Basel)** 1998; 161(1–4):254–74 (162 ref.)

EMBRYOLOGY

Prenatal traces of aberrant neurofacial growth. Kjaer I. **Acta Odontol Scand** 1998 Dec;56(6):326–30 (15 ref.)
From head to toe: conservation of molecular signals regulating limb and craniofacial morphogenesis. Schneider RA, et al. **Cell Tissue Res** 1999 Apr;296(1):103–9 (36 ref.)

GROWTH & DEVELOPMENT

Basic science and clinical experimental primate studies in craniofaciodental biology: a personal historical review. Sarnat BG. **J Oral Maxillofac Surg** 1999 Jun;57(6):714–24 (30 ref.)

PATHOLOGY

Is craniofacial morphology in Apert and Crouzon syndromes the same? Kreiborg S, et al. **Acta Odontol Scand** 1998 Dec; 56(6):339–41 (19 ref.)
Normal and increased functional asymmetries in the craniofacial area. Pirttiniemi P. **Acta Odontol Scand** 1998 Dec;56(6):342–5 (44 ref.)
Ellis-van Creveld syndrome: craniofacial morphology and multidisciplinary treatment. Susami T, et al. **Cleft Palate Craniofac J** 1999 Jul;36(4):345–52 (29 ref.)
Neurenteric cyst at the craniovertebral junction: report of two cases. Fuse T, et al. **Surg Neurol** 1998 Nov;50(5):431–6 (21 ref.)
Spontaneous disappearance of a middle cranial fossa arachnoid cyst after suppurative meningitis [see comments] Yoshioka H, et al. **Surg Neurol** 1998 Nov;50(5):487–91 (26 ref.) Comment in: Surg Neurol 1999 Jun;51(6):687–8.

PHYSIOLOGY

Tissue engineering of bone in the craniofacial complex. Hollinger JO, et al. **Ann N Y Acad Sci** 1999 Jun 18; 875:379–85 (74 ref.)

RADIOGRAPHY

Spontaneous disappearance of a middle cranial fossa arachnoid cyst after suppurative meningitis [see comments] Yoshioka H, et al. **Surg Neurol** 1998 Nov;50(5):487–91 (26 ref.) Comment in: Surg Neurol 1999 Jun;51(6):687–8.

SURGERY

Hemispherectomy complications in the light of craniocerebral disproportion: review of the literature and rationale for a filling-reduction cranioplasty. Sorano V, et al. **Childs Nerv Syst** 1998 Sep;14(9):440–7 (63 ref.)
An infantile intraosseous hematoma of the skull. Report of a case and review of the literature. Yücesoy K, et al. **Childs Nerv Syst** 1999 Jan;15(1):69–72 (13 ref.)
BoneSource hydroxyapatite cement: a novel biomaterial for craniofacial skeletal tissue engineering and reconstruction. Friedman CD, et al. **J Biomed Mater Res** 1998 Winter; 43(4):428–32 (13 ref.)
Some basic factors essential to autogeneic nonvascularized onlay bone grafting to the craniofacial skeleton. Gordh M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Jun; 33(2):129–46 (134 ref.)
Neurenteric cyst at the craniovertebral junction: report of two cases. Fuse T, et al. **Surg Neurol** 1998 Nov;50(5):431–6 (21 ref.)

TRANSPLANTATION

Reconstruction of the temporomandibular joint using calvarial bone after a failed Teflon-Proplast implant. Lee JJ, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):457–61 (14 ref.)

ULTRASONOGRAPHY

Cranial sonographic findings in Joubert's syndrome. al-Talabani JA, et al. **J Clin Ultrasound** 1999 Jan;27(1):41–4 (8 ref.)

SKULL BASE

INJURIES

[Skull base fractures in childhood. The role of CT in the accuracy of diagnosis] Süle TP, et al. **Orv Hetil** 1999 Mar 28;140(13):703–9 (25 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Application of skull base techniques to pediatric neurosurgery. Teo C, et al. **Childs Nerv Syst** 1999 Mar;

SKULL BASE

15(2-3):103-9 (18 ref.)
Technical developments in intra-operative monitoring for the preservation of cranial motor nerves and hearing in skull base surgery. Schlake HP, et al. **Neurol Res** 1999 Jan; 21(1):11-24 (90 ref.)
Skull base techniques for aneurysm occlusion. Moore AJ, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):713-24 (54 ref.)
[The retro-auricular, transmastoid, infralabyrinth approach. A simple route for excision of tumors of the jugular foramen] Fournier HD, et al. **Neurochirurgie** 1998 Apr; 44(2):111-6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Plastic repair of a defect in the base of the skull with soft tissues from the orbit after the removal of an extensive esthesioneuroepithelioma] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):25-7 (24 ref.) (Eng. Abstr.) **(Rus)**

SKULL BASE NEOPLASMS

DIAGNOSIS

Destruction of the glenoid joint fossa by a tenosynovial giant-cell tumour of the skull base: a case report. Stojadinovic S, et al. **Int J Oral Maxillofac Surg** 1999 Apr; 28(2):132-4 (11 ref.)
Paraganglioma in the frontal skull base--case report. Yamauchi T, et al. **Neurol Med Chir (Tokyo)** 1999 Apr; 39(4):308-12 (16 ref.)
A follow-up of rhabdomyosarcoma of the infratemporal fossa region in adults based on the magnetic resonance imaging findings: case reports. Goto TK, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Nov;86(5):616-25 (20 ref.)
[A combination of a meningioma of the base of the skull and an arteriovenous micromalformation of the brain stem] Konovalov AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):21-4 (23 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Sudden unexpected death from primary posterior fossa tumors. Gleckman AM, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):303-8 (13 ref.)
Temporal bone and lateral skull base malignancy: experience and results with 81 patients. Manolidis S, et al. **Am J Otol** 1998 Nov;19(6 Suppl):S1-15 (787 ref.)
[Bone neogenesis in a rare space-occupying lesion of the inner ear canal] Relic A, et al. **HNO** 1999 Jun;47(6):563-8 (39 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Proton therapy for tumors of the skull base. Munzenrider JE, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:57-63 (46 ref.)

SURGERY

Epidermoid and dermoid cysts of the posterior fossa. Cobbs CS, et al. **Clin Neurosurg** 1997;44:511-28 (44 ref.)
Cranial base chordomas. Menezes AH, et al. **Clin Neurosurg** 1997;44:491-509 (40 ref.)
Benign tumors of the cavernous sinus. Rosseau G. **Clin Neurosurg** 1999;45:260-2 (20 ref.)
The case for aggressive resection. Sekhar LN, et al. **Clin Neurosurg** 1999;45:263-78 (18 ref.)
Microsurgical treatment of midfacial tumours involving the skull base. Joos U, et al. **J Craniomaxillofac Surg** 1998 Aug; 26(4):226-34 (16 ref.)
Craniofacial resection for malignant neoplasms of the skull base: an overview. Boyle JO, et al. **J Surg Oncol** 1998 Dec; 69(4):275-84 (78 ref.)
Fractionated stereotactic radiotherapy: rationale and methods. Solberg TD, et al. **Med Dosim** 1998 Fall; 23(3):209-19 (69 ref.)
Paraganglioma in the frontal skull base--case report. Yamauchi T, et al. **Neurol Med Chir (Tokyo)** 1999 Apr; 39(4):308-12 (16 ref.)
[Surgery of malignant tumors affecting the skull base] Saito K, et al. **No Shinkei Geka** 1999 Jun;27(6):505-14 (21 ref.) **(Jpn)**
[Plastic repair of a defect in the base of the skull with soft tissues from the orbit after the removal of an extensive esthesioneuroepithelioma] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):25-7 (24 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Temporal bone and lateral skull base malignancy: experience and results with 81 patients. Manolidis S, et al. **Am J Otol** 1998 Nov;19(6 Suppl):S1-15 (787 ref.)

SKULL FRACTURES

COMPLICATIONS

An unusual variant of a growing skull fracture in an adolescent. Colak A, et al. **Pediatr Neurosurg** 1998 Jul; 29(1):36-9 (14 ref.)
Blindness after reduction of facial fractures. Girotto JA, et al. **Plast Reconstr Surg** 1998 Nov;102(6):1821-34 (70 ref.)
Traumatic leptomeningeal cyst in an adult: a case report and review of the literature. Britz GW, et al. **Surg Neurol** 1998 Nov;50(5):465-9 (19 ref.)

DIAGNOSIS

Adult growing skull fracture mimicking a skull tumor. Weinberg JS, et al. **Acta Neurochir (Wien)** 1999; 141(5):545-6 (20 ref.)

RADIOGRAPHY

[Skull base fractures in childhood. The role of CT in the accuracy of diagnosis] Sült TP, et al. **Orv Hetil** 1999 Mar 28;140(13):703-9 (25 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Subunit principles in midface fractures: the importance of sagittal buttresses, soft-tissue reductions, and sequencing treatment of segmental fractures. Manson PN, et al. **Plast Reconstr Surg** 1999 Apr;103(4):1287-306; quiz 1307 (57 ref.)

VETERINARY

Imaging basilar skull fractures in the horse: a review. Ramirez O 3rd, et al. **Vet Radiol Ultrasound** 1998 Sep-Oct; 39(5):391-5 (17 ref.)

SKULL NEOPLASMS

Giant cell tumors of the jugular foramen. Rosenbloom JS, et al. **Am J Otolaryngol** 1999 May-Jun;20(3):176-9 (20 ref.)
Meningeal chondrosarcomas, a review of 31 patients. Forbes RB, et al. **Br J Neurosurg** 1998 Oct;12(5):461-4 (30 ref.)
Long-term survival of a patient with a giant-cell tumor of the sphenoid body: a case report. Pau A, et al. **Tumori** 1999 Mar-Apr;85(2):137-9 (28 ref.)

COMPLICATIONS

Solitary plasmacytoma of the skull base presenting with unilateral sensorineural hearing loss. Vijaya-Sekaran S, et al. **J Laryngol Otol** 1999 Feb;113(2):164-6 (13 ref.)

CONGENITAL

Congenital chondromyxoid fibroma of the ethmoid: case report. Mendoza M, et al. **Pediatr Radiol** 1998 May; 28(5):339-41 (5 ref.)

DIAGNOSIS

Adult growing skull fracture mimicking a skull tumor. Weinberg JS, et al. **Acta Neurochir (Wien)** 1999; 141(5):545-6 (20 ref.)
Pictorial review: radiology of the sphenoid bone. Chong VF, et al. **Clin Radiol** 1998 Dec;53(12):882-93 (26 ref.)
Chondromyxoid fibroma of skull base: a tumour prone to local recurrence. Shek TW, et al. **J Laryngol Otol** 1999 Apr;113(4):380-5 (18 ref.)
Diffuse calvarial meningioma. Case report and review of the literature. Anegawa S, et al. **J Neurosurg** 1999 May; 90(5):970-3 (21 ref.)
Solitary plasmacytoma of the skull: a case report. Tanaka M, et al. **Jpn J Clin Oncol** 1998 Oct;28(10):626-30 (35 ref.)
Primary spheno-orbital angiosarcoma: case report and review of the literature. Lopes M, et al. **Neurosurgery** 1999 Feb;44(2):405-7; discussion 407-8 (39 ref.)
Giant cell tumor of the skull. Lee JA, et al. **Radiographics** 1998 Sep-Oct;18(5):1295-302 (11 ref.)
[Diabetes insipidus revealing primary malignant non-Hodgkin's lymphoma of bone] Liozon E, et al. **Rev Med Interne** 1998 Nov;19(11):830-4 (24 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The molecular pathology of tumours of the ear and temporal bone. Irving RM. **J Laryngol Otol** 1998 Nov;112(11):1011-8 (74 ref.)

PATHOLOGY

Merkel cell carcinoma of the external auditory canal invading the intracranial compartment. Litofsky NS, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):330-4 (18 ref.)
Intracranial extension of an eccrine porocarcinoma. Case report and review of the literature. Ritter AM, et al. **J Neurosurg** 1999 Jan;90(1):138-40 (13 ref.)
Temporal dermoid with intracranial extension: report of a case. Niederhagen B, et al. **J Oral Maxillofac Surg** 1998 Nov;56(11):1352-4 (20 ref.)
Meningiomas presenting in the temporal bone: the pathways of spread from an intracranial site of origin. Chang CY, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):658-64 (31 ref.)
Juxtaorbital en plaque meningiomas. Report of four cases and review of literature. Charbel FT, et al. **Radiol Clin North Am** 1999 Jan;37(1):89-100, x (59 ref.)

RADIOGRAPHY

Merkel cell carcinoma of the external auditory canal invading the intracranial compartment. Litofsky NS, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):330-4 (18 ref.)
Dural osteochondroma: case report, review of the literature and proposal of a new classification. Haddad GF, et al. **Br J Neurosurg** 1998 Aug;12(4):380-4 (35 ref.)

RADIOTHERAPY

The role of high-LET radiotherapy compared to conformal photon radiotherapy in adenoid cystic carcinoma. Debus J, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:63-5 (12 ref.)

SECONDARY

Extracranial metastatic meningioma. Figueroa BE, et al. **Br J Radiol** 1999 May;72(857):513-6 (48 ref.)
Malignant granular cell tumor: report of a case and review of the literature. Sonobe H, et al. **Pathol Res Pract** 1998; 194(7):507-13; discussion 515-6 (50 ref.)
[Cranial metastases from a follicular carcinoma of the thyroid. A clinical case report and review of the literature] Conzo G, et al. **Minerva Chir** 1998 Sep;53(9):751-6 (25 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Microsurgical treatment of midfacial tumours involving the skull base. Joos U, et al. **J Craniomaxillofac Surg** 1998 Aug; 26(4):226-34 (16 ref.)

SLAUGHTERHOUSES see **ABATTOIRS**

SLEEP

see related

POLYSOMNOGRAPHY

Side sleeping position and bed sharing in the sudden infant death syndrome. Scragg RK, et al. **Ann Med** 1998 Aug; 30(4):345-9 (41 ref.)
Respiratory control during upper airway infection mechanism for prolonged reflex apnoea and sudden infant death with special reference to infant sleep position. Lindgren C. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1-2):97-102 (45 ref.)
Nocturnal hypoventilation. Lévy P, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):296-304 (72 ref.)
Is there an optimal sleep-wake pattern in shift work? Akerstedt T. **Scand J Work Environ Health** 1998;24 Suppl 3:18-27 (98 ref.)
[Sleep and the treatment of bronchial obstruction] Grote L, et al. **Pneumologie** 1999 May;53(5):255-61 (48 ref.) (Eng. Abstr.) **(Ger)**
[Assymetric skull? Early correct diagnosis is a must! Positional skull deformities can be avoided (see comments)] Lauritzen C, et al. **Lakartidningen** 1999 Mar 24; 96(12):1447-53 (10 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Mar 24;96(12):1404-5. **(Swe)**

DRUG EFFECTS

Alcohol, slow wave sleep, and the somatotropic axis. Lands WE. **Alcohol** 1999 Jun-Jul;18(2-3):109-22 (101 ref.)
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Boger DL, et al. **Curr Pharm Des** 1998 Aug; 4(4):303-14 (81 ref.)
gamma-Hydroxybutyric acid, imidazoleacetic acid, cerebral metabolism and induced sleep. Rick JT, et al. **Isr J Med Sci** 1973;9 Suppl:55-62 (12 ref.)
Effects of muramyl peptides on macrophages, monokines, and sleep. Pabst MJ, et al. **Neuroimmunomodulation** 1999 Jul-Aug;6(4):261-83 (177 ref.)
[Antihypertensive medication and sleep] Grote L. **Dtsch Med Wochenschr** 1998 Nov 13;123(46):1389-94 (50 ref.) **(Ger)**

GENETICS

Differences in gene expression during sleep and wakefulness. Cirelli C, et al. **Ann Med** 1999 Apr;31(2):117-24 (66 ref.)

PHYSIOLOGY

Sleep as a behavioral model of neuro-immune interactions. Opp MR, et al. **Acta Neurobiol Exp (Warsz)** 1999; 59(1):45-53 (71 ref.)
The neural basis of consciousness across the sleep-waking cycle. Jones BE. **Adv Neurol** 1998;77:75-94 (89 ref.)
Sleep, sleeping sites, and sleep-related activities: awakening to their significance. Anderson JR. **Am J Primatol** 1998; 46(1):63-75 (64 ref.)
Circadian regulation of human sleep and age-related changes in its timing, consolidation and EEG characteristics. Dijk DJ, et al. **Ann Med** 1999 Apr;31(2):130-40 (93 ref.)
Effects of sex steroids on sleep. Empson JA, et al. **Ann Med** 1999 Apr;31(2):141-5 (93 ref.)
Adenosine in sleep and wakefulness. Porkka-Heiskanen T. **Ann Med** 1999 Apr;31(2):125-9 (40 ref.)
Sleep. A physiologic role for IL-1 beta and TNF-alpha. Krueger JM, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:148-59 (74 ref.)
Sleep and its disorders. Vgontzas AN, et al. **Annu Rev Med** 1999;50:387-400 (28 ref.)
Sleep promotion in adults. Floyd JA. **Annu Rev Nurs Res** 1999;17:27-56 (100 ref.)
Prostaglandin D2 and sleep regulation. Urade Y, et al. **Biochim Biophys Acta** 1999 Jan 4;1436(3):606-15 (111 ref.)
Sleep and stress in man: an approach through exercise and exposure to extreme environments. Buguet A, et al. **Can J Physiol Pharmacol** 1998 May;76(5):553-61 (81 ref.)

Hypothalamus-pituitary-adrenal activity during human sleep: a coordinating role for the limbic hippocampal system. Born J, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):153–63 (81 ref.)
The impact of sleep on gonadotropin secretion. Rossmanith WG. **Gynecol Endocrinol** 1998 Dec;12(6):381–9 (67 ref.)
Understanding sleep ontogeny to assess brain dysfunction in neonates and infants. Scher MS. **J Child Neurol** 1998 Oct; 13(10):467–74 (45 ref.)
Importance of sleep in the management of pediatric pain. Lewin DS, et al. **J Dev Behav Pediatr** 1999 Aug; 20(4):244–52 (75 ref.)
The determinants of long-term blood pressure stability: control of trough blood pressure during sleep [editorial] Dickinson CJ. **J Hypertens** 1998 Jul;16(7):907–12 (54 ref.)
Hierarchy of micro-arousals and the microstructure of sleep. Halász P. **Neurophysiol Clin** 1998 Dec;28(6):461–75 (73 ref.)
Sleep and serotonin: an unfinished story. Jouvet M. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):24S–27S (21 ref.)
Adaptations and pathologies linked to dynamic stabilization of neural circuitry. Kavanau JL. **Neurosci Biobehav Rev** 1999 May;23(5):635–48 (133 ref.)
Does sleep promote recovery after bone marrow transplantation?--A hypothesis. Yarrington A, et al. **Pediatr Transplant** 1998 Feb;2(1):51–5 (42 ref.)
Endogenous and exogenous factors on sleep-wake cycle regulation. García-García F, et al. **Prog Neurobiol** 1999 Jul;58(4):297–314 (294 ref.)
The neurophysiology of sleep and waking: intracerebral connections, functioning and ascending influences of the medulla oblongata. Gottesmann C. **Prog Neurobiol** 1999 Sep;59(1):1–54 (267 ref.)
Normal human sleep. Keenan SA. **Respir Care Clin N Am** 1999 Sep;5(3):319–31, vii (27 ref.)
Novel neurotransmitters for sleep and energy homeostasis. Sutcliffe JG, et al. **Results Probl Cell Differ** 1999;26:239–55 (30 ref.)
Changes in sleep and wakefulness following 5-HT1A ligands given systemically and locally in different brain regions. Bjorvatn B, et al. **Rev Neurosci** 1998;9(4):265–73 (97 ref.)
[Determinants of insomnia in relatively healthy elderly. A literature review] Beullens J. **Tijdschr Gerontol Geriatr** 1999 Feb;30(1):31–8 (29 ref.) (Eng. Abstr.) **(Dut)**
[Starling resister and stability of sleep ventilation] Krieger J, et al. **Neurophysiol Clin** 1998 Dec;28(6):493–506 (11 ref.) (Eng. Abstr.) **(Fre)**
[Measurement of respiratory effort (esophageal pressure) and estimation of resistance of the upper airway in polysomnography: indications, limitations and results] Loiodice C, et al. **Neurophysiol Clin** 1998 Dec;28(6):507–20 (29 ref.) (Eng. Abstr.) **(Fre)**
[Sleep physiology and sleep disorders] Penzel T. **Med Monatsschr Pharm** 1999 Feb;22(2):30–8 (7 ref.) **(Ger)**
[Sleep and old age] Sanner BM, et al. **Med Monatsschr Pharm** 1999 Feb;22(2):39–44 (20 ref.) **(Ger)**
[Sleep and exercise dysfunction in respiratory insufficiency] Akashiba T. **Nippon Naika Gakkai Zasshi** 1999 Jan 10; 88(1):24–31 (6 ref.) **(Jpn)**
[Sleep-promoting substances] Fujitani Y, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):811–6 (53 ref.) **(Jpn)**
[Molecular and neuroanatomical mechanisms of sleep-wakefulness regulation by prostaglandins D2 and E2] Onoe H. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):343–9 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Physiologic rhythm of sleep and waking] Tafil-Klawe M, et al. **Postepy Hig Med Dosw** 1999;53(3):497–503 (30 ref.) (Eng. Abstr.) **(Pol)**
[Familial fatal insomnia: a human prion disease which opens the door to a greater understanding of the thalamus] Barriga F, et al. **Rev Med Univ Navarra** 1997 Oct–Dec; 41(4):224–8 (24 ref.) (Eng. Abstr.) **(Spa)**

SLEEP APNEA SYNDROMES

Sleep-disordered breathing in children. Guilleminault C, et al. **Ann Med** 1998 Aug;30(4):350–6 (50 ref.)
Obstructive sleep apnoea. Worsnop C, et al. **Aust N Z J Med** 1998 Aug;28(4):421–7 (40 ref.)
The upper airway resistance syndrome. Exar EN, et al. **Chest** 1999 Apr;115(4):1127–39 (79 ref.)
The sleep apnoea syndromes. van Houwelingen KG, et al. **Eur Heart J** 1999 Jun;20(12):858–66 (77 ref.)
Nocturnal hypoventilation. Lévy P, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):296–304 (72 ref.)
Overview of sleep disorders: where does obstructive sleep apnea syndrome fit in? Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):187–93 (9 ref.)
Disordered breathing during sleep in newborns, infants, and children. Symptoms, diagnosis, and treatment. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):211–22 (23 ref.)
[Sleep apnea and non-invasive positive-pressure respiration] Oi M. **Nippon Naika Gakkai Zasshi** 1998 Oct 10; 87(10):2100–6 (22 ref.) **(Jpn)**
[Snoring and vascular diseases] Zamarrón C. **An Med Interna** 1998 Dec;15(12):669–71 (49 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Interaction of sleep apnoea syndrome with various diseases. Tomori Z, et al. **Bratisl Lek Listy** 1999 Feb;100(2):80–4 (27 ref.)
Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction? Silverberg DS, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):353–7 (39 ref.)
Respiratory aspects of neurological disease. Polkey MI, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):5–15 (170 ref.)
Habitual snoring, OSA and craniofacial modification. Orthodontic clinical and diagnostic aspects in a case control study. Caprioglio A, et al. **Minerva Stomatol** 1999 Apr; 48(4):125–37 (43 ref.) **(Eng, Ita)**
What is the evidence that obstructive sleep apnoea is an important illness? Marrone O, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):630–9 (155 ref.)
Sleep disordered breathing and cardiomyopathy. Mohsenin V. **Monaldi Arch Chest Dis** 1998 Oct;53(5):589–92 (37 ref.)
Complications of snoring, upper airway resistance syndrome, and obstructive sleep apnea syndrome in adults. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):223–34 (39 ref.)
The behavioral morbidity of obstructive sleep apnea. Day R, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):341–54 (80 ref.)
Cardiovascular morbidity in obstructive sleep apnea. Weiss JW, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):367–76 (68 ref.)
Heart block in patients with sleep apnoea. Becker HF, et al. **Thorax** 1998 Oct;53 Suppl 3:S29–32 (20 ref.)
Sleep apnoea in women. Edwards N, et al. **Thorax** 1998 Oct; 53 Suppl 3:S12–5 (45 ref.)
Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Naughton MT. **Thorax** 1998 Oct;53 Suppl 3:S37–40 (40 ref.)
Sleep apnoea and snoring: potential links with vascular disease. Sullivan CE, et al. **Thorax** 1998 Oct;53 Suppl 3:S8–11 (35 ref.)
Prognosis and sleep disordered breathing in heart failure. Wilcox I, et al. **Thorax** 1998 Oct;53 Suppl 3:S33–6 (24 ref.)
"Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Wilcox I, et al. **Thorax** 1998 Oct; 53 Suppl 3:S25–8 (40 ref.)
[Advances in the study on sleep apnea syndrome and multiple organ injuries] Ci S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Feb; 20(1):39–41 (18 ref.) **(Chi)**
[Sleep apnea and erectile dysfunction] Konermann M, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):631–5 (37 ref.) **(Ger)**
[Pulmonary artery hypertension and obstructive sleep apnea. Pathophysiology and clinical relevance] Steiner S, et al. **Internist (Berl)** 1999 Jul;40(7):739–46 (61 ref.) **(Ger)**
[Obesity and diseases. 2. Obesity and obstructive sleep apnea syndrome] Chin K, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1793–6 (18 ref.) **(Jpn)**
[Cardiovascular manifestations of obstructive sleep apnea. Effects of the treatment] Soto F. **Rev Med Chil** 1998 Sep; 126(9):1112–6 (38 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Idiopathic congenital central hypoventilation syndrome: diagnosis and management. American Thoracic Society. **Am J Respir Crit Care Med** 1999 Jul;160(1):368–73 (56 ref.)
Congenital central hypoventilation syndrome: an update. Gozal D. **Pediatr Pulmonol** 1998 Oct;26(4):273–82 (102 ref.)

DIAGNOSIS

Diagnostic and treatment implications of nasal obstruction in snoring and obstructive sleep apnea. Scharf MB, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):279–87; quiz 287–90 (114 ref.)
Daytime sleepiness: when is it normal? When to refer? Benbadis SR. **Cleve Clin J Med** 1998 Nov–Dec; 65(10):543–9 (36 ref.)
The use of sleep tests for suspected sleep disordered breathing. Mickelson SA. **Ear Nose Throat J** 1999 Sep; 78(9):716–22 (13 ref.)
An overview of sleep disordered breathing for the otolaryngologist. Sher AE. **Ear Nose Throat J** 1999 Sep; 78(9):694–5, 698–700, 703–6 passim (35 ref.)
Systematic review of the literature regarding the diagnosis of sleep apnea. **Evid Rep Technol Assess (Summ)** 1999 Feb; (1):i–viii, 1–154 (225 ref.)
Autocontinuous positive airway pressure in the diagnosis and treatment of obstructive sleep apnoea. Braghiroli A, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):621–4 (20 ref.)
Upper airway imaging in sleep apnoea syndrome: clinical applications. Smurra MV, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):520–3 (26 ref.)
Sleep studies. Current techniques and future trends. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):195–210 (25 ref.)
Diagnostic techniques in obstructive sleep apnea. George CF. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):355–66 (78 ref.)
Clinical presentations of obstructive sleep apnea syndrome. Skomro RP, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr; 41(5):331–40 (76 ref.)
Sleep-disordered breathing in infants and children. Perkin RM, et al. **Respir Care Clin N Am** 1999 Sep;5(3):395–426, viii (122 ref.)
Pulse transit time: an appraisal of potential clinical applications. Smith RP, et al. **Thorax** 1999 May;54(5):452–7 (27 ref.)
New strategies of screening and treatment for sleep apnea syndrome. Hida W. **Tohoku J Exp Med** 1998 Dec; 186(4):225–41 (120 ref.)
[Obstructive sleep apnea syndrome in children] Joosten KF, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2665–9 (25 ref.) (Eng. Abstr.) **(Dut)**
[Diagnosis and therapy of sleep-related breathing disorders. 1: Terminology] Maurer JT, et al. **HNO** 1998 Dec; 46(12):958–68 (57 ref.) (Eng. Abstr.) **(Ger)**
[Sleep apnea syndrome] Miyamoto M, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):832–7 (8 ref.) **(Jpn)**
[The therapeutic considerations in the "overlap syndrome"] Mihăltan F, et al. **Pneumoftiziologia** 1998 Jan–Mar; 47(1):41–4 (12 ref.) (Eng. Abstr.) **(Rum)**

EPIDEMIOLOGY

Sleep apnoea: clinical importance and facilities for investigation and treatment in the UK. Addendum to the 1993 Royal College of Physicians Sleep Apnoea report [see comments] Gibson GJ, et al. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):540–4 (46 ref.) Comment in: J R Coll Physicians Lond 1999 Mar–Apr;33(2):191–2.
Snoring and sleep apnea. A study of evolution and consequences in a male population. Minireview based on a doctoral thesis. Lindberg E. **Ups J Med Sci** 1998; 103(3):155–202 (198 ref.)
[The sleep apnea syndrome as a health problem. An estimation of its prevalence and morbimortality] Racionero Casero MA, et al. **An Med Interna** 1999 Feb;16(2):97–102 (53 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Changes in airway and hyoid position in response to mandibular protrusion in subjects with obstructive sleep apnoea (OSA). Battagel JM, et al. **Eur J Orthod** 1999 Aug; 21(4):363–76 (46 ref.)
Obesity and obstructive sleep apnea syndrome. Chin K, et al. **Intern Med** 1999 Feb;38(2):200–2 (20 ref.)
Implications of pathophysiology for management of the obstructive sleep apnoea syndrome. McNicholas WT. **Monaldi Arch Chest Dis** 1998 Oct;53(5):524–9 (64 ref.)
The nasal airway and obstructed breathing during sleep. Mirza N, et al. **Otolaryngol Clin North Am** 1999 Apr; 32(2):243–62 (61 ref.)
Sleep-related disorders and chronic obstructive pulmonary disease. Brown LK. **Respir Care Clin N Am** 1998 Sep; 4(3):493–512 (97 ref.)
[Influence of nasal obstruction on sleep-associated breathing disorders] Dreher A, et al. **Laryngorhinootologie** 1999 Jun; 78(6):313–7 (82 ref.) (Eng. Abstr.) **(Ger)**
[Respiratory sleep disorders in COPD] Masa Jiménez JF. **Arch Bronconeumol** 1999 May;35 Suppl 3:28–33 (64 ref.) **(Spa)**

PHYSIOPATHOLOGY

Respiratory control during upper airway infection mechanism for prolonged reflex apnoea and sudden infant death with special reference to infant sleep position. Lindgren C. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1–2):97–102 (45 ref.)
Non-CPAP treatment of obstructive sleep apnoea. De Backer W. **Monaldi Arch Chest Dis** 1998 Dec;53(6):625–9 (43 ref.)
Implications of pathophysiology for management of the obstructive sleep apnoea syndrome. McNicholas WT. **Monaldi Arch Chest Dis** 1998 Oct;53(5):524–9 (64 ref.)
Introduction to the mechanism of obstructive sleep apnoea and snoring. Simonds AK. **Monaldi Arch Chest Dis** 1998 Dec;53(6):617–20 (7 ref.)
Pathogenesis of obstructive sleep apnea. Badr MS. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):323–30 (37 ref.)
Cardiovascular morbidity in obstructive sleep apnea. Weiss JW, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):367–76 (68 ref.)
The spectrum of sleep-disordered breathing. Anstead M, et al. **Respir Care Clin N Am** 1999 Sep;5(3):363–77, viii (58 ref.)
Sleep apnoea and autonomic function. Zwillich CW. **Thorax** 1998 Oct;53 Suppl 3:S20–4 (34 ref.)
[Dilator muscles of the pharynx and their implication in the sleep apnea syndrome of obstructive type. Review of the literature] Blumen M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 May;115(2):73–84 (91 ref.) (Eng. Abstr.) **(Fre)**
[Pharyngeal muscles and sleep obstructive apnea syndrome] Fleury B. **Rev Mal Respir** 1999 Feb;16(1):51–6 (44 ref.) (Eng. Abstr.) **(Fre)**
[Autonomic nervous system and obstructive sleep apneas] Smith R, et al. **Rev Mal Respir** 1999 Jun;16(3):287–304 (108 ref.) (Eng. Abstr.) **(Fre)**
[Influence of nasal obstruction on sleep-associated breathing disorders] Dreher A, et al. **Laryngorhinootologie** 1999 Jun; 78(6):313–7 (82 ref.) (Eng. Abstr.) **(Ger)**
[Chronobiology in medical practice] Markiewicz A. **Postepy Hig Med Dosw** 1999;53(3):473–82 (32 ref.) (Eng. Abstr.) **(Pol)**

SLEEP APNEA SYNDROMES

PREVENTION & CONTROL

Oral appliances for the management of snoring and obstructive sleep apnoea. Bennett LS, et al. **Thorax** 1998 Aug;53 Suppl 2:S58–64 (47 ref.)

PSYCHOLOGY

The behavioral morbidity of obstructive sleep apnea. Day R, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):341–54 (80 ref.)

RADIOGRAPHY

Upper airway assessment: radiographic and other imaging techniques. Schwab RJ, et al. **Otolaryngol Clin North Am** 1998 Dec;31(6):931–68 (111 ref.)

SURGERY

Snoring, obstructive sleep apnea, and surgery. Barthel SW, et al. **Med Clin North Am** 1999 Jan;83(1):85–96 (104 ref.)

Oropharyngeal surgery in the management of upper airway obstruction during sleep. Coleman J, et al. **Otolaryngol Clin North Am** 1999 Apr;32(2):263–76 (33 ref.)

Suspension sutures for the treatment of obstructive sleep apnea and snoring. Coleman J, et al. **Otolaryngol Clin North Am** 1999 Apr;32(2):277–85 (8 ref.)

Oral and maxillofacial surgery for the management of obstructive sleep apnea syndrome. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):235–41 (11 ref.)

Upper airway bypass surgery for obstructive sleep apnea syndrome. Mickelson SA. **Otolaryngol Clin North Am** 1998 Dec;31(6):1013–23 (19 ref.)

Surgical management of the hypopharyngeal airway in sleep disordered breathing. Troell RJ, et al. **Otolaryngol Clin North Am** 1998 Dec;31(6):979–1012 (55 ref.)

Long-term results of surgical management of sleep disordered breathing: are our patients really benefiting? Troell RJ, et al. **Otolaryngol Clin North Am** 1998 Dec; 31(6):1031–5 (13 ref.)

Surgical management of obstructive sleep apnea. Sher AE. **Prog Cardiovasc Dis** 1999 Mar–Apr;41(5):387–96 (47 ref.)

[Surgical therapy of sleep-related respiratory disorders] Hörmann K, et al. **HNO** 1999 Apr;47(4):226–35 (37 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diagnostic and treatment implications of nasal obstruction in snoring and obstructive sleep apnea. Scharf MB, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):279–87; quiz 287–90 (114 ref.)

An overview of sleep disordered breathing for the otolaryngologist. Sher AE. **Ear Nose Throat J** 1999 Sep; 78(9):694–5, 698–700, 703–6 passim (35 ref.)

Auto-CPAP: an effective and low-cost procedure in the management of OSAS? [editorial; comment] Lévy P, et al. **Eur Respir J** 1998 Oct;12(4):753–5 (19 ref.) Comment on: Eur Respir J 1998 Oct;12(4):759–63.

Sleep apnoea: clinical importance and facilities for investigation and treatment in the UK. Addendum to the 1993 Royal College of Physicians Sleep Apnoea report [see comments] Gibson GJ, et al. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):540–4 (46 ref.) Comment in: J R Coll Physicians Lond 1999 Mar–Apr;33(2):191–2.

Autocontinuous positive airway pressure in the diagnosis and treatment of obstructive sleep apnoea. Braghiroli A, et al. **Monaldi Arch Chest Dis** 1998 Dec;53(6):621–4 (20 ref.)

Non-CPAP treatment of obstructive sleep apnoea. De Backer W. **Monaldi Arch Chest Dis** 1998 Dec;53(6):625–9 (43 ref.)

New frontiers in the management of obstructive sleep apnoea syndrome. Krieger J. **Monaldi Arch Chest Dis** 1998 Oct; 53(5):515–9 (29 ref.)

How to improve compliance to nasal continuous positive airway pressure in sleep apnoea syndrome. Rodenstein D. **Monaldi Arch Chest Dis** 1998 Oct;53(5):586–8 (15 ref.)

Advances in management of sleep apnea syndromes in infants and children. Marcus CL. **Pediatr Pulmonol Suppl** 1999; 18:188–9 (8 ref.)

Medical management of obstructive sleep apnea. Henderson JH 2nd, et al. **Prog Cardiovasc Dis** 1999 Mar–Apr; 41(5):377–86 (109 ref.)

Treatment of obstructive sleep apnea. Hudgel DW, et al. **Respir Care Clin N Am** 1999 Sep;5(3):379–94, viii (75 ref.)

Sleep-disordered breathing in infants and children. Perkin RM, et al. **Respir Care Clin N Am** 1999 Sep;5(3):395–426, viii (122 ref.)

CPAP therapy: outcomes and patient use. Douglas NJ, et al. **Thorax** 1998 Oct;53 Suppl 3:S47–8 (20 ref.)

Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Naughton MT. **Thorax** 1998 Oct;53 Suppl 3:S37–40 (40 ref.)

Intelligent CPAP systems: clinical experience. Teschler H, et al. **Thorax** 1998 Oct;53 Suppl 3:S49–54 (34 ref.)

New strategies of screening and treatment for sleep apnea syndrome. Hida W. **Tohoku J Exp Med** 1998 Dec; 186(4):225–41 (120 ref.)

[Obstructive sleep apnea syndrome in children] Joosten KF, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2665–9 (25 ref.) (Eng. Abstr.) **(Dut)**

[Sleep-related respiration disorders: their relevance in intensive care medicine] Sanner BM, et al. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):296–8 (34 ref.) **(Ger)**

[Sleep apnea syndrome] Miyamoto M, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):832–7 (8 ref.) **(Jpn)**

[Effective nasal CPAP therapy for heavy snoring and paradoxical respiration during sleep in a case of multiple system atrophy] Miyamoto M, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1059–63 (14 ref.) (Eng. Abstr.) **(Jpn)**

SLEEP DEPRIVATION

Sleep deprivation in depression: what do we know, where do we go? Wirz-Justice A, et al. **Biol Psychiatry** 1999 Aug 15;46(4):445–53 (76 ref.)

Vehicle accidents related to sleep: a review. Horne J, et al. **Occup Environ Med** 1999 May;56(5):289–94 (60 ref.)

Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation. Ebert D, et al. **Psychopharmacology (Berl)** 1998 Nov;140(1):1–10 (98 ref.)

[Effect of awakening and sleep deprivation in triggering idiopathic generalized epilepsy] Crespel A, et al. **Rev Neurol (Paris)** 1999 Feb;155(2):131–4 (39 ref.) (Eng. Abstr.) **(Fre)**

[Work shifts, sleep and biological rhythms] Gaspar S, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):239–45 (13 ref.) **(Por)**

PHYSIOLOGY

Transcriptional activity in the brain during sleep deprivation. Toppila J, et al. **Ann Med** 1999 Apr;31(2):146–51 (44 ref.)

Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Boger DL, et al. **Curr Pharm Des** 1998 Aug; 4(4):303–14 (81 ref.)

Effects of method, duration, and sleep stage on rebounds from sleep deprivation in the rat. Rechtschaffen A, et al. **Sleep** 1999 Feb 1;22(1):11–31 (105 ref.)

SLEEP–DISORDERED BREATHING see **SLEEP APNEA SYNDROMES**

SLEEP DISORDERS

Sleep disorders in older people. Gentili A, et al. **Aging (Milano)** 1999 Jun;11(3):137–41 (44 ref.)

Sleep problems in the elderly. Neubauer DN. **Am Fam Physician** 1999 May 1;59(9):2551–8, 2559–60 (15 ref.)

Sleep disorders and the dental patient: an overview. Lavigne GJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):257–72 (100 ref.)

CHEMICALLY INDUCED

Drug-induced nightmares. Thompson DF, et al. **Ann Pharmacother** 1999 Jan;33(1):93–8 (72 ref.)

CLASSIFICATION

Applying classifications of sleep disorders to children with neurologic conditions. Scher MS. **J Child Neurol** 1998 Nov; 13(11):525–36 (71 ref.)

Overview of sleep disorders: where does obstructive sleep apnea syndrome fit in? Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):187–93 (9 ref.)

COMPLICATIONS

Review of strategies for treating sleep problems in persons with severe or profound mental retardation or multiple handicaps. Lancioni GE, et al. **Am J Ment Retard** 1999 Mar;104(2):170–86 (82 ref.)

Melatonin in circadian sleep disorders in the blind. Skene DJ, et al. **Biol Signals Recept** 1999 Jan–Apr;8(1–2):90–5 (37 ref.)

Children's sleep disorders: modern approaches, developmental effects, and children at special risk. Stores G. **Dev Med Child Neurol** 1999 Aug;41(8):568–73 (69 ref.)

Applying classifications of sleep disorders to children with neurologic conditions. Scher MS. **J Child Neurol** 1998 Nov; 13(11):525–36 (71 ref.)

Sleep in patients with respiratory disease. Lewis DA. **Respir Care Clin N Am** 1999 Sep;5(3):447–60, ix (69 ref.)

[Paroxysmal disorders and episodic non-epileptic symptoms related to sleep] Rufo-Campos M. **Rev Neurol** 1999 Jan 1–15;28(1):84–9 (32 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Recognizing problem sleepiness in your patients. National Center on Sleep Disorders Research Working Group. **Am Fam Physician** 1999 Feb 15;59(4):937–44 (61 ref.)

Daytime sleepiness: when is it normal? When to refer? Benbadis SR. **Cleve Clin J Med** 1998 Nov–Dec; 65(10):543–9 (36 ref.)

Children's sleep disorders: modern approaches, developmental effects, and children at special risk. Stores G. **Dev Med Child Neurol** 1999 Aug;41(8):568–73 (69 ref.)

Medical-legal aspects of sleep medicine. Mahowald MW, et al. **Neurol Clin** 1999 May;17(2):215–34 (204 ref.)

Sleep disorders presenting as psychiatric disorders. Reite M. **Psychiatr Clin North Am** 1998 Sep;21(3):591–607 (85 ref.)

[Diagnosis and differential diagnosis of sleep disorders in children] Frölich J, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66(12):553–69 (185 ref.) (Eng. Abstr.) **(Ger)**

[Sleep disorders--the problem with chrono-medicine] Prusiński A. **Postepy Hig Med Dosw** 1999;53(3):505–15 (34 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Melatonin in circadian sleep disorders in the blind. Skene DJ, et al. **Biol Signals Recept** 1999 Jan–Apr;8(1–2):90–5 (37 ref.)

Therapy of behavioral disorders in Parkinson's disease. Valldeoriola F, et al. **Biomed Pharmacother** 1999 Apr; 53(3):149–53 (56 ref.)

Melatonin treatment of sleep-wake cycle disorders in children and adolescents. Jan JE, et al. **Dev Med Child Neurol** 1999 Jul;41(7):491–500 (191 ref.)

Melatonin: aeromedical, toxicopharmacological, and analytical aspects. Sanders DC, et al. **J Anal Toxicol** 1999 May–Jun;23(3):159–67 (100 ref.)

Melatonin: from biochemistry to therapeutic applications. Zawilska JB, et al. **Pol J Pharmacol** 1999 Jan–Feb; 51(1):3–23 (222 ref.)

Melatonin and clinical application. Wetterberg L. **Reprod Nutr Dev** 1999 May–Jun;39(3):367–82 (70 ref.)

EPIDEMIOLOGY

Are sleep disturbances risk factors for anxiety, depressive and addictive disorders? Gillin JC. **Acta Psychiatr Scand Suppl** 1998;393:39–43 (9 ref.)

ETIOLOGY

The development and disorders of sleep. Dahl RE. **Adv Pediatr** 1998;45:73–90 (35 ref.)

Complications of allergic rhinitis. Settipane RA. **Allergy Asthma Proc** 1999 Jul–Aug;20(4):209–13 (39 ref.)

Recognizing problem sleepiness in your patients. National Center on Sleep Disorders Research Working Group. **Am Fam Physician** 1999 Feb 15;59(4):937–44 (61 ref.)

Sleep and its disorders. Vgontzas AN, et al. **Annu Rev Med** 1999;50:387–400 (28 ref.)

Melatonin treatment of non-epileptic myoclonus in children. Jan JE, et al. **Dev Med Child Neurol** 1999 Apr;41(4):255–9 (48 ref.)

Sleep disorders in visually impaired children. Stores G, et al. **Dev Med Child Neurol** 1999 May;41(5):348–52 (49 ref.)

Sleep disorders in the elderly. Asplund R. **Drugs Aging** 1999 Feb;14(2):91–103 (121 ref.)

Importance of sleep in the management of pediatric pain. Lewin DS, et al. **J Dev Behav Pediatr** 1999 Aug; 20(4):244–52 (75 ref.)

A review of the effects of moderate alcohol intake on psychiatric and sleep disorders. Castaneda R, et al. **Recent Dev Alcohol** 1998;14:197–226 (189 ref.)

Sleep-related disorders and chronic obstructive pulmonary disease. Brown LK. **Respir Care Clin N Am** 1998 Sep; 4(3):493–512 (97 ref.)

PHYSIOPATHOLOGY

Understanding sleep ontogeny to assess brain dysfunction in neonates and infants. Scher MS. **J Child Neurol** 1998 Oct; 13(10):467–74 (45 ref.)

Sleep in patients with respiratory disease. Lewis DA. **Respir Care Clin N Am** 1999 Sep;5(3):447–60, ix (69 ref.)

Sleep in the elderly. Martin J, et al. **Respir Care Clin N Am** 1999 Sep;5(3):461–72, ix (52 ref.)

[Wake disorders. I. Primary wake disorders] Billiard M, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):111–29 (189 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of depression and sleep disorders. Significance of serotonin and L-tryptophan in pathophysiology and therapy] Riemann D, et al. **Fortschr Med** 1998 Nov 20; 116(32):40–2 (25 ref.) (Eng. Abstr.) **(Ger)**

[Sleep physiology and sleep disorders] Penzel T. **Med Monatsschr Pharm** 1999 Feb;22(2):30–8 (7 ref.) **(Ger)**

[Sleep and old age] Sanner BM, et al. **Med Monatsschr Pharm** 1999 Feb;22(2):39–44 (20 ref.) **(Ger)**

PREVENTION & CONTROL

Accidents related to sleepiness: review of medical causes and prevention with special reference to Switzerland [published erratum appears in Schweiz Med Wochenschr 1999 Jan 23;129(3):98] Laube I, et al. **Schweiz Med Wochenschr** 1998 Oct 3;128(40):1487–99 (65 ref.)

PSYCHOLOGY

An 18-month old who sleeps badly. Crawley H, et al. **Practitioner** 1999 Mar;243(1596):155, 159–60, 162 (3 ref.)

THERAPY

Review of strategies for treating sleep problems in persons with severe or profound mental retardation or multiple handicaps. Lancioni GE, et al. **Am J Ment Retard** 1999 Mar;104(2):170–86 (82 ref.)

Daytime sleepiness: when is it normal? When to refer?

Benbadis SR. **Cleve Clin J Med** 1998 Nov-Dec; 65(10):543-9 (36 ref.)
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms. **Oncology (Huntingt)** 1999 Apr;13(4):551-4, 557-60, 563 passim (36 ref.)
[Sleep disorders--the problem with chrono-medicine] Prusiński A. **Postepy Hig Med Dosw** 1999;53(3):505-15 (34 ref.) (Eng. Abstr.) **(Pol)**

SLEEP, FAST-WAVE see **SLEEP, REM**

SLEEP, REM

Genetic studies in narcolepsy, a disorder affecting REM sleep. Faraco J, et al. **J Hered** 1999 Jan-Feb;90(1):129-32 (34 ref.)
[Painful erections related to sleeping] Menéndez López V, et al. **Actas Urol Esp** 1999 Jun;23(6):539-41 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Lancel M. **Sleep** 1999 Feb 1;22(1):33-42 (128 ref.)

GENETICS

Differences in brain gene expression between sleep and waking as revealed by mRNA differential display and cDNA microarray technology. Cirelli C, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:44-52 (66 ref.)
Prostaglandin D2 and sleep--a molecular genetic approach. Hayaishi O. **J Sleep Res** 1999 Jun;8 Suppl 1:60-4 (24 ref.)
Humoral regulation of physiological sleep: cytokines and GHRH. Krueger JM, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:53-9 (49 ref.)
EEG sleep patterns in twins. Linkowski P. **J Sleep Res** 1999 Jun;8 Suppl 1:11-3 (30 ref.)
Molecular approaches towards the isolation of sleep-related genes. Schibler U, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:1-10 (45 ref.)

IMMUNOLOGY

Humoral regulation of physiological sleep: cytokines and GHRH. Krueger JM, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:53-9 (49 ref.)

PHYSIOLOGY

Cerebral blood flow regulation in REM sleep: a model for flow-metabolism coupling. Lenzi P, et al. **Arch Ital Biol** 1999 May;137(2-3):165-79 (101 ref.)
Selective brain cooling is impaired in REM sleep. Parmeggiani PL, et al. **Arch Ital Biol** 1999 May; 137(2-3):161-4 (18 ref.)
Control of REM sleep: an aspect of the regulation of physiological homeostasis. Zamboni G, et al. **Arch Ital Biol** 1999 Aug;137(4):249-62 (43 ref.)
Why does arterial blood pressure rise actively during REM sleep? Sei H, et al. **J Med Invest** 1999 Feb;46(1-2):11-7 (45 ref.)
Monotremes and the evolution of rapid eye movement sleep. Siegel JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29;353(1372):1147-57 (35 ref.)
Effects of method, duration, and sleep stage on rebounds from sleep deprivation in the rat. Rechtschaffen A, et al. **Sleep** 1999 Feb 1;22(1):11-31 (105 ref.)
Interrelations between sleep and the somatotropic axis. Van Cauter E, et al. **Sleep** 1998 Sep 15;21(6):553-66 (129 ref.)
[Effect of awakening and sleep deprivation in triggering idiopathic generalized epilepsy] Crespel A, et al. **Rev Neurol (Paris)** 1999 Feb;155(2):131-4 (39 ref.) (Eng. Abstr.) **(Fre)**

SLEEP, SLOW-WAVE see **SLEEP**

SLEEP STAGES

Recognizing problem sleepiness in your patients. National Center on Sleep Disorders Research Working Group. **Am Fam Physician** 1999 Feb 15;59(4):937-44 (61 ref.)

PHYSIOLOGY

Automated sleep staging systems in rats. Robert C, et al. **J Neurosci Methods** 1999 May 1;88(2):111-22 (75 ref.)

SLEEP TERROR DISORDER see **SLEEP DISORDERS**

SLEEPWALKING see **SOMNAMBULISM**

SLIM DISEASE see **HIV WASTING SYNDROME**

SLIME BACTERIA see **MYXOCOCCALES**

SLIME MOLDS, PLASMODIAL see **MYXOMYCETES**

SLIME MOLDS, TRUE see **MYXOMYCETES**

SLIPPED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

SLOTHS

PARASITOLOGY

Characterization of Endotrypanum (Kinetoplastida: Trypanosomatidae), a unique parasite infecting the neotropical tree sloths (Edentata). Franco AM, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr;94(2):261-8 (62 ref.)

SLOW ALPHA 2-MACROGLOBULINS see **ALPHA-MACROGLOBULINS**

SLOW VIRUS DISEASES

see related
PRION DISEASES

SLUDGE see **SEWAGE**

SLUDGE, BILIARY see **BILE**

SLY SYNDROME see **MUCOPOLYSACCHARIDOSIS VII**

SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U1 see **RIBONUCLEOPROTEINS, SMALL, U1**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U3 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U7 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

SMALL ROUND-STRUCTURED VIRUSES see **NORWALK VIRUS**

SMALLPOX

Smallpox: gone but not forgotten. Ellner PD. **Infection** 1998 Sep-Oct;26(5):263-9 (49 ref.)
[Smallpox] Kurashige T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):141-4 (10 ref.) **(Jpn)**

EPIDEMIOLOGY

The siren song of eradication. Henderson DA. **J R Coll Physicians Lond** 1998 Nov-Dec;32(6):580-4 (21 ref.)

PREVENTION & CONTROL

The threat of bioterrorism returns the fear of smallpox. Atlas RM. **Curr Opin Microbiol** 1998 Dec;1(6):719-21 (10 ref.)
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. Henderson DA, et al. **JAMA** 1999 Jun 9;281(22):2127-37 (51 ref.)

SMALLPOX VIRUS see **VARIOLA VIRUS**

SMELL

see related
ANOSMIA
ODORS

5-HT4 receptors: gene, transduction and effects on olfactory memory. Bockaert J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:1-15 (61 ref.)
Clinical tests of olfaction. Dawes PJ. **Clin Otolaryngol** 1998 Dec;23(6):484-90 (53 ref.)
Olfaction and symptoms in the multiple chemical sensitivities syndrome. Ross PM, et al. **Prev Med** 1999 May; 28(5):467-80 (140 ref.)

GENETICS

Olfactory cues associated with the major histocompatibility complex. Eggert F, et al. **Genetica** 1998-99;104(3):191-7 (35 ref.)
Soluble MHC antigens and olfactory recognition of genetic individuality: the mechanism. Pearse-Pratt R, et al. **Genetica** 1998-99;104(3):223-30 (13 ref.)

IMMUNOLOGY

Olfactory cues associated with the major histocompatibility complex. Eggert F, et al. **Genetica** 1998-99;104(3):191-7 (35 ref.)
Soluble MHC antigens and olfactory recognition of genetic individuality: the mechanism. Pearse-Pratt R, et al. **Genetica** 1998-99;104(3):223-30 (13 ref.)
Origin, functions and chemistry of H-2 regulated odorants. Yamazaki K, et al. **Genetica** 1998-99;104(3):235-40 (59 ref.)

PHYSIOLOGY

Using olfaction to study memory. Eichenbaum H. **Ann N Y Acad Sci** 1998 Nov 30;855:657-69 (24 ref.)
Odor memory in normal aging and Alzheimer's disease. Nordin S, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:686-93 (33 ref.)
The neurophysiology of taste and olfaction in primates, and umami flavor. Rolls ET, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:426-37 (30 ref.)
Molecular development of sensory maps: representing sights and smells in the brain. O'Leary DD, et al. **Cell** 1999 Jan 22;96(2):255-69 (87 ref.)
Is there an inner nose? Elmes DG. **Chem Senses** 1998 Aug; 23(4):443-5 (21 ref.)
Development of the vertebrate main olfactory system. Lin DM, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):74-8 (41 ref.)
Olfaction and human kin recognition. Porter RH. **Genetica** 1998-99;104(3):259-63 (37 ref.)
Elements of the olfactory signaling pathways in insect antennae. Krieger J, et al. **Invert Neurosci** 1997 Sep-Dec; 3(2-3):137-44 (50 ref.)
New kid on the block: a role for the Na/Ca exchanger in odor transduction [comment] Dionne VE. **J Gen Physiol** 1998 Nov;112(5):527-8 (5 ref.) Comment on: J Gen Physiol 1998 Nov;112(5):529-35.
Computation of molecular information in mammalian olfactory systems. Mori K, et al. **Network** 1998 Nov; 9(4):R79-102 (89 ref.)
The smell of representations. Dudai Y. **Neuron** 1999 Aug; 23(4):633-5 (18 ref.)
Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Moberg PJ, et al. **Neuropsychopharmacology** 1999 Sep;21(3):325-40 (90 ref.)
Loss of olfactory function in dementing disease. Murphy C. **Physiol Behav** 1999 Apr;66(2):177-82 (59 ref.)
Do chemosensory changes influence food intake in the elderly? Rolls BJ. **Physiol Behav** 1999 Apr;66(2):193-7 (35 ref.)
The influence of aging on oral health and consequences for taste and smell. Ship JA. **Physiol Behav** 1999 Apr; 66(2):209-15 (72 ref.)
Chemosensation: molecular mechanisms in worms and mammals. Prasad BC, et al. **Trends Genet** 1999 Apr; 15(4):150-3 (46 ref.)
Molecular aspects of pheromonal communication via the vomeronasal organ of mammals. Tirindelli R, et al. **Trends Neurosci** 1998 Nov;21(11):482-6 (58 ref.)
[Metabotropic glutamate receptor: its ligands and function in the olfactory system] Hayashi Y. **Nippon Yakurigaku Zasshi** 1999 Feb;113(2):73-83 (38 ref.) (Eng. Abstr.) **(Jpn)**

SMITH-LEMLI-OPITZ SYNDROME

Smith-Lemli-Opitz syndrome: a treatable inherited error of metabolism causing mental retardation. Nowaczyk MJ, et al. **CMAJ** 1999 Jul 27;161(2):165-70 (40 ref.)

BLOOD

Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses [letter] Bradley LA, et al. **Am J Med Genet** 1999 Feb 12;82(4):355-8 (23 ref.)

DIAGNOSIS

Prenatal diagnosis of Smith-Lemli-Opitz syndrome in a pregnancy with low maternal serum oestriol and a sex-reversed fetus. Bick DP, et al. **Prenat Diagn** 1999 Jan; 19(1):68-71 (16 ref.)

GENETICS

RSH/Smith-Lemli-Opitz syndrome: mutations and metabolic morphogenesis [editorial; comment] Kelley RI. **Am J Hum Genet** 1998 Aug;63(2):322-6 (41 ref.) Comment on: Am J Hum Genet 1998 Aug;63(2):329-38.
Molecular genetics of the Smith-Lemli-Opitz syndrome and postsqualene sterol metabolism. Fitzky BU, et al. **Curr Opin Lipidol** 1999 Apr;10(2):123-31 (69 ref.)
RSH (so-called Smith-Lemli-Opitz) syndrome. Opitz JM. **Curr Opin Pediatr** 1999 Aug;11(4):353-62 (60 ref.)
Endocrine and metabolism [editorial] Root AW. **Curr Opin Pediatr** 1999 Aug;11(4):329-32 (12 ref.)

METABOLISM

Further delineation of the classical Smith-Lemli-Opitz syndrome phenotype at different patient ages: clinical and biochemical studies. Krajewska-Walasek M, et al. **Clin Dysmorphol** 1999 Jan;8(1):29-40 (39 ref.)

PATHOLOGY

Further delineation of the classical Smith-Lemli-Opitz syndrome phenotype at different patient ages: clinical and biochemical studies. Krajewska-Walasek M, et al. **Clin Dysmorphol** 1999 Jan;8(1):29-40 (39 ref.)

SMOKE

Drug interactions with tobacco smoking. An update. Zevin S, et al. **Clin Pharmacokinet** 1999 Jun;36(6):425-38 (128 ref.)

SMOKE

ADVERSE EFFECTS

PM2.5 and mortality in long-term prospective cohort studies: cause-effect or statistical associations? Gamble JF. **Environ Health Perspect** 1998 Sep;106(9):535-49 (57 ref.)

[Effects of iron-containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27-37 (123 ref.) **(Rus)**

SMOKE INHALATION INJURY

Smoke inhalation injury. Lee-Chiong TL Jr. **Postgrad Med** 1999 Feb;105(2):55-62 (21 ref.)

ETIOLOGY

Acute lung injury, acute respiratory distress syndrome and inhalation injury: an overview. Kimmel EC, et al. **Drug Chem Toxicol** 1999 Feb;22(1):91-128 (140 ref.)

SMOKELESS TOBACCO see **TOBACCO, SMOKELESS**

SMOKING

see related
TOBACCO SMOKE POLLUTION
TOBACCO USE DISORDER

What aspects of human performance are truly enhanced by nicotine? [editorial] Heishman SJ. **Addiction** 1998 Mar; 93(3):317-20 (36 ref.)

Misclassification rates for current smokers misclassified as nonsmokers. Wells AJ, et al. **Am J Public Health** 1998 Oct; 88(10):1503-9 (22 ref.)

The benefits of smoking in skin diseases. Wolf R, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):641-7 (107 ref.)

Drug interactions with tobacco smoking. An update. Zevin S, et al. **Clin Pharmacokinet** 1999 Jun;36(6):425-38 (128 ref.)

Cigarette smoking. Bergen AW, et al. **J Natl Cancer Inst** 1999 Aug 18;91(16):1365-75 (184 ref.)

Covariance of breast cancer incidence with smoking-, oestrogen- and diet-related cancers in pre- and postmenopausal women in Sweden. Manjer J, et al. **Med Hypotheses** 1999 Jun;52(6):561-8 (21 ref.)

Estimated occurrence of tobacco, alcohol, and other drug use among 12- to 18-year-old students in Panama: results of Panama's 1996 National Youth Survey on Alcohol and Drug Use. González GB, et al. **Rev Panam Salud Publica** 1999 Jan;5(1):9-16 (30 ref.)

Teaching medical students about tobacco [see comments] Richmond R. **Thorax** 1999 Jan;54(1):70-8 (110 ref.) Comment in: Thorax 1999 Jan;54(1):2. Comment in: Thorax 1999 Jul;54(7):657-8.

[Tobacco, hypertension and kidney (editorial)] Muller S, et al. **Nephrologie** 1998;19(5):235-7 (27 ref.) **(Fre)**

ADVERSE EFFECTS

Consensus on synergism between cigarette smoke and other environmental carcinogens in the causation of lung cancer. Reif AE, et al. **Adv Cancer Res** 1999;76:161-86 (147 ref.)

Disentangling the separate effects of prenatal and postnatal smoking on the risk of SIDS [comment] Spiers PS. **Am J Epidemiol** 1999 Apr 1;149(7):603-6; discussion 607 (33 ref.) Comment on: Am J Epidemiol 1999 Apr 1;149(7):593-602.

Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Castelli WP. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 2):S349-56 (46 ref.)

Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives. Roy S. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 2):S364-8 (10 ref.)

Positive association between resting pulse and cancer incidence in current and former smokers. Cerhan JR, et al. **Ann Epidemiol** 1999 Jan;9(1):34-44 (31 ref.)

Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system. Taylor BV, et al. **Can J Cardiol** 1998 Sep;14(9):1129-39 (128 ref.)

Is primary prevention of asthma possible? Becker AB. **Can Respir J** 1998 Jul-Aug;5 Suppl A:45A-9A (32 ref.)

Cigarette smoking, wound healing, and face-lift. Campanile G, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):575-8 (48 ref.)

Smoker's wrinkles: epidemiological and pathogenic considerations. Francès C. **Clin Dermatol** 1998 Sep-Oct; 16(5):565-70 (49 ref.)

Cigarette smoking, cutaneous vasculature, and tissue oxygen. Leow YH, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):579-84 (46 ref.)

Cigarette smoking and oral lesions other than cancer. Meraw SJ, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):625-31 (52 ref.)

Cigarette smoking and skin cancer. Merimsky O, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):585-8 (32 ref.)

Cigarette smoking, cutaneous immunity, and inflammatory response. Mills CM. **Clin Dermatol** 1998 Sep-Oct; 16(5):589-94 (38 ref.)

Cigarette smoking and psoriasis. Naldi L. **Clin Dermatol** 1998 Sep-Oct;16(5):571-4 (24 ref.)

Cigarette smoking, hormonal changes, and the skin. Shuiman A, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):595-8 (35 ref.)

Health effects of cigarette smoking. Skurnik Y, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):545-56 (106 ref.)

Smoking and the skin, radically speaking. Wolf R, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):633-9 (72 ref.)

Clinical pharmacology of nicotine. Zevin S, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):557-64 (59 ref.)

Imaging the 'dirty lung'--has high resolution computed tomography cleared the smoke? Gückel C, et al. **Clin Radiol** 1998 Oct;53(10):717-22 (43 ref.)

Is there an increased risk of stroke associated with oral contraceptives? Zeitoun K, et al. **Drug Saf** 1999 Jun; 20(6):467-73 (43 ref.)

Management of the hypertensive patient who smokes. Pardell H, et al. **Drugs** 1998 Aug;56(2):177-87 (106 ref.)

Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Dybing E, et al. **Hum Exp Toxicol** 1999 Apr;18(4):202-5 (30 ref.)

Mortality and morbidity from smoking-induced cardiovascular diseases: the necessity of the cardiologist's involvement and commitment. Milei J, et al. **Int J Cardiol** 1998 Dec 1;67(2):95-109 (104 ref.)

Smoking tobacco, microcirculatory changes and the role of nicotine. Haustein KO. **Int J Clin Pharmacol Ther** 1999 Feb;37(2):76-85 (69 ref.)

Risk from tobacco and potentials for health gain [see comments] Doll R. **Int J Tuberc Lung Dis** 1999 Feb; 3(2):90-9 (87 ref.) Comment in: Int J Tuberc Lung Dis 1999 Feb;3(2):85-6.

Bladder cancer in women. van der Poel HG, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(3):207-12 (65 ref.)

Smoking in women. Mueller L, et al. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S7-10 (29 ref.)

Effects of cigarette smoking on gastric ulcer formation and healing: possible mechanisms of action. Ma L, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S80-6 (81 ref.)

Economic issues in lung cancer: a review. Goodwin PJ, et al. **J Clin Oncol** 1998 Dec;16(12):3900-12 (66 ref.)

Smoking and gastric ulcers: the possible role of nicotine. Ogle CW. **J Clin Pharmacol** 1999 May;39(5):448-53 (34 ref.)

The saga of tobacco products liability litigation: a look back and a proposal for the future. Nusbaum NJ. **J Community Health** 1998 Oct;23(5):325-35 (43 ref.)

Pharmacotherapy of chronic obstructive pulmonary disease. Borron W, et al. **J La State Med Soc** 1998 Dec; 150(12):596-600 (26 ref.)

It's about health, it's about time: information everyone should know. Cabelka JF 2nd. **J Med Assoc Ga** 1998 Nov; 87(4):328-9 (17 ref.)

Tobacco smoke carcinogens and lung cancer. Hecht SS. **J Natl Cancer Inst** 1999 Jul 21;91(14):1194-210 (249 ref.)

Addressing nicotine addiction in women. Role of the midwife. Ward S. **J Nurse Midwifery** 1999 Jan-Feb; 44(1):3-18 (103 ref.)

Cigarette smoking and erectile dysfunction. Jeremy JY, et al. **J R Soc Health** 1998 Jun;118(3):151-5 (61 ref.)

Smoking and urological disease. Mikhailidis DP, et al. **J R Soc Health** 1998 Aug;118(4):210-2 (34 ref.)

Cardiovascular risk factors, smoking and kidney function. Baggio B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:2-5 (47 ref.)

Cigarette use during adolescence: effects on nutritional status. Hampl JS, et al. **Nutr Rev** 1999 Jul;57(7):215-21 (63 ref.)

Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253-62 (34 ref.)

Maternal cocaine use and cigarette smoking in pregnancy in relation to amino acid transport and fetal growth. Pastrakuljic A, et al. **Placenta** 1999 Sep;20(7):499-512 (136 ref.)

Cigarette smoking and pregnancy II: vascular effects. Salafia C, et al. **Placenta** 1999 May;20(4):273-9 (89 ref.)

Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Shiverick KT, et al. **Placenta** 1999 May; 20(4):265-72 (103 ref.)

Trends in smoking-related diseases. Why smoking cessation is still the best medicine. Hays JT, et al. **Postgrad Med** 1998 Dec;104(6):56-62, 65-6, 71 (22 ref.)

Smoking and low back pain. A systematic literature review of 41 journal articles reporting 47 epidemiologic studies. Leboeuf-Yde C. **Spine** 1999 Jul 15;24(14):1463-70 (53 ref.)

Smoking-induced elevations in blood carboxyhaemoglobin levels. Effect on maximal oxygen uptake. McDonough P, et al. **Sports Med** 1999 May;27(5):275-83 (77 ref.)

Taking aim at the bull's-eye: the nicotine in tobacco products [editorial] Douglas CE. **Tob Control** 1998 Autumn; 7(3):215-8 (92 ref.)

Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Henningfield JE, et al. **Tob Control** 1998 Autumn; 7(3):281-93 (144 ref.)

Effects of air pollution and smoking on chronic obstructive pulmonary disease and bronchial asthma. Sasaki H, et al. **Tohoku J Exp Med** 1998 Nov;186(3):151-67 (73 ref.)

[The effect of tobacco smoking on risks in connection in anesthesia and surgery. Development of complications and the preventive effect of smoking cessation] Møller AM, et al. **Ugeskr Laeger** 1999 Jul 26;161(30):4273-6 (27 ref.) (Eng. Abstr.) **(Dan)**

[Roaming through methodology. XV. Smoking grandfathers and other selection biases] van Gijn J, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1515-7 (7 ref.) (Eng. Abstr.) **(Dut)**

[Tobacco: an atherogenic, thrombogenic or spasmogenic factor?] Adnot S. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:53-8 (45 ref.) (Eng. Abstr.) **(Fre)**

[Smoking and periodontal health] Obeid P, et al. **Rev Belge Med Dent** 1998;53(4):237-56 (123 ref.) (Eng. Abstr.) **(Fre)**

[Survey of the effects of smoking in an occupational cohort study. Value and limits of a new method] Moulin JJ, et al. **Rev Epidemiol Sante Publique** 1998 Sep;46(4):289-97 (31 ref.) (Eng. Abstr.) **(Fre)**

[Smoking or nicotine as the reason for coronary circulation disorders and possibilities for treatment of nicotine dependence] Haustein KO. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):363-9 (53 ref.) **(Ger)**

[Tobacco: ashes, smoke and carbon] Ullmer E, et al. **Schweiz Med Wochenschr** 1999 Jan 30;129(4):103-12 (30 ref.) (Eng. Abstr.) **(Ger)**

[Selected problems concerning harmful effects of smoking on the upper segment of the alimentary tract] Semianów-Wejchert J. **Pol Merkuriusz Lek** 1998 Aug; 5(26):89-91 (29 ref.) (Eng. Abstr.) **(Pol)**

[Nicotine and cardiovascular complications of chronic hypertensive disease] Goldman J, et al. **Przegl Lek** 1998; 55(2):74-6 (23 ref.) (Eng. Abstr.) **(Pol)**

[Smoking as a risk factor for chronic bronchitis (review of literature)] Guseĭnov KhIu. **Probl Tuberk** 1999;(4):42-4 (52 ref.) **(Rus)**

[Role of tobacco smoking on cardiovascular morbidity and mortality in today's Russia] Ioffina OB, et al. **Ter Arkh** 1999;71(1):69-73 (32 ref.) **(Rus)**

[Effect of smoking on the feto-placental unit] Habek D. **Lijec Vjesn** 1998 Jul-Aug;120(7-8):215-9 (46 ref.) (Eng. Abstr.) **(Scr)**

[Pregnancy and smoking: significance of the problem and health-service based prevention] Castellanos E, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):670-4 (76 ref.) **(Spa)**

BLOOD

Smoking-induced elevations in blood carboxyhaemoglobin levels. Effect on maximal oxygen uptake. McDonough P, et al. **Sports Med** 1999 May;27(5):275-83 (77 ref.)

DRUG THERAPY

Recent advances in the pharmacotherapy of smoking [see comments] Hughes JR, et al. **JAMA** 1999 Jan 6;281(1):72-6 (56 ref.) Comment in: JAMA 1999 Jun 2;281(21):1983; discussion 1984-5. Comment in: JAMA 1999 Jun 2;281(21):1983-4; discussion 1984-5. Comment in: JAMA 1999 Jun 2;281(21);1984; discussion 1984-5. Comment in: JAMA 1999 Jun 2;281(21):1984-5.

EPIDEMIOLOGY

Adolescent tobacco, alcohol, and drug use: current findings. Windle M, et al. **Adolesc Med** 1999 Feb;10(1):153-63, vii (37 ref.)

Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Beto JA, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S172-83 (47 ref.)

Global perspective of tobacco habits and lung cancer: a lesson for third world countries. Pandey M, et al. **Eur J Cancer Prev** 1999 Aug;8(4):271-9 (58 ref.)

Trends in adolescent cigarette use: the diffusion of daily smoking. Redmond WH. **J Behav Med** 1999 Aug; 22(4):379-95 (24 ref.)

Smoking, diabetes and hyperlipidaemia. Mikhailidis DP, et al. **J R Soc Health** 1998 Apr;118(2):91-3 (35 ref.)

Helicobacter pylori and smoking: two additive risk factors for organic dyspepsia. Halter F, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):91-9 (35 ref.)

[Roaming through methodology. XV. Smoking grandfathers and other selection biases] van Gijn J, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1515-7 (7 ref.) (Eng. Abstr.) **(Dut)**

[Educational intervention in schools for the prevention of smoking: evaluation of the process. Project: OCTOPUS] López González L, et al. **Rev Esp Salud Publica** 1998 Jul-Aug;72(4):303-18 (27 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Controlling tobacco use within prisons [letter] Awofeso N. **Int J Tuberc Lung Dis** 1999 Jun;3(6):547-8 (9 ref.)

The saga of tobacco products liability litigation: a look back and a proposal for the future. Nusbaum NJ. **J Community Health** 1998 Oct;23(5):325-35 (43 ref.)

Social movements as catalysts for policy change: the case of smoking and guns. Nathanson CA. **J Health Polit Policy Law** 1999 Jun;24(3):421-88 (146 ref.)

Arizona's tobacco control initiative illustrates the need for continuing oversight by tobacco control advocates. Aguinaga Bialous S, et al. **Tob Control** 1999 Summer; 8(2):141-51 (110 ref.)

[The requisite internationalization of the campaign against smoking] Dubois G. **Bull Acad Natl Med** 1998; 182(5):939-50; discussion 951-3 (61 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Advanced glycation endproducts and cigarette smoking. Nicholl ID, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov; 44(7):1025-33 (55 ref.)

PHYSIOPATHOLOGY

Sympathetic activity and aging: relationship to smoking habits, physical fitness, blood volume, and intracellular signalling. Jensen EW. **Dan Med Bull** 1999 Apr; 46(2):106–17 (135 ref.)

Tobacco smoking, alcohol, and special diet in drug trials: exclusion criteria or target of specific investigations? Fuhr U. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):604–6 (20 ref.)

Smoking and anxiety in combat veterans with chronic posttraumatic stress disorder: a review. Beckham JC. **J Psychoactive Drugs** 1999 Apr–Jun;31(2):103–10 (69 ref.)

Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Dursun SM, et al. **Med Hypotheses** 1999 Feb; 52(2):101–9 (78 ref.)

Interleukin–6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down–regulation with essential fatty acids, ethanol and pentoxifylline. McCarty MF. **Med Hypotheses** 1999 May;52(5):465–77 (229 ref.)

Neurobiology of tobacco smoking and other addictive disorders. Gamberino WC, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):301–12 (49 ref.)

PREVENTION & CONTROL

Tobacco, youth, and sports. Epps RP, et al. **Adolesc Med** 1998 Oct;9(3):483–90, vi (20 ref.)

Smoking prevention and cessation in adolescents. Rutishauser C, et al. **Aust Fam Physician** 1998 Dec;27(12):1110–3 (19 ref.)

School–based smoking control: a research agenda [see comments] Manske SR, et al. **Cancer Prev Control** 1997 Aug;1(3):196–212 (110 ref.) Comment in: Cancer Prev Control 1997 Aug;1(3):190–1.

Prevention of lung cancer by long–term use of alternative nicotine delivery systems? Kunze U, et al. **Eur J Cancer** 1999 Feb;35(2):195–6 (19 ref.)

Controlling tobacco use within prisons [letter] Awofeso N. **Int J Tuberc Lung Dis** 1999 Jun;3(6):547–8 (9 ref.)

Rethinking anti–smoking media campaigns: two generations of research and issues for the next. Logan RA, et al. **J Health Care Finance** 1999 Summer;25(4):77–90 (59 ref.)

Social movements as catalysts for policy change: the case of smoking and guns. Nathanson CA. **J Health Polit Policy Law** 1999 Jun;24(3):421–88 (146 ref.)

Smoking intervention with adolescent substance abusers. Initial recommendations. Myers MG. **J Subst Abuse Treat** 1999 Jun;16(4):289–98 (59 ref.)

A theoretical model for the study of active and passive smoking in military women: an at–risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475–80 (56 ref.)

Consensus statement on prevention and early diagnosis of lung cancer. Varese, Italy, December, 1998. **Oncology (Huntingt)** 1999 Mar;13(3):298 (0 ref.)

Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253–62 (34 ref.)

Very delayed smoking relapse warrants research attention. Brandon TH, et al. **Psychol Rep** 1998 Aug;83(1):72–4 (10 ref.)

Can we stop children and adolescents from smoking? [comment] Yach D, et al. **Soc Sci Med** 1999 Mar; 48(6):757–8 (15 ref.) Comment on: Soc Sci Med 1999 Mar;48(6):759–75.

Arizona's tobacco control initiative illustrates the need for continuing oversight by tobacco control advocates. Aguinaga Bialous S, et al. **Tob Control** 1999 Summer; 8(2):141–51 (110 ref.)

[Pregnancy and smoking: significance of the problem and health–service based prevention] Castellanos E, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):670–4 (76 ref.) **(Spa)**

[Influence of coronary risk factors in secondary prevention: tobacco] López García–Aranda V, et al. **Rev Esp Cardiol** 1998;51 Suppl 6:10–7 (59 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Selections from current literature: smoking and depression. Shiesha S. **Fam Pract** 1999 Apr;16(2):202–5 (3 ref.)

Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Dursun SM, et al. **Med Hypotheses** 1999 Feb; 52(2):101–9 (78 ref.)

A theoretical model for the study of active and passive smoking in military women: an at–risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475–80 (56 ref.)

Smoking behaviour and compensation: a review of the literature. Scherer G. **Psychopharmacology (Berl)** 1999 Jul; 145(1):1–20 (185 ref.)

Psychosocial factors related to adolescent smoking: a critical review of the literature. Tyas SL, et al. **Tob Control** 1998 Winter;7(4):409–20 (226 ref.)

TRENDS

Trends in adolescent cigarette use: the diffusion of daily smoking. Redmond WH. **J Behav Med** 1999 Aug; 22(4):379–95 (24 ref.)

SMOKING CESSATION

Invited commentary on "early and late weight gain following smoking cessation in the Lung Health Study" [comment] Thun MJ, et al. **Am J Epidemiol** 1998 Nov 1;148(9):831–2 (21 ref.) Comment on: Am J Epidemiol 1998 Nov 1;148(9):821–30.

Buspirone use for smoking cessation. Farid P, et al. **Ann Pharmacother** 1998 Dec;32(12):1362–4 (12 ref.)

Nicotine replacement therapy. Thompson GH, et al. **Ann Pharmacother** 1998 Oct;32(10):1067–75 (43 ref.)

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta–analysis. Girolami B, et al. **Arch Intern Med** 1999 Feb 22;159(4):337–45 (116 ref.)

Smoking cessation: evidence based recommendations for the healthcare system [see comments] Raw M, et al. **BMJ** 1999 Jan 16;318(7177):182–5 (22 ref.) Comment in: BMJ 1999 Jan 16;318(7177):138–9.

Prevention: tobacco control and cancer nursing. Sarna L. **Cancer Nurs** 1999 Feb;22(1):21–8 (80 ref.)

Physicians can make a difference with smokers: evidence–based clinical approaches. Presentation given during the Symposium on Smoking Cessation at the 29th World Conference of the IUATLD/UICTMR and Global Congress on Lung Health, Bangkok, Thailand, 23–26 November 1998. International Union Against Tuberculosis and Lung Disease. Richmond RL. **Int J Tuberc Lung Dis** 1999 Feb;3(2):100–12 (120 ref.)

Smoking in women. Mueller L, et al. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S7–10 (29 ref.)

Effects of cessation of smoking after myocardial infarction. Wilhelmsen L. **J Cardiovasc Risk** 1998 Jun;5(3):173–6 (24 ref.)

Non–pharmacological modification of cardiac risk factors: part 3. Smoking cessation and alcohol consumption. Eagles CJ, et al. **J Clin Pharm Ther** 1998 Feb;23(1):1–9 (90 ref.)

Addressing nicotine addiction in women. Role of the midwife. Ward S. **J Nurse Midwifery** 1999 Jan–Feb; 44(1):3–18 (103 ref.)

Studies of factors in relapse to alcohol, drug and nicotine use: a critical review of methodologies and findings. McKay JR. **J Stud Alcohol** 1999 Jul;60(4):566–76 (70 ref.)

Optimizing smoking cessation strategies. Andrews J. **Nurse Pract** 1998 Aug;23(8):47–8, 51–2, 57–8 passim (25 ref.)

Using the transtheoretical model in guiding smoking cessation [letter] Coward R. **Nurse Pract** 1999 Feb;24(2):146–50 (6 ref.)

Trends in smoking–related diseases. Why smoking cessation is still the best medicine. Hays JT, et al. **Postgrad Med** 1998 Dec;104(6):56–62, 65–6, 71 (22 ref.)

Population–based recruitment for quit–smoking programs: an analytic review of communication variables. McDonald PW. **Prev Med** 1999 Jun;28(6):545–57 (86 ref.)

Smoking cessation treatment for substance misusers in early recovery: a review of the literature and recommendations for practice. Kalman D. **Subst Use Misuse** 1998 Aug; 33(10):2021–47 (120 ref.)

Effects of thirty–four adolescent tobacco use cessation and prevention trials on regular users of tobacco products. Sussman S, et al. **Subst Use Misuse** 1999 Sep; 34(11):1469–503 (61 ref.)

An overview of tobacco measures. Davis RM. **Tob Control** 1998 Winter;7 Suppl:S36–40; discussion S47–9 (14 ref.)

[Smoking cessation and pregnancy] Møller AM, et al. **Ugeskr Laeger** 1999 Sep 6;161(36):4985–6 (10 ref.) (Eng. Abstr.) **(Dan)**

[The effect of tobacco smoking on risks in connection in anesthesia and surgery. Development of complications and the preventive effect of smoking cessation] Møller AM, et al. **Ugeskr Laeger** 1999 Jul 26;161(30):4273–6 (27 ref.) (Eng. Abstr.) **(Dan)**

[Predictive factors of smoking cessation after myocardial infarction. Review of the literature (see comments)] Aboyans V, et al. **Ann Cardiol Angeiol (Paris)** 1998 Mar; 47(3):177–82 (37 ref.) (Eng. Abstr.) Comment in: Ann Cardiol Angeiol (Paris) 1998 Mar;47(3):183–4. **(Fre)**

[Smoking, cardiovascular diseases and possibilities for treating nicotine dependence] Haustein KO. **Wien Med Wochenschr** 1999;149(1):19–24 (71 ref.) (Eng. Abstr.) **(Ger)**

[Respiratory tract diseases and instructions on smoking cessation] Kawakami M. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):362–7 (11 ref.) **(Jpn)**

[Nicotine preparations and other preparations for smoking cessation] Tonstad S. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1289–93 (45 ref.) (Eng. Abstr.) **(Nor)**

[Influence of coronary risk factors in secondary prevention: tobacco] López García–Aranda V, et al. **Rev Esp Cardiol** 1998;51 Suppl 6:10–7 (59 ref.) (Eng. Abstr.) **(Spa)**

[Educational intervention in schools for the prevention of smoking: evaluation of the process. Project: OCTOPUS] López González L, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):303–18 (27 ref.) (Eng. Abstr.) **(Spa)**

[Nicotine replacement always better than further smoking or using snuff] Bolinder G, et al. **Lakartidningen** 1999 May 26;96(21):2614–8 (20 ref.) **(Swe)**

ECONOMICS

The cost to society of smoking cessation. Cohen D, et al. **Thorax** 1998 Aug;53 Suppl 2:S38–42 (47 ref.)

[Practical guides for stopping the tobacco habit: a cost–effectiveness analysis?] Pérez Trullén A, et al. **Arch Bronconeumol** 1999 May;35 Suppl 3:89–94 (24 ref.) **(Spa)**

METHODS

Smoking prevention and cessation in adolescents. Rutishauser C, et al. **Aust Fam Physician** 1998 Dec;27(12):1110–3 (19 ref.)

The nicotine transdermal system. Gore AV, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):599–615 (105 ref.)

Adverse skin reactions to the nicotine transdermal system. Wolf R, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):617–23 (78 ref.)

Recent advances in the pharmacotherapy of smoking [see comments] Hughes JR, et al. **JAMA** 1999 Jan 6;281(1):72–6 (56 ref.) Comment in: JAMA 1999 Jun 2;281(21):1983; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21):1983–4; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21):1984; discussion 1984–5. Comment in: JAMA 1999 Jun 2;281(21):1984–5.

Drug therapy to aid in smoking cessation. Tips on maximizing patients' chances for success. Dale LC, et al. **Postgrad Med** 1998 Dec;104(6):75–8, 83–4 (11 ref.)

[Group therapy and smoking cessation] Møller AM, et al. **Ugeskr Laeger** 1999 Sep 6;161(36):4987–8 (8 ref.) (Eng. Abstr.) **(Dan)**

[Hypnosis for smoking cessation] Tønnesen P, et al. **Ugeskr Laeger** 1999 Jul 26;161(30):4270–2 (10 ref.) **(Dan)**

PSYCHOLOGY

Smoking intervention with adolescent substance abusers. Initial recommendations. Myers MG. **J Subst Abuse Treat** 1999 Jun;16(4):289–98 (59 ref.)

Very delayed smoking relapse warrants research attention. Brandon TH, et al. **Psychol Rep** 1998 Aug;83(1):72–4 (10 ref.)

SMOKING, PASSIVE see **TOBACCO SMOKE POLLUTION**

SMOOTH MUSCLE TUMOR

PATHOLOGY

Prognosis and surveillance of gastrointestinal stromal/smooth muscle tumors. Emory TS, et al. **Ann Chir Gynaecol** 1998; 87(4):306–10 (29 ref.)

SNAIL VENOMS see **MOLLUSK VENOMS**

SNAILS

[Chemistry of conotoxins from cone snails] Sato K. **Seikagaku** 1999 Mar;71(3):183–92 (56 ref.) **(Jpn)**

GENETICS

Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Olivera BM, et al. **Ann N Y Acad Sci** 1999 May 18;870:223–37 (37 ref.)

METABOLISM

Antioxidant defenses and metabolic depression. The hypothesis of preparation for oxidative stress in land snails. Hermes–Lima M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jul; 120(3):437–48 (102 ref.)

PARASITOLOGY

Eosinophilic meningitis/angiostrongyliasis from eating aquaculture–raised snails: a case report. Marsh CM. **Hawaii Med J** 1998 Oct;57(10):652–4 (10 ref.)

SNAKE BITES

see related
ANTIVENINS
SNAKE VENOMS

Envenomations. Walter FG, et al. **Crit Care Clin** 1999 Apr; 15(2):353–86, ix (173 ref.)

Snake, spider, and scorpion envenomation in North America. Bond GR. **Pediatr Rev** 1999 May;20(5):147–50; quiz 151 (0 ref.)

[Snake venoms] Imaizumi H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):668–71 (14 ref.) **(Jpn)**

COMPLICATIONS

[An accelerated idioventricular rhythm and incomplete right bundle–branch block secondary to the bite of Vipera latasti (letter) (published erratum appears in Med Clin (Barc) 1999 Apr 17;112(13):494)] Meseguer Ruiz VA, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):278–9 (9 ref.) **(Spa)**

SNAKE BITES

DIAGNOSIS

[Acute management of patients bitten by poisonous snakes (see comments)] Carels RA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 19;142(51):2773–7 (20 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Mar 6;143(10):541. **(Dut)**

EPIDEMIOLOGY

Snake-bites: appraisal of the global situation. Chippaux JP. **Bull World Health Organ** 1998;76(5):515–24 (114 ref.)

THERAPY

Antivenom therapy in the Americas. Heard K, et al. **Drugs** 1999 Jul;58(1):5–15 (62 ref.)

Field treatment of snakebites in the Israel Defense Forces. Haviv J, et al. **Public Health Rev** 1998;26(3):247–56 (17 ref.)

Venomous snakes of Israel: ecology and snakebite. Kochva E. **Public Health Rev** 1998;26(3):209–32 (25 ref.)

Vipera palaestinae antivenin. Moroz C. **Public Health Rev** 1998;26(3):233–6 (8 ref.)

Snake envenomation and protective natural endogenous proteins: a mini review of the recent developments (1991–1997). Thwin MM, et al. **Toxicon** 1998 Nov; 36(11):1471–82 (64 ref.)

[Acute management of patients bitten by poisonous snakes (see comments)] Carels RA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 19;142(51):2773–7 (20 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Mar 6;143(10):541. **(Dut)**

SNAKE ENVENOMATION see **SNAKE BITES**

SNAKE VENOMS

see related
ANTIVENINS

Use of snake venom fractions in the coagulation laboratory. Marsh NA. **Blood Coagul Fibrinolysis** 1998 Jul;9(5):395–404 (119 ref.)

ADVERSE EFFECTS

[Acute management of patients bitten by poisonous snakes (see comments)] Carels RA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 19;142(51):2773–7 (20 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Mar 6;143(10):541. **(Dut)**

ANALYSIS

Tests for detection of snake venoms, toxins and venom antibodies: review on recent trends (1987–1997). Selvanayagam ZE, et al. **Toxicon** 1999 Apr;37(4):565–86 (127 ref.)

CHEMISTRY

Snake venom hemorrhagins. Hati R, et al. **Crit Rev Toxicol** 1999 Jan;29(1):1–19 (142 ref.)

Snake venom alpha-neurotoxins and other 'three-finger' proteins. Tsetlin V. **Eur J Biochem** 1999 Sep;264(2):281–6 (60 ref.)

Lysine 49 phospholipase A2 proteins. Ownby CL, et al. **Toxicon** 1999 Mar;37(3):411–45 (120 ref.)

CLASSIFICATION

Synopsis of recent developments in venomous snake systematics, No. 3. Wüster W, et al. **Toxicon** 1999 Aug; 37(8):1123–9 (34 ref.)

ENZYMOLOGY

Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Pérez JC, et al. **Toxicon** 1999 May;37(5):703–28 (116 ref.)

PHARMACOLOGY

Acetylcholinesterase from snake venom as a model for its nerve and muscle counterpart. Cousin X, et al. **J Nat Toxins** 1999 Jun;8(2):285–94 (81 ref.)

Snake venoms and the hemostatic system. Markland FS. **Toxicon** 1998 Dec;36(12):1749–800 (254 ref.)

[Use of snake venom proteins in medicine] Stocker K. **Schweiz Med Wochenschr** 1999 Feb 13;129(6):205–16 (51 ref.) (Eng. Abstr.) **(Ger)**

POISONING

[Snake venoms] Imaizumi H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):668–71 (14 ref.) **(Jpn)**

TOXICITY

Nephrotoxicity in snake envenomation. Sitprija V, et al. **J Nat Toxins** 1999 Jun;8(2):271–7 (48 ref.)

SNAKES

see related
SNAKE BITES
SNAKE VENOMS

Venomous snakes of Israel: ecology and snakebite. Kochva E. **Public Health Rev** 1998;26(3):209–32 (25 ref.)

ANATOMY & HISTOLOGY

Structure, function, and evolution of the oviducts of squamate reptiles, with special reference to viviparity and placentation. Blackburn DG. **J Exp Zool** 1998 Nov–Dec 1;282(4–5):560–617 (314 ref.)

SNEDDON-WILKINSON DISEASE see **SKIN DISEASES, VESICULOBULLOUS**

SNORING

When snoring requires serious attention. Stone P. **Practitioner** 1998 Jun;242(1587):458–62, 464 (14 ref.)

[Snoring and vascular diseases] Zamarrón C. **An Med Interna** 1998 Dec;15(12):669–71 (49 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Complications of snoring, upper airway resistance syndrome, and obstructive sleep apnea syndrome in adults. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):223–34 (39 ref.)

Sleep apnoea and snoring: potential links with vascular disease. Sullivan CE, et al. **Thorax** 1998 Oct;53 Suppl 3:S8–11 (35 ref.)

EPIDEMIOLOGY

Snoring and sleep apnea. A study of evolution and consequences in a male population. Minireview based on a doctoral thesis. Lindberg E. **Ups J Med Sci** 1998; 103(3):155–202 (198 ref.)

ETIOLOGY

Habitual snoring, OSA and craniofacial modification. Orthodontic clinical and diagnostic aspects in a case control study. Caprioglio A, et al. **Minerva Stomatol** 1999 Apr; 48(4):125–37 (43 ref.) **(Eng, Ita)**

PHYSIOPATHOLOGY

Diagnostic and treatment implications of nasal obstruction in snoring and obstructive sleep apnea. Scharf MB, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):279–87; quiz 287–90 (114 ref.)

Introduction to the mechanism of obstructive sleep apnoea and snoring. Simonds AK. **Monaldi Arch Chest Dis** 1998 Dec;53(6):617–20 (7 ref.)

PREVENTION & CONTROL

Oral appliances for the management of snoring and obstructive sleep apnoea. Bennett LS, et al. **Thorax** 1998 Aug;53 Suppl 2:S58–64 (47 ref.)

SURGERY

Snoring, obstructive sleep apnea, and surgery. Barthel SW, et al. **Med Clin North Am** 1999 Jan;83(1):85–96 (104 ref.)

Oropharyngeal surgery in the management of upper airway obstruction during sleep. Coleman J, et al. **Otolaryngol Clin North Am** 1999 Apr;32(2):263–76 (33 ref.)

Suspension sutures for the treatment of obstructive sleep apnea and snoring. Coleman J, et al. **Otolaryngol Clin North Am** 1999 Apr;32(2):277–85 (8 ref.)

THERAPY

[Effective nasal CPAP therapy for heavy snoring and paradoxical respiration during sleep in a case of multiple system atrophy] Miyamoto M, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1059–63 (14 ref.) (Eng. Abstr.) **(Jpn)**

SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U1 SNRNP see **RIBONUCLEOPROTEINS, SMALL, U1**

U3 SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U7 SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SNUFF see **TOBACCO, SMOKELESS**

SOCCER

INJURIES

How can injuries be prevented in the World Cup soccer athlete? Engström BK, et al. **Clin Sports Med** 1998 Oct; 17(4):755–68, vii (61 ref.)

Youth soccer: an epidemiologic perspective. Metzl JD, et al. **Clin Sports Med** 1998 Oct;17(4):663–73, v (25 ref.)

Are there long-term sequelae from soccer? Roos H. **Clin Sports Med** 1998 Oct;17(4):819–31, viii (88 ref.)

Muscle injuries associated with soccer. Saartok T. **Clin Sports Med** 1998 Oct;17(4):811–7, viii (29 ref.)

Is heading a soccer ball injurious to brain function? Baroff GS. **J Head Trauma Rehabil** 1998 Apr;13(2):45–52 (20 ref.)

Stress fracture of the proximal fibula in a young soccer player: a case report and a review of the literature. DiFiori JP. **Med Sci Sports Exerc** 1999 Jul;31(7):925–8 (30 ref.)

Sports-specific concerns in the young athlete: soccer. Metzl JD. **Pediatr Emerg Care** 1999 Apr;15(2):130–4 (19 ref.)

Fracture of the anterior nasal spine. Escada P, et al. **Rhinology** 1999 Mar;37(1):40–2 (15 ref.)

PHYSIOLOGY

The biomechanics of kicking in soccer. Barfield WR. **Clin Sports Med** 1998 Oct;17(4):711–28, vi (52 ref.)

Fluid and electrolyte replacement in soccer. Kirkendall DT. **Clin Sports Med** 1998 Oct;17(4):729–38, vi (23 ref.)

SOCIAL ACCOUNTABILITY see **SOCIAL RESPONSIBILITY**

SOCIAL ADJUSTMENT

Peer relationships and social competence during early and middle childhood. Ladd GW. **Annu Rev Psychol** 1999; 50:333–59 (131 ref.)

Marital conflict, divorce, and children's adjustment. Kelly JB. **Child Adolesc Psychiatr Clin N Am** 1998 Apr; 7(2):259–71, v–vi (52 ref.)

Joint custody and shared parenting. Research and interventions. Pruett MK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):273–94, vi (76 ref.)

The psychologic assessment and psychosocial recovery of the patient with an amputation. Fitzpatrick MC. **Clin Orthop** 1999 Apr;(361):98–107 (17 ref.)

Social anxiety and drinking in college students: a social cognitive theory analysis. Burke RS, et al. **Clin Psychol Rev** 1999 Aug;19(5):513–30 (140 ref.)

Neuropsychologic and adaptive functioning in adolescents and young adults shunted for congenital hydrocephalus. Hommet C, et al. **J Child Neurol** 1999 Mar;14(3):144–50 (48 ref.)

Play, creativity, and adaptive functioning: implications for play interventions. Russ SW. **J Clin Child Psychol** 1998 Dec;27(4):469–80 (98 ref.)

Private and public in the lives of chronic schizophrenic patients. Leferink K. **Psychiatry** 1998 Summer;61(2):147–62 (60 ref.)

Perceptions of psychosocial adjustment to aphasia: applications of the Code--Müller Protocols. Code C, et al. **Semin Speech Lang** 1999;20(1):51–62; quiz 63 (30 ref.)

SOCIAL BEHAVIOR

Taking time seriously. A theory of socioemotional selectivity. Carstensen LL, et al. **Am Psychol** 1999 Mar;54(3):165–81 (109 ref.)

The medial extended amygdala in male reproductive behavior. A node in the mammalian social behavior network. Newman SW. **Ann N Y Acad Sci** 1999 Jun 29; 877:242–57 (103 ref.)

Interpersonal processes: the interplay of cognitive, motivational, and behavioral activities in social interaction. Snyder M, et al. **Annu Rev Psychol** 1999;50:273–303 (138 ref.)

Serotonin and neuropeptides in affiliative behaviors. Insel TR, et al. **Biol Psychiatry** 1998 Aug 1;44(3):207–19 (45 ref.)

Can social cognitive models contribute to the effectiveness of HIV-preventive behavioural interventions? A brief review of the literature and a reply to Joffe (1996; 1997) and Fife-Schaw (1997) [comment] Abraham C, et al. **Br J Med Psychol** 1998 Sep;71 (Pt 3):297–310 (73 ref.) Comment on: Br J Med Psychol 1996 Sep;69 (Pt 3):169–90. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):65–73. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):75–83.

The transformation of everyday social experience: what a mental and social health perspective reveals about Chinese communities under global and local change. Kleinman A, et al. **Cult Med Psychiatry** 1999 Mar;23(1):7–24 (43 ref.)

Preferences, quantities and concerns: socio-cultural perspectives on the gendered consumption of foods. O'Doherty Jensen K, et al. **Eur J Clin Nutr** 1999 May; 53(5):351–9 (66 ref.)

Ageing and social rank effects on the reproductive system of free-ranging yellow baboons (Papio cynocephalus) at Mikumi National Park, Tanzania. Wasser SK, et al. **Hum Reprod Update** 1998 Jul–Aug;4(4):430–8 (40 ref.)

Do measures of externalising behaviour in normal populations predict later outcome?: Implications for targeted interventions to prevent conduct disorder. Bennett KJ, et al. **J Child Psychol Psychiatry** 1998 Nov;39(8):1059–70 (64 ref.)

Social interpersonal dimensions of the psychoses. Lindsay JS. **Med Hypotheses** 1999 Apr;52(4):335–47 (28 ref.)

The developmental psychobiology of behavioural plasticity in mice: the role of social experiences in the family unit. Laviola G, et al. **Neurosci Biobehav Rev** 1998;23(2):197–213 (123 ref.)

Socioemotional development across cultures: context, complexity, and pathways. Sharma D, et al. **New Dir Child Dev** 1998 Fall;(81):3–20 (133 ref.)

Role of vasopressin and oxytocin in the control of social behavior in Syrian hamsters (Mesocricetus auratus). Albers HE, et al. **Prog Brain Res** 1998;119:395–408 (71 ref.)

Vasopressin, gonadal steroids and social recognition. Dantzer R. **Prog Brain Res** 1998;119:409–14 (23 ref.)
Neurohypophyseal peptides and social recognition in rats. Popik P, et al. **Prog Brain Res** 1998;119:415–36 (167 ref.)
Neuroendocrine perspectives on social attachment and love. Carter CS. **Psychoneuroendocrinology** 1998 Nov; 23(8):779–818 (205 ref.)
Effects of early stress on adult affiliative behavior. Henry JP, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):863–75 (54 ref.)
[Advances in the study of HIV/AIDS associated social behavior] Li H, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1998 Mar; 32(2):120–1 (16 ref.) **(Chi)**

SOCIAL BEHAVIOR DISORDERS

see related
ANTISOCIAL PERSONALITY DISORDER

DRUG THERAPY

From symptoms to social functioning: differential effects of antidepressant therapy. Kasper S.
Int Clin Psychopharmacol 1999 May;14 Suppl 1:S27–31 (28 ref.)
[Psychopharmacotherapy of behavioral disorders in patients with dementia] Stoppe G, et al. **Z Gerontol Geriatr** 1999 Jun;32(3):153–8 (42 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Juvenile violence. Scott CL. **Psychiatr Clin North Am** 1999 Mar;22(1):71–83 (76 ref.)

PREVENTION & CONTROL

Stalking. An old behavior, a new crime. Meloy JR.
Psychiatr Clin North Am 1999 Mar;22(1):85–99 (49 ref.)

THERAPY

Behavioral approaches for reducing agitation in residents of long-term-care facilities: critical review and suggestions for future research. Landreville P, et al.
Int Psychogeriatr 1998 Dec;10(4):397–419 (56 ref.)
[The course of behavior disorders and their psychosocial treatment in patients with dementia] Haupt M.
Z Gerontol Geriatr 1999 Jun;32(3):159–66 (36 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL CHANGE

Becoming modern after all these years: social change and mental health in Latin America. Almeida-Filho N.
Cult Med Psychiatry 1998 Sep;22(3):285–316 (73 ref.)
Water pollution and human health in China. Wu C, et al.
Environ Health Perspect 1999 Apr;107(4):251–6 (32 ref.)
Modernization, stress, and blood pressure: new directions in research. Dressler WW. **Hum Biol** 1999 Aug;71(4):583–605 (65 ref.)
Social movements as catalysts for policy change: the case of smoking and guns. Nathanson CA.
J Health Polit Policy Law 1999 Jun;24(3):421–88 (146 ref.)
Motivation, mobilization, and monitoring: the role of groups in health policy [editorial] Peterson MA.
J Health Polit Policy Law 1999 Jun;24(3):415–20 (17 ref.)
Hospice and palliative care as a new social movement: a case illustration from South Australia. Elsey B.
J Palliat Care 1998 Winter;14(4):38–46 (21 ref.)
Personality disorders in sociocultural perspective. Paris J.
J Personal Disord 1998 Winter;12(4):289–301 (74 ref.)
Developing health insurance in transitional Asia. Ensor T.
Soc Sci Med 1999 Apr;48(7):871–9 (25 ref.)

SOCIAL CLASS

Where do we stand? Research and policy issues concerning inequalities in health and in healthcare. Whitehead MM.
Acta Oncol 1999;38(1):41–50 (55 ref.)
Social psychophysiology, social circumstances, and health. Carroll D, et al. **Ann Behav Med** 1998 Fall;20(4):333–7 (80 ref.)
Inequalities in oral health: a review of the evidence and recommendations for action. Watt R, et al. **Br Dent J** 1999 Jul 10;187(1):6–12 (69 ref.)
Income inequality and health: pathways and mechanisms. Kawachi I, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):215–27 (42 ref.)
Income inequality, social cohesion, and class relations: a critique of Wilkinson's neo-Durkheimian research program. Muntaner C, et al. **Int J Health Serv** 1999; 29(1):59–81 (127 ref.)
Strengthening domestic violence theories: intersections of race, class, sexual orientation, and gender. Bograd M.
J Marital Fam Ther 1999 Jun;25(3):275–89 (92 ref.)
Teaching social inequalities in health: barriers and opportunities. Muntaner C. **Scand J Public Health** 1999 Sep;27(3):161–5 (58 ref.)
Socioeconomic inequalities in stroke mortality among middle-aged men: an international overview. European Union Working Group on Socioeconomic Inequalities in Health. Kunst AE, et al. **Stroke** 1998 Nov;29(11):2285–91 (49 ref.)

SOCIAL CLUBS, THERAPEUTIC see **SELF-HELP GROUPS**

SOCIAL CONDITIONS

Can we measure the social importance of health care? Buck D, et al. **Int J Technol Assess Health Care** 1999 Winter; 15(1):89–107 (35 ref.)
Social and ethical aspects of in vitro fertilization. Heitman E. **Int J Technol Assess Health Care** 1999 Winter; 15(1):22–35 (81 ref.)
Individual and social determinants of shiftwork tolerance. Nachreiner F. **Scand J Work Environ Health** 1998;24 Suppl 3:35–42 (50 ref.)
The Russian concept of schizophrenia: a review of the literature. Lavretsky H. **Schizophr Bull** 1998;24(4):537–57 (166 ref.)

SOCIAL CONFORMITY

see related
SOCIAL CONTROL, INFORMAL
Mohawks and combat boots: the schizoid dilemma of punks. McAllister MJ. **Bull Menninger Clin** 1999 Winter; 63(1):89–102 (25 ref.)
Theoretical and treatment issues of personality disorders in individualistic and collectivistic societies. Kim HA.
Psychiatry Clin Neurosci 1998 Dec;52 Suppl:S242–5 (12 ref.)

SOCIAL CONTROL, FORMAL

The corruption process of a law enforcement officer: a paradigm of occupational stress and deviancy [see comments] McCafferty FL, et al.
J Am Acad Psychiatry Law 1998;26(3):433–58 (85 ref.)
Comment in: J Am Acad Psychiatry Law 1999;27(1):178–9.
A brief review of moonshine use [letter] Montgomery R, et al. **Psychiatr Serv** 1999 Aug;50(8):1088 (5 ref.)

SOCIAL CONTROL, INFORMAL

Understanding women's risk of HIV infection in Thailand through critical hermeneutics. Ruangjiratain S, et al.
ANS Adv Nurs Sci 1998 Dec;21(2):42–51 (28 ref.)

SOCIAL DISCRIMINATION see **PREJUDICE**

SOCIAL DOMINANCE

Testosterone and dominance in men. Mazur A, et al.
Behav Brain Sci 1998 Jun;21(3):353–63; discussion 363–97 (372 ref.)

SOCIAL ENVIRONMENT

see related
LIFE STYLE
The social environments of adolescents: associations between socioenvironmental factors and health behaviors during adolescence. Neumark-Sztainer D. **Adolesc Med** 1999 Feb; 10(1):41–55, v (54 ref.)
Endocrine function and emergency contraception: physiology and society. Anderson M. **Am J Physiol** 1998 Jun;274(6 Pt 2):S46–52 (29 ref.)
Environmental and policy interventions to promote physical activity. Sallis JF, et al. **Am J Prev Med** 1998 Nov; 15(4):379–97 (73 ref.)
Social psychophysiology, social circumstances, and health. Carroll D, et al. **Ann Behav Med** 1998 Fall;20(4):333–7 (80 ref.)
The effects of the social environment on stress-related cardiovascular activation: current findings, prospects, and implications. Kamarck TW, et al. **Ann Behav Med** 1998 Fall;20(4):247–56 (83 ref.)
A case for the usefulness of laboratory social stressors. Linden W, et al. **Ann Behav Med** 1998 Fall;20(4):310–6 (57 ref.)
Psychosocial correlates of dietary intake: advancing dietary intervention. Baranowski T, et al. **Annu Rev Nutr** 1999; 19:17–40 (99 ref.)
The social environment and health: a discussion of the epidemiologic literature. Yen IH, et al.
Annu Rev Public Health 1999;20:287–308 (127 ref.)
Whither menstrual synchrony? McClintock MK.
Annu Rev Sex Res 1998;9:77–95 (43 ref.)
Environmental influences on neural plasticity, the limbic system, emotional development and attachment: a review. Joseph R. **Child Psychiatry Hum Dev** 1999 Spring; 29(3):189–208 (97 ref.)
Psychological and social characteristics and precipitants of vomiting in children with cyclic vomiting syndrome. Forbes D, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):19S–22S (30 ref.)
Working in a moving environment. Wertheim AH.
Ergonomics 1998 Dec;41(12):1845–58 (70 ref.)
Feeding laboratory studies in patients with eating disorders: a review. Mitchell JE, et al. **Int J Eat Disord** 1998 Sep; 24(2):115–24 (21 ref.)
An invitation to join in difficulty: realizing the deeper promise of group psychotherapy. Hawkins DM.
Int J Group Psychother 1998 Oct;48(4):423–38 (17 ref.)
Social influences on endocrine activity in guinea pigs, with comparisons to findings in nonhuman primates. Hennessy MB. **Neurosci Biobehav Rev** 1999 May;23(5):687–98 (102 ref.)
Socioemotional development across cultures: context, complexity, and pathways. Sharma D, et al.
New Dir Child Dev 1998 Fall;(81):3–20 (133 ref.)
The role of cultural and social factors in the cause of addictive disorders. Westermeyer J.
Psychiatr Clin North Am 1999 Jun;22(2):253–73 (66 ref.)
Private and public in the lives of chronic schizophrenic patients. Leferink K. **Psychiatry** 1998 Summer;61(2):147–62 (60 ref.)
Implications of the restricted range of family environments for estimates of heritability and nonshared environment in behavior-genetic adoption studies. Stoolmiller M.
Psychol Bull 1999 Jul;125(4):392–409 (110 ref.)
Psychosocial factors related to adolescent smoking: a critical review of the literature. Tyas SL, et al. **Tob Control** 1998 Winter;7(4):409–20 (226 ref.)
Society and public health: crisis and rebirth. Mann JM.
West J Med 1998 Aug;169(2):118–21 (4 ref.)
[Evaluating genetics and environment in development of obesity] Lechleitner M, et al. **Acta Med Austriaca** 1998; 25(4–5):129–30 (6 ref.) (Eng. Abstr.) **(Ger)**
[Socio-acousis. Non-occupationally-induced hearing loss due to noise, 1] Plath P. **HNO** 1998 Oct;46(10):887–92 (46 ref.) **(Ger)**
[Psychological and social etiology of drug dependence] Türk D, et al. **Internist (Berl)** 1999 Jun;40(6):583–9 (52 ref.) **(Ger)**

SOCIAL IDENTIFICATION

'Coming out' as a life transition: homosexual identity formation and its implications for health care practice. Taylor B. **J Adv Nurs** 1999 Aug;30(2):520–5 (52 ref.)
Understanding fraternity drinking: five recurring themes in the literature, 1980–1998. Borsari BE, et al.
J Am Coll Health 1999 Jul;48(1):30–7 (77 ref.)
Primary socialization theory: culture, ethnicity, and cultural identification. The links between culture and substance use. IV. Oetting ER, et al. **Subst Use Misuse** 1998 Aug; 33(10):2075–107 (60 ref.)

SOCIAL INSURANCE see **SOCIAL SECURITY**

SOCIAL INTERACTION see **INTERPERSONAL RELATIONS**

SOCIAL ISOLATION

Social isolation and cardiovascular disease: an atherosclerotic pathway? Knox SS, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):877–90 (93 ref.)
[Chronic lead poisoning in children today. A pathology of poverty and social exclusion] Sinnaeve O, et al.
Arch Pediatr 1999 Jul;6(7):762–7 (37 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Clinical interpretation of "My Secret Life": the emergence of one gay man's authentic identity" [comment] Crepeau EB. **Am J Occup Ther** 1998 Jul-Aug;52(7):570–2 (20 ref.)
Comment on: Am J Occup Ther 1998 Jul-Aug;52(7):563–9.
"My secret life": the emergence of one gay man's authentic identity [see comments] Walsh AL, et al.
Am J Occup Ther 1998 Jul-Aug;52(7):563–9 (41 ref.)
Comment in: Am J Occup Ther 1998 Jul-Aug;52(7):570–2.

SOCIAL JUSTICE

see related
CIVIL RIGHTS
HUMAN RIGHTS
The stress of being a poor child in America. Garbarino J.
Child Adolesc Psychiatr Clin N Am 1998 Jan;7(1):105–19, ix (23 ref.)
The new biotech world order. Cahill LS.
Hastings Cent Rep 1999 Mar-Apr;29(2):45–8 (9 ref.)
Ethics, justice and women's health. Cook RJ, et al.
Int J Gynaecol Obstet 1999 Jan;64(1):81–5 (23 ref.)
A fundamental shift in the approach to international health by WHO, UNICEF, and the World Bank: instances of the practice of "intellectual fascism" and totalitarianism in some Asian countries. Banerji D. **Int J Health Serv** 1999; 29(2):227–59 (146 ref.)
Embodying inequality: a review of concepts, measures, and methods for studying health consequences of discrimination. Krieger N. **Int J Health Serv** 1999; 29(2):295–352 (338 ref.)
The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL.
J Health Polit Policy Law 1999 Jun;24(3):531–65 (35 ref.)
Managed care: rationing without justice, but not unjustly [see comments] Buchanan A. **J Health Polit Policy Law** 1998 Aug;23(4):617–34 (16 ref.) Comment in: J Health Polit Policy Law 1998 Aug;23(4):687–95.
Selecting subjects for participation in clinical research: one sphere of justice. Weijer C. **J Med Ethics** 1999 Feb; 25(1):31–6 (34 ref.)
[Justice--the most demanding of virtues] Gulbrandsen P.
Tidsskr Nor Laegeforen 1999 Mar 20;119(8):1149–53 (29

SOCIAL JUSTICE

ref.) (Eng. Abstr.) **(Nor)**

SOCIAL MEDICINE

[Prevention--illusion or hope for the future?] Allander E. **Lakartidningen** 1999 Feb 10;96(6):620–2 (29 ref.) **(Swe)**

STATISTICS & NUMERICAL DATA

Measuring aspects of women's life and work for the study of variations in health. Dunnell K, et al. **Am J Ind Med** 1999 Jul;36(1):25–33 (15 ref.)

TRENDS

[Problem orientation in social medicine--participation in social medicine] Rásky E, et al. **Gesundheitswesen** 1999 May;61(5):252–4 (7 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL MOBILITY

The perils of outperformance: sensitivity about being the target of a threatening upward comparison. Exline JJ, et al. **Psychol Bull** 1999 May;125(3):307–37 (312 ref.)

SOCIAL PERCEPTION

see related
STEREOTYPING

The changing moral economy of ancestor worship in a Chinese emigrant district. Eng KK. **Cult Med Psychiatry** 1999 Mar;23(1):99–132 (61 ref.)

The transformation of everyday social experience: what a mental and social health perspective reveals about Chinese communities under global and local change. Kleinman A, et al. **Cult Med Psychiatry** 1999 Mar;23(1):7–24 (43 ref.)

Trends in adolescent cigarette use: the diffusion of daily smoking. Redmond WH. **J Behav Med** 1999 Aug; 22(4):379–95 (24 ref.)

Language, social cognitive processing, and behavioral characteristics of psychiatrically disturbed children with previously identified and unsuspected language impairments. Cohen NJ, et al. **J Child Psychol Psychiatry** 1998 Sep;39(6):853–64 (117 ref.)

Social movements as catalysts for policy change: the case of smoking and guns. Nathanson CA. **J Health Polit Policy Law** 1999 Jun;24(3):421–88 (146 ref.)

Extent of relational stigmatization of lesbians and their children by heterosexual college students. King BR, et al. **J Homosex** 1999;37(2):65–81 (62 ref.)

Identity in political context: lesbian/gay representation in the public sphere. Smith RR, et al. **J Homosex** 1999;37(2):25–45 (86 ref.)

Quality of life in psychiatry as an ethical duty: from the clinical to the societal perspective. Kilian R, et al. **Psychopathology** 1999 May–Jun;32(3):127–34 (28 ref.)

Perceptions of psychosocial adjustment to aphasia: applications of the Code--Müller Protocols. Code C, et al. **Semin Speech Lang** 1999;20(1):51–62; quiz 63 (30 ref.)

SOCIAL POLICY see **PUBLIC POLICY**

SOCIAL PROBLEMS

see related
ALCOHOLISM
SUBSTANCE-RELATED DISORDERS

[Anisakiasis as a growing ecological and social problem] Gorokhov VV, et al. **Med Parazitol (Mosk)** 1998 Oct–Dec; (4):50–4 (15 ref.) **(Rus)**

STATISTICS & NUMERICAL DATA

[The current status of drug abuse and dependence in Japan] Wada K. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1998 Oct;33(5):587–96 (1 ref.) **(Jpn)**

SOCIAL PSYCHIATRY see **COMMUNITY PSYCHIATRY**

SOCIAL PSYCHOLOGY see **PSYCHOLOGY, SOCIAL**

SOCIAL REINFORCEMENT see **REINFORCEMENT, SOCIAL**

SOCIAL RESPONSIBILITY

Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility [editorial] Marks G, et al. **AIDS** 1999 Feb 25;13(3):297–306 (119 ref.)

Multiple pathways to inflated responsibility beliefs in obsessional problems: possible origins and implications for therapy and research. Salkovskis P, et al. **Behav Res Ther** 1999 Nov;37(11):1055–72 (40 ref.)

Professional self respect: rights and responsibilities in the new NHS [see comments] Richards P. **BMJ** 1998 Oct 24; 317(7166):1146–8 (20 ref.) Comment in: BMJ 1999 Mar 13;318(7185):734. Comment in: BMJ 1999 Mar 13;318(7185):734–5.

Child sexual abuse: victim age, victim gender, and observer gender as factors contributing to attributions of responsibility. Back S, et al. **Child Abuse Negl** 1998 Dec; 22(12):1239–52 (49 ref.)

The changing moral economy of ancestor worship in a Chinese emigrant district. Eng KK. **Cult Med Psychiatry** 1999 Mar;23(1):99–132 (61 ref.)

Psychiatric criteria of legal responsibility after the consumption of alcohol: the German situation. Kröber HL. **Eur Addict Res** 1998 Sep;4(3):107–12 (19 ref.)

Personal responsibility for health? A review of the arguments and the evidence at century's end. Minkler M. **Health Educ Behav** 1999 Feb;26(1):121–40 (118 ref.)

Animal and plant cell technology: a critical evaluation of the technology/society interface. Spier RE. **J Biotechnol** 1998 Oct 27;65(2–3):111–25 (35 ref.)

Public trust and accountability for clinical performance: lessons from the national press reportage of the Bristol hearing [see comments] Davies HT, et al. **J Eval Clin Pract** 1999 Aug;5(3):335–42 (28 ref.) Comment in: J Eval Clin Pract 1999 Aug;5(3):343–6.

The Health Insurance Portability and Accountability Act of 1996: understanding the anti-kickback laws. Tomes JP. **J Health Care Finance** 1998 Winter;25(2):55–62 (9 ref.)

Sharing responsibility for the public's health. Stoto MA. **Public Health Rep** 1999 May–Jun;114(3):231–5 (8 ref.)

SOCIAL SCIENCES

How can statistical mechanics contribute to social science? Durlauf SN. **Proc Natl Acad Sci U S A** 1999 Sep 14; 96(19):10582–4 (11 ref.)

Social capital and health: implications for public health and epidemiology. Lomas J. **Soc Sci Med** 1998 Nov; 47(9):1181–8 (40 ref.)

Social work in health care: do practitioners' writings suggest an applied social science? Rehr H, et al. **Soc Work Health Care** 1998;28(2):63–81 (33 ref.)

EDUCATION

Prevention of sexually transmitted diseases: the need for social and behavioral science expertise in public health departments [editorial; comment] Van Devanter N. **Am J Public Health** 1999 Jun;89(6):815–8 (38 ref.) Comment on: Am J Public Health 1999 Jun;89(6):899–902.

METHODS

Explicit guidelines for qualitative research: a step in the right direction, a defence of the 'soft' option, or a form of sociological imperialism? Chapple A, et al. **Fam Pract** 1998 Dec;15(6):556–61 (34 ref.)

STANDARDS

Explicit guidelines for qualitative research: a step in the right direction, a defence of the 'soft' option, or a form of sociological imperialism? Chapple A, et al. **Fam Pract** 1998 Dec;15(6):556–61 (34 ref.)

SOCIAL SECURITY

LEGISLATION & JURISPRUDENCE

The Mexican Social Security counterreform: pensions for profit. Laurell AC. **Int J Health Serv** 1999;29(2):371–91 (48 ref.)

ORGANIZATION & ADMINISTRATION

Retirement income security in the United Kingdom. Liu L. **Soc Secur Bull** 1999;62(1):23–46 (87 ref.)

Individual Social Security accounts: issues of administrative feasibility and cost, 1998. Olsen KA, et al. **Soc Secur Bull** 1999;62(1):75–90 (103 ref.)

Noncitizens and the Supplemental Security Income program. Parrott TM, et al. **Soc Secur Bull** 1998;61(4):3–31 (0 ref.)

Pension integration and Social Security reform. Slusher C. **Soc Secur Bull** 1998;61(3):20–7 (10 ref.)

[Market effect on social security and occupational health services (comment) [see comments] Plomp HN, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1374–8 (10 ref.) (Eng. Abstr.) Comment on: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1369–73. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1379–82. **(Dut)**

SOCIAL SERVICE see **SOCIAL WORK**

SOCIAL SUPPORT

see related
SELF-HELP GROUPS

The social construction of cardiovascular reactivity. Christenfeld N, et al. **Ann Behav Med** 1998 Fall; 20(4):317–25 (53 ref.)

Problems and prospects for the social support–reactivity hypothesis. Lepore SJ. **Ann Behav Med** 1998 Fall; 20(4):257–69 (93 ref.)

Social relationships and the progression of human immunodeficiency virus infection: a review of evidence and possible underlying mechanisms. Miller GE, et al. **Ann Behav Med** 1998 Summer;20(3):181–9 (54 ref.)

Psychosocial support or active management of labour or both to improve the outcome of labour. Arulkumaran S, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):617–9 (17 ref.)

Psychosocial concerns and quality of life in breast cancer survivors. Leedham B, et al. **Cancer Invest** 1999;17(5):342–8 (79 ref.)

Family-centered practice for children with communication disorders. Rini DL, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Jan;8(1):153–74 (72 ref.)

Models of service support for parents of disabled children. What do we know? What do we need to know? Sloper P. **Child Care Health Dev** 1999 Mar;25(2):85–99 (61 ref.)

Comfort in labor and midwifery art. Schuiling KD, et al. **Image J Nurs Sch** 1999;31(1):77–81 (40 ref.)

Quality of life and social issues in older depressed patients. Warner JP. **Int Clin Psychopharmacol** 1998 Sep;13 Suppl 5:S19–24 (36 ref.)

Health visiting as therapy: a phenomenological perspective. Cody A. **J Adv Nurs** 1999 Jan;29(1):119–27 (68 ref.)

Social support: factors to consider when designing studies that measure social support. Hutchison C. **J Adv Nurs** 1999 Jun;29(6):1520–6 (46 ref.)

Psychosocial needs of patients and families. Vachon ML. **J Palliat Care** 1998 Autumn;14(3):49–56 (43 ref.)

Meeting impossible psychosocial demands in pediatric oncology: creative solutions to universal challenges [see comments] Whitsett SF, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):289–91 (0 ref.) Comment in: Med Pediatr Oncol 1999 Apr;32(4):292–3.

Psychiatric rehabilitation technology: operationalizing the "black box" of the psychiatric rehabilitation process. Anthony WA. **New Dir Ment Health Serv** 1998 Fall; (79):79–87 (41 ref.)

Companion animals: social support for orthopedic clients. Carmack BJ. **Nurs Clin North Am** 1998 Dec;33(4):701–11 (59 ref.)

The care of women with AIDS: special needs and considerations. Sowell RL, et al. **Nurs Clin North Am** 1999 Mar;34(1):179–99 (147 ref.)

A closer look at psychosocial care. Powel LL. **Oncol Nurs Forum** 1998 Nov–Dec;25(10):1677 (9 ref.)

On the role of immunological factors as mediators between psychosocial factors and cancer progression. Garssen B, et al. **Psychiatry Res** 1999 Jan 18;85(1):51–61 (64 ref.)

Psychosocial assessment of pain in patients having rheumatic diseases. Keefe FJ, et al. **Rheum Dis Clin North Am** 1999 Feb;25(1):81–103 (111 ref.)

Social network ties, self-efficacy, and condom use among women who use crack cocaine: a pilot study. Montoya ID. **Subst Use Misuse** 1998 Aug;33(10):2049–73 (70 ref.)

[The parental maturity of elderly dependent parents. Contributions to a contextual definition] Mahieu S, et al. **Tijdschr Gerontol Geriatr** 1999 Apr;30(2):64–72 (18 ref.) (Eng. Abstr.) **(Dut)**

[Psychosocial factors at work and cardiovascular diseases: contribution of the Effort-Reward Imbalance model] Niedhammer I, et al. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):398–410 (92 ref.) (Eng. Abstr.) **(Fre)**

[Melanoma patients: psychosocial stress, coping with illness and social support. A systematic review] Söllner W, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):338–48 (62 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation in schizophrenia--guidelines for including psychosocial measures] Katschnig H. **Wien Med Wochenschr** 1998;148(11–12):273–80 (41 ref.) (Eng. Abstr.) **(Ger)**

[Basic functions and specialty standards of support management] Wissert M. **Z Gerontol Geriatr** 1998 Oct; 31(5):331–7 (19 ref.) (Eng. Abstr.) **(Ger)**

[Psychosocial impacts of surgical techniques] Hawighorst-Knapstein S, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:27–30 (12 ref.) **(Ger)**

SOCIAL VALUES

Social capital and community development: practitioner emptor. Labonte R. **Aust N Z J Public Health** 1999 Aug; 23(4):430–3 (12 ref.)

Social capital and its relevance to health and family policy. Leeder S, et al. **Aust N Z J Public Health** 1999 Aug; 23(4):424–9 (12 ref.)

Assessing the arguments for and against euthanasia and assisted suicide: Part Two. Thomasma DC. **Camb Q Healthc Ethics** 1998 Fall;7(4):388–401 (37 ref.)

The stress of being a poor child in America. Garbarino J. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):105–19, ix (23 ref.)

The death of humanitarianism?: an anatomy of the attack. Macrae J. **Disasters** 1998 Dec;22(4):309–17 (13 ref.)

The authority of the clinical ethicist. Casarett DJ, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):6–11 (19 ref.)

Social aspects in assisted reproduction. Fasouliotis SJ, et al. **Hum Reprod Update** 1999 Jan–Feb;5(1):26–39 (90 ref.)

Is caring a virtue? Allmark P. **J Adv Nurs** 1998 Sep; 28(3):466–72 (34 ref.)

Is the societal perspective in cost–effectiveness analysis useful for decision makers? Russell LB, et al. **Jt Comm J Qual Improv** 1999 Sep;25(9):447–54 (16 ref.)

Families, culture, and mental illness: constructing new realities. Lefley HP. **Psychiatry** 1998 Winter;61(4):335–55 (90 ref.)

Theoretical and treatment issues of personality disorders in individualistic and collectivistic societies. Kim HA. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S242–5 (12 ref.)

SOCIAL WELFARE

What's a mother to do? Welfare, work, and family [editorial; comment] Chavkin W. **Am J Public Health** 1999 Apr; 89(4):477–9 (13 ref.) Comment on: Am J Public Health 1999 Apr;89(4):502–5.

The hospital emergency department as a social welfare institution. Gordon JA. **Ann Emerg Med** 1999 Mar; 33(3):321–5 (45 ref.)

ECONOMICS

Neoliberalism revised? A critical account of World Bank conceptions of good governance and market friendly intervention. Kiely R. **Int J Health Serv** 1998;28(4):683–702 (65 ref.)

Neoliberalism, "globalization," unemployment, inequalities, and the welfare state. Navarro V. **Int J Health Serv** 1998; 28(4):607–82 (91 ref.)

The political economy of the welfare state in developed capitalist countries. Navarro V. **Int J Health Serv** 1999; 29(1):1–50 (36 ref.)

LEGISLATION & JURISPRUDENCE

Assessing the effects of welfare reform policies on reproductive and infant health [see comments] Wise P, et al. **Am J Public Health** 1999 Oct;89(10):1514–21 (79 ref.) Comment in: Am J Public Health 1999 Oct;89(10):1476–8. Comment in: Am J Public Health 1999 Oct;89(10):1479–82.

Monitoring the health consequences of welfare reform. Pappas G. **Int J Health Serv** 1998;28(4):703–13 (31 ref.)

The tuberculosis crisis: the deadly consequence of immigration policies and welfare reform. Johns KA, et al. **J Contemp Health Law Policy** 1998 Fall;15(1):101–30 (0 ref.)

Welfare reform and women's health: review of the literature and implications for state policy. O'Campo P, et al. **J Public Health Policy** 1998;19(4):420–46 (59 ref.)

TRENDS

The political economy of the welfare state in developed capitalist countries. Navarro V. **Int J Health Serv** 1999; 29(1):1–50 (36 ref.)

Women, the welfare state, and their transnational dimension: the case of Mexico's community health worker programs. Ramirez-Valles J. **Int J Health Serv** 1999;29(3):597–621 (117 ref.)

SOCIAL WORK

see related
COMMUNITY HEALTH SERVICES
RELIEF WORK

Perceptions of dementia, caregiving, and help seeking among Asian and Pacific Islander Americans. Braun KL, et al. **Health Soc Work** 1998 Nov;23(4):262–74 (67 ref.)

Preserving end-of-life autonomy: the Patient Self-Determination Act and the Uniform Health Care Decisions Act. Galambos CM. **Health Soc Work** 1998 Nov; 23(4):275–81 (21 ref.)

Genetics cultural lag: what can social workers do to help? Oktay JS. **Health Soc Work** 1998 Nov;23(4):310–5 (23 ref.)

Social work in health care: do practitioners' writings suggest an applied social science? Rehr H, et al. **Soc Work Health Care** 1998;28(2):63–81 (33 ref.)

Latinas and sexually transmitted diseases: implications of recent research for prevention. Suarez ZE, et al. **Soc Work Health Care** 1998;28(1):1–19 (61 ref.)

The role of social work in HIV/AIDS clinical trials. Williams JK, et al. **Soc Work Health Care** 1999;29(1):35–56 (19 ref.)

[Personal biography in the aging process and attitude to personal biography in social work with the elderly] Schweppe C. **Z Gerontol Geriatr** 1998 Oct;31(5):325–30 (35 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Using benefit-cost analysis to assess child abuse prevention and intervention programs. Plotnick RD, et al. **Child Welfare** 1999 May–Jun;78(3):381–407 (33 ref.)

[Repositioning social work with the elderly? Effect of competitive elements and new guidance models on the profile of a profession] Schmidt R, et al. **Z Gerontol Geriatr** 1998 Oct;31(5):304–12 (54 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

The role of the supervisor in training social workers treating HIV infected persons in a hospital. Itzhaky H, et al. **Soc Work Health Care** 1999;29(1):57–74 (32 ref.)

[Secondary traumatization while under care of child protective services] Schmitt A. **Prax Kinderpsychol Kinderpsychiatr** 1999 Jul–Aug; 48(6):411–24 (41 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Towards quality of care in child health programmes: a challenge for the partnership in health and social sciences. Kanani S. **Soc Sci Med** 1998 Nov;47(9):1223–30 (16 ref.)

Organizing social work services with adult cancer patients: integrating empirical research. Cwikel JG, et al. **Soc Work Health Care** 1999;28(3):55–76 (94 ref.)

TRENDS

Occupational social work for the 21st century. Iversen RR. **Soc Work** 1998 Nov;43(6):551–66 (112 ref.)

[Social work in public health service as reflected by selected studies--a description of current status] Reinicke P. **Gesundheitswesen** 1999 Apr;61(4):197–202 (19 ref.) (Eng. Abstr.) **(Ger)**

[Ambulatory nursing-care related social work] Jansen B. **Z Gerontol Geriatr** 1998 Oct;31(5):319–24 (13 ref.) (Eng. Abstr.) **(Ger)**

[Basic functions and specialty standards of support management] Wissert M. **Z Gerontol Geriatr** 1998 Oct; 31(5):331–7 (19 ref.) (Eng. Abstr.) **(Ger)**

[Social work with the elderly--current orientation and strategies] Zeman P. **Z Gerontol Geriatr** 1998 Oct; 31(5):313–8 (34 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL WORK DEPARTMENT, HOSPITAL

The role of the supervisor in training social workers treating HIV infected persons in a hospital. Itzhaky H, et al. **Soc Work Health Care** 1999;29(1):57–74 (32 ref.)

SOCIAL WORKERS see **SOCIAL WORK**

SOCIALIZATION

Seasonal and weekly rhythms: windows into variability in family socialization experiences in early adolescence. Crouter AC, et al. **New Dir Child Dev** 1998 Winter; (82):69–82 (16 ref.)

Communication as social engagement: implications for interactions between deaf and hearing persons. Foster S. **Scand Audiol Suppl** 1998;49:116–24 (20 ref.)

Environmental supports to enhance social-communication. Quill KA. **Semin Speech Lang** 1998;19(4):407–22; quiz 422–3; 424 (77 ref.)

Primary socialization theory: culture, ethnicity, and cultural identification. The links between culture and substance use. IV. Oetting ER, et al. **Subst Use Misuse** 1998 Aug; 33(10):2075–107 (60 ref.)

SOCIALIZED MEDICINE see **STATE MEDICINE**

SOCIETIES, MEDICAL

Medical and scientific organizations and scientific evidence in U.S. trials: lessons from European legal theory. Deftos LJ. **Acad Med** 1999 Mar;74(3):231–5 (44 ref.)

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Epstein JI, et al. **Am J Surg Pathol** 1998 Dec;22(12):1435–48 (44 ref.)

The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. Williams H, et al. **Arch Dermatol** 1998 Dec; 134(12):1620–6 (43 ref.)

American Diabetes Association Annual Meeting, 1998. Nephropathy and retinopathy [news] Bloomgarden ZT. **Diabetes Care** 1999 Apr;22(4):640–4 (5 ref.)

Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced [editorial; comment] Pyörälä K, et al. **Eur Heart J** 1998 Oct;19(10):1413–5 (14 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1434–503.

AGA technical review on the evaluation and management of chronic diarrhea. Fine KD, et al. **Gastroenterology** 1999 Jun;116(6):1464–86 (217 ref.)

AFM/MDA 1st International Myotonic Dystrophy Consortium Conference 30 June–1 July 1997, Paris, France. **Neuromuscul Disord** 1998 Aug;8(6):432–7 (0 ref.)

The American Institute of Ultrasound in Medicine and the Society of Radiologists in Ultrasound--future directions in diagnostic US. Kremkau FW, et al. **Radiology** 1998 Nov; 209(2):305–11; discussion 312–3 (48 ref.)

[Importance of the new classification of primary cutaneous lymphomas elaborated by the EORTC (European Organization for Research and Treatment of Cancer) group] Wechsler J. **Ann Pathol** 1998 Oct;18(4):315–23 (45 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of the Council of the Order of Physicians] Dubois O. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:249–58 (22 ref.) **(Fre)**

[62nd Congress of the American College of Rheumatology, San Diego, 8–12 November 1998] Cherin P. **Rev Med Interne** 1999 Apr;20(4):311–7 (34 ref.) **(Fre)**

[Informed consent in cardiology. The Committee on Informed Consent of the Commission on Professional Matters of the Sociedad Española de Cardiologia] de los Reyes López M, et al. **Rev Esp Cardiol** 1998 Oct; 51(10):782–96 (39 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

An historical perspective on atherosclerosis research in Germany [editorial] Siegel G. **Atherosclerosis** 1999 May; 144(1):1–6 (45 ref.)

ORGANIZATION & ADMINISTRATION

Regionalization of SAM and evolution of the international movement in adolescent health. Society for Adolescent Medicine. Cromer BA, et al. **J Adolesc Health** 1998 Dec; 23(6 Suppl):152–6 (0 ref.)

The Society for Adolescent Medicine's role in promoting education. MacKenzie RG, et al. **J Adolesc Health** 1998 Dec;23(6 Suppl):135–42 (3 ref.)

International cooperation in world cardiology: the role of the World Heart Federation [editorial] Bayés de Luna A. **J Am Coll Cardiol** 1999 Apr;33(5):1427–30 (20 ref.)

Strategic plan. Connors VJ, et al. **J Am Optom Assoc** 1999 Jul;70(7):417–26 (0 ref.)

SOCIETIES, PHARMACEUTICAL

Report of the ASHP Task Force on Science: American Society of Health-System Pharmacists. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2519–24 (0 ref.)

American Pharmaceutical Association review of literature on prescription to over-the-counter drug switches. Schulke DG. **Clin Ther** 1998;20 Suppl C:C124–33 (14 ref.)

SOCIETIES, SCIENTIFIC

Medical and scientific organizations and scientific evidence in U.S. trials: lessons from European legal theory. Deftos LJ. **Acad Med** 1999 Mar;74(3):231–5 (44 ref.)

SOCIOECONOMIC FACTORS

Sociodemographic factors in Health Psychology research: 12 years in review. Park TL, et al. **Health Psychol** 1998 Jul;17(4):381–3 (10 ref.)

Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. Gómez-Almaguer D, et al. **Int J Cancer Suppl** 1998;11:52–5 (17 ref.)

Relationship between socioeconomic status and ischaemic heart disease in cohort and case-control studies: 1960–1993. González MA, et al. **Int J Epidemiol** 1998 Jun;27(3):350–8 (90 ref.)

Older men's health. Sociocultural and ecological perspectives. Eckert JK, et al. **Med Clin North Am** 1999 Sep;83(5):1151–72, v (122 ref.)

Socioeconomic aspects. Rutkow IM. **World J Surg** 1999 Aug; 23(8):781–5 (15 ref.)

[Acting on clinical trials. Experience of organizations for the fight against AIDS] Barbot J. **Rev Epidemiol Sante Publique** 1998 Sep;46(4):305–15 (37 ref.) (Eng. Abstr.) **(Fre)**

[Re-emergence of tuberculosis and socioeconomic uncertainty] Poinsignon Y, et al. **Rev Med Interne** 1998 Sep;19(9):649–57 (39 ref.) (Eng. Abstr.) **(Fre)**

SOCIOECONOMIC STATUS see **SOCIAL CLASS**

SOCIOENVIRONMENTAL THERAPY

Soteria and other alternatives to acute psychiatric hospitalization: a personal and professional review. Mosher LR. **J Nerv Ment Dis** 1999 Mar;187(3):142–9 (48 ref.)

[Rehabilitation in schizophrenia--guidelines for including psychosocial measures] Katschnig H. **Wien Med Wochenschr** 1998;148(11–12):273–80 (41 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Coping and social skills training for alcohol and cocaine dependence. Monti PM, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):447–70, xi (57 ref.)

SOCIOLOGY

see related
GROUP PROCESSES

Critical nursing scholarship: exploring critical social theory with African American studies. Boutain DM. **ANS Adv Nurs Sci** 1999 Jun;21(4):37–47 (46 ref.)

SOCIOLOGY, MEDICAL

The importance of theories in health care. Alderson P. **BMJ** 1998 Oct 10;317(7164):1007–10 (13 ref.)

Integrating sociological and biological models [editorial] Fremont AM, et al. **J Health Soc Behav** 1999 Jun; 40(2):126–9 (17 ref.)

Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247–61 (81 ref.)

Assignments of meaning in epidemiology. Little M. **Soc Sci Med** 1998 Nov;47(9):1135–45 (31 ref.)

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of sociologists] Akrich M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:197–204 (7 ref.) **(Fre)**

SOCIOPATHIC PERSONALITY see **ANTISOCIAL PERSONALITY DISORDER**

SODIUM

see related
HYPERNATREMIA
HYPONATREMIA
NATRIURESIS

Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension. Katori M, et al. **Biol Res** 1998;31(3):143-9 (22 ref.)

ADMINISTRATION & DOSAGE

Sodium management in dialysis by conductivity. Bosetto A, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):243-54 (10 ref.)

BLOOD

Hyponatremia: how to approach this confusing abnormality [editorial; comment] Oiso Y. **Intern Med** 1998 Nov; 37(11):907-8 (7 ref.) Comment on: Intern Med 1998 Nov;37(11):950-4.

CHEMISTRY

The binding site of sodium in the gramicidin A channel. Roux B, et al. **Novartis Found Symp** 1999;225:113-24; discussion 124-7 (35 ref.)

DEFICIENCY

The ontogeny of salt hunger in the rat. Leshem M. **Neurosci Biobehav Rev** 1999 May;23(5):649-59 (86 ref.)
Potential mechanisms for functional changes in taste receptor cells following sodium deficiency in mammals. Lundy RF Jr. **Neurosci Biobehav Rev** 1998;23(1):103-9 (85 ref.)

METABOLISM

Sodium management in dialysis by conductivity. Bosetto A, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):243-54 (10 ref.)
Sodium-coupled transporters for Krebs cycle intermediates. Pajor AM. **Annu Rev Physiol** 1999;61:663-82 (77 ref.)
The kidney in chronic liver disease: circulatory abnormalities, renal sodium handling and role of natriuretic peptides. Valdivieso A. **Biol Res** 1998;31(3):291-304 (101 ref.)
Effect of metabolic acidosis on renal tubular sodium handling in rats as determined by lithium clearance. Menegon LF, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1269-73 (26 ref.)
Preventive nutritional factors in epidemiology: interaction between sodium and calcium. Mizushima S, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):573-5 (27 ref.)
Volume regulation and 'cross-talk' in sodium-absorbing epithelial cells. Schultz SG, et al. **Contrib Nephrol** 1998; 123:205-19 (82 ref.)
Cell volume-regulated cation channels. Wehner F. **Contrib Nephrol** 1998;123:8-20 (79 ref.)
Cell localization and ontogeny of sodium transport pathways in the distal nephron: perspectives in function and failure. Bachmann S. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):31-8 (90 ref.)
A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system. Bridges RJ, et al. **Curr Pharm Des** 1999 May;5(5):363-79 (127 ref.)
Molecular physiology of colonic epithelial sodium absorption. Clauss W. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):453-5 (57 ref.)
Control of Na+ transport in salivary duct epithelial cells by cytosolic Cl- and Na+. Cook DI, et al. **Eur J Morphol** 1998 Aug;36 Suppl:67-73 (20 ref.)
Sodium balance and hypertension: rare genetic disorders expose pathogenic mechanisms. Burnier M. **Exp Nephrol** 1998 Nov-Dec;6(6):496-501 (29 ref.)
Molecular pathophysiology of inborn renal Na+ transport defects. Greger R. **Kidney Blood Press Res** 1998; 21(2-4):222-5 (30 ref.)
Molecular genetics and clinical phenotype in heritable disorders of tubular Na+ transport. Hildebrandt F. **Kidney Blood Press Res** 1998;21(2-4):217-21 (50 ref.)
Pathogenesis of renal sodium retention in congestive heart failure. Andreoli TE. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):11-20 (46 ref.)
Pathogenesis of sodium and water retention in cardiac failure. Schrier RW, et al. **Ren Fail** 1998 Nov;20(6):773-81 (41 ref.)
Hypertension. Warnock DG. **Semin Nephrol** 1999 Jul; 19(4):374-80 (55 ref.)
[Na(+)-Ca2+ exchange] Matsuoka S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1555-60 (49 ref.) **(Jpn)**
[The mechanisms of Na+, K(+)-ATPase in renal tubular epithelium] Beltowski J. **Postepy Biochem** 1998; 44(4):282-91 (159 ref.) **(Pol)**
[Paracellular ion transfer in kidney and tissues and its pharmacological regulation] Lebedev AA. **Vestn Ross Akad Med Nauk** 1999;(3):25-8 (12 ref.) (Eng. Abstr.) **(Rus)**
[Effect of transition metal cations on Na+-Ca2+-exchange in cell membrane] Man'ko VV. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):3-12 (78 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Rapid structural changes in nerve fibers and cells associated with their excitation processes. Tasaki I. **Jpn J Physiol** 1999 Apr;49(2):125-38 (62 ref.)
Potential mechanisms for functional changes in taste receptor cells following sodium deficiency in mammals. Lundy RF Jr. **Neurosci Biobehav Rev** 1998;23(1):103-9 (85 ref.)

SODIUM AZIDE

POISONING

[Sodium azide: a review of biological effects and case reports] Chiba M, et al. **Nippon Eiseigaku Zasshi** 1999 Jan; 53(4):572-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

SODIUM BICARBONATE

see related
BUFFERS

THERAPEUTIC USE

Medication use in neonatal resuscitation. Burchfield DJ. **Clin Perinatol** 1999 Sep;26(3):683-91 (57 ref.)
Buffer treatment for cardiac resuscitation: putting the cart before the horse? [editorial; comment] Gazmuri RJ. **Crit Care Med** 1999 May;27(5):875-6 (17 ref.) Comment on: Crit Care Med 1999 May;27(5):1009-13.
Adrenaline dosage and buffers in cardiac arrest. Adgey AA. **Heart** 1998 Oct;80(4):412-4 (10 ref.)
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Alkalinisation in the management of tricyclic antidepressant overdose. Mackway-Jones K. **J Accid Emerg Med** 1999 Mar; 16(2):139-40 (4 ref.)
Targeted management strategies for cardiovascular toxicity from tricyclic antidepressant overdose: the pivotal role for alkalinization and sodium loading. Shanon M, et al. **Pediatr Emerg Care** 1998 Aug;14(4):293-8 (40 ref.)

SODIUM-CALCIUM CARRIER see **SODIUM-CALCIUM EXCHANGER**

SODIUM-CALCIUM EXCHANGER

Regulatory function of Na-Ca exchange in the heart: milestones and outlook. Egger M, et al. **J Membr Biol** 1999 Mar 15;168(2):107-30 (208 ref.)

CHEMISTRY

The Ca2+ pumps and the Na+/Ca2+ exchangers. Guerini D. **Biometals** 1998 Dec;11(4):319-30 (116 ref.)

METABOLISM

Influence of SR Ca(2+)-ATPase and Na(+)-Ca(2+)-exchanger on the force-frequency relation. Schillinger W, et al. **Basic Res Cardiol** 1998;93 Suppl 1:38-45 (38 ref.)
Metabolic pathways in the regulation of invertebrate and vertebrate Na+/Ca2+ exchange. DiPolo R, et al. **Biochim Biophys Acta** 1999 Feb 25;1422(1):57-71 (82 ref.)
The Ca2+ pumps and the Na+/Ca2+ exchangers. Guerini D. **Biometals** 1998 Dec;11(4):319-30 (116 ref.)

PHYSIOLOGY

New kid on the block: a role for the Na/Ca exchanger in odor transduction [comment] Dionne VE. **J Gen Physiol** 1998 Nov;112(5):527-8 (5 ref.) Comment on: J Gen Physiol 1998 Nov;112(5):529-35.
Sodium/calcium exchange: its physiological implications. Blaustein MP, et al. **Physiol Rev** 1999 Jul;79(3):763-854 (1010 ref.)
[Na(+)-Ca2+ exchange] Matsuoka S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1555-60 (49 ref.) **(Jpn)**

SODIUM CHANNELS

see related
NA(+)-K(+)-EXCHANGING ATPASE

ANTAGONISTS & INHIBITORS

Scorpion toxins specific for Na+-channels. Possani LD, et al. **Eur J Biochem** 1999 Sep;264(2):287-300 (156 ref.)
Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167-74 (50 ref.)
Volatile anesthetics significantly suppress central and peripheral mammalian sodium channels. Duch DS, et al. **Toxicol Lett** 1998 Nov 23;100-101:255-63 (47 ref.)

BIOSYNTHESIS

The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Waxman SG. **Pain** 1999 Aug;Suppl 6:S133-40 (59 ref.)

CHEMISTRY

Molecular and kinetic determinants of local anaesthetic action on sodium channels. French RJ, et al. **Toxicol Lett** 1998 Nov 23;100-101:247-54 (31 ref.)

DRUG EFFECTS

Neuroprotection--rationale for pharmacological modulation of Na(+)-channels. Urenjak J, et al. **Amino Acids** 1998; 14(1-3):151-8 (67 ref.)
The insect voltage-gated sodium channel as target of insecticides. Zlotkin E. **Annu Rev Entomol** 1999;44:429-55 (73 ref.)
Reversal of convention: from man to experimental animal in elucidating the function of the renal amiloride-sensitive sodium channel. Hummler E. **Exp Nephrol** 1998 Jul-Aug; 6(4):265-71 (56 ref.)
Molecular and kinetic determinants of local anaesthetic action on sodium channels. French RJ, et al. **Toxicol Lett** 1998 Nov 23;100-101:247-54 (31 ref.)
Molecular genetical analysis of Drosophila ether sensitive mutants. Gamo S, et al. **Toxicol Lett** 1998 Nov 23; 100-101:329-37 (24 ref.)

GENETICS

Involvement of genes encoding a K+ channel (ether a go-go) and a Na+ channel (smellblind) in Drosophila olfaction. Dubin AE, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:212-22 (28 ref.)
Diversity of mammalian voltage-gated sodium channels. Goldin AL. **Ann N Y Acad Sci** 1999 Apr 30;868:38-50 (110 ref.)
RNA editing of a Drosophila sodium channel gene. Hanrahan CJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:51-66 (54 ref.)
Oncogenes and signal transduction pathways involved in the regulation of Na+ channel expression. Sashihara S, et al. **Crit Rev Oncog** 1998;9(1):19-34 (142 ref.)
Amiloride-sensitive Na channels. Horisberger JD. **Curr Opin Cell Biol** 1998 Aug;10(4):443-9 (43 ref.)
Evolution and diversity of mammalian sodium channel genes. Plummer NW, et al. **Genomics** 1999 Apr 15;57(2):323-31 (88 ref.)
Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. Corvol P, et al. **Hypertension** 1999 Jun; 33(6):1324-31 (68 ref.)
Ion channels and the genetic contribution to epilepsy. Ryan SG. **J Child Neurol** 1999 Jan;14(1):58-66 (68 ref.)
Epithelial sodium channel regulatory proteins identified by functional expression cloning. Vallet V, et al. **Kidney Int Suppl** 1998 Sep;67:S109-14 (25 ref.)
The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Waxman SG. **Pain** 1999 Aug;Suppl 6:S133-40 (59 ref.)
Molecular genetical analysis of Drosophila ether sensitive mutants. Gamo S, et al. **Toxicol Lett** 1998 Nov 23; 100-101:329-37 (24 ref.)

METABOLISM

Regulation of voltage-sensitive sodium and calcium channels by phosphorylation. Rossie S. **Adv Second Messenger Phosphoprotein Res** 1999;33:23-48 (135 ref.)
Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Hummler E, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G567-71 (34 ref.)
H(+)-gated cation channels. Waldmann R, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:67-76 (37 ref.)
Sodium channels in alveolar epithelial cells: molecular characterization, biophysical properties, and physiological significance. Matalon S, et al. **Annu Rev Physiol** 1999; 61:627-61 (188 ref.)
Oncogenes and signal transduction pathways involved in the regulation of Na+ channel expression. Sashihara S, et al. **Crit Rev Oncog** 1998;9(1):19-34 (142 ref.)
Monitoring early neuronal differentiation by ion channels in ascidian embryos. Takahashi K, et al. **J Neurobiol** 1998 Oct;37(1):3-22 (60 ref.)
Epithelial sodium channel and its implication in the control of blood pressure. Hummler E. **Kidney Blood Press Res** 1998;21(2-4):253-5 (14 ref.)
Epithelial sodium channel regulatory proteins identified by functional expression cloning. Vallet V, et al. **Kidney Int Suppl** 1998 Sep;67:S109-14 (25 ref.)
Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Hicke L. **Trends Cell Biol** 1999 Mar;9(3):107-12 (52 ref.)

PHYSIOLOGY

The importance of voltage-dependent sodium channels in cerebral ischaemia. Carter AJ. **Amino Acids** 1998; 14(1-3):159-69 (91 ref.)
Cell volume-regulated cation channels. Wehner F. **Contrib Nephrol** 1998;123:8-20 (79 ref.)
Cell localization and ontogeny of sodium transport pathways in the distal nephron: perspectives in function and failure. Bachmann S. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):31-8 (90 ref.)
Molecular physiology of colonic epithelial sodium absorption. Clauss W. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):453-5 (57 ref.)
Reversal of convention: from man to experimental animal in elucidating the function of the renal amiloride-sensitive

sodium channel. Hummler E. **Exp Nephrol** 1998 Jul-Aug; 6(4):265-71 (56 ref.)

A new approach to insect-pest control--combination of neurotoxins interacting with voltage sensitive sodium channels to increase selectivity and specificity. Gordon D. **Invert Neurosci** 1997 Sep-Dec;3(2-3):103-16 (55 ref.)

Implication of ENaC in salt-sensitive hypertension. Hummler E. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):385-90 (49 ref.)

The molecular basis for electrogenic computation in the brain: you can't step in the same river twice. Waxman SG. **Mol Psychiatry** 1999 May;4(3):222-8 (45 ref.)

Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Waxman SG, et al. **Muscle Nerve** 1999 Sep;22(9):1177-87 (62 ref.)

From channels to behavior: an integrative model of NaCl taste. Boughter JD Jr, et al. **Neuron** 1999 Feb;22(2):213-5 (17 ref.)

Touch channels sense blood pressure [comment] Franco-Obregón A, et al. **Neuron** 1998 Dec;21(6):1224-6 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1435-41.

Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Gold MS. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7645-9 (69 ref.)

The dual role of calcium: pore blocker and modulator of gating [comment] Horn R. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3331-2 (26 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):4154-7. Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):4158-63.

A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Porreca F, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7640-4 (41 ref.)

Sodium channels and pain. Waxman SG, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7635-9 (53 ref.)

Spatial distribution of NA+ and K+ channels in spinal dorsal horn neurones: role of the soma, axon and dendrites in spike generation. Safronov BV. **Prog Neurobiol** 1999 Oct; 59(3):217-41 (125 ref.)

Neuroprotective strategies: voltage-gated Na+-channel down-modulation versus presynaptic glutamate release inhibition. Obrenovitch TP. **Rev Neurosci** 1998 Jul-Dec; 9(3):203-11 (74 ref.)

SODIUM CHLORIDE

see related

DIET, SODIUM-RESTRICTED

Towards the production of salt-tolerant crops. Barkla BJ, et al. **Adv Exp Med Biol** 1999;464:77-89 (60 ref.)

Impact evaluation of iron & iodine fortified salt. Nair KM, et al. **Indian J Med Res** 1998 Nov;108:203-11 (26 ref.)

From channels to behavior: an integrative model of NaCl taste. Boughter JD Jr, et al. **Neuron** 1999 Feb;22(2):213-5 (17 ref.)

ADMINISTRATION & DOSAGE

Normal saline instillation with endotracheal suctioning: primum non nocere (first do no harm). Blackwood B. **J Adv Nurs** 1999 Apr;29(4):928-34 (38 ref.)

ADVERSE EFFECTS

Salt and hypertension in end-stage renal disease [editorial] Kooman JP, et al. **Blood Purif** 1998;16(6):301-11 (69 ref.)

METABOLISM

Cystic fibrosis and the salt controversy. Guggino WB. **Cell** 1999 Mar 5;96(5):607-10 (20 ref.)

Mechanisms of tubular sodium chloride transport. Venkatesh S, et al. **Ren Fail** 1998 Nov;20(6):783-99 (128 ref.)

PHARMACOLOGY

Signalling and gene regulation by urea and NaCl in the renal medulla. Cohen DM. **Clin Exp Pharmacol Physiol** 1999 Jan; 26(1):69-73 (44 ref.)

Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Weir MR. **Miner Electrolyte Metab** 1998;24(6):438-45 (56 ref.)

Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Raij L. **Semin Nephrol** 1999 May; 19(3):296-303 (58 ref.)

SODIUM CHLORIDE, DIETARY

Genetic analysis in Dahl salt-sensitive rats. Kato N. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):539-40 (20 ref.)

ADMINISTRATION & DOSAGE

Amiloride and vertebrate gustatory responses to NaCl. Halpern BP. **Neurosci Biobehav Rev** 1998;23(1):5-47 (128 ref.)

[Development of preventive iodine administration in Austria] Eber O. **Wien Klin Wochenschr** 1998 Nov 13;110(21):733-7 (25 ref.) **(Ger)**

ADVERSE EFFECTS

Salt-sensitive hypertension: renal and cardiovascular implications. Campese VM. **Nutr Metab Cardiovasc Dis** 1999 Jun;9(3):143-56 (147 ref.)

Dietary salt reduction in hypertension--what is the evidence and why is it still controversial? Chrysant GS, et al. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):23-38 (73 ref.)

Salt and hypertension at the close of the millenium. Luft FC. **Wien Klin Wochenschr** 1998 Jul 31;110(13-14):459-66 (55 ref.)

METABOLISM

Dietary salt reduction in hypertension--what is the evidence and why is it still controversial? Chrysant GS, et al. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):23-38 (73 ref.)

SODIUM CHLORIDE SOLUTION, HYPERTONIC see **SALINE SOLUTION, HYPERTONIC**

SODIUM COMPOUNDS

THERAPEUTIC USE

The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. Lawrence JE, et al. **J Endocrinol Invest** 1999 May;22(5):405-7 (16 ref.)

SODIUM CROMOGLYCATE see **CROMOLYN SODIUM**

SODIUM DEXTRAN SULFATE see **DEXTRAN SULFATE**

SODIUM, DIETARY

The extended amygdala and salt appetite. Johnson AK, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:258-80 (77 ref.)

The ontogeny of salt hunger in the rat. Leshem M. **Neurosci Biobehav Rev** 1999 May;23(5):649-59 (86 ref.)

ADMINISTRATION & DOSAGE

Universal recommendations for sodium intake should be avoided [see comments] Kincaid-Smith P, et al. **Med J Aust** 1999 Feb 15;170(4):174-5 (00 ref.) Comment in: Med J Aust 1999 Aug 2;171(3):162; discussion 162-3.

Restriction of salt intake is needed to ameliorate the cardiovascular disease epidemic. Morgan TO. **Med J Aust** 1999 Feb 15;170(4):176-8 (00 ref.)

The salt dilemma: some answers, many questions. Nicholls MG, et al. **Med J Aust** 1999 Feb 15;170(4):178-80 (82 ref.)

ADVERSE EFFECTS

What is the role of dietary sodium and potassium in hypertension and target organ injury? He J, et al. **Am J Med Sci** 1999 Mar;317(3):152-9 (50 ref.)

Salt and hypertension in end-stage renal disease [editorial] Kooman JP, et al. **Blood Purif** 1998;16(6):301-11 (69 ref.)

Universal recommendations for sodium intake should be avoided [see comments] Kincaid-Smith P, et al. **Med J Aust** 1999 Feb 15;170(4):174-5 (00 ref.) Comment in: Med J Aust 1999 Aug 2;171(3):162; discussion 162-3.

Restriction of salt intake is needed to ameliorate the cardiovascular disease epidemic. Morgan TO. **Med J Aust** 1999 Feb 15;170(4):176-8 (00 ref.)

The salt dilemma: some answers, many questions. Nicholls MG, et al. **Med J Aust** 1999 Feb 15;170(4):178-80 (82 ref.)

Salt: blood pressure, the kidney, and other harmful effects. MacGregor GA. **Nephrol Dial Transplant** 1998 Oct; 13(10):2471-9 (32 ref.)

Dietary sodium intake and mortality. Esslinger KA, et al. **Nutr Rev** 1998 Oct;56(10):311-3 (13 ref.)

Salt in hypertension: physiological and molecular aspects. Gavras I, et al. **Recent Prog Horm Res** 1998;53:1-6 (46 ref.)

PHARMACOLOGY

Importance of the blood pressure-heart rate relationship. Folkow B, et al. **Blood Press** 1998 May;7(3):133-8 (30 ref.)

SODIUM DODECYL SULFATE

Horizontal SDS-PAGE for IPG-Dalt. Görg A, et al. **Methods Mol Biol** 1999;112:235-44 (15 ref.)

SODIUM DODECYL SULFATE-PAGE see **ELECTROPHORESIS, POLYACRYLAMIDE GEL**

SODIUM ETIDRONATE see **ETIDRONATE DISODIUM**

SODIUM GAMMA-HYDROXYBUTYRATE see **SODIUM OXYBATE**

SODIUM-GLUCOSE TRANSPORT SYSTEM see **MONOSACCHARIDE TRANSPORT PROTEINS**

SODIUM GLUTAMATE

ADVERSE EFFECTS

[L-tryptophan-induced eosinophilia-myalgia syndrome, Chinese restaurant syndrome] Terao T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):650-3 (11 ref.) **(Jpn)**

SODIUM GOLD THIOSULFATE see **GOLD SODIUM THIOSULFATE**

SODIUM-HYDROGEN ANTIPORTER

ANTAGONISTS & INHIBITORS

Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Avkiran M. **Am J Cardiol** 1999 May 20;83(10A):10G-17G; discussion 17G-18G (64 ref.)

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Buerke M, et al. **Am J Cardiol** 1999 May 20; 83(10A):19G-22G (35 ref.)

Protection of the myocardial cell during ischemia. Théroux P. **Am J Cardiol** 1999 May 20;83(10A):3G-9G (29 ref.)

Mechanisms of protection of the ischemic and reperfused myocardium by sodium-hydrogen exchange inhibition. Karmazyn M. **J Thromb Thrombolysis** 1999 Jul;8(1):33-8 (38 ref.)

Protection of the myocardium with sodium-hydrogen exchange inhibitors: A cardiac surgical perspective. Myers ML. **J Thromb Thrombolysis** 1999 Jul;8(1):53-60 (49 ref.)

Development of the Na+/H+ exchange inhibitor cariporide as a cardioprotective drug: from the laboratory to the GUARDIAN trial. Scholz W, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):61-70 (27 ref.)

Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167-74 (50 ref.)

CHEMISTRY

Regulation and characterization of the Na+/H+ exchanger. Fliegel L, et al. **Biochem Cell Biol** 1998;76(5):735-41 (79 ref.)

Na+/H+ exchanger: proton modifier site regulation of activity. Kinsella JL, et al. **Biochem Cell Biol** 1998; 76(5):743-9 (22 ref.)

DRUG EFFECTS

Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. Levitsky J, et al. **J Clin Pharmacol** 1998 Oct;38(10):887-97 (74 ref.)

METABOLISM

Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. Hannan KM, et al. **Biochem Cell Biol** 1998;76(5):751-9 (85 ref.)

Na+/H+ exchanger: proton modifier site regulation of activity. Kinsella JL, et al. **Biochem Cell Biol** 1998; 76(5):743-9 (22 ref.)

The molecular mechanism of regulation of the NhaA Na+/H+ antiporter of Escherichia coli, a key transporter in the adaptation to Na+ and H+. Padan E, et al. **Novartis Found Symp** 1999;221:183-96; discussion 196-9 (57 ref.)

[Effect of angiotensin ii on Na+/H+ exchangers of the renal tubule] Poggioli J, et al. **Nephrologie** 1998;19(7):421-5 (56 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Regulation of cardiac sarcolemmal Na+/H+ exchanger activity by endogenous ligands. Relevance to ischemia. Avkiran M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:335-45 (77 ref.)

The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Karmazyn M. **Ann N Y Acad Sci** 1999 Jun 30;874:326-34 (33 ref.)

Na+/H+ exchangers. Molecular diversity and relevance to heart. Orlowski J. **Ann N Y Acad Sci** 1999 Jun 30; 874:346-53 (81 ref.)

Regulation and characterization of the Na+/H+ exchanger. Fliegel L, et al. **Biochem Cell Biol** 1998;76(5):735-41 (79 ref.)

Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. Levitsky J, et al. **J Clin Pharmacol** 1998 Oct;38(10):887-97 (74 ref.)

Regulation of cardiac sarcolemmal Na+/H+ exchanger activity: potential pathophysiological significance of endogenous mediators and oxidant stress. Avkiran M, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):25-32 (84 ref.)

Functional and cellular regulation of the myocardial Na+/H+ exchanger. Fliegel L. **J Thromb Thrombolysis** 1999 Jul;8(1):9-14 (52 ref.)

Role of the sodium-hydrogen exchanger in ischemia-reperfusion injury in diabetes. Goel DP, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):45-52 (94 ref.)

If ischemic preconditioning is the gold standard, has a platinum standard of cardioprotection arrived? Comparison with NHE inhibition. Gumina RJ, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):39-44 (37 ref.)

Protection of the myocardium with sodium-hydrogen exchange inhibitors: A cardiac surgical perspective. Myers ML. **J Thromb Thrombolysis** 1999 Jul;8(1):53-60 (49 ref.)

Sodium-hydrogen exchange and platelet function. Rosskopf D. **J Thromb Thrombolysis** 1999 Jul;8(1):15-24 (128 ref.)

Sodium proton exchanger (NHE) isoforms--potential relevance to hypertension and its complications [editorial] Ng LL. **Nephrol Dial Transplant** 1998 Dec;13(12):2994-6 (21 ref.)

SODIUM HYDROXIDE

CHEMISTRY

[Soda lime: a review] Freys G. **Ann Fr Anesth Reanim** 1999 Mar;18(3):299–302 (29 ref.) **(Fre)**
[The soda-lime problem] Förster H. **Anaesthesist** 1999 Jun; 48(6):409–16 (71 ref.) **(Ger)**

SODIUM HYPOCHLORITE

POISONING

Fatal ingestion of sodium hypochlorite bleach with associated hypernatremia and hyperchloremic metabolic acidosis. Ross MP, et al. **Vet Hum Toxicol** 1999 Apr;41(2):82–6 (34 ref.)

THERAPEUTIC USE

[Detoxication and disinfection by sodium hypochlorite] Eventov VL, et al. **Med Tekh** 1998 Nov–Dec;(6):36–9 (15 ref.) (Eng. Abstr.) **(Rus)**

SODIUM LAURYL SULFATE see **SODIUM DODECYL SULFATE**

SODIUM NITRITE

ADVERSE EFFECTS

[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

[Effect of nitrates and nitrites on small intestine] Grudziński IP. **Rocz Panstw Zakl Hig** 1998;49(3):321–30 (44 ref.) (Eng. Abstr.) **(Pol)**

SODIUM OXYBATE

PHARMACOLOGY

gamma-Hydroxybutyric acid, imidazoleacetic acid, cerebral metabolism and induced sleep. Rick JT, et al. **Isr J Med Sci** 1973;9 Suppl:55–62 (12 ref.)

POISONING

Gamma-hydroxybutyric acid: an emerging recreational drug. Kam PC, et al. **Anaesthesia** 1998 Dec;53(12):1195–8 (29 ref.)

SODIUM OXYBUTYRATE see **SODIUM OXYBATE**

SODIUM, POTASSIUM ADENOSINETRIPHOSPHATASE see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM, POTASSIUM ATPASE see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM-POTASSIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM VALPROATE see **VALPROIC ACID**

SODOKU see **RAT-BITE FEVER**

SOFT TISSUE INFECTIONS

see related
SKIN DISEASES, INFECTIOUS

Obturator internus muscle abscess in children: report of seven cases and review. Viani RM, et al. **Clin Infect Dis** 1999 Jan;28(1):117–22 (14 ref.)
Hand infections in the trauma patient. Tsai E, et al. **Hand Clin** 1999 May;15(2):373–86 (59 ref.)
[Skin and soft-tissue infections caused by Pseudomonas aeruginosa] Cainzos Fernández M. **Rev Clin Esp** 1998 Sep; 198 Suppl 2:21–4 (21 ref.) **(Spa)**

DIAGNOSIS

[Anaerobic bacteria soft tissue infection. Etiology, diagnosis, treatment] Jarrin I, et al. **Rev Prat** 1998 May 15; 48(10):1109–14 (3 ref.) **(Fre)**

DRUG THERAPY

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Langtry HD, et al. **Drugs** 1998 Sep;56(3):487–515 (126 ref.)
Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Deery HG 2nd. **Infect Dis Clin North Am** 1998 Dec;12(4):935–49, vii (50 ref.)
Targeting lurking pathogens in acute traumatic and chronic wounds. Eron LJ. **J Emerg Med** 1999 Jan–Feb;17(1):189–95 (35 ref.)

THERAPY

Hyperbaric oxygen in the treatment of life-threatening soft-tissue infections. Clark LA, et al. **Respir Care Clin N Am** 1999 Jun;5(2):203–19 (101 ref.)
[Anaerobic bacteria soft tissue infection. Etiology, diagnosis, treatment] Jarrin I, et al. **Rev Prat** 1998 May 15; 48(10):1109–14 (3 ref.) **(Fre)**

SOFT TISSUE INJURIES

Adult posttraumatic osteomyelitis of the tibia. Mader JT, et al. **Clin Orthop** 1999 Mar;(360):14–21 (53 ref.)

CLASSIFICATION

[Classification in trauma surgery (2)] Petersen PF, et al. **Zentralbl Chir** 1999;124(1):W1–6 (20 ref.) **(Ger)**

DIAGNOSIS

MR imaging of musculoskeletal trauma to the pelvis and the lower limb. Brossmann J, et al. **Eur Radiol** 1999;9(2):183–91 (78 ref.)
Magnetic resonance imaging in the evaluation of ligament injuries. Farooki S, et al. **Skeletal Radiol** 1999 Feb; 28(2):61–74 (107 ref.)
[Diagnosis, first aid and classification of muscle injuries in sports medicine] Bily W, et al. **Sportverletz Sportschaden** 1998 Sep;12(3):87–93 (70 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Assessment of tissue oxygenation. Robertson PW, et al. **Respir Care Clin N Am** 1999 Jun;5(2):221–63 (192 ref.)

PHYSIOPATHOLOGY

Pathophysiology of posttraumatic osteomyelitis. Tsukayama DT. **Clin Orthop** 1999 Mar;(360):22–9 (61 ref.)
Ankle sprains and other soft tissue injuries. Liu SH, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):132–7 (71 ref.)

RADIOGRAPHY

CT of soft tissue injury and orbital fractures. Mauriello JA Jr, et al. **Radiol Clin North Am** 1999 Jan;37(1):241–52, xii (35 ref.)

REHABILITATION

Perspectives on prognosis of soft tissue musculoskeletal disorders. Hudak PL, et al. **Int J Rehabil Res** 1998 Mar; 21(1):29–40 (38 ref.)

SURGERY

Treatment of composite tissue loss following hand and forearm trauma. Tomaino MM. **Hand Clin** 1999 May; 15(2):319–33, ix (31 ref.)

THERAPY

Assessment of tissue oxygenation. Robertson PW, et al. **Respir Care Clin N Am** 1999 Jun;5(2):221–63 (192 ref.)

SOFT TISSUE NEOPLASMS

Adult soft tissue sarcoma. Mann GB, et al. **Aust N Z J Surg** 1999 May;69(5):336–43 (85 ref.)
Liposarcoma: a review of current diagnosis and management. Wong CK, et al. **Br J Hosp Med** 1998 Dec 10;58(11):589–91 (19 ref.)
Ossifying fibromyxoid tumor of soft parts in a child: a case report. Ijiri R, et al. **J Pediatr Surg** 1999 Aug;34(8):1294–6 (18 ref.)
Soft tissue sarcomas of infancy. Palumbo JS, et al. **Semin Perinatol** 1999 Aug;23(4):299–309 (61 ref.)

CLASSIFICATION

Myofibroblastic tumours: an update. Fletcher CD. **Verh Dtsch Ges Pathol** 1998;82:75–82 (74 ref.)
[Cutaneous and subcutaneous soft tissue tumors] Meister P. **Verh Dtsch Ges Pathol** 1998;82:112–20 (36 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Application of immunocytochemistry in the diagnosis of soft tissue sarcomas: a review and update. Ordóñez NG. **Adv Anat Pathol** 1998 Mar;5(2):67–85 (277 ref.)
Recent advances in soft tissue tumor diagnosis. Mentzel T, et al. **Am J Clin Pathol** 1998 Nov;110(5):660–70 (66 ref.)
Benign bone and soft-tissue tumors about the knee. Wurtz LD, et al. **Am J Knee Surg** 1998 Fall;11(4):246–56 (21 ref.)
Presentation and diagnosis of unilateral maxillary swelling in children. Koch BL, et al. **Am J Otolaryngol** 1999 Mar–Apr;20(2):106–29 (92 ref.)
The diagnosis and management of soft tissue sarcomas of the extremities in the adult. Rougraff B. **Curr Probl Cancer** 1999 Jan–Feb;23(1):1–50 (134 ref.)
Magnetic resonance imaging of musculoskeletal tumors: skeletal and soft tissue masses. Ma LD. **Curr Probl Diagn Radiol** 1999 Mar–Apr;28(2):29–62 (32 ref.)
Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. Erlandson RA, et al. **Hum Pathol** 1998 Dec; 29(12):1372–81 (71 ref.)
Diagnosis and treatment of soft tissue tumors. Iwamoto Y. **J Orthop Sci** 1999;4(1):54–65 (28 ref.)
Extraosseous osteogenic sarcoma--a rare pediatric malignancy: case report and review of the literature. Humphrey GM, et al. **J Pediatr Surg** 1999 Jun;34(6):1025–8 (29 ref.)
Recent advances in the diagnosis of pediatric soft-tissue tumors. Kilpatrick SE, et al. **Med Pediatr Oncol** 1999 May; 32(5):373–6 (22 ref.)
An unusual presentation of congenital infantile myofibromatosis arising from the interspinous ligament. Kubota A, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):138–9 (14 ref.)
MR imaging of benign soft-tissue masses of the foot and ankle. Llauger J, et al. **Radiographics** 1998 Nov–Dec; 18(6):1481–98 (27 ref.)
Prognostic factors in soft tissue sarcoma. Levine EA. **Semin Surg Oncol** 1999 Jul–Aug;17(1):23–32 (76 ref.)
Soft tissue sarcomas in children. Pappo AS, et al. **Semin Surg Oncol** 1999 Mar;16(2):121–43 (127 ref.)
New diagnostic modalities in soft tissue sarcoma. Singer S. **Semin Surg Oncol** 1999 Jul–Aug;17(1):11–22 (78 ref.)
Optimal radiologic imaging of soft tissue sarcomas. Varma DG. **Semin Surg Oncol** 1999 Jul–Aug;17(1):2–10 (56 ref.)
[New entities and pitfalls in the diagnosis of soft tissue tumors] Michal M, et al. **Rozhl Chir** 1999 Feb;78(2):76–82 (76 ref.) (Eng. Abstr.) **(Cze)**
[Soft tissue tumors. II] Schneider G, et al. **Radiologe** 1999 Apr;39(4):330–41 (0 ref.) **(Ger)**
[Intra-abdominal desmoplastic small-cell tumor--the rare differential diagnosis of a malignant peritoneal tumor] Rozeik C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):321–3 (10 ref.) **(Ger)**

DRUG THERAPY

TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Eggermont AM. **Anticancer Res** 1998 Sep–Oct;18(5D):3899–905 (80 ref.)
Should patients with advanced sarcomas be treated with chemotherapy? [see comments] Benjamin RS, et al. **Eur J Cancer** 1998 Jun;34(7):958–65 (43 ref.) Comment in: Eur J Cancer 1999 Feb;35(2):327.
New chemotherapeutic strategies for soft tissue sarcomas. Patel SR, et al. **Semin Surg Oncol** 1999 Jul–Aug;17(1):47–51 (31 ref.)
Chemoradiation treatment strategies for localized sarcoma: conventional and investigational approaches. Pisters PW. **Semin Surg Oncol** 1999 Jul–Aug;17(1):66–71 (25 ref.)
[Chemotherapy of soft tissue sarcoma in the adult (published erratum appears in Cancer Radiother 1999 Jan–Feb;3(1):85)] Lagarde P, et al. **Cancer Radiother** 1998 Dec;2(6):747–51 (18 ref.) (Eng. Abstr.) **(Fre)**
[Adjuvant chemotherapy in early soft tissue sarcoma and palliative chemotherapy in advanced soft tissue sarcoma in adults] Sauer H. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1066–71 (72 ref.) (Eng. Abstr.) **(Ger)**
[How do we treat refractory soft tissue sarcomas? (editorial)] Colucci G. **Clin Ter** 1998 Sep–Oct;149(5):327–8 (22 ref.) **(Ita)**

EPIDEMIOLOGY

A review of the epidemiology of soft tissue sarcoma. Olsson H. **Acta Orthop Scand Suppl** 1999 Jun;285:8–10 (29 ref.)

ETIOLOGY

Development of a desmoid tumor at the site of a total hip replacement. Gebhart M, et al. **Acta Orthop Belg** 1999 Jun; 65(2):230–4 (24 ref.)
Squamous cell carcinoma in chronic ulcerative lesions: a case report and literature review. Hensel KS, et al. **Am J Orthop** 1999 Apr;28(4):253–6 (14 ref.)
The pneumoperitoneum and its role in tumor seeding. Reymond MA, et al. **Dig Surg** 1998;15(2):105–9 (48 ref.)

GENETICS

Genetic changes in bone and soft tissue tumors. Mandahl N, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:30–40 (59 ref.)
Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience. Rydholm A, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:50–7 (72 ref.)
Molecular alterations in bone and soft-tissue sarcoma. Bell RS, et al. **Can J Surg** 1999 Aug;42(4):259–66 (45 ref.)
Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature. Joyama S, et al. **Cancer** 1999 Oct 1;86(7):1246–50 (24 ref.)
The cytogenetic and molecular characterization of benign and malignant soft tissue tumors. Sreekantaiah C. **Cytogenet Cell Genet** 1998;82(1–2):13–29 (277 ref.)
Translocation (11;22)(q24;q12) in a small cell tumor of the thigh in a 2-year-old boy: immunohistology, cytogenetics, molecular genetics, and review of the literature. Mastik MF, et al. **Hum Pathol** 1999 Mar;30(3):352–5 (22 ref.)
Cytogenetics of soft tissue tumours. Dal Cin P. **Verh Dtsch Ges Pathol** 1998;82:47–58 (100 ref.)

[What is the value of recent molecular biology knowledge for surgical oncologic therapy of soft tissue sarcoma?] Willeke F. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:393–8 (28 ref.) (Eng. Abstr.) **(Ger)**

[Morphology and molecular biology of malignant soft tissue sarcomas] Katenkamp D. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1043–9 (60 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience. Rydholm A, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:50–7 (72 ref.)

Histopathologic diagnosis of superficial soft tissue tumors, related lesions, and simulators: an algorithmic approach based on colors. Diaz-Cascajo C. **Am J Dermatopathol** 1999 Apr;21(2):193–9 (4 ref.)

Low-grade myofibroblastic sarcoma: analysis of 18 cases in the spectrum of myofibroblastic tumors. Mentzel T, et al. **Am J Surg Pathol** 1998 Oct;22(10):1228–38 (31 ref.)

Synovial sarcoma. Fisher C. **Ann Diagn Pathol** 1998 Dec; 2(6):401–21 (179 ref.)

Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Kilpatrick SE. **Ann Diagn Pathol** 1999 Feb;3(1):48–61 (97 ref.)

Myxomatous soft tissue tumors: correlation of cytopathology and histopathology. Wakely PE Jr. **Ann Diagn Pathol** 1999 Aug;3(4):227–42 (64 ref.)

Giant trichoblastoma mimicking malignancy. Ogata T, et al. **Arch Orthop Trauma Surg** 1999;119(3–4):225–7 (16 ref.)

Sacrococcygeal teratoma in adults: case reports and a review of the literature. Ng EW, et al. **Cancer** 1999 Oct 1; 86(7):1198–202 (25 ref.)

Pulmonary cysts as the sole metastatic manifestation of soft tissue sarcoma: case report and consideration of the pathogenesis. Hasegawa S, et al. **Chest** 1999 Jul; 116(1):263–5 (12 ref.)

Pacinian neurofibroma of the hand: a case report and literature review. MacLennan SE, et al. **J Hand Surg [Am]** 1999 Mar;24(2):413–6 (13 ref.)

Myoepithelioma of soft tissue. Sasaguri T, et al. **Pathol Int** 1999 Jun;49(6):571–6 (19 ref.)

Intergroup Rhabdomyosarcoma Study: update for pathologists. Qualman SJ, et al. **Pediatr Dev Pathol** 1998 Nov-Dec;1(6):550–61 (35 ref.)

Tumors of the soft tissues composed of large eosinophilic cells. d'Amore ES, et al. **Semin Diagn Pathol** 1999 May; 16(2):178–89 (100 ref.)

Alveolar soft-part sarcoma: a review of the pathology and histogenesis. Ordóñez NG, et al. **Ultrastruct Pathol** 1998 Jul-Aug;22(4):275–92 (114 ref.)

Cytogenetics of soft tissue tumours. Dal Cin P. **Verh Dtsch Ges Pathol** 1998;82:47–58 (100 ref.)

Recent developments in soft tissue tumors. Fletcher CD. **Verh Dtsch Ges Pathol** 1998;82:33–46 (80 ref.)

Myofibroblastic tumours: an update. Fletcher CD. **Verh Dtsch Ges Pathol** 1998;82:75–82 (74 ref.)

[Staging of musculoskeletal tumors in diagnostic imaging] Funovics M, et al. **Radiologe** 1999 Jul;39(7):591–9 (48 ref.) (Eng. Abstr.) **(Ger)**

[Morphology and molecular biology of malignant soft tissue sarcomas] Katenkamp D. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1043–9 (60 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous and subcutaneous soft tissue tumors] Meister P. **Verh Dtsch Ges Pathol** 1998;82:112–20 (36 ref.) (Eng. Abstr.) **(Ger)**

[Clear cell sarcoma of soft tissues. Clinico-pathological and ultrastructural analysis of a case in the head-neck region and a literature review] Bisceglia M, et al. **Pathologica** 1998 Aug;90(4):391–6 (40 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

Adjuvant brachytherapy in the treatment of soft-tissue sarcomas. Crownover RL, et al. **Hematol Oncol Clin North Am** 1999 Jun;13(3):595–607 (40 ref.)

Use of brachytherapy to preserve function in children with soft-tissue sarcomas. Nag S, et al. **Oncology (Huntingt)** 1999 Mar;13(3):361–69; discussion 369–70, 373–4 (32 ref.)

Chemoradiation treatment strategies for localized sarcoma: conventional and investigational approaches. Pisters PW. **Semin Surg Oncol** 1999 Jul-Aug;17(1):66–71 (25 ref.)

Contemporary radiotherapy for soft tissue sarcoma. Wylie JP, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):33–46 (91 ref.)

[Late results of radiotherapy of soft tissue sarcoma] Schultze J, et al. **Rontgenpraxis** 1998;51(11):413–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Radiotherapy of soft tissue sarcomas] Schwarz R, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1072–80 (100 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[Surgical management of soft tissue sarcomas: principles of resection and reconstructive plastic procedures] Steinau HU, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19; 87(34):1061–5 (17 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Carcinoma of the uterine cervix metastatic to behind the zygomatic arch: a case report. Challagalla JD, et al. **Am J Otolaryngol** 1999 May-Jun;20(3):195–7 (14 ref.)

SURGERY

Local recurrence after surgery for soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Trovik CS, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:45–6 (16 ref.)

Solitary fibrous tumour of the forearm. A rare tumour in an atypical site. Harrington P, et al. **J Hand Surg [Br]** 1999 Jun;24(3):370–2 (8 ref.)

Reconstructive approaches in soft tissue sarcoma. Langstein HN, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):52–65 (27 ref.)

[Cutaneous and subcutaneous sarcomas] Champeau F, et al. **Ann Chir Plast Esthet** 1998 Aug;43(4):421–38 (33 ref.) (Eng. Abstr.) **(Fre)**

[Surgical aspects in the multidisciplinary treatment of soft tissue sarcomas] Röhrborn A, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19;87(34):1050–60 (50 ref.) (Eng. Abstr.) **(Ger)**

[Surgical management of soft tissue sarcomas: principles of resection and reconstructive plastic procedures] Steinau HU, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19; 87(34):1061–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Should desmoid fibromas be operated?] Chissov VI, et al. **Khirurgiia (Mosk)** 1998;(12):5–9 (5 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

The Scandinavian Sarcoma Group Register. Bauer HC, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:41–4 (19 ref.)

Soft tissue sarcoma in adults. Dirix LY, et al. **Curr Opin Oncol** 1999 Jul;11(4):285–95 (66 ref.)

Diagnosis and treatment of soft tissue tumors. Iwamoto Y. **J Orthop Sci** 1999;4(1):54–65 (28 ref.)

Preclinical experimental therapeutic approaches in soft tissue sarcoma. Hunt KK, et al. **Semin Surg Oncol** 1999 Jul-Aug; 17(1):78–82 (27 ref.)

Immunotherapeutic approaches to sarcoma. Linehan DC, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):72–7 (37 ref.)

Soft tissue sarcomas in children. Pappo AS, et al. **Semin Surg Oncol** 1999 Mar;16(2):121–43 (127 ref.)

[Determinants for operative and multimodal treatment of malignant soft tissue tumors] Schlag PM, et al. **Verh Dtsch Ges Pathol** 1998;82:64–6 (8 ref.) (Eng. Abstr.) **(Ger)**

[Recent advances in management of musculoskeletal tumors] Uchida A. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:185–90 (4 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. Erlandson RA, et al. **Hum Pathol** 1998 Dec; 29(12):1372–81 (71 ref.)

Granular cell tumor: a review of the pathology and histogenesis. Ordóñez NG, et al. **Ultrastruct Pathol** 1999 Jul-Aug;23(4):207–22 (154 ref.)

VETERINARY

Etiology of feline vaccine-associated sarcomas: history and update. Bergman PJ. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1424–5 (5 ref.)

Review of treatment options for vaccine-associated feline sarcoma. Couto CG, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1426–7 (4 ref.)

Feline vaccine-associated sarcomas: current studies on pathogenesis. Hendrick MJ. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1425–6 (5 ref.)

Historical review and current knowledge of risk factors involved in feline vaccine-associated sarcomas. Hendrick MJ. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1422–3 (7 ref.)

Education/communication: history and current status. Richards JR. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1429–30 (0 ref.)

SOFTBALL see **BASEBALL**

SOFTWARE

Analysing qualitative data: computerized and other approaches. Webb C. **J Adv Nurs** 1999 Feb;29(2):323–30 (29 ref.)

Overview of nucleic acid analysis programs. Lu XJ, et al. **J Biomol Struct Dyn** 1999 Feb;16(4):833–43 (42 ref.)

Assessment of quality of life in the younger child: the use of an animated computer program. Büller H. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S53–5 (11 ref.)

GIDEON computer program for diagnosing and teaching geographic medicine. Keystone JS. **J Travel Med** 1999 Jun; 6(2):152–4 (4 ref.)

Protein identification and analysis tools in the ExPASy server. Wilkins MR, et al. **Methods Mol Biol** 1999; 112:531–52 (16 ref.)

Pacemaker trials: software or hardware randomization? [editorial] Gribbin GM, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1503–7 (37 ref.)

Modern architectures for intelligent systems: reusable ontologies and problem-solving methods. Musen MA. **Proc AMIA Symp** 1998;:46–52 (31 ref.)

CAMPASS: a database of structurally aligned protein superfamilies. Sowdhamini R, et al. **Structure** 1998 Sep 15; 6(9):1087–94 (50 ref.)

Iterated profile searches with PSI-BLAST--a tool for discovery in protein databases. Altschul SF, et al. **Trends Biochem Sci** 1998 Nov;23(11):444–7 (30 ref.)

Applying neural networks as software sensors for enzyme engineering. Linko S, et al. **Trends Biotechnol** 1999 Apr; 17(4):155–62 (56 ref.)

[Analog-digital conversion using pCLAMP and DOS/V] Kohara M. **Nippon Seirigaku Zasshi** 1998;60(4):187–99 (6 ref.) **(Jpn)**

TRENDS

Spilling the beans on java 3D: a tool for the virtual anatomist. Guttmann GD. **Anat Rec** 1999 Apr 15;257(2):73–9 (14 ref.)

SOFTWARE DESIGN

Interface design for health care environments: the role of cognitive science. Patel VL, et al. **Proc AMIA Symp** 1998; :29–37 (42 ref.)

SOFTWARE ENGINEERING see **SOFTWARE**

SOFTWARE TOOLS see **SOFTWARE**

SOFTWARE VALIDATION

Episodes of care: theoretical frameworks versus current operational realities. Rosen AK, et al. **Jt Comm J Qual Improv** 1999 Mar;25(3):111–28 (51 ref.)

SOFTWARE VERIFICATION see **SOFTWARE VALIDATION**

SOIL

Use of plant roots for phytoremediation and molecular farming. Gleba D, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5973–7 (42 ref.)

ANALYSIS

Trace element inputs into soils by anthropogenic activities and implications for human health. Senesi GS, et al. **Chemosphere** 1999 Jul;39(2):343–77 (111 ref.)

Peroxide-modified titanium dioxide: a chemical analog of putative Martian soil oxidants. Quinn RC, et al. **Orig Life Evol Biosph** 1999 Jan;29(1):59–72 (27 ref.)

Fate and effects of linear alkylbenzene sulphonates (LAS) in the terrestrial environment. Jensen J. **Sci Total Environ** 1999 Feb 9;226(2–3):93–111 (90 ref.)

SOIL MICROBIOLOGY

Zoophilic and geophilic fungi as a cause of skin disease in farmers. Spiewak R. **Ann Agric Environ Med** 1998; 5(2):97–102 (23 ref.)

Barriers to horizontal gene transfer by natural transformation in soil bacteria. Nielsen KM. **APMIS Suppl** 1998;84:77–84 (60 ref.)

Bacterial dehalogenation. Fetzner S. **Appl Microbiol Biotechnol** 1998 Dec;50(6):633–57 (183 ref.)

Horizontal gene transfers in the environment: natural transformation as a putative process for gene transfers between transgenic plants and microorganisms. Bertolla F, et al. **Res Microbiol** 1999 Jul-Aug;150(6):375–84 (81 ref.)

SOIL POLLUTANTS

Effects of processing of heavy metal content of foods. Morgan JN. **Adv Exp Med Biol** 1999;459:195–211 (25 ref.)

Use of plant roots for phytoremediation and molecular farming. Gleba D, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):5973–7 (42 ref.)

ANALYSIS

Environmental analysis. Clement RE, et al. **Anal Chem** 1999 Jun 15;71(12):257R–292R (756 ref.)

Nuclear magnetic resonance in environmental engineering: principles and applications. Lens PN, et al. **Biodegradation** 1998;9(6):393–409 (107 ref.)

Chelant extraction of heavy metals from contaminated soils. Peters RW. **J Hazard Mater** 1999 Apr 23;66(1–2):151–210 (91 ref.)

Microbial methods for assessing contaminant effects in sediments. Eismann F, et al. **Rev Environ Contam Toxicol** 1999;159:41–93 (349 ref.)

METABOLISM

Metal contaminated soil--is natural attenuation acceptable? Eccles H. **Biochem Soc Trans** 1998 Nov;26(4):657–61 (10 ref.)

Fungi as potential bioremediation agents in soil contaminated with heavy or radioactive metals. Gray SN. **Biochem Soc Trans** 1998 Nov;26(4):666–70 (34 ref.)

Developments in terrestrial bacterial remediation of metals. Stephen JR, et al. **Curr Opin Biotechnol** 1999 Jun; 10(3):230–3 (36 ref.)

SOIL POLLUTANTS

PHARMACOKINETICS

Assessment of organic contaminant fate in waste water treatment plants. I: Selected compounds and physicochemical properties. Alcock RE, et al. **Chemosphere** 1999 Apr;38(10):2247–62 (60 ref.)

TOXICITY

Development of toxicity criteria for petroleum hydrocarbon fractions in the Petroleum Hydrocarbon Criteria Working Group approach for risk-based management of total petroleum hydrocarbons in soil. Twerdok LE. **Drug Chem Toxicol** 1999 Feb;22(1):275–91 (31 ref.)

Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Van den Berg M, et al. **Environ Health Perspect** 1998 Dec;106(12):775–92 (225 ref.)

Spatial and temporal trends of contaminants in Canadian Arctic freshwater and terrestrial ecosystems: a review. Braune B, et al. **Sci Total Environ** 1999 Jun 1; 230(1–3):145–207 (204 ref.)

SOIL POLLUTANTS, RADIOACTIVE

ANALYSIS

Application of remedy studies to the development of a soil washing pilot plant that uses mineral processing technology: a practical experience. Richardson WS 3rd, et al. **J Hazard Mater** 1999 Apr 23;66(1–2):47–65 (20 ref.)

METABOLISM

Fungi as potential bioremediation agents in soil contaminated with heavy or radioactive metals. Gray SN. **Biochem Soc Trans** 1998 Nov;26(4):666–70 (34 ref.)

SOLANACEAE

PHYSIOLOGY

Self-incompatibility and other pollen-pistil interactions. McCormick S. **Curr Opin Plant Biol** 1998 Feb;1(1):18–25 (43 ref.)

SOLANACEOUS ALKALOIDS

see related
PARASYMPATHOLYTICS

CHEMISTRY

Postharvest changes in glycoalkaloid content of potatoes. Friedman M, et al. **Adv Exp Med Biol** 1999;459:121–43 (124 ref.)

[Steroidal glycoalkaloids from the Solanaceae family] Zimowski J. **Postepy Biochem** 1998;44(3):254–62 (72 ref.) **(Pol)**

SOLANUM ALKALOIDS see **SOLANACEOUS ALKALOIDS**

SOLANUM TUBEROSUM see **POTATOES**

SOLAR ACTIVITY

see related
COSMIC RADIATION

[Heliogeophysical factors and ENT diseases] Kubyshkina IV. **Vestn Otorinolaringol** 1998;(6):54–6 (39 ref.) **(Rus)**

SOLAR AGING OF SKIN see **SKIN AGING**

SOLAR ENERGY

How photosynthetic bacteria harvest solar energy. Cogdell RJ, et al. **J Bacteriol** 1999 Jul;181(13):3869–79 (77 ref.)

[The electric furnace of Henri Moissan at one hundred years: connection with the electric furnace, the solar furnace, the plasma furnace?] Royère C. **Ann Pharm Fr** 1999 Mar; 57(2):116–30 (70 ref.) (Eng. Abstr.) **(Fre)**

SOLAR FLARES see **SOLAR ACTIVITY**

SOLAR PARTICLE EVENTS see **SOLAR ACTIVITY**

SOLAR PLEXUS see **CELIAC PLEXUS**

SOLDIERS see **MILITARY PERSONNEL**

SOLEUS MUSCLE see **MUSCLE, SKELETAL**

SOLITARY CYSTS see **BONE CYSTS**

SOLITARY NUCLEUS

PHYSIOLOGY

Neural circuits for taste. Excitation, inhibition, and synaptic plasticity in the rostral gustatory zone of the nucleus of the solitary tract. Bradley RM, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:467–74 (22 ref.)

Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Johnson RA, et al. **Braz J Med Biol Res** 1999 Jan;32(1):1–14 (57 ref.)

Endogenous vasopressin and the central control of heart rate during dynamic exercise. Michelini LC. **Braz J Med Biol Res** 1998 Sep;31(9):1185–95 (52 ref.)

Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system. Yew DT, et al. **Microsc Res Tech** 1999 Jun 15;45(6):389–400 (123 ref.)

SOLO PRACTICE see **PRIVATE PRACTICE**

SOLUBILITY

Comparison of various cosolvency models for calculating solute solubility in water–cosolvent mixtures. Jouyban-Gharamaleki A, et al. **Int J Pharm** 1999 Jan 15; 177(1):93–101 (35 ref.)

SOLUTIONS

ADVERSE EFFECTS

Toxicity of ocular surgical solutions. Anderson NJ, et al. **Int Ophthalmol Clin** 1999 Spring;39(2):91–106 (56 ref.)

CHEMISTRY

Solution phase combinatorial chemistry. Merritt AT. **Comb Chem High Throughput Screen** 1998 Jun;1(2):57–72 (72 ref.)

Phase behavioral effects on particle formation processes using supercritical fluids. Palakodaty S et al. **Pharm Res** 1999 Jul;16(7):976–85 (55 ref.)

SOLUTIONS, HEMODIALYSIS see **HEMODIALYSIS SOLUTIONS**

SOLUTIONS, ORGAN PRESERVATION see **ORGAN PRESERVATION SOLUTIONS**

SOLVENTS

Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Biesert L, et al. **Vox Sang** 1998;74 Suppl 1:207–12 (12 ref.)

Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Horowitz B, et al. **Vox Sang** 1998;74 Suppl 1:203–6 (22 ref.)

ADVERSE EFFECTS

The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea. Yu IJ, et al. **Appl Occup Environ Hyg** 1999 Jun;14(6):356–8 (15 ref.)

Non-Hodgkin's lymphoma risk derived from exposure to organic solvents: a review of epidemiologic studies. Rêgo MA. **Cad Saude Publica** 1998;14 Suppl 3:41–66 (98 ref.)

Effects of occupational solvent exposure on fertility. Lindbohm ML. **Scand J Work Environ Health** 1999;25 Suppl 1:44–6 (10 ref.)

[The neurobehavioral effects of solvents] Tsenova B. **Probl Khig** 1997;22:39–54 (19 ref.) (Eng. Abstr.) **(Bul)**

[Polyneuropathy and encephalopathy caused by organic solvents and mixed solvent solutions. Occupational medicine and neurologic aspects of a new occupational disease] Triebig G, et al. **Nervenarzt** 1999 Apr;70(4):306–14 (59 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Solvents in urine as exposure markers. Ikeda M. **Toxicol Lett** 1999 Sep 5;108(2–3):99–106 (18 ref.)

CHEMISTRY

Computer simulations with explicit solvent: recent progress in the thermodynamic decomposition of free energies and in modeling electrostatic effects. Levy RM, et al. **Annu Rev Phys Chem** 1998;49:531–67 (199 ref.)

PHARMACOKINETICS

Toxicokinetics of organic solvents: a review of modifying factors. Löf A, et al. **Crit Rev Toxicol** 1998 Nov; 28(6):571–650 (650 ref.)

Developments toward large-scale bacterial bioprocesses in the presence of bulk amounts of organic solvents. Schmid A, et al. **Extremophiles** 1998 Aug;2(3):249–56 (40 ref.)

PHARMACOLOGY

The modulation of membrane structure and stability by dimethyl sulphoxide (review). Yu ZW, et al. **Mol Membr Biol** 1998 Apr-Jun;15(2):59–68 (61 ref.)

POISONING

[Polyneuropathies from solvents] Neundörfer B, et al. **Fortschr Neurol Psychiatr** 1998 Dec;66(12):539–44 (67 ref.) (Eng. Abstr.) **(Ger)**

[Acute dimethylformamide (DMF) poisoning: a case report] Amatimaggio F, et al. **Med Lav** 1998 Nov-Dec;89(6):533–7 (14 ref.) (Eng. Abstr.) **(Ita)**

[Organic solvents (poisoning)] Kumamoto T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):633–7 (12 ref.) **(Jpn)**

STANDARDS

Clinical effectiveness of low-temperature sterilization technologies. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):798–804 (27 ref.)

THERAPEUTIC USE

Medical management of common bile duct stones. González-Koch A, et al. **World J Surg** 1998 Nov; 22(11):1145–50 (48 ref.)

TOXICITY

Improvement of organic solvent tolerance level of Escherichia coli by overexpression of stress-responsive genes. Aono R. **Extremophiles** 1998 Aug;2(3):239–48 (48 ref.)

Bacteria tolerant to organic solvents. Isken S, et al. **Extremophiles** 1998 Aug;2(3):229–38 (113 ref.)

Safety assessment of lactate esters. Clary JJ, et al. **Regul Toxicol Pharmacol** 1998 Apr;27(2):88–97 (67 ref.)

Psychiatric disorders related to solvent-exposure. Trabert W. **Zentralbl Hyg Umweltmed** 1999 Aug;202(2–4):121–6 (13 ref.)

SOMAN

Medical management of organophosphate-induced seizures. Lallement G, et al. **J Physiol Paris** 1998 Oct-Dec; 92(5–6):369–73 (32 ref.)

SOMATIC CELL HYBRIDS see **HYBRID CELLS**

SOMATIC GENE THERAPY see **GENE THERAPY**

SOMATIZATION DISORDER see **SOMATOFORM DISORDERS**

SOMATOCRININ see **SOMATOTROPIN-RELEASING HORMONE**

SOMATOFORM DISORDERS

Managing somatic preoccupation [see comments] Righter EL, et al. **Am Fam Physician** 1999 Jun;59(11):3113–20 (44 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2980, 2982.

Functional somatic syndromes. Barsky AJ, et al. **Ann Intern Med** 1999 Jun 1;130(11):910–21 (204 ref.)

Psychogenic nonepileptic seizures: theoretic and clinical considerations. Sirven JI, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Oct; 11(4):225–35 (75 ref.)

Psychogenic parasitosis. A case series and literature review. Slaughter JR, et al. **Psychosomatics** 1998 Nov-Dec; 39(6):491–500 (38 ref.)

CLASSIFICATION

Problems with psychodiagnostics at "environmental patients". Tretter F. **Zentralbl Hyg Umweltmed** 1999 Aug; 202(2–4):139–51 (27 ref.)

COMPLICATIONS

[Paranoid nosogenic reactions in patients with somatoform disorders] Vybornykh DE. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(12):18–21 (34 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Malingering assessment in behavioral toxicology: what, why, and how. Ben-Avi I, et al. **Am J Ind Med** 1998 Oct; 34(4):325–30 (32 ref.)

Psychological assessment of patients requesting orthognathic surgery and the relevance of body dysmorphic disorder. Cunningham SJ, et al. **Br J Orthod** 1998 Nov;25(4):293–8 (22 ref.)

The somatoform conundrum: a question of nosological values. Martin RD. **Gen Hosp Psychiatry** 1999 May-Jun; 21(3):177–86 (22 ref.)

Hysteria--a chameleon or a fossil? Bhatia MS, et al. **Indian J Med Sci** 1998 Jun;52(6):227–30 (24 ref.)

A comprehensive approach to the chronically somatizing patient [editorial] Barsky AJ. **J Psychosom Res** 1998 Oct; 45(4):301–6 (33 ref.)

Functional somatic syndromes: one or many? Wessely S, et al. **Lancet** 1999 Sep 11;354(9182):936–9 (29 ref.)

The somatizing patient. Servan-Schreiber D, et al. **Prim Care** 1999 Jun;26(2):225–42 (38 ref.)

Minor head trauma. Weight DG. **Psychiatr Clin North Am** 1998 Sep;21(3):609–24 (58 ref.)

Cosmetic surgery: surgical tools--psychosocial goals. Grossbart TA, et al. **Semin Cutan Med Surg** 1999 Jun; 18(2):101–11 (32 ref.)

Psychosocial factors and the fibromyalgia syndrome. Wolfe F, et al. **Z Rheumatol** 1998;57 Suppl 2:88–91 (24 ref.)

[Somatization in general practice] Jørgensen CK, et al. **Ugeskr Laeger** 1998 Oct 5;160(41):5919–23 (37 ref.) (Eng. Abstr.) **(Dan)**

[Painful somatoform disorder and work incapacity] Fauchère PA. **Rev Med Suisse Romande** 1998 Sep;118(9):801–5 (10 ref.) **(Fre)**

[Paranoid nosogenic reactions in patients with somatoform disorders] Vybornykh DE.
Zh Nevrol Psikhiatr Im S S Korsakova 1998;98(12):18–21 (34 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. Maier W, et al.
Int Clin Psychopharmacol 1999 May;14 Suppl 2:S1–6 (28 ref.)
Medically unexplained symptoms in primary care. Katon WJ, et al. **J Clin Psychiatry** 1998;59 Suppl 20:15–21 (54 ref.)

ETHNOLOGY

Culture and somatization: clinical, epidemiological, and ethnographic perspectives [see comments] Kirmayer LJ, et al. **Psychosom Med** 1998 Jul–Aug;60(4):420–30 (95 ref.) Comment in: Psychosom Med 1998 Jul–Aug;60(4):389–93.
Estranged bodies, simulated harmony, and misplaced cultures: neurasthenia in contemporary Chinese society [see comments] Lee S. **Psychosom Med** 1998 Jul–Aug; 60(4):448–57 (52 ref.) Comment in: Psychosom Med 1998 Jul–Aug;60(4):389–93.

ETIOLOGY

Multiple forms of stress in refugee and immigrant children. Sack WH. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):153–67, ix–x (54 ref.)
Problems with psychodiagnostics at "environmental patients". Tretter F. **Zentralbl Hyg Umweltmed** 1999 Aug; 202(2–4):139–51 (27 ref.)

PHYSIOPATHOLOGY

Psychic and somatic anxiety: worries, somatic symptoms and physiological changes. Hoehn-Saric R.
Acta Psychiatr Scand Suppl 1998;393:32–8 (36 ref.)

PSYCHOLOGY

Somatization reconsidered: incorporating the patient's experience of illness [see comments] Epstein RM, et al. **Arch Intern Med** 1999 Feb 8;159(3):215–22 (86 ref.) Comment in: Arch Intern Med 1999 Aug 9–23;159(15):1813–4.
Dhat syndrome—culture bound sex neurosis. Bhatia MS, et al. **Indian J Med Sci** 1998 Jan;52(1):30–5 (25 ref.)
Notes on an evolutionary medicine. Weiner H.
Psychosom Med 1998 Jul–Aug;60(4):510–20 (83 ref.)
Irritable bowel syndrome and recurrent abdominal pain. A comparative review. Burke P, et al. **Psychosomatics** 1999 Jul–Aug;40(4):277–85 (86 ref.)
Attachment and interpersonal communication in somatization. Stuart S, et al. **Psychosomatics** 1999 Jan–Feb; 40(1):34–43 (68 ref.)
Psychological and psychiatric aspects of fibromyalgia syndrome (FMS). Keel P. **Z Rheumatol** 1998;57 Suppl 2:97–100 (15 ref.)
The fibromyalgia syndrome as a manifestation of neuroticism? Netter P, et al. **Z Rheumatol** 1998;57 Suppl 2:105–8 (32 ref.)
[Anxiety and somatoform disorders. Their diagnosis, epidemiology, biological causes and therapy] Maier W.
Fortschr Neurol Psychiatr 1998 Dec;66 Suppl 1:S3–8 (17 ref.) **(Ger)**
[Difficulties in the physician-patient relationship in somaticizers (I). Patient expectations] García-Campayo J, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):102–5 (37 ref.) **(Spa)**

REHABILITATION

[Homeopathy—possibilities and limits] Halter K.
Schweiz Rundsch Med Prax 1998 Aug 5;87(31–32):969–74 (0 ref.) **(Ger)**

THERAPY

The somatizing patient. Servan-Schreiber D, et al.
Prim Care 1999 Jun;26(2):225–42 (38 ref.)
[Geriatric psychosomatic disorders and psychotherapy of the elderly. Current concept and approaches to treatment] Heuft G. **Psychother Psychosom Med Psychol** 1998 Jul; 48(7):232–42 (130 ref.) (Eng. Abstr.) **(Ger)**
[Clinical hypnosis. Current status of theory and empirical aspects] Revenstorf D.
Psychother Psychosom Med Psychol 1999 Jan;49(1):5–13 (68 ref.) (Eng. Abstr.) **(Ger)**

SOMATOMAMMOTROPIN, CHORIONIC see **PLACENTAL LACTOGEN**

SOMATOMAMMOTROPIN RECEPTORS see **RECEPTORS, SOMATOTROPIN**

SOMATOMEDIN-BINDING PROTEINS see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

SOMATOMEDIN C see **INSULIN-LIKE GROWTH FACTOR I**

SOMATOMEDIN C RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

SOMATOMEDIN MSA see **INSULIN-LIKE GROWTH FACTOR II**

SOMATOMEDIN RECEPTORS see **RECEPTORS, SOMATOMEDIN**

SOMATOMEDINS

see related
RECEPTORS, SOMATOMEDIN

ANALYSIS

Insulin-like growth factors in human breast cancer. Ellis MJ, et al. **Breast Cancer Res Treat** 1998;52(1–3):175–84 (62 ref.)

METABOLISM

Insulin-like growth factors and prostate cancer. Pollak M, et al. **Cancer Metastasis Rev** 1998–99;17(4):383–90 (44 ref.)
Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Rosen CJ.
Clin Chem 1999 Aug;45(8 Pt 2):1384–90 (75 ref.)
Some of my not so favorite things about insulin and insulin-like growth factors in fish. Plisetskaya EM.
Comp Biochem Physiol B Biochem Mol Biol 1998 Sep; 121(1):3–11 (78 ref.)
Growth factors in preimplantation development: role of insulin and insulin-like growth factors. Heyner S.
Early Pregnancy 1997 Sep;3(3):153–63 (86 ref.)
Role of insulin-like growth factor binding proteins in controlling IGF actions. Clemmons DR.
Mol Cell Endocrinol 1998 May 25;140(1–2):19–24 (32 ref.)
["Prostatic" kallikreins, sex hormones and insulin-like growth factors: complex of male and female regulatory elements in health and carcinogenesis] Zezerov EG, et al.
Vestn Ross Akad Med Nauk 1999;(3):49–56 (63 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Peptide growth factors and prostate cancer: new models, new opportunities. Foster BA, et al. **Cancer Metastasis Rev** 1998–99;17(4):317–24 (55 ref.)
Insulin-like growth factors and prostate cancer. Pollak M, et al. **Cancer Metastasis Rev** 1998–99;17(4):383–90 (44 ref.)
The insulin-related ovarian regulatory system in health and disease. Poretsky L, et al. **Endocr Rev** 1999 Aug; 20(4):535–82 (811 ref.)
Growth factor action on ovarian function in polycystic ovary syndrome. Giudice LC.
Endocrinol Metab Clin North Am 1999 Jun;28(2):325–39, vi (117 ref.)
Insulin-like growth factor binding proteins: new proteins, new functions. Ferry Jr RJ, et al. **Horm Res** 1999; 51(2):53–67 (166 ref.)
The IGF axis and programmed cell death. Butt AJ, et al.
Immunol Cell Biol 1999 Jun;77(3):256–62 (76 ref.)
IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. Wang HS, et al.
J Endocrinol 1999 Apr;161(1):1–13 (136 ref.)
Insulin-like growth factors and ovarian physiology. Yoshimura Y. **J Obstet Gynaecol Res** 1998 Oct;24(5):305–23 (117 ref.)
Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. Giudice LC, et al. **J Reprod Immunol** 1998 Aug;39(1–2):133–48 (66 ref.)
Do insulin-like growth factors mediate the effect of alcohol on breast cancer risk? Yu H, et al. **Med Hypotheses** 1999 Jun;52(6):491–6 (76 ref.)
Asphyxial brain injury—the role of the IGF system. Gluckman PD, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1–2):95–9 (33 ref.)
The IGF system during fetal-placental development of the mouse. van Kleffens M, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):129–35 (59 ref.)
The growth hormone-insulin-like growth factor axis in kidney re-revisited. Hammerman MR.
Nephrol Dial Transplant 1999 Aug;14(8):1853–60 (54 ref.)
Interactions between glucocorticoids and the growth hormone-insulin-like growth factor axis. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):183–9 (62 ref.)
Roles of the insulinlike growth factor family in nonpregnant human endometrium and at the decidual: trophoblast interface. Giudice LC, et al. **Semin Reprod Endocrinol** 1999; 17(1):13–21 (92 ref.)

SOMATOSENSORY CORTEX

ANATOMY & HISTOLOGY

Experience-dependent changes in function and anatomy of adult barrel cortex. Kossut M. **Exp Brain Res** 1998 Nov; 123(1–2):110–6 (30 ref.)

PHYSIOLOGY

Hierarchical somatosensory processing. Iwamura Y.
Curr Opin Neurobiol 1998 Aug;8(4):522–8 (90 ref.)
Experience-dependent changes in function and anatomy of adult barrel cortex. Kossut M. **Exp Brain Res** 1998 Nov; 123(1–2):110–6 (30 ref.)
Gating of the sensory activity within barrel cortex of the awake rat. Wróbel A, et al. **Exp Brain Res** 1998 Nov; 123(1–2):117–23 (39 ref.)
Magnetoencephalography in the study of human somatosensory cortical processing. Hari R, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jul 29; 354(1387):1145–54 (99 ref.)
[Post-lesional plasticity of somatosensory cortex maps: a review] Xerri C. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):135–51 (113 ref.) **(Fre)**
[Functional localization of the somatomotor area by magnetoencephalography] Nagamine T.
Rinsho Shinkeigaku 1999 Jan;39(1):42–3 (4 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Generators of short latency human somatosensory-evoked potentials recorded over the spine and scalp. Lee EK, et al. **J Clin Neurophysiol** 1998 May;15(3):227–34 (65 ref.)
Pain perception: is there a role for primary somatosensory cortex? Bushnell MC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7705–9 (51 ref.)
[Do systems theory models promote understanding of disorders of sensorimotor function in neurology?] Glasauer S, et al. **Nervenarzt** 1998 Oct;69(10):919–23 (18 ref.) **(Ger)**

SOMATOSENSORY EVOKED POTENTIALS see **EVOKED POTENTIALS, SOMATOSENSORY**

SOMATOSTATIN

see related
RECEPTORS, SOMATOSTATIN

AGONISTS

2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity. Liu S, et al. **Curr Pharm Des** 1999 Apr;5(4):255–63 (59 ref.)
[Somatostatin agonists in the treatment of acromegaly] Jaquet P, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):301–4 (20 ref.) **(Fre)**

ANALOGS & DERIVATIVES

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Eriksson B, et al.
Ann Oncol 1999;10 Suppl 2:S31–8 (63 ref.)
The role of octreoscan in thyroid eye disease. Krassas GE, et al. **Eur J Endocrinol** 1999 May;140(5):373–5 (24 ref.)
Growth-hormone and prolactin excess. Colao A, et al.
Lancet 1998 Oct 31;352(9138):1455–61 (70 ref.)
Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)
The potential role of somatostatin analogues in breast cancer treatment. Pollak M. **Yale J Biol Med** 1997 Sep–Dec; 70(5–6):535–9 (40 ref.)
[The use of somatostatin analogs in the treatment of patients with digestive system diseases] Frol'kis AV. **Ter Arkh** 1999; 71(2):83–5 (40 ref.) **(Rus)**
[Pregnancy in an acromegalic patient treated with lanreotide and bromocryptin (letter)] Sánchez R, et al.
Med Clin (Barc) 1999 Jul 10;113(5):198 (4 ref.) **(Spa)**

ANTAGONISTS & INHIBITORS

Homogeneous pharmacologic and cell-based screens provide diverse strategies in drug discovery: somatostatin antagonists as a case study. Zysk JR, et al.
Comb Chem High Throughput Screen 1998 Dec;1(4):171–83 (59 ref.)

GENETICS

Somatostatin and its receptor family. Patel YC.
Front Neuroendocrinol 1999 Jul;20(3):157–98 (233 ref.)

METABOLISM

Somatostatin and its receptor family. Patel YC.
Front Neuroendocrinol 1999 Jul;20(3):157–98 (233 ref.)

PHYSIOLOGY

The role of somatostatin in the pathophysiology of rheumatoid arthritis. Sakane T, et al.
Clin Exp Rheumatol 1998 Nov–Dec;16(6):745–9 (44 ref.)
Evolution of neuroendocrine peptide systems: gonadotropin-releasing hormone and somatostatin. Lin XW, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Jun;119(3):375–88 (105 ref.)
Somatostatin and octreotide: physiological background and pharmacological application. Beglinger C, et al.
Digestion 1999;60 Suppl 2:2–8 (24 ref.)
Growth hormone and somatostatin in glomerular injury. Baud L, et al. **J Nephrol** 1999 Jan–Feb;12(1):18–23 (65 ref.)
Somatostatin and the gastrointestinal tract. Tulassay Z.
Scand J Gastroenterol Suppl 1998;228:115–21 (45 ref.)
[Somatostatin: a ubiquitous peptide] Epelbaum J, et al.
C R Seances Soc Biol Fil 1998;192(4):597–606 (44 ref.) (Eng.

SOMATOSTATIN

Abstr.) **(Fre)**

[Cellular mechanism of growth hormone secretion by hypothalamic peptides] Kato M. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):402–4 (21 ref.) **(Jpn)**

[Somatostatin as a regulator of cardiovascular system functions] Osadchii OE, et al. **Usp Fiziol Nauk** 1998 Oct–Dec;29(4):24–41 (146 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Calcitonin-producing pancreatic somatostatinoma: report of a case. Sugimoto F, et al. **Surg Today** 1998;28(12):1279–82 (9 ref.)

THERAPEUTIC USE

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Eriksson B, et al. **Ann Oncol** 1999;10 Suppl 2:S31–8 (63 ref.)

Role of octreotide and somatostatin in the treatment of intestinal fistulae. Dorta G. **Digestion** 1999;60 Suppl 2:53–6 (23 ref.)

Somatostatin or octreotide in acute variceal bleeding. Hadengue A. **Digestion** 1999;60 Suppl 2:31–41 (60 ref.)

The role of octreotide and somatostatin in acute and chronic pancreatitis. Uhl W, et al. **Digestion** 1999;60 Suppl 2:23–31 (95 ref.)

Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)

The potential role of somatostatin analogues in breast cancer treatment. Pollak M. **Yale J Biol Med** 1997 Sep–Dec; 70(5–6):535–9 (40 ref.)

[The use of somatostatin analogs in the treatment of patients with digestive system diseases] Frol'kis AV. **Ter Arkh** 1999; 71(2):83–5 (40 ref.) **(Rus)**

SOMATOSTATIN RECEPTORS see **RECEPTORS, SOMATOSTATIN**

SOMATOSTATIN-14 see **SOMATOSTATIN**

SOMATOSTATINOMA

COMPLICATIONS

Duodenal somatostatinoma presenting as upper gastrointestinal bleeding. Saifuddin T, et al. **Am J Gastroenterol** 1999 May;94(5):1405–8 (20 ref.)

[Glucagonoma--somatostatinoma] Schusdziarra V. **Z Gastroenterol** 1999 Jun;Suppl 1:33–5 (20 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Von Recklinghausen type I neurofibromatosis and neuroendocrine tumor (somatostatinoma) in a 50-year-old woman] Reichardt M, et al. **Med Klin** 1998 Sep 15; 93(9):550–3 (26 ref.) (Eng. Abstr.) **(Ger)**

SOMATOTROPIN

see related
RECEPTORS, SOMATOTROPIN

BIOSYNTHESIS

Endocrine regulation of gonadotropin and growth hormone gene transcription in fish. Melamed P, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):325–38 (125 ref.)

BLOOD

Resistance to growth hormone in children with chronic liver disease. Bucuvalas JC, et al. **Pediatr Transplant** 1997 Aug; 1(1):73–9 (46 ref.)

DEFICIENCY

Growth hormone--a panacea for aging? [editorial] Nugent AG, et al. **Aust N Z J Med** 1998 Dec;28(6):761–4 (36 ref.)

Growth hormone deficiency and atherosclerosis--is there a link? McGrath S, et al. **Growth Horm IGF Res** 1999 Apr; 9 Suppl A:9–13 (20 ref.)

The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency. Grumbach MM, et al. **Horm Res** 1998;49 Suppl 2:41–57 (129 ref.)

[New growth hormone secretagogues: from physiology to the first therapeutic applications] Ahnfelt-Rønne I, et al. **Arch Pediatr** 1998;5 Suppl 4:390S–396S (35 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Endocrine regulation of gonadotropin and growth hormone gene transcription in fish. Melamed P, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):325–38 (125 ref.)

Duplicate growth hormone genes in sheep and goat. Wallis M, et al. **J Mol Endocrinol** 1998 Aug;21(1):1–5 (28 ref.)

[The genetic polymorphism of somatotropin] Balatskiĭ VN, et al. **Tsitol Genet** 1998 Mar–Apr;32(2):92–104 (77 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Yu-Lee L, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1067–75 (103 ref.)

Immunological aspects of human growth hormone and prolactin. Hattori N, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):371–5 (11 ref.)

Endocrine modulation of physiological responses to catabolic disease. Sartin JL, et al. **Domest Anim Endocrinol** 1998 Sep; 15(5):423–9 (38 ref.)

METABOLISM

Congenital growth hormone insensitivity syndromes and their relevance to idiopathic short stature. Clayton PE, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):275–83 (44 ref.)

Blood-brain barrier for human growth hormone and insulin-like growth factor-I. Coculescu M. **J Pediatr Endocrinol Metab** 1999 Mar–Apr;12(2):113–24 (82 ref.)

PHARMACOLOGY

Transgenic models of growth hormone action. Kopchick JJ, et al. **Annu Rev Nutr** 1999;19:437–61 (162 ref.)

Effects of testosterone and growth hormone on muscle function. Urban RJ. **J Lab Clin Med** 1999 Jul;134(1):7–10 (34 ref.)

The haematopoietic effects of growth hormone and insulin-like growth factor-I. Merchav S. **J Pediatr Endocrinol Metab** 1998 Nov–Dec;11(6):677–85 (97 ref.)

Growth hormone and the heart. Cittadini A, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):51–5 (39 ref.)

[Bone and hormones. Effects of growth hormone on bone tissue in adults] Chapurlat RD, et al. **Presse Med** 1999 Mar 13;28(10):559–62 (48 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cytokines in endocrine function. Silva CM, et al. **Adv Protein Chem** 1998;52:199–221 (72 ref.)

Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Lund PK. **Ann N Y Acad Sci** 1998 Nov 17;859:18–36 (87 ref.)

Growth hormone and a partial mediator of its biological action, insulin-like growth factor I. Pankov YA. **Biochemistry (Mosc)** 1999 Jan;64(1):1–7 (85 ref.)

Could some biomechanical effects of growth hormone help to explain its effects on bone formation and resorption? Frost HM. **Bone** 1998 Nov;23(5):395–8 (35 ref.)

A role for growth hormone and prolactin in leukaemia and lymphoma? Hooghe R, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1095–101 (85 ref.)

The role of growth hormone and insulin-like growth factors in the immune system. van Buul-Offers SC, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1083–94 (160 ref.)

Growth hormone: a paracrine growth factor in embryonic development? Harvey S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):305–15 (103 ref.)

Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Heemskerk VH, et al. **Cytokine Growth Factor Rev** 1999 Mar;10(1):5–14 (109 ref.)

Role of prolactin and growth hormone on thymus physiology. De Mello-Coelho V, et al. **Dev Immunol** 1998; 6(3–4):317–23 (45 ref.)

Molecular mechanism of growth hormone signalling. Billestrup N, et al. **Endocr J** 1998 Apr;45 Suppl:S41–5 (34 ref.)

Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19–26 (35 ref.)

Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Yamauchi T, et al. **Endocr J** 1998 Apr;45 Suppl:S27–31 (25 ref.)

The fetal adrenal and the maturation of the growth hormone and prolactin axes [editorial] Freemark M. **Endocrinology** 1999 May;140(5):1963–5 (41 ref.)

Does growth hormone prevent or accelerate aging? Bartke A, et al. **Exp Gerontol** 1998 Nov–Dec;33(7–8):675–87 (78 ref.)

Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Rudling M, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:1–7 (41 ref.)

Physiological role of human placental growth hormone. Alsat E, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):121–7 (36 ref.)

The growth hormone-insulin-like growth factor axis in kidney re-revisited. Hammerman MR. **Nephrol Dial Transplant** 1999 Aug;14(8):1853–60 (54 ref.)

The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-I. Burgess W, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):56–68 (133 ref.)

Growth factors in children with end-stage liver disease before and after liver transplantation: a review. Maes M, et al. **Pediatr Transplant** 1997 Nov;1(2):171–5 (34 ref.)

[Physiopathology of the somatotropin axis in chronic renal insufficiency] Cabrol S, et al. **Arch Pediatr** 1998;5 Suppl 4:348S–353S (44 ref.) (Eng. Abstr.) **(Fre)**

[Bone and hormones. Effects of growth hormone on bone tissue in adults] Chapurlat RD, et al. **Presse Med** 1999 Mar 13;28(10):559–62 (48 ref.) (Eng. Abstr.) **(Fre)**

[The role of the GH/IGF-1 axis in cardiovascular physiopathology and therapy: the lessons from animal studies] Cittadini A, et al. **Cardiologia** 1998 Nov; 43(11):1185–92 (53 ref.) **(Ita)**

SECRETION

Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility? Chappel S. **Clin Endocrinol (Oxf)** 1999 May; 50(5):547–56 (113 ref.)

Growth hormone and exercise. Jenkins PJ. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):683–9 (70 ref.)

The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Lissett CA, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):653–7 (16 ref.)

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Giustina A, et al. **Endocr Rev** 1998 Dec;19(6):717–97 (1103 ref.)

Orally active growth hormone secretagogues. Patchett AA, et al. **Pharm Biotechnol** 1998;11:525–54 (97 ref.)

[New growth hormone secretagogues: from physiology to the first therapeutic applications] Ahnfelt-Rønne I, et al. **Arch Pediatr** 1998;5 Suppl 4:390S–396S (35 ref.) (Eng. Abstr.) **(Fre)**

[Cellular mechanism of growth hormone secretion by hypothalamic peptides] Kato M. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):402–4 (21 ref.) **(Jpn)**

[An autoregulatory system of growth hormone secretion] Minami S. **Nippon Ika Daigaku Zasshi** 1998 Oct; 65(5):409–12 (14 ref.) **(Jpn)**

THERAPEUTIC USE

Growth hormone--a panacea for aging? [editorial] Nugent AG, et al. **Aust N Z J Med** 1998 Dec;28(6):761–4 (36 ref.)

Growth hormone as a potential future therapy for congestive heart failure. Fazio S, et al. **Coron Artery Dis** 1999 Sep; 10(6):383–8 (43 ref.)

Growth hormone therapy for non-growth hormone-deficient children with short stature. Guyda HJ. **Curr Opin Pediatr** 1998 Aug;10(4):416–21 (47 ref.)

Therapy with growth hormone: major prospects for the treatment of male subfertility? Breier BH, et al. **Endocr J** 1998 Apr;45 Suppl:S53–60 (31 ref.)

The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency. Grumbach MM, et al. **Horm Res** 1998;49 Suppl 2:41–57 (129 ref.)

Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Woody MA, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):69–80 (10[illegible] ref.)

Combined use of growth hormone and gonadotropin-releasing hormone analogues in precocious puberty: theoretic and practical considerations. Walvoord EC, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1010–4 (38 ref.)

Who benefits from growth hormone? Bareille P, et al. **Practitioner** 1998 Jun;242(1587):486–8 (11 ref.)

[Critical evaluation of growth hormone treatment in children with chronic renal insufficiency] Perfumo F, et al. **Arch Pediatr** 1998;5 Suppl 4:354S–359S (39 ref.) (Eng. Abstr.) **(Fre)**

[Effect of hormonal treatment on bone mineralization in Turner syndrome] Saggese G, et al. **Arch Pediatr** 1998;5 Suppl 4:371S–374S (28 ref.) (Eng. Abstr.) **(Fre)**

SOMATOTROPIN (HUMAN) see **SOMATROPIN**

SOMATOTROPIN RECEPTORS see **RECEPTORS, SOMATOTROPIN**

SOMATOTROPIN RELEASE-INHIBITING HORMONE see **SOMATOSTATIN**

SOMATOTROPIN-RELEASING FACTOR 44 see **SOMATOTROPIN-RELEASING HORMONE**

SOMATOTROPIN-RELEASING HORMONE

DIAGNOSTIC USE

Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Ghigo E, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):341–58 (100 ref.)

DRUG EFFECTS

Alcohol, slow wave sleep, and the somatotropic axis. Lands WE. **Alcohol** 1999 Jun–Jul;18(2–3):109–22 (101 ref.)

GENETICS

Humoral regulation of physiological sleep: cytokines and GHRH. Krueger JM, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:53–9 (49 ref.)

IMMUNOLOGY

Humoral regulation of physiological sleep: cytokines and GHRH. Krueger JM, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:53–9 (49 ref.)

PHARMACOLOGY

Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility? Chappel S. **Clin Endocrinol (Oxf)** 1999 May; 50(5):547–56 (113 ref.)

PHYSIOLOGY

Galanin: analysis of its coexpression in gonadotropin-releasing hormone and growth hormone-releasing hormone neurons. Hohmann JG, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:221–35 (62 ref.)

[Cellular mechanism of growth hormone secretion by hypothalamic peptides] Kato M. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):402–4 (21 ref.) **(Jpn)**

SECRETION

Interrelations between sleep and the somatotropic axis. Van Cauter E, et al. **Sleep** 1998 Sep 15;21(6):553–66 (129 ref.)

THERAPEUTIC USE

Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Ghigo E, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):341–58 (100 ref.)

SOMATOTROPINS, RECOMBINANT

ADMINISTRATION & DOSAGE

Safety of high doses of recombinant human growth hormone. Van Loon K. **Horm Res** 1998;49 Suppl 2:78–81 (2 ref.)

ADVERSE EFFECTS

Safety of high doses of recombinant human growth hormone. Van Loon K. **Horm Res** 1998;49 Suppl 2:78–81 (2 ref.)

THERAPEUTIC USE

Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Ghigo E, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):341–58 (100 ref.)

Recombinant human growth hormone as potential therapy for osteoporosis. Marcus R. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):251–60 (43 ref.)

Management of recombinant human growth hormone therapy at puberty. Albers N. **Horm Res** 1998;49 Suppl 2:58–61 (13 ref.)

Factors affecting growth and strategies for treatment in children after renal transplantation. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):176–82 (37 ref.)

Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older? Zachwieja JJ, et al. **Phys Ther** 1999 Jan;79(1):76–82 (38 ref.)

SOMATOTYPES

A woman's build and the risk of breast cancer. Cold S, et al. **Eur J Cancer** 1998 Jul;34(8):1163–74 (129 ref.)

SOMATROPIN

Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. Rosenbloom AL. **J Pediatr** 1999 Sep;135(3):280–9 (45 ref.)

ADMINISTRATION & DOSAGE

Can growth hormone counteract the effects of glucocorticoids on protein metabolism? Beaufrère B. **Acta Paediatr Suppl** 1999 Feb;88(428):97–9 (24 ref.)

Growth hormone therapy in hypochondroplasia. Ramaswami U, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):116–7 (9 ref.)

Acute metabolic effects of human growth hormone on 15N-nitrogen balance in patients with thalassaemia as compared to patients with other types of short stature. Zachmann M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:851–6 (30 ref.)

Small bowel adaptation with growth hormone and glutamine after massive resection of rat's small bowel. Waitzberg DL, et al. **Nutr Hosp** 1999 Mar–Apr;14(2):81–90 (66 ref.)

ADVERSE EFFECTS

A red flag unfurled? Growth hormone treatment and testicular function [editorial; comment] Frasier SD. **J Pediatr** 1999 Sep;135(3):278–9 (11 ref.) Comment on: J Pediatr 1999 Sep;135(3):367–70.

BIOSYNTHESIS

Growth disorders caused by genetic defects in the growth hormone pathway. Cogan JD, et al. **Adv Pediatr** 1998; 45:337–61 (46 ref.)

BLOOD

Growth hormone heterogeneity in human pituitary and plasma. Baumann G. **Horm Res** 1999;51 Suppl 1:2–6 (22 ref.)

DEFICIENCY

Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Ghigo E, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):341–58 (100 ref.)

Growth hormone deficiency and cardiovascular risk. Hew FL, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):199–216 (74 ref.)

Growth hormone therapy and fracture risk in the growth hormone-deficient adult. Johannsson G, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):233–50 (107 ref.)

Adult growth hormone deficiency syndrome: a personal approach to diagnosis, treatment and monitoring. Cook DM. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:129–33 (26 ref.)

The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans. Peino R, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:101–5 (38 ref.)

Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27–28 March 1998. Saggese G, et al. **Horm Res** 1998;50(6):320–40 (101 ref.)

Interpretative difficulties with growth hormone provocative retesting in childhood-onset growth hormone deficiency. Van den Broeck J, et al. **Horm Res** 1999;51(1):1–9 (74 ref.)

The molecular genetics of growth hormone deficiency. Procter AM, et al. **Hum Genet** 1998 Sep;103(3):255–72 (181 ref.)

Growth hormone and the metabolic syndrome. Johannsson G, et al. **J Endocrinol Invest** 1999;22(5 Suppl):41–6 (42 ref.)

The use of self-rating questionnaires as a quantitative measure of quality of life in adult growth hormone deficiency. Murray RD, et al. **J Endocrinol Invest** 1999;22(5 Suppl):118–26 (37 ref.)

A red flag unfurled? Growth hormone treatment and testicular function [editorial; comment] Frasier SD. **J Pediatr** 1999 Sep;135(3):278–9 (11 ref.) Comment on: J Pediatr 1999 Sep;135(3):367–70.

The diagnosis of childhood growth hormone insufficiency and growth hormone resistance. McGrath SA, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:803–9 (49 ref.)

Growth hormone therapy in adults and children. Vance ML, et al. **N Engl J Med** 1999 Oct 14;341(16):1206–16 (99 ref.)

Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Bennett RM. **Z Rheumatol** 1998;57 Suppl 2:72–6 (36 ref.)

DRUG EFFECTS

Alcohol, slow wave sleep, and the somatotropic axis. Lands WE. **Alcohol** 1999 Jun–Jul;18(2–3):109–22 (101 ref.)

GENETICS

Human growth disorders: molecular genetics of the growth hormone-insulin-like growth factor I axis. Rotwein P. **Acta Paediatr Suppl** 1999 Feb;88(428):148–51; discussion 152 (32 ref.)

Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Woods KA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):158–62; discussion 163 (13 ref.)

Variations on a theme: testis-derived neuropeptide hormones [comment] DiMeglio LA, et al. **Eur J Endocrinol** 1998 Oct; 139(4):361–2 (11 ref.) Comment on: Eur J Endocrinol 1998 Oct;139(4):424–7.

Growth hormone heterogeneity in human pituitary and plasma. Baumann G. **Horm Res** 1999;51 Suppl 1:2–6 (22 ref.)

[The genetic polymorphism of somatotropin] Balatskiĭ VN, et al. **Tsitol Genet** 1998 Mar–Apr;32(2):92–104 (77 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Growth hormone in immune reconstitution. Chappel S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):423–31 (132 ref.)

METABOLISM

Growth retardation in chronic diseases: possible mechanisms. Underwood LE. **Acta Paediatr Suppl** 1999 Feb; 88(428):93–6 (10 ref.)

Growth hormone and ovarian function. Franks S. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):331–40 (47 ref.)

Acquired growth hormone resistance in adults. Jenkins RC, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):315–29 (73 ref.)

Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Bereket A, et al. **Horm Metab Res** 1999 Feb–Mar;31(2–3):172–81 (76 ref.)

Beta cell proliferation and growth factors. Nielsen JH, et al. **J Mol Med** 1999 Jan;77(1):62–6 (49 ref.)

Regulation of insulin-like growth factor-I in starvation and injury. Thissen JP, et al. **Nutr Rev** 1999 Jun;57(6):167–76 (53 ref.)

PHARMACOLOGY

Effect of growth hormone on adipose tissue and skeletal muscle lipoprotein lipase activity in humans. Richelsen B. **J Endocrinol Invest** 1999;22(5 Suppl):10–5 (31 ref.)

The diagnosis of childhood growth hormone insufficiency and growth hormone resistance. McGrath SA, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:803–9 (49 ref.)

PHYSIOLOGY

Height, health and growth hormone [see comments] Samaras TT, et al. **Acta Paediatr** 1999 Jun;88(6):602–9 (61 ref.) Comment in: Acta Paediatr 1999 Jun;88(6):588–9.

Growth factors and malnutrition in chronic renal failure. Fouque DP, et al. **Adv Nephrol Necker Hosp** 1998; 28:259–85 (88 ref.)

The maternal, fetal and postnatal somatotrophic axes in intrauterine growth retardation. Oliver MH, et al. **Biochem Soc Trans** 1999 Feb;27(2):69–73 (62 ref.)

Prolactin, growth hormone and the immune system in humans. Velkeniers B, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1102–8 (75 ref.)

GH signalling in pancreatic beta-cells. Sekine N, et al. **Endocr J** 1998 Apr;45 Suppl:S33–40 (36 ref.)

Growth hormone and bone diseases. Tanaka H. **Endocr J** 1998 Apr;45 Suppl:S47–52 (8 ref.)

Neuroendocrinology of the human growth hormone-insulin-like growth factor I axis during ageing. Arvat E, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:111–5 (55 ref.)

The role of growth hormone and insulin-like growth factor I in the regulation of apoptosis. Isgaard J, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:125–8 (43 ref.)

Frailty and the somatopause [see comments] Martin F. **Growth Horm IGF Res** 1999 Feb;9(1):3–10 (84 ref.) Comment in: Growth Horm IGF Res 1999 Feb;9(1):1–2.

Growth hormone and ageing. van der Lely AJ. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:117–9 (16 ref.)

The role of the GH/IGF-I axis for cardiac function and structure. Isgaard J, et al. **Horm Metab Res** 1999 Feb–Mar; 31(2–3):50–4 (62 ref.)

Growth hormone and prostate cancer: guilty by association? Grimberg A, et al. **J Endocrinol Invest** 1999;22(5 Suppl):64–73 (71 ref.)

Growth hormone and somatostatin in glomerular injury. Baud L, et al. **J Nephrol** 1999 Jan–Feb;12(1):18–23 (65 ref.)

Interactions between glucocorticoids and the growth hormone-insulin-like growth factor axis. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):183–9 (62 ref.)

Neuroendocrine control of growth hormone secretion. Müller EE, et al. **Physiol Rev** 1999 Apr;79(2):511–607 (1131 ref.)

[The growth hormone and aging] Fernández-Tresguerres JA. **An R Acad Nac Med (Madr)** 1998;115(4):907–17; discussion 917–22 (56 ref.) **(Spa)**

SECRETION

Maternal endocrine adaptations to placental hormones in humans. Evain-Brion D. **Acta Paediatr Suppl** 1999 Feb; 88(428):12–6 (46 ref.)

Interaction between body composition, leptin and growth hormone status. Casanueva FF, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):297–314 (96 ref.)

Ageing and growth hormone status. Toogood AA, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):281–96 (81 ref.)

Growth hormone (GH) secretagogues and neuroendocrine regulation of GH secretion. Dickson SL, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:89–91 (20 ref.)

Interpretative difficulties with growth hormone provocative retesting in childhood-onset growth hormone deficiency. Van den Broeck J, et al. **Horm Res** 1999;51(1):1–9 (74 ref.)

Growth hormone in obesity. Scacchi M, et al. **Int J Obes Relat Metab Disord** 1999 Mar;23(3):260–71 (150 ref.)

The role of nitric oxide in L-arginine-stimulated growth hormone release. Fisker S, et al. **J Endocrinol Invest** 1999; 22(5 Suppl):89–93 (31 ref.)

Regulation of growth hormone secretion by signals produced by the adipose tissue. Pombo M, et al. **J Endocrinol Invest** 1999;22(5 Suppl):22–6 (28 ref.)

Is the somatopause an indication for growth hormone replacement? Savine R, et al. **J Endocrinol Invest** 1999;22(5 Suppl):142–9 (49 ref.)

The somatopause is no indication for growth hormone therapy. von Werder K. **J Endocrinol Invest** 1999;22(5 Suppl):137–41 (20 ref.)

New GH secretagogues and potential usefulness in thalassemia. Karydis I, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:857–62 (60 ref.)

Growth-hormone and prolactin excess. Colao A, et al.

SOMATROPIN

Lancet 1998 Oct 31;352(9138):1455–61 (70 ref.)
Neuroendocrine control of growth hormone secretion. Müller EE, et al. **Physiol Rev** 1999 Apr;79(2):511–607 (1131 ref.)
Interrelations between sleep and the somatotropic axis. Van Cauter E, et al. **Sleep** 1998 Sep 15;21(6):553–66 (129 ref.)

THERAPEUTIC USE

Partial growth hormone insensitivity--idiopathic short stature is not always idiopathic. Saenger P. **Acta Paediatr Suppl** 1999 Feb;88(428):194–8 (20 ref.)
Growth hormone therapy in patients with congestive heart failure: need for further research [editorial; comment] Johnson MR, et al. **Am Heart J** 1999 Jun;137(6):989–91 (21 ref.) Comment on: Am Heart J 1999 Jun;137(6):1035–43.
How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults? Chrisoulidou A, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):261–79 (52 ref.)
Growth hormone deficiency and cardiovascular risk. Hew FL, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):199–216 (74 ref.)
Growth hormone therapy and fracture risk in the growth hormone-deficient adult. Johannsson G, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):233–50 (107 ref.)
Recombinant human growth hormone as potential therapy for osteoporosis. Marcus R. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):251–60 (43 ref.)
Growth hormone: a new therapy for heart failure? Saccà L. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):217–31 (83 ref.)
Growth hormone, cardiomyocyte contractile reserve, and heart failure [editorial; comment] Ross J Jr. **Circulation** 1999 Jan 5–12;99(1):15–7 (19 ref.) Comment on: Circulation 1999 Jan 5–12;99(1):127–34.
Assessing new technology, another chapter: lung volume reduction surgery/recombinant human growth hormone [editorial; comment] Slonim AD, et al. **Crit Care Med** 1999 Aug;27(8):1687–8 (15 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634–8.
Growth hormone and bone diseases. Tanaka H. **Endocr J** 1998 Apr;45 Suppl:S47–52 (8 ref.)
Growth hormone for the failing heart. Hussain MA. **Eur J Endocrinol** 1998 Nov;139(5):476–8 (37 ref.)
Administration of growth hormone to catabolic patients. Hinds CJ. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:71–5 (49 ref.)
Growth hormone treatment in critical illness--a critical appraisal. Isaksson OG. **Growth Horm IGF Res** 1999 Apr; 9 Suppl A:83–4 (2 ref.)
Growth hormone therapy in patients with Turner syndrome. Haeusler G. **Horm Res** 1998;49 Suppl 2:62–6 (36 ref.)
High-dose growth hormone therapy in idiopathic short stature. Kamp GA, et al. **Horm Res** 1998;49 Suppl 2:67–72 (47 ref.)
Growth hormone treatment of Russell-Silver syndrome. Stanhope R, et al. **Horm Res** 1998;49 Suppl 2:37–40 (24 ref.)
Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Own observations and review of the literature. Van Erum R, et al. **Horm Res** 1998 Sep;50(3):141–6 (35 ref.)
Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. Böger RH. **J Endocrinol Invest** 1999;22(5 Suppl):75–81 (42 ref.)
Dynamics of lipoprotein metabolism in adult growth hormone deficiency. Christ ER, et al. **J Endocrinol Invest** 1999;22(5 Suppl):16–21 (23 ref.)
The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients. Deijen JB, et al. **J Endocrinol Invest** 1999;22(5 Suppl):127–36 (54 ref.)
Growth hormone and body composition in athletes. Frisch H. **J Endocrinol Invest** 1999;22(5 Suppl):106–9 (24 ref.)
Determinants of circulating insulin-like growth factor-I. Hall K, et al. **J Endocrinol Invest** 1999;22(5 Suppl):48–57 (58 ref.)
Gender difference in growth hormone response in adults. Johansson AG. **J Endocrinol Invest** 1999;22(5 Suppl):58–60 (22 ref.)
Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults. Johnston DG, et al. **J Endocrinol Invest** 1999;22(5 Suppl):37–40 (19 ref.)
Two hot topics in the field of GH therapy: quality of life in hypopituitary adults, and clinical implications of the somatopause. Report from an interactive discussion. Jørgensen JO. **J Endocrinol Invest** 1999;22(5 Suppl):150–6 (26 ref.)
Treatments for wasting in patients with the acquired immunodeficiency syndrome. Corcoran C, et al. **N Engl J Med** 1999 Jun 3;340(22):1740–50 (78 ref.)
Growth hormone therapy in adults and children. Vance ML, et al. **N Engl J Med** 1999 Oct 14;341(16):1206–16 (99 ref.)
Long-term experience with growth hormone treatment in children with chronic renal failure. Schaefer F, et al. **Perit Dial Int** 1999;19 Suppl 2:S467–72 (35 ref.)
Anticatabolic and anabolic strategies in critical illness: a review of current treatment modalities. Chang DW, et al. **Shock** 1998 Sep;10(3):155–60 (77 ref.)
[New conditions for the use of growth hormone and outcomes for different indications] Rochiccioli P, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):296–9 (8 ref.) **(Fre)**
[Growth hormone: a magical potion?] Schlienger JL, et al. **Rev Med Interne** 1998 Apr;19(4):279–85 (47 ref.) (Eng. Abstr.) **(Fre)**
[Growth hormone in adolescents and in young adults] Saggese G, et al. **Minerva Pediatr** 1998 Jun;50(6):197–201 (34 ref.) **(Ita)**

SOMITES

PHYSIOLOGY

Role of growth factors in shaping the developing somite. Hirsinger E, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1–2):83–7 (20 ref.)

SOMNAMBULISM

COMPLICATIONS

Somnambulism and trauma: case report and short review of the literature. Milliet N, et al. **J Trauma** 1999 Aug; 47(2):420–2 (12 ref.)

SOMNOGRAPHY see **POLYSOMNOGRAPHY**

SONGBIRDS

PHYSIOLOGY

Sensitive periods and circuits for learned birdsong. Mooney R. **Curr Opin Neurobiol** 1999 Feb;9(1):121–7 (66 ref.)

SONOGRAPHY, TRANSCRANIAL DOPPLER see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

SOR GENE PRODUCTS see **GENE PRODUCTS, VIF**

SORBIC ACID

ANALOGS & DERIVATIVES

Analysis and evaluation of trans,trans-muconic acid as a biomarker for benzene exposure. Scherer G, et al. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9; 717(1–2):179–99 (96 ref.)

SORBITOL

METABOLISM

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34–49 (78 ref.)

SORE THROAT see **PHARYNGITIS**

SORPTION DETOXIFICATION

[Clinical immunoadsorption] Toepfer M, et al. **Dtsch Med Wochenschr** 1999 Apr 16;124(15):461–5 (59 ref.) **(Ger)**

SOS RESPONSE (GENETICS)

SOS and Mayday: multiple inducible mutagenic pathways in Escherichia coli. Humayun MZ. **Mol Microbiol** 1998 Dec;30(5):905–10 (39 ref.)

SOTALIA see **DOLPHINS**

SOTALOL

THERAPEUTIC USE

Sotalol: An important new antiarrhythmic. Anderson JL, et al. **Am Heart J** 1999 Mar;137(3):388–409 (81 ref.)

SOUND

see related
ACOUSTIC STIMULATION
NOISE

Cortical processing of complex sounds. Rauschecker JP. **Curr Opin Neurobiol** 1998 Aug;8(4):516–21 (53 ref.)

SOUND LOCALIZATION

PHYSIOLOGY

Auditory perception: does practice make perfect? King AJ. **Curr Biol** 1999 Feb 25;9(4):R143–6 (25 ref.)

SOUSA see **DOLPHINS**

SOUTHERN DOLPHINS see **DOLPHINS**

SOY BEANS see **SOYBEANS**

SOY PROTEINS

Nutritional adequacy of cow's milk substitutes. Lombardo G, et al. **Allergy** 1998;53(46 Suppl):118–21 (50 ref.)
The story of soy formula feeding in infants: a road paved with good intentions [letter] Zoppi G, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):541–3 (39 ref.)

ADMINISTRATION & DOSAGE

Use of soy-protein formulas and soyfood for feeding infants and children in Asia. Quak SH, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1444S–1446S (16 ref.)
Soy intake and risk of breast cancer in Asians and Asian Americans. Wu AH, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1437S–1443S (46 ref.)

METABOLISM

Influence of feeding alkaline/heat processed proteins on growth and protein and mineral status of rats. Sarwar G, et al. **Adv Exp Med Biol** 1999;459:161–77 (29 ref.)
Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Setchell KD. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1333S–1346S (226 ref.)
Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Setchell KD, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1453S–1461S (86 ref.)

PHARMACOLOGY

Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Lu LJ, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1500S–1504S (35 ref.)

THERAPEUTIC USE

Effects of soy protein on renal function and proteinuria in patients with type 2 diabetes. Anderson JW, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1347S–1353S (46 ref.)
Soy protein for the prevention and treatment of children with cow-milk allergy. Businco L, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1447S–1452S (78 ref.)
Soy protein, isoflavones and cardiovascular disease risk. Lichtenstein AH. **J Nutr** 1998 Oct;128(10):1589–92 (56 ref.)

SOYBEAN PROTEINS see **SOY PROTEINS**

SOYBEANS

Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Messina M, et al. **Baillieres Clin Endocrinol Metab** 1998 Dec;12(4):707–28 (109 ref.)
China: the soyabean-pork dilemma. Geissler C. **Proc Nutr Soc** 1999 May;58(2):345–53 (54 ref.)

CHEMISTRY

Relationship between chemical structures and biological activities of triterpenoid saponins from soybean. Yoshiki Y, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2291–9 (60 ref.)
Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Fournier DB, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov;7(11):1055–65 (137 ref.)

PARASITOLOGY

The soybean cyst nematode, Heterodera glycines: a genetic model system for the study of plant-parasitic nematodes. Opperman CH, et al. **Curr Opin Plant Biol** 1998 Aug; 1(4):342–6 (27 ref.)

THERAPEUTIC USE

Cardiovascular and renal benefits of dry bean and soybean intake. Anderson JW, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):464S–474S (154 ref.)
Legumes and soybeans: overview of their nutritional profiles and health effects. Messina MJ. **Am J Clin Nutr** 1999 Sep; 70(3 Suppl):439S–450S (188 ref.)
Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Fournier DB, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov;7(11):1055–65 (137 ref.)
The clinical applications of Ginkgo biloba, St. John's wort, saw palmetto, and soy. Glisson J, et al. **Nurse Pract** 1999 Jun;24(6):28, 31, 35–6 passim; quiz 47–9 (65 ref.)
Soy, disease prevention, and prostate cancer. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):97–102 (110 ref.)

SP1-BINDING SITE, HIV see **HIV LONG TERMINAL REPEAT**

SP1 TRANSCRIPTION FACTOR see **TRANSCRIPTION FACTOR, SP1**

SP-K RECEPTORS see **RECEPTORS, NEUROKININ-2**

SP-P RECEPTORS see **RECEPTORS, NEUROKININ-1**

SPACE ADAPTATION SYNDROME see **SPACE MOTION SICKNESS**

SPACE (ASTRONOMY) see **EXTRATERRESTRIAL ENVIRONMENT**

SPACE CRAFT see **SPACECRAFT**

SPACE EXPLORATION see **SPACE FLIGHT**

SPACE FLIGHT

see related
ASTRONAUTS
ECOLOGICAL SYSTEMS, CLOSED
EXTRATERRESTRIAL ENVIRONMENT
SPACECRAFT
WEIGHTLESSNESS

Artificial gravity considerations for a mars exploration mission. Young LR. **Ann N Y Acad Sci** 1999 May 28; 871:367–78 (37 ref.)

Surgical care in space. Campbell MR.
Aviat Space Environ Med 1999 Feb;70(2):181–4 (24 ref.)

Medical issues for a mission to Mars. Davis JR.
Aviat Space Environ Med 1999 Feb;70(2):162–8 (18 ref.)

Psychiatric issues affecting long duration space missions. Kanas N. **Aviat Space Environ Med** 1998 Dec;69(12):1211–6 (42 ref.)

Biomedical investigations conducted in support of the Extended Duration Orbiter Medical Project. Sawin CF.
Aviat Space Environ Med 1999 Feb;70(2):169–80 (20 ref.)

Musculoskeletal change during spaceflight: a new view of an old problem. Goode A. **Br J Sports Med** 1999 Jun; 33(3):154 (9 ref.)

Neuronal plasticity: adaptation and readaptation to the environment of space. Correia MJ.
Brain Res Brain Res Rev 1998 Nov;28(1–2):61–5 (25 ref.)

In-flight electrocorticograms compared to ground controls in behaving monkeys: differences in attentional states? Graille C, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):52–60 (18 ref.)

Mental performance during short-term and long-term spaceflight. Manzey D, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):215–21 (25 ref.)

Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Reschke MF, et al.
Brain Res Brain Res Rev 1998 Nov;28(1–2):102–17 (189 ref.)

Postnatal development under conditions of simulated weightlessness and space flight. Walton K.
Brain Res Brain Res Rev 1998 Nov;28(1–2):25–34 (35 ref.)

Post-spaceflight orthostatic intolerance: possible relationship to microgravity-induced plasticity in the vestibular system. Yates BJ, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1–2):73–82 (61 ref.)

Gravity and space flight: effects on nutritional status. Smith SM, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul; 2(4):335–8 (35 ref.)

Spin-offs from blood pressure and heart rate studies for health care and space research. Halberg F, et al.
In Vivo 1999 Jan–Feb;13(1):67–76 (133 ref.)

Immune responses in space flight. Sonnenfeld G.
Int J Sports Med 1998 Jul;19 Suppl 3:S195–202; discussion S202–4 (71 ref.)

Gas chromatography in space. Akapo SO, et al.
J Chromatogr A 1999 May 28;843(1–2):147–62 (55 ref.)

[Concept of acceptable risk in space flight medical support system] Petrov VM. **Aviakosm Ekolog Med** 1998; 32(5):46–51 (3 ref.) (Eng. Abstr.) **(Rus)**

[Hybrid biophysical-chemical life support systems for human] Shepelev ELa, et al. **Aviakosm Ekolog Med** 1998; 32(6):27–30 (8 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

[The history of the development of life support systems under the conditions of the vacuum of space] Cherniakov IN. **Usp Fiziol Nauk** 1999 Jan–Mar;30(1):90–6 (31 ref.) **(Rus)**

SPACE MAINTENANCE

METHODS

Management of space problems in the primary and mixed dentitions. Ngan P, et al. **J Am Dent Assoc** 1999 Sep; 130(9):1330–9 (52 ref.)

SPACE MEDICINE see **AEROSPACE MEDICINE**

SPACE MOTION SICKNESS

PHYSIOPATHOLOGY

Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Reschke MF, et al.
Brain Res Brain Res Rev 1998 Nov;28(1–2):102–17 (189 ref.)

SPACE PERCEPTION

Reduce risk of inducing spatial disorientation using physiologically compatible ground lighting. Schmidt RT.
Aviat Space Environ Med 1999 Jun;70(6):598–603 (22 ref.)

Spatial orientation of the angular vestibulo-ocular reflex. Cohen B, et al. **J Vestib Res** 1999;9(3):163–72 (49 ref.)

Unilateral spatial neglect in dissociable frames of reference: a comment on Farah, Brunn, Wong, Wallace, and Carpenter (1990) [comment] Hillis AE, et al.
Neuropsychologia 1998 Nov;36(11):1257–62 (23 ref.)
Comment on: Neuropsychologia 1990;28(4):335–47.

PHYSIOLOGY

Visual and visual cognitive dysfunction in Parkinson's disease: spatial and chromatic vision. Bodis-Wollner IG, et al. **Adv Neurol** 1999;80:383–8 (30 ref.)

The contributions of vestibular signals to the representations of space in the posterior parietal cortex. Andersen RA, et al. **Ann N Y Acad Sci** 1999 May 28;871:282–92 (44 ref.)

Space and attention in parietal cortex. Colby CL, et al.
Annu Rev Neurosci 1999;22:319–49 (84 ref.)

Neuroethology of spatial learning: the birds and the bees. Capaldi EA, et al. **Annu Rev Psychol** 1999;50:651–82 (216 ref.)

The Corsi block-tapping task: methodological and theoretical considerations. Berch DB, et al. **Brain Cogn** 1998 Dec; 38(3):317–38 (92 ref.)

Perception of spatial orientation in microgravity. Glasauer S, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):185–93 (34 ref.)

Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Reschke MF, et al.
Brain Res Brain Res Rev 1998 Nov;28(1–2):102–17 (189 ref.)

Idiothetic input into object-place configuration as the contribution to memory of the monkey and human hippocampus: a review. Gaffan D. **Exp Brain Res** 1998 Nov;123(1–2):201–9 (64 ref.)

Visual size processing in spatial neglect. Milner AD, et al. **Exp Brain Res** 1998 Nov;123(1–2):192–200 (41 ref.)

A new view on grasping [see comments] Smeets JB, et al. **Motor Control** 1999 Jul;3(3):237–71 (86 ref.) Comment in: Motor Control 1999 Jul;3(3):272–5; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):276–9; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):280–4; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):285–8; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):289–97; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):298–301; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):302–6; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):307–11; discussion 316–25. Comment in: Motor Control 1999 Jul;3(3):312–5; discussion 316–25.

The cerebellum in the spatial problem solving: a co-star or a guest star? Petrosini L, et al. **Prog Neurobiol** 1998 Oct; 56(2):191–210 (117 ref.)

Visual and mental exploration of visuo-spatial configurations: behavioral and neuroimaging approaches. Cocude M, et al. **Psychol Res** 1999;62(2–3):93–106 (57 ref.)

Visual-spatial working memory, attention, and scene representation: a neuro-cognitive theory. Schneider WX. **Psychol Res** 1999;62(2–3):220–36 (106 ref.)

Dynamic characteristics of spatial mechanisms coding contour structures. Dresp B. **Spat Vis** 1999;12(2):129–42 (37 ref.)

[The role of the right and left cerebral hemispheres in space perception. II. Depth perception as an interhemispheric phenomenon] Nikolaenko NN, et al. **Fiziol Cheloveka** 1998 Nov–Dec;24(6):21–31 (32 ref.) **(Rus)**

[Role of the right and left cerebral hemispheres in space perception. I. Object perception and reflection in the frontal plane] Nikolaenko NN, et al. **Fiziol Cheloveka** 1998 Sep–Oct;24(5):54–64 (38 ref.) **(Rus)**

SPACE SIMULATION

see related
WEIGHTLESSNESS SIMULATION

SPACE-TIME CLUSTERING

see related
DISEASE OUTBREAKS

SPACECRAFT

Biomedical investigations conducted in support of the Extended Duration Orbiter Medical Project. Sawin CF.
Aviat Space Environ Med 1999 Feb;70(2):169–80 (20 ref.)

Vestibulo-oculomotor research and measurement technology for the space station era. Clarke AH.
Brain Res Brain Res Rev 1998 Nov;28(1–2):173–84 (72 ref.)

[Biological life support systems: investigations on board of orbital complex "Mir"] Sychev VN, et al.
Aviakosm Ekolog Med 1999;33(1):10–6 (17 ref.) (Eng. Abstr.) **(Rus)**

SPANISH AMERICANS see **HISPANIC AMERICANS**

SPARGANOSIS

see related
DIPHYLLOBOTHRIASIS

DIAGNOSIS

[Laboratory diagnosis of protozoan and parasitic diseases. 2. Helminthiasis. a. Sparganosis] Hasegawa H.
Rinsho Byori 1998 Nov;Suppl 108:210–4 (6 ref.) **(Jpn)**

SPARROWS see **SONGBIRDS**

SPASM

see related
MUSCLE CRAMP
MYOTONIA

EPIDEMIOLOGY

Satoyoshi's syndrome in an adult: a review of the literature of adult onset cases. Ikeda K, et al. **Intern Med** 1998 Sep; 37(9):784–7 (19 ref.)

PATHOLOGY

Vasospasm, vascular injury, and atherogenesis: a perspective. Gutstein WH. **Hum Pathol** 1999 Apr;30(4):365–71 (111 ref.)

THERAPY

Should people with nocturnal leg cramps drink tonic water and bitter lemon? Brasić JR. **Psychol Rep** 1999 Apr; 84(2):355–67 (69 ref.)

SPASM, ESOPHAGEAL see **ESOPHAGEAL SPASM, DIFFUSE**

SPASM, HEMIFACIAL see **HEMIFACIAL SPASM**

SPASMOLYTICS see **PARASYMPATHOLYTICS**

SPASMOPHILIA see **TETANY**

SPASMS, INFANTILE

[General principles of treatment and effects of childhood intractable epilepsy] Iinuma K. **Rinsho Shinkeigaku** 1999 Jan;39(1):75–6 (0 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. Hancock E, et al.
J Child Neurol 1999 Feb;14(2):71–4 (26 ref.)

DRUG THERAPY

Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. Hancock E, et al.
J Child Neurol 1999 Feb;14(2):71–4 (26 ref.)

Pneumocystis carinii pneumonia in a child receiving ACTH for infantile spasms. Dunagan DP, et al.
Pediatr Pulmonol 1999 Apr;27(4):286–9 (17 ref.)

[Ventricular outflow tract obstruction by cardiac tumors during ACTH therapy of an infant with tuberous sclerosis] Yoshimi S, et al. **No To Hattatsu** 1999 Mar;31(2):165–70 (12 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Epilepsy in the first year of life: a review. Kramer U.
J Child Neurol 1999 Aug;14(8):485–9 (57 ref.)

GENETICS

Benign familial neonatal epilepsy with mutations in two potassium channel genes. Leppert M, et al.
Curr Opin Neurol 1999 Apr;12(2):143–7 (36 ref.)

SPASMUS NUTANS see **SPASMS, INFANTILE**

SPASTIC DIPLEGIA see **CEREBRAL PALSY**

SPASTIC PARAPARESIS see **PARAPARESIS, TROPICAL SPASTIC**

SPASTIC PARAPLEGIA see **PARAPLEGIA**

SPASTIC PARAPLEGIA, HEREDITARY

[Familial spastic paraplegia (FSP)] Shibasaki Y, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):221–3 (6 ref.) **(Jpn)**

[Molecular genetics of familial spastic paraplegia] Shibasaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):224–6 (8 ref.) **(Jpn)**

GENETICS

Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Pearce DA. **Hum Genet** 1999 Jun;104(6):443–8 (54 ref.)

"Pure" hereditary spastic paraplegias: the story becomes complicated [editorial; comment] Figlewicz DA, et al.
Neurology 1999 Jul 13;53(1):5–7 (16 ref.) Comment on: Neurology 1999 Jul 13;53(1):44–50. Comment on: Neurology 1999 Jul 13;53(1):50–6.

SPASTIC PARAPLEGIA, HEREDITARY

PATHOLOGY

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia [see comments] Schapira AH. **Biochim Biophys Acta** 1999 Feb 9;1410(2):159–70 (112 ref.) Comment in: Biochim Biophys Acta 1999 Feb 9;1410(2):99–102.

[Neuropathology of familial spastic paraplegia] Iwabuchi K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):227–30 (12 ref.) **(Jpn)**

SPASTICITY, MUSCLE see **MUSCLE SPASTICITY**

SPATIAL BEHAVIOR

PHYSIOLOGY

Avian hippocampus as a model to study spatial orientation-related synaptic plasticity. Wieraszko A. **Adv Exp Med Biol** 1998;446:107–29 (150 ref.)

Motion sickness and development of synergy within the spatial orientation system. A hypothetical unifying concept. Guedry FE, et al. **Brain Res Bull** 1998 Nov 15;47(5):475–80 (60 ref.)

The associative parietal cortex and spatial processing in rodents. Thinus-Blanc C, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):179–83 (45 ref.)

Human spatial navigation: cognitive maps, sexual dimorphism, and neural substrates. Maguire EA, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):171–7 (76 ref.)

What do comparative studies of inbred mice add to current investigations on the neural basis of spatial behaviors? Rossi-Arnaud C, et al. **Exp Brain Res** 1998 Nov; 123(1–2):36–44 (48 ref.)

Gaze shifts in three-dimensional space: A closer look at the superior colliculus [comment] Guitton D. **J Comp Neurol** 1999 Oct 11;413(1):77–82 (52 ref.) Comment on: J Comp Neurol 1999 Oct 11;413(1):68–70.

A theory of geometric constraints on neural activity for natural three-dimensional movement. Zhang K, et al. **J Neurosci** 1999 Apr 15;19(8):3122–45 (124 ref.)

Spatial attention and neglect: parietal, frontal and cingulate contributions to the mental representation and attentional targeting of salient extrapersonal events. Mesulam MM. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1325–46 (191 ref.)

SPEARMAN RANK CORRELATION COEFFICIENT see **STATISTICS, NONPARAMETRIC**

SPECIALISM

The nature of ethical expertise. Yoder SD. **Hastings Cent Rep** 1998 Nov–Dec;28(6):11–9 (35 ref.)

[Colorectal surgery--an integral part of general surgery!] Renzulli P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:619–26 (21 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Has surgical subspecialization gone too far? Black J. **Hosp Med** 1999 Mar;60(3):206–9 (16 ref.)

Occupational health psychology: an emerging discipline. Sauter SL, et al. **Ind Health** 1999 Apr;37(2):199–211 (90 ref.)

[Infectiology] Ruf BR, et al. **Internist (Berl)** 1999 Apr; 40(4):369–80 (42 ref.) **(Ger)**

[Biogerontology: status and current developments] Ahlert G. **Z Gerontol Geriatr** 1999 Apr;32(2):112–23 (97 ref.) (Eng. Abstr.) **(Ger)**

SPECIALTIES, MEDICAL

Critical care--the worldwide perspective. Fisher M. **Ann Acad Med Singapore** 1998 May;27(3):376–80 (22 ref.)

Intensivists for the intensive care unit--do they make a difference? [editorial] Lew TW, et al. **Ann Acad Med Singapore** 1998 May;27(3):305–7 (20 ref.)

The role of transfusion medicine physicians. A vanishing breed? AuBuchon JP. **Arch Pathol Lab Med** 1999 Aug; 123(8):663–7 (31 ref.)

The role of the maternal-fetal medicine specialist. Philipson EH. **Cleve Clin J Med** 1999 Jul–Aug;66(7):407–9, 413–4 (10 ref.)

Principles of generalist-specialist relationships. Pearson SD. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S13–20 (30 ref.)

The role of the hypertension specialist [see comments] Beevers DG. **J Hum Hypertens** 1998 Oct;12(10):659–61 (16 ref.) Comment in: J Hum Hypertens 1999 Feb;13(2):151–2.

Palliative medicine: is it really specialist territory? [see comments] Fordham S, et al. **J R Soc Med** 1998 Nov; 91(11):568–72 (78 ref.) Comment in: J R Soc Med 1998 Nov;91(11):563–4. Comment in: J R Soc Med 1999 Jan;92(1):53. Comment in: J R Soc Med 1999 Jan;92(1):54. Comment in: J R Soc Med 1999 Feb;92(2):100. Comment in: J R Soc Med 1999 Feb;92(2):100–1. Comment in: J R Soc Med 1999 Feb;92(2):101. Comment in: J R Soc Med 1999 Mar;92(3):157. Comment in: J R Soc Med 1999 May;92(5):269.

Is downsizing and disbanding specialty care teams a counterproductive strategy for cost reduction in health care? Ryder M, et al. **Nutrition** 1998 Sep;14(9):725–8 (40 ref.)

The transfusion medicine consultant and hospital transfusion committee. Popovsky MA. **Vox Sang** 1998;74 Suppl 2:391–3 (6 ref.)

METHODS

The good (gatekeeper), the bad (gatekeeper), and the ugly (situation) [editorial; comment] Laine C, et al. **J Gen Intern Med** 1999 May;14(5):320–1 (17 ref.) Comment on: J Gen Intern Med 1999 May;14(5):281–6. Comment on: J Gen Intern Med 1999 May;14(5):287–96.

ORGANIZATION & ADMINISTRATION

The rise, heyday, and incipient decline of specialization: hospitals in Denmark, 1930–1990. Vallgårda S. **Int J Health Serv** 1999;29(2):431–57 (34 ref.)

Governmental steering of highly specialized medical services [editorial] [see comments] Forfang K. **Scand Cardiovasc J** 1998;32(4):197–9 (5 ref.) Comment in: Scand Cardiovasc J 1998;32(4):195.

STATISTICS & NUMERICAL DATA

Knowledge, patterns of care, and outcomes of care for generalists and specialists [see comments] Harrold LR, et al. **J Gen Intern Med** 1999 Aug;14(8):499–511 (92 ref.) Comment in: J Gen Intern Med 1999 Aug;14(8):514–5.

Productivity of SCI Korean medical papers: 1996–1997. Lee CS. **J Korean Med Sci** 1999 Aug;14(4):351–8 (20 ref.)

TRENDS

Is the orthopedic generalist moving toward extinction? Goldner JL, et al. **Am J Orthop** 1999 Jul;28(7):389–96 (16 ref.)

SPECIALTIES, NURSING

Evaluating community-based Parkinson's disease nurse specialists: rationale, methodology, and representativeness of patient sample in a large randomized controlled trial. Hurwitz B, et al. **Adv Neurol** 1999;80:431–8 (10 ref.)

ORGANIZATION & ADMINISTRATION

Neuroscience nursing practice in a new millennium. Hickey JV, et al. **Nurs Clin North Am** 1999 Sep;34(3):541–54 (24 ref.)

Ethical perspectives in neuroscience nursing practice. Murphy WJ. **Nurs Clin North Am** 1999 Sep;34(3):621–35 (38 ref.)

STANDARDS

Outcomes research and the neuroscience nurse: what's in it for clinical practice? Mitchell PH. **J Neurosci Nurs** 1998 Oct;30(5):318–21 (35 ref.)

SPECIALTIES, SURGICAL

STANDARDS

[Systematic scientific quality improvement in surgical specialties. The AQS mode] Rageth JC, et al. **Swiss Surg** 1999;5(2):62–72 (23 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Has surgical subspecialization gone too far? Black J. **Hosp Med** 1999 Mar;60(3):206–9 (16 ref.)

SPECIALTY BOARDS

LEGISLATION & JURISPRUDENCE

Impaired doctors. The modern approach of medical boards. Breen KJ, et al. **Aust Fam Physician** 1998 Nov; 27(11):1005–8 (0 ref.)

STANDARDS

Meritocracy in graduate medical education? Some suggestions for creating a report card. Iverson DJ. **Acad Med** 1998 Dec;73(12):1223–5 (21 ref.)

SPECIFICITY see **SENSITIVITY AND SPECIFICITY**

SPECIMEN HANDLING

The application of near patient testing to microbiology. Bevan VM, et al. **Commun Dis Public Health** 1999 Jan; 2(1):14–21 (28 ref.)

[With special reference to clinical specimen handlings] Takagi Y. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):1980–4 (2 ref.) **(Jpn)**

[Sampling and quality assurance] Kayamori Y, et al. **Rinsho Byori** 1998 Dec;46(12):1190–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Newborn infants do feel pain! Technique and environment in connection with specimen collection can be improved] Finnström O, et al. **Lakartidningen** 1998 Dec 9; 95(50):5718–20 (20 ref.) **(Swe)**

METHODS

Specimen banks for cancer prognostic factor research. Burke HB, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):871–4 (38 ref.)

Protocol for the examination of specimens removed from patients with carcinomas of the upper aerodigestive tract: carcinomas of the oral cavity including lip and tongue, nasal and paranasal sinuses, pharynx, larynx, salivary glands, hypopharynx, oropharynx, and nasopharynx. Cancer Committee, College of American Pathologists. Min KW, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):222–30 (58 ref.)

A safe, simple, standardized method should be used for sputum induction for research purposes [editorial; comment] Fahy JV. **Clin Exp Allergy** 1998 Sep; 28(9):1047–9 (18 ref.) Comment on: Clin Exp Allergy 1998 Sep;28(9):1081–8.

Methods of semen collection not based on masturbation or surgical sperm retrieval. Gerris J. **Hum Reprod Update** 1999 May–Jun;5(3):211–5 (20 ref.)

Practical approach to processing osteosarcomas in the surgical pathology laboratory. Wold LE. **Pediatr Dev Pathol** 1998 Sep–Oct;1(5):449–54 (4 ref.)

Difficulties in interpretation of culture results in sinusitis. Verschraegen G, et al. **Rhinology** 1998 Jun;36(2):55–8 (17 ref.)

Retrieval of specimens in laparoscopy using reclosable zipper-type plastic bags: a simple, cheap, and useful method. Weber A, et al. **Surg Laparosc Endosc** 1998 Dec; 8(6):457–9 (21 ref.)

[Collection of samples, their management and examination to identify the causative organisms] Yamaguchi K. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2223–7 (4 ref.) **(Jpn)**

STANDARDS

A safe, simple, standardized method should be used for sputum induction for research purposes [editorial; comment] Fahy JV. **Clin Exp Allergy** 1998 Sep; 28(9):1047–9 (18 ref.) Comment on: Clin Exp Allergy 1998 Sep;28(9):1081–8.

[Securing evidence after sexual offences is an important task for physicians. Increasing severity of crimes and use of DNA analyses necessitate higher quality standards] Ansell R. **Lakartidningen** 1998 Oct 14;95(42):4626–8, 4630–1 (10 ref.) (Eng. Abstr.) **(Swe)**

SPECT see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

SPECTACLED BEAR see **BEARS**

SPECTRIN

GENETICS

Genetic studies of spectrin: new life for a ghost protein. Dubreuil RR, et al. **Bioessays** 1998 Nov;20(11):875–8 (25 ref.)

Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis. Gallagher PG, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):539–43 (48 ref.)

METABOLISM

The role of ankyrin and spectrin in membrane transport and domain formation. De Matteis MA, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):542–9 (51 ref.)

PHYSIOLOGY

A spectrin membrane skeleton of the Golgi complex. Beck KA, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1–2):153–60 (43 ref.)

SPECTROFLUOROMETRY see **SPECTROMETRY, FLUORESCENCE**

SPECTROMETRY, FLUORESCENCE

Application of fluorescence resonance energy transfer in the clinical laboratory: routine and research. Szöllosi J, et al. **Cytometry** 1998 Aug 15;34(4):159–79 (132 ref.)

Fluorescence spectroscopy: a technique with potential to improve the early detection of aerodigestive tract neoplasia. Gillenwater A, et al. **Head Neck** 1998 Sep;20(6):556–62 (23 ref.)

Instrumentation for the diagnosis of term and preterm labour. Garfield RE, et al. **J Perinat Med** 1998;26(6):413–36 (128 ref.)

Fluorescence spectroscopy for diagnosis of squamous intraepithelial lesions of the cervix. Mitchell MF, et al. **Obstet Gynecol** 1999 Mar;93(3):462–70 (70 ref.)

Fluorescence spectroscopy of single biomolecules. Weiss S. **Science** 1999 Mar 12;283(5408):1676–83 (87 ref.)

INSTRUMENTATION

Fluorescence correlation spectroscopy as a tool to investigate chemical reactions in solutions and on cell surfaces. Widengren J, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):857–79 (77 ref.)

METHODS

New time-resolved techniques in two-photon microscopy. So PT, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul; 44(5):771-93 (85 ref.)

Fluorescence correlation spectroscopy as a tool to investigate chemical reactions in solutions and on cell surfaces. Widengren J, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):857-79 (77 ref.)

Fluorescence-based expression monitoring using microarrays. Winzeler EA, et al. **Methods Enzymol** 1999; 306:3-18 (25 ref.)

In vivo fluorescence spectroscopy and imaging for oncological applications. Wagnières GA, et al. **Photochem Photobiol** 1998 Nov;68(5):603-32 (400 ref.)

Using GFP in FRET-based applications. Pollok BA, et al. **Trends Cell Biol** 1999 Feb;9(2):57-60 (14 ref.)

[Single molecule detection using fluorescence correlation spectroscopy] Kinjo M. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1431-8 (39 ref.) **(Jpn)**

SPECTROMETRY, MASS see **SPECTRUM ANALYSIS, MASS**

SPECTROMETRY, MASS-GAS CHROMATOGRAPHY see **MASS FRAGMENTOGRAPHY**

SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION

The Australian Proteome Analysis Facility (APAF): assembling large scale proteomics through integration and automation. Walsh BJ, et al. **Electrophoresis** 1998 Aug; 19(11):1883-90 (31 ref.)

Peptide and protein identification by matrix-assisted laser desorption ionization (MALDI) and MALDI-post-source decay time-of-flight mass spectrometry. Chaurand P, et al. **J Am Soc Mass Spectrom** 1999 Feb;10(2):91-103 (67 ref.)

Contribution of mass spectrometry to contemporary immunology. de Jong A. **Mass Spectrom Rev** 1998 Sep-Oct;17(5):311-35 (127 ref.)

METHODS

Proteomics and automation. Quadroni M, et al. **Electrophoresis** 1999 Apr-May;20(4-5):664-77 (108 ref.)

Ultramicroanalysis of peptide profiles in biological samples using MALDI mass spectrometry. Jiménez CR, et al. **Exp Nephrol** 1998 Sep-Oct;6(5):421-8 (26 ref.)

Identification of proteins by matrix-assisted laser desorption/ionization mass spectrometry using peptide and fragment ion masses. Courchesne PL, et al. **Methods Mol Biol** 1999;112:487-511 (28 ref.)

Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. Jensen ON, et al. **Methods Mol Biol** 1999;112:513-30 (56 ref.)

Obtaining molecular weights of proteins and their cleavage products by directly combining gel electrophoresis with mass spectrometry. Ogorzalek Loo RR, et al. **Methods Mol Biol** 1999;112:473-85 (31 ref.)

SPECTROMETRY, NEAR-INFRARED see **SPECTROSCOPY, NEAR-INFRARED**

SPECTROMETRY, X-RAY EMISSION, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

SPECTROMETRY, X-RAY EMISSION, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

SPECTROPHOTOMETRY

METHODS

Advances in photoacoustic noninvasive glucose testing. MacKenzie HA, et al. **Clin Chem** 1999 Sep;45(9):1587-95 (58 ref.)

Applications of fiber-optic evanescent wave spectroscopy. Squillante E 3rd. **Drug Dev Ind Pharm** 1998 Dec; 24(12):1163-75 (73 ref.)

[Pulse dye-densitometry] Iijima T. **Masui** 1998 Dec;47 Suppl:S101-8 (9 ref.) **(Jpn)**

SPECTROPHOTOMETRY, INFRARED

METHODS

Infrared spectroscopy. Ng LM, et al. **Anal Chem** 1999 Jun 15;71(12):343R-350R (106 ref.)

Attenuated total reflection infrared spectroscopy of proteins and lipids in biological membranes. Goormaghtigh E, et al. **Biochim Biophys Acta** 1999 Jul 6;1422(2):105-85 (397 ref.)

Near-infrared spectrophotometry of the brain in cardiovascular surgery. Nollert G, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):167-75 (98 ref.)

SPECTROSCOPY see **SPECTRUM ANALYSIS**

SPECTROSCOPY, FOURIER TRANSFORM INFRARED

METHODS

Vibrational circular dichroism: an incisive tool for stereochemical applications. Nafie LA, et al. **Enantiomer** 1998;3(4-5):283-97 (27 ref.)

Role of Fourier transform infrared spectroscopy in the rehearsal phase of combinatorial chemistry: a thin-layer chromatography equivalent for on-support monitoring of solid-phase organic synthesis. Yan B, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 2;725(1):91-102 (54 ref.)

SPECTROSCOPY, INFRARED, FOURIER TRANSFORM see **SPECTROSCOPY, FOURIER TRANSFORM INFRARED**

SPECTROSCOPY, MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

SPECTROSCOPY, MASS see **SPECTRUM ANALYSIS, MASS**

SPECTROSCOPY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

SPECTROSCOPY, NEAR-INFRARED

Near-infrared spectroscopy in the pharmaceutical industry. Blanco M, et al. **Analyst** 1998 Aug;123(8):135R-150R (204 ref.)

Application of standardisation methods to correct the spectral differences induced by a fibre optic probe used for the near-infrared analysis of pharmaceutical tablets. Bouveresse E, et al. **J Pharm Biomed Anal** 1998 Oct; 18(1-2):35-42 (33 ref.)

Near-infrared oximetry of the brain. Madsen PL, et al. **Prog Neurobiol** 1999 Aug;58(6):541-60 (192 ref.)

[Fundamentals and clinical application of near-infrared spectrophotometry--with special reference to cytochrome oxidase] Tamura M, et al. **Masui** 1998 Dec;47 Suppl:S33-45 (23 ref.) **(Jpn)**

METHODS

Near infrared spectroscopy. Owen-Reece H, et al. **Br J Anaesth** 1999 Mar;82(3):418-26 (74 ref.)

Multivariate calibration: applications to pharmaceutical analysis. Forina M, et al. **J Pharm Biomed Anal** 1998 Oct; 18(1-2):21-33 (11 ref.)

New technologies in pediatric neurology. Near-infrared spectroscopy. Soul JS, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):101-10 (53 ref.)

SPECTROSCOPY, NMR see **NUCLEAR MAGNETIC RESONANCE**

SPECTROSCOPY, NUCLEAR MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

SPECTRUM ANALYSIS

Technical and clinical aspects of spectrometric analysis of trace elements in clinical samples. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):615-29 (40 ref.)

Spectral imaging for quantitative histology and cytogenetics. Rothmann C, et al. **Histol Histopathol** 1998 Jul;13(3):921-6 (27 ref.)

METHODS

Flame, flameless, and plasma spectroscopy. Komaromy-Hiller G. **Anal Chem** 1999 Jun 15; 71(12):338R-342R (127 ref.)

Separation and analysis of peptides and proteins. Larive CK, et al. **Anal Chem** 1999 Jun 15;71(12):389R-423R (80 ref.)

Geochemical and cosmochemical materials. Lipschutz ME, et al. **Anal Chem** 1999 Jun 15;71(12):1R-20R (312 ref.)

Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter. Sharom FJ, et al. **Biochem Cell Biol** 1998; 76(5):695-708 (69 ref.)

Spectroscopic and clinical aspects of noninvasive glucose measurements. Khalil OS. **Clin Chem** 1999 Feb;45(2):165-77 (141 ref.)

Microcirculatory oxygenation and shunting in sepsis and shock [see comments] Ince C, et al. **Crit Care Med** 1999 Jul;27(7):1369-77 (75 ref.) Comment in: Crit Care Med 1999 Jul;27(7):1400-1.

Implications of lag time concept in the oxidation of LDL. Parthasarathy S, et al. **Free Radic Res** 1998 Jun; 28(6):583-91 (39 ref.)

Applications of chiroptical spectroscopy for the characterization of pharmaceutical compounds. Brittain HG. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):933-40 (44 ref.)

Spatially resolved force spectroscopy of biological surfaces using the atomic force microscope. Heinz WF, et al. **Trends Biotechnol** 1999 Apr;17(4):143-50 (74 ref.)

SPECTRUM ANALYSIS, MASS

Electrospray ionization mass spectrometry: a promising new technique in the study of protein/DNA noncovalent complexes. Veenstra TD. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):1-5 (21 ref.)

Mass spectrometric analysis in combinatorial chemistry. Swali V, et al. **Curr Opin Chem Biol** 1999 Jun;3(3):337-41 (36 ref.)

Database searching using mass spectrometry data. Yates JR 3rd. **Electrophoresis** 1998 May;19(6):893-900 (48 ref.)

Impact of mass spectrometry on combinatorial chemistry. Süssmuth RD, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 2;725(1):49-65 (102 ref.)

Tandem mass spectrometry--the potential. Bartlett K, et al. **J Inherit Metab Dis** 1999 Jun;22(4):568-71 (12 ref.)

[Chemical analysis of clinical materials using mass spectrometry] Shimizu A, et al. **Rinsho Byori** 1999 Feb; Suppl 109:116-25 (16 ref.) **(Jpn)**

INSTRUMENTATION

Ion/ion chemistry of high-mass multiply charged ions [published erratum appears in Mass Spectrom Rev 1999 Jan-Feb;18(1):83-6] McLuckey SA, et al. **Mass Spectrom Rev** 1998 Nov-Dec;17(6):369-407 (107 ref.)

METHODS

Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. Hellerstein MK, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1146-70 (40 ref.)

Advances in CE/MS. Ding J, et al. **Anal Chem** 1999 Jun 1;71(11):378A-385A (47 ref.)

Mass Spectrometry in DNA analysis. Guo B. **Anal Chem** 1999 Jun 15;71(12):333R-337R (47 ref.)

Flame, flameless, and plasma spectroscopy. Komaromy-Hiller G. **Anal Chem** 1999 Jun 15; 71(12):338R-342R (127 ref.)

Geochemical and cosmochemical materials. Lipschutz ME, et al. **Anal Chem** 1999 Jun 15;71(12):1R-20R (312 ref.)

The important contribution of high precision mass spectrometric methods in the study of the structure-function relationship of proteins and enzymes. Devreese B, et al. **Analyst** 1998 Dec;123(12):2457-61 (38 ref.)

Bioanalytic applications of mass spectrometry. Costello CE. **Curr Opin Biotechnol** 1999 Feb;10(1):22-8 (60 ref.)

Tandem spectrometry in newborn screening. Seashore MR. **Curr Opin Pediatr** 1998 Dec;10(6):609-14 (30 ref.)

High sensitivity analysis of proteins and peptides by capillary electrophoresis-tandem mass spectrometry: recent developments in technology and applications. Figeys D, et al. **Electrophoresis** 1998 May;19(6):885-92 (126 ref.)

Differential sequencing with mass spectrometry. Graber JH, et al. **Genet Anal** 1999 Feb;14(5-6):215-9 (24 ref.)

Analysis of lipophilic peptides and therapeutic drugs: on-line-nonaqueous capillary electrophoresis-mass spectrometry. Yang Q, et al. **J Biochem Biophys Methods** 1999 Jan 29;38(2):103-21 (49 ref.)

High-performance liquid chromatographic-electrospray ionization mass spectrometric analyses for the integration of natural products with modern high-throughput screening. Strege MA. **J Chromatogr B Biomed Sci Appl** 1999 Apr 2;725(1):67-78 (37 ref.)

Surface mass spectrometry of molecular species. Hanley L, et al. **J Mass Spectrom** 1999 Jul;34(7):705-23 (130 ref.)

Ion/ion chemistry of high-mass multiply charged ions [published erratum appears in Mass Spectrom Rev 1999 Jan-Feb;18(1):83-6] McLuckey SA, et al. **Mass Spectrom Rev** 1998 Nov-Dec;17(6):369-407 (107 ref.)

Charge derivatization of peptides for analysis by mass spectrometry. Roth KD, et al. **Mass Spectrom Rev** 1998 Jul-Aug;17(4):255-74 (73 ref.)

Peptide sequencing of 2-DE gel-isolated proteins by nanoelectrospray tandem mass spectrometry. Jensen ON, et al. **Methods Mol Biol** 1999;112:571-88 (34 ref.)

Automated protein identification using microcolumn liquid chromatography-tandem mass spectrometry. Yates JR 3rd, et al. **Methods Mol Biol** 1999;112:553-69 (17 ref.)

Applications of mass spectrometry to signal transduction. Resing KA, et al. **Prog Biophys Mol Biol** 1999; 71(3-4):501-23 (166 ref.)

Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Barker J, et al. **Rapid Commun Mass Spectrom** 1999; 13(4):285-93 (42 ref.)

On the analysis of iodine-129 and iodine-127 in environmental materials by accelerator mass spectrometry and ion chromatography. Schmidt A, et al. **Sci Total Environ** 1998 Nov 10;223(2-3):131-56 (102 ref.)

Application of electrospray tandem mass spectrometry to neonatal screening. Rashed MS, et al. **Semin Perinatol** 1999 Apr;23(2):183-93 (55 ref.)

TRENDS

High sensitivity analysis of proteins and peptides by capillary electrophoresis-tandem mass spectrometry: recent developments in technology and applications. Figeys D,

SPECTRUM ANALYSIS, MASS

et al. **Electrophoresis** 1998 May;19(6):885–92 (126 ref.)
Proteomics: quantitative and physical mapping of cellular proteins. Blackstock WP, et al. **Trends Biotechnol** 1999 Mar; 17(3):121–7 (44 ref.)

SPECTRUM ANALYSIS, MASS-GAS CHROMATOGRAPHY see **MASS FRAGMENTOGRAPHY**

SPECTRUM ANALYSIS, RAMAN

Raman spectroscopy, the sleeping giant in structural biology, awakes. Carey PR. **J Biol Chem** 1999 Sep 17; 274(38):26625–8 (46 ref.)

METHODS

Raman spectroscopy of protein and nucleic acid assemblies. Thomas GJ Jr. **Annu Rev Biophys Biomol Struct** 1999; 28:1–27 (97 ref.)

SPECULUM see **SURGICAL INSTRUMENTS**

SPEECH

see related
VERBAL BEHAVIOR

The evolution of human speech: the role of enhanced breathing control. MacLarnon AM, et al.
Am J Phys Anthropol 1999 Jul;109(3):341–63 (160 ref.)
Understanding the continuum of discrete-trial traditional behavioral to social–pragmatic developmental approaches in communication enhancement for young children with autism/PDD. Prizant BM, et al. **Semin Speech Lang** 1998; 19(4):329–52; quiz 353; 424 (98 ref.)

PHYSIOLOGY

Birdsong and human speech: common themes and mechanisms. Doupe AJ, et al. **Annu Rev Neurosci** 1999; 22:567–631 (220 ref.)
The frame/content theory of evolution of speech production. MacNeilage PF. **Behav Brain Sci** 1998 Aug;21(4):499–511; discussion 511–46 (456 ref.)
Linear correlates in the speech signal: the orderly output constraint. Sussman HM, et al. **Behav Brain Sci** 1998 Apr; 21(2):241–59; discussion 260–99 (248 ref.)
The relationship between oral and written language [see comments] de Montfort Supple M.
Folia Phoniatr Logop 1998;50(5):243–55 (86 ref.) Comment in: Folia Phoniatr Logop 1998 ;50(5):239–42.
From the big bang to the brain. Boliek CA, et al.
J Commun Disord 1999 Jul–Aug;32(4):271–6 (12 ref.)

SPEECH ACOUSTICS

Acoustic studies of dysarthric speech: methods, progress, and potential. Kent RD, et al. **J Commun Disord** 1999 May–Jun; 32(3):141–80, 183–6; quiz 181–3, 187–9 (140 ref.)

SPEECH, ALARYNGEAL

see related
LARYNX, ARTIFICIAL

The treatment of hypertonicity of the pharyngo–oesophageal segment after laryngectomy. Brok HA, et al.
Clin Otolaryngol 1998 Aug;23(4):302–7 (51 ref.)
[Voice restoration and clinical outcome in patients undergoing laryngectomy with voice prostheses] Kumazawa H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Nov;101(11):1303–10 (31 ref.) (Eng. Abstr.) **(Jpn)**

SPEECH ARTICULATION TESTS

STANDARDS

DDK rates in the paediatric clinic: a methodological minefield. Cohen W, et al. **Int J Lang Commun Disord** 1998; 33 Suppl:428–33 (13 ref.)

SPEECH DISCRIMINATION see **SPEECH PERCEPTION**

SPEECH DISORDERS

see related
LANGUAGE DISORDERS

Evaluation and management of the child with speech delay. Leung AK, et al. **Am Fam Physician** 1999 Jun; 59(11):3121–8, 3135 (23 ref.)
[Disability because of hearing and speech disorders has low priority in society. Cooperation and resources are needed] Lundborg T, et al. **Lakartidningen** 1998 Oct 21; 95(43):4757–8 (5 ref.) **(Swe)**

COMPLICATIONS

[A case report of dementia with cluttering-like speech disorder and apraxia of gait] Hashimoto R, et al.
Rinsho Shinkeigaku 1999 May;39(5):520–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Assessing speech, language and communication. Paul R, et al. **Child Adolesc Psychiatr Clin N Am** 1999 Apr; 8(2):297–322, vii (44 ref.)
Screening for speech and language delay: a systematic review of the literature. Law J, et al. **Health Technol Assess** 1998; 2(9):1–184 (598 ref.)
DDK rates in the paediatric clinic: a methodological minefield. Cohen W, et al. **Int J Lang Commun Disord** 1998; 33 Suppl:428–33 (13 ref.)
Screening for primary speech and language delay: a systematic review of the literature. Law J, et al.
Int J Lang Commun Disord 1998;33 Suppl:21–3 (3 ref.)
Precursors to speech in infancy: the prediction of speech and language disorders [see comments] Oller DK, et al.
J Commun Disord 1999 Jul–Aug;32(4):223–45 (47 ref.) Comment in: J Commun Disord 1999 Jul–Aug;32(4):247–50.

ETIOLOGY

Early ear problems and developmental problems at school age. Lindsay RL, et al. **Clin Pediatr (Phila)** 1999 Mar; 38(3):123–32 (30 ref.)
Language, speech, and educational outcomes of otitis media. Gravel JS, et al. **J Otolaryngol** 1998;27 Suppl 2:17–25 (74 ref.)

PATHOLOGY

Smith–Fineman–Myers syndrome in apparently monozygotic twins. Guion–Almeida ML, et al. **Am J Med Genet** 1998 Sep 23;79(3):205–8 (4 ref.)

REHABILITATION

Issues in augmentative and alternative communication in child psychiatry. Sevcik RA, et al.
Child Adolesc Psychiatr Clin N Am 1999 Jan;8(1):77–87 (29 ref.)

SURGERY

Muscular reconstruction to improve the deterioration of facial appearance and speech caused by mandibular atrophy: technique and case reports. Bosker H, et al.
Br J Oral Maxillofac Surg 1999 Aug;37(4):277–84 (11 ref.)

THERAPY

Issues to consider in the evaluation of speech and language therapy for preschool children. Roulstone S, et al.
Child Care Health Dev 1999 Mar;25(2):141–55 (31 ref.)
Speechreading: advances in understanding its cortical bases and implications for deafness and speech rehabilitation. Campbell R. **Scand Audiol Suppl** 1998;49:80–6 (31 ref.)

SPEECH, ESOPHAGEAL

METHODS

Restoration of voice after laryngectomy. Jassar P, et al.
J R Soc Med 1999 Jun;92(6):299–302 (25 ref.)

SPEECH INTELLIGIBILITY

see related
SPEECH PRODUCTION MEASUREMENT

SPEECH-LANGUAGE PATHOLOGY

METHODS

Communicative intervention for children with psychiatric and communication disorders. Roth FP.
Child Adolesc Psychiatr Clin N Am 1999 Jan;8(1):137–52 (36 ref.)

SPEECH PATHOLOGY see **SPEECH-LANGUAGE PATHOLOGY**

SPEECH PERCEPTION

Instruments for assessment of auditory hallucinations. Frederick JA, et al. **Arch Psychiatr Nurs** 1998 Oct; 12(5):255–63 (24 ref.)
Narrowing the distance to language: one step at a time [see comments] Jusczyk PW. **J Commun Disord** 1999 Jul–Aug; 32(4):207–22 (60 ref.) Comment in: J Commun Disord 1999 Jul–Aug;32(4):247–50.
The case for early identification of hearing loss in children. Auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Sininger YS, et al. **Pediatr Clin North Am** 1999 Feb;46(1):1–14 (62 ref.)
Connectionist modeling of speech perception. Protopapas A. **Psychol Bull** 1999 Jul;125(4):410–36 (145 ref.)

PHYSIOLOGY

Auditory hallucinations: phenomenology, neuropsychology and neuroimaging update. David AS.
Acta Psychiatr Scand Suppl 1999;395:95–104 (112 ref.)
Influences on infant speech processing: toward a new synthesis. Werker JF, et al. **Annu Rev Psychol** 1999; 50:509–35 (126 ref.)
Sentence processing in Parkinson's disease. Grossman M.
Brain Cogn 1999 Jul;40(2):387–413 (92 ref.)
Acoustic-phonetic approach toward understanding neural processes and speech perception. Koch DB, et al.
J Am Acad Audiol 1999 Jun;10(6):304–18 (96 ref.)
Auditory gap detection, perceptual channels, and temporal resolution in speech perception. Phillips DP.
J Am Acad Audiol 1999 Jun;10(6):343–54 (72 ref.)
Rate of forgetting in amnesia: I. Recall and recognition of prose. Isaac CL, et al. **J Exp Psychol Learn Mem Cogn** 1999 Jul;25(4):942–62 (75 ref.)
Functional anatomy of dominance for speech comprehension in left handers vs right handers. Tzourio N, et al.
Neuroimage 1998 Jul;8(1):1–16 (100 ref.)
Speechreading: advances in understanding its cortical bases and implications for deafness and speech rehabilitation. Campbell R. **Scand Audiol Suppl** 1998;49:80–6 (31 ref.)
[Auditory speech-evoked cerebral cortex potentials in patients with stuttering syndromes] Rosanowski F, et al.
Laryngorhinootologie 1998 Dec;77(12):709–14 (29 ref.) (Eng. Abstr.) **(Ger)**

SPEECH PRODUCTION MEASUREMENT

METHODS

Acoustic studies of dysarthric speech: methods, progress, and potential. Kent RD, et al. **J Commun Disord** 1999 May–Jun; 32(3):141–80, 183–6; quiz 181–3, 187–9 (140 ref.)

SPEECH RECEPTION THRESHOLD TEST

METHODS

Speech audiometry in noise–exposed workers: the SRT–PTA relationship revisited. Picard M, et al. **Audiology** 1999 Jan–Feb;38(1):30–43 (106 ref.)

SPEECH SOUNDS see **PHONETICS**

SPEECH SYNTHESIZERS see **COMMUNICATION AIDS FOR DISABLED**

SPEECH THERAPY

see related
VOICE TRAINING

Treatment for aphasia following stroke: evidence for effectiveness. Greener J, et al.
Int J Lang Commun Disord 1998;33 Suppl:158–61 (13 ref.)

METHODS

A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. Carding PN, et al. **J Voice** 1999 Mar;13(1):72–104 (77 ref.)

STANDARDS

Issues to consider in the evaluation of speech and language therapy for preschool children. Roulstone S, et al.
Child Care Health Dev 1999 Mar;25(2):141–55 (31 ref.)

SPEECHREADING see **LIPREADING**

SPERM see **SPERMATOZOA**

SPERM CAPACITATION

PHYSIOLOGY

Mammalian sperm chemotaxis and its association with capacitation. Eisenbach M. **Dev Genet** 1999;25(2):87–94 (58 ref.)
An update on human fertilization. De Jonge CJ.
Semin Reprod Endocrinol 1998;16(3):209–17 (84 ref.)

SPERM COUNT

see related
OLIGOSPERMIA

Declining sperm counts in the United States? A critical review. Saidi JA, et al. **J Urol** 1999 Feb;161(2):460–2 (7 ref.)
Are sperm counts really falling? de Kretser DM.
Reprod Fertil Dev 1998;10(1):93–5 (33 ref.)
[The spermogram and the exigencies of quality] Clavert A, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):334–6 (19 ref.) **(Fre)**
[Is today's man really less fertile?] Marmor D, et al.
Presse Med 1998 Oct 3;27(29):1484–90 (59 ref.) (Eng. Abstr.) **(Fre)**
[Analysis of decline in seminal fluid in the Italian population during the past 15 years] Bilotta P, et al.
Minerva Ginecol 1999 Jun;51(6):223–31 (53 ref.) (Eng. Abstr.) **(Ita)**
[Decrease in sperm count of human semen] Omura M.
Fukuoka Igaku Zasshi 1998 Jul;89(7):201–6 (27 ref.) **(Jpn)**

SPERM HEAD

METABOLISM

FISH on sperm heads allows the analysis of chromosome segregation and interchromosomal effects in carriers of structural rearrangements: results in a translocation carrier, t(5;8)(q33;q13). Blanco J, et al. **Cytogenet Cell Genet** 1998; 83(3-4):275-80 (47 ref.)

SPERM MATURATION

PHYSIOLOGY

Contribution of epididymal factors to sperm maturation and storage. Moore HD. **Andrologia** 1998 Aug-Sep; 30(4-5):233-9 (63 ref.)

Assisted reproduction for testicular failure: management of germ cell maturation arrest. Tesarik J, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):283-8 (48 ref.)

SPERM MOTILITY

Hyperactivated motility of human spermatozoa: a review of physiological function and application in assisted reproduction. Kay VJ, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):776-86 (128 ref.)

PHYSIOLOGY

[The movement of the human spermatozoon] Jouannet P, et al. **Bull Acad Natl Med** 1998;182(5):1025-34; discussion 1034-6 (25 ref.) (Eng. Abstr.) **(Fre)**

SPERM NUMBER see **SPERM COUNT**

SPERM-OVUM INTERACTIONS

Mammalian fertilization misread? Sperm penetration of the eutherian zona pellucida is unlikely to be a lytic event. Bedford JM. **Biol Reprod** 1998 Dec;59(6):1275-87 (149 ref.)

Genetic risk in natural and medically assisted procreation. Koulischer L, et al. **Early Pregnancy** 1997 Sep;3(3):164-71 (41 ref.)

Sperm disintegrins, egg integrins, and other cell adhesion molecules of mammalian gamete plasma membrane interactions. Evans JP. **Front Biosci** 1999 Jan 15;4:D114-31 (147 ref.)

Carbohydrate-based interactions on the route of a spermatozoon to fertilization. Töpfer-Petersen E. **Hum Reprod Update** 1999 Jul-Aug;5(4):314-29 (129 ref.)

Sperm chemotaxis. Eisenbach M. **Rev Reprod** 1999 Jan; 4(1):56-66 (77 ref.)

IMMUNOLOGY

Molecular basis of sperm-egg interaction and the prospects for immunocontraception. Kerr LE, et al. **J Reprod Immunol** 1998 Nov;40(2):103-18 (87 ref.)

PHYSIOLOGY

Protein-carbohydrate interactions during fertilization. Sinowatz F, et al. **Acta Anat (Basel)** 1998;161(1-4):196-205 (92 ref.)

Molecular mechanisms of sperm-egg interactions and egg activation. Evans JP, et al. **Andrologia** 1998 Aug-Sep; 30(4-5):297-307 (68 ref.)

New aspects of sperm-zona pellucida binding. Franken DR. **Andrologia** 1998 Aug-Sep;30(4-5):263-8 (35 ref.)

Do human eggs attract spermatozoa? Eisenbach M, et al. **Bioessays** 1999 Mar;21(3):203-10 (68 ref.)

Mammalian sperm-egg recognition: does fertilin beta have a major role to play? Frayne J, et al. **Bioessays** 1999 Mar; 21(3):183-7 (20 ref.)

Early events in mammalian egg activation. Raz T, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:133-45 (93 ref.)

Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Seppälä M, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:262-9; discussion 270 (39 ref.)

The role of sperm morphology in assisted reproduction. Kruger TF, et al. **Hum Reprod Update** 1999 Mar-Apr; 5(2):172-8 (72 ref.)

Modulation of integrin function inhibits HIV transmission to epithelial cells and fertilization. Davidson JB, et al. **J Reprod Immunol** 1998 Dec;41(1-2):271-90 (91 ref.)

Investigations into the molecular basis of human sperm-egg interactions: what's next? [comment] Benoff S. **Mol Hum Reprod** 1998 Oct;4(10):925-8 (85 ref.) Comment on: Mol Hum Reprod 1998 Jun;4(6):523-4. Comment on: Mol Hum Reprod 1998 Jun;4(6):524-5.

Sperm conceive cues in surprising ways. Gurwitz D. **Mol Med Today** 1999 Jan;5(1):8 (3 ref.)

SPERM PENETRATION see **SPERM-OVUM INTERACTIONS**

SPERM PRESERVATION see **SEMEN PRESERVATION**

SPERM WHALE see **WHALES**

SPERM WHALES see **WHALES**

SPERMATIC CORD

[Liposarcoma of the spermatic cord: a report of a new case and a review of the literature] Soler Soler JL, et al. **Actas Urol Esp** 1999 May;23(5):447-54 (38 ref.) (Eng. Abstr.) **(Spa)**

SPERMATIC CORD TORSION

Diagnosis and treatment of the acute scrotum. Galejs LE. **Am Fam Physician** 1999 Feb 15;59(4):817-24 (15 ref.)

DIAGNOSIS

Assessment of acute scrotal symptoms and findings. A clinician's dilemma. Hawtrey CE. **Urol Clin North Am** 1998 Nov;25(4):715-23, x (45 ref.)

EMBRYOLOGY

Fusional anomalies of the testis and epididymis. Merksz M. **Acta Chir Hung** 1998;37(3-4):153-70 (56 ref.)

SURGERY

Neonatal testicular torsion. Driver CP, et al. **Br J Urol** 1998 Dec;82(6):855-8 (47 ref.)

ULTRASONOGRAPHY

Clinical and imaging features of testicular torsion: role of ultrasound. Sidhu PS. **Clin Radiol** 1999 Jun;54(6):343-52 (104 ref.)

SPERMATIDS

Spermatid injection: reconsidering spermatid injection. Prapas Y, et al. **Hum Reprod** 1999 Sep;14(9):2186-8 (36 ref.)

Is there a future for spermatid injections? Vanderzwalmen P, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:71-84 (48 ref.)

Can we justify spermatid microinjection for severe male factor infertility? Aslam I, et al. **Hum Reprod Update** 1998 May-Jun;4(3):213-22 (93 ref.)

Micro- and macro-consequences of ooplasmic injections of early haploid male gametes. Sofikitis N, et al. **Hum Reprod Update** 1998 May-Jun;4(3):197-212 (87 ref.)

PHYSIOLOGY

Transcriptional and translational regulation of gene expression in haploid spermatids. Steger K. **Anat Embryol (Berl)** 1999 Jun;199(6):471-87 (174 ref.)

Round spermatid transfer and embryo development. Sasagawa I, et al. **Arch Androl** 1998 Nov-Dec;41(3):151-7 (32 ref.)

Spermatids as gametes: indications and limitations. Tesarik J, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:89-107; discussion 108-11 (84 ref.)

SPERMATOBLASTS see **SPERMATIDS**

SPERMATOCYTES

see related
SPERM MATURATION

Micromanipulation of chromosomes and spindles in insect spermatocytes. Zhang D, et al. **Methods Cell Biol** 1999; 61:209-18 (18 ref.)

SPERMATOCYTOGENESIS see **SPERMATOGENESIS**

SPERMATOGENESIS

Protective mechanisms in germ cells: stress proteins in spermatogenesis. Dix DJ, et al. **Adv Exp Med Biol** 1998; 444:137-43; discussion 143-4 (28 ref.)

Spermatogonial stem cells. de Rooij DG, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):694-701 (67 ref.)

The effect of industrial and agricultural pollution on human spermatogenesis. Spira A, et al. **Hum Reprod** 1998 Aug; 13(8):2041-2 (17 ref.)

Stem cells in the testis. de Rooij DG. **Int J Exp Pathol** 1998 Apr;79(2):67-80 (97 ref.)

Regulating the balance between differentiation and apoptosis: role of CREM in the male germ cells. Sassone-Corsi P. **J Mol Med** 1998 Nov-Dec;76(12):811-7 (34 ref.)

GENETICS

Advances in Y chromosome mapping. Yen PH. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):275-81 (71 ref.)

Mammalian spermatogenesis investigated by genetic engineering. Escalier D. **Histol Histopathol** 1999 Jul; 14(3):945-58 (83 ref.)

Genetic contribution to male infertility. Chandley AC. **Hum Reprod** 1998 Jun;13 Suppl 3:76-83; discussion 84-8 (43 ref.)

Developmental and genetic disorders in spermatogenesis. Diemer T, et al. **Hum Reprod Update** 1999 Mar-Apr; 5(2):120-40 (154 ref.)

Expression of mitochondrial marker proteins during spermatogenesis. Meinhardt A, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):108-19 (116 ref.)

Y bind RNA for spermatogenesis? Ruggiu M, et al. **Int J Androl** 1999 Feb;22(1):19-27 (73 ref.)

Gene expression in the epididymis. Kirchhoff C. **Int Rev Cytol** 1999;188:133-202 (311 ref.)

The role of transcriptional control during spermatogenesis. Lele K, et al. **J Androl** 1998 Nov-Dec;19(6):639-49 (90 ref.)

Knockout mouse model and gametogenic failure. Grootegoed JA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1-2):161-6 (45 ref.)

Genetic disorders and spermatogenesis. McLachlan RI, et al. **Reprod Fertil Dev** 1998;10(1):97-104 (52 ref.)

Y chromosome and male infertility. Cooke HJ. **Rev Reprod** 1999 Jan;4(1):5-10 (40 ref.)

Hormonal and genetic control of germ cell apoptosis in the testis. Sinha Hikim AP, et al. **Rev Reprod** 1999 Jan; 4(1):38-47 (57 ref.)

Post-transcriptional control of gene expression during spermatogenesis. Braun RE. **Semin Cell Dev Biol** 1998 Aug; 9(4):483-9 (50 ref.)

Regulation of gene expression during spermatogenesis [see comments] Eddy EM. **Semin Cell Dev Biol** 1998 Aug; 9(4):451-7 (40 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

Genetic control of cell proliferation and differentiation in Drosophila spermatogenesis [see comments] Fuller MT. **Semin Cell Dev Biol** 1998 Aug;9(4):433-44 (63 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

Spermatogenesis as a model system for developmental analysis of regulatory mechanisms associated with tissue-specific gene expression [see comments] McCarrey JR. **Semin Cell Dev Biol** 1998 Aug;9(4):459-66 (28 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

CREM: a master-switch governing male germ cells differentiation and apoptosis. Sassone-Corsi P. **Semin Cell Dev Biol** 1998 Aug;9(4):475-82 (28 ref.)

[Genetic control of spermatogenesis: Y chromosome and male infertility] Krausz C, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):309-17 (50 ref.) **(Fre)**

PHYSIOLOGY

Lanosterol 14alpha-demethylase (CYP51) and spermatogenesis. Rozman D, et al. **Drug Metab Dispos** 1998 Dec;26(12):1199-201 (11 ref.)

What are the germ cell phenotypes from infertile men telling us about spermatogenesis? Escalier D. **Histol Histopathol** 1999 Jul;14(3):959-71 (113 ref.)

Recent biochemical approaches to post-testicular, epididymal contraception. Cooper TG, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):141-52 (117 ref.)

A matter of death and life: the significance of germ cell death during spermatogenesis. Blanco-Rodriguez J. **Int J Androl** 1998 Oct;21(5):236-48 (138 ref.)

The Parkes Lecture. Heat and the testis. Setchell BP. **J Reprod Fertil** 1998 Nov;114(2):179-94 (258 ref.)

The ubiquitin system in gametogenesis. Baarends WM, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):5-16 (120 ref.)

Role of heat shock protein HSP70-2 in spermatogenesis. Eddy EM. **Rev Reprod** 1999 Jan;4(1):23-30 (62 ref.)

Androgen receptor transactivation domain and control of spermatogenesis. Yong EL, et al. **Rev Reprod** 1998 Sep; 3(3):141-4 (21 ref.)

The role of Y-encoded genes in mammalian spermatogenesis [see comments] Burgoyne PS. **Semin Cell Dev Biol** 1998 Aug;9(4):423-32 (56 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

Dynamics of meiotic prophase I during spermatogenesis: from pairing to division [see comments] Cobb J, et al. **Semin Cell Dev Biol** 1998 Aug;9(4):445-50 (31 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

The central role of Sertoli cells in spermatogenesis [see comments] Griswold MD. **Semin Cell Dev Biol** 1998 Aug; 9(4):411-6 (41 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

Spermatogenesis as a model system for developmental analysis of regulatory mechanisms associated with tissue-specific gene expression [see comments] McCarrey JR. **Semin Cell Dev Biol** 1998 Aug;9(4):459-66 (28 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

CREM: a master-switch governing male germ cells differentiation and apoptosis. Sassone-Corsi P. **Semin Cell Dev Biol** 1998 Aug;9(4):475-82 (28 ref.)

Spermatogenesis: its regulation by testosterone and FSH [see comments] Zirkin BR. **Semin Cell Dev Biol** 1998 Aug; 9(4):417-21 (39 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

Spermatogenesis and spermatogenic control: a state of the art. Verhoeven G. **Verh K Acad Geneeskd Belg** 1999; 61(3):417-32 (35 ref.)

[Apoptosis in normal and pathological spermatogenesis] Angelopoulou R, et al. **Contracept Fertil Sex** 1999 Feb; 27(2):99-106 (86 ref.) **(Fre)**

[Spermatogenesis in developmental age] De Sanctis V, et al. **Minerva Pediatr** 1998 Jun;50(6):269-74 (17 ref.) **(Ita)**

SPERMATOGONIA

TRANSPLANTATION

Spermatogonial stem cell transplantation, cryopreservation and culture [see comments] Brinster RL, et al. **Semin Cell Dev Biol** 1998 Aug;9(4):401-9 (33 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

SPERMATOPHORES

SPERMATOPHORES see **SPERMATOGONIA**

SPERMATOZOA

see related

OLIGOSPERMIA

Cryopreservation of non-human primate sperm: priorities for future research. Morrell JM, et al. **Anim Reprod Sci** 1998 Oct;53(1-4):43-63 (66 ref.)

Reprogramming the male gamete genome: a window to successful gene therapy. Krawetz SA, et al. **Gene** 1999 Jun 24;234(1):1-9 (70 ref.)

Testicular sperm extraction and intracytoplasmic sperm injection. Devroey P. **Hum Reprod** 1998 Aug;13(8):2045-6 (14 ref.)

Clinical application of new micromanipulative technologies to treat the male. Devroey P. **Hum Reprod** 1998 Jun;13 Suppl 3:112-22; discussion 123-6 (44 ref.)

Expression of mitochondrial marker proteins during spermatogenesis. Meinhardt A, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):108-19 (116 ref.)

Structure of the avian oviduct with emphasis on sperm storage in poultry. Bakst MR. **J Exp Zool** 1998 Nov-Dec 1;282(4-5):618-26 (29 ref.)

Oviductal sperm storage as a reproductive tactic of turtles. Gist DH, et al. **J Exp Zool** 1998 Nov-Dec 1; 282(4-5):526-34 (48 ref.)

Sperm/DNA interaction: integration of foreign DNA sequences in the mouse sperm genome. Magnano AR, et al. **J Reprod Immunol** 1998 Dec;41(1-2):187-96 (23 ref.)

ABNORMALITIES

Teratozoospermia and its effect on male fertility potential. Szczygiel M, et al. **Andrologia** 1999 Mar;31(2):63-75 (107 ref.)

CHEMISTRY

Ion channels in sperm physiology. Darszon A, et al. **Physiol Rev** 1999 Apr;79(2):481-510 (327 ref.)

CYTOLOGY

A matter of death and life: the significance of germ cell death during spermatogenesis. Blanco-Rodríguez J. **Int J Androl** 1998 Oct;21(5):236-48 (138 ref.)

Germline cysts: a conserved phase of germ cell development? Pepling ME, et al. **Trends Cell Biol** 1999 Jul;9(7):257-62 (53 ref.)

DRUG EFFECTS

Effects of progesterone on human spermatozoa: clinical implications. Forti G, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):107-10 (31 ref.)

Recent biochemical approaches to post-testicular, epididymal contraception. Cooper TG, et al. **Hum Reprod Update** 1999 Mar-Apr;5(2):141-52 (117 ref.)

A re-appraisal of the post-testicular action and toxicity of chlorinated antifertility compounds. Jones AR, et al. **Int J Androl** 1999 Jun;22(3):130-8 (62 ref.)

[Exposure to pseudo-estrogens and the quality of sperm] van Kooij RJ, et al. **Ned Tijdschr Geneeskd** 1998 Nov 14; 142(46):2505-8 (20 ref.) (Eng. Abstr.) **(Dut)**

ENZYMOLOGY

Role of phospholipases during sperm acrosomal exocytosis. Roldan ER. **Front Biosci** 1998 Nov 1;3:D1109-19 (122 ref.)

[Male germ cells. A new source of estrogens in the mammalian testis] Carreau S, et al. **Ann Endocrinol (Paris)** 1998 Jul;59(2):79-92 (142 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Do autoantibodies to sperm reduce fecundity? A mini-review in historical perspective. Hjort T. **Am J Reprod Immunol** 1998 Sep;40(3):215-22 (50 ref.)

Antisperm antibodies: etiology, pathogenesis, diagnosis, and treatment. Mazumdar S, et al. **Fertil Steril** 1998 Nov; 70(5):799-810 (100 ref.)

Detection of antisperm antibodies: an argument against therapeutic nihilism. Bronson R. **Hum Reprod** 1999 Jul; 14(7):1671-3 (27 ref.)

Antisperm antibodies: detection assays for antisperm antibodies: what do they test? Helmerhorst FM, et al. **Hum Reprod** 1999 Jul;14(7):1669-71 (34 ref.)

Immunomodulators in human seminal plasma: a vital protection for spermatozoa in the presence of infection? Kelly RW. **Int J Androl** 1999 Feb;22(1):2-12 (121 ref.)

Antisperm antibody: a monkey wrench in conception/magic bullet of contraception? Kamada M, et al. **J Med Invest** 1999 Feb;46(1-2):19-28 (51 ref.)

The potential use of sperm antigens as targets for immunocontraception; past, present and future. Frayne J, et al. **J Reprod Immunol** 1999 May;43(1):1-33 (202 ref.)

HLA expression on immature and mature human germ cells. Hutter H, et al. **J Reprod Immunol** 1998 Jul;38(2):101-22 (99 ref.)

Sperm survival in the female reproductive tract: presence of immunosuppression or absence of recognition? [see comments] Barratt CL, et al. **Mol Hum Reprod** 1998 Apr; 4(4):309-13 (56 ref.) Comment in: Mol Hum Reprod 1998 Apr;4(4):313-7.

Spermatozoa and antibodies [comment] Cohen J. **Mol Hum Reprod** 1998 Apr;4(4):313-7 (32 ref.) Comment on: Mol Hum Reprod 1998 Apr;4(4):309-12.

METABOLISM

GABA and human spermatozoa: characterization and regulation of GABA transport proteins. Aanesen A. **Acta Physiol Scand Suppl** 1998 Nov;642:1-61 (243 ref.)

Molecular cloning and developmental pattern of expression of MSJ-1, a new male germ cell-specific DNAJ homologue. Berruti G, et al. **Adv Exp Med Biol** 1998; 444:145-50; discussion 151 (14 ref.)

Major histocompatibility complex expression on human, male germ cells: a review. Fiszer D, et al. **Am J Reprod Immunol** 1998 Sep;40(3):172-6 (34 ref.)

News and views of non-genomic progesterone receptors on spermatozoa. Blackmore PF. **Andrologia** 1998 Aug-Sep; 30(4-5):255-61 (69 ref.)

New aspects of sperm-zona pellucida binding. Franken DR. **Andrologia** 1998 Aug-Sep;30(4-5):263-8 (35 ref.)

Adhesion molecules and matrix proteins on human spermatozoa. Glander HJ, et al. **Andrologia** 1998 Aug-Sep; 30(4-5):289-96 (35 ref.)

Voltage dependent calcium channels in mammalian spermatozoa. Benoff S. **Front Biosci** 1998 Dec 1; 3:D1220-40 (254 ref.)

The Amoroso Lecture. The human spermatozoon--a cell in crisis? Aitken RJ. **J Reprod Fertil** 1999 Jan;115(1):1-7 (49 ref.)

Isolation of the Ca2+ releasing component(s) of mammalian sperm extracts: the search continues. Fissore RA, et al. **Mol Hum Reprod** 1999 Mar;5(3):189-92 (57 ref.)

Origin and roles of genomic methylation patterns in male germ cells [see comments] Trasler JM. **Semin Cell Dev Biol** 1998 Aug;9(4):467-74 (68 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

Nongenomic progesterone receptor on human spermatozoa: biochemical aspects and clinical implications. Baldi E, et al. **Steroids** 1999 Jan-Feb;64(1-2):143-8 (53 ref.)

PATHOLOGY

Sex chromosome aneuploidies in sperm of 47,XYY men. Morel F, et al. **Arch Androl** 1999 Jul-Aug;43(1):27-36 (28 ref.)

What are the germ cell phenotypes from infertile men telling us about spermatogenesis? Escalier D. **Histol Histopathol** 1999 Jul;14(3):959-71 (113 ref.)

[Apoptosis in normal and pathological spermatogenesis] Angelopoulou R, et al. **Contracept Fertil Sex** 1999 Feb; 27(2):99-106 (86 ref.) **(Fre)**

[The role of oxygen radicals in the physiology and pathology of human sperm] Man'kovs'ka IM, et al. **Fiziol Zh** 1998; 44(5-6):118-25 (37 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Modulation of mammalian sperm function by fertilization promoting peptide (FPP). Fraser LR. **Andrologia** 1998 Aug-Sep;30(4-5):241-7 (33 ref.)

Spermadhesins: a new protein family. Facts, hypotheses and perspectives. Töpfer-Petersen E, et al. **Andrologia** 1998 Aug-Sep;30(4-5):217-24 (65 ref.)

Effects of progesterone on human spermatozoa: clinical implications. Forti G, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):107-10 (31 ref.)

Men's bodies, men's minds: seminal emissions and sexual anxiety in the Middle Ages. Murray J. **Annu Rev Sex Res** 1997;8:1-26 (66 ref.)

Is sperm galactosyltransferase a signaling subunit of a multimeric gamete receptor? Shur BD. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):537-43 (79 ref.)

Do human eggs attract spermatozoa? Eisenbach M, et al. **Bioessays** 1999 Mar;21(3):203-10 (68 ref.)

New insights into the t-complex and control of sperm function. Fraser LR, et al. **Bioessays** 1999 Apr;21(4):304-12 (53 ref.)

Sperm cells and foreign DNA: a controversial relation. Spadafora C. **Bioessays** 1998 Nov;20(11):955-64 (52 ref.)

Wise, winsome, or weird? Mechanisms of sperm storage in female animals. Neubaum DM, et al. **Curr Top Dev Biol** 1999;41:67-97 (156 ref.)

Sperm nuclear activation during fertilization. Wright SJ. **Curr Top Dev Biol** 1999;46:133-78 (238 ref.)

Mammalian sperm chemotaxis and its association with capacitation. Eisenbach M. **Dev Genet** 1999;25(2):87-94 (58 ref.)

Genetic risk in natural and medically assisted procreation. Koulischer L, et al. **Early Pregnancy** 1997 Sep;3(3):164-71 (41 ref.)

Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implications. Baldi E, et al. **Front Biosci** 1998 Nov 1;3:D1051-9 (86 ref.)

Signaling events during male germ cell differentiation: bases and perspectives. Berruti G. **Front Biosci** 1998 Nov 1; 3:D1097-108 (117 ref.)

Role of fertilization promoting peptide (FPP) in modulating mammalian sperm function. Fraser LR. **Front Biosci** 1998 Dec 1;3:D1187-91 (34 ref.)

The role of carbohydrates in mammalian sperm-egg interactions: how important are carbohydrate epitopes? Zara J, et al. **Front Biosci** 1998 Oct 15;3:D1028-38 (96 ref.)

The modulation of sperm function by fertilization promoting peptide. Fraser LR. **Hum Reprod** 1998 Dec;13 Suppl 4:1-10 (32 ref.)

Role of the ionic environment and internal pH on sperm activity. Hamamah S, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:20-30 (62 ref.)

Voltage-operated Ca2+ channels and the acrosome reaction: which channels are present and what do they do? Publicover SJ, et al. **Hum Reprod** 1999 Apr;14(4):873-9 (74 ref.)

Sperm nuclear DNA damage and altered chromatin structure: effect on fertilization and embryo development. Sakkas D, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:11-9 (39 ref.)

Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Seppälä M, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:262-9; discussion 270 (39 ref.)

Hyperactivated motility of human spermatozoa: a review of physiological function and application in assisted reproduction. Kay VJ, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):776-86 (128 ref.)

Carbohydrate-based interactions on the route of a spermatozoon to fertilization. Töpfer-Petersen E. **Hum Reprod Update** 1999 Jul-Aug;5(4):314-29 (129 ref.)

To store or mature spermatozoa? The primary role of the epididymis. Jones RC. **Int J Androl** 1999 Apr;22(2):57-67 (91 ref.)

Attributes of fertile spermatozoa: an update. De Jonge C. **J Androl** 1999 Jul-Aug;20(4):463-73 (114 ref.)

Investigations into the molecular basis of human sperm-egg interactions: what's next? [comment] Benoff S. **Mol Hum Reprod** 1998 Oct;4(10):925-8 (85 ref.) Comment on: Mol Hum Reprod 1998 Jun;4(6):523-4. Comment on: Mol Hum Reprod 1998 Jun;4(6):524-5.

Sperm-induced calcium oscillations. Soluble factor, factors or receptors? Dale B, et al. **Mol Hum Reprod** 1999 Jan; 5(1):1-4 (65 ref.)

On the search for the sperm oscillogen. Swann K, et al. **Mol Hum Reprod** 1998 Nov;4(11):1010-2 (31 ref.)

Ion channels in sperm physiology. Darszon A, et al. **Physiol Rev** 1999 Apr;79(2):481-510 (327 ref.)

Sperm chemotaxis. Eisenbach M. **Rev Reprod** 1999 Jan; 4(1):56-66 (77 ref.)

Fertilization promoting peptide: an important regulator of sperm function in vivo? Fraser LR. **Rev Reprod** 1998 Sep; 3(3):151-4 (32 ref.)

Origin of DNA damage in ejaculated human spermatozoa. Sakkas D, et al. **Rev Reprod** 1999 Jan;4(1):31-7 (59 ref.)

Hormonal and genetic control of germ cell apoptosis in the testis. Sinha Hikim AP, et al. **Rev Reprod** 1999 Jan; 4(1):38-47 (57 ref.)

Oxidation and the spermatozoa. Kim JG, et al. **Semin Reprod Endocrinol** 1998;16(4):235-9 (43 ref.)

Extragenomic actions of progesterone in human sperm and progesterone metabolites in human platelets. Blackmore PF. **Steroids** 1999 Jan-Feb;64(1-2):149-56 (71 ref.)

[Computer-assisted analysis of sperm morphology in veterinary medicine] Boersma A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Mar;112(3):81-5 (50 ref.) (Eng. Abstr.) **(Ger)**

[In vitro assessment of semen for the prediction of fertility] Waberski D, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):1-7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Spermatogenesis in developmental age] De Sanctis V, et al. **Minerva Pediatr** 1998 Jun;50(6):269-74 (17 ref.) **(Ita)**

[The role of oxygen radicals in the physiology and pathology of human sperm] Man'kovs'ka IM, et al. **Fiziol Zh** 1998; 44(5-6):118-25 (37 ref.) (Eng. Abstr.) **(Ukr)**

TRANSPLANTATION

Prospects and problems for germ cell transplantation in the male. Schlatt S. **Int J Androl** 1999 Feb;22(1):13-8 (27 ref.)

ULTRASTRUCTURE

Sperm nuclear DNA damage and altered chromatin structure: effect on fertilization and embryo development. Sakkas D, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:11-9 (39 ref.)

The role of sperm morphology in assisted reproduction. Kruger TF, et al. **Hum Reprod Update** 1999 Mar-Apr; 5(2):172-8 (72 ref.)

The glycocalyx of the sperm surface. Schröter S, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):302-13 (115 ref.)

Ultrastructural aspects of mammalian fertilization: new discoveries and inspirations from the work of Daniel Szöllösi. Sutovsky P, et al. **Reprod Nutr Dev** 1998 Nov-Dec;38(6):629-41 (105 ref.)

VIROLOGY

HIV and germinal cells: how close an association? Alexander NJ. **J Reprod Immunol** 1998 Dec;41(1-2):17-26 (62 ref.)

The debate on the presence of HIV-1 in human gametes. Baccetti B, et al. **J Reprod Immunol** 1998 Dec;41(1-2):41-67 (48 ref.)

Microscopic evidence against HIV-1 infection of germ cells or attachment to sperm. Pudney J, et al. **J Reprod Immunol** 1998 Dec;41(1-2):105-25 (29 ref.)

The case against an association between HIV-1 and sperm:

molecular evidence. Quayle AJ, et al.
J Reprod Immunol 1998 Dec;41(1-2):127-36 (20 ref.)
Sperm as infection-potentiating cofactors in HIV transmission. Scofield VL. **J Reprod Immunol** 1998 Dec; 41(1-2):359-72 (58 ref.)

SPERMIDINE

ANALOGS & DERIVATIVES

The Achilles' heel of trypanosomatids: trypanothione-mediated hydroperoxide metabolism. Flohé L. **Biofactors** 1998;8(1-2):87-91 (20 ref.)
Endogenous glutathione conjugates: occurrence and biological functions. Wang W, et al. **Pharmacol Rev** 1998 Sep;50(3):335-56 (204 ref.)

SPERMINE

ANALOGS & DERIVATIVES

Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. Kramer DL, et al. **Biochem Soc Trans** 1998 Nov; 26(4):609-14 (25 ref.)

PHYSIOLOGY

Mg-ATP binding: its modification by spermine, the relevance to cytosolic Mg2+ buffering, changes in the intracellular ionized Mg2+ concentration and the estimation of Mg2+ by 31P-NMR. Lüthi D, et al. **Exp Physiol** 1999 Mar; 84(2):231-52 (57 ref.)

SPERMIOCYTES see **SPERMATOCYTES**

SPERMIOGENESIS see **SPERMATOGENESIS**

SPHAEROPHORUS INFECTIONS see **FUSOBACTERIUM INFECTIONS**

SPHAEROPHORUS NECROPHORUS see **FUSOBACTERIUM NECROPHORUM**

SPHAEROTILUS see **GRAM-NEGATIVE AEROBIC BACTERIA**

SPHAGNUM see **MOSSES**

SPHENOID BONE

Primary spheno-orbital angiosarcoma: case report and review of the literature. Lopes M, et al. **Neurosurgery** 1999 Feb;44(2):405-7; discussion 407-8 (39 ref.)
Long-term survival of a patient with a giant-cell tumor of the sphenoid body: a case report. Pau A, et al. **Tumori** 1999 Mar-Apr;85(2):137-9 (28 ref.)

PATHOLOGY

Juxtaorbital en plaque meningiomas. Report of four cases and review of literature. Charbel FT, et al.
Radiol Clin North Am 1999 Jan;37(1):89-100, x (59 ref.)
[Spheno-ethmoidal rhinoscleroma. Report of a case and review of the literature] Evrard I, et al.
Ann Otolaryngol Chir Cervicofac 1998 May;115(2):85-8 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Pictorial review: radiology of the sphenoid bone. Chong VF, et al. **Clin Radiol** 1998 Dec;53(12):882-93 (26 ref.)

SPHENOID SINUS

RADIOGRAPHY

Squamous cell carcinoma of the sinonasal cavities. Hermans R, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):150-61 (12 ref.)

SURGERY

A combined transorbital-transclinoid and transsylvian approach to carotid-ophthalmic aneurysms without retraction of the brain. Dolenc VV.
Acta Neurochir Suppl (Wien) 1999;72:89-97 (97 ref.)
Neurosurgical aspects of sphenoid sinus mucocele. Iqbal J, et al. **Br J Neurosurg** 1998 Dec;12(6):527-30 (23 ref.)
Olfactory groove meningioma with paranasal sinus and nasal cavity extension: removal by combined subfrontal and nasal approach. Maiuri F, et al. **J Craniomaxillofac Surg** 1998 Oct;26(5):314-7 (21 ref.)
Use of the superior meatus and superior turbinate in the endoscopic approach to the sphenoid sinus. Bolger WE, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):308-13 (13 ref.)

SPHENOID SINUSITIS

[Acute and chronic sphenoid sinusitis. Review of the literature] Erminy M, et al.
Ann Otolaryngol Chir Cervicofac 1998 Jun;115(3):106-16; quiz 117 (73 ref.) (Eng. Abstr.) **(Fre)**
[Sphenoid sinusitis] Takayama M, et al.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):298-9 (3 ref.) **(Jpn)**

SPHEROCYTOSIS, HEREDITARY

see related
ANEMIA, SIDEROBLASTIC

[Hereditary membrane-deficient hemolytic anemias] Shamov IA. **Klin Med (Mosk)** 1998;76(9):63-7 (0 ref.) **(Rus)**

GENETICS

Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis. Gallagher PG, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):539-43 (48 ref.)

SPHEROIDS

PATHOLOGY

Multicellular spheroids as an in vitro tumor model. Hamilton G. **Cancer Lett** 1998 Sep 11;131(1):29-34 (40 ref.)
Three-dimensional spheroid model in tumor biology. Santini MT, et al. **Pathobiology** 1999 May-Jun;67(3):148-57 (63 ref.)

RADIATION EFFECTS

Multicellular tumour spheroids in radiation biology. Santini MT, et al. **Int J Radiat Biol** 1999 Jul;75(7):787-99 (51 ref.)

SPHINCTEROTOMY, ENDOSCOPIC

Early ERCP is an essential part of the management of all cases of acute pancreatitis. Gupta R, et al.
Ann R Coll Surg Engl 1999 Jan;81(1):46-50 (23 ref.)
Therapeutic biliary endoscopy. Choudari CP, et al.
Endoscopy 1999 Jan;31(1):80-7 (52 ref.)
Endoscopic papillotomy: surgery should not be forgotten. Feussner H. **Endoscopy** 1998 Nov;30(9):A228-30 (27 ref.)
The role of ERCP and sphincterotomy in acute biliary pancreatitis. Fölsch UR. **Endoscopy** 1998 Nov;30(9):A253-5 (13 ref.)
Long-term sequelae of endoscopic papillotomy. Frimberger E. **Endoscopy** 1998 Nov;30(9):A221-7 (71 ref.)
The prediction of common bile duct stones using a neural network. Golub R, et al. **J Am Coll Surg** 1998 Dec; 187(6):584-90 (64 ref.)
Endoscopic management of choledocholithiasis. Soetikno RM, et al. **J Clin Gastroenterol** 1998 Dec;27(4):296-305 (35 ref.)
Endoscopic management of choledocholithiasis: to cut, stretch or relax? Misra SP, et al.
J Gastroenterol Hepatol 1998 Dec;13(12):1180-2 (23 ref.)
[Symptomatic common bile duct lithiasis: endoscopic treatment or surgical treatment?] Hay JM.
J Chir (Paris) 1998 Feb;135(1):4-9 (17 ref.) (Eng. Abstr.) **(Fre)**
[Successful endoscopic accessory sphincterotomy for pancreas divisum with a pancreatic stone] Sasada Y, et al.
Nippon Shokakibyo Gakkai Zasshi 1998 Dec;95(12):1387-91 (15 ref.) **(Jpn)**

ADVERSE EFFECTS

Complications of endoscopic sphincterotomy. Freeman ML.
Endoscopy 1998 Nov;30(9):A216-20 (36 ref.)
Endoscopic sphincterotomy for acute pancreatitis: arguments in favour. Uomo G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):557-61 (58 ref.)

CONTRAINDICATIONS

Endoscopic sphincterotomy for acute pancreatitis: arguments against. Nitsche R, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):562-5 (9 ref.)

ECONOMICS

Cost-effectiveness of endoscopic sphincterotomy. Costamagna G, et al. **Endoscopy** 1998 Nov;30(9):A212-5 (35 ref.)

METHODS

To what extent is surgery superior to endoscopic therapy in the management of chronic pancreatitis? Bassi C, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):571-9 (35 ref.)
Endoscopic treatment in chronic pancreatitis. Laugier R, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):566-70 (46 ref.)
Endoscopic sphincterotomy for acute pancreatitis: arguments against. Nitsche R, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):562-5 (9 ref.)
Endoscopic sphincterotomy for acute pancreatitis: arguments in favour. Uomo G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):557-61 (58 ref.)

SPHINGOGLYCOLIPIDS see **GLYCOSPHINGOLIPIDS**

SPHINGOLIPIDS

see related
SPHINGOSINE

ANTAGONISTS & INHIBITORS

Fumonisins and human health. Nair MG.
Ann Trop Paediatr 1998 Sep;18 Suppl:S47-52 (41 ref.)

BIOSYNTHESIS

Yeast sphingolipids. Dickson RC, et al.
Biochim Biophys Acta 1999 Jan 6;1426(2):347-57 (99 ref.)
[Biosynthesis and intracellular trafficking of sphingolipids in mammalian cells] Hanada K, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1200-6 (43 ref.) **(Jpn)**

CHEMISTRY

On the character and functions of sphingolipids. Karlsson KA. **Acta Biochim Pol** 1998;45(2):429-38 (25 ref.)
Use of sphingolipid analogs: benefits and risks. Ghidoni R, et al. **Biochim Biophys Acta** 1999 Jul 9;1439(1):17-39 (285 ref.)
The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Rietveld A, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):467-79 (143 ref.)

METABOLISM

On the character and functions of sphingolipids. Karlsson KA. **Acta Biochim Pol** 1998;45(2):429-38 (25 ref.)
Sphingolipid functions in Saccharomyces cerevisiae: comparison to mammals. Dickson RC.
Annu Rev Biochem 1998;67:27-48 (138 ref.)
Metabolism and selected functions of sphingolipids in the yeast Saccharomyces cerevisiae. Dickson RC, et al.
Biochim Biophys Acta 1999 Jun 10;1438(3):305-21 (125 ref.)
Sphingolipid metabolism in the regulation of bioactive molecules. Luberto C, et al. **Lipids** 1999;34 Suppl:S5-11 (62 ref.)
[Sphingolipids and cancer] Diatlovitskaia EV.
Bioorg Khim 1998 Oct;24(10):723-30 (115 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Futerman AH.
Acta Biochim Pol 1998;45(2):469-78 (33 ref.)
Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function. Ohanian J, et al. **Acta Physiol Scand** 1998 Dec; 164(4):533-48 (138 ref.)
Sphingolipids in atherosclerosis and vascular biology. Chatterjee S. **Arterioscler Thromb Vasc Biol** 1998 Oct; 18(10):1523-33 (101 ref.)
Sphingolipids and cell signalling. Fredman P.
J Inherit Metab Dis 1998 Aug;21(5):472-80 (38 ref.)
Sphingolipids in food and the emerging importance of sphingolipids to nutrition. Vesper H, et al. **J Nutr** 1999 Jul;129(7):1239-50 (181 ref.)
[Glycosphingolipid microdomains/caveolae and signal transduction] Kasahara K, et al.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2522-30 (46 ref.) **(Jpn)**

SPHINGOMYELIN CHOLINEPHOSPHOHYDROLASE see **SPHINGOMYELIN PHOSPHODIESTERASE**

SPHINGOMYELIN CLEAVING ENZYME see **SPHINGOMYELIN PHOSPHODIESTERASE**

SPHINGOMYELIN PHOSPHODIESTERASE

see related
NIEMANN-PICK DISEASE

METABOLISM

Signalling sphingomyelinases: which, where, how and why? Levade T, et al. **Biochim Biophys Acta** 1999 Apr 19; 1438(1):1-17 (186 ref.)
Measurement of sphingomyelin and ceramide cellular levels after sphingomyelinase-mediated sphingomyelin hydrolysis. Santana P, et al. **Methods Mol Biol** 1998; 105:217-21 (6 ref.)

PHYSIOLOGY

[Implications of "ceramide-regulating biostat system" from the discovery of "sphingomyelin cycle"] Okazaki T.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1052-8 (11 ref.) **(Jpn)**

SPHINGOMYELINASE see **SPHINGOMYELIN PHOSPHODIESTERASE**

SPHINGOMYELINS

ANALYSIS

Analysis of molecular species of cellular sphingomyelins and ceramides. Clejan S. **Methods Mol Biol** 1998;105:275-85 (11 ref.)
Sphingomyelin and ceramide mass assay. Santana P, et al. **Methods Mol Biol** 1998;105:223-31 (5 ref.)

SPHINGOMYELINS

Measurement of sphingomyelin and ceramide cellular levels after sphingomyelinase-mediated sphingomyelin hydrolysis. Santana P, et al. **Methods Mol Biol** 1998; 105:217-21 (6 ref.)

BIOSYNTHESIS

Sphingomyelin synthesis in helminths: a minireview. Bankov I, et al. **Folia Parasitol (Praha)** 1998;45(4):257-60 (19 ref.)

METABOLISM

Lipid and glycolipid mediators in CD95-induced apoptotic signaling. Malisan F, et al. **Results Probl Cell Differ** 1999; 23:65-76 (59 ref.)

Sphingomyelin hydrolysis in the gut and clinical implications in colorectal tumorigenesis and other gastrointestinal diseases. Duan RD. **Scand J Gastroenterol** 1998 Jul; 33(7):673-83 (101 ref.)

SPHINGOSINE

see related
SPHINGOLIPIDS

ANALOGS & DERIVATIVES

Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles. Igarashi Y, et al. **Acta Biochim Pol** 1998;45(2):299-309 (29 ref.)

Sphingosine-1-phosphate: extracellular mediator or intracellular second messenger? Hla T, et al. **Biochem Pharmacol** 1999 Jul 15;58(2):201-7 (61 ref.)

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. Goetzl EJ, et al. **FASEB J** 1998 Dec;12(15):1589-98 (52 ref.)

Sphingosine 1-phosphate: a prototype of a new class of second messengers. Spiegel S. **J Leukoc Biol** 1999 Mar; 65(3):341-4 (41 ref.)

[Recent development of sphingosin 1-phosphate studies as a second messenger or a second agonist in cell signaling] Igarashi Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1059-66 (43 ref.) **(Jpn)**

[Signal transduction related to sphingosine 1-phosphate] Yatomi Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2510-5 (44 ref.) **(Jpn)**

SPHYGMOMANOMETERS, CONTINUOUS see **BLOOD PRESSURE MONITORS**

SPICES

ADVERSE EFFECTS

[Occupational skin changes in persons working in contact with food spices] Swierczyńska MK, et al. **Med Pr** 1998; 49(2):187-90 (13 ref.) **(Pol)**

SPIDER BITE see **ARACHNIDISM**

SPIDER MONKEY see **CEBIDAE**

SPIDER VENOMS

CHEMISTRY

Polypeptide neurotoxins from spider venoms. Grishin E. **Eur J Biochem** 1999 Sep;264(2):276-80 (39 ref.)

PHARMACOKINETICS

Mechanisms of alpha-latrotoxin action. Henkel AW, et al. **Cell Tissue Res** 1999 May;296(2):229-33 (29 ref.)

PHARMACOLOGY

Norepinephrine exocytosis stimulated by alpha-latrotoxin requires both external and stored Ca2+ and is mediated by latrophilin, G proteins and phospholipase C. Rahman MA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1381):379-86 (46 ref.)

THERAPEUTIC USE

Sicarius (six-eyed crab spider): a homeopathic treatment for Ebola haemorrhagic fever and disseminated intravascular coagulation? Richardson-Boedler C. **Br Homeopath J** 1999 Jan;88(1):24-7 (23 ref.)

TOXICITY

Mechanisms of alpha-latrotoxin action. Henkel AW, et al. **Cell Tissue Res** 1999 May;296(2):229-33 (29 ref.)

SPIDERS

CHEMISTRY

Biology of spider silk. Vollrath F. **Int J Biol Macromol** 1999 Mar-Apr;24(2-3):81-8 (33 ref.)

ENZYMOLOGY

Biosynthesis of D-amino acid-containing peptides: exploring the role of peptide isomerases. Volkmann RA, et al. **EXS** 1998;85:87-105 (65 ref.)

SPIKE POTENTIALS see **ACTION POTENTIALS**

SPIN LABELS

see related
ELECTRON SPIN RESONANCE SPECTROSCOPY
SPIN TRAPPING

Nitroxide spin-spin interactions: applications to protein structure and dynamics. Hustedt EJ, et al. **Annu Rev Biophys Biomol Struct** 1999;28:129-53 (71 ref.)

Recent advances in site-directed spin labeling of proteins. Hubbell WL, et al. **Curr Opin Struct Biol** 1998 Oct; 8(5):649-56 (35 ref.)

Iron diethyldithiocarbamate as spin trap for nitric oxide detection. Vanin AF. **Methods Enzymol** 1999;301:269-79 (36 ref.)

Recent developments in spin labelling. Marsh D, et al. **Phys Med Biol** 1998 Jul;43(7):1977-86 (30 ref.)

The efficacy of paramagnetic ions on spin lattice relaxation time in biological systems. Akber SF. **Physiol Chem Phys Med NMR** 1998;30(2):175-84 (38 ref.)

SPIN TRAPPING

METHODS

Iron diethyldithiocarbamate as spin trap for nitric oxide detection. Vanin AF. **Methods Enzymol** 1999;301:269-79 (36 ref.)

SPINA BIFIDA see **SPINAL DYSRAPHISM**

SPINA BIFIDA OCCULTA

COMPLICATIONS

Dermal sinus and intramedullary spinal cord abscess. Report of two cases and review of the literature. Morandi X, et al. **Childs Nerv Syst** 1999 Apr;15(4):202-6; discussion 207-8 (25 ref.)

Intramedullary spinal teratoma and diastematomyelia. Case report and review of the literature. Hader WJ, et al. **Pediatr Neurosurg** 1999 Mar;30(3):140-5 (19 ref.)

ETIOLOGY

[Lumbosacral intraspinal lipomas associated or not with a tethered cord syndrome (series of 8 cases)] Sakho Y, et al. **Dakar Med** 1998;43(1):13-20 (18 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Neurenteric cyst at the craniovertebral junction: report of two cases. Fuse T, et al. **Surg Neurol** 1998 Nov;50(5):431-6 (21 ref.)

SURGERY

Recurrent intracranial neurenteric cysts. Chaynes P, et al. **Acta Neurochir (Wien)** 1998;140(9):905-11 (33 ref.)

Neurenteric cyst at the craniovertebral junction: report of two cases. Fuse T, et al. **Surg Neurol** 1998 Nov;50(5):431-6 (21 ref.)

ULTRASONOGRAPHY

Fetal neurenteric cyst causing hydrops: case report and review of the literature. Wilkinson CC, et al. **Prenat Diagn** 1999 Feb;19(2):118-21 (17 ref.)

SPINAL ACCESSORY NERVE see **ACCESSORY NERVE**

SPINAL BIFIDA, CLOSED see **SPINA BIFIDA OCCULTA**

SPINAL CANAL

Revisited: spinal angiolipoma--three additional cases. Labram EK, et al. **Br J Neurosurg** 1999 Feb;13(1):25-9 (29 ref.)

PHYSIOPATHOLOGY

A review of biomechanics of the central nervous system--Part I: spinal canal deformations resulting from changes in posture. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 May;22(4):227-34 (67 ref.)

SPINAL CORD

see related
MOTOR NEURONS

Recovery of locomotion following transplantation of monoaminergic neurons in the spinal cord of paraplegic rats. Gimenez y Ribotta M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:393-411 (73 ref.)

Mechanisms of spontaneous activity in the developing spinal cord and their relevance to locomotion. O'Donovan MJ, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:130-41 (33 ref.)

[Spinal cord stimulation in angina pectoris--what is the current situation?] Norrsell H, et al. **Lakartidningen** 1999 Mar 24;96(12):1430-2, 1435-7 (37 ref.) (Eng. Abstr.) **(Swe)**

ABNORMALITIES

MR imaging of congenital anomalies of the pediatric spine. Egelhoff JC. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):459-79 (97 ref.)

Congenital intraspinal lipomas: histological analysis of 234 cases and review of the literature. Lellouch-Tubiana A, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):346-52 (25 ref.)

Intramedullary spinal teratoma and diastematomyelia. Case report and review of the literature. Hader WJ, et al. **Pediatr Neurosurg** 1999 Mar;30(3):140-5 (19 ref.)

BLOOD SUPPLY

Multiple cerebral arteriovenous malformations (AVMs) associated with spinal AVM. Hasegawa S, et al. **Acta Neurochir (Wien)** 1999;141(3):315-9 (27 ref.)

Spinal cord monitoring with somatosensory techniques. Nuwer MR. **J Clin Neurophysiol** 1998 May;15(3):183-93 (118 ref.)

Spinal epidural hematoma caused by extradural arteriovenous malformation: a case report and review of the literature. Saeheng S, et al. **J Med Assoc Thai** 1999 May;82(5):520-7 (80 ref.)

Vascular anatomy and disorders of the lumbar spine and spinal cord. Bowen BC, et al. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):555-71 (54 ref.)

Spinal arteriovenous malformations. Detweiler PW, et al. **Neurosurg Clin N Am** 1999 Jan;10(1):89-100 (51 ref.)

Intramedullary cavernous malformations of the spinal cord. Ghogawala Z, et al. **Neurosurg Clin N Am** 1999 Jan; 10(1):101-11 (28 ref.)

Clinical syndromes, natural history, and pathophysiology of vascular lesions of the spinal cord. Grote EH, et al. **Neurosurg Clin N Am** 1999 Jan;10(1):17-45 (101 ref.)

Vascular anatomy of the spinal cord. Krauss WE. **Neurosurg Clin N Am** 1999 Jan;10(1):9-15 (8 ref.)

Vascular lesions of the spinal cord: history and classification. Marsh WR. **Neurosurg Clin N Am** 1999 Jan;10(1):1-8 (42 ref.)

Outcome from treatment for spinal arteriovenous malformation. Morgan MK. **Neurosurg Clin N Am** 1999 Jan;10(1):113-9 (26 ref.)

Endovascular treatment of spinal vascular malformations. Niimi Y, et al. **Neurosurg Clin N Am** 1999 Jan;10(1):47-71 (76 ref.)

The surgical management of spinal dural vascular malformations. Watson JC, et al. **Neurosurg Clin N Am** 1999 Jan;10(1):73-87 (47 ref.)

Familial occurrence of an arteriovenous fistula with a giant perimedullary pseudoaneurysm of the thoracic spinal cord in 2 young siblings. Khoo LT, et al. **Pediatr Neurosurg** 1998 Jun;28(6):286-92 (32 ref.)

[Angiitis of the central nervous system in systemic diseases] Biousse V, et al. **Rev Med Interne** 1998 Jun;19(6):415-26 (77 ref.) (Eng. Abstr.) **(Fre)**

[A case of aortic coarctation presenting with Brown-Séquard syndrome due to radicular artery aneurysm] Tsutsumi K, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):625-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

[An arteriovenous malformation of the cervical spinal cord with drainage into the cranial cavity combined with thymus hyperplasia] Panuntsev VS, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):28-30 (18 ref.) **(Rus)**

CHEMISTRY

NMDA receptor-mediated oscillatory properties: potential role in rhythm generation in the mammalian spinal cord. Schmidt BJ, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:189-202 (82 ref.)

Spatial distribution of NA+ and K+ channels in spinal dorsal horn neurones: role of the soma, axon and dendrites in spike generation. Safronov BV. **Prog Neurobiol** 1999 Oct; 59(3):217-41 (125 ref.)

VIP and PACAP: very important in pain? Dickinson T, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):324-9 (77 ref.)

CYTOLOGY

GABAergic control of spinal locomotor networks in the neonatal rat. Cazalets JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:168-80 (58 ref.)

How do we approach the locomotor network in the mammalian spinal cord? Hultborn H, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:70-82 (36 ref.)

Modulation of information forwarded to feline cerebellum by monoamines. Jankowska E, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:106-9 (8 ref.)

Distribution of central pattern generators for rhythmic motor outputs in the spinal cord of limbed vertebrates. Kiehn O, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:110-29 (50 ref.)

Reorganization of locomotor activity during development in the prenatal rat. Kudo N, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:306-17 (36 ref.)

Modeling of the spinal neuronal circuitry underlying locomotion in a lower vertebrate. Lansner A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:239-49 (35 ref.)

Cerebellar-induced locomotion: reticulospinal control of spinal rhythm generating mechanism in cats. Mori S, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:94-105 (40 ref.)

Development and aminergic neuromodulation of a spinal

locomotor network controlling swimming in Xenopus larvae. Sillar KT, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:318–32 (49 ref.)

Engines, accelerators, and brakes on functional spinal cord repair. Steeves JD, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:412–24 (51 ref.)

Spinal motor patterns in the turtle. Stein PS, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:142–54 (53 ref.)

Development of electrical excitability in embryonic neurons: mechanisms and roles. Spitzer NC, et al. **J Neurobiol** 1998 Oct;37(1):190–7 (86 ref.)

Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Alvares D, et al. **Pain** 1999 Aug;Suppl 6:S71–85 (193 ref.)

Vasopressin acting at V1-type receptors produces membrane depolarization in neonatal rat spinal lateral column neurons. Kolaj M, et al. **Prog Brain Res** 1998;119:275–84 (63 ref.)

DRUG EFFECTS

Mechanism of action of nonsteroidal anti-inflammatory drugs [see comments] Yaksh TL, et al. **Cancer Invest** 1998; 16(7):509–27 (154 ref.) Comment in: Cancer Invest 1998 ;16(7):538–9.

General anesthesia. Nash HA. **Curr Biol** 1999 Feb 11; 9(3):R83–5 (7 ref.)

Commentary: neurotoxicity of local anesthetics--an issue or a scapegoat? Moore DC, et al. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6):605–10 (78 ref.)

Macroscopic sites of anesthetic action: brain versus spinal cord. Antognini JF, et al. **Toxicol Lett** 1998 Nov 23; 100–101:51–8 (30 ref.)

EMBRYOLOGY

Reorganization of locomotor activity during development in the prenatal rat. Kudo N, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:306–17 (36 ref.)

Cell lineage in the developing neural tube. Kalyani AJ, et al. **Biochem Cell Biol** 1998;76(6):1051–68 (168 ref.)

Cell differentiation in the embryonic mammalian spinal cord. Mayer-Pröschel M. **J Neural Transm Suppl** 1999;55:1–8 (40 ref.)

Mechanisms of spontaneous activity in developing spinal networks. O'Donovan MJ, et al. **J Neurobiol** 1998 Oct; 37(1):131–45 (73 ref.)

Colonisation of the developing human brain and spinal cord by microglia: a review. Rezaie P, et al. **Microsc Res Tech** 1999 Jun 15;45(6):359–82 (241 ref.)

Molecular mechanisms of commissural axon pathfinding. Stoeckli ET. **Prog Brain Res** 1998;117:105–14 (641 ref.)

[How to construct a neural tube: molecular genetics of neuro-embryological development] Sarnat HB. **Rev Neurol** 1999 Jan 16–31;28(2):110–6 (48 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

The controversy about spinal neuronal nitric oxide synthase: under which conditions is it up- or downregulated? Callsen-Cencic P, et al. **Cell Tissue Res** 1999 Feb; 295(2):183–94 (104 ref.)

Abnormalities of protein kinases in neurodegenerative diseases. Wagey RT, et al. **Prog Drug Res** 1998;51:133–83 (248 ref.)

GROWTH & DEVELOPMENT

Physiological functions of GABA-induced depolarizations in the developing rat spinal cord. Ziskind-Conhaim L. **Perspect Dev Neurobiol** 1998;5(2–3):279–87 (70 ref.)

METABOLISM

Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. Esik O, et al. **J Neurol Sci** 1999 Feb 1; 163(1):39–43 (15 ref.)

PATHOLOGY

Newer sequences for spinal MR imaging: smorgasbord or succotash of acronyms? Ross JS. **AJNR Am J Neuroradiol** 1999 Mar;20(3):361–73 (82 ref.)

Spinal cord involvement in pediatric systemic lupus erythematosus: case report and literature review. al-Mayouf SM, et al. **Clin Exp Rheumatol** 1999 Jul–Aug; 17(4):505–8 (20 ref.)

Bulbo-spinal pathology in neurocardiac sudden death of adults: a pragmatic approach to a neglected problem. Rossi L. **Int J Legal Med** 1999;112(2):83–90 (53 ref.)

Use of magnetic resonance imaging in spinal trauma: indications, techniques, and utility. Slucky AV, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):134–45 (22 ref.)

Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Filippi M, et al. **Mult Scler** 1999 Aug;5(4):273–82 (86 ref.)

Are there any body fluid markers of brain atrophy in multiple sclerosis? Giovannoni G, et al. **Mult Scler** 1998 Jun; 4(3):138–42 (40 ref.)

Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Stevenson VL, et al. **Mult Scler** 1999 Aug;5(4):268–72 (49 ref.)

Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. van Waesberghe JH, et al. **Neurology** 1999;53(5 Suppl 3):S46–8 (11 ref.)

A rare case of extramedullary spinal cord germinoma. Kiyuna M, et al. **Pathol Int** 1999 Jul;49(7):633–7 (13 ref.)

Spontaneous resolution of a cervicothoracic syrinx in a child. Case report and review of the literature. Avellino AM, et al. **Pediatr Neurosurg** 1999 Jan;30(1):43–6 (24 ref.)

The applied neuropathology of human spinal cord injury. Kakulas BA. **Spinal Cord** 1999 Feb;37(2):79–88 (70 ref.)

[Polyneuropathies of pregnancy. Clinical neurophysiological, and anatomo-pathological study apropos of 38 cases collected at the Neurology Clinic of the the Fann University Hospital Center] Thiam A, et al. **Dakar Med** 1996;41(1):47–54 (20 ref.) (Eng. Abstr.) **(Fre)**

[Superficial siderosis of the central nervous system] Durieux A, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):201–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous epidural spinal hematoma: report of 2 cases and review of the literature] Horcajadas A, et al. **Neurologia** 1998 Oct;13(8):401–4 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

GABAergic control of spinal locomotor networks in the neonatal rat. Cazalets JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:168–80 (58 ref.)

How do we approach the locomotor network in the mammalian spinal cord? Hultborn H, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:70–82 (36 ref.)

Modulation of information forwarded to feline cerebellum by monoamines. Jankowska E, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:106–9 (8 ref.)

Distribution of central pattern generators for rhythmic motor outputs in the spinal cord of limbed vertebrates. Kiehn O, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:110–29 (50 ref.)

Modeling of the spinal neuronal circuitry underlying locomotion in a lower vertebrate. Lansner A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:239–49 (35 ref.)

Cerebellar-induced locomotion: reticulospinal control of spinal rhythm generating mechanism in cats. Mori S, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:94–105 (40 ref.)

NMDA receptor-mediated oscillatory properties: potential role in rhythm generation in the mammalian spinal cord. Schmidt BJ, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:189–202 (82 ref.)

Analysis and modeling of the locomotor central pattern generator as a network of coupled oscillators. Sigvardt KA, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:250–65 (63 ref.)

Development and aminergic neuromodulation of a spinal locomotor network controlling swimming in Xenopus larvae. Sillar KT, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:318–32 (49 ref.)

Engines, accelerators, and brakes on functional spinal cord repair. Steeves JD, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:412–24 (51 ref.)

Spinal motor patterns in the turtle. Stein PS, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:142–54 (53 ref.)

Tapping into spinal circuits to restore motor function. Barbeau H, et al. **Brain Res Brain Res Rev** 1999 Jul; 30(1):27–51 (203 ref.)

Branching and/or collateral projections of spinal dorsal horn neurons. Lu GW, et al. **Brain Res Brain Res Rev** 1999 Jan; 29(1):50–82 (231 ref.)

Transmitters involved in antinociception in the spinal cord. Fürst S. **Brain Res Bull** 1999 Jan 15;48(2):129–41 (97 ref.)

Neurogastroenterology--information processing from the viscera to the brain in humans. Enck P, et al. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):468–71 (28 ref.)

Muscarinic-mediated analgesia. Eisenach JC. **Life Sci** 1999; 64(6–7):549–54 (29 ref.)

Regulation of neuronal plasticity in the central nervous system by phosphorylation and dephosphorylation. Tokuda M, et al. **Mol Neurobiol** 1998 Winter;17(1–3):137–56 (131 ref.)

Corticomotoneuronal PSTH studies [editorial; comment] Mills KR. **Muscle Nerve** 1999 Mar;22(3):297–8 (13 ref.) Comment on: Muscle Nerve 1999 Mar;22(3):299–306.

Spinal cord monitoring: current state of the art. Padberg AM, et al. **Orthop Clin North Am** 1999 Jul;30(3):407–33, viii (71 ref.)

Response properties of spinal interneurons in awake, behaving primates. Fetz EE. **Pain** 1999 Aug;Suppl 6:S55–60 (37 ref.)

Physiological functions of GABA-induced depolarizations in the developing rat spinal cord. Ziskind-Conhaim L. **Perspect Dev Neurobiol** 1998;5(2–3):279–87 (70 ref.)

The postnatal development of spinal sensory processing. Fitzgerald M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7719–22 (49 ref.)

Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Thompson SW, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7714–8 (28 ref.)

Vasopressin in the locus coeruleus and dorsal pontine tegmentum affects posture and vestibulospinal reflexes. Pompeiano O. **Prog Brain Res** 1998;119:537–54 (65 ref.)

Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Wolswijk G. **Prog Brain Res** 1998;117:233–47 (82 ref.)

Brain, heal thyself. Lowenstein DH, et al. **Science** 1999 Feb 19;283(5405):1126–7 (13 ref.)

Spinal cord stimulation in chronic pain syndromes. ten Vaarwerk IA, et al. **Spinal Cord** 1998 Oct;36(10):671–82 (80 ref.)

Advances in spinal cord regeneration. Lu J, et al. **Spine** 1999 May 1;24(9):926–30 (68 ref.)

[Monitoring the neurogenic mixed evoked potentials during surgery of the spine: a good solution?] Péréon Y, et al. **Neurophysiol Clin** 1998 Sep;28(4):321–34 (64 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Regulation of expression of galanin and galanin receptors in dorsal root ganglia and spinal cord after axotomy and inflammation. Zhang X, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:402–13 (50 ref.)

Free radicals as mediators of neuronal injury. Facchinetti F, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):667–82 (126 ref.)

Regeneration in the spinal cord. Bregman BS. **Curr Opin Neurobiol** 1998 Dec;8(6):800–7 (56 ref.)

Generators of short latency human somatosensory-evoked potentials recorded over the spine and scalp. Lee EK, et al. **J Clin Neurophysiol** 1998 May;15(3):227–34 (65 ref.)

A review of biomechanics of the central nervous system--part II: spinal cord strains from postural loads. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 Jun; 22(5):322–32 (49 ref.)

A review of biomechanics of the central nervous system--Part I: spinal canal deformations resulting from changes in posture. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 May;22(4):227–34 (67 ref.)

MR imaging of cerebrospinal fluid flow and spinal cord motion in neurologic disorders of the spine. Levy LM. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):573–87 (60 ref.)

Regulation of spinal nociceptive processing: where we went when we wandered onto the path marked by the gate. Yaksh TL. **Pain** 1999 Aug;Suppl 6:S149–52 (26 ref.)

Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Mayer DJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7731–6 (47 ref.)

Supraspinal contributions to hyperalgesia. Urban MO, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7687–92 (53 ref.)

A visceral pain pathway in the dorsal column of the spinal cord. Willis WD, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7675–9 (13 ref.)

The spinal biology in humans and animals of pain states generated by persistent small afferent input. Yaksh TL, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7680–6 (80 ref.)

Spinal mechanisms of acute and persistent pain. Basbaum AI. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):59–67 (46 ref.)

[Changes in excitability of the spinal cord and dorsal column nucleus and gene expression in neuropathic pain models] Noguchi K. **Masui** 1998 Dec;47 Suppl:S218–23 (7 ref.) **(Jpn)**

RADIATION EFFECTS

Radiation myelopathy. Rampling R, et al. **Curr Opin Neurol** 1998 Dec;11(6):627–32 (69 ref.)

Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. Esik O, et al. **J Neurol Sci** 1999 Feb 1; 163(1):39–43 (15 ref.)

RADIOGRAPHY

[Spontaneous epidural spinal hematoma: report of 2 cases and review of the literature] Horcajadas A, et al. **Neurologia** 1998 Oct;13(8):401–4 (26 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Intraoperative motor evoked potentials monitoring in spinal neurosurgery. Cioni B, et al. **Arch Ital Biol** 1999 May; 137(2–3):115–26 (36 ref.)

Endoscopy of spinal cord and posterior fossa by a lumbar percutaneous approach: endoscopic anatomy in cadavers. Eguchi T, et al. **Minim Invasive Neurosurg** 1999 Jun; 42(2):74–8 (9 ref.)

Extracranial stereotactic radiosurgery: applications for the spine and beyond. Takacs I, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):257–70 (54 ref.)

ULTRASTRUCTURE

Branching and/or collateral projections of spinal dorsal horn neurons. Lu GW, et al. **Brain Res Brain Res Rev** 1999 Jan; 29(1):50–82 (231 ref.)

SPINAL CORD COMPRESSION

COMPLICATIONS

[Spontaneous epidural spinal hematoma: report of 2 cases and review of the literature] Horcajadas A, et al. **Neurologia** 1998 Oct;13(8):401–4 (26 ref.) (Eng. Abstr.) **(Spa)**

SPINAL CORD COMPRESSION

DIAGNOSIS

Cervical myelopathy due to rheumatoid arthritis. Case report and review of the literature. Keersmackers A, et al. **Acta Neurol Belg** 1998 Sep;98(3):284–8 (22 ref.)

Spinal cord monitoring with somatosensory techniques. Nuwer MR. **J Clin Neurophysiol** 1998 May;15(3):183–93 (118 ref.)

Pitfalls of bungee jumping. Case report and review of the literature. Louw D, et al. **J Neurosurg** 1998 Dec; 89(6):1040–2 (08 ref.)

[Spontaneous epidural spinal hematoma: report of 2 cases and review of the literature] Horcajadas A, et al. **Neurologia** 1998 Oct;13(8):401–4 (26 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Compressive cervical myelopathy due to calcium pyrophosphate dihydrate deposition disease: report of a case and review of the literature. Fye KH, et al. **Arch Intern Med** 1999 Jan 25;159(2):189–93 (21 ref.)

Multiple extradural arachnoid cysts as a cause of spinal cord compression in a child. Case report. Myles LM, et al. **J Neurosurg** 1999 Jul;91(1 Suppl):116–20 (22 ref.)

Cervical actinomycosis causing spinal cord compression and multisegmental root failure: case report and review of the literature. Oruçkaptan HH, et al. **Neurosurgery** 1998 Oct; 43(4):937–40 (20 ref.)

Cervical myelopathy caused by hypoplasia of the atlas: two case reports and review of the literature. Phan N, et al. **Neurosurgery** 1998 Sep;43(3):629–33 (33 ref.)

The solitary intraspinal vertebral osteochondroma. An unusual cause of compressive myelopathy: features and literature review. Khosla A, et al. **Spine** 1999 Jan 1; 24(1):77–81 (16 ref.)

Spinal cord compression caused by unusual location and extension of ossified ligamenta flava in a Caucasian male. A case report and literature review. van Oostenbrugge RJ, et al. **Spine** 1999 Mar 1;24(5):486–8 (21 ref.)

[Spinal cord compression due to tophaceous vertebral gout: a case report and literature review] Marsaudon E, et al. **Rev Med Interne** 1999 Mar;20(3):253–7 (39 ref.) (Eng. Abstr.) **(Fre)**

[Spinal cord compression secondary to epidural extramedullary hematopoiesis in thalassemia: a clinical case and review of literature] Martinez-Rodrigo MA, et al. **Rev Neurol** 1998 Dec;27(160):998–1004 (61 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Metastatic epidural spinal cord compression. Bucholtz JD. **Semin Oncol Nurs** 1999 Aug;15(3):150–9 (27 ref.)

PHYSIOPATHOLOGY

A review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury. Fehlings MG, et al. **Spine** 1998 Dec 15;23(24):2730–7 (74 ref.)

SURGERY

Expansive laminoplasty for myelopathy in ossification of the longitudinal ligament. Hirabayashi K, et al. **Clin Orthop** 1999 Feb;(359):35–48 (100 ref.)

Cervical spondylotic myelopathy. Approaches to surgical treatment. Orr RD, et al. **Clin Orthop** 1999 Feb;(359):58–66 (44 ref.)

Surgical management of cervical myelopathy. Emery SE. **Instr Course Lect** 1999;48:423–6 (21 ref.)

Multisegmental cervical spondylotic myelopathy and radiculopathy treated by multilevel oblique corpectomies without fusion. George B, et al. **Neurosurgery** 1999 Jan; 44(1):81–90 (117 ref.)

THERAPY

Management of pain and spinal cord compression in patients with advanced cancer. ACP-ASIM End-of-life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Abrahm JL. **Ann Intern Med** 1999 Jul 6;131(1):37–46 (115 ref.)

Management of patients with vertebral compression fractures. Lyles KW. **Pharmacotherapy** 1999 Jan;19(1 Pt 2):21S–24S (27 ref.)

SPINAL CORD DISEASES

COMPLICATIONS

Dermal sinus and intramedullary spinal cord abscess. Report of two cases and review of the literature. Morandi X, et al. **Childs Nerv Syst** 1999 Apr;15(4):202–6; discussion 207–8 (25 ref.)

Myelopathy secondary to spinal epidural abscess: case reports and a review. Yin KS, et al. **J Spinal Cord Med** 1998 Oct; 21(4):348–54 (32 ref.)

[A case of hereditary motor and sensory neuropathy with pyramidal tract sign, optic nerve atrophy and mental retardation] Adachi T, et al. **Rinsho Shinkeigaku** 1998 Dec; 38(12):1037–41 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Profile of non-compressive myelopathy in eastern India: a 2-year study. Das K, et al. **Acta Neurol Scand** 1999 Feb; 99(2):100–5 (28 ref.)

MR imaging of cerebrospinal fluid flow and spinal cord motion in neurologic disorders of the spine. Levy LM. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):573–87 (60 ref.)

Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Ferrari TC. **Medicine (Baltimore)** 1999 May;78(3):176–90 (104 ref.)

Idiopathic spinal cord herniation: case report and review of the literature. Marshman LA, et al. **Neurosurgery** 1999 May;44(5):1129–33 (22 ref.)

[MRI aspects of spinal cord abscesses. Report of 5 cases and review of the literature] Condette-Auliac S, et al. **J Neuroradiol** 1998 Oct;25(3):189–200 (36 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

MR appearance of an intracranial dural arteriovenous fistula leading to cervical myelopathy. Hähnel S, et al. **Neurology** 1998 Oct;51(4):1131–5 (10 ref.)

MRI of the spinal cord in myelopathy complicating vitamin B12 deficiency: two additional cases and a review of the literature. Bassi SS, et al. **Neuroradiology** 1999 Apr; 41(4):271–4 (17 ref.)

Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Urmey WF, et al. **Reg Anesth Pain Med** 1998 Nov-Dec;23(6 Suppl 2):146–51 (16 ref.)

[Radiation myelopathy] Arakawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):438–41 (15 ref.) **(Jpn)**

[Neurological disorders of vitamin B12 deficiency] Tomczykiewicz K, et al. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1473–84 (20 ref.) (Eng. Abstr.) **(Pol)**

[Myelopathy and human immunodeficiency virus infection] Lleó A, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):423–7 (86 ref.) **(Spa)**

PARASITOLOGY

Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Ferrari TC. **Medicine (Baltimore)** 1999 May;78(3):176–90 (104 ref.)

PATHOLOGY

Dermal sinus and intramedullary spinal cord abscess. Report of two cases and review of the literature. Morandi X, et al. **Childs Nerv Syst** 1999 Apr;15(4):202–6; discussion 207–8 (25 ref.)

Spinal cord lesions--pathologist point of view [editorial] Soomro IN. **JPMA J Pak Med Assoc** 1998 Sep;48(9):260–1 (12 ref.)

PHYSIOPATHOLOGY

Intramedullary abscess of the spinal cord in the antibiotic era: clinical features, microbial etiologies, trends in pathogenesis, and outcomes. Chan CT, et al. **Clin Infect Dis** 1998 Sep;27(3):619–26 (36 ref.)

RADIOGRAPHY

Interventional neuroradiology. Nakstad PH. **Acta Radiol** 1999 Jul;40(4):344–59 (148 ref.)

SURGERY

Measuring outcomes in cervical myelopathy and radiculopathy. Ludwig SC, et al. **Instr Course Lect** 1999; 48:417–21 (27 ref.)

Extracranial stereotactic radiosurgery: applications for the spine and beyond. Takacs I, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):257–70 (54 ref.)

Idiopathic spinal cord herniation: case report and review of the literature. Marshman LA, et al. **Neurosurgery** 1999 May;44(5):1129–33 (22 ref.)

SPINAL CORD INJURIES

Spinal cord trauma. Buckley DA, et al. **Nurs Clin North Am** 1999 Sep;34(3):661–87 (38 ref.)

[Neurotrophic factors and spinal cord injury. A review] Liu W, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):19–21 (26 ref.) **(Chi)**

COMPLICATIONS

Cellular and molecular causes of male infertility in spinal cord injury. Rajasekaran M, et al. **J Androl** 1999 May-Jun; 20(3):326–30 (52 ref.)

Autonomic dysreflexia. Karlsson AK. **Spinal Cord** 1999 Jun; 37(6):383–91 (85 ref.)

[Evaluation and repair of bladder function after spinal cord injuries] Liu Z, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Mar;35(3):189–91 (21 ref.) **(Chi)**

[Respiratory problems after injuries of the cervical spine] Stocker R, et al. **Schweiz Med Wochenschr** 1998 Sep 26; 128(39):1462–6 (13 ref.) (Eng. Abstr.) **(Ger)**

[Posttraumatic syringomyelia. A report of an atypical case] Bucciero A, et al. **Minerva Chir** 1998 Nov;53(11):943–6 (21 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Evaluation of the patient with spinal trauma and back pain: an evidence based approach. Petri R, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):25–39, vii–viii (28 ref.)

Use of magnetic resonance imaging in spinal trauma: indications, techniques, and utility. Slucky AV, et al. **J Am Acad Orthop Surg** 1998 May-Jun;6(3):134–45 (22 ref.)

Spinal cord monitoring with somatosensory techniques. Nuwer MR. **J Clin Neurophysiol** 1998 May;15(3):183–93 (118 ref.)

MR imaging of the spine in sports injuries. Gundry CR, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):85–103 (48 ref.)

Electrophysiological recordings in patients with spinal cord injury: significance for predicting outcome. Curt A, et al. **Spinal Cord** 1999 Mar;37(3):157–65 (58 ref.)

[Tingling in the hands] Geelen JA, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1593–7 (9 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Amar AP, et al. **Neurosurgery** 1999 May;44(5):1027–39; discussion 1039–40 (106 ref.)

ETIOLOGY

Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Amar AP, et al. **Neurosurgery** 1999 May;44(5):1027–39; discussion 1039–40 (106 ref.)

NURSING

Pregnancy in women with spinal cord injuries. Atterbury JL, et al. **Nurs Clin North Am** 1998 Dec;33(4):603–13 (52 ref.)

PATHOLOGY

Spinal cord injury in the rat. Taoka Y, et al. **Prog Neurobiol** 1998 Oct;56(3):341–58 (190 ref.)

Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Yoshimura N. **Prog Neurobiol** 1999 Apr;57(6):583–606 (123 ref.)

The applied neuropathology of human spinal cord injury. Kakulas BA. **Spinal Cord** 1999 Feb;37(2):79–88 (70 ref.)

Why does the central nervous system not regenerate after injury? Nicholls JG, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S136–41 (21 ref.)

PHYSIOPATHOLOGY

Engines, accelerators, and brakes on functional spinal cord repair. Steeves JD, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:412–24 (51 ref.)

Stepping in nonhuman primates with a complete spinal cord transection: old and new data, and implications for humans. Vilensky JA, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:528–30 (15 ref.)

Incomplete spinal cord injury: neuronal mechanisms of motor recovery and hyperreflexia. Little JW, et al. **Arch Phys Med Rehabil** 1999 May;80(5):587–99 (119 ref.)

The glial scar and central nervous system repair. Fawcett JW, et al. **Brain Res Bull** 1999 Aug;49(6):377–91 (216 ref.)

Effect of spinal cord injury on the heart and cardiovascular fitness. Phillips WT, et al. **Curr Probl Cardiol** 1998 Nov; 23(11):641–716 (246 ref.)

Semen retrieval by penile vibratory stimulation in men with spinal cord injury. Brackett NL. **Hum Reprod Update** 1999 May-Jun;5(3):216–22 (46 ref.)

In vitro central nervous system models of mechanically induced trauma: a review. Morrison B 3rd, et al. **J Neurotrauma** 1998 Nov;15(11):911–28 (137 ref.)

Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. Juurlink BH, et al. **J Spinal Cord Med** 1998 Oct;21(4):309–34 (285 ref.)

The spinal biology in humans and animals of pain states generated by persistent small afferent input. Yaksh TL, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7680–6 (80 ref.)

Pathophysiological mechanisms involved in systemic and metabolic alterations secondary to spinal cord injury. Guizar-Sahagún G, et al. **Proc West Pharmacol Soc** 1998; 41:237–40 (40 ref.)

Glutamate and its receptors in the pathophysiology of brain and spinal cord injuries. Alessandri B, et al. **Prog Brain Res** 1998;116:303–30 (180 ref.)

Spinal cord injury: bridging the lesion and the role of neurotrophic factors in repair. Houweling DA, et al. **Prog Brain Res** 1998;117:455–71 (140 ref.)

Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. Stichel CC, et al. **Prog Neurobiol** 1998 Oct;56(2):119–48 (467 ref.)

Theoretical aspects of sensory substitution and of neurotransmission-related reorganization in spinal cord injury. Bach-y-Rita P. **Spinal Cord** 1999 Jul;37(7):465–74

(81 ref.)
Central pain following spinal and supraspinal lesions. Bowsher D. **Spinal Cord** 1999 Apr;37(4):235–8 (34 ref.)
Pathophysiological mechanisms of central neuropathic pain after spinal cord injury. Eide PK. **Spinal Cord** 1998 Sep; 36(9):601–12 (93 ref.)
Spinal shock and brain death': somatic pathophysiological equivalence and implications for the integrative-unity rationale. Shewmon DA. **Spinal Cord** 1999 May; 37(5):313–24 (102 ref.)
[Methods to observe the experimental study of spinal cord injuries] Li P, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):254–6 (19 ref.) **(Chi)**

REHABILITATION

Does neurorehabilitation play a role in the recovery of walking in neurological populations? Barbeau H, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:377–92 (60 ref.)
Walking after spinal cord injury: evaluation, treatment, and functional recovery. Barbeau H, et al. **Arch Phys Med Rehabil** 1999 Feb;80(2):225–35 (153 ref.)
Predicting neurologic recovery in traumatic cervical spinal cord injury [see comments] Kirshblum SC, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1456–66 (132 ref.) Comment in: Arch Phys Med Rehabil 1999 Apr;80(4):474. Comment in: Arch Phys Med Rehabil 1999 May;80(5):607–8.
Incomplete spinal cord injury: neuronal mechanisms of motor recovery and hyperreflexia. Little JW, et al. **Arch Phys Med Rehabil** 1999 May;80(5):587–99 (119 ref.)
Biological interventions for spinal cord injury. Giménez y Ribotta M, et al. **Curr Opin Neurol** 1998 Dec;11(6):647–54 (80 ref.)
New assistive technology for passive standing. Gear AJ, et al. **J Burn Care Rehabil** 1999 Mar–Apr;20(2):164–9 (14 ref.)
Restorative treatment of persons with spinal cord injury: current trends [editorial] Ragnarsson KT. **J Rehabil Res Dev** 1998 Oct;35(4):xi–xiv (8 ref.)
Donal Munro Lecture: Functional and neurologic recovery following acute SCI. Waters RL, et al. **J Spinal Cord Med** 1998 Jul;21(3):195–9 (11 ref.)

SURGERY

Recovery of locomotion following transplantation of monoaminergic neurons in the spinal cord of paraplegic rats. Gimenez y Ribotta M, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:393–411 (73 ref.)
Surgical controversies in the management of spinal cord injury. Amar AP, et al. **J Am Coll Surg** 1999 May; 188(5):550–66 (169 ref.)
Potential repair of rat spinal cord injuries using stimulated homologous macrophages. Schwartz M, et al. **Neurosurgery** 1999 May;44(5):1041–5; discussion 1045–6 (41 ref.)
Spinal cord injury: bridging the lesion and the role of neurotrophic factors in repair. Houweling DA, et al. **Prog Brain Res** 1998;117:455–71 (140 ref.)
Spinal cord repair: from experimental models to human application. Fawcett JW. **Spinal Cord** 1998 Dec; 36(12):811–7 (22 ref.)
[Surgical management of tetraplegia [see comments] Bühren V, et al. **Unfallchirurg** 1999 Jan;102(1):2–12 (37 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1999 Jan;102(1):1. **(Ger)**

THERAPY

Does neurorehabilitation play a role in the recovery of walking in neurological populations? Barbeau H, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:377–92 (60 ref.)
ABC of intensive care: neurological support. Grant IS, et al. **BMJ** 1999 Jul 10;319(7202):110–3 (0 ref.)
Acute management of traumatic cervical spinal cord injuries. Dyson-Hhudson TA, et al. **Mt Sinai J Med** 1999 May; 66(3):170–8 (34 ref.)
A clinical overview of treatment decisions in the management of spasticity. Gormley ME Jr, et al. **Muscle Nerve Suppl** 1997;6:S14–20 (14 ref.)
Indications for prehospital spinal immobilization. National Association of EMS Physicians Standards and Clinical Practice Committee. Domeier RM. **Prehosp Emerg Care** 1999 Jul–Sep;3(3):251–3 (37 ref.)
Neurotrophin gene therapy in CNS models of trauma and degeneration. Blesch A, et al. **Prog Brain Res** 1998; 117:473–84 (116 ref.)
Quality indicators in spinal cord injury care: a Swedish collaborative project. The Swedish Spinal Cord Injury Council 1998. Levi R, et al. **Scand J Rehabil Med Suppl** 1998;38:1–80 (26 ref.)
Repairing the damaged spinal cord. McDonald JW. **Sci Am** 1999 Sep;281(3):64–73 (4 ref.)
Gait after spinal cord injury and the central pattern generator for locomotion. Pinter MM, et al. **Spinal Cord** 1999 Aug; 37(8):531–7 (40 ref.)

VETERINARY

Spinal cord injury in small animals. 1. Mechanisms of spontaneous recovery. Jeffery ND, et al. **Vet Rec** 1999 Apr 10;144(15):407–13 (81 ref.)

SPINAL CORD NEOPLASMS

Cavernous haemangiomas of the spinal cord. A review of 117 cases. Zevgaridis D, et al. **Acta Neurochir (Wien)** 1999; 141(3):237–45 (55 ref.)

COMPLICATIONS

Intramedullary spinal teratoma presenting with urinary retention: case report and review of the literature. Poeze M, et al. **Neurosurgery** 1999 Aug;45(2):379–85 (62 ref.)
Intramedullary spinal teratoma and diastematomyelia. Case report and review of the literature. Hader WJ, et al. **Pediatr Neurosurg** 1999 Mar;30(3):140–5 (19 ref.)
[A case of primary central nervous system lymphoma with the onset of impotence] Hori T, et al. **Rinsho Shinkeigaku** 1999 Feb–Mar;39(2–3):333–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Prognosis of ependymoma. Schiffer D, et al. **Childs Nerv Syst** 1998 Aug;14(8):357–61 (59 ref.)
Dumbbell lymphoma of the cervical spine in a child. Case report. Gezen F, et al. **J Neurosurg Sci** 1998 Dec; 42(4):239–44 (27 ref.)
Thoracic intramedullary schwannoma. Lee DY, et al. **J Spinal Disord** 1999 Apr;12(2):174–6 (22 ref.)
[Tingling in the hands] Geelen JA, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1593–7 (9 ref.) (Eng. Abstr.) **(Dut)**
[Diagnosis and treatment of spinal cord tumors] Seppälä M. **Duodecim** 1995;111(21):2071–7 (17 ref.) **(Fin)**
[Intramedullary spinal cord metastasis and leptomeningeal involvement in Hodgkin's disease. Case report and review of the literature] Jardin F, et al. **Rev Med Interne** 1999 Mar;20(3):267–71 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pathologic quiz case. Extrarenal rhabdoid tumor. Zhou Y, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):853–4 (9 ref.)
Pediatric intramedullary spinal cord tumors. Critical review of the literature. Nadkarni TD, et al. **Childs Nerv Syst** 1999 Jan;15(1):17–28 (75 ref.)
Oligodendroglioma of the "widespread" type in the spinal cord. Ushida T, et al. **Childs Nerv Syst** 1998 Dec; 14(12):751–5 (19 ref.)
A rare case of extramedullary spinal cord germinoma. Kiyuna M, et al. **Pathol Int** 1999 Jul;49(7):633–7 (13 ref.)
Extraneural metastasizing ependymoma of the spinal cord. Graf M, et al. **Pathol Oncol Res** 1999;5(1):56–60 (36 ref.)
Congenital intraspinal lipomas: histological analysis of 234 cases and review of the literature. Lellouch-Tubiana A, et al. **Pediatr Dev Pathol** 1999 Jul–Aug;2(4):346–52 (25 ref.)

RADIOTHERAPY

Radiation myelopathy. Rampling R, et al. **Curr Opin Neurol** 1998 Dec;11(6):627–32 (69 ref.)

THERAPY

[Diagnosis and treatment of spinal cord tumors] Seppälä M. **Duodecim** 1995;111(21):2071–7 (17 ref.) **(Fin)**

SPINAL CORD SYPHILIS see **TABES DORSALIS**

SPINAL CURVATURES

Spinal deformity in progressive neuromuscular disease. Natural history and management. Hart DA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):213–32, viii (92 ref.)

CONGENITAL

Congenital spine deformities: scoliosis, kyphosis, and lordosis. Lonstein JE. **Orthop Clin North Am** 1999 Jul;30(3):387–405, viii (38 ref.)

SPINAL DISEASES

Juvenile rheumatoid arthritis and spondyloarthropathies. Dressler F. **Curr Opin Rheumatol** 1998 Sep;10(5):468–74 (63 ref.)

CHEMICALLY INDUCED

[Corticosteroid-induced epidural lipomatosis. Efficacy of medical treatment] Lemaire M, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):459–63 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Acute anterior uveitis and spondyloarthropathies. Feltkamp TE, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):314–8 (50 ref.)
Primary hydatid disease of the spine: an unusual cause of progressive paraplegia. Case report and review of the literature. Bhojraj SY, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):216–8 (16 ref.)
Evaluation of lower back pain with bone scintigraphy and SPECT. De Maeseneer M, et al. **Radiographics** 1999 Jul–Aug;19(4):901–12; discussion 912–4 (25 ref.)
[Therapeutic approaches in chronic back pain] Hildebrandt J. **Ther Umsch** 1999 Aug;56(8):455–9 (9 ref.) (Eng. Abstr.) **(Ger)**
[Calcification of the intervertebral disks in childhood as the cause of acute torticollis] Ferrer Ferrán J, et al. **An Esp Pediatr** 1999 Jun;50(6):607–9 (9 ref.) **(Spa)**

DIAGNOSIS

Bilateral ganglion cysts: case report and review of the literature. Diamantopoulos J, et al. **Acta Neurochir (Wien)** 1999;141(7):783–4 (5 ref.)
Degenerative conditions of the spine. Current diagnostic procedures and treatment modalities. Garfin SR. **Acta Orthop Scand Suppl** 1998 Jun;281:38–46 (134 ref.)
Conditions of the spine. Stanitski CL. **Adolesc Med** 1998 Oct; 9(3):515–32, vi (17 ref.)
MR imaging changes of lumbar vertebral sarcoidosis. Fisher AJ, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):354–6 (8 ref.)
MRI findings of isolated beta-2 microglobulin amyloidosis presenting as a cervical spine mass. Case report and review of literature. Moonis G, et al. **Clin Imaging** 1999 Jan–Feb; 23(1):11–4 (12 ref.)
Spinal aspergillus osteomyelitis. Vinas FC, et al. **Clin Infect Dis** 1999 Jun;28(6):1223–9 (49 ref.)
Diagnosis and monitoring of spondyloarthropathy. Dougados M. **Compr Ther** 1998 Nov–Dec;24(11–12):590–5 (22 ref.)
Blastomycosis of the lumbar spine: case report and review of the literature, with emphasis on diagnostic laboratory tools and management. Hadjipavlou AG, et al. **Eur Spine J** 1998;7(5):416–21 (34 ref.)
Evaluation of the spine utilizing the AMA Guides to the Evaluation of Permanent Impairment, 4th edition. Haralson RH 3rd. **Instr Course Lect** 1999;48:451–61 (3 ref.)
Back pain in childhood and adolescence. Richards BS, et al. **Instr Course Lect** 1999;48:525–42 (115 ref.)
Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)
Aneurysmal bone cyst of the spine: 31 cases and the importance of the surgical approach. de Kleuver M, et al. **J Pediatr Orthop B** 1998 Oct;7(4):286–92 (19 ref.)
Spinal epidural abscess: a review of epidemiology, diagnosis, and treatment. Sampath P, et al. **J Spinal Disord** 1999 Apr; 12(2):89–93 (31 ref.)
Degenerative disc disease and back pain. Modic MT. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):481–91, viii (67 ref.)
Clinical neurophysiologic studies: which test is useful and when? Lomen-Hoerth C, et al. **Neurol Clin** 1999 Feb; 17(1):65–74 (27 ref.)
Differential diagnosis: a reasonable clinical approach. Swenson R. **Neurol Clin** 1999 Feb;17(1):43–63 (81 ref.)
MRI in primary intraspinal extradural hydatid disease: case report. Berk C, et al. **Neuroradiology** 1998 Jun;40(6):390–2 (12 ref.)
Spinal disease in neurologically symptomatic HIV-positive patients. Taber KH, et al. **Neuroradiology** 1999 May; 41(5):360–8 (53 ref.)
Management of vertebral diskitis and osteomyelitis. Khan IA, et al. **Orthopedics** 1999 Aug;22(8):758–65 (56 ref.)
MRI description of vertebral osteomyelitis, neoplasm, and compression fracture. Vaccaro AR, et al. **Orthopedics** 1999 Jan;22(1):67–73; quiz 74–5 (18 ref.)
Spinal imaging and intervention: 1998. Mink JH, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):343–80, viii (116 ref.)
Psoriatic arthritis. Gladman DD. **Rheum Dis Clin North Am** 1998 Nov;24(4):829–44, x (81 ref.)
Sclerotome distribution of melorheostosis and multicentric fibromatosis. Rhys R, et al. **Skeletal Radiol** 1998 Nov; 27(11):633–6 (16 ref.)
Diagnosis and treatment of common metabolic spinal disorders in the geriatric population. Eck JC, et al. **South Med J** 1998 Dec;91(12):1090–7 (32 ref.)
Epidemiology, physical examination, and neurodiagnostics. Dvorák J. **Spine** 1998 Dec 15;23(24):2663–73 (56 ref.)
Imaging of the cervical spine. Kaiser JA, et al. **Spine** 1998 Dec 15;23(24):2701–12 (70 ref.)
Chronic progressive hematomyelia: case reports and review of the literature. Matsumura A, et al. **Surg Neurol** 1999 May;51(5):559–63 (27 ref.)
[Vertebral necrosis] Legaye J. **Acta Orthop Belg** 1999;65 Suppl 1:97–8 (11 ref.) **(Fre)**
[Spinal cord compression due to tophaceous vertebral gout: a case report and literature review] Marsaudon E, et al. **Rev Med Interne** 1999 Mar;20(3):253–7 (39 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic assessment in lumbar back pain. I. Anamnesis and clinical examination] Boos N, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):305–13 (13 ref.) (Eng. Abstr.) **(Ger)**
[Diagnostic assessment in lumbar back pain. II. Imaging and image-guided infiltrations] Pfirrmann CW, et al. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):315–21 (19 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic approaches in chronic back pain] Hildebrandt J. **Ther Umsch** 1999 Aug;56(8):455–9 (9 ref.) (Eng. Abstr.) **(Ger)**
[Radicular and pseudo-radicular pain syndrome] Knutti O, et al. **Ther Umsch** 1998 Oct;55(10):601–12 (29 ref.) (Eng. Abstr.) **(Ger)**

SPINAL DISEASES

DRUG THERAPY

Glucocorticoid therapy in common lumbar spinal disorders. Rozenberg S. **Rev Rhum Engl Ed** 1998 Nov;65(11):649–55 (77 ref.)

EPIDEMIOLOGY

Nine cases of nontraumatic spinal epidural hematoma. Hejazi N, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):718–23; discussion 723–4 (18 ref.)

Juxtafacet cysts of the cervical spine. Krauss WE, et al. **Neurosurgery** 1998 Dec;43(6):1363–8 (10 ref.)

Bowel inflammation and the spondyloarthropathies. De Keyser F, et al. **Rheum Dis Clin North Am** 1998 Nov; 24(4):785–813, ix–x (146 ref.)

Epidemiology, physical examination, and neurodiagnostics. Dvorák J. **Spine** 1998 Dec 15;23(24):2663–73 (56 ref.)

ETIOLOGY

Vertebral osteomyelitis associated with cat-scratch disease. Hulzebos CV, et al. **Clin Infect Dis** 1999 Jun;28(6):1310–2 (28 ref.)

Ochronotic arthropathy: case report and review of the literature. Hamdi N, et al. **Int Orthop** 1999;23(2):122–5 (13 ref.)

Spinal epidural abscess associated with epidural catheterization: report of a case and a review of the literature. Okano K, et al. **Jpn J Clin Oncol** 1999 Jan; 29(1):49–52 (31 ref.)

Spinal subdural hematoma: a rare complication of lumbar puncture. Case report and review of the literature. Egede LE, et al. **Md Med J** 1999 Jan–Feb;48(1):15–7 (15 ref.)

GENETICS

Molecular biology and spinal disorders. A survey for the clinician. Altman DA, et al. **Spine** 1999 Apr 1;24(7):723–30 (14 ref.)

MICROBIOLOGY

MR imaging of spinal infections. Dagirmanjian A, et al. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):525–38 (52 ref.)

PATHOLOGY

Anatomy and pathology of the aging spine. Prescher A. **Eur J Radiol** 1998 Jul;27(3):181–95 (50 ref.)

Lumbar intraspinal synovial cysts of different etiologies: diagnosis by CT and MR imaging. Farrokh D. **J Belge Radiol** 1998 Dec;81(6):275–8 (20 ref.)

Anteroposterior atlantoaxial subluxation in cervical spine osteoarthritis: case reports and review of the literature. Daumen-Legré V, et al. **J Rheumatol** 1999 Mar; 26(3):687–91 (30 ref.)

Pitfalls and artifacts encountered in clinical MR imaging of the spine. Taber KH, et al. **Radiographics** 1998 Nov–Dec; 18(6):1499–521 (62 ref.)

PHYSIOPATHOLOGY

HLA-B27 and other predisposing factors in spondyloarthropathies. Khare SD, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):282–91 (73 ref.)

Use of patient-centered function and symptom rating systems in spinal disorders. Deen HG Jr. **Mayo Clin Proc** 1999 Jan; 74(1):40–4 (42 ref.)

Spinal factors in the generation of fibromyalgia syndrome. Müller W, et al. **Z Rheumatol** 1998;57 Suppl 2:36–42 (21 ref.)

RADIOGRAPHY

[Radiological imaging in lumbago and sciatica] Dullerud R. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1778–81 (14 ref.) (Eng. Abstr.) **(Nor)**

[The cauda equina syndrome and a sacral lithic mass] Zambrana García JL, et al. **Rev Clin Esp** 1999 Jul; 199(7):471–2 (7 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Evaluation of lower back pain with bone scintigraphy and SPECT. De Maeseneer M, et al. **Radiographics** 1999 Jul–Aug;19(4):901–12; discussion 912–4 (25 ref.)

REHABILITATION

Dysafferentation: a novel term to describe the neuropathologic effects of joint complex dysfunction--a look at likely mechanisms of symptom generation [letter; comment] Knutson GA. **J Manipulative Physiol Ther** 1999 Jan;22(1):45–8 (21 ref.) Comment on: J Manipulative Physiol Ther 1998 May;21(4):267–80.

SURGERY

Outcome analysis in lumbar spine: instabilities/degenerative disease. Fessler RG. **Clin Neurosurg** 1997;44:297–303 (12 ref.)

Neurosurgery of the spine in the year 2001: a four-year review. Haid RW Jr, et al. **Clin Neurosurg** 1999;45:153–9 (18 ref.)

Degenerative lumbar spinal instability: technical aspects of operative treatment. Karahalios DG, et al. **Clin Neurosurg** 1997;44:109–35 (38 ref.)

Selection criteria for degenerative lumbar spine instability. McCormick PC. **Clin Neurosurg** 1997;44:29–39 (39 ref.)

Transpedicle screw fixation of the cervical spine. Ludwig SC, et al. **Clin Orthop** 1999 Feb;(359):77–88 (24 ref.)

Radiology of intervertebral cages in spinal surgery. Hanley SD, et al. **Clin Radiol** 1999 Apr;54(4):201–6 (7 ref.)

A multi-center prospective study of the CD Spinal System in patients with degenerative disc disease. Michelsen C, et al. **J Spinal Disord** 1998 Dec;11(6):465–70; discussion 471 (10 ref.)

Indications for thoracic and lumbar spine fusion and trends in use. Abraham DJ, et al. **Orthop Clin North Am** 1998 Oct;29(4):803 (70 ref.)

Indications and trends in use in cervical spinal fusions. Abraham DJ, et al. **Orthop Clin North Am** 1998 Oct; 29(4):731–44 (116 ref.)

Complications in spinal fusion. Brown CA, et al. **Orthop Clin North Am** 1998 Oct;29(4):679–99 (120 ref.)

Clinical outcome after fusion of the thoracic or lumbar spine in the adult patient. Hellman EW, et al. **Orthop Clin North Am** 1998 Oct;29(4):859–69 (84 ref.)

The use of diagnostic imaging to assess spinal arthrodesis. Hilibrand AS, et al. **Orthop Clin North Am** 1998 Oct; 29(4):591–601 (34 ref.)

Clinical outcomes after cervical spine fusion. Huckell CB. **Orthop Clin North Am** 1998 Oct;29(4):787–99 (51 ref.)

Alternatives to spinal fusion. Kostuik JP. **Orthop Clin North Am** 1998 Oct;29(4):701–15 (37 ref.)

Percutaneous interbody fusions. Mathews HH. **Orthop Clin North Am** 1998 Oct;29(4):647–53 (28 ref.)

Minimally invasive posterolateral lumbar arthrodesis. Moskovitz PA. **Orthop Clin North Am** 1998 Oct;29(4):665–7 (10 ref.)

Biomechanical testing sequelae relevant to spinal fusion and instrumentation. Puttlitz CM, et al. **Orthop Clin North Am** 1998 Oct;29(4):571–89 (130 ref.)

Cervical degenerative disease: rationale for selecting the appropriate fusion technique (Anterior, posterior, and 360 degree). Rushton SA, et al. **Orthop Clin North Am** 1998 Oct;29(4):755–77 (78 ref.)

Biologic enhancement of spinal fusion. Sandhu HS, et al. **Orthop Clin North Am** 1998 Oct;29(4):621–31 (75 ref.)

Laparoscopic spinal fusion. Zdeblick TA. **Orthop Clin North Am** 1998 Oct;29(4):635–45 (43 ref.)

Surgery in the degenerative cervical spine. Grob D. **Spine** 1998 Dec 15;23(24):2674–83 (64 ref.)

Anterior cervical discectomy with freeze-dried fibula allograft. Overview of 317 cases and literature review. Martin GJ Jr, et al. **Spine** 1999 May 1;24(9):852–8; discussion 858–9 (51 ref.)

Surgical management for instability and paraplegia caused by spinal sarcoidosis. A case report. Tzagarakis GP, et al. **Spine** 1998 Aug 1;23(15):1711–4 (24 ref.)

THERAPY

Degenerative conditions of the spine. Current diagnostic procedures and treatment modalities. Garfin SR. **Acta Orthop Scand Suppl** 1998 Jun;281:38–46 (134 ref.)

Conditions of the spine. Stanitski CL. **Adolesc Med** 1998 Oct; 9(3):515–32, vi (17 ref.)

Aspiration of intraspinal synovial cyst: recurrence after temporal improvement. Imai K, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):103–5 (10 ref.)

Diagnosis and monitoring of spondyloarthropathy. Dougados M. **Compr Ther** 1998 Nov–Dec;24(11–12):590–5 (22 ref.)

Blastomycosis of the lumbar spine: case report and review of the literature, with emphasis on diagnostic laboratory tools and management. Hadjipavlou AG, et al. **Eur Spine J** 1998;7(5):416–21 (34 ref.)

Nonsurgical treatment of cervical degenerative disease. Rechtine GR. **Instr Course Lect** 1999;48:433–5 (18 ref.)

Aneurysmal bone cyst of the spine: 31 cases and the importance of the surgical approach. de Kleuver M, et al. **J Pediatr Orthop B** 1998 Oct;7(4):286–92 (19 ref.)

Spinal epidural abscess: a review of epidemiology, diagnosis, and treatment. Sampath P, et al. **J Spinal Disord** 1999 Apr; 12(2):89–93 (31 ref.)

Management of vertebral diskitis and osteomyelitis. Khan IA, et al. **Orthopedics** 1999 Aug;22(8):758–65 (56 ref.)

Spinal imaging and intervention: 1998. Mink JH, et al. **Phys Med Rehabil Clin N Am** 1998 May;9(2):343–80, viii (116 ref.)

Prognosis, course of disease, and treatment of the spondyloarthropathies. Leirisalo-Repo M. **Rheum Dis Clin North Am** 1998 Nov;24(4):737–51, viii (81 ref.)

[Corticosteroid-induced epidural lipomatosis. Efficacy of medical treatment] Lemaire M, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):459–63 (20 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

The spine. Adams WH. **Clin Tech Small Anim Pract** 1999 Aug;14(3):148–59 (74 ref.)

Osseous spinal pathology. Haussler KK. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):103–12, vii (53 ref.)

Back problems. Chiropractic evaluation and management. Haussler KK. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):195–209 (43 ref.)

Back problems. Historical perspective and clinical indications. Jeffcott LB. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):1–12, v (17 ref.)

Spinal muscle pathology. Valberg SJ. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):87–96, vi–vii (15 ref.)

SPINAL DYSRAPHISM

COMPLICATIONS

Cervical spine dysraphism with teratoma exhibiting pulmonary differentiation: case report and review of the literature. Ramdial PK, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):528–33 (22 ref.)

DIAGNOSIS

Pediatric neurosurgical disease. Dias MS, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1539–78, x (105 ref.)

[Prenatal diagnosis and outcome of patients with spina bifida] Gressens P, et al. **Arch Pediatr** 1998 Sep;5(9):1004–8 (10 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Accessory limbs associated with spina bifida – a second look. Krishna A, et al. **Pediatr Surg Int** 1999;15(3–4):248–50 (16 ref.)

PHYSIOPATHOLOGY

[Prenatal diagnosis and outcome of patients with spina bifida] Gressens P, et al. **Arch Pediatr** 1998 Sep;5(9):1004–8 (10 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Neuropsychologic and adaptive functioning in adolescents and young adults shunted for congenital hydrocephalus. Hommet C, et al. **J Child Neurol** 1999 Mar;14(3):144–50 (48 ref.)

SURGERY

A case of split notochord syndrome: presence of dorsal enteric diverticulum adjacent to the dorsal enteric fistula. Akgür FM, et al. **J Pediatr Surg** 1998 Aug;33(8):1317–9 (19 ref.)

Pediatric neurosurgical disease. Dias MS, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1539–78, x (105 ref.)

SPINAL FRACTURES

Pediatric spine fractures. Akbarnia BA. **Orthop Clin North Am** 1999 Jul;30(3):521–36, x (90 ref.)

Cervical spine trauma. An HS. **Spine** 1998 Dec 15; 23(24):2713–29 (107 ref.)

COMPLICATIONS

Managing acute osteoporotic vertebral fractures with calcitonin. Maksymowych WP. **Can Fam Physician** 1998 Oct;44:2160–6 (27 ref.)

Traumatic L5–S1 spondylolisthesis: report of three cases and a review of the literature. Fabris D, et al. **Eur Spine J** 1999;8(4):290–5 (25 ref.)

Detection of vertebral artery injury after cervical spine trauma using magnetic resonance angiography. Weller SJ, et al. **J Trauma** 1999 Apr;46(4):660–6 (40 ref.)

[Posttraumatic syringomyelia. A report of an atypical case] Bucciero A, et al. **Minerva Chir** 1998 Nov;53(11):943–6 (21 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Use of magnetic resonance imaging in spinal trauma: indications, techniques, and utility. Slucky AV, et al. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):134–45 (22 ref.)

MRI description of vertebral osteomyelitis, neoplasm, and compression fracture. Vaccaro AR, et al. **Orthopedics** 1999 Jan;22(1):67–73; quiz 74–5 (18 ref.)

ETIOLOGY

Fracture of the axis after dome-like cervical laminoplasty. Ito H, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):106–8 (3 ref.)

Lesson of the week: fractures of the thoracolumbar spine in major trauma patients [see comments] Meek S. **BMJ** 1998 Nov 21;317(7170):1442–3 (11 ref.) Comment in: BMJ 1999 May 8;318(7193):1287–8. Comment in: BMJ 1999 May 8;318(7193):1288.

PATHOLOGY

Classification of thoracolumbar fractures and posterior instrumentation for treatment of thoracolumbar fractures. Capen DA. **Instr Course Lect** 1999;48:437–41 (24 ref.)

Thoracolumbar trauma imaging overview. Flanders AE. **Instr Course Lect** 1999;48:429–31 (16 ref.)

RADIOGRAPHY

Clay-shoveler's fracture. Stress fracture of the lower cervical and upper thoracic spinous processes. Dellestable F, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):575–82 (35 ref.)

[Combined surgery for fractures of the thoraco-lumbar junction using the inlay-span method] Kossmann T, et al. **Orthopade** 1999 May;28(5):432-40 (47 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Occipito-cervical fusion with the cervical Cotrel-Dubousset rod system. Heidecke V, et al. **Acta Neurochir (Wien)** 1998; 140(9):969-76 (31 ref.)
Upper cervical spine trauma: outcome assessment. Alexander JT, et al. **Clin Neurosurg** 1997;44:305-13 (37 ref.)
Surgical techniques for upper cervical spine decompression and stabilization. Dickman CA, et al. **Clin Neurosurg** 1997; 44:137-60 (42 ref.)
Evidence-based management of type II odontoid fractures. Traynelis VC. **Clin Neurosurg** 1997;44:41-9 (22 ref.)
Combined anterior and posterior surgery for fractures of the thoracolumbar spine. Vaccaro AR. **Instr Course Lect** 1999; 48:443-9 (9 ref.)
[Effect of a crosslink or cerclage on the mechanical stability of an internal fixator] Bastian L, et al. **Orthopade** 1999 Aug; 28(8):714-22 (37 ref.) (Eng. Abstr.) **(Ger)**
[Transpedicular implantation of screws in the thoracolumbar spine. Results of a survey of methods, frequency and complications] Bastian L, et al. **Orthopade** 1999 Aug; 28(8):693-702 (31 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the cervical spine in children] Blauth M, et al. **Unfallchirurg** 1998 Aug;101(8):590-612 (167 ref.) (Eng. Abstr.) **(Ger)**
[Indications for surgical management of injuries of the cervical spine] Bühren V, et al. **Zentralbl Chir** 1998; 123(8):907-13 (11 ref.) (Eng. Abstr.) **(Ger)**
[Dorsal stabilization of fractures of the thoracic and lumbar spine by external fixator--technique and outcome] Pizanis A, et al. **Zentralbl Chir** 1998;123(8):936-43 (20 ref.) (Eng. Abstr.) **(Ger)**
[Surgical therapy of dens fracture] Roth R, et al. **Zentralbl Chir** 1998;123(8):914-8 (13 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Nonsurgical treatment of thoracic and lumbar fractures. Rechtine GR. **Instr Course Lect** 1999;48:413-6 (20 ref.)
Management of patients with vertebral compression fractures. Lyles KW. **Pharmacotherapy** 1999 Jan;19(1 Pt 2):21S-24S (27 ref.)

SPINAL FUSION

see related

LAMINECTOMY

Upper cervical spine trauma: outcome assessment. Alexander JT, et al. **Clin Neurosurg** 1997;44:305-13 (37 ref.)
Selection criteria for degenerative lumbar spine instability. McCormick PC. **Clin Neurosurg** 1997;44:29-39 (39 ref.)
Bone repair and enhancement clinical trial design. Spine applications. Boden SD. **Clin Orthop** 1998 Oct;(355 Suppl):S336-46 (48 ref.)
Modern alternatives and techniques for one-level discectomy and fusion. Whitecloud TS 3rd. **Clin Orthop** 1999 Feb; (359):67-76 (27 ref.)
Lumbar arthrodesis for the treatment of back pain. Hanley EN Jr, et al. **J Bone Joint Surg Am** 1999 May;81(5):716-30 (228 ref.)
Bilateral vocal cord paralysis following anterior cervical discectomy and fusion. Case report. Manski TJ, et al. **J Neurosurg** 1998 Nov;89(5):839-43 (97 ref.)
Indications and trends in use in cervical spinal fusions. Abraham DJ, et al. **Orthop Clin North Am** 1998 Oct; 29(4):731-44 (116 ref.)
Indications for thoracic and lumbar spine fusion and trends in use. Abraham DJ, et al. **Orthop Clin North Am** 1998 Oct;29(4):803 (70 ref.)
The biology of posterolateral lumbar spinal fusion. Boden SD. **Orthop Clin North Am** 1998 Oct;29(4):603-19 (127 ref.)
Clinical outcome after fusion of the thoracic or lumbar spine in the adult patient. Hellman EW, et al. **Orthop Clin North Am** 1998 Oct;29(4):859-69 (84 ref.)
The use of diagnostic imaging to assess spinal arthrodesis. Hilibrand AS, et al. **Orthop Clin North Am** 1998 Oct; 29(4):591-601 (34 ref.)
Clinical outcomes after cervical spine fusion. Huckell CB. **Orthop Clin North Am** 1998 Oct;29(4):787-99 (51 ref.)
Thoracic and lumbar trauma: rationale for selecting the appropriate fusion technnique. McCullen G, et al. **Orthop Clin North Am** 1998 Oct;29(4):813-28 (87 ref.)
Biomechanical testing sequelae relevant to spinal fusion and instrumentation. Puttlitz CM, et al. **Orthop Clin North Am** 1998 Oct;29(4):571-89 (130 ref.)
Biologic enhancement of spinal fusion. Sandhu HS, et al. **Orthop Clin North Am** 1998 Oct;29(4):621-31 (75 ref.)
Spondyloptosis of the cervical spine in neurofibromatosis. A case report. Goffin J, et al. **Spine** 1999 Mar 15; 24(6):587-90 (18 ref.)
Management of degenerative disc disease above an L5-S1 segment requiring arthrodesis. Herkowitz HN, et al. **Spine** 1999 Jun 15;24(12):1268-70 (15 ref.)
Intraoperative electromyography during thoracolumbar spinal surgery. Holland NR. **Spine** 1998 Sep 1; 23(17):1915-22 (35 ref.)
Surgical management for instability and paraplegia caused by spinal sarcoidosis. A case report. Tzagarakis GP, et al. **Spine** 1998 Aug 1;23(15):1711-4 (24 ref.)
[Transpedicular fusion of the thoraco-lumbar junction. Clinical, radiographic and CT results] Knop C, et al. **Orthopade** 1999 Aug;28(8):703-13 (35 ref.) (Eng. Abstr.) **(Ger)**
[Surgical management of severe thoracic lordosis in myelomeningocele--a case report with review of the literature] Niemeyer T, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep-Oct;136(5):463-6 (17 ref.) (Eng. Abstr.) **(Ger)**
[Tuberculosis of the spine--surgical treatment] Yokozeki K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):184-7 (10 ref.) **(Jpn)**

ADVERSE EFFECTS

Paradoxical cerebral embolism complicating a major orthopaedic operation. A report of two cases. Della Valle CJ, et al. **J Bone Joint Surg Am** 1999 Jan;81(1):108-10 (20 ref.)
Pharyngeal pouch following anterior cervical fusion. Sood S, et al. **J Laryngol Otol** 1998 Nov;112(11):1085-6 (15 ref.)
Complications in spinal fusion. Brown CA, et al. **Orthop Clin North Am** 1998 Oct;29(4):679-99 (120 ref.)

INSTRUMENTATION

Occipito-cervical fusion with the cervical Cotrel-Dubousset rod system. Heidecke V, et al. **Acta Neurochir (Wien)** 1998; 140(9):969-76 (31 ref.)
Surgical techniques for upper cervical spine decompression and stabilization. Dickman CA, et al. **Clin Neurosurg** 1997; 44:137-60 (42 ref.)
The argument for single-level anterior cervical discectomy and fusion with anterior plate fixation. Geer CP, et al. **Clin Neurosurg** 1999;45:25-9; discussion 21 (21 ref.)
Degenerative lumbar spinal instability: technical aspects of operative treatment. Karahalios DG, et al. **Clin Neurosurg** 1997;44:109-35 (38 ref.)
A concept of idiopathic scoliosis deformities as imperfect torsion(s). Asher MA, et al. **Clin Orthop** 1999 Jul; (364):11-25 (50 ref.)
Transpedicle screw fixation of the cervical spine. Ludwig SC, et al. **Clin Orthop** 1999 Feb;(359):77-88 (24 ref.)
Radiology of intervertebral cages in spinal surgery. Hanley SD, et al. **Clin Radiol** 1999 Apr;54(4):201-6 (7 ref.)
Interbody fusion cages in reconstructive operations on the spine. McAfee PC. **J Bone Joint Surg Am** 1999 Jun; 81(6):859-80 (110 ref.)
A multi-center prospective study of the CD Spinal System in patients with degenerative disc disease. Michelsen C, et al. **J Spinal Disord** 1998 Dec;11(6):465-70; discussion 471 (10 ref.)
[Ventral interbody spondylodesis in injuries of the cervical spine. Indications, surgical technique and results] Blauth M, et al. **Zentralbl Chir** 1998;123(8):919-29 (40 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Practical biomechanical considerations for spine implant testing. Margulies JY, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):347-64 (66 ref.)
A concept of idiopathic scoliosis deformities as imperfect torsion(s). Asher MA, et al. **Clin Orthop** 1999 Jul; (364):11-25 (50 ref.)
The treatment of neuromuscular scoliosis. Banta JV, et al. **Instr Course Lect** 1999;48:551-62 (84 ref.)
Percutaneous interbody fusions. Mathews HH. **Orthop Clin North Am** 1998 Oct;29(4):647-53 (28 ref.)
Minimally invasive posterolateral lumbar arthrodesis. Moskovitz PA. **Orthop Clin North Am** 1998 Oct;29(4):665-7 (10 ref.)
Cervical degenerative disease: rationale for selecting the appropriate fusion technique (Anterior, posterior, and 360 degree). Rushton SA, et al. **Orthop Clin North Am** 1998 Oct;29(4):755-77 (78 ref.)
Laparoscopic bone dowel fusions of the lumbar spine. Silcox DH 3rd. **Orthop Clin North Am** 1998 Oct;29(4):655-63 (22 ref.)
Laparoscopic spinal fusion. Zdeblick TA. **Orthop Clin North Am** 1998 Oct;29(4):635-45 (43 ref.)
Anterior cervical discectomy with freeze-dried fibula allograft. Overview of 317 cases and literature review. Martin GJ Jr, et al. **Spine** 1999 May 1;24(9):852-8; discussion 858-9 (51 ref.)
[Retroperitoneoscopic anterior approach to the L2, L3, L4 vertebral bodies] De Peretti F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 May; 85(2):183-8 (10 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of scoliosis in the adolescent by anterior release and vertebral arthrodesis under thoracoscopy. Preliminary results] Papin P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):231-8 (21 ref.) (Eng. Abstr.) **(Fre)**
[Lumbar interbody fusion. Biomechanical significance for the spine] Maciejczak A, et al. **Neurol Neurochir Pol** 1998 Sep-Oct;32(5):1247-59 (20 ref.) (Eng. Abstr.) **(Pol)**

SPINAL GANGLIA see **GANGLIA, SPINAL**

SPINAL INJURIES

CLASSIFICATION

[Management of injuries of the thoracic and lumbar vertebrae in children] Kathrein A, et al. **Orthopade** 1999 May; 28(5):441-50 (60 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Traumatic L5-S1 spondylolisthesis: report of three cases and a review of the literature. Fabris D, et al. **Eur Spine J** 1999;8(4):290-5 (25 ref.)
Risk factors and precipitating neck movements causing vertebrobasilar artery dissection after cervical trauma and spinal manipulation. Haldeman S, et al. **Spine** 1999 Apr 15;24(8):785-94 (211 ref.)
[Cerebral and basilar artery thrombosis following cervical spinal injury] Niedeggen A, et al. **Zentralbl Neurochir** 1999; 60(1):20-6 (25 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

MR imaging of the spine in sports injuries. Gundry CR, et al. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):85-103 (48 ref.)
Imaging of the cervical spine. Kaiser JA, et al. **Spine** 1998 Dec 15;23(24):2701-12 (70 ref.)

PHYSIOPATHOLOGY

[Correction of posttraumatic deformities. Principles and methods] Stoltze D, et al. **Orthopade** 1999 Aug;28(8):731-45 (70 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Cervical spine radiographs in the trauma patient. Graber MA, et al. **Am Fam Physician** 1999 Jan 15;59(2):331-42 (34 ref.)
Imaging of neurological emergencies: trauma, hemorrhage, and infarction. Bagley LJ. **Semin Roentgenol** 1999 Apr; 34(2):144-59 (64 ref.)

REHABILITATION

Musculoskeletal rehabilitation and sports medicine. 1. Head and spine injuries. Sherman AL, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S40-9 (109 ref.)

SURGERY

Lateral extracavitary approach for thoracic and thoracolumbar spine trauma: operative complications. Resnick DK, et al. **Neurosurgery** 1998 Oct;43(4):796-802; discussion 802-3 (22 ref.)
[Effect of a crosslink or cerclage on the mechanical stability of an internal fixator] Bastian L, et al. **Orthopade** 1999 Aug; 28(8):714-22 (37 ref.) (Eng. Abstr.) **(Ger)**
[Transpedicular implantation of screws in the thoracolumbar spine. Results of a survey of methods, frequency and complications] Bastian L, et al. **Orthopade** 1999 Aug; 28(8):693-702 (31 ref.) (Eng. Abstr.) **(Ger)**
[Transpedicular fusion of the thoraco-lumbar junction. Clinical, radiographic and CT results] Knop C, et al. **Orthopade** 1999 Aug;28(8):703-13 (35 ref.) (Eng. Abstr.) **(Ger)**
[Biomechanical and clinical aspects of spondylodesis of the lower cervical spine. Methods and implants] Ulrich C, et al. **Orthopade** 1999 Aug;28(8):637-50 (74 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the cervical spine in children] Blauth M, et al. **Unfallchirurg** 1998 Aug;101(8):590-612 (167 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the thoracic and lumbar spine] Eggers C, et al. **Unfallchirurg** 1998 Oct;101(10):779-90 (11 ref.) **(Ger)**
[Ventral interbody spondylodesis in injuries of the cervical spine. Indications, surgical technique and results] Blauth M, et al. **Zentralbl Chir** 1998;123(8):919-29 (40 ref.) (Eng. Abstr.) **(Ger)**
[Reduction and positioning of cervical spine injuries] Blauth M, et al. **Zentralbl Chir** 1998;123(8):894-906 (68 ref.) (Eng. Abstr.) **(Ger)**
[Thoraco-lumbar spinal injuries--surgical indications and timing] Weckback A, et al. **Zentralbl Chir** 1998; 123(8):930-5 (6 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Management of spinal trauma] Wettstein M, et al. **Rev Med Suisse Romande** 1998 Aug;118(8):695-700 (13 ref.) **(Fre)**

VETERINARY

Equine back rehabilitation. Ridgway K, et al. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):263-80, x (23 ref.)

SPINAL MANIPULATION see **MANIPULATION, SPINAL**

SPINAL MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

SPINAL MUSCULAR ATROPHY, INFANTILE see **WERDNIG-HOFFMANN DISEASE**

SPINAL NEOPLASMS

Meningeal chondrosarcomas, a review of 31 patients. Forbes RB, et al. **Br J Neurosurg** 1998 Oct;12(5):461–4 (30 ref.)
Primary bone and metastatic tumors of the cervical spine. Abdu WA, et al. **Spine** 1998 Dec 15;23(24):2767–77 (73 ref.)

COMPLICATIONS

Cervical spine dysraphism with teratoma exhibiting pulmonary differentiation: case report and review of the literature. Ramdial PK, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):528–33 (22 ref.)
The solitary intraspinal vertebral osteochondroma. An unusual cause of compressive myelopathy: features and literature review. Khosla A, et al. **Spine** 1999 Jan 1; 24(1):77–81 (16 ref.)

DIAGNOSIS

CT and MRI appearances of a thoracic chordoma. Murphy JM, et al. **Eur Radiol** 1998;8(9):1677–9 (13 ref.)
MR imaging of neoplasms of the lumbar spine. Sevick RJ, et al. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):539–53, ix (64 ref.)
Differential diagnosis: a reasonable clinical approach. Swenson R. **Neurol Clin** 1999 Feb;17(1):43–63 (81 ref.)
Solitary plasmacytoma in the thoracic spine. Two case reports. Takahashi T, et al. **Neurosurg Rev** 1998; 21(2–3):121–5 (13 ref.)
MRI description of vertebral osteomyelitis, neoplasm, and compression fracture. Vaccaro AR, et al. **Orthopedics** 1999 Jan;22(1):67–73; quiz 74–5 (18 ref.)
[The role of TC and MRI in the identification, characterization and staging of tumors of the spinal vertebrae] Gualdi GF, et al. **Clin Ter** 1999 Jan–Feb; 150(1):51–65 (51 ref.) (Eng. Abstr.) **(Ita)**

EMBRYOLOGY

An unusual case of the complete Currarino triad: case report, discussion of the literature and the embryogenic implications. Gegg CA, et al. **Neurosurgery** 1999 Mar; 44(3):658–62 (17 ref.)

EPIDEMIOLOGY

[Lumbosacral intraspinal lipomas associated or not with a tethered cord syndrome (series of 8 cases)] Sakho Y, et al. **Dakar Med** 1998;43(1):13–20 (18 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Chronic renal failure causing brown tumors and myelopathy. Case report and review of pathophysiology and treatment. Fineman I, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):242–6 (18 ref.)

PATHOLOGY

Primary cervical malignant teratoma with a rib metastasis in an adult: five-year survival after surgery and chemotherapy. A case report with a review of the literature. Als C, et al. **Ann Oncol** 1998 Sep;9(9):1015–22 (51 ref.)
An unusual case of the complete Currarino triad: case report, discussion of the literature and the embryogenic implications. Gegg CA, et al. **Neurosurgery** 1999 Mar; 44(3):658–62 (17 ref.)
Primary intraosseous malignant peripheral nerve sheath tumor: a case report and review of the literature. Khan RJ, et al. **Pathology** 1998 Aug;30(3):237–41 (72 ref.)

RADIOGRAPHY

Radiologic and surgical aspects of pure spinal epidural cavernous angiomas. Report on 5 cases and review of the literature. Talacchi A, et al. **Surg Neurol** 1999 Aug; 52(2):198–203 (43 ref.)

RADIOTHERAPY

Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Khan DC, et al. **Cancer Invest** 1999;17(2):110–3 (24 ref.)
Proton therapy for tumors of the skull base. Munzenrider JE, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:57–63 (46 ref.)

SECONDARY

Metastatic disease of the cervical spine. A review. Jenis LG, et al. **Clin Orthop** 1999 Feb;(359):89–103 (73 ref.)
Pilomatrix carcinoma with multiple metastases: report of a case and review of the literature. Bremnes RM, et al. **Eur J Cancer** 1999 Mar;35(3):433–7 (44 ref.)
Primary bone and metastatic tumors of the cervical spine. Abdu WA, et al. **Spine** 1998 Dec 15;23(24):2767–77 (73 ref.)

SURGERY

Revisited: spinal angiolipoma—three additional cases. Labram EK, et al. **Br J Neurosurg** 1999 Feb;13(1):25–9 (29 ref.)
Spinal angiolipomas: report of a case and review of the cases published since the discovery of the tumour in 1890. Turgut M. **Br J Neurosurg** 1999 Feb;13(1):30–40 (64 ref.)
Neurosurgery of the spine in the year 2001: a four-year review. Haid RW Jr, et al. **Clin Neurosurg** 1999;45:153–9 (18 ref.)
Long-term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. Spiegel DA, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):848–55 (52 ref.)
Radiologic and surgical aspects of pure spinal epidural cavernous angiomas. Report on 5 cases and review of the literature. Talacchi A, et al. **Surg Neurol** 1999 Aug; 52(2):198–203 (43 ref.)

SPINAL NERVE ROOTS

see related
POLYRADICULITIS
RADICULITIS

AAEM minimonograph 32: the electrodiagnostic examination in patients with radiculopathies. American Association of Electrodiagnostic Medicine. Wilbourn AJ, et al. **Muscle Nerve** 1998 Dec;21(12):1612–31 (147 ref.)
Clinical neurophysiologic studies: which test is useful and when? Lomen-Hoerth C, et al. **Neurol Clin** 1999 Feb; 17(1):65–74 (27 ref.)
Cervical actinomycosis causing spinal cord compression and multisegmental root failure: case report and review of the literature. Oruçkaptan HH, et al. **Neurosurgery** 1998 Oct; 43(4):937–40 (20 ref.)
[Cervical deficit radiculopathy in 3 cases of vertebral artery dissection] de Bray JM, et al. **Rev Neurol (Paris)** 1998 Nov; 154(11):762–6 (13 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

The impact of sacral root anatomy on selective electrical stimulation for bladder evacuation. Dahms SE, et al. **World J Urol** 1998;16(5):322–8 (46 ref.)

PATHOLOGY

[Ewing's sarcoma of the soft tissues: apropos of 3 cases and review of the literature] Paoletti H, et al. **J Radiol** 1999 May;80(5):477–82 (26 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Computer modelling of spinal cord stimulation and its contribution to therapeutic efficacy. Holsheimer J. **Spinal Cord** 1998 Aug;36(8):531–40 (58 ref.)

PHYSIOPATHOLOGY

Sacral nerve root cysts: A review on pathophysiology. ArunKumar MJ, et al. **Neurol India** 1999 Mar;47(1):61–4 (18 ref.)
[New information concerning pain caused by herniated disk and sciatica. Exposure to disk tissue sensitizes the nerve roots] Olmarker K, et al. **Lakartidningen** 1998 Dec 2; 95(49):5618–22 (46 ref.) (Eng. Abstr.) **(Swe)**

SURGERY

Operative techniques and clinicopathologic correlation in the surgical treatment of cranial rhizopathies (honored guest lecture). Jannetta PJ. **Clin Neurosurg** 1997;44:181–95 (18 ref.)
Multisegmental cervical spondylotic myelopathy and radiculopathy treated by multilevel oblique corpectomies without fusion. George B, et al. **Neurosurgery** 1999 Jan; 44(1):81–90 (117 ref.)
[Surgical treatment of chronic neurogenic pain—clinical use of the DREZ operation] Spaić M, et al. **Vojnosanit Pregl** 1998 Sep–Oct;55(5):533–40 (48 ref.) **(Scc)**

SPINAL NERVES

Selective lumbar spinal nerve block, a review. Pang WW, et al. **Acta Anaesthesiol Sin** 1999 Mar;37(1):21–6 (48 ref.)
Thoracic paravertebral block [see comments] Richardson J, et al. **Br J Anaesth** 1998 Aug;81(2):230–8 (104 ref.) Comment in: Br J Anaesth 1999 Jan;82(1):149–50.
Clinical neurophysiologic studies: which test is useful and when? Lomen-Hoerth C, et al. **Neurol Clin** 1999 Feb; 17(1):65–74 (27 ref.)

DRUG EFFECTS

Commentary: neurotoxicity of local anesthetics—an issue or a scapegoat? Moore DC, et al. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6):605–10 (78 ref.)

PHYSIOLOGY

Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Yaksh TL. **Trends Pharmacol Sci** 1999 Aug;20(8):329–37 (98 ref.)

SPINAL OSTEOPHYTOSIS

COMPLICATIONS

Dysphagia secondary to cervical osteophytes. Ladenheim SE, et al. **Am J Otolaryngol** 1999 May–Jun;20(3):184–9 (26 ref.)
Managing pain from cervical spondylosis. Sari-Kouzel H, et al. **Practitioner** 1999 Apr;243(1597):334–8 (1 ref.)

METABOLISM

Fatal cervical spondyloarthropathy in a hemodialysis patient with systemic deposition of beta2-microglobulin amyloid. Danesh FR, et al. **Am J Kidney Dis** 1999 Mar;33(3):563–6 (17 ref.)

PHYSIOPATHOLOGY

A review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury. Fehlings MG, et al. **Spine** 1998 Dec 15;23(24):2730–7 (74 ref.)

SURGERY

The argument for single-level anterior cervical discectomy and fusion with anterior plate fixation. Geer CP, et al. **Clin Neurosurg** 1999;45:25–9; discussion 21 (21 ref.)
Cervical spondylotic myelopathy. Approaches to surgical treatment. Orr RD, et al. **Clin Orthop** 1999 Feb;(359):58–66 (44 ref.)
Modern alternatives and techniques for one-level discectomy and fusion. Whitecloud TS 3rd. **Clin Orthop** 1999 Feb; (359):67–76 (27 ref.)

SPINAL PUNCTURE

[Reasons against lumbar puncture diagnosis with cerebrospinal fluid drainage in subarachnoid hemorrhage] Profeta G, et al. **Minerva Anestesiol** 1998 Apr;64(4):137–9 (10 ref.) (Eng. Abstr.) **(Ita)**
[Reasons in favor of lumbar puncture diagnosis (or lavage)] Schisano G. **Minerva Anestesiol** 1998 Apr;64(4):135–6 (6 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Post-lumbar puncture headache and backache in pediatrics: a case series and demonstration of magnetic resonance imaging findings. Atabaki S, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):770–3 (21 ref.)
Spinal subdural hematoma: a rare complication of lumbar puncture. Case report and review of the literature. Egede LE, et al. **Md Med J** 1999 Jan–Feb;48(1):15–7 (15 ref.)
[Lumbar puncture headache. Routines of Danish hospital departments compared with recommendations found in the literature] Winge K, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2368–72 (20 ref.) (Eng. Abstr.) **(Dan)**
[Bilateral intracranial subdural hematoma following lumbar puncture: report of a case] Lavie F, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):703–5 (12 ref.) (Eng. Abstr.) **(Fre)**

SPINAL ROOTS see **SPINAL NERVE ROOTS**

SPINAL STENOSIS

COMPLICATIONS

A review of basic science issues in low back pain. Gordon SL, et al. **Phys Med Rehabil Clin N Am** 1998 May; 9(2):323–42, vii (172 ref.)

DIAGNOSIS

MR evaluation of stenosis involving the neural foramina, lateral recesses, and central canal of the lumbosacral spine. Jinkins JR. **Magn Reson Imaging Clin N Am** 1999 Aug; 7(3):493–511, viii (43 ref.)
A physiological approach to the evaluation of lumbosacral spinal stenosis. Kraft GH. **Phys Med Rehabil Clin N Am** 1998 May;9(2):381–9, viii (19 ref.)

PHYSIOPATHOLOGY

A physiological approach to the evaluation of lumbosacral spinal stenosis. Kraft GH. **Phys Med Rehabil Clin N Am** 1998 May;9(2):381–9, viii (19 ref.)

SURGERY

Degenerative lumbar stenosis: diagnosis and management. Hilibrand AS, et al. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):239–49 (41 ref.)
Surgical management of lumbar spinal stenosis. Postacchini F. **Spine** 1999 May 15;24(10):1043–7 (21 ref.)

SPINDLE APPARATUS, MITOTIC see **MITOTIC SPINDLE APPARATUS**

SPINE

see related
LAMINECTOMY

ABNORMALITIES

Conditions of the spine. Stanitski CL. **Adolesc Med** 1998 Oct; 9(3):515–32, vi (17 ref.)
Spinal manifestations of skeletal dysplasias. Kornblum M, et

al. **Orthop Clin North Am** 1999 Jul;30(3):501–20, x (119 ref.)
Perosomus elumbis (vertebral agenesis and arthrogryposis) in a stillborn Holstein calf. Jones CJ. **Vet Pathol** 1999 Jan; 36(1):64–70 (41 ref.)

ANATOMY & HISTOLOGY

The spine. Adams WH. **Clin Tech Small Anim Pract** 1999 Aug;14(3):148–59 (74 ref.)
On the homology of structures and Hox genes: the vertebral column. Galis F. **Novartis Found Symp** 1999;222:80–91; discussion 91–4 (47 ref.)
Anatomy of the thoracolumbar vertebral region. Haussler KK. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):13–26, v (34 ref.)

BLOOD SUPPLY

[Neurological complications of aortic artery surgery] Carrascal Y, et al. **Rev Neurol** 1998 Nov;27(159):854–61 (89 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

The embryogenesis of congenital vertebral dislocation: early embryonic buckling? Dias MS, et al. **Pediatr Neurosurg** 1998 Dec;29(6):281–9 (33 ref.)

MICROBIOLOGY

Vertebral Aspergillus osteomyelitis and acute diskitis in patients with chronic obstructive pulmonary disease. Martinez M, et al. **Mayo Clin Proc** 1999 Jun;74(6):579–83 (31 ref.)

PATHOLOGY

Newer sequences for spinal MR imaging: smorgasbord or succotash of acronyms? Ross JS.
AJNR Am J Neuroradiol 1999 Mar;20(3):361–73 (82 ref.)
Anatomy and pathology of the aging spine. Prescher A.
Eur J Radiol 1998 Jul;27(3):181–95 (50 ref.)
Bracing (and screening)—yes or no? Dickson RA, et al.
J Bone Joint Surg Br 1999 Mar;81(2):193–8 (47 ref.)
Pitfalls and artifacts encountered in clinical MR imaging of the spine. Taber KH, et al. **Radiographics** 1998 Nov–Dec; 18(6):1499–521 (62 ref.)

PHYSIOLOGY

The spine in swimming. Ferrell MC. **Clin Sports Med** 1999 Apr;18(2):389–93, viii (2 ref.)
A review of biomechanics of the central nervous system—Part III: spinal cord stresses from postural loads and their neurologic effects. Harrison DE, et al.
J Manipulative Physiol Ther 1999 Jul–Aug;22(6):399–410 (84 ref.)
The effect of modelling and remodelling on human vertebral body architecture. Mosekilde L. **Technol Health Care** 1998 Dec;6(5–6):287–97 (29 ref.)
Spinal biomechanics and functional anatomy. Denoix JM. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):27–60 (32 ref.)

PHYSIOPATHOLOGY

A review of biomechanics of the central nervous system—part II: spinal cord strains from postural loads. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 Jun; 22(5):322–32 (49 ref.)
[The epidemiology of musculoskeletal changes due to biomechanical overload of the spine in the manual lifting of patients] Bordini L, et al. **Med Lav** 1999 Mar–Apr; 90(2):103–16 (47 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Long-term radiographic follow-up in a patient with osteosclerotic sarcoidosis of the spine and pelvis. Franco M, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):586–90 (17 ref.)
Back problems. Radiology and scintigraphy. Weaver MP, et al. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):113–29, vii–viii (20 ref.)

RADIONUCLIDE IMAGING

Back problems. Radiology and scintigraphy. Weaver MP, et al. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):113–29, vii–viii (20 ref.)

SURGERY

Practical biomechanical considerations for spine implant testing. Margulies JY, et al.
Chir Narzadow Ruchu Ortop Pol 1999;64(3):347–64 (66 ref.)
Bone repair and enhancement clinical trial design. Spine applications. Boden SD. **Clin Orthop** 1998 Oct;(355 Suppl):S336–46 (48 ref.)
Is there a rational basis for post-surgical lifting restrictions? 1. Current understanding. Magnusson ML, et al.
Eur Spine J 1999;8(3):170–8 (93 ref.)
Spinal cord monitoring: current state of the art. Padberg AM, et al. **Orthop Clin North Am** 1999 Jul;30(3):407–33, viii (71 ref.)
[Neuromonitoring and anesthesia in surgery of the spine] Laureau E, et al. **Neurophysiol Clin** 1998 Sep;28(4):299–320 (106 ref.) (Eng. Abstr.) **(Fre)**
[Monitoring the neurogenic mixed evoked potentials during surgery of the spine: a good solution?] Péréon Y, et al. **Neurophysiol Clin** 1998 Sep;28(4):321–34 (64 ref.) (Eng. Abstr.) **(Fre)**
[Laparoscopic-transperitoneal and lumboscopic-retroperitoneal surgery of the spine.Developments from animal experiments for use in clinical practice] Olinger A, et al. **Zentralbl Chir** 1999; 124(4):311–7 (22 ref.) (Eng. Abstr.) **(Ger)**

SPINNER DOLPHINS see **DOLPHINS**

SPINOCEREBELLAR ATAXIAS see **SPINOCEREBELLAR DEGENERATION**

SPINOCEREBELLAR DEGENERATION

[Clinical, neuropathological and genetic characteristics of spinocerebellar ataxia type 6 (SCA6)] Ishikawa K, et al. **Nippon Rinsho** 1999 Apr;57(4):880–5 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Nonne syndrome] Kamiya K.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):309–12 (9 ref.) **(Jpn)**
[Marinesco Sjögren syndrome] Komiyama A, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):299–302 (5 ref.) **(Jpn)**
[Cerebello-olivary atrophy (COA)] Mizusawa H.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):239–42 (15 ref.) **(Jpn)**
[Holmes type cortical cerebellar atrophy (CCA)] Mizusawa H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):231–4 (15 ref.) **(Jpn)**
[Spinocerebellar ataxia type 6 (SCA6)] Mizusawa H.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):235–8 (15 ref.) **(Jpn)**
[Joubert syndrome (Joubert-Boltshauser syndrome)] Saito Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):313–5 (19 ref.) **(Jpn)**
[Spinocerebellar ataxia type 4 (SCA4)] Sasaki H, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):280–2 (6 ref.) **(Jpn)**
[Spinocerebellar ataxia type 5 (SCA5)] Sasaki H, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):283–4 (3 ref.) **(Jpn)**
[Spinocerebellar ataxia type 7 (SCA7)] Sasaki H, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):285–7 (15 ref.) **(Jpn)**
[Late cortical cerebellar atrophy] Takiyama Y, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):247–50 (14 ref.) **(Jpn)**
[Spinocerebellar ataxia type 1 (SCA1)] Uchiyama T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):262–5 (15 ref.) **(Jpn)**
[Spinocerebellar ataxia type 2 (SCA2)] Uchiyama T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):266–9 (11 ref.) **(Jpn)**

CLASSIFICATION

[An introduction to spinocerebellar degeneration: special reference to a newly revised classification] Yuasa T.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):206–11 (24 ref.) **(Jpn)**

DIAGNOSIS

[Non-epileptic paroxysmal movement disorders] Klein C, et al. **Nervenarzt** 1998 Aug;69(8):647–59 (177 ref.) (Eng. Abstr.) **(Ger)**
[Neuroimaging of motor disturbances] Iwata M.
Rinsho Shinkeigaku 1998 Dec;38(12):1010–2 (6 ref.) (Eng. Abstr.) **(Jpn)**
[The contribution of molecular genetics to the nosology and diagnosis of neurological disorders of childhood] Aicardi J. **Rev Neurol** 1999 Jan 1–15;28(1):1–4 (22 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Molecular and clinical features in spinocerebellar ataxia type 6 (SCA6) in Japanese] Ikeuchi T. **Nippon Rinsho** 1999 Apr; 57(4):891–5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Frequencies of triplet repeat disorders in dominantly inherited spinocerebellar ataxia (SCA) in the Japanese] Sasaki H, et al. **Nippon Rinsho** 1999 Apr;57(4):787–91 (20 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

[Acquired cortical cerebellar atrophy] Fujimoto K, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):243–6 (15 ref.) **(Jpn)**

GENETICS

A clinicogenetic analysis of six Indian spinocerebellar ataxia (SCA2) pedigrees. The significance of slow saccades in diagnosis. Wadia N, et al. **Brain** 1998 Dec;121 (Pt 12):2341–55 (81 ref.)
To be or not to be an aggregate. Nasir J. **Clin Genet** 1999 Jan;55(1):9–10 (2 ref.)
Pathogenesis of polyglutamine-induced disease: A model for SCA1. Klement IA, et al. **Mol Genet Metab** 1999 Mar; 66(3):172–8 (38 ref.)
Progress in pathogenesis studies of spinocerebellar ataxia type 1. Cummings CJ, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1079–81 (20 ref.)
CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci. Frontali M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1089–94 (38 ref.)
Molecular pathology of dentatorubral-pallidoluysian atrophy. Kanazawa I.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1069–74 (26 ref.)
[New insights in the molecular genetics and pathophysiology of hereditary ataxias] Bürk K, et al. **Nervenarzt** 1999 Jun; 70(6):491–5 (39 ref.) (Eng. Abstr.) **(Ger)**
[Clinical and genetic characteristics of SCA1] Abe K.
Nippon Rinsho 1999 Apr;57(4):796–800 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular analyses of intergenerational instability of CAG repeat in SCA2 gene] Igarashi S, et al. **Nippon Rinsho** 1999 Apr;57(4):811–7 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular and clinical features in spinocerebellar ataxia type 6 (SCA6) in Japanese] Ikeuchi T. **Nippon Rinsho** 1999 Apr; 57(4):891–5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[The function of spinocerebellar ataxia type 2 (SCA2) gene product, ataxin-2 and the mechanism of pathogenesis for SCA2] Sanpei K. **Nippon Rinsho** 1999 Apr;57(4):822–4 (14 ref.) (Eng. Abstr.) **(Jpn)**
[The phenotype variation correlates with the size of CAG repeat in SCA2] Sasaki H, et al. **Nippon Rinsho** 1999 Apr; 57(4):818–21 (10 ref.) (Eng. Abstr.) **(Jpn)**
[The contribution of molecular genetics to the nosology and diagnosis of neurological disorders of childhood] Aicardi J. **Rev Neurol** 1999 Jan 1–15;28(1):1–4 (22 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

A clinical, genetic, neuropathological study in a Japanese family with SCA 6 and a review of Japanese autopsy cases of autosomal dominant cortical cerebellar atrophy. Tsuchiya K, et al. **J Neurol Sci** 1998 Sep 18;160(1):54–9 (22 ref.)
Progress in pathogenesis studies of spinocerebellar ataxia type 1. Cummings CJ, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1079–81 (20 ref.)
Molecular pathology of dentatorubral-pallidoluysian atrophy. Kanazawa I.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1069–74 (26 ref.)
[Correlation of clinichopathological features and CAG repeats in SCA2] Koyano S, et al. **Nippon Rinsho** 1999 Apr;57(4):805–10 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

A clinicogenetic analysis of six Indian spinocerebellar ataxia (SCA2) pedigrees. The significance of slow saccades in diagnosis. Wadia N, et al. **Brain** 1998 Dec;121 (Pt 12):2341–55 (81 ref.)
Calcium channelopathies in the central nervous system. Jen J. **Curr Opin Neurobiol** 1999 Jun;9(3):274–80 (52 ref.)
[Electrophysiological findings in patients with SCA6] Kumagai R, et al. **Nippon Rinsho** 1999 Apr;57(4):886–90 (15 ref.) (Eng. Abstr.) **(Jpn)**

SPIRAL GANGLION

CYTOLOGY

Growth factors, auditory neurones and cochlear implants: a review. Marzella PL, et al. **Acta Otolaryngol** 1999; 119(4):407–12 (60 ref.)

SPIRAL ORGAN see **ORGAN OF CORTI**

SPIRAMYCIN

THERAPEUTIC USE

Spiramycin renaissance. Rubinstein E, et al.
J Antimicrob Chemother 1998 Nov;42(5):572–6 (24 ref.)

SPIRAMYCIN ADIPATE see **SPIRAMYCIN**

SPIRITUAL HEALING see **MENTAL HEALING**

SPIRO COMPOUNDS

PHARMACOLOGY

Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist. Serradeil-Le Gal C.
Adv Exp Med Biol 1998;449:427–38 (36 ref.)

TOXICITY

[Plant toxicity-coriamyrtin, anisatin, cicutoxin] Fujii M.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):682–4 (8 ref.) **(Jpn)**

SPIROGYRA

SPIROGYRA see **ALGAE, GREEN**

SPIROLACTONE see **SPIRONOLACTONE**

SPIROMETRY

Post-thoracotomy spirometric lung function: the effect of analgesia. A review. Richardson J, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):445–56 (85 ref.)

METHODS

Chronic obstructive pulmonary disease and '150 years of blowing'. Miller MR. **Hosp Med** 1998 Sep;59(9):719–22 (25 ref.)

STANDARDS

Paediatric reference values for spirometry. Kivastik J. **Clin Physiol** 1998 Nov;18(6):489–97 (42 ref.)

STATISTICS & NUMERICAL DATA

Paediatric reference values for spirometry. Kivastik J. **Clin Physiol** 1998 Nov;18(6):489–97 (42 ref.)

SPIRONOLACTONE

THERAPEUTIC USE

Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Struthers AD. **Br J Clin Pharmacol** 1999 May;47(5):479–82 (25 ref.)

SPIRURIDA INFECTIONS

[Gnathostomiasis] Fujita K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):458–60 (7 ref.) **(Jpn)**

DIAGNOSIS

[Laboratory diagnosis of protozoan and parasitic infections. 2. Helminthiasis. i. Spirurida infections] Otaki R, et al. **Rinsho Byori** 1998 Nov;Suppl 108:258–63 (10 ref.) **(Jpn)**

PATHOLOGY

Creeping eruption caused by a larva of the suborder Spirurina type X. Goto Y, et al. **Br J Dermatol** 1998 Aug;139(2):315–8 (21 ref.)

SPIRURINA

Creeping eruption caused by a larva of the suborder Spirurina type X. Goto Y, et al. **Br J Dermatol** 1998 Aug;139(2):315–8 (21 ref.)

SPITZ NEVUS see **NEVUS, EPITHELIOID AND SPINDLE CELL**

SPLANCHNIC CIRCULATION

Total splanchnic resuscitation, SIRS, and MODS [editorial; comment] Marik PE. **Crit Care Med** 1999 Feb;27(2):257–8 (43 ref.) Comment on: Crit Care Med 1999 Feb;27(2):394–400.

'Nonportal' splanchnic venous supply to the liver: abnormal findings on CT, US and MRI. Itai Y, et al. **Eur Radiol** 1999;9(2):237–43 (35 ref.)

Hepatic and splanchnic microvascular responses to inflammation and shock. McCuskey RS. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1464–7 (49 ref.)

Role of enteral nutrition-induced splanchnic hyperemia in ameliorating splanchnic ischemia [editorial] Eleftheriadis E. **Nutrition** 1999 Mar;15(3):247–8 (13 ref.)

[Duplex Doppler sonography of splanchnic circulation in man. Clinical and physiological importance] Dauzat M, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):394–404 (111 ref.) **(Fre)**

[Splanchnic hypoperfusion and distant organ injury] Koike K, et al. **Nippon Geka Gakkai Zasshi** 1998 May;100(5):357–60 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Neuronal control of mesenteric circulation] Takenaga M, et al. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):249–59 (79 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Intestinal mucosal permeability: mechanisms and implications for treatment [editorial; comment] Marik PE, et al. **Crit Care Med** 1999 Aug;27(8):1650–1 (24 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1429–36.

An intensivist's dilemma: support of the splanchnic circulation in critical illness [editorial; comment] Marshall JC. **Crit Care Med** 1998 Oct;26(10):1637–8 (20 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1749–58.

Catecholamines and the splanchnic circulation [editorial; comment] Russell JA. **Crit Care Med** 1999 Feb;27(2):242–3 (13 ref.) Comment on: Crit Care Med 1999 Feb;27(2):325–31.

Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. Hansen MB, et al. **Physiol Res** 1998;47(5):307–27 (130 ref.)

[Perfusion and metabolism of liver and splanchnic nerve area under sevoflurane anesthesia] Schindler E, et al. **Anaesthesist** 1998 Nov;47 Suppl 1:S19–23 (60 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

How to use articles about diagnostic technology: gastric tonometry. Keenan SP, et al. **Crit Care Med** 1999 Sep;27(9):1726–31 (38 ref.)

Splanchnic circulatory physiology. Ralevic V. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1409–13 (35 ref.)

SPLEEN

see related
SPLENECTOMY

ABNORMALITIES

Polysplenia syndrome detected in adulthood: report of eight cases and review of the literature. Gayer G, et al. **Abdom Imaging** 1999 Mar–Apr;24(2):178–84 (17 ref.)

[A case of accessory spleen presenting as retroperitoneal tumor] Kato Y, et al. **Hinyokika Kiyo** 1998 Oct;44(10):711–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Mobile spleen] Kurguzov OP, et al. **Khirurgiia (Mosk)** 1999;(1):66–9 (138 ref.) **(Rus)**

BLOOD SUPPLY

Splenic vascular lesions: unusual features and a review of the literature. Lam KY, et al. **Aust N Z J Surg** 1999 Jun;69(6):422–5 (64 ref.)

[Ischemic necrosis of the spleen and gastric fundus. A rare complication of acute pancreatitis (letter)] Soria Aledo V, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):209 (8 ref.) **(Spa)**

IMMUNOLOGY

Regeneration of autotransplanted splenic fragments: basic immunological and clinical relevance [editorial; comment] Pabst R. **Clin Exp Immunol** 1999 Sep;117(3):423–4 (29 ref.) Comment on: Clin Exp Immunol 1999 Sep;117(3):596–604.

[Relation between AIDS, spleen and splenectomy] Qui Q, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):718–20 (18 ref.) **(Chi)**

INJURIES

Delayed diagnosis of splenic injury after falls from less than 10 feet. Young KD, et al. **Pediatr Emerg Care** 1998 Dec;14(6):413–5 (19 ref.)

METABOLISM

Fatal cervical spondyloarthropathy in a hemodialysis patient with systemic deposition of beta2-microglobulin amyloid. Danesh FR, et al. **Am J Kidney Dis** 1999 Mar;33(3):563–6 (17 ref.)

PATHOLOGY

Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Kraus MD, et al. **Am J Surg Pathol** 1998 Oct;22(10):1255–66 (35 ref.)

Small B-cell lymphomas of the lymph nodes and spleen: practical insights to diagnosis and pathogenesis. Swerdlow SH. **Mod Pathol** 1999 Feb;12(2):125–40 (193 ref.)

PHYSIOPATHOLOGY

Haemophilia and the mysterious spleen: the story of a hate-love relationship. Ingram GI. **Haemophilia** 1998 Jan;4(1):69–74 (76 ref.)

TRANSPLANTATION

[On the review of literature by V.A. Zurnadzh'iants and Yu.V. Nazarochkin "Autotransplantation of splenic tissue"] Grigor'ev EG, et al. **Khirurgiia (Mosk)** 1998;(7):44–7 (81 ref.) **(Rus)**

SPLENECTOMY

Splenectomy in recurrent epithelial ovarian cancer. Gemignani ML, et al. **Gynecol Oncol** 1999 Mar;72(3):407–10 (13 ref.)

Massive intracranial bleeding requiring emergency splenectomy in a patient with CMV-associated thrombocytopenia. Gural A, et al. **Haemostasis** 1998 Sep–Oct;28(5):250–5 (16 ref.)

Gastro-esophageal decongestion and splenectomy GEDS (Hassab), in the management of bleeding varices. Review of literature. Hassab MA. **Int Surg** 1998 Jan–Mar;83(1):38–41 (31 ref.)

[Relation between AIDS, spleen and splenectomy] Qui Q, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):718–20 (18 ref.) **(Chi)**

[Babesiosis--a dangerous infection for splenectomized children and adults] Hohenschild S. **Klin Padiatr** 1999 May–Jun;211(3):137–40 (39 ref.) (Eng. Abstr.) **(Ger)**

[A survival case of fulminant pneumococcal meningitis as overwhelming postsplenectomy infection (OPSI) syndrome] Yamashita S, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1054–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999;77(7):56–9 (0 ref.) **(Rus)**

ADVERSE EFFECTS

Prevention and management of overwhelming postsplenectomy infection--an update. Brigden ML, et al. **Crit Care Med** 1999 Apr;27(4):836–42 (46 ref.)

METHODS

Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Katkhouda N, et al. **Ann Surg** 1998 Oct;228(4):568–78 (49 ref.)

Splenectomy in hematology. Current practice and new perspectives. Baccarani U, et al. **Haematologica** 1999 May;84(5):431–6 (43 ref.)

Present status of laparoscopic splenectomy for hematologic diseases: certitudes and unresolved issues. Gigot JF, et al. **Semin Laparosc Surg** 1998 Sep;5(3):147–67 (184 ref.)

Laparoscopic splenectomy. Rescorla FJ. **Semin Pediatr Surg** 1998 Nov;7(4):207–12 (28 ref.)

Laparoscopic splenectomy: evolution and current status. Klingler PJ, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):1–8 (66 ref.)

Laparoscopic splenectomy. Glasgow RE, et al. **World J Surg** 1999 Apr;23(4):384–8 (25 ref.)

SPLENIC ARTERY

Post-traumatic pancreatitis with associated aneurysm of the splenic artery: report of 2 cases and review of the literature. Tandon V, et al. **Can J Surg** 1999 Jun;42(3):215–9 (28 ref.)

Vascular complications (splenic and hepatic artery aneurysms) in the occipital horn syndrome: report of a patient and review of the literature. Mentzel HJ, et al. **Pediatr Radiol** 1999 Jan;29(1):19–22 (12 ref.)

[Splenic pseudoaneurysms following acute pancreatitis] Cirocchi R, et al. **Minerva Chir** 1999 Apr;54(4):277–82 (66 ref.) (Eng. Abstr.) **(Ita)**

SPLENIC DISEASES

see related
SPLENOSIS

COMPLICATIONS

Hepatosplenic candidiasis in patients with acute leukemia: increasingly encountered complication. Sallah S. **Anticancer Res** 1999 Jan–Feb;19(1B):757–60 (14 ref.)

Inflammatory pseudotumor of the spleen associated with a cavernous hemangioma diagnosed at intra-operative cytology: report of a case and review of literature. Nasir A, et al. **In Vivo** 1999 Jan–Feb;13(1):87–92 (40 ref.)

Spontaneous rupture of splenic hamartoma: a case report. Yoshizawa J, et al. **J Pediatr Surg** 1999 Mar;34(3):498–9 (8 ref.)

DIAGNOSIS

Splenic abscess: a diagnostic and therapeutic challenge. de Bree E, et al. **Acta Chir Belg** 1998 Oct;98(5):199–202 (21 ref.)

[Diagnostic imaging in hepatosplenic candidiasis] Müller D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):587–90 (24 ref.) (Eng. Abstr.) **(Ger)**

[2 cases of a true splenic cyst] Marchesi M, et al. **Ann Ital Chir** 1998 Jul–Aug;69(4):525–8 (14 ref.) (Eng. Abstr.) **(Ita)**

[Splenic abscess] Wysocki A, et al. **Przegl Lek** 1999;56(3):242–3 (8 ref.) (Eng. Abstr.) **(Pol)**

[Splenic abscess: a case report and review of the literature] Canora Lebrato J, et al. **An Med Interna** 1999 Jan;16(1):31–4 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Mobile spleen] Kurguzov OP, et al. **Khirurgiia (Mosk)** 1999;(1):66–9 (138 ref.) **(Rus)**

PATHOLOGY

Splenic vascular lesions: unusual features and a review of the literature. Lam KY, et al. **Aust N Z J Surg** 1999 Jun;69(6):422–5 (64 ref.)

Splenic peliosis: a rare complication following liver transplantation. Raghavan R, et al. **Dig Dis Sci** 1999 Jun;44(6):1128–31 (24 ref.)

SURGERY

Laparoscopic splenectomy: evolution and current status. Klingler PJ, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):1–8 (66 ref.)

[Primary cysts of the spleen: apropos 3 cases with a review of the literature] Fusetti C, et al. **Ann Ital Chir** 1998 Nov–Dec;69(6):783–7; discussion 787–8 (31 ref.) (Eng. Abstr.) **(Ita)**

SPLENIC INFARCTION

ETIOLOGY

Splenic syndrome in sickle cell trait: four case presentations and a review of the literature. Franklin QJ, et al.

Mil Med 1999 Mar;164(3):230–3 (17 ref.)

SPLENIC NEOPLASMS

Primary malignant fibrous histiocytoma of spleen. Mallipudi BV, et al. **Eur J Surg Oncol** 1998 Oct;24(5):448–9 (07 ref.)
Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Catovsky D, et al. **Semin Hematol** 1999 Apr;36(2):148–54 (31 ref.)

COMPLICATIONS

Splenic metastasis from a rectal tumour: an unusual presentation. Achuthan R, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):139 (4 ref.)

DIAGNOSIS

Inflammatory pseudotumor of the spleen associated with a cavernous hemangioma diagnosed at intra-operative cytology: report of a case and review of literature. Nasir A, et al. **In Vivo** 1999 Jan–Feb;13(1):87–92 (40 ref.)
[Littoral-cell angioma--a rare differential diagnosis on splenic tumors] Sauer J, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):624–8 (9 ref.) (Eng. Abstr.) **(Ger)**
[2D and 3D parameter images for the analysis of contrast medium distribution in dynamic CT and MRI] Beier J, et al. **Radiologe** 1998 Oct;38(10):832–40 (27 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Mucinous cystadenocarcinoma of the spleen presenting a point mutation of the Kirsten-ras oncogene at codon 12. Hirota M, et al. **Dig Dis Sci** 1999 Apr;44(4):768–74 (16 ref.)
[Primary splenic lymphoma with t(3;14)(q27;q32) chromosomal abnormality and rearrangement of BCL-6 gene] Yata K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):587–92 (14 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Chang KL, et al. **Adv Anat Pathol** 1998 Jan;5(1):21–9 (22 ref.)
Littoral cell angioma of the spleen: an additional report of four cases with emphasis on the association with visceral organ cancers. Bisceglia M, et al. **Tumori** 1998 Sep–Oct; 84(5):595–9 (21 ref.)

SECONDARY

Splenic metastasis from a rectal tumour: an unusual presentation. Achuthan R, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):139 (4 ref.)
Splenectomy in recurrent epithelial ovarian cancer. Gemignani ML, et al. **Gynecol Oncol** 1999 Mar; 72(3):407–10 (13 ref.)
Gastric enterochromaffin-like-cell tumor with liver and splenic metastases. Eriguchi N, et al. **J Gastroenterol** 1999 Jun;34(3):383–6 (10 ref.)
[Splenic metastases] Vadalà G, et al. **Minerva Chir** 1999 Apr; 54(4):273–6 (14 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Splenectomy in recurrent epithelial ovarian cancer. Gemignani ML, et al. **Gynecol Oncol** 1999 Mar; 72(3):407–10 (13 ref.)

SPLENIC RUPTURE

COMPLICATIONS

Splenic rupture in a newborn with hemophilia A: case report and review of the literature. Johnson-Robbins LA, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):117–9 (15 ref.)

DIAGNOSIS

Occult splenic rupture: a case report. Baert D, et al. **Acta Clin Belg** 1999 Jun;54(3):169–71 (13 ref.)

ETIOLOGY

Splenic metastasis from a rectal tumour: an unusual presentation. Achuthan R, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):139 (4 ref.)
Spontaneous rupture of splenic hamartoma: a case report. Yoshizawa J, et al. **J Pediatr Surg** 1999 Mar;34(3):498–9 (8 ref.)

ULTRASONOGRAPHY

Spontaneous rupture of the spleen: role of ultrasound in diagnosis, treatment, and monitoring. Klinkert P, et al. **Eur J Surg** 1999 Jul;165(7):712–3 (5 ref.)

SPLENOMEGALY

DIAGNOSIS

[Splenomegaly. Diagnostic trends] Bordessoule D. **Rev Prat** 1998 Sep 15;48(14):1575–80 (0 ref.) **(Fre)**

PATHOLOGY

Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Kraus MD, et al. **Am J Surg Pathol** 1998 Oct;22(10):1255–66 (35 ref.)
Spontaneous decrease of spleen size in a patient with type 1 Gaucher's disease [letter] Djaldetti M, et al. **Haematologica** 1998 Aug;83(8):766–7 (7 ref.)

SPLENOPORTOGRAPHY see **PORTOGRAPHY**

SPLENOSIS

DIAGNOSIS

Isolated hepatic splenosis: first reported case. D'Angelica M, et al. **HPB Surg** 1998;11(1):39–42 (5 ref.)

SPLICEOSOMES

see related
RNA SPLICING

CHEMISTRY

Structure and assembly of the spliceosomal small nuclear ribonucleoprotein particles. Kambach C, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):222–30 (64 ref.)

GENETICS

Recognition of the 5' splice site by the spliceosome. Konarska MM. **Acta Biochim Pol** 1998;45(4):869–81 (53 ref.)
The recent origins of spliceosomal introns revisited. Logsdon JMJr. **Curr Opin Genet Dev** 1998 Dec;8(6):637–48 (92 ref.)

METABOLISM

Nuclear organization of pre-mRNA splicing factors. Sleeman JE, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):372–7 (61 ref.)

PHYSIOLOGY

Recognition of the 5' splice site by the spliceosome. Konarska MM. **Acta Biochim Pol** 1998;45(4):869–81 (53 ref.)
Flipping the switch to an active spliceosome. Murray HL, et al. **Cell** 1999 Mar 5;96(5):599–602 (14 ref.)
Spliceosome assembly: the unwinding role of DEAD-box proteins. Hamm J, et al. **Curr Biol** 1998 Jul 16;8(15):R532–4 (9 ref.)

SPLICING, ALTERNATIVE see **ALTERNATIVE SPLICING**

SPLICING, RNA see **RNA SPLICING**

SPLINTS

see related
STENTS

Bimaxillary surgery using an intermediate splint to position the maxilla [see comments] Ellis E 3rd. **J Oral Maxillofac Surg** 1999 Jan;57(1):53–6 (52 ref.)
Comment in: J Oral Maxillofac Surg 1999 Jan;57(1):57–60.
[Management and after-care of extensor tendon injuries of the hand] Partecke BD, et al. **Unfallchirurg** 1998 Nov; 101(11):807–12 (18 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Neoprene splinting: dermatological issues. Stern EB, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):573–8 (40 ref.)

SPLINTS, PERIODONTAL see **PERIODONTAL SPLINTS**

SPLIT GENES see **GENES**

SPONDYLARTHRITIS ANKYLOPOIETICA see **SPONDYLITIS, ANKYLOSING**

SPONDYLITIS

Inflammatory disorders of the cervical spine. Reiter MF, et al. **Spine** 1998 Dec 15;23(24):2755–66 (79 ref.)

COMPLICATIONS

The role of inflammation in disk herniation-associated radiculopathy. Goupille P, et al. **Semin Arthritis Rheum** 1998 Aug;28(1):60–71 (103 ref.)

DIAGNOSIS

Clinical aspects of the spondyloarthropathies. Gladman DD. **Am J Med Sci** 1998 Oct;316(4):234–8 (29 ref.)
Spinal infection. Tyrrell PN, et al. **Eur Radiol** 1999; 9(6):1066–77 (50 ref.)
[Candida spondylitis. Case report and review of the literature] Andermahr J, et al. **Unfallchirurg** 1998 Dec;101(12):955–9 (27 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

HLA-B27 and the seronegative spondyloarthropathies. Reveille JD. **Am J Med Sci** 1998 Oct;316(4):239–49 (132 ref.)

MICROBIOLOGY

[Osteoarticular tuberculosis with emphasis on tuberculous spondylitis] Ehara S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):211–3 (7 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Clinical aspects of the spondyloarthropathies. Gladman DD. **Am J Med Sci** 1998 Oct;316(4):234–8 (29 ref.)

SPONDYLITIS, ANKYLOSING

Clinical aspects, outcome assessment, disease course, and extra-articular features of spondyloarthropathies. Kerr HE, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):235–7 (13 ref.)
Ankylosing spondylitis: time to focus on ankylosis [editorial] Archer JR, et al. **J Rheumatol** 1999 Apr;26(4):761–4 (37 ref.)
Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):1003–5 (16 ref.)
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr;26(4):951–4 (12 ref.)
Inflammatory disorders of the cervical spine. Reiter MF, et al. **Spine** 1998 Dec 15;23(24):2755–66 (79 ref.)

BLOOD

Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. Ruof J, et al. **J Rheumatol** 1999 Apr;26(4):966–70 (36 ref.)

CLASSIFICATION

The spondylarthropathies: classification and diagnosis. Do we need new terminologies? Schumacher HR, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):551–65 (75 ref.)

COMPLICATIONS

Ankylosing spondylitis and multiple sclerosis. Libbrecht N, et al. **Acta Clin Belg** 1999 Jan–Feb;54(1):30–2 (6 ref.)
Spondyloarthritides in females. Gran JT, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):695–715 (98 ref.)
Pulmonary manifestations of ankylosing spondylitis and relapsing polychondritis. Lee-Chiong TL Jr. **Clin Chest Med** 1998 Dec;19(4):747–57, ix (89 ref.)
Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Strobel ES, et al. **Clin Rheumatol** 1998;17(6):524–30 (43 ref.)
Enthesitis in spondyloarthropathy. McGonagle D, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):244–50 (39 ref.)

DIAGNOSIS

The spectrum of skin, mucosa and other extra-articular manifestations. Angulo J, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):649–64 (76 ref.)
The spondylarthropathies: classification and diagnosis. Do we need new terminologies? Schumacher HR, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):551–65 (75 ref.)
Bacterial antigens in reactive arthritis and spondarthritis. Rational use of laboratory testing in diagnosis and follow-up. Wollenhaupt J, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):627–47 (61 ref.)
Clinimetric concepts in outcome assessment: the OMERACT filter. Bellamy N. **J Rheumatol** 1999 Apr;26(4):948–50 (19 ref.)
Features of spondyloarthritis around the world. Lau CS, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):753–70 (88 ref.)
Ankylosing spondylitis. Clinical features. van der Linden S, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):663–76, vii (40 ref.)
[Imaging diagnosis in suspected inflammatory rheumatoid axial skeleton diseases (sacroiliitis)] Bollow M, et al. **Z Rheumatol** 1999 Apr;58(2):61–70 (40 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Current guidelines for the drug treatment of ankylosing spondylitis. Toussirot E, et al. **Drugs** 1998 Aug;56(2):225–40 (126 ref.)
Therapeutic aspects of spondyloarthropathies — a review. Leirisalo-Repo M. **Scand J Rheumatol** 1998;27(5):323–8 (71 ref.)
[Vitamin E in therapy of rheumatic diseases (see comments)] Sangha O, et al. **Z Rheumatol** 1998 Aug;57(4):207–14 (63 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1998 Aug;57(4):203–6. **(Ger)**

EPIDEMIOLOGY

Eye involvement in the spondyloarthropathies. Bañares A, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):771–84, ix (42 ref.)

SPONDYLITIS, ANKYLOSING

ETIOLOGY

Androgens and ankylosing spondylitis: a role in the pathogenesis? Giltay EJ, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:340–64; discussion 365 (129 ref.)

Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Montenegro V, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):265–72 (103 ref.)

[Pathogenesis of Bechterew disease] Gran JT. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4537–40 (51 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Animal models and in vitro models for the study of aetiopathogenesis of spondyloarthropathies. Breban M. **Baillieres Clin Rheumatol** 1998 Nov;12(4):611–26 (72 ref.)

The immunogenetics of the seronegative spondyloarthropathies. al–Khonizy W, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):567–88 (136 ref.)

Immunogenetics, HLA–B27 and spondyloarthropathies. González S, et al. **Curr Opin Rheumatol** 1999 Jul; 11(4):257–64 (58 ref.)

The role of HLA–B27 polymorphism and molecular mimicry in spondylarthropathy. López–Larrea C, et al. **Mol Med Today** 1998 Dec;4(12):540–9 (49 ref.)

Unusual MHC–I genes and spondylarthropathies. Wanner V, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):41S–44S (26 ref.)

Genes in the spondyloarthropathies. Wordsworth P. **Rheum Dis Clin North Am** 1998 Nov;24(4):845–63 (48 ref.)

IMMUNOLOGY

The pathogenesis of HLA–B27 arthritis: role of HLA–B27 in bacterial defense. Ikeda M, et al. **Am J Med Sci** 1998 Oct;316(4):257–63 (38 ref.)

HLA–B27 and the seronegative spondyloarthropathies. Reveille JD. **Am J Med Sci** 1998 Oct;316(4):239–49 (132 ref.)

Arthritis in HLA–B27 transgenic animals. Taurog JD. **Am J Med Sci** 1998 Oct;316(4):250–6 (43 ref.)

The immunogenetics of the seronegative spondyloarthropathies. al–Khonizy W, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):567–88 (136 ref.)

Immunogenetics, HLA–B27 and spondyloarthropathies. González S, et al. **Curr Opin Rheumatol** 1999 Jul; 11(4):257–64 (58 ref.)

Spondyloarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1999 Jul;11(4):233–4 (5 ref.)

Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Montenegro V, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):265–72 (103 ref.)

Animal models of human leukocyte antigen B27–linked arthritides [published erratum appears in Rheum Dis Clin North Am 1998 Feb;25(1):preceding Preface] Khare SD, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):883–94, xi–xii (66 ref.)

Ankylosing spondylitis. Clinical features. van der Linden S, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):663–76, vii (40 ref.)

MICROBIOLOGY

Aetiological agents: their molecular biology and phagocyte–host interaction. Koehler L, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):589–609 (64 ref.)

PATHOLOGY

The histopathology of ankylosing spondylitis: are there unifying hypotheses? Poole AR. **Am J Med Sci** 1998 Oct; 316(4):228–33 (33 ref.)

Clinical, epidemiologic, and therapeutic aspects of ankylosing spondylitis. Gran JT, et al. **Curr Opin Rheumatol** 1998 Jul; 10(4):292–8 (43 ref.)

PHYSIOPATHOLOGY

The histopathology of ankylosing spondylitis: are there unifying hypotheses? Poole AR. **Am J Med Sci** 1998 Oct; 316(4):228–33 (33 ref.)

Measures of outcome in ankylosing spondylitis and other spondyloarthritides. van der Heijde DM, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):683–93 (26 ref.)

Spondyloarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1999 Jul;11(4):233–4 (5 ref.)

Comparison of the Dougados Functional Index and the Bath Ankylosing Spondylitis Functional Index. A literature review. Ruof J, et al. **J Rheumatol** 1999 Apr;26(4):955–60 (38 ref.)

Classification of inflammatory arthritis by enthesitis [see comments] McGonagle D, et al. **Lancet** 1998 Oct 3; 352(9134):1137–40 (43 ref.) Comment in: Lancet 1998 Dec 12;352(9144):1938. Comment in: Lancet 1998 Dec 12;352(9144):1938–9. Comment in: Lancet 1999 May 1;353(9163):1526–7.

PSYCHOLOGY

Quality of life in patients with ankylosing spondylitis. Ward MM. **Rheum Dis Clin North Am** 1998 Nov;24(4):815–27, x (60 ref.)

RADIOGRAPHY

Plain radiographs as an outcome measure in ankylosing spondylitis. van der Heijde D, et al. **J Rheumatol** 1999 Apr; 26(4):985–7 (17 ref.)

Radiologic diagnosis and pathology of the spondyloarthropathies. Braun J, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):697–735 (178 ref.)

REHABILITATION

Quality of life in patients with ankylosing spondylitis. Ward MM. **Rheum Dis Clin North Am** 1998 Nov;24(4):815–27, x (60 ref.)

SURGERY

Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Van Royen BJ, et al. **Ann Rheum Dis** 1999 Jul;58(7):399–406 (65 ref.)

Multisegmental cervical spondylotic myelopathy and radiculopathy treated by multilevel oblique corpectomies without fusion. George B, et al. **Neurosurgery** 1999 Jan; 44(1):81–90 (117 ref.)

Rheumatic diseases. **Scand J Rheumatol Suppl** 1999;110:4–6 (17 ref.)

THERAPY

Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Dougados M, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):717–36 (56 ref.)

Clinical, epidemiologic, and therapeutic aspects of ankylosing spondylitis. Gran JT, et al. **Curr Opin Rheumatol** 1998 Jul; 10(4):292–8 (43 ref.)

SPONDYLODESIS see **SPINAL FUSION**

SPONDYLODISCITIS see **DISCITIS**

SPONDYLOEPIPHYSEAL DYSPLASIA see **OSTEOCHONDRODYSPLASIAS**

SPONDYLOLISTHESIS

COMPLICATIONS

[Progressive paraparesis due to cervical spondyloptosis in a child with the Klippel–Feil syndrome] Martínez Campos M, et al. **An Esp Pediatr** 1998 Sep;49(3):302–4 (11 ref.) **(Spa)**

ETIOLOGY

Traumatic L5–S1 spondylolisthesis: report of three cases and a review of the literature. Fabris D, et al. **Eur Spine J** 1999;8(4):290–5 (25 ref.)

Spondyloptosis of the cervical spine in neurofibromatosis. A case report. Goffin J, et al. **Spine** 1999 Mar 15; 24(6):587–90 (18 ref.)

SURGERY

Traumatic L5–S1 spondylolisthesis: report of three cases and a review of the literature. Fabris D, et al. **Eur Spine J** 1999;8(4):290–5 (25 ref.)

L4–L5 degenerative spondylolisthesis: indications and technique for operative management. O'Rourke MR, et al. **Iowa Orthop J** 1998;18:76–86 (42 ref.)

Degenerative lumbar stenosis: diagnosis and management. Hilibrand AS, et al. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):239–49 (41 ref.)

Management of spondylolysis and spondylolisthesis in the pediatric and adolescent population. Smith JA, et al. **Orthop Clin North Am** 1999 Jul;30(3):487–99, ix (95 ref.)

Spondyloptosis of the cervical spine in neurofibromatosis. A case report. Goffin J, et al. **Spine** 1999 Mar 15; 24(6):587–90 (18 ref.)

Management of degenerative disc disease above an L5–S1 segment requiring arthrodesis. Herkowitz HN, et al. **Spine** 1999 Jun 15;24(12):1268–70 (15 ref.)

[Lumbar interbody fusion. Biomechanical significance for the spine] Maciejczak A, et al. **Neurol Neurochir Pol** 1998 Sep–Oct;32(5):1247–59 (20 ref.) (Eng. Abstr.) **(Pol)**

SPONDYLOLYSIS

DIAGNOSIS

The radiological investigation of lumbar spondylolysis. Harvey CJ, et al. **Clin Radiol** 1998 Oct;53(10):723–8 (39 ref.)

SURGERY

Degenerative lumbar stenosis: diagnosis and management. Hilibrand AS, et al. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):239–49 (41 ref.)

Management of spondylolysis and spondylolisthesis in the pediatric and adolescent population. Smith JA, et al. **Orthop Clin North Am** 1999 Jul;30(3):487–99, ix (95 ref.)

SPONDYLOSIS see **SPINAL OSTEOPHYTOSIS**

SPONDYLOSIS DEFORMANS see **SPINAL OSTEOPHYTOSIS**

SPONDYLOSYNDESIS see **SPINAL FUSION**

SPONGES (ZOOLOGY) see **PORIFERA**

SPONGIFORM ENCEPHALOPATHIES, TRANSMISSIBLE see **PRION DISEASES**

SPONGIFORM ENCEPHALOPATHY, BOVINE see **ENCEPHALOPATHY, BOVINE SPONGIFORM**

SPONGY DISEASE OF WHITE MATTER see **CANAVAN DISEASE**

SPORES

PHYSIOLOGY

Control of sigma factor activity during Bacillus subtilis sporulation. Kroos L, et al. **Mol Microbiol** 1999 Mar; 31(5):1285–94 (51 ref.)

SPORES, BACTERIAL

GENETICS

Linking asymmetric division to cell fate: teaching an old microbe new tricks [comment] Losick R, et al. **Genes Dev** 1999 Feb 15;13(4):377–81 (43 ref.) Comment on: Genes Dev 1999 Feb 15;13(4):394–9.

An evolutionary link between sporulation and prophage induction in the structure of a repressor:anti–repressor complex. Lewis RJ, et al. **J Mol Biol** 1998 Nov 13; 283(5):907–12 (34 ref.)

PHYSIOLOGY

An evolutionary link between sporulation and prophage induction in the structure of a repressor:anti–repressor complex. Lewis RJ, et al. **J Mol Biol** 1998 Nov 13; 283(5):907–12 (34 ref.)

Bacillus subtilis spore coat. Driks A. **Microbiol Mol Biol Rev** 1999 Mar;63(1):1–20 (153 ref.)

SPOROTHRIX

ISOLATION & PURIFICATION

Sporothrix meningitis. Wescott BL, et al. **Nurse Pract** 1999 Feb;24(2):90, 93–4, 97–8 passim (19 ref.)

SPOROTRICHOSIS

[Exotic pulmonary mycoses] Dupont B. **Rev Pneumol Clin** 1998 Dec;54(6):301–8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Sporotrichosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):378–80 (17 ref.) **(Jpn)**

DIAGNOSIS

Sporothrix meningitis. Wescott BL, et al. **Nurse Pract** 1999 Feb;24(2):90, 93–4, 97–8 passim (19 ref.)

SPOROTRICHUM see **SPOROTHRIX**

SPORTS

see related
ATHLETIC INJURIES
DOPING IN SPORTS

Tobacco, youth, and sports. Epps RP, et al. **Adolesc Med** 1998 Oct;9(3):483–90, vi (20 ref.)

Assessment and management of concussion in sports [see comments] Harmon KG. **Am Fam Physician** 1999 Sep 1; 60(3):887–92, 894 (17 ref.) Comment in: Am Fam Physician 1999 Sep 1;60(3):738, 741–2.

Stimulant use in sports. Jones AR, et al. **Am J Addict** 1998 Fall;7(4):243–55 (57 ref.)

Physical fitness and vegetarian diets: is there a relation? Nieman DC. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):570S–575S (81 ref.)

Arrhythmias in the athlete with congenital heart disease: guidelines for participation. Liberthson RR. **Annu Rev Med** 1999;50:441–52 (19 ref.)

Nutrition for sport. Getting the most out of training. Burke L. **Aust Fam Physician** 1999 Jun;28(6):561–7 (9 ref.)

Viruses and athletes. Madeley CR. **Br J Sports Med** 1998 Dec;32(4):281–6 (9 ref.)

Is prevention of sudden death in young athletes feasible? Thiene G, et al. **Cardiologia** 1999 Jun;44(6):497–505 (70 ref.)

Adult participation in youth sports. A developmental perspective. Libman S. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):725–44, vii (71 ref.)

Oral creatine supplementation and athletic performance: a critical review. Juhn MS, et al. **Clin J Sport Med** 1998 Oct;8(4):286–97 (67 ref.)

Dietary examples. A practical approach to feeding athletes. Bloch TD, et al. **Clin Sports Med** 1999 Jul;18(3):703–11 (7 ref.)

Steroids and steroid–like compounds. Blue JG, et al. **Clin Sports Med** 1999 Jul;18(3):667–89, ix (109 ref.)

The female athlete triad. Putukian M. **Clin Sports Med** 1998 Oct;17(4):675–96, v (89 ref.)

Cardiac arrhythmias and the athlete. Link MS, et al. **Curr Opin Cardiol** 1999 Jan;14(1):24-9 (38 ref.)
Heart disease and other causes of sudden death in young athletes. Maron BJ. **Curr Probl Cardiol** 1998 Sep; 23(9):477-529 (148 ref.)
Sports-related cutaneous reactions: Part II. Allergic contact dermatitis to sports equipment [news] Fisher AA. **Cutis** 1999 Apr;63(4):202-4 (10 ref.)
Genetic determinants of sports participation and daily physical activity. Beunen G, et al. **Int J Obes Relat Metab Disord** 1999 Apr;23 Suppl 3:S55-63 (43 ref.)
Nutrition support programs for young adult athletes. Clark N. **Int J Sport Nutr** 1998 Dec;8(4):416-25 (33 ref.)
Pyruvate: beyond the marketing hype. Sukala WR. **Int J Sport Nutr** 1998 Sep;8(3):241-9 (36 ref.)
Effective nutrition support programs for college athletes. Vinci DM. **Int J Sport Nutr** 1998 Sep;8(3):308-20 (31 ref.)
Exercise-induced loss of bone density in athletes. Voss LA, et al. **J Am Acad Orthop Surg** 1998 Nov-Dec;6(6):349-57 (41 ref.)
Health issues for women athletes: exercise-induced amenorrhea. Warren MP. **J Clin Endocrinol Metab** 1999 Jun;84(6):1892-6 (19 ref.)
Growth hormone and body composition in athletes. Frisch H. **J Endocrinol Invest** 1999;22(5 Suppl):106-9 (24 ref.)
Pitfalls of bungee jumping. Case report and review of the literature. Louw D, et al. **J Neurosurg** 1998 Dec; 89(6):1040-2 (08 ref.)
Dehydroepiandrosterone and sport. Corrigan AB. **Med J Aust** 1999 Aug 16;171(4):206-8 (48 ref.)
The significance of dietary boron, with particular reference to athletes. Naghii MR. **Nutr Health** 1999;13(1):31-7 (15 ref.)
Exercise induced asthma in children and adolescents and the relationship to sports. Carlsen KH. **Pediatr Allergy Immunol** 1998 Nov;9(4):173-80 (80 ref.)
Exercise in hypertensive children and adolescents: any harm done? Alpert BS. **Pediatr Cardiol** 1999 Jan-Feb;20(1):66-9; discussion 70 (17 ref.)
The effect of ankle bracing on athletic performance. Bot SD, et al. **Sports Med** 1999 Mar;27(3):171-8 (54 ref.)
Anaemia and iron deficiency in athletes. Practical recommendations for treatment. Chatard JC, et al. **Sports Med** 1999 Apr;27(4):229-40 (105 ref.)
The zone diet and athletic performance. Cheuvront SN. **Sports Med** 1999 Apr;27(4):213-28 (106 ref.)
Sudden death in athletes: an update. Futterman LG, et al. **Sports Med** 1998 Nov;26(5):335-50 (35 ref.)
Attention deficit hyperactivity disorder, CNS stimulants and sport. Hickey G, et al. **Sports Med** 1999 Jan;27(1):11-21 (30 ref.)
Smoking-induced elevations in blood carboxyhaemoglobin levels. Effect on maximal oxygen uptake. McDonough P, et al. **Sports Med** 1999 May;27(5):275-83 (77 ref.)
Iron supplementation in athletes. Current recommendations. Nielsen P, et al. **Sports Med** 1998 Oct;26(4):207-16 (45 ref.)
Axillary nerve injuries in contact sports: recommendations for treatment and rehabilitation. Perlmutter GS, et al. **Sports Med** 1998 Nov;26(5):351-61 (30 ref.)
[Screening for exogenous erythropoietin] Cayla JL, et al. **Presse Med** 1999 May 15;28(18):992-6 (45 ref.) (Eng. Abstr.) **(Fre)**
[Cardiovascular diseases and sports] Stampfli U, et al. **Schweiz Rundsch Med Prax** 1999 Apr 1;88(14):601-8 (20 ref.) (Eng. Abstr.) **(Ger)**
[Clinico-functional respiratory assessment of the athlete with exercise-induced asthma or bronchospasm] Romano A, et al. **Minerva Med** 1998 Sep;89(9):315-22 (20 ref.) (Eng. Abstr.) **(Ita)**
[Use of natural vitamin supplements in children during convalescence and in children with athletic activities] Savino F, et al. **Minerva Pediatr** 1999 Jan-Feb;51(1-2):1-9 (48 ref.) (Eng. Abstr.) **(Ita)**
[The cardiovascular system and sports] Medved R, et al. **Lijec Vjesn** 1998 Jul-Aug;120(7-8):228-36 (40 ref.) (Eng. Abstr.) **(Scr)**

CLASSIFICATION

Seeking misclassification: "doping" in disability sport. Firth FY. **Br J Sports Med** 1999 Jun;33(3):152 (6 ref.)

PHYSIOLOGY

The physically challenged athlete. Clark MW. **Adolesc Med** 1998 Oct;9(3):491-9, vi (19 ref.)
Diabetes mellitus and sports. Draznin MB, et al. **Adolesc Med** 1998 Oct;9(3):457-65, v (17 ref.)
Amenorrhea in the athlete. Gidwani GP. **Adolesc Med** 1999 Jun;10(2):275-90, vii (24 ref.)
The breast and sports: issues for the clinician. Greydanus DE, et al. **Adolesc Med** 1998 Oct;9(3):533-50, vi-vii (60 ref.)
Exercise and sports in the adolescent with chronic pulmonary disease. Homnick DN, et al. **Adolesc Med** 1998 Oct; 9(3):467-81, v (78 ref.)
Nutritional supplements: fact vs. fiction. Johnson WA, et al. **Adolesc Med** 1998 Oct;9(3):501-13, vi (69 ref.)
Cardiovascular evaluation of the young athlete. Luckstead EF. **Adolesc Med** 1998 Oct;9(3):441-55, v (25 ref.)
Adolescent growth, development, and psychosocial aspects of sports participation: an overview. Patel DR, et al. **Adolesc Med** 1998 Oct;9(3):425-40, v (68 ref.)
Glutamine: a potentially useful supplement for athletes. Antonio J, et al. **Can J Appl Physiol** 1999 Feb;24(1):1-14 (64 ref.)
Effects of dehydration on exercise performance. Barr SI. **Can J Appl Physiol** 1999 Apr;24(2):164-72 (30 ref.)
Dehydration, rehydration, and exercise in the heat: rehydration strategies for athletic competition. Galloway SD. **Can J Appl Physiol** 1999 Apr;24(2):188-200 (56 ref.)
Exercise in the heat: thermoregulatory limitations to performance in humans and horses. Lindinger MI. **Can J Appl Physiol** 1999 Apr;24(2):152-63 (48 ref.)
Limitations to fluid replacement during exercise. Maughan RJ, et al. **Can J Appl Physiol** 1999 Apr;24(2):173-87 (52 ref.)
A developmental overview of child and youth sports in society. Stryer BK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):697-724, vii (88 ref.)
Nutritional requirements to increase lean mass. Grandjean A. **Clin Sports Med** 1999 Jul;18(3):623-32 (18 ref.)
Role of carbohydrate in physical activity. Ivy JL. **Clin Sports Med** 1999 Jul;18(3):469-84, v (67 ref.)
Creatine supplementation. Its role in human performance. Kraemer WJ, et al. **Clin Sports Med** 1999 Jul;18(3):651-66, ix (66 ref.)
Water and electrolyte requirements for exercise. Latzka WA, et al. **Clin Sports Med** 1999 Jul;18(3):513-24 (74 ref.)
Nutritional needs of the female athlete. Manore MM. **Clin Sports Med** 1999 Jul;18(3):549-63 (66 ref.)
Nutrition, exercise, and immune system function. Nieman DC. **Clin Sports Med** 1999 Jul;18(3):537-48 (86 ref.)
Facts and fallacies of purported ergogenic amino acid supplements. Williams MH. **Clin Sports Med** 1999 Jul; 18(3):633-49 (90 ref.)
Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Friman G, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S172-82 (85 ref.)
Future directions in exercise and immunology: regulation and integration. Mackinnon LT. **Int J Sports Med** 1998 Jul;19 Suppl 3:S205-9; discussion S209-11 (44 ref.)
The influence of training characteristics and tapering on the adaptation in highly trained individuals: a review. Mujika I. **Int J Sports Med** 1998 Oct;19(7):439-46 (83 ref.)
Effects of intensive exercise training on immunity in athletes. Pyne DB, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S183-91; discussion S191-4 (101 ref.)
Hyperhydrating with glycerol: implications for athletic performance. Wagner DR. **J Am Diet Assoc** 1999 Feb; 99(2):207-12 (19 ref.)
Exercise and the Marfan syndrome. Braverman AC. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S387-95 (37 ref.)
Does preseason screening for cardiac disease really work?: the British perspective. MacAuley D. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S345-50 (45 ref.)
The influence of exercise-induced plasma volume changes on the interpretation of biochemical parameters used for monitoring exercise, training and sport. Kargotich S, et al. **Sports Med** 1998 Aug;26(2):101-17 (123 ref.)
Applied physiology of water polo. Smith HK. **Sports Med** 1998 Nov;26(5):317-34 (74 ref.)
Lower leg pain. Diagnosis and treatment of compartment syndromes and other pain syndromes of the leg. Touliopolous S, et al. **Sports Med** 1999 Mar;27(3):193-204 (73 ref.)
The female athlete. The triad of disordered eating, amenorrhoea and osteoporosis. West RV. **Sports Med** 1998 Aug;26(2):63-71 (35 ref.)
[Effect of high performance sports on energy metabolism] Schmidt W, et al. **Wien Med Wochenschr** 1998; 148(10):239-42 (34 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Sport psychiatry. Macleod AD. **Aust N Z J Psychiatry** 1998 Dec;32(6):860-6 (66 ref.)
Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Bahrke MS, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct; 7(4):821-38 (91 ref.)
Young females in the athletic arena. Baum AL. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):745-55, viii (48 ref.)
The psychotherapist and the adolescent athlete. Begel D. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):867-77 (19 ref.)
Using sports to strengthen resiliency in children. Training heart. Bell CC, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):859-65 (33 ref.)
The psychiatric consultant in professional team sports. Calhoun JW, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):791-802 (18 ref.)
Exercise and sports in children and adolescents with developmental disabilities. Positive physical and psychosocial effects. Dykens EM, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):757-71, viii (60 ref.)
Eating disorders among athletes. Research and recommendations. Garner DM, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):839-57, x (95 ref.)
Comprehending role conflicts in the coaching of children, adolescents, and young adults. Transference, countertransference, and achievement by proxy distortion paradigms. Ogilvie BC, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):879-90 (31 ref.)
A developmental overview of child and youth sports in society. Stryer BK, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):697-724, vii (88 ref.)
The achievement by proxy spectrum in youth sports. Historical perspective and clinical approach to pressured and high-achieving children and adolescents. Tofler IR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct; 7(4):803-20, ix (47 ref.)
Relationship between sport knowledge, sport performance and academic ability: empirical evidence from GCSE Physical Education. General Certificate of Secondary Education. Dexter T. **J Sports Sci** 1999 Apr;17(4):283-95 (41 ref.)

SPORTS EQUIPMENT

see related
PROTECTIVE DEVICES

ADVERSE EFFECTS

Alpine ski bindings and injuries. Current findings. Natri A, et al. **Sports Med** 1999 Jul;28(1):35-48 (71 ref.)

SPORTS INJURIES see **ATHLETIC INJURIES**

SPORTS MEDICINE

see related
ATHLETIC INJURIES
PROTECTIVE DEVICES

Cardiovascular disease in athletes. Basilico FC. **Am J Sports Med** 1999 Jan-Feb;27(1):108-21 (70 ref.)
Deterrents to the successful clinical use of growth factors that enhance protein anabolism. Wilmore DW. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):15-21 (45 ref.)
Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine. Atkinson G, et al. **Sports Med** 1998 Oct;26(4):217-38 (90 ref.)
[Ethics in sports medicine--health and/or performance?] Andrén-Sandberg A, et al. **Lakartidningen** 1998 Nov 25; 95(48):5517-21 (9 ref.) (Eng. Abstr.) **(Swe)**

EDUCATION

Musculoskeletal rehabilitation and sports medicine. 3. Knee and lower extremity injuries. Ellen MI, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S59-67 (100 ref.)
Musculoskeletal rehabilitation and sports medicine. 4. Miscellaneous sports medicine topics. Smith J, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S68-89 (246 ref.)

METHODS

Sports medicine at work. Brown GJ. **Br J Sports Med** 1999 Feb;33(1):5 (6 ref.)
Boxing and medicine. O'Neill G. **Br J Sports Med** 1999 Jun; 33(3):153 (8 ref.)
Glycemic index--a new tool in sport nutrition? Burke LM, et al. **Int J Sport Nutr** 1998 Dec;8(4):401-15 (52 ref.)

STANDARDS

Clinical coding in sports medicine--it's good to talk. Kemp S. **Br J Sports Med** 1999 Feb;33(1):4-5 (11 ref.)
Science or show business [editorial] MacAuley D. **Br J Sports Med** 1999 Jun;33(3):147-8 (11 ref.)

SPOTTED DOLPHINS see **DOLPHINS**

SPOUSAL CONSENT see **THIRD-PARTY CONSENT**

SPOUSE ABUSE

The dynamics of leaving and recovering from an abusive relationship. Landenburger KM. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec; 27(6):700-6 (30 ref.)
Domestic violence. Eisenstat SA, et al. **N Engl J Med** 1999 Sep 16;341(12):886-92 (69 ref.)
Mandatory reporting of intimate partner violence by health care professionals: a policy review. Glass N, et al. **Nurs Outlook** 1998 Nov-Dec;46(6):279-83 (35 ref.)

DIAGNOSIS

Violence during pregnancy. Datner EM, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):645-56, vi (62 ref.)
Domestic violence against women in the international community. Haile-Mariam T, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):617-30, vi (22 ref.)

SPOUSE ABUSE

Violence against women. Haywood YC, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):603–15, vi (40 ref.)
Women battering in primary care practice. Naumann P, et al. **Fam Pract** 1999 Aug;16(4):343–52 (79 ref.)
Assessment of women for partner abuse. Fishwick NJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):661–70 (15 ref.)
Psychological abuse: a variable deserving critical attention in domestic violence. O'Leary KD. **Violence Vict** 1999 Spring;14(1):3–23 (55 ref.)

PREVENTION & CONTROL

Physical abuse during pregnancy: a significant threat to maternal and child health [editorial; comment] MacMillan HL. **CMAJ** 1999 Apr 6;160(7):1022–3 (11 ref.) Comment on: CMAJ 1999 Apr 6;160(7):1007–11.
Clergy perspectives and practices regarding intimate violence: a rural view. Strickland GA, et al. **J Rural Health** 1998 Fall;14(4):305–11 (29 ref.)

PSYCHOLOGY

Review of psychological issues in victims of domestic violence seen in emergency settings. Frank JB, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):657–77, vii (140 ref.)
Psychological abuse: a variable deserving critical attention in domestic violence. O'Leary KD. **Violence Vict** 1999 Spring;14(1):3–23 (55 ref.)

STATISTICS & NUMERICAL DATA

Women, violence with intimates, and substance abuse: relevant theory, empirical findings, and recommendations for future research. Hien D, et al. **Am J Drug Alcohol Abuse** 1998 Aug;24(3):419–38 (79 ref.)

THERAPY

Violence during pregnancy. Datner EM, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):645–56, vi (62 ref.)
Domestic violence against women in the international community. Haile-Mariam T, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):617–30, vi (22 ref.)
Violence against women. Haywood YC, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):603–15, vi (40 ref.)
Women battering in primary care practice. Naumann P, et al. **Fam Pract** 1999 Aug;16(4):343–52 (79 ref.)

SPOUSE CAREGIVERS see **CAREGIVERS**

SPOUSES

PSYCHOLOGY

Patterns of burden in wives who care for husbands with dementia. Winslow BW, et al. **Nurs Clin North Am** 1999 Jun;34(2):275–87 (31 ref.)

SPRAINS AND STRAINS

DIAGNOSIS

Lateral ankle sprains: a comprehensive review: part 1: etiology, pathoanatomy, histopathogenesis, and diagnosis. Safran MR, et al. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S429–37 (86 ref.)

ETIOLOGY

Lateral ankle sprains: a comprehensive review: part 1: etiology, pathoanatomy, histopathogenesis, and diagnosis. Safran MR, et al. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S429–37 (86 ref.)

PHYSIOPATHOLOGY

Ankle sprains and other soft tissue injuries. Liu SH, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):132–7 (71 ref.)
A review of biomechanics of the central nervous system--part II: spinal cord strains from postural loads. Harrison DE, et al. **J Manipulative Physiol Ther** 1999 Jun; 22(5):322–32 (49 ref.)

REHABILITATION

Muscle strain injury: diagnosis and treatment. Noonan TJ, et al. **J Am Acad Orthop Surg** 1999 Jul–Aug;7(4):262–9 (20 ref.)

THERAPY

Double bandaging of sprained ankles. Wilson S, et al. **BMJ** 1998 Dec 19–26;317(7174):1722–3 (14 ref.)
Managing ankle injuries in the emergency department. Birrer RB, et al. **J Emerg Med** 1999 Jul–Aug;17(4):651–60 (58 ref.)
Lateral ankle sprains: a comprehensive review part 2: treatment and rehabilitation with an emphasis on the athlete. Safran MR, et al. **Med Sci Sports Exerc** 1999 Jul; 31(7 Suppl):S438–47 (145 ref.)

SPRUE see **CELIAC DISEASE**

SPUMAVIRINAE see **SPUMAVIRUS**

SPUMAVIRUS

GENETICS

[The retroviral spumaviruses: new data in retrovirology] Saib A. **Bull Acad Natl Med** 1999;183(3):559–68 (13 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Foamy viruses are unconventional retroviruses. Linial ML. **J Virol** 1999 Mar;73(3):1747–55 (93 ref.)

SPURGE see **EUPHORBIACEAE**

SPUTUM

A safe, simple, standardized method should be used for sputum induction for research purposes [editorial; comment] Fahy JV. **Clin Exp Allergy** 1998 Sep; 28(9):1047–9 (18 ref.) Comment on: Clin Exp Allergy 1998 Sep;28(9):1081–8.

CYTOLOGY

How to measure airway inflammation: induced sputum. Gibson PG. **Can Respir J** 1998 Jul–Aug;5 Suppl A:22A–6A (28 ref.)
Induced sputum for the investigation of airway inflammation: evidence for its clinical application. Hargreave FE. **Can Respir J** 1999 Mar–Apr;6(2):169–74 (56 ref.)
Use of induced sputum to examine airway inflammation in childhood asthma. Gibson PG. **J Allergy Clin Immunol** 1998 Nov;102(5):S100–1 (14 ref.)
Induced sputum and response to glucocorticoids. Hargreave FE. **J Allergy Clin Immunol** 1998 Nov;102(5):S102–5 (36 ref.)
Analysis of induced sputum: a new approach to the study of airway inflammation in asthma. Alvarez Puebla MJ, et al. **J Investig Allergol Clin Immunol** 1999 Mar–Apr; 9(2):73–81 (81 ref.)

SQUALENE

ANALOGS & DERIVATIVES

Inhibitors of 2,3-oxidosqualene cyclase as tools for studying the mechanism and function of the enzyme. Cattel L, et al. **Crit Rev Biochem Mol Biol** 1998;33(5):353–73 (101 ref.)

METABOLISM

Molecular genetics of the Smith–Lemli–Opitz syndrome and postsqualene sterol metabolism. Fitzky BU, et al. **Curr Opin Lipidol** 1999 Apr;10(2):123–31 (69 ref.)

SQUALUS see **DOGFISH**

SQUASH see **RACQUET SPORTS**

SQUINT see **STRABISMUS**

SQUIRREL MONKEY see **SAIMIRI**

SRC-FAMILY KINASES

IMMUNOLOGY

Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway. Cornall RJ, et al. **Curr Top Microbiol Immunol** 1999;244:57–68 (67 ref.)

METABOLISM

CD45 and Src-family kinases: and now for something completely different. Ashwell JD, et al. **Immunol Today** 1999 Sep;20(9):412–6 (63 ref.)
Positive and negative regulation of Src-family membrane kinases by CD45. Thomas ML, et al. **Immunol Today** 1999 Sep;20(9):406–11 (47 ref.)
Integrin signal transduction in myeloid leukocytes. Lowell CA, et al. **J Leukoc Biol** 1999 Mar;65(3):313–20 (94 ref.)
The many faces of Src: multiple functions of a prototypical tyrosine kinase. Schwartzberg PL. **Oncogene** 1998 Sep 17; 17(11 Reviews):1463–8 (65 ref.)
Antigen receptor signaling: integration of protein tyrosine kinase functions. Tamir I, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1353–64 (203 ref.)

PHYSIOLOGY

Src-related protein tyrosine kinases in hematopoiesis. Corey SJ, et al. **Blood** 1999 Jan 1;93(1):1–14 (163 ref.)

SRC GENES see **GENES, SRC**

SRC HOMOLOGY DOMAINS

Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Buday L. **Biochim Biophys Acta** 1999 Jul 6;1422(2):187–204 (246 ref.)
The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events. McCarty JH. **Bioessays** 1998 Nov;20(11):913–21 (71 ref.)
Src homology-2 domains: structure, mechanisms, and drug discovery. Sawyer TK. **Biopolymers** 1998;47(3):243–61 (44 ref.)
The abnormal gene in X-linked lymphoproliferative syndrome. Sullivan JL. **Curr Opin Immunol** 1999 Aug; 11(4):431–4 (16 ref.)
Enigmatic relationship of Pleckstrin homology domain with phospholipid breakdown mediated signal transduction. Tyagi MG, et al. **Indian J Exp Biol** 1999 Jan;37(1):1–5 (34 ref.)
The many faces of Src: multiple functions of a prototypical tyrosine kinase. Schwartzberg PL. **Oncogene** 1998 Sep 17; 17(11 Reviews):1463–8 (65 ref.)
From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'. Sudol M. **Oncogene** 1998 Sep 17;17(11 Reviews):1469–74 (64 ref.)
[Tyrosine kinases of the Src family, enzymes with multiple functions: from the growth of fibroblasts to the migration of epithelial cells] Roche S. **C R Seances Soc Biol Fil** 1998; 192(2):357–65 (18 ref.) (Eng. Abstr.) **(Fre)**
[Structural biology of SH2 and SH3] Inagaki F. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):355–67 (35 ref.) **(Jpn)**
[Structural biology for PH and other domains involved in signal transduction] Koshiba S, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):368–79 (76 ref.) **(Jpn)**

GENETICS

Ligand recognition by SH3 and WW domains: the role of N-alkylation in PPII helices. Aghazadeh B, et al. **Chem Biol** 1999 Sep;6(9):R241–6 (34 ref.)
SOCS: suppressors of cytokine signalling. Starr R, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1081–5 (13 ref.)

PHYSIOLOGY

Regulatory role of SH3 domain-mediated protein-protein interactions in synaptic vesicle endocytosis. McPherson PS. **Cell Signal** 1999 Apr;11(4):229–38 (127 ref.)
The role of the SRC homology 2-containing inositol 5'-phosphatase in Fc epsilon R1-induced signaling. Huber M, et al. **Curr Top Microbiol Immunol** 1999;244:29–41 (39 ref.)
Binding of SH2 containing proteins to the insulin receptor: a new way for modulating insulin signalling. Liu F, et al. **Mol Cell Biochem** 1998 May;182(1–2):73–8 (42 ref.)
Emerging roles for SH2/PTB-containing Shc adaptor proteins in the developing mammalian brain. Cattaneo E, et al. **Trends Neurosci** 1998 Nov;21(11):476–81 (65 ref.)

SRC ONCOGENE PROTEIN PP60 see **ONCOGENE PROTEIN PP60(V-SRC)**

SRIH see **SOMATOSTATIN**

SRP see **SIGNAL RECOGNITION PARTICLE**

SRS-A RECEPTORS see **RECEPTORS, LEUKOTRIENE**

SSCP see **POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL**

SSPE see **SUBACUTE SCLEROSING PANENCEPHALITIS**

ST. JOHNS WORT see **THEALES**

STA-MCA BYPASS see **CEREBRAL REVASCULARIZATION**

STABILIZING AGENTS see **EXCIPIENTS**

STABLE FACTOR see **FACTOR VII**

STABLE FLY see **MUSCIDAE**

STAFF DEVELOPMENT

METHODS

Transitional portfolios: orchestrating our professional competence. Crist P, et al. **Am J Occup Ther** 1998 Oct; 52(9):729–36 (24 ref.)

STAFF DOWNSIZING see **PERSONNEL DOWNSIZING**

STAFF WORKLOAD see **WORKLOAD**

STAFFING AND SCHEDULING see **PERSONNEL STAFFING AND SCHEDULING**

STAGGERER MICE see **MICE, NEUROLOGIC MUTANTS**

STAGING, NEOPLASM see **NEOPLASM STAGING**

STAINING

see related
DYES

METHODS

Tissue staining (chromoscopy) of the gastrointestinal tract. Fennerty MB. **Can J Gastroenterol** 1999 Jun;13(5):423–9 (24 ref.)
Staining in gastrointestinal endoscopy: the basics. Canto MI. **Endoscopy** 1999 Aug;31(6):479–86 (37 ref.)
Staining in gastrointestinal endoscopy: clinical applications and limitations. Shim CS. **Endoscopy** 1999 Aug; 31(6):487–96 (72 ref.)
The Feulgen reaction 75 years on. Chieco P, et al. **Histochem Cell Biol** 1999 May;111(5):345–58 (125 ref.)
Analyzing morphogenetic cell behaviors in vitally stained zebrafish embryos. Cooper MS, et al. **Methods Mol Biol** 1999;122:185–204 (12 ref.)
General preparation of material and staining of sections. Davies HA. **Methods Mol Biol** 1999;117:1–11 (5 ref.)
Multiple antigen immunostaining procedures. Krenacs T, et al. **Methods Mol Biol** 1999;115:223–33 (15 ref.)
Staining of preparative 2–D gels. Coomassie blue and imidazole–zinc negative staining. Matsui NM, et al. **Methods Mol Biol** 1999;112:307–11 (10 ref.)
Protein detection using reversible metal chelate stains. Patton WF, et al. **Methods Mol Biol** 1999;112:331–9 (23 ref.)
Cell grafting and labeling in postimplantation mouse embryos. Quinlan GA, et al. **Methods Mol Biol** 1999;97:41–59 (13 ref.)
Immunohistochemical staining of fixed tissues. Scanziani E. **Methods Mol Biol** 1998;104:133–40 (15 ref.)

STAINLESS STEEL

The esthetic stainless steel crown bridge: report of two cases. Wright JT, et al. **Pediatr Dent** 1999 Mar–Apr;21(2):137–41 (15 ref.)

CHEMISTRY

Electrochemical concepts and techniques in the study of stainless steel ennoblement. Dickinson WH, et al. **Biodegradation** 1998;9(1):11–21 (43 ref.)

STAINS see **DYES**

STAMMERING see **STUTTERING**

STANDARD PREPARATIONS see **REFERENCE STANDARDS**

STANDARDS, REFERENCE see **REFERENCE STANDARDS**

STANNIC FLUORIDE see **TIN FLUORIDES**

STANNOUS FLUORIDE see **TIN FLUORIDES**

STANOLONE

METABOLISM

Characterization of UDP–glucuronosyltransferases active on steroid hormones. Hum DW, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):413–23 (73 ref.)
3D–structure of human estrogenic 17beta–HSD1: binding with various steroids. Lin SX, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):425–9 (16 ref.)
[Reduction of 5alpha–dehydrotestosterone in sex steroid target cells—catabolism or directed biotransformation into hormones?] Degtiar' VG, et al. **Izv Akad Nauk Ser Biol** 1998 Nov–Dec;(6):664–9 (46 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Dihydrotestosterone: a rationale for its use as a non–aromatizable androgen replacement therapeutic agent. Swerdloff RS, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):501–6 (32 ref.)

STANOZOLOL

ADVERSE EFFECTS

[Severe cholestasis with kidney failure from anabolic steroids in a body builder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Sep 10;124(36):1029–32 (17 ref.) (Eng. Abstr.) **(Ger)**

STAPES

ABNORMALITIES

Proximal symphalangism and congenital conductive hearing loss: otologic aspects. Ensink RJ, et al. **Am J Otol** 1999 May;20(3):344–9 (17 ref.)

STAPHYLOCOAGULASE see **COAGULASE**

STAPHYLOCOCCAL CLUMPING FACTOR see **COAGULASE**

STAPHYLOCOCCAL FOOD POISONING

[Staphylococcal food poisoning] Obana M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):460–2 (4 ref.) **(Jpn)**

STAPHYLOCOCCAL INFECTIONS

see related
CROSS INFECTION

Coagulase–negative staphylococci: role as pathogens. Huebner J, et al. **Annu Rev Med** 1999;50:223–36 (68 ref.)
Basic aspects of the pathogenesis of staphylococcal polymer–associated infections. von Eiff C, et al. **Infection** 1999;27 Suppl 1:S7–10 (55 ref.)
Staphylococcal infections in children: Part 1. Jain A, et al. **Pediatr Rev** 1999 Jun;20(6):183–91 (0 ref.)
[Carriers of Staphylococcus aureus as a source of nosocomial infections. Epidemiological and prophylactic aspects] Kolmos HJ. **Ugeskr Laeger** 1999 Mar 15;161(11):1580–4 (36 ref.) (Eng. Abstr.) **(Dan)**
[Methicillin resistant Staphylococcus aureus infection] Fukayama M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):179–81 (6 ref.) **(Jpn)**
[Staphylococcal sepsis] Kikuchi K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):245–7 (2 ref.) **(Jpn)**
[Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)] Kuwahara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):182–5 (15 ref.) **(Jpn)**
[Staphylococcal enterocolitis] Mizuno Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):466–9 (15 ref.) **(Jpn)**
[Staphylococcus meningitis] Nakamura I. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):293–6 (8 ref.) **(Jpn)**
[Abscess of the apocrine sweat glands] Yamamoto Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):582–4 (4 ref.) **(Jpn)**

COMPLICATIONS

Mycotic pulmonary arterial aneurysms in an intravenous drug user. McLean L, et al. **Can Respir J** 1998 Jul–Aug; 5(4):307–11 (13 ref.)
Thrombosis of a mitral valve prosthesis resulting from Staphylococcus epidermidis endocarditis. Costa GM, et al. **Cardiologia** 1999 Jul;44(7):675–8 (12 ref.)
Coagulase–negative staphylococcus endocarditis restricted to the normal pulmonic valve in a patient with end–stage renal disease: case report and review. Hussain KM, et al. **Clin Infect Dis** 1998 Dec;27(6):1550–2 (10 ref.)
A patient who survived total colonic type ulcerative colitis complicated by toxic megacolon, disseminated intravascular coagulation, methicillin–resistant Staphylococcus aureus infection and bilateral femoral phlebothrombosis. Arai H, et al. **J Gastroenterol** 1999 Jun; 34(3):395–9 (8 ref.)
Endovascular occlusion of a carotid pseudoaneurysm complicating deep neck space infection in a child. Case report. Reisner A, et al. **J Neurosurg** 1999 Sep;91(3):510–4 (31 ref.)
Schistosomiasis and associated infections. Lambertucci JR, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:135–9 (49 ref.)
[Meningioma with a peritumoral abscess] Onopchenko EV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar; (1):28–30 (16 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Abscess formation as a complication caused by postoperative osteomyelitis of the femur. Itokazu M, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):99–102 (7 ref.)
Staphylococcus capitis causing aortic valve endocarditis. al–Rashdan A, et al. **J Heart Valve Dis** 1998 Sep; 7(5):518–20 (9 ref.)
Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. Fouladi M, et al. **J Neurosurg** 1999 Sep;91(3):499–502 (17 ref.)
Life–threatening rashes: dermatologic signs of four infectious diseases. Drage LA. **Mayo Clin Proc** 1999 Jan;74(1):68–72 (10 ref.)
[Systemic infection due to implanted leads of a cardiac pacemaker. Apropos of a case and review of the literature] Delpierre S, et al. **Ann Med Interne (Paris)** 1999 Apr; 150(3):265–8 (22 ref.) (Eng. Abstr.) **(Fre)**
[Natural–valve endocarditis in patients wearing pacemakers] Climent Payá V, et al. **Rev Clin Esp** 1999 Jan;199(1):28–30 (9 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Methicillin–resistant Staphylococcus aureus: long–term care concerns. Bradley SF. **Am J Med** 1999 May 3; 106(5A):2S–10S; discussion 48S–52S (40 ref.)
Control of methicillin–resistant Staphylococcus aureus in the hospital setting. Herwaldt LA. **Am J Med** 1999 May 3; 106(5A):11S–18S; discussion 48S–52S (52 ref.)
Epidemiology of methicillin–resistant Staphylococcus aureus. Fluckiger U, et al. **Chemotherapy** 1999 Mar–Apr; 45(2):121–34 (106 ref.)
Methicillin–resistance in Staphylococcus aureus – molecular basis, novel targets and antibiotic therapy. Ehlert K. **Curr Pharm Des** 1999 Feb;5(2):45–55 (111 ref.)
The role of glycopeptide antibiotics in the treatment of infective endocarditis. Grüneberg RN, et al. **Int J Antimicrob Agents** 1999 Aug;12(3):191–8 (48 ref.)
Catalase–negative Staphylococcus aureus septicaemia [letter] Turner DP, et al. **J Infect** 1999 Mar;38(2):132–3 (11 ref.)
Methicillin–resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis—a novel hazard emerging on the horizon [editorial] Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):2999–3001 (14 ref.)
Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis [see comments] McCaffery K, et al. **Thorax** 1999 May;54(5):380–3 (20 ref.) Comment in: Thorax 1999 May;54(5):377–8.
[Emergence of hetero–VRSA strains in Japanese hospitals and its countermeasure] Inaba Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2699–705 (21 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Complicated neonatal submandibular suppurative sialadenitis. Bafaqeeh SA. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10; 44(3):267–71 (8 ref.)

ETIOLOGY

Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded–skin syndrome. Ladhani S, et al. **Clin Microbiol Rev** 1999 Apr;12(2):224–42 (290 ref.)
Staphylococcus aureus infections in trauma patients [editorial; comment] Sheagren JN. **Crit Care Med** 1999 Apr; 27(4):692–3 (8 ref.) Comment on: Crit Care Med 1999 Apr;27(4):798–801.
The nose: an underestimated source of Staphylococcus aureus causing wound infection. Casewell MW. **J Hosp Infect** 1998 Sep;40 Suppl B:S3–11 (41 ref.)
Spinal epidural abscess associated with epidural catheterization: report of a case and a review of the literature. Okano K, et al. **Jpn J Clin Oncol** 1999 Jan; 29(1):49–52 (31 ref.)
Internal jugular vein haemodialysis catheter–induced right atrium endocarditis—case report and review of the literature. Tarng DC, et al. **Scand J Urol Nephrol** 1998 Dec;32(6):411–4 (17 ref.)
[Infection in burn patients: the problems of pathogenesis, prevention and treatment] Alekseev AA, et al. **Khirurgiia (Mosk)** 1999;(6):4–9 (14 ref.) (Eng. Abstr.) **(Rus)**
[Infectious endocarditis of prosthetic valves due to Staphylococcus capitis: a new case] Dominguez Rodriguez A, et al. **Rev Esp Cardiol** 1999 Apr;52(4):277–8 (7 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Staphylococcus aureus adhesion to bone matrix and bone–associated biomaterials. Hudson MC, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):279–84 (39 ref.)
Increasing bacteremia due to coagulase–negative staphylococci: fiction or reality? Thylefors JD, et al. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):581–9 (75 ref.)
Destructive native valve endocarditis caused by Staphylococcus lugdunensis. Burgert SJ, et al. **South Med J** 1999 Aug;92(8):812–4 (30 ref.)
[Current role of coagulase–negative staphylococci in urology] Herard A, et al. **Prog Urol** 1998 Sep;8(4):579–85 (60 ref.) (Eng. Abstr.) **(Fre)**
[Extracellular polysaccharides of coagulase–negative staphylococci and their role in pathogenicity] Kübler J. **Postepy Hig Med Dosw** 1998;52(4):311–23 (48 ref.) (Eng. Abstr.) **(Pol)**
[7 cases of Staphylococcus lugdunensis infection] Sanchis–Bayarri Vaillant V, et al. **An Med Interna** 1999 Jul;16(7):361–2 (6 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Methicillin–resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Monnet DL. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):552–9 (100 ref.)
Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. Ross EV, et al. **J Am Acad Dermatol** 1998 Dec;39(6):975–81 (33 ref.)
Eradication of nasal carriage of Staphylococcus aureus—is it cost–effective? Davey P. **J Hosp Infect** 1998 Sep;40 Suppl B:S31–7 (14 ref.)
Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. Herwaldt LA. **J Hosp Infect** 1998 Sep;40 Suppl B:S13–23 (38 ref.)
Reduction of surgical site infections in major surgery by elimination of nasal carriage of Staphylococcus aureus. Kluytmans J. **J Hosp Infect** 1998 Sep;40 Suppl B:S25–9

STAPHYLOCOCCAL INFECTIONS

(26 ref.)
New strategies for the use of mupirocin for the prevention of serious infection. Mehtar S. **J Hosp Infect** 1998 Sep;40 Suppl B:S39–44 (33 ref.)

SURGERY

[Valve repair in tricuspid endocarditis in the drug addict. Apropos a case] Castedo Mejuto E, et al. **Rev Esp Cardiol** 1999 Jan;52(1):67–70 (6 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Septic arthritis. Perry CR. **Am J Orthop** 1999 Mar; 28(3):168–78 (93 ref.)

ULTRASONOGRAPHY

Pacemaker lead infection: report of three cases and review of the literature. Voet JG, et al. **Heart** 1999 Jan;81(1):88–91 (17 ref.)
[Chronic bacterial endocarditis on the electrical catheter in a pacemaker wearer: a clinical case report] Perrone C, et al. **G Ital Cardiol** 1999 May;29(5):558–61 (21 ref.) (Eng. Abstr.) **(Ita)**

STAPHYLOCOCCAL PNEUMONIA see **PNEUMONIA, STAPHYLOCOCCAL**

STAPHYLOCOCCAL PROTEIN A

GENETICS

The analysis of translational activity using a reporter gene constructed from repeats of an antibody-binding domain from protein A. Björnsson A, et al. **Methods Mol Biol** 1998; 77:75–91 (23 ref.)

STAPHYLOCOCCAL SCALDED SKIN SYNDROME

[Staphylococcal scalded skin syndrome] Hayashi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):564–6 (15 ref.) **(Jpn)**

STAPHYLOCOCCAL SKIN INFECTIONS

Diagnosis and treatment of cutaneous bacterial infections. Khorshid SM. **Practitioner** 1998 Oct;242(1591):692–7 (2 ref.)

COMPLICATIONS

Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Abeck D, et al. **Br J Dermatol** 1998 Dec;139 Suppl 53:13–6 (31 ref.)

DRUG THERAPY

Fusidic acid in dermatology. Wilkinson JD. **Br J Dermatol** 1998 Dec;139 Suppl 53:37–40 (36 ref.)

IMMUNOLOGY

[Superantigens and their importance for inflammatory skin diseases] Olsen JV, et al. **Ugeskr Laeger** 1999 Aug 23; 161(34):4747–50 (40 ref.) (Eng. Abstr.) **(Dan)**

PHYSIOPATHOLOGY

[Cutaneous Staphylococcus aureus colonisation of atopic eczema. Mechanisms, pathophysiological importance and therapeutic consequences] Abeck D, et al. **Hautarzt** 1998 Dec;49(12):902–6 (32 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Cutaneous Staphylococcus aureus colonisation of atopic eczema. Mechanisms, pathophysiological importance and therapeutic consequences] Abeck D, et al. **Hautarzt** 1998 Dec;49(12):902–6 (32 ref.) (Eng. Abstr.) **(Ger)**

STAPHYLOCOCCUS

Leukocidal toxins of staphylococci. Szmigielski S, et al. **Zentralbl Bakteriol** 1999 Apr;289(2):185–201 (40 ref.)
[Current role of coagulase-negative staphylococci in urology] Herard A, et al. **Prog Urol** 1998 Sep;8(4):579–85 (60 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Phenotypic characteristics of coagulase-negative staphylococci: typing and antibiotic susceptibility. Jarløv JO. **APMIS Suppl** 1999;91:1–42 (92 ref.)
Destructive native valve endocarditis caused by Staphylococcus lugdunensis. Burgert SJ, et al. **South Med J** 1999 Aug;92(8):812–4 (30 ref.)

DRUG EFFECTS

Phenotypic characteristics of coagulase-negative staphylococci: typing and antibiotic susceptibility. Jarløv JO. **APMIS Suppl** 1999;91:1–42 (92 ref.)
Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. Chambers HF. **J Infect Dis** 1999 Mar;179 Suppl 2:S353–9 (58 ref.)

ENZYMOLOGY

Increasing bacteremia due to coagulase-negative staphylococci: fiction or reality? Thylefors JD, et al. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):581–9 (75 ref.)

ISOLATION & PURIFICATION

[7 cases of Staphylococcus lugdunensis infection] Sanchis-Bayarri Vaillant V, et al. **An Med Interna** 1999 Jul;16(7):361–2 (6 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. Chambers HF. **J Infect Dis** 1999 Mar;179 Suppl 2:S353–9 (58 ref.)

PATHOGENICITY

Coagulase-negative staphylococci: role as pathogens. Huebner J, et al. **Annu Rev Med** 1999;50:223–36 (68 ref.)
Basic aspects of the pathogenesis of staphylococcal polymer-associated infections. von Eiff C, et al. **Infection** 1999;27 Suppl 1:S7–10 (55 ref.)
[Extracellular polysaccharides of coagulase-negative staphylococci and their role in pathogenicity] Kübler J. **Postepy Hig Med Dosw** 1998;52(4):311–23 (48 ref.) (Eng. Abstr.) **(Pol)**

STAPHYLOCOCCUS AUREUS

Staphylococcus aureus infections in trauma patients [editorial; comment] Sheagren JN. **Crit Care Med** 1999 Apr; 27(4):692–3 (8 ref.) Comment on: Crit Care Med 1999 Apr;27(4):798–801.
Carriage of Staphylococcus aureus: epidemiology and clinical relevance. Vandenbergh MF, et al. **J Lab Clin Med** 1999 Jun;133(6):525–34 (169 ref.)
Spinal epidural abscess associated with epidural catheterization: report of a case and a review of the literature. Okano K, et al. **Jpn J Clin Oncol** 1999 Jan; 29(1):49–52 (31 ref.)
Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis [see comments] McCaffery K, et al. **Thorax** 1999 May;54(5):380–3 (20 ref.) Comment in: Thorax 1999 May;54(5):377–8.
[Carriers of Staphylococcus aureus as a source of nosocomial infections. Epidemiological and prophylactic aspects] Kolmos HJ. **Ugeskr Laeger** 1999 Mar 15;161(11):1580–4 (36 ref.) (Eng. Abstr.) **(Dan)**
[Cutaneous Staphylococcus aureus colonisation of atopic eczema. Mechanisms, pathophysiological importance and therapeutic consequences] Abeck D, et al. **Hautarzt** 1998 Dec;49(12):902–6 (32 ref.) (Eng. Abstr.) **(Ger)**
[Methicillin-cephem-resistant Staphylococcus aureus enteritis] Agawa S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):453–5 (15 ref.) **(Jpn)**
[Methicillin resistant Staphylococcus aureus infection] Fukayama M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):179–81 (6 ref.) **(Jpn)**
[Staphylococcal enterocolitis] Mizuno Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):466–9 (15 ref.) **(Jpn)**
[Staphylococcal food poisoning] Obana M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):460–2 (4 ref.) **(Jpn)**
[The mechanisms of the synergistic lethal action of enterobacterial lipopolysaccharide and staphylococcal enterotoxin type A] Riabichenko EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):80–5 (50 ref.) **(Rus)**

DRUG EFFECTS

Methicillin-resistant Staphylococcus aureus: long-term care concerns. Bradley SF. **Am J Med** 1999 May 3; 106(5A):2S–10S; discussion 48S–52S (40 ref.)
Control of methicillin-resistant Staphylococcus aureus in the hospital setting. Herwaldt LA. **Am J Med** 1999 May 3; 106(5A):11S–18S; discussion 48S–52S (52 ref.)
The threat of vancomycin resistance. Perl TM. **Am J Med** 1999 May 3;106(5A):26S–37S; discussion 48S–52S (67 ref.)
Epidemiology of methicillin-resistant Staphylococcus aureus. Fluckiger U, et al. **Chemotherapy** 1999 Mar–Apr; 45(2):121–34 (106 ref.)
Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Proctor RA, et al. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S68–74 (83 ref.)
Methicillin-resistance in Staphylococcus aureus – molecular basis, novel targets and antibiotic therapy. Ehlert K. **Curr Pharm Des** 1999 Feb;5(2):45–55 (111 ref.)
Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods. Low DE. **Infect Dis Clin North Am** 1998 Sep;12(3):613–30, viii (124 ref.)
MRSA in cystic fibrosis. London, 16 June 1997. **J Hosp Infect** 1998 Nov;40(3):179–91 (17 ref.)
Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Giesbrecht P, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1371–414 (146 ref.)
Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis--a novel hazard emerging on the horizon [editorial] Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):2999–3001 (14 ref.)
[Methicillin-resistant Staphylococcus aureus: evolution and epidemiology, clinical impact, and prevention] Brun-Buisson C. **Pathol Biol (Paris)** 1998 Apr;46(4):227–34 (80 ref.) (Eng. Abstr.) **(Fre)**
[Emergence of hetero-VRSA strains in Japanese hospitals and its countermeasure] Inaba Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2699–705 (21 ref.) (Eng. Abstr.) **(Jpn)**
[MRSA] Machida K. **Rinsho Byori** 1999 Jun;47(6):533–8 (0 ref.) **(Jpn)**
[Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)] Kuwahara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):182–5 (15 ref.) **(Jpn)**

GENETICS

Expression of a clone specific DNA sequence from Staphylococcus aureus in Escherichia coli. el-Adhami W. **J Biotechnol** 1999 Aug 20;73(2–3):181–4 (18 ref.)
Decreased antimicrobial resistance after changes in antibiotic use. Smith DW. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):129S–132S; discussion 133S–137S (26 ref.)

GROWTH & DEVELOPMENT

Reduced susceptibility of Staphylococcus aureus to vancomycin--a review of current knowledge. Paterson DL. **Commun Dis Intell** 1999 Mar 18;23(3):69–73 (30 ref.)

IMMUNOLOGY

Structure and function of streptococcal and staphylococcal superantigens in septic shock. Bannan J, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):387–96, ix (69 ref.)

ISOLATION & PURIFICATION

Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. Ross EV, et al. **J Am Acad Dermatol** 1998 Dec;39(6):975–81 (33 ref.)
Catalase-negative Staphylococcus aureus septicaemia [letter] Turner DP, et al. **J Infect** 1999 Mar;38(2):132–3 (11 ref.)
Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Hsieh WS, et al. **Pediatrics** 1999 Apr;103(4):e53 (30 ref.)

METABOLISM

[Pore-forming leukotoxins from Staphylococcus aureus: variability of the target cells and 2 pharmacological processes] Prévost G, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):435–41 (40 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Ladhani S, et al. **Clin Microbiol Rev** 1999 Apr;12(2):224–42 (290 ref.)
Staphyloccal alpha toxin. Palmer M. **Soc Appl Bacteriol Symp Ser** 1998;27:125S–126S (1 ref.)
[Staphylococcal scalded skin syndrome] Hayashi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):564–6 (15 ref.) **(Jpn)**
[Impetigo contagiosa (staphylococcal, streptococcal)] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):560–3 (10 ref.) **(Jpn)**

PHYSIOLOGY

Staphylococcus aureus adhesion to bone matrix and bone-associated biomaterials. Hudson MC, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):279–84 (39 ref.)
Surface protein adhesins of Staphylococcus aureus. Foster TJ, et al. **Trends Microbiol** 1998 Dec;6(12):484–8 (48 ref.)
Acquisition of methicillin resistance and progression of multiantibiotic resistance in methicillin-resistant Staphylococcus aureus. Ito T, et al. **Yonsei Med J** 1998 Dec;39(6):526–33 (31 ref.)

ULTRASTRUCTURE

Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Giesbrecht P, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1371–414 (146 ref.)

STAPHYLOCOCCUS EPIDERMIDIS

Thrombosis of a mitral valve prosthesis resulting from Staphylococcus epidermidis endocarditis. Costa GM, et al. **Cardiologia** 1999 Jul;44(7):675–8 (12 ref.)
Pacemaker lead infection: report of three cases and review of the literature. Voet JG, et al. **Heart** 1999 Jan;81(1):88–91 (17 ref.)
Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. Fouladi M, et al. **J Neurosurg** 1999 Sep;91(3):499–502 (17 ref.)
[Chronic bacterial endocarditis on the electrical catheter in a pacemaker wearer: a clinical case report] Perrone C, et

al. **G Ital Cardiol** 1999 May;29(5):558–61 (21 ref.) (Eng. Abstr.) **(Ita)**
[Natural-valve endocarditis in patients wearing pacemakers] Climent Payá V, et al. **Rev Clin Esp** 1999 Jan;199(1):28–30 (9 ref.) (Eng. Abstr.) **(Spa)**

STAPHYLOMYCIN see **VIRGINIAMYCIN**

STAPLES, SURGICAL see **SUTURES**

STARCH

[Pica in Germany—amylophagia as the etiology of iron deficiency anemia] Menge H, et al. **Z Gastroenterol** 1998 Aug;36(8):635–40 (27 ref.) (Eng. Abstr.) **(Ger)**
[A new hydroxyethyl starch for volume replacement: Elohes 6%] Medel J, et al. **Rev Esp Anestesiol Reanim** 1998 Nov; 45(9):389–96 (68 ref.) (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Starch granules: structure and biosynthesis. Buléon A, et al. **Int J Biol Macromol** 1998 Aug;23(2):85–112 (211 ref.)

CHEMISTRY

Starch granules: structure and biosynthesis. Buléon A, et al. **Int J Biol Macromol** 1998 Aug;23(2):85–112 (211 ref.)

IMMUNOLOGY

Polymer-grafted starch microparticles for oral and nasal immunization. McDermott MR, et al. **Immunol Cell Biol** 1998 Jun;76(3):256–62 (52 ref.)

METABOLISM

Commodity scale production of sugars from starches. Crabb WD, et al. **Curr Opin Microbiol** 1999 Jun;2(3):252–6 (30 ref.)
Starch digestion in infancy. Christian M, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):116–24 (112 ref.)

PHARMACOLOGY

[Medical aspect of food starch] Maksimov VI, et al. **Vopr Pitan** 1999;68(1):46–8 (49 ref.) (Eng. Abstr.) **(Rus)**

STARFISH

CYTOLOGY

Cell cycle arrest and release in starfish oocytes and eggs [see comments] Kishimoto T. **Semin Cell Dev Biol** 1998 Oct; 9(5):549–57 (50 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–7.

STARTLE REACTION

DRUG EFFECTS

Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Geyer MA. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:73–9 (47 ref.)

PHYSIOLOGY

Cross-species studies of sensorimotor gating of the startle reflex. Swerdlow NR, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:202–16 (108 ref.)
Physiologic measures of emotion. Bauer RM. **J Clin Neurophysiol** 1998 Sep;15(5):388–96 (62 ref.)
Anatomic and physiologic substrates of emotion in an animal model. Davis M. **J Clin Neurophysiol** 1998 Sep;15(5):378–87 (67 ref.)
The neurobiology of startle. Koch M. **Prog Neurobiol** 1999 Oct;59(2):107–28 (259 ref.)

STARVATION

see related
HUNGER

METABOLISM

Adaptation to low energy intakes: the responses and limits to low intakes in infants, children and adults. Shetty PS. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S14–33 (151 ref.)
Regulation of insulin-like growth factor-I in starvation and injury. Thissen JP, et al. **Nutr Rev** 1999 Jun;57(6):167–76 (53 ref.)

PHYSIOPATHOLOGY

Physiological effects of starvation interpreted as food allergy. Bethune CA, et al. **BMJ** 1999 Jul 31;319(7205):304–5 (4 ref.)
Adaptation to low energy intakes: the responses and limits to low intakes in infants, children and adults. Shetty PS. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S14–33 (151 ref.)

STASIS ULCER see **VARICOSE ULCER**

STATE GOVERNMENT

An overview of state efforts to improve transfusion medicine. The New York state model. Linden JV, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):482–5 (10 ref.)
Antitrust enforcement in the healthcare industry: the expanding scope of state activity. Hellinger FJ. **Health Serv Res** 1998 Dec;33(5 Pt 2):1477–94 (35 ref.)
Nonprofit conversion: theory, evidence, and state policy options. Marsteller JA, et al. **Health Serv Res** 1998 Dec; 33(5 Pt 2):1495–535 (90 ref.)
The spread of state any willing provider laws. Ohsfeldt RL, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1537–62 (26 ref.)
Sending a policy signal: state legislatures, medical schools, and primary care mandates. Weissert CS, et al. **J Health Polit Policy Law** 1998 Oct;23(5):743–70 (39 ref.)

STATE HEALTH PLANNING, UNITED STATES see **HEALTH PLANNING**

STATE HEALTH PLANS

LEGISLATION & JURISPRUDENCE

State regulation of managed care: the impact on children. Anderson GF. **Future Child** 1998 Summer-Fall;8(2):76–92 (70 ref.)

ORGANIZATION & ADMINISTRATION

The Oregon Health Plan and the political paradox of rationing: what advocates and critics have claimed and what Oregon did. Jacobs L, et al. **J Health Polit Policy Law** 1999 Feb;24(1):161–80 (19 ref.)
Oregon's bold experiment: whatever happened to rationing? Leichter HM. **J Health Polit Policy Law** 1999 Feb; 24(1):147–60 (17 ref.)
The new child health insurance expansions: how will school-based health centers fit in? Koppelman J, et al. **J Sch Health** 1998 Dec;68(10):441–6 (8 ref.)
A systems approach to developing staff training. Giffort DW. **New Dir Ment Health Serv** 1998 Fall;(79):25–33 (23 ref.)
Medicaid managed care and public health data. Rutherford GW, et al. **Public Health Rep** 1999 May-Jun;114(3):225–30 (25 ref.)

TRENDS

Improving state Medicaid contracts and plan practices for children with special needs. Fox HB, et al. **Future Child** 1998 Summer-Fall;8(2):105–18 (10 ref.)

STATE MEDICINE

Evidence-based policy-making in the NHS: exploring the interface between research and the commissioning process. Harries U, et al. **J Public Health Med** 1999 Mar;21(1):29–36 (16 ref.)

LEGISLATION & JURISPRUDENCE

Mental incapacity: some proposals for legislative reform. McHale JV. **J Med Ethics** 1998 Oct;24(5):322–7 (67 ref.)

ORGANIZATION & ADMINISTRATION

Professional self respect: rights and responsibilities in the new NHS [see comments] Richards P. **BMJ** 1998 Oct 24; 317(7166):1146–8 (20 ref.) Comment in: BMJ 1999 Mar 13;318(7185):734. Comment in: BMJ 1999 Mar 13;318(7185):734–5.
Long stay care and the NHS: discontinuities between policy and practice [see comments] Turrell AR, et al. **BMJ** 1998 Oct 3;317(7163):942–4 (21 ref.) Comment in: BMJ 1999 Mar 6;318(7184):668.
New labour and the third way in the British National Health Service. Powell M. **Int J Health Serv** 1999;29(2):353–70 (82 ref.)
The new public management and the new nursing: related by rhetoric? Some reflections on the policy process and nursing. Hewison A. **J Adv Nurs** 1999 Jun;29(6):1377–84 (49 ref.)
The lack of integration of clinical audit and the maintenance of medical dominance within British hospital trusts. McErlain-Burns TL, et al. **J Eval Clin Pract** 1999 Aug; 5(3):323–33 (36 ref.)
Genuine federalism in the Russian health care system: changing roles of government. Chernichovsky D, et al. **J Health Polit Policy Law** 1999 Feb;24(1):115–44 (38 ref.)
Models of commissioning health services in the British National Health Service: a literature review. Chappel D, et al. **J Public Health Med** 1999 Jun;21(2):221–7 (75 ref.)
A knowledge-based health service: how do the new initiatives work? Stevens A, et al. **J R Soc Med** 1998;91 Suppl 35:26–31 (26 ref.)
The role and education of doctors in the delivery of health care. Chantler C. **Lancet** 1999 Apr 3;353(9159):1178–81 (17 ref.)
Organizational changes in Estonia. Everaus H. **Vox Sang** 1998;74 Suppl 2:531–3 (7 ref.)

STANDARDS

Performance indicators for primary care groups: an evidence based approach [see comments] McColl A, et al. **BMJ** 1998 Nov 14;317(7169):1354–60 (43 ref.) Comment in: BMJ 1999 Mar 20;318(7186):803; discussion 804–5. Comment in: BMJ 1999 Mar 20;318(7186):803–4; discussion 804–5. Comment in: BMJ 1999 Mar 20;318(7186):804–5.

TRENDS

Telemedicine in the NHS for the millennium and beyond. Wallace S, et al. **Postgrad Med J** 1998 Dec;74(878):721–8 (49 ref.)

STATE-OF-THE-ART REVIEW see **REVIEW LITERATURE**

STATIC ELECTRICITY see **ELECTROSTATICS**

STATISTICAL BIAS see **BIAS (EPIDEMIOLOGY)**

STATISTICAL COMPUTING see **MATHEMATICAL COMPUTING**

STATISTICAL MODELS see **MODELS, STATISTICAL**

STATISTICAL REGRESSION see **REGRESSION ANALYSIS**

STATISTICS

see related
BIBLIOMETRICS
BIOMETRY
META-ANALYSIS
MODELS, STATISTICAL
PSYCHOMETRICS

Précis of statistical significance: rationale, validity, and utility. Chow SL. **Behav Brain Sci** 1998 Apr;21(2):169–94; discussion 194–239 (241 ref.)
Statistics notes: variables and parameters. Altman DG, et al. **BMJ** 1999 Jun 19;318(7199):1667 (2 ref.)
Fundamental concepts in statistics: elucidation and illustration. Curran-Everett D, et al. **J Appl Physiol** 1998 Sep;85(3):775–86 (51 ref.)
The significance of non-significance. Berry EM, et al. **QJM** 1998 Sep;91(9):647–53 (13 ref.)
Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine. Atkinson G, et al. **Sports Med** 1998 Oct;26(4):217–38 (90 ref.)
[Capture-recapture methods and its uses in epidemiology] Qiu C, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):54–5 (8 ref.) **(Chi)**
[Key points in applying statistics to toxicological tests] Hamada C. **J Toxicol Sci** 1998 Dec;23(5):App.185–9 (5 ref.) **(Jpn)**

METHODS

People and eyes: statistical approaches in ophthalmology. Murdoch IE, et al. **Br J Ophthalmol** 1998 Aug;82(8):971–3 (17 ref.)
Statistical analysis of the performance of diagnostic tests. Sasieni PD. **Cytopathology** 1999 Apr;10(2):73–8 (1 ref.)
Analysing qualitative data: computerized and other approaches. Webb C. **J Adv Nurs** 1999 Feb;29(2):323–30 (29 ref.)
Conceptual and statistical issues in the validation of analytic dilution assays for pharmaceutical applications. Smith WC, et al. **J Biopharm Stat** 1998 Nov;8(4):509–32 (26 ref.)
Statistics of sexual size dimorphism. Smith RJ. **J Hum Evol** 1999 Apr;36(4):423–58 (150 ref.)
Tree-type algorithm for statistical analysis in chronic toxicity studies. Hamada C, et al. **J Toxicol Sci** 1998 Aug; 23(3):173–81 (15 ref.)
The presentation of statistics. Bryant TN. **Pediatr Allergy Immunol** 1998 Aug;9(3):108–15 (16 ref.)

STATISTICS, NONPARAMETRIC

Review of inference procedures for the interclass correlation coefficient with emphasis on applications to family studies. Donner A, et al. **Genet Epidemiol** 1998;15(6):627–46 (47 ref.)
Identifying efficiently and economically operated hospitals: the prospects and pitfalls of applying frontier regression techniques. Chirikos TN. **J Health Polit Policy Law** 1998 Dec;23(6):879–904 (16 ref.)
Misuse of correlation and regression in three medical journals. Porter AM. **J R Soc Med** 1999 Mar;92(3):123–8 (39 ref.)
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Gooley TA, et al. **Stat Med** 1999 Mar 30;18(6):695–706 (20 ref.)
Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Koch GG, et al. **Stat Med** 1998 Aug 15-30;17(15-16):1863–92 (46 ref.)

STATOCONIA see **OTOLITHIC MEMBRANE**

STATUS ASTHMATICUS

DRUG THERAPY

Intravenous magnesium sulfate treatment in a child with

STATUS ASTHMATICUS

status asthmaticus. Dib JG, et al. **Am J Health Syst Pharm** 1999 May 15;56(10):997–1000 (24 ref.)
[The treatment of asthmatic crisis] Puente-Maestu L, et al. **Rev Clin Esp** 1999 Jul;199(7):473–7 (43 ref.) **(Spa)**

THERAPY

Ventilatory care in status asthmaticus. Smyth RJ. **Can Respir J** 1998 Nov–Dec;5(6):485–90 (43 ref.)

STATUS DYSRAPHICUS see **SPINAL DYSRAPHISM**

STATUS EPILEPTICUS

Status epilepticus: new concepts. Alldredge BK, et al. **Curr Opin Neurol** 1999 Apr;12(2):183–90 (53 ref.)

COMPLICATIONS

Evidence against permanent neurologic damage from nonconvulsive status epilepticus. Drislane FW. **J Clin Neurophysiol** 1999 Jul;16(4):323–31; discussion 353 (50 ref.)
Epidemiology and evidence for morbidity of nonconvulsive status epilepticus. Krumholz A. **J Clin Neurophysiol** 1999 Jul;16(4):314–22; discussion 353 (55 ref.)
[Hemicerebral atrophy and epilepsy in an adult] Viala K, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):45–50 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Status epilepticus: an overview of the clinical problem. Lowenstein DH. **Epilepsia** 1999;40 Suppl 1:S3–8; discussion S21–2 (25 ref.)
An algorithm for diagnosis and treatment of status epilepticus in adults. Gilbert K. **J Neurosci Nurs** 1999 Feb;31(1):27–9, 34–6 (19 ref.)
Seizure management in pediatric patients for the nineties. Wolf SM, et al. **Pediatr Ann** 1998 Oct;27(10):653–64 (46 ref.)
[Status epilepticus. Rational diagnosis and current therapeutic concepts] Schwarz S, et al. **Anaesthesist** 1999 Jul; 48(7):455–64 (87 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Role of propofol in refractory status epilepticus. Brown LA, et al. **Ann Pharmacother** 1998 Oct;32(10):1053–9 (33 ref.)
Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Rey E, et al. **Clin Pharmacokinet** 1999 Jun;36(6):409–24 (98 ref.)
Use of midazolam in the treatment of refractory status epilepticus. Hanley DF, et al. **Clin Ther** 1998 Nov–Dec; 20(6):1093–105 (44 ref.)
Management approaches to prolonged seizures and status epilepticus. Bleck TP. **Epilepsia** 1999;40 Suppl 1:S59–63; discussion S64–6 (24 ref.)
Use of midazolam for refractory status epilepticus in pediatric patients. Pellock JM. **J Child Neurol** 1998 Dec;13(12):581–7 (58 ref.)
Use of intramuscular midazolam for status epilepticus. Towne AR, et al. **J Emerg Med** 1999 Mar–Apr;17(2):323–8 (44 ref.)
An algorithm for diagnosis and treatment of status epilepticus in adults. Gilbert K. **J Neurosci Nurs** 1999 Feb;31(1):27–9, 34–6 (19 ref.)
Midazolam and pentobarbital for refractory status epilepticus. Holmes GL, et al. **Pediatr Neurol** 1999 Apr;20(4):259–64 (37 ref.)

EPIDEMIOLOGY

Epidemiology and evidence for morbidity of nonconvulsive status epilepticus. Krumholz A. **J Clin Neurophysiol** 1999 Jul;16(4):314–22; discussion 353 (55 ref.)

ETIOLOGY

De novo status epilepticus as the presenting sign of neurosyphilis. Primavera A, et al. **Epilepsia** 1998 Dec; 39(12):1367–9 (11 ref.)
Non-convulsive status epilepticus complicating electroconvulsive therapy [letter] Solomons K, et al. **Int J Geriatr Psychiatry** 1998 Oct;13(10):731–4 (20 ref.)
Nonconvulsive status epilepticus in acute brain injury. Jordan KG. **J Clin Neurophysiol** 1999 Jul;16(4):332–40; discussion 353 (32 ref.)

PATHOLOGY

Status epilepticus-induced neuronal injury and network reorganization. Sloviter RS. **Epilepsia** 1999;40 Suppl 1:S34–9; discussion S40–1 (59 ref.)

PHYSIOPATHOLOGY

Status epilepticus in epileptogenesis. Kapur J. **Curr Opin Neurol** 1999 Apr;12(2):191–5 (31 ref.)
Chronic epileptogenic cellular alterations in the limbic system after status epilepticus. Coulter DA. **Epilepsia** 1999;40 Suppl 1:S23–33; discussion S40–1 (82 ref.)
Acute cellular alterations in the hippocampus after status epilepticus. Macdonald RL, et al. **Epilepsia** 1999;40 Suppl 1:S9–20; discussion S21–2 (65 ref.)
Evidence against permanent neurologic damage from nonconvulsive status epilepticus. Drislane FW. **J Clin Neurophysiol** 1999 Jul;16(4):323–31; discussion 353 (50 ref.)
Animal models of nonconvulsive status epilepticus. Hosford DA. **J Clin Neurophysiol** 1999 Jul;16(4):306–13; discussion 353 (83 ref.)
Nonconvulsive status epilepticus in acute brain injury. Jordan KG. **J Clin Neurophysiol** 1999 Jul;16(4):332–40; discussion 353 (32 ref.)
Assessing the outcomes in patients with nonconvulsive status epilepticus: nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity. Kaplan PW. **J Clin Neurophysiol** 1999 Jul; 16(4):341–52; discussion 353 (65 ref.)

THERAPY

Epilepsy emergencies: the first seizure and status epilepticus. Willmore LJ. **Neurology** 1998 Nov;51(5 Suppl 4):S34–8 (25 ref.)
Status epilepticus: current concepts [published erratum appears in Pediatr Emerg Care 1999 Jun;15(3):230] Haafiz A, et al. **Pediatr Emerg Care** 1999 Apr;15(2):119–29 (87 ref.)
[Status epilepticus. Rational diagnosis and current therapeutic concepts] Schwarz S, et al. **Anaesthesist** 1999 Jul; 48(7):455–64 (87 ref.) (Eng. Abstr.) **(Ger)**

STATUS LYMPHATICUS see **LYMPHATIC DISEASES**

STAUROSPORINE

ANALOGS & DERIVATIVES

Analogs of staurosporine: potential anticancer drugs? Gescher A. **Gen Pharmacol** 1998 Nov;31(5):721–8 (65 ref.)
[PKC 412] Lansiaux A, et al. **Bull Cancer** 1999 Jul–Aug; 86(7–8):614–7 (25 ref.) **(Fre)**

STEAM

[Treatment of subglottic laryngitis (pseudocroup): steroids instead of steam (see comments)] Roorda RJ, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1658–62 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2117. Comment in: Ned Tijdschr Geneeskd 1998 Nov 28;142(48):2646–7. **(Dut)**

STEAROYL-COA DESATURASE

GENETICS

Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. Ntambi JM. **J Lipid Res** 1999 Sep;40(9):1549–58 (86 ref.)

STEARYL-COA DESATURASE see **STEAROYL-COA DESATURASE**

STEATONECROSIS see **FAT NECROSIS**

STEATORRHEA see **CELIAC DISEASE**

STEEL FACTOR see **STEM CELL FACTOR**

STEELE-RICHARDSON-OLSZEWSKI SYNDROME see **SUPRANUCLEAR PALSY, PROGRESSIVE**

STEELHEAD see **ONCORHYNCHUS MYKISS**

STEELY HAIR SYNDROME see **KINKY HAIR SYNDROME**

STEIN-LEVENTHAL SYNDROME see **POLYCYSTIC OVARY SYNDROME**

STEINERT'S DISEASE see **MYOTONIA ATROPHICA**

STEM CELL FACTOR

PHYSIOLOGY

Stimulation of hematopoiesis in vivo by stem cell factor. Andrews RG, et al. **Curr Opin Hematol** 1994 May; 1(3):187–96 (123 ref.)

STEM CELL FACTOR RECEPTORS see **PROTO-ONCOGENE PROTEINS C-KIT**

STEM CELL MOBILIZATION see **HEMATOPOIETIC STEM CELL MOBILIZATION**

STEM CELL TRANSPLANTATION see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

STEM CELLS

CNS development: The obscure origins of adult stem cells. Temple S. **Curr Biol** 1999 Jun 3;9(11):R397–9 (10 ref.)
The roles of intrinsic and extrinsic cues and bHLH genes in the determination of retinal cell fates. Cepko CL. **Curr Opin Neurobiol** 1999 Feb;9(1):37–46 (55 ref.)
The germ cell--the mother of all stem cells. Donovan PJ. **Int J Dev Biol** 1998;42(7 Spec No):1043–50 (85 ref.)
Gene trapping in mouse embryonic stem cells. Brennan J, et al. **Methods Mol Biol** 1999;97:123–38 (22 ref.)
[Establishment of human ES cell lines: its potential significance and ethical consideration] Nakatuji N. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):291–4 (18 ref.) **(Jpn)**

CYTOLOGY

Multipotent and restricted precursors in the central nervous system. Rao MS. **Anat Rec** 1999 Aug 15;257(4):137–48 (52 ref.)
Hierarchical differentiation of multipotent progenitor cells. Flickinger RA. **Bioessays** 1999 Apr;21(4):333–8 (67 ref.)
Origins, functions, and potential of adult neural stem cells. Kuhn HG, et al. **Bioessays** 1999 Aug;21(8):625–30 (50 ref.)
The hemangioblast--an elusive cell captured in culture. Robb L, et al. **Bioessays** 1998 Aug;20(8):611–4 (37 ref.)
Building brains: neural chimeras in the study of nervous system development and repair. Brüstle O. **Brain Pathol** 1999 Jul;9(3):527–45 (152 ref.)
Genetic regulatory elements introduced into neural stem and progenitor cell populations. Foster GA, et al. **Brain Pathol** 1999 Jul;9(3):547–67 (215 ref.)
Postnatal cerebral cortical multipotent progenitors: regulatory mechanisms and potential role in the development of novel neural regenerative strategies. Mehler MF, et al. **Brain Pathol** 1999 Jul;9(3):515–26 (82 ref.)
Human neural stem cells: isolation, expansion and transplantation. Svendsen CN, et al. **Brain Pathol** 1999 Jul; 9(3):499–513 (93 ref.)
Establishment and properties of neural stem cell clones: plasticity in vitro and in vivo. Vescovi AL, et al. **Brain Pathol** 1999 Jul;9(3):569–98 (143 ref.)
A new role for glia: generation of neurons! Barres BA. **Cell** 1999 Jun 11;97(6):667–70 (23 ref.)
Central nervous system stem cells in the embryo and adult. Frisén J, et al. **Cell Mol Life Sci** 1998 Sep;54(9):935–45 (93 ref.)
From preadipocyte to adipocyte: differentiation-directed signals of insulin from the cell surface to the nucleus. Sorisky A. **Crit Rev Clin Lab Sci** 1999 Feb;36(1):1–34 (159 ref.)
Stem cells: A tale of two kingdoms. Benfey PN. **Curr Biol** 1999 Mar 11;9(5):R171–2 (10 ref.)
Progenitor cells: what do they know and when do they know it? Lillien L. **Curr Biol** 1998 Dec 3;8(24):R872–4 (9 ref.)
Cell therapy: in search of pluripotency. Smith A. **Curr Biol** 1998 Nov 5;8(22):R802–4 (13 ref.)
Liver stem cells: a two compartment system. Alison M. **Curr Opin Cell Biol** 1998 Dec;10(6):710–5 (43 ref.)
Spermatogonial stem cells. de Rooij DG, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):694–701 (67 ref.)
The self-renewing mechanism of stem cells in the germline. Lin H. **Curr Opin Cell Biol** 1998 Dec;10(6):687–93 (70 ref.)
Plasticity and stem cells in the vertebrate nervous system. Panchision D, et al. **Curr Opin Cell Biol** 1998 Dec; 10(6):727–33 (75 ref.)
Stem cells and neurogenesis in the adult brain. Cameron HA, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):677–80 (45 ref.)
Stem cells of the central nervous system. Gage FH. **Curr Opin Neurobiol** 1998 Oct;8(5):671–6 (35 ref.)
Stem cells in the adult mammalian central nervous system. Temple S, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):135–41 (67 ref.)
Seeking muscle stem cells. Miller JB, et al. **Curr Top Dev Biol** 1999;43:191–219 (156 ref.)
Lineage commitment and maturation of epithelial cells in the gut. Karam SM. **Front Biosci** 1999 Mar 15;4:D286–98 (82 ref.)
B cell development in the mouse from early progenitors to mature B cells. Rolink AG, et al. **Immunol Lett** 1999 May 3;68(1):89–93 (19 ref.)
The modulation of cell shape influences porcine preadipocyte differentiation [letter] Boone C, et al. **In Vitro Cell Dev Biol Anim** 1999 Feb;35(2):61–3 (16 ref.)
Stem cells in the testis. de Rooij DG. **Int J Exp Pathol** 1998 Apr;79(2):67–80 (97 ref.)
Stem cells in breast epithelia. Li P, et al. **Int J Exp Pathol** 1998 Aug;79(4):193–206 (79 ref.)
Lymphoid development from hematopoietic stem cells. Akashi K, et al. **Int J Hematol** 1999 Jun;69(4):217–26 (90 ref.)
Bone stem cells. Aubin JE. **J Cell Biochem Suppl** 1998; 30–31:73–82 (35 ref.)
Neural stem cells: from fly to vertebrates. Doe CQ, et al. **J Neurobiol** 1998 Aug;36(2):111–27 (119 ref.)
Architecture and cell types of the adult subventricular zone: in search of the stem cells. García-Verdugo JM, et al. **J Neurobiol** 1998 Aug;36(2):234–48 (119 ref.)
Glial progenitor cells in normal and pathological states. Nishiyama A. **Keio J Med** 1998 Dec;47(4):205–8 (28 ref.)
Extracellular matrix receptors and the differentiation of human megakaryocytes in vitro. Molla A, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):15–23 (46 ref.)
Regulation of oligodendrocyte development. Orentas DM, et al. **Mol Neurobiol** 1998 Dec;18(3):247–59 (90 ref.)
"Turning brain into blood"--clinical applications of stem-cell research in neurobiology and hematology. Moore MA. **N Engl J Med** 1999 Aug 19;341(8):605–7 (8 ref.)
Neural cells derived by in vitro differentiation of P19 and

embryonic stem cells. Bain G, et al. **Perspect Dev Neurobiol** 1998;5(2-3):175-8 (15 ref.)
Transduction of a preselected population of human epidermal stem cells: consequences for gene therapy. Bickenbach JR, et al. **Proc Assoc Am Physicians** 1999 May-Jun; 111(3):184-9 (44 ref.)
Properties and uses of embryonic stem cells: prospects for application to human biology and gene therapy. Rathjen PD, et al. **Reprod Fertil Dev** 1998;10(1):31-47 (171 ref.)
Marrow-mindedness: a perspective on neuropoiesis. Scheffler B, et al. **Trends Neurosci** 1999 Aug;22(8):348-57 (127 ref.)
[Cell cycle-dependent change of the adhesive character of CD34+ progenitor cells and their VLA-4 expression] Yamaguchi M, et al. **Rinsho Byori** 1999 May;47(5):439-46 (30 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Stem cells in the adult mammalian central nervous system. Temple S, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):135-41 (67 ref.)

METABOLISM

Stem cell genes in androgen-independent prostate cancer. Bui M, et al. **Cancer Metastasis Rev** 1998-99;17(4):391-9 (60 ref.)
Glial progenitor cells in normal and pathological states. Nishiyama A. **Keio J Med** 1998 Dec;47(4):205-8 (28 ref.)

PATHOLOGY

Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. McCulloch EA. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2676-81 (81 ref.)
Stem cell features of benign and malignant prostate epithelial cells. De Marzo AM, et al. **J Urol** 1998 Dec;160(6 Pt 2):2381-92 (148 ref.)

PHYSIOLOGY

Investigating stem cells in the lung. Magdaleno SM, et al. **Adv Pediatr** 1998;45:363-96 (125 ref.)
Embryonic stem cell models of development [see comments] O'Shea KS. **Anat Rec** 1999 Feb 15;257(1):32-41 (56 ref.) Comment in: Anat Rec 1999 Feb 15;257(1):1-2.
Structural and genetic analysis of laminin-nidogen interaction. Mayer U, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:130-42 (21 ref.)
Progenitor cell biology: implications for neural regeneration. Mehler MF, et al. **Arch Neurol** 1999 Jul;56(7):780-4 (60 ref.)
Origins, functions, and potential of adult neural stem cells. Kuhn HG, et al. **Bioessays** 1999 Aug;21(8):625-30 (50 ref.)
Osteoclast precursors as leukocytes: importance of the area code. Parfitt AM. **Bone** 1998 Dec;23(6):491-4 (43 ref.)
Reluctant remyelination: the missing precursors [editorial; comment] Perry VH. **Brain** 1998 Dec;121 (Pt 12):2219-20 (12 ref.) Comment on: Brain 1998 Dec;121 (Pt 12):2221-8.
Mesenchymal stem cells in osteobiology and applied bone regeneration. Bruder SP, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S247-56 (60 ref.)
The role of osteochondral progenitor cells in fracture repair. Yoo JU, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S73-81 (69 ref.)
Cloning and embryonic stem cells: a new era in human biology and medicine [editorial] Solter D. **Croat Med J** 1999 Sep;40(3):309-18 (61 ref.)
Uno, nessuno e centomila: searching for the identity of mesodermal progenitors. Bianco P, et al. **Exp Cell Res** 1999 Sep 15;251(2):257-63 (62 ref.)
Using EC and ES cell culture to study early development: recent observations on Indian hedgehog and Bmps. Grabel L, et al. **Int J Dev Biol** 1998;42(7 Spec No):917-25 (67 ref.)
Hepatic stem cells. Alison M, et al. **J Hepatol** 1998 Oct; 29(4):676-82 (67 ref.)
Mammary epithelial stem cells: our current understanding. Chepko G, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):35-52 (57 ref.)
Stem cells in the developing and adult nervous system. Alvarez-Buylla A, et al. **J Neurobiol** 1998 Aug; 36(2):105-10 (16 ref.)
The neuronal stem cell of the olfactory epithelium. Calof AL, et al. **J Neurobiol** 1998 Aug;36(2):190-205 (71 ref.)
Multipotent progenitor cells in the adult dentate gyrus. Gage FH, et al. **J Neurobiol** 1998 Aug;36(2):249-66 (102 ref.)
Induction and patterning of the neural crest, a stem cell-like precursor population. LaBonne C, et al. **J Neurobiol** 1998 Aug;36(2):175-89 (117 ref.)
Neuroblasts of the postnatal mammalian forebrain: their phenotype and fate. Luskin MB. **J Neurobiol** 1998 Aug; 36(2):221-33 (87 ref.)
Multipotential stem cells and progenitors in the vertebrate retina. Reh TA, et al. **J Neurobiol** 1998 Aug;36(2):206-20 (114 ref.)
Stem cells in the embryonic cerebral cortex: their role in histogenesis and patterning. Shen Q, et al. **J Neurobiol** 1998 Aug;36(2):162-74 (78 ref.)
CNS stem cells: where's the biology (a.k.a. beef)? Weiss S, et al. **J Neurobiol** 1998 Aug;36(2):307-14 (51 ref.)
Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Bouwens L. **Microsc Res Tech** 1998 Nov 15;43(4):332-6 (40 ref.)
Inhibitors of preadipocyte replication: opportunities for the treatment of obesity. Kirkland JL, et al. **Prog Mol Subcell Biol** 1998;20:177-95 (99 ref.)
Brain, heal thyself. Lowenstein DH, et al. **Science** 1999 Feb 19;283(5405):1126-7 (13 ref.)
Marrow-mindedness: a perspective on neuropoiesis. Scheffler B, et al. **Trends Neurosci** 1999 Aug;22(8):348-57 (127 ref.)
[Endothelial cell precursors in the avian embryo] Eichmann A, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):307-13 (45 ref.) (Eng. Abstr.) **(Fre)**
[Role of cytokines and SDF-1 in the regulation of hematopoietic cell localization in microenvironment] Gotou A. **Rinsho Ketsueki** 1999 Apr;40(4):272-4 (9 ref.) **(Jpn)**

RADIATION EFFECTS

Radiation-induced genomic instability in haemopoietic cells. Wright EG. **Int J Radiat Biol** 1998 Dec;74(6):681-7 (49 ref.)

TRANSPLANTATION

Future potentials for using osteogenic stem cells and biomaterials in orthopedics. Oreffo RO, et al. **Bone** 1999 Aug;25(2 Suppl):5S-9S (58 ref.)
Building brains: neural chimeras in the study of nervous system development and repair. Brüstle O. **Brain Pathol** 1999 Jul;9(3):527-45 (152 ref.)
Human neural stem cells: isolation, expansion and transplantation. Svendsen CN, et al. **Brain Pathol** 1999 Jul; 9(3):499-513 (93 ref.)
Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Harousseau JL. **Haematologica** 1999 Jun;84(6):548-53 (45 ref.)
Limbal stem-cell transplantation. Akpek EK, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):71-82 (67 ref.)
Marrow stromal cells as stem cells for continual renewal of nonhematopoietic tissues and as potential vectors for gene therapy. Prockop DJ. **J Cell Biochem Suppl** 1998; 30-31:284-5 (23 ref.)
Transplantation as a tool to study progenitors within the vertebrate nervous system. Gaiano N, et al. **J Neurobiol** 1998 Aug;36(2):152-61 (85 ref.)
Cultivation of human keratinocyte stem cells: current and future clinical applications. Pellegrini G, et al. **Med Biol Eng Comput** 1998 Nov;36(6):778-90 (190 ref.)
Spermatogonial stem cell transplantation, cryopreservation and culture [see comments] Brinster RL, et al. **Semin Cell Dev Biol** 1998 Aug;9(4):401-9 (33 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.
New prospects for human stem-cell therapy in the nervous system. Svendsen CN, et al. **Trends Neurosci** 1999 Aug; 22(8):357-64 (86 ref.)
[New nerve cells for the adult brain. Adult neurogenesis and stem cell concepts in neurologic research] Kempermann G, et al. **Nervenarzt** 1998 Oct;69(10):851-7 (50 ref.) (Eng. Abstr.) **(Ger)**

STEM CELLS, ERYTHROID see **ERYTHROID PROGENITOR CELLS**

STEM CELLS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

STEM CELLS, NEOPLASTIC see **TUMOR STEM CELLS**

STENELLA see **DOLPHINS**

STENO see **DOLPHINS**

STENOCARDIA see **ANGINA PECTORIS**

STENTS

Current role of stenting in acute myocardial infarction. Antoniucci D, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):147-52 (34 ref.)
Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. Colombo A, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):153-7 (37 ref.)
Coronary stent implantation in acute myocardial infarction. Mehta RH, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):603-11 (78 ref.)
The stent decade: 1987 to 1997. Stanford Stent Summit faculty. Oesterle SN, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):578-99 (45 ref.)
Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Gibson CM. **Ann Intern Med** 1999 May 18;130(10):841-7 (33 ref.)
Angioplasty and stenting for atherosclerotic carotid artery disease. Gul YA, et al. **Ann R Coll Surg Engl** 1999 Mar; 81(2):90-3 (17 ref.)
Carotid artery stenosis: treatment by angioplasty with or without stent. Kritpracha B, et al. **Ann Vasc Surg** 1998 Nov;12(6):621-4 (30 ref.)
Management and outcome of stents in 1998: long-term outcome. Fleisch M, et al. **Cardiol Rev** 1999 Jul-Aug; 7(4):215-8 (16 ref.)
Infection of endovascular stents: an uncommon but important complication. Latham JA, et al. **Cardiovasc Surg** 1999 Mar; 7(2):179-82 (15 ref.)
Treatment of May-Thurner syndrome with catheter-directed thrombolysis and stent placement, complicated by heparin-induced thrombocytopenia. Seidensticker D, et al. **Cardiovasc Surg** 1998 Dec;6(6):607-13 (29 ref.)
Coronary artery stenting for spontaneous coronary artery dissection: a case report and review of the literature. Vale PR, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):280-6 (76 ref.)
Frontiers in interventional cardiology. Topol EJ, et al. **Circulation** 1998 Oct 27;98(17):1802-20 (198 ref.)
Intracoronary stenting: an overview for the clinician. Marso SP, et al. **Cleve Clin J Med** 1999 Jul-Aug;66(7):434-42 (29 ref.)
Airway stents. Mehta AC, et al. **Clin Chest Med** 1999 Mar; 20(1):139-51 (68 ref.)
The case for stenting. Lanzino G, et al. **Clin Neurosurg** 1999; 45:249-55 (38 ref.)
New intracoronary stent designs: form follows function versus function follows form. Fry ET, et al. **Curr Opin Cardiol** 1998 Jul;13(4):232-9 (46 ref.)
Rotablator plus stent therapy (rotastent). Lasala JM, et al. **Curr Opin Cardiol** 1998 Jul;13(4):240-7 (32 ref.)
Stents in acute myocardial infarction. Overlie PA. **Curr Opin Cardiol** 1998 Jul;13(4):280-8 (67 ref.)
Endovascular stents for renal artery revascularization. Tuttle KR, et al. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):695-701 (49 ref.)
Metal stents for benign and malignant bile duct strictures stents for benign and malignant bile duct strictures. Rösch T. **Endoscopy** 1998 Nov;30(9):A247-52 (64 ref.)
The perfect biliary stent: the search goes on [editorial; comment] Sackmann M. **Endoscopy** 1998 Oct;30(8):727-9 (35 ref.) Comment on: Endoscopy 1998 Oct;30(8):681-6. Comment on: Endoscopy 1998 Oct;30(8):687-90. Comment on: Endoscopy 1998 Oct;30(8):718-20.
Which stents do we need? The case for plastic stents. Seitz U, et al. **Endoscopy** 1998 Nov;30(9):A242-6 (42 ref.)
Self-expandable metal stents for malignant gastric outlet obstruction: a modified technique. Venu RP, et al. **Endoscopy** 1998 Aug;30(6):553-8 (18 ref.)
The development of biliary drainage and stenting. Wurbs D. **Endoscopy** 1998 Nov;30(9):A202-6 (36 ref.)
Does stent design influence restenosis? Gunn J, et al. **Eur Heart J** 1999 Jul;20(14):1009-13 (59 ref.)
Has stenting killed local drug delivery? Gunn J, et al. **Eur Heart J** 1998 May;19(5):689-92 (35 ref.)
Carotid before coronary stenting: the way forward? [editorial; comment] Sigwart U. **Eur Heart J** 1998 Sep; 19(9):1278-9 (7 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1365-70.
Long-term follow-up after coronary stent implantation [editorial] Stables RH, et al. **Eur Heart J** 1998 Oct; 19(10):1424-6 (8 ref.)
Stent-grafts in the superficial femoral artery. Stockx L. **Eur J Radiol** 1998 Oct;28(3):182-8 (24 ref.)
Stent-graft treatment of iatrogenic iliac artery perforations: report of three cases. Nyman U, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):259-63 (18 ref.)
Improvement of myocardial ischemia by subclavian stent implantation in patients with internal mammary grafts: a case report and review of the literature. Patti G, et al. **G Ital Cardiol** 1999 Apr;29(4):431-4 (13 ref.)
Coronary stenting in patients with situs viscerum inversus. Patti G, et al. **G Ital Cardiol** 1999 Mar;29(3):304-7 (10 ref.)
Controversies in coronary stenting. Debate: conditional stenting is the way to go. 20th Meeting of the European Society of Cardiology (Vienna, 22 August 1998) [editorial] Ribichini F. **G Ital Cardiol** 1999 May;29(5):495-504 (36 ref.) **(Eng, Ita)**
Proximal migration of a pancreatic duct stent: endoscopic retrieval using interventional cardiology accessories. Baron TH, et al. **Gastrointest Endosc** 1999 Jul;50(1):124-5 (9 ref.)
Bird nest deformity of a self-expanding esophageal stent and a technique of removal. Berg JC. **Gastrointest Endosc** 1999 Jul;50(1):108-10 (6 ref.)
The use of endoprostheses in biliary fistula of hydatid cyst. de Aretxabala X, et al. **Gastrointest Endosc** 1999 Jun; 49(6):797-9 (20 ref.)
Late migration of a self-expandable metal stent and successful endoscopic management. Rollhauser C, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):541-4 (26 ref.)
Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. Tung BY, et al. **Gastrointest Endosc** 1999 May;49(5):647-51 (18 ref.)
The radioisotope stent for the prevention of restenosis. Fischell TA, et al. **Herz** 1998 Sep;23(6):373-9 (22 ref.)
Chest pain after coronary interventional procedures. Incidence and pathophysiology. Jeremias A, et al. **Herz** 1999 Apr;24(2):126-31 (33 ref.)
Radiological management of oesophageal strictures. Cowling MG, et al. **Hosp Med** 1998 Sep;59(9):693-7 (17 ref.)
Imaging and stenting for renal artery stenosis. Dowling RJ, et al. **Hosp Med** 1999 May;60(5):329-36 (49 ref.)
Acute myocardial infarction: thrombolysis, angioplasty or stenting. Ebersole DG, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:40-4 (25 ref.)
Present status of coronary stenting: hopes and hypes. Fleisch M, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:14-7 (17 ref.)
Insights into the mechanism of restenosis after PTCA and stenting. Lansky AJ, et al. **Indian Heart J** 1998 Oct;50

Suppl 1:104–8 (19 ref.)
Renal artery stent placement: indications, techniques and clinical results. White CJ, et al. **Indian Heart J** 1998 Oct; 50 Suppl 1:153–60 (43 ref.)
Left postpneumonectomy syndrome successfully treated with endobronchial stent. Nakamura Y, et al. **Intern Med** 1998 Oct;37(10):880–3 (12 ref.)
ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology. Holmes DR Jr, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1471–82 (85 ref.)
Long lesions, long stents and the long process of stent optimization [editorial; comment] Schömig A, et al. **J Am Coll Cardiol** 1999 Sep;34(3):660–2 (26 ref.) Comment on: J Am Coll Cardiol 1999 Sep;34(3):651–9.
Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. Denstedt JD, et al. **J Endourol** 1998 Dec;12(6):493–500 (75 ref.)
Randomizing carotid endarterectomy to carotid stenting? [editorial] Wholey MH. **J Endovasc Surg** 1999 May; 6(2):127–9; discussion 130 (12 ref.)
Micromechanical devices for intravascular drug delivery. Reed ML, et al. **J Pharm Sci** 1998 Nov;87(11):1387–94 (37 ref.)
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999. McCullough PA, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):233–9 (28 ref.)
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. Steinhubl SR, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):227–31 (22 ref.)
Endoluminal stent placement for the treatment of traumatic carotid artery pseudoaneurysm: case report and review of the literature. Shames ML, et al. **J Trauma** 1999 Apr; 46(4):724–6 (16 ref.)
Use of self-expanding permanent endoluminal stents for benign ureteral strictures: mid-term results. Pauer W, et al. **J Urol** 1999 Aug;162(2):319–22 (22 ref.)
Stents for atherosclerotic renovascular disease. Rees CR. **J Vasc Interv Radiol** 1999 Jun;10(6):689–705 (86 ref.)
Endobronchial stents: primary and adjuvant therapy for endobronchial airway obstruction. Sonett JR. **Md Med J** 1998 Nov;47(5):260–3 (10 ref.)
Primary stenting in acute myocardial infarction: paving the way to arterial patency [editorial; comment] Meredith IT. **Med J Aust** 1999 Jun 7;170(11):518–9 (19 ref.) Comment on: Med J Aust 1999 Jun 7;170(11):537–40.
Stents in the management of malignant airway obstruction. Stöhr S, et al. **Monaldi Arch Chest Dis** 1999 Jun;54(3):264–8 (24 ref.)
Endovascular stenting of an acutely thrombosed basilar artery: technical case report and review of the literature. Phatouros CC, et al. **Neurosurgery** 1999 Mar;44(3):667–73 (26 ref.)
The role of endoscopic biliary stents in palliative care. Roth LJ, et al. **Palliat Med** 1999 Jan;13(1):63–8 (24 ref.)
Management of renovascular disease: a review of renal artery stenting in ten studies. Isles CG, et al. **QJM** 1999 Mar; 92(3):159–67 (39 ref.)
Stenting therapy for stenosing airway disease. Kim H. **Respirology** 1998 Dec;3(4):221–8 (38 ref.)
Stenting therapy for stenosing airway diseases. Phillips MJ. **Respirology** 1998 Dec;3(4):215–9 (14 ref.)
Coronary stenting: "current state of the art". Moussa I, et al. **Rev Port Cardiol** 1999 Feb;18 Suppl 1:I75–84 (26 ref.)
New techniques in interventional cardiology. Pavlides GS. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III69–72 (17 ref.)
Stenting of the peripheral, renal and supraaortic arteries and the aorta. Mahler F, et al. **Schweiz Med Wochenschr** 1999 Mar 13;129(10):399–409 (59 ref.)
Antithrombotic stent coatings: hirudin/iloprost combination. Alt E, et al. **Semin Interv Cardiol** 1998 Sep–Dec; 3(3–4):177–83 (40 ref.)
Biomimicry 1: PC. Cumberland DC, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):149–50 (11 ref.)
Bifurcational stenting. Di Mario C, et al. **Semin Interv Cardiol** 1998 Jun;3(2):65–76 (41 ref.)
On the production of radioactive stents. Fehsenfeld P, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):157–61 (11 ref.)
Radioactive stents. Fischell TA. **Semin Interv Cardiol** 1998 Jun;3(2):51–6 (18 ref.)
Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents. Gershlick AH. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):185–90 (26 ref.)
Antiproliferative stent coatings: Taxol and related compounds. Herdeg C, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):197–9 (26 ref.)
Modification of molecular events in coronary restenosis using coated stents: The Mayo Clinic Approach. Keelan PC, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):211–5 (47 ref.)
Treatment of in-stent restenosis. Mintz GS, et al. **Semin Interv Cardiol** 1998 Jun;3(2):117–21 (45 ref.)
Stenting in acute myocardial infarction. Morice MC, et al. **Semin Interv Cardiol** 1998 Jun;3(2):77–80 (7 ref.)
Plaque removal prior to stent implantation in native coronary arteries: why? When? And how? Moussa I, et al. **Semin Interv Cardiol** 1998 Jun;3(2):57–63 (36 ref.)
Prevention of in-stent restenosis. Narins CR, et al. **Semin Interv Cardiol** 1998 Jun;3(2):91–103 (106 ref.)
Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Neumann FJ, et al. **Semin Interv Cardiol** 1998 Jun;3(2):81–90 (96 ref.)
Coated stents: local pharmacology. Raman VK, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):133–7 (17 ref.)
The emerging role of stenting for acute myocardial infarction. Suryapranata H. **Semin Interv Cardiol** 1999 Mar; 4(1):35–41 (42 ref.)
Synthetic polymers. van Beusekom HM, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):145–8 (37 ref.)
Heparin-coating of coronary stents. van der Giessen WJ, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):173–6 (21 ref.)
Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease. van der Wieken LR. **Semin Interv Cardiol** 1999 Jun;4(2):77–83 (25 ref.)
Comparative pathology: radiation-induced coronary artery disease in man and animals. Virmani R, et al. **Semin Interv Cardiol** 1998 Sep–Dec;3(3–4):163–72 (25 ref.)
Cervical carotid artery stent placement. Wholey MH, et al. **Semin Interv Cardiol** 1998 Jun;3(2):105–15 (28 ref.)
The role of carotid angioplasty and stenting. Gomez CR. **Semin Neurol** 1998;18(4):501–11 (43 ref.)
Imaging of abdominal aortic aneurysms after endoluminal repair. Golzarian J, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):16–24 (34 ref.)
Endovascular grafts. Marin ML, et al. **Semin Vasc Surg** 1999 Mar;12(1):64–73 (36 ref.)
Percutaneous transluminal angioplasty and stenting for iliac artery occlusive disease. Hood DB, et al. **Surg Clin North Am** 1999 Jun;79(3):575–96 (34 ref.)
Stent grafts in occlusive arterial disease. Ramaswami G, et al. **Surg Clin North Am** 1999 Jun;79(3):597–609 (28 ref.)
Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. Schindler N, et al. **Surg Clin North Am** 1999 Jun;79(3):683–94, xi (36 ref.)
Successful surgical treatment of aortogastric fistula after an esophagectomy and subsequent endovascular graft placement: report of a case. Sato O, et al. **Surg Today** 1999; 29(5):431–4 (10 ref.)
Advances in therapeutic endoscopic treatment of common bile duct stones. Seitz U, et al. **World J Surg** 1998 Nov; 22(11):1133–44 (97 ref.)
[Clinical strategies for development of intracoronary stents] Dong W, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Jun; 14(2):156–63 (29 ref.) (Eng. Abstr.) **(Chi)**
[Treatment of renal artery stenosis with intra-arterial stents] Postma CT, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26; 142(39):2132–7 (22 ref.) (Eng. Abstr.) **(Dut)**
[Intra-aortic covered endoprosthesis] Rousseau H, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jul–Sep;47(7):469–80 (41 ref.) (Eng. Abstr.) **(Fre)**
[Self-expanding metallic stents in the palliative treatment of colorectal neoplastic stenoses. Report of two cases] el Khaddari S, et al. **Gastroenterol Clin Biol** 1999 May; 23(5):569–72 (13 ref.) (Eng. Abstr.) **(Fre)**
[Carotid angioplasty: review of the literature] Hassen-Khodja R, et al. **J Mal Vasc** 1998 Oct;23(4):243–50 (61 ref.) (Eng. Abstr.) **(Fre)**
[Coronary disease: therapeutic gains] Vogt P. **Rev Med Suisse Romande** 1999 May;119(5):367–71 (21 ref.) **(Fre)**
[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents] Pinton P. **Therapie** 1998 Jul–Aug; 53(4):341–7 (32 ref.) (Eng. Abstr.) **(Fre)**
[Stent restenosis: therapy concepts and possibilities for prevention] Radke PW, et al. **Med Klin** 1999 Feb 15; 94(2):88–92 (53 ref.) (Eng. Abstr.) **(Ger)**
[Percutaneous revascularization of renal artery stenosis. Balloon angioplasty vs. stent implantation] Blum U, et al. **Radiologe** 1999 Feb;39(2):135–43 (42 ref.) (Eng. Abstr.) **(Ger)**
[Management of abdominal aortic and peripheral aneurysm using stent grafts] Dorffner R, et al. **Radiologe** 1999 Feb; 39(2):110–7 (30 ref.) (Eng. Abstr.) **(Ger)**
[A coated stent as alternative therapy for stopping a tumor-induced arrosive hemorrhage] Steudel A, et al. **Rofo Fortschr Geb Rontgenstr Neuer Bildgeb Verfahr** 1998 Sep;169(3):324–6 (10 ref.) **(Ger)**
[Recanalization of an extensive fresh portal vein thrombosis by transjugular intrahepatic portosystemic stent-shunt (TIPS)] Vogl T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):163–5 (10 ref.) **(Ger)**
[Endoscopic palliation in esophageal carcinoma] Criblez DH. **Schweiz Med Wochenschr** 1999 Aug 28;129(34):1217–23 (32 ref.) (Eng. Abstr.) **(Ger)**
[Stent therapy] Schwacha H. **Schweiz Rundsch Med Prax** 1999 Jan 14;88(3):81–4 (17 ref.) (Eng. Abstr.) **(Ger)**
[Metal stents in the biliopancreatic duct system--assessment of current status] Hoepffner N, et al. **Z Gastroenterol** 1998 Dec;36(12):1059–73 (123 ref.) (Eng. Abstr.) **(Ger)**
[Percutaneous transhepatic metal stents in therapy of bile duct stenoses] von Bubnoff AC, et al. **Z Gastroenterol** 1998 Dec;36(12):1037–46 (36 ref.) (Eng. Abstr.) **(Ger)**
[Arguments against conventional balloon dilatation of recurrences within the stent] Haude M, et al. **Z Kardiol** 1998;87 Suppl 3:72–7 (45 ref.) (Eng. Abstr.) **(Ger)**
[Prevention and treatment of restenosis after percutaneous transluminal coronary angioplasty] Hehrlein C, et al. **Z Kardiol** 1998 Sep;87(9):699–706 (76 ref.) (Eng. Abstr.) **(Ger)**
[Catheter-assisted techniques for decreasing the rate of restenosis after coronary angioplasty: an overview of radiotherapy] Hehrlein C, et al. **Z Kardiol** 1998;87 Suppl 2:166–70 (42 ref.) (Eng. Abstr.) **(Ger)**
[Can recurrences be mechanically prevented?] Heintzen MP, et al. **Z Kardiol** 1998;87 Suppl 3:52–4; discussion 59 (21 ref.) (Eng. Abstr.) **(Ger)**
[Balloon angioplasty of stent restenosis: early and late results of first and second PTCA in focal and diffuse stenosis] Reifart N, et al. **Z Kardiol** 1998;87 Suppl 3:65–71; discussion 79–80 (11 ref.) (Eng. Abstr.) **(Ger)**
[Conventional dilatation of recurrence in the stent?] Rutsch W, et al. **Z Kardiol** 1998;87 Suppl 3:60–4 (18 ref.) **(Ger)**
[Fatal ventricular rupture after stent implantation in acute myocardial infarct with subsequent stent thrombosis: discussion of reperfusion injury as the cause] Schröter V, et al. **Z Kardiol** 1999 Jun;88(6):454–8 (14 ref.) (Eng. Abstr.) **(Ger)**
[Direct stenting of the unprotected common trunk in patients at an elevated surgical risk; the authors' personal experience and a review of the literature] Danzi GB, et al. **G Ital Cardiol** 1999 May;29(5):568–74 (21 ref.) **(Ita)**
[Coronary lesion with an aneurysm: their correction via angioplasty and the implantation of a coated stent] Poli A, et al. **G Ital Cardiol** 1998 Jul;28(7):797–9 (6 ref.) (Eng. Abstr.) **(Ita)**
[The application of the endovascular prosthesis (stent)] Branco G, et al. **Acta Med Port** 1999 Apr–Jun; 12(4–6):177–81 (11 ref.) (Eng. Abstr.) **(Por)**
[Stents. Review of the literature] Guérios EE, et al. **Arq Bras Cardiol** 1998 Jul;71(1):77–87 (133 ref.) **(Por)**
[Angioplasty for acute coronary syndromes in the era of the stent] Avilés FF, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:131–40 (73 ref.) (Eng. Abstr.) **(Spa)**
[Intracoronary ultrasound: A necessary tool for stent implantation? Arguments in favor] Botas J. **Rev Esp Cardiol** 1999 Jun;52(6):383–9 (38 ref.) (Eng. Abstr.) **(Spa)**
[Is prior balloon dilatation necessary before implanting a stent? (editorial; comment)] Delcán JL. **Rev Esp Cardiol** 1999 May;52(5):308–10 (12 ref.) Comment on: Rev Esp Cardiol 1999 May;52(5):301–7. **(Spa)**
[Coronary angioplasty: always a stent in arteries larger than 2.5 mm? The arguments con] Goicolea Ruigómez FJ, et al. **Rev Esp Cardiol** 1999 Feb;52(2):85–94 (48 ref.) (Eng. Abstr.) **(Spa)**
[Coronary angioplasty: always a stent in arteries larger than 2.5 mm? The arguments pro] Pan M. **Rev Esp Cardiol** 1999 Feb;52(2):79–84 (43 ref.) (Eng. Abstr.) **(Spa)**
[Intracoronary ultrasound: A necessary tool for stent implantation? Arguments in against] Serra Peñaranda A. **Rev Esp Cardiol** 1999 Jun;52(6):390–7 (24 ref.) (Eng. Abstr.) **(Spa)**
[Register Alacant: register of the treatment of supra-aortic trunk stenosis with angioplasty and stent placement. Study group of Register Alacant] Morera-Guitart J. **Rev Neurol** 1998 Dec;27(160):1055–8 (19 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Endovascular haute couture revisited: ready-to-wear comes of age [editorial; comment] Heuser RR. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):314 (5 ref.) Comment on: Cathet Cardiovasc Diagn 1998 Nov;45(3):310–3.
Instent restenosis: balloon angioplasty, rotablation or laser therapy. Sharma SK, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:109–19 (55 ref.)
[Transluminal treatment of abdominal aortic aneurysms. Might one obstruct the renal arteries?] Desgranges P, et al. **J Mal Vasc** 1998 Dec;23(5):385–6 (9 ref.) (Eng. Abstr.) **(Fre)**
[Stent migration with perforation of the portal vein after transjugular intrahepatic portosystemic shunt (TIPS) with a self-expanding stent] Adamus R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):174–6 (0 ref.) **(Ger)**
[PTA stent implantation in the carotid artery: dangerous experiment or the treatment of the future? (editorial)] Minar E, et al. **Wien Klin Wochenschr** 1999 Jul 9;111(13):495–500 (32 ref.) **(Ger)**

CLASSIFICATION

Stenting in Europe, what lessons can we learn? Development of a stent classification system based on a survey of European clinical experiences [editorial] [see comments] Jost CM. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):217–32 (19 ref.) Comment in: Cathet Cardiovasc Diagn 1998 Nov;45(3):233–4.

STANDARDS

Multivessel coronary artery disease: elective stenting versus bypass surgery. Foley DP, et al. **Indian Heart J** 1998 Oct; 50 Suppl 1:27–39 (110 ref.)

TRENDS

Fortnightly review: Intracoronary stents. Gandhi MM, et al. **BMJ** 1999 Mar 6;318(7184):650–3 (28 ref.)
Complications and lessons learned from 10 years of expandable gastrointestinal prostheses. Kozarek RA. **Dig Dis** 1999;17(1):14–22 (35 ref.)

[PTA stent implantation in the carotid artery: dangerous experiment or the treatment of the future? (editorial)] Minar E, et al. **Wien Klin Wochenschr** 1999 Jul 9;111(13):495–500 (32 ref.) **(Ger)**

[Coronary stents. Where are we? Where are we going?] Gaxiola E, et al. **Arch Inst Cardiol Mex** 1998 Jul–Aug; 68(4):337–45 (43 ref.) **(Spa)**

STEP TEST see **EXERCISE TEST**

STEPFAMILY see **FAMILY**

STEPHANURUS DENTATUS INFECTIONS see **STRONGYLIDA INFECTIONS**

STEP-PARENTS see **PARENTS**

STEREOISOMERISM

Dynamic kinetic resolution. Gihani MT, et al. **Curr Opin Chem Biol** 1999 Feb;3(1):11–5 (19 ref.)

Vibrational circular dichroism: an incisive tool for stereochemical applications. Nafie LA, et al. **Enantiomer** 1998;3(4–5):283–97 (27 ref.)

Homochirality and life. Bonner WA. **EXS** 1998;85:159–88 (89 ref.)

Characterization and analysis of D-amino acids. Scaloni A, et al. **EXS** 1998;85:3–26 (90 ref.)

Applications of chiroptical spectroscopy for the characterization of pharmaceutical compounds. Brittain HG. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):933–40 (44 ref.)

Pharmaceutical development and specification of stereoisomers. Williams RC, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):917–24 (17 ref.)

STEREOISOMERS see **STEREOISOMERISM**

STEREOPSIS see **DEPTH PERCEPTION**

STEREOSCOPIC VISION see **DEPTH PERCEPTION**

STEREOTACTIC RADIOSURGERY see **RADIOSURGERY**

STEREOTAXIC TECHNIQUES

see related
BRAIN MAPPING

Image-guided surgical navigation in otology and neurotology. Selesnick SH, et al. **Am J Otol** 1999 Sep; 20(5):688–93; discussion 693–7 (21 ref.)

Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. Bronstein JM, et al. **Arch Neurol** 1999 Sep;56(9):1064–9 (41 ref.)

Stereotactic radiosurgery for acoustic neuroma: a Canadian perspective [see comments] Ross IB, et al. **Can J Neurol Sci** 1998 Nov;25(4):310–4 (20 ref.) Comment in: Can J Neurol Sci 1999 May;26(2):154–5.

Selection of patients for surgery for Parkinson's disease. Tasker RR. **Clin Neurosurg** 1997;44:63–7 (18 ref.)

Image-guided neurosurgery. Wadley J, et al. **Hosp Med** 1999 Jan;60(1):34–8 (15 ref.)

The role of stereotactic biopsy in the management of gliomas. Kondziolka D, et al. **J Neurooncol** 1999 May;42(3):205–13 (25 ref.)

Stereotactically guided endoscopy for the treatment of arachnoid cysts. Rampini P, et al. **Pediatr Neurosurg** 1998 Aug;29(2):102–4 (17 ref.)

Stereotactically guided conformal radiotherapy: a new tool for the treatment of intra-cranial benign tumors [editorial; comment] Kantor G. **Radiother Oncol** 1999 Feb;50(2):143–4 (17 ref.) Comment on: Radiother Oncol 1999 Feb;50(2):145–50.

Surgical palliation of dyskinesiae in Parkinson's disease. Brophy BP. **Stereotact Funct Neurosurg** 1998; 70(2–4):107–13 (31 ref.)

Stereotactic surgery and Parkinson's disease. Narabayashi H. **Stereotact Funct Neurosurg** 1998;70(2–4):114–21 (18 ref.)

Stereotactic treatment of central pain. Ohye C. **Stereotact Funct Neurosurg** 1998;70(2–4):71–6 (26 ref.)

[Indications for surgical treatment of tremor] Bötzel K, et al. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):287–90 (13 ref.) **(Ger)**

INSTRUMENTATION

Posterior ventral pallidotomy: techniques and theoretical considerations. Bakay RA, et al. **Clin Neurosurg** 1997; 44:197–210 (10 ref.)

Endoscopy and stereotaxy for aneurysms. Frazee JG, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):869 (18 ref.)

[Neuronavigation. Methods and prospects] Wirtz CR, et al. **Nervenarzt** 1998 Dec;69(12):1029–36 (29 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Stereotactic surgery—the past and the future. Gildenberg PL. **Stereotact Funct Neurosurg** 1998;70(2–4):57–70 (151 ref.)

STEREOTYPED BEHAVIOR

see related
STEREOTYPIC MOVEMENT DISORDER

The neural substrate for 'learned' and 'nonlearned' activities in birds: a discussion of the organization of bulbar reticular premotor systems with side-lights on the mammalian situation. Dubbeldam JL. **Acta Anat (Basel)** 1998; 163(3):157–72 (84 ref.)

Ethological remarks on mannerisms. Conceptualisation and proposal for a definition. off Brüne M. **Psychopathology** 1998;31(4):188–96 (43 ref.)

DRUG EFFECTS

Does the noncompetitive NMDA receptor antagonist dizocilpine (MK801) really block behavioural sensitization associated with repeated drug administration? [see comments] Tzschentke TM, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):447–51 (67 ref.) Comment in: Trends Pharmacol Sci 1999 May;20(5):187–8; discussion 189–90. Comment in: Trends Pharmacol Sci 1999 May;20(5):188–9; discussion 189–90.

PHYSIOLOGY

Genetic analysis of the role of protein kinase C signaling pathways in behaviors by direct gene transfer with HSV-1 vectors. Geller AI. **Rev Neurosci** 1999;10(1):1–13 (106 ref.)

STEREOTYPIC MOVEMENT DISORDER

see related
STEREOTYPED BEHAVIOR

REHABILITATION

Applying behavior analysis to clinical problems: review and analysis of habit reversal. Miltenberger RG, et al. **J Appl Behav Anal** 1998 Fall;31(3):447–69 (113 ref.)

STEREOTYPING

Colonizing images and diagnostic labels: oppressive mechanisms for African American women's health. Taylor JY. **ANS Adv Nurs Sci** 1999 Mar;21(3):32–45 (58 ref.)

Evidence-based nursing: a stereotyped view of quantitative and experimental research could work against professional autonomy and authority. Bonell C. **J Adv Nurs** 1999 Jul; 30(1):18–23 (40 ref.)

Dimensions and process of stigmatization in leprosy. Bainson KA, et al. **Lepr Rev** 1998 Dec;69(4):341–50 (15 ref.)

The dark side of nursing: impact of stigmatizing responses on patients. Corley MC, et al. **Sch Inq Nurs Pract** 1998 Summer;12(2):99–118; discussion 119–22 (83 ref.)

STERIGMATOCYSTIN

BIOSYNTHESIS

Coordinate control of secondary metabolite production and asexual sporulation in Aspergillus nidulans. Adams TH, et al. **Curr Opin Microbiol** 1998 Dec;1(6):674–7 (38 ref.)

STERILITY see **INFERTILITY**

STERILITY, FEMALE see **INFERTILITY, FEMALE**

STERILITY, MALE see **INFERTILITY, MALE**

STERILIZATION

Sterilization vs. disinfection vs. clean. Alvarado CJ. **Nurs Clin North Am** 1999 Jun;34(2):483–91 (34 ref.)

The treatment of blood components with ultraviolet-B irradiation. Pamphilon DH. **Vox Sang** 1998;74 Suppl 2:15–9 (9 ref.)

METHODS

Re-implantation of autoclaved bone segments in musculoskeletal tumor surgery. Clinical experience in 9 patients followed for 1.1–8.4 years and review of the literature. Böhm P, et al. **Arch Orthop Trauma Surg** 1998; 118(1–2):57–65 (59 ref.)

Sterilisation of tonometers and gonioscopes. Sood D, et al. **Indian J Ophthalmol** 1998 Jun;46(2):113–6 (15 ref.)

Clinical effectiveness of low-temperature sterilization technologies. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):798–804 (27 ref.)

Inactivation of pathogens in blood and blood products. Ben-Hur E. **Med Health R I** 1998 Dec;81(12):396–9 (11 ref.)

Solvent/detergent treatment of human plasma—a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Biesert L, et al. **Vox Sang** 1998;74 Suppl 1:207–12 (12 ref.)

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates. Corash L. **Vox Sang** 1998;74 Suppl 2:173–6 (45 ref.)

Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Horowitz B, et al. **Vox Sang** 1998;74 Suppl 1:203–6 (22 ref.)

Virus inactivation of fresh plasma. Mohr H. **Vox Sang** 1998; 74 Suppl 2:171–2 (12 ref.)

[Detoxication and disinfection by sodium hypochlorite] Eventov VL, et al. **Med Tekh** 1998 Nov–Dec;(6):36–9 (15 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Clinical effectiveness of low-temperature sterilization technologies. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):798–804 (27 ref.)

STERILIZATION REVERSAL

METHODS

Single suture laparoscopic tubal re-anastomosis. Dubuisson JB, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):307–13 (28 ref.)

[Methods, efficacy, complications and reversibility of female tubal sterilization] Girardin E, et al. **Contracept Fertil Sex** 1998 Oct;26(10):I–VII (48 ref.) **(Fre)**

STERILIZATION, SEXUAL

see related
PEST CONTROL, BIOLOGICAL

ADVERSE EFFECTS

Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Kessel E. **Adv Contracept** 1998 Jun;14(2):81–90 (37 ref.)

Migration of sterilisation clips: case report and review. AmuO, et al. **Br J Fam Plann** 1999 Apr;25(1):27–8 (14 ref.)

METHODS

Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Kessel E. **Adv Contracept** 1998 Jun;14(2):81–90 (37 ref.)

STANDARDS

ACOG committee opinion. Sterilization of women, including those with mental disabilities. Number 216, April 1999 (replaces number 63, September 1988, and number 73, September 1989). Committee on Ethics. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jun;65(3):317–20 (3 ref.)

VETERINARY

Early spay-neuter in the dog and cat. Kustritz MV. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):935–43, vii (37 ref.)

STERILIZATION, TUBAL

see related
STERILIZATION REVERSAL

Intrauterine devices. The optimal long-term contraceptive method? Fortney JA, et al. **J Reprod Med** 1999 Mar; 44(3):269–74 (19 ref.)

[Complications of tubal sterilization by minilaparotomy under local anesthesia] Cisse CT, et al. **Dakar Med** 1997; 42(2):96–8 (15 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

[Methods, efficacy, complications and reversibility of female tubal sterilization] Girardin E, et al. **Contracept Fertil Sex** 1998 Oct;26(10):I–VII (48 ref.) **(Fre)**

METHODS

Office single puncture laparoscopy sterilization with local anesthesia. Miller GH. **J Soc Laparoendosc Surg** 1997 Jan–Mar;1(1):55–9 (18 ref.)

Laparoscopic tubal sterilization. Methods, effectiveness, and sequelae. Ryder RM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):83–97 (82 ref.)

Laparoscopic sterilization. Filshie M. **Semin Laparosc Surg** 1999 Jun;6(2):112–7 (50 ref.)

[Methods, efficacy, complications and reversibility of female tubal sterilization] Girardin E, et al. **Contracept Fertil Sex** 1998 Oct;26(10):I–VII (48 ref.) **(Fre)**

STERNOCLAVICULAR JOINT

Tophaceous pseudogout of the sternoclavicular joint. Richman KM, et al. **AJR Am J Roentgenol** 1999 Jun; 172(6):1587–9 (6 ref.)

INJURIES

Scapulothoracic dissociation. Lee L, et al. **Am J Orthop** 1998 Oct;27(10):699–702 (31 ref.)

STERNOCOSTOCLAVICULAR HYPEROSTOSIS see **HYPEROSTOSIS, STERNOCOSTOCLAVICULAR**

STERNUM

Alloplastic sternal replacement in malignant sternal tumors. Case report and review of the literature. Meyer M, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):853–7 (42 ref.)

[Tuberculosis of the thoracic wall. Presentation of 4 personal cases and review of the literature] Mathlouthi A, et al. **Rev Pneumol Clin** 1998 Sep;54(4):182–6 (22 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Development of the Sternal Wound Infection Prediction Scale. Hussey LC, et al. **Heart Lung** 1998 Sep–Oct; 27(5):326–36 (44 ref.)

Transposition of the great omentum for infected sternotomy wounds in cardiac surgery. Report of 16 cases and review of published reports. Moor EV, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):25–9 (35 ref.)

[Minimally invasive mitral surgery: mitral valve repair with a right-sided partial sternotomy] Kasegawa H. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):817–20 (6 ref.) (Eng. Abstr.) **(Jpn)**

STEROID 11-HYDROXYLASE see **STEROID 11 BETA-MONOOXYGENASE**

STEROID 17-HYDROXYLASE see **STEROID 17 ALPHA-MONOOXYGENASE**

STEROID 18-HYDROXYLASE see **CYTOCHROME P-450 CYP11B2**

STEROID HYDROXYLASES

GENETICS

Pharmacogenetics of CYP2C subfamily in a Japanese population. Ieiri I, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:129–31 (12 ref.)

[Genetic polymorphism of the CYP2C subfamily] Chiba K. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):15–21 (47 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Targeted inactivation of vitamin D hydroxylases in mice. St-Arnaud R. **Bone** 1999 Jul;25(1):127–9 (21 ref.)

Recent advances in applied and mechanistic aspects of the enzymatic hydroxylation of steroids by whole-cell biocatalysts. Holland HL. **Steroids** 1999 Mar;64(3):178–86 (60 ref.)

PHYSIOLOGY

The renal function of 25-hydroxyvitamin D3-1alpha-hydroxylase. Zehnder D, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):213–20 (60 ref.)

STEROID 17 ALPHA-MONOOXYGENASE

ANTAGONISTS & INHIBITORS

Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Njar VC, et al. **Curr Pharm Des** 1999 Mar;5(3):163–80 (165 ref.)

Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase. Jarman M, et al. **Nat Prod Rep** 1998 Oct;15(5):495–512 (103 ref.)

DEFICIENCY

The molecular basis of isolated 17,20 lyase deficiency. Miller WL, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):817–25 (45 ref.)

Spontaneous growth and bone age development in a patient with 17alpha-hydroxylase deficiency: evidence of the role of sexual steroids in prepubertal bone maturation. Mayer EI, et al. **J Pediatr** 1999 Mar;134(3):371–5 (25 ref.)

GENETICS

The molecular basis of isolated 17,20 lyase deficiency. Miller WL, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):817–25 (45 ref.)

METABOLISM

Role of cytochrome P450c17 in polycystic ovary syndrome. Qin KN, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):111–21 (116 ref.)

Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase. Jarman M, et al. **Nat Prod Rep** 1998 Oct;15(5):495–512 (103 ref.)

PHYSIOLOGY

[The regulation of steroidogenesis by 17 alpha-hydroxylase/17,20-lyase (P450c17)] Katagiri M, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):43–50 (43 ref.) (Eng. Abstr.) **(Jpn)**

STEROID 11 BETA-MONOOXYGENASE

see related
ADRENAL HYPERPLASIA, CONGENITAL

GENETICS

Regulation of aldosterone biosynthesis: the end of the road? Müller J. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov; 25:S79–85 (49 ref.)

PHYSIOLOGY

Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Rainey WE. **Mol Cell Endocrinol** 1999 May 25;151(1–2):151–60 (79 ref.)

STEROID 17-MONOOXYGENASE see **STEROID 17 ALPHA-MONOOXYGENASE**

STEROID 21-MONOOXYGENASE

GENETICS

Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Speiser PW, et al. **Clin Endocrinol (Oxf)** 1998 Oct;49(4):411–7 (55 ref.)

STEROID MONOOXYGENASES see **STEROID HYDROXYLASES**

STEROID RECEPTORS see **RECEPTORS, STEROID**

STEROID 21-HYDROXYLASE see **STEROID 21-MONOOXYGENASE**

STEROIDAL ANTI-INFLAMMATORY AGENTS see **ANTI-INFLAMMATORY AGENTS, STEROIDAL**

STEROIDS

see related
RECEPTORS, STEROID

A tale of dwarfs and drugs: brassinosteroids to the rescue. Altmann T. **Trends Genet** 1998 Dec;14(12):490–5 (53 ref.)

ADMINISTRATION & DOSAGE

Role of endoscopic ultrasonography in guiding intralesional steroid injections in esophageal strictures [letter; comment] Sriram PV, et al. **Endoscopy** 1998 Oct;30(8):742–3 (9 ref.) Comment on: Endoscopy 1997 Oct;29(8):757–9.

Targeting inhaled steroids. Leach C. **Int J Clin Pract Suppl** 1998 Sep;96:23–7 (26 ref.)

ADVERSE EFFECTS

Inhaled steroid asthma treatment: 'Primum non nocere'. Toogood JH. **Can Respir J** 1998 Jul–Aug;5 Suppl A:50A–3A (36 ref.)

ANALYSIS

Clinical applications of gas chromatography and gas chromatography-mass spectrometry of steroids. Wolthers BG, et al. **J Chromatogr A** 1999 May 28;843(1–2):247–74 (134 ref.)

BIOSYNTHESIS

Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Miller WL. **Clin Perinatol** 1998 Dec;25(4):799–817, v (104 ref.)

Tracing steroid synthesis in plants. Groeneveld HW. **Crit Rev Biochem Mol Biol** 1999;34(2):59–69 (49 ref.)

Biochemical diversity of peptide-hormone-dependent regulation of steroidogenic P450s. Kagawa N, et al. **Drug Metab Rev** 1999 May;31(2):333–42 (25 ref.)

Control of ecdysteroidogenesis: activation and inhibition of prothoracic gland activity. Gilbert LI, et al. **Invert Neurosci** 1997 Sep–Dec;3(2–3):205–16 (83 ref.)

Interactions between testicular macrophages and Leydig cells. Hutson JC. **J Androl** 1998 Jul–Aug;19(4):394–8 (55 ref.)

In vitro studies on the role of the peripheral-type benzodiazepine receptor in steroidogenesis. Culty M, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):123–30 (47 ref.)

Alterations in gonadal steroidogenesis in individuals expressing a common genetic variant of luteinizing hormone. Huhtaniemi IT, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):281–5 (26 ref.)

Molecular medicine of steroid hormone biosynthesis. Biason-Lauber A. **Mol Aspects Med** 1998 Jun; 19(3):155–220 (160 ref.)

Signal transduction involving cyclic AMP-dependent and cyclic AMP-independent mechanisms in the control of steroidogenesis. Cooke BA. **Mol Cell Endocrinol** 1999 May 25;151(1–2):25–35 (100 ref.)

Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Mensah-Nyagan AG, et al. **Pharmacol Rev** 1999 Mar;51(1):63–81 (298 ref.)

Steroidogenic acute regulatory protein. Stocco DM. **Vitam Horm** 1999;55:399–441 (186 ref.)

[Steroidogenesis in epithelial cells of rat epididymis] Wiszniewska B. **Ann Acad Med Stetin** 1998;Suppl 40:1–66 (263 ref.) (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

[Terpenoids and steroids from several euphorbiaceae and pinaceae plants] Tanaka R, et al. **Yakugaku Zasshi** 1999 May;119(5):319–39 (64 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

A personal history of the early development of the concept and methods of measurement of the metabolic clearance rate particularly of steroid hormones. Tait JF, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S101–18 (79 ref.)

Neurosteroids in the cerebellar Purkinje neuron and their actions (review). Tsutsui K, et al. **Int J Mol Med** 1999 Jul;4(1):49–56 (60 ref.)

Lipophilic compounds in biotechnology--interactions with cells and technological problems. Angelova B, et al. **J Biotechnol** 1999 Jan 8;67(1):13–32 (178 ref.)

Steroid metabolism and effects in central and peripheral glial cells. Melcangi RC, et al. **J Neurobiol** 1999 Sep 15; 40(4):471–83 (126 ref.)

Molecular determinants of steroid recognition and catalysis in aldo-keto reductases. Lessons from 3alpha-hydroxysteroid dehydrogenase. Penning TM. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):211–25 (59 ref.)

Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. Rosner W, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun; 69(1–6):481–5 (26 ref.)

The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Spelsberg TC, et al. **Mol Endocrinol** 1999 Jun;13(6):819–28 (62 ref.)

Molecular mysteries of polycystic ovary syndrome. Strauss JF 3rd, et al. **Mol Endocrinol** 1999 Jun;13(6):800–5 (46 ref.)

Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Nussdorfer GG, et al. **Pharmacol Rev** 1999 Sep;51(3):403–38 (402 ref.)

Recent advances in applied and mechanistic aspects of the enzymatic hydroxylation of steroids by whole-cell biocatalysts. Holland HL. **Steroids** 1999 Mar;64(3):178–86 (60 ref.)

[Polymorphism of the genes of steroidogenesis and risk of malignant tumor development] Berstein LM, et al. **Vopr Onkol** 1999;45(3):213–8 (34 ref.) **(Rus)**

PHARMACOLOGY

Nongenomic steroid actions: completing the puzzle. Aldosterone as an example. Schmidt BM, et al. **Exp Clin Endocrinol Diabetes** 1998;106(6):441–5 (40 ref.)

Steroid-induced developmental plasticity in hypothalamic astrocytes: implications for synaptic patterning. Mong JA, et al. **J Neurobiol** 1999 Sep 15;40(4):602–19 (153 ref.)

Neuropsychopharmacological properties of neuroactive steroids. Rupprecht R, et al. **Steroids** 1999 Jan–Feb; 64(1–2):83–91 (84 ref.)

Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Rupprecht R, et al. **Trends Neurosci** 1999 Sep;22(9):410–6 (63 ref.)

Nongenomic steroid actions: fact or fantasy? Christ M, et al. **Vitam Horm** 1999;57:325–73 (229 ref.)

PHYSIOLOGY

Integration of chemosensory and hormonal input in the male Syrian hamster brain. Wood RI. **Ann N Y Acad Sci** 1998 Nov 30;855:362–72 (20 ref.)

The transcriptional basis of steroid physiology. Lin RJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:577–85 (56 ref.)

Premenstrual syndrome, neuroactive steroids and the brain. Sundström I, et al. **Gynecol Endocrinol** 1999 Jun; 13(3):206–20 (160 ref.)

The biology of breast cancer. Nass SJ, et al. **Hematol Oncol Clin North Am** 1999 Apr;13(2):311–32 (123 ref.)

Glia as mediators of steroid hormone action on the nervous system: An overview. Jordan CL. **J Neurobiol** 1999 Sep 15;40(4):434–45 (84 ref.)

Steroid metabolism and effects in central and peripheral glial cells. Melcangi RC, et al. **J Neurobiol** 1999 Sep 15; 40(4):471–83 (126 ref.)

Glial responses to steroids as markers of brain aging. Nichols NR. **J Neurobiol** 1999 Sep 15;40(4):585–601 (144 ref.)

The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects. Krozowski Z. **Mol Cell Endocrinol** 1999 May 25;151(1–2):121–7 (70 ref.)

Thymus-derived glucocorticoids and the regulation of antigen-specific T-cell development. Tolosa E, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):90–6 (70 ref.)

Molecular physiology of brassinosteroids revealed by the analysis of mutants. Altmann T. **Planta** 1999 Mar; 208(1):1–11 (97 ref.)

Membrane-initiated steroid actions and the proteins that mediate them. Watson CS, et al.

Proc Soc Exp Biol Med 1999 Jan;220(1):9–19 (176 ref.)
Neurosteroids: a novel function of the brain. Baulieu EE. **Psychoneuroendocrinology** 1998 Nov;23(8):963–87 (84 ref.)
Regulation of the preovulatory gonadotropin surge by endogenous steroids. Mahesh VB, et al. **Steroids** 1998 Dec; 63(12):616–29 (248 ref.)
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Rupprecht R, et al. **Trends Neurosci** 1999 Sep;22(9):410–6 (63 ref.)
[Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma] Clavière C, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):73–86 (166 ref.) **(Fre)**
[Regulation of expression of adrenergic receptors by steroid hormones] Dygalo NN, et al.
Ross Fiziol Zh Im I M Sechenova 1998 Oct;84(10):1115–20 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

No steroids or STITCH for CPB? [editorial; comment] Kan H, et al. **Crit Care Med** 1999 Mar;27(3):463–4 (16 ref.) Comment on: Crit Care Med 1999 Mar;27(3):545–8.
Use of postoperative steroids to reduce pain and inflammation. Fleischli JW, et al. **J Foot Ankle Surg** 1999 May–Jun;38(3):232–7 (31 ref.)
Steroids in muscular dystrophy: where do we stand? Dubrovsky AL, et al. **Neuromuscul Disord** 1998 Aug; 8(6):380–4 (34 ref.)
Management of acute laryngotracheo–bronchitis. Orlicek SL. **Pediatr Infect Dis J** 1998 Dec;17(12):1164–5 (13 ref.)
Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Gasior M, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):107–12 (60 ref.)

STEROIDS, ANABOLIC see **ANABOLIC STEROIDS**

STEROIDS, HETEROCYCLIC

METABOLISM

Recent advances in brassinosteroid molecular genetics. Altmann T. **Curr Opin Plant Biol** 1998 Oct;1(5):378–83 (33 ref.)

STEROL O-ACYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Burnett JR, et al. **Clin Chim Acta** 1999 Aug;286(1–2):231–42 (51 ref.)

METABOLISM

Acyl–coenzyme A:cholesteryl acyltransferase 2. Joyce C, et al. **Curr Opin Lipidol** 1999 Apr;10(2):89–95 (40 ref.)

PHYSIOLOGY

Acyl–coenzyme A:cholesteryl acyltransferase 2. Joyce C, et al. **Curr Opin Lipidol** 1999 Apr;10(2):89–95 (40 ref.)
[Roles of acyl–coenzyme A: cholesterol acyltransferase (ACAT) isozymes] Miyazaki A, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1312–8 (28 ref.) **(Jpn)**

STEROLS

Meiosis–activating sterols: background, discovery, and possible use. Byskov AG, et al. **J Mol Med** 1998 Nov–Dec; 76(12):818–23 (30 ref.)
[Function of sterylglucoside in cell differentiation and stress responses] Murakami–Murofushi K, et al.
Tanpakushitsu Kakusan Koso 1999 Jun;44(8 Suppl):1111–7 (32 ref.) **(Jpn)**

BIOSYNTHESIS

Biochemistry and molecular biology of sterol synthesis in Saccharomyces cerevisiae. Lees ND, et al.
Crit Rev Biochem Mol Biol 1999;34(1):33–47 (96 ref.)

METABOLISM

Variability of metabolism and function of sterols in insects. Svoboda JA. **Crit Rev Biochem Mol Biol** 1999;34(1):49–57 (56 ref.)
Oxysterols and apoptosis: evidence for gene regulation outside the cholesterol pathway. Thompson EB, et al.
Crit Rev Biochem Mol Biol 1999;34(1):25–32 (44 ref.)
Cholesterol homeostasis: a role for oxysterols. Accad M, et al. **Curr Biol** 1998 Aug 27;8(17):R601–4 (11 ref.)
The LXRs: a new class of oxysterol receptors. Peet DJ, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):571–5 (37 ref.)
Molecular genetics of the Smith–Lemli–Opitz syndrome and postsqualene sterol metabolism. Fitzky BU, et al.
Curr Opin Lipidol 1999 Apr;10(2):123–31 (69 ref.)
Gonadotropin–induced resumption of oocyte meiosis and meiosis–activating sterols. Andersen CY, et al.
Curr Top Dev Biol 1999;41:163–85 (120 ref.)
Toxins from sea cucumbers (holothuroids): chemical structures, properties, taxonomic distribution, biosynthesis and evolution. Stonik VA, et al. **J Nat Toxins** 1999 Jun; 8(2):235–48 (71 ref.)
Selective modification of sterol composition of hepatomas: new opportunities for chemotherapy. Feigin AM.
Med Hypotheses 1999 May;52(5):383–8 (46 ref.)
[Biosynthesis and transport of sterols in the yeast Saccharomyces cerevisiae] Soustre I, et al.
C R Seances Soc Biol Fil 1998;192(5):977–90 (70 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Regulation of cholesterol metabolism by dietary plant sterols. Miettinen TA, et al. **Curr Opin Lipidol** 1999 Feb;10(1):9–14 (54 ref.)
Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c–myc. Thompson EB, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):453–61 (32 ref.)

THERAPEUTIC USE

Inhibition of cholesterol absorption by plant sterols for mass intervention. Ikeda I, et al. **Curr Opin Lipidol** 1998 Dec; 9(6):527–31 (42 ref.)

STEVENS–JOHNSON SYNDROME

CHEMICALLY INDUCED

Lamotrigine–induced severe cutaneous adverse reactions. Schlienger RG, et al. **Epilepsia** 1998;39 Suppl 7:S22–6 (40 ref.)

ETIOLOGY

Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Micali G, et al. **Pharmacotherapy** 1999 Feb;19(2):223–7 (39 ref.)

STICKLEBACKS see **FISHES**

STIFF–MAN SYNDROME

Stiff–man syndrome: from the bedside to the bench. Helfgott SM. **Arthritis Rheum** 1999 Jul;42(7):1312–20 (91 ref.)

CLASSIFICATION

The stiff man and stiff man plus syndromes. Brown P, et al. **J Neurol** 1999 Aug;246(8):648–52 (48 ref.)

DIAGNOSIS

[Non–hereditary +hyperekplexia. Study of a patient with unusual ictal EEG features and review of the literature] Rodriguez–Barrionuevo AC, et al. **Rev Neurol** 1998 Dec; 27(160):1015–8 (29 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The stiff–person syndrome: an autoimmune disorder affecting neurotransmission of gamma–aminobutyric acid. Levy LM, et al. **Ann Intern Med** 1999 Oct 5;131(7):522–30 (63 ref.)

STIGMATA see **CHRISTIANITY**

STIGMATIZATION see **STEREOTYPING**

STILBENES

ANALYSIS

Stilbene compounds: from the grapevine to wine. Bavaresco L, et al. **Drugs Exp Clin Res** 1999;25(2–3):57–63 (56 ref.)

CHEMISTRY

Mechanism of competition between chloride and stilbenedisulfonates for binding to human erythrocyte band 3 (AE1). Salhany JM. **Biochem Cell Biol** 1998;76(5):715–22 (37 ref.)

PHARMACOLOGY

Clinical pharmacology of selective estrogen receptor modulators. Haynes B, et al. **Drugs Aging** 1999 May; 14(5):323–36 (168 ref.)
Nonalcoholic compounds of wine: the phytoestrogen resveratrol and moderate red wine consumption during menopause. Calabrese G. **Drugs Exp Clin Res** 1999; 25(2–3):111–4 (32 ref.)
Cardioprotection of red wine: role of polyphenolic antioxidants. Das DK, et al. **Drugs Exp Clin Res** 1999; 25(2–3):115–20 (25 ref.)
Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Tredici G, et al.
Drugs Exp Clin Res 1999;25(2–3):99–103 (21 ref.)

THERAPEUTIC USE

Chemoprevention of cancer and cardiovascular disease by resveratrol. Lin JK, et al.
Proc Natl Sci Counc Repub China B 1999 Jul;23(3):99–106 (99 ref.)

STILBESTROL see **DIETHYLSTILBESTROL**

STILLBIRTH see **FETAL DEATH**

STILL'S DISEASE, ADULT-ONSET

[Adult Still's disease] Nara H, et al. **Nippon Rinsho** 1999 Feb; 57(2):384–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Pulmonary involvement in adult–onset Still's disease. Cheema GS, et al. **Curr Opin Pulm Med** 1999 Sep;5(5):305–9 (36 ref.)
[Amyloidosis in adult Still's disease. Value of cyclophosphamide treatment] Kchir MM, et al.
Ann Med Interne (Paris) 1998 Dec;149(8):527–9 (26 ref.) **(Fre)**

DIAGNOSIS

Schnitzler's syndrome versus adult onset Still's disease [published erratum appears in Eur J Dermatol 1998 Jun;8(4):234] Tomková H, et al. **Eur J Dermatol** 1998 Mar; 8(2):118–21 (20 ref.)

STILL'S DISEASE, JUVENILE-ONSET see **ARTHRITIS, JUVENILE RHEUMATOID**

STIMULATION, ACOUSTIC see **ACOUSTIC STIMULATION**

STIMULATION, AUDITORY see **ACOUSTIC STIMULATION**

STIMULATION, ELECTRIC see **ELECTRIC STIMULATION**

STIMULATION, PHOTIC see **PHOTIC STIMULATION**

STIMULATION, PHYSICAL see **PHYSICAL STIMULATION**

STINGS see **BITES AND STINGS**

STLV

The simian origins of the pathogenic human T–cell lymphotropic virus type I. Vandamme AM, et al.
Trends Microbiol 1998 Dec;6(12):477–83 (54 ref.)

GENETICS

Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T–cell leukemia/lymphotropic viruses. Slattery JP, et al.
Genome Res 1999 Jun;9(6):525–40 (113 ref.)

STLV-I see **STLV**

STLV-III see **SIV**

STOCHASTIC PROCESSES

Identifying efficiently and economically operated hospitals: the prospects and pitfalls of applying frontier regression techniques. Chirikos TN. **J Health Polit Policy Law** 1998 Dec;23(6):879–904 (16 ref.)
The stochastic diffusion models of nerve membrane depolarization and interspike interval generation. Lánský P, et al. **J Peripher Nerv Syst** 1999;4(1):27–42 (81 ref.)
Stochastic game theory: for playing games, not just for doing theory. Goeree JK, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10564–7 (36 ref.)

STOCKINGS, COMPRESSION see **BANDAGES**

STOCKINGS, ELASTIC see **BANDAGES**

STOICISM see **PHILOSOPHY**

STOMACH

see related
FUNDOPLICATION
GASTRECTOMY
GASTROPLASTY
GASTROSCOPY
GASTROSTOMY

A new technique for endoscopic retrieval of retained internal PEG bumper. Brown RL, et al. **Gastrointest Endosc** 1999 Jul;50(1):126–7 (11 ref.)
Late migration of a self–expandable metal stent and successful endoscopic management. Rollhauser C, et al.
Gastrointest Endosc 1999 Apr;49(4 Pt 1):541–4 (26 ref.)
Trichotillomania resulting in a trichobezoar: a case report. Stone KD, et al. **J La State Med Soc** 1998 Oct; 150(10):478–81 (14 ref.)
An unusual complication of endotracheal intubation: ingestion of a laryngoscope bulb. Ince Z, et al.
Pediatr Emerg Care 1998 Aug;14(4):275–6 (4 ref.)

ABNORMALITIES

[Duplication of the stomach as a rare cause of cystic epigastric tumor] Rudolph J, et al. **Zentralbl Chir** 1998; 123(7):850–4 (26 ref.) (Eng. Abstr.) **(Ger)**

STOMACH

BLOOD SUPPLY

Aneurysm of the gastroduodenal artery. Matsuzaki Y, et al. **Intern Med** 1998 Nov;37(11):930–3 (13 ref.)

Pseudolesion in segments II and III of the liver on CT during arterial portography caused by aberrant right gastric venous drainage. Yoon KH, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):306–9 (12 ref.)

Esophagogastric anastomotic leaks: the importance of gastric ischemia and therapeutic applications of gastric conditioning. Urschel JD. **J Invest Surg** 1998 Jul–Aug; 11(4):245–50 (55 ref.)

[Ischemic necrosis of the spleen and gastric fundus. A rare complication of acute pancreatitis (letter)] Soria Aledo V, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):209 (8 ref.) **(Spa)**

DRUG EFFECTS

Toxicity of NSAIDs in the stomach and duodenum. Lanas A, et al. **Eur J Gastroenterol Hepatol** 1999 Apr;11(4):375–81 (49 ref.)

ENZYMOLOGY

Structural aspects of the gastric H,K ATPase: the M5/M6 domain and alpha beta association. Melle-Milovanovic D, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:147–62 (39 ref.)

Gastric H+/K(+)-ATPase: targeting signals in the regulation of physiologic function. Caplan MJ. **Curr Opin Cell Biol** 1998 Aug;10(4):468–73 (51 ref.)

[Human gastric alcohol dehydrogenase] Chrostek L, et al. **Postepy Hig Med Dosw** 1999;53(1):87–97 (53 ref.) (Eng. Abstr.) **(Pol)**

INJURIES

Laparoscopic Nissen fundoplication complicated by late gastroesophageal herniation and intrathoracic perforation: a case report with review of the literature. Boggi U, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):57–9 (14 ref.)

METABOLISM

CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Håkanson R, et al. **Regul Pept** 1999 Mar 17;80(1–2):1–12 (117 ref.)

MICROBIOLOGY

Helicobacter pylori induced apoptosis. Shirin H, et al. **Gut** 1998 Nov;43(5):592–4 (34 ref.)

Helicobacter pylori virulence and genetic geography. Covacci A, et al. **Science** 1999 May 21;284(5418):1328–33 (57 ref.)

[Relation of Helicobacter pylori and the stomach operated on for peptic ulcer] Hurtado-Andrade H. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4):187–97 (90 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Hematemesis due to prolapse gastropathy: an emetogenic injury. Byfield F, et al. **Gastrointest Endosc** 1998 Nov; 48(5):527–9 (10 ref.)

Atrophy, metaplasia and dysplasia: are they reversible? Genta RM. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S324–5 (15 ref.)

[Interferon-alpha treatment for chemotherapy-resistant primary macroglobulinemia with stomach and lung invasion] Kitamura N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):137–44 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Progression and the clinical implications of metaplasia and dysplasia in the stomach] Sancho Poch FJ. **Gastroenterol Hepatol** 1999 May;22(5):238–41 (39 ref.) **(Spa)**

[Gastric necrosis due to vasculitis in an HIV+ patient (letter)] Alcántara Gijón F, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):152–3 (6 ref.) **(Spa)**

PHYSIOLOGY

Imidazoline recognition sites and stomach function. Molderings GJ, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:332–43 (56 ref.)

Electrogastrography: a noninvasive technique to evaluate gastric electrical activity. Sanmiguel CP, et al. **Can J Gastroenterol** 1998 Sep;12(6):423–30 (78 ref.)

Non-adrenergic non-cholinergic relaxation of the rat stomach. Currò D, et al. **Gen Pharmacol** 1998 Nov; 31(5):697–703 (77 ref.)

Prostaglandins in the stomach: an update. Arakawa T, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S1–11 (42 ref.)

PHYSIOPATHOLOGY

Gastric motor and sensory function testing. Tack J. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):470–5 (39 ref.)

[Biochemical markers of gastric functioning] Basso D, et al. **Recenti Prog Med** 1999 Jun;90(6):342–6 (36 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Esophagogastric anastomotic leaks: the importance of gastric ischemia and therapeutic applications of gastric conditioning. Urschel JD. **J Invest Surg** 1998 Jul–Aug; 11(4):245–50 (55 ref.)

[Pouch stomach reconstruction after gastrectomy] Schwarz A, et al. **Z Gastroenterol** 1999 Apr;37(4):287–91 (28 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

Gastrocystoplasty: long-term complications in 22 patients. Mingin GC, et al. **J Urol** 1999 Sep;162(3 Pt 2):1122–5 (16 ref.)

Gastrocystoplasty: is there a consensus? Kurzrock EA, et al. **World J Urol** 1998;16(4):242–50 (51 ref.)

ULTRASONOGRAPHY

EUS in gastric sarcoidosis. De Angelis C, et al. **Gastrointest Endosc** 1999 May;49(5):639–41 (18 ref.)

STOMACH DISEASES

Isolated gastric tuberculosis of the cardia. Lin OS, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):258–61 (22 ref.)

Electrogastrography: its role in managing gastric disorders. Levanon D, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct; 27(4):431–43 (109 ref.)

[Gastric anisakiasis] Yamaguchi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):461–3 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Drug-induced disorders of the stomach and duodenum. Gore RM, et al. **Abdom Imaging** 1999 Jan–Feb;24(1):9–16 (49 ref.)

Molecular mechanisms involved in NSAID-induced gastropathy. Morise Z, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S87–90 (37 ref.)

[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs] Steen KS, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7;143(32):1649–52 (27 ref.) (Eng. Abstr.) **(Dut)**

[Consequences of achlorhydria secondary to antisecretory treatments] Cadiot G. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S110–20 (96 ref.) **(Fre)**

COMPLICATIONS

Hematemesis due to prolapse gastropathy: an emetogenic injury. Byfield F, et al. **Gastrointest Endosc** 1998 Nov; 48(5):527–9 (10 ref.)

[Treatment of gastroesophageal reflux: should Helicobacter pylori infection be taken into account?] De Korwin JD. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S121–9 (87 ref.) **(Fre)**

[Portal hypertensive gastropathy] Toyonaga A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):619–26 (32 ref.) **(Jpn)**

DIAGNOSIS

Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Koch KL. **Dig Dis Sci** 1999 Jun; 44(6):1061–75 (66 ref.)

Hematemesis due to prolapse gastropathy: an emetogenic injury. Byfield F, et al. **Gastrointest Endosc** 1998 Nov; 48(5):527–9 (10 ref.)

["Giant" gastric lipomas in asymptomatic adolescent] Gheza G, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):123–5 (8 ref.) **(Ita)**

[Gastric necrosis due to vasculitis in an HIV+ patient (letter)] Alcántara Gijón F, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):152–3 (6 ref.) **(Spa)**

DIET THERAPY

Gastric disorders and nutritional management. Kotler DP. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):825–40 (61 ref.)

DRUG THERAPY

Acid suppression therapy. Tavenor T. **Can J Gastroenterol** 1998 Jul–Aug;12(5):320–1 (0 ref.)

Domperidone. A review of its use in diabetic gastropathy. Prakash A, et al. **Drugs** 1998 Sep;56(3):429–45 (94 ref.)

[Treatment of gastroesophageal reflux: should Helicobacter pylori infection be taken into account?] De Korwin JD. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S121–9 (87 ref.) **(Fre)**

ETIOLOGY

Lymphoid hyperplasia of the stomach caused by Helicobacter pylori: upper gastrointestinal findings. Lee EY, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):362–3 (8 ref.)

Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Kong MF, et al. **Clin Geriatr Med** 1999 May;15(2):321–38 (98 ref.)

Domperidone. A review of its use in diabetic gastropathy. Prakash A, et al. **Drugs** 1998 Sep;56(3):429–45 (94 ref.)

Metabolism of ethanol and some associated adverse effects on the liver and the stomach. Lieber CS, et al. **Recent Dev Alcohol** 1998;14:7–40 (245 ref.)

[Dieulafoy's lesion—a rare cause of gastric hemorrhage] Damianov D, et al. **Khirurgiia (Sofiia)** 1998;51(1):60–2 (8 ref.) **(Bul)**

[Gastric and duodenal intramural hematoma: report of two cases] Dibuz M, et al. **Orv Hetil** 1998 Dec 6;139(49):2963 (39 ref.) (Eng. Abstr.) **(Hun)**

[Portal hypertensive gastropathy and colopathy] Ohashi K, et al. **Nippon Rinsho** 1998 Sep;56(9):2369–75 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Acute gastroduodenal mucosal lesion] Yakabi K, et al. **Nippon Rinsho** 1998 Sep;56(9):2336–42 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A case of systemic lupus erythematosus overlapping with progressive systemic sclerosis accompanied by deposition of AA amyloid in the stomach] Obata T, et al. **Ryumachi** 1998 Dec;38(6):810–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Gastric motor dysfunction in diabetic patients: pathogenesis, clinical manifestations, diagnosis and treatment] Sokup A, et al. **Przegl Lek** 1998;55(6):342–5 (19 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Animal models for gastric Helicobacter immunology and vaccine studies. Nedrud JG. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):243–50 (45 ref.)

METABOLISM

[Oxygen metabolism disturbances in the pathogenesis of gastric and duodenal diseases] Swiątkowski M, et al. **Przegl Lek** 1999;56(3):220–6 (58 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Are all helicobacters equal? Mechanisms of gastroduodenal pathology and their clinical implications. Axon AT. **Gut** 1999 Jul;45 Suppl 1:I1–4 (28 ref.)

Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Blaser MJ. **Gut** 1998 Nov; 43(5):721–7 (101 ref.)

Helicobacter pylori induced apoptosis. Shirin H, et al. **Gut** 1998 Nov;43(5):592–4 (34 ref.)

New acquisitions in Helicobacter pylori infection. Introduction. Gasbarrini G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S243 (3 ref.)

Eradication therapies for Helicobacter pylori. Borody TJ, et al. **J Gastroenterol** 1998;33 Suppl 10:53–6 (10 ref.)

Are there more clinically important complications of Helicobacter pylori infection than peptic ulcer disease? A review of current literature. Unge P. **J Gastroenterol** 1998; 33 Suppl 10:48–52 (47 ref.)

Helicobacter pylori in childhood: new insights into the immunopathogenesis of gastric disease and implications for managing infection in children. Ernst PB, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):462–73 (117 ref.)

Is Helicobacter pylori really the cause of gastroduodenal disease? Weiner H, et al. **QJM** 1998 Oct;91(10):707–11 (50 ref.)

[Peptic ulcer disease and hemorrhagic gastritis with H. pylori infection] Yamamoto I, et al. **Nippon Rinsho** 1998 Sep; 56(9):2263–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Cryptosporidium-induced gastric obstruction in a child with congenital HIV infection: case report and review of the literature. Moon A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):108–11 (23 ref.)

PATHOLOGY

Gastric polypoid lesions—illustrative cases and literature review. Lau CF, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2559–64 (36 ref.)

Sessile polypoid gastric heterotopia of rectum: a report of 2 cases and review of the literature. Srinivasan R, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):222–4 (16 ref.)

[A case report of pancreatic mucinous cystadenocarcinoma with penetration to the stomach] Baek Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):685–90 (12 ref.) **(Jpn)**

[Gastric calcinosis (letter)] Pallarés H, et al. **Rev Esp Enferm Dig** 1999 Jun;91(6):461–2 (6 ref.) **(Spa)**

PHYSIOPATHOLOGY

Gastric motor and sensory function testing. Tack J. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):470–5 (39 ref.)

PREVENTION & CONTROL

[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs] Steen KS, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7;143(32):1649–52 (27 ref.) (Eng. Abstr.) **(Dut)**

SURGERY

Endoluminal surgery. Martínez-Serna T, et al.

World J Surg 1999 Apr;23(4):368–77 (57 ref.)

THERAPY

Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Kong MF, et al. **Clin Geriatr Med** 1999 May;15(2):321–38 (98 ref.)

Helicobacter pylori in childhood: new insights into the immunopathogenesis of gastric disease and implications for managing infection in children. Ernst PB, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):462–73 (117 ref.)

ULTRASONOGRAPHY

Endoscopic ultrasonography in large gastric folds. Caletti G, et al. **Endoscopy** 1998 Aug;30 Suppl 1:A72–5 (31 ref.)

EUS in gastric sarcoidosis. De Angelis C, et al. **Gastrointest Endosc** 1999 May;49(5):639–41 (18 ref.)

VETERINARY

Diagnosis and treatment of gastric motility disorders. Hall JA, et al. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):377–95 (83 ref.)

Gastric disease in the dog and cat. Sullivan M, et al. **Vet J** 1998 Sep;156(2):91–106 (59 ref.)

STOMACH NEOPLASMS

Gastric polyps. Debongnie JC. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):187–9 (14 ref.)

Acid-related disorders in the new millennium: European, Japanese and North American perspectives. Freston JW, et al. **Eur J Gastroenterol Hepatol** 1998 Sep;10 Suppl 2:S1–40 (120 ref.)

Gastric cancer. Triantafillidis JK. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1930–4 (25 ref.)

Acquired gastric mucosa-associated lymphoid tissue (MALT): a review with special emphasis on association with extragastric diseases and management problems of gastric MALT [see comments] Tursi A, et al. **J Clin Gastroenterol** 1999 Sep;29(2):133–7 (34 ref.) Comment in: J Clin Gastroenterol 1999 Sep;29(2):116–7.

Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. Wiedenmann B, et al. **J Mol Med** 1998 Aug;76(9):637–47 (103 ref.)

The Carney Triad: a lesson in observation, creativity, and perseverance [editorial; comment] Appelman HD. **Mayo Clin Proc** 1999 Jun;74(6):638–40 (15 ref.) Comment on: Mayo Clin Proc 1999 Jun;74(6):543–52.

Gastric cancer. O'Connor KG. **Semin Oncol Nurs** 1999 Feb; 15(1):26–35 (41 ref.)

[What's new in cancer of the stomach? An overview of the literature of this year] Perrot L, et al. **J Chir (Paris)** 1998 Oct;135(4):148–54 (50 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenesis and clinical pathology of mucosa-associated lymphoid tissue (MALT) lymphoma] Akagi T. **Rinsho Ketsueki** 1999 Mar;40(3):177–81 (16 ref.) **(Jpn)**

COMPLICATIONS

Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and H. pylori infection. Itatsu T, et al. **Dig Dis Sci** 1999 Sep;44(9):1823–36 (67 ref.)

The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Spechler SJ. **Gastroenterology** 1999 Jul;117(1):218–28 (69 ref.)

Gastric carcinoma in association with remitting seronegative symmetrical synovitis with pitting edema. Ethiopia A, et al. **J Rheumatol** 1999 May;26(5):1203–4 (10 ref.)

Hyperplastic gastric polyp causing progressive gastric outlet obstruction. Dean PG, et al. **Mayo Clin Proc** 1998 Oct; 73(10):964–7 (17 ref.)

[Gastric polypoid angioma: a rare cause of bleeding in the elderly. Report of a case and review of the literature] Pelizzari E, et al. **Minerva Chir** 1998 May;53(5):405–10 (18 ref.) (Eng. Abstr.) **(Ita)**

[Microangiopathic hemolytic anemia. A form of presentation of stomach neoplasm] Oliveira A, et al. **Acta Med Port** 1998 Jun;11(6):569–72 (12 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Pedunculated exogastric leiomyosarcoma: case report and brief literature review. Shimoji H, et al. **Clin Imaging** 1999 Mar-Apr;23(2):94–8 (15 ref.)

Adenocarcinoma of the stomach: an update. Stefanini M. **Compr Ther** 1998 Nov-Dec;24(11–12):582–9 (23 ref.)

Mass screening programs in Japan: what can we learn in the West? [editorial; comment] Lambert R. **Endoscopy** 1998 Oct;30(8):721–3 (14 ref.) Comment on: Endoscopy 1998 Oct;30(8):669–74.

Diagnosis of esophagogastric tumors: a trend toward virtual biopsy. Lambert R. **Endoscopy** 1999 Jan;31(1):38–46 (50 ref.)

Health-related quality of life evaluations of gastric and pancreatic cancer. Schmier J, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1998–2004 (42 ref.)

Unusual gastric polyp showing submucosal proliferation of glands: case report and literature review. Itoh K, et al. **J Gastroenterol** 1998 Oct;33(5):720–3 (23 ref.)

Role of laparoscopy in the management of stomach cancer. Goh PM, et al. **Semin Surg Oncol** 1999 Jun;16(4):321–6 (25 ref.)

Imaging diagnosis for staging of gastric cancer. Kuntz C, et al. **Semin Surg Oncol** 1999 Sep;17(2):96–102 (43 ref.)

Diagnosis of gastric carcinoma: Japanese fairy tales or Western deficiency? [editorial] Stolte M. **Virchows Arch** 1999 Apr;434(4):279–80 (8 ref.)

Diagnosis and treatment of ECL cell tumors. Cadiot G, et al. **Yale J Biol Med** 1998 May-Aug;71(3–4):311–23 (63 ref.)

[New prognostic factors in gastric cancer] Herszényi L. **Orv Hetil** 1999 Aug 8;140(32):1771–7 (50 ref.) (Eng. Abstr.) **(Hun)**

[Gastric leiomyoblastoma. (Review of the literature in the light of a case)] Simeth C, et al. **Ann Ital Chir** 1999 Jan-Feb; 70(1):57–60 (15 ref.) (Eng. Abstr.) **(Ita)**

[Gastric adenocarcinoma and carcinoid] Cunha P, et al. **Acta Med Port** 1998 Jun;11(6):577–80 (9 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Adjuvant chemotherapy in gastric adenocarcinomas. Costa F, et al. **Cancer Treat Res** 1998;98:41–63 (115 ref.)

CPT-11 in gastrointestinal cancer. Bleiberg H. **Eur J Cancer** 1999 Mar;35(3):371–9 (85 ref.)

Chemotherapy for gastric carcinoma: new and old options. Ajani JA. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):44–7 (35 ref.)

Current status of therapy for advanced gastric carcinoma. Ajani JA. **Oncology (Huntingt)** 1998 Aug;12(8 Suppl 6):99–102 (28 ref.)

Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Bozzetti F, et al. **Tumori** 1998 Jul-Aug;84(4):483–8 (75 ref.)

[Stomach carcinoma. Optimizing therapy by neoadjuvant or adjuvant therapy?] Rosen H. **Zentralbl Chir** 1999; 124(5):387–93 (40 ref.) (Eng. Abstr.) **(Ger)**

[Improving the anti-tumor activity of 5-fluorouracil by methotrexate] Konishi T, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):431–9 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Why not standard practice guidelines in Japan?] Nakajima T. **Gan To Kagaku Ryoho** 1999 Apr;26(5):597–601 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Leucovorin and 5-FU for advanced gastrointestinal cancer] Sasaki T, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):440–6 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Recent arguments in advanced gastric cancer treatment] Sasaki T, et al. **Gan To Kagaku Ryoho** 1998 Oct; 25(12):1849–56 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Adjuvant intraperitoneal chemotherapy in radical and palliative treatment of stomach neoplasms (review of foreign literature)] Chissov VI, et al. **Khirurgiia (Mosk)** 1999;(1):61–5 (57 ref.) **(Rus)**

[Clinical significance of the chemotherapy dosage in gastric cancer] Shparik IaV. **Klin Khir** 1999;(5):47–51 (20 ref.) **(Ukr)**

ECONOMICS

Economic perspectives in the management of Helicobacter pylori infections. Sonnenberg A, et al. **Curr Top Microbiol Immunol** 1999;241:237–60 (52 ref.)

Economic evaluations of gastric and pancreatic cancer. Elixhauser A, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1206–13 (20 ref.)

ENZYMOLOGY

Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase. Shimada S, et al. **J Exp Clin Cancer Res** 1999 Mar;18(1):111–8 (38 ref.)

EPIDEMIOLOGY

Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Danesh J. **Aliment Pharmacol Ther** 1999 Jul;13(7):851–6 (65 ref.)

Role of endoscopy in the prevention of digestive cancer: application to colorectal cancer. Lambert R. **Endoscopy** 1998 Sep;30(7):628–40 (47 ref.)

Gastric cancer: epidemiologic and biological aspects. Maltoni M, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):199–207 (43 ref.)

Helicobacter pylori, peptic ulcer and gastric cancer in China. Lam SK, et al. **Yale J Biol Med** 1998 Jan-Feb;71(1):1–6 (43 ref.)

[Is gastric adenocarcinoma in a phase of retreat? (editorial)] Boixeda de Miquel D. **Rev Clin Esp** 1999 May;199(5):261–3 (32 ref.) **(Spa)**

ETIOLOGY

Helicobacter pylori and gastric malignancies. Melange M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):305–6 (9 ref.)

GENETICS

The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Oliveira C, et al. **Am J Pathol** 1998 Oct;153(4):1211–9 (44 ref.)

Gastric carcinoma in Sotos syndrome (cerebral gigantism). Le Marec B, et al. **Ann Genet** 1999;42(2):113–6 (23 ref.)

Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Berx G, et al. **Cell Adhes Commun** 1998;6(2–3):171–84 (88 ref.)

Molecular mechanism of human stomach carcinogenesis implicated in Helicobacter pylori infection. Tahara E. **Exp Toxicol Pathol** 1998 Sep;50(4–6):375–8 (21 ref.)

Gastric cancer: epidemiologic and biological aspects. Maltoni M, et al. **Forum (Genova)** 1998 Apr-Jun;8(2):199–207 (43 ref.)

Mutations of the human E-cadherin (CDH1) gene. Berx G, et al. **Hum Mutat** 1998;12(4):226–37 (71 ref.)

Genetic events underlying morphological complexity of gastric carcinoma. Rhyu MG. **J Korean Med Sci** 1998 Aug; 13(4):339–49 (86 ref.)

Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Hsieh HF, et al. **Mol Pathol** 1999 Feb; 52(1):25–8 (47 ref.)

A rat model system for predisposition to stomach cancer. Ushijima T, et al. **Prog Exp Tumor Res** 1999;35:120–30 (29 ref.)

Genetic predisposition to gastric cancer. Bevan S, et al. **QJM** 1999 Jan;92(1):5–10 (62 ref.)

[The role of genetic factors in the development of gastric cancer] Taal BG, et al. **Ned Tijdschr Geneeskd** 1999 Feb 13;143(7):342–6 (37 ref.) (Eng. Abstr.) **(Dut)**

[New molecular prognostic markers in gastric carcinoma] Yoshida K, et al. **Gan To Kagaku Ryoho** 1998 Nov; 25(13):2021–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Protein p53 in gastric carcinoma: clinical use of cancer research on neoplasms (editorial)] Starzyńska T. **Pol Merkuriusz Lek** 1999 Feb;6(32):61–4 (30 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Helicobacter pylori factors associated with disease [editorial; comment] Cover TL, et al. **Gastroenterology** 1999 Jul; 117(1):257–61 (36 ref.) Comment on: Gastroenterology 1999 Jul;117(1):82–8.

METABOLISM

Relations of nm23 expression to clinicopathologic variables and proliferative activity of gastric cancer lesions. Nakamura T, et al. **Cancer Detect Prev** 1998;22(3):246–50 (23 ref.)

Progesterone receptors in gastric leiomyosarcoma [letter] Munoz E. **Eur J Surg** 1998 Oct;164(10):796 (5 ref.)

Histamine metabolism of gastric carcinoids in Mastomys natalensis. Kölby L, et al. **Yale J Biol Med** 1998 May-Aug; 71(3–4):207–15 (44 ref.)

Relationship of ECL cells and gastric neoplasia. Waldum HL, et al. **Yale J Biol Med** 1998 May-Aug;71(3–4):325–35 (87 ref.)

MICROBIOLOGY

Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Danesh J. **Aliment Pharmacol Ther** 1999 Jul;13(7):851–6 (65 ref.)

Review article: the role of inflammation in the pathogenesis of gastric cancer. Ernst P. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:13–8 (18 ref.)

Review article: exploring the link between Helicobacter pylori and gastric cancer. Kuipers EJ. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:3–11 (27 ref.)

Helicobacter pylori and gastric cancer. Scheiman JM, et al. **Am J Med** 1999 Feb;106(2):222–6 (55 ref.)

Role of Helicobacter pylori in the pathogenesis of gastric carcinoma and progression of lymphoid nodules to lymphoma. Guindi M. **Can J Gastroenterol** 1999 Apr; 13(3):224–7 (39 ref.)

Gastric cancer and lymphoma. Mukhopadhyay P. **Curr Top Microbiol Immunol** 1999;241:57–69 (91 ref.)

Helicobacter pylori and gastric cancer. **Drug Ther Bull** 1998 Aug;36(8):57–9 (30 ref.)

Helicobacter pylori and lymphoproliferative disorders. Fischbach W. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S299–303 (39 ref.)

Helicobacter pylori and gastric cancer. McNamara D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S294–8 (49 ref.)

Lymphocytic gastritis, Helicobacter pylori, and gastric cancer: is vitamin C the common link? [editorial] Hayat M, et al. **Nutrition** 1999 May;15(5):402–3 (20 ref.)

Is Helicobacter pylori really the cause of gastric cancer? Nyrén O. **Semin Cancer Biol** 1998 Aug;8(4):275–83 (72 ref.)

[Progresses in the study of gastroenterology in China, 1997] Lu X. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):888–90 (0 ref.) **(Chi)**

[Relation between Helicobacter pylori and stomach cancers] Guo F, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr; 36(4):276–8 (20 ref.) **(Chi)**

[Helicobacter pylori, gastritis and stomach tumors (editorial)] Fléjou JF. **Gastroenterol Clin Biol** 1999 Jun-Jul; 23(6-7):737–9 (23 ref.) **(Fre)**

[Occurrence of Helicobacter pylori in patients with gastroesophageal tumors] Szilvás A, et al. **Orv Hetil** 1999 May 9;140(19):1049–52 (52 ref.) (Eng. Abstr.) **(Hun)**

[Helicobacter pylori and gastric cancer] Asaka M. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):627–33 (35 ref.) **(Jpn)**

STOMACH NEOPLASMS

PATHOLOGY

Gastric small-cell carcinoma in Japan: a case report and review of the literature. Arai K, et al. **Am J Clin Oncol** 1998 Oct;21(5):458–61 (22 ref.)

Primary advanced gastric small cell carcinoma: a case report and review of the literature. Takaku H, et al. **Am J Gastroenterol** 1999 May;94(5):1402–4 (16 ref.)

Vasculitis carcinomatosa occurring in association with adenocarcinoma of the stomach. Sweeney S, et al. **Ann Diagn Pathol** 1998 Aug;2(4):247–9 (12 ref.)

Relations of nm23 expression to clinicopathologic variables and proliferative activity of gastric cancer lesions. Nakamura T, et al. **Cancer Detect Prev** 1998;22(3):246–50 (23 ref.)

Significance of cell proliferation measurement in gastric cancer. Schipper DL, et al. **Eur J Cancer** 1998 May; 34(6):781–90 (79 ref.)

Small mucosal carcinoma of the stomach with para-aortic lymph node metastasis: a case report and review of the literature. Miyaji M, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):343–6 (15 ref.)

Bone and skeletal muscle metastases from gastric adenocarcinoma: unusual radiographic, CT and scintigraphic features. Narváez JA, et al. **Eur Radiol** 1998; 8(8):1366–9 (23 ref.)

EUS and EUS-guided fine-needle aspiration for the diagnosis of rectal linitis plastica secondary to prostate carcinoma. Bhutani MS. **Gastrointest Endosc** 1999 Jul; 50(1):117–9 (13 ref.)

Gastric precancerous lesions: heading for an international consensus. Genta RM, et al. **Gut** 1999 Jul;45 Suppl 1:I5–8 (38 ref.)

Gastric enterochromaffin-like-cell tumor with liver and splenic metastases. Eriguchi N, et al. **J Gastroenterol** 1999 Jun;34(3):383–6 (10 ref.)

Genetic events underlying morphological complexity of gastric carcinoma. Rhyu MG. **J Korean Med Sci** 1998 Aug; 13(4):339–49 (86 ref.)

Synchronous and metachronous gastric adenocarcinoma: case report and literature review. Gnanalingham KK, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):61–2 (15 ref.)

Primary gastric T-cell lymphomas: report of two cases and a review of the literature. Horie R, et al. **Jpn J Clin Oncol** 1999 Mar;29(3):171–8 (58 ref.)

Gastric low-grade mucosa-associated lymphoid tissue lymphomas: their histogenesis and high-grade transformation. Yoshino T, et al. **Pathol Int** 1998 May; 48(5):323–31 (104 ref.)

Signet ring cell carcinoma of the stomach: a clinicopathological comparison with the other histological types. Yokota T, et al. **Tohoku J Exp Med** 1998 Oct; 186(2):121–30 (16 ref.)

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Lehnert T. **Transplantation** 1998 Nov 27;66(10):1307–12 (37 ref.)

Pathogenesis of ECL cell tumors in humans. Bordi C, et al. **Yale J Biol Med** 1998 May–Aug;71(3–4):273–84 (50 ref.)

[Advances in clinicopathological study on gastric endocrine neoplasms] Yu J, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Jun;26(3):185–6 (12 ref.) **(Chi)**

[Gastric mucosa-associated lymphoid tissue lymphomas (MALT) and their treatment] Ruskoné-Fourmestraux A. **Ann Chir** 1999;53(2):143–9 (50 ref.) **(Fre)**

[Clinical case of the month. Metastatic endocarditis: clinical observation and review of the literature] Graas MP, et al. **Rev Med Liege** 1998 Oct;53(10):588–91 (12 ref.) (Eng. Abstr.) **(Fre)**

[Staging of carcinomas of the upper gastrointestinal tract. The current status of diagnostic imaging] Pokieser P, et al. **Radiologe** 1999 Jul;39(7):555–61 (26 ref.) (Eng. Abstr.) **(Ger)**

[MALT gastric lymphoma: update] Doglioni C, et al. **Pathologica** 1998 Jun;90(3):313–7 (27 ref.) **(Ita)**

[Pathology of the cardia] Takubo K, et al. **Nippon Geka Gakkai Zasshi** 1998 Sep;99(9):547–51 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Interventional radiology for recurrent cancer] Uchida H, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):220–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of perforated early gastric cancer] Kitakado Y, et al. **Nippon Geka Hokan** 1997 Jul 1;66(3):86–90 (18 ref.) (Eng. Abstr.) **(Jpn)**

[A gastric cancer showing an exclusive metastatic nest at the gastroenemius muscle] Kobayashi D, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1013–7 (24 ref.) **(Jpn)**

[A case of triple cancers with gastric, jejunal and colonic cancers] Nanba M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):953–8 (22 ref.) **(Jpn)**

[Disseminated carcinomatosis of the bone marrow occurring 11 years after subtotal gastrectomy for gastric cancer] Mizuno I, et al. **Rinsho Ketsueki** 1998 Sep;39(9):670–5 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Gastric xanthogranuloma (inflammatory malignant fibrohistiocytoma). Case report and literature review] Lespi PJ. **Acta Gastroenterol Latinoam** 1998;28(4):309–10 (7 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Gastric MALT lymphoma: from concept to cure. Isaacson PG. **Ann Oncol** 1999 Jun;10(6):637–45 (96 ref.)

Prostaglandins in the stomach: an update. Arakawa T, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S1–11 (42 ref.)

[Gastric carcinoid--pathogenesis and treatment] Bründler R, et al. **Schweiz Med Wochenschr** 1999 Jun 26;129(25):945–50 (46 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Aspirin induced apoptosis in gastric cancer cells. Wong BC, et al. **Biomed Pharmacother** 1999 Aug;53(7):315–8 (32 ref.)

The role of endoscopy in the prevention of esophagogastric cancer. Lambert R. **Endoscopy** 1999 Feb;31(2):180–99 (95 ref.)

Unconventional vaccine targets. Immunization for pregnancy, peptic ulcer, gastric cancer, cocaine abuse, and atherosclerosis. Lutwick LI. **Infect Dis Clin North Am** 1999 Mar;13(1):245–64, ix (115 ref.)

Vitamin C, Helicobacter pylori infection and gastric carcinogenesis. Reed PI. **Int J Vitam Nutr Res** 1999 May; 69(3):220–7 (71 ref.)

[Helicobacter pylori and stomach carcinoma. Is a preventive intervention study of value? (see comments)] Stolte M, et al. **Pathologe** 1998 Jul;19(4):330–3 (28 ref.) Comment in: Pathologe 1999 Mar;20(2):148–9. **(Ger)**

[Prevention of gastric cancer: Helicobacter--eradication and immunization] Koop H. **Schweiz Rundsch Med Prax** 1998 Sep 16;87(38):1233–5 (6 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Present day radiation diagnosis of upper stomach neoplasms] Portnoi LM. **Vestn Rentgenol Radiol** 1998 Sep–Oct; (5):13–20 (40 ref.) (Eng. Abstr.) **(Rus)**

RADIOTHERAPY

Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. King TC, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):4–11 (58 ref.)

[Concomitant chemoradiotherapy in the therapeutic strategy of adenocarcinoma of the exocrine pancreas and stomach] Mornex F, et al. **Cancer Radiother** 1998 Dec;2(6):696–702 (48 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

[A case of superficial esophageal cancer with intramural metastasis to the stomach] Tajika M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Mar;96(3):280–5 (19 ref.) **(Jpn)**

[Microangiopathic hemolytic anemia. A form of presentation of stomach neoplasm] Oliveira A, et al. **Acta Med Port** 1998 Jun;11(6):569–72 (12 ref.) (Eng. Abstr.) **(Por)**

SURGERY

Gastric carcinoma. Karpeh MS Jr, et al. **Ann Surg Oncol** 1998 Oct–Nov;5(7):650–6 (33 ref.)

Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Roukos DH. **Ann Surg Oncol** 1999 Jan–Feb;6(1):46–56 (86 ref.)

Endoscopic mucosal resection for esophageal and gastric mucosal cancers. Inoue H. **Can J Gastroenterol** 1998 Jul–Aug;12(5):355–9 (15 ref.)

Adenocarcinoma of the stomach: an update. Stefanini M. **Compr Ther** 1998 Nov–Dec;24(11–12):582–9 (23 ref.)

Treatment of esophageal and gastric tumors. Inoue H, et al. **Endoscopy** 1999 Jan;31(1):47–55 (55 ref.)

Surgical treatment of patients with invasive gastric cancer: dogma, debate and data. Cuschieri A. **Eur J Surg Oncol** 1999 Apr;25(2):205–8 (22 ref.)

Reflections and proposals for the worldwide standardization of lymphadenectomy for gastric carcinoma [letter] Elias D. **J Surg Oncol** 1999 Jun;71(2):120–2 (20 ref.)

Stromal sarcoma of the stomach--a report of 20 surgically treated patients. Peiper M, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):442–6 (24 ref.)

Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients--is reconstruction with a reservoir worthwhile? Liedman B. **Nutrition** 1999 Sep;15(9):677–82 (94 ref.)

Role of laparoscopy in the management of stomach cancer. Goh PM, et al. **Semin Surg Oncol** 1999 Jun;16(4):321–6 (25 ref.)

Endoscopic mucosal resection for early gastric cancer. Makuuchi H, et al. **Semin Surg Oncol** 1999 Sep;17(2):108–16 (44 ref.)

Lymph node dissection for gastric cancer. Meyer HJ, et al. **Semin Surg Oncol** 1999 Sep;17(2):117–24 (51 ref.)

Surgical resection for cancer of the cardia. Siewert JR, et al. **Semin Surg Oncol** 1999 Sep;17(2):125–31 (48 ref.)

Effectiveness of immunochemotherapy for gastric cancer: a review of the current status. Toge T. **Semin Surg Oncol** 1999 Sep;17(2):139–43 (40 ref.)

D2 dissection for gastric cancer. Lee JS, et al. **Surg Oncol** 1997 Dec;6(4):215–25 (55 ref.)

Standard resection for cancer of the esophagus and cardia. Ellis FH Jr. **Surg Oncol Clin N Am** 1999 Apr;8(2):279–94 (54 ref.)

[Lymph node excision in cancer of the stomach] Msika S. **J Chir (Paris)** 1998 Oct;135(4):155–61 (52 ref.) (Eng. Abstr.) **(Fre)**

[Gastrointestinal stroma tumor: a surgical oncology problem child?] Irani S, et al. **Chirurg** 1999 Mar;70(3):259–64 (25 ref.) (Eng. Abstr.) **(Ger)**

[The physiology of intestinal pouches] Teixeira FV, et al. **Chirurg** 1999 May;70(5):513–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Cecum reservoir] von Flüe M, et al. **Chirurg** 1999 May; 70(5):552–61 (41 ref.) (Eng. Abstr.) **(Ger)**

[Pouch stomach reconstruction after gastrectomy] Schwarz A, et al. **Z Gastroenterol** 1999 Apr;37(4):287–91 (28 ref.) (Eng. Abstr.) **(Ger)**

[Stomach carcinoma. Optimizing therapy by stomach replacement or subtotal resection?] Meyer HJ, et al. **Zentralbl Chir** 1999;124(5):381–6 (25 ref.) (Eng. Abstr.) **(Ger)**

[Early gastric cancer. The therapeutic options] Cavallaro V, et al. **Minerva Chir** 1999 Apr;54(4):257–60 (24 ref.) (Eng. Abstr.) **(Ita)**

[Interventional radiology for recurrent cancer] Uchida H, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb;100(2):220–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[A rare nosological association: a villous gastric polyp and asymptomatic choledocholithiasis] Aldea A, et al. **Chirurgia (Bucur)** 1998 Nov–Dec;93(6):423–5 (9 ref.) (Eng. Abstr.) **(Rum)**

[Polypectomy of the digestive tract] Gallo Reynoso S. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4 Suppl 1):S74–9 (30 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Gastric cancer in the elderly. Kranenbarg EK, et al. **Eur J Surg Oncol** 1998 Oct;24(5):384–90 (51 ref.)

Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Bozzetti F, et al. **Tumori** 1998 Jul–Aug;84(4):483–8 (75 ref.)

Diagnosis and treatment of ECL cell tumors. Cadiot G, et al. **Yale J Biol Med** 1998 May–Aug;71(3–4):311–23 (63 ref.)

[Gastric mucosa-associated lymphoid tissue lymphomas (MALT) and their treatment] Ruskoné-Fourmestraux A. **Ann Chir** 1999;53(2):143–9 (50 ref.) **(Fre)**

[Hypothetical and reliable aspects of pre-, intra- and postoperative adjuvant therapy of stomach carcinoma] Meyer HJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:312–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Gastric carcinoid--pathogenesis and treatment] Bründler R, et al. **Schweiz Med Wochenschr** 1999 Jun 26;129(25):945–50 (46 ref.) (Eng. Abstr.) **(Ger)**

[Twenty-five years of progress in the treatment of esophageal and gastric cancers] Konishi T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:118–28 (69 ref.) (Eng. Abstr.) **(Jpn)**

[Development of cancer treatment practice guidelines in Japan: advantages and disadvantages] Yamaguchi T, et al. **Gan To Kagaku Ryoho** 1999 Apr;26(5):609–13 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of gastric cancer] Fuster Obregón J. **Gastroenterol Hepatol** 1999 Mar;22(3):147–53 (43 ref.) **(Spa)**

ULTRASONOGRAPHY

Endoscopic ultrasonography in large gastric folds. Caletti G, et al. **Endoscopy** 1998 Aug;30 Suppl 1:A72–5 (31 ref.)

Role of endoscopic ultrasonography for gastric lesions. Shim CS. **Endoscopy** 1998 Aug;30 Suppl 1:A55–9 (57 ref.)

Systemic review of endoscopic ultrasound in gastro-oesophageal cancer. Harris KM, et al. **Health Technol Assess** 1998;2(18):i–iv, 1–134 (129 ref.)

VETERINARY

Gastric neoplasia. Gualtieri M, et al. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):415–40 (57 ref.)

STOMACH, RUMINANT

METABOLISM

Do forestomach epithelia exhibit a $Mg2+/2H(+)$-exchanger? Leonhard-Marek S. **Magnes Res** 1999 Jun;12(2):99–108 (89 ref.)

PHYSIOLOGY

[The role of the forestomachs in the adaptation of the alimentary function in ruminants] Chalyshev AV. **Usp Fiziol Nauk** 1998 Jul–Sep;29(3):92–104 (92 ref.) (Eng. Abstr.) **(Rus)**

STOMACH RUPTURE

PATHOLOGY

[A case report of perforated early gastric cancer] Kitakado Y, et al. **Nippon Geka Hokan** 1997 Jul 1;66(3):86–90 (18 ref.) (Eng. Abstr.) **(Jpn)**

STOMACH ULCER

Ulcer and gastritis. Anand BS, et al. **Endoscopy** 1999 Feb; 31(2):215–25 (50 ref.)
Acid-related disorders in the new millennium: European, Japanese and North American perspectives. Freston JW, et al. **Eur J Gastroenterol Hepatol** 1998 Sep;10 Suppl 2:S1–40 (120 ref.)

CHEMICALLY INDUCED

Gastroprotective agents for the prevention of NSAID-induced gastropathy. Ares JJ, et al. **Curr Pharm Des** 1998 Feb;4(1):17–36 (173 ref.)
Clinical symptoms, endoscopic findings and histologic features of gastroduodenal non-steroidal anti-inflammatory drugs lesions. Aabakken L. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S19–22 (19 ref.)
Pathogenesis of non-steroidal anti-inflammatory drug gastropathy. Fiorucci S, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S6–13 (87 ref.)
Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum. Langman MJ. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S2–5 (18 ref.)
Non-steroidal anti-inflammatory drug gastropathy: clinical results with antacids and sucralfate. Lazzaroni M, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S48–53 (40 ref.)
Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy. Russell RI. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S14–8 (31 ref.)
Pharmacological approach to the prevention of non-steroidal anti-inflammatory drug-induced gastropathy. Whittle BJ. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S43–7 (32 ref.)
[Present position in the prevention and therapy of NSAID-induced ulcers] Lehmann FS, et al. **Schweiz Med Wochenschr** 1999 Jul 27;129(29–30):1073–80 (69 ref.) (Eng. Abstr.) **(Ger)**
[Drug-induced stomach ulcers--the views of recent years] Gurin NN, et al. **Ter Arkh** 1998;70(8):84–6 (22 ref.) **(Rus)**
[Prevention of gastroduodenal ulcer induced by non-steroidal anti-inflammatory agents] Vallano A, et al. **Med Clin (Barc)** 1999 May 29;112(19):755–6 (6 ref.) **(Spa)**

COMPLICATIONS

Changing trends in the management of ulcer bleeding. Sontheimer J. **Dig Surg** 1998;15(4):315–6 (7 ref.)
Helicobacter pylori and reflux disease. Dent J. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S51–7; discussion S73 (36 ref.)
Open vs. laparoscopic repair of perforated peptic ulcer [letter; comment] Bergamaschi R. **Surg Laparosc Endosc** 1998 Dec; 8(6):479–80 (8 ref.) Comment on: Surg Laparosc Endosc 1998 Apr;8(2):153–6.
[The treatment of patients with peptic gastroduodenal ulcers and severe concomitant diseases] Chechurin NS. **Vestn Khir Im I I Grek** 1999;158(1):73–6 (50 ref.) **(Rus)**
[Laparoscopic surgery in the treatment of perforating gastroduodenal ulcers] Shurkalin BK, et al. **Vestn Khir Im I I Grek** 1999;158(3):100–2 (39 ref.) **(Rus)**

DIAGNOSIS

Ulcers and nonvariceal bleeding. Rollhauser C, et al. **Endoscopy** 1999 Jan;31(1):17–25 (50 ref.)
Clinical symptoms, endoscopic findings and histologic features of gastroduodenal non-steroidal anti-inflammatory drugs lesions. Aabakken L. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S19–22 (19 ref.)

DRUG THERAPY

Pharmacoeconomics in HP-related diseases: more questions than answers. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):352–6 (49 ref.)
Ulcer treatment. Bursey RF. **Can J Gastroenterol** 1998 Oct; 12(7):472–3 (0 ref.)
Therapy for ulcers and erosions associated with nonsteroidal anti-inflammatory drugs. Freeman HJ. **Can J Gastroenterol** 1998 Nov–Dec;12(8):537–9 (0 ref.)
Non-steroidal anti-inflammatory drug gastropathy: clinical results with antacids and sucralfate. Lazzaroni M, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S48–53 (40 ref.)
Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. Lazzaroni M, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S73–8 (39 ref.)
A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy. Yeomans ND. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S89–92 (26 ref.)
The possible role of vascular endothelial growth factor (VEGF) in gastric ulcer healing: effect of sofalcone on VEGF release in vitro. Takahashi M, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S178–82 (33 ref.)
Gastric ulcer, motility, and trimebutine [editorial; comment] Tanaka M. **J Gastroenterol** 1998 Dec;33(6):916–7 (14 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):823–7.
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Kromer W, et al. **Pharmacology** 1999 Aug;59(2):57–77 (165 ref.)
Proton pump inhibitors. Grover JK, et al. **Trop Gastroenterol** 1999 Jan–Mar;20(1):16–28 (182 ref.)
[Mechanism of proton pump inhibitors in the treatment of Holicobacter pylori-associated ulcers] Huang J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):488–91 (20 ref.) **(Chi)**
[Modern policy of anti-helicobacter therapy of ulcer disease] Ryss ES. **Klin Med (Mosk)** 1998;76(10):7–11 (10 ref.) **(Rus)**
[Non-narcotic analgesics and non-steroid anti-inflammatory drugs and gastric erosions and ulcer] Sheptulin AA. **Klin Med (Mosk)** 1999;77(2):12–6 (40 ref.) **(Rus)**
[Evidence-based management of gastroduodenal ulcer] Rodriguez Téllez M, et al. **An Med Interna** 1998 Oct; 15(10):548–53 (64 ref.) **(Spa)**
[Omeprazole and gastric protection] Madridejos Mora R. **Aten Primaria** 1999 Apr 30;23(7):441–4 (31 ref.) **(Spa)**
[Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance] Nilsson F, et al. **Lakartidningen** 1999 Feb 3;96(5):460–3 (12 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum. Langman MJ. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S2–5 (18 ref.)

ETIOLOGY

Ulcer treatment. Bursey RF. **Can J Gastroenterol** 1998 Oct; 12(7):472–3 (0 ref.)
Effects of cigarette smoking on gastric ulcer formation and healing: possible mechanisms of action. Ma L, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S80–6 (81 ref.)
Smoking and gastric ulcers: the possible role of nicotine. Ogle CW. **J Clin Pharmacol** 1999 May;39(5):448–53 (34 ref.)
[Mucosal microcirculation and angiogenesis in gastrointestinal tract] Tsuji S, et al. **Nippon Rinsho** 1998 Sep;56(9):2247–52 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Gastroduodenal lesions and non-steroidal anti-inflammatory agents. What role does Helicobacter pylori play in this relationship?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1998 Sep;90(9):655–64 (159 ref.) (Eng. Abstr.) **(Spa)**
[Dyspepsia--can we follow dogmatic guidelines in a nuanced reality? Individual management of patients with dyspepsia with risk of stomach ulcer] Agréus L, et al. **Lakartidningen** 1999 May 26;96(21):2591–5 (35 ref.) (Eng. Abstr.) **(Swe)**

MICROBIOLOGY

The role of Helicobacter pylori infection in duodenal and gastric ulcer. Veldhuyzen van zanten SJ, et al. **Curr Top Microbiol Immunol** 1999;241:47–56 (46 ref.)
Gastritis and peptic ulcer disease in childhood. Blecker U, et al. **Eur J Pediatr** 1999 Jul;158(7):541–6 (62 ref.)
Non-steroidal anti-inflammatory drug gastropathy and Helicobacter pylori infection. Taha AS. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S23–6 (24 ref.)

PATHOLOGY

Pathogenesis of non-steroidal anti-inflammatory drug gastropathy. Fiorucci S, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S6–13 (87 ref.)

PHYSIOPATHOLOGY

Prostaglandins in the stomach: an update. Arakawa T, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S1–11 (42 ref.)
Effects of cigarette smoking on gastric ulcer formation and healing: possible mechanisms of action. Ma L, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S80–6 (81 ref.)
The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. Tarnawski AS, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S12–20 (63 ref.)
[Effects of Helicobacter pylori(Hp) eradication on gastric mucosal pathophysiology in Hp-positive, NSAIDs-induced gastric ulcer] Yanaka A, et al. **Nippon Rinsho** 1999 Jan;57(1):201–7 (48 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Raskin JB. **Am J Med** 1999 May 31; 106(5B):3S–12S (73 ref.)
Gastroprotective agents for the prevention of NSAID-induced gastropathy. Ares JJ, et al. **Curr Pharm Des** 1998 Feb;4(1):17–36 (173 ref.)
Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. La Corte R, et al. **Drug Saf** 1999 Jun;20(6):527–43 (103 ref.)
Pharmacological approach to the prevention of non-steroidal anti-inflammatory drug-induced gastropathy. Whittle BJ. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S43–7 (32 ref.)
Nitric oxide: a regulator of mucosal defense and injury. Elliott SN, et al. **J Gastroenterol** 1998 Dec;33(6):792–803 (103 ref.)
[Non-steroidal anti-inflammatory agents (NSAID's) with lesser side effects by selective inhibition of cyclo-oxygenase-2] Bijlsma JW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1;142(31):1762–5 (20 ref.) (Eng. Abstr.) **(Dut)**

THERAPY

Gastro-duodenal ulcers. Who? When to treat? Colemont L. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):303–4 (11 ref.)
Preventing ulcer rebleeding: the role of second-look endoscopy. Chung SC. **Can J Gastroenterol** 1999 Jun; 13(5):409–11 (11 ref.)
Spots and clots – leave them or treat them? Why and how to treat. Jensen DM. **Can J Gastroenterol** 1999 Jun; 13(5):413–5 (9 ref.)

STOMAS

ADVERSE EFFECTS

Complications of abdominal stoma surgery. Shellito PC. **Dis Colon Rectum** 1998 Dec;41(12):1562–72 (113 ref.)

PHYSIOLOGY

[Intestinal pouches: gastric reconstruction] Schuhmacher C, et al. **Chirurg** 1999 May;70(5):520–9 (47 ref.) (Eng. Abstr.) **(Ger)**
[The physiology of intestinal pouches] Teixeira FV, et al. **Chirurg** 1999 May;70(5):513–9 (29 ref.) (Eng. Abstr.) **(Ger)**
[Cecum reservoir] von Flüe M, et al. **Chirurg** 1999 May; 70(5):552–61 (41 ref.) (Eng. Abstr.) **(Ger)**

STOMATITIS

[Infective stomatitis of the palate] Iriarte Ortabe JI, et al. **An Otorrinolaringol Ibero Am** 1999;26(2):137–61 (116 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Factors contributing to adverse soft tissue reactions due to the use of tartar control toothpastes: report of a case and literature review. DeLattre VF. **J Periodontol** 1999 Jul; 70(7):803–7 (36 ref.)
Prevention and treatment of oral mucositis following cancer chemotherapy. Wilkes JD. **Semin Oncol** 1998 Oct; 25(5):538–51 (134 ref.)

DIAGNOSIS

Pyodermatitis-pyostomatitis vegetans: report of a case and review of the literature. Soriano ML, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):322–6 (35 ref.)

DRUG THERAPY

New frontiers in the management of chemotherapy-induced mucositis. Spijkervet FK, et al. **Curr Opin Oncol** 1998 Aug; 10 Suppl 1:S23–7 (15 ref.)
The biological basis for the attenuation of mucositis: the example of interleukin-11. Sonis S, et al. **Leukemia** 1999 Jun;13(6):831–4 (42 ref.)

ETIOLOGY

Cigarette smoking and oral lesions other than cancer. Meraw SJ, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):625–31 (52 ref.)
Oral mucositis in myelosuppressive cancer therapy. Epstein JB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):273–6 (12 ref.)
Prevention and management of oral infections in cancer patients [see comments] Heimdahl A. **Support Care Cancer** 1999 Jul;7(4):224–8 (19 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):217–8.
Oral infection [editorial; comment] Peterson DE. **Support Care Cancer** 1999 Jul;7(4):217–8 (8 ref.) Comment on: Support Care Cancer 1999 Jul;7(4):224–8. Comment on: Support Care Cancer 1999 Jul;7(4):244–52.

PATHOLOGY

Plasma cell mucositis: a review and case report. Smith ME, et al. **J Oral Pathol Med** 1999 Apr;28(4):183–6 (11 ref.)

PREVENTION & CONTROL

Prevention and treatment of oral mucositis following cancer chemotherapy. Wilkes JD. **Semin Oncol** 1998 Oct; 25(5):538–51 (134 ref.)
Prevention and management of oral infections in cancer patients [see comments] Heimdahl A. **Support Care Cancer** 1999 Jul;7(4):224–8 (19 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):217–8.
Current practices for management of oral mucositis in cancer patients. Raber-Durlacher JE. **Support Care Cancer** 1999 Mar;7(2):71–4 (23 ref.)

THERAPY

Research advances in oral mucositis. Peterson DE. **Curr Opin Oncol** 1999 Jul;11(4):261–6 (31 ref.)

STOMATITIS

VETERINARY

Vesicular stomatitis. Letchworth GJ, et al. **Vet J** 1999 May; 157(3):239–60 (267 ref.)

STOMATITIS, APHTHOUS

Behçet's disease and complex aphthosis. Ghate JV, et al. **J Am Acad Dermatol** 1999 Jan;40(1):1–18; quiz 19–20 (252 ref.)

Periodic fever syndrome. Thomas KT, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):68–9 (11 ref.)

[Aphthous stomatitis] Michiwaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):366–8 (1 ref.) **(Jpn)**

STOMATITIS, DENTURE

ETIOLOGY

The aetiology, diagnosis and management of denture stomatitis. Wilson J. **Br Dent J** 1998 Oct 24;185(8):380–4 (30 ref.)

STOMATITIS, GANGRENOUS see **NOMA**

STOMATITIS, HERPETIC

[Herpetic gingivostomatitis] Iwata S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):179–80 (4 ref.) **(Jpn)**

STOMATITIS, ULCERATIVE see **GINGIVITIS, NECROTIZING ULCERATIVE**

STOMATOGNATHIC DISEASES

VIROLOGY

Manifestations of AIDS in the head and neck. Reisacher WR, et al. **South Med J** 1999 Jul;92(7):684–97 (66 ref.)

STOMATOGNATHIC SYSTEM

PHYSIOLOGY

Current evaluation and treatment of patients with swallowing disorders. Broniatowski M, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):464–73 (35 ref.)

STOMOXYS CALCITRANS see **MUSCIDAE**

STORAGE POOL DEFICIENCY see **PLATELET STORAGE POOL DEFICIENCY**

STOREROOM see **MATERIALS MANAGEMENT, HOSPITAL**

STOREROOMS see **MATERIALS MANAGEMENT, HOSPITAL**

STRABISMUS

DIAGNOSIS

[Examination and rehabilitation of visual functions of preverbal infant with strabismus] Jacquier MT, et al. **J Fr Ophtalmol** 1998 Nov;21(9):671–86 (67 ref.) **(Fre)**

ETIOLOGY

[Concomitant strabismus: of strabismus in strabismus syndromes] Roth A. **Klin Monatsbl Augenheilkd** 1999 May; 214(5):340–5 (7 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Acro-renal-ocular syndrome: expansion of the phenotype. Guillén-Navarro E, et al. **Clin Dysmorphol** 1998 Oct; 7(4):243–8 (9 ref.)

PHYSIOPATHOLOGY

Neural mechanisms underlying amblyopia. Kiorpes L, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):480–6 (54 ref.)

[Interocular inhibition in strabismus] Herzau V. **Ophthalmologe** 1998 Oct;95(10):710–6 (19 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[Examination and rehabilitation of visual functions of preverbal infant with strabismus] Jacquier MT, et al. **J Fr Ophtalmol** 1998 Nov;21(9):671–86 (67 ref.) **(Fre)**

SURGERY

The goal of adult strabismus surgery is not cosmetic [editorial] Rosenbaum AL. **Arch Ophthalmol** 1999 Feb; 117(2):250 (8 ref.)

Adjustable sutures in pediatric ophthalmology and strabismus. Strominger MB, et al. **J Pediatr Ophthalmol Strabismus** 1999 May–Jun; 36(3):112–7; quiz 134–5 (49 ref.)

[Brown syndrome: current status] Hadjadj E, et al. **J Fr Ophtalmol** 1998 Apr;21(4):276–82 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

An efficient treatment and new criteria for cure of strabismic amblyopia: reading and Bangerter foils. Lang J. **Binocul Vis Strabismus Q** 1999 Spring;14(1):9–10 (6 ref.)

STRABISMUS, CONVERGENT see **ESOTROPIA**

STRAMONIUM

ADVERSE EFFECTS

[Mydriasis due to accidental contact with stramonium (Datura stramonium) (letter)] Alcaraz García SF, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):156 (9 ref.) **(Spa)**

STREET CHILDREN see **HOMELESS YOUTH**

STREET DRUG TESTING see **SUBSTANCE ABUSE DETECTION**

STREET DRUGS

Recreational drugs. Current trends in the 90s. Ropero-Miller JD, et al. **Clin Lab Med** 1998 Dec;18(4):727–46, x (52 ref.)

Ten years of 'ecstasy'. Milroy CM. **J R Soc Med** 1999 Feb; 92(2):68–71 (41 ref.)

Drug prohibition and public health: 25 years of evidence [see comments] Drucker E. **Public Health Rep** 1999 Jan–Feb;114(1):14–29 (55 ref.) Comment in: Public Health Rep 1999 Mar–Apr;114(2):99–100.

Illicit substance use among adolescents: a matrix of prospective predictors. Petraitis J, et al. **Subst Use Misuse** 1998 Nov;33(13):2561–604 (67 ref.)

[Role of science in the formulation of social policy on drugs] Kalant H. **C R Seances Soc Biol Fil** 1998;192(5):905–15 (29 ref.) (Eng. Abstr.) **(Fre)**

[Drug substitution from the legal viewpoint] Joachimski J. **Internist (Berl)** 1999 Jun;40(6):640–4 (0 ref.) **(Ger)**

[The evaluation of the drug situation: the need for a comprehensive and rigorous information strategy (editorial; comment)] Vicente J. **Gac Sanit** 1999 Mar–Apr;13(2):79–81 (20 ref.) Comment on: Gac Sanit 1999 Mar–Apr;13(2):82–7. Comment on: Gac Sanit 1999 Mar–Apr;13(2):88–95. Comment on: Gac Sanit 1999 Mar–Apr;13(2):96–101. Comment on: Gac Sanit 1999 Mar–Apr;13(2):109–18. Comment on: Gac Sanit 1999 Mar–Apr;13(2):126–34. **(Spa)**

ADVERSE EFFECTS

Mechanisms of action of drugs of abuse on the developing fetal brain. Malanga CJ 3rd, et al. **Clin Perinatol** 1999 Mar; 26(1):17–37, v–vi (120 ref.)

Prenatal effects of drugs of abuse on brain development. Levitt P. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):109–25 (224 ref.)

G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Roth BL, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):73–85 (152 ref.)

Genetic toxicology of abused drugs: a brief review. Li JH, et al. **Mutagenesis** 1998 Nov;13(6):557–65 (138 ref.)

[Principles of withdrawal from illicit drugs during inpatient therapy] Singer W, et al. **Internist (Berl)** 1999 Jun; 40(6):634–9 (21 ref.) **(Ger)**

ANALYSIS

Perspiration versus saliva—basic aspects concerning their use in roadside drug testing. Skopp G, et al. **Int J Legal Med** 1999;112(4):213–21 (74 ref.)

ECONOMICS

Burma: the political economy of violence. Brown C. **Disasters** 1999 Sep;23(3):234–56 (55 ref.)

PHARMACOLOGY

Neurotransmitter transporters as molecular targets for addictive drugs. Amara SG, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):87–96 (76 ref.)

Neural basis of inhalant abuse. Balster RL. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):207–14 (87 ref.)

Addiction and imaging of the living human brain. Gatley SJ, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):97–108 (113 ref.)

Common aspects of the action of nicotine and other drugs of abuse. Picciotto MR. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):165–72 (117 ref.)

Drug-activation of brain reward pathways. Wise RA. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):13–22 (121 ref.)

Flunitrazepam: a review of "roofies". Waltzman ML. **Pediatr Emerg Care** 1999 Feb;15(1):59–60 (6 ref.)

Pharmacology versus social process: competing or complementary views on the nature of addiction? Davies JB. **Pharmacol Ther** 1998 Dec;80(3):265–75 (40 ref.)

[Pharmacology of drugs of abuse] Haen E, et al. **Internist (Berl)** 1999 Jun;40(6):605–10 (7 ref.) **(Ger)**

[Gamma-hydroxybutyric acid or "liquid ecstasy": a poisoning to come? (editorial)] Dueñas Laita A. **Med Clin (Barc)** 1998 Oct 17;111(12):458–60 (36 ref.) **(Spa)**

POISONING

Gamma-hydroxybutyric acid: an emerging recreational drug. Kam PC, et al. **Anaesthesia** 1998 Dec;53(12):1195–8 (29 ref.)

[Poisoning with amphetamines and designer drugs] Felgenhauer N, et al. **Internist (Berl)** 1999 Jun;40(6):617–23 (50 ref.) **(Ger)**

TOXICITY

Genetic toxicology of abused drugs: a brief review. Li JH, et al. **Mutagenesis** 1998 Nov;13(6):557–65 (138 ref.)

URINE

The role of gas chromatography/mass spectrometry. Instrumental techniques in forensic urine drug testing. Lehrer M. **Clin Lab Med** 1998 Dec;18(4):631–49 (18 ref.)

STREET PEOPLE see **HOMELESS PERSONS**

STREET YOUTH see **HOMELESS YOUTH**

STREETER SYNDROME see **AMNIOTIC BAND SYNDROME**

STREPTAVIDIN

Colloidal gold/streptavidin methods. Oliver C. **Methods Mol Biol** 1999;115:335–9 (6 ref.)

[Development of streptavidin-based neoglycoprotein as a glycoprobe] Hashimoto Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2479–83 (4 ref.) **(Jpn)**

GENETICS

Genetic engineering of streptavidin, a versatile affinity tag. Sano T, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 11;715(1):85–91 (47 ref.)

STREPTOBACILLUS

ISOLATION & PURIFICATION

Streptobacillus moniliformis infection: 2 cases and a literature review. Hagelskjaer L, et al. **Scand J Infect Dis** 1998; 30(3):309–11 (23 ref.)

STREPTOCOCCACEAE

Three cases of serious infection caused by Aerococcus urinae. Schuur PM, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):368–71 (11 ref.)

GENETICS

Gene expression systems for lactic acid bacteria. de Vos WM. **Curr Opin Microbiol** 1999 Jun;2(3):289–95 (68 ref.)

PHYSIOLOGY

Lactic acid bacteria and the human gastrointestinal tract. Hove H, et al. **Eur J Clin Nutr** 1999 May;53(5):339–50 (120 ref.)

STREPTOCOCCAL INFECTIONS

Invasive group A streptococcal infections in children. Davies HD, et al. **Adv Pediatr Infect Dis** 1999;14:129–45 (98 ref.)

Streptococcal pyomyositis: case report and review. Wheeler DS, et al. **Pediatr Emerg Care** 1998 Dec;14(6):411–2 (13 ref.)

[Streptococcal pneumonia] Hashiguchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):350–3 (12 ref.) **(Jpn)**

[Penicillin resistant Streptococcus pneumoniae infection] Matsushima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):175–8 (5 ref.) **(Jpn)**

COMPLICATIONS

Acute rheumatic pancarditis associated with poststreptococcal acute glomerulonephritis: a patient report. Kakkera DR, et al. **Clin Pediatr (Phila)** 1998 Sep; 37(9):569–72 (11 ref.)

Streptococcus bovis bacteremia in patients infected with the human immunodeficiency virus: case reports and literature review. Manfredi R, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):148–50 (4 ref.)

Acute post streptococcal interstitial nephritis in an adult and review of the literature. Dharmarajan TS, et al. **Int Urol Nephrol** 1999;31(2):145–8 (15 ref.)

PANDAS: the search for environmental triggers of pediatric neuropsychiatric disorders. Lessons from rheumatic fever. Garvey MA, et al. **J Child Neurol** 1998 Sep;13(9):413–23 (123 ref.)

Fisher's syndrome and group A streptococcal infection. Yuki N, et al. **J Neurol Sci** 1998 Sep 18;160(1):64–6 (9 ref.)

[Endocarditis manifesting as a spondylodiscitis and psoas abscess] Berger A, et al. **Rev Med Suisse Romande** 1999 Jan;119(1):55–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[A case of brain abscess accompanied with sudden-onset

hemiplegia as initial manifestation] Okubo K, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1232–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Acute post–streptococcal glomerulonephritis] Nishiyama J, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):541–4 (15 ref.) **(Jpn)**

[Fecal incontinence caused by a streptococcal perianal disease (letter)] de Arriba Méndez JJ, et al. **An Esp Pediatr** 1998 Dec;49(6):653–4 (10 ref.) **(Spa)**

[Meningitis caused by Streptococcus mitis in a cocaine addict (letter)] Echeverría MJ, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):441–2 (9 ref.) **(Spa)**

CONGENITAL

Prevention of neonatal group B streptococcal infections. Is there a rational prevention strategy? Schimmel MS, et al. **Clin Perinatol** 1998 Sep;25(3):687–97, x (49 ref.)

Neonatal sepsis caused by Streptococcus pyogenes: resurgence of an old etiology? Greenberg D, et al. **Pediatr Infect Dis J** 1999 May;18(5):479–81 (15 ref.)

DIAGNOSIS

Lemierre syndrome: a complication of acute pharyngitis. Williams A, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):51–7 (5 ref.)

Management of dental caries as a chronic infectious disease. Anusavice KJ. **J Dent Educ** 1998 Oct;62(10):791–802 (64 ref.)

Life–threatening rashes: dermatologic signs of four infectious diseases. Drage LA. **Mayo Clin Proc** 1999 Jan;74(1):68–72 (10 ref.)

Serious group A streptococcal infection around delivery. Udagawa H, et al. **Obstet Gynecol** 1999 Jul;94(1):153–7 (22 ref.)

Another toxic shock syndrome. Streptococcal infection is even more dangerous than the staphylococcal form. Hauser AR. **Postgrad Med** 1998 Dec;104(6):31–4, 39, 43–4 (18 ref.)

["Streptococcal toxic shock–like syndrome"] Broll R, et al. **Chirurg** 1998 Aug;69(8):806–12 (41 ref.) (Eng. Abstr.) **(Ger)**

[Infected aneurysms of the abdominal aorta. Personal case reports] Azzarone M, et al. **Minerva Chir** 1998 Jun; 53(6):535–8 (8 ref.) (Eng. Abstr.) **(Ita)**

[Streptococcus bovis endocarditis and colonic involvement] Baptista SB, et al. **Rev Port Cardiol** 1998 Dec; 17(12):1025–30 (31 ref.) (Eng. Abstr.) **(Por)**

[Recurrent neonatal sepsis due to Streptococcus B] Casanovas Lax J, et al. **An Esp Pediatr** 1999 Jan;50(1):69–70 (10 ref.) **(Spa)**

[Acute suppurative thyroiditis due to Streptococcus intermedius (letter)] Cabezas Agrícola JM, et al. **An Med Interna** 1999 Feb;16(2):107–8 (7 ref.) **(Spa)**

[Streptococcus bovis sepsis, purulent meningitis and colonic diverticulosis (letter)] Fresco Benito FJ, et al. **An Med Interna** 1999 Jul;16(7):383–4 (10 ref.) **(Spa)**

[Septic arthritis by beta–hemolytic Streptococcus group G: presentation of one case and review of the literature (letter)] Bachiller FJ, et al. **Enferm Infecc Microbiol Clin** 1999 Jun–Jul;17(6):318–9 (7 ref.) **(Spa)**

DRUG THERAPY

Aminoacyl tRNA synthetases as targets for new anti–infectives. Schimmel P, et al. **FASEB J** 1998 Dec; 12(15):1599–609 (79 ref.)

Antibiotic resistance and therapeutic options in lower respiratory tract infections. Bouza E. **Int J Antimicrob Agents** 1999 Mar;11 Suppl 1:S3–6; discussion S31–2 (32 ref.)

Failure of penicillin in Streptococcus pyogenes pharyngeal infection [comment] Gillespie SH. **Lancet** 1998 Dec 19–26; 352(9145):1954–6 (18 ref.) Comment on: Lancet 1998 Dec 19–26;352(9145):1974–7.

[Toxic shock–like syndrome caused by streptococci (see comments)] van Dissel JT, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1452–5 (33 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 10;143(28):1452–5. **(Dut)**

[Acute rheumatic fever in today's children] Olivier C. **Presse Med** 1998 Jun 27;27(23):1159–67 (51 ref.) (Eng. Abstr.) **(Fre)**

[Susceptibility to antimicrobial agents in isolates from invasive Streptococcus pneumoniae in Colombia] Leal AL, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):157–63 (31 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Management of sore throats in children: a cost–effectiveness analysis [see comments] Tsevat J, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):681–8 (73 ref.) Comment in: Arch Pediatr Adolesc Med 1999 Jul;153(7):672–4.

EPIDEMIOLOGY

Pyogenic lung infections. Mwandumba HC, et al. **Curr Opin Pulm Med** 1999 May;5(3):151–6 (71 ref.)

Risk factors for early–onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Benitz WE, et al. **Pediatrics** 1999 Jun;103(6):e77 (165 ref.)

[The vir regulon—a new epidemiological marker for Streptococcus pyogenes] Shundi L. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul–Sep; 43(3):195–8 (26 ref.) **(Rum)**

ETIOLOGY

The flesh–eating bacterium: what's next? Stevens DL. **J Infect Dis** 1999 Mar;179 Suppl 2:S366–74 (96 ref.)

Latex hypersensitivity/glove component reaction as a contributing factor to osteomyelitis of the hand: a case report and review of the literature. Duplechain MT, et al. **J La State Med Soc** 1998 Nov;150(11):527–32 (22 ref.)

Viridans streptococcal infections in patients with neutropenia. Patrick CC. **Pediatr Infect Dis J** 1999 Mar; 18(3):280–1 (10 ref.)

The role of streptococcal toxins in disease. Mitchell TJ. **Soc Appl Bacteriol Symp Ser** 1998;27:119S–124S (38 ref.)

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

Retained fecalith after laparoscopic appendectomy. Strathern DW, et al. **Surg Endosc** 1999 Mar;13(3):287–9 (40 ref.)

[Amebic liver abscesses with bacterial superinfection in a nonendemic area] Ciriza C, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):286–9 (16 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Spontaneous bacterial peritonitis caused by Streptococcus gordonii. Collazos J, et al. **J Clin Gastroenterol** 1999 Jan; 28(1):45–6 (12 ref.)

Group B streptococcal osteomyelitis in adults. García–Lechuz JM, et al. **Medicine (Baltimore)** 1999 May; 78(3):191–9 (68 ref.)

Neonatal sepsis caused by Streptococcus pyogenes: resurgence of an old etiology? Greenberg D, et al. **Pediatr Infect Dis J** 1999 May;18(5):479–81 (15 ref.)

[Toxic shock–like syndrome caused by streptococci (see comments)] van Dissel JT, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1452–5 (33 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 10;143(28):1452–5. **(Dut)**

MORTALITY

[The impact of antimicrobial resistance and Streptococcus pneumoniae serotype distribution on the mortality of children under 5 years of age with invasive disease] Ríos AM, et al. **Rev Panam Salud Publica** 1999 Feb;5(2):69–76 (40 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Prevention of neonatal group B streptococcal infections. Is there a rational prevention strategy? Schimmel MS, et al. **Clin Perinatol** 1998 Sep;25(3):687–97, x (49 ref.)

Group A streptococcal vaccines. Dale JB. **Infect Dis Clin North Am** 1999 Mar;13(1):227–43, viii (29 ref.)

Group B streptococcus. Schuchat A. **Lancet** 1999 Jan 2; 353(9146):51–6 (33 ref.)

Prevention of perinatal group B streptococcal infections. Morita JY, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):279–80 (13 ref.)

Antimicrobial prevention of early–onset group B streptococcal sepsis: estimates of risk reduction based on a critical literature review. Benitz WE, et al. **Pediatrics** 1999 Jun;103(6):e78 (112 ref.)

[Justification of a prevention policy of perinatal disease by group B streptococci (GBS). Recommendations] Andreu A, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):138–40 (8 ref.) **(Spa)**

THERAPY

Another toxic shock syndrome. Streptococcal infection is even more dangerous than the staphylococcal form. Hauser AR. **Postgrad Med** 1998 Dec;104(6):31–4, 39, 43–4 (18 ref.)

TRANSMISSION

Group B streptococcal infections. McKenna DS, et al. **Semin Perinatol** 1998 Aug;22(4):267–76 (83 ref.)

VETERINARY

Agents of the "suis–ide diseases" of swine: Actinobacillus suis, Haemophilus parasuis, and Streptococcus suis. MacInnes JI, et al. **Can J Vet Res** 1999 Apr;63(2):83–9 (52 ref.)

Streptococcus uberis: a permanent barrier to the control of bovine mastitis? Leigh JA. **Vet J** 1999 May;157(3):225–38 (97 ref.)

STREPTOCOCCAL OK–432 see **PICIBANIL**

STREPTOCOCCAL PREPARATION OK–432 see **PICIBANIL**

STREPTOCOCCUS

CLASSIFICATION

[Recent classification of the genus Streptococcus] Kawamura Y. **Nippon Saikingaku Zasshi** 1998 Aug;53(3):493–507 (77 ref.) **(Jpn)**

DRUG EFFECTS

Susceptibility and resistance emergence studies with macrolides. Retsema JA. **Int J Antimicrob Agents** 1999 Mar; 11 Suppl 1:S15–21; discussion S31–2 (22 ref.)

ISOLATION & PURIFICATION

Spontaneous bacterial peritonitis caused by Streptococcus gordonii. Collazos J, et al. **J Clin Gastroenterol** 1999 Jan; 28(1):45–6 (12 ref.)

Streptococcus uberis: a permanent barrier to the control of bovine mastitis? Leigh JA. **Vet J** 1999 May;157(3):225–38 (97 ref.)

[Meningitis caused by Streptococcus mitis in a cocaine addict (letter)] Echeverría MJ, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):441–2 (9 ref.) **(Spa)**

METABOLISM

Inorganic cation transport and energy transduction in Enterococcus hirae and other streptococci. Kakinuma Y. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1021–45 (271 ref.)

PATHOGENICITY

Streptococcal invasion. Molinari G, et al. **Curr Opin Microbiol** 1999 Feb;2(1):56–61 (50 ref.)

The role of streptococcal toxins in disease. Mitchell TJ. **Soc Appl Bacteriol Symp Ser** 1998;27:119S–124S (38 ref.)

STREPTOCOCCUS AGALACTIAE

Prevention of neonatal group B streptococcal infections. Is there a rational prevention strategy? Schimmel MS, et al. **Clin Perinatol** 1998 Sep;25(3):687–97, x (49 ref.)

Prevention of perinatal group B streptococcal infections. Morita JY, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):279–80 (13 ref.)

Risk factors for early–onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Benitz WE, et al. **Pediatrics** 1999 Jun;103(6):e77 (165 ref.)

Antimicrobial prevention of early–onset group B streptococcal sepsis: estimates of risk reduction based on a critical literature review. Benitz WE, et al. **Pediatrics** 1999 Jun;103(6):e78 (112 ref.)

Group B streptococcal infections. McKenna DS, et al. **Semin Perinatol** 1998 Aug;22(4):267–76 (83 ref.)

[Endocarditis manifesting as a spondylodiscitis and psoas abscess] Berger A, et al. **Rev Med Suisse Romande** 1999 Jan;119(1):55–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent neonatal sepsis due to Streptococcus B] Casanovas Lax J, et al. **An Esp Pediatr** 1999 Jan;50(1):69–70 (10 ref.) **(Spa)**

[Justification of a prevention policy of perinatal disease by group B streptococci (GBS). Recommendations] Andreu A, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):138–40 (8 ref.) **(Spa)**

ISOLATION & PURIFICATION

Group B streptococcus. Schuchat A. **Lancet** 1999 Jan 2; 353(9146):51–6 (33 ref.)

Group B streptococcal osteomyelitis in adults. García–Lechuz JM, et al. **Medicine (Baltimore)** 1999 May; 78(3):191–9 (68 ref.)

STREPTOCOCCUS BOVIS

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

[Streptococcus bovis endocarditis and colonic involvement] Baptista SB, et al. **Rev Port Cardiol** 1998 Dec; 17(12):1025–30 (31 ref.) (Eng. Abstr.) **(Por)**

[Streptococcus bovis sepsis, purulent meningitis and colonic diverticulosis (letter)] Fresco Benito FJ, et al. **An Med Interna** 1999 Jul;16(7):383–4 (10 ref.) **(Spa)**

ISOLATION & PURIFICATION

Streptococcus bovis bacteremia in patients infected with the human immunodeficiency virus: case reports and literature review. Manfredi R, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):148–50 (4 ref.)

STREPTOCOCCUS FAECALIS see **ENTEROCOCCUS FAECALIS**

STREPTOCOCCUS FAECIUM see **ENTEROCOCCUS FAECIUM**

STREPTOCOCCUS GROUP A see **STREPTOCOCCUS PYOGENES**

STREPTOCOCCUS GROUP B see **STREPTOCOCCUS AGALACTIAE**

STREPTOCOCCUS LACTIS see **LACTOCOCCUS LACTIS**

STREPTOCOCCUS MUTANS

Management of dental caries as a chronic infectious disease. Anusavice KJ. **J Dent Educ** 1998 Oct;62(10):791–802 (64

STREPTOCOCCUS MUTANS

ref.)

IMMUNOLOGY

Secretory immunity in defense against cariogenic mutans streptococci. Russell MW, et al. **Caries Res** 1999;33(1):4–15 (105 ref.)

STREPTOCOCCUS PNEUMONIAE

see related
PNEUMOCOCCAL INFECTIONS

Purpura fulminans associated with Streptococcus pneumoniae infection in a child. Cnota JF, et al. **Pediatr Emerg Care** 1999 Jun;15(3):187–8 (17 ref.)

[Penicillin resistant Streptococcus pneumoniae infection] Matsushima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):175–8 (5 ref.) **(Jpn)**

[Reduced frequency of resistant pneumococci in Southern Sweden. Community based disease control projects to minimize antibiotic resistance] Ekdahl K, et al. **Lakartidningen** 1999 Jun 16;96(24):2962–5 (39 ref.) (Eng. Abstr.) **(Swe)**

CLASSIFICATION

Typing of Streptococcus pneumoniae: past, present, and future. Henrichsen J. **Am J Med** 1999 Jul 26; 107(1A):50S–54S (32 ref.)

DRUG EFFECTS

Strategies in the treatment of penicillin-resistant Streptococcus pneumoniae. Lund BC, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19):1987–94 (76 ref.)

Therapy for pneumococcal infection at the millennium: doubts and certainties. Ball P. **Am J Med** 1999 Jul 26; 107(1A):77S–85S (97 ref.)

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America. Barry AL. **Am J Med** 1999 Jul 26;107(1A):28S–33S (50 ref.)

Treatment of pneumococcal pneumonia: the case for penicillin G. Bryan CS. **Am J Med** 1999 Jul 26; 107(1A):63S–68S (73 ref.)

Pneumococcal vaccines: history, current status, and future directions. Butler JC, et al. **Am J Med** 1999 Jul 26; 107(1A):69S–76S (72 ref.)

Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Jacobs MR. **Am J Med** 1999 May 3; 106(5A):19S–25S; discussion 48S–52S (52 ref.)

New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Tomasz A. **Am J Med** 1999 Jul 26;107(1A):55S–62S (38 ref.)

Multiple antibiotic resistance in Streptococcus pneumoniae. Crook DW, et al. **Br Med Bull** 1998;54(3):595–610 (39 ref.)

beta-lactam-resistant Streptococcus pneumoniae: epidemiology and evolutionary mechanism. Hakenbeck R. **Chemotherapy** 1999 Mar–Apr;45(2):83–94 (102 ref.)

Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Kaplan SL, et al. **Clin Microbiol Rev** 1998 Oct;11(4):628–44 (148 ref.)

Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem. Klugman KP, et al. **Drugs** 1999 Jul;58(1):1–4 (29 ref.)

Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods. Low DE. **Infect Dis Clin North Am** 1998 Sep;12(3):613–30, viii (124 ref.)

Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). Fenoll A, et al. **J Clin Microbiol** 1998 Dec;36(12):3447–54 (45 ref.)

Multi-resistant pneumococci in children in day-care centres [comment] Allen KD. **J Infect** 1998 Jul;37(1):5–8 (24 ref.) Comment on: J Infect 1998 Jul;37(1):9–14.

Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. Chambers HF. **J Infect Dis** 1999 Mar;179 Suppl 2:S353–9 (58 ref.)

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group [published erratum appears in Pediatr Infect Dis J 1999 Apr;18(4):341] [see comments] Dowell SF, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):1–9 (59 ref.) Comment in: Pediatr Infect Dis J 1999 Jun;18(6):571–2.

Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update. Jacobs MR. **Pediatr Infect Dis J** 1998 Oct;17(10):947–52 (30 ref.)

Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Butler JC, et al. **Vaccine** 1998 Nov;16(18):1693–7 (56 ref.)

[Pharmacodynamic assessment of antibiotic sensitivity of Streptococcus pneumoniae] Soriano F. **Med Clin (Barc)** 1999 Jun 26;113(3):103–8 (62 ref.) **(Spa)**

[Susceptibility to antimicrobial agents in isolates from invasive Streptococcus pneumoniae in Colombia] Leal AL, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):157–63 (31 ref.) (Eng. Abstr.) **(Spa)**

[The impact of antimicrobial resistance and Streptococcus pneumoniae serotype distribution on the mortality of children under 5 years of age with invasive disease] Rios AM, et al. **Rev Panam Salud Publica** 1999 Feb;5(2):69–76 (40 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Tomasz A. **Am J Med** 1999 Jul 26;107(1A):55S–62S (38 ref.)

Bacterial gene transfer by natural genetic transformation. Håvarstein LS. **APMIS Suppl** 1998;84:43–6 (19 ref.)

Identification of a competence regulon in Streptococcus pneumoniae by genomic analysis. Håvarstein LS. **Trends Microbiol** 1998 Aug;6(8):297–9; discussion 299–300 (14 ref.)

GROWTH & DEVELOPMENT

Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Ghaffar F, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):638–46 (100 ref.)

IMMUNOLOGY

Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Briles DE, et al. **Clin Microbiol Rev** 1998 Oct; 11(4):645–57 (147 ref.)

Clinical evaluation of new pneumococcal vaccines: the Finnish approach. Eskola J, et al. **Dev Biol Stand** 1998; 95:85–92 (16 ref.)

The place of pneumococcal vaccination. **Drug Ther Bull** 1998 Oct;36(10):73–6 (43 ref.)

Prophylaxis of bacterial meningitis. Peltola H. **Infect Dis Clin North Am** 1999 Sep;13(3):685–710, viii (138 ref.)

Pneumococcal conjugate vaccines. Eskola J, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):543–51 (59 ref.)

Pneumococcal disease in sub-Saharan Africa: could currently available vaccines avert a crisis? Gordon SB, et al. **Trop Doct** 1999 Jan;29(1):5–7 (20 ref.)

[Conjugated pneumococcal vaccines] Reinert P. **Arch Pediatr** 1999;6 Suppl 3:643s–646s (25 ref.) **(Fre)**

ISOLATION & PURIFICATION

Typing of Streptococcus pneumoniae: past, present, and future. Henrichsen J. **Am J Med** 1999 Jul 26; 107(1A):50S–54S (32 ref.)

Molecular techniques for the diagnosis of respiratory bacterial infection. Gillespie S. **Curr Opin Pulm Med** 1999 May;5(3):174–8 (35 ref.)

METABOLISM

Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. Chambers HF. **J Infect Dis** 1999 Mar;179 Suppl 2:S353–9 (58 ref.)

Opsonic and nonopsonic interactions of C3 with Streptococcus pneumoniae. Hostetter MK. **Microb Drug Resist** 1999 Summer;5(2):85–9 (29 ref.)

PATHOGENICITY

[Current microbiologic problems. Pulmonary infection by Streptococcus pneumoniae. Current physiopathological aspects] Bédos JP, et al. **Presse Med** 1999 Feb 27; 28(8):442–9 (84 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Molecular and cellular biology of pneumococcal infection. Tuomanen E. **Curr Opin Microbiol** 1999 Feb;2(1):35–9 (37 ref.)

Emergence and spread of antimicrobial resistance of Streptococcus pneumoniae in Korea. Song JH. **Yonsei Med J** 1998 Dec;39(6):546–53 (44 ref.)

STREPTOCOCCUS PNEUMONIAE INFECTIONS see **PNEUMOCOCCAL INFECTIONS**

STREPTOCOCCUS PYOGENES

Invasive group A streptococcal infections in children. Davies HD, et al. **Adv Pediatr Infect Dis** 1999;14:129–45 (98 ref.)

Endocarditis caused by group A beta-hemolytic Streptococcus in an infant: case report and review. Winterbotham A, et al. **Clin Infect Dis** 1999 Jul;29(1):196–8 (18 ref.)

Aminoacyl tRNA synthetases as targets for new anti-infectives. Schimmel P, et al. **FASEB J** 1998 Dec; 12(15):1599–609 (79 ref.)

Serious group A streptococcal infection around delivery. Udagawa H, et al. **Obstet Gynecol** 1999 Jul;94(1):153–7 (22 ref.)

Streptococcal pyomyositis: case report and review. Wheeler DS, et al. **Pediatr Emerg Care** 1998 Dec;14(6):411–2 (13 ref.)

Another toxic shock syndrome. Streptococcal infection is even more dangerous than the staphylococcal form. Hauser AR. **Postgrad Med** 1998 Dec;104(6):31–4, 39, 43–4 (18 ref.)

[A case of brain abscess accompanied with sudden-onset hemiplegia as initial manifestation] Okubo K, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1232–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Streptococcal toxic shock-like syndrome] Shimizu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):115–8 (9 ref.) **(Jpn)**

[Toxic shock-like syndrome] Shiseki M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):237–40 (12 ref.) **(Jpn)**

DRUG EFFECTS

Clonal differences among erythromycin-resistant Streptococcus pyogenes in Spain. Perez-Trallero E, et al. **Emerg Infect Dis** 1999 Mar–Apr;5(2):235–40 (29 ref.)

Failure of penicillin in Streptococcus pyogenes pharyngeal infection [comment] Gillespie SH. **Lancet** 1998 Dec 19–26; 352(9145):1954–6 (18 ref.) Comment on: Lancet 1998 Dec 19–26;352(9145):1974–7.

[Resistance to macrolides in Streptococcus pyogenes] Bellido JL, et al. **Rev Esp Quimioter** 1998 Sep;11(3):196–204 (78 ref.) **(Spa)**

GENETICS

[The vir regulon--a new epidemiological marker for Streptococcus pyogenes] Shundi L. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul–Sep; 43(3):195–8 (26 ref.) **(Rum)**

IMMUNOLOGY

Structure and function of streptococcal and staphylococcal superantigens in septic shock. Bannan J, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):387–96, ix (69 ref.)

Group A streptococcal vaccines. Dale JB. **Infect Dis Clin North Am** 1999 Mar;13(1):227–43, viii (29 ref.)

ISOLATION & PURIFICATION

Management of sore throats in children: a cost-effectiveness analysis [see comments] Tsevat J, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):681–8 (73 ref.) Comment in: Arch Pediatr Adolesc Med 1999 Jul;153(7):672–4.

Pyogenic lung infections. Mwandumba HC, et al. **Curr Opin Pulm Med** 1999 May;5(3):151–6 (71 ref.)

Neonatal sepsis caused by Streptococcus pyogenes: resurgence of an old etiology? Greenberg D, et al. **Pediatr Infect Dis J** 1999 May;18(5):479–81 (15 ref.)

PATHOGENICITY

The flesh-eating bacterium: what's next? Stevens DL. **J Infect Dis** 1999 Mar;179 Suppl 2:S366–74 (96 ref.)

The changing face of rheumatic fever in the 20th century [editorial] Stollerman GH. **J Med Microbiol** 1998 Aug; 47(8):655–7 (30 ref.)

Fisher's syndrome and group A streptococcal infection. Yuki N, et al. **J Neurol Sci** 1998 Sep 18;160(1):64–6 (9 ref.)

[Toxic shock-like syndrome caused by streptococci (see comments)] van Dissel JT, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1452–5 (33 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jul 10;143(28):1452–5. **(Dut)**

["Streptococcal toxic shock-like syndrome"] Broll R, et al. **Chirurg** 1998 Aug;69(8):806–12 (41 ref.) (Eng. Abstr.) **(Ger)**

[Impetigo contagiosa (staphylococcal, streptococcal)] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):560–3 (10 ref.) **(Jpn)**

STREPTOCOCCUS SUIS

Agents of the "suis-ide diseases" of swine: Actinobacillus suis, Haemophilus parasuis, and Streptococcus suis. MacInnes JI, et al. **Can J Vet Res** 1999 Apr;63(2):83–9 (52 ref.)

STREPTODORNASE see **DEOXYRIBONUCLEASE I**

STREPTOGRAMIN see **VIRGINIAMYCIN**

STREPTOKINASE

ADMINISTRATION & DOSAGE

Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Sahn SA. **Thorax** 1998 Aug;53 Suppl 2:S65–72 (65 ref.)

THERAPEUTIC USE

Streptokinase and urokinase for the treatment of pleural effusions and empyemas. Barletta JF. **Ann Pharmacother** 1999 Apr;33(4):495–8 (24 ref.)

Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Massel D. **Can J Cardiol** 1999 Feb;15(2):173–9 (37 ref.)

Thrombolytic treatment of type A right atrial thrombi: description of three cases and review of the literature. Mezzani A, et al. **G Ital Cardiol** 1999 Apr;29(4):441–6 (24 ref.)

Biochemical markers of thrombolytic success. IFCC Committee on Standardization of Markers of Cardiac Damage. Apple FS. **Scand J Clin Lab Invest Suppl** 1999; 230:60–6 (25 ref.)

Utility of fibrinolytic agents for draining intrapleural infections. Bouros D, et al. **Semin Respir Infect** 1999 Mar; 14(1):39–47 (39 ref.)

STREPTOMYCES

CHEMISTRY

X-ray crystallographic structures of gramicidin and their relation to the Streptomyces lividans potassium channel structure. Wallace BA. **Novartis Found Symp** 1999; 225:23–32; discussion 33–7 (31 ref.)

GENETICS

Biosynthesis and molecular genetics of clavulanic acid. Jensen SE, et al. **Antonie Van Leeuwenhoek** 1999 Jan–Feb; 75(1–2):125–33 (40 ref.)

Initiation of aerial mycelium formation in Streptomyces [published erratum appears in Curr Opin Microbiol 1999 Feb;2(1):106] Kelemen GH, et al. **Curr Opin Microbiol** 1998 Dec;1(6):656–62 (44 ref.)

[Dynamic structural changes of the linear chromosomes of streptomyces and the origin and evolution of chromosomes] Kinashi H. **Tanpakushitsu Kakusan Koso** 1998 Sep; 43(11):1453–60 (41 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Initiation of aerial mycelium formation in Streptomyces [published erratum appears in Curr Opin Microbiol 1999 Feb;2(1):106] Kelemen GH, et al. **Curr Opin Microbiol** 1998 Dec;1(6):656–62 (44 ref.)

METABOLISM

Biosynthesis and molecular genetics of clavulanic acid. Jensen SE, et al. **Antonie Van Leeuwenhoek** 1999 Jan–Feb; 75(1–2):125–33 (40 ref.)

Biosynthesis and molecular genetics of cephamycins. Cephamycins produced by actinomycetes. Liras P. **Antonie Van Leeuwenhoek** 1999 Jan–Feb;75(1–2):109–24 (85 ref.)

STREPTOMYCIN

THERAPEUTIC USE

[Chemotherapy for tuberculosis; yesterday, today, and tomorrow—basic and clinical studies] Aoyagi T. **Kekkaku** 1998 Jul;73(7):459–70 (114 ref.) (Eng. Abstr.) **(Jpn)**

STREPTOZOCIN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

STREPTOZOTOCIN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

STRESS

see related

GENERAL ADAPTATION SYNDROME

Nitric oxide in the stress axis. López-Figueroa MO, et al. **Histol Histopathol** 1998 Oct;13(4):1243–52 (90 ref.)

Modeling stress: a methodological review. Roesch SC. **J Behav Med** 1999 Jun;22(3):249–69 (152 ref.)

The stressful condition as a nutritionally dependent adaptive dichotomy. Ingenbleek Y, et al. **Nutrition** 1999 Apr; 15(4):305–20 (272 ref.)

Stress-activated kinases regulate protein stability. Fuchs SY, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1483–90 (87 ref.)

Thioredoxin in the endocrine response to stress. Tanaka H, et al. **Vitam Horm** 1999;57:153–75 (93 ref.)

[Cellular and molecular mechanisms of the stress response in marine bivalves] Gourdon I, et al. **C R Seances Soc Biol Fil** 1998;192(4):749–74 (93 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of stress response and gene expression of glyoxalase I in yeast] Inoue Y. **Seikagaku** 1998 Oct; 70(10):1278–83 (18 ref.) **(Jpn)**

[Roles of the ubiquitin system in stress responses] Iwai K. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):759–65 (43 ref.) **(Jpn)**

[Function of sterylglucoside in cell differentiation and stress responses] Murakami-Murofushi K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1111–7 (32 ref.) **(Jpn)**

COMPLICATIONS

Stress-associated preterm delivery: the role of corticotropin-releasing hormone. Lockwood CJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S264–6 (18 ref.)

Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Elenkov IJ, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:1–11; discussion 11–3 (59 ref.)

Field research on the relationship between stress and disease activity in rheumatoid arthritis. Zautra AJ, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:397–412 (39 ref.)

Acute coronary syndromes: "unifying" theory versus adrenergic stress. Baroldi G. **G Ital Cardiol** 1998 Nov; 28(11):1303–16 (24 ref.) **(Eng, Ita)**

Modifying perfusion, nutrition, and stress to promote wound healing in patients with acute wounds. Whitney JD, et al. **Heart Lung** 1999 Mar–Apr;28(2):123–33 (74 ref.)

Stress and HIV disease progression: psychoneuroimmunological framework. Robinson FP, et al. **J Assoc Nurses AIDS Care** 1999 Jan–Feb;10(1):21–31 (56 ref.)

Neural sensitization model for multiple chemical sensitivity: overview of theory and empirical evidence. Bell IR, et al. **Toxicol Ind Health** 1999 Apr–Jun;15(3–4):295–304 (116 ref.)

[Organ failure during the perioperative period: pathophysiology and strategy] Murakami M, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):518–22 (12 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Stress and brain angiotensin II receptors. Watanabe T, et al. **Crit Rev Neurobiol** 1998;12(4):305–17 (109 ref.)

Maternal care and the development of stress responses. Francis DD, et al. **Curr Opin Neurobiol** 1999 Feb; 9(1):128–34 (49 ref.)

Surgical stress response: does endoscopic surgery confer an advantage? Kehlet H. **World J Surg** 1999 Aug;23(8):801–7 (55 ref.)

GENETICS

Phosphorylation of RNA polymerase II C-terminal domain (CTD): a new control for heat shock gene expression? Dubois MF, et al. **Cell Stress Chaperones** 1998 Sep; 3(3):147–51 (52 ref.)

Modulation of drug metabolism in infectious and inflammatory diseases. Iber H, et al. **Drug Metab Rev** 1999 Feb;31(1):29–41 (41 ref.)

Stress genes and species survival. Ray PK. **Mol Cell Biochem** 1999 Jun;196(1–2):117–23 (43 ref.)

Stress-axis, coping and dementia: gene-manipulation studies. Heinrichs SC. **Trends Pharmacol Sci** 1999 Aug;20(8):311–5 (51 ref.)

IMMUNOLOGY

Stress, depression, and the role of cytokines. Leonard BE, et al. **Adv Exp Med Biol** 1999;461:251–65 (94 ref.)

Stress, learned helplessness, and brain interleukin-1 beta. Maier SF, et al. **Adv Exp Med Biol** 1999;461:235–49 (63 ref.)

Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Tilders FJ, et al. **Adv Exp Med Biol** 1999;461:179–97 (106 ref.)

Effects of stress on leukocyte trafficking and immune responses: implications for vaccination. Kehrli ME, et al. **Adv Vet Med** 1999;41:61–81 (108 ref.)

Norman Cousins Memorial Lecture 1998. Stress, personal relationships, and immune function: health implications. Kiecolt-Glaser JK. **Brain Behav Immun** 1999 Mar; 13(1):61–72 (57 ref.)

Immune responses to inflammation and trauma: a physical training model. Shephard RJ, et al. **Can J Physiol Pharmacol** 1998 May;76(5):469–72 (33 ref.)

Immune deficits induced by strenuous exertion under adverse environmental conditions: manifestations and countermeasures. Shephard RJ, et al. **Crit Rev Immunol** 1998;18(6):545–68 (224 ref.)

Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine-immunological sexual dimorphism. Gaillard RC, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):345–52 (18 ref.)

A new theory on the common evolutionary origin of natural immunity, inflammation and stress response: the invertebrate phagocytic immunocyte as an eye-witness. Ottaviani E, et al. **Domest Anim Endocrinol** 1998 Sep; 15(5):291–6 (30 ref.)

Stress and immunity: implications for viral disease and wound healing. Rozlog LA, et al. **J Periodontol** 1999 Jul; 70(7):786–92 (57 ref.)

Tumor necrosis factor-alpha: is there a continuum of liability between stress, anxiety states and anorexia nervosa? Holden RJ, et al. **Med Hypotheses** 1999 Feb;52(2):155–62 (83 ref.)

METABOLISM

ATF3 and stress responses. Hai T, et al. **Gene Expr** 1999; 7(4–6):321–35 (144 ref.)

Induction of metallothionein by stress and its molecular mechanisms. Jacob ST, et al. **Gene Expr** 1999;7(4–6):301–10 (56 ref.)

Coping with stress in rats and mice: differential peptidergic modulation of the amygdala-lateral septum complex. Koolhaas JM, et al. **Prog Brain Res** 1998;119:437–48 (68 ref.)

Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoid feedback. Kovács KJ. **Prog Brain Res** 1998;119:31–43 (70 ref.)

[Internal diseases and carbonyl stress] Miyata T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):347–54 (21 ref.) **(Jpn)**

[Albumin, transport of saturated fatty acids, and metabolic stress-syndrome (literature review)] Titov VN. **Klin Lab Diagn** 1999 Apr;(4):3–11 (93 ref.) **(Rus)**

[Dehydroepiandrosterone, reticular area of adrenal cortex and resistance to stress and disease] Obut TA. **Vestn Ross Akad Med Nauk** 1998;(10):18–22 (52 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Stress signals for apoptosis: ceramide and c-Jun kinase. Basu S, et al. **Oncogene** 1998 Dec 24;17(25):3277–85 (75 ref.)

Stress: metaplastic effects in the hippocampus. Kim JJ, et al. **Trends Neurosci** 1998 Dec;21(12):505–9 (61 ref.)

PHYSIOPATHOLOGY

Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Dunn AJ, et al. **Adv Exp Med Biol** 1999;461:117–27 (60 ref.)

Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Tilders FJ, et al. **Adv Exp Med Biol** 1999;461:179–97 (106 ref.)

New insights into cardioprotection by ischemic preconditioning and other forms of stress. de Zeeuw S, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:178–91 (70 ref.)

Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Elenkov IJ, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:1–11; discussion 11–3 (59 ref.)

Stress and immune dysfunction in Gulf War veterans. Everson MP, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:413–8 (27 ref.)

Stress and hippocampal plasticity. McEwen BS. **Annu Rev Neurosci** 1999;22:105–22 (111 ref.)

Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Feder ME, et al. **Annu Rev Physiol** 1999;61:243–82 (373 ref.)

Adrenergic regulation of the force-frequency effect. Ross J Jr. **Basic Res Cardiol** 1998;93 Suppl 1:95–101 (32 ref.)

Stress, adaptation, and nitric oxide. Malyshev IY, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):840–53 (148 ref.)

Molecular chaperones and the heat shock response. Sponsored by Cold Spring Harbor Laboratory, 6–10 May 1998. Kaufman RJ. **Biochim Biophys Acta** 1999 Jan 29; 1423(1):R13–27 (27 ref.)

The neuroendocrine stress response and modern intensive care: the concept revisited. Van den Berghe GH. **Burns** 1999 Feb;25(1):7–16 (98 ref.)

Stress, inflammation and the irritable bowel syndrome. Collins SM, et al. **Can J Gastroenterol** 1999 Mar;13 Suppl A:47A–49A (27 ref.)

Stress and visceral perception. Delvaux MM. **Can J Gastroenterol** 1999 Mar;13 Suppl A:32A–36A (27 ref.)

Stress-induced changes in the gastrointestinal motor system. Plourde V. **Can J Gastroenterol** 1999 Mar;13 Suppl A:26A–31A (33 ref.)

Corticotropin-releasing factor and the brain-gut motor response to stress. Taché Y, et al. **Can J Gastroenterol** 1999 Mar;13 Suppl A:18A–25A (118 ref.)

Sleep and stress in man: an approach through exercise and exposure to extreme environments. Buguet A, et al. **Can J Physiol Pharmacol** 1998 May;76(5):553–61 (81 ref.)

Cellular responses to moderate and heavy exercise. Nehlsen-Cannarella SL. **Can J Physiol Pharmacol** 1998 May;76(5):485–9 (58 ref.)

Heat shock proteins: regulators of stress response and apoptosis. Samali A, et al. **Cell Stress Chaperones** 1998 Dec; 3(4):228–36 (94 ref.)

The adrenergic stress response in fish: control of catecholamine storage and release. Reid SG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jul;120(1):1–27 (308 ref.)

Intracellular signaling in response to osmotic stress. Kültz D, et al. **Contrib Nephrol** 1998;123:94–109 (70 ref.)

The stress response of critical illness. Epstein J, et al. **Crit Care Clin** 1999 Jan;15(1):17–33, v (56 ref.)

Insulin resistance: a marker of surgical stress. Thorell A, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):69–78 (68 ref.)

Stress and the aging hippocampus. McEwen BS. **Front Neuroendocrinol** 1999 Jan;20(1):49–70 (155 ref.)

The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Scott LV, et al. **Funct Neurol** 1999 Jan–Mar;14(1):3–11 (59 ref.)

Modernization, stress, and blood pressure: new directions in research. Dressler WW. **Hum Biol** 1999 Aug;71(4):583–605 (65 ref.)

Stress and the adaptive self-organization of neuronal connectivity during early childhood. Huether G. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):297–306 (58 ref.)

Perinatal characteristics and schizophrenia: electrodermal activity as a mediating link in a vulnerability-stress perspective. Hultman CM, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):307–16 (99 ref.)

Anterior pituitary response to stress: time-related changes and adaptation. Marti O, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):241–60 (230 ref.)

Prenatal stress: consequences of glucocorticoids on hippocampal development and function. Takahashi LK. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):199–207 (80 ref.)

New developments in the multi-site phosphorylation and integration of stress signalling at p53. Meek DW. **Int J Radiat Biol** 1998 Dec;74(6):729–37 (84 ref.)

Development of the cerebral cortex: XII. Stress and brain development: I. Lombroso PJ, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Dec; 37(12):1337–9 (6 ref.)

Clinical review 105: Stress and the reproductive cycle. Ferin M. **J Clin Endocrinol Metab** 1999 Jun;84(6):1768–74 (76

ref.)
Prenatal stress and glucocorticoid effects on the developing gender-related brain. Reznikov AG, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):109-15 (40 ref.)
c-Fos as a transcription factor: a stressful (re)view from a functional map. Kovács KJ. **Neurochem Int** 1998 Oct; 33(4):287-97 (118 ref.)
Serotonin and stress. Chaouloff F, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):28S-32S (37 ref.)
Post-translational modification of p53 and the integration of stress signals. Meek DW. **Pathol Biol (Paris)** 1997 Dec; 45(10):804-14 (96 ref.)
Cycling, stressed-out and nervous: cellular functions of c-Abl. Van Etten RA. **Trends Cell Biol** 1999 May; 9(5):179-86 (62 ref.)
Heat-shock protein protection. Sharp FR, et al. **Trends Neurosci** 1999 Mar;22(3):97-9 (70 ref.)
[The significance of physical activity on the physiological stress reaction] Dickhuth HH, et al. **Z Kardiol** 1999 May; 88(5):305-14 (78 ref.) (Eng. Abstr.) **(Ger)**
[Functional role of nur77 family in T-cell apoptosis and stress response] Okabe T, et al. **Nippon Rinsho** 1998 Jul; 56(7):1734-8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[The aged and stress response] Higashi K. **Sangyo Ika Daigaku Zasshi** 1999 Jun 1;21(2):157-69 (65 ref.) (Eng. Abstr.) **(Jpn)**
[Environmental stress and genetic variation in animal populations] Imasheva AG. **Genetika** 1999 Apr; 35(4):421-31 (87 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[Mechanism of the antistressor and antiradiation action of plant phenol compounds] Baraboi VA, et al. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):13-23 (82 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Commentary: is maternal stimulation the mediator of the handling effect in infancy? Denenberg VH. **Dev Psychobiol** 1999 Jan;34(1):1-3 (15 ref.)

THERAPY

The surgical significance of therapeutic touch. Ramnarine-Singh S. **AORN J** 1999 Feb;69(2):358-69 (52 ref.)

VETERINARY

Farmed deer: a large animal model for stress. Griffin JF, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):445-56 (75 ref.)
Influence of mental states on somatic health in animals. McMillan FD. **J Am Vet Med Assoc** 1999 Apr 15; 214(8):1221-5 (56 ref.)
Physiological stress and welfare of broiler chickens in transit: solutions not problems! Mitchell MA, et al. **Poult Sci** 1998 Dec;77(12):1803-14 (59 ref.)
A review of the road transport of slaughter sheep. Knowles TG. **Vet Rec** 1998 Aug 22;143(8):212-9 (69 ref.)

STRESS DISORDERS, POST-TRAUMATIC

see related
COMBAT DISORDERS
Course and treatment of patients with both substance use and posttraumatic stress disorders. Ouimette PC, et al. **Addict Behav** 1998 Nov-Dec;23(6):785-95 (40 ref.)
Does stress damage the brain? Bremner JD. **Biol Psychiatry** 1999 Apr 1;45(7):797-805 (93 ref.)
Biological factors associated with susceptibility to posttraumatic stress disorder [see comments] Yehuda R. **Can J Psychiatry** 1999 Feb;44(1):34-9 (46 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.
Posttraumatic stress disorder in the elderly: a review. Weintraub D, et al. **Harv Rev Psychiatry** 1999 Sep-Oct; 7(3):144-52 (102 ref.)

CLASSIFICATION

Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21-33 (281 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.

COMPLICATIONS

Functional associations among trauma, PTSD, and substance-related disorders. Stewart SH, et al. **Addict Behav** 1998 Nov-Dec;23(6):797-812 (90 ref.)
Smoking and anxiety in combat veterans with chronic posttraumatic stress disorder: a review. Beckham JC. **J Psychoactive Drugs** 1999 Apr-Jun;31(2):103-10 (69 ref.)
[Secondary traumatization while under care of child protective services] Schmitt A. **Prax Kinderpsychol Kinderpsychiatr** 1999 Jul-Aug; 48(6):411-24 (41 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems [see comments] De Bellis MD, et al. **Biol Psychiatry** 1999 May 15;45(10):1259-70 (67 ref.) Comment in: Biol Psychiatry 1999 May 15;45(10):1235-6.
Posttraumatic stress disorders in children and adolescents. Perry BD, et al. **Curr Opin Pediatr** 1999 Aug;11(4):310-6 (49 ref.)
Awareness during anesthesia and posttraumatic stress disorder. Osterman JE, et al. **Gen Hosp Psychiatry** 1998 Sep;20(5):274-81 (74 ref.)
Chronic posttraumatic stress disorder: a review and checklist of factors influencing prognosis. Simon RI. **Harv Rev Psychiatry** 1999 Mar-Apr;6(6):304-12 (71 ref.)
Diagnosis of Holocaust survivors and their children. Kellermann NP. **Isr J Psychiatry Relat Sci** 1999;36(1):55-64 (38 ref.)
Management of posttraumatic stress disorder: diagnostic and therapeutic issues. Davidson JR, et al. **J Clin Psychiatry** 1999;60 Suppl 18:33-8 (38 ref.)
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda R. **J Clin Psychiatry** 1999;60 Suppl 15:33-7 (24 ref.)
Posttraumatic stress disorder in children: implications for assessment, prevention, and referral in primary care. Pfefferbaum B, et al. **J Okla State Med Assoc** 1999 Jul; 92(7):309-15 (67 ref.)
MMPI, MMPI-2 and PTSD: overview of scores, scales, and profiles. Lyons JA, et al. **J Trauma Stress** 1999 Jan; 12(1):175-83 (22 ref.)
Diagnoses commonly missed in childhood. Long-term outcome and implications for treatment. Burger FL, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):927-40, viii (59 ref.)
Subtle presentations of post-traumatic stress disorder. Diagnostic issues. Jacobs WJ, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):835-45, vii (38 ref.)
The cascade model: an alternative to comorbidity in the pathogenesis of posttraumatic stress disorder. Alarcon RD, et al. **Psychiatry** 1999 Summer;62(2):114-24 (70 ref.)
[Post-traumatic stress disorder after traffic accidents] Meyer C, et al. **Unfallchirurg** 1998 Dec;101(12):878-93 (152 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Mirtazapine: other indications. Falkai P. **J Clin Psychiatry** 1999;60 Suppl 17:36-40; discussion 46-8 (30 ref.)
Antidepressants and posttraumatic stress disorder. Meek JK, et al. **J La State Med Soc** 1998 Oct;150(10):487-9 (16 ref.)

EPIDEMIOLOGY

[The epidemiology of post-traumatic stress disorders] Andersen HS. **Ugeskr Laeger** 1998 Dec 14;160(51):7408-13 (34 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

Post-traumatic stress reactions following motor vehicle accidents. Butler DJ, et al. **Am Fam Physician** 1999 Aug; 60(2):524-31 (22 ref.)
Stress in children exposed to violence. Reenactment and rage. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):121-35, ix (50 ref.)
Contagion in stress. An infectious disease model for posttraumatic stress in children. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):183-94, x (50 ref.)
Multiple forms of stress in refugee and immigrant children. Sack WH. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):153-67, ix-x (54 ref.)
Relations among psychological trauma, dissociative phenomena, and trauma-related distress: a review and integration. Gershuny BS, et al. **Clin Psychol Rev** 1999 Aug; 19(5):631-57 (182 ref.)
Chronic posttraumatic stress disorder: a review and checklist of factors influencing prognosis. Simon RI. **Harv Rev Psychiatry** 1999 Mar-Apr;6(6):304-12 (71 ref.)
Posttraumatic stress disorder and traumatic brain injury: are they mutually exclusive? Joseph S, et al. **J Trauma Stress** 1999 Jul;12(3):437-53 (73 ref.)
[Development of post-traumatic stress following severe work-related accidents] Carstensen O, et al. **Ugeskr Laeger** 1999 Mar 1;161(9):1249-53 (21 ref.) (Eng. Abstr.) **(Dan)**

PHYSIOPATHOLOGY

Stressors and development: a reciprocal relationship. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):1-17 (93 ref.)
The trauma response of children and adolescents. Future directions in research. Schwarz ED, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):229-39, xi (72 ref.)
Potential role of the anterior cingulate cortex in PTSD: review and hypothesis. Hamner MB, et al. **Depress Anxiety** 1999;9(1):1-14 (138 ref.)
Neuroendocrine activity and memory-related impairments in posttraumatic stress disorder. Golier J, et al. **Dev Psychopathol** 1998 Fall;10(4):857-69 (63 ref.)
Neural plasticity and emotional memory. Post RM, et al. **Dev Psychopathol** 1998 Fall;10(4):829-55 (112 ref.)
Nightmare after trauma as paradigm for all dreams: a new approach to the nature and functions of dreaming. Hartmann E. **Psychiatry** 1998 Fall;61(3):223-38 (54 ref.)
Do panic disorder and posttraumatic stress disorder share a common psychoneuroendocrinology? Kellner M, et al. **Psychoneuroendocrinology** 1999 Jul;24(5):485-504 (160 ref.)

PREVENTION & CONTROL

Of resilience, vulnerability, and a woman who never lived. Allen JR. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):53-71, viii (177 ref.)
Understanding the needs of children following large-scale disasters and the role of government. Flynn BW, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):211-27, x (32 ref.)
Caring for children affected by disaster. Pfefferbaum B. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):579-97, ix (59 ref.)
A public mental health approach to the postdisaster treatment of children and adolescents. Pynoos RS, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):195-210, x (21 ref.)
Traumatic stress—is prevention better than cure? [see comments] Deahl M. **J R Soc Med** 1998 Oct;91(10):531-3 (21 ref.) Comment in: J R Soc Med 1999 Jan;92(1):52.
[How to prevent post-traumatic stress disorder before traumatization occurs?] Melançon G, et al. **Can J Psychiatry** 1999 Apr;44(3):253-8 (50 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event. Yehuda R, et al. **Biol Psychiatry** 1998 Dec 15;44(12):1305-13 (75 ref.)
What if Astyanax had survived? War, children, and youth. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):137-51 (106 ref.)
The impact of trauma and disaster on young children. Gurwitch RH, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):19-32, vii-viii (68 ref.)
Is posttraumatic stress a viable model for understanding responses to childhood cancer? Stuber ML, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):169-82 (56 ref.)
Experimental approaches to cognitive abnormality in posttraumatic stress disorder. McNally RJ. **Clin Psychol Rev** 1998 Dec;18(8):971-82 (58 ref.)
Neuroendocrine activity and memory-related impairments in posttraumatic stress disorder. Golier J, et al. **Dev Psychopathol** 1998 Fall;10(4):857-69 (63 ref.)
Whiplash and post-traumatic stress disorder. Jaspers JP. **Disabil Rehabil** 1998 Nov;20(11):397-404 (31 ref.)
Posttraumatic polarization in psychiatry and law. Beahrs JO. **J Am Acad Psychiatry Law** 1999;27(2):335-43 (60 ref.)
A neural network explanation of posttraumatic stress disorder. Tryon WW. **J Anxiety Disord** 1998 Jul-Aug; 12(4):373-85 (45 ref.)
Acute myocardial infarction and posttraumatic stress disorder: the consequences of cumulative adversity. Alonzo AA. **J Cardiovasc Nurs** 1999 Apr;13(3):33-45 (73 ref.)
The psychosocial effects of torture, mass human rights violations, and refugee trauma: toward an integrated conceptual framework. Silove D. **J Nerv Ment Dis** 1999 Apr;187(4):200-7 (68 ref.)
Posttraumatic stress disorder: understanding the psychosocial impact of surviving childhood cancer into young adulthood [see comments] Rourke MT, et al. **J Pediatr Oncol Nurs** 1999 Jul;16(3):126-35 (25 ref.) Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115-6.
Posttraumatic stress disorder and traumatic brain injury: are they mutually exclusive? Joseph S, et al. **J Trauma Stress** 1999 Jul;12(3):437-53 (73 ref.)
Psychological trauma and the psychiatric emergency service. Briere J. **New Dir Ment Health Serv** 1999 Summer; (82):43-51 (33 ref.)

THERAPY

Treatment for traumatic memories: review and recommendations. Leskin GA, et al. **Clin Psychol Rev** 1998 Dec;18(8):983-1001 (106 ref.)
Posttraumatic stress disorders in children and adolescents. Perry BD, et al. **Curr Opin Pediatr** 1999 Aug;11(4):310-6 (49 ref.)
Psychodynamic-supportive group therapy model for elderly Holocaust survivors. Müller U, et al. **Int J Group Psychother** 1998 Oct;48(4):461-75 (41 ref.)
Traumatic memories, eye movements, phobia, and panic: a critical note on the proliferation of EMDR. Muris P, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):209-23 (63 ref.)
Management of posttraumatic stress disorder: diagnostic and therapeutic issues. Davidson JR, et al. **J Clin Psychiatry** 1999;60 Suppl 18:33-8 (38 ref.)
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda R. **J Clin Psychiatry** 1999;60 Suppl 15:33-7 (24 ref.)
Posttraumatic stress disorder in children: implications for assessment, prevention, and referral in primary care. Pfefferbaum B, et al. **J Okla State Med Assoc** 1999 Jul; 92(7):309-15 (67 ref.)

Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. Triffleman E, et al. **J Subst Abuse Treat** 1999 Jul-Sep;17(1-2):3-14 (91 ref.)
Brief early psychological interventions following trauma: a systematic review of the literature. Rose S, et al. **J Trauma Stress** 1998 Oct;11(4):697-710 (45 ref.)
Critical incident stress debriefing in international aid workers. Townsend CJ, et al. **J Travel Med** 1998 Dec;5(4):226-7 (8 ref.)
A critique of seven assumptions behind psychological trauma programmes in war-affected areas. Summerfield D. **Soc Sci Med** 1999 May;48(10):1449-62 (52 ref.)
[Intuitive dialogue--a way out of emotional blockages with defocusing imagination] Drees A. **Wien Med Wochenschr** 1998;148(6):166-70 (19 ref.) (Eng. Abstr.) **(Ger)**

STRESS FRACTURES see **FRACTURES, STRESS**

STRESS, MECHANICAL

Regulation of cardiovascular collagen synthesis by mechanical load. Bishop JE, et al. **Cardiovasc Res** 1999 Apr;42(1):27-44 (181 ref.)
Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. Goldspink G. **J Anat** 1999 Apr;194 (Pt 3):323-34 (67 ref.)

STRESS, OXIDATIVE see **OXIDATIVE STRESS**

STRESS PROTEINS see **HEAT-SHOCK PROTEINS**

STRESS, PSYCHOLOGICAL

see related
CROWDING
LIFE CHANGE EVENTS

The role of stress in anaesthetists' health and well-being. Jackson SH. **Acta Anaesthesiol Scand** 1999 Jul; 43(6):583-602 (101 ref.)
Cancer pain--a provoker of emotional, social and existential distress. Strang P. **Acta Oncol** 1998;37(7-8):641-4 (31 ref.)
Psychological changes accompanying and mediating stress-management training for essential hypertension. García-Vera MP, et al. **Appl Psychophysiol Biofeedback** 1998 Sep;23(3):159-78 (47 ref.)
The neurology of traumatic "dissociative" amnesia: commentary and literature review. Joseph R. **Child Abuse Negl** 1999 Aug;23(8):715-27 (140 ref.)
Children's recollections of traumatic and nontraumatic events. Fivush R. **Dev Psychopathol** 1998 Fall; 10(4):699-716 (105 ref.)
Stress, coping, and adjustment in children with a chronic disease: a review of the literature. Boekaerts M, et al. **Disabil Rehabil** 1999 Jul;21(7):311-37 (117 ref.)
Mental stress and ischaemic heart disease: an underestimated connection. Währborg P. **Eur Heart J** 1998 Nov;19 Suppl O:O20-3 (49 ref.)
Modeling stress: a methodological review. Roesch SC. **J Behav Med** 1999 Jun;22(3):249-69 (152 ref.)
Review: Central non-glucocorticoid inhibitors of the hypothalamo-pituitary-adrenal axis. Jessop DS. **J Endocrinol** 1999 Feb;160(2):169-80 (139 ref.)
Psychological aspects of in vitro fertilization: a review. Eugster A, et al. **Soc Sci Med** 1999 Mar;48(5):575-89 (65 ref.)
[Stress, personality and cardiovascular diseases] Lahlou K, et al. **Rev Med Interne** 1998;19 Suppl 3:339S-342S (16 ref.) **(Fre)**
[Neuroendocrine disorders cause stress-related disease. "Civilization syndrome" is a growing health problem] Björntorp P, et al. **Lakartidningen** 1999 Feb 24;96(8):893-6 (21 ref.) (Eng. Abstr.) **(Swe)**
[Free from stress by autogenic therapy. Relaxation technique yielding peace of mind and self-insight] Broms C. **Lakartidningen** 1999 Feb 10;96(6):588-92 (20 ref.) (Eng. Abstr.) **(Swe)**
[Male depression--stress reaction combined with serotonin deficiency? (see comments)] Rutz W, et al. **Lakartidningen** 1999 Mar 10;96(10):1177-8 (14 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Jun 9;96(23):2836. **(Swe)**

BLOOD

Do early-life events permanently alter behavioral and hormonal responses to stressors? Anisman H, et al. **Int J Dev Neurosci** 1998 Jun-Jul;16(3-4):149-64 (104 ref.)

COMPLICATIONS

Stress-associated immune modulation: relevance to viral infections and chronic fatigue syndrome. Glaser R, et al. **Am J Med** 1998 Sep 28;105(3A):35S-42S (81 ref.)
Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272-4 (50 ref.)
Depressogenic cognitive styles: predictive validity, information processing and personality characteristics, and developmental origins. Alloy LB, et al. **Behav Res Ther** 1999 Jun;37(6):503-31 (120 ref.)
Does stress damage the brain? Bremner JD. **Biol Psychiatry** 1999 Apr 1;45(7):797-805 (93 ref.)
Multiple forms of stress in refugee and immigrant children. Sack WH. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):153-67, ix-x (54 ref.)
Psychological aspects of endocrine disease. Sonino N, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):1-7 (64 ref.)
The relationship between stress and migraine. Fanciullacci C, et al. **Funct Neurol** 1998 Jul-Sep;13(3):215-23 (51 ref.)
Psychosocial stress-induced heart rate reactivity and atherogenesis: cause or correlation? Sharpley CF. **J Behav Med** 1998 Oct;21(5):411-32 (110 ref.)
Mast cells: a possible link between psychological stress, enteric infection, food allergy and gut hypersensitivity in the irritable bowel syndrome. Gui XY. **J Gastroenterol Hepatol** 1998 Oct;13(10):980-9 (149 ref.)
Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218-28 (36 ref.)
Modeling the involvement of the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes in autoimmune and stress-related rheumatic syndromes in women. Crofford LJ, et al. **J Womens Health** 1999 Mar;8(2):203-15 (58 ref.)
Depression in pediatric chronic illness. A diathesis-stress model. Burke P, et al. **Psychosomatics** 1999 Jan-Feb; 40(1):5-17 (102 ref.)
General psychosocial and work-related stress and reduced fertility. Henriksen TB. **Scand J Work Environ Health** 1999; 25 Suppl 1:38-9 (11 ref.)
Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Coker KH. **Semin Urol Oncol** 1999 May;17(2):111-8 (30 ref.)
Family caregiving for patients with stroke. Review and analysis. Han B, et al. **Stroke** 1999 Jul;30(7):1478-85 (48 ref.)
Review of psychosocial stress and asthma: an integrated biopsychosocial approach. Wright RJ, et al. **Thorax** 1998 Dec;53(12):1066-74 (120 ref.)
Stress and hypertension. Kulkarni S, et al. **WMJ** 1998 Dec; 97(11):34-8 (25 ref.)
[Interaction between breast cancer, psychosocial stress and the immune response] Boermeester MA, et al. **Ned Tijdschr Geneeskd** 1999 Apr 17;143(16):838-42 (35 ref.) (Eng. Abstr.) **(Dut)**
[Pharma clinics. How I diagnose and treat...stress ulcers] Fraipont V, et al. **Rev Med Liege** 1998 Aug;53(8):444-9 (23 ref.) (Eng. Abstr.) **(Fre)**
[Workload and stress in caring for the elderly: status of research and research agenda] Zimber A. **Z Gerontol Geriatr** 1998 Dec;31(6):417-25 (78 ref.) (Eng. Abstr.) **(Ger)**
[New animal models for psychogenic impotence: an ethological approach to copulatory disorder induced by social stress] Yoshimura H. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Oct; 18(5):169-80 (77 ref.) (Eng. Abstr.) **(Jpn)**
[Stress ulceration related bleeding (SURB) in intensive care unit] Kitamura N, et al. **Nippon Rinsho** 1998 Sep; 56(9):2396-400 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Role of emotional stress in development of somatic injuries in liquidators of the Chernobyl power plant accident irradiated with small doses] Moroz BB, et al. **Radiats Biol Radioecol** 1999 Jan-Feb;39(1):97-105 (41 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Consensus criteria for traumatic grief. A preliminary empirical test. Prigerson HG, et al. **Br J Psychiatry** 1999 Jan;174:67-73 (17 ref.)
Measuring job stressors and strains: where we have been, where we are, and where we need to go [see comments] Hurrell JJ Jr, et al. **J Occup Health Psychol** 1998 Oct; 3(4):368-89 (144 ref.) Comment in: J Occup Health Psychol 1999 Jul;4(3):288-92.
Measuring job stressors and studying the health impact of the work environment: an epidemiologic commentary [see comments] Kasl SV. **J Occup Health Psychol** 1998 Oct; 3(4):390-401 (38 ref.) Comment in: J Occup Health Psychol 1999 Jul;4(3):288-92.

EPIDEMIOLOGY

Long-term outcome of migration in childhood and adolescence. Moilanen I, et al. **Int J Circumpolar Health** 1998 Jul;57(2-3):180-7 (38 ref.)
The impact of lean production and related new systems of work organization on worker health. Landsbergis PA, et al. **J Occup Health Psychol** 1999 Apr;4(2):108-30 (132 ref.)

ETIOLOGY

The role of stress in anaesthetists' health and well-being. Jackson SH. **Acta Anaesthesiol Scand** 1999 Jul; 43(6):583-602 (101 ref.)
Adolescent storm and stress, reconsidered. Arnett JJ. **Am Psychol** 1999 May;54(5):317-26 (76 ref.)
Calling for the absent male. Edgar D. **Aust Fam Physician** 1999 Aug;28(8):797-9 (5 ref.)
Long-term effects of pain in infants. Porter FL, et al. **J Dev Behav Pediatr** 1999 Aug;20(4):253-61 (133 ref.)
Suffering: the contributions of persistent pain. Chapman CR, et al. **Lancet** 1999 Jun 26;353(9171):2233-7 (39 ref.)
Patterns of burden in wives who care for husbands with dementia. Winslow BW, et al. **Nurs Clin North Am** 1999 Jun;34(2):275-87 (31 ref.)
Psychosocial aspects of stress, health and safety on North Sea installations. Parkes KR. **Scand J Work Environ Health** 1998 Oct;24(5):321-33 (84 ref.)
The psychological effects of work experiences and disagreements about gender role beliefs in dual-earner couples: a longitudinal study. James JB, et al. **Womens Health** 1998 Winter;4(4):341-68 (50 ref.)
Does child care involvement increase or decrease distress among dual-earner couples? Ozer EM, et al. **Womens Health** 1998 Winter;4(4):285-311 (71 ref.)

IMMUNOLOGY

Anhedonic and anxiogenic effects of cytokine exposure. Anisman H, et al. **Adv Exp Med Biol** 1999;461:199-233 (153 ref.)
Cytokines, stress, and depression. Conclusions and perspectives. Dantzer R, et al. **Adv Exp Med Biol** 1999; 461:317-29 (18 ref.)
Stress, depression, and the role of cytokines. Leonard BE, et al. **Adv Exp Med Biol** 1999;461:251-65 (94 ref.)
Stress, learned helplessness, and brain interleukin-1 beta. Maier SF, et al. **Adv Exp Med Biol** 1999;461:235-49 (63 ref.)
Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. Vitaliano PP, et al. **Ann Behav Med** 1998 Summer;20(3):199-208 (91 ref.)
Stress and immunity: implications for viral disease and wound healing. Rozlog LA, et al. **J Periodontol** 1999 Jul; 70(7):786-92 (57 ref.)
An immunological model connecting the pathogenesis of stress, depression and carcinoma. Holden RJ, et al. **Med Hypotheses** 1998 Oct;51(4):309-14 (60 ref.)
The measurement of stress-related immune dysfunction in psychoneuroimmunology. Vedhara K, et al. **Neurosci Biobehav Rev** 1999 May;23(5):699-715 (85 ref.)
On the role of immunological factors as mediators between psychosocial factors and cancer progression. Garssen B, et al. **Psychiatry Res** 1999 Jan 18;85(1):51-61 (64 ref.)
Stress, depression and immunity: the role of defense and coping styles [comment] Olff M. **Psychiatry Res** 1999 Jan 18;85(1):7-15 (78 ref.) Comment on: Psychiatry Res 1999 Jan 18;85(1):17-31.
Nitric oxide and biopterin in depression and stress. van Amsterdam JG, et al. **Psychiatry Res** 1999 Jan 18;85(1):33-8 (42 ref.)
Stress and mind-body impact on the course of inflammatory bowel diseases. Anton PA. **Semin Gastrointest Dis** 1999 Jan;10(1):14-9 (52 ref.)
[Psychoimmunology: a model in question] Vuitton DA. **Rev Med Interne** 1998;19 Suppl 3:343S-346S (12 ref.) **(Fre)**

METABOLISM

Induction of metallothionein by stress and its molecular mechanisms. Jacob ST, et al. **Gene Expr** 1999;7(4-6):301-10 (56 ref.)
Emotional stress and characteristics of brain noradrenaline release in the rat. Tanaka M. **Ind Health** 1999 Apr; 37(2):143-56 (27 ref.)
Corticotropin-releasing hormone signals adversity in both the placenta and the brain: regulation by glucocorticoids and allostatic overload. Schulkin J. **J Endocrinol** 1999 Jun; 161(3):349-56 (108 ref.)
Brain N-acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. Poland RE, et al. **J Psychiatr Res** 1999 Jan-Feb;33(1):41-51 (126 ref.)
Nitric oxide and biopterin in depression and stress. van Amsterdam JG, et al. **Psychiatry Res** 1999 Jan 18;85(1):33-8 (42 ref.)

NURSING

Guided imagery interventions for symptom management. Eller LS. **Annu Rev Nurs Res** 1999;17:57-84 (100 ref.)
Nursing interventions to reduce stress in parents of hospitalized preterm infants. Griffin T, et al. **J Pediatr Nurs** 1998 Oct;13(5):290-5 (31 ref.)

PATHOLOGY

Stress, glucocorticoids and structural plasticity of the hippocampus. Fuchs E, et al. **Neurosci Biobehav Rev** 1998; 23(2):295-300 (77 ref.)

PHYSIOPATHOLOGY

Differential central and peripheral release of vasopressin and oxytocin in response to swim stress in rats. Engelmann M, et al. **Adv Exp Med Biol** 1998;449:175-7 (15 ref.)
Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272-4 (50 ref.)
The social construction of cardiovascular reactivity. Christenfeld N, et al. **Ann Behav Med** 1998 Fall; 20(4):317-25 (57 ref.)
The effects of the social environment on stress-related cardiovascular activation: current findings, prospects, and

implications. Kamarck TW, et al. **Ann Behav Med** 1998 Fall;20(4):247–56 (83 ref.)
Problems and prospects for the social support–reactivity hypothesis. Lepore SJ. **Ann Behav Med** 1998 Fall; 20(4):257–69 (93 ref.)
Differential effects of psychological and immunological challenge on the hypothalamo–pituitary–adrenal axis function in adjuvant-induced arthritis. Harbuz MS, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:43–52 (28 ref.)
Excess catecholamine syndrome. Pathophysiology and therapy. Rupp H. **Ann N Y Acad Sci** 1999 Jun 21; 881:430–44 (98 ref.)
Health psychology: mapping biobehavioral contributions to health and illness. Baum A, et al. **Annu Rev Psychol** 1999; 50:137–63 (208 ref.)
Stressors and development: a reciprocal relationship. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):1–17 (93 ref.)
Homeostasis, stress, trauma, and adaptation. A neurodevelopmental view of childhood trauma. Perry BD, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan; 7(1):33–51, viii (107 ref.)
The trauma response of children and adolescents. Future directions in research. Schwarz ED, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):229–39, xi (72 ref.)
Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Rozanski A, et al. **Circulation** 1999 Apr 27;99(16):2192–217 (279 ref.)
Neural plasticity and emotional memory. Post RM, et al. **Dev Psychopathol** 1998 Fall;10(4):829–55 (112 ref.)
Forebrain pathways mediating stress-induced hormone secretion. Van de Kar LD, et al. **Front Neuroendocrinol** 1999 Jan;20(1):1–48 (380 ref.)
Stress and water balance: the roles of ANP, AVP and isatin. Bhattacharya SK, et al. **Indian J Exp Biol** 1998 Dec; 36(12):1195–200 (85 ref.)
The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Licinio J, et al. **Mol Psychiatry** 1999 Jul;4(4):317–27 (92 ref.)
Serotonin and stress. Chaouloff F, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):28S–32S (37 ref.)
Psychological stress and neuroendocrine function in humans: the last two decades of research. Biondi M, et al. **Psychother Psychosom** 1999;68(3):114–50 (210 ref.)
[Nuclear transcription factor kappa B (NF–kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945–7 (13 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Some theoretical remarks regarding the integration of somatic and psychosocial risk factors of coronary artery disease in preventive programmes in occupational medicine. Schmahl FW. **Int J Occup Med Environ Health** 1998;11(4):285–9 (12 ref.)
Nursing interventions to reduce stress in parents of hospitalized preterm infants. Griffin T, et al. **J Pediatr Nurs** 1998 Oct;13(5):290–5 (31 ref.)
Behavioral medicine. Vogel ME, et al. **Prim Care** 1999 Jun; 26(2):385–400 (9 ref.)
Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Coker KH. **Semin Urol Oncol** 1999 May;17(2):111–8 (30 ref.)
The role of the supervisor in training social workers treating HIV infected persons in a hospital. Itzhaky H, et al. **Soc Work Health Care** 1999;29(1):57–74 (32 ref.)
[How to prevent post-traumatic stress disorder before traumatization occurs?] Melançon G, et al. **Can J Psychiatry** 1999 Apr;44(3):253–8 (50 ref.) (Eng. Abstr.) **(Fre)**
[Psychosocial factors at work and cardiovascular diseases: contribution of the Effort–Reward Imbalance model] Niedhammer I, et al. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):398–410 (92 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Social psychophysiology, social circumstances, and health. Carroll D, et al. **Ann Behav Med** 1998 Fall;20(4):333–7 (80 ref.)
A case for the usefulness of laboratory social stressors. Linden W, et al. **Ann Behav Med** 1998 Fall;20(4):310–6 (57 ref.)
Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. Vitaliano PP, et al. **Ann Behav Med** 1998 Summer;20(3):199–208 (91 ref.)
The comparison of individuals with recurrent tension-type headache and headache-free controls in physiological response, appraisal, and coping with stressors: a review of the literature. Wittrock DA, et al. **Ann Behav Med** 1998 Spring;20(2):118–34 (89 ref.)
Fear of contagion: a response to stress? Bennett J. **ANS Adv Nurs Sci** 1998 Sep;21(1):76–87 (45 ref.)
Stress and intervention strategies in mental health professionals. Rabin S, et al. **Br J Med Psychol** 1999 Jun; 72 (Pt 2):159–69 (64 ref.)
What if Astyanax had survived? War, children, and youth. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):137–51 (106 ref.)
The stress of being a poor child in America. Garbarino J. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):105–19, ix (23 ref.)
The impact of trauma and disaster on young children. Gurwitch RH, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):19–32, vii–viii (68 ref.)
Relations among psychological trauma, dissociative phenomena, and trauma-related distress: a review and integration. Gershuny BS, et al. **Clin Psychol Rev** 1999 Aug; 19(5):631–57 (182 ref.)
Stressors and concerns in teen asthma. Randolph C, et al. **Curr Probl Pediatr** 1999 Mar;29(3):82–93 (83 ref.)
The effects of stress on memory and the hippocampus throughout the life cycle: implications for childhood development and aging. Bremner JD, et al. **Dev Psychopathol** 1998 Fall;10(4):871–85 (98 ref.)
Individual differences in factors that modulate storage and retrieval of traumatic memories. Howe ML. **Dev Psychopathol** 1998 Fall;10(4):681–98 (118 ref.)
The effects of stress and trauma on brain and memory: a view from developmental cognitive neuroscience. Nelson CA, et al. **Dev Psychopathol** 1998 Fall;10(4):793–809 (87 ref.)
Stress, memory, and emotion: developmental considerations from the study of child maltreatment. Pollak S, et al. **Dev Psychopathol** 1998 Fall;10(4):811–28 (98 ref.)
Neural plasticity and emotional memory. Post RM, et al. **Dev Psychopathol** 1998 Fall;10(4):829–55 (112 ref.)
Glucocorticoids, stress, and behavior: shifting the timeframe. Orchinik M. **Horm Behav** 1998 Dec;34(3):320–7 (47 ref.)
Emotional stress and characteristics of brain noradrenaline release in the rat. Tanaka M. **Ind Health** 1999 Apr; 37(2):143–56 (27 ref.)
The corruption process of a law enforcement officer: a paradigm of occupational stress and deviancy [see comments] McCafferty FL, et al. **J Am Acad Psychiatry Law** 1998;26(3):433–58 (85 ref.) Comment in: J Am Acad Psychiatry Law 1999;27(1):178–9.
Measuring job stressors and strains: where we have been, where we are, and where we need to go [see comments] Hurrell JJ Jr, et al. **J Occup Health Psychol** 1998 Oct; 3(4):368–89 (144 ref.) Comment in: J Occup Health Psychol 1999 Jul;4(3):288–92.
Children's reactions to disaster. Coffman S. **J Pediatr Nurs** 1998 Dec;13(6):376–82 (22 ref.)
Siblings of children with cancer: a review of the literature. Murray JS. **J Pediatr Oncol Nurs** 1999 Jan;16(1):25–34 (20 ref.)
Conceptual understanding of resilience in the adolescent with cancer: Part I. Woodgate RL. **J Pediatr Oncol Nurs** 1999 Jan;16(1):35–43 (28 ref.)
Brain N–acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. Poland RE, et al. **J Psychiatr Res** 1999 Jan–Feb;33(1):41–51 (126 ref.)
Assessment of stressors in families with a child who has a chronic condition. Burke SO, et al. **MCN Am J Matern Child Nurs** 1999 Mar–Apr;24(2):98–106 (30 ref.)
Effects of sigma receptor ligands on conditioned fear stress. Kamei H, et al. **Methods Find Exp Clin Pharmacol** 1998 Sep;20(7):613–8 (24 ref.)
The time dimension in stress responses: relevance for survival and health. Eriksen HR, et al. **Psychiatry Res** 1999 Jan 18;85(1):39–50 (72 ref.)
On the role of immunological factors as mediators between psychosocial factors and cancer progression. Garssen B, et al. **Psychiatry Res** 1999 Jan 18;85(1):51–61 (64 ref.)
Stress, depression and immunity: the role of defense and coping styles [comment] Olff M. **Psychiatry Res** 1999 Jan 18;85(1):7–15 (78 ref.) Comment on: Psychiatry Res 1999 Jan 18;85(1):17–31.
The bezoaric effect: working with traumatic process. Stanton M. **Psychoanal Rev** 1998 Jun;85(3):331–48 (31 ref.)
The perils of outperformance: sensitivity about being the target of a threatening upward comparison. Exline JJ, et al. **Psychol Bull** 1999 May;125(3):307–37 (312 ref.)
Effects of early stress on adult affiliative behavior. Henry JP, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):863–75 (54 ref.)

THERAPY

Dealing with stress and trauma in families. Kiser LJ, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):87–103, viii–ix (55 ref.)
Active listening to cancer patients' stories. ten Kroode HF. **Neth J Med** 1998 Aug;53(2):41–52 (4 ref.)
Coping without a counsellor. Persaud R. **Practitioner** 1998 Jul;242(1588):542–5 (7 ref.)

STRESS TEST see **EXERCISE TEST**

STRESSFUL EVENTS see **LIFE CHANGE EVENTS**

STRETCH RECEPTORS see **MECHANORECEPTORS**

STRETCH RECEPTORS, ARTERIAL see **PRESSORECEPTORS**

STRETCH RECEPTORS, VASCULAR see **PRESSORECEPTORS**

STRIA VASCULARIS

PHYSIOLOGY

Anatomic and physiologic substrates of emotion in an animal model. Davis M. **J Clin Neurophysiol** 1998 Sep;15(5):378–87 (67 ref.)

STRIATE CORTEX see **VISUAL CORTEX**

STRIATED BORDER see **MICROVILLI**

STRIATONIGRAL DEGENERATION see **MULTIPLE SYSTEM ATROPHY**

STRIDOR see **RESPIRATORY SOUNDS**

STRIPED DOLPHIN see **DOLPHINS**

STROKE see **CEREBROVASCULAR DISORDERS**

STROKE VOLUME

Effects of injectate volume on thermodilution measurements of cardiac output in patients with low ventricular ejection fraction. McCloy K, et al. **Am J Crit Care** 1999 Mar; 8(2):86–92 (33 ref.)
The non–invasive assessment of stroke volume and cardiac output by impedance cardiography: a review. Newman DG, et al. **Aviat Space Environ Med** 1999 Aug;70(8):780–9 (82 ref.)

DRUG EFFECTS

Ejection fraction improvement by beta–blocker treatment in patients with heart failure: an analysis of studies published in the literature. van Campen LC, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S31–5 (50 ref.)

PHYSIOLOGY

Importance of the blood pressure–heart rate relationship. Folkow B, et al. **Blood Press** 1998 May;7(3):133–8 (30 ref.)

STROMAL CELLS

CYTOLOGY

Cell interaction molecules utilized in bone marrow. Kincade PW, et al. **Cell Adhes Commun** 1998;6(2–3):211–5 (34 ref.)
Multipotential cells in the bone marrow stroma: regulation in the context of organ physiology. Bianco P, et al. **Crit Rev Eukaryot Gene Expr** 1999;9(2):159–73 (102 ref.)
Thymic microenvironments, 3–D versus 2–D? van Ewijk W, et al. **Semin Immunol** 1999 Feb;11(1):57–64 (29 ref.)
[Hematopoietic stem cells and stromal cells in AGM region of mouse embryo] Tuji K. **Rinsho Ketsueki** 1999 Apr; 40(4):268–71 (7 ref.) **(Jpn)**

IMMUNOLOGY

The human thymic microenvironment: new approaches to functional analysis. Ritter MA, et al. **Semin Immunol** 1999 Feb;11(1):13–21 (62 ref.)

PATHOLOGY

Atypical prostatic stromal lesions. Cohen MB. **Adv Anat Pathol** 1998 Nov;5(6):359–66 (13 ref.)
What might a stromal response mean to prostate cancer progression? Rowley DR. **Cancer Metastasis Rev** 1998–99; 17(4):411–9 (79 ref.)
Diseases of bone and the stromal cell lineage. Bianco P, et al. **J Bone Miner Res** 1999 Mar;14(3):336–41 (35 ref.)
[Leukemias—diseases of haemopoietic organs stroma (hypothesis)] Morozova VT. **Klin Lab Diagn** 1999 Jun; (6):3–13 (29 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The role of stromal cells in prostate cancer development and progression. Condon MS, et al. **In Vivo** 1999 Jan–Feb; 13(1):61–5 (37 ref.)
[Commitment and differentiation of osteoclast on stromal cells] Yamazaki H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):854–64 (63 ref.) **(Jpn)**

STROMAL DYSTROPHIES, CORNEAL see **CORNEAL DYSTROPHIES, HEREDITARY**

STROMELYSIN 1

ANTAGONISTS & INHIBITORS

Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications. Leff RL. **Ann N Y Acad Sci** 1999 Jun 30;878:201–7 (12 ref.)

STRONGYLIDA INFECTIONS

[Angiostrongyliasis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):474–6 (4 ref.)

(Jpn)

COMPLICATIONS

[Eosinophilic meningitis due to Angiostrongylus cantonensis] Legrand G, et al. **Rev Neurol (Paris)** 1998 Apr; 154(3):236–42 (58 ref.) (Eng. Abstr.) **(Fre)**

[Meningoencephalomyelitis due to Angiostrongylus cantonensis with lung involvement] Siles Cadillá J, et al. **An Esp Pediatr** 1998 Sep;49(3):308–10 (12 ref.) **(Spa)**

DIAGNOSIS

[Laboratory diagnosis of protozoan and parasitic infections. 2. Helminthiasis. f. Angiostrongyliasis cantonensis] Nakamoto M. **Rinsho Byori** 1998 Nov;Suppl 108:239–46 (9 ref.) **(Jpn)**

ETIOLOGY

Eosinophilic meningitis/angiostrongyliasis from eating aquaculture-raised snails: a case report. Marsh CM. **Hawaii Med J** 1998 Oct;57(10):652–4 (10 ref.)

TRANSMISSION

Parasitic meningitis [editorial; comment] Prociv P. **Med J Aust** 1999 Jun 7;170(11):517–8 (14 ref.) Comment on: Med J Aust 1999 Jun 7;170(11):541–3.

VETERINARY

Immunity in equine cyathostome infections. Klei TR, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):123–33; discussion 133–6, 215–25 (30 ref.)

Pathogenicity of cyathostome infection. Love S, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):113–21; discussion 121–2, 215–25 (44 ref.)

Historical perspective of cyathostomes: prevalence, treatment and control programs. Lyons ET, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):97–111; discussion 111–2, 215–25 (121 ref.)

STRONGYLOIDEA

Immunity in equine cyathostome infections. Klei TR, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):123–33; discussion 133–6, 215–25 (30 ref.)

Pathogenicity of cyathostome infection. Love S, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):113–21; discussion 121–2, 215–25 (44 ref.)

Historical perspective of cyathostomes: prevalence, treatment and control programs. Lyons ET, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):97–111; discussion 111–2, 215–25 (121 ref.)

STRONGYLOIDES STERCORALIS

Duodenal obstruction caused by Strongyloides stercoralis enteritis in an HTLV-1-infected host. Friedenberg F, et al. **Dig Dis Sci** 1999 Jun;44(6):1184–8 (17 ref.)

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

[Laboratory diagnosis of protozoan and parasitic infections. 2. Helminthiasis. j. Strongyloides stercoralis infection] Iwamasa T. **Rinsho Byori** 1998 Nov;Suppl 108:264–9 (5 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Chemo- and thermosensory neurons: structure and function in animal parasitic nematodes. Ashton FT, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):297–316 (49 ref.)

ISOLATION & PURIFICATION

Strongyloidiasis colitis: a case report and review of the literature. Al Samman M, et al. **J Clin Gastroenterol** 1999 Jan;28(1):77–80 (20 ref.)

STRONGYLOIDIASIS

Case studies in international medicine. Kitchen LW. **Am Fam Physician** 1999 Jun;59(11):3040–4 (06 ref.)

[Pulmonary strongyloidiasis] Yamamoto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):442–5 (15 ref.) **(Jpn)**

COMPLICATIONS

Duodenal obstruction caused by Strongyloides stercoralis enteritis in an HTLV-1-infected host. Friedenberg F, et al. **Dig Dis Sci** 1999 Jun;44(6):1184–8 (17 ref.)

Mortality associated with concurrent strongyloidosis and cytomegalovirus infection in a patient on steroid therapy. Wang BY, et al. **Mt Sinai J Med** 1999 Mar;66(2):128–32 (35 ref.)

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

DIAGNOSIS

[Laboratory diagnosis of protozoan and parasitic infections. 2. Helminthiasis. j. Strongyloides stercoralis infection] Iwamasa T. **Rinsho Byori** 1998 Nov;Suppl 108:264–9 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

Strongyloidiasis colitis: a case report and review of the literature. Al Samman M, et al. **J Clin Gastroenterol** 1999 Jan;28(1):77–80 (20 ref.)

STRONTIUM

see related
STRONTIUM RADIOISOTOPES

METABOLISM

Strontium and bone. Cabrera WE, et al. **J Bone Miner Res** 1999 May;14(5):661–8 (81 ref.)

STRONTIUM RADIOISOTOPES

THERAPEUTIC USE

Postoperative irradiation of pterygium with 90Sr eye applicator. Fukushima S, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):597–600 (15 ref.)

[A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment] Jager PL, et al. **Ned Tijdschr Geneeskd** 1999 May 8;143(19):969–73 (26 ref.) (Eng. Abstr.) **(Dut)**

[Intracoronary brachytherapy with strontium/yttrium-90. Initial experiences in Germany] Silber S, et al. **Herz** 1998 Sep;23(6):380–93 (36 ref.) (Eng. Abstr.) **(Ger)**

G-STROPHANTHIN see **OUABAIN**

STRUCTURAL GENES see **GENES, STRUCTURAL**

STRUCTURE-ACTIVITY RELATIONSHIP

Structure-based drug design: combinatorial chemistry and molecular modeling. Kirkpatrick DL, et al. **Comb Chem High Throughput Screen** 1999 Aug;2(4):211–21 (54 ref.)

Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Khanolkar AD, et al. **Life Sci** 1999;65(6–7):607–16 (45 ref.)

Correlative and mechanistic QSAR models in toxicology. Lipnick RL. **SAR QSAR Environ Res** 1999;10(2–3):239–48 (21 ref.)

STRUCTURE, MOLECULAR see **MOLECULAR STRUCTURE**

STRUMA OVARII

PATHOLOGY

Malignant struma ovarii: two case reports and a review of the literature. Dardik RB, et al. **Gynecol Oncol** 1999 Jun; 73(3):447–51 (17 ref.)

STRUTHIONIFORMES see **OSTRICHES**

STUART FACTOR see **FACTOR X**

STUART-PROWER FACTOR see **FACTOR X**

STUDENT HEALTH SERVICES

Brief therapy in college counseling and mental health [see comments] Cooper S, et al. **J Am Coll Health** 1999 Jul; 48(1):21–8 (47 ref.) Comment in: J Am Coll Health 1999 Jul;48(1):3–6.

ORGANIZATION & ADMINISTRATION

Osteoporosis: implications for risk reduction in the college setting [see comments] Leslie M, et al. **J Am Coll Health** 1999 Sep;48(2):67–71 (25 ref.) Comment in: J Am Coll Health 1999 Sep;48(2):51–4.

STUDENT LOANS see **TRAINING SUPPORT**

STUDENT SELECTION see **SCHOOL ADMISSION CRITERIA**

STUDENTS

The involvement of genome researchers in high school science education. Munn M, et al. **Genome Res** 1999 Jul; 9(7):597–607 (23 ref.)

Understanding fraternity drinking: five recurring themes in the literature, 1980–1998. Borsari BE, et al. **J Am Coll Health** 1999 Jul;48(1):30–7 (77 ref.)

Osteoporosis: implications for risk reduction in the college setting [see comments] Leslie M, et al. **J Am Coll Health** 1999 Sep;48(2):67–71 (25 ref.) Comment in: J Am Coll Health 1999 Sep;48(2):51–4.

[Hemoglobinopathies in students at the Russian University of the Friendship of Peoples] Troitskaia OV, et al. **Klin Lab Diagn** 1999 May;(5):19–24, 41–6 (51 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Social anxiety and drinking in college students: a social cognitive theory analysis. Burke RS, et al. **Clin Psychol Rev** 1999 Aug;19(5):513–30 (140 ref.)

Brief therapy in college counseling and mental health [see comments] Cooper S, et al. **J Am Coll Health** 1999 Jul; 48(1):21–8 (47 ref.) Comment in: J Am Coll Health 1999 Jul;48(1):3–6.

Extent of relational stigmatization of lesbians and their children by heterosexual college students. King BR, et al. **J Homosex** 1999;37(2):65–81 (62 ref.)

Anxiety and depression among law students: current knowledge and future directions. Dammeyer MM, et al. **Law Hum Behav** 1999 Feb;23(1):55–73 (43 ref.)

[Epidemiology of psychosomatic symptoms and subjective health evaluation among secondary school students] Pikó B. **Orv Hetil** 1999 Jun 6;140(23):1297–304 (40 ref.) (Eng. Abstr.) **(Hun)**

STATISTICS & NUMERICAL DATA

The shape of our river. Healton CG. **Am J Prev Med** 1999 Apr;16(3 Suppl):1–4 (6 ref.)

Anxiety and depression among law students: current knowledge and future directions. Dammeyer MM, et al. **Law Hum Behav** 1999 Feb;23(1):55–73 (43 ref.)

STUDENTS, DENTAL

Student evaluations of dental faculty and courses. Jasinevicius TR, et al. **J Dent Educ** 1998 Dec;62(12):957–63 (46 ref.)

STUDENTS, MEDICAL

Teaching and learning gross anatomy: dissection, prosection, or "both of the above?". Dinsmore CE, et al. **Clin Anat** 1999;12(2):110–4 (25 ref.)

Predictors of success in medicine. Reede JY. **Clin Orthop** 1999 May;(362):72–7 (64 ref.)

Learner contracts. Ferrante J. **Fam Med** 1998 Nov–Dec; 30(10):703–4 (4 ref.)

Teaching medical students about tobacco [see comments] Richmond R. **Thorax** 1999 Jan;54(1):70–8 (110 ref.) Comment in: Thorax 1999 Jan;54(1):2. Comment in: Thorax 1999 Jul;54(7):657–8.

[Methods in the evaluation of medical students] Tscherning T, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):22–6 (29 ref.) (Eng. Abstr.) **(Dan)**

CLASSIFICATION

Evaluating applicants to emergency medicine residency programs. Balentine J, et al. **J Emerg Med** 1999 Jan–Feb; 17(1):131–4 (32 ref.)

PSYCHOLOGY

Toward creating physician-healers: fostering medical students' self-awareness, personal growth, and well-being. Novack DH, et al. **Acad Med** 1999 May;74(5):516–20 (51 ref.)

[Debaters in Läkartidningen do not agree with the students about active euthanasia] Ahvenainen J, et al. **Lakartidningen** 1999 Apr 7;96(14):1731–4 (47 ref.) **(Swe)**

[Alcohol and drug use among medical students 1995: more than every tenth male student had hazardous alcohol drinking habits] Borschos B, et al. **Lakartidningen** 1999 Jul 14;96(28–29):3253–8 (18 ref.) (Eng. Abstr.) **(Swe)**

STUDENTS, NURSING

A perspective on clinical evaluation in nursing education. Mahara MS. **J Adv Nurs** 1998 Dec;28(6):1339–46 (48 ref.)

Potential for violence toward psychiatric nursing students: risk reduction techniques. Echternacht MR. **J Psychosoc Nurs Ment Health Serv** 1999 Mar;37(3):36–9 (9 ref.)

Partnership in nursing education: a vision or a fantasy? Paterson B. **Nurs Outlook** 1998 Nov–Dec;46(6):284–9 (43 ref.)

STUNNED MYOCARDIUM see **MYOCARDIAL STUNNING**

STURGE-WEBER SYNDROME

PATHOLOGY

Phacomatosis pigmentovascularis type IIb associated with Sturge-Weber syndrome and pyogenic granuloma. Hagiwara K, et al. **J Dermatol** 1998 Nov;25(11):721–9 (26 ref.)

The neuropathology of selected neurocutaneous diseases. Nelson JS. **Semin Pediatr Neurol** 1995 Sep;2(3):192–9 (42 ref.)

STUTTERING

PHYSIOPATHOLOGY

[Auditory speech-evoked cerebral cortex potentials in patients with stuttering syndromes] Rosanowski F, et al. **Laryngorhinootologie** 1998 Dec;77(12):709–14 (29 ref.) (Eng. Abstr.) **(Ger)**

STYE

STYE see **HORDEOLUM**

SUBACROMIAL IMPINGEMENT SYNDROME see **SHOULDER IMPINGEMENT SYNDROME**

SUBACUTE CARE

Subacute care: which patients benefit? Mistry PR, et al. **Cleve Clin J Med** 1999 Jul-Aug;66(7):443-6 (12 ref.)

SUBACUTE SCLEROSING PANENCEPHALITIS

[Subacute sclerosing panencephalitis (SSPE)] Nihei K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):57-62 (15 ref.) **(Jpn)**

DIAGNOSIS

Subacute sclerosing panencephalitis. Garg RK., et al. **Indian Pediatr** 1998 Apr;35(4):337-44 (41 ref.)

Case report and molecular analysis of subacute sclerosing panencephalitis in a South African Child. Vardas E, et al. **J Clin Microbiol** 1999 Mar;37(3):775-7 (15 ref.)

VIROLOGY

Pathogenic aspects of measles virus infections. Schneider-Schaulies S, et al. **Arch Virol Suppl** 1999; 15:139-58 (79 ref.)

SUBARACHNOID HEMORRHAGE

COMPLICATIONS

Acute lung injury in head trauma patients. Mascia L, et al. **Intensive Care Med** 1998 Oct;24(10):1115-6 (4 ref.)

Cardiologic complications of subarachnoid hemorrhage. Di Pasquale G, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):33-6 (22 ref.)

Epidemiology and pathophysiology of cerebral vasospasm following subarachnoid hemorrhage. Pasqualin A. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):15-21 (61 ref.)

The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage. Dorsch NW. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:156-60 (13 ref.)

Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo JE, et al. **Neurosurgery** 1998 Dec;43(6):1409-17; discussion 1417-8 (95 ref.)

[Seizures associated with acute subarachnoid hemorrhage. Emergency diagnosis and treatment] Beretta L, et al. **Minerva Anestesiol** 1998 Apr;64(4):131-3 (5 ref.) (Eng. Abstr.) **(Ita)**

[Targets and prevention of complications in nursing of subarachnoid hemorrhage] De Bellis P, et al. **Minerva Anestesiol** 1998 May;64(5):247-9 (6 ref.) (Eng. Abstr.) **(Ita)**

[Hydrocephalus and rebleeding in subarachnoid hemorrhage] Marini G. **Minerva Anestesiol** 1998 May;64(5):239-41 (0 ref.) (Eng. Abstr.) **(Ita)**

[Hyponatremia in patients with subarachnoid hemorrhage] Ori C. **Minerva Anestesiol** 1998 May;64(5):235-8 (5 ref.) (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage and pregnancy] Rossi A, et al. **Minerva Anestesiol** 1998 Apr;64(4):189-91 (3 ref.) (Eng. Abstr.) **(Ita)**

[The prevention and treatment of vasospasm in subarachnoid hemorrhage] Tomasello F, et al. **Minerva Anestesiol** 1998 May;64(5):217-20 (7 ref.) (Eng. Abstr.) **(Ita)**

[Giant aneurysms] Zavanone M, et al. **Minerva Anestesiol** 1998 Apr;64(4):167-70 (7 ref.) (Eng. Abstr.) **(Ita)**

[Myocardial stunning in the context of a subarachnoid hemorrhage] Delgado C, et al. **Rev Esp Cardiol** 1998 Oct; 51(10):840-3 (8 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Erotomania after aneurysmal subarachnoid hemorrhage: case report and literature review. Anderson CA, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer;10(3):330-7 (57 ref.)

[Acute severe headache: a subarachnoidal hemorrhage?] Linn FH, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):545-50 (17 ref.) (Eng. Abstr.) **(Dut)**

[Differential diagnosis of subarachnoid hemorrhage] Andrioli G, et al. **Minerva Anestesiol** 1998 Apr;64(4):141-4 (7 ref.) (Eng. Abstr.) **(Ita)**

[The clinical grading of subarachnoid hemorrhage] Ducati A. **Minerva Anestesiol** 1998 Apr;64(4):109-12 (8 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis and general assessment of acute subarachnoid hemorrhage] Leonardi M. **Minerva Anestesiol** 1998 Apr; 64(4):145-7 (0 ref.) (Eng. Abstr.) **(Ita)**

[Therapeutic decisions and grading of subarachnoid hemorrhage] Pagni CA, et al. **Minerva Anestesiol** 1998 Apr; 64(4):159-62 (8 ref.) (Eng. Abstr.) **(Ita)**

[Reasons against lumbar puncture diagnosis with cerebrospinal fluid drainage in subarachnoid hemorrhage] Profeta G, et al. **Minerva Anestesiol** 1998 Apr;64(4):137-9 (10 ref.) (Eng. Abstr.) **(Ita)**

[Reasons in favor of lumbar puncture diagnosis (or lavage)] Schisano G. **Minerva Anestesiol** 1998 Apr;64(4):135-6 (6 ref.) (Eng. Abstr.) **(Ita)**

[The management of subarachnoid hemorrhage. Ad hoc Editorial Committee of the Task Force on Cerebrovascular Diseases of SEN] Vivancos Mora J, et al. **Neurologia** 1998; 13 Suppl 3:42-52 (90 ref.) **(Spa)**

DRUG THERAPY

Systematic review of antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage. Roos YB, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):942-3 (8 ref.)

[Prospective pharmacologic treatments for subarachnoid hemorrhage] Carteri A, et al. **Minerva Anestesiol** 1998 May; 64(5):257-9 (6 ref.) (Eng. Abstr.) **(Ita)**

[Pharmacologic therapy of subarachnoid hemorrhage] Pagni CA, et al. **Minerva Anestesiol** 1998 May;64(5):221-4 (7 ref.) (Eng. Abstr.) **(Ita)**

[Indications for steroid and tirilazad treatment in patients with subarachnoid hemorrhage] Tommasino C, et al. **Minerva Anestesiol** 1998 May;64(5):225-7 (12 ref.) (Eng. Abstr.) **(Ita)**

[Traumatic subarachnoid hemorrhages (the current aspects of the use of calcium blockers)] Amcheslavskiĭ VG. **Zh Vopr Neirokhir im N N Burdenko** 1998 Jul-Sep;(3):54-5 (16 ref.) **(Rus)**

EPIDEMIOLOGY

[Spontaneous subarachnoid hemorrhage: risk factors] Della Corte F, et al. **Minerva Anestesiol** 1998 Apr;64(4):113-4 (5 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Intracranial aneurysms and subarachnoid hemorrhage management of the poor grade patient. Le Roux PD, et al. **Acta Neurochir Suppl (Wien)** 1999;72:7-26 (177 ref.)

Dural arteriovenous fistula of the cervical spine presenting with subarachnoid hemorrhage. Do HM, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):348-50 (11 ref.)

Systematic review of antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage. Roos YB, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):942-3 (8 ref.)

Subarachnoid hemorrhage caused by Aspergillus aneurysm as a complication of transcranial biopsy of an orbital apex lesion--case report. Okada Y, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):432-7 (37 ref.)

Recognizing aneurysmal subarachnoid hemorrhage [letter] Routson JL. **Nurse Pract** 1999 Apr;24(4):19-20 (9 ref.)

Ruptured anterior spinal artery aneurysm: a case report. Kawamura S, et al. **Surg Neurol** 1999 Jun;51(6):608-12 (25 ref.)

[Subarachnoid hemorrhage from ruptured aneurysms in elderly patients] Collice M. **Minerva Anestesiol** 1998 Apr; 64(4):163-5 (7 ref.) (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage of unknown origin] Infuso L. **Minerva Anestesiol** 1998 Apr;64(4):149-53 (14 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Antioxidant therapy against cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Asano T, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):31-44 (83 ref.)

NURSING

Recognizing aneurysmal subarachnoid hemorrhage [letter] Routson JL. **Nurse Pract** 1999 Apr;24(4):19-20 (9 ref.)

[Targets and prevention of complications in nursing of subarachnoid hemorrhage] De Bellis P, et al. **Minerva Anestesiol** 1998 May;64(5):247-9 (6 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Subarachnoid haemorrhage: what happens to the cerebral arteries? Sobey CG, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):867-76 (106 ref.)

Endothelin and subarachnoid hemorrhage: an overview. Zimmermann M, et al. **Neurosurgery** 1998 Oct;43(4):863-75; discussion 875-6 (150 ref.)

[Subarachnoid hemorrhage and systemic arterial pressure. Physiopathology and perioperative management] De Vivo P, et al. **Minerva Anestesiol** 1999 Mar;65(3):115-24 (66 ref.) (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage and the heart] Martorano PP, et al. **Minerva Anestesiol** 1998 May;64(5):231-3 (16 ref.) (Eng. Abstr.) **(Ita)**

[Monitoring and protection of the central nervous system in subarachnoid hemorrhage during intensive care] Stocchetti N, et al. **Minerva Anestesiol** 1998 May; 64(5):193-7 (0 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Distal posterior cerebral artery aneurysm associated with multiple aneurysms. Sawada M, et al. **Acta Neurol Scand** 1998 Sep;98(3):204-8 (33 ref.)

REHABILITATION

[Rehabilitative strategies in patients with subarachnoid hemorrhage] Mazzucchi A, et al. **Minerva Anestesiol** 1998 May;64(5):251-4 (9 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Functional outcome after aneurysmal subarachnoid hemorrhage. Hütter BO, et al. **Acta Neurochir Suppl (Wien)** 1999;72:157-74 (118 ref.)

The role of transcranial Doppler in the management of patients with subarachnoid haemorrhage--a review. Lindegaard KF. **Acta Neurochir Suppl (Wien)** 1999; 72:59-71 (107 ref.)

The case for surgery. Martin NA. **Clin Neurosurg** 1999; 45:208-17 (30 ref.)

[Early versus delayed surgery for treatment of aneurysmal subarachnoid hemorrhage] Cantore G, et al. **Minerva Anestesiol** 1998 Apr;64(4):155-8 (10 ref.) (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage and systemic arterial pressure. Physiopathology and perioperative management] De Vivo P, et al. **Minerva Anestesiol** 1999 Mar;65(3):115-24 (66 ref.) (Eng. Abstr.) **(Ita)**

[Anesthesiologic problems in candidates for delayed surgery] Montanini S, et al. **Minerva Anestesiol** 1998 Apr;64(4):181-4 (9 ref.) (Eng. Abstr.) **(Ita)**

[Therapeutic decisions and grading of subarachnoid hemorrhage] Pagni CA, et al. **Minerva Anestesiol** 1998 Apr; 64(4):159-62 (8 ref.) (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage and pregnancy] Rossi A, et al. **Minerva Anestesiol** 1998 Apr;64(4):189-91 (3 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Intracranial aneurysms and subarachnoid hemorrhage management of the poor grade patient. Le Roux PD, et al. **Acta Neurochir Suppl (Wien)** 1999;72:7-26 (177 ref.)

Neurointensive care of aneurysmal SAH. Persson L, et al. **Acta Neurochir Suppl (Wien)** 1999;72:73-80 (30 ref.)

Intensive care management of subarachnoid hemorrhage, ischemic stroke, and hemorrhagic stroke. Martin NA, et al. **Clin Neurosurg** 1999;45:101-12 (75 ref.)

Treatment of aneurysmal subarachnoid hemorrhage. Bendok BR, et al. **Semin Neurol** 1998;18(4):521-31 (70 ref.)

[Seizures associated with acute subarachnoid hemorrhage. Emergency diagnosis and treatment] Beretta L, et al. **Minerva Anestesiol** 1998 Apr;64(4):131-3 (5 ref.) (Eng. Abstr.) **(Ita)**

[Anesthesia in early surgery and endovascular therapy for aneurysmic subarachnoid hemorrhage] Levati A, et al. **Minerva Anestesiol** 1998 Apr;64(4):185-7 (8 ref.) (Eng. Abstr.) **(Ita)**

[Strategy for intensive care in patients with subarachnoid hemorrhage] Procaccio F. **Minerva Anestesiol** 1998 May; 64(5):207-8 (4 ref.) (Eng. Abstr.) **(Ita)**

[Immediate treatment of factors leading to death or sever cerebral damage in patients with subarachnoid hemorrhage] Procaccio F. **Minerva Anestesiol** 1998 Apr;64(4):127-9 (8 ref.) (Eng. Abstr.) **(Ita)**

[The management of subarachnoid hemorrhage. Ad hoc Editorial Committee of the Task Force on Cerebrovascular Diseases of SEN] Vivancos Mora J, et al. **Neurologia** 1998; 13 Suppl 3:42-52 (90 ref.) **(Spa)**

ULTRASONOGRAPHY

The role of transcranial Doppler in the management of patients with subarachnoid haemorrhage--a review. Lindegaard KF. **Acta Neurochir Suppl (Wien)** 1999; 72:59-71 (107 ref.)

[The use of TCD in intensive care and for identification of complications in subarachnoid hemorrhage] Cabrini GP. **Minerva Anestesiol** 1998 May;64(5):203-6 (10 ref.) (Eng. Abstr.) **(Ita)**

SUBARACHNOID PRESSURE see **INTRACRANIAL PRESSURE**

SUBCELLULAR FRACTIONS

CHEMISTRY

Proteome analysis. II. Protein subcellular redistribution: linking physiology to genomics via the proteome and separation technologies involved. Patton WF. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1-2):203-23 (138 ref.)

ENZYMOLOGY

Localization and possible functions of phospholipase D isozymes. Liscovitch M, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):245-63 (160 ref.)

METABOLISM

The subcellular distribution of nitric oxide synthase relative to the NR1 subunit of NMDA receptors in the cerebral cortex. Aoki C, et al. **Prog Brain Res** 1998;118:83-97 (40 ref.)

SUBCHONDRAL CYSTS see **BONE CYSTS**

SUBCLAVIAN ARTERY

Bilateral subclavian artery aneurysms with pseudocoarctation

of the aorta. Case report and review of the literature. Argotte AF, et al. **J Cardiovasc Surg (Torino)** 1998 Dec; 39(6):747-50 (27 ref.)

Subclavian artery aneurysms. A report of 2 cases and a review of the literature. Witz M, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):429-32 (25 ref.)

PTA of the subclavian and innominate arteries: long-term results. Körner M, et al. **Vasa** 1999 May;28(2):117-22 (25 ref.)

[Endovascular treatment of supra-aortic stenosing lesions] Désiron Q. **Rev Med Liege** 1998 Jul;53(7):431-6 (26 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Anomalous origin of the right vertebral artery: review of the literature and case report of right vertebral artery origin distal to the left subclavian artery. Lemke AJ, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1318-21 (10 ref.)

Dissecting aortic aneurysm involving an anomalous right subclavian artery and isolated left vertebral artery: case report and review of the literature. Nonami Y, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):743-6 (10 ref.)

SURGERY

Improvement of myocardial ischemia by subclavian stent implantation in patients with internal mammary grafts: a case report and review of the literature. Patti G, et al. **G Ital Cardiol** 1999 Apr;29(4):431-4 (13 ref.)

SUBCLAVIAN STEAL SYNDROME

NURSING

Coronary subclavian steal syndrome: implications for nursing care. Ferrara LE, et al. **Prog Cardiovasc Nurs** 1998 Fall; 13(4):24-9 (16 ref.)

SUBCLAVIAN VEIN

Upper extremity deep vein thrombosis. Prandoni P, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):222-6 (39 ref.)

The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation [editorial] Parsonnet V, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):695-7 (17 ref.)

SURGERY

[Prevention and principles of management in case of cardiac tamponade after catheterisation of the subclavian vein in parenteral nutrition] Gluszek S, et al. **Wiad Lek** 1999; 52(1-2):42-8 (16 ref.) (Eng. Abstr.) **(Pol)**

SUBCONSCIOUS see **UNCONSCIOUS (PSYCHOLOGY)**

SUBCORNEAL PUSTULAR DERMATOSIS see **SKIN DISEASES, VESICULOBULLOUS**

SUBCUTANEOUS EMPHYSEMA

ETIOLOGY

Surgical emphysema following percutaneous tracheostomy. Douglas WE, et al. **Anaesth Intensive Care** 1999 Feb; 27(1):69-72 (12 ref.)

Bilateral cervicofacial, axillary, and anterior mediastinal emphysema: a rare complication of third molar extraction. Capes JO, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):996-9 (12 ref.)

SUBDURAL EMPYEMA see **EMPYEMA, SUBDURAL**

SUBDURAL SPACE

ANATOMY & HISTOLOGY

[Does the subdural space exist?] Reina MA, et al. **Rev Esp Anestesiol Reanim** 1998 Nov;45(9):367-76 (57 ref.) (Eng. Abstr.) **(Spa)**

SUBFORNICAL ORGAN

CYTOLOGY

Vasopressin and sensory circumventricular organs. Jurzak M, et al. **Prog Brain Res** 1998;119:221-45 (181 ref.)

DRUG EFFECTS

Effect of glutamate and angiotensin II on whole cell currents and release of nitric oxide in the rat subfornical organ. Schmid HA. **Amino Acids** 1998;14(1-3):113-9 (25 ref.)

PHYSIOLOGY

Interaction of circulating hormones with the brain: the roles of the subfornical organ and the organum vasculosum of the lamina terminalis. McKinley MJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S61-7 (47 ref.)

SUBICULUM see **HIPPOCAMPUS**

SUBLIMINAL PERCEPTION see **SUBLIMINAL STIMULATION**

SUBLIMINAL STIMULATION

Unconscious processes, subliminal stimulation, and anxiety. Mayer B, et al. **Clin Psychol Rev** 1999 Aug;19(5):571-90 (92 ref.)

SUBLINGUAL REGION see **MOUTH FLOOR**

SUBMANDIBULAR GLAND

METABOLISM

Control of Na+ transport in salivary duct epithelial cells by cytosolic Cl- and Na+. Cook DI, et al. **Eur J Morphol** 1998 Aug;36 Suppl:67-73 (20 ref.)

SURGERY

Frey's syndrome following submandibular gland excision: an unusual postoperative complication. Teague A, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec; 60(6):346-8 (30 ref.)

ULTRASTRUCTURE

Comparative ultrastructure of intercalated ducts in major salivary glands: a review. Tandler B, et al. **Anat Rec** 1998 Sep;252(1):64-91 (282 ref.)

SUBMANDIBULAR GLAND DISEASES

EPIDEMIOLOGY

Complicated neonatal submandibular suppurative sialadenitis. Bafaqeeh SA. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10; 44(3):267-71 (8 ref.)

SUBMANDIBULAR GLAND NEOPLASMS

GENETICS

[Cystadenolymphoma of the salivary glands: is there a familial role?] Russo F, et al. **Ann Ital Chir** 1999 Mar-Apr; 70(2):233-7; discussion 237-8 (27 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[Papillary cystadenoma of the minor salivary glands] Mahler V, et al. **Hautarzt** 1998 Oct;49(10):784-8 (39 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Isolated submandibular gland metastasis from oral cavity squamous cell carcinoma. Vaidya AM, et al. **Am J Otolaryngol** 1999 May-Jun;20(3):172-5 (21 ref.)

SUBMARINE MEDICINE

see related
ECOLOGICAL SYSTEMS, CLOSED

SUBMARINERS see **MILITARY PERSONNEL**

SUBMAXILLARY GLAND see **SUBMANDIBULAR GLAND**

SUBSIDIES, EDUCATIONAL see **TRAINING SUPPORT**

SUBSIDIES, GOVERNMENT see **FINANCING, GOVERNMENT**

SUBSIDIES, RESEARCH see **RESEARCH SUPPORT**

SUBSTANCE ABUSE see **SUBSTANCE-RELATED DISORDERS**

SUBSTANCE ABUSE DETECTION

Drug testing as part of the war on drugs. Gerson B, et al. **Clin Lab Med** 1998 Dec;18(4):781-803, xi (9 ref.)

The role of the EAP in the identification and treatment of substance abuse. Kramer RM. **Clin Lab Med** 1998 Dec; 18(4):747-53, x (0 ref.)

[Detection of drugs of abuse] von Meyer L. **Internist (Berl)** 1999 Jun;40(6):601-4 (14 ref.) **(Ger)**

[Testing problems regarding narcotic substances in hair analysis] Kriukov VN, et al. **Sud Med Ekspert** 1999 May-Jun;42(3):18-20 (26 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Perspiration versus saliva--basic aspects concerning their use in roadside drug testing. Skopp G, et al. **Int J Legal Med** 1999;112(4):213-21 (74 ref.)

METHODS

Rapid assessment methodology: its origins, development and use by the United Nations International Drug Control Programme [editorial] **Bull Narc** 1996;48(1-2):1-10 (40 ref.)

The role of gas chromatography/mass spectrometry. Instrumental techniques in forensic urine drug testing. Lehrer M. **Clin Lab Med** 1998 Dec;18(4):631-49 (18 ref.)

Drugs of abuse testing in a psychiatric outpatient service. Shearer DS, et al. **Clin Lab Med** 1998 Dec;18(4):713-26 (100 ref.)

Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Ostrea EM Jr. **Curr Probl Pediatr** 1999 Feb;29(2):37-56 (86 ref.)

Supercritical fluid chromatography in forensic science: a critical appraisal. McAvoy Y, et al. **Forensic Sci Int** 1999 Jan 11;99(2):107-22 (27 ref.)

[New discoveries in forensic medicine. Hair analysis] Kaempe B. **Ugeskr Laeger** 1999 Mar 29;161(13):1901-5 (16 ref.) (Eng. Abstr.) **(Dan)**

STANDARDS

Drug testing [letter] Dawson RT. **Br J Sports Med** 1999 Jun; 33(3):219 (13 ref.)

SUBSTANCE ABUSE, INTRAVENOUS

Methadone: where are we now? Henry JA. **Hosp Med** 1999 Mar;60(3):161-4 (15 ref.)

COMPLICATIONS

Histologic spectrum of arterial and arteriolar lesions in acute and chronic cocaine-induced mesenteric ischemia: report of three cases and literature review. Hoang MP, et al. **Am J Surg Pathol** 1998 Nov;22(11):1404-10 (25 ref.)

Mycotic pulmonary arterial aneurysms in an intravenous drug user. McLean L, et al. **Can Respir J** 1998 Jul-Aug; 5(4):307-11 (13 ref.)

Medical consequences of substance abuse. Stein MD. **Psychiatr Clin North Am** 1999 Jun;22(2):351-70 (74 ref.)

[Hepatitis C and drug dependence] Monnat M, et al. **Rev Med Suisse Romande** 1998 Sep;118(9):755-6 (12 ref.) **(Fre)**

[Bacterial endocarditis in injection drug addicts] Gurevich MA, et al. **Klin Med (Mosk)** 1999;77(3):50-3 (36 ref.) **(Rus)**

[Valve repair in tricuspid endocarditis in the drug addict. Apropos a case] Castedo Mejuto E, et al. **Rev Esp Cardiol** 1999 Jan;52(1):67-70 (6 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Self-report among injecting drug users: a review [see comments] Darke S. **Drug Alcohol Depend** 1998 Aug 1; 51(3):253-63; discussion 267-8 (41 ref.) Comment in: Drug Alcohol Depend 1998 Aug 1;51(3):265-6.

PREVENTION & CONTROL

Needles, syringes, injection drug users, and the Oklahoma State Medical Association. Dewberry GP Jr, et al. **J Okla State Med Assoc** 1999 May;92(5):231-3 (16 ref.)

Rapid assessment, injecting drug use, and public health. Rhodes T, et al. **Lancet** 1999 Jul 3;354(9172):65-8 (32 ref.)

REHABILITATION

[Heroin-assisted treatment of opiate dependent patients. Experiences from Swiss trials for medical prescription of narcotics (PROVE)] Steffen T, et al. **Internist (Berl)** 1999 Jun;40(6):651-6 (30 ref.) **(Ger)**

SUBSTANCE ABUSE TESTING see **SUBSTANCE ABUSE DETECTION**

SUBSTANCE ABUSE TREATMENT CENTERS

ECONOMICS

Cost-effectiveness of substance abuse services. Implications for public policy. Shepard DS, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):385-400, x (14 ref.)

ORGANIZATION & ADMINISTRATION

A review of recent findings on substance abuse treatment for pregnant women. Howell EM, et al. **J Subst Abuse Treat** 1999 Apr;16(3):195-219 (128 ref.)

The substance abuse treatment system in Rhode Island: an ecological view. Marshall RJ Jr, et al. **Med Health R I** 1999 Mar;82(3):82-6 (7 ref.)

STANDARDS

Promotion of evaluation as a strategy towards an effective substance prevention. Ostaszewski K. **Eur Addict Res** 1998 Sep;4(3):128-33 (33 ref.)

SUBSTANCE DEPENDENCE see **SUBSTANCE-RELATED DISORDERS**

SUBSTANCE K RECEPTORS see **RECEPTORS, NEUROKININ-2**

SUBSTANCE P

see related
RECEPTORS, NEUROKININ-1

ANALYSIS

Peptidergic peripheral nervous systems in the mammalian pineal gland. Matsushima S, et al. **Microsc Res Tech** 1999 Aug 15-Sep 1;46(4-5):265-80 (77 ref.)

PHARMACOLOGY

Effects of substance P on cellular signalling systems in the rat anterior pituitary. Mau SE. **Dan Med Bull** 1999 Feb; 46(1):35-56 (243 ref.)

SUBSTANCE P RECEPTORS see **RECEPTORS, NEUROKININ-1**

SUBSTANCE-RELATED DISORDERS

see related
ALCOHOL-RELATED DISORDERS
DESIGNER DRUGS
DRUG AND NARCOTIC CONTROL
PSYCHOSES, ALCOHOLIC
STREET DRUGS

Manualized treatment for substance abusers with personality disorders: dual focus schema therapy. Ball SA. **Addict Behav** 1998 Nov-Dec;23(6):883-91 (30 ref.)

Course and treatment of patients with both substance use and posttraumatic stress disorders. Ouimette PC, et al. **Addict Behav** 1998 Nov-Dec;23(6):785-95 (40 ref.)

Managing anxiety and depression in alcohol and drug dependence. Scott J, et al. **Addict Behav** 1998 Nov-Dec; 23(6):919-31 (55 ref.)

Transgenic mice in drug dependence research. Pich EM, et al. **Ann Med** 1998 Aug;30(4):390-6 (46 ref.)

What perioperative nurses need to know about substance abuse. Bailes B. **AORN J** 1998 Oct;68(4):611-4, 617-22, 625-6 (50 ref.)

Role of the primary care physician in problems of substance abuse. Weaver MF, et al. **Arch Intern Med** 1999 May 10; 159(9):913-24 (47 ref.)

Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Bahrke MS, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Oct; 7(4):821-38 (91 ref.)

Recreational drugs. Current trends in the 90s. Ropero-Miller JD, et al. **Clin Lab Med** 1998 Dec;18(4):727-46, x (52 ref.)

Perinatal effects of prenatal drug exposure. Neonatal aspects. Bauer CR. **Clin Perinatol** 1999 Mar;26(1):87-106 (181 ref.)

Early development of infants exposed to drugs prenatally. Eyler FD, et al. **Clin Perinatol** 1999 Mar;26(1):107-50, vii (146 ref.)

Adolescent pregnancy and substance use. Flanagan P, et al. **Clin Perinatol** 1999 Mar;26(1):185-200 (68 ref.)

Treatment strategies for drug-exposed neonates. Kandall SR. **Clin Perinatol** 1999 Mar;26(1):231-43 (68 ref.)

Prenatal drug exposure and child outcome. Past, present, future. Smeriglio VL, et al. **Clin Perinatol** 1999 Mar; 26(1):1-16 (61 ref.)

Impact of addictive and harmful substances on fetal brain development. Ferriero DM, et al. **Curr Opin Neurol** 1999 Apr;12(2):161-6 (54 ref.)

Drug dependence: stress and dysregulation of brain reward pathways. Kreek MJ, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):23-47 (285 ref.)

Androgen abuse: the price of growth and performance. Yates SW. **Hosp Pract (Off Ed)** 1999 May 15;34(5):113-4, 119 (9 ref.)

Ten years of 'ecstasy'. Milroy CM. **J R Soc Med** 1999 Feb; 92(2):68-71 (41 ref.)

Drug addiction and dental care. Sainsbury D. **N Z Dent J** 1999 Jun;95(420):58-61 (12 ref.)

Estimated occurrence of tobacco, alcohol, and other drug use among 12- to 18-year-old students in Panama: results of Panama's 1996 National Youth Survey on Alcohol and Drug Use. González GB, et al. **Rev Panam Salud Publica** 1999 Jan;5(1):9-16 (30 ref.)

[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity] de Visme PG. **Ugeskr Laeger** 1998 Oct 12;160(42):6088-91 (40 ref.) (Eng. Abstr.) **(Dan)**

[Role of science in the formulation of social policy on drugs] Kalant H. **C R Seances Soc Biol Fil** 1998;192(5):905-15 (29 ref.) (Eng. Abstr.) **(Fre)**

[The concept of "gateway drug"] Wada K. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1999 Apr; 34(2):95-106 (27 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Antidepressants are not drugs of abuse or dependence. Lichtigfeld FJ, et al. **Postgrad Med J** 1998 Sep; 74(875):529-32 (34 ref.)

Nosology and epidemiology of addictive disorders and their comorbidity. Bucholz KK. **Psychiatr Clin North Am** 1999 Jun;22(2):221-40 (28 ref.)

COMPLICATIONS

Functional associations among trauma, PTSD, and substance-related disorders. Stewart SH, et al. **Addict Behav** 1998 Nov-Dec;23(6):797-812 (90 ref.)

Massive intracerebral hemorrhage in an amphetamine addict. Chaudhuri C, et al. **Am J Med Sci** 1999 May;317(5):350-2 (23 ref.)

Gamma-hydroxybutyric acid: an emerging recreational drug. Kam PC, et al. **Anaesthesia** 1998 Dec;53(12):1195-8 (29 ref.)

The substance-abusing parturient: implications for analgesia and anaesthesia management. Birnbach DJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Sep;12(3):443-60 (120 ref.)

Alcohol, social behavior disorders, and their cutaneous manifestations. Sanchez MR. **Clin Dermatol** 1999 Jul-Aug; 17(4):479-89 (109 ref.)

Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use? Elseviers MM, et al. **Drug Saf** 1999 Jan;20(1):15-24 (48 ref.)

Intoxication, the law and criminal responsibility--a sparkling cocktail at times: the case studies of Canada and Germany. Fischer B, et al. **Eur Addict Res** 1998 Sep;4(3):89-101 (53 ref.)

Drug policies and harms: a conceptual framework. Longshore D, et al. **Eur Addict Res** 1998 Dec;4(4):172-82 (41 ref.)

The AIDS dilemma: drug diseases blamed on a passenger virus [see comments] Duesberg P, et al. **Genetica** 1998; 104(2):85-132 (398 ref.) Comment in: Genetica 1998 ;104(2):133-42.

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Green AI, et al. **Harv Rev Psychiatry** 1999 Mar-Apr;6(6):287-96 (94 ref.)

The effect of comorbid substance use disorders on the course of bipolar disorder: a review. Tohen M, et al. **Harv Rev Psychiatry** 1998 Sep-Oct;6(3):133-41 (72 ref.)

Toxic keratopathy. DeRosa AJ. **Int Ophthalmol Clin** 1998 Fall;38(4):15-22 (57 ref.)

Mental illness and substance abuse: implications for women's health and health care access. Reed BG, et al. **J Am Med Womens Assoc** 1999 Spring;54(2):71-8 (171 ref.)

Substance abuse: infant and childhood outcomes. D'Apolito K. **J Pediatr Nurs** 1998 Oct;13(5):307-16 (92 ref.)

Drug abusers who die during arrest or in custody. Karch SB, et al. **J R Soc Med** 1999 Mar;92(3):110-3 (40 ref.)

Smoking intervention with adolescent substance abusers. Initial recommendations. Myers MG. **J Subst Abuse Treat** 1999 Jun;16(4):289-98 (59 ref.)

Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Dixon L. **Schizophr Res** 1999 Mar 1;35 Suppl:S93-100 (36 ref.)

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Krystal JH, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S35-49 (128 ref.)

[The practitioner and reduction of risks] Leckie M. **Rev Med Suisse Romande** 1998 Sep;118(9):739-42 (12 ref.) **(Fre)**

[Cardiorespiratory disorders in drug addiction] Kochetkova EA, et al. **Ter Arkh** 1998;70(12):84-7 (81 ref.) **(Rus)**

[Congenital defects and drugs of noninstitutional use (editorial; comment] Villalbi JR. **Med Clin (Barc)** 1999 Jan 23;112(2):57-8 (24 ref.) Comment on: Med Clin (Barc) 1999 Jan 23;112(2):41-4. **(Spa)**

DIAGNOSIS

Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Schweizer E, et al. **Acta Psychiatr Scand Suppl** 1998;393:95-101 (39 ref.)

Severe mental illness and addictions: assessment considerations. Carey KB, et al. **Addict Behav** 1998 Nov-Dec;23(6):735-48 (70 ref.)

Drug abuse headache: recognition and management. Antonaci F. **Cephalalgia** 1998 Aug;18 Suppl 22:47-52; discussion 52-5 (43 ref.)

The role of the EAP in the identification and treatment of substance abuse. Kramer RM. **Clin Lab Med** 1998 Dec; 18(4):747-53, x (0 ref.)

Critical issues in adolescent substance use assessment. Meyers K, et al. **Drug Alcohol Depend** 1999 Jul 1;55(3):235-46 (95 ref.)

Methods used to detect drug abuse in pregnancy: a brief review. Strano-Rossi S. **Drug Alcohol Depend** 1999 Feb 1;53(3):257-71 (98 ref.)

Research on chronic, low-level exposure to formaldehyde: implications for neuropsychological assessment. Williams CW, et al. **J Clin Psychol** 1998 Oct;54(6):851-62 (90 ref.)

Psychotropic medication management in persons with co-occurring psychiatric and substance use disorders. Sowers W, et al. **J Psychoactive Drugs** 1999 Jan-Mar; 31(1):59-70 (57 ref.)

Over-the-counter stimulants: abuse and addiction. Tinsley JA, et al. **Mayo Clin Proc** 1998 Oct;73(10):977-82 (36 ref.)

Frequently missed diagnoses in adolescent psychiatry. Berenson CK. **Psychiatr Clin North Am** 1998 Dec; 21(4):917-26, viii (37 ref.)

Substance use disorders. Difficulties in diagnoses. Ross SM, et al. **Psychiatr Clin North Am** 1998 Dec;21(4):803-28 (37 ref.)

Diagnostic evaluation of alcohol and drug abuse problems in women. Mendelson JH, et al. **Psychopharmacol Bull** 1998;34(3):279-81 (39 ref.)

Illicit substance use among adolescents: a matrix of prospective predictors. Petraitis J, et al. **Subst Use Misuse** 1998 Nov;33(13):2561-604 (67 ref.)

[Diagnosis of drug dependence] Backmund M. **Internist (Berl)** 1999 Jun;40(6):597-600 (30 ref.) **(Ger)**

[Poisoning with amphetamines and designer drugs] Felgenhauer N, et al. **Internist (Berl)** 1999 Jun;40(6):617-23 (50 ref.) **(Ger)**

[Pharmacology of drugs of abuse] Haen E, et al. **Internist (Berl)** 1999 Jun;40(6):605-10 (7 ref.) **(Ger)**

[Detection of drugs of abuse] von Meyer L. **Internist (Berl)** 1999 Jun;40(6):601-4 (14 ref.) **(Ger)**

[Polyneuropathy and encephalopathy caused by organic solvents and mixed solvent solutions. Occupational medicine and neurologic aspects of a new occupational disease] Triebig G, et al. **Nervenarzt** 1999 Apr;70(4):306-14 (59 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Outpatient detoxification of the addicted or alcoholic patient. Prater CD, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1175-83 (29 ref.)

Novel benztropine [3a-(diphenylmethoxy)tropane] analogs as probes for the dopamine transporter. Newman AH, et al. **Curr Med Chem** 1998 Aug;5(4):305-19 (55 ref.)

Rational treatment of addiction. Terenius L. **Curr Opin Chem Biol** 1998 Aug;2(4):541-7 (62 ref.)

The effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka J. **J Clin Psychiatry** 1999;60 Suppl 12:43-6 (25 ref.)

Depression and stimulant dependence: neurobiology and pharmacotherapy. Kosten TR, et al. **J Nerv Ment Dis** 1998 Dec;186(12):737-45 (129 ref.)

Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings. Litten RZ, et al. **J Subst Abuse Treat** 1999 Mar;16(2):105-12 (57 ref.)

Pharmacologic treatments for drug and alcohol dependence. Kranzler HR, et al. **Psychiatr Clin North Am** 1999 Jun; 22(2):401-23 (43 ref.)

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Krystal JH, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S35-49 (128 ref.)

[Substitution therapy of drug addicts] Weber JC, et al. **Presse Med** 1998 Dec 12;27(39):2088-99 (108 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

An expensive policy: the impact of inadequate funding for substance abuse treatment [editorial] Amaro H. **Am J Public Health** 1999 May;89(5):657-9 (32 ref.)

Economic costs of substance abuse, 1995. Rice DP. **Proc Assoc Am Physicians** 1999 Mar-Apr;111(2):119-25 (26 ref.)

Cost-effectiveness of substance abuse services. Implications for public policy. Shepard DS, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):385-400, x (14 ref.)

A review of literature on drug use in Sub-Saharan Africa countries and its economic and social implications. Affinnih YH. **Subst Use Misuse** 1999 Feb;34(3):443-54 (25 ref.)

EPIDEMIOLOGY

Are sleep disturbances risk factors for anxiety, depressive and addictive disorders? Gillin JC. **Acta Psychiatr Scand Suppl** 1998;393:39-43 (9 ref.)

Adolescent tobacco, alcohol, and drug use: current findings. Windle M, et al. **Adolesc Med** 1999 Feb;10(1):153-63, vii (37 ref.)

Women, violence with intimates, and substance abuse: relevant theory, empirical findings, and recommendations for future research. Hien D, et al. **Am J Drug Alcohol Abuse** 1998 Aug;24(3):419-38 (79 ref.)

Psychotropic drugs used in anesthesia practice: abuse liability and epidemiology of abuse. Zacny JP, et al. **Anesthesiology** 1999 Jan;90(1):269-88 (309 ref.)

A review of comorbidity: major mental illness and problematic substance use. Siegfried N. **Aust N Z J Psychiatry** 1998 Oct;32(5):707-17 (69 ref.)

Rapid assessment methodology: its origins, development and use by the United Nations International Drug Control Programme [editorial] **Bull Narc** 1996;48(1-2):1-10 (40 ref.)

Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Sellers EM, et al. **Can J Clin Pharmacol** 1999 Spring;6(1):18-25 (56 ref.)

Demographic and psychosocial characteristics of substance-abusing pregnant women. Hans SL. **Clin Perinatol** 1999 Mar;26(1):55-74 (131 ref.)

Recent patterns of use and associated risks of illicit drug use in adolescents. Bravender T, et al. **Curr Opin Pediatr** 1998 Aug;10(4):344-9 (49 ref.)

Epidemiology of substance use in adolescence: prevalence, trends and policy implications. Bauman A, et al. **Drug Alcohol Depend** 1999 Jul 1;55(3):187-207 (116 ref.)

Individual risk factors for adolescent substance use. Swadi H. **Drug Alcohol Depend** 1999 Jul 1;55(3):209-24 (154 ref.)

Psychiatric comorbidity with substance misuse in children and teenagers. Zeitlin H. **Drug Alcohol Depend** 1999 Jul 1;55(3):225-34 (51 ref.)

Domestic violence and substance abuse. Bhatt RV. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S25-31 (17 ref.)

Comorbidity. Angold A, et al.

J Child Psychol Psychiatry 1999 Jan;40(1):57–87 (276 ref.)
Suicide attempts in major affective disorder patients with comorbid substance use disorders. Tondo L, et al. **J Clin Psychiatry** 1999;60 Suppl 2:63–9; discussion 75–6, 113–6 (60 ref.)
Depression and stimulant dependence: neurobiology and pharmacotherapy. Kosten TR, et al. **J Nerv Ment Dis** 1998 Dec;186(12):737–45 (129 ref.)
Children of substance abusers: overview of research findings. Johnson JL, et al. **Pediatrics** 1999 May;103(5 Pt 2):1085–99 (202 ref.)
Mortality and morbidity attributable to use of addictive substances in the United States. McGinnis JM, et al. **Proc Assoc Am Physicians** 1999 Mar–Apr;111(2):109–18 (84 ref.)
Gender differences in substance use disorders. Brady KT, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):241–52 (51 ref.)
Nosology and epidemiology of addictive disorders and their comorbidity. Bucholz KK. **Psychiatr Clin North Am** 1999 Jun;22(2):221–40 (28 ref.)
Overview of psychiatric comorbidity. Practical and theoretic considerations. Goldsmith RJ. **Psychiatr Clin North Am** 1999 Jun;22(2):331–49, ix (43 ref.)
Addictive disorders in adolescents. Kaminer Y. **Psychiatr Clin North Am** 1999 Jun;22(2):275–88 (37 ref.)
Juvenile violence. Scott CL. **Psychiatr Clin North Am** 1999 Mar;22(1):71–83 (76 ref.)
The role of cultural and social factors in the cause of addictive disorders. Westermeyer J. **Psychiatr Clin North Am** 1999 Jun;22(2):253–73 (66 ref.)
Complications of severe mental illness related to alcohol and drug use disorders. Drake RE, et al. **Recent Dev Alcohol** 1998;14:285–99 (127 ref.)
Epidemiological methods for research with drug misusers: review of methods for studying prevalence and morbidity. Dunn J, et al. **Rev Saude Publica** 1999 Apr;33(2):206–15 (52 ref.)
A review of literature on drug use in Sub-Saharan Africa countries and its economic and social implications. Affinnih YH. **Subst Use Misuse** 1999 Feb;34(3):443–54 (25 ref.)
[Drug abuse in Japan] Matsumura Y. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1998 Oct; 33(5):597–602 (8 ref.) **(Jpn)**
[The current status of drug abuse and dependence in Japan] Wada K. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1998 Oct;33(5):587–96 (1 ref.) **(Jpn)**
[AIDS and tuberculosis in the light of spreading drug abuse] Volkova KI, et al. **Klin Med (Mosk)** 1999;77(2):7–12 (68 ref.) **(Rus)**
[The evaluation of the drug situation: the need for a comprehensive and rigorous information strategy (editorial; comment)] Vicente J. **Gac Sanit** 1999 Mar–Apr;13(2):79–81 (20 ref.) Comment on: Gac Sanit 1999 Mar–Apr;13(2):82–7. Comment on: Gac Sanit 1999 Mar–Apr;13(2):88–95. Comment on: Gac Sanit 1999 Mar–Apr;13(2):96–101. Comment on: Gac Sanit 1999 Mar–Apr;13(2):109–18. Comment on: Gac Sanit 1999 Mar–Apr;13(2):126–34. **(Spa)**

ETHNOLOGY

The social ecology of addiction: race, risk, and resilience. Wallace JM Jr. **Pediatrics** 1999 May;103(5 Pt 2):1122–7 (41 ref.)
Primary socialization theory: culture, ethnicity, and cultural identification. The links between culture and substance use. IV. Oetting ER, et al. **Subst Use Misuse** 1998 Aug; 33(10):2075–107 (60 ref.)

ETIOLOGY

Dual diagnosis: a review of etiological theories. Mueser KT, et al. **Addict Behav** 1998 Nov–Dec;23(6):717–34 (163 ref.)
Recent patterns of use and associated risks of illicit drug use in adolescents. Bravender T, et al. **Curr Opin Pediatr** 1998 Aug;10(4):344–9 (49 ref.)
Drug addiction as dopamine-dependent associative learning disorder. Di Chiara G. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):13–30 (140 ref.)
Psychopathology as risk for adolescent substance use disorders: a developmental psychopathology perspective. Cicchetti D, et al. **J Clin Child Psychol** 1999 Sep; 28(3):355–65 (49 ref.)
Child psychopathology risk factors for drug abuse: overview. Weinberg NZ, et al. **J Clin Child Psychol** 1999 Sep; 28(3):290–7 (49 ref.)
Over-the-counter stimulants: abuse and addiction. Tinsley JA, et al. **Mayo Clin Proc** 1998 Oct;73(10):977–82 (36 ref.)
Pharmacology versus social process: competing or complementary views on the nature of addiction? Davies JB. **Pharmacol Ther** 1998 Dec;80(3):265–75 (40 ref.)
The role of cultural and social factors in the cause of addictive disorders. Westermeyer J. **Psychiatr Clin North Am** 1999 Jun;22(2):253–73 (66 ref.)
Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship to addiction and abdiction. Miller CS. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):284–94 (39 ref.)
Evolutionary game theory and multiple chemical sensitivity. Newlin DB. **Toxicol Ind Health** 1999 Apr-Jun; 15(3–4):313–22 (56 ref.)
Multiple chemical sensitivity as a conditional response. Siegel S. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):323–30 (71 ref.)
Ethanol tolerance and synaptic plasticity. Chandler LJ, et al. **Trends Pharmacol Sci** 1998 Dec;19(12):491–5 (48 ref.)
[Addiction: from the drug to the individual] Piazza V. **Rev Med Suisse Romande** 1998 Sep;118(9):735–7 (11 ref.) **(Fre)**
[Central stimulants in adults with AD/HD. Can they be abused? (see comments)] Lie N. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4227–9 (25 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1999 Jan 10;119(1):82–3. **(Nor)**
[Is caffeine addictive? The most widely used psychoactive substance in the world affects same parts of the brain as cocaine] Daly JW, et al. **Lakartidningen** 1998 Dec 16; 95(51–52):5878–83 (41 ref.) (Eng. Abstr.) **(Swe)**
[High risk for children with DAMP/ADHD to become addicts later in life] Modigh K, et al. **Lakartidningen** 1998 Nov 18;95(47):5316–9 (53 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Genetic studies of alcoholism and substance dependence. Reich T, et al. **Am J Hum Genet** 1999 Sep;65(3):599–605 (45 ref.)
Molecular genetics of substance abuse vulnerability: a current approach. Uhl GR. **Neuropsychopharmacology** 1999 Jan; 20(1):3–9 (35 ref.)
Genetics of alcoholism and substance abuse. Enoch MA, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):289–99, viii (34 ref.)
Identifying genes for alcohol and drug sensitivity: recent progress and future directions. Crabbe JC, et al. **Trends Neurosci** 1999 Apr;22(4):173–9 (72 ref.)

METABOLISM

G protein–coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Roth BL, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):73–85 (152 ref.)

MORTALITY

Substance abuse and drug-related death, suicidal ideation, and suicide: a review. Mino A, et al. **Crisis** 1999;20(1):28–35 (52 ref.)
Mortality and morbidity attributable to use of addictive substances in the United States. McGinnis JM, et al. **Proc Assoc Am Physicians** 1999 Mar–Apr;111(2):109–18 (84 ref.)

PATHOLOGY

[Current problems in the morphological diagnosis of somatic disorders in drug addictions] Sherstiuk BV, et al. **Sud Med Ekspert** 1999 Mar–Apr;42(2):29–32 (66 ref.) **(Rus)**

PHYSIOPATHOLOGY

Role of the limbic system in dependence on drugs. Rodriguez de Fonseca F, et al. **Ann Med** 1998 Aug;30(4):397–405 (87 ref.)
Neural substrates of drug craving and relapse in drug addiction. Self DW. **Ann Med** 1998 Aug;30(4):379–89 (93 ref.)
Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Di Chiara G, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:461–85 (96 ref.)
Associative processes in addiction and reward. The role of amygdala–ventral striatal subsystems. Everitt BJ, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:412–38 (126 ref.)
A multicomponent learning model of drug abuse. Drug taking and craving may involve separate brain circuits underlying instrumental and classical conditioning, respectively. Haracz JL, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:811–9 (74 ref.)
The role of the striatopallidal and extended amygdala systems in drug addiction. Koob GF. **Ann N Y Acad Sci** 1999 Jun 29;877:445–60 (85 ref.)
Maternal and obstetric effects of prenatal drug exposure. Bishai R, et al. **Clin Perinatol** 1999 Mar;26(1):75–86, vii (65 ref.)
Neural basis of inhalant abuse. Balster RL. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):207–14 (87 ref.)
Caffeine—an atypical drug of dependence. Daly JW, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):199–206 (63 ref.)
Alcohol and benzodiazepines: recent mechanistic studies. Harris RA, et al. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):155–64 (105 ref.)
Relapse to drug-seeking: neural and molecular mechanisms. Self DW, et al. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):49–60 (135 ref.)
Drug-activation of brain reward pathways. Wise RA. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):13–22 (121 ref.)
Mapping of functional changes associated with administration of substances of abuse in the rat. Pontieri FE, et al. **Funct Neurol** 1998 Oct–Dec;13(4):311–26 (82 ref.)
Neuroscience of addiction. Koob GF, et al. **Neuron** 1998 Sep;21(3):467–76 (86 ref.)
Opioids, reward and addiction: An encounter of biology, psychology, and medicine. van Ree JM, et al. **Pharmacol Rev** 1999 Jun;51(2):341–96 (740 ref.)
Drugs of abuse and the brain. Leshner AI, et al. **Proc Assoc Am Physicians** 1999 Mar–Apr;111(2):99–108 (83 ref.)
Gender differences in substance use disorders. Brady KT, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):241–52 (51 ref.)
Oxytocin and addiction: a review. Kovács GL, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):945–62 (66 ref.)

PREVENTION & CONTROL

Substance abuse studies and prevention efforts among Arabs in the 1990s in Israel, Jordan and the Palestinian Authority—a literature review. Weiss S, et al. **Addiction** 1999 Feb;94(2):177–98 (86 ref.)
Innovations in adolescent substance abuse intervention. Wagner EF, et al. **Alcohol Clin Exp Res** 1999 Feb; 23(2):236–49 (67 ref.)
An expensive policy: the impact of inadequate funding for substance abuse treatment [editorial] Amaro H. **Am J Public Health** 1999 May;89(5):657–9 (32 ref.)
Social, community, and preventive interventions. Reppucci ND, et al. **Annu Rev Psychol** 1999;50:387–418 (192 ref.)
Substance abuse in children: prediction, protection, and prevention [see comments] Belcher HM, et al. **Arch Pediatr Adolesc Med** 1998 Oct;152(10):952–60 (113 ref.) Comment in: Arch Pediatr Adolesc Med 1998 Oct;152(10):943–4. Comment in: Arch Pediatr Adolesc Med 1999 Mar;153(3):313.
Drug testing as part of the war on drugs. Gerson B, et al. **Clin Lab Med** 1998 Dec;18(4):781–803, xi (9 ref.)
Psychoactive substance use (drug abuse) and a resource-oriented strategy to confront it in the eastern Mediterranean region. Mohit A. **East Mediterr Health J** 1998;4 Suppl:S149–64 (13 ref.)
Addiction, intoxication, criminal law and criminal justice: an introduction. Albrecht H. **Eur Addict Res** 1998 Sep; 4(3):85–8 (13 ref.)
Recent changes in Danish law on drugs and drug offences. Jepsen J, et al. **Eur Addict Res** 1998 Sep;4(3):113–27 (18 ref.)
Promotion of evaluation as a strategy towards an effective substance prevention. Ostaszewski K. **Eur Addict Res** 1998 Sep;4(3):128–33 (33 ref.)
A systematic review of vinpocetine therapy in acute ischaemic stroke. Bereczki D, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):349–52 (30 ref.)
Defining peer education. Shiner M. **J Adolesc** 1999 Aug; 22(4):555–66 (37 ref.)
The physician's role in preventing alcohol and drug abuse. Dube C. **Med Health R I** 1999 Mar;82(3):95–8 (21 ref.)
Disease, drugs and alcohol induced driving impairment: the law and the medicine. Marks P. **Med Leg J** 1998;66 (Pt 3):109–15 (27 ref.)
Outcome measures of interventions in the study of children of substance-abusing parents. Kumpfer KL. **Pediatrics** 1999 May;103(5 Pt 2):1128–44 (112 ref.)
Screening, early identification, and office-based intervention with children and youth living in substance-abusing families. Werner MJ, et al. **Pediatrics** 1999 May;103(5 Pt 2):1099–112 (53 ref.)
Preventing problems from psychoactive substance use. Room R. **Proc Assoc Am Physicians** 1999 Mar–Apr;111(2):141–7 (30 ref.)
Drug prohibition and public health: 25 years of evidence [see comments] Drucker E. **Public Health Rep** 1999 Jan–Feb;114(1):14–29 (55 ref.) Comment in: Public Health Rep 1999 Mar–Apr;114(2):99–100.
[The practitioner and reduction of risks] Leckie M. **Rev Med Suisse Romande** 1998 Sep;118(9):739–42 (12 ref.) **(Fre)**
[Secondary prevention: an approach to improve the German drug abuse prevention system] Schmidt B, et al. **Gesundheitswesen** 1999 Mar;61(3):130–6 (58 ref.) (Eng. Abstr.) **(Ger)**
[Substance dependence is easier to prevent than to treat. But is early identification of individuals at risk and aimed prevention ethically justified?] Heilig M. **Lakartidningen** 1999 Apr 14;96(15):1796–801 (25 ref.) **(Swe)**

PSYCHOLOGY

Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Di Chiara G, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:461–85 (96 ref.)
Associative processes in addiction and reward. The role of amygdala–ventral striatal subsystems. Everitt BJ, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:412–38 (126 ref.)
A multicomponent learning model of drug abuse. Drug taking and craving may involve separate brain circuits underlying instrumental and classical conditioning, respectively. Haracz JL, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:811–9 (74 ref.)
Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers [see comments] Fischman MW, et al. **Behav Pharmacol** 1998 Nov;9(7):479–98 (19 ref.) Comment in: Behav Pharmacol 1998 Nov;9(7):499–501. Comment in: Behav Pharmacol 1998 Nov;9(7):503–7.
Methods used to detect drug abuse in pregnancy: a brief review. Strano-Rossi S. **Drug Alcohol Depend** 1999 Feb

1;53(3):257-71 (98 ref.)
Intoxication, the law and criminal responsibility--a sparkling cocktail at times: the case studies of Canada and Germany. Fischer B, et al. **Eur Addict Res** 1998 Sep;4(3):89-101 (53 ref.)
Are we dependent upon coffee and caffeine? A review on human and animal data. Nehlig A. **Neurosci Biobehav Rev** 1999 Mar;23(4):563-76 (200 ref.)
Opioids, reward and addiction: An encounter of biology, psychology, and medicine. van Ree JM, et al. **Pharmacol Rev** 1999 Jun;51(2):341-96 (740 ref.)
Pharmacology versus social process: competing or complementary views on the nature of addiction? Davies JB. **Pharmacol Ther** 1998 Dec;80(3):265-75 (40 ref.)
Addiction to benzodiazepines. Salzman C. **Psychiatr Q** 1998 Winter;69(4):251-61 (28 ref.)
Stressful life events and adolescent substance use and depression: conditional and gender differentiated effects. Hoffmann JP, et al. **Subst Use Misuse** 1998 Sep; 33(11):2219-62 (120 ref.)
Pathological gambling and substance misuse: a review of the literature. Spunt B, et al. **Subst Use Misuse** 1998 Nov; 33(13):2535-60 (67 ref.)
[Addiction: from the drug to the individual] Piazza V. **Rev Med Suisse Romande** 1998 Sep;118(9):735-7 (11 ref.) **(Fre)**
[Psychiatric definition of addiction. Habituation, abuse and dependence] Soyka M. **Internist (Berl)** 1999 Jun;40(6):590-6 (33 ref.) **(Ger)**
[Psychological and social etiology of drug dependence] Türk D, et al. **Internist (Berl)** 1999 Jun;40(6):583-9 (52 ref.) **(Ger)**
[Substance abuse and dependence in adolescents] Essau CA, et al. **Prax Kinderpsychol Kinderpsychiatr** 1998 Dec; 47(10):754-66 (50 ref.) (Eng. Abstr.) **(Ger)**
[Alcohol and drug use among medical students 1995: more than every tenth male student had hazardous alcohol drinking habits] Borschos B, et al. **Lakartidningen** 1999 Jul 14;96(28-29):3253-8 (18 ref.) (Eng. Abstr.) **(Swe)**

RADIONUCLIDE IMAGING

Addiction and imaging of the living human brain. Gatley SJ, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):97-108 (113 ref.)

REHABILITATION

The relationship between substance use disorders, impulse control disorders, and pathological aggression. Brady KT, et al. **Am J Addict** 1998 Summer;7(3):221-30 (82 ref.)
Treatment of comorbid affective and substance use disorders. Therapeutic potential of anticonvulsants. Donovan SJ, et al. **Am J Addict** 1998 Summer;7(3):210-20 (70 ref.)
The pharmacotherapy of relapse prevention using anticonvulsants. Kosten TR. **Am J Addict** 1998 Summer; 7(3):205-9 (21 ref.)
Use of anticonvulsants in benzodiazepine withdrawal. Pages KP, et al. **Am J Addict** 1998 Summer;7(3):198-204 (52 ref.)
Impaired doctors. The modern approach of medical boards. Breen KJ, et al. **Aust Fam Physician** 1998 Nov; 27(11):1005-8 (0 ref.)
Treatment interventions-looking towards the millennium. Crome IB. **Drug Alcohol Depend** 1999 Jul 1;55(3):247-63 (182 ref.)
A stage of change approach to addiction in the medical setting. Peteet JR, et al. **Gen Hosp Psychiatry** 1998 Sep; 20(5):267-73 (13 ref.)
Studies of factors in relapse to alcohol, drug and nicotine use: a critical review of methodologies and findings. McKay JR. **J Stud Alcohol** 1999 Jul;60(4):566-76 (70 ref.)
Work dysfunction and addiction. Common roots. Comerford AW. **J Subst Abuse Treat** 1999 Apr;16(3):247-53 (64 ref.)
Addressing trauma in substance abuse treatment with American Indian adolescents. Gray N. **J Subst Abuse Treat** 1998 Sep-Oct;15(5):393-9 (42 ref.)
Drug abuse and incarcerated women. A research review. Henderson DJ. **J Subst Abuse Treat** 1998 Nov-Dec; 15(6):579-87 (100 ref.)
A review of recent findings on substance abuse treatment for pregnant women. Howell EM, et al. **J Subst Abuse Treat** 1999 Apr;16(3):195-219 (128 ref.)
Reflections on volatile substance dependency treatment. Negotiating the boundary between inner and outer reality. McCartney J. **J Subst Abuse Treat** 1999 Apr;16(3):255-64 (36 ref.)
Treating substance abuse among patients with schizophrenia. Bellack AS, et al. **Psychiatr Serv** 1999 Jan;50(1):75-80 (57 ref.)
Smoking cessation treatment for substance misusers in early recovery: a review of the literature and recommendations for practice. Kalman D. **Subst Use Misuse** 1998 Aug; 33(10):2021-47 (120 ref.)
The relevance of problems and models to treatment outcome: a comparative study of two agencies. Keene J, et al. **Subst Use Misuse** 1999 Aug;34(10):1347-69 (30 ref.)
[Drug substitution from the legal viewpoint] Joachimski J. **Internist (Berl)** 1999 Jun;40(6):640-4 (0 ref.) **(Ger)**
[Drug withdrawal therapies] Ladewig D, et al. **Internist (Berl)** 1999 Jun;40(6):624-7 (16 ref.) **(Ger)**
[Principles of withdrawal from illicit drugs during inpatient therapy] Singer W, et al. **Internist (Berl)** 1999 Jun; 40(6):634-9 (21 ref.) **(Ger)**
[Principles of ambulatory drug withdrawal treatment] Waldmann H, et al. **Internist (Berl)** 1999 Jun;40(6):628-33 (11 ref.) **(Ger)**
[Drug interactions of methadone with CNS-active agents] Moreno Brea MR, et al. **Actas Esp Psiquiatr** 1999 Mar-Apr; 27(2):103-10 (61 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Substance abuse treatment for people with schizophrenia. Bellack AS, et al. **Addict Behav** 1998 Nov-Dec; 23(6):749-66 (94 ref.)
The role of the EAP in the identification and treatment of substance abuse. Kramer RM. **Clin Lab Med** 1998 Dec; 18(4):747-53, x (0 ref.)
Behavioral couples treatment of alcohol and drug use disorders: current status and innovations. Epstein EE, et al. **Clin Psychol Rev** 1998 Sep;18(6):689-711 (123 ref.)
The design and effectiveness of therapeutic community research in Europe: an overview. Broekaert E, et al. **Eur Addict Res** 1999 Mar;5(1):21-35 (62 ref.)
The pregnant addict: treat or prosecute? Implications for midwifery management. Stephany TM. **J Nurse Midwifery** 1999 Mar-Apr;44(2):154-6 (27 ref.)
Smoking intervention with adolescent substance abusers. Initial recommendations. Myers MG. **J Subst Abuse Treat** 1999 Jun;16(4):289-98 (59 ref.)
Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. Triffleman E, et al. **J Subst Abuse Treat** 1999 Jul-Sep;17(1-2):3-14 (91 ref.)
Science, policy, and the future of substance abuse treatment in Rhode Island. Knapp S, et al. **Med Health R I** 1999 Mar;82(3):78-80 (10 ref.)
The substance abuse treatment system in Rhode Island: an ecological view. Marshall RJ Jr, et al. **Med Health R I** 1999 Mar;82(3):82-6 (7 ref.)
Treatment for drug dependence. Des Jarlais DC, et al. **Proc Assoc Am Physicians** 1999 Mar-Apr;111(2):126-30 (10 ref.)
Cost-effectiveness of substance abuse services. Implications for public policy. Shepard DS, et al. **Psychiatr Clin North Am** 1999 Jun;22(2):385-400, x (14 ref.)
Common myths and misconceptions in the treatment of addicted women. **Rep Group Adv Psychiatry** 1998; (142):137-56 (53 ref.)
Review of integrated mental health and substance abuse treatment for patients with dual disorders. Drake RE, et al. **Schizophr Bull** 1998;24(4):589-608 (119 ref.)
Drug use--chronic and relapsing or a treatable condition? Brown BS. **Subst Use Misuse** 1998 Oct;33(12):2515-20 (11 ref.)
[The drug emergency] Vollenweider-Scherpenhuyzen MF, et al. **Anaesthesist** 1998 Nov;47(11):946-55 (16 ref.) **(Ger)**
[Treatment system for drug-dependence syndrome] Konuma K. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1998 Oct; 33(5):603-12 (8 ref.) **(Jpn)**

VIROLOGY

Substance abuse and HIV-gp120: are opiates protective? Stefano GB. **Arch Immunol Ther Exp (Warsz)** 1999; 47(2):99-106 (101 ref.)

SUBSTANCE USE DISORDERS see **SUBSTANCE-RELATED DISORDERS**

SUBSTANCE WITHDRAWAL, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

SUBSTANCE WITHDRAWAL SYNDROME

[Antiandrogen withdrawal syndrome] Akimoto S. **Nippon Rinsho** 1998 Aug;56(8):2135-9 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Schweizer E, et al. **Acta Psychiatr Scand Suppl** 1998;393:95-101 (39 ref.)
Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Ostrea EM Jr. **Curr Probl Pediatr** 1999 Feb;29(2):37-56 (86 ref.)
Extended antidepressant maintenance and discontinuation syndromes. Maixner SM, et al. **Depress Anxiety** 1998;8 Suppl 1:43-53 (98 ref.)
[Drug withdrawal therapies] Ladewig D, et al. **Internist (Berl)** 1999 Jun;40(6):624-7 (16 ref.) **(Ger)**

DRUG THERAPY

Benzodiazepine treatment for alcohol-dependent patients. Lejoyeux M, et al. **Alcohol Alcohol** 1998 Nov-Dec; 33(6):563-75 (45 ref.)
Phenobarbital for alcohol withdrawal syndrome. Rodgers JE, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):175-8 (18 ref.)
Extended antidepressant maintenance and discontinuation syndromes. Maixner SM, et al. **Depress Anxiety** 1998;8 Suppl 1:43-53 (98 ref.)
Managing alcohol withdrawal in the elderly. Kraemer KL, et al. **Drugs Aging** 1999 Jun;14(6):409-25 (177 ref.)

ETIOLOGY

Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini RJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:77-84; discussion 111-6 (58 ref.)
Neuroleptic discontinuation syndromes. Tranter R, et al. **J Psychopharmacol** 1998;12(4):401-6 (40 ref.)

PREVENTION & CONTROL

Alcohol withdrawal in the surgical patient: prevention and treatment. Spies CD, et al. **Anesth Analg** 1999 Apr; 88(4):946-54 (86 ref.)

REHABILITATION

Use of anticonvulsants in benzodiazepine withdrawal. Pages KP, et al. **Am J Addict** 1998 Summer;7(3):198-204 (52 ref.)
[Drug substitution from the legal viewpoint] Joachimski J. **Internist (Berl)** 1999 Jun;40(6):640-4 (0 ref.) **(Ger)**
[Principles of withdrawal from illicit drugs during inpatient therapy] Singer W, et al. **Internist (Berl)** 1999 Jun; 40(6):634-9 (21 ref.) **(Ger)**

THERAPY

Alcohol withdrawal in the surgical patient: prevention and treatment. Spies CD, et al. **Anesth Analg** 1999 Apr; 88(4):946-54 (86 ref.)
[Progress in the researches on traditional Chinese medicine in the treatment of abstinence syndrome] Li GX. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jul; 17(7):446-8 (23 ref.) **(Chi)**

SUBSTANTIA GELATINOSA

PHYSIOPATHOLOGY

Second messengers, the substantia gelatinosa and injury-induced persistent pain. Petersen-Zeitz KR, et al. **Pain** 1999 Aug;Suppl 6:S5-12 (87 ref.)

SUBSTANTIA INNOMINATA

DRUG EFFECTS

C-fos expression in the rat nucleus basalis upon excitotoxic lesion with quisqualic acid: a study in adult and aged animals. Giovannelli L, et al. **J Neural Transm** 1998; 105(8-9):935-48 (29 ref.)

METABOLISM

C-fos expression in the rat nucleus basalis upon excitotoxic lesion with quisqualic acid: a study in adult and aged animals. Giovannelli L, et al. **J Neural Transm** 1998; 105(8-9):935-48 (29 ref.)

PATHOLOGY

Morphological, biochemical and behavioural changes induced by neurotoxic and inflammatory insults to the nucleus basalis. Casamenti F, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):705-14 (67 ref.)

PHYSIOLOGY

Some cholinergic themes related to Alzheimer's disease. synaptology of the nucleus basalis, location of m2 receptors, interactions with amyloid metabolism, and perturbations of cortical plasticity. Mesulam MM. **J Physiol Paris** 1998 Jun-Aug;92(3-4):293-8 (56 ref.)
[Role of nucleus basalis magnocellularis cholinergic neuron in cognition] Guan BX, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):338-40 (10 ref.) **(Chi)**

SUBSTANTIA NIGRA

PATHOLOGY

[Pallido-nigro-luysial atrophy] Hasegawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):78-81 (6 ref.) **(Jpn)**

SUBTALAR JOINT

SURGERY

Triple arthrodesis and subtalar joint arthrodesis. For the treatment of end-stage posterior tibial tendon dysfunction. Laughlin TJ, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):527-55 (50 ref.)
Bilateral intraosseous cystic formation in the talus: a complication of subtalar arthroeresis. Rockett AK, et al. **J Foot Ankle Surg** 1998 Sep-Oct;37(5):421-5 (14 ref.)

SUBTILISINS

CHEMICAL SYNTHESIS

Chemical engineering of enzymes: altered catalytic activity, predictable selectivity and exceptional stability of the

semisynthetic peroxidase seleno-subtilisin. Häring D, et al. **Naturwissenschaften** 1999 Jul;86(7):307-12 (32 ref.)

CHEMISTRY

Plant subtilisins. Bogacheva AM. **Biochemistry (Mosc)** 1999 Mar;64(3):287-93 (20 ref.)

METABOLISM

Plant subtilisins. Bogacheva AM. **Biochemistry (Mosc)** 1999 Mar;64(3):287-93 (20 ref.)

Can high maternal melatonin concentrations be responsible for inducing fetal pathologies, and can melatonin participate in immunohormonal homeostasis by determining prohormone convertase activity?--Hypothesis and facts. Ciesla W. **Med Hypotheses** 1998 Oct;51(4):269-80 (100 ref.)

The cell biology of the prohormone convertases PC1 and PC2. Muller L, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 63:69-108 (183 ref.)

Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Molloy SS, et al. **Trends Cell Biol** 1999 Jan;9(1):28-35 (64 ref.)

SUBTRACTION ANGIOGRAPHY, DIGITAL see **ANGIOGRAPHY, DIGITAL SUBTRACTION**

SUBTROCHANTERIC FRACTURES see **HIP FRACTURES**

SUBURBAN HEALTH SERVICES

see related
RURAL HEALTH SERVICES

SUBVALVULAR STENOSIS, IDIOPATHIC HYPERTROPHIC see **CARDIOMYOPATHY, HYPERTROPHIC**

SUBWAYS see **RAILROADS**

SUCCINATE DEHYDROGENASE

CHEMISTRY

The membrane-integral domain of succinate:quinone oxidoreductases--a secretive haem-containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408-13 (33 ref.)

Structure and function of flavocytochrome c3, the soluble fumarate reductase from Shewanella NCIMB400. Reid GA, et al. **Biochem Soc Trans** 1998 Aug;26(3):418-21 (17 ref.)

METABOLISM

The membrane-integral domain of succinate:quinone oxidoreductases--a secretive haem-containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408-13 (33 ref.)

Structure and function of flavocytochrome c3, the soluble fumarate reductase from Shewanella NCIMB400. Reid GA, et al. **Biochem Soc Trans** 1998 Aug;26(3):418-21 (17 ref.)

SUCCINIC ACIDS

see related
SUCCINIMIDES

SUCCINIC OXIDASE see **SUCCINATE DEHYDROGENASE**

SUCCINIMIDES

PHARMACOLOGY

Succinimide and saccharin-based enzyme-activated inhibitors of serine proteases. Martyn DC, et al. **Curr Pharm Des** 1999 Jun;5(6):405-15 (49 ref.)

SUCCINYLCHOLINE

ADMINISTRATION & DOSAGE

Severe laryngospasm without intravenous access--a case report and literature review of the non-intravenous routes of administration of suxamethonium. Seah TG, et al. **Singapore Med J** 1998 Jul;39(7):328-30 (21 ref.)

ADVERSE EFFECTS

[Toxic and adverse effects of local anesthetics/neuromuscular blocker: lidocaine, succinylcholine] Takagi A. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):542-4 (4 ref.) **(Jpn)**

SUCCINYLDICHOLINE see **SUCCINYLCHOLINE**

SUCKING BEHAVIOR

PHYSIOLOGY

Oral feeding in infants. Lau C, et al. **Curr Probl Pediatr** 1999 Apr;29(4):105-24 (142 ref.)

SUCRALFATE

ADVERSE EFFECTS

[Sucralfate and bezoars: data from the system of pharmacologic vigilance and review of the literature] Guy C, et al. **Therapie** 1999 Jan-Feb;54(1):55-8 (13 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Non-steroidal anti-inflammatory drug gastropathy: clinical results with antacids and sucralfate. Lazzaroni M, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S48-53 (40 ref.)

SUCROSE

ANALOGS & DERIVATIVES

Review article: olestra and its gastrointestinal safety. Thomson AB, et al. **Aliment Pharmacol Ther** 1998 Dec; 12(12):1185-200 (94 ref.)

The selling of olestra [see comments] Nestle M. **Public Health Rep** 1998 Nov-Dec;113(6):508-20 (68 ref.) Comment in: Public Health Rep 1999 Jan-Feb;114(1):5-6.

METABOLISM

Sugars as signal molecules in plant seed development. Wobus U, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):937-44 (40 ref.)

SUCROSE, DIETARY see **DIETARY SUCROSE**

SUCTION

Comparing ultrasound-assisted lipoplasty with suction-assisted lipoplasty. Gingrass MK, et al. **Clin Plast Surg** 1999 Apr;26(2):283-8; ix (2 ref.)

[The BMW (biosurgical mechanical wound treatment) in diabetic foot] Moch D, et al. **Zentralbl Chir** 1999;124 Suppl 1:69-72 (10 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of extraorganic local liquorous accumulations in abdominal cavity under US control] Karpova RV, et al. **Khirurgiia (Mosk)** 1999;(4):63-7 (121 ref.) **(Rus)**

INSTRUMENTATION

The development of biliary drainage and stenting. Wurbs D. **Endoscopy** 1998 Nov;30(9):A202-6 (36 ref.)

Selecting pumps for breastfeeding mothers. Biancuzzo M. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):417-26 (20 ref.)

METHODS

Laparoscopic management of benign ovarian disease. Mane S, et al. **Semin Laparosc Surg** 1999 Jun;6(2):104-11 (25 ref.)

SUCTION LIPECTOMY see **LIPECTOMY**

SUDDEN CARDIAC DEATH see **DEATH, SUDDEN, CARDIAC**

SUDDEN DEAFNESS see **DEAFNESS, SUDDEN**

SUDDEN INFANT DEATH

Sudden infant death syndrome, child sexual abuse, and child development. Blatt SD, et al. **Curr Opin Pediatr** 1999 Apr; 11(2):175-86 (46 ref.)

[The sudden and unexpected death syndrome in nursing infants] Kolev D. **Akush Ginekol (Sofiia)** 1998;37(1):42-4 (5 ref.) **(Bul)**

EPIDEMIOLOGY

Optimality of the birth population reduces learning and behaviour disorders and sudden infant death after the first month. Saugstad LF. **Acta Paediatr Suppl** 1999 May; 88(429):9-28 (171 ref.)

Side sleeping position and bed sharing in the sudden infant death syndrome. Scragg RK, et al. **Ann Med** 1998 Aug; 30(4):345-9 (41 ref.)

Sudden infant death syndrome: what questions should we ask? Pearce JL, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):7-10 (15 ref.)

ETIOLOGY

Disentangling the separate effects of prenatal and postnatal smoking on the risk of SIDS [comment] Spiers PS. **Am J Epidemiol** 1999 Apr 1;149(7):603-6; discussion 607 (33 ref.) Comment on: Am J Epidemiol 1999 Apr 1;149(7):593-602.

Infection, inflammation and sleep: more pieces to the puzzle of sudden infant death syndrome (SIDS). Blackwell CC, et al. **APMIS** 1999 May;107(5):455-73 (142 ref.)

The role of infection in sudden infant death syndrome. Blackwell CC, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):1-6 (52 ref.)

Immune and inflammatory responses in sudden infant death syndrome. Forsyth KD. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):79-83 (27 ref.)

Respiratory control during upper airway infection mechanism for prolonged reflex apnoea and sudden infant death with special reference to infant sleep position. Lindgren C. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1-2):97-102 (45 ref.)

The common bacterial toxins hypothesis of sudden infant death syndrome. Morris JA. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):11-7 (36 ref.)

Sudden infant death syndrome: what questions should we ask? Pearce JL, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):7-10 (15 ref.)

Sudden infant death syndrome, virus infections and cytokines. Raza MW, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):85-96 (140 ref.)

Animal models used to test the interactions between infectious agents and products of cigarette smoked implicated in sudden infant death syndrome. Sayers NM, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1-2):115-23 (94 ref.)

Inflammatory responses in sudden infant death syndrome -- past and present views. Vege A, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):67-78 (135 ref.)

Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Dybing E, et al. **Hum Exp Toxicol** 1999 Apr;18(4):202-5 (30 ref.)

Sudden infant death syndrome: hypothalamic failure to sense elevated blood pyrogens. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):569-75 (69 ref.)

Sudden infant death syndrome: oxidative stress. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):577-80 (24 ref.)

Sudden infant death syndrome and the modulation of neuropeptides released during shock. Reid GM. **Med Hypotheses** 1998 Jul;51(1):23-6 (26 ref.)

The story of the internal carotid artery of mammals: from Galen to sudden infant death syndrome. du Boulay GH, et al. **Neuroradiology** 1998 Nov;40(11):697-703 (36 ref.)

Sudden death due to ventricular septal defect. Cohle SD, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):327-32 (29 ref.)

Sudden and unexpected neonatal death: a protocol for the postmortem diagnosis of fatty acid oxidation disorders. Rinaldo P, et al. **Semin Perinatol** 1999 Apr;23(2):204-10 (52 ref.)

IMMUNOLOGY

Immune and inflammatory responses in sudden infant death syndrome. Forsyth KD. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):79-83 (27 ref.)

Sudden infant death syndrome, virus infections and cytokines. Raza MW, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):85-96 (140 ref.)

Inflammatory responses in sudden infant death syndrome -- past and present views. Vege A, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):67-78 (135 ref.)

PATHOLOGY

Infantile disseminated visceral giant cell arteritis presenting as sudden infant death. Kagata Y, et al. **Pathol Int** 1999 Mar;49(3):226-30 (19 ref.)

Histiocytoid cardiomyopathy: three new cases and a review of the literature. Shehata BM, et al. **Pediatr Dev Pathol** 1998 Jan-Feb;1(1):56-69 (45 ref.)

PREVENTION & CONTROL

[Prematurity and sudden infant death syndrome. Polysomnography in question] Lequien P, et al. **Arch Pediatr** 1999 Jun;6(6):683-5 (16 ref.) (Eng. Abstr.) **(Fre)**

[Polysomnographic screening of infants at risk for SIDS] Hirsch A, et al. **Orv Hetil** 1999 Jan 10;140(2):67-72 (49 ref.) (Eng. Abstr.) **(Hun)**

[Cardiorespiratory monitoring in hospital and at home] Carnelli V, et al. **Pediatr Med Chir** 1998 Nov-Dec; 20(6):361-5 (10 ref.) (Eng. Abstr.) **(Ita)**

SUDECK'S ATROPHY see **REFLEX SYMPATHETIC DYSTROPHY**

SUFENTANIL

ADMINISTRATION & DOSAGE

Intrathecal lipophilic opioids as adjuncts to surgical spinal anesthesia. Hamber EA, et al. **Reg Anesth Pain Med** 1999 May-Jun;24(3):255-63 (59 ref.)

SUFFOCATION see **ASPHYXIA**

SUGAR ACIDS

[KDNology: a new frontier in glycobiology] Inoue S. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2418-25 (49 ref.) **(Jpn)**

SUGAR SUBSTITUTES see **SWEETENING AGENTS**

SUGARS see **CARBOHYDRATES**

SUGARS, DIETARY

SUGARS, DIETARY see **DIETARY SUCROSE**

SUGGESTION

The suggestibility of children's memory. Bruck M, et al. **Annu Rev Psychol** 1999;50:419–39 (56 ref.)

Trauma, memory, and suggestibility in children. Eisen ML, et al. **Dev Psychopathol** 1998 Fall;10(4):717–38 (155 ref.)

Psychophysiological correlates of hypnosis and hypnotic susceptibility. de Pascalis V. **Int J Clin Exp Hypn** 1999 Apr;47(2):117–43 (104 ref.)

Repressed memories. When are they real? How are they false? Loftus EF, et al. **Psychiatr Clin North Am** 1999 Mar; 22(1):61–70 (29 ref.)

SUICIDE

Fatal colchicine overdose: report of a case and review of the literature. Milne ST, et al. **Am J Emerg Med** 1998 Oct; 16(6):603–8 (64 ref.)

Hanging deaths in children. Wyatt JP, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):343–6 (28 ref.)

Annotation: mood disorder in suicidal children and adolescents: recent developments. Flisher AJ. **J Child Psychol Psychiatry** 1999 Mar;40(3):315–24 (51 ref.)

An unusual case of railway suicide. Romero Palanco JL, et al. **J Forensic Sci** 1999 Mar;44(2):444–6 (27 ref.)

Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Mann JJ. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):99S–105S (65 ref.)

Fatal ingestion of sodium hypochlorite bleach with associated hypernatremia and hyperchloremic metabolic acidosis. Ross MP, et al. **Vet Hum Toxicol** 1999 Apr;41(2):82–6 (34 ref.)

[Suicide—a neglected public health problem] Wasserman D. **Lakartidningen** 1998 Dec 2;95(49):5593–7 (19 ref.) **(Swe)**

LEGISLATION & JURISPRUDENCE

[Phenomenology of ether administration. With a review of the literature] Kernbach-Wighton G, et al. **Arch Kriminol** 1998 Sep–Oct;202(3–4):87–94 (33 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Evaluation and treatment of patients with suicidal ideation. Gliatto MF, et al. **Am Fam Physician** 1999 Mar 15; 59(6):1500–6 (24 ref.)

Studies of suicide in later life: methodologic considerations and research directions. Pearson JL, et al. **Am J Geriatr Psychiatry** 1999 Summer;7(3):203–10 (75 ref.)

Suicide and violence risk in law enforcement: practical guidelines for risk assessment, prevention, and intervention. Mohandie K, et al. **Behav Sci Law** 1999;17(3):357–76 (56 ref.)

Suicidality in borderline personality disorder. Kjellander C, et al. **Crisis** 1998;19(3):125–35 (89 ref.)

Epidemiology, risk factors, intervention, and prevention of adolescent suicide. Rosewater KM, et al. **Curr Opin Pediatr** 1998 Aug;10(4):338–43 (53 ref.)

Talisman or taboo: the controversy of the suicide-prevention contract. Miller MC, et al. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):78–87 (64 ref.)

An integrative conceptual framework for assessing and treating suicidal behavior in adolescents. Rudd MD, et al. **J Adolesc** 1998 Aug;21(4):489–98 (25 ref.)

A process model for assessing adolescent risk for suicide. Stoelb M, et al. **J Adolesc** 1998 Aug;21(4):359–70 (36 ref.)

Anticonvulsant therapy and suicide risk in affective disorders. Goodwin FK. **J Clin Psychiatry** 1999;60 Suppl 2:89–93; discussion 111–6 (54 ref.)

Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Palmer DD, et al. **J Clin Psychiatry** 1999;60 Suppl 2:100–3; discussion 111–6 (43 ref.)

Electroconvulsive therapy and suicide risk. Prudic J, et al. **J Clin Psychiatry** 1999;60 Suppl 2:104–10; discussion 111–6 (42 ref.)

Methods of adolescent suicide prevention. Shaffer D, et al. **J Clin Psychiatry** 1999;60 Suppl 2:70–4; discussion 75–6, 113–6 (19 ref.)

Suicide across the life span: pathways to prevention. King CA. **Suicide Life Threat Behav** 1998 Winter;28(4):328–37 (31 ref.)

PSYCHOLOGY

Suicidal ideation and sense of coherence in male conscripts. Mehlum L. **Acta Psychiatr Scand** 1998 Dec;98(6):487–92 (37 ref.)

Childhood sexual and physical abuse and adult self-harm and suicidal behaviour: a literature review [see comments] Santa Mina EE, et al. **Can J Psychiatry** 1998 Oct;43(8):793–800 (52 ref.) Comment in: Can J Psychiatry 1998 Oct;43(8):783.

Suicidality in borderline personality disorder. Kjellander C, et al. **Crisis** 1998;19(3):125–35 (89 ref.)

Substance abuse and drug-related death, suicidal ideation, and suicide: a review. Mino A, et al. **Crisis** 1999;20(1):28–35 (52 ref.)

Negative life events and adolescent suicidal behavior: a critical analysis from the stress process perspective. Sandin B, et al. **J Adolesc** 1998 Aug;21(4):415–26 (52 ref.)

The psychological autopsy approach to studying suicide: a review of methodological issues. Hawton K, et al. **J Affect Disord** 1998 Sep;50(2–3):269–76 (34 ref.)

The neurobiology of suicide risk: a review for the clinician. Mann JJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:7–11; discussion 18–20, 113–6 (50 ref.)

The chronological assessment of suicide events: a practical interviewing strategy for the elicitation of suicidal ideation. Shea SC. **J Clin Psychiatry** 1998;59 Suppl 20:58–72 (10 ref.)

Suicide in the course of the treatment of depression. Healy D, et al. **J Psychopharmacol** 1999;13(1):94–9 (59 ref.)

Blindness, fear of sight loss, and suicide. De Leo D, et al. **Psychosomatics** 1999 Jul–Aug;40(4):339–44 (30 ref.)

The role of objective personality inventories in suicide risk assessment: an evaluation and proposal. Johnson WB, et al. **Suicide Life Threat Behav** 1999 Summer;29(2):165–85 (99 ref.)

Problem solving and suicidal behavior. Pollock LR, et al. **Suicide Life Threat Behav** 1998 Winter;28(4):375–87 (75 ref.)

[The risk of suicide] Cremniter D, et al. **Presse Med** 1998 Dec 19;27(40):2151–6 (48 ref.) (Eng. Abstr.) **(Fre)**

[Adolescents and suicide. Some comments on the role of the pediatrician in researching the motivations for suicidal behaviors] Franchini F, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):251–3 (14 ref.) (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

The influence of alcohol drinking and alcohol use disorders on psychiatric disorders and suicidal behavior. Berglund M, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):333S–345S (112 ref.)

Studies of suicide in later life: methodologic considerations and research directions. Pearson JL, et al. **Am J Geriatr Psychiatry** 1999 Summer;7(3):203–10 (75 ref.)

Why are men killing themselves? A look at the evidence. Russell D, et al. **Aust Fam Physician** 1999 Aug;28(8):791–5 (22 ref.)

Suicide and recency of health care contacts. A systematic review. Pirkis J, et al. **Br J Psychiatry** 1998 Dec;173:462–74 (37 ref.)

Substance abuse and drug-related death, suicidal ideation, and suicide: a review. Mino A, et al. **Crisis** 1999;20(1):28–35 (52 ref.)

Suicide, euthanasia and AIDS. Mishara BL. **Crisis** 1998; 19(2):87–96 (49 ref.)

Epidemiology, risk factors, intervention, and prevention of adolescent suicide. Rosewater KM, et al. **Curr Opin Pediatr** 1998 Aug;10(4):338–43 (53 ref.)

Seasonal and circadian rhythms in suicide in Cagliari, Italy. Altamura C, et al. **J Affect Disord** 1999 Apr;53(1):77–85 (51 ref.)

The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. Schou M. **J Affect Disord** 1998 Sep;50(2–3):253–9 (33 ref.)

Suicide risk in patients with major depressive disorder. Angst J, et al. **J Clin Psychiatry** 1999;60 Suppl 2:57–62; discussion 75–6, 113–6 (56 ref.)

Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini RJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:77–84; discussion 111–6 (58 ref.)

The neurobiology of suicide risk: a review for the clinician. Mann JJ, et al. **J Clin Psychiatry** 1999;60 Suppl 2:7–11; discussion 18–20, 113–6 (50 ref.)

Antidepressants and suicidal risk. Müller-Oerlinghausen B, et al. **J Clin Psychiatry** 1999;60 Suppl 2:94–9; discussion 111–6 (67 ref.)

Genetics of suicide in depression. Roy A, et al. **J Clin Psychiatry** 1999;60 Suppl 2:12–7; discussion 18–20, 113–6 (43 ref.)

The risk of suicide in patients with bipolar disorders. Simpson SG, et al. **J Clin Psychiatry** 1999;60 Suppl 2:53–6; discussion 75–6, 113–6 (19 ref.)

Suicide in nurses. Hawton K, et al. **Suicide Life Threat Behav** 1999 Spring;29(1):86–95 (48 ref.)

[Epidemiological study of suicide in Japan—is it possible to reduce committing suicide?] Yoshioka N. **Nippon Hoigaku Zasshi** 1998 Oct;52(5):286–93 (8 ref.) (Eng. Abstr.) **(Jpn)**

SUICIDE, ASSISTED

Exit association-mediated suicide: toxicologic and forensic aspects. Giroud C, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):40–4 (9 ref.)

Currently accepted practices that are known to lead to death, and PAS: is there an ethically relevant difference? Cavanaugh TA. **Camb Q Healthc Ethics** 1998 Fall; 7(4):375–81 (8 ref.)

Physician-assisted death: can philosophical bioethics aid social policy? Kuczewski MG. **Camb Q Healthc Ethics** 1998 Fall;7(4):339–47 (19 ref.)

Critical notice: why killing is not always worse—and is sometimes better—than letting die. Kuhse H. **Camb Q Healthc Ethics** 1998 Fall;7(4):371–4 (9 ref.)

Assessing the arguments for and against euthanasia and assisted suicide: Part Two. Thomasma DC. **Camb Q Healthc Ethics** 1998 Fall;7(4):388–401 (37 ref.)

The case against physician assisted suicide. Boehnlein JK. **Community Ment Health J** 1999 Feb;35(1):5–14 (17 ref.)

Euthanasia and assisted suicide: facts, figures and fancies with special regard to old age. Muller MT, et al. **Drugs Aging** 1998 Sep;13(3):185–91 (32 ref.)

Euthanasia and assisted suicide in The Netherlands: clarifying the practice and the nurse's role. van der Arend AJ. **Int Nurs Rev** 1998 Sep–Oct;45(5):145–51 (16 ref.)

Assisted suicide and nursing: possibly compatible? White BC. **J Prof Nurs** 1999 May–Jun;15(3):151–9 (52 ref.)

Why nurses must actively participate in the debate on assisted suicide: a symposium. White BC, et al. **J Prof Nurs** 1999 May–Jun;15(3):139–41 (17 ref.)

The moral appeal of assisted suicide in end-of-life decisions. Zimbelman J, et al. **J Prof Nurs** 1999 May–Jun;15(3):142–5 (9 ref.)

Is euthanasia compatible with palliative care? Low JA, et al. **Singapore Med J** 1999 May;40(5):365–70 (24 ref.)

Euthanasia and physician-assisted suicide. Gittelman DK. **South Med J** 1999 Apr;92(4):369–74 (29 ref.)

LEGISLATION & JURISPRUDENCE

The pharmacist and assisted suicide. Veatch RM. **Am J Health Syst Pharm** 1999 Feb 1;56(3):260–6 (29 ref.)

Pulling up the runaway: the effect of new evidence on euthanasia's slippery slope [see comments] Ryan CJ. **J Med Ethics** 1998 Oct;24(5):341–4 (29 ref.) Comment in: J Med Ethics 1999 Feb;25(1):60.

Legal decisions and public opinion informing the debate on assisted suicide. Zimbelman J. **J Prof Nurs** 1999 May–Jun; 15(3):146–50 (30 ref.)

Changing the present legal prohibitions on assisted suicide is a bad idea. Zimbelman J. **J Prof Nurs** 1999 May–Jun; 15(3):160–9 (46 ref.)

The right to die and physician-assisted suicide: medical, legal, and ethical aspects (Part II). Wecht CH. **Med Law** 1998; 17(4):581–601 (27 ref.)

Active euthanasia and assisted suicide: a perspective from an American abortion and Dutch euthanasia scenario. Musgrave CF. **Oncol Nurs Forum** 1998 Oct;25(9):1587–91 (32 ref.)

Physician-assisted suicide in psychiatry: developments in The Netherlands. Schoevers RA, et al. **Psychiatr Serv** 1998 Nov; 49(11):1475–80 (54 ref.)

TRENDS

Physician-assisted suicide in psychiatry: developments in The Netherlands. Schoevers RA, et al. **Psychiatr Serv** 1998 Nov; 49(11):1475–80 (54 ref.)

SUICIDE, ATTEMPTED

Soft tissue injection of hydrocarbons: a case report and review of the literature. Shusterman EM, et al. **J Emerg Med** 1999 Jan–Feb;17(1):63–5 (25 ref.)

[A sibling of delayed post-anoxic encephalopathy after strangulation] Matsui M, et al. **No To Hattatsu** 1998 Nov; 30(6):529–34 (21 ref.) (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Suicidal patients in the ED: ethical issues. Schmidt TA, et al. **Emerg Med Clin North Am** 1999 May;17(2):371–83, x (82 ref.)

PREVENTION & CONTROL

Suicidality in borderline personality disorder. Kjellander C, et al. **Crisis** 1998;19(3):125–35 (89 ref.)

Suicidal patients in the ED: ethical issues. Schmidt TA, et al. **Emerg Med Clin North Am** 1999 May;17(2):371–83, x (82 ref.)

An integrative conceptual framework for assessing and treating suicidal behavior in adolescents. Rudd MD, et al. **J Adolesc** 1998 Aug;21(4):489–98 (25 ref.)

PSYCHOLOGY

Suicide and suicidal behaviours: implications for mental health services [see comments] Rhodes AE, et al. **Can J Psychiatry** 1998 Oct;43(8):785–91 (76 ref.) Comment in: Can J Psychiatry 1998 Oct;43(8):783.

Suicidality in borderline personality disorder. Kjellander C, et al. **Crisis** 1998;19(3):125–35 (89 ref.)

Negative life events and adolescent suicidal behavior: a critical analysis from the stress process perspective. Sandin B, et al. **J Adolesc** 1998 Aug;21(4):415–26 (52 ref.)

[Adolescents and suicide. Some comments on the role of the pediatrician in researching the motivations for suicidal behaviors] Franchini F, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):251–3 (14 ref.) (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. Schou M. **J Affect Disord** 1998 Sep;50(2–3):253–9 (33 ref.)

Suicide attempts in major affective disorder patients with comorbid substance use disorders. Tondo L, et al. **J Clin Psychiatry** 1999;60 Suppl 2:63–9; discussion 75–6, 113–6 (60 ref.)

SUIPOXVIRUS

IMMUNOLOGY

Swinepox virus as a vaccine vector for swine pathogens. Tripathy DN. **Adv Vet Med** 1999;41:463–80 (45 ref.)

SULFADIAZINE

THERAPEUTIC USE

[Empirical anti-toxoplasma therapy in cerebral AIDS and Chagas disease. Presentation of 2 cases, review of the literature and proposal of an algorithm] Montero A, et al. **Medicina (B Aires)** 1998;58(5 Pt 1):504–6 (19 ref.) (Eng. Abstr.) **(Spa)**

SULFADIMIDINE see **SULFAMETHAZINE**

SULFAMETHAZINE

TOXICITY

Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system. Capen CC. **Toxicol Lett** 1998 Dec 28;102–103:405–9 (7 ref.)

SULFAMYL DIURETICS see **DIURETICS, SULFAMYL**

SULFANILIC ACIDS

see related
INDICATORS AND REAGENTS

SULFASALAZINE

ADVERSE EFFECTS

[A case of ulcerative colitis with folate deficient megaloblastic anemia induced by sulfasalazine] Hoshino J, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jul; 96(7):840–5 (18 ref.) **(Jpn)**

[A vertiginous syndrome due to sulfasalazine (letter)] Sáez J, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):207–8 (5 ref.) **(Spa)**

THERAPEUTIC USE

The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis. Furst DE. **Clin Exp Rheumatol** 1999 Jan–Feb; 17(1):39–40 (2 ref.)

Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? O'Dell JR. **Drugs** 1999 Mar; 57(3):279–82 (38 ref.)

Therapeutic aspects of spondyloarthropathies — a review. Leirisalo-Repo M. **Scand J Rheumatol** 1998;27(5):323–8 (71 ref.)

SULFATASES

METABOLISM

Computational analysis of bacterial sulfatases and their modifying enzymes. Schirmer A, et al. **Chem Biol** 1998 Aug;5(8):R181–6 (30 ref.)

SULFATES

METABOLISM

Bioenergetics of sulphate-reducing bacteria in relation to their environmental impact. Hamilton WA. **Biodegradation** 1998;9(3–4):201–12 (77 ref.)

Anaerobic treatment of sulphate-rich wastewaters. Hulshoff Pol LW, et al. **Biodegradation** 1998;9(3–4):213–24 (75 ref.)

Plant sulfur metabolism—the reduction of sulfate to sulfite. Bick JA, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):240–4 (37 ref.)

Pendred's syndrome: identification of the genetic defect a century after its recognition. Kopp P. **Thyroid** 1999 Jan; 9(1):65–9 (47 ref.)

SULFATES, INORGANIC see **SULFATES**

SULFATES, ORGANIC see **SULFURIC ACID ESTERS**

SULFATIDES see **SULFOGLYCOSPHINGOLIPIDS**

SULFATIDOSIS see **LEUKODYSTROPHY, METACHROMATIC**

SULFATION FACTOR see **SOMATOMEDINS**

SULFATOGLYCOSPHINGOLIPIDS see **SULFOGLYCOSPHINGOLIPIDS**

SULFHYDRYL COMPOUNDS

CHEMISTRY

Nitric oxide and thiol groups. Gaston B. **Biochim Biophys Acta** 1999 May 5;1411(2–3):323–33 (76 ref.)

METABOLISM

Cellular thiol production and oxidation of low-density lipoprotein. Graham A. **Free Radic Res** 1998 Jun; 28(6):611–21 (105 ref.)

Thiyl radicals in biochemically important thiols in the presence of metal ions. Hartmann HJ, et al. **Met Ions Biol Syst** 1999;36:389–413 (81 ref.)

Metabolic labeling of protein-derived lipid thioesters in palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:213–9 (10 ref.)

Fatty acid analysis of protein-derived lipid thioesters isolated from palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:221–8 (4 ref.)

PHARMACOLOGY

Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Hausheer FH, et al. **Semin Oncol** 1998 Oct;25(5):584–99 (56 ref.)

SULFHYDRYL REAGENTS

see related
ENZYME INHIBITORS

SULFIDES

METABOLISM

Reasons why 'Leptospirillum'-like species rather than Thiobacillus ferrooxidans are the dominant iron-oxidizing bacteria in many commercial processes for the biooxidation of pyrite and related ores. Rawlings DE, et al. **Microbiology** 1999 Jan;145 (Pt 1):5–13 (34 ref.)

Endogenous glutathione conjugates: occurrence and biological functions. Wang W, et al. **Pharmacol Rev** 1998 Sep;50(3):335–56 (204 ref.)

SULFITES

METABOLISM

Plant sulfur metabolism—the reduction of sulfate to sulfite. Bick JA, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):240–4 (37 ref.)

SULFITES, INORGANIC see **SULFITES**

SULFOGLYCOSPHINGOLIPIDS

IMMUNOLOGY

[Anti-sulfatide antibody associated neuropathy] Kaida K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):500–2 (11 ref.) **(Jpn)**

SULFOLOBUS

CHEMISTRY

Protein engineering on enzymes of the peptide elongation cycle in Sulfolobus solfataricus. Bocchini V, et al. **Biochimie** 1998 Nov;80(11):895–8 (19 ref.)

ENZYMOLOGY

Domain organization and biochemical features of Sulfolobus solfataricus DNA polymerase. Pisani FM, et al. **Extremophiles** 1998 Aug;2(3):171–7 (40 ref.)

GENETICS

Completing the sequence of the Sulfolobus solfataricus P2 genome. Sensen CW, et al. **Extremophiles** 1998 Aug; 2(3):305–12 (30 ref.)

Genetic elements in the extremely thermophilic archaeon Sulfolobus. Zillig W, et al. **Extremophiles** 1998 Aug; 2(3):131–40 (34 ref.)

SULFONAMIDES

ADMINISTRATION & DOSAGE

COX 2-selective NSAIDs: biology, promises, and concerns. Mandell BF. **Cleve Clin J Med** 1999 May;66(5):285–92 (17 ref.)

ADVERSE EFFECTS

Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Koopmans PP, et al. **Pharm World Sci** 1998 Dec; 20(6):253–7 (43 ref.)

Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Bjarnason I, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:24–32 (87 ref.)

Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rainsford KD. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:4–10 (22 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of nimesulide. Bernareggi A. **Clin Pharmacokinet** 1998 Oct;35(4):247–74 (94 ref.)

Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rainsford KD. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:4–10 (22 ref.)

PHARMACOLOGY

Celecoxib, a COX-2--specific inhibitor: the clinical data. Fort J. **Am J Orthop** 1999 Mar;28(3 Suppl):13–8 (14 ref.)

Endothelin antagonism with bosentan: a review of potential applications. Roux S, et al. **J Mol Med** 1999 Apr; 77(4):364–76 (180 ref.)

Overview of nimesulide. Bennett A. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:1–3 (19 ref.)

Molecular model of the interaction between nimesulide and human cyclooxygenase-2. Garcia-Nieto R, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:14–8 (26 ref.)

The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Shah AA, et al. **Rheumatology (Oxford)** 1999 May;38 Suppl 1:19–23 (47 ref.)

THERAPEUTIC USE

Cyclooxygenase-2 specificity and its clinical implications. Lefkowith JB. **Am J Med** 1999 May 31;106(5B):43S–50S (14 ref.)

Celecoxib, a COX-2--specific inhibitor: the clinical data. Fort J. **Am J Orthop** 1999 Mar;28(3 Suppl):13–8 (14 ref.)

Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Howard PA. **Ann Pharmacother** 1999 Jan;33(1):38–47 (58 ref.)

Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Davis DR, et al. **Can J Cardiol** 1999 Feb;15(2):193–200 (47 ref.)

Sulfonamides and trimethoprim. Kalkut G. **Cancer Invest** 1998;16(8):612–5 (24 ref.)

COX 2-selective NSAIDs: biology, promises, and concerns. Mandell BF. **Cleve Clin J Med** 1999 May;66(5):285–92 (17 ref.)

Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS. **J Rheumatol** 1999 Apr;26 Suppl 56:31–6 (19 ref.)

Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Ponticello GS, et al. **Pharm Biotechnol** 1998;11:555–74 (45 ref.)

Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS. **Scand J Rheumatol Suppl** 1999;109:31–7 (19 ref.)

Treatment advances in rheumatoid arthritis. Arriola ER, et al. **West J Med** 1999 May;170(5):278–81 (16 ref.)

SULFONES

Development of the Na+/H+ exchange inhibitor cariporide as a cardioprotective drug: from the laboratory to the GUARDIAN trial. Scholz W, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):61–70 (27 ref.)

PHARMACOLOGY

Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. Levitsky J, et al. **J Clin Pharmacol** 1998 Oct;38(10):887–97 (74 ref.)

Mechanisms of protection of the ischemic and reperfused myocardium by sodium-hydrogen exchange inhibition. Karmazyn M. **J Thromb Thrombolysis** 1999 Jul;8(1):33–8 (38 ref.)

Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167–74 (50 ref.)

THERAPEUTIC USE

Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Avkiran M. **Am J Cardiol** 1999 May 20;83(10A):10G–17G; discussion 17G–18G (64 ref.)

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Buerke M, et al. **Am J Cardiol** 1999 May 20; 83(10A):19G–22G (35 ref.)

Protection of the myocardial cell during ischemia. Théroux P. **Am J Cardiol** 1999 May 20;83(10A):3G–9G (29 ref.)

SULFONYLUREA COMPOUNDS

ADVERSE EFFECTS

[Interaction between converting enzyme inhibitors and hypoglycemic sulfonamides or insulin] Girardin E, et al. **Presse Med** 1998 Nov 28;27(37):1914–23 (48 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Campbell RK. **Ann Pharmacother** 1998 Oct;32(10):1044–52 (42 ref.)

[Use of sulfonylurea (SU) in the treatment of diabetes mellitus] Tasaka Y. **Nippon Rinsho** 1999 Mar;57(3):663–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Sulfonylurea drug—a new sulfonylurea drug for type 2

SULFONYLUREA COMPOUNDS

diabetes] Toyota T. **Nippon Rinsho** 1999 Mar;57(3):695–701 (39 ref.) (Eng. Abstr.) **(Jpn)**

SULFOTRANSFERASES

[Glycolipid sulfotransferase and cancer] Honke K. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2373–7 (16 ref.) **(Jpn)**

GENETICS

Dopamine sulphate: an enigma resolved. Eisenhofer G, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S41–53 (117 ref.)

Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Dooley TP. **Exp Dermatol** 1999 Aug;8(4):328–9 (11 ref.)

Genetic analysis of functions for cell surface proteoglycans [see comments] Selleck S. **Matrix Biol** 1998 Nov; 17(7):473–6 (30 ref.) Comment in: Matrix Biol 1998 Nov;17(7):461–3.

Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Hengstler JG, et al. **Recent Results Cancer Res** 1998; 154:47–85 (178 ref.)

PHYSIOLOGY

Carbohydrate sulfotransferases: mediators of extracellular communication. Bowman KG, et al. **Chem Biol** 1999 Jan; 6(1):R9–R22 (132 ref.)

[Sulfotransferases involved in the biosynthesis of glycosaminoglycans] Habuchi O, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2378–86 (64 ref.) **(Jpn)**

SULFOXIDES

THERAPEUTIC USE

[Role of pantoprazole in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1998 Oct;198(10):678–83 (50 ref.) **(Spa)**

SULFUR

[Development of new reactions utilizing feature of sulfur atom and the applications] Iwata C. **Yakugaku Zasshi** 1999 Feb;119(2):126–69 (31 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Nitric oxide and thiol groups. Gaston B. **Biochim Biophys Acta** 1999 May 5;1411(2–3):323–33 (76 ref.)

METABOLISM

Desulphurisation of benzothiophene and dibenzothiophene by actinomycete organisms belonging to the genus Rhodococcus, and related taxa. Oldfield C, et al. **Antonie Van Leeuwenhoek** 1998 Jul–Oct;74(1–3):119–32 (65 ref.)

Sulfur metabolism in higher plants: potential for phytoremediation. Ernst WH. **Biodegradation** 1998; 9(3–4):311–8 (86 ref.)

Zinc-catalyzed sulfur alkyation:insights from protein farnesyltransferase. Hightower KE, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):176–81 (57 ref.)

Plant sulfur metabolism--the reduction of sulfate to sulfite. Bick JA, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):240–4 (37 ref.)

SULFUR COMPOUNDS

METABOLISM

Microbial desulfurization of organic sulfur compounds in petroleum. Ohshiro T, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):1–9 (92 ref.)

Biodesulfurization. McFarland BL. **Curr Opin Microbiol** 1999 Jun;2(3):257–64 (62 ref.)

SULFUR-REDUCING BACTERIA

METABOLISM

Bioenergetics of sulphate-reducing bacteria in relation to their environmental impact. Hamilton WA. **Biodegradation** 1998;9(3–4):201–12 (77 ref.)

Anaerobic treatment of sulphate-rich wastewaters. Hulshoff Pol LW, et al. **Biodegradation** 1998;9(3–4):213–24 (75 ref.)

SULFURIC ACID ESTERS

TOXICITY

Dimethyl sulfate. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:575–88 (55 ref.)

SULINDAC

PHARMACOLOGY

Stimulation of apoptosis by sulindac and piroxicam. Waddell WR. **Clin Sci (Colch)** 1998 Sep;95(3):385–8 (34 ref.)

THERAPEUTIC USE

[Complete remission of a mesenteric fibromatosis after taking sulindac] D'Alteroche L, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1098–101 (21 ref.) (Eng. Abstr.) **(Fre)**

SULPIRIDE

PHARMACOLOGY

[Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature] Rzewuska M. **Psychiatr Pol** 1998 Sep–Oct;32(5):655–66 (46 ref.) (Eng. Abstr.) **(Pol)**

SUMATRIPTAN

ADMINISTRATION & DOSAGE

Appropriate migraine therapy for children and adolescents. Farkas V. **Cephalalgia** 1999 Mar;19 Suppl 23:24–6; discussion 26–8 (26 ref.)

ADVERSE EFFECTS

Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? Dahlöf CG, et al. **Cephalalgia** 1998 Oct; 18(8):539–45 (73 ref.)

PHARMACOLOGY

[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stępień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341–3 (28 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D, et al. **Acta Neurol Belg** 1999 Jun;99(2):85–95 (89 ref.)

Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Salonen R, et al. **Cephalalgia** 1999 Jan;19(1):16–9 (16 ref.)

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen P. **Cephalalgia** 1998 Oct;18(8):532–8 (56 ref.)

Present and future of 5-HT receptor agonists as antimigraine drugs. Pauwels PJ, et al. **Clin Neuropharmacol** 1999 May–Jun;22(3):123–36 (137 ref.)

Current concepts of migraine and its treatment. Dahlöf CG. **Neurologia** 1999 Feb;14(2):67–77 (72 ref.)

[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks] Stępień A. **Pol Merkuriusz Lek** 1999 Jun;6(36):341–3 (28 ref.) (Eng. Abstr.) **(Pol)**

SUN GLASSES, NONPRESCRIPTION see **EYE PROTECTIVE DEVICES**

SUNBATHING see **HELIOTHERAPY**

SUNBURN

see related
SUNSCREENING AGENTS

ETIOLOGY

[Photo-aging] Paredes BE, et al. **Ther Umsch** 1999 Apr; 56(4):188–93 (23 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Workshop report: research, policy and program planning on sun protective behaviours. Ashbury FD, et al. **Cancer Prev Control** 1998 Jun;2(3):129–32 (12 ref.)

Living a "shady life": sun-protective behaviour for Canadians. Adam JE. **CMAJ** 1999 May 18;160(10):1471–4 (26 ref.)

Skin cancer prevention for children: a critical review. Buller DB, et al. **Health Educ Behav** 1999 Jun;26(3):317–43 (52 ref.)

Sunblocks: mechanisms of action. Murphy GM. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):34–6 (12 ref.)

[Sunscreening creams] Leroy D. **Ann Dermatol Venereol** 1999 Apr;126(4):357–63 (60 ref.) **(Fre)**

SUNLIGHT

see related
HELIOTHERAPY

The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition. Hug DH, et al. **J Photochem Photobiol B** 1998 Jul 10; 44(2):117–23 (81 ref.)

The impact of UVB radiation on marine plankton. Davidson AT. **Mutat Res** 1998 Nov 9;422(1):119–29 (116 ref.)

Human pigmentation genes and their response to solar UV radiation. Sturm RA. **Mutat Res** 1998 Nov 9;422(1):69–76 (42 ref.)

[Disease caused by lack of sunlight: rickets and osteomalacia] Wauters IM, et al. **Ned Tijdschr Geneeskd** 1999 Mar 20; 143(12):593–7 (22 ref.) (Eng. Abstr.) **(Dut)**

ADVERSE EFFECTS

Potentials and limitations of the natural antioxidants RRR-alpha-tocopherol, L-ascorbic acid and beta-carotene in cutaneous photoprotection. Fuchs J. **Free Radic Biol Med** 1998 Nov 1;25(7):848–73 (380 ref.)

Solar urticaria: the annoying photodermatosis. Roelandts R, et al. **Int J Dermatol** 1999 Jun;38(6):411–8 (123 ref.)

Melanoma and sun exposure: where are we now? Whiteman DC, et al. **Int J Dermatol** 1999 Jul;38(7):481–9 (99 ref.)

Sun-protective clothing. Adam J. **J Cutan Med Surg** 1998 Jul;3(1):50–3 (10 ref.)

Influence of dietary factors on actinically-induced skin cancer. Black HS. **Mutat Res** 1998 Nov 9;422(1):185–90 (31 ref.)

Protection against solar ultraviolet radiation. Gies PH, et al. **Mutat Res** 1998 Nov 9;422(1):15–22 (37 ref.)

[Skin cancers and environmental factors] Autier P. **Rev Med Brux** 1998 Sep;19(4):A346–50 (20 ref.) (Eng. Abstr.) **(Fre)**

[Photoprotection, cancer protection and solar protection factor] Heenen M. **Rev Med Brux** 1999 Jun;20(3):143–6 (42 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of malignant melanoma] Blum A, et al. **Hautarzt** 1998 Nov;49(11):826–34 (54 ref.) (Eng. Abstr.) **(Ger)**

[The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythematosus] Aharon-Maor A, et al. **Harefuah** 1998 Oct;135(7–8):295–9 (38 ref.) **(Heb)**

SUNSCREENING AGENTS

Sunscreens: are Australians getting the good oil? [see comments] Hayden CG, et al. **Aust N Z J Med** 1998 Oct; 28(5):639–46 (38 ref.) Comment in: Aust N Z J Med 1999 Feb;29(1):104.

The value of sunscreens. Burke KE. **Int J Dermatol** 1999 Feb;38(2):88–90 (35 ref.)

ADMINISTRATION & DOSAGE

[Prevention of ultraviolet ray damage: external and internal sunscreens] Grundmann JU, et al. **Ther Umsch** 1999 Apr; 56(4):225–32 (48 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Allergy to sunscreens] Mancel E, et al. **Allerg Immunol (Paris)** 1999 Jun;31(6):195–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Photoprotection, cancer protection and solar protection factor] Heenen M. **Rev Med Brux** 1999 Jun;20(3):143–6 (42 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Shedding light on sunscreens. Roelandts R. **Clin Exp Dermatol** 1998 Jul;23(4):147–57 (169 ref.)

PHARMACOLOGY

Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. Ananthaswamy HN, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):52–6 (71 ref.)

Sunblocks: mechanisms of action. Murphy GM. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):34–6 (12 ref.)

THERAPEUTIC USE

Do sunscreens prevent skin cancer? **Drug Ther Bull** 1998 Jul;36(7):49–51 (18 ref.)

Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. Ananthaswamy HN, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):52–6 (71 ref.)

Recent advances in sun protection. Schaefer H, et al. **Semin Cutan Med Surg** 1998 Dec;17(4):266–75 (52 ref.)

[Sunscreening creams] Leroy D. **Ann Dermatol Venereol** 1999 Apr;126(4):357–63 (60 ref.) **(Fre)**

SUNSPOTS see **SOLAR ACTIVITY**

SUPERANTIGENS

see related
APOPTOSIS
CLONAL ANERGY
RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA

[Superantigens and their importance for inflammatory skin diseases] Olsen JV, et al. **Ugeskr Laeger** 1999 Aug 23; 161(34):4747–50 (40 ref.) (Eng. Abstr.) **(Dan)**

ADMINISTRATION & DOSAGE

The structural basis of T cell activation by superantigens. Li H, et al. **Annu Rev Immunol** 1999;17:435–66 (183 ref.)

CHEMISTRY

Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Kotb M. **Curr Opin Microbiol** 1998 Feb;1(1):56-65 (79 ref.)
Structure and function of streptococcal and staphylococcal superantigens in septic shock. Bannan J, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):387-96, ix (69 ref.)

IMMUNOLOGY

Mechanism of HIV pathogenesis: role of superantigens in disease. Torres BA, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):188S-192S (58 ref.)
The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. Leung DY, et al. **Br J Dermatol** 1998 Dec;139 Suppl 53:17-29 (91 ref.)
Modulation of disease by superantigens. Torres BA, et al. **Curr Opin Immunol** 1998 Aug;10(4):465-70 (44 ref.)
Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Kotb M. **Curr Opin Microbiol** 1998 Feb;1(1):56-65 (79 ref.)
Understanding the mechanism of action of bacterial superantigens from a decade of research. Lavoie PM, et al. **Immunol Rev** 1999 Apr;168:257-69 (143 ref.)
Structure-function studies of T-cell receptor-superantigen interactions. Li H, et al. **Immunol Rev** 1998 Jun;163:177-86 (52 ref.)
Superantigens in human disease. Bernal A, et al. **J Clin Immunol** 1999 May;19(3):149-57 (83 ref.)
[The role of bacterial superantigens in pathophysiology of the skin] Bochncke WH, et al. **Hautarzt** 1999 Feb;50(2):91-7 (67 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The role of superantigens in vasculitis. Cohen Tervaert JW, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):24-33 (92 ref.)
Structure and function of streptococcal and staphylococcal superantigens in septic shock. Bannan J, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):387-96, ix (69 ref.)
[The role of superantigens in infectious diseases] Santolaya ME. **Rev Med Chil** 1998 Jul;126(7):846-54 (52 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Targeted superantigens for immunotherapy of haematopoietic tumours. Tötterman TH, et al. **Vox Sang** 1998;74 Suppl 2:483-7 (36 ref.)

SUPERINFECTION

ETIOLOGY

[Amebic liver abscesses with bacterial superinfection in a nonendemic area] Ciriza C, et al. **Gastroenterol Hepatol** 1999 Jun-Jul;22(6):286-9 (16 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[The diabetic foot from the viewpoint of infection surgery] Brunner U. **Zentralbl Chir** 1999;124 Suppl 1:13-6 (22 ref.) (Eng. Abstr.) **(Ger)**
[The BMW (biosurgical mechanical wound treatment) in diabetic foot] Moch D, et al. **Zentralbl Chir** 1999;124 Suppl 1:69-72 (10 ref.) (Eng. Abstr.) **(Ger)**

SUPERINVASION, MICROBIAL see **SUPERINFECTION**

SUPERIOR CERVICAL GANGLION

CYTOLOGY

Noradrenergic synaptic transmission in the superior cervical ganglion. Kawai Y. **Kaibogaku Zasshi** 1999 Apr; 74(2):167-73 (38 ref.)

METABOLISM

Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons. Hille B, et al. **Life Sci** 1995; 56(11-12):989-92 (34 ref.)

PHYSIOLOGY

Mechanisms of pituitary adenylate cyclase activating polypeptide (PACAP)-induced depolarization of sympathetic superior cervical ganglion (SCG) neurons. May V, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:164-75 (54 ref.)

SUPERIOR COLLICULUS

ANATOMY & HISTOLOGY

Retinal projections and retinal ganglion cell distribution patterns in a sturgeon (Acipenser transmontanus), a non-teleost actinopterygian fish. Ito H, et al. **Brain Behav Evol** 1999;53(3):127-41 (85 ref.)

GROWTH & DEVELOPMENT

Mechanisms involved in development of retinotectal connections: roles of Eph receptor tyrosine kinases, NMDA receptors and nitric oxide. Ernst AF, et al. **Prog Brain Res** 1998;118:115-31 (131 ref.)
The role of nitric oxide in development of the patch-cluster system and retinocollicular pathways in the rodent superior colliculus. Mize RR, et al. **Prog Brain Res** 1998;118:133-52 (92 ref.)
Plasticity in the tectum of Xenopus laevis: binocular maps. Udin SB, et al. **Prog Neurobiol** 1999 Oct;59(2):81-106 (162 ref.)

PHYSIOLOGY

Retinal projections and retinal ganglion cell distribution patterns in a sturgeon (Acipenser transmontanus), a non-teleost actinopterygian fish. Ito H, et al. **Brain Behav Evol** 1999;53(3):127-41 (85 ref.)
Tectal fiber connections in a non-teleost actinopterygian fish, the sturgeon Acipenser. Yamamoto N, et al. **Brain Behav Evol** 1999;53(3):142-55 (47 ref.)
Gaze shifts in three-dimensional space: A closer look at the superior colliculus [comment] Guitton D. **J Comp Neurol** 1999 Oct 11;413(1):77-82 (52 ref.) Comment on: J Comp Neurol 1999 Oct 11;413(1):68-70.
Reading neural representations. Groh JM. **Neuron** 1998 Oct; 21(4):661-4 (11 ref.)
The synaptic pharmacology underlying sensory processing in the superior colliculus. Binns KE. **Prog Neurobiol** 1999 Oct;59(2):129-59 (172 ref.)

SUPERIOR MESENTERIC ARTERY SYNDROME

[Aorto-mesenteric compression syndrome. Description of clinical case and critical review of the literature] Gasbarro V, et al. **Minerva Chir** 1999 May;54(5):335-8 (16 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Superior mesenteric artery syndrome after segmental instrumentation: a biomechanical analysis. Vitale MG, et al. **Am J Orthop** 1999 Aug;28(8):461-7 (27 ref.)

RADIOGRAPHY

Radiological case of the month. Superior mesenteric artery syndrome. Shetty AK, et al. **Arch Pediatr Adolesc Med** 1999 Mar;153(3):303-4 (18 ref.)

SUPERIOR VENA CAVA OBSTRUCTION see **SUPERIOR VENA CAVA SYNDROME**

SUPERIOR VENA CAVA SYNDROME

DIAGNOSIS

Diagnosis and management of superior vena cava syndrome. Markman M. **Cleve Clin J Med** 1999 Jan;66(1):59-61 (5 ref.)
[Painless aortic dissection late after aortic valve replacement, presenting as superior vena cava syndrome] Hayashi Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):724-9 (31 ref.) (Eng. Abstr.) **(Jpn)**
[The superior vena cava syndrome as a manifestation of aortic dissection following aortic valve replacement (letter)] Vericat MC, et al. **An Med Interna** 1999 Jan;16(1):48-9 (10 ref.) **(Spa)**

ETIOLOGY

Benign superior vena cava syndrome due to suppurative mediastinal lymphadenitis: anterior mediastinoscopic management. Roy D, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1185-7 (17 ref.)
Compression syndromes caused by substernal goitres [see comments] Anders HJ. **Postgrad Med J** 1998 Jun; 74(872):327-9 (31 ref.) Comment in: Postgrad Med J 1998 Nov;74(877):701-2.
Cardiac tamponade. Knoop T, et al. **Semin Oncol Nurs** 1999 Aug;15(3):168-73 (24 ref.)

NURSING

Superior vena cava syndrome. Haapoja IS, et al. **Semin Oncol Nurs** 1999 Aug;15(3):183-9 (24 ref.)
Oncologic emergencies in the patient with lymphoma. Hogan DK, et al. **Semin Oncol Nurs** 1998 Nov;14(4):312-20 (38 ref.)

RADIOGRAPHY

[Superior vena cava endoprostheses] Lacombe P, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S157-61 (22 ref.) **(Fre)**

SURGERY

Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. Schindler N, et al. **Surg Clin North Am** 1999 Jun;79(3):683-94, xi (36 ref.)
[Superior vena cava endoprostheses] Lacombe P, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S157-61 (22 ref.) **(Fre)**

SUPERIOR VENA CAVA THROMBOSIS see **SUPERIOR VENA CAVA SYNDROME**

SUPEROXIDE DISMUTASE

Biological chemistry of copper-zinc superoxide dismutase and its link to amyotrophic lateral sclerosis. Lyons TJ, et al. **Met Ions Biol Syst** 1999;36:125-77 (287 ref.)

ANTAGONISTS & INHIBITORS

[Manganese superoxide dismutase-inhibiting autoantibodies in cholestatic Epstein-Barr viral hepatitis] Schaade L, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1478-82 (22 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Stability of S-nitrosothiols in presence of copper, zinc-superoxide dismutase. Jourd'heuil D, et al. **Methods Enzymol** 1999;301:220-7 (19 ref.)

GENETICS

Copper, zinc superoxide dismutase (SOD1) and its role in neuronal function and disease with particular relevance to motor neurone disease/amyotrophic lateral sclerosis. de Belleroche J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):476-80 (36 ref.)
Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Morrison BM, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):121-35 (140 ref.)
Recent advances in research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutations: neuronal Lewy body-like hyaline inclusions and astrocytic hyaline inclusions. Kato S, et al. **Histol Histopathol** 1999 Jul;14(3):973-89 (113 ref.)
Mutant CuZn superoxide dismutase in motor neuron disease. Gurney ME, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):587-97 (42 ref.)

IMMUNOLOGY

[Manganese superoxide dismutase-inhibiting autoantibodies in cholestatic Epstein-Barr viral hepatitis] Schaade L, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1478-82 (22 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Intracellular pathways of copper trafficking in yeast and humans. Culotta VC, et al. **Adv Exp Med Biol** 1999; 448:247-54 (44 ref.)
Copper, zinc superoxide dismutase (SOD1) and its role in neuronal function and disease with particular relevance to motor neurone disease/amyotrophic lateral sclerosis. de Belleroche J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):476-80 (36 ref.)
Role of superoxide dismutase in ischemic brain injury: a study using SOD-1 transgenic mice. Kinouchi H, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):609-20 (33 ref.)
Metal binding and radical generation of proteins in human neurological diseases and aging. Multhaup G, et al. **Met Ions Biol Syst** 1999;36:365-87 (105 ref.)

PHYSIOLOGY

A study of the dual role of copper in superoxide dismutase as antioxidant and pro-oxidant in cellular models of amyotrophic lateral sclerosis. Carrì MT, et al. **Adv Exp Med Biol** 1999;448:205-13 (38 ref.)
Copper-zinc superoxide dismutase and ALS. Valentine JS, et al. **Adv Exp Med Biol** 1999;448:193-203 (50 ref.)
Familial amyotrophic lateral sclerosis and Alzheimer's disease. Transgenic models. Wong PC, et al. **Adv Exp Med Biol** 1998;446:145-59 (117 ref.)
Oxidative stress and motor neurone disease. Cookson MR, et al. **Brain Pathol** 1999 Jan;9(1):165-86 (148 ref.)
The role of manganese superoxide dismutase in health and disease. Robinson BH. **J Inherit Metab Dis** 1998 Aug; 21(5):598-603 (26 ref.)

SUPEROXIDES

see related
RESPIRATORY BURST

ANALYSIS

Detection of active oxygen species in biological systems. Nakano M. **Cell Mol Neurobiol** 1998 Dec;18(6):565-79 (19 ref.)
Nitric oxide and superoxide detection in human platelets. Freedman JE, et al. **Methods Enzymol** 1999;301:61-70 (21 ref.)
Analysis of aromatic nitration, chlorination, and hydroxylation by gas chromatography-mass spectrometry. van der Vliet A, et al. **Methods Enzymol** 1999;301:471-83 (48 ref.)
Electron spin resonance spin-trapping detection of superoxide generated by neuronal nitric oxide synthase. Vásquez-Vivar J, et al. **Methods Enzymol** 1999;301:169-77 (30 ref.)

CHEMISTRY

Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Squadrito GL, et al. **Free Radic Biol Med** 1998 Sep;25(4-5):392-403 (102 ref.)

SUPEROXIDES

METABOLISM

Ras, superoxide and signal transduction. Irani K, et al. **Biochem Pharmacol** 1998 May 1;55(9):1339–46 (90 ref.)

Stress, superoxide, and signal transduction. Goldschmidt-Clermont PJ, et al. **Gene Expr** 1999; 7(4–6):255–60 (47 ref.)

Normal and pathological distribution of nitric oxide in the cardiovascular system. Malinski T. **Pol J Pharmacol** 1998 Nov–Dec;50(6):387–91 (29 ref.)

Role of coenzyme Q and superoxide in vitamin E cycling. Kagan VE, et al. **Subcell Biochem** 1998;30:491–507 (77 ref.)

Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1055–8 (18 ref.)

PHARMACOLOGY

[Superoxide, nitric oxide and peroxynitrite] Fukuyama N, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):169–76 (47 ref.) (Eng. Abstr.) **(Jpn)**

SUPERSTITIONS

PSYCHOLOGY

Motivation, cognition and pseudoscience. Lindeman M. **Scand J Psychol** 1998 Dec;39(4):257–65 (84 ref.)

SUPINE POSITION

[Assymetric skull? Early correct diagnosis is a must! Positional skull deformities can be avoided (see comments)] Lauritzen C, et al. **Lakartidningen** 1999 Mar 24; 96(12):1447–53 (10 ref.) (Eng. Abstr.) Comment in: Lakartidningen 1999 Mar 24;96(12):1404–5. **(Swe)**

[Recommendations are not changed--let infants sleep in supine position. Surgical specialists' contribution to population studies would be of value] Sedin G. **Lakartidningen** 1999 May 12;96(19):2357–8 (16 ref.) **(Swe)**

SUPPLEMENTARY MEDICAL INSURANCE PROGRAM, MEDICARE see **MEDICARE PART B**

SUPPORT GROUPS see **SELF-HELP GROUPS**

SUPPORTED EMPLOYMENT see **EMPLOYMENT, SUPPORTED**

SUPPRESSION, GENETIC

GENETICS

The suppressor-mutator element and the evolutionary riddle of transposons. Fedoroff NV. **Genes Cells** 1999 Jan; 4(1):11–9 (97 ref.)

SUPPRESSOR CELLS see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

SUPPRESSOR-EFFECTOR T-LYMPHOCYTES see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

SUPPRESSOR FACTOR, T-CELL, GLIOBLASTOMA-DERIVED see **TRANSFORMING GROWTH FACTOR BETA**

SUPPRESSOR MUTATION see **SUPPRESSION, GENETIC**

SUPPRESSOR TRANSFER RNA see **RNA, TRANSFER**

SUPRACHIASMATIC NUCLEUS

CYTOLOGY

PASting together the mammalian clock. Whitmore D, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):635–41 (45 ref.)

Functional morphology of the suprachiasmatic nucleus. Ibata Y, et al. **Front Neuroendocrinol** 1999 Jul;20(3):241–68 (102 ref.)

METABOLISM

Functional morphology of the suprachiasmatic nucleus. Ibata Y, et al. **Front Neuroendocrinol** 1999 Jul;20(3):241–68 (102 ref.)

Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Ingram CD, et al. **Prog Brain Res** 1998;119:351–64 (92 ref.)

PHYSIOLOGY

Conditioning in the circadian system. Amir S, et al. **Chronobiol Int** 1998 Sep;15(5):447–56 (55 ref.)

Cellular requirements of suprachiasmatic nucleus transplants for restoration of circadian rhythm. Boer GJ, et al. **Chronobiol Int** 1998 Sep;15(5):551–66 (50 ref.)

Output signals of the SCN. LeSauter J, et al. **Chronobiol Int** 1998 Sep;15(5):535–50 (89 ref.)

The SCN is comprised of a population of coupled oscillators. Miller JD. **Chronobiol Int** 1998 Sep;15(5):489–511 (133 ref.)

Suprachiasmatic nucleus organization. Moore RY, et al. **Chronobiol Int** 1998 Sep;15(5):475–87 (44 ref.)

Photic entrainment of circadian rhythms in rodents. Rea MA. **Chronobiol Int** 1998 Sep;15(5):395–423 (227 ref.)

The suprachiasmatic nucleus and circadian function: an introduction. Silver R, et al. **Chronobiol Int** 1998 Sep; 15(5):vii–x (20 ref.)

Restoration of circadian behavior by anterior hypothalamic grafts containing the suprachiasmatic nucleus: graft/host interconnections. Sollars PJ, et al. **Chronobiol Int** 1998 Sep; 15(5):513–33 (104 ref.)

Generation and entrainment of circadian rhythms. Kennaway DJ. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):862–5 (32 ref.)

The suprachiasmatic nucleus–paraventricular nucleus interactions: a bridge to the neuroendocrine and autonomic nervous system. Buijs RM, et al. **Prog Brain Res** 1998; 119:365–82 (93 ref.)

[Understanding the action of the circadian clock: from phenomenologic ideas to molecular activity] Serviere J. **C R Seances Soc Biol Fil** 1998;192(4):683–710 (120 ref.) (Eng. Abstr.) **(Fre)**

[The biological clock in mammals: structure and function] Lewandowski MH. **Postepy Hig Med Dosw** 1999; 53(3):405–22 (40 ref.) (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Cellular requirements of suprachiasmatic nucleus transplants for restoration of circadian rhythm. Boer GJ, et al. **Chronobiol Int** 1998 Sep;15(5):551–66 (50 ref.)

SUPRANUCLEAR PALSY, PROGRESSIVE

Progressive supranuclear palsy revisited [corrected and republished with original paging, article originally printed in Acta Neurol Scand 1998 Aug;98(2):73–84] Litvan I. **Acta Neurol Scand** 1998 Dec;98(6):73–84 (145 ref.)

Progressive supranuclear palsy revisited [corrected and republished in Acta Neurol Scand 1998 Dec;98(6):73–84] Litvan I. **Acta Neurol Scand** 1998 Aug;98(2):73–84 (144 ref.)

[Progressive supranuclear palsy (PSP)] Nishimiya J, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):45–8 (16 ref.) **(Jpn)**

DIAGNOSIS

Progressive supranuclear palsy. Litvan I, et al. **Adv Neurol** 1999;80:341–5 (54 ref.)

Progressive supranuclear palsy. Pahwa R. **Med Clin North Am** 1999 Mar;83(2):369–79, v–vi (75 ref.)

[Cortical lesions in progressive supranuclear palsy (Steele-Richardson-Olszewski disease)] Verny M, et al. **Rev Neurol (Paris)** 1999 Jan;155(1):15–26 (117 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Clinical and genetic aspects of progressive supranuclear palsy. Litvan I, et al. **J Geriatr Psychiatry Neurol** 1998 Summer;11(2):107–14 (92 ref.)

PATHOLOGY

Progressive supranuclear palsy. Litvan I, et al. **Adv Neurol** 1999;80:341–5 (54 ref.)

SUPRAOPTIC NUCLEUS

PHYSIOLOGY

Electrophysiological distinctions between oxytocin and vasopressin neurons in the supraoptic nucleus. Armstrong WE, et al. **Adv Exp Med Biol** 1998;449:67–77 (47 ref.)

Mechanisms of neuroendocrine cell excitability. Hatton GI, et al. **Adv Exp Med Biol** 1998;449:79–95 (86 ref.)

Intrahypothalamic vasopressin release. An inhibitor of systemic vasopressin secretion? Ludwig M, et al. **Adv Exp Med Biol** 1998;449:163–73 (50 ref.)

New aspects of firing pattern autocontrol in oxytocin and vasopressin neurones. Moos F, et al. **Adv Exp Med Biol** 1998;449:153–62 (32 ref.)

GABAB receptors and supraoptic neuronal activity. Pittman QJ, et al. **Adv Exp Med Biol** 1998;449:107–15 (38 ref.)

Galanin-galanin receptor systems in the hypothalamic paraventricular and supraoptic nuclei. Some recent findings and future challenges. Gundlach AL, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:241–51 (52 ref.)

SUPRAPUBIC CYSTOSTOMY see **CYSTOSTOMY**

SUPRASELLAR CYST see **CRANIOPHARYNGIOMA**

SUPRATENTORIAL NEOPLASMS

PHYSIOPATHOLOGY

Supratentorial cavernous haemangiomas and epilepsy: a review of the literature and case series. Moran NF, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):561–8 (74 ref.)

SURGERY

Multiple postoperative intracerebral haematomas remote from the site of craniotomy. Rapanà A, et al. **Br J Neurosurg** 1998 Aug;12(4):364–8 (32 ref.)

SURAL NERVE

PATHOLOGY

Adult polyglucosan body disease associated with an extrapyramidal syndrome. Robertson NP, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):788–90 (22 ref.)

Congenital hypomyelinating neuropathy: two patients with long-term follow-up. Phillips JP, et al. **Pediatr Neurol** 1999 Mar;20(3):226–32 (28 ref.)

SURFACE-ACTIVE AGENTS

see related **PULMONARY SURFACTANTS**

Recent trends in the biochemistry of surfactin. Peypoux F, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):553–63 (95 ref.)

ADMINISTRATION & DOSAGE

Drug-surfactant-propellant interactions in HFA-formulations. Vervaet C, et al. **Int J Pharm** 1999 Sep 10;186(1):13–30 (84 ref.)

ANALYSIS

Coatings. Anderson DG. **Anal Chem** 1999 Jun 15; 71(12):21R–32R (500 ref.)

CHEMICAL SYNTHESIS

Synthetic neoglycolipids for biological applications: correlation between their structures and their interactions with membrane proteins. Rico-Lattes I, et al. **Biochimie** 1998 May–Jun;80(5–6):483–7 (18 ref.)

CHEMISTRY

Surface-active lipids in rhodococci. Lang S, et al. **Antonie Van Leeuwenhoek** 1998 Jul–Oct;74(1–3):59–70 (70 ref.)

Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution. Krafft MP, et al. **Biochimie** 1998 May–Jun;80(5–6):489–514 (154 ref.)

Surfactants in membrane solubilisation. Jones MN. **Int J Pharm** 1999 Jan 25;177(2):137–59 (115 ref.)

[Interaction of apolipoprotein A1 with phospholipids and structure of mixed micelles] Misharin AIu. **Bioorg Khim** 1998 Aug;24(8):563–85 (205 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Synthesis of biosurfactants in extreme conditions. Cameotra SS, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):520–9 (90 ref.)

Rhamnose lipids--biosynthesis, microbial production and application potential. Lang S, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):22–32 (116 ref.)

PHARMACOLOGY

Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution. Krafft MP, et al. **Biochimie** 1998 May–Jun;80(5–6):489–514 (154 ref.)

Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Benita S. **Biomed Pharmacother** 1999 May;53(4):193–206 (68 ref.)

THERAPEUTIC USE

[Surfactants as agents for the individual prevention of HIV/AIDS] Krivorutchenko IuL. **Mikrobiol Z** 1999 Jan–Feb;61(1):95–103 (65 ref.) (Eng. Abstr.) **(Rus)**

SURFACE ANTIGENS see **ANTIGENS, SURFACE**

SURFACE GLYCOPROTEINS see **MEMBRANE GLYCOPROTEINS**

SURFACE MARKERS, IMMUNOLOGICAL see **ANTIGENS, SURFACE**

SURFACE PLASMON RESONANCE

Surface plasmon resonance biosensors as a tool in antibody engineering. Alfthan K. **Biosens Bioelectron** 1998 Sep 15; 13(6):653–63 (93 ref.)

Applications of fiber-optic evanescent wave spectroscopy. Squillante E 3rd. **Drug Dev Ind Pharm** 1998 Dec; 24(12):1163–75 (73 ref.)

INSTRUMENTATION

Plasmon resonance spectroscopy: probing molecular interactions within membranes. Salamon Z, et al. **Trends Biochem Sci** 1999 Jun;24(6):213–9 (33 ref.)

METHODS

Plasmon resonance spectroscopy: probing molecular interactions within membranes. Salamon Z, et al. **Trends Biochem Sci** 1999 Jun;24(6):213–9 (33 ref.)

SURFACE PROPERTIES

Reactions of cells to topography. Curtis AS, et al. **J Biomater Sci Polym Ed** 1998;9(12):1313–29 (46 ref.)

SURFACE PROTEINS see **MEMBRANE PROTEINS**

SURFACE TENSION

The role of lipids in pulmonary surfactant. Veldhuizen R, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):90–108 (80 ref.)

SURFACE VARIANT GLYCOPROTEINS, TRYPANOSOMA see **VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA**

SURFACTANTS see **SURFACE-ACTIVE AGENTS**

SURFACTANTS, PULMONARY see **PULMONARY SURFACTANTS**

SURGERY

see related
SURGICAL PROCEDURES, OPERATIVE

Surgical Internet at a glance: volume IX. Allen J. **Am J Surg** 1999 Mar;177(3):183 (0 ref.)

Hepatitis B--are surgeons putting patients at risk? Birrell LN, et al. **Occup Med (Lond)** 1998 Nov;48(8):529–31 (13 ref.)

Ethical considerations in prenatal surgical consultation [see comments] Caniano DA, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):303–9 (21 ref.) Comment in: Pediatr Surg Int 1999 Jul;15(5–6):301–2.

[Blood and plasma product safety from viewpoint of the surgeon] Kussmann J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):495–7 (18 ref.) **(Ger)**

ECONOMICS

[Surgical aid for population in conditions of compulsory medical insurance] Gusev LI, et al. **Khirurgiia (Mosk)** 1999; (8):45–9 (33 ref.) (Eng. Abstr.) **(Rus)**

EDUCATION

Training, retraining and retaining rural general surgeons. Kiroff G. **Aust N Z J Surg** 1999 Jun;69(6):413–4 (8 ref.)

[Attitude of surgeons] Mizumoto R. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):846–54 (0 ref.) **(Jpn)**

METHODS

A surgeon's response to the intersex controversy. Schober JM. **J Clin Ethics** 1998 Winter;9(4):393–7 (12 ref.)

Clinical research in surgery: questions but few answers. Beger HG, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):300–5 (55 ref.)

Basic surgical research. Messmer K. **Langenbecks Arch Surg** 1998 Oct;383(5):297–9 (9 ref.)

Conceptional and structural conditions for successful clinical research. Troidl H. **Langenbecks Arch Surg** 1998 Oct; 383(5):306–16 (30 ref.)

Prognostic factors: guidelines for investigation design and state of the art analytical methods. Drew PJ, et al. **Surg Oncol** 1998 Jul–Aug;7(1–2):71–6 (31 ref.)

ORGANIZATION & ADMINISTRATION

[Surgical tactics in firearm wounds of abdomen] Revskoi AK, et al. **Khirurgiia (Mosk)** 1998;(10):15–9 (4 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Reflections on randomised controlled trials in surgery. Baum M. **Lancet** 1999 Apr;353 Suppl 1:SI6–8 (19 ref.)

TRENDS

Gene therapy: into the future of surgery. Hollingsworth SJ, et al. **Lancet** 1999 Apr;353 Suppl 1:SI19–20 (9 ref.)

Surgery and the randomised controlled trial: past, present and future [see comments] Solomon MJ, et al. **Med J Aust** 1998 Oct 5;169(7):380–3 (49 ref.) Comment in: Med J Aust 1998 Oct 5;169(7):348–9. Comment in: Med J Aust 1999 Mar 1;170(5):237–8.

SURGERY, COSMETIC see **SURGERY, PLASTIC**

SURGERY, ESTHETIC see **SURGERY, PLASTIC**

SURGERY, FILTRATION see **FILTERING SURGERY**

SURGERY, LASER see **LASER SURGERY**

SURGERY, MAXILLOFACIAL see **SURGERY, ORAL**

SURGERY, OFFICE see **AMBULATORY SURGICAL PROCEDURES**

SURGERY, ORAL

see related
DENTISTRY, OPERATIVE
ORAL SURGICAL PROCEDURES

LEGISLATION & JURISPRUDENCE

Medicolegal considerations for office-based anesthesia in dentistry. Whitmire HC Jr. **Dent Clin North Am** 1999 Apr; 43(2):361–72, vii, 373–7 (26 ref.)

SURGERY, ORTHOPEDIC see **ORTHOPEDICS**

SURGERY, OUTPATIENT see **AMBULATORY SURGICAL PROCEDURES**

SURGERY, PLASTIC

see related
RECONSTRUCTIVE SURGICAL PROCEDURES

The goal of adult strabismus surgery is not cosmetic [editorial] Rosenbaum AL. **Arch Ophthalmol** 1999 Feb; 117(2):250 (8 ref.)

Common problems seen by the plastic surgery emergency room service. Shook JE. **Clin Plast Surg** 1998 Oct; 25(4):619–29, ix (41 ref.)

Genital skin loss: unified reconstructive approach to a heterogeneous entity. Wessells H. **World J Urol** 1999 Apr; 17(2):107–14 (21 ref.)

[Facial epitheliomas: general considerations, surgical techniques and indications] Martin D, et al. **Ann Chir Plast Esthet** 1998 Aug;43(4):311–64 (142 ref.) (Eng. Abstr.) **(Fre)**

[Augmentation phalloplasty according to the G. Tritto technique] Randone D, et al. **Arch Ital Urol Androl** 1998 Dec;70(5):235–9 (8 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

[Laser surgery in esthetic surgery. Review] Mang WL, et al. **Mund Kiefer Gesichtschir** 1999 May;3 Suppl 1:S162–7 (13 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Fortnightly review: cosmetic surgery. Hoeyberghs JL. **BMJ** 1999 Feb 20;318(7182):512–6 (39 ref.)

Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Edelstein C, et al. **Dermatol Surg** 1998 Nov; 24(11):1208–12 (12 ref.)

Topical agents used in association with cosmetic surgery. Draelos ZD. **Semin Cutan Med Surg** 1999 Jun;18(2):112–8 (33 ref.)

[Surgical management of soft tissue sarcomas: principles of resection and reconstructive plastic procedures] Steinau HU, et al. **Schweiz Rundsch Med Prax** 1998 Aug 19; 87(34):1061–5 (17 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Cosmetic surgery: surgical tools--psychosocial goals. Grossbart TA, et al. **Semin Cutan Med Surg** 1999 Jun; 18(2):101–11 (32 ref.)

TRENDS

Plastic surgery. Kuzon WM Jr. **J Am Coll Surg** 1999 Feb; 188(2):171–7 (57 ref.)

SURGERY, UNNECESSARY see **UNNECESSARY PROCEDURES**

SURGERY, VETERINARY

Fluid therapy and newer blood products. Broadstone RV. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):611–28 (30 ref.)

Analgesics and pain. Carroll GL. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):701–17, vi (66 ref.)

Management of geriatric patients. A common occurrence. Harvey RC, et al. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):683–99, vi (26 ref.)

Newer diagnostic and surgical techniques and their impact on anesthesia. Robertson SA. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):665–82 (37 ref.)

Newer analgesics. Nonsteroid anti-inflammatory drugs, opioids, and combinations. Taylor PM. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):719–35, vii (68 ref.)

SURGICAL ANASTOMOSIS see **ANASTOMOSIS, SURGICAL**

SURGICAL BLOOD LOSS see **BLOOD LOSS, SURGICAL**

SURGICAL CLAMPS see **SURGICAL INSTRUMENTS**

SURGICAL CLIPS see **SURGICAL INSTRUMENTS**

SURGICAL DIATHERMY see **ELECTROCOAGULATION**

SURGICAL EQUIPMENT

Image-guided neurosurgery/neuronavigation/the SurgiScope--reflexions on a theme. Haase J. **Minim Invasive Neurosurg** 1999 Jun;42(2):53–9 (37 ref.)

SURGICAL ERRORS see **MEDICAL ERRORS**

SURGICAL FLAPS

The role of emergency free flaps for hand trauma. McCabe SJ, et al. **Hand Clin** 1999 May;15(2):275–88, viii–ix (18 ref.)

Platysma myocutaneous flap for intraoral reconstruction: an option in the compromised patient. Berenholz L, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):285–7 (11 ref.)

Distraction osteogenesis of a fibula free flap used for mandibular reconstruction: preliminary report. Siciliano S, et al. **J Craniomaxillofac Surg** 1998 Dec;26(6):386–90 (20 ref.)

Z-plasty closure of the donor defect of the radial forearm free flap. Hui KC, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):19–21 (10 ref.)

Grafting techniques. Wehrs RE. **Otolaryngol Clin North Am** 1999 Jun;32(3):443–55 (11 ref.)

Use of apron flap incision for neck dissection. Yii NW, et al. **Plast Reconstr Surg** 1999 May;103(6):1655–60 (24 ref.)

Transposition of the great omentum for infected sternotomy wounds in cardiac surgery. Report of 16 cases and review of published reports. Moor EV, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):25–9 (35 ref.)

The transeyelid superiosteal midface-lift in the unhappy postblepharoplasty patient. Edelstein C, et al. **Semin Ophthalmol** 1998 Sep;13(3):107–14 (13 ref.)

[Effects of hyperbaric oxygen on the skin graft survival] Jiang P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):91–3 (23 ref.) **(Chi)**

[Advance in the study of restoration of sensation in skin flaps] Kuang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):94–6 (25 ref.) **(Chi)**

[Progress in the clinical uses of fasciocutaneous flap] Wan W, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):97–9 (37 ref.) **(Chi)**

[Serratus anterior muscle flap: indications and sequelae. 26 cases and review of the literature] Fassio E, et al. **Ann Chir Plast Esthet** 1999 Apr;44(2):175–82; discussion 183 (34 ref.) (Eng. Abstr.) **(Fre)**

[Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?] Mariéthoz S, et al. **Ann Chir Plast Esthet** 1999 Feb;44(1):81–8 (77 ref.) (Eng. Abstr.) **(Fre)**

[Update mid-term review of the pedicular extension in reverse YV flow. Review of a 7-year experience] Martin D, et al. **Ann Chir Plast Esthet** 1997 Dec;42(6):581–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Plea for accelerated rehabilitation after ligament plasty of the knee by a bone-patellar tendon-bone graft] Boileau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):475–90 (97 ref.) (Eng. Abstr.) **(Fre)**

[Myocutaneous flaps: some remarks on genesis of the method] Noszczyk BH. **Pol Merkuriusz Lek** 1998 Apr;4(22):226–9 (45 ref.) (Eng. Abstr.) **(Pol)**

[Muscle-aponeurotic transposition for treatment of anal incontinence] Sobrado CW, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Jul–Aug; 53(4):205–13 (74 ref.) (Eng. Abstr.) **(Por)**

[Expanders in plastic ophthalmologic surgery] Fadeeva EA, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):47–9 (26 ref.) **(Rus)**

[The use of the temporal muscle for closing postoperative wounds] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct–Dec; (4):51–4 (22 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Flap complications of lamellar refractive surgery [editorial; comment] Gimbel HV. **Am J Ophthalmol** 1999 Feb; 127(2):202–4 (6 ref.) Comment on: Am J Ophthalmol 1999 Feb;127(2):129–36.

BLOOD SUPPLY

[Techniques for postoperative monitoring of tissue circulation after free microvascular tissue transplantation] Machens HG, et al. **Handchir Mikrochir Plast Chir** 1999 Mar; 31(2):107–12 (40 ref.) (Eng. Abstr.) **(Ger)**

SURGICAL GLOVES see **GLOVES, SURGICAL**

SURGICAL HOOKS see **SURGICAL INSTRUMENTS**

SURGICAL INJURIES see **INTRAOPERATIVE COMPLICATIONS**

SURGICAL INSTRUMENTS

Three-trocar laparoscopic cholecystectomy: a continued debate [letter; comment] Slim K, et al.

SURGICAL INSTRUMENTS

Surg Laparosc Endosc 1998 Dec;8(6):480–1 (5 ref.)
Comment on: Surg Laparosc Endosc 1997 Apr;7(2):180–1.
Comment on: Surg Laparosc Endosc 1998 Apr;8(2):159–60.
[Using the electric scalpel in laparoscopy. Principles and prevention of complications] Mutter D. **Ann Chir** 1998; 52(1):53–60 (20 ref.) **(Fre)**

ADVERSE EFFECTS

Virtues and drawbacks of titanium alloy aneurysm clips. Steiger HJ, et al. **Acta Neurochir Suppl (Wien)** 1999;72:81–8 (18 ref.)

MICROBIOLOGY

[Non-transfusional and non-intravenous drug addiction related transmission of hepatitis C virus] Serfaty L. **Presse Med** 1999 Jun 12;28(21):1135–40 (56 ref.) (Eng. Abstr.) **(Fre)**

SURGICAL MESH

Intraparietal retrorectus tension-free prosthetic mesh: a simple and effective method of repair of complex ventral hernias via a modified Stoppa technique. Surgical technique. Sakorafas GH, et al. **Acta Chir Belg** 1999 May–Jun;99(3):109–12 (12 ref.)
Groin hernia and surgical truth [editorial] McGreevy JM. **Am J Surg** 1998 Oct;176(4):301–4 (22 ref.)
Does the mesh require fixation? Macintyre IMC. **Semin Laparosc Surg** 1998 Dec;5(4):224–6 (20 ref.)
The Lichtenstein repair. Kurzer M, et al. **Surg Clin North Am** 1998 Dec;78(6):1025–46 (61 ref.)
Inguinal hernia repair. The Nyhus posterior preperitoneal operation. Patiño JF, et al. **Surg Clin North Am** 1998 Dec; 78(6):1063–74 (39 ref.)
[The use of prosthetic materials placed intraperitoneally in the repair of large defects of the abdominal wall, reflections on a limited case series] Miro AG, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):277–81; discussion 281–2 (30 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Extrusion and granuloma formation with mersilene mesh brow suspension. Mutlu FM, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):47–51 (17 ref.)
Pathophysiology, prevention, and management of prosthetic infections in hernia surgery. Deysine M. **Surg Clin North Am** 1998 Dec;78(6):1105–15, viii (26 ref.)

SURGICAL NURSING see **PERIOPERATIVE NURSING**

SURGICAL PLUGS see **SURGICAL INSTRUMENTS**

SURGICAL PROCEDURES, ELECTIVE

Insulin resistance: a marker of surgical stress. Thorell A, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):69–78 (68 ref.)
The role of antibiotics in the management of elective and post-traumatic hand surgery. Hoffman RD, et al. **Hand Clin** 1998 Nov;14(4):657–66 (89 ref.)
Elective surgery and the HIV-positive patient: medical, legal, and ethical issues. Clarke SR, et al. **J La State Med Soc** 1999 May;151(5):245–9 (17 ref.)
Weighing risks in abdominal aortic aneurysm. Best repaired in an elective, not an emergency, procedure. Gorski Y, et al. **Postgrad Med** 1999 Aug;106(2):69–70, 75–80 (17 ref.)
[Nasogastric tubes after elective abdominal surgery is not justified] Gouzi JL, et al. **J Chir (Paris)** 1998 Dec; 135(6):273–4 (11 ref.) (Eng. Abstr.) **(Fre)**
[Elective surgery and emergency surgery in patients undergoing oral anticoagulant therapy] Berrettini M. **Minerva Anestesiol** 1999 Jan–Feb;65(1–2 Suppl 1):53–9 (19 ref.) **(Ita)**
[The multifocality problem in elective partial nephrectomy for renal-cell carcinoma (editorial)] Cabezas CA, et al. **Actas Urol Esp** 1999 Jan;23(1):1–4 (18 ref.) **(Spa)**

METHODS

Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinoma? Marquet RL, et al. **Eur J Cancer** 1999 Mar;35(3):352–60 (75 ref.)
[Variceal hemorrhage in portal hypertension: role of surgery in the acute and elective situation] Krähenbühl L, et al. **Schweiz Med Wochenschr** 1999 Apr 24;129(16):631–8 (70 ref.) (Eng. Abstr.) **(Ger)**
[Surgical versus medical treatment of idiopathic trigeminal neuralgia] Mariani L, et al. **Schweiz Med Wochenschr** 1998 Oct 3;128(40):1512–8 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGICAL PROCEDURES, ENDOSCOPIC

Intracranial endoscopy. Fries G, et al. **Adv Tech Stand Neurosurg** 1999;25:21–60 (145 ref.)
Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. van den Boogert J, et al. **Am J Gastroenterol** 1999 May;94(5):1153–60 (85 ref.)
Endoscopic management of low-grade papillary adenocarcinoma of the ethmoid sinus: case report and review of the literature. Shah UK, et al. **Am J Otolaryngol** 1999 May–Jun;20(3):190–4 (25 ref.)
The present status of endoscopy. Poindexter BD, et al. **Ann Plast Surg** 1998 Dec;41(6):679–83 (52 ref.)
Thoracoscopic resection of a giant leiomyoma of the esophagus with a mediastinal outgrowth. Tamura K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):351–3 (11 ref.)
Endoscopic mucosal resection for esophageal and gastric mucosal cancers. Inoue H. **Can J Gastroenterol** 1998 Jul–Aug;12(5):355–9 (15 ref.)
Video-assisted thoracic surgery for diagnosis of the solitary lung nodule. Hazelrigg SR, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):763–74, vii (31 ref.)
Effect of minimally invasive thoracic surgical approaches on acute and chronic postoperative pain. Landreneau RJ, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):891–906 (70 ref.)
Management of periampullary adenoma. Norton ID, et al. **Dig Dis** 1998 Sep–Oct;16(5):266–73 (52 ref.)
Premedication, preparation, and surveillance. Lazzaroni M, et al. **Endoscopy** 1999 Jan;31(1):2–8 (50 ref.)
Minimally invasive surgery. Montori A. **Endoscopy** 1999 Jan; 31(1):110–6 (46 ref.)
Percutaneous endoscopic gastrostomy: an update. Safadi BY, et al. **Endoscopy** 1998 Nov;30(9):781–9 (110 ref.)
Endoscopic treatment of Zenker's diverticulum [editorial; comment] Bremner CG, et al. **Gastrointest Endosc** 1999 Jan;49(1):126–8 (16 ref.) Comment on: Gastrointest Endosc 1999 Jan;49(1):93–7.
Multiple granular cell tumors of the esophagus removed endoscopically: a case report. Esaki M, et al. **Gastrointest Endosc** 1998 Nov;48(5):536–9 (22 ref.)
Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Haag S, et al. **Gastrointest Endosc** 1999 Aug;50(2):229–40 (118 ref.)
Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations. Van Os EC, et al. **Gastrointest Endosc** 1999 Oct;50(4):536–43 (27 ref.)
Ophthalmic endoscopy: applications in intraocular surgery. Sheindlin JA, et al. **Int Ophthalmol Clin** 1999 Winter; 39(1):237–47 (20 ref.)
Part I: The use of arthroscopic surgery for treatment of temporomandibular joint disorders. Israel HA. **J Oral Maxillofac Surg** 1999 May;57(5):579–82 (21 ref.)
Bone density measurements of the paranasal sinuses on plastinated whole-organ sections: anatomic data to prevent complications in endoscopic sinus surgery. Sprinzl GM, et al. **Laryngoscope** 1999 Mar;109(3):400–6 (33 ref.)
The role of endoscopic third ventriculostomy in the management of shunt malfunction. Cinalli G, et al. **Neurosurgery** 1998 Dec;43(6):1323–7; discussion 1327–9 (34 ref.)
Ultrasound guidance during endoscopic procedures. Letterie GS. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):63–82 (48 ref.)
Laparoscopy and hysteroscopy. Schenk LM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):1–22, v (61 ref.)
Endoscopic myomectomy. Laparoscopy and hysteroscopy. Tulandi T, et al. **Obstet Gynecol Clin North Am** 1999 Mar; 26(1):135–48, viii (65 ref.)
Anaesthetic implications of thoracoscopic surgery in children. Tobias JD. **Paediatr Anaesth** 1999;9(2):103–10 (36 ref.)
The endoscopic browlift for forehead rejuvenation. Holck DE, et al. **Semin Ophthalmol** 1998 Sep;13(3):149–57 (25 ref.)
Thoracoscopy in infants and children. Rothenberg SS. **Semin Pediatr Surg** 1998 Nov;7(4):194–201 (27 ref.)
Combined laparoscopic and flexible endoscopic techniques in the management of malignant gastrointestinal lesions. Franklin ME Jr, et al. **Semin Surg Oncol** 1998 Oct–Nov; 15(3):183–8 (12 ref.)
Endoscopic mucosal resection for early gastric cancer. Makuuchi H, et al. **Semin Surg Oncol** 1999 Sep;17(2):108–16 (44 ref.)
Video-assisted and robotic mitral valve surgery: toward an endoscopic surgery. Chitwood WR Jr. **Semin Thorac Cardiovasc Surg** 1999 Jul;11(3):194–205 (39 ref.)
Interventional treatment of acute and chronic pancreatitis. Endoscopic procedures. Norton ID, et al. **Surg Clin North Am** 1999 Aug;79(4):895–911, xii (82 ref.)
CO(2) pneumoperitoneum: what we know and what we need to know. Holthausen UH, et al. **World J Surg** 1999 Aug; 23(8):794–800 (40 ref.)
Surgical stress response: does endoscopic surgery confer an advantage? Kehlet H. **World J Surg** 1999 Aug;23(8):801–7 (55 ref.)
Second step: testing-outcome measurements. Lorenz W, et al. **World J Surg** 1999 Aug;23(8):768–80 (112 ref.)
Endoscopic surgery: fit for malignancy? Müller JM, et al. **World J Surg** 1999 Aug;23(8):808–15 (54 ref.)
Advances in therapeutic endoscopic treatment of common bile duct stones. Seitz U, et al. **World J Surg** 1998 Nov; 22(11):1133–44 (97 ref.)
Minimally invasive vascular surgery: review of current modalities. Weiss VJ, et al. **World J Surg** 1999 Apr; 23(4):406–14 (73 ref.)
[Progresses in the study of gynecology in China, 1997] Lang J. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):923–4 (0 ref.) **(Chi)**
[Endoscopy in the diagnosis and treatment of ear diseases] Tu D, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Nov;11(11):532–4 (10 ref.) **(Chi)**
[Treatment of urinary incontinence by the laparotomic or laparoscopic Burch technique] Cosson M, et al. **Ann Chir** 1999;53(6):515–21 (8 ref.) **(Fre)**
[Endoscopic treatment of lithiasis of the common bile duct. Results and indications] Sautereau D. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B17–22 (35 ref.) **(Fre)**
[Endoscopic treatment of vesico-renal reflux] **Prog Urol** 1998 Nov;8(5):841–62 (116 ref.) **(Fre)**
[Interventional bronchoscopic procedures--indications] Schönfeld N, et al. **Dtsch Med Wochenschr** 1999 May 28; 124(21):659–61 (8 ref.) **(Ger)**
[Ulna impaction syndrome therapy: decompressive surgical procedures of the head of the ulna] Krimmer H, et al. **Handchir Mikrochir Plast Chir** 1998 Nov;30(6):370–4 (20 ref.) (Eng. Abstr.) **(Ger)**
[Endoscopic therapy of solid tumors of the gastrointestinal tract] Arnold JC, et al. **Internist (Berl)** 1998 Nov; 39(11):1148–58 (58 ref.) **(Ger)**
[Value of external dacryocystorhinostomy (editorial)] Struck HG. **Klin Monatsbl Augenheilkd** 1999 Jul;215(1):1–3 (31 ref.) (Eng. Abstr.) **(Ger)**
[Arthroscopic ankle surgery. Indications, methods, results, complications] Jerosch J. **Orthopade** 1999 Jun;28(6):538–49 (43 ref.) (Eng. Abstr.) **(Ger)**
[Surgical lung volume reduction--an option for treating severe pulmonary emphysema] Russi EW, et al. **Ther Umsch** 1999 Mar;56(3):157–60 (5 ref.) (Eng. Abstr.) **(Ger)**
[Endoscopic therapy of Barrett esophagus--a supplement to drug and surgical options?] Ell C. **Z Gastroenterol** 1999 Jan;37(1):21–5 (24 ref.) (Eng. Abstr.) **(Ger)**
[Role of endoscopy in the palliative therapy of pancreatic cancer] Spinelli P, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S60–3 (26 ref.) (Eng. Abstr.) **(Ita)**
[Twenty-five years of progress in the treatment of esophageal and gastric cancers] Konishi T. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:118–28 (69 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical application and future prospect of neuroendoscopic surgery] Oi S. **No To Hattatsu** 1999 Jul;31(4):299–304 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Endoscopic surgery for thoracic spine. Critical review] Martins JW, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2B):520–7 (35 ref.) (Eng. Abstr.) **(Por)**
[Pathogenetic substantiation of lung denervation in bronchial asthma and it's indications] Smakov GM. **Khirurgiia (Mosk)** 1999;(2):67–9 (48 ref.) **(Rus)**
[Endoscopic drainage of the biliary system] Blancas Valencia JM. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4 Suppl 1):S62–8 (27 ref.) (Eng. Abstr.) **(Spa)**
[Endoscopic resection of the digestive tract mucosa] de la Torre Bravo A. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4 Suppl 1):S32–7 (30 ref.) (Eng. Abstr.) **(Spa)**
[Polypectomy of the digestive tract] Gallo Reynoso S. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4 Suppl 1):S74–9 (30 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Rapid growth of residual colonic tumor after incomplete mucosal resection. Matsuda K, et al. **J Gastroenterol** 1999 Apr;34(2):260–3 (5 ref.)

ECONOMICS

Socioeconomic aspects. Rutkow IM. **World J Surg** 1999 Aug; 23(8):781–5 (15 ref.)

HISTORY

The history of enteroscopy. Lewis BS. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):1–11 (51 ref.)

INSTRUMENTATION

The use of spacers to prevent postoperative middle meatal adhesions. Yanagisawa E, et al. **Ear Nose Throat J** 1999 Aug;78(8):530–2 (3 ref.)
The perfect biliary stent: the search goes on [editorial; comment] Sackmann M. **Endoscopy** 1998 Oct;30(8):727–9 (35 ref.) Comment on: Endoscopy 1998 Oct;30(8):681–6. Comment on: Endoscopy 1998 Oct;30(8):687–90. Comment on: Endoscopy 1998 Oct;30(8):718–20.
Which stents do we need? The case for plastic stents. Seitz U, et al. **Endoscopy** 1998 Nov;30(9):A242–6 (42 ref.)
Technical advances and experimental devices for enteroscopy. Mosse CA, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):145–61 (57 ref.)
Expanding role of flexible nephroscopy in the upper urinary tract. Beaghler MA, et al. **J Endourol** 1999 Mar;13(2):93–7 (12 ref.)
Endoscopy and stereotaxy for aneurysms. Frazee JG, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):869 (18 ref.)
Endoscopic surgery: what has passed the test? Köhler L. **World J Surg** 1999 Aug;23(8):816–24 (137 ref.)
Endoscopic surgery: ideal for endocrine surgery? Marescaux J, et al. **World J Surg** 1999 Aug;23(8):825–34 (58 ref.)
Disasters of endoscopic surgery and how to avoid them: error analysis. Troidl H. **World J Surg** 1999 Aug;23(8):846–55

(35 ref.)
[Fetal surgery in the head-neck area. Current status and new possibilities with the endoscope] Wagner W, et al. **HNO** 1998 Nov;46(11):903–13 (86 ref.) (Eng. Abstr.) **(Ger)**
[Navigation surgery in diseases of the paranasal sinuses] Grevers G, et al. **Laryngorhinootologie** 1999 Jan;78(1):41–6 (29 ref.) (Eng. Abstr.) **(Ger)**
[Selected aspects of endonasal paranasal sinus surgery] Reiss M. **Wien Med Wochenschr** 1998;148(20):469–73 (17 ref.) (Eng. Abstr.) **(Ger)**
[Minimally invasive heart surgery—a fad or a clinically recognized therapy method?] Reichenspurner H, et al. **Z Kardiol** 1998 Aug;87(8):594–603 (32 ref.) (Eng. Abstr.) **(Ger)**
[Endoscopic interventions in the tracheobronchial system] Schmidt B, et al. **Zentralbl Chir** 1998;123(10):1134–9 (37 ref.) (Eng. Abstr.) **(Ger)**
[VATS (video-assisted thoracoscopic surgery): possibilities and limits of surgical therapy of malignant lung diseases] Stoelben E, et al. **Zentralbl Chir** 1998;123(10):1129–33 (36 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Arthroscopy of the elbow. Baker CL Jr, et al. **Am J Sports Med** 1999 Mar–Apr;27(2):251–64 (77 ref.)
Endopyelotomy review. Bernardo N, et al. **Arch Esp Urol** 1999 Jun;52(5):541–8 (45 ref.)
Extracranial repair of pediatric traumatic cerebrospinal fluid rhinorrhea. Ng M, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1125–30 (19 ref.)
Arthroscopic knot typing techniques. Nottage WM, et al. **Arthroscopy** 1999 Jul–Aug;15(5):515–21 (12 ref.)
Endoscopic treatment of uterine fibroids. Wood C, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):289–316 (67 ref.)
Endoscopic incision for the treatment of a ureteric valve. Nishio S, et al. **BJU Int** 1999 Jun;83(9):1081–2 (3 ref.)
How to do it in surgery: transanal endoscopic microsurgery. van Dalen RM, et al. **Br J Hosp Med** 1998 Nov 19–Dec 9;58(10):498–500 (13 ref.)
Endoscopic band ligation of oesophageal varices. Tait IS, et al. **Br J Surg** 1999 Apr;86(4):437–46 (54 ref.)
Open versus arthroscopic decompression for subacromial impingement. A comprehensive review of the literature from the last 25 years. Checroun AJ, et al. **Bull Hosp Jt Dis** 1998;57(3):145–51 (41 ref.)
Asymptomatic esophageal varices should be endoscopically treated. Soehendra N. **Can J Gastroenterol** 1998 Jul–Aug; 12(5):347–50 (30 ref.)
Complications after video-assisted thoracic surgery. Downey RJ. **Chest Surg Clin N Am** 1998 Nov;8(4):907–17, x (52 ref.)
Thoracoscopic lung biopsy or open lung biopsy for interstitial lung disease. Ferson PF, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):749–62 (24 ref.)
Video-assisted thoracic surgery for lung volume reduction surgery. Fischel RJ, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):789–807, viii (41 ref.)
Video-assisted thoracic surgery pericardial resection for effusive disease. Flores RM, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):835–51 (54 ref.)
The role of video-assisted thoracic surgery in esophageal disease. Gamliel Z, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):853–70, ix (43 ref.)
Video-assisted thoracic surgery thymectomy for myasthenia gravis. Mack MJ, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):809–25, viii; discussion 827–34 (27 ref.)
The current status of video-assisted thoracic surgery lobectomy. McKenna RJ Jr. **Chest Surg Clin N Am** 1998 Nov;8(4):775–85, viii; discussion 787–8 (27 ref.)
Video-assisted thoracoscopy for pleural disease. Ronson RS, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):919–32, x (49 ref.)
Minimally invasive pediatric cardiac surgery. Burke RP. **Curr Opin Cardiol** 1999 Jan;14(1):67–72 (21 ref.)
Thoracoscopy and video-assisted thoracic surgery. Yim AP. **Curr Opin Pulm Med** 1999 Jul;5(4):256–8 (24 ref.)
Treatment of esophageal and gastric tumors. Inoue H, et al. **Endoscopy** 1999 Jan;31(1):47–55 (55 ref.)
Use of intranasal endoscopic surgery to relieve ostiomeatal complex obstruction in fibrous dysplasia of the paranasal sinuses. Kessler A, et al. **Eur Arch Otorhinolaryngol** 1998; 255(9):454–6 (12 ref.)
Arthroscopy of the great toe. Frey C, et al. **Instr Course Lect** 1999;48:343–6 (4 ref.)
Arthroscopic management for degenerative arthritis of the knee. Stuart MJ. **Instr Course Lect** 1999;48:135–41 (29 ref.)
Endoscopic treatment of colloid cysts of the third ventricle. Technical note and review of the literature. Abdou MS, et al. **J Neurosurg** 1998 Dec;89(6):1062–8 (32 ref.)
Fixation techniques for endoscopic browlift. Kennedy BD, et al. **J Oral Maxillofac Surg** 1999 May;57(5):588–94 (24 ref.)
Endoscopy of spinal cord and posterior fossa by a lumbar percutaneous approach: endoscopic anatomy in cadavers. Eguchi T, et al. **Minim Invasive Neurosurg** 1999 Jun; 42(2):74–8 (9 ref.)
Use of the superior meatus and superior turbinate in the endoscopic approach to the sphenoid sinus. Bolger WE, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):308–13 (13 ref.)
Endoscopic third ventriculostomy: an outcome analysis. Brockmeyer D, et al. **Pediatr Neurosurg** 1998 May; 28(5):236–40 (16 ref.)
Stereotactically guided endoscopy for the treatment of arachnoid cysts. Rampini P, et al. **Pediatr Neurosurg** 1998 Aug;29(2):102–4 (17 ref.)
Thoracoscopic procedure for intrathoracic diseases: current status in mainland China. Ren H. **Respirology** 1999 Jun; 4(2):111–6 (28 ref.)
Anterior cruciate ligament instability and reconstruction. Review of current trends in treatment. Roos H, et al. **Scand J Med Sci Sports** 1998 Dec;8(6):426–31 (68 ref.)
Less-invasive saphenous harvest. Iafrati MM. **Surg Clin North Am** 1999 Jun;79(3):623–44 (62 ref.)
Endoscopic perforating vein surgery. Rhodes JM, et al. **Surg Clin North Am** 1999 Jun;79(3):667–81 (55 ref.)
Thoracoscopic resection of intrathoracic vagus neurofibroma. Yamagishi T, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):122–4 (8 ref.)
[Endoscopic treatment of Barrett esophagus] Hinnen P, et al. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2341–5 (32 ref.) (Eng. Abstr.) **(Dut)**
[Role of arthroscopy in knee joint osteonecrosis] Baillon M, et al. **Acta Orthop Belg** 1999;65 Suppl 1:127–8 (8 ref.) **(Fre)**
[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700–4 (17 ref.) **(Fre)**
[Retroperitoneoscopic anterior approach to the L2, L3, L4 vertebral bodies] De Peretti F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 May; 85(2):183–8 (10 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Evidence-based surgery: A passing fad? Black N. **World J Surg** 1999 Aug;23(8):789–93 (28 ref.)

SURGICAL PROCEDURES, LAPAROSCOPIC

Is surgery the treatment of choice for long term control of gastro-esophageal reflux disease?Société Royale Belge de Gastro-entérolgie. Legrand MJ, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):450–8 (82 ref.)
The laparoscopic management of gastroesophageal reflux disease. Chekan EG, et al. **Adv Surg** 1999;32:305–30 (69 ref.)
Groin hernia and surgical truth [editorial] McGreevy JM. **Am J Surg** 1998 Oct;176(4):301–4 (22 ref.)
Laparoscopic pancreatic surgery. Park A, et al. **Am J Surg** 1999 Feb;177(2):158–63 (41 ref.)
Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Katkhouda N, et al. **Ann Surg** 1998 Oct;228(4):568–78 (49 ref.)
The place of laparoscopic surgery in surgical gynaecology. Wood C, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov; 38(4):440–5 (38 ref.)
How to do it in surgery: laparoscopic rectopexy. van Dalen RM, et al. **Br J Hosp Med** 1998 Dec 10;58(11):587–8 (10 ref.)
Correcting reflux laparoscopically. Poulin EC, et al. **Can J Gastroenterol** 1998 Jul–Aug;12(5):327–32 (21 ref.)
The virtues and pitfalls of minimally invasive surgery for gynecological malignancies: an update. Childers JM. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):51–9 (47 ref.)
Laparoscopy or open Burch colposuspension? Ross J. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):405–9 (57 ref.)
Laparoscopic hernia surgery: an overview. Krähenbühl L, et al. **Dig Surg** 1998;15(2):158–66 (72 ref.)
Port site recurrences after laparoscopic surgery. A review. Schaeff B, et al. **Dig Surg** 1998;15(2):124–34 (95 ref.)
Comparison of adhesion formation in open and laparoscopic surgery. Schäfer M, et al. **Dig Surg** 1998;15(2):148–52 (48 ref.)
Laparoscopic colorectal surgery and cancer. Wexner SD, et al. **Dig Surg** 1998;15(2):117–23 (69 ref.)
Laparoscopic management of pelvic organ prolapse. Margossian H, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):57–62 (25 ref.)
Splenectomy in hematology. Current practice and new perspectives. Baccarani U, et al. **Haematologica** 1999 May; 84(5):431–6 (43 ref.)
Laparoscopic assisted vaginal hysterectomy/laparoscopic hysterectomy. Wakabayashi MT. **Hawaii Med J** 1999 Jan; 58(1):12–4 (25 ref.)
Laparoscopic techniques for gynecologic cancer: description and indications. Dargent DF. **Hematol Oncol Clin North Am** 1999 Feb;13(1):1–19, vii (25 ref.)
Antireflux surgery: a current comparison of open and laparoscopic approaches. Stein HJ, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1328–37 (55 ref.)
Laparoscopic surgery for genuine stress incontinence. Paraiso MF, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(4):237–47 (48 ref.)
Treatment of achalasia: recent advances in surgery. Seelig MH, et al. **J Clin Gastroenterol** 1999 Apr;28(3):202–7 (61 ref.)
Current status of laparoscopic surgery of the pancreas. Underwood RA, et al. **J Hepatobiliary Pancreat Surg** 1999; 6(2):154–64 (67 ref.)
Simple technique for rectus sheath closure after laparoscopic surgery using straight needles, with review of the literature. Chatzipapas IK, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):205–9 (22 ref.)
Laparoscopic repair of a Morgagni hernia: report of a case and review of the literature. Contini S, et al. **J Laparoendosc Adv Surg Tech A** 1999 Feb;9(1):93–9 (15 ref.)
Laparoscopy during pregnancy: a literature review. Nezhat FR, et al. **J Soc Laparoendosc Surg** 1997 Jan–Mar; 1(1):17–27 (106 ref.)
Laparoscopic bowel injury: incidence and clinical presentation. Bishoff JT, et al. **J Urol** 1999 Mar; 161(3):887–90 (31 ref.)
Double gallbladder originating from left hepatic duct: a case report and review of literature. Gorecki PJ, et al. **JSLS** 1998 Oct–Dec;2(4):337–9 (7 ref.)
Laparoscopic management of gallbladder duplication: a case report and review of literature. Maddox JM, et al. **JSLS** 1999 Apr–Jun;3(2):137–40 (11 ref.)
Laparoscopic hernia repair -- the facts, but no fashion. Leibl BJ, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):302–11 (80 ref.)
Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications. Sietses C, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):250–8 (85 ref.)
Anesthesia for laparoscopic general surgery. A special review. Takrouri MS. **Middle East J Anesthesiol** 1999 Feb; 15(1):39–62 (104 ref.)
Laparoscopic live donor nephrectomy: the four year Johns Hopkins University experience. Ratner LE, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2090–3 (10 ref.)
Laparoscopic-assisted bowel resections in inflammatory bowel disease: state of the art. Bemelman WA, et al. **Neth J Med** 1998 Dec;53(6):S39–46 (45 ref.)
Nasogastric tubes and dietary advancement after laparoscopic and open colorectal surgery. Sands DR, et al. **Nutrition** 1999 May;15(5):347–50 (34 ref.)
Gynecologic cancer and laparoscopy. Chi DS, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):201–15 (83 ref.)
Ultrasound guidance during endoscopic procedures. Letterie GS. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):63–82 (48 ref.)
Laparoscopy and hysteroscopy. Schenk LM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):1–22, v (61 ref.)
Laparoscopically assisted vaginal hysterectomy. Shwayder JM. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):169–87 (76 ref.)
Endoscopic myomectomy. Laparoscopy and hysteroscopy. Tulandi T, et al. **Obstet Gynecol Clin North Am** 1999 Mar; 26(1):135–48, viii (65 ref.)
Laparoscopic bone dowel fusions of the lumbar spine. Silcox DH 3rd. **Orthop Clin North Am** 1998 Oct;29(4):655–63 (22 ref.)
Laparoscopic spinal fusion. Zdeblick TA. **Orthop Clin North Am** 1998 Oct;29(4):635–45 (43 ref.)
Laparoscopic pancreatic resections. Cuschieri SA, et al. **Semin Laparosc Surg** 1998 Sep;5(3):168–79 (38 ref.)
Laparoscopic surgery of the fallopian tubes and ovaries. Dawood MY. **Semin Laparosc Surg** 1999 Jun;6(2):58–67 (50 ref.)
Laparoscopic sterilization. Filshie M. **Semin Laparosc Surg** 1999 Jun;6(2):112–7 (50 ref.)
Laparoscopic choledochoenterostomy. Franklin ME, et al. **Semin Laparosc Surg** 1998 Sep;5(3):180–4 (10 ref.)
Technology for in situ ablation by laparoscopic and image-guided interstitial laser hyperthermia. Germer CT, et al. **Semin Laparosc Surg** 1998 Sep;5(3):195–203 (65 ref.)
Laparoscopic management of ectopic pregnancy. Ghosh S, et al. **Semin Laparosc Surg** 1999 Jun;6(2):68–72 (23 ref.)
Present status of laparoscopic splenectomy for hematologic diseases: certitudes and unresolved issues. Gigot JF, et al. **Semin Laparosc Surg** 1998 Sep;5(3):147–67 (184 ref.)
Laparoscopic hysterectomy. Hawe JA, et al. **Semin Laparosc Surg** 1999 Jun;6(2):80–9 (45 ref.)
Does the mesh require fixation? Macintyre IMC. **Semin Laparosc Surg** 1998 Dec;5(4):224–6 (20 ref.)
Laparoscopic management of benign ovarian disease. Mane S, et al. **Semin Laparosc Surg** 1999 Jun,6(2):104–11 (25 ref.)
Laparoscopic myomectomy. Miskry T, et al. **Semin Laparosc Surg** 1999 Jun;6(2):73–9 (40 ref.)
Laparoscopic biliary bypass for inoperable pancreatic cancer. Scott-Conner CE. **Semin Laparosc Surg** 1998 Sep; 5(3):185–8 (19 ref.)
The learning curve for laparoscopic hernia repair. Wright D, et al. **Semin Laparosc Surg** 1998 Dec;5(4):227–32 (26 ref.)
Fundoplication and gastrostomy. Chung DH, et al. **Semin Pediatr Surg** 1998 Nov;7(4):213–9 (38 ref.)
Laparoscopic pyloromyotomy. Downey EC Jr. **Semin Pediatr Surg** 1998 Nov;7(4):220–4 (18 ref.)
Laparoscopic splenectomy. Rescorla FJ. **Semin Pediatr Surg** 1998 Nov;7(4):207–12 (28 ref.)
Pneumoperitoneum in the cancer patient: advantages and pitfalls. Greene FL. **Semin Surg Oncol** 1998 Oct–Nov; 15(3):151–4 (24 ref.)

SURGICAL PROCEDURES, LAPAROSCOPIC

Laparoscopic evaluation in pancreatic cancer. Merchant NB, et al. **Semin Surg Oncol** 1998 Oct-Nov;15(3):155-65 (53 ref.)

Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Köhler L, et al. **Surg Endosc** 1999 Apr;13(4):430-6 (93 ref.)

Surgical approach to adrenal neoplasms: laparoscopic versus open adrenalectomy. Godellas CV, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):807-17 (23 ref.)

Prophylactic ureteral catheterization in gynecologic surgery. Kuno K, et al. **Urology** 1998 Dec;52(6):1004-8 (17 ref.)

Laparoscopic common bile duct exploration. Crawford DL, et al. **World J Surg** 1999 Apr;23(4):343-9 (28 ref.)

Laparoscopic versus open appendectomy: time to decide. Fingerhut A, et al. **World J Surg** 1999 Aug;23(8):835-45 (90 ref.)

Laparoscopic splenectomy. Glasgow RE, et al. **World J Surg** 1999 Apr;23(4):384-8 (25 ref.)

Minimally invasive surgery for inguinal hernia. Lucas SW, et al. **World J Surg** 1999 Apr;23(4):350-5 (23 ref.)

Endoluminal surgery. Martinez-Serna T, et al. **World J Surg** 1999 Apr;23(4):368-77 (57 ref.)

Laparoscopic surgery of the gastroesophageal junction. Spivak H, et al. **World J Surg** 1999 Apr;23(4):356-67 (81 ref.)

Laparoscopic surgery of the colon and rectum. Tomita H, et al. **World J Surg** 1999 Apr;23(4):397-405 (116 ref.)

Laparoscopy and peripancreatic neoplasia. Westcott CJ, et al. **World J Surg** 1999 Apr;23(4):378-83 (49 ref.)

[The role of laparoscopy in gynecologic oncology] Holub Z. **Ceska Gynekol** 1999 Jan;64(1):63-8 (34 ref.) **(Cze)**

[Hospitalization and convalescence after hysterectomy. Open or laparoscopic surgery?] Møller C, et al. **Ugeskr Laeger** 1999 Aug 16;161(33):4620-4 (26 ref.) (Eng. Abstr.) **(Dan)**

[Laparoscopic surgery during the second trimester of pregnancy: indications, technique, and fetal repercussions. Report of nine cases and review the literature] Batallan A, et al. **Ann Chir** 1999;53(4):285-90 (36 ref.) (Eng. Abstr.) **(Fre)**

[Value of celioscopy in treatment of isolated torsion of the Fallopian tube. Review of the literature. Apropos of 3 cases] Habib E, et al. **Ann Chir** 1998;52(2):137-45 (41 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic treatment of small intestine obstruction] Slim K. **Chirurgie** 1999 Apr;124(2):177-81 (26 ref.) (Eng. Abstr.) **(Fre)**

[Endoscopic surgery of colorectal cancers: is it legitimate?] Slim K, et al. **Chirurgie** 1999 Feb;124(1):77-86 (122 ref.) **(Fre)**

[Hysteroscopic surgery and fertility] Cravello L, et al. **Contracept Fertil Sex** 1998 Jul-Aug;26(7-8):589-92 (25 ref.) (Eng. Abstr.) **(Fre)**

[Inguinal hernia treatment] Boudet MJ, et al. **J Chir (Paris)** 1998 May;135(2):57-64 (89 ref.) (Eng. Abstr.) **(Fre)**

[Review on the use of CO2 in laparoscopy surgery] Van Glabeke E, et al. **Prog Urol** 1998 Sep;8(4):586-9 (34 ref.) (Eng. Abstr.) **(Fre)**

[Minimally invasive surgery and Crohn disease] Hildebrandt U, et al. **Chirurg** 1998 Sep;69(9):915-21 (23 ref.) (Eng. Abstr.) **(Ger)**

[New approaches in surgery--visceral surgery in the tension field between trauma from surgical access and radicality] Siewert JR, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:53-60 (13 ref.) (Eng. Abstr.) **(Ger)**

[Antibiotic prophylaxis in appendectomy. Often neglected--but necessary!] Hell K. **Zentralbl Chir** 1998;123 Suppl 4:82-4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic-transperitoneal and lumboscopic-retroperitoneal surgery of the spine.Developments from animal experiments for use in clinical practice] Olinger A, et al. **Zentralbl Chir** 1999; 124(4):311-7 (22 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic myomectomy] Dicker D, et al. **Harefuah** 1998 Oct;135(7-8):310-2 (8 ref.) **(Heb)**

[Laparoscopic adrenalectomy. A critical review of the literature] Dalla Valle R, et al. **Acta Biomed Ateneo Parmense** 1996;67(1-2):39-47 (35 ref.) (Eng. Abstr.) **(Ita)**

[A case of internal hernia through a defect in the falciform ligament treated with laparoscopic surgery] Kobayashi S, et al. **Nippon Geka Gakkai Zasshi** 1999 Aug;100(8):513-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[High time to make choice: preventive or curative appendectomy?] Kulik IaP, et al. **Khirurgiia (Mosk)** 1999; (7):23-6 (68 ref.) (Eng. Abstr.) **(Rus)**

[Laparoscopic surgery in the treatment of perforating gastroduodenal ulcers] Shurkalin BK, et al. **Vestn Khir Im I I Grek** 1999;158(3):100-2 (39 ref.) **(Rus)**

[The indications for laparoscopic surgery in the palliative treatment of digestive cancer] Targarona EM, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):200-5 (72 ref.) **(Spa)**

[Laparoscopy in acute abdomen as diagnostic and surgical aid] Montgomery A, et al. **Lakartidningen** 1999 Feb 10; 96(6):593-6 (20 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Pneumoperitoneum--physiology and nursing interventions [published erratum appears in AORN J 1999 Jan;69(1):21] Steuer K. **AORN J** 1998 Sep;68(3):412-25; quiz 426, 429-32 (54 ref.)

Migration of sterilisation clips: case report and review. AmuO, et al. **Br J Fam Plann** 1999 Apr;25(1):27-8 (14 ref.)

Risk factors contributing to early occurrence of port site metastases of laparoscopic surgery for malignancy. Wang PH, et al. **Gynecol Oncol** 1999 Jan;72(1):38-44 (77 ref.)

Laparoscopic hernias: two case reports and a review of the literature. Bemporad JA, et al. **J Comput Assist Tomogr** 1999 Jan-Feb;23(1):86-9 (10 ref.)

Laparoscopic surgery complications associated with trocar tip design: review of literature and own results. Leibl BJ, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr; 9(2):135-40 (33 ref.)

Review of investigations regarding the etiology of port site tumor recurrence. Whelan RL, et al. **J Laparoendosc Adv Surg Tech A** 1999 Feb;9(1):1-16 (61 ref.)

Bowel obstruction in the postoperative period of laparoscopic inguinal hernia repair (TAPP): review of the literature. Cueto J, et al. **J Soc Laparoendosc Surg** 1998 Jul-Sep; 2(3):277-80 (27 ref.)

Complications of laparoscopy. Strategies for prevention and cure. Lin P, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):23-38, v (37 ref.)

Port site recurrences after laparoscopy for malignant disease. Pearlstone DB, et al. **Semin Surg Oncol** 1999 Jun; 16(4):307-12 (64 ref.)

Fatal carbon dioxide embolism as an unreported complication of retroperitoneoscopy. Blaser A, et al. **Surg Endosc** 1999 Jul;13(7):713-4 (11 ref.)

Pain after laparoscopy. Mouton WG, et al. **Surg Endosc** 1999 May;13(5):445-8 (41 ref.)

Nerve irritation after laparoscopic hernia repair. Stark E, et al. **Surg Endosc** 1999 Sep;13(9):878-81 (39 ref.)

Retained fecalith after laparoscopic appendectomy. Strathern DW, et al. **Surg Endosc** 1999 Mar;13(3):287-9 (40 ref.)

Laparoscopic Nissen fundoplication complicated by late gastroesophageal herniation and intrathoracic perforation: a case report with review of the literature. Boggi U, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):57-9 (14 ref.)

[Complications of laparoscopy in gynecology] Abboud J, et al. **Contracept Fertil Sex** 1999 May;27(5):383-7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Myomectomy by laparoscopy and infertility: status of the controversy] Dubuisson JB, et al. **Contracept Fertil Sex** 1998 Oct;26(10):728-31 (42 ref.) (Eng. Abstr.) **(Fre)**

[Cardiorespiratory effects of laparoscopic surgery] Bazin JE. **Presse Med** 1998 Mar 7;27(9):388-93 (60 ref.) (Eng. Abstr.) **(Fre)**

[Vascular complications during laparoscopy. An analysis of a personal case] Esposito C, et al. **Minerva Chir** 1999 Mar; 54(3):163-5 (9 ref.) (Eng. Abstr.) **(Ita)**

[Thromboembolic complications, venous hemodynamics and lower extremities in laparoscopic operations] Starkov IuG, et al. **Khirurgiia (Mosk)** 1999;(8):63-7 (68 ref.) **(Rus)**

CONTRAINDICATIONS

Pregnancy: A contraindication? Holthausen UH, et al. **World J Surg** 1999 Aug;23(8):856-62 (72 ref.)

ECONOMICS

Cost efficacy of laparoscopic vs open surgery. Hospitals vs community [editorial; comment] Cuschieri A. **Surg Endosc** 1998 Oct;12(10):1197-8 (3 ref.) Comment on: Surg Endosc 1998 Oct;12(10):1199-203.

Cost-effective minimally invasive surgery: What procedures make sense? Newman RM, et al. **World J Surg** 1999 Apr; 23(4):415-21 (52 ref.)

HISTORY

Kurt Semm and the fight against skepticism: endoscopic hemostasis, laparoscopic appendectomy, and Semm's impact on the "laparoscopic revolution". Litynski GS. **J Soc Laparoendosc Surg** 1998 Jul-Sep;2(3):309-13 (27 ref.)

INSTRUMENTATION

Laparoscopic surgery complications associated with trocar tip design: review of literature and own results. Leibl BJ, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr; 9(2):135-40 (33 ref.)

Suture? Staple? Electrosurgery? How to decide what is best for you [see comments] Carter JE. **J Soc Laparoendosc Surg** 1997 Apr-Jun;1(2):171-4 (17 ref.) Comment in: J Soc Laparoendosc Surg 1997 Jul-Sep;1(3):293.

The making of an instrument: from concept to market. Christoudias GC. **J Soc Laparoendosc Surg** 1998 Jul-Sep; 2(3):301-7 (7 ref.)

A 3 trocar technique for transperitoneal laparoscopic nephrectomy. Desgrandchamps F, et al. **J Urol** 1999 May; 161(5):1530-2 (13 ref.)

Endoscopic surgery: ideal for endocrine surgery? Marescaux J, et al. **World J Surg** 1999 Aug;23(8):825-34 (58 ref.)

[Using the electric scalpel in laparoscopy. Principles and prevention of complications] Mutter D. **Ann Chir** 1998; 52(1):53-60 (20 ref.) **(Fre)**

[Laparoscopic stoma technique] Schlemminger R, et al. **Chirurg** 1999 Jun;70(6):656-61 (21 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic gastric banding in morbid obesity] Baca I, et al. **Zentralbl Chir** 1999;124(5):451-60 (39 ref.) (Eng. Abstr.) **(Ger)**

[Technique of total extraperitoneal endoscopic hernioplasty of the inguinal canal] Kuthe A, et al. **Zentralbl Chir** 1998; 123(12):1428-35 (29 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic transabdominal adrenalectomy] Nies C, et al. **Zentralbl Chir** 1998;123(12):1422-7 (9 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Durability of laparoscopic repair of paraesophageal hernia. Edye MB, et al. **Ann Surg** 1998 Oct;228(4):528-35 (30 ref.)

What alternatives has minimally invasive surgery provided the surgeon? Rothschild JG. **Arch Surg** 1998 Nov; 133(11):1156-9 (68 ref.)

Retroperitoneal laparoscopy. Keeley FX Jr, et al. **BJU Int** 1999 Jul;84(2):212-5 (30 ref.)

Laparoscopic fundoplication. Georgeson KE. **Curr Opin Pediatr** 1998 Jun;10(3):318-22 (22 ref.)

Laparoscopic surgery in children. Lobe TE. **Curr Probl Surg** 1998 Oct;35(10):859-948 (227 ref.)

Laparoscopic antireflux surgery--It's a wrap! Hinder RA, et al. **Dig Surg** 1999;16(1):7-11 (30 ref.)

Update: total versus partial laparoscopic fundoplication. Watson A. **Dig Surg** 1998;15(2):172-80 (58 ref.)

Laparoscopic para-aortic and pelvic lymphadenectomy: experience with 150 patients and review of the literature. Possover M, et al. **Gynecol Oncol** 1998 Oct;71(1):19-28 (50 ref.)

Laparoscopic ultrasound: a valuable adjunct to laparoscopic surgery. Machi J. **Hawaii Med J** 1998 Nov;57(11):696-9 (25 ref.)

Advanced laparoscopy: "the next generation". The adrenal, kidney, spleen, pancreas, and liver. Payne JH Jr, et al. **Hawaii Med J** 1998 Nov;57(11):710-4 (29 ref.)

Energy systems for operative laparoscopy. Brill AI. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):333-45; quiz 347-9 (58 ref.)

Combined laparoscopic and thoracoscopic approach to esophagectomy. Nguyen NT, et al. **J Am Coll Surg** 1999 Mar;188(3):328-32 (11 ref.)

Laparoscopic repair of a Morgagni-Larrey hernia. Bortul M, et al. **J Laparoendosc Adv Surg Tech A** 1998 Oct; 8(5):309-13 (15 ref.)

Laparoscopic removal of a right adrenal pheochromocytoma in a pregnant woman. Demeure MJ, et al. **J Laparoendosc Adv Surg Tech A** 1998 Oct;8(5):315-9 (16 ref.)

Surgical treatment for chronic pelvic pain. Carter JE. **J Soc Laparoendosc Surg** 1998 Apr-Jun;2(2):129-39 (77 ref.)

Alternatives to total abdominal hysterectomy. Carter JE. **J Soc Laparoendosc Surg** 1997 Jul-Sep;1(3):259-62 (8 ref.)

Laparoscopic pyelolithotomy in a pelvic kidney: a case report and review of the literature. Hoenig DM, et al. **J Soc Laparoendosc Surg** 1997 Apr-Jun;1(2):163-5 (6 ref.)

Endoscopic management of adnexal masses. Mettler L, et al. **J Soc Laparoendosc Surg** 1997 Apr-Jun;1(2):103-12 (17 ref.)

Office single puncture laparoscopy sterilization with local anesthesia. Miller GH. **J Soc Laparoendosc Surg** 1997 Jan-Mar;1(1):55-9 (18 ref.)

Operative laparoscopy: redefining the limits. Nezhat C, et al. **J Soc Laparoendosc Surg** 1997 Jul-Sep;1(3):213-6 (30 ref.)

The laparoscopic approach for repair of Morgagni hernias. Nguyen T, et al. **J Soc Laparoendosc Surg** 1998 Jan-Mar; 2(1):85-8 (20 ref.)

A 3 trocar technique for transperitoneal laparoscopic nephrectomy. Desgrandchamps F, et al. **J Urol** 1999 May; 161(5):1530-2 (13 ref.)

Laparoscopic tubal sterilization. Methods, effectiveness, and sequelae. Ryder RM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):83-97 (82 ref.)

Laparoscopic biliary and enteric bypass. Chekan EG, et al. **Semin Surg Oncol** 1999 Jun;16(4):313-20 (21 ref.)

Role of laparoscopy in the management of stomach cancer. Goh PM, et al. **Semin Surg Oncol** 1999 Jun;16(4):321-6 (25 ref.)

Laparoscopic adrenalectomy for cancer. Heniford BT, et al. **Semin Surg Oncol** 1999 Jun;16(4):293-306 (45 ref.)

Laparoscopic cryoablation of hepatic metastases. Heniford BT, et al. **Semin Surg Oncol** 1998 Oct-Nov;15(3):194-201 (51 ref.)

Laparoscopically assisted abdominal aortic aneurysm repair. Cerveira JJ, et al. **Surg Clin North Am** 1999 Jun; 79(3):541-50 (24 ref.)

Laparoscopic repair and groin hernia surgery. Crawford DL, et al. **Surg Clin North Am** 1998 Dec;78(6):1047-62 (37 ref.)

Safety of adrenal vein ligation during endoscopic adrenalectomy: a technical note. Pietrabissa A, et al. **Surg Endosc** 1999 Mar;13(3):298-302 (23 ref.)

Open vs. laparoscopic repair of perforated peptic ulcer [letter; comment] Bergamaschi R. **Surg Laparosc Endosc** 1998 Dec; 8(6):479-80 (8 ref.) Comment on: Surg Laparosc Endosc 1998 Apr;8(2):153-6.

Laparoscopic splenectomy: evolution and current status. Klingler PJ, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):1-8

(66 ref.)
Retrieval of specimens in laparoscopy using reclosable zipper-type plastic bags: a simple, cheap, and useful method. Weber A, et al. **Surg Laparosc Endosc** 1998 Dec; 8(6):457-9 (21 ref.)
Achalasia in a sixty-four-year-old man. Komisaruk EA, et al. **Yale J Biol Med** 1998 Jan-Feb;71(1):23-30 (24 ref.)
[Laparoscopic treatment of a diaphragmatic hernia through the foramen of Morgagni in children. A case report and review of eleven cases reported in the adult literature] Becmeur F, et al. **Ann Chir** 1998;52(10):1060-3 (16 ref.) (Eng. Abstr.) **(Fre)**
[Myomectomy by laparoscopy and infertility: status of the controversy] Dubuisson JB, et al. **Contracept Fertil Sex** 1998 Oct;26(10):728-31 (42 ref.) (Eng. Abstr.) **(Fre)**
[Surgical treatment of gastroesophageal reflux: modalities and results of endoscopic surgery] Gayet B. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S145-54 (72 ref.) **(Fre)**
[Laparoscopic surgery and pregnancy] Slim K, et al. **J Chir (Paris)** 1998 Dec;135(6):261-6 (53 ref.) (Eng. Abstr.) **(Fre)**
[Laparoscopic adrenalectomy for pheochromocytoma. Case report and review of the literature] Abboud B, et al. **J Med Liban** 1998 Sep-Oct;46(5):291-4 (32 ref.) (Eng. Abstr.) **(Fre)**
[The right laparoscopic adrenalectomy of an incidentaloma] Mazzetti J, et al. **Ann Ital Chir** 1998 Jul-Aug;69(4):521-3; discussion 524 (15 ref.) (Eng. Abstr.) **(Ita)**
[Cornual pregnancy. Its laparoscopic management and a case report] Cortés Algara A, et al. **Ginecol Obstet Mex** 1999 Jul;67:300-1 (6 ref.) (Eng. Abstr.) **(Spa)**
[The justification for laparoscopic appendectomy] del Río Martin JV, et al. **Rev Esp Enferm Dig** 1999 Jun;91(6):447-55 (63 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Pneumoperitoneum--physiology and nursing interventions [published erratum appears in AORN J 1999 Jan;69(1):21] Steuer K. **AORN J** 1998 Sep;68(3):412-25; quiz 426, 429-32 (54 ref.)

STANDARDS

Current status of laparoscopic appendectomy in children. Blakely ML, et al. **Curr Opin Pediatr** 1998 Jun;10(3):315-7 (17 ref.)
Laparoscopic inguinal herniorrhaphy: the new gold standard of hernia repair? Oishi AJ, et al. **Hawaii Med J** 1998 Nov; 57(11):700-3 (7 ref.)
Towards consensus on the fate of the normal appendix at laparoscopy for suspected appendicitis. Delaney CP, et al. **Ir J Med Sci** 1999 Apr-Jun;168(2):109-10 (7 ref.)
Laparoscopic adrenalectomy: new gold standard. Smith CD, et al. **World J Surg** 1999 Apr;23(4):389-96 (36 ref.)

STATISTICS & NUMERICAL DATA

[Is laparoscopic surgical practice "factual" (evidence based)? Results of a prospective regional survey] Slim K, et al. **Presse Med** 1998 Nov 21;27(36):1829-33 (33 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Ambulatory laparoscopic surgery. Beretvas RI, et al. **Semin Laparosc Surg** 1999 Mar;6(1):17-20 (24 ref.)
Minilaparoscopy. Schauer PR, et al. **Semin Laparosc Surg** 1999 Mar;6(1):21-31 (29 ref.)
Beyond the laparoscope: minimally invasive surgery in the new millennium. Rattner DW. **Surgery** 1999 Jan; 125(1):19-22 (8 ref.)

VETERINARY

Common laparoscopic procedures in swine: a review. Srinivasan A, et al. **J Invest Surg** 1999 Jan-Feb;12(1):5-14 (25 ref.)

SURGICAL PROCEDURES, MINIMALLY INVASIVE

see related
SURGICAL PROCEDURES, LAPAROSCOPIC
"Alternative" surgery in trauma management. Britt LD, et al. **Arch Surg** 1998 Nov;133(11):1177-81 (44 ref.)
Anesthesia for minimally invasive surgery. Badner NH. **Can J Anaesth** 1999 May;46(5 Pt 2):R101-10 (26 ref.) **(Eng, Fre)**
Minimally invasive coronary surgery at the beginning of the new millennium. Mariani MA, et al. **Cardiologia** 1998 Sep; 43(9):883-8 (43 ref.)
Minimally invasive pediatric cardiac surgery. Burke RP. **Curr Opin Pediatr** 1998 Oct;10(5):527-31 (21 ref.)
The case for ultrasound [editorial] Kavic MS. **J Soc Laparoendosc Surg** 1997 Apr-Jun;1(2):101-2 (6 ref.)
Advances in abdominal interventional radiology. Dondelinger RF. **Lancet** 1999 Apr;353 Suppl 1:SI15-8 (11 ref.)
New initiatives in minimally invasive cardiac surgery. Fonger JD. **Md Med J** 1998 Nov;47(5):253-6 (51 ref.)
Minimally invasive surgery for solid tumors. Holcomb GW 3rd. **Semin Surg Oncol** 1999 Mar;16(2):184-92 (60 ref.)
[Minimally invasive cardiac surgery: surgical techniques and anesthetic problems] Blanc P, et al. **Ann Fr Anesth Reanim** 1999 Aug;18(7):748-71 (138 ref.) (Eng. Abstr.) **(Fre)**
[Interventional radiology--an option in minimally invasive therapy] Mutze S, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):238-44 (24 ref.) (Eng. Abstr.) **(Ger)**
[Minimally invasive therapeutic concepts in fracture surgery] Richter D, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun; 93(4):245-51 (32 ref.) (Eng. Abstr.) **(Ger)**
[Evolution of operative approach in abdominal surgery] Slesarenko SS, et al. **Khirurgiia (Mosk)** 1999;(5):31-3 (14 ref.) (Eng. Abstr.) **(Rus)**
[Minimally invasive techniques make fetal surgery possible. Disabling abnormalities can be corrected] Bui TH, et al. **Lakartidningen** 1998 Oct 28;95(44):4848-50, 4853-4 (40 ref.) (Eng. Abstr.) **(Swe)**

INSTRUMENTATION

[Minimally invasive heart surgery--a fad or a clinically recognized therapy method?] Reichenspurner H, et al. **Z Kardiol** 1998 Aug;87(8):594-603 (32 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Minimally invasive coronary artery bypass surgery: state of the art. Emery RW, et al. **Adv Card Surg** 1998;10:1-23 (63 ref.)
Expanding surgical options using minimally invasive techniques for cardio-aortic and aortic procedures. Svensson LG, et al. **Arch Surg** 1998 Nov;133(11):1160-5 (25 ref.)
Less-invasive saphenous harvest. Iafrati MM. **Surg Clin North Am** 1999 Jun;79(3):623-44 (62 ref.)
Minimally invasive in situ bypass. Rosenthal D, et al. **Surg Clin North Am** 1999 Jun;79(3):645-52, x (07 ref.)
[Minimally invasive cardiac surgery for aortic valve disease] Fujimura Y, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec; 99(12):821-4 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Minimally invasive mitral surgery: mitral valve repair with a right-sided partial sternotomy] Kasegawa H. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):817-20 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Basic approaches in minimally invasive cardiac surgery (MICS) and its selection] Yozu R, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):810-6 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Functional disorders after organ salvaging surgery of perforative pyloroduodenal ulcer discovered in follow-up studies] Chislenko IV. **Klin Khir** 1999;(5):51-2 (6 ref.) **(Rus)**

NURSING

Minimally invasive direct coronary artery bypass surgery. Coulson AS, et al. **AORN J** 1997 Dec;66(6):1012-37; quiz 1039-42 (22 ref.)

TRENDS

Minimally invasive cardiac surgery: current status and perspective. Matsuda H, et al. **Artif Organs** 1998 Sep; 22(9):759-64 (17 ref.)
Less invasive coronary artery bypass without cardiopulmonary bypass. Shiono M, et al. **Artif Organs** 1998 Sep;22(9):769-74 (23 ref.)
Minimally invasive surgical techniques for the treatment of gastroesophageal reflux disease. Klingler PJ, et al. **Dig Dis** 1999;17(1):23-36 (74 ref.)
Epilepsy surgery: past, present and future [editorial] Wieser HG. **Seizure** 1998 Jun;7(3):173-84 (98 ref.)
Beyond the laparoscope: minimally invasive surgery in the new millennium. Rattner DW. **Surgery** 1999 Jan; 125(1):19-22 (8 ref.)
Minimally invasive surgery: the next frontier. Hunter JG. **World J Surg** 1999 Apr;23(4):422-4 (0 ref.)

SURGICAL PROCEDURES, OPERATIVE

see related
INTRAOPERATIVE COMPLICATIONS
OPERATING ROOMS
POSTOPERATIVE COMPLICATIONS
SURGERY
When is the pulmonary artery catheter needed in care of the surgical patient? Bender JS. **Adv Surg** 1999;32:365-84 (60 ref.)
The alcohol patient and surgery. Tønnesen H. **Alcohol Alcohol** 1999 Mar-Apr;34(2):148-52 (34 ref.)
Groin hernia and surgical truth [editorial] McGreevy JM. **Am J Surg** 1998 Oct;176(4):301-4 (22 ref.)
Prokinetic agents in the surgical patient. Thompson JS, et al. **Am J Surg** 1999 Jun;177(6):508-14 (96 ref.)
Anesthetic and perioperative management of adult transplant recipients in nontransplant surgery. Kostopanagiotou G, et al. **Anesth Analg** 1999 Sep;89(3):613-22 (147 ref.)
Alcohol withdrawal in the surgical patient: prevention and treatment. Spies CD, et al. **Anesth Analg** 1999 Apr; 88(4):946-54 (86 ref.)
Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence [see comments] Nathens AB, et al. **Arch Surg** 1999 Feb; 134(2):170-6 (76 ref.) Comment in: ACP J Club 1999 Sep-Oct;131(2):37.
Surgical care in space. Campbell MR. **Aviat Space Environ Med** 1999 Feb;70(2):181-4 (24 ref.)
Risk scoring in surgical patients. Jones HJ, et al. **Br J Surg** 1999 Feb;86(2):149-57 (72 ref.)
The nonspecific inflammatory response to injury. Mayers I, et al. **Can J Anaesth** 1998 Sep;45(9):871-9 (94 ref.)
Assessment of cardiovascular risks and overall risks for noncardiac surgery. Chung OY, et al. **Cardiol Clin** 1999 Feb;17(1):197-211 (70 ref.)
Preoperative cardiac preparation. Belzberg H, et al. **Chest** 1999 May;115(5 Suppl):82S-95S (158 ref.)
What intraoperative monitoring makes sense? Brodsky JB. **Chest** 1999 May;115(5 Suppl):101S-105S (20 ref.)
Assessing and modifying the risk of postoperative pulmonary complications. Doyle RL. **Chest** 1999 May;115(5 Suppl):77S-81S (43 ref.)
Preoperative assessment of pulmonary risk. Ferguson MK. **Chest** 1999 May;115(5 Suppl):58S-63S (59 ref.)
Cost-effective preoperative evaluation and testing. Fischer SP. **Chest** 1999 May;115(5 Suppl):96S-100S (41 ref.)
Preoperative cardiac risk assessment. Hollenberg SM. **Chest** 1999 May;115(5 Suppl):51S-57S (27 ref.)
Preoperative issues in clinical nutrition. McClave SA, et al. **Chest** 1999 May;115(5 Suppl):64S-70S (50 ref.)
Special problems in the elderly. Oskvig RM. **Chest** 1999 May; 115(5 Suppl):158S-164S (56 ref.)
Erythropoietin therapy in the perioperative setting. Goodnough LT, et al. **Clin Orthop** 1998 Dec;(357):82-8 (44 ref.)
Anemia in the patient undergoing surgery and the transfusion decision. A review. Spence RK. **Clin Orthop** 1998 Dec; (357):19-29 (64 ref.)
Effects of surgery on the pharmacokinetic parameters of drugs. Kennedy JM, et al. **Clin Pharmacokinet** 1998 Oct; 35(4):293-312 (126 ref.)
Metabolic response to neonatal surgery. Pierro A. **Curr Opin Pediatr** 1999 Jun;11(3):230-6 (65 ref.)
Cytokines in surgical trauma: cholecystectomy as an example. Reber PU, et al. **Dig Surg** 1998;15(2):92-101 (94 ref.)
Surgical therapy of pancreatic cancer. Heywood G, et al. **Front Biosci** 1998 Nov 1;3:E175-80 (77 ref.)
Measurement of quality of life in surgery. Camilleri-Brennan J, et al. **J R Coll Surg Edinb** 1999 Aug;44(4):252-9 (59 ref.)
Nuclear medicine and the surgeon. Krag D, et al. **Lancet** 1999 Sep 18;354(9183):1019-22 (33 ref.)
Surgery in the patient with liver disease. Patel T. **Mayo Clin Proc** 1999 Jun;74(6):593-9 (21 ref.)
Anesthesia for neonatal surgical emergencies. Mellor DJ, et al. **Semin Perinatol** 1998 Oct;22(5):363-79 (74 ref.)
Using quality-of-life instruments to assess surgical outcomes. Velanovich V. **Surgery** 1999 Jul;126(1):1-4 (13 ref.)
Laparoscopic live donor nephrectomy: con [editorial; comment] Novick AC. **Urology** 1999 Apr;53(4):668-70 (18 ref.) Comment on: Urology 1999 Apr;53(4):665-7.
Postoperative total parenteral nutrition. Waitzberg DL, et al. **World J Surg** 1999 Jun;23(6):560-4 (42 ref.)
Postoperative protein sparing. Wilmore DW. **World J Surg** 1999 Jun;23(6):545-52 (49 ref.)
[Inflammatory response of the body to surgery illustrated by pro-inflammatory and anti-inflammatory cytokines] Christensen VB, et al. **Ugeskr Laeger** 1998 Nov 23; 160(48):6951-3 (11 ref.) **(Dan)**
[Frequency, intensity, development and repercussions of postoperative pain as a function of the type of surgery] Beaussier M. **Ann Fr Anesth Reanim** 1998;17(6):471-93 (147 ref.) (Eng. Abstr.) **(Fre)**
[General or locoregional anesthesia: which to choose for a patient at risk?] Meunier JF, et al. **Presse Med** 1999 Jan 23;28(3):143-8 (34 ref.) (Eng. Abstr.) **(Fre)**
[Is erythropoietin an adjuvant in hemotherapy?] Michaelis G. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Oct;33(10):661-4 (9 ref.) **(Ger)**
[Anesthetic management of coronary patients in non-cardiac surgical procedures] Stephan H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Mar; 34(3):185-8 (12 ref.) **(Ger)**
[Anesthesia in surgery] Fritz H, et al. **Zentralbl Chir** 1998; 123(7):877-92 (15 ref.) **(Ger)**
[Hemotherapy in operative medicine (part 2)] Taleghani BM, et al. **Zentralbl Chir** 1999;124(4):W27-41 (33 ref.) **(Ger)**
[The nutrition of the elderly surgical patient] Nano M, et al. **Minerva Chir** 1999 Jan-Feb;54(1-2):67-71 (25 ref.) (Eng. Abstr.) **(Ita)**
[Empirical antimicrobial chemoprophylaxis and chemotherapy of infections in surgical patients] Kostiuchenko AL. **Anesteziol Reanimatol** 1999 Mar-Apr; (2):45-8 (9 ref.) (Eng. Abstr.) **(Rus)**
[Perioperative use of ultra-fast acting beta blockers] Van-Besoy DP. **Anesteziol Reanimatol** 1999 Mar-Apr; (2):65-8 (17 ref.) **(Rus)**

ADVERSE EFFECTS

ABC of sexual health: a woman's sexual life after an operation. de Marquiegui A, et al. **BMJ** 1999 Jan 16; 318(7177):178-81 (0 ref.)
Augmented enhancement of in vitro production of inflammatory cytokines...[editorial; comment] Dunn DL. **Crit Care Med** 1999 May;27(5):859-60 (10 ref.) Comment

on: Crit Care Med 1999 May;27(5):929–36.
Postsurgical pemphigus [letter] Micali G, et al. **Dermatology** 1998;197(2):192–3 (14 ref.)
The risk of surgery in patients with liver disease. Friedman LS. **Hepatology** 1999 Jun;29(6):1617–23 (124 ref.)
Pre-operative assessment of cardiac risk for non-cardiac surgery [see comments] Turner M, et al. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):545–7 (14 ref.) Comment in: J R Coll Physicians Lond 1999 Mar–Apr;33(2):192.
[Incidence and prevention of coronary complications after general surgery] Coriat P, et al. **Arch Mal Coeur Vaiss** 1998 Aug;91 Spec No 4:17–22; discussion 29–30 (39 ref.) (Eng. Abstr.) **(Fre)**
[Organ failure during the perioperative period: pathophysiology and strategy] Murakami M, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug;99(8):518–22 (12 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Cost efficacy of laparoscopic vs open surgery. Hospitals vs community [editorial; comment] Cuschieri A. **Surg Endosc** 1998 Oct;12(10):1197–8 (3 ref.) Comment on: Surg Endosc 1998 Oct;12(10):1199–203.

METHODS

Surgical excision margins: a pathologist's perspective. Batsakis JG. **Adv Anat Pathol** 1999 May;6(3):140–8 (35 ref.)
Surgical care in space. Campbell MR. **Aviat Space Environ Med** 1999 Feb;70(2):181–4 (24 ref.)
Subglottic stenosis: evaluation and management. Brodner DC, et al. **J La State Med Soc** 1999 Apr;151(4):159–64 (11 ref.)
Operative release for elbow contracture: the lateral collateral ligament sparing technique. Cohen MS, et al. **Orthop Clin North Am** 1999 Jan;30(1):133–9 (19 ref.)
Mastoid and tympanomastoid procedures in otitis media: classic mastoidectomy (simple, modified, and radical) and current adaptations; open-cavity, closed-cavity, and intact-bridge tympanomastoidectomy. Goycoolea MV. **Otolaryngol Clin North Am** 1999 Jun;32(3):513–23 (4 ref.)
Closed tympanomastoidectomy. Graham MD, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):547–54 (35 ref.)
Flexible approach to tympanomastoidectomy. Kimberley BP, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):585–95 (3 ref.)
Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567–83 (56 ref.)
Open-cavity tympanomastoidectomy. Roland PS, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):525–46 (17 ref.)
A one-stage, versatile procedure: intact-bridge mastoidectomy. Sajjadi H. **Otolaryngol Clin North Am** 1999 Jun;32(3):555–65 (12 ref.)
Chemoradiation for rectal cancer: current methods. Barrett MW. **Semin Surg Oncol** 1998 Sep;15(2):114–9 (25 ref.)
Total mesorectal excision in the treatment of rectal cancer: a view from the USA. Goldberg S, et al. **Semin Surg Oncol** 1998 Sep;15(2):87–90 (17 ref.)
Transanal treatment of rectal cancer: ablative methods and open resection. Kim DG, et al. **Semin Surg Oncol** 1998 Sep;15(2):101–13 (65 ref.)
Inguinal hernia repair. The Nyhus posterior preperitoneal operation. Patiño JF, et al. **Surg Clin North Am** 1998 Dec; 78(6):1063–74 (39 ref.)
Giant prosthetic reinforcement of the visceral sac. The Stoppa groin hernia repair. Wantz GE. **Surg Clin North Am** 1998 Dec;78(6):1075–87 (16 ref.)
[How can pain of surgery be limited?] Pélissier EP. **Ann Fr Anesth Reanim** 1998;17(6):613–21 (77 ref.) (Eng. Abstr.) **(Fre)**
[The Virtual University applied to telesurgery: from tele-education to tele-manipulation] Marescaux J, et al. **Bull Acad Natl Med** 1999;183(3):509–21; discussion 521–2 (10 ref.) (Eng. Abstr.) **(Fre)**
[Telematic and surgery: methods, terminology and instructions] Demartines N, et al. **Swiss Surg** 1999;5(2):73–9 (51 ref.) (Eng. Abstr.) **(Fre)**
[Surgery of malignant tumors affecting the skull base] Saito K, et al. **No Shinkei Geka** 1999 Jun;27(6):505–14 (21 ref.) **(Jpn)**
[Modern approach to surgical treatment of duodenal ulcers] Sukhodolia AI. **Klin Khir** 1999;(4):47–9 (43 ref.) **(Ukr)**

NURSING

The surgical significance of therapeutic touch. Ramnarine-Singh S. **AORN J** 1999 Feb;69(2):358–69 (52 ref.)

STANDARDS

Practice guidelines [editorial] Junginger T, et al. **G Chir** 1999 Apr;20(4):141–7 (33 ref.)
Clinical research in surgery: questions but few answers. Beger HG, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):300–5 (55 ref.)
Conceptional and structural conditions for successful clinical research. Troidl H. **Langenbecks Arch Surg** 1998 Oct; 383(5):306–16 (30 ref.)
Mesorectal excision for rectal cancer: a view from Europe. Wiig JN, et al. **Semin Surg Oncol** 1998 Sep;15(2):78–86 (104 ref.)

STATISTICS & NUMERICAL DATA

Epidemiologic, economic, and sociologic aspects of hernia surgery in the United States in the 1990s. Rutkow IM. **Surg Clin North Am** 1998 Dec;78(6):941–51, v–vi (20 ref.)

TRENDS

Emergent surgical techniques of the next decade. Mendes da Costa P. **Acta Chir Belg** 1999 May–Jun;99(3):97–9 (36 ref.)
Recent advances: paediatric surgery. Losty PD. **BMJ** 1999 Jun 19;318(7199):1668–72 (40 ref.)
New trends in gastrointestinal surgical oncology. Meszoely IM, et al. **Cancer Treat Res** 1998;98:239–91 (242 ref.)
Nutritional support of the pediatric surgical patient. Amii LA, et al. **Curr Opin Pediatr** 1999 Jun;11(3):237–40 (18 ref.)
Advances in ventilatory support of the pediatric surgical patient. Hemmila MR, et al. **Curr Opin Pediatr** 1999 Jun; 11(3):241–8 (67 ref.)
Pediatric surgery. Rodgers BM. **J Am Coll Surg** 1999 Feb; 188(2):152–60 (60 ref.)
Health-technology assessment in surgery. Reeves B. **Lancet** 1999 Apr;353 Suppl 1:SI3–5 (20 ref.)
[Telematic and surgery: methods, terminology and instructions] Demartines N, et al. **Swiss Surg** 1999;5(2):73–9 (51 ref.) (Eng. Abstr.) **(Fre)**
[The message of genomes in surgery] Stelzner F. **Swiss Surg** 1999;5(3):147–50 (9 ref.) **(Ger)**
[An update, history and the outlook for the use of the human umbilical cord vein in surgery] Polupan SV. **Klin Khir** 1998; (9–10):67–9 (16 ref.) **(Rus)**

SURGICAL REPLANTATION see **REPLANTATION**

SURGICAL SCISSORS see **SURGICAL INSTRUMENTS**

SURGICAL SCRUB see **HANDWASHING**

SURGICAL SPONGES

ADVERSE EFFECTS

Gossypiboma revisited: a case report and review of the literature. Zbar AP, et al. **J R Coll Surg Edinb** 1998 Dec; 43(6):417–8 (12 ref.)

SURGICAL STAPLES see **SUTURES**

SURGICAL STAPLING

METHODS

Staple augmentation to treat a humeral nonunion after failed Seidel locked nailing. Wu CC, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):42–4 (10 ref.)

SURGICAL VALVES see **SURGICAL INSTRUMENTS**

SURGICAL WOUND DEHISCENCE

EPIDEMIOLOGY

Use of apron flap incision for neck dissection. Yii NW, et al. **Plast Reconstr Surg** 1999 May;103(6):1655–60 (24 ref.)

ETIOLOGY

Systemic thrombolysis causing anastomotic dehiscence of an aortobifemoral graft [see comments] Sequeira MJ, et al. **Ann R Coll Surg Engl** 1998 Sep;80(5):343–6 (11 ref.) Comment in: Ann R Coll Surg Engl 1999 Jan;81(1):72.

SURGERY

[Epidural anesthesia and analgesia in the perioperative treatment of a patient with Kartagener syndrome] Errando CL, et al. **Rev Esp Anestesiol Reanim** 1998 Dec; 45(10):431–2 (8 ref.) (Eng. Abstr.) **(Spa)**

SURGICAL WOUND INFECTION

Management of bacterial complications in critically ill patients: surgical wound and catheter-related infections. Nichols RL, et al. **Diagn Microbiol Infect Dis** 1999 Feb; 33(2):121–30 (30 ref.)
Pathophysiology, prevention, and management of prosthetic infections in hernia surgery. Deysine M. **Surg Clin North Am** 1998 Dec;78(6):1105–15, viii (26 ref.)

COMPLICATIONS

Cardiocutaneous fistula. Danias PG, et al. **Heart** 1999 Mar; 81(3):325–6 (10 ref.)

DIAGNOSIS

Abscess formation as a complication caused by postoperative osteomyelitis of the femur. Itokazu M, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):99–102 (7 ref.)

DRUG THERAPY

[Antibiotic treatment of peritonitis] Chalfine A, et al. **J Chir (Paris)** 1999 Mar;136(1):15–20 (21 ref.) (Eng. Abstr.) **(Fre)**
[Antibiotic therapy in surgery] Zimmerli W. **Chirurg** 1998 Dec;69(12):1392–8 (10 ref.) **(Ger)**
[The use of fluorquinolones in the treatment of purulent surgical infection] Korzhyk NP. **Klin Khir** 1999;(2):43–5 (39 ref.) **(Ukr)**

EPIDEMIOLOGY

[Infectious risk from ventriculostomy] Korinek AM. **Ann Fr Anesth Reanim** 1999 May;18(5):554–7 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Surgical site infections. Lauwers S, et al. **Acta Clin Belg** 1998 Oct;53(5):303–10 (54 ref.)
Bacterial infections after renal transplantation. Schmaldienst S, et al. **Contrib Nephrol** 1998;124:18–33; discussion 34–42 (101 ref.)
Postoperative infection in hand surgery. Cause, prevention, and treatment. Shapiro DB. **Hand Clin** 1998 Nov; 14(4):669–81, x (127 ref.)
Development of the Sternal Wound Infection Prediction Scale. Hussey LC, et al. **Heart Lung** 1998 Sep–Oct; 27(5):326–36 (44 ref.)
The nose: an underestimated source of Staphylococcus aureus causing wound infection. Casewell MW. **J Hosp Infect** 1998 Sep;40 Suppl B:S3–11 (41 ref.)
Animal models of orthopedic implant infection. An YH, et al. **J Invest Surg** 1998 Mar–Apr;11(2):139–46 (38 ref.)
Asymptomatic brain abscess as a complication of halo orthosis: report of a case and review of the literature. Kameyama O, et al. **J Orthop Sci** 1999;4(1):39–41 (13 ref.)
[Central nervous system infections in neurosurgery. Cerebral ischemia] Ravussin P, et al. **Ann Fr Anesth Reanim** 1999 May;18(5):481–6 (32 ref.) **(Fre)**
[Infections secondary to implantation of cardiac pacemakers] Da Costa A, et al. **Arch Mal Coeur Vaiss** 1998 Jun; 91(6):753–7 (30 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Microbiology in intraabdominal infections: what is the message for clinical studies? (Opinion paper). Condon RE. **Infection** 1999 Jan–Feb;27(1):63–66 (9 ref.)
Vancomycin-resistant enterococci: implications for surgeons. Fleenor-Ford A, et al. **Surgery** 1999 Feb;125(2):121–5 (10 ref.)

NURSING

Prevention of infection in the orthopedic surgery patient. DeBaun BJ. **Nurs Clin North Am** 1998 Dec;33(4):671–84 (93 ref.)

PREVENTION & CONTROL

Overview of quinolones in the treatment and prevention of surgical infection. Weigelt JA. **Am J Surg** 1998 Dec;176(6A Suppl):4S–7S (40 ref.)
Surgical face masks: are they mandatory for interventional endovascular procedures? Taylor PR, et al. **Cardiovasc Intervent Radiol** 1998 Nov–Dec;21(6):448–9 (22 ref.)
Preventing postoperative infections: current treatment recommendations. Gyssens IC. **Drugs** 1999 Feb; 57(2):175–85 (61 ref.)
Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. Ross EV, et al. **J Am Acad Dermatol** 1998 Dec;39(6):975–81 (33 ref.)
Eradication of nasal carriage of Staphylococcus aureus--is it cost-effective? Davey P. **J Hosp Infect** 1998 Sep;40 Suppl B:S31–7 (14 ref.)
Reduction of surgical site infections in major surgery by elimination of nasal carriage of Staphylococcus aureus. Kluytmans J. **J Hosp Infect** 1998 Sep;40 Suppl B:S25–9 (26 ref.)
New strategies for the use of mupirocin for the prevention of serious infection. Mehtar S. **J Hosp Infect** 1998 Sep;40 Suppl B:S39–44 (33 ref.)
Prevention of infection in the orthopedic surgery patient. DeBaun BJ. **Nurs Clin North Am** 1998 Dec;33(4):671–84 (93 ref.)

SURGERY

Anastomic dehiscence and severe peritonitis. Frileux P, et al. **Infection** 1999 Jan–Feb;27(1):67–70 (14 ref.)
Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. Brooks DH, et al. **J Arthroplasty** 1998 Sep;13(6):707–12 (15 ref.)
Transposition of the great omentum for infected sternotomy wounds in cardiac surgery. Report of 16 cases and review of published reports. Moor EV, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):25–9 (35 ref.)
[Postoperative management. Critical care in intra-abdominal infection after surgical intervention] Montravers P, et al. **Presse Med** 1999 Jan 30;28(4):196–202 (51 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Overview of quinolones in the treatment and prevention of surgical infection. Weigelt JA. **Am J Surg** 1998 Dec;176(6A Suppl):4S–7S (40 ref.)
Postoperative infection in hand surgery. Cause, prevention, and treatment. Shapiro DB. **Hand Clin** 1998 Nov; 14(4):669–81, x (127 ref.)
Vascular infections: medical and surgical therapies. Wipke–Tevis DD. **J Cardiovasc Nurs** 1999 Jan;13(2):70–81 (56 ref.)

SURGICENTERS

ECONOMICS

Ambulatory surgery center joint ventures involving tax–exempt entities. Becker S, et al.
J Health Care Finance 1999 Summer;25(4):47–58 (3 ref.)

SURROGATE MARKERS see **BIOLOGICAL MARKERS**

SURROGATE MOTHERS

LEGISLATION & JURISPRUDENCE

Informed consent issues in assisted reproduction. Reame N. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):331–8 (31 ref.)

SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM see **SEER PROGRAM**

SURVEILLANCE, IMMUNOLOGIC see **IMMUNOLOGIC SURVEILLANCE**

SURVEY METHODS see **DATA COLLECTION**

SURVEYS see **DATA COLLECTION**

SURVIVAL

PHYSIOLOGY

Stress genes and species survival. Ray PK.
Mol Cell Biochem 1999 Jun;196(1–2):117–23 (43 ref.)
The time dimension in stress responses: relevance for survival and health. Eriksen HR, et al. **Psychiatry Res** 1999 Jan 18;85(1):39–50 (72 ref.)

SURVIVAL ANALYSIS

see related
PROPORTIONAL HAZARDS MODELS

Severity scoring systems in the modern intensive care unit. Clermont G, et al. **Ann Acad Med Singapore** 1998 May; 27(3):397–403 (44 ref.)
Time–dependent covariates in the Cox proportional–hazards regression model. Fisher LD, et al.
Annu Rev Public Health 1999;20:145–57 (13 ref.)
Survival probabilities (the Kaplan–Meier method). Bland JM, et al. **BMJ** 1998 Dec 5;317(7172):1572 (3 ref.)
Survival analysis: caveats and pitfalls. Mathew A, et al.
Eur J Surg Oncol 1999 Jun;25(3):321–9 (23 ref.)
Analysis of time–to–pregnancy data. Keiding N.
Scand J Work Environ Health 1999;25 Suppl 1:10–1 (10 ref.)
Counts and times to events. Lindsey JK. **Stat Med** 1998 Aug 15–30;17(15–16):1745–51 (7 ref.)

SURVIVAL RATE

TRENDS

Estimating relative survival among people registered with cancer in England and Wales. Reeves GK, et al.
Br J Cancer 1999 Jan;79(1):18–22 (16 ref.)

SURVIVORS

Long–term survival (10 years or more) in 30 patients with primary amyloidosis. Kyle RA, et al. **Blood** 1999 Feb 1; 93(3):1062–6 (10 ref.)
Long–term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Nguyen HN, et al.
Dig Dis Sci 1999 Jun;44(6):1148–55 (37 ref.)
Long–term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. Spiegel DA, et al.
J Bone Joint Surg Am 1999 Jun;81(6):848–55 (52 ref.)
Working with childhood sexual abuse survivors during pregnancy, labor, and birth. Heritage C.
J Obstet Gynecol Neonatal Nurs 1998 Nov–Dec; 27(6):671–7 (17 ref.)
Pregnancy outcome in long–term survivors of childhood cancer. Blatt J. **Med Pediatr Oncol** 1999 Jul;33(1):29–33 (32 ref.)
Infertility and premature menopause in childhood cancer survivors. Byrne J. **Med Pediatr Oncol** 1999 Jul;33(1):24–8 (11 ref.)
Factors of importance for implantation and problems after treatment for childhood cancer. Critchley HO.
Med Pediatr Oncol 1999 Jul;33(1):9–14 (41 ref.)
Pharmacological protection of the gonads. Howell SJ, et al.
Med Pediatr Oncol 1999 Jul;33(1):41–5 (48 ref.)
Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Mulder JE.
Med Pediatr Oncol 1999 Jul;33(1):46–52 (59 ref.)
Reproductive technologies 1998: options available for the cancer patient. Pfeifer SM, et al. **Med Pediatr Oncol** 1999 Jul;33(1):34–40 (31 ref.)
Reproductive physiology and treatment–related loss of sex hormone production. Sklar C. **Med Pediatr Oncol** 1999 Jul; 33(1):2–8 (63 ref.)
Long–term survivors of childhood cancer: the late effects of therapy. Schwartz CL. **Oncologist** 1999;4(1):45–54 (67 ref.)
Lymphomas: long–term sequelae and survivorship issues. Fernsler J, et al. **Semin Oncol Nurs** 1998 Nov;14(4):321–8 (82 ref.)
Long–term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. Byrne J. **Teratology** 1999 Apr; 59(4):210–5 (30 ref.)

PSYCHOLOGY

"Nothing about me, without me": participatory action research with self–help/mutual aid organizations for psychiatric consumer/survivors. Nelson G, et al.
Am J Community Psychol 1998 Dec;26(6):881–912 (92 ref.)
Biological factors associated with susceptibility to posttraumatic stress disorder [see comments] Yehuda R. **Can J Psychiatry** 1999 Feb;44(1):34–9 (46 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.
What if Astyanax had survived? War, children, and youth. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):137–51 (106 ref.)
Is posttraumatic stress a viable model for understanding responses to childhood cancer? Stuber ML, et al.
Child Adolesc Psychiatr Clin N Am 1998 Jan;7(1):169–82 (56 ref.)
Psychodynamic–supportive group therapy model for elderly Holocaust survivors. Müller U, et al.
Int J Group Psychother 1998 Oct;48(4):461–75 (41 ref.)
Diagnosis of Holocaust survivors and their children. Kellermann NP. **Isr J Psychiatry Relat Sci** 1999;36(1):55–64 (38 ref.)
Practitioner review: long–term consequences of childhood cancer. Eiser C. **J Child Psychol Psychiatry** 1998 Jul; 39(5):621–33 (60 ref.)
The treatment of the long–term sequelae of child abuse. Stevenson J. **J Child Psychol Psychiatry** 1999 Jan; 40(1):89–111 (146 ref.)
Children's reactions to disaster. Coffman S.
J Pediatr Nurs 1998 Dec;13(6):376–82 (22 ref.)
Young adult survivors of childhood cancer: attending to emerging medical and psychosocial needs [see comments] Richardson RC, et al. **J Pediatr Oncol Nurs** 1999 Jul; 16(3):136–44 (41 ref.) Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115–6.
Posttraumatic stress disorder: understanding the psychosocial impact of surviving childhood cancer into young adulthood [see comments] Rourke MT, et al.
J Pediatr Oncol Nurs 1999 Jul;16(3):126–35 (25 ref.) Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115–6.
Attitude and disposition: Do they make a difference in cancer survival? Creagan ET. **J Prosthet Dent** 1999 Sep; 82(3):352–5 (24 ref.)
Surviving cancer: the importance of sexual self–concept. Andersen BL. **Med Pediatr Oncol** 1999 Jul;33(1):15–23 (45 ref.)
Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Schover LR. **Med Pediatr Oncol** 1999 Jul;33(1):53–9 (44 ref.)
Resilience in child survivors of the Holocaust: toward the concept of resilience. Valent P. **Psychoanal Rev** 1998 Aug; 85(4):517–35 (33 ref.)

STATISTICS & NUMERICAL DATA

A–bomb survivors: reassessment of the radiation hazard. Stewart AM, et al. **Med Confl Surviv** 1999 Jan–Mar; 15(1):47–56 (14 ref.)

SURVIVORSHIP see **SURVIVAL RATE**

SUSPENDING AGENTS see **EXCIPIENTS**

SUSTAINED–RELEASE PREPARATIONS see **DELAYED–ACTION PREPARATIONS**

SUSUS see **DOLPHINS**

SUTURE TECHNIQUES

Laceration management. Hollander JE, et al.
Ann Emerg Med 1999 Sep;34(3):356–67 (118 ref.)
Arthroscopic knot typing techniques. Nottage WM, et al.
Arthroscopy 1999 Jul–Aug;15(5):515–21 (12 ref.)
Pubic bone anchoring in the treatment of women with stress urinary incontinence: new applications to an old concept. Madjar S, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(6):416–8 (18 ref.)
Simple technique for rectus sheath closure after laparoscopic surgery using straight needles, with review of the literature. Chatzipapas IK, et al.
J Laparoendosc Adv Surg Tech A 1999 Apr;9(2):205–9 (22 ref.)
Fixation techniques for endoscopic browlift. Kennedy BD, et al. **J Oral Maxillofac Surg** 1999 May;57(5):588–94 (24 ref.)
Adjustable sutures in pediatric ophthalmology and strabismus. Strominger MB, et al.
J Pediatr Ophthalmol Strabismus 1999 May–Jun; 36(3):112–7; quiz 134–5 (49 ref.)
Suture? Staple? Electrosurgery? How to decide what is best for you [see comments] Carter JE.
J Soc Laparoendosc Surg 1997 Apr–Jun;1(2):171–4 (17 ref.) Comment in: J Soc Laparoendosc Surg 1997 Jul–Sep;1(3):293.
Suspension sutures for the treatment of obstructive sleep apnea and snoring. Coleman J, et al.
Otolaryngol Clin North Am 1999 Apr;32(2):277–85 (8 ref.)
[A surgical technic for cesarean section and gynecological laparotomy without suturing of the parietal and visceral peritoneum and the single–layer suturing of the uterus during the section (a review of the literature and initial experience)] Katsulov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):40–6 (25 ref.) **(Bul)**
[Single–row intestinal sutures and and the current suture materials in colorectal surgery] Buianov VM, et al.
Vestn Khir Im I I Grek 1999;158(2):77–82 (83 ref.) **(Rus)**

ADVERSE EFFECTS

Topical anesthesia. Keyes PD, et al. **Can Fam Physician** 1998 Oct;44:2152–6 (13 ref.)

SUTURES

[Sutureless methods of surgeries on gastrointestinal organs in clinic and experiment] Liashenko AA, et al.
Klin Khir 1999;(4):49–52 (30 ref.) **(Rus)**
[Single–row intestinal sutures and and the current suture materials in colorectal surgery] Buianov VM, et al.
Vestn Khir Im I I Grek 1999;158(2):77–82 (83 ref.) **(Rus)**

SUXAMETHONIUM see **SUCCINYLCHOLINE**

SV40 T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

SV40 T PROTEINS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

SV40 VIRUS see **POLYOMAVIRUS MACACAE**

SWAINSONINE

PHARMACOLOGY

Inhibitors of carbohydrate processing: A new class of anticancer agents. Goss PE, et al. **Clin Cancer Res** 1995 Sep;1(9):935–44 (127 ref.)
The pathogenesis and toxicokinetics of locoweed (Astragalus and Oxytropis spp.) poisoning in livestock. Stegelmeier BL, et al. **J Nat Toxins** 1999 Feb;8(1):35–45 (81 ref.)

SWALLOWING see **DEGLUTITION**

SWALLOWS see **SONGBIRDS**

SWAN–GANZ CATHETERIZATION see **CATHETERIZATION, SWAN–GANZ**

SWEAT

CHEMISTRY

Perspiration versus saliva––basic aspects concerning their use in roadside drug testing. Skopp G, et al.
Int J Legal Med 1999;112(4):213–21 (74 ref.)

SWEAT GLAND DISEASES

[Abscess of the apocrine sweat glands] Yamamoto Y.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):582–4 (4 ref.) **(Jpn)**

PATHOLOGY

Eccrine angiomatous hamartoma. Kwon OC, et al.
Int J Dermatol 1998 Oct;37(10):787–9 (18 ref.)

SWEAT GLAND NEOPLASMS

Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment. Chamberlain RS, et al. **Am J Clin Oncol** 1999 Apr;22(2):131–5 (19 ref.)
Malignant eccrine spiradenoma: a previously unreported presentation and review of the literature. Beekley AC, et al. **Am Surg** 1999 Mar;65(3):236–40 (17 ref.)

COMPLICATIONS

A reactive acrosyringeal proliferation in a patient with

SWEAT GLAND NEOPLASMS

ectodermal dysplasia: eccrine syringofibroadenoma-like lesion. Utani A, et al. **J Dermatol** 1999 Jan;26(1):36–43 (19 ref.)

DIAGNOSIS

[Diseases associated with adnexal tumors. II--Sebaceous tumors, sudoral tumors] Cribier B. **Ann Dermatol Venereol** 1999 May;126(5):455–62 (100 ref.) **(Fre)**

[An apocrine hidrocystoma of the scrotum. A case report] Flessati P, et al. **Minerva Chir** 1999 Jan-Feb;54(1-2):87–9 (7 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Giant malignant eccrine spiradenoma of the scalp. Jamshidi M, et al. **Dermatol Surg** 1999 Jan;25(1):45–8 (20 ref.)

Ectopic hidradenoma papilliferum: a case report and review of the literature. Vang R, et al. **J Am Acad Dermatol** 1999 Jul;41(1):115–8 (21 ref.)

Intracranial extension of an eccrine porocarcinoma. Case report and review of the literature. Ritter AM, et al. **J Neurosurg** 1999 Jan;90(1):138–40 (13 ref.)

Nodular hidradenoma of the breast: report of two cases with literature review. Domoto H, et al. **Pathol Int** 1998 Nov; 48(11):907–11 (20 ref.)

SURGERY

A rare case of atypical eccrine acrospiroma of the scalp and a literature review. Wilhelmi BJ, et al. **Ann Plast Surg** 1999 May;42(5):568–9 (13 ref.)

SWEAT GLANDS

INNERVATION

Hyperhidrosis treated by botulinum A exotoxin. Odderson IR. **Dermatol Surg** 1998 Nov;24(11):1237–41 (26 ref.)

PHYSIOLOGY

Development of muscarinic receptors and regulation of secretory responsiveness in rodent sweat glands. Landis SC. **Life Sci** 1999;64(6-7):381–5 (35 ref.)

PHYSIOPATHOLOGY

[The assessment of sudomotor function for diagnosis of autonomic diseases. Principles and methods] Birklein F, et al. **Fortschr Neurol Psychiatr** 1999 Jul;67(7):287–95 (87 ref.) (Eng. Abstr.) **(Ger)**

SWEATING

see related
CYSTIC FIBROSIS
HYPERHIDROSIS

Human perspiration measurement. Ohhashi T, et al. **Physiol Meas** 1998 Nov;19(4):449–61 (29 ref.)

[Parotid swelling with night sweat, fever and weight loss symptoms. A rare differential diagnosis] Herrmann G. **Dtsch Med Wochenschr** 1999 Feb 26;124(8):209–12 (25 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Thermoregulation and body fluid osmolality. Morimoto T, et al. **J Basic Clin Physiol Pharmacol** 1998;9(1):51–72 (45 ref.)

[The assessment of sudomotor function for diagnosis of autonomic diseases. Principles and methods] Birklein F, et al. **Fortschr Neurol Psychiatr** 1999 Jul;67(7):287–95 (87 ref.) (Eng. Abstr.) **(Ger)**

SWEATING, GUSTATORY

Frey's syndrome and parotid surgery. Sood S, et al. **Clin Otolaryngol** 1998 Aug;23(4):291–301 (129 ref.)

ETIOLOGY

Frey's syndrome after carotid endarterectomy. Mehta M, et al. **Ann Vasc Surg** 1999 Mar;13(2):232–4 (9 ref.)

Frey's syndrome following submandibular gland excision: an unusual postoperative complication. Teague A, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec; 60(6):346–8 (30 ref.)

SWEET POTATO see **SOLANACEAE**

SWEETENING AGENTS

Modulation of sweet taste. Birch GG. **Biofactors** 1999; 9(1):73–80 (29 ref.)

Noncariogenic intense natural sweeteners. Kinghorn AD, et al. **Med Res Rev** 1998 Sep;18(5):347–60 (69 ref.)

ADVERSE EFFECTS

Characteristics and significance of D-tagatose-induced liver enlargement in rats: An interpretative review. Bär A. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S83–93 (122 ref.)

TOXICITY

Erythritol: an interpretive summary of biochemical, metabolic, toxicological and clinical data [published erratum appears in Food Chem Toxicol 1999 Jun;37(6):I–II] Munro IC, et al. **Food Chem Toxicol** 1998 Dec; 36(12):1139–74 (210 ref.)

SWEET'S SYNDROME

[Sweet syndrome: practical conduct] Djien V, et al. **Ann Dermatol Venereol** 1999 Apr;126(4):343–7 (13 ref.) **(Fre)**

[Sweet's syndrome] Kato Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):575–7 (15 ref.) **(Jpn)**

COMPLICATIONS

Myelodysplasia presenting with pulmonary manifestations associated with neutrophilic dermatosis. Peters FP, et al. **Ann Hematol** 1998 Sep;77(3):135–8 (20 ref.)

PATHOLOGY

Acute febrile neutrophilic dermatosis (Sweet's syndrome). Review of the cases diagnosed at the dermatological clinic of Berne from 1994 to 1997. van Rooijen MM, et al. **Dermatology** 1998;197(3):299 (3 ref.)

SWIMMING

Athletic training issues in synchronized swimming. Chu DA. **Clin Sports Med** 1999 Apr;18(2):437–45, ix (2 ref.)

The spine in swimming. Ferrell MC. **Clin Sports Med** 1999 Apr;18(2):389–93, viii (2 ref.)

Nonorthopaedic problems in the aquatic athlete. Nichols AW. **Clin Sports Med** 1999 Apr;18(2):395–411, viii (40 ref.)

INJURIES

Aquatic sports massage therapy. Bell GW. **Clin Sports Med** 1999 Apr;18(2):427–35, ix (17 ref.)

Injuries in water polo. Brooks JM. **Clin Sports Med** 1999 Apr;18(2):313–9, vi (9 ref.)

Competitive water polo. Upper extremity injuries. Colville JM, et al. **Clin Sports Med** 1999 Apr;18(2):305–12, vi (7 ref.)

Shoulder injuries in competitive swimmers. McMaster WC. **Clin Sports Med** 1999 Apr;18(2):349–59, vii (51 ref.)

Injuries and considerations in masters aquatics sports. Miller JW. **Clin Sports Med** 1999 Apr;18(2):413–26, viii–ix (16 ref.)

The basics of synchronized swimming and its injuries. Mountjoy M. **Clin Sports Med** 1999 Apr;18(2):321–36 (19 ref.)

Thoracic outlet syndrome in aquatic athletes. Richardson AB. **Clin Sports Med** 1999 Apr;18(2):361–78 (46 ref.)

Injuries in competitive swimming. Richardson AB. **Clin Sports Med** 1999 Apr;18(2):287–91, v–vi (1 ref.)

Knee pain in competitive swimming. Rodeo SA. **Clin Sports Med** 1999 Apr;18(2):379–87, viii (9 ref.)

Swimming overuse injuries. Jones JH. **Phys Med Rehabil Clin N Am** 1999 Feb;10(1):77–94, vi (6 ref.)

PHYSIOLOGY

Analysis of the central pattern generator for swimming in the mollusk Clione. Arshavsky YI, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:51–69 (49 ref.)

Vertebrate locomotion--a lamprey perspective. Grillner S, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:1–18 (70 ref.)

Neuromodulation intrinsic to the central pattern generator for escape swimming in Tritonia. Katz PS. **Ann N Y Acad Sci** 1998 Nov 16;860:181–8 (39 ref.)

Modeling of the spinal neuronal circuitry underlying locomotion in a lower vertebrate. Lansner A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:239–49 (35 ref.)

Intersegmental coordination of swimmeret movements: mathematical models and neural circuits. Mulloney B, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:266–80 (32 ref.)

Central circuits controlling locomotion in young frog tadpoles. Roberts A, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:19–34 (39 ref.)

Development and aminergic neuromodulation of a spinal locomotor network controlling swimming in Xenopus larvae. Sillar KT, et al. **Ann N Y Acad Sci** 1998 Nov 16; 860:318–32 (49 ref.)

Open water swimming. Particular medical problems. Gerrard DF. **Clin Sports Med** 1999 Apr;18(2):337–47, vii (20 ref.)

The physiology and biomechanics of competitive swimming. Troup JP. **Clin Sports Med** 1999 Apr;18(2):267–85 (69 ref.)

Effects of intensive exercise training on immunity in athletes. Pyne DB, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S183–91; discussion S191–4 (101 ref.)

Use of heart rate monitors by endurance athletes: lessons from triathletes. O'Toole ML, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):181–7 (21 ref.)

PSYCHOLOGY

The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Lucki I. **Behav Pharmacol** 1997 Nov;8(6-7):523–32 (63 ref.)

Ethopharmacology of imipramine in the forced-swimming test: gender differences. Barros HM, et al. **Neurosci Biobehav Rev** 1998;23(2):279–86 (60 ref.)

SWINE

A swine integrator's perspective on nutrient management procedures. Coffey MT. **J Anim Sci** 1999 Feb;77(2):445–9 (5 ref.)

Alternatives to minimize the environmental impact of large swine production units. Miner JR. **J Anim Sci** 1999 Feb; 77(2):440–4 (7 ref.)

Potential for reduction of odorous compounds in swine manure through diet modification. Sutton AL, et al. **J Anim Sci** 1999 Feb;77(2):430–9 (59 ref.)

Xenotransplantation. The viral issue. Groth CG. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV26 (5 ref.)

[Iodine deficiency, iodine requirement and iodine excess of farm animals--experiments on growing pigs] Schöne F. **Berl Munch Tierarztl Wochenschr** 1999 Feb;112(2):64–70 (34 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

The major histocompatibility complex in swine. Chardon P, et al. **Immunol Rev** 1999 Feb;167:179–92 (66 ref.)

Objectives and strategies in pig improvement: an applied perspective. Webb AJ. **J Dairy Sci** 1998 Sep;81 Suppl 2:36–46 (27 ref.)

Studies of synaptonemal complexes in farm mammals--a review. Switoński M, et al. **J Hered** 1998 Nov-Dec; 89(6):473–80 (71 ref.)

[Transgenic pigs for xenotransplants for humans] Niemann H. **Zentralbl Chir** 1998;123(7):781–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Xenotransplantation. Possibilities of animal breeding] Wolf E, et al. **Zentralbl Chir** 1999;124(7):585–90 (43 ref.) (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

The comparative roles of polyunsaturated fatty acids in pig neonatal development. Leskanich CO, et al. **Br J Nutr** 1999 Feb;81(2):87–106 (157 ref.)

Nutrient management procedures to enhance environmental conditions: an introduction. Adeola O. **J Anim Sci** 1999 Feb;77(2):427–9 (11 ref.)

IMMUNOLOGY

Neuroendocrine-immune interactions in the neonate. Matteri RL, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):397–407 (76 ref.)

The major histocompatibility complex in swine. Chardon P, et al. **Immunol Rev** 1999 Feb;167:179–92 (66 ref.)

[Phenotypic and functional characterization of porcine T-lymphocytes] Saalmüller A, et al. **Zentralbl Chir** 1998; 123(7):798–802 (43 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Environmental concerns about animal manure. Jongbloed AW, et al. **J Anim Sci** 1998 Oct;76(10):2641–8 (32 ref.)

Artificial pigs in space: using artificial intelligence and artificial life techniques to design animal housing. Stricklin WR, et al. **J Anim Sci** 1998 Oct;76(10):2609–13 (18 ref.)

[Nutrition of young piglets in relation to weaning problems] Everts H, et al. **Tijdschr Diergeneeskd** 1999 Jan 15; 124(2):44–7 (15 ref.) (Eng. Abstr.) **(Dut)**

SWINE DISEASES

DIAGNOSIS

[Foot-and-mouth disease: clinical aspects, epizootiology and diagnosis] Dekker A, et al. **Tijdschr Diergeneeskd** 1999 Feb 1;124(3):74–9 (8 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Enteric viral infections of pigs and strategies for induction of mucosal immunity. Saif LJ. **Adv Vet Med** 1999;41:429–46 (54 ref.)

Genetic effects on vaccination. Wilkie BN, et al. **Adv Vet Med** 1999;41:39–51 (43 ref.)

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447–61 (60 ref.)

Cytokines as markers for infections and their effect on growth performance and well-being in the pig. Fossum C. **Domest Anim Endocrinol** 1998 Sep;15(5):439–44 (32 ref.)

Immune and endocrine regulation of food intake in sick animals. Johnson RW. **Domest Anim Endocrinol** 1998 Sep; 15(5):309–19 (81 ref.)

PREVENTION & CONTROL

Agents of the "suis-ide diseases" of swine: Actinobacillus suis, Haemophilus parasuis, and Streptococcus suis. MacInnes JI, et al. **Can J Vet Res** 1999 Apr;63(2):83–9 (52 ref.)

Managing an animal health emergency in Taipei China: foot and mouth disease. Chen BJ, et al. **Rev Sci Tech** 1999 Apr; 18(1):186–92 (5 ref.)

[Disease prevention in swine production] Keller H, et al. **Schweiz Arch Tierheilkd** 1999;141(3):115–20 (0 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Common laparoscopic procedures in swine: a review. Srinivasan A, et al. **J Invest Surg** 1999 Jan–Feb;12(1):5–14 (25 ref.)

TRANSMISSION

[Swine and wild pigs as carriers of zoonoses] Deutz A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Aug; 112(8):305–10 (48 ref.) (Eng. Abstr.) **(Ger)**

[Risk of infection causes by viruses in xenotransplantation] von der Helm K, et al. **Zentralbl Chir** 1999;124(7):600–3 (19 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Swinepox virus as a vaccine vector for swine pathogens. Tripathy DN. **Adv Vet Med** 1999;41:463–80 (45 ref.)

SWINE FEVER see **HOG CHOLERA**

SWINE FEVER VIRUS see **HOG CHOLERA VIRUS**

SWINE HERPESVIRUS 1 see **HERPESVIRUS 1, SUID**

SWINE INFLUENZA VIRUS see **INFLUENZA A VIRUS, PORCINE**

SWINEPOX VIRUS see **SUIPOXVIRUS**

SWISS BLUE see **METHYLENE BLUE**

SWISS MICE see **MICE**

SWITCH GENES see **GENES, SWITCH**

SWITCH REGION, IMMUNOGLOBULIN see **IMMUNOGLOBULIN SWITCH REGION**

SWITCHBOARD SERVICE see **TELEPHONE**

SWITCHING COMPLEX see **GENES, SWITCH**

SWYER SYNDROME see **GONADAL DYSGENESIS, 46,XY**

SYCOSIS see **FOLLICULITIS**

SYLVIAN VEIN see **CEREBRAL VEINS**

SYMBIOSIS

Fungal symbioses. Jakucs E.
Acta Microbiol Immunol Hung 1999;46(2–3):193–5 (13 ref.)

Genealogy of legume–Rhizobium symbioses. Broughton WJ, et al. **Curr Opin Plant Biol** 1999 Aug;2(4):305–11 (50 ref.)

Development of the arbuscular mycorrhizal symbiosis. Harrison MJ. **Curr Opin Plant Biol** 1998 Aug;1(4):360–5 (46 ref.)

Bacterial symbiosis in arthropods and the control of disease transmission. Beard CB, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):581–91 (84 ref.)

Endosymbiosis in protozoa of the Trypanosomatidae family. de Souza W, et al. **FEMS Microbiol Lett** 1999 Apr 1; 173(1):1–8 (38 ref.)

Intracellular bacteria in protozoa. Görtz HD, et al.
Naturwissenschaften 1998 Aug;85(8):359–68 (93 ref.)

GENETICS

Genes involved in the formation and assembly of rhizobial cytochromes and their role in symbiotic nitrogen fixation. Delgado MJ, et al. **Adv Microb Physiol** 1998;40:191–231 (160 ref.)

Genes and signal molecules involved in the rhizobia–leguminoseae symbiosis. Bladergroen MR, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):353–9 (61 ref.)

PHYSIOLOGY

Flavonoids and arbuscular–mycorrhizal fungi. Vierheilig H, et al. **Adv Exp Med Biol** 1998;439:9–33 (72 ref.)

Carbohydrate determinants of Rhizobium–legume symbioses. Price NP. **Carbohydr Res** 1999 Apr 30;317(1–4):1–9 (89 ref.)

Intracellular life. Corsaro D, et al. **Crit Rev Microbiol** 1999; 25(1):39–79 (310 ref.)

Legume nodulation and mycorrhizae formation; two extremes in host specificity meet. Albrecht C, et al.
EMBO J 1999 Jan 15;18(2):281–8 (66 ref.)

Metabolic symbiosis at the origin of eukaryotes. López–Garc P, et al. **Trends Biochem Sci** 1999 Mar;24(3):88–93 (39 ref.)

[Biochemical and molecular basis of symbiotic plant and microbe interactions] Jakubowska A, et al.
Postepy Biochem 1998;44(1):72–82 (104 ref.) **(Pol)**

SYMBIOTES see **RICKETTSIACEAE**

SYMBIOTIC RELATIONS (PSYCHOLOGY) see **OBJECT ATTACHMENT**

SYMPATHECTOMY

The change in concept and surgical treatment on Buerger's disease--personal experience and review. Nakajima N. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S273–80; discussion S281 (5 ref.)

SYMPATHECTOMY, CHEMICAL

Hyperhidrosis treated by botulinum A exotoxin. Odderson IR. **Dermatol Surg** 1998 Nov;24(11):1237–41 (26 ref.)

SYMPATHETIC-BLOCKING AGENTS see **SYMPATHOLYTICS**

SYMPATHETIC DENERVATION see **SYMPATHECTOMY**

SYMPATHETIC FIBERS see **ADRENERGIC FIBERS**

SYMPATHETIC GANGLIA see **GANGLIA, SYMPATHETIC**

SYMPATHETIC NERVE BLOCK see **AUTONOMIC NERVE BLOCK**

SYMPATHETIC NERVOUS SYSTEM

see related
SYMPATHECTOMY
SYMPATHOLYTICS
SYMPATHOMIMETICS

How to assess sympathetic activity in humans. Grassi G, et al. **J Hypertens** 1999 Jun;17(6):719–34 (170 ref.)

CYTOLOGY

Sympathetic neurons of the chick embryo are rescued by PACAP from apoptotic death. Wakade AR, et al.
Ann N Y Acad Sci 1998 Dec 11;865:176–80 (20 ref.)

Cellular and molecular determinants of sympathetic neuron development. Francis NJ, et al. **Annu Rev Neurosci** 1999; 22:541–66 (148 ref.)

Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)

Vasopressin acting at V1-type receptors produces membrane depolarization in neonatal rat spinal lateral column neurons. Kolaj M, et al. **Prog Brain Res** 1998;119:275–84 (63 ref.)

DRUG EFFECTS

Sympathetic activation in heart failure and its treatment with beta-blockade. Pepper GS, et al. **Arch Intern Med** 1999 Feb 8;159(3):225–34 (65 ref.)

Effects of antihypertensive therapies on the sympathetic nervous system. de Champlain J, et al. **Can J Cardiol** 1999 Mar;15 Suppl A:8A–14A (30 ref.)

Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Hegde SS, et al.
Curr Pharm Des 1998 Dec;4(6):469–79 (57 ref.)

Interactions between furosemide and the renal sympathetic nerves. Petersen JS. **Pharmacol Toxicol** 1999;84 Suppl 1:1–47 (390 ref.)

METABOLISM

Cardiovascular consequences of sympathetic hyperactivity. Leenen FH. **Can J Cardiol** 1999 Mar;15 Suppl A:2A–7A (34 ref.)

[Interaction between the sympathetic and renin-angiotensin system] K-Laflamme A, et al. **Therapie** 1998 May–Jun; 53(3):245–52 (55 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Causes and consequences of sympathetic basket formation in dorsal root ganglia. Ramer MS, et al. **Pain** 1999 Aug; Suppl 6:S111–20 (77 ref.)

[Pathomorphologic changes in the sympathetic portion of the autonomic nervous system and cardiovascular pathology] Shvalev VN. **Arkh Patol** 1999 May–Jun; 61(3):50–2 (23 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Innervation of mammalian white adipose tissue: implications for the regulation of total body fat. Bartness TJ, et al.
Am J Physiol 1998 Nov;275(5 Pt 2):R1399–411 (141 ref.)

Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Gurrera RJ.
Am J Psychiatry 1999 Feb;156(2):169–80 (167 ref.)

Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Smyth DD, et al.
Ann N Y Acad Sci 1999 Jun 21;881:344–57 (72 ref.)

Sympathetic neurons of the chick embryo are rescued by PACAP from apoptotic death. Wakade AR, et al.
Ann N Y Acad Sci 1998 Dec 11;865:176–80 (20 ref.)

The sympathetic nervous system and the kidney: its importance in renal diseases. Ritz E, et al. **Blood Press** 1998; Suppl 3:14–9 (35 ref.)

Gender differences in sympathetic nervous system regulation. Hinojosa-Laborde C, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):122–6 (50 ref.)

Autoinhibition, sympathetic cotransmission and biphasic contractile responses to trains of nerve stimulation in the rodent vas deferens. Ventura S.
Clin Exp Pharmacol Physiol 1998 Dec;25(12):965–73 (74 ref.)

Sympathetic activity and aging: relationship to smoking habits, physical fitness, blood volume, and intracellular signalling. Jensen EW. **Dan Med Bull** 1999 Apr; 46(2):106–17 (135 ref.)

Effects of fetal and neonatal environment on sympathetic nervous system development. Young JB, et al.
Diabetes Care 1998 Aug;21 Suppl 2:B156–60 (25 ref.)

Sympathetic contribution to blood pressure variability. Pagani M, et al. **Fundam Clin Pharmacol** 1998;12 Suppl 1:42s–47s (26 ref.)

Dynamic nonlinear vago-sympathetic interaction in regulating heart rate. Sunagawa K, et al. **Heart Vessels** 1998;13(4):157–74 (49 ref.)

Neural control of kidney function. Veelken R.
Kidney Blood Press Res 1998;21(2–4):249–52 (67 ref.)

Sympathetic neuromuscular transmission at a varicosity in a syncytium. Bennett MR, et al. **Microsc Res Tech** 1998 Sep 15;42(6):433–50 (59 ref.)

Sympathetic efferent pathways projecting to the vas deferens. Kihara K, et al. **Microsc Res Tech** 1998 Sep 15; 42(6):398–408 (80 ref.)

The regulation of neurotransmitter secretion by protein kinase C. Vaughan PF, et al. **Mol Neurobiol** 1998 Oct; 18(2):125–55 (237 ref.)

Regulation of leptin production: a dominant role for the sympathetic nervous system? Trayhurn P, et al.
Proc Nutr Soc 1998 Aug;57(3):413–9 (70 ref.)

Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons. Davies AM. **Prog Brain Res** 1998;117:47–56 (90 ref.)

The rhythmicity of sympathetic nerve activity. Malpas SC.
Prog Neurobiol 1998 Oct;56(1):65–96 (245 ref.)

The MONA LISA hypothesis in the time of leptin. Bray GA, et al. **Recent Prog Horm Res** 1998;53:95–117; discussion 117–8 (122 ref.)

[Progress in the study of actions of cardiac sympathetic nerve] Ma XY, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):341–3 (10 ref.) **(Chi)**

[Airway autonomic nervous system dysfunction and asthma] Ichinose M. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan; 37(1):3–9 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Cholinergic neural regulation of regional cerebral blood flow] Akio S. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:5P–9P (31 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

How to study sympatho-vagal balance in arterial hypertension and the effect of antihypertensive drugs? Presciuttini B, et al. **Acta Cardiol** 1998;53(3):143–52 (67 ref.)

Sympathetic control of circulation in hypertension and congestive heart failure. Lanfranchi A, et al.
Blood Press 1998;Suppl 3:40–5 (39 ref.)

Baroreflex control of sympathetic activity in experimental hypertension. Irigoyen MC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1213–20 (49 ref.)

The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina. Singh BN.
Can J Cardiol 1999 Mar;15 Suppl A:15A–21A (33 ref.)

Neural mechanisms in nitric-oxide-deficient hypertension. Sander M, et al. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):61–73 (165 ref.)

What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Astrup A, et al.
Exp Clin Endocrinol Diabetes 1998;106 Suppl 2:29–34 (42 ref.)

Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. Esler M, et al.
J Auton Nerv Syst 1998 Oct 15;72(2–3):210–9 (47 ref.)

The sympathetic nervous system in liver disease. Henriksen JH, et al. **J Hepatol** 1998 Aug;29(2):328–41 (169 ref.)

Role of the sympathetic nervous system in human hypertension. Grassi G. **J Hypertens** 1998 Dec;16(12 Pt 2):1979–87 (60 ref.)

Sympatho-adrenal mechanisms regulating cardiovascular hypertrophy in primary hypertension: a role for rilmenidine? Bobik A, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S51–4 (32 ref.)

Calcium antagonists and sympathetic activity in congestive heart failure. Grassi G, et al. **J Hypertens Suppl** 1998 Oct; 16(6):S9–14 (43 ref.)

Acute sympathetic hyperfunction in overlapping syndromes of systemic lupus erythematosus and polymyositis. Nakajima A, et al. **J Rheumatol** 1998 Aug;25(8):1638–41 (12 ref.)

Causalgia and reflex sympathetic dystrophy: does the sympathetic nervous system contribute to the generation of pain? Baron R, et al. **Muscle Nerve** 1999 Jun;22(6):678–95 (179 ref.)

[Cardiac sympathetic nerve activity in ischemic heart failure] Richardt G, et al. **Z Kardiol** 1998;87 Suppl 2:33–6 (14 ref.) (Eng. Abstr.) **(Ger)**

[Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension] Mancia G, et al.
Ann Ital Med Int 1997 Oct–Dec;12(4):217–22 (42 ref.) (Eng. Abstr.) **(Ita)**

[The role of the sympathetic system in ocular pathology] Cernea P, et al. **Oftalmologia** 1998;44(3):5–12 (15 ref.) (Eng. Abstr.) **(Rum)**

SYMPATHETIC TRANSMITTER RELEASERS see **ADRENERGIC AGENTS**

SYMPATHINS see **CATECHOLAMINES**

SYMPATHOLYTICS

see related
ADRENERGIC AGENTS
ADRENERGIC ANTAGONISTS

DIAGNOSTIC USE

Clonidine suppression test revisited. Lenz T, et al. **Blood Press** 1998 May;7(3):153–9 (28 ref.)

PHARMACOLOGY

Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. Head GA, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):163–9 (40 ref.)

THERAPEUTIC USE

Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. Esler M, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):210–9 (47 ref.)

SYMPATHOMIMETICS

see related
ADRENERGIC AGONISTS
ADRENERGIC UPTAKE INHIBITORS
CARDIOTONIC AGENTS
CARDIOVASCULAR AGENTS
MONOAMINE OXIDASE INHIBITORS
RECEPTORS, ADRENERGIC

ADVERSE EFFECTS

Adverse events associated with commonly used glaucoma drugs. Vogel R, et al. **Int Ophthalmol Clin** 1999 Spring; 39(2):107–24 (82 ref.)

Ritodrine-related liver injury. Case reports and review of the literature [see comments] Ceriani R, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):315–7 (8 ref.) Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):318–9.

Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. Onuigbo M, et al. **South Med J** 1998 Dec;91(12):1153–5 (17 ref.)

[Acute hepatitis due to ritodrine (letter)] Castro Fernández M, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (9 ref.) **(Spa)**

THERAPEUTIC USE

Topical therapies for glaucoma: what family physicians need to know. Lewis PR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1871–9, 1882 (30 ref.)

The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Colucci WS. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I20–4 (42 ref.)

SYMPORT see **ION TRANSPORT**

SYNAPSES

see related
GAP JUNCTIONS
SYNAPTIC TRANSMISSION
SYNAPTOSOMES

Wnt factors in axonal remodelling and synaptogenesis. Salinas PC. **Biochem Soc Symp** 1999;65:101–9 (48 ref.)

Topographic maps: developing roles of synaptic plasticity. Cline HT. **Curr Biol** 1998 Nov 19;8(23):R836–9 (21 ref.)

CHEMISTRY

A new approach to estimate the number, density and variability of receptors at central synapses. Nusser Z. **Eur J Neurosci** 1999 Mar;11(3):745–52 (52 ref.)

Pathophysiological implications of the structural organization of the excitatory synapse. Cattabeni F, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):339–47 (72 ref.)

The diversity of cadherins and implications for a synaptic adhesive code in the CNS. Shapiro L, et al. **Neuron** 1999 Jul;23(3):427–30 (20 ref.)

Synaptic PDZ domain-containing proteins. Hata Y, et al. **Neurosci Res** 1998 Sep;32(1):1–7 (65 ref.)

DRUG EFFECTS

Steroid-induced developmental plasticity in hypothalamic astrocytes: implications for synaptic patterning. Mong JA, et al. **J Neurobiol** 1999 Sep 15;40(4):602–19 (153 ref.)

Manganese neurotoxicity: a mechanistic hypothesis. Verity MA. **Neurotoxicology** 1999 Apr–Jun;20(2–3):489–97 (41 ref.)

The role of the NMDA synapse in general anesthesia. Flohr H, et al. **Toxicol Lett** 1998 Nov 23;100–101:23–9 (35 ref.)

GENETICS

Immediate-early genes and synaptic function. Lanahan A, et al. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):37–43 (34 ref.)

METABOLISM

Clearance of glutamate inside the synapse and beyond. Bergles DE, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):293–8 (64 ref.)

Antidepressants for the new millennium. Skolnick P. **Eur J Pharmacol** 1999 Jun 30;375(1–3):31–40 (72 ref.)

Redox mechanisms at the glutamate synapse and their significance: a review. Smythies J. **Eur J Pharmacol** 1999 Apr 1;370(1):1–7 (87 ref.)

Mechanisms of neurotransmitter release. Littleton JT, et al. **Int Rev Neurobiol** 1999;43:139–61 (94 ref.)

Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse. Nagano T, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):869–75 (74 ref.)

Effects of ion channel activity on development of dorsal root ganglion neurons. Fields RD. **J Neurobiol** 1998 Oct; 37(1):158–70 (89 ref.)

mRNA trafficking and local protein synthesis at the synapse [comment] Schuman EM. **Neuron** 1999 Aug;23(4):645–8 (20 ref.) Comment on: Neuron 1999 Aug;23(4):641–4.

Making proteins at the synapse: activity-regulated translation and CPEB [see comments] Worley P. **Neuron** 1998 Nov; 21(5):936–8 (12 ref.) Comment in: Neuron 1998 Nov;21(5):1129–39.

Extracellular glutamate diffusion determines the occupancy of glutamate receptors at CA1 synapses in the hippocampus. Kullmann DM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):395–402 (57 ref.)

Anchoring of glutamate receptors at the synapse. Hsueh YP, et al. **Prog Brain Res** 1998;116:123–31 (46 ref.)

Synaptic arrangement of glutamate receptors. Takumi Y, et al. **Prog Brain Res** 1998;116:105–21 (94 ref.)

Molecular complexity at the synapse: new proteins and multiple isoforms detected in Drosophila. Buchner E. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):159–66 (58 ref.)

The effect of volatile anaesthetics on synaptic release and uptake of glutamate. Larsen M, et al. **Toxicol Lett** 1998 Nov 23;100–101:59–64 (29 ref.)

Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Kullmann DM, et al. **Trends Neurosci** 1998 Jan;21(1):8–14 (57 ref.)

Kainate receptors: subunits, synaptic localization and function. Chittajallu R, et al. **Trends Pharmacol Sci** 1999 Jan;20(1):26–35 (93 ref.)

[Molecular mechanism of the assembly of neurotransmitter receptors and cell adhesion molecules at postsynaptic density] Hata Y. **Seikagaku** 1998 Dec;70(12):1414–8 (16 ref.) **(Jpn)**

[Electrical feedback in the chemical synapses] Byzov AL, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):1074–84 (19 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

The neuropathology of schizophrenia. A critical review of the data and their interpretation. Harrison PJ. **Brain** 1999 Apr;122 (Pt 4):593–624 (394 ref.)

Mechanisms of synaptic pathology in Alzheimer's disease. Masliah E. **J Neural Transm Suppl** 1998;53:147–58 (88 ref.)

PHYSIOLOGY

Synaptic and extrasynaptic roles of glutamate in the mammalian hippocampus. Kullmann DM. **Acta Physiol Scand** 1999 Jun;166(2):79–83 (25 ref.)

Molecular specificity of synaptic changes responsible for associative memory. Alkon DL. **Adv Exp Med Biol** 1998; 446:1–15 (49 ref.)

The synaptic framework for chemical signaling in nucleus accumbens. Meredith GE. **Ann N Y Acad Sci** 1999 Jun 29;877:140–56 (84 ref.)

Neurotrophins and synaptic plasticity. McAllister AK, et al. **Annu Rev Neurosci** 1999;22:295–318 (192 ref.)

Synaptic mechanisms for coding timing in auditory neurons. Trussell LO. **Annu Rev Physiol** 1999;61:477–96 (118 ref.)

Modes of interactions between signaling pathways. Jordan JD, et al. **Biochem Pharmacol** 1998 May 1;55(9):1347–52 (35 ref.)

The Fe65 and X11 families of proteins: proteins that interact with the Alzheimer's disease amyloid precursor protein. McLoughlin DM, et al. **Biochem Soc Trans** 1998 Aug; 26(3):497–500 (28 ref.)

"Painting" the target: how local molecular cues define synaptic relationships. Chiba A, et al. **Bioessays** 1998 Nov; 20(11):941–8 (68 ref.)

Neuromodulation, development and synaptic plasticity. Foehring RC, et al. **Can J Exp Psychol** 1999 Mar; 53(1):45–61 (125 ref.)

Synaptic plasticity and the organization of behaviour after early and late brain injury. Kolb B. **Can J Exp Psychol** 1999 Mar;53(1):62–76 (63 ref.)

Specification of neuronal connectivity: ETS marks the spot [comment] Ghosh A, et al. **Cell** 1998 Oct 30;95(3):303–6 (17 ref.) Comment on: Cell 1998 Oct 30;95(3):393–407.

Finding a partner in a crowd: neuronal diversity and synaptogenesis. Serafini T. **Cell** 1999 Jul 23;98(2):133–6 (20 ref.)

Making more synapses: a way to store information? Moser MB. **Cell Mol Life Sci** 1999 Apr;55(4):593–600 (68 ref.)

Introduction: molecular mechanisms of memory formation--from receptor activation to synaptic changes. Riedel G, et al. **Cell Mol Life Sci** 1999 Apr;55(4):521–4 (18 ref.)

Synaptic plasticity: regulated translation in dendrites. Huang EP. **Curr Biol** 1999 Mar 11;9(5):R168–70 (14 ref.)

Electrical synapses: beyond speed and synchrony to computation. Marder E. **Curr Biol** 1998 Nov 5; 8(22):R795–7 (9 ref.)

Synaptic plasticity: step-wise strengthening. Murthy VN. **Curr Biol** 1998 Sep 10;8(18):R650–3 (9 ref.)

Synaptogenesis: The MAP location of GABA receptors. Passafaro M, et al. **Curr Biol** 1999 Apr 8;9(7):R261–3 (10 ref.)

Organization and regulation of proteins at synapses [published erratum appears in Curr Opin Cell Biol 1999 Jun;11(3):407–8] Kim JH, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):248–54 (64 ref.)

Cellular, synaptic, network, and modulatory mechanisms involved in rhythm generation. Calabrese RL. **Curr Opin Neurobiol** 1998 Dec;8(6):710–7 (45 ref.)

Interaction between superficial layers of the entorhinal cortex and the hippocampus in normal and epileptic temporal lobe. Gloveli T, et al. **Epilepsy Res** 1998 Sep;32(1–2):183–93 (81 ref.)

New perspectives for the development of selective metabotropic glutamate receptor ligands. Pin JP, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):277–94 (129 ref.)

Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions [see comments] Vizi ES, et al. **Hippocampus** 1998;8(6):566–607 (384 ref.) Comment in: Hippocampus 1998 ;8(6):565.

Fluorescence microscopy of calcium and synaptic vesicle dynamics during synapse formation in tissue culture. Dai Z, et al. **Histochem J** 1998 Mar;30(3):189–96 (22 ref.)

Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Woolley CS. **Horm Behav** 1998 Oct;34(2):140–8 (47 ref.)

Roles of neurotrophins on synaptic development and functions in the central nervous system. Takei N, et al. **Hum Cell** 1998 Sep;11(3):157–65 (64 ref.)

Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul;95(1–2):133–40 (58 ref.)

Drosophila melanogaster as a model system for the study of the function of calcium/calmodulin-dependent protein kinase II in synaptic plasticity. Griffith LC. **Invert Neurosci** 1997 Sep–Dec;3(2–3):93–102 (72 ref.)

Regulation of neurotrophic functions: proteinase inhibitors. Fumagalli L, et al. **Ital J Anat Embryol** 1999 Apr–Jun; 104(2):53–88 (110 ref.)

Synaptic plasticity in the mormyrid electrosensory lobe. Bell CC, et al. **J Exp Biol** 1999 May;202 (Pt 10):1339–47 (26 ref.)

Role of astroglia in estrogen regulation of synaptic plasticity and brain repair. Garcia-Segura LM, et al. **J Neurobiol** 1999 Sep 15;40(4):574–84 (99 ref.)

Mechanisms of spontaneous activity in developing spinal networks. O'Donovan MJ, et al. **J Neurobiol** 1998 Oct; 37(1):131–45 (73 ref.)

Regulation of gene expression by trans-synaptic activity: a role for the transcription factor NF-kappa B. Gisiger V. **J Physiol Paris** 1998 Jun–Aug;92(3–4):163–6 (35 ref.)

Some cholinergic themes related to Alzheimer's disease: synaptology of the nucleus basalis, location of m2 receptors, interactions with amyloid metabolism, and perturbations of cortical plasticity. Mesulam MM. **J Physiol Paris** 1998 Jun–Aug;92(3–4):293–8 (56 ref.)

Targeting acetylcholinesterase molecules to the neuromuscular synapse. Rotundo RL, et al. **J Physiol Paris** 1998 Jun–Aug;92(3–4):195–8 (23 ref.)

Arcachon and cholinergic transmission. Whittaker VP. **J Physiol Paris** 1998 Apr;92(2):53–7 (29 ref.)

Assessing the machinery of mind: synapses in neuropsychiatric disorders. Honer WG. **J Psychiatry Neurosci** 1999 Mar;24(2):116–21 (21 ref.)

Long-lasting forms of synaptic potentiation in the mammalian hippocampus. Huang YY, et al. **Learn Mem** 1996 Sep–Oct;3(2–3):74–85 (56 ref.)

Regulation of synaptic function by neurotrophic factors in vertebrates and invertebrates: implications for development and learning. McKay SE, et al. **Learn Mem** 1999 May–Jun; 6(3):193–215 (196 ref.)

The predictive brain: temporal coincidence and temporal order in synaptic learning mechanisms. Montague PR, et al. **Learn Mem** 1994 May–Jun;1(1):1–33 (165 ref.)

Development of specific synaptic network functions in organotypic central nervous system (CNS) cultures: implications for transplantation of CNS neural cells in vivo. Crain SM. **Methods** 1998 Nov;16(3):228–38 (90 ref.)

Modification of glutamate receptor channels: molecular mechanisms and functional consequences. Hatt H. **Naturwissenschaften** 1999 Apr;86(4):177–86 (51 ref.)

Integrated regulation of signal coding and plasticity by NMDA receptors at a central synapse. D'Angelo E, et al. **Neural Plast** 1998 Jul–Sep;6(3):8–16 (38 ref.)

Contributions of cell adhesion molecules to altered synaptic weightings during memory consolidation. Murphy KJ, et al. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):73–81 (35

ref.)
Specifying motor neurons and their connections. Goulding M. **Neuron** 1998 Nov;21(5):943–6 (20 ref.)
Eph receptors, ephrins, and PDZs gather in neuronal synapses [comment] Hsueh YP, et al. **Neuron** 1998 Dec; 21(6):1227–9 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1453–63.
Silencing the controversy in LTP? [comment] Malinow R. **Neuron** 1998 Dec;21(6):1226–7 (12 ref.) Comment on: Neuron 1998 Dec;21(6):1443–51.
The diversity of cadherins and implications for a synaptic adhesive code in the CNS. Shapiro L, et al. **Neuron** 1999 Jul;23(3):427–30 (20 ref.)
Synaptic [Ca2+]: intracellular stores spill their guts. Svoboda K, et al. **Neuron** 1999 Mar;22(3):427–30 (20 ref.)
Synaptic plasticity in the hippocampus during afferent activation reproducing the pattern of the theta rhythm (theta plasticity). Kleshchevnikov AM. **Neurosci Behav Physiol** 1999 Mar–Apr;29(2):185–96 (76 ref.)
Is learning blocked by saturation of synaptic weights in the hippocampus? Moser EI, et al. **Neurosci Biobehav Rev** 1999 May;23(5):661–72 (110 ref.)
Effects of gamma-aminobutyric acid (GABA) on synaptogenesis and synaptic function. Belhage B, et al. **Perspect Dev Neurobiol** 1998;5(2–3):235–46 (112 ref.)
The role of glial cells in synaptic function. Bacci A, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):403–9 (52 ref.)
Homosynaptic long-term depression: a mechanism for memory? Bear MF. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9457–8 (24 ref.)
Osmoregulation of vasopressin neurons: a synergy of intrinsic and synaptic processes. Bourque CW. **Prog Brain Res** 1998; 119:59–76 (120 ref.)
Synaptic plasticity in ischemia: role of NMDA receptors. Crepel V, et al. **Prog Brain Res** 1998;116:273–85 (110 ref.)
The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Farber NB, et al. **Prog Brain Res** 1998;116:421–37 (60 ref.)
Eph receptors and ligands in axon pathway choice, target recognition, and synaptogenesis. Lemke G. **Prog Brain Res** 1998;117:171–6 (34 ref.)
Instructive roles of neurotrophins in synaptic plasticity. Lo DC. **Prog Brain Res** 1998;117:65–70 (27 ref.)
The glutamate synapse as a therapeutical target: perspectives for the future. Meldrum BS. **Prog Brain Res** 1998; 116:441–58 (132 ref.)
Control of time course of glutamatergic synaptic currents. Trussell L. **Prog Brain Res** 1998;116:59–69 (74 ref.)
The glutamate synapse: a target in the pharmacological management of hyperalgesic pain states. Urban MO, et al. **Prog Brain Res** 1998;116:407–20 (81 ref.)
Synapse formation molecules in muscle and autonomic ganglia: the dual constraint hypothesis. Bennett MR. **Prog Neurobiol** 1999 Feb;57(2):225–87 (257 ref.)
Synaptic excitation in the dorsal nucleus of the lateral lemniscus. Wu SH. **Prog Neurobiol** 1999 Feb;57(3):357–75 (106 ref.)
Hebbian synapses in cortical and hippocampal pathways. Skrebitsky VG, et al. **Rev Neurosci** 1998;9(4):243–64 (246 ref.)
Long-term potentiation—a decade of progress? Malenka RC, et al. **Science** 1999 Sep 17;285(5435):1870–4 (62 ref.)
Modulation of reconstructed peptidergic synapses and electrical synapses by general anaesthetics. Winlow W, et al. **Toxicol Lett** 1998 Nov 23;100–101:77–84 (38 ref.)
Tripartite synapses: glia, the unacknowledged partner. Araque A, et al. **Trends Neurosci** 1999 May;22(5):208–15 (61 ref.)
Glutamatergic synapses onto hippocampal interneurons: precision timing without lasting plasticity. McBain CJ, et al. **Trends Neurosci** 1999 May;22(5):228–35 (61 ref.)
Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction. Ruegg MA, et al. **Trends Neurosci** 1998 Jan;21(1):22–7 (74 ref.)
The amphiphysin family of proteins and their role in endocytosis at the synapse. Wigge P, et al. **Trends Neurosci** 1998 Aug;21(8):339–44 (49 ref.)
[Memory: clinico-pathologic data] Duyckaerts C, et al. **Rev Neurol (Paris)** 1998;154 Suppl 2:S8–17 (84 ref.) **(Eng. Abstr.) (Fre)**
[A functional role for PDZ proteins in synapse organization and synaptic plasticity] Inokuchi K. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1355–64 (49 ref.) **(Jpn)**
[Electrical feedback in the chemical synapses] Byzov AL, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):1074–84 (19 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

"Painting" the target: how local molecular cues define synaptic relationships. Chiba A, et al. **Bioessays** 1998 Nov; 20(11):941–8 (68 ref.)
Integrating bits and pieces: synapse structure and formation in Drosophila embryos. Prokop A. **Cell Tissue Res** 1999 Aug;297(2):169–86 (115 ref.)
Morphological changes associated with long-term potentiation. Agnihotri N, et al. **Histol Histopathol** 1998 Oct;13(4):1155–62 (93 ref.)
Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias [see comments] West MJ. **Trends Neurosci** 1999 Feb;22(2):51–61 (49 ref.) Comment in: Trends Neurosci 1999 Aug;22(8):345–6. Comment in: Trends Neurosci 1999 Aug;22(8):346–7.
Synapsoarchitectonics of cerebral cortex: ontogenetic aspects] Bogolepov NN. **Vestn Ross Akad Med Nauk** 1999; (6):38–43 (21 ref.) (Eng. Abstr.) **(Rus)**

SYNAPSIN I see **SYNAPSINS**

SYNAPSIN II see **SYNAPSINS**

SYNAPSINS

PHYSIOLOGY

Synapsins as regulators of neurotransmitter release. Hilfiker S, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1381):269–79 (88 ref.)

SYNAPTIC BOUTONS see **PRESYNAPTIC TERMINALS**

SYNAPTIC MEMBRANES

see related
SYNAPTOSOMES

METABOLISM

Membrane traffic in polarized neurons. Bradke F, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1–2):245–58 (136 ref.)
[3H]-GABA binding to GABAA and GABAB sites on rat brain crude synaptic membranes. Bruton R, et al. **Methods Mol Biol** 1999;106:27–35 (16 ref.)

PHYSIOLOGY

Assembly of signaling machinery at the postsynaptic membrane. Kirsch J. **Curr Opin Neurobiol** 1999 Jun; 9(3):329–35 (61 ref.)

SECRETION

Monitoring secretory membrane with FM1-43 fluorescence. Cochilla AJ, et al. **Annu Rev Neurosci** 1999;22:1–10 (76 ref.)

SYNAPTIC POTENTIALS see **SYNAPTIC TRANSMISSION**

SYNAPTIC RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

SYNAPTIC TERMINALS see **PRESYNAPTIC TERMINALS**

SYNAPTIC TRANSMISSION

see related
GAP JUNCTIONS
NEUROTRANSMITTERS
SYNAPSES

Exploring brain circuitry with neurotropic viruses: new horizons in neuroanatomy. Card JP. **Anat Rec** 1998 Dec; 253(6):176–85 (44 ref.)
Heteromeric complexes of alpha 5 and/or alpha 7 subunits. Effects of calcium and potential role in nicotine-induced presynaptic facilitation. Girod R, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:578–90 (81 ref.)
Clinical uses and controversies of neuromuscular blocking agents in infants and children. Martin LD, et al. **Crit Care Med** 1999 Jul;27(7):1358–68 (128 ref.)
Noradrenergic synaptic transmission in the superior cervical ganglion. Kawai Y. **Kaibogaku Zasshi** 1999 Apr; 74(2):167–73 (38 ref.)
Sympathetic neuromuscular transmission at a varicosity in a syncytium. Bennett MR, et al. **Microsc Res Tech** 1998 Sep 15;42(6):433–50 (59 ref.)
Modeling dopamine system dysfunction in experimental animals. Hantraye P. **Nucl Med Biol** 1998 Nov;25(8):721–8 (31 ref.)
Volume transmission in the CNS and its relevance for neuropsychopharmacology. Zoli M, et al. **Trends Pharmacol Sci** 1999 Apr;20(4):142–50 (119 ref.)

DRUG EFFECTS

Cognition enhancement strategies by ion channel modulation of neurotransmission. Eid CN Jr, et al. **Curr Pharm Des** 1999 May;5(5):345–61 (351 ref.)
Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients. Sirviö J. **Gerontology** 1999;45 Suppl 1:3–14 (127 ref.)
Glutamatergic neurotransmission in alcoholism. Tsai G. **J Biomed Sci** 1998 Sep–Oct;5(5):309–20 (146 ref.)
Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Yamada KA. **Neurobiol Dis** 1998 Aug;5(2):67–80 (84 ref.)
What the actions of anaesthetics on fast synaptic transmission reveal about the molecular mechanism of anaesthesia. Richards CD. **Toxicol Lett** 1998 Nov 23;100–101:41–50 (65 ref.)
Therapeutic potential of histamine H3 receptor agonists and antagonists. Leurs R, et al. **Trends Pharmacol Sci** 1998 May; 19(5):177–83 (97 ref.)

GENETICS

Genetic evidence for an equilibrium between docked and undocked vesicles. Li J, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):299–306 (29 ref.)

IMMUNOLOGY

Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Dunn AJ, et al. **Adv Exp Med Biol** 1999;461:117–27 (60 ref.)

PHYSIOLOGY

Synaptic and extrasynaptic roles of glutamate in the mammalian hippocampus. Kullmann DM. **Acta Physiol Scand** 1999 Jun;166(2):79–83 (25 ref.)
Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Blier P, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:204–16 (51 ref.)
Autoimmunity and neurological disease: antibody modulation of synaptic transmission. Whitney KD, et al. **Annu Rev Neurosci** 1999;22:175–95 (98 ref.)
Timing of synaptic transmission. Sabatini BL, et al. **Annu Rev Physiol** 1999;61:521–42 (117 ref.)
Branching and/or collateral projections of spinal dorsal horn neurons. Lu GW, et al. **Brain Res Brain Res Rev** 1999 Jan; 29(1):50–82 (231 ref.)
Hierarchical neuronal modeling of cognitive functions: from synaptic transmission to the Tower of London. Changeux JP, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):241–7 (39 ref.)
Quantal analysis of synaptic processes in the neocortex. Thomson AM. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):131–3 (16 ref.)
Development of the cholinergic neurotransmitter phenotype in postganglionic sympathetic neurons. Ernsberger U, et al. **Cell Tissue Res** 1999 Sep;297(3):339–61 (137 ref.)
Synaptic transmission: spillover at central synapses. Huang EP. **Curr Biol** 1998 Aug 27;8(17):R613–5 (11 ref.)
Synaptic transmission: two players team up for a new tune. Jahn R. **Curr Biol** 1998 Nov 19;8(23):R856–8 (18 ref.)
Organization and regulation of proteins at synapses [published erratum appears in Curr Opin Cell Biol 1999 Jun;11(3):407–8] Kim JH, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):248–54 (64 ref.)
Synaptic vesicle docking and fusion. Bajjalieh SM. **Curr Opin Neurobiol** 1999 Jun;9(3):321–8 (96 ref.)
The origin of spontaneous activity in developing networks of the vertebrate nervous system. O'Donovan MJ. **Curr Opin Neurobiol** 1999 Feb;9(1):94–104 (75 ref.)
Neurotrophin regulation of synaptic transmission. Schuman EM. **Curr Opin Neurobiol** 1999 Feb;9(1):105–9 (45 ref.)
Time as coding space? Singer W. **Curr Opin Neurobiol** 1999 Apr;9(2):189–94 (70 ref.)
Sex-steroid actions on neurotransmission. Bicknell RJ. **Curr Opin Neurol** 1998 Dec;11(6):667–71 (40 ref.)
The inhibitory glycine receptor: prospects for a therapeutic orphan? Breitinger HG, et al. **Curr Pharm Des** 1998 Aug; 4(4):315–34 (274 ref.)
Actions of the pro-inflammatory cytokine IL-1 beta on central synaptic transmission. O'Connor JJ, et al. **Exp Physiol** 1999 Jul;84(4):601–14 (82 ref.)
Alcohol and anesthetic mechanisms in genetically engineered mice. Homanics GE, et al. **Front Biosci** 1998 Jun 8; 3:D548–58 (104 ref.)
Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. Lessmann V. **Gen Pharmacol** 1998 Nov;31(5):667–74 (79 ref.)
Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions [see comments] Vizi ES, et al. **Hippocampus** 1998;8(6):566–607 (384 ref.) Comment in: Hippocampus 1998 ;8(6):565.
Development of electrical properties and synaptic transmission at the embryonic neuromuscular junction. Broadie KS. **Int Rev Neurobiol** 1999;43:45–67 (39 ref.)
Strength of synaptic transmission at neuromuscular junctions of crustaceans and insects in relation to calcium entry. Atwood HL, et al. **Invert Neurosci** 1997 Sep–Dec; 3(2–3):81–7 (39 ref.)
Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. Sheng ZH, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):335–45 (80 ref.)
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy DL, et al. **J Clin Psychiatry** 1998;59 Suppl 15:4–12 (118 ref.)
Arcachon and cholinergic transmission. Whittaker VP. **J Physiol Paris** 1998 Apr;92(2):53–7 (29 ref.)
Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Jones EA, et al. **Metab Brain Dis** 1998 Dec;13(4):351–60 (49 ref.)
Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Schmitz D, et al. **Mol Neurobiol** 1998 Winter;17(1–3):59–72 (85 ref.)
Firing rate distributions and efficiency of information

transmission of inferior temporal cortex neurons to natural visual stimuli. Treves A, et al. **Neural Comput** 1999 Apr 1;11(3):601–32 (39 ref.)
Cannabinoid transmission and reward-related events. Gardner EL, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):502–33 (314 ref.)
Cannabinoid transmission and pain perception. Martin BR, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):447–61 (131 ref.)
The neurobiology of cannabinoid transmission: from anandamide signaling to higher cerebral functions and disease. Navarro M, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):379–85 (48 ref.)
Synaptic plasticity and learning and memory: 15 years of progress. Baudry M. **Neurobiol Learn Mem** 1998 Jul–Sep; 70(1–2):113–8 (19 ref.)
Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Jueptner M, et al. **Neuroimage** 1995 Jun;2(2):148–56 (60 ref.)
Thinking globally, acting locally: AMPA receptor turnover and synaptic strength [comment] Turrigiano GG, et al. **Neuron** 1998 Nov;21(5):933–5 (10 ref.) Comment on: Neuron 1998 Nov;21(5):1067–78.
Synaptic PDZ domain-containing proteins. Hata Y, et al. **Neurosci Res** 1998 Sep;32(1):1–7 (65 ref.)
Effects of gamma-aminobutyric acid (GABA) on synaptogenesis and synaptic function. Belhage B, et al. **Perspect Dev Neurobiol** 1998;5(2–3):235–46 (112 ref.)
Differentially expressed GABAA-receptor subunits result in structurally and functionally receptor assemblies following excitatory afferent synaptic transmission. Grayson DR, et al. **Perspect Dev Neurobiol** 1998;5(2–3):193–205 (72 ref.)
Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Yu XM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7697–704 (118 ref.)
Nonsynaptic diffusion neurotransmission and some other emerging concepts. Bach-y-Rita P. **Proc West Pharmacol Soc** 1998;41:211–8 (89 ref.)
Glutamate in the human brain: possible roles in synaptic transmission and ischemia. Berg-Johnsen J, et al. **Prog Brain Res** 1998;116:287–302 (126 ref.)
Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Ingram CD, et al. **Prog Brain Res** 1998;119:351–64 (92 ref.)
Dynamic modulation of cerebral cortex synaptic function by nitric oxide. Kara P, et al. **Prog Brain Res** 1998;118:183–98 (135 ref.)
Release of neurotransmitters in the locus coeruleus. Singewald N, et al. **Prog Neurobiol** 1998 Oct;56(2):237–67 (328 ref.)
Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Klann E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):359–76 (94 ref.)
Theoretical aspects of sensory substitution and of neurotransmission-related reorganization in spinal cord injury. Bach-y-Rita P. **Spinal Cord** 1999 Jul;37(7):465–74 (81 ref.)
Mechanisms of excitatory synaptic transmission in the enteric nervous system. Galligan JJ. **Tokai J Exp Clin Med** 1998 Jun;23(3):129–36 (38 ref.)
Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Liu Y, et al. **Trends Cell Biol** 1999 Sep;9(9):356–63 (73 ref.)
Tripartite synapses: glia, the unacknowledged partner. Araque A, et al. **Trends Neurosci** 1999 May;22(5):208–15 (61 ref.)
Paracrine neurotransmission in the CNS: involvement of 5-HT. Bunin MA, et al. **Trends Neurosci** 1999 Sep; 22(9):377–82 (50 ref.)
Cellular mechanisms of cerebellar LTD. Daniel H, et al. **Trends Neurosci** 1998 Sep;21(9):401–7 (63 ref.)
Recognition of slow processes in rhythmic networks. Golowasch J, et al. **Trends Neurosci** 1999 Sep;22(9):375–7 (24 ref.)
A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Paulsen O, et al. **Trends Neurosci** 1998 Jul;21(7):273–8 (61 ref.)
Hippocampal synapses: do they talk to their neighbours? Rusakov DA, et al. **Trends Neurosci** 1999 Sep;22(9):382–8 (37 ref.)
Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Murphy DL, et al. **Trends Pharmacol Sci** 1999 Jun;20(6):246–52 (75 ref.)
[Molecular biology, and molecular genetics in the field of otorhinolaryngology--mechanism of neural transmission in the cochlea] Doi K. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Aug;101(8):1048–51 (4 ref.) **(Jpn)**
[Modulatory mechanisms involved in the parasympathetic excitatory neuro-effector transmission in the airway and gastrointestinal tracts--perspective for a new drug creation] Ito Y. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:28P–31P (9 ref.) (Eng. Abstr.) **(Jpn)**
[Long-term potentiation of synaptic transmission] Manabe T. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1841–8 (23 ref.) **(Jpn)**
[Long-term depression of synaptic transmission] Shibuki K. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1849–54 (45 ref.) **(Jpn)**
[Characterization of the facilitatory modulation of adrenergic neurotransmission via prejunctional purinoceptors in rabbit ear artery] Ishii-Nozawa R, et al. **Yakugaku Zasshi** 1999 Jun;119(6):417–28 (47 ref.) (Eng. Abstr.) **(Jpn)**
[Electrical feedback in the chemical synapses] Byzov AL, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct; 84(10):1074–84 (19 ref.) (Eng. Abstr.) **(Rus)**
[The role of volume transmission of the adaptogenic signals in the formation of adaptive brain responses] Samoilov MO, et al. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):4–20 (105 ref.) (Eng. Abstr.) **(Rus)**
[Interneuronal signaling mediated by the trans-synaptic diffusion of neurotransmitters] Kopanitsia MV, et al. **Fiziol Zh** 1999;45(4):132–47 (95 ref.) (Eng. Abstr.) **(Ukr)**

SYNAPTIC VESICLES

METABOLISM

Voltage-operated calcium channels in secretory vesicles? Sher E. **Cell Biol Int** 1997 Dec;21(12):779–81 (14 ref.)
Fluorescence microscopy of calcium and synaptic vesicle dynamics during synapse formation in tissue culture. Dai Z, et al. **Histochem J** 1998 Mar;30(3):189–96 (22 ref.)
Interactions between presynaptic calcium channels and proteins implicated in synaptic vesicle trafficking and exocytosis. Seagar M, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):347–56 (58 ref.)
Uptake of glutamate into synaptic vesicles. Fonnum F, et al. **Prog Brain Res** 1998;116:87–101 (83 ref.)

PHYSIOLOGY

Genetics of synaptic vesicle function: toward the complete functional anatomy of an organelle. Fernández-Chacón R, et al. **Annu Rev Physiol** 1999;61:753–76 (106 ref.)
Electrophysiology of synaptic vesicle cycling. von Gersdorff H, et al. **Annu Rev Physiol** 1999;61:725–52 (134 ref.)
Use of fluorescent probes to follow membrane traffic in nerve terminals. Guatimosim C, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1491–500 (60 ref.)
Regulatory role of SH3 domain-mediated protein-protein interactions in synaptic vesicle endocytosis. McPherson PS. **Cell Signal** 1999 Apr;11(4):229–38 (127 ref.)
Vesicle formation: dynamic dynamin lives up to its name. Kirchhausen T. **Curr Biol** 1998 Nov 5;8(22):R792–4 (22 ref.)
Endocytosis: an assembly protein for clathrin cages. McMahon HT. **Curr Biol** 1999 May 6;9(9):R332–5 (25 ref.)
Synaptic vesicle docking and fusion. Bajjalieh SM. **Curr Opin Neurobiol** 1999 Jun;9(3):321–8 (96 ref.)
Optical detection of synaptic vesicle exocytosis and endocytosis. Murthy VN. **Curr Opin Neurobiol** 1999 Jun; 9(3):314–20 (51 ref.)
Vesicle recycling at the Drosophila neuromuscular junction. Stimson DT, et al. **Int Rev Neurobiol** 1999;43:163–89 (118 ref.)
Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. Sheng ZH, et al. **J Bioenerg Biomembr** 1998 Aug;30(4):335–45 (80 ref.)
Tailoring uniform coats for synaptic vesicles during endocytosis. Zhang B, et al. **Neuron** 1999 Jul;23(3):419–22 (21 ref.)
[Molecular biology of neurosecretion and its inhibition bu tetanus and botulinum toxins (review)] Veit M. **Berl Munch Tierarztl Wochenschr** 1999 Jun;112(5):186–91 (20 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

[Molecular mechanisms of exocytosis] Cui ZJ. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):233–7 (20 ref.) (Eng. Abstr.) **(Chi)**

ULTRASTRUCTURE

Synaptic-like microvesicles in mammalian pinealocytes. Redecker P. **Int Rev Cytol** 1999;191:201–55 (285 ref.)

SYNAPTONEMAL COMPLEX

Studies of synaptonemal complexes in farm mammals--a review. Switoński M, et al. **J Hered** 1998 Nov–Dec; 89(6):473–80 (71 ref.)

SYNAPTOSOMES

METABOLISM

Key role of acetyl-CoA in cytoplasm of nerve terminals in disturbances of acetylcholine metabolism in brain. Szutowicz A, et al. **Folia Neuropathol** 1997;35(4):241–3 (26 ref.)

PHYSIOLOGY

The regulation of neurotransmitter secretion by protein kinase C. Vaughan PF, et al. **Mol Neurobiol** 1998 Oct; 18(2):125–55 (237 ref.)

SYNCERUS see **BUFFALOES**

SYNCHROTRONS

[Synchrotron radiation and biological crystallography] Tomizaki T, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar; 44(4 Suppl):566–73 (6 ref.) **(Jpn)**

SYNCOPE

Pulmonary embolism presenting as syncope: case report and review of the literature. Koutkia P, et al. **Heart Lung** 1999 Sep–Oct;28(5):342–7 (19 ref.)
[Malaise, syncope and short loss of consciousness. Diagnostic indications] Blanc JJ. **Rev Prat** 1998 Mar 15;48(6):675–8 (00 ref.) **(Fre)**

COMPLICATIONS

Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. Grubb BP, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):798–810 (77 ref.)

DIAGNOSIS

Syncope in the pediatric patient. The cardiologist's perspective. Lewis DA, et al. **Pediatr Clin North Am** 1999 Apr;46(2):205–19 (26 ref.)
[Syncopal vasospastic angina in a patient with familial nonobstructive hypertrophic cardiomyopathy] Astarita C, et al. **G Ital Cardiol** 1999 Feb;29(2):159–62 (10 ref.) (Eng. Abstr.) **(Ita)**
[The Brugada syndrome--a clinical case] Cavaco D, et al. **Rev Port Cardiol** 1999 Feb;18(2):169–73 (8 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Pharmacotherapy of neurally mediated syncope. Benditt DG, et al. **Circulation** 1999 Sep 14;100(11):1242–8 (72 ref.)

ETIOLOGY

Using a tilt table to evaluate syncope. Kapoor WN. **Am J Med Sci** 1999 Feb;317(2):110–6 (70 ref.)
Evaluation of the patient with syncope: an evidence based approach. Meyer MD, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):189–201, ix (21 ref.)
The long QT syndrome and seizures in childhood. Davis AM, et al. **J Paediatr Child Health** 1998 Oct;34(5):410–1 (15 ref.)
Syncope in the pediatric patient. The cardiologist's perspective. Lewis DA, et al. **Pediatr Clin North Am** 1999 Apr;46(2):205–19 (26 ref.)
[Micturition syncope: a peculiar cause of diagnostic doubt] Kasperek S, et al. **Neurol Neurochir Pol** 1998 Sep–Oct; 32(5):1289–93; discussion 1293–4 (8 ref.) (Eng. Abstr.) **(Pol)**
[The patient with syncope--which are the most useful clinical parameters for defining a diagnostic strategy?] Brandão L. **Rev Port Cardiol** 1999 Apr;18(4):433–6 (10 ref.) (Eng. Abstr.) **(Por)**
[Syncope due to hair grooming (letter)] Silveira Cancela M, et al. **An Esp Pediatr** 1999 Jun;50(6):637–8 (9 ref.) **(Spa)**
[An anomalous origin of the left coronary artery associated with a right coronary spasm as the cause of angina and presyncope] Gómez Pajuelo C, et al. **Rev Esp Cardiol** 1999 Feb;52(2):139–41 (6 ref.) (Eng. Abstr.) **(Spa)**
[It is not easy to examine the causes of fainting. Vasovagal syncope is mostly not dangerous, cardiac syncope is potentially life-threatening] Linde C. **Lakartidningen** 1999 Mar 17;96(11):1294–9 (12 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

Using a tilt table to evaluate syncope. Kapoor WN. **Am J Med Sci** 1999 Feb;317(2):110–6 (70 ref.)
Neurally mediated syncope: pathophysiology and implications for treatment. Robertson RM, et al. **Am J Med Sci** 1999 Feb;317(2):102–9 (75 ref.)

THERAPY

Neurally mediated syncope: pathophysiology and implications for treatment. Robertson RM, et al. **Am J Med Sci** 1999 Feb;317(2):102–9 (75 ref.)
Should ICDs be implanted in all patients with dilated cardiomyopathy and unexplained syncope? [editorial; comment] Josephson ME. **J Am Coll Cardiol** 1999 Jun; 33(7):1971–3 (29 ref.) Comment on: J Am Coll Cardiol 1999 Jun;33(7):1964–70.

SYNCOPE, NEUROCARDIOGENIC see **SYNCOPE, VASOVAGAL**

SYNCOPE, NEUROGENIC see **SYNCOPE, VASOVAGAL**

SYNCOPE, VASOVAGAL

DIAGNOSIS

[Diagnosis and treatment of vasovagal syncope in the child and adolescent] Massin M. **Arch Pediatr** 1998 Aug; 5(8):923–6 (18 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic

disturbances. Grubb BP, et al.
J Interv Card Electrophysiol 1998 Dec;2(4):325–32 (75 ref.)
[It is not easy to examine the causes of fainting. Vasovagal syncope is mostly not dangerous, cardiac syncope is potentially life-threatening] Linde C. **Lakartidningen** 1999 Mar 17;96(11):1294–9 (12 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

Review article: heart rate and blood pressure control in vasovagal syncope. Benditt DG, et al.
J Interv Card Electrophysiol 1998 Mar;2(1):25–32 (68 ref.)

THERAPY

[Pharma-clinics. How I treat vasovagal syncope] Kulbertus H, et al. **Rev Med Liege** 1999 Jun;54(6):510–3 (19 ref.) (Eng. Abstr.) **(Fre)**

SYNCYTIUM see **GIANT CELLS**

SYNDROME

Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Woods KA, et al.
Acta Paediatr Suppl 1999 Feb;88(428):158–62; discussion 163 (13 ref.)
Perspectives on overgrowth syndromes. Cohen MM Jr.
Am J Med Genet 1998 Oct 2;79(4):234–7 (48 ref.)
Baller-Gerold syndrome associated with congenital portal venous malformation. Savarirayan R, et al.
J Med Genet 1998 Sep;35(9):767–9 (28 ref.)
Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. Meldrum DR, et al. **J Surg Res** 1999 Aug; 85(2):185–99 (206 ref.)
The role of troglitazone in treating the insulin resistance syndrome. Granberry MC, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):973–87 (112 ref.)
Problems, solutions, and challenges in syndromic management of sexually transmitted diseases. Dallabetta GA, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S1–11 (88 ref.)
[Central apnea in newborns] van Putten MJ, et al.
Ned Tijdschr Geneeskd 1999 Feb 27;143(9):441–4 (17 ref.) (Eng. Abstr.) **(Dut)**

SYNDROME X

Insulin resistance syndrome: options for treatment. Granberry MC, et al. **South Med J** 1999 Jan;92(1):2–15 (123 ref.)
[Syndrome X and microvascular angina] Ferrara L, et al. **Minerva Cardioangiol** 1998 Jun;46(6):181–93 (74 ref.) (Eng. Abstr.) **(Ita)**
[Chest pain in patients with normal coronary angiography (syndrome X): new concepts] Ramires JA, et al.
Rev Assoc Med Bras 1998 Jul–Sep;44(3):229–38 (86 ref.) **(Por)**

COMPLICATIONS

[From type 2 diabetes to metabolic X syndrome] Pogátsa G. **Orv Hetil** 1999 Mar 21;140(12):635–40 (45 ref.) (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Development of the multiple metabolic syndrome: an epidemiologic perspective. Liese AD, et al.
Epidemiol Rev 1998;20(2):157–72 (209 ref.)

ETIOLOGY

Thiazolidinediones--tools for the research of metabolic syndrome X. Komers R, et al. **Physiol Res** 1998; 47(4):215–25 (83 ref.)
[Syndrome X--open problem of contemporary medicine] Bednarska-Chabowska D, et al. **Przegl Lek** 1998; 55(9):450–6 (68 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Abnormal cardiac nerve function in syndrome X. Lanza GA. **Herz** 1999 Apr;24(2):97–106 (51 ref.)
Growth hormone and the metabolic syndrome. Johannsson G, et al. **J Endocrinol Invest** 1999;22(5 Suppl):41–6 (42 ref.)

THERAPY

[Syndrome X: one, none and a hundred thousand] Masoni A. **G Ital Cardiol** 1999 Aug;29(8):925–36 (83 ref.) **(Ita)**

SYNECHOCYSTIS GROUP

METABOLISM

A model for early events in the assembly pathway of cyanobacterial phycobilisomes. Anderson LK, et al.
Mol Microbiol 1998 Nov;30(3):467–74 (45 ref.)

SYNGAMIASIS see **STRONGYLIDA INFECTIONS**

SYNOSTOSIS

Musculoskeletal manifestations of the Antley-Bixler syndrome. Rumball KM, et al. **J Pediatr Orthop B** 1999 Apr;8(2):139–43 (17 ref.)

SYNOVIA see **SYNOVIAL FLUID**

SYNOVIAL CHONDROMATOSIS see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIAL CHONDROMETAPLASIA see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIAL CYST

COMPLICATIONS

Subaxial cervical synovial cyst presenting with myelopathy. Report of three cases. Cudlip S, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):141–4 (17 ref.)
Suprascapular entrapment neuropathy and ganglion cysts about the shoulder. Ferrick MR, et al. **Orthopedics** 1999 Apr;22(4):430–4; discussion 434–5; quiz 436–7 (47 ref.)

DIAGNOSIS

Bilateral ganglion cysts: case report and review of the literature. Diamantopoulos J, et al.
Acta Neurochir (Wien) 1999;141(7):783–4 (5 ref.)
Cervical synovial cysts: case report and review of the literature. Lunardi P, et al. **Eur Spine J** 1999;8(3):232–7 (62 ref.)
Lumbar intraspinal synovial cysts of different etiologies: diagnosis by CT and MR imaging. Farrokh D.
J Belge Radiol 1998 Dec;81(6):275–8 (20 ref.)
Subaxial cervical synovial cyst presenting with myelopathy. Report of three cases. Cudlip S, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):141–4 (17 ref.)
Multiple rheumatoid bursitis with migrating chylous cysts. Report of a case in a European woman and review of the literature. Berthelot JM, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):354–8 (47 ref.)
Bilateral lunate intraosseous ganglia. Pablos JM, et al.
Skeletal Radiol 1998 Dec;27(12):708–10 (10 ref.)

EPIDEMIOLOGY

A ganglion of the spinoglenoid notch. Steinwachs MR, et al. **J Shoulder Elbow Surg** 1998 Sep–Oct;7(5):550–4 (25 ref.)

ETIOLOGY

Multiple rheumatoid bursitis with migrating chylous cysts. Report of a case in a European woman and review of the literature. Berthelot JM, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):354–8 (47 ref.)

PATHOLOGY

Craniocervical junction synovial cyst associated with atlanto-axial dislocation--case report. Akiyama H, et al. **Neurol Med Chir (Tokyo)** 1999 Jul;39(7):539–43 (21 ref.)

SURGERY

Ganglions of the hand and wrist. Thornburg LE.
J Am Acad Orthop Surg 1999 Jul–Aug;7(4):231–8 (21 ref.)
Craniocervical junction synovial cyst associated with atlanto-axial dislocation--case report. Akiyama H, et al. **Neurol Med Chir (Tokyo)** 1999 Jul;39(7):539–43 (21 ref.)

THERAPY

Aspiration of intraspinal synovial cyst: recurrence after temporal improvement. Imai K, et al.
Arch Orthop Trauma Surg 1998;118(1-2):103–5 (10 ref.)

SYNOVIAL FLUID

IMMUNOLOGY

Molecular mechanism of immune response, synovial proliferation and apoptosis in rheumatoid arthritis. Hasunuma T, et al. **Springer Semin Immunopathol** 1998; 20(1-2):41–52 (94 ref.)

METABOLISM

Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Day RO, et al. **Clin Pharmacokinet** 1999 Mar;36(3):191–210 (79 ref.)
Synovial fluid markers in osteoarthritis. Myers SL.
Rheum Dis Clin North Am 1999 May;25(2):433–49, viii–ix (99 ref.)

SYNOVIAL MEMBRANE

MR imaging of synovial tumours and tumour-like lesions. Ritchie DA. **Br J Radiol** 1999 Feb;72(854):212–8 (8 ref.)
Monoarticular synovial lesions: radiologic pictorial essay with pathologic illustration. Wong K, et al. **Clin Radiol** 1999 May;54(5):273–84 (24 ref.)

BLOOD SUPPLY

Influence of hypoxia in inflammatory synovitis. Bodamyali T, et al. **Ann Rheum Dis** 1998 Dec;57(12):703–10 (71 ref.)

EMBRYOLOGY

BMP/GDF-signalling interactions during synovial joint development. Francis-West PH, et al. **Cell Tissue Res** 1999 Apr;296(1):111–9 (81 ref.)

METABOLISM

COX-2 in synovial tissues. Crofford LJ.
Osteoarthritis Cartilage 1999 Jul;7(4):406–8 (18 ref.)

MICROBIOLOGY

Synovial actinomycosis of the hip: case report and review. Dom K, et al. **Acta Orthop Belg** 1999 Jun;65(2):242–4 (5 ref.)
Critical appraisal of molecular biology techniques for detecting bacteria in synovial specimens. Kuipers JG, et al. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):3S–8S (25 ref.)

PATHOLOGY

The importance of arthroscopy in diagnosing synovial haemangioma of the knee joint. Farkas C, et al.
Acta Chir Hung 1998;37(1-2):17–22 (22 ref.)
Control of the synovium in haemophilia. Eickhoff HH, et al. **Haemophilia** 1998 Jul;4(4):511–3 (23 ref.)
Synovium in haemophilic arthropathy. Roosendaal G, et al. **Haemophilia** 1998 Jul;4(4):502–5 (23 ref.)
Polymyalgia rheumatica: a disorder of extraarticular synovial structures? [editorial] Salvarani C, et al. **J Rheumatol** 1999 Mar;26(3):517–21 (33 ref.)
Lipoma arborescens of the knee. Narváez J, et al.
Rev Rhum Engl Ed 1999 Jun;66(6):351–3 (17 ref.)

PHYSIOPATHOLOGY

Apomodulation as a novel therapeutic concept for the regulation of apoptosis in rheumatoid synoviocytes. Kobayashi T, et al. **Curr Opin Rheumatol** 1999 May; 11(3):188–93 (59 ref.)
Signaling and effector pathways. Müller-Ladner U, et al. **Curr Opin Rheumatol** 1999 May;11(3):194–201 (78 ref.)

SYNOVIAL OSTEOCHONDROMATOSIS see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIOMA see **SARCOMA, SYNOVIAL**

SYNOVITIS

Control of the synovium in haemophilia. Eickhoff HH, et al. **Haemophilia** 1998 Jul;4(4):511–3 (23 ref.)

COMPLICATIONS

Significance of synovitis in Legg-Calvé-Perthes disease. Wingstrand H. **J Pediatr Orthop B** 1999 Jul;8(3):156–60 (56 ref.)
Gastric carcinoma in association with remitting seronegative symmetrical synovitis with pitting edema. Ethiopia A, et al. **J Rheumatol** 1999 May;26(5):1203–4 (10 ref.)

DIAGNOSIS

Value of magnetic resonance imaging in synovitis. Laredo JD, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):630–3 (15 ref.)

DRUG THERAPY

Haemophilic synovitis: is rifampicin an alternative? Caviglia H, et al. **Haemophilia** 1998 Jul;4(4):514–7 (54 ref.)
Treatment of acute and chronic synovitis by non-surgical means. Fernandez-Palazzi F. **Haemophilia** 1998 Jul; 4(4):518–23 (21 ref.)

ETIOLOGY

Influence of hypoxia in inflammatory synovitis. Bodamyali T, et al. **Ann Rheum Dis** 1998 Dec;57(12):703–10 (71 ref.)

PATHOLOGY

Synovial inflammation in arthroscopically obtained biopsy specimens from the temporomandibular joint: a review of the literature and a proposed histologic grading system. Gynther GW, et al. **J Oral Maxillofac Surg** 1998 Nov; 56(11):1281–6; discussion 1287 (26 ref.)

PHYSIOPATHOLOGY

Classification of inflammatory arthritis by enthesitis [see comments] McGonagle D, et al. **Lancet** 1998 Oct 3; 352(9134):1137–40 (43 ref.) Comment in: Lancet 1998 Dec 12;352(9144):1938. Comment in: Lancet 1998 Dec 12;352(9144):1938–9. Comment in: Lancet 1999 May 1;353(9163):1526–7.

SURGERY

[Joint empyema] Lungershausen W, et al. **Chirurg** 1998 Aug; 69(8):828–35 (21 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Polysynovitis associated with acute Epstein-Barr virus infection [letter] McCarty DJ, et al. **J Rheumatol** 1998 Oct; 25(10):2039–40 (6 ref.)

SYNOVITIS, PIGMENTED VILLONODULAR

DIAGNOSIS

Pigmented villonodular synovitis of the elbow: a case report and literature review. DiCaprio MR, et al. **J Hand Surg [Am]** 1999 Mar;24(2):386–91 (19 ref.)

Pigmented villonodular synovitis of the shoulder: review and case report. Müller LP, et al. **Knee Surg Sports Traumatol Arthrosc** 1999;7(4):249–56 (39 ref.)

SURGERY

[Villonodular synovitis of the knee. Analysis of a series of 17 cases and review of the literature] Le Tiec T, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(7):607–16 (57 ref.) (Eng. Abstr.) **(Fre)**

SYNOVIUM see **SYNOVIAL MEMBRANE**

2–5A SYNTHETASE see **2',5'-OLIGOADENYLATE SYNTHETASE**

SYNTHETASES see **LIGASES**

SYNTHETIC VACCINES see **VACCINES, SYNTHETIC**

SYPHILIS

Resolving the common clinical dilemmas of syphilis. Birnbaum NR, et al. **Am Fam Physician** 1999 Apr 15; 59(8):2233–40, 2245–6 (26 ref.)

Syphilis in pregnancy. Sheffield JS, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):97–106; quiz 174–5 (35 ref.)

Syphilis. Darville T. **Pediatr Rev** 1999 May;20(5):160–4, quiz 165 (0 ref.)

Syphilis. Hollier LM, et al. **Semin Perinatol** 1998 Aug; 22(4):323–31 (58 ref.)

COMPLICATIONS

TORCH testing in HIV-infected women. Helfgott A. **Clin Obstet Gynecol** 1999 Mar;42(1):149–62; quiz 174–5 (69 ref.)

DIAGNOSIS

Diagnosing the systemic associations of anterior uveitis. Smith JR, et al. **Aust N Z J Ophthalmol** 1998 Nov; 26(4):319–26 (36 ref.)

DRUG THERAPY

Treatment of syphilis, 1998: nonpregnant adults. Augenbraun MH, et al. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S21–8 (50 ref.)

EPIDEMIOLOGY

Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Singh AE, et al. **Clin Microbiol Rev** 1999 Apr;12(2):187–209 (370 ref.)

PREVENTION & CONTROL

Syphilis management and treatment. van Voorst Vader PC. **Dermatol Clin** 1998 Oct;16(4):699–711, xi (90 ref.)

RADIOGRAPHY

[Osteoarticular involvement in parasitic diseases: bone treponematosis] Arteaga C, et al. **J Radiol** 1998 Nov; 79(11):1363–6 (7 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

Elimination of syphilis transmission in the United States: historic perspectives and practical considerations. Hook EW 3rd. **Trans Am Clin Climatol Assoc** 1999;110:195–203; discussion 203–4 (17 ref.)

SYPHILIS, CARDIOVASCULAR

[Syphilitic aortitis] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):24–6 (15 ref.) **(Jpn)**

SYPHILIS, CONGENITAL

[Congenital syphilis: update and perspectives] Hoarau C, et al. **Sante** 1999 Jan–Feb;9(1):38–45 (38 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Congenital syphilis] Kitagawa H. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):21–3 (7 ref.) **(Jpn)**

DRUG THERAPY

[Congenital syphilis] Kitagawa H. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):21–3 (7 ref.) **(Jpn)**

RADIOGRAPHY

[Osteoarticular involvement in parasitic diseases: bone treponematosis] Arteaga C, et al. **J Radiol** 1998 Nov; 79(11):1363–6 (7 ref.) (Eng. Abstr.) **(Fre)**

SYPHILIS SERODIAGNOSIS

METHODS

Syphilis. Serology. Young H. **Dermatol Clin** 1998 Oct; 16(4):691–8 (44 ref.)

SYPHILIS, SPINAL CORD see **TABES DORSALIS**

SYRINGADENOMA see **ADENOMA, SWEAT GLAND**

SYRINGES

CONTRAINDICATIONS

When not to syringe an ear. Blake P, et al. **N Z Med J** 1998 Nov 13;111(1077):422–4 (6 ref.)

SYRINGOMA, CHONDROID see **ADENOMA, PLEOMORPHIC**

SYRINGOMYELIA

COMPLICATIONS

Extensive arachnoid ossification with associated syringomyelia presenting as thoracic myelopathy. Case report and review of the literature. Slavin KV, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):223–9 (63 ref.)

EMBRYOLOGY

[Neuroembryologic considerations on the so-called malformative syringomyelia] Catala M. **Neurochirurgie** 1999 Jun;45 Suppl 1:9–22 (544 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Posttraumatic syringomyelia. A report of an atypical case] Bucciero A, et al. **Minerva Chir** 1998 Nov;53(11):943–6 (21 ref.) (Eng. Abstr.) **(Ita)**

HISTORY

[History, controversy and pathogenesis] Hurth M, et al. **Neurochirurgie** 1999 Jun;45 Suppl 1:138–57 (0 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Spontaneous resolution of a cervicothoracic syrinx in a child. Case report and review of the literature. Avellino AM, et al. **Pediatr Neurosurg** 1999 Jan;30(1):43–6 (24 ref.)

[Neuroembryologic considerations on the so-called malformative syringomyelia] Catala M. **Neurochirurgie** 1999 Jun;45 Suppl 1:9–22 (544 ref.) (Eng. Abstr.) **(Fre)**

[Imaging of syringomyelia] Doyon D, et al. **Neurochirurgie** 1999 Jun;45 Suppl 1:105–14 (0 ref.) (Eng. Abstr.) **(Fre)**

[History, controversy and pathogenesis] Hurth M, et al. **Neurochirurgie** 1999 Jun;45 Suppl 1:138–57 (0 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Imaging of syringomyelia] Doyon D, et al. **Neurochirurgie** 1999 Jun;45 Suppl 1:105–14 (0 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Treatment of syringomyelia] David P, et al. **Neurochirurgie** 1999 Jun;45 Suppl 1:130–7 (0 ref.) (Eng. Abstr.) **(Fre)**

SYRUP OF IPECAC see **IPECAC**

SYSTEMATIC BIAS see **BIAS (EPIDEMIOLOGY)**

SYSTEMATICS see **CLASSIFICATION**

SYSTEMIC CAPILLARY LEAK SYNDROME see **CAPILLARY LEAK SYNDROME**

SYSTEMIC INFLAMMATORY RESPONSE SYNDROME see **SEPSIS SYNDROME**

SYSTEMS ANALYSIS

see related
TASK PERFORMANCE AND ANALYSIS

A systems approach to developing staff training. Giffort DW. **New Dir Ment Health Serv** 1998 Fall;(79):25–33 (23 ref.)

SYSTEMS INTEGRATION

Integrating HIS-RIS-PACS: the Freiburg experience. Kotter E, et al. **Eur Radiol** 1998;8(9):1707–18 (47 ref.)

SYSTEMS THEORY

see related
MODELS, THEORETICAL
SYSTEMS ANALYSIS

Biofeedback systems architecture. Paolini F, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):255–64 (23 ref.)

Tumour biology, chaos and non-linear dynamics. Rew DA. **Eur J Surg Oncol** 1999 Feb;25(1):86–9 (17 ref.)

[Do systems theory models promote understanding of disorders of sensorimotor function in neurology?] Glasauer S, et al. **Nervenarzt** 1998 Oct;69(10):919–23 (18 ref.) **(Ger)**

[The interactions of functional systems at the homeostatic level in normal children and adolescents and in a radioecologically unfavorable environment] Glazachev OS, et al. **Usp Fiziol Nauk** 1999 Jul–Sep;30(3):73–92 (81 ref.) (Eng. Abstr.) **(Rus)**

[Biotechnological functional systems] Bokser OIa. **Vestn Ross Akad Med Nauk** 1999;(6):29–34 (19 ref.) (Eng. Abstr.) **(Rus)**

[Use of academician P.K.Anokhin's creative heritage for analysis of mechanisms responsible for homeostasis formation under microgravity] Grigor'ev AI, et al. **Vestn Ross Akad Med Nauk** 1999;(6):11–5 (21 ref.) (Eng. Abstr.) **(Rus)**

[Theory of functional systems and integrative physiology] Sudakov KV. **Vestn Ross Akad Med Nauk** 1999;(6):5–10 (40 ref.) (Eng. Abstr.) **(Rus)**

SYSTOLE

Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits. Kocemba J, et al. **J Hum Hypertens** 1998 Sep;12(9):621–6 (51 ref.)

Hypertension corner. Wide pulse pressure: diagnostic, prognostic and therapeutic implications [editorial] Birbari AE. **J Med Liban** 1998 Nov–Dec;46(6):303–5 (22 ref.)

Role of total arterial compliance and peripheral resistance in the determination of systolic and diastolic aortic pressure. Stergiopulos N, et al. **Pathol Biol (Paris)** 1999 Jun; 47(6):641–7 (14 ref.)

PHYSIOLOGY

Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart. Feldman AM, et al. **Cardiol Clin** 1998 Nov;16(4):677–89, ix (143 ref.)

Left ventricular systolic function after acute myocardial infarction: prognostic importance, relation to congestive heart failure and as a target for intervention. Køber L. **Dan Med Bull** 1999 Jun;46(3):235–48 (53 ref.)

The use of pacemakers as treatment for systolic dysfunction. Gottlieb SS. **J Card Fail** 1998 Jun;4(2):145–50 (68 ref.)

Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function [see comments] Stainback RF. **Tex Heart Inst J** 1999; 26(1):34–41 (45 ref.) Comment in: Tex Heart Inst J 1999;26(2):158.

Predicting healing of arterial leg ulcers by means of segmental systolic pressure measurements. Wütschert R, et al. **Vasa** 1998 Nov;27(4):224–8 (13 ref.)

SYSTOLIC CLICK-MURMUR SYNDROME see **MITRAL VALVE PROLAPSE**

SYSTOLIC TIME INTERVAL see **SYSTOLE**

2,4,5-T see **2,4,5-TRICHLOROPHENOXYACETIC ACID**

T3 ANTIGENS see **ANTIGENS, CD3**

T3 RECEPTORS see **RECEPTORS, THYROID HORMONE**

T4 ANTIGENS, T-CELL see **ANTIGENS, CD4**

T4 CELLS see **CD4-POSITIVE T-LYMPHOCYTES**

T4 PHAGE see **BACTERIOPHAGE T4**

T4 RECEPTORS see **RECEPTORS, THYROID HORMONE**

T6 ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

T7 PHAGE see **BACTERIOPHAGE T7**

T8 ANTIGENS, T-CELL see **ANTIGENS, CD8**

T8 CELLS see **CD8-POSITIVE T-LYMPHOCYTES**

T11 ERYTHROCYTE-BINDING GLYCOPROTEIN see **ANTIGENS, CD2**

T-ALL see **LEUKEMIA, T-CELL, ACUTE**

T-CELL ACTIVATION ANTIGEN see **ANTIGENS, CD27**

T-CELL ANTIGEN RECEPTOR-CD3 COMPLEX see **RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL**

T-CELL DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

T-CELL EPITOPES see **EPITOPES, T-LYMPHOCYTE**

T-CELL GENE REARRANGEMENT see **GENE REARRANGEMENT, T-LYMPHOCYTE**

T-CELL GROWTH FACTOR see **INTERLEUKIN-2**

T-CELL GROWTH FACTOR RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

T-CELL LEUKEMIA see **LEUKEMIA, T-CELL**

T-CELL LEUKEMIA, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

T-CELL LEUKEMIA, ADULT see **LEUKEMIA, T-CELL**

T-CELL LEUKEMIA, CHRONIC see **LEUKEMIA, T-CELL, CHRONIC**

T-CELL LEUKEMIA-LYMPHOMA, ADULT see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

T-CELL LEUKEMIA-LYMPHOMA, HTLV-I-ASSOCIATED see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

T-CELL LEUKEMIA VIRUS I, HUMAN see **HTLV-I**

T-CELL LEUKEMIA VIRUS II, HUMAN see **HTLV-II**

T-CELL LYMPHOMA see **LYMPHOMA, T-CELL**

T-CELL LYMPHOMA, CUTANEOUS see **LYMPHOMA, T-CELL, CUTANEOUS**

T-CELL LYMPHOMA, PERIPHERAL see **LYMPHOMA, T-CELL, PERIPHERAL**

T-CELL RECEPTOR BETA GENES see **GENES, T-CELL RECEPTOR BETA**

T-CELL RECEPTOR GENES see **GENES, T-CELL RECEPTOR**

T-CELL RECEPTORS see **RECEPTORS, ANTIGEN, T-CELL**

T-CELL RECEPTORS, ALPHA-BETA see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

T-CELL RECEPTORS ALPHA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

T-CELL RECEPTORS BETA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

T-CELL RECEPTORS DELTA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

T-CELL RECEPTORS GAMMA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

T-CELL RECEPTORS, GAMMA-DELTA see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

T-CELL REPLACING FACTOR see **INTERLEUKIN-5**

T-CELL SUBSETS see **T-LYMPHOCYTE SUBSETS**

T-CELLS see **T-LYMPHOCYTES**

T-CELLS, HELPER-INDUCER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-CELLS, SUPPRESSOR-EFFECTOR see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

T-MYCOPLASMA see **UREAPLASMA**

TABES DORSALIS

[Tabes dorsalis] Kitagawa Y.
Ryoikibetsu Shokogun Shirizu 1999;(23 Pt 1):324–5 (7 ref.) **(Jpn)**

TABLE SALT see **SODIUM CHLORIDE, DIETARY**

TABLETS

Adhesion of polymeric films to pharmaceutical solids. Felton LA, et al. **Eur J Pharm Biopharm** 1999 Jan;47(1):3–14 (69 ref.)

ADVERSE EFFECTS

Pill esophagitis. Kikendall JW. **J Clin Gastroenterol** 1999 Jun; 28(4):298–305 (39 ref.)

TABLETS, ENTERIC-COATED

Coatings for controlled-release drug delivery systems. Rhodes CT, et al. **Drug Dev Ind Pharm** 1998 Dec; 24(12):1139–54 (104 ref.)

TAC PEPTIDE see **RECEPTORS, INTERLEUKIN-2**

TAC P55 PEPTIDE see **RECEPTORS, INTERLEUKIN-2**

TACHYARRHYTHMIA see **TACHYCARDIA**

TACHYCARDIA

Role of arterial baroreceptor function on cardiovascular adjustments to acute and chronic dynamic exercise. Krieger EM, et al. **Biol Res** 1998;31(3):273–9 (33 ref.)

Palpitations: reassurance or more? Vohra JK. **Med J Aust** 1999 May 3;170(9):442–8 (22 ref.)

CLASSIFICATION

[Indications for electrophysiological investigation of tachycardia] Saoudi N, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:23–8 (49 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Orthostatic intolerance. A review and clinical case] Freitas J, et al. **Rev Port Cardiol** 1998 Sep;17(9):715–20 (5 ref.) (Eng. Abstr.) **(Por)**

[Practical approximation to the diagnosis of tachyarrhythmias] Albaladejo VJ, et al. **Rev Med Univ Navarra** 1998 Jul–Sep;42(3):156–65 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS). Low PA, et al. **Am J Med Sci** 1999 Feb;317(2):124–33 (80 ref.)

The epidemic of orthostatic tachycardia and orthostatic intolerance. Robertson D. **Am J Med Sci** 1999 Feb; 317(2):75–7 (12 ref.)

PHYSIOPATHOLOGY

Idiopathic orthostatic intolerance and postural tachycardia syndromes. Jacob G, et al. **Am J Med Sci** 1999 Feb; 317(2):88–101 (74 ref.)

Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS). Low PA, et al. **Am J Med Sci** 1999 Feb;317(2):124–33 (80 ref.)

The importance of orthostatic intolerance in the chronic fatigue syndrome. Schondorf R, et al. **Am J Med Sci** 1999 Feb;317(2):117–23 (87 ref.)

Orthostatic intolerance. A historical introduction to the pathophysiological mechanisms. Streeten DH. **Am J Med Sci** 1999 Feb;317(2):78–87 (55 ref.)

[Mechanism for the development of tachyarrhythmia and its treatment] oe T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1939–45 (12 ref.) **(Jpn)**

SURGERY

Cryothermal ablation: mechanism of tissue injury and current experience in the treatment of tachyarrhythmias. Lustgarten DL, et al. **Prog Cardiovasc Dis** 1999 May–Jun; 41(6):481–98 (88 ref.)

TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY

DIAGNOSIS

Accessory pathway reciprocating tachycardia. Obel OA, et al. **Eur Heart J** 1998 May;19 Suppl E:E13–24, E50–1 (66 ref.)

[Permanent junctional reciprocating tachycardia (Coumel type): an unusual location of a retrograde accessory pathway] Mantovan R, et al. **G Ital Cardiol** 1999 Mar; 29(3):315–20 (9 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

'Para' AV nodal re-entry tachycardias. Hauer RN, et al. **Eur Heart J** 1998 May;19 Suppl E:E2–9, E46–7 (20 ref.)

PHYSIOPATHOLOGY

Functional reentry: leading circle or spiral wave? Janse MJ. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):621–2 (5 ref.)

SURGERY

Radiofrequency catheter ablation of atrio-ventricular accessory pathways. Pitzalis MV, et al. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III15–22 (28 ref.)

TACHYCARDIA, AV NODAL REENTRANT see **TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY**

TACHYCARDIA, ECTOPIC ATRIAL

DIAGNOSIS

'True' atrial tachycardia. Steinbeck G, et al. **Eur Heart J** 1998 May;19 Suppl E:E10–2, E48–9 (15 ref.)

Magnetic electroanatomical mapping for ablation of focal atrial tachycardias. Marchlinski F, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1621–35 (22 ref.)

DRUG THERAPY

Atrial tachyarrhythmia after cardiac surgery [see comments] Stricker KH, et al. **Intensive Care Med** 1998 Jul; 24(7):654–62 (78 ref.) Comment in: Intensive Care Med 1999 Feb;25(2):242–3. Comment in: Intensive Care Med 1999 Feb;25(2):243.

ETIOLOGY

Atrial tachyarrhythmia after cardiac surgery [see comments] Stricker KH, et al. **Intensive Care Med** 1998 Jul; 24(7):654–62 (78 ref.) Comment in: Intensive Care Med 1999 Feb;25(2):242–3. Comment in: Intensive Care Med 1999 Feb;25(2):243.

TACHYCARDIA, ECTOPIC JUNCTIONAL

DIAGNOSIS

[Permanent junctional reciprocating tachycardia (Coumel type): an unusual location of a retrograde accessory pathway] Mantovan R, et al. **G Ital Cardiol** 1999 Mar; 29(3):315–20 (9 ref.) (Eng. Abstr.) **(Ita)**

TACHYCARDIA, PAROXYSMAL

DIAGNOSIS

[Idiopathic left fascicular ventricular tachycardia: the evidence for a "bystander" bundle of His participation] Ducceschi V, et al. **G Ital Cardiol** 1999 Jun;29(6):710–3 (11 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. Rae AP. **Am J Cardiol** 1998 Oct 16; 82(8A):59N–65N (55 ref.)

Problems in the pharmacological evaluation of paroxysmal atrial fibrillation [editorial; comment] Tanabe T. **Intern Med** 1998 Dec;37(12):997–8 (7 ref.) Comment on: Intern Med 1998 Dec;37(12):1005–8.

Management of intermittent atrial fibrillation: drugs to maintain sinus rhythm. Olgin JE, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):433–41 (63 ref.)

ETIOLOGY

"Atrial fibrillopathy": is atrial fibrillation really self-perpetuating? [editorial; comment] Langberg JJ. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1109–11 (19 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1101–8.

TACHYCARDIA, RECIPROCAL see **TACHYCARDIA, PAROXYSMAL**

TACHYCARDIA, SA NODAL REENTRANT see **TACHYCARDIA, SINOATRIAL NODAL REENTRY**

TACHYCARDIA, SINOATRIAL NODAL REENTRY

DIAGNOSIS

'True' atrial tachycardia. Steinbeck G, et al. **Eur Heart J** 1998 May;19 Suppl E:E10–2, E48–9 (15 ref.)

DRUG THERAPY

[Cardiac electrophysiological effect and clinical use of adenosine] Fazekas T, et al. **Orv Hetil** 1999 May 30; 140(22):1219–26 (52 ref.) (Eng. Abstr.) **(Hun)**

TACHYCARDIA, SUPRAVENTRICULAR

DIAGNOSIS

Accessory pathway reciprocating tachycardia. Obel OA, et al. **Eur Heart J** 1998 May;19 Suppl E:E13–24, E50–1 (66 ref.)

Incessant tachycardias. Wren C. **Eur Heart J** 1998 May;19 Suppl E:E32–6, E54–9 (25 ref.)

[How to confirm significant arrhythmias] Viitasalo M. **Duodecim** 1995;111(24):2385–91 (18 ref.) **(Fin)**

DRUG THERAPY

Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. Rae AP. **Am J Cardiol** 1998 Oct 16; 82(8A):59N–65N (55 ref.)

Adenosine-induced atrial pro-arrhythmia in children. Jaeggi

E, et al. **Can J Cardiol** 1999 Feb;15(2):169–72 (29 ref.)

ETIOLOGY

[Supraventricular arrhythmia after pneumonectomy. Apropos of 100 cases and review of the literature] Douchet MP, et al. **Ann Cardiol Angeiol (Paris)** 1998 May; 47(5):323–7 (30 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Accessory pathways and supraventricular tachycardia] Navarčiková S. **Bratisl Lek Listy** 1999 May;100(5):263–6 (26 ref.) (Eng. Abstr.) **(Slo)**

SURGERY

[How I treat ... tachyarrhythmias with percutaneous radiofrequency ablation] Mélon P. **Rev Med Liege** 1999 Jan;54(1):6–11 (14 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of arrhythmias by endocavitary ablation] Schläpfer J. **Rev Med Suisse Romande** 1999 May; 119(5):399–402 (11 ref.) **(Fre)**

[Radiofrequency ablation of supraventricular tachycardias] García Bolao I, et al. **Rev Med Univ Navarra** 1998 Jan–Mar; 42(1):34–41 (22 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Managing atrial tachyarrhythmias in patients with implantable cardioverter defibrillators. Schaumann A. **Am J Cardiol** 1999 Mar 11;83(5B):214D–217D (34 ref.)

Mode switching for atrial tachyarrhythmias. Sutton R, et al. **Am J Cardiol** 1999 Mar 11;83(5B):202D–210D (12 ref.)

Entrainment of supraventricular tachycardias: a review. Saoudi N, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2105–25 (59 ref.)

[Long term treatment of cardiac arrhythmias] Anttonen O. **Duodecim** 1995;111(24):2399–405 (23 ref.) **(Fin)**

[Supraventricular tachycardias: therapeutic attitude in 1998] Zimmermann M. **Rev Med Suisse Romande** 1998 Aug; 118(8):657–63 (9 ref.) **(Fre)**

[Modern therapy of paroxysmal supraventricular tachycardia] Junga G, et al. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):273–7 (2 ref.) (Eng. Abstr.) **(Ger)**

[The therapeutic approach in refractory supraventricular tachycardias] Brandão L, et al. **Rev Port Cardiol** 1999 Mar; 18(3):309–14 (17 ref.) (Eng. Abstr.) **(Por)**

TACHYCARDIA, VENTRICULAR

Ventricular arrhythmias, electrophysiologic studies, and devices. Dhala A, et al. **Cardiol Clin** 1999 Feb;17(1):189–95, x (34 ref.)

CHEMICALLY INDUCED

Second-generation antihistamines: the risk of ventricular arrhythmias. DuBuske LM. **Clin Ther** 1999 Feb; 21(2):281–95 (58 ref.)

COMPLICATIONS

Treatment and prevention of sudden cardiac death: effect of recent clinical trials. Goldberger JJ. **Arch Intern Med** 1999 Jun 28;159(12):1281–7 (41 ref.)

[Idiopathic ventricular fibrillation] Chevalier P, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:29–36 (33 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Repolarization abnormalities in patients with idiopathic ventricular tachycardias. Ducceschi V, et al. **Can J Cardiol** 1998 Dec;14(12):1451–5 (37 ref.)

Right bundle branch block, intermittent ST segment elevation and inducible ventricular tachycardia in an asymptomatic patient: an unusual presentation of the Brugada syndrome? Bertaglia E, et al. **G Ital Cardiol** 1998 Aug;28(8):893–8 (10 ref.)

Risk assessment of patients having congenital heart disease using electrophysiologic testing: finally, opening the right door...or, an impossible chore? [editorial; comment] Kanter RJ. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1045–8 (25 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1033–44.

Ventricular arrhythmias in congestive heart failure: clinical significance and management. Khoshnevis GR, et al. **Tex Heart Inst J** 1999;26(1):42–59 (149 ref.)

[How to confirm significant arrhythmias] Viitasalo M. **Duodecim** 1995;111(24):2385–91 (18 ref.) **(Fin)**

[Is programmed ventricular stimulation still up to date in the medicinal evaluation of ventricular tachycardia?] Kouakam C, et al. **Therapie** 1998 Nov–Dec;53(6):533–41 (64 ref.) (Eng. Abstr.) **(Fre)**

[Idiopathic left fascicular ventricular tachycardia: the evidence for a "bystander" bundle of His participation] Ducceschi V, et al. **G Ital Cardiol** 1999 Jun;29(6):710–3 (11 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Beta blockers: evidence versus wishful thinking. Andresen D, et al. **Am J Cardiol** 1999 Mar 11;83(5B):64D–67D (29 ref.)

Safety of antiarrhythmics during pregnancy: case report and review of the literature. Fagih B, et al. **Can J Cardiol** 1999 Jan;15(1):113–7 (30 ref.)

Drugs for ventricular arrhythmias in the era of the implantable cardioverter defibrillator [editorial; comment] Peters NS. **Eur Heart J** 1999 Mar;20(5):321–3 (6 ref.) Comment on: Eur Heart J 1999 Mar;20(5):364–74.

Management of the older person with ventricular arrhythmias. Aronow WS. **J Am Geriatr Soc** 1999 Jul; 47(7):886–95 (93 ref.)

Tale of two (or three or more) cities [editorial; comment] Gettes LS. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):165–7 (15 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Feb;10(2):154–64.

Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. Gonzalez ER, et al. **Resuscitation** 1998 Oct–Nov;39(1–2):33–42 (51 ref.)

Philosophy of antiarrhythmic approaches to ventricular tachyarrhythmias close to the 21st century. Breithardt G, et al. **Rev Port Cardiol** 1998 Dec;17(12):981–91 (49 ref.)

[Heart failure and treatment of ventricular arrhythmias] Junga G, et al. **Schweiz Rundsch Med Prax** 1999 Feb 4; 88(6):215–22 (48 ref.) (Eng. Abstr.) **(Ger)**

[What role does pharmacological therapy have in hyperkinetic ventricular arrhythmias?] Tullio D, et al. **G Ital Cardiol** 1998 Jul;28(7):824–32 (55 ref.) **(Ita)**

ETIOLOGY

Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Schumacher B, et al. **Am J Cardiol** 1998 Oct 16;82(8A):29N–36N (82 ref.)

Management of the older person with ventricular arrhythmias. Aronow WS. **J Am Geriatr Soc** 1999 Jul; 47(7):886–95 (93 ref.)

The long QT syndrome and seizures in childhood. Davis AM, et al. **J Paediatr Child Health** 1998 Oct;34(5):410–1 (15 ref.)

[Left ventricular aneurysm of indeterminate etiology revealed by an episode of ventricular tachycardia] Diop IB, et al. **Dakar Med** 1995;40(2):143–50 (30 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

[Risk assessment in coronary heart disease: ventricular arrhythmias, myocardial ischemia and sudden cardiac death] Meinertz T, et al. **Z Kardiol** 1998;87 Suppl 2:106–15 (85 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Idiopathic ventricular tachycardia. Altemose GT, et al. **Annu Rev Med** 1999;50:159–77 (101 ref.)

Is the postpacing interval of any value during ablation of postinfarction ventricular tachycardia? Friedman PL. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):52–5 (22 ref.)

U wave: facts, hypotheses, misconceptions, and misnomers. Surawicz B. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1117–28 (35 ref.)

[Is programmed ventricular stimulation still up to date in the medicinal evaluation of ventricular tachycardia?] Kouakam C, et al. **Therapie** 1998 Nov–Dec;53(6):533–41 (64 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial ischemia and ventricular arrhythmia] Vester EG. **Z Kardiol** 1998;87 Suppl 2:49–60 (51 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Brugada P, et al. **Am J Cardiol** 1999 Mar 11;83(5B):98D–100D (6 ref.)

SURGERY

Radiofrequency catheter ablation for postinfarct ventricular tachycardia. Miller JM, et al. **Curr Opin Cardiol** 1999 Jan; 14(1):30–5 (20 ref.)

Radiofrequency catheter ablation of right ventricular outflow tract tachycardia in a preschooler. Millane T, et al. **Pediatr Cardiol** 1999 Mar–Apr;20(2):143–6 (12 ref.)

[How I treat ... tachyarrhythmias with percutaneous radiofrequency ablation] Mélon P. **Rev Med Liege** 1999 Jan;54(1):6–11 (14 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of arrhythmias by endocavitary ablation] Schläpfer J. **Rev Med Suisse Romande** 1999 May; 119(5):399–402 (11 ref.) **(Fre)**

[The ablation of ventricular tachycardias postinfarct: the search for tools and candidates (editorial)] Ruiz Granell R. **Rev Esp Cardiol** 1999 Mar;52(3):169–71 (11 ref.) **(Spa)**

THERAPY

The implantable cardioverter defibrillator and primary prevention of sudden death: the Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)–Patch Trial. Block M, et al. **Am J Cardiol** 1999 Mar 11;83(5B):74D–78D (18 ref.)

Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart". Böcker D, et al. **Am J Cardiol** 1999 Mar 11;83(5B):83D–87D (36 ref.)

Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study. Cappato R. **Am J Cardiol** 1999 Mar 11;83(5B):68D–73D (45 ref.)

Navigation in the mega-trials waters: reflections on the Multicenter Automatic Defibrillator Implantation Trial and the Antiarrhythmics Versus Implantable Defibrillators Study. Farré J. **Am J Cardiol** 1999 Mar 11;83(5B):5D–7D (28 ref.)

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Klein H, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):91D–97D (23 ref.)

A preview of implantable cardioverter defibrillator systems in the next millennium: an integrative cardiac rhythm management approach. Morris MM, et al. **Am J Cardiol** 1999 Mar 11;83(5B):48D–54D (50 ref.)

What risk should justify implantable cardioverter defibrillator therapy? Schläpfer J, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):101D–103D (31 ref.)

Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Schumacher B, et al. **Am J Cardiol** 1998 Oct 16;82(8A):29N–36N (82 ref.)

Implantable cardioverter-defibrillator follow-up: what everyone needs to know. Wilbur SL, et al. **Cardiol Rev** 1999 Jul–Aug;7(4):176–90 (32 ref.)

Technologic advances in implantable cardioverter defibrillators. Swygman CA, et al. **Curr Opin Cardiol** 1999 Jan;14(1):9–14 (34 ref.)

A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators [see comments] Naccarelli GV, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):864–91 (156 ref.) Comment in: J Cardiovasc Electrophysiol 1999 Mar;10(3):420–1.

Ventricular tachycardia and sudden cardiac death. Reddy PC, et al. **J La State Med Soc** 1999 May;151(5):281–7 (31 ref.)

The modern treatment of ventricular arrhythmias: drugs or defibrillators. Gill JS. **J R Coll Physicians Lond** 1999 Mar–Apr;33(2):116–23 (11 ref.)

CABG and ICD for all patients with hemodynamically significant ventricular arrhythmia and significant coronary artery disease? Do we know enough to decide--or to design a randomized trial? [editorial; comment] Bergfeldt L. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1129–31 (9 ref.) Comment on: Pacing Clin Electrophysiol 1999 Aug;22(8):1132–9.

[Long term treatment of cardiac arrhythmias] Anttonen O. **Duodecim** 1995;111(24):2399–405 (23 ref.) **(Fin)**

VETERINARY

High-resolution electrocardiography. Calvert CA. **Vet Clin North Am Small Anim Pract** 1998 Nov; 28(6):1429–47, viii (46 ref.)

TACHYKININ RECEPTORS see **RECEPTORS, TACHYKININ**

TACHYKININS

see related
RECEPTORS, TACHYKININ

Molecular diversity, localization, and biological actions of elasmobranch tachykinins. Conlon JM. **J Exp Zool** 1999 Oct 1;284(5):535–40 (44 ref.)

ANALYSIS

Tachykinin-related peptides in invertebrates: a review. Nässel DR. **Peptides** 1999;20(1):141–58 (113 ref.)

PHARMACOLOGY

Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. Debeljuk L, et al. **Peptides** 1999; 20(2):285–99 (139 ref.)

PHYSIOLOGY

Role of tachykinins as contractile agonists of human airways in asthma. Advenier C, et al. **Clin Exp Allergy** 1999 May; 29(5):579–84 (57 ref.)

Tachykinins and in vivo gut motility. Sarna SK. **Dig Dis Sci** 1999 Aug;44(8 Suppl):114S–118S (28 ref.)

Regulation of airway neurogenic inflammation by neutral endopeptidase [see comments] Di Maria GU, et al. **Eur Respir J** 1998 Dec;12(6):1454–62 (109 ref.) Comment in: Eur Respir J 1998 Dec;12(6):1250–1.

Regulatory role of tachykinins on intestinal propulsive activity. Onori L, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):346–51 (62 ref.)

Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Raffa RB. **Neurosci Biobehav Rev** 1998 Oct;22(6):789–813 (307 ref.)

Tachykinins and airway function. Lagente V, et al. **Pulm Pharmacol Ther** 1998 Oct–Dec;11(5–6):331–40 (122 ref.)

TACHYPLEUS see **HORSESHOE CRABS**

TACRINE

THERAPEUTIC USE

The therapeutic potential of tacrine. Kurz A. **J Neural Transm Suppl** 1998;54:295–9 (12 ref.)
What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Shadlen MF, et al. **Postgrad Med** 1999 Jan;105(1):109–18 (25 ref.)

TACROLIMUS

Tacrolimus (FK 506). Letko E, et al. **Ann Allergy Asthma Immunol** 1999 Sep;83(3):179–89; quiz 189–90 (136 ref.)

ADMINISTRATION & DOSAGE

Tacrolimus in kidney transplantation. Kliem V, et al. **Contrib Nephrol** 1998;124:103–16; discussion 116–25 (73 ref.)
Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis [editorial; comment] Bieber T. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):555–7 (12 ref.) Comment on: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):637–44.

ADVERSE EFFECTS

Cyclosporin nephrotoxicity: pathophysiology and comparison with FK–506. Ader JL, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):539–45 (79 ref.)
Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation—is tacrolimus the answer? [editorial] Grupp C, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1629–31 (28 ref.)
FK506 nephrotoxicity. Finn WF. **Ren Fail** 1999 May–Jul; 21(3–4):319–29 (48 ref.)
FK506–associated thrombotic microangiopathy: report of two cases and review of the literature. Trimarchi HM, et al. **Transplantation** 1999 Feb 27;67(4):539–44 (18 ref.)

ANALOGS & DERIVATIVES

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW, et al. **Curr Pharm Des** 1998 Oct; 4(5):367–79 (100 ref.)
Ascomycins in dermatology. Paul C, et al. **Semin Cutan Med Surg** 1998 Dec;17(4):256–9 (21 ref.)

PHARMACOKINETICS

Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Oellerich M, et al. **Clin Biochem** 1998 Jul;31(5):309–16 (22 ref.)
Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. Soldin SJ. **Clin Biochem** 1998 Jul;31(5):381–4 (27 ref.)

PHARMACOLOGY

Tacrolimus: a new agent for the prevention of graft–versus–host disease in hematopoietic stem cell transplantation. Jacobson P, et al. **Bone Marrow Transplant** 1998 Aug;22(3):217–25 (129 ref.)
Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW, et al. **Curr Pharm Des** 1998 Oct; 4(5):367–79 (100 ref.)
FK506 and the role of the immunophilin FKBP–52 in nerve regeneration. Gold BG. **Drug Metab Rev** 1999 Aug; 31(3):649–63 (75 ref.)
Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes–treated rats. Toshima K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S51–4 (19 ref.)
[Immunosuppressive drugs and calcineurin] Masugi T, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1739–43 (18 ref.) **(Jpn)**

THERAPEUTIC USE

Tacrolimus: the drug for the turn of the millennium? Ruzicka T, et al. **Arch Dermatol** 1999 May;135(5):574–80 (76 ref.)
Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Oellerich M, et al. **Clin Biochem** 1998 Jul;31(5):309–16 (22 ref.)
The role of tacrolimus in adult kidney transplantation: a review. Laskow DA, et al. **Clin Transplant** 1998 Dec; 12(6):489–503 (36 ref.)
Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis [editorial; comment] Bieber T. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):555–7 (12 ref.) Comment on: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):637–44.
Tacrolimus in pediatric renal transplantation: a review. Shapiro R. **Pediatr Transplant** 1998 Nov;2(4):270–6 (50 ref.)

TADPOLES see **LARVA**

TAE KWON DO see **MARTIAL ARTS**

TAENIA

see related
CYSTICERCOSIS
NEUROCYSTICERCOSIS

TAENIA COLI see **COLON**

TAENIA INFECTIONS see **TAENIASIS**

TAENIASIS

see related
CYSTICERCOSIS
NEUROCYSTICERCOSIS

Human coenurosis in North America: case reports and review. Ing MB, et al. **Clin Infect Dis** 1998 Sep;27(3):519–23 (26 ref.)

DRUG THERAPY

Review of taeniasis in Asia. Fan PC. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 May;28(2):79–94 (115 ref.)
Taeniasis and cysticercosis. Cook GC. **J R Soc Med** 1998 Oct;91(10):534–5 (19 ref.)

T'AI CHI see **MARTIAL ARTS**

TAI–JI see **MARTIAL ARTS**

TAIL

Differential response of the tail and body epidermis of Rana catesbeiana tadpoles in vitro to the anticancer drug, cisplatin [letter] Menon J, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan;35(1):8–11 (12 ref.)

ANATOMY & HISTOLOGY

Tunicate tails, stolons, and the origin of the vertebrate trunk. Lacalli TC. **Biol Rev Camb Philos Soc** 1999 May; 74(2):177–98 (142 ref.)

PHYSIOLOGY

Retinoids as endogenous components of the regenerating limb and tail. Maden M. **Wound Repair Regen** 1998 Jul–Aug; 6(4):358–65 (53 ref.)

TAKA–AMYLASE A see **ALPHA–AMYLASE**

TAKATSUKI'S SYNDROME see **POEMS SYNDROME**

TAKAYASU SYNDROME see **TAKAYASU'S ARTERITIS**

TAKAYASU'S ARTERITIS

Takayasu arteritis—beyond pulselessness. Numano F, et al. **Intern Med** 1999 Mar;38(3):226–32 (41 ref.)

COMPLICATIONS

Takayasu's arteritis presenting as fever of unknown origin: report of two cases and literature review. Uthman IW, et al. **Semin Arthritis Rheum** 1999 Feb;28(4):280–5 (29 ref.)

DIAGNOSIS

Takayasu's arteritis involving proximal pulmonary arteries and mimicking thromboembolic disease. Haque U, et al. **J Rheumatol** 1999 Feb;26(2):450–3 (15 ref.)
[Takayasu's arteritis: towards less invasive management (editorial)] Blétry O, et al. **Rev Med Interne** 1998 Dec; 19(12):867–9 (29 ref.) **(Fre)**

EPIDEMIOLOGY

[Epidemiology and etiological factors in giant cell arteritis (Horton's disease and Takayasu's disease)] Emmerich J, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):425–32 (77 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pathology of isolated nonclassical and catastrophic manifestations of Takayasu arteritis. Lie JT. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S11–21 (41 ref.)
Takayasu arteritis, Buerger disease and inflammatory abdominal aortic aneurysms: is there a common pathway in their pathogenesis? Numano F. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S5–10 (40 ref.)
[Epidemiology and etiological factors in giant cell arteritis (Horton's disease and Takayasu's disease)] Emmerich J, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):425–32 (77 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Takayasu's arteritis: a cell–mediated large–vessel vasculitis. Rizzi R, et al. **Int J Clin Lab Res** 1999;29(1):8–13 (61 ref.)

PATHOLOGY

Pathology of isolated nonclassical and catastrophic manifestations of Takayasu arteritis. Lie JT. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S11–21 (41 ref.)
[Pathology of giant cell arteritis] Amouroux J. **Ann Med Interne (Paris)** 1998 Nov;149(7):415–9 (18 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Takayasu's arteritis: an unusual manifestation—a case report. Safi AM, et al. **Angiology** 1999 Apr;50(4):341–4 (5 ref.)
[Acute ischemia of the legs and rapidly progressing renal failure in a 39–year–old patient] Büchner N, et al. **Internist (Berl)** 1999 May;40(5):555–60 (20 ref.) **(Ger)**

SURGERY

Surgical treatment of Takayasu's Arteritis [editorial; comment] Yasuda K. **Intern Med** 1998 Nov;37(11):903–4 (16 ref.) Comment on: Intern Med 1998 Nov;37(11):934–9.

THERAPY

[Takayasu's arteritis: towards less invasive management (editorial)] Blétry O, et al. **Rev Med Interne** 1998 Dec; 19(12):867–9 (29 ref.) **(Fre)**

TALENT see **APTITUDE**

TALIPES CAVUS see **FOOT DEFORMITIES**

TALIPES EQUINOVARUS see **CLUBFOOT**

TALOCALCANEAL JOINT see **SUBTALAR JOINT**

TALUS

Bilateral intraosseous cystic formation in the talus: a complication of subtalar arthroeresis. Rockett AK, et al. **J Foot Ankle Surg** 1998 Sep–Oct;37(5):421–5 (14 ref.)

INJURIES

Subtalar subluxation in ballet dancers. Ménétrey J, et al. **Am J Sports Med** 1999 Mar–Apr;27(2):143–9 (45 ref.)
Open reduction and internal fixation of fracture of the posterior process of the talus: a case report and review of the literature. Nadim Y, et al. **Foot Ankle Int** 1999 Jan; 20(1):50–2 (7 ref.)
Traumatic extrusion of the talus (missing talus). Papaioannou NA, et al. **Foot Ankle Int** 1998 Sep;19(9):590–3 (3 ref.)
Fractures of the lateral process of the talus: two case reports and a comprehensive literature review. Tucker DJ, et al. **Foot Ankle Int** 1998 Sep;19(9):641–6 (29 ref.)
Talar neck fractures and rates of avascular necrosis. Metzger MJ, et al. **J Foot Ankle Surg** 1999 Mar–Apr;38(2):154–62 (37 ref.)
[Acute and chronic osteochondral lesions of the talus] Josten C, et al. **Orthopade** 1999 Jun;28(6):500–8 (49 ref.) (Eng. Abstr.) **(Ger)**
[Process fractures. A diagnostic problem in ankle injuries] Thermann H, et al. **Orthopade** 1999 Jun;28(6):518–28 (40 ref.) (Eng. Abstr.) **(Ger)**
[Calcaneus cyst—an indication for surgery? Case report and review of the literature] Schnabel M, et al. **Unfallchirurg** 1998 Sep;101(9):704–7 (26 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Triple arthrodesis in adults. Wapner KL. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):188–96 (31 ref.)

TAMOXIFEN

ADMINISTRATION & DOSAGE

New agents for chemoprevention of prostate cancer. Sporn MB. **Eur Urol** 1999;35(5–6):420–3 (9 ref.)

ADVERSE EFFECTS

Surveillance for endometrial cancer in women receiving tamoxifen. Suh–Burgmann EJ, et al. **Ann Intern Med** 1999 Jul 20;131(2):127–35 (87 ref.)
The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review. Law CH, et al. **Can J Surg** 1999 Jun;42(3):211–4 (20 ref.)
The tamoxifen dilemma. White IN. **Carcinogenesis** 1999 Jul; 20(7):1153–60 (95 ref.)
Endometrial carcinoma and tamoxifen: clearing up a controversy [see comments] Jordan VC, et al. **Clin Cancer Res** 1995 May;1(5):467–72 (61 ref.) Comment in: Clin Cancer Res 1996 Jan;2(1):223–4.
Tamoxifen–induced endometrial polyp. A case report and review of the literature. Nomikos IN, et al. **Eur J Gynaecol Oncol** 1998;19(5):476–8 (13 ref.)
Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment. Seoud M, et al. **Eur J Gynaecol Oncol** 1999;20(3):237–9 (29 ref.)
Tamoxifen–associated polyps (basalomas) arising in multiple endometriotic foci: A case report and review of the literature. Schlesinger C, et al. **Gynecol Oncol** 1999 May; 73(2):305–11 (34 ref.)
Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Assikis VJ, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):241–57 (87 ref.)

TAMOXIFEN

METABOLISM

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Crommentuyn KM, et al. **Cancer Treat Rev** 1998 Oct;24(5):345–66 (91 ref.)

Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Favoni RE, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):406–15 (50 ref.)

PHARMACOLOGY

Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. Takimoto GS, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):45–50 (28 ref.)

Tamoxifen effects on menopause--associated risk factors and symptoms. Benshushan A, et al. **Obstet Gynecol Surv** 1999 Apr;54(4):272–8 (33 ref.)

THERAPEUTIC USE

Tamoxifen as a potential treatment of glioma. Mastronardi L, et al. **Anticancer Drugs** 1998 Aug;9(7):581–6 (65 ref.)

Clinical use of selective estrogen receptor modulators. Delmas PD. **Bone** 1999 Jul;25(1):115–8 (31 ref.)

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. De Placido S, et al. **Breast Cancer Res Treat** 1998;52(1–3):55–64 (38 ref.)

The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer. Overmoyer BA. **Cleve Clin J Med** 1999 Jan;66(1):33–40 (35 ref.)

Tamoxifen, raloxifene, and the prevention of breast cancer. Jordan VC, et al. **Endocr Rev** 1999 Jun;20(3):253–78 (264 ref.)

The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Rusthoven JJ. **Eur J Cancer** 1998 Jul;34 Suppl 3:S31–6 (47 ref.)

Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy. Piura B, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):57–61 (22 ref.)

Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review). Toma S, et al. **Int J Oncol** 1999 Aug;15(2):321–37 (87 ref.)

Tamoxifen and contralateral breast cancer [see comments] O'Regan R, et al. **J Am Coll Surg** 1999 Jun;188(6):678–83 (38 ref.) Comment in: J Am Coll Surg 1999 Jun;188(6):684.

Prevention of breast cancer in high-risk women. Kardinal CG, et al. **J La State Med Soc** 1999 Apr;151(4):198–201 (6 ref.)

Current status of tamoxifen use: An update for the surgical oncologist. Heerdt AS, et al. **J Surg Oncol** 1999 Sep; 72(1):42–9 (57 ref.)

Tamoxifen in the treatment of breast cancer. Osborne CK. **N Engl J Med** 1998 Nov 26;339(22):1609–18 (111 ref.)

Providing accurate information to women about tamoxifen therapy for breast cancer: current indications, effects, and controversies. Pasacreta JV, et al. **Oncol Nurs Forum** 1998 Oct;25(9):1577–83 (51 ref.)

The primary use of endocrine therapies. Howell A, et al. **Recent Results Cancer Res** 1998;152:227–44 (52 ref.)

Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene. Jordan VC. **Recent Results Cancer Res** 1998;152:265–76 (56 ref.)

Development of a new prevention maintenance therapy for postmenopausal women. Jordan VC. **Recent Results Cancer Res** 1999;151:96–109 (51 ref.)

Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Favoni RE, et al. **Trends Pharmacol Sci** 1998 Oct;19(10):406–15 (50 ref.)

[Chemoprevention of breast cancer by tamoxifen: should we still ask this question?] Sasco AJ. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):279–85 (20 ref.) (Eng. Abstr.) **(Fre)**

[Tamoxifen and breast cancer: is everything known already?] Marchetti P, et al. **Tumori** 1998 Nov–Dec;84(6):A1–5 (20 ref.) **(Ita)**

TANDEM REPEAT SEQUENCES

Analysis of intrachromosomal homologous recombination in mammalian cell, using tandem repeat sequences. Lambert S, et al. **Mutat Res** 1999 Apr 9;433(3):159–68 (72 ref.)

GENETICS

The utility of short tandem repeat loci beyond human identification: implications for development of new DNA typing systems. Chakraborty R, et al. **Electrophoresis** 1999 Jun;20(8):1682–96 (42 ref.)

TANGIER DISEASE

[Tangier disease (familial high density lipoprotein deficiency)] Tsukamoto T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):554–6 (9 ref.) **(Jpn)**

[Lipid metabolism in Tangier disease] Yokoyama S. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1277–81 (19 ref.) **(Jpn)**

TANNINS

Tannins and human health: a review. Chung KT, et al. **Crit Rev Food Sci Nutr** 1998 Aug;38(6):421–64 (311 ref.)

CHEMISTRY

Characteristics and occurrence of phenolic phytochemicals. King A, et al. **J Am Diet Assoc** 1999 Feb;99(2):213–8 (42 ref.)

TAPE RECORDING, VIDEO see **VIDEOTAPE RECORDING**

TAPETORETINAL DEGENERATION see **RETINITIS PIGMENTOSA**

TAPEWORM INFECTION see **CESTODE INFECTIONS**

TAPEWORMS see **CESTODA**

TAPIOCA see **CASSAVA**

TARGETED RADIOTHERAPY see **RADIOTHERAPY**

TARGETED TOXINS see **IMMUNOTOXINS**

TARICHA see **SALAMANDRIDAE**

TARICHATOXIN see **TETRODOTOXIN**

TARSAL BONES

ABNORMALITIES

Tarsal coalition and painful flatfoot. Vincent KA. **J Am Acad Orthop Surg** 1998 Sep–Oct;6(5):274–81 (14 ref.)

INJURIES

[Injuries of the tarsus and mid-foot] Randt T, et al. **Unfallchirurg** 1998 Dec;101(12):935–49; quiz 949 (14 ref.) **(Ger)**

SURGERY

[Os trigonum syndrome] Zeichen J, et al. **Unfallchirurg** 1999 Apr;102(4):320–3 (21 ref.) (Eng. Abstr.) **(Ger)**

TARSAL JOINT

Total contact casting. Conti SF. **Instr Course Lect** 1999; 48:305–15 (42 ref.)

ABNORMALITIES

An accessory ossification centre in the calcaneus with talonavicular and second metatarsocuneiform coalitions. Turhan AU, et al. **Eur Radiol** 1999;9(3):481–2 (4 ref.)

INJURIES

Biomechanics as a basis for management of intra-articular fractures of the calcaneus. Lewis G. **J Am Podiatr Med Assoc** 1999 May;89(5):234–46 (51 ref.)

[Injuries of the tarsus and mid-foot] Randt T, et al. **Unfallchirurg** 1998 Dec;101(12):935–49; quiz 949 (14 ref.) **(Ger)**

PHYSIOPATHOLOGY

The pathomechanic effects of rheumatic diseases on the pedal joints. Albert SF. **Clin Podiatr Med Surg** 1999 Apr; 16(2):259–70 (9 ref.)

RADIOGRAPHY

Radiographic manifestations of rheumatic diseases affecting the foot and ankle. Loredo R. **Clin Podiatr Med Surg** 1999 Apr;16(2):215–58, v (39 ref.)

SURGERY

Triple arthrodesis and subtalar joint arthrodesis. For the treatment of end-stage posterior tibial tendon dysfunction. Laughlin TJ, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):527–55 (50 ref.)

Evaluation and surgical management of the arthritic midfoot secondary to rheumatic disease. Mandracchia VJ, et al. **Clin Podiatr Med Surg** 1999 Apr;16(2):303–26 (32 ref.)

Talonavicular arthrodesis for correction of posterior tibial tendon dysfunction. Mothershed RA, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):501–26 (24 ref.)

Reconstruction of the rheumatoid forefoot. Solomon MG, et al. **Clin Podiatr Med Surg** 1999 Apr;16(2):285–301 (37 ref.)

Surgical correction of the rearfoot in rheumatoid arthritis. Steinberg JS, et al. **Clin Podiatr Med Surg** 1999 Apr; 16(2):327–36 (31 ref.)

TARSAL TUNNEL SYNDROME

Tarsal tunnel syndrome: a review of the literature. Lau JT, et al. **Foot Ankle Int** 1999 Mar;20(3):201–9 (71 ref.)

DIAGNOSIS

[Os trigonum syndrome] Zeichen J, et al. **Unfallchirurg** 1999 Apr;102(4):320–3 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Os trigonum syndrome] Zeichen J, et al. **Unfallchirurg** 1999 Apr;102(4):320–3 (21 ref.) (Eng. Abstr.) **(Ger)**

TARSUS

see related
TARSAL BONES

INJURIES

[Injuries of the tarsus and mid-foot] Randt T, et al. **Unfallchirurg** 1998 Dec;101(12):935–49; quiz 949 (14 ref.) **(Ger)**

TARSUS OSSEUS see **TARSAL BONES**

TARTAR see **DENTAL CALCULUS**

TASK PERFORMANCE AND ANALYSIS

see related
WORKLOAD

Current techniques for assessing physical exposure to work-related musculoskeletal risks, with emphasis on posture-based methods. Li G, et al. **Ergonomics** 1999 May; 42(5):674–95 (147 ref.)

HTA as a framework for task analysis. Shepherd A. **Ergonomics** 1998 Nov;41(11):1537–52 (20 ref.)

TASMACETUS see **WHALES**

TASTE

Modulation of sweet taste. Birch GG. **Biofactors** 1999; 9(1):73–80 (29 ref.)

The naturally occurring furanones: formation and function from pheromone to food. Colin Slaughter J. **Biol Rev Camb Philos Soc** 1999 Aug;74(3):259–76 (110 ref.)

Cyclodextrin derivatives as chiral selectors for direct gas chromatographic separation of enantiomers in the essential oil, aroma and flavour fields. Bicchi C, et al. **J Chromatogr A** 1999 May 28;843(1–2):99–121 (118 ref.)

Flavour of coffee. A review. Grosch W. **Nahrung** 1998 Dec; 42(6):344–50 (59 ref.)

Volatile flavour of wine: correlation between instrumental analysis and sensory perception. Rapp A. **Nahrung** 1998 Dec;42(6):351–63 (77 ref.)

Energy density, palatability, and satiety: implications for weight control. Drewnowski A. **Nutr Rev** 1998 Dec; 56(12):347–53 (42 ref.)

Taste and flavour: their importance in food choice and acceptance. Clark JE. **Proc Nutr Soc** 1998 Nov; 57(4):639–43 (12 ref.)

Taste and flavour perception. Woods MP. **Proc Nutr Soc** 1998 Nov;57(4):603–7 (37 ref.)

Taste, palatability and the control of appetite. Yeomans MR. **Proc Nutr Soc** 1998 Nov;57(4):609–15 (66 ref.)

DRUG EFFECTS

Amiloride and vertebrate gustatory responses to NaCl. Halpern BP. **Neurosci Biobehav Rev** 1998;23(1):5–47 (128 ref.)

GENETICS

6-n-Propylthiouracil: a genetic marker for taste, with implications for food preference and dietary habits. Tepper BJ. **Am J Hum Genet** 1998 Nov;63(5):1271–6 (29 ref.)

PHYSIOLOGY

Neural circuits for taste. Excitation, inhibition, and synaptic plasticity in the rostral gustatory zone of the nucleus of the solitary tract. Bradley RM, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:467–74 (22 ref.)

Molecular and physiological evidence for glutamate (umami) taste transduction via a G protein-coupled receptor. Chaudhari N, et al. **Ann N Y Acad Sci** 1998 Nov 30; 855:398–406 (32 ref.)

The role of innervation in induction and differentiation of taste organs: introduction and background. Mistretta CM. **Ann N Y Acad Sci** 1998 Nov 30;855:1–13 (29 ref.)

Taste neurons have multiple inductive roles in mammalian gustatory development. Oakley B. **Ann N Y Acad Sci** 1998 Nov 30;855:50–7 (41 ref.)

The neurophysiology of taste and olfaction in primates, and umami flavor. Rolls ET, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:426–37 (30 ref.)

Excitatory and inhibitory modulation of taste responses in the hamster brainstem. Smith DV, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:450–6 (29 ref.)

Cellular mechanisms of taste transduction. Herness MS, et al. **Annu Rev Physiol** 1999;61:873–900 (175 ref.)

The parabrachial nucleus and conditioned taste aversion. Reilly S. **Brain Res Bull** 1999 Feb;48(3):239–54 (170 ref.)

Taste processing: whetting our appetites. Smith DV, et al. **Curr Biol** 1999 Jun 17;9(12):R453–5 (12 ref.)

Gustatory mechanisms for the detection of fat. Gilbertson TA. **Curr Opin Neurobiol** 1998 Aug;8(4):447–52 (42 ref.)

Neural coding of gustatory information. Smith DV, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):427–35 (70 ref.)
Ontogeny of taste sense. Rao BS, et al. **Indian J Physiol Pharmacol** 1997 Jul;41(3):193–203 (54 ref.)
From channels to behavior: an integrative model of NaCl taste. Boughter JD Jr, et al. **Neuron** 1999 Feb;22(2):213–5 (17 ref.)
The smell of representations. Dudai Y. **Neuron** 1999 Aug; 23(4):633–5 (18 ref.)
A sweet beginning. Dulac C. **Neuron** 1999 Feb;22(2):204–6 (12 ref.)
Glutamate and the UMAMI taste: sensory, metabolic, nutritional and behavioural considerations. A review of the literature published in the last 10 years. Bellisle F. **Neurosci Biobehav Rev** 1999;23(3):423–38 (152 ref.)
The role of the gustatory thalamus in taste-guided behavior. Reilly S. **Neurosci Biobehav Rev** 1998 Oct;22(6):883–901 (233 ref.)
Taste aversion learning: a contemporary perspective. Bernstein IL. **Nutrition** 1999 Mar;15(3):229–34 (67 ref.)
Food aversion learning: a risk factor for nutritional problems in the elderly? Bernstein IL. **Physiol Behav** 1999 Apr; 66(2):199–201 (28 ref.)
Do chemosensory changes influence food intake in the elderly? Rolls BJ. **Physiol Behav** 1999 Apr;66(2):193–7 (35 ref.)
The influence of aging on oral health and consequences for taste and smell. Ship JA. **Physiol Behav** 1999 Apr; 66(2):209–15 (72 ref.)
Clinical undernutrition states and their influence on taste. Davidson HI, et al. **Proc Nutr Soc** 1998 Nov;57(4):633–8 (43 ref.)
Taste and appetite regulation in the elderly. Hetherington MM. **Proc Nutr Soc** 1998 Nov;57(4):625–31 (56 ref.)

TASTE BUDS

EMBRYOLOGY

The role of innervation in induction and differentiation of taste organs: introduction and background. Mistretta CM. **Ann N Y Acad Sci** 1998 Nov 30;855:1–13 (29 ref.)
Taste neurons have multiple inductive roles in mammalian gustatory development. Oakley B. **Ann N Y Acad Sci** 1998 Nov 30;855:50–7 (41 ref.)
A taste for development. Barlow LA. **Neuron** 1999 Feb; 22(2):209–12 (21 ref.)

GROWTH & DEVELOPMENT

Amphibians provide new insights into taste-bud development [see comments] Northcutt RG, et al. **Trends Neurosci** 1998 Jan;21(1):38–43 (55 ref.) Comment in: Trends Neurosci 1998 Aug;21(8):337–8.

PHYSIOLOGY

Neural circuits for taste. Excitation, inhibition, and synaptic plasticity in the rostral gustatory zone of the nucleus of the solitary tract. Bradley RM, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:467–74 (22 ref.)
Molecular and physiological evidence for glutamate (umami) taste transduction via a G protein–coupled receptor. Chaudhari N, et al. **Ann N Y Acad Sci** 1998 Nov 30; 855:398–406 (32 ref.)
The role of innervation in induction and differentiation of taste organs: introduction and background. Mistretta CM. **Ann N Y Acad Sci** 1998 Nov 30;855:1–13 (29 ref.)
Taste neurons have multiple inductive roles in mammalian gustatory development. Oakley B. **Ann N Y Acad Sci** 1998 Nov 30;855:50–7 (41 ref.)
Neural coding of gustatory information. Smith DV, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):427–35 (70 ref.)
Potential mechanisms for functional changes in taste receptor cells following sodium deficiency in mammals. Lundy RF Jr. **Neurosci Biobehav Rev** 1998;23(1):103–9 (85 ref.)

TASTE DISORDERS

[Taste function tests and taste disorders] Inokuchi A. **Fukuoka Igaku Zasshi** 1998 Jul;89(7):195–200 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Smell and taste disorders] Knecht M, et al. **Schweiz Med Wochenschr** 1999 Jul 13;129(27–28):1039–46 (32 ref.) (Eng. Abstr.) **(Ger)**

TASTE THRESHOLD

[Taste function tests and taste disorders] Inokuchi A. **Fukuoka Igaku Zasshi** 1998 Jul;89(7):195–200 (5 ref.) **(Jpn)**

PHYSIOLOGY

Glutamate and the UMAMI taste: sensory, metabolic, nutritional and behavioural considerations. A review of the literature published in the last 10 years. Bellisle F. **Neurosci Biobehav Rev** 1999;23(3):423–38 (152 ref.)

TAT GENE PRODUCTS see **GENE PRODUCTS, TAT**

TAT PROTEIN see **GENE PRODUCTS, TAT**

TATA BOX

The DPE, a conserved downstream core promoter element that is functionally analogous to the TATA box. Burke TW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:75–82 (37 ref.)
Mechanism and regulation of yeast RNA polymerase II transcription. Kornberg RD. **Cold Spring Harb Symp Quant Biol** 1998;63:229–32 (26 ref.)
[TAFII230 regulates transcription by molecular mimicry of the TATA box] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):123–9 (60 ref.) **(Jpn)**

TATTOOING

Q-switched ruby laser treatment of tattoos and benign pigmented skin lesions: a critical review. Raulin C, et al. **Ann Plast Surg** 1998 Nov;41(5):555–65 (66 ref.)

TAU PROTEINS

BIOSYNTHESIS

Tau protein pathology in neurodegenerative diseases. Spillantini MG, et al. **Trends Neurosci** 1998 Oct; 21(10):428–33 (66 ref.)

CEREBROSPINAL FLUID

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. Galasko D. **J Neural Transm Suppl** 1998;53:209–21 (42 ref.)

GENETICS

Tau mutations in frontotemporal dementia. Wilhelmsen KC, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:88–92 (28 ref.)
Toxic neuronal apoptosis and modifications of tau and APP gene and protein expressions. Hugon J, et al. **Drug Metab Rev** 1999 Aug;31(3):635–47 (38 ref.)
Tau mutations cause frontotemporal dementias. Goedert M, et al. **Neuron** 1998 Nov;21(5):955–8 (20 ref.)
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101–18 (148 ref.)
Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Goedert M. **Prog Brain Res** 1998;117:287–306 (119 ref.)
[The amyloid and tau hypothesis in degenerative dementia] Fladby T, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10; 119(7):976–9 (36 ref.) (Eng. Abstr.) **(Nor)**

IMMUNOLOGY

A new kind of Alzheimer's disease plaque. Baum L, et al. **Adv Anat Pathol** 1998 May;5(3):170–4 (11 ref.)

METABOLISM

Influence of phospholipids and sequential kinase activities on tau in vitro. Shea TB, et al. **Adv Exp Med Biol** 1998; 446:181–201 (84 ref.)
Movement disorders with tau protein cytoskeletal pathology. Jellinger KA. **Adv Neurol** 1999;80:303–11 (36 ref.)
Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Goedert M, et al. **Biochem Soc Trans** 1998 Aug;26(3):463–71 (49 ref.)
Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Pavia J, et al. **Fundam Clin Pharmacol** 1998;12(5):473–81 (99 ref.)
REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Tolnay M, et al. **Neuropathol Appl Neurobiol** 1999 Jun;25(3):171–87 (111 ref.)
Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease. Oyama F, et al. **Neurosci Res** 1998 May;31(1):1–8 (70 ref.)

PHYSIOLOGY

The tauopathies: toward an experimental animal model [comment] Goedert M, et al. **Am J Pathol** 1999 Jan; 154(1):1–6 (63 ref.) Comment on: Am J Pathol 1999 Jan;154(1):255–70.
Tau in Alzheimer's disease. Mandelkow EM, et al. **Trends Cell Biol** 1998 Nov;8(11):425–7 (38 ref.)

TAURINE

ANALOGS & DERIVATIVES

The pharmacological treatment of alcohol dependence: needs and possibilities. Mann K. **Alcohol Alcohol Suppl** 1996 Mar; 1:55–8 (24 ref.)
Clinical pharmacokinetics of acamprosate. Saivin S, et al. **Clin Pharmacokinet** 1998 Nov;35(5):331–45 (44 ref.)
[Prevention of recurrent alcoholism with acamprosate. Neurobiological principles and clinical results] Soyka M, et al. **Internist (Berl)** 1999 Mar;40(3):330–6 (27 ref.) **(Ger)**

METABOLISM

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34–49 (78 ref.)

PHYSIOLOGY

An updated view of the value of taurine in infant nutrition. Chesney RW, et al. **Adv Pediatr** 1998;45:179–200 (88 ref.)

THERAPEUTIC USE

The effectiveness of taurine and levocarnitine in dogs with heart disease. Pion PD, et al. **Vet Clin North Am Small Anim Pract** 1998 Nov; 28(6):1495–514, ix (43 ref.)

TAX EXEMPTION

LEGISLATION & JURISPRUDENCE

Ambulatory surgery center joint ventures involving tax-exempt entities. Becker S, et al. **J Health Care Finance** 1999 Summer;25(4):47–58 (3 ref.)

TAX GENE PRODUCTS see **GENE PRODUCTS, TAX**

TAX PROTEIN see **GENE PRODUCTS, TAX**

TAXES

Prevention of alcohol abuse-related birth effects--II. Targeting and pricing. Abel EL. **Alcohol Alcohol** 1998 Jul–Aug;33(4):417–20 (30 ref.)

LEGISLATION & JURISPRUDENCE

Arizona's tobacco control initiative illustrates the need for continuing oversight by tobacco control advocates. Aguinaga Bialous S, et al. **Tob Control** 1999 Summer; 8(2):141–51 (110 ref.)

TAXOL see **PACLITAXEL**

TAXONOMY see **CLASSIFICATION**

TAY-SACHS DISEASE

[Tay-Sachs disease] Itoh T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):389–92 (15 ref.) **(Jpn)**

COMPLICATIONS

[Spinal muscular atrophy: a hexosaminidase A deficiency phenotype] Kawanami T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):379–81 (15 ref.) **(Jpn)**

DIAGNOSIS

Tay-Sachs disease carrier screening: a model for prevention of genetic disease. Kaplan F. **Genet Test** 1998;2(4):271–92 (192 ref.)

METABOLISM

Glycosphingolipid degradation and animal models of GM2-gangliosidoses. Kolter T, et al. **J Inherit Metab Dis** 1998 Aug;21(5):548–63 (54 ref.)

TAY-SACHS DISEASE GANGLIOSIDE see **G(M2) GANGLIOSIDE**

TBARS see **THIOBARBITURIC ACID REACTIVE SUBSTANCES**

TC 99M-ALBUMIN see **TECHNETIUM TC 99M AGGREGATED ALBUMIN**

TC 99M-ALBUMIN COLLOID see **TECHNETIUM TC 99M AGGREGATED ALBUMIN**

99MTC-DIMERCAPTOSUCCINIC ACID see **TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID**

99MTC-DMSA see **TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID**

TC-DTPA see **TECHNETIUM TC 99M PENTETATE**

TC 99M-DTPA see **TECHNETIUM TC 99M PENTETATE**

99MTC-HEXAMIBI see **TECHNETIUM TC 99M SESTAMIBI**

TC MIBI see **TECHNETIUM TC 99M SESTAMIBI**

TC 99M-PYROPHOSPHATE see **TECHNETIUM TC 99M PYROPHOSPHATE**

99MTC-SESTAMIBI see **TECHNETIUM TC 99M SESTAMIBI**

99TC-SUCCIMER see **TECHNETIUM TC 99M**

DIMERCAPTOSUCCINIC ACID

TCDD see **TETRACHLORODIBENZODIOXIN**

TCDD RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

TCGF see **INTERLEUKIN-2**

TCR ALPHA-BETA see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

TCR BETA GENES see **GENES, T-CELL RECEPTOR BETA**

TCR-CD3 COMPLEX see **RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL**

TCR GAMMA-DELTA see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

TCR GENES see **GENES, T-CELL RECEPTOR**

TEA

see related
THEOPHYLLINE

Red wine, green tea and vitamins: do their antioxidants play a role in immunologic protection against cancer or even AIDS? [editorial] Mathé G. **Biomed Pharmacother** 1999 May;53(4):165–7 (19 ref.)

Antimutagenic and anticarcinogenic activity of tea polyphenols. Kuroda Y, et al. **Mutat Res** 1999 Jan; 436(1):69–97 (131 ref.)

Green tea and cancer in humans: a review of the literature. Bushman JL. **Nutr Cancer** 1998;31(3):151–9 (46 ref.)

Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. Dashwood RH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):239–43 (28 ref.)

Mechanistic findings of green tea as cancer preventive for humans. Fujiki H, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):225–8 (14 ref.)

Mechanism of cancer chemopreventive activity of green Tea. Mukhtar H, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):234–8 (31 ref.)

Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Rice-Evans C. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):262–6 (21 ref.)

Tea and health: the underlying mechanisms. Weisburger JH. **Proc Soc Exp Biol Med** 1999 Apr;220(4):271–5 (42 ref.)

Tea--a potent agent to prevent disease? [editorial] Najemnik C, et al. **Wien Klin Wochenschr** 1999 Apr 9;111(7):259–61 (21 ref.)

[Inhibitory effect of green tea infusion of hepatotoxicity] Hasegawa R, et al.
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 1998;(116):82–91 (63 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Lin JK, et al.
Biochem Pharmacol 1999 Sep 15;58(6):911–5 (28 ref.)

Green tea polyphenols and cancer: biologic mechanisms and practical implications. Ahmad N, et al. **Nutr Rev** 1999 Mar; 57(3):78–83 (41 ref.)

Analysis of tea polyphenols. Beecher GR, et al.
Proc Soc Exp Biol Med 1999 Apr;220(4):267–70 (31 ref.)

Tea flavonols in cardiovascular disease and cancer epidemiology. Hollman PC, et al.
Proc Soc Exp Biol Med 1999 Apr;220(4):198–202 (29 ref.)

METABOLISM

Antioxidant capacity and polyphenolic components of teas: implications for altering in vivo antioxidant status. Prior RL, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):255–61 (40 ref.)

THERAPEUTIC USE

The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Chung FL. **Proc Soc Exp Biol Med** 1999 Apr;220(4):244–8 (28 ref.)

Inhibitory effect of green and black tea on tumor growth. Conney AH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):229–33 (11 ref.)

Preclinical efficacy studies of green and black tea extracts. Steele VE, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):210–2 (5 ref.)

Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Yang CS, et al. **Proc Soc Exp Biol Med** 1999 Apr;220(4):213–7 (31 ref.)

Prostate cancer chemoprevention by green tea. Gupta S, et al. **Semin Urol Oncol** 1999 May;17(2):70–6 (82 ref.)

TEACHING

see related
FACULTY

Teaching and learning communication in medicine: a rhetorical approach. Lingard L, et al. **Acad Med** 1999 May; 74(5):507–10 (10 ref.)

Issues in teaching and learning time-limited psychodynamic psychotherapy. Binder JL. **Clin Psychol Rev** 1999 Sep; 19(6):705–19 (67 ref.)

Who should be educated? Education strategies: could children educate their parents? Basdevant A, et al.
Int J Obes Relat Metab Disord 1999 May;23 Suppl 4:S10–2, discussion S12–3 (7 ref.)

Using reflective thinking to develop personal professional philosophies. Brown SC, et al. **J Nurs Educ** 1999 Apr; 38(4):171–5 (20 ref.)

Improving practice in marriage preparation. Silliman B, et al. **J Sex Marital Ther** 1999 Jan-Mar;25(1):23–43 (95 ref.)

Vocal problems among teachers: a review of prevalence, causes, prevention, and treatment. Mattiske JA, et al.
J Voice 1998 Dec;12(4):489–99 (42 ref.)

Grab their attention! Make your point! Gerstle DS.
MCN Am J Matern Child Nurs 1999 Sep-Oct;24(5):257–61 (12 ref.)

What is anatomy for? Considerations on the body as a whole and whole anatomy. Wakuri H, et al.
Okajimas Folia Anat Jpn 1998 Oct;75(4):173–84 (151 ref.)

Considerations in the education of children with hearing loss. Matkin ND, et al. **Pediatr Clin North Am** 1999 Feb; 46(1):143–52 (19 ref.)

Pivotal responses and the natural language teaching paradigm. Koegel LK, et al. **Semin Speech Lang** 1998; 19(4):355–71; quiz 372; 424 (102 ref.)

Social work in health care: do practitioners' writings suggest an applied social science? Rehr H, et al.
Soc Work Health Care 1998;28(2):63–81 (33 ref.)

[Plan diagnosis with children] Klemenz B.
Prax Kinderpsychol Kinderpsychiatr 1998 Dec; 47(10):722–39 (45 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Learner centred approaches in medical education. Spencer JA, et al. **BMJ** 1999 May 8;318(7193):1280–3 (36 ref.)

Teaching and learning gross anatomy: dissection, prosection, or "both of the above?". Dinsmore CE, et al. **Clin Anat** 1999;12(2):110–4 (25 ref.)

Ethics and teaching the art of emergency medicine. Totten VY. **Emerg Med Clin North Am** 1999 May;17(2):429–41, xi-xii (40 ref.)

Learner contracts. Ferrante J. **Fam Med** 1998 Nov-Dec; 30(10):703–4 (4 ref.)

How to make nutrition education more meaningful through facilitated group discussions. Abusabha R, et al.
J Am Diet Assoc 1999 Jan;99(1):72–6 (28 ref.)

Teaching complementary healing therapies to nurses. Breda KL, et al. **J Nurs Educ** 1998 Dec;37(9):394–7 (19 ref.)

The Cloutterbuck Minimum Data Matrix: a teaching mechanism for the new millennium. Cloutterbuck JC, et al. **J Nurs Educ** 1998 Dec;37(9):385–93 (70 ref.)

Culture and loss: a project of self-reflection. Lewis ML.
J Nurs Educ 1998 Dec;37(9):398–400 (19 ref.)

Shift report: a time for learning. Yurkovich E, et al.
J Nurs Educ 1998 Dec;37(9):401–3 (12 ref.)

Bright smiles, shining futures. Yehieli M, et al.
J Sch Health 1999 Apr;69(4):162–4 (1 ref.)

Listening to Hispanic mothers: guidelines for teaching. Wilson AH, et al. **J Soc Pediatr Nurs** 1999 Jul-Sep; 4(3):125–7 (10 ref.)

A rationale for staged teaching of basic life support. Assar D, et al. **Resuscitation** 1998 Dec;39(3):137–43 (54 ref.)

Teaching social inequalities in health: barriers and opportunities. Muntaner C. **Scand J Public Health** 1999 Sep;27(3):161–5 (58 ref.)

[The introduction of new teaching methods in medical studies or student-focused teaching: application to the initial training in hepatogastroenterology] Tran A, et al.
Gastroenterol Clin Biol 1998 Nov;22(11):851–4 (21 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Total quality strategy in the formative process of the occupational physician. Franco G, et al.
Scand J Work Environ Health 1999 Apr;25(2):153–6 (12 ref.)

STANDARDS

Evaluating without fear. Kaprielian VS, et al. **Fam Med** 1999 Mar;31(3):155–6 (0 ref.)

Are clinician-teachers good for anything other than teaching? [editorial; comment] Redelmeier DA, et al.
J Gen Intern Med 1999 Jun;14(6):386–7 (12 ref.) Comment on: J Gen Intern Med 1999 Jun;14(6):327–32. Comment on: J Gen Intern Med 1999 Jun;14(6):370–2.

TEACHING MATERIALS

A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Kenny T, et al.
Fam Pract 1998 Oct;15(5):471–9 (96 ref.)

Using picture identification for research with preschool children. Wiley DC, et al. **J Sch Health** 1998 Aug; 68(6):227–30 (26 ref.)

Hyperbilirubinemia in the healthy term newborn. Augustine MC. **Nurse Pract** 1999 Apr;24(4):24–6, 29–32, 34–6 passim; quiz 42–3 (30 ref.)

Management of chronic stable angina. Beattie S.
Nurse Pract 1999 May;24(5):44, 49, 53 passim (25 ref.)

Preventing human rabies before and after exposure. Garcia R. **Nurse Pract** 1999 Apr;24(4):91–2, 95–7, 101–2 passim (32 ref.)

Using physiologic and pharmacologic stress testing in the evaluation of coronary artery disease. Meyer N.
Nurse Pract 1999 Apr;24(4):70–2, 75–6, 78 passim (12 ref.)

Evaluating mild to moderate hypertension. Tobin LJ.
Nurse Pract 1999 May;24(5):22, 25–6, 29–30 passim; quiz 42–3 (42 ref.)

TEARS

CHEMISTRY

Three interferometric methods for measuring the thickness of layers of the tear film. King-Smith PE, et al.
Optom Vis Sci 1999 Jan;76(1):19–32 (30 ref.)

[Physiology and pathology of tear film in the course of dry eye syndrome] Stankiewicz A, et al. **Klin Oczna** 1998; 100(5):323–9 (23 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Tear dynamics and dry eye. Tsubota K.
Prog Retin Eye Res 1998 Oct;17(4):565–96 (89 ref.)

[Physiology and pathology of tear film in the course of dry eye syndrome] Stankiewicz A, et al. **Klin Oczna** 1998; 100(5):323–9 (23 ref.) (Eng. Abstr.) **(Pol)**

TEARS, ARTIFICIAL see **OPHTHALMIC SOLUTIONS**

TEAS, HERBAL see **BEVERAGES**

TEAS, MEDICINAL see **BEVERAGES**

TECHNETIUM

see related
ORGANOTECHNETIUM COMPOUNDS

CHEMISTRY

[Antibody radiolabeling with technetium-99m] Perera A, et al. **Rev Esp Med Nucl** 1998;17(4):302–9 (63 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSTIC USE

Technetium-99m labeled myocardial perfusion imaging agents. Jain D. **Semin Nucl Med** 1999 Jul;29(3):221–36 (103 ref.)

PHARMACOKINETICS

The influence of stereoisomerism on the pharmacokinetics of Tc radiopharmaceuticals. Hansen L, et al.
Q J Nucl Med 1998 Dec;42(4):280–93 (69 ref.)

TECHNETIUM 99M see **TECHNETIUM**

TECHNETIUM COMPOUNDS

ADVERSE EFFECTS

Is technetium-99 (Tc-99) radiologically significant? Barnaby F, et al. **Med Confl Surviv** 1999 Jan-Mar;15(1):57–70 (28 ref.)

DIAGNOSTIC USE

Radionuclide scanning in parathyroid diseases. Pattou F, et al. **Br J Surg** 1998 Dec;85(12):1605–16 (130 ref.)

TECHNETIUM-DTPA see **TECHNETIUM TC 99M PENTETATE**

TECHNETIUM TC 99M AGGREGATED ALBUMIN

DIAGNOSTIC USE

[Nuclear medicine of the liver--focusing on functional diagnosis] Ha-Kawa SK. **Kaku Igaku** 1999 Apr;36(3):203–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID

DIAGNOSTIC USE

[Role of DMSA scintigraphy in managing pediatric pyelonephritis] Girardin E, et al. **Arch Pediatr** 1998;5 Suppl 3:285S–289S (15 ref.) (Eng. Abstr.) **(Fre)**

TECHNETIUM TC 99M PENTETATE

DIAGNOSTIC USE

[Nuclear medicine of the liver--focusing on functional diagnosis] Ha-Kawa SK. **Kaku Igaku** 1999 Apr;36(3):203–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

TECHNETIUM TC 99M PYROPHOSPHATE

DIAGNOSTIC USE

The current role of infarct avid imaging. Khaw BA. **Semin Nucl Med** 1999 Jul;29(3):259–70 (59 ref.)

TECHNETIUM TC 99M SESTAMIBI

DIAGNOSTIC USE

Technetium Tc 99m sestamibi myocardial perfusion imaging: current role for evaluation of prognosis. Mandalapu BP, et al. **Chest** 1999 Jun;115(6):1684–94 (77 ref.)

Clinical imaging of multidrug resistance in cancer. Del Vecchio S, et al. **Q J Nucl Med** 1999 Jun;43(2):125–31 (47 ref.)

The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Taillefer R. **Semin Nucl Med** 1999 Jan;29(1):16–40 (133 ref.)

[Nuclear oncology update] Maublant J, et al. **Bull Cancer** 1999 Jan;86(1):57–64 (66 ref.) **(Fre)**

TECHNOLOGY

Maintaining the habitable condition of the planet: balancing technological and ecosystem services. Cairns J Jr. **Qual Assur** 1998 Jan–Mar;6(1):13–22 (13 ref.)

TECHNOLOGY ASSESSMENT, BIOMEDICAL

Medical technology assessment: an overview. Fleisher LA, et al. **Anesth Analg** 1998 Dec;87(6):1271–82 (50 ref.)

What alternatives has minimally invasive surgery provided the surgeon? Rothschild JG. **Arch Surg** 1998 Nov; 133(11):1156–9 (68 ref.)

Methods in health service research. An introduction to bayesian methods in health technology assessment. Spiegelhalter DJ, et al. **BMJ** 1999 Aug 21;319(7208):508–12 (29 ref.)

Analysis and introduction of a technology: Ultrasound-assisted Lipoplasty Task Force. Fredricks S. **Clin Plast Surg** 1999 Apr;26(2):187–204; vii (5 ref.)

Assessing new technology, another chapter: lung volume reduction surgery/recombinant human growth hormone [editorial; comment] Slonim AD, et al. **Crit Care Med** 1999 Aug;27(8):1687–8 (15 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634–8.

Technology status evaluation: endoscopic ultrasonography: update November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):705–7 (26 ref.)

Technology status evaluation: virtual colonoscopy: November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):708–10 (12 ref.)

Technology status evaluation: developments in laser technology: November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):711–6 (63 ref.)

Technology status evaluation: device reprocessing companies: May 1998. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):717–22 (23 ref.)

Technology status evaluation: endoscopic pancreatic therapy: update May 1998. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):723–6 (44 ref.)

Implantable brain chips? Time for debate. Maguire GQ Jr, et al. **Hastings Cent Rep** 1999 Jan–Feb;29(1):7–13 (35 ref.)

Digital film processing: a comparison of wet and dry processing methods. **Health Devices** 1998 Aug;27(8):293–8 (11 ref.)

Telemedicine: an overview. **Health Devices** 1999 Mar; 28(3):88–103 (34 ref.)

Screening for cystic fibrosis. Murray J, et al. **Health Technol Assess** 1999;3(8):i–iv, 1–104 (455 ref.)

The debridement of chronic wounds: a systematic review. Bradley M, et al. **Health Technol Assess (Rockv)** 1999;3(17 Pt 1):iii–iv, 1–78 (62 ref.)

Swan to phoenix: the metamorphosis [editorial] Brandstetter RD, et al. **Heart Lung** 1998 Jul–Aug;27(4):215–7 (21 ref.)

Evaluating technologies in reproductive health: case studies of a consumer protection approach. Silver LD, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S75–83 (28 ref.)

A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. Thomason MJ, et al. **J Public Health Med** 1998 Sep;20(3):331–43 (63 ref.)

An evidence-based approach to interactive health communication: a challenge to medicine in the information age. Science Panel on Interactive Communication and Health. Robinson TN, et al. **JAMA** 1998 Oct 14; 280(14):1264–9 (82 ref.)

Health-technology assessment in surgery. Reeves B. **Lancet** 1999 Apr;353 Suppl 1:SI3–5 (20 ref.)

A review of database management systems suitable for neuroimaging. Diallo B, et al. **Methods Inf Med** 1999 Jun; 38(2):132–9 (46 ref.)

Psychiatric rehabilitation technology: operationalizing the "black box" of the psychiatric rehabilitation process. Anthony WA. **New Dir Ment Health Serv** 1998 Fall; (79):79–87 (41 ref.)

Endoscopic surgery: what has passed the test? Köhler L. **World J Surg** 1999 Aug;23(8):816–24 (137 ref.)

ECONOMICS

Economic evaluation studies in nuclear medicine: the need for standardization. Dietlein M, et al. **Eur J Nucl Med** 1999 Jun;26(6):663–80 (60 ref.)

A review of the use of health status measures in economic evaluation. Brazier J, et al. **Health Technol Assess** 1999; 3(9):i–iv, 1–164 (1135 ref.)

The once and future application of cost–effectiveness analysis. Berger ML. **Jt Comm J Qual Improv** 1999 Sep; 25(9):455–61 (15 ref.)

METHODS

A hierarchical outcomes approach to test assessment. Pearl WS. **Ann Emerg Med** 1999 Jan;33(1):77–84 (49 ref.)

How to use articles about diagnostic technology: gastric tonometry. Keenan SP, et al. **Crit Care Med** 1999 Sep; 27(9):1726–31 (38 ref.)

Qualitative research methods in health technology assessment: a review of the literature. Murphy E, et al. **Health Technol Assess** 1998;2(16):iii–ix, 1–274 (785 ref.)

Technology assessment of magnetic resonance angiography. Why pretty pictures are not enough: an overview. Flamm CR. **Invest Radiol** 1998 Sep;33(9):547–52 (19 ref.)

ORGANIZATION & ADMINISTRATION

Health care technology in public health institutions in Kenya. Ogembo–Kachieng'a M. **East Afr Med J** 1998 Nov; 75(11):632–6 (20 ref.)

Harnessing innovative technologies: what can you do with a shoe? Brennan PF. **Nurs Outlook** 1999 May–Jun; 47(3):128–32 (14 ref.)

Simulation studies: a new method of prospective technology assessment and design. Kumbruck C, et al. **Qual Life Res** 1999;8(1–2):161–70 (10 ref.)

STANDARDS

Ethical issues in technology assessment. Conceptual categories and procedural considerations. Heitman E. **Int J Technol Assess Health Care** 1998 Summer; 14(3):544–66 (88 ref.)

TRENDS

Trends in assessment of IT-based solutions in healthcare and recommendations for the future. Brender J. **Int J Med Inf** 1998 Oct–Dec;52(1–3):217–27 (74 ref.)

TECHNOLOGY, FOOD see **FOOD TECHNOLOGY**

TECHNOLOGY, MEDICAL

Neonatal viability in the 1990s: held hostage by technology. Muraskas J, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):160–70; discussion 170–2 (43 ref.)

Qualitative research methods in health technology assessment: a review of the literature. Murphy E, et al. **Health Technol Assess** 1998;2(16):iii–ix, 1–274 (785 ref.)

Technology and family-centered perinatal care: conflict or synergy? Gordin P, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):401–8 (28 ref.)

Prescriptions: autonomy, humanism and the purpose of health technology. Krakauer EL. **Theor Med Bioeth** 1998 Dec; 19(6):525–45 (27 ref.)

The role of science in medicine. Nordin I. **Theor Med Bioeth** 1999 Jun;20(3):229–44 (18 ref.)

[Early warning systems. Is it sufficient to be watchful prior to introduction of new medical technology?] Werkö L. **Lakartidningen** 1999 Jul 14;96(28–29):3265–7 (14 ref.) **(Swe)**

ORGANIZATION & ADMINISTRATION

Health care technology in public health institutions in Kenya. Ogembo–Kachieng'a M. **East Afr Med J** 1998 Nov; 75(11):632–6 (20 ref.)

Multiple-perspectives model of medical technology. Geisler E. **Health Care Manage Rev** 1999 Summer;24(3):55–63 (29 ref.)

TRENDS

Computerized physiologic monitoring. Booth FV. **Crit Care Clin** 1999 Jul;15(3):547–62, vi (40 ref.)

Bacteremia in the intensive care unit: a predicament propagated by progress [editorial; comment] Willy ME, et al. **Crit Care Med** 1999 Aug;27(8):1648–50 (12 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1421–8.

Endoscope technology in the future. Terada M. **Endoscopy** 1998 Nov;30(9):A190–3 (4 ref.)

Nurse versus machine: slaves or masters of technology? Buus–Frank M. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):433–41 (42 ref.)

Experimental pathology and breast cancer genetics: new technologies. Osin P, et al. **Recent Results Cancer Res** 1998; 152:35–48 (37 ref.)

TECHNOLOGY, MEDICAL LABORATORY

see related
LABORATORY TECHNIQUES AND PROCEDURES

INSTRUMENTATION

[Progress in molecular medicine: "laser capture microdissection" (see comments)] Bornstein SR, et al. **Med Klin** 1998 Dec 15;93(12):739–43 (29 ref.) (Eng. Abstr.) Comment in: Med Klin 1998 Dec 15;93(12):738. **(Ger)**

METHODS

Murine mentors: transgenic and knockout models of surgical disease. Arbeit JM, et al. **Ann Surg** 1999 Jan;229(1):21–40 (166 ref.)

TECHNOLOGY, PHARMACEUTICAL

Near-infrared spectroscopy in the pharmaceutical industry. Blanco M, et al. **Analyst** 1998 Aug;123(8):135R–150R (204 ref.)

Neural networks in multivariate calibration. Despagne F, et al. **Analyst** 1998 Nov;123(11):157R–178R (99 ref.)

The role of metabolic engineering in the production of secondary metabolites. Nielsen J. **Curr Opin Microbiol** 1998 Jun;1(3):330–6 (43 ref.)

Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents. **Dev Biol Stand** 1998; 93:133–4 (0 ref.)

Drug development for stroke: importance of protecting cerebral white matter. Dewar D, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):41–50 (67 ref.)

An overview of chemotherapeutic targets for antimalarial drug discovery. Olliaro PL, et al. **Pharmacol Ther** 1999 Feb;81(2):91–110 (206 ref.)

Chimaeric G alpha proteins: their potential use in drug discovery [published erratum appears in Trends Pharmacol Sci 1999 Jun;20(6):252] Milligan G, et al. **Trends Pharmacol Sci** 1999 Mar;20(3):118–24 (42 ref.)

[Biological calculation methods and their application in pharmaceutical science] Massart DL. **Verh K Acad Geneeskd Belg** 1998;60(6):535–64; discussion 564–5 (22 ref.) (Eng. Abstr.) **(Dut)**

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (1): The role of general/safety pharmacology studies in the development of pharmaceuticals: international harmonization of guidelines] Fujimori K. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):31–40 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Pharmacological evaluation of the development candidate] Nagao T. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):15–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (2): Pharmacokinetics] Ohno Y. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):41–5 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Proteomics in pharmaceutical industry] Blackstock WP, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2214–21 (46 ref.) **(Jpn)**

METHODS

Combinatorial biosynthesis for new drug discovery. Hutchinson CR. **Curr Opin Microbiol** 1998 Jun;1(3):319–29 (74 ref.)

Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Adamson SR. **Dev Biol Stand** 1998;93:89–96 (18 ref.)

STANDARDS

Residual host cell protein from continuous cell lines. Effect on the safety of protein pharmaceuticals. Lupker JH. **Dev Biol Stand** 1998;93:61–4 (19 ref.)

TRENDS

CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back. Paul S. **Br J Psychiatry Suppl** 1999;(37):23–5 (17 ref.)

Multi-component methodologies in solid-phase organic synthesis. Dax SL, et al. **Curr Med Chem** 1999 Mar; 6(3):255–70 (29 ref.)

[The trends of new drug development in the 21st century] Mizushima Y. **Nippon Yakurigaku Zasshi** 1999 Jan; 113(1):7–14 (20 ref.) (Eng. Abstr.) **(Jpn)**

TECHNOLOGY, PHARMACY see **TECHNOLOGY, PHARMACEUTICAL**

TECHNOLOGY, RADIOLOGIC

Caring for elderly patients who have paranoia. Davidhizar R, et al. **Radiol Technol** 1999 May–Jun;70(5):461–4 (18 ref.)

INSTRUMENTATION

Principles of digital radiography with large-area,

TECHNOLOGY, RADIOLOGIC

electronically readable detectors: a review of the basics. Chotas HG, et al. **Radiology** 1999 Mar;210(3):595–9 (21 ref.)

STANDARDS

Ethics and law for the radiologic technologist. Lynn SD. **Radiol Technol** 1999 Jan–Feb;70(3):257–66; quiz 267–9 (22 ref.)

TRENDS

Recent advances: diagnostic radiology. Hawnsur J. **BMJ** 1999 Jul 17;319(7203):168–71 (35 ref.)

The development of x-ray imaging to study renal function. Lerman LO, et al. **Kidney Int** 1999 Feb;55(2):400–16 (101 ref.)

TECTUM MESENCEPHALI see **CORPORA QUADRIGEMINA**

TEENAGE PREGNANCY see **PREGNANCY IN ADOLESCENCE**

TEETHING see **TOOTH ERUPTION**

TEFLON see **POLYTETRAFLUOROETHYLENE**

TEGAFUR

ADVERSE EFFECTS

Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. Ohara S, et al. **Acta Neuropathol (Berl)** 1998 Nov;96(5):527–31 (18 ref.)

PHARMACOLOGY

Clinical implications of dihydropyrimidine dehydrogenase inhibition. Diasio RB. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):17–21 (33 ref.)

THERAPEUTIC USE

UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM, et al. **Anticancer Drugs** 1998 Jul;9(6):479–90 (90 ref.)

Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. Sulkes A, et al. **J Clin Oncol** 1998 Oct; 16(10):3461–75 (72 ref.)

Oral 5-FU analogues in the treatment of breast cancer. Bunnell CA, et al. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):39–43 (33 ref.)

TEICHOMYCIN see **TEICOPLANIN**

TEICOPLANIN

PHARMACOLOGY

Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. MacGowan AP. **Ther Drug Monit** 1998 Oct;20(5):473–7 (59 ref.)

THERAPEUTIC USE

A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours. Davies JM. **Infection** 1998 Nov–Dec;26(6):389–95 (54 ref.)

Infective endocarditis and glycopeptides. Pittet D, et al. **J Infect** 1998 Sep;37(2):127–35 (50 ref.)

[Teicoplanin. New treatment potentials for gram-positive infections in the hospital (editorial)] Iakovlev SV. **Antibiot Khimioter** 1999;44(2):3–7 (10 ref.) **(Rus)**

TELANGIECTASIA, HEREDITARY HEMORRHAGIC

Hereditary hemorrhagic telangiectasias: a challenge for the clinician. Bergler W, et al. **Eur Arch Otorhinolaryngol** 1999; 256(1):10–5 (70 ref.)

[Hereditary hemorrhagic telangiectasia] Kumagai T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):391–3 (9 ref.) **(Jpn)**

GENETICS

Genetic abnormalities in hereditary hemorrhagic telangiectasia. Marchuk DA. **Curr Opin Hematol** 1998 Sep; 5(5):332–8 (54 ref.)

Hereditary hemorrhagic telangiectasia with juvenile polyposis--coincidence or linked autosomal dominant inheritance? Ballauff A, et al. **Z Gastroenterol** 1999 May; 37(5):385–8 (15 ref.)

THERAPY

Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Shovlin CL, et al. **Thorax** 1999 Aug;54(8):714–29 (193 ref.)

TELANGIECTASIS

CONGENITAL

[Primary cerebral hemiatrophy associated with other malformations. A case report] Martí Aromir G, et al. **An Esp Pediatr** 1998 Sep;49(3):305–7 (12 ref.) **(Spa)**

DIAGNOSIS

Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119–31, x (64 ref.)

ETIOLOGY

Saphenous vein graft ectasia: an unusual late complication of coronary artery bypass surgery. A case report. Sharifi M, et al. **Angiology** 1999 Jun;50(6):497–501 (16 ref.)

Reticular veins, incompetent reticular veins, and their relationship to telangiectases. Green D. **Dermatol Surg** 1998 Oct;24(10):1129–40; discussion 1140–1 (2 ref.)

SURGERY

The krypton yellow-green laser for the treatment of facial vascular and pigmented lesions. Patel BC. **Semin Ophthalmol** 1998 Sep;13(3):158–70 (7 ref.)

THERAPY

Pitfalls in the evaluation of ablative therapy for telangiectases. Green D. **Dermatol Surg** 1998 Oct; 24(10):1143–5; discussion 1145–6 (8 ref.)

TELECOMMUNICATION NETWORKS see **COMPUTER COMMUNICATION NETWORKS**

TELECOMMUNICATIONS

see related
COMPUTER COMMUNICATION NETWORKS

LEGISLATION & JURISPRUDENCE

Biomedical concerns in wireless communications. Stuchly MA. **Crit Rev Biomed Eng** 1998;26(1-2):117–51 (115 ref.)

ORGANIZATION & ADMINISTRATION

Synchronous communication technology tools in practice--future and current uses. Miller PA, et al. **Comput Nurs** 1998 Nov–Dec;16(6):303–6 (13 ref.)

STANDARDS

Simulation studies: a new method of prospective technology assessment and design. Kumbruck C, et al. **Qual Life Res** 1999;8(1-2):161–70 (10 ref.)

TRENDS

Biomedical concerns in wireless communications. Stuchly MA. **Crit Rev Biomed Eng** 1998;26(1-2):117–51 (115 ref.)

TELECOMMUNICATIONS, SATELLITE see **SATELLITE COMMUNICATIONS**

TELECONFERENCE see **TELECOMMUNICATIONS**

TELECONSULTATION see **REMOTE CONSULTATION**

TELEGRAPHY see **TELECOMMUNICATIONS**

TELEMEDICINE

see related
TELEMETRY

A telehealth odyssey. Chaffee M. **Am J Nurs** 1999 Jul; 99(7):27–32; quiz 32–3 (10 ref.)

A distributed system for diabetic patient management. Bellazzi R, et al. **Comput Methods Programs Biomed** 1998 May;56(2):93–107 (27 ref.)

Telemedicine: a new dimension in the practice of medicine. Zajtchuk R, et al. **Dis Mon** 1999 Jun;45(6):197–262 (55 ref.)

Telemedicine: an overview. **Health Devices** 1999 Mar; 28(3):88–103 (34 ref.)

The use of videoconferencing for telepsychiatry in Finland. Mielonen ML, et al. **J Telemed Telecare** 1998;4(3):125–31 (21 ref.)

Telemedicine and ophthalmology. Li HK. **Surv Ophthalmol** 1999 Jul–Aug;44(1):61–72 (76 ref.)

[The Virtual University applied to telesurgery: from tele-education to tele-manipulation] Marescaux J, et al. **Bull Acad Natl Med** 1999;183(3):509–21; discussion 521–2 (10 ref.) (Eng. Abstr.) **(Fre)**

[Telemedical support in emergency medicine] Toshio U, et al. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):455–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Video transmission for telemedicine. Squibb NJ. **J Telemed Telecare** 1999;5(1):1–10 (11 ref.)

LEGISLATION & JURISPRUDENCE

The legal and ethical aspects of telemedicine. 4: Product liability and jurisdictional problems. Stanberry B. **J Telemed Telecare** 1998;4(3):132–9 (39 ref.)

METHODS

Home telecare. Ruggiero C, et al. **J Telemed Telecare** 1999; 5(1):11–7 (17 ref.)

"Telestroke" : the application of telemedicine for stroke. Levine SR, et al. **Stroke** 1999 Feb;30(2):464–9 (74 ref.)

The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)

ORGANIZATION & ADMINISTRATION

Telemedicine and telepharmacy: current status and future implications. Angaran DM. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1405–26 (128 ref.)

[Telemedicine] Abetti P, et al. **Ann Ig** 1997 Sep–Oct; 9(5):407–16 (12 ref.) **(Ita)**

TRENDS

Present technology and future applications. Bailes JE. **Clin Neurosurg** 1999;45:192–201 (16 ref.)

Telemedicine in the NHS for the millennium and beyond. Wallace S, et al. **Postgrad Med J** 1998 Dec;74(878):721–8 (49 ref.)

[Telematic and surgery: methods, terminology and instructions] Demartines N, et al. **Swiss Surg** 1999;5(2):73–9 (51 ref.) (Eng. Abstr.) **(Fre)**

[Psychiatry and psychotherapy on the internet. Current overview] Seemann O, et al. **Nervenarzt** 1999 Jan; 70(1):76–80 (17 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

Home telecare in the United States. Kinsella A. **J Telemed Telecare** 1998;4(4):195–200 (27 ref.)

TELEMETRY

see related
TELEMEDICINE

INSTRUMENTATION

Taking advantage of sophisticated pacemaker diagnostics. Nowak B. **Am J Cardiol** 1999 Mar 11;83(5B):172D–179D (22 ref.)

Instrumentation for the remote monitoring of physiological and behavioral variables. Andrews RD. **J Appl Physiol** 1998 Nov;85(5):1974–81 (12 ref.)

TELENCEPHALON

ANATOMY & HISTOLOGY

The dopaminergic innervation of the avian telencephalon. Durstewitz D, et al. **Prog Neurobiol** 1999 Oct;59(2):161–95 (271 ref.)

METABOLISM

Nitrinergic neurons in the developing and adult human telencephalon: transient and permanent patterns of expression in comparison to other mammals. Judas M, et al. **Microsc Res Tech** 1999 Jun 15;45(6):401–19 (178 ref.)

PHYSIOLOGY

Developmental and aging aspects of the cholinergic innervation of the olfactory bulb. Durand M, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):777–85 (93 ref.)

The dopaminergic innervation of the avian telencephalon. Durstewitz D, et al. **Prog Neurobiol** 1999 Oct;59(2):161–95 (271 ref.)

TELEOLOGICAL ETHICS see **ETHICS**

TELEPATHINE see **HARMINE**

TELEPATHOLOGY

Telepathology and pathology at distance: an overview. Jukić DM, et al. **Croat Med J** 1999 Sep;40(3):421–4 (45 ref.)

TELEPHONE

Telephone monitoring after early discharge for cardiac surgery patients. Savage LS, et al. **Am J Crit Care** 1999 May;8(3):154–9 (14 ref.)

Ambulatory obstetrical care: strategies to reduce telephone liability. Phelan JP. **Clin Obstet Gynecol** 1998 Sep; 41(3):640–6 (22 ref.)

Biological effects of amplitude-modulated radiofrequency radiation [see comments] Juutilainen J, et al. **Scand J Work Environ Health** 1998 Aug;24(4):245–54 (64 ref.) Comment in: Scand J Work Environ Health 1998 Aug;24(4):241–3.

[Effects of the microwave radiation from the cellular phones on humans and animals] Galeev AL. **Ross Fiziol Zh Im I M Sechenova** 1998 Nov; 84(11):1293–302 (42 ref.) (Eng. Abstr.) **(Rus)**

[ELectro-trauma by lightning through the telephone (letter)] Santonja JM, et al. **Rev Neurol** 1998 Dec;27(160):1073 (11

ref.) (Spa)

TELERADIOISOTOPE THERAPY see **RADIOISOTOPE TELETHERAPY**

TELERADIOLOGY

Wide area networking in nuclear cardiology. Bateman TM, et al. **J Nucl Cardiol** 1999 Mar-Apr;6(2):211-8 (22 ref.)
Use of digital cameras for radiographs: how to get the best pictures. Whitehouse RW. **J R Soc Med** 1999 Apr; 92(4):178-82 (6 ref.)
[Clinical computer applications in the radiology department] Ando Y. **Rinsho Byori** 1999 Feb;47(2):111-8 (15 ref.) (Eng. Abstr.) (Jpn)

METHODS

Application of the advanced communications technology satellite to teleradiology and real-time compressed ultrasound video telemedicine. Stewart BK, et al. **J Digit Imaging** 1999 May;12(2):68-76 (12 ref.)

TRENDS

The use of teleradiology in an emergency setting with speculation on the near future. Baker SR, et al. **Radiol Clin North Am** 1999 Sep;37(5):1035-44 (19 ref.)

TELEROBOTICS see **ROBOTICS**

TELEVISION

Video transmission for telemedicine. Squibb NJ. **J Telemed Telecare** 1999;5(1):1-10 (11 ref.)
Children, adolescents, and the media: issues and solutions. Strasburger VC, et al. **Pediatrics** 1999 Jan;103(1):129-39 (156 ref.)

TELLURIUM

PHARMACOLOGY

Bacterial tellurite resistance. Taylor DE. **Trends Microbiol** 1999 Mar;7(3):111-5 (21 ref.)

TELOMERASE

Telomere structure, replication and length maintenance. Muniyappa K, et al. **Crit Rev Biochem Mol Biol** 1998; 33(4):297-336 (324 ref.)

ANALYSIS

[Telomerase and cancer: importance of detection of telomerase activity in pathology (editorial)] Brousset P. **Ann Pathol** 1998 Nov;18(5):375-6 (16 ref.) (Fre)
[Telomerase and cancer] Soria JC, et al. **Ann Pathol** 1998 Nov;18(5):391-403 (111 ref.) (Fre)
[Telomerase and telomeres in lung neoplasms--biological and clinical significance] Kuchta G, et al. **Pneumonol Alergol Pol** 1998;66(11-12):568-73 (25 ref.) (Pol)

ANTAGONISTS & INHIBITORS

For better or worse? Telomerase inhibition and cancer. de Lange T, et al. **Cell** 1999 Aug 6;98(3):273-5 (21 ref.)

CHEMISTRY

Telomerases. O'Reilly M, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):56-65 (66 ref.)

DIAGNOSTIC USE

[Telomerase--its potential and limits for clinical applicability] Hoos A, et al. **Dtsch Med Wochenschr** 1999 Feb 26; 124(8):223-30 (73 ref.) (Ger)

GENETICS

For better or worse? Telomerase inhibition and cancer. de Lange T, et al. **Cell** 1999 Aug 6;98(3):273-5 (21 ref.)
Role of telomerase in cellular proliferation and cancer. Holt SE, et al. **J Cell Physiol** 1999 Jul;180(1):10-8 (104 ref.)
[Telomerase in tumors: facts and perspectives] Rohde V, et al. **Urologe A** 1998 Jul;37(4):386-94 (52 ref.) (Eng. Abstr.) (Ger)

METABOLISM

Telomerase activity in cancer: a magic bullet or a mirage? Soria JC, et al. **Adv Anat Pathol** 1998 Mar;5(2):86-94 (76 ref.)
Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Vasef MA, et al. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S68-75 (101 ref.)
Telomerase in cancer: clinical applications. Urquidi V, et al. **Ann Med** 1998 Oct;30(5):419-30 (179 ref.)
Genes involved in the control of cellular proliferative potential. Reddel RR. **Ann N Y Acad Sci** 1998 Nov 20; 854:8-19 (83 ref.)
Telomeres: influencing the rate of aging. von Zglinicki T. **Ann N Y Acad Sci** 1998 Nov 20;854:318-27 (58 ref.)
Telomeres and telomerase: more than the end of the line. Pardue ML, et al. **Chromosoma** 1999 May;108(2):73-82 (90 ref.)
Telomerase and the maintenance of chromosome ends. Bryan TM, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):318-24 (61 ref.)
Telomeres and telomerase: broad effects on cell growth. Price CM. **Curr Opin Genet Dev** 1999 Apr;9(2):218-24 (53 ref.)
Three molecular determinants of malignant conversion and their potential as therapeutic targets [published erratum appears in Curr Opin Oncol 1999 Mar;11(2):145] Dome JS, et al. **Curr Opin Oncol** 1999 Jan;11(1):58-67 (112 ref.)
Telomerases. O'Reilly M, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):56-65 (66 ref.)
Telomeres and telomerase in endocrine pathology. Kontogeorgos G, et al. **Endocrine** 1998 Oct;9(2):133-8 (50 ref.)
Telomerase activity in experimental animal tumors. Tsujiuchi T, et al. **Exp Toxicol Pathol** 1998 Sep;50(4-6):371-4 (16 ref.)
Do human normal somatic cells lack telomerase activity? [letter] Güll, et al. **Gynecol Oncol** 1999 Jul;74(1):147; discussion 147-8 (5 ref.)
Applications of telomerase research in the fight against cancer. McKenzie KE, et al. **Mol Med Today** 1999 Mar; 5(3):114-22 (65 ref.)
Crisis intervention: the role of telomerase [comment] Lustig AJ. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3339-41 (38 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Dec 8;95(25):14723-8. Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3723-8.
Telomerase activation. One step on the road to cancer? Greider CW. **Trends Genet** 1999 Mar;15(3):109-12 (68 ref.)
[Telomerase and gastrointestinal cancer (editorial)] Długosz A, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):57-9 (35 ref.) (Eng. Abstr.) (Pol)

PHYSIOLOGY

Telomerase enzyme activation and human cell immortalization. Meyerson M. **Toxicol Lett** 1998 Dec 28; 102-103:41-5 (44 ref.)
Telomeres and telomerase: at the end, it all comes together. Evans SK, et al. **Trends Cell Biol** 1999 Aug;9(8):329-31 (14 ref.)

URINE

Urinary telomerase and its possible role as a marker for bladder cancer. Droller MJ, et al. **Keio J Med** 1998 Sep; 47(3):135-41 (42 ref.)

TELOMERE

Telomeres and telomerase: more than the end of the line. Pardue ML, et al. **Chromosoma** 1999 May;108(2):73-82 (90 ref.)
Telomeres: structure of a chromosome's aglet. Gottschling DE, et al. **Curr Biol** 1999 Mar 11;9(5):R164-7 (29 ref.)
Telomeres and telomerase: broad effects on cell growth. Price CM. **Curr Opin Genet Dev** 1999 Apr;9(2):218-24 (53 ref.)
Telomeres and telomerase in endocrine pathology. Kontogeorgos G, et al. **Endocrine** 1998 Oct;9(2):133-8 (50 ref.)
[Telomeric retrotransposon HeT-A and its role in forming Drosophila telomeres] Danilevskaia ON, et al. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):38-47 (31 ref.) (Rus)

GENETICS

Telomeres and essential hypertension. Aviv A, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):427-32 (56 ref.)
De novo inverted duplication 9p21pter involving telomeric repeated sequences. Sanlaville D, et al. **Am J Med Genet** 1999 Mar 12;83(2):125-31 (11 ref.)
Role of the telomeric DNA-binding protein TRF2 in the stability of human chromosome ends. Ancelin K, et al. **Bioessays** 1998 Nov;20(11):879-83 (40 ref.)
A reassessment of the telomere hypothesis of senescence. Reddel RR. **Bioessays** 1998 Dec;20(12):977-84 (88 ref.)
Telomeres and mechanisms of Robertsonian fusion. Slijepcevic P. **Chromosoma** 1998 May;107(2):136-40 (29 ref.)
Telomerase and the maintenance of chromosome ends. Bryan TM, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):318-24 (61 ref.)
Telomere length regulation--a view from the individual chromosome perspective. Slijepcevic P. **Exp Cell Res** 1998 Oct 10;244(1):268-74 (38 ref.)
Meiotic telomeres: a matchmaker for homologous chromosomes. Hiraoka Y. **Genes Cells** 1998 Jul;3(7):405-13 (55 ref.)
Telomere length, aging, and somatic cell turnover. Hodes RJ. **J Exp Med** 1999 Jul 19;190(2):153-6 (30 ref.)
[Replicative senescence as a model of aging: the role of oxidative stress and telomere shortening--an overview] Saretzki G, et al. **Z Gerontol Geriatr** 1999 Apr;32(2):69-75 (84 ref.) (Eng. Abstr.) (Ger)

METABOLISM

Telomere maintenance mechanisms and cellular immortalization [published erratum appears in Curr Opin Genet Dev 1999 Apr;9(2):247] Colgin LM, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):97-103 (100 ref.)

PATHOLOGY

The role of telomeres in ageing and cancer. Mera SL. **Br J Biomed Sci** 1998 Sep;55(3):221-5 (18 ref.)

PHYSIOLOGY

Telomeres: influencing the rate of aging. von Zglinicki T. **Ann N Y Acad Sci** 1998 Nov 20;854:318-27 (58 ref.)
Cytological and functional aspects of telomere maintenance. Dandjinou AT, et al. **Histol Histopathol** 1999 Apr; 14(2):517-24 (77 ref.)
Telomeres and telomerase: at the end, it all comes together. Evans SK, et al. **Trends Cell Biol** 1999 Aug;9(8):329-31 (14 ref.)
[Telomerase and telomeres in lung neoplasms--biological and clinical significance] Kuchta G, et al. **Pneumonol Alergol Pol** 1998;66(11-12):568-73 (25 ref.) (Pol)

ULTRASTRUCTURE

Telomeres do D-loop-T-loop [comment] Greider CW. **Cell** 1999 May 14;97(4):419-22 (21 ref.) Comment on: Cell 1999 May 14;97(4):503-14.

TEMPERAMENT

Toward a definition of generalized anxiety disorder as an anxious temperament type. Akiskal HS. **Acta Psychiatr Scand Suppl** 1998;393:66-73 (50 ref.)
Towards a genetics of anxious temperament: from mice to men. Gershenfeld HK, et al. **Acta Psychiatr Scand Suppl** 1998;393:56-65 (109 ref.)

DRUG EFFECTS

The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? Healy D, et al. **J Affect Disord** 1998 Dec; 51(3):313-22 (57 ref.)

TEMPERANCE

PSYCHOLOGY

Craving and relapse measurement in alcoholism. Potgieter AS, et al. **Alcohol Alcohol** 1999 Mar-Apr;34(2):254-60 (30 ref.)

TEMPERATURE

see related
BODY TEMPERATURE

International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297-308 (28 ref.)
Temperature-dependent sex determination and gonadal differentiation in reptiles. Pieau C, et al. **Cell Mol Life Sci** 1999 Jun;55(6-7):887-900 (92 ref.)
Clinical effectiveness of low-temperature sterilization technologies. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):798-804 (27 ref.)
Temperature sensing in bacterial gene regulation--what it all boils down to. Hurme R, et al. **Mol Microbiol** 1998 Oct;30(1):1-6 (40 ref.)
[Global warming and communicable diseases] Yu C, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Apr; 19(2):114-7 (16 ref.) (Chi)

TEMPERATURE SENSE

PHYSIOLOGY

Reliability of cephalic thermal thresholds in healthy subjects. Becser N, et al. **Cephalalgia** 1998 Oct;18(8):574-82 (45 ref.)

TEMPLATE BLEEDING TIME see **BLEEDING TIME**

TEMPORAL ARTERIES

Atherosclerotic superficial temporal artery aneurysm: report of a case. Uchida N, et al. **Surg Today** 1999;29(6):575-8 (31 ref.)

INJURIES

Traumatic aneurysms of the face and temple: a patient report and literature review, 1644 to 1998. Conner WC 3rd, et al. **Ann Plast Surg** 1998 Sep;41(3):321-6 (84 ref.)

TEMPORAL ARTERITIS

see related
POLYMYALGIA RHEUMATICA

COMPLICATIONS

Update in pathology: temporal arteritis and its ocular manifestations. Heathcote JG. **Can J Ophthalmol** 1999 Apr; 34(2):63-8 (37 ref.)

TEMPORAL ARTERITIS

DIAGNOSIS

Bilateral internuclear ophthalmoplegia: an initial presenting sign of giant cell arteritis. Ahmad I, et al. **J Am Geriatr Soc** 1999 Jun;47(6):734–6 (30 ref.)

[Otorhinolaryngologic findings in Horton temporal arteritis. Review of the literature and case report] Schmidt D, et al. **HNO** 1999 Mar;47(3):176–82 (119 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

[Principles of acute treatment of Horton's disease. Role of high-dose corticosteroid therapy] Barrier JH, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):448–53 (34 ref.) (Eng. Abstr.) **(Fre)**

[Immunosuppressive agents in Horton's disease. Which drug for which indication?] Roblot P. **Ann Med Interne (Paris)** 1998 Nov;149(7):441–7 (45 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

[Epidemiology and etiological factors in giant cell arteritis (Horton's disease and Takayasu's disease)] Emmerich J, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):425–32 (77 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Arterial wall injury in giant cell arteritis. Weyand CM, et al. **Arthritis Rheum** 1999 May;42(5):844–53 (74 ref.)

[Epidemiology and etiological factors in giant cell arteritis (Horton's disease and Takayasu's disease)] Emmerich J, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):425–32 (77 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Giant cell arteritis--a molecular approach to the multiple facets of the syndrome. Weyand CM, et al. **Ann Med Interne (Paris)** 1998 Nov;149(7):420–4 (24 ref.)

PATHOLOGY

Actinically degenerate elastic tissue is the likely antigenic basis of actinic granuloma of the skin and of temporal arteritis. O'Brien JP, et al. **J Am Acad Dermatol** 1999 Feb; 40(2 Pt 1):214–22 (62 ref.)

Infantile disseminated visceral giant cell arteritis presenting as sudden infant death. Kagata Y, et al. **Pathol Int** 1999 Mar;49(3):226–30 (19 ref.)

[Pathology of giant cell arteritis] Amouroux J. **Ann Med Interne (Paris)** 1998 Nov;149(7):415–9 (18 ref.) (Eng. Abstr.) **(Fre)**

[Giant cell arteritis and necrosis of the small intestine. Report of a case] Tozzi N, et al. **J Mal Vasc** 1998 Oct;23(4):293–6 (28 ref.) (Eng. Abstr.) **(Fre)**

TEMPORAL BONE

see related

LABYRINTH

Giant cell tumors of the jugular foramen. Rosenbloom JS, et al. **Am J Otolaryngol** 1999 May–Jun;20(3):176–9 (20 ref.)

A case of bilateral eosinophilic granuloma in the temporal bone. Akisada T, et al. **Auris Nasus Larynx** 1999 Jul; 26(3):343–8 (24 ref.)

The molecular pathology of tumours of the ear and temporal bone. Irving RM. **J Laryngol Otol** 1998 Nov;112(11):1011–8 (74 ref.)

Meningiomas presenting in the temporal bone: the pathways of spread from an intracranial site of origin. Chang CY, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):658–64 (31 ref.)

Giant cell tumor of the skull. Lee JA, et al. **Radiographics** 1998 Sep–Oct;18(5):1295–302 (11 ref.)

ABNORMALITIES

Unusual sinus of the styloid process. Schick B, et al. **Eur Arch Otorhinolaryngol** 1998;255(9):478–81 (8 ref.)

ANATOMY & HISTOLOGY

Bones of contention. The supply of temporal bones for dissection: the legalities, problems and solutions. Morris DP, et al. **J Laryngol Otol** 1998 Dec;112(12):1138–41 (14 ref.)

INJURIES

Management of facial nerve injury due to temporal bone trauma. Chang CY, et al. **Am J Otol** 1999 Jan;20(1):96–114 (56 ref.)

PATHOLOGY

Temporal bone and lateral skull base malignancy: experience and results with 81 patients. Manolidis S, et al. **Am J Otol** 1998 Nov;19(6 Suppl):S1–15 (787 ref.)

Antigen retrieval immunohistochemistry used for routinely processed celloidin-embedded human temporal bone sections: standardization and development. Shi SR, et al. **Auris Nasus Larynx** 1998 Dec;25(4):425–43 (148 ref.)

Temporal dermoid with intracranial extension: report of a case. Niederhagen B, et al. **J Oral Maxillofac Surg** 1998 Nov;56(11):1352–4 (20 ref.)

Imaging of pediatric temporal bone abnormalities. Robson CD, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):133–55 (95 ref.)

RADIOGRAPHY

The syndrome of elongated styloid process. Ghosh LM, et al. **Auris Nasus Larynx** 1999 Apr;26(2):169–75 (28 ref.)

SURGERY

Percutaneous implants in the temporal bone for securing a bone conductor: surgical methods and results. van der Pouw CT, et al. **Ann Otol Rhinol Laryngol** 1999 Jun; 108(6):532–6 (18 ref.)

TEMPORAL LOBE

Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review. Swartz RH, et al. **Can J Neurol Sci** 1999 May;26(2):77–88 (190 ref.)

[Frontotemporal dementia] Doval O, et al. **Actas Esp Psiquiatr** 1999 Mar–Apr;27(2):111–26 (144 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

The planum temporale: a systematic, quantitative review of its structural, functional and clinical significance. Shapleske J, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):26–49 (142 ref.)

Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Schacter DL, et al. **Hippocampus** 1999;9(1):7–24 (86 ref.)

METABOLISM

Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias. Delacourte A. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:75–9 (19 ref.)

Tau mutations in frontotemporal dementia. Wilhelmsen KC, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:88–92 (28 ref.)

Tau mutations cause frontotemporal dementias. Goedert M, et al. **Neuron** 1998 Nov;21(5):955–8 (20 ref.)

PATHOLOGY

Magnetic resonance imaging and temporal lobe epilepsy. King D, et al. **Acta Neurol Scand** 1998 Oct;98(4):217–23 (70 ref.)

Upper motor neuron predominant degeneration with frontal and temporal lobe atrophy. Konagaya M, et al. **Acta Neuropathol (Berl)** 1998 Nov;96(5):532–6 (22 ref.)

Ventromedial temporal lobe pathology in dementia, brain trauma, and schizophrenia. Van Hoesen GW, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:575–94 (96 ref.)

Febrile convulsions and mesial temporal sclerosis. Lewis DV. **Curr Opin Neurol** 1999 Apr;12(2):197–201 (39 ref.)

Neurons and their dendrites in frontotemporal dementia. Ferrer I. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:55–60 (15 ref.)

MR contribution in surgery of epilepsy. Meiners LC, et al. **Eur Radiol** 1999;9(3):493–507 (57 ref.)

Frontotemporal dementia genetics. Wilhelmsen KC. **J Geriatr Psychiatry Neurol** 1998 Summer;11(2):55–60 (65 ref.)

Temporal dermoid with intracranial extension: report of a case. Niederhagen B, et al. **J Oral Maxillofac Surg** 1998 Nov;56(11):1352–4 (20 ref.)

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neary D, et al. **Neurology** 1998 Dec; 51(6):1546–54 (48 ref.)

Surgical pathology of epilepsy resections in childhood. Jay V, et al. **Semin Pediatr Neurol** 1995 Sep;2(3):227–36 (64 ref.)

[Hippocampal pathology in dementia patients with amyotrophic lateral sclerosis] Okamoto K. **No To Shinkei** 1998 Oct;50(10):915–22 (27 ref.) **(Jpn)**

[Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP 17)] Nakano I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):20–3 (14 ref.) **(Jpn)**

[Mesial temporal sclerosis (II): clinical features and complementary studies] Serrano-Castro PJ, et al. **Rev Neurol** 1998 Apr;26(152):592–7 (72 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The planum temporale: a systematic, quantitative review of its structural, functional and clinical significance. Shapleske J, et al. **Brain Res Brain Res Rev** 1999 Jan;29(1):26–49 (142 ref.)

A neuronal model of attentional spotlight: parietal guiding the temporal. Vidyasagar TR. **Brain Res Brain Res Rev** 1999 Jul;30(1):66–76 (104 ref.)

Evidence accumulation in cell populations responsive to faces: an account of generalisation of recognition without mental transformations. Perrett DI, et al. **Cognition** 1998 Jul;67(1–2):111–45 (105 ref.)

Object vision and visual awareness. Logothetis N. **Curr Opin Neurobiol** 1998 Aug;8(4):536–44 (67 ref.)

Correlation between mesial temporal and temporal neocortical interictal spiking in acute ECoG and chronic depth electrode recordings. Wennberg RA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:123–31 (52 ref.)

Interaction between superficial layers of the entorhinal cortex and the hippocampus in normal and epileptic temporal lobe. Gloveli T, et al. **Epilepsy Res** 1998 Sep;32(1–2):183–93 (81 ref.)

Automatic activation of the medial temporal lobe during encoding: lateralized influences of meaning and novelty. Martin A. **Hippocampus** 1999;9(1):62–70 (57 ref.)

Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Schacter DL, et al. **Hippocampus** 1999;9(1):7–24 (86 ref.)

Bridging the gap: integrating cellular and functional magnetic resonance imaging studies of the hippocampus. Stern CE, et al. **Hippocampus** 1999;9(1):45–53 (103 ref.)

Positron emission tomography correlations in and beyond medial temporal lobes. Tulving E, et al. **Hippocampus** 1999; 9(1):71–82 (75 ref.)

Neuronal tuning and associative mechanisms in form representation. Sakai K, et al. **Learn Mem** 1994 Jul–Aug; 1(2):83–105 (137 ref.)

Firing rate distributions and efficiency of information transmission of inferior temporal cortex neurons to natural visual stimuli. Treves A, et al. **Neural Comput** 1999 Apr 1;11(3):601–32 (39 ref.)

Images of medial temporal lobe functions in human learning and memory. Gabrieli JD, et al. **Neurobiol Learn Mem** 1998 Jul–Sep;70(1–2):275–83 (51 ref.)

Functional anatomy of dominance for speech comprehension in left handers vs right handers. Tzourio N, et al. **Neuroimage** 1998 Jul;8(1):1–16 (100 ref.)

Visual recognition based on temporal cortex cells: viewer-centred processing of pattern configuration. Perrett DI, et al. **Z Naturforsch [C]** 1998 Jul–Aug;53(7–8):518–41 (108 ref.)

PHYSIOPATHOLOGY

Frontal, temporal and lateralized brain function in children with attention-deficit hyperactivity disorder: a psychophysiological and neuropsychological viewpoint on development. Oades RD. **Behav Brain Res** 1998 Jul; 94(1):83–95 (131 ref.)

Experimental partial epileptogenesis. Bausch SB, et al. **Curr Opin Neurol** 1999 Apr;12(2):203–9 (81 ref.)

Cognition, language and behaviour in motor neurone disease: evidence of frontotemporal dysfunction. Bak TH, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:29–32 (37 ref.)

Frontotemporal dementia and Alzheimer's disease: differential diagnosis. Duara R, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:37–42 (26 ref.)

Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Kertesz A, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:46–9 (33 ref.)

Overview of frontotemporal dementias and the consensus applied. Neary D. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:6–9 (11 ref.)

Semantic dysfunction in frontotemporal lobar degeneration. Snowden JS. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:33–6 (8 ref.)

Behavioral symptomatology and care of patients with frontotemporal lobe degeneration - based on the aspects of the phylogenetic and ontogenetic processes. Tanabe H, et al. **Dement Geriatr Cogn Disord** 1999;10 Suppl 1:50–4 (22 ref.)

Role of ECoG in 'en bloc' temporal lobe resection: the Maudsley experience. Binnie CD, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998;48:17–23 (10 ref.)

RADIOGRAPHY

Positron emission tomography correlations in and beyond medial temporal lobes. Tulving E, et al. **Hippocampus** 1999; 9(1):71–82 (75 ref.)

SURGERY

Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Klein R, et al. **Childs Nerv Syst** 1998 Jun;14(6):288–91 (23 ref.)

Analysis of outcome: temporal lobe resection. Pilcher WH, et al. **Clin Neurosurg** 1997;44:401–21 (50 ref.)

TEMPORAL MUSCLE

TRANSPLANTATION

[The use of the temporal muscle for closing postoperative wounds] Belov AI, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct–Dec; (4):51–4 (22 ref.) (Eng. Abstr.) **(Rus)**

TEMPOROMANDIBULAR JOINT

Destruction of the glenoid joint fossa by a tenosynovial giant-cell tumour of the skull base: a case report. Stojadinovic S, et al. **Int J Oral Maxillofac Surg** 1999 Apr; 28(2):132–4 (11 ref.)

INJURIES

Whiplash injuries of the temporomandibular joint in motor vehicle accidents: speculations and facts. McKay DC, et al. **J Oral Rehabil** 1998 Oct;25(10):731–46 (95 ref.)

PHYSIOLOGY

Physical mechanisms involved in the genesis of temporomandibular joint sounds. Prinz JF. **J Oral Rehabil** 1998 Sep;25(9):706–14 (53 ref.)

PHYSIOPATHOLOGY

Jaws: diversities of gnathological history and temporomandibular joint enterprise. Nelson DA, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):141–7 (80 ref.)

SURGERY

Reconstruction of the temporomandibular joint using calvarial bone after a failed Teflon–Proplast implant. Lee JJ, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):457–61 (14 ref.)

TEMPOROMANDIBULAR JOINT DISORDERS

DIAGNOSIS

Destruction of the glenoid joint fossa by a tenosynovial giant-cell tumour of the skull base: a case report. Stojadinovic S, et al. **Int J Oral Maxillofac Surg** 1999 Apr; 28(2):132–4 (11 ref.)

Chondroblastoma of the temporomandibular region. Goga D, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1270–2 (10 ref.)

Annual review of selected dental literature: report of the Committee on Scientific Investigation of the American Academy of Restorative Dentistry. Allen EP, et al. **J Prosthet Dent** 1999 Jul;82(1):27–66 (309 ref.)

ETIOLOGY

Temporomandibular disorders--an overview. Yap AU, et al. **Singapore Med J** 1999 Mar;40(3):179–82 (14 ref.)

PATHOLOGY

Synovial inflammation in arthroscopically obtained biopsy specimens from the temporomandibular joint: a review of the literature and a proposed histologic grading system. Gynther GW, et al. **J Oral Maxillofac Surg** 1998 Nov; 56(11):1281–6; discussion 1287 (26 ref.)

PHYSIOPATHOLOGY

Jaws: diversities of gnathological history and temporomandibular joint enterprise. Nelson DA, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):141–7 (80 ref.)

SURGERY

Part II: The use of arthrocentesis for treatment of temporomandibular joint disorders. Frost DE, et al. **J Oral Maxillofac Surg** 1999 May;57(5):583–7 (24 ref.)

Part I: The use of arthroscopic surgery for treatment of temporomandibular joint disorders. Israel HA. **J Oral Maxillofac Surg** 1999 May;57(5):579–82 (21 ref.)

Functional restoration by gap arthroplasty in temporomandibular joint ankylosis: a report of 50 cases. Roychoudhury A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):166–9 (15 ref.)

THERAPY

Clinical aspects of orthodontic treatment for children with juvenile chronic arthritis. Pedersen TK. **Acta Odontol Scand** 1998 Dec;56(6):366–8 (32 ref.)

Smallest detectable difference in outcome variables related to painful restriction of the temporomandibular joint. Kropmans TJ, et al. **J Dent Res** 1999 Mar;78(3):784–9 (50 ref.)

Therapeutic outcome assessment in permanent temporomandibular joint disc displacement. Kropmans TJ, et al. **J Oral Rehabil** 1999 May;26(5):357–63 (50 ref.)

Temporomandibular disorders--an overview. Yap AU, et al. **Singapore Med J** 1999 Mar;40(3):179–82 (14 ref.)

TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME

DIAGNOSIS

[Limited mouth opening. Diagnostic indications] Chossegros C, et al. **Rev Prat** 1998 Jun 15;48(12):1373–6 (00 ref.) **(Fre)**

ETIOLOGY

Condylar axis position, as determined by the occlusion and measured by the CPI instrument, and signs and symptoms of temporomandibular dysfunction. Crawford SD. **Angle Orthod** 1999 Apr;69(2):103–15; discussion 115–6 (64 ref.)

Whiplash and temporomandibular disorders: a critical review [see comments] Ferrari R, et al. **J Am Dent Assoc** 1998 Dec;129(12):1739–45 (41 ref.) Comment in: J Am Dent Assoc 1999 Feb;130(2):162, 164; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Feb;130(2):164, 166; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Feb;130(2):166, 168; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Feb;130(2):168; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Mar;130(3):316, 318. Comment in: J Am Dent Assoc 1999 Apr;130(4):468, 470.

Temporomandibular disorders and mandibular function in relation to Class II malocclusion and orthodontic treatment. A controlled, prospective and longitudinal study. Henrikson T. **Swed Dent J Suppl** 1999;134:1–144 (131 ref.)

TEMPOROMANDIBULAR JOINT SYNDROME see **TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME**

TENASCIN

PHYSIOLOGY

The role of tenascin-C and related glycoproteins in early chondrogenesis. Mackie EJ, et al. **Microsc Res Tech** 1998 Oct 15;43(2):102–10 (59 ref.)

TENASCIN-C see **TENASCIN**

TENCH see **CYPRINIDAE**

TENDINITIS

Disorders of the Achilles tendon insertion and Achilles tendinitis. Myerson MS, et al. **Instr Course Lect** 1999; 48:211–8 (52 ref.)

CHEMICALLY INDUCED

Fluoroquinolone-induced tendinopathy: what do we know? Harrell RM. **South Med J** 1999 Jun;92(6):622–5 (26 ref.)

EPIDEMIOLOGY

Risk factors for musculoskeletal disorders among computer users. Tittiranonda P, et al. **Occup Med** 1999 Jan–Mar; 14(1):17–38, iii (73 ref.)

ETIOLOGY

Enthesitis in spondyloarthropathy. McGonagle D, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):244–50 (39 ref.)

Tendinitis and other chronic tendinopathies. Almekinders LC. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):157–64 (20 ref.)

METABOLISM

[The mechanical effects of shock waves in extracorporeal shock wave treatment of calcific tendinitis--an in vitro model] Perlick L, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan–Feb;137(1):10–6 (27 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Histopathology of common tendinopathies. Update and implications for clinical management. Khan KM, et al. **Sports Med** 1999 Jun;27(6):393–408 (145 ref.)

ULTRASONOGRAPHY

Tendon and nerve sonography. Martinoli C, et al. **Radiol Clin North Am** 1999 Jul;37(4):691–711, viii (81 ref.)

TENDON INJURIES

Dislocation of posterior tibial tendon. Loncarich DP, et al. **Foot Ankle Int** 1998 Dec;19(12):821–4 (13 ref.)

Achilles tendon injuries. Saltzman CL, et al. **J Am Acad Orthop Surg** 1998 Sep–Oct;6(5):316–25 (18 ref.)

Closed rupture of the anterior tibial tendon. A case report. Miller RR, et al. **J Am Podiatr Med Assoc** 1998 Aug; 88(8):394–9 (30 ref.)

COMPLICATIONS

The long-term effects of an untreated tibialis anterior tendon rupture [letter] Cohen DA, et al. **J Am Podiatr Med Assoc** 1999 Mar;89(3):149–52 (14 ref.)

DIAGNOSIS

Recurrent dislocation of tibialis posterior tendon. A report of two cases. Miki T, et al. **Arch Orthop Trauma Surg** 1998; 118(1–2):96–8 (7 ref.)

MR imaging of rotator interval, long biceps, and associated injuries in the overhead-throwing athlete. Ho CP. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):23–37 (18 ref.)

Peroneal tendon subluxation in athletes: new exam technique, case reports, and review. Safran MR, et al. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S487–92 (16 ref.)

Magnetic resonance imaging of the peroneal tendons. Mota J, et al. **Top Magn Reson Imaging** 1998 Oct;9(5):273–85 (51 ref.)

ETIOLOGY

Posterior tibial tendon tears in young competitive athletes: two case reports. Porter DA, et al. **Foot Ankle Int** 1998 Sep;19(9):627–30 (12 ref.)

PATHOLOGY

Histopathology of common tendinopathies. Update and implications for clinical management. Khan KM, et al. **Sports Med** 1999 Jun;27(6):393–408 (145 ref.)

PHYSIOPATHOLOGY

Cytokines and the role they play in the healing of ligaments and tendons. Evans CH. **Sports Med** 1999 Aug;28(2):71–6 (43 ref.)

REHABILITATION

Treatment of flexor tendon injuries: therapist's commentary. Steelman P. **J Hand Ther** 1999 Apr–Jun;12(2):149–51 (12 ref.)

SURGERY

Biceps tendon injury. Morrey BF. **Instr Course Lect** 1999; 48:405–10 (34 ref.)

An update on repair of Achilles tendon rupture. Acute and delayed. Kuwada GT. **J Am Podiatr Med Assoc** 1999 Jun; 89(6):302–6 (33 ref.)

Rupture of the Achilles tendon. Maffulli N. **J Bone Joint Surg Am** 1999 Jul;81(7):1019–36 (293 ref.)

Simultaneous ipsilateral avulsion of the extensor carpi radialis longus and brevis tendon insertions: case report and review of the literature. Boles SD, et al. **J Hand Surg [Am]** 1999 Jul;24(4):845–9 (8 ref.)

Treatment of flexor tendon injuries: surgeons' perspective. Taras JS, et al. **J Hand Ther** 1999 Apr–Jun;12(2):141–8 (41 ref.)

Peroneal tendon subluxation in athletes: new exam technique, case reports, and review. Safran MR, et al. **Med Sci Sports Exerc** 1999 Jul;31(7 Suppl):S487–92 (16 ref.)

Biceps and triceps injuries of the elbow. Strauch RJ. **Orthop Clin North Am** 1999 Jan;30(1):95–107 (79 ref.)

[Proximal and distal biceps tendon rupture--an indication for surgery?] Klonz A, et al. **Unfallchirurg** 1998 Sep; 101(9):735–9 (42 ref.) (Eng. Abstr.) **(Ger)**

[Management and after-care of extensor tendon injuries of the hand] Partecke BD, et al. **Unfallchirurg** 1998 Nov; 101(11):807–12 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Anterior tibialis tendon ruptures: an outcome analysis of operative versus nonoperative treatment. Markarian GG, et al. **Foot Ankle Int** 1998 Dec;19(12):792–802 (12 ref.)

ULTRASONOGRAPHY

Tendon and nerve sonography. Martinoli C, et al. **Radiol Clin North Am** 1999 Jul;37(4):691–711, viii (81 ref.)

TENDON TRANSFER

[The semitendinosus tendon as replacement for the anterior cruciate ligament] Hoffmann F, et al. **Zentralbl Chir** 1998; 123(9):994–1001 (48 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The Cobb procedure for stage II posterior tibial tendon dysfunction. Benton-Weil W, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):471–7 (11 ref.)

Treatment of posterior tibial tendon dysfunction with tendon procedures from the posterior muscle group. Fleischli JG, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):453–70 (39 ref.)

[Golden standard: patellar tendon-plasty--technique and management of postoperative complications] Lobenhoffer P. **Zentralbl Chir** 1998;123(9):981–93 (61 ref.) (Eng. Abstr.) **(Ger)**

TENDONS

see related
TENDON TRANSFER

Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. Graadt van Roggen JF, et al. **J Pathol** 1998 Sep;186(1):3–7 (43 ref.)

[Whitlow and phlegmon of the tendon sheaths. Diagnosis, evolution, treatment] Loy S, et al. **Rev Prat** 1998 Oct 1; 48(15):1723–8 (00 ref.) **(Fre)**

INNERVATION

The role of afferent feedback in the control of hamstrings activity during human gait. Duysens J, et al. **Eur J Morphol** 1998 Dec;36(4–5):293–9 (31 ref.)

PATHOLOGY

Tendinitis and other chronic tendinopathies. Almekinders LC. **J Am Acad Orthop Surg** 1998 May–Jun;6(3):157–64 (20 ref.)

TENDONS

PHYSIOLOGY

Anatomy, function, and pathophysiology of the posterior tibial tendon. Smith CF. **Clin Podiatr Med Surg** 1999 Jul; 16(3):399–406 (20 ref.)

Muscle–tendon stresses and elastic energy storage during locomotion in the horse. Biewener AA. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):73–87 (44 ref.)

The role of afferent feedback in the control of hamstrings activity during human gait. Duysens J, et al. **Eur J Morphol** 1998 Dec;36(4–5):293–9 (31 ref.)

Fibrocartilage in tendons and ligaments—an adaptation to compressive load. Benjamin M, et al. **J Anat** 1998 Nov;193 (Pt 4):481–94 (100 ref.)

PHYSIOPATHOLOGY

The Cobb procedure for stage II posterior tibial tendon dysfunction. Benton–Weil W, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):471–7 (11 ref.)

Planar dominance. A major determinant in flatfoot stabilization. Borrelli AH. **Clin Podiatr Med Surg** 1999 Jul; 16(3):407–21 (35 ref.)

Treatment of posterior tibial tendon dysfunction with tendon procedures from the posterior muscle group. Fleischli JG, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):453–70 (39 ref.)

Calcaneal osteotomy for the treatment of posterior tibial tendon dysfunction. LaFontaine J, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):491–9 (21 ref.)

Triple arthrodesis and subtalar joint arthrodesis. For the treatment of end–stage posterior tibial tendon dysfunction. Laughlin TJ, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):527–55 (50 ref.)

Use of the Maxwell–Brancheau arthroereisis implant for the correction of posterior tibial tendon dysfunction. Maxwell JR, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):479–89 (20 ref.)

Talonavicular arthrodesis for correction of posterior tibial tendon dysfunction. Mothershed RA, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):501–26 (24 ref.)

Anatomy, function, and pathophysiology of the posterior tibial tendon. Smith CF. **Clin Podiatr Med Surg** 1999 Jul; 16(3):399–406 (20 ref.)

Conservative management of posterior tibial tendon dysfunction, subtalar joint complex, and pes planus deformity. Steb HS, et al. **Clin Podiatr Med Surg** 1999 Jul; 16(3):439–51 (7 ref.)

SURGERY

The Cobb procedure for stage II posterior tibial tendon dysfunction. Benton–Weil W, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):471–7 (11 ref.)

Treatment of posterior tibial tendon dysfunction with tendon procedures from the posterior muscle group. Fleischli JG, et al. **Clin Podiatr Med Surg** 1999 Jul;16(3):453–70 (39 ref.)

Anterior tibialis tendon ruptures: an outcome analysis of operative versus nonoperative treatment. Markarian GG, et al. **Foot Ankle Int** 1998 Dec;19(12):792–802 (12 ref.)

[Methods of rehabilitation of fingers after the repair of flexor tendon injuries of first and second degree] Zyluk A. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):327–33 (15 ref.) (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Meniscal substitutes—human experience. Goble EM, et al. **Scand J Med Sci Sports** 1999 Jun;9(3):146–57 (55 ref.)

Anterior cruciate ligament instability and reconstruction. Review of current trends in treatment. Roos H, et al. **Scand J Med Sci Sports** 1998 Dec;8(6):426–31 (68 ref.)

ULTRASONOGRAPHY

Sonography of the rotator cuff and biceps tendon: technique, normal anatomy, and pathology. Thain LM, et al. **J Clin Ultrasound** 1999 Oct;27(8):446–58 (8 ref.)

Tendon and nerve sonography. Martinoli C, et al. **Radiol Clin North Am** 1999 Jul;37(4):691–711, viii (81 ref.)

Ultrasonographic evaluation of equine tendons: a quantitative in vitro study of the effects of amplifier gain level, transducer–tilt, and transducer–displacement. van Schie JT, et al. **Vet Radiol Ultrasound** 1999 Mar–Apr;40(2):151–60 (48 ref.)

TENDONS, PARA-ARTICULAR

Destruction of the glenoid joint fossa by a tenosynovial giant–cell tumour of the skull base: a case report. Stojadinovic S, et al. **Int J Oral Maxillofac Surg** 1999 Apr; 28(2):132–4 (11 ref.)

INJURIES

Recurrent dislocation of tibialis posterior tendon. A report of two cases. Miki T, et al. **Arch Orthop Trauma Surg** 1998; 118(1–2):96–8 (7 ref.)

Biceps tendon injury. Morrey BF. **Instr Course Lect** 1999; 48:405–10 (34 ref.)

Treatment of flexor tendon injuries: surgeons' perspective. Taras JS, et al. **J Hand Ther** 1999 Apr–Jun;12(2):141–8 (41 ref.)

PATHOLOGY

Magnetic resonance imaging of the peroneal tendons. Mota J, et al. **Top Magn Reson Imaging** 1998 Oct;9(5):273–85 (51 ref.)

PHYSIOPATHOLOGY

Acquired flatfoot in adults due to dysfunction of the posterior tibial tendon. Pomeroy GC, et al. **J Bone Joint Surg Am** 1999 Aug;81(8):1173–82 (74 ref.)

TENEBRIO

GROWTH & DEVELOPMENT

GABA and serotonin immunoreactivity during postembryonic brain development in the beetle Tenebrio molitor. Wegerhoff R. **Microsc Res Tech** 1999 May 1; 45(3):154–64 (55 ref.)

TENNIS

INJURIES

Common sports injuries in young tennis players. Bylak J, et al. **Sports Med** 1998 Aug;26(2):119–32 (28 ref.)

TENNIS ELBOW

Acute and chronic tendinopathies at the elbow. Gabel GT. **Curr Opin Rheumatol** 1999 Mar;11(2):138–43 (25 ref.)

Epicondylitis in the athlete. Ciccotti MG. **Instr Course Lect** 1999;48:375–81 (20 ref.)

Tendinosis of the elbow (tennis elbow). Clinical features and findings of histological, immunohistochemical, and electron microscopy studies. Kraushaar BS, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):259–78 (73 ref.)

Painful conditions around the elbow. Putnam MD, et al. **Orthop Clin North Am** 1999 Jan;30(1):109–18 (32 ref.)

["Tennis elbow" is usually caused by other than tennis. The earlier the treatment the better; spontaneous remission occurs often within 8–13 months] Sölveborn SA. **Lakartidningen** 1999 Feb 3;96(5):483–5 (12 ref.) (Eng. Abstr.) **(Swe)**

ETIOLOGY

[Relationship between occupation and elbow pain, epicondylitis] Pedersen LK, et al. **Ugeskr Laeger** 1999 Aug 23;161(34):4751–5 (32 ref.) (Eng. Abstr.) **(Dan)**

THERAPY

Treatment of tennis elbow by acupuncture and moxibustion. Guo Z, et al. **J Tradit Chin Med** 1998 Dec;18(4):304–7 (14 ref.)

TENOSYNOVITIS

[Whitlow and phlegmon of the tendon sheaths. Diagnosis, evolution, treatment] Loy S, et al. **Rev Prat** 1998 Oct 1; 48(15):1723–8 (00 ref.) **(Fre)**

DIAGNOSIS

Kluyvera cryocrescens finger infection: case report and review of eighteen Kluyvera infections in human beings. West BC, et al. **Diagn Microbiol Infect Dis** 1998 Nov; 32(3):237–41 (17 ref.)

Trigger wrist and flexor tenosynovitis. Smith RD, et al. **J Hand Surg [Br]** 1998 Dec;23(6):813–4 (8 ref.)

Mycobacterium malmoense infection. An unusual cause of wrist swelling. Syed AA, et al. **J Hand Surg [Br]** 1998 Dec;23(6):811–2 (12 ref.)

THERAPY

Pyogenic flexor tenosynovitis. Boles SD, et al. **Hand Clin** 1998 Nov;14(4):567–78 (51 ref.)

TENS see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

TENSION HEADACHE

DIAGNOSIS

The comparison of individuals with recurrent tension–type headache and headache–free controls in physiological response, appraisal, and coping with stressors: a review of the literature. Wittrock DA, et al. **Ann Behav Med** 1998 Spring;20(2):118–34 (89 ref.)

GENETICS

[Familiar occurrence of chronic tension headache] Friederichs H, et al. **Ugeskr Laeger** 1999 Feb 1;161(5):576–8 (17 ref.) (Eng. Abstr.) **(Dan)**

PHYSIOPATHOLOGY

Chronic tension–type headache: where are we? [editorial; comment] Goadsby PJ. **Brain** 1999 Sep;122 (Pt 9):1611–2 (11 ref.) Comment on: Brain 1999 Sep;122 (Pt 9):1629–35.

Pathophysiological mechanisms of tension–type headache: a review of epidemiological and experimental studies. Jensen R. **Cephalalgia** 1999 Jul;19(6):602–21 (188 ref.)

PSYCHOLOGY

The comparison of individuals with recurrent tension–type headache and headache–free controls in physiological response, appraisal, and coping with stressors: a review of the literature. Wittrock DA, et al. **Ann Behav Med** 1998 Spring;20(2):118–34 (89 ref.)

THERAPY

Chronic tension–type headache: where are we? [editorial; comment] Goadsby PJ. **Brain** 1999 Sep;122 (Pt 9):1611–2 (11 ref.) Comment on: Brain 1999 Sep;122 (Pt 9):1629–35.

Mechanisms and management of headache. Goadsby PJ. **J R Coll Physicians Lond** 1999 May–Jun;33(3):228–34 (47 ref.)

TENSION–TYPE HEADACHE see **TENSION HEADACHE**

TENTH CRANIAL NERVE see **VAGUS NERVE**

TERATOCARCINOMA

PATHOLOGY

In vitro survival of human neoplastic germ cells. Rajpert–De Meyts E, et al. **Adv Exp Med Biol** 1998;444:59–65; discussion 65–6 (44 ref.)

TERATOGENS

see related

ABNORMALITIES, DRUG-INDUCED

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part II: The developmental toxicity testing guideline. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):554–63 (67 ref.)

Methimazole embryopathy: delineation of the phenotype. Clementi M, et al. **Am J Med Genet** 1999 Mar 5;83(1):43–6 (16 ref.)

Teratogenic hearing loss: a clinical perspective. Dyer JJ, et al. **Am J Otol** 1998 Sep;19(5):671–8 (47 ref.)

Fortnightly review: drug treatment during pregnancy [see comments] Rubin P. **BMJ** 1998 Nov 28;317(7171):1503–6 (29 ref.) Comment in: BMJ 1999 May 8;318(7193):1286.

The return of thalidomide: can birth defects be prevented? Lary JM, et al. **Drug Saf** 1999 Sep;21(3):161–9 (24 ref.)

Teratology: general considerations and principles. Finnell RH. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S337–42 (8 ref.)

Valproic acid use in psychiatry: issues in treating women of reproductive age. Kennedy D, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):223–8 (49 ref.)

Teratogen update: methylene blue. Cragan JD. **Teratology** 1999 Jul;60(1):42–8 (85 ref.)

TOXICITY

Teratology of retinoids. Collins MD, et al. **Annu Rev Pharmacol Toxicol** 1999;39:399–430 (197 ref.)

Problems in testing and risk assessment of endocrine disrupting chemicals with regard to developmental toxicology. Mantovani A, et al. **Chemosphere** 1999 Oct; 39(8):1293–300 (36 ref.)

Use of chick embryo in screening for teratogenicity. Kotwani A. **Indian J Physiol Pharmacol** 1998 Apr;42(2):189–204 (90 ref.)

Lupines, poison–hemlock and Nicotiana spp: toxicity and teratogenicity in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):117–34 (88 ref.)

The possibility of epigenetic transmission of defects induced by teratogens. Holliday R. **Mutat Res** 1998 Dec 3; 422(2):203–5 (21 ref.)

Mutagenicity, carcinogenicity, and teratogenicity of acrylonitrile. Léonard A, et al. **Mutat Res** 1999 May; 436(3):263–83 (188 ref.)

Procedures for calculating benchmark doses for health risk assessment. Gaylor D, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):150–64 (62 ref.)

Hygienic classification of pesticides in the Russian Federation. Potapov AI, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):79–84 (4 ref.)

[Toxicology of reproduction: predictive value of experimental models. Round Table No 1 at Giens XIII] Guittin P, et al. **Therapie** 1998 Jul–Aug;53(4):355–63 (39 ref.) (Eng. Abstr.) **(Fre)**

TERATOID TUMOR see **TERATOMA**

TERATOLOGY

METHODS

Use of chick embryo in screening for teratogenicity. Kotwani A. **Indian J Physiol Pharmacol** 1998 Apr;42(2):189–204 (90 ref.)

TERATOMA

Intracavernous teratoma in a school–aged child. Becherer

TA, et al. **Pediatr Neurosurg** 1999 Mar;30(3):135–9 (20 ref.)
[Thyroid teratomas in the adult] Torrico Román P, et al. **Acta Otorrinolaringol Esp** 1999 Jan–Feb;50(1):75–7 (10 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Eustachian tube teratoma and its terminological correctness. Ruah CB, et al. **J Laryngol Otol** 1999 Mar;113(3):271–4 (25 ref.)

COMPLICATIONS

Intramedullary spinal teratoma presenting with urinary retention: case report and review of the literature. Poeze M, et al. **Neurosurgery** 1999 Aug;45(2):379–85 (62 ref.)
Cervical spine dysraphism with teratoma exhibiting pulmonary differentiation: case report and review of the literature. Ramdial PK, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):528–33 (22 ref.)
Intramedullary spinal teratoma and diastematomyelia. Case report and review of the literature. Hader WJ, et al. **Pediatr Neurosurg** 1999 Mar;30(3):140–5 (19 ref.)

CONGENITAL

Congenital thyroid teratoma: a case with persistent neuroglial involvement of cervical lymph nodes. Keen CE, et al. **Pediatr Dev Pathol** 1998 Jul–Aug;1(4):322–7 (11 ref.)
Teratoma of the tongue in neonates: report of a case and review of the literature. Uchida K, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):79–81 (15 ref.)

DIAGNOSIS

Giant posterior fossa teratoma. Bavbek M, et al. **Childs Nerv Syst** 1999 Jul;15(6–7):359–61 (16 ref.)
Ultrafast fetal MR images of intracranial teratoma. Peng SS, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):318–9 (8 ref.)
Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. Hilden JM, et al. **J Neurooncol** 1998 Dec; 40(3):265–75 (39 ref.)

EMBRYOLOGY

An unusual case of the complete Currarino triad: case report, discussion of the literature and the embryogenic implications. Gegg CA, et al. **Neurosurgery** 1999 Mar; 44(3):658–62 (17 ref.)

EPIDEMIOLOGY

[Cervical teratomas in the child (apropos of 8 cases)] Wandaogo A, et al. **Dakar Med** 1997;42(2):103–5 (16 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Huge fetal sacrococcygeal teratoma with a completely formed eye and intratumoral DNA ploidy heterogeneity. Sergi C, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):50–7 (48 ref.)
Pathogenesis of testicular germ cell tumours. Looijenga LH, et al. **Rev Reprod** 1999 May;4(2):90–100 (78 ref.)
Intracranial germ cell tumour (embryonal carcinoma with teratoma) with complex karyotype including isochromosome 12p. Losi L, et al. **Virchows Arch** 1998 Dec; 433(6):571–4 (18 ref.)

PATHOLOGY

Dermoid cysts of the ovary with malignant transformation: MR appearance. Kido A, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):445–9 (12 ref.)
Sacrococcygeal teratoma in adults: case reports and a review of the literature. Ng EW, et al. **Cancer** 1999 Oct 1; 86(7):1198–202 (25 ref.)
Parasitic ovarian dermoid tumor of the omentum–A review of the literature and report of two new cases. Ushakov FB, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 81(1):77–82 (32 ref.)
Glioblastoma multiforme in a mature ovarian teratoma with recurring brain tumours. Yadav A, et al. **Histopathology** 1999 Aug;35(2):170–3 (10 ref.)
An unusual case of the complete Currarino triad: case report, discussion of the literature and the embryogenic implications. Gegg CA, et al. **Neurosurgery** 1999 Mar; 44(3):658–62 (17 ref.)
Immature teratoma originating from the pituitary gland: case report. Nishioka H, et al. **Neurosurgery** 1999 Mar; 44(3):644–7; discussion 647–8 (12 ref.)

RADIOGRAPHY

Intra–fourth–ventricle teratoma. Srinivasan US, et al. **Pediatr Neurosurg** 1999 Apr;30(4):200–2 (5 ref.)

SECONDARY

Primary cervical malignant teratoma with a rib metastasis in an adult: five–year survival after surgery and chemotherapy. A case report with a review of the literature. Als C, et al. **Ann Oncol** 1998 Sep;9(9):1015–22 (51 ref.)

THERAPY

Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. Hilden JM, et al. **J Neurooncol** 1998 Dec; 40(3):265–75 (39 ref.)

ULTRASONOGRAPHY

Benign intracardiac teratoma detected prenatally. Case report and review of the literature. Campagne G, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):105–8 (28 ref.)

TERATOMA, CYSTIC see **TERATOMA**

TERATOMA, MATURE see **TERATOMA**

TERBUTALINE

THERAPEUTIC USE

Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Lam F, et al. **Obstet Gynecol Surv** 1998 Nov;53(11 Suppl):S85–95 (99 ref.)

TERFENADINE

ANALOGS & DERIVATIVES

Cardiovascular safety of fexofenadine HCl. Pratt CM, et al. **Am J Cardiol** 1999 May 15;83(10):1451–4 (23 ref.)
The systemic safety of fexofenadine HCl. Mason J, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:163–70; discussion 171–3 (19 ref.)

PHARMACOLOGY

[The effect of new H1–receptor antagonists on cardiovascular system] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):360–2 (34 ref.) (Eng. Abstr.) **(Pol)**

TERMINAL CARE

see related
HOSPICE CARE
LIFE SUPPORT CARE
PALLIATIVE CARE

Preparing the ground: contributions of the preclinical years to medical education for care near the end of life. Working Group on the Pre–clinical Years of the National Consensus Conference on Medical Education for Care Near the End of Life. Barnard D, et al. **Acad Med** 1999 May; 74(5):499–505 (16 ref.)
Theories in health care and research: theories and studying the care of dying people. Seale C. **BMJ** 1998 Nov 28; 317(7171):1518–20 (15 ref.)
The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Viganò A, et al. **Cancer** 1999 Jul 1;86(1):170–6 (29 ref.)
European life–support questionnaire [editorial; comment] Leonard C, et al. **Crit Care Med** 1999 Aug;27(8):1686–7 (9 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1626–33.
Emergency physicians' role in end–of–life care. Schears RM. **Emerg Med Clin North Am** 1999 May;17(2):539–59, xiv (111 ref.)
Home care for children with life–threatening illness. Liben S, et al. **J Palliat Care** 1998 Autumn;14(3):33–8 (36 ref.)
Psychosocial needs of patients and families. Vachon ML. **J Palliat Care** 1998 Autumn;14(3):49–56 (43 ref.)
Assisted suicide and nursing: possibly compatible? White BC. **J Prof Nurs** 1999 May–Jun;15(3):151–9 (52 ref.)
Home–care of the dying. Qureshi R. **JPMA J Pak Med Assoc** 1999 Jan;49(1):20–2 (8 ref.)
An analysis of "dignity". Johnson PR. **Theor Med Bioeth** 1998 Aug;19(4):337–52 (35 ref.)
[Palliation of dyspnea in malignant disease (see comments)] de la Fuente Fonnest I, et al. **Ugeskr Laeger** 1999 Jan 18; 161(3):244–8 (39 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1999 Mar 15;161(11):1621. Comment in: Ugeskr Laeger 1999 Mar 22;161(12):1781–2. **(Dan)**
[Spiritual needs of severely ill patients are neglected in health care] Einhorn S. **Lakartidningen** 1999 May 12;96(19):2362–6 (20 ref.) (Eng. Abstr.) **(Swe)**
[Midazolam (Dormicum) in terminal anxiety and agitation. The last choice alternative in palliative care] Jakobsson M, et al. **Lakartidningen** 1999 Apr 28;96(17):2079–81 (9 ref.) (Eng. Abstr.) **(Swe)**
["Meaningless treatment" in terminal care. Importance of declaring do–not–resuscitate orders] Löfmark R, et al. **Lakartidningen** 1998 Oct 21;95(43):4759–61 (20 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Dying to pay: the cost of end–of–life care. Chochinov HM, et al. **J Palliat Care** 1998 Winter;14(4):5–15 (69 ref.)

LEGISLATION & JURISPRUDENCE

Respect for patients should dominate health care decisions [comment] Alpers A. **West J Med** 1999 May;170(5):291–2 (11 ref.) Comment on: West J Med 1999 May;170(5):287–90.

METHODS

Terminal sedation as palliative care: revalidating a right to a good death. Smith GP 2nd. **Camb Q Healthc Ethics** 1998 Fall;7(4):382–7 (37 ref.)
Assessing the arguments for and against euthanasia and assisted suicide: Part Two. Thomasma DC. **Camb Q Healthc Ethics** 1998 Fall;7(4):388–401 (37 ref.)
End–of–life care in patients dying of gynecologic cancer. Finlay I. **Hematol Oncol Clin North Am** 1999 Feb; 13(1):77–108, viii (118 ref.)
End–of–life confusion in patients with cancer [see comments] Boyle DM, et al. **Oncol Nurs Forum** 1998 Sep;25(8):1335–43 (47 ref.) Comment in: Oncol Nurs Forum 1999 Apr;26(3):497–8.
[Spiritual needs at the end of life] Boubakeur D. **Bull Acad Natl Med** 1999;183(5):929–33 (16 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Palliative care in managed Medicare: reasons for hope––and for concern. Rousseau P. **Geriatrics** 1998 Nov;53(11):59–60, 63–5; quiz 66 (20 ref.)
Incorporating education on palliative care into the long–term care setting. National Consensus Conference on Medical Education for Care Near the End of Life. Steel K, et al. **J Am Geriatr Soc** 1999 Jul;47(7):904–7 (15 ref.)

PSYCHOLOGY

A review of current theories of death and dying. Copp G. **J Adv Nurs** 1998 Aug;28(2):382–90 (31 ref.)
Articulating the concept of palliative care: philosophical and theological perspectives. Janssens RM, et al. **J Palliat Care** 1999 Summer;15(2):38–44 (29 ref.)
The moral appeal of assisted suicide in end–of–life decisions. Zimbelman J, et al. **J Prof Nurs** 1999 May–Jun;15(3):142–5 (9 ref.)
Theory construction based on standards of care: a proposed theory of the peaceful end of life. Ruland CM, et al. **Nurs Outlook** 1998 Jul–Aug;46(4):169–75 (19 ref.)

STANDARDS

Environmental ethics and medical ethics: some implications for end–of–life care, Part II. Carrick P. **Camb Q Healthc Ethics** 1999 Spring;8(2):250–6 (15 ref.)
The dying thoracic patient. Krishna G, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):723–39 (98 ref.)
Incorporating palliative care into critical care education: principles, challenges, and opportunities [see comments] Danis M, et al. **Crit Care Med** 1999 Sep;27(9):2005–13 (59 ref.) Comment in: Crit Care Med 1999 Sep;27(9):2068–9.
Nutrition and hydration: moral and pastoral reflections. National Conference of Catholic Bishops Committee for Pro–life Activities. **J Contemp Health Law Policy** 1999 Spring;15(2):455–77 (47 ref.)
Methodological challenges for measuring quality of care at the end of life. Fowler FJ Jr, et al. **J Pain Symptom Manage** 1999 Feb;17(2):114–9 (7 ref.)
The concept of quality of life of dying persons in the context of health care. Stewart AL, et al. **J Pain Symptom Manage** 1999 Feb;17(2):93–108 (75 ref.)
Research agenda for developing measures to examine quality of care and quality of life of patients diagnosed with life–limiting illness. Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):75–82 (29 ref.)
For every numerator, you need a denominator: a simple statement but key to measuring the quality of care of the "dying". Teno JM, et al. **J Pain Symptom Manage** 1999 Feb;17(2):109–13 (9 ref.)
Theory construction based on standards of care: a proposed theory of the peaceful end of life. Ruland CM, et al. **Nurs Outlook** 1998 Jul–Aug;46(4):169–75 (19 ref.)
Ethics perspectives on end–of–life care. Tilden VP. **Nurs Outlook** 1999 Jul–Aug;47(4):162–7 (88 ref.)

TRENDS

Incorporating palliative care into primary care education. National Consensus Conference on Medical Education for Care Near the End of Life. Block SD, et al. **J Gen Intern Med** 1998 Nov;13(11):768–73 (28 ref.)

TERMINALLY ILL

A test of parenthood: dilemmas of parents of terminally ill adolescents. Hayout I, et al. **Cancer Nurs** 1999 Feb; 22(1):71–9 (26 ref.)
Health service studies in the terminally ill cancer patient. Smith TJ. **Cancer Treat Res** 1998;97:81–97 (77 ref.)
End–of–life care in patients dying of gynecologic cancer. Finlay I. **Hematol Oncol Clin North Am** 1999 Feb; 13(1):77–108, viii (118 ref.)
Psychosocial needs of patients and families. Vachon ML. **J Palliat Care** 1998 Autumn;14(3):49–56 (43 ref.)
Some elements of prognosis in terminal cancer. Lamont EB, et al. **Oncology (Huntingt)** 1999 Aug;13(8):1165–70; discussion 1172–4, 1179–80 (48 ref.)

LEGISLATION & JURISPRUDENCE

Regulating research on the terminally ill: a proposal for heightened safeguards. Addicott DC. **J Contemp Health Law Policy** 1999 Spring;15(2):479–524

TERMINALLY ILL

(225 ref.)

PSYCHOLOGY

Home-care of the dying. Qureshi R.
JPMA J Pak Med Assoc 1999 Jan;49(1):20–2 (8 ref.)
[Hope] Kaasa S, et al. **Tidsskr Nor Laegeforen** 1999 Apr 10; 119(9):1313–5 (13 ref.) (Eng. Abstr.) **(Nor)**

TERMINALS, COMPUTER see **COMPUTER TERMINALS**

TERMINATOR REGIONS (GENETICS)

Termination of DNA replication of bacterial and plasmid chromosomes. Bussiere DE, et al. **Mol Microbiol** 1999 Mar; 31(6):1611–8 (42 ref.)

TERMINATOR SEQUENCE see **TERMINATOR REGIONS (GENETICS)**

TERMINOLOGY

A new epileptic seizure classification based exclusively on ictal semiology [editorial] Lüders H, et al.
Acta Neurol Scand 1999 Mar;99(3):137–41 (26 ref.)
How many types of biliary hamartomas and adenomas are there? Tsui WM. **Adv Anat Pathol** 1998 Jan;5(1):16–20 (28 ref.)
Physical functioning: definitions, measurement, and expectations. Painter P, et al. **Adv Ren Replace Ther** 1999 Apr;6(2):110–23 (56 ref.)
The language of plants. McGovern TW.
Am J Contact Dermat 1999 Mar;10(1):45–7 (2 ref.)
Orbital vascular malformations: a consensus statement on terminology and its clinical implications. Orbital Society. Harris GJ. **Am J Ophthalmol** 1999 Apr;127(4):453–5 (7 ref.)
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Epstein JI, et al.
Am J Surg Pathol 1998 Dec;22(12):1435–48 (44 ref.)
Clarity on the diagnosis line (the devil is in the details). Heffner DK, et al. **Ann Diagn Pathol** 1999 Jun;3(3):187–91 (2 ref.)
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
Arthritis Rheum 1999 Apr;42(4):599–608 (123 ref.)
A methodology for partitioning a vocabulary hierarchy into trees. Gu H, et al. **Artif Intell Med** 1999 Jan;15(1):77–98 (35 ref.)
Representation of change in controlled medical terminologies. Oliver DE, et al. **Artif Intell Med** 1999 Jan; 15(1):53–76 (45 ref.)
Terminology and concept representation languages: where are we? Rector AL. **Artif Intell Med** 1999 Jan;15(1):1–4 (24 ref.)
Recognition and classification of psychopathology in preschool children. Pavuluri MN, et al.
Aust N Z J Psychiatry 1998 Oct;32(5):642–9 (53 ref.)
Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts. Holtmann G, et al. **Baillieres Clin Gastroenterol** 1998 Sep;12(3):417–33 (94 ref.)
The spondylarthropathies: classification and diagnosis. Do we need new terminologies? Schumacher HR, et al.
Baillieres Clin Rheumatol 1998 Nov;12(4):551–65 (75 ref.)
Operational terminology for stimulus exposure (SE) conditioning. Brown GD. **Behav Brain Res** 1998 Oct; 95(2):143–50 (45 ref.)
Terminology for early pregnancy loss must be changed [letter; see comments] Hutchon DJ, et al. **BMJ** 1998 Oct 17;317(7165):1081 (4 ref.) Comment in: BMJ 1998 Oct 17;317(7165):1028–9.
Clinical coding in sports medicine—it's good to talk. Kemp S. **Br J Sports Med** 1999 Feb;33(1):4–5 (11 ref.)
East meets West: what is early cancer? Riddell RH.
Can J Gastroenterol 1999 Jul–Aug;13(6):495–7 (7 ref.)
Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21–33 (281 ref.) Comment in: Can J Psychiatry 1999 Feb;44(1):20.
Autism and other pervasive developmental disorders: exploring the dimensional view. Myhr G.
Can J Psychiatry 1998 Aug;43(6):589–95 (42 ref.)
Diagnostic terminology in fine-needle aspiration biopsy of the breast: redefining the term "atypia" [editorial; comment] Masood S. **Cancer** 1999 Feb 25;87(1):1–4 (25 ref.) Comment on: Cancer 1999 Feb 25;87(1):19–24.
Living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. A Consensus Statement from the Cardiac Nomenclature Study Group, Working Group of Arrhythmias, European Society of Cardiology, and the Task Force on Cardiac Nomenclature from NASPE. Cosio FG, et al. **Circulation** 1999 Aug 3; 100(5):e31–7 (26 ref.)
Anatomical spaces: a review [see comments] Newell RL.
Clin Anat 1999;12(1):66–9 (31 ref.) Comment in: Clin Anat 1999 ;12(1):70–1.
The cycloid type and its differentiation from core schizophrenia: a phenomenological approach. Sigmund D, et al. **Compr Psychiatry** 1999 Jan–Feb;40(1):4–18 (92 ref.)
Classification of herpes simplex virus keratitis. Holland EJ, et al. **Cornea** 1999 Mar;18(2):144–54 (30 ref.)
Molecular biology for the critical care physician part I: terminology and technology. Santis G, et al.
Crit Care Med 1999 Apr;27(4):825–31 (5 ref.)
Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Nebert DW, et al. **Drug Metab Rev** 1999 May;31(2):467–87 (72 ref.)
Living anatomy of the atrioventricular junctions. A guide to electrophysiological mapping. A Consensus Statement from the Cardiac Nomenclature Study Group, Working Group of Arrythmias, European Society of Cardiology, and the Task Force on Cardiac Nomenclature from NASPE. North American Society of Pacing and Electrophysiology. Cosio FG, et al. **Eur Heart J** 1999 Aug; 20(15):1068–75 (26 ref.)
Cancer--a degenerative disorder? Rew DA.
Eur J Surg Oncol 1998 Oct;24(5):362–6 (44 ref.)
The relationship of hypochondriasis to anxiety disorders [see comments] Noyes R Jr. **Gen Hosp Psychiatry** 1999 Jan–Feb;21(1):8–17 (87 ref.) Comment in: Gen Hosp Psychiatry 1999 Jan–Feb;21(1):5–7.
Proposal of a new nomenclature for Budd–Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Okuda K, et al.
Hepatology 1998 Nov;28(5):1191–8 (105 ref.)
Problems arising from eastern and western classification systems for gastrointestinal dysplasia and carcinoma: are they resolvable? Riddell RH, et al. **Histopathology** 1998 Sep;33(3):197–202 (6 ref.)
Changing terminology of hepatitis B and C carrier: consensus statement. Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S15–20 (0 ref.)
Dementia in Ayurveda. Manyam BV.
J Altern Complement Med 1999 Feb;5(1):81–8 (30 ref.)
Feline urologic syndrome, feline lower urinary tract disease, feline interstitial cystitis: what's in a name? [see comments] Osborne CA, et al. **J Am Vet Med Assoc** 1999 May 15; 214(10):1470–80 (108 ref.) Comment in: J Am Vet Med Assoc 1999 Jul 15;215(2):186–8.
ESCWGA/NASPE/P experts consensus statement: living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. Working Group of Arrhythmias of the European Society of Cardiology. North American Society of Pacing and Electrophysiology. Cosio FG, et al. **J Cardiovasc Electrophysiol** 1999 Aug; 10(8):1162–70 (26 ref.)
Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. Pavlakis SG, et al. **J Child Neurol** 1999 May;14(5):277–81 (36 ref.)
The tale of normal-tension glaucoma [editorial; comment] Van Buskirk EM. **J Glaucoma** 1998 Dec;7(6):363–5 (13 ref.) Comment on: J Glaucoma 1998 Dec;7(6):366–71.
Long-term non-progression in HIV infection: definitions and epidemiological issues. Easterbrook PJ. **J Infect** 1999 Mar; 38(2):71–3 (13 ref.)
Definitions and endpoints for device clinical trials in atrial fibrillation--a pressing need [editorial] Saksena S.
J Interv Card Electrophysiol 1997 Nov;1(3):173–4 (17 ref.)
Congenital malformations: an inquiry into classification and nomenclature. Kalter H. **J Med Genet** 1998 Aug; 35(8):661–5 (36 ref.)
17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. Peltoketo H, et al. **J Mol Endocrinol** 1999 Aug; 23(1):1–11 (89 ref.)
The place of culture in DSM-IV. Mezzich JE, et al.
J Nerv Ment Dis 1999 Aug;187(8):457–64 (50 ref.)
Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. Teasdale GM, et al. **J Neurotrauma** 1998 Aug;15(8):587–97 (23 ref.)
A case of a new entity named unilateral dysplasia of the mandibular condyle [letter; comment] Martín-Granizo R, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):486–7 (4 ref.) Comment on: J Oral Maxillofac Surg 1998 Jun;56(6):765–9.
Pathogen status in the 1990s: abused terminology and compromised principles [editorial] [see comments] Lindsey JR. **Lab Anim Sci** 1998 Dec;48(6):557–8 (22 ref.) Comment in: Lab Anim Sci 1999 Apr;49(2):132.
The nature of lexical knowledge. McCray AT.
Methods Inf Med 1998 Nov;37(4–5):353–60 (35 ref.)
Modeling concepts in medicine for medical language understanding. Rassinoux AM, et al. **Methods Inf Med** 1998 Nov;37(4–5):361–72 (0 ref.)
Renal tumours: the new order. Delahunt B, et al.
N Z Med J 1998 Aug 28;111(1072):307–9 (29 ref.)
Explaining presbyopia to patients [editorial] [see comments] Shabany RY, et al. **Optom Vis Sci** 1998 Sep;75(9):627–8 (7 ref.) Comment in: Optom Vis Sci 1999 Feb;76(2):81.
Terminology for the definition of arterial elastic properties. Lehmann ED. **Pathol Biol (Paris)** 1999 Jun;47(6):656–64 (70 ref.)
International nomenclature and classification of the osteochondrodysplasias (1997). Lachman RS.
Pediatr Radiol 1998 Oct;28(10):737–44 (9 ref.)
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Lukas RJ, et al. **Pharmacol Rev** 1999 Jun;51(2):397–401 (35 ref.)
Mechanical ventilation: simplifying the terminology. Kapadia F. **Postgrad Med J** 1998 Jun;74(872):330–5 (8 ref.)
The Copernican era of healthcare terminology: a re-centering of health information systems. Chute CG.
Proc AMIA Symp 1998;:68–73 (35 ref.)
Passive-aggressive personality disorder: the demise of a syndrome. Wetzler S, et al. **Psychiatry** 1999 Spring; 62(1):49–59 (47 ref.)
Inventory of exogenous hemostatic factors derived form arthropods. Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Subcommittee of the International Society on Thrombosis and Haemostasis. Arocha-Piñango CL, et al. **Thromb Haemost** 1999 Apr; 81(4):647–56 (125 ref.)
Synopsis of recent developments in venomous snake systematics, No. 3. Wüster W, et al. **Toxicon** 1999 Aug; 37(8):1123–9 (34 ref.)
[Sensitivity and specificity revisited: significance of the terms in analytic and diagnostic language] Saah AJ, et al.
Ann Dermatol Venereol 1998 Apr;125(4):291–4 (26 ref.) (Eng. Abstr.) **(Fre)**
[Electroencephalography of the premature and term newborn. Maturational aspects and glossary] Lamblin MD, et al. **Neurophysiol Clin** 1999 Apr;29(2):123–219 (77 ref.) (Eng. Abstr.) **(Fre)**
[What is the utility of medical terminology?] Nossent A.
Rev Med Liege 1999 Jan;54(1):49–53 (18 ref.) (Eng. Abstr.) **(Fre)**
[Epilepsies. Did you say 'epilepsy'?] Loiseau P, et al.
Rev Neurol (Paris) 1999 Mar;155(3):193–8 (48 ref.) (Eng. Abstr.) **(Fre)**
[Numeric terminology of erythrocyte blood group antigens] Chiaroni J. **Transfus Clin Biol** 1998 Oct;5(5):366–71 (3 ref.) (Eng. Abstr.) **(Fre)**
[History of nomenclature of Salmonella species and the legitimate names] Ezaki T. **Nippon Saikingaku Zasshi** 1998 Nov;53(4):629–33 (14 ref.) **(Jpn)**
[Nomenclature and classification of the rheumatic diseases (editorial)] Shichikawa K. **Ryumachi** 1998 Aug; 38(4):577–80 (8 ref.) **(Jpn)**
[Some comments on the discussion about so-called functional diseases] Briazgunov IP. **Klin Med (Mosk)** 1999;77(7):63–4 (0 ref.) **(Rus)**
[Prion terminology] Makarov VV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Mar–Apr; (2):96–9 (11 ref.) **(Rus)**
[Definitions and diagnostic criteria of digestive hemorrhage and its causes in cirrhosis] Sanz E, et al.
Gastroenterol Hepatol 1999 Apr;22(4):191–9 (91 ref.) **(Spa)**
[Limb girdle dystrophy: a syndrome clinically and genetically heterogeneous (editorial)] Urtasun M, et al. **Neurologia** 1999 Mar;14(3):97–101 (65 ref.) **(Spa)**
[The concept of handicap must be discussed in psychiatry!] Grunewald K. **Lakartidningen** 1999 Mar 10;96(10):1153–8 (14 ref.) **(Swe)**

TERMITES see **ISOPTERA**

TERPENE PHOSPHATES see **POLYISOPRENYL PHOSPHATES**

TERPENES

[Molecular evolution and origin of biomembranes] Ourisson G, et al. **Tanpakushitsu Kakusan Koso** 1998 Oct; 43(13):1953–62 (50 ref.) **(Jpn)**

CHEMISTRY

Manoalide. Soriente A, et al. **Curr Med Chem** 1999 May; 6(5):415–31 (100 ref.)
Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Elson CE, et al.
Proc Soc Exp Biol Med 1999 Sep;221(4):294–311 (315 ref.)

ISOLATION & PURIFICATION

[Terpenoids and steroids from several euphorbiaceae and pinaceae plants] Tanaka R, et al. **Yakugaku Zasshi** 1999 May;119(5):319–39 (64 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Monoterpenes in essential oils. Biosynthesis and properties. Loza-Tavera H. **Adv Exp Med Biol** 1999;464:49–62 (63 ref.)
Biochemical and molecular tools for the production of useful terpene products from pepper (Capsicum annuum). Lozoya-Gloria E. **Adv Exp Med Biol** 1999;464:63–76 (68 ref.)
The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Eisenreich W, et al. **Chem Biol** 1998 Sep;5(9):R221–33 (81 ref.)
Biotransformation of monoterpenes, bile acids, and other isoprenoids in anaerobic ecosystems. Hylemon PB, et al.
FEMS Microbiol Rev 1998 Dec;22(5):475–88 (75 ref.)

THERAPEUTIC USE

Prevention and therapy of cancer by dietary monoterpenes.

Crowell PL. **J Nutr** 1999 Mar;129(3):775S–778S (64 ref.)

TERRORISM see **VIOLENCE**

TEST-TUBE FERTILIZATION see **FERTILIZATION IN VITRO**

TESTICULAR DISEASES

COMPLICATIONS

Testicular microlithiasis is associated with testicular pathology. Ganem JP, et al. **Urology** 1999 Jan;53(1):209–13 (28 ref.)

DIAGNOSIS

[A fibrous pseudotumor of the tunica vaginalis testis. A report of a new case and a review of the literature] Garcia Carriazo M, et al. **Actas Urol Esp** 1999 Jan;23(1):68–70 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Mulder JE. **Med Pediatr Oncol** 1999 Jul;33(1):46–52 (59 ref.)

ETIOLOGY

Gonadal damage from chemotherapy and radiotherapy. Howell S, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):927–43 (94 ref.)

[Testicular microlithiasis] Said M, et al. **Ann Urol (Paris)** 1998;32(5):321–4 (24 ref.) (Eng. Abstr.) **(Fre)**

[The deterioration of the parameters of the human semen: myth or reality?] Mędraś M, et al. **Ginekol Pol** 1999 Mar; 70(3):155–60 (20 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Testicular biopsy. Contemporary interpretation. Nistal M, et al. **Urol Clin North Am** 1999 Aug;26(3):555–93, vi (172 ref.)

ULTRASONOGRAPHY

Testicular microlithiasis: US findings in six pediatric cases and literature review. Dell'Acqua A, et al. **Eur Radiol** 1999; 9(5):940–4 (40 ref.)

[Testicular microlithiasis] Said M, et al. **Ann Urol (Paris)** 1998;32(5):321–4 (24 ref.) (Eng. Abstr.) **(Fre)**

TESTICULAR FEMINIZATION

ETIOLOGY

[Pathogenesis of androgen insensitivity syndrome] Okabe T, et al. **Nippon Rinsho** 1998 Jul;56(7):1881–6 (4 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Physiology and pathophysiology of androgen action. Hiort O, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr; 12(1):115–32 (96 ref.)

TESTICULAR HORMONES

PHYSIOLOGY

Abnormal sexual development and psychosexual issues. Hines M. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):173–89 (69 ref.)

The role of anti-Müllerian hormone in gonadal development. Josso N, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):3–7 (23 ref.)

TESTICULAR INTERSTITIAL CELLS see **LEYDIG CELLS**

TESTICULAR NEOPLASMS

Testicular cancer. Kinkade S. **Am Fam Physician** 1999 May 1;59(9):2539–44, 2549–50 (26 ref.)

Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Plas E, et al. **Cancer** 1998 Dec 15;83(12):2437–46 (61 ref.)

Pediatric genitourinary tumors. Lee HH, et al. **Curr Opin Oncol** 1999 May;11(3):218–25 (57 ref.)

Advanced testicular cancer: update for urologists [see comments] Einhorn LH, et al. **J Urol** 1998 Dec;160(6 Pt 1):1964–9 (50 ref.) Comment in: J Urol 1998 Dec;160(6 Pt 1):1970.

Primary lymphoma of the epididymis. Kausch I, et al. **J Urol** 1998 Nov;160(5):1801–2 (9 ref.)

Markers and management of germ-cell tumours of the testes [see comments] Horwich A, et al. **Lancet** 1998 Nov 7; 352(9139):1535–8 (44 ref.) Comment in: Lancet 1999 Jan 30;353(9150):410.

Transgenic mouse models for gonadal tumorigenesis. Rahman NA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):167–74 (70 ref.)

Testicular germ cell tumors: molecular understanding and clinical implications. Lutzker SG, et al. **Mol Med Today** 1998 Sep;4(9):404–11 (50 ref.)

What to do when you discover testicular cancer. Helping patients overcome fear and choose treatment. Sonpavde G, et al. **Postgrad Med** 1999 Apr;105(4):229–36 (19 ref.)

Testicular lymphoma. Shahab N, et al. **Semin Oncol** 1999 Jun;26(3):259–69 (119 ref.)

Quality-of-life issues in the treatment of testicular cancer. Heidenreich A, et al. **World J Urol** 1999 Aug;17(4):230–8 (40 ref.)

[Testicular germ cell tumors] Dourthe LM, et al. **Bull Cancer** 1998 Sep;(1 Suppl):26–39 (106 ref.) (Eng. Abstr.) **(Fre)**

[Cancer of the testicle] Lugagne-Delpon PM. **Rev Prat** 1999 Jan 15;49(2):216–22 (0 ref.) **(Fre)**

[Paratesticular rhabdomyosarcoma. Report of a case and review of the literature] Guinda Sevillano C, et al. **Actas Urol Esp** 1998 Sep;22(8):690–4 (17 ref.) (Eng. Abstr.) **(Spa)**

[Malignant Leydig cell tumor. Report of a case and review of the literature] Jiménez López-Lucendo N, et al. **Arch Esp Urol** 1999 Mar;52(2):174–7 (15 ref.) (Eng. Abstr.) **(Spa)**

[Testicular tumors: our experience] Soto Delgado M, et al. **Arch Esp Urol** 1999 Mar;52(2):123–31; discussion 132 (18 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Staging of malignant testicular tumors] Savran VR, et al. **Vopr Onkol** 1999;45(3):223–8 (30 ref.) **(Rus)**

DIAGNOSIS

Tumour markers in germ cell cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2795–8 (18 ref.)

Testicular cancer. Nichols CR. **Curr Probl Cancer** 1998 Jul-Aug;22(4):187–274 (294 ref.)

Case of gonadoblastoma in a 9-year-old boy without physical abnormalities. Hatano T, et al. **Int J Urol** 1999 Mar; 6(3):164–6 (9 ref.)

[The rare differential diagnosis of a mediastinal space-occupying lesion] Bohle W, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):245–7 (9 ref.) (Eng. Abstr.) **(Ger)**

[Guidelines for diagnosis of testicular tumors] **Urologe A** 1999 Jan;38(1):73–82 (47 ref.) **(Ger)**

[Bilateral testicular germ cell cancer] Lalowicz I. **Pol Merkuriusz Lek** 1998 Sep;5(27):155–6 (18 ref.) (Eng. Abstr.) **(Pol)**

[Adenomatoid tumor of the epididymis] Alapont Pérez FM, et al. **Actas Urol Esp** 1999 Jul-Aug;23(7):613–6 (20 ref.) (Eng. Abstr.) **(Spa)**

[The Leydig-cell testicular tumor. A case report with magnetic resonance images] Tamayo Ruiz JC, et al. **Arch Esp Urol** 1998 Nov;51(9):928–31 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Testicular cancer: an oncological success story. Einhorn EH. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2630–2 (27 ref.)

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. Böhlen D, et al. **J Urol** 1999 Apr;161(4):1148–52 (37 ref.)

[Chemotherapy of testicular cancer] Witjes JA, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13;143(11):557–60 (15 ref.) (Eng. Abstr.) **(Dut)**

[Metastatic pure seminomas of the testicle: role of chemotherapy] Ceccaldi B, et al. **Bull Cancer** 1998 Oct; 85(10):887–91 (36 ref.) (Eng. Abstr.) **(Fre)**

[Bleomycin-induced PSS-like pseudoscleroderma. Case report and review of the literature] Behrens S, et al. **Hautarzt** 1998 Sep;49(9):725–9 (21 ref.) (Eng. Abstr.) **(Ger)**

[Late toxicity after chemotherapy of malignant testicular tumors] Jakob A, et al. **Urologe A** 1998 Nov;37(6):635–47 (111 ref.) (Eng. Abstr.) **(Ger)**

[Current therapeutic orientation toward testicular germ cell tumors] Catani M, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):113–7 (24 ref.) (Eng. Abstr.) **(Ita)**

[Platinum-based chemotherapy in renal transplant recipients with malignancies: a case report and review of literature] Wójcik J, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):145–6 (19 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Geographical epidemiology of ovarian and testicular germ cell cancers. Kamdar RH, et al. **Br J Cancer** 1998 Dec; 78(11):1401 (6 ref.)

Why is the rate of testicular cancer increasing? [editorial; comment] Klotz LH. **CMAJ** 1999 Jan 26;160(2):213–4 (20 ref.) Comment on: CMAJ 1999 Jan 26;160(2):201–5.

ETIOLOGY

Why is the rate of testicular cancer increasing? [editorial; comment] Klotz LH. **CMAJ** 1999 Jan 26;160(2):213–4 (20 ref.) Comment on: CMAJ 1999 Jan 26;160(2):201–5.

Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Cook JC, et al. **Crit Rev Toxicol** 1999 Mar; 29(2):169–261 (550 ref.)

The case for iron repletion as a promoter in testicular cancer. Crawford RD. **Med Hypotheses** 1998 Aug;51(2):129–32 (35 ref.)

Growing evidence that several human cancers may originate in utero. Ekbom A. **Semin Cancer Biol** 1998 Aug; 8(4):237–44 (76 ref.)

Testis risk and prognostic factors. The pathologist's perspective. Ulbright TM. **Urol Clin North Am** 1999 Aug; 26(3):611–26 (143 ref.)

[Cancer in patients infected with the human immunodeficiency virus. The unusual aspects] Peyrade F, et al. **Presse Med** 1999 Apr 17;28(15):809–14 (39 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Pathogenesis of testicular germ cell tumours. Looijenga LH, et al. **Rev Reprod** 1999 May;4(2):90–100 (78 ref.)

[Molecular pathogenesis and prognostic factors in testicular tumor] Heidenreich A, et al. **Urologe A** 1998 Nov; 37(6):593–608 (113 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

In vitro survival of human neoplastic germ cells. Rajpert-De Meyts E, et al. **Adv Exp Med Biol** 1998;444:59–65; discussion 65–6 (44 ref.)

Contralateral solitary testis metastasis antedating renal cell carcinoma: a case-report and review. Lauro S, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4683–4 (7 ref.)

Testicular fibroma of gonadal stromal origin with minor sex cord elements: clinicopathologic and immunohistochemical study of 2 cases. de Pinieux G, et al. **Arch Pathol Lab Med** 1999 May;123(5):391–4 (12 ref.)

Prognostic factors in prostate and testis cancer. Van Brussel JP, et al. **BJU Int** 1999 May;83(8):910–6; quiz 916–7 (64 ref.)

Metastatic germ cell tumor to the heart presenting with syncope. Vohra A, et al. **Clin Cardiol** 1999 Jun;22(6):429–33 (13 ref.)

Spermatocytic seminoma: a cytology and histology case report with review of the literature. Saran RK, et al. **Diagn Cytopathol** 1999 Apr;20(4):233–6 (18 ref.)

Malignant mesothelioma of the tunica vaginalis testis: a report of two cases and review of literature. Gupta NP, et al. **J Surg Oncol** 1999 Apr;70(4):251–4 (18 ref.)

Testicular serous papillary cystadenomatous tumor of low malignant potential in a child. Austin PF, et al. **J Urol** 1998 Dec;160(6 Pt 1):2202–3 (3 ref.)

False-negative biopsies for testicular intraepithelial neoplasia. Dieckmann KP, et al. **J Urol** 1999 Aug;162(2):364–8 (30 ref.)

Monoclonal antibody confirmation of a primary leiomyoma of the testis. Gonzalez CM, et al. **J Urol** 1999 Jun; 161(6):1908 (4 ref.)

Mixed germ cell testis tumor in an 86-year-old man. Steinbronn DV, et al. **J Urol** 1999 Jul;162(1):161 (3 ref.)

Sclerosing sertoli cell tumor of the testis--a case report and review of the literature. Gravas S, et al. **Scand J Urol Nephrol** 1999 Jun;33(3):197–9 (8 ref.)

Classification and pathology of testicular germ cell and sex cord-stromal tumors. Cheville JC. **Urol Clin North Am** 1999 Aug;26(3):595–609 (110 ref.)

Testis risk and prognostic factors. The pathologist's perspective. Ulbright TM. **Urol Clin North Am** 1999 Aug; 26(3):611–26 (143 ref.)

Primary adenocarcinoma of the epididymis: case report and review of the literature. Ganem JP, et al. **Urology** 1998 Nov;52(5):904–8 (43 ref.)

[The lymph node staging of malignant testicular germ-cell tumors] Krug B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):87–94 (66 ref.) (Eng. Abstr.) **(Ger)**

[A case of metachronous bilateral testicular tumors with burned-out histology in one side] Suzuki K, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Apr;90(4):526–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Staging of malignant testicular tumors] Savran VR, et al. **Vopr Onkol** 1999;45(3):223–8 (30 ref.) **(Rus)**

[An occult Leydig-cell tumor in a cryptorchid testis] Medina Pérez M, et al. **Arch Esp Urol** 1999 Jan-Feb;52(1):76–8 (7 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Contralateral solitary testis metastasis antedating renal cell carcinoma: a case-report and review. Lauro S, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4683–4 (7 ref.)

SURGERY

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. Böhlen D, et al. **J Urol** 1999 Apr;161(4):1148–52 (37 ref.)

[Bilateral simultaneous epididymal leiomyoma: a case report] Kimura T, et al. **Hinyokika Kiyo** 1998 Dec;44(12):901–3 (4 ref.) (Eng. Abstr.) **(Jpn)**

[A case of leiomyosarcoma of the testis] Nagae H, et al. **Hinyokika Kiyo** 1998 Dec;44(12):905–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Testicular cancer. Nichols CR. **Curr Probl Cancer** 1998 Jul-Aug;22(4):187–274 (294 ref.)

[Bilateral testicular germ cell cancer] Lalowicz I.

TESTICULAR NEOPLASMS

Pol Merkuriusz Lek 1998 Sep;5(27):155–6 (18 ref.) (Eng. Abstr.) **(Pol)**

VETERINARY

Treatment of aggressive testicular tumors in four dogs. Dhaliwal RS, et al. **J Am Anim Hosp Assoc** 1999 Jul–Aug; 35(4):311–8 (43 ref.)

TESTICULAR TORSION see **SPERMATIC CORD TORSION**

TESTING, BIOCOMPATIBLE MATERIALS see **MATERIALS TESTING**

TESTIS

see related
ORCHIECTOMY

Gonadal tissue cryopreservation in boys with paediatric cancers. Bahadur G, et al. **Hum Reprod** 1999 Jan;14(1):11–7 (81 ref.)

ABNORMALITIES

Fusional anomalies of the testis and epididymis. Merksz M. **Acta Chir Hung** 1998;37(3–4):153–70 (56 ref.)

Equine castration: review of anatomy, approaches, techniques and complications in normal, cryptorchid and monorchid horses. Searle D, et al. **Aust Vet J** 1999 Jul;77(7):428–34 (25 ref.)

Long arm deletion of chromosome 10 in a boy with monorchidism. Mutoh A, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):77–8 (9 ref.)

Diagnostic laparoscopy for contralateral patent processus vaginalis and nonpalpable testes. Holcomb GW 3rd. **Semin Pediatr Surg** 1998 Nov;7(4):232–8 (32 ref.)

CHEMISTRY

Variations on a theme: testis-derived neuropeptide hormones [comment] DiMeglio LA, et al. **Eur J Endocrinol** 1998 Oct; 139(4):361–2 (11 ref.) Comment on: Eur J Endocrinol 1998 Oct;139(4):424–7.

CYTOLOGY

Testicular sperm extraction and intracytoplasmic sperm injection. Devroey P. **Hum Reprod** 1998 Aug;13(8):2045–6 (14 ref.)

Stem cells in the testis. de Rooij DG. **Int J Exp Pathol** 1998 Apr;79(2):67–80 (97 ref.)

Interactions between testicular macrophages and Leydig cells. Hutson JC. **J Androl** 1998 Jul–Aug;19(4):394–8 (55 ref.)

DRUG EFFECTS

Current and future contributions of transgenic mice to the analysis of germline toxicology. Collick A, et al. **Adv Exp Med Biol** 1998;444:119–25; discussion 125–7 (11 ref.)

In vitro models for the investigation of reproductive toxicology in the testis. Cooke BA. **Adv Exp Med Biol** 1998;444:95–102; discussion 102–3 (33 ref.)

Protective mechanisms in germ cells: stress proteins in spermatogenesis. Dix DJ, et al. **Adv Exp Med Biol** 1998; 444:137–43; discussion 143–4 (28 ref.)

A red flag unfurled? Growth hormone treatment and testicular function [editorial; comment] Frasier SD. **J Pediatr** 1999 Sep;135(3):278–9 (11 ref.) Comment on: J Pediatr 1999 Sep;135(3):367–70.

EMBRYOLOGY

Sry and Sox9: mammalian testis-determining genes. Koopman P. **Cell Mol Life Sci** 1999 Jun;55(6–7):839–56 (187 ref.)

ENZYMOLOGY

Lanosterol 14alpha-demethylase (CYP51) and spermatogenesis. Rozman D, et al. **Drug Metab Dispos** 1998 Dec;26(12):1199–201 (11 ref.)

Cyclic-AMP-dependent protein kinase (PKA) in testicular cells. Cell specific expression, differential regulation and targeting of subunits of PKA. Hansson V, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):367–78 (126 ref.)

[Male germ cells. A new source of estrogens in the mammalian testis] Carreau S, et al. **Ann Endocrinol (Paris)** 1998 Jul;59(2):79–92 (142 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Sexual dimorphism in the neonatal gonad. Hughes IA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):23–30 (54 ref.)

The prepubertal testis: a quiescent or a silently active organ? Rey R. **Histol Histopathol** 1999 Jul;14(3):991–1000 (66 ref.)

[The participation of apoptosis in the development and function of the male gonad] Reyes Fuentes A, et al. **Ginecol Obstet Mex** 1999 Jul;67:330–40 (82 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cancer–testis antigens: targets for cancer immunotherapy [comment] Chen YT, et al. **Cancer J Sci Am** 1999 Jan–Feb; 5(1):16–7 (11 ref.) Comment on: Cancer J Sci Am 1999 Jan–Feb;5(1):20–5.

INJURIES

Penile fracture and testicular rupture. Haas CA, et al. **World J Urol** 1999 Apr;17(2):101–6 (31 ref.)

METABOLISM

Molecular cloning and developmental pattern of expression of MSJ-1, a new male germ cell-specific DNAJ homologue. Berruti G, et al. **Adv Exp Med Biol** 1998; 444:145–50; discussion 151 (14 ref.)

Sources of oestrogen in the testis and reproductive tract of the male. Carreau S, et al. **Int J Androl** 1999 Aug; 22(4):211–23 (135 ref.)

The thyrotropin-releasing hormone gene 1998: cloning, characterization, and transcriptional regulation in the central nervous system, heart, and testis. Wilber JF, et al. **Thyroid** 1998 Oct;8(10):897–901 (14 ref.)

[Oncogenes and function of the gonads] Zheng YH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):344–6 (10 ref.) **(Chi)**

PATHOLOGY

Cryptorchidism: strategies in detection. Nguyen HT, et al. **Eur Radiol** 1999;9(2):336–43 (37 ref.)

A red flag unfurled? Growth hormone treatment and testicular function [editorial; comment] Frasier SD. **J Pediatr** 1999 Sep;135(3):278–9 (11 ref.) Comment on: J Pediatr 1999 Sep;135(3):367–70.

Malignant mesothelioma of the tunica vaginalis testis: a report of two cases and review of literature. Gupta NP, et al. **J Surg Oncol** 1999 Apr;70(4):251–4 (18 ref.)

Testicular biopsy. Contemporary interpretation. Nistal M, et al. **Urol Clin North Am** 1999 Aug;26(3):555–93, vi (172 ref.)

[The Leydig-cell testicular tumor. A case report with magnetic resonance images] Tamayo Ruiz JC, et al. **Arch Esp Urol** 1998 Nov;51(9):928–31 (10 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Intragonadal regulation of male and female reproduction. Hillier SG. **Ann Endocrinol (Paris)** 1999 Jul;60(2):111–7 (84 ref.)

Role of FSH in male gonadal function. Simoni M, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):102–6 (22 ref.)

Adaptive interactions between cytokines and the hypothalamic-pituitary-gonadal axis. Cannon JG. **Ann N Y Acad Sci** 1998 Sep 29;856:234–42 (64 ref.)

Gonadotropin receptors and the control of gonadal steroidogenesis: physiology and pathology. Misrahi M, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):35–66 (170 ref.)

Testis and temperature: an historical, clinical, and research perspective. Morgentaler A, et al. **J Androl** 1999 Mar–Apr; 20(2):189–95 (48 ref.)

Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis. Veldhuis JD. **J Androl** 1999 Jan–Feb;20(1):1–17 (141 ref.)

The Parkes Lecture. Heat and the testis. Setchell BP. **J Reprod Fertil** 1998 Nov;114(2):179–94 (258 ref.)

The role of anti-Müllerian hormone in gonadal development. Josso N, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):3–7 (23 ref.)

Activating and inactivating mutations in LH receptors. Themmen AP, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):137–42 (28 ref.)

Leptin and reproduction. Clarke IJ, et al. **Rev Reprod** 1999 Jan;4(1):48–55 (74 ref.)

Hormonal and genetic control of germ cell apoptosis in the testis. Sinha Hikim AP, et al. **Rev Reprod** 1999 Jan; 4(1):38–47 (57 ref.)

PHYSIOPATHOLOGY

Role of cytokines in testicular function. Hales DB, et al. **Endocrine** 1999 Jun;10(3):201–17 (247 ref.)

Inactivating FSH receptor mutations and gonadal dysfunction. Tapanainen JS, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):129–35 (54 ref.)

RADIATION EFFECTS

[The risks of exposure to ionizing radiation during pregnancy and of the exposure of the gonads before conception] Moreno García M, et al. **Rev Clin Esp** 1999 Jul;199(7):442–8 (81 ref.) **(Spa)**

TESTIS, UNDESCENDED see **CRYPTORCHIDISM**

TESTOSTERONE

ADVERSE EFFECTS

Potential adverse effects of long-term testosterone therapy. Rolf C, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):521–34 (66 ref.)

BLOOD

[Testosterone and atherosclerosis in males during andropause] Medraś M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):205–7 (12 ref.) (Eng. Abstr.) **(Pol)**

DEFICIENCY

Androgen deficiency in aging men. Morley JE, et al. **Med Clin North Am** 1999 Sep;83(5):1279–89, vii (64 ref.)

METABOLISM

Physiology and pathophysiology of androgen action. Hiort O, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr; 12(1):115–32 (96 ref.)

Selections from current literature: androgenetic alopecia: the science behind a new oral treatment. Baumann LS, et al. **Fam Pract** 1998 Oct;15(5):493–6 (19 ref.)

Testosterone, body composition and aging. Vermeulen A, et al. **J Endocrinol Invest** 1999;22(5 Suppl):110–6 (31 ref.)

PHARMACOLOGY

The use of testosterone as a male contraceptive. Amory JK, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):471–84 (59 ref.)

Sex steroid treatment of constitutionally tall stature. Drop SL, et al. **Endocr Rev** 1998 Oct;19(5):540–58 (226 ref.)

Effects of testosterone and growth hormone on muscle function. Urban RJ. **J Lab Clin Med** 1999 Jul;134(1):7–10 (34 ref.)

Testosterone and its metabolites modulate 5HT1A and 5HT1B agonist effects on intermale aggression. Simon NG, et al. **Neurosci Biobehav Rev** 1998;23(2):325–36 (104 ref.)

PHYSIOLOGY

The Japanese quail as a model system for the investigation of steroid-catecholamine interactions mediating appetitive and consummatory aspects of male sexual behavior. Balthazart J, et al. **Annu Rev Sex Res** 1998;9:96–176 (215 ref.)

Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Bross R, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):365–78 (45 ref.)

Testosterone and dominance in men. Mazur A, et al. **Behav Brain Sci** 1998 Jun;21(3):353–63; discussion 363–97 (372 ref.)

Testosterone regulation of gonadotropin production in goldfish. Habibi HR, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):339–44 (59 ref.)

Gonadal steroid-dependent neuronal circuitries in avian limbic and preoptic regions. Panzica GC, et al. **Eur J Morphol** 1999 Apr;37(2–3):112–6 (21 ref.)

Spontaneous growth and bone age development in a patient with 17alpha-hydroxylase deficiency: evidence of the role of sexual steroids in prepubertal bone maturation. Mayer EI, et al. **J Pediatr** 1999 Mar;134(3):371–5 (25 ref.)

Vasopressin, gonadal steroids and social recognition. Dantzer R. **Prog Brain Res** 1998;119:409–14 (23 ref.)

Spermatogenesis: its regulation by testosterone and FSH [see comments] Zirkin BR. **Semin Cell Dev Biol** 1998 Aug; 9(4):417–21 (39 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379–91.

SECRETION

Testosterone and depression in aging men. Seidman SN, et al. **Am J Geriatr Psychiatry** 1999 Winter;7(1):18–33 (77 ref.)

THERAPEUTIC USE

Testosterone and depression in aging men. Seidman SN, et al. **Am J Geriatr Psychiatry** 1999 Winter;7(1):18–33 (77 ref.)

Testosterone replacement therapy. Velázquez E, et al. **Arch Androl** 1998 Sep–Oct;41(2):79–90 (96 ref.)

Current status of testosterone replacement therapy in men. Winters SJ. **Arch Fam Med** 1999 May–Jun;8(3):257–63 (41 ref.)

Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Casaburi R. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):407–18 (89 ref.)

The rationale for physiological testosterone replacement in women. Davis SR, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):391–405 (60 ref.)

Androgen therapy in AIDS wasting. Dobs AS. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):379–90 (63 ref.)

Androgen therapy in chronic renal failure. Handelsman DJ, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):485–500 (76 ref.)

Androgen replacement in children with constitutional delay of puberty: the case for aggressive therapy. Houchin LD, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):427–40 (65 ref.)

Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Tenover JS. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):419–25 (39 ref.)

The effects of testosterone on osteoporosis in men. Francis

RM. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):411–4 (43 ref.)
The therapeutic use of androgens in women. Davis SR. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):177–84 (66 ref.)
Androgen deficiency in aging men. Morley JE, et al. **Med Clin North Am** 1999 Sep;83(5):1279–89, vii (64 ref.)
Androgen treatment in women. Davis SR. **Med J Aust** 1999 Jun 7;170(11):545–9 (44 ref.)
Treatments for wasting in patients with the acquired immunodeficiency syndrome. Corcoran C, et al. **N Engl J Med** 1999 Jun 3;340(22):1740–50 (78 ref.)

TESTOSTERONE 5-ALPHA-REDUCTASE

ANTAGONISTS & INHIBITORS

Selections from current literature: androgenetic alopecia: the science behind a new oral treatment. Baumann LS, et al. **Fam Pract** 1998 Oct;15(5):493–6 (19 ref.)
Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase. Jarman M, et al. **Nat Prod Rep** 1998 Oct;15(5):495–512 (103 ref.)
Molecular action of androgen in the normal and neoplastic prostate. Kokontis JM, et al. **Vitam Horm** 1999;55:219–307 (560 ref.)
[Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition] Wolff H, et al. **Hautarzt** 1998 Nov;49(11):813–7 (32 ref.) **(Ger)**

DEFICIENCY

Natural potent androgens: lessons from human genetic models. Zhu YS, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):83–113 (170 ref.)

GENETICS

What knockout mice can tell us about parturition. Kimura T, et al. **Rev Reprod** 1999 May;4(2):73–80 (71 ref.)

METABOLISM

Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer. Habib FK, et al. **Eur Urol** 1999;35(5–6):439–42 (9 ref.)
Androgen-activating enzymes in the central nervous system. Poletti A, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):117–22 (48 ref.)
Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase. Jarman M, et al. **Nat Prod Rep** 1998 Oct;15(5):495–512 (103 ref.)

PHYSIOLOGY

[Pathogenetic significance of 5-alpha reductase isoenzymes for androgenetic alopecia] Hoffmann R, et al. **Hautarzt** 1999 Mar;50(3):165–73 (71 ref.) (Eng. Abstr.) **(Ger)**

TESTOSTERONE DEHYDROGENASES see **17-HYDROXYSTEROID DEHYDROGENASES**

TESTOSTERONE DELTA-4-5-ALPHA-REDUCTASE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

TESTOSTERONE-ESTRADIOL BINDING GLOBULIN see **SEX HORMONE-BINDING GLOBULIN**

TESTOSTERONE PROPIONATE see **TESTOSTERONE**

TETANUS

see related
TRISMUS

[Tetanus] Kato T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):611–3 (2 ref.) **(Jpn)**

COMPLICATIONS

Autism and Clostridium tetani. Bolte ER. **Med Hypotheses** 1998 Aug;51(2):133–44 (117 ref.)

DIAGNOSIS

Human diseases caused by exotoxins produced by anaerobes and their rapid detection. Kato N, et al. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998;9(2):97–104 (26 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Vaccination against diphtheria and tetanus. Assays, antigens, adjuvants and application. Aggerbeck H. **APMIS Suppl** 1998;81:1–40 (275 ref.)

TETANUS ANTITOXIN

see related
TETANUS TOXOID

TETANUS TOXIN

Autism and Clostridium tetani. Bolte ER. **Med Hypotheses** 1998 Aug;51(2):133–44 (117 ref.)
Clostridial toxins: molecular probes of Rho-dependent signaling and apoptosis. Bobak DA. **Mol Cell Biochem** 1999 Mar;193(1–2):37–42 (28 ref.)

IMMUNOLOGY

Modulation by epitope-specific antibodies of class II MHC-restricted presentation of the tetanus toxin antigen. Watts C, et al. **Immunol Rev** 1998 Aug;164:11–6 (22 ref.)

PHARMACOLOGY

Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Pellizzari R, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28;354(1381):259–68 (149 ref.)
[Molecular biology of neurosecretion and its inhibition bu tetanus and botulinum toxins (review)] Veit M. **Berl Munch Tierarztl Wochenschr** 1999 Jun;112(5):186–91 (20 ref.) (Eng. Abstr.) **(Ger)**

TETANUS TOXOID

IMMUNOLOGY

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S117–22 (19 ref.)

TETANUS VACCINE see **TETANUS TOXOID**

TETANY

ETIOLOGY

[Tetany, spasmophilia, hyperventilation syndrome: theoretical and therapeutic synthesis] Delvaux M, et al. **Rev Med Liege** 1998 Oct;53(10):610–8 (46 ref.) (Eng. Abstr.) **(Fre)**

TETHERED CORD SYNDROME see **SPINA BIFIDA OCCULTA**

TETRACEMATE see **EDETIC ACID**

TETRACHLORODIBENZODIOXIN

ADVERSE EFFECTS

Agent Orange in war medicine: an aftermath myth. Hardell L, et al. **Int J Health Serv** 1998;28(4):715–24 (45 ref.)

ANALOGS & DERIVATIVES

Neurodevelopmental, immunological and endocrinological indices of perinatal human exposure to PCBs and dioxins. Weisglas-Kuperus N. **Chemosphere** 1998 Oct–Nov;37(9–12):1845–53 (55 ref.)
Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Van den Berg M, et al. **Environ Health Perspect** 1998 Dec;106(12):775–92 (225 ref.)
Metabolism of polychlorinated dibenzo-p-dioxins and related dioxin-like compounds. Hu K, et al. **J Toxicol Environ Health B Crit Rev** 1999 Apr–Jun;2(2):183–210 (182 ref.)
Dioxins and furans in air and deposition: a review of levels, behaviour and processes. Lohmann R, et al. **Sci Total Environ** 1998 Aug 12;219(1):53–81 (145 ref.)

TOXICITY

The physiopathology of endometriosis: pollution and dioxin. Koninckx PR. **Gynecol Obstet Invest** 1999;47 Suppl 1:47–9; discussion 50 (11 ref.)
Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin [see comments] Andersen ME, et al. **Hum Exp Toxicol** 1998 Dec;17(12):683–90; discussion 701–4, 708–18 (36 ref.) Comment in: Hum Exp Toxicol 1998 Dec;17(12):705–7; discussion 701–4, 716–8.
Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses [see comments] Wilson CL, et al. **Toxicol Pathol** 1998 Sep–Oct;26(5):657–71 (200 ref.) Comment in: Toxicol Pathol 1998 Sep–Oct;26(5):672–3.

TETRACYCLINE

ADMINISTRATION & DOSAGE

Local delivery of tetracycline: from concept to clinical application. Tonetti MS. **J Clin Periodontol** 1998 Nov;25(11 Pt 2):969–77 (80 ref.)

PHARMACOLOGY

Transgene regulation by the tetracycline-controlled transactivation system. Kitamura M. **Exp Nephrol** 1998 Nov–Dec;6(6):576–80 (21 ref.)
Tet B or not tet B: advances in tetracycline-inducible gene expression [comment] Blau HM, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):797–9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 2;96(3):1013–8.

THERAPEUTIC USE

Use of topical products for maintaining remission in rosacea [editorial; comment] Wilkin JK. **Arch Dermatol** 1999 Jan;135(1):79–80 (6 ref.) Comment on: Arch Dermatol 1994 Mar;130(3):359–62. Comment on: Arch Dermatol 1998 Jun;134(6):679–83.
Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. de Boer WA. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):697–700 (40 ref.)
Therapeutic aspects of spondyloarthropathies — a review. Leirisalo-Repo M. **Scand J Rheumatol** 1998;27(5):323–8 (71 ref.)

TETRACYCLINE ANTIBIOTICS see **ANTIBIOTICS, TETRACYCLINE**

TETRACYCLINES

The tetracyclines. Smilack JD. **Mayo Clin Proc** 1999 Jul;74(7):727–9 (23 ref.)

ADVERSE EFFECTS

[Neurotoxicity of antibacterial agents (tetracyclines, chloramphenicol, aminoglycosides, beta-lactams and others)] Kanemitsu K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):545–51 (15 ref.) **(Jpn)**

TETRADECANOYLPHORBOL ACETATE

TOXICITY

Upregulation of E2F transcription factors in chemically induced mouse skin tumors. Balasubramanian S, et al. **Int J Oncol** 1999 Aug;15(2):387–90 (25 ref.)

TETRAETHYLTHIURAM DISULFIDE see **DISULFIRAM**

TETRAGASTRIN

see related
GASTROINTESTINAL AGENTS

ANALOGS & DERIVATIVES

Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). de Tullio P, et al. **Curr Med Chem** 1999 Jun;6(6):433–55 (201 ref.)

TETRAGASTRIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

TETRAHYDRO-1,4-OXAZINES see **MORPHOLINES**

TETRAHYDROAMINOACRIDINE see **TACRINE**

TETRAHYDROCANNABINOL

ADVERSE EFFECTS

Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. McPartland JM, et al. **Altern Ther Health Med** 1999 Jul;5(4):57–62 (100 ref.)

IMMUNOLOGY

[Impact of delta-9-tetrahydrocannabinol and its metabolites on the immune system] Masset D, et al. **Acta Clin Belg Suppl** 1999;1:39–43 (20 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. Ueda N, et al. **J Med Invest** 1998 Aug;45(1–4):27–36 (54 ref.)

TOXICITY

Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors. Kobayashi H, et al. **J Toxicol Sci** 1999 Feb;24(1):1–16 (96 ref.)

TETRAHYDROFOLATE DEHYDROGENASE

GENETICS

In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors. Sorrentino BP, et al. **Prog Exp Tumor Res** 1999;36:143–61 (47 ref.)

METABOLISM

Comparative properties of three pteridine reductases. Chang CF, et al. **Adv Exp Med Biol** 1999;463:403–10 (20 ref.)
PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Rosowsky A. **Curr Med Chem** 1999

Apr;6(4):329–52 (30 ref.)
The molecular basis of substrate channeling. Miles EW, et al. **J Biol Chem** 1999 Apr 30;274(18):12193–6 (50 ref.)

TETRAHYDRONAPHTHALENES

PHARMACOKINETICS

Clinical pharmacokinetics of mibefradil. Welker HA, et al. **Clin Pharmacokinet** 1998 Dec;35(6):405–23 (44 ref.)

THERAPEUTIC USE

The relevance of T-type calcium antagonists: a profile of mibefradil. Glasser SP. **J Clin Pharmacol** 1998 Aug; 38(8):659–69 (58 ref.)
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Takeuchi M, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):441–51 (53 ref.)

TETRAHYMENA PYRIFORMIS

Tetrahymena pyriformis: a tool for toxicological studies. A review. Sauvant MP, et al. **Chemosphere** 1999 Mar; 38(7):1631–69 (177 ref.)

TETRAIODOFLUORESCEIN see **ERYTHROSINE**

L-3,5,3',5'-TETRAIODOTHYRONINE see **LEVOTHYROXINE**

TETRALINS see **TETRAHYDRONAPHTHALENES**

TETRALOGY OF FALLOT

COMPLICATIONS

Cyanotic congenital heart disease with decreased pulmonary blood flow in children. Waldman JD, et al. **Pediatr Clin North Am** 1999 Apr;46(2):385–404 (15 ref.)

PHYSIOPATHOLOGY

Exercise studies in tetralogy of Fallot: a review. Wessel HU, et al. **Pediatr Cardiol** 1999 Jan–Feb;20(1):39–47; discussion 48 (94 ref.)

SURGERY

Electrophysiological follow-up of tetralogy of fallot. Friedli B. **Pediatr Cardiol** 1999 Sep–Oct;20(5):326–30 (49 ref.)

THERAPY

Is balloon dilation a reasonable option for the palliation of Fallot's tetralogy? [editorial; comment] Arnold R. **Cardiol Young** 1999 Jan;9(1):4–5 (15 ref.) Comment on: Cardiol Young 1999 Jan;9(1):24–36.

TETRANUCLEOTIDE REPEATS see **MICROSATELLITE REPEATS**

TETRAPLEGIA see **QUADRIPLEGIA**

TETRAZOLES

[Irbesartan] Caballero E, et al. **Rev Med Univ Navarra** 1998 Jul–Sep;42(3):166–9 (23 ref.) **(Spa)**

PHARMACOLOGY

Angiotensin and cerebral blood flow. Saavedra JM, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):553–73 (111 ref.)
Valsartan/hydrochlorothiazide. Langtry HD, et al. **Drugs** 1999 May;57(5):751–5; discussion 756–8 (9 ref.)
Cilostazol. Sorkin EM, et al. **Drugs Aging** 1999 Jan; 14(1):63–71; discussion 72–3 (35 ref.)
Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. Navar LG, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S266–72 (65 ref.)
ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models. Taal MW, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S51–6; discussion S61 (41 ref.)

THERAPEUTIC USE

Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Julius S. **Cardiology** 1999;91 Suppl 1:8–13 (47 ref.)
Clinical advantage of valsartan. McInnes GT. **Cardiology** 1999;91 Suppl 1:14–8 (34 ref.)
Growth hormone secretagogues as therapeutic agents. Svensson J. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:107–9 (26 ref.)
Irbesartan treatment in hypertension. Brown MJ. **Hosp Med** 1998 Oct;59(10):808–11 (14 ref.)
Angiotensin II antagonism in clinical practice: experience with valsartan. McInnes GT. **J Cardiovasc Pharmacol** 1999; 33 Suppl 1:S29–32; discussion S41–3 (14 ref.)
Valsartan and the kidney: present and future. Mann JF. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S37–40; discussion S41–3 (19 ref.)
A look through the new therapeutic window: irbesartan. Waeber B, et al. **J Hypertens Suppl** 1998 Sep;16(7):S11–6 (24 ref.)
[Pharma-clinics. The drug of the month. Candesartan (Atacand)] Kulbertus H. **Rev Med Liege** 1999 Jun; 54(6):557–60 (18 ref.) (Eng. Abstr.) **(Fre)**
[New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan)] Ivleva AIa. **Ter Arkh** 1998;70(9):85–8 (26 ref.) **(Rus)**

TETRAZOLIUM SALTS

METABOLISM

Understanding the biological activity of amyloid proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostatis. Liu Y. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):377–95 (53 ref.)

TETRODOTOXIN

PHARMACOLOGY

Temporal characterization of subcortical nuclei in mnemonic processes: results of tetrodotoxin reversible inactivation studies in the rat. Ambrogi Lorenzini CG, et al. **Arch Ital Biol** 1998 Nov;136(4):279–96 (82 ref.)
Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Gold MS. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7645–9 (69 ref.)

POISONING

[Puffer fish poisoning] Matsunaga K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):657–9 (9 ref.) **(Jpn)**

TEXTBOOKS

Paradigms in epidemiology textbooks: in the footsteps of Thomas Kuhn. Bhopal R. **Am J Public Health** 1999 Aug; 89(8):1162–5 (49 ref.)

STANDARDS

Anatomy atlases. Rosse C. **Clin Anat** 1999;12(4):293–9 (22 ref.)

TEXTILES

Postoperative textilomas: review of 14 cases. Fernandez Lobato R, et al. **Int Surg** 1998 Jan–Mar;83(1):63–6 (25 ref.)

TFE see **POLYTETRAFLUOROETHYLENE**

TFII TRANSCRIPTION FACTORS see **TRANSCRIPTION FACTORS, TFII**

TGF-ALPHA see **TRANSFORMING GROWTH FACTOR ALPHA**

TGF-ALPHA RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

TGF-BETA see **TRANSFORMING GROWTH FACTOR BETA**

TGF-BETA RECEPTORS see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

TH1 CELLS

CYTOLOGY

Checkpoints for regulation of development and interferon gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):41–2 (10 ref.)

IMMUNOLOGY

Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Louis JA, et al. **Adv Exp Med Biol** 1998;452:53–60 (35 ref.)
Inheritable defects in interleukin-12- and interferon-gamma-mediated immunity and the TH1/TH2 paradigm in man. Döffinger R, et al. **Allergy** 1999 May; 54(5):409–12 (32 ref.)
Immunomodulatory properties of interferon-gamma. An update. Billiau A, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:22–32 (50 ref.)
Th1 and Th2 cells and immunity to intestinal helminths. Bancroft AJ, et al. **Chem Immunol** 1998;71:192–208 (91 ref.)
Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease. Azar ST, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):306–10 (93 ref.)
Development of T-cell memory against inhalant allergens: risks for the future. Holt PG. **Clin Exp Allergy** 1999 Jun; 29 Suppl 2:8–13 (51 ref.)
Is allergy increasing?--early life influences. Howarth PH. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:2–7 (35 ref.)
The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Kapsenberg ML, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:33–6 (23 ref.)
Crossregulation between Th1 and Th2 cells. Morel PA, et al. **Crit Rev Immunol** 1998;18(4):275–303 (195 ref.)
Th1 and Th2 cytokines in organ transplantation: paradigm lost? Zhai Y, et al. **Crit Rev Immunol** 1999;19(2):155–72 (134 ref.)
The stability and reversibility of Th1 and Th2 populations. Coffman RL, et al. **Curr Top Microbiol Immunol** 1999; 238:1–12 (57 ref.)
Redirecting Th1 and Th2 responses in autoimmune disease. Pearson CI, et al. **Curr Top Microbiol Immunol** 1999; 238:79–122 (238 ref.)
The role of helper T cell subsets in autoimmune diseases. Lafaille JJ. **Cytokine Growth Factor Rev** 1998 Jun; 9(2):139–51 (103 ref.)
Regulation of chemokine receptors in mononuclear phagocytes versus dendritic cells and in the amplification of Th1 versus Th2 responses. Mantovani A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):76–80 (28 ref.)
Ignition of the type 1 response to intracellular infection by dendritic cell-derived interleukin-12. Sher A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):65–8 (18 ref.)
Checkpoints for regulation of development and IFN-gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Immunol Lett** 1999 Jan;65(1–2):41–4 (23 ref.)
Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Tian J, et al. **Immunol Rev** 1998 Aug;164:119–27 (51 ref.)
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Sallusto F, et al. **Immunol Today** 1998 Dec;19(12):568–74 (89 ref.)
Evolution of the type-1 (Th1)-type-2 (Th2) cytokine paradigm. Lucey DR. **Infect Dis Clin North Am** 1999 Mar; 13(1):1–9, v (36 ref.)
Molecular regulation of cytokine gene expression during the immune response. Viola JP, et al. **J Clin Immunol** 1999 Mar;19(2):98–108 (129 ref.)
Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs. Tokura Y. **J Dermatol Sci** 1998 Sep;18(1):1–10 (43 ref.)
The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases. Hässig A, et al. **Med Hypotheses** 1998 Jul;51(1):59–63 (28 ref.)
Type 1 and type 2 cytokines: from basic science to fungal infections. Murphy JW, et al. **Med Mycol** 1998;36 Suppl 1:109–18 (45 ref.)
The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions [editorial] Kunzendorf U, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2445–8 (28 ref.)
Signals that regulate the host response to Mycobacterium tuberculosis. Beyers AD, et al. **Novartis Found Symp** 1998; 217:145–57; discussion 157–9 (40 ref.)
Specific and non-specific immunity to Candida albicans: a lesson from genetically modified animals. Mencacci A, et al. **Res Immunol** 1998 May–Jun;149(4–5):352–61; discussion 517–9 (50 ref.)
[Maternal anti-paternal reactivity--depends on etiology] Schütt C. **Zentralbl Gynakol** 1999;121(4):202–5 (10 ref.) (Eng. Abstr.) **(Ger)**
[TH1/TH2 balance in chronic rheumatoid arthritis] Ishida H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1595–600 (14 ref.) **(Jpn)**
[A role for T-helper type 1 and type 2 cytokines in the pathogenesis of various human diseases] Kasakura S. **Rinsho Byori** 1998 Sep;46(9):915–21 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Cytokine measurement at a single-cell level to analyze human Th1 and Th2 cells] Morinobu A, et al. **Rinsho Byori** 1998 Sep;46(9):908–14 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Molecules associated with human Th1 or Th2 cells. Annunziato F, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):12–6 (30 ref.)
Checkpoints for regulation of development and interferon gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):41–2 (10 ref.)
Ignition of the type 1 response to intracellular infection by dendritic cell-derived interleukin-12. Sher A, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):65–8 (18 ref.)

PHYSIOLOGY

The Th1/Th2 paradigm and allergic disorders. Romagnani S. **Allergy** 1998;53(46 Suppl):12–5 (33 ref.)
The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Wold AE. **Allergy** 1998;53(46 Suppl):20–5 (73 ref.)
Interleukin-12: basic principles and clinical applications. Trinchieri G, et al. **Curr Top Microbiol Immunol** 1999; 238:57–78 (126 ref.)
Checkpoints for regulation of development and IFN-gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Immunol Lett** 1999 Jan;65(1–2):41–4 (23 ref.)
Vitamins and the regulation of the immune response. Long KZ, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):283–90 (100 ref.)
Modulating the Th1/Th2 balance in inflammatory arthritis.

Müller B, et al. **Springer Semin Immunopathol** 1998; 20(1-2):181-96 (90 ref.)
[Molecular mechanism of cytokine gene expression in Th1 and Th2] Naito Y. **Rinsho Byori** 1998 Sep;46(9):900-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Restricted replication of non-syncytium-inducing HIV in Th1 and Th2 lymphocytes. Poli G, et al.
Eur Cytokine Netw 1998 Sep;9(3 Suppl):95-6 (10 ref.)

TH2 CELLS

CHEMISTRY

Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. Seo N, et al.
J Interferon Cytokine Res 1999 Jun;19(6):555-61 (66 ref.)

CYTOLOGY

Some of the early events underlying Th2 cell maturation and susceptibility to Leishmania major infection in BALB/c mice. Himmelrich H, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):909-14 (31 ref.)

DRUG EFFECTS

Cytokine inhibitor strategies. Walker C.
Pulm Pharmacol Ther 1999;12(2):73-7 (19 ref.)

IMMUNOLOGY

Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Louis JA, et al. **Adv Exp Med Biol** 1998;452:53-60 (35 ref.)
The initiation and function of Th2 responses during infection with Schistosoma mansoni. Pearce EJ, et al.
Adv Exp Med Biol 1998;452:67-73 (30 ref.)
Inheritable defects in interleukin-12- and interferon-gamma-mediated immunity and the TH1/TH2 paradigm in man. Döffinger R, et al. **Allergy** 1999 May; 54(5):409-12 (32 ref.)
Immunological aspects of human schistosomiasis. Butterworth AE. **Br Med Bull** 1998;54(2):357-68 (40 ref.)
Th1 and Th2 cells and immunity to intestinal helminths. Bancroft AJ, et al. **Chem Immunol** 1998;71:192-208 (91 ref.)
Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease. Azar ST, et al.
Clin Diagn Lab Immunol 1999 May;6(3):306-10 (93 ref.)
Development of T-cell memory against inhalant allergens: risks for the future. Holt PG. **Clin Exp Allergy** 1999 Jun; 29 Suppl 2:8-13 (51 ref.)
Is allergy increasing?--early life influences. Howarth PH. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:2-7 (35 ref.)
The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Kapsenberg ML, et al.
Clin Exp Allergy 1999 Jun;29 Suppl 2:33-6 (23 ref.)
Immunoregulatory networks in asthma. Le Gros G, et al.
Clin Exp Allergy 1998 Nov;28 Suppl 5:92-6; discussion 117-8 (19 ref.)
Crossregulation between Th1 and Th2 cells. Morel PA, et al. **Crit Rev Immunol** 1998;18(4):275-303 (195 ref.)
Th1 and Th2 cytokines in organ transplantation: paradigm lost? Zhai Y, et al. **Crit Rev Immunol** 1999;19(2):155-72 (134 ref.)
The stability and reversibility of Th1 and Th2 populations. Coffman RL, et al. **Curr Top Microbiol Immunol** 1999; 238:1-12 (57 ref.)
Redirecting Th2 responses in allergy. Parronchi P, et al.
Curr Top Microbiol Immunol 1999;238:27-56 (193 ref.)
Redirecting Th1 and Th2 responses in autoimmune disease. Pearson CI, et al. **Curr Top Microbiol Immunol** 1999; 238:79-122 (238 ref.)
The role of helper T cell subsets in autoimmune diseases. Lafaille JJ. **Cytokine Growth Factor Rev** 1998 Jun; 9(2):139-51 (103 ref.)
Regulation of chemokine receptors in mononuclear phagocytes versus dendritic cells and in the amplification of Th1 versus Th2 responses. Mantovani A, et al.
Eur Cytokine Netw 1998 Sep;9(3 Suppl):76-80 (28 ref.)
Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Bagenstose LM, et al. **Immunol Res** 1999;20(1):67-78 (92 ref.)
The development of CD4+ T effector cells during the type 2 immune response. Gause WC, et al. **Immunol Res** 1999; 20(1):55-65 (66 ref.)
Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Tian J, et al. **Immunol Rev** 1998 Aug;164:119-27 (51 ref.)
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Sallusto F, et al.
Immunol Today 1998 Dec;19(12):568-74 (89 ref.)
Evolution of the type-1 (Th1)-type-2 (Th2) cytokine paradigm. Lucey DR. **Infect Dis Clin North Am** 1999 Mar; 13(1):1-9, v (36 ref.)
Intestinal nematode parasites, cytokines and effector mechanisms. Else KJ, et al. **Int J Parasitol** 1998 Aug; 28(8):1145-58 (104 ref.)
Molecular regulation of cytokine gene expression during the immune response. Viola JP, et al. **J Clin Immunol** 1999 Mar;19(2):98-108 (129 ref.)
The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases. Hässig A, et al.
Med Hypotheses 1998 Jul;51(1):59-63 (28 ref.)
Type 1 and type 2 cytokines: from basic science to fungal infections. Murphy JW, et al. **Med Mycol** 1998;36 Suppl 1:109-18 (45 ref.)
The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions [editorial] Kunzendorf U, et al.
Nephrol Dial Transplant 1998 Oct;13(10):2445-8 (28 ref.)
Signals that regulate the host response to Mycobacterium tuberculosis. Beyers AD, et al. **Novartis Found Symp** 1998; 217:145-57; discussion 157-9 (40 ref.)
[Maternal anti-paternal reactivity--depends on etiology] Schütt C. **Zentralbl Gynakol** 1999;121(4):202-5 (10 ref.) (Eng. Abstr.) **(Ger)**
[TH1/TH2 balance in chronic rheumatoid arthritis] Ishida H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1595-600 (14 ref.) **(Jpn)**
[A role for T-helper type 1 and type 2 cytokines in the pathogenesis of various human diseases] Kasakura S.
Rinsho Byori 1998 Sep;46(9):915-21 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Cytokine measurement at a single-cell level to analyze human Th1 and Th2 cells] Morinobu A, et al.
Rinsho Byori 1998 Sep;46(9):908-14 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Molecules associated with human Th1 or Th2 cells. Annunziato F, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):12-6 (30 ref.)

PHYSIOLOGY

The Th1/Th2 paradigm and allergic disorders. Romagnani S. **Allergy** 1998;53(46 Suppl):12-5 (33 ref.)
The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Wold AE. **Allergy** 1998;53(46 Suppl):20-5 (73 ref.)
Which is the true regulator of TH2 cell development in allergic immune responses? [editorial; comment] Kirman J, et al. **Clin Exp Allergy** 1998 Aug;28(8):908-10 (35 ref.)
Comment on: Clin Exp Allergy 1998 Aug;28(8):950-5.
Receptors and cytokines involved in allergic TH2 cell responses. de Vries JE, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S492-6 (31 ref.)
Vitamins and the regulation of the immune response. Long KZ, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):283-90 (100 ref.)
Modulating the Th1/Th2 balance in inflammatory arthritis. Müller B, et al. **Springer Semin Immunopathol** 1998; 20(1-2):181-96 (90 ref.)
[Molecular mechanism of cytokine gene expression in Th1 and Th2] Naito Y. **Rinsho Byori** 1998 Sep;46(9):900-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Restricted replication of non-syncytium-inducing HIV in Th1 and Th2 lymphocytes. Poli G, et al.
Eur Cytokine Netw 1998 Sep;9(3 Suppl):95-6 (10 ref.)

THALAMIC DISEASES

DRUG THERAPY

Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report. Ejaz AA, et al. **Angiology** 1999 Apr;50(4):327-30 (7 ref.)

ETIOLOGY

Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report. Ejaz AA, et al. **Angiology** 1999 Apr;50(4):327-30 (7 ref.)

THALAMIC NUCLEI

ANATOMY & HISTOLOGY

The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al.
J Chem Neuroanat 1999 May;16(3):153-65 (36 ref.)

PHYSIOLOGY

Efferent connections of the anteromedial nucleus of the thalamus of the rat. van Groen T, et al.
Brain Res Brain Res Rev 1999 Jul;30(1):1-26 (200 ref.)
The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al.
J Chem Neuroanat 1999 May;16(3):153-65 (36 ref.)
Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. Piallat B, et al. **J Neural Transm Suppl** 1999;55:71-7 (21 ref.)
Long-term electrical inhibition of deep brain targets in movement disorders. Benabid AL, et al. **Mov Disord** 1998; 13 Suppl 3:119-25 (19 ref.)
Physiology and anatomy of possible oscillators in the central nervous system. Rothwell JC. **Mov Disord** 1998;13 Suppl 3:24-8 (11 ref.)
A massively connected subthalamic nucleus leads to the generation of widespread pulses. Gillies AJ, et al.
Proc R Soc Lond B Biol Sci 1998 Nov 7;265(1410):2101-9 (45 ref.)
Paying attention to the thalamic reticular nucleus. Guillery RW, et al. **Trends Neurosci** 1998 Jan;21(1):28-32 (44 ref.)

PHYSIOPATHOLOGY

[Familial fatal insomnia: a human prion disease which opens the door to a greater understanding of the thalamus] Barriga F, et al. **Rev Med Univ Navarra** 1997 Oct-Dec; 41(4):224-8 (24 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Chronic electrical stimulation of the left ventrointermediate (Vim) thalamic nucleus for the treatment of pharmacotherapy-resistant Parkinson's disease: a differential impact on access to semantic and episodic memory? Tröster AI, et al. **Brain Cogn** 1998 Nov; 38(2):125-49 (120 ref.)
Targeting the subthalamic nucleus in the treatment of Parkinson's disease [published erratum appears in Brain Res Bull 1998 Sep 15;47(2):193] Henderson JM, et al.
Brain Res Bull 1998 Aug;46(6):467-74 (71 ref.)
Thalamic surgery and tremor. Speelman JD, et al.
Mov Disord 1998;13 Suppl 3:103-6 (52 ref.)

THALAMOSTRIATE VEIN see **CEREBRAL VEINS**

THALAMUS

ANATOMY & HISTOLOGY

Is the "nonspecific" thalamus still "nonspecific"? Macchi G, et al. **Arch Ital Biol** 1999 May;137(2-3):201-26 (130 ref.)
The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al.
J Chem Neuroanat 1999 May;16(3):153-65 (36 ref.)
Viewpoint: the core and matrix of thalamic organization. Jones EG. **Neuroscience** 1998 Jul;85(2):331-45 (78 ref.)

BLOOD SUPPLY

Is there a syndrome of tuberothalamic artery infarction? A case report and critical review. Ebert AD, et al.
J Clin Exp Neuropsychol 1999 Jun;21(3):397-411 (53 ref.)

METABOLISM

Monitoring neuronal NO release in vivo in cerebellum, thalamus and hippocampus. Vincent SR, et al.
Prog Brain Res 1998;118:27-35 (91 ref.)

PATHOLOGY

Diffuse bilateral thalamic astrocytomas as examined serially by MRI. Yoshida M, et al. **Childs Nerv Syst** 1998 Aug; 14(8):384-8 (14 ref.)
Pathology of symptomatic tremors. Vidailhet M, et al.
Mov Disord 1998;13 Suppl 3:49-54 (61 ref.)
Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation. Gruzelier JH.
Schizophr Bull 1999;25(1):91-120 (235 ref.)
[Thalamic degeneration] Sahashi K, et al.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):402-5 (15 ref.) **(Jpn)**

PHYSIOLOGY

A new view of specific and nonspecific thalamocortical connections. Jones EG. **Adv Neurol** 1998;77:49-71; discussion 72-3 (69 ref.)
Temporal conjunction in thalamocortical transactions. Llinás RR, et al. **Adv Neurol** 1998;77:95-102; discussion 102-3 (34 ref.)
Corticothalamic networks, oscillations, and plasticity. Steriade M. **Adv Neurol** 1998;77:105-34 (91 ref.)
The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Davis M, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:281-91 (40 ref.)
Involvement of the pallidal-thalamocortical circuit in adaptive behavior. Kalivas PW, et al.
Ann N Y Acad Sci 1999 Jun 29;877:64-70 (23 ref.)
Is the "nonspecific" thalamus still "nonspecific"? Macchi G, et al. **Arch Ital Biol** 1999 May;137(2-3):201-26 (130 ref.)
The organization of corticothalamic projections: reciprocity versus parity. Deschênes M, et al.
Brain Res Brain Res Rev 1998 Dec;28(3):286-308 (118 ref.)
Selection of actions in the basal ganglia-thalamocortical circuits: review and model. Kropotov JD, et al.
Int J Psychophysiol 1999 Mar;31(3):197-217 (104 ref.)
Thalamic interaction between the input and the output systems of the basal ganglia. Mengual E, et al.
J Chem Neuroanat 1999 May;16(3):187-200 (80 ref.)
The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al.
J Chem Neuroanat 1999 May;16(3):153-65 (36 ref.)

THALAMUS

The role of the gustatory thalamus in taste-guided behavior. Reilly S. **Neurosci Biobehav Rev** 1998 Oct;22(6):883-901 (233 ref.)
Viewpoint: the core and matrix of thalamic organization. Jones EG. **Neuroscience** 1998 Jul;85(2):331-45 (78 ref.)
Immediate and long-term plasticity in human somatosensory thalamus and its involvement in phantom limbs. Dostrovsky JO. **Pain** 1999 Aug;Suppl 6:S37-43 (28 ref.)
Is most of neural plasticity in the thalamus cortical? [comment] Kaas JH. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7622-3 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8200-5.
Learning-induced physiological plasticity in the thalamo-cortical sensory systems: a critical evaluation of receptive field plasticity, map changes and their potential mechanisms. Edeline JM. **Prog Neurobiol** 1999 Feb; 57(2):165-224 (369 ref.)
Potential circuit mechanisms underlying concurrent thalamic and cortical plasticity. Nicolelis MA, et al. **Rev Neurosci** 1998 Jul-Dec;9(3):213-24 (41 ref.)
Consciousness and complexity. Tononi G, et al. **Science** 1998 Dec 4;282(5395):1846-51 (51 ref.)
Coherent oscillations and short-term plasticity in corticothalamic networks. Steriade M. **Trends Neurosci** 1999 Aug;22(8):337-45 (58 ref.)

PHYSIOPATHOLOGY

Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398-403 (70 ref.)

SURGERY

Surgical treatment of dystonia. Lang AE. **Adv Neurol** 1998; 78:185-98 (63 ref.)
Deep brain stimulation reduces symptoms of Parkinson disease. Montgomery EB Jr. **Cleve Clin J Med** 1999 Jan; 66(1):9-11 (6 ref.)
Selection of patients for surgery for Parkinson's disease. Tasker RR. **Clin Neurosurg** 1997;44:63-7 (18 ref.)
[Pathophysiological bases, clinical results and indications for surgical treatment in Parkinson disease] Obeso JA, et al. **Neurologia** 1999 May;14 Suppl 1:54-71 (106 ref.) (Eng. Abstr.) **(Spa)**

THALASSEMIA

DIAGNOSIS

Severe thalassaemia intermedia: clinical problems in the absence of hypertransfusion. Mohamed N, et al. **Blood Rev** 1998 Sep;12(3):163-70 (86 ref.)

GENETICS

Thrombosis in heritable hemolytic disorders. Barker JE, et al. **Curr Opin Hematol** 1999 Mar;6(2):71-5 (48 ref.)
Thalassemia and malaria: new insights into an old problem. Clegg JB, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug; 111(4):278-82 (35 ref.)

THERAPY

Severe thalassaemia intermedia: clinical problems in the absence of hypertransfusion. Mohamed N, et al. **Blood Rev** 1998 Sep;12(3):163-70 (86 ref.)

THALASSEMIA-ALPHA see **ALPHA-THALASSEMIA**

THALASSEMIA MAJOR see **BETA-THALASSEMIA**

THALASSEMIA MINOR see **BETA-THALASSEMIA**

THALIDOMIDE

ADVERSE EFFECTS

The return of thalidomide: can birth defects be prevented? Lary JM, et al. **Drug Saf** 1999 Sep;21(3):161-9 (24 ref.)

THERAPEUTIC USE

The management of Behçet's syndrome: how are we doing? [editorial] Yazici H, et al. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):145-7 (24 ref.)
The return of thalidomide: can birth defects be prevented? Lary JM, et al. **Drug Saf** 1999 Sep;21(3):161-9 (24 ref.)
Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Mehta P, et al. **Pediatrics** 1999 Apr;103(4):e44 (13 ref.)
Thalidomide and its impact in dermatology. Stirling DI. **Semin Cutan Med Surg** 1998 Dec;17(4):231-42 (87 ref.)

TOXICITY

The possibility of epigenetic transmission of defects induced by teratogens. Holliday R. **Mutat Res** 1998 Dec 3; 422(2):203-5 (21 ref.)

THALLIUM

see related
THALLIUM RADIOISOTOPES

POISONING

Thallium toxicity. Galván-Arzate S, et al. **Toxicol Lett** 1998 Sep 30;99(1):1-13 (67 ref.)

TOXICITY

Thallium toxicity. Galván-Arzate S, et al. **Toxicol Lett** 1998 Sep 30;99(1):1-13 (67 ref.)

THALLIUM RADIOISOTOPES

DIAGNOSTIC USE

Lung thallium imaging in coronary transplant arteriopathy: "Ce n'est pas un pipe" [editorial; comment] Miller DD. **Am Heart J** 1999 May;137(5):782-5 (25 ref.) Comment on: Am Heart J 1999 May;137(5):942-8.
Rest-injected 201thallium in the evaluation of myocardial viability. Perrone-Filardi P, et al. **Cardiologia** 1999 Jun; 44(6):515-20 (31 ref.)
BMIPP compared with thallium redistribution. Taki J, et al. **Int J Card Imaging** 1999 Feb;15(1):49-59 (58 ref.)
Radionuclide techniques for the assessment of myocardial viability. Skoufis E, et al. **Tex Heart Inst J** 1998;25(4):272-9 (77 ref.)
[Tumor imaging using 201Tl chloride and 67Ga citrate in nucleomedical surveys] Togawa T, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):749-55 (14 ref.) (Eng. Abstr.) **(Jpn)**

THANATOLOGY

see related
DEATH

THANATOPHORIC DWARFISM see **THANATOPHORIC DYSPLASIA**

THANATOPHORIC DYSPLASIA

DIAGNOSIS

Bone dysplasia series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review and update. Lemyre E, et al. **Can Assoc Radiol J** 1999 Jun;50(3):185-97 (46 ref.)

THC see **TETRAHYDROCANNABINOL**

THEA see **THEALES**

THEA SINENSIS see **TEA**

THEACEAE see **THEALES**

THEALES

ADVERSE EFFECTS

Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Ernst E, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):589-94 (40 ref.)

CHEMISTRY

Hypericum perforatum extracts as potential antidepressants. Vitiello B. **J Pharm Pharmacol** 1999 May;51(5):513-7 (20 ref.)

THERAPEUTIC USE

Neuropharmacology of St. John's Wort (Hypericum). Bennett DA Jr, et al. **Ann Pharmacother** 1998 Nov; 32(11):1201-8 (38 ref.)
St. John's wort: a new alternative for depression? Josey ES, et al. **Int J Clin Pharmacol Ther** 1999 Mar;37(3):111-9 (31 ref.)
The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. Deltito J, et al. **J Affect Disord** 1998 Dec;51(3):345-51 (39 ref.)
Hypericum perforatum (St John's wort) in depression: pest or blessing? Rey JM, et al. **Med J Aust** 1998 Dec 7-21; 169(11-12):583-6 (38 ref.)
The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Nathan P. **Mol Psychiatry** 1999 Jul;4(4):333-8 (68 ref.)
The clinical applications of Ginkgo biloba, St. John's wort, saw palmetto, and soy. Glisson J, et al. **Nurse Pract** 1999 Jun;24(6):28, 31, 35-6 passim; quiz 47-9 (65 ref.)

THECA CELLS

see related
OVARIAN FOLLICLE

THEILER MURINE ENCEPHALOMYELITIS VIRUS

Genetics of susceptibility to Theiler's virus infection. Brahic M, et al. **Bioessays** 1998 Aug;20(8):627-33 (56 ref.)
The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Vanderlugt CL, et al. **Immunol Rev** 1998 Aug;164:63-72 (58 ref.)
[Viral infection of the central nervous system: from experimental model to human application] Monteyne P. **Ann Fr Anesth Reanim** 1999 May;18(5):550-3 (23 ref.) (Eng. Abstr.) **(Fre)**

THEILERIA ANNULATA

IMMUNOLOGY

Review: the cellular basis of the immunity to and immunopathogenesis of tropical theileriosis. Ahmed JS, et al. **Parasitol Res** 1999 Jul;85(7):539-49 (80 ref.)

PHYSIOLOGY

Directing differentiation in Theileria annulata: old methods and new possibilities for control of apicomplexan parasites. Shiels B, et al. **Int J Parasitol** 1998 Nov;28(11):1659-70 (59 ref.)
Review: Theileria schizonts induce fundamental alterations in their host cells. Ahmed JS, et al. **Parasitol Res** 1999 Jul;85(7):527-38 (90 ref.)

THEILERIA PARVA

GENETICS

Organisation and informational content of the Theileria parva genome. Nene V, et al. **Mol Biochem Parasitol** 1998 Sep 1;95(1):1-8 (47 ref.)

PHYSIOLOGY

Review: Theileria schizonts induce fundamental alterations in their host cells. Ahmed JS, et al. **Parasitol Res** 1999 Jul;85(7):527-38 (90 ref.)

THEILERIASIS

IMMUNOLOGY

Review: the cellular basis of the immunity to and immunopathogenesis of tropical theileriosis. Ahmed JS, et al. **Parasitol Res** 1999 Jul;85(7):539-49 (80 ref.)

PARASITOLOGY

Organisation and informational content of the Theileria parva genome. Nene V, et al. **Mol Biochem Parasitol** 1998 Sep 1;95(1):1-8 (47 ref.)

PREVENTION & CONTROL

Directing differentiation in Theileria annulata: old methods and new possibilities for control of apicomplexan parasites. Shiels B, et al. **Int J Parasitol** 1998 Nov;28(11):1659-70 (59 ref.)

THEILER'S MURINE ENCEPHALOMYELITIS VIRUS see **THEILER MURINE ENCEPHALOMYELITIS VIRUS**

THEOLOGY see **RELIGION**

THEOPHYLLINE

ADMINISTRATION & DOSAGE

Reduction in health care resource utilization associated with extended-release theophylline. Schulz RM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):267-72 (23 ref.)

ADVERSE EFFECTS

[Adverse-effects of theophylline on the central nervous system; clinical characteristics of theophylline-associated seizures] Maegaki Y. **Ryoikibetsu Shokogun Shirizu** 1999; (27 Pt 2):593-6 (19 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

Reproterol: beta-2-agonist, theophylline, or both? [editorial; comment] Virchow JC Jr. **Respiration** 1999;66(3):210-1 (12 ref.) Comment on: Respiration 1999 ;66(3):220-4.

PHARMACOLOGY

Reproterol: beta-2-agonist, theophylline, or both? [editorial; comment] Virchow JC Jr. **Respiration** 1999;66(3):210-1 (12 ref.) Comment on: Respiration 1999 ;66(3):220-4.

THERAPEUTIC USE

Asthma therapy: theophylline. Thomson NC. **Can Respir J** 1998 Jul-Aug;5 Suppl A:60A-3A (23 ref.)
Asthma, adenosine, mast cells and theophylline. Coward WR, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:42-6 (28 ref.)
Nocturnal asthma and the use of theophylline. Martin RJ. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:64-70 (47 ref.)
Therapeutic activities of theophylline in chronic obstructive pulmonary disease. Peleman RA, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:53-6 (36 ref.)
Theophylline and airway inflammation. Rabe KF, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:35-41 (51 ref.)
The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Spina D, et al.

Clin Exp Allergy 1998 Aug;28 Suppl 3:24–34 (100 ref.)
Theophylline. A review of its potential steroid sparing effects in asthma. Markham A, et al. **Drugs** 1998 Dec;56(6):1081–91 (33 ref.)
Recent advances in our understanding of the use of theophylline in the treatment of asthma. Page CP. **J Clin Pharmacol** 1999 Mar;39(3):237–40 (50 ref.)
Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease. Cazzola M, et al. **Thorax** 1999 Aug;54(8):730–6 (85 ref.)
[The reasons for the use of theophylline in allergic rhinitis management] Kaniuk W, et al. **Otolaryngol Pol** 1998; 52(4):401–4 (30 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC COMMUNITY

The importance of the therapeutic alliance. Kaplan S. **J Am Optom Assoc** 1998 Oct;69(10):637–42 (32 ref.)

THERAPEUTIC CULTS see **ALTERNATIVE MEDICINE**

THERAPEUTIC EQUIVALENCY

Similar, the same or just not different: a guide for deciding whether treatments are clinically equivalent. [Dept. of Medicine, Division of Cardiology, Univ. of Western Ontario, London, Ontario] Massel D. **Can J Cardiol** 1999 May;15(5):556–62 (30 ref.)
Therapeutic equivalence investigations: statistical considerations. Röhmel J. **Stat Med** 1998 Aug 15–30; 17(15–16):1703–14 (14 ref.)

THERAPEUTIC RADIOLOGY see **RADIATION ONCOLOGY**

THERAPEUTIC TOUCH

The efficacy of complementary medical treatments, as used by spas: a review of the evidence. Tabacchi MH. **Altern Ther Health Med** 1998 Nov;Suppl:1–5 (120 ref.)
Therapeutic touch. A viable link to midwifery practice. Fischer S, et al. **J Nurse Midwifery** 1999 May–Jun; 44(3):300–9 (44 ref.)
Energy healing with women and children. Starn JR. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):576–84 (48 ref.)

NURSING

The surgical significance of therapeutic touch. Ramnarine-Singh S. **AORN J** 1999 Feb;69(2):358–69 (52 ref.)

THERAPEUTICS

Managed care organizations' assessment of reimbursement for new technology, procedures, and drugs. Zarkowsky H. **Arch Pathol Lab Med** 1999 Aug;123(8):677–9 (2 ref.)
The GABA-A receptor gene family: new targets for therapeutic intervention. Whiting PJ. **Neurochem Int** 1999 May;34(5):387–90 (38 ref.)

STATISTICS & NUMERICAL DATA

A primer on measures of treatment effectiveness and diagnostic test performance. Katz DA. **WMJ** 1999 Mar–Apr;98(2):37–43 (19 ref.)

TRENDS

Paget's disease of bone: treatment philosophy for the twenty-first century. Siris ES. **Bone** 1999 May;24(5 Suppl):55S–56S (5 ref.)
Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime. Scheiflinger F, et al. **Wien Klin Wochenschr** 1999 Mar 12;111(5):172–80 (117 ref.)

THERAPY, COMBINED MODALITY see **COMBINED MODALITY THERAPY**

THERAPY, COMPUTER-ASSISTED

INSTRUMENTATION

[Computer assisted localization in endoscopic sinus surgery--state of the art? The Insta Trak system] Luxenberger W, et al. **Laryngorhinootologie** 1999 Jun; 78(6):318–25 (12 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)
[The method of computer-assisted orthopedic surgery based on two-dimensional fluoroscopy: the principles of action] Słomczykowski M, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(5):443–50 (12 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

[Computer assisted localization in endoscopic sinus surgery--state of the art? The Insta Trak system] Luxenberger W, et al. **Laryngorhinootologie** 1999 Jun; 78(6):318–25 (12 ref.) (Eng. Abstr.) **(Ger)**

THERAPY, HOME INFUSION see **HOME INFUSION THERAPY**

THERMAL WATER POLLUTION see **WATER POLLUTION**

THERMOCOAGULATION see **ELECTROCOAGULATION**

THERMOCOAGULATION, LASER see **LASER COAGULATION**

THERMODILUTION

METHODS

Effects of injectate volume on thermodilution measurements of cardiac output in patients with low ventricular ejection fraction. McCloy K, et al. **Am J Crit Care** 1999 Mar; 8(2):86–92 (33 ref.)
Cardiac output minute to minute with a standard pulmonary artery catheter, without fluid overload? [editorial; comment] Tremper KK. **Crit Care Med** 1999 Aug; 27(8):1665–6 (16 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1505–10.
Continuous cardiac output and mixed venous oxygen saturation monitoring. Cariou A, et al. **J Crit Care** 1998 Dec;13(4):198–213 (101 ref.)

THERMODYNAMICS

Clothing evaporative heat resistance--proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339–46 (17 ref.) Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.
Computer simulations with explicit solvent: recent progress in the thermodynamic decomposition of free energies and in modeling electrostatic effects. Levy RM, et al. **Annu Rev Phys Chem** 1998;49:531–67 (199 ref.)
Hydrophobic interactions of peptides with membrane interfaces. White SH, et al. **Biochim Biophys Acta** 1998 Nov 10;1376(3):339–52 (75 ref.)
The thermodynamics and evolution of complexity in biological systems. Toussaint O, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 May; 120(1):3–9 (31 ref.)
A thermodynamic analysis of the contribution of hydroxyproline to the structural stability of the collagen triple helix. Burjanadze TV, et al. **Connect Tissue Res** 1997; 36(4):347–65 (92 ref.)
Thermodynamic analysis of biomolecules: a volumetric approach. Chalikian TV, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):657–64 (60 ref.)
DNA crossovers and type II DNA topoisomerases: A thermodynamical study. Sikorav JL, et al. **J Mol Biol** 1998 Dec 18;284(5):1279–87 (40 ref.)
(Extra)thermodynamics of the drug–receptor interaction. Raffa RB. **Life Sci** 1999;65(10):967–80 (29 ref.)
[Thermodynamics of aging] Gladyshev GP. **Izv Akad Nauk Ser Biol** 1998 Sep–Oct;(5):533–43 (28 ref.) (Eng. Abstr.) **(Rus)**

THERMOELECTRIC POWER PLANTS see **POWER PLANTS**

THERMOGRAPHY

A reappraisal of the use of infrared thermal image analysis in medicine. Jones BF. **IEEE Trans Med Imaging** 1998 Dec; 17(6):1019–27 (27 ref.)
[Telethermography in pulmonology] Voloshyn HH. **Lik Sprava** 1999 Apr–May;(3):24–9 (46 ref.) **(Ukr)**

METHODS

Functional imaging of the brain by infrared radiation (thermoencephaloscopy). Shevelev IA. **Prog Neurobiol** 1998 Oct;56(3):269–305 (198 ref.)

VETERINARY

Thermographic diagnostics in equine back pain. Graf von Schweinitz D. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):161–77, viii (54 ref.)

THERMOLUMINESCENT DOSIMETRY

[Dental CT: image quality and radiation exposure in relation to scan parameters] Schorn C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):137–44 (24 ref.) (Eng. Abstr.) **(Ger)**

THERMOLYSIN

CHEMISTRY

Design of protein function by physical perturbation method. Kidokoro S. **Adv Biophys** 1998;35:121–43 (18 ref.)

METABOLISM

Design of protein function by physical perturbation method. Kidokoro S. **Adv Biophys** 1998;35:121–43 (18 ref.)

THERMORECEPTORS

see related
BODY TEMPERATURE REGULATION

PHYSIOLOGY

[Modulating effect of peripheral thermoreceptors on human respiration] Kozyreva TV, et al. **Vestn Ross Akad Med Nauk** 1998;(10):14–8 (25 ref.) (Eng. Abstr.) **(Rus)**

THERMOREGULATION see **BODY TEMPERATURE REGULATION**

THERMOTHERAPY see **HYPERTHERMIA, INDUCED**

THERMUS

GENETICS

[What we can learn from the whole genome sequences of thermophiles] Masui R, et al. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):165–70 (43 ref.) **(Jpn)**

THESAURISMOSIS see **METABOLIC DISEASES**

THESAURUS see **VOCABULARY, CONTROLLED**

THETA RHYTHM

Regarding the database for the Peniston alpha-theta EEG biofeedback protocol. Graap K, et al. **Appl Psychophysiol Biofeedback** 1998 Dec;23(4):265–72; 273–5 (13 ref.)
EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Klimesch W. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):169–95 (169 ref.)
Electro-oscillographic correlation between dorsal raphe nucleus, neocortex and hippocampus during wakefulness before and after serotoninergic inactivation. Fonoff ET, et al. **Braz J Med Biol Res** 1999 Apr;32(4):469–72 (14 ref.)
Synaptic plasticity in the hippocampus during afferent activation reproducing the pattern of the theta rhythm (theta plasticity). Kleshchevnikov AM. **Neurosci Behav Physiol** 1999 Mar–Apr;29(2):185–96 (76 ref.)

PSYCHOLOGY

Frontal midline theta rhythm and mental activity. Inanaga K. **Psychiatry Clin Neurosci** 1998 Dec;52(6):555–66 (57 ref.)

THIAMAZOLE see **METHIMAZOLE**

THIAMINE

Optimum nutrition: thiamin, biotin and pantothenate. Bender DA. **Proc Nutr Soc** 1999 May;58(2):427–33 (64 ref.)

ADMINISTRATION & DOSAGE

[Thiamine treatment today] Tallaksen CM, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3946–9 (22 ref.) (Eng. Abstr.) **(Nor)**

BIOSYNTHESIS

Thiamin biosynthesis in prokaryotes. Begley TP, et al. **Arch Microbiol** 1999 Apr;171(5):293–300 (55 ref.)

THERAPEUTIC USE

Early diagnosis of pediatric Wernicke's encephalopathy. Vasconcelos MM, et al. **Pediatr Neurol** 1999 Apr; 20(4):289–94 (43 ref.)

THIAMINE DEFICIENCY

CHEMICALLY INDUCED

Do diuretics cause thiamine deficiency? [editorial; comment] Wilcox CS. **J Lab Clin Med** 1999 Sep;134(3):192–3 (12 ref.) Comment on: J Lab Clin Med 1999 Sep;134(3):232–7.

COMPLICATIONS

Early diagnosis of pediatric Wernicke's encephalopathy. Vasconcelos MM, et al. **Pediatr Neurol** 1999 Apr; 20(4):289–94 (43 ref.)

DRUG THERAPY

[Thiamine treatment today] Tallaksen CM, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3946–9 (22 ref.) (Eng. Abstr.) **(Nor)**

THIAMINE DIPHOSPHATE see **THIAMINE PYROPHOSPHATE**

THIAMINE PYROPHOSPHATE

THIAMINE PYROPHOSPHATE

METABOLISM

Interplay of organic and biological chemistry in understanding coenzyme mechanisms: example of thiamin diphosphate-dependent decarboxylations of 2-oxo acids. Jordan F. **FEBS Lett** 1999 Sep 3;457(3):298-301 (33 ref.)

PHYSIOLOGY

Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Schenk G, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1297-318 (186 ref.)

THIAZEPINES

THERAPEUTIC USE

Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC Jr. **J Hypertens Suppl** 1999 Feb; 17(1):S37-43 (49 ref.)

THIAZIDE DIURETICS see **DIURETICS, THIAZIDE**

THIAZINES

PHARMACOKINETICS

Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Davies NM, et al. **Clin Pharmacokinet** 1999 Feb;36(2):115-26 (37 ref.)

THERAPEUTIC USE

Meloxicam--a safer NSAID? **Drug Ther Bull** 1998 Aug; 36(8):62-4 (19 ref.)

THIAZOLES

ADVERSE EFFECTS

An update of the risk assessment for methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) with focus on rinse-off products. Fewings J, et al. **Contact Dermatitis** 1999 Jul;41(1):1-13 (97 ref.)

[Ebrotidine-induced acute hepatitis (letter) Rausell V, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):28 (10 ref.) **(Spa)**

METABOLISM

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6-7):511-8 (17 ref.)

Thiazole and oxazole peptides: biosynthesis and molecular machinery. Roy RS, et al. **Nat Prod Rep** 1999 Apr; 16(2):249-63 (124 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Davies NM, et al. **Clin Pharmacokinet** 1999 Feb;36(2):115-26 (37 ref.)

PHARMACOLOGY

D-3 receptor agonists: combined action neurologic and neuropsychiatric agents [editorial; comment] Cummings JL. **J Neurol Sci** 1999 Feb 1;163(1):2-3 (17 ref.) Comment on: J Neurol Sci 1999 Feb 1;163(1):25-31.

Troglitazone. Is it all over? Wagenaar LJ, et al. **Neth J Med** 1999 Jul;55(1):4-12 (57 ref.)

Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167-74 (50 ref.)

Thiazolidinediones--tools for the research of metabolic syndrome X. Komers R, et al. **Physiol Res** 1998; 47(4):215-25 (83 ref.)

THERAPEUTIC USE

Cardiovascular effects of troglitazone. Umland EM, et al. **Ann Pharmacother** 1999 Feb;33(2):229-32 (18 ref.)

Ropinirole and pramipexole, the new agonists. Hobson DE, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S27-33 (53 ref.)

Thiazolidinediones--the new insulin enhancers. Jha RJ. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):157-66 (19 ref.)

The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders. Subramaniam S. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):121-36 (37 ref.)

New therapeutic approaches to reversing insulin resistance. Sonnenberg GE, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):551-5 (51 ref.)

Thiazolidinediones: a new class of antidiabetic drugs. Day C. **Diabet Med** 1999 Mar;16(3):179-92 (140 ref.)

Learning to use troglitazone [editorial; comment] Riddle MC. **Diabetes Care** 1998 Sep;21(9):1389-90 (14 ref.) Comment on: Diabetes Care 1998 Sep;21(9):1455-61. Comment on: Diabetes Care 1998 Sep;21(9):1462-9.

Meloxicam--a safer NSAID? **Drug Ther Bull** 1998 Aug; 36(8):62-4 (19 ref.)

Rosiglitazone. Balfour JA, et al. **Drugs** 1999 Jun;57(6):921-30; discussion 931-2 (66 ref.)

Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL, et al. **Drugs** 1999 Mar; 57(3):409-38 (159 ref.)

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease [see comments] Bennett JP Jr, et al. **J Neurol Sci** 1999 Feb 1;163(1):25-31 (34 ref.) Comment in: J Neurol Sci 1999 Feb 1;163(1):2-3.

New frontiers in the management of obstructive sleep apnoea syndrome. Krieger J. **Monaldi Arch Chest Dis** 1998 Oct; 53(5):515-9 (29 ref.)

Troglitazone. Is it all over? Wagenaar LJ, et al. **Neth J Med** 1999 Jul;55(1):4-12 (57 ref.)

The role of troglitazone in treating the insulin resistance syndrome. Granberry MC, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):973-87 (112 ref.)

[Insulin-sensitizing agents] Kadowaki T. **Nippon Rinsho** 1999 Mar;57(3):688-94 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Insulin-sensitizing agent] Yamanouchi T. **Nippon Rinsho** 1999 Mar;57(3):675-80 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Thiazolidenediones, diabetes and adipogenesis (editorial)] Moreno L, et al. **Med Clin (Barc)** 1999 Apr 10; 112(12):457-8 (19 ref.) **(Spa)**

THIENAMYCINS

Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Hellinger WC, et al. **Mayo Clin Proc** 1999 Apr; 74(4):420-34 (218 ref.)

ADMINISTRATION & DOSAGE

Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin. Yew WW, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):126-9 (15 ref.)

ADVERSE EFFECTS

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Norrby SR, et al. **Scand J Infect Dis** 1999;31(1):3-10 (32 ref.)

THERAPEUTIC USE

Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Segal-Maurer S, et al. **Clin Infect Dis** 1999 May; 28(5):1134-8 (36 ref.)

THIGH

see related

FEMUR

Fibrous dysplasia with intramuscular myxoma (Mazabraud's syndrome). Report of a case and review of the literature. Thomachot B, et al. **Rev Rhum Engl Ed** 1999 Mar; 66(3):180-3 (15 ref.)

INJURIES

Hip, pelvic, and thigh injuries and disorders in the adolescent athlete. Mares SC. **Adolesc Med** 1998 Oct;9(3):551-68, vii (24 ref.)

Lipoatrophia semicircularis--a traumatic panniculitis: report of seven cases and review of the literature. Nagore E, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):879-81 (18 ref.)

INNERVATION

The role of afferent feedback in the control of hamstrings activity during human gait. Duysens J, et al. **Eur J Morphol** 1998 Dec;36(4-5):293-9 (31 ref.)

PHYSIOLOGY

The role of afferent feedback in the control of hamstrings activity during human gait. Duysens J, et al. **Eur J Morphol** 1998 Dec;36(4-5):293-9 (31 ref.)

THIMEROSAL

PHARMACOLOGY

Thimerosal: a versatile sulfhydryl reagent, calcium mobilizer, and cell function-modulating agent. Elferink JG. **Gen Pharmacol** 1999 Jul;33(1):1-6 (32 ref.)

THIN SECTIONING see **MICROTOMY**

THINKING

Suicidal ideation and sense of coherence in male conscripts. Mehlum L. **Acta Psychiatr Scand** 1998 Dec;98(6):487-92 (37 ref.)

Thought-starting: a review of new developments. de Silva P. **Behav Res Ther** 1999 Jul;37 Suppl 1:S175-80 (22 ref.)

Thought suppression and psychopathology. Purdon C. **Behav Res Ther** 1999 Nov;37(11):1029-54 (84 ref.)

Schizophrenia--a disorder of the corollary discharge systems that integrate the motor systems of thought with the sensory systems of consciousness. Feinberg I, et al. **Br J Psychiatry** 1999 Mar;174:196-204 (62 ref.)

Cognitive-behavioural approach to understanding obsessional thinking. Salkovskis PM, et al. **Br J Psychiatry Suppl** 1998;(35):53-63 (34 ref.)

Catching the wave: understanding the concept of critical thinking. Boychuk Duchscher JE. **J Adv Nurs** 1999 Mar; 29(3):577-83 (46 ref.)

Critical thinking as an outcome of nursing education. What is it? Why is it important to nursing practice? Daly WM. **J Adv Nurs** 1998 Aug;28(2):323-31 (55 ref.)

Paradigm dialogues and dogma: finding a place for research, nursing models and reflective practice. Heath H. **J Adv Nurs** 1998 Aug;28(2):288-94 (71 ref.)

An investigation of anxious thought in patients with DSM-IV agoraphobia/panic disorder: rationale and design. Compton A. **J Am Psychoanal Assoc** 1998;46(3):691-721 (105 ref.)

Belief term development in children with autism, Asperger syndrome, specific language impairment, and normal development: links to theory of mind development. Ziatas K, et al. **J Child Psychol Psychiatry** 1998 Jul;39(5):755-63 (60 ref.)

Nursing education for critical thinking: an integrative review [see comments] Adams BL. **J Nurs Educ** 1999 Mar; 38(3):111-9 (34 ref.) Comment in: J Nurs Educ 1999 Mar;38(3):99.

Using reflective thinking to develop personal professional philosophies. Brown SC, et al. **J Nurs Educ** 1999 Apr; 38(4):171-5 (20 ref.)

PHYSIOLOGY

Mental performance during short-term and long-term spaceflight. Manzey D, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):215-21 (25 ref.)

Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Sarter M, et al. **Trends Neurosci** 1999 Feb; 22(2):67-74 (95 ref.)

THIOBACILLUS

GENETICS

Proteic toxin-antitoxin, bacterial plasmid addiction systems and their evolution with special reference to the pas system of pTF-FC2. Rawlings DE. **FEMS Microbiol Lett** 1999 Jul 15;176(2):269-77 (46 ref.)

THIOBACTERIACEAE see **GRAM-NEGATIVE CHEMOLITHOTROPHIC BACTERIA**

THIOBARBITURIC ACID REACTIVE SUBSTANCES

ANALYSIS

[Evaluation of lipid peroxidation by measuring thiobarbituric acid reactive substances] Lefèvre G, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):305-19 (90 ref.) (Eng. Abstr.) **(Fre)**

THIOCTIC ACID

ANALYSIS

Chromatographic analysis of lipoic acid and related compounds. Kataoka H. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9; 717(1-2):247-62 (110 ref.)

METABOLISM

Interplay of organic and biological chemistry in understanding coenzyme mechanisms: example of thiamin diphosphate-dependent decarboxylations of 2-oxo acids. Jordan F. **FEBS Lett** 1999 Sep 3;457(3):298-301 (33 ref.)

Alpha-lipoic acid in liver metabolism and disease. Bustamante J, et al. **Free Radic Biol Med** 1998 Apr; 24(6):1023-39 (141 ref.)

PHYSIOLOGY

Redox regulation of cell functions by alpha-lipoate: biochemical and molecular aspects. Roy S, et al. **Biofactors** 1998;8(1-2):17-21 (30 ref.)

THIOETHERS see **SULFIDES**

THIOGLYCOSIDES

CHEMICAL SYNTHESIS

Thio sugars: biological relevance as potential new therapeutics. Witczak ZJ. **Curr Med Chem** 1999 Feb; 6(2):165-78 (100 ref.)

CHEMISTRY

Thio sugars: biological relevance as potential new therapeutics. Witczak ZJ. **Curr Med Chem** 1999 Feb; 6(2):165-78 (100 ref.)

THIOL PROTEINASES see **CYSTEINE PROTEINASES**

THIOLESTER HYDROLASES

GENETICS

Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5. Mole SE, et al. **Hum Mutat** 1999;14(3):199–215 (81 ref.)

METABOLISM

Metabolic labeling of protein-derived lipid thioesters in palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:213–9 (10 ref.)

Fatty acid analysis of protein-derived lipid thioesters isolated from palmitoyl-protein thioesterase-deficient cells. Hofmann SL, et al. **Methods Mol Biol** 1999;116:221–8 (4 ref.)

THIOLS see **SULFHYDRYL COMPOUNDS**

THIOMEBUMAL see **THIOPENTAL**

THIOMERSAL see **THIMEROSAL**

THIOMERSALATE see **THIMEROSAL**

THIONES

PHARMACOLOGY

Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Hegde SS, et al. **Curr Pharm Des** 1998 Dec;4(6):469–79 (57 ref.)

THIONUCLEOTIDES

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):95–100 (35 ref.)

METABOLISM

[Antisense strategy--new trends] Koziołkiewicz M. **Postepy Biochem** 1998;44(2):125–35 (89 ref.) **(Pol)**

THERAPEUTIC USE

Antisense therapeutics. Agrawal S, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):519–28 (52 ref.)

Fomivirsen. Perry CM, et al. **Drugs** 1999 Mar;57(3):375–80; discussion 381 (21 ref.)

Synthetic oligonucleotides: the development of antisense therapeutics. Monteith DK, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):8–13 (40 ref.)

[Antisense strategy--new trends] Koziołkiewicz M. **Postepy Biochem** 1998;44(2):125–35 (89 ref.) **(Pol)**

THIOPENTAL

PHARMACOKINETICS

Pharmacodynamics and pharmacokinetics of thiopental. Russo H, et al. **Clin Pharmacokinet** 1998 Aug;35(2):95–134 (235 ref.)

THIOPENTOBARBITAL see **THIOPENTAL**

THIOPHENES

METABOLISM

Desulphurisation of benzothiophene and dibenzothiophene by actinomycete organisms belonging to the genus Rhodococcus, and related taxa. Oldfield C, et al. **Antonie Van Leeuwenhoek** 1998 Jul–Oct;74(1–3):119–32 (65 ref.)

A review of the occurrence, toxicity, and biodegradation of condensed thiophenes found in petroleum. Kropp KG, et al. **Can J Microbiol** 1998 Jul;44(7):605–22 (95 ref.)

THERAPEUTIC USE

Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo JE, et al. **Neurosurgery** 1998 Dec;43(6):1409–17; discussion 1417–8 (95 ref.)

Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Ponticello GS, et al. **Pharm Biotechnol** 1998;11:555–74 (45 ref.)

TOXICITY

A review of the occurrence, toxicity, and biodegradation of condensed thiophenes found in petroleum. Kropp KG, et al. **Can J Microbiol** 1998 Jul;44(7):605–22 (95 ref.)

THIOREDOXIN

GENETICS

The thioredoxin superfamily: redundancy, specificity, and gray-area genomics. Aslund F, et al. **J Bacteriol** 1999 Mar; 181(5):1375–9 (53 ref.)

METABOLISM

Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Ganther HE. **Carcinogenesis** 1999 Sep;20(9):1657–66 (86 ref.)

Thioredoxin in the endocrine response to stress. Tanaka H, et al. **Vitam Horm** 1999;57:153–75 (93 ref.)

THIOREDOXIN REDUCTASE (NADPH)

PHYSIOLOGY

Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Ganther HE. **Carcinogenesis** 1999 Sep;20(9):1657–66 (86 ref.)

THIOSULFURIC ACID ESTERS see **SULFURIC ACID ESTERS**

THIOUREA

PHARMACOLOGY

2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity. Liu S, et al. **Curr Pharm Des** 1999 Apr;5(4):255–63 (59 ref.)

THIRD CRANIAL NERVE see **OCULOMOTOR NERVE**

THIRD-NERVE PALSY see **OCULOMOTOR NERVE PARALYSIS**

THIRD-NERVE PARALYSIS see **OCULOMOTOR NERVE PARALYSIS**

THIRD-PARTY CONSENT

see related

PROXY

Mental health services in schools: utilization, effectiveness, and consent. Evans SW. **Clin Psychol Rev** 1999 Mar; 19(2):165–78 (67 ref.)

LEGISLATION & JURISPRUDENCE

[Legal representatives of the child with respect to the Act on Consent to Medical Treatment (WGBO): more representatives possible the under the new family law] Hulst EH. **Ned Tijdschr Geneeskd** 1999 Jun 12; 143(24):1268–71 (10 ref.) (Eng. Abstr.) **(Dut)**

THIRD-PARTY PAYMENTS see **INSURANCE, HEALTH, REIMBURSEMENT**

THIRD-WORLD COUNTRIES see **DEVELOPING COUNTRIES**

THIRST

Osmoregulation in clinical disorders of thirst appreciation. McKenna K, et al. **Clin Endocrinol (Oxf)** 1998 Aug; 49(2):139–52 (91 ref.)

[Polyuropolydipsic syndromes] Fouqueray B, et al. **Presse Med** 1998 Oct 10;27(30):1545–53 (67 ref.) (Eng. Abstr.) **(Fre)**

THORACIC ARTERIES

INJURIES

Bronchial blocker placement through the lumen of an in situ tracheal tube. Ho AM. **J Trauma** 1999 Aug;47(2):423–5 (9 ref.)

SURGERY

[Internal thoracic artery bypass--basic principles of Doppler ultrasound for pre- and postoperative diagnosis] Marx R, et al. **Z Kardiol** 1998;87 Suppl 2:80–6 (19 ref.) (Eng. Abstr.) **(Ger)**

THORACIC CYST see **MEDIASTINAL CYST**

THORACIC DISEASES

Thoracic complications in solid organ transplantation. Sommers KE, et al. **Chest Surg Clin N Am** 1999 Feb; 9(1):125–38, ix (32 ref.)

DIAGNOSIS

Cartilaginous disorders of the chest. Meyer CA, et al. **Radiographics** 1998 Sep–Oct;18(5):1109–23; quiz 1241–2 (52 ref.)

Thoracoscopic procedure for intrathoracic diseases: current status in mainland China. Ren H. **Respirology** 1999 Jun; 4(2):111–6 (28 ref.)

[Angina pectoris in extracoronary diseases] Wilke A, et al. **Herz** 1999 Apr;24(2):132–9 (53 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Gladwin MT, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1368–76 (87 ref.)

Thoracic complications related to bone marrow transplantation. Floreani AA, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):139–65 (157 ref.)

PHYSIOPATHOLOGY

The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Gladwin MT, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1368–76 (87 ref.)

SURGERY

Thoracoscopic procedures for intrathoracic diseases: the present status. Asamura H. **Respirology** 1999 Mar;4(1):9–17 (32 ref.)

Thoracoscopic procedure for intrathoracic diseases: current status in mainland China. Ren H. **Respirology** 1999 Jun; 4(2):111–6 (28 ref.)

Thoracoscopic procedures for intrathoracic and pulmonary diseases. Sung SW, et al. **Respirology** 1999 Mar;4(1):19–29 (61 ref.)

[Operations of the chest wall and thorax] Dienemann H. **Zentralbl Chir** 1998;123(10):1205–15 (0 ref.) **(Ger)**

THORACIC DUCT

Mediastinal thoracic duct cyst. Chen F, et al. **Chest** 1999 Feb;115(2):584–5 (6 ref.)

THORACIC INJURIES

A case of traumatic pericardiophrenic rupture. Stefani A, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):859–61 (10 ref.)

[Closed thoracic injuries: physiopathology, diagnosis, management in emergencies] de Wailly G, et al. **Rev Prat** 1998 Nov 1;48(17):1953–7 (0 ref.) **(Fre)**

[Thoracic wounds: review of 90 cases] Ruiz Zafra J, et al. **Arch Bronconeumol** 1999 Feb;35(2):84–90 (19 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Systemic air embolism after lung trauma. Ho AM, et al. **Anesthesiology** 1999 Feb;90(2):564–75 (107 ref.)

Pneumopericardium and pneumoperitoneum after penetrating chest injury. Rashid MA, et al. **Eur J Surg** 1999 Mar;165(3):278–9 (8 ref.)

Perforation of the intrathoracic esophagus from blunt trauma in a child: case report and review of the literature. Sartorelli KH, et al. **J Pediatr Surg** 1999 Mar;34(3):495–7 (17 ref.)

Imaging of acute thoracic aortic injury due to blunt trauma: a review. Patel NH, et al. **Radiology** 1998 Nov; 209(2):335–48 (182 ref.)

[Dissection of the ramus interventricularis anterior in blunt chest trauma] Kettering K, et al. **Dtsch Med Wochenschr** 1999 Aug 6;124(31–32):930–4 (10 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Evaluation of the patient with blunt chest trauma: an evidence based approach. Greenberg MD, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):41–62, viii (95 ref.)

ETIOLOGY

Trauma to the aorta and aortic arch branches. Ahrar K, et al. **Curr Opin Cardiol** 1998 Sep;13(5):355–68 (110 ref.)

PHYSIOPATHOLOGY

The pathophysiology of primary blast injury and its implications for treatment. Part I: The thorax. Guy RJ, et al. **J R Nav Med Serv** 1998;84(2):79–86 (71 ref.)

RADIOGRAPHY

Use of CT scan and transesophageal echocardiography in blunt thoracic trauma. Cinnella G. **Intensive Care Med** 1998 Sep;24(9):986–7 (4 ref.)

Radiographic and CT findings of blunt chest trauma: aortic injuries and looking beyond them. Kuhlman JE, et al. **Radiographics** 1998 Sep–Oct;18(5):1085–106; discussion 1107–8; quiz 1 (28 ref.)

CT in blunt chest trauma: indications and limitations. Van Hise ML, et al. **Radiographics** 1998 Sep–Oct;18(5):1071–84 (29 ref.)

Imaging diagnosis of nonaortic thoracic injury. Shanmuganathan K, et al. **Radiol Clin North Am** 1999 May; 37(3):533–51, vi (99 ref.)

[Intrathoracic dislocation fracture of the head of the humerus] al-Kaar M, et al. **J Radiol** 1998 Jan;79(1):57–9 (6 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Reconstruction of a severe chest and abdominal wall electrical burn injury in a pediatric patient. MacKinnon

THORACIC INJURIES

C, et al. **Plast Reconstr Surg** 1999 May;103(6):1775–7; quiz 1778 (16 ref.)
[Operations of the chest wall and thorax. Chest wall operations including thoracotomy. 2] Dienemann H. **Zentralbl Chir** 1998;123(11):1317–21 (6 ref.) **(Ger)**

ULTRASONOGRAPHY

Use of CT scan and transesophageal echocardiography in blunt thoracic trauma. Cinnella G. **Intensive Care Med** 1998 Sep;24(9):986–7 (4 ref.)

THORACIC NEOPLASMS

Primary angiosarcomas of the chest wall and pleura. Alexiou C, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):523–6 (13 ref.)

COMPLICATIONS

Dyspnea in cancer patients [editorial; comment] Drings P. **Support Care Cancer** 1999 Jul;7(4):215–6 (7 ref.) Comment on: Support Care Cancer 1999 Jul;7(4):229–32. Comment on: Support Care Cancer 1999 Jul;7(4):233–43.
Assessment of dyspnea in advanced cancer patients [see comments] Mancini I, et al. **Support Care Cancer** 1999 Jul;7(4):229–32 (15 ref.) Comment in: Support Care Cancer 1999 Jul;7(4):215–6.

DIAGNOSIS

Imaging evaluation of chest wall tumors in children. Karmazyn B, et al. **Acad Radiol** 1998 Sep;5(9):642–54 (41 ref.)
Cartilaginous disorders of the chest. Meyer CA, et al. **Radiographics** 1998 Sep–Oct;18(5):1109–23; quiz 1241–2 (52 ref.)
[Malignant small-cell thoracic pulmonary tumor (Askin tumor)] Kabiri H, et al. **Rev Pneumol Clin** 1999 Mar;55(1):21–5 (12 ref.) (Eng. Abstr.) **(Fre)**
[Progress in diagnostic imaging of the thorax (CT, MRI, intervention)--significance and value for the surgeon] Schildberg FW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:255–60 (0 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Watanabe M, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):559–62 (19 ref.)

PATHOLOGY

[Radiologic staging of thoracic and abdominal tumors in childhood] Hörmann M, et al. **Radiologe** 1999 Jul;39(7):538–45 (32 ref.) (Eng. Abstr.) **(Ger)**
[Results of surgical treatment of T3 lung carcinoma according to the combined resection of involved organs] Shirakusa T, et al. **Kyobu Geka** 1998 Oct;51(11):949–53 (13 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment. Connolly JE Jr, et al. **Clin Radiol** 1999 Aug;54(8):487–94 (17 ref.)
[Thoracic lymphoma] Vidal Carreira JJ, et al. **Sangre (Barc)** 1998 Dec;43(6):515–20 (16 ref.) **(Spa)**

SECONDARY

Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment. Connolly JE Jr, et al. **Clin Radiol** 1999 Aug;54(8):487–94 (17 ref.)

SURGERY

Adverse effects of medications commonly administered to thoracic surgical patients. Weill D, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):681–702, x (27 ref.)
Chondroma and chondrosarcoma. Somers J, et al. **Semin Thorac Cardiovasc Surg** 1999 Jul;11(3):270–7 (37 ref.)
[Update on reconstructive surgery in cancer] Bertrand P, et al. **Bull Cancer** 1999 Jan;86(1):65–9 (18 ref.) **(Fre)**
[Operations of the chest wall and thorax] Dienemann H. **Zentralbl Chir** 1998;123(10):1205–15 (0 ref.) **(Ger)**
[A desmoid tumor of the chest wall] Tsuchishima S, et al. **Kyobu Geka** 1998 Nov;51(12):1055–9 (39 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Complications of multimodality therapy. Putnam JB Jr. **Chest Surg Clin N Am** 1998 Aug;8(3):663–80, x (21 ref.)
Follow-up of patients with thoracic malignancies. Virgo KS, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):355–69 (72 ref.)

ULTRASONOGRAPHY

Prenatal sonographic features of embryonal rhabdomyosarcoma. Onderoğlu LS, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):210–2 (7 ref.)

THORACIC OUTLET SYNDROME

Thoracic outlet syndrome in aquatic athletes. Richardson AB. **Clin Sports Med** 1999 Apr;18(2):361–78 (46 ref.)
[Vascular aspects of thoracic outlet syndrome] Luthi JF. **Rev Med Suisse Romande** 1998 Oct;118(10):829–32 (12 ref.) **(Fre)**

DIAGNOSIS

Diagnosis, treatment, and complications of thoracic outlet syndrome. Abe M, et al. **J Orthop Sci** 1999;4(1):66–9 (9 ref.)
Thoracic outlet syndrome. Rayan GM. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):440–51 (55 ref.)
Thoracic outlet syndromes. Wilbourn AJ. **Neurol Clin** 1999 Aug;17(3):477–97, vi (95 ref.)

SURGERY

Neurovascular compression in the thoracic outlet: changing management over 50 years. Urschel HC Jr, et al. **Ann Surg** 1998 Oct;228(4):609–17 (38 ref.)

THERAPY

Diagnosis, treatment, and complications of thoracic outlet syndrome. Abe M, et al. **J Orthop Sci** 1999;4(1):66–9 (9 ref.)
Thoracic outlet syndrome. Rayan GM. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):440–51 (55 ref.)

THORACIC SURGERY

see related
CARDIOVASCULAR SURGICAL PROCEDURES
THORACIC SURGICAL PROCEDURES

Pediatric cardiac surgery in Indonesia [see comments] Asou T, et al. **Cardiol Young** 1998 Oct;8(4):437–9 (11 ref.) Comment in: Cardiol Young 1998 Oct;8(4):425–7.
Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Peters DC, et al. **Drugs** 1999 Feb;57(2):233–60 (124 ref.)
Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective. Blakeman B. **Semin Hematol** 1999 Jan;36(1 Suppl 1):37–41 (14 ref.)
[The Internet for pneumologists and thoracic surgeons: an interactive fantasy (editorial)] Moreno Balsalobre R, et al. **Arch Bronconeumol** 1999 Jan;35(1):1–4 (19 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Cardiac surgery beyond the Urals [editorial] Borst HG. **Eur J Cardiothorac Surg** 1998 Sep;14(3):223–8 (0 ref.)

TRENDS

Cardiac surgery. Verrier ED. **J Am Coll Surg** 1999 Feb;188(2):104–10 (71 ref.)

THORACIC SURGICAL PROCEDURES

see related
THORACIC SURGERY

Preoperative assessment of pulmonary risk. Ferguson MK. **Chest** 1999 May;115(5 Suppl):58S–63S (59 ref.)
Cardiac arrhythmias. Amar D. **Chest Surg Clin N Am** 1998 Aug;8(3):479–93, vii (43 ref.)
Preparation of high-risk patients for major thoracic surgery. Bisson A, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):541–55, viii (58 ref.)
The thoracic surgeon's role in the management of patients with HIV infection and AIDS. DiMaio JM, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):97–111 (42 ref.)
Neurologic complications in thoracic surgery. Feins RH. **Chest Surg Clin N Am** 1998 Aug;8(3):633–43 (26 ref.)
Postoperative atelectasis. Massard G, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):503–28, viii (75 ref.)
Video-assisted thoracic surgery (VATS). Rao A, et al. **Heart Lung** 1999 Jan–Feb;28(1):15–9 (38 ref.)
Anaesthetic implications of thoracoscopic surgery in children. Tobias JD. **Paediatr Anaesth** 1999;9(2):103–10 (36 ref.)
Anaesthesia and monitoring for minimally invasive cardiac surgery with special reference to minimally invasive direct coronary artery bypass surgery. Hultman J. **Perfusion** 1998 Jul;13(4):259–64 (9 ref.)
Hypertonic-hyperoncotic solutions in open-heart surgery. Tølløfsrud S, et al. **Perfusion** 1998 Sep;13(5):289–96 (43 ref.)
Monitoring of oxygen delivery in cardiac and vascular surgery. Spahn DR. **Vox Sang** 1998;74 Suppl 2:395–7 (17 ref.)
[Progresses in the study of thoracic surgery in China, 1997] Li Z. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):907–9 (0 ref.) **(Chi)**
[Anesthesia in thoracic surgery] Zollinger A. **Anaesthesist** 1999 Mar;48(3):193–204 (21 ref.) **(Ger)**

ADVERSE EFFECTS

Pulmonary function after cardiac and thoracic surgery. Weissman C. **Anesth Analg** 1999 Jun;88(6):1272–9 (66 ref.)
Protection of the myocardium with sodium-hydrogen exchange inhibitors: A cardiac surgical perspective. Myers ML. **J Thromb Thrombolysis** 1999 Jul;8(1):53–60 (49 ref.)
Retrograde cerebral perfusion: clinical and experimental aspects. Wong CH, et al. **Perfusion** 1999 Jul;14(4):247–56 (82 ref.)

CLASSIFICATION

[Classification of surgical procedures in lung cancer] Bisenkov LN, et al. **Khirurgiia (Mosk)** 1999;(4):47–9 (5 ref.) (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Early video-assisted thoracic surgery in the management of empyema. Grewal H, et al. **Pediatrics** 1999 May;103(5):e63 (30 ref.)
Thoracoscopic major lung resections: an Asian perspective. Yim AP, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):326–31 (25 ref.)
[Signal analysis of the hemodynamics of extracorporeal circulation for the evaluation of patient status] Schwarzhaupt A, et al. **Biomed Tech (Berl)** 1999 May;44(5):120–8 (11 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Role of video-assisted thoracic surgery (VATS) in staging, diagnosis and treatment of lung cancer. Van Schil P. **Acta Chir Belg** 1999 May–Jun;99(3):103–8 (39 ref.)
Complications after video-assisted thoracic surgery. Downey RJ. **Chest Surg Clin N Am** 1998 Nov;8(4):907–17, x (52 ref.)
Thoracoscopic procedures for intrathoracic diseases: the present status. Asamura H. **Respirology** 1999 Mar;4(1):9–17 (32 ref.)
Thoracoscopic procedure for intrathoracic diseases: current status in mainland China. Ren H. **Respirology** 1999 Jun;4(2):111–6 (28 ref.)
Thoracoscopic procedures for intrathoracic and pulmonary diseases. Sung SW, et al. **Respirology** 1999 Mar;4(1):19–29 (61 ref.)
Video-assisted thoracic surgery: a renaissance in surgical therapy. Yim AP, et al. **Respirology** 1999 Mar;4(1):1–8 (37 ref.)
Thoracoscopic major lung resections: an Asian perspective. Yim AP, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):326–31 (25 ref.)
[Pulmonary nodule. The surgeon's approach] Hoffmann H, et al. **Zentralbl Chir** 1999;124(2):128–35 (14 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

The dying thoracic patient. Krishna G, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):723–39 (98 ref.)

THORACIC VERTEBRAE

ABNORMALITIES

[A case of an anomaly of the upper thoracic spine with lower spastic paraplegia simulating progressive disease of the nervous system] Evtushenko SK, et al. **Lik Sprava** 1999 Mar;(2):126–8 (7 ref.) **(Rus)**

ANATOMY & HISTOLOGY

[Anatomical and functional aspects of the thoracic and lumbar spine] Graichen H, et al. **Orthopade** 1999 May;28(5):424–31 (43 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Lesson of the week: fractures of the thoracolumbar spine in major trauma patients [see comments] Meek S. **BMJ** 1998 Nov 21;317(7170):1442–3 (11 ref.) Comment in: BMJ 1999 May 8;318(7193):1287–8. Comment in: BMJ 1999 May 8;318(7193):1288.
Nonsurgical treatment of thoracic and lumbar fractures. Rechtine GR. **Instr Course Lect** 1999;48:413–6 (20 ref.)
Lateral extracavitary approach for thoracic and thoracolumbar spine trauma: operative complications. Resnick DK, et al. **Neurosurgery** 1998 Oct;43(4):796–802; discussion 802–3 (22 ref.)
Thoracic and lumbar trauma: rationale for selecting the appropriate fusion technnique. McCullen G, et al. **Orthop Clin North Am** 1998 Oct;29(4):813–28 (87 ref.)
Clay-shoveler's fracture. Stress fracture of the lower cervical and upper thoracic spinous processes. Dellestable F, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):575–82 (35 ref.)
[Management of injuries of the thoracic and lumbar vertebrae in children] Kathrein A, et al. **Orthopade** 1999 May;28(5):441–50 (60 ref.) (Eng. Abstr.) **(Ger)**
[Transpedicular fusion of the thoraco-lumbar junction. Clinical, radiographic and CT results] Knop C, et al. **Orthopade** 1999 Aug;28(8):703–13 (35 ref.) (Eng. Abstr.) **(Ger)**
[Combined surgery for fractures of the thoraco-lumbar junction using the inlay-span method] Kossmann T, et al. **Orthopade** 1999 May;28(5):432–40 (47 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the thoracic and lumbar spine] Eggers C, et al. **Unfallchirurg** 1998 Oct;101(10):779–90 (11 ref.) **(Ger)**
[Dorsal stabilization of fractures of the thoracic and lumbar spine by external fixator--technique and outcome] Pizanis A, et al. **Zentralbl Chir** 1998;123(8):936–43 (20 ref.) (Eng. Abstr.) **(Ger)**
[Thoraco-lumbar spinal injuries--surgical indications and

timing] Weckback A, et al. **Zentralbl Chir** 1998; 123(8):930–5 (6 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

CT and MRI appearances of a thoracic chordoma. Murphy JM, et al. **Eur Radiol** 1998;8(9):1677–9 (13 ref.)
Classification of thoracolumbar fractures and posterior instrumentation for treatment of thoracolumbar fractures. Capen DA. **Instr Course Lect** 1999;48:437–41 (24 ref.)
Thoracolumbar trauma imaging overview. Flanders AE. **Instr Course Lect** 1999;48:429–31 (16 ref.)
Solitary plasmacytoma in the thoracic spine. Two case reports. Takahashi T, et al. **Neurosurg Rev** 1998; 21(2–3):121–5 (13 ref.)
Spontaneous resolution of a cervicothoracic syrinx in a child. Case report and review of the literature. Avellino AM, et al. **Pediatr Neurosurg** 1999 Jan;30(1):43–6 (24 ref.)
The solitary intraspinal vertebral osteochondroma. An unusual cause of compressive myelopathy: features and literature review. Khosla A, et al. **Spine** 1999 Jan 1; 24(1):77–81 (16 ref.)

SURGERY

Combined anterior and posterior surgery for fractures of the thoracolumbar spine. Vaccaro AR. **Instr Course Lect** 1999; 48:443–9 (9 ref.)
Indications for thoracic and lumbar spine fusion and trends in use. Abraham DJ, et al. **Orthop Clin North Am** 1998 Oct;29(4):803 (70 ref.)
Clinical outcome after fusion of the thoracic or lumbar spine in the adult patient. Hellman EW, et al. **Orthop Clin North Am** 1998 Oct;29(4):859–69 (84 ref.)
Intraoperative electromyography during thoracolumbar spinal surgery. Holland NR. **Spine** 1998 Sep 1; 23(17):1915–22 (35 ref.)
[Thoracic intervertebral disk herniation] Malawski S. **Chir Narzadow Ruchu Ortop Pol** 1999;64(2):147–57 (42 ref.) (Eng. Abstr.) **(Pol)**
[Endoscopic surgery for thoracic spine. Critical review] Martins JW, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2B):520–7 (35 ref.) (Eng. Abstr.) **(Por)**

THORACOPLASTY

METHODS

[The use of the pleural tent in superior lobectomies] Solli P, et al. **Acta Biomed Ateneo Parmense** 1996;67(5–6):173–6 (8 ref.) (Eng. Abstr.) **(Ita)**

THORACOSCOPY

Thoracoscopic resection of a giant leiomyoma of the esophagus with a mediastinal outgrowth. Tamura K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):351–3 (11 ref.)
Video-assisted thoracic surgery (VATS). Rao A, et al. **Heart Lung** 1999 Jan–Feb;28(1):15–9 (38 ref.)
Unusual and infrequent indications for thoracoscopy. Dieter RA Jr, et al. **Int Surg** 1998 Jan–Mar;83(1):15–20 (25 ref.)
Combined laparoscopic and thoracoscopic approach to esophagectomy. Nguyen NT, et al. **J Am Coll Surg** 1999 Mar;188(3):328–32 (11 ref.)
Anaesthetic implications of thoracoscopic surgery in children. Tobias JD. **Paediatr Anaesth** 1999;9(2):103–10 (36 ref.)
Thoracoscopy in infants and children. Rothenberg SS. **Semin Pediatr Surg** 1998 Nov;7(4):194–201 (27 ref.)
Thoracoscopic resection of intrathoracic vagus neurofibroma. Yamagishi T, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):122–4 (8 ref.)
[Treatment of scoliosis in the adolescent by anterior release and vertebral arthrodesis under thoracoscopy. Preliminary results] Papin P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):231–8 (21 ref.) (Eng. Abstr.) **(Fre)**
[Surgical lung volume reduction—an option for treating severe pulmonary emphysema] Russi EW, et al. **Ther Umsch** 1999 Mar;56(3):157–60 (5 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

The pathogenesis of port-site recurrences. Reymond MA, et al. **J Gastrointest Surg** 1998 Sep–Oct;2(5):406–14 (88 ref.)

INSTRUMENTATION

[Minimally invasive heart surgery—a fad or a clinically recognized therapy method?] Reichenspurner H, et al. **Z Kardiol** 1998 Aug;87(8):594–603 (32 ref.) (Eng. Abstr.) **(Ger)**
[VATS (video-assisted thoracoscopic surgery): possibilities and limits of surgical therapy of malignant lung diseases] Stoelben E, et al. **Zentralbl Chir** 1998;123(10):1129–33 (36 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Treatment of malignant pleural effusions. Erasmus JJ, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):250–5 (55 ref.)
Thoracoscopic procedures for intrathoracic diseases: the present status. Asamura H. **Respirology** 1999 Mar;4(1):9–17 (32 ref.)
Thoracoscopic procedure for intrathoracic diseases: current status in mainland China. Ren H. **Respirology** 1999 Jun; 4(2):111–6 (28 ref.)
Thoracoscopic procedures for intrathoracic and pulmonary diseases. Sung SW, et al. **Respirology** 1999 Mar;4(1):19–29 (61 ref.)
Analysis of thoracoscopy in trauma. Villavicencio RT, et al. **Surg Endosc** 1999 Jan;13(1):3–9 (39 ref.)

THORACOSTOMY

see related
CHEST TUBES

Surgical management of intrapleural infections. Ferguson MK. **Semin Respir Infect** 1999 Mar;14(1):73–81 (34 ref.)
Image-guided drainage techniques. Moulton JS. **Semin Respir Infect** 1999 Mar;14(1):59–72 (25 ref.)

METHODS

Tension pneumothorax. Barton ED. **Curr Opin Pulm Med** 1999 Jul;5(4):269–74 (24 ref.)

THORACOTOMY

Choices in pain management following thoracotomy. Peeters-Asdourian C, et al. **Chest** 1999 May;115(5 Suppl):122S–124S (19 ref.)
Pathogenesis and management of persistent postthoracotomy pain. d'Amours RH, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):703–22 (90 ref.)
Mechanical ventilation for respiratory failure postthoracotomy. D'Arsigny C, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):585–610 (124 ref.)
Postoperative pneumonia. Ferdinand B, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):529–39, viii (48 ref.)
Myocardial ischemia and infarction postthoracotomy. Herrington CS, et al. **Chest Surg Clin N Am** 1998 Aug; 8(3):495–502, vii (24 ref.)
Gastrointestinal complications postthoracotomy and postvagotomy. Kokoska ER, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):645–61 (47 ref.)
The role of thoracic surgery in diagnosing interstitial lung disease. Rizzato G. **Curr Opin Pulm Med** 1999 Sep; 5(5):284–6 (27 ref.)
Post-thoracotomy analgesia and perioperative outcome. Sandler AN. **Minerva Anestesiol** 1999 May;65(5):267–74 (55 ref.)
Pain management in cardiothoracic practice. Kruger M, et al. **Surg Clin North Am** 1999 Apr;79(2):387–400 (97 ref.)
[Operations of the chest wall and thorax. Chest wall operations including thoracotomy. 2] Dienemann H. **Zentralbl Chir** 1998;123(11):1317–21 (6 ref.) **(Ger)**

ADVERSE EFFECTS

Con: every postthoracotomy patient does not deserve thoracic epidural analgesia. Grant RP. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):355–7 (43 ref.)
Pro: every postthoracotomy patient deserves thoracic epidural analgesia. Slinger PD. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):350–4 (43 ref.)
Post-thoracotomy spirometric lung function: the effect of analgesia. A review. Richardson J, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):445–56 (85 ref.)

METHODS

Effect of minimally invasive thoracic surgical approaches on acute and chronic postoperative pain. Landreneau RJ, et al. **Chest Surg Clin N Am** 1998 Nov;8(4):891–906 (70 ref.)
Analysis of thoracoscopy in trauma. Villavicencio RT, et al. **Surg Endosc** 1999 Jan;13(1):3–9 (39 ref.)
[Operations of the chest wall and thorax] Dienemann H. **Zentralbl Chir** 1998;123(10):1205–15 (0 ref.) **(Ger)**

THORAX

see related
RADIOGRAPHY, THORACIC
THORACIC SURGERY
THORACOPLASTY
THORACOSCOPY
THORACOSTOMY
THORACOTOMY

Thoracic foreign bodies in adults. Kavanagh PV, et al. **Clin Radiol** 1999 Jun;54(6):353–60 (17 ref.)
[Serratus anterior muscle flap: indications and sequelae. 26 cases and review of the literature] Fassio E, et al. **Ann Chir Plast Esthet** 1999 Apr;44(2):175–82; discussion 183 (34 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Modalities of ventilation in neuromuscular disorders and thoracic deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Oct;53(5):552–5 (10 ref.)
Rehabilitation in neuromuscular disorders and thoracic wall deformities. Shneerson JM. **Monaldi Arch Chest Dis** 1998 Aug;53(4):415–8 (26 ref.)
Prosopo-thoracopagus conjoined twins and other cephalopagus-thoracopagus intermediates: case report and review of the literature. Spencer R, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):164–71 (18 ref.)

BLOOD SUPPLY

Three-dimensional CT angiography of the thorax: clinical applications. Kawamoto S, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):425–38 (46 ref.)

ULTRASONOGRAPHY

[Diagnosis of parenchymal lung diseases. Possibilities and limits of transthoracic sonography] Kroegel C, et al. **Dtsch Med Wochenschr** 1999 Jun 18;124(24):765–72 (22 ref.) **(Ger)**

THORIUM

[Thorium a radioactive element in current use: physical-chemical properties and biological processing] Laroche P, et al. **Ann Pharm Fr** 1998;56(3):115–22 (32 ref.) (Eng. Abstr.) **(Fre)**

THORIUM DIOXIDE

ADVERSE EFFECTS

Thorotrast associated nodular regenerative hyperplasia of the liver. Beer TW, et al. **J Clin Pathol** 1998 Dec;51(12):941–2 (12 ref.)

THORIUM OXIDE see **THORIUM DIOXIDE**

THORNAPPLE see **STRAMONIUM**

THORNY-HEADED WORMS see **ACANTHOCEPHALA**

THREE-DAY SICKNESS see **EPHEMERAL FEVER**

3TC see **LAMIVUDINE**

THREONINE

METABOLISM

The anaerobic degradation of L-serine and L-threonine in enterobacteria: networks of pathways and regulatory signals. Sawers G. **Arch Microbiol** 1998 Dec;171(1):1–5 (30 ref.)

THRESHOLD LIMIT VALUES see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

THROAT see **PHARYNX**

THROMBASE see **THROMBIN**

THROMBASTHENIA

see related
PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX

[Glanzmann's thrombasthenia type I] Sugimoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):354–7 (9 ref.) **(Jpn)**
[Type II thrombasthenia] Sugimoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):358–60 (4 ref.) **(Jpn)**

IMMUNOLOGY

[Thrombasthenia with anti-platelet antibodies] Sagawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):385–7 (8 ref.) **(Jpn)**

THROMBECTOMY

see related
EMBOLECTOMY

INSTRUMENTATION

The use of the Fogarty catheter in 1998. Hill B, et al. **Cardiovasc Surg** 1999 Apr;7(3):273–8 (7 ref.)
[Percutaneous thrombectomy and mechanical thrombolysis] Brossmann J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):344–54 (85 ref.) (Eng. Abstr.) **(Ger)**

THROMBIN

see related
COAGULANTS

ANTAGONISTS & INHIBITORS

The mechanisms of action of alpha- and beta-isoforms of antithrombin. Swedenborg J. **Blood Coagul Fibrinolysis** 1998 Nov;9 Suppl 3:S7–10 (26 ref.)
Thrombin inhibitor design. Sanderson PE, et al. **Curr Med Chem** 1998 Aug;5(4):289–304 (94 ref.)
Therapeutic inhibition of thrombin activities, receptors, and production. Harker LA. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1211–30 (86 ref.)
Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. Januzzi JL Jr,

et al. **J Thromb Thrombolysis** 1999 Jun;7(3):259–64 (28 ref.)
Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Hauptmann J, et al. **Thromb Res** 1999 Mar 1; 93(5):203–41 (277 ref.)
[New antithrombotic oligosaccharides] Petitou M, et al. **Ann Pharm Fr** 1999 May;57(3):232–9 (15 ref.) (Eng. Abstr.) **(Fre)**
[Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation] Pastorova VE, et al. **Usp Fiziol Nauk** 1999 Apr–Jun;30(2):80–91 (66 ref.) (Eng. Abstr.) **(Rus)**
[Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role] Rossi EB, et al. **Medicina (B Aires)** 1999;59(1):95–104 (77 ref.) (Eng. Abstr.) **(Spa)**
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] López-Sendón J, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:76–89 (66 ref.) (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Tissue factor expression by monocytes: regulation and pathophysiological roles. Osterud B. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S9–14 (36 ref.)
Therapeutic inhibition of thrombin activities, receptors, and production. Harker LA. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1211–30 (86 ref.)

CHEMISTRY

Thrombin interaction with platelet GpIb: structural mapping and effects on platelet activation (review). De Cristofaro R, et al. **Int J Mol Med** 1999 Apr;3(4):363–71 (78 ref.)

DRUG EFFECTS

Is thrombin a pharmacological target during reperfusion? White HD. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S55–7 (18 ref.)

METABOLISM

Pathobiology of thrombin in acute coronary syndromes. Becker RC, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S19–31 (45 ref.)
Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis. Pavone V, et al. **Biol Chem** 1998 Aug–Sep;379(8–9):987–1006 (140 ref.)
Thrombin interaction with platelet GpIb: structural mapping and effects on platelet activation (review). De Cristofaro R, et al. **Int J Mol Med** 1999 Apr;3(4):363–71 (78 ref.)
The clearance of thrombin–antithrombin and related serpin–enzyme complexes from the circulation: role of various hepatocyte receptors. Wells MJ, et al. **Thromb Haemost** 1999 Mar;81(3):325–37 (179 ref.)
A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding. Buchanan MR, et al. **Wien Klin Wochenschr** 1999 Feb 12;111(3):81–9 (88 ref.)

PHARMACOLOGY

Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms. Puri RN. **Int J Biochem Cell Biol** 1998 Oct;30(10):1107–22 (152 ref.)

PHYSIOLOGY

Thrombin: a novel renal growth factor. Grandaliano G, et al. **Exp Nephrol** 1999 Jan–Feb;7(1):20–5 (47 ref.)
How the protease thrombin talks to cells. Coughlin SR. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11023–7 (66 ref.)
[Thrombin and its pharmacologic regulation] Guillin MC. **Presse Med** 1998 Jun;27 Suppl 2:22–7 (42 ref.) (Eng. Abstr.) **(Fre)**
[The role of thrombin in hemostasis] Olas B, et al. **Postepy Hig Med Dosw** 1998;52(5):471–87 (85 ref.) (Eng. Abstr.) **(Pol)**

THROMBIN RECEPTORS see **RECEPTORS, THROMBIN**

THROMBOANGIITIS OBLITERANS

[Buerger's disease or thromboangiitis obliterans] Reny JL, et al. **Rev Med Interne** 1998 Jan;19(1):34–43 (71 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Buerger's disease with intestinal involvement. Iwai T. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S257–63; discussion S265 (25 ref.)
Visceral intestinal Buerger's disease. Lie JT. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S249–56 (30 ref.)

ETIOLOGY

Takayasu arteritis, Buerger disease and inflammatory abdominal aortic aneurysms: is there a common pathway in their pathogenesis? Numano F. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S5–10 (40 ref.)
Pathology and pathogenesis of Buerger's disease. Tanaka K. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S237–42 (28 ref.)

PATHOLOGY

Pathology and pathogenesis of Buerger's disease. Tanaka K. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S237–42 (28 ref.)

SURGERY

The change in concept and surgical treatment on Buerger's disease--personal experience and review. Nakajima N. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S273–80; discussion S281 (5 ref.)
Buerger's disease: the role of omental transfer [letter] Puneet, et al. **Trop Doct** 1999 Apr;29(2):118–20 (4 ref.)

THROMBOCYTAPHERESIS see **PLATELETPHERESIS**

THROMBOCYTES see **BLOOD PLATELETS**

THROMBOCYTHEMIA see **THROMBOCYTOSIS**

THROMBOCYTHEMIA, ESSENTIAL see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTHEMIA, HEMORRHAGIC

Essential thrombocythemia: another "heterogeneous disease" better understood? [comment] Nimer SD. **Blood** 1999 Jan 15;93(2):415–6 (12 ref.) Comment on: Blood 1999 Jan 15;93(2):417–24.

DIAGNOSIS

Essential thrombocythaemia. Bentley MA, et al. **Med J Aust** 1999 Aug 16;171(4):210–3 (28 ref.)
Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Murphy S. **Semin Hematol** 1999 Jan;36(1 Suppl 2):9–13 (35 ref.)

DRUG THERAPY

Essential thrombocythaemia. Bentley MA, et al. **Med J Aust** 1999 Aug 16;171(4):210–3 (28 ref.)
Clinical parameters for determining when and when not to treat essential thrombocythemia. Barbui T, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 2):14–8 (41 ref.)
Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Gilbert HS. **Semin Hematol** 1999 Jan;36(1 Suppl 2):19–22 (32 ref.)
Treatment of essential thrombocythemia with anagrelide. Silverstein MN, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 2):23–5 (28 ref.)

GENETICS

Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Aviram A, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):77–82 (32 ref.)

THERAPY

Management of essential thrombocythemia. Barbui T, et al. **Crit Rev Oncol Hematol** 1999 Feb;29(3):257–66 (64 ref.)

THROMBOCYTHEMIA, IDIOPATHIC see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTHEMIA, PRIMARY see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTOPATHY see **BLOOD PLATELET DISORDERS**

THROMBOCYTOPENIA

Gestational thrombocytopenia. Shehata N, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):327–34 (22 ref.)
[Thrombocytopenia and neutropenia] Hasegawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):329–31 (15 ref.) **(Jpn)**
[Sebastian platelet syndrome] Maeda M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):320–1 (7 ref.) **(Jpn)**
[Epstein syndrome] Maeda M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):314–5 (12 ref.) **(Jpn)**
[Amegakaryocytic thrombocytopenia] Nagasawa T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):342–6 (18 ref.) **(Jpn)**
[Fechtner syndrome] Ohata M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):322–5 (15 ref.) **(Jpn)**
[Lupoid thrombocytopenia] Shimizu K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):326–8 (5 ref.) **(Jpn)**
[May-Hegglin anomaly] Shinjo K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):56–8 (13 ref.) **(Jpn)**
[Kasabach-Merrit syndrome] Suzuki S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):513–6 (14 ref.) **(Jpn)**
[Cyclic thrombocytopenia] Terada H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):335–8 (21 ref.) **(Jpn)**

CHEMICALLY INDUCED

Carbamazepine-induced thrombocytopenia defined by a challenge test. Ishikita T, et al. **Am J Hematol** 1999 Sep; 62(1):52–5 (20 ref.)
Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Jubelirer SJ, et al. **Am J Hematol** 1999 Jul;61(3):205–8 (11 ref.)
Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44–8 (36 ref.)
Drug-induced thrombocytopenia: a systematic review of published case reports. George JN, et al. **Ann Intern Med** 1998 Dec 1;129(11):886–90 (18 ref.)
Heparin-induced thrombocytopenia: a ten-year retrospective. Warkentin TE. **Annu Rev Med** 1999; 50:129–47 (59 ref.)
Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. Amiral J, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):447–60 (73 ref.)
Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. Greinacher A. **Baillieres Clin Haematol** 1998 Jun;11(2):461–74 (74 ref.)
Heparin-induced thrombocytopenia. Kaplan KL, et al. **Blood Rev** 1999 Mar;13(1):1–7 (75 ref.)
Treatment of May-Thurner syndrome with catheter-directed thrombolysis and stent placement, complicated by heparin-induced thrombocytopenia. Seidensticker D, et al. **Cardiovasc Surg** 1998 Dec;6(6):607–13 (29 ref.)
Heparin-induced thrombocytopenia and thrombosis. Arepally G, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):237–47 (94 ref.)
Drug-induced thrombocytopenia. Rizvi MA, et al. **Curr Opin Hematol** 1999 Sep;6(5):349–53 (35 ref.)
Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. Kadidal VV, et al. **J Intern Med** 1999 Sep;246(3):325–9 (22 ref.)
Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. Januzzi JL Jr, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):259–64 (28 ref.)
Newer strategies for the treatment of heparin-induced thrombocytopenia. Warkentin TE, et al. **Pharmacotherapy** 1999 Feb;19(2):181–95 (84 ref.)
Antigens involved in heparin-induced thrombocytopenia. Amiral J. **Semin Hematol** 1999 Jan;36(1 Suppl 1):7–11 (29 ref.)
Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective. Blakeman B. **Semin Hematol** 1999 Jan;36(1 Suppl 1):37–41 (14 ref.)
Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Chong BH, et al. **Semin Hematol** 1998 Oct;35(4 Suppl 5):3–8; discussion 35–6 (26 ref.)
Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes. Cohen M. **Semin Hematol** 1999 Jan;36(1 Suppl 1):33–6 (14 ref.)
The clinical management of heparin-induced thrombocytopenia. Kelton JG. **Semin Hematol** 1999 Jan; 36(1 Suppl 1):17–21 (12 ref.)
New treatment options for heparin-induced thrombocytopenia. Ortel TL, et al. **Semin Hematol** 1998 Oct;35(4 Suppl 5):26–34; discussion 35–6 (29 ref.)
Heparin-induced thrombocytopenia. Ortel TL. **Semin Hematol** 1998 Oct;35(4 Suppl 5):1–2 (18 ref.)
Limitations of conventional treatment options for heparin-induced thrombocytopenia. Warkentin TE. **Semin Hematol** 1998 Oct;35(4 Suppl 5):17–25; discussion 35–6 (27 ref.)
Clinical presentation of heparin-induced thrombocytopenia. Warkentin TE. **Semin Hematol** 1998 Oct;35(4 Suppl 5):9–16; discussion 35–6 (30 ref.)
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. Budd GT, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):41–50 (41 ref.)
[Heparin-induced thrombopenia. Clinical manifestations and physiopathology] Gruel Y. **Presse Med** 1998 Jun;27 Suppl 2:7–12 (37 ref.) (Eng. Abstr.) **(Fre)**
[Biological diagnosis and surveillance of heparin-induced thrombopenia] Nguyên P. **Presse Med** 1998 Jun;27 Suppl 2:13–7 (18 ref.) (Eng. Abstr.) **(Fre)**
[Management of a suspicion of heparin-induced thrombopenia] Samama CM. **Presse Med** 1998 Jun;27 Suppl 2:18–21 (10 ref.) (Eng. Abstr.) **(Fre)**
[Heparin-induced thrombopenias: new treatments (editorial; comment)] Lecompte T, et al. **Rev Med Interne** 1998 Nov; 19(11):783–6 (15 ref.) Comment on: Rev Med Interne 1998 Nov;19(11):819–22. **(Fre)**
[Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation] Madei W, et al. **Dtsch Med Wochenschr** 1999 Apr 23; 124(16):487–90 (16 ref.) (Eng. Abstr.) **(Ger)**
[Current treatment concepts in heparin-induced thrombocytopenia] Ranze O, et al. **Dtsch Med Wochenschr** 1999 Jul 16;124(28–29):865–73 (67 ref.) **(Ger)**
[Drug-induced thrombocytopenia] Higuchi W, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):311–3 (6 ref.) **(Jpn)**

[Heparin-induced thrombocytopenia] Koide M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):307-10 (15 ref.) **(Jpn)**
[Giant intracavitary thrombi secondary to a heparin-induced thrombocytopenia-thrombosis syndrome] Fernández Ratero JA, et al. **Rev Esp Cardiol** 1999 Apr;52(4):269-72 (8 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999; 77(6):55-9 (2 ref.) **(Rus)**

COMPLICATIONS

Hematologic complications of heparin-induced thrombocytopenia. Raible MD. **Semin Thromb Hemost** 1999;25 Suppl 1:17-21 (60 ref.)
[Intestinal complications of thrombotic microangiopathy in the adult. 4 cases and review of the literature] Klisnick A, et al. **Ann Med Interne (Paris)** 1999 Jan;150(1):4-9 (36 ref.) (Eng. Abstr.) **(Fre)**
[Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation] Madei W, et al. **Dtsch Med Wochenschr** 1999 Apr 23; 124(16):487-90 (16 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. Amiral J, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):447-60 (73 ref.)
Review of autoimmune thrombocytopenia: pathogenesis, diagnosis, and management in pregnancy. Johnson JR, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):317-26 (16 ref.)
Alloimmune thrombocytopenia. Skupski DW, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):335-48 (41 ref.)
Consultation with the specialist. Thrombocytopenia. Murphy S, et al. **Pediatr Rev** 1999 Feb;20(2):64-8; quiz 69 (5 ref.)
Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Chong BH, et al. **Semin Hematol** 1998 Oct;35(4 Suppl 5):3-8; discussion 35-6 (26 ref.)
Clinical presentation of heparin-induced thrombocytopenia. Warkentin TE. **Semin Hematol** 1998 Oct;35(4 Suppl 5):9-16; discussion 35-6 (30 ref.)
[Heparin-induced thrombocytopenia] Novotný J, et al. **Vnitr Lek** 1998 May;44(5):282-7 (31 ref.) (Eng. Abstr.) **(Cze)**
[Pseudothrombocytopenia] Tsukada T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):347-9 (19 ref.) **(Jpn)**

DRUG THERAPY

Anagrelide, a selective thrombocytopenic agent. Oertel MD. **Am J Health Syst Pharm** 1998 Oct 1;55(19):1979-86 (24 ref.)
Uracil mustard revisited. Kennedy BJ, et al. **Cancer** 1999 May 15;85(10):2265-72 (51 ref.)
Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Apr;13 Suppl 1:S14-8 (23 ref.)
The clinical management of heparin-induced thrombocytopenia. Kelton JG. **Semin Hematol** 1999 Jan; 36(1 Suppl 1):17-21 (12 ref.)
New treatment options for heparin-induced thrombocytopenia. Ortel TL, et al. **Semin Hematol** 1998 Oct;35(4 Suppl 5):26-34; discussion 35-6 (29 ref.)
Limitations of conventional treatment options for heparin-induced thrombocytopenia. Warkentin TE. **Semin Hematol** 1998 Oct;35(4 Suppl 5):17-25; discussion 35-6 (27 ref.)
[An unusual effect of cyclosporine A in a patient with chronic lympholeukemia complicated by autoimmune hemolysis and thrombocytolysis] Vinogradova OA, et al. **Ter Arkh** 1998;70(7):75-7 (12 ref.) **(Rus)**

ETIOLOGY

Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14-8 (23 ref.)
[Refractoriness to platelet transfusion] Tsurumi H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):332-4 (8 ref.) **(Jpn)**
[Thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999; 77(6):55-9 (2 ref.) **(Rus)**
[Severe thrombocytopenia secondary to cytomegalovirus infection in an immunocompetent adult (letter)] López Vivancos J, et al. **An Med Interna** 1998 Oct;15(10):561-2 (8 ref.) **(Spa)**
[Thrombocytopenia in the antiphospholipid syndrome (editorial)] Martin H, et al. **Med Clin (Barc)** 1998 Dec 12; 111(20):776-8 (27 ref.) **(Spa)**
[Treatment of Kasabach Merritt syndrome] Lanau Arilla MP, et al. **Sangre (Barc)** 1998 Jun;43(3):218-22 (35 ref.) **(Spa)**

IMMUNOLOGY

T cell immunobiology of alloimmune thrombocytopenias. Gorski J, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):269-75 (33 ref.)
Management of fetal and neonatal alloimmune thrombocytopenia. Forestier F, et al. **Biol Neonate** 1998 Dec;74(6):395-401 (34 ref.)
Antigens involved in heparin-induced thrombocytopenia. Amiral J. **Semin Hematol** 1999 Jan;36(1 Suppl 1):7-11 (29 ref.)
The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients. Novotný VM, et al. **Transfus Med Rev** 1999 Apr;13(2):95-105 (60 ref.)
Neonatal alloimmune thrombocytopenia due to anti-HPA-1b (PLA2)(Zwb). A case report and review. Winters JL, et al. **Vox Sang** 1998;74(4):256-9 (19 ref.)

PATHOLOGY

Sebastian syndrome: case report and review of the literature. Young G, et al. **Am J Hematol** 1999 May;61(1):62-5 (15 ref.)

PHYSIOPATHOLOGY

Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. Greinacher A. **Baillieres Clin Haematol** 1998 Jun;11(2):461-74 (74 ref.)
Pathophysiology and management of thrombotic microangiopathies. Ruggenenti P, et al. **J Nephrol** 1998 Nov-Dec;11(6):300-10 (58 ref.)
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed J, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:37-42 (24 ref.)
[Heparin-induced thrombopenia. Clinical manifestations and physiopathology] Gruel Y. **Presse Med** 1998 Jun;27 Suppl 2:7-12 (37 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Thrombopoietin: biology and potential clinical applications. Prow D, et al. **Oncology (Huntingt)** 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4 (78 ref.)
Incorporating new modalities into practice guidelines: platelet growth factors. Rubenstein EB, et al. **Oncology (Huntingt)** 1998 Nov;12(11A):381-6 (15 ref.)
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. Budd GT, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):41-50 (41 ref.)
The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation. Wagemaker G, et al. **Stem Cells** 1998;16(6):375-86 (97 ref.)
Prevention and management of platelet transfusion refractoriness. Novotny VM. **Vox Sang** 1999;76(1):1-13 (109 ref.)
Screening programmes for foetomaternal alloimmune thrombocytopenia. Williamson LM. **Vox Sang** 1998;74 Suppl 2:385-9 (32 ref.)

THERAPY

Management of fetal and neonatal alloimmune thrombocytopenia. Forestier F, et al. **Biol Neonate** 1998 Dec;74(6):395-401 (34 ref.)
Hematopoietic supportive care. Hester J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2666-70 (27 ref.)
Review of autoimmune thrombocytopenia: pathogenesis, diagnosis, and management in pregnancy. Johnson JR, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):317-26 (16 ref.)
Alloimmune thrombocytopenia. Skupski DW, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):335-48 (41 ref.)
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14-8 (23 ref.)
Newer strategies for the treatment of heparin-induced thrombocytopenia. Warkentin TE, et al. **Pharmacotherapy** 1999 Feb;19(2):181-95 (84 ref.)
Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective. Blakeman B. **Semin Hematol** 1999 Jan;36(1 Suppl 1):37-41 (14 ref.)
Prevention and management of platelet transfusion refractoriness. Novotny VM. **Vox Sang** 1999;76(1):1-13 (109 ref.)
[Management of a suspicion of heparin-induced thrombopenia] Samama CM. **Presse Med** 1998 Jun;27 Suppl 2:18-21 (10 ref.) (Eng. Abstr.) **(Fre)**
[Heparin-induced thrombopenias: new treatments (editorial; comment)] Lecompte T, et al. **Rev Med Interne** 1998 Nov; 19(11):783-6 (15 ref.) Comment on: Rev Med Interne 1998 Nov;19(11):819-22. **(Fre)**
[Treatment of thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999;77(7):56-9 (0 ref.) **(Rus)**
[Alternatives to platelet transfusion] Mazzara R, et al. **Sangre (Barc)** 1998 Aug;43(4):331-8 (64 ref.) **(Spa)**

THROMBOCYTOSIS

[Reactive (secondary) thrombocytosis] Saito H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):281-3 (5 ref.) **(Jpn)**
[Montreal platelet syndrome] Shimasaki AK. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):316-9 (14 ref.) **(Jpn)**

BLOOD

Functional roles of thrombopoietin-c-mpl system in essential thrombocythemia. Matsumura I, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):351-8 (57 ref.)

DIAGNOSIS

[Thrombocytosis. Diagnostic guidance] Brière J. **Rev Prat** 1998 May 15;48(10):1141-5 (1 ref.) **(Fre)**

THROMBOEMBOLISM

Venous thromboembolic disease in the pediatric intensive care unit. Donnelly KM. **Curr Opin Pediatr** 1999 Jun; 11(3):213-7 (36 ref.)
Thromboembolism after hip and knee arthroplasty: diagnosis and treatment. Della Valle CJ, et al. **J Am Acad Orthop Surg** 1998 Nov-Dec;6(6):327-36 (31 ref.)
Thromboembolic complications of cardiac radiofrequency catheter ablation: a review of the reported incidence, pathogenesis and current research directions. Zhou L, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):611-20 (48 ref.)
Thromboembolism in the right side of the heart. Thompson CA, et al. **South Med J** 1999 Aug;92(8):826-30 (29 ref.)
[Postoperative thromboembolic disease. Prevention, diagnosis, treatment] Paquin S, et al. **Presse Med** 1998 Mar 7;27(9):407-15 (68 ref.) (Eng. Abstr.) **(Fre)**
[Thromboembolic diseases in children] Holmström H, et al. **Tidsskr Nor Laegeforen** 1999 Aug 30;119(20):3006-12 (63 ref.) (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

The adverse effects of hormone replacement therapy. Tavani A, et al. **Drugs Aging** 1999 May;14(5):347-57 (99 ref.)

COMPLICATIONS

The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. McColl MD, et al. **Br J Obstet Gynaecol** 1999 Aug;106(8):756-66 (106 ref.)
Cancer and venous thromboembolism: an overview. Prandoni P, et al. **Haematologica** 1999 May;84(5):437-45 (102 ref.)

DIAGNOSIS

Thromboembolic disease in total knee arthroplasty. Lonner JH. **Am J Knee Surg** 1999 Winter;12(1):43-8 (47 ref.)
Venous thromboembolism. Hyers TM. **Am J Respir Crit Care Med** 1999 Jan;159(1):1-14 (160 ref.)
Venous thromboembolic events in pediatric patients. Diagnosis and management. Streif W, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1283-312, vii (167 ref.)
Rational diagnosis of pulmonary embolism (RADIA PE) in symptomatic outpatients with suspected PE: an improved strategy to exclude or diagnose venous thromboembolism by the sequential use of a clinical model, rapid ELISA D-dimer test, perfusion lung scan, ultrasonography, spiral CT, and pulmonary angiography. Michiels JJ. **Semin Thromb Hemost** 1998;24(4):413-8 (28 ref.)

DRUG THERAPY

Fortnightly review: anticoagulation in heart disease. Hardman SM, et al. **BMJ** 1999 Jan 23;318(7178):238-44 (43 ref.)
Thrombolytic therapy in the management of paediatric thromboembolic disease. Chalmers EA, et al. **Br J Haematol** 1999 Jan;104(1):14-21 (70 ref.)
Anticoagulation. Brown HL, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):545-54 (49 ref.)
Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins. Hirsh J. **Curr Opin Hematol** 1998 Sep; 5(5):360-5 (12 ref.)
Treatment and prevention of venous thromboembolic disease in pregnancy. Valentine KA. **Curr Opin Pulm Med** 1999 Jul;5(4):238-43 (60 ref.)
Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring [editorial] Hull RD, et al. **Int Angiol** 1998 Dec; 17(4):213-24 (95 ref.)
Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme [editorial] Hull RD, et al. **Int Angiol** 1998 Sep;17(3):131-4 (31 ref.)
Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings. Schulman S. **J Intern Med** 1999 Apr;245(4):399-403 (25 ref.)
Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Haustein KO. **Semin Thromb Hemost** 1999;25(1):5-11 (20 ref.)
Treatment of venous thromboembolism in cancer patients. Levine MN, et al. **Semin Thromb Hemost** 1999;25(2):245-9 (35 ref.)
[New antiplatelet agents] Beer JH. **Schweiz Rundsch Med Prax** 1999 May 6;88(19):853-60 (45 ref.) (Eng. Abstr.) **(Ger)**
[Low molecular weight heparin--1998 status] Marbet GA. **Schweiz Rundsch Med Prax** 1999 Apr 29;88(18):802-7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Heparin therapy: 1998 (current use of the 80-year-old heparin)] Rák K. **Orv Hetil** 1999 Jan 10;140(2):59–66 (59 ref.) (Eng. Abstr.) **(Hun)**

[Heparin in anesthesia. Pharmacological and clinical aspects in the prophylaxis of venous thromboembolism] Verso M, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):35–9 (28 ref.) **(Ita)**

EPIDEMIOLOGY

Risk factors for venous thromboembolism in pregnancy. McColl MD, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):227–32 (49 ref.)

[Evaluation of the risk of venous thromboembolism in the medical patients] Mismetti P, et al. **Therapie** 1998 Nov–Dec; 53(6):565–70 (14 ref.) (Eng. Abstr.) **(Fre)**

[Thromboembolism--genetic and acquired risk factors] Pabinger-Fasching I. **Acta Med Austriaca** 1999;26(2):37–40 (6 ref.) (Eng. Abstr.) **(Ger)**

[Incidence of thromboembolism after heart valve replacement: modifying factors] Burckhardt D, et al. **Z Kardiol** 1998;87 Suppl 4:33–6 (11 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Thromboembolism in inflammatory bowel disease. Schapira M, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):182–6 (55 ref.)

Thromboembolic disease in total knee arthroplasty. Lonner JH. **Am J Knee Surg** 1999 Winter;12(1):43–8 (47 ref.)

Concerning thromboembolism associated with left ventricular assist devices. Gross DR. **Cardiovasc Res** 1999 Apr;42(1):45–7 (30 ref.)

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Oger E, et al. **Drugs Aging** 1999 Jan;14(1):55–61 (38 ref.)

Natural anticoagulants, aging, and thromboembolism. Sagripanti A, et al. **Exp Gerontol** 1998 Nov–Dec; 33(7–8):891–6 (29 ref.)

Does heart failure confer a hypercoagulable state? Virchow's triad revisited. Lip GY, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1424–6 (23 ref.)

Venous thromboembolism in the patient with acute traumatic brain injury: screening, diagnosis, prophylaxis, and treatment issues. Hammond FM, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):36–50 (100 ref.)

Oral anticoagulation in nonvalvular atrial fibrillation. Koefoed BG, et al. **J Intern Med** 1999 Apr;245(4):375–81 (40 ref.)

Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty. Maling TJ. **N Z Med J** 1999 Aug 27;112(1094):305–7 (30 ref.)

Venous thromboembolism in multiple trauma patients. Erstad BL. **Pharmacotherapy** 1998 Sep–Oct;18(5):1011–23 (70 ref.)

Treatment of venous thromboembolism in cancer patients. Levine MN, et al. **Semin Thromb Hemost** 1999;25(2):245–9 (35 ref.)

[Thromboembolic syndrome from prolonged sitting and flights of long duration: experience of the Emergency Medical Service of the Paris Airports] Clérel M, et al. **Bull Acad Natl Med** 1999;183(5):985–97; discussion 997–1001 (34 ref.) (Eng. Abstr.) **(Fre)**

[Thromboembolism--genetic and acquired risk factors] Pabinger-Fasching I. **Acta Med Austriaca** 1999;26(2):37–40 (6 ref.) (Eng. Abstr.) **(Ger)**

[Cancer and thromboembolism] Hara N, et al. **Nippon Rinsho** 1999 Jul;57(7):1648–52 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Thromboembolic complications, venous hemodynamics and lower extremities in laparoscopic operations] Starkov IuG, et al. **Khirurgiia (Mosk)** 1999;(8):63–7 (68 ref.) **(Rus)**

[Moderate hyperhomocysteinemia and atherothrombosis] Falcón CR. **Medicina (B Aires)** 1998;58(5 Pt 1):511–4 (17 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Factor VLeiden: death and DNA [editorial; comment] Florell SR, et al. **Am J Clin Pathol** 1999 Mar;111(3):302–3 (8 ref.) Comment on: Am J Clin Pathol 1999 Mar;111(3):413–7.

PREVENTION & CONTROL

Long-term antithrombotic treatment for atrial fibrillation. Nademanee K, et al. **Am J Cardiol** 1998 Oct 16; 82(8A):37N–42N (22 ref.)

The role of low molecular weight heparin in total knee arthroplasty. Iobst CA, et al. **Am J Knee Surg** 1999 Winter; 12(1):55–60 (14 ref.)

Warfarin prophylaxis after total knee arthroplasty. Lieberman JR. **Am J Knee Surg** 1999 Winter;12(1):49–53 (22 ref.)

The role of aspirin for thromboembolic disease in total joint arthroplasty. Lotke PA. **Am J Knee Surg** 1999 Winter; 12(1):61–3 (15 ref.)

The role of mechanical and other adjuncts. Westrich GH. **Am J Knee Surg** 1999 Winter;12(1):64–71 (92 ref.)

Risk reduction in the intensive care unit [see comments] Saint S, et al. **Am J Med** 1998 Dec;105(6):515–23 (117 ref.) Comment in: Am J Med 1998 Dec;105(6):551–3.

Current clinical concepts in perioperative anticoagulation. Hewitt RL, et al. **Am Surg** 1999 Mar;65(3):270–3 (15 ref.)

Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous? Nurmohamed MT, et al. **Ann Rheum Dis** 1999 Jul;58(7):392–5 (38 ref.)

Antithrombin substitution therapy. Schinzel H, et al. **Blood Coagul Fibrinolysis** 1998 Nov;9 Suppl 3:S17–21; discussion S21–2 (45 ref.)

Antithrombotic agents in coronary artery disease. Cairns JA, et al. **Chest** 1998 Nov;114(5 Suppl):611S–633S (157 ref.)

Prevention of venous thromboembolism. Clagett GP, et al. **Chest** 1998 Nov;114(5 Suppl):531S–560S (424 ref.)

Antithrombotic therapy for venous thromboembolic disease. Hyers TM, et al. **Chest** 1998 Nov;114(5 Suppl):561S–578S (260 ref.)

Antithrombotic therapy in valvular heart disease. Salem DN, et al. **Chest** 1998 Nov;114(5 Suppl):590S–601S (142 ref.)

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Stein PD, et al. **Chest** 1998 Nov;114(5 Suppl):602S–610S (57 ref.)

Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. van Gorp EC, et al. **Drugs Aging** 1998 Aug;13(2):145–57 (94 ref.)

Anticoagulant therapy, anti-platelet agents and gastrointestinal endoscopy. Miller AM, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):109–13 (43 ref.)

Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. Cannegieter SC, et al. **J Intern Med** 1999 Apr;245(4):369–74 (34 ref.)

Oral anticoagulation in nonvalvular atrial fibrillation. Koefoed BG, et al. **J Intern Med** 1999 Apr;245(4):375–81 (40 ref.)

Oral anticoagulation in peripheral vascular surgery: how intense, for how long, or at all? Kretschmer G, et al. **J Intern Med** 1999 Apr;245(4):389–97 (44 ref.)

Cardioversion in atrial fibrillation: indications, thromboembolic prophylaxis, and role of transesophageal echocardiography. Main ML, et al. **J Thromb Thrombolysis** 1999 Jan;7(1):53–60 (60 ref.)

Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty. Maling TJ. **N Z Med J** 1999 Aug 27;112(1094):305–7 (30 ref.)

Low molecular weight heparin use during pregnancy: issues of safety and practicality. Chan WS, et al. **Obstet Gynecol Surv** 1999 Oct;54(10):649–54 (38 ref.)

Venous thromboembolism in multiple trauma patients. Erstad BL. **Pharmacotherapy** 1998 Sep–Oct;18(5):1011–23 (70 ref.)

Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. Garg RK, et al. **Prog Cardiovasc Dis** 1998 Nov–Dec;41(3):225–36 (76 ref.)

Aspirin: benefit and risk in thromboprophylaxis. Dickinson JP, et al. **QJM** 1998 Aug;91(8):523–38 (125 ref.)

Prevention of venous thromboembolism in cancer patients. Kakkar AK, et al. **Semin Thromb Hemost** 1999;25(2):239–43 (39 ref.)

[Risk factors in venous thromboembolism] Le Pecq-Gentil B, et al. **Presse Med** 1998 Apr 25;27(16):779–85 (40 ref.) **(Fre)**

[Evaluation of the risk of venous thromboembolism in the medical patients] Mismetti P, et al. **Therapie** 1998 Nov–Dec; 53(6):565–70 (14 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of venous thrombosis: role of heparins] Wahl D, et al. **Therapie** 1998 Nov–Dec;53(6):575–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy. Modern therapeutic approaches] Harenberg J, et al. **Internist (Berl)** 1999 Aug;40(8):885–93 (61 ref.) **(Ger)**

[Prevention of thrombosis in heart valve diseases] Meyer BJ, et al. **Ther Umsch** 1998 Dec;55(12):756–61 (9 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in surgery, after hemorrhagic complications and in pregnancy] Gohlke-Bärwolf C. **Z Kardiol** 1998;87 Suppl 4:56–62 (41 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in patients with heart valve replacement in pregnancy] Harenberg J. **Z Kardiol** 1998;87 Suppl 4:63–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Intracardiac thrombosis and consecutive thromboembolisms in patients with heart valve diseases: predisposition and concepts for prevention] Piper C, et al. **Z Kardiol** 1998;87 Suppl 4:1–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Intensity of oral anticoagulant therapy after heart valve replacement] Stenzinger W. **Z Kardiol** 1998;87 Suppl 4:37–41 (12 ref.) (Eng. Abstr.) **(Ger)**

[Inhibition of thrombocyte aggregation after heart valve replacement] von Schacky C. **Z Kardiol** 1998;87 Suppl 4:46–55 (64 ref.) (Eng. Abstr.) **(Ger)**

[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)] Martyin T, et al. **Orv Hetil** 1998 Dec 20;139(51):3065–9 (29 ref.) (Eng. Abstr.) **(Hun)**

[Anticoagulant therapy in patients with dilated cardiomyopathy] Gensini GF, et al. **Ann Ital Med Int** 1998 Oct–Dec;13(4):227–32 (20 ref.) (Eng. Abstr.) **(Ita)**

[The assessment of the thromboembolic risk and the role of antithrombotic prophylaxis in nonrheumatic atrial fibrillation] Fera MS, et al. **G Ital Cardiol** 1999 Feb; 29(2):193–213 (122 ref.) **(Ita)**

[The embolic risk and oral anticoagulant therapy in chronic heart failure] Urbinati S, et al. **G Ital Cardiol** 1999 Feb; 29(2):183–92 (52 ref.) **(Ita)**

[Frontiers in prevention of thromboembolism in nonvalvular atrial fibrillation] Fukunami M. **J Cardiol** 1999 Mar;33 Suppl 1:65–70 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Anticoagulation in atrial fibrillation: not yet settled] Montagna R, et al. **Rev Med Chil** 1998 Jun;126(6):689–701 (42 ref.) (Eng. Abstr.) **(Spa)**

[The prevention of thromboembolic complications in neurosurgery] Polishchuk MIe, et al. **Klin Khir** 1998; (9–10):76–9 (22 ref.) **(Ukr)**

THERAPY

Venous thromboembolism. Hyers TM. **Am J Respir Crit Care Med** 1999 Jan;159(1):1–14 (160 ref.)

The use of the Fogarty catheter in 1998. Hill B, et al. **Cardiovasc Surg** 1999 Apr;7(3):273–8 (7 ref.)

Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. van Gorp EC, et al. **Drugs Aging** 1998 Aug;13(2):145–57 (94 ref.)

Venous thromboembolic events in pediatric patients. Diagnosis and management. Streif W, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1283–312, vii (167 ref.)

ULTRASONOGRAPHY

Echocardiography in prosthetic valve disease. Garcia MJ. **Indian Heart J** 1998 May–Jun;50(3):267–76 (72 ref.)

THROMBOEMBOLISM, PULMONARY see **PULMONARY EMBOLISM**

THROMBOENDARTERECTOMY see **ENDARTERECTOMY**

THROMBOKINASE see **FACTOR XA**

THROMBOLYSIN see **PLASMIN**

THROMBOLYSIS, THERAPEUTIC see **THROMBOLYTIC THERAPY**

THROMBOLYTIC AGENTS see **FIBRINOLYTIC AGENTS**

THROMBOLYTIC THERAPY

Thrombolytic therapy. Goldhaber SZ. **Adv Intern Med** 1999; 44:311–25 (49 ref.)

Stroke: part II. Management of acute ischemic stroke. Benavente O, et al. **Am Fam Physician** 1999 May 15; 59(10):2828–34 concl (21 ref.)

Coagulation markers and outcomes in acute coronary syndromes. Ardissino D, et al. **Am Heart J** 1998 Oct;136(4 Pt 2 Su):S7–18 (28 ref.)

Infarct size: thrombolysis versus PTCA [editorial; comment] Keeley EC, et al. **Am Heart J** 1999 Jun;137(6):1007–9 (25 ref.) Comment on: Am Heart J 1999 Jun;137(6):1169–72.

Primary PTCA versus thrombolytic therapy: an evidence-based summary. Ryan TJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):96–104 (37 ref.)

The future of antithrombotic and antiplatelet therapy for ischemic heart disease. Topol EJ. **Am Heart J** 1998 Oct; 136(4 Pt 2 Su):S66–8 (12 ref.)

Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Manginas A, et al. **Am J Cardiol** 1999 Jun 1;83(11):1562–5, A7 (20 ref.)

Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Gibson CM. **Ann Intern Med** 1999 May 18;130(10):841–7 (33 ref.)

New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile. Maksimenko AV. **Ann N Y Acad Sci** 1998 Dec 13;864:96–105 (50 ref.)

Intraperitoneal thrombolytic therapy for peritoneal dialysis-associated peritonitis. Worland MA, et al. **Ann Pharmacother** 1998 Nov;32(11):1216–20 (22 ref.)

Prehospital management of acute myocardial infarction: Electrocardiogram acquisition and interpretation, and thrombolysis by prehospital care providers. Myers RB. **Can J Cardiol** 1998 Oct;14(10):1231–40 (56 ref.)

Atrial fibrillation: overview of therapeutic trials. Sharif MN, et al. **Can J Cardiol** 1998 Oct;14(10):1241–54 (130 ref.)

Proceedings of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy. 1998. **Chest** 1998 Nov;114(5 Suppl):439S–769S (0 ref.)

Antithrombotic and thrombolytic therapy for ischemic stroke. Albers GW, et al. **Chest** 1998 Nov;114(5 Suppl):683S–698S (133 ref.)

Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Arcasoy SM, et al. **Chest** 1999 Jun;115(6):1695–707 (102 ref.)

Coronary thrombolysis. Cairns JA, et al. **Chest** 1998 Nov;. 114(5 Suppl):634S–657S (175 ref.)

Prehospital thrombolysis: an idea whose time has come. Cannon CP, et al. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV10–9 (75 ref.)

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV37–43 (57 ref.)

Reperfusion revisited: beyond TIMI 3 flow. Gassler JP, et al. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV20–9 (80 ref.)

New plasminogen activators: a clinical review. Ross AM.

Clin Cardiol 1999 Mar;22(3):165–71 (54 ref.)
Advances in the medical management of acute coronary syndromes. Cannon CP. **Curr Opin Cardiol** 1998 Sep; 13(5):327–47 (157 ref.)
Antithrombotic therapy and venous graft disease. Schussheim AE, et al. **Curr Opin Cardiol** 1998 Nov;13(6):459–64 (43 ref.)
Thrombolytic therapy for venous thromboembolism. Elliott G. **Curr Opin Hematol** 1999 Sep;6(5):304–8 (35 ref.)
Thrombolytic therapy for arterial thrombosis. Shortell CK, et al. **Curr Opin Hematol** 1999 Sep;6(5):309–13 (16 ref.)
Drug therapy for acute ischaemic stroke: risks versus benefits. Lindley RI. **Drug Saf** 1998 Nov;19(5):373–82 (40 ref.)
Thrombolysis versus primary angioplasty in older patients with acute myocardial infarction. Maynard C, et al. **Drugs Aging** 1999 Jun;14(6):427–35 (33 ref.)
Applying the open artery theory: use of predictive survival markers [see comments] White HD, et al. **Eur Heart J** 1998 Aug;19(8):1132–9 (45 ref.) Comment in: Eur Heart J 1999 Mar;20(6):471.
Thrombolysis enters the race: a new era for acute ischaemic stroke? Famularo G, et al. **Eur J Emerg Med** 1998 Jun; 5(2):249–52 (16 ref.)
Thrombolytic treatment of type A right atrial thrombi: description of three cases and review of the literature. Mezzani A, et al. **G Ital Cardiol** 1999 Apr;29(4):441–6 (24 ref.)
Critical importance of myocardial salvage: relationship with the choice of reperfusion strategies. Coccolini S, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S79–83 (37 ref.)
GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction. Salame M, et al. **Int J Cardiol** 1999 Jun 1;69(3):231–6 (22 ref.)
Treatment of pulmonary thromboembolism. Goldhaber SZ. **Intern Med** 1999 Aug;38(8):620–5 (42 ref.)
Percutaneous coronary intervention versus thrombolysis: the ongoing debate. Talley JD. **J Ark Med Soc** 1998 Oct; 95(5):191–6 (15 ref.)
Thrombolytic therapy versus primary angioplasty in the treatment of acute myocardial infarction. McErlean ES. **J Cardiovasc Nurs** 1999 Apr;13(3):46–59 (62 ref.)
Acute ischaemic stroke: revascularizing therapy.Stroke Council of the American Heart Association. Spranger M, et al. **J Neurol** 1998 Sep;245(9):567–72 (31 ref.)
Thrombolysis of a neonatal brachial artery thrombosis with tissue plasminogen activator. Grieg A. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):460–2 (11 ref.)
New thrombolytic strategy: bolus administration of tPA and urokinase–fibrinogen conjugate. Maksimenko AV, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):307–12 (50 ref.)
Stroke treatment: time is brain [see comments] Hill MD, et al. **Lancet** 1998 Oct;352 Suppl 3:SIII10–4 (37 ref.) Comment in: Lancet 1999 Jan 9;353(9147):151–2.
The challenge of acute coronary syndromes. Simoons ML, et al. **Lancet** 1999 Jun;353 Suppl 2:SII1–4 (34 ref.)
Thrombolytic stroke therapy: past, present, and future. Zivin JA. **Neurology** 1999 Jul 13;53(1):14–9 (30 ref.)
Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. Simons GR, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2651–63 (74 ref.)
'Rescue' after failed thrombolysis for acute myocardial infarction [see comments] Mahy IR, et al. **Postgrad Med J** 1998 Jun;74(872):355–7 (20 ref.) Comment in: Postgrad Med J 1998 Nov;74(877):702–3.
Recanalization therapies for acute ischemic stroke. Broderick JP. **Semin Neurol** 1998;18(4):471–84 (59 ref.)
A multi-modal approach to the management of bypass graft failure. Greenberg RK, et al. **Vasc Med** 1998;3(3):215–20 (19 ref.)
[Thrombolytic therapy is efficient only within the first three hours after ischemic apoplexy (see comments)] Overgaard K, et al. **Ugeskr Laeger** 1999 Mar 15;161(11):1573–6 (30 ref.) Comment in: Ugeskr Laeger 1999 May 24;161(21):3111. Comment in: Ugeskr Laeger 1999 May 24;161(21):3111–2. **(Dan)**
[Pre-hospitalization management of evolving myocardial infarction. 2d conference of south-eastern region emergency medicine experts] Bonnet JL, et al. **Ann Fr Anesth Reanim** 1997;16(5):541–8 (34 ref.) **(Fre)**
[Concepts for stroke therapy] Weissenborn K. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Feb; 34(2):110–4 (39 ref.) (Eng. Abstr.) **(Ger)**
[Fibrinolytic therapy of deep vein thrombosis] Weidmann B, et al. **Med Klin** 1999 Mar 15;94(3):140–9 (81 ref.) (Eng. Abstr.) **(Ger)**
[Local fibrinolysis of peripheral arterial occlusions] Schwarzenberg H. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):227–35 (68 ref.) (Eng. Abstr.) **(Ger)**
[Assessment of the anti-ischemic effect in patients with therapy refractory angina pectoris in end-stage coronary heart disease—results of chronic intermittent urokinase therapy] Schoebel FC, et al. **Z Kardiol** 1998;87 Suppl 2:188–92 (11 ref.) (Eng. Abstr.) **(Ger)**
[Pre-infarction angina and post-thrombolysis recanalization] Andreotti F, et al. **Cardiologia** 1998 Sep;43(9):893–9 (67 ref.) **(Ita)**
[The effect of thrombolytic treatment on the development of global and regional left ventricular function] Paparoni S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:85–8 (25 ref.) **(Ita)**
[Thrombolytic therapy] Matsuda T. **Nippon Rinsho** 1998 Oct; 56(10):2577–81 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Thrombolytic treatment of acute myocardial infarct. 1] Soares-Costa JT, et al. **Acta Med Port** 1998 May; 11(5):409–19 (0 ref.) (Eng. Abstr.) **(Por)**
[Thrombolytic treatment of acute myocardial infarct. 2] Soares-Costa TJ, et al. **Acta Med Port** 1998 May; 11(5):421–9 (0 ref.) (Eng. Abstr.) **(Por)**
[Patient selection for direct and rescue angioplasty] Carvalho HC. **Rev Port Cardiol** 1999 Feb;18(2):193–9 (12 ref.) (Eng. Abstr.) **(Por)**
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke] Warlow C. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(2):47–50 (0 ref.) **(Rus)**
[A different focus on the current status of thrombolysis in pulmonary thromboembolism] Jerjes Sánchez C, et al. **Arch Inst Cardiol Mex** 1998 Mar–Apr;68(2):166–80 (90 ref.) **(Spa)**
[The antithrombotic treatment of acute ischemic stroke: a problem solved? (editorial)] Chamorro A. **Med Clin (Barc)** 1998 Dec 5;111(19):736–7 (14 ref.) **(Spa)**

ADVERSE EFFECTS

Systemic thrombolysis causing anastomotic dehiscence of an aortobifemoral graft [see comments] Sequeira MJ, et al. **Ann R Coll Surg Engl** 1998 Sep;80(5):343–6 (11 ref.) Comment in: Ann R Coll Surg Engl 1999 Jan;81(1):72.
Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid-dependent rheumatoid arthritis. Kotha P, et al. **Clin Cardiol** 1998 Nov;21(11):853–6 (22 ref.)
Spontaneous coronary artery dissection. Case report and literature review. Elming H, et al. **Scand Cardiovasc J** 1999; 33(3):175–9 (39 ref.)
Acute cerebral infarction caused by aortic dissection: caution in the thrombolytic era [letter] Flemming KD, et al. **Stroke** 1999 Feb;30(2):477–8 (5 ref.)
[Evaluation of ischemic risk in infarct patients submitted for fibronolysis: how and when should it be carried out?] Romano S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:89–93 (28 ref.) **(Ita)**
[Complications after treatment of acute coronary syndrome] Kodama K, et al. **Nippon Rinsho** 1998 Oct;56(10):2659–65 (16 ref.) (Eng. Abstr.) **(Jpn)**

CONTRAINDICATIONS

[Myocardial infarct with ST segment depression: an absolute contraindication to thrombolytic therapy?] Imperadore F, et al. **G Ital Cardiol** 1999 Jun;29(6):705–9 (25 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice? Weber JJ, et al. **Am J Health Syst Pharm** 1998 Nov 15; 55(22):2414–6 (16 ref.)

INSTRUMENTATION

Treatment of May–Thurner syndrome with catheter-directed thrombolysis and stent placement, complicated by heparin-induced thrombocytopenia. Seidensticker D, et al. **Cardiovasc Surg** 1998 Dec;6(6):607–13 (29 ref.)
[Percutaneous thrombectomy and mechanical thrombolysis] Brossmann J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):344–54 (85 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Antithrombotic therapy in acute coronary syndromes. Sabatine MS, et al. **Acta Cardiol** 1999 Feb;54(1):3–29 (196 ref.)
Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis. Grossman C, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):667–72 (42 ref.)
Advances in antithrombotic therapy of acute myocardial infarction. Gensini GF, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):171–6 (41 ref.)
Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era [editorial; comment] Tan HL, et al. **Am Heart J** 1999 May;137(5):770–3 (27 ref.) Comment on: Am Heart J 1999 May;137(5):792–8. Comment on: Am Heart J 1999 May;137(5):799–805.
Current issues in reperfusion therapy. Gersh BJ. **Am J Cardiol** 1998 Oct 22;82(8B):3P–11P (77 ref.)
Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator. Lam KK, et al. **Am J Kidney Dis** 1998 Dec;32(6):1075–9 (27 ref.)
Thrombolytic therapy in the management of paediatric thromboembolic disease. Chalmers EA, et al. **Br J Haematol** 1999 Jan;104(1):14–21 (70 ref.)
Have we reached the limit with thrombolytic therapy? Fox KA. **Cardiovasc Drugs Ther** 1999 May;13(3):211–6 (22 ref.)
Therapy with thrombolytic agents in coronary artery disease. Hanna GP, et al. **Curr Opin Cardiol** 1998 Jul;13(4):267–73 (39 ref.)
Prehospital thrombolysis in acute myocardial infarction. Stern R, et al. **Eur J Emerg Med** 1998 Dec;5(4):471–9 (66 ref.)
What should a new thrombolytic bring us? Verheugt F. **Int J Clin Pract Suppl** 1998 Nov;99:3–5 (6 ref.)
Applications of thrombolytic therapy. Curzen N, et al. **Intensive Care Med** 1998 Aug;24(8):756–68 (90 ref.)
Optimal thrombolytic strategies for acute myocardial infarction—bolus administration. McMechan SR, et al. **QJM** 1998 Nov;91(11):719–25 (24 ref.)
Prehospital thrombolytic treatment of massive pulmonary embolism with reteplase during cardiopulmonary resuscitation. Kuisma M, et al. **Resuscitation** 1998 Jul; 38(1):47–50 (10 ref.)
Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Sahn SA. **Thorax** 1998 Aug;53 Suppl 2:S65–72 (65 ref.)
[Systemic lysis therapy in retinal vascular occlusions] Hattenbach LO. **Ophthalmologe** 1998 Aug;95(8):568–75 (47 ref.) (Eng. Abstr.) **(Ger)**
[Current value of intrapleural fibrinolysis in the treatment of exudative fibrinous pleural effusions in pleural empyema and hemothorax] Kemper P, et al. **Pneumologie** 1999 Aug; 53(8):373–84 (96 ref.) (Eng. Abstr.) **(Ger)**
[Thrombolytic, antiplatelet and anticoagulant therapy for thrombotic disorders] Homma S, et al. **Nippon Rinsho** 1999 Jul;57(7):1561–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Fibrinolytic treatment of pulmonary embolism] Tomkowski WZ. **Pneumonol Alergol Pol** 1997;65(11–12):849–53 (15 ref.) **(Pol)**

NURSING

Neuroprotective and thrombolytic agents: advances in stroke treatment. Hock N. **J Neurosci Nurs** 1998 Jun;30(3):175–84 (51 ref.)

STANDARDS

Acute myocardial infarction: failed thrombolysis revisited [see comments] Sutton AG, et al. **Hosp Med** 1998 Oct; 59(10):797–802 (21 ref.) Comment in: Hosp Med 1999 Apr;60(4):309.
Biochemical markers of thrombolytic success. IFCC Committee on Standardization of Markers of Cardiac Damage. Apple FS. **Scand J Clin Lab Invest Suppl** 1999; 230:60–6 (25 ref.)

TRENDS

One year after CAPRIE, IST and ESPS 2. Any changes in concepts? Hankey GJ. **Cerebrovasc Dis** 1998;8 Suppl 5:1–7 (45 ref.)
Antithrombotic drugs: insights from cardiology. Meyer BJ. **Cerebrovasc Dis** 1998;8 Suppl 5:19–27 (45 ref.)
Future directions in thrombolysis. Willerson JT, et al. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV44–53 (88 ref.)
Antiplatelet therapy in acute cerebral ischemia. Bednar MM, et al. **Stroke** 1999 Apr;30(4):887–93 (96 ref.)

THROMBOMODULIN

METABOLISM

[Endothelial activation markers (thrombomodulin, Willebrand's factor antigen and angiotensin-converting enzyme): clinical significance] Nasonov EL, et al. **Klin Med (Mosk)** 1998;76(11):4–10 (116 ref.) **(Rus)**

PHYSIOLOGY

Thrombomodulin: an overview and potential implications in vascular disorders. Boffa MC, et al. **Lupus** 1998;7 Suppl 2:S120–5 (67 ref.)

THROMBOPENIA see **THROMBOCYTOPENIA**

THROMBOPHILIA

Inherited thrombophilia and pregnancy: the obstetric perspective. Bonnar J, et al. **Semin Thromb Hemost** 1998; 24 Suppl 1:49–53 (21 ref.)
[Thrombophilic states] Chrobák L, et al. **Vnitr Lek** 1998 Aug; 44(8):481–6 (51 ref.) (Eng. Abstr.) **(Cze)**
[Acquired thrombophilia] Ishida F, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):588–91 (5 ref.) **(Jpn)**

BLOOD

Laboratory evaluation of hypercoagulable states. Van Cott EM, et al. **Hematol Oncol Clin North Am** 1998 Dec; 12(6):1141–66, v (117 ref.)
[Blood coagulation and fibrinolysis in arteriosclerosis] Hoffmeister HM, et al. **Z Kardiol** 1999 May;88(5):315–23 (96 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44–8 (36 ref.)

COMPLICATIONS

Coagulopathies and osteonecrosis. Jones JP Jr. **Acta Orthop Belg** 1999;65 Suppl 1:5–8 (24 ref.)
Thrombophilia: disorders predisposing to venous thromboembolism. Pineo GF, et al.

THROMBOPHILIA

Baillieres Clin Haematol 1998 Sep;11(3):525–40 (89 ref.)
The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. McColl MD, et al. **Br J Obstet Gynaecol** 1999 Aug;106(8):756–66 (106 ref.)
Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Waselenko JK, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:33–9 (48 ref.)
Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May–Jun;85(3):199–204 (41 ref.)
[Risk factors in venous thromboembolism] Le Pecq–Gentil B, et al. **Presse Med** 1998 Apr 25;27(16):779–85 (40 ref.) **(Fre)**

CONGENITAL

Thrombosis in pregnancy: maternal and fetal issues [see comments] Greer IA. **Lancet** 1999 Apr 10; 353(9160):1258–65 (61 ref.) Comment in: Lancet 1999 Jul 10;354(9173):162–3.

DIAGNOSIS

Current concepts of coagulation and fibrinolysis. Narayanan S, et al. **Adv Clin Chem** 1998;33:133–68 (119 ref.)
Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why? de Moerloose P, et al. **Semin Thromb Hemost** 1998;24(4):321–7 (57 ref.)
Laboratory diagnosis of hereditary thrombophilia. Michiels JJ, et al. **Semin Thromb Hemost** 1998;24(4):309–20 (65 ref.)
[Hemostaseology––rational diagnosis] Spannagl M, et al. **Internist (Berl)** 1999 Jun;40(6):657–65; quiz 665 (5 ref.) **(Ger)**
[The concomitant presence of prohemorrhagic and thrombophilic changes in coagulation factor V: a severe defect of coagulant activity and homozygote resistance to activated protein C (see comments)] Rossi V, et al. **Ann Ital Med Int** 1999 Apr–Jun;14(2):127–9 (10 ref.) (Eng. Abstr.) Comment in: Ann Ital Med Int 1999 Apr–Jun;14(2):71–3. **(Ita)**
[Evaluation and usefulness of hypercoagulability markers in medical pathology] Iturbe T, et al. **Sangre (Barc)** 1998 Oct; 43(5):415–20 (88 ref.) **(Spa)**

DRUG THERAPY

The investigation and management of inherited thrombophilia. Cumming AM, et al. **Clin Lab Haematol** 1999 Apr;21(2):77–92 (135 ref.)
Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations. Nevarre DR, et al. **J Endovasc Surg** 1998 Aug;5(3):282–91 (47 ref.)
[Hereditary thrombophilia] Moia M, et al. **Minerva Anestesiol** 1999 Jan–Feb;65(1–2 Suppl 1):23–7 (22 ref.) **(Ita)**

ETIOLOGY

Thrombophilia and activated protein C resistance. Selzman CH, et al. **Ann Vasc Surg** 1998 Nov;12(6):601–4 (12 ref.)
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Khamashta MA. **Lupus** 1998; 7 Suppl 2:S162–5 (48 ref.)
Detection of cerebral microemboli in APS––introducing a novel investigation method and implications of analogies with carotid artery disease. Specker C, et al. **Lupus** 1998; 7 Suppl 2:S75–80 (41 ref.)
Acquired thrombophilia in pregnancy. Ballem P. **Semin Thromb Hemost** 1998;24 Suppl 1:41–7 (41 ref.)
Pathophysiology of the thrombophilic state in the cancer patient. Falanga A, et al. **Semin Thromb Hemost** 1999; 25(2):173–82 (115 ref.)
The thrombophilic state induced by therapeutic agents in the cancer patient. Lee AY, et al. **Semin Thromb Hemost** 1999;25(2):137–45 (105 ref.)
Hyperhomocysteinemia, atherosclerosis and thrombosis. Cattaneo M. **Thromb Haemost** 1999 Feb;81(2):165–76 (156 ref.)

GENETICS

Hereditary thrombophilia and venous thromboembolism. Murin S, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1369–73 (35 ref.)
The investigation and management of inherited thrombophilia. Cumming AM, et al. **Clin Lab Haematol** 1999 Apr;21(2):77–92 (135 ref.)
Thrombophilia. Huisman MV, et al. **Curr Opin Hematol** 1999 Sep;6(5):291–7 (48 ref.)
A patient homozygous for mutation 20210A in the prothrombin gene with venous thrombosis and transient ischemic attacks of thrombotic origin [letter] González Ordóñez AJ, et al. **Haematologica** 1998 Nov;83(11):1050–1 (9 ref.)
Thrombophilia as a multigenic disease. Zöller B, et al. **Haematologica** 1999 Jan;84(1):59–70 (120 ref.)
Thrombophilia as a multigenic disorder. Miletich JP. **Semin Thromb Hemost** 1998;24 Suppl 1:13–20 (47 ref.)
Inherited thrombophilic states. Rao AK, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:3–12 (84 ref.)
Thrombophilia: a genetic predisposition to thrombosis. Sacher RA. **Trans Am Clin Climatol Assoc** 1999;110:51–60; discussion 60–1 (27 ref.)
[Thrombophilia caused by congenital disorders of blood coagulation] Hiller E, et al. **Fortschr Med** 1998 Oct 20; 116(29):26–8, 30, 32 passim (17 ref.) (Eng. Abstr.) **(Ger)**
[Screening methods in genetic diagnosis of hereditary protein C deficiency] Dávid M, et al. **Orv Hetil** 1999 Jan 17; 140(3):125–32 (44 ref.) (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

Anti–prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. de Groot PG, et al. **Lupus** 1998;7 Suppl 2:S32–6 (36 ref.)
Mechanisms of autoantibody–mediated thrombosis. Roubey RA. **Lupus** 1998;7 Suppl 2:S114–9 (32 ref.)
Many faces of lupus anticoagulants. Triplett DA. **Lupus** 1998; 7 Suppl 2:S18–22 (30 ref.)
Significance of IgA antiphospholipid antibodies. Wilson WA, et al. **Lupus** 1998;7 Suppl 2:S110–3 (34 ref.)

PHYSIOPATHOLOGY

Pathophysiology of the thrombophilic state in the cancer patient. Falanga A, et al. **Semin Thromb Hemost** 1999; 25(2):173–82 (115 ref.)
The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: pathomechanisms and new tools for assessing its clinical relevance. Kraus M. **Semin Thromb Hemost** 1998;24(4):337–54 (142 ref.)

THROMBOPHLEBITIS

see related
VENA CAVA FILTERS

DIAGNOSIS

The special case of venous thromboembolism in pregnancy. Greer IA. **Haemostasis** 1998;28 Suppl 3:22–34 (45 ref.)
Long–term consequences of deep vein thrombosis. Leizorovicz A. **Haemostasis** 1998;28 Suppl 3:1–7 (23 ref.)
Venous thromboembolism in the intensive care unit. Legere BM, et al. **Clin Chest Med** 1999 Jun;20(2):367–84, ix (116 ref.)
Hughes–Stovin syndrome: a case report and review of the literature. Riantawan P, et al. **J Med Assoc Thai** 1999 Mar; 82(3):312–6 (7 ref.)
MR assessment of the extremity veins. Polak JF, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):36–46 (27 ref.)
[Puerperal thrombophlebitis of the ovarian vein revealed by renal colic] Sappey O, et al. **Prog Urol** 1999 Apr;9(2):313–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Incidence of pulmonary embolism in venous thrombosis] Mostbeck A. **Wien Med Wochenschr** 1999;149(2–4):72–5 (29 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Disorders of pulmonary circulation [editorial; comment] Pineo GF, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):209–11 (24 ref.) Comment on: Curr Opin Pulm Med 1999 Jul;5(4):216–21.
Heparin and low molecular weight heparin for treatment of acute pulmonary embolism [see comments] Raskob GE. **Curr Opin Pulm Med** 1999 Jul;5(4):216–21 (34 ref.) Comment in: Curr Opin Pulm Med 1999 Jul;5(4):209.
Low molecular weight heparins: current use and indications [see comments] Quader MA, et al. **J Am Coll Surg** 1998 Dec;187(6):641–58 (95 ref.) Comment in: J Am Coll Surg 1999 Jul;189(1):141–2.
Outpatient treatment of deep vein thrombosis with LMWH. Koopman MM. **Wien Med Wochenschr** 1999;149(2–4):46–9; discussion 49 (18 ref.)
[Therapy of thromboses with low–molecular–weight heparins] Haas S, et al. **Wien Med Wochenschr** 1999; 149(2–4):39–45; discussion 45 (24 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

[Aspects of cost effectiveness in therapy of acute leg/pelvic vein thrombosis] Blättler W. **Wien Med Wochenschr** 1999; 149(2–4):61–5 (22 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Venous thromboembolism in the intensive care unit. Legere BM, et al. **Clin Chest Med** 1999 Jun;20(2):367–84, ix (116 ref.)

ETIOLOGY

Venous thrombosis after extracorporeal shock–wave lithotripsy in a patient with heterozygous APC–resistance [letter] Brodmann M, et al. **Thromb Haemost** 1998 Nov; 80(5):861 (4 ref.)
[Deep venous thrombosis caused by central venous catheter] Lersch C, et al. **Vasa** 1999 May;28(2):71–8 (157 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

A patient homozygous for mutation 20210A in the prothrombin gene with venous thrombosis and transient ischemic attacks of thrombotic origin [letter] González Ordóñez AJ, et al. **Haematologica** 1998 Nov;83(11):1050–1 (9 ref.)

PREVENTION & CONTROL

Prevention of venous thrombosis after elective hip surgery [see comments] Turpie AG, et al. **Orthopedics** 1998 Dec; 21(12):1275–81 (45 ref.) Comment in: Orthopedics 1999 May;22(5):476–7.
[Risk factors in venous thromboembolism] Le Pecq–Gentil B, et al. **Presse Med** 1998 Apr 25;27(16):779–85 (40 ref.) **(Fre)**
[Guidelines for prevention of thrombosis in orthopedics] Pauschert R, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct; 136(5):471–9 (62 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Deep venous insufficiency of the lower extremities] Sica GS, et al. **Minerva Cardioangiol** 1998 Nov;46(11):435–44 (43 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

[Thrombosis therapy with compression stockings] Bruhn HD. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):371–2 (2 ref.) **(Ger)**
[Ambulatory therapy for deep leg vein thrombosis?] Schellong SM, et al. **Dtsch Med Wochenschr** 1999 Jun 25; 124(25–26):810–5 (28 ref.) **(Ger)**

ULTRASONOGRAPHY

Current role of venography in the diagnosis of deep–vein thrombosis. Rossi R, et al. **Minerva Cardioangiol** 1998 Dec; 46(12):507–14 (56 ref.)
[Place of duplex sonography in the differential diagnosis of deep vein thrombosis] Habscheid W. **Dtsch Med Wochenschr** 1998 Oct 2;123(40):1185–90 (51 ref.) **(Ger)**

THROMBOPLASTIN

see related
COAGULANTS

ANALYSIS

Some thoughts about localization and expression of tissue factor. Nemerson Y, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S45–7 (10 ref.)

BIOSYNTHESIS

Cell–cell interaction and tissue factor expression. Lorenzet R, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S49–59 (116 ref.)
Tissue factor expression by monocytes: regulation and pathophysiological roles. Osterud B. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S9–14 (36 ref.)

METABOLISM

Tissue factor on cells. Rao LV, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S27–35 (82 ref.)
The interaction of activated factor VII with tissue factor: insight into the mechanism of cofactor–mediated activation of activated factor VII. Ruf W. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S73–8 (45 ref.)

PHARMACOLOGY

Interaction of activated factor VII and active site–inhibited activated factor VII with tissue factor. Sørensen BB, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S67–71 (32 ref.)

PHYSIOLOGY

Tissue factor in atherosclerosis. Tremoli E, et al. **Atherosclerosis** 1999 Jun;144(2):273–83 (115 ref.)
The effects of activated factor VII in a cell–based model for tissue factor–initiated coagulation. Kjalke M, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S21–5 (14 ref.)
The role of the tissue factor pathway in initiation of coagulation. Mann KG, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S3–7 (14 ref.)
The role of tissue factor in the pathogenesis of thrombosis and atherosclerosis. Asada Y, et al. **J Atheroscler Thromb** 1998;4(3):135–9 (38 ref.)
[The mechanism of regulation of blood coagulation on the cell surface––the role of tissue factor] Takeya H, et al. **Seikagaku** 1998 Dec;70(12):1436–41 (21 ref.) **(Jpn)**
[The role of tissue factor and its inhibitor in hemostasis] Naumnik B, et al. **Przegl Lek** 1998;55(2):68–73 (36 ref.) (Eng. Abstr.) **(Pol)**

THROMBOPLASTIN TIME, PARTIAL see **PARTIAL THROMBOPLASTIN TIME**

THROMBOPLASTINOGEN see **FACTOR VIII**

THROMBOPOIETIN

Thrombopoietin: its role in platelet disorders and as a new drug in clinical medicine. von dem Borne AE, et al.

Baillieres Clin Haematol 1998 Jun;11(2):427–45 (66 ref.)
[Thrombopoietin: current and future status] Teramura M, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):421–8 (34 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Native thrombopoietin: structure and function. Kato T, et al. **Stem Cells** 1998;16(5):322–8 (70 ref.)

METABOLISM

Thrombopoietin signal transduction: studies from cell lines and primary cells. Drachman JG, et al. **Methods** 1999 Mar; 17(3):238–49 (80 ref.)

PHARMACOLOGY

Thrombopoietin: biology and potential clinical applications. Prow D, et al. **Oncology (Huntingt)** 1998 Nov; 12(11):1597–604, 1607–8; discussion 1611–4 (78 ref.)
The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation. Wagemaker G, et al. **Stem Cells** 1998;16(6):375–86 (97 ref.)

PHYSIOLOGY

The Mpl ligand and platelet homeostasis. Nichol JL. **Acta Paediatr Suppl** 1998 Jun;424:7–15 (49 ref.)
Thrombopoietin and hematopoietic stem cell development. Kaushansky K. **Ann N Y Acad Sci** 1999 Apr 30;872:314–9 (38 ref.)
Thrombopoietin and its receptor: structure, function and role in the regulation of platelet production. von dem Borne AE, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):409–26 (111 ref.)
Thrombopoietin stimulation of hematopoietic stem/progenitor cells. Long MW. **Curr Opin Hematol** 1999 May;6(3):159–63 (52 ref.)
Thrombopoietin and its receptor. Wendling F, et al. **Eur Cytokine Netw** 1998 Sep;9(3):221–31 (139 ref.)
Thrombopoietin: its role from early hematopoiesis to platelet production. Wendling F. **Haematologica** 1999 Feb; 84(2):158–66 (138 ref.)
Functional roles of thrombopoietin–c–mpl system in essential thrombocythemia. Matsumura I, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):351–8 (57 ref.)
Native thrombopoietin: structure and function. Kato T, et al. **Stem Cells** 1998;16(5):322–8 (70 ref.)
[Functional roles of signaling molecules in cytokine–induced cell growth] Matumura I. **Rinsho Ketsueki** 1999 Apr; 40(4):275–9 (9 ref.) **(Jpn)**

THERAPEUTIC USE

The Mpl ligand and platelet homeostasis. Nichol JL. **Acta Paediatr Suppl** 1998 Jun;424:7–15 (49 ref.)
Thrombopoietic factors potentially useful in the treatment of acute leukemia. Archimbaud E, et al. **Leuk Res** 1998 Dec;22(12):1155–64 (141 ref.)
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Jan; 13(1):14–8 (23 ref.)
Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Hofmann WK, et al. **Leukemia** 1999 Apr;13 Suppl 1:S14–8 (23 ref.)
Thrombopoietins and thrombopoiesis: a clinical perspective. Kuter DJ. **Vox Sang** 1998;74 Suppl 2:75–85 (43 ref.)
[Therapeutic use of hematopoietic growth factors. I. Erythropoietin and thrombopoietin] Royer B, et al. **Ann Biol Clin (Paris)** 1998 Mar–Apr;56(2):143–52 (31 ref.) (Eng. Abstr.) **(Fre)**
[Clinical use of thrombopoietin (c–Mpl Ligand)] Borota R, et al. **Med Pregl** 1998 Nov–Dec;51(11–12):501–8 (56 ref.) (Eng. Abstr.) **(Ser)**

THROMBOSIS

see related

THROMBECTOMY

Pharmacological remodeling of the thrombus architecture. Collet JP, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S49–53 (32 ref.)
Fibrin–fibrinogen and dethrombosis. Muhlestein JB. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S59–62 (24 ref.)
Proposal of a new nomenclature for Budd–Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Okuda K, et al. **Hepatology** 1998 Nov;28(5):1191–8 (105 ref.)
Adhesion–dependent signalling and the initiation of haemostasis and thrombosis. Andrews RK, et al. **Histol Histopathol** 1998 Jul;13(3):837–44 (70 ref.)
Reflections of thrombosis research in Oklahoma City—1975 to the present. Green R. **J Okla State Med Assoc** 1999 Mar;92(3):131–9 (9 ref.)
The emerging impact of phage display technology in thrombosis and haemostasis. Arza B, et al. **Thromb Haemost** 1998 Sep;80(3):354–65 (159 ref.)

BLOOD

Plasma gamma'/gamma fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Drouet L, et al. **Blood Coagul Fibrinolysis** 1999 Feb; 10 Suppl 1:S35–9 (30 ref.)
Role of red blood cells in thrombosis. Andrews DA, et al. **Curr Opin Hematol** 1999 Mar;6(2):76–82 (131 ref.)
Mechanisms of hypercoagulation in malignancy and during chemotherapy. Falanga A. **Haemostasis** 1998;28 Suppl 3:50–60 (59 ref.)
Modulation of annexin II by homocysteine: implications for atherothrombosis. Hajjar KA, et al. **J Investig Med** 1998 Oct;46(8):364–9 (87 ref.)
Proteolytic modifications of lipoprotein(a): potential relevance to its postulated atherothrombogenic role. Scanu AM. **J Investig Med** 1998 Oct;46(8):359–63 (38 ref.)
[Diagnostics: hematological diagnosis] Michibayashi T. **Nippon Rinsho** 1999 Jul;57(7):1549–54 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Oral contraceptives and thrombosis. From risk estimates to health impact. Lidegaard O, et al. **Acta Obstet Gynecol Scand** 1999 Feb;78(2):142–9 (41 ref.)
Effects of oral contraceptives on hemostasis and thrombosis. Rosing J, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 2):S375–82 (28 ref.)
Heparin–induced thrombocytopenia and thrombosis. Arepally G, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):237–47 (94 ref.)
Oral contraceptives and thrombosis. Thorogood M. **Curr Opin Hematol** 1998 Sep;5(5):350–4 (20 ref.)
The role of tissue factor in the pathogenesis of thrombosis and atherosclerosis. Asada Y, et al. **J Atheroscler Thromb** 1998;4(3):135–9 (38 ref.)
FK506–associated thrombotic microangiopathy: report of two cases and review of the literature. Trimarchi HM, et al. **Transplantation** 1999 Feb 27;67(4):539–44 (18 ref.)
[Venous and arterial thrombotic events induced by synthetic–steroid hormones or oral contraceptives] Sugawara H, et al. **Nippon Rinsho** 1999 Jul;57(7):1657–64 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Giant intracavitary thrombi secondary to a heparin–induced thrombocytopenia–thrombosis syndrome] Fernández Ratero JA, et al. **Rev Esp Cardiol** 1999 Apr;52(4):269–72 (8 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Recurrent embolism caused by floating thrombus in the thoracic aorta. Lozano P, et al. **Ann Vasc Surg** 1998 Nov; 12(6):609–11 (27 ref.)
Airway obstruction arising from blood clot: three reports and a review of the literature. Arney KL, et al. **Chest** 1999 Jan;115(1):293–300 (27 ref.)
Issues of thrombosis and hemorrhagic events in patients with cancer. Frenkel EP, et al. **In Vivo** 1998 Nov–Dec; 12(6):625–8 (35 ref.)
Thrombosis and malignancy: pathogenesis and prevention. Schwartz JD, et al. **In Vivo** 1998 Nov–Dec;12(6):619–24 (108 ref.)
Prothrombotic risk factors and acute kidney transplant rejection. Heidenreich S, et al. **Kidney Blood Press Res** 1998;21(2–4):293–5 (13 ref.)
Multiple cerebral infarctions from nonbacterial thrombotic endocarditis mimicking cerebral vasculitis. Vassallo R, et al. **Mayo Clin Proc** 1999 Aug;74(8):798–802 (15 ref.)
The interface of atherosclerosis and thrombosis: basic mechanisms. Libby P. **Vasc Med** 1998;3(3):225–9 (57 ref.)
[The role of thrombotic and hemostatic mechanisms in the initial phases of atherosclerosis] Drouet L, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:41–51 (42 ref.) (Eng. Abstr.) **(Fre)**
[Cerebral and basilar artery thrombosis following cervical spinal injury] Niedeggen A, et al. **Zentralbl Neurochir** 1999; 60(1):20–6 (25 ref.) (Eng. Abstr.) **(Ger)**
[Atherothrombosis in rheumatic diseases: pathogenesis analysis] Nasonov EL. **Ter Arkh** 1998;70(9):92–5 (74 ref.) **(Rus)**

CONGENITAL

[Heparin cofactor II deficiency] Sakuragawa N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):31–3 (20 ref.) **(Jpn)**

DIAGNOSIS

Lemierre syndrome: a complication of acute pharyngitis. Williams A, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):51–7 (5 ref.)
Laboratory diagnosis of the thrombophilic state in cancer patients. Gouin–Thibault I, et al. **Semin Thromb Hemost** 1999;25(2):167–72 (47 ref.)
[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971–5 (18 ref.) (Eng. Abstr.) **(Ger)**
[CT and MRI diagnosis] Takasu J, et al. **Nippon Rinsho** 1999 Jul;57(7):1543–8 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Angioscopy and intravascular ultrasound] Tomaru T, et al. **Nippon Rinsho** 1999 Jul;57(7):1531–6 (12 ref.) **(Jpn)**

DRUG THERAPY

A perspective on the regulation of the evaluation of new antithrombotic drugs. Califf RM. **Am J Cardiol** 1998 Oct 22;82(8B):25P–35P (32 ref.)
Is thrombin a pharmacological target during reperfusion? White HD. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S55–7 (18 ref.)
Treatment of May–Thurner syndrome with catheter–directed thrombolysis and stent placement, complicated by heparin–induced thrombocytopenia. Seidensticker D, et al. **Cardiovasc Surg** 1998 Dec;6(6):607–13 (29 ref.)
Thrombolytic therapy for arterial thrombosis. Shortell CK, et al. **Curr Opin Hematol** 1999 Sep;6(5):309–13 (16 ref.)
Antithrombotic therapy in children [see comments] Streif W, et al. **Curr Opin Pediatr** 1999 Feb;11(1):56–64 (101 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):31–2.
Thrombolytic treatment of type A right atrial thrombi: description of three cases and review of the literature. Mezzani A, et al. **G Ital Cardiol** 1999 Apr;29(4):441–6 (24 ref.)
Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti–integrin agents. Calverley DC, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1231–49, vi (122 ref.)
Applications of thrombolytic therapy. Curzen N, et al. **Intensive Care Med** 1998 Aug;24(8):756–68 (90 ref.)
Thrombolysis of a neonatal brachial artery thrombosis with tissue plasminogen activator. Grieg A. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):460–2 (11 ref.)
New thrombolytic strategy: bolus administration of tPA and urokinase–fibrinogen conjugate. Maksimenko AV, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):307–12 (50 ref.)
New antithrombotic agents [published erratum appears in Lancet 1999 May 22;353(9166):1804] Hirsh J, et al. **Lancet** 1999 Apr 24;353(9162):1431–6 (50 ref.)
Management of oral anticoagulant therapy in Italy. Berrettini M, et al. **Semin Thromb Hemost** 1999;25(1):27–31 (8 ref.)
Monitoring therapy with anticoagulants in The Netherlands. Breukink–Engbers WG. **Semin Thromb Hemost** 1999; 25(1):37–42 (9 ref.)
Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Kitchen S, et al. **Semin Thromb Hemost** 1999;25(1):17–25 (62 ref.)
Alternative models of delivery of anticoagulant services. Makris M. **Semin Thromb Hemost** 1999;25(1):33–6 (26 ref.)
Improved therapeutic safety of oral anticoagulant therapy in Germany: the Saarland model. Mörsdorf S, et al. **Semin Thromb Hemost** 1999;25(1):49–55 (34 ref.)
State–of–the–art patient self–management for control of oral anticoagulation. Taborski U, et al. **Semin Thromb Hemost** 1999;25(1):43–7 (18 ref.)
Safety of low–molecular–weight heparin in pregnancy: a systematic review. Sanson BJ, et al. **Thromb Haemost** 1999 May;81(5):668–72 (33 ref.)
[Thrombosis of prosthetic heart valves: diagnosis and management] Horstkotte D, et al. **Z Kardiol** 1998;87 Suppl 4:20–32 (69 ref.) (Eng. Abstr.) **(Ger)**
[Oral anticoagulants] Palareti G. **Minerva Anestesiol** 1999 Jan–Feb;65(1–2 Suppl 1):41–51 (46 ref.) **(Ita)**
[Rheologic modifications induced by heparin therapy. Capillary blood viscosity, erythrocyte deformability, aggregation index] Achilli E, et al. **Minerva Cardioangiol** 1999 Apr;47(4):95–119 (37 ref.) (Eng. Abstr.) **(Ita)**
[Thrombolytic, antiplatelet and anticoagulant therapy for thrombotic disorders] Homma S, et al. **Nippon Rinsho** 1999 Jul;57(7):1561–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Anti–hyperlipidemic drug] Nakaya N. **Nippon Rinsho** 1999 Jul;57(7):1570–6 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Enoxaparin: molecular structure aspects, pharmacokinetics, efficiency in internal medicine] Panchenko EP. **Klin Med (Mosk)** 1998;76(11):14–9 (34 ref.) **(Rus)**

EPIDEMIOLOGY

Update on genetic risk factors for thrombosis and atherosclerotic vascular disease. Neufeld EJ. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1193–209, vi (73 ref.)

ETIOLOGY

Thromboprophylaxis in hip arthroplasty. New frontiers and future strategy [see comments] Dahl OE. **Acta Orthop Scand** 1998 Aug;69(4):339–42 (37 ref.) Comment in: Acta Orthop Scand 1998 Aug;69(4):343–4.
Nephropathy and hypertension as manifestations in a 13–y–old girl with primary antiphospholipid syndrome. Ohtomo Y, et al. **Acta Paediatr** 1998 Aug;87(8):903–7 (44 ref.)
Atherothrombogenicity of lipoprotein(a): the debate. Scanu AM. **Am J Cardiol** 1998 Nov 5;82(9A):26Q–33Q (91 ref.)
Hypoxia/Hypoxemia–Induced activation of the procoagulant pathways and the pathogenesis of ischemia–associated thrombosis. Yan SF, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2029–35 (41 ref.)
Thrombosis of a mitral valve prosthesis resulting from Staphylococcus epidermidis endocarditis. Costa GM, et al. **Cardiologia** 1999 Jul;44(7):675–8 (12 ref.)
Homocysteine and risk for atherothrombotic events. Puddu P. **Cardiologia** 1999 Jul;44(7):627–31 (40 ref.)
Bleeding and thrombosis in myeloproliferative disorders.

Landolfi R. **Curr Opin Hematol** 1998 Sep;5(5):327-31 (33 ref.)

Mechanisms of thrombosis in hyperhomocysteinemia. Lentz SR. **Curr Opin Hematol** 1998 Sep;5(5):343-9 (79 ref.)

Cellular and molecular mechanisms of inflammation and thrombosis. Tan P, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):373-89 (181 ref.)

Mechanisms of hypercoagulation in malignancy and during chemotherapy. Falanga A. **Haemostasis** 1998;28 Suppl 3:50-60 (59 ref.)

Thromboprophylaxis in non-surgical patients: who, when and how? Gallus AS, et al. **Haemostasis** 1998;28 Suppl 3:71-82 (71 ref.)

Thromboprophylaxis in the cancer patient. Kakkar AK, et al. **Haemostasis** 1998;28 Suppl 3:61-5 (17 ref.)

The antiphospholipid or Hughes' syndrome: an underdiagnosed cause of thrombosis. Williams FM, et al. **Int J Clin Pract** 1999 Jan-Feb;53(1):39-43 (52 ref.)

Aortic thrombosis after acetabular revision of a total hip arthroplasty. Leung AG, et al. **J Arthroplasty** 1998 Dec; 13(8):961-5 (19 ref.)

NHLBI/FDA conference on thrombosis and infections with cardiovascular devices. **J Biomed Mater Res** 1998 Dec 5; 42(3):341-6 (0 ref.)

Pathogenesis of vascular disease in hyperhomocysteinaemia. Domagala TB, et al. **J Cardiovasc Risk** 1998 Aug; 5(4):239-47 (100 ref.)

Mural left atrial thrombus: a hidden danger accompanying cardiac surgery. Leslie D, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):649-50 (6 ref.)

Mechanisms of autoantibody-mediated thrombosis. Roubey RA. **Lupus** 1998;7 Suppl 2:S114-9 (32 ref.)

Femoro-femoral graft after unilateral obstruction of aorto-bifemoral bypass. Testini M, et al. **Minerva Cardioangiol** 1998 Jan-Feb;46(1-2):15-9 (32 ref.)

How to identify the haemodialysis access at risk of thrombosis? Are flow measurements the answer? [editorial] Blankestijn PJ, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1068-71 (29 ref.)

The clotted central vein catheter for haemodialysis. Twardowski ZJ. **Nephrol Dial Transplant** 1998 Sep; 13(9):2203-6 (20 ref.)

Thrombotic complications of central venous catheters in cancer patients. Bona RD. **Semin Thromb Hemost** 1999; 25(2):147-55 (73 ref.)

Hyperhomocysteinemia and atherothrombotic disease. de Jong SC, et al. **Semin Thromb Hemost** 1998;24(4):381-5 (32 ref.)

Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Gordon LI, et al. **Semin Thromb Hemost** 1999;25(2):217-21 (82 ref.)

Thrombophilic state in breast cancer. Schmitt M, et al. **Semin Thromb Hemost** 1999;25(2):157-66 (94 ref.)

Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Waselenko JK, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:33-9 (48 ref.)

Possible role of systemic inflammatory reaction in vascular access thrombosis. Jurado R, et al. **South Med J** 1999 Sep; 92(9):877-81 (56 ref.)

Mechanical factors affecting hemostasis and thrombosis. Turitto VT, et al. **Thromb Res** 1998 Dec 15;92(6 Suppl 2):S25-31 (37 ref.)

[Low molecular weight heparin in atherothrombotic cardiovascular diseases. Value in coronary disease, ischemic stroke and peripheral arterial occlusive disease] Stammler F, et al. **Dtsch Med Wochenschr** 1999 Jun 25; 124(25-26):802-9 (51 ref.) **(Ger)**

[Atrial thrombosis following the low-energy DC internal countershock of chronic AF: considerations of a clinical case] Palermo P, et al. **G Ital Cardiol** 1998 Dec; 28(12):1413-7 (23 ref.) (Eng. Abstr.) **(Ita)**

[Coagulant factor VII hyperactivity] Matsuo T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):43-6 (15 ref.) **(Jpn)**

[Plasminogen activator inhibitor-1 in thrombotic disease] Niiya K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):24-7 (15 ref.) **(Jpn)**

[Congenital hypoplasminogenemia and dysplasminogenemia (type I and type II congenital plasminogen deficiency)] Shigekiyo T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):9-10 (14 ref.) **(Jpn)**

GENETICS

Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Santoro SA. **Blood** 1999 Jun 1;93(11):3575-7 (32 ref.)

Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Humphries SE, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S17-21 (22 ref.)

Thrombosis in heritable hemolytic disorders. Barker JE, et al. **Curr Opin Hematol** 1999 Mar;6(2):71-5 (48 ref.)

The prothrombin 20210 G to A variation and thrombosis. Bertina RM. **Curr Opin Hematol** 1998 Sep;5(5):339-42 (34 ref.)

The prothrombin gene variant 20210A in venous and arterial thromboembolism [see comments] Vicente V, et al. **Haematologica** 1999 Apr;84(4):356-62 (78 ref.) Comment in: Haematologica 1999 Apr;84(4):290.

Update on genetic risk factors for thrombosis and atherosclerotic vascular disease. Neufeld EJ. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1193-209, vi (73 ref.)

Genetic markers: genes involved in thrombosis. Wu KK. **J Cardiovasc Risk** 1997 Oct-Dec;4(5-6):347-52 (44 ref.)

Thrombophilia: a genetic predisposition to thrombosis. Sacher RA. **Trans Am Clin Climatol Assoc** 1999;110:51-60; discussion 60-1 (27 ref.)

[Coagulation disorders--with special reference to thrombotic tendencies] Saito H. **Nippon Naika Gakkai Zasshi** 1999 Feb 20;88 Suppl:65-8 (0 ref.) **(Jpn)**

[Molecular patho-biochemistry and genetic diagnosis for plasminogen-apolipoprotein (a) gene family related to atherosclerosis and thrombosis] Ichinose A. **Rinsho Byori** 1998 Dec;46(12):1210-8 (25 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Lupus anticoagulants, thrombosis and the protein C system. Esmon NL, et al. **Haematologica** 1999 May;84(5):446-51 (32 ref.)

Antiphospholipid antibodies and thrombosis [see comments] Greaves M. **Lancet** 1999 Apr 17;353(9161):1348-53 (65 ref.) Comment in: Lancet 1999 Jul 3;354(9172):71. Comment in: Lancet 1999 Jul 3;354(9172):71-2. Comment in: Lancet 1999 Jul 3;354(9172):72-3. Comment in: Lancet 1999 Jul 3;354(9172):73.

Antibody-mediated thrombosis: relation to the antiphospholipid syndrome. Vermylen J, et al. **Lupus** 1998; 7 Suppl 2:S63-6 (25 ref.)

Possible role of systemic inflammatory reaction in vascular access thrombosis. Jurado R, et al. **South Med J** 1999 Sep; 92(9):877-81 (56 ref.)

METABOLISM

Effects of lipids and lipoproteins on thrombosis and rheology. Rosenson RS, et al. **Atherosclerosis** 1998 Oct;140(2):271-80 (135 ref.)

[The role of PAI-1 in thrombotic events] Orbe J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):63-9 (115 ref.) **(Spa)**

[The principal mechanisms of thrombosis (report I). Mechanisms of vascular wall thromboresistance] Hereliuk IP, et al. **Klin Khir** 1998;(7):50-2 (25 ref.) **(Ukr)**

PATHOLOGY

[Histopathology of thrombotic vascular diseases] Asada Y, et al. **Nippon Rinsho** 1999 Jul;57(7):1555-60 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Functions and the regulation of cytokines and growth factors in the thrombotic event of arteries and veins] Harada H, et al. **Nippon Rinsho** 1999 Jul;57(7):1497-501 (16 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Intercellular adhesion in vascular biology, thrombosis and cancer. Giddings JC. **Br J Biomed Sci** 1999;56(1):66-77 (35 ref.)

Platelet receptors for the complement component C1q: implications for hemostasis and thrombosis. Peerschke EI, et al. **Immunobiology** 1998 Aug;199(2):239-49 (47 ref.)

Platelet-dependent and procoagulant mechanisms in arterial thrombosis. Eisenberg PR, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S3-10 (53 ref.)

Factor XI and protection of the fibrin clot against lysis--a role for the intrinsic pathway of coagulation in fibrinolysis [see comments] Bouma BN, et al. **Thromb Haemost** 1998 Jul;80(1):24-7 (51 ref.) Comment in: Thromb Haemost 1999 Apr;81(4):657.

[General classification of hemostasis] Baudo F, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):1-5 (24 ref.) **(Ita)**

[Assessment of blood flow by Doppler method] Inoue Y, et al. **Nippon Rinsho** 1999 Jul;57(7):1537-41 (10 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Thromboprophylaxis in hip arthroplasty. New frontiers and future strategy [see comments] Dahl OE. **Acta Orthop Scand** 1998 Aug;69(4):339-42 (37 ref.) Comment in: Acta Orthop Scand 1998 Aug;69(4):343-4.

Prevention and management of central venous catheter thrombosis. Cobos E, et al. **Curr Opin Hematol** 1998 Sep; 5(5):355-9 (31 ref.)

Wine and polyphenols related to platelet aggregation and atherothrombosis. Ruf JC. **Drugs Exp Clin Res** 1999; 25(2-3):125-31 (49 ref.)

Thromboprophylaxis in non-surgical patients: who, when and how? Gallus AS, et al. **Haemostasis** 1998;28 Suppl 3:71-82 (71 ref.)

Thromboprophylaxis in the cancer patient. Kakkar AK, et al. **Haemostasis** 1998;28 Suppl 3:61-5 (17 ref.)

Thrombosis and malignancy: pathogenesis and prevention. Schwartz JD, et al. **In Vivo** 1998 Nov-Dec;12(6):619-24 (108 ref.)

Diamond-like carbon coating and plasma or glow discharge treatment of mechanical heart valves. Tran HS, et al. **J Invest Surg** 1999 May-Jun;12(3):133-40 (50 ref.)

Low molecular weight heparins in the cardiac catheterization laboratory. Montalescot G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):319-23 (27 ref.)

Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Khamashta MA. **Lupus** 1998; 7 Suppl 2:S162-5 (48 ref.)

Vascular gene therapy. Thomas JW, et al. **Radiographics** 1998 Nov-Dec;18(6):1373-94 (109 ref.)

Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis [see comments] Horlocker TT, et al. **Reg Anesth Pain Med** 1998 Nov-Dec;23(6 Suppl 2):164-77 (27 ref.) Comment in: Reg Anesth Pain Med 1999 Jul-Aug;24(4):375-7.

Homocyst(e)ine, atherosclerosis, and thrombosis. Alpert MA. **South Med J** 1999 Sep;92(9):858-65 (70 ref.)

[Heparins, antivitamins K. Principles and rules for their use. Dosage of non-fractionated heparins] Sié P. **Rev Prat** 1998 Jun 15;48(12):1361-5 (3 ref.) **(Fre)**

[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis] Sinzinger H. **Dtsch Med Wochenschr** 1998 Sep 18;123(38):1116-22 (49 ref.) **(Ger)**

[Intracardiac thrombosis and consecutive thromboembolisms in patients with heart valve diseases: predisposition and concepts for prevention] Piper C, et al. **Z Kardiol** 1998;87 Suppl 4:1-6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Molecular mechanisms and indicators of thrombogenesis after heart valve replacement] Scharf RE, et al. **Z Kardiol** 1998;87 Suppl 4:7-19 (46 ref.) (Eng. Abstr.) **(Ger)**

[Control of thrombosis] Saitoh H. **Rinsho Ketsueki** 1999 Jun; 40(6):441-5 (14 ref.) **(Jpn)**

[Prevention and treatment of unstable atherosclerotic lesions in atherosclerosis] Gavornik P. **Vnitr Lek** 1998 Sep; 44(9):563-70 (45 ref.) (Eng. Abstr.) **(Slo)**

RADIOGRAPHY

[Acute ischemia of the legs and rapidly progressing renal failure in a 39-year-old patient] Büchner N, et al. **Internist (Berl)** 1999 May;40(5):555-60 (20 ref.) **(Ger)**

[Angiography of occlusive vascular disease] Fujiwara H, et al. **Nippon Rinsho** 1999 Jul;57(7):1526-30 (7 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Portal hypertension and variceal bleeding: shunt in concomitant or general prehepatic block] Hirner A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:443-50 (25 ref.) (Eng. Abstr.) **(Ger)**

[An iliac-mesenteric-atrial shunt in the Budd-Chiari syndrome with extensive thrombosis of the inferior vena cava] Bancu S, et al. **Chirurgia (Bucur)** 1998 May-Jun; 93(3):165-9 (7 ref.) (Eng. Abstr.) **(Rum)**

THERAPY

Prevention and management of central venous catheter thrombosis. Cobos E, et al. **Curr Opin Hematol** 1998 Sep; 5(5):355-9 (31 ref.)

Ultrasonic thrombolysis: catheter-delivered and transcutaneous applications. Atar S, et al. **Eur J Ultrasound** 1999 Mar;9(1):39-54 (47 ref.)

Therapeutic inhibition of thrombin activities, receptors, and production. Harker LA. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1211-30 (86 ref.)

[A new medical treatment for thrombosis by genetic engineering] Kida I, et al. **Nippon Rinsho** 1999 Jul; 57(7):1519-25 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical characteristics of thrombotic diseases of arteries and veins] Shindo S, et al. **Nippon Rinsho** 1999 Jul;57(7):1473-9 (3 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Role of echocardiography in systemic arterial embolism. A review with recommendations. Egeblad H, et al. **Scand Cardiovasc J** 1998;32(6):323-42 (168 ref.)

[Detection and surveillance of left atrial thrombosis by transesophageal echocardiography] Canavy I, et al. **Arch Mal Coeur Vaiss** 1999 Jan;92(1):35-42 (29 ref.) (Eng. Abstr.) **(Fre)**

[Duplex ultrasound of the liver and portal vein system] Mohr HH, et al. **Med Klin** 1998 Nov 15;93(11):669-77 (72 ref.) (Eng. Abstr.) **(Ger)**

[A right atrial thrombus in transit: its echocardiographic diagnosis 72 hours before a pulmonary embolism] Valenzuela García LF, et al. **Rev Esp Cardiol** 1999 Jan; 52(1):59-62 (7 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Herpesviruses and thrombosis: activation of coagulation on the endothelium. Nicholson AC, et al. **Clin Chim Acta** 1999 Aug;286(1-2):23-9 (27 ref.)

THROMBOSIS, CAROTID ARTERY see **CAROTID ARTERY THROMBOSIS**

THROMBOSIS, CORONARY see **CORONARY THROMBOSIS**

THROMBOSIS, RETINAL VEIN see **RETINAL VEIN OCCLUSION**

THROMBOSIS, VENOUS see **VENOUS THROMBOSIS**

THROMBOSPONDIN RECEPTORS see **ANTIGENS, CD36**

THROMBOSPONDIN 1

PHYSIOLOGY

Thrombospondin-1, PECAM-1, and regulation of angiogenesis. Sheibani N, et al. **Histol Histopathol** 1999 Jan;14(1):285-94 (81 ref.)
[Thrombospondins, tumor angiogenesis and breast cancer] Clézardin P, et al. **Pathol Biol (Paris)** 1999 Apr; 47(4):368-74 (39 ref.) (Eng. Abstr.) **(Fre)**

THROMBOSPONDINS

PHYSIOLOGY

[Thrombospondins, tumor angiogenesis and breast cancer] Clézardin P, et al. **Pathol Biol (Paris)** 1999 Apr; 47(4):368-74 (39 ref.) (Eng. Abstr.) **(Fre)**
[Thrombospondins: multimodular proteins with angiostatic function] Feige JJ. **Pathol Biol (Paris)** 1999 Apr; 47(4):339-44 (33 ref.) (Eng. Abstr.) **(Fre)**

THROMBOTEST see **PROTHROMBIN TIME**

THROMBOXANE A SYNTHASE see **THROMBOXANE-A SYNTHASE**

THROMBOXANE-A SYNTHASE

[Prostanoid synthases] Shimonishi M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1097-103 (48 ref.) **(Jpn)**

DEFICIENCY

[Platelet thromboxane synthase deficiency] Fuse I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):374-6 (5 ref.) **(Jpn)**

GENETICS

Thromboxanes: synthase and receptors. Shen RF, et al. **J Biomed Sci** 1998;5(3):153-72 (206 ref.)

METABOLISM

Thromboxanes: synthase and receptors. Shen RF, et al. **J Biomed Sci** 1998;5(3):153-72 (206 ref.)

THROMBOXANE A2

[Thrombocytopathy due to defective response to thromboxane A2] Okuma M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):365-8 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[Thromboxane A2 antagonist--discovery of seratrodast] Terao S, et al. **Yakugaku Zasshi** 1999 May;119(5):377-90 (26 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A genetic approach for studying the role of thromboxane A2 in the kidney. Thomas DW, et al. **Kidney Int Suppl** 1998 Sep;67:S84-7 (61 ref.)

METABOLISM

A genetic approach for studying the role of thromboxane A2 in the kidney. Thomas DW, et al. **Kidney Int Suppl** 1998 Sep;67:S84-7 (61 ref.)

THROMBOXANE A2 RECEPTORS see **RECEPTORS, THROMBOXANE**

THROMBOXANE RECEPTORS see **RECEPTORS, THROMBOXANE**

THROMBOXANE SYNTHETASE see **THROMBOXANE-A SYNTHASE**

THROMBOXANES

see related
RECEPTORS, THROMBOXANE

ANALYSIS

Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. Tsikas D. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9;717(1-2):201-45 (304 ref.)

THROMBUS see **THROMBOSIS**

THRUSH see **CANDIDIASIS, ORAL**

THUMB

INJURIES

Complete dorsal dislocation of the metacarpophalangeal joint of the thumb. Takami H, et al. **Arch Orthop Trauma Surg** 1998;118(1-2):21-4 (10 ref.)
Microvascular reconstruction of the traumatized thumb. Shin AY, et al. **Hand Clin** 1999 May;15(2):347-71 (86 ref.)
Acute dislocation of the trapeziometacarpal joint in a child. McLaughlin MJ, et al. **J Hand Surg [Am]** 1998 Nov; 23(6):1097-9 (11 ref.)
[Post-traumatic osteoid osteoma of the hand. A rare cause of chronic pain. Case report and review of the literature] Rotzer A, et al. **Handchir Mikrochir Plast Chir** 1998 Sep; 30(5):335-7 (15 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Role of thenar electromyography in the evaluation of carpal tunnel syndrome. Mazur A. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):755-64 (48 ref.)

SURGERY

Microvascular reconstruction of the traumatized thumb. Shin AY, et al. **Hand Clin** 1999 May;15(2):347-71 (86 ref.)

THYME see **LAMIACEAE**

THYMECTOMY

Thymectomy in the integrated management of myasthenia gravis. Wilkins KB, et al. **Adv Surg** 1999;32:105-33 (76 ref.)
Preoperative preparation and anesthetic management of patients with myasthenia gravis. Krucylak PE, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):47-53 (53 ref.)

METHODS

Thoracoscopic thymectomy for myasthenia gravis: a case report. Sim EK, et al. **Ann Acad Med Singapore** 1998 Jul; 27(4):570-2 (7 ref.)
Video-assisted thoracic surgery thymectomy for myasthenia gravis. Mack MJ, et al. **Chest Surg Clin N Am** 1998 Nov; 8(4):809-25, viii; discussion 827-34 (27 ref.)

THYMIC CYST see **MEDIASTINAL CYST**

THYMIC FACTOR, CIRCULATING

PHARMACOLOGY

Cytokine-mediated or direct effects of thymulin on the nervous system as assessed by pain-related behavior. Safieh-Garabedian B, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):39-44 (34 ref.)

THYMIC GROUP VIRUSES see **HERPESVIRIDAE**

THYMIC HORMONES see **THYMUS HORMONES**

THYMIDINE

DIAGNOSTIC USE

Prognostic and predictive value of thymidine labelling index in breast cancer. Amadori D, et al. **Breast Cancer Res Treat** 1998;51(3):267-81 (70 ref.)

THYMIDINE KINASE

GENETICS

Gene marking and gene therapy in multiple myeloma. Gahrton G, et al. **Adv Exp Med Biol** 1998;451:493-7 (15 ref.)
Issues for conducting the microtiter version of the mouse lymphoma thymidine kinase (tk) assay and a critical review of data generated in a collaborative trial using the microtiter method. Moore MM, et al. **Mutagenesis** 1999 May;14(3):271-81 (16 ref.)
Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Blasberg RG, et al. **Q J Nucl Med** 1999 Jun;43(2):163-9 (29 ref.)

PHYSIOLOGY

Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341-3 (7 ref.)

THYMIDYLATE SYNTHASE

ANTAGONISTS & INHIBITORS

Thymidylate synthase inhibitors. Touroutoglou N, et al. **Clin Cancer Res** 1996 Feb;2(2):227-43 (145 ref.)
Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumour agents. Bavetsias V, et al. **Curr Med Chem** 1998 Aug;5(4):265-88 (74 ref.)
Novel therapeutic strategies for colorectal cancer. Kerr DJ, et al. **Hosp Med** 1998 Aug;59(8):617-21 (34 ref.)

GENETICS

Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Banerjee D, et al. **Prog Exp Tumor Res** 1999;36:107-14 (29 ref.)
[Regulation of thymidylate synthase gene expression] Dabrowska M. **Postepy Biochem** 1998;44(3):228-36 (103 ref.) **(Pol)**

METABOLISM

The molecular basis of substrate channeling. Miles EW, et al. **J Biol Chem** 1999 Apr 30;274(18):12193-6 (50 ref.)

THYMINE

METABOLISM

Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Ahmad SI, et al. **Annu Rev Microbiol** 1998; 52:591-625 (226 ref.)

THYMINE DIMERS see **PYRIMIDINE DIMERS**

THYMINS see **THYMOPOIETINS**

THYMOANALEPTICS see **ANTIDEPRESSIVE AGENTS**

THYMOLEPTICS see **ANTIDEPRESSIVE AGENTS**

THYMOMA

[Standards, options and recommendations (SOR) for clinical care of malignant thymoma. Groupe de Travail SOR] Ruffié P, et al. **Bull Cancer** 1999 Apr;86(4):365-84 (121 ref.) (Eng. Abstr.) **(Fre)**
[Good's syndrome (thymoma with immunodeficiency)] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):258-60 (10 ref.) **(Jpn)**

CLASSIFICATION

Thymoma classification. A siren's song of simplicity [editorial] [see comments] Harris NL, et al. **Am J Clin Pathol** 1999 Sep;112(3):299-303 (24 ref.) Comment in: Am J Clin Pathol 1999 Sep;112(3):308-10.
Thymoma classification: my opinion [editorial] [see comments] Kornstein MJ. **Am J Clin Pathol** 1999 Sep; 112(3):304-7 (19 ref.) Comment in: Am J Clin Pathol 1999 Sep;112(3):308-10.

COMPLICATIONS

Thymoma associated with myasthenia gravis and minimal lesion nephrotic syndrome. Lasseur C, et al. **Am J Kidney Dis** 1999 May;33(5):e4 (19 ref.)
Thymoma-associated dermatomyositis and polymyositis [editorial; comment] Nagasawa K. **Intern Med** 1999 Feb; 38(2):81-2 (10 ref.) Comment on: Intern Med 1999 Feb;38(2):155-9.
Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature. Mizobuchi S, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):696-701 (37 ref.)
Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Levy Y, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):73-9 (45 ref.)
[A case of nephrotic syndrome associated with myasthenia gravis and malignant thymoma] Tomida C, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):77-82 (19 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A thymoma with clonal complex chromosome abnormalities [letter] Sonobe H, et al. **Cancer Genet Cytogenet** 1999 Apr; 110(1):72-4 (9 ref.)

IMMUNOLOGY

Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Levy Y, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):73-9 (45 ref.)

PATHOLOGY

Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Suster S, et al. **Am J Clin Pathol** 1999 Jun;111(6):826-33 (44 ref.)
Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. Cather JC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):858-63 (54 ref.)
Spindle epithelial tumor with thymus-like differentiation: a case report and review of the literature. Bradford CR, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):603-6 (9 ref.)
Primary carcinomas of the thymus gland. Ritter JH, et al. **Semin Diagn Pathol** 1999 Feb;16(1):18-31 (71 ref.)
Primary thymic epithelial neoplasms: spectrum of differentiation and histological features. Suster S, et al. **Semin Diagn Pathol** 1999 Feb;16(1):2-17 (58 ref.)

THYMOMA

RADIOTHERAPY

The long-term clinical outcome of myasthenia gravis in patients with thymoma. Bril V, et al. **Neurology** 1998 Oct; 51(4):1198-200 (10 ref.)

SURGERY

Current management of thymoma. Langenfeld J, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):327-39 (49 ref.)

THERAPY

Nonsurgical management of malignant thymoma. Hejna M, et al. **Cancer** 1999 May 1;85(9):1871-84 (98 ref.)

THYMOPENTIN

PHARMACOLOGY

Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action. Gonser S, et al. **Pharm Acta Helv** 1999 Jun; 73(6):265-73 (82 ref.)

THYMOPOIETIN PENTAPEPTIDE see **THYMOPENTIN**

THYMOPOIETINS

BIOSYNTHESIS

Reviewing the potential utility of interleukin-7 as a promoter of thymopoiesis and immune recovery. Or R, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):287-94 (71 ref.)

GENETICS

Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Funakoshi M, et al. **Neuromuscul Disord** 1999 Mar;9(2):108-14 (55 ref.)

THYMOSIN

PHYSIOLOGY

Homeostasis, thymic hormones and aging. Goya RG, et al. **Gerontology** 1999 May-Jun;45(3):174-8 (65 ref.)

THYMOTAXIN see **BETA 2-MICROGLOBULIN**

THYMOXAMINE see **MOXISYLYTE**

THYMOXYALCYLAMINE see **MOXISYLYTE**

THYMUS-DEPENDENT LYMPHOCYTES see **T-LYMPHOCYTES**

THYMUS GLAND

see related

THYMECTOMY

Pathologic quiz case 2. Cervical thymus. Shah UK, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):695, 697-8 (8 ref.)

The thymus: from past misconception to present recognition. Leonidas JC. **Pediatr Radiol** 1998 May;28(5):275-82 (29 ref.)

Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Haks MC, et al. **Semin Immunol** 1999 Feb;11(1):23-37 (143 ref.)

Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Naquet P, et al. **Semin Immunol** 1999 Feb;11(1):47-55 (83 ref.)

Developmental stages in the human thymus. Res P, et al. **Semin Immunol** 1999 Feb;11(1):39-46 (62 ref.)

ANATOMY & HISTOLOGY

The human thymus. A chimeric organ comprised of central and peripheral lymphoid components [corrected and republished article originally printed in Immunol Res 1998;18(2):61-78] Haynes BF, et al. **Immunol Res** 1998; 18(3):175-92 (70 ref.)

Using thymus anatomy to dissect T cell repertoire selection. Laufer TM, et al. **Semin Immunol** 1999 Feb;11(1):65-70 (49 ref.)

CYTOLOGY

Thymus-independent development of gut T cells. Klein JR. **Chem Immunol** 1998;71:88-102 (58 ref.)

Positive and negative thymocyte selection. Saito T, et al. **Crit Rev Immunol** 1998;18(4):359-70 (89 ref.)

Cyclosporin A-induced changes of the thymic microenvironment. A review of morphological studies. Milićević NM, et al. **Histol Histopathol** 1998 Oct; 13(4):1183-96 (84 ref.)

Thymocyte selection: not by TCR alone. Amsen D, et al. **Immunol Rev** 1998 Oct;165:209-29 (202 ref.)

Molecular requirements for lineage commitment in the thymus--antibody-mediated receptor engagements reveal a central role for lck in lineage decisions. Basson MA, et al. **Immunol Rev** 1998 Oct;165:181-94 (94 ref.)

Thymocyte selection in Vav and IRF-1 gene-deficient mice. Penninger JM, et al. **Immunol Rev** 1998 Oct;165:149-66 (213 ref.)

The linkage between T-cell and dendritic cell development in the mouse thymus. Shortman K, et al. **Immunol Rev** 1998 Oct;165:39-46 (42 ref.)

Early stages in the development of human T, natural killer and thymic dendritic cells. Spits H, et al. **Immunol Rev** 1998 Oct;165:75-86 (79 ref.)

Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment. Bodey B, et al. **In Vivo** 1999 May-Jun;13(3):267-94 (489 ref.)

The role of vitamin E in T-cell differentiation and the decrease of cellular immunity with aging. Moriguchi S, et al. **J Med Invest** 1998 Aug;45(1-4):1-8 (35 ref.)

In vitro models of T cell development. Hare KJ, et al. **Semin Immunol** 1999 Feb;11(1):3-12 (66 ref.)

Thymic microenvironments, 3-D versus 2-D? van Ewijk W, et al. **Semin Immunol** 1999 Feb;11(1):57-64 (29 ref.)

[The molecular mechanisms governing T cell development in the thymus] Kimura M, et al. **Nippon Rinsho** 1999 Feb; 57(2):267-72 (35 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Cyclosporin A-induced changes of the thymic microenvironment. A review of morphological studies. Milićević NM, et al. **Histol Histopathol** 1998 Oct; 13(4):1183-96 (84 ref.)

EMBRYOLOGY

Fetal thymic organ culture in rotating bioreactors [letter] Tabourn B, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan; 35(1):4-7 (32 ref.)

Intrathymic non-lymphatic hematopoiesis during mammalian ontogenesis. Bodey B, et al. **In Vivo** 1998 Nov-Dec; 12(6):599-618 (236 ref.)

The ontogeny of T cell recirculation during foetal life. Cahill RN, et al. **Semin Immunol** 1999 Apr;11(2):105-14 (44 ref.)

[Biological capabilities of the thymus of human fetus during normal development and during constant exposure to small doses of radiation after the accident at the Chernobyl power plant] Khlystova ZS, et al. **Arkh Patol** 1998 Sep-Oct;60(5):74-9 (41 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment. Bodey B, et al. **In Vivo** 1999 May-Jun;13(3):267-94 (489 ref.)

Effect of age on thymic development, T cell immunity, and helper T cell function. Shen SS, et al. **Rev Physiol Biochem Pharmacol** 1999;139:123-39 (52 ref.)

IMMUNOLOGY

Alpha beta/gamma delta lineage commitment in the thymus of normal and genetically manipulated mice. Fehling HJ, et al. **Adv Immunol** 1999;71:1-76 (236 ref.)

T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Stockinger B. **Adv Immunol** 1999; 71:229-65 (255 ref.)

Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Hanahan D. **Curr Opin Immunol** 1998 Dec;10(6):656-62 (36 ref.)

Positive and negative selection in the thymus and the thymic paradox. Reza JN, et al. **Dev Immunol** 1998;5(3):161-8 (90 ref.)

Thymic function, aging, and AIDS. Haynes BF, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):59-60, 63-5, 69-70, passim (12 ref.)

The human thymus. A chimeric organ comprised of central and peripheral lymphoid components [corrected and republished in Immunol Res 1998;18(3):175-92] Haynes BF, et al. **Immunol Res** 1998;18(2):61-78 (70 ref.)

The human thymus. A chimeric organ comprised of central and peripheral lymphoid components [corrected and republished article originally printed in Immunol Res 1998;18(2):61-78] Haynes BF, et al. **Immunol Res** 1998; 18(3):175-92 (70 ref.)

T-cell and natural killer cell development in thymectomized Xenopus. Horton JD, et al. **Immunol Rev** 1998 Dec; 166:245-58 (90 ref.)

Thymic involution and HIV progression [letter] Beltz L. **Immunol Today** 1999 Sep;20(9):429 (9 ref.)

On the intrathymic intercellular transfer of self-determinants. Viret C, et al. **Immunol Today** 1999 Jan;20(1):8-10 (20 ref.)

Intrathymic non-lymphatic hematopoiesis during mammalian ontogenesis. Bodey B, et al. **In Vivo** 1998 Nov-Dec; 12(6):599-618 (236 ref.)

Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. Kim TJ, et al. **J Korean Med Sci** 1998 Oct;13(5):455-8 (14 ref.)

The ontogeny of T cell recirculation during foetal life. Cahill RN, et al. **Semin Immunol** 1999 Apr;11(2):105-14 (44 ref.)

In vitro models of T cell development. Hare KJ, et al. **Semin Immunol** 1999 Feb;11(1):3-12 (66 ref.)

Using thymus anatomy to dissect T cell repertoire selection. Laufer TM, et al. **Semin Immunol** 1999 Feb;11(1):65-70 (49 ref.)

Fas/APO-1/CD95 in health and autoimmune disease: thymic and peripheral aspects. Moulian N, et al. **Semin Immunol** 1998 Dec;10(6):449-56 (71 ref.)

The human thymic microenvironment: new approaches to functional analysis. Ritter MA, et al. **Semin Immunol** 1999 Feb;11(1):13-21 (62 ref.)

METABOLISM

Thymic expression of neuroendocrine self-peptide precursors: role in T cell survival and self-tolerance. Geenen V, et al. **J Neuroendocrinol** 1998 Nov;10(11):811-22 (137 ref.)

PATHOLOGY

Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71-6 (55 ref.)

PHYSIOLOGY

Role of prolactin and growth hormone on thymus physiology. De Mello-Coelho V, et al. **Dev Immunol** 1998; 6(3-4):317-23 (45 ref.)

Homeostasis, thymic hormones and aging. Goya RG, et al. **Gerontology** 1999 May-Jun;45(3):174-8 (65 ref.)

Extracellular ATP: a further modulator in neuroendocrine control of the thymus. Alves LA, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):81-9 (90 ref.)

Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Delgado M, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):97-107 (81 ref.)

The thymic repertoire of neuroendocrine-related self antigens: biological role in T-cell selection and pharmacological implications. Geenen V, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):115-25 (107 ref.)

The thymus-pituitary axis and its changes during aging. Goya RG, et al. **Neuroimmunomodulation** 1999 Jan-Apr; 6(1-2):137-42 (87 ref.)

Use of cultured thymic tissues for the regeneration of the thymus. Jones GV, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):6-22 (132 ref.)

Immunoneuroendocrine connectivity: the paradigm of the thymus-hypothalamus/pituitary axis. Savino W, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):126-36 (151 ref.)

Thymic expression of the pancreatic endocrine hormones. Throsby M, et al. **Neuroimmunomodulation** 1999 Jan-Apr; 6(1-2):108-14 (48 ref.)

Thymus-derived glucocorticoids and the regulation of antigen-specific T-cell development. Tolosa E, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):90-6 (70 ref.)

[The thyroid and thymus glands and the immune system] Shidlovs'kyĭ VO, et al. **Lik Sprava** 1998 Oct-Nov;(7):21-5 (43 ref.) **(Ukr)**

TRANSPLANTATION

Use of cultured thymic tissues for the regeneration of the thymus. Jones GV, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):6-22 (132 ref.)

[From transplantation of the thymus to molecular reconstruction of the immune system] Arion VIa, et al. **Vestn Ross Akad Med Nauk** 1999;(5):15-9 (20 ref.) (Eng. Abstr.) **(Rus)**

THYMUS HORMONES

PHARMACOLOGY

Thymic peptides and preparations: an update. Cordero OJ, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):77-82 (40 ref.)

THYMUS HYPERPLASIA

DIAGNOSIS

[An arteriovenous malformation of the cervical spinal cord with drainage into the cranial cavity combined with thymus hyperplasia] Panuntsev VS, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):28-30 (18 ref.) **(Rus)**

THYMUS NEOPLASMS

Tumors of the thymus. Strollo DC, et al. **J Thorac Imaging** 1999 Jul;14(3):152-71 (109 ref.)

The thymus: from past misconception to present recognition. Leonidas JC. **Pediatr Radiol** 1998 May;28(5):275-82 (29 ref.)

Germ cell, mesenchymal, and thymic tumors of the mediastinum. Billmire DF. **Semin Pediatr Surg** 1999 May; 8(2):85-91 (49 ref.)

[Standards, options and recommendations (SOR) for clinical care of malignant thymoma. Groupe de Travail SOR] Ruffié P, et al. **Bull Cancer** 1999 Apr;86(4):365-84 (121 ref.) (Eng. Abstr.) **(Fre)**

[Good's syndrome (thymoma with immunodeficiency)] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):258-60 (10 ref.) **(Jpn)**

CLASSIFICATION

Thymoma classification. A siren's song of simplicity [editorial] [see comments] Harris NL, et al. **Am J Clin Pathol** 1999 Sep;112(3):299–303 (24 ref.) Comment in: Am J Clin Pathol 1999 Sep;112(3):308–10.

Thymoma classification: my opinion [editorial] [see comments] Kornstein MJ. **Am J Clin Pathol** 1999 Sep; 112(3):304–7 (19 ref.) Comment in: Am J Clin Pathol 1999 Sep;112(3):308–10.

COMPLICATIONS

Thymoma associated with myasthenia gravis and minimal lesion nephrotic syndrome. Lasseur C, et al. **Am J Kidney Dis** 1999 May;33(5):e4 (19 ref.)

Thymoma-associated dermatomyositis and polymyositis [editorial; comment] Nagasawa K. **Intern Med** 1999 Feb; 38(2):81–2 (10 ref.) Comment on: Intern Med 1999 Feb;38(2):155–9.

Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature. Mizobuchi S, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):696–701 (37 ref.)

Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Levy Y, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):73–9 (45 ref.)

[A case of nephrotic syndrome associated with myasthenia gravis and malignant thymoma] Tomida C, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):77–82 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Thoracic carcinoids: radiologic-pathologic correlation. Rosado de Christenson ML, et al. **Radiographics** 1999 May–Jun;19(3):707–36 (79 ref.)

DRUG THERAPY

Effective treatment of thymic carcinoma with operation and combination chemotherapy against acute monocyte leukemia: case report and review of the literature. Kitami A, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):555–8 (28 ref.)

GENETICS

A thymoma with clonal complex chromosome abnormalities [letter] Sonobe H, et al. **Cancer Genet Cytogenet** 1999 Apr; 110(1):72–4 (9 ref.)

IMMUNOLOGY

Murine models of thymic lymphomas: premalignant scenarios amenable to prophylactic therapy. Yefenof E. **Adv Immunol** 1999;73:511–39 (172 ref.)

Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Levy Y, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):73–9 (45 ref.)

PATHOLOGY

Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Suster S, et al. **Am J Clin Pathol** 1999 Jun;111(6):826–33 (44 ref.)

Thymic carcinoid in the pancreas: metastatic disease or new primary tumours. Axelson J, et al. **Eur J Surg** 1999 Mar; 165(3):270–3 (16 ref.)

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. Cather JC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):858–63 (54 ref.)

Spindle epithelial tumor with thymus-like differentiation: a case report and review of the literature. Bradford CR, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):603–6 (9 ref.)

Primary neuroendocrine carcinomas of the thymus. Klemm KM, et al. **Semin Diagn Pathol** 1999 Feb;16(1):32–41 (77 ref.)

Primary carcinomas of the thymus gland. Ritter JH, et al. **Semin Diagn Pathol** 1999 Feb;16(1):18–31 (71 ref.)

Primary thymic epithelial neoplasms: spectrum of differentiation and histological features. Suster S, et al. **Semin Diagn Pathol** 1999 Feb;16(1):2–17 (58 ref.)

Cardiac tamponade. Knoop T, et al. **Semin Oncol Nurs** 1999 Aug;15(3):168–73 (24 ref.)

PHYSIOPATHOLOGY

[Disturbance of signalling pathways for apoptosis in thymic lymphomas from TCR transgenic mice] Strządała L. **Postepy Hig Med Dosw** 1999;53(2):345–50 (15 ref.) (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)

RADIOTHERAPY

The long-term clinical outcome of myasthenia gravis in patients with thymoma. Bril V, et al. **Neurology** 1998 Oct; 51(4):1198–200 (10 ref.)

SURGERY

Effective treatment of thymic carcinoma with operation and combination chemotherapy against acute monocyte leukemia: case report and review of the literature. Kitami A, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):555–8 (28 ref.)

Current management of thymoma. Langenfeld J, et al. **Surg Oncol Clin N Am** 1999 Apr;8(2):327–39 (49 ref.)

THERAPY

Nonsurgical management of malignant thymoma. Hejna M, et al. **Cancer** 1999 May 1;85(9):1871–84 (98 ref.)

THYROCALCITONIN see **CALCITONIN**

THYROGLOBULIN

BIOSYNTHESIS

A comparative review of the structure and biosynthesis of thyroglobulin. Venkatesh SG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):13–20 (99 ref.)

BLOOD

Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Ladenson PW. **Thyroid** 1999 May; 9(5):429–33 (12 ref.)

Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Spencer CA, et al. **Thyroid** 1999 May;9(5):435–41 (11 ref.)

[Serum thyroglobulin measurement and its clinical significance] Ieiri T. **Nippon Rinsho** 1999 Aug;57(8):1800–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. Deshpande V, et al. **Biochim Biophys Acta** 1999 Mar 19;1430(2):157–78 (226 ref.)

A comparative review of the structure and biosynthesis of thyroglobulin. Venkatesh SG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):13–20 (99 ref.)

GENETICS

[Recent advance in the thyroid testing with special reference to the gene analysis] Ieiri T, et al. **Rinsho Byori** 1998 Nov; 46(11):1071–81 (91 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Anti-thyroglobulin antibodies] Toyoda N, et al. **Nippon Rinsho** 1999 Aug;57(8):1810–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The importance of thyroglobulin structure for thyroid hormone biosynthesis. Dunn JT, et al. **Biochimie** 1999 May; 81(5):505–9 (45 ref.)

Selective endocytosis of thyroglobulin: a review of potential mechanisms for protecting newly synthesized molecules from premature degradation. Hatipoglu BA, et al. **Biochimie** 1999 May;81(5):549–55 (60 ref.)

Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Pacini F, et al. **Biochimie** 1999 May;81(5):463–7 (34 ref.)

Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid-specific gene expression. Suzuki K, et al. **Biochimie** 1999 Apr;81(4):329–40 (78 ref.)

THYROGLOSSAL CYST

CONGENITAL

[Congenital cysts and fistulas of the face and neck: often unrecognized dysembryoplasias] Jellouli Elloumi A, et al. **Tunis Med** 1999 Mar;77(3):117–26 (39 ref.) **(Fre)**

EMBRYOLOGY

[Congenital cysts and fistulas of the face and neck: often unrecognized dysembryoplasias] Jellouli Elloumi A, et al. **Tunis Med** 1999 Mar;77(3):117–26 (39 ref.) **(Fre)**

THYROGLOSSAL DUCT CYST see **THYROGLOSSAL CYST**

THYROID ANTAGONISTS see **ANTITHYROID AGENTS**

THYROID-ASSOCIATED OPHTHALMOPATHY see **GRAVES' DISEASE**

THYROID CRISIS

[Thyrotoxic storm and myxedema coma] Takasu N. **Nippon Rinsho** 1999 Aug;57(8):1859–65 (2 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Thyrotoxic crisis] Diez JJ, et al. **Rev Clin Esp** 1999 May; 199(5):294–301 (97 ref.) **(Spa)**

THYROID DISEASES

Thyroid disease and pregnancy. Mortimer RH. **Aust N Z J Med** 1998 Oct;28(5):647–53 (57 ref.)

Managing lumps in the neck. Mady SM. **Practitioner** 1998 Jun;242(1587):472–5 (4 ref.)

An introduction to benign thyroid disease: pathophysiologic, epidemiologic aspects and diagnostic methodology. Andreoli M, et al. **Rays** 1999 Apr–Jun;24(2):169–81 (29 ref.) **(Eng, Ita)**

BLOOD

Methods for measuring iodine in urine and serum. Rendl J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S34–41 (46 ref.)

Soluble CD27 in thyroid disorders [editorial; comment] Wenisch C, et al. **J Lab Clin Med** 1998 Dec;132(6):448–50 (43 ref.) Comment on: J Lab Clin Med 1998 Dec;132(6):478–82.

[Determination of thyroid hormone] Ochi Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1794–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Kinetics of acute and chronic iodine excess. Saller B, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 3:S34–8 (29 ref.)

Is thyroxine during lithium therapy necessary? [see comments] Lazarus JH. **J Endocrinol Invest** 1998 Dec; 21(11):784–6 (15 ref.) Comment in: J Endocrinol Invest 1999 Mar;22(3):220–2.

Too much versus too little: the implications of current iodine intake in the United States. Lee K, et al. **Nutr Rev** 1999 Jun;57(6):177–81 (21 ref.)

Effects of environmental synthetic chemicals on thyroid function. Brucker-Davis F. **Thyroid** 1998 Sep;8(9):827–56 (381 ref.)

The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Lazarus JH. **Thyroid** 1998 Oct;8(10):909–13 (52 ref.)

[Autoimmune thyroid disease induced by interferon therapy] Murakami M, et al. **Nippon Rinsho** 1999 Aug;57(8):1779–83 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The black thyroid syndrome. A case report (letter)] Cos M, et al. **Rev Clin Esp** 1999 Jul;199(7):478–9 (10 ref.) **(Spa)**

COMPLICATIONS

Chronic urticaria and angioedema associated with thyroid autoimmunity: review and therapeutic implications. Heymann WR. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):229–32 (19 ref.)

Thyroid disease in pregnancy. Drake WM, et al. **Postgrad Med J** 1998 Oct;74(876):583–6 (22 ref.)

[Is there a need for treatment in subclinical hypo- and hyperthyroidism?] Lerch M, et al. **Ther Umsch** 1999 Jul; 56(7):369–73 (15 ref.) (Eng. Abstr.) **(Ger)**

[Relationship between primary Sjögren's syndrome and autoimmune thyroid disease] Kohriyama K, et al. **Nippon Rinsho** 1999 Aug;57(8):1878–81 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The association between autoimmune thyroid diseases and rheumatic diseases: a review] MasukoHongo K, et al. **Nippon Rinsho** 1999 Aug;57(8):1873–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Thyroid disease in autoimmune liver diseases] Zeniya M. **Nippon Rinsho** 1999 Aug;57(8):1882–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

[The influence of thyroid diseases and their treatment on the development of osteoporosis] Ciesielska-Kopacz N, et al. **Przegl Lek** 1998;55(5):271–3 (19 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Diagnosis of thyroid disease in hospitalized patients: a systematic review. Attia J, et al. **Arch Intern Med** 1999 Apr 12;159(7):658–65 (38 ref.)

Diffuse lipomatosis of thyroid gland. Arslan A, et al. **Auris Nasus Larynx** 1999 Apr;26(2):213–5 (20 ref.)

Clinical perspectives in the diagnosis of thyroid disease. Kaplan MM. **Clin Chem** 1999 Aug;45(8 Pt 2):1377–83 (33 ref.)

Interpretation of thyroid function tests: an update. Peery WH, et al. **Compr Ther** 1998 Nov–Dec;24(11–12):567–73 (13 ref.)

Diagnosis and management of maternal and fetal thyroid disorders. Mestman JH. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):167–75 (60 ref.)

Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Peschen-Rosin R, et al. **Eur Neurol** 1999;41(2):79–84 (37 ref.)

Clinical and laboratory assessment of subclinical thyroid disease. Madeddu G, et al. **Rays** 1999 Apr–Jun;24(2):229–42 (54 ref.) **(Eng, Ita)**

Diagnostic imaging of the thyroid: methodology and normal patterns. Mirk P, et al. **Rays** 1999 Apr–Jun;24(2):215–28 (40 ref.) **(Eng, Ita)**

[Diagnostic imaging of thyroid gland diseases] Karstrup S, et al. **Ugeskr Laeger** 1998 Nov 30;160(49):7101–4 (11 ref.) **(Dan)**

[Non-biological explorations of the thyroid gland. Work

Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Gerson M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115 Suppl 1:S89–104 (137 ref.) **(Fre)**

[A functional biologic study of the thyroid: pitfalls to avoid] Sapin R, et al. **Rev Med Interne** 1999;20 Suppl 1:9S–11S (24 ref.) **(Fre)**

[Changes in thyroxine-binding globulin: pitfalls in thyroid function diagnosis] John MR, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1219–25 (50 ref.) **(Ger)**

[Iodine deficiency disorders with functional autonomy. Diagnostic and therapeutic indications (editorial)] Emrich D. **Nuklearmedizin** 1999;38(1):3–5 (25 ref.) **(Ger)**

[ABC of thyroid diseases and their treatment] Bürgi U, et al. **Ther Umsch** 1999 Jul;56(7):353–5 (11 ref.) (Eng. Abstr.) **(Ger)**

[Monitoring of treatment in thyroid diseasc:] de Marco D, et al. **Ther Umsch** 1999 Jul;56(7):400–2 (00 ref.) (Eng. Abstr.) **(Ger)**

[New clinical tests that physicians should know for diagnosis of endocrine and metabolic disorders] Ikeda H. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2023–6 (4 ref.) **(Jpn)**

[Serum thyroglobulin measurement and its clinical significance] Ieiri T. **Nippon Rinsho** 1999 Aug;57(8):1800–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Anti-thyroid peroxidase antibody] Inukai T, et al. **Nippon Rinsho** 1999 Aug;57(8):1819–23 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Microsomal antibody] Kuwabara A, et al. **Nippon Rinsho** 1999 Aug;57(8):1815–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of autoimmune thyroid disease (ATD) complicated by pregnancy] Momotani N. **Nippon Rinsho** 1999 Aug;57(8):1866–72 (25 ref.) (Eng. Abstr.) **(Jpn)**

[TSH receptor autoantibody: its historical background and interpretation of the data on TSAb, TSBAb and TBII] Saito J, et al. **Nippon Rinsho** 1999 Aug;57(8):1829–33 (25 ref.) **(Jpn)**

[Anti-thyroglobulin antibodies] Toyoda N, et al. **Nippon Rinsho** 1999 Aug;57(8):1810–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Too much versus too little: the implications of current iodine intake in the United States. Lee K, et al. **Nutr Rev** 1999 Jun;57(6):177–81 (21 ref.)

Medical therapy of benign thyroid diseases. Corsello SM, et al. **Rays** 1999 Apr-Jun;24(2):315–30 (65 ref.) **(Eng, Ita)**

Antithyroid drug therapy: predictive parameters. Feldt-Rasmussen U. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:53–5 (10 ref.)

[Monitoring of treatment in thyroid diseases] de Marco D, et al. **Ther Umsch** 1999 Jul;56(7):400–2 (00 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of thyroid diseases in iodine sufficiency. Lind P, et al. **Thyroid** 1998 Dec;8(12):1179–83 (45 ref.)

Subclinical thyroid disease in the elderly. Samuels MH. **Thyroid** 1998 Sep;8(9):803–13 (94 ref.)

ETIOLOGY

[The thyroid in the aged subject] Frankart L, et al. **Ann Endocrinol (Paris)** 1998 Jul;59(2):59–66 (44 ref.) (Eng. Abstr.) **(Fre)**

[Genetic and environmental factors of autoimmune thyroid diseases] Akamizu T. **Nippon Rinsho** 1999 Aug; 57(8):1697–702 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Postpartum autoimmune thyroid syndrome] Hidaka Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1775–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Thyroid defects due to Pax8 gene mutations. Damante G. **Eur J Endocrinol** 1998 Dec;139(6):563–6 (27 ref.)

Autoimmune thyroid disease genes come in many styles and colors [editorial; comment] Davies TF. **J Clin Endocrinol Metab** 1998 Oct;83(10):3391–3 (43 ref.) Comment on: J Clin Endocrinol Metab 1998 Oct;83(10):3394–7.

Molecular genetics of benign thyroid disease. Pontecorvi A, et al. **Rays** 1999 Apr-Jun;24(2):197–214 (65 ref.) **(Eng, Ita)**

[Signal transduction and thyroid pathology: environment and genetics] Pirson I, et al. **C R Seances Soc Biol Fil** 1998; 192(5):847–56 (86 ref.) **(Fre)**

[Mutations in TSH receptors: pathogenetic significance and clinical relevance] Führer D, et al. **Dtsch Med Wochenschr** 1999 May 28;124(21):662–9 (48 ref.) **(Ger)**

[Immunoregulatory genes in autoimmune thyroid disease] Gemma R, et al. **Nippon Rinsho** 1999 Aug;57(8):1737–42 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenesis of disorder due to thyroid hormone receptor mutation] Nagaya T, et al. **Rinsho Byori** 1998 Oct; 46(10):1017–22 (12 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Apoptosis in the pathogenesis of autoimmune thyroid disease] Abe Y. **Nippon Rinsho** 1999 Aug;57(8):1717–22 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Animal models for autoimmune thyroid disease] Nishikawa M, et al. **Nippon Rinsho** 1999 Aug;57(8):1723–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[B-cell, T-cell surface phenotypes and epitopes in autoimmune thyroid diseases] Nishiya K, et al. **Nippon Rinsho** 1999 Aug;57(8):1743–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Bodenner DL, et al. **Am J Med** 1998 Dec;105(6):524–38 (80 ref.)

Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Pacini F, et al. **Biochimie** 1999 May;81(5):463–7 (34 ref.)

Leptin and the thyroid--a puzzle with missing pieces [comment] Korbonits M. **Clin Endocrinol (Oxf)** 1998 Nov; 49(5):569–72 (29 ref.) Comment on: Clin Endocrinol (Oxf) 1998 Nov;49(5):583–8.

[The sodium-iodide-symporter (NIS): function, regulation and clinical importance] Köhrle J. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:17–22 (48 ref.) (Eng. Abstr.) **(Ger)**

[The role of iodine in various thyroid disorders] Widala E, et al. **Przegl Lek** 1998;55(3):140–2 (21 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Diagnosis of benign thyroid lesions: fine-needle aspiration and histopathologic correlation. Oertel YC, et al. **Ann Diagn Pathol** 1998 Aug;2(4):250–63 (48 ref.)

The role of fine needle aspiration cytology in the diagnosis of thyroid lesions. McKee G. **J R Soc Med** 1998;91 Suppl 33:28–32 (20 ref.)

Histology and aspiration cytology of benign thyroid diseases. Fadda G, et al. **Rays** 1999 Apr-Jun;24(2):182–96 (60 ref.) **(Eng, Ita)**

Melanosis thyroidi. Veinot JP, et al. **Ultrastruct Pathol** 1998 Sep-Oct;22(5):401–6 (25 ref.)

[Thyroid biopsy in the auto-immune thyroid diseases] Fukuuchi A. **Nippon Rinsho** 1999 Aug;57(8):1841–5 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Models to study the pathogenesis of thyroid autoimmunity. Krogh Rasmussen A, et al. **Biochimie** 1999 May;81(5):511–5 (41 ref.)

The thyroid axis and depression. Jackson IM. **Thyroid** 1998 Oct;8(10):951–6 (55 ref.)

Thyroid hormone and intellectual development: a clinician's view. Lazarus JH. **Thyroid** 1999 Jul;9(7):659–60 (12 ref.)

Clinical manifestations of postpartum thyroid disease. Lazarus JH. **Thyroid** 1999 Jul;9(7):685–9 (34 ref.)

[Signal transduction and thyroid pathology: environment and genetics] Pirson I, et al. **C R Seances Soc Biol Fil** 1998; 192(5):847–56 (86 ref.) **(Fre)**

[Autoimmune thyroid diseases complicated with reversible changes of thyroid function] Kajita Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1764–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Postpartum depression and thyroid antibody status. Harris B. **Thyroid** 1999 Jul;9(7):699–703 (42 ref.)

RADIONUCLIDE IMAGING

Scintigraphic evaluation of functional thyroidal autonomy. Meller J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S45–51 (56 ref.)

SURGERY

Surgical treatment of thyroid disease, thyroidectomy and parathyroidectomy: a medical guide for doctors and nurses. Giddings AE. **J R Soc Med** 1998;91 Suppl 33:36–41 (0 ref.)

The technique of thyroidectomy. Wheeler MH. **J R Soc Med** 1998;91 Suppl 33:12–6 (15 ref.)

[Extemporaneous anatomo-pathological examinations in breast and thyroid diseases. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Bataille N, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115 Suppl 1:S46–74 (225 ref.) **(Fre)**

THERAPY

Diagnosis and management of maternal and fetal thyroid disorders. Mestman JH. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):167–75 (60 ref.)

[Iodine deficiency disorders with functional autonomy. Diagnostic and therapeutic indications (editorial)] Emrich D. **Nuklearmedizin** 1999;38(1):3–5 (25 ref.) **(Ger)**

[ABC of thyroid diseases and their treatment] Bürgi U, et al. **Ther Umsch** 1999 Jul;56(7):353–5 (11 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism--advantages and disadvantages of pharmacologic, surgical, and radioactive iodine treatments] Meier CA. **Ther Umsch** 1999 Jul;56(7):364–8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of autoimmune thyroid disease (ATD) complicated by pregnancy] Momotani N. **Nippon Rinsho** 1999 Aug;57(8):1866–72 (25 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Clinical application of ultrasonography to the autoimmune thyroid disease] Kitaoka M. **Nippon Rinsho** 1999 Aug; 57(8):1834–40 (11 ref.) (Eng. Abstr.) **(Jpn)**

URINE

Methods for measuring iodine in urine and serum. Rendl J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S34–41 (46 ref.)

THYROID FUNCTION TESTS

Interpretation of thyroid function tests: an update. Peery WH, et al. **Compr Ther** 1998 Nov-Dec;24(11-12):567–73 (13 ref.)

Sick euthyroid syndrome. What to do when thyroid function tests are abnormal in critically ill patients. Camacho PM, et al. **Postgrad Med** 1999 Apr;105(4):215–9 (12 ref.)

[Changes in thyroxine-binding globulin: pitfalls in thyroid function diagnosis] John MR, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1219–25 (50 ref.) **(Ger)**

[Non-thyroid illness" or changed thyroid hormone parameter syndrome with non-thyroid illnesses] Reinhardt W, et al. **Med Klin** 1998 Nov 15;93(11):662–8 (83 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[New clinical tests that physicians should know for diagnosis of endocrine and metabolic disorders] Ikeda H. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2023–6 (4 ref.) **(Jpn)**

THYROID GLAND

see related
STRUMA OVARII
THYROIDECTOMY

Cervical ectopic thyroid. Wong RJ, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):397–400 (14 ref.)

Benign intratracheal thyroid: a possible cause for preoperative overstaging. Brandwein M, et al. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1266–9 (16 ref.)

Identification and characterization of mRNAs differentially expressed in thyroid cells stimulated by a mitogenic treatment. Pirson I, et al. **Biochimie** 1999 Apr;81(4):309–14 (38 ref.)

Intralaryngotracheal thyroid--ectopic thyroid or invasive carcinoma? See AC, et al. **J Laryngol Otol** 1998 Jul; 112(7):673–6 (26 ref.)

[Intracardiac ectopic thyroid: a report of a clinical case with a long-term follow-up] Pistono M, et al. **Cardiologia** 1999 Jan;44(1):83–8 (10 ref.) (Eng. Abstr.) **(Ita)**

ANATOMY & HISTOLOGY

Diagnostic imaging of the thyroid: methodology and normal patterns. Mirk P, et al. **Rays** 1999 Apr-Jun;24(2):215–28 (40 ref.) **(Eng, Ita)**

[The thyroid in the aged subject] Frankart L, et al. **Ann Endocrinol (Paris)** 1998 Jul;59(2):59–66 (44 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Hard GC. **Environ Health Perspect** 1998 Aug;106(8):427–36 (193 ref.)

Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system. Capen CC. **Toxicol Lett** 1998 Dec 28;102-103:405–9 (7 ref.)

[Amiodarone and the thyroid gland] Modlinska A, et al. **Pol Arch Med Wewn** 1998 Jul;100(1):74–81 (20 ref.) **(Pol)**

[Amiodarone and the thyroid] Lahera Vargas M, et al. **Rev Clin Esp** 1999 Apr;199(4):227–32 (77 ref.) **(Spa)**

EMBRYOLOGY

Radioiodine and pregnancy. Gorman CA. **Thyroid** 1999 Jul; 9(7):721–6 (45 ref.)

GROWTH & DEVELOPMENT

Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease. Di Cerbo A, et al. **Biochimie** 1999 May;81(5):415–24 (118 ref.)

Minireview: discussion about the limit between normal thyroid goiter. Langer P. **Endocr Regul** 1999 Mar; 33(1):39–45 (44 ref.)

Molecular events involved in differentiation of thyroid follicular cells. Missero C, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):37–43 (49 ref.)

IMMUNOLOGY

Models to study the pathogenesis of thyroid autoimmunity. Krogh Rasmussen A, et al. **Biochimie** 1999 May;81(5):511-5 (41 ref.)

Thyroid autoimmunity and aging. Mariotti S, et al. **Exp Gerontol** 1998 Sep;33(6):535-41 (32 ref.)

Chronic urticaria and angioedema associated with thyroid autoimmunity: review and therapeutic implications. Heymann WR. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):229-32 (19 ref.)

The thyroid immunology of the postpartum period. Davies TF. **Thyroid** 1999 Jul;9(7):675-84 (66 ref.)

Postpartum depression and thyroid antibody status. Harris B. **Thyroid** 1999 Jul;9(7):699-703 (42 ref.)

The thyroid gland 1998: new ideas about an ancient structure. Wilber JF. **Trans Am Clin Climatol Assoc** 1999;110:205-13 (6 ref.)

[Microsomal antibody] Kuwabara A, et al. **Nippon Rinsho** 1999 Aug;57(8):1815-8 (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The trace element selenium and the thyroid gland. Köhrle J. **Biochimie** 1999 May;81(5):527-33 (81 ref.)

Hormone synthesis and storage in the thyroid of human preterm and term newborns: effect of thyroxine treatment. van den Hove MF, et al. **Biochimie** 1999 May;81(5):563-70 (40 ref.)

Leptin and the thyroid--a puzzle with missing pieces [comment] Korbonits M. **Clin Endocrinol (Oxf)** 1998 Nov; 49(5):569-72 (29 ref.) Comment on: Clin Endocrinol (Oxf) 1998 Nov;49(5):583-8.

Growth factors and goitrogenesis. Bidey SP, et al. **J Endocrinol** 1999 Mar;160(3):321-32 (123 ref.)

Iodide channel of the thyroid: reconstitution of iodide conductance in proteoliposomes. Golstein PE, et al. **Methods Enzymol** 1999;294:304-19 (12 ref.)

[Effects of the combined deficiency of selenium and iodine on thyroid function] Miniero R, et al. **Ann Ist Super Sanita** 1998;34(3):349-55 (39 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Diagnosis of benign thyroid lesions: fine-needle aspiration and histopathologic correlation. Oertel YC, et al. **Ann Diagn Pathol** 1998 Aug;2(4):250-63 (48 ref.)

Radioactive iodine-associated cytomorphologic alterations in thyroid follicular epithelium: is recognition possible in fine-needle aspiration specimens? Sturgis CD. **Diagn Cytopathol** 1999 Sep;21(3):207-10 (21 ref.)

Histology and aspiration cytology of benign thyroid diseases. Fadda G, et al. **Rays** 1999 Apr-Jun;24(2):182-96 (60 ref.) **(Eng, Ita)**

Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Kebebew E, et al. **Thyroid** 1999 Feb;9(2):127-31 (17 ref.)

[Extemporaneous anatomo-pathological examinations in breast and thyroid diseases. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Bataille N, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115 Suppl 1:S46-74 (225 ref.) **(Fre)**

[Thyroid biopsy in the auto-immune thyroid diseases] Fukuuchi A. **Nippon Rinsho** 1999 Aug;57(8):1841-5 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid-specific gene expression. Suzuki K, et al. **Biochimie** 1999 Apr;81(4):329-40 (78 ref.)

Thyroid and fertility. Mayer G, et al. **Coll Antropol** 1998 Jun;22(1):17-21 (38 ref.)

Inhibition and activation of the thyroidal axis by the adrenal axis in vertebrates. Kühn ER, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 May; 120(1):169-74 (49 ref.)

Endocrine changes in critically ill patients. Van den Berghe G. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:77-81 (28 ref.)

What happens to the normal thyroid during pregnancy? Glinoer D. **Thyroid** 1999 Jul;9(7):631-5 (15 ref.)

Thyroid function in the preterm infant. LaFranchi S. **Thyroid** 1999 Jan;9(1):71-8 (33 ref.)

[A functional biologic study of the thyroid: pitfalls to avoid] Sapin R, et al. **Rev Med Interne** 1999;20 Suppl 1:9S-11S (24 ref.) **(Fre)**

[Thyroid disease in ageing] Hashizume K. **Nippon Ronen Igakkai Zasshi** 1998 Sep;35(9):662-4 (10 ref.) **(Jpn)**

[The thyroid and thymus glands and the immune system] Shidlovs'kyĭ VO, et al. **Lik Sprava** 1998 Oct-Nov;(7):21-5 (43 ref.) **(Ukr)**

PHYSIOPATHOLOGY

Alterations of neonatal thyroid function. Grüters A, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):17-22 (29 ref.)

Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease. Di Cerbo A, et al. **Biochimie** 1999 May;81(5):415-24 (118 ref.)

Thyroid hormones in depressive disorders: a reappraisal of clinical utility. Lasser RA, et al. **Harv Rev Psychiatry** 1997 Mar-Apr;4(6):291-305 (137 ref.)

Graves' disease: xenotransplantation model (athymic nude mice). Jungheim K, et al. **J Mol Med** 1999 Jan;77(1):185-8 (28 ref.)

Effects of environmental synthetic chemicals on thyroid function. Brucker-Davis F. **Thyroid** 1998 Sep;8(9):827-56 (381 ref.)

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Hershman JM. **Thyroid** 1999 Jul;9(7):653-7 (42 ref.)

The thyroid axis and depression. Jackson IM. **Thyroid** 1998 Oct;8(10):951-6 (55 ref.)

Postpartum mood and anxiety disorders: a guide for the nonpsychiatric clinician with an aside on thyroid associations with postpartum mood. Pedersen CA. **Thyroid** 1999 Jul;9(7):691-7 (51 ref.)

[Signal transduction and thyroid pathology: environment and genetics] Pirson I, et al. **C R Seances Soc Biol Fil** 1998; 192(5):847-56 (86 ref.) **(Fre)**

[Euthyroid sick syndrome: recent physiopathologic findings] Goichot B, et al. **Rev Med Interne** 1998 Sep;19(9):640-8 (66 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune thyroid diseases complicated with reversible changes of thyroid function] Kajita Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1764-9 (19 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Nikiforov YE, et al. **Adv Anat Pathol** 1999 Mar;6(2):78-91 (44 ref.)

RADIONUCLIDE IMAGING

[Present status and progress of endocrine nuclear medicine] Nakajo M. **Kaku Igaku** 1999 Jan;36(1):1-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Graves' disease: xenotransplantation model (athymic nude mice). Jungheim K, et al. **J Mol Med** 1999 Jan;77(1):185-8 (28 ref.)

ULTRASONOGRAPHY

Thyroid sonography: current applications and future directions. Tessler FN, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):437-43 (62 ref.)

THYROID HORMONE RECEPTORS see **RECEPTORS, THYROID HORMONE**

THYROID HORMONE RESISTANCE SYNDROME

see related
EUTHYROID SICK SYNDROMES

ETIOLOGY

[Thyroid hormone receptors and the disorders] Nagaya T, et al. **Nippon Rinsho** 1998 Jul;56(7):1861-5 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular basis of resistance to thyroid hormone (RTH). Nagaya T, et al. **Endocr J** 1998 Dec;45(6):709-18 (62 ref.)

THERAPY

Treatment of resistance to thyroid hormone--primum non nocere [editorial; comment] Weiss RE, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):401-4 (40 ref.) Comment on: J Clin Endocrinol Metab 1999 Feb;84(2):405-10.

THYROID HORMONES

see related
HYPERTHYROIDISM
HYPOTHYROIDISM
RECEPTORS, THYROID HORMONE
THYROGLOBULIN

BIOSYNTHESIS

The importance of thyroglobulin structure for thyroid hormone biosynthesis. Dunn JT, et al. **Biochimie** 1999 May; 81(5):505-9 (45 ref.)

BLOOD

Diagnosis of thyroid disease in hospitalized patients: a systematic review. Attia J, et al. **Arch Intern Med** 1999 Apr 12;159(7):658-65 (38 ref.)

Thyrotoxic period paralysis: report of three cases and review of the literature. Papadopoulos KI, et al. **J Intern Med** 1997 Jun;241(6):521-4 (14 ref.)

Sick euthyroid syndrome. What to do when thyroid function tests are abnormal in critically ill patients. Camacho PM, et al. **Postgrad Med** 1999 Apr;105(4):215-9 (12 ref.)

[Non-thyroid illness" or changed thyroid hormone parameter syndrome with non-thyroid illnesses] Reinhardt W, et al. **Med Klin** 1998 Nov 15;93(11):662-8 (83 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. Deshpande V, et al. **Biochim Biophys Acta** 1999 Mar 19;1430(2):157-78 (226 ref.)

METABOLISM

Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Bodenner DL, et al. **Am J Med** 1998 Dec;105(6):524-38 (80 ref.)

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Biochimie** 1999 Apr;81(4):359-66 (63 ref.)

Hormone synthesis and storage in the thyroid of human preterm and term newborns: effect of thyroxine treatment. van den Hove MF, et al. **Biochimie** 1999 May;81(5):563-70 (40 ref.)

Zinc, exercise, and thyroid hormone function. Ganapathy S, et al. **Crit Rev Food Sci Nutr** 1999 Jul;39(4):369-90 (122 ref.)

PHARMACOLOGY

Thyroid hormone action: down novel paths. Focus on "thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells" [editorial] Brent GA. **Am J Physiol** 1999 May;276(5 Pt 1):C1012-3 (14 ref.)

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Ann Endocrinol (Paris)** 1998;59(6):433-42 (56 ref.)

The effect of thyroid hormone on skeletal integrity. Greenspan SL, et al. **Ann Intern Med** 1999 May 4; 130(9):750-8 (81 ref.)

PHYSIOLOGY

Development effects of thyroid hormone: the role of deiodinases in regulatory control. St Germain DL. **Biochem Soc Trans** 1999 Feb;27(2):83-8 (57 ref.)

Evolving concepts of thyroid hormone action. Oppenheimer JH. **Biochimie** 1999 May;81(5):539-43 (44 ref.)

Amphibian metamorphosis as a model for studying the developmental actions of thyroid hormone. Tata JR. **Cell Res** 1998 Dec;8(4):259-72 (63 ref.)

Antenatal hormone therapy for fetal lung maturation. Merrill JD, et al. **Clin Perinatol** 1998 Dec;25(4):983-97 (86 ref.)

The molecular basis of thyroid hormone-dependent central nervous system remodeling during amphibian metamorphosis. Denver RJ. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):219-28 (101 ref.)

Molecular basis of resistance to thyroid hormone (RTH). Nagaya T, et al. **Endocr J** 1998 Dec;45(6):709-18 (62 ref.)

Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Hard GC. **Environ Health Perspect** 1998 Aug;106(8):427-36 (193 ref.)

Action of thyroid hormones at the cellular level: the mitochondrial target. Goglia F, et al. **FEBS Lett** 1999 Jun 11;452(3):115-20 (59 ref.)

Thyroid hormones in depressive disorders: a reappraisal of clinical utility. Lasser RA, et al. **Harv Rev Psychiatry** 1997 Mar-Apr;4(6):291-305 (137 ref.)

Thyroid hormone and other regulators of uncoupling proteins. Reitman ML, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 6:S56-9 (36 ref.)

Role of thyroid hormones and their receptors in peripheral nerve regeneration. Barakat-Walter I. **J Neurobiol** 1999 Sep 15;40(4):541-59 (113 ref.)

Oligodendrocyte development and thyroid hormone. Rodriguez-Peña A. **J Neurobiol** 1999 Sep 15;40(4):497-512 (118 ref.)

Regulation of thyroid hormone metabolism during fetal development. Darras VM, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):37-47 (98 ref.)

Local activation and inactivation of thyroid hormones: the deiodinase family. Köhrle J. **Mol Cell Endocrinol** 1999 May 25;151(1-2):103-19 (152 ref.)

Multiple isoforms of thyroid hormone receptor: an analysis of their relative contribution in mediating thyroid hormone action. Murata Y. **Nagoya J Med Sci** 1998 Oct; 61(3-4):103-15 (55 ref.)

Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. Ribeiro RC, et al. **Recent Prog Horm Res** 1998;53:351-92; discussion 392-4 (190 ref.)

Thyroid hormone induces a reprogramming of gene expression in the liver of premetamorphic Rana catesbeiana tadpoles. Atkinson BG, et al. **Wound Repair Regen** 1998 Jul-Aug;6(4):323-37 (56 ref.)

Thyroid hormone regulation of Xenopus laevis metamorphosis: functions of thyroid hormone receptors and roles of extracellular matrix remodeling. Shi YB, et al. **Wound Repair Regen** 1998 Jul-Aug;6(4):314-22 (63 ref.)

[Thyroid hormones and the heart] Zyśko D. **Pol Merkuriusz Lek** 1999 Mar;6(33):157-60 (31 ref.) (Eng. Abstr.) **(Pol)**

THYROID HORMONES

THERAPEUTIC USE

Antenatal hormone therapy for fetal lung maturation. Merrill JD, et al. **Clin Perinatol** 1998 Dec;25(4):983–97 (86 ref.)

Thyroid hormone and thyroid hormone analogues in the treatment of heart failure. Spooner PH, et al. **Coron Artery Dis** 1999 Sep;10(6):395–9 (33 ref.)

Guidelines for the use of radio-iodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Paloyan E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):665–80 (37 ref.)

[Non-thyroid indications of treatment with thyroid hormones] Goichot B, et al. **Rev Med Interne** 1998 Oct; 19(10):720–5 (30 ref.) (Eng. Abstr.) **(Fre)**

[Thyroid hormones and the heart] Zyśko D. **Pol Merkuriusz Lek** 1999 Mar;6(33):157–60 (31 ref.) (Eng. Abstr.) **(Pol)**

THYROID NEOPLASMS

Current diagnosis and management of medullary thyroid carcinoma. Giuffrida D, et al. **Ann Oncol** 1998 Jul; 9(7):695–701 (63 ref.)

Summary of observations on transplantable tumors of the rat thyroid gland. Wollman SH. **Biochimie** 1999 Apr; 81(4):409–12 (6 ref.)

Many faces of mixed medullary-follicular and papillary carcinoma of the thyroid [editorial; comment] Monden T, et al. **Intern Med** 1998 Nov;37(11):909–10 (12 ref.) Comment on: Intern Med 1998 Nov;37(11):955–7.

Primary thyroid lymphoma. Ansell SM, et al. **Semin Oncol** 1999 Jun;26(3):316–23 (55 ref.)

[Medullary cancer of the thyroid] Modigliani E. **Rev Med Interne** 1999 Jun;20(6):490–503 (68 ref.) (Eng. Abstr.) **(Fre)**

[From Hashimoto thyroiditis to B-cell lymphoma of the thyroid gland] Fehr-Merhof A, et al. **Schweiz Med Wochenschr** 1999 Jun 12;129(23):883–9 (32 ref.) (Eng. Abstr.) **(Ger)**

[Thyroid teratomas in the adult] Torrico Román P, et al. **Acta Otorrinolaringol Esp** 1999 Jan-Feb;50(1):75–7 (10 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Hard GC. **Environ Health Perspect** 1998 Aug;106(8):427–36 (193 ref.)

COMPLICATIONS

Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Cetta F, et al. **Am J Pathol** 1999 Jul;155(1):7–9 (20 ref.)

Hyperthyroidism due to lymphoma involving the thyroid gland in a patient with acquired immunodeficiency syndrome: case report and review of the literature. Samuels MH, et al. **Thyroid** 1998 Aug;8(8):673–7 (41 ref.)

CONGENITAL

Congenital thyroid teratoma: a case with persistent neuroglial involvement of cervical lymph nodes. Keen CE, et al. **Pediatr Dev Pathol** 1998 Jul-Aug;1(4):322–7 (11 ref.)

DIAGNOSIS

RET protooncogene analysis in the diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type II. Matias-Guiu X. **Adv Anat Pathol** 1998 May;5(3):196–201 (19 ref.)

The incidental diagnosis. Silverberg LI. **J Am Osteopath Assoc** 1999 Apr;99(4):214–6 (18 ref.)

The diagnosis of recurrent thyroid cancer--a new approach [editorial; comment] Haber RS. **J Clin Endocrinol Metab** 1998 Dec;83(12):4189–90 (15 ref.) Comment on: J Clin Endocrinol Metab 1998 Dec;83(12):4435–42.

Follicular neoplasms: the role for observation, fine needle aspiration biopsy, thyroid suppression, and surgery. St. Louis JD, et al. **Semin Surg Oncol** 1999 Jan-Feb;16(1):5–11 (42 ref.)

The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. James C, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):145–69 (114 ref.)

Ectopic thymic carcinoid masquerading as a thyroid nodule. Inzucchi SE, et al. **Thyroid** 1998 Jul;8(7):589–95 (26 ref.)

Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Spencer CA, et al. **Thyroid** 1999 May;9(5):435–41 (11 ref.)

[Cervical lymphadenopathy revealing differentiated thyroid cancer. Review of the literature and therapeutic approach] Rodier JF, et al. **Ann Chir** 1998;52(9):922–6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Differentiated thyroid gland carcinoma in children and adolescents] Meller J, et al. **Klin Padiatr** 1998 Sep-Oct; 210(5):373–8 (45 ref.) (Eng. Abstr.) **(Ger)**

[Hashimoto's thyroiditis and thyroid cancer: a report of a clinical case and a review of the literature] Zardo F, et al. **G Chir** 1999 Apr;20(4):174–6 (20 ref.) (Eng. Abstr.) **(Ita)**

[Medullary carcinoma of the thyroid. A clinical case] Faccini M, et al. **Minerva Chir** 1999 Jan-Feb;54(1-2):79–81 (10 ref.) (Eng. Abstr.) **(Ita)**

[Endocrine surgery. Diagnosis and therapy for thyroid malignant lymphoma] Akasu H, et al. **Nippon Ika Daigaku Zasshi** 1998 Aug;65(4):320–3 (9 ref.) **(Jpn)**

[Differential diagnosis of Hashimoto's thyroiditis from thyroidal neoplastic diseases] Aozasa K, et al. **Nippon Rinsho** 1999 Aug;57(8):1894–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Serum thyroglobulin measurement and its clinical significance] Ieiri T. **Nippon Rinsho** 1999 Aug;57(8):1800–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Rare presentations of thyroid carcinoma] Lapuente Arruebo MJ, et al. **An Med Interna** 1999 Jul;16(7):357–8 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Substitution therapy after surgery for autonomous adenomas. Feldkamp J, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S85–7 (33 ref.)

Ultrasound-guided percutaneous ethanol injection in the treatment of autonomous thyroid nodules--a review. Schumm-Draeger PM. **Exp Clin Endocrinol Diabetes** 1998; 106 Suppl 4:S59–62 (25 ref.)

EPIDEMIOLOGY

Pediatric thyroid nodules: insights in management. Lugo-Vicente H, et al. **Bol Asoc Med P R** 1998 Apr-Jun; 90(4–6):74–8 (26 ref.)

ETIOLOGY

Advances in the pathogenesis and treatment of thyroid cancer. Hanna NN, et al. **Curr Opin Oncol** 1999 Jan; 11(1):42–7 (22 ref.)

Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Derwahl M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S6–9 (41 ref.)

Iodine intake and thyroid carcinoma--a potential risk factor. Franceschi S. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 3:S38–44 (56 ref.)

Evaluation of risk in autonomously functioning thyroid nodules. Mann K. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S23–6 (43 ref.)

[Nuclear risk and thyroid neoplasms in infancy] Calbo L, et al. **Chir Ital** 1997;49(4–5):27–9 (20 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Cetta F, et al. **Am J Pathol** 1999 Jul;155(1):7–9 (20 ref.)

Different mutations of the RET gene cause different human tumoral diseases. Santoro M, et al. **Biochimie** 1999 Apr; 81(4):397–402 (57 ref.)

Mechanisms of mutagenesis in mammalian cells. Application to human thyroid tumours. Sarasin A, et al. **C R Acad Sci III** 1999 Feb-Mar;322(2–3):143–9 (24 ref.)

RET proto-oncogene in the development of human cancer. Eng C. **J Clin Oncol** 1999 Jan;17(1):380–93 (127 ref.)

A ret transgenic mouse model of thyroid carcinogenesis. Capen C, et al. **Lab Anim Sci** 1998 Dec;48(6):580–3 (3 ref.)

Studies of oncogenes and tumor-suppressor genes in human thyroid carcinomas, and their clinical implications. Goretzki PE, et al. **Langenbecks Arch Surg** 1999 Feb; 384(1):1–8 (97 ref.)

Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Pierotti MA, et al. **Recent Results Cancer Res** 1998;154:237–47 (47 ref.)

Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Rabes HM, et al. **Recent Results Cancer Res** 1998;154:248–64 (92 ref.)

Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Chi DD, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):681–706 (105 ref.)

Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Kebebew E, et al. **Thyroid** 1999 Feb;9(2):127–31 (17 ref.)

Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl. Pisarchik AV, et al. **Thyroid** 1998 Nov;8(11):1003–8 (39 ref.)

[Molecular basis of tumors arising in thyroid follicular cells] Wynford-Thomas D. **Ann Chir** 1999;53(3):237–43 (56 ref.) (Eng. Abstr.) **(Fre)**

[Activating mutations of the TSH receptor: a synthesis highlighting certain pediatric aspects] Polak M. **Arch Pediatr** 1998;5 Suppl 4:375S–379S (32 ref.) (Eng. Abstr.) **(Fre)**

[Type 2 endocrine neoplasms. Clinical aspects] Modigliani E. **Presse Med** 1998 Apr 4;27(13):628–32 (34 ref.) (Eng. Abstr.) **(Fre)**

[Mutations in TSH receptors: pathogenetic significance and clinical relevance] Führer D, et al. **Dtsch Med Wochenschr** 1999 May 28;124(21):662–9 (48 ref.) **(Ger)**

[Multiple endocrine adenomatosis IIB] Dohán O, et al. **Orv Hetil** 1998 Dec 27;139(52):3117–20 (14 ref.) (Eng. Abstr.) **(Hun)**

[Multiple endocrine neoplasia-type medullary thyroid carcinoma in three generations of a family] Takácsi NZ, et al. **Orv Hetil** 1998 Nov 29;139(48):2883–8 (39 ref.) (Eng. Abstr.) **(Hun)**

[Familial medullary carcinoma of the thyroid. The usefulness of ultrasonography and Doppler color] Fernández García P, et al. **Rev Clin Esp** 1998 Nov;198(11):745–8 (17 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. Derwahl M, et al. **J Clin Endocrinol Metab** 1999 Mar; 84(3):829–34 (91 ref.)

Signet ring cell adenoma of the thyroid with mucin predominance. Yoshida J, et al. **Thyroid** 1999 Apr; 9(4):401–4 (14 ref.)

[Elevated expression of met protein in papillary carcinoma of the thyroid facilitates tumor cell invasiveness] Scarpino S, et al. **Pathologica** 1998 Dec;90(6):818–20 (8 ref.) **(Ita)**

PATHOLOGY

Metastatic papillary thyroid carcinoma presenting as a retropharyngeal mass. DiLeo MD, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):404–6 (7 ref.)

Diagnosis of malignant epithelial thyroid lesions: fine needle aspiration and histopathologic correlation. Oertel YC, et al. **Ann Diagn Pathol** 1998 Dec;2(6):377–400 (170 ref.)

Benign intratracheal thyroid: a possible cause for preoperative overstaging. Brandwein M, et al. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1266–9 (16 ref.)

Insular carcinoma: an infrequent subtype of thyroid cancer. Rodriguez JM, et al. **J Am Coll Surg** 1998 Nov;187(5):503–8 (16 ref.)

Simultaneous metastatic ameloblastoma and thyroid carcinoma in the cervical region: report of a case. Sugiyama M, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1255–8 (18 ref.)

Solitary, multiple, and familial oxyphil tumours of the thyroid gland. Katoh R, et al. **J Pathol** 1998 Nov;186(3):292–9 (26 ref.)

Problems in the management of solitary nodules and diffuse goitres. Webb AJ. **J R Soc Med** 1998;91 Suppl 33:17–20 (21 ref.)

Multiple primary cancers of the esophagus and thyroid gland. Naomoto Y, et al. **Jpn J Clin Oncol** 1999 Jul;29(7):349–52 (17 ref.)

Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Cameselle-Teijeiro J, et al. **Mod Pathol** 1999 Apr;12(4):400–11 (47 ref.)

Management of the neck in thyroid cancer. Shaha AR. **Otolaryngol Clin North Am** 1998 Oct;31(5):823–31 (25 ref.)

Spindle epithelial tumor with thymus-like differentiation: a case report and review of the literature. Bradford CR, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):603–6 (9 ref.)

Anaplastic cancer, lymphoma, and metastases of the thyroid gland. Pasieka JL. **Surg Oncol Clin N Am** 1998 Oct; 7(4):707–20 (61 ref.)

Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Ain KB. **Thyroid** 1998 Aug; 8(8):715–26 (134 ref.)

Papillary and follicular thyroid carcinoma metastatic to the skin: a case report and review of the literature. Koller EA, et al. **Thyroid** 1998 Nov;8(11):1045–50 (33 ref.)

Signet ring cell adenoma of the thyroid with mucin predominance. Yoshida J, et al. **Thyroid** 1999 Apr; 9(4):401–4 (14 ref.)

[Extemporaneous anatomo-pathological examinations in breast and thyroid diseases. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Bataille N, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115 Suppl 1:S46–74 (225 ref.) **(Fre)**

[Hyperthyroidism and thyroid carcinoma--coincidence or association?] Oertli D, et al. **Schweiz Med Wochenschr** 1998 Nov 28;128(48):1910–4 (26 ref.) (Eng. Abstr.) **(Ger)**

[Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism] Derwahl M. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:25–8 (35 ref.) (Eng. Abstr.) **(Ger)**

[Cranial metastases from a follicular carcinoma of the thyroid. A clinical case report and review of the literature] Conzo G, et al. **Minerva Chir** 1998 Sep;53(9):751–6 (25 ref.) (Eng. Abstr.) **(Ita)**

[Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: description of a case] Cavazza A, et al. **Pathologica** 1999 Feb;91(1):31–5 (20 ref.) (Eng. Abstr.) **(Ita)**

[Thyroid biopsy in the auto-immune thyroid diseases] Fukuuchi A. **Nippon Rinsho** 1999 Aug;57(8):1841–5 (8 ref.) (Eng. Abstr.) **(Jpn)**

[The bilateral ureteral metastasis of a medullary carcinoma of the thyroid] Valero Puerta JA, et al. **Arch Esp Urol** 1999 Jun;52(5):522–5 (11 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Thyrotropin receptor: a role for thyroid tumourigenesis? Russo D, et al. **Forum (Genova)** 1999 Apr-Jun;9(2):166-75 (75 ref.)

PREVENTION & CONTROL

C-cell cancer--prevention and treatment. Gimm O, et al. **Langenbecks Arch Surg** 1999 Feb;384(1):16-23 (69 ref.)

RADIONUCLIDE IMAGING

Detection of residual and recurrent thyroid cancer by radionuclide imaging. Maxon HR. **Thyroid** 1999 May; 9(5):443-6 (11 ref.)

[Progress of nuclear oncology] Endo K. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1261-8 (3 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Radiotherapy planning techniques for thyroid cancer. Harmer C, et al. **Br J Radiol** 1998 Oct;71(850):1069-75 (25 ref.)

Acute leukemias after treatment with radioiodine for thyroid cancer [letter] Roldán Schilling V, et al. **Haematologica** 1998 Aug;83(8):767-8 (6 ref.)

Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique. Roos DE, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):493-5 (12 ref.)

The use of radioactive iodine in patients with papillary and follicular thyroid cancer. Wartofsky L, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4195-203 (77 ref.)

Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. Esik O, et al. **J Neurol Sci** 1999 Feb 1; 163(1):39-43 (15 ref.)

Ablation in differentiated thyroid carcinoma: how much surgery? How much iodine? [editorial] al-Nahhas AM. **Nucl Med Commun** 1999 Jul;20(7):595-7 (27 ref.)

External-beam radiation therapy in the treatment of differentiated thyroid cancer. Brierley JD, et al. **Semin Surg Oncol** 1999 Jan-Feb;16(1):42-9 (29 ref.)

Guidelines for the use of radio-iodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Paloyan E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):665-80 (37 ref.)

[The basis for radioiodine therapy in differentiated thyroid cancer] Haldemann AR. **Ther Umsch** 1999 Jul;56(7):403-7 (11 ref.) (Eng. Abstr.) **(Ger)**

[Internal radiation therapy for malignant neoplasm] Yokoyama K, et al. **Gan To Kagaku Ryoho** 1999 May; 26(6):768-74 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Consensus proposal on the use of 131I in the treatment of thyrotoxicosis and thyroid cancer] Michaud P. **Rev Med Chil** 1998 Jul;126(7):855-65 (58 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Colonic adenocarcinoma metastatic to the thyroid gland: a case report with immunohistochemical investigation. Kim CH, et al. **J Korean Med Sci** 1999 Aug;14(4):455-9 (22 ref.)

Renal cell carcinoma metastasizing to the thyroid gland. Palazzo FF, et al. **Scand J Urol Nephrol** 1999 Jun; 33(3):202-4 (7 ref.)

SURGERY

Current perspectives in the surgery of multiple endocrine neoplasias [see comments] Proye CA, et al. **Aust N Z J Surg** 1999 Feb;69(2):106-16 (123 ref.) Comment in: Aust N Z J Surg 1999 Feb;69(2):83.

C-cell cancer--prevention and treatment. Gimm O, et al. **Langenbecks Arch Surg** 1999 Feb;384(1):16-23 (69 ref.)

Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits? Mann B, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):355-8 (24 ref.)

Compartment-mediated dissection for papillary thyroid cancer. Moley JF, et al. **Langenbecks Arch Surg** 1999 Feb; 384(1):9-15 (25 ref.)

Ablation in differentiated thyroid carcinoma: how much surgery? How much iodine? [editorial] al-Nahhas AM. **Nucl Med Commun** 1999 Jul;20(7):595-7 (27 ref.)

The surgical treatment of medullary thyroid carcinoma. Evans DB, et al. **Semin Surg Oncol** 1999 Jan-Feb; 16(1):50-63 (41 ref.)

Follicular neoplasms: the role for observation, fine needle aspiration biopsy, thyroid suppression, and surgery. St. Louis JD, et al. **Semin Surg Oncol** 1999 Jan-Feb;16(1):5-11 (42 ref.)

Papillary carcinoma of the thyroid gland: treatment based on risk group definition. Cady B. **Surg Oncol Clin N Am** 1998 Oct;7(4):633-44 (32 ref.)

Papillary thyroid carcinoma: justification for total thyroidectomy and management of lymph node metastases. Chen H, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):645-63 (64 ref.)

Management of follicular and Hürthle cell neoplasms of the thyroid gland. McHenry CR, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):893-910 (74 ref.)

[Therapeutic approach of differentiated and nondifferentiated cancer of the thyroid] Visset J, et al. **J Chir (Paris)** 1998 Nov;135(5):212-6 (39 ref.) (Eng. Abstr.) **(Fre)**

[Differentiated thyroid gland carcinoma p-T2/T3--extent of lymphadenectomy] Wahl RA, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:203-11 (35 ref.) (Eng. Abstr.) **(Ger)**

[Surgery for thyroid carcinoma] Hoffmann S, et al. **Ther Umsch** 1999 Jul;56(7):390-5 (13 ref.) (Eng. Abstr.) **(Ger)**

[Medullary thyroid carcinoma] De Medici A, et al. **Minerva Chir** 1999 May;54(5):343-54 (46 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Advances in the pathogenesis and treatment of thyroid cancer. Hanna NN, et al. **Curr Opin Oncol** 1999 Jan; 11(1):42-7 (22 ref.)

Medullary thyroid carcinoma: therapy and management [editorial; comment] Hashizume K. **Intern Med** 1999 Jan; 38(1):3 (8 ref.) Comment on: Intern Med 1999 Jan;38(1):17-21.

Thyroid swelling--a protocol for management. Thomas WE. **J R Soc Med** 1998;91 Suppl 33:21-7 (36 ref.)

Radiofrequency ablation: an outpatient percutaneous treatment. Dupuy DE. **Med Health R I** 1999 Jun; 82(6):213-6 (8 ref.)

Anaplastic thyroid carcinoma: a therapeutic challenge. Ain KB. **Semin Surg Oncol** 1999 Jan-Feb;16(1):64-9 (78 ref.)

Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Ain KB. **Thyroid** 1998 Aug; 8(8):715-26 (134 ref.)

Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Ladenson PW. **Thyroid** 1999 May; 9(5):429-33 (12 ref.)

An overview of the management of papillary and follicular thyroid carcinoma. Mazzaferri EL. **Thyroid** 1999 May; 9(5):421-7 (38 ref.)

[Management of 29 children with thyroid cancer following the Chernobyl accident] Aurengo A, et al. **Bull Acad Natl Med** 1998;182(5):955-76; discussion 976-9 (77 ref.) (Eng. Abstr.) **(Fre)**

[New developments in the treatment of medullary thyroid carcinoma] Vitale G, et al. **Minerva Endocrinol** 1998 Dec; 23(4):121-8 (62 ref.) (Eng. Abstr.) **(Ita)**

[Endocrine surgery. Diagnosis and therapy for thyroid malignant lymphoma] Akasu H, et al. **Nippon Ika Daigaku Zasshi** 1998 Aug;65(4):320-3 (9 ref.) **(Jpn)**

ULTRASONOGRAPHY

Role of ultrasound in the diagnosis of thyroid autonomy. Reschke K, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S42-4 (18 ref.)

[Familial medullary carcinoma of the thyroid. The usefulness of ultrasonography and Doppler color] Fernández García P, et al. **Rev Clin Esp** 1998 Nov;198(11):745-8 (17 ref.) (Eng. Abstr.) **(Spa)**

THYROID NODULE

see related
GOITER, NODULAR

BLOOD

Routine calcitonin determination in thyroid nodules--an effective approach? [comment] Raue F. **Exp Clin Endocrinol Diabetes** 1998;106(4):289-91 (12 ref.) Comment on: Exp Clin Endocrinol Diabetes 1998 ;106(4):353-9.

COMPLICATIONS

Coincidence of hot thyroid nodules and primary hyperparathyroidism. Klemm T, et al. **Exp Clin Endocrinol Diabetes** 1999;107(5):295-8 (25 ref.)

Evaluation of risk in autonomously functioning thyroid nodules. Mann K. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S23-6 (43 ref.)

DIAGNOSIS

Fine needle aspiration cytology of the thyroid. Gutman PD, et al. **Clin Lab Med** 1998 Sep;18(3):461-82, vi (134 ref.)

Ectopic thymic carcinoid masquerading as a thyroid nodule. Inzucchi SE, et al. **Thyroid** 1998 Jul;8(7):589-95 (26 ref.)

[Imaging of thyroid nodules (see comments)] Tramalloni J, et al. **J Radiol** 1999 Mar;80(3):271-7 (43 ref.) (Eng. Abstr.) Comment in: J Radiol 1999 Mar;80(3):267-9. **(Fre)**

[Thyroid nodules: diagnostic and therapeutic approaches] Meier CA. **Rev Med Suisse Romande** 1999 Jun; 119(6):487-91 (12 ref.) **(Fre)**

[Diffused goiter and thyroid nodule. Diagnostic indications] Nunez S, et al. **Rev Prat** 1998 Mar 15;48(6):653-6 (00 ref.) **(Fre)**

[Goiter and nodular thyroid disease: clinical guidelines for diagnosis and treatment. (Waiting? Hormone therapy? Surgery? radioiodine?)] Cattaneo F, et al. **Ther Umsch** 1999 Jul;56(7):356-63 (42 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Ultrasound-guided percutaneous ethanol injection in the treatment of autonomous thyroid nodules--a review. Schumm-Draeger PM. **Exp Clin Endocrinol Diabetes** 1998; 106 Suppl 4:S59-62 (25 ref.)

EPIDEMIOLOGY

Pediatric thyroid nodules: insights in management. Lugo-Vicente H, et al. **Bol Asoc Med P R** 1998 Apr-Jun; 90(4-6):74-8 (26 ref.)

ETIOLOGY

Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Derwahl M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S6-9 (41 ref.)

PATHOLOGY

Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Nikiforov YE, et al. **Adv Anat Pathol** 1999 Mar;6(2):78-91 (44 ref.)

Post fine-needle aspiration histologic alterations of thyroid revisited. Baloch ZW, et al. **Am J Clin Pathol** 1999 Sep; 112(3):311-6 (29 ref.)

Problems in the management of solitary nodules and diffuse goitres. Webb AJ. **J R Soc Med** 1998;91 Suppl 33:17-20 (21 ref.)

SURGERY

Concepts for thyroid surgery. Petti GH Jr, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):387-93 (32 ref.)

THERAPY

Thyroid swelling--a protocol for management. Thomas WE. **J R Soc Med** 1998;91 Suppl 33:21-7 (36 ref.)

Percutaneous ethanol injection of autonomously functioning thyroid nodule. Solbiati L, et al. **Rays** 1999 Apr-Jun; 24(2):348-57 (23 ref.) **(Eng, Ita)**

[Thyroid nodules: diagnostic and therapeutic approaches] Meier CA. **Rev Med Suisse Romande** 1999 Jun; 119(6):487-91 (12 ref.) **(Fre)**

[Goiter and nodular thyroid disease: clinical guidelines for diagnosis and treatment. (Waiting? Hormone therapy? Surgery? radioiodine?)] Cattaneo F, et al. **Ther Umsch** 1999 Jul;56(7):356-63 (42 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Role of ultrasound in the diagnosis of thyroid autonomy. Reschke K, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S42-4 (18 ref.)

THYROID PEROXIDASE see **IODIDE PEROXIDASE**

THYROID-STIMULATING ANTIBODIES see **IMMUNOGLOBULINS, THYROID-STIMULATING**

THYROID-STIMULATING HORMONE see **THYROTROPIN**

THYROID STIMULATING HORMONE RECEPTORS see **RECEPTORS, THYROTROPIN**

THYROID-STIMULATING IMMUNOGLOBULINS see **IMMUNOGLOBULINS, THYROID-STIMULATING**

THYROID STIMULATOR, LONG-ACTING see **LONG-ACTING THYROID STIMULATOR**

THYROID STORM see **THYROID CRISIS**

THYROIDECTOMY

Papillary thyroid carcinoma: justification for total thyroidectomy and management of lymph node metastases. Chen H, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):645-63 (64 ref.)

Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Kebebew E, et al. **Thyroid** 1999 Feb;9(2):127-31 (17 ref.)

[Hyperthyroidism from the viewpoint of the surgeon] Thermann M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):38-9 (5 ref.) **(Ger)**

[Surgery for thyroid carcinoma] Hoffmann S, et al. **Ther Umsch** 1999 Jul;56(7):390-5 (13 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism--advantages and disadvantages of pharmacologic, surgical, and radioactive iodine treatments] Meier CA. **Ther Umsch** 1999 Jul;56(7):364-8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Medullary thyroid carcinoma] De Medici A, et al. **Minerva Chir** 1999 May;54(5):343-54 (46 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Thyroidectomy and parathyroidectomy: a guide for patients. Giddings AE. **J R Soc Med** 1998;91 Suppl 33:33-5 (0 ref.)

THYROIDECTOMY

Surgical treatment of thyroid disease, thyroidectomy and parathyroidectomy: a medical guide for doctors and nurses. Giddings AE. **J R Soc Med** 1998;91 Suppl 33:36–41 (0 ref.)

The technique of thyroidectomy. Wheeler MH. **J R Soc Med** 1998;91 Suppl 33:12–6 (15 ref.)

Compartment-mediated dissection for papillary thyroid cancer. Moley JF, et al. **Langenbecks Arch Surg** 1999 Feb; 384(1):9–15 (25 ref.)

[Surgery for hyperthyroidism] Lorenz K, et al. **Ther Umsch** 1999 Jul;56(7):385–9 (21 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

[Complications of thyroid surgery, apropos of 104 thyroidectomies at the Ougadougou University Hospital Center] Ouoba K, et al. **Dakar Med** 1998;43(1):122–5 (13 ref.) (Eng. Abstr.) **(Fre)**

THYROIDITIS

Postpartum thyroiditis. Terry AJ, et al. **Semin Perinatol** 1998 Dec;22(6):497–502 (40 ref.)

COMPLICATIONS

[Painless (silent) thyroiditis] Ozawa Y. **Nippon Rinsho** 1999 Aug;57(8):1770–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Therapeutic controversy: Screening for postpartum thyroiditis. Amino N, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1813–21 (92 ref.)

Thyroiditis: clinical aspects and diagnostic imaging. Vitti P, et al. **Rays** 1999 Apr–Jun;24(2):301–14 (33 ref.) **(Eng, Ita)**

[Differential diagnosis of transient destructive thyroiditis from hyperthyroid Graves' disease] Mori K, et al. **Nippon Rinsho** 1999 Aug;57(8):1899–903 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Acute suppurative thyroiditis due to Streptococcus intermedius (letter)] Cabezas Agricola JM, et al. **An Med Interna** 1999 Feb;16(2):107–8 (7 ref.) **(Spa)**

THYROIDITIS, AUTOIMMUNE

[From Hashimoto thyroiditis to B-cell lymphoma of the thyroid gland] Fehr-Merhof A, et al. **Schweiz Med Wochenschr** 1999 Jun 12;129(23):883–9 (32 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Pseudogout attack associated with chronic thyroiditis and Sjögren's syndrome. Hama Y, et al. **Intern Med** 1999 Jan; 38(1):59–62 (18 ref.)

Mid-dermal elastolysis associated with Hashimoto's thyroiditis. Gambichler T, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):245–9 (48 ref.)

Pediatric manifestations of Hashimoto's encephalopathy. Vasconcellos E, et al. **Pediatr Neurol** 1999 May;20(5):394–8 (21 ref.)

[Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: description of a case] Cavazza A, et al. **Pathologica** 1999 Feb;91(1):31–5 (20 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Peschen-Rosin R, et al. **Eur Neurol** 1999;41(2):79–84 (37 ref.)

[Hashimoto's thyroiditis and thyroid cancer: a report of a clinical case and a review of the literature] Zardo F, et al. **G Chir** 1999 Apr;20(4):174–6 (20 ref.) (Eng. Abstr.) **(Ita)**

[Differential diagnosis of Hashimoto's thyroiditis from thyroidal neoplastic diseases] Aozasa K, et al. **Nippon Rinsho** 1999 Aug;57(8):1894–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Hashimoto disease] Eto S. **Nippon Rinsho** 1999 Aug; 57(8):1749–54 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis. Ohsako S, et al. **Cell Death Differ** 1999 Jan;6(1):13–21 (75 ref.)

Lymphocyte traffic and homing in autoimmune thyroid disorders. Marazuela M. **Eur J Endocrinol** 1999 Apr; 140(4):287–90 (12 ref.)

[Autoantibody against Na+/I- symporter (NaIS)] Zeki K. **Nippon Rinsho** 1999 Aug;57(8):1824–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Amino N, et al. **Thyroid** 1999 Jul;9(7):705–13 (50 ref.)

The thyroid immunology of the postpartum period. Davies TF. **Thyroid** 1999 Jul;9(7):675–84 (66 ref.)

THYROIDITIS, CHRONIC see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, INFECTIOUS see **THYROIDITIS, SUPPURATIVE**

THYROIDITIS, LYMPHOCYTIC see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, LYMPHOMATOUS see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, SUPPURATIVE

[Acute suppurative thyroiditis] Ito K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):621–4 (5 ref.) **(Jpn)**

COMPLICATIONS

Suppurative Acinetobacter baumanii thyroiditis with bacteremic pneumonia: case report and review. Yu EH, et al. **Clin Infect Dis** 1998 Nov;27(5):1286–90 (74 ref.)

DIAGNOSIS

Fourth branchial pouch anomalies: a study of six cases and review of the literature. Nicollas R, et al. **Int J Pediatr Otorhinolaryngol** 1998 Jun 1;44(1):5–10 (12 ref.)

THYROLIBERIN see **PROTIRELIN**

THYROLIBERIN RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

THYROLINGUAL CYST see **THYROGLOSSAL CYST**

THYROTOXIC CRISIS see **THYROID CRISIS**

THYROTOXIC STORM see **THYROID CRISIS**

THYROTOXICOSIS

CHEMICALLY INDUCED

[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism] Gerber H, et al. **Ther Umsch** 1999 Jul; 56(7):374–9 (20 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Thyrotoxic periodic paralysis: a case report and review of the literature. Kodali VR, et al. **J Emerg Med** 1999 Jan–Feb;17(1):43–5 (12 ref.)

Thyrotoxic period paralysis: report of three cases and review of the literature. Papadopoulos KI, et al. **J Intern Med** 1997 Jun;241(6):521–4 (14 ref.)

DIAGNOSIS

A case report of acute confusional state in thyrotoxicosis. Tavintharan S, et al. **Ann Acad Med Singapore** 1998 Jul; 27(4):586–8 (11 ref.)

Thyrotoxicosis in old age: a different clinical entity? Bhattacharyya A, et al. **Hosp Med** 1999 Feb;60(2):115–8 (19 ref.)

Thyrotoxic period paralysis: report of three cases and review of the literature. Papadopoulos KI, et al. **J Intern Med** 1997 Jun;241(6):521–4 (14 ref.)

Thyrotoxicosis: clinical and laboratory assessment. Maussier ML, et al. **Rays** 1999 Apr–Jun;24(2):263–72 (34 ref.) **(Eng, Ita)**

Diagnostic imaging in thyrotoxicosis. Summaria V, et al. **Rays** 1999 Apr–Jun;24(2):273–300 (77 ref.) **(Eng, Ita)**

[Thyrotoxic hypokalemic periodic paralysis in a male Kurd] Gamper G, et al. **Acta Med Austriaca** 1998;25(3):106–8 (17 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism] Gerber H, et al. **Ther Umsch** 1999 Jul; 56(7):374–9 (20 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. Lawrence JE, et al. **J Endocrinol Invest** 1999 May;22(5):405–7 (16 ref.)

RADIOTHERAPY

Radioiodine therapy of thyrotoxicosis. Gross MD, et al. **Rays** 1999 Apr–Jun;24(2):334–47 (69 ref.) **(Eng, Ita)**

[Consensus proposal on the use of 131I in the treatment of thyrotoxicosis and thyroid cancer] Michaud P. **Rev Med Chil** 1998 Jul;126(7):855–65 (58 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Thyroid swelling--a protocol for management. Thomas WE. **J R Soc Med** 1998;91 Suppl 33:21–7 (36 ref.)

THYROTROPIN

see related **RECEPTORS, THYROTROPIN**

ANTAGONISTS & INHIBITORS

The effect of thyroid hormone on skeletal integrity. Greenspan SL, et al. **Ann Intern Med** 1999 May 4; 130(9):750–8 (81 ref.)

BLOOD

[Determination of thyroid hormone] Ochi Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1794–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Serum TSH measurement] Tatsumi K, et al. **Nippon Rinsho** 1999 Aug;57(8):1806–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Increased level of TSH can be a sign of adrenal cortex failure. Not necessarily thyroid gland disease] Sjöberg S, et al. **Lakartidningen** 1999 Feb 3;96(5):464–5 (20 ref.) **(Swe)**

DIAGNOSTIC USE

Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Ladenson PW. **Thyroid** 1999 May; 9(5):429–33 (12 ref.)

Detection of residual and recurrent thyroid cancer by radionuclide imaging. Maxon HR. **Thyroid** 1999 May; 9(5):443–6 (11 ref.)

Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Spencer CA, et al. **Thyroid** 1999 May;9(5):435–41 (11 ref.)

GENETICS

Alterations of neonatal thyroid function. Grüters A, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):17–22 (29 ref.)

Development and in vitro characterization of human recombinant thyrotropin. Weintraub BD, et al. **Thyroid** 1999 May;9(5):447–50 (12 ref.)

METABOLISM

The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies [published erratum appears in Endocr Rev 1999 Feb;20(i):100] Rapoport B, et al. **Endocr Rev** 1998 Dec;19(6):673–716 (396 ref.)

Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. Derwahl M, et al. **J Clin Endocrinol Metab** 1999 Mar; 84(3):829–34 (91 ref.)

PHARMACOLOGY

Pharmacology of bovine and human thyrotropin: an historical perspective. Robbins J. **Thyroid** 1999 May; 9(5):451–3 (13 ref.)

PHYSIOLOGY

Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Hard GC. **Environ Health Perspect** 1998 Aug;106(8):427–36 (193 ref.)

Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Persani L. **Thyroid** 1998 Oct;8(10):941–6 (45 ref.)

Development and in vitro characterization of human recombinant thyrotropin. Weintraub BD, et al. **Thyroid** 1999 May;9(5):447–50 (12 ref.)

SECRETION

Medical therapy for gonadotroph and thyrotroph tumors. Shomali ME, et al. **Endocrinol Metab Clin North Am** 1999 Mar;28(1):223–40, viii (103 ref.)

Current medical approach to thyroid stimulating hormone-secreting pituitary adenomas [editorial; comment] Demura R. **Intern Med** 1998 Dec;37(12):999–1000 (12 ref.) Comment on: Intern Med 1998 Dec;37(12):1027–30.

[The syndrome of inappropriate TSH secretion of neoplastic origin (NIST)] Grzywa M, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):101–3 (36 ref.) (Eng. Abstr.) **(Pol)**

[Thyrotropin-producing hypophyseal adenomas] Calvo Romero JM, et al. **Rev Clin Esp** 1999 May;199(5):285–7 (13 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

An overview of the management of papillary and follicular thyroid carcinoma. Mazzaferri EL. **Thyroid** 1999 May; 9(5):421–7 (38 ref.)

THYROTROPIN RECEPTORS see **RECEPTORS, THYROTROPIN**

THYROTROPIN-RELEASING HORMONE see **PROTIRELIN**

THYROTROPIN RELEASING HORMONE RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

THYROXINE

see related
RECEPTORS, THYROID HORMONE

ADMINISTRATION & DOSAGE

[High dosage thyroxine treatment in therapy and prevention refractory patients with affective psychoses] Bauer M, et al. **Nervenarzt** 1998 Nov;69(11):1019–22 (19 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Screening methods for thyroid hormone disruptors. DeVito M, et al. **Environ Health Perspect** 1999 May;107(5):407–15 (108 ref.)

BLOOD

Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)

[Determination of thyroid hormone] Ochi Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1794–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Hormone synthesis and storage in the thyroid of human preterm and term newborns: effect of thyroxine treatment. van den Hove MF, et al. **Biochimie** 1999 May;81(5):563–70 (40 ref.)

[Changes in thyroxine-binding globulin: pitfalls in thyroid function diagnosis] John MR, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1219–25 (50 ref.) **(Ger)**

PHYSIOLOGY

Thyroid hormone and intellectual development: a clinician's view. Lazarus JH. **Thyroid** 1999 Jul;9(7):659–60 (12 ref.)

THERAPEUTIC USE

Is thyroxine during lithium therapy necessary? [comment] Bartalena L, et al. **J Endocrinol Invest** 1999 Mar;22(3):220–2 (12 ref.) Comment on: J Endocrinol Invest 1998 Dec;21(11):784–6.

Is thyroxine during lithium therapy necessary? [see comments] Lazarus JH. **J Endocrinol Invest** 1998 Dec; 21(11):784–6 (15 ref.) Comment in: J Endocrinol Invest 1999 Mar;22(3):220–2.

Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)

[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism] Gerber H, et al. **Ther Umsch** 1999 Jul; 56(7):374–9 (20 ref.) (Eng. Abstr.) **(Ger)**

L-THYROXINE see **LEVOTHYROXINE**

THYROXINE-BINDING GLOBULIN see **THYROXINE-BINDING PROTEINS**

THYROXINE-BINDING PREALBUMIN see **THYROXINE-BINDING PROTEINS**

THYROXINE-BINDING PROTEINS

METABOLISM

[Changes in thyroxine-binding globulin: pitfalls in thyroid function diagnosis] John MR, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1219–25 (50 ref.) **(Ger)**

THYROXINE 5'-DEIODINASE see **IODIDE PEROXIDASE**

THYROXINE 5'-MONODEIODINASE see **IODIDE PEROXIDASE**

THYROXINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

TIAPRIDE

ADVERSE EFFECTS

[Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate] Noda S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):538–41 (15 ref.) **(Jpn)**

THERAPEUTIC USE

[Value of tiapride for agitation in the elderly. Review of published studies] Roger M, et al. **Encephale** 1998 Sep–Oct; 24(5):462–8 (61 ref.) (Eng. Abstr.) **(Fre)**

TIBIA

Ewing's sarcoma masquerading as osteomyelitis. Durbin M, et al. **Clin Orthop** 1998 Dec;(357):176–85 (36 ref.)

Adult posttraumatic osteomyelitis of the tibia. Mader JT, et al. **Clin Orthop** 1999 Mar;(360):14–21 (53 ref.)

Intracortical hemangioma of bone. Report of two cases and review of the literature. López-Barea F, et al. **J Bone Joint Surg Am** 1998 Nov;80(11):1673–8 (22 ref.)

Paget's disease of the tibia. Wang CL, et al. **J Formos Med Assoc** 1999 Jun;98(6):444–7 (17 ref.)

ABNORMALITIES

Congenital deficiency of the tibia: a report on 22 cases. Fernandez-Palazzi F, et al. **J Pediatr Orthop B** 1998 Oct; 7(4):298–302 (21 ref.)

BLOOD SUPPLY

Malignant fibrous histiocytoma associated with a bone infarct in a patient with hereditary bone dysplasia. Kenan S, et al. **Skeletal Radiol** 1998 Aug;27(8):463–7 (15 ref.)

PATHOLOGY

Osteolysis associated with cemented total knee arthroplasty. Griffin FM, et al. **J Arthroplasty** 1998 Aug;13(5):592–8 (10 ref.)

RADIOGRAPHY

Intracortical chondroma. Rudman DP, et al. **Skeletal Radiol** 1998 Oct;27(10):581–3 (6 ref.)

SURGERY

The influence of clinical and biomechanical factors on the results of valgus high tibial osteotomy. Catani F, et al. **Chir Organi Mov** 1998 Jul–Sep;83(3):249–62 (37 ref.) **(Eng, Ita)**

Socket considerations for the patient with a transtibial amputation. Fergason J, et al. **Clin Orthop** 1999 Apr; (361):76–84 (23 ref.)

Proximal valgus tibial osteotomy for osteoarthritis of the knee. Hutchison CR, et al. **Instr Course Lect** 1999;48:131–4 (24 ref.)

Limb shortening for the management of leg length discrepancy. Coppola C, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):46–54 (107 ref.)

Role of tibial osteotomy in the treatment of medial femorotibial osteoarthritis [editorial] Nizard RS. **Rev Rhum Engl Ed** 1998 Jul–Sep;65(7–9):443–6 (28 ref.)

[Anterior cruciate ligament-plasty and high valgus tibial osteotomy as a combined procedure in anterior instability and varus deviation] Roscher E, et al. **Zentralbl Chir** 1998; 123(9):1019–26 (42 ref.) (Eng. Abstr.) **(Ger)**

TIBIAL FRACTURES

COMPLICATIONS

Prosthetic options for below knee amputations after osteomyelitis and nonunion of the tibia. Moshirfar A, et al. **Clin Orthop** 1999 Mar;(360):110–21 (41 ref.)

DIAGNOSIS

Fractures of the proximal tibia. Perry CR, et al. **Instr Course Lect** 1999;48:497–513 (30 ref.)

DRUG THERAPY

Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites [see comments] Cook SD. **Orthopedics** 1999 Jul;22(7):669–71 (10 ref.) Comment in: Orthopedics 1999 Jul;22(7):659–60.

ETIOLOGY

Stress fracture of the tibia: an unusual complication of reconstructive surgery of the mandible. Westesson PL, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):70–4 (21 ref.)

Total knee arthroplasty: periprosthetic tibial fractures. Stuart MJ, et al. **Orthop Clin North Am** 1999 Apr;30(2):279–86 (7 ref.)

SURGERY

Fractures of the proximal tibia. Perry CR, et al. **Instr Course Lect** 1999;48:497–513 (30 ref.)

Salvage of open tibial fracture with segmental loss of tibial nerve: case report and review of the literature. Higgins TF, et al. **J Orthop Trauma** 1999 Jun–Jul;13(5):380–5 (14 ref.)

The management of femoral and tibial diaphyseal fractures [see comments] Court-Brown CM. **J R Coll Surg Edinb** 1998 Dec;43(6):374–80 (38 ref.) Comment in: J R Coll Surg Edinb 1999 Jun;44(3):205.

[Fractures of the tibial pilon. Long-term retrospective study of 51 fractures treated with open reduction and osteosynthesis] Arlettaz Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Apr; 84(2):180–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[Supramalleolar corrective osteotomy] Verheyden P, et al. **Chirurg** 1998 Nov;69(11):1178–87 (26 ref.) (Eng. Abstr.) **(Ger)**

[Treatment concept in complex fractures of the head of the tibia] Ballmer FT, et al. **Swiss Surg** 1998;(6):288–95 (33 ref.) (Eng. Abstr.) **(Ger)**

[Critical thoughts on nailing of compound tibia fractures not previously drilled] Brug E, et al. **Unfallchirurg** 1999 Mar; 102(3):245–7 (12 ref.) **(Ger)**

[Calcaneus cyst—an indication for surgery? Case report and review of the literature] Schnabel M, et al. **Unfallchirurg** 1998 Sep;101(9):704–7 (26 ref.) (Eng. Abstr.) **(Ger)**

[Fractures of the diaphysis in childhood. 1: Lower extremity] Weinberg AM, et al. **Unfallchirurg** 1999 Feb;102(2):132–40 (7 ref.) **(Ger)**

THERAPY

Infected tibial nonunions (1981–1995). The evolution of change. Cierny G 3rd. **Clin Orthop** 1999 Mar;(360):97–105 (69 ref.)

Functional fracture bracing. Sarmiento A, et al. **J Am Acad Orthop Surg** 1999 Jan;7(1):66–75 (37 ref.)

Management of open tibial fractures. De Wind CM. **Trop Doct** 1999 Jan;29(1):46–9 (12 ref.)

[Osteogenic characteristics of bone marrow and composite bone marrow transplantation. A review] Li Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):39–41 (15 ref.) **(Chi)**

TIBIAL MENISCI see **MENISCI, TIBIAL**

TIBIAL NERVE

see related
TARSAL TUNNEL SYNDROME

Compression and entrapment neuropathies of the lower extremity. McCluskey LF, et al. **Clin Podiatr Med Surg** 1999 Jan;16(1):97–125, vii (25 ref.)

Tibial neuroma presenting as a Baker cyst. A case report. DeLuca PF, et al. **J Bone Joint Surg Am** 1999 Jun; 81(6):856–8 (10 ref.)

Entrapment neuropathies of the tibial (posterior tibial) nerve. Oh SJ, et al. **Neurol Clin** 1999 Aug;17(3):593–617, vii (77 ref.)

SURGERY

Salvage of open tibial fracture with segmental loss of tibial nerve: case report and review of the literature. Higgins TF, et al. **J Orthop Trauma** 1999 Jun–Jul;13(5):380–5 (14 ref.)

TIC see **TIC DISORDERS**

TIC DISORDERS

Gilles de la Tourette syndrome. Arzimanoglou AA. **J Neurol** 1998 Dec;245(12):761–5 (17 ref.)

[Relationship between tics and compulsion] Moll GH, et al. **Nervenarzt** 1999 Jan;70(1):1–10 (17 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Recognition and management of Tourette's syndrome and tic disorders. Bagheri MM, et al. **Am Fam Physician** 1999 Apr 15;59(8):2263–72, 2274 (32 ref.)

DRUG THERAPY

Stimulants and tic disorders: from dogma to data [comment] Castellanos FX. **Arch Gen Psychiatry** 1999 Apr;56(4):337–8 (18 ref.) Comment on: Arch Gen Psychiatry 1999 Apr;56(4):330–6.

The use of tricyclic antidepressants in children and adolescents. Daly JM, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1123–35 (92 ref.)

Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Newcorn JH, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1099–22, viii (76 ref.)

GENETICS

[Tic disease. Current genetic and neurochemical factors] De Mattos JP, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2B):528–30 (12 ref.) (Eng. Abstr.) **(Por)**

METABOLISM

[Tic disease. Current genetic and neurochemical factors] De Mattos JP, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2B):528–30 (12 ref.) (Eng. Abstr.) **(Por)**

THERAPY

Recognition and management of Tourette's syndrome and tic disorders. Bagheri MM, et al. **Am Fam Physician** 1999 Apr 15;59(8):2263–72, 2274 (32 ref.)

TIC DOULOUREUX see **TRIGEMINAL NEURALGIA**

TICK-BORNE DISEASES

Tick-borne pulmonary disease: update on diagnosis and management. Faul JL, et al. **Chest** 1999 Jul;116(1):222–30 (95 ref.)

[Spotted fever group rickettsiosis: introduction] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):255–9 (15 ref.) **(Jpn)**

[Japanese spotted fever] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):264–6 (15 ref.)

TICK-BORNE DISEASES

(Jpn)

[Queensland tick typhus, and other SFG rickettsiosis] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):270–2 (17 ref.) **(Jpn)**

[African tick-bite fever] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):273–5 (8 ref.) **(Jpn)**

EPIDEMIOLOGY

Ticks and tick-borne diseases in Oklahoma. Moody EK, et al. **J Okla State Med Assoc** 1998 Nov;91(8):438–45 (15 ref.)

MICROBIOLOGY

Lyme borreliosis and emerging tick-borne diseases in Europe [editorial] Stanek G, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):847–9 (29 ref.)

PREVENTION & CONTROL

Ticks as the main target of human tick-borne disease control: Russian practical experience and its lessons. Uspensky I. **J Vector Ecol** 1999 Jun;24(1):40–53 (81 ref.)

TICK CONTROL

Reflections on the control of mites and mite allergens. de Boer R. **Allergy** 1998;53(48 Suppl):41–6 (72 ref.)

Towards a permanent solution for controlling cattle ticks. Frisch JE. **Int J Parasitol** 1999 Jan;29(1):57–71; discussion 73–5 (44 ref.)

METHODS

The poultry red mite Dermanyssus gallinae (De Geer, 1778): current situation and future prospects for control. Chauve C. **Vet Parasitol** 1998 Nov 16;79(3):239–45 (24 ref.)

TRENDS

Ticks as the main target of human tick-borne disease control: Russian practical experience and its lessons. Uspensky I. **J Vector Ecol** 1999 Jun;24(1):40–53 (81 ref.)

TICK INFESTATIONS

VETERINARY

Arthropod vaccines. Lee R, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):209–26 (125 ref.)

Towards a permanent solution for controlling cattle ticks. Frisch JE. **Int J Parasitol** 1999 Jan;29(1):57–71; discussion 73–5 (44 ref.)

Immunological control of arthropod ectoparasites—a review. Pruett JH. **Int J Parasitol** 1999 Jan;29(1):25–32 (61 ref.)

TICK PARALYSIS

VETERINARY

Tick paralysis: development of a vaccine. Masina S, et al. **Int J Parasitol** 1999 Apr;29(4):535–41 (38 ref.)

TICKS

Pathogens and predators of ticks and their potential in biological control. Samish M, et al. **Annu Rev Entomol** 1999;44:159–82 (215 ref.)

Tick-borne pulmonary disease: update on diagnosis and management. Faul JL, et al. **Chest** 1999 Jul;116(1):222–30 (95 ref.)

Ticks as the main target of human tick-borne disease control: Russian practical experience and its lessons. Uspensky I. **J Vector Ecol** 1999 Jun;24(1):40–53 (81 ref.)

GROWTH & DEVELOPMENT

Ticks and tick-borne diseases in Oklahoma. Moody EK, et al. **J Okla State Med Assoc** 1998 Nov;91(8):438–45 (15 ref.)

IMMUNOLOGY

Arthropod vaccines. Lee R, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):209–26 (125 ref.)

TICLOPIDINE

ADVERSE EFFECTS

Ticlopidine-induced phenytoin toxicity. Klaassen SL. **Ann Pharmacother** 1998 Dec;32(12):1295–8 (18 ref.)

Hepatotoxicity due to ticlopidine [letter] Martínez Pérez-Balsa A, et al. **Ann Pharmacother** 1998 Nov; 32(11):1250–1 (17 ref.)

Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature [see comments] Chen DK, et al. **Arch Intern Med** 1999 Feb 8;159(3):311–4 (26 ref.) Comment in: Arch Intern Med 1999 Jul 26;159(14):1624.

Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature. Iqbal M, et al. **Dig Dis Sci** 1998 Oct;43(10):2223–6 (33 ref.)

Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Grieco A, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):713–5 (24 ref.)

Thrombotic thrombocytopenic purpura associated with ticlopidine therapy. Leavey SF, et al. **J Am Soc Nephrol** 1997 Apr;8(4):689–93 (26 ref.)

Ticlopidine-induced thrombotic thrombocytopenic purpura. Muszkat M, et al. **Pharmacotherapy** 1998 Nov-Dec; 18(6):1352–5 (22 ref.)

ANALOGS & DERIVATIVES

Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)

Atherosclerosis: a unifying disorder with diverse manifestations. Gonzalez ER, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19 Suppl 1):S4–7 (18 ref.)

Clopidogrel: a new antiplatelet agent. Feret B. **Conn Med** 1999 Jun;63(6):331–3 (7 ref.)

Clopidogrel: secondary prevention of vascular ischaemic events. Misson J, et al. **J Clin Pharm Ther** 1998 Apr; 23(2):91–5 (17 ref.)

Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. Steinhubl SR, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):227–31 (22 ref.)

Antiplatelet agents and the role of clopidogrel in the prevention of secondary atherosclerotic events. Jackson A, et al. **Med Health R I** 1999 Aug;82(8):297–9 (18 ref.)

Using clopidogrel bisulfate: a new antiplatelet drug [news] Pfister SM. **Nurse Pract** 1999 Sep;24(9):100–1, 105–8, 110 (12 ref.)

Clopidogrel: the future choice for preventing platelet activation during coronary stenting? Gurbel PA, et al. **Pharmacol Res** 1999 Aug;40(2):107–11 (53 ref.)

Antiplatelet drugs in secondary prevention after acute myocardial infarction. Thizon-de-Gaulle I. **Rev Port Cardiol** 1998 Dec;17(12):993–7 (12 ref.)

Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Gorelick PB, et al. **Stroke** 1999 Aug;30(8):1716–21 (47 ref.)

Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Creager MA. **Vasc Med** 1998; 3(3):257–60 (8 ref.)

Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Schrör K. **Vasc Med** 1998; 3(3):247–51 (49 ref.)

[Clopidogrel] Castillo J. **Neurologia** 1998 Nov;13(9):431–5 (25 ref.) **(Spa)**

THERAPEUTIC USE

Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999. McCullough PA, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):233–9 (28 ref.)

[Ticlid: clinical effectiveness and significance in combined conservative treatment of chronic obliterating diseases of lower limb arteries] Koskin VM, et al. **Ter Arkh** 1998; 70(9):89–91 (22 ref.) **(Rus)**

TIDAL VOLUME

Tidal volume, positive end-expiratory pressure, and mortality in acute respiratory distress syndrome [editorial; comment] Brochard L, et al. **Crit Care Med** 1999 Aug;27(8):1661–3 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1492–8.

Tidal volume, PaCO2, and lung injury [editorial; comment] Gregory GA, et al. **Crit Care Med** 1998 Oct;26(10):1632–3 (16 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1690–7.

Ventilator-induced lung injury: more studies, more questions [editorial; comment] Kavanagh BP, et al. **Crit Care Med** 1999 Aug;27(8):1669–71 (23 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1533–41.

TIETZE'S SYNDROME

COMPLICATIONS

Pleomorphic T-cell lymphoma with chondropathia tuberosa; a case report and review. Krohn-Grimberghe B, et al. **Anticancer Res** 1999 May-Jun;19(3B):2221–8 (29 ref.)

DIAGNOSIS

[Lymphomas presenting as Tietze's syndrome: a report of 4 clinical cases] Cocco R, et al. **Ann Ital Med Int** 1999 Apr-Jun;14(2):118–23 (20 ref.) (Eng. Abstr.) **(Ita)**

TIGERS see **CARNIVORA**

TIGHT JUNCTIONS

CHEMISTRY

Tight junction proteins. Citi S, et al. **Biochim Biophys Acta** 1998 Nov 19;1448(1):1–11 (113 ref.)

METABOLISM

Transmembrane proteins in the tight junction barrier. Fanning AS, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1337–45 (80 ref.)

[Tight junctional permeability of intestinal epithelium and its regulation by food factors] Shimizu M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):874–80 (35 ref.) **(Jpn)**

PHYSIOLOGY

The effect of copper on tight junctional permeability in a human intestinal cell line (Caco-2). Ferruzza S, et al. **Adv Exp Med Biol** 1999;448:215–22 (32 ref.)

The tight junction: morphology to molecules. Stevenson BR, et al. **Annu Rev Cell Dev Biol** 1998;14:89–109 (125 ref.)

Overcoming barriers in the study of tight junction functions: from occludin to claudin. Tsukita S, et al. **Genes Cells** 1998 Sep;3(9):569–73 (40 ref.)

Occludin and the functions of tight junctions. Matter K, et al. **Int Rev Cytol** 1999;186:117–46 (108 ref.)

Occludin and claudins in tight-junction strands: leading or supporting players? Tsukita S, et al. **Trends Cell Biol** 1999 Jul;9(7):268–73 (45 ref.)

ULTRASTRUCTURE

Occludin and claudins in tight-junction strands: leading or supporting players? Tsukita S, et al. **Trends Cell Biol** 1999 Jul;9(7):268–73 (45 ref.)

VIROLOGY

Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. Hocini H, et al. **J Infect Dis** 1999 May;179 Suppl 3:S448–53 (35 ref.)

TILETAMINE

Etomidate and telazol. Pablo LS, et al. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):779–92 (57 ref.)

TILT-TABLE TEST

Using a tilt table to evaluate syncope. Kapoor WN. **Am J Med Sci** 1999 Feb;317(2):110–6 (70 ref.)

TIME

Evolution of time coding systems. Carr CE, et al. **Neural Comput** 1999 Jan 1;11(1):1–20 (84 ref.)

Time and qualitative research. Sandelowski M. **Res Nurs Health** 1999 Feb;22(1):79–87 (31 ref.)

Time in human endurance models. From empirical models to physiological models. Billat LV, et al. **Sports Med** 1999 Jun;27(6):359–79 (79 ref.)

TIME PERCEPTION

PHYSIOLOGY

Taking time seriously. A theory of socioemotional selectivity. Carstensen LL, et al. **Am Psychol** 1999 Mar;54(3):165–81 (109 ref.)

Temporal discrimination in the cerebellar cortex during conditioned eyelid responses [published erratum appears in Exp Brain Res 1998 Aug;121(3):359] Perrett SP. **Exp Brain Res** 1998 Jul;121(2):115–24 (64 ref.)

Auditory gap detection, perceptual channels, and temporal resolution in speech perception. Phillips DP. **J Am Acad Audiol** 1999 Jun;10(6):343–54 (72 ref.)

Time and memory: towards a pacemaker-free theory of interval timing [see comments] Staddon JE, et al. **J Exp Anal Behav** 1999 Mar;71(2):215–51 (143 ref.) Comment in: J Exp Anal Behav 1999 Mar;71(2):253–6; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):257–63; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):264–71; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):272–5; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):275–80; discussion 293–301. Comment in: J Exp Anal Behav 1999 Mar;71(2):281–4. Comment in: J Exp Anal Behav 1999 Mar;71(2):284–88. Comment in: J Exp Anal Behav 1999 Mar;71(2):288–91.

TIME-RESOLVED IMMUNOFLUOROMETRIC ASSAY see **FLUOROIMMUNOASSAY**

TIMED-RELEASE PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

TIMED VITAL CAPACITY see **FORCED EXPIRATORY VOLUME**

TIMP-1 see **TISSUE-INHIBITOR OF METALLOPROTEINASE-1**

TIMP-2 see **TISSUE INHIBITOR-OF METALLOPROTEINASE-2**

TIN

see related
ORGANOTIN COMPOUNDS

TIN DIFLUORIDE see **TIN FLUORIDES**

TIN FLUORIDES

ADVERSE EFFECTS

Tissue necrosis after subgingival irrigation with fluoride solution. Sjöström S, et al. **J Clin Periodontol** 1999 Apr; 26(4):257–60 (27 ref.)

TIN TETRAFLUORIDE see **TIN FLUORIDES**

TINEA

DIAGNOSIS

Annular skin lesions with a smooth surface. Hogan P. **Aust Fam Physician** 1998 Dec;27(12):1133–4 (0 ref.)

DRUG THERAPY

Dermatophyte infections in children. Howard RM, et al. **Adv Pediatr Infect Dis** 1999;14:73–107 (147 ref.)

Oral therapy of common superficial fungal infections of the skin. Lesher JL Jr. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 2):S31–4 (24 ref.)

IMMUNOLOGY

The immune response to dermatophytes. Woodfolk JA, et al. **Res Immunol** 1998 May–Jun;149(4–5):436–45; discussion 522–3 (65 ref.)

TINEA CAPITIS

Ecology, epidemiology and diagnosis of tinea capitis. Aly R. **Pediatr Infect Dis J** 1999 Feb;18(2):180–5 (32 ref.)

Tinea capitis: asymptomatic carriage of infection. Frieden IJ. **Pediatr Infect Dis J** 1999 Feb;18(2):186–90 (32 ref.)

DIAGNOSIS

[Tinea] Viguié–Vallanet C. **Ann Dermatol Venereol** 1999 Apr; 126(4):349–56 (15 ref.) **(Fre)**

DRUG THERAPY

Treatment of tinea capitis: beyond griseofulvin. Elewski BE. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 2):S27–30 (28 ref.)

Pharmacotherapy of tinea capitis. Temple ME, et al. **J Am Board Fam Pract** 1999 May–Jun;12(3):236–42 (34 ref.)

Tinea capitis: an overview with emphasis on management. Gupta AK, et al. **Pediatr Dermatol** 1999 May–Jun; 16(3):171–89 (177 ref.)

Pharmacologic basis for the treatment of tinea capitis. Blumer JL. **Pediatr Infect Dis J** 1999 Feb;18(2):191–9 (37 ref.)

The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Friedlander SF. **Pediatr Infect Dis J** 1999 Feb;18(2):205–10 (27 ref.)

Management of tinea capitis. A status report. Del Rosso JQ, et al. **Postgrad Med** 1999 Jul;Spec No:38–45 (40 ref.)

MICROBIOLOGY

[Tinea] Viguié–Vallanet C. **Ann Dermatol Venereol** 1999 Apr; 126(4):349–56 (15 ref.) **(Fre)**

PREVENTION & CONTROL

Tinea capitis: recommendations for school attendance. Honig PJ. **Pediatr Infect Dis J** 1999 Feb;18(2):211–4 (23 ref.)

TRANSMISSION

Tinea capitis: recommendations for school attendance. Honig PJ. **Pediatr Infect Dis J** 1999 Feb;18(2):211–4 (23 ref.)

TINEA PEDIS

Tinea pedis. Malcolm B. **Practitioner** 1998 Mar;242(1584):225 (0 ref.)

[Tinea pedis] Ishii N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):402–4 (1 ref.) **(Jpn)**

DRUG THERAPY

Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. Tanuma H. **Mycoses** 1999 Apr;42(1–2):21–8 (49 ref.)

Itraconazole and terbinafine in perspective. From petri dish to patient. De Doncker P, et al. **Postgrad Med** 1999 Jul; Spec No:6–11 (19 ref.)

PATHOLOGY

Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. Tanuma H. **Mycoses** 1999 Apr;42(1–2):21–8 (49 ref.)

TINEA UNGUIUM see **ONYCHOMYCOSIS**

TINEA VERSICOLOR

Tinea versicolor [see comments] Sunenshine PJ, et al. **Int J Dermatol** 1998 Sep;37(9):648–55 (105 ref.) Comment in: Int J Dermatol 1999 Jul;38(7):558.

DRUG THERAPY

[Pityriasis versicolor and Malassezia folliculitis] Katoh T, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(2):69–71 (11 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Pityrosporum species as a cause of allergy and infection. Faergemann J. **Allergy** 1999 May;54(5):413–9 (59 ref.)

TINNITUS

DIAGNOSIS

[Pulsatile tinnitus in contralateral carotid stenosis] Pato U, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):69–71 (12 ref.) **(Ger)**

DRUG THERAPY

Recent advances in the pharmacological treatment of tinnitus. Simpson JJ, et al. **Trends Pharmacol Sci** 1999 Jan;20(1):12–8 (98 ref.)

ETIOLOGY

Cutaneous-evoked tinnitus. II. Review Of neuroanatomical, physiological and functional imaging studies. Cacace AT, et al. **Audiol Neurootol** 1999 Sep–Oct;4(5):258–68 (118 ref.)

Tinnitus: etiology and management. Peifer KJ, et al. **Clin Geriatr Med** 1999 Feb;15(1):193–204, viii (27 ref.)

Palatal myoclonus as a cause of objective tinnitus: a report of six cases and a review of the literature. Seidman MD, et al. **Ear Nose Throat J** 1999 Apr;78(4):292–4, 296–7 (27 ref.)

[Guidelines of the German Society of Otorhinolaryngology, Head and Neck Surgery. Tinnitus. German Society of Otorhinolaryngology] **HNO** 1999 Jan;47(1):14–8 (11 ref.) **(Ger)**

[Systematics for mechanisms of tinnitus development (comment)] Zenner HP. **HNO** 1998 Aug;46(8):699–704 (22 ref.) Comment on: HNO 1998 Feb;46(2):157–69. **(Ger)**

PSYCHOLOGY

A critical analysis of directive counselling as a component of tinnitus retraining therapy. Wilson PH, et al. **Br J Audiol** 1998 Oct;32(5):273–86 (56 ref.)

Some psychological aspects of tinnitus. Reiss M, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):790–2 (12 ref.)

THERAPY

A critical analysis of directive counselling as a component of tinnitus retraining therapy. Wilson PH, et al. **Br J Audiol** 1998 Oct;32(5):273–86 (56 ref.)

Tinnitus: etiology and management. Peifer KJ, et al. **Clin Geriatr Med** 1999 Feb;15(1):193–204, viii (27 ref.)

A review of randomized clinical trials in tinnitus. Dobie RA. **Laryngoscope** 1999 Aug;109(8):1202–11 (85 ref.)

[Psychological principles in the treatment of tinnitus patients] Greimel KV, et al. **HNO** 1999 Feb;47(2):130–4 (20 ref.) **(Ger)**

[Rational foundations of tinnitus therapy] Wilhelm T, et al. **Med Monatsschr Pharm** 1998 Nov;21(11):336–44 (65 ref.) **(Ger)**

TIPSS see **PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC**

TISSUE ADHESIVES

see related
BONE CEMENTS

Antigen retrieval immunohistochemistry used for routinely processed celloidin-embedded human temporal bone sections: standardization and development. Shi SR, et al. **Auris Nasus Larynx** 1998 Dec;25(4):425–43 (148 ref.)

Tissues and bone adhesives--historical aspects. Donkerwolcke M, et al. **Biomaterials** 1998 Aug; 19(16):1461–6 (57 ref.)

Hydroxyapatite: catalyst or conjurer? Freeman MA. **Orthopedics** 1998 Sep;21(9):959–62 (7 ref.)

STANDARDS

Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Venkatraman S, et al. **Biomaterials** 1998 Jul;19(13):1119–36 (32 ref.)

THERAPEUTIC USE

Laceration management. Hollander JE, et al. **Ann Emerg Med** 1999 Sep;34(3):356–67 (118 ref.)

TISSUE BANKS

Specimen banks for cancer prognostic factor research. Burke HB, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):871–4 (38 ref.)

Chromosomal characterization of MRC-5 cell banks utilizing G-banding technique. Rosolowsky M, et al. **Dev Biol Stand** 1998;93:109–17 (11 ref.)

[Importance of tumor banks in hemo-lymphatic pathology] Delsol G, et al. **Ann Pathol** 1998;18(5 Suppl):27–32 (25 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

[Donor coordination at bone marrow banks and the role of coordinators] Morishima Y. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1522–5 (5 ref.) **(Jpn)**

[Bone marrow banks and transplantation of bone marrow from unrelated donors] Okamoto S. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1510–5 (5 ref.) **(Jpn)**

STANDARDS

Safety of biological products prepared from mammalian cell culture. Detecting viruses in cell banks. **Dev Biol Stand** 1998;93:129 (0 ref.)

Cell line banking and authentication. Hay RJ. **Dev Biol Stand** 1998;93:15–9 (16 ref.)

TISSUE COMPATIBILITY see **HISTOCOMPATIBILITY**

TISSUE CULTURE

see related
CELL LINE
CELLS, CULTURED
CELLS, IMMOBILIZED
CLONE CELLS
TUMOR CELLS, CULTURED
VIRUS CULTIVATION

Reappraisal of the multicellular preparation for the in vitro physiopharmacological evaluation of myocardial performance. Sys SU, et al. **Adv Exp Med Biol** 1998; 453:441–50; discussion 451 (34 ref.)

Development of serum-free media for the culture and transfer of human blastocysts. Gardner DK. **Hum Reprod** 1998 Dec;13 Suppl 4:218–25 (42 ref.)

Reflections on the culture of the preimplantation embryo. Biggers JD. **Int J Dev Biol** 1998;42(7 Spec No):879–84 (75 ref.)

Artificial juxtacrine stimulation for tissue engineering. Ito Y, et al. **J Biomater Sci Polym Ed** 1998;9(8):879–90 (59 ref.)

Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Vacanti JP, et al. **Lancet** 1999 Jul;354 Suppl 1:SI32–4 (26 ref.)

Culture of postimplantation mouse embryos. Martin P, et al. **Methods Mol Biol** 1999;97:7–22 (22 ref.)

The golden age of retinal cell culture. Seigel GM. **Mol Vis** 1999 Apr 19;5:4 (157 ref.)

HISTORY

Egg culture: the foundation. Hammer RE. **Int J Dev Biol** 1998;42(7 Spec No):833–9 (60 ref.)

METHODS

Postimplantation mouse development: whole embryo culture and micro-manipulation. Tam PP. **Int J Dev Biol** 1998;42(7 Spec No):895–902 (65 ref.)

Analysis of zebrafish development using explant culture assays. Grinblat Y, et al. **Methods Cell Biol** 1999;59:127–56 (31 ref.)

Protoplast isolation, culture, and plant regeneration from Passiflora. Anthony P, et al. **Methods Mol Biol** 1999; 111:169–81 (21 ref.)

Callus initiation, maintenance, and shoot induction in rice. Blackhall NW, et al. **Methods Mol Biol** 1999;111:19–29 (22 ref.)

Micropropagation of strawberry via axillary shoot proliferation. Boxus P. **Methods Mol Biol** 1999;111:103–14 (13 ref.)

Callus initiation, maintenance, and shoot induction in potato. Monitoring of spontaneous genetic variability in vitro and in vivo. Curry RF, et al. **Methods Mol Biol** 1999;111:31–42 (27 ref.)

Somatic embryogenesis in Picea suspension cultures. Egertsdotter U. **Methods Mol Biol** 1999;111:51–60 (26 ref.)

Spore-derived axenic cultures of ferns as a method of propagation. Ford MV, et al. **Methods Mol Biol** 1999; 111:159–68 (33 ref.)

Noncryogenic, long-term germplasm storage. Golmirzaie A, et al. **Methods Mol Biol** 1999;111:95–101 (12 ref.)

In vitro propagation of succulent plants. Gratton J, et al. **Methods Mol Biol** 1999;111:135–40 (4 ref.)

Meristem-tip culture for propagation and virus elimination. Grout BW. **Methods Mol Biol** 1999;111:115–25 (20 ref.)

Clonal propagation of woody species. Harry IS, et al. **Methods Mol Biol** 1999;111:149–57 (33 ref.)

Somatic embryogenesis in barley suspension cultures. Kihara M, et al. **Methods Mol Biol** 1999;111:43–9 (12 ref.)

Micropropagation of flower bulbs. Lily and narcissus. Langens-Gerrits MM, et al. **Methods Mol Biol** 1999; 111:141–7 (17 ref.)

Direct cyclic somatic embryogenesis of cassava for mass production purposes. Raemakers KJ, et al. **Methods Mol Biol** 1999;111:61–70 (31 ref.)

Immature inflorescence culture of cereals. A highly responsive system for regeneration and transformation. Rasco-Gaunt S, et al. **Methods Mol Biol** 1999;111:71–81 (19 ref.)

Clonal propagation of orchids. Tisserat B, et al.

TISSUE CULTURE

Methods Mol Biol 1999;111:127-34 (20 ref.)
Development of primary tissue culture techniques for use in radiobiology. Mothersill C. **Radiat Res** 1998 Nov;150(5 Suppl):S121-5 (58 ref.)

STANDARDS

Comparison of basic methods in clinical studies and in vitro tissue and cell culture studies reported in three anaesthesia journals. Watters MP, et al. **Br J Anaesth** 1999 Feb; 82(2):295-8 (10 ref.)

TISSUE DISTRIBUTION

[Microdialysis. A method for measurement of local tissue metabolism] Nielsen PS, et al. **Ugeskr Laeger** 1999 Mar 22;161(12):1735-8 (40 ref.) (Eng. Abstr.) **(Dan)**

TISSUE DONORS

see related
LIVING DONORS

The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Allan JS. **Ann N Y Acad Sci** 1998 Dec 30;862:87-99 (76 ref.)
International issues in transplantation. Setting the scene and flagging the most urgent and controversial issues. Miranda B, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:129-43 (43 ref.)
Researcher-driven versus policy-driven economic appraisal. The case of xenotransplantation. Moatti JP. **Ann N Y Acad Sci** 1998 Dec 30;862:188-201 (28 ref.)
Cadaveric organ donation: rethinking donor motivation [see comments] Sade RM. **Arch Intern Med** 1999 Mar 8; 159(5):438-42 (25 ref.) Comment in: Arch Intern Med 1999 Mar 8;159(5):427-8.
HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. McGuirk JP, et al. **Cancer J Sci Am** 1998 Sep-Oct; 4(5):278-86 (134 ref.)
Xenogeneic cell therapy: current progress and future developments in porcine cell transplantation. Edge AS, et al. **Cell Transplant** 1998 Nov-Dec;7(6):525-39 (181 ref.)
Update in transplantation--1997. Ciancio G, et al. **Clin Transpl** 1997;:241-64 (328 ref.)
Organ transplantation after fatal cyanide poisoning [letter; comment] Hantson P, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):72-3 (9 ref.) Comment on: Clin Transplant 1998 Apr;12(2):142-3.
Non-heartbeating kidney donors. Laskowski IA, et al. **Clin Transplant** 1999 Aug;13(4):281-6 (34 ref.)
Is donor age an important determinant of graft survival? Beck RW, et al. **Cornea** 1999 Sep;18(5):503-10 (29 ref.)
Current methodologies of human leukocyte antigen typing utilized for bone marrow donor selection. Little AM, et al. **Curr Opin Hematol** 1998 Nov;5(6):419-28 (77 ref.)
Non-heartbeating donors: are they worth the effort? Jacobs RW, et al. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):655-8 (17 ref.)
In situ hybridization evidence of the donor origin of a post-transplant lymphoproliferative disorder [letter] Kerim S, et al. **Eur J Haematol** 1999 Jul;63(1):61-3 (17 ref.)
An approach to the rational use of steatotic donor livers in liver transplantation. Urena MA, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1164-73 (89 ref.)
How can we increase the number of organ and tissue donors? Howard RJ. **J Am Coll Surg** 1999 Mar;188(3):317-27 (74 ref.)
End-of-life issues: Anencephalic infants as organ donors. Lafreniere R, et al. **J Am Coll Surg** 1998 Oct;187(4):443-7 (14 ref.)
Age before beauty: the use of "older" donor hearts for cardiac transplantation [comment] Young JB. **J Heart Lung Transplant** 1999 May;18(5):488-91 (13 ref.) Comment on: J Heart Lung Transplant 1998 Sep;17(9):901-5.
The commodification of human reproductive materials. Resnik DB. **J Med Ethics** 1998 Dec;24(6):388-93 (21 ref.)
Unrelated donor bone marrow transplantation in adults: some current controversies. Marks DI, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):459-66 (43 ref.)
Organ donation. Sarti A. **Paediatr Anaesth** 1999;9(4):287-94 (48 ref.)
A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Hurley CK, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):394-406 (88 ref.)
A consideration of potential donors with active infection--is this a way to expand the donor pool? [editorial] Rubin RH, et al. **Transpl Int** 1998;11(5):333-5 (13 ref.)
Future concepts in transplantation. Calne R. **Transplant Proc** 1999 Feb-Mar;31(1-2A):21S-24S (00 ref.)
Understanding "marginal" liver grafts [comment] Melendez HV, et al. **Transplantation** 1999 Aug 27;68(4):469-71 (16 ref.) Comment on: Transplantation 1999 Aug 27;68(4):572-5.
Brain death and its influence on donor organ quality and outcome after transplantation. Pratschke J, et al. **Transplantation** 1999 Feb 15;67(3):343-8 (56 ref.)
Improving the approach to organ donation: a review. Jenkins DH, et al. **World J Surg** 1999 Jul;23(7):644-9 (66 ref.)
[Organ procurement from cardiac arrest donors: outcome of kidney grafts and recommendations] Benoit G, et al. **Presse Med** 1999 Jan 9;28(1):3-7 (37 ref.) (Eng. Abstr.) **(Fre)**
[Isolation of islands of Langerhans from human and porcine pancreas for transplantation to humans] Brandhorst D, et al. **Zentralbl Chir** 1998;123(7):814-22 (113 ref.) (Eng. Abstr.) **(Ger)**
[Donor coordination at bone marrow banks and the role of coordinators] Morishima Y. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1522-5 (5 ref.) **(Jpn)**
[Bone marrow banks and transplantation of bone marrow from unrelated donors] Okamoto S. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1510-5 (5 ref.) **(Jpn)**
[Biophysical parity of a donor with a recipient that represents their metabolic parity is suggested as a criterion of histocompatibility] Piruzian LA, et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):100-5 (35 ref.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Do the dead have interests? Policy issues for research after life. Nelkin D, et al. **Am J Law Med** 1998;24(2-3):261-91 (288 ref.)
Legal developments in transplantation. Dickens BM. **Ann Transplant** 1998;3(3):30-7 (39 ref.)
The posthumous gift of life: the world according to Kane. Shuster E. **J Contemp Health Law Policy** 1999 Spring; 15(2):401-23 (91 ref.)
Informed consent issues in assisted reproduction. Reame N. **J Obstet Gynecol Neonatal Nurs** 1999 May-Jun;28(3):331-8 (31 ref.)
Cadaveric organ donation: comparison of legislation in various countries of Europe. Matesanz R. **Nephrol Dial Transplant** 1998 Jul;13(7):1632-5 (19 ref.)

PSYCHOLOGY

Proposal for a mutual insurance pool for transplant organs. Schwindt R, et al. **J Health Polit Policy Law** 1998 Oct; 23(5):725-41 (44 ref.)

STATISTICS & NUMERICAL DATA

Applying a readiness model to increasing organ donation and transplantation. Robbins ML. **Med Health R I** 1998 Sep; 81(9):294-6 (21 ref.)

SUPPLY & DISTRIBUTION

Xenotransplantation: A potential solution to the critical organ donor shortage. Sim KH, et al. **Can J Gastroenterol** 1999 May;13(4):311-8 (77 ref.)
Are efforts at expanding the donor pool misdirected? Rayburn BK, et al. **J Heart Lung Transplant** 1998 Oct; 17(10):998-1003 (40 ref.)
Reducing the shortage of donor livers: what would It take to reliably split livers for transplantation into two adult recipients? Strasberg SM, et al. **Liver Transpl Surg** 1999 Sep;5(5):437-50 (47 ref.)

TISSUE EMBEDDING

METHODS

Histological methods to determine blood flow distribution with fluorescent microspheres. Luchtel DL, et al. **Biotech Histochem** 1998 Nov;73(6):291-309 (26 ref.)
Low-temperature embedding in acrylic resins. Gounon P. **Methods Mol Biol** 1999;117:111-24 (19 ref.)
Fixation and embedding. Oliver C, et al. **Methods Mol Biol** 1999;115:319-26 (10 ref.)
Quantitative aspects of immunogold labeling in embedded and nonembedded sections. Rabouille C. **Methods Mol Biol** 1999;117:125-44 (23 ref.)

TISSUE EXPANDERS

[Expanders in plastic ophthalmologic surgery] Fadeeva EA, et al. **Vestn Oftalmol** 1998 Nov-Dec;114(6):47-9 (26 ref.) **(Rus)**

TISSUE EXPANSION

METHODS

[The use of the internal tissue expansion procedure in reconstructive surgery. Preliminary study and report of 2 cases] Horn G. **Ann Chir Plast Esthet** 1997 Dec;42(6):623-8 (25 ref.) (Eng. Abstr.) **(Fre)**

TISSUE FACTOR see **THROMBOPLASTIN**

TISSUE FIXATION

see related
FIXATIVES

METHODS

Antigen retrieval immunohistochemistry used for routinely processed celloidin-embedded human temporal bone sections: standardization and development. Shi SR, et al. **Auris Nasus Larynx** 1998 Dec;25(4):425-43 (148 ref.)
Dynamic morphology of erythrocytes revealed by cryofixation technique. Terada N, et al. **Kaibogaku Zasshi** 1998 Dec;73(6):587-93 (29 ref.)
Calibration and standardization of microwave ovens for fixation of brain and peripheral nerve tissue. Login GR, et al. **Methods** 1998 Jun;15(2):107-17 (49 ref.)
Overview of cell fixatives and cell membrane permeants. Melan MA. **Methods Mol Biol** 1999;115:45-55 (24 ref.)
Fixation and embedding. Oliver C, et al. **Methods Mol Biol** 1999;115:319-26 (10 ref.)

STANDARDS

Calibration and standardization of microwave ovens for fixation of brain and peripheral nerve tissue. Login GR, et al. **Methods** 1998 Jun;15(2):107-17 (49 ref.)

TISSUE GRAFTS see **TRANSPLANTS**

TISSUE-INHIBITOR OF METALLOPROTEINASE-1

ANALYSIS

Metalloproteinases and tissue inhibitors of metalloproteinases. Toi M, et al. **Breast Cancer Res Treat** 1998;52(1-3):113-24 (89 ref.)

CHEMISTRY

Endoproteinase-protein inhibitor interactions. Bode W, et al. **APMIS** 1999 Jan;107(1):3-10 (40 ref.)

METABOLISM

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. Arthur MJ, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S33-8 (59 ref.)

TISSUE INHIBITOR-OF METALLOPROTEINASE-2

ANALYSIS

Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Chen WT, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:361-71 (52 ref.)
Metalloproteinases and tissue inhibitors of metalloproteinases. Toi M, et al. **Breast Cancer Res Treat** 1998;52(1-3):113-24 (89 ref.)

TISSUE INHIBITOR OF METALLOPROTEINASES

ANALYSIS

Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Zucker S, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:212-27 (75 ref.)

CHEMISTRY

Insights into MMP-TIMP interactions. Bode W, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:73-91 (72 ref.)
Engineering of selective TIMPs. Nagase H, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:1-11 (32 ref.)

GENETICS

Matrix metalloproteinases and their inhibitors. Kugler A. **Anticancer Res** 1999 Mar-Apr;19(2C):1589-92 (21 ref.)

METABOLISM

Insights into MMP-TIMP interactions. Bode W, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:73-91 (72 ref.)
Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Woessner JF Jr. **Ann N Y Acad Sci** 1999 Jun 30;878:388-403 (111 ref.)
Matrix metalloproteinases and their inhibitors. Kugler A. **Anticancer Res** 1999 Mar-Apr;19(2C):1589-92 (21 ref.)
Matrix metalloproteinases. Nagase H, et al. **J Biol Chem** 1999 Jul 30;274(31):21491-4 (91 ref.)
Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. Bramhall SR. **J Hepatobiliary Pancreat Surg** 1998;5(4):392-401 (108 ref.)
Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Pérez JC, et al. **Toxicon** 1999 May;37(5):703-28 (116 ref.)
[Matrix metalloproteases and their inhibitors in the pleura] Eickelberg O, et al. **Pneumologie** 1998 Sep;52(9):526-30 (33 ref.) **(Ger)**

PHYSIOLOGY

Tissue inhibitors of matrix metalloproteinases in cancer. Blavier L, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:108-19 (60 ref.)
Evaluation of some newer matrix metalloproteinases. Murphy G, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:25-39 (29 ref.)
Role of matrix metalloproteinases and their inhibition in

cutaneous wound healing and allergic contact hypersensitivity. Pilcher BK, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:12–24 (34 ref.)
[Focalized matrix proteolysis and inflammation] Gaudin P, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec;56(6):661–9 (62 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Pérez JC, et al. **Toxicon** 1999 May;37(5):703–28 (116 ref.)

TISSUE PLASMINOGEN ACTIVATOR

ADMINISTRATION & DOSAGE

Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator. Lam KK, et al. **Am J Kidney Dis** 1998 Dec;32(6):1075–9 (27 ref.)
New thrombolytic strategy: bolus administration of tPA and urokinase–fibrinogen conjugate. Maksimenko AV, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):307–12 (50 ref.)
Optimal thrombolytic strategies for acute myocardial infarction—bolus administration. McMechan SR, et al. **QJM** 1998 Nov;91(11):719–25 (24 ref.)

BLOOD

Predictive value of fibrinolytic factors in coronary heart disease. Wiman B. **Scand J Clin Lab Invest Suppl** 1999; 230:23–31 (50 ref.)

PHYSIOLOGY

[Tissue plasminogen activator and diabetes mellitus] Galajda P, et al. **Vnitr Lek** 1998 Nov;44(11):661–4 (24 ref.) (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Stroke: part II. Management of acute ischemic stroke. Benavente O, et al. **Am Fam Physician** 1999 May 15; 59(10):2828–34 concl (21 ref.)
What do new lytics add to t-PA? Van de Werf F. **Am Heart J** 1999 Aug;138(2 Pt 2):115–20 (33 ref.)
Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Massel D. **Can J Cardiol** 1999 Feb;15(2):173–9 (37 ref.)
Thrombolysis enters the race: a new era for acute ischaemic stroke? Famularo G, et al. **Eur J Emerg Med** 1998 Jun; 5(2):249–52 (16 ref.)
Thrombolytic treatment of type A right atrial thrombi: description of three cases and review of the literature. Mezzani A, et al. **G Ital Cardiol** 1999 Apr;29(4):441–6 (24 ref.)
Thrombolysis of a neonatal brachial artery thrombosis with tissue plasminogen activator. Grieg A. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):460–2 (11 ref.)
Endocrine therapy in pancreatic carcinoma. Yamashita J, et al. **Oncology** 1998 Dec;55 Suppl 1:17–22 (52 ref.)
[New thrombolytic agents in myocardial infarction] Helft G, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92(4):411–7 (34 ref.) (Eng. Abstr.) **(Fre)**
[Thrombolytic therapy] Matsuda T. **Nippon Rinsho** 1998 Oct; 56(10):2577–81 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Inflammatory changes and immunological disturbances in stroke] Fiszer U, et al. **Neurol Neurochir Pol** 1998 Sep–Oct; 32(5):1219–27 (30 ref.) (Eng. Abstr.) **(Pol)**

TISSUE POLYPEPTIDE ANTIGEN

see related
KERATIN

BLOOD

Significance of tissue polypeptide specific antigen (TPS) in diagnosis and monitoring of treatment in ovarian cancer. Zygmunt A, et al. **Eur J Gynaecol Oncol** 1998;19(5):484–6 (19 ref.)
Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Tuxen MK, et al. **Gynecol Oncol** 1999 Jul; 74(1):12–22 (42 ref.)

TISSUE PRESERVATION

METHODS

Processing, storage and experimental transplantation of human fetal pancreatic cells. Hayek A, et al. **Ann Transplant** 1997;2(3):46–54 (52 ref.)
Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: impact of processing techniques and study methodology. Russell JL, et al. **Orthopedics** 1999 May;22(5):524–31; quiz 532–3 (79 ref.)
[Methods of preserving the cornea] Zemba M. **Oftalmologia** 1998;42(2):13–8 (36 ref.) (Eng. Abstr.) **(Rum)**

TISSUE PROCUREMENT see **ORGAN PROCUREMENT**

TISSUE STAINS see **DYES**

TISSUE SURVIVAL

Assessment of brain tissue viability under clinical circumstances. Fieschi C, et al. **Acta Neurochir Suppl (Wien)** 1999;73:73–80 (62 ref.)
[The first-choice technic for assessing myocardial viability. Cardiac perfusion gammagraphy] Coma-Canella I. **Rev Esp Cardiol** 1998 Oct;51(10):797–800 (16 ref.) (Eng. Abstr.) **(Spa)**
[The first-choice technic for assessing myocardial viability. Stress echocardiography] Evangelista A. **Rev Esp Cardiol** 1998 Oct;51(10):801–5 (45 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

[Diagnosis of myocardial vitality using contrast echocardiography—ready for routine clinical use?] Firschke C. **Herz** 1998 Dec;23(8):483–90 (33 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis of myocardial viability in chronic myocardial ischemia with nuclear medicine techniques] vom Dahl J, et al. **Z Kardiol** 1998;87 Suppl 2:92–9 (61 ref.) (Eng. Abstr.) **(Ger)**
[Myocardial viability. Concept, physiopathology. Methods and diagnostic value] Aleixo A, et al. **Acta Med Port** 1998 May;11(5):465–71 (22 ref.) (Eng. Abstr.) **(Por)**
[The functional activity, energetics and survival of the heart under hypothermia] Aliukhin IuS. **Usp Fiziol Nauk** 1998 Jul–Sep;29(3):66–78 (52 ref.) (Eng. Abstr.) **(Rus)**

TISSUE THERAPY

Xenogeneic cell therapy: current progress and future developments in porcine cell transplantation. Edge AS, et al. **Cell Transplant** 1998 Nov–Dec;7(6):525–39 (181 ref.)
[The use of tissue preparations in the health resort treatment of cardiovascular diseases] Babov KD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 May–Jun; (3):53–5 (41 ref.) **(Rus)**

METHODS

Remyelination: cellular and gene therapy. Billinghurst LL, et al. **Semin Pediatr Neurol** 1998 Sep;5(3):211–28 (118 ref.)

TISSUE THROMBOPLASTIN see **THROMBOPLASTIN**

TISSUE TRANSPLANTATION

see related
TISSUE DONORS
TISSUE PRESERVATION
TRANSPLANTATION IMMUNOLOGY

The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? Harlan DM, et al. **JAMA** 1999 Sep 15;282(11):1076–82 (68 ref.)
The histo-blood group ABO system and tissue transplantation. Eastlund T. **Transfusion** 1998 Oct; 38(10):975–88 (134 ref.)

METHODS

Recent advances in soft tissue augmentation. Krauss MC. **Semin Cutan Med Surg** 1999 Jun;18(2):119–28 (71 ref.)

TISSUE TRANSPLANTS see **TRANSPLANTS**

TISSUE-TYPE PLASMINOGEN ACTIVATOR see **TISSUE PLASMINOGEN ACTIVATOR**

TISSUE TYPING see **HISTOCOMPATIBILITY TESTING**

TITANIUM

Virtues and drawbacks of titanium alloy aneurysm clips. Steiger HJ, et al. **Acta Neurochir Suppl (Wien)** 1999;72:81–8 (18 ref.)
Titanium alloys in total joint replacement—a materials science perspective. Long M, et al. **Biomaterials** 1998 Sep; 19(18):1621–39 (146 ref.)
The effects of the surface topography of micromachined titanium substrata on cell behavior in vitro and in vivo. Brunette DM, et al. **J Biomech Eng** 1999 Feb;121(1):49–57 (56 ref.)

CHEMISTRY

Development of plasma-sprayed bioceramic coatings with bond coats based on titania and zirconia. Kurzweg H, et al. **Biomaterials** 1998 Aug;19(16):1507–11 (20 ref.)
Peroxide-modified titanium dioxide: a chemical analog of putative Martian soil oxidants. Quinn RC, et al. **Orig Life Evol Biosph** 1999 Jan;29(1):59–72 (27 ref.)

TITRATION see **TITRIMETRY**

TITRIMETRY

METHODS

Low-tech electrophoresis, small but beautiful, and effective: electrophoretic titration curves of proteins. Gianazza E, et al. **Electrophoresis** 1999 Jun;20(7):1325–38 (112 ref.)

TLV see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

TMJ DISORDERS see **TEMPOROMANDIBULAR JOINT DISORDERS**

TMJ SYNDROME see **TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME**

TN ELEMENTS see **DNA TRANSPOSABLE ELEMENTS**

TNF-ALPHA see **TUMOR NECROSIS FACTOR**

TNF-BETA see **LYMPHOTOXIN**

TNF RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

TOAD, FIRE-BELLIED see **ANURA**

TOADS AND FROGS see **ANURA**

TOADS, TRUE see **BUFONIDAE**

TOBACCO

see related
NICOTINE
SMOKING
TOBACCO USE DISORDER

ADVERSE EFFECTS

DNA adduct formation from tobacco-specific N-nitrosamines. Hecht SS. **Mutat Res** 1999 Mar 8; 424(1-2):127–42 (95 ref.)
Arizona's tobacco control initiative illustrates the need for continuing oversight by tobacco control advocates. Aguinaga Bialous S, et al. **Tob Control** 1999 Summer; 8(2):141–51 (110 ref.)
Green tobacco sickness. McBride JS, et al. **Tob Control** 1998 Autumn;7(3):294–8 (33 ref.)
[Tobaccoism and albuminuria in hypertension and diabetes: is tobacco also harmful for the kidney? (editorial)] Martínez Ocaña JC, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):176–8 (61 ref.) **(Spa)**

EMBRYOLOGY

Microspore embryogenesis and in vitro pollen maturation in tobacco. Touraev A, et al. **Methods Mol Biol** 1999; 111:281–91 (26 ref.)

GENETICS

Mutagenesis and the selection of resistant mutants. Dix PJ. **Methods Mol Biol** 1999;111:309–18 (10 ref.)
Interactions between tobacco mosaic virus and the tobacco N gene. Erickson FL, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):653–8 (41 ref.)

GROWTH & DEVELOPMENT

The generation of plastid mutants in vitro. Dix PJ. **Methods Mol Biol** 1999;111:319–26 (12 ref.)
Mutagenesis and the selection of resistant mutants. Dix PJ. **Methods Mol Biol** 1999;111:309–18 (10 ref.)

METABOLISM

Involvement of plasma membrane proteins in plant defense responses. Analysis of the cryptogein signal transduction in tobacco. Lebrun-Garcia A, et al. **Biochimie** 1999 Jun; 81(6):663–8 (52 ref.)

POISONING

[Accidental ingestion of cigarettes by children] Hulzebos CV, et al. **Ned Tijdschr Geneeskd** 1998 Nov 21;142(47):2569–71 (14 ref.) (Eng. Abstr.) **(Dut)**

TOXICITY

Lupines, poison-hemlock and Nicotiana spp: toxicity and teratogenicity in livestock. Panter KE, et al. **J Nat Toxins** 1999 Feb;8(1):117–34 (88 ref.)
[Tobacco: an atherogenic, thrombogenic or spasmogenic factor?] Adnot S. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:53–8 (45 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Tobacco mosaic virus virulence and avirulence. Dawson WO. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):645–51 (61 ref.)

TOBACCO DEPENDENCE see **TOBACCO USE DISORDER**

TOBACCO HORNWORM see **MANDUCA**

TOBACCO INDUSTRY

Taking aim at the bull's-eye: the nicotine in tobacco products

TOBACCO INDUSTRY

[editorial] Douglas CE. **Tob Control** 1998 Autumn; 7(3):215–8 (92 ref.)

LEGISLATION & JURISPRUDENCE

The saga of tobacco products liability litigation: a look back and a proposal for the future. Nusbaum NJ.
J Community Health 1998 Oct;23(5):325–35 (43 ref.)

Arizona's tobacco control initiative illustrates the need for continuing oversight by tobacco control advocates. Aguinaga Bialous S, et al. **Tob Control** 1999 Summer; 8(2):141–51 (110 ref.)

[The requisite internationalization of the campaign against smoking] Dubois G. **Bull Acad Natl Med** 1998; 182(5):939–50; discussion 951–3 (61 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

The saga of tobacco products liability litigation: a look back and a proposal for the future. Nusbaum NJ.
J Community Health 1998 Oct;23(5):325–35 (43 ref.)

TOBACCO MOSAIC VIRUS

Tobacco mosaic virus and the virescence of biotechnology. Turpen TH. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):665–73 (64 ref.)

Tobacco mosaic virus. Pioneering research for a century. Creager AN, et al. **Plant Cell** 1999 Mar;11(3):301–8 (62 ref.)

[Tobacco mosaic virus] Okada Y. **Uirusu** 1998 Jun; 48(1):97–102 (20 ref.) **(Jpn)**

GENETICS

Replication of tobacco mosaic virus RNA. Buck KW.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):613–27 (145 ref.)

Interactions between tobacco mosaic virus and the tobacco N gene. Erickson FL, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):653–8 (41 ref.)

Historical overview of research on the tobacco mosaic virus genome: genome organization, infectivity and gene manipulation. Okada Y.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):569–82 (160 ref.)

Elucidation of the genome organization of tobacco mosaic virus. Zaitlin M. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):587–91 (40 ref.)

IMMUNOLOGY

The antigenicity of tobacco mosaic virus. Van Regenmortel MH. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):559–68 (88 ref.)

PATHOGENICITY

Coat-protein-mediated resistance to tobacco mosaic virus: discovery mechanisms and exploitation. Beachy RN.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):659–64 (34 ref.)

Tobacco mosaic virus virulence and avirulence. Dawson WO. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):645–51 (61 ref.)

Tobacco mosaic virus and the study of early events in virus infections. Shaw JG.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):603–11 (48 ref.)

PHYSIOLOGY

History of coat protein-mediated protection. Miller ED, et al. **Methods Mol Biol** 1998;81:25–38 (87 ref.)

Identification and study of tobacco mosaic virus movement function by complementation tests. Atabekov JG, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):629–35 (50 ref.)

Self-assembly of tobacco mosaic virus: the role of an intermediate aggregate in generating both specificity and speed. Butler PJ. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):537–50 (80 ref.)

Tobacco mosaic virus: a pioneer of cell-to-cell movement. Citovsky V. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):637–43 (60 ref.)

Virus reconstitution and the proof of the existence of genomic RNA. Fraenkel-Conrat H, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):583–6 (24 ref.)

The tobacco mosaic virus particle: structure and assembly. Klug A. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):531–5 (20 ref.)

ULTRASTRUCTURE

Tobacco mosaic virus particle structure and the initiation of disassembly. Stubbs G.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):551–7 (45 ref.)

TOBACCO MOSAIC VIRUS SATELLITE

GENETICS

Satellite tobacco mosaic virus. Dodds JA.
Curr Top Microbiol Immunol 1999;239:145–57 (22 ref.)

TOBACCO SMOKE POLLUTION

Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system. Taylor BV, et al. **Can J Cardiol** 1998 Sep;14(9):1129–39 (128 ref.)

Animal models used to test the interactions between infectious agents and products of cigarette smoked implicated in sudden infant death syndrome. Sayers NM, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1–2):115–23 (94 ref.)

ADVERSE EFFECTS

Accumulating evidence on health hazards of passive smoking. Pershagen G. **Acta Paediatr** 1999 May;88(5):490–2 (13 ref.)

Environmental tobacco smoke and lung cancer incidence. Leonard CT, et al. **Curr Opin Pulm Med** 1999 Jul; 5(4):189–93 (24 ref.)

Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Dybing E, et al.
Hum Exp Toxicol 1999 Apr;18(4):202–5 (30 ref.)

From in utero and childhood exposure to parental smoking to childhood cancer: a possible link and the need for action. Sasco AJ, et al. **Hum Exp Toxicol** 1999 Apr;18(4):192–201 (115 ref.)

Environmental tobacco smoke and ischaemic heart disease: a case study in applying causal criteria. Mengersen KL, et al. **Int Arch Occup Environ Health** 1999 May;72 Suppl:R1–40 (156 ref.)

It's about health, it's about time: information everyone should know. Cabelka JF 2nd. **J Med Assoc Ga** 1998 Nov; 87(4):328–9 (17 ref.)

Linear extrapolation models of lung cancer risk associated with exposure to environmental tobacco smoke. Rosenbaum WL, et al. **Regul Toxicol Pharmacol** 1998 Oct; 28(2):106–14 (30 ref.)

Health effects of passive smoking–10: Summary of effects of parental smoking on the respiratory health of children and implications for research. Cook DG, et al. **Thorax** 1999 Apr;54(4):357–66 (62 ref.)

[Tobacco: ashes, smoke and carbon] Ullmer E, et al. **Schweiz Med Wochenschr** 1999 Jan 30;129(4):103–12 (30 ref.) (Eng. Abstr.) **(Ger)**

[Pediatric diseases associated with passive smoking] Ferris Tortajada J, et al. **An Esp Pediatr** 1998 Oct;49(4):339–47 (83 ref.) **(Spa)**

[Passive smoking in childhood] Carrión Valero F, et al. **Arch Bronconeumol** 1999 Jan;35(1):39–47 (137 ref.) **(Spa)**

ANALYSIS

Biomarkers of environmental tobacco smoke exposure. Benowitz NL. **Environ Health Perspect** 1999 May;107 Suppl 2:349–55 (63 ref.)

Tracers for assessing exposure to environmental tobacco smoke: what are they tracing? Daisey JM.
Environ Health Perspect 1999 May;107 Suppl 2:319–27 (58 ref.)

Exposure of U.S. workers to environmental tobacco smoke. Hammond SK. **Environ Health Perspect** 1999 May;107 Suppl 2:329–40 (48 ref.)

An introduction to the indirect exposure assessment approach: modeling human exposure using microenvironmental measurements and the recent National Human Activity Pattern Survey. Klepeis NE.
Environ Health Perspect 1999 May;107 Suppl 2:365–74 (36 ref.)

Mathematical models for predicting indoor air quality from smoking activity. Ott WR. **Environ Health Perspect** 1999 May;107 Suppl 2:375–81 (37 ref.)

Workshop summary: assessing exposure to environmental tobacco smoke in the workplace. Samet JM.
Environ Health Perspect 1999 May;107 Suppl 2:309–12 (20 ref.)

[Methodology of determination of environmental tobacco smoke exposure and health in human beings] Wu JM.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Dec; 18(6):364–6 (10 ref.) **(Chi)**

[Cotinine--the biomarker of exposure to tobacco smoke] Dziuda MR, et al. **Przegl Lek** 1999;56(2):161–3 (62 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Buildings operations and ETS exposure. Spengler JD.
Environ Health Perspect 1999 May;107 Suppl 2:313–7 (18 ref.)

A theoretical model for the study of active and passive smoking in military women: an at-risk population. Martinelli AM. **Mil Med** 1999 Jul;164(7):475–80 (56 ref.)

STATISTICS & NUMERICAL DATA

Exposure of U.S. workers to environmental tobacco smoke. Hammond SK. **Environ Health Perspect** 1999 May;107 Suppl 2:329–40 (48 ref.)

TOBACCO, SMOKELESS

ADVERSE EFFECTS

Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25–27, 1996. Zain RB, et al. **J Oral Pathol Med** 1999 Jan;28(1):1–4 (15 ref.)

Is pan masala-containing tobacco carcinogenic? Chaudhry K. **Natl Med J India** 1999 Jan–Feb;12(1):21–7 (78 ref.)

A qualitative and quantitative risk assessment of snuff dipping [published erratum appears in Regul Toxicol Pharmacol 1999 Feb;29(1):97] Nilsson R. **Regul Toxicol Pharmacol** 1998 Aug;28(1):1–16 (112 ref.)

CHEMISTRY

The Swedish snus and the Sudanese toombak: are they different? Idris AM, et al. **Oral Oncol** 1998 Nov; 34(6):558–66 (53 ref.)

TOXICITY

Smokeless tobacco and oral cancer: an assessment of evidence derived from laboratory animals. Grasso P, et al.
Food Chem Toxicol 1998 Nov;36(11):1015–29 (61 ref.)

TOBACCO USE DISORDER

see related

SMOKING CESSATION

[Mechanism of nicotine dependence] Miyata H, et al.
Nihon Arukoru Yakubutsu Igakkai Zasshi 1998 Oct; 33(5):557–73 (83 ref.) (Eng. Abstr.) **(Jpn)**

[Tobacco dependence] Saito T, et al.
Nihon Arukoru Yakubutsu Igakkai Zasshi 1998 Oct; 33(5):549–56 (40 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Smoking intervention with adolescent substance abusers. Initial recommendations. Myers MG.
J Subst Abuse Treat 1999 Jun;16(4):289–98 (59 ref.)

[Tobaccoism and albuminuria in hypertension and diabetes: is tobacco also harmful for the kidney? (editorial)] Martinez Ocaña JC, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):176–8 (61 ref.) **(Spa)**

DIAGNOSIS

Validity of the Fagerström test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Etter JF, et al. **Addiction** 1999 Feb;94(2):269–81 (38 ref.)

DRUG THERAPY

Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings. Litten RZ, et al.
J Subst Abuse Treat 1999 Mar;16(2):105–12 (57 ref.)

EPIDEMIOLOGY

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Dalack GW, et al.
Am J Psychiatry 1998 Nov;155(11):1490–501 (100 ref.)

PHYSIOPATHOLOGY

Common aspects of the action of nicotine and other drugs of abuse. Picciotto MR. **Drug Alcohol Depend** 1998 Jun–Jul; 51(1–2):165–72 (117 ref.)

Is dopamine important in nicotine dependence? Shoaib M. **J Physiol Paris** 1998 Jun–Aug;92(3–4):229–33 (21 ref.)

Neurobiology of tobacco smoking and other addictive disorders. Gamberino WC, et al.
Psychiatr Clin North Am 1999 Jun;22(2):301–12 (49 ref.)

PREVENTION & CONTROL

Effects of thirty-four adolescent tobacco use cessation and prevention trials on regular users of tobacco products. Sussman S, et al. **Subst Use Misuse** 1999 Sep; 34(11):1469–503 (61 ref.)

An overview of tobacco measures. Davis RM.
Tob Control 1998 Winter;7 Suppl:S36–40; discussion S47–9 (14 ref.)

THERAPY

Tobacco and alcohol abuse: clinical opportunities for effective intervention. Fiore MC, et al.
Proc Assoc Am Physicians 1999 Mar–Apr;111(2):131–40 (60 ref.)

[Smoking or nicotine as the reason for coronary circulation disorders and possibilities for treatment of nicotine dependence] Haustein KO. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):363–9 (53 ref.) **(Ger)**

TOBAMOVIRUS

Evolution and origins of tobamoviruses. Gibbs A.
Philos Trans R Soc Lond B Biol Sci 1999 Mar 29; 354(1383):593–602 (80 ref.)

GENETICS

Plant viral vectors based on tobamoviruses. Yusibov V, et al. **Curr Top Microbiol Immunol** 1999;240:81–94 (60 ref.)

TOCOLYTIC AGENTS

Use of nitroglycerin for uterine relaxation. Smith GN, et al. **Obstet Gynecol Surv** 1998 Sep;53(9):559–65 (57 ref.)

ADVERSE EFFECTS

Ritodrine-related liver injury. Case reports and review of the literature [see comments] Ceriani R, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):315–7 (8 ref.) Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):318–9.

Is the pharmacological use of intravenous magnesium before preterm cerebroprotective or deleterious for premature infants? Possible importance of the use of magnesium sulphate [comment] Durlach J, et al. **Magnes Res** 1998 Dec; 11(4):323–5 (22 ref.) Comment on: Magnes Res 1996 Oct;9(3):217–9.

[Acute hepatitis due to ritodrine (letter)] Castro Fernández M, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (9 ref.) **(Spa)**

THERAPEUTIC USE

Preterm labor. Weismiller DG. **Am Fam Physician** 1999 Feb 1;59(3):593–602 (41 ref.)

Tocolytic therapy in preterm PROM. Allen SR. **Clin Obstet Gynecol** 1998 Dec;41(4):842–8 (16 ref.)

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

Value of maintenance therapy with oral tocolytics: a systematic review. Meirowitz NB, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):177–83 (11 ref.)

The control of labor. Norwitz ER, et al. **N Engl J Med** 1999 Aug 26;341(9):660–6 (70 ref.)

Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Lam F, et al. **Obstet Gynecol Surv** 1998 Nov;53(11 Suppl):S85–95 (99 ref.)

Neurologic issues in eclampsia. Kaplan PW. **Rev Neurol (Paris)** 1999 May;155(5):335–41 (63 ref.)

[Tocolytic agents] Thoulon JM. **Contracept Fertil Sex** 1998 Sep;26(9):627–33 (53 ref.) **(Fre)**

TOCOPHEROL see **VITAMIN E**

TOES

A case of infantile digital fibromatosis with spontaneous regression. Kawaguchi M, et al. **J Dermatol** 1998 Aug; 25(8):523–6 (9 ref.)

ABNORMALITIES

Polydactyly of the foot. Overview with case presentations. Kleanthous JK, et al. **J Am Podiatr Med Assoc** 1998 Oct; 88(10):493–9 (49 ref.)

MICROBIOLOGY

Management of toenail onychomycosis. Tom CM, et al. **Am J Health Syst Pharm** 1999 May 1;56(9):865–71 (35 ref.)

PATHOLOGY

Pedal manifestations of disseminated intravascular coagulation. Gregory JL, et al. **J Foot Ankle Surg** 1999 Jan–Feb;38(1):50–4 (29 ref.)

SURGERY

Arthroscopy of the great toe. Frey C, et al. **Instr Course Lect** 1999;48:343–6 (4 ref.)

Hammer toe syndrome. American College of Foot and Ankle Surgeons. **J Foot Ankle Surg** 1999 Mar–Apr;38(2):166–78 (86 ref.)

TOGAVIRIDAE

ENZYMOLOGY

Virus-encoded proteinases of the Togaviridae. ten Dam E, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1879–88 (72 ref.)

TOILET TRAINING

Treatment guidelines for primary nonretentive encopresis and stool toileting refusal. Kuhn BR, et al. **Am Fam Physician** 1999 Apr 15;59(8):2171–8, 2184–6 (25 ref.)

Instruction, timeliness, and medical influences affecting toilet training. Brazelton TB, et al. **Pediatrics** 1999 Jun;103(6 Pt 2):1353–8 (34 ref.)

A review of bowel and bladder control development in children: how gastrointestinal and urologic conditions relate to problems in toilet training. Issenman RM, et al. **Pediatrics** 1999 Jun;103(6 Pt 2):1346–52 (32 ref.)

TOLMETIN

ANALOGS & DERIVATIVES

Intravenous analgesia. McArdle P. **Crit Care Clin** 1999 Jan; 15(1):89–104 (49 ref.)

TOLOSA-HUNT SYNDROME see **OPHTHALMOPLEGIA**

TOLUENE

ANALOGS & DERIVATIVES

Toluene diisocyanates. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:865–79 (45 ref.)

alpha-Chlorinated toluenes and benzoyl chloride. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:453–77 (83 ref.)

TOXICITY

Toluene. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:829–64 (144 ref.)

Toluene diisocyanates. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:865–79 (45 ref.)

TOLUENESULFONYL COMPOUNDS see **TOSYL COMPOUNDS**

TOMATO SPOTTED WILT VIRUS see **TOSPOVIRUS**

TOMATOES

Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. Giovannucci E. **J Natl Cancer Inst** 1999 Feb 17;91(4):317–31 (125 ref.)

CHEMISTRY

The anti-carcinogenic role of lycopene, abundantly present in tomato. Sengupta A, et al. **Eur J Cancer Prev** 1999 Aug; 8(4):325–30 (47 ref.)

GENETICS

Signal transduction in the wound response of tomato plants. Bowles D. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1495–510 (148 ref.)

Genetic and molecular analysis of tomato Cf genes for resistance to Cladosporium fulvum. Thomas CM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1413–24 (59 ref.)

GROWTH & DEVELOPMENT

Genetic control of branching in Arabidopsis and tomato. Schmitz G, et al. **Curr Opin Plant Biol** 1999 Feb;2(1):51–5 (39 ref.)

METABOLISM

Signal transduction in the wound response of tomato plants. Bowles D. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29;353(1374):1495–510 (148 ref.)

MICROBIOLOGY

Avirulence and resistance genes in the Cladosporium fulvum–tomato interaction. de Wit PJ, et al. **Curr Opin Microbiol** 1999 Aug;2(4):368–73 (49 ref.)

Genetic and molecular analysis of tomato Cf genes for resistance to Cladosporium fulvum. Thomas CM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Sep 29; 353(1374):1413–24 (59 ref.)

STANDARDS

The production and quality of tomato concentrates. Hayes WA, et al. **Crit Rev Food Sci Nutr** 1998 Oct;38(7):557–64 (67 ref.)

TOMODENSITOMETRY see **TOMOGRAPHY, X-RAY COMPUTED**

TOMOGRAPHY

Electron microscopic tomography of rat-liver mitochondria and their interaction with the endoplasmic reticulum. Mannella CA, et al. **Biofactors** 1998;8(3–4):225–8 (6 ref.)

Optic nerve assessment: a clinical endpoint of optic neuropathy. Antón López A. **Eur J Ophthalmol** 1999 Jan–Mar;9 Suppl 1:S37–9 (11 ref.)

METHODS

Optical coherence tomography. Ripandelli G, et al. **Semin Ophthalmol** 1998 Dec;13(4):199–202 (12 ref.)

TOMOGRAPHY, EMISSION-COMPUTED

see related GAMMA CAMERAS

Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography. Piccini P, et al. **Adv Neurol** 1999;80:227–31 (24 ref.)

The in vivo metabolic investigation of brain gliomas with positron emission tomography. Derlon JM. **Adv Tech Stand Neurosurg** 1998;24:41–76 (184 ref.)

Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies. Epstein J, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:562–74 (97 ref.)

18FDG-positron emission tomography in pancreatic cancer. Zimny M, et al. **Ann Oncol** 1999;10 Suppl 4:28–32 (57 ref.)

18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Rose DM, et al. **Ann Surg** 1999 May;229(5):729–37; discussion 737–8 (42 ref.)

Positron emission tomography in paediatric cardiology. Quinlivan RM, et al. **Arch Dis Child** 1998 Dec;79(6):520–2 (38 ref.)

Positron emission tomography and the central nervous system. Robinson RO, et al. **Arch Dis Child** 1999 Sep; 81(3):263–70 (135 ref.)

Brain imaging technologies: how, what, when and why? Gordon E. **Aust N Z J Psychiatry** 1999 Apr;33(2):187–96 (53 ref.)

Brain imaging and memory systems in humans: the contribution of PET methods. Perani D. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):199–205 (37 ref.)

Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Baron J. **Cerebrovasc Dis** 1999 Jul–Aug;9(4):193–201 (39 ref.)

Functional imaging of recovery from stroke: A review of personal experience. Frackowiak R. **Cerebrovasc Dis** 1999; 9 Suppl 5:23–8 (15 ref.)

Emission tomography contribution to clinical neurology. Iacoboni M, et al. **Clin Neurophysiol** 1999 Jan;110(1):2–23 (187 ref.)

Role of PET FDG in the management of head and neck squamous cell cancer. Wong WL, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):361–6 (41 ref.)

Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Stoessl AJ, et al. **Curr Opin Neurol** 1998 Aug;11(4):327–33 (77 ref.)

Addiction and imaging of the living human brain. Gatley SJ, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):97–108 (113 ref.)

Nuclear medicine procedures in lung cancer. Chiti A, et al. **Eur J Nucl Med** 1999 May;26(5):533–55 (194 ref.)

Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia. Krasikova RN, et al. **Eur J Nucl Med** 1999 Jul;26(7):774–88 (125 ref.)

Update on diagnostic strategies of pulmonary embolism. Kauczor HU, et al. **Eur Radiol** 1999;9(2):262–75 (109 ref.)

Positron emission tomography as a diagnostic tool in oncology. Schiepers C, et al. **Eur Radiol** 1998;8(8):1481–94 (160 ref.)

Transcranial magnetic stimulation during PET: reaching and verifying the target site. Paus T, et al. **Hum Brain Mapp** 1998;6(5–6):399–402 (23 ref.)

Implications of brain imaging for the management of schizophrenia. Nyberg S, et al. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S15–20 (52 ref.)

Neuro-functional imaging and profound deafness. Truy E. **Int J Pediatr Otorhinolaryngol** 1999 Feb 15;47(2):131–6 (27 ref.)

Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography. Marchal G, et al. **J Cereb Blood Flow Metab** 1999 May;19(5):467–82 (93 ref.)

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington G, et al. **J Clin Psychiatry** 1999;60 Suppl 10:15–9 (50 ref.)

Normal and pathological aging--findings of positron-emission-tomography. Mielke R, et al. **J Neural Transm** 1998;105(8–9):821–37 (58 ref.)

Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. Mielke R, et al. **J Neural Transm Suppl** 1998;53:237–50 (65 ref.)

Ultra-high-resolution imaging of small animals: implications for preclinical and research studies. Weber DA, et al. **J Nucl Cardiol** 1999 May–Jun;6(3):332–44 (42 ref.)

PET in lung cancer. Coleman RE. **J Nucl Med** 1999 May; 40(5):814–20 (65 ref.)

Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. Delbeke D. **J Nucl Med** 1999 Apr;40(4):591–603 (81 ref.)

PET and drug research and development. Fowler JS, et al. **J Nucl Med** 1999 Jul;40(7):1154–63 (102 ref.)

Potential applications of PET imaging in developing novel cancer therapies. Hustinx R, et al. **J Nucl Med** 1999 Jun; 40(6):995–1002 (73 ref.)

Radiopharmaceuticals in PET imaging. Duncan K. **J Nucl Med Technol** 1998 Dec;26(4):228–34; quiz 242 (17 ref.)

Nuclear cardiology, Part IV: Viability. Mesotten L, et al. **J Nucl Med Technol** 1999 Jun;27(2):93–102; quiz 104–5 (74 ref.)

18-Fluorodeoxyglucose imaging in oncology. Harolds JA. **J Okla State Med Assoc** 1999 Sep;92(9):457–61 (36 ref.)

Nuclear medicine in cancer diagnosis. Eary JF. **Lancet** 1999 Sep 4;354(9181):853–7 (43 ref.)

Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Kiesewetter DO, et al. **Life Sci** 1999;64(6–7):511–8 (17 ref.)

Positron emission tomography in the study of hepatic encephalopathy. Lockwood AH. **Metab Brain Dis** 1998 Dec;13(4):303–9 (12 ref.)

Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Jueptner M, et al. **Neuroimage** 1995 Jun;2(2):148–56 (60 ref.)

Reopening the mental imagery debate: lessons from functional anatomy. Mellet E, et al. **Neuroimage** 1998 Aug; 8(2):129–39 (90 ref.)

Functional anatomy of dominance for speech comprehension in left handers vs right handers. Tzourio N, et al. **Neuroimage** 1998 Jul;8(1):1–16 (100 ref.)

Positron emission tomography in partial epilepsies: the clinical point of view. Koutroumanidis M, et al. **Nucl Med Commun** 1998 Dec;19(12):1123–6 (23 ref.)

Brain imaging of affective disorders and schizophrenia. Kishimoto H, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S212–4 (20 ref.)

Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Blasberg RG, et al. **Q J Nucl Med** 1999 Jun;43(2):163–9 (29 ref.)

Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Frey KA, et al. **Q J Nucl Med** 1998 Sep;42(3):166–78 (130 ref.)

Imaging neurochemistry of cerebrovascular disease with PET and SPECT. Hatazawa J, et al. **Q J Nucl Med** 1998 Sep;42(3):193–8 (35 ref.)

Neuropharmacological imaging in epilepsy with PET and SPECT. Henry TR, et al. **Q J Nucl Med** 1998 Sep; 42(3):199–210 (77 ref.)

Functional imaging of neurotransmitter systems in movement disorders. Ilgin N. **Q J Nucl Med** 1998 Sep;42(3):179–92 (106 ref.)

Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Laruelle M. **Q J Nucl Med** 1998 Sep; 42(3):211–21 (84 ref.)

Special issues in quantitation of brain receptors and related markers by emission computed tomography. Links JM. **Q J Nucl Med** 1998 Sep;42(3):158–65 (56 ref.)

What are we measuring with PET? Morgan AE, et al. **Q J Nucl Med** 1998 Sep;42(3):151–7 (57 ref.)

PET measurements of dopaminergic pathways in the brain. Perlmutter JS, et al. **Q J Nucl Med** 1999 Jun;43(2):140–54 (158 ref.)

Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Boiselle PM, et al. **Radiographics** 1998 Sep–Oct; 18(5):1061–9 (17 ref.)

Positron emission tomography receptor studies in epilepsy. Duncan JS. **Rev Neurol (Paris)** 1999 Jul;155(6–7):482–8 (50 ref.)

Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Buchsbaum MS, et al. **Schizophr Bull** 1998;24(3):343–64 (165 ref.)

Skeletal metastases from breast cancer: imaging with nuclear medicine. Cook GJ, et al. **Semin Nucl Med** 1999 Jan; 29(1):69–79 (61 ref.)

PET in breast cancer. Flanagan FL, et al. **Semin Nucl Med** 1998 Oct;28(4):290–302 (58 ref.)

18-FDG imaging in breast cancer. Hoh CK, et al. **Semin Nucl Med** 1999 Jan;29(1):49–56 (35 ref.)

The evaluation of lung function with PET. Schuster DP. **Semin Nucl Med** 1998 Oct;28(4):341–51 (75 ref.)

Applications of PET in lung cancer. Al-Sugair A, et al. **Semin Nucl Med** 1998 Oct;28(4):303–19 (63 ref.)

The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Taillefer R. **Semin Nucl Med** 1999 Jan;29(1):16–40 (133 ref.)

Relevance of positron emission tomography (PET) in oncology. Weber WA, et al. **Strahlenther Onkol** 1999 Aug; 175(8):356–73 (168 ref.)

Current role of positron emission tomography in thoracic oncology. Lowe VJ, et al. **Thorax** 1998 Aug;53(8):703–12 (76 ref.)

Positron emission tomography (PET) in the evaluation of patients with cancer. Godwin HA Jr, et al. **Trans Am Clin Climatol Assoc** 1999;110:181–94 (25 ref.)

Diagnosis and staging of pancreatic cancer by positron emission tomography. Berberat P, et al. **World J Surg** 1999 Sep;23(9):882–7 (54 ref.)

[Progresses in the study of nuclear medicine in China, 1997] Lin X. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):929–30 (0 ref.) **(Chi)**

[Current data and perspectives on positron emission tomography oncology-radiotherapy] Lonneux M, et al. **Cancer Radiother** 1999 Jul–Aug;3(4):275–88 (64 ref.) (Eng. Abstr.) **(Fre)**

[Functional imaging in idiopathic generalized epilepsy] Ryvlin P, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):691–3 (13 ref.) (Eng. Abstr.) **(Fre)**

[Role of 18F-FDG positron emission tomography in surgical evaluation] Franzius C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:261–9 (53 ref.) (Eng. Abstr.) **(Ger)**

[Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference] Kuwert T, et al. **Nervenarzt** 1998 Dec;69(12):1045–60 (234 ref.) (Eng. Abstr.) **(Ger)**

[FDG-PET in oncology. Methodological principles and clinical applications] Kletter K, et al. **Radiologe** 1999 Jul; 39(7):600–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Quantitative computer tomography] Prevrhal S, et al. **Radiologe** 1999 Mar;39(3):194–202 (62 ref.) (Eng. Abstr.) **(Ger)**

[Positron emission tomography of the skeletal system using 18FNa: frequency, distribution and appearance of skeletal metastases] Schirrmeister H, et al. **Rontgenpraxis** 1999; 52(1):19–25 (30 ref.) **(Ger)**

[Current status of positron emission tomography in diagnosis of abdominal tumors] Reske SN. **Schweiz Rundsch Med Prax** 1999 Jan 14;88(3):52–8, 60–4 (52 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis of myocardial viability in chronic myocardial ischemia with nuclear medicine techniques] vom Dahl J, et al. **Z Kardiol** 1998;87 Suppl 2:92–9 (61 ref.) (Eng. Abstr.) **(Ger)**

[Positron emission tomography (PET) in diagnosis of breast carcinoma] Ivancevic V. **Zentralbl Chir** 1998;123 Suppl 5:53–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[The place of positron-emission tomography in contemporary patient care] Borbély K. **Orv Hetil** 1999 Jan 24;140(4):171–8 (50 ref.) (Eng. Abstr.) **(Hun)**

[PET evaluation of glucose metabolism in cancer] Yasuda S, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):756–61 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Functional imaging for disorders of basal ganglia] Otsuka M, et al. **Rinsho Shinkeigaku** 1999 Jan;39(1):30–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Strategy and cost in investigating solitary pulmonary nodules. Gould MK, et al. **Thorax** 1998 Aug;53 Suppl 2:S32–7 (26 ref.)

INSTRUMENTATION

Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation. Hume SP, et al. **Nucl Med Biol** 1998 Nov;25(8):729–32 (43 ref.)

In vivo radiolabel quantification in small-animal models. Ploux L, et al. **Nucl Med Biol** 1998 Nov;25(8):737–42 (37 ref.)

PET imaging using dual-headed gamma cameras: an update. Lewellen TK, et al. **Nucl Med Commun** 1999 Jan;20(1):5–12 (35 ref.)

[Fluorodeoxyglucose and bronchopulmonary cancer. Initial French results with positron emission tomography] Vaylet F, et al. **Rev Pneumol Clin** 1998 Sep;54(4):187–95 (43 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Advanced neuroimaging methods in the study of movement disorders: dystonia and blepharospasm. Mazziotta JC, et al. **Adv Neurol** 1998;78:153–60 (38 ref.)

Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Burns HD, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):388–94 (32 ref.)

Usefulness of positron emission tomography imaging in the management of lung cancer. Sarinas PS, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):201–7 (58 ref.)

Positron emission tomography correlations in and beyond medial temporal lobes. Tulving E, et al. **Hippocampus** 1999; 9(1):71–82 (75 ref.)

Fast spatio-temporal image reconstruction for dynamic PET. Wernick MN, et al. **IEEE Trans Med Imaging** 1999 Mar; 18(3):185–95 (20 ref.)

Measurement of brain GABA-benzodiazepine receptor levels in vivo using emission tomography. Lingford-Hughes A, et al. **Methods Mol Biol** 1999;106:119–36 (24 ref.)

The role of FDG PET in the clinical management of head and neck cancer. Stokkel MP, et al. **Oral Oncol** 1998 Nov; 34(6):466–71 (63 ref.)

PET in child psychiatry: the risks and benefits of studying normal healthy children. Ernst M. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 May; 23(4):561–70 (22 ref.)

SPECT and PET in the evaluation of coronary artery disease. Jadvar H, et al. **Radiographics** 1999 Jul–Aug;19(4):915–26 (62 ref.)

Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Shreve PD, et al. **Radiographics** 1999 Jan–Feb;19(1):61–77; quiz 150–1 (39 ref.)

Positron emission tomography in pediatric neurology. Mohan KK, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):111–9 (43 ref.)

Three-dimensional CT angiography of the thorax: clinical applications. Kawamoto S, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):425–38 (46 ref.)

[Diagnostic techniques for bronchial cancer. New scintigraphic techniques (immunoscintigraphy and positron-emission tomography)] Vayle F, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S78–82 (24 ref.) **(Fre)**

[Value of functional imaging in Parkinson's disease and related movement disorders] Heiss WD, et al. **Nervenarzt** 1999 Jan;70 Suppl 1:S2–10 (71 ref.) (Eng. Abstr.) **(Ger)**

[Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer] Oyama N, et al. **Nippon Rinsho** 1998 Aug;56(8):2052–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Myocardial imaging using PET and SPECT] Tamaki N, et al. **Nippon Rinsho** 1998 Oct;56(10):2550–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[SPM analysis on PET and SPECT data] Fukuyama H. **Rinsho Shinkeigaku** 1999 Jan;39(1):36–8 (3 ref.) (Eng. Abstr.) **(Jpn)**

[PET study of cholinergic system in the brain] Shinotoh H. **Rinsho Shinkeigaku** 1999 Jan;39(1):33–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[The first-choice technic for assessing myocardial viability. Cardiac perfusion gammagraphy] Coma-Canella I. **Rev Esp Cardiol** 1998 Oct;51(10):797–800 (16 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

18F-labeled 2-deoxy-2-fluoro-D-glucose positron-emission tomography scans for the localization of the epileptogenic foci. Hotta SS. **Health Technol Assess (Rockv)** 1998 Jul; (12):i–vi, 1–17 (71 ref.)

TRENDS

Application of new imaging techniques for the evaluation of squamous cell carcinoma of the head and neck. Fischbein N, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):187–212 (103 ref.)

TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON

Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? [editorial; comment] Sias TM, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):206–9 (26 ref.) Comment on: Am Heart J 1999 Aug;138(2 Pt 1):369–75.

Cardiac pheochromocytoma: resection after diagnosis by 111-indium octreotide scan. Lin JC, et al. **Ann Thorac Surg** 1999 Feb;67(2):555–8 (8 ref.)

Brain imaging technologies: how, what, when and why? Gordon E. **Aust N Z J Psychiatry** 1999 Apr;33(2):187–96 (53 ref.)

Can SPECT predict the future for mild cognitive impairment? [editorial] Black SE. **Can J Neurol Sci** 1999 Feb;26(1):4–6 (32 ref.)

Technetium Tc 99m sestamibi myocardial perfusion imaging: current role for evaluation of prognosis. Mandalapu BP, et al. **Chest** 1999 Jun;115(6):1684–94 (77 ref.)

Emission tomography contribution to clinical neurology. Iacoboni M, et al. **Clin Neurophysiol** 1999 Jan;110(1):2–23 (187 ref.)

Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Stoessl AJ, et al. **Curr Opin Neurol** 1998 Aug;11(4):327–33 (77 ref.)

Addiction and imaging of the living human brain. Gatley SJ, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):97–108 (113 ref.)

Nuclear medicine procedures in lung cancer. Chiti A, et al. **Eur J Nucl Med** 1999 May;26(5):533–55 (194 ref.)

Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia. Krasikova RN, et al. **Eur J Nucl Med** 1999 Jul;26(7):774–88 (125 ref.)

Imaging of McCune-Albright syndrome using bone single photon emission computed tomography. Kairemo KJ, et al. **Eur J Pediatr** 1999 Feb;158(2):123–6 (16 ref.)

BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction. Franken PR, et al. **Int J Card Imaging** 1999 Feb;15(1):27–34 (28 ref.)

BMIPP-design and development. Knapp FF Jr, et al. **Int J Card Imaging** 1999 Feb;15(1):1–9 (61 ref.)

Cardiac BMIPP imaging in acute myocardial infarction. Nakata T, et al. **Int J Card Imaging** 1999 Feb;15(1):21–6 (24 ref.)

Clinical review of attenuation-corrected cardiac SPECT. Corbett JR, et al. **J Nucl Cardiol** 1999 Jan–Feb;6(1 Pt 1):54–68 (109 ref.)

Quantitative myocardial perfusion SPECT. Tsui BM, et al. **J Nucl Cardiol** 1998 Sep–Oct;5(5):507–22 (77 ref.)

Ultra-high-resolution imaging of small animals: implications for preclinical and research studies. Weber DA, et al. **J Nucl Cardiol** 1999 May–Jun;6(3):332–44 (42 ref.)

Women's health issues and nuclear medicine, Part I: Women and heart disease. Mann A. **J Nucl Med Technol** 1999 Jun; 27(2):89–92; quiz 103, 105 (45 ref.)

Nuclear cardiology, Part IV: Viability. Mesotten L, et al. **J Nucl Med Technol** 1999 Jun;27(2):93–102; quiz 104–5 (74 ref.)

18-Fluorodeoxyglucose imaging in oncology. Harolds JA. **J Okla State Med Assoc** 1999 Sep;92(9):457–61 (36 ref.)

Nuclear medicine in cancer diagnosis. Eary JF. **Lancet** 1999 Sep 4;354(9181):853–7 (43 ref.)

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA, et al. **Prostate** 1998 Dec 1;37(4):261–9 (29 ref.)

Brain imaging of affective disorders and schizophrenia.

Kishimoto H, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S212-4 (20 ref.)
Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Frey KA, et al. **Q J Nucl Med** 1998 Sep;42(3):166-78 (130 ref.)
Imaging neurochemistry of cerebrovascular disease with PET and SPECT. Hatazawa J, et al. **Q J Nucl Med** 1998 Sep;42(3):193-8 (35 ref.)
Neuropharmacological imaging in epilepsy with PET and SPECT. Henry TR, et al. **Q J Nucl Med** 1998 Sep; 42(3):199-210 (77 ref.)
Functional imaging of neurotransmitter systems in movement disorders. Ilgin N. **Q J Nucl Med** 1998 Sep;42(3):179-92 (106 ref.)
Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Laruelle M. **Q J Nucl Med** 1998 Sep; 42(3):211-21 (84 ref.)
Special issues in quantitation of brain receptors and related markers by emission computed tomography. Links JM. **Q J Nucl Med** 1998 Sep;42(3):158-65 (56 ref.)
Evaluation of lower back pain with bone scintigraphy and SPECT. De Maeseneer M, et al. **Radiographics** 1999 Jul-Aug;19(4):901-12; discussion 912-4 (25 ref.)
SPECT and PET in the evaluation of coronary artery disease. Jadvar H, et al. **Radiographics** 1999 Jul-Aug;19(4):915-26 (62 ref.)
Fatty acids for myocardial imaging. Corbett JR. **Semin Nucl Med** 1999 Jul;29(3):237-58 (89 ref.)
Attenuation and scatter compensation in myocardial perfusion SPECT. Galt JR, et al. **Semin Nucl Med** 1999 Jul;29(3):204-20 (118 ref.)
Technetium-99m labeled myocardial perfusion imaging agents. Jain D. **Semin Nucl Med** 1999 Jul;29(3):221-36 (103 ref.)
The current role of infarct avid imaging. Khaw BA. **Semin Nucl Med** 1999 Jul;29(3):259-70 (59 ref.)
Gated SPECT imaging. Mansoor MR, et al. **Semin Nucl Med** 1999 Jul;29(3):271-8 (33 ref.)
Neurotoxicity in single photon emission computed tomography brain scans of patients reporting chemical sensitivities. Ross GH, et al. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):415-20 (26 ref.)
[Diagnosis of myocardial viability in chronic myocardial ischemia with nuclear medicine techniques] vom Dahl J, et al. **Z Kardiol** 1998;87 Suppl 2:92-9 (61 ref.) (Eng. Abstr.) **(Ger)**
[Assessment of cardiac function and myocardial metabolism by nuclear medicine] Hasegawa S, et al. **Kaku Igaku** 1999 Apr;36(3):209-17 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical significance of 123I-BMIPP myocardial SPECT] Yamazaki J. **Kaku Igaku** 1998 Jul;35(6):367-73 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Application of SPECT to child neurology] Matsuda H. **No To Hattatsu** 1999 May;31(3):201-10 (16 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera. Sandler MP, et al. **J Nucl Med** 1998 Dec;39(12):2035-43 (71 ref.)
In vivo radiolabel quantification in small-animal models. Ploux L, et al. **Nucl Med Biol** 1998 Nov;25(8):737-42 (37 ref.)

METHODS

Advanced neuroimaging methods in the study of movement disorders: dystonia and blepharospasm. Mazziotta JC, et al. **Adv Neurol** 1998;78:153-60 (38 ref.)
An EM algorithm for dynamic SPECT. Bauschke HH, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):252-61 (38 ref.)
Myocardial imaging with 123I-BMIPP in patients with congestive heart failure. Ishida Y, et al. **Int J Card Imaging** 1999 Feb;15(1):71-7 (20 ref.)
BMIPP in angina pectoris. Nishimura S, et al. **Int J Card Imaging** 1999 Feb;15(1):35-9 (20 ref.)
beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Nishimura T. **Int J Card Imaging** 1999 Feb;15(1):41-8 (30 ref.)
BMIPP compared with thallium redistribution. Taki J, et al. **Int J Card Imaging** 1999 Feb;15(1):49-59 (58 ref.)
Future aspects of BMIPP. Tamaki N, et al. **Int J Card Imaging** 1999 Feb;15(1):79-89 (64 ref.)
Electrocardiographically gated myocardial perfusion SPECT: technical principles and quality control considerations. Cullom SJ, et al. **J Nucl Cardiol** 1998 Jul-Aug;5(4):418-25 (36 ref.)
An introduction to attenuation correction. Miles J, et al. **J Nucl Cardiol** 1999 Jul-Aug;6(4):449-57 (39 ref.)
Measurement of brain GABA-benzodiazepine receptor levels in vivo using emission tomography. Lingford-Hughes A, et al. **Methods Mol Biol** 1999;106:119-36 (24 ref.)
Quantitative SPECT techniques. Watson DD. **Semin Nucl Med** 1999 Jul;29(3):192-203 (35 ref.)
[Myocardial imaging using PET and SPECT] Tamaki N, et al. **Nippon Rinsho** 1998 Oct;56(10):2550-5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[SPM analysis on PET and SPECT data] Fukuyama H. **Rinsho Shinkeigaku** 1999 Jan;39(1):36-8 (3 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Trends in myocardial perfusion single-photon emission technique. Hesse B. **Clin Physiol** 1999 May;19(3):204-10 (23 ref.)

TOMOGRAPHY, NMR see **MAGNETIC RESONANCE IMAGING**

TOMOGRAPHY, POSITRON-EMISSION see **TOMOGRAPHY, EMISSION-COMPUTED**

TOMOGRAPHY, PROTON SPIN see **MAGNETIC RESONANCE IMAGING**

TOMOGRAPHY, RADIONUCLIDE-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED**

TOMOGRAPHY SCANNERS, X-RAY COMPUTED

see related
RADIOGRAPHIC IMAGE ENHANCEMENT

TOMOGRAPHY, SINGLE-PHOTON, EMISSION-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

TOMOGRAPHY, TRANSMISSION COMPUTED see **TOMOGRAPHY, X-RAY COMPUTED**

TOMOGRAPHY, ULTRASONIC see **ULTRASONOGRAPHY**

TOMOGRAPHY, X-RAY COMPUTED

Angiomyolipoma of the liver: significance of CT and MR dynamic study. Ahmadi T, et al. **Abdom Imaging** 1998 Sep-Oct;23(5):520-6 (41 ref.)
Polysplenia syndrome detected in adulthood: report of eight cases and review of the literature. Gayer G, et al. **Abdom Imaging** 1999 Mar-Apr;24(2):178-84 (17 ref.)
Cerebral aneurysm associated with persistent primitive olfactory artery aneurysm. Nozaki K, et al. **Acta Neurochir (Wien)** 1998;140(4):397-401; discussion 401-2 (11 ref.)
Instrumental diagnosis of osteoporosis. Rossini M, et al. **Aging (Milano)** 1998 Jun;10(3):240-8 (62 ref.)
Absence of the infrarenal inferior vena cava with preservation of the suprarenal segment as revealed by CT and MR venography. Bass JE, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1610-2 (8 ref.)
CT enteroclysis: a superfluous diagnostic procedure or valuable when investigating small-bowel disease? Bender GN, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):373-8 (15 ref.)
Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities. Dodd GD 3rd, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1031-6 (8 ref.)
Using CT to reveal fat-containing abnormalities of the pancreas. Katz DS, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):393-6 (8 ref.)
Pneumoparotitis: diagnosis by computed tomography. Golz A, et al. **Am J Otolaryngol** 1999 Jan-Feb;20(1):68-71 (21 ref.)
Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography. King GG, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):992-1004 (37 ref.)
Role of spiral computed tomography in the diagnosis of pulmonary embolism in the emergency department. Holbert JM, et al. **Ann Emerg Med** 1999 May;33(5):520-8 (47 ref.)
Computed tomography in the diagnosis and staging of cholangiocarcinoma and pancreatic carcinoma. Freeny PC. **Ann Oncol** 1999;10 Suppl 4:12-7 (25 ref.)
Dosimetry for optimisation of patient protection in computed tomography. Jessen KA, et al. **Appl Radiat Isot** 1999 Jan; 50(1):165-72 (27 ref.)
Brain imaging technologies: how, what, when and why? Gordon E. **Aust N Z J Psychiatry** 1999 Apr;33(2):187-96 (53 ref.)
CT of unusual nasal masses. Grainger AJ, et al. **Br J Radiol** 1999 Mar;72(855):313-6 (8 ref.)
Computed tomography in abdominal tuberculosis. Suri S, et al. **Br J Radiol** 1999 Jan;72(853):92-8 (12 ref.)
Gastrointestinal manifestations of cystic fibrosis in adults: pictorial essay. Brown JA, et al. **Can Assoc Radiol J** 1999 Jun;50(3):165-9 (9 ref.)
Electron beam computed tomography: screening for coronary artery disease. Budoff MJ, et al. **Clin Cardiol** 1999 Sep;22(9):554-8 (34 ref.)
Optimization of contrast delivery for pulmonary CT angiography. Yankelevitz DF, et al. **Clin Imaging** 1998 Nov-Dec;22(6):398-403 (13 ref.)
Scrotal cystocele: US and CT findings in two cases. Casas JD, et al. **Comput Med Imaging Graph** 1998 Jan-Feb; 22(1):53-6 (12 ref.)
Acute pancreatitis: the role of diagnostic imaging. Dalzell DP, et al. **Crit Rev Diagn Imaging** 1998 Sep;39(5):339-63 (42 ref.)
Imaging of abdominal manifestations of melanoma. Kamel IR, et al. **Crit Rev Diagn Imaging** 1998 Dec;39(6):447-86 (24 ref.)
Postpartum complications in the abdomen and pelvis: CT evaluation. Urban BA, et al. **Crit Rev Diagn Imaging** 1999 Apr;40(1):1-21 (8 ref.)
Recent advances in pediatric pulmonary imaging. Harty MP, et al. **Curr Opin Pediatr** 1998 Jun;10(3):227-35 (45 ref.)
The utility of CT in imaging chest infections in HIV-negative patients. Richenberg J, et al. **Curr Opin Pulm Med** 1999 May;5(3):179-84 (33 ref.)
Virtual colonoscopy in 1999: computed tomography or magnetic resonance imaging? Debatin JF, et al. **Endoscopy** 1999 Feb;31(2):174-9 (20 ref.)
The use of spiral computed tomography in musculoskeletal radiology of the lower limb: the calcaneus as an example. Bearcroft PW. **Eur J Radiol** 1998 Aug;28(1):30-8 (32 ref.)
Increasing spiral CT benefits with postprocessing applications. Kirchgeorg MA, et al. **Eur J Radiol** 1998 Aug; 28(1):39-54 (81 ref.)
Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Miles KA. **Eur J Radiol** 1999 Jun;30(3):198-205 (34 ref.)
Spiral CT: thoracic applications. Padhani AR. **Eur J Radiol** 1998 Aug;28(1):2-17 (77 ref.)
Spiral CT: vascular applications. Rankin SC. **Eur J Radiol** 1998 Aug;28(1):18-29 (55 ref.)
Plain CT of the degenerative lumbar spine. Tallroth K. **Eur J Radiol** 1998 Jul;27(3):206-13 (29 ref.)
Hamartoma of the urinary bladder: case report and review of the literature. Brancatelli G, et al. **Eur Radiol** 1999; 9(1):42-4 (15 ref.)
Accessory cardiac bronchus: 3D CT demonstration in nine cases. Ghaye B, et al. **Eur Radiol** 1999;9(1):45-8 (21 ref.)
MR imaging and CT of the female pelvis: radiologic-pathologic correlation. Hamm B, et al. **Eur Radiol** 1999;9(1):3-15 (49 ref.)
Nonportal' splanchnic venous supply to the liver: abnormal findings on CT, US and MRI. Itai Y, et al. **Eur Radiol** 1999;9(2):237-43 (35 ref.)
Update on diagnostic strategies of pulmonary embolism. Kauczor HU, et al. **Eur Radiol** 1999;9(2):262-75 (109 ref.)
CT and MRI of the male genital tract: radiologic-pathologic correlation. Kubik-Huch RA, et al. **Eur Radiol** 1999; 9(1):16-28 (85 ref.)
Imaging pulmonary disease in AIDS: state of the art. Kuhlman JE. **Eur Radiol** 1999;9(3):395-408 (206 ref.)
Non-invasive imaging of the great vessels of the chest. Marchal G, et al. **Eur Radiol** 1998;8(7):1099-105 (56 ref.)
CT and MRI appearances of a thoracic chordoma. Murphy JM, et al. **Eur Radiol** 1998;8(9):1677-9 (13 ref.)
Bone and skeletal muscle metastases from gastric adenocarcinoma: unusual radiographic, CT and scintigraphic features. Narváez JA, et al. **Eur Radiol** 1998; 8(8):1366-9 (23 ref.)
Cryptorchidism: strategies in detection. Nguyen HT, et al. **Eur Radiol** 1999;9(2):336-43 (37 ref.)
CT angiography. Rankin SC. **Eur Radiol** 1999;9(2):297-310 (94 ref.)
Spiral CT of pulmonary embolism: diagnostic approach, interpretive pitfalls and current indications. Remy-Jardin M, et al. **Eur Radiol** 1998;8(8):1376-90 (63 ref.)
Use of CT scan and transesophageal echocardiography in blunt thoracic trauma. Cinnella G. **Intensive Care Med** 1998 Sep;24(9):986-7 (4 ref.)
Using sector endoluminal ultrasound to identify the normal pancreas when axial computed tomography is falsely positive. Bender GN, et al. **Invest Radiol** 1999 Jan; 34(1):71-4 (13 ref.)
Lumbar intraspinal synovial cysts of different etiologies: diagnosis by CT and MR imaging. Farrokh D. **J Belge Radiol** 1998 Dec;81(6):275-8 (20 ref.)
Computed tomography of laryngeal carcinoma: technique, imaging findings and implications for radiation therapy. Hermans R, et al. **J Belge Radiol** 1998 Aug;81(4):190-8 (25 ref.)
Computed tomography in abdominal cocoon [corrected and republished article originally printed in J Clin Gastroenterol 1998 Mar;26(2): 156-7] Wig JD, et al. **J Clin Gastroenterol** 1998 Oct;27(3):259-60 (11 ref.)
Celiac artery aneurysm: diagnosis by color Doppler sonography and three-dimensional CT angiography. Soudack M, et al. **J Clin Ultrasound** 1999 Jan;27(1):49-51 (7 ref.)
CT demonstration of fibrous stroma in chronic pancreatitis: pathologic correlation. Kusano S, et al. **J Comput Assist Tomogr** 1999 Mar-Apr;23(2):297-300 (11 ref.)
Pseudolesion in segments II and III of the liver on CT during arterial portography caused by aberrant right gastric venous drainage. Yoon KH, et al. **J Comput Assist Tomogr** 1999 Mar-Apr;23(2):306-9 (12 ref.)
Growing blood clot mimicking an aneurysm on postoperative computerized tomography and magnetic resonance imaging studies. Case report and review of the literature. Bertalanffy A, et al. **J Neurosurg** 1999 Oct;91(4):679-81 (20 ref.)
Greater superficial petrosal nerve neurinoma. Case report. Kumon Y, et al. **J Neurosurg** 1999 Oct;91(4):691-6 (22 ref.)
Retropharyngeal abscesses: a clinical and radiologic correlation. Boucher C, et al. **J Otolaryngol** 1999 Jun; 28(3):134-7 (13 ref.)

Perilobular pulmonary opacities: high-resolution CT findings and pathologic correlation. Johkoh T, et al. **J Thorac Imaging** 1999 Jul;14(3):172–7 (10 ref.)

Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. Kindrick AV, et al. **J Urol** 1998 Dec;160(6 Pt 1):2102–6 (15 ref.)

Unilateral renal cystic disease in adults. Hwang DY, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1999–2003 (23 ref.)

Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Davis PC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):93–114 (80 ref.)

Cerebellar involvement in metabolic disorders: a pattern-recognition approach. Steinlin M, et al. **Neuroradiology** 1998 Jun;40(6):347–54 (41 ref.)

Computed tomography of the lacrimal drainage system: retrospective study of 107 cases of dacryostenosis. Francis IC, et al. **Ophthal Plast Reconstr Surg** 1999 May; 15(3):217–26 (68 ref.)

Pneumocephalus complicating general anaesthesia in a nine-year-old child. Hatcher IS, et al. **Paediatr Anaesth** 1999;9(3):265–7 (7 ref.)

Intra-fourth-ventricle teratoma. Srinivasan US, et al. **Pediatr Neurosurg** 1999 Apr;30(4):200–2 (5 ref.)

Imaging of pediatric mesenteric abnormalities. Zarewych ZM, et al. **Pediatr Radiol** 1999 Sep;29(9):711–9 (24 ref.)

Central nervous system imaging. When is CT more appropriate than MRI? Laughlin S, et al. **Postgrad Med** 1998 Nov;104(5):73–6, 81–4, 87–8 (30 ref.)

Morphological brain imaging studies on major psychoses. Okazaki Y. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S215–8 (23 ref.)

A primary hepatic carcinoid tumor: evaluation by computed tomography and magnetic resonance imaging. Fujino K, et al. **Radiat Med** 1998 Sep–Oct;16(5):371–3 (15 ref.)

Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Boiselle PM, et al. **Radiographics** 1998 Sep–Oct; 18(5):1061–9 (17 ref.)

Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Kawamoto S, et al. **Radiographics** 1999 Jul–Aug;19(4):887–97 (38 ref.)

Radiographic and CT findings of blunt chest trauma: aortic injuries and looking beyond them. Kuhlman JE, et al. **Radiographics** 1998 Sep–Oct;18(5):1085–106; discussion 1107–8; quiz 1 (28 ref.)

CT in blunt chest trauma: indications and limitations. Van Hise ML, et al. **Radiographics** 1998 Sep–Oct;18(5):1071–84 (29 ref.)

Pancreatic disease in children and young adults: evaluation with CT. Vaughn DD, et al. **Radiographics** 1998 Sep–Oct; 18(5):1171–87 (45 ref.)

Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119–31, x (64 ref.)

MR imaging and CT of orbital infections and complications in acute rhinosinusitis. Eustis HS, et al. **Radiol Clin North Am** 1998 Nov;36(6):1165–83, xi (56 ref.)

Helical CT grading of traumatic aortic injuries. Impact on clinical guidelines for medical and surgical management. Gavant ML. **Radiol Clin North Am** 1999 May;37(3):553–74, vi (61 ref.)

Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Hidayat AA, et al. **Radiol Clin North Am** 1998 Nov;36(6):1229–40, xii (68 ref.)

Retinoblastoma and simulating lesions. Role of CT, MR imaging and use of Gd-DTPA contrast enhancement. Kaufman LM, et al. **Radiol Clin North Am** 1998 Nov; 36(6):1101–17 (63 ref.)

Helical CT of cervical spine and soft tissue injuries of the neck. LeBlang SD, et al. **Radiol Clin North Am** 1999 May; 37(3):515–32, v–vi (81 ref.)

Helical (spiral) CT in the evaluation of emergent thoracic aortic syndromes. Traumatic aortic rupture, aortic aneurysm, aortic dissection, intramural hematoma, and penetrating atherosclerotic ulcer. Ledbetter S, et al. **Radiol Clin North Am** 1999 May;37(3):575–89 (86 ref.)

CT of soft tissue injury and orbital fractures. Mauriello JA Jr, et al. **Radiol Clin North Am** 1999 Jan;37(1):241–52, xii (35 ref.)

Helical CT of abdominal trauma. Novelline RA, et al. **Radiol Clin North Am** 1999 May;37(3):591–612, vi–vii (30 ref.)

Spiral CT and three-dimensional CT of musculoskeletal pathology. Emergency room applications. Pretorius ES, et al. **Radiol Clin North Am** 1999 Sep;37(5):953–74, vi (45 ref.)

Helical CT of appendicitis and diverticulitis. Rao PM, et al. **Radiol Clin North Am** 1999 Sep;37(5):895–910 (61 ref.)

Helical CT and three-dimensional CT of facial and orbital injury. Rhea JT, et al. **Radiol Clin North Am** 1999 May; 37(3):489–513 (73 ref.)

Imaging diagnosis of nonaortic thoracic injury. Shanmuganathan K, et al. **Radiol Clin North Am** 1999 May; 37(3):533–51, vi (99 ref.)

Helical CT of urinary tract stones. Epidemiology, origin, pathophysiology, diagnosis, and management. Smith RC, et al. **Radiol Clin North Am** 1999 Sep;37(5):911–52, v (136 ref.)

Fibro-osseous, osseous, and cartilaginous lesions of the orbit and paraorbital region. Correlative clinicopathologic and radiographic features, including the diagnostic role of CT and MR imaging. Wenig BM, et al. **Radiol Clin North Am** 1998 Nov;36(6):1241–59, xii (67 ref.)

Imaging of acute cerebral ischemia. Beauchamp NJ Jr, et al. **Radiology** 1999 Aug;212(2):307–24 (177 ref.)

Subservience of excretory urography to unenhanced CT in evaluating renal colic: a good idea?—benefits and consequences [letter] Lautin EM, et al. **Radiology** 1998 Oct; 209(1):286–7 (12 ref.)

Spiral CT angiography of the pulmonary circulation. Remy-Jardin M, et al. **Radiology** 1999 Sep;212(3):615–36 (132 ref.)

Computed tomography in the assessment of diffuse lung disease. Grenier P, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):47–56 (81 ref.)

High resolution computed tomography in sarcoidosis: a clinical perspective. Wells A. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):140–6 (41 ref.)

Imaging of neurological emergencies: trauma, hemorrhage, and infarction. Bagley LJ. **Semin Roentgenol** 1999 Apr; 34(2):144–59 (64 ref.)

Plain films and cross-sectional imaging for acute abdominal pain: unresolved issues. Baker SR. **Semin Ultrasound CT MR** 1999 Apr;20(2):142–7 (24 ref.)

Helical CT angiography of transjugular intrahepatic portosystemic shunts. Chopra S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):25–35 (21 ref.)

CT bronchoscopy. Hopper KD. **Semin Ultrasound CT MR** 1999 Feb;20(1):10–5 (22 ref.)

Unenhanced CT of abdominal and pelvic hemorrhage. Katz DS, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):94–107 (56 ref.)

Appendicitis and its mimickers. Lane MJ, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):77–85 (27 ref.)

The acute abdomen: current CT imaging techniques. Mindelzun RE, et al. **Semin Ultrasound CT MR** 1999 Apr; 20(2):63–7 (15 ref.)

Unenhanced CT in the evaluation of urinary calculi: application of advanced computer methods. Olcott EW, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):136–41 (24 ref.)

CT of diverticulitis and alternative conditions. Rao PM. **Semin Ultrasound CT MR** 1999 Apr;20(2):86–93 (31 ref.)

Acute flank pain: a modern approach to diagnosis and management. Smith RC, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):108–35 (107 ref.)

Imaging of the cervical spine. Kaiser JA, et al. **Spine** 1998 Dec 15;23(24):2701–12 (70 ref.)

New imaging techniques in endovascular surgery. Fillinger MF. **Surg Clin North Am** 1999 Jun;79(3):451–75 (36 ref.)

Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis. Wells A. **Thorax** 1998 Dec;53(12):1080–7 (67 ref.)

Current concepts in imaging of adrenal masses. Teeger S, et al. **World J Urol** 1999 Feb;17(1):3–8 (18 ref.)

[Diagnostic x-ray computed tomography pf craniocerebral tumors. Apropos of 108 cases collected at the Soweto Center of Dakar] Badiane M, et al. **Dakar Med** 1998; 43(1):34–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Spiral CT in pulmonary embolism] Coche E, et al. **J Belge Radiol** 1998 Aug;81(4):199–203 (20 ref.) (Eng. Abstr.) **(Fre)**

[Which investigations should be selected for the preoperative assessment before the decision for treatment of abdominal aortic aneurysm by endoprosthesis: arteriography, tomodensitometry or magnetic resonance imaging?] Kobeiter H. **J Mal Vasc** 1998 Dec;23(5):387–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Computed tomography-guided diagnostic puncture in abdominal pathology] de Mey J, et al. **J Radiol** 1999 Jan; 80(1):11–6 (33 ref.) (Eng. Abstr.) **(Fre)**

[Bronchiolitis: computed tomographic findings] Essadki O, et al. **J Radiol** 1999 Jan;80(1):17–24 (50 ref.) (Eng. Abstr.) **(Fre)**

[Intrathoracic dislocation fracture of the head of the humerus] al-Kaar M, et al. **J Radiol** 1998 Jan;79(1):57–9 (6 ref.) (Eng. Abstr.) **(Fre)**

[Computerized tomography of 150 cases of lymphedema of the leg] Marotel M, et al. **J Radiol** 1998 Nov;79(11):1373–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary embolism. The role of computed tomography angiography] Ghossain M, et al. **Presse Med** 1998 May 2–9;27(17):819–27 (38 ref.) (Eng. Abstr.) **(Fre)**

[The value of the CT scanner in intensive care] Berthezène Y, et al. **Rev Mal Respir** 1998 Sep;15(4):489–93 (16 ref.) (Eng. Abstr.) **(Fre)**

[Clinical imaging of osteo-condensed metastases] Buthiau D, et al. **Rev Med Interne** 1999 Apr;20(4):353–64 (62 ref.) (Eng. Abstr.) **(Fre)**

[Value and limits of spiral computerized tomography angiography in diagnosis of pulmonary embolism] Rémy J, et al. **Rev Pneumol Clin** 1998 Sep;54(4):196–204 (13 ref.) **(Fre)**

[Value of spiral computer tomography for the diagnosis of acute pulmonary embolism] Rademaker J, et al. **Dtsch Med Wochenschr** 1999 Feb 12;124(6):153–7 (40 ref.) **(Ger)**

[Progress in diagnostic imaging of the thorax (CT, MRI, intervention)—significance and value for the surgeon] Schildberg FW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:255–60 (0 ref.) (Eng. Abstr.) **(Ger)**

[2D and 3D parameter images for the analysis of contrast medium distribution in dynamic CT and MRI] Beier J, et al. **Radiologe** 1998 Oct;38(10):832–40 (27 ref.) (Eng. Abstr.) **(Ger)**

[Spontaneous porto-pulmonary shunt with pulmonary infiltrates in liver cirrhosis: their CT and MRI imaging] Hast J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):172–4 (0 ref.) **(Ger)**

[The CT diagnosis of an isolated congenital corrected transposition of the great vessels] Kostovic N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Mar;170(3):322–3 (0 ref.) **(Ger)**

[CT angiography in neuroradiology—clinical applications] Aschoff AJ, et al. **Rontgenpraxis** 1998;51(8–9):347–51 (39 ref.) **(Ger)**

[Partial priapism. Case report and review of the literature of diagnostic and therapeutic measures] Schneede P, et al. **Urologe A** 1999 Mar;38(2):179–83 (8 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiologic diagnosis in acute stroke] Brückmann H, et al. **Z Arztl Fortbild Qualitatssich** 1999 May;93(3):191–6 (10 ref.) (Eng. Abstr.) **(Ger)**

[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[The role of TC and MRI in the identification, characterization and staging of tumors of the spinal vertebrae] Gualdi GF, et al. **Clin Ter** 1999 Jan–Feb; 150(1):51–65 (51 ref.) (Eng. Abstr.) **(Ita)**

[Lipomatous hypertrophy of the interatrial septum: its assessment with TEE, CT and MRI] Iacovoni A, et al. **G Ital Cardiol** 1998 Nov;28(11):1273–7 (18 ref.) (Eng. Abstr.) **(Ita)**

[The diagnostic contribution of computed tomography in a case of volvulus of the small intestine after an ileoanal anastomosis] Catalano O. **Minerva Chir** 1998 Sep; 53(9):747–50 (14 ref.) (Eng. Abstr.) **(Ita)**

[Computerized tomography with lipiodol in hepatocarcinoma. Assessment of its diagnostic accuracy with anatomo-pathological control] Veltri A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):81–6 (33 ref.) (Eng. Abstr.) **(Ita)**

[Computerized tomography of pancreatic tumors] Fargnoli R, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S3–5 (15 ref.) (Eng. Abstr.) **(Ita)**

[CT diagnosis of solitary pulmonary nodule] Adachi S. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 May; 59(6):231–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[CT diagnosis of hyperdense intracranial neoplasms: review of the literature] Ishikura R, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 Mar; 59(4):105–12 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Computed tomography of brain infarct with special reference to vascular territories and collateral pathways] Tanohata K. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 Mar;59(4):113–21 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Radiologic-pathologic correlation of respiratory tract diseases —with special reference to HRCT] Ito H. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):498–506 (3 ref.) **(Jpn)**

[MR images of mycobacterial infection] Ohno Y, et al. **Nippon Rinsho** 1998 Dec;56(12):3067–72 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Hemoperitoneum as the form of presentation of hepatocellular carcinoma. The contribution of computed tomography to the diagnosis] da Fonseca CR, et al. **Acta Med Port** 1999 Apr-Jun;12(4–6):223–6 (15 ref.) (Eng. Abstr.) **(Por)**

[Significance and role of radiation studies in complex diagnosis of exogenous allergic alveolitis] Dmitrieva LI, et al. **Probl Tuberk** 1998;(6):40–4 (0 ref.) (Eng. Abstr.) **(Rus)**

[Computed tomography in metastatic lung lesions (a review of the literature and the author's own data). II. Detection and differential diagnosis] Tiurin IE. **Vestn Rentgenol Radiol** 1998 Mar–Apr;(2):45–50 (25 ref.) **(Rus)**

[Computed tomography in metastatic lung lesions (a review of the literature and the author's own data). I. Pathogenesis and the CT semeiotics] Tiurin IE. **Vestn Rentgenol Radiol** 1998 Mar–Apr;(2):38–44 (28 ref.) **(Rus)**

[Spiral computer tomography in the diagnosis of intracranial aneurysms] Till V, et al. **Med Pregl** 1998 Nov–Dec; 51(11–12):518–21 (19 ref.) (Eng. Abstr.) **(Scr)**

[The benefits of computed tomography in the study of Crohn disease and its complications] del Campo del Val ML, et al. **Gastroenterol Hepatol** 1999 May;22(5):242–6 (22 ref.) **(Spa)**

[X-ray computed tomography in the diagnosis of perinatal cerebrovascular lesions in infants] Honchar OA. **Lik Sprava** 1998 Dec;(8):23–9 (53 ref.) **(Ukr)**

ADVERSE EFFECTS

[Radiation exposure and computed tomography] Trigaux JP, et al. **Rev Mal Respir** 1999 Apr;16(2):127–36 (21 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

The use of CT scanning in dementia. A systematic review. Foster GR, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):406–23 (66 ref.)

INSTRUMENTATION

CT and MR colography (virtual colonoscopy): status report. Rex DK. **J Clin Gastroenterol** 1998 Oct;27(3):199–203 (37 ref.)

A horizontal CT system dedicated to heavy-ion beam treatment. Kamada T, et al. **Radiother Oncol** 1999 Feb; 50(2):235–7 (4 ref.)

[Dental CT: image quality and radiation exposure in relation to scan parameters] Schorn C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):137–44 (24 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Hepatic abnormalities related to blood flow: evaluation with dual-phase helical CT. Choi BI, et al. **Abdom Imaging** 1999 Jul–Aug;24(4):340–56 (88 ref.)

Helical CT of the urinary tract. Fielding JR, et al. **AJR Am J Roentgenol** 1999 May;172(5):1199–206 (55 ref.)

Helical CT colonography (virtual colonoscopy): the challenge that exists between advancing technology and generalizability. McFarland EG, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):549–59 (60 ref.)

Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT. Yuh BI, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):747–55 (22 ref.)

Image-guided surgical navigation in otology and neurotology. Selesnick SH, et al. **Am J Otol** 1999 Sep; 20(5):688–93; discussion 693–7 (21 ref.)

Advanced imaging of bone macro and micro structure. Genant HK, et al. **Bone** 1999 Jul;25(1):149–52 (56 ref.)

Enhancement of subtle density differences of the lung parenchyma on CT. Yang GZ, et al. **Br J Radiol** 1998 Jun;71(846):686–90 (6 ref.)

Imaging the 'dirty lung'--has high resolution computed tomography cleared the smoke? Gückel C, et al. **Clin Radiol** 1998 Oct;53(10):717–22 (43 ref.)

Spiral CT and pulmonary embolism: is the emperor still unclothed? Lally JF, et al. **Del Med J** 1999 May;71(5):221–3 (5 ref.)

Spiral CT of the abdomen: increased diagnostic potential. El Sherif A, et al. **Eur J Radiol** 1999 Jul;31(1):43–52 (46 ref.)

Kinematic CT and MR imaging of the patellofemoral joint. Muhle C, et al. **Eur Radiol** 1999;9(3):508–18 (47 ref.)

Technology status evaluation: virtual colonoscopy: November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):708–10 (12 ref.)

Spiral computed tomography: principles and clinical use. Albrecht T, et al. **Hosp Med** 1998 Feb;59(2):120–5 (27 ref.)

Xenon-enhanced CT: clinical applications. Massaro LM. **J Cardiovasc Nurs** 1998 Oct;13(1):45–56 (20 ref.)

Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons [published erratum appears in Mayo Clin Proc 1999 May;74(5):538] Rumberger JA, et al. **Mayo Clin Proc** 1999 Mar;74(3):243–52 (53 ref.)

Do acute lesions of Wernicke's encephalopathy show contrast enhancement? Report of three cases and review of the literature. Mascalchi M, et al. **Neuroradiology** 1999 Apr;41(4):249–54 (20 ref.)

Imaging modalities in x-ray computerized tomography and in selected volume tomography. Carlsson CA. **Phys Med Biol** 1999 Mar;44(3):R23–56 (82 ref.)

Helical CT applications in the thorax and abdomen. Rappaport DC. **Postgrad Med** 1998 Nov;104(5):105–8, 113–4 (19 ref.)

A case of acute interstitial pneumonia indistinguishable from bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia: high-resolution CT findings and pathologic correlation. Ichikado K, et al. **Radiat Med** 1998 Sep–Oct;16(5):367–70 (12 ref.)

CT and MR imaging of benign hepatic and biliary tumors. Horton KM, et al. **Radiographics** 1999 Mar–Apr; 19(2):431–51 (30 ref.)

Three-dimensional imaging of congenital disorders involving the orbit. Zonneveld FW, et al. **Radiol Clin North Am** 1998 Nov;36(6):1261–79, xii (78 ref.)

Real-time CT fluoroscopy: evolution of an interventional tool. Daly B, et al. **Radiology** 1999 May;211(2):309–15 (19 ref.)

Helical CT in children: technical considerations and body applications. Frush DP, et al. **Radiology** 1998 Oct; 209(1):37–48 (74 ref.)

CT and MR assessment of osteoporosis. Grampp S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):2–9 (66 ref.)

CT angiography of the abdominal and thoracic aorta. Jeffrey RB Jr. **Semin Ultrasound CT MR** 1998 Oct;19(5):405–12 (17 ref.)

Technical aspects of CT angiography. Kuszyk BS, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):383–93 (35 ref.)

Neurovascular applications of CT angiography. Kuszyk BS, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):394–404 (46 ref.)

Unenhanced CT in the evaluation of the acute abdomen: the community hospital experience. Malone AJ. **Semin Ultrasound CT MR** 1999 Apr;20(2):68–76 (18 ref.)

CT angiography of the visceral vasculature. Nghiem HV, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):439–46 (43 ref.)

Three-dimensional CT angiography: renal applications. Smith PA, et al. **Semin Ultrasound CT MR** 1998 Oct; 19(5):413–24 (30 ref.)

Segmentation techniques for analysis of bone by three-dimensional computed tomographic imaging. Dufresne T. **Technol Health Care** 1998 Dec;6(5–6):351–9 (10 ref.)

Mechanical analysis of bone and its microarchitecture based on in vivo voxel images. Ulrich D, et al. **Technol Health Care** 1998 Dec;6(5–6):421–7 (16 ref.)

Spiral computed tomographic scanning and magnetic resonance angiography for the diagnosis of pulmonary embolism. Grenier PA, et al. **Thorax** 1998 Aug;53 Suppl 2:S25–31 (43 ref.)

Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Miller OF, et al. **Urology** 1998 Dec; 52(6):982–7 (23 ref.)

[Helical CT of the liver. Principles and applications] Blum A, et al. **Gastroenterol Clin Biol** 1998 Jun–Jul; 22(6–7):576–89 (55 ref.) **(Fre)**

[High-resolution virtual laryngoscopy based on spiral CT data] Aschoff AJ, et al. **Radiologe** 1998 Oct;38(10):810–5 (47 ref.) (Eng. Abstr.) **(Ger)**

[Technical bases and acquisition conditions of electron-beam computed tomography (published erratum appears in Radiologe 1999 Apr;39(4):268)] Becker CR, et al. **Radiologe** 1998 Dec;38(12):987–92 (22 ref.) (Eng. Abstr.) **(Ger)**

[Ultrafast CT, MRI] Nakanishi T, et al. **Nippon Rinsho** 1998 Oct;56(10):2544–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[CT and MRI diagnosis] Takasu J, et al. **Nippon Rinsho** 1999 Jul;57(7):1543–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Image deformation resulting from panoramic zonography of different facial cranial regions] Arzhantsev AP, et al. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):36–8 (0 ref.) **(Rus)**

[Spiral computed tomography--solution to diagnostic problems in pulmonary embolism?] Tylén U, et al. **Lakartidningen** 1999 Jun 2;96(22):2712–7 (40 ref.) (Eng. Abstr.) **(Swe)**

STANDARDS

CT evaluation of mediastinal masses in children: spectrum of disease with pathologic correlation. Buckley JA, et al. **Crit Rev Diagn Imaging** 1998 Sep;39(5):365–92 (8 ref.)

[Role of angiographic scanning in the diagnostic strategy for pulmonary embolism] Perrier A. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S61–2 (11 ref.) **(Fre)**

TRENDS

Current status and future trends in abdominal CT. Federle MP. **Radiographics** 1998 Nov–Dec;18(6):1555–68 (69 ref.)

[The prospects and problems of electron-beam CT (EBT) (editorial)] Georgi M. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 May;170(5):413–5 (11 ref.) **(Ger)**

UTILIZATION

Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army Personnel. O'Malley PG, et al. **Am Heart J** 1999 May; 137(5):932–41 (38 ref.)

VETERINARY

Advanced imaging concepts: a pictorial glossary of CT and MRI technology. Tidwell AS, et al. **Clin Tech Small Anim Pract** 1999 May;14(2):65–111 (67 ref.)

TONGUE

INJURIES

Traumatic macroglossia: a new approach [editorial; comment] Lebovics RS. **Crit Care Med** 1999 Aug; 27(8):1689–90 (11 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1634–45.

Tongue piercing and associated tooth fracture. Botchway C, et al. **J Can Dent Assoc** 1998 Dec;64(11):803–5 (9 ref.)

PHYSIOLOGY

Neurotrophic factors in the tongue: expression patterns, biological activity, relation to innervation and studies of neurotrophin knockout mice. Nosrat CA. **Ann N Y Acad Sci** 1998 Nov 30;855:28–49 (103 ref.)

Undifferentiated lingual gestures in children with articulation/phonological disorders. Gibbon FE. **J Speech Lang Hear Res** 1999 Apr;42(2):382–97 (76 ref.)

Licking behavior in the rat: measurement and situational control of licking frequency. Weijnen JA. **Neurosci Biobehav Rev** 1998 Oct;22(6):751–60 (65 ref.)

TONGUE DISEASES

EPIDEMIOLOGY

[Epidemiologic survey of tongue lesions and analysis of the etiologic factors involved] Vörös-Balog T, et al. **Fogorv Sz** 1999 May;92(5):157–63 (17 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Lingual cyst with respiratory epithelium: an entity of debatable histogenesis. Manor Y, et al. **J Oral Maxillofac Surg** 1999 Feb;57(2):124–7; discussion 128–9 (38 ref.)

Glial choristoma of the tongue: a case report and review of the literature. Abdelsayed RA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):215–22 (36 ref.)

Symmetric lipomatosis of the tongue: report of a case and review of the literature. Calvo-García N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 May;87(5):610–2 (9 ref.)

TONGUE, FISSURED

see related
MELKERSSON-ROSENTHAL SYNDROME

TONGUE, HAIRY

see related
LEUKOPLAKIA, HAIRY

TONGUE NEOPLASMS

Squamous carcinoma of the tongue: review. Prince S, et al. **Br J Oral Maxillofac Surg** 1999 Jun;37(3):164–74 (115 ref.)

CONGENITAL

Teratoma of the tongue in neonates: report of a case and review of the literature. Uchida K, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):79–81 (15 ref.)

ETIOLOGY

Squamous cell carcinoma of the tongue arising in lichen planus: a case report and review of the literature. Camisa C, et al. **Cutis** 1998 Oct;62(4):175–8 (13 ref.)

GENETICS

Carcinoma of the tongue in two siblings. Ide F, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):66–8; discussion 69 (25 ref.)

PATHOLOGY

Isolated submandibular gland metastasis from oral cavity squamous cell carcinoma. Vaidya AM, et al. **Am J Otolaryngol** 1999 May–Jun;20(3):172–5 (21 ref.)

Squamous cell carcinoma of the tongue arising in lichen planus: a case report and review of the literature. Camisa C, et al. **Cutis** 1998 Oct;62(4):175–8 (13 ref.)

Primary osteogenic sarcoma of the tongue. Dubey SP, et al. **J Laryngol Otol** 1999 Apr;113(4):376–9 (8 ref.)

Angiosarcoma of the tongue: report of a case with immunohistochemical findings. Tabata M, et al. **J Oral Pathol Med** 1999 Feb;28(2):92–5 (24 ref.)

TONOFILAMENTS see **INTERMEDIATE FILAMENTS**

TONOMETRY

Tonometry and corneal thickness [editorial; comment] Brubaker RF. **Arch Ophthalmol** 1999 Jan;117(1):104–5 (12 ref.) Comment on: Arch Ophthalmol 1999 Jan;117(1):14–6.

INSTRUMENTATION

Disinfection of tonometers and contact lenses in the office setting: are current techniques adequate? Smith CA, et al. **Am J Ophthalmol** 1999 Jan;127(1):77–84 (58 ref.)

Sterilisation of tonometers and gonioscopes. Sood D, et al. **Indian J Ophthalmol** 1998 Jun;46(2):113–6 (15 ref.)

TONSIL

see related
TONSILLECTOMY

IMMUNOLOGY

Regionalized immune function of tonsils and adenoids [letter] Brandtzaeg P. **Immunol Today** 1999 Aug;20(8):383–4 (25 ref.)

MICROBIOLOGY

[The tonsils and adenoids as a site of infection and the cause of obstruction] Battistini A, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):237–47 (47 ref.) (Eng. Abstr.) **(Ita)**

TONSIL, PALATINE see **TONSIL**

TONSIL, PHARYNGEAL see **ADENOIDS**

TONSILLAR NEOPLASMS

DIAGNOSIS

Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Lonardo A, et al. **Dig Dis Sci** 1998 Nov;43(11):2489–92 (46 ref.)

TONSILLECTOMY

[Indications for adenoidectomy and/or tonsillectomy in children. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Senez B, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115 Suppl 1:S22–45 (135 ref.) **(Fre)**

METHODS

Pediatric tonsillectomy with bipolar electrosurgical scissors. Isaacson G, et al. **Am J Otolaryngol** 1998 Sep–Oct; 19(5):291–5 (21 ref.)

[Complications at anesthesia in tonsillectomy] Protasevich GS. **Vestn Otorinolaringol** 1999;(3):57–60 (89 ref.) **(Rus)**

[Tonsillectomy by electrical dissection versus blunt dissection: a study of 838 cases (Randomized trial of 207 cases and non-randomized prospective study of 631 cases] Esteban F, et al. **Acta Otorrinolaringol Esp** 1998 Oct; 49(7):541–7 (44 ref.) (Eng. Abstr.) **(Spa)**

TONSILLITIS

[Acute tonsillitis] Harada T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):410–3 (7 ref.) **(Jpn)**

[Acute tonsillitis, peritonsillitis, and deep neck infection] Nonomura N. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):304–6 (7 ref.) **(Jpn)**

COMPLICATIONS

Fisher's syndrome and group A streptococcal infection. Yuki N, et al. **J Neurol Sci** 1998 Sep 18;160(1):64–6 (9 ref.)

DIAGNOSIS

Sore throat, tonsillitis, and adenoiditis. Richardson MA. **Med Clin North Am** 1999 Jan;83(1):75–83, viii (16 ref.)

DRUG THERAPY

[Pharyngotonsillitis in the adult (editorial)] Gobernado M. **Rev Esp Quimioter** 1998 Jun;11(2):105–9 (74 ref.) **(Spa)**

TOOTH

see related
DENTITION
MALOCCLUSION
MASTICATION
ODONTOGENESIS

ANATOMY & HISTOLOGY

Postural disorders and dentofacial morphology. Huggare J. **Acta Odontol Scand** 1998 Dec;56(6):383–6 (39 ref.)

The relationship between satisfaction with mouth and number and position of teeth. Elias AC, et al. **J Oral Rehabil** 1998 Sep;25(9):649–61 (118 ref.)

Canine dental disease. Holmstrom SE. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1049–56, v (3 ref.)

CHEMISTRY

Proteomic analysis of enamel cells from developing rat teeth: big returns from a small tissue. Hubbard MJ. **Electrophoresis** 1998 Aug;19(11):1891–900 (29 ref.)

A review of the methodological aspects of aspartic acid racemization analysis for use in forensic science. Waite ER, et al. **Forensic Sci Int** 1999 Jul 26;103(2):113–24 (59 ref.)

EMBRYOLOGY

Molecular regulation of tooth development. Thesleff I, et al. **Bone** 1999 Jul;25(1):123–5 (24 ref.)

Molecular genetics of tooth morphogenesis and patterning: the right shape in the right place. Tucker AS, et al. **J Dent Res** 1999 Apr;78(4):826–34 (58 ref.)

Organ culture in the analysis of tissue interactions. Thesleff I, et al. **Methods Mol Biol** 1999;97:23–31 (17 ref.)

GROWTH & DEVELOPMENT

Regulation of amelogenin gene expression. Gibson CW. **Crit Rev Eukaryot Gene Expr** 1999;9(1):45–57 (86 ref.)

PATHOLOGY

The effects of myotonic dystrophy and Duchenne muscular dystrophy on the orofacial muscles and dentofacial morphology. Kiliaridis S, et al. **Acta Odontol Scand** 1998 Dec;56(6):369–74 (33 ref.)

Tooth surface loss: an overview. Kelleher M, et al. **Br Dent J** 1999 Jan 23;186(2):61–6 (53 ref.)

RADIOGRAPHY

Radiographic evaluation. Gorrel C. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1089–110 (34 ref.)

TRANSPLANTATION

Autotransplantation of teeth: is there a role? Thomas S, et al. **Br J Orthod** 1998 Nov;25(4):275–82 (38 ref.)

TOOTH ABNORMALITIES

DIAGNOSIS

Simultaneous occurrence of segmental odontomaxillary dysplasia and Becker's nevus. Jones AC, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1251–4 (17 ref.)

EPIDEMIOLOGY

A clinical and statistical study of etiologic aspects related to associated tooth anomalies in number, size, and position. Baccetti T. **Minerva Stomatol** 1998 Dec;47(12):655–63 (25 ref.)

GENETICS

Rare dental abnormalities seen in oculo–facio–cardio–dental (OFCD) syndrome: three new cases and review of nine patients. Schulze BR, et al. **Am J Med Genet** 1999 Feb 19;82(5):429–35 (9 ref.)

TOOTH ABRASION

ETHNOLOGY

Anthropology, tooth wear, and occlusion ab origine. Young WG. **J Dent Res** 1998 Nov;77(11):1860–3 (31 ref.)

THERAPY

[Targeted enamel erosion/abrasion. The treatment of enamel dysplasia by a microabrasion technic] Otto T. **Schweiz Monatsschr Zahnmed** 1999;109(5):488–97 (13 ref.) **(Ger, Fre)**

TOOTH, ARTIFICIAL

see related
ACRYLIC RESINS
DENTAL PORCELAIN

TOOTH ATTRITION

PHYSIOPATHOLOGY

Attrition, eruption, and the periodontium. Newman HN. **J Dent Res** 1999 Mar;78(3):730–4 (56 ref.)

PREVENTION & CONTROL

Tooth surface loss. 6. Prevention and maintenance. Wickens JL. **Br Dent J** 1999 Apr 24;186(8):371–6 (19 ref.)

TOOTH AVULSION

THERAPY

[Injuries to the permanent teeth. Periodontal lesions] Vinckier F, et al. **Rev Belge Med Dent** 1998;53(3):105–51 (52 ref.) (Eng. Abstr.) **(Fre)**

TOOTH CROWDING see **MALOCCLUSION**

TOOTH CROWN

GROWTH & DEVELOPMENT

Radiographic and histological methodologies in estimating the chronology of crown development in modern humans and great apes: a review, with some applications for studies on juvenile hominids. Beynon AD, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):351–70 (57 ref.)

Utilization of periodic markings in enamel to obtain information on tooth growth. Shellis RP. **J Hum Evol** 1998 Oct–Nov;35(4–5):387–400 (42 ref.)

INJURIES

Incisal edge reattachment: indications for use and clinical technique. Murchison DF, et al. **Br Dent J** 1999 Jun 26; 186(12):614–9 (56 ref.)

TOOTH, DECIDUOUS

Oral health for the preschool child [editorial] [see comments] Kilpatrick N. **Med J Aust** 1999 Jan 4;170(1):6–7 (16 ref.) Comment in: Med J Aust 1999 May 3;170(9):455–6.

ABNORMALITIES

Dentin dysplasia, type II: report of 2 new families and review of the literature. Brenneise CV, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):752–5 (22 ref.)

PATHOLOGY

Odontogenic cysts related to pulpotomized deciduous molars: clinical features and treatment outcome. Lustig JP, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):499–503 (15 ref.)

TOOTH DEMINERALIZATION

see related
DENTAL CARIES

TOOTH DEPRESSION see **TOOTH MOVEMENT**

TOOTH, DEVITALIZED see **TOOTH, NONVITAL**

TOOTH DISCOLORATION

see related
ENAMEL MICROABRASION

CHEMICALLY INDUCED

Oral and systemic effects of prolonged minocycline therapy. Patel K, et al. **Br Dent J** 1998 Dec 12–26;185(11–12):560–2 (19 ref.)

ETIOLOGY

Discoloration of dental carious lesions (a review). Kleter GA. **Arch Oral Biol** 1998 Aug;43(8):629–32 (33 ref.)

TOOTH DISEASES

see related
MOUTH REHABILITATION

ETIOLOGY

Significance of oral health in persons with Down syndrome: a literature review. Hennequin M, et al. **Dev Med Child Neurol** 1999 Apr;41(4):275–83 (108 ref.)

PREVENTION & CONTROL

Significance of oral health in persons with Down syndrome: a literature review. Hennequin M, et al. **Dev Med Child Neurol** 1999 Apr;41(4):275–83 (108 ref.)

Preventive dentistry during pregnancy [letter] Holder R, et al. **Nurse Pract** 1999 Feb;24(2):21–4 (15 ref.)

THERAPY

Pretherapy dental decisions in patients with head and neck cancer. A proposed model for dental decision support. Bruins HH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Sep;86(3):256–67 (71 ref.)

VETERINARY

Oral–dental radiographic examination technique. Eisner ER. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1063–87, v (20 ref.)

Radiographic evaluation. Gorrel C. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1089–110 (34 ref.)

Canine dental disease. Holmstrom SE. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1049–56, v (3 ref.)

Dental diseases of puppies and kittens. Lobprise HB, et al. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):871–93 (19 ref.)

[Dental problems in rabbits and rodents. I. Anatomy, physiology, symptomatology, diagnosis] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1;123(23):698–706 (30 ref.) (Eng. Abstr.) **(Dut)**

[Dental problems in rabbits and rodents. II. Dental treatment] van Foreest AW. **Tijdschr Diergeneeskd** 1998 Dec 1; 123(23):707–13 (30 ref.) (Eng. Abstr.) **(Dut)**

TOOTH, ENDODONTICALLY-TREATED see **TOOTH, NONVITAL**

TOOTH EROSION

ETIOLOGY

Dental erosion. Moss SJ. **Int Dent J** 1998 Dec;48(6):529–39 (40 ref.)

THERAPY

[Targeted enamel erosion/abrasion. The treatment of enamel dysplasia by a microabrasion technic] Otto T. **Schweiz Monatsschr Zahnmed** 1999;109(5):488–97 (13 ref.) **(Ger, Fre)**

TOOTH ERUPTION

A re-examination of the pre-eruptive and post-eruptive mechanism of the anti-caries effects of fluoride: is there any anti-caries benefit from swallowing fluoride? Limeback H. **Community Dent Oral Epidemiol** 1999 Feb;27(1):62–71 (35 ref.)

PHYSIOLOGY

Attrition, eruption, and the periodontium. Newman HN. **J Dent Res** 1999 Mar;78(3):730–4 (56 ref.)

TOOTH ERUPTION, ECTOPIC

COMPLICATIONS

[Dental infectious foci and their complications. Etiology, diagnosis, evolution, treatment] Ragot JP. **Rev Prat** 1998 Oct 1;48(15):1711–21 (4 ref.) **(Fre)**

ETIOLOGY

The ectopic maxillary canine: a review. McSherry PF. **Br J Orthod** 1998 Aug;25(3):209–16 (74 ref.)

GENETICS

Mandibular lateral incisor–canine transposition, concomitant dental anomalies, and genetic control. Peck S, et al. **Angle Orthod** 1998 Oct;68(5):455–66 (53 ref.)

SURGERY

Palatally ectopic canines: closed eruption versus open eruption. Burden DJ, et al. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):640–4 (24 ref.)

TOOTH EXTRACTION

Aspiration of gauze pressure-pack following a dental extraction: a case report. Villasenor A. **Pediatr Dent** 1999 Mar–Apr;21(2):135–6 (6 ref.)

ADVERSE EFFECTS

Wisdom tooth removal and lingual nerve damage [editorial] McGurk M, et al. **Br J Oral Maxillofac Surg** 1999 Aug; 37(4):253–4 (22 ref.)

Bilateral cervicofacial, axillary, and anterior mediastinal emphysema: a rare complication of third molar extraction. Capes JO, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):996–9 (12 ref.)

UTILIZATION

Third molars: a dilemma! Or is it? Bishara SE. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):628–33 (30 ref.)

More than lip service: facial esthetics in orthodontics. Bowman SJ. **J Am Dent Assoc** 1999 Aug;130(8):1173–81 (87 ref.)

TOOTH EXTRUSION see **TOOTH MOVEMENT**

TOOTH FRACTURES

DIAGNOSIS

Diagnosis and management of teeth with vertical root fractures. Moule AJ, et al. **Aust Dent J** 1999 Jun; 44(2):75–87 (54 ref.)

ETIOLOGY

Tongue piercing and associated tooth fracture. Botchway C, et al. **J Can Dent Assoc** 1998 Dec;64(11):803–5 (9 ref.)

THERAPY

Incisal edge reattachment: indications for use and clinical technique. Murchison DF, et al. **Br Dent J** 1999 Jun 26; 186(12):614–9 (56 ref.)

[Definitive injuries to the teeth. Lesions of hard tissue and pulp] Vinckier F, et al. **Rev Belge Med Dent** 1998; 53(2):29–91 (53 ref.) (Eng. Abstr.) **(Fre)**

TOOTH GERM

see related
ODONTOGENESIS

Evolutionary analysis of "hagfish amelogenin". Girondot M, et al. **Anat Rec** 1998 Dec;252(4):608–11 (16 ref.)

Spontaneous uprighting of permanent tooth germs after elimination of local eruption obstacles. Wagner M, et al. **J Orofac Orthop** 1999;60(4):279–85 (8 ref.) **(Eng, Ger)**

TOOTH INJURIES

ECONOMICS

[Injury—damages—insurance: legal implications] Yvo V. **Rev Belge Med Dent** 1998;53(2):9–28 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Oro-dental injuries during intubation anesthesia] Folwaczny M, et al. **Anaesthesist** 1998 Sep;47(9):707–31 (204 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Evaluation for tooth stabilization and treatment of traumatized teeth. McDonald N, et al. **Dent Clin North Am** 1999 Jan;43(1):135–49, vii (38 ref.)

Traumatic dental injuries: current treatment concepts [see comments] Diangelis AJ, et al. **J Am Dent Assoc** 1998 Oct; 129(10):1401–14 (73 ref.) Comment in: J Am Dent Assoc 1999 Mar;130(3):312, 315.

Common pediatric dental problems. Creighton PR. **Pediatr Clin North Am** 1998 Dec;45(6):1579–60 (21 ref.)

TOOTH INTRUSION see **TOOTH MOVEMENT**

TOOTH LOSS

EPIDEMIOLOGY

Aspects of dental health in adult rural population in Poland. Szymańska J, et al. **Ann Agric Environ Med** 1998;5(2):103–8 (32 ref.)

On oral disease, illness and impairment among 50-year-olds in two Swedish counties. Unell L. **Swed Dent J Suppl** 1999; 135:1–45 (105 ref.)

[Dynamics of tooth loss In the adult population in Hungary] Fejérdy P, et al. **Fogorv Sz** 1998 Nov;91(11):327–36 (36 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Periodontal disease and tooth loss. Ong G. **Int Dent J** 1998 Jun;48(3 Suppl 1):233–8 (47 ref.)

PATHOLOGY

[The effects of tooth loss on the anatomy of the maxilla] Solar P, et al. **Schweiz Monatsschr Zahnmed** 1998; 108(9):871–8 (22 ref.) **(Ger, Fre)**

TOOTH LUXATION see **TOOTH AVULSION**

TOOTH MIGRATION

GENETICS

Mandibular lateral incisor–canine transposition, concomitant dental anomalies, and genetic control. Peck S, et al. **Angle Orthod** 1998 Oct;68(5):455–66 (53 ref.)

TOOTH MOBILITY

THERAPY

Tooth stabilization and splinting before and after periodontal therapy with fixed partial dentures. Siegel SC, et al. **Dent Clin North Am** 1999 Jan;43(1):45–76 (95 ref.)

New-generation bonded reinforcing materials for anterior periodontal tooth stabilization and splinting. Strassler HE, et al. **Dent Clin North Am** 1999 Jan;43(1):105–26, vi (28 ref.)

TOOTH MOVEMENT

Gingival response to orthodontic force. Redlich M, et al. **Am J Orthod Dentofacial Orthop** 1999 Aug;116(2):152–8 (54 ref.)

ADVERSE EFFECTS

Neural modulation of inflammatory reactions in dental tissues incident to orthodontic tooth movement. A review of the literature. Vandevska-Radunovic V. **Eur J Orthod** 1999 Jun;21(3):231–47 (176 ref.)

INSTRUMENTATION

Rare earth magnets in orthodontics: an overview. Noar JH, et al. **Br J Orthod** 1999 Mar;26(1):29–37 (51 ref.)

TOOTH MOVEMENT, MINOR see **TOOTH MOVEMENT**

TOOTH, NATAL see **NATAL TEETH**

TOOTH, NONVITAL

The management of endodontically treated teeth using a Computer-Aided Design and Computer-Assisted Manufacturing/Computer-Aided Design and Computer-Integrated Manufacturing system. Foerster JG, et al. **Mil Med** 1999 Jan;164(1):37–40 (21 ref.)

REHABILITATION

Predictably restoring endodontically treated teeth. McLean A. **J Can Dent Assoc** 1998 Dec;64(11):782–7 (55 ref.)

TOOTH PREPARATION

INSTRUMENTATION

[Oscillating procedures in the preparation technic (I)] Hugo B. **Schweiz Monatsschr Zahnmed** 1999;109(2):140–60 (81 ref.) (Eng. Abstr.) **(Ger, Fre)**

METHODS

[Oscillating procedures in the preparation technic (II). Their development and application possibilities] Hugo B. **Schweiz Monatsschr Zahnmed** 1999;109(3):269–85 (42 ref.) (Eng. Abstr.) **(Ger, Fre)**

TOOTH PREPARATION, PROSTHODONTIC

see related
DENTAL CAVITY PREPARATION

INSTRUMENTATION

[Oscillating procedures in the preparation technic (I)] Hugo B. **Schweiz Monatsschr Zahnmed** 1999;109(2):140–60 (81 ref.) (Eng. Abstr.) **(Ger, Fre)**

TOOTH, PRIMARY see **TOOTH, DECIDUOUS**

TOOTH, PULPLESS see **TOOTH, NONVITAL**

TOOTH REMINERALIZATION

METHODS

[Factors that modify de- and remineralization in dental enamel from the aspect of caries susceptibility] Buczkowska-Radlińska J. **Ann Acad Med Stetin** 1999;Suppl 47:1–89 (221 ref.) (Eng. Abstr.) **(Pol)**

TOOTH ROOT

ANATOMY & HISTOLOGY

Mandibular first and second molar. The variability of roots and root canal system. Maggiore C, et al. **Minerva Stomatol** 1998 Sep;47(9):409–16 (43 ref.)

INJURIES

Diagnosis and management of teeth with vertical root fractures. Moule AJ, et al. **Aust Dent J** 1999 Jun; 44(2):75–87 (54 ref.)

TOOTH SUPPORTING STRUCTURES see **PERIODONTIUM**

TOOTH, UNERUPTED

A re-examination of the pre-eruptive and post-eruptive mechanism of the anti-caries effects of fluoride: is there any anti-caries benefit from swallowing fluoride? Limeback H. **Community Dent Oral Epidemiol** 1999 Feb;27(1):62–71 (35 ref.)

DIAGNOSIS

Localization of the unerupted maxillary canine: how to and when to. Jacobs SG. **Am J Orthod Dentofacial Orthop** 1999 Mar;115(3):314–22 (20 ref.)

THERAPY

Spontaneous uprighting of permanent tooth germs after elimination of local eruption obstacles. Wagner M, et al. **J Orofac Orthop** 1999;60(4):279–85 (8 ref.) **(Eng, Ger)**

TOOTH UPRIGHTING see **TOOTH MOVEMENT**

TOOTH, WISDOM see **MOLAR, THIRD**

TOOTHBRUSHING

Bright smiles, shining futures. Yehieli M, et al. **J Sch Health** 1999 Apr;69(4):162–4 (1 ref.)

TOOTHPASTE

ADVERSE EFFECTS

Factors contributing to adverse soft tissue reactions due to the use of tartar control toothpastes: report of a case and literature review. DeLattre VF. **J Periodontol** 1999 Jul; 70(7):803–7 (36 ref.)

TOPECTOMY see **PSYCHOSURGERY**

TOPOGRAPHIC BRAIN MAPPING see **BRAIN MAPPING**

TOPOGRAPHY, CORNEAL see **CORNEAL TOPOGRAPHY**

TOPOGRAPHY, MEDICAL

Geography and mental health: a review. Holley HL. **Soc Psychiatry Psychiatr Epidemiol** 1998 Nov; 33(11):535–42 (106 ref.)

TOPOTECAN

ADMINISTRATION & DOSAGE

Topotecan: what dose, what schedule, what route? [editorial; comment] O'Reilly S. **Clin Cancer Res** 1999 Jan;5(1):3–5 (21 ref.) Comment on: Clin Cancer Res 1999 Jan;5(1):69–75.

TOPOTECAN

PHARMACOLOGY

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Kollmannsberger C, et al. **Oncology** 1999;56(1):1-12 (99 ref.)

An overview of topoisomerase I-targeting agents. Arbuck SG, et al. **Semin Hematol** 1998 Jul;35(3 Suppl 4):3-12 (127 ref.)

Induction of apoptosis by topotecan: implications for the treatment of leukemia. Seiter K. **Semin Hematol** 1998 Jul; 35(3 Suppl 4):22-5 (24 ref.)

THERAPEUTIC USE

Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Cersosimo RJ. **Ann Pharmacother** 1998 Dec; 32(12):1334-43 (85 ref.)

Topotecan. A review of its potential in advanced ovarian cancer. Brogden RN, et al. **Drugs** 1998 Oct;56(4):709-23 (73 ref.)

Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Bookman MA. **Oncologist** 1999;4(2):87-94 (31 ref.)

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Kollmannsberger C, et al. **Oncology** 1999;56(1):1-12 (99 ref.)

Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes. Estey EH. **Oncology (Huntingt)** 1998 Nov;12(11A):81-6 (14 ref.)

An overview of topoisomerase I-targeting agents. Arbuck SG, et al. **Semin Hematol** 1998 Jul;35(3 Suppl 4):3-12 (127 ref.)

TORNADOES see **NATURAL DISASTERS**

TORQUE

Commentary: torque misuse revisited [letter; comment] Herzog W. **J Manipulative Physiol Ther** 1999 Jun; 22(5):347-8 (3 ref.) Comment on: J Manipulative Physiol Ther 1998 Nov-Dec;21(9):649-55.

TORSADES DE POINTES

Experimental models of torsade de pointes. Eckardt L, et al. **Cardiovasc Res** 1998 Jul;39(1):178-93 (246 ref.)

CHEMICALLY INDUCED

Exploring the hidden danger of noncardiac drugs [editorial; comment] Priori SG. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1114-6 (12 ref.) Comment on: J Cardiovasc Electrophysiol 1998 Oct;9(10):1109-13.

PHYSIOPATHOLOGY

The long QT syndrome and torsade de pointes. el-Sherif N, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 1):91-110 (75 ref.)

TORSION DYSTONIA see **DYSTONIA MUSCULORUM DEFORMANS**

TORTICOLLIS

[Cervical dystonia (spasmodic torticollis)] Nomoto M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):122-7 (32 ref.) **(Jpn)**

ETIOLOGY

[Recurrent torticollis due to cervical osteochondroma. Case report and review of the literature] Caso Martinez J, et al. **An Esp Pediatr** 1998 Aug;49(2):177-8 (13 ref.) **(Spa)**

[Calcification of the intervertebral disks in childhood as the cause of acute torticollis] Ferrer Ferrán J, et al. **An Esp Pediatr** 1999 Jun;50(6):607-9 (9 ref.) **(Spa)**

TORTURE

PSYCHOLOGY

The psychosocial effects of torture, mass human rights violations, and refugee trauma: toward an integrated conceptual framework. Silove D. **J Nerv Ment Dis** 1999 Apr;187(4):200-7 (68 ref.)

TORULA see **CRYPTOCOCCUS**

TORULOPSIS UTILIS see **CANDIDA**

TORULOSIS see **CRYPTOCOCCOSIS**

TOSPOVIRUS

ISOLATION & PURIFICATION

Tomato spotted wilt virus in ornamental plants, vegetables and weeds in the Czech Republic. Mertelík J, et al. **Acta Virol** 1998 Nov;42(5):347-51 (27 ref.)

TOSYL COMPOUNDS

THERAPEUTIC USE

Antileukotrienes and asthma: alternative or adjunct to inhaled steroids? Kavuru MS, et al. **Cleve Clin J Med** 1998 Nov-Dec;65(10):519-26 (25 ref.)

Montelukast and zafirlukast in asthma. **Drug Ther Bull** 1998 Sep;36(9):65-8 (13 ref.)

Leukotriene-receptor antagonists. Lipworth BJ. **Lancet** 1999 Jan 2;353(9146):57-62 (49 ref.)

Leukotriene antagonism in asthma and rhinitis. Lane SJ. **Respir Med** 1998 Jun;92(6):795-809 (150 ref.)

TOTAL BODY CLEARANCE RATE see **METABOLIC CLEARANCE RATE**

TOTAL BODY IRRADIATION see **WHOLE-BODY IRRADIATION**

TOTAL LYMPHOCYTE COUNT see **LYMPHOCYTE COUNT**

TOTAL MASTECTOMY see **MASTECTOMY, SIMPLE**

TOTAL PARENTERAL NUTRITION see **PARENTERAL NUTRITION, TOTAL**

TOTAL QUALITY MANAGEMENT

see related
QUALITY CONTROL

Web applications for total quality management. Golaz O, et al. **Clin Chem Lab Med** 1999 May;37(5):487-93 (11 ref.)

Improving the quality of care for children in health systems. Homer CJ, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1091-109 (58 ref.)

Achievable benchmarks of care: the ABCs of benchmarking. Weissman NW, et al. **J Eval Clin Pract** 1999 Aug; 5(3):269-81 (75 ref.)

[Quality management in the German health care system] Bangha E, et al. **Hautarzt** 1999 May;50(5):330-7 (53 ref.) (Eng. Abstr.) **(Ger)**

[Quality management of early clinical treatment of severely injured patients] Nast-Kolb D, et al. **Unfallchirurg** 1999 May;102(5):338-46 (52 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Reengineering: deja vu all over again. Arndt M, et al. **Health Care Manage Rev** 1998 Summer;23(3):58-66 (65 ref.)

LEGISLATION & JURISPRUDENCE

The role of regulation in quality improvement [see comments] Brennan TA. **Milbank Q** 1998;76(4):709-31, 512 (49 ref.) Comment in: Milbank Q 1998 ;76(4):745-7.

METHODS

Improving the utilization of clinical laboratory tests. Wu AH. **J Eval Clin Pract** 1998 Aug;4(3):171-81 (43 ref.)

The utility of decision support, clinical guidelines, and financial incentives as tools to achieve improved clinical performance. Goldfarb S. **Jt Comm J Qual Improv** 1999 Mar;25(3):137-44 (19 ref.)

Vital records for quality improvement. Gould JB. **Pediatrics** 1999 Jan;103(1 Suppl E):278-90 (39 ref.)

ORGANIZATION & ADMINISTRATION

Interventions to improve the delivery of preventive services in primary care. Hulscher ME, et al. **Am J Public Health** 1999 May;89(5):737-46 (83 ref.)

Intensivists for the intensive care unit--do they make a difference? [editorial] Lew TW, et al. **Ann Acad Med Singapore** 1998 May;27(3):305-7 (20 ref.)

The potential for improved teamwork to reduce medical errors in the emergency department. The MedTeams Research Consortium [see comments] Risser DT, et al. **Ann Emerg Med** 1999 Sep;34(3):373-83 (25 ref.) Comment in: Ann Emerg Med 1999 Sep;34(3):370-2.

Measuring the benefits of clinical decision support: return on investment. Rosenstein AH. **Health Care Manage Rev** 1999 Spring;24(2):32-43 (26 ref.)

Improving clinical outcome in bacteremia. Herchline T, et al. **J Eval Clin Pract** 1998 Aug;4(3):191-5 (22 ref.)

Collaboration in improving care for patients: how can we find out what we haven't been able to figure out yet? Batalden PB, et al. **Jt Comm J Qual Improv** 1998 Oct; 24(10):609-18 (39 ref.)

Overview: working inside, outside, and side by side to improve the quality of health care. Wasson JH, et al. **Jt Comm J Qual Improv** 1998 Oct;24(10):513-7 (7 ref.)

Are ethics committees retarding the improvement of health services in Australia? [see comments] Jamrozik K, et al. **Med J Aust** 1999 Jan 4;170(1):26-8 (10 ref.) Comment in: Med J Aust 1999 Jan 4;170(1):9-10. Comment in: Med J Aust 1999 Jul 5;171(1):51. Comment in: Med J Aust 1999 Jul 5;171(1):51-2. Comment in: Med J Aust 1999 Jul 5;171(1):52. Comment in: Med J Aust 1999 Jul 5;171(1):53.

Clinical pathways [editorial; comment] [see comments] Kitchiner DJ, et al. **Med J Aust** 1999 Jan 18;170(2):54-5 (12 ref.) Comment on: Med J Aust 1999 Jan 18;170(2):59-62. Comment in: Med J Aust 1999 Jun 7;170(11):568.

Total quality management in behavioral health care. Sluyter GV. **New Dir Ment Health Serv** 1998 Fall;(79):35-43 (29 ref.)

Total quality strategy in the formative process of the occupational physician. Franco G, et al. **Scand J Work Environ Health** 1999 Apr;25(2):153-6 (12 ref.)

STANDARDS

Overview of quality measurement and improvement. Loewenstein JI. **Int Ophthalmol Clin** 1998 Summer; 38(3):59-68 (33 ref.)

UTILIZATION

A report card on continuous quality improvement [see comments] Blumenthal D, et al. **Milbank Q** 1998; 76(4):625-48, 511 (29 ref.) Comment in: Milbank Q 1998 ;76(4):749-53. Comment in: Milbank Q 1998 ;76(4):755-7.

Assessing the impact of continuous quality improvement on clinical practice: what it will take to accelerate progress [see comments] Shortell SM, et al. **Milbank Q** 1998; 76(4):593-624, 510 (106 ref.) Comment in: Milbank Q 1998 ;76(4):755-7.

TOUCH

Cutaneous-evoked tinnitus. II. Review Of neuroanatomical, physiological and functional imaging studies. Cacace AT, et al. **Audiol Neurootol** 1999 Sep-Oct;4(5):258-68 (118 ref.)

PHYSIOLOGY

Somesthesis. Craig JC, et al. **Annu Rev Psychol** 1999; 50:305-31 (210 ref.)

The world of touch--from evoked potentials to conscious perception. McComas AJ. **Can J Neurol Sci** 1999 Feb; 26(1):7-17 (58 ref.)

Dynamics of effortful touch and interlimb coordination. Turvey MT. **J Biomech** 1998 Oct;31(10):873-82 (74 ref.)

Sensory input and control of grip. Johansson RS. **Novartis Found Symp** 1998;218:45-59; discussion 59-63 (40 ref.)

Topographical features of cutaneous tactile hypoesthetic and hyperesthetic abnormalities in chronic pain. Moriwaki K, et al. **Pain** 1999 May;81(1-2):1-6 (43 ref.)

TOURETTE SYNDROME

Gilles de la Tourette syndrome. Arzimanoglou AA. **J Neurol** 1998 Dec;245(12):761-5 (17 ref.)

[Gilles de la Tourette syndrome (TS)] Nomura Y. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):118-21 (13 ref.) **(Jpn)**

DIAGNOSIS

Recognition and management of Tourette's syndrome and tic disorders. Bagheri MM, et al. **Am Fam Physician** 1999 Apr 15;59(8):2263-72, 2274 (32 ref.)

ETIOLOGY

Tourette's and comorbid syndromes: obsessive compulsive and attention deficit hyperactivity disorder. A common etiology? Sheppard DM, et al. **Clin Psychol Rev** 1999 Aug; 19(5):531-52 (133 ref.)

PHYSIOPATHOLOGY

Tic disorders: new developments in Tourette syndrome and related disorders. Robertson MM, et al. **Curr Opin Neurol** 1998 Aug;11(4):373-80 (94 ref.)

THERAPY

Recognition and management of Tourette's syndrome and tic disorders. Bagheri MM, et al. **Am Fam Physician** 1999 Apr 15;59(8):2263-72, 2274 (32 ref.)

TOURETTE'S DISORDER see **TOURETTE SYNDROME**

TOURNIQUET PAIN TEST see **PAIN MEASUREMENT**

TOURNIQUETS

Pneumatic ankle tourniquets: physiological factors related to minimal arterial occlusion pressure. Massey KA, et al. **J Foot Ankle Surg** 1999 Jul-Aug;38(4):256-63; discussion 306-7 (42 ref.)

TOXIC SHOCK SYNDROME see **SHOCK, SEPTIC**

TOXIC SUBSTANCES, ENVIRONMENTAL see **HAZARDOUS SUBSTANCES**

TOXICITY TESTS

Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment. Haddad S, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1377-84 (31 ref.)

Fish cell lines as a tool in aquatic toxicology. Segner H. **EXS** 1998;86:1-38 (207 ref.)

Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Lake BG. **Food Chem Toxicol** 1999 Apr;37(4):423-53 (210 ref.)

A critical review of the assessment of eye irritation potential

using the Draize rabbit eye test. York M, et al. **J Appl Toxicol** 1998 Jul–Aug;18(4):233–40 (25 ref.)
Preclinical evaluation of radiopharmaceutical toxicological prerequisites. Marzin D. **Nucl Med Biol** 1998 Nov; 25(8):733–6 (10 ref.)
Expanded clinical observations in toxicity studies: historical perspectives and contemporary issues. Ross JF, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):17–26 (50 ref.)
The duration of non-rodent toxicity studies for pharmaceuticals. DeGeorge JJ, et al. **Toxicol Sci** 1999 Jun; 49(2):143–55 (6 ref.)
Deer velvet antler: some unanswered questions on toxicology. Dalefield RR, et al. **Vet Hum Toxicol** 1999 Feb; 41(1):39–41 (25 ref.)
[Toxicity evaluation of pharmaceuticals and mechanisms of their effects] Hayashi Y, et al. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):19–30 (37 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part I: The reproduction and fertility testing guidelines. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):543–53 (75 ref.)
Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part II: The developmental toxicity testing guideline. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):554–63 (67 ref.)
Tetrahymena pyriformis: a tool for toxicological studies. A review. Sauvant MP, et al. **Chemosphere** 1999 Mar; 38(7):1631–69 (177 ref.)
Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. Yang RS, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1385–93 (65 ref.)
Applications of reconstructed skin models in pharmaco-toxicological trials. Damour O, et al. **Med Biol Eng Comput** 1998 Nov;36(6):825–32 (71 ref.)
Tumor models: assessing toxicity in efficacy studies. Arp LH. **Toxicol Pathol** 1999 Jan–Feb;27(1):121–2 (7 ref.)
Stimulating research to improve the scientific basis of risk assessment. Conolly RB, et al. **Toxicol Sci** 1999 May; 49(1):1–4 (11 ref.)
Altered cytokine (receptor) mRNA expression as a tool in immunotoxicology. Vandebriel RJ, et al. **Toxicology** 1998 Sep 1;130(1):43–67 (225 ref.)
[Key points in applying statistics to toxicological tests] Hamada C. **J Toxicol Sci** 1998 Dec;23(5):App.185–9 (5 ref.) **(Jpn)**
[Endocrine disrupting substances (continued)--characteristic actions and test methods] Inoue T, et al. **J Toxicol Sci** 1998 Dec;23(5):App.191–9 (16 ref.) **(Jpn)**
[Studies on development and improvement of toxicity guidelines conducted at the Biological Safety Research Center] Inoue T, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):149–52 (0 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

[The role of general pharmacological studies and pharmacokinetics in the evaluation of drugs (1): The role of general/safety pharmacology studies in the development of pharmaceuticals: international harmonization of guidelines] Fujimori K. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):31–40 (37 ref.) (Eng. Abstr.) **(Jpn)**

TOXICOKINETICS see **PHARMACOKINETICS**

TOXICOLOGY

see related
POISONS

Evaluation (not validation) of quantitative models. Oreskes N. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1453–60 (62 ref.)
The internal critical level concept of nonspecific toxicity. Chaisuksant Y, et al. **Rev Environ Contam Toxicol** 1999; 162:1–41 (196 ref.)
Clinical assessment of DNA analysis for toxicology. Weedn VW. **Ther Drug Monit** 1998 Oct;20(5):532–8 (8 ref.)
Alternatives for morphometric and stereologic analysis in toxicopathology. Collan Y. **Toxicol Lett** 1998 Dec 28; 102–103:393–7 (34 ref.)
Recent developments in analytical toxicology: for better or for worse. de Zeeuw RA. **Toxicol Lett** 1998 Dec 28; 102–103:103–8 (25 ref.)
Use of biomarkers--new frontiers in occupational toxicology and epidemiology. Vainio H. **Toxicol Lett** 1998 Dec 28; 102–103:581–9 (63 ref.)
The pathologist and toxicologist in pharmaceutical product discovery. Alden CL, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):104–6 (4 ref.)
Revolution through genomics in investigative and discovery toxicology. Rodi CP, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):107–10 (12 ref.)
Concise review of the glutathione S-transferases and their significance to toxicology. Eaton DL, et al. **Toxicol Sci** 1999 Jun;49(2):156–64 (71 ref.)
[Effects of chemical mixtures on embryonic development: examples of experimental models and problems in risk assessment] Ricciardi C, et al. **Ann Ist Super Sanita** 1998; 34(4):519–27 (24 ref.) (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Transgenic animal models for mutagenesis studies: role in mutagenesis research and regulatory testing. MacGregor JT. **Environ Mol Mutagen** 1998;32(2):106–9 (26 ref.)
Regulatory implications of hormesis. Foran J. **Hum Exp Toxicol** 1998 Aug;17(8):441–3 (3 ref.)
Implications of the hormesis hypothesis for risk perception and communication. Renn O. **Hum Exp Toxicol** 1998 Aug; 17(8):431–8 (37 ref.)

METHODS

Current and future contributions of transgenic mice to the analysis of germline toxicology. Collick A, et al. **Adv Exp Med Biol** 1998;444:119–25; discussion 125–7 (11 ref.)
Evaluation of the placenta: suggestions for a greater role in developmental toxicology. Maranghi F, et al. **Adv Exp Med Biol** 1998;444:129–36 (23 ref.)
An overview of current in vivo test procedures to reproductive toxicology. Nunziata A. **Adv Exp Med Biol** 1998;444:171–83 (0 ref.)
Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology. Gillam EM. **Clin Exp Pharmacol Physiol** 1998 Nov; 25(11):877–86 (74 ref.)
Development of toxicity criteria for petroleum hydrocarbon fractions in the Petroleum Hydrocarbon Criteria Working Group approach for risk-based management of total petroleum hydrocarbons in soil. Twerdok LE. **Drug Chem Toxicol** 1999 Feb;22(1):275–91 (31 ref.)
Critical analysis of methods for assessment of predicted no-effect concentration. Roman G, et al. **Ecotoxicol Environ Saf** 1999 Jun;43(2):117–25 (29 ref.)
Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: a pharmaceutical industry perspective. Krishna G, et al. **Environ Mol Mutagen** 1998;32(2):115–20 (33 ref.)
Genetically modified animals in pharmacological research: future trends. Rudolph U, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):327–37 (87 ref.)
Tree-type algorithm for statistical analysis in chronic toxicity studies. Hamada C, et al. **J Toxicol Sci** 1998 Aug; 23(3):173–81 (15 ref.)
Microarrays and toxicology: the advent of toxicogenomics. Nuwaysir EF, et al. **Mol Carcinog** 1999 Mar;24(3):153–9 (48 ref.)
Correlative and mechanistic QSAR models in toxicology. Lipnick RL. **SAR QSAR Environ Res** 1999;10(2–3):239–48 (21 ref.)
Applications of the case/multicase SAR method to environmental and public health situations. Rosenkranz HS, et al. **SAR QSAR Environ Res** 1999;10(2–3):263–76 (34 ref.)
Development, characterization and application of predictive-toxicology models. Rosenkranz HS, et al. **SAR QSAR Environ Res** 1999;10(2–3):277–98 (50 ref.)
Biochemical and molecular neurotoxicology: relevance to biomarker development, neurotoxicity testing and risk assessment. Costa LG. **Toxicol Lett** 1998 Dec 28; 102–103:417–21 (19 ref.)
Biological monitoring in occupational and environmental toxicology. Mutti A. **Toxicol Lett** 1999 Sep 5; 108(2–3):77–89 (52 ref.)
Testing strategies in immunotoxicology. Pallardy M, et al. **Toxicol Lett** 1998 Dec 28;102–103:257–60 (17 ref.)
Concise review: gene expression applied to toxicology. Farr S, et al. **Toxicol Sci** 1999 Jul;50(1):1–9 (56 ref.)
Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential. Rockett JC, et al. **Xenobiotica** 1999 Jul;29(7):655–91 (123 ref.)
[The role of laboratory methods in clinical and forensic toxicology] Klys M. **Przegl Lek** 1999;56(6):455–8 (16 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Stereochemical origin of some clinically significant drug safety concerns: lessons for future drug development [see comments] Shah RR, et al. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep; 17(2–3):145–90 (147 ref.) Comment in: Adverse Drug React Toxicol Rev 1998 Jun–Sep;17(2–3):60–2.
[Toxicology of reproduction: predictive value of experimental models. Round Table No 1 at Giens XIII] Guittin P, et al. **Therapie** 1998 Jul–Aug;53(4):355–63 (39 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Toxicology of chemical mixtures: international perspective. Feron VJ, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1281–9 (111 ref.)
Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential. Rockett JC, et al. **Xenobiotica** 1999 Jul;29(7):655–91 (123 ref.)

TOXIN-ANTIBODY CONJUGATES see **IMMUNOTOXINS**

TOXIN-ANTIBODY HYBRIDS see **IMMUNOTOXINS**

TOXIN CARRIERS see **IMMUNOTOXINS**

TOXIN CONJUGATES see **IMMUNOTOXINS**

TOXINS

ADVERSE EFFECTS

Drugs and toxins: fact and fancy. Bernstein RM. **Curr Opin Rheumatol** 1999 Jan;11(1):79–82 (26 ref.)
Drugs and toxins associated with myopathies. Pascuzzi RM. **Curr Opin Rheumatol** 1998 Nov;10(6):511–20 (64 ref.)

BIOSYNTHESIS

Why do microbes have toxins? Williams PH, et al. **Soc Appl Bacteriol Symp Ser** 1998;27:1S–6S (25 ref.)

BLOOD

Genesis of the uraemic syndrome: role of uraemic toxins [editorial] Hörl WH. **Wien Klin Wochenschr** 1998 Aug 21; 110(15):511–20 (125 ref.)
The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Kraus LM, et al. **Wien Klin Wochenschr** 1998 Aug 21;110(15):521–30 (97 ref.)
[Multiple chemical sensitivity: a new type of toxicity?] Gralewicz S. **Med Pr** 1998;49(5):473–81 (42 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Activation of toxin ADP-ribosyltransferases by eukaryotic ADP-ribosylation factors. Moss J, et al. **Mol Cell Biochem** 1999 Mar;193(1–2):153–7 (30 ref.)
Recent advances in chemical ecology. Harborne JB. **Nat Prod Rep** 1999 Aug;16(4):509–23 (172 ref.)

PHARMACOLOGY

Insect cytochromes P450: diversity, insecticide resistance and tolerance to plant toxins. Scott JG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):147–55 (74 ref.)
The nutrient-toxin dosage continuum in human evolution and modern health. Gerber LM, et al. **Q Rev Biol** 1999 Sep;74(3):273–89 (82 ref.)
[Endocrine disrupting substances (continued)--characteristic actions and test methods] Inoue T, et al. **J Toxicol Sci** 1998 Dec;23(5):App.191–9 (16 ref.) **(Jpn)**

POISONING

A review of the toxicosis and biological properties of the genus Eupatorium. Sharma OP, et al. **Nat Toxins** 1998; 6(1):1–14 (158 ref.)

TOXICITY

Food toxins, ampa receptors, and motor neuron diseases. Spencer PS. **Drug Metab Rev** 1999 Aug;31(3):561–87 (99 ref.)
Protein toxins produced by pathogenic vibrios. Shinoda S. **J Nat Toxins** 1999 Jun;8(2):259–69 (78 ref.)
Biological factors which may influence an older child's or adolescent's responses to toxic chemicals. Bruckner JV, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 1):158–64 (50 ref.)

TOXINS, CHIMERIC see **IMMUNOTOXINS**

TOXINS, TARGETED see **IMMUNOTOXINS**

TOXOCARA CANIS

[The association between human toxocariasis and pyogenic abscesses] Rayes AA, et al. **Rev Soc Bras Med Trop** 1999 Jul–Aug;32(4):425–38 (110 ref.) (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

[Toxocariasis caused by Toxocara canis: clinico-epidemiological aspects] Minvielle MC, et al. **Enferm Infecc Microbiol Clin** 1999 Jun–Jul;17(6):300–6 (90 ref.) **(Spa)**

TOXOCARIASIS

[Toxocariasis caused by Toxocara canis: clinico-epidemiological aspects] Minvielle MC, et al. **Enferm Infecc Microbiol Clin** 1999 Jun–Jul;17(6):300–6 (90 ref.) **(Spa)**

COMPLICATIONS

[Myotomy for esophageal muscular hypertrophy with eosinophil infiltration of the esophagus associated with toxocariasis revealed by esophageal motor disorder] D'Alteroche L, et al. **Gastroenterol Clin Biol** 1998 May; 22(5):541–5 (28 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Laboratory diagnosis of protozoan and parasitic infections. 2. Helminthiasis. h. Toxocariasis] Uga S. **Rinsho Byori** 1998 Nov;Suppl 108:253–7 (5 ref.) **(Jpn)**

TOXOIDS

see related
TOXINS

TOXOPLASMA

GENETICS

Toxoplasma gondii: ESTs and gene discovery. Ajioka JW. **Int J Parasitol** 1998 Jul;28(7):1025–31 (6 ref.)

GROWTH & DEVELOPMENT

Advances in the life cycle of Toxoplasma gondii. Dubey JP. **Int J Parasitol** 1998 Jul;28(7):1019–24 (38 ref.)

IMMUNOLOGY

The role of dendritic cells in the initiation of host resistance to Toxoplasma gondii. Sher A, et al. **Adv Exp Med Biol** 1998;452:103–10 (23 ref.)

ISOLATION & PURIFICATION

Disseminated toxoplasmosis after liver transplantation: case report and review. Lappalainen M, et al. **Clin Infect Dis** 1998 Nov;27(5):1327–8 (5 ref.)

Polymerase chain reaction approaches for the detection of Neospora caninum and Toxoplasma gondii. Ellis JT. **Int J Parasitol** 1998 Jul;28(7):1053–60 (67 ref.)

PHYSIOLOGY

The use of confocal laser scanning microscopy to analyze the process of parasitic protozoon–host cell interaction. de-Souza W, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1459–70 (49 ref.)

TOXOPLASMA GONDII see **TOXOPLASMA**

TOXOPLASMA GONDII INFECTION see **TOXOPLASMOSIS**

TOXOPLASMOSIS

Toxoplasmosis. Beazley DM, et al. **Semin Perinatol** 1998 Aug; 22(4):332–8 (42 ref.)

[Toxoplasmosis] Kano S. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):164–6 (3 ref.) **(Jpn)**

[Toxoplasmic lymphadenitis] Kobayashi H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):335–7 (16 ref.) **(Jpn)**

COMPLICATIONS

TORCH testing in HIV-infected women. Helfgott A. **Clin Obstet Gynecol** 1999 Mar;42(1):149–62; quiz 174–5 (69 ref.)

DIAGNOSIS

Disseminated toxoplasmosis after liver transplantation: case report and review. Lappalainen M, et al. **Clin Infect Dis** 1998 Nov;27(5):1327–8 (5 ref.)

Diagnosis of perinatal TORCH infections. Newton ER. **Clin Obstet Gynecol** 1999 Mar;42(1):59–70; quiz 174–5 (32 ref.)

Polymerase chain reaction approaches for the detection of Neospora caninum and Toxoplasma gondii. Ellis JT. **Int J Parasitol** 1998 Jul;28(7):1053–60 (67 ref.)

Opportunistic infections of the central nervous system during HIV-1 infection (emphasis on cytomegalovirus disease). Roullet E. **J Neurol** 1999 Apr;246(4):237–43 (55 ref.)

[Laboratory diagnosis of protozoan and parasitic infections. 1. Protozoan infections. f. Toxoplasmosis] Yano A. **Rinsho Byori** 1998 Nov;Suppl 108:204–9 (9 ref.) **(Jpn)**

DRUG THERAPY

Perinatal cytomegalovirus and toxoplasmosis: challenges of antepartum therapy. Piper JM, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):81–96; quiz 174–5 (74 ref.)

[Empirical anti-toxoplasma therapy in cerebral AIDS and Chagas disease. Presentation of 2 cases, review of the literature and proposal of an algorithm] Montero A, et al. **Medicina (B Aires)** 1998;58(5 Pt 1):504–6 (19 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Mother–child pass in Austria and primary toxoplasmosis infections in pregnant women. Moese JR, et al. **Cent Eur J Public Health** 1998 Nov;6(4):261–4 (9 ref.)

IMMUNOLOGY

The role of dendritic cells in the initiation of host resistance to Toxoplasma gondii. Sher A, et al. **Adv Exp Med Biol** 1998;452:103–10 (23 ref.)

Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Denkers EY, et al. **Clin Microbiol Rev** 1998 Oct;11(4):569–88 (239 ref.)

[Toxoplasmosis and immunosuppression] Djurković-Djaković O. **Srp Arh Celok Lek** 1998 May–Jun; 126(5–6):197–203 (48 ref.) (Eng. Abstr.) **(Scc)**

PREVENTION & CONTROL

Mother–child pass in Austria and primary toxoplasmosis infections in pregnant women. Moese JR, et al. **Cent Eur J Public Health** 1998 Nov;6(4):261–4 (9 ref.)

TOXOPLASMOSIS, ANIMAL

PARASITOLOGY

Advances in the life cycle of Toxoplasma gondii. Dubey JP. **Int J Parasitol** 1998 Jul;28(7):1019–24 (38 ref.)

TOXOPLASMOSIS, CEREBRAL

[Cerebral toxoplasmosis] Ribera Pascuet E, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:45–51 (59 ref.) (Eng. Abstr.) **(Spa)**

TOXOPLASMOSIS, CONGENITAL

[TORCH syndrome] Hidaka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):85–8 (7 ref.) **(Jpn)**

COMPLICATIONS

Fetal cataract in congenital toxoplasmosis. Pedreira DA, et al. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):266–7 (10 ref.)

DIAGNOSIS

Is routine antenatal toxoplasmosis screening justified in the United States? Statistical considerations in the application of medical screening tests. Mittendorf R, et al. **Clin Obstet Gynecol** 1999 Mar;42(1):163–73; quiz 174–5 (16 ref.)

[Problems of congenital toxoplasmosis. Evolution over four decades] Couvreur J. **Presse Med** 1999 Apr 10;28(14):753–7 (27 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Fetal cataract in congenital toxoplasmosis. Pedreira DA, et al. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):266–7 (10 ref.)

TOXOPLASMOSIS, OCULAR

DRUG THERAPY

Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Bosch-Driessen EH, et al. **Br J Ophthalmol** 1998 Aug;82(8):858–60 (36 ref.)

TOYS see **PLAY AND PLAYTHINGS**

TP-5 see **THYMOPENTIN**

TP53 GENES see **GENES, P53**

TP53 PROTEIN see **PROTEIN P53**

TP RECEPTORS see **RECEPTORS, THROMBOXANE**

TPA ANTIGEN see **TISSUE POLYPEPTIDE ANTIGEN**

TR ALPHA see **RECEPTORS, THYROID HORMONE**

TR BETA see **RECEPTORS, THYROID HORMONE**

TRABECULAR MESHWORK

ANATOMY & HISTOLOGY

Functional morphology of the trabecular meshwork in primate eyes. Lütjen-Drecoll E. **Prog Retin Eye Res** 1999 Jan;18(1):91–119 (136 ref.)

DRUG EFFECTS

Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Wordinger RJ, et al. **Prog Retin Eye Res** 1999 Sep;18(5):629–67 (224 ref.)

PHYSIOLOGY

Functional morphology of the trabecular meshwork in primate eyes. Lütjen-Drecoll E. **Prog Retin Eye Res** 1999 Jan;18(1):91–119 (136 ref.)

TRABECULECTOMY

ADVERSE EFFECTS

Endocapsular hematoma: report of a case following glaucoma surgery in a pseudophakic eye. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):389–93 (22 ref.)

Three types of retinal bleeding as a complication of hypotony after trabeculectomy. Suzuki R, et al. **Ophthalmologica** 1999;213(2):135–8 (11 ref.)

Control of intraocular pressure after trabeculectomy. Haynes WL, et al. **Surv Ophthalmol** 1999 Jan–Feb;43(4):345–55 (82 ref.)

INSTRUMENTATION

[Trabeculotomy, deep sclerectomy and viscocanalostomy. Non-fistulating microsurgical glaucoma operation ab externo] Schwenn O, et al. **Ophthalmologe** 1998 Dec; 95(12):835–43 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Reaffirming the role of the laser in glaucoma management [editorial] Higginbotham EJ. **Arch Ophthalmol** 1999 Aug; 117(8):1075–6 (13 ref.)

Nonpenetrating trabecular surgery: it's worth the change [editorial; comment] Sourdille P. **J Cataract Refract Surg** 1999 Mar;25(3):298–300 (8 ref.) Comment on: J Cataract Refract Surg 1999 Mar;25(3):316–22. Comment on: J Cataract Refract Surg 1999 Mar;25(3):323–31. Comment on: J Cataract Refract Surg 1999 Mar;25(3):332–9. Comment on: J Cataract Refract Surg 1999 Mar;25(3):340–6.

TRABECULOPLASTY see **TRABECULECTOMY**

TRACE ELEMENTS

see related
MICRONUTRIENTS

ADMINISTRATION & DOSAGE

The effect of essentiality on risk assessment. Becking GC. **Biol Trace Elem Res** 1998 Winter;66(1–3):423–38 (23 ref.)

Technical aspects of trace element supplementation. Hardy G, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul; 2(4):277–85 (75 ref.)

Compatibility and stability of additives in parenteral nutrition admixtures. Allwood MC, et al. **Nutrition** 1998 Sep; 14(9):697–706 (78 ref.)

ADVERSE EFFECTS

Trace element inputs into soils by anthropogenic activities and implications for human health. Senesi GS, et al. **Chemosphere** 1999 Jul;39(2):343–77 (111 ref.)

ANALYSIS

Advances in instrumental methods for the measurement and speciation of trace metals. Savory J, et al. **Ann Clin Lab Sci** 1999 Apr–Jun;29(2):118–26 (47 ref.)

Trace elements in coal: environmental and health significance. Finkelman RB. **Biol Trace Elem Res** 1999 Mar; 67(3):197–204 (22 ref.)

Trace element inputs into soils by anthropogenic activities and implications for human health. Senesi GS, et al. **Chemosphere** 1999 Jul;39(2):343–77 (111 ref.)

Technical and clinical aspects of spectrometric analysis of trace elements in clinical samples. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):615–29 (40 ref.)

Organochlorine residues and elemental contaminants in U.S. freshwater fish, 1976–1986: National Contaminant Biomonitoring Program. Schmitt CJ, et al. **Rev Environ Contam Toxicol** 1999;162:43–104 (160 ref.)

BLOOD

Concentrations of essential trace elements in maternal serum and the effect on birth weight and newborn body mass index in sub-arctic and arctic populations of Norway and Russia. Odland JO, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):605–14 (44 ref.)

DEFICIENCY

[Disorders of trace element homeostasis] Henning BF, et al. **Internist (Berl)** 1998 Aug;39(8):831–9 (47 ref.) **(Ger)**

METABOLISM

Genetic determinants of trace element metabolism. Templeton DM. **Ann Clin Lab Sci** 1999 Jan–Mar; 29(1):24–32 (76 ref.)

PHARMACOKINETICS

Trace element trophic transfer in aquatic organisms: a critique of the kinetic model approach. Reinfelder JR, et al. **Sci Total Environ** 1998 Aug 28;219(2–3):117–35 (124 ref.)

PHARMACOLOGY

Effect of antioxidant trace elements on the response of cardiac tissue to oxidative stress. Barandier C, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:138–55 (84 ref.)

PHYSIOLOGY

Review of the scientific basis for establishing the essentiality of trace elements. Mertz W. **Biol Trace Elem Res** 1998 Winter;66(1–3):185–91 (15 ref.)

Trace elements and apoptosis. Koudrine AV. **J Trace Elem Med Biol** 1998 Jul;12(2):65–76 (116 ref.)

STANDARDS

The effect of essentiality on risk assessment. Becking GC. **Biol Trace Elem Res** 1998 Winter;66(1–3):423–38 (23 ref.)

THERAPEUTIC USE

[Vitamins and trace elements in abnormal hemostasis] Khoksi DK. **Klin Med (Mosk)** 1998;76(8):15–8 (29 ref.) **(Rus)**

TRACHEA

see related
ANESTHESIA, INTRATRACHEAL
INTUBATION, INTRATRACHEAL
TRACHEOSTOMY
TRACHEOTOMY

Foley catheter technique for removal of a tracheal foreign body in a cat. Pratschke KM, et al. **Vet Rec** 1999 Feb 13; 144(7):181–2 (16 ref.)

[Tracheotomy in the child with a foreign body in the lower respiratory passages] Diop EM, et al. **Dakar Med** 1997; 42(2):165–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[The current prospects for tracheal prostheses (editorial)] Beltrami V. **G Chir** 1998 Oct;19(10):373–6 (11 ref.) **(Ita)**

[Torpid pneumonia secondary to the aspiration of a phonation prosthesis (letter)] García Gasalla M, et al. **Rev Clin Esp** 1999 Jul;199(7):481–2 (10 ref.) **(Spa)**

ABNORMALITIES

Tracheal agenesis revisited: analysis of associated anomalies. Evans JA, et al. **Am J Med Genet** 1999 Feb 19;82(5):415–22 (48 ref.)

The near complete tracheal ring deformity. Faust RA, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 2;45(2):171–6 (20 ref.)

Congenital laryngotracheoesophageal cleft. Carr MM, et al. **J Otolaryngol** 1999 Apr;28(2):112–7 (45 ref.)

BLOOD SUPPLY

Chronic inflammation: links with angiogenesis and wound healing [comment] Majno G. **Am J Pathol** 1998 Oct; 153(4):1035–9 (27 ref.) Comment on: Am J Pathol 1998 Oct;153(4):1099–112.

DRUG EFFECTS

Muscarinic receptor antagonists. Watson N, et al. **Pulm Pharmacol Ther** 1999;12(2):115–8 (41 ref.)

INJURIES

Surgical emphysema following percutaneous tracheostomy. Douglas WE, et al. **Anaesth Intensive Care** 1999 Feb; 27(1):69–72 (12 ref.)

Nonsurgical treatment of a severe tracheal rupture after endotracheal intubation. Zettl R, et al. **Crit Care Med** 1999 Mar;27(3):661–3 (9 ref.)

Airway rupture from double-lumen tubes. Fitzmaurice BG, et al. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):322–9 (74 ref.)

Tracheobronchial avulsion and associated innominate artery injury in blunt trauma: case report and literature review. Hemmila MR, et al. **J Trauma** 1999 Mar;46(3):505–12 (31 ref.)

Partial transsection of the neonatal trachea. Krause MF, et al. **Resuscitation** 1998 Jul;38(1):43–6 (17 ref.)

[Fistula between the trachea and innominate artery—a rare complication following tracheostenosis treatment with silastic tubes] Grundmann T, et al. **Laryngorhinootologie** 1999 Feb;78(2):91–6 (45 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Ca2+-activated Cl- channels: focus on "molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland". Cuppoletti J, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1259–60 (19 ref.)

PHYSIOPATHOLOGY

Afferent receptors in the airways and cough. Widdicombe JG. **Respir Physiol** 1998 Oct;114(1):5–15 (57 ref.)

SURGERY

Tracheal resection and reconstruction. Pinsonneault C, et al. **Can J Anaesth** 1999 May;46(5 Pt 1):439–55 (74 ref.)

Long-segment congenital tracheal stenosis: treatment by slide-tracheoplasty. Lang FJ, et al. **J Pediatr Surg** 1999 Aug;34(8):1216–22 (22 ref.)

Current approaches in tracheal surgery. Filler RM. **Pediatr Pulmonol Suppl** 1999;18:105–8 (11 ref.)

TRACHEAL CYST see **MEDIASTINAL CYST**

TRACHEAL DISEASES

CONGENITAL

Current approaches in tracheal surgery. Filler RM. **Pediatr Pulmonol Suppl** 1999;18:105–8 (11 ref.)

[Genetic aspects of congenital pathology of the larynx and trachea] Maslova IV, et al. **Vestn Otorinolaringol** 1999; (2):30–3 (17 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Airway coccidioidomycosis—report of cases and review. Polesky A, et al. **Clin Infect Dis** 1999 Jun;28(6):1273–80 (34 ref.)

Intralaryngotracheal thyroid—ectopic thyroid or invasive carcinoma? See AC, et al. **J Laryngol Otol** 1998 Jul; 112(7):673–6 (26 ref.)

Epidermolysis bullosa of the head and neck: a case report of laryngotracheal involvement and 10-year review of cases at the Hospital for Sick Children. Liu RM, et al. **J Otolaryngol** 1999 Apr;28(2):76–82 (17 ref.)

GENETICS

[Genetic aspects of congenital pathology of the larynx and trachea] Maslova IV, et al. **Vestn Otorinolaringol** 1999; (2):30–3 (17 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Benign intratracheal thyroid: a possible cause for preoperative overstaging. Brandwein M, et al. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1266–9 (16 ref.)

SURGERY

Tracheal resection and reconstruction: a review of 82 patients. Sharpe DA, et al. **Eur J Cardiothorac Surg** 1996; 10(12):1040–5; discussion 1045–6 (23 ref.)

Epidermolysis bullosa of the head and neck: a case report of laryngotracheal involvement and 10-year review of cases at the Hospital for Sick Children. Liu RM, et al. **J Otolaryngol** 1999 Apr;28(2):76–82 (17 ref.)

Current approaches in tracheal surgery. Filler RM. **Pediatr Pulmonol Suppl** 1999;18:105–8 (11 ref.)

THERAPY

[Endoscopic interventions in the tracheobronchial system] Schmidt B, et al. **Zentralbl Chir** 1998;123(10):1134–9 (37 ref.) (Eng. Abstr.) **(Ger)**

TRACHEAL NEOPLASMS

Tracheobronchial mucoepidermoid carcinoma in childhood and adolescence: case report and review of the literature. Welsh JH, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 15;45(3):265–73 (38 ref.)

DIAGNOSIS

Tracheal chondrosarcoma: a case report. Farrell ML, et al. **Head Neck** 1998 Sep;20(6):568–72 (22 ref.)

Granular cell tumor of the trachea. Desai DP, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):595–8 (11 ref.)

EPIDEMIOLOGY

Chondroma of the trachea. Jortay AM, et al. **Acta Otorhinolaryngol Belg** 1998;52(3):247–51 (18 ref.)

PATHOLOGY

[Malignant lymphoproliferative lesions of the trachea] Kharchenko VP, et al. **Arkh Patol** 1998 Nov-Dec; 60(6):52–6 (31 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Malignant fibrous histiocytoma of the trachea. Vinod SK, et al. **Respirology** 1999 Sep;4(3):271–4 (23 ref.)

Primary tracheal tumor management. Mathisen DJ. **Surg Oncol Clin N Am** 1999 Apr;8(2):307 (13 ref.)

[A case of tracheal neurilemoma] Kase M, et al. **Kyobu Geka** 1999 Apr;52(4):336–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Tracheal chondrosarcoma: a case report. Farrell ML, et al. **Head Neck** 1998 Sep;20(6):568–72 (22 ref.)

[Endoscopic interventions in the tracheobronchial system] Schmidt B, et al. **Zentralbl Chir** 1998;123(10):1134–9 (37 ref.) (Eng. Abstr.) **(Ger)**

TRACHEAL STENOSIS

COMPLICATIONS

Anterior mediastinal masses: an anaesthetic challenge. Goh MH, et al. **Anaesthesia** 1999 Jul;54(7):670–4 (14 ref.)

CONGENITAL

Long-segment congenital tracheal stenosis: treatment by slide-tracheoplasty. Lang FJ, et al. **J Pediatr Surg** 1999 Aug;34(8):1216–22 (22 ref.)

Current approaches in tracheal surgery. Filler RM. **Pediatr Pulmonol Suppl** 1999;18:105–8 (11 ref.)

ETIOLOGY

Intrathoracic retroesophageal goiter causing tracheal stenosis. Tsukada H, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Apr;47(4):174–7 (10 ref.)

Endobronchial stents: primary and adjuvant therapy for endobronchial airway obstruction. Sonett JR. **Md Med J** 1998 Nov;47(5):260–3 (10 ref.)

Compression syndromes caused by substernal goitres [see comments] Anders HJ. **Postgrad Med J** 1998 Jun; 74(872):327–9 (31 ref.) Comment in: Postgrad Med J 1998 Nov;74(877):701–2.

[Tracheal stenosis due to metastatic adenopathic compression from breast carcinoma] Malerba M, et al. **Recenti Prog Med** 1999 Mar;90(3):152–4 (12 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Long-segment congenital tracheal stenosis: treatment by slide-tracheoplasty. Lang FJ, et al. **J Pediatr Surg** 1999 Aug;34(8):1216–22 (22 ref.)

The vocal athlete and endotracheal intubation: a management protocol. Loucks TM, et al. **J Voice** 1998 Sep;12(3):349–59 (35 ref.)

Current approaches in tracheal surgery. Filler RM. **Pediatr Pulmonol Suppl** 1999;18:105–8 (11 ref.)

THERAPY

Endobronchial stents: primary and adjuvant therapy for endobronchial airway obstruction. Sonett JR. **Md Med J** 1998 Nov;47(5):260–3 (10 ref.)

Stenting therapy for stenosing airway disease. Kim H. **Respirology** 1998 Dec;3(4):221–8 (38 ref.)

Stenting therapy for stenosing airway diseases. Phillips MJ. **Respirology** 1998 Dec;3(4):215–9 (14 ref.)

TRACHEITIS

MICROBIOLOGY

Is bacterial tracheitis changing? A 14-month experience in a pediatric intensive care unit. Bernstein T, et al. **Clin Infect Dis** 1998 Sep;27(3):458–62 (21 ref.)

PATHOLOGY

Chronic inflammation: links with angiogenesis and wound healing [comment] Majno G. **Am J Pathol** 1998 Oct; 153(4):1035–9 (27 ref.) Comment on: Am J Pathol 1998 Oct;153(4):1099–112.

TRACHEOESOPHAGEAL FISTULA

Esophageal atresia and tracheoesophageal fistula. Clark DC. **Am Fam Physician** 1999 Feb 15;59(4):910–6, 919–20 (21 ref.)

COMPLICATIONS

Congenital cystic adenomatoid malformation of the lung associated with esophageal atresia and tracheoesophageal fistula. De Felice C, et al. **Pediatr Surg Int** 1999; 15(3–4):260–3 (17 ref.)

RADIOGRAPHY

Adult presentation of a tracheoesophageal fistula with co-existing laryngeal cleft. Lancaster JL, et al. **J Laryngol Otol** 1999 May;113(5):469–72 (17 ref.)

SURGERY

Restoration of voice after laryngectomy. Jassar P, et al. **J R Soc Med** 1999 Jun;92(6):299–302 (25 ref.)

TRACHEOSTOMY

Tracheostomy in the critically ill: clinical impact of new procedures. Quintel M, et al. **Intensive Care Med** 1999 Mar; 25(3):326–8 (4 ref.)

If and when to close tracheostomy. Clini E, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):377–80 (31 ref.)

Upper airway bypass surgery for obstructive sleep apnea syndrome. Mickelson SA. **Otolaryngol Clin North Am** 1998 Dec;31(6):1013–23 (19 ref.)

Correction of the depressed, retracted, post-tracheostomy scar. Skigen AL, et al. **Plast Reconstr Surg** 1999 May; 103(6):1703–5 (8 ref.)

[Tracheostomy in intensive care] Westphal K, et al. **Anaesthesist** 1999 Mar;48(3):142–56 (70 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Surgical emphysema following percutaneous tracheostomy. Douglas WE, et al. **Anaesth Intensive Care** 1999 Feb; 27(1):69–72 (12 ref.)

METHODS

Percutaneous tracheostomy: a comprehensive evaluation. Moe KS, et al. **Ann Otol Rhinol Laryngol** 1999 Apr; 108(4):384–91 (37 ref.)

Provision of long-term mechanical ventilation. Scheinhorn DJ, et al. **Crit Care Clin** 1998 Oct;14(4):819–32, viii (68 ref.)

Percutaneous versus surgical tracheostomy: procedure of choice or choice of procedure [editorial; comment] Friedman Y, et al. **Crit Care Med** 1999 Aug;27(8):1684–5 (27 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1617–25.

Conventional surgical tracheostomy as the preferred method of airway management. Bernard AC, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):310–5 (47 ref.)

TRACHEOSTOMY

Percutaneous dilational tracheostomy as the preferred method of airway management. Griffen MM, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):316–20 (39 ref.)
[Percutaneous dilatational tracheostomy] Welte T, et al. **Med Klin** 1999 Apr;94(1 Spec No):51–4 (15 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Tracheostomy management in ordinary wards. Heafield S, et al. **Hosp Med** 1999 Apr;60(4):261–2 (4 ref.)

TRACHEOTOMY

Primary tracheal tumor management. Mathisen DJ. **Surg Oncol Clin N Am** 1999 Apr;8(2):307 (13 ref.)
[Tracheotomy in the child with a foreign body in the lower respiratory passages] Diop EM, et al. **Dakar Med** 1997; 42(2):165–8 (10 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

[Ciaglia percutaneous dilatation tracheotomy with endoscopic control. Analysis of complication-fraught steps] Koitschev A, et al. **HNO** 1998 Jul;46(7):678–83 (20 ref.) (Eng. Abstr.) **(Ger)**
[Bronchoscopically controlled percutaneous puncture tracheotomy] Achtzehn U, et al. **Pneumologie** 1998 Nov; 52(11):629–34 (39 ref.) (Eng. Abstr.) **(Ger)**

TRACHOMA

[Trachoma] Aoki K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):233–5 (4 ref.) **(Jpn)**

PREVENTION & CONTROL

WHO alliance for the global elimination of blinding trachoma and the potential use of azithromycin. Négrel AD, et al. **Int J Antimicrob Agents** 1998 Nov;10(4):259–62 (18 ref.)
[New vaccine against trachoma] Vérin P, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1996;73:63–71 (4 ref.) (Eng. Abstr.) **(Fre)**

TRACK AND FIELD

see related
RUNNING

TRACTION

ADVERSE EFFECTS

Erectile dysfunction induced by orthopedic trauma managed with a fracture table: a case report and review of the literature. Chan PT, et al. **J Trauma** 1999 Jul;47(1):183–5 (22 ref.)

TRADE UNIONS see **LABOR UNIONS**

TRADEMARKS see **PATENTS**

TRADITIONAL BIRTH ATTENDANT see **MIDWIFERY**

TRADITIONAL MEDICINE, AFRICAN see **MEDICINE, AFRICAN TRADITIONAL**

TRADITIONAL MEDICINE, CHINESE see **MEDICINE, CHINESE TRADITIONAL**

TRADITIONAL MEDICINE, ORIENTAL see **MEDICINE, ORIENTAL TRADITIONAL**

TRAINING PROGRAMS see **EDUCATION**

TRAINING SUPPORT

METHODS

Family medicine training grants as a method of faculty development: are we doing it right? [editorial] Baldor RA, et al. **Fam Med** 1999 Mar;31(3):205–6 (1 ref.)

ORGANIZATION & ADMINISTRATION

Creating training opportunities for public health practitioners. Greene D, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):80–5 (18 ref.)

TRAMADOL

THERAPEUTIC USE

Pain management in dental practice: tramadol vs. codeine combinations. Moore PA. **J Am Dent Assoc** 1999 Jul; 130(7):1075–9 (29 ref.)
Analgesics in ophthalmic practice: a review of the oral non-narcotic agent tramadol. Gaynes BI, et al. **Optom Vis Sci** 1999 Jul;76(7):455–61 (36 ref.)

TRANEXAMIC ACID

ADMINISTRATION & DOSAGE

[Tranexamic acid reduces the blood loss in knee arthroplasty--if it's administered at the right time] Benoni G. **Lakartidningen** 1999 Jun 16;96(24):2967–9 (42 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Tranexamic acid: a review of its use in surgery and other indications. Dunn CJ, et al. **Drugs** 1999 Jun;57(6):1005–32 (132 ref.)

TRANQUILIZING AGENTS

see related
HYPNOTICS AND SEDATIVES

POISONING

[Acute poisoning by barbiturates, tranquilizers, tricyclics, paracetamol, salicylates. Diagnosis, treatment] Flesch F, et al. **Rev Prat** 1998 Jun 1;48(11):1257–61 (0 ref.) **(Fre)**

THERAPEUTIC USE

Tranquilizers, stimulants, and enhancers of cognition. Flitman SS. **Phys Med Rehabil Clin N Am** 1999 May;10(2):463–72, ix (44 ref.)

TRANQUILIZING AGENTS, MAJOR see **ANTIPSYCHOTIC AGENTS**

TRANQUILIZING AGENTS, MINOR see **ANTI-ANXIETY AGENTS**

TRANS-ACTING FACTORS see **TRANS-ACTIVATORS**

TRANS-ACTING RESPONSIVE REGION, HIV see **HIV LONG TERMINAL REPEAT**

TRANS-ACTING TRANSCRIPTION FACTOR, HIV see **GENE PRODUCTS, TAT**

TRANS-ACTIVATION (GENETICS)

Transcriptional regulation of smooth muscle contractile apparatus expression. Solway J, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S100–8 (98 ref.)
Use of artificial activators to define a role for protein-protein and protein-DNA contacts in transcriptional activation. Dove SL, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:173–80 (56 ref.)
Mechanisms of activation by CREB and CREM: phosphorylation, CBP, and a novel coactivator, ACT. Fimia GM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:631–42 (74 ref.)
Cofactor requirements for transcriptional activation by Sp1. Näär AM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:189–99 (59 ref.)
Activation of RNA polymerase II transcription. Berk AJ. **Curr Opin Cell Biol** 1999 Jun;11(3):330–5 (51 ref.)
Positive activation of gene expression. Rhodius VA, et al. **Curr Opin Microbiol** 1998 Apr;1(2):152–9 (51 ref.)
Transcriptional activation of the catechol and chlorocatechol operons: variations on a theme. McFall SM, et al. **Gene** 1998 Nov 26;223(1-2):257–67 (41 ref.)
Androgen receptor transactivation domain and control of spermatogenesis. Yong EL, et al. **Rev Reprod** 1998 Sep; 3(3):141–4 (21 ref.)
[Characterization of ligand-dependent transactivation regions of the human vitamin D receptor] Nakajima S. **Nippon Rinsho** 1998 Jul;56(7):1717–21 (12 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Transgene regulation by the tetracycline-controlled transactivation system. Kitamura M. **Exp Nephrol** 1998 Nov-Dec;6(6):576–80 (21 ref.)
Insulin inhibition of glucocorticoid-stimulated gene transcription: requirement for an insulin response element? Pierreux CE, et al. **Mol Cell Endocrinol** 1999 Jan 25; 147(1-2):1–5 (33 ref.)

GENETICS

Inducible control of gene expression: prospects for gene therapy. Harvey DM, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):512–8 (47 ref.)
Alternative processing of growth hormone receptor transcripts. Edens A, et al. **Endocr Rev** 1998 Oct; 19(5):559–82 (131 ref.)

PHYSIOLOGY

Signal transduction and transcription factors in rheumatic disease. Firestein GS, et al. **Arthritis Rheum** 1999 Apr; 42(4):609–21 (126 ref.)
Repression by the Mad(Mxi1)-Sin3 complex. Schreiber-Agus N, et al. **Bioessays** 1998 Oct;20(10):808–18 (86 ref.)
Signal transduction: fast lane to transcriptional activation. Rhodes D, et al. **Curr Biol** 1998 Oct 22;8(21):R765–7 (13 ref.)
Transcription: activation by cooperating conformations. Travers A. **Curr Biol** 1998 Aug 27;8(17):R616–8 (10 ref.)
Transgene regulation by the tetracycline-controlled transactivation system. Kitamura M. **Exp Nephrol** 1998 Nov-Dec;6(6):576–80 (21 ref.)
Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoid feedback. Kovács KJ. **Prog Brain Res** 1998;119:31–43 (70 ref.)
Signalling through the JAK-STAT pathway. Cattaneo E, et al. **Trends Neurosci** 1999 Aug;22(8):365–9 (82 ref.)

TRANS-ACTIVATOR PROTEIN, HIV see **GENE PRODUCTS, REV**

TRANS-ACTIVATOR PROTEIN P40(TAX) see **GENE PRODUCTS, TAX**

TRANS-ACTIVATOR PROTEIN P40(X) see **GENE PRODUCTS, TAX**

TRANS-ACTIVATORS

[Structure and dynamics of the transcription factor, Myb, in DNA-sequence recognition] Ogata K. **Seikagaku** 1998 Oct;70(10):1233–50 (44 ref.) **(Jpn)**
[Structural biology of transcription factors and coactivators] Nishimura Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):457–74 (50 ref.) **(Jpn)**
[Interaction of transcription factor PU. 1 with coactivator CBP] Yamamoto H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1389–95 (35 ref.) **(Jpn)**

GENETICS

Molecular approach to the pathogenesis of renal anomalies in Kallmann's syndrome and in the branchio-oto-renal syndrome. Hardelin JP, et al. **Adv Nephrol Necker Hosp** 1998;28:419–28 (22 ref.)
Induction of type I PACAP receptor expression by the new zinc finger protein Zac1 and p53. Hoffmann A, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:49–58 (29 ref.)
DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Schutte M. **Ann Oncol** 1999;10 Suppl 4:56–9 (43 ref.)
STAT structure and function in signaling. Hoey T, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):582–7 (51 ref.)
Developmental competence of the gut endoderm: genetic potentiation by GATA and HNF3/fork head proteins. Zaret K. **Dev Biol** 1999 May 1;209(1):1–10 (114 ref.)
Otx1 and Otx2 in the development and evolution of the mammalian brain. Simeone A. **EMBO J** 1998 Dec 1; 17(23):6790–8 (97 ref.)
Thyroid defects due to Pax8 gene mutations. Damante G. **Eur J Endocrinol** 1998 Dec;139(6):563–6 (27 ref.)
B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments. Sala A, et al. **J Cell Physiol** 1999 Jun;179(3):245–50 (49 ref.)
Myb-transformed hematopoietic cells as a model for monocyte differentiation into dendritic cells and macrophages. Banyer JL, et al. **J Leukoc Biol** 1999 Aug; 66(2):217–23 (82 ref.)
The bicoid-related Pitx gene family in development. Gage PJ, et al. **Mamm Genome** 1999 Feb;10(2):197–200 (45 ref.)
Otx genes and the genetic control of brain morphogenesis. Acampora D, et al. **Mol Cell Neurosci** 1999 Jan;13(1):1–8 (61 ref.)
Going mad with Smads. Zhou S, et al. **N Engl J Med** 1999 Oct 7;341(15):1144–6 (8 ref.)
Myb targeted therapeutics for the treatment of human malignancies. Gewirtz AM. **Oncogene** 1999 May 13; 18(19):3056–62 (73 ref.)
[Mutations in the genes of the HNF-family cause maturity-onset diabetes of the young (MODY)] Takeda J. **Nippon Rinsho** 1998 Sep;56(9):2419–26 (24 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Nuclear receptors, their coactivators and modulation of transcription. Manteuffel-Cymborowska M. **Acta Biochim Pol** 1999;46(1):77–89 (90 ref.)
Can't get no SMADisfaction: Smad proteins as positive and negative regulators of TGF-beta family signals. Christian JL, et al. **Bioessays** 1999 May;21(5):382–90 (60 ref.)
Smads: transcriptional activators of TGF-beta responses. Derynck R, et al. **Cell** 1998 Dec 11;95(6):737–40 (28 ref.)
Net results of nucleolar dynamics. Garcia SN, et al. **Cell** 1999 Jun 25;97(7):825–8 (21 ref.)
Sir-Ku-itous routes to make ends meet. Haber JE. **Cell** 1999 Jun 25;97(7):829–32 (19 ref.)
The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Oikawa T, et al. **Cell Death Differ** 1999 Jul; 6(7):599–608 (161 ref.)
STAT6: an intracellular target for the inhibition of allergic disease [editorial; comment] Foster PS. **Clin Exp Allergy** 1999 Jan;29(1):12–6 (38 ref.) Comment on: Clin Exp Allergy 1999 Jan;29(1):114–23.
Mechanisms of viral activators. Berk AJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:243–52 (65 ref.)
Targeting Sir proteins to sites of action: a general mechanism for regulated repression. Cockell M, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:401–12 (59 ref.)
Mechanisms of activation by CREB and CREM: phosphorylation, CBP, and a novel coactivator, ACT.

Fimia GM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:631–42 (74 ref.)
Cofactor requirements for transcriptional activation by Sp1. Näär AM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:189–99 (59 ref.)
Transcriptional regulation during mesenchymal cell differentiation: the role of coactivators. St-Arnaud R. **Crit Rev Eukaryot Gene Expr** 1998;8(2):191–202 (81 ref.)
Multidrug resistance: Versatile drug sensors of bacterial cells. Lewis K. **Curr Biol** 1999 Jun 3;9(11):R403–7 (14 ref.)
Signal transduction: fast lane to transcriptional activation. Rhodes D, et al. **Curr Biol** 1998 Oct 22;8(21):R765–7 (13 ref.)
STAT structure and function in signaling. Hoey T, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):582–7 (51 ref.)
Transcriptional regulation in Archaea. Leigh JA. **Curr Opin Microbiol** 1999 Apr;2(2):131–4 (27 ref.)
Positive activation of gene expression. Rhodius VA, et al. **Curr Opin Microbiol** 1998 Apr;1(2):152–9 (51 ref.)
Nuclear receptor coregulators: cellular and molecular biology. McKenna NJ, et al. **Endocr Rev** 1999 Jun; 20(3):321–44 (216 ref.)
Regulatory implications of protein assemblies at the gamma origin of plasmid R6K – a review. Filutowicz M, et al. **Gene** 1998 Nov 26;223(1–2):195–204 (90 ref.)
Transcriptional regulation of the heat shock protein genes by STAT family transcription factors. Stephanou A, et al. **Gene Expr** 1999;7(4–6):311–9 (45 ref.)
Signal transduction of the TGF-beta superfamily by Smad proteins. Kawabata M, et al. **J Biochem (Tokyo)** 1999 Jan; 125(1):9–16 (67 ref.)
The coactivators p300 and CBP have different functions during the differentiation of F9 cells. Ugai H, et al. **J Mol Med** 1999 Jun;77(6):481–94 (105 ref.)
The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. Heim MH. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):75–120 (239 ref.)
Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. McKenna NJ, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):3–12 (92 ref.)
STAT signaling in the pathogenesis and treatment of cancer. Frank DA. **Mol Med** 1999 Jul;5(7):432–56 (245 ref.)
Myb binding proteins: regulators and cohorts in transformation. Ness SA. **Oncogene** 1999 May 13; 18(19):3039–46 (62 ref.)
What sets the TonE during osmotic stress? [comment] Kültz D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1814–6 (24 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2538–42.
The STAT family of proteins in cytokine signaling. Shuai K. **Prog Biophys Mol Biol** 1999;71(3–4):405–22 (117 ref.)
The search for trans-acting factors controlling messenger RNA decay. Wilson GM, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:257–91 (146 ref.)
Transcriptional coregulators in development. Mannervik M, et al. **Science** 1999 Apr 23;284(5414):606–9 (56 ref.)
Advances in cytokine signaling: the role of Jaks and STATs. Chen E, et al. **Transplant Proc** 1999 May;31(3):1482–7 (72 ref.)
Down-modulation of IL-2-triggered JAK3-STAT5 signaling following CD4-ligand binding. Lowry RP, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):820–1 (16 ref.)
Serpentine receptors and STAT activation: more than one way to twin a STAT. Williams JG. **Trends Biochem Sci** 1999 Sep;24(9):333–4 (15 ref.)
Regulation of Smad signalling by protein associations and signalling crosstalk. Zhang Y, et al. **Trends Cell Biol** 1999 Jul;9(7):274–9 (60 ref.)
[Interaction of transcription factor PU. 1 with coactivator CBP] Yamamoto H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1389–95 (35 ref.) **(Jpn)**

PHARMACOLOGY

Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. Darnell JE Jr. **J Interferon Cytokine Res** 1998 Aug;18(8):549–54 (64 ref.)
Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Yeh S, et al. **Keio J Med** 1999 Jun;48(2):87–92 (40 ref.)

PHYSIOLOGY

Myb and oncogenesis. Ganter B, et al. **Adv Cancer Res** 1999; 76:21–60 (289 ref.)
STATs as mediators of cytokine-induced responses. Hoey T, et al. **Adv Immunol** 1999;71:145–62 (113 ref.)
Gene expression in pancreatic adenocarcinoma. Frazier ML. **Ann N Y Acad Sci** 1999 Jun 30;880:1–4 (23 ref.)
Cytokines, Jaks, Stats, health and disease. Brown MP. **Aust N Z J Med** 1999 Feb;29(1):73–8 (49 ref.)
Cross-talk between angiotensin II and interleukin-6-induced signaling through Stat3 transcription factor. Bhat GJ, et al. **Basic Res Cardiol** 1998;93 Suppl 3:26–9 (20 ref.)
Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Milner LA, et al. **Blood** 1999 Apr 15;93(8):2431–48 (189 ref.)
T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Murphy KM, et al. **Curr Top Microbiol Immunol** 1999;238:13–26 (72 ref.)
The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Andrisani OM, et al. **Int J Oncol** 1999 Aug;15(2):373–9 (93 ref.)
The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Hildt E, et al. **Recent Results Cancer Res** 1998;154:315–29 (50 ref.)
Functional roles of STAT family proteins: lessons from knockout mice. Akira S. **Stem Cells** 1999;17(3):138–46 (80 ref.)
[Recent progresses in the JAK-STAT signaling pathways] Nakajima K. **Nippon Rinsho** 1998 Jul;56(7):1763–72 (55 ref.) (Eng. Abstr.) **(Jpn)**
[Proteins of the Stat family: role in cell signalling] Evdonin AL. **Tsitologiia** 1998;40(12):1053–62 (108 ref.) (Eng. Abstr.) **(Rus)**

TRANSACTIVATION see **TRANS-ACTIVATION (GENETICS)**

TRANSAMINASES

BIOSYNTHESIS

Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Amacher DE. **Regul Toxicol Pharmacol** 1998 Apr;27(2):119–30 (107 ref.)

METABOLISM

Novel biosynthetic approaches to the production of unnatural amino acids using transaminases. Taylor PP, et al. **Trends Biotechnol** 1998 Oct;16(10):412–8 (42 ref.)

TRANSCENDENTAL MEDITATION see **MEDITATION**

TRANSCOBALAMIN II see **TRANSCOBALAMINS**

TRANSCOBALAMINS

DEFICIENCY

[Hereditary transcobalamin II deficiency] Wakabayashi Y. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):221–3 (12 ref.) **(Jpn)**

TRANSCRIPTASES see **DNA-DIRECTED RNA POLYMERASE**

TRANSCRIPTION FACTOR AP-1

see related
PROTO-ONCOGENE PROTEINS C-FOS
PROTO-ONCOGENE PROTEINS C-JUN

GENETICS

AP-1 transcription factors in yeast. Toone WM, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):55–61 (42 ref.)
Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. Roebuck KA, et al. **J Leukoc Biol** 1999 Mar;65(3):291–8 (93 ref.)
Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1. Gius D, et al. **Toxicol Lett** 1999 Jun 1;106(2–3):93–106 (94 ref.)

METABOLISM

Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Kyriakis JM. **Gene Expr** 1999; 7(4–6):217–31 (76 ref.)
Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Roebuck KA. **Int J Mol Med** 1999 Sep;4(3):223–30 (102 ref.)
Chronic alcohol intake interferes with retinoid metabolism and signaling. Wang XD. **Nutr Rev** 1999 Feb;57(2):51–9 (68 ref.)

PHYSIOLOGY

Deciphering the early-response transcription factor networks in mast cells. Nechushtan H, et al. **Immunol Today** 1998 Oct;19(10):441–4 (30 ref.)
Role of the transcription factor AP-1 in melanoma differentiation (review). Kang DC, et al. **Int J Oncol** 1998 Dec;13(6):1117–26 (104 ref.)
Signal transduction during liver regeneration. Brenner DA. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S93–5 (11 ref.)

TRANSCRIPTION FACTOR NF-KB see **NF-KAPPA B**

TRANSCRIPTION FACTOR, SP1

METABOLISM

Cofactor requirements for transcriptional activation by Sp1. Näär AM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:189–99 (59 ref.)
A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Philipsen S, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):2991–3000 (113 ref.)

PHYSIOLOGY

Sp1 and its likes: biochemical and functional predictions for a growing family of zinc finger transcription factors. Cook T, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:94–102 (38 ref.)

TRANSCRIPTION FACTORS

see related
TRANS-ACTIVATORS

The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Downing JR. **Br J Haematol** 1999 Aug;106(2):296–308 (134 ref.)
Association of hepatic nuclear factor-4 in the apolipoprotein B promoter: a preliminary report. Nóvak EM, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1405–8 (15 ref.)
Developmental competence of the gut endoderm: genetic potentiation by GATA and HNF3/fork head proteins. Zaret K. **Dev Biol** 1999 May 1;209(1):1–10 (114 ref.)
Transcription factor ETS-1 as a molecular target for angiogenesis inhibition. Sato Y. **Hum Cell** 1998 Dec; 11(4):207–14 (52 ref.)
Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. Gonzalez FJ, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1702–9 (77 ref.)
Transcription-factor-modulating agents: precision and selectivity in drug design. Papavassiliou AG. **Mol Med Today** 1998 Aug;4(8):358–66 (38 ref.)
[Current topics in the regulation of prostanoids--4. The feedback regulation by PPAR-gamma] Ohara M, et al. **Masui** 1999 Feb;48(2):146–51 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Lipid metabolism related nuclear receptor--the structure, function, expression and classification of peroxisome proliferation-activated receptor (PPAR)] Kawada T. **Nippon Rinsho** 1998 Jul;56(7):1722–8 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Structure and dynamics of the transcription factor, Myb, in DNA-sequence recognition] Ogata K. **Seikagaku** 1998 Oct;70(10):1233–50 (44 ref.) **(Jpn)**
[Structural biology of transcription factors and coactivators] Nishimura Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):457–74 (50 ref.) **(Jpn)**

AGONISTS

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Fruchart JC, et al. **Curr Opin Lipidol** 1999 Jun;10(3):245–57 (99 ref.)

ANALYSIS

Eukaryotic transcription factors: identification, characterization and functions. Yang VW. **J Nutr** 1998 Nov;128(11):2045–51 (25 ref.)
Measurement of nitric oxide-mediated effects on zinc homeostasis and zinc finger transcription factors. Kröncke KD, et al. **Methods Enzymol** 1999;301:126–35 (23 ref.)

BIOSYNTHESIS

Relations of nm23 expression to clinicopathologic variables and proliferative activity of gastric cancer lesions. Nakamura T, et al. **Cancer Detect Prev** 1998;22(3):246–50 (23 ref.)

CHEMISTRY

New perceptions of transcription factor properties from NMR. Bagby S, et al. **Biochem Cell Biol** 1998; 76(2–3):368–78 (85 ref.)
X-ray crystallographic studies of eukaryotic transcription factors. Burley SK. **Cold Spring Harb Symp Quant Biol** 1998;63:33–40 (53 ref.)
Transcription factors: the right combination for the DNA lock. Khorasanizadeh S, et al. **Curr Biol** 1999 Jun 17; 9(12):R456–8 (10 ref.)
Transcription: activation by cooperating conformations. Travers A. **Curr Biol** 1998 Aug 27;8(17):R616–8 (10 ref.)
Combinatorial transcription factors. Wolberger C. **Curr Opin Genet Dev** 1998 Oct;8(5):552–9 (54 ref.)
Combinatorial gene regulation by eukaryotic transcription factors. Chen L. **Curr Opin Struct Biol** 1999 Feb;9(1):48–55 (52 ref.)
The TBP-like factor: an alternative transcription factor in metazoa? Dantonel JC, et al. **Trends Biochem Sci** 1999 Sep; 24(9):335–9 (34 ref.)

DRUG EFFECTS

New targets for anti-inflammatory drugs. Lewis AJ, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):489–94 (56 ref.)
Immunopharmacology: anti-inflammatory therapy targeting transcription factors. Pfeilschifter J, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):237–45 (103 ref.)

GENETICS

HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Tallini G, et al. **Adv Anat Pathol** 1999 Sep;6(5):237–46 (94 ref.)
Specificity within the ets family of transcription factors

Graves BJ, et al. **Adv Cancer Res** 1998;75:1-55 (236 ref.)
POU domain factors in neural development. Schonemann MD, et al. **Adv Exp Med Biol** 1998;449:39-53 (128 ref.)
A new twist: some patients with Saethre-Chotzen syndrome have a microdeletion syndrome [editorial; comment] Zackai EH, et al. **Am J Hum Genet** 1998 Nov;63(5):1277-81 (33 ref.) Comment on: Am J Hum Genet 1998 Nov;63(5):1282-93.
Rarity of PIT1 involvement in children from Russia with combined pituitary hormone deficiency. Fofanova OV, et al. **Am J Med Genet** 1998 Jun 5;77(5):360-5 (31 ref.)
Pathways of Egr-1-mediated gene transcription in vascular biology [comment] Silverman ES, et al. **Am J Pathol** 1999 Mar;154(3):665-70 (56 ref.) Comment on: Am J Pathol 1999 Mar;154(3):937-44.
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Coughlin SS, et al. **Am J Prev Med** 1999 Feb;16(2):91-8 (64 ref.)
Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Strout MP, et al. **Ann Hematol** 1999 Jun;78(6):251-64 (123 ref.)
Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Foley KP, et al. **Biochim Biophys Acta** 1999 May 31; 1423(3):M37-47 (70 ref.)
Deconstructing cell determination: proneural genes and neuronal identity. Brunet JF, et al. **Bioessays** 1999 Apr; 21(4):313-8 (39 ref.)
The SCL gene: from case report to critical hematopoietic regulator. Begley CG, et al. **Blood** 1999 May 1; 93(9):2760-70 (141 ref.)
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167-215 (605 ref.)
BRCA1 and BRCA2 in breast cancer. Yang X, et al. **Breast Cancer Res Treat** 1999 Mar;54(1):1-10 (78 ref.)
DAX-1, an 'antitestis' gene. Goodfellow PN, et al. **Cell Mol Life Sci** 1999 Jun;55(6-7):857-63 (26 ref.)
Sry and Sox9: mammalian testis-determining genes. Koopman P. **Cell Mol Life Sci** 1999 Jun;55(6-7):839-56 (187 ref.)
Do 5'Hoxd genes play a role in initiating or maintaining A-P polarizing signals in the limb? Mackem S, et al. **Cell Tissue Res** 1999 Apr;296(1):27-31 (43 ref.)
Gli genes and limb development. Theil T, et al. **Cell Tissue Res** 1999 Apr;296(1):75-83 (79 ref.)
Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Eccles MR, et al. **Clin Genet** 1999 Jul;56(1):1-9 (39 ref.)
Transcription factors in dysmorphology. Lacombe D. **Clin Genet** 1999 Mar;55(3):137-43 (44 ref.)
Inherited breast cancer: an emerging picture. Welcsh PL, et al. **Clin Genet** 1998 Dec;54(6):447-58 (139 ref.)
Histone deacetylase directs the dominant silencing of transcription in chromatin: association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase. Wade PA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:435-45 (72 ref.)
The role of Pax3 and Pax7 in development and cancer. Mansouri A. **Crit Rev Oncog** 1998;9(2):141-9 (62 ref.)
pRb and E2f-1 in mouse development and tumorigenesis. Macleod K. **Curr Opin Genet Dev** 1999 Feb;9(1):31-9 (64 ref.)
New developments in bone formation. Owen MJ, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):363-6 (19 ref.)
Transcribing pancreas. Edlund H. **Diabetes** 1998 Dec; 47(12):1817-23 (50 ref.)
PPARgamma, the ultimate thrifty gene. Auwerx J. **Diabetologia** 1999 Sep;42(9):1033-49 (190 ref.)
Transcription factors and their genes in higher plants functional domains, evolution and regulation. Liu L, et al. **Eur J Biochem** 1999 Jun;262(2):247-57 (128 ref.)
The BRCA paradox in breast and ovarian cancer. Ponzone R, et al. **Eur J Cancer** 1998 Jun;34(7):966-7 (9 ref.)
Pluripotent PPARgamma polymorphisms. Berg JP. **Eur J Endocrinol** 1999 Apr;140(4):293-5 (17 ref.)
Genetic basis of uterine leiomyoma: involvement of high mobility group protein genes. Van de Ven WJ. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):289-93 (22 ref.)
Transcription factors and asthma. Barnes PJ, et al. **Eur Respir J** 1998 Jul;12(1):221-34 (156 ref.)
Mammalian sex determination: a molecular drama. Swain A, et al. **Genes Dev** 1999 Apr 1;13(7):755-67 (87 ref.)
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. Neuhausen SL, et al. **Genet Test** 1997; 1(2):75-83 (79 ref.)
Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related? Wang NM, et al. **Int J Mol Med** 1999 May;3(5):491-5 (54 ref.)
BRCA-associated cancer risk: molecular biology and clinical practice. van Golen K, et al. **J Lab Clin Med** 1999 Jul; 134(1):11-8 (80 ref.)
How can oncogenic transcription factors cause cancer: a critical review of the myb story. Introna M, et al. **Leukemia** 1999 Sep;13(9):1301-6 (70 ref.)
The bicoid-related Pitx gene family in development. Gage PJ, et al. **Mamm Genome** 1999 Feb;10(2):197-200 (45 ref.)
The PTX family of homeodomain transcription factors during pituitary developments. Drouin J, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):31-6 (16 ref.)
Xist and X chromosome inactivation. Kay GF. **Mol Cell Endocrinol** 1998 May 25;140(1-2):71-6 (57 ref.)
Candidate genes in complete and partial XY sex reversal: mutation analysis of SRY, SRY-related genes and FTZ-F1. Lim HN, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1-2):51-8 (60 ref.)
Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Schedl A, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):65-9 (35 ref.)
A genetic mutation in PPAR gamma is associated with enhanced fat cell differentiation: implications for human obesity. Freake HC. **Nutr Rev** 1999 May;57(5 Pt 1):154-6 (12 ref.)
The role of PAX2 in normal and abnormal development of the urinary tract. Eccles MR. **Pediatr Nephrol** 1998 Nov; 12(9):712-20 (61 ref.)
The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pritchard-Jones K. **Pediatr Nephrol** 1999 Sep;13(7):620-5 (37 ref.)
MADS about Gnetales. Frohlich MW. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8811-3 (29 ref.)
Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system. Hughes PE, et al. **Prog Neurobiol** 1999 Feb;57(4):421-50 (254 ref.)
Nuclear factors and type 2 diabetes. Froguel P. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1936-9 (11 ref.)
The taxonomy of developmental control in Caenorhabditis elegans [see comments] Ruvkun G, et al. **Science** 1998 Dec 11;282(5396):2033-41 (51 ref.) Comment in: Science 1998 Dec 11;282(5396):1972-4. Comment in: Science 1999 Jul 9;285(5425):167.
HAND proteins: molecular mediators of cardiac development and congenital heart disease. Srivastava D. **Trends Cardiovasc Med** 1999 Jan-Feb;9(1-2):11-8 (42 ref.)
T-box genes: what they do and how they do it. Smith J. **Trends Genet** 1999 Apr;15(4):154-8 (62 ref.)
[Transcriptional regulation by CREB and proteins of CREB family] Tian JH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):227-32 (20 ref.) (Eng. Abstr.) **(Chi)**
[Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes] Sobol H, et al. **Ann Endocrinol (Paris)** 1998;59(6):459-64 (71 ref.) (Eng. Abstr.) **(Fre)**
[Inhibitors of cyclins/CDK of the 9p21 chromosomal region and malignant hemopathies] Quesnel B. **Bull Cancer** 1998 Sep;85(9):747-54 (43 ref.) (Eng. Abstr.) **(Fre)**
[BRCA1 and BRCA2: mutations and other genetic changes--practical relevance] Scherneck S, et al. **Chirurg** 1999 Apr;70(4):373-9 (32 ref.) (Eng. Abstr.) **(Ger)**
[Molecular biology and molecular genetics in the field of otorhinolaryngology--isolation of genes responsible for deafness] Tamagawa T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Jul;101(7):932-5 (5 ref.) **(Jpn)**
[Mutations in the genes of the HNF-family cause maturity-onset diabetes of the young (MODY)] Takeda J. **Nippon Rinsho** 1998 Sep;56(9):2419-26 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Primary splenic lymphoma with t(3;14)(q27;q32) chromosomal abnormality and rearrangement of BCL-6 gene] Yata K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):587-92 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Brachyury genes and notochord differentiation in chordate embryos] Takahashi H, et al. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1347-54 (34 ref.) **(Jpn)**

METABOLISM

Hypothalamic transcription factors and the regulation of the hypothalamo-neurohypophysial system. Burbach JP, et al. **Adv Exp Med Biol** 1998;449:29-37 (59 ref.)
POU domain factors in neural development. Schonemann MD, et al. **Adv Exp Med Biol** 1998;449:39-53 (128 ref.)
Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors. Wahli W, et al. **Adv Exp Med Biol** 1999;447:199-209 (40 ref.)
Copper-regulatory domain involved in gene expression. Winge DR. **Adv Exp Med Biol** 1999;448:237-46 (49 ref.)
Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Grilli M, et al. **Biochem Pharmacol** 1999 Jan 1;57(1):1-7 (60 ref.)
Regulation of surfactant protein gene transcription. Whitsett JA, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):303-11 (50 ref.)
Transcription factor IIH: a key player in the cellular response to DNA damage. Frit P, et al. **Biochimie** 1999 Jan-Feb; 81(1-2):27-38 (154 ref.)
E2F target genes and cell-cycle checkpoint control. Lavia P, et al. **Bioessays** 1999 Mar;21(3):221-30 (71 ref.)
Being at the right place at the right time: the role of nuclear transport in dynamic transcriptional regulation in yeast. Görner W, et al. **Biol Chem** 1999 Feb;380(2):147-50 (20 ref.)
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Melnick A, et al. **Blood** 1999 May 15; 93(10):3167-215 (605 ref.)
Role of the HAP1 protein in repair of oxidative DNA damage and regulation of transcription factors. Barzilay G, et al. **Br J Cancer Suppl** 1996 Jul;27:S145-50 (32 ref.)
Specification of neuronal connectivity: ETS marks the spot [comment] Ghosh A, et al. **Cell** 1998 Oct 30;95(3):303-6 (17 ref.) Comment on: Cell 1998 Oct 30;95(3):393-407.
Sex, cell death, and the genome of C. elegans [comment] Hodgkin J. **Cell** 1999 Aug 6;98(3):277-80 (16 ref.) Comment on: Cell 1999 Aug 6;98(3):317-27.
Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Nevins JR. **Cell Growth Differ** 1998 Aug;9(8):585-93 (100 ref.)
Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Chakraborti S, et al. **Cell Signal** 1998 Nov;10(10):675-83 (33 ref.)
Signalling into the T-cell nucleus: NFAT regulation. Masuda ES, et al. **Cell Signal** 1998 Oct;10(9):599-611 (132 ref.)
Transcription in Archaea. Bell SD, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:41-51 (71 ref.)
Mechanisms of viral activators. Berk AJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:243-52 (65 ref.)
The DPE, a conserved downstream core promoter element that is functionally analogous to the TATA box. Burke TW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:75-82 (37 ref.)
The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Chédin S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:381-9 (103 ref.)
Ten years of TFIIH. Coin F, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:105-10 (72 ref.)
Cooperative assembly of RNA polymerase II transcription complexes. Ellwood K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:253-61 (36 ref.)
Mechanisms of activation by CREB and CREM: phosphorylation, CBP, and a novel coactivator, ACT. Fimia GM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:631-42 (74 ref.)
Autoinhibition as a transcriptional regulatory mechanism. Graves BJ, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:621-9 (60 ref.)
Crossing the line between RNA polymerases: transcription of human snRNA genes by RNA polymerases II and III. Henry RW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:111-20 (54 ref.)
Mechanism and regulation of yeast RNA polymerase II transcription. Kornberg RD. **Cold Spring Harb Symp Quant Biol** 1998;63:229-32 (26 ref.)
TBP-associated factors in the PCAF histone acetylase complex. Kotani T, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:493-9 (53 ref.)
Transcription factor IIIB: the architecture of its DNA complex, and its roles in initiation of transcription by RNA polymerase III. Kumar A, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:121-9 (60 ref.)
Promoter-associated pausing in promoter architecture and postinitiation transcriptional regulation. Lis J. **Cold Spring Harb Symp Quant Biol** 1998;63:347-56 (59 ref.)
SWI/SNF complex: dissection of a chromatin remodeling cycle. Peterson CL. **Cold Spring Harb Symp Quant Biol** 1998;63:545-52 (37 ref.)
The RNA polymerase II general transcription factors: past, present, and future. Reinberg D, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:83-103 (168 ref.)
Role of general and gene-specific cofactors in the regulation of eukaryotic transcription. Roeder RG. **Cold Spring Harb Symp Quant Biol** 1998;63:201-18 (167 ref.)
The bacterial enhancer-binding protein NtrC as a molecular machine. Rombel I, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:157-66 (50 ref.)
Activation and repression mechanisms in yeast. Struhl K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:413-21 (66 ref.)
The regulation of gene activity by histones and the histone deacetylase RPD3. Suka N, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:391-9 (58 ref.)
Polarity of transcription on Pol II and archaeal promoters: where is the "one-way sign" and how is it read? Tsai FT, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:53-61 (25 ref.)
Histone deacetylase directs the dominant silencing of transcription in chromatin: association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase. Wade PA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:435-45 (72 ref.)
The SAGA of Spt proteins and transcriptional analysis in yeast: past, present, and future. Winston F, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:553-61 (59 ref.)
Building transcriptional regulatory complexes: signals and surfaces. Yamamoto KR, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:587-98 (70 ref.)
Drosophila metamorphosis: the only way is USP? Buszczak M, et al. **Curr Biol** 1998 Dec 3;8(24):R879-82 (24 ref.)
Gene activation by histone and factor acetyltransferases. Berger SL. **Curr Opin Cell Biol** 1999 Jun;11(3):336-41 (53 ref.)
Therapeutic potential of selective modulators of nuclear

receptor action. Resche-Rigon M, et al. **Curr Opin Chem Biol** 1998 Aug;2(4):501-7 (57 ref.)

Muscle differentiation: more complexity to the network of myogenic regulators. Arnold HH, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):539-44 (51 ref.)

STAT structure and function in signaling. Hoey T, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):582-7 (51 ref.)

The nuclear receptor PPARgamma - bigger than fat. Kliewer SA, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):576-81 (50 ref.)

The LXRs: a new class of oxysterol receptors. Peet DJ, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):571-5 (37 ref.)

Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Semenza GL. **Curr Opin Genet Dev** 1998 Oct; 8(5):588-94 (62 ref.)

A transcription factor party during blood cell differentiation. Sieweke MH, et al. **Curr Opin Genet Dev** 1998 Oct; 8(5):545-51 (58 ref.)

Genetic dissection of glucocorticoid receptor function in mice. Tronche F, et al. **Curr Opin Genet Dev** 1998 Oct; 8(5):532-8 (49 ref.)

Combinatorial transcription factors. Wolberger C. **Curr Opin Genet Dev** 1998 Oct;8(5):552-9 (54 ref.)

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151-9 (97 ref.)

The sigmaE and Cpx regulatory pathways: overlapping but distinct envelope stress responses. Raivio TL, et al. **Curr Opin Microbiol** 1999 Apr;2(2):159-65 (52 ref.)

Combinatorial gene regulation by eukaryotic transcription factors. Chen L. **Curr Opin Struct Biol** 1999 Feb;9(1):48-55 (52 ref.)

Regulation of gene expression by multiple forms of TFIID and other novel TAFII-containing complexes. Bell B, et al. **Exp Cell Res** 1999 Jan 10;246(1):11-9 (93 ref.)

Steroidogenic factor-1: its role in endocrine organ development and differentiation. Hammer GD, et al. **Front Neuroendocrinol** 1999 Jul;20(3):199-223 (136 ref.)

Emerging roles for PAX transcription factors in cancer biology. Schäfer BW. **Gen Physiol Biophys** 1998 Sep; 17(3):211-24 (42 ref.)

Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein, p50. Evdokimova VM, et al. **Int J Biochem Cell Biol** 1999 Jan; 31(1):139-49 (95 ref.)

Upregulation of E2F transcription factors in chemically induced mouse skin tumors. Balasubramanian S, et al. **Int J Oncol** 1999 Aug;15(2):387-90 (25 ref.)

Biological role of the CCAAT/enhancer-binding protein family of transcription factors. Lekstrom-Himes J, et al. **J Biol Chem** 1998 Oct 30;273(44):28545-8 (87 ref.)

POU family transcription factors in the nervous system. Latchman DS. **J Cell Physiol** 1999 May;179(2):126-33 (68 ref.)

Transcription factor activities and gene expression during mouse mammary gland involution. Marti A, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):145-52 (53 ref.)

Angiotensin peptides and inducible transcription factors. Blume A, et al. **J Mol Med** 1999 Mar;77(3):339-57 (253 ref.)

Human Ad4BP/SF-1 and its related nuclear receptor. Nawata H, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):323-8 (27 ref.)

Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia. Okabe-Kado J, et al. **Leuk Lymphoma** 1998 Dec;32(1-2):19-28 (40 ref.)

Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Behre G, et al. **Methods** 1999 Mar;17(3):231-7 (61 ref.)

Analyzing chromatin structure and transcription factor binding in yeast. Gregory PD, et al. **Methods** 1998 Aug; 15(4):295-302 (31 ref.)

The GnRH promoter: target of transcription factors, hormones, and signaling pathways. Nelson SB, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):151-5 (22 ref.)

FadR, transcriptional co-ordination of metabolic expediency. Cronan JE Jr, et al. **Mol Microbiol** 1998 Aug;29(4):937-43 (30 ref.)

A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Philipsen S, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):2991-3000 (113 ref.)

The role of oxidized low-density lipoprotein in the activation of peroxisome proliferator-activated receptor gamma: implications for atherosclerosis. Wolf G. **Nutr Rev** 1999 Mar;57(3):88-91 (11 ref.)

New Myc-interacting proteins: a second Myc network emerges. Sakamuro D, et al. **Oncogene** 1999 May 13; 18(19):2942-54 (150 ref.)

News in chloroplast protein import. Caliebe A, et al. **Plant Mol Biol** 1999 Mar;39(4):641-5 (14 ref.)

What sets the TonE during osmotic stress? [comment] Kültz D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1814-6 (24 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2538-42.

The role of POU domain proteins in the regulation of mammalian pituitary and nervous system development. McEvilly RJ, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 63:223-55 (138 ref.)

The nucleosome: a powerful regulator of transcription. Wolffe AP, et al. **Prog Nucleic Acid Res Mol Biol** 1998; 61:379-422 (166 ref.)

Regulation of DNA virus transcription by cellular POU family transcription factors. Latchman DS. **Rev Med Virol** 1999 Jan-Mar;9(1):31-8 (62 ref.)

Transcriptional coregulators in development. Mannervik M, et al. **Science** 1999 Apr 23;284(5414):606-9 (56 ref.)

Thyroid hormone receptor coactivators and corepressors. Koenig RJ. **Thyroid** 1998 Aug;8(8):703-13 (105 ref.)

The TBP-like factor: an alternative transcription factor in metazoa? Dantonel JC, et al. **Trends Biochem Sci** 1999 Sep; 24(9):335-9 (34 ref.)

Histone deacetylases: transcriptional repression with SINers and NuRDs. Ayer DE. **Trends Cell Biol** 1999 May; 9(5):193-8 (66 ref.)

NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Foo SY, et al. **Trends Genet** 1999 Jun; 15(6):229-35 (50 ref.)

Control of histidine decarboxylase gene expression in enterochromaffin-like cells. Dimaline R, et al. **Yale J Biol Med** 1998 May-Aug;71(3-4):195-205 (56 ref.)

[Transcription factors of the Ets family and morphogenesis of the vascular tree] Mattot V, et al. **J Soc Biol** 1999; 193(2):147-53 (68 ref.) (Eng. Abstr.) **(Fre)**

[Regulated nuclear localization of transcription factors: nuclear export of yAP-1 is sensitive to oxidative stress] Kuge S. **Tanpakushitsu Kakusan Koso** 1999 Apr; 44(5):668-75 (41 ref.) **(Jpn)**

[The role of MAP kinases and inducible transcription factors in the regulation of cell death and survival] Kamińska B, et al. **Postepy Hig Med Dosw** 1999;53(2):291-303 (60 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Role of transcriptional factors in stellate cell activation. Rippe RA. **Alcohol Clin Exp Res** 1999 May;23(5):926-9 (33 ref.)

Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. Clarke SD, et al. **Am J Clin Nutr** 1999 Oct;70(4):566-71 (66 ref.)

Forkhead transcription factor HFH-4 and respiratory epithelial cell differentiation. Whitsett JA, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):153-4 (17 ref.)

Sp1 and its likes: biochemical and functional predictions for a growing family of zinc finger transcription factors. Cook T, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:94-102 (38 ref.)

Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Black BL, et al. **Annu Rev Cell Dev Biol** 1998;14:167-96 (141 ref.)

P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Waxman DJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):11-23 (128 ref.)

Signal transduction and transcription factors in rheumatic disease. Firestein GS, et al. **Arthritis Rheum** 1999 Apr; 42(4):609-21 (126 ref.)

Clathrin and adaptors. Hirst J, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):173-93 (186 ref.)

Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Yamasaki L. **Biochim Biophys Acta** 1999 Mar 25;1423(2):M9-15 (58 ref.)

The role of interferon regulatory factors in the interferon system and cell growth control. Harada H, et al. **Biochimie** 1998 Aug-Sep;80(8-9):641-50 (72 ref.)

Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Pitha PM, et al. **Biochimie** 1998 Aug-Sep;80(8-9):651-8 (50 ref.)

Mammalian sex determination: joining pieces of the genetic puzzle. Jiménez R, et al. **Bioessays** 1998 Sep;20(9):696-9 (24 ref.)

WT1: what has the last decade told us? Little M, et al. **Bioessays** 1999 Mar;21(3):191-202 (87 ref.)

In line with our ancestors: Oct-4 and the mammalian germ [published erratum appears in Bioessays 1998 Dec;20(12):1056] Pesce M, et al. **Bioessays** 1998 Sep; 20(9):722-32 (55 ref.)

Repression by the Mad(Mxi1)-Sin3 complex. Schreiber-Agus N, et al. **Bioessays** 1998 Oct;20(10):808-18 (86 ref.)

Negative regulation of the JAK/STAT pathway. Starr R, et al. **Bioessays** 1999 Jan;21(1):47-52 (44 ref.)

The cell cycle-regulating transcription factors E2F-RB. Brehm A, et al. **Br J Cancer** 1999 Jul;80 Suppl 1:38-41 (26 ref.)

Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Herdegen T, et al. **Brain Res Brain Res Rev** 1998 Dec;28(3):370-490 (1440 ref.)

Core-binding factor: a central player in hematopoiesis and leukemia. Speck NA, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1789s-1793s (47 ref.)

Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Crabtree GR. **Cell** 1999 Mar 5;96(5):611-4 (25 ref.)

Nuclear orphan receptors control cholesterol catabolism. Russell DW. **Cell** 1999 May 28;97(5):539-42 (17 ref.)

Anterior pituitary development and Pit-1/GHF-1 transcription factor. de la Hoya M, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1059-66 (39 ref.)

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Gelman L, et al. **Cell Mol Life Sci** 1999 Jun;55(6-7):932-43 (141 ref.)

Transcriptional regulation: SWItching circuitry. Wade PA, et al. **Curr Biol** 1999 Mar 25;9(6):R221-4 (12 ref.)

Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Eastman Q, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):233-40 (102 ref.)

Peroxisome proliferator-activated receptors: mediators of a fast food impact on gene regulation. Gelman L, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):307-12 (72 ref.)

The role of Xist in X-inactivation. Brockdorff N. **Curr Opin Genet Dev** 1998 Jun;8(3):328-33 (45 ref.)

Cbfa1 in bone development. Komori T, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):494-9 (50 ref.)

Control of lymphocyte development by the Ikaros gene family. Cortes M, et al. **Curr Opin Immunol** 1999 Apr; 11(2):167-71 (23 ref.)

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151-9 (97 ref.)

Transcriptional control of neurotransmitter phenotype. Goridis C, et al. **Curr Opin Neurobiol** 1999 Feb;9(1):47-53 (49 ref.)

PASting together the mammalian clock. Whitmore D, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):635-41 (45 ref.)

PPARgamma, the ultimate thrifty gene. Auwerx J. **Diabetologia** 1999 Sep;42(9):1033-49 (190 ref.)

Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1. Taniguchi T, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):43-8 (48 ref.)

PPARgamma: from adipose tissue to the atherosclerotic plaque. Lopez-Liuchi JV, et al. **Eur J Endocrinol** 1998 Oct; 139(4):363-4 (9 ref.)

A gut check for PPARgamma [editorial; comment] Wu GD, et al. **Gastroenterology** 1998 Nov;115(5):1283-5 (48 ref.) Comment on: Gastroenterology 1998 Nov;115(5):1049-55.

Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Thomas MJ, et al. **Gene** 1999 Aug 20;236(2):197-208 (100 ref.)

ATF3 and stress responses. Hai T, et al. **Gene Expr** 1999; 7(4-6):321-35 (144 ref.)

Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals. Morano KA, et al. **Gene Expr** 1999;7(4-6):271-82 (92 ref.)

Deciphering the early-response transcription factor networks in mast cells. Nechushtan H, et al. **Immunol Today** 1998 Oct;19(10):441-4 (30 ref.)

The Brn-3a transcription factor. Latchman DS. **Int J Biochem Cell Biol** 1998 Nov;30(11):1153-7 (16 ref.)

NM23-NDP kinase. Postel EH. **Int J Biochem Cell Biol** 1998 Dec;30(12):1291-5 (21 ref.)

The C/EBP family of transcription factors in the liver and other organs. Takiguchi M. **Int J Exp Pathol** 1998 Dec; 79(6):369-91 (232 ref.)

CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review). Yamanaka R, et al. **Int J Mol Med** 1998 Jan;1(1):213-21 (106 ref.)

The role of C/EBP genes in adipocyte differentiation. Darlington GJ, et al. **J Biol Chem** 1998 Nov 13; 273(46):30057-60 (36 ref.)

Recent advances in understanding thyroid hormone receptor coregulators. Lee H, et al. **J Biomed Sci** 1999 Mar-Apr; 6(2):71-8 (54 ref.)

Triggering the interferon response: the role of IRF-3 transcription factor. Hiscott J, et al. **J Interferon Cytokine Res** 1999 Jan;19(1):1-13 (100 ref.)

Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. Holden PR, et al. **J Mol Endocrinol** 1999 Feb;22(1):1-8 (70 ref.)

Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. Vanden Heuvel JP. **J Nutr** 1999 Feb;129(2S Suppl):575S-580S (60 ref.)

Steroidogenic factor 1 (SF-1) is essential for endocrine development and function. Luo X, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):13-8 (38 ref.)

Medical significance of peroxisome proliferator-activated receptors. Vamecq J, et al. **Lancet** 1999 Jul 10; 354(9173):141-8 (55 ref.)

Roles of lipid-activated receptors in the adipogenic action of fatty acids. Grimaldi PA. **Lipids** 1999;34 Suppl:S205-8 (23 ref.)

Dietary polyunsaturated fatty acids and hepatic gene expression. Jump DB, et al. **Lipids** 1999;34 Suppl:S209-12 (25 ref.)

After chromatin is SWItched-on can it be RUSHed? Devine JH, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):49-56 (47 ref.)

Molecular events involved in differentiation of thyroid follicular cells. Missero C, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):37-43 (49 ref.)

The roles of steroidogenic factor 1 in endocrine development and function. Parker KL. **Mol Cell Endocrinol** 1998 May 25;140(1-2):59-63 (25 ref.)

The roles of steroidogenic factor 1 in endocrine development and function. Parker KL. **Mol Cell Endocrinol** 1998 Oct

TRANSCRIPTION FACTORS

25;145(1-2):15-20 (36 ref.)
The molecular biology of Oct-4 in the early mouse embryo. Ovitt CE, et al. **Mol Hum Reprod** 1998 Nov;4(11):1021-31 (95 ref.)
BRCA1 and BRCA2 proteins: roles in health and disease. Duncan JA, et al. **Mol Pathol** 1998 Oct;51(5):237-47 (85 ref.)
Liver enriched transcription factors and differentiation of hepatocellular carcinoma. Hayashi Y, et al. **Mol Pathol** 1999 Feb;52(1):19-24 (86 ref.)
Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Terada Y, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:45-7 (7 ref.)
c-Fos as a transcription factor: a stressful (re)view from a functional map. Kovács KJ. **Neurochem Int** 1998 Oct; 33(4):287-97 (118 ref.)
Making proteins at the synapse: activity-regulated translation and CPEB [see comments] Worley P. **Neuron** 1998 Nov; 21(5):936-8 (12 ref.) Comment in: Neuron 1998 Nov;21(5):1129-39.
The role of transcription factors in circadian gene expression. Kako K, et al. **Neurosci Res** 1998 Aug;31(4):257-64 (61 ref.)
GATA transcription factors and cardiac development. Charron F, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):85-91 (50 ref.)
The mammalian SWI/SNF complex and the control of cell growth [see comments] Muchardt C, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):189-95 (57 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.
Liver development: a paradigm for hepatobiliary disease in later life. Bezerra JA. **Semin Liver Dis** 1998;18(3):203-16 (84 ref.)
Role of transcription factors in inflammatory lung diseases. Rahman I, et al. **Thorax** 1998 Jul;53(7):601-12 (119 ref.)
Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Hertz R, et al. **Toxicol Lett** 1998 Dec 28;102-103:85-90 (40 ref.)
Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. James NH, et al. **Toxicol Lett** 1998 Dec 28;102-103:91-6 (40 ref.)
Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Vanden Heuvel JP. **Toxicol Sci** 1999 Jan; 47(1):1-8 (72 ref.)
WT1--more than a transcription factor? Englert C. **Trends Biochem Sci** 1998 Oct;23(10):389-93 (53 ref.)
Mammalian Krüppel-like transcription factors: more than just a pretty finger. Turner J, et al. **Trends Biochem Sci** 1999 Jun;24(6):236-40 (41 ref.)
Gene regulation by Y-box proteins: coupling control of transcription and translation. Matsumoto K, et al. **Trends Cell Biol** 1998 Aug;8(8):318-23 (53 ref.)
The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. O'Donovan KJ, et al. **Trends Neurosci** 1999 Apr; 22(4):167-73 (52 ref.)
[Differentiating the activity of anticancer drugs: the role of transcription factors] Gillet R, et al. **Ann Pharm Fr** 1998; 56(1):1-8 (37 ref.) (Eng. Abstr.) **(Fre)**
[Hypoxia and tumors: does HIF-1 transcription factor favor tumor growth or hypoxia?] Vandenbunder B. **Bull Cancer** 1998 Oct;85(10):843-5 (10 ref.) (Eng. Abstr.) **(Fre)**
[Transcription factors and angiogenesis] Soncin F, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):358-63 (42 ref.) (Eng. Abstr.) **(Fre)**
[Function and expression of transcription factors implicated in gonadal differentiation] Morohashi K. **Nippon Rinsho** 1998 Jul;56(7):1739-44 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Functional role of nur77 family in T-cell apoptosis and stress response] Okabe T, et al. **Nippon Rinsho** 1998 Jul; 56(7):1734-8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[The role of NF-E2 related transcription factors in hematopoiesis] Itou E. **Rinsho Ketsueki** 1999 Apr; 40(4):280-3 (9 ref.) **(Jpn)**
[Elongin BC complex as the regulator of multiple cellular functions] Aso T. **Seikagaku** 1999 Apr;71(4):278-82 (23 ref.) **(Jpn)**
[Analysis of the unfolded protein response: an intracellular signaling pathway from the endoplasmic reticulum to the nucleus] Mori K. **Seikagaku** 1998 Jul;70(7):505-15 (42 ref.) **(Jpn)**
[Mechanisms of eosinophil development] Yamaguchi Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2161-71 (27 ref.) **(Jpn)**

TRANSCRIPTION FACTORS, TFII

[Function and structural biology of general transcription factors and RNA polymerase II in eukaryotes] Ohkuma Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):438-56 (99 ref.) **(Jpn)**

CHEMISTRY

Functional and structural analysis of the subunits of human transcription factor TFIID. Davidson I, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:233-41 (60 ref.)
Functional analysis of TFIID components. Shen WC, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:219-27 (115 ref.)

METABOLISM

The DPE, a conserved downstream core promoter element that is functionally analogous to the TATA box. Burke TW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:75-82 (37 ref.)
Functional and structural analysis of the subunits of human transcription factor TFIID. Davidson I, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:233-41 (60 ref.)
Functional analysis of TFIID components. Shen WC, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:219-27 (115 ref.)
Polarity of transcription on Pol II and archaeal promoters: where is the "one-way sign" and how is it read? Tsai FT, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:53-61 (25 ref.)
Regulation of gene expression by multiple forms of TFIID and other novel TAFII-containing complexes. Bell B, et al. **Exp Cell Res** 1999 Jan 10;246(1):11-9 (93 ref.)

PHYSIOLOGY

The role of TAFs in RNA polymerase II transcription. Hahn S. **Cell** 1998 Nov 25;95(5):579-82 (26 ref.)
[TAFII230 regulates transcription by molecular mimicry of the TATA box] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):123-9 (60 ref.) **(Jpn)**

TRANSCRIPTION, GENETIC

see related
GENE PRODUCTS, REV
GENE PRODUCTS, TAT
GENE PRODUCTS, TAX
TRANS-ACTIVATORS
TRANSCRIPTION FACTORS

Nuclear receptors, their coactivators and modulation of transcription. Manteuffel-Cymborowska M. **Acta Biochim Pol** 1999;46(1):77-89 (90 ref.)
The molecular basis of oxytocin and oxytocin receptor gene expression in reproductive tissues. Ivell R, et al. **Adv Exp Med Biol** 1998;449:297-306 (46 ref.)
A new model for coronavirus transcription. Sawicki SG, et al. **Adv Exp Med Biol** 1998;440:215-9 (14 ref.)
Genetic organization of polytene chromosomes. Zhimulev IF. **Adv Genet** 1999;39:1-589 (2190 ref.)
Endothelial cell fibrinolysis: transcriptional regulation of fibrinolytic protein gene expression (t-PA, u-PA, and PAI-1) by low alcohol. Booyse FM, et al. **Alcohol Clin Exp Res** 1999 Jun;23(6):1119-24 (30 ref.)
Cis-regulatory elements controlling basal and inducible VIP gene transcription. Hahm SH, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:10-26 (48 ref.)
Regulation of levels of 5-HT2A receptor mRNA. Wohlpart KL, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:128-35 (19 ref.)
Novel technology for detection of genomic and transcriptional alterations in pancreatic cancer. Wallrapp C, et al. **Ann Oncol** 1999;10 Suppl 4:64-8 (31 ref.)
Alteration of nucleosome structure as a mechanism of transcriptional regulation. Workman JL, et al. **Annu Rev Biochem** 1998;67:545-79 (270 ref.)
Multiprotein-DNA complexes in transcriptional regulation. Wolberger C. **Annu Rev Biophys Biomol Struct** 1999; 28:29-56 (115 ref.)
Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Black BL, et al. **Annu Rev Cell Dev Biol** 1998;14:167-96 (141 ref.)
Gene therapy of gliomas: receptor and transcriptional targeting. Spear MA. **Anticancer Res** 1998 Sep-Oct; 18(5A):3223-31 (123 ref.)
Transcriptional control of expression of fungal beta-lactam biosynthesis genes. Litzka O, et al. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1-2):95-105 (60 ref.)
Transcriptional regulation via redox-sensitive iron-sulphur centres in an oxidative stress response. Demple B, et al. **Biochem Soc Symp** 1999;64:119-28 (53 ref.)
Regulation of surfactant protein gene transcription. Whitsett JA, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):303-11 (50 ref.)
Effect of DNA lesions on transcription elongation. Tornaletti S, et al. **Biochimie** 1999 Jan-Feb;81(1-2):139-46 (86 ref.)
Unraveling the role of helicases in transcription. Eisen A, et al. **Bioessays** 1998 Aug;20(8):634-41 (81 ref.)
Nuclear domain 10, the site of DNA virus transcription and replication. Maul GG. **Bioessays** 1998 Aug;20(8):660-7 (63 ref.)
Autonomous regulation in mammalian mitochondrial DNA transcription. Enriquez JA, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):737-47 (104 ref.)
Ca2+/calmodulin-dependent protein kinase IV and calcium signaling. Anderson KA, et al. **Biometals** 1998 Dec; 11(4):331-43 (70 ref.)
Control of gene expression in Trypanosomatidae. Teixeira SM. **Braz J Med Biol Res** 1998 Dec;31(12):1503-16 (60 ref.)
The role of TAFs in RNA polymerase II transcription. Hahn S. **Cell** 1998 Nov 25;95(5):579-82 (26 ref.)
Transcriptional mechanisms regulating MyoD expression in the mouse. Chen JC, et al. **Cell Tissue Res** 1999 Apr; 296(1):213-9 (59 ref.)
Transcription regulation by repressosome and by RNA polymerase contact. Adhya S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:1-9 (58 ref.)
Role of chromatin structure and distal enhancers in tissue-specific transcriptional regulation in vitro. Bagga R, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:569-76 (48 ref.)
The establishment of active chromatin domains. Bell A, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:509-14 (30 ref.)
Transcription in Archaea. Bell SD, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:41-51 (71 ref.)
Mechanisms of viral activators. Berk AJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:243-52 (65 ref.)
Interaction of Escherichia coli sigma 70 with core RNA polymerase. Burgess RR, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:277-87 (99 ref.)
The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Chédin S, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:381-9 (103 ref.)
Transcription regulation, initiation, and "DNA scrunching" by T7 RNA polymerase. Cheetham GM, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:263-7 (29 ref.)
Targeting Sir proteins to sites of action: a general mechanism for regulated repression. Cockell M, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:401-12 (59 ref.)
Ten years of TFIIH. Coin F, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:105-10 (72 ref.)
Functional and structural analysis of the subunits of human transcription factor TFIID. Davidson I, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:233-41 (60 ref.)
Use of artificial activators to define a role for protein-protein and protein-DNA contacts in transcriptional activation. Dove SL, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:173-80 (56 ref.)
RNA polymerase-DNA interaction: structures of intermediate, open, and elongation complexes. Ebright RH. **Cold Spring Harb Symp Quant Biol** 1998;63:11-20 (78 ref.)
Cooperative assembly of RNA polymerase II transcription complexes. Ellwood K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:253-61 (36 ref.)
Strength and regulation without transcription factors: lessons from bacterial rRNA promoters. Gourse RL, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:131-9 (63 ref.)
Autoinhibition as a transcriptional regulatory mechanism. Graves BJ, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:621-9 (60 ref.)
Structure and mechanism in transcriptional antitermination by the bacteriophage lambda N protein. Greenblatt J, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:327-36 (88 ref.)
The functional and regulatory roles of sigma factors in transcription. Gross CA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:141-55 (98 ref.)
Activation and the role of reinitiation in the control of transcription by RNA polymerase II. Hahn S. **Cold Spring Harb Symp Quant Biol** 1998;63:181-8 (91 ref.)
Crossing the line between RNA polymerases: transcription of human snRNA genes by RNA polymerases II and III. Henry RW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:111-20 (54 ref.)
The herpes simplex virus VP16-induced complex: mechanisms of combinatorial transcriptional regulation. Herr W. **Cold Spring Harb Symp Quant Biol** 1998; 63:599-607 (61 ref.)
Mechanism and regulation of yeast RNA polymerase II transcription. Kornberg RD. **Cold Spring Harb Symp Quant Biol** 1998;63:229-32 (26 ref.)
TBP-associated factors in the PCAF histone acetylase complex. Kotani T, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:493-9 (53 ref.)
Transcription factor IIIB: the architecture of its DNA complex, and its roles in initiation of transcription by RNA polymerase III. Kumar A, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:121-9 (60 ref.)
The transcriptional basis of steroid physiology. Lin RJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:577-85 (56 ref.)
Promoter-associated pausing in promoter architecture and postinitiation transcriptional regulation. Lis J. **Cold Spring Harb Symp Quant Biol** 1998;63:347-56 (59 ref.)
Summary: three decades after sigma. Losick R. **Cold Spring Harb Symp Quant Biol** 1998;63:653-66 (0 ref.)
The transition from initiation to elongation by RNA polymerase II. Luse DS, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:289-300 (34 ref.)
The Mad protein family links transcriptional repression to cell differentiation. McArthur GA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:423-33 (100 ref.)
Signaling to chromatin through histone modifications: how clear is the signal? Mizzen C, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:469-81 (109 ref.)
Cofactor requirements for transcriptional activation by Sp1. Näär AM, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:189-99 (59 ref.)
The RNA polymerase II general transcription factors: past, present, and future. Reinberg D, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:83-103 (168 ref.)

Antitermination by bacteriophage lambda Q protein. Roberts JW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:319–25 (35 ref.)
Role of general and gene-specific cofactors in the regulation of eukaryotic transcription. Roeder RG. **Cold Spring Harb Symp Quant Biol** 1998;63:201–18 (167 ref.)
The bacterial enhancer-binding protein NtrC as a molecular machine. Rombel I, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:157–66 (50 ref.)
Transcriptional regulation by DNA structural transitions and single-stranded DNA-binding proteins. Rothman-Denes LB, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:63–73 (124 ref.)
Functional analysis of TFIID components. Shen WC, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:219–27 (115 ref.)
The initiator element: a paradigm for core promoter heterogeneity within metazoan protein-coding genes. Smale ST, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:21–31 (50 ref.)
Regulation of transcription by multisubunit complexes that alter nucleosome structure. Steger DJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:483–91 (81 ref.)
Activation and repression mechanisms in yeast. Struhl K, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:413–21 (66 ref.)
The regulation of gene activity by histones and the histone deacetylase RPD3. Suka N, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:391–9 (58 ref.)
Polarity of transcription on Pol II and archaeal promoters: where is the "one-way sign" and how is it read? Tsai FT, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:53–61 (25 ref.)
Histone deacetylase directs the dominant silencing of transcription in chromatin: association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase. Wade PA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:435–45 (72 ref.)
The SAGA of Spt proteins and transcriptional analysis in yeast: past, present, and future. Winston F, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:553–61 (59 ref.)
Fractions to functions: RNA polymerase II thirty years later. Woychik NA. **Cold Spring Harb Symp Quant Biol** 1998; 63:311–7 (97 ref.)
Building transcriptional regulatory complexes: signals and surfaces. Yamamoto KR, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:587–98 (70 ref.)
Gene transcription by recruitment. Zaman Z, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:167–71 (44 ref.)
Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Chen JD, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(2):169–90 (130 ref.)
Target genes and cellular regulators of the Myc transcription complex. Peters MA, et al. **Crit Rev Eukaryot Gene Expr** 1998;8(3–4):277–96 (225 ref.)
Transcriptional regulation during mesenchymal cell differentiation: the role of coactivators. St-Arnaud R. **Crit Rev Eukaryot Gene Expr** 1998;8(2):191–202 (81 ref.)
Coupling RNA polymerase II transcription with pre-mRNA processing. Bentley D. **Curr Opin Cell Biol** 1999 Jun; 11(3):347–51 (51 ref.)
Activation of RNA polymerase II transcription. Berk AJ. **Curr Opin Cell Biol** 1999 Jun;11(3):330–5 (51 ref.)
mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. Minvielle-Sebastia L, et al. **Curr Opin Cell Biol** 1999 Jun; 11(3):352–7 (52 ref.)
Histone acetylation and cancer. Archer SY, et al. **Curr Opin Genet Dev** 1999 Apr;9(2):171–4 (32 ref.)
Muscle differentiation: more complexity to the network of myogenic regulators. Arnold HH, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):539–44 (51 ref.)
The LXRs: a new class of oxysterol receptors. Peet DJ, et al. **Curr Opin Genet Dev** 1998 Oct;8(5):571–5 (37 ref.)
Transcriptional control of erythropoiesis. Andrews NC, et al. **Curr Opin Hematol** 1994 Mar;1(2):119–24 (29 ref.)
Green fluorescent protein as a reporter of transcription and protein localization in fungi. Cormack B. **Curr Opin Microbiol** 1998 Aug;1(4):406–10 (42 ref.)
DNA structure and transcription. Dai X, et al. **Curr Opin Microbiol** 1999 Apr;2(2):126–30 (50 ref.)
Transcriptional regulation in Archaea. Leigh JA. **Curr Opin Microbiol** 1999 Apr;2(2):131–4 (27 ref.)
Some repressors of bacterial transcription. Müller-Hill B. **Curr Opin Microbiol** 1998 Apr;1(2):145–51 (51 ref.)
Transcriptional control of plant genes responsive to pathogens. Rushton PJ, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):311–5 (47 ref.)
TGF-beta family signal transduction in Drosophila development: from Mad to Smads. Raftery LA, et al. **Dev Biol** 1999 Jun 15;210(2):251–68 (160 ref.)
Transcriptional regulation of mammalian cytochrome c oxidase genes. Grossman LI, et al. **Electrophoresis** 1998 Jun;19(8–9):1254–9 (41 ref.)
Alternative processing of growth hormone receptor transcripts. Edens A, et al. **Endocr Rev** 1998 Oct; 19(5):559–82 (131 ref.)
Factors regulating the transcriptional elongation activity of RNA polymerase II. Shilatifard A. **FASEB J** 1998 Nov; 12(14):1437–46 (84 ref.)
Chromatin and transcription in Saccharomyces cerevisiae. Pérez-Martín J. **FEMS Microbiol Rev** 1999 Jul; 23(4):503–23 (155 ref.)
Modulation of the nucleoid, the transcription apparatus, and the translation machinery in bacteria for stationary phase survival. Ishihama A. **Genes Cells** 1999 Mar;4(3):135–43 (65 ref.)
Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Kaufman RJ. **Genes Dev** 1999 May 15; 13(10):1211–33 (186 ref.)
Transcriptional enhancers and the evolution of the IgH locus. Magor BG, et al. **Immunol Today** 1999 Jan;20(1):13–7 (35 ref.)
Analysis of transcriptional regulatory regions in vivo. MacDonald RJ, et al. **Int J Dev Biol** 1998;42(7 Spec No):983–94 (65 ref.)
Human immunodeficiency virus type-1 transcription: role of the 5'-untranslated leader region (review). Al-Harthi L, et al. **Int J Mol Med** 1998 May;1(5):875–81 (71 ref.)
CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review). Yamanaka R, et al. **Int J Mol Med** 1998 Jan;1(1):213–21 (106 ref.)
The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Andrisani OM, et al. **Int J Oncol** 1999 Aug;15(2):373–9 (93 ref.)
The role of transcriptional control during spermatogenesis. Lele K, et al. **J Androl** 1998 Nov-Dec;19(6):639–49 (90 ref.)
Processive antitermination. Weisberg RA, et al. **J Bacteriol** 1999 Jan;181(2):359–67 (105 ref.)
Chromatin remodeling and transcription. Hirose S. **J Biochem (Tokyo)** 1998 Dec 1;124(6):1060–4 (44 ref.)
Protein crystallization on lipid layers and structure determination of the RNA polymerase II transcription initiation complex. Asturias FJ, et al. **J Biol Chem** 1999 Mar 12;274(11):6813–6 (29 ref.)
Facilitated target location on DNA by individual Escherichia coli RNA polymerase molecules observed with the scanning force microscope operating in liquid. Bustamante C, et al. **J Biol Chem** 1999 Jun 11;274(24):16665–8 (19 ref.)
C/EBP and the control of phosphoenolpyruvate carboxykinase gene transcription in the liver. Croniger C, et al. **J Biol Chem** 1998 Nov 27;273(48):31629–32 (52 ref.)
Transcription signals of mitochondrial and nuclear genes for mitochondrial proteins in dicot plants. Brennicke A, et al. **J Hered** 1999 May-Jun;90(3):345–50 (34 ref.)
Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. Kagnoff MF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S444–7 (11 ref.)
DNA repair and transcription in human premature aging disorders. Bohr VA, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):11–3 (27 ref.)
Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. Freedman LP. **J Nutr** 1999 Feb;129(2S Suppl):581S–586S (34 ref.)
Molecular mechanisms for the regulation of the expression and function of muscarinic acetylcholine receptors. Hamilton SE, et al. **J Physiol Paris** 1998 Jun-Aug; 92(3-4):275–8 (15 ref.)
The cholinergic locus: ChAT and VAChT genes. Mallet J, et al. **J Physiol Paris** 1998 Apr;92(2):145–7 (17 ref.)
Natural endogenous reverse transcription of HIV-1. Zhang H, et al. **J Reprod Immunol** 1998 Dec;41(1-2):255–60 (11 ref.)
Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. Takimoto GS, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):45–50 (28 ref.)
Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, and posttranslational levels. Kühn H, et al. **Lipids** 1999;34 Suppl:S273–9 (34 ref.)
A model for the development of the hypothalamic-pituitary axis: transcribing the hypophysis. Kioussi C, et al. **Mech Dev** 1999 Mar;81(1-2):23–35 (82 ref.)
In vitro transcription and translation of lipoprotein lipase. Ranganathan G, et al. **Methods Mol Biol** 1999;109:337–41 (16 ref.)
Continuous-flow cell-free translation, transcription-translation, and replication-translation systems. Ryabova LA, et al. **Methods Mol Biol** 1998; 77:179–93 (31 ref.)
Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Ghatpande S, et al. **Mol Cell Biochem** 1999 Jun;196(1-2):93–7 (50 ref.)
Long chain fatty acids as modulators of gene transcription in preadipose cells. Grimaldi PA, et al. **Mol Cell Biochem** 1999 Feb;192(1-2):63–8 (33 ref.)
After chromatin is SWItched-on can it be RUSHed? Devine JH, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):49–56 (47 ref.)
Effects of differentiation on the transcriptional regulation of the FGF-4 gene: critical roles played by a distal enhancer. Lamb KA, et al. **Mol Reprod Dev** 1998 Oct;51(2):218–24 (57 ref.)
Transcription response and nucleotide excision repair. Mullenders LH. **Mutat Res** 1998 Nov 12;409(2):59–64 (46 ref.)
Coupling physiology and gene regulation in bacteria: the phosphotransferase sugar uptake system delivers the signals. Stülke J, et al. **Naturwissenschaften** 1998 Dec; 85(12):583–92 (95 ref.)
Transcriptional regulation of metabolic processes: implications for cardiac metabolism. van Bilsen M, et al. **Pflugers Arch** 1998 Dec;437(1):2–14 (114 ref.)
Transgene-induced gene silencing in plants. Vaucheret H, et al. **Plant J** 1998 Dec;16(6):651–9 (67 ref.)
Tet B or not tet B: advances in tetracycline-inducible gene expression [comment] Blau HM, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):797–9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 2;96(3):1013–8.
What sets the TonE during osmotic stress? [comment] Kültz D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1814–6 (24 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2538–42.
Chemicals that footprint DNA: hitting HIV-1 in the minor groove [comment]] Tutter A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12739–41 (26 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):12890–5.
Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7723–30 (83 ref.)
Regulation of brain-derived neurotrophic factor mRNA levels in hippocampus by neuronal activity. Castrén E, et al. **Prog Brain Res** 1998;117:57–64 (28 ref.)
Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Grummt I. **Prog Nucleic Acid Res Mol Biol** 1999;62:109–54 (232 ref.)
Transcriptional and posttranscriptional regulation of proteoglycan gene expression. Iozzo RV, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:19–53 (134 ref.)
Structural organization and transcription regulation of nuclear genes encoding the mammalian cytochrome c oxidase complex. Lenka N, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:309–44 (210 ref.)
Regulation of RNA polymerase I transcription in yeast and vertebrates. Reeder RH. **Prog Nucleic Acid Res Mol Biol** 1999;62:293–327 (212 ref.)
Regulation of the Bacillus subtilis pyrimidine biosynthetic operon by transcriptional attenuation: control of gene expression by an mRNA-binding protein. Switzer RL, et al. **Prog Nucleic Acid Res Mol Biol** 1999;62:329–67 (82 ref.)
The nucleosome: a powerful regulator of transcription. Wolffe AP, et al. **Prog Nucleic Acid Res Mol Biol** 1998; 61:379–422 (166 ref.)
Mechanisms of transcriptional regulation. Franklin GC. **Results Probl Cell Differ** 1999;25:171–87 (70 ref.)
Regulation of DNA virus transcription by cellular POU family transcription factors. Latchman DS. **Rev Med Virol** 1999 Jan-Mar;9(1):31–8 (62 ref.)
The organization of replication and transcription. Cook PR. **Science** 1999 Jun 11;284(5421):1790–5 (52 ref.)
Transcriptional coregulators in development. Mannervik M, et al. **Science** 1999 Apr 23;284(5414):606–9 (56 ref.)
Thyroid hormone receptor coactivators and corepressors. Koenig RJ. **Thyroid** 1998 Aug;8(8):703–13 (105 ref.)
Forty years under the central dogma [see comments] Thieffry D, et al. **Trends Biochem Sci** 1998 Aug;23(8):312–6 (36 ref.) Comment in: Trends Biochem Sci 1998 Dec;23(12):468.
Gene regulation by Y-box proteins: coupling control of transcription and translation. Matsumoto K, et al. **Trends Cell Biol** 1998 Aug;8(8):318–23 (53 ref.)
NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Foo SY, et al. **Trends Genet** 1999 Jun; 15(6):229–35 (50 ref.)
Early steps in pituitary organogenesis. Sheng HZ, et al. **Trends Genet** 1999 Jun;15(6):236–40 (36 ref.)
Transcriptional regulation of angiotensinogen gene expression. Brasier AR, et al. **Vitam Horm** 1999;57:217–47 (110 ref.)
[Transcriptional regulation by CREB and proteins of CREB family] Tian JH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul;27(3):227–32 (20 ref.) (Eng. Abstr.) **(Chi)**
[Mutant mice as a model of human diseases of aging. Defective transcription and premature aging] de Boer J, et al. **Tijdschr Gerontol Geriatr** 1999 Aug;30(4):168–70 (13 ref.) (Eng. Abstr.) **(Dut)**
[Impact of damaged genes: effects on replication and transcription] Nakabeppu Y. **Fukuoka Igaku Zasshi** 1999 Jul;90(7):311–7 (5 ref.) **(Jpn)**
[Transcriptional regulation and subcellular localization of mutant androgen receptor in spinal and bulbar muscular atrophy] Miwa S, et al. **Nippon Rinsho** 1999 Apr; 57(4):869–73 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Expression of a novel transcript for the TRH receptor in human pituitary adenomas] Yamada M, et al. **Nippon Rinsho** 1999 Mar;57(3):737–45 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Structural biology of Escherichia coli RNA polymerase] Fujita N. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):421–9 (45 ref.) **(Jpn)**
[A prelude to chromatin transcription] Hirose S. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2057–8 (0 ref.) **(Jpn)**
[Regulatory mechanisms of transcription from chromosomes] Horikoshi M, et al. **Tanpakushitsu Kakusan Koso** 1998 Nov; 43(14):2059–78 (106 ref.) **(Jpn)**
[Histone-like TAFs within the PCAF histone acetylase

complex] Nakatani Y. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2079–86 (20 ref.) **(Jpn)**

[Structural basis for chromatin transcription] Nakatani Y, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):430–7 (29 ref.) **(Jpn)**

[Function and structural biology of general transcription factors and RNA polymerase II in eukaryotes] Ohkuma Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):438–56 (99 ref.) **(Jpn)**

[Transcriptional regulation mediated by chromatin remodeling] Okada M, et al. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2094–100 (25 ref.) **(Jpn)**

[Transcription in Xenopus early embryos and apoptotic program preset in the fertilized egg] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):32–41 (26 ref.) **(Jpn)**

[TAFII230 regulates transcription by molecular mimicry of the TATA box] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1999 Feb;44(2):123–9 (60 ref.) **(Jpn)**

DRUG EFFECTS

Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level. Zewail-Foote M, et al. **Anticancer Drug Des** 1999 Feb; 14(1):1–9 (51 ref.)

Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Yeh S, et al. **Keio J Med** 1999 Jun;48(2):87–92 (40 ref.)

Regulation of cytochrome P450 gene transcription by phenobarbital. Kemper B. **Prog Nucleic Acid Res Mol Biol** 1998;61:23–64 (78 ref.)

GENETICS

Transcription-coupled repair of DNA damage: unanticipated players, unexpected complexities. Leadon SA. **Am J Hum Genet** 1999 May;64(5):1259–63 (39 ref.)

Dietary lipids: ancestral ligands and regulators of cell signaling pathways [editorial; comment] Zaloga GP. **Crit Care Med** 1999 Aug;27(8):1646–8 (10 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1409–20.

CREB-mediated transcriptional control. Andrisani OM. **Crit Rev Eukaryot Gene Expr** 1999;9(1):19–32 (132 ref.)

Mechanism and regulation of transcriptional elongation by RNA polymerase II. Reines D, et al. **Curr Opin Cell Biol** 1999 Jun;11(3):342–6 (56 ref.)

Eubacterial sigma-factors. Wösten MM. **FEMS Microbiol Rev** 1998 Sep;22(3):127–50 (206 ref.)

Repression of transcription initiation in bacteria. Rojo F. **J Bacteriol** 1999 May;181(10):2987–91 (68 ref.)

Transcriptional control by cell-cycle regulators: a review. Lania L, et al. **J Cell Physiol** 1999 May;179(2):134–41 (67 ref.)

Differences in brain gene expression between sleep and waking as revealed by mRNA differential display and cDNA microarray technology. Cirelli C, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:44–52 (66 ref.)

Human genes involved in chromatin remodeling in transcription initiation, and associated diseases: An overview using the GENATLAS database. Roux-Rouquie M, et al. **Mol Genet Metab** 1999 Aug;67(4):261–77 (158 ref.)

A spatial approach to transcriptional profiling: mechanotransduction and the focal origin of atherosclerosis. Davies PF, et al. **Trends Biotechnol** 1999 Sep;17(9):347–51 (29 ref.)

Cardiosensor mice and transcriptional subdomains of the vertebrate heart. Kelly RG, et al. **Trends Cardiovasc Med** 1999 Jan-Feb;9(1-2):3–10 (59 ref.)

[Transcription antitermination in bacteria and bacteriophages] Wolska KI. **Postepy Biochem** 1998; 44(1):32–9 (149 ref.) **(Pol)**

IMMUNOLOGY

Transcriptional regulation in B cell differentiation. Liberg D, et al. **Crit Rev Immunol** 1999;19(2):127–53 (287 ref.)

PHYSIOLOGY

Pathways of Egr-1-mediated gene transcription in vascular biology [comment] Silverman ES, et al. **Am J Pathol** 1999 Mar;154(3):665–70 (56 ref.) Comment on: Am J Pathol 1999 Mar;154(3):937–44.

Early aldosterone action: toward filling the gap between transcription and transport. Verrey F. **Am J Physiol** 1999 Sep;277(3 Pt 2):F319–27 (68 ref.)

Transcriptional and translational regulation of gene expression in haploid spermatids. Steger K. **Anat Embryol (Berl)** 1999 Jun;199(6):471–87 (174 ref.)

Transcriptional activity in the brain during sleep deprivation. Toppila J, et al. **Ann Med** 1999 Apr;31(2):146–51 (44 ref.)

Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control. Wagner M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:1–10 (36 ref.)

Chromatin remodeling: a marriage between two families? Pollard KJ, et al. **Bioessays** 1998 Sep;20(9):771–80 (68 ref.)

Phosphorylation of RNA polymerase II C-terminal domain (CTD): a new control for heat shock gene expression? Dubois MF, et al. **Cell Stress Chaperones** 1998 Sep; 3(3):147–51 (52 ref.)

Endocrine regulation of gonadotropin and growth hormone gene transcription in fish. Melamed P, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):325–38 (125 ref.)

Transcriptional control: repression by local chromatin modification. Ashraf SI, et al. **Curr Biol** 1998 Sep 24; 8(19):R683–6 (23 ref.)

Transcriptional regulation: SWItching circuitry. Wade PA, et al. **Curr Biol** 1999 Mar 25;9(6):R221–4 (12 ref.)

Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Eastman Q, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):233–40 (102 ref.)

Multiple signals converging on NF-kappaB. Mercurio F, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):226–32 (50 ref.)

Nuclear transport and transcriptional regulation. Turpin P, et al. **FEBS Lett** 1999 Jun 4;452(1-2):82–6 (41 ref.)

Steroid receptors at the nexus of transcriptional regulation. Barrett TJ, et al. **J Cell Biochem Suppl** 1998;30-31:185–93 (40 ref.)

B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments. Sala A, et al. **J Cell Physiol** 1999 Jun;179(3):245–50 (49 ref.)

Transcription elongation: structural basis and mechanisms. Nudler E. **J Mol Biol** 1999 Apr 23;288(1):1–12 (98 ref.)

Cell volume-regulated gene transcription. Waldegger S, et al. **Kidney Blood Press Res** 1998;21(2-4):241–4 (33 ref.)

Transcriptional regulation of the StAR gene. Reinhart AJ, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):161–9 (86 ref.)

Transcription initiation in Archaea: facts, factors and future aspects. Soppa J. **Mol Microbiol** 1999 Mar;31(5):1295–305 (46 ref.)

Transcriptional regulation of Syndecan-1 expression by growth factors. Jaakkola P, et al. **Prog Nucleic Acid Res Mol Biol** 1999;63:109–38 (130 ref.)

Intersecting signalling and transcriptional pathways in Drosophila heart specification. Frasch M. **Semin Cell Dev Biol** 1999 Feb;10(1):61–71 (45 ref.)

Cellular memory of transcriptional states by Polycomb-group proteins [see comments] Jacobs JJ, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):227–35 (90 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.

Concise review of the glutathione S-transferases and their significance to toxicology. Eaton DL, et al. **Toxicol Sci** 1999 Jun;49(2):156–64 (71 ref.)

Histone deacetylases: transcriptional repression with SINers and NuRDs. Ayer DE. **Trends Cell Biol** 1999 May; 9(5):193–8 (66 ref.)

[Transcriptional regulation of Huntington disease gene] Nagao Y, et al. **Nippon Rinsho** 1999 Apr;57(4):912–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of transcriptional regulation by bent DNA structures] Ohyama T. **Seikagaku** 1998 Nov;70(11):1339–44 (18 ref.) **(Jpn)**

[Regulation of protein S100 expression during transcription] Leśniak W, et al. **Postepy Hig Med Dosw** 1999;53(2):183–93 (32 ref.) (Eng. Abstr.) **(Pol)**

TRANSCRIPTIONAL ACTIVATION see **TRANS-ACTIVATION (GENETICS)**

TRANSCRIPTIONAL REGULATORY ELEMENTS see **GENES, REGULATOR**

TRANSCULTURAL NURSING

Illness as a problem of meaning: moving culture from the classroom to the clinic. McGrath BB. **ANS Adv Nurs Sci** 1998 Dec;21(2):17–29 (40 ref.)

Global migration and health: ecofeminist perspectives. McGuire S. **ANS Adv Nurs Sci** 1998 Dec;21(2):1–16 (50 ref.)

From the desert: transcultural aspects of cancer nursing care in Israel. Delbar V. **Cancer Nurs** 1999 Feb;22(1):45–51 (15 ref.)

The experience of having cancer in Latin America. Granda-Cameron C. **Cancer Nurs** 1999 Feb;22(1):51–7 (35 ref.)

Cultural views of cancer around the world. Navon L. **Cancer Nurs** 1999 Feb;22(1):39–45 (43 ref.)

Patterns of mental health care among Mexican Americans. Bechtel GA, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Nov;36(11):20–7 (28 ref.)

METHODS

Caring for the Islamic patient. McKennis AT. **AORN J** 1999 Jun;69(6):1187–96; quiz 1199–206 (18 ref.)

Cut from the right wood: spiritual and ethical pluralism in professional nursing practice. Cusveller B. **J Adv Nurs** 1998 Aug;28(2):266–73 (26 ref.)

ORGANIZATION & ADMINISTRATION

Health and quality of life within Colonias settlements along the United States and Mexico border. Davidhizar R, et al. **Public Health Nurs** 1999 Aug;16(4):301–6 (18 ref.)

TRANSCULTURAL STUDIES see **CROSS-CULTURAL COMPARISON**

TRANSCUTANEOUS ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

TRANSCUTANEOUS BLOOD GAS MONITORING see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

TRANSCUTANEOUS CAPNOMETRY see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

TRANSCUTANEOUS ELECTRIC NERVE STIMULATION

Acupuncture: neurophysiological perspectives. Hirokawa S. **Disabil Rehabil** 1999 Mar;21(3):131–2; discussion 137–8 (6 ref.)

Transcutaneous cranial electrical stimulation (TCES): a review 1998. Limoge A, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):529–38 (108 ref.)

Gait after spinal cord injury and the central pattern generator for locomotion. Pinter MM, et al. **Spinal Cord** 1999 Aug; 37(8):531–7 (40 ref.)

[Spinal cord stimulation in angina pectoris—what is the current situation?] Norrsell H, et al. **Lakartidningen** 1999 Mar 24;96(12):1430–2, 1435–7 (37 ref.) (Eng. Abstr.) **(Swe)**

INSTRUMENTATION

Visceral chest pain in unstable angina pectoris and effects of transcutaneous electrical nerve stimulation. (TENS). A review. Börjesson M. **Herz** 1999 Apr;24(2):114–25 (130 ref.)

TRANSCUTANEOUS OXIMETRY see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

TRANSDERMAL ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

TRANSDERMAL ELECTROSTIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

TRANSDUCERS, PRESSURE

Technology and application of ultraminiature catheter pressure transducers. Zimmer HG, et al. **Can J Cardiol** 1998 Oct;14(10):1259–66 (34 ref.)

TRANSDUCTION, GENETIC

Bacteriophage and gene transfer. Lindqvist BH. **APMIS Suppl** 1998;84:15–8 (14 ref.)

Transduction of a preselected population of human epidermal stem cells: consequences for gene therapy. Bickenbach JR, et al. **Proc Assoc Am Physicians** 1999 May-Jun; 111(3):184–9 (44 ref.)

In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors. Sorrentino BP, et al. **Prog Exp Tumor Res** 1999;36:143–61 (47 ref.)

TRANSESOPHAGEAL ECHOCARDIOGRAPHY see **ECHOCARDIOGRAPHY, TRANSESOPHAGEAL**

TRANSFECTION

see related
ELECTROPORATION
TRANSFORMATION, BACTERIAL

Liposomes as a gene delivery system. Ropert C. **Braz J Med Biol Res** 1999 Feb;32(2):163–9 (50 ref.)

Adoptive transfer of genetically modified macrophages elucidated TGF-beta-mediated 'self-defence' of the glomerulus against local action of macrophages. Kitamura M. **Nephrol Dial Transplant** 1999;14 Suppl 1:35–8 (18 ref.)

METHODS

Gene therapy for renal fibroblasts [editorial] Clarke HC, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1615–7 (28 ref.)

RNA virus vectors: where are we and where do we need to go? [comment] Palese P. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12750–2 (39 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):12989–94.

PHYSIOLOGY

The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Raymond JR, et al. **Br J Pharmacol** 1999 Aug;127(8):1751–64 (160 ref.)

TRANSFER (PSYCHOLOGY)

Exploring the etiology of content specificity: factors influencing analogic transfer and problem solving. Eva KW, et al. **Acad Med** 1998 Oct;73(10 Suppl):S1–5 (45 ref.)

TRANSFER OF LEARNING see **TRANSFER (PSYCHOLOGY)**

TRANSFER OF TRAINING see **TRANSFER (PSYCHOLOGY)**

TRANSFER RNA see **RNA, TRANSFER**

TRANSFER RNA, AMINO ACID-SPECIFIC see **RNA,**

TRANSFER, AMINO ACID-SPECIFIC

TRANSFER RNA, AMINO ACYL see **RNA, TRANSFER, AMINO ACYL**

TRANSFER RNA, LEU see **RNA, TRANSFER, LEU**

TRANSFERASES

CHEMISTRY

Enzymology of phytosterol transformations. Nes WD, et al. **Crit Rev Biochem Mol Biol** 1999;34(2):81–93 (40 ref.)

ISOLATION & PURIFICATION

Reconstitution of yeast farnesyltransferase from individually purified subunits. Urano J, et al. **Methods Mol Biol** 1999; 116:145–59 (24 ref.)

METABOLISM

The oligosaccharyltransferase complex from yeast. Knauer R, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):259–73 (114 ref.)

[Human drug metabolizing enzymes. II. Conjugation enzymes] Vereczkey L, et al. **Acta Pharm Hung** 1998 Sep; 68(5):284–8 (21 ref.) (Eng. Abstr.) **(Hun)**

TRANSFERENCE (PSYCHOLOGY)

Events in the life of the therapist: the effect on transference and countertransference. Gold JH. **Harv Rev Psychiatry** 1999 Jan–Feb;6(5):263–9 (51 ref.)

The "ideologic" view of transference. Biancoli R. **J Am Acad Psychoanal** 1998 Spring;26(1):15–28 (50 ref.)

TRANSFERRIN

see related
RECEPTORS, TRANSFERRIN

ADMINISTRATION & DOSAGE

Transferrin As A targeting ligand for liposomes and anticancer drugs. Singh M. **Curr Pharm Des** 1999 Jun; 5(6):443–51 (51 ref.)

ANALOGS & DERIVATIVES

New 'state' markers for the detection of alcoholism. Lesch OM, et al. **Alcohol Alcohol Suppl** 1996 Mar;1:59–62 (26 ref.)

CHEMISTRY

Three-dimensional structure of lactoferrin. Implications for function, including comparisons with transferrin. Baker EN, et al. **Adv Exp Med Biol** 1998;443:1–14 (32 ref.)

IMMUNOLOGY

Overcoming the histocompatibility barrier: transferrins as carriers and modulators of immunogenic identity. Pierpaoli W. **Cell Transplant** 1998 Nov–Dec;7(6):541–8 (60 ref.)

METABOLISM

Three-dimensional structure of lactoferrin. Implications for function, including comparisons with transferrin. Baker EN, et al. **Adv Exp Med Biol** 1998;443:1–14 (32 ref.)

Carbohydrate-deficient glycoprotein syndromes: inborn errors of protein glycosylation. Keir G, et al. **Ann Clin Biochem** 1999 Jan;36 (Pt 1):20–36 (96 ref.)

Non-transferrin-bound iron and cellular toxicity [editorial; comment] Anderson GJ. **J Gastroenterol Hepatol** 1999 Feb; 14(2):105–8 (26 ref.) Comment on: J Gastroenterol Hepatol 1999 Feb;14(2):126–32.

Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. Fletcher LM, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):202–14 (157 ref.)

[Diagnosis and treatment of primary hemochromatosis] Swinkels DW, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1404–8 (57 ref.) (Eng. Abstr.) **(Dut)**

TRANSFERRIN RECEPTORS see **RECEPTORS, TRANSFERRIN**

TRANSFORMATION, BACTERIAL

see related
TRANSFECTION

Bacterial gene transfer by natural genetic transformation. Håvarstein LS. **APMIS Suppl** 1998;84:43–6 (19 ref.)

Competence for natural transformation in Neisseria gonorrhoeae: a model system for studies of horizontal gene transfer. Koomey M. **APMIS Suppl** 1998;84:56–61 (50 ref.)

Barriers to horizontal gene transfer by natural transformation in soil bacteria. Nielsen KM. **APMIS Suppl** 1998;84:77–84 (60 ref.)

Bacterial evolution: bacteria play pass the gene. Saunders NJ, et al. **Curr Biol** 1999 Mar 11;9(5):R180–3 (21 ref.)

Transformation of mycoplasmas. Minion FC, et al. **Methods Mol Biol** 1998;104:227–34 (19 ref.)

TRANSFORMATION, GENETIC

see related
DNA, RECOMBINANT

Foreign DNA in mammalian systems. Doerfler W, et al. **APMIS Suppl** 1998;84:62–8 (23 ref.)

Genome instability. Kolstø AB. **APMIS Suppl** 1998;84:69–73 (22 ref.)

Bacteriophage and gene transfer. Lindqvist äH. **APMIS Suppl** 1998;84:15–8 (14 ref.)

Transposons as gene haulers. Mahillon J. **APMIS Suppl** 1998; 84:29–36 (10 ref.)

The potential of integrons and connected programmed rearrangements for mediating horizontal gene transfer. Sundström L. **APMIS Suppl** 1998;84:37–42 (50 ref.)

Broad-host-range plasmids and their role in gene transfer in nature. Valla S. **APMIS Suppl** 1998;84:19–24 (13 ref.)

Particle bombardment mediated transformation. Finer JJ, et al. **Curr Top Microbiol Immunol** 1999;240:59–80 (110 ref.)

Lessons in gene transfer to plants by a gifted microbe. Hansen G, et al. **Curr Top Microbiol Immunol** 1999;240:21–57 (200 ref.)

DNA issues. Meulien P. **Dev Biol Stand** 1998;93:57–60 (5 ref.)

Overview of biological effects of addition of DNA molecules to cells. Temin HM. **Dev Biol Stand** 1998;93:37–44 (36 ref.)

Sperm/DNA interaction: integration of foreign DNA sequences in the mouse sperm genome. Magnano AR, et al. **J Reprod Immunol** 1998 Dec;41(1–2):187–96 (23 ref.)

Fate of transforming DNA in pathogenic fungi. Kwon-Chung KJ, et al. **Med Mycol** 1998;36 Suppl 1:38–44 (43 ref.)

Plant transformation via protoplast electroporation. Bates GW. **Methods Mol Biol** 1999;111:359–66 (18 ref.)

Transformation of rice via PEG-mediated DNA uptake into protoplasts. Datta K, et al. **Methods Mol Biol** 1999; 111:335–47 (19 ref.)

Transformation of maize via tissue electroporation. D'Halluin K, et al. **Methods Mol Biol** 1999;111:367–73 (14 ref.)

Transformation of maize using silicon carbide whiskers. Dunwell JM. **Methods Mol Biol** 1999;111:375–82 (26 ref.)

Agrobacterium-mediated transformation of Petunia leaf disks. van der Meer IM. **Methods Mol Biol** 1999;111:327–34 (13 ref.)

Transformation of wheat via particle bombardment. Vasil IK, et al. **Methods Mol Biol** 1999;111:349–58 (18 ref.)

[Genetic transformation of plants, recombination processes, and gene expression regulation in transgenic plants] Kurochkina SD, et al. **Mol Gen Mikrobiol Virusol** 1998; (4):3–12 (131 ref.) (Eng. Abstr.) **(Rus)**

TRANSFORMED CELL LINE see **CELL LINE, TRANSFORMED**

TRANSFORMING GENES see **ONCOGENES**

TRANSFORMING GROWTH FACTOR ALPHA

PHYSIOLOGY

[Transforming growth factors and cancer] Zhu ZW, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):335–7 (10 ref.) **(Chi)**

TRANSFORMING GROWTH FACTOR ALPHA RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

TRANSFORMING GROWTH FACTOR BETA

Molecular and functional aspects of latent transforming growth factor-beta binding protein: just a masking protein? Mangasser-Stephan K, et al. **Cell Tissue Res** 1999 Sep; 297(3):363–70 (62 ref.)

Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Sinha S, et al. **Matrix Biol** 1998 Dec;17(8–9):529–45 (72 ref.)

ANTAGONISTS & INHIBITORS

Follistatin. Patel K. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1087–93 (17 ref.)

TGF beta inhibitors. New and unexpected requirements in vertebrate development. Smith WC. **Trends Genet** 1999 Jan; 15(1):3–5 (23 ref.)

BIOSYNTHESIS

The antiproliferative effect of glucocorticoids: is it related to induction of TGF-beta? [editorial] Almawi WY, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2450–2 (12 ref.)

DRUG EFFECTS

Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Kim H, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1418S–1425S (102 ref.)

GENETICS

Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Miyazono K. **Bone** 1999 Jul;25(1):91–3 (39 ref.)

Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Gauldie J, et al. **Curr Top Pathol** 1999;93:35–45 (38 ref.)

Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). Lu L, et al. **J Leukoc Biol** 1999 Aug; 66(2):293–6 (31 ref.)

IMMUNOLOGY

Effects of TGF-beta on the immune system: implications for cancer immunotherapy. de Visser KE, et al. **Leukemia** 1999 Aug;13(8):1188–99 (152 ref.)

METABOLISM

Specificity in transforming growth factor-beta signaling pathways. Ring CJ, et al. **Am J Hum Genet** 1999 Mar; 64(3):691–7 (37 ref.)

TGF-beta signal transduction. Massagué J. **Annu Rev Biochem** 1998;67:753–91 (290 ref.)

Proteolytic control of growth factor availability. Rifkin DB, et al. **APMIS** 1999 Jan;107(1):80–5 (52 ref.)

Smads: transcriptional activators of TGF-beta responses. Derynck R, et al. **Cell** 1998 Dec 11;95(6):737–40 (28 ref.)

Regulation and regulatory activities of transforming growth factor beta. Bonewald LF. **Crit Rev Eukaryot Gene Expr** 1999;9(1):33–44 (93 ref.)

Intracellular signaling: Fleshing out the TGFbeta pathway. Padgett RW. **Curr Biol** 1999 Jun 3;9(11):R408–11 (14 ref.)

Extracellular modulation of the Hedgehog, Wnt and TGF-beta signalling pathways during embryonic development. Capdevila J, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):427–33 (91 ref.)

BMPs, Smads and metalloproteases: extracellular and intracellular modes of negative regulation. Cho KW, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):443–9 (55 ref.)

An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs. Hutchinson IV. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):665–71 (90 ref.)

Signal transduction of the TGF-beta superfamily by Smad proteins. Kawabata M, et al. **J Biochem (Tokyo)** 1999 Jan; 125(1):9–16 (67 ref.)

Transforming growth factor beta-angiotensin II interaction: implications for cardiac and renal disease. Luft FC. **J Mol Med** 1999 Jul;77(7):517–8 (15 ref.)

TGF-beta activity and expression of its receptors in B-cell chronic lymphocytic leukemia. Lagneaux L, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):99–106 (25 ref.)

Transforming growth factor-beta in benign and malignant prostate. Lee C, et al. **Prostate** 1999 Jun 1;39(4):285–90 (50 ref.)

[Activation of latent TGF-beta. A required mechanism for vascular integrity] Gleizes PE, et al. **Pathol Biol (Paris)** 1999 Apr;47(4):322–9 (62 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Taipale J, et al. **Adv Cancer Res** 1998;75:87–134 (440 ref.)

Specificity in transforming growth factor-beta signaling pathways. Ring CJ, et al. **Am J Hum Genet** 1999 Mar; 64(3):691–7 (37 ref.)

Three distinct roles for TGF-beta during intercellular induction of apoptosis: a review. Häufel T, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):105–11 (61 ref.)

Development of TGF-beta resistance during malignant progression. Kim YS, et al. **Arch Pharm Res** 1999 Feb; 22(1):1–8 (57 ref.)

Can't get no SMADisfaction: Smad proteins as positive and negative regulators of TGF-beta family signals. Christian JL, et al. **Bioessays** 1999 May;21(5):382–90 (60 ref.)

Smad4 (DPC4)--a potent tumour suppressor? Duff EK, et al. **Br J Cancer** 1998 Dec;78(12):1615–9 (49 ref.)

Regulation by members of the transforming growth factor beta superfamily of the digital and interdigital fates of the autopodial limb mesoderm. Macias D, et al. **Cell Tissue Res** 1999 Apr;296(1):95–102 (51 ref.)

Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Ständer M, et al. **Cell Tissue Res** 1999 May;296(2):221–7 (48 ref.)

Transforming growth factor beta in fracture repair. Bostrom MP, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S124–31 (46 ref.)

The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Basile DP. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):21–30 (135 ref.)

TGF-beta family signal transduction in Drosophila development: from Mad to Smads. Raftery LA, et al. **Dev Biol** 1999 Jun 15;210(2):251–68 (160 ref.)

Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Chang NS. **Int J Mol Med** 1998 Dec;2(6):653–9 (53 ref.)

Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. Engel ME, et al. **J Cell Biochem Suppl** 1998;30–31:111–22 (61 ref.)

MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. Fairlie WD, et al. **J Leukoc Biol** 1999 Jan;65(1):2-5 (12 ref.)
Genetic events and the role of TGF beta in epithelial tumour progression. Akhurst RJ, et al. **J Pathol** 1999 Jan; 187(1):82-90 (138 ref.)
Autocrine regulation of Leydig cell differentiated functions by insulin-like growth factor I and transforming growth factor beta. Le Roy C, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):379-84 (50 ref.)
Transforming growth factor beta signal transduction in the kidney. Böttinger EP, et al. **Kidney Blood Press Res** 1998; 21(2-4):259-61 (19 ref.)
Vasoactive factors and tubulointerstitial injury. Wolf G. **Kidney Blood Press Res** 1999;22(1-2):62-70 (89 ref.)
Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy [editorial; comment] Border WA, et al. **Kidney Int** 1998 Oct;54(4):1390-1 (10 ref.) Comment on: Kidney Int 1996 Apr;49(4):1120-6. Comment on: Kidney Int 1998 Oct;54(4):1052-62.
Downstream factors in transforming growth factor-beta family signaling. Visser JA, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1-2):7-17 (113 ref.)
Going mad with Smads. Zhou S, et al. **N Engl J Med** 1999 Oct 7;341(15):1144-6 (8 ref.)
Adoptive transfer of genetically modified macrophages elucidated TGF-beta-mediated 'self-defence' of the glomerulus against local action of macrophages. Kitamura M. **Nephrol Dial Transplant** 1999;14 Suppl 1:35-8 (18 ref.)
Growth inhibitors for mammary epithelial cells. Brandt R, et al. **Prog Mol Subcell Biol** 1998;20:197-248 (117 ref.)
The growth-inhibitory effects of TGF beta. Herrera RE. **Prog Mol Subcell Biol** 1998;20:11-24 (101 ref.)
Experimental and human liver fibrogenesis. Kovalszky I, et al. **Scand J Gastroenterol Suppl** 1998;228:51-5 (25 ref.)
The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Klahr S, et al. **Semin Nephrol** 1998 Nov;18(6):622-32 (89 ref.)
Loss of growth regulation by transforming growth factor-beta (TGF-beta) in human cancers: studies on endometrial carcinoma. Gold LI, et al. **Semin Reprod Endocrinol** 1999;17(1):73-92 (228 ref.)
Regulation of Smad signalling by protein associations and signalling crosstalk. Zhang Y, et al. **Trends Cell Biol** 1999 Jul;9(7):274-9 (60 ref.)
Transforming growth factor beta in infectious disease: always there for the host and the pathogen. Fitzpatrick DR, et al. **Trends Microbiol** 1999 Jun;7(6):232-6 (57 ref.)
Perspective article: transforming growth factor-beta: crossroad of glucocorticoid and bleomycin regulation of collagen synthesis in lung fibroblasts. Shukla A, et al. **Wound Repair Regen** 1999 May-Jun;7(3):133-40 (73 ref.)
[Transforming growth factors and cancer] Zhu ZW, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):335-7 (10 ref.) **(Chi)**
[Receptors and signal transduction for the TGF-beta related factors] Miyazono K. **Nippon Ronen Igakkai Zasshi** 1999 Mar;36(3):162-6 (27 ref.) **(Jpn)**

THERAPEUTIC USE

The potential role of transforming growth factor beta in fracture healing. Rosier RN, et al. **Clin Orthop** 1998 Oct; (355 Suppl):S294-300 (28 ref.)
New frontiers in the management of chemotherapy-induced mucositis. Spijkervet FK, et al. **Curr Opin Oncol** 1998 Aug; 10 Suppl 1:S23-7 (15 ref.)

TRANSFORMING GROWTH FACTOR BETA RECEPTORS see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

TRANSFORMING REGION see **BASE SEQUENCE**

TRANSGENES

see related
ANIMALS, TRANSGENIC

Viruses and gene silencing in plants. Baulcombe D. **Arch Virol Suppl** 1999;15:189-201 (50 ref.)
Successful survival of grafted transgenic neural plate cells in adult central nervous system environment. Uchida K, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):79-86 (29 ref.)
Use of herpes simplex virus type 1 for transgene expression within the nervous system. Lachmann RH, et al. **Clin Sci (Colch)** 1999 Jun;96(6):533-41 (57 ref.)
Controlling gene expression in transgenics. Gallie DR. **Curr Opin Plant Biol** 1998 Apr;1(2):166-72 (55 ref.)
Position effects and epigenetic silencing of plant transgenes. Matzke AJ, et al. **Curr Opin Plant Biol** 1998 Apr;1(2):142-8 (56 ref.)
Using gene knockout and transgenic techniques to study the physiology and pharmacology of beta3-adrenergic receptors. Lowell BB. **Endocr J** 1998 Apr;45 Suppl:S9-13 (19 ref.)
Transgenic studies of peripheral and central glia. Messing A. **Int J Dev Biol** 1998;42(7 Spec No):1019-24 (43 ref.)
Immunoglobulin transgenes as targets for somatic hypermutation. Storb U, et al. **Int J Dev Biol** 1998;42(7 Spec No):977-82 (39 ref.)
Physiologically responsive gene therapy. Varley AW, et al. **Mol Med Today** 1998 Oct;4(10):445-51 (36 ref.)

GENETICS

Dissecting the mechanisms of posttranscriptional gene silencing: divide and conquer. Grant SR. **Cell** 1999 Feb 5;96(3):303-6 (24 ref.)
Transgene regulation by the tetracycline-controlled transactivation system. Kitamura M. **Exp Nephrol** 1998 Nov-Dec;6(6):576-80 (21 ref.)
Modifiable gene expression in mice: kidney-specific deletion of a target gene via the cre-loxP system. Stec DE, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):568-75 (41 ref.)

IMMUNOLOGY

Review--the use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product. Potter MA, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:159-74 (26 ref.)
Checkpoints for regulation of development and interferon gamma production by Th1 cells in TCR-transgenic models. O'Garra A. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):41-2 (10 ref.)

PHYSIOLOGY

Tandem constructs: preventing the rise of superweeds. Gressel J. **Trends Biotechnol** 1999 Sep;17(9):361-6 (62 ref.)

TRANSGENIC ANIMALS see **ANIMALS, TRANSGENIC**

TRANSGENIC MICE see **MICE, TRANSGENIC**

TRANSGENIC ORGANISMS see **ORGANISMS, TRANSGENIC**

TRANSGENIC PLANTS see **PLANTS, TRANSGENIC**

TRANSGLUTAMINASE see **PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE**

TRANSIENT ISCHEMIC ATTACK see **CEREBRAL ISCHEMIA, TRANSIENT**

TRANSIENT TIC DISORDER see **TIC DISORDERS**

TRANSIENTS AND MIGRANTS

see related
HOMELESS PERSONS

Metabolic consequences of the West African diaspora: lessons from the thrifty gene. Osei K. **J Lab Clin Med** 1999 Feb; 133(2):98-111 (65 ref.)
The occupational health status of hired farm workers. Villarejo D, et al. **Occup Med** 1999 Jul-Sep;14(3):613-35 (100 ref.)
Cancer epidemiology in migrant populations. McCredie M. **Recent Results Cancer Res** 1998;154:298-305 (26 ref.)

PSYCHOLOGY

Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247-61 (81 ref.)

STATISTICS & NUMERICAL DATA

Migrant populations and the incidence of type 1 diabetes mellitus: an overview of the literature with a focus on the Spanish-heritage countries in Latin America. Serrano-Rios M, et al. **Diabetes Metab Res Rev** 1999 Mar-Apr; 15(2):113-32 (140 ref.)
[HIV prevention for migrant prostitutes] Nitschke-Ozbay H. **Zentralbl Gynakol** 1999;121(1):36-41 (5 ref.) (Eng. Abstr.) **(Ger)**

TRANSIN see **STROMELYSIN 1**

TRANSKETOLASE

PHYSIOLOGY

Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Schenk G, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1297-318 (186 ref.)

TRANSLATION, GENETIC

Control of translation initiation in animals. Gray NK, et al. **Annu Rev Cell Dev Biol** 1998;14:399-458 (381 ref.)
Evolution and mechanism of translation in chloroplasts. Sugiura M, et al. **Annu Rev Genet** 1998;32:437-59 (128 ref.)
Activities of cold-shock domain proteins in translation control. Sommerville J. **Bioessays** 1999 Apr;21(4):319-25 (57 ref.)
Reading DNA differently. Gat Y, et al. **Biopolymers** 1998; 48(1):19-28 (71 ref.)
Synaptic plasticity: regulated translation in dendrites. Huang EP. **Curr Biol** 1999 Mar 11;9(5):R168-70 (14 ref.)
Recent advances in producing and selecting functional proteins by using cell-free translation. Jermutus L, et al. **Curr Opin Biotechnol** 1998 Oct;9(5):534-48 (120 ref.)
Translational selection and molecular evolution. Akashi H, et al. **Curr Opin Genet Dev** 1998 Dec;8(6):688-93 (74 ref.)
Structural studies of the translational apparatus. Agrawal RK, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):215-21 (56 ref.)
Co-translational folding. Hardesty B, et al. **Curr Opin Struct Biol** 1999 Feb;9(1):111-4 (26 ref.)
How translational accuracy influences reading frame maintenance. Farabaugh PJ, et al. **EMBO J** 1999 Mar 15; 18(6):1427-34 (55 ref.)
Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire. Budisa N, et al. **FASEB J** 1999 Jan;13(1):41-51 (50 ref.)
Dynamics of translation on the ribosome: molecular mechanics of translocation. Rodnina MV, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):317-33 (97 ref.)
Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis. Das S, et al. **Front Biosci** 1998 Dec 1;3:D1241-52 (61 ref.)
Initiation of translation in prokaryotes and eukaryotes. Kozak M. **Gene** 1999 Jul 8;234(2):187-208 (260 ref.)
Modulation of the nucleoid, the transcription apparatus, and the translation machinery in bacteria for stationary phase survival. Ishihama A. **Genes Cells** 1999 Mar;4(3):135-43 (65 ref.)
Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Kaufman RJ. **Genes Dev** 1999 May 15; 13(10):1211-33 (186 ref.)
Translational control: the cancer connection. Clemens MJ, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):1-23 (165 ref.)
Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein, p50. Evdokimova VM, et al. **Int J Biochem Cell Biol** 1999 Jan; 31(1):139-49 (95 ref.)
Translational infidelity and human cancer: role of the PTI-1 oncogene. Gopalkrishnan RV, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):151-62 (47 ref.)
Eukaryotic initiation factor eIF2. Kimball SR. **Int J Biochem Cell Biol** 1999 Jan;31(1):25-9 (29 ref.)
Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Shantz LM, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):107-22 (113 ref.)
The role of the 5' untranslated region of an mRNA in translation regulation during development. van der Velden AW, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):87-106 (102 ref.)
Translational control of growth factor and proto-oncogene expression. Willis AE. **Int J Biochem Cell Biol** 1999 Jan; 31(1):73-86 (77 ref.)
Apolipoprotein B in the rough endoplasmic reticulum: translation, translocation and the initiation of lipoprotein assembly. Shelness GS, et al. **J Nutr** 1999 Feb;129(2S Suppl):456S-462S (78 ref.)
Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, and posttranslational levels. Kühn H, et al. **Lipids** 1999;34 Suppl:S273-9 (34 ref.)
The analysis of translational activity using a reporter gene constructed from repeats of an antibody-binding domain from protein A. Björnsson A, et al. **Methods Mol Biol** 1998; 77:75-91 (23 ref.)
Translational control by repressor proteins binding to the 5'UTR of mRNAs. Gray NK. **Methods Mol Biol** 1998; 77:379-97 (42 ref.)
Analysis of translational activity of extracts derived from oocytes and eggs of Xenopus laevis. Pain VM, et al. **Methods Mol Biol** 1998;77:195-209 (20 ref.)
In vitro transcription and translation of lipoprotein lipase. Ranganathan G, et al. **Methods Mol Biol** 1999;109:337-41 (16 ref.)
Continuous-flow cell-free translation, transcription-translation, and replication-translation systems. Ryabova LA, et al. **Methods Mol Biol** 1998; 77:179-93 (31 ref.)
The measurement of missense errors during in vivo protein synthesis. Violand BN, et al. **Methods Mol Biol** 1998; 77:143-51 (33 ref.)
Gel retardation and UV-crosslinking assays to detect specific RNA-protein interactions in the 5' or 3' UTRs of translationally regulated mRNAs. Walker J, et al. **Methods Mol Biol** 1998;77:365-78 (30 ref.)
Analyses of ribosome distribution during in vitro translation. Wolin SL. **Methods Mol Biol** 1998;77:1-9 (17 ref.)
Posttranscriptional control of gene expression in yeast. McCarthy JEG. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1492-553 (620 ref.)
Making proteins at the synapse: activity-regulated translation and CPEB [see comments] Worley P. **Neuron** 1998 Nov; 21(5):936-8 (12 ref.) Comment in: Neuron 1998 Nov;21(5):1129-39.
mRNA surveillance in eukaryotes: kinetic proofreading of proper translation termination as assessed by mRNP domain organization? Hilleren P, et al. **RNA** 1999 Jun; 5(6):711-9 (67 ref.)
Internal ribosome entry sites (IRESs): reality and use. Houdebine LM, et al. **Transgenic Res** 1999 Jun;8(3):157-77 (200 ref.)
Forty years under the central dogma [see comments] Thieffry D, et al. **Trends Biochem Sci** 1998 Aug;23(8):312-6 (36 ref.) Comment in: Trends Biochem Sci 1998 Dec;23(12):468.
Gene regulation by Y-box proteins: coupling control of transcription and translation. Matsumoto K, et al. **Trends Cell Biol** 1998 Aug;8(8):318-23 (53 ref.)
[A bacterial RNA that functions both as a tRNA and an mRNA] Muto A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(11):1433-42 (30 ref.) **(Jpn)**

DRUG EFFECTS

Antisense RNA gene therapy for studying and modulating biological processes. Weiss B, et al. **Cell Mol Life Sci** 1999 Mar;55(3):334–58 (164 ref.)

GENETICS

[Translational control in eucaryote: recent progress] Isoyama T, et al. **Tanpakushitsu Kakusan Koso** 1999 Feb; 44(2):149–56 (46 ref.) **(Jpn)**

PHYSIOLOGY

Transcriptional and translational regulation of gene expression in haploid spermatids. Steger K. **Anat Embryol (Berl)** 1999 Jun;199(6):471–87 (174 ref.)

Termination of translation in eukaryotes: new results and new hypotheses. Kisselev LL, et al. **Biochemistry (Mosc)** 1999 Jan;64(1):8–16 (49 ref.)

The role for translational control of the cell cycle. Parsels LA, et al. **Cancer J Sci Am** 1998 Sep–Oct;4(5):287–95 (74 ref.)

Involvement of ribosomal proteins in regulating cell growth and apoptosis: translational modulation or recruitment for extraribosomal activity? Naora H. **Immunol Cell Biol** 1999 Jun;77(3):197–205 (74 ref.)

Back to Camelot: defining the specific role of tRNA in protein synthesis. Weisblum B. **Trends Biochem Sci** 1999 Jun;24(6):247–50 (24 ref.)

TRANSLOCATION (GENETICS)

Three cases of mosaicism for balanced reciprocal translocations. Leegte B, et al. **Am J Med Genet** 1998 Oct 12;79(5):362–5 (22 ref.)

A case of de novo translocation 16;21: trisomy 16q phenotype and origin of the aberration. Eggermann T, et al. **Ann Genet** 1998;41(4):205–8 (14 ref.)

Partial Xp duplication due to a translocation t(X;15) in two male and two female patients: a familial case report and review of the literature. Melaragno MI, et al. **Ann Genet** 1998;41(4):189–94 (27 ref.)

The critical role of chromosome translocations in human leukemias. Rowley JD. **Annu Rev Genet** 1998;32:495–519 (94 ref.)

Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype. Désangles F, et al. **Cancer Genet Cytogenet** 1999 Sep;113(2):141–4 (22 ref.)

Unusual presentation of multiple myeloma with "jumping translocation" involving 1q21. A case report and review of the literature. Keung YK, et al. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):135–9 (46 ref.)

Translocation (1;22) in refractory anemia and the prognostic significance of karyotypic abnormalities in refractory anemia. Keung YK, et al. **Cancer Genet Cytogenet** 1998 Oct 1;106(1):72–5 (25 ref.)

Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis. Martinez-Climent JA, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):111–4 (9 ref.)

Jumping translocations involving chromosome 1q in a patient with Crohn disease and acute monocytic leukemia: a review of the literature on jumping translocations in hematological malignancies and Crohn disease. Reddy KS, et al. **Cancer Genet Cytogenet** 1999 Mar;109(2):144–9 (40 ref.)

Complex variant 15;17 translocations in acute promyelocytic leukemia. A case report and review of three-way translocations. Wan TS, et al. **Cancer Genet Cytogenet** 1999 Jun;111(2):139–43 (16 ref.)

Role of TCL1 and ALL1 in human leukemias and development. Croce CM. **Cancer Res** 1999 Apr 1;59(7 Suppl):1778s–1783s (46 ref.)

Oncogenes and tumor suppressor genes: therapeutic implications. Stass SA, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 2):2687–95 (58 ref.)

Biology and clinical significance of the TEL/AML1 rearrangement [see comments] Borkhardt A, et al. **Curr Opin Pediatr** 1999 Feb;11(1):33–8 (39 ref.) Comment in: Curr Opin Pediatr 1999 Feb;11(1):31–2.

Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. Klein G. **Curr Top Microbiol Immunol** 1999;246:161–7 (17 ref.)

FISH on sperm heads allows the analysis of chromosome segregation and interchromosomal effects in carriers of structural rearrangements: results in a translocation carrier, t(5;8)(q33;q13). Blanco J, et al. **Cytogenet Cell Genet** 1998; 83(3–4):275–80 (47 ref.)

Is there a simple answer to the origin of complex chromosome exchanges? Edwards AA, et al. **Int J Radiat Biol** 1999 Jan;75(1):19–22 (15 ref.)

Molecular abnormalities in leukemia: the 11q23 story so far. Gregorini A, et al. **J Biol Regul Homeost Agents** 1998 Oct–Dec;12(4):95–105 (127 ref.)

Seminars from the University of Minnesota. Chromosome translocations: dangerous liaisons. Rowley JD. **J Lab Clin Med** 1998 Oct;132(4):244–50 (29 ref.)

Perspective: chromosomal translocations can affect genes controlling gene expression and differentiation--why are these functions targeted? Rabbitts TH. **J Pathol** 1999 Jan; 187(1):39–42 (41 ref.)

Congenital leukemia: successful treatment of a newborn with t(5;11)(q31;q23). Fernandez MC, et al. **J Pediatr Hematol Oncol** 1999 Mar–Apr;21(2):152–7 (47 ref.)

Acute myelomonoblastic leukemia carrying the PEBP2beta/MYH11 fusion gene. Asou N, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):81–91 (65 ref.)

Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Iida S, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):25–33 (51 ref.)

Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR. Tobal K, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):115–20 (39 ref.)

Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Sawyers CL. **Leuk Res** 1998 Dec;22(12):1113–22 (88 ref.)

Myelodysplastic syndrome (MDS) with unbalanced t(1;7) after severe aplastic anemia (SAA) in childhood as a variant form of monosomy 7 [letter] Kikuchi A, et al. **Leukemia** 1998 Dec;12(12):2036–8 (8 ref.)

The role of TEL fusion genes in pediatric leukemias. Rubnitz JE, et al. **Leukemia** 1999 Jan;13(1):6–13 (85 ref.)

Abortive apoptosis as an initiator of chromosomal translocations. Khodarev NN, et al. **Med Hypotheses** 1999 May;52(5):373–6 (31 ref.)

Leukemia in infants. Felix CA, et al. **Oncologist** 1999; 4(3):225–40 (221 ref.)

Prenatal diagnosis of a satellited non-acrocentric chromosome derived from a maternal translocation (10;13)(p13;p12) and review of literature. Faivre L, et al. **Prenat Diagn** 1999 Mar;19(3):282–6 (16 ref.)

Chromosome translocations: segregation modes and strategies for preimplantation genetic diagnosis [see comments] Scriven PN, et al. **Prenat Diagn** 1998 Dec; 18(13):1437–49 (31 ref.) Comment in: Prenat Diagn 1998 Dec;18(13):1343–4.

A child with a t(11;19)(q14–21;p12) in a pulmonary mucoepidermoid carcinoma. Stenman G, et al. **Virchows Arch** 1998 Dec;433(6):579–81 (13 ref.)

[t(3;5) (q21;q31) chromosomal abnormality in a patient with acute myelogenous leukemia with trilineage myelodysplasia] Sasai Y, et al. **Rinsho Ketsueki** 1998 Sep; 39(9):658–64 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Primary splenic lymphoma with t(3;14)(q27;q32) chromosomal abnormality and rearrangement of BCL-6 gene] Yata K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):587–92 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Structure–function relationships in the Ca(2+)-binding and translocation domain of SERCA1: physiological correlates in Brody disease. MacLennan DH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:55–67 (52 ref.)

Late appearance of t(5;12)(q31;p12) in acute myeloid leukemia associated with eosinophilia. Yahata N, et al. **Cancer Genet Cytogenet** 1998 Dec;107(2):147–50 (17 ref.)

t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma. Amakawa R, et al. **Int J Hematol** 1999 Feb;69(2):65–9 (37 ref.)

Translocations, fusion genes, and acute leukemia. Saha V, et al. **J Cell Biochem Suppl** 1998;30–31:264–76 (64 ref.)

[Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes] al Saati T, et al. **Bull Cancer** 1998 Oct;85(10):847–54 (64 ref.) (Eng. Abstr.) **(Fre)**

[Trisomy 4p as result of a maternal translocation t(4;8)(q11;p23)] Stumm M, et al. **Klin Padiatr** 1999 Jan–Feb; 211(1):35–9 (5 ref.) (Eng. Abstr.) **(Ger)**

TRANSLOCATION, BACTERIAL see **BACTERIAL TRANSLOCATION**

TRANSLOCATION, CHROMOSOMAL see **TRANSLOCATION (GENETICS)**

TRANSLUMINAL CORONARY BALLOON DILATATION see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

TRANSMEMBRANE POTENTIALS see **MEMBRANE POTENTIALS**

TRANSMISSIBLE DEMENTIAS see **PRION DISEASES**

TRANSMISSIBLE ENTERITIS OF TURKEYS see **ENTERITIS, TRANSMISSIBLE, OF TURKEYS**

TRANSMISSION, DENTIST-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON**

TRANSMISSION, HEALTH CARE WORKER-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, HORIZONTAL see **DISEASE TRANSMISSION, HORIZONTAL**

TRANSMISSION, PATIENT-TO-PROFESSIONAL see **DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL**

TRANSMISSION, PHYSICIAN-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, PROFESSIONAL-TO-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, VERTICAL see **DISEASE TRANSMISSION, VERTICAL**

TRANSMITTER UPTAKE INHIBITORS, NEURONAL see **NEUROTRANSMITTER UPTAKE INHIBITORS**

TRANSMITTERS, BIOGENIC AMINE see **BIOGENIC AMINE NEUROTRANSMITTERS**

TRANSPHOSPHORIBOSIDASE see **ADENINE PHOSPHORIBOSYLTRANSFERASE**

TRANSPHOSPHORYLASES see **PHOSPHOTRANSFERASES**

TRANSPLACENTAL EXPOSURE see **MATERNAL-FETAL EXCHANGE**

TRANSPLANT REJECTION see **GRAFT REJECTION**

TRANSPLANTATION

see related
HISTOCOMPATIBILITY TESTING
LIVING DONORS
NEOPLASM TRANSPLANTATION
ORGAN PRESERVATION SOLUTIONS
ORGAN TRANSPLANTATION
TISSUE DONORS
TISSUE TRANSPLANTATION
TRANSPLANTATION CHIMERA

Anesthetic and perioperative management of adult transplant recipients in nontransplant surgery. Kostopanagiotou G, et al. **Anesth Analg** 1999 Sep;89(3):613–22 (147 ref.)

The role of lipid lowering in transplantation. Wierzbicki AS. **Int J Clin Pract** 1999 Jan–Feb;53(1):54–9 (78 ref.)

Preoperative assessment of the transplant patient. Morgan CB, et al. **J Foot Ankle Surg** 1998 Jul–Aug;37(4):350–4 (30 ref.)

Developments in the clinical science of transplantation during the 20th century. Vella JP, et al. **Pediatr Transplant** 1998 Nov;2(4):257–62 (41 ref.)

Therapeutic implications of interleukin-10 in surgical disease. Selzman CH, et al. **Shock** 1998 Nov;10(5):309–18 (156 ref.)

ADVERSE EFFECTS

The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Haque T, et al. **Br J Haematol** 1999 Aug; 106(2):309–16 (68 ref.)

[Post-transplant lymphoproliferative disorders] Kita K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):159–62 (12 ref.) **(Jpn)**

PHYSIOLOGY

Gene targeting: applications in transplantation research. Mannon RB, et al. **Kidney Int** 1999 Jul;56(1):18–27 (87 ref.)

TRANSPLANTATION, ALLOGENEIC see **TRANSPLANTATION, HOMOLOGOUS**

TRANSPLANTATION, AUTOLOGOUS

[Experimental and clinical studies of small joint transplantation] Chen M, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1997 May;13(3):205–7 (23 ref.) **(Chi)**

[Autologous osteochondral transplantation on various joints] Imhoff AB, et al. **Orthopade** 1999 Jan;28(1):33–44 (49 ref.) (Eng. Abstr.) **(Ger)**

[On the review of literature by V.A. Zurnadzh'iants and Yu.V. Nazarochkin "Autotransplantation of splenic tissue"] Grigor'ev EG, et al. **Khirurgiia (Mosk)** 1998;(7):44–7 (81 ref.) **(Rus)**

ADVERSE EFFECTS

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Re D, et al. **Bone Marrow Transplant** 1999 Feb;23(3):295–8 (23 ref.)

METHODS

A comparison of graft implantation techniques for hair transplantation. Whitworth JM, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):177–83 (7 ref.)

NURSING

Cardiac explantation and autotransplantation. Wagner S, et al. **AORN J** 1999 Jul;70(1):99–100, 102, 104–7; quiz 108–12 (13 ref.)

TRANSPLANTATION, BONE see **BONE TRANSPLANTATION**

TRANSPLANTATION, BONE MARROW

TRANSPLANTATION, BONE MARROW see **BONE MARROW TRANSPLANTATION**

TRANSPLANTATION, BRAIN TISSUE see **BRAIN TISSUE TRANSPLANTATION**

TRANSPLANTATION, CARDIAC see **HEART TRANSPLANTATION**

TRANSPLANTATION CHIMERA

see related
ANIMALS, TRANSGENIC

Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Exner BG, et al. **Acta Haematol** 1999;101(2):78–81 (30 ref.)

Clinical applications of mixed chimerism. Exner BG, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:377–85; discussion 385–6 (39 ref.)

The role of the facilitating cell in the establishment of donor chimerism and transplantation tolerance. Davenport C, et al. **Clin Biochem** 1998 Jul;31(5):359–67 (99 ref.)

Pediatric transplantation. Reyes J, et al. **Surg Clin North Am** 1999 Feb;79(1):163–89 (94 ref.)

Chimerism in transplantation and in spontaneously occurring autoimmune disease. Nelson JL. **Transplant Proc** 1999 Feb–Mar;31(1–2):798–9 (14 ref.)

IMMUNOLOGY

Mixed chimerism: preclinical studies and clinical applications. McSweeney PA, et al. **Biol Blood Marrow Transplant** 1999; 5(4):192–203 (62 ref.)

Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? Gammie JS, et al. **Curr Opin Cardiol** 1999 Mar;14(2):126–32 (52 ref.)

Dendritic cells/chimerism/alleviation of chronic allograft rejection. Murase N, et al. **J Leukoc Biol** 1999 Aug; 66(2):297–300 (15 ref.)

Chimerism and xenotransplantation. New concepts. Starzl TE, et al. **Surg Clin North Am** 1999 Feb;79(1):191–205 (58 ref.)

Transplantation tolerance, microchimerism, and the two-way paradigm [see comments] Starzl TE, et al. **Theor Med Bioeth** 1998 Sep;19(5):441–55 (83 ref.) Comment in: Theor Med Bioeth 1998 Sep;19(5):457–73.

Conceptual shifts in immunology: comments on the "two-way paradigm" [comment] Tauber AI. **Theor Med Bioeth** 1998 Sep;19(5):457–73 (39 ref.) Comment on: Theor Med Bioeth 1998 Sep;19(5):441–55.

TRANSPLANTATION CONDITIONING

see related
TRANSPLANTATION

Immune ablation and stem cell transplantation for severe Evans syndrome and refractory thrombocytopenic purpura. Marmont AM. **Bone Marrow Transplant** 1999 Jun; 23(12):1215–6 (26 ref.)

Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Balzarotti M, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):66–71 (32 ref.)

Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Slattery JT, et al. **Ther Drug Monit** 1998 Oct;20(5):543–9 (21 ref.)

[Stem cell transplantation in multiple myeloma] Fukuda S, et al. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1407–14 (27 ref.) (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION, CORNEAL see **CORNEAL TRANSPLANTATION**

TRANSPLANTATION, FETAL TISSUE see **FETAL TISSUE TRANSPLANTATION**

TRANSPLANTATION, HEART see **HEART TRANSPLANTATION**

TRANSPLANTATION, HEART-LUNG see **HEART-LUNG TRANSPLANTATION**

TRANSPLANTATION, HEMATOPOIETIC STEM CELL see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

TRANSPLANTATION, HEPATIC see **LIVER TRANSPLANTATION**

TRANSPLANTATION, HETEROLOGOUS

Characterization of purified and ex vivo manipulated human hematopoietic progenitor and stem cells in xenograft recipients. Bock TA, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:200–7; discussion 207–10 (42 ref.)

Analysis of factors for the prediction of the response to xenotransplantation. Daar AS. **Ann N Y Acad Sci** 1998 Dec 30;862:222–33 (45 ref.)

Researcher-driven versus policy-driven economic appraisal. The case of xenotransplantation. Moatti JP. **Ann N Y Acad Sci** 1998 Dec 30;862:188–201 (28 ref.)

The future promises of xenotransplantation. Platt JL, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:5–18 (53 ref.)

Genetic engineering in the pig. Gene knockout and alternative techniques. Vanhove B, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:28–36 (59 ref.)

Porcine islet xenotransplantation utilizing a vascularized bioartificial pancreas. Maki T, et al. **Ann Transplant** 1997; 2(3):69–71 (11 ref.)

Porcine neonatal pancreatic cell clusters (NPCCs): a potential source of tissue for islet transplantation. Weir GC, et al. **Ann Transplant** 1997;2(3):63–8 (55 ref.)

Tilapia Brockmann Bodies: an inexpensive, simple model for discordant islet xenotransplantation. Wright JR Jr, et al. **Ann Transplant** 1997;2(3):72–5 (35 ref.)

The SCID-hu xenogeneic transplantation model: complex but telling. Boehncke WH. **Arch Dermatol Res** 1999 Jul–Aug;291(7–8):367–73 (46 ref.)

Xenotransplantation. Weiss RA. **BMJ** 1998 Oct 3; 317(7163):931–4 (22 ref.)

Animal-to-human organ transplants—a solution or a new problem? Daar AS. **Bull World Health Organ** 1999; 77(1):54–61 (21 ref.)

Xenotransplantation and public health: identifying the legal issues. Florencio PS, et al. **Can J Public Health** 1999 Jul–Aug;90(4):282–4 (32 ref.)

Xenogeneic cell therapy: current progress and future developments in porcine cell transplantation. Edge AS, et al. **Cell Transplant** 1998 Nov–Dec;7(6):525–39 (181 ref.)

Stentless xenograft aortic valves. Reardon MJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):84–9 (17 ref.)

Xenotransplantation—state of the art—update 1999. Bühler L, et al. **Front Biosci** 1999 Apr 15;4:D416–32 (150 ref.)

Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction (Review). Dao MA, et al. **Int J Mol Med** 1998 Jan;1(1):257–64 (50 ref.)

Factors in discordant xenograft survival. Bach FH. **J Mol Med** 1999 Jan;77(1):161–4 (19 ref.)

Xenoislet transplantation: experimental and clinical aspects. Groth CG, et al. **J Mol Med** 1999 Jan;77(1):153–4 (9 ref.)

Graves' disease: xenotransplantation model (athymic nude mice). Jungheim K, et al. **J Mol Med** 1999 Jan;77(1):185–8 (28 ref.)

Fetal islet xenotransplantation in rodents and primates. Mandel TE. **J Mol Med** 1999 Jan;77(1):155–60 (43 ref.)

Xenotransplant-associated infections. Michaels MG. **Lab Anim Sci** 1998 Jun;48(3):228–33 (67 ref.)

Prospects for xenotransplantation. Platt JL. **Pediatr Transplant** 1999 Aug;3(3):193–200 (57 ref.)

Barriers to xenotransplantation. Bach FH, et al. **Transplant Proc** 1999 Jun;31(4):1819–20 (11 ref.)

Future concepts in transplantation. Calne R. **Transplant Proc** 1999 Feb–Mar;31(1–2A):21S–24S (00 ref.)

Genetic engineering for xenotransplantation. Platt JL. **Transplant Proc** 1999 May;31(3):1488–90 (30 ref.)

Review of allo- and xenogeneic neural grafts in neurodegenerative disorders. Neural Tissue Transplantation Team(NETTLU). Widner H. **Transplant Proc** 1999 Feb–Mar;31(1–2):936–8 (18 ref.)

Literature update 1998, part 2. Auchincloss H Jr. **Xenotransplantation** 1998 Nov;5(4):305–9 (66 ref.)

Literature update 1998, part 3. Auchincloss H Jr. **Xenotransplantation** 1999 Feb;6(1):66–71 (81 ref.)

Literature update 1998, Part 1. Koulmanda M, et al. **Xenotransplantation** 1998 Aug;5(3):226–31 (102 ref.)

[Xenogeneic antigens and immune response in pig to man xenograft] Li T, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):42–7 (29 ref.) (Eng. Abstr.) **(Chi)**

[Clinical xenotransplantation: current progress, problems and solutions] Li Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):99–107 (70 ref.) (Eng. Abstr.) **(Chi)**

[Xenografts: clinical trials and perspectives] Camsonne R, et al. **Presse Med** 1998 May 16;27(18):865–8 (28 ref.) (Eng. Abstr.) **(Fre)**

[Xenotransplantation from the ethical viewpoint. An outline] Beckmann JP. **Zentralbl Chir** 1999;124(7):636–40 (12 ref.) (Eng. Abstr.) **(Ger)**

[Isolation of islands of Langerhans from human and porcine pancreas for transplantation to humans] Brandhorst D, et al. **Zentralbl Chir** 1998;123(7):814–22 (113 ref.) (Eng. Abstr.) **(Ger)**

[Experimental xenogenic lung transplantation] Fraund S, et al. **Zentralbl Chir** 1999;124(7):609–15 (41 ref.) (Eng. Abstr.) **(Ger)**

[Transgenic pigs for xenotransplants for humans] Niemann H. **Zentralbl Chir** 1998;123(7):781–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Human xenogenic kidney transplantation from the clinical viewpoint] Storck M, et al. **Zentralbl Chir** 1999; 124(7):616–20 (20 ref.) (Eng. Abstr.) **(Ger)**

[Transplantation of porcine Langerhans islets for therapy of type I diabetes. The way to clinical application] Ulrichs K, et al. **Zentralbl Chir** 1999;124(7):628–35 (37 ref.) (Eng. Abstr.) **(Ger)**

[Risk of infection causes by viruses in xenotransplantation] von der Helm K, et al. **Zentralbl Chir** 1999;124(7):600–3 (19 ref.) (Eng. Abstr.) **(Ger)**

[Xenotransplantation of the liver] Winkler M, et al. **Zentralbl Chir** 1999;124(7):621–7 (62 ref.) (Eng. Abstr.) **(Ger)**

[Xenotransplantation. Possibilities of animal breeding] Wolf E, et al. **Zentralbl Chir** 1999;124(7):585–90 (43 ref.) (Eng. Abstr.) **(Ger)**

[Downregulation of alpha-galactosyl epitope in xenograft] Miyagawa S, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2618–24 (29 ref.) **(Jpn)**

[Xenotransplantation, soon a clinical reality? Biological barriers must be overcome] Tibell A. **Lakartidningen** 1998 Nov 18;95(47):5262–6 (19 ref.) **(Swe)**

ADVERSE EFFECTS

The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Allan JS. **Ann N Y Acad Sci** 1998 Dec 30;862:87–99 (76 ref.)

Infection and xenotransplantation. Developing strategies to minimize risk. Fishman JA. **Ann N Y Acad Sci** 1998 Dec 30;862:52–66 (78 ref.)

The risk of infection in xenotransplantation. Introduction. Fishman JA. **Ann N Y Acad Sci** 1998 Dec 30;862:45–51 (15 ref.)

Endogenous retroviruses: a potential problem for xenotransplantation? Stoye JP, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:67–74 (26 ref.)

Zoonosis in xenotransplantation. Patience C, et al. **Curr Opin Immunol** 1998 Oct;10(5):539–42 (39 ref.)

Xenotransplantation. The viral issue. Groth CG. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV26 (5 ref.)

Infection in xenotransplantation: a clinical approach. Fishman JA. **Transplant Proc** 1999 Sep;31(6):2225–7 (23 ref.)

IMMUNOLOGY

The promise of xenografting. Hanaway MJ, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):299–308 (55 ref.)

Immunosuppression by retroviruses: implications for xenotransplantation. Denner J. **Ann N Y Acad Sci** 1998 Dec 30;862:75–86 (38 ref.)

Absence of CD34 on some human SCID-repopulating cells. Dick JE. **Ann N Y Acad Sci** 1999 Apr 30;872:211–7; discussion 217–9 (30 ref.)

Control of complement activities for immunoisolation. Iwata H, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:7–23 (28 ref.)

Factors in xenograft rejection. Robson SC, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:261–76 (131 ref.)

Immunologic barriers in pig-to-primate cardiac xenotransplantation. Artrip JH, et al. **Ann Transplant** 1997; 2(1):5–11 (48 ref.)

Xenotransplantation [see comments] Bigam D, et al. **Can J Surg** 1999 Feb;42(1):12–6 (33 ref.) Comment in: Can J Surg 1999 Feb;42(1):5–6.

Overcoming the histocompatibility barrier: transferrins as carriers and modulators of immunogenic identity. Pierpaoli W. **Cell Transplant** 1998 Nov–Dec;7(6):541–8 (60 ref.)

T cell response in xenorecognition and xenografts: a review. Brouard S, et al. **Hum Immunol** 1999 Jun;60(6):455–68 (98 ref.)

Efficacy of adhesive interactions in pig-to-human xenotransplantation. Simon AR, et al. **Immunol Today** 1999 Jul;20(7):323–30 (59 ref.)

Molecular remodeling of complement regulatory proteins for xenotransplantation. Seya T, et al. **Immunopharmacology** 1999 May;42(1–3):75–80 (52 ref.)

Anti-Gal, alpha-Gal epitopes, and xenotransplantation. Kobayashi T, et al. **Subcell Biochem** 1999;32:229–57 (220 ref.)

Anti-xenograft immune responses in alpha 1,3-galactosyltransferase knock-out mice. Pearse MJ, et al. **Subcell Biochem** 1999;32:281–310 (71 ref.)

Chimerism and xenotransplantation. New concepts. Starzl TE, et al. **Surg Clin North Am** 1999 Feb;79(1):191–205 (58 ref.)

Significance of anti-Gal IgG in chronic xenograft rejection. Galili U. **Transplant Proc** 1999 Feb–Mar;31(1–2):940–1 (14 ref.)

Hyperacute rejection models: ex vivo xenoperfusion systems. Grinyo JM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):970–1 (15 ref.)

The role of cytokines in rejection of discordant xenotransplants. Saadi S, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):911–2 (18 ref.)

Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):763–8 (44 ref.)

T cell-mediated xenograft rejection: specific tolerance is probably required for long term xenograft survival. Dorling A, et al. **Xenotransplantation** 1998 Nov;5(4):234–45 (119 ref.)

[Immunology in clinical practice. XXIII. Xenotransplantation] Schraa EO, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1455–60 (16 ref.) (Eng. Abstr.) **(Dut)**

[Mechanisms of xenotransplant rejection] Candinas D, et al. **Zentralbl Chir** 1999;124(7):591–9 (73 ref.) (Eng. Abstr.) **(Ger)**

[Graft rejection in experimental xenogenic transplantation of isolated islands of Langerhans of the pig] Jahr H, et al. **Zentralbl Chir** 1998;123(7):823–9 (73 ref.) (Eng. Abstr.) **(Ger)**

[Significance of the complement system for xenotransplantation: strategies for therapeutic intervention] Kirschfink M, et al. **Zentralbl Chir** 1998;123(7):793–7 (43

ref.) (Eng. Abstr.) **(Ger)**
[Xenotransplantation of solid organs: study of rejection mechanisms and its prevention] Rodriguez Villa A, et al. **Rev Clin Esp** 1998 Oct;198(10):673–7 (63 ref.) **(Spa)**

METHODS

Genetically engineered organs. John R, et al. **Adv Card Surg** 1998;10:229–44 (57 ref.)
Xenotransplantation: A potential solution to the critical organ donor shortage. Sim KH, et al. **Can J Gastroenterol** 1999 May;13(4):311–8 (77 ref.)
Xenotransplantation: how to overcome the complement obstacle? Molines TE, et al. **Mol Immunol** 1999 Mar–Apr; 36(4–5):269–76 (68 ref.)

PHYSIOLOGY

Physiological obstacles after xenotransplantation. Hammer C. **Ann N Y Acad Sci** 1998 Dec 30;862:19–27 (38 ref.)
Physiologic incompatibilities in discordant xenotransplantation. Breimer ME. **Transplant Proc** 1999 Feb–Mar;31(1–2):905–8 (43 ref.)
[Can man live with a pig kidney?] Valentin JF, et al. **Nephrologie** 1999;20(4):189–92 (33 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Xenotransplantation. The viral issue. Groth CG. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV26 (5 ref.)

TRANSPLANTATION, HOMOLOGOUS

New strategies for allogeneic bone marrow transplantation and organ allografts. Ikehara S. **Acta Haematol** 1999; 101(2):68–77 (32 ref.)
Porcine islet xenotransplantation utilizing a vascularized bioartificial pancreas. Maki T, et al. **Ann Transplant** 1997; 2(3):69–71 (11 ref.)
Pathogenesis of chronic allograft nephropathy [editorial] Paul LC. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):635–7 (17 ref.)
Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Armenti VT, et al. **Drug Saf** 1998 Sep;19(3):219–32 (70 ref.)
Bone marrow transplantation for severe aplastic anemia from HLA identical siblings [editorial] Bacigalupo A. **Haematologica** 1999 Jan;84(1):2–4 (18 ref.)
Review of allo– and xenogeneic neural grafts in neurodegenerative disorders. Neural Tissue Transplantation Team(NETTLU). Widner H. **Transplant Proc** 1999 Feb–Mar;31(1–2):936–8 (18 ref.)

ADVERSE EFFECTS

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Gross TG, et al. **Bone Marrow Transplant** 1999 Feb;23(3):251–8 (42 ref.)
Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation. Romano V, et al. **Bone Marrow Transplant** 1999 Feb;23(3):271–5 (14 ref.)
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Stocchi R, et al. **Haematologica** 1999 Jan;84(1):71–9 (113 ref.)
Unrelated donor bone marrow transplantation in adults: some current controversies. Marks DI, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):459–66 (43 ref.)
Current understanding of chemokine involvement in allograft transplantation. Melter M, et al. **Pediatr Transplant** 1999 Feb;3(1):10–21 (113 ref.)

IMMUNOLOGY

Lymphohematopoietic stem cell engraftment. Quesenberry PJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:40–5; discussion 45–7 (19 ref.)
Extracellular matrix proteins: bystanders or active participants in the allograft rejection cascade? Coito AJ, et al. **Ann Transplant** 1996;1(3):14–8 (35 ref.)
Graft rejection in sensitized recipients. Kupiec-Węgliński JW. **Ann Transplant** 1996;1(1):34–40 (61 ref.)
Direct and indirect antigen recognition: the pathways to allograft immune rejection. Benichou G. **Front Biosci** 1999 May 15;4:D476–80 (30 ref.)
Dendritic cells/chimerism/alleviation of chronic allograft rejection. Murase N, et al. **J Leukoc Biol** 1999 Aug; 66(2):297–300 (15 ref.)
Indirect recognition of allo MHC peptides--potential role in human transplantation [editorial] Watschinger B. **Nephrol Dial Transplant** 1999 Jan;14(1):8–11 (29 ref.)
Current understanding of chemokine involvement in allograft transplantation. Melter M, et al. **Pediatr Transplant** 1999 Feb;3(1):10–21 (113 ref.)
"Almost tolerance" in the clinic. Calne R. **Transplant Proc** 1998 Nov;30(7):3846–8 (10 ref.)
Chronic allograft vasculopathy: new strategies for drug development. Häyry P. **Transplant Proc** 1998 Dec; 30(8):3989–90 (22 ref.)
Cytokine genotypes in allograft rejection: guidelines for immunosuppression. Hutchinson IV, et al. **Transplant Proc** 1998 Dec;30(8):3991–2 (11 ref.)
Humoral transplantation antibodies. Milgrom F. **Transplant Proc** 1999 Feb–Mar;31(1–2):30–3 (33 ref.)
Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo– and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):763–8 (44 ref.)
Ischemia reperfusion injury and chronic allograft rejection. Szabo A, et al. **Transplant Proc** 1998 Dec;30(8):4281–4 (59 ref.)
Integrins and T helper cell activation [see comments] van Seventer GA, et al. **Transplant Proc** 1998 Dec;30(8):4270–4 (60 ref.) Comment in: Transplant Proc 1998 Dec;30(8):4269.

METHODS

[Intestinal transplantation: a clinical reality in 1998] Pirenne J. **Bull Mem Acad R Med Belg** 1998;153(2):171–8; discussion 178–81 (7 ref.) (Eng. Abstr.) **(Fre)**
[Bone marrow allograft. Part 1: principles--modalities and indications] Ladeb S, et al. **Tunis Med** 1999 Apr; 77(4):185–90 (30 ref.) **(Fre)**

PATHOLOGY

Postischemic reperfusion injury and allograft arteriosclerosis. Fellström B, et al. **Transplant Proc** 1998 Dec;30(8):4278–80 (36 ref.)
Chronic allograft vasculopathy: new strategies for drug development. Häyry P. **Transplant Proc** 1998 Dec; 30(8):3989–90 (22 ref.)

TRANSPLANTATION IMMUNOLOGY

see related
HISTOCOMPATIBILITY TESTING
IMMUNOSUPPRESSION

Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Exner BG, et al. **Acta Haematol** 1999;101(2):78–81 (30 ref.)
The new immunosuppressive era (editorial)] Lo Monte AI, et al. **Ann Ital Chir** 1999 Jan–Feb;70(1):1–19 (201 ref.)
Control of complement activities for immunoisolation. Iwata H, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:7–23 (28 ref.)
Sirolimus, a potent new immunosuppressive drug for organ transplantation. Stepkowski SM. **Ann Transplant** 1996; 1(3):19–25 (71 ref.)
Minor transplantation antigens: mouse models for human host–versus–graft, graft–versus–host and graft–versus–leukemia reactions. Simpson E. **Arch Immunol Ther Exp (Warsz)** 1998;46(6):331–9 (60 ref.)
Overcoming the histocompatibility barrier: transferrins as carriers and modulators of immunogenic identity. Pierpaoli W. **Cell Transplant** 1998 Nov–Dec;7(6):541–8 (60 ref.)
The role of the facilitating cell in the establishment of donor chimerism and transplantation tolerance. Davenport C, et al. **Clin Biochem** 1998 Jul;31(5):359–67 (99 ref.)
Emerging strategies for the clinical application of rapamycin. Kahan BD. **Clin Biochem** 1998 Jul;31(5):341–4 (22 ref.)
Antisense oligodeoxynucleotides for organ transplantation. Stepkowski SM. **Clin Biochem** 1998 Jul;31(5):375–9 (29 ref.)
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Trepanier DJ, et al. **Clin Biochem** 1998 Jul;31(5):345–51 (49 ref.)
Preclinical evaluation of a new immunosuppressive agent, FTY720. Troncoso P, et al. **Clin Biochem** 1998 Jul; 31(5):369–73 (21 ref.)
Th1 and Th2 cytokines in organ transplantation: paradigm lost? Zhai Y, et al. **Crit Rev Immunol** 1999;19(2):155–72 (134 ref.)
Transplantation immunology--the role of human leucocyte antigen in allorecognition. Vartdal F, et al. **Curr Top Pathol** 1999;92:1–18 (64 ref.)
The implications of granulocyte–monocyte colony–stimulating factor (GM–CSF) in cytotoxicity of bone marrow transplantation. Toren A, et al. **Cytokines Cell Mol Ther** 1998 Sep;4(3):199–206 (102 ref.)
Antigen localization and migration in immunity and tolerance. Starzl TE, et al. **N Engl J Med** 1998 Dec 24; 339(26):1905–13 (69 ref.)
Indirect recognition of allo MHC peptides--potential role in human transplantation [editorial] Watschinger B. **Nephrol Dial Transplant** 1999 Jan;14(1):8–11 (29 ref.)
Transplantation tolerance: the concept and its applicability. Dong VM, et al. **Pediatr Transplant** 1999 Aug;3(3):181–92 (192 ref.)
Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Jordan SC, et al. **Pediatr Transplant** 1998 May; 2(2):92–105 (61 ref.)
Transplantation and cytokines. Bumgardner GL, et al. **Semin Liver Dis** 1999;19(2):189–204 (140 ref.)
Immunologic privilege of the eye. Streilein JW. **Springer Semin Immunopathol** 1999;21(2):95–111 (74 ref.)
Paradigm changes in organ transplantation: a journey toward selflessness? Schaffner KF. **Theor Med Bioeth** 1998 Sep; 19(5):425–40 (55 ref.)
Induction protocols: yesterday, today, and tomorrow. Abramowicz D, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1100–1 (20 ref.)
Future concepts in transplantation. Calne R. **Transplant Proc** 1999 Feb–Mar;31(1–2A):21S–24S (00 ref.)
Clinical aspects of immunologic monitoring. Chatenoud L, et al. **Transplant Proc** 1999 Jun;31(4):1812–3 (8 ref.)
T–cell activation pathways: a transplantation perspective. Halloran PF. **Transplant Proc** 1999 Feb–Mar; 31(1–2):769–71 (10 ref.)
On costimulatory signals and T cell tolerance: relevance for transplantation immunity. Holländer GA, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2A):25S–31S (78 ref.)
New usage paradigms in antibody therapy: induction or true prophylaxis? Kirkman RL. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1234–5 (7 ref.)
A few steps along the path to adult transplantation tolerance. Lafferty KJ. **Transplant Proc** 1999 Feb–Mar; 31(1–2A):11S–13S (21 ref.)
Current use of polyclonal antilymphocyte antibody preparations. Merion RM. **Transplant Proc** 1999 Sep; 31(6):2208–9 (19 ref.)
Humoral transplantation antibodies. Milgrom F. **Transplant Proc** 1999 Feb–Mar;31(1–2):30–3 (33 ref.)
Adverse effects of immunosuppressive drugs on long–term graft outcome. Paul LC. **Transplant Proc** 1998 Dec; 30(8):4001–4 (62 ref.)
New usage paradigms in antibody therapy: safety of the new agents. Pescovitz MD. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1201–2 (27 ref.)
Immunosuppression through inhibition of interleukin–2/interleukin–2 receptor interaction. Soulillou JP. **Transplant Proc** 1999 Feb–Mar;31(1–2A):49S–51S (23 ref.)
Immunity and tolerance are related, and governed by antigen migration and localization. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1406–11 (62 ref.)
Potential of gene transfer for the induction of specific unresponsiveness to alloantigens in vivo. Wood KJ. **Transplant Proc** 1999 Feb–Mar;31(1–2A):19S–20S (16 ref.)
Mixed chimerism as an approach for the induction of transplantation tolerance. Wekerle T, et al. **Transplantation** 1999 Aug 27;68(4):459–67 (118 ref.)
Human–porcine receptor–ligand compatibility within the immune system: relevance for xenotransplantation. Warrens AN, et al. **Xenotransplantation** 1999 May;6(2):75–8 (20 ref.)
[Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?] Haymann JP, et al. **Nephrologie** 1999; 20(3):139–43 (28 ref.) (Eng. Abstr.) **(Fre)**
[Pulmonary infections other than AIDS] Perdu D, et al. **Presse Med** 1998 May 23–30;27(19):934–40 (39 ref.) **(Fre)**
[Transplantation immunology] Volk HD, et al. **Z Arztl Fortbild Qualitatssich** 1999 Mar;93(2):84–91 (8 ref.) (Eng. Abstr.) **(Ger)**
[Downregulation of alpha–galactosyl epitope in xenograft] Miyagawa S, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2618–24 (29 ref.) **(Jpn)**
[Biophysical parity of a donor with a recipient that represents their metabolic parity is suggested as a criterion of histocompatibility] Piruzian LA, et al. **Fiziol Cheloveka** 1998 Sep–Oct;24(5):100–5 (35 ref.) **(Rus)**
[Chlamydia as the agent responsible for disease in the immunosuppressed and transplanted patient] Muñoz García–Paredes P, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 1:35–9 (61 ref.) **(Spa)**
[Xenotransplantation of solid organs: study of rejection mechanisms and its prevention] Rodriguez Villa A, et al. **Rev Clin Esp** 1998 Oct;198(10):673–7 (63 ref.) **(Spa)**

DRUG EFFECTS

Advances in immunosuppression for heart transplantation. Kobashigawa JA. **Adv Card Surg** 1998;10:155–74 (46 ref.)
The current status of mycophenolate mofetil in pediatric renal transplantation [editorial; comment] Tönshoff B. **Pediatr Transplant** 1999 Feb;3(1):5–9 (29 ref.) Comment on: Pediatr Transplant 1999 Feb;3(1):33–7. Comment on: Pediatr Transplant 1999 Feb;3(1):79–82.

IMMUNOLOGY

Advances in immunosuppression for heart transplantation. Kobashigawa JA. **Adv Card Surg** 1998;10:155–74 (46 ref.)
Cellular and molecular mechanisms in transplant arteriosclerosis (Review). Akyürek ML. **Int J Mol Med** 1998 Jan;1(1):279–88 (148 ref.)
Immunosuppressive strategies in transplantation. Denton MD, et al. **Lancet** 1999 Mar 27;353(9158):1083–91 (87 ref.)
Current understanding of chemokine involvement in allograft transplantation. Melter M, et al. **Pediatr Transplant** 1999 Feb;3(1):10–21 (113 ref.)
Developments in the clinical science of transplantation during the 20th century. Vella JP, et al. **Pediatr Transplant** 1998 Nov;2(4):257–62 (41 ref.)
Induction of immunologic tolerance for transplantation. Rossini AA, et al. **Physiol Rev** 1999 Jan;79(1):99–141 (460 ref.)
Transplantation tolerance, microchimerism, and the two–way paradigm [see comments] Starzl TE, et al. **Theor Med Bioeth** 1998 Sep;19(5):441–55 (83 ref.) Comment in: Theor Med Bioeth 1998 Sep;19(5):457–73.
Conceptual shifts in immunology: comments on the "two–way paradigm" [comment] Tauber AI. **Theor Med Bioeth** 1998 Sep;19(5):457–73 (39 ref.) Comment on: Theor Med Bioeth 1998 Sep;19(5):441–55.
[Mechanisms of xenotransplant rejection] Candinas D, et al. **Zentralbl Chir** 1999;124(7):591–9 (73 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION IMMUNOLOGY

PHYSIOLOGY

Bacterial infections after renal transplantation. Schmaldienst S, et al. **Contrib Nephrol** 1998;124:18–33; discussion 34–42 (101 ref.)

Porokeratosis and immunosuppression. Kanitakis J, et al. **Eur J Dermatol** 1998 Oct–Nov;8(7):459–65 (88 ref.)

Role of cytokines in transplantation tolerance: lessons learned from gene–knockout mice. Lakkis FG. **J Am Soc Nephrol** 1998 Dec;9(12):2361–7 (83 ref.)

Costimulatory molecules as targets for the induction of transplantation tolerance. Alegre ML. **Nephrol Dial Transplant** 1999 Feb;14(2):322–32 (81 ref.)

TRANSPLANTATION, ISLETS OF LANGERHANS see **ISLETS OF LANGERHANS TRANSPLANTATION**

TRANSPLANTATION, ISOGENEIC

PHYSIOLOGY

The nature of ischemia/reperfusion injury. Massberg S, et al. **Transplant Proc** 1998 Dec;30(8):4217–23 (82 ref.)

TRANSPLANTATION, KIDNEY see **KIDNEY TRANSPLANTATION**

TRANSPLANTATION, LIVER see **LIVER TRANSPLANTATION**

TRANSPLANTATION, LUNG see **LUNG TRANSPLANTATION**

TRANSPLANTATION, ORGAN see **ORGAN TRANSPLANTATION**

TRANSPLANTATION, PANCREAS see **PANCREAS TRANSPLANTATION**

TRANSPLANTATION, PANCREATIC ISLETS see **ISLETS OF LANGERHANS TRANSPLANTATION**

TRANSPLANTATION, RENAL see **KIDNEY TRANSPLANTATION**

TRANSPLANTATION, SKIN see **SKIN TRANSPLANTATION**

TRANSPLANTATION, SYNGENEIC see **TRANSPLANTATION, ISOGENEIC**

TRANSPLANTATION, TISSUE see **TISSUE TRANSPLANTATION**

TRANSPLANTS

Diagnosis of respiratory viruses in cancer and transplant patients. Englund JA, et al. **Curr Clin Top Infect Dis** 1999; 19:30–59 (121 ref.)

TRANSPORT, BIOLOGICAL see **BIOLOGICAL TRANSPORT**

TRANSPORT OF WOUNDED AND SICK see **TRANSPORTATION OF PATIENTS**

TRANSPORT PROTEINS see **CARRIER PROTEINS**

TRANSPORTATION

Cross–country truck drivers: a vulnerable population. Renner DA. **Nurs Outlook** 1998 Jul–Aug;46(4):164–8 (32 ref.)

Physiological stress and welfare of broiler chickens in transit: solutions not problems! Mitchell MA, et al. **Poult Sci** 1998 Dec;77(12):1803–14 (59 ref.)

A review of the road transport of cattle. Knowles TG. **Vet Rec** 1999 Feb 20;144(8):197–201 (52 ref.)

A review of the road transport of slaughter sheep. Knowles TG. **Vet Rec** 1998 Aug 22;143(8):212–9 (69 ref.)

LEGISLATION & JURISPRUDENCE

A different route to health: implications of transport policies. Dora C. **BMJ** 1999 Jun 19;318(7199):1686–9 (37 ref.)

TRANSPORTATION OF PATIENTS

ABC of intensive care. Transport of critically ill patients. Wallace PG, et al. **BMJ** 1999 Aug 7;319(7206):368–71 (0 ref.)

METHODS

Intrahospital transport of critically ill children—should we pay attention? [editorial; comment] Venkataraman ST. **Crit Care Med** 1999 Apr;27(4):694–5 (7 ref.) Comment on: Crit Care Med 1999 Apr;27(4):802–6.

ORGANIZATION & ADMINISTRATION

[Networks in perinatology. The French experience] Dreyfus M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:70–5 (13 ref.) **(Fre)**

[Different organizational modalities in perinatal care as a function of demographic context and budgetary constraints] Papiernik E. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:76–84 (17 ref.) **(Fre)**

TRANSPOSABLE ELEMENTS see **DNA TRANSPOSABLE ELEMENTS**

TRANSPOSASE

Genetic applications of transposons and other repetitive elements in zebrafish. Ivics Z, et al. **Methods Cell Biol** 1999; 60:99–131 (110 ref.)

TRANSPOSITION OF GREAT VESSELS

COMPLICATIONS

Cyanotic congenital heart disease with increased pulmonary blood flow. Grifka RG. **Pediatr Clin North Am** 1999 Apr; 46(2):405–25 (65 ref.)

Cyanotic congenital heart disease with decreased pulmonary blood flow in children. Waldman JD, et al. **Pediatr Clin North Am** 1999 Apr;46(2):385–404 (15 ref.)

DIAGNOSIS

[Complete D–transposition of the great vessels diagnosed late in a 10–month infant. Rashkind manoeuvre] Diop IB, et al. **Dakar Med** 1997;42(2):138–42 (17 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Exercise studies in patients with transposition of the great arteries after atrial repair operations (Mustard/Senning): a review. Paul MH, et al. **Pediatr Cardiol** 1999 Jan–Feb; 20(1):49–55; discussion 56 (50 ref.)

RADIOGRAPHY

[The CT diagnosis of an isolated congenital corrected transposition of the great vessels] Kostovic N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Mar;170(3):322–3 (0 ref.) **(Ger)**

TRANSSEXUALISM

A follow–up study for estimating the effectiveness of a cross–gender hormone substitution therapy on transsexual patients. Schlatterer K, et al. **Arch Sex Behav** 1998 Oct; 27(5):475–92 (34 ref.)

DIAGNOSIS

Transsexualism: a review of etiology, diagnosis and treatment. Cohen–Kettenis PT, et al. **J Psychosom Res** 1999 Apr;46(4):315–33 (171 ref.)

[Transsexualism. Current status of research and clinical practice] Sigusch V. **Nervenarzt** 1997 Nov;68(11):870–7 (92 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Osteo–anabolic estrogen therapy in a transsexual man] Hierl T, et al. **Dtsch Med Wochenschr** 1999 Apr 30; 124(17):519–22 (24 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

For the sake of the children: destigmatizing intersexuality. Preves SE. **J Clin Ethics** 1998 Winter;9(4):411–20 (24 ref.)

SURGERY

Transsexualism: a review of etiology, diagnosis and treatment. Cohen–Kettenis PT, et al. **J Psychosom Res** 1999 Apr;46(4):315–33 (171 ref.)

[Expert phoniatric assessment of voice adaptation in male to female transsexualism] Rosanowski F, et al. **HNO** 1999 Jun;47(6):556–62 (36 ref.) (Eng. Abstr.) **(Ger)**

TRANSTHORACIC ECHOCARDIOGRAPHY see **ECHOCARDIOGRAPHY**

TRANSTHYRETIN see **PREALBUMIN**

TRANSUDATES see **EXUDATES AND TRANSUDATES**

TRANSURETHRAL RESECTION OF PROSTATE see **PROSTATECTOMY**

TRAUMA see **WOUNDS AND INJURIES**

TRAUMA CENTERS

ORGANIZATION & ADMINISTRATION

Introduction to the Academic Symposium to Evaluate Evidence Regarding the Efficacy of Trauma Systems. Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S3–7 (10 ref.)

[Cranial trauma and multiple trauma: from the street to the operating room] Stocchetti N, et al. **Minerva Anestesiol** 1999 Jun;65(6):353–6 (6 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Systematic review of trauma system effectiveness based on registry comparisons [see comments] Jurkovich GJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S46–55 (28 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S56–8.

Systematic review of published evidence regarding trauma system effectiveness. Mann NC, et al. **J Trauma** 1999 Sep; 47(3 Suppl):S25–33 (72 ref.)

Population–based research assessing the effectiveness of trauma systems [see comments] Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S59–66 (32 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S67–8.

Invited commentary: panel reviews of trauma mortality. Trunkey DD. **J Trauma** 1999 Sep;47(3 Suppl):S44–5 (28 ref.)

STATISTICS & NUMERICAL DATA

Pediatric trauma systems: critical distinctions. Hulka F. **J Trauma** 1999 Sep;47(3 Suppl):S85–9 (28 ref.)

TRAUMA DISORDERS, CUMULATIVE see **CUMULATIVE TRAUMA DISORDERS**

TRAUMA, MULTIPLE see **MULTIPLE TRAUMA**

TRAUMA SEVERITY INDICES

Current trauma scoring systems and their applications. Van Camp LA, et al. **Eur J Emerg Med** 1998 Sep;5(3):341–53 (73 ref.)

Classification of thoracolumbar fractures and posterior instrumentation for treatment of thoracolumbar fractures. Capen DA. **Instr Course Lect** 1999;48:437–41 (24 ref.)

ABCs of scoring systems for pediatric trauma. Furnival RA, et al. **Pediatr Emerg Care** 1999 Jun;15(3):215–23 (90 ref.)

[Clinical examination of accident victims] Echtermeyer V, et al. **Unfallchirurg** 1999 Apr;102(4):305–18 (21 ref.) **(Ger)**

[Classification in trauma surgery (2)] Petersen PF, et al. **Zentralbl Chir** 1999;124(1):W1–6 (20 ref.) **(Ger)**

TRAUMA UNITS see **TRAUMA CENTERS**

TRAUMATOLOGY

see related
WOUNDS AND INJURIES

EDUCATION

Evolution of the Emergency Management of Severe Burns (EMSB) course in the UK. Stone CA, et al. **Burns** 1999 May;25(3):262–4 (3 ref.)

TRENDS

Trauma and critical care. Fallon WF Jr. **J Am Coll Surg** 1999 Feb;188(2):191–7 (35 ref.)

TRAVEL

Medical advice for commercial air travelers. Bettes TN, et al. **Am Fam Physician** 1999 Sep 1;60(3):801–8, 810 (16 ref.)

Prevention and treatment of traveler's diarrhea. Juckett G. **Am Fam Physician** 1999 Jul;60(1):119–24, 135–6 (12 ref.)

Malaria prevention in travelers. Juckett G. **Am Fam Physician** 1999 May 1;59(9):2523–30, 2535–6 (13 ref.)

Malaria. The latest in advice for travellers. Pellegrini M, et al. **Aust Fam Physician** 1999 Jul;28(7):683–8 (8 ref.)

Advances in the prevention and management of traveler's diarrhea. Passaro DJ, et al. **Curr Clin Top Infect Dis** 1998; 18:217–36 (144 ref.)

Imported tropical respiratory tract infections. Zuckerman JN. **Curr Opin Pulm Med** 1999 May;5(3):164–7 (20 ref.)

The United States military and leishmaniasis. Kenner JR, et al. **Dermatol Clin** 1999 Jan;17(1):77–92, viii (77 ref.)

Unusual cutaneous infectious and parasitic diseases. Lemons–Estes FM, et al. **Dermatol Clin** 1999 Jan; 17(1):151–85, ix (64 ref.)

Travel vaccines. Thompson RF, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):149–67, vii (65 ref.)

Melatonin: aeromedical, toxicopharmacological, and analytical aspects. Sanders DC, et al. **J Anal Toxicol** 1999 May–Jun;23(3):159–67 (100 ref.)

Antiretroviral treatment and travel to developing countries. Colebunders R, et al. **J Travel Med** 1999 Mar;6(1):27–31 (19 ref.)

Dangers in the ocean: the traveler and marine envenomation. I. jellyfish. Fenner PJ. **J Travel Med** 1998 Sep;5(3):135–41 (18 ref.)

Dangers in the ocean: the traveler and marine envenomation. II. Marine vertebrates. Fenner PJ. **J Travel Med** 1998 Dec; 5(4):213–6 (11 ref.)

HIV and the returning expatriate. Jones ME. **J Travel Med** 1999 Jun;6(2):99–106 (47 ref.)

GIDEON computer program for diagnosing and teaching geographic medicine. Keystone JS. **J Travel Med** 1999 Jun; 6(2):152–4 (4 ref.)

Traveling with children. Leggat PA, et al. **J Travel Med** 1998 Sep;5(3):142–6 (14 ref.)

Sore eyes and travelers. Leggat PA, et al. **J Travel Med** 1999

Mar;6(1):45–7 (6 ref.)
Vaccination of travelers against hepatitis A and B. Löscher T, et al. **J Travel Med** 1999 Jun;6(2):107–14 (68 ref.)
Emergency contraception in a travel context [see comments] Patton PG. **J Travel Med** 1999 Mar;6(1):24–6 (20 ref.) Comment in: J Travel Med 1999 Mar;6(1):1–2.
Mefloquine for malaria chemoprophylaxis 1992–1998: a review. Schlagenhauf P. **J Travel Med** 1999 Jun;6(2):122–33 (96 ref.)
Diving and marine medicine review part I: diving physics and physiology. Spira A. **J Travel Med** 1999 Mar;6(1):32–44 (72 ref.)
International tourists, motor vehicles and road safety: a review of the literature leading up to the Sydney 2000 Olympics. Wilks J. **J Travel Med** 1999 Jun;6(2):115–21 (43 ref.)
Prevention and empiric treatment of traveler's diarrhea. Ansdell VE, et al. **Med Clin North Am** 1999 Jul; 83(4):945–73, vi (102 ref.)
Prevention of malaria in travelers. Baird JK, et al. **Med Clin North Am** 1999 Jul;83(4):923–44, vi (77 ref.)
Emerging infectious diseases and risk to the traveler. Freedman DO, et al. **Med Clin North Am** 1999 Jul; 83(4):865–83, v (79 ref.)
Travel immunizations. Jong EC. **Med Clin North Am** 1999 Jul;83(4):903–22, vi (36 ref.)
Skin lesions in returned travelers. Kain KC. **Med Clin North Am** 1999 Jul;83(4):1077–102 (25 ref.)
Intestinal parasites in returned travelers. MacPherson DW. **Med Clin North Am** 1999 Jul;83(4):1053–75 (88 ref.)
Evaluation of fever in the returned traveler. Suh KN, et al. **Med Clin North Am** 1999 Jul;83(4):997–1017 (78 ref.)
Chronic diarrhea in the returned traveler. Taylor DN, et al. **Med Clin North Am** 1999 Jul;83(4):1033–52, vii (81 ref.)
Medical considerations for wilderness and adventure travelers. Weiss EA. **Med Clin North Am** 1999 Jul; 83(4):885–902, v–vi (31 ref.)
Eosinophilia in the returning traveler. Wolfe MS. **Med Clin North Am** 1999 Jul;83(4):1019–32, vii (52 ref.)
Advising patients about international travel. What they can do to protect their health and safety. Bratton RL. **Postgrad Med** 1999 Jul;106(1):57–64; quiz 143 (14 ref.)
Have diabetes, will travel. Dewey CM, et al. **Postgrad Med** 1999 Feb;105(2):111–3, 117–8, 124–6 (11 ref.)
Key developments in travel medicine. Chiodini P, et al. **Practitioner** 1998 May;242(1586):342–4, 346 (2 ref.)
Travelling with heart disease. Cleland J. **Practitioner** 1998 Feb;242(1583):130–3 (4 ref.)
Treatment and prevention of diarrhoea. Farthing M. **Practitioner** 1998 May;242(1586):388–90, 392, 394 (11 ref.)
Diagnosing imported rashes and skin lesions. McCarron B. **Practitioner** 1998 May;242(1586):366–8, 371, 374 passim (3 ref.)
A patient with heart disease plans a long flight. Matthews S, et al. **Practitioner** 1997 Dec;241(1581):711–4, 716, 719 (0 ref.)
Advising the traveller with lung disease. Sullivan P, et al. **Practitioner** 1998 May;242(1586):379–83 (0 ref.)
[Vaccinations of the traveller] Marchou B, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):332–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Thromboembolic syndrome from prolonged sitting and flights of long duration: experience of the Emergency Medical Service of the Paris Airports] Clérel M, et al. **Bull Acad Natl Med** 1999;183(5):985–97; discussion 997–1001 (34 ref.) (Eng. Abstr.) **(Fre)**
[Protection of travellers against biting arthropod vectors] Carnevale P. **Bull Soc Pathol Exot** 1998;91(5 Pt 1–2):474–85 (113 ref.) (Eng. Abstr.) **(Fre)**
[The principal arthropod vectors of disease. What are the risks of travellers' to be bitten? To be infected?] Coosemans M, et al. **Bull Soc Pathol Exot** 1998;91(5 Pt 1–2):467–73 (47 ref.) (Eng. Abstr.) **(Fre)**
[Kidney transplantation and travel in the tropics] Receveur MC, et al. **Nephrologie** 1999;20(3):145–51 (32 ref.) (Eng. Abstr.) **(Fre)**
[Travel outside our frontiers: parasitic diseases not to be missed] Pelloux H. **Rev Med Suisse Romande** 1999 Feb; 119(2):93–7 (24 ref.) **(Fre)**
[Fever after returning from travel to a tropical zone: what infectious diseases should be considered?] Reinhardt MC, et al. **Rev Med Suisse Romande** 1999 Feb;119(2):99–102 (6 ref.) **(Fre)**
[Malaria prophylaxis] Bouchaud O, et al. **Rev Prat** 1998 Feb 1;48(3):279–86 (28 ref.) (Eng. Abstr.) **(Fre)**
[Malaria in airports and their neighborhoods] Giacomini T. **Rev Prat** 1998 Feb 1;48(3):264–7 (25 ref.) (Eng. Abstr.) **(Fre)**
[Traveler's diarrhea] Döller PC. **Med Monatsschr Pharm** 1999 Jul;22(7):205–10 (15 ref.) **(Ger)**
[Imported infectious disease] Nagatake T. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):380–3 (7 ref.) **(Jpn)**
[Communicable disease control in connection with international air traffic to Norway] Aavitsland P, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3649–53 (36 ref.) (Eng. Abstr.) **(Nor)**
[Primaquine and travelers from the Arab world. A report and recommendations] Menéndez Capote R, et al. **Rev Cubana Med Trop** 1995;47(3):221–3 (11 ref.) (Eng. Abstr.) **(Spa)**
[Travels, risks and advice. Certain health recommendations to travellers abroad are not necessary; the non-medical risks are often underestimated] Rombo L. **Lakartidningen** 1999 Apr 28;96(17):2088–91 (15 ref.) **(Swe)**
[Increased travelling—increased risk of imported viruses. A review of the diagnostic capacity of the Swedish Institute for Infectious Disease Control] Vene S, et al. **Lakartidningen** 1999 Jun 9;96(23):2838–41 (20 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247–61 (81 ref.)

TREACHER COLLINS SYNDROME see **MANDIBULOFACIAL DYSOSTOSIS**

TREADMILL TEST see **EXERCISE TEST**

TREATMENT COSTS see **HEALTH CARE COSTS**

TREATMENT EFFECTIVENESS see **TREATMENT OUTCOME**

TREATMENT FUTILITY see **MEDICAL FUTILITY**

TREATMENT OUTCOME

Metaanalytic revision of endpoints [editorial; comment] Gallagher EJ. **Ann Emerg Med** 1999 Jul;34(1):91–5 (44 ref.) Comment on: Ann Emerg Med 1999 Jul;34(1):8–18.
Similar, the same or just not different: a guide for deciding whether treatments are clinically equivalent. [Dept. of Medicine, Division of Cardiology, Univ. of Western Ontario, London, Ontario] Massel D. **Can J Cardiol** 1999 May;15(5):556–62 (30 ref.)
Impact of "non-physician factors" on the "physician factor" of in vitro fertilization success: is it the broth, the cooks, or the statistics? [editorial; comment] Lu MC. **Fertil Steril** 1999 Jun;71(6):998–1000 (4 ref.) Comment on: Fertil Steril 1998 Jun;71(6):1001–9.
Deriving treatment recommendations from evidence within randomized trials. The role and limitation of meta-analysis. Freemantle N, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):304–15 (46 ref.)
Ecological analysis of intended treatment effects: caveat emptor [comment] Naylor CD. **J Clin Epidemiol** 1999 Jan; 52(1):1–5 (11 ref.) Comment on: J Clin Epidemiol 1999 Jan;52(1):7–12.
The effect of medical nutrition therapy on malnutrition and clinical outcomes. Gallagher-Allred CR, et al. **Nutrition** 1999 Jun;15(6):512–4 (39 ref.)
Subjective outcome measurement—a primer. Tully MP, et al. **Pharm World Sci** 1999 Jun;21(3):101–9 (91 ref.)
The impact of acute radiation morbidity on therapeutic outcome [editorial] Zimmermann JS, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:1–3 (24 ref.)
[Decision analysis and initiation of an "empiric" therapy Van Meerhaeghe A. **Rev Med Brux** 1999 Feb;20(1):21–4 (14 ref.) (Eng. Abstr.) **(Fre)**
[The value of gastrointestinal tumor surgery should be scrutinized. The therapeutic results are not always correctly interpreted] Lundell L. **Lakartidningen** 1999 May 5;96(18):2174–7 (28 ref.) **(Swe)**

TREATMENT PROTOCOLS see **CLINICAL PROTOCOLS**

TREATMENT REFUSAL

see related
PATIENT DROPOUTS

An AIDS patient's right to refuse life-sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161–4 (46 ref.)
Foregoing life support in medically futile patients. Tai DY, et al. **Ann Acad Med Singapore** 1998 May;27(3):430–6 (28 ref.)
Hemodialysis morbidity and mortality: links to patient non-compliance. Bander SJ, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):649–53 (30 ref.)
The difficult patient. Simon JR, et al. **Emerg Med Clin North Am** 1999 May;17(2):353–70, x (22 ref.)
Intra-abdominal abscess due to patient non-compliance after construction of an ileal neobladder: case report and review of the literature. Doehn C, et al. **Int J Urol** 1999 May; 6(5):264–7 (12 ref.)
Insight in severe mental illness: implications for treatment decisions. Husted JR. **J Am Acad Psychiatry Law** 1999; 27(1):33–49 (33 ref.)
Existing treatment strategies: does noncompliance make a difference? Caro JJ, et al. **J Hypertens Suppl** 1998 Sep; 16(7):S31–4 (17 ref.)
Bioethics of the refusal of blood by Jehovah's Witnesses: Part 1. Should bioethical deliberation consider dissidents' views? [published erratum appears in J Med Ethics 1998 Dec;24(6):375] Muramoto O. **J Med Ethics** 1998 Aug; 24(4):223–30 (40 ref.)
The cost of refusing treatment and equality of outcome. Savulescu J. **J Med Ethics** 1998 Aug;24(4):231–6 (23 ref.)
Compliance issues with the geriatric population: complexity with aging. De Geest S, et al. **Nurs Clin North Am** 1998 Sep;33(3):467–80 (62 ref.)
[Anesthesia in Jehovah's Witnesses] Chassot PG. **Rev Med Suisse Romande** 1999 Mar;119(3):179–89 (28 ref.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Forced cesareans. Ikemoto LC. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):465–8 (17 ref.)
The right to refuse psychiatric treatment. Wettstein RM. **Psychiatr Clin North Am** 1999 Mar;22(1):173–82, viii (15 ref.)

PSYCHOLOGY

Rebels with a cause [see comments] Muscari ME. **Am J Nurs** 1998 Dec;98(12):26–30; quiz 31 (12 ref.) Comment in: Am J Nurs 1999 Apr;99(4):14.
Issues of non-compliance in mental health. Lowry DA. **J Adv Nurs** 1998 Aug;28(2):280–7 (51 ref.)
Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's motives. Malyon D. **J Med Ethics** 1998 Dec;24(6):376–81 (31 ref.)
Non-compliance following renal transplantation in children and adolescents. Wolff G, et al. **Pediatr Nephrol** 1998 Nov; 12(9):703–8 (32 ref.)

STATISTICS & NUMERICAL DATA

Is default from colposcopy a problem, and if so what can we do? A systematic review of the literature. Lester H, et al. **Br J Gen Pract** 1999 Mar;49(440):223–9 (65 ref.)

TREE SHREWS see **TUPAIIDAE**

TREEHOPPERS see **HEMIPTERA**

TREES

CHEMISTRY

Constituents of the yew trees. Parmar VS, et al. **Phytochemistry** 1999 Apr;50(8):1267–304 (257 ref.)
[Terpenoids and steroids from several euphorbiaceae and pinaceae plants] Tanaka R, et al. **Yakugaku Zasshi** 1999 May;119(5):319–39 (64 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

Somatic embryogenesis in Picea suspension cultures. Egertsdotter U. **Methods Mol Biol** 1999;111:51–60 (26 ref.)

METABOLISM

Unexpected variation in lignin. Sederoff RR, et al. **Curr Opin Plant Biol** 1999 Apr;2(2):145–52 (75 ref.)

THERAPEUTIC USE

The clinical applications of Ginkgo biloba, St. John's wort, saw palmetto, and soy. Glisson J, et al. **Nurse Pract** 1999 Jun;24(6):28, 31, 35–6 passim; quiz 47–9 (65 ref.)

TREHALOSE

METABOLISM

Thermotolerance in Saccharomyces cerevisiae: the Yin and Yang of trehalose. Singer MA, et al. **Trends Biotechnol** 1998 Nov;16(11):460–8 (71 ref.)

TREMARCTOS see **BEARS**

TREMATODA

see related
ANTIPLATYHELMINTIC AGENTS

ANATOMY & HISTOLOGY

Monogenean neuromusculature: some structural and functional correlates. Halton DW, et al. **Int J Parasitol** 1998 Oct;28(10):1609–23 (33 ref.)

CLASSIFICATION

Non-monophyly of the monogeneans? Justine JL. **Int J Parasitol** 1998 Oct;28(10):1653–7 (35 ref.)
South American Monogenea—list of species, hosts and geographical distribution. Kohn A, et al. **Int J Parasitol** 1998 Oct;28(10):1517–54 (212 ref.)
Diversity of monogeneans in Southeast Asia. Lim LH. **Int J Parasitol** 1998 Oct;28(10):1495–515 (98 ref.)

PHYSIOLOGY

The selection of habitats among the monogenea. Euzet L, et al. **Int J Parasitol** 1998 Oct;28(10):1645–52 (38 ref.)
Monogenean neuromusculature: some structural and functional correlates. Halton DW, et al. **Int J Parasitol** 1998 Oct;28(10):1609–23 (33 ref.)
Diversity of monogeneans in Southeast Asia. Lim LH. **Int J Parasitol** 1998 Oct;28(10):1495–515 (98 ref.)
Correlation of parasite speciation and specificity with host evolutionary relationships. Tinsley RC, et al.

TREMATODA

Int J Parasitol 1998 Oct;28(10):1573–82 (34 ref.)
Diversity "down under": monogeneans in the Antipodes (Australia) with a prediction of monogenean biodiversity worldwide. Whittington ID. **Int J Parasitol** 1998 Oct; 28(10):1481–93 (76 ref.)
Life history specializations of monogenean flatworms: a review of experimental and microscopical studies. Cable J, et al. **Microsc Res Tech** 1998 Aug 1;42(3):186–99 (50 ref.)
Ecology of host parasite relationships in the Baltic Sea. Zander CD. **Naturwissenschaften** 1998 Sep;85(9):426–36 (38 ref.)

TREMATODE INFECTIONS

see related
ANTIPLATYHELMINTIC AGENTS
[Metagonimiasis yokogawai] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):493–5 (2 ref.) **(Jpn)**

DIAGNOSIS

[Laboratory diagnosis of protozoan and parasitic diseases. 2. Helminthiasis. d. Trematode infections] Nawa Y. **Rinsho Byori** 1998 Nov;Suppl 108:226–31 (6 ref.) **(Jpn)**

VETERINARY

Correlation of parasite speciation and specificity with host evolutionary relationships. Tinsley RC, et al. **Int J Parasitol** 1998 Oct;28(10):1573–82 (34 ref.)

TREMOR

Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Deuschl G, et al. **Mov Disord** 1998;13 Suppl 3:2–23 (207 ref.)
[Essential tremor] Hashimoto T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):151–5 (15 ref.) **(Jpn)**
[Essential tremor: a review of pathogenic mechanisms] Tapiador MJ, et al. **Rev Neurol** 1998 Dec;27(160):1059–65 (101 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Parkinsonian and essential tremors: different entities or different manifestations of the same disorder? Lücking CH, et al. **Adv Neurol** 1999;80:335–9 (9 ref.)

DIAGNOSIS

Neurophysiological tests for the assessment of tremors. Deuschl G. **Adv Neurol** 1999;80:57–65 (51 ref.)
Visual–vestibular control of posture and gait: physiological mechanisms and disorders. Bronstein AM, et al. **Curr Opin Neurol** 1999 Feb;12(1):5–11 (62 ref.)
Differential diagnosis of tremor. Deuschl G. **J Neural Transm Suppl** 1999;56:211–20 (22 ref.)
Overview of human tremor physiology. Hallett M. **Mov Disord** 1998;13 Suppl 3:43–8 (19 ref.)
Oscillations of the human sensorimotor system as revealed by magnetoencephalography. Volkmann J. **Mov Disord** 1998;13 Suppl 3:73–6 (17 ref.)

DRUG THERAPY

A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor. Louis ED. **Arch Neurol** 1999 Jul;56(7):807–8 (18 ref.)
Pharmacologic treatment of tremor. Wasielewski PG, et al. **Mov Disord** 1998;13 Suppl 3:90–100 (152 ref.)

EPIDEMIOLOGY

Epidemiology and genetics of essential tremor. Brin MF, et al. **Mov Disord** 1998;13 Suppl 3:55–63 (129 ref.)

ETIOLOGY

Classification of tremor and update on treatment. Charles PD, et al. **Am Fam Physician** 1999 Mar 15;59(6):1565–72 (23 ref.)
Animal models of action tremor. Elble RJ. **Mov Disord** 1998; 13 Suppl 3:35–9 (58 ref.)
Neural transplantation in Parkinson's disease and its effects on rest tremor: a review of the literature. Pogarell O, et al. **Mov Disord** 1998;13 Suppl 3:101–2 (14 ref.)
Physiology and anatomy of possible oscillators in the central nervous system. Rothwell JC. **Mov Disord** 1998;13 Suppl 3:24–8 (11 ref.)

GENETICS

Epidemiology and genetics of essential tremor. Brin MF, et al. **Mov Disord** 1998;13 Suppl 3:55–63 (129 ref.)

PATHOLOGY

Functional imaging of tremor. Boecker H, et al. **Mov Disord** 1998;13 Suppl 3:64–72 (65 ref.)
Pathology of symptomatic tremors. Vidailhet M, et al. **Mov Disord** 1998;13 Suppl 3:49–54 (61 ref.)

PHYSIOPATHOLOGY

Parkinsonian and essential tremors: different entities or different manifestations of the same disorder? Lücking CH, et al. **Adv Neurol** 1999;80:335–9 (9 ref.)
Tremulous jaw movements in rats: a model of parkinsonian tremor. Salamone JD, et al. **Prog Neurobiol** 1998 Dec; 56(6):591–611 (190 ref.)

RADIONUCLIDE IMAGING

Functional imaging of tremor. Boecker H, et al. **Mov Disord** 1998;13 Suppl 3:64–72 (65 ref.)

SURGERY

Pallidotomy for tremor. Lozano AM, et al. **Mov Disord** 1998; 13 Suppl 3:107–10 (11 ref.)
Thalamic surgery and tremor. Speelman JD, et al. **Mov Disord** 1998;13 Suppl 3:103–6 (52 ref.)
[Indications for surgical treatment of tremor] Bötzel K, et al. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):287–90 (13 ref.) **(Ger)**

THERAPY

Classification of tremor and update on treatment. Charles PD, et al. **Am Fam Physician** 1999 Mar 15;59(6):1565–72 (23 ref.)

TRENCH FEVER

[Trench fever] Tachibana N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):294–6 (7 ref.) **(Jpn)**

TRENCH MOUTH see **GINGIVITIS, NECROTIZING ULCERATIVE**

TREPONEMA PALLIDUM

GENETICS

The genome of Treponema pallidum: new light on the agent of syphilis. Weinstock GM, et al. **FEMS Microbiol Rev** 1998 Oct;22(4):323–32 (50 ref.)

TRETINOIN

see related
RECEPTORS, RETINOIC ACID

ADVERSE EFFECTS

Tretinoin-induced sticky skin: a case report and review of the literature. Lockridge J, et al. **Cutis** 1999 Mar; 63(3):142–4 (7 ref.)
Extramedullary disease in acute promyelocytic leukemia. Evans GD, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):219–29 (86 ref.)
[Extramedullary relapse in the external auditory canal in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and autologous peripheral blood stem cell transplantation] Yagita M, et al. **Rinsho Ketsueki** 1998 Sep;39(9):709–15 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Miller WH Jr. **Cancer** 1998 Oct 15;83(8):1471–82 (146 ref.)
Metabolism of retinoic acid: implications for development and cancer. Sonneveld E, et al. **Int J Vitam Nutr Res** 1998; 68(6):404–10 (47 ref.)
Interaction of neurotrophins and retinoic acid in neuronal differentiation. Cheung WM, et al. **Mol Cells** 1998 Aug 31;8(4):496–502 (74 ref.)
Retinoic acid: its biosynthesis and metabolism. Napoli JL. **Prog Nucleic Acid Res Mol Biol** 1999;63:139–88 (214 ref.)

PHARMACOLOGY

Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1–regulated matrix metalloproteinases that degrade human skin in vivo. Fisher GJ, et al. **J Investig Dermatol Symp Proc** 1998 Aug; 3(1):61–8 (48 ref.)
Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Chelbi-Alix MK, et al. **Leukemia** 1999 Aug;13(8):1167–74 (107 ref.)
Treatment of mice with retinoids in vivo and in vitro. Skeletal staining. Morriss-Kay GM. **Methods Mol Biol** 1999;97:33–9 (15 ref.)

PHYSIOLOGY

Retinoid-induced apoptosis in normal and neoplastic tissues [see comments] Nagy L, et al. **Cell Death Differ** 1998 Jan; 5(1):11–9 (86 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1–3.
Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors [see comments] Szondy Z, et al. **Cell Death Differ** 1998 Jan; 5(1):4–10 (78 ref.) Comment in: Cell Death Differ 1998 Jan;5(1):1–3.
Neutrophil maturation and the role of retinoic acid. Lawson ND, et al. **Exp Hematol** 1999 Sep;27(9):1355–67 (132 ref.)
Retinoids and mammalian development. Morriss-Kay GM, et al. **Int Rev Cytol** 1999;188:73–131 (235 ref.)

THERAPEUTIC USE

Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Lo Coco F, et al. **Blood** 1999 Jul 1;94(1):12–22 (119 ref.)
Current approaches to acute promyelocytic leukemia. Frankel SR, et al. **Cancer Treat Res** 1999;99:125–53 (172 ref.)
All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Miyauchi J. **Leuk Lymphoma** 1999 Apr;33(3–4):267–80 (138 ref.)
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Takeuchi M, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):441–51 (53 ref.)
[Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?] de Thé H. **C R Seances Soc Biol Fil** 1998;192(2):273–81 (40 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

The interaction of ethanol and vitamin A as a potential mechanism for the pathogenesis of Fetal Alcohol syndrome. Zachman RD, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1544–56 (127 ref.)

TRH RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

TRIACYLGLYCEROL LIPASE see **LIPASE**

TRIACYLGLYCEROLS see **TRIGLYCERIDES**

TRIAGE

METHODS

Impact of the measurement of troponin on the triage, prognosis, and treatment of patients with chest pain. Jesse RL. **Clin Chim Acta** 1999 Jun 30;284(2):213–21 (19 ref.)
Focused Assessment with Sonography for Trauma (FAST): results from an international consensus conference. Scalea TM, et al. **J Trauma** 1999 Mar;46(3):466–72 (25 ref.)
ABCs of scoring systems for pediatric trauma. Furnival RA, et al. **Pediatr Emerg Care** 1999 Jun;15(3):215–23 (90 ref.)

TRIAL OF LABOR

see related
CESAREAN SECTION
DELIVERY
Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Plaut MM, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1535–42 (27 ref.)
High risk pregnancy outcome by route of delivery. Ben Shachar I, et al. **Curr Opin Obstet Gynecol** 1998 Dec; 10(6):447–52 (40 ref.)
[Monitoring of the course of labor: how to monitor childbirth 25 years after the institution of monitoring] Thoulon JM, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct; 27(6):577–83 (39 ref.) **(Fre)**

TRIALKYLTIN COMPOUNDS

TOXICITY

Risk assessment and immunotoxicology. Van Loveren H, et al. **Toxicol Lett** 1998 Dec 28;102–103:261–5 (13 ref.)

TRIAMCINOLONE

ADVERSE EFFECTS

Hypopigmentation along subcutaneous veins following intrakeloid triamcinolone injection: a case report and review of literature. Kumar P, et al. **Burns** 1998 Aug; 24(5):487–8 (11 ref.)

TRIAZINES

ADVERSE EFFECTS

Rash in adult and pediatric patients treated with lamotrigine. Messenheimer JA. **Can J Neurol Sci** 1998 Nov;25(4):S14–8 (13 ref.)
Lamotrigine-associated rash: risk/benefit considerations in adults and children. Guberman AH, et al. **Epilepsia** 1999 Jul;40(7):985–91 (44 ref.)
Lamotrigine-induced severe cutaneous adverse reactions. Schlienger RG, et al. **Epilepsia** 1998;39 Suppl 7:S22–6 (40 ref.)
Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Schlienger RG, et al. **Neurology** 1998 Oct; 51(4):1172–5 (10 ref.)

PHARMACOLOGY

Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder. Xie X, et al.

Neuropsychobiology 1998 Oct;38(3):119–30 (80 ref.)

THERAPEUTIC USE

Lamotrigine--an effective mood stabilizer? Maidment ID. **Ann Pharmacother** 1999 Jul–Aug;33(7–8):864–7 (18 ref.)
Neurophysiologic and neuropsychologic profiles of lamotrigine in epilepsy. Marciani MG, et al. **Clin Neuropharmacol** 1999 May–Jun;22(3):159–63 (49 ref.)
Lamotrigine in the treatment of epilepsy in people with intellectual disability. Besag FM. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:50–6 (30 ref.)
Clinical studies on the use of lamotrigine in bipolar disorder. Calabrese JR, et al. **Neuropsychobiology** 1998 Oct; 38(3):185–91 (47 ref.)
Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder. Ferrier IN. **Neuropsychobiology** 1998 Oct; 38(3):192–7 (45 ref.)

TOXICITY

An ecological risk assessment for the use of Irgarol 1051 as an algaecide for antifoulant paints. Hall LW Jr, et al. **Crit Rev Toxicol** 1999 Jul;29(4):367–437 (103 ref.)

TRIAZOLAM

PHARMACOKINETICS

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1999 Aug;19(4):293–6 (51 ref.)

TRIAZOLES

PHARMACOLOGY

Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Goss PE. **Breast Cancer Res Treat** 1998;49 Suppl 1:S59–65; discussion S73–7 (21 ref.)
Pharmacological and clinical profile of anastrozole. Lønning PE, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S53–7; discussion S73–7 (26 ref.)
Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Smith IE, et al. **Breast Cancer Res Treat** 1998;49 Suppl 1:S67–71; discussion S73–7 (18 ref.)
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Horst WD, et al. **J Affect Disord** 1998 Dec; 51(3):237–54 (97 ref.)

THERAPEUTIC USE

Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Lamb HM, et al. **Drugs** 1998 Dec;56(6):1125–40 (54 ref.)
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Wiseman LR, et al. **Drugs Aging** 1998 Oct;13(4):321–32 (34 ref.)
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Horst WD, et al. **J Affect Disord** 1998 Dec; 51(3):237–54 (97 ref.)

TRIBAVIRIN see **RIBAVIRIN**

TRIBUTYRINASE see **LIPASE**

TRICARBOXYLIC ACID CYCLE see **CITRIC ACID CYCLE**

TRICARBOXYLIC ACIDS

METABOLISM

Anaplerosis of the tricarboxylic acid cycle in human skeletal muscle during exercise. Magnitude, sources, and potential physiological significance. Graham TE, et al. **Adv Exp Med Biol** 1998;441:271–86 (44 ref.)

TRICHECHUS MANATUS

PHYSIOLOGY

The Florida manatee: on the verge of extinction? Bossart GD. **J Am Vet Med Assoc** 1999 Apr 15;214(8):1178–83 (21 ref.)

TRICHINELLIASIS see **TRICHINOSIS**

TRICHINOSIS

[Trichinosis; trichinellosis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):466–8 (6 ref.) **(Jpn)**

TRICHLORFON

Metrifonate: a new agent for the treatment of Alzheimer's disease. Williams BR. **Am J Health Syst Pharm** 1999 Mar 1;56(5):427–32 (64 ref.)

ADVERSE EFFECTS

The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Schmidt BH, et al. **Dement Geriatr Cogn Disord** 1998;9 Suppl 2:15–9 (28 ref.)

THERAPEUTIC USE

Therapeutic and operational profiles of metrifonate and praziquantel in Schistosoma haematobium infection. Feldmeier H, et al. **Arzneimittelforschung** 1999 Jul; 49(7):557–65 (81 ref.)
The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Schmidt BH, et al. **Dement Geriatr Cogn Disord** 1998;9 Suppl 2:15–9 (28 ref.)

TRICHLOROETHANES

TOXICITY

1,1,1-Trichloroethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:881–903 (93 ref.)

TRICHLOROETHYLENE

ANALOGS & DERIVATIVES

Trichloroethylene. III. Prediction of carcinogenicity of investigated compounds including trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):221–4 (14 ref.)

METABOLISM

Methanotrophs, Methylosinus trichosporium OB3b, sMMO, and their application to bioremediation. Sullivan JP, et al. **Crit Rev Microbiol** 1998;24(4):335–73 (165 ref.)

TOXICITY

Trichloroethylene. I. Carcinogenicity of trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):211–4 (37 ref.)
Trichloroethylene. II. Mechanism of carcinogenicity of trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):215–9 (20 ref.)
Trichloroethylene. III. Prediction of carcinogenicity of investigated compounds including trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):221–4 (14 ref.)

2,4,5-TRICHLOROPHENOXYACETIC ACID

ADVERSE EFFECTS

Agent Orange in war medicine: an aftermath myth. Hardell L, et al. **Int J Health Serv** 1998;28(4):715–24 (45 ref.)

TRICHOBEZOARS see **BEZOARS**

TRICHOCEPHALIASIS see **TRICHURIASIS**

TRICHOCEPHALUS see **TRICHURIS**

TRICHODERMA

GENETICS

Heterologous expression of genes in filamentous fungi. Kruszewska JS. **Acta Biochim Pol** 1999;46(1):181–95 (97 ref.)

ISOLATION & PURIFICATION

Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. Richter S, et al. **J Clin Microbiol** 1999 Apr;37(4):1154–60 (37 ref.)

PATHOGENICITY

Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. Richter S, et al. **J Clin Microbiol** 1999 Apr;37(4):1154–60 (37 ref.)

TRICHOMONAS

see related
ANTITRICHOMONAL AGENTS

TRICHOMONAS INFECTIONS

see related
ANTITRICHOMONAL AGENTS

DIAGNOSIS

[Trichomonas in pleural empyema] Garcia ER, et al. **Rev Med Panama** 1997 Jan;22(1):16–9 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Issues in the management of sexually transmitted diseases in Papua New Guinea. Passey M. **P N G Med J** 1996 Sep; 39(3):252–60 (14 ref.)

TRICHOMONAS VAGINALIS

DRUG EFFECTS

Trichomonads, hydrogenosomes and drug resistance. Kulda J. **Int J Parasitol** 1999 Feb;29(2):199–212 (73 ref.)
[Microflora of the female genitalia and its sensitivity to antibacterial drugs] Voropaeva SD. **Antibiot Khimioter** 1999;44(3):42–5 (14 ref.) **(Rus)**

TRICHOMONAS VAGINITIS

[Trichomoniasis] Kubota T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):77–9 (2 ref.) **(Jpn)**

TRICHOPHYTON

Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. Tanuma H. **Mycoses** 1999 Apr;42(1–2):21–8 (49 ref.)

DRUG EFFECTS

Kill power of oral antifungals against dermatophytes. Hazen KC, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):200–4 (6 ref.)

IMMUNOLOGY

The immune response to dermatophytes. Woodfolk JA, et al. **Res Immunol** 1998 May–Jun;149(4–5):436–45; discussion 522–3 (65 ref.)

TRICHOPHYTOSIS see **TINEA**

TRICHOSPORON

Evaluation of new method for diagnosis of opportunistic fungal infection. Hashimoto A, et al. **Nippon Ishinkin Gakkai Zasshi** 1998;39(4):187–92 (17 ref.)
[Disseminated trichosporonosis] Tokimatsu I, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):390–2 (14 ref.) **(Jpn)**

TRICHOSTRONGYLOIDEA

DRUG EFFECTS

Anthelmintic resistance revisited: under-dosing, chemoprophylactic strategies, and mating probabilities. Smith G, et al. **Int J Parasitol** 1999 Jan;29(1):77–91; discussion 93–4 (41 ref.)

TRICHOSTRONGYLOIDIASIS

VETERINARY

Anthelmintic resistance revisited: under-dosing, chemoprophylactic strategies, and mating probabilities. Smith G, et al. **Int J Parasitol** 1999 Jan;29(1):77–91; discussion 93–4 (41 ref.)

TRICHOSTRONGYLOSIS

[Trichostrongyliasis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):472–3 (2 ref.) **(Jpn)**

TRICHOTILLOMANIA

[Trichotillomania] Pacan P, et al. **Psychiatr Pol** 1998 Nov–Dec;32(6):799–805 (15 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Trichotillomania resulting in a trichobezoar: a case report. Stone KD, et al. **J La State Med Soc** 1998 Oct; 150(10):478–81 (14 ref.)

DIAGNOSIS

Trichobezoars in trichotillomania: case report and literature overview. Bouwer C, et al. **Psychosom Med** 1998 Sep–Oct; 60(5):658–60 (36 ref.)

TRICHURIASIS

[Trichuriasis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):469–70 (5 ref.) **(Jpn)**

THERAPY

Diagnosis of Trichuris trichiura (whipworm) by colonoscopic extraction. Chandra B, et al. **J Clin Gastroenterol** 1998 Sep; 27(2):152–3 (6 ref.)

TRICHURIS

Diagnosis of Trichuris trichiura (whipworm) by colonoscopic

TRICHURIS

extraction. Chandra B, et al. **J Clin Gastroenterol** 1998 Sep; 27(2):152–3 (6 ref.)

TRICHURIS TRICHIURA see **TRICHURIS**

TRICUSPID ATRESIA

see related
FONTAN PROCEDURE

TRICUSPID INCOMPETENCE see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID REGURGITATION see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID VALVE

Tricuspid valve disease. Clinical evaluation, physiopathology, and management. Blaustein AS, et al. **Cardiol Clin** 1998 Aug;16(3):551–72, x (168 ref.)

ABNORMALITIES

Cyanotic congenital heart disease with decreased pulmonary blood flow in children. Waldman JD, et al. **Pediatr Clin North Am** 1999 Apr;46(2):385–404 (15 ref.)

SURGERY

[Valve repair in tricuspid endocarditis in the drug addict. Apropos a case] Castedo Mejuto E, et al. **Rev Esp Cardiol** 1999 Jan;52(1):67–70 (6 ref.) (Eng. Abstr.) **(Spa)**

TRICUSPID VALVE INCOMPETENCE see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID VALVE INSUFFICIENCY

SURGERY

[Tricuspid valve insufficiency: what should be done?] von Segesser LK, et al. **Ther Umsch** 1998 Dec;55(12):767–72 (20 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Assessment of valvular regurgitation with Doppler echocardiography. Nagueh SF. **Cardiol Clin** 1998 Aug; 16(3):405–19, vii (42 ref.)

TRICYCLIC ANTIDEPRESSIVE AGENTS see **ANTIDEPRESSIVE AGENTS, TRICYCLIC**

TRIFLUOROETHANOL

CHEMISTRY

Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Buck M. **Q Rev Biophys** 1998 Aug;31(3):297–355 (263 ref.)

TRIFLUOROETHYL ALCOHOL see **TRIFLUOROETHANOL**

TRIGEMINAL GANGLION

PHYSIOLOGY

Trigeminal innervation of the mammalian pineal gland. Reuss S. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):305–9 (43 ref.)

SURGERY

[Evaluation of the Mullan's technique in the treatment of trigeminal neuralgia] Urculo E, et al. **Rev Neurol** 1998 Sep; 27(157):477–84 (50 ref.) (Eng. Abstr.) **(Spa)**

TRIGEMINAL NERVE

see related
TRIGEMINAL NEURALGIA

Trigeminal neurinoma presenting as intratumoral hemorrhage--case report. Lieu AS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Mar; 14(3):181–5 (15 ref.)

[Trigeminal neurinoma] Yoshida K, et al. **No Shinkei Geka** 1999 May;27(5):407–16 (94 ref.) **(Jpn)**

BLOOD SUPPLY

Unilateral trismus in a patient with trigeminal neuralgia due to microvascular compression of the trigeminal motor root. Thompson TP, et al. **J Oral Maxillofac Surg** 1999 Jan; 57(1):90–2 (13 ref.)

PATHOLOGY

Benign triton tumor of the trigeminal nerve. Vajramani G, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):140–4 (8 ref.)

PHYSIOPATHOLOGY

The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. May A, et al. **J Cereb Blood Flow Metab** 1999 Feb;19(2):115–27 (142 ref.)

SURGERY

Trigeminal neurinomas extending into multiple fossae: surgical methods and review of the literature. Yoshida K, et al. **J Neurosurg** 1999 Aug;91(2):202–11 (65 ref.)

TRIGEMINAL NEURALGIA

Medically unexplained chronic orofacial pain. Temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia. Marbach JJ. **Med Clin North Am** 1999 May;83(3):691–710, vi–vii (36 ref.)

[Trigeminal neuralgia] Brito AJ. **Acta Med Port** 1999 Apr–Jun;12(4–6):187–93 (15 ref.) (Eng. Abstr.) **(Por)**

COMPLICATIONS

Unilateral trismus in a patient with trigeminal neuralgia due to microvascular compression of the trigeminal motor root. Thompson TP, et al. **J Oral Maxillofac Surg** 1999 Jan; 57(1):90–2 (13 ref.)

DIAGNOSIS

When is facial pain trigeminal neuralgia? Kumar GK, et al. **Postgrad Med** 1998 Oct;104(4):149–51, 155–6 (19 ref.)

[Trigeminal neuralgia. Diagnosis] Dousset V, et al. **Rev Prat** 1998 Jun 15;48(12):1387–8 (1 ref.) **(Fre)**

EPIDEMIOLOGY

Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review. Kobata H, et al. **Neurosurgery** 1998 Dec; 43(6):1351–61; discussion 1361–2 (109 ref.)

SURGERY

Radiosurgery for trigeminal neuralgia and epilepsy. Régis J, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):359–77 (86 ref.)

[Surgical versus medical treatment of idiopathic trigeminal neuralgia] Mariani L, et al. **Schweiz Med Wochenschr** 1998 Oct 3;128(40):1512–8 (16 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of the Mullan's technique in the treatment of trigeminal neuralgia] Urculo E, et al. **Rev Neurol** 1998 Sep; 27(157):477–84 (50 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

[Surgical versus medical treatment of idiopathic trigeminal neuralgia] Mariani L, et al. **Schweiz Med Wochenschr** 1998 Oct 3;128(40):1512–8 (16 ref.) (Eng. Abstr.) **(Ger)**

TRIGEMINAL NUCLEUS, SPINAL

PHYSIOLOGY

Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system. Yew DT, et al. **Microsc Res Tech** 1999 Jun 15;45(6):389–400 (123 ref.)

TRIGGER POINTS, MYOFASCIAL see **MYOFASCIAL PAIN SYNDROMES**

TRIGLYCERIDE LIPASE see **LIPASE**

TRIGLYCERIDES

BIOSYNTHESIS

[Biosynthesis of triacylglycerol and related intracellular lipid transport in fungi and yeasts] Kamisaka Y. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1207–12 (35 ref.) **(Jpn)**

BLOOD

Triglyceride as a risk factor for coronary artery disease. Gotto AM Jr. **Am J Cardiol** 1998 Nov 5;82(9A):22Q–25Q (26 ref.)

Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis [editorial; comment] Hodis HN. **Circulation** 1999 Jun 8;99(22):2852–4 (20 ref.) Comment on: Circulation 1999 Jun 8;99(22):2858–60.

The epidemiology of triglyceride as a coronary artery disease risk factor. Miller M. **Clin Cardiol** 1999 Jun;22(6 Suppl):II1–6 (22 ref.)

The atherogenic significance of an elevated plasma triglyceride level. Ooi TC, et al. **Crit Rev Clin Lab Sci** 1998 Dec;35(6):489–516 (130 ref.)

Relevance of the reduction of triglycerides in the prevention of coronary heart disease. Kesäniemi YA. **Curr Opin Lipidol** 1998 Dec;9(6):571–4 (19 ref.)

In vivo studies of VLDL metabolism and LDL heterogeneity. Demant T, et al. **Eur Heart J** 1998 Jul;19 Suppl H:H7–10 (13 ref.)

Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Ericsson CG. **Eur Heart J** 1998 Jul;19 Suppl H:H37–41 (20 ref.)

Diabetic dyslipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul; 19 Suppl H:H27–40 (14 ref.)

Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul;19 Suppl H:H23–6 (13 ref.)

Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Patsch J. **Eur Heart J** 1998 Jul;19 Suppl H:H2–6 (15 ref.)

Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Thompson GR. **Eur Heart J** 1998 Jul;19 Suppl H:H31–6 (16 ref.)

Plasma triglyceride-rich lipoprotein and high density lipoproteins disorders associated with atherosclerosis. Genest J Jr, et al. **J Investig Med** 1998 Oct;46(8):351–8 (73 ref.)

Effects of inulin on lipid parameters in humans. Williams CM. **J Nutr** 1999 Jul;129(7 Suppl):1471S–3S (14 ref.)

Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Roche HM, et al. **Lipids** 1999;34 Suppl:S259–65 (68 ref.)

Dietary carbohydrates and triacylglycerol metabolism. Roche HM. **Proc Nutr Soc** 1999 Feb;58(1):201–7 (66 ref.)

[Serum triglycerides as a risk factor for atherosclerosis] Stalenhoef AF. **Ned Tijdschr Geneeskd** 1999 Feb 6; 143(6):284–7 (20 ref.) (Eng. Abstr.) **(Dut)**

[Hypertriglyceridemias] Silva JM, et al. **Rev Port Cardiol** 1999 Apr;18(4):419–29 (107 ref.) (Eng. Abstr.) **(Por)**

CHEMISTRY

Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Ferezou J, et al. **Nutrition** 1999 Jan;15(1):44–50 (46 ref.)

DIAGNOSTIC USE

"Mixed" triglyceride breath test: methodological problems and clinical applications. Perri F, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):99–103 (15 ref.)

METABOLISM

Hormone-sensitive lipase (HSL) expression and regulation in skeletal muscle. Langfort J, et al. **Adv Exp Med Biol** 1998;441:219–28 (23 ref.)

Triglycerides as a risk factor for coronary artery disease. Sprecher DL. **Am J Cardiol** 1998 Dec 17; 82(12A):49U–56U; discussion 85U–86U (20 ref.)

Triglycerides are more important in atherosclerosis than epidemiology has suggested. Durrington PN. **Atherosclerosis** 1998 Dec;141 Suppl 1:S57–62 (36 ref.)

The influence of exercise on postprandial triacylglycerol metabolism. Hardman AE. **Atherosclerosis** 1998 Dec;141 Suppl 1:S93–100 (88 ref.)

Postprandial triglyceride metabolism in diabetes mellitus. Georgopoulos A. **Clin Cardiol** 1999 Jun;22(6 Suppl):II28–33 (14 ref.)

Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Otvos J. **Clin Cardiol** 1999 Jun;22(6 Suppl):II21–7 (8 ref.)

Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Ferezou J, et al. **Nutrition** 1999 Jan;15(1):44–50 (46 ref.)

PHYSIOLOGY

Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Byrne CD. **Atherosclerosis** 1999 Jul;145(1):1–15 (115 ref.)

TRIIODOBENZOIC ACIDS

DIAGNOSTIC USE

[New non-ionic monomeric and dimeric contrasting agents in radiology] Sviridov NK. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):56–7 (25 ref.) **(Rus)**

TRIIODOTHYRONINE

see related
RECEPTORS, THYROID HORMONE

ANTAGONISTS & INHIBITORS

Screening methods for thyroid hormone disruptors. DeVito M, et al. **Environ Health Perspect** 1999 May;107(5):407–15 (108 ref.)

METABOLISM

Thyroid hormone receptor coactivators and corepressors. Koenig RJ. **Thyroid** 1998 Aug;8(8):703–13 (105 ref.)

[Changes in thyroxine-binding globulin: pitfalls in thyroid function diagnosis] John MR, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1219–25 (50 ref.) **(Ger)**

PHYSIOLOGY

Thyroid hormone regulates protein expression in C6 glioma

cells. Trentin AG, et al. **Braz J Med Biol Res** 1998 Oct; 31(10):1281–4 (20 ref.)

TRIIODOTHYRONINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

TRIMEBUTINE

ADMINISTRATION & DOSAGE

Gastric ulcer, motility, and trimebutine [editorial; comment] Tanaka M. **J Gastroenterol** 1998 Dec;33(6):916–7 (14 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):823–7.

TRIMESTER, FIRST see **PREGNANCY TRIMESTER, FIRST**

TRIMESTER, THIRD see **PREGNANCY TRIMESTER, THIRD**

TRIMETAZIDINE

THERAPEUTIC USE

Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. McClellan KJ, et al. **Drugs** 1999 Jul;58(1):143–57 (64 ref.)

Trimetazidine: potential mechanisms of action in hypertrophic cardiomyopathy. D'hahan N. **J Cardiovasc Pharmacol** 1999 Mar;33(3):500–6 (89 ref.)

[Contribution of vastarel 20 mg (trimetazidine) in the treatment of vertigo: synopsis of clinical trials] Bouccara D. **Ann Otolaryngol Chir Cervicofac** 1999 Apr;116(1):43–6 (6 ref.) **(Fre)**

TRIMETHOPRIM

ADVERSE EFFECTS

[Hyperkalemia after trimethoprim or pentamidine. Until now, a little noticed side effect of antimicrobial therapeutic measures in AIDS patients] Gabriëls G, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1351–5 (25 ref.) **(Ger)**

THERAPEUTIC USE

Sulfonamides and trimethoprim. Kalkut G. **Cancer Invest** 1998;16(8):612–5 (24 ref.)

Cystitis: treat quickly, and suggest hygiene precautions. Shah J. **Practitioner** 1998 Oct;242(1591):698–702 (2 ref.)

TRIMETHOPRIM RESISTANCE

GENETICS

Genes and spectrum: the theoretical limits. Amyes SG. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S21–8 (63 ref.)

TRIMETHOPRIM–SULFAMETHOXAZOLE COMBINATION

Trimethoprim–sulfamethoxazole. Smilack JD. **Mayo Clin Proc** 1999 Jul;74(7):730–4 (45 ref.)

ADVERSE EFFECTS

Hyperkalemic renal tubular acidosis induced by trimethoprim/sulfamethoxazole in an AIDS patient. Sheehan MT, et al. **Clin Nephrol** 1998 Sep;50(3):188–93 (39 ref.)

Trimethoprim–induced hyperkalemia: An analysis of reported cases. Marinella MA. **Gerontology** 1999 Jul–Aug; 45(4):209–12 (21 ref.)

Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Koopmans PP, et al. **Pharm World Sci** 1998 Dec; 20(6):253–7 (43 ref.)

[Co-trimoxazole administration: a rare cause of hypoglycemia in elderly persons] Rutschmann OT, et al. **Schweiz Med Wochenschr** 1998 Aug 4;128(31–32):1171–4 (23 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Cyclospora: review of an emerging parasite. Brown GH, et al. **Pharmacotherapy** 1999 Jan;19(1):70–5 (39 ref.)

TRINUCLEOTIDE REPEAT EXPANSION

see related
ANTICIPATION, GENETIC
CHROMOSOME FRAGILITY
FRAGILE X SYNDROME
MYOTONIA ATROPHICA

Unstable mutations and neurodegenerative disorders. Brice A. **J Neurol** 1998 Aug;245(8):505–10 (58 ref.)

Schizophrenia genetics: expansion of knowledge? [editorial; comment] Ross CA. **Mol Psychiatry** 1999 Jan;4(1):4–5 (14 ref.) Comment on: Mol Psychiatry 1999 Jan;4(1):53–7. Comment on: Mol Psychiatry 1999 Jan;4(1):58–63.

Polyglutamine pathogenesis. Ross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1005–11 (82 ref.)

[Dynamic mutations in hereditary neurodegenerative disorders] Nilssen O. **Tidsskr Nor Laegeforen** 1999 Aug 30;119(20):3021–7 (61 ref.) (Eng. Abstr.) **(Nor)**

[Growing genes cause neurological diseases] Johansson J, et al. **Lakartidningen** 1999 Feb 24;96(8):897–900 (25 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

To be or not to be an aggregate. Nasir J. **Clin Genet** 1999 Jan;55(1):9–10 (2 ref.)

Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Claij N, et al. **Exp Cell Res** 1999 Jan 10;246(1):1–10 (137 ref.)

Pathogenesis of inclusion bodies in (CAG)n/Qn–expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. Cooper AJ, et al. **J Neurochem** 1999 Mar;72(3):889–99 (98 ref.)

Expanded (CAG)n, (CGG)n and (GAA)n trinucleotide repeat microsatellites, and mutant purine synthesis and pigmentation genes cause schizophrenia and autism. Fischer KM. **Med Hypotheses** 1998 Sep;51(3):223–33 (89 ref.)

Nuclear inclusions in CAG repeat diseases: toxic or protective? Hernandez D. **Mol Med Today** 1999 Jan;5(1):7 (2 ref.)

Androgen receptor mutation in Kennedy's disease. Fischbeck KH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29;354(1386):1075–8 (26 ref.)

CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci. Frontali M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1089–94 (38 ref.)

Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Lunkes A, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1013–9 (38 ref.)

CAG–polyglutamine–repeat mutations: independence from gene context. Ordway JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1083–8 (34 ref.)

Microsatellite and trinucleotide–repeat evolution: evidence for mutational bias and different rates of evolution in different lineages. Rubinsztein DC, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1095–9 (31 ref.)

[Triple expansion diseases: a new mutational concept] Schorderet DF. **Rev Med Suisse Romande** 1999 Feb; 119(2):103–6 (6 ref.) (Eng. Abstr.) **(Fre)**

TRINUCLEOTIDE REPEATS

Biological implications of the DNA structures associated with disease–causing triplet repeats. Sinden RR. **Am J Hum Genet** 1999 Feb;64(2):346–53 (32 ref.)

The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Kantoff P, et al. **Biochim Biophys Acta** 1998 Nov 26;1378(3):C1–5 (25 ref.)

Expanding complexity in myotonic dystrophy. Groenen P, et al. **Bioessays** 1998 Nov;20(11):901–12 (75 ref.)

Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. Choong CS, et al. **J Mol Endocrinol** 1998 Dec;21(3):235–57 (211 ref.)

[Triplet repeat] Abe K. **Nippon Rinsho** 1999 Apr;57(4):768–70 (5 ref.) **(Jpn)**

[Recent progress in the research field on triplet repeat diseases] Kakizuka A. **Rinsho Shinkeigaku** 1998 Dec; 38(12):988–92 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Medical pathology due to trinucleotide repeats] Arenas–Aranda D, et al. **Gac Med Mex** 1999 Jan–Feb; 135(1):53–65 (132 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Brain glyceraldehyde–3–phosphate dehydrogenase activity in human trinucleotide repeat disorders. Kish SJ, et al. **Arch Neurol** 1998 Oct;55(10):1299–304 (29 ref.)

Microsatellite and trinucleotide–repeat evolution: evidence for mutational bias and different rates of evolution in different lineages. Rubinsztein DC, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1095–9 (31 ref.)

Recent advances in understanding the pathogenesis of Huntington's disease. Reddy PH, et al. **Trends Neurosci** 1999 Jun;22(6):248–55 (70 ref.)

[Hereditary neurological diseases caused by amplification of triplet repetitions] Warter JM, et al. **Presse Med** 1998 Feb 28;27(8):376–81 (70 ref.) (Eng. Abstr.) **(Fre)**

[Effect on gene expression of the expanded CTG repeat on 3'–untranslated region of myotonic dystrophy (DM) protein kinase] Furuya H, et al. **Nippon Rinsho** 1999 Apr; 57(4):932–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Dynamic mutation and its molecular cytogenetics] Hori T, et al. **Nippon Rinsho** 1999 Apr;57(4):771–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Linkage disequilibrium between the Machado–Joseph disease and intragenic polymorphisms] Ichikawa Y. **Nippon Rinsho** 1999 Apr;57(4):832–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular analyses of intergenerational instability of CAG repeat in SCA2 gene] Igarashi S, et al. **Nippon Rinsho** 1999 Apr;57(4):811–7 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular and clinical features in spinocerebellar ataxia type 6 (SCA6) in Japanese] Ikeuchi T. **Nippon Rinsho** 1999 Apr; 57(4):891–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical, neuropathological and genetic characteristics of spinocerebellar ataxia type 6 (SCA6)] Ishikawa K, et al. **Nippon Rinsho** 1999 Apr;57(4):880–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of CAG repeats size in the nervous system of dentatorubral–pallidoluysian atrophy (DRPLA)] Ito Y, et al. **Nippon Rinsho** 1999 Apr;57(4):850–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Correlation between CTG triplet repeat length and the extent of multisystesmic disorders in myotonic dystrophy] Kinoshita M, et al. **Nippon Rinsho** 1999 Apr;57(4):917–26 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Premutation in myotonic dystrophy] Komai K, et al. **Nippon Rinsho** 1999 Apr;57(4):927–31 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Correlation of clinichopathological features and CAG repeats in SCA2] Koyano S, et al. **Nippon Rinsho** 1999 Apr;57(4):805–10 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Transcriptional regulation and subcellular localization of mutant androgen receptor in spinal and bulbar muscular atrophy] Miwa S, et al. **Nippon Rinsho** 1999 Apr; 57(4):869–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical and molecular genetic studies of Machado–Joseph disease] Nishizawa M. **Nippon Rinsho** 1999 Apr; 57(4):826–31 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Problem of molecular psychiatry in view of the trinucleotide repeat expansion disease] Ohara K. **Nippon Rinsho** 1999 Apr;57(4):792–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Cloning and characterization of cDNA for DRPLA interacting protein] Okamumoho Y, et al. **Nippon Rinsho** 1999 Apr;57(4):856–61 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Frequencies of triplet repeat disorders in dominantly inherited spinocerebellar ataxia (SCA) in the Japanese] Sasaki H, et al. **Nippon Rinsho** 1999 Apr;57(4):787–91 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Unstable expansion of CAG repeat and molecular mechanism of neurodegeneration in SCA1] Sasaki H. **Nippon Rinsho** 1999 Apr;57(4):801–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The phenotype variation correlates with the size of CAG repeat in SCA2] Sasaki H, et al. **Nippon Rinsho** 1999 Apr; 57(4):818–21 (10 ref.) (Eng. Abstr.) **(Jpn)**

[DM pathogenesis and expansion of CTG trinucleotide repeat within 3' untranslated region of DMPK gene] Takahashi N, et al. **Nippon Rinsho** 1999 Apr;57(4):937–42 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of expanded CAG trinucleotide repeat in spinal and bulbar muscular atrophy (SBMA)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr;57(4):862–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Somatic mosaicism of expanded CAG trinucleotide repeat in the neural and nonneural tissues of Machado–Joseph disease (MJD)] Tanaka F, et al. **Nippon Rinsho** 1999 Apr; 57(4):838–42 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Friedreich ataxia with GAA repeat expansion: molecular mechanism and clinical feature] Tanaka H. **Nippon Rinsho** 1999 Apr;57(4):960–6 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Future prospect of molecular genetics studies on DRPLA] Tsuji S. **Nippon Rinsho** 1999 Apr;57(4):843–9 (33 ref.) **(Jpn)**

[Advances in understanding of clinical presentations and molecular mechanisms of triplet repeat diseases] Tsuji S. **Nippon Rinsho** 1999 Apr;57(4):778–86 (55 ref.) (Eng. Abstr.) **(Jpn)**

[Huntington's disease: clinical and molecular genetics] Warita H, et al. **Nippon Rinsho** 1999 Apr;57(4):896–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular cytogenetics of fragile X syndrome] Yamauchi M, et al. **Nippon Rinsho** 1999 Apr;57(4):943–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Myotonic dystrophy: the role of RNA CUG triplet repeats. Timchenko LT. **Am J Hum Genet** 1999 Feb;64(2):360–4 (34 ref.)

TRIOSE–PHOSPHATE ISOMERASE

see related
ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC

DEFICIENCY

The feasibility of replacement therapy for inherited disorder of glycolysis: triosephosphate isomerase deficiency (review). Ationu A, et al. **Int J Mol Med** 1998 Dec; 2(6):701–4 (25 ref.)

TRIOSEPHOSPHATE DEHYDROGENASE see **GLYCERALDEHYDE–3–PHOSPHATE DEHYDROGENASES**

TRIOSEPHOSPHATE ISOMERASE see **TRIOSE–PHOSPHATE ISOMERASE**

TRIOSEPHOSPHATE MUTASE

TRIOSEPHOSPHATE MUTASE see **TRIOSE-PHOSPHATE ISOMERASE**

TRIOSES

PHARMACOLOGY

Trioses and related substances: tools for the study of pancreatic beta-cell function. Best L, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):583-8 (53 ref.)

TRIPHOSPHOPYRIDINE NUCLEOTIDE see **NADP**

TRIPLE-SYMPTOM COMPLEX see **BEHCET'S SYNDROME**

TRIPLET REPEATS see **TRINUCLEOTIDE REPEATS**

TRIPLETS

The retained twin/triplet following a preterm delivery--an analysis of the literature. Trivedi AN, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):461-5 (26 ref.)

Should multifetal pregnancy reduction be used for prevention of preterm deliveries in triplet or higher order multiple pregnancies? Papiernik E, et al. **J Perinat Med** 1998; 26(5):365-70 (22 ref.)

Early prenatal diagnosis of cord entanglement in monoamniotic multiple pregnancies [see comments] Arabin B, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):181-6 (24 ref.) Comment in: Ultrasound Obstet Gynecol 1999 Mar;13(3):157-60.

GENETICS

Triplets with schizophrenia [letter; comment] Torrey EF, et al. **Biol Psychiatry** 1999 Mar 1;45(5):655 (4 ref.) Comment on: Biol Psychiatry 1997 Dec 15;42(12):1186-7.

TRIPTORELIN

ADVERSE EFFECTS

Triptorelin acetate administration in early pregnancy: case reports and review of the literature. Chardonnens D, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):143-9 (71 ref.)

TRIS BUFFER see **TROMETHAMINE**

TRISACCHARIDES

[Downregulation of alpha-galactosyl epitope in xenograft] Miyagawa S, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2618-24 (29 ref.) **(Jpn)**

ADVERSE EFFECTS

Acarbose-associated hepatotoxicity [letter] Andrade RJ, et al. **Diabetes Care** 1998 Nov;21(11):2029-30 (11 ref.)

ANALYSIS

The Griffonia simplicifolia I-B4 isolectin. A probe for alpha-D-galactosyl end groups. Goldstein IJ, et al. **Subcell Biochem** 1999;32:127-41 (67 ref.)

alpha-Gal epitopes on viral glycoproteins. Rother RP, et al. **Subcell Biochem** 1999;32:143-72 (116 ref.)

CHEMISTRY

alpha-Gal epitopes in animal tissue glycoproteins and glycolipids. Rydberg L, et al. **Subcell Biochem** 1999; 32:107-25 (88 ref.)

GENETICS

Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope. Galili U. **Subcell Biochem** 1999;32:1-23 (90 ref.)

IMMUNOLOGY

alpha-Galactosyl-bearing epitopes as potent immunogens in Chagas' disease and leishmaniasis. Avila JL. **Subcell Biochem** 1999;32:173-213 (100 ref.)

Graves' disease as a model for anti-Gal involvement in autoimmune diseases. Galili U. **Subcell Biochem** 1999; 32:339-60 (53 ref.)

The natural anti-Gal antibody. Galili U, et al. **Subcell Biochem** 1999;32:79-106 (75 ref.)

Anti-Gal, alpha-Gal epitopes, and xenotransplantation. Kobayashi T, et al. **Subcell Biochem** 1999;32:229-57 (220 ref.)

Enhancement of autologous tumor vaccine immunogenicity by anti-Gal. LaTemple DC, et al. **Subcell Biochem** 1999; 32:361-79 (80 ref.)

Enterotoxin A of Clostridium difficile and alpha-Gal epitopes. Pothoulakis C. **Subcell Biochem** 1999;32:215-27 (221 ref.)

Significance of anti-Gal IgG in chronic xenograft rejection. Galili U. **Transplant Proc** 1999 Feb-Mar;31(1-2):940-1 (14 ref.)

THERAPEUTIC USE

Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Trachtman H, et al. **Curr Opin Pediatr** 1999 Apr;11(2):162-8 (51 ref.)

Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Scheen AJ. **Diabetes Metab** 1998 Sep;24(4):311-20 (79 ref.)

Effects of the alpha-glucosidase inhibitor acarbose on the development of long-term complications in diabetic animals: pathophysiological and therapeutic implications. Creutzfeldt W. **Diabetes Metab Res Rev** 1999 Jul-Aug; 15(4):289-96 (30 ref.)

The evolving role of alpha-glucosidase inhibitors. Göke B, et al. **Diabetes Metab Rev** 1998 Sep;14 Suppl 1:S31-8 (60 ref.)

[Role of acarbose in the treatment of diabetes mellitus] Scheen AJ. **Diabetes Metab** 1998 Sep;24(4):385-90 (36 ref.) **(Fre)**

TRISAMINE see **TROMETHAMINE**

TRISMUS

ETIOLOGY

Unilateral trismus in a patient with trigeminal neuralgia due to microvascular compression of the trigeminal motor root. Thompson TP, et al. **J Oral Maxillofac Surg** 1999 Jan; 57(1):90-2 (13 ref.)

TRISOMY

De novo complete trisomy 5p: clinical report and FISH studies. Reichenbach H, et al. **Am J Med Genet** 1999 Aug 27;85(5):447-51 (12 ref.)

Case of partial trisomy 2q3 with clinical manifestations of Marshall-Smith syndrome. Seidahmed MZ, et al. **Am J Med Genet** 1999 Jul 16;85(2):185-8 (11 ref.)

Are cells with trisomy 10 always malignant in hematopoietic disorders? Berger R, et al. **Ann Genet** 1999;42(1):5-10 (20 ref.)

A case of de novo translocation 16;21: trisomy 16q phenotype and origin of the aberration. Eggermann T, et al. **Ann Genet** 1998;41(4):205-8 (14 ref.)

Characterization of a partial trisomy 16q with FISH. Report of a patient and review of the literature. Engelen JJ, et al. **Ann Genet** 1999;42(2):101-4 (17 ref.)

Zygodactyly as the most striking physical anomaly in an adult male patient with pure partial trisomy 1q. Lukusa T, et al. **Ann Genet** 1998;41(4):199-204 (29 ref.)

Ophthalmic findings with partial trisomy (duplication) of the long arm of chromosome 7. Coats DK, et al. **Can J Ophthalmol** 1998 Oct;33(6):337-41 (30 ref.)

Trisomy 6 as a primary karyotypic aberration in hematologic disorders. Mohamed AN, et al. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):152-5 (27 ref.)

Trisomy 14 and leukemia. Reddy KS. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):144-51 (30 ref.)

The mouse with trisomy 16 as a model of human hearts with common atrioventricular junction. Anderson RH, et al. **Cardiovasc Res** 1998 Jul;39(1):155-64 (29 ref.)

The common features of patients with partial trisomy of the long arm of chromosome 1 [letter] Gfatter R, et al. **Clin Genet** 1998 Aug;54(2):161-3 (7 ref.)

Genetics of oocyte ageing. Eichenlaub-Ritter U. **Maturitas** 1998 Oct 12;30(2):143-69 (222 ref.)

Case report of a 22-week fetus with 47,XXX karyotype and multiple lower mesodermal defects. Hoang MP, et al. **Pediatr Dev Pathol** 1999 Jan-Feb;2(1):58-61 (17 ref.)

Sonographically detected fetal and placental abnormalities associated with trisomy 16 confined to the placenta. A case report and review of the literature. Astner A, et al. **Prenat Diagn** 1998 Dec;18(12):1308-15 (31 ref.)

Prenatal findings in trisomy 16q of paternal origin. Paladini D, et al. **Prenat Diagn** 1999 May;19(5):472-5 (28 ref.)

Mouse autosomal trisomy: two's company, three's a crowd. Hernandez D, et al. **Trends Genet** 1999 Jun;15(6):241-7 (60 ref.)

DIAGNOSIS

Trisomy 16 and trisomy 16 Mosaicism: a review. Benn P. **Am J Med Genet** 1998 Sep 1;79(2):121-33 (72 ref.)

[Trisomy 4p as result of a maternal translocation t(4;8)(q11;p23)] Stumm M, et al. **Klin Padiatr** 1999 Jan-Feb; 211(1):35-9 (5 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Trisomy 16 and trisomy 16 Mosaicism: a review. Benn P. **Am J Med Genet** 1998 Sep 1;79(2):121-33 (72 ref.)

De novo inverted duplication 9p21pter involving telomeric repeated sequences. Sanlaville D, et al. **Am J Med Genet** 1999 Mar 12;83(2):125-31 (11 ref.)

Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Oliver JW, et al. **Cancer Genet Cytogenet** 1998 Dec;107(2):111-7 (49 ref.)

Genetic risk in natural and medically assisted procreation. Koulischer L, et al. **Early Pregnancy** 1997 Sep;3(3):164-71 (41 ref.)

[Trisomy 4p as result of a maternal translocation t(4;8)(q11;p23)] Stumm M, et al. **Klin Padiatr** 1999 Jan-Feb; 211(1):35-9 (5 ref.) (Eng. Abstr.) **(Ger)**

TRISOMY 21 see **DOWN SYNDROME**

TRITERPENES

CHEMISTRY

Relationship between chemical structures and biological activities of triterpenoid saponins from soybean. Yoshiki Y, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2291-9 (60 ref.)

TRITICALE see **CEREALS**

TRITICUM see **WHEAT**

TRITONS see **POLYETHYLENE GLYCOLS**

TRITRICHOMONAS FOETUS

DRUG EFFECTS

Trichomonads, hydrogenosomes and drug resistance. Kulda J. **Int J Parasitol** 1999 Feb;29(2):199-212 (73 ref.)

TRNA see **RNA, TRANSFER**

TRNA-AMINO ACID see **RNA, TRANSFER, AMINO ACID-SPECIFIC**

TRNA-AMINO ACYL see **RNA, TRANSFER, AMINO ACYL**

TRNALEU see **RNA, TRANSFER, LEU**

TROCAR see **SURGICAL INSTRUMENTS**

TROCHANTER see **FEMUR**

TROCHANTERIC FRACTURES see **HIP FRACTURES**

TROMETAMOL see **TROMETHAMINE**

TROMETHAMINE

ANALOGS & DERIVATIVES

Fosfomycin tromethamine: single-dose treatment of acute cystitis. Stein GE. **Int J Fertil Womens Med** 1999 Mar-Apr; 44(2):104-9 (41 ref.)

THERAPEUTIC USE

Tribonat--a comprehensive summary of its properties [see comments] Bjerneroth G. **Crit Care Med** 1999 May; 27(5):1009-13 (76 ref.) Comment in: Crit Care Med 1999 May;27(5):875-6.

Buffer treatment for cardiac resuscitation: putting the cart before the horse? [editorial; comment] Gazmuri RJ. **Crit Care Med** 1999 May;27(5):875-6 (17 ref.) Comment on: Crit Care Med 1999 May;27(5):1009-13.

Alkaline buffers for correction of metabolic acidosis during cardiopulmonary resuscitation with focus on Tribonat--a review. Bjerneroth G. **Resuscitation** 1998 Jun;37(3):161-71 (170 ref.)

TROPHIC FACTOR RECEPTORS see **RECEPTORS, GROWTH FACTOR**

TROPHOBLAST

Trophoblast interferons. Roberts RM, et al. **Placenta** 1999 May;20(4):259-64 (60 ref.)

IMMUNOLOGY

The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1999 Jul; 42(1):44-8 (47 ref.)

From the decidual cell internet: trophoblast-recognizing T cells. Arck P, et al. **Biol Reprod** 1999 Feb;60(2):227-33 (98 ref.)

Immunotolerant functions of HLA-G. Carosella ED, et al. **Cell Mol Life Sci** 1999 Mar;55(3):327-33 (42 ref.)

HLA expression at the maternal-fetal interface. Hutter H, et al. **Dev Immunol** 1998;6(3-4):197-204 (57 ref.)

Natural killer cell-mediated recognition of human trophoblast. Biassoni R, et al. **Semin Cancer Biol** 1999 Feb; 9(1):13-8 (38 ref.)

[Immunologic and tumor biology aspects of placentation in humans] Marzusch K, et al. **Zentralbl Gynakol** 1999; 121(4):206-13 (99 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Physiological role of human placental growth hormone. Alsat E, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):121-7 (36 ref.)

PHYSIOLOGY

Placenta growth factor: potential role in pregnancy. Torry DS, et al. **Am J Reprod Immunol** 1999 Jan;41(1):79-85 (64 ref.)

Trophoblast pseudo-vasculogenesis: faking it with

endothelial adhesion receptors. Damsky CH, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):660–6 (73 ref.)

Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. Giudice LC, et al. **J Reprod Immunol** 1998 Aug;39(1–2):133–48 (66 ref.)

Functional regulation of human trophoblast differentiation. Morrish DW, et al. **J Reprod Immunol** 1998 Aug; 39(1–2):179–95 (83 ref.)

Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. Zhou Y, et al. **J Reprod Immunol** 1998 Aug;39(1–2):197–213 (16 ref.)

Expression of 11 beta-hydroxysteroid dehydrogenase in early pregnancy: implications in human trophoblast-endometrial interactions. Arcuri F, et al. **Semin Reprod Endocrinol** 1999; 17(1):53–61 (63 ref.)

Roles of the insulinlike growth factor family in nonpregnant human endometrium and at the decidual: trophoblast interface. Giudice LC, et al. **Semin Reprod Endocrinol** 1999; 17(1):13–21 (92 ref.)

VIROLOGY

Vertical transmission of HIV: parameters which might affect infection of placental trophoblasts by HIV-1: a review. Biomed Group on the Study of in Utero Transmission of HIV 1. Moussa M, et al. **Am J Reprod Immunol** 1999 May; 41(5):312–9 (82 ref.)

TROPHOBLASTIC NEOPLASMS

Recent advances in gestational trophoblastic disease. Newlands ES, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):225–44, x (77 ref.)

CLASSIFICATION

The classification of gestational trophoblastic disease: a critical review. Tham KF, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S39–49 (31 ref.)

PATHOLOGY

[Trophoblast lesions and trophoblast tumors] Herbst H, et al. **Pathologe** 1999 Jan;20(1):72–81 (19 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Hershman JM. **Thyroid** 1999 Jul;9(7):653–7 (42 ref.)

SECONDARY

Metastatic trophoblastic disease following partial hydatidiform mole: case report and literature review. Menczer J, et al. **Gynecol Oncol** 1999 Aug;74(2):304–7 (17 ref.)

THERAPY

Optimal treatment in gestational trophoblastic disease. Ilancheran A. **Ann Acad Med Singapore** 1998 Sep; 27(5):698–704 (24 ref.)

TROPHOBLASTIC TUMOR see **TROPHOBLASTIC NEOPLASMS**

TROPHOBLASTIC TUMOR, PLACENTAL SITE

SECONDARY

Metastatic placental site trophoblastic tumor. Twiggs LB, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S51–5 (13 ref.)

SURGERY

Pregnancy with primary tubal placental site trophoblastic tumor—A case report and literature review. Su YN, et al. **Gynecol Oncol** 1999 May;73(2):322–5 (11 ref.)

THERAPY

Prognostic factors and treatment for placental site trophoblastic tumor-report of 3 cases and analysis of 88 cases. Chang YL, et al. **Gynecol Oncol** 1999 May; 73(2):216–22 (57 ref.)

TROPICAL CLIMATE

Impacts of global environmental change on future health and health care in tropical countries. McMichael AJ, et al. **Br Med Bull** 1998;54(2):475–88 (51 ref.)

Diarrhoeal diseases. Mathan VI. **Br Med Bull** 1998; 54(2):407–19 (38 ref.)

Treatment issues in interstitial lung disease in tropical countries. Jindal SK, et al. **Curr Opin Pulm Med** 1999 Sep; 5(5):287–92 (44 ref.)

[Kidney transplantation and travel in the tropics] Receveur MC, et al. **Nephrologie** 1999;20(3):145–51 (32 ref.) (Eng. Abstr.) **(Fre)**

[Fever after returning from travel to a tropical zone: what infectious diseases should be considered?] Reinhardt MC, et al. **Rev Med Suisse Romande** 1999 Feb;119(2):99–102 (6 ref.) **(Fre)**

[Malaria, a worldwide scourge] Danis M, et al. **Rev Prat** 1998 Feb 1;48(3):254–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Human transmission and plasmodium resistance] Le Bras J, et al. **Rev Prat** 1998 Feb 1;48(3):258–63 (15 ref.) (Eng. Abstr.) **(Fre)**

TROPICAL MEDICINE

Tropical infectious diseases in human immunodeficiency virus-infected patients. Karp CL, et al. **Clin Infect Dis** 1999 May;28(5):947–63; quiz 964–5 (120 ref.)

Tropical myeloneuropathies revisited. Román G. **Curr Opin Neurol** 1998 Oct;11(5):539–44 (92 ref.)

Management of open tibial fractures. De Wind CM. **Trop Doct** 1999 Jan;29(1):46–9 (12 ref.)

The differential diagnosis and management of breast lumps in the tropics. Holcombe C, et al. **Trop Doct** 1999 Jan; 29(1):42–6 (17 ref.)

Fluid and electrolyte balance for adults (without a biochemical laboratory). Tovey F. **Trop Doct** 1999 Jan; 29(1):49–53 (0 ref.)

Incorporating gender in the anthropology of infectious diseases [see comments] Vlassoff C, et al. **Trop Med Int Health** 1998 Dec;3(12):1011–9 (45 ref.) Comment in: Trop Med Int Health 1998 Dec;3(12):993–5.

[Tropical myositis] Saissy JM, et al. **Med Trop (Mars)** 1998; 58(3):297–306 (68 ref.) (Eng. Abstr.) **(Fre)**

[Tropical viral diseases] Meyer CG, et al. **Dtsch Med Wochenschr** 1999 Sep 10;124(36):1043–51 (49 ref.) **(Ger)**

[Tropical medicine and the pathology of poverty. New paradigms in international health policy] Stefanini A. **Ann Ig** 1998 Sep-Dec;10(5–6):387–93 (28 ref.) (Eng. Abstr.) **(Ita)**

[Travels, risks and advice. Certain health recommendations to travellers abroad are not necessary; the non-medical risks are often underestimated] Rombo L. **Lakartidningen** 1999 Apr 28;96(17):2088–91 (15 ref.) **(Swe)**

[Increased travelling—increased risk of imported viruses. A review of the diagnostic capacity of the Swedish Institute for Infectious Disease Control] Vene S, et al. **Lakartidningen** 1999 Jun 9;96(23):2838–41 (20 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

National Institutes of Health (USA): role in tropical medicine research. Western KA. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):316–8 (0 ref.)

EDUCATION

Tropical paediatrics and international child health in Liverpool, 1968–1998. Hendrickse RG. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S5–8 (5 ref.)

Australia's role in training and research in tropical medicine. Leggat PA. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):311–5 (22 ref.)

METHODS

Health policy reforms and their impact on the practice of tropical medicine. Mills A. **Br Med Bull** 1998;54(2):503–13 (32 ref.)

ORGANIZATION & ADMINISTRATION

Australia's role in training and research in tropical medicine. Leggat PA. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):311–5 (22 ref.)

National Institutes of Health (USA): role in tropical medicine research. Western KA. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):316–8 (0 ref.)

TRENDS

The future role of molecular and cell biology in medical practice in the tropical countries. Weatherall D. **Br Med Bull** 1998;54(2):489–501 (33 ref.)

TROPICAL SPASTIC PARAPARESIS see **PARAPARESIS, TROPICAL SPASTIC**

TROPISM

Molecular and structural basis of the evolution of parvovirus tropism. Tijssen P. **Acta Vet Hung** 1999;47(3):379–94 (59 ref.)

HIV-1 envelope determinants for cell tropism and chemokine receptor use. Hoffman TL, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):57–65 (106 ref.)

[Cell tropism of HIV] Koyanagi Y. **Uirusu** 1998 Dec; 48(2):153–61 (56 ref.) **(Jpn)**

GENETICS

Determinants of organ tropism of sendai virus. Tashiro M, et al. **Front Biosci** 1999 Oct 1;4:D642–5 (26 ref.)

PHYSIOLOGY

HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Clapham PR, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):49–55 (58 ref.)

TROPOELASTIN

METABOLISM

Biochemistry of tropoelastin. Vrhovski B, et al. **Eur J Biochem** 1998 Nov 15;258(1):1–18 (233 ref.)

TROPOMYOSIN

CHEMISTRY

Structural interactions between actin, tropomyosin, caldesmon and calcium binding protein and the regulation of smooth muscle thin filaments. Marston S, et al. **Acta Physiol Scand** 1998 Dec;164(4):401–14 (64 ref.)

IMMUNOLOGY

B- and T-cell epitopes of tropomyosin, the major shrimp allergen. Subba Rao PV, et al. **Allergy** 1998;53(46 Suppl):44–7 (20 ref.)

Tropomyosin: an invertebrate pan-allergen. Reese G, et al. **Int Arch Allergy Immunol** 1999 Aug;119(4):247–58 (57 ref.)

PHYSIOLOGY

Structural interactions between actin, tropomyosin, caldesmon and calcium binding protein and the regulation of smooth muscle thin filaments. Marston S, et al. **Acta Physiol Scand** 1998 Dec;164(4):401–14 (64 ref.)

Creating intracellular structural domains: spatial segregation of actin and tropomyosin isoforms in neurons. Gunning P, et al. **Bioessays** 1998 Nov;20(11):892–900 (75 ref.)

TROPONIN

BLOOD

Understanding true risk: evaluating troponins in the emergency setting [editorial; comment] Gibler WB. **Am Heart J** 1999 Jun;137(6):985–6 (11 ref.) Comment on: Am Heart J 1999 Jun;137(6):1137–44.

Cardiac biomarkers: past, present, and future [see comments] Adams JE 3rd, et al. **Am J Crit Care** 1998 Nov;7(6):418–23; quiz 424–5 (11 ref.) Comment in: Am J Crit Care 1999 May;8(3):204.

Impact of troponins on the evaluation and treatment of patients with acute coronary syndromes. Adams J 3rd. **Curr Opin Cardiol** 1999 Jul;14(4):310–3 (18 ref.)

The cardiac troponins: uses in routine clinical practice. Experiences from GUSTO and other clinical trials. Stubbs P. **Eur Heart J** 1998 Nov;19 Suppl N:N59–63 (28 ref.)

The use of troponin measurements in patients with unstable angina. Jaffe AS. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S49–53 (42 ref.)

Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM). Wu AH. **Scand J Clin Lab Invest Suppl** 1999;230:74–82 (44 ref.)

[Troponin, a new myocardial infarction marker] Chapelle JP. **Rev Med Liege** 1998 Oct;53(10):619–24 (26 ref.) (Eng. Abstr.) **(Fre)**

[Use of serum troponin level measurement in clinical practice] Szyguła J, et al. **Pol Arch Med Wewn** 1998 Dec; 100(6):586–9 (11 ref.) **(Pol)**

[Troponin as myocardial cell injury marker] de Godoy MF, et al. **Arq Bras Cardiol** 1998 Oct;71(4):629–33 (30 ref.) **(Por)**

CHEMISTRY

Molecular switches in troponin. Gergely J. **Adv Exp Med Biol** 1998;453:169–76 (61 ref.)

PHYSIOLOGY

Role of cardiac troponins for risk stratification in unstable coronary artery disease. Gambhir DS, et al. **Indian Heart J** 1999 Jan-Feb;51(1):35–6 (15 ref.)

TROPONIN C

CHEMISTRY

The NMR angle on troponin C. Gagné SM, et al. **Biochem Cell Biol** 1998;76(2–3):302–12 (45 ref.)

METABOLISM

Thermodynamic analyses of calcium binding to troponin C, calmodulin and parvalbumins by using microcalorimetry. Yamada K. **Mol Cell Biochem** 1999 Jan;190(1–2):39–45 (53 ref.)

PHYSIOLOGY

[Calcium regulation of contraction and relaxation in skeletal muscle] Morimoto S, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1744–52 (42 ref.) **(Jpn)**

TROPONIN I

TROPONIN I

ANALYSIS

Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. Wu AH, et al. **Eur Heart J** 1998 Nov;19 Suppl N:N25–9 (15 ref.)

BLOOD

The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. Tanasijevic MJ, et al. **Clin Cardiol** 1999 Jan;22(1):13–6 (13 ref.)

Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Chapelle JP. **Clin Chem Lab Med** 1999 Jan;37(1):11–20 (102 ref.)

Impact of the measurement of troponin on the triage, prognosis, and treatment of patients with chest pain. Jesse RL. **Clin Chim Acta** 1999 Jun 30;284(2):213–21 (19 ref.)

A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. Wu AH. **Coron Artery Dis** 1999;10(2):69–74 (32 ref.)

Cardiac troponin I and non-Q-wave myocardial infarction: how useful is it after coronary artery bypass surgery? [editorial; comment] Barron JT. **Crit Care Med** 1998 Dec; 26(12):1936–7 (9 ref.) Comment on: Crit Care Med 1998 Dec;26(12):1986–90.

Appropriate roles of cardiac troponins in evaluating patients with chest pain. Rice MS, et al. **J Am Board Fam Pract** 1999 May–Jun;12(3):214–8 (15 ref.)

The use of cardiac markers in acute coronary syndromes. Agrawal B. **Scand J Clin Lab Invest Suppl** 1999;230:50–9 (64 ref.)

[Biochemical markers for acute coronary syndromes] Aikawa R, et al. **Nippon Rinsho** 1998 Oct;56(10):2569–75 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

A strategy for the use of cardiac injury markers (troponin I and T, creatine kinase-MB mass and isoforms, and myoglobin) in the diagnosis of acute myocardial infarction [see comments] Kost GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):245–51 (79 ref.) Comment in: Arch Pathol Lab Med 1998 Nov;122(11):949–50.

Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. Apple FS. **Clin Chim Acta** 1999 Jun 30;284(2):151–9 (24 ref.)

Clinical insights on the use of highly sensitive cardiac troponin assays. Missov ED, et al. **Clin Chim Acta** 1999 Jun 30;284(2):175–85 (31 ref.)

Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Wu AH, et al. **Clin Chim Acta** 1999 Jun 30;284(2):161–74 (36 ref.)

PHYSIOLOGY

Troponin I, stunning, hypertrophy, and failure of the heart [editorial; comment] Solaro RJ. **Circ Res** 1999 Jan 8–22; 84(1):122–4 (19 ref.) Comment on: Circ Res 1999 Jan 8–22;84(1):1–8. Comment on: Circ Res 1999 Jan 8–22;84(1):9–20.

Troponin I: inhibitor or facilitator. Perry SV. **Mol Cell Biochem** 1999 Jan;190(1–2):9–32 (178 ref.)

TROPONIN T

ANALYSIS

Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. Wu AH, et al. **Eur Heart J** 1998 Nov;19 Suppl N:N25–9 (15 ref.)

BLOOD

Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Chapelle JP. **Clin Chem Lab Med** 1999 Jan;37(1):11–20 (102 ref.)

Impact of the measurement of troponin on the triage, prognosis, and treatment of patients with chest pain. Jesse RL. **Clin Chim Acta** 1999 Jun 30;284(2):213–21 (19 ref.)

A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. Wu AH. **Coron Artery Dis** 1999;10(2):69–74 (32 ref.)

Inflammation and outcome in unstable angina [editorial; comment] Curzen N, et al. **Eur Heart J** 1999 Apr; 20(8):554–5 (10 ref.) Comment on: Eur Heart J 1999 Apr;20(8):562–74.

Biochemical markers in the diagnosis of coronary artery disease. Hartmann F, et al. **Eur Heart J** 1998 Nov;19 Suppl N:N2–7 (31 ref.)

Cardiac markers: present and future. Plebani M, et al. **Int J Clin Lab Res** 1999;29(2):56–63 (49 ref.)

Appropriate roles of cardiac troponins in evaluating patients with chest pain. Rice MS, et al. **J Am Board Fam Pract** 1999 May–Jun;12(3):214–8 (15 ref.)

The use of cardiac markers in acute coronary syndromes. Agrawal B. **Scand J Clin Lab Invest Suppl** 1999;230:50–9 (64 ref.)

Biochemical markers of thrombolytic success. IFCC Committee on Standardization of Markers of Cardiac Damage. Apple FS. **Scand J Clin Lab Invest Suppl** 1999; 230:60–6 (25 ref.)

Evidence based approach to practice guides and decision thresholds for cardiac markers. Christenson RH, et al. **Scand J Clin Lab Invest Suppl** 1999;230:90–102 (28 ref.)

Strategies for clinical assessment of patients with suspected acute coronary syndromes. Giannitsis E, et al. **Scand J Clin Lab Invest Suppl** 1999;230:36–42 (26 ref.)

Therapeutic implications of the use of cardiac markers in acute coronary syndromes. Lindahl B. **Scand J Clin Lab Invest Suppl** 1999;230:43–9 (26 ref.)

[Biochemical markers for acute coronary syndromes] Aikawa R, et al. **Nippon Rinsho** 1998 Oct;56(10):2569–75 (10 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Troponin T: genetics, properties and function. Perry SV. **J Muscle Res Cell Motil** 1998 Aug;19(6):575–602 (195 ref.)

GENETICS

Troponin T: genetics, properties and function. Perry SV. **J Muscle Res Cell Motil** 1998 Aug;19(6):575–602 (195 ref.)

METABOLISM

A strategy for the use of cardiac injury markers (troponin I and T, creatine kinase-MB mass and isoforms, and myoglobin) in the diagnosis of acute myocardial infarction [see comments] Kost GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):245–51 (79 ref.) Comment in: Arch Pathol Lab Med 1998 Nov;122(11):949–50.

Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. Apple FS. **Clin Chim Acta** 1999 Jun 30;284(2):151–9 (24 ref.)

Clinical insights on the use of highly sensitive cardiac troponin assays. Missov ED, et al. **Clin Chim Acta** 1999 Jun 30;284(2):175–85 (31 ref.)

Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Wu AH, et al. **Clin Chim Acta** 1999 Jun 30;284(2):161–74 (36 ref.)

PHYSIOLOGY

Calcium ion regulation of muscle contraction: the regulatory role of troponin T. Ohtsuki I. **Mol Cell Biochem** 1999 Jan; 190(1–2):33–8 (40 ref.)

TROUT, RAINBOW see **ONCORHYNCHUS MYKISS**

TROUT, REDBAND see **ONCORHYNCHUS MYKISS**

D-TRP-6-LH-RH see **TRIPTORELIN**

TRS-ART GENE PROTEIN, HIV see **GENE PRODUCTS, REV**

TRUNCUS ARTERIOSUS, PERSISTENT

COMPLICATIONS

Cyanotic congenital heart disease with increased pulmonary blood flow. Grifka RG. **Pediatr Clin North Am** 1999 Apr; 46(2):405–25 (65 ref.)

Cyanotic congenital heart disease with decreased pulmonary blood flow in children. Waldman JD, et al. **Pediatr Clin North Am** 1999 Apr;46(2):385–404 (15 ref.)

SURGERY

Repair of truncus arteriosus. Barbero-Marcial ML, et al. **Adv Card Surg** 1998;10:43–73 (54 ref.)

TRUTH DISCLOSURE

Truth and consequences. Foster GS. **Acad Med** 1998 Dec; 73(12):1226–7 (1 ref.)

Are physicians aware of what patients know about what physicians know? [editorial] Sabbioni ME, et al. **Ann Oncol** 1999 Jan;10(1):11–2 (8 ref.)

Breaking bad news. 3: Encouraging the adoption of best practices. Campbell EM, et al. **Behav Med** 1998 Summer; 24(2):73–80 (47 ref.)

Breaking bad news. 1: Current best advice for clinicians. Girgis A, et al. **Behav Med** 1998 Summer;24(2):53–9 (42 ref.)

Breaking bad news. 2: What evidence is available to guide clinicians? Walsh RA, et al. **Behav Med** 1998 Summer; 24(2):61–72 (65 ref.)

Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives? Wilcke JT. **BMJ** 1998 Sep 12; 317(7160):744–7 (17 ref.)

Allegations of sexual abuse by nonverbal autistic people via facilitated communication: testing of validity. Konstantareas MM. **Child Abuse Negl** 1998 Oct; 22(10):1027–41 (46 ref.)

Self-report among injecting drug users: a review [see comments] Darke S. **Drug Alcohol Depend** 1998 Aug 1; 51(3):253–63; discussion 267–8 (41 ref.) Comment in: Drug Alcohol Depend 1998 Aug 1;51(3):265–6.

The manipulation of international scientific organizations [editorial] Castleman BI, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):53–5 (17 ref.)

The conflict-prone nature of occupational health research and practice. Nemery B. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):35–7 (12 ref.)

Truth telling and palliative medicine. Kashiwagi T. **Intern Med** 1999 Feb;38(2):190–2 (4 ref.)

Disclosure of operating practices by managed-care organizations to consumers of healthcare: obligations of informed consent. Khanna V, et al. **J Clin Ethics** 1998 Fall; 9(3):291–6 (27 ref.)

False complaints of sexual assault: recovered memories of childhood sexual abuse. Boakes J. **Med Sci Law** 1999 Apr; 39(2):112–20 (9 ref.)

Earwitness testimony. Bull R, et al. **Med Sci Law** 1999 Apr; 39(2):120–7 (42 ref.)

The influence of drugs upon testimony. Lader M. **Med Sci Law** 1999 Apr;39(2):99–105 (9 ref.)

Obtaining witness statements: the psychology, best practice and proposals for innovation. Milne B, et al. **Med Sci Law** 1999 Apr;39(2):127–38 (49 ref.)

Physiological illnesses and their potential for influencing testimony. Norfolk GA. **Med Sci Law** 1999 Apr; 39(2):105–12 (31 ref.)

'Non-barking dogs and other odd species': identifying anomaly in witness testimony. Shepherd E. **Med Sci Law** 1999 Apr;39(2):138–45 (4 ref.)

People with mental retardation as witnesses in court: a review. Kebbell MR, et al. **Ment Retard** 1999 Jun; 37(3):179–87 (75 ref.)

Discussing disease progression and end-of-life decisions. Baile WF, et al. **Oncology (Huntingt)** 1999 Jul; 13(7):1021–31; discussion 1031–6, 1038 (57 ref.)

Secrecy, anonymity, and deception in donor insemination: a genetic, psycho-social and ethical critique. Landau R. **Soc Work Health Care** 1998;28(1):75–89 (19 ref.)

[Diagnostic disclosure. Psychological impact and practical aspects] Baillet F, et al. **Encephale** 1998 Dec;24 Spec No 2:35–41 (19 ref.) **(Fre)**

[Current status of cancer therapy. 5. Informing patients the true nature of their illnesses and palliative treatment] Kashiwagi T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10; 87(9):1772–6 (14 ref.) **(Jpn)**

TRYPANOCIDAL AGENTS

CHEMISTRY

The Achilles' heel of trypanosomatids: trypanothione-mediated hydroperoxide metabolism. Flohé L. **Biofactors** 1998;8(1–2):87–91 (20 ref.)

PHARMACOKINETICS

The Achilles' heel of trypanosomatids: trypanothione-mediated hydroperoxide metabolism. Flohé L. **Biofactors** 1998;8(1–2):87–91 (20 ref.)

THERAPEUTIC USE

Chemotherapy of Chagas' disease: the how and the why. Urbina JA. **J Mol Med** 1999 Mar;77(3):332–8 (63 ref.)

Therapy of human African trypanosomiasis: current situation. Atouguia J, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):221–4 (24 ref.)

Pharmacological approaches to antitrypanosomal chemotherapy. Croft SL. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr;94(2):215–20 (53 ref.)

Laboratory and field evaluation of biodegradable polyesters for sustained release of isometamidium and ethidium. Geerts S, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):211–4 (17 ref.)

[Chemotherapy of leishmaniasis and human trypanosomiasis: status and new developments] Kayser O, et al. **Pharm Unserer Zeit** 1999 Jul;28(4):177–85 (31 ref.) **(Ger)**

TRYPANOSOMA

see related
TRYPANOCIDAL AGENTS

CLASSIFICATION

Characterization of Trypanosoma rangeli strains isolated in Central and South America: an overview. Grisard EC, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr;94(2):203–9 (46 ref.)

Trypanosoma evansi and T. equiperdum: distribution, biology, treatment and phylogenetic relationship (a review). Brun R, et al. **Vet Parasitol** 1998 Oct;79(2):95–107 (59 ref.)

DRUG EFFECTS

Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Barrett MP, et al. **Trends Microbiol** 1999 Feb;7(2):82–8 (40 ref.)

GENETICS

Genetic exchange in the trypanosomatidae. Gibson W, et al. **Adv Parasitol** 1999;43:1–46 (150 ref.)

Characterization of Trypanosoma rangeli strains isolated in Central and South America: an overview. Grisard EC, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr;94(2):203–9 (46 ref.)

METABOLISM

pH and volume homeostasis in trypanosomatids: current views and perspectives. Vieira LL.
Biochim Biophys Acta 1998 Aug 21;1376(2):221–41 (266 ref.)

PATHOGENICITY

Roles of cysteine proteinases of trypanosomes and Leishmania in host–parasite interactions. Mottram JC, et al. **Curr Opin Microbiol** 1998 Aug;1(4):455–60 (47 ref.)

TRYPANOSOMA BRUCEI see **TRYPANOSOMA BRUCEI BRUCEI**

TRYPANOSOMA BRUCEI BRUCEI

GENETICS

Genetic exchange in the trypanosomatidae. Gibson W, et al. **Adv Parasitol** 1999;43:1–46 (150 ref.)

Segregation of minichromosomes in trypanosomes: implications for mitotic mechanisms. Gull K, et al.
Trends Microbiol 1998 Aug;6(8):319–23 (26 ref.)

METABOLISM

Diamine auxotrophy in a eukaryotic parasite. Ariyanayagam MR, et al. **Biochem Soc Trans** 1998 Nov;26(4):606–9 (20 ref.)

Surface coats and secretory trafficking in African trypanosomes. Bangs JD. **Curr Opin Microbiol** 1998 Aug; 1(4):448–54 (63 ref.)

PHYSIOLOGY

Surface receptors and transporters of Trypanosoma brucei. Borst P, et al. **Annu Rev Microbiol** 1998;52:745–78 (144 ref.)

TRYPANOSOMA BRUCEI GAMBIENSE

Human African trypanosomiasis: an emerging public health crisis. Smith DH, et al. **Br Med Bull** 1998;54(2):341–55 (28 ref.)

TRYPANOSOMA BRUCEI RHODESIENSE

Human African trypanosomiasis: an emerging public health crisis. Smith DH, et al. **Br Med Bull** 1998;54(2):341–55 (28 ref.)

TRYPANOSOMA CONGOLENSE

DRUG EFFECTS

Laboratory and field evaluation of biodegradable polyesters for sustained release of isometamidium and ethidium. Geerts S, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):211–4 (17 ref.)

IMMUNOLOGY

Immune response of cattle infected with African trypanosomes. Taylor KA, et al.
Mem Inst Oswaldo Cruz 1999 Mar–Apr;94(2):239–44 (62 ref.)

TRYPANOSOMA CRUZI

Trypanosoma cruzi meningoencephalitis in HIV-infected patients. Silva N, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 1;20(4):342–9 (27 ref.)

DRUG EFFECTS

Chemotherapy of Chagas' disease: the how and the why. Urbina JA. **J Mol Med** 1999 Mar;77(3):332–8 (63 ref.)

IMMUNOLOGY

Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection. Costa F, et al. **Braz J Med Biol Res** 1999 Feb; 32(2):235–9 (25 ref.)

METABOLISM

Diamine auxotrophy in a eukaryotic parasite. Ariyanayagam MR, et al. **Biochem Soc Trans** 1998 Nov;26(4):606–9 (20 ref.)

PATHOGENICITY

Signaling and host cell invasion by Trypanosoma cruzi. Burleigh BA, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):461–5 (47 ref.)

PHYSIOLOGY

The use of confocal laser scanning microscopy to analyze the process of parasitic protozoon-host cell interaction. de-Souza W, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1459–70 (49 ref.)

TRYPANOSOMA GAMBIENSE see **TRYPANOSOMA BRUCEI GAMBIENSE**

TRYPANOSOMA (NANNOMONAS) CONGOLENSE see **TRYPANOSOMA CONGOLENSE**

TRYPANOSOMA RHODESIENSE see **TRYPANOSOMA BRUCEI RHODESIENSE**

TRYPANOSOMA VARIANT SURFACE COAT GLYCOPROTEINS see **VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA**

TRYPANOSOMATIDAE see **TRYPANOSOMATINA**

TRYPANOSOMATINA

CLASSIFICATION

Characterization of Endotrypanum (Kinetoplastida: Trypanosomatidae), a unique parasite infecting the neotropical tree sloths (Edentata). Franco AM, et al.
Mem Inst Oswaldo Cruz 1999 Mar–Apr;94(2):261–8 (62 ref.)

GENETICS

Control of gene expression in Trypanosomatidae. Teixeira SM. **Braz J Med Biol Res** 1998 Dec;31(12):1503–16 (60 ref.)

Status of protozoan genome analysis: trypanosomatids. Blackwell JM, et al. **Parasitology** 1999;118 Suppl:S11–4 (25 ref.)

ISOLATION & PURIFICATION

Characterization of Endotrypanum (Kinetoplastida: Trypanosomatidae), a unique parasite infecting the neotropical tree sloths (Edentata). Franco AM, et al.
Mem Inst Oswaldo Cruz 1999 Mar–Apr;94(2):261–8 (62 ref.)

METABOLISM

The Achilles' heel of trypanosomatids: trypanothione-mediated hydroperoxide metabolism. Flohé L. **Biofactors** 1998;8(1–2):87–91 (20 ref.)

MICROBIOLOGY

Endosymbiosis in protozoa of the Trypanosomatidae family. de Souza W, et al. **FEMS Microbiol Lett** 1999 Apr 1; 173(1):1–8 (38 ref.)

PHYSIOLOGY

Phytomonas and other trypanosomatid parasites of plants and fruit. Camargo EP. **Adv Parasitol** 1999;42:29–112 (340 ref.)

Apoptosis in parasites and parasite-induced apoptosis in the host immune system: a new approach to parasitic diseases. Barcinski MA, et al. **Braz J Med Biol Res** 1999 Apr; 32(4):395–401 (50 ref.)

TRYPANOSOMIASIS

see related
TRYPANOCIDAL AGENTS

[Trypanosomiasis] Kume H, et al.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):405–8 (5 ref.) **(Jpn)**

DRUG THERAPY

[Chemotherapy of leishmaniasis and human trypanosomiasis: status and new developments] Kayser O, et al.
Pharm Unserer Zeit 1999 Jul;28(4):177–85 (31 ref.) **(Ger)**

PARASITOLOGY

Genetic exchange in the trypanosomatidae. Gibson W, et al. **Adv Parasitol** 1999;43:1–46 (150 ref.)

PREVENTION & CONTROL

Tsetse and trypanosomiasis control problems in south-east Uganda: past, present and alternative strategies. Okoth JO. **Schweiz Med Wochenschr** 1999 Aug 10;129(31–32):1091–8 (26 ref.)

VETERINARY

Trypanosoma evansi and T. equiperdum: distribution, biology, treatment and phylogenetic relationship (a review). Brun R, et al. **Vet Parasitol** 1998 Oct;79(2):95–107 (59 ref.)

TRYPANOSOMIASIS, AFRICAN

DRUG THERAPY

Therapy of human African trypanosomiasis: current situation. Atouguia J, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):221–4 (24 ref.)

Pharmacological approaches to antitrypanosomal chemotherapy. Croft SL. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr;94(2):215–20 (53 ref.)

EPIDEMIOLOGY

Human African trypanosomiasis: an emerging public health crisis. Smith DH, et al. **Br Med Bull** 1998;54(2):341–55 (28 ref.)

Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee.
World Health Organ Tech Rep Ser 1998;881:I–VI, 1–114 (8 ref.)

HISTORY

Review of tsetse flies and trypanosomosis in South Africa. Kappmeier K, et al. **Onderstepoort J Vet Res** 1998 Sep; 65(3):195–203 (33 ref.)

PREVENTION & CONTROL

Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee.
World Health Organ Tech Rep Ser 1998;881:I–VI, 1–114 (8 ref.)

VETERINARY

Review on the molecular tools for the understanding of the epidemiology of animal trypanosomosis in West Africa. Duvallet G, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):245–8 (19 ref.)

Laboratory and field evaluation of biodegradable polyesters for sustained release of isometamidium and ethidium. Geerts S, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):211–4 (17 ref.)

Immune response of cattle infected with African trypanosomes. Taylor KA, et al.
Mem Inst Oswaldo Cruz 1999 Mar–Apr;94(2):239–44 (62 ref.)

TRYPANOSOMIASIS, BOVINE

EPIDEMIOLOGY

Review on the molecular tools for the understanding of the epidemiology of animal trypanosomosis in West Africa. Duvallet G, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):245–8 (19 ref.)

IMMUNOLOGY

Immune response of cattle infected with African trypanosomes. Taylor KA, et al.
Mem Inst Oswaldo Cruz 1999 Mar–Apr;94(2):239–44 (62 ref.)

PREVENTION & CONTROL

Laboratory and field evaluation of biodegradable polyesters for sustained release of isometamidium and ethidium. Geerts S, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):211–4 (17 ref.)

TRYPANOSOMIASIS, CARDIOVASCULAR see **CHAGAS CARDIOMYOPATHY**

TRYPANOSOMIASIS, SOUTH AMERICAN see **CHAGAS DISEASE**

TRYPSIN INHIBITOR, ALPHA 1-ANTITRYPSIN see **ALPHA 1-ANTITRYPSIN**

TRYPSIN INHIBITOR, BASIC, PANCREATIC see **APROTININ**

TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN

THERAPEUTIC USE

The Bowman–Birk inhibitor from soybeans as an anticarcinogenic agent. Kennedy AR. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1406S–1412S (75 ref.)

TRYPSIN INHIBITOR, KAZAL PANCREATIC

ANALYSIS

[Usefulness of selected circulating biochemical markers in diagnosis and monitoring of endometriosis] Wieczorek J, et al. **Ginekol Pol** 1999 Mar;70(3):161–5 (41 ref.) (Eng. Abstr.) **(Pol)**

TRYPSIN INHIBITOR, KUNITZ, PANCREATIC see **APROTININ**

TRYPSIN INHIBITORS

THERAPEUTIC USE

The Bowman–Birk inhibitor from soybeans as an anticarcinogenic agent. Kennedy AR. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1406S–1412S (75 ref.)

TRYPSINOGEN

GENETICS

Hereditary pancreatitis. Gene defects and their implications.

TRYPSINOGEN

Gates LK Jr, et al. **Surg Clin North Am** 1999 Aug; 79(4):711–22, vii–viii (22 ref.)

TRYPTAMINE RECEPTORS see **RECEPTORS, SEROTONIN**

TRYPTAMINES

see related
RECEPTORS, SEROTONIN

TRYPTOPHAN

see related
EOSINOPHILIA-MYALGIA SYNDROME

ADVERSE EFFECTS

[L-tryptophan-induced eosinophilia-myalgia syndrome, Chinese restaurant syndrome] Terao T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):650–3 (11 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile. Trivedi BK, et al. **Pharm Biotechnol** 1998;11:481–505 (51 ref.)

ANALYSIS

[What determines the characteristics of the intrinsic UV-fluorescence of proteins? Analysis of the properties of the microenvironment and features of the localization of their tryptophan residues] Kuznetsova IM, et al. **Tsitologiia** 1998;40(8–9):747–62 (45 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Moroni F. **Eur J Pharmacol** 1999 Jun 30;375(1–3):87–100 (183 ref.)

PHYSIOLOGY

[Tryptophan, its metabolism and function in the human body (with emphasis on metabolic diseases and depressive syndromes)] Kuzmiaková M, et al. **Vnitr Lek** 1998 May; 44(5):288–93 (55 ref.) (Eng. Abstr.) **(Cze)**

THERAPEUTIC USE

[Treatment of depression and sleep disorders. Significance of serotonin and L-tryptophan in pathophysiology and therapy] Riemann D, et al. **Fortschr Med** 1998 Nov 20; 116(32):40–2 (25 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Metodiewa D. **Amino Acids** 1998;14(1–3):181–7 (19 ref.)

TRYPTOPHAN HYDROXYLASE

BIOSYNTHESIS

Melatonin synthesis pathway: circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Bernard M, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):325–34 (44 ref.)

CHEMISTRY

Advances in the molecular characterization of tryptophan hydroxylase. Mockus SM, et al. **J Mol Neurosci** 1998 Jun; 10(3):163–79 (149 ref.)

METABOLISM

Advances in the molecular characterization of tryptophan hydroxylase. Mockus SM, et al. **J Mol Neurosci** 1998 Jun; 10(3):163–79 (149 ref.)

TRYPTOPHAN MONOOXYGENASE see **TRYPTOPHAN HYDROXYLASE**

TRYPTOPHAN OXYGENASE

GENETICS

A myoglobin evolved from indoleamine 2,3-dioxygenase, a tryptophan-degrading enzyme. Suzuki T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):117–28 (65 ref.)

METABOLISM

A myoglobin evolved from indoleamine 2,3-dioxygenase, a tryptophan-degrading enzyme. Suzuki T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):117–28 (65 ref.)

TRYPTOPHAN PYRROLASE see **TRYPTOPHAN OXYGENASE**

TRYPTOPHAN SYNTHASE

CHEMISTRY

Structure, evolution and action of vitamin B6-dependent enzymes. Jansonius JN. **Curr Opin Struct Biol** 1998 Dec; 8(6):759–69 (59 ref.)

METABOLISM

The molecular basis of substrate channeling. Miles EW, et al. **J Biol Chem** 1999 Apr 30;274(18):12193–6 (50 ref.)

TRYPTOPHAN SYNTHETASE see **TRYPTOPHAN SYNTHASE**

TSETSE FLIES

Review of tsetse flies and trypanosomosis in South Africa. Kappmeier K, et al. **Onderstepoort J Vet Res** 1998 Sep; 65(3):195–203 (33 ref.)

Tsetse and trypanosomiasis control problems in south-east Uganda: past, present and alternative strategies. Okoth JO. **Schweiz Med Wochenschr** 1999 Aug 10;129(31–32):1091–8 (26 ref.)

TSH see **THYROTROPIN**

TSH RECEPTORS see **RECEPTORS, THYROTROPIN**

TSP-1 see **THROMBOSPONDIN 1**

TSUTSUGAMUSHI DISEASE see **SCRUB TYPHUS**

TUBAL EMBRYO TRANSFER see **EMBRYO TRANSFER**

TUBAL LIGATION see **STERILIZATION, TUBAL**

TUBE FEEDING see **ENTERAL NUTRITION**

TUBE ILEOSTOMY see **ILEOSTOMY**

TUBERCULID see **TUBERCULOSIS, CUTANEOUS**

TUBERCULIN

Accurately interpreting PPD skin test results. King AB. **Nurse Pract** 1999 May;24(5):144–7 (9 ref.)

IMMUNOLOGY

Delayed-type hypersensitivity reactions to nominal protein antigens and to environmental allergens: similarities and differences. Tsicopoulos A, et al. **Eur J Dermatol** 1999 Jun; 9(4):261–8 (59 ref.)

TUBERCULIN TEST

Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Menzies D. **Am J Respir Crit Care Med** 1999 Jan;159(1):15–21 (58 ref.)

[Recent clinical aspect of tuberculin reaction] Morikawa S. **Nippon Rinsho** 1998 Dec;56(12):3185–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of mycobacterial disease by biochemical and immunological parameters] Yoshikawa M, et al. **Nippon Rinsho** 1998 Dec;56(12):3057–61 (21 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Tuberculin PPD RT23: still going strong [see comments] Hasløv K, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):793–5 (11 ref.) Comment in: Int J Tuberc Lung Dis 1998 Oct;2(10):795–6.

TUBERCULIN-TYPE HYPERSENSITIVITY see **HYPERSENSITIVITY, DELAYED**

TUBERCULOID BACILLUS see **MYCOBACTERIA, ATYPICAL**

TUBERCULOID INFECTIONS see **MYCOBACTERIUM INFECTIONS, ATYPICAL**

TUBERCULOMA

DIAGNOSIS

Intramedullary tuberculoma of the spinal cord. Case report and review of the literature. Ratliff JK, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):125–8 (26 ref.)

Proton MR spectroscopy in inflammatory and infectious brain disorders. Cecil KM, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):863–80 (50 ref.)

[Intramedullary tuberculoma: a case report] Vukusic S, et al. **Rev Neurol (Paris)** 1998 Jul;154(6–7):535–8 (10 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Advances in diagnosis, treatment and prognosis of intracerebral tuberculomas in the last 50 years. Report of 21 cases. Artico M, et al. **Neurochirurgie** 1999 May; 45(2):129–33 (17 ref.)

TUBERCULOMA, INTRACRANIAL

[Intracranial tuberculoma] Nakamura H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):180–3 (14 ref.) **(Jpn)**

TUBERCULOSIS

see related
ANTITUBERCULAR AGENTS
TUBERCULIN TEST

Tuberculosis: 6. Extrapulmonary disease [see comments] Fanning A. **CMAJ** 1999 Jun 1;160(11):1597–603 (36 ref.) Comment in: CMAJ 1999 Sep 7;161(5):488–9.

Pneumonia, tuberculosis, and urinary tract infections in pregnancy. Riley LE. **Curr Clin Top Infect Dis** 1999; 19:181–97 (112 ref.)

Pancreatic tuberculosis in non-immunocompromised patients: reports of two cases, and a literature review. Ladas SD, et al. **Eur J Gastroenterol Hepatol** 1998 Nov; 10(11):973–6 (41 ref.)

Tuberculosis in patients with human immunodeficiency virus infection. Havlir DV, et al. **N Engl J Med** 1999 Feb 4; 340(5):367–73 (75 ref.)

Tuberculosis of the central nervous system. Garg RK. **Postgrad Med J** 1999 Mar;75(881):133–40 (54 ref.)

[Tuberculosis and migration] Pedersen JT, et al. **Ugeskr Laeger** 1999 Jun 7;161(23):3440–3 (31 ref.) (Eng. Abstr.) **(Dan)**

[Head and neck tuberculosis] Kumoi K. **Nippon Rinsho** 1998 Dec;56(12):3148–52 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculosis in respiratory system--tracheo-bronchial tuberculosis, pulmonary tuberculosis, tuberculous pleurisy and thoracic empyema] Nagao K. **Nippon Rinsho** 1998 Dec; 56(12):3104–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculosis] Mori T. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):127–30 (5 ref.) **(Jpn)**

[Tuberculosis in children] Tamaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):134–7 (11 ref.) **(Jpn)**

COMPLICATIONS

Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. Del Amo J, et al. **AIDS** 1999 Jul 9;13(10):1151–8 (91 ref.)

Malnutrition in tuberculosis. Macallan DC. **Diagn Microbiol Infect Dis** 1999 Jun;34(2):153–7 (14 ref.)

Tuberculosis in HIV-infected persons with special emphasis on sub-Saharan Africa. Harries AD. **J Infect** 1998 Nov; 37(3):205–9 (31 ref.)

Tuberculosis, HIV infection, and malnutrition: an infernal trio in central Africa [editorial] Perronne C. **Nutrition** 1999 Apr;15(4):321–2 (12 ref.)

Tuberculosis and HIV infection: a global perspective. Murray JF. **Respiration** 1998;65(5):335–42 (45 ref.)

[Mycobacterial infection in patients with hematologic disorders] Morii T, et al. **Nippon Rinsho** 1998 Dec; 56(12):3209–11 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Aids] Nagai H. **Nippon Rinsho** 1998 Dec;56(12):3217–20 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculosis and AIDS 15 years later (1981–1996): new perspectives] de March Ayuela P, et al. **Med Clin (Barc)** 1998 Nov 14;111(16):628–34 (132 ref.) **(Spa)**

CONGENITAL

Congenital and perinatal tuberculosis: discussion of difficult issues in diagnosis and management. Hageman JR. **J Perinatol** 1998 Sep-Oct;18(5):389–94 (31 ref.)

DIAGNOSIS

Diagnosing the systemic associations of anterior uveitis. Smith JR, et al. **Aust N Z J Ophthalmol** 1998 Nov; 26(4):319–26 (36 ref.)

Tuberculosis in the 1990's: From bedside to bench and back. Jamieson FB, et al. **Can Respir J** 1999 Jul-Aug;6(4):341–4 (15 ref.)

Molecular techniques for the diagnosis of respiratory bacterial infection. Gillespie S. **Curr Opin Pulm Med** 1999 May;5(3):174–8 (35 ref.)

Obstructive jaundice caused by biliary tuberculosis: spectrum of the diagnosis and management. Yeh TS, et al. **Gastrointest Endosc** 1999 Jul;50(1):105–8 (9 ref.)

Tuberculin PPD RT23: still going strong [see comments] Hasløv K, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):793–5 (11 ref.) Comment in: Int J Tuberc Lung Dis 1998 Oct;2(10):795–6.

How to combat tuberculosis in the year 2000? Rieder HL. **Respiration** 1998;65(6):423–31 (142 ref.)

The role of rapid diagnostic tests for tuberculosis in Singapore. Lim TK. **Singapore Med J** 1999 Apr; 40(4):298–302 (33 ref.)

[Pharyngeal tuberculosis: an analytical study and report of 10 cases] Kharoubi S. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(3):203–7 (21 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of infections with difficulty in isolation and identification of the causative organisms. 3) Acid-fast bacterial infections (caused by Mycobacterium tuberculosis or atypical acid-fast organisms)] Watanabe A. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2203–10 (7 ref.) **(Jpn)**

[Advances in genetic diagnostics for mycobacterial infection] Koga H. **Nippon Rinsho** 1998 Dec;56(12):3051–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[MR images of mycobacterial infection] Ohno Y, et al. **Nippon Rinsho** 1998 Dec;56(12):3067–72 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of mycobacterial disease by biochemical and immunological parameters] Yoshikawa M, et al. **Nippon Rinsho** 1998 Dec;56(12):3057–61 (21 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

The treatment of tuberculosis in HIV-infected persons [editorial] Pozniak AL, et al. **AIDS** 1999 Mar 11; 13(4):435–45 (99 ref.)

Ethambutol in tuberculosis: time to reconsider? Graham SM, et al. **Arch Dis Child** 1998 Sep;79(3):274–8 (55 ref.)

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Burman WJ, et al. **Clin Infect Dis** 1999 Mar;28(3):419–29; quiz 430 (108 ref.)

Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Schluger NW. **Clin Infect Dis** 1999 Jan;28(1):130–5 (13 ref.)

Approaches to combat tuberculosis. Young DB, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):650–2 (13 ref.)

Contemporary treatment of tuberculosis in HIV prevalent countries in sub-Saharan Africa. Nuwaha F. **East Afr Med J** 1998 Jun;75(6):358–63 (41 ref.)

Tuberculosis treatment for the beginning of the next century. Schraufnagel DE. **Int J Tuberc Lung Dis** 1999 Aug; 3(8):651–62 (176 ref.)

Tuberculosis: a search for novel therapy starting with natural products. Mitscher LA, et al. **Med Res Rev** 1998 Nov; 18(6):363–74 (19 ref.)

[Principles of antituberculosis chemotherapy and drug susceptibility tests] Suzuki K. **Nippon Rinsho** 1998 Dec; 56(12):3082–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Resurgence of tuberculosis and the impact of HIV infection. Glynn JR. **Br Med Bull** 1998;54(3):579–93 (87 ref.)

Tuberculosis in the 1990's: From bedside to bench and back. Jamieson FB, et al. **Can Respir J** 1999 Jul–Aug;6(4):341–4 (15 ref.)

Epidemiology of mycobacterial resistance (especially Mycobacterium tuberculosis). Fischer B. **Chemotherapy** 1999 Mar–Apr;45(2):109–20 (45 ref.)

Tuberculosis: 3. Epidemiology of the disease in Canada. Long R, et al. **CMAJ** 1999 Apr 20;160(8):1185–90 (20 ref.)

The return of tuberculosis. Fätkenheuer G, et al. **Diagn Microbiol Infect Dis** 1999 Jun;34(2):139–46 (60 ref.)

Contemporary treatment of tuberculosis in HIV prevalent countries in sub-Saharan Africa. Nuwaha F. **East Afr Med J** 1998 Jun;75(6):358–63 (41 ref.)

Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Coovadia HM, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):844–51 (60 ref.)

Information management in national tuberculosis control programmes and national health information systems. Trébucq A, et al. **Int J Tuberc Lung Dis** 1998 Oct; 2(10):852–6 (6 ref.)

Strain typing of Mycobacterium tuberculosis. Saunders NA. **J Infect** 1999 Mar;38(2):80–6 (49 ref.)

The tuberculosis pandemic--which way now? Zumla A, et al. **J Infect** 1999 Mar;38(2):74–9 (41 ref.)

Seasonal variations in vitamin-D status and the incidence of tuberculosis in different countries [letter] Chan TY. **Respiration** 1999;66(2):196 (6 ref.)

[Control of tuberculosis in China] Song WH. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):109–11 (2 ref.) **(Chi)**

[Study of the reasons for spread of communicable diseases] Wei CY. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr;18(2):102–5 (8 ref.) **(Chi)**

[Re-emergence of tuberculosis and socioeconomic uncertainty] Poinsignon Y, et al. **Rev Med Interne** 1998 Sep;19(9):649–57 (39 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiological review of tuberculosis] Mori T. **Nippon Rinsho** 1998 Dec;56(12):3221–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[The annual risk of infection with Koch's bacillus--its epidemiological importance and the methods for its estimation] Ioanaş M. **Pneumoftiziologia** 1998 Apr–Jun; 47(2):99–103 (8 ref.) **(Rum)**

[AIDS and tuberculosis in the light of spreading drug abuse] Volkova KI, et al. **Klin Med (Mosk)** 1999;77(2):7–12 (68 ref.) **(Rus)**

[Multilevel automatic monitoring system for epidemiological tuberculous process in the north-western region, project and implementation] Nechaeva NE, et al. **Probl Tuberk** 1999;(3):10–4 (6 ref.) (Eng. Abstr.) **(Rus)**

[Tuberculosis in Russia] Punga VV, et al. **Probl Tuberk** 1999; (1):14–6 (0 ref.) (Eng. Abstr.) **(Rus)**

[Current problems of tuberculosis in the north-wester region of Russia] Vasil'ev AV. **Probl Tuberk** 1999;(3):5–7 (0 ref.) (Eng. Abstr.) **(Rus)**

[New errors in epidemiology of tuberculosis in Spain, especially in reference to childhood] de March Ayuela P, et al. **Arch Bronconeumol** 1999 Mar;35(3):136–9 (64 ref.) **(Spa)**

[Tuberculosis and AIDS 15 years later (1981–1996): new perspectives] de March Ayuela P, et al. **Med Clin (Barc)** 1998 Nov 14;111(16):628–34 (132 ref.) **(Spa)**

ETIOLOGY

Three cases of tuberculosis after heart transplantation in Spain. Muñoz RM, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):801–6 (15 ref.)

[The mechanisms of Mycobacterium tuberculosis disease and the implications for its prevention in patients with HIV infection] Diez Ruiz-Navarro M, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):150–5 (57 ref.) **(Spa)**

GENETICS

Genetics and pulmonary medicine. 3. Genetic susceptibility to tuberculosis in human populations [see comments] Bellamy R. **Thorax** 1998 Jul;53(7):588–93 (64 ref.) Comment in: Thorax 1998 Dec;53(12):1095.

HISTORY

The early history of tuberculosis in central East Africa: insights from the clinical records of the first twenty years of Mengo Hospital and review of relevant literature. Daniel TM. **Int J Tuberc Lung Dis** 1998 Oct;2(10):784–90 (28 ref.)

[History of control measures against bovine tuberculosis--contributions from the Institute of Microbiology and Contagious Diseases of the Tierärztlichen Hochschule Hannover] Bisping W. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):362–7 (46 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Cytotoxic T lymphocytes in resistance to tuberculosis. Mazzaccaro RJ, et al. **Adv Exp Med Biol** 1998;452:85–101 (73 ref.)

Vaccination against tuberculosis: recent progress. Orme IM. **Adv Vet Med** 1999;41:135–43 (36 ref.)

DNA encoding individual mycobacterial antigens protects mice against tuberculosis. Silva CL, et al. **Braz J Med Biol Res** 1999 Feb;32(2):231–4 (16 ref.)

Cell-mediated immunity: dealing a direct blow to pathogens. Kaufmann SH. **Curr Biol** 1999 Feb 11;9(3):R97–9 (10 ref.)

Immunological defense mechanisms in tuberculosis and MAC-infection. Hartmann P, et al. **Diagn Microbiol Infect Dis** 1999 Jun;34(2):147–52 (45 ref.)

Immunity to tuberculosis: a delicate balance between protection and pathology. Ehlers S. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):149–58 (69 ref.)

Live antigen carriers as tools for improved anti-tuberculosis vaccines. Hess J, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):165–73 (38 ref.)

Tuberculosis I: a conceptual frame for the immunopathology of the disease. Maes HH, et al. **Med Hypotheses** 1999 Jun; 52(6):583–93 (81 ref.)

How important is Nramp1 in tuberculosis? North RJ, et al. **Trends Microbiol** 1998 Nov;6(11):441–3 (20 ref.)

[Mechanisms of induction and expression of anti-tuberculous immunity] Mitsuyama M. **Kekkaku** 1998 Nov;73(11):639–44 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Immune responses of tuberculosis patients] Honda J, et al. **Nippon Rinsho** 1998 Dec;56(12):3030–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

[Pathogenesis of tuberculosis] Kawabata Y. **Nippon Rinsho** 1998 Dec;56(12):3041–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Biopsy for diagnosis of tuberculosis] Ohno H, et al. **Nippon Rinsho** 1998 Dec;56(12):3077–81 (15 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

BCG and tuberculosis. Bannon MJ. **Arch Dis Child** 1999 Jan; 80(1):80–3 (33 ref.)

Tuberculosis acquired in laboratories and necropsy rooms. Collins CH, et al. **Commun Dis Public Health** 1999 Sep; 2(3):161–7 (100 ref.)

Approaches to combat tuberculosis. Young DB, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):650–2 (13 ref.)

Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa. Nuwaha F. **East Afr Med J** 1998 Sep;75(9):520–7 (53 ref.)

Live antigen carriers as tools for improved anti-tuberculosis vaccines. Hess J, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):165–73 (38 ref.)

Tuberculosis: what you don't know can hurt you [editorial; comment] Woeltje KF. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):626–8 (12 ref.) Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):629–34. Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):635–9.

New vaccines against tuberculosis. The status of current research. Orme IM. **Infect Dis Clin North Am** 1999 Mar; 13(1):169–85, vii–viii (101 ref.)

Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services. Binkin NJ, et al. **Int J Tuberc Lung Dis** 1999 Aug; 3(8):663–74 (77 ref.)

Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Hawken MP, et al. **Int J Tuberc Lung Dis** 1999 Aug;3(8):646–50 (26 ref.)

Tuberculosis control and directly observed therapy from the public health/human rights perspective. Hurtig AK, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):553–60 (62 ref.)

DNA vaccines: application to tuberculosis. Huygen K. **Int J Tuberc Lung Dis** 1998 Dec;2(12):971–8 (67 ref.)

Community contribution to tuberculosis care in countries with high tuberculosis prevalence: past, present and future. Maher D, et al. **Int J Tuberc Lung Dis** 1999 Sep;3(9):762–8 (20 ref.)

The tuberculosis crisis: the deadly consequence of immigration policies and welfare reform. Johns KA, et al. **J Contemp Health Law Policy** 1998 Fall;15(1):101–30 (0 ref.)

Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. Blower SM, et al. **J Mol Med** 1998 Aug;76(9):624–36 (19 ref.)

How to combat tuberculosis in the year 2000? Rieder HL. **Respiration** 1998;65(6):423–31 (142 ref.)

[Control of tuberculosis in China] Song WH. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):109–11 (2 ref.) **(Chi)**

[Tuberculosis in children] Toyoshima K, et al. **Nippon Rinsho** 1998 Dec;56(12):3176–80 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Special comprehensive inter-department program for tuberculosis control in the Cheliabinsk region] Alekseeva RS, et al. **Probl Tuberk** 1998;(5):13–5 (0 ref.) (Eng. Abstr.) **(Rus)**

[Results of DOTS use in Russia] Grishina TA. **Probl Tuberk** 1999;(1):9–12 (0 ref.) (Eng. Abstr.) **(Rus)**

[Organization of antituberculous work with homeless in Saint Petersburg] Grishko AN, et al. **Probl Tuberk** 1999;(3):8–10 (2 ref.) (Eng. Abstr.) **(Rus)**

[DOTS strategy and its application in Russia] Khomenko AG. **Probl Tuberk** 1999;(1):4–8 (13 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Computed tomography in abdominal tuberculosis. Suri S, et al. **Br J Radiol** 1999 Jan;72(853):92–8 (12 ref.)

THERAPY

Atypical hand infections. Hoyen HA, et al. **Hand Clin** 1998 Nov;14(4):613–34, ix (101 ref.)

TRANSMISSION

[Contribution of molecular techniques to the study of tuberculosis transmission] Chaves Sánchez F. **Rev Clin Esp** 1998 Aug;198(8):529–36 (95 ref.) **(Spa)**

VETERINARY

Tuberculosis [news] **J Small Anim Pract** 1999 Mar; 40(3):145–7 (8 ref.)

VIROLOGY

Tuberculosis: 8. The disease in association with HIV infection. FitzGerald JM, et al. **CMAJ** 1999 Jul 13; 161(1):47–51 (48 ref.)

TUBERCULOSIS, BOVINE

HISTORY

[History of control measures against bovine tuberculosis--contributions from the Institute of Microbiology and Contagious Diseases of the Tierärztlichen Hochschule Hannover] Bisping W. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):362–7 (46 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Vaccination against tuberculosis: recent progress. Orme IM. **Adv Vet Med** 1999;41:135–43 (36 ref.)

TUBERCULOSIS, CARDIOVASCULAR

Tuberculous infection of the descending thoracic and abdominal aorta: case report and literature review. Allins AD, et al. **Ann Vasc Surg** 1999 Jul;13(4):439–44 (45 ref.)

Tuberculous mycotic aneurysm of the aorta: review of published medical and surgical experience. Long R, et al. **Chest** 1999 Feb;115(2):522–31 (74 ref.)

[Tuberculosis in circulation system] Ashizawa N, et al. **Nippon Rinsho** 1998 Dec;56(12):3114–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. Seelig MH, et al. **J Vasc Surg** 1999 Feb;29(2):377–81 (19 ref.)

TUBERCULOSIS, CUTANEOUS

PATHOLOGY

Scrofuloderma of the lower extremity treated with wide resection: a case report and review of the literature. Connolly B, et al. **Am J Orthop** 1999 Jul;28(7):417-20 (24 ref.)

[Tuberculosis of the skin] Imamura S. **Nippon Rinsho** 1998 Dec;56(12):3144-7 (3 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Scrofuloderma of the lower extremity treated with wide resection: a case report and review of the literature. Connolly B, et al. **Am J Orthop** 1999 Jul;28(7):417-20 (24 ref.)

TUBERCULOSIS, DRUG-RESISTANT see **TUBERCULOSIS, MULTIDRUG-RESISTANT**

TUBERCULOSIS, ENDOCRINE

[Tuberculosis of the endocrine system] Yoshida A, et al. **Nippon Rinsho** 1998 Dec;56(12):3118-21 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Tuberculous pancreatic abscess in an HIV antibody-negative patient: case report and review. Jenney AW, et al. **Scand J Infect Dis** 1998;30(2):99-104 (42 ref.)

[Tuberculosis of the breast] Ohgaki K, et al. **Nippon Rinsho** 1998 Dec;56(12):3126-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

TUBERCULOSIS, FEMALE GENITAL

[Tuberculosis in the field of gynecology] Mizuno K. **Nippon Rinsho** 1998 Dec;56(12):3153-6 (20 ref.) (Eng. Abstr.) **(Jpn)**

TUBERCULOSIS, GASTROINTESTINAL

Abdominal tuberculosis: the Indian contribution. Kapoor VK. **Indian J Gastroenterol** 1998 Oct-Dec;17(4):141-7 (116 ref.)

Isolated gastric tuberculosis of the cardia. Lin OS, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):258-61 (22 ref.)

[Intestinal tuberculosis and tuberculous peritonitis] Iwasaki Y, et al. **Nippon Rinsho** 1998 Dec;56(12):3110-3 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Intestinal tuberculosis] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):201-3 (10 ref.) **(Jpn)**

COMPLICATIONS

Duodenal tuberculosis presenting as acute ulcer perforation. Berney T, et al. **Am J Gastroenterol** 1998 Oct; 93(10):1989-91 (24 ref.)

DIAGNOSIS

Perianal disease of tuberculous origin: report of a case and review of the literature. Candela F, et al. **Dis Colon Rectum** 1999 Jan;42(1):110-2 (15 ref.)

Abdominal tuberculosis. Kapoor VK. **Postgrad Med J** 1998 Aug;74(874):459-67 (115 ref.)

[Two cases of duodenal tuberculosis] Takeshita K, et al. **Kekkaku** 1999 Jul;74(7):579-84 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Intestinal tuberculosis and AIDS. Case report and literature review] Cendoya C, et al. **Acta Gastroenterol Latinoam** 1998;28(4):305-8 (17 ref.) (Eng. Abstr.) **(Spa)**

TUBERCULOSIS, HEPATIC

Hepatobiliary tuberculosis. Alvarez SZ. **J Gastroenterol Hepatol** 1998 Aug;13(8):833-9 (53 ref.)

DIAGNOSIS

Acute hepatobiliary tuberculosis: a report of two cases and a review of the literature. Hickey N, et al. **Eur Radiol** 1999; 9(5):886-9 (25 ref.)

[Hepato-splenic and peritoneal tuberculosis. A difficult diagnosis] Saed G, et al. **Minerva Med** 1998 Oct; 89(10):371-7 (39 ref.) (Eng. Abstr.) **(Ita)**

[A tuberculous liver abscess in HIV (letter)] Fernández Muinelo M, et al. **An Med Interna** 1999 Feb;16(2):105-6 (10 ref.) **(Spa)**

TUBERCULOSIS, LARYNGEAL

REHABILITATION

[Ambulatory follow-up of patients with respiratory tract tuberculosis and ways of its improvement] Muminov TA, et al. **Probl Tuberk** 1999;(4):49-50 (6 ref.) (Eng. Abstr.) **(Rus)**

TUBERCULOSIS, LYMPH NODE

[Tuberculous lymphadenitis] Kato M, et al. **Nippon Rinsho** 1998 Dec;56(12):3122-5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Cervical tuberculous lymphadenitis] Harada T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):208-10 (16 ref.) **(Jpn)**

[Tuberculous hilar lymphadenopathy] Tsuyuguchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):192-3 (5 ref.) **(Jpn)**

SURGERY

Surgical treatment of atypical mycobacterial cervicofacial adenitis in children. Fergusson JA, et al. **Aust N Z J Surg** 1999 Jun;69(6):426-9 (24 ref.)

TUBERCULOSIS, MALE GENITAL

DIAGNOSIS

[Recurrent orchiepididymitis, 6 months after likely miliary tuberculosis] Lacambra Calvet C, et al. **Arch Esp Urol** 1999 Jun;52(5):518-20 (13 ref.) (Eng. Abstr.) **(Spa)**

TUBERCULOSIS, MENINGEAL

[Central nervous system tuberculosis: diagnosis and therapy] Nozaki H, et al. **Nippon Rinsho** 1998 Dec;56(12):3100-3 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculous meningitis] Motohiro T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):177-9 (3 ref.) **(Jpn)**

COMPLICATIONS

[Precocious puberty secondary to tuberculous meningitis] Buño Soto M, et al. **An Esp Pediatr** 1998 Dec;49(6):635-7 (9 ref.) **(Spa)**

DIAGNOSIS

[Cerebral lesions in a patient with human immunodeficiency virus infection and prior tuberculous meningitis] Merino Muñoz D, et al. **Rev Clin Esp** 1998 Nov;198(11):775-6 (9 ref.) **(Spa)**

TUBERCULOSIS, MILIARY

[Miliary tuberculosis] Nagai H. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):173-6 (11 ref.) **(Jpn)**

DIAGNOSIS

Intramedullary tuberculoma of the spinal cord. Case report and review of the literature. Ratliff JK, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):125-8 (26 ref.)

[Recurrent orchiepididymitis, 6 months after likely miliary tuberculosis] Lacambra Calvet C, et al. **Arch Esp Urol** 1999 Jun;52(5):518-20 (13 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Miliary pneumonia after the intravesical BCG therapy of a superficial urothelial carcinoma of the bladder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Aug 27; 124(34-35):993-7 (21 ref.) (Eng. Abstr.) **(Ger)**

TUBERCULOSIS, MULTIDRUG-RESISTANT

Mycobacterium tuberculosis and other mycobacteria. Mault JR, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):227-38, x (26 ref.)

Pulmonary tuberculosis: the essentials. Leung AN. **Radiology** 1999 Feb;210(2):307-22 (133 ref.)

[Multidrug-resistant tuberculosis] Mori T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):192-4 (8 ref.) **(Jpn)**

DIAGNOSIS

Multiple drug resistant tuberculosis: aetiology, diagnosis and outcome. Eltringham IJ, et al. **Br Med Bull** 1998; 54(3):569-78 (29 ref.)

DRUG THERAPY

Rational DOTS plus' for the control of MDR-TB. Espinal MA, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):561-3 (18 ref.)

Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century [see comments] Heifets LB, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):564-81 (127 ref.) Comment in: Int J Tuberc Lung Dis 1999 Jul;3(7):549.

Drug resistant tuberculosis in adults and its treatment [see comments] Drobniewski F. **J R Coll Physicians Lond** 1998 Jul-Aug;32(4):314-8 (18 ref.) Comment in: J R Coll Physicians Lond 1998 Sep-Oct;32(5):491.

The treatment of tuberculosis. Albino JA, et al. **Respiration** 1998;65(4):237-55 (63 ref.)

[Chemotherapy for tuberculosis; yesterday, today, and tomorrow--basic and clinical studies] Aoyagi T. **Kekkaku** 1998 Jul;73(7):459-70 (114 ref.) (Eng. Abstr.) **(Jpn)**

[Current status and perspectives on the development of rifamycin derivative antibiotics] Hidaka T. **Kekkaku** 1999 Jan;74(1):53-61 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of new quinolores as antituberculosis drugs] Kawahara S, et al. **Kekkaku** 1999 Jan;74(1):71-5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[View of development of fluoroquinolones] Namba K. **Kekkaku** 1999 Jan;74(1):47-52 (17 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Portaels F, et al. **Int J Tuberc Lung Dis** 1999 Jul; 3(7):582-8 (42 ref.)

GENETICS

Antibiotic resistance in mycobacteria. Davies J. **Novartis Found Symp** 1998;217:195-205; discussion 205-8 (32 ref.)

Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Telenti A. **Thorax** 1998 Sep; 53(9):793-7 (66 ref.)

MICROBIOLOGY

[Multidrug-resistant tuberculosis. 1. Drug susceptibility testing and its standardization] Abe C. **Kekkaku** 1998 Nov; 73(11):649-55 (20 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Multiple drug resistant tuberculosis: aetiology, diagnosis and outcome. Eltringham IJ, et al. **Br Med Bull** 1998; 54(3):569-78 (29 ref.)

[Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)--its feasibility] Tsuyuguchi I. **Kekkaku** 1999 Jun;74(6):479-91 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of multi drug resistant tuberculosis] Sumitomo S. **Nippon Rinsho** 1998 Dec;56(12):3171-5 (14 ref.) (Eng. Abstr.) **(Jpn)**

TUBERCULOSIS, OCULAR

DIAGNOSIS

[Ocular tuberculosis] Ishihara M, et al. **Nippon Rinsho** 1998 Dec;56(12):3157-61 (21 ref.) (Eng. Abstr.) **(Jpn)**

TUBERCULOSIS, OSTEOARTICULAR

[Osteoarticular tuberculosis with emphasis on tuberculous spondylitis] Ehara S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):211-3 (7 ref.) **(Jpn)**

DIAGNOSIS

The evolving role of direct amplification tests in diagnosing osteoarticular infections caused by mycobacteria and fungi. Harrington JT. **Curr Opin Rheumatol** 1999 Jul;11(4):289-92 (29 ref.)

Two cases of chronic arthritis of the forearm due to Mycobacterium tuberculosis. Hunfeld KP, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):344-8 (339 ref.)

Calvarial tuberculosis. Unüvar E, et al. **J Paediatr Child Health** 1999 Apr;35(2):221-2 (8 ref.)

[Tuberculosis of the thoracic wall. Presentation of 4 personal cases and review of the literature] Mathlouthi A, et al. **Rev Pneumol Clin** 1998 Sep;54(4):182-6 (22 ref.) (Eng. Abstr.) **(Fre)**

[Bone and joint tuberculosis in the field of orthopedics] Fujita M, et al. **Nippon Rinsho** 1998 Dec;56(12):3140-3 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Calvarial tuberculosis. Unüvar E, et al. **J Paediatr Child Health** 1999 Apr;35(2):221-2 (8 ref.)

Medical therapy of bone and joint tuberculosis in 1998. Pertuiset E. **Rev Rhum Engl Ed** 1999 Mar;66(3):152-7 (36 ref.)

[Chemotherapy of osteoarticular tuberculosis] Serke M, et al. **Orthopade** 1999 Apr;28(4):375-80 (27 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Radiology of skeletal tuberculosis. Ridley N, et al. **Orthopedics** 1998 Nov;21(11):1213-20 (35 ref.)

Primary multifocal tuberculous osteomyelitis with involvement of the ribs. Chang DS, et al. **Skeletal Radiol** 1998 Nov;27(11):641-5 (21 ref.)

THERAPY

[Bone and joint tuberculosis in the field of orthopedics] Fujita M, et al. **Nippon Rinsho** 1998 Dec;56(12):3140-3 (20 ref.) (Eng. Abstr.) **(Jpn)**

TUBERCULOSIS, PERITONEAL

Abdominal tuberculosis: the Indian contribution. Kapoor VK. **Indian J Gastroenterol** 1998 Oct–Dec;17(4):141–7 (116 ref.)

[Intestinal tuberculosis and tuberculous peritonitis] Iwasaki Y, et al. **Nippon Rinsho** 1998 Dec;56(12):3110–3 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Tuberculous peritonitis: fatality associated with delayed diagnosis. Ahmad M, et al. **South Med J** 1999 Apr; 92(4):406–8 (11 ref.)

[Hepato-splenic and peritoneal tuberculosis. A difficult diagnosis] Saed G, et al. **Minerva Med** 1998 Oct; 89(10):371–7 (39 ref.) (Eng. Abstr.) **(Ita)**

TUBERCULOSIS, PLEURAL

[Tuberculosis in respiratory system--tracheo-bronchial tuberculosis, pulmonary tuberculosis, tuberculous pleurisy and thoracic empyema] Nagao K. **Nippon Rinsho** 1998 Dec; 56(12):3104–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculosis pleurisy] Cho K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):194–7 (15 ref.) **(Jpn)**

DIAGNOSIS

[Role of endoscopy for the diagnosis of tuberculosis] Ozawa S, et al. **Nippon Rinsho** 1998 Dec;56(12):3073–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of pleural tuberculosis (editorial)] Light RW, et al. **Arch Bronconeumol** 1999 Mar;35(3):105–7 (15 ref.) **(Spa)**

TUBERCULOSIS, PULMONARY

see related

PNEUMONECTOMY

Mycobacterium tuberculosis and other mycobacteria. Mault JR, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):227–38, x (26 ref.)

Tuberculosis: an eminently curable enemy. White V, et al. **Practitioner** 1998 Mar;242(1584):192–6 (6 ref.)

Pulmonary tuberculosis: the essentials. Leung AN. **Radiology** 1999 Feb;210(2):307–22 (133 ref.)

Tuberculosis control in less developed countries: can culture explain the whole picture? Jaramillo E. **Trop Doct** 1998 Oct;28(4):196–200 (35 ref.)

[Tuberculosis in respiratory system--tracheo-bronchial tuberculosis, pulmonary tuberculosis, tuberculous pleurisy and thoracic empyema] Nagao K. **Nippon Rinsho** 1998 Dec; 56(12):3104–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary tuberculosis in the elderly] Saito T, et al. **Nippon Rinsho** 1998 Dec;56(12):3181–4 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary tuberculosis] Amitani R. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):188–91 (10 ref.) **(Jpn)**

[Tuberculous hilar lymphadenopathy] Tsuyuguchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):192–3 (5 ref.) **(Jpn)**

[Training of high-skilled researchers at the Saint-Petersburg Research Institute of Phtisiopulmonology in 1994–1998] Vinogradova TI. **Probl Tuberk** 1999;(3):50–2 (0 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Rapidly evolving constrictive tuberculous pericarditis: case presentation and review of the literature. Gobeil F, et al. **Can J Cardiol** 1998 Dec;14(12):1467–9 (14 ref.)

Granuloma formation and tuberculosis transmission in HIV-infected patients [letter] Ledru E, et al. **Immunol Today** 1999 Jul;20(7):336–7 (14 ref.)

The role of mycobacteria in the pathogenesis of sarcoidosis. Hance AJ. **Semin Respir Infect** 1998 Sep;13(3):197–205 (80 ref.)

[Tuberculosis sequelae in Japan] Mori M. **Kekkaku** 1999 Jan; 74(1):1–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of pulmonary tuberculosis complicated with chronic liver disease] Harada H, et al. **Nippon Rinsho** 1998 Dec;56(12):3212–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The coexistence of pulmonary tuberculosis and lung cancer] Kurasawa T. **Nippon Rinsho** 1998 Dec;56(12):3167–70 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and management of tuberculosis in diabetics] Nakamoto A, et al. **Nippon Rinsho** 1998 Dec;56(12):3205–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Respiratory failure based on pulmonary tuberculosis sequelae and its management] Tsurutani H, et al. **Nippon Rinsho** 1998 Dec;56(12):3190–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Harries AD, et al. **Bull World Health Organ** 1998; 76(6):651–62 (85 ref.)

Tuberculosis: 7. Laboratory aspects of diagnosis. Laszlo A. **CMAJ** 1999 Jun 15;160(12):1725–9 (13 ref.)

Tuberculosis: 5. Pediatric disease. Nobert E, et al. **CMAJ** 1999 May 18;160(10):1479–82 (10 ref.)

New tools for the diagnosis of tuberculosis: the perspective of developing countries [see comments] Foulds J, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):778–83 (32 ref.) Comment in: Int J Tuberc Lung Dis 1998 Oct;2(10):777.

Accurately interpreting PPD skin test results. King AB. **Nurse Pract** 1999 May;24(5):144–7 (9 ref.)

Tuberculosis screening: a review and a potential role for prehospital care providers. Cannon GM Jr, et al. **Prehosp Emerg Care** 1999 Jan–Mar;3(1):47–53 (75 ref.)

The role of rapid diagnostic tests for tuberculosis in Singapore. Lim TK. **Singapore Med J** 1999 Apr; 40(4):298–302 (33 ref.)

[Endobronchial tuberculosis presenting as an obstructive tumor in an HIV-1-positive patient. Apropos of a case and review of the literature] Saadoun R, et al. **Rev Med Interne** 1998 May;19(5):344–7 (9 ref.) (Eng. Abstr.) **(Fre)**

[Role of endoscopy for the diagnosis of tuberculosis] Ozawa S, et al. **Nippon Rinsho** 1998 Dec;56(12):3073–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Harries AD, et al. **Bull World Health Organ** 1998; 76(6):651–62 (85 ref.)

Optimizing tuberculosis control in the inner city [editorial; comment] FitzGerald JM. **CMAJ** 1999 Mar 23;160(6):821–2 (14 ref.) Comment on: CMAJ 1999 Mar 23;160(6):789–94. Comment on: CMAJ 1999 Mar 23;160(6):799–802.

Tuberculosis: 9. Treatment. Hershfield E. **CMAJ** 1999 Aug 24;161(4):405–11 (49 ref.)

Tuberculosis: 5. Pediatric disease. Nobert E, et al. **CMAJ** 1999 May 18;160(10):1479–82 (10 ref.)

Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Veen J, et al. **Eur Respir J** 1998 Aug;12(2):505–10 (27 ref.)

Drug resistant tuberculosis in adults and its treatment [see comments] Drobniewski F. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):314–8 (18 ref.) Comment in: J R Coll Physicians Lond 1998 Sep–Oct;32(5):491.

Tuberculosis in patients infected with the human immunodeficiency virus. Gerard M. **Monaldi Arch Chest Dis** 1998 Dec;53(6):688–92 (31 ref.)

Ocular toxicity from ethambutol: a review of four cases and recommended precautions [see comments] Sivakumaran P, et al. **N Z Med J** 1998 Nov 13;111(1077):428–30 (18 ref.) Comment in: N Z Med J 1999 Feb 26;112(1082):57–8.

Therapeutic drug monitoring in antituberculosis chemotherapy [see comments] Yew WW. **Ther Drug Monit** 1998 Oct;20(5):469–72 (31 ref.) Comment in: Ther Drug Monit 1999 Aug;21(4):426–7.

Directly observed therapy (DOT) for tuberculosis: why, when, how and if? Ormerod LP. **Thorax** 1999 Aug;54 Suppl 2:S42–5 (53 ref.)

[An update on the antibiotic therapy of tuberculosis] Rossi G. **Recenti Prog Med** 1999 May;90(5):241–3 (28 ref.) **(Ita)**

[Short-course chemotherapy of tuberculosis with pyrazinamide] Asai S, et al. **Nippon Rinsho** 1998 Dec; 56(12):3087–90 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment and prognosis of nontuberculous mycobacterial pulmonary infection] Kurashima A. **Nippon Rinsho** 1998 Dec;56(12):3199–204 (5 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Pulmonary tuberculosis. Hirsch CS, et al. **Curr Opin Pulm Med** 1999 May;5(3):143–50 (51 ref.)

Tuberculosis today: evolution of a disease [editorial] Fiorani CM, et al. **Eur Rev Med Pharmacol Sci** 1998 Jan–Feb; 2(1):3–9 (47 ref.)

Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. De Cock KM, et al. **Int J Tuberc Lung Dis** 1999 Jun;3(6):457–65 (54 ref.)

The effects of poverty and ageing on the increase in tuberculosis. Davies PD. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):168–71 (12 ref.)

Using conventional and molecular epidemiological analyses to target tuberculosis control interventions in a low incidence area. Hopewell PC. **Novartis Found Symp** 1998; 217:42–54; discussion 54–6 (23 ref.)

Tuberculosis control in the face of the HIV epidemic. Harries AD, et al. **Trop Doct** 1998 Oct;28(4):243–5 (5 ref.)

[Re-emergence of tuberculosis and socioeconomic uncertainty] Poinsignon Y, et al. **Rev Med Interne** 1998 Sep;19(9):649–57 (39 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary tuberculosis: data of general somatic hospital] Shul'ga IA, et al. **Probl Tuberk** 1998;(6):4–7 (45 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

[Miliary pneumonia after the intravesical BCG therapy of a superficial urothelial carcinoma of the bladder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Aug 27; 124(34–35):993–7 (21 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Host genetic susceptibility to human tuberculosis. Bellamy RJ, et al. **Novartis Found Symp** 1998;217:3–13; discussion 13–23 (37 ref.)

Using conventional and molecular epidemiological analyses to target tuberculosis control interventions in a low incidence area. Hopewell PC. **Novartis Found Symp** 1998; 217:42–54; discussion 54–6 (23 ref.)

IMMUNOLOGY

Cytokine/chemokine cascades in immunity to tuberculosis. Orme IM, et al. **Immunol Today** 1999 Jul;20(7):307–12 (57 ref.)

Signals that regulate the host response to Mycobacterium tuberculosis. Beyers AD, et al. **Novartis Found Symp** 1998; 217:145–57; discussion 157–9 (40 ref.)

Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Rook GA, et al. **Novartis Found Symp** 1998;217:73–87; discussion 87–98 (36 ref.)

The immune responses in tuberculosis: role for pathogenesis, diagnosis and prevention. Lagrange PH, et al. **Pediatr Pulmonol Suppl** 1999;18:136–9 (12 ref.)

[Immunology of tuberculosis: current status] Litvinov VI, et al. **Vestn Ross Akad Med Nauk** 1999;(7):8–11 (14 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Identification of Mycobacterium shimoidei by molecular techniques: case report and summary of the literature. Mayall B, et al. **Int J Tuberc Lung Dis** 1999 Feb;3(2):169–73 (23 ref.)

[Pulmonary infections during AIDS] Deslée G, et al. **Presse Med** 1998 May 23–30;27(19):927–33 (40 ref.) **(Fre)**

MORTALITY

[Clinical epidemiology and treatment of tuberculosis in elderly patients] Janssens JP, et al. **Schweiz Med Wochenschr** 1999 Jan 23;129(3):80–9 (37 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Accurately interpreting PPD skin test results. King AB. **Nurse Pract** 1999 May;24(5):144–7 (9 ref.)

PREVENTION & CONTROL

Catching patients: tuberculosis and detention in the 1990s. Lerner BH. **Chest** 1999 Jan;115(1):236–41 (47 ref.)

Tuberculosis: 10. Prevention. Menzies D, et al. **CMAJ** 1999 Sep 21;161(6):717–24 (61 ref.)

Vaccines, genes and trials. Fine PE. **Novartis Found Symp** 1998;217:57–69; discussion 69–72 (32 ref.)

Tuberculosis control in the face of the HIV epidemic. Harries AD, et al. **Trop Doct** 1998 Oct;28(4):243–5 (5 ref.)

[Evaluation of new programs to prevent tuberculosis infection. I. Chemoprophylaxis] Prados C, et al. **An Med Interna** 1998 Dec;15(12):664–8 (35 ref.) (Eng. Abstr.) **(Spa)**

[An evaluation of new prevention programs for tuberculous infection. II. BCG vaccination] Prados C, et al. **An Med Interna** 1999 Jan;16(1):38–40 (11 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Roentgenological diagnosis of pulmonary mycobacteriosis] Kurasawa T. **Nippon Rinsho** 1998 Dec;56(12):3062–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Differential diagnosis of pulmonary tuberculosis] Morishita M, et al. **Nippon Rinsho** 1998 Dec;56(12):3162–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Multiple pulmonary nodules as the form of presentation of tuberculosis in the adult (letter)] García de Lucas MD, et al. **An Med Interna** 1999 Jul;16(7):380–1 (10 ref.) **(Spa)**

REHABILITATION

[Ambulatory follow-up of patients with respiratory tract tuberculosis and ways of its improvement] Muminov TA, et al. **Probl Tuberk** 1999;(4):49–50 (6 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Rook GA, et al. **Novartis Found Symp** 1998;217:73–87; discussion 87–98 (36 ref.)

[Management of the patient with a bacilliferous pulmonary tuberculosis. Recommendations and reasoning] Veber B. **Ann Fr Anesth Reanim** 1998;17(10):1261–6 (35 ref.) **(Fre)**

TUBERCULOSIS, PULMONARY

[Home mechanical ventilation as a treatment of the sequelae of tuberculosis surgery] Prats Soro E, et al. **An Med Interna** 1999 Jan;16(1):35–7 (12 ref.) (Eng. Abstr.) **(Spa)**

TRANSMISSION

[A consensus document on the study of the contacts of tuberculosis patients. The Contacts Study Group of the Research Unit on Tuberculosis in Barcelona (UITB)] **Med Clin (Barc)** 1999 Feb 6;112(4):151–6 (50 ref.) **(Spa)**

TUBERCULOSIS, RENAL

[Tuberculosis and the kidney] Gusmão L, et al. **Acta Med Port** 1998 Dec;11(12):1107–11 (31 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

[Tuberculosis and renal cancer] Conde Redondo C, et al. **Actas Urol Esp** 1999 Jul–Aug;23(7):617–20 (9 ref.) (Eng. Abstr.) **(Spa)**

TUBERCULOSIS, SPINAL

DIAGNOSIS

Intramedullary tuberculoma of the spinal cord. Case report and review of the literature. Ratliff JK, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):125–8 (26 ref.)

Atypical forms of spinal tuberculosis: case report and review of the literature. Naim-Ur-Rahman, et al. **Surg Neurol** 1999 Jun;51(6):602–7 (19 ref.)

SURGERY

[Tuberculosis of the spine--surgical treatment] Yokozeki K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):184–7 (10 ref.) **(Jpn)**

TUBERCULOSIS, SPLENIC

DIAGNOSIS

[Hepato-splenic and peritoneal tuberculosis. A difficult diagnosis] Saed G, et al. **Minerva Med** 1998 Oct; 89(10):371–7 (39 ref.) (Eng. Abstr.) **(Ita)**

TUBERCULOSIS, UROGENITAL

[Genitourinary tuberculosis] Yokoyama M. **Nippon Rinsho** 1998 Dec;56(12):3134–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Urinary tuberculosis] Goto T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):204–7 (5 ref.) **(Jpn)**

PATHOLOGY

[Epididymal manifestations of urogenital tuberculosis] Gueye SM, et al. **Dakar Med** 1996;41(1):55–8 (20 ref.) (Eng. Abstr.) **(Fre)**

TUBERCULOSIS VACCINES see **BCG VACCINE**

TUBERCULOSTATIC AGENTS see **ANTITUBERCULAR AGENTS**

TUBEROUS SCLEROSIS

The tuberous sclerosis complex: a comprehensive review. Weiner DM, et al. **J Am Coll Surg** 1998 Nov;187(5):548–61 (85 ref.)

[Tuberous sclerosis] Hino O. **No To Shinkei** 1999 Jan; 51(1):11–6 (21 ref.) **(Jpn)**

[Tuberous sclerosis. Apropos of 22 cases] León P, et al. **Rev Med Univ Navarra** 1997 Jul–Sep;41(3):152–8 (47 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Autism and tuberous sclerosis. Smalley SL. **J Autism Dev Disord** 1998 Oct;28(5):407–14 (45 ref.)

Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. Hancock E, et al. **J Child Neurol** 1999 Feb;14(2):71–4 (26 ref.)

Intraosseous fibrous lesions of the jaws: a manifestation of tuberous sclerosis. Damm DD, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):334–40 (21 ref.)

Tuberous sclerosis with intracardiac rhabdomyoma in a fetus with trisomy 21: case report and review of literature. Krapp M, et al. **Prenat Diagn** 1999 Jul;19(7):610–3 (26 ref.)

[A case of renal cell carcinoma associated with tuberous sclerosis] Kakimoto K, et al. **Hinyokika Kiyo** 1999 May; 45(5):335–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Ventricular outflow tract obstruction by cardiac tumors during ACTH therapy of an infant with tuberous sclerosis] Yoshimi S, et al. **No To Hattatsu** 1999 Mar;31(2):165–70 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Atrial fibrillation and the Wolff–Parkinson—White syndrome in a 68-year-old patient with tuberous sclerosis] López-Mínguez JR, et al. **Rev Esp Cardiol** 1999 Mar; 52(3):207–10 (10 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. Roach ES, et al. **J Child Neurol** 1999 Jun; 14(6):401–7 (38 ref.)

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. Roach ES, et al. **J Child Neurol** 1998 Dec;13(12):624–8 (28 ref.)

Does the tuberous sclerosis complex include intracranial aneurysms? A case report with a review of the literature. Beltramello A, et al. **Pediatr Radiol** 1999 Mar;29(3):206–11 (40 ref.)

Diagnosis and management of tuberous sclerosis complex. Franz DN. **Semin Pediatr Neurol** 1998 Dec;5(4):253–68 (65 ref.)

Parallels between tuberous sclerosis complex and neurofibromatosis 1: common threads in the same tapestry. Gutmann DH. **Semin Pediatr Neurol** 1998 Dec;5(4):276–86 (74 ref.)

Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Neumann HP, et al. **Semin Pediatr Neurol** 1998 Dec;5(4):269–75 (49 ref.)

GENETICS

Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Jones AC, et al. **Am J Hum Genet** 1999 May; 64(5):1305–15 (47 ref.)

Tuberous sclerosis-related gene expression in normal and dysplastic brain. Vinters HV, et al. **Epilepsy Res** 1998 Sep; 32(1–2):12–23 (51 ref.)

Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. Roach ES, et al. **J Child Neurol** 1999 Jun; 14(6):401–7 (38 ref.)

The genetic basis of tuberous sclerosis. Young J, et al. **Mol Med Today** 1998 Jul;4(7):313–9 (48 ref.)

New insights into the tumor suppression function of P27(kip1) [comment] Clurman BE, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15158–60 (56 ref.) Comment on: Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15653–8.

TSC2 gene mutant (Eker) rat model of a Mendelian dominantly inherited cancer. Hino O, et al. **Prog Exp Tumor Res** 1999;35:95–108 (52 ref.)

PATHOLOGY

The neuropathology of selected neurocutaneous diseases. Nelson JS. **Semin Pediatr Neurol** 1995 Sep;2(3):192–9 (42 ref.)

TUBULIN

ANTAGONISTS & INHIBITORS

Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Shi Q, et al. **Curr Pharm Des** 1998 Jun;4(3):219–48 (211 ref.)

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Dumontet C, et al. **J Clin Oncol** 1999 Mar;17(3):1061–70 (116 ref.)

CHEMISTRY

Tubulin structure: insights into microtubule properties and functions. Downing KH, et al. **Curr Opin Struct Biol** 1998 Dec;8(6):785–91 (50 ref.)

Gamma-tubulin complexes and their interaction with microtubule-organizing centers. Wiese C, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):250–9 (75 ref.)

Gamma-tubulin complexes: size does matter. Jeng R, et al. **Trends Cell Biol** 1999 Sep;9(9):339–42 (36 ref.)

METABOLISM

Microtubule treadmilling: what goes around comes around. Margolis RL, et al. **Bioessays** 1998 Oct;20(10):830–6 (55 ref.)

Gamma-tubulin complexes and their interaction with microtubule-organizing centers. Wiese C, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):250–9 (75 ref.)

General features of the recognition by tubulin of colchicine and related compounds. Engelborghs Y. **Eur Biophys J** 1998;27(5):437–45 (51 ref.)

PHYSIOLOGY

[Calcium inhibition] Nakamura A, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1870–6 (68 ref.) **(Jpn)**

TUBULOINTERSTITIAL NEPHRITIS see **NEPHRITIS, INTERSTITIAL**

TUCUXI DOLPHIN see **DOLPHINS**

TUFTSIN

DEFICIENCY

[Congenital familial tuftsin deficiency] Otsuka T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):67–9 (11 ref.) **(Jpn)**

TULAREMIA

[Francisella pneumonia] Masuda G. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):387–8 (3 ref.) **(Jpn)**

[Tularemia (editorial)] Eiros Bouza JM, et al. **Rev Clin Esp** 1998 Dec;198(12):785–8 (50 ref.) **(Spa)**

IMMUNOLOGY

[Tularemia, "volume" two] Macela A. **Epidemiol Mikrobiol Imunol** 1998 Aug;47(3):103–20 (122 ref.) (Eng. Abstr.) **(Cze)**

TULLIDORA see **RHAMNUS**

TUMESCENCE, PENILE see **PENILE ERECTION**

TUMOR ANTIBODIES see **ANTIBODIES, NEOPLASM**

TUMOR ANTIGENS see **ANTIGENS, NEOPLASM**

TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

TUMOR CELLS, CULTURED

see related
COCULTURE
DRUG SCREENING ASSAYS, ANTITUMOR

[Tumor radiosensitivity tests: state of assays in 1998] Girinsky T, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):530–3 (24 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

History and classification of human leukemia–lymphoma cell lines. Drexler HG, et al. **Leuk Lymphoma** 1998 Oct; 31(3–4):305–16 (128 ref.)

CYTOLOGY

[Stimulation of the proliferation of metastatic cancer cells by environmental growth factors and cytokines] Yamori T, et al. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1209–13 (12 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro- and cis-diiodo-Pt(IV)-ethylenediamines. Kratochwil NA, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):279–85 (30 ref.)

Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs. Xia Z, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):286–94 (43 ref.)

Use of Syrian hamster embryo and BALB/c 3T3 cell transformation for assessing the carcinogenic potential of chemicals. LeBoeuf RA, et al. **IARC Sci Publ** 1999; (146):409–25 (82 ref.)

RADIATION EFFECTS

[Biological principles of chemoradiotherapy] Bourhis J, et al. **Cancer Radiother** 1998 Dec;2(6):657–62 (41 ref.) (Eng. Abstr.) **(Fre)**

TUMOR CELLS, EMBOLIC see **NEOPLASM CIRCULATING CELLS**

TUMOR-DERIVED ACTIVATED CELLS see **LYMPHOCYTES, TUMOR-INFILTRATING**

TUMOR ESCAPE

see related
IMMUNE TOLERANCE

Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Salazar-Onfray F. **Med Oncol** 1999 Jul;16(2):86–94 (97 ref.)

GENETICS

[Genetic techniques to overcome antitumor anergy] Dall P. **Zentralbl Gynakol** 1999;121(4):198–201 (14 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Tumor escape from immune surveillance. Costello RT, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):83–8 (58 ref.)

HLA and cancer: from research to clinical impact. Ruiz-Cabello F, et al. **Immunol Today** 1998 Dec; 19(12):539–42 (15 ref.)

Immunosuppressive factors: role in cancer development and progression. Botti C, et al. **Int J Biol Markers** 1998 Apr–Jun;13(2):51–69 (221 ref.)

[Immunologic and tumor biology aspects of placentation in humans] Marzusch K, et al. **Zentralbl Gynakol** 1999;

121(4):206-13 (99 ref.) (Eng. Abstr.) **(Ger)**

TUMOR-INFILTRATING LYMPHOCYTES see **LYMPHOCYTES, TUMOR-INFILTRATING**

TUMOR INITIATORS see **CARCINOGENS**

TUMOR LYSIS SYNDROME

see related
TUMOR NECROSIS FACTOR

ETIOLOGY

Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Castro MP, et al. **Cancer** 1999 Mar 1;85(5):1055-9 (40 ref.)

Fatal tumor lysis syndrome and gastric hemorrhage associated with metastatic small-cell lung carcinoma. Marinella MA. **Med Pediatr Oncol** 1999 Jun;32(6):464-5 (10 ref.)

NURSING

Tumor lysis syndrome. Ezzone SA. **Semin Oncol Nurs** 1999 Aug;15(3):202-8 (15 ref.)

Oncologic emergencies in the patient with lymphoma. Hogan DK, et al. **Semin Oncol Nurs** 1998 Nov;14(4):312-20 (38 ref.)

THERAPY

Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature. Schelling JR, et al. **Ren Fail** 1998 Jul;20(4):635-44 (32 ref.)

TUMOR MARKERS, BIOCHEMICAL see **TUMOR MARKERS, BIOLOGICAL**

TUMOR MARKERS, BIOLOGICAL

Nuclear matrix proteins and their potential applications to diagnostic pathology. Hughes JH, et al.
Am J Clin Pathol 1999 Feb;111(2):267-74 (44 ref.)

Protective role of wheat bran fiber: data from marker trials. Earnest DL, et al. **Am J Med** 1999 Jan 25;106(1A):32S-37S (34 ref.)

Biomarkers in carcinoma of the cervix: emphasis on tissue-related factors and their potential prognostic factors. Busmanis I. **Ann Acad Med Singapore** 1998 Sep;27(5):671-5 (47 ref.)

Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Salomon DS, et al. **Bioessays** 1999 Jan;21(1):61-70 (71 ref.)

Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Lo Coco F, et al. **Blood** 1999 Jul 1;94(1):12-22 (119 ref.)

New metabolic-endocrine risk markers in endometrial cancer. Stoll BA. **Br J Obstet Gynaecol** 1999 May; 106(5):402-6 (84 ref.)

Steroid hormone receptors in breast cancer management. Osborne CK. **Breast Cancer Res Treat** 1998;51(3):227-38 (76 ref.)

Polyps as biomarkers for colorectal neoplasia. Tobi M.
Front Biosci 1999 Mar 15;4:D329-38 (95 ref.)

Surface marker abnormalities in myelodysplastic syndromes. Elghetany MT. **Haematologica** 1998 Dec;83(12):1104-15 (105 ref.)

Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Byers HR, et al.
Hematol Oncol Clin North Am 1998 Aug;12(4):717-35 (65 ref.)

Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens. Kirollos MM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(4):228-35 (60 ref.)

Bladder tumor markers: need, nature and application. 1. Nucleus-based markers. Kirollos MM, et al.
Int Urogynecol J Pelvic Floor Dysfunct 1998;9(4):221-7 (68 ref.)

Serum CD44 in non-Hodgkin's lymphoma. Ristamäki R, et al. **Leuk Lymphoma** 1999 May;33(5-6):433-40 (53 ref.)

Hematopathology: integration of morphologic features and biologic markers for diagnosis. Jaffe ES. **Mod Pathol** 1999 Feb;12(2):109-15 (36 ref.)

Tumor progression, micrometastasis, and genetic instability tracked with histochemical marker genes. Culp LA, et al. **Prog Histochem Cytochem** 1998;33(3-4):XI-XV, 329-48 (35 ref.)

Citrate in the diagnosis of prostate cancer. Costello LC, et al. **Prostate** 1999 Feb 15;38(3):237-45 (34 ref.)

Determination of clinical utility of tumor markers: a tumor marker utility grading system. Hayes DF.
Recent Results Cancer Res 1998;152:71-85 (10 ref.)

Markers of androgen-independent progression of prostatic carcinoma. Daliani D, et al. **Semin Oncol** 1999 Aug; 26(4):399-406 (112 ref.)

Prognostic markers in rectal carcinoma. Jessup JM, et al. **Semin Surg Oncol** 1998 Sep;15(2):131-40 (83 ref.)

[Study on the individual sensitivity to some tumors and their related biological markers in residents in Guangdong Province] Zhang Q, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Dec; 18(6):379-80 (7 ref.) **(Chi)**

[Molecular biologic markers and cancer risk assessment] Zi XL, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug;18(4):244-6 (19 ref.) **(Chi)**

[Possibilities, failures and prospects of studies on tumor markers in oncological clinics. 1. (lecture)] Kushlinskii NE. **Klin Lab Diagn** 1999 Mar;(3):25-32 (9 ref.) **(Rus)**

ANALYSIS

Tumor progression, early diagnosis and prognosis of melanoma. Elder D. **Acta Oncol** 1999;38(5):535-47 (124 ref.)

In search of a positive immunohistochemical marker for mesothelioma: an update. Ordóñez NG.
Adv Anat Pathol 1998 Jan;5(1):53-60 (56 ref.)

Tumor markers: reclassification and new approaches to evaluation. Aziz KJ. **Adv Clin Chem** 1998;33:169-99 (39 ref.)

Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Ordóñez NG.
Am J Surg Pathol 1998 Nov;22(11):1314-27 (98 ref.)

Proteases in cutaneous melanoma. Ferrier CM, et al.
Ann Med 1998 Oct;30(5):431-42 (86 ref.)

Telomerase in cancer: clinical applications. Urquidi V, et al. **Ann Med** 1998 Oct;30(5):419-30 (179 ref.)

Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Zucker S, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:212-27 (75 ref.)

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Lambrechts AC, et al.
Ann Oncol 1998 Dec;9(12):1269-76 (60 ref.)

Role of tumour markers, cytogenetics. Lamerz R.
Ann Oncol 1999;10 Suppl 4:145-9 (53 ref.)

Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. López-Guillermo A, et al. **Ann Oncol** 1998 Aug;9(8):849-55 (38 ref.)

Usefulness of novel tumour markers. Rhodes JM.
Ann Oncol 1999;10 Suppl 4:118-21 (22 ref.)

Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer. Tascilar M, et al. **Ann Oncol** 1999;10 Suppl 4:107-10 (70 ref.)

Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2811-5 (39 ref.)

Quality requirements and control: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2791-4 (12 ref.)

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Hayes DF, et al. **Breast Cancer Res Treat** 1998;52(1-3):305-19 (19 ref.)

HER-2/neu as a predictive marker of response to breast cancer therapy. Pegram MD, et al.
Breast Cancer Res Treat 1998;52(1-3):65-77 (39 ref.)

Immunohistochemical study of the expression of human chorionic gonadotropin-beta in oral squamous cell carcinoma. Bhalang K, et al. **Cancer** 1999 Feb 15; 85(4):757-62 (30 ref.)

Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Ravaioli A, et al. **Cell Prolif** 1998 Jun-Aug;31(3-4):113-26 (96 ref.)

Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment. van Delft JH, et al. **Crit Rev Toxicol** 1998 Sep;28(5):477-510 (176 ref.)

Immunohistochemistry in diagnostic dermatopathology. Hudson AR, et al. **Dermatol Clin** 1999 Jul;17(3):667-89, x (303 ref.)

Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Reed JA, et al. **Dermatol Clin** 1999 Jul;17(3):631-43 (108 ref.)

Bronchogenic cyst of the esophagus with high tumor marker levels--a case report and review of the literature. Ott K, et al. **Dis Esophagus** 1998 Apr;11(2):130-3 (24 ref.)

Premalignant breast lesions: role for biological markers in predicting progression to cancer. Stoll BA.
Eur J Cancer 1999 May;35(5):693-7 (70 ref.)

The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials. Crawford ED.
Eur Urol 1999;35(5-6):511-4 (14 ref.)

Chemoprevention of prostate cancer: concepts and strategies. Kelloff GJ, et al. **Eur Urol** 1999;35(5-6):342-50 (37 ref.)

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Moul JW.
Eur Urol 1999;35(5-6):399-407 (67 ref.)

PIN I-III: when should we interfere? Newling D.
Eur Urol 1999;35(5-6):504-7 (9 ref.)

Tissue markers of colon cancer risk. Ahnen DJ.
Gastrointest Endosc 1999 Mar;49(3 Pt 2):S50-9 (18 ref.)

Angiogenesis-related markers and their potential clinical significance. Malone C, et al. **Int J Biol Markers** 1999 Jan-Mar;14(1):3-7 (33 ref.)

CA 125 in biological fluids. Molina R, et al.
Int J Biol Markers 1998 Oct-Dec;13(4):224-30 (29 ref.)

Proliferation markers in tumours: interpretation and clinical value. van Diest PJ, et al. **J Clin Pathol** 1998 Oct; 51(10):716-24 (156 ref.)

Expression of sulfated carbohydrate in Barrett's esophagus: sugar for sure? [editorial; comment] Adachi M, et al.
J Gastroenterol 1998 Dec;33(6):914-5 (10 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):811-5.

Tumor markers. Introduction. Abelev GI, et al.
Semin Cancer Biol 1999 Apr;9(2):61-5 (32 ref.)

Biochemical diagnosis of neuroendocrine GEP tumor. Oberg K. **Yale J Biol Med** 1997 Sep-Dec;70(5-6):501-8 (21 ref.)

[Progresses in the study of laboratory medicine in China, 1997] Yang Z. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):934-5 (0 ref.) **(Chi)**

[Markers of prostatic carcinoma] Safařík L. **Cas Lek Cesk** 1998 Aug 31;137(17):525-7 (22 ref.) (Eng. Abstr.) **(Cze)**

[Contribution of immunohistochemistry to diagnosis of cutaneous tumors] Kanitakis J, et al.
Ann Dermatol Venereol 1998 May;125(5):354-69 (143 ref.) **(Fre)**

[New diagnostic tests for urothelial tumors of the bladder] Irani J. **Prog Urol** 1998 Sep;8(4):481-6 (23 ref.) (Eng. Abstr.) **(Fre)**

[Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast] Nizze H, et al.
Zentralbl Chir 1998;123 Suppl 5:14-8 (46 ref.) (Eng. Abstr.) **(Ger)**

[Selected biochemical tumor markers in clinical monitoring of head and neck neoplasm progression] Adamiak G.
Otolaryngol Pol 1999;53(3):359-60 (181 ref.) **(Pol)**

[Telomerase and telomeres in lung neoplasms--biological and clinical significance] Kuchta G, et al.
Pneumonol Alergol Pol 1998;66(11-12):568-73 (25 ref.) **(Pol)**

[The role of cystatin in neoplastic progression and diagnosis] Warwas M, et al. **Postepy Hig Med Dosw** 1998;52(5):515-26 (59 ref.) (Eng. Abstr.) **(Pol)**

[Possibilities, failures and prospects of studies on tumor markers in oncological clinics. 1. (lecture)] Kushlinskii NE. **Klin Lab Diagn** 1999 Apr;(4):25-32 (10 ref.) **(Rus)**

BIOSYNTHESIS

Relations of nm23 expression to clinicopathologic variables and proliferative activity of gastric cancer lesions. Nakamura T, et al. **Cancer Detect Prev** 1998;22(3):246-50 (23 ref.)

An autopsy case of hepatoid carcinoma of the ovary with PIVKA-II production: immunohistochemical study and literature review. Senzaki H, et al. **Pathol Int** 1999 Feb; 49(2):164-9 (22 ref.)

BLOOD

CA 15-3 and related mucins as circulating markers in breast cancer. Duffy MJ. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):579-86 (46 ref.)

Review of circulating tumor markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene. Wu JT. **Ann Clin Lab Sci** 1999 Apr-Jun;29(2):106-11 (33 ref.)

PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases [see comments] Barry MJ.
Ann Oncol 1998 Dec;9(12):1279-82 (20 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

PSA screening for prostate cancer: the current controversy [see comments] de Koning HJ, et al. **Ann Oncol** 1998 Dec; 9(12):1293-6 (19 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

Screening for prostate cancer [see comments] Neal DE, et al. **Ann Oncol** 1998 Dec;9(12):1289-92 (30 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

PSA screening--current controversy [see comments] Svetec D, et al. **Ann Oncol** 1998 Dec;9(12):1283-8 (42 ref.) Comment in: Ann Oncol 1998 Dec;9(12):1263-4.

Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2817-9 (24 ref.)

Tumour markers in germ cell cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2795-8 (18 ref.)

Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2799-801 (40 ref.)

Tumour markers in breast cancer--EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2803-5 (41 ref.)

Tumour markers in gynaecological cancers--EGTM recommendations. European Group on Tumour Markers. **Anticancer Res** 1999 Jul-Aug;19(4A):2807-10 (27 ref.)

Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Stearns V, et al.
Breast Cancer Res Treat 1998;52(1-3):239-59 (112 ref.)

Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Bidart JM, et al.
Clin Chem 1999 Oct;45(10):1695-707 (164 ref.)

Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression [letter] [see comments] Kos J, et al. **Clin Chem** 1998 Dec;44(12):2556-7 (7 ref.) Comment in: Clin Chem 1999 May;45(5):718-9.

New prognostic factors in melanoma: mRNA tumour markers. Keilholz U. **Eur J Cancer** 1998 Jul;34 Suppl 3:S37-41 (37 ref.)

Significance of tissue polypeptide specific antigen (TPS) in

diagnosis and monitoring of treatment in ovarian cancer. Zygmunt A, et al. **Eur J Gynaecol Oncol** 1998;19(5):484–6 (19 ref.)

Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection? Anguita E, et al. **Haematologica** 1998 Aug;83(8):744–7 (16 ref.)

CA 125: the past and the future. Bast RC Jr, et al. **Int J Biol Markers** 1998 Oct–Dec;13(4):179–87 (40 ref.)

Review of clinical studies of CA 27.29 in breast cancer management. Beveridge RA. **Int J Biol Markers** 1999 Jan–Mar;14(1):36–9 (11 ref.)

Blood-borne tumour markers--a sideways look. Price MR, et al. **Int J Biol Markers** 1999 Jan–Mar;14(1):27–8 (0 ref.)

TPS monitoring in metastatic breast cancer. van Dalen A. **Int J Biol Markers** 1999 Jan–Mar;14(1):45–8 (21 ref.)

Spontaneous regression of hepatocellular carcinoma. Misawa K, et al. **J Gastroenterol** 1999 Jun;34(3):410–4 (15 ref.)

Detection and clinical importance of micrometastatic disease. Pantel K, et al. **J Natl Cancer Inst** 1999 Jul 7;91(13):1113–24 (180 ref.)

Tumor markers in retinoblastoma. Mul D, et al. **Med Pediatr Oncol** 1999 Feb;32(2):146–7 (9 ref.)

Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Smith BD, et al. **Radiat Oncol Investig** 1999; 7(3):125–44 (134 ref.)

Race and serum prostate-specific antigen levels: current status and future directions. Abdalla I, et al. **Semin Urol Oncol** 1998 Nov;16(4):207–13 (55 ref.)

The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy. de la Taille A, et al. **Semin Urol Oncol** 1998 Aug;16(3):137–44 (74 ref.)

Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Spencer CA, et al. **Thyroid** 1999 May;9(5):435–41 (11 ref.)

SCC antigen in malignant and nonmalignant squamous lesions. Torre GC. **Tumour Biol** 1998;19(6):517–26 (69 ref.)

[Bibliographic analysis of the use of laboratory blood parameters for the prognosis of primary lung cancer] Watine J, et al. **Ann Biol Clin (Paris)** 1999 Jan–Feb; 57(1):57–68 (123 ref.) (Eng. Abstr.) **(Fre)**

[Serum markers for breast and colorectal cancers. Working group reunited by the National Health Agency for Accreditation and Evaluation (NHAAE)] Mlika-Cabanne N, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):442–57 (167 ref.) **(Fre)**

[Good clinical use of serum tumor markers] Boussen H, et al. **Tunis Med** 1998 Feb;76(2):1020–6 (30 ref.) **(Fre)**

[S-100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience] Jäckel A, et al. **Hautarzt** 1999 Apr;50(4):250–6 (35 ref.) (Eng. Abstr.) **(Ger)**

[The relative importance of humoral tumor markers in the diagnosis and therapy of primary bronchial carcinoma and pulmonary metastasis] Heckmayr M. **Pneumologie** 1999 May;53(5):276–82 (86 ref.) **(Ger)**

[CA19-9 has no value as a tumor marker in obstructive jaundice] Peterli R, et al. **Schweiz Med Wochenschr** 1999 Jan 23;129(3):77–9 (14 ref.) (Eng. Abstr.) **(Ger)**

[Tumor marker squamous cell carcinoma antigen] Lavie O, et al. **Harefuah** 1998 Sep;135(5–6):222–5 (22 ref.) **(Heb)**

[Limitations on the interpretation of prostate-specific antigen serum levels] Sciarra A, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):105–12 (27 ref.) (Eng. Abstr.) **(Ita)**

[Intralobar pulmonary sequestration presenting increased serum CEA, CA 19-9, and CA 125, and associated with asymptomatic pulmonary aspergillosis] Sekiya M, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 May;37(5):433–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Respiratory tract diseases and tumor markers] kono N. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):141–7 (12 ref.) **(Jpn)**

[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer] Akino H, et al. **Nippon Rinsho** 1998 Aug;56(8):2003–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The significance and limitation of prostate specific antigen in the mass screening for prostate cancer] Imai K, et al. **Nippon Rinsho** 1998 Aug;56(8):1994–7 (7 ref.) (Eng. Abstr.) **(Jpn)**

[The clinical value of prostate-specific antigen velocity as a method for prostate cancer detection] Ito K, et al. **Nippon Rinsho** 1998 Aug;56(8):2021–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The efficacy of PSA density for the early detection of prostate cancer] Kanehara H, et al. **Nippon Rinsho** 1998 Aug;56(8):2012–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Standardization of PSA assays] Kuriyama M. **Nippon Rinsho** 1998 Aug;56(8):1998–2002 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Percent free prostate-specific antigen: a marker for detection of prostate cancer] Miyanaga N, et al. **Nippon Rinsho** 1998 Aug;56(8):2006–11 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status] Nakata S, et al. **Nippon Rinsho** 1998 Aug;56(8):2026–30 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer] Saito Y. **Nippon Rinsho** 1998 Aug;56(8):1989–93 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case of adenosquamous pancreatic cancer with high serum level of parathyroid related protein in which both primary and liver metastatic lesions showed remarkable cystic changes] Hyodo N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):181–8 (13 ref.) **(Jpn)**

CLASSIFICATION

Tumor markers: reclassification and new approaches to evaluation. Aziz KJ. **Adv Clin Chem** 1998;33:169–99 (39 ref.)

Molecular markers of B-cell lymphoma. Stevenson GT, et al. **Semin Cancer Biol** 1999 Apr;9(2):139–47 (38 ref.)

DIAGNOSTIC USE

Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Gregory JJ Jr, et al. **Drugs** 1999 Apr;57(4):463–7 (9 ref.)

[Evidence of new diagnostic and prognostic human astrocytoma tumor markers. Potential therapeutic applications. I] Salmon I. **Bull Mem Acad R Med Belg** 1998; 153(3):199–207 (8 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors of infiltrating bladder tumors] Durdux C, et al. **Cancer Radiother** 1998 Sep–Oct;2(5):491–8 (88 ref.) (Eng. Abstr.) **(Fre)**

[From dysplasia to cancer: cytologic, histopathologic and molecular aspects] Vignaud JM. **Rev Mal Respir** 1999 Jan; 16 Suppl 3:S107–11 (18 ref.) **(Fre)**

[Telomerase--its potential and limits for clinical applicability] Hoos A, et al. **Dtsch Med Wochenschr** 1999 Feb 26; 124(8):223–30 (73 ref.) **(Ger)**

GENETICS

Role of p53 assessment in management of Barrett's esophagus. Kubba AK, et al. **Dig Dis Sci** 1999 Apr;44(4):659–67 (77 ref.)

Tumour markers - new aspects of an old discussion? Fleischhacker M, et al. **Eur J Med Res** 1999 Apr 27; 4(4):144–8 (45 ref.)

Translational infidelity and human cancer: role of the PTI-1 oncogene. Gopalkrishnan RV, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):151–62 (47 ref.)

Molecular genetic characteristics of lung cancer--useful as real tumor markers? Fleischhacker M, et al. **Lung Cancer** 1999 Jul;25(1):7–24 (117 ref.)

Multidrug resistance in human tumors--molecular diagnosis and clinical significance. Ramachandran C, et al. **Mol Diagn** 1999 Jun;4(2):81–94 (145 ref.)

SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Silverman GA, et al. **Tumour Biol** 1998;19(6):480–7 (23 ref.)

IMMUNOLOGY

CD30 in normal and neoplastic cells. Chiarle R, et al. **Clin Immunol** 1999 Feb;90(2):157–64 (101 ref.)

METABOLISM

Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Ordóñez NG. **Am J Surg Pathol** 1998 Oct;22(10):1203–14 (85 ref.)

Prognostic markers in localized prostate cancer: from microscopes to molecules. Harding MA, et al. **Cancer Metastasis Rev** 1998–99;17(4):429–37 (64 ref.)

Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation. Jørgensen LG. **Dan Med Bull** 1999 Feb;46(1):1–12 (200 ref.)

The immunohistochemical diagnosis of epithelial mesothelioma. Ordóñez NG. **Hum Pathol** 1999 Mar; 30(3):313–23 (107 ref.)

Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. Duffy MJ, et al. **J Surg Oncol** 1999 Jun;71(2):130–5 (59 ref.)

Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Moll R. **Subcell Biochem** 1998; 31:205–62 (239 ref.)

Biochemical diagnosis of neuroendocrine GEP tumor. Oberg K. **Yale J Biol Med** 1997 Sep–Dec;70(5–6):501–8 (21 ref.)

[Tumor markers in the diagnosis of pancreatic cancer] Cappelli G, et al. **Tumori** 1999 Jan–Feb;85(1 Suppl 1):S19–21 (09 ref.) (Eng. Abstr.) **(Ita)**

[Fibrinolytic substances formation by cancer. Pathogenetic sequelae] Uszyński M. **Ginekol Pol** 1999 Feb;70(2):105–11 (18 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Biological role of SCC antigen. Suminami Y, et al. **Tumour Biol** 1998;19(6):488–93 (42 ref.)

URINE

Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies. Halliwell B. **Free Radic Res** 1998 Dec;29(6):469–86 (142 ref.)

Urinary telomerase and its possible role as a marker for bladder cancer. Droller MJ, et al. **Keio J Med** 1998 Sep; 47(3):135–41 (42 ref.)

TUMOR NECROSIS FACTOR

Tumor necrosis factors in 1998. Wajant H, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):297–302 (0 ref.)

[Structural biology of apoptosis proteins: recent advances in structural analysis of TNF-related, Fas-related, Bcl-2 family and caspase family proteins] Aritomi M, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):395–403 (25 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Clinical applications of TNF-alpha in cancer. Lejeune FJ, et al. **Curr Opin Immunol** 1998 Oct;10(5):573–80 (42 ref.)

Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Schraffordt Koops H, et al. **Radiother Oncol** 1998 Jul; 48(1):1–4 (19 ref.)

ADVERSE EFFECTS

Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. Meldrum DR, et al. **J Surg Res** 1999 Aug; 85(2):185–99 (206 ref.)

ANALYSIS

TNF in trauma--whither our focus? [editorial; comment] Reines HD. **Crit Care Med** 1999 Feb;27(2):239 (9 ref.) Comment on: Crit Care Med 1999 Feb;27(2):313–8.

[Determination of the tumor necrosis factor in the peritoneal fluid of gynecologic patients with intraperitoneal infections and endometriosis] Guerra-Infante FM, et al. **Ginecol Obstet Mex** 1999 May;67:221–6 (26 ref.) (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Tumor necrosis factor inhibitors for rheumatoid arthritis. Jones RE, et al. **Bull Rheum Dis** 1999;48(3):1–4 (16 ref.)

Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Moreland LW. **Cleve Clin J Med** 1999 Jun;66(6):367–74 (27 ref.)

The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease [published erratum appears in Drugs 1999 Jan;57(1):79] van Hogezand RA, et al. **Drugs** 1998 Sep;56(3):299–305 (28 ref.)

New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis. Breedveld F. **Eur Cytokine Netw** 1998 Sep;9(3):233–8 (39 ref.)

Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. Newton RC, et al. **J Med Chem** 1999 Jul 1;42(13):2295–314 (249 ref.)

Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt? [editorial] [see comments] Kavanaugh A, et al. **J Rheumatol** 1998 Nov;25(11):2049–53 (30 ref.) Comment in: J Rheumatol 1998 Nov;25(11):2049.

The role of tumor necrosis factor antagonism in clinical practice. Keystone EC. **J Rheumatol** 1999 May;26 Suppl 57:22–8 (20 ref.)

Inhibitors of tumor necrosis factor for rheumatoid arthritis. Moreland LW. **J Rheumatol** 1999 May;26 Suppl 57:7–15 (20 ref.)

Rheumatology. Biological agents--is the promise realised? Felson D, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV25 (5 ref.)

An ataxia telangiectasia model: inefficient cell differentiation and possible reversal by serine protease inhibitors, tumor necrosis factor inhibitors, dexamethasone, and glutathione enhancers. Knittweis J. **Med Hypotheses** 1998 Jul; 51(1):53–7 (88 ref.)

New therapeutic targets for rheumatoid arthritis. Dinant HJ, et al. **Pharm World Sci** 1999 Apr;21(2):49–59 (109 ref.)

[Prospects of clinical uses of tumor necrosis factor antagonists] Guo X, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(1):64–5 (11 ref.) **(Chi)**

[Treatment of rheumatoid arthritis with cytokine antagonists] Manger B. **Z Arztl Fortbild Qualitatssich** 1999 Mar; 93(2):101–4 (14 ref.) (Eng. Abstr.) **(Ger)**

[Immunopharmacologic profile and therapeutic prospects of anti-TNF-alpha therapy] Fenner H. **Z Rheumatol** 1998 Oct;57(5):294–7 (4 ref.) (Eng. Abstr.) **(Ger)**

[Experimental therapy of rheumatoid arthritis with antibodies to tumor necrosis factor] Manger B. **Z Rheumatol** 1998 Oct;57(5):298–301 (15 ref.) **(Ger)**

BIOSYNTHESIS

Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Wilder RL, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:14–31 (152 ref.)

IgE and tumor necrosis factor in malaria infection. Perlmann P, et al. **Immunol Lett** 1999 Jan;65(1–2):29–33 (43 ref.)

Antigen-specific CD4+ T cells that survive after the induction of peripheral tolerance possess an intrinsic lymphokine production defect. Pape KA, et al. **Novartis Found Symp** 1998;215:103–13; discussion 113–9, 186–90 (30 ref.)

DRUG EFFECTS

Alcoholic hepatitis as a T-cell mediated disorder: an hypothesis. Batey RG, et al. **Alcohol Clin Exp Res** 1999 Jul;23(7):1207-9 (32 ref.)

GENETICS

Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models. Ruuls SR, et al. **Am J Hum Genet** 1999 Aug;65(2):294-301 (38 ref.)

Influence of human leukocyte antigen and tumour necrosis factor genes on the development of pre-eclampsia. Kilpatrick DC. **Hum Reprod Update** 1999 Mar-Apr; 5(2):94-102 (98 ref.)

Genetics of tumour necrosis factor (TNF) in autoimmune liver diseases: red hot or red herring? [editorial; comment] Wilson AG. **J Hepatol** 1999 Feb;30(2):331-3 (26 ref.) Comment on: J Hepatol 1999 Feb;30(2):232-6. Comment on: J Hepatol 1999 Feb;30(2):237-41.

Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Knight JC, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):290-8 (50 ref.)

IMMUNOLOGY

Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha [editorial] Rifas L. **Calcif Tissue Int** 1999 Jan;64(1):1-7 (106 ref.)

Regulation of autoimmunity by proinflammatory cytokines. Cope AP. **Curr Opin Immunol** 1998 Dec;10(6):669-76 (58 ref.)

Tumor necrosis factor locus: genetic organisation and biological implications. Makhatadze NJ. **Hum Immunol** 1998 Sep;59(9):571-9 (83 ref.)

Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice. Green EA, et al. **Immunol Rev** 1999 Jun;169:11-22 (107 ref.)

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Kollias G, et al. **Immunol Rev** 1999 Jun;169:175-94 (198 ref.)

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Sandborn WJ, et al. **Inflamm Bowel Dis** 1999 May;5(2):119-33 (81 ref.)

Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Baert FJ, et al. **Int J Colorectal Dis** 1999 Feb;14(1):47-51 (29 ref.)

Peptide modulation of inflammatory processes within the brain. Lipton JM, et al. **Neuroimmunomodulation** 1998 May-Aug;5(3-4):178-83 (50 ref.)

Riding on a carousel with IFN-alpha and TNF-alpha [editorial; comment] Zierhut M. **Ocul Immunol Inflamm** 1998 Dec;6(4):209-10 (15 ref.) Comment on: Ocul Immunol Inflamm 1998 Dec;6(4):215-26.

Tumour necrosis factor-alpha and lymphotoxin-alpha in the pathology of experimental autoimmune encephalomyelitis: is either one responsible or is there another ligand-mediating disease? Willenborg DO, et al. **Res Immunol** 1998 Nov-Dec;149(9):804-10; discussion 849-50, 855-60 (41 ref.)

Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Feldman M, et al. **Transplant Proc** 1998 Dec;30(8):4126-7 (9 ref.)

[Treatment of Crohn's disease with anti-TNF alpha] Lémann M. **Rev Prat** 1998 May 15;48(10):1049-50 (8 ref.) **(Fre)**

METABOLISM

Characterization of the tumour necrosis factor alpha-converting enzyme, TACE/ADAM17. Cerretti DP. **Biochem Soc Trans** 1999 Feb;27(2):219-23 (20 ref.)

The cytokine response to strenuous exercise. Pedersen BK, et al. **Can J Physiol Pharmacol** 1998 May;76(5):505-11 (54 ref.)

TNF-related ligands and their receptors. Orlinick JR, et al. **Cell Signal** 1998 Sep;10(8):543-51 (129 ref.)

The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Graves DT. **Clin Infect Dis** 1999 Mar;28(3):482-90 (82 ref.)

An overview of tumor necrosis factor alpha and the failing human heart. Torre-Amione G, et al. **Curr Opin Cardiol** 1999 May;14(3):206-10 (44 ref.)

TNF-alpha in acute cardiac transplant rejection. Azzawi M, et al. **Cytokines Cell Mol Ther** 1999 Mar;5(1):41-9 (66 ref.)

Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Burke F. **Cytokines Cell Mol Ther** 1999 Mar;5(1):51-61 (182 ref.)

Tumour necrosis factor, a key role in obesity? Bulló-Bonet M, et al. **FEBS Lett** 1999 May 28;451(3):215-9 (72 ref.)

Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Kyriakis JM. **Gene Expr** 1999; 7(4-6):217-31 (76 ref.)

Invited editorial on "tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs". Al-Mehdi AB, et al. **J Appl Physiol** 1998 Dec;85(6):2003-4 (16 ref.)

The role of TNFalpha and TNF receptors in obesity and insulin resistance. Hotamisligil GS. **J Intern Med** 1999 Jun; 245(6):621-5 (37 ref.)

From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Tracey KJ, et al. **Shock** 1999 Mar;11(3):224-5 (9 ref.)

PHARMACOLOGY

TRAIL induces apoptosis and activation of NFkappaB. Jeremias I, et al. **Eur Cytokine Netw** 1998 Dec;9(4):687-8 (14 ref.)

Cardiodepression by tumor necrosis factor-alpha. Müller-Werdan U, et al. **Eur Cytokine Netw** 1998 Dec; 9(4):689-91 (16 ref.)

Therapeutic strategy for post-transfusion graft-vs.-host disease. Saigo K, et al. **Int J Hematol** 1999 Apr;69(3):147-51 (29 ref.)

The Sixth John M. Kinney-Nestlé Clinical Nutrition Award for Enteral Nutrition. Recombinant human tumor necrosis factor and recombinant murine interleukin-1 alter the binding of Escherichia coli to intestine, mucin glycoprotein, and the HT29-C1 intestinal cell line: a context [see comments] Wanke CA. **Nutrition** 1999 Jun;15(6):427-9 (20 ref.) Comment in: Nutrition 1999 Jun;15(6):430.

Activation and injury of endothelial cells by cytokines. Pober JS. **Pathol Biol (Paris)** 1998 Mar;46(3):159-63 (31 ref.)

PHYSIOLOGY

Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models. Ruuls SR, et al. **Am J Hum Genet** 1999 Aug;65(2):294-301 (38 ref.)

Sleep. A physiologic role for IL-1 beta and TNF-alpha. Krueger JM, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:148-59 (74 ref.)

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Takahashi N, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):449-55 (55 ref.)

Protein kinase cascades in intracellular signalling by interleukin-1 and tumour necrosis factor. Saklatvala J, et al. **Biochem Soc Symp** 1999;64:63-77 (65 ref.)

TNF, apoptosis and autoimmunity: a common thread? Beutler B, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):216-30 (133 ref.)

Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Goeddel DV. **Chest** 1999 Jul;116(1 Suppl):69S-73S (37 ref.)

Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Herrera-Garza EH, et al. **Chest** 1999 Apr;115(4):1170-4 (21 ref.)

Apoptosis control by death and decoy receptors. Ashkenazi A, et al. **Curr Opin Cell Biol** 1999 Apr;11(2):255-60 (66 ref.)

TRAIL: a molecule with multiple receptors and control mechanisms. Griffith TS, et al. **Curr Opin Immunol** 1998 Oct;10(5):559-63 (25 ref.)

Mechanisms of TNF-alpha-induced insulin resistance [see comments] Hotamisligil GS. **Exp Clin Endocrinol Diabetes** 1999;107(2):119-25 (48 ref.) Comment in: Exp Clin Endocrinol Diabetes 1999 ;107(2):111-2.

Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Chang NS. **Int J Mol Med** 1998 Dec;2(6):653-9 (53 ref.)

Tumour necrosis factor alpha--mediator of apoptosis and cell proliferation of hepatocytes. Plümpe J, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):235-43 (96 ref.)

Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion. Cain BS, et al. **J Mol Cell Cardiol** 1999 May; 31(5):931-47 (142 ref.)

The roie of tumor necrosis factor in health and disease. Beutler BA. **J Rheumatol** 1999 May;26 Suppl 57:16-21 (13 ref.)

Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. Meldrum DR, et al. **J Surg Res** 1999 Aug; 85(2):185-99 (206 ref.)

Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. Donnahoo KK, et al. **J Urol** 1999 Jul;162(1):196-203 (96 ref.)

Identification of ceramide targets in interleukin-1 and tumor necrosis factor-alpha signaling in mesangial cells. Pfeilschifter J, et al. **Kidney Int Suppl** 1998 Sep;67:S34-9 (34 ref.)

Recent advances in the molecular basis of TNF signal transduction. Ledgerwood EC, et al. **Lab Invest** 1999 Sep; 79(9):1041-50 (113 ref.)

Tumor necrosis factor-alpha: is there a continuum of liability between stress, anxiety states and anorexia nervosa? Holden RJ, et al. **Med Hypotheses** 1999 Feb;52(2):155-62 (83 ref.)

Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review). Holden RJ, et al. **Med Hypotheses** 1999 Apr; 52(4):319-23 (55 ref.)

TNF-alpha and insulin resistance: summary and future prospects. Peraldi P, et al. **Mol Cell Biochem** 1998 May; 182(1-2):169-75 (58 ref.)

The role of TNF in cardiovascular disease [see comments] Ferrari R. **Pharmacol Res** 1999 Aug;40(2):97-105 (96 ref.) Comment in: Pharmacol Res 1999 Aug;40(2):91.

Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interaction with insulin-like growth factor-1. Loddick SA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9449-51 (33 ref.)

The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Muñoz-Fernández MA, et al. **Prog Neurobiol** 1998 Oct; 56(3):307-40 (486 ref.)

GLUT-4, tumor necrosis factor, essential fatty acids and daf-genes and their role in insulin resistance and non-insulin dependent diabetes mellitus. Das UN. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jan; 60(1):13-20 (43 ref.)

The role of TNF alpha in adipocyte metabolism. Sethi JK, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):19-29 (132 ref.)

The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Klahr S, et al. **Semin Nephrol** 1998 Nov;18(6):622-32 (89 ref.)

Role of pro-inflammatory cytokines in rheumatoid arthritis. Brennan FM, et al. **Springer Semin Immunopathol** 1998; 20(1-2):133-47 (147 ref.)

Joint inflammation and cartilage destruction may occur uncoupled. van den Berg WB. **Springer Semin Immunopathol** 1998;20(1-2):149-64 (53 ref.)

Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. Ohkohchi N, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1055-8 (18 ref.)

[Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis] Mathurin P, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):311-9 (81 ref.) **(Fre)**

[Induction of apoptosis by receptors for factors from the TNF family] Grzela T, et al. **Postepy Hig Med Dosw** 1999; 53(2):351-63 (74 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

The effect of 21-aminosteroids on endotoxin-induced TNF-alpha release [editorial; comment] Kimura RE, et al. **Crit Care Med** 1999 Jun;27(6):1058-9 (7 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1164-7.

THERAPEUTIC USE

TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Eggermont AM. **Anticancer Res** 1998 Sep-Oct;18(5D):3899-905 (80 ref.)

Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Mueller H. **Cell Mol Life Sci** 1998 Dec; 54(12):1291-8 (117 ref.)

Tumour necrosis factor: strategies for improving the therapeutic index. Corti A, et al. **J Drug Target** 1998; 5(6):403-13 (76 ref.)

TOXICITY

Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: role of glutathione. Obrador E, et al. **Biofactors** 1998;8(1-2):23-6 (20 ref.)

TUMOR NECROSIS FACTOR-ALPHA see **TUMOR NECROSIS FACTOR**

TUMOR NECROSIS FACTOR-BETA see **LYMPHOTOXIN**

TUMOR NECROSIS FACTOR RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

TUMOR PROMOTERS see **CARCINOGENS**

TUMOR SPHEROIDS see **SPHEROIDS**

TUMOR STAGING see **NEOPLASM STAGING**

TUMOR STEM CELLS

CYTOLOGY

Cell biology of CML cells. Gordon MY, et al. **Leukemia** 1999 Apr;13 Suppl 1:S65-71 (45 ref.)

Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia? Pasternak G, et al. **Leukemia** 1999 Apr;13 Suppl 1:S55-64 (60 ref.)

Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Albini A. **Pathol Oncol Res** 1998; 4(3):230-41 (148 ref.)

IMMUNOLOGY

Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Bruserud O. **Leukemia** 1999 Aug; 13(8):1175-87 (177 ref.)

PATHOLOGY

The detection of minimal numbers of contaminating epithelial

TUMOR STEM CELLS

tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Lambrechts AC, et al. **Ann Oncol** 1998 Dec;9(12):1269–76 (60 ref.)

Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. Garcia SB, et al. **J Pathol** 1999 Jan;187(1):61–81 (287 ref.)

Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia [see comments] Suzuki R, et al. **Leuk Res** 1999 Jul;23(7):615–24 (50 ref.) Comment in: Leuk Res 1999 Jul;23(7):675–6.

TUMOR SUPPRESSOR GENES see **GENES, SUPPRESSOR, TUMOR**

TUMOR VACCINES see **CANCER VACCINES**

TUMOR VIRUS INFECTIONS

Advances in the diagnosis and treatment of human papillomavirus infections. Sedlacek TV. **Clin Obstet Gynecol** 1999 Jun;42(2):206–20 (20 ref.)

Recurrent respiratory papillomatosis. Murray LN, et al. **J La State Med Soc** 1998 Oct;150(10):456–9 (15 ref.)

Post-transplantation polyomavirus infections. Boubenider S, et al. **J Nephrol** 1999 Jan–Feb;12(1):24–9 (44 ref.)

Epstein-Barr virus involvement in T-cell malignancy: significance in adult T-cell leukemia. Ohtsubo H, et al. **Leuk Lymphoma** 1999 May;33(5–6):451–8 (71 ref.)

Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Jarrett RF, et al. **Semin Hematol** 1999 Jul;36(3):260–9 (102 ref.)

[Epstein-Barr virus encephalitis] Fukaya S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):25–8 (20 ref.) **(Jpn)**

[EB virus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):126–8 (10 ref.) **(Jpn)**

[HPV infection of the genital system: new findings] Hrgović Z, et al. **Lijec Vjesn** 1999 Jun;121(6):198–203 (49 ref.) (Eng. Abstr.) **(Scr)**

COMPLICATIONS

BK virus as a potential co-factor in human cancer. Harris KF, et al. **Dev Biol Stand** 1998;94:81–91 (53 ref.)

Relevance of photo-immunosuppression for viral infections (i.e. human papilloma virus). Vermeer BJ, et al. **Eur J Dermatol** 1998 Apr–May;8(3):205–6 (12 ref.)

Human papillomavirus and the development of non-melanoma skin cancer. Harwood CA, et al. **J Clin Pathol** 1999 Apr;52(4):249–53 (51 ref.)

Human papillomavirus infection with particular reference to genital disease. Sonnex C. **J Clin Pathol** 1998 Sep; 51(9):643–8 (65 ref.)

Cell and molecular biology of simian virus 40: implications for human infections and disease. Butel JS, et al. **J Natl Cancer Inst** 1999 Jan 20;91(2):119–34 (134 ref.)

Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Spitzer M. **Obstet Gynecol Surv** 1999 Feb;54(2):131–7 (51 ref.)

[HPV infection and its significance in cervical oncogenesis] Zlatkov V. **Akush Ginekol (Sofiia)** 1998;37(1):45–6 (16 ref.) **(Bul)**

[Post-transplantation lymphomas and Epstein-Barr virus] Caillard S, et al. **Nephrologie** 1998;19(8):481–8 (100 ref.) (Eng. Abstr.) **(Fre)**

[The current concepts of papillomavirus infection and its role in the pathogenesis of pretumorous and tumorous processes of the cervix uteri] Lakatosh VP, et al. **Lik Sprava** 1999 Mar;(2):22–31 (83 ref.) **(Ukr)**

DIAGNOSIS

Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening and HPV testing. Sigurdsson K. **Acta Obstet Gynecol Scand** 1999 Jul; 78(6):467–77 (126 ref.)

HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. Apgar BS, et al. **Am Fam Physician** 1999 May 15;59(10):2794–801 (29 ref.)

Is human papillomavirus testing of value in clinical practice? Kaufman RH, et al. **Am J Obstet Gynecol** 1999 May; 180(5):1049–53 (27 ref.)

[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women] Küppers V, et al. **Zentralbl Gynakol** 1999;121(1):27–30 (5 ref.) (Eng. Abstr.) **(Ger)**

[Laboratory diagnosis of viral infections. 6. Tumor viruses] Hoshina S. **Rinsho Byori** 1998 Nov;Suppl 108:93–7 (9 ref.) **(Jpn)**

[Verruca plana juvenilis] Egawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):259–61 (12 ref.) **(Jpn)**

[Advances in the diagnosis and treatment of infections caused by herpesvirus and JC virus] Arribas JR, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:11–9 (38 ref.) (Eng. Abstr.) **(Spa)**

[The current concepts of the clinical picture, diagnosis and treatment of papillomavirus lesions of the female genitalia] Lakatosh VP, et al. **Lik Sprava** 1999 Apr–May;(3):29–37 (72 ref.) **(Ukr)**

DRUG THERAPY

[Advances in the diagnosis and treatment of infections caused by herpesvirus and JC virus] Arribas JR, et al. **Enferm Infecc Microbiol Clin** 1998;16 Suppl 1:11–9 (38 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer--a review of the epidemiological evidence. Strickler HD, et al. **Dev Biol Stand** 1998;94:235–44 (26 ref.)

Epidemiology of genital human papillomavirus. Tortolero-Luna G. **Hematol Oncol Clin North Am** 1999 Feb;13(1):245–57, x (55 ref.)

[Biology of papillomavirus infections. IV. Sero-epidemiological data] Seilles E, et al. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):393–400 (53 ref.) (Eng. Abstr.) **(Fre)**

[How technology and vaccination have changed the Pap test] Bondi A, et al. **Pathologica** 1999 Feb;91(1):36–41 (28 ref.) **(Ita)**

ETIOLOGY

AIDS-associated malignancies: research perspectives. Feigal EG. **Biochim Biophys Acta** 1999 Jan 29;1423(1):C1–9 (72 ref.)

Role of human papillomaviruses in warts and cancer. Proby CM, et al. **Hosp Med** 1998 Jan;59(1):33–6 (20 ref.)

GENETICS

Chronic retroviruses and oncogenesis. Patarca R. **Crit Rev Oncog** 1998;9(2):151–98 (375 ref.)

SV40 DNA sequences in mesotheliomas. Gibbs AR, et al. **Dev Biol Stand** 1998;94:41–5 (8 ref.)

Simian virus 40 footprints in normal human tissues, brain and bone tumours of different histotypes. Martini F, et al. **Dev Biol Stand** 1998;94:55–66 (30 ref.)

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. Rizzo P, et al. **Dev Biol Stand** 1998;94:33–40 (19 ref.)

Search for SV40 in human mesotheliomas. Shah KV. **Dev Biol Stand** 1998;94:67–8 (5 ref.)

New molecular and epidemiological issues in mesothelioma: role of SV40. Carbone M, et al. **J Cell Physiol** 1999 Aug; 180(2):167–72 (34 ref.)

IMMUNOLOGY

Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Acha-Orbea H, et al. **Immunol Rev** 1999 Apr;168:287–303 (130 ref.)

Potential strategies utilised by papillomavirus to evade host immunity. Frazer IH, et al. **Immunol Rev** 1999 Apr; 168:131–42 (82 ref.)

[The biology of papillomavirus infections. III. Immune response] Greslin I, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):267–76 (39 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Detection of human papilloma virus type 56 in extragenital Bowen's disease. Uezato H, et al. **Acta Derm Venereol** 1999 Jul;79(4):311–3 (18 ref.)

Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature. Klein R, et al. **Am J Surg Pathol** 1999 Apr;23(4):477–81 (31 ref.)

Isolated leptomeningeal Castleman's disease with viral particles in the follicular dendritic cells. Gulati P, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):1026–9 (18 ref.)

Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Fazel N, et al. **Dermatol Clin** 1999 Jul;17(3):521–36, viii (138 ref.)

Oncogenic potential of human neurotropic papovavirus, JCV, in CNS. Gordon J, et al. **Dev Biol Stand** 1998; 94:93–101 (26 ref.)

Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. Palefsky JM. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S42–8 (28 ref.)

Juvenile-onset recurrent respiratory papillomatosis involving the lung: A case report and review of the literature. Magid MS, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):157–63 (29 ref.)

X-linked lymphoproliferative disease: pathology and diagnosis. Maia DM, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):72–7 (18 ref.)

PREVENTION & CONTROL

Papillomaviruses: prophylactic vaccine prospects. Lowy DR, et al. **Biochim Biophys Acta** 1999 Jan 29;1423(1):M1–8 (60 ref.)

Papillomavirus vaccines. Duggan-Keen MF, et al. **Front Biosci** 1998 Dec 1;3:D1192–208 (195 ref.)

THERAPY

Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies. Moss DJ, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S80–3 (27 ref.)

[Characteristics of anal carcinoma with therapeutic consequences] Hohenberger P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:363–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women] Küppers V, et al. **Zentralbl Gynakol** 1999;121(1):27–30 (5 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Gillison ML, et al. **Curr Opin Oncol** 1999 May;11(3):191–9 (110 ref.)

SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Procopio A, et al. **Dev Biol Stand** 1998;94:361–7 (16 ref.)

Transmission of cervical cancer-associated human papilloma viruses from mother to child. Cason J, et al. **Intervirology** 1998;41(4–5):213–8 (44 ref.)

High risk genital papillomavirus infections are not spread vertically. Dillner J, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):23–9 (63 ref.)

High risk genital papillomavirus infections are spread vertically. Rice PS, et al. **Rev Med Virol** 1999 Jan–Mar; 9(1):15–21 (52 ref.)

VETERINARY

Canine papillomavirus--A centenary review. Nicholls PK, et al. **J Comp Pathol** 1999 Apr;120(3):219–33 (95 ref.)

Mucosotropic papillomavirus infections. Sundberg JP, et al. **Lab Anim Sci** 1998 Jun;48(3):240–2 (25 ref.)

VIROLOGY

Detection of authentic SV40 DNA sequences in human brain and bone tumours. Butel JS, et al. **Dev Biol Stand** 1998; 94:23–32 (15 ref.)

Molecular biology and pathogenesis of human polyomavirus infections. Dörries K. **Dev Biol Stand** 1998;94:71–9 (24 ref.)

SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Furth PA. **Dev Biol Stand** 1998; 94:281–7 (15 ref.)

SV40 infections in simians and humans. Shah KV. **Dev Biol Stand** 1998;94:9–12 (12 ref.)

Simian virus 40 DNA sequences in human brain and bone tumours. Wang J, et al. **Dev Biol Stand** 1998;94:13–21 (27 ref.)

SV40 as an oncogenic virus and possible human pathogen. Weiss R, et al. **Dev Biol Stand** 1998;94:355–60, 369–82 (0 ref.)

Polyomaviruses and human tumors: a brief review of current concepts and interpretations. Lednicky JA, et al. **Front Biosci** 1999 Feb 15;4:D153–64 (168 ref.)

Simian virus 40 infection via MHC class I molecules and caveolae. Norkin LC. **Immunol Rev** 1999 Apr;168:13–22 (55 ref.)

Yohei Ito Memorial Lecture: Papillomaviruses in human cancers. zur Hausen H. **Leukemia** 1999 Jan;13(1):1–5 (40 ref.)

Human herpesvirus 8 in hematologic diseases. Mikala G, et al. **Pathol Oncol Res** 1999;5(1):73–9 (42 ref.)

The role of the human papilloma virus in esophageal cancer. Sur M, et al. **Pathology** 1998 Nov;30(4):348–54 (65 ref.)

Human papillomavirus infection in adolescents. Moscicki AB. **Pediatr Clin North Am** 1999 Aug;46(4):783–807 (90 ref.)

HPV and cancer: the story unfolds. Campo MS. **Trends Microbiol** 1998 Nov;6(11):424–6 (20 ref.)

[Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma] Niedobitek G. **Pathologe** 1998 Sep;19(5):337–44 (16 ref.) (Eng. Abstr.) **(Ger)**

TUMOR VIRUSES see **ONCOGENIC VIRUSES**

TUMORICIDAL ACTIVITY, IMMUNOLOGIC see **CYTOTOXICITY, IMMUNOLOGIC**

TUMORIGENICITY TESTS see **CARCINOGENICITY TESTS**

TUMORS see **NEOPLASMS**

TUNICA INTIMA

[An intimal sarcoma of the pulmonary artery. An immunohistochemical study] Pérez del Río MJ, et al. **Rev Esp Cardiol** 1998 Oct;51(10):850–2 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Low molecular weight heparins in the cardiac catheterization laboratory. Montalescot G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):319–23 (27 ref.)

METABOLISM

Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Nielsen LB. **Atherosclerosis** 1999 Apr;143(2):229–43 (112 ref.)

Oxidized low-density lipoprotein enhances intimal thickening and alters vascular reactivity. Herman A, et al. **Verh K Acad Geneeskd Belg** 1999;61(1):19–36; discussion

36–8 (63 ref.)

PATHOLOGY

Irradiation for the treatment of intimal hyperplasia. Fortunato JE, et al. **Ann Vasc Surg** 1998 Sep;12(5):495–503 (53 ref.)
Endovascular irradiation for the prevention of restenosis after percutaneous transluminal angioplasty [editorial] Bruijninckx CM, et al. **Eur J Vasc Endovasc Surg** 1998 Nov;16(5):371–2 (19 ref.)
Myointimal hyperplasia: basic science and clinical considerations. Neville RF, et al. **Semin Vasc Surg** 1998 Sep;11(3):142–8 (46 ref.)
Peptide growth factors and signal transduction. Sidawy AN, et al. **Semin Vasc Surg** 1998 Sep;11(3):149–55 (64 ref.)
[Effect of lipoprotein metabolism abnormality for intimal thickening] Oguchi S, et al. **Nippon Rinsho** 1999 Jul; 57(7):1486–91 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Roles of platelets and neutrophils in intimal thickening following endothelial injury] Umemura K. **Nippon Rinsho** 1999 Jul;57(7):1480–5 (5 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Irradiation for the treatment of intimal hyperplasia. Fortunato JE, et al. **Ann Vasc Surg** 1998 Sep;12(5):495–503 (53 ref.)

TUNICA INTIMA VASORUM see **TUNICA INTIMA**

TUNICA MEDIA

[Mönckeberg's medial sclerosis] Sucker C, et al. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):497–500 (16 ref.) **(Ger)**
[Media calcinosis from the viewpoint of the cardiologist] Lanzer P. **Z Kardiol** 1998 Dec;87(12):928–38 (73 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Segmental mediolytic arteritis [correction of arteries]: a case report with review of the literature [published erratum appears in Pathol Res Pract 1999;195(1):38] Nagashima Y, et al. **Pathol Res Pract** 1998;194(9):643–7 (11 ref.)

TUNICATA see **UROCHORDATA**

TUPAIIDAE

EMBRYOLOGY

The morphogenesis of the arteries of the pelvic extremity. A comparative study of mammals with special reference to the tree shrew Tupaia belangeri (Tupaiidae, Scandentia, Mammalia). Funke C, et al. **Adv Anat Embryol Cell Biol** 1998;144:1–97 (115 ref.)

TUPAIINAE see **TUPAIIDAE**

TURBINATES

ANATOMY & HISTOLOGY

Use of the superior meatus and superior turbinate in the endoscopic approach to the sphenoid sinus. Bolger WE, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):308–13 (13 ref.)

PATHOLOGY

Controversies in the management of inferior turbinate hypertrophy: a comprehensive review. Jackson LE, et al. **Plast Reconstr Surg** 1999 Jan;103(1):300–12 (81 ref.)

SURGERY

[Treatment of nasal obstruction with subtotal inferior turbinectomy in chronic rhinitis: a retrospective study on 50 patients] Faulcon P, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115(4):228–33 (30 ref.) (Eng. Abstr.) **(Fre)**
[On the impact of surgery on mucosal vessels of the turbinates (10 years of submucosal vasotomy)] Piskunov SZ. **Vestn Otorinolaringol** 1999;(2):19–22 (29 ref.) (Eng. Abstr.) **(Rus)**

TURKEYS

Rapid growth problems: ascites and skeletal deformities in broilers. Julian RJ. **Poult Sci** 1998 Dec;77(12):1773–80 (36 ref.)

ANATOMY & HISTOLOGY

Structure of the avian oviduct with emphasis on sperm storage in poultry. Bakst MR. **J Exp Zool** 1998 Nov–Dec 1;282(4–5):618–26 (29 ref.)

PHYSIOLOGY

Mechanisms of excreta formation and elimination in turkeys and ostriches. Duke GE. **J Exp Zool** 1999 Mar–Apr 1; 283(4–5):478–9 (7 ref.)
Welfare during stunning and slaughter of poultry. Raj M. **Poult Sci** 1998 Dec;77(12):1815–9 (24 ref.)

TURNER'S SYNDROME

COMPLICATIONS

Medical problems in adult women with Turner's syndrome. Elsheikh M, et al. **Ann Med** 1999 Apr;31(2):99–105 (47 ref.)
Pregnancies in women with Turner's syndrome. Hovatta O. **Ann Med** 1999 Apr;31(2):106–10 (46 ref.)

DIAGNOSIS

[Management in an adolescent with Turner syndrome] Pasquino AM, et al. **Minerva Pediatr** 1998 Jun;50(6):203–8 (51 ref.) **(Ita)**

DRUG THERAPY

Growth hormone therapy in patients with Turner syndrome. Haeusler G. **Horm Res** 1998;49 Suppl 2:62–6 (36 ref.)
[Effect of hormonal treatment on bone mineralization in Turner syndrome] Saggese G, et al. **Arch Pediatr** 1998;5 Suppl 4:371S–374S (28 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

De novo duplication xq22–q23 in a girl with short stature and gonadal dysgenesis. Correa-Cerro L, et al. **Ann Genet** 1999;42(1):41–4 (20 ref.)
Turner syndrome and haploinsufficiency. Zinn AR, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):322–7 (48 ref.)

TURNER'S SYNDROME, MALE see **NOONAN SYNDROME**

TURNIP see **BRASSICA**

TURSIOPS see **DOLPHINS**

TURTLES

Skin disease affecting the conservation of the western swamp tortoise (Pseudemydura umbrina) [see comments] Ladyman JM, et al. **Aust Vet J** 1998 Nov;76(11):743–5 (16 ref.) Comment in: Aust Vet J 1998 Nov;76(11):738.

PARASITOLOGY

Diversity of monogeneans in Southeast Asia. Lim LH. **Int J Parasitol** 1998 Oct;28(10):1495–515 (98 ref.)

PHYSIOLOGY

Spinal motor patterns in the turtle. Stein PS, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:142–54 (53 ref.)
Role of urinary and cloacal bladders in chelonian water economy: historical and comparative perspectives. Jørgensen CB. **Biol Rev Camb Philos Soc** 1998 Nov; 73(4):347–66 (134 ref.)
Oviductal sperm storage as a reproductive tactic of turtles. Gist DH, et al. **J Exp Zool** 1998 Nov–Dec 1; 282(4–5):526–34 (48 ref.)

TWELFTH CRANIAL NERVE see **HYPOGLOSSAL NERVE**

20TH CENT. HISTORY see **HISTORY OF MEDICINE, 20TH CENT.**

20TH CENT. HISTORY (MEDICINE) see **HISTORY OF MEDICINE, 20TH CENT.**

20TH CENT. MEDICINE see **HISTORY OF MEDICINE, 20TH CENT.**

TWENTY-FOUR HOUR RHYTHM see **CIRCADIAN RHYTHM**

TWIN STUDIES

The role of twin studies in the genetics of skin diseases. Bataille V. **Clin Exp Dermatol** 1999 Jul;24(4):286–90 (37 ref.)
Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Kalow W, et al. **Pharmacogenetics** 1998 Aug;8(4):283–9 (36 ref.)

TWIN TRANSFUSION see **FETOFETAL TRANSFUSION**

TWIN TRANSFUSION SYNDROME see **FETOFETAL TRANSFUSION**

TWINS

see related
DISEASES IN TWINS

Perinatal morbidity and mortality rates in twin pregnancies--a 15-year review study from Athens. Liapis AE, et al. **Acta Genet Med Gemellol (Roma)** 1997; 46(4):185–91 (25 ref.)
The retained twin/triplet following a preterm delivery--an analysis of the literature. Trivedi AN, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):461–5 (26 ref.)
Delivery of twins. Hofmeyr GJ, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):91–108 (53 ref.)
Controversies in the intrapartum management of twin gestations. Stone J, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):327–43 (68 ref.)
Early prenatal diagnosis of cord entanglement in monoamniotic multiple pregnancies [see comments] Arabin B, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):181–6 (24 ref.) Comment in: Ultrasound Obstet Gynecol 1999 Mar;13(3):157–60.
[Reversed arterial perfusion in twins. Extreme twin pregnancies can increase the knowledge of normal fetal development] Ek S. **Lakartidningen** 1999 Apr 21; 96(16):1976–9 (12 ref.) **(Swe)**

GENETICS

The role of twin studies in the genetics of skin diseases. Bataille V. **Clin Exp Dermatol** 1999 Jul;24(4):286–90 (37 ref.)
EEG sleep patterns in twins. Linkowski P. **J Sleep Res** 1999 Jun;8 Suppl 1:11–3 (30 ref.)

PSYCHOLOGY

To be born as a twin--risks and sequelae. Moilanen I, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):138–47 (30 ref.)

STATISTICS & NUMERICAL DATA

To be born as a twin--risks and sequelae. Moilanen I, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):138–47 (30 ref.)

TWINS, CONJOINED

CLASSIFICATION

Minimally conjoined omphalopagus twinning: a case report. Koltuksuz U, et al. **Eur J Pediatr Surg** 1998 Dec; 8(6):368–70 (11 ref.)

PATHOLOGY

Prosopo-thoracopagus conjoined twins and other cephalopagus-thoracopagus intermediates: case report and review of the literature. Spencer R, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):164–71 (18 ref.)

SURGERY

Minimally conjoined omphalopagus twinning: a case report. Koltuksuz U, et al. **Eur J Pediatr Surg** 1998 Dec; 8(6):368–70 (11 ref.)

TWINS, DIZYGOTIC

The endocrinology of dizygotic twinning in the human. Lambalk CB, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):97–102 (26 ref.)

GENETICS

The timing of twinning: more insights from X inactivation [editorial; comment] Puck JM. **Am J Hum Genet** 1998 Aug; 63(2):327–8 (12 ref.) Comment on: Am J Hum Genet 1998 Aug;63(2):339–36.

TWINS, FRATERNAL see **TWINS, DIZYGOTIC**

TWINS, IDENTICAL see **TWINS, MONOZYGOTIC**

TWINS, MONOZYGOTIC

Long first metacarpal in monozygotic twins with probable Baller-Gerold syndrome. Franceschini P, et al. **Am J Med Genet** 1998 Dec 4;80(4):303–8 (26 ref.)
Gastric carcinoma in Sotos syndrome (cerebral gigantism). Le Marec B, et al. **Ann Genet** 1999;42(2):113–6 (23 ref.)
The consequences of monochorionic placentation. Denbow ML, et al. **Baillieres Clin Obstet Gynaecol** 1998 Mar; 12(1):37–51 (77 ref.)
A spare or an individual? Cloning and the implications of monozygotic twinning. Bryan EM. **Hum Reprod Update** 1998 Nov–Dec;4(6):812–5 (32 ref.)
Slipped capital femoral epiphysis in identical twins: HLA predisposition. Bednarz PA, et al. **Orthopedics** 1998 Dec; 21(12):1291–3 (7 ref.)
Trichorhinophalangeal syndrome type I in monozygotic twins discordant for hip pathology. Report on the morphological evolution of cone-shaped epiphyses and the unusual pattern of skeletal maturation. Naselli A, et al. **Pediatr Radiol** 1998 Nov;28(11):851–5 (9 ref.)
Neurofibromatosis type 2 with multiple primary brain tumors in monozygotic twins. Harada H, et al. **Surg Neurol** 1999 May;51(5):528–35 (30 ref.)
[Monozygotic twins: reproductive anomaly or successful natural cloning?] Blickstein I. **Harefuah** 1998 Sep; 135(5–6):213–7 (27 ref.) **(Heb)**
[Monozygotic twins with suspected hereditary sensory and autonomic neuropathy (HSAN) type V] Itoh Y, et al. **No To Hattatsu** 1999 Jan;31(1):63–9 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Syngeneic peripheral blood stem cell transplantation for chronic myelogenous leukemia associated with Klinefelter's

TWINS, MONOZYGOTIC

syndrome] Fujii H, et al. **Rinsho Ketsueki** 1999 Mar; 40(3):218–23 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The timing of twinning: more insights from X inactivation [editorial; comment] Puck JM. **Am J Hum Genet** 1998 Aug; 63(2):327–8 (12 ref.) Comment on: Am J Hum Genet 1998 Aug;63(2):339–36.

Smith–Fineman–Myers syndrome in apparently monozygotic twins. Guion–Almeida ML, et al. **Am J Med Genet** 1998 Sep 23;79(3):205–8 (4 ref.)

Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. Kimber TE, et al. **J Neurol Sci** 1998 Sep 18;160(1):33–40 (25 ref.)

TWINS, SIAMESE see **TWINS, CONJOINED**

TWO-PARAMETER MODELS see **MODELS, STATISTICAL**

TY1 TRANSPOSON see **RETROELEMENTS**

TYMPANIC CAVITY see **EAR, MIDDLE**

TYMPANIC MEMBRANE

see related
MYRINGOPLASTY
TYMPANOPLASTY

[Bullous myringitis] Satoh H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):283–5 (13 ref.) **(Jpn)**

PATHOLOGY

[Cavernous hemangioma of the tympanic membrane. Otoscopic image] Ramirez Anguiano J, et al. **Rev Invest Clin** 1999 Jan–Feb;51(1):39–42 (8 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Mastoid and tympanomastoid procedures in otitis media: classic mastoidectomy (simple, modified, and radical) and current adaptations; open–cavity, closed–cavity, and intact–bridge tympanomastoidectomy. Goycoolea MV. **Otolaryngol Clin North Am** 1999 Jun;32(3):513–23 (4 ref.)

Closed tympanomastoidectomy. Graham MD, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):547–54 (35 ref.)

Flexible approach to tympanomastoidectomy. Kimberley BP, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):585–95 (3 ref.)

Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567–83 (56 ref.)

TYMPANIC MEMBRANE PERFORATION

SURGERY

Grafting techniques. Wehrs RE. **Otolaryngol Clin North Am** 1999 Jun;32(3):443–55 (11 ref.)

[Prognostic factors in pediatric myringoplasty. A review of 90 cases] Lassaletta Atienza L, et al. **Acta Otorrinolaringol Esp** 1999 Jan–Feb;50(1):1–5 (90 ref.) (Eng. Abstr.) **(Spa)**

TYMPANIC MEMBRANE RUPTURE see **TYMPANIC MEMBRANE PERFORATION**

TYMPANOPLASTY

see related
MYRINGOPLASTY

METHODS

The flexible endaural tympanoplasty: pathology–guided, pathogenesis–oriented surgery for the middle ear. da Costa SS, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):413–41 (66 ref.)

Mastoid and tympanomastoid procedures in otitis media: classic mastoidectomy (simple, modified, and radical) and current adaptations; open–cavity, closed–cavity, and intact–bridge tympanomastoidectomy. Goycoolea MV. **Otolaryngol Clin North Am** 1999 Jun;32(3):513–23 (4 ref.)

A review of type 3 tympanoplasty. Preciado DA, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):401–11 (31 ref.)

Open–cavity tympanomastoidectomy. Roland PS, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):525–46 (17 ref.)

Tympanoplasty: prudent considerations of silent otitis media and interactions of middle ear and inner ear. Vambutas A, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):505–12 (29 ref.)

Grafting techniques. Wehrs RE. **Otolaryngol Clin North Am** 1999 Jun;32(3):443–55 (11 ref.)

[Principles of uncomplicated epi– and epimesotympanitis treatment] Melan'in VD, et al. **Vestn Otorinolaringol** 1999; (4):8–10 (3 ref.) (Eng. Abstr.) **(Rus)**

TYMPANOSTOMY TUBE INSERTION see **MIDDLE EAR VENTILATION**

TYMPANUM see **EAR, MIDDLE**

TYPE A PERSONALITY

[Present status and prospects of researches on type A behavior] Zhang SY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Apr; 17(4):251–3 (18 ref.) **(Chi)**

TYPE C ONCOVIRUSES see **RETROVIRIDAE**

TYPE D ONCORNAVIRUSES see **RETROVIRUSES TYPE D**

TYPE D ONCOVIRUSES see **RETROVIRUSES TYPE D**

TYPE D RETROVIRUSES see **RETROVIRUSES TYPE D**

TYPE I HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

TYPE I RENAL TUBULAR ACIDOSIS see **ACIDOSIS, RENAL TUBULAR**

TYPE II RENAL TUBULAR ACIDOSIS see **ACIDOSIS, RENAL TUBULAR**

TYPE II RESTRICTION ENZYMES see **DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC**

TYPE III HYPERSENSITIVITY see **IMMUNE COMPLEX DISEASES**

TYPE IV HYPERSENSITIVITY see **HYPERSENSITIVITY, DELAYED**

TYPE IV RENAL TUBULAR ACIDOSIS see **HYPOALDOSTERONISM**

TYPHOID

Salmonella hepatitis. Pramoolsinsap C, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):745–50 (67 ref.)

[Pleuropulmonary manifestations of salmonellosis] Hovette P, et al. **Med Trop (Mars)** 1998;58(4):403–7 (67 ref.) (Eng. Abstr.) **(Fre)**

[Typhoid fever--paratyphoid fever] Nagatake T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):486–9 (4 ref.) **(Jpn)**

EPIDEMIOLOGY

Typhoid fever--an update. Sharma V, et al. **Indian J Med Sci** 1998 Apr;52(4):163–5 (10 ref.)

PREVENTION & CONTROL

Bivalent cholera and typhoid vaccine. Foster RH, et al. **Drugs** 1999 Jul;58(1):91–6; discussion 97–8 (10 ref.)

TYPHOID–PARATYPHOID VACCINES

ADMINISTRATION & DOSAGE

[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects] Ivanoff B, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):340–50 (54 ref.) (Eng. Abstr.) **(Fre)**

TYPHUS see **TYPHUS, EPIDEMIC LOUSE-BORNE**

TYPHUS, ABDOMINAL see **TYPHOID**

TYPHUS, ENDEMIC FLEA-BORNE

[Murine typhus] Aoki N. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):279–80 (15 ref.) **(Jpn)**

TYPHUS, EPIDEMIC LOUSE-BORNE

[Brill–Zinsser disease] Aoki N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):281–2 (8 ref.) **(Jpn)**

[Epidemic typhus] Aoki N. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):283–5 (15 ref.) **(Jpn)**

TYPHUS, MURINE see **TYPHUS, ENDEMIC FLEA-BORNE**

TYPHUS, SAO PAULO see **ROCKY MOUNTAIN SPOTTED FEVER**

TYPHUS, SCRUB see **SCRUB TYPHUS**

TYPING, BACTERIAL see **BACTERIAL TYPING TECHNIQUES**

TYPING, FUNGAL see **MYCOLOGICAL TYPING TECHNIQUES**

TYPOLOGY see **SOMATOTYPES**

TYRAMINE

Amplification methods to increase the sensitivity of in situ hybridization: play card(s). Speel EJ, et al. **J Histochem Cytochem** 1999 Mar;47(3):281–8 (74 ref.)

TYROSINASE see **MONOPHENOL MONOOXYGENASE**

TYROSINE

Molecular bases for the recognition of tyrosine–based sorting signals. Bonifacino JS, et al. **J Cell Biol** 1999 May 31; 145(5):923–6 (42 ref.)

ANALOGS & DERIVATIVES

Economic issues in glycoprotein IIb/IIIa receptor therapy. Hillegass WB, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S24–32 (28 ref.)

Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM. **Am J Cardiol** 1998 Oct 22;82(8B):36P–42P (24 ref.)

Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? van der Vliet A, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):1–9 (78 ref.)

Lamifiban. Dooley M, et al. **Drugs** 1999 Feb;57(2):215–21; discussion 222–3 (14 ref.)

Tirofiban. A review of its use in acute coronary syndromes. McClellan KJ, et al. **Drugs** 1998 Dec;56(6):1067–80 (29 ref.)

Measurement and significance of free and protein–bound 3–nitrotyrosine, 3–chlorotyrosine, and free 3–nitro–4–hydroxyphenylacetic acid in biologic samples: a high–performance liquid chromatography method using electrochemical detection. Crow JP. **Methods Enzymol** 1999;301:151–60 (28 ref.)

Quantitation of protein–bound 3–nitrotyrosine by high–performance liquid chromatography with electrochemical detection. Shigenaga MK. **Methods Enzymol** 1999;301:27–40 (18 ref.)

Analytical methods for 3–nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Herce–Pagliai C, et al. **Nitric Oxide** 1998;2(5):324–36 (68 ref.)

Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Kettle AJ, et al. **Redox Rep** 1997 Oct–Dec;3(5–6):257–8 (17 ref.)

Harnessing free radicals: formation and function of the tyrosyl radical in ribonucleotide reductase. Stubbe J, et al. **Trends Biochem Sci** 1998 Nov;23(11):438–43 (45 ref.)

ANALYSIS

Immunoprecipitation of nitrotyrosine–containing proteins. MacMillan–Crow LA, et al. **Methods Enzymol** 1999; 301:135–45 (16 ref.)

Immunohistochemical methods to detect nitrotyrosine. Viera L, et al. **Methods Enzymol** 1999;301:373–81 (34 ref.)

METABOLISM

Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? van der Vliet A, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):1–9 (78 ref.)

Protein tyrosine dephosphorylation and the maintenance of cell adhesions in the pancreas. Schnekenburger J, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:157–65 (31 ref.)

Some aspects of tyrosine secondary metabolism. Rescigno A, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1089–96 (78 ref.)

Regulation of phospholipase C isozymes: activation of phospholipase C–gamma in the absence of tyrosine–phosphorylation. Sekiya F, et al. **Chem Phys Lipids** 1999 Apr;98(1–2):3–11 (41 ref.)

Biology of immunoreceptor tyrosine–based inhibition motif–bearing molecules. Daëron M, et al. **Curr Top Microbiol Immunol** 1999;244:1–12 (78 ref.)

Peroxynitrite inactivates prostacyclin synthase by heme–thiolate–catalyzed tyrosine nitration. Zou M, et al. **Drug Metab Rev** 1999 May;31(2):343–9 (23 ref.)

Growth hormone–induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Yamauchi T, et al. **Endocr J** 1998 Apr;45 Suppl:S27–31 (25 ref.)

Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis. Takeuchi T, et al. **Int Rev Immunol** 1998;17(5–6):365–81 (69 ref.)

Tyrosinaemia type I and NTBC (2–(2–nitro–4–trifluoromethylbenzoyl)–1,3–cyclohexanedione). Holme E, et al. **J Inherit Metab Dis** 1998 Aug;21(5):507–17 (23 ref.)

Integrin–mediated stimulation of tyrosine phosphorylation in lymphoid cells. Gismondi A, et al. **Methods Mol Biol** 1999; 96:205–10 (8 ref.)

PHYSIOLOGY

Role of tyrosine phosphorylation in excitation–contraction coupling in vascular smooth muscle. Hughes AD, et al. **Acta Physiol Scand** 1998 Dec;164(4):457–69 (139 ref.)

Immunoreceptor tyrosine–based inhibition motif–bearing receptors regulate the immunoreceptor tyrosine–based activation motif–induced activation of immune competent cells. Gergely J, et al. **Immunol Lett** 1999 May 3;68(1):3–15

(161 ref.)

TOXICITY

Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Metodiewa D. **Amino Acids** 1998;14(1-3):181-7 (19 ref.)

TYROSINE HYDROXYLASE see **TYROSINE 3-MONOOXYGENASE**

TYROSINE 3-MONOOXYGENASE

ANALYSIS

Peptidergic peripheral nervous systems in the mammalian pineal gland. Matsushima S, et al. **Microsc Res Tech** 1999 Aug 15-Sep 1;46(4-5):265-80 (77 ref.)

DEFICIENCY

A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). Wevers RA, et al. **J Inherit Metab Dis** 1999 Jun;22(4):364-73 (23 ref.)

GENETICS

A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). Wevers RA, et al. **J Inherit Metab Dis** 1999 Jun;22(4):364-73 (23 ref.)

[Recessive dopa-responsive form of dystonia due to a mutation of the tyrosine hydroxylase gene] Rondot P, et al. **Bull Acad Natl Med** 1999;183(3):639-46; discussion 646-7 (25 ref.) (Eng. Abstr.) **(Fre)**

TYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

TYROSINE PROTEIN KINASE see **PROTEIN-TYROSINE KINASE**

TYROSINE-SPECIFIC PROTEIN KINASE see **PROTEIN-TYROSINE KINASE**

TYROSYL PHOSPHOPROTEIN PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

U1 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL, U1**

U1 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U2 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U3 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U3 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U4 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U5 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U6 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U7 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U7 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U-50488

PHARMACOLOGY

U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990. Szmuszkovicz J. **Prog Drug Res** 1999;52:167-95 (74 ref.)

U50488H see **U-50488**

UBIQUINOL-CYTOCHROME-C REDUCTASE

CHEMISTRY

A novel electron transfer mechanism suggested by crystallographic studies of mitochondrial cytochrome bc1 complex. Xia D, et al. **Biochem Cell Biol** 1998;76(5):673-9 (27 ref.)

Energy transduction function of the quinone reactions in cytochrome bc complexes. Cramer WA, et al. **Biofactors** 1999;9(2-4):81-6 (22 ref.)

Three-dimensional structure and functions of bovine heart mitochondrial cytochrome bc1 complex. Yu CA, et al. **Biofactors** 1998;8(3-4):187-9 (6 ref.)

[Structure of cytochrome bc1 complex from bovine heart mitochondria] Iwata M, et al. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):643-54 (28 ref.) **(Jpn)**

DEFICIENCY

Respiratory chain complex in deficiency with pruritus: a novel vitamin responsive clinical feature. Mowat D, et al. **J Pediatr** 1999 Mar;134(3):352-4 (13 ref.)

METABOLISM

Energy transduction function of the quinone reactions in cytochrome bc complexes. Cramer WA, et al. **Biofactors** 1999;9(2-4):81-6 (22 ref.)

Three-dimensional structure and functions of bovine heart mitochondrial cytochrome bc1 complex. Yu CA, et al. **Biofactors** 1998;8(3-4):187-9 (6 ref.)

UBIQUINONE

ADMINISTRATION & DOSAGE

[Ubiquinone--what should one, as physician, think of it?] Ernst E. **Fortschr Med** 1998 Aug 30;116(24):18-9 (16 ref.) **(Ger)**

ANALOGS & DERIVATIVES

Coenzyme Q10. Pepping J. **Am J Health Syst Pharm** 1999 Mar 15;56(6):519-21 (27 ref.)

Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Beal MF. **Biofactors** 1999; 9(2-4):261-6 (35 ref.)

CoQ10: could it have a role in cancer management? Hodges S, et al. **Biofactors** 1999;9(2-4):365-70 (17 ref.)

Coenzyme Q10, a cutaneous antioxidant and energizer. Hoppe U, et al. **Biofactors** 1999;9(2-4):371-8 (33 ref.)

Overview of the use of CoQ10 in cardiovascular disease. Langsjoen PH, et al. **Biofactors** 1999;9(2-4):273-84 (92 ref.)

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Shults CW, et al. **Biofactors** 1999;9(2-4):267-72 (27 ref.)

A role for reduced coenzyme Q in atherosclerosis? Thomas SR, et al. **Biofactors** 1999;9(2-4):207-24 (119 ref.)

beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Nishimura T. **Int J Card Imaging** 1999 Feb;15(1):41-8 (30 ref.)

BIOSYNTHESIS

[Recent advance of the biosynthesis and the function of ubiquinone] Kawamukai M. **Seikagaku** 1998 Nov; 70(11):1344-9 (19 ref.) **(Jpn)**

CHEMISTRY

Localization and mobility of coenzyme Q in lipid bilayers and membranes. Lenaz G, et al. **Biofactors** 1999; 9(2-4):87-93 (21 ref.)

DEFICIENCY

Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? McCarty MF. **Med Hypotheses** 1999 May;52(5):397-400 (31 ref.)

METABOLISM

Proton translocation in the respiratory chain involving ubiquinone--a hypothetical semiquinone switch mechanism for complex I. Brandt U. **Biofactors** 1999;9(2-4):95-101 (30 ref.)

Localization and mobility of coenzyme Q in lipid bilayers and membranes. Lenaz G, et al. **Biofactors** 1999; 9(2-4):87-93 (21 ref.)

Role of coenzyme Q and superoxide in vitamin E cycling. Kagan VE, et al. **Subcell Biochem** 1998;30:491-507 (77 ref.)

Prooxidant functions of coenzyme Q. Nohl H, et al. **Subcell Biochem** 1998;30:509-26 (32 ref.)

PHYSIOLOGY

The biochemical, pathophysiological, and medical aspects of ubiquinone function. Nohl H, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:394-409 (25 ref.)

A role for reduced coenzyme Q in atherosclerosis? Thomas SR, et al. **Biofactors** 1999;9(2-4):207-24 (119 ref.)

Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? McCarty MF. **Med Hypotheses** 1999 May;52(5):397-400 (31 ref.)

THERAPEUTIC USE

[Antioxidants in the comprehensive therapy of myocardial infarction] Simonenko VB. **Klin Med (Mosk)** 1998; 76(11):20-5 (70 ref.) **(Rus)**

UBIQUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

UBIQUITIN

[Human diseases associated with ubiquitin/proteasome proteolytic system] Anan T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):776-86 (45 ref.) **(Jpn)**

[Ubiquitin-like proteins and its ligation systems] Chiba T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):744-51 (44 ref.) **(Jpn)**

[Roles of the ubiquitin system in stress responses] Iwai K. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):759-65 (43 ref.) **(Jpn)**

[The ubiquitin-ligating system: from the discovery to the present] Tanaka K. **Tanpakushitsu Kakusan Koso** 1999 May; 44(6):737-43 (22 ref.) **(Jpn)**

[The ubiquitin world: a novel cellular control system] Yokosawa H. **Tanpakushitsu Kakusan Koso** 1999 May; 44(6):732-6 (21 ref.) **(Jpn)**

ANALYSIS

Familial neuronal intranuclear inclusion -disease with ubiquitin positive inclusions. Kimber TE, et al. **J Neurol Sci** 1998 Sep 18;160(1):33-40 (25 ref.)

GENETICS

Structure and evolution of genes encoding polyubiquitin in marine sponges. Gamulin V, et al. **Prog Mol Subcell Biol** 1998;21:157-81 (73 ref.)

METABOLISM

The ubiquitin system. Hershko A, et al. **Annu Rev Biochem** 1998;67:425-79 (298 ref.)

Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Bonifacino JS, et al. **Annu Rev Cell Dev Biol** 1998;14:19-57 (164 ref.)

P62 and the sequestosome, a novel mechanism for protein metabolism. Shin J. **Arch Pharm Res** 1998 Dec;21(6):629-33 (35 ref.)

Substrate targeting in the ubiquitin system. Laney JD, et al. **Cell** 1999 May 14;97(4):427-30 (25 ref.)

The role of the ubiquitin-proteasome pathway in apoptosis. Orlowski RZ. **Cell Death Differ** 1999 Apr;6(4):303-13 (115 ref.)

Deubiquitinating enzymes: a new class of biological regulators. D'Andrea A, et al. **Crit Rev Biochem Mol Biol** 1998;33(5):337-52 (58 ref.)

Protein regulation: tag wrestling with relatives of ubiquitin. Hodges M, et al. **Curr Biol** 1998 Oct 22;8(21):R749-52 (25 ref.)

The measurement of ubiquitin and ubiquitinated proteins. Mimnaugh EG, et al. **Electrophoresis** 1999 Feb;20(2):418-28 (99 ref.)

The ubiquitin-proteasome pathway: on protein death and cell life. Ciechanover A. **EMBO J** 1998 Dec 15;17(24):7151-60 (75 ref.)

Subunits and substrates of the anaphase-promoting complex. Peters JM. **Exp Cell Res** 1999 May 1;248(2):339-49 (102 ref.)

Ubiquitin superfolds: intrinsic and attachable regulators of cellular activities? Mayer RJ, et al. **Fold Des** 1998; 3(5):R97-9 (35 ref.)

The involvement of the ubiquitin system in Alzheimer's disease (review). Pallares-Trujillo J, et al. **Int J Mol Med** 1998 Jul;2(1):3-15 (156 ref.)

Ubiquitin system: selectivity and timing of protein destruction. Yamao F. **J Biochem (Tokyo)** 1999 Feb; 125(2):223-9 (48 ref.)

Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. Lecker SH, et al. **J Nutr** 1999 Jan;129(1S Suppl):227S-237S (103 ref.)

Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Attaix D, et al. **Mol Biol Rep** 1999 Apr;26(1-2):77-82 (43 ref.)

Role of the ubiquitin-proteasome pathway in sepsis-induced muscle catabolism. Hasselgren PO. **Mol Biol Rep** 1999 Apr; 26(1-2):71-6 (39 ref.)

The ligation systems for ubiquitin and ubiquitin-like proteins. Tanaka K, et al. **Mol Cells** 1998 Oct 31;8(5):503-12 (65 ref.)

Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions. Harvey KF, et al. **Trends Cell Biol** 1999 May;9(5):166-9 (34 ref.)

Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Hicke L. **Trends Cell Biol** 1999 Mar;9(3):107-12 (52 ref.)

PHYSIOLOGY

The ubiquitin-proteasome pathway and pathogenesis of human diseases. Schwartz AL, et al. **Annu Rev Med** 1999; 50:57-74 (79 ref.)

The ubiquitin-proteasome system and endocytosis. Strous GJ, et al. **J Cell Sci** 1999 May;112 (Pt 10):1417-23 (80 ref.)

The ubiquitin system in gametogenesis. Baarends WM, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):5-16 (120 ref.)

Ubiquitin and its role in neurodegeneration. Arnold J, et al. **Prog Brain Res** 1998;117:23-34 (53 ref.)

Ubiquitin, cellular inclusions and their role in neurodegeneration. Alves-Rodrigues A, et al. **Trends Neurosci** 1998 Dec;21(12):516-20 (60 ref.)

[Regulation of cell division by ubiquitin-dependent proteolysis and spindle assembly checkpoint] Kazuo T. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):253-62 (41 ref.) **(Jpn)**

[Molecular mechanism of ubiquitin proteasome-regulated quality control in the endoplasmic reticulum] Tokunaga F. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):766-75 (67 ref.) **(Jpn)**

UBIQUITIN

[Role of the ubiquitin system in the etiology of cancer and other diseases] Argilés JM, et al. **Med Clin (Barc)** 1998 Oct 10;111(11):423–6 (23 ref.) **(Spa)**

UDDER see **MAMMAE**

UDP GLUCURONOSYLTRANSFERASE see **GLUCURONOSYLTRANSFERASE**

UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE

see related
GALACTOSEMIA

ULCER

see related
CORNEAL ULCER
PEPTIC ULCER
SKIN ULCER

Solitary rectal ulcer syndrome. Vaizey CJ, et al. **Br J Surg** 1998 Dec;85(12):1617–23 (89 ref.)

[The solitary rectal ulcer today. A review of the literature] Nincheri Kunz M, et al. **Minerva Chir** 1998 Nov; 53(11):919–34 (99 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

[An ileal ulcer and diaphragm-type colonic stenosis due to diclofenac] Aguirre Palacio A, et al. **Gastroenterol Hepatol** 1999 May;22(5):232–4 (21 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Esophageal stricture from idiopathic ulcers in an AIDS patient: a case report and review of the literature. Borum ML, et al. **J Clin Gastroenterol** 1999 Apr;28(3):260–1 (13 ref.)

[Dieulafoy colonic ulcer. A rare cause of lower gastrointestinal hemorrhage] Maire F, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):958–60 (25 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Ulcer of the thoracic aorta: diagnosis, therapy and prognosis] von Kodolitsch Y, et al. **Z Kardiol** 1998 Dec;87(12):917–27 (70 ref.) (Eng. Abstr.) **(Ger)**

[The solitary benign ulcer of the colon: a report of a case located in the cecum] Damiani S, et al. **G Chir** 1998 Oct; 19(10):381–5 (28 ref.) (Eng. Abstr.) **(Ita)**

[Ulcers and regional adenopathies in a butcher] Maradona Hidalgo JA, et al. **Rev Clin Esp** 1998 Nov;198(11):773–4 (4 ref.) **(Spa)**

THERAPY

The chronic non-healing wound: how to make it better. Grey JE, et al. **Hosp Med** 1998 Jul;59(7):557–63 (28 ref.)

VIROLOGY

Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Hudson LB, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):642–4 (4 ref.)

Genital ulcers associated with acute Epstein-Barr virus infection. Taylor S, et al. **Sex Transm Infect** 1998 Aug; 74(4):296–7 (6 ref.)

ULCER, APHTHOUS see **STOMATITIS, APHTHOUS**

ULCER, RODENT see **CARCINOMA, BASAL CELL**

ULNA

Small cell osteosarcoma of the ulna: a case report and review of the literature. Mulligan ME, et al. **J Hand Surg [Am]** 1999 Mar;24(2):417–20 (12 ref.)

INJURIES

["Around the head of the ulna": injury pattern and classification] van Schoonhoven J, et al. **Handchir Mikrochir Plast Chir** 1998 Nov;30(6):351–60 (22 ref.) (Eng. Abstr.) **(Ger)**

ULNA FRACTURES

COMPLICATIONS

Forearm and distal radius fractures in children. Noonan KJ, et al. **J Am Acad Orthop Surg** 1998 May-Jun;6(3):146–56 (43 ref.)

[Combined fractures of the radius and the ulna at the elbow level in the adult. Analysis of 120 cases after more than 1 year] Heim U. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Apr; 84(2):142–53 (24 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Periprosthetic fractures about the elbow. O'Driscoll SW, et al. **Orthop Clin North Am** 1999 Apr;30(2):319–25 (18 ref.)

SURGERY

The radioulnar joints and forearm axis: surgeons' perspective. Tang P, et al. **J Hand Ther** 1999 Apr-Jun;12(2):75–84 (40 ref.)

[Combined fractures of the radius and the ulna at the elbow level in the adult. Analysis of 120 cases after more than 1 year] Heim U. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Apr; 84(2):142–53 (24 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The treatment of forearm fractures from penetrating trauma. Kozin SH, et al. **Hand Clin** 1999 May;15(2):221–31, viii (29 ref.)

Functional fracture bracing. Sarmiento A, et al. **J Am Acad Orthop Surg** 1999 Jan;7(1):66–75 (37 ref.)

ULNAR ARTERY

SURGERY

Vascular disorders of the hand: surgeons' perspective. Levin LS, et al. **J Hand Ther** 1999 Apr-Jun;12(2):152–9 (14 ref.)

ULNAR NERVE

Ulnar neuropathy at the wrist. Kothari MJ. **Neurol Clin** 1999 Aug;17(3):463–76, vi (37 ref.)

INJURIES

Traumatic forearm amputation with avulsions of the ulnar and median nerves from the brachial plexus. Kaleli T, et al. **Arch Orthop Trauma Surg** 1998;118(1-2):119–20 (9 ref.)

Medial collateral ligament instability and ulnar neuritis in the athlete's elbow. Ciccotti MG, et al. **Instr Course Lect** 1999;48:383–91 (36 ref.)

PATHOLOGY

Anatomic considerations in evaluation of the proximal ulnar nerve. Oswald TA. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):777–94 (84 ref.)

PHYSIOLOGY

Premotor potentials. Mandel JD. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):765–76, vi (21 ref.)

Median and ulnar nerves in the hand. Sable AW. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):737–53 (74 ref.)

SURGERY

Surgical management of ulnar nerve compression at the elbow: an analysis of the literature. Bartels RH, et al. **J Neurosurg** 1998 Nov;89(5):722–7 (69 ref.)

ULNAR NERVE COMPRESSION see **ULNAR NERVE COMPRESSION SYNDROME**

ULNAR NERVE COMPRESSION SYNDROME

Compressive ulnar neuropathies at the elbow: I. Etiology and diagnosis. Posner MA. **J Am Acad Orthop Surg** 1998 Sep-Oct;6(5):282–8 (21 ref.)

DIAGNOSIS

Ulnar neuropathy at the elbow. Bradshaw DY, et al. **Neurol Clin** 1999 Aug;17(3):447–61, v-vi (72 ref.)

Anatomic considerations in evaluation of the proximal ulnar nerve. Oswald TA. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):777–94 (84 ref.)

SURGERY

Treatment of peripheral nerve injuries: surgeons' perspective. Seiler JG 3rd, et al. **J Hand Ther** 1999 Apr-Jun; 12(2):135–40 (23 ref.)

Surgical management of ulnar nerve compression at the elbow: an analysis of the literature. Bartels RH, et al. **J Neurosurg** 1998 Nov;89(5):722–7 (69 ref.)

THERAPY

Compressive ulnar neuropathies at the elbow: II. treatment. Posner MA. **J Am Acad Orthop Surg** 1998 Sep-Oct; 6(5):289–97 (26 ref.)

ULNAR NERVE ENTRAPMENT see **ULNAR NERVE COMPRESSION SYNDROME**

ULTIMOBRANCHIAL BODY

see related
CALCITONIN

ULTRACENTRIFUGATION

Recent developments towards a unified theory for separation science (minireview). Bowser MT, et al. **Electrophoresis** 1998 Jul;19(10):1586–9 (34 ref.)

[Applications and future perspectives of analytical ultracentrifugation] Arisaka F. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):82–91 (17 ref.) **(Jpn)**

[Analytical ultracentrifugation] Arisaka F. **Tanpakushitsu Kakusan Koso** 1998 Oct;43(13):2024–32 (3 ref.) **(Jpn)**

METHODS

Fast ultracentrifugation methods for the separation of plasma lipoproteins. Ordovas JM. **Methods Mol Biol** 1998; 110:93–103 (7 ref.)

[Introduction to analytical ultracentrifugation and its new development] Arisaka F. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2145–52 (11 ref.) **(Jpn)**

[Sedimentation equilibrium] Arisaka F. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(15):2238–44 (21 ref.) **(Jpn)**

ULTRADIAN CYCLES see **ACTIVITY CYCLES**

ULTRAFILTRATION

see related
HEMOFILTRATION

Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy [editorial] Wang SN, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2072–4 (12 ref.)

ULTRAHIGH FREQUENCY WAVES see **RADIO WAVES**

ULTRAMICROTOMY see **MICROTOMY**

ULTRASONIC DIAGNOSIS see **ULTRASONOGRAPHY**

ULTRASONIC ENDOSCOPY see **ENDOSONOGRAPHY**

ULTRASONIC IMAGING see **ULTRASONOGRAPHY**

ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

ULTRASONIC THERAPY

Massage and ultrasound as therapeutic modalities in exercise-induced muscle damage. Tiidus PM. **Can J Appl Physiol** 1999 Jun;24(3):267–78 (50 ref.)

Enhancement of fracture healing by low intensity ultrasound. Hadjiargyrou M, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S216–29 (38 ref.)

Wetting solutions in ultrasound-assisted lipoplasty. Fodor PB, et al. **Clin Plast Surg** 1999 Apr;26(2):289–93; ix (27 ref.)

Analysis and introduction of a technology: Ultrasound-assisted Lipoplasty Task Force. Fredricks S. **Clin Plast Surg** 1999 Apr;26(2):187–204; vii (5 ref.)

Comparing ultrasound-assisted lipoplasty with suction-assisted lipoplasty. Gingrass MK, et al. **Clin Plast Surg** 1999 Apr;26(2):283–8; ix (2 ref.)

Patient selection, planning, and marking in ultrasound-assisted lipoplasty. Hughes CE 3rd. **Clin Plast Surg** 1999 Apr;26(2):279–82; ix (0 ref.)

Ultrasound-assisted lipoplasty. Basic science and clinical research. Kenkel JM, et al. **Clin Plast Surg** 1999 Apr; 26(2):221–34; vii (35 ref.)

Staff education and training for ultrasound-assisted lipoplasty. Mustoe TA. **Clin Plast Surg** 1999 Apr; 26(2):295–8; ix (3 ref.)

Positioning for ultrasound-assisted lipoplasty. Nahai F. **Clin Plast Surg** 1999 Apr;26(2):235–43 (2 ref.)

Operative principles for optimizing results in circumferential body contouring with ultrasound-assisted lipoplasty. Rohrich RJ, et al. **Clin Plast Surg** 1999 Apr;26(2):305–16; x (12 ref.)

Patient evaluation and indications for ultrasound-assisted lipoplasty. Rohrich RJ, et al. **Clin Plast Surg** 1999 Apr; 26(2):269–78; viii (11 ref.)

Basic physics for ultrasound-assisted lipoplasty. Zocchi ML. **Clin Plast Surg** 1999 Apr;26(2):209–20; vii (0 ref.)

Ultrasonic thrombolysis: catheter-delivered and transcutaneous applications. Atar S, et al. **Eur J Ultrasound** 1999 Mar;9(1):39–54 (47 ref.)

Therapeutic ultrasound. ter Haar G. **Eur J Ultrasound** 1999 Mar;9(1):3–9 (47 ref.)

Ultrasonic assisted liposuction. Kanter WR, et al. **Md Med J** 1999 Jul-Aug;48(4):165–8 (18 ref.)

Ultrasound technology for hyperthermia. Diederich CJ, et al. **Ultrasound Med Biol** 1999 Jul;25(6):871–87 (138 ref.)

INSTRUMENTATION

A comparison of various ultrasound technologies. Chang CC, et al. **Clin Plast Surg** 1999 Apr;26(2):261–8; viii (5 ref.)

The solid-probe technique in ultrasound-assisted lipoplasty. Grotting JC, et al. **Clin Plast Surg** 1999 Apr;26(2):245–54; viii (9 ref.)

Use of hollow cannula technology in ultrasound-assisted lipoplasty. Maxwell GP. **Clin Plast Surg** 1999 Apr; 26(2):255–60; viii (7 ref.)

Equipment and instrumentation for ultrasound-assisted lipoplasty. Thornton LK, et al. **Clin Plast Surg** 1999 Apr; 26(2):299-304; x (7 ref.)

METHODS

High intensity focused ultrasound in benign prostatic hyperplasia. Hegarty NJ, et al. **Eur J Ultrasound** 1999 Mar; 9(1):55-60 (27 ref.)

Hemostasis using high intensity focused ultrasound. Vaezy S, et al. **Eur J Ultrasound** 1999 Mar;9(1):79-87 (23 ref.)

[Ultrasound techniques of diagnosis in treatment in modern medicine] Genina EA, et al. **Vestn Rentgenol Radiol** 1998 Sep-Oct;(5):52-5 (36 ref.) **(Rus)**

STANDARDS

Safety issues in ultrasound-assisted large-volume lipoplasty. Gilliland MD, et al. **Clin Plast Surg** 1999 Apr;26(2):317-35; x (86 ref.)

ULTRASONICS

Biot theory: a review of its application to ultrasound propagation through cancellous bone. Haire TJ, et al. **Bone** 1999 Apr;24(4):291-5 (53 ref.)

Application of the advanced communications technology satellite to teleradiology and real-time compressed ultrasound video telemedicine. Stewart BK, et al. **J Digit Imaging** 1999 May;12(2):68-76 (12 ref.)

ADVERSE EFFECTS

Liposculpture with ultrasound: biomedical considerations. Bruno G, et al. **Aesthetic Plast Surg** 1998 Nov-Dec; 22(6):401-3 (20 ref.)

Thermal teratology. **Ultraschall Med** 1999 Jun;20(3):125-7 (13 ref.)

ULTRASONOGRAPHY

Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria. Creinin MD, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):35-41 (18 ref.)

Emergency medicine resident education: making a case for training residents to perform and interpret bedside sonographic examinations. Sankoff J, et al. **Ann Emerg Med** 1999 Jul;34(1):105-8 (28 ref.)

Gastrointestinal manifestations of cystic fibrosis in adults: pictorial essay. Brown JA, et al. **Can Assoc Radiol J** 1999 Jun;50(3):165-9 (9 ref.)

Hamartoma of the urinary bladder: case report and review of the literature. Brancatelli G, et al. **Eur Radiol** 1999; 9(1):42-4 (15 ref.)

Safety of ultrasonic contrast agents. **Ultraschall Med** 1999 Jun;20(3):122-3 (15 ref.)

[Patient with right-sided epigastric pain and "negative" ultrasound] Rosien U, et al. **Schweiz Rundsch Med Prax** 1998 Nov 11;87(46):1563-70 (28 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

European Committee for Medical Ultrasound Safety (ECMUS). Rott HD. **Eur J Ultrasound** 1999 May; 9(2):191-3 (6 ref.)

Acoustic cavitation and capillary bleeding. **Ultraschall Med** 1999 Jun;20(3):124-5 (10 ref.)

INSTRUMENTATION

Rationale and derivation of MI and TI--a review. Abbott JG. **Ultrasound Med Biol** 1999 Mar;25(3):431-41 (19 ref.)

[Physical and technical principles of B-image ultrasound] Lorenz A, et al. **Radiologe** 1999 Jul;39(7):W624-42 (11 ref.) **(Ger)**

[Ultrasound--already clinically relevant?] Glüer CC, et al. **Ther Umsch** 1998 Nov;55(11):667-75 (34 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Impaired endothelial function in hypertensive elderly patients evaluated by high resolution ultrasonography. Kimura Y, et al. **Can J Cardiol** 1999 May;15(5):563-8 (36 ref.)

Safety of ultrasonic contrast agents. European Committee for Medical Ultrasound Safety. Rott HD. **Eur J Ultrasound** 1999 May;9(2):195-7 (15 ref.)

Detection of lines and boundaries in speckle images--application to medical ultrasound. Czerwinski RN, et al. **IEEE Trans Med Imaging** 1999 Feb;18(2):126-36 (37 ref.)

Applications of musculoskeletal sonography. Hashimoto BE, et al. **J Clin Ultrasound** 1999 Jul-Aug;27(6):293-318 (153 ref.)

The case for ultrasound [editorial] Kavic MS. **J Soc Laparoendosc Surg** 1997 Apr-Jun;1(2):101-2 (6 ref.)

Ultrasound in blunt abdominal trauma. Fernandez L, et al. **J Trauma** '998 Oct;45(4):841-8 (53 ref.)

Measurements of organ volume by ultrasonography. Gilja OH, et al. **Proc Inst Mech Eng [H]** 1999;213(3):247-59 (119 ref.)

Acoustic and ultrasonic tissue characterization--assessment of osteoporosis. Langton CM, et al. **Proc Inst Mech Eng [H]** 1999;213(3):261-9 (54 ref.)

Three-dimensional morphometry in ultrasound. Linney AD, et al. **Proc Inst Mech Eng [H]** 1999;213(3):235-45 (62 ref.)

Elastography: ultrasonic estimation and imaging of the elastic properties of tissues. Ophir J, et al. **Proc Inst Mech Eng [H]** 1999;213(3):203-33 (135 ref.)

Pulse compression for finite amplitude distortion based harmonic imaging using coded waveforms. Li PC. **Ultrason Imaging** 1999 Jan;21(1):1-16 (23 ref.)

Three-dimensional ultrasound imaging. Nelson TR, et al. **Ultrasound Med Biol** 1998 Nov;24(9):1243-70 (300 ref.)

[13-MHc high frequency ultrasound of the lateral ligaments of the ankle joint and the anterior tibia-fibular ligament. Comparison and results of MRI in 64 patients] Milz P, et al. **Radiologe** 1999 Jan;39(1):34-40 (25 ref.) (Eng. Abstr.) **(Ger)**

[Tridimensional ultrasonography. First clinical experience with dedicated devices and review of the literature] Cesarani F, et al. **Radiol Med (Torino)** 1999 Apr; 97(4):256-64 (54 ref.) (Eng. Abstr.) **(Ita)**

[Ultrasound contrast agents] Drop A. **Ann Univ Mariae Curie Sklodowska [Med]** 1997;52:167-71 (9 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Should UK emergency physicians undertake diagnostic ultrasound examinations? Robinson NA, et al. **J Accid Emerg Med** 1999 Jul;16(4):248-9 (21 ref.)

Focused abdominal sonogram for trauma: the learning curve of nonradiologist clinicians in detecting hemoperitoneum. Shackford SR, et al. **J Trauma** 1999 Apr;46(4):553-62; discussion 562-4 (40 ref.)

High-quality gynecological ultrasound can be highly beneficial, but poor-quality gynecological ultrasound can do harm [editorial] Valentin L. **Ultrasound Obstet Gynecol** 1999 Jan;13(1):1-7 (60 ref.)

TRENDS

Enthusiasm for ultrasound for osteoporosis screening is premature [editorial; comment] Richmond BJ. **Cleve Clin J Med** 1998 Sep;65(8):403-4 (9 ref.) Comment on: Cleve Clin J Med 1998 Sep;65(8):398-401.

Current and future role of ultrasound in the emergency department. Burnett HC, et al. **J Accid Emerg Med** 1999 Jul;16(4):250-4 (16 ref.)

The American Institute of Ultrasound in Medicine and the Society of Radiologists in Ultrasound--future directions in diagnostic US. Kremkau FW, et al. **Radiology** 1998 Nov; 209(2):305-11; discussion 312-3 (48 ref.)

ULTRASONOGRAPHY, COLOR DOPPLER see **ULTRASONOGRAPHY, DOPPLER, COLOR**

ULTRASONOGRAPHY, DOPPLER

Transcranial and orbital Doppler ultrasound in normal pregnancy and preeclampsia. Belfort MA, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):479-506 (57 ref.)

Clinical and imaging features of testicular torsion: role of ultrasound. Sidhu PS. **Clin Radiol** 1999 Jun;54(6):343-52 (104 ref.)

Diagnosis of renal artery stenosis and renovascular hypertension. Karasch T, et al. **Eur J Ultrasound** 1998 Jul; 7 Suppl 3:S27-39 (60 ref.)

Carotid artery stenosis--where do we go from here? Strandness DE, et al. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S17-26 (29 ref.)

Focal liver lesions: Doppler ultrasound. Hosten N, et al. **Eur Radiol** 1999;9(3):428-35 (34 ref.)

'Nonportal' splanchnic venous supply to the liver: abnormal findings on CT, US and MRI. Itai Y, et al. **Eur Radiol** 1999;9(2):237-43 (35 ref.)

Pelvic Doppler. Levine D. **Semin Ultrasound CT MR** 1999 Aug;20(4):239-49 (62 ref.)

Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Piscaglia F, et al. **Ultrasound Med Biol** 1999 Jul;25(6):923-32 (90 ref.)

The assessment of ovarian tumor angiogenesis: what does three-dimensional power Doppler add? Kurjak A, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):136-46 (98 ref.)

[Contrast media in ultrasonography] Karstrup S, et al. **Ugeskr Laeger** 1999 May 17;161(20):2938-43 (38 ref.) (Eng. Abstr.) **(Dan)**

[Echo-doppler surveillance of revascularization of the legs in asymptomatic postoperative patients. Why? With what rhythm? How much time? How?] Mellière D, et al. **J Mal Vasc** 1999 Jun;24(3):233-8 (20 ref.) (Eng. Abstr.) **(Fre)**

[Doppler ultrasonographic examination in glaucoma] Borisova SA. **Vestn Oftalmol** 1998 Jul-Aug;114(4):52-5 (76 ref.) **(Rus)**

[Study of intervillous blood circulation using color and pulsed doppler ultrasound] Kurjak A, et al. **Lijec Vjesn** 1999 Jun;121(6):194-8 (31 ref.) (Eng. Abstr.) **(Scr)**

[Obstetric Doppler--justified i high-risk pregnancies] Grunewald C. **Lakartidningen** 1998 Sep 30;95(40):4360-4 (72 ref.) (Eng. Abstr.) **(Swe)**

INSTRUMENTATION

The role of endoscopic Doppler-sonography. Kohler B, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):732-6 (17 ref.)

METHODS

Portohepatic vascular pathology and liver disease: diagnosis and monitoring. Bolondi L, et al. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S41-52 (41 ref.)

Assessment of hemodialysis access performance by color-flow Doppler ultrasound. Sands JJ, et al. **J Biomater Appl** 1999 Jan;13(3):224-37 (15 ref.)

Measurement of tissue motion. Anderson T, et al. **Proc Inst Mech Eng [H]** 1999;213(3):181-91 (39 ref.)

Ultrasonic investigation of blood flow. Fish PJ. **Proc Inst Mech Eng [H]** 1999;213(3):169-80 (28 ref.)

Estimation of blood perfusion using ultrasound. Jansson T, et al. **Proc Inst Mech Eng [H]** 1999;213(2):91-106 (110 ref.)

[Assessment of blood flow by Doppler method] Inoue Y, et al. **Nippon Rinsho** 1999 Jul;57(7):1537-41 (10 ref.) (Eng. Abstr.) **(Jpn)**

[The application of color doppler sonography in contemporary mammary studies] Golovko TS. **Klin Khir** 1998;(6):40-2 (45 ref.) **(Rus)**

STANDARDS

In search of the Holy Grail: noninvasive or "low-invasive" cardiac output monitoring [editorial; comment] Soble JS. **Crit Care Med** 1998 Dec;26(12):1953-4 (10 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2066-72.

ULTRASONOGRAPHY, DOPPLER, COLOR

Color Doppler applications in hepatic imaging. Shapiro RS, et al. **Clin Imaging** 1998 Jul-Aug;22(4):272-9 (23 ref.)

Investigation of peripheral arterial disease--the expanding role of echo-enhanced color flow doppler and duplex sonography. Langholz J. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S53-61 (25 ref.)

Power Doppler sonography: general principles, clinical applications, and future prospects. Martinoli C, et al. **Eur Radiol** 1998;8(7):1224-35 (57 ref.)

Aneurysm of the celiac trunk: diagnosis with US-color-Doppler. Presentation of a new case and review of the literature. Veraldi GF, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):781-3 (25 ref.)

Celiac artery aneurysm: diagnosis by color Doppler sonography and three-dimensional CT angiography. Soudack M, et al. **J Clin Ultrasound** 1999 Jan;27(1):49-51 (7 ref.)

Transcranial color-coded duplex sonography. Baumgartner RW. **J Neurol** 1999 Aug;246(8):637-47 (96 ref.)

Color Doppler imaging of the eye and orbit. Lieb WE. **Radiol Clin North Am** 1998 Nov;36(6):1059-71 (91 ref.)

The role of color Doppler ultrasonography in obstetrics. Abrahim-Zadeh R, et al. **Semin Roentgenol** 1998 Oct; 33(4):351-9 (29 ref.)

Color Doppler imaging of the retrobulbar circulation in glaucoma. Rankin SJ. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S176-82 (28 ref.)

Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Bogers HA, et al. **Urology** 1999 Jul;54(1):97-104 (34 ref.)

[Contribution of doppler imaging of the myocardium to the study of cardiomyopathies] Pellerin D, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12 Suppl):51-8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Possibilities and limits of Doppler ultrasound in the area of the head-neck] Issing PR. **HNO** 1999 Jan;47(1):6-13 (42 ref.) (Eng. Abstr.) **(Ger)**

[Duplex ultrasound of the liver and portal vein system] Mohr HH, et al. **Med Klin** 1998 Nov 15;93(11):669-77 (72 ref.) (Eng. Abstr.) **(Ger)**

[Computer-assisted quantitative evaluation method of color Doppler images in tumor diagnosis] Huber S. **Radiologe** 1998 Oct;38(10):867-71 (31 ref.) (Eng. Abstr.) **(Ger)**

[Preoperative assessment of primary varicose veins] Pfyffer M. **Schweiz Med Wochenschr** 1998 Nov 7;128(45):1772-80 (50 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Amplitude-coded color doppler: clinical applications. Turetschek K, et al. **Eur Radiol** 1999;9(1):115-21 (52 ref.)

METHODS

Power Doppler imaging: principles and applications. Hudson-Dixon CM, et al. **Radiol Technol** 1999 Jan-Feb; 70(3):235-43 (36 ref.)

Three-dimensional power Doppler imaging of the fallopian tube. Sladkevicius P. **Ultrasound Obstet Gynecol** 1999 Apr; 13(4):287 (2 ref.)

ULTRASONOGRAPHY, DOPPLER, DUPLEX

Vascular surgery without arteriography: use of Duplex ultrasound. Zierler RE. **Cardiovasc Surg** 1999 Jan; 7(1):74-82 (63 ref.)

Transcranial color-coded duplex sonography. Baumgartner RW. **J Neurol** 1999 Aug;246(8):637-47 (96 ref.)

[Duplex Doppler sonography of splanchnic circulation in man. Clinical and physiological importance] Dauzat M, et

ULTRASONOGRAPHY, DOPPLER, DUPLEX

al. **Gastroenterol Clin Biol** 1998 Apr;22(4):394–404 (111 ref.) **(Fre)**

[Duplex ultrasound of the liver and portal vein system] Mohr HH, et al. **Med Klin** 1998 Nov 15;93(11):669–77 (72 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY, DOPPLER, PULSED

[Vascular exploration of erectile dysfunction] Sussman H. **J Mal Vasc** 1999 May;24(2):143–7 (12 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL

Transcranial Doppler: preventing stroke during carotid endarterectomy. Gaunt ME. **Ann R Coll Surg Engl** 1998 Nov;80(6):377–87 (43 ref.)

Echo-enhanced ultrasound for diagnosis and management in stroke patients. Ringelstein EB. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S3–15 (57 ref.)

Transcranial color-coded duplex sonography. Baumgartner RW. **J Neurol** 1999 Aug;246(8):637–47 (96 ref.)

Transcranial Doppler ultrasound [editorial] Markus HS. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):135–7 (22 ref.)

Consensus opinion on diagnosis of cerebral circulatory arrest using Doppler-sonography: Task Force Group on cerebral death of the Neurosonology Research Group of the World Federation of Neurology. Ducrocq X, et al. **J Neurol Sci** 1998 Aug 14;159(2):145–50 (41 ref.)

Detection of cerebral microemboli in APS—introducing a novel investigation method and implications of analogies with carotid artery disease. Specker C, et al. **Lupus** 1998; 7 Suppl 2:S75–80 (41 ref.)

[Transcranial Doppler and cerebral vasospasm] Cattin F, et al. **J Neuroradiol** 1999 Mar;26(1):S22–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Role of transcranial ultrasonography in neuroradiological diagnosis] Fontaine S, et al. **J Radiol** 1998 Mar;79(3):213–25 (97 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasound diagnosis in acute stroke] Siebler M, et al. **Z Arztl Fortbild Qualitatssich** 1999 May;93(3):175–81 (51 ref.) (Eng. Abstr.) **(Ger)**

[The use of TCD in intensive care and for identification of complications in subarachnoid hemorrhage] Cabrini GP. **Minerva Anestesiol** 1998 May;64(5):203–6 (10 ref.) (Eng. Abstr.) **(Ita)**

METHODS

The role of transcranial Doppler in the management of patients with subarachnoid haemorrhage—a review. Lindegaard KF. **Acta Neurochir Suppl (Wien)** 1999; 72:59–71 (107 ref.)

ULTRASONOGRAPHY, DUPLEX DOPPLER see **ULTRASONOGRAPHY, DOPPLER, DUPLEX**

ULTRASONOGRAPHY, ENDOSCOPIC see **ENDOSONOGRAPHY**

ULTRASONOGRAPHY, FETAL see **ULTRASONOGRAPHY, PRENATAL**

ULTRASONOGRAPHY, INTERVENTIONAL

In vivo tomographic assessment of the heart and blood vessels with intravascular ultrasound. Görge G, et al. **Basic Res Cardiol** 1998 Aug;93(4):219–40 (186 ref.)

Noncritical disease of the left main coronary artery: limitations of angiography and the role of intravascular ultrasound. Johnston PW, et al. **Can J Cardiol** 1999 Mar; 15(3):297–302 (37 ref.)

Characterization of the unstable lesion by angiography, angioscopy, and intravascular ultrasound. Waxman S. **Cardiol Clin** 1999 May;17(2):295–305, viii (64 ref.)

Impact of residual plaque burden on clinical outcomes of coronary interventions [see comments] Honda Y, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):265–76 (56 ref.) Comment in: Catheter Cardiovasc Interv 1999 Mar;46(3):277–81.

Intracoronary ultrasound. Weissman NJ. **Coron Artery Dis** 1998;9(7):435–41 (23 ref.)

Impact of intravascular ultrasound in understanding transplant coronary artery disease. Kapadia SR, et al. **Curr Opin Cardiol** 1999 Mar;14(2):140–50 (76 ref.)

EUS and EUS-guided fine-needle aspiration for the diagnosis of rectal linitis plastica secondary to prostate carcinoma. Bhutani MS. **Gastrointest Endosc** 1999 Jul; 50(1):117–9 (13 ref.)

Intracardiac echocardiography: computerized detection of left ventricular borders. Sonka M, et al. **Int J Card Imaging** 1998 Dec;14(6):397–411 (20 ref.)

Laparoscopic ultrasonography versus operative cholangiography during laparoscopic cholecystectomy: review of the literature and a comparison with open intraoperative ultrasonography. Machi J, et al. **J Am Coll Surg** 1999 Apr;188(4):360–7 (32 ref.)

Ultrasound guidance during endoscopic procedures. Letterie GS. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):63–82 (48 ref.)

The value of intravascular ultrasound in interventional cardiology. Pinto FJ. **Rev Port Cardiol** 1999 Feb;18 Suppl 1:I97–104 (54 ref.)

Intraoperative and laparoscopic ultrasound. Machi J. **Surg Oncol Clin N Am** 1999 Jan;8(1):205–26 (47 ref.)

[Intraoperative echography: the state of the art] Angelini L, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):223–30 (43 ref.) (Eng. Abstr.) **(Ita)**

[Intraoperative echography in biliopancreatic surgery] Marrano D, et al. **Ann Ital Chir** 1999 Mar–Apr;70(2):217–22 (24 ref.) (Eng. Abstr.) **(Ita)**

[Value of intravascular ultrasound and angioscopy for diagnosis and prediction of acute coronary syndrome] Komiyama N. **Nippon Rinsho** 1998 Oct;56(10):2532–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Ultrasound techniques of diagnosis in treatment in modern medicine] Genina EA, et al. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):52–5 (36 ref.) **(Rus)**

[Intracoronary ultrasound: A necessary tool for stent implantation? Arguments in favor] Botas J. **Rev Esp Cardiol** 1999 Jun;52(6):383–9 (38 ref.) (Eng. Abstr.) **(Spa)**

[Intracoronary ultrasound: A necessary tool for stent implantation? Arguments in against] Serra Peñaranda A. **Rev Esp Cardiol** 1999 Jun;52(6):390–7 (24 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Intraoperative abdominal ultrasonography. Luck AJ, et al. **Br J Surg** 1999 Jan;86(1):5–16 (65 ref.)

The current status of intravascular ultrasound imaging. Ziada KM, et al. **Curr Probl Cardiol** 1999 Sep;24(9):541–66 (211 ref.)

Radiofrequency thermal ablation of liver tumors. Rhim H, et al. **J Clin Ultrasound** 1999 Jun;27(5):221–9 (37 ref.)

[Endocavitary and endovascular ultrasonography] Jeanrenaud X, et al. **Rev Med Suisse Romande** 1999 May; 119(5):373–81 (57 ref.) **(Fre)**

TRENDS

New developments in intravascular ultrasound. Oshima A, et al. **Vasc Med** 1998;3(4):281–90 (56 ref.)

ULTRASONOGRAPHY, INTRAVASCULAR see **ULTRASONOGRAPHY, INTERVENTIONAL**

ULTRASONOGRAPHY, MAMMARY

Sonography of nonmammary malignancies of the breast. Yang WT, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):343–8 (8 ref.)

Imaging breasts with silicone implants. Azavedo E, et al. **Eur Radiol** 1999;9(2):349–55 (60 ref.)

Breast cancer imaging. Hurd TC, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):1–15 (50 ref.)

INSTRUMENTATION

Imaging-guided core biopsies in the breast. Soo MS. **South Med J** 1998 Nov;91(11):994–1000 (21 ref.)

METHODS

Advances in breast imaging. Reynolds HE. **Hematol Oncol Clin North Am** 1999 Apr;13(2):333–48, v (59 ref.)

ULTRASONOGRAPHY, PRENATAL

Ultrasonographic screening for fetal chromosomal abnormalities in early pregnancy. Taipale P, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):563–72 (88 ref.)

Prophylactic cesarean delivery for fetal macrosomia diagnosed by means of ultrasonography—A Faustian bargain? Rouse DJ, et al. **Am J Obstet Gynecol** 1999 Aug; 181(2):332–8 (44 ref.)

Prenatal diagnosis of crossed ectopic multicystic kidney. Maayan A, et al. **Am J Perinatol** 1998 Aug;15(8):499–502 (5 ref.)

Antepartum fetal intracranial hemorrhage, predisposing factors and prenatal sonography: a review. Sherer DM, et al. **Am J Perinatol** 1998 Jul;15(7):431–41 (97 ref.)

First-trimester nuchal translucency screening for fetal aneuploidy. Sherer DM, et al. **Am J Perinatol** 1999; 16(3):103–20 (85 ref.)

Left ventricular aneurysm in the fetus: a diagnosis with a mixed prognosis [editorial; comment] McElhinney DB, et al. **Cardiol Young** 1999 Mar;9(2):123–6 (11 ref.) Comment on: Cardiol Young 1999 Mar;9(2):175–84.

Prenatal ultrasonographic diagnosis of homozygous alpha-thalassaemia-1. Lam YH, et al. **Chin Med J (Engl)** 1997 Nov;110(11):832–3 (21 ref.)

Fetal lung abnormalities—what do they mean? Pilling D. **Clin Radiol** 1998 Nov;53(11):789–95 (35 ref.)

Assessment of fetal cardiovascular function: ultrasound study of the fetal circulatory compartments. Achiron R, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):119–23 (27 ref.)

Prenatal diagnosis of complicated abdominal wall defects. Fogata ML, et al. **Curr Probl Diagn Radiol** 1999 Jul–Aug; 28(4):101–28 (98 ref.)

Benign intracardiac teratoma detected prenatally. Case report and review of the literature. Campagne G, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):105–8 (28 ref.)

First trimester malformation screening. Kurjak A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):93–6 (45 ref.)

Debate about ultrasound screening policies. Antsaklis AJ. **Fetal Diagn Ther** 1998 Jul–Aug;13(4):209–15 (35 ref.)

Prenatal diagnosis of congenital neuroblastoma. Analysis of 4 cases and review of the literature. Heling KS, et al. **Fetal Diagn Ther** 1999 Jan–Feb;14(1):47–52 (28 ref.)

Prenatal diagnosis of a benign facial tumor. Magalhães JA, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):212–5 (20 ref.)

Acardiac twins: pathophysiology, diagnosis, outcome and treatment. Six cases and review of the literature. Spgaard K, et al. **Fetal Diagn Ther** 1999 Jan–Feb;14(1):53–9 (34 ref.)

Sirenomelia. Pathological features, antenatal ultrasonographic clues, and a review of current embryogenic theories. Valenzano M, et al. **Hum Reprod Update** 1999 Jan–Feb;5(1):82–6 (25 ref.)

Foetal echocardiography. Kothari SS. **Indian Heart J** 1999 Jan–Feb;51(1):92–4 (36 ref.)

Prenatal diagnosis of abnormal persistence of the right or left umbilical vein: report of 4 cases and literature review. Lai WW. **J Am Soc Echocardiogr** 1998 Sep;11(9):905–9 (15 ref.)

Prenatal diagnosis of bladder exstrophy: what counseling? Cacciari A, et al. **J Urol** 1999 Jan;161(1):259–61; discussion 262 (32 ref.)

Vasa previa: an avoidable obstetric tragedy. Oyelese KO, et al. **Obstet Gynecol Surv** 1999 Feb;54(2):138–45 (58 ref.)

First trimester ultrasonography of multiple gestations: a review. Sherer DM. **Obstet Gynecol Surv** 1998 Nov; 53(11):715–26 (114 ref.)

A growing role for ultrasound. Booker M. **Practitioner** 1998 Apr;242(1585):297–9 (0 ref.)

Sonographically detected fetal and placental abnormalities associated with trisomy 16 confined to the placenta. A case report and review of the literature. Astner A, et al. **Prenat Diagn** 1998 Dec;18(12):1308–15 (31 ref.)

Calcification of the fetal heart—four case reports and a literature review. Hajdu J, et al. **Prenat Diagn** 1998 Nov; 18(11):1186–90 (13 ref.)

Prenatal ultrasonographic diagnosis of the cerebro-costo-mandibular syndrome: case report and review of the literature. Megier P, et al. **Prenat Diagn** 1998 Dec;18(12):1294–9 (30 ref.)

Prenatal findings in trisomy 16q of paternal origin. Paladini D, et al. **Prenat Diagn** 1999 May;19(5):472–5 (28 ref.)

Fetal neurenteric cyst causing hydrops: case report and review of the literature. Wilkinson CC, et al. **Prenat Diagn** 1999 Feb;19(2):118–21 (17 ref.)

The role of color Doppler ultrasonography in obstetrics. Abrahim-Zadeh R, et al. **Semin Roentgenol** 1998 Oct; 33(4):351–9 (29 ref.)

The fetal genitourinary tract. Angtuaco TL, et al. **Semin Roentgenol** 1999 Jan;34(1):13–28 (51 ref.)

Emergency obstetrical ultrasonography. Doubilet PM, et al. **Semin Roentgenol** 1998 Oct;33(4):339–50 (45 ref.)

Practical approach to evaluating the fetal neural axis. Gushiken BJ, et al. **Semin Roentgenol** 1999 Jan;34(1):5–12 (56 ref.)

The fetal gastrointestinal tract. Hertzberg BS. **Semin Roentgenol** 1998 Oct;33(4):360–8 (60 ref.)

Diagnosis and management of fetal nuchal translucency. Jackson M, et al. **Semin Roentgenol** 1998 Oct;33(4):333–8 (18 ref.)

Sonographic assessment of the incompetent cervix during pregnancy. Marder SJ, et al. **Semin Roentgenol** 1999 Jan; 34(1):35–40 (33 ref.)

The role of ultrasonography in fetal surgery and invasive fetal procedures. Shaaban AF, et al. **Semin Roentgenol** 1999 Jan;34(1):62–77 (90 ref.)

Borderline findings in fetal cardiac sonography. Brown DL. **Semin Ultrasound CT MR** 1998 Aug;19(4):329–35 (52 ref.)

Screening for chromosomal abnormality. Dubbins PA. **Semin Ultrasound CT MR** 1998 Aug;19(4):310–7 (43 ref.)

The fetal head: borderlines. McGahan JP. **Semin Ultrasound CT MR** 1998 Aug;19(4):318–28 (27 ref.)

Sonographic borderlands in the fetal abdomen. Perez CG, et al. **Semin Ultrasound CT MR** 1998 Aug;19(4):336–46 (36 ref.)

Borderline genitourinary tract abnormalities. Seeds JW. **Semin Ultrasound CT MR** 1998 Aug;19(4):347–54 (35 ref.)

Early prenatal diagnosis of cord entanglement in monoamniotic multiple pregnancies [see comments] Arabin B, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):181–6 (24 ref.) Comment in: Ultrasound Obstet Gynecol 1999 Mar;13(3):157–60.

Poor perinatal outcome associated with vasa previa: is it preventable? A report of three cases and review of the literature [see comments] Fung TY, et al. **Ultrasound Obstet Gynecol** 1998 Dec;12(6):430–3 (43 ref.) Comment in: Ultrasound Obstet Gynecol 1998 Dec;12(6):377–9.

Prenatal diagnosis of prune belly syndrome at 12 weeks of pregnancy: case report and review of the literature. Hoshino T, et al. **Ultrasound Obstet Gynecol** 1998 Nov; 12(5):362–6 (20 ref.)

Prenatal sonographic features of embryonal rhabdomyosarcoma. Onderoğlu LS, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):210–2 (7 ref.)

Significance of echogenic foci in the fetal heart. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1998 Dec;12(6):445–9 (18 ref.)
Prenatal diagnosis of dacryocystocele: a possible marker for syndromes. Sharony R, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):71–3 (14 ref.)
Prenatal ultrasonographic diagnosis of nuchal cord(s): disregard, inform, monitor or intervene? [editorial] Sherer DM, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):1–8 (58 ref.)
First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: a happy union? Thilaganathan B. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):229–30 (23 ref.)
[Progresses in the study of ultrasonics in China, 1997] Dong B. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):927–9 (0 ref.) **(Chi)**
[Fetal echocardiography] Schleich JM, et al. **Arch Pediatr** 1998 Nov;5(11):1236–45 (43 ref.) (Eng. Abstr.) **(Fre)**
[Prenatal diagnosis of fetal goiter revealing iodine utilization defect] Gire C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27(8):811–3 (8 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic prenatal ultrasonography of malformations of the fetal anterior abdominal wall] Brun M, et al. **J Radiol** 1998 Dec;79(12):1461–8 (42 ref.) (Eng. Abstr.) **(Fre)**
[Intravaginal ultrasonography of the uterine cervix: hope in the campaign against premature births] Rozenberg P. **J Radiol** 1999 May;80(5):421–9 (48 ref.) (Eng. Abstr.) **(Fre)**
[How early and how specifically can hypoxic-ischemic brain lesions be detected with diagnostic imaging?] Krägeloh-Mann I, et al. **Z Geburtshilfe Neonatol** 1998 Sep; 202(5):182–6 (35 ref.) (Eng. Abstr.) **(Ger)**
[Familial heterotaxy syndrome. Case report and review of the international literature] Cesko I, et al. **Orv Hetil** 1998 Nov 15;139(46):2775–8 (45 ref.) (Eng. Abstr.) **(Hun)**
[Obstetric Doppler—justified i high-risk pregnancies] Grunewald C. **Lakartidningen** 1998 Sep 30;95(40):4360–4 (72 ref.) (Eng. Abstr.) **(Swe)**
[The potentials of dopplerometry in studying fetal-placental circulation] Kuz'mina IIu. **Lik Sprava** 1998 Aug;(6):24–7 (16 ref.) **(Ukr)**

ADVERSE EFFECTS

Intrauterine effects of ultrasound: animal studies. Jensh RP, et al. **Teratology** 1999 Apr;59(4):240–51 (140 ref.)
Intrauterine effects of ultrasound: human epidemiology. Ziskin MC. **Teratology** 1999 Apr;59(4):252–60 (45 ref.)
Thermal teratology. **Ultraschall Med** 1999 Jun;20(3):125–7 (13 ref.)

METHODS

Doppler ultrasound in multiple pregnancies. Giles WB. **Baillieres Clin Obstet Gynaecol** 1998 Mar;12(1):77–89 (81 ref.)
Ultrasonography in the detection of fetal anomalies in early pregnancy. Economides DL, et al. **Br J Obstet Gynaecol** 1999 Jun;106(6):516–23 (50 ref.)
Prenatal diagnosis of left ventricular aneurysm: a report of three cases and a review [see comments] Matias A, et al. **Cardiol Young** 1999 Mar;9(2):175–84 (22 ref.) Comment in: Cardiol Young 1999 Mar;9(2):123–6.
Sequential segmental approach to fetal congenital heart disease. Yoo SJ, et al. **Cardiol Young** 1999 Jul;9(4):430–44 (18 ref.)
Congenital glioblastoma diagnosed by fetal sonography. Lee DY, et al. **Childs Nerv Syst** 1999 Apr;15(4):197–201 (27 ref.)
Ultrasound evaluation of the fetal heart: is it possible? Izquierdo LA, et al. **Compr Ther** 1999 Apr;25(4):193–7 (20 ref.)
Routine use of ultrasound during pregnancy. Lowe SW, et al. **Nurse Pract** 1998 Oct;23(10):60, 63–6, 71 (15 ref.)
Three-dimensional fetal echocardiography. Nelson TR. **Prog Biophys Mol Biol** 1998;69(2–3):257–72 (93 ref.)
Fetal face: what we can see using two-dimensional and three-dimensional ultrasound imaging. Hull AD, et al. **Semin Roentgenol** 1998 Oct;33(4):369–74 (25 ref.)
[Prenatal diagnosis of anomalies of the corpus callosum with ultrasound: the echographist's point of view] Maheut-Lourmière J, et al. **Neurochirurgie** 1998 May;44(1 Suppl):85–92 (14 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Small for gestational age is not a diagnosis [editorial] Soothill PW, et al. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):225–8 (27 ref.)

ULTRASONOGRAPHY, PULSED DOPPLER see **ULTRASONOGRAPHY, DOPPLER, PULSED**

ULTRASONOGRAPHY, TRANSCRANIAL DOPPLER see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

ULTRASOUND, INTERVENTIONAL see **ULTRASONOGRAPHY, INTERVENTIONAL**

ULTRAVIOLET RAYS

Radiation inducible DNA repair processes in eukaryotes. Eckardt-Schupp F, et al. **Biochimie** 1999 Jan-Feb; 81(1–2):161–71 (102 ref.)
Ultraviolet radiation screening compounds. Cockell CS, et al. **Biol Rev Camb Philos Soc** 1999 Aug;74(3):311–45 (232 ref.)
Disparate effects of photoprotection on ultraviolet radiation-induced immunosuppression. Bergstresser PR. **Eur J Dermatol** 1998 Apr-May;8(3):203–4 (21 ref.)
Ultraviolet A radiation-induced immunomodulation: molecular and photobiological mechanims. Krutmann J. **Eur J Dermatol** 1998 Apr-May;8(3):200–2 (19 ref.)
Immunomodulation by UV light: role of neuropeptides. Luger TA. **Eur J Dermatol** 1998 Apr-May;8(3):198–9 (18 ref.)
Ultraviolet light and dendritic cells. Meunier L. **Eur J Dermatol** 1999 Jun;9(4):269–75 (106 ref.)
Relevance of photo-immunosuppression for viral infections (i.e. human papilloma virus). Vermeer BJ, et al. **Eur J Dermatol** 1998 Apr-May;8(3):205–6 (12 ref.)
Ultraviolet radiation-induced p53 responses in the epidermis are differentiation-dependent. Tron VA, et al. **J Cutan Med Surg** 1999 Jul;3(5):280–3 (43 ref.)
Langerhans cell responses to ultraviolet B radiation. Kitajima T, et al. **J Dermatol Sci** 1999 Apr;19(3):153–60 (58 ref.)
Effects of increased solar ultraviolet radiation on materials. Andrady AL, et al. **J Photochem Photobiol B** 1998 Oct; 46(1–3):96–103 (54 ref.)
Health risks. Longstreth J, et al. **J Photochem Photobiol B** 1998 Oct;46(1–3):20–39 (167 ref.)
Changes in biologically active ultraviolet radiation reaching the Earth's surface. Madronich S, et al. **J Photochem Photobiol B** 1998 Oct;46(1–3):5–19 (164 ref.)
UV light affects cell membrane and cytoplasmic targets. Schwarz T. **J Photochem Photobiol B** 1998 Jul 10; 44(2):91–6 (35 ref.)
Changes in tropospheric composition and air quality. Tang X, et al. **J Photochem Photobiol B** 1998 Oct;46(1–3):83–95 (108 ref.)
Cellular target of UVB-induced DNA damage resulting in local suppression of contact hypersensitivity. Vink AA, et al. **J Photochem Photobiol B** 1998 Jul 10;44(2):107–11 (36 ref.)
A new concept of skin-associated lymphoid tissue (SALT): UVB light impaired cutaneous immunity reveals a prominent role for cutaneous nerves. Streilein JW, et al. **Keio J Med** 1999 Mar;48(1):22–7 (33 ref.)
The impact of UVB radiation on marine plankton. Davidson AT. **Mutat Res** 1998 Nov 9;422(1):119–29 (116 ref.)
Bacterial gene products in response to near-ultraviolet radiation. Eisenstark A. **Mutat Res** 1998 Nov 9;422(1):85–95 (103 ref.)
Mechanisms of photosensitization by phototoxic drugs. Moore DE. **Mutat Res** 1998 Nov 9;422(1):165–73 (12 ref.)
UV-induced immunosuppression in virus infections. Norval M, et al. **Mutat Res** 1998 Nov 9;422(1):131–8 (29 ref.)
Human pigmentation genes and their response to solar UV radiation. Sturm RA. **Mutat Res** 1998 Nov 9;422(1):69–76 (42 ref.)
The treatment of blood components with ultraviolet-B irradiation. Pamphilon DH. **Vox Sang** 1998;74 Suppl 2:15–9 (9 ref.)
[Use of short wave ultraviolet radiation for disinfection in operating rooms] Bånrud H, et al. **Tidsskr Nor Laegeforen** 1999 Aug 10;119(18):2670–3 (45 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Ultraviolet radiation exposure in children: a review of measurement strategies. Creech LL, et al. **Ann Behav Med** 1998 Fall;19(4):399–407 (83 ref.)
EMS and UV-light-induced colony sectoring and delayed mutation in Chinese hamster cells. Stamato TD, et al. **Int J Radiat Biol** 1998 Dec;74(6):739–45 (45 ref.)
Actinically degenerate elastic tissue is the likely antigenic basis of actinic granuloma of the skin and of temporal arteritis. O'Brien JP, et al. **J Am Acad Dermatol** 1999 Feb; 40(2 Pt 1):214–22 (62 ref.)
Solar retinopathy in a hospital-based primary care clinic. Stokkermans TJ, et al. **J Am Optom Assoc** 1998 Oct; 69(10):625–36 (75 ref.)
The UV-induced SOS response: importance to aging skin. Gilchrest BA. **J Dermatol** 1998 Dec;25(12):775–7 (7 ref.)
A possible link between neural tube defects and ultraviolet light exposure. Jablonski NG. **Med Hypotheses** 1999 Jun; 52(6):581–2 (11 ref.)
Free-radical and cyclooxygenase-catalyzed lipid peroxidation in membranes of blood cells under UV irradiation. Roshchupkin DI, et al. **Membr Cell Biol** 1998; 12(2):279–86 (14 ref.)
Influence of dietary factors on actinically-induced skin cancer. Black HS. **Mutat Res** 1998 Nov 9;422(1):185–90 (31 ref.)
UV-induced mutations and skin cancer: how important is the link? Bridges BA. **Mutat Res** 1998 Nov 9;422(1):23–30 (38 ref.)
Protection against solar ultraviolet radiation. Gies PH, et al. **Mutat Res** 1998 Nov 9;422(1):15–22 (37 ref.)
The pathogenesis of melanoma induced by ultraviolet radiation. Gilchrest BA, et al. **N Engl J Med** 1999 Apr 29;340(17):1341–8 (94 ref.)
Optical radiation hazards of welding arcs. Tenkate TD. **Rev Environ Health** 1998 Jul-Sep;13(3):131–46 (99 ref.)
The photomutagenicity of fluoroquinolones and other drugs. Gocke E, et al. **Toxicol Lett** 1998 Dec 28;102–103:375–81 (20 ref.)
Photochemical genotoxicity and photochemical carcinogenesis—two sides of a coin? Müller L, et al. **Toxicol Lett** 1998 Dec 28;102–103:383–7 (18 ref.)
[UV-induced immunosuppression and skin cancers] Meunier L, et al. **Rev Med Interne** 1998 Apr;19(4):247–54 (72 ref.) (Eng. Abstr.) **(Fre)**
[Skin carcinogenesis] Soufir N, et al. **Rev Prat** 1999 Apr 15; 49(8):813–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of ultraviolet ray damage: external and internal sunscreens] Grundmann JU, et al. **Ther Umsch** 1999 Apr; 56(4):225–32 (48 ref.) (Eng. Abstr.) **(Ger)**
[Risk factors for the development of malignant melanomas] Itin PH. **Ther Umsch** 1999 Jun;56(6):298–301 (18 ref.) (Eng. Abstr.) **(Ger)**
[The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythematosus] Aharon-Maor A, et al. **Harefuah** 1998 Oct;135(7–8):295–9 (38 ref.) **(Heb)**
[Sun and skin] Gelmetti C. **Minerva Pediatr** 1998 Jun; 50(6):283–7 (37 ref.) **(Ita)**
[The factors of individual sensitivity to ultraviolet radiation] Strzhizhovskiĭ AD. **Usp Fiziol Nauk** 1998 Jul-Sep; 29(3):130–43 (96 ref.) (Eng. Abstr.) **(Rus)**
["Ozone holes"—ultraviolet radiation—heliotherapy] Slutskaia GF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep-Oct;(5):50–1 (19 ref.) **(Rus)**

DIAGNOSTIC USE

Photodynamic diagnosis and therapy in dermatology. Fritsch C, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):358–73 (74 ref.)

ULTRAVIOLET THERAPY

see related
PHOTOCHEMOTHERAPY

Tazarotene in combination with phototherapy. Koo JY. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 2):S144–8 (29 ref.)
Acitretin in combination with UVB or PUVA. Lebwohl M. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 2):S22–4 (10 ref.)
HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)
[Ultraviolet A–I phototherapy for skin diseases] Polderman MC, et al. **Ned Tijdschr Geneeskd** 1999 May 1;143(18):931–4 (25 ref.) (Eng. Abstr.) **(Dut)**

METHODS

[Narrow band UVB 311 nm versus broad band UVB. New developments in phototherapy] Degitz K, et al. **Hautarzt** 1998 Oct;49(10):795–806; quiz 806 (15 ref.) **(Ger)**

UMBILICAL ARTERIES

PHYSIOLOGY

Intrapartum umbilical artery Doppler velocimetry as a predictor of adverse perinatal outcome: a systematic review. Farrell T, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):783–92 (58 ref.)
Arterial pressure, vascular input impedance, and resistance as determinants of pulsatile blood flow in the umbilical artery. Adamson SL. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):119–25 (24 ref.)

PHYSIOPATHOLOGY

Abnormal Doppler velocities in the umbilical artery [editorial] Karsdorp VH. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):129–31 (11 ref.)

UMBILICAL CORD

Experience with fetoscopic cord ligation. Deprest JA, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):157–64 (34 ref.)

PATHOLOGY

Poor perinatal outcome associated with vasa previa: is it preventable? A report of three cases and review of the literature [see comments] Fung TY, et al. **Ultrasound Obstet Gynecol** 1998 Dec;12(6):430–3 (43 ref.) Comment in: Ultrasound Obstet Gynecol 1998 Dec;12(6):377–9.
[Cavernous hemangioma of the umbilical cord] Nawroth F, et al. **Zentralbl Gynakol** 1998;120(9):458–61 (17 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Amniotic fluid and the umbilical cord: the fetal milieu and lifeline. Sohaey R. **Semin Ultrasound CT MR** 1998 Aug; 19(4):355–69 (86 ref.)
Early prenatal diagnosis of cord entanglement in monoamniotic multiple pregnancies [see comments] Arabin

UMBILICAL CORD

B, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):181–6 (24 ref.) Comment in: Ultrasound Obstet Gynecol 1999 Mar;13(3):157–60.

Poor perinatal outcome associated with vasa previa: is it preventable? A report of three cases and review of the literature [see comments] Fung TY, et al. **Ultrasound Obstet Gynecol** 1998 Dec;12(6):430–3 (43 ref.) Comment in: Ultrasound Obstet Gynecol 1998 Dec;12(6):377–9.

Prenatal ultrasonographic diagnosis of nuchal cord(s): disregard, inform, monitor or intervene? [editorial] Sherer DM, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):1–8 (58 ref.)

UMBILICAL CORD BLOOD see **FETAL BLOOD**

UMBILICAL HERNIA see **HERNIA, UMBILICAL**

UMBILICAL VEINS

[An update, history and the outlook for the use of the human umbilical cord vein in surgery] Polupan SV. **Klin Khir** 1998; (9–10):67–9 (16 ref.) **(Rus)**

ABNORMALITIES

Prenatal diagnosis of abnormal persistence of the right or left umbilical vein: report of 4 cases and literature review. Lai WW. **J Am Soc Echocardiogr** 1998 Sep;11(9):905–9 (15 ref.)

Patent ductus venosus. Nagano K, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):285–8 (23 ref.)

PHYSIOLOGY

Dynamics of fetal circulatory responses to hypoxia and asphyxia. Jensen A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):155–72 (136 ref.)

Hemodynamics of the ductus venosus. Kiserud T. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):139–47 (86 ref.)

UMBILICUS

Heterotopic pancreatic tissue at umbilicus. Avolio L, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):373–5 (6 ref.)

Late development of umbilical metastasis after laparoscopic cholecystectomy for a gallbladder carcinoma. Jeon HM, et al. **Oncol Rep** 1999 Mar–Apr;6(2):283–7 (31 ref.)

[Sister Mary Joseph's nodule. Its clinical significance and management] Giner Galvañ V. **An Med Interna** 1999 Jul; 16(7):365–70 (99 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Migration of sterilisation clips: case report and review. AmuO, et al. **Br J Fam Plann** 1999 Apr;25(1):27–8 (14 ref.)

[Usefulness of the trans-umbilical incision in laparoscopic surgery] Weber Sánchez A, et al. **Ginecol Obstet Mex** 1998 Dec;66:503–6 (25 ref.) (Eng. Abstr.) **(Spa)**

UMBRELLA FILTERS see **VENA CAVA FILTERS**

UNCONSCIOUS (PSYCHOLOGY)

Unconscious processes, subliminal stimulation, and anxiety. Mayer B, et al. **Clin Psychol Rev** 1999 Aug;19(5):571–90 (92 ref.)

Unconscious pregnancy fantasies as an underlying dynamism in panic disorder. Milrod B. **J Am Psychoanal Assoc** 1998; 46(3):673–90 (24 ref.)

UNCONSCIOUSNESS

see related
SYNCOPE

UNCOUPLING AGENTS

see related
IONOPHORES

METABOLISM

Structure and function of the uncoupling protein from brown adipose tissue. Klingenberg M, et al. **Biochim Biophys Acta** 1999 Jan 8;1415(2):271–96 (152 ref.)

Contributions of studies on uncoupling proteins to research on metabolic diseases. Ricquier D, et al. **J Intern Med** 1999 Jun;245(6):637–42 (27 ref.)

Human uncoupling proteins and obesity. Schrauwen P, et al. **Obes Res** 1999 Jan;7(1):97–105 (51 ref.)

Effects of leptin on mitochondrial 'proton leak' and uncoupling proteins: implications for mammalian energy metabolism. Porter RK, et al. **Proc Nutr Soc** 1998 Aug; 57(3):455–60 (86 ref.)

[Thermoregulation mechanisms of brown adipose tissue] Wang ZK, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct; 27(4):353–5 (8 ref.) **(Chi)**

UNDER-DEVELOPED COUNTRIES see **DEVELOPING COUNTRIES**

UNDERACHIEVEMENT

Language, achievement, and cognitive processing in psychiatrically disturbed children with previously identified and unsuspected language impairments. Cohen NJ, et al. **J Child Psychol Psychiatry** 1998 Sep;39(6):865–77 (104 ref.)

Language, speech, and educational outcomes of otitis media. Gravel JS, et al. **J Otolaryngol** 1998;27 Suppl 2:17–25 (74 ref.)

UNDULANT FEVER see **BRUCELLOSIS**

UNEMPLOYMENT

Neoliberalism, "globalization," unemployment, inequalities, and the welfare state. Navarro V. **Int J Health Serv** 1998; 28(4):607–82 (91 ref.)

UNESCO see **UNITED NATIONS**

UNICEF see **UNITED NATIONS**

UNIFIED MEDICAL LANGUAGE SYSTEM

see related
TERMINOLOGY

UNIPOLAR DEPRESSION see **DEPRESSIVE DISORDER**

UNIPORT see **ION TRANSPORT**

UNITED NATIONS

The application of the UNSCOM experience to international biological arms control. United Nations Special Commission. Barton R. **Crit Rev Microbiol** 1998; 24(3):219–33 (3 ref.)

Verifying compliance to the biological and toxin weapons convention. Zilinskas RA. **Crit Rev Microbiol** 1998; 24(3):195–218 (124 ref.)

A fundamental shift in the approach to international health by WHO, UNICEF, and the World Bank: instances of the practice of "intellectual fascism" and totalitarianism in some Asian countries. Banerji D. **Int J Health Serv** 1999; 29(2):227–59 (146 ref.)

Neoliberalism revised? A critical account of World Bank conceptions of good governance and market friendly intervention. Kiely R. **Int J Health Serv** 1998;28(4):683–702 (65 ref.)

To South Sudan with operation lifeline Sudan and UNICEF. Taylor-Robinson SD. **J R Coll Physicians Lond** 1999 May–Jun;33(3):276–9 (4 ref.)

Disease prevention and preparedness: the Food and Agriculture Organization Emergency Prevention System. Cheneau Y, et al. **Rev Sci Tech** 1999 Apr;18(1):122–34 (16 ref.)

ORGANIZATION & ADMINISTRATION

Levels of medical support for United Nations peacekeeping operations. Seet B. **Mil Med** 1999 Jul;164(7):451–6 (24 ref.)

UNITED STATES AGENCY FOR HEALTH CARE POLICY AND RESEARCH

ORGANIZATION & ADMINISTRATION

Outcomes and effectiveness research in the private sector. Mendelson DN, et al. **Health Aff (Millwood)** 1998 Sep–Oct; 17(5):75–90 (19 ref.)

AHCPR focuses on information for health care decision makers. Eisenberg JM. **Health Serv Res** 1998 Oct;33(4 Pt 1):767–81 (11 ref.)

UNITED STATES CENTERS FOR DISEASE CONTROL AND PREVENTION see **CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.)**

UNITED STATES DEPARTMENT OF VETERANS AFFAIRS

Changing policies in the Veterans Health Administration. Will they make a difference? [editorial] Jones DB. **Arch Ophthalmol** 1999 Jan;117(1):106–7 (3 ref.)

Priorities for patient-centered research. Feussner JR. **Med Care** 1999 Sep;37(9):843–5 (11 ref.)

Psychiatric emergency services in the Veterans Health Administration: a review. Noronha SF, et al. **New Dir Ment Health Serv** 1999 Summer;(82):75–84 (30 ref.)

ECONOMICS

Review of methods to determine VA health care costs. Barnett PG. **Med Care** 1999 Apr;37(4 Suppl Va):AS9–17 (40 ref.)

More or less?: Methods to compare VA and non-VA health care costs. Hendricks AM, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS54–62 (29 ref.)

Cost analysis in the Department of Veterans Affairs: consensus and future directions. Swindle R, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS3–8 (13 ref.)

ORGANIZATION & ADMINISTRATION

The "new VA": a national laboratory for health care quality management. Kizer KW. **Am J Med Qual** 1999 Jan–Feb; 14(1):3–20 (108 ref.)

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

STANDARDS

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part I: The reproduction and fertility testing guidelines. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):543–53 (75 ref.)

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part II: The developmental toxicity testing guideline. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):554–63 (67 ref.)

UNITED STATES FEDERAL TRADE COMMISSION

LEGISLATION & JURISPRUDENCE

Marketing health care products on the Internet: a proposal for updated federal regulations. Green K. **Am J Law Med** 1998;24(2–3):365–86 (145 ref.)

UNITED STATES FOOD AND DRUG ADMINISTRATION

Direct-to-consumer prescription drug advertising. Terzian TV. **Am J Law Med** 1999;25(1):149–67 (0 ref.)

FDA's role in anesthetic drug development. Landow L, et al. **Anesthesiology** 1999 Mar;90(3):882–9 (13 ref.)

New chemoimmunotherapy: courtesy of a more flexible Food and Drug Administration. Greenspan EM. **Cancer Invest** 1999;17(5):371–3 (17 ref.)

Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies. Asher DM. **Dev Biol Stand** 1999;99:41–4 (14 ref.)

New drugs of 1998. Hussar DA. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr;39(2):151–206; quiz 289–92 (0 ref.)

The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL. **J Health Polit Policy Law** 1999 Jun;24(3):531–65 (35 ref.)

The selling of olestra [see comments] Nestle M. **Public Health Rep** 1998 Nov–Dec;113(6):508–20 (68 ref.) Comment in: Public Health Rep 1999 Jan–Feb;114(1):5–6.

LEGISLATION & JURISPRUDENCE

Marketing health care products on the Internet: a proposal for updated federal regulations. Green K. **Am J Law Med** 1998;24(2–3):365–86 (145 ref.)

Blood safety. The Food and Drug Administration's role. Gustafson M. **Arch Pathol Lab Med** 1999 Jun;123(6):475–7 (9 ref.)

The US Food and Drug Administration Modernization Act of 1997: impact on consumers. Golodner LF. **Clin Ther** 1998;20 Suppl C:C20–5 (5 ref.)

Overview of the US Food and Drug Administration's reform legislation. Rheinstein PH. **Clin Ther** 1998;20 Suppl C:C4–11 (8 ref.)

Realizing the promise of the US Food and Drug Administration Modernization Act. Wolgemuth RL. **Clin Ther** 1998;20 Suppl C:C26–31 (0 ref.)

Product liability and prescription diet drug cocktail, Fen-Phen: a hard combination to swallow. Crisanti CA. **J Contemp Health Law Policy** 1998 Fall;15(1):207–44 (0 ref.)

FDA treads delicate line between safety and speed. **Oncology (Huntingt)** 1999 Jan;13(1):16 (0 ref.)

ORGANIZATION & ADMINISTRATION

Overview of the US Food and Drug Administration's reform legislation. Rheinstein PH. **Clin Ther** 1998;20 Suppl C:C4–11 (8 ref.)

UNITED STATES HEALTH CARE FINANCING ADMINISTRATION

Health Care Financing Administration/clinical laboratory improvement amendments of 1988. Wanamaker V. **Arch Pathol Lab Med** 1999 Jun;123(6):478–81 (8 ref.)

UNITED STATES NATIONAL HEALTH INSURANCE see **NATIONAL HEALTH INSURANCE, UNITED STATES**

UNITED STATES NATIONAL INSTITUTES OF HEALTH see **NATIONAL INSTITUTES OF HEALTH (U.S.)**

UNITED STATES NATIONAL LIBRARY OF MEDICINE see **NATIONAL LIBRARY OF MEDICINE (U.S.)**

UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION

Analysis of third-party certification approaches using an occupational health and safety conformity-assessment model. Redinger CF, et al. **Am Ind Hyg Assoc J** 1998 Nov; 59(11):802-12 (48 ref.)

UNITED STATES PUBLIC HEALTH SERVICE

Childhood lead poisoning: the promise and abandonment of primary prevention [see comments] Needleman HL. **Am J Public Health** 1998 Dec;88(12):1871-7 (38 ref.) Comment in: Am J Public Health 1998 Dec;88(12):1759-60. Comment in: Am J Public Health 1999 Jul;89(7):1126-31.

UNITED STATES VETERANS ADMINISTRATION see **UNITED STATES DEPARTMENT OF VETERANS AFFAIRS**

UNIVERSAL COVERAGE

Summary and next steps in achieving universal access. Haggerty RJ. **J Urban Health** 1998 Dec;75(4):772-6 (0 ref.)

ORGANIZATION & ADMINISTRATION

German health care reform: the next steps. Jost T. **J Health Polit Policy Law** 1998 Aug;23(4):697-711 (42 ref.)

UNIVERSAL PRECAUTIONS

METHODS

The radiology department and nosocomial infections. Shagam JY. **Radiol Technol** 1999 May-Jun;70(5):418-30; quiz 431-3 (6 ref.)

[Safety measures for handling laboratory specimen and patients with Creutzfeldt-Jakob disease] Van Everbroeck B, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1511-4 (24 ref.) (Eng. Abstr.) **(Dut)**

UNIVERSITIES

Understanding fraternity drinking: five recurring themes in the literature, 1980-1998. Borsari BE, et al. **J Am Coll Health** 1999 Jul;48(1):30-7 (77 ref.)

Osteoporosis: implications for risk reduction in the college setting [see comments] Leslie M, et al. **J Am Coll Health** 1999 Sep;48(2):67-71 (25 ref.) Comment in: J Am Coll Health 1999 Sep;48(2):51-4.

[The Virtual University applied to telesurgery: from tele-education to tele-manipulation] Marescaux J, et al. **Bull Acad Natl Med** 1999;183(3):509-21; discussion 521-2 (10 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacovigilance: education and continuing updating. The role of university institutes] Mariani L. **Clin Ter** 1998 May-Jun;149(3):219-25 (15 ref.) (Eng. Abstr.) **(Ita)**

ORGANIZATION & ADMINISTRATION

Ten years on and more: establishing programmes of rehabilitation education: the New Zealand case. Gregory RJ. **Disabil Rehabil** 1998 Oct;20(10):385-90 (12 ref.)

TRENDS

WebWise: guide to the Washington University Center for Genetics in Medicine web site. Pruitt KD. **Genome Res** 1998 Jul;8(7):686-9 (0 ref.)

UNIVERSITY HEALTH SERVICES see **STUDENT HEALTH SERVICES**

UNIVERSITY MEDICAL CENTERS see **ACADEMIC MEDICAL CENTERS**

UNKNOWN PRIMARY TUMORS see **NEOPLASMS, UNKNOWN PRIMARY**

UNNECESSARY PROCEDURES

TRENDS

[Pro and con the trend to an increasing frequency of cesarean sections] Dimitrov A. **Akush Ginekol (Sofiia)** 1998;37(3):1-5 (34 ref.) (Eng. Abstr.) **(Bul)**

UTILIZATION

Gastrointestinal endoscopy: Do we perform too many or not enough procedures? Froehlich F, et al. **Can J Gastroenterol** 1999 May;13(4):345-6 (11 ref.)

UNNECESSARY SURGERY see **UNNECESSARY PROCEDURES**

UNSATURATED DIETARY FATS see **DIETARY FATS, UNSATURATED**

UNSATURATED FATS see **FATS, UNSATURATED**

UNSATURATED OILS see **FATS, UNSATURATED**

UNSTABLE DNA SEQUENCE see **TRINUCLEOTIDE REPEAT EXPANSION**

3' UNTRANSLATED REGIONS

The influence of mRNA stability on glucose transporter (GLUT1) gene expression. Qi C, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):265-9 (75 ref.)

GENETICS

3'-End processing of pre-mRNA in eukaryotes. Wahle E, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):277-95 (141 ref.)

METABOLISM

Regulation of endothelial NO synthase mRNA stability: RNA-binding proteins crowd on the 3'-untranslated region [editorial; comment] Bloch KD. **Circ Res** 1999 Oct 1; 85(7):653-5 (10 ref.) Comment on: Circ Res 1999 Oct 1;85(7):588-95.

3'-End processing of pre-mRNA in eukaryotes. Wahle E, et al. **FEMS Microbiol Rev** 1999 Jun;23(3):277-95 (141 ref.)

5' UNTRANSLATED REGIONS

The role of the 5' untranslated region of an mRNA in translation regulation during development. van der Velden AW, et al. **Int J Biochem Cell Biol** 1999 Jan;31(1):87-106 (102 ref.)

GENETICS

Alternative processing of growth hormone receptor transcripts. Edens A, et al. **Endocr Rev** 1998 Oct; 19(5):559-82 (131 ref.)

METABOLISM

Translational control by repressor proteins binding to the 5'UTR of mRNAs. Gray NK. **Methods Mol Biol** 1998; 77:379-97 (42 ref.)

PHYSIOLOGY

Human immunodeficiency virus type-1 transcription: role of the 5'-untranslated leader region (review). Al-Harthi L, et al. **Int J Mol Med** 1998 May;1(5):875-81 (71 ref.)

UNVENTILATED SPACES see **CONFINED SPACES**

UP-REGULATION (PHYSIOLOGY)

see related
DOWN-REGULATION (PHYSIOLOGY)

PHYSIOLOGY

Ca2+ channels, ryanodine receptors and Ca(2+)-activated K+ channels: a functional unit for regulating arterial tone. Jaggar JH, et al. **Acta Physiol Scand** 1998 Dec; 164(4):577-87 (69 ref.)

New insights into the upregulation and function of the salivary Na+-K+-2Cl- cotransporter. Evans RL, et al. **Eur J Morphol** 1998 Aug;36 Suppl:142-6 (14 ref.)

UPHILL TRANSPORT see **BIOLOGICAL TRANSPORT, ACTIVE**

UPPER EXTREMITY see **ARM**

UPPER RESPIRATORY INFECTIONS see **RESPIRATORY TRACT INFECTIONS**

UPREGULATION see **UP-REGULATION (PHYSIOLOGY)**

URACIL

ANALOGS & DERIVATIVES

Oral 5-FU analogues in the treatment of breast cancer. Bunnell CA, et al. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):39-43 (33 ref.)

Clinical implications of dihydropyrimidine dehydrogenase inhibition. Diasio RB. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):17-21 (33 ref.)

Clinical development of eniluracil: current status. Hohneker JA. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):52-6 (17 ref.)

THERAPEUTIC USE

UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM, et al. **Anticancer Drugs** 1998 Jul;9(6):479-90 (90 ref.)

Oral 5-FU analogues in the treatment of breast cancer. Bunnell CA, et al. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 7):39-43 (33 ref.)

URACIL MUSTARD

THERAPEUTIC USE

Uracil mustard revisited. Kennedy BJ, et al. **Cancer** 1999 May 15;85(10):2265-72 (51 ref.)

URACIL NUCLEOTIDES

PHARMACOLOGY

Uridine and its nucleotides: biological actions, therapeutic potentials. Connolly GP, et al. **Trends Pharmacol Sci** 1999 May;20(5):218-25 (65 ref.)

URAMUSTINE see **URACIL MUSTARD**

URANIUM

POISONING

Medical effects of internal contamination with uranium. Duraković A. **Croat Med J** 1999 Mar;40(1):49-66 (146 ref.)

URBAN DEVELOPMENT see **URBAN RENEWAL**

URBAN HEALTH

Intra-oral squamous cell carcinoma in Ibadan: a review of 90 cases. Lawoyin JO, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):187-8 (13 ref.)

Public health and brownfields: reviving the past to protect the future [editorial; comment] Greenberg M, et al. **Am J Public Health** 1998 Dec;88(12):1759-60 (12 ref.) Comment on: Am J Public Health 1998 Dec;88(12):1762-6. Comment on: Am J Public Health 1998 Dec;88(12):1834-6. Comment on: Am J Public Health 1998 Dec;88(12):1837-9. Comment on: Am J Public Health 1998 Dec;88(12):1840-5. Comment on: Am J Public Health 1998 Dec;88(12):1871-7.

Optimizing tuberculosis control in the inner city [editorial; comment] FitzGerald JM. **CMAJ** 1999 Mar 23;160(6):821-2 (14 ref.) Comment on: CMAJ 1999 Mar 23;160(6):789-94. Comment on: CMAJ 1999 Mar 23;160(6):799-802.

Becoming modern after all these years: social change and mental health in Latin America. Almeida-Filho N. **Cult Med Psychiatry** 1998 Sep;22(3):285-316 (73 ref.)

The healthy city. Taggart SC. **J R Coll Physicians Lond** 1998 Nov-Dec;32(6):568-71 (6 ref.)

Opportunities to improve health care for low-income adolescents. Collins KS, et al. **J Urban Health** 1998 Dec; 75(4):660-76 (14 ref.)

Child development and pediatrics for the 21st century: the healthy steps approach. McLearn KT, et al. **J Urban Health** 1998 Dec;75(4):704-23 (20 ref.)

Children with chronic conditions in the 21st century. Stein RE. **J Urban Health** 1998 Dec;75(4):732-8 (7 ref.)

Health care coverage and access for children in an urban state: the New York perspective. Tallon JR Jr, et al. **J Urban Health** 1998 Dec;75(4):693-701 (8 ref.)

STATISTICS & NUMERICAL DATA

At issue: is household crowding a risk factor for schizophrenia and bipolar disorder? Torrey EF, et al. **Schizophr Bull** 1998;24(3):321-4 (38 ref.)

Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison [see comments] Ng'ang'a LW, et al. **Thorax** 1998 Nov;53(11):919-26 (30 ref.) Comment in: Thorax 1998 Nov;53(11):909-10.

TRENDS

Leveling the playing field: a report of the Commonwealth Fund Task Force on Academic Health Centers. Blumenthal D, et al. **J Urban Health** 1998 Jun;75(2):330-46 (18 ref.)

Early antecedents of adult health. Susser E, et al. **J Urban Health** 1998 Jun;75(2):236-41 (12 ref.)

African-American health: the role of the social environment. Williams DR. **J Urban Health** 1998 Jun;75(2):300-21 (93 ref.)

Urban health: an ecological perspective. Lawrence RJ. **Rev Environ Health** 1999 Jan-Mar;14(1):1-10 (24 ref.)

URBAN POPULATION

see related
URBANIZATION

Profile of non-compressive myelopathy in eastern India: a 2-year study. Das K, et al. **Acta Neurol Scand** 1999 Feb; 99(2):100-5 (28 ref.)

[Epidemiologic surveillance for the prevention and control urban violence] Concha-Eastman A, et al. **Rev Panam Salud Publica** 1999 Apr-May;5(4-5):322-31 (49 ref.) (Eng. Abstr.) **(Spa)**

[Victimization by urban violence: incidence and associated factors in cities in Latin America and Spain] Cruz JM. **Rev Panam Salud Publica** 1999 Apr-May;5(4-5):259-67 (39 ref.) (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

African-American health: the role of the social environment. Williams DR. **J Urban Health** 1998 Jun;75(2):300-21 (93 ref.)

URBAN RENEWAL

URBAN RENEWAL

see related
HOUSING

ORGANIZATION & ADMINISTRATION

Public health and brownfields: reviving the past to protect the future [editorial; comment] Greenberg M, et al. **Am J Public Health** 1998 Dec;88(12):1759–60 (12 ref.)
Comment on: Am J Public Health 1998 Dec;88(12):1762–6.
Comment on: Am J Public Health 1998 Dec;88(12):1834–6.
Comment on: Am J Public Health 1998 Dec;88(12):1837–9.
Comment on: Am J Public Health 1998 Dec;88(12):1840–5.
Comment on: Am J Public Health 1998 Dec;88(12):1871–7.

URBANIZATION

TRENDS

The impact of urbanization on health in the countries of the eastern Mediterranean region. Khosh-Chashm K. **East Mediterr Health J** 1998;4 Suppl:S137–48 (19 ref.)

UREA

see related
BLOOD UREA NITROGEN

ANALOGS & DERIVATIVES

[Landiolol hydrochloride, a new sympathetic beta blocker] Yoshiya I. **Masui** 1998 Dec;47 Suppl:S126–32 (17 ref.) **(Jpn)**

ANALYSIS

Urea breath test: a diagnostic tool in the management of Helicobacter pylori-related gastrointestinal diseases. Peeters M. **Acta Gastroenterol Belg** 1998 Jul–Sep; 61(3):332–5 (26 ref.)
Urea sensors--a world of possibilities. Sternby J. **Adv Ren Replace Ther** 1999 Jul;6(3):265–72 (26 ref.)
Methodological problems and pitfalls of urea breath test. Perri F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S315–9 (44 ref.)

BLOOD

Blood flow rate: an important determinant of urea clearance and delivered Kt/V [published erratum appears in Adv Ren Replace Ther 1999 Jul;6(3):following 293] Ward RA. **Adv Ren Replace Ther** 1999 Jan;6(1):75–9 (22 ref.)
The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Kraus LM, et al. **Wien Klin Wochenschr** 1998 Aug 21;110(15):521–30 (97 ref.)

DIAGNOSTIC USE

[The 13C-urea breath test efficacy in determining Helicobacter pylori eradication] Toyama J, et al. **Nippon Rinsho** 1999 Jan;57(1):93–6 (17 ref.) (Eng. Abstr.) **(Jpn)**
[The breath test with labeled urea for the diagnosis of Helicobacter pylori infection] Pérez Páramo M, et al. **Rev Esp Med Nucl** 1998;17(6):455–67 (53 ref.) **(Spa)**

METABOLISM

Urea excretion revisited: physiology and transporters. Bankir L, et al. **Adv Nephrol Necker Hosp** 1998;28:83–135 (200 ref.)
Urea: diverse functions of a 'waste' product. Withers PC. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):722–7 (45 ref.)
Regulation of renal urea transporters. Sands JM. **J Am Soc Nephrol** 1999 Mar;10(3):635–46 (137 ref.)
Unique evolution of neurohypophysial hormones in cartilaginous fishes: possible implications for urea-based osmoregulation. Acher R, et al. **J Exp Zool** 1999 Oct 1; 284(5):475–84 (60 ref.)
Significant role of the nitrogen recycling system through the ceca occurs in protein-depleted chickens. Karasawa Y. **J Exp Zool** 1999 Mar–Apr 1;283(4–5):418–25 (44 ref.)
Clinical studies of 13C-urea breath test in Japan. Kato M, et al. **J Gastroenterol** 1998;33 Suppl 10:36–9 (22 ref.)
Treatment of urea cycle disorders [editorial; comment] Thoene JG. **J Pediatr** 1999 Mar;134(3):255–6 (8 ref.)
Comment on: J Pediatr 1999 Mar;134(3):268–72.
Urea rebound and effectively delivered dialysis dose. Alloatti S, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:25–30 (49 ref.)
Benefits of more frequent dialysis: lower TAC at the same Kt/V. Depner TA. **Nephrol Dial Transplant** 1998;13 Suppl 6:20–4 (15 ref.)
The current place of urea kinetic modelling with respect to different dialysis modalities. Gotch FA. **Nephrol Dial Transplant** 1998;13 Suppl 6:10–4 (10 ref.)
Relationships between creatinine clearance and Kt/V in peritoneal dialysis: a defense of the DOQI document. Dialysis Outcomes Quality Initiative [editorial; comment] Gotch FA. **Perit Dial Int** 1999 Mar–Apr;19(2):107–12 (24 ref.) Comment on: Perit Dial Int 1998 May–Jun;18(3):252–5.
[Inherited hyperammonemia] Bik-Multanowski M. **Przegl Lek** 1998;55(6):337–41 (4 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Signalling and gene regulation by urea and NaCl in the renal medulla. Cohen DM. **Clin Exp Pharmacol Physiol** 1999 Jan; 26(1):69–73 (44 ref.)

UREAPLASMA

GROWTH & DEVELOPMENT

Cultivation of ureaplasmas. Furr PM. **Methods Mol Biol** 1998; 104:53–9 (8 ref.)

UREASE

ANALYSIS

Detection of Helicobacter pylori infection by biopsy urease test. Ramdani B, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):330–1 (11 ref.)
[Possible availability of rapid urease tests for diagnosis of Helicobacter pylori eradication: comparative study with culture and histology] Murata H, et al. **Nippon Rinsho** 1999 Jan;57(1):97–100 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Structure, function and localization of Helicobacter pylori urease. Dunn BE, et al. **Yale J Biol Med** 1998 Mar–Apr; 71(2):63–73 (67 ref.)

UREMIA

Uraemic pruritus. Schwartz IF, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):834–9 (82 ref.)

BLOOD

Circulating biochemical markers of bone remodeling in uremic patients. Ureña P, et al. **Kidney Int** 1999 Jun; 55(6):2141–56 (189 ref.)
Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Perna AF, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):95–9 (24 ref.)

COMPLICATIONS

Carbonyl stress and long-term uremic complications. Miyata T, et al. **Adv Nephrol Necker Hosp** 1998;28:311–9 (41 ref.)
Factors causing malnutrition in patients with chronic uremia. Mitch WE, et al. **Am J Kidney Dis** 1999 Jan;33(1):176–9 (22 ref.)
Medical management of secondary hyperparathyroidism in uremia. Drüeke TB. **Am J Med Sci** 1999 Jun;317(6):383–9 (51 ref.)
Surgical management of secondary hyperparathyroidism in uremia. Tominaga Y. **Am J Med Sci** 1999 Jun;317(6):390–7 (50 ref.)
Management of bleeding with uremia and liver disease. DeLoughery TG. **Curr Opin Hematol** 1999 Sep;6(5):329–33 (32 ref.)
Sexual dysfunction in uremia. Palmer BF. **J Am Soc Nephrol** 1999 Jun;10(6):1381–8 (33 ref.)
Mechanisms of uremic suppression of appetite. Bergstrom J. **J Ren Nutr** 1999 Jul;9(3):129–32 (6 ref.)
Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Perna AF, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):95–9 (24 ref.)
Mechanism of parathyroid tumourigenesis in uraemia. Tominaga Y. **Nephrol Dial Transplant** 1999;14 Suppl 1:63–5 (11 ref.)
[Gastric haemorrhagic mucosal lesion in uremic patients] Itoh K. **Nippon Rinsho** 1998 Sep;56(9):2391–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

The use of the artificial kidney in the treatment of uremia. 1952 [classical article] Merrill JP. **J Urban Health** 1998 Dec;75(4):911–8; discussion 919–21 (9 ref.)

METABOLISM

Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Witko-Sarsat V, et al. **Adv Nephrol Necker Hosp** 1998; 28:321–41 (80 ref.)
Modulation of parathyroid cell function by calcium ion in health and uremia. Akizawa T, et al. **Am J Med Sci** 1999 Jun;317(6):358–62 (48 ref.)
Cell biology of parathyroid hyperplasia in uremia. Fukagawa M. **Am J Med Sci** 1999 Jun;317(6):377–82 (59 ref.)
Introduction to renal osteodystrophy: calcium metabolism in health and uremia. Kurokawa K, et al. **Am J Med Sci** 1999 Jun;317(6):355–7 (33 ref.)
The pathogenesis and consequences of AGE formation in uraemia and its treatment. Dawnay A, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1081–94 (110 ref.)
Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes. Buoncristiani U, et al. **Contrib Nephrol** 1999;125:133–58 (72 ref.)
Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Miyata T, et al. **Kidney Int** 1999 Feb; 55(2):389–99 (90 ref.)
Importance of vitamin D repletion in uraemia [editorial; comment] Fournier A, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):819–23 (43 ref.) Comment on: Nephrol Dial Transplant 1997 Jan;12(1):16–8.
Implication of carbonyl stress in long-term uraemic complications. Wada T, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:79–81 (16 ref.)
Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Witko-Sarsat V, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:76–8 (23 ref.)

PHYSIOPATHOLOGY

Calciotropic hormones and the skeleton in uraemia [comment] Lewin E, et al. **Eur J Clin Invest** 1999 Jun; 29(6):466–8 (13 ref.) Comment on: Eur J Clin Invest 1999 Jun;29(6):529–35.
Pathophysiologic effects of uremic retention solutes. Vanholder R, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1815–23 (137 ref.)
Cardiovascular abnormalities in ageing and in uraemia--only analogy or shared pathomechanisms? Amann K, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:6–11 (27 ref.)
Genesis of the uraemic syndrome: role of uraemic toxins [editorial] Hörl WH. **Wien Klin Wochenschr** 1998 Aug 21; 110(15):511–20 (125 ref.)
The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Kraus LM, et al. **Wien Klin Wochenschr** 1998 Aug 21;110(15):521–30 (97 ref.)
[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1338–48 (61 ref.) **(Fre)**

SURGERY

Tumoral calcinosis regression after subtotal parathyroidectomy: a case presentation and review of the literature. Thakur A, et al. **Surgery** 1999 Jul;126(1):95–8 (10 ref.)

THERAPY

The pathogenesis and consequences of AGE formation in uraemia and its treatment. Dawnay A, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1081–94 (110 ref.)
[Treatment with erythropoietin in Central and Eastern Europe] Rutkowski B. **Przegl Lek** 1998;55 Suppl 1:67–71 (25 ref.) (Eng. Abstr.) **(Pol)**

URETER

see related
URETEROSCOPY
URINARY DIVERSION

ABNORMALITIES

Endoscopic incision for the treatment of a ureteric valve. Nishio S, et al. **BJU Int** 1999 Jun;83(9):1081–2 (3 ref.)
Bladder agenesis with urometrocolpos. Kasat LS, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):415–6 (9 ref.)
Upper-pole pelviureteric junction obstruction: a critical review [letter] Ng JW. **Pediatr Surg Int** 1999;15(3–4):298–9 (15 ref.)
[Vesico-renal reflux and duplication of the urinary tract] **Prog Urol** 1998 Nov;8(5):869–81 (54 ref.) **(Fre)**
[A case of renal pelvic carcinoma in a completely duplicated pelvis and ureter] Tamada H, et al. **Hinyokika Kiyo** 1998 Oct;44(10):733–5 (19 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

[Uretero-external iliac artery fistula: a case report] Kawabata G, et al. **Hinyokika Kiyo** 1998 Nov;44(11):829–32 (14 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

Relevance of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Wallner EI, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F467–77 (128 ref.)
Embryonic development of the ureter. Baker LA, et al. **Semin Nephrol** 1998 Nov;18(6):569–84 (86 ref.)
[Molecular basis of renal development] Lelongt B, et al. **Nephrologie** 1998;19(6):319–27 (62 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Bladder and ureteral injury: prevention and management. Utrie JW Jr. **Clin Obstet Gynecol** 1998 Sep;41(3):755–63 (26 ref.)
Management of injuries to the urinary and gastrointestinal tract during cesarean section. Davis JD. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):469–80 (19 ref.)
Reconstructive surgery for trauma of the upper urinary tract. Brandes SB, et al. **Urol Clin North Am** 1999 Feb; 26(1):183–99, x (52 ref.)
Prophylactic ureteral catheterization in gynecologic surgery. Kuno K, et al. **Urology** 1998 Dec;52(6):1004–8 (17 ref.)

Current methods of diagnosis and management of ureteral injuries. Armenakas NA. **World J Urol** 1999 Apr; 17(2):78–83 (22 ref.)
[Ureteral reimplantation on psoas bladder: long-term results] el Kahder K, et al. **Acta Urol Belg** 1998 Dec;66(4):15–20 (24 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Myogenic and neurogenic factors in the control of pyeloureteral motility and ureteral peristalsis. Santicioli P, et al. **Pharmacol Rev** 1998 Dec;50(4):683–722 (248 ref.)

PHYSIOLOGY

Myogenic and neurogenic factors in the control of pyeloureteral motility and ureteral peristalsis. Santicioli P, et al. **Pharmacol Rev** 1998 Dec;50(4):683–722 (248 ref.)

SURGERY

Ileal ureteral substitution in reconstructive urological surgery: is an antireflux procedure necessary? Waldner M, et al. **J Urol** 1999 Aug;162(2):323–6 (20 ref.)
Upper ureteral reconstructive surgery. Borhan A, et al. **Urol Clin North Am** 1999 Feb;26(1):175–81, x (35 ref.)
Reconstructive surgery for trauma of the upper urinary tract. Brandes SB, et al. **Urol Clin North Am** 1999 Feb; 26(1):183–99, x (52 ref.)
Lower ureteral reconstruction. Koo HP, et al. **Urol Clin North Am** 1999 Feb;26(1):167–73, x (29 ref.)
[Ureteral reimplantation on psoas bladder: long-term results] el Kahder K, et al. **Acta Urol Belg** 1998 Dec;66(4):15–20 (24 ref.) (Eng. Abstr.) **(Fre)**

URETERAL CALCULI

COMPLICATIONS

Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Miller OF, et al. **Urology** 1998 Dec; 52(6):982–7 (23 ref.)

RADIOGRAPHY

Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Miller OF, et al. **Urology** 1998 Dec; 52(6):982–7 (23 ref.)

URETERAL DISEASES

COMPLICATIONS

[Aspects of etiology, pathogenesis and clinical course of the megaureter] Stakhovskii EA. **Klin Khir** 1998;(8):37–9 (3 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Rupture of an iliac artery pseudo-aneurysm into a ureter. Levi N, et al. **Eur J Vasc Endovasc Surg** 1999 Mar; 17(3):264–5 (14 ref.)
[The involvement of the urinary tract in inguinal hernias] Carrieri P, et al. **Ann Ital Chir** 1998 Nov–Dec;69(6):795–7 (7 ref.) (Eng. Abstr.) **(Ita)**
[Aspects of etiology, pathogenesis and clinical course of the megaureter] Stakhovskii EA. **Klin Khir** 1998;(8):37–9 (3 ref.) (Eng. Abstr.) **(Rus)**
[Giant calcifications of a double-J ureteral catheter] Belvis Esclapés V, et al. **Actas Urol Esp** 1999 May;23(5):432–5 (14 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Teratoid Wilms tumor arising as a botryoid growth within a supernumerary ectopic ureteropelvic structure. Pawel BR, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):925–8 (26 ref.)
Uretero-arterial fistula: a case report and review of the literature. Camps JI, et al. **Bol Asoc Med P R** 1998 Apr–Jun;90(4–6):82–4 (11 ref.)

THERAPY

Angiographic arterial occlusion and extra-anatomical vascular bypass for the management of a ureteral-iliac fistula: case report and review of the literature. Gheiler EL, et al. **Urol Int** 1998 Oct;61(1):62–6 (33 ref.)
[Aspects of etiology, pathogenesis and clinical course of the megaureter] Stakhovskii EA. **Klin Khir** 1998;(8):37–9 (3 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Ureteral diverticula in two dogs. Jakovljevic S, et al. **Vet Radiol Ultrasound** 1998 Sep–Oct;39(5):425–9 (35 ref.)

URETERAL NEOPLASMS

DIAGNOSIS

[Fibroepithelial polyps of the upper urinary tract: their diagnostic evaluation and treatment in pediatrics] Mora Durbán MJ, et al. **Arch Esp Urol** 1999 Jan–Feb;52(1):61–7 (38 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

[The bilateral ureteral metastasis of a medullary carcinoma of the thyroid] Valero Puerta JA, et al. **Arch Esp Urol** 1999 Jun;52(5):522–5 (11 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours. Lümmen G, et al. **Pharmacol Res** 1998 Sep;38(3):151–64 (70 ref.)

URETERAL OBSTRUCTION

Upper-pole pelviureteric junction obstruction: a critical review [letter] Ng JW. **Pediatr Surg Int** 1999;15(3–4):298–9 (15 ref.)

COMPLICATIONS

Molecular and cellular pathophysiology of obstructive nephropathy. Chevalier RL. **Pediatr Nephrol** 1999 Sep; 13(7):612–9 (95 ref.)
[Tubulo-interstitial nephropathies caused by obstructive nephrosis] Fukuzaki A. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1475–9 (5 ref.) **(Jpn)**

CONGENITAL

Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. Yerkes E, et al. **Kidney Int Suppl** 1998 Sep;67:S75–7 (12 ref.)
Uroradiology in the fetus and newborn: diagnosis and follow-up of congenital obstruction of the urinary tract [see comments] Ebel KD. **Pediatr Radiol** 1998 Aug; 28(8):630–5 (54 ref.) Comment in: Pediatr Radiol 1998 Nov;28(11):902.
Pathophysiology of obstructive nephropathy in the newborn. Chevalier RL. **Semin Nephrol** 1998 Nov;18(6):585–93 (74 ref.)

DIAGNOSIS

The diagnosis of upper urinary tract obstruction. Shokeir AA. **BJU Int** 1999 May;83(8):893–900; quiz 900–1 (40 ref.)

ETIOLOGY

Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. Demko TM, et al. **J Am Soc Nephrol** 1997 Apr;8(4):684–8 (26 ref.)
Thermal radiofrequency induced porcine ureteral stricture: a convenient endourologic model. Anidjar M, et al. **J Urol** 1999 Jan;161(1):298–303 (16 ref.)
Idiopathic retroperitoneal fibrosis with bilateral lower ureteric obstruction--a case report with literature review. Koh JS, et al. **Singapore Med J** 1998 Sep;39(9):416–7 (15 ref.)

METABOLISM

The kininogen gene family in obstructive uropathy. El-Dahr SS. **Semin Nephrol** 1998 Nov;18(6):633–40 (75 ref.)

PATHOLOGY

Mechanisms of interstitial fibrosis in obstructive nephropathy. Diamond JR, et al. **Semin Nephrol** 1998 Nov;18(6):594–602 (71 ref.)
The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Klahr S, et al. **Semin Nephrol** 1998 Nov;18(6):622–32 (89 ref.)
Transcription factor NF-kappaB regulation of renal fibrosis during ureteral obstruction. Morrissey J, et al. **Semin Nephrol** 1998 Nov;18(6):603–11 (79 ref.)
Cell apoptosis and proliferation in obstructive uropathy. Truong LD, et al. **Semin Nephrol** 1998 Nov;18(6):641–51 (66 ref.)
Obstructive nephropathy: an update of the experimental research. Wen JG, et al. **Urol Res** 1999;27(1):29–39 (109 ref.)

PHYSIOPATHOLOGY

Obstructive nephropathy in the pig. Aspects of renal hemodynamics and hormonal changes during acute unilateral ureteral obstruction. Frøkiaer J. **APMIS Suppl** 1998;82:7–48 (259 ref.)
Recoverability of renal function after relief of chronic partial upper urinary tract obstruction. Shokeir AA, et al. **BJU Int** 1999 Jan;83(1):11–7 (43 ref.)
Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. Yerkes E, et al. **Kidney Int Suppl** 1998 Sep;67:S75–7 (12 ref.)
Obstructive nephropathy: an update of the experimental research. Wen JG, et al. **Urol Res** 1999;27(1):29–39 (109 ref.)

RADIOGRAPHY

Acute flank pain: a modern approach to diagnosis and management. Smith RC, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):108–35 (107 ref.)

RADIONUCLIDE IMAGING

[Radioisotopic studies in the diagnosis of obstructive uropathy] Testa HJ. **Rev Esp Med Nucl** 1999 Jun; 18(3):214–24 (43 ref.) **(Spa)**

SURGERY

Use of self-expanding permanent endoluminal stents for benign ureteral strictures: mid-term results. Pauer W, et al. **J Urol** 1999 Aug;162(2):319–22 (22 ref.)
Ureteroscopic treatment of ureteropelvic junction obstruction. Tawfiek ER, et al. **J Urol** 1998 Nov; 160(5):1643–6; discussion 1646–7 (34 ref.)
Upper ureteral reconstructive surgery. Borhan A, et al. **Urol Clin North Am** 1999 Feb;26(1):175–81, x (35 ref.)

THERAPY

Cost-effectiveness analysis: application to endourology. Chandhoke PS, et al. **J Endourol** 1998 Dec;12(6):485–91 (38 ref.)
Endourological treatment of ureteroenteric strictures: efficacy of Acucise endoureterotomy. Lin DW, et al. **J Urol** 1999 Sep;162(3 Pt 1):696–8 (20 ref.)
Therapeutic approaches in obstructive uropathy. Chevalier RL, et al. **Semin Nephrol** 1998 Nov;18(6):652–8 (49 ref.)

URETEROCELE

DIAGNOSIS

[Genital prolapse. Diagnosis] Jacob D, et al. **Rev Prat** 1998 May 15;48(10):1103–7 (0 ref.) **(Fre)**

URETEROLITHIASIS see **URETERAL CALCULI**

URETEROSCOPY

Cystourethroscopy for the practicing gynecologist. Weinberger MW. **Clin Obstet Gynecol** 1998 Sep; 41(3):764–76 (20 ref.)
Ureteroscopic lithotripsy [see comments] Grasso M 3rd. **Curr Opin Urol** 1999 Jul;9(4):329–33 (40 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315–7.
Expanding role of flexible nephroscopy in the upper urinary tract. Beaghler MA, et al. **J Endourol** 1999 Mar;13(2):93–7 (12 ref.)
Ureteroscopic treatment of ureteropelvic junction obstruction. Tawfiek ER, et al. **J Urol** 1998 Nov; 160(5):1643–6; discussion 1646–7 (34 ref.)
[Endoscopic treatment of vesico-renal reflux] **Prog Urol** 1998 Nov;8(5):841–62 (116 ref.) **(Fre)**

INSTRUMENTATION

Small diameter, actively deflectable, flexible ureteropyeloscopy. Grasso M, et al. **J Urol** 1998 Nov; 160(5):1648–53; discussion 1653–4 (33 ref.)

URETHANE

see related
POLYURETHANES

ADMINISTRATION & DOSAGE

Commentary: paternal legacies. Anderson D, et al. **Teratog Carcinog Mutagen** 1999;19(2):105–8 (14 ref.)

ADVERSE EFFECTS

Formation of DNA etheno adducts in rodents and humans and their role in carcinogenesis. Barbin A. **Acta Biochim Pol** 1998;45(1):145–61 (93 ref.)

PHARMACOLOGY

Commentary: paternal legacies. Anderson D, et al. **Teratog Carcinog Mutagen** 1999;19(2):105–8 (14 ref.)

URETHRA

[Urethral foreign bodies. Apropos 2 cases] García Riestra V, et al. **Arch Esp Urol** 1999 Jan–Feb;52(1):74–6 (7 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

The long-term complications of posterior urethral valves. Nguyen HT, et al. **BJU Int** 1999 Apr;83 Suppl 3:23–8 (54 ref.)
Congenital prepubic sinus: possible variant of dorsal urethral duplication. Ergün O, et al. **Eur J Pediatr Surg** 1998 Dec; 8(6):380–1 (7 ref.)
Complete duplication of bladder and urethra in the coronal plane in a girl: case report and review of the literature. Berrocal T, et al. **Pediatr Radiol** 1999 Mar;29(3):171–3 (12 ref.)
Incomplete hypospadiac urethral duplication with posterior urethral valves. Ramanujam TM, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):134–7 (12 ref.)
[Transient pseudohypoaldosteronism secondary to congenital malformation pathology of the urinary tract (valves of the posterior urethra): a report of a case with elements of a physiopathological nature] Parisi G, et al. **Pediatr Med Chir** 1998 Jul–Aug;20(4):289–93 (32 ref.) (Eng. Abstr.) **(Ita)**
[Posterior urethral valves: a change of concept] Close CE,

URETHRA

et al. **Arch Esp Urol** 1998 Jul-Aug;51(6):581-7 (21 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Preclinical pharmacology of alpha1-adrenoceptor antagonists. Martin DJ. **Eur Urol** 1999;36 Suppl 1:35-41; discussion 65 (23 ref.)

INJURIES

Pelvic fracture urethral injuries: the unresolved controversy. Koraitim MM. **J Urol** 1999 May;161(5):1433-41 (65 ref.)

Heterotopic bone formation in association with pelvic fracture and urethral disruption. Zagaja GP, et al. **J Urol** 1999 Jun;161(6):1950-3 (19 ref.)

Reconstructive surgery for trauma of the lower urinary tract. Morey AF, et al. **Urol Clin North Am** 1999 Feb;26(1):49-60, viii (36 ref.)

Traumatic posterior urethral injury and early primary endoscopic realignment: evaluation of long-term follow-up. Jepson BR, et al. **Urology** 1999 Jun; 53(6):1205-10 (23 ref.)

Anterior urethral injury. Hernandez J, et al. **World J Urol** 1999 Apr;17(2):96-100 (29 ref.)

Pelvic fracture injuries of the posterior urethra. Mundy AR. **World J Urol** 1999 Apr;17(2):90-5 (53 ref.)

INNERVATION

Functional anatomy and neural regulation of the lower urinary tract in female dogs: a review. Nickel RF, et al. **Vet Q** 1999 Jun;21(3):83-5 (30 ref.)

PHYSIOLOGY

Functional anatomy and neural regulation of the lower urinary tract in female dogs: a review. Nickel RF, et al. **Vet Q** 1999 Jun;21(3):83-5 (30 ref.)

SURGERY

Fascia lata sling cystourethropexy for the management of female urinary incontinence. Griebling TL, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(3):165-73 (67 ref.)

Reconstructive surgery for trauma of the lower urinary tract. Morey AF, et al. **Urol Clin North Am** 1999 Feb;26(1):49-60, viii (36 ref.)

URETHRAL DISEASES

CONGENITAL

Congenital anterior urethrocutaneous fistula. Caldamone AA, et al. **J Urol** 1999 Oct;162(4):1430-2 (22 ref.)

[A congenital diverticulum of the bulbar urethra] Rodríguez Rincón JP, et al. **Arch Esp Urol** 1999 Jun;52(5):529-31 (15 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Complete duplication of bladder and urethra in the coronal plane in a girl: case report and review of the literature. Berrocal T, et al. **Pediatr Radiol** 1999 Mar;29(3):171-3 (12 ref.)

ETIOLOGY

Syndromic management of sexually transmitted diseases. Part 2--The management of genital discharge. Latif AS. **Cent Afr J Med** 1998 Sep;44(9):236-41 (14 ref.)

Urethral diverticulum: an unusual presentation of Wegener's granulomatosis. Goldman HB, et al. **J Urol** 1999 Mar; 161(3):917-8 (3 ref.)

Heterotopic bone formation in association with pelvic fracture and urethral disruption. Zagaja GP, et al. **J Urol** 1999 Jun;161(6):1950-3 (19 ref.)

PATHOLOGY

[Parameatal cyst: presentation of two cases and a review of the literature] Suárez Cuenca JA, et al. **Arch Esp Urol** 1998 Sep;51(7):716-8 (10 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Congenital anterior urethrocutaneous fistula. Caldamone AA, et al. **J Urol** 1999 Oct;162(4):1430-2 (22 ref.)

URETHRAL NEOPLASMS

COMPLICATIONS

[Nephrogenic adenoma arising from an urethral diverticulum in a female. Report of a case and review of the literature] Greco A, et al. **Minerva Urol Nefrol** 1999 Mar;51(1):39-43 (30 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Primary carcinoma of the male urethra. Report of a case and review of the literature] Martín García C, et al. **Actas Urol Esp** 1998 Sep;22(8):686-9 (19 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Leiomyoma of the female urethra (case report and review of the literature] Saidi R, et al. **Tunis Med** 1999 Jan; 77(1):54-6 (13 ref.) **(Fre)**

SURGERY

Review. The fate of the urethra after definitive treatment of invasive transitional cell carcinoma of the urinary bladder. Bell CR, et al. **BJU Int** 1999 Apr;83(6):607-12 (47 ref.)

URETHRAL OBSTRUCTION

CONGENITAL

Uroradiology in the fetus and newborn: diagnosis and follow-up of congenital obstruction of the urinary tract [see comments] Ebel KD. **Pediatr Radiol** 1998 Aug; 28(8):630-5 (54 ref.) Comment in: Pediatr Radiol 1998 Nov;28(11):902.

VETERINARY

Canine retrograde urohydropropulsion. Lessons from 25 years of experience. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1999 Jan; 29(1):267-81, xiv (7 ref.)

URETHRITIS

[Mycoplasmal urethritis] Matsukawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):27-9 (15 ref.) **(Jpn)**

[Urethritis] Ogawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):532-6 (11 ref.) **(Jpn)**

DIAGNOSIS

Urethritis and cervicitis. Molodysky E. **Aust Fam Physician** 1999 Apr;28(4):333-8 (6 ref.)

DRUG THERAPY

Urethritis and cervicitis. Molodysky E. **Aust Fam Physician** 1999 Apr;28(4):333-8 (6 ref.)

Nongonococcal urethritis--a new paradigm. Burstein GR, et al. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S66-73 (42 ref.)

MICROBIOLOGY

Urethritis treatment. Erbelding EJ, et al. **Dermatol Clin** 1998 Oct;16(4):735-8, xi-xii (16 ref.)

Etiology of nongonococcal nonchlamydial urethritis. Schwartz MA, et al. **Dermatol Clin** 1998 Oct;16(4):727-33, xi (72 ref.)

URIC ACID

BLOOD

Gout and hyperuricemia. Harris MD, et al. **Am Fam Physician** 1999 Feb 15;59(4):925-34 (33 ref.)

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease [editorial] Johnson RJ, et al. **Am J Kidney Dis** 1999 Feb;33(2):225-34 (82 ref.)

Is serum uric acid a risk factor for coronary heart disease? Wannamethee SG. **J Hum Hypertens** 1999 Mar;13(3):153-6 (46 ref.)

Hyperuricemic nephropathies. Steele TH. **Nephron** 1999;81 Suppl 1:45-9 (42 ref.)

[Physiopathology and treatment of gout and hyperuricemia] Yamanaka H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):718-23 (11 ref.) **(Jpn)**

[Serum uric acid level and fractional excretion of urate in fluid and electrolyte disturbances] Shichiri M, et al. **Rinsho Byori** 1999 May;47(5):417-23 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[The effects of angiotensin II receptor antagonists on glucose, lipid, and uric acid metabolism in essential hypertensives] Takizawa H, et al. **Nippon Rinsho** 1999 May;57(5):1137-40 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Development of arterial hypertension in urate tubulointerstitial renal damage (editorial)] Mukhin NA, et al. **Ter Arkh** 1999;71(6):23-7 (14 ref.) **(Rus)**

URINE

Regulation of renal urate excretion: a critical review. Maesaka JK, et al. **Am J Kidney Dis** 1998 Dec;32(6):917-33 (176 ref.)

[Serum uric acid level and fractional excretion of urate in fluid and electrolyte disturbances] Shichiri M, et al. **Rinsho Byori** 1999 May;47(5):417-23 (15 ref.) (Eng. Abstr.) **(Jpn)**

URIDINE

PHARMACOLOGY

Uridine and its nucleotides: biological actions, therapeutic potentials. Connolly GP, et al. **Trends Pharmacol Sci** 1999 May;20(5):218-25 (65 ref.)

URIDINE PHOSPHATES see **URACIL NUCLEOTIDES**

URINALYSIS

Urinalysis: current status and prospects for the future. Lorincz AE, et al. **Ann Clin Lab Sci** 1999 Jul-Sep; 29(3):169-75 (18 ref.)

METHODS

[Urinalysis using dipsticks] Cochat P, et al. **Arch Pediatr** 1998 Jan;5(1):65-70 (16 ref.) (Eng. Abstr.) **(Fre)**

URINARY CALCULI

CHEMISTRY

The architecture and composition of uroliths. Sperrin MW, et al. **Br J Urol** 1998 Dec;82(6):781-4 (18 ref.)

Calcium salt urolithiasis. Review of theory for diagnosis and management. Györy AZ, et al. **Clin Nephrol** 1999 Apr; 51(4):197-208 (49 ref.)

[Inhibitors in calcium oxalate crystals] Suzuki K. **Nippon Hinyokika Gakkai Zasshi** 1999 Mar;90(3):411-20 (105 ref.) **(Jpn)**

DRUG THERAPY

Historical perspectives and current advancements in the bacteriology and medical therapy of struvite urinary stone disease. Schwartz BF. **Curr Pharm Des** 1999 Jul;5(7):503-13 (93 ref.)

The physiologic approach to the medical management of stone disease. Dretler SP. **Urol Clin North Am** 1998 Nov; 25(4):613-23, ix (46 ref.)

[Idiopathic calcium lithiasis. Diuresis treatment] Pruna A, et al. **Presse Med** 1998 Feb 7;27(5):225-9 (33 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Renal stone disease in children. Santos-Victoriano M, et al. **Clin Pediatr (Phila)** 1998 Oct;37(10):583-99 (150 ref.)

[Urolithiasis] Piasecki Z, et al. **Przegl Lek** 1998;55(9):485-7 (15 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

[Idiopathic calcium lithiasis. Practical guide for dietary measures prescriptions (published erratum appears in Presse Med 1998 Mar 7;27(9):415)] Achard JM, et al. **Presse Med** 1998 Feb 7;27(5):230-7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Idiopathic calcium lithiasis. Dietary correction of metabolic risk factors. Physiopathological bases] Bataille P, et al. **Presse Med** 1998 Feb 7;27(5):218-24 (63 ref.) (Eng. Abstr.) **(Fre)**

[Idiopathic calcium lithiasis. Diuresis treatment] Pruna A, et al. **Presse Med** 1998 Feb 7;27(5):225-9 (33 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The physiologic approach to the medical management of stone disease. Dretler SP. **Urol Clin North Am** 1998 Nov; 25(4):613-23, ix (46 ref.)

MICROBIOLOGY

Historical perspectives and current advancements in the bacteriology and medical therapy of struvite urinary stone disease. Schwartz BF. **Curr Pharm Des** 1999 Jul;5(7):503-13 (93 ref.)

PHYSIOPATHOLOGY

[Medical aspects of urinary tract lithiasis] Barbosa AP, et al. **Acta Med Port** 1998 Oct;11(10):913-7 (16 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Abnormal calcifications in the urinary tract. Dyer RB, et al. **Radiographics** 1998 Nov-Dec;18(6):1405-24 (37 ref.)

Helical CT of urinary tract stones. Epidemiology, origin, pathophysiology, diagnosis, and management. Smith RC, et al. **Radiol Clin North Am** 1999 Sep;37(5):911-52, v (136 ref.)

Unenhanced CT in the evaluation of urinary calculi: application of advanced computer methods. Olcott EW, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):136-41 (24 ref.)

Acute flank pain: a modern approach to diagnosis and management. Smith RC, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):108-35 (107 ref.)

THERAPY

Ureteroscopic lithotripsy [see comments] Grasso M 3rd. **Curr Opin Urol** 1999 Jul;9(4):329-33 (40 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315-7.

Percutaneous nephrolithotripsy [see comments] Puppo P. **Curr Opin Urol** 1999 Jul;9(4):325-8 (14 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315-7.

Current advances in shock wave lithotripsy [see comments] Tolley DA, et al. **Curr Opin Urol** 1999 Jul;9(4):319-23 (21 ref.) Comment in: Curr Opin Urol 1999 Jul;9(4):315-7.

Cost-effectiveness analysis: application to endourology. Chandhoke PS, et al. **J Endourol** 1998 Dec;12(6):485-91

(38 ref.)
[Urolithiasis] Piasecki Z, et al. **Przegl Lek** 1998;55(9):485–7 (15 ref.) (Eng. Abstr.) **(Pol)**

URINE

[Calcium-dependent calcium oxalate lithiasis (type IIa). The importance of urinary citrate and the calcium/citrate ratio] Boess G, et al. **Presse Med** 1999 Apr 17;28(15):784–6 (10 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Electrohydraulic and extracorporeal shock-wave lithotripsy. Adams LG, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):293–302, xv (27 ref.)
Methods for evaluating treatment of uroliths. Bartges JW, et al. **Vet Clin North Am Small Anim Pract** 1999 Jan; 29(1):45–57, x (19 ref.)
Canine urate urolithiasis. Etiopathogenesis, diagnosis, and management. Bartges JW, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):161–91, xii–xiii (100 ref.)
Imaging canine urocystoliths. Detection and prediction of mineral content. Feeney DA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan;29(1):59–72, x–xi (24 ref.)
Canine calcium phosphate uroliths. Etiopathogenesis, diagnosis, and management. Kruger JM, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):141–59, xii (32 ref.)
Epidemiology of canine calcium oxalate uroliths. Identifying risk factors. Lulich JP, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):113–22, xi (27 ref.)
Canine calcium oxalate urolithiasis. Case-based applications of therapeutic principles. Lulich JP, et al.
Vet Clin North Am Small Anim Pract 1999 Jan;29(1):123–39 (13 ref.)
Voiding urohydropropulsion. Lessons from 5 years of experience. Lulich JP, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):283–91, xiv (2 ref.)
Risk and protective factors for urolithiasis. What do they mean? Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan;29(1):39–43, x (8 ref.)
Medical dissolution and prevention of canine struvite urolithiasis. Twenty years of experience. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1999 Jan; 29(1):73–111, xi (84 ref.)
Medical dissolution and prevention of canine uroliths. Seven steps from science to service. Osborne CA.
Vet Clin North Am Small Anim Pract 1999 Jan;29(1):1–15, ix (64 ref.)
Analysis of 77,000 canine uroliths. Perspectives from the Minnesota Urolith Center. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan;29(1):17–38, ix–x (6 ref.)
Canine cystine urolithiasis. Cause, detection, treatment, and prevention. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):193–211, xiii (48 ref.)
Canine retrograde urohydropropulsion. Lessons from 25 years of experience. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):267–81, xiv (7 ref.)
Canine silica urolithiasis. Risk factors, detection, treatment, and prevention. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):213–30, xiii (31 ref.)
Drug-induced urolithiasis. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1999 Jan; 29(1):251–66, xiv (17 ref.)

URINARY CATHETERIZATION

Postoperative urinary drainage. Young SB, et al.
Clin Obstet Gynecol 1998 Sep;41(3):735–43 (7 ref.)
Prophylactic ureteral catheterization in gynecologic surgery. Kuno K, et al. **Urology** 1998 Dec;52(6):1004–8 (17 ref.)

ADVERSE EFFECTS

Preventing catheter-related bacteriuria: should we? Can we? How? Saint S, et al. **Arch Intern Med** 1999 Apr 26; 159(8):800–8 (103 ref.)
Catheter-associated infections in urology: possible use of silver-impregnated catheters and the Erlanger silver catheter. Rösch W, et al. **Infection** 1999;27 Suppl 1:S74–7 (36 ref.)
[Giant calcifications of a double-J ureteral catheter] Belvis Esclapés V, et al. **Actas Urol Esp** 1999 May;23(5):432–5 (14 ref.) (Eng. Abstr.) **(Spa)**
[The role of urethral catheterization in penile necrosis] Serrano Durba A, et al. **Actas Urol Esp** 1999 May; 23(5):444–6 (14 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

[The double-J ureteral catheter: its historical development and current status] Vallejo Herrador J, et al.
Arch Esp Urol 1999 Jun;52(5):499–504 (48 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. Denstedt JD, et al. **J Endourol** 1998 Dec;12(6):493–500 (75 ref.)
[Ruptures of double-J ureteral catheter. Our experience and review of the literature] Rodrigo Aliaga M, et al.
Actas Urol Esp 1998 Oct;22(9):751–6 (20 ref.) (Eng. Abstr.) **(Spa)**

URINARY DIVERSION

Gastrocystoplasty: long-term followup. Kurzrock EA, et al. **J Urol** 1998 Dec;160(6 Pt 1):2182–6 (32 ref.)
Endourological treatment of ureteroenteric strictures: efficacy of Acucise endoureterotomy. Lin DW, et al.
J Urol 1999 Sep;162(3 Pt 1):696–8 (20 ref.)
Metabolic consequences of urinary diversion with intestinal segments. Djavan B, et al. **Tech Urol** 1998 Dec;4(4):177–81 (48 ref.)
When the bladder is gone: quality of life following different types of urinary diversion. Månsson A, et al.
World J Urol 1999 Aug;17(4):211–8 (34 ref.)

ADVERSE EFFECTS

Intra-abdominal abscess due to patient non-compliance after construction of an ileal neobladder: case report and review of the literature. Doehn C, et al. **Int J Urol** 1999 May; 6(5):264–7 (12 ref.)

METHODS

The artificial bladder. Desgrandchamps F, et al. **Eur Urol** 1999 Apr;35(4):257–66 (77 ref.)
Replacement of the urinary bladder. Neal DE. **Lancet** 1999 Apr;353 Suppl 1:SI24–5 (11 ref.)
Continent urinary diversion. Benson MC, et al.
Urol Clin North Am 1999 Feb;26(1):125–47, ix (70 ref.)
Reconstructive surgery for urinary incontinence. Leng WW, et al. **Urol Clin North Am** 1999 Feb;26(1):61–80, viii (49 ref.)
Gastrocystoplasty: is there a consensus? Kurzrock EA, et al. **World J Urol** 1998;16(4):242–50 (51 ref.)

URINARY FISTULA

COMPLICATIONS

Non-parasitic chyluria: a case report and review of the literature. Cortvriend J, et al. **Acta Urol Belg** 1998 Oct; 66(3):11–5 (15 ref.)

CONGENITAL

Congenital anterior urethrocutaneous fistula. Caldamone AA, et al. **J Urol** 1999 Oct;162(4):1430–2 (22 ref.)

ETIOLOGY

Rupture of an iliac artery pseudo-aneurysm into a ureter. Levi N, et al. **Eur J Vasc Endovasc Surg** 1999 Mar; 17(3):264–5 (14 ref.)

PATHOLOGY

Uretero-arterial fistula: a case report and review of the literature. Camps JI, et al. **Bol Asoc Med P R** 1998 Apr-Jun;90(4–6):82–4 (11 ref.)

SURGERY

Congenital anterior urethrocutaneous fistula. Caldamone AA, et al. **J Urol** 1999 Oct;162(4):1430–2 (22 ref.)
[A case of spontaneous pyeloduodenal fistula] Hamamoto Y, et al. **Hinyokika Kiyo** 1999 May;45(5):355–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

URINARY INCONTINENCE

see related
INCONTINENCE PADS
URINARY SPHINCTER, ARTIFICIAL

Urinary incontinence in the older man. Johnson TM 2nd, et al. **Med Clin North Am** 1999 Sep;83(5):1247–66 (42 ref.)
The wet child. Wojcik LJ, et al. **Urol Clin North Am** 1998 Nov;25(4):735–44, xi (68 ref.)
Statements of the committees of the WHO consensus conference, 20 August 1997. 1st International Conference on Urinary Incontinence in the Elderly. Bonn, Germany, 20–21 August 1997. **World J Urol** 1998;16 Suppl 1:S1–73 (0 ref.)

CHEMICALLY INDUCED

Pharmacologic causes of female incontinence. Steele AC, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(2):106–10 (41 ref.)

CLASSIFICATION

[Classification of vesico-urethral dysfunction] Palmtag H.
Urologe A 1999 Jan;38(1):6–9 (8 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Urinary incontinence and concomitant prolapse. Grody MH.
Clin Obstet Gynecol 1998 Sep;41(3):777–85 (21 ref.)

DIAGNOSIS

Physical examination and pretreatment testing of the incontinent woman. Julian TM. **Clin Obstet Gynecol** 1998 Sep;41(3):663–71 (10 ref.)
Office assessment of female urinary incontinence. Young SB, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):249–66 (20 ref.)
Female urinary incontinence. An overview of a report presented to the French Urological Association. Ballanger P, et al. **Eur Urol** 1999 Sep;36(3):165–74 (75 ref.)
Pad testing in incontinent women: a review. Ryhammer AM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(2):111–5 (38 ref.)
Physiologic evaluation of the pelvic floor. Coates KW.
Obstet Gynecol Clin North Am 1998 Dec;25(4):805–24 (88 ref.)

DRUG THERAPY

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. Kobelt G, et al.
BJU Int 1999 Apr;83(6):583–90 (30 ref.)
Pharmacologic therapy for urinary incontinence and voiding dysfunctions. Portera SG, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):691–701 (22 ref.)
Urinary incontinence in the elderly. Drug treatment options. Chutka DS, et al. **Drugs** 1998 Oct;56(4):587–95 (58 ref.)
Pharmacological management of incontinence. Sullivan J, et al. **Eur Urol** 1999;36 Suppl 1:89–95 (29 ref.)
Desensitization of bladder sensory fibers by intravesical capsaicin or capsaicin analogs. A new strategy for treatment of urge incontinence in patients with spinal detrusor hyperreflexia or bladder hypersensitivity disorders. Cruz F.
Int Urogynecol J Pelvic Floor Dysfunct 1998;9(4):214–20 (47 ref.)
Medical treatment and medical side effects in urinary incontinence in the elderly. Thüroff JW, et al.
World J Urol 1998;16 Suppl 1:S48–61 (91 ref.)

EPIDEMIOLOGY

Heterogeneity in epidemiological investigations of bladder control problems: a problem of definition. Hampel C, et al. **BJU Int** 1999 Mar;83 Suppl 2:10–5 (56 ref.)
The epidemiology of incontinence in the elderly. Rutchik SD, et al. **Br J Urol** 1998 Dec;82 Suppl 1:1–4 (29 ref.)
Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. Thom DH, et al.
J Am Geriatr Soc 1998 Nov;46(11):1411–7 (98 ref.)
Birth trauma and the pelvic floor: lessons from the developing world. Wall LL. **J Womens Health** 1999 Mar;8(2):149–55 (36 ref.)
Epidemiology and etiology of urinary incontinence in the elderly. McGrother C, et al. **World J Urol** 1998;16 Suppl 1:S3–9 (94 ref.)
[Enuresis and pediatric urinary incontinence--epidemiology, diagnosis and therapy today] Stehr M, et al.
Wien Med Wochenschr 1998;148(22):521–4 (19 ref.) (Eng. Abstr.) **(Ger)**
[Urinary incontinence in men--a neglected problem? A quarter of all 80-year old men suffer of urinary leakage] Fall M. **Lakartidningen** 1999 May 5;96(18):2227–31 (20 ref.) (Eng. Abstr.) **(Swe)**

ETIOLOGY

Urinary incontinence in the elderly. Establishing a cause may allow a cure. Whishaw M. **Aust Fam Physician** 1998 Dec; 27(12):1087–90 (7 ref.)
Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. Thom DH, et al.
J Am Geriatr Soc 1998 Nov;46(11):1411–7 (98 ref.)
Epidemiology and etiology of urinary incontinence in the elderly. McGrother C, et al. **World J Urol** 1998;16 Suppl 1:S3–9 (94 ref.)
Medical treatment and medical side effects in urinary incontinence in the elderly. Thüroff JW, et al.
World J Urol 1998;16 Suppl 1:S48–61 (91 ref.)
[Pelvic and perineal sequelae of delivery] Fatton B, et al.
Rev Prat 1999 Jan 15;49(2):160–6 (29 ref.) (Eng. Abstr.) **(Fre)**
[Urodynamic studies in the child with urinary incontinence] Schwöbel M, et al. **Wien Med Wochenschr** 1998; 148(22):508–10 (2 ref.) (Eng. Abstr.) **(Ger)**
[Urinary incontinence in neurogenic defects and urogenital anomalies in childhood] Steiner G, et al.
Wien Med Wochenschr 1998;148(13):299–304 (25 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Urinary incontinence among elderly persons who live at home: a literature review. Steeman E, et al.
Nurs Clin North Am 1998 Sep;33(3):441–55 (63 ref.)
Interdisciplinary care of urinary incontinence in the elderly. Füsgen I, et al. **World J Urol** 1998;16 Suppl 1:S62–70 (39 ref.)

URINARY INCONTINENCE

PATHOLOGY

The aging bladder: morphology and urodynamics. Elbadawi A, et al. **World J Urol** 1998;16 Suppl 1:S10–34 (196 ref.)

PHYSIOPATHOLOGY

Urinary incontinence update: old traditions and new concepts. Schmidt RA, et al. **Adv Intern Med** 1999;44:19–57 (150 ref.)

Urodynamic evaluation for female urinary incontinence. Kohli N, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):672–90 (27 ref.)

Pathophysiology of female lower urinary tract dysfunction. Robinson D. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):747–56, vi (28 ref.)

The impact of sacral root anatomy on selective electrical stimulation for bladder evacuation. Dahms SE, et al. **World J Urol** 1998;16(5):322–8 (46 ref.)

The aging bladder: morphology and urodynamics. Elbadawi A, et al. **World J Urol** 1998;16 Suppl 1:S10–34 (196 ref.)

Urge incontinence in the elderly--supraspinal reflex incontinence. Madersbacher H, et al. **World J Urol** 1998; 16 Suppl 1:S35–43 (34 ref.)

[Pathophysiology and diagnosis of functional disorders of micturition] Schultz-Lampel D. **Urologe A** 1999 Jan; 38(1):14–9 (38 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Incontinence in women. Don't suffer it. Rane A. **Aust Fam Physician** 1999 Jun;28(6):584–6 (18 ref.)

Prevention of urinary incontinence in older people. Fonda D, et al. **Br J Urol** 1998 Dec;82 Suppl 1:5–10 (53 ref.)

[Radical prostatectomy: improving urinary incontinence (editorial)] Rodriguez-Rubio Cortadellas FI, et al. **Actas Urol Esp** 1998 Sep;22(8):629–41 (54 ref.) **(Spa)**

PSYCHOLOGY

The impact of urinary incontinence on the quality of life of women. Swithinbank LV, et al. **World J Urol** 1999 Aug; 17(4):225–9 (51 ref.)

REHABILITATION

Nonsurgical management of pelvic floor dysfunction. Visco AG, et al. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):849–65, vii (40 ref.)

SURGERY

Why anti-incontinence surgery succeeds or fails. Rovner ES, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):719–34 (32 ref.)

Postoperative urinary drainage. Young SB, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):735–43 (7 ref.)

A review of the complications and results of implantation of the AMS artificial urinary sphincter. Hajivassiliou CA. **Eur Urol** 1999 Jan;35(1):36–44 (124 ref.)

The artificial urinary sphincter in the female: indications for use, surgical approach and results. Elliott DS, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(6):409–15 (4 ref.)

Fascia lata sling cystourethropexy for the management of female urinary incontinence. Griebling TL, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(3):165–73 (67 ref.)

Surgical management of urinary incontinence. Bent AE, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):883–906 (91 ref.)

Reconstructive surgery for urinary incontinence. Leng WW, et al. **Urol Clin North Am** 1999 Feb;26(1):61–80, viii (49 ref.)

Consensus report on pelvic floor weakness of the elderly female. Stanton SL. **World J Urol** 1998;16 Suppl 1:S44–7 (27 ref.)

THERAPY

Urinary incontinence in the elderly. Managing for maximum outcomes. Whishaw M. **Aust Fam Physician** 1998 Dec; 27(12):1091–4 (7 ref.)

The management of urinary incontinence in the elderly. Wagg A, et al. **Br J Urol** 1998 Dec;82 Suppl 1:11–7 (53 ref.)

Nonsurgical therapies for urinary incontinence. Amuzu BJ. **Clin Obstet Gynecol** 1998 Sep;41(3):702–11 (38 ref.)

Office assessment of female urinary incontinence. Young SB, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):249–66 (20 ref.)

Incontinence in the elderly. Khullar V, et al. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):391–4 (37 ref.)

Female urinary incontinence. An overview of a report presented to the French Urological Association. Ballanger P, et al. **Eur Urol** 1999 Sep;36(3):165–74 (75 ref.)

Office management of female urinary incontinence. Iselin CE, et al. **Urol Clin North Am** 1998 Nov;25(4):625–45, ix (120 ref.)

New advances in injectable therapies for the treatment of incontinence and vesicoureteral reflux. Kershen RT, et al. **Urol Clin North Am** 1999 Feb;26(1):81–94, viii (77 ref.)

URINARY INCONTINENCE, STRESS

DRUG THERAPY

Injection therapy for stress incontinence in women. Su TH, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(3):200–6 (77 ref.)

PHYSIOPATHOLOGY

VLPP in the evaluation of the female with stress urinary incontinence. Petrou SP, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(4):254–9 (43 ref.)

REHABILITATION

The physiological basis of pelvic floor exercises in the treatment of stress urinary incontinence [see comments] Jóźwik M, et al. **Br J Obstet Gynaecol** 1998 Oct; 105(10):1046–51 (91 ref.) Comment in: Br J Obstet Gynaecol 1999 Jun;106(6):615–6.

SURGERY

Surgical management of pelvic organ prolapse and stress urinary incontinence. Drutz HP, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):786–93 (26 ref.)

Common operations for stress incontinence: selecting the correct operation. Portera JC, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):712–8 (21 ref.)

Laparoscopy or open Burch colposuspension? Ross J. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):405–9 (57 ref.)

Surgical treatment of stress urinary incontinence. Cervigni M, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul; 85(1):63–70 (102 ref.)

Pubic bone anchoring in the treatment of women with stress urinary incontinence: new applications to an old concept. Madjar S, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(6):416–8 (18 ref.)

Laparoscopic surgery for genuine stress incontinence. Paraiso MF, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(4):237–47 (48 ref.)

The Burch procedure: a comprehensive review. Dainer M, et al. **Obstet Gynecol Surv** 1999 Jan;54(1):49–60 (82 ref.)

[Results of artificial sphincter in a case of sphincter incontinence in the multiple surgery patient] Leduc F, et al. **Acta Urol Belg** 1998 Dec;66(4):9–13 (15 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of urinary incontinence by the laparotomic or laparoscopic Burch technique] Cosson M, et al. **Ann Chir** 1999;53(6):515–21 (8 ref.) **(Fre)**

[Treatment of urinary stress incontinence. Crtical review of randomized comparative results] Houfflin-Debarge V, et al. **Ann Chir** 1999;53(4):324–34 (58 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of stress and urge urinary incontinence in women. Glavind K, et al. **Acta Obstet Gynecol Scand** 1999 Feb;78(2):75–81 (74 ref.)

Stress urinary incontinence. Kobashi KC, et al. **Curr Opin Urol** 1999 Jul;9(4):285–90 (31 ref.)

Electrical stimulation for stress incontinence. Yamanishi T, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998; 9(5):281–90 (94 ref.)

URINARY RESERVOIRS, CONTINENT

Orthotopic bladder augmentation and substitution. Hohenfellner M, et al. **Curr Opin Urol** 1999 Jul;9(4):309–14 (46 ref.)

The use of small intestine in bladder reconstruction. Kashif KM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998; 9(5):275–80 (29 ref.)

Metabolic consequences of continent urinary diversion. Mills RD, et al. **J Urol** 1999 Apr;161(4):1057–66 (129 ref.)

Continent urinary diversion. Benson MC, et al. **Urol Clin North Am** 1999 Feb;26(1):125–47, ix (70 ref.)

Gastrocystoplasty: is there a consensus? Kurzrock EA, et al. **World J Urol** 1998;16(4):242–50 (51 ref.)

PHYSIOLOGY

Continence and urodynamic parameters of continent urinary reservoirs: comparison of gastric, ileal, ileocolic, right colon, and sigmoid segments. Santucci RA, et al. **Urology** 1999 Aug;54(2):252–7 (21 ref.)

URINARY RETENTION

see related
URINARY CATHETERIZATION

Acute urinary retention in men: an age old problem. Emberton M, et al. **BMJ** 1999 Apr 3;318(7188):921–5 (33 ref.)

DIAGNOSIS

[Acute urinary retention in women (see comments)] van der Linden EF, et al. **Ned Tijdschr Geneeskd** 1998 Jul 11; 142(28):1603–6 (24 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2216–7. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2217. **(Dut)**

ETIOLOGY

'Appropriateness of referral to urologists': can it be defined for symptoms of benign prostatic obstruction and used as a quality measure? Elwyn G, et al. **BJU Int** 1999 Feb; 83(3):238–42 (19 ref.)

Giant bladder diverticulum in Ehlers-Danlos syndrome type I causing outflow obstruction. Burrows NP, et al. **Clin Exp Dermatol** 1998 May;23(3):109–12 (22 ref.)

Intramedullary spinal teratoma presenting with urinary retention: case report and review of the literature. Poeze M, et al. **Neurosurgery** 1999 Aug;45(2):379–85 (62 ref.)

[Three cases of urinary retention caused by uterine leiomyoma] Kuroda K, et al. **Hinyokika Kiyo** 1999 Feb; 45(2):115–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Pathophysiologic effects of uremic retention solutes. Vanholder R, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1815–23 (137 ref.)

THERAPY

[Acute urinary retention in women (see comments)] van der Linden EF, et al. **Ned Tijdschr Geneeskd** 1998 Jul 11; 142(28):1603–6 (24 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2216–7. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2217. **(Dut)**

URINARY SPHINCTER, ARTIFICIAL

The artificial urinary sphincter in the female: indications for use, surgical approach and results. Elliott DS, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(6):409–15 (4 ref.)

[Results of artificial sphincter in a case of sphincter incontinence in the multiple surgery patient] Leduc F, et al. **Acta Urol Belg** 1998 Dec;66(4):9–13 (15 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

A review of the complications and results of implantation of the AMS artificial urinary sphincter. Hajivassiliou CA. **Eur Urol** 1999 Jan;35(1):36–44 (124 ref.)

URINARY TRACT

see related
UROGRAPHY

ABNORMALITIES

Role of the renin-angiotensin system in disorders of the urinary tract. Brock JW 3rd, et al. **J Urol** 1998 Nov; 160(5):1812–9 (85 ref.)

The role of PAX2 in normal and abnormal development of the urinary tract. Eccles MR. **Pediatr Nephrol** 1998 Nov; 12(9):712–20 (61 ref.)

Uroradiology in the fetus and newborn: diagnosis and follow-up of congenital obstruction of the urinary tract [see comments] Ebel KD. **Pediatr Radiol** 1998 Aug; 28(8):630–5 (54 ref.) Comment in: Pediatr Radiol 1998 Nov;28(11):902.

ANATOMY & HISTOLOGY

Virtual reality of the lower urinary tract in women. Stenzl A, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(4):248–53 (42 ref.)

DRUG EFFECTS

Pharmacological effects of epidermal growth factor (EGF) with focus on the urinary and gastrointestinal tracts. Vinter-Jensen L. **APMIS Suppl** 1999;93:1–42 (311 ref.)

EMBRYOLOGY

Obstruction of the fetal urinary tract. Peters CA. **J Am Soc Nephrol** 1997 Apr;8(4):653–63 (65 ref.)

Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Schedl A, et al. **Mol Cell Endocrinol** 1998 May 25;140(1–2):65–9 (35 ref.)

GROWTH & DEVELOPMENT

Role of angiotensin in the development of the kidney and urinary tract. Pope JC 4th, et al. **Nephrologie** 1998; 19(7):433–6 (45 ref.)

The role of PAX2 in normal and abnormal development of the urinary tract. Eccles MR. **Pediatr Nephrol** 1998 Nov; 12(9):712–20 (61 ref.)

INJURIES

[Injuries to the urinary tract] de Matos S, et al. **Acta Med Port** 1999 Jan-Mar;12(1–3):49–56 (49 ref.) (Eng. Abstr.) **(Por)**

INNERVATION

Neuromodulation of the lower urinary tract. Craggs M, et al. **Exp Physiol** 1999 Jan;84(1):149–60 (42 ref.)

PATHOLOGY

State-of-the-art magnetic resonance imaging of the kidneys and upper urinary tract. Dockery WD, et al. **J Endourol** 1999 Jul-Aug;13(6):417–23 (19 ref.)

RADIONUCLIDE IMAGING

[Radioisotopic studies in the diagnosis of obstructive uropathy] Testa HJ. **Rev Esp Med Nucl** 1999 Jun; 18(3):214–24 (43 ref.) **(Spa)**

URINARY TRACT DISEASES see **UROLOGIC DISEASES**

URINARY TRACT INFECTIONS

see related

ANTI-INFECTIVE AGENTS, URINARY

Urinary tract infections in adults. Orenstein R, et al. **Am Fam Physician** 1999 Mar 1;59(5):1225–34, 1237 (29 ref.)

Pediatric urinary tract infection and reflux. Ross JH, et al. **Am Fam Physician** 1999 Mar 15;59(6):1472–8, 1485–6 (28 ref.)

Prostatitis and urinary tract infection in men: what's new; what's true? Lipsky BA. **Am J Med** 1999 Mar;106(3):327–34 (76 ref.)

Urinary tract infections in the elderly. Eykyn SJ. **Br J Urol** 1998 Dec;82 Suppl 1:79–84 (6 ref.)

Urinary tract infections. Faro S, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):744–54 (53 ref.)

Pneumonia, tuberculosis, and urinary tract infections in pregnancy. Riley LE. **Curr Clin Top Infect Dis** 1999; 19:181–97 (112 ref.)

[Urinary tract infection] Kino M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):142–4 (13 ref.) **(Jpn)**

[Candida urinary tract infection] Matsukawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):345–8 (11 ref.) **(Jpn)**

[Schistosomiasis (intestinal, hepatic, urinary tract)] Ohnishi K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):481–4 (4 ref.) **(Jpn)**

[Urinary tract infections in children] Prandota J, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):197–201 (48 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. Starr M, et al. **Clin Infect Dis** 1998 Aug;27(2):310–5 (47 ref.)

Bladder cancer in women. van der Poel HG, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(3):207–12 (65 ref.)

Urinary tract infections and renal stone disease. Pupek-Musialik D. **Przegl Lek** 1998;55 Suppl 1:51–3 (12 ref.) **(Eng, Pol)**

DIAGNOSIS

Early neonatal urinary tract infection: a case report and review. Verma RP, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):480–4 (31 ref.)

A strategy for UTI in children. Fidler K, et al. **Practitioner** 1998 Jul;242(1588):538–41 (5 ref.)

Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Engel JD, et al. **Urol Clin North Am** 1998 Nov;25(4):685–701, x (68 ref.)

[Urinary tract infection and biological markers: C-reactive protein, interleukins and procalcitonin] Gendrel D. **Arch Pediatr** 1998;5 Suppl 3:269S–273S (21 ref.) (Eng. Abstr.) **(Fre)**

[Initial imaging in pediatric urinary tract infection] Guillot M, et al. **Arch Pediatr** 1998;5 Suppl 3:282S–284S (15 ref.) (Eng. Abstr.) **(Fre)**

[Current definition of urinary tract infection in the child] Quinet B. **Arch Pediatr** 1998;5 Suppl 3:250S–253S (20 ref.) (Eng. Abstr.) **(Fre)**

[Microbiological diagnosis of urinary tract infections in the child. Importance of rapid tests] Raymond J, et al. **Arch Pediatr** 1998;5 Suppl 3:260S–265S (17 ref.) (Eng. Abstr.) **(Fre)**

[Urinary infection in children] Coelho H, et al. **Acta Med Port** 1999 Jan–Mar;12(1–3):63–8 (15 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Empiric treatment of uncomplicated urinary tract infections. Preston SL, et al. **Ann Pharmacother** 1998 Nov; 32(11):1231–3 (18 ref.)

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Langtry HD, et al. **Drugs** 1998 Sep;56(3):487–515 (126 ref.)

Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Onrust SV, et al. **Drugs** 1998 Nov;56(5):895–928 (212 ref.)

Variation by specialty in the treatment of urinary tract infection in women. Wigton RS, et al. **J Gen Intern Med** 1999 Aug;14(8):491–4 (11 ref.)

Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Engel JD, et al. **Urol Clin North Am** 1998 Nov;25(4):685–701, x (68 ref.)

[Preventive treatment of urinary tract infections in the child] Gaudelus J. **Arch Pediatr** 1998;5 Suppl 3:307S–311S (39 ref.) (Eng. Abstr.) **(Fre)**

[Antibiotic therapy of acute pyelonephritis: which treatment to offer?] Gaudelus J. **Arch Pediatr** 1999;6 Suppl 2:403s–405s (10 ref.) **(Fre)**

[Co-trimoxazole administration: a rare cause of hypoglycemia in elderly persons] Rutschmann OT, et al. **Schweiz Med Wochenschr** 1998 Aug 4;128(31–32):1171–4 (23 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

[Enzymuria and urinary tract infection] Kiliś-Pstrusińska K, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):194–6 (39 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Vesico ureteric reflux and urinary tract infections in children. Woodward A. **Aust Fam Physician** 1998 Dec;27(12):1095–7 (4 ref.)

Bacterial infections after renal transplantation. Schmaldienst S, et al. **Contrib Nephrol** 1998;124:18–33; discussion 34–42 (101 ref.)

Catheter-associated infections in urology: possible use of silver-impregnated catheters and the Erlanger silver catheter. Rösch W, et al. **Infection** 1999;27 Suppl 1:S74–7 (36 ref.)

Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. Denstedt JD, et al. **J Endourol** 1998 Dec;12(6):493–500 (75 ref.)

[Renal transplantation and urinary infection. Review] Burgos Revilla FJ, et al. **Actas Urol Esp** 1999 Feb;23(2):95–104 (47 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Urinary tract infections--pathogenetical aspects. Fünfstück R, et al. **Przegl Lek** 1998;55 Suppl 1:45–6 (0 ref.)

[Escherichia coli virulence factors in pediatric urinary tract infections] Bingen E. **Arch Pediatr** 1998;5 Suppl 3:279S–281S (16 ref.) (Eng. Abstr.) **(Fre)**

[Antibiotic sensitivity to isolated bacteria in pediatric urinary tract infections] Vu-Thien H. **Arch Pediatr** 1998;5 Suppl 3:266S–268S (8 ref.) (Eng. Abstr.) **(Fre)**

[Current role of coagulase-negative staphylococci in urology] Herard A, et al. **Prog Urol** 1998 Sep;8(4):579–85 (60 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Catheter-associated infections in urology: possible use of silver-impregnated catheters and the Erlanger silver catheter. Rösch W, et al. **Infection** 1999;27 Suppl 1:S74–7 (36 ref.)

RADIONUCLIDE IMAGING

Consensus on renal cortical scintigraphy in children with urinary tract infection. Scientific Committee of Radionuclides in Nephrourology. Piepsz A, et al. **Semin Nucl Med** 1999 Apr;29(2):160–74 (125 ref.)

THERAPY

Vesico ureteric reflux and urinary tract infections in children. Woodward A. **Aust Fam Physician** 1998 Dec;27(12):1095–7 (4 ref.)

The office management of recurrent urinary tract infection and vesicoureteral reflux in children. Shapiro E, et al. **Urol Clin North Am** 1998 Nov;25(4):725–34, x (73 ref.)

[The combined use of antibiotics, immunomodulators and physiotherapy in urogenital infections in men] Titova TM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jan–Feb; (1):45–7 (49 ref.) **(Rus)**

URINARY TRACT PHYSIOLOGY

The physiology of the mammalian urinary outflow tract. Brading AF. **Exp Physiol** 1999 Jan;84(1):215–21 (22 ref.)

Metabolic factors influencing lower urinary tract function. Levin RM, et al. **Exp Physiol** 1999 Jan;84(1):171–94 (116 ref.)

URINATION

Voiding urohydropropulsion. Lessons from 5 years of experience. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1999 Jan; 29(1):283–91, xiv (2 ref.)

[Bladder pheochromocytoma: a variation in the plasma catecholamines during micturition (letter)] Lecube A, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):477–8 (10 ref.) **(Spa)**

PHYSIOLOGY

The central control of micturition and continence: implications for urology. Blok BF, et al. **BJU Int** 1999 Mar;83 Suppl 2:1–6 (32 ref.)

Brain activation during micturition [editorial; comment] Fowler CJ. **Brain** 1998 Nov;121 (Pt 11):2031–2 (11 ref.) Comment on: Brain 1998 Nov;121 (Pt 11):2033–42.

Modulation of voiding and storage reflexes by activation of alpha1-adrenoceptors. de Groat WC, et al. **Eur Urol** 1999; 36 Suppl 1:68–73 (20 ref.)

Mechanisms of excreta formation and elimination in turkeys and ostriches. Duke GE. **J Exp Zool** 1999 Mar–Apr 1; 283(4–5):478–9 (7 ref.)

Functional anatomy and neural regulation of the lower urinary tract in female dogs: a review. Nickel RF, et al. **Vet Q** 1999 Jun;21(3):83–5 (30 ref.)

[Graphic interpretation of pressure-flow analysis (published erratum appears in Prog Urol 1999 Feb;9(1):13)] Boiteux JP. **Prog Urol** 1998 Dec;8(6):1065–73 (8 ref.) **(Fre)**

[Micturition syncope: a peculiar cause of diagnostic doubt] Kasperek S, et al. **Neurol Neurochir Pol** 1998 Sep–Oct; 32(5):1289–93; discussion 1293–4 (8 ref.) (Eng. Abstr.) **(Pol)**

URINATION DISORDERS

Fluid balance therapy of nocturia in women. Reynard J. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(1):43–8 (35 ref.)

DIAGNOSIS

Female voiding dysfunction and movement disorders. Dmochowski RR. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):144–51 (36 ref.)

Evaluation and management of lower urinary tract disorders in women with multiple sclerosis. Rackley RR, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):139–43 (25 ref.)

Uroflowmetry and evaluation of voiding disorders. Ather MH, et al. **Tech Urol** 1998 Sep;4(3):111–7 (15 ref.)

Office evaluation of men with lower urinary tract symptoms. Jepsen JV, et al. **Urol Clin North Am** 1998 Nov; 25(4):545–54, vii (76 ref.)

[Dysuria and prostatic adenoma: information provided by uroflowmetry] Grise P, et al. **Prog Urol** 1999 Feb; 9(1):146–50 (32 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Pharmacologic therapy for urinary incontinence and voiding dysfunctions. Portera SG, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):691–701 (22 ref.)

An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Goldenberg MM. **Clin Ther** 1999 Apr;21(4):634–42 (27 ref.)

Pharmacologic management of pelvic floor dysfunction. Nygaard IE. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):867–82 (102 ref.)

Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Guay DR. **Pharmacotherapy** 1999 Mar;19(3):267–80 (26 ref.)

ETIOLOGY

Evaluation of dysuria in men. Roberts RG, et al. **Am Fam Physician** 1999 Sep 1;60(3):865–72 (35 ref.)

The overactive bladder: current aetiological concepts. Bosch JL. **BJU Int** 1999 Mar;83 Suppl 2:7–9 (30 ref.)

The overactive bladder and the role of the pelvic floor muscles. Messelink EJ. **BJU Int** 1999 Mar;83 Suppl 2:31–5 (26 ref.)

Assessment of lower urinary tract dysfunction in children with non-neuropathic bladder sphincter dysfunction. Hoebeke P, et al. **Eur Urol** 1999 Jan;35(1):57–69 (60 ref.)

Female voiding dysfunction and movement disorders. Dmochowski RR. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):144–51 (36 ref.)

Voiding dysfunction in women with diabetes mellitus. Goldman HB, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):130–3 (22 ref.)

Voiding dysfunction in women with lumbar disc prolapse. Goldman HB, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):134–8 (18 ref.)

[Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach] Jolliet P, et al. **Therapie** 1998 Jan–Feb;53(1):61–6 (28 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Voiding and MRI analysis of the brain. Sakakibara R, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(3):192–9 (47 ref.)

PHYSIOPATHOLOGY

Overactive detrusor. Sullivan J, et al. **Curr Opin Urol** 1999 Jul;9(4):291–6 (54 ref.)

[Graphic interpretation of pressure-flow analysis (published erratum appears in Prog Urol 1999 Feb;9(1):13)] Boiteux JP. **Prog Urol** 1998 Dec;8(6):1065–73 (8 ref.) **(Fre)**

THERAPY

Neurological disorders of micturition and their treatment. Fowler CJ. **Brain** 1999 Jul;122 (Pt 7):1213–31 (153 ref.)

Overactive detrusor. Sullivan J, et al. **Curr Opin Urol** 1999 Jul;9(4):291–6 (54 ref.)

Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Bemelmans BL, et al. **Eur Urol** 1999 Aug;36(2):81–91 (51 ref.)

Evaluation and management of lower urinary tract disorders in women with multiple sclerosis. Rackley RR, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(2):139–43 (25 ref.)

URINATION DISORDERS

The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. Holtgrewe HL. **Urol Clin North Am** 1998 Nov;25(4):555–69, vii (90 ref.)

[Treatment of micturation troubles] Pigné A. **Contracept Fertil Sex** 1999 Mar;27(3):175–7 (0 ref.) **(Fre)**

[Therapeutic possibilities in functional disorders of micturition] Schönberger B. **Urologe A** 1999 Jan;38(1):20–3 (19 ref.) (Eng. Abstr.) **(Ger)**

URINE

see related
ALBUMINURIA
ALKAPTONURIA
BACTERIURIA
CYSTINURIA
HEMATURIA
HEMOGLOBINURIA
PHENYLKETONURIA
POLYURIA
PROTEINURIA
PYURIA

[Urinalysis using dipsticks] Cochat P, et al. **Arch Pediatr** 1998 Jan;5(1):65–70 (16 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Solvents in urine as exposure markers. Ikeda M. **Toxicol Lett** 1999 Sep 5;108(2–3):99–106 (18 ref.)

CYTOLOGY

Methods of semen collection not based on masturbation or surgical sperm retrieval. Gerris J. **Hum Reprod Update** 1999 May–Jun;5(3):211–5 (20 ref.)

PHYSIOLOGY

Urine volume: stone risk factor and preventive measure. Borghi L, et al. **Nephron** 1999;81 Suppl 1:31–7 (51 ref.)

URINE CONCENTRATING ABILITY see **KIDNEY CONCENTRATING ABILITY**

UROCANIC ACID

Urocanic acid photochemistry and photobiology. Mohammad T, et al. **Photochem Photobiol** 1999 Feb; 69(2):115–35 (182 ref.)

IMMUNOLOGY

The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition. Hug DH, et al. **J Photochem Photobiol B** 1998 Jul 10; 44(2):117–23 (81 ref.)

Urocanic acid and cutaneous antigen presentation. Lappin MB, et al. **J Photochem Photobiol B** 1998 Jul 10;44(2):112–6 (34 ref.)

UROCHORDATA

ANATOMY & HISTOLOGY

Tunicate tails, stolons, and the origin of the vertebrate trunk. Lacalli TC. **Biol Rev Camb Philos Soc** 1999 May; 74(2):177–98 (142 ref.)

CHEMISTRY

[Marine natural products influencing larval settlement and metamorphosis of marine sessile organisms] Tsukamoto S. **Yakugaku Zasshi** 1999 Jul;119(7):457–71 (45 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Ins and outs of meiosis in ascidians [see comments] Russo GL, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):559–67 (82 ref.) Comment in: Semin Cell Dev Biol 1998 Oct;9(5):535–72.

EMBRYOLOGY

Ascidian embryogenesis and the origins of the chordate body plan. Di Gregorio A, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):457–63 (68 ref.)

Formation and localization of cytoplasmic domains in leech and ascidian zygotes. Fernández J, et al. **Int J Dev Biol** 1998 Nov;42(8):1075–84 (86 ref.)

Monitoring early neuronal differentiation by ion channels in ascidian embryos. Takahashi K, et al. **J Neurobiol** 1998 Oct;37(1):3–22 (60 ref.)

Protochordates. Holland PW, et al. **Methods Mol Biol** 1999; 97:513–6 (2 ref.)

IMMUNOLOGY

Complement systems in invertebrates. The ancient alternative and lectin pathways. Smith LC, et al. **Immunopharmacology** 1999 May;42(1–3):107–20 (64 ref.)

PHYSIOLOGY

Cell adhesion in the process of asexual reproduction of tunicates. Kawamura K, et al. **Microsc Res Tech** 1999 Feb 15;44(4):269–78 (70 ref.)

Slime molds, ascidians, and the utility of evolutionary theory [comment] Buss LW. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8801–3 (13 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):9148–53.

URODELA

ANATOMY & HISTOLOGY

Developmental basis of limb homology in urodeles: heterochronic evidence from the primitive hynobiid family. Hinchliffe JR, et al. **Novartis Found Symp** 1999;222:95–105; discussion 105–9 (39 ref.)

URODYNAMICS

Towards a noninvasive urodynamic diagnosis of infravesical obstruction. Van Mastrigt R, et al. **BJU Int** 1999 Jul; 84(2):195–203 (34 ref.)

Urodynamic evaluati[illegible] for female urinary incontinence. Kohli N, et al. **Clin[illegible]stet Gynecol** 1998 Sep;41(3):672–90 (27 ref.)

VLPP in the evaluation of the female with stress urinary incontinence. Petrou SP, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(4):254–9 (43 ref.)

Uroflowmetry and evaluation of voiding disorders. Ather MH, et al. **Tech Urol** 1998 Sep;4(3):111–7 (15 ref.)

Continence and urodynamic parameters of continent urinary reservoirs: comparison of gastric, ileal, ileocolic, right colon, and sigmoid segments. Santucci RA, et al. **Urology** 1999 Aug;54(2):252–7 (21 ref.)

[Graphic interpretation of pressure–flow analysis (published erratum appears in Prog Urol 1999 Feb;9(1):13)] Boiteux JP. **Prog Urol** 1998 Dec;8(6):1065–73 (8 ref.) **(Fre)**

[Dysuria and prostatic adenoma: information provided by uroflowmetry] Grise P, et al. **Prog Urol** 1999 Feb; 9(1):146–50 (32 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of pressure–flow relationship studies in the evaluation of benign hypertrophy of the prostate] Haab F. **Prog Urol** 1999 Feb;9(1):151–5 (24 ref.) (Eng. Abstr.) **(Fre)**

[Urodynamic studies in the child with urinary incontinence] Schwöbel M, et al. **Wien Med Wochenschr** 1998; 148(22):508–10 (2 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The aging bladder: morphology and urodynamics. Elbadawi A, et al. **World J Urol** 1998;16 Suppl 1:S10–34 (196 ref.)

UROGASTRONE see **EPIDERMAL GROWTH FACTOR–UROGASTRONE**

UROGASTRONE RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR–UROGASTRONE**

UROGENITAL ABNORMALITIES

COMPLICATIONS

[Urinary incontinence in neurogenic defects and urogenital anomalies in childhood] Steiner G, et al. **Wien Med Wochenschr** 1998;148(13):299–304 (25 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Fetal uropathy. Johnson MP, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):185–94 (40 ref.)

Complete uterine septum with cervical duplication, longitudinal vaginal septum and duplication of a renal collecting system. A case report. Sharara FI. **J Reprod Med** 1998 Dec;43(12):1055–9 (5 ref.)

PHYSIOPATHOLOGY

Fetal uropathy. Johnson MP, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):185–94 (40 ref.)

ULTRASONOGRAPHY

Borderline genitourinary tract abnormalities. Seeds JW. **Semin Ultrasound CT MR** 1998 Aug;19(4):347–54 (35 ref.)

UROGENITAL DISEASES

COMPLICATIONS

Haematuria. Mukherjee B. **J Indian Med Assoc** 1998 Apr; 96(4):121–2 (0 ref.)

DIAGNOSIS

Diagnosis of urogenital Chlamydia trachomatis infection by use of DNA amplification. Ostergaard L. **APMIS Suppl** 1999;89:5–36 (283 ref.)

Common urological problems in women. O'Connell HE, et al. **Aust Fam Physician** 1998 Dec;27(12):1098–104 (21 ref.)

The spectrum of skin, mucosa and other extra-articular manifestations. Angulo J, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):649–64 (76 ref.)

Magnetic resonance imaging in urology. Probert JL, et al. **BJU Int** 1999 Feb;83(3):201–14 (88 ref.)

The clinical evaluation of pelvic floor dysfunction. Theofrastous JP, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):783–804 (76 ref.)

Imaging studies of the pelvic floor. Weidner AC, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):825–48, vii (52 ref.)

[Laboratory diagnosis of viral infections. 12. Urogenital diseases and sexually transmitted diseases] Kubota T. **Rinsho Byori** 1998 Nov;Suppl 108:128–31 (2 ref.) **(Jpn)**

DRUG THERAPY

Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future. Truss MC, et al. **BJU Int** 1999 Mar;83 Suppl 2:36–41 (33 ref.)

Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Onrust SV, et al. **Drugs** 1998 Nov;56(5):895–928 (212 ref.)

Pharmacologic management of pelvic floor dysfunction. Nygaard IE. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):867–82 (102 ref.)

EPIDEMIOLOGY

Epidemiology and natural history of pelvic floor dysfunction. Bump RC, et al. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):723–46 (129 ref.)

PATHOLOGY

Cervical cytology and colposcopy in young patients attending genitourinary medicine clinics: invalid intrusion or preventive opportunity and definitive audit? Moss TR. **Cytopathology** 1999 Feb;10(1):2–7 (21 ref.)

Müllerian cysts of the mesentery and retroperitoneum: a case report and literature review. Lee J, et al. **Pathol Int** 1998 Nov;48(11):902–6 (9 ref.)

PREVENTION & CONTROL

The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Grayston JT, et al. **Sex Transm Dis** 1978 Apr–Jun;5(2):73–7 (19 ref.)

RADIOGRAPHY

Abnormal calcification on plain radiographs of the abdomen. Chen MY, et al. **Crit Rev Diagn Imaging** 1999 Jun; 40(2–3):63–202 (133 ref.)

REHABILITATION

Nonsurgical management of pelvic floor dysfunction. Visco AG, et al. **Obstet Gynecol Clin North Am** 1998 Dec; 25(4):849–65, vii (40 ref.)

SURGERY

Medical photography and genitourinary surgery. Ferro F, et al. **Br J Urol** 1998 Sep;82(3):325–30 (5 ref.)

THERAPY

Common urological problems in women. O'Connell HE, et al. **Aust Fam Physician** 1998 Dec;27(12):1098–104 (21 ref.)

[Urology is more than Viagra. Potpourri of new developments in urology] Hobi C, et al. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2047–51 (3 ref.) **(Ger)**

UROGENITAL NEOPLASMS

AIDS-related malignancies. Smith C, et al. **Ann Med** 1998 Aug;30(4):323–44 (212 ref.)

Pediatric genitourinary tumors. Lee HH, et al. **Curr Opin Oncol** 1999 May;11(3):218–25 (57 ref.)

[Urogential rhabdomyosarcoma] Wald M, et al. **Harefuah** 1998 Aug;135(3–4):142–4 (13 ref.) **(Heb)**

BLOOD SUPPLY

Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. Jones A, et al. **BJU Int** 1999 Mar; 83(5):535–55; quiz 555–6 (230 ref.)

DIAGNOSIS

[Lymphoma of the urogenital system] Parlorio de Andrés E, et al. **Sangre (Barc)** 1998 Dec;43(6):499–505 (34 ref.) **(Spa)**

ETIOLOGY

The role of obesity and diet in urological carcinogenesis. Mydlo JH, et al. **BJU Int** 1999 Aug;84(3):225–34 (99 ref.)

GENETICS

Strategies for gene cloning [editorial] Schamhart DH, et al. **Urol Res** 1999 Apr;27(2):83–96 (83 ref.)

[Telomerase in tumors: facts and perspectives] Rohde V, et al. **Urologe A** 1998 Jul;37(4):386–94 (52 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Involvement of the urogenital tract in patients with five or more separate malignant neoplasms. Case and review. Rohde D, et al. **Eur Urol** 1998 Dec;34(6):512–7 (31 ref.)

Rhabdomyosarcoma: an overview. Dagher R, et al.

Oncologist 1999;4(1):34–44 (80 ref.)

PREVENTION & CONTROL

Retinoids in chemoprevention. Whelan P. **Eur Urol** 1999; 35(5–6):424–8 (47 ref.)

REHABILITATION

[Quality of life in urologic oncology] Biermann CW, et al. **Urologe A** 1999 Mar;38(2):W189–200 (64 ref.) **(Ger)**

THERAPY

[Recent advancement of the treatment of urological malignancies] Akaza H. **Gan To Kagaku Ryoho** 1999 Jun; 26 Suppl 1:157–64 (50 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Role of human papillomaviruses in warts and cancer. Proby CM, et al. **Hosp Med** 1998 Jan;59(1):33–6 (20 ref.)

UROGENITAL SURGICAL PROCEDURES

Urinary incontinence and concomitant prolapse. Grody MH. **Clin Obstet Gynecol** 1998 Sep;41(3):777–85 (21 ref.)

METHODS

Surgical management of pelvic organ prolapse and stress urinary incontinence. Drutz HP, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):786–93 (26 ref.)

Future perspectives in reconstructive surgery using tissue engineering. Atala A. **Urol Clin North Am** 1999 Feb; 26(1):157–65, ix–x (53 ref.)

UROGENITAL SYSTEM

see related
UROGRAPHY

DRUG EFFECTS

Estradiol-releasing vaginal ring delivery system for urogenital atrophy. Experience over the past decade. Bachmann G. **J Reprod Med** 1998 Nov;43(11):991–8 (25 ref.)

INNERVATION

The distribution of noradrenergic nerves in the human lower urinary tract. A review. Gosling JA, et al. **Eur Urol** 1999; 36 Suppl 1:23–30 (40 ref.)

METABOLISM

[The process of cell degeneration] Cortés-Gallegos V, et al. **Ginecol Obstet Mex** 1999 Aug;67:397–403 (48 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Ultrafast MR imaging of the pelvis. Outwater EK. **Eur J Radiol** 1999 Mar;29(3):233–44 (54 ref.)

Estradiol-releasing vaginal ring delivery system for urogenital atrophy. Experience over the past decade. Bachmann G. **J Reprod Med** 1998 Nov;43(11):991–8 (25 ref.)

PHYSIOLOGY

Adrenoceptor pharmacology: urogenital applications. Ruffolo RR Jr, et al. **Eur Urol** 1999;36 Suppl 1:17–22 (57 ref.)

ULTRASONOGRAPHY

The fetal genitourinary tract. Angtuaco TL, et al. **Semin Roentgenol** 1999 Jan;34(1):13–28 (51 ref.)

UROGRAPHY

Unilateral renal cystic disease in adults. Hwang DY, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1999–2003 (23 ref.)

Subservience of excretory urography to unenhanced CT in evaluating renal colic: a good idea?--benefits and consequences [letter] Lautin EM, et al. **Radiology** 1998 Oct; 209(1):286–7 (12 ref.)

Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Miller OF, et al. **Urology** 1998 Dec; 52(6):982–7 (23 ref.)

METHODS

Helical CT of the urinary tract. Fielding JR, et al. **AJR Am J Roentgenol** 1999 May;172(5):1199–206 (55 ref.)

UROKINASE

ADMINISTRATION & DOSAGE

New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate. Maksimenko AV, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):307–12 (50 ref.)

[Assessment of the anti-ischemic effect in patients with therapy refractory angina pectoris in end-stage coronary heart disease--results of chronic intermittent urokinase therapy] Schoebel FC, et al. **Z Kardiol** 1998;87 Suppl 2:188–92 (11 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Clinical relevance of the urokinase plasminogen activator system in breast cancer. Look MP, et al. **APMIS** 1999 Jan; 107(1):150–9 (50 ref.)

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Stephens RW, et al. **Breast Cancer Res Treat** 1998;52(1–3):99–111 (45 ref.)

BIOSYNTHESIS

Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Ghiso JA, et al. **Eur J Biochem** 1999 Jul;263(2):295–304 (118 ref.)

GENETICS

Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer [editorial] Del Rosso M, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):389–93 (56 ref.)

Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Ghiso JA, et al. **Eur J Biochem** 1999 Jul;263(2):295–304 (118 ref.)

METABOLISM

The urokinase-type plasminogen activator system and inflammatory joint diseases. Del Rosso M, et al. **Clin Exp Rheumatol** 1999 Jul–Aug;17(4):485–98 (162 ref.)

Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review). Shen GX. **Int J Mol Med** 1998 Feb;1(2):399–408 (170 ref.)

Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Reuning U, et al. **Int J Oncol** 1998 Nov;13(5):893–906 (207 ref.)

Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. Duffy MJ, et al. **J Surg Oncol** 1999 Jun;71(2):130–5 (59 ref.)

[Urokinase plasminogen activation system and its role in cancer progression] Blasiak J, et al. **Postepy Biochem** 1999; 45(1):42–50 (95 ref.) **(Pol)**

PHYSIOLOGY

[Involvement of urokinase and its receptor in the remodeling of normal and pathological tissue] Tkachuk VA, et al. **Vestn Ross Akad Med Nauk** 1998;(8):36–41 (61 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice? Weber JJ, et al. **Am J Health Syst Pharm** 1998 Nov 15; 55(22):2414–6 (16 ref.)

Streptokinase and urokinase for the treatment of pleural effusions and empyemas. Barletta JF. **Ann Pharmacother** 1999 Apr;33(4):495–8 (24 ref.)

Clinical profile of saruplase: angiographic findings. Meyer J. **Int J Clin Pract Suppl** 1998 Nov;99:9–15 (18 ref.)

Utility of fibrinolytic agents for draining intrapleural infections. Bouros D, et al. **Semin Respir Infect** 1999 Mar; 14(1):39–47 (39 ref.)

[Thrombolytic therapy] Matsuda T. **Nippon Rinsho** 1998 Oct; 56(10):2577–81 (20 ref.) (Eng. Abstr.) **(Jpn)**

UROKINASE-TYPE PLASMINOGEN ACTIVATOR see **UROKINASE**

UROLITHIASIS see **URINARY CALCULI**

UROLOGIC DISEASES

Health-related quality-of-life studies in urology: conceptual and methodological considerations. Browne JP. **World J Urol** 1999 Aug;17(4):193–8 (31 ref.)

CLASSIFICATION

An anatomical classification--a new paradigm for management of female lower urinary tract dysfunction. Petros PP, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):87–94 (26 ref.)

CONGENITAL

Family studies of infantile visceral myopathy: a congenital myopathic pseudo-obstruction syndrome. Guzé CD, et al. **Am J Med Genet** 1999 Jan 15;82(2):114–22 (51 ref.)

Emerging roles of obstruction and mutations in renal malformations. Woolf AS. **Pediatr Nephrol** 1998 Oct; 12(8):690–4 (61 ref.)

DIAGNOSIS

Evaluation of dysuria in men. Roberts RG, et al. **Am Fam Physician** 1999 Sep 1;60(3):865–72 (35 ref.)

Evaluation of asymptomatic microscopic hematuria in adults. Thaller TR, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1143–52, 1154 (28 ref.)

Cystourethroscopy for the practicing gynecologist. Weinberger MW. **Clin Obstet Gynecol** 1998 Sep; 41(3):764–76 (20 ref.)

[Urinalysis using dipsticks] Cochat P, et al. **Arch Pediatr** 1998 Jan;5(1):65–70 (16 ref.) (Eng. Abstr.) **(Fre)**

[New clinical tests that physicians should know for diagnosis of urological diseases] Kimura H, et al. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2010–5 (5 ref.) **(Jpn)**

DRUG THERAPY

Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy. Schwantes U, et al. **Int J Clin Pharmacol Ther** 1999 May; 37(5):209–18 (79 ref.)

Urinary and gastrointestinal systems medications. Schryvers O, et al. **Phys Med Rehabil Clin N Am** 1999 May; 10(2):473–92, ix–x (147 ref.)

[Capsaicin in urology] Scultéty S. **Orv Hetil** 1999 Apr 18; 140(16):867–72 (41 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Neurological disorders in the ageing population and their urological implications. Evans SN, et al. **Br J Urol** 1998 Dec;82 Suppl 1:71–8 (51 ref.)

Multiple sclerosis and the urologist [published erratum appears in J Urol 1999 Jul;162(1):172] Litwiller SE, et al. **J Urol** 1999 Mar;161(3):743–57 (182 ref.)

GENETICS

A gene hunting we will go! [editorial] Gingrich JR, et al. **Urol Res** 1998;26(6):361–9 (31 ref.)

PATHOLOGY

Obstruction of the fetal urinary tract. Peters CA. **J Am Soc Nephrol** 1997 Apr;8(4):653–63 (65 ref.)

PREVENTION & CONTROL

Review. Guidelines for the urological screening and initial management of lower urinary tract dysfunction in children with anorectal malformations--the ARGUS protocol. Boemers TM, et al. **BJU Int** 1999 Apr;83(6):662–71 (24 ref.)

SURGERY

Retroperitoneal laparoscopy. Keeley FX Jr, et al. **BJU Int** 1999 Jul;84(2):212–5 (30 ref.)

[Urologic surgery and allergy to natural latex] Chartier-Kastler E, et al. **Presse Med** 1998 Apr 25; 27(16):771–8 (48 ref.) **(Fre)**

THERAPY

Lasers in urology. Floratos DL, et al. **BJU Int** 1999 Jul; 84(2):204–11 (59 ref.)

A systematic review of the clinical efficacy and effectiveness of the holmium:YAG laser in urology. Larizgoitia I, et al. **BJU Int** 1999 Jul;84(1):1–9 (85 ref.)

An anatomical classification--a new paradigm for management of female lower urinary tract dysfunction. Petros PP, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):87–94 (26 ref.)

Willet F. Whitore, Jr. Lecture: back to the future--the role of complementary medicine in urology. Fair WR. **J Urol** 1999 Aug;162(2):411–20 (59 ref.)

Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms. **Oncology (Huntingt)** 1999 Apr;13(4):551–4, 557–60, 563 passim (36 ref.)

Urologic applications of gene therapy. Rodriguez R, et al. **Urology** 1999 Sep;54(3):401–6 (29 ref.)

VETERINARY

Feline interstitial cystitis. Buffington CA, et al. **J Am Vet Med Assoc** 1999 Sep 1;215(5):682–7 (71 ref.)

Feline urologic syndrome, feline lower urinary tract disease, feline interstitial cystitis: what's in a name? [see comments] Osborne CA, et al. **J Am Vet Med Assoc** 1999 May 15; 214(10):1470–80 (108 ref.) Comment in: J Am Vet Med Assoc 1999 Jul 15;215(2):186–8.

The effect of diet on lower urinary tract diseases in cats. Markwell PJ, et al. **J Nutr** 1998 Dec;128(12 Suppl):2753S–2757S (44 ref.)

UROLOGIC NEOPLASMS

[Clinical studies on inverted papilloma of the urinary tract] Asano K, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Apr; 90(4):514–20 (42 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Chemotherapy for urothelial infiltrating tumors] Culine S. **Cancer Radiother** 1998 Sep–Oct;2(5):515–20 (51 ref.) (Eng. Abstr.) **(Fre)**

UROLOGIC NEOPLASMS

EPIDEMIOLOGY

[Urologic neoplasms in patients with renal transplantation. Experience and review of the literature] Hermida Gutiérrez JF, et al. **Actas Urol Esp** 1998 Nov-Dec;22(10):818-27 (75 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Smoking and urological disease. Mikhailidis DP, et al. **J R Soc Health** 1998 Aug;118(4):210-2 (34 ref.)

GENETICS

[Microsatellite instability and mismatch repair system] Uchida T. **Nippon Hinyokika Gakkai Zasshi** 1998 Dec; 89(12):917-30 (96 ref.) **(Jpn)**

SURGERY

[Progresses in the study of urologic surgery in China, 1997] Guo Y. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):912-3 (0 ref.) **(Chi)**

UROLOGIC SURGICAL PROCEDURES

see related
UROLOGY

Common operations for stress incontinence: selecting the correct operation. Portera JC, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):712-8 (21 ref.)

Why anti-incontinence surgery succeeds or fails. Rovner ES, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):719-34 (32 ref.)

Laser tissue welding: a urological surgeon's perspective. Poppas DP, et al. **Haemophilia** 1998 Jul;4(4):456-62 (33 ref.)

CONTRAINDICATIONS

[The prenatal diagnosis of hydronephrosis: when and why NOT to operate?] Koff SA. **Arch Esp Urol** 1998 Jul-Aug; 51(6):569-74 (18 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Biomaterials in Urology II: future usage and management. Reid G, et al. **J Endourol** 1999 Feb;13(1):1-7 (73 ref.)

METHODS

Endopyelotomy review. Bernardo N, et al. **Arch Esp Urol** 1999 Jun;52(5):541-8 (45 ref.)

The endourological management of upper urinary tract tumours. Borkowski A, et al. **BJU Int** 1999 Mar; 83(4):369-77 (64 ref.)

Bladder and ureteral injury: prevention and management. Utrie JW Jr. **Clin Obstet Gynecol** 1998 Sep;41(3):755-63 (26 ref.)

Bladder neck reconstruction in children. Kropp KA. **Urol Clin North Am** 1999 Aug;26(3):661-72, viii (27 ref.)

[Treatment of urinary stress incontinence. Crtical review of randomized comparative results] Houfflin-Debarge V, et al. **Ann Chir** 1999;53(4):324-34 (58 ref.) (Eng. Abstr.) **(Fre)**

[The prenatal diagnosis of hydronephrosis, when and why to operate?] González R, et al. **Arch Esp Urol** 1998 Jul-Aug;51(6):575-9 (18 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

Urology. Richie JP. **J Am Coll Surg** 1999 Feb;188(2):198-201 (27 ref.)

UROLOGIC SURGICAL PROCEDURES, MALE

METHODS

Neonatal testicular torsion. Driver CP, et al. **Br J Urol** 1998 Dec;82(6):855-8 (47 ref.)

Tubularized incised plate hypospadias repair: indications, technique, and complications. Snodgrass WT. **Urology** 1999 Jul;54(1):6-11 (32 ref.)

[The surgical treatment of distal hypospadias] Cendron M. **Arch Esp Urol** 1998 Jul-Aug;51(6):539-49 (25 ref.) (Eng. Abstr.) **(Spa)**

[Proximal hypospadias] Mollard P, et al. **Arch Esp Urol** 1998 Jul-Aug;51(6):551-9 (18 ref.) (Eng. Abstr.) **(Spa)**

[The treatment of hypospadias complexes] Woodard JR, et al. **Arch Esp Urol** 1998 Jul-Aug;51(6):561-8 (19 ref.) (Eng. Abstr.) **(Spa)**

UROLOGY

see related
UROLOGIC DISEASES
UROLOGIC SURGICAL PROCEDURES

Biomaterials in Urology II: future usage and management. Reid G, et al. **J Endourol** 1999 Feb;13(1):1-7 (73 ref.)

INSTRUMENTATION

Vacuum devices in erectile dysfunction: indications and efficacy. Oakley N, et al. **Br J Urol** 1998 Nov;82(5):673-81 (90 ref.)

METHODS

Initial assessment: the history in women with pelvic floor problems. Brubaker L. **Clin Obstet Gynecol** 1998 Sep; 41(3):657-62 (0 ref.)

Willet F. Whitore, Jr. Lecture: back to the future--the role of complementary medicine in urology. Fair WR. **J Urol** 1999 Aug;162(2):411-20 (59 ref.)

TRENDS

The future of British urology. Mundy AR. **Br J Urol** 1998 Oct;82(4):476-86 (15 ref.)

Urology. Richie JP. **J Am Coll Surg** 1999 Feb;188(2):198-201 (27 ref.)

Willet F. Whitore, Jr. Lecture: back to the future--the role of complementary medicine in urology. Fair WR. **J Urol** 1999 Aug;162(2):411-20 (59 ref.)

UROPEPSINOGEN see **PEPSINOGEN A**

UROPORPHYRINOGEN CARBOXY-LYASE see **UROPORPHYRINOGEN DECARBOXYLASE**

UROPORPHYRINOGEN DECARBOXYLASE

METABOLISM

Porphyria cutanea tarda. Fritsch C, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):321-35 (86 ref.)

UROPORPHYRINOGEN I SYNTHASE see **HYDROXYMETHYLBILANE SYNTHASE**

UROTHELIUM

CYTOLOGY

Primary uroepithelial cultures. A model system to analyze umbrella cell barrier function. Truschel ST, et al. **J Biol Chem** 1999 May 21;274(21):15020-9 (76 ref.)

DRUG EFFECTS

Short-chain fatty acids: good for the colon, good also for the urothelium? [editorial; comment] Scheppach W. **J Lab Clin Med** 1998 Oct;132(4):242-3 (10 ref.) Comment on: J Lab Clin Med 1998 Oct;132(4):279-83.

PATHOLOGY

An approach to papillary urothelial lesions, including a discussion of newly described papillary lesions of the urinary bladder. Goetsch SJ, et al. **Adv Anat Pathol** 1998 Sep;5(5):329-45 (28 ref.)

[An unusual variant of urothelial carcinoma: the "nested variant of urothelial carcinoma." Report of two cases] Badoual C, et al. **Ann Pathol** 1999 Apr;19(2):119-23 (13 ref.) (Eng. Abstr.) **(Fre)**

URSIDAE see **BEARS**

URSODEOXYCHOLIC ACID

PHARMACOLOGY

Mechanism of hepatoprotective action of bile salts in liver disease. Stiehl A, et al. **Gastroenterol Clin North Am** 1999 Mar;28(1):195-209, viii (108 ref.)

THERAPEUTIC USE

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Trauner M, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):979-96 (188 ref.)

Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Beuers U, et al. **Hepatology** 1998 Dec;28(6):1449-53 (95 ref.)

Eosinophils and primary biliary cirrhosis-stoking the fire? [editorial; comment] Neuberger J. **Hepatology** 1999 Jul; 30(1):335-7 (44 ref.) Comment on: Hepatology 1999 Jul;30(1):71-8.

The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Younossi ZM, et al. **Semin Liver Dis** 1999;19 Suppl 1:95-102 (32 ref.)

[Ursodeoxycholic acid: prospect for treatment of gravidic cholestasis? Report of 3 cases] Calmelet P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):617-21 (25 ref.) (Eng. Abstr.) **(Fre)**

[Primary biliary cirrhosis: progress in its therapy] Kuroki T, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10; 88(4):615-9 (9 ref.) **(Jpn)**

URSUS see **BEARS**

URTICARIA

Urticaria and angioedema: diagnostic and treatment considerations. Kumar SA, et al. **J Am Osteopath Assoc** 1999 Mar;99(3 Suppl):S1-4 (23 ref.)

CHEMICALLY INDUCED

Generalized urticaria after skin cleansing and urethral instillation with chlorhexidine-containing products. Stables GI, et al. **Br J Urol** 1998 Nov;82(5):756-7 (7 ref.)

Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Wütschert R, et al. **Drug Saf** 1999 Jun;20(6):515-25 (68 ref.)

Urticaria due to airborne permethrin exposure. Fuortes L. **Vet Hum Toxicol** 1999 Apr;41(2):92-3 (16 ref.)

[Urticaria (angioedema type sensitivity) caused by aspirin (editorial)] Grzelewska-Rzymowska I. **Pol Merkuriusz Lek** 1998 May;4(23):233-7 (54 ref.) (Eng. Abstr.) **(Pol)**

CLASSIFICATION

[Round Table: Urticaria and angioedema: introduction and classification] Alonso Lebrero E. **Allergol Immunopathol (Madr)** 1999 Mar-Apr;27(2):71-3 (10 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Annular skin lesions with a smooth surface. Hogan P. **Aust Fam Physician** 1998 Dec;27(12):1133-4 (0 ref.)

Assessment of urticaria and angio-oedema. Friedmann PS. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:109-12; discussion 113-5 (15 ref.)

Chronic urticaria: review of the literature. Sharma JK, et al. **J Cutan Med Surg** 1999 Apr;3(4):221-8 (65 ref.)

New diagnostic and therapeutic possibilities in chronic idiopathic urticaria. Mekkes JR, et al. **Neth J Med** 1998 Sep;53(3):139-40 (14 ref.)

Urticaria and angioedema: pathophysiology, diagnosis, and treatment [see comments] Kwong KY, et al. **Pediatr Ann** 1998 Nov;27(11):719-24 (20 ref.) Comment in: Pediatr Ann 1998 Nov;27(11):708.

[From psychosomatic disorder to autoimmune disease--50 years urticaria and Quincke edema] Wyss M. **Schweiz Rundsch Med Prax** 1998 Sep 30;87(40):1325-9 (25 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Chronic urticaria. Leznoff A. **Can Fam Physician** 1998 Oct; 44:2170-6 (33 ref.)

What's eating you? Sand flies. (Diptera: Psychodidae, Phlebotominae: Lutzomyia, Phlebotomus). Elston DM. **Cutis** 1998 Oct;62(4):164 (4 ref.)

Solar urticaria: the annoying photodermatosis. Roelandts R, et al. **Int J Dermatol** 1999 Jun;38(6):411-8 (123 ref.)

Chronic urticaria and angioedema associated with thyroid autoimmunity: review and therapeutic implications. Heymann WR. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):229-32 (19 ref.)

[Round Table: Urticaria caused by arthropod bites and stings (excluding Hymenoptera)] Martínez-Molero MI. **Allergol Immunopathol (Madr)** 1999 Mar-Apr;27(2):96-104 (25 ref.) (Eng. Abstr.) **(Spa)**

[Round Table: urticaria with a physical cause] Martorell A, et al. **Allergol Immunopathol (Madr)** 1999 Mar-Apr; 27(2):85-96 (39 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Most chronic urticaria is food-dependent, and not idiopathic. Henz BM, et al. **Exp Dermatol** 1998 Aug;7(4):139-42 (29 ref.)

[Round Table: Immunological urticaria mediated by IgE] Eseverri JL, et al. **Allergol Immunopathol (Madr)** 1999 Mar-Apr;27(2):104-11 (28 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Helicobacter pylori eradication in patients with chronic urticaria [letter] Ozkaya-Bayazit E, et al. **Arch Dermatol** 1998 Sep;134(9):1165-6 (6 ref.)

THERAPY

Chronic urticaria. Leznoff A. **Can Fam Physician** 1998 Oct; 44:2170-6 (33 ref.)

New diagnostic and therapeutic possibilities in chronic idiopathic urticaria. Mekkes JR, et al. **Neth J Med** 1998 Sep;53(3):139-40 (14 ref.)

URTICARIA, GIANT see **ANGIONEUROTIC EDEMA**

URTICARIA PIGMENTOSA

RADIOTHERAPY

[Ultraviolet A-1 phototherapy for skin diseases] Polderman MC, et al. **Ned Tijdschr Geneeskd** 1999 May 1;143(18):931-4 (25 ref.) (Eng. Abstr.) **(Dut)**

USER-COMPUTER INTERFACE

Developing visual systems and exposure to virtual reality and stereo displays: some concerns and speculations about the demands on accommodation and vergence. Rushton SK, et al. **Appl Ergon** 1999 Feb;30(1):69-78 (45 ref.)

Virtual environments applications and applied ergonomics Wilson JR. **Appl Ergon** 1999 Feb;30(1):3-9 (39 ref.)

Virtual bronchoscopy. Haponik EF, et al.

THE PAPER AND INK U
PUBLICATION MAY AFI
THE MICROFORM EDI

Clin Chest Med 1999 Mar;20(1):201–17 (46 ref.)

Virtual colonoscopy in 1999: computed tomography or magnetic resonance imaging? Debatin JF, et al. **Endoscopy** 1999 Feb;31(2):174–9 (20 ref.)

Technology status evaluation: virtual colonoscopy: November 1997. ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):708–10 (12 ref.)

Occupational stress in human computer interaction. Smith MJ, et al. **Ind Health** 1999 Apr;37(2):157–73 (82 ref.)

Will virtual reality simulators end the credentialing arms race in gastrointestinal endoscopy or the need for family physician faculty with endoscopic skills? [editorial; comment] [see comments] Rodney WM. **J Am Board Fam Pract** 1998 Nov–Dec;11(6):492–6 (43 ref.) Comment on: J Am Board Fam Pract 1998 Nov–Dec;11(6):426–33. Comment in: J Am Board Fam Pract 1999 Mar–Apr;12(2):182.

CT and MR colography (virtual colonoscopy): status report. Rex DK. **J Clin Gastroenterol** 1998 Oct;27(3):199–203 (37 ref.)

Computer interviews for depression management. Greist JH. **J Clin Psychiatry** 1998;59 Suppl 16:20–4; discussion 40–2 (21 ref.)

Improving the human–computer interface: a human factors engineering approach. Salvemini AV. **MD Comput** 1998 Sep–Oct;15(5):311–5 (37 ref.)

Clinical documentation: the handheld computer as a survival tool. Wofford MM, et al. **MD Comput** 1998 Nov–Dec; 15(6):352–4, 356, 358 (30 ref.)

The Brain Bench: virtual tools for stereotactic frame neurosurgery. Serra L, et al. **Med Image Anal** 1997 Sep; 1(4):317–29 (28 ref.)

Interface design for health care environments: the role of cognitive science. Patel VL, et al. **Proc AMIA Symp** 1998; :29–37 (42 ref.)

The use of PC based VR in clinical medicine: the VREPAR projects. Riva G, et al. **Technol Health Care** 1999;7(4):261–9 (58 ref.)

[The scientific bases of virtual endoscopy] Coatrieux JL. **Bull Acad Natl Med** 1999;183(3):455–64 (17 ref.) (Eng. Abstr.) **(Fre)**

[The Virtual University applied to telesurgery: from tele–education to tele–manipulation] Marescaux J, et al. **Bull Acad Natl Med** 1999;183(3):509–21; discussion 521–2 (10 ref.) (Eng. Abstr.) **(Fre)**

[Virtual endoscopy] Picard JD, et al. **Bull Acad Natl Med** 1999;183(3):465–75; discussion 475–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Possibilities of virtual gastrointestinal endoscopy] Fleiter T, et al. **Schweiz Rundsch Med Prax** 1999 Jan 14;88(3):65–71 (8 ref.) (Eng. Abstr.) **(Ger)**

[Fundamental theory and efficacy in clinical application of virtual endoscopy] Azemoto S, et al. **Nippon Rinsho** 1999 Aug;57(8):1911–9 (4 ref.) **(Jpn)**

UTERINE CONTRACTION

see related
CARDIOTOCOGRAPHY
LABOR, PREMATURE
OXYTOCICS
TOCOLYTIC AGENTS

DRUG EFFECTS

Use of nitroglycerin for uterine relaxation. Smith GN, et al. **Obstet Gynecol Surv** 1998 Sep;53(9):559–65 (57 ref.)

PHYSIOLOGY

G protein signalling pathways in myometrium: affecting the balance between contraction and relaxation. Sanborn BM, et al. **Rev Reprod** 1998 Sep;3(3):196–205 (77 ref.)

UTERINE DISEASES

Vesicouterine fistula: an updated review. Yip SK, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1998;9(5):252–6 (44 ref.)

COMPLICATIONS

The diagnosis of intrauterine infection in women with preterm premature rupture of the membranes (PPROM). Greig PC. **Clin Obstet Gynecol** 1998 Dec;41(4):849–63 (48 ref.)

Generalized peritonitis with pneumoperitoneum caused by the spontaneous perforation of pyometra without malignancy: report of a case. Inui A, et al. **Surg Today** 1999;29(9):935–8 (15 ref.)

DIAGNOSIS

Incarceration of the retroverted gravid uterus—a review. Jacobsson B, et al. **Acta Obstet Gynecol Scand** 1999 Sep; 78(8):665–8 (19 ref.)

The diagnosis of intrauterine infection in women with preterm premature rupture of the membranes (PPROM). Greig PC. **Clin Obstet Gynecol** 1998 Dec;41(4):849–63 (48 ref.)

Office hysteroscopy. Valle RF. **Clin Obstet Gynecol** 1999 Jun;42(2):276–89 (20 ref.)

[Disseminated pelvic endometriosis with hyperplastic and metaplastic changes. A case report] Mainkhard K, et al. **Akush Ginekol (Sofiia)** 1998;37(2):52–5 (8 ref.) **(Bul)**

EPIDEMIOLOGY

Uterine anomalies. How common are they, and what is their distribution among subtypes? Nahum GG. **J Reprod Med** 1998 Oct;43(10):877–87 (106 ref.)

ETIOLOGY

Vesico–uterine fistula secondary to cesarean section. Michielsen DP, et al. **Acta Urol Belg** 1998 Oct;66(3):21–3 (13 ref.)

PHYSIOPATHOLOGY

Immunoendocrinology of preterm labor: the link between corticotropin–releasing hormone and inflammation. Dudley DJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S251–6 (62 ref.)

SURGERY

Alternatives to total abdominal hysterectomy. Carter JE. **J Soc Laparoendosc Surg** 1997 Jul–Sep;1(3):259–62 (8 ref.)

[Hysteroscopic surgery and fertility] Cravello L, et al. **Contracept Fertil Sex** 1998 Jul–Aug;26(7–8):589–92 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Incarceration of the retroverted gravid uterus—a review. Jacobsson B, et al. **Acta Obstet Gynecol Scand** 1999 Sep; 78(8):665–8 (19 ref.)

Uterine emergencies. Atony, inversion, and rupture. Ripley DL. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):419–34, vii (41 ref.)

ULTRASONOGRAPHY

Sonographic assessment of endometrial disorders. Fleischer AC. **Semin Ultrasound CT MR** 1999 Aug;20(4):259–66 (21 ref.)

Sonohysterography: technique, endometrial findings, and clinical applications. Sohaey R, et al. **Semin Ultrasound CT MR** 1999 Aug;20(4):250–8 (17 ref.)

UTERINE ENDOSCOPY see **HYSTEROSCOPY**

UTERINE HEMORRHAGE

see related
MENORRHAGIA
METRORRHAGIA

Overview of common obstetric bleeding disorders. Carter S. **Nurse Pract** 1999 Mar;24(3):50–1, 54, 57–8 passim (29 ref.)

Peripartum hemorrhage. Alamia V Jr, et al. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):385–98 (63 ref.)

DIAGNOSIS

Common peripartum emergencies [see comments] Morrison EH. **Am Fam Physician** 1998 Nov 1;58(7):1593–604 (39 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2984, 2989; discussion 2990. Comment in: Am Fam Physician 1999 Jun;59(11):2989–90.

Management of vaginal bleeding presenting to the accident and emergency department. Buckingham K, et al. **J Accid Emerg Med** 1999 Mar;16(2):130–5 (17 ref.)

Menstrual disorders. Dysfunctional uterine bleeding. Bravender T, et al. **Pediatr Clin North Am** 1999 Jun; 46(3):545–53, viii (37 ref.)

DRUG THERAPY

Menstrual disorders. Dysfunctional uterine bleeding. Bravender T, et al. **Pediatr Clin North Am** 1999 Jun; 46(3):545–53, viii (37 ref.)

ETIOLOGY

Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy. Piura B, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):57–61 (22 ref.)

[Anomalous uterine hemorrhages in the climacteric. Their etiopathogenesis] Grio R, et al. **Minerva Ginecol** 1998 Sep; 50(9):383–8 (14 ref.) (Eng. Abstr.) **(Ita)**

[Diffuse myometrial hypertrophy. Cause of abnormal uterine bleeding. Clinico–pathological study of 4 cases and review of the literature] Mendoza Ramón HC, et al. **Ginecol Obstet Mex** 1999 Aug;67:370–3 (11 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Common peripartum emergencies [see comments] Morrison EH. **Am Fam Physician** 1998 Nov 1;58(7):1593–604 (39 ref.) Comment in: Am Fam Physician 1999 Jun;59(11):2984, 2989; discussion 2990. Comment in: Am Fam Physician 1999 Jun;59(11):2989–90.

Management of vaginal bleeding presenting to the accident and emergency department. Buckingham K, et al. **J Accid Emerg Med** 1999 Mar;16(2):130–5 (17 ref.)

Hysteroscopy in the management of abnormal uterine bleeding. Cooper JM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):217–36 (65 ref.)

ULTRASONOGRAPHY

Evaluation of postmenopausal endometrium [editorial] Parsons AK. **Ultrasound Obstet Gynecol** 1998 Nov; 12(5):295–300 (52 ref.)

UTERINE MUSCLE see **MYOMETRIUM**

UTERINE NEOPLASMS

Introduction: the epidemiology of uterine leiomyomas. Vollenhoven B. **Baillieres Clin Obstet Gynaecol** 1998 Jun; 12(2):169–76 (35 ref.)

Recent advances in gestational trophoblastic disease. Newlands ES, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):225–44, x (77 ref.)

[Gynecologic oncologists and their practice in the U.S.A.] Tsukamoto N. **Gan To Kagaku Ryoho** 1999 Jan;26(1):69–75 (13 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Hydropic degenerating leiomyoma presenting as pseudo–Meigs syndrome with elevated CA 125. Dunn JS Jr, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):648–9 (9 ref.)

CLASSIFICATION

The classification of gestational trophoblastic disease: a critical review. Tham KF, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S39–49 (31 ref.)

COMPLICATIONS

Clinical presentation of uterine fibroids. Lumsden MA, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):177–95 (88 ref.)

Molar pregnancy—associated ectopic decidua: report of a case and review of the literature. Kularbkaew C, et al. **J Med Assoc Thai** 1998 Nov;81(11):918–22 (45 ref.)

Deep vein thrombosis in patients with large uterine myomata. Chong YS, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):707 (4 ref.)

Aborted leiomyosarcoma after treatment with leuprolide acetate. Mesia AF, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):664–6 (7 ref.)

[Three cases of urinary retention caused by uterine leiomyoma] Kuroda K, et al. **Hinyokika Kiyo** 1999 Feb; 45(2):115–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Imaging techniques for fibroid detection. Hurley V. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):213–24 (28 ref.)

Differential diagnosis of gynaecological "stained glass" tumours on MRI. Tanaka YO, et al. **Br J Radiol** 1999 Apr; 72(856):414–20 (8 ref.)

Uterine malignant leiomyoblastoma (epithelioid leiomyosarcoma) during pregnancy. Bekkers RL, et al. **Gynecol Oncol** 1999 Mar;72(3):433–6 (14 ref.)

Choriocarcinoma co–existent with an intact pregnancy: case report and review of the literature. Steigrad SJ, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):197–203 (30 ref.)

Hydropic degenerating leiomyoma presenting as pseudo–Meigs syndrome with elevated CA 125. Dunn JS Jr, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):648–9 (9 ref.)

Uterine adenomyosis: current concepts in imaging. Tafazoli F, et al. **Semin Ultrasound CT MR** 1999 Aug;20(4):267–77 (57 ref.)

[The course of pregnancy, labor and the postpartum period in a woman with a myomatous node of the uterus who gave birth to twins] Istatkov M, et al. **Akush Ginekol (Sofiia)** 1998;37(4):56–8 (6 ref.) **(Bul)**

[The value of MRT in the diagnosis of benign and malignant tumors of the uterus] Hamm B. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Apr;170(4):327–37 (42 ref.) (Eng. Abstr.) **(Ger)**

[Clinical experience with uterine sarcoma] Melilli GA, et al. **Minerva Ginecol** 1998 Jul–Aug;50(7–8):291–5 (25 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Effects of leuprolide acetate on treatment of leiomyomata—clues to mechanisms of action. Demopoulos RI, et al. **Adv Anat Pathol** 1998 Mar;5(2):129–36 (38 ref.)

Other medical management of uterine fibroids. Eldar–Geva T, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun; 12(2):269–88 (76 ref.)

Gonadotrophin hormone–releasing hormone analogue treatment of fibroids. Shaw RW. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):245–68 (67 ref.)

Aborted leiomyosarcoma after treatment with leuprolide acetate. Mesia AF, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):664–6 (7 ref.)

[Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(1):55–7 (20 ref.) **(Bul)**

INK USED IN THE ORIGINAL
AY AFFECT THE QUALITY OF
M EDITION.

UTERINE NEOPLASMS

GENETICS

Warner-Lambert/Parke-Davis Award lecture. Many tumors and many genes: genetics of uterine leiomyomata. Morton CC. **Am J Pathol** 1998 Oct;153(4):1015-20 (41 ref.)

Genetic basis of uterine leiomyoma: involvement of high mobility group protein genes. Van de Ven WJ. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):289-93 (22 ref.)

Involvement of IGF2 and H19 imprinting in choriocarcinoma development. Wake N, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S1-8 (21 ref.)

NURSING

Uterine myomas: treatment options. Grabo TN, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan-Feb;28(1):23-31 (44 ref.)

PATHOLOGY

Müllerian carcinofibroma of the uterus. A case report. Imai H, et al. **Acta Cytol** 1999 Jul-Aug;43(4):667-74 (11 ref.)

Unexpected death due to gestational choriocarcinoma: a report of two cases. Filkins JA, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):387-90 (9 ref.)

Florid cystic endosalpingiosis with tumor-like manifestations: a report of four cases including the first reported cases of transmural endosalpingiosis of the uterus. Clement PB, et al. **Am J Surg Pathol** 1999 Feb;23(2):166-75 (50 ref.)

Factors in fibroid growth. Andersen J. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):225-43 (100 ref.)

Pathology of uterine fibroids. Crow J. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):197-211 (21 ref.)

Extrarenal Wilms' tumor of the uterus. Jiskoot P, et al. **Eur J Gynaecol Oncol** 1999;20(3):195-7 (7 ref.)

Malignant mixed Müllerian tumor with rhabdoid features: a report of two cases and a review of the literature. Baschinsky DY, et al. **Gynecol Oncol** 1999 Apr;73(1):145-50 (23 ref.)

Primary malignant schwannoma of the uterine cervix: a case report and literature review. Bernstein HB, et al. **Gynecol Oncol** 1999 Aug;74(2):288-92 (17 ref.)

Metastatic trophoblastic disease following partial hydatidiform mole: case report and literature review. Menczer J, et al. **Gynecol Oncol** 1999 Aug;74(2):304-7 (17 ref.)

Metastatic placental site trophoblastic tumor. Twiggs LB, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S51-5 (13 ref.)

A case of intraplacental choriocarcinoma associated with placental hemangioma. Aonahata M, et al. **Pathol Int** 1998 Nov;48(11):897-901 (21 ref.)

[Trophoblast lesions and trophoblast tumors] Herbst H, et al. **Pathologe** 1999 Jan;20(1):72-81 (19 ref.) (Eng. Abstr.) **(Ger)**

[Multiple lungs tumors found 17 years after hysterectomy--a case of benign metastasizing leiomyoma] Mikami I, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Jul;46(7):634-8 (27 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):520-5 (37 ref.)

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Hershman JM. **Thyroid** 1999 Jul;9(7):653-7 (42 ref.)

SECONDARY

Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy. Piura B, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):57-61 (22 ref.)

SURGERY

Hysterectomy and myomectomy by laparotomy. West CP. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):317-35 (41 ref.)

Endoscopic treatment of uterine fibroids. Wood C, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):289-316 (67 ref.)

Pregnancy with primary tubal placental site trophoblastic tumor--A case report and literature review. Su YN, et al. **Gynecol Oncol** 1999 May;73(2):322-5 (11 ref.)

Endoscopic myomectomy. Laparoscopy and hysteroscopy. Tulandi T, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):135-48, viii (65 ref.)

Laparoscopic myomectomy. Miskry T, et al. **Semin Laparosc Surg** 1999 Jun;6(2):73-9 (40 ref.)

[Laparoscopic myomectomy] Dicker D, et al. **Harefuah** 1998 Oct;135(7-8):310-2 (8 ref.) **(Heb)**

THERAPY

Optimal treatment in gestational trophoblastic disease. Ilancheran A. **Ann Acad Med Singapore** 1998 Sep;27(5):698-704 (24 ref.)

Management of uterine leiomyosarcoma in Australia. Gard GB, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):93-8 (17 ref.)

Uterine artery embolization for fibroid disease. Reidy JF, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):357-60 (17 ref.)

Ambulatory management of uterine leiomyomata. Barbieri RL. **Clin Obstet Gynecol** 1999 Jun;42(2):196-205 (27 ref.)

Prognostic factors and treatment for placental site trophoblastic tumor-report of 3 cases and analysis of 88 cases. Chang YL, et al. **Gynecol Oncol** 1999 May;73(2):216-22 (57 ref.)

Uterine myomas: treatment options. Grabo TN, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan-Feb;28(1):23-31 (44 ref.)

ULTRASTRUCTURE

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):520-5 (37 ref.)

UTERINE PERFORATION

COMPLICATIONS

Generalized peritonitis with pneumoperitoneum caused by the spontaneous perforation of pyometra without malignancy: report of a case. Inui A, et al. **Surg Today** 1999;29(9):935-8 (15 ref.)

ETIOLOGY

[Peritonitis secondary to perforated pyometra in a patient with cervical cancer: report of a case] Saleh Mata G, et al. **Ginecol Obstet Mex** 1998 Sep;66:389-91 (20 ref.) (Eng. Abstr.) **(Spa)**

UTERINE PROLAPSE

COMPLICATIONS

Urinary incontinence and concomitant prolapse. Grody MH. **Clin Obstet Gynecol** 1998 Sep;41(3):777-85 (21 ref.)

DIAGNOSIS

The clinical evaluation of pelvic floor dysfunction. Theofrastous JP, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):783-804 (76 ref.)

[Genital prolapse. Diagnosis] Jacob D, et al. **Rev Prat** 1998 May 15;48(10):1103-7 (0 ref.) **(Fre)**

PHYSIOPATHOLOGY

Pathophysiology of pelvic organ prolapse. Gill EJ, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):757-69 (51 ref.)

SURGERY

Surgical management of pelvic organ prolapse and stress urinary incontinence. Drutz HP, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):786-93 (26 ref.)

Urinary incontinence and concomitant prolapse. Grody MH. **Clin Obstet Gynecol** 1998 Sep;41(3):777-85 (21 ref.)

Management of pelvic organ prolapse. Cundiff GW, et al. **Obstet Gynecol Clin North Am** 1998 Dec;25(4):907-21, viii (67 ref.)

UTERINE RUPTURE

EPIDEMIOLOGY

Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Plaut MM, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1535-42 (27 ref.)

[Uterine rupture at the Niamey Central Maternity Reference Center, Nigeria. Epidemiologic features and prevention strategies] Diallo FB, et al. **Dakar Med** 1998;43(1):74-8 (15 ref.) (Eng. Abstr.) **(Fre)**

UTERINE STIMULANTS see **OXYTOCICS**

UTEROGLOBIN

PHYSIOLOGY

Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice [see comments] Mukherjee AB, et al. **Am J Kidney Dis** 1998 Dec;32(6):1106-20 (151 ref.) Comment in: Am J Kidney Dis 1998 Dec;32(6):1084-5.

Uteroglobin: a novel cytokine? Mukherjee AB, et al. **Cell Mol Life Sci** 1999 May;55(5):771-87 (179 ref.)

UTEROPLACENTAL CIRCULATION

PHYSIOLOGY

Current knowledge about fetal blood cells in the maternal circulation. Bianchi DW. **J Perinat Med** 1998;26(3):175-85 (83 ref.)

First trimester utero-placental circulation: maternal-fetal interaction. Jaffe R. **J Perinat Med** 1998;26(3):168-74 (49 ref.)

UTERUS

see related
HYSTERECTOMY
HYSTEROSCOPY

ABNORMALITIES

Uterine anomalies. How common are they, and what is their distribution among subtypes? Nahum GG. **J Reprod Med** 1998 Oct;43(10):877-87 (106 ref.)

Complete uterine septum with cervical duplication, longitudinal vaginal septum and duplication of a renal collecting system. A case report. Sharara FI. **J Reprod Med** 1998 Dec;43(12):1055-9 (5 ref.)

Bladder agenesis with urometrocolpos. Kasat LS, et al. **Pediatr Surg Int** 1999 Jul;15(5-6):415-6 (9 ref.)

[Hysteroscopic surgery and fertility] Cravello L, et al. **Contracept Fertil Sex** 1998 Jul-Aug;26(7-8):589-92 (25 ref.) (Eng. Abstr.) **(Fre)**

[Anomalies of Müllerian duct fusion. A report of 3 cases of uterus didelphys associated with a double vagina and ipsilateral renal agenesis] Ruibal Francisco JL, et al. **An Esp Pediatr** 1999 Jun;50(6):616-8 (14 ref.) **(Spa)**

BLOOD SUPPLY

Uterine artery embolization for fibroid disease. Reidy JF, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):357-60 (17 ref.)

Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. Damsky CH, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):660-6 (73 ref.)

Uterine artery embolization for the treatment of uterine fibroids. Goodwin SC, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):315-20 (13 ref.)

Uteroplacental vascular involvement in recurrent spontaneous abortion. Torry DS, et al. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):379-82 (33 ref.)

Decidual and vascular pathophysiology in pregnancy compromise. Starzyk KA, et al. **Semin Reprod Endocrinol** 1999;17(1):63-72 (113 ref.)

CYTOLOGY

Myometrial zonal differentiation and uterine junctional zone hyperplasia in the non-pregnant uterus. Brosens JJ, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):496-502 (55 ref.)

Granulated metrial gland cells in 'minor' species. Stewart IJ. **J Reprod Immunol** 1998 Nov;40(2):129-46 (76 ref.)

DRUG EFFECTS

Dose-response characteristics of uterine responses in rats exposed to estrogen agonists. Barton HA, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):133-49 (50 ref.)

IMMUNOLOGY

Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. Clark DA, et al. **Am J Reprod Immunol** 1999 Jan;41(1):5-22 (165 ref.)

Human uterine lymphocytes. King A, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):480-5 (49 ref.)

Regulation of uterine immune function by progesterone--lessons from the sheep. Hansen PJ. **J Reprod Immunol** 1998 Oct;40(1):63-79 (61 ref.)

The influence of the maternal uterine immune response on placentation in human subjects. King A, et al. **Proc Nutr Soc** 1999 Feb;58(1):69-73 (36 ref.)

METABOLISM

Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Cicinelli E, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):365-72 (43 ref.)

Key enzymes of prostaglandin biosynthesis and metabolism. Coordinate regulation of expression by cytokines in gestational tissues: a review. Hansen WR, et al. **Prostaglandins Other Lipid Mediat** 1999 Jun;57(4):243-57 (128 ref.)

PHYSIOLOGY

The kallikrein-kinin system along the different stages of gestation: experimental and clinical findings. Valdés G, et al. **Biol Res** 1998;31(3):235-41 (49 ref.)

Utero-ovarian interaction in the regulation of reproductive function. Alexander H, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):550-9 (35 ref.)

Myometrial zonal differentiation and uterine junctional zone hyperplasia in the non-pregnant uterus. Brosens JJ, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):496-502 (55 ref.)

Mucin expression and function in the female reproductive tract. Carson DD, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):459-64 (53 ref.)

Control and assessment of the uterus and cervix during pregnancy and labour. Garfield RE, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):673-95 (87 ref.)

Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Spitz IM, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):584-93 (71 ref.)

Review: effect of protein nutrition on ovarian and uterine physiology in dairy cattle. Butler WR. **J Dairy Sci** 1998

Sep;81(9):2533–9 (40 ref.)
Review: The role of leukaemia inhibitory factor in the establishment of pregnancy. Vogiagis D, et al. **J Endocrinol** 1999 Feb;160(2):181–90 (82 ref.)
Mechanisms of full-term and preterm labor: factors influencing uterine activity. Ruiz RJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):652–60 (47 ref.)
Role for cell surface oligosaccharide in cell–cell recognition during implantation. Zhu ZM, et al. **Mol Hum Reprod** 1998 Aug;4(8):735–8 (30 ref.)
Regulation of uterine smooth muscle function during gestation. Riemer RK, et al. **Pediatr Res** 1998 Nov; 44(5):615–27 (146 ref.)
Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Shiverick KT, et al. **Placenta** 1999 May; 20(4):265–72 (103 ref.)
Models for the study of uterine receptivity for blastocyst implantation. Sharpe-Timms KL, et al. **Semin Reprod Endocrinol** 1999;17(1):107–15 (73 ref.)
[Renin-angiotensin-aldosterone system in the reproductive system] Tanaka M, et al. **Nippon Rinsho** 1999 May; 57(5):1060–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Role of nitric oxide in the uterus and cervix: implications for the management of labor. Chwalisz K, et al. **J Perinat Med** 1998;26(6):448–57 (51 ref.)

SURGERY

[A surgical technic for cesarean section and gynecological laparotomy without suturing of the parietal and visceral peritoneum and the single-layer suturing of the uterus during the section (a review of the literature and initial experience)] Katsulov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):40–6 (25 ref.) **(Bul)**
[Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(1):55–7 (20 ref.) **(Bul)**
[Myomectomy by laparoscopy and infertility: status of the controversy] Dubuisson JB, et al. **Contracept Fertil Sex** 1998 Oct;26(10):728–31 (42 ref.) (Eng. Abstr.) **(Fre)**
[Hormonal dependence of vesicouterine fistulas] Jóźwik M, et al. **Ginekol Pol** 1998 Sep;69(9):717–21 (21 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Role of pelvic ultrasonography in evaluation of symptomatic first-trimester pregnancy. Dart RG. **Ann Emerg Med** 1999 Mar;33(3):310–20 (38 ref.)
Sonohysterography: technique, endometrial findings, and clinical applications. Sohaey R, et al. **Semin Ultrasound CT MR** 1999 Aug;20(4):250–8 (17 ref.)
Sonographic images of a lost intrauterine device [letter] Zalel Y, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):376–7 (5 ref.)
[Contrast hysterosonography: an efficient means of investigation in gynecology. Review of the literature] van den Brûle FA, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Nov; 27(7):655–64 (59 ref.) (Eng. Abstr.) **(Fre)**

UTILITARIANISM see **ETHICS**

UTILIZATION REVIEW

see related
INSURANCE CLAIM REVIEW

LEGISLATION & JURISPRUDENCE

Is utilization review the practice of medicine? Implications for managed care administrators. Andresen JS. **J Leg Med** 1998 Sep;19(3):431–54 (158 ref.)

UTILIZATION REVIEW, DRUG see **DRUG UTILIZATION REVIEW**

UTP-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE

see related
GALACTOSEMIA

3'UTR see **3' UNTRANSLATED REGIONS**

5'UTR see **5' UNTRANSLATED REGIONS**

UVEA

METABOLISM

Binding of drugs to eye melanin is not predictive of ocular toxicity. Leblanc B, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):124–32 (120 ref.)

SURGERY

[Surgical stimulation of uveoscleral discharge in primary glaucoma] Kornilaeva GG. **Vestn Oftalmol** 1999 Jan–Feb; 115(1):34–5 (30 ref.) **(Rus)**

UVEAL NEOPLASMS

DIAGNOSIS

Uveal melanoma, choroidal hemangioma, and simulating lesions. Role of MR imaging. Mafee MF. **Radiol Clin North Am** 1998 Nov;36(6):1083–99, x (67 ref.)

GENETICS

Genetic predisposition to ocular melanoma. Houlston RS, et al. **Eye** 1999;13 (Pt 1):43–6 (58 ref.)

MORTALITY

Cause-specific versus all-cause survival [editorial; comment] McLean IW, et al. **Ophthalmology** 1998 Nov; 105(11):1989–90 (3 ref.) Comment on: Ophthalmology 1998 Nov;105(11):2035–45.

SECONDARY

Intraocular metastases of cutaneous malignant melanoma: a case report and review of the literature. Ramaesh K, et al. **Eye** 1999 Apr;13 (Pt 2):247–50 (24 ref.)

THERAPY

The treatment of metastatic uveal melanoma. Pyrhönen S. **Eur J Cancer** 1998 Jul;34 Suppl 3:S27–30 (29 ref.)
[Uveal melanomas and their treatment] Zografos L. **Rev Med Suisse Romande** 1998 Nov;118(11):915–26 (59 ref.) **(Fre)**
[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature] Terheyden P, et al. **Hautarzt** 1998 Oct;49(10):770–3 (23 ref.) (Eng. Abstr.) **(Ger)**

UVEITIS

Tubulointerstitial nephritis and uveitis in children and adolescents. Four new cases and a review of the literature. Vohra S, et al. **Pediatr Nephrol** 1999 Jun;13(5):426–32 (35 ref.)

DIAGNOSIS

Diagnostic vitrectomy and uveitis. Uy HS, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):223–35 (49 ref.)

DRUG THERAPY

Immunosuppression in uveitis therapy. Van Gelder RN, et al. **Springer Semin Immunopathol** 1999;21(2):179–90 (38 ref.)
[Immunosuppressive therapy in intraocular inflammation. II. Basic principles, indications, contraindications, side-effects] Manthey KF. **Ophthalmologe** 1998 Dec;95(12):846–58 (15 ref.) **(Ger)**

EPIDEMIOLOGY

Ocular sarcoidosis in Kuwait with a review of literature. Hegab SM, et al. **Int Ophthalmol** 1997–98;21(5):255–60 (51 ref.)
Eye involvement in the spondyloarthropathies. Bañares A, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):771–84, ix (42 ref.)

ETIOLOGY

Eye involvement in children's rheumatic diseases. Dollfus H. **Baillieres Clin Rheumatol** 1998 May;12(2):309–28 (71 ref.)
Clinical aspects, outcome assessment, disease course, and extra-articular features of spondyloarthropathies. Kerr HE, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):235–7 (13 ref.)
Systemic autoimmune diseases and their effect on the eye. Zervos T, et al. **Med Health R I** 1999 Feb;82(2):53–7 (9 ref.)

IMMUNOLOGY

Immune mechanisms in uveitis. Caspi RR. **Springer Semin Immunopathol** 1999;21(2):113–24 (61 ref.)

THERAPY

Riding on a carousel with IFN-alpha and TNF-alpha [editorial; comment] Zierhut M. **Ocul Immunol Inflamm** 1998 Dec;6(4):209–10 (15 ref.) Comment on: Ocul Immunol Inflamm 1998 Dec;6(4):215–26.
Strategies for the treatment of intraocular inflammatory disease. Nussenblatt RB, et al. **Transplant Proc** 1998 Dec; 30(8):4124–5 (13 ref.)
[Prospects of immunotropic therapy of traumatic uveitis] Valeeva RG, et al. **Vestn Oftalmol** 1998 Jul–Aug; 114(4):26–8 (9 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Understanding uveitis through the eyes of a horse: relevance of models of ocular inflammation to human disease [editorial] Dick AD. **Ocul Immunol Inflamm** 1998 Dec; 6(4):211–4 (19 ref.)

UVEITIS, ANTERIOR

CLASSIFICATION

Classification of herpes simplex virus keratitis and anterior uveitis. Liesegang TJ. **Cornea** 1999 Mar;18(2):127–43 (110 ref.)

COMPLICATIONS

Acute anterior uveitis and spondyloarthropathies. Feltkamp TE, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):314–8 (50 ref.)

DIAGNOSIS

Diagnosing the systemic associations of anterior uveitis. Smith JR, et al. **Aust N Z J Ophthalmol** 1998 Nov; 26(4):319–26 (36 ref.)

DRUG THERAPY

New corticosteroids for the treatment of ocular inflammation [editorial; comment] Whitcup SM, et al. **Am J Ophthalmol** 1999 May;127(5):597–9 (9 ref.) Comment on: Am J Ophthalmol 1999 May;127(5):537–44.

ETIOLOGY

Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Smith JR, et al. **Immunol Cell Biol** 1998 Dec;76(6):497–512 (138 ref.)

PHYSIOPATHOLOGY

Inflammatory response after cataract surgery. Laurell CG. **Acta Ophthalmol Scand** 1998 Oct;76(5):632–3 (5 ref.)

VIROLOGY

Classification of herpes simplex virus keratitis and anterior uveitis. Liesegang TJ. **Cornea** 1999 Mar;18(2):127–43 (110 ref.)
Herpes simplex anterior uveitis. Tabbara KF, et al. **Int Ophthalmol Clin** 1998 Fall;38(4):137–47 (31 ref.)

UVEITIS, POSTERIOR

Birdshot retinochoroidopathy. Gasch AT, et al. **Br J Ophthalmol** 1999 Feb;83(2):241–9 (54 ref.)

UVEITIS, SYMPATHETIC see **OPHTHALMIA, SYMPATHETIC**

UVEOMENINGOENCEPHALITIC SYNDROME

COMPLICATIONS

Vogt-Koyanagi-Harada syndrome in children. Rathinam SR, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):155–61 (25 ref.)

UVOMORULIN see **CADHERINS**

V1 RECEPTORS see **RECEPTORS, VASOPRESSIN**

V2 RECEPTORS see **RECEPTORS, VASOPRESSIN**

V-ABL GENES see **GENES, ABL**

V-ABL PROTEINS see **ONCOGENE PROTEINS V-ABL**

V-FOS GENES see **GENES, FOS**

V-HA-RAS GENES see **GENES, RAS**

V-JUN GENES see **GENES, JUN**

V-KI-RAS GENES see **GENES, RAS**

V-MYC GENES see **GENES, MYC**

V-ONC PROTEINS see **ONCOGENE PROTEINS, VIRAL**

V-SRC GENES see **GENES, SRC**

V-SRC PROTEIN PP60 see **ONCOGENE PROTEIN PP60(V-SRC)**

VACCINATION

Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Nara PL. **Adv Vet Med** 1999;41:115–34 (69 ref.)
Active and passive immunization against HIV type 1 infection in chimpanzees. Murthy KK, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S271–6 (36 ref.)
Maternal immunization. Glezen WP, et al. **Clin Infect Dis** 1999 Feb;28(2):219–24 (51 ref.)
Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Zajac AJ, et al. **Curr Opin Immunol** 1998 Aug; 10(4):444–9 (53 ref.)
Human dendritic cells: natural adjuvants in antitumor immunotherapy. Di Nicola M, et al.

Cytokines Cell Mol Ther 1998 Dec;4(4):265–73 (81 ref.)
Immunisation and the maturation of infant immune responses. Goldblatt D. **Dev Biol Stand** 1998;95:125–32 (21 ref.)
Immunologic "vaccination" for the prevention of autoimmune diabetes (type 1A). Simone EA, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B7–15 (102 ref.)
Modulating the immune response to genetic immunization. Cohen AD, et al. **FASEB J** 1998 Dec;12(15):1611–26 (110 ref.)
Travel vaccines. Thompson RF, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):149–67, vii (65 ref.)
Adjuvants and delivery issues related to immunization: a survey of the recent patent literature [editorial] Mrsny RJ. **J Drug Target** 1998;6(4):243–9 (9 ref.)
Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application [published erratum appears in J Immunol Methods 1999 Apr 22;224(1–2):211] Thurner B, et al. **J Immunol Methods** 1999 Feb 1;223(1):1–15 (33 ref.)
Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Tarte K, et al. **Leukemia** 1999 May; 13(5):653–63 (127 ref.)
Molecular basis of vaccination. Del Giudice G, et al. **Mol Aspects Med** 1998 Feb;19(1):1–70 (312 ref.)
DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Davis HL. **Mt Sinai J Med** 1999 Mar;66(2):84–90 (48 ref.)
Echinococcus granulosus: immunodiagnosis and vaccination, a perspective. Craig PS. **Parassitologia** 1997 Dec; 39(4):345–7 (35 ref.)
Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine. Mellstedt H, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):211–5 (21 ref.)
Immunizations for the immunocompromised child. McFarland E. **Pediatr Ann** 1999 Aug;28(8):487–96 (32 ref.)
Childhood immunizations and type 1 diabetes: summary of an Institute for Vaccine Safety Workshop. The Institute for Vaccine Safety Diabetes Workshop Panel. **Pediatr Infect Dis J** 1999 Mar;18(3):217–22 (52 ref.)
Recommended immunization practices for pediatric renal transplant recipients. Neu AM, et al. **Pediatr Transplant** 1998 Nov;2(4):263–9 (44 ref.)
Vaccination--the scares in perspective. Aston R. **Practitioner** 1998 Jul;242(1588):524–6 (3 ref.)
Animal models of antiphospholipid syndrome. Tincani A, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):614–8 (42 ref.)
Vaccination of the immunosuppressed adult patient with rheumatologic disease. Avery RK. **Rheum Dis Clin North Am** 1999 Aug;25(3):567–84, viii (73 ref.)
Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Nara PL, et al. **Vaccine** 1998 Nov;16(19):1780–7 (80 ref.)
Ethical aspects of vaccines and vaccination. Spier RE. **Vaccine** 1998 Nov;16(19):1788–94 (13 ref.)
[Vaccination calendar and new risks of infection] Bégué P. **Ann Med Interne (Paris)** 1998 Oct;149(6):379–84 (21 ref.) (Eng. Abstr.) **(Fre)**
[Vaccinations and systemic diseases. Vaccinations and immunosuppression] Bouchaud O, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):351–60 (56 ref.) (Eng. Abstr.) **(Fre)**
[Expanded program of vaccination. Results and prospects] Guérin N, et al. **Ann Med Interne (Paris)** 1998 Oct; 149(6):372–8 (6 ref.) (Eng. Abstr.) **(Fre)**
[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects] Ivanoff B, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):340–50 (54 ref.) (Eng. Abstr.) **(Fre)**
[Vaccinations of the traveller] Marchou B, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):332–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Should premature infants be vaccinated? (editorial)] Floret D, et al. **Arch Pediatr** 1999 Jun;6(6):607–9 (17 ref.) **(Fre)**
[Which are the vaccines that human immunodeficiency virus infected patients must receive?] Valencia Ortega ME, et al. **An Med Interna** 1998 Aug;15(8):439–42 (36 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

[Risks associated with vaccinations] Loupi E, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):361–71 (99 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Edmunds WJ. **Commun Dis Public Health** 1998 Dec;1(4):221–8 (34 ref.)
Sustainable introduction of affordable new vaccines: the targeting strategy. Batson A. **Vaccine** 1998 Nov;16 Suppl:S93–8 (5 ref.)
Economic evaluations applied to HB vaccination: general observations. Beutels P. **Vaccine** 1998 Nov;16 Suppl:S84–92 (31 ref.)
Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Da Villa G, et al. **Vaccine** 1999 Mar 26;17(13–14):1734–8 (17 ref.)
[Economic evaluations of pneumococcal vaccination. A critical analysis] Beutels P. **Presse Med** 1998 May;27 Suppl 1:33–8 (22 ref.) **(Fre)**

HISTORY

Grease, anthraxgate, and kennel cough: a revisionist history of early veterinary vaccines. Tizard I. **Adv Vet Med** 1999; 41:7–24 (37 ref.)

LEGISLATION & JURISPRUDENCE

[Is vaccination a private matter?] Ruef C. **Schweiz Med Wochenschr** 1999 Apr 3;129(13):495–8 (14 ref.) **(Ger)**

METHODS

Vaccination against diphtheria and tetanus. Assays, antigens, adjuvants and application. Aggerbeck H. **APMIS Suppl** 1998;81:1–40 (275 ref.)
An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1998–1999 season. **Can Commun Dis Rep** 1998 Jul 1;24:1–12 (45 ref.) **(Eng, Fre)**
Preventing pneumococcal disease. Thomas R. **Can Fam Physician** 1998 Oct;44:2180–1, 2184–5 (7 ref.) **(Eng, Fre)**
Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Kovarik J, et al. **Immunol Cell Biol** 1998 Jun;76(3):222–36 (134 ref.)
Polymer-grafted starch microparticles for oral and nasal immunization. McDermott MR, et al. **Immunol Cell Biol** 1998 Jun;76(3):256–62 (52 ref.)
Development of vaccines and their use in the prevention of fungal infections. Dixon DM, et al. **Med Mycol** 1998;36 Suppl 1:57–67 (90 ref.)
Immunisation strategies for viral diseases in developing countries. Ruff TA. **Rev Med Virol** 1999 Apr-Jun; 9(2):121–38 (61 ref.)
Melanoma vaccines as a therapeutic option. McGee JM, et al. **South Med J** 1999 Jul;92(7):698–704 (54 ref.)
[Vaccination strategies for the general practitioner. II. New vaccines] Limme C, et al. **Rev Med Liege** 1998 Oct; 53(10):625–32 (35 ref.) (Eng. Abstr.) **(Fre)**
[Aerosol vaccination against dangerous infectious diseases] Stepanov AV, et al. **Vestn Ross Akad Med Nauk** 1999; (8):47–54 (48 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1998–1999 season. **Can Commun Dis Rep** 1998 Jul 1;24:1–12 (45 ref.) **(Eng, Fre)**
New vaccines for disease prevention. Banker DD. **Indian J Med Sci** 1998 Mar;52(3):125–9 (0 ref.)
Control of hepatitis A infection in the U.S. Le C. **West J Med** 1999 Jun;170(6):324 (10 ref.)

STATISTICS & NUMERICAL DATA

[Factors affecting acceptance rate of measles vaccine] Isomura S. **Uirusu** 1998 Dec;48(2):183–8 (8 ref.) **(Jpn)**

TRENDS

Vaccination against tuberculosis: recent progress. Orme IM. **Adv Vet Med** 1999;41:135–43 (36 ref.)
Prospects of new vaccines for resurgent and emergent diseases. Everest P, et al. **Br Med Bull** 1998;54(3):557–68 (46 ref.)
Genetically modified tumour vaccines--where we are today. Nawrocki S, et al. **Cancer Treat Rev** 1999 Feb;25(1):29–46 (112 ref.)
Synthetic peptides: a modern approach to vaccination. Sood A, et al. **Indian J Exp Biol** 1998 Sep;36(9):849–61 (81 ref.)
Recent developments in bacterial conjugate vaccines. Goldblatt D. **J Med Microbiol** 1998 Jul;47(7):563–7 (41 ref.)
Vaccination for the new millennium. Baird MA, et al. **N Z Med J** 1998 Dec 11;111(1079):461–2 (08 ref.)
The business of science and the science of business in the quest for an AIDS vaccine. Hilleman MR. **Vaccine** 1999 Mar 5;17(9–10):1211–22 (52 ref.)

UTILIZATION

Annotation: children's disengagement from medical homes--a neglected public health imperative [editorial] Irigoyen M, et al. **Am J Public Health** 1999 Feb;89(2):157–9 (25 ref.)
Immunization performance measurement in a changing immunization environment. Rodewald L, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):889–97 (79 ref.)
Ending polio immunization: when and how are we sure that the needle is out of the haystack? Kimman TG, et al. **Vaccine** 1999 Feb 26;17(7–8):624–7 (22 ref.)

VETERINARY

Forty years of canine vaccination. Appel MJ. **Adv Vet Med** 1999;41:309–24 (95 ref.)
Nutritional effects on vaccination. Cook ME. **Adv Vet Med** 1999;41:53–9 (35 ref.)
Cross-species vaccination in wild and exotic animals. Curlee JF Jr. **Adv Vet Med** 1999;41:551–6 (25 ref.)
More bumps on the vaccine road. Dodds WJ. **Adv Vet Med** 1999;41:715–32 (68 ref.)
Weighing the risks and benefits of vaccination. Glickman LT. **Adv Vet Med** 1999;41:701–13 (24 ref.)
Effects of stress on leukocyte trafficking and immune responses: implications for vaccination. Kehrli ME, et al. **Adv Vet Med** 1999;41:61–81 (108 ref.)
ISCOM: a delivery system for neonates and for mucosal administration. Morein B, et al. **Adv Vet Med** 1999; 41:405–13 (20 ref.)
The equine influenza surveillance program. Mumford JA. **Adv Vet Med** 1999;41:379–87 (11 ref.)
Vaccination of cats against emerging and reemerging zoonotic pathogens. Olsen CW. **Adv Vet Med** 1999; 41:333–46 (62 ref.)
In ovo vaccination technology. Ricks CA, et al. **Adv Vet Med** 1999;41:495–515 (51 ref.)
Mechanistic bases for adverse vaccine reactions and vaccine failures. Roth JA. **Adv Vet Med** 1999;41:681–700 (82 ref.)
Evaluation of risks and benefits associated with vaccination against coronavirus infections in cats. Scott FW. **Adv Vet Med** 1999;41:347–58 (52 ref.)
Introduction to poultry vaccines and immunity. Sharma JM. **Adv Vet Med** 1999;41:481–94 (62 ref.)
Viral vectors for veterinary vaccines. Sheppard M. **Adv Vet Med** 1999;41:145–61 (90 ref.)
An introduction to analytical methods for the postmarketing surveillance of veterinary vaccines. Siev D. **Adv Vet Med** 1999;41:749–74 (26 ref.)
Grease, anthraxgate, and kennel cough: a revisionist history of early veterinary vaccines. Tizard I. **Adv Vet Med** 1999; 41:7–24 (37 ref.)
Fish vaccines. Vinitnantharat S, et al. **Adv Vet Med** 1999; 41:539–50 (10 ref.)
Genetic effects on vaccination. Wilkie BN, et al. **Adv Vet Med** 1999;41:39–51 (43 ref.)
Vaccination of dogs and cats: general principles and duration of immunity [see comments] Kruth SA, et al. **Can Vet J** 1998 Jul;39(7):423–6 (14 ref.) Comment in: Can Vet J 1999 Jan;40(1):7.
Etiology of feline vaccine-associated sarcomas: history and update. Bergman PJ. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1424–5 (5 ref.)
Review of treatment options for vaccine-associated feline sarcoma. Couto CG, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1426–7 (4 ref.)
Feline vaccine-associated sarcomas: current studies on pathogenesis. Hendrick MJ. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1425–6 (5 ref.)
Historical review and current knowledge of risk factors involved in feline vaccine-associated sarcomas. Hendrick MJ. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1422–3 (7 ref.)
Education/communication: history and current status. Richards JR. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1429–30 (0 ref.)
Managing an animal health emergency in Taipei China: foot and mouth disease. Chen BJ, et al. **Rev Sci Tech** 1999 Apr; 18(1):186–92 (5 ref.)
Vaccination for control of Salmonella in poultry. Zhang-Barber L, et al. **Vaccine** 1999 Jun 4; 17(20–21):2538–45 (79 ref.)
Vaccination of cattle against bovine viral diarrhoea. van Oirschot JT, et al. **Vet Microbiol** 1999 Jan;64(2–3):169–83 (73 ref.)

VACCINATION ENCEPHALITIS see **ENCEPHALOMYELITIS, ACUTE DISSEMINATED**

VACCINE THERAPY see **IMMUNOTHERAPY, ACTIVE**

VACCINES

Vaccines against human parasitic diseases: an overview. Abath FG, et al. **Acta Trop** 1998 Nov 30;71(3):237–54 (80 ref.)
Progress and expectations for helminth vaccines. Meeusen EN, et al. **Adv Vet Med** 1999;41:241–56 (41 ref.)
Contribution of advances in immunology to vaccine development. Morrison WI, et al. **Adv Vet Med** 1999; 41:181–95 (44 ref.)
Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Nara PL. **Adv Vet Med** 1999;41:115–34 (69 ref.)
Vaccine technology: looking to the future. Dorner F, et al. **Ann Med** 1999 Feb;31(1):51–60 (47 ref.)
Dendritic cell vaccines for cancer immunotherapy. Timmerman JM, et al. **Annu Rev Med** 1999;50:507–29 (111 ref.)
Eradication of vaccine-preventable diseases. Hinman A. **Annu Rev Public Health** 1999;20:211–29 (62 ref.)
Prospects of new vaccines for resurgent and emergent diseases. Everest P, et al. **Br Med Bull** 1998;54(3):557–68 (46 ref.)
Liposomes: from biophysics to the design of peptide vaccines. Frézard F. **Braz J Med Biol Res** 1999 Feb;32(2):181–9 (37 ref.)
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Lima KM, et al. **Braz J Med Biol Res** 1999 Feb;32(2):171–80 (63 ref.)
Approaches to new vaccines. Mahon BP, et al. **Crit Rev Biotechnol** 1998;18(4):257–82 (125 ref.)

Leishmania transmission-blocking vaccines: a review. Tonui WK. **East Afr Med J** 1999 Feb;76(2):93-6 (30 ref.)
Unconventional vaccine targets. Immunization for pregnancy, peptic ulcer, gastric cancer, cocaine abuse, and atherosclerosis. Lutwick LI. **Infect Dis Clin North Am** 1999 Mar;13(1):245-64, ix (115 ref.)
Immunological control of arthropod ectoparasites--a review. Pruett JH. **Int J Parasitol** 1999 Jan;29(1):25-32 (61 ref.)
Schistosomiasis vaccine development: progress and prospects. Bergquist NR. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:95-101 (30 ref.)
Glutathione S-transferases of 28kDa as major vaccine candidates against schistosomiasis. Riveau G, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:87-94 (41 ref.)
Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Peter G, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):942-50 (57 ref.)
Fasciola gigantica: studies of the tegument as a basis for the developments of immunodiagnosis and vaccine. Sobhon P, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):387-400 (82 ref.)
Broadening the approaches to developing more effective vaccines. Babiuk LA. **Vaccine** 1999 Mar 26; 17(13-14):1587-95 (45 ref.)
Promises and pitfalls of meta-analysis in vaccine research. Jacobson RM. **Vaccine** 1999 Mar 26;17(13-14):1628-34 (85 ref.)
Current paradoxes and changing paradigms in vaccinology. Poland GA. **Vaccine** 1999 Mar 26;17(13-14):1605-11 (63 ref.)

ADMINISTRATION & DOSAGE

Vaccines and their impact on the control of disease. McLean AR. **Br Med Bull** 1998;54(3):545-56 (26 ref.)
The potential of liposomes in oral drug delivery. Rogers JA, et al. **Crit Rev Ther Drug Carrier Syst** 1998;15(5):421-80 (254 ref.)
Mucosal responses to parenteral and mucosal vaccines. Kaul D, et al. **Dev Biol Stand** 1998;95:141-6 (10 ref.)
New vaccines for disease prevention. Banker DD. **Indian J Med Sci** 1998 Mar;52(3):125-9 (0 ref.)
Design and delivery of non-parenteral vaccines. Nugent J, et al. **J Clin Pharm Ther** 1998 Aug;23(4):257-85 (214 ref.)
Adjuvants and delivery issues related to immunization: a survey of the recent patent literature [editorial] Mrsny RJ. **J Drug Target** 1998;6(4):243-9 (9 ref.)
Adult immunizations: recommendations for practice. Reid KC, et al. **Mayo Clin Proc** 1999 Apr;74(4):377-84 (22 ref.)
Fully mobilizing host defense: building better vaccines. Raychaudhuri S, et al. **Nat Biotechnol** 1998 Nov; 16(11):1025-31 (112 ref.)
Vaccination of the immunosuppressed adult patient with rheumatologic disease. Avery RK. **Rheum Dis Clin North Am** 1999 Aug;25(3):567-84, viii (73 ref.)
Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells? Kaiserlian D, et al. **Semin Immunol** 1999 Jun;11(3):217-24 (50 ref.)
Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Cleland JL. **Trends Biotechnol** 1999 Jan;17(1):25-9 (33 ref.)

ADVERSE EFFECTS

More bumps on the vaccine road. Dodds WJ. **Adv Vet Med** 1999;41:715-32 (68 ref.)
Mechanistic bases for adverse vaccine reactions and vaccine failures. Roth JA. **Adv Vet Med** 1999;41:681-700 (82 ref.)
Feline vaccine-associated sarcomas. Hendrick MJ. **Cancer Invest** 1999;17(4):273-7 (26 ref.)
Review of treatment options for vaccine-associated feline sarcoma. Couto CG, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1426-7 (4 ref.)
No-fault vaccine insurance: lessons from the National Vaccine Injury Compensation Program. Ridgway D. **J Health Polit Policy Law** 1999 Feb;24(1):59-90 (47 ref.)
[Immunologic safety of vaccines] Medunitsyn NV. **Patol Fiziol Eksp Ter** 1999 Jan-Mar;(1):20-2 (28 ref.) **(Rus)**

CHEMICAL SYNTHESIS

New technologies for vaccines. Dorner F, et al. **Wien Klin Wochenschr** 1999 Mar 12;111(5):199-206 (44 ref.)

GENETICS

Maintaining and enhancing vaccine immunogenicity. Gradon JD, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):39-60, vi (102 ref.)

IMMUNOLOGY

Strategies for mucosal vaccine development. Boyaka PN, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):35-45 (117 ref.)
Oral tolerance and anti-pathological vaccines. Czerkinsky C, et al. **Curr Top Microbiol Immunol** 1999;236:79-91 (50 ref.)
Cytokines and the mechanisms of action of vaccine adjuvants. Brewer JM, et al. **Cytokines Cell Mol Ther** 1997 Dec; 3(4):233-46 (162 ref.)
Immunogenicity assays and surrogate markers to predict vaccine efficacy. Käyhty H. **Dev Biol Stand** 1998;95:175-80 (17 ref.)
Maintaining and enhancing vaccine immunogenicity. Gradon JD, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):39-60, vi (102 ref.)
Prospects for vaccines of helminth parasites of grazing ruminants. Smith WD. **Int J Parasitol** 1999 Jan;29(1):17-24 (54 ref.)
New technologies for making vaccines. Ellis RW. **Vaccine** 1999 Mar 26;17(13-14):1596-604 (52 ref.)
[Post-vaccination immunity after allogenic and autologous bone marrow transplantation] Skovránková J. **Cas Lek Cesk** 1999 May 10;138(10):298-300 (23 ref.) **(Eng. Abstr.)** **(Cze)**
[Immune response to different vaccines] Bégué P. **Arch Pediatr** 1998;5 Suppl 2:182s-187s (12 ref.) **(Fre)**

PHARMACOLOGY

Measuring protection: efficacy versus effectiveness. Fedson DS. **Dev Biol Stand** 1998;95:195-201 (17 ref.)
Immunogenicity assays and surrogate markers to predict vaccine efficacy. Käyhty H. **Dev Biol Stand** 1998;95:175-80 (17 ref.)
Experimental challenge studies in the development of vaccines for infectious diseases. Levine MM. **Dev Biol Stand** 1998;95:169-74 (17 ref.)

STANDARDS

Weighing the risks and benefits of vaccination. Glickman LT. **Adv Vet Med** 1999;41:701-13 (24 ref.)
An introduction to analytical methods for the postmarketing surveillance of veterinary vaccines. Siev D. **Adv Vet Med** 1999;41:749-74 (26 ref.)
Vaccination of dogs and cats: general principles and duration of immunity [see comments] Kruth SA, et al. **Can Vet J** 1998 Jul;39(7):423-6 (14 ref.) Comment in: Can Vet J 1999 Jan;40(1):7.

THERAPEUTIC USE

The role of allergen-specific T cells in the allergic immune response: relevance to allergy vaccination. van Neerven RJ. **Allergy** 1999 Jun;54(6):552-61 (134 ref.)
Antiinfectives update: focus on treatment and prevention of viral and associated infections. McNicholl IR, et al. **Ann Pharmacother** 1999 May;33(5):607-14 (67 ref.)
IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS. Bizzini B, et al. **Biomed Pharmacother** 1999 Mar;53(2):87-9 (21 ref.)
Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. Bousquet J, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):558-62 (58 ref.)

VACCINES, ATTENUATED

Irradiated vaccines for helminth control in livestock. Bain RK. **Int J Parasitol** 1999 Jan;29(1):185-91 (36 ref.)

ADVERSE EFFECTS

Immunisation of patients with systemic lupus erythematosus: the current state of play. Ioannou Y, et al. **Lupus** 1999; 8(7):497-501 (51 ref.)

IMMUNOLOGY

Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. Killeen K, et al. **Curr Top Microbiol Immunol** 1999;236:237-54 (68 ref.)
Immune responses to the radiation-attenuated schistosome vaccine: what can we learn from knock-out mice? Wilson RA, et al. **Immunol Lett** 1999 Jan;65(1-2):117-23 (31 ref.)

THERAPEUTIC USE

Bivalent cholera and typhoid vaccine. Foster RH, et al. **Drugs** 1999 Jul;58(1):91-6; discussion 97-8 (10 ref.)

VACCINES, CANCER see **CANCER VACCINES**

VACCINES, COMBINED

Pediatric combination vaccines. Choo S, et al. **Curr Opin Pediatr** 1999 Feb;11(1):14-20 (60 ref.)
Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). **Pediatrics** 1999 May;103(5 Pt 1):1064-77 (80 ref.)

ADVERSE EFFECTS

Clinical safety evaluation of combination vaccines. Midthun K, et al. **Dev Biol Stand** 1998;95:245-9 (11 ref.)

IMMUNOLOGY

Development and clinical application of new polyvalent combined paediatric vaccines. André FE. **Vaccine** 1999 Mar 26;17(13-14):1620-7 (35 ref.)
New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Eko FO, et al. **Vaccine** 1999 Mar 26;17(13-14):1643-9 (24 ref.)
Development of combination vaccines. Ellis RW. **Vaccine** 1999 Mar 26;17(13-14):1635-42 (28 ref.)
New acellular pertussis-containing paediatric combined vaccines. Pines E, et al. **Vaccine** 1999 Mar 26; 17(13-14):1650-6 (51 ref.)

PHARMACOLOGY

Clinical safety evaluation of combination vaccines. Midthun K, et al. **Dev Biol Stand** 1998;95:245-9 (11 ref.)

THERAPEUTIC USE

Bivalent cholera and typhoid vaccine. Foster RH, et al. **Drugs** 1999 Jul;58(1):91-6; discussion 97-8 (10 ref.)
Current combined vaccines with hepatitis B. Papaevangelou G. **Vaccine** 1998 Nov;16 Suppl:S69-72 (16 ref.)

VACCINES, CONJUGATE

Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Levine OS, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S95-113 (131 ref.)
[Conjugated pneumococcal vaccines] Reinert P. **Arch Pediatr** 1999;6 Suppl 3:643s-646s (25 ref.) **(Fre)**

IMMUNOLOGY

Conjugated polysaccharide vaccines. Ahmad H, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):113-33, vii (133 ref.)
Pneumococcal conjugate vaccines. Eskola J, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):543-51 (59 ref.)
Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S117-22 (19 ref.)
[A new vaccine concept: polysaccharide conjugate vaccines] Moreau M. **Ann Pharm Fr** 1999 May;57(3):223-31 (22 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Standardization may suffice for licensure of conjugate vaccines. Robbins JB, et al. **Dev Biol Stand** 1998;95:161-7 (39 ref.)

VACCINES, DNA

Strategies to elicit anti-idiotypic immune response in B-lymphoma patients. Peptide and genetic immunization. Rinaldi M, et al. **Adv Exp Med Biol** 1998;451:323-30 (37 ref.)
DNA immunization: present and future. Babiuk LA, et al. **Adv Vet Med** 1999;41:163-79 (55 ref.)
New viral vectors for HIV vaccine delivery. Cairns JS, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1501-8 (26 ref.)
New vaccine strategies against enterotoxigenic Escherichia coli. I: DNA vaccines against the CFA/I fimbrial adhesin. Alves AM, et al. **Braz J Med Biol Res** 1999 Feb;32(2):223-9 (25 ref.)
Main features of DNA-based immunization vectors. Azevedo V, et al. **Braz J Med Biol Res** 1999 Feb;32(2):147-53 (41 ref.)
DNA vaccines for viral diseases. Donnelly JJ, et al. **Braz J Med Biol Res** 1999 Feb;32(2):215-22 (25 ref.)
DNA encoding individual mycobacterial antigens protects mice against tuberculosis. Silva CL, et al. **Braz J Med Biol Res** 1999 Feb;32(2):231-4 (16 ref.)
DNA vaccines: a ray of hope. Tuteja R. **Crit Rev Biochem Mol Biol** 1999;34(1):1-24 (103 ref.)
DNA vaccines. Lai WC, et al. **Crit Rev Immunol** 1998; 18(5):449-84 (235 ref.)
Implications of sequencing bacterial genomes for pathogenesis and vaccine development. Saunders NJ, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):618-23 (56 ref.)
The gut as target organ for oral immunovaccination with allergen DNA: new hope for patients with anaphylactic reactions to food? Bischoff SC. **Gut** 1999 Jul;45(1):11-12 (7 ref.)
DNA vaccines: application to tuberculosis. Huygen K. **Int J Tuberc Lung Dis** 1998 Dec;2(12):971-8 (67 ref.)
Dendritic cells in genetic immunization. Takashima A, et al. **J Leukoc Biol** 1999 Aug;66(2):350-6 (78 ref.)
New approaches to the development of virus vaccines for veterinary use. Yamanouchi K, et al. **Rev Sci Tech** 1998 Dec;17(3):641-53 (61 ref.)
Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Simons JW, et al. **Semin Oncol** 1998 Dec;25(6):661-76 (59 ref.)
DNA-vaccines against hepatitis B and C viral infections: a brief overview. Irshad M. **Trop Gastroenterol** 1999 Apr-Jun;20(2):64-7 (30 ref.)
DNA/genetic vaccination (minireview). Kucerova L. **Viral Immunol** 1998;11(2):55-63 (52 ref.)
DNA-antiviral vaccines: new developments and approaches--a review. Giese M. **Virus Genes** 1998; 17(3):219-32 (86 ref.)
[Induction of immune responses by DNA vaccine] Takahashi H. **Uirusu** 1998 Dec;48(2):201-10 (33 ref.) **(Jpn)**
[Progress in developing viral polynucleotide (DNA) vaccines] Gendon IuZ. **Vopr Virusol** 1999 Jul-Aug; 44(4):148-54 (64 ref.) (Eng. Abstr.) **(Rus)**

VACCINES, DNA

ADMINISTRATION & DOSAGE

Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection. Costa F, et al. **Braz J Med Biol Res** 1999 Feb; 32(2):235-9 (25 ref.)

Immunological properties of gene vaccines delivered by different routes. Oliveira SC, et al. **Braz J Med Biol Res** 1999 Feb;32(2):207-14 (35 ref.)

Epicutaneous and transcutaneous immunization using DNA or proteins. Kaiserlian D, et al. **Eur J Dermatol** 1999 Apr-May;9(3):169-76 (35 ref.)

Delivery of DNA vaccines by attenuated intracellular bacteria. Dietrich G, et al. **Immunol Today** 1999 Jun; 20(6):251-3 (14 ref.)

Genetic vaccines. Haynes JR. **Infect Dis Clin North Am** 1999 Mar;13(1):11-26, v (114 ref.)

[DNA vaccines] Gendaszewska E. **Postepy Biochem** 1998; 44(2):117-24 (46 ref.) **(Pol)**

BIOSYNTHESIS

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. Liljeqvist S, et al. **J Biotechnol** 1999 Jul 30; 73(1):1-33 (365 ref.)

CHEMICAL SYNTHESIS

DNA vaccines: vector design, delivery, and antigen presentation. Feltquate DM. **J Cell Biochem Suppl** 1998; 30-31:304-11 (39 ref.)

GENETICS

DNA vaccines: vector design, delivery, and antigen presentation. Feltquate DM. **J Cell Biochem Suppl** 1998; 30-31:304-11 (39 ref.)

Roles of Langerhans cells in genetic immunization. Morita A, et al. **J Dermatol Sci** 1998 May;20(1):39-52 (145 ref.)

IMMUNOLOGY

DNA vaccines. Mechanisms for generation of immune responses. Liu MA, et al. **Adv Exp Med Biol** 1998; 452:187-91 (20 ref.)

The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Sasaki S, et al. **Anticancer Res** 1998 Sep-Oct; 18(5D):3907-15 (77 ref.)

Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Schirmbeck R, et al. **Biol Chem** 1999 Mar; 380(3):285-91 (90 ref.)

Immunological properties of gene vaccines delivered by different routes. Oliveira SC, et al. **Braz J Med Biol Res** 1999 Feb;32(2):207-14 (35 ref.)

Immune responses to DNA vaccines. Kowalczyk DW, et al. **Cell Mol Life Sci** 1999 May;55(5):751-70 (223 ref.)

Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Webster RG. **Clin Infect Dis** 1999 Feb;28(2):225-9 (26 ref.)

Epicutaneous and transcutaneous immunization using DNA or proteins. Kaiserlian D, et al. **Eur J Dermatol** 1999 Apr-May;9(3):169-76 (35 ref.)

Modulating the immune response to genetic immunization. Cohen AD, et al. **FASEB J** 1998 Dec;12(15):1611-26 (110 ref.)

Immune recognition of foreign DNA: a cure for bioterrorism? Klinman DM, et al. **Immunity** 1999 Aug;11(2):123-9 (93 ref.)

HIV-1 DNA vaccines. Fomsgaard A. **Immunol Lett** 1999 Jan;65(1-2):127-31 (36 ref.)

Genetic vaccines. Haynes JR. **Infect Dis Clin North Am** 1999 Mar;13(1):11-26, v (114 ref.)

Immunoglobulin variable regions as idiotype vaccines. Hefty PS, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):27-37, vi (57 ref.)

Roles of Langerhans cells in genetic immunization. Morita A, et al. **J Dermatol Sci** 1998 May;20(1):39-52 (145 ref.)

Genes that induce immunity--DNA vaccines. Sasaki S, et al. **Microbiol Immunol** 1999;43(3):191-200 (85 ref.)

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Davis HL. **Mt Sinai J Med** 1999 Mar;66(2):84-90 (48 ref.)

DNA vaccination against multiple myeloma. Stevenson FK, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):38-42 (10 ref.)

Perspective: edible vaccines--a concept coming of age. Mor TS, et al. **Trends Microbiol** 1998 Nov;6(11):449-53 (36 ref.)

DNA immunization: mechanistic studies. Whitton JL, et al. **Vaccine** 1999 Mar 26;17(13-14):1612-9 (47 ref.)

[Present status of basic studies and development of DNA vaccines] Kurane I. **Nippon Rinsho** 1999 Apr;57(4):975-81 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

DNA vaccines. Donnelly JJ, et al. **Dev Biol Stand** 1998; 95:43-53 (69 ref.)

Polynucleotide vaccines: potential for inducing immunity in animals. Babiuk LA, et al. **J Biotechnol** 1999 Aug 20; 73(2-3):131-40 (61 ref.)

Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. Beard C, et al. **J Biotechnol** 1999 Aug 20;73(2-3):243-9 (33 ref.)

Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. Berlyn KA, et al. **J Biotechnol** 1999 Aug 20;73(2-3):155-79 (78 ref.)

Strategies for improving responses to DNA vaccines. Boyle JS, et al. **Mol Med** 1999 Jan;5(1):1-8 (37 ref.)

Targeting the skin for genetic immunization. Falo LD Jr. **Proc Assoc Am Physicians** 1999 May-Jun;111(3):211-9 (55 ref.)

STANDARDS

Safety of biological products prepared from mammalian cell culture. DNA. **Dev Biol Stand** 1998;93:136-8 (0 ref.)

SUPPLY & DISTRIBUTION

[Promising experiments with DNA vaccine against HIV. A complete eradication of the virus is a formidable task] Wahren B. **Lakartidningen** 1999 Feb 17;96(7):722-5 (20 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Alarcon JB, et al. **Adv Parasitol** 1999;42:343-410 (400 ref.)

DNA vaccine strategies for hepatitis C. Inchauspé G. **J Hepatol** 1999 Feb;30(2):339-46 (44 ref.)

Out on the farm with DNA vaccines. Beard CW, et al. **Nat Biotechnol** 1998 Dec;16(13):1325-8 (37 ref.)

[Vaccination and gene therapy with naked DNA] Mölling K. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):681-3 (9 ref.) (Eng. Abstr.) **(Ger)**

VACCINES, INACTIVATED

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447-61 (60 ref.)

ADVERSE EFFECTS

Immunisation of patients with systemic lupus erythematosus: the current state of play. Ioannou Y, et al. **Lupus** 1999; 8(7):497-501 (51 ref.)

VACCINES, KILLED see **VACCINES, INACTIVATED**

VACCINES, NEOPLASM see **CANCER VACCINES**

VACCINES, RECOMBINANT see **VACCINES, SYNTHETIC**

VACCINES, RECOMBINANT DNA see **VACCINES, DNA**

VACCINES, SYNTHETIC

Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Arakawa T, et al. **Adv Exp Med Biol** 1999;464:161-78 (70 ref.)

Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Mackowiak M, et al. **Adv Vet Med** 1999;41:571-83 (18 ref.)

Foot-and-mouth disease and beyond: vaccine design, past, present and future. Brown F. **Arch Virol Suppl** 1999; 15:179-88 (43 ref.)

New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles. Roy P, et al. **Arch Virol Suppl** 1998;14:177-202 (41 ref.)

MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Cunha-Neto E. **Braz J Med Biol Res** 1999 Feb; 32(2):199-205 (45 ref.)

Genetically modified tumour vaccines--where we are today. Nawrocki S, et al. **Cancer Treat Rev** 1999 Feb;25(1):29-46 (112 ref.)

Cowpea mosaic virus-based vaccines. Lomonossoff GP, et al. **Curr Top Microbiol Immunol** 1999;240:177-89 (25 ref.)

Transgenic plants as edible vaccines. Richter L, et al. **Curr Top Microbiol Immunol** 1999;240:159-76 (60 ref.)

Plant viral vectors based on tobamoviruses. Yusibov V, et al. **Curr Top Microbiol Immunol** 1999;240:81-94 (60 ref.)

The optimization of helper T lymphocyte (HTL) function in vaccine development. Alexander J, et al. **Immunol Res** 1998;18(2):79-92 (145 ref.)

Synthetic peptides: a modern approach to vaccination. Sood A, et al. **Indian J Exp Biol** 1998 Sep;36(9):849-61 (81 ref.)

Arthropod vaccines. Lee R, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):209-26 (125 ref.)

Progress on developing a recombinant coccidiosis vaccine. Jenkins MC. **Int J Parasitol** 1998 Jul;28(7):1111-9 (105 ref.)

Progress in recombinant vaccine development against coccidiosis. A review and prospects into the next millennium. Vermeulen AN. **Int J Parasitol** 1998 Jul; 28(7):1121-30 (39 ref.)

Malaria vaccines [comment] Holder AA. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1167-9 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1615-20.

[Progress in the study of Helicobacter pylori vaccines] Pan Q. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):492-3 (7 ref.) **(Chi)**

[Genetics of immune response and vaccines of tomorrow] Khaitov RM. **Vestn Ross Akad Med Nauk** 1999;(4):9-18 (56 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Extended recombinant bacterial ghost system. Lubitz W, et al. **J Biotechnol** 1999 Aug 20;73(2-3):261-73 (34 ref.)

ADVERSE EFFECTS

[A case of intense cytolysis following the administration of a hepatitis B vaccine (letter)] Lasheras Carbajo MD, et al. **Rev Clin Esp** 1999 Jan;199(1):49-50 (11 ref.) **(Spa)**

BIOSYNTHESIS

Plant expression systems for the production of vaccines. Ma JK, et al. **Curr Top Microbiol Immunol** 1999;236:275-92 (45 ref.)

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. Liljeqvist S, et al. **J Biotechnol** 1999 Jul 30; 73(1):1-33 (365 ref.)

IMMUNOLOGY

Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review. Russell MW, et al. **Am J Reprod Immunol** 1999 Jul;42(1):58-63 (42 ref.)

The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Murray K, et al. **Biol Chem** 1999 Mar;380(3):277-83 (37 ref.)

Recombinant viruses as vectors for mucosal immunity. Morrow CD, et al. **Curr Top Microbiol Immunol** 1999; 236:255-73 (49 ref.)

Live antigen carriers as tools for improved anti-tuberculosis vaccines. Hess J, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):165-73 (38 ref.)

Vaccination as a modality to prevent Lyme disease. A status report. Wormser GP. **Infect Dis Clin North Am** 1999 Mar; 13(1):135-48, vii (65 ref.)

Prospects for vaccines of helminth parasites of grazing ruminants. Smith WD. **Int J Parasitol** 1999 Jan;29(1):17-24 (54 ref.)

New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Eko FO, et al. **Vaccine** 1999 Mar 26;17(13-14):1643-9 (24 ref.)

STANDARDS

[The prospects for improving chemical cholera vaccines] Markov Elu, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug;(4):91-6 (73 ref.) **(Rus)**

THERAPEUTIC USE

Developing recombinant and synthetic vaccines for the treatment of melanoma. Restifo NP, et al. **Curr Opin Oncol** 1999 Jan;11(1):50-7 (81 ref.)

Tick paralysis: development of a vaccine. Masina S, et al. **Int J Parasitol** 1999 Apr;29(4):535-41 (38 ref.)

Mutated Ras peptides as vaccines in immunotherapy of cancer. Gjertsen MK, et al. **Vox Sang** 1998;74 Suppl 2:489-95 (49 ref.)

VACCINES, TUMOR see **CANCER VACCINES**

VACCINIA

IMMUNOLOGY

Immune modulation by proteins secreted from cells infected by vaccinia virus. Smith GL, et al. **Arch Virol Suppl** 1999; 15:111-29 (56 ref.)

[Vaccinia virus and its application in molecular biology and immunology] Kmieciak D. **Postepy Biochem** 1998; 44(3):220-8 (103 ref.) **(Pol)**

VIROLOGY

[Vaccinia virus and its application in molecular biology and immunology] Kmieciak D. **Postepy Biochem** 1998; 44(3):220-8 (103 ref.) **(Pol)**

VACCINIA VIRUS

ENZYMOLOGY

Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme. Shuman S. **Biochim Biophys Acta** 1998 Oct 1;1400(1-3):321-37 (68 ref.)

IMMUNOLOGY

Vaccinia virus immune evasion. Smith GL. **Immunol Lett** 1999 Jan;65(1-2):55-62 (43 ref.)

METABOLISM

Immune modulation by proteins secreted from cells infected by vaccinia virus. Smith GL, et al. **Arch Virol Suppl** 1999; 15:111-29 (56 ref.)

PHYSIOLOGY

Extracellular enveloped vaccinia virus. Entry, egress, and

evasion. Smith GL, et al. **Adv Exp Med Biol** 1998; 440:395–414 (87 ref.)
[Vaccinia virus and its application in molecular biology and immunology] Kmieciak D. **Postepy Biochem** 1998; 44(3):220–8 (103 ref.) **(Pol)**

VACUOLATING AGENT see **POLYOMAVIRUS MACACAE**

VACUOLES

ENZYMOLOGY

Structure, function and regulation of the vacuolar (H+)-ATPases. Forgac M. **FEBS Lett** 1998 Dec 4; 440(3):258–63 (106 ref.)
Vacuolar and plasma membrane proton-adenosinetriphosphatases. Nelson N, et al. **Physiol Rev** 1999 Apr;79(2):361–85 (233 ref.)

METABOLISM

Multiple sorting pathways between the late Golgi and the vacuole in yeast. Conibear E, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):211–30 (135 ref.)
Delivery of proteins and organelles to the vacuole from the cytoplasm. Scott SV, et al. **Curr Opin Cell Biol** 1998 Aug; 10(4):523–9 (53 ref.)

PARASITOLOGY

The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Antoine JC, et al. **Trends Microbiol** 1998 Oct;6(10):392–401 (46 ref.)

PHYSIOLOGY

Structure and function of the parasitophorous vacuole in Eimeria species. Entzeroth R, et al. **Int J Parasitol** 1998 Jul;28(7):1015–8 (34 ref.)
Novel pathways, membrane coats and PI kinase regulation in yeast lysosomal trafficking. Burd CG, et al. **Semin Cell Dev Biol** 1998 Oct;9(5):527–33 (77 ref.)

ULTRASTRUCTURE

Ionic channels of the vacuolar membrane of higher plants. Tikhonova LI. **Membr Cell Biol** 1998;12(3):301–18 (117 ref.)
ECL cell morphology [see comments] Chen D, et al. **Yale J Biol Med** 1998 May-Aug;71(3-4):217–31 (39 ref.) Comment in: Yale J Biol Med 1998 May-Aug;71(3-4):163–71.

VAGINA

see related

COLPOSCOPY

Douching: a problem for adolescent girls and young women. Merchant JS, et al. **Arch Pediatr Adolesc Med** 1999 Aug; 153(8):834–7 (47 ref.)
Transvaginal access heralds the end of standard diagnostic laparoscopy in infertility. Brosens I, et al. **Hum Reprod** 1998 Jul;13(7):1762–3 (19 ref.)

ABNORMALITIES

Surgical management of vaginal agenesis. Templeman CL, et al. **Obstet Gynecol Surv** 1999 Sep;54(9):583–91 (41 ref.)
Gartner's duct cyst with unilateral renal dysplasia presenting as an introital mass in a new born. Holmes M, et al. **Pediatr Surg Int** 1999;15(3-4):277–9 (12 ref.)
Bladder agenesis with urometrocolpos. Kasat LS, et al. **Pediatr Surg Int** 1999 Jul;15(5-6):415–6 (9 ref.)
Vaginal reconstruction. Hensle TW, et al. **Urol Clin North Am** 1999 Feb;26(1):39–47, vii (39 ref.)
[Anomalies of Müllerian duct fusion. A report of 3 cases of uterus didelphys associated with a double vagina and ipsilateral renal agenesis] Ruibal Francisco JL, et al. **An Esp Pediatr** 1999 Jun;50(6):616–8 (14 ref.) **(Spa)**
[Congenital absence of the vagina. Mayer-Rokitansky-Kuster-Hauser syndrome. Presentation of a case and review of the literature] Cabra Zurita R, et al. **Ginecol Obstet Mex** 1998 Sep;66:354–7 (19 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

Clinical application of the vaginal maturation index. McEndree B. **Nurse Pract** 1999 Sep;24(9):48, 51–2, 55–6 (31 ref.)

INJURIES

Impalement and anorectal injuries in childhood: a retrospective study of 12 cases. Beiler HA, et al. **J Pediatr Surg** 1998 Aug;33(8):1287–91 (11 ref.)

INNERVATION

[Total excision of the mesorectum and preservation of the genitourinary innervation in surgery of rectal cancer] Tiret E, et al. **Ann Chir** 1999;53(6):507–14 (16 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Cicinelli E, et al. **Hum Reprod Update** 1999 Jul-Aug; 5(4):365–72 (43 ref.)

PATHOLOGY

An anatomical classification--a new paradigm for management of female lower urinary tract dysfunction. Petros PP, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):87–94 (26 ref.)

PHYSIOLOGY

Clinical application of the vaginal maturation index. McEndree B. **Nurse Pract** 1999 Sep;24(9):48, 51–2, 55–6 (31 ref.)

PHYSIOPATHOLOGY

An anatomical classification--a new paradigm for management of female lower urinary tract dysfunction. Petros PP, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):87–94 (26 ref.)

SECRETION

A vaginal fluid simulant. Owen DH, et al. **Contraception** 1999 Feb;59(2):91–5 (43 ref.)

SURGERY

Long-term outcomes and changing attitudes to intersexuality. Schober JM. **BJU Int** 1999 Apr;83 Suppl 3:39–50 (106 ref.)
Surgical management of vaginal agenesis. Templeman CL, et al. **Obstet Gynecol Surv** 1999 Sep;54(9):583–91 (41 ref.)
Vaginal reconstruction. Hensle TW, et al. **Urol Clin North Am** 1999 Feb;26(1):39–47, vii (39 ref.)
[Vaginal reconstruction in girls and young adults] Hensle TW, et al. **Arch Esp Urol** 1998 Jul-Aug;51(6):527–36 (24 ref.) (Eng. Abstr.) **(Spa)**

VAGINAL BIRTH AFTER CESAREAN

Evidence based case report: use of prostaglandins to induce labour in women with a caesarean section scar. Vause S, et al. **BMJ** 1999 Apr 17;318(7190):1056–8 (37 ref.)
ACOG practice bulletin. Vaginal birth after previous cesarean delivery. Number 2, October 1998. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Feb;64(2):201–8 (71 ref.)
Vaginal birth after cesarean delivery. Mastrobattista JM. **Obstet Gynecol Clin North Am** 1999 Jun;26(2):295–304 (34 ref.)
[2 or more cesarean sections--elective repeat cesarean or vaginal delivery?] Faridi A, et al. **Z Geburtshilfe Neonatol** 1999 Jan-Feb;203(1):8–14 (44 ref.) (Eng. Abstr.) **(Ger)**

VAGINAL DISCHARGE

ETIOLOGY

Syndromic management of sexually transmitted diseases. Part 2--The management of genital discharge. Latif AS. **Cent Afr J Med** 1998 Sep;44(9):236–41 (14 ref.)

MICROBIOLOGY

The laboratory investigation of vaginal discharge. Macsween KF, et al. **J Clin Pathol** 1998 Aug;51(8):564–7 (3 ref.)

VAGINAL DISEASES

DIAGNOSIS

[Disseminated pelvic endometriosis with hyperplastic and metaplastic changes. A case report] Mainkhard K, et al. **Akush Ginekol (Sofiia)** 1998;37(2):52–5 (8 ref.) **(Bul)**
[Bacterial vaginosis] Kubota T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):18–20 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

Epidemiology of genital human papillomavirus. Tortolero-Luna G. **Hematol Oncol Clin North Am** 1999 Feb;13(1):245–57, x (55 ref.)

PHYSIOPATHOLOGY

Pelvic organ prolapse: anterior, superior, and posterior vaginal segment defects. Shull BL. **Am J Obstet Gynecol** 1999 Jul;181(1):6–11 (25 ref.)
[Vaginal infections and sexually transmitted diseases] van den Brûle F. **Rev Med Liege** 1999 Apr;54(4):296–302 (25 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Pelvic organ prolapse: anterior, superior, and posterior vaginal segment defects. Shull BL. **Am J Obstet Gynecol** 1999 Jul;181(1):6–11 (25 ref.)

THERAPY

Evidence based case report: chlamydia infection in general practice. Hicks NR, et al. **BMJ** 1999 Mar 20; 318(7186):790–2 (10 ref.)
Management of radiation injuries of vulva and vagina. Fraunholz IB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:90–2 (29 ref.)

VIROLOGY

Epidemiology of genital human papillomavirus. Tortolero-Luna G. **Hematol Oncol Clin North Am** 1999 Feb;13(1):245–57, x (55 ref.)

VAGINAL NEOPLASMS

DIAGNOSIS

Choriocarcinoma co-existent with an intact pregnancy: case report and review of the literature. Steigrad SJ, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):197–203 (30 ref.)

ETIOLOGY

[Extrapleural mesothelioma] Lalowicz I. **Pol Merkuriusz Lek** 1999 Jan;6(31):47–9 (31 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

The role of the clinical psychologist in gynecological cancer. Rieger E, et al. **J Psychosom Res** 1998 Sep;45(3):201–14 (88 ref.)

SECONDARY

Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy. Piura B, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):57–61 (22 ref.)

SURGERY

[Update on reconstructive surgery in cancer] Bertrand P, et al. **Bull Cancer** 1999 Jan;86(1):65–9 (18 ref.) **(Fre)**
[Laser surgery in the conservative management of vaginal intraepithelial neoplasms] Sopracordevole F, et al. **Minerva Ginecol** 1998 Dec;50(12):507–12 (38 ref.) (Eng. Abstr.) **(Ita)**

VAGINAL PROLAPSE see **UTERINE PROLAPSE**

VAGINAL SMEARS

Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening and HPV testing. Sigurdsson K. **Acta Obstet Gynecol Scand** 1999 Jul; 78(6):467–77 (126 ref.)
HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. Apgar BS, et al. **Am Fam Physician** 1999 May 15;59(10):2794–801 (29 ref.)
Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to papanicolaou smear in the triage of women with cervical cytologic abnormalities. Franco EL, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):382–6 (10 ref.)
The management dilemma of the mildly abnormal smear: fact or fiction? Jones MH. **Ann Acad Med Singapore** 1998 Sep; 27(5):666–70 (30 ref.)
Training in cervical cytology, past, present and future. Denton KJ. **Cytopathology** 1999 Jun;10(3):147–52 (6 ref.)
A cytologist's view of China--Citizen Ambassador Program Cytopathology Delegation to the People's Republic of China, February 1997. Waddell CA. **Cytopathology** 1999 Jun;10(3):201–5 (7 ref.)
Cervical cancer: developments in screening and evaluation of the abnormal Pap smear. Walsh JM. **West J Med** 1998 Nov;169(5):304–10 (60 ref.)
[Management of a low grade smear] Baldauf JJ, et al. **Contracept Fertil Sex** 1999 Apr;27(4):269–74 (46 ref.) **(Fre)**

CLASSIFICATION

The Bethesda system and evaluation of abnormal pap smears. Nguyen HN, et al. **Semin Surg Oncol** 1999 Apr-May; 16(3):217–21 (21 ref.)
[Management of a high-grade cervical-vaginal smear] Bilhaut JP. **Contracept Fertil Sex** 1999 Feb;27(2):114–7 (21 ref.) **(Fre)**

ECONOMICS

Automated Papanicolaou smear analysis as a screening tool for female lower genital tract malignancies. Ku NN. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):41–3 (6 ref.)
The cost-effectiveness of cervical screening [see comments] Smith WJ. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):83–5 (23 ref.) Comment in: Curr Opin Obstet Gynecol 1999 Feb;11(1):81.

METHODS

Pap smears: screening, interpretation, treatment. Perlman SE. **Adolesc Med** 1999 Jun;10(2):243–54, vi (65 ref.)

VAGINAL SMEARS

Clinical application of the vaginal maturation index. McEndree B. **Nurse Pract** 1999 Sep;24(9):48, 51-2, 55-6 (31 ref.)

STANDARDS

Automated Papanicolaou smear analysis as a screening tool for female lower genital tract malignancies. Ku NN. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):41-3 (6 ref.)

Bridging the knowledge gap and communicating uncertainties for informed consent in cervical cytology screening: we need unbiased information and a culture change. Anderson CM, et al. **Cytopathology** 1999 Aug; 10(4):221-8 (28 ref.)

The pathologic obsession with turnaround time in gynecologic cytology: is it warranted? [editorial] Yu GH, et al. **Diagn Cytopathol** 1998 Nov;19(5):321-2 (5 ref.)

[Cervical-vaginal smears: an unpopular test!] Gompel C. **Presse Med** 1998 Jun 6;27(20):971-3 (33 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

[How technology and vaccination have changed the Pap test] Bondi A, et al. **Pathologica** 1999 Feb;91(1):36-41 (28 ref.) **(Ita)**

VAGINISMUS see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

VAGINITIS

Vaginitis in the adolescent patient. Nyirjesy P. **Pediatr Clin North Am** 1999 Aug;46(4):733-45, xi (43 ref.)

DIAGNOSIS

Current evaluation and management of vulvovaginitis. Haefner HK. **Clin Obstet Gynecol** 1999 Jun;42(2):184-95 (21 ref.)

DRUG THERAPY

The "prescription-to-OTC switch" movement. Its effects on antifungal vaginitis preparations. Lipsky MS, et al. **Arch Fam Med** 1999 Jul-Aug;8(4):297-300 (27 ref.)

MICROBIOLOGY

The "prescription-to-OTC switch" movement. Its effects on antifungal vaginitis preparations. Lipsky MS, et al. **Arch Fam Med** 1999 Jul-Aug;8(4):297-300 (27 ref.)

Clinical and microbiological aspects of vaginitis. Nagesha CN, et al. **Indian J Med Sci** 1998 Nov;52(11):526-32 (40 ref.)

THERAPY

Current evaluation and management of vulvovaginitis. Haefner HK. **Clin Obstet Gynecol** 1999 Jun;42(2):184-95 (21 ref.)

VAGINITIS, BACTERIAL see **VAGINOSIS, BACTERIAL**

VAGINITIS, MONILIAL see **CANDIDIASIS, VULVOVAGINAL**

VAGINITIS, NONSPECIFIC see **VAGINOSIS, BACTERIAL**

VAGINOSIS, BACTERIAL

[Bacterial vaginitis] Kawabata M. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):209-11 (5 ref.) **(Jpn)**

COMPLICATIONS

Perinatal infectious disease. Introduction. Duff P. **Semin Perinatol** 1998 Aug;22(4):241 (78 ref.)

DIAGNOSIS

The laboratory investigation of vaginal discharge. Macsween KF, et al. **J Clin Pathol** 1998 Aug;51(8):564-7 (3 ref.)

Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Dammann O, et al. **Semin Pediatr Neurol** 1998 Sep;5(3):190-201 (116 ref.)

DRUG THERAPY

A review of the role of trials of the use of antibiotics in women with preterm labor and intact membranes. Chaim W, et al. **Arch Gynecol Obstet** 1998;261(4):167-72 (21 ref.)

Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Joesoef MR, et al. **Clin Infect Dis** 1999 Jan;28 Suppl 1:S57-65 (60 ref.)

VAGOTOMY

Gastrointestinal complications postthoracotomy and postvagotomy. Kokoska ER, et al. **Chest Surg Clin N Am** 1998 Aug;8(3):645-61 (47 ref.)

METHODS

[Organ-salvaging surgeries in combination with vagotomy for perforative pyloroduodenal ulcer] Chislenko IV. **Klin Khir** 1998;(5):40-2 (25 ref.) **(Rus)**

VAGUS NERVE

see related
VAGOTOMY

Experience with vagus nerve stimulation for intractable epilepsy: some questions and answers. Amar AP, et al. **Neurol Med Chir (Tokyo)** 1999 Jul;39(7):489-95 (28 ref.)

Thoracoscopic resection of intrathoracic vagus neurofibroma. Yamagishi T, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):122-4 (8 ref.)

PHYSIOLOGY

Vagus nerve in fever. Recent developments. Romanovsky AA, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:298-9 (9 ref.)

Dynamic nonlinear vago-sympathetic interaction in regulating heart rate. Sunagawa K, et al. **Heart Vessels** 1998;13(4):157-74 (49 ref.)

An institutional experience with cervical vagus nerve trunk stimulation for medically refractory epilepsy: rationale, technique, and outcome. Amar AP, et al. **Neurosurgery** 1998 Dec;43(6):1265-76; discussion 1276-80 (59 ref.)

[Paraventriculovagal path of carbohydrate homeostasis regulation--a perspective biological model in studies on neuroimmunoendocrine interactions] Akmaev IG. **Biull Eksp Biol Med** 1999 Feb;127(2):124-8 (35 ref.) **(Rus)**

PHYSIOPATHOLOGY

How to study sympatho-vagal balance in arterial hypertension and the effect of antihypertensive drugs? Presciuttini B, et al. **Acta Cardiol** 1998;53(3):143-52 (67 ref.)

Vagal nerve stimulator: a new approach to medically refractory epilepsy. FineSmith RB, et al. **N J Med** 1999 Jun;96(6):37-40 (21 ref.)

VALIDITY OF RESULTS see **REPRODUCIBILITY OF RESULTS**

VALINE

ANALOGS & DERIVATIVES

Herpesviruses--a rationale for antiviral treatment in multiple sclerosis. Bergström T. **Antiviral Res** 1999 Feb;41(1):1-19 (160 ref.)

Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Julius S. **Cardiology** 1999;91 Suppl 1:8-13 (47 ref.)

Clinical advantage of valsartan. McInnes GT. **Cardiology** 1999;91 Suppl 1:14-8 (34 ref.)

Valsartan/hydrochlorothiazide. Langtry HD, et al. **Drugs** 1999 May;57(5):751-5; discussion 756-8 (9 ref.)

Angiotensin II antagonism in clinical practice: experience with valsartan. McInnes GT. **J Cardiovasc Pharmacol** 1999; 33 Suppl 1:S29-32; discussion S41-3 (14 ref.)

Valsartan and the kidney: present and future. Mann JF. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S37-40; discussion S41-3 (19 ref.)

[Valacyclovir] Biernat-Sudolska M. **Przegl Lek** 1998; 55(11):596-8 (22 ref.) (Eng. Abstr.) **(Pol)**

[New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan)] Ivleva AIa. **Ter Arkh** 1998;70(9):85-8 (26 ref.) **(Rus)**

VALPROIC ACID

ADMINISTRATION & DOSAGE

[Therapy of bipolar affective illnesses with valproate. A review of the literature] Retzow A, et al. **Psychiatr Prax** 1998 Jul;25(4):163-71 (59 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Valproic acid use in psychiatry: issues in treating women of reproductive age. Kennedy D, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):223-8 (49 ref.)

[Recommendations for blood studies and clinical monitoring in early detection of valproate-associated liver failure. Results of a consensus conferences 9 May - 11 May 1997 in Berlin] König SA, et al. **Nervenarzt** 1998 Oct; 69(10):835-40 (32 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Löscher W. **Prog Neurobiol** 1999 May;58(1):31-59 (237 ref.)

PHARMACOLOGY

Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji HK, et al. **J Clin Psychiatry** 1999;60 Suppl 2:27-39; discussion 40-1, 113-6 (138 ref.)

THERAPEUTIC USE

Valproate in the treatment of epilepsy in people with intellectual disability. Friis ML. **J Intellect Disabil Res** 1998 Dec;42 Suppl 1:32-5 (26 ref.)

Divalproex sodium--review of prophylactic migraine efficacy, safety and dosage, with recommendations. Landy SH, et al. **Tenn Med** 1999 Apr;92(4):135-6 (19 ref.)

[Current trends in the therapeutic use of thymic regulators] Dardennes R, et al. **Presse Med** 1998 Dec 19;27(40):2157-63 (74 ref.) (Eng. Abstr.) **(Fre)**

[Valproic acid in prophylactic treatment of migraine] Arnold G, et al. **Nervenarzt** 1998 Oct;69(10):913-8 (28 ref.) (Eng. Abstr.) **(Ger)**

VALSALVA'S MANEUVER

Atraumatic pneumocephalus: a case report and review of the literature. Babl FE, et al. **Pediatr Emerg Care** 1999 Apr;15(2):106-9 (30 ref.)

VALVES, SURGICAL see **SURGICAL INSTRUMENTS**

VAN BOGAERT'S LEUKOENCEPHALITIS see **SUBACUTE SCLEROSING PANENCEPHALITIS**

VANADIUM

Vanadium and diabetes. Thompson KH. **Biofactors** 1999; 10(1):43-51 (86 ref.)

METABOLISM

[Insulin-like effect of vanadium compounds] Kiersztan A. **Postepy Biochem** 1998;44(4):275-82 (103 ref.) **(Pol)**

PHARMACOLOGY

Vanadium and diabetes. Poucheret P, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):73-80 (67 ref.)

From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling. Morinville A, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):452-60 (89 ref.)

[Insulin-like effect of vanadium compounds] Kiersztan A. **Postepy Biochem** 1998;44(4):275-82 (103 ref.) **(Pol)**

THERAPEUTIC USE

Vanadium: a review of its potential role in the fight against diabetes. Badmaev V, et al. **J Altern Complement Med** 1999 Jun;5(3):273-91 (188 ref.)

TOXICITY

Vanadium. Barceloux DG. **J Toxicol Clin Toxicol** 1999; 37(2):265-78 (101 ref.)

VANADIUM COMPOUNDS

PHARMACOLOGY

Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Fantus IG, et al. **Mol Cell Biochem** 1998 May;182(1-2):109-19 (89 ref.)

From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling. Morinville A, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):452-60 (89 ref.)

VANCOMYCIN

Hospital wards spreading vancomycin-resistant enterococci to intensive care units: returning coals to Newcastle [editorial; comment] Farr BM. **Crit Care Med** 1998 Dec; 26(12):1942-3 (14 ref.) Comment on: Crit Care Med 1998 Dec;26(12):2001-4.

[Emergence of hetero-VRSA strains in Japanese hospitals and its countermeasure] Inaba Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2699-705 (21 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Nousari HC, et al. **Medicine (Baltimore)** 1999 Jan;78(1):1-8 (34 ref.)

Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Smith PF, et al. **Pharmacotherapy** 1999 Feb;19(2):240-4 (34 ref.)

ANTAGONISTS & INHIBITORS

Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. Nelson RR. **J Hosp Infect** 1999 Aug;42(4):275-82 (70 ref.)

BIOSYNTHESIS

VanX, a bacterial D-alanyl-D-alanine dipeptidase: resistance, immunity, or survival function? Lessard IA, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11028-32 (33 ref.)

BLOOD

Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Somerville AL, et al. **Pharmacotherapy** 1999 Jun;19(6):702–7 (28 ref.)

PHARMACOLOGY

The threat of vancomycin resistance. Perl TM. **Am J Med** 1999 May 3;106(5A):26S–37S; discussion 48S–52S (67 ref.)
Vancomycin resistant enterococci. Holder IA, et al. **Burns** 1998 Aug;24(5):389–91 (27 ref.)
Aminoglycosides, vancomycin, and quinolones. McGowan JP. **Cancer Invest** 1998;16(7):528–37 (91 ref.)
Enterococci and vancomycin resistance. French GL. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S75–83 (105 ref.)
Reduced susceptibility of Staphylococcus aureus to vancomycin--a review of current knowledge. Paterson DL. **Commun Dis Intell** 1999 Mar 18;23(3):69–73 (30 ref.)
Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Linden PK, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):113–20 (50 ref.)
Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Wegener HC, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):329–35 (50 ref.)
Symposium on antimicrobial agents--Part XII. Vancomycin. Wilhelm MP, et al. **Mayo Clin Proc** 1999 Sep;74(9):928–35 (87 ref.)
Vancomycin-resistant Enterococcus. Bensoussan R, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1233–8 (63 ref.)
Vancomycin-resistant enterococci: implications for surgeons. Fleenor-Ford A, et al. **Surgery** 1999 Feb;125(2):121–5 (10 ref.)
Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. MacGowan AP. **Ther Drug Monit** 1998 Oct;20(5):473–7 (59 ref.)
[Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)] Kuwahara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):182–5 (15 ref.) **(Jpn)**

THERAPEUTIC USE

Spread of vancomycin-resistant enterococci: why did it happen in the United States? Martone WJ. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):539–45 (72 ref.)
Infective endocarditis and glycopeptides. Pittet D, et al. **J Infect** 1998 Sep;37(2):127–35 (50 ref.)
Symposium on antimicrobial agents--Part XII. Vancomycin. Wilhelm MP, et al. **Mayo Clin Proc** 1999 Sep;74(9):928–35 (87 ref.)
Vancomycin-resistant enterococcal infections in Korea. Kim JM, et al. **Yonsei Med J** 1998 Dec;39(6):562–8 (32 ref.)

VAPORIZATION, LASER see **LASER SURGERY**

VAPORIZERS see **NEBULIZERS AND VAPORIZERS**

VARIABLE NUMBER OF TANDEM REPEATS see **MINISATELLITE REPEATS**

VARIABLE REGION, IG see **IMMUNOGLOBULIN VARIABLE REGION**

VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA

METABOLISM

Surface coats and secretory trafficking in African trypanosomes. Bangs JD. **Curr Opin Microbiol** 1998 Aug; 1(4):448–54 (63 ref.)

VARIATION, ANTIGENIC see **ANTIGENIC VARIATION**

VARIATION (GENETICS)

Naturally occurring variants of hepatitis B virus. Günther S, et al. **Adv Virus Res** 1999;52:25–137 (508 ref.)
Genetic variation of HIV type 1: relevance of interclade variation to vaccine development. van der Groen G, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S211–21 (77 ref.)
Paraoxonase genes and disease. Hegele RA. **Ann Med** 1999 Jun;31(3):217–24 (48 ref.)
5-HT4 receptors: cloning and expression of new splice variants. Claeysen S, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:49–56 (25 ref.)
Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role. Göthert M, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:26–30 (20 ref.)
Serotonin receptor variants in disease: new therapeutic opportunities? Peroutka SJ. **Ann N Y Acad Sci** 1998 Dec 15;861:16–25 (21 ref.)
Origin, genetic diversity, and genome structure of the domestic dog. Wayne RK, et al. **Bioessays** 1999 Mar; 21(3):247–57 (71 ref.)
Diversity of prokaryotic chromosomal proteins and the origin of the nucleosome. Sandman K, et al. **Cell Mol Life Sci** 1998 Dec;54(12):1350–64 (145 ref.)
Biodiversity and bioseparation of HIV-1 envelope glycoproteins. Shao Y, et al. **Crit Rev Oncog** 1999; 10(1–2):1–16 (50 ref.)
Sequence variation: looking for effects of genetic linkage. Charlesworth D, et al. **Curr Biol** 1998 Sep 10;8(18):R658–61 (15 ref.)
The value of microbial diversity. Hunter-Cevera JC. **Curr Opin Microbiol** 1998 Jun;1(3):278–85 (41 ref.)
Functional and evolutionary implications of natural variation in clock genes. Costa R, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):659–64 (58 ref.)
Polymerase chain reaction-single strand conformation polymorphism or how to detect reliably and efficiently each sequence variation in many samples and many genes. Jaeckel S, et al. **Electrophoresis** 1998 Dec;19(18):3055–61 (68 ref.)
Two-dimensional gene scanning: exploring human genetic variability. Vijg J, et al. **Electrophoresis** 1999 Jun; 20(6):1239–49 (31 ref.)
Structural roles of acetylcholinesterase variants in biology and pathology. Grisaru D, et al. **Eur J Biochem** 1999 Sep; 264(3):672–86 (161 ref.)
Diversity of extremely halophilic bacteria. Kamekura M. **Extremophiles** 1998 Aug;2(3):289–95 (47 ref.)
The modulation of DNA content: proximate causes and ultimate consequences. Gregory TR, et al. **Genome Res** 1999 Apr;9(4):317–24 (72 ref.)
In search of human variation. Weiss KM. **Genome Res** 1998 Jul;8(7):691–7 (23 ref.)
Evolution and diversity of mammalian sodium channel genes. Plummer NW, et al. **Genomics** 1999 Apr 15;57(2):323–31 (88 ref.)
Genetics of Hb F/F cell variance in adults and heterocellular hereditary persistence of fetal hemoglobin. Thein SL, et al. **Hemoglobin** 1998 Sep–Nov;22(5–6):401–14 (18 ref.)
Growth hormone heterogeneity in human pituitary and plasma. Baumann G. **Horm Res** 1999;51 Suppl 1:2–6 (22 ref.)
Genomics and hypertension: concepts, potentials, and opportunities. Pratt RE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):238–47 (73 ref.)
The salmonid class I MHC: limited diversity in a primitive teleost. Miller KM, et al. **Immunol Rev** 1998 Dec; 166:279–93 (25 ref.)
Evolutionary variation of immunoglobulin mu heavy chain RNA processing pathways: origins, effects, and implications. Ross DA, et al. **Immunol Rev** 1998 Dec; 166:143–51 (37 ref.)
Evolution and diversity of the complement system of poikilothermic vertebrates. Sunyer JO, et al. **Immunol Rev** 1998 Dec;166:39–57 (119 ref.)
The importance of genetic diversity in livestock populations of the future. Notter DR. **J Anim Sci** 1999 Jan;77(1):61–9 (66 ref.)
Mitochondrial DNA diversity in nematodes. Blouin MS. **J Helminthol** 1998 Dec;72(4):285–9 (39 ref.)
Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? Drosopoulos WC, et al. **J Mol Med** 1998 Aug;76(9):604–12 (83 ref.)
The role of interindividual variation in human carcinogenesis. Lai C, et al. **J Nutr** 1999 Feb;129(2S Suppl):552S–555S (34 ref.)
Homology and homoplasy: the retention of genetic programmes. Meyer A. **Novartis Found Symp** 1999; 222:141–53; discussion 153–7 (27 ref.)
Bacterial genetics and strain variation. van Helden PD. **Novartis Found Symp** 1998;217:178–90; discussion 190–4 (30 ref.)
Evolutionary dissociations between homologous genes and homologous structures. Wray GA. **Novartis Found Symp** 1999;222:189–203; discussion 203–6 (52 ref.)
Genetic variation and nutrition. Simopoulos AP. **Nutr Rev** 1999 May;57(5 Pt 2):S10–9 (99 ref.)
Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Lupski JR. **Pediatr Res** 1999 Feb;45(2):159–65 (67 ref.)
Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Kalow W, et al. **Pharmacogenetics** 1998 Aug;8(4):283–9 (36 ref.)
Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Kalow W, et al. **Pharmacology** 1999 Jun;58(6):281–4 (13 ref.)
Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Knight JC, et al. **Proc Assoc Am Physicians** 1999 Jul–Aug;111(4):290–8 (50 ref.)
Good genes, oxidative stress and condition-dependent sexual signals. von Schantz T, et al. **Proc R Soc Lond B Biol Sci** 1999 Jan 7;266(1414):1–12 (162 ref.)
A three-dimensional consideration of variant human fibrinogens. Everse SJ, et al. **Thromb Haemost** 1998 Jul; 80(1):1–9 (69 ref.)
Suppression mechanisms: themes from variations. Prelich G. **Trends Genet** 1999 Jul;15(7):261–6 (39 ref.)
Variation and evolution of the citric-acid cycle: a genomic perspective. Huynen MA, et al. **Trends Microbiol** 1999 Jul; 7(7):281–91 (32 ref.)
Potential of assisted breeding techniques for the conservation of endangered mammalian species in captivity: a review. Bainbridge DR, et al. **Vet Rec** 1998 Aug 8;143(6):159–68 (137 ref.)
Genetic variation and nutrition. Simopoulos AP. **World Rev Nutr Diet** 1999;84:118–40 (121 ref.)
[CD44 gene expression and gynecologic neoplasms] Qu F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1997 Dec; 32(12):756–62 (22 ref.) **(Chi)**
[Are prehistoric epidemics reflected in the genetic variability of Danes and in current pathogenesis of HIV infections?] Eugen-Olsen J, et al. **Ugeskr Laeger** 1998 Dec 21; 160(52):7585–8 (22 ref.) **(Dan)**
[Molecular epidemiology of yellow fever] Tolou H, et al. **Med Trop (Mars)** 1998;58(2 Suppl):37–41 (13 ref.) (Eng. Abstr.) **(Fre)**
[The association of TTV genetic variant with liver disease] Kurihara C, et al. **Nippon Rinsho** 1999 Jun;57(6):1256–61 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Cambrian explosion and diversification of genes] Suga H, et al. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(3):207–16 (30 ref.) **(Jpn)**
[Environmental stress and genetic variation in animal populations] Imasheva AG. **Genetika** 1999 Apr; 35(4):421–31 (87 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Phenotypic variability in the chromosome 9 ring. Cavaliere ML, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:85–9 (10 ref.)
Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Lesch KP, et al. **Biol Psychiatry** 1998 Aug 1;44(3):179–92 (75 ref.)
Balancing selection and MHC. Hedrick PW. **Genetica** 1998–99;104(3):207–14 (66 ref.)
Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. Staessen JA, et al. **J Cardiovasc Risk** 1997 Oct–Dec;4(5–6):401–22 (267 ref.)
Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. Jensen PN, et al. **J Leukoc Biol** 1999 Apr;65(4):428–38 (99 ref.)
Hepatitis C virus infection: virus/host interactions. Pawlotsky JM. **J Viral Hepat** 1998 Sep;5 Suppl 1:3–8 (19 ref.)
Helicobacter pylori--a conundrum of genetic diversity. Marshall DG, et al. **Microbiology** 1998 Nov;144 (Pt 11):2925–39 (160 ref.)
Population genetics--making sense out of sequence. Chakravarti A. **Nat Genet** 1999 Jan;21(1 Suppl):56–60 (52 ref.)
[Gene instability induced by mobile genetic elements in Drosophila melanogaster] Shcherbata HR, et al. **Tsitol Genet** 1999 Jan–Feb;33(1):54–70 (120 ref.) (Eng. Abstr.) **(Ukr)**

IMMUNOLOGY

Balancing selection and MHC. Hedrick PW. **Genetica** 1998–99;104(3):207–14 (66 ref.)
Genetic B-cell variation based on immunoglobulin heavy G-chain (Gm) genes. Oxelius VA. **Scand J Immunol** 1999 Apr;49(4):345–6 (10 ref.)

PHYSIOLOGY

A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy [see comments] Walsh MT. **Am J Pathol** 1999 Jan;154(1):11–4 (37 ref.) Comment in: Am J Pathol 1999 Jan;154(1):221–7.
Prion infections in Creutzfeldt-Jakob disease and its variants. Parker JC Jr, et al. **Ann Clin Lab Sci** 1999 Apr–Jun; 29(2):112–7 (33 ref.)

VARICELLA see **CHICKENPOX**

VARICELLA VACCINE see **CHICKENPOX VACCINE**

VARICELLA-ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

VARICES see **VARICOSE VEINS**

VARICOCELE

DIAGNOSIS

Varicocele: strategies in diagnosis and treatment. Cornud F, et al. **Eur Radiol** 1999;9(3):536–45 (51 ref.)
[Phimosis, hydrocele and varicocele. 3 frequent pathologies in the male child and adolescent] Pereira NM. **Acta Med Port** 1999 Jan–Mar;12(1–3):137–43 (25 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

[Idiopathic varicocele in adolescents] Radicioni A. **Minerva Pediatr** 1998 Jun;50(6):261–7 (18 ref.) **(Ita)**

THERAPY

Varicocele: strategies in diagnosis and treatment. Cornud F, et al. **Eur Radiol** 1999;9(3):536–45 (51 ref.)
[Should varicoceles be treated in the adolescent? How?] Becmeur F, et al. **J Chir (Paris)** 1999 Jun;136(2):93–6 (49 ref.) (Eng. Abstr.) **(Fre)**

VARICOSE ULCER

DRUG THERAPY

[Infections and treatment of chronic leg ulcers: the use of antibiotics is too excessive, restrictive prescription is recommended] Wiström J, et al. **Lakartidningen** 1999 Jan 6;96(1-2):42-6 (18 ref.) (Eng. Abstr.) **(Swe)**

ETIOLOGY

Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Herouy Y, et al. **Int J Mol Med** 1999 May; 3(5):511-5 (25 ref.)

[Differential ulcus cruris diagnosis] Hafner J. **Ther Umsch** 1998 Oct;55(10):632-42 (7 ref.) (Eng. Abstr.) **(Ger)**

[Ulcus cruris--vascular etiology and surgical treatment options] Kniemeyer HW, et al. **Ther Umsch** 1998 Oct; 55(10):643-9 (27 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Herouy Y, et al. **Int J Mol Med** 1999 May; 3(5):511-5 (25 ref.)

PHYSIOPATHOLOGY

[Physiopathology of venous leg ulcers] Aubin F, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):825-32 (61 ref.) **(Fre)**

SURGERY

Surgical intervention in venous ulceration. Padberg FT Jr. **Cardiovasc Surg** 1999 Jan;7(1):83-90 (44 ref.)

Apligraf living skin equivalent for healing venous and chronic wounds. Sibbald RG. **J Cutan Med Surg** 1998 Dec; 3 Suppl 1:S1-24-8 (27 ref.)

Apligraf treatment of venous ulcers and other chronic wounds. Falanga V. **J Dermatol** 1998 Dec;25(12):812-7 (18 ref.)

THERAPY

Management of venous ulcers. Bello YM, et al. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1-6-12 (28 ref.)

Venous ulcer reappraisal: insights from an international task force. Veines International Task Force. Clement DL. **J Vasc Res** 1999;36 Suppl 1:42-7 (23 ref.)

[Differentiated local therapy of chronic wounds with modern wound dressings] Eich D, et al. **Vasa** 1999 Feb;28(1):3-9 (57 ref.) (Eng. Abstr.) **(Ger)**

VARICOSE VEINS

see related
ESOPHAGEAL AND GASTRIC VARICES SCLEROTHERAPY

COMPLICATIONS

Reticular veins, incompetent reticular veins, and their relationship to telangiectases. Green D. **Dermatol Surg** 1998 Oct;24(10):1129-40; discussion 1140-1 (2 ref.)

Ileal varices associated with recurrent bleeding in a patient with liver cirrhosis. Ohtani T, et al. **J Gastroenterol** 1999 Apr;34(2):264-8 (12 ref.)

DIAGNOSIS

Intrafibular varix: MR diagnosis. Díaz-Cendamio MJ, et al. **J Comput Assist Tomogr** 1999 Mar-Apr;23(2):328-30 (4 ref.)

[Portal hypertension and enterostomy: a dangerous combination. Colostomy-induced varices as a rare cause of gastrointestinal hemorrhage. Report of a case and review of the literature] Arcidiaco M, et al. **Ann Ital Chir** 1999 Jan-Feb;70(1):61-5 (21 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Varicosities of the paravertebral plexus of veins associated with nocturnal spinal pain as imaged by magnetic resonance venography: a brief report. LaBan MM, et al. **Am J Phys Med Rehabil** 1999 Jan-Feb;78(1):72-6 (23 ref.)

GENETICS

[Familial varices of the colon. Report of four cases] Bernardini D, et al. **Gastroenterol Clin Biol** 1998 Oct; 22(10):827-30 (21 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Venous leg ulcers: modern evaluation and management. Zimmet SE. **Dermatol Surg** 1999 Mar;25(3):236-41 (44 ref.)

SURGERY

[Preoperative assessment of primary varicose veins] Pfyffer M. **Schweiz Med Wochenschr** 1998 Nov 7;128(45):1772-80 (50 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of primary varicose veins] Wigger P. **Schweiz Med Wochenschr** 1998 Nov 7;128(45):1781-8 (39 ref.) (Eng. Abstr.) **(Ger)**

[Perforating veins and venous insufficiency] Clerici T, et al. **Zentralbl Chir** 1999;124(6):525-9 (10 ref.) (Eng. Abstr.) **(Ger)**

[Methods of concealed exclusion of lower extremities perforated and varicose veins in chronic venous insufficiency] Gervaziev VB. **Khirurgiia (Mosk)** 1999; (4):52-5 (6 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Prevention of first variceal bleed: an appraisal of current therapies. Shahi HM, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2348-58 (95 ref.)

Venous leg ulcers: modern evaluation and management. Zimmet SE. **Dermatol Surg** 1999 Mar;25(3):236-41 (44 ref.)

Management of ectopic varices. Norton ID, et al. **Hepatology** 1998 Oct;28(4):1154-8 (35 ref.)

[Leg perforating veins] Perrin M. **J Mal Vasc** 1999 Feb; 24(1):19-24 (39 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of lower limbs varicose veins in outpatient clinic] Kutin AA, et al. **Khirurgiia (Mosk)** 1999;(3):66-71 (135 ref.) **(Rus)**

ULTRASONOGRAPHY

[Place of duplex sonography in the differential diagnosis of deep vein thrombosis] Habscheid W. **Dtsch Med Wochenschr** 1998 Oct 2;123(40):1185-90 (51 ref.) **(Ger)**

VARIOLA see **SMALLPOX**

VARIOLA MINOR see **SMALLPOX**

VARIOLA VIRUS

The threat of bioterrorism returns the fear of smallpox. Atlas RM. **Curr Opin Microbiol** 1998 Dec;1(6):719-21 (10 ref.)

Smallpox: gone but not forgotten. Ellner PD. **Infection** 1998 Sep-Oct;26(5):263-9 (49 ref.)

VARNISH see **PAINT**

VAS DEFERENS

see related
VASECTOMY

ABNORMALITIES

Cystic fibrosis and reproduction. Phillipson G. **Reprod Fertil Dev** 1998;10(1):113-9 (44 ref.)

ANATOMY & HISTOLOGY

Structure and autonomic innervation of the human vas deferens: a review. Dixon JS, et al. **Microsc Res Tech** 1998 Sep 15;42(6):423-32 (90 ref.)

INNERVATION

Sympathetic neuromuscular transmission at a varicosity in a syncytium. Bennett MR, et al. **Microsc Res Tech** 1998 Sep 15;42(6):433-50 (59 ref.)

Structure and autonomic innervation of the human vas deferens: a review. Dixon JS, et al. **Microsc Res Tech** 1998 Sep 15;42(6):423-32 (90 ref.)

Origin and neurochemical characteristics of nerve fibres supplying the mammalian vas deferens. Kaleczyc J. **Microsc Res Tech** 1998 Sep 15;42(6):409-22 (110 ref.)

Sympathetic efferent pathways projecting to the vas deferens. Kihara K, et al. **Microsc Res Tech** 1998 Sep 15; 42(6):398-408 (80 ref.)

PHYSIOLOGY

Autoinhibition, sympathetic cotransmission and biphasic contractile responses to trains of nerve stimulation in the rodent vas deferens. Ventura S. **Clin Exp Pharmacol Physiol** 1998 Dec;25(12):965-73 (74 ref.)

VASA VASORUM

PHYSIOLOGY

[Modeling of elastic deformation and vascular resistance of arterial and venous vasa vasorum] Maurice G, et al. **J Mal Vasc** 1998 Oct;23(4):282-8 (21 ref.) (Eng. Abstr.) **(Fre)**

VASCULAR ACCESS PORTS see **CATHETERS, INDWELLING**

VASCULAR-ASSIST DEVICES see **HEART-ASSIST DEVICES**

VASCULAR CAPACITANCE

see related
VASCULAR RESISTANCE

PHYSIOLOGY

Vascular compliance as a measure of biological age. Bulpitt CJ, et al. **J Am Geriatr Soc** 1999 Jun;47(6):657-63 (64 ref.)

Influence of aging on arterial compliance. Van Bortel LM, et al. **J Hum Hypertens** 1998 Sep;12(9):583-6 (36 ref.)

VASCULAR CELL ADHESION MOLECULE-1

IMMUNOLOGY

[The role of cell adhesion molecules in certain neurological diseases] Niezgoda A, et al. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1485-96 (36 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

[The role of cell adhesion molecules in certain neurological diseases] Niezgoda A, et al. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1485-96 (36 ref.) (Eng. Abstr.) **(Pol)**

VASCULAR DEMENTIA see **DEMENTIA, VASCULAR**

VASCULAR DISEASES

Animal models for the study of lower extremity chronic venous disease: lessons learned and future needs. Dalsing MC, et al. **Ann Vasc Surg** 1998 Sep;12(5):487-94 (47 ref.)

Intestinal (mesenteric) vasculopathy. I. Acute superior mesenteric arteriopathy and venopathy. Cappell MS. **Gastroenterol Clin North Am** 1998 Dec;27(4):783-825, vi (285 ref.)

Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Cappell MS. **Gastroenterol Clin North Am** 1998 Dec;27(4):827-60, vi (355 ref.)

BLOOD

High plasma homocysteine: a risk factor for vascular disease in the elderly. Moustapha A, et al. **Coron Artery Dis** 1998; 9(11):725-30 (36 ref.)

Thrombomodulin: an overview and potential implications in vascular disorders. Boffa MC, et al. **Lupus** 1998;7 Suppl 2:S120-5 (67 ref.)

CLASSIFICATION

[Large vessel vasculitides] Bruneval P, et al. **Ann Pathol** 1999 Jun;19(3):223-37 (95 ref.) **(Fre)**

COMPLICATIONS

Lower extremity manifestations of vascular disease. Ward K, et al. **Clin Podiatr Med Surg** 1998 Oct;15(4):629-72 (59 ref.)

Collagen vascular diseases and radiation therapy: a critical review. De Naeyer B, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 15;44(5):975-80 (17 ref.)

Immunologic and nonimmunologic risk factors of chronic rejection. Fellström B, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1304-5 (20 ref.)

DIAGNOSIS

Sarcoidosis in children [letter] Shetty AK, et al. **Acta Paediatr** 1999 Feb;88(2):235 (9 ref.)

International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Savige J, et al. **Am J Clin Pathol** 1999 Apr;111(4):507-13 (48 ref.)

Developments in diagnosis and classification of venous disorders: non-invasive diagnosis. Lynch TG, et al. **Cardiovasc Surg** 1999 Mar;7(2):160-78 (140 ref.)

Advances in the diagnosis and management of scleroderma-related vascular complications. Kerin K, et al. **Compr Ther** 1998 Nov-Dec;24(11-12):574-81 (28 ref.)

Vascular disorders of the small bowel. Sorbi D, et al. **Gastrointest Endosc Clin N Am** 1999 Jan;9(1):71-92 (97 ref.)

Determinants of image appearance in contrast-enhanced magnetic resonance angiography. A review. Saloner D. **Invest Radiol** 1998 Sep;33(9):488-95 (15 ref.)

Vascular anatomy and disorders of the lumbar spine and spinal cord. Bowen BC, et al. **Magn Reson Imaging Clin N Am** 1999 Aug;7(3):555-71 (54 ref.)

[Vascular imaging with magnetic resonance angiography (MRA)] Goyen M, et al. **Z Arztl Fortbild Qualitatssich** 1998 Sep;92(7):491-3 (9 ref.) (Eng. Abstr.) **(Ger)**

[Media calcinosis from the viewpoint of the cardiologist] Lanzer P. **Z Kardiol** 1998 Dec;87(12):928-38 (73 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[The role of heparinoids in the treatment of vascular diseases] Undas A, et al. **Pol Arch Med Wewn** 1998 May;99(5):430-5 (29 ref.) **(Pol)**

EMBRYOLOGY

The molecular basis of vascular disorders. Towbin JA, et al. **Am J Hum Genet** 1999 Mar;64(3):678-84 (31 ref.)

ENZYMOLOGY

Oxygen radical stress in vascular disease: the role of endothelial nitric oxide synthase. Stroes ES, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S14-21 (129 ref.)

EPIDEMIOLOGY

Epidemiology of the arterial stiffness. Breithaupt-Grögler K, et al. **Pathol Biol (Paris)** 1999 Jun;47(6):604-13 (90 ref.)
[Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants] Lajemi M, et al. **Pathol Biol (Paris)** 1999 Jun;47(6):614-22 (60 ref.) (Eng. Abstr.) **(Fre)**
[Cardiovascular risk and hormone replacement therapy in menopause] Plu-Bureau G. **Therapie** 1999 May-Jun; 54(3):375-80 (23 ref.) (Eng. Abstr.) **(Fre)**
[Epidemiologic and socioeconomic aspects of venous disease] Novo S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:47-52 (44 ref.) **(Ita)**

ETIOLOGY

Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. Liu Z, et al. **Atherosclerosis** 1998 Sep; 140(1):1-14 (170 ref.)
Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. San Antonio JD, et al. **Connect Tissue Res** 1998;37(1-2):87-103 (96 ref.)
Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. Realdi G, et al. **Dig Dis Sci** 1999 Feb;44(2):229-36 (70 ref.)
Homocysteine and hypomethylation. A novel link to vascular disease. Lee ME, et al. **Trends Cardiovasc Med** 1999 Jan-Feb;9(1-2):49-54 (52 ref.)
[Vascular aspects of thoracic outlet syndrome] Luthi JF. **Rev Med Suisse Romande** 1998 Oct;118(10):829-32 (12 ref.) **(Fre)**

GENETICS

Understanding molecular biology. Gahtan V, et al. **Semin Vasc Surg** 1998 Sep;11(3):125-33 (23 ref.)
[Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants] Lajemi M, et al. **Pathol Biol (Paris)** 1999 Jun;47(6):614-22 (60 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Schmidt AM, et al. **Circ Res** 1999 Mar 19;84(5):489-97 (89 ref.)

MICROBIOLOGY

Extradigestive manifestations of Helicobacter pylori gastric infection. Gasbarrini A, et al. **Gut** 1999 Jul;45 Suppl 1:I9-I12 (50 ref.)
Helicobacter pylori infection and vascular diseases. Gasbarrini A, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S307-9 (25 ref.)
[Microorganisms in vascular pathology and myocardial ischemia] López-Sendón J, et al. **Rev Clin Esp** 1998 Sep; 198 Suppl 1:40-3 (22 ref.) **(Spa)**

MORTALITY

Prognosis of diastolic and systolic orthostatic hypotension in older persons. Luukinen H, et al. **Arch Intern Med** 1999 Feb 8;159(3):273-80 (35 ref.)

PATHOLOGY

Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. San Antonio JD, et al. **Connect Tissue Res** 1998;37(1-2):87-103 (96 ref.)
Vasospasm, vascular injury, and atherogenesis: a perspective. Gutstein WH. **Hum Pathol** 1999 Apr;30(4):365-71 (111 ref.)
Phlebosclerosis of the colon with positive anti-centromere antibody [see comments] Kitamura T, et al. **Intern Med** 1999 May;38(5):416-21 (18 ref.) Comment in: Intern Med 1999 May;38(5):381.
The role of lipids in transplant vascular disease. McDonald PC, et al. **Lab Invest** 1998 Oct;78(10):1187-201 (125 ref.)
[Vascular disease and cellular activation: exploration of cell adhesion phenotype by quantitative flow cytometry] Latger V, et al. **J Mal Vasc** 1999 Feb;24(1):11-8 (59 ref.) (Eng. Abstr.) **(Fre)**
[Hypertrophy of the arterial wall and arterial rigidity] Laurent S, et al. **Pathol Biol (Paris)** 1999 Jun;47(6):648-55 (43 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Endothelium-derived nitric oxide and vascular physiology and pathology. Arnal JF, et al. **Cell Mol Life Sci** 1999 Jul;55(8-9):1078-87 (85 ref.)
The triphasic effects of exercise on blood rheology: which relevance to physiology and pathophysiology? Brun JF, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):89-104 (164 ref.)
Novel cardiovascular actions of the activins. Molloy CJ, et al. **J Endocrinol** 1999 May;161(2):179-85 (52 ref.)
Vascular dysregulation: a principal risk factor for glaucomatous damage? Flammer J, et al. **J Glaucoma** 1999 Jun;8(3):212-9 (112 ref.)
The role of lipids in transplant vascular disease. McDonald PC, et al. **Lab Invest** 1998 Oct;78(10):1187-201 (125 ref.)
Mechanics of the large artery vascular wall. Levy BI. **Pathol Biol (Paris)** 1999 Jun;47(6):634-40 (32 ref.)
Mechanical principles. Arterial stiffness and wave reflection. O'Rourke MF. **Pathol Biol (Paris)** 1999 Jun;47(6):623-33 (44 ref.)
Arterial hemodynamics and wall mechanics. Vorp DA, et al. **Semin Vasc Surg** 1998 Sep;11(3):169-80 (95 ref.)
Endothelial dysfunction and vascular disease. Vanhoutte PM. **Verh K Acad Geneeskd Belg** 1998;60(3):251-66 (65 ref.)
[Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus] Nawroth PP, et al. **Med Klin** 1999 Jan 15;94(1):29-38 (156 ref.) (Eng. Abstr.) **(Ger)**
[What role does homocysteine play in vascular diseases?] Ecker-Schlipf B. **Med Monatsschr Pharm** 1999 Jan; 22(1):19-23 (3 ref.) **(Ger)**

PSYCHOLOGY

[Vascular risk factors and cognitive change in the elderly] Fernández García C, et al. **Rev Clin Esp** 1999 Jul; 199(7):456-64 (170 ref.) **(Spa)**

RADIOGRAPHY

CT angiography. Rankin SC. **Eur Radiol** 1999;9(2):297-310 (94 ref.)
Interventional neuroradiology. Recent developments and anaesthesiologic aspects. Luginbühl M, et al. **Minerva Anestesiol** 1999 Jun;65(6):445-54 (80 ref.)

SURGERY

Minimally invasive vascular surgery: review of current modalities. Weiss VJ, et al. **World J Surg** 1999 Apr; 23(4):406-14 (73 ref.)
[Endovascular graft for treatment of vascular disease] Avrahami R, et al. **Harefuah** 1998 Oct;135(7-8):299-304 (25 ref.) **(Heb)**

THERAPY

Gene therapy and vascular disease. Kibbe M, et al. **Adv Pharmacol** 1999;46:85-150 (230 ref.)
Advances in the diagnosis and management of scleroderma-related vascular complications. Kerin K, et al. **Compr Ther** 1998 Nov-Dec;24(11-12):574-81 (28 ref.)
Manipulating angiogenesis against vascular disease. Isner JM. **Hosp Pract (Off Ed)** 1999 Jun 15;34(6):69-74, 76, 79-80 passim (8 ref.)
Vascular medicine: breakthrough of a concept. Bounameaux H, et al. **Schweiz Med Wochenschr** 1999 Mar 13; 129(10):393-4 (0 ref.)
Gene therapy. Golden MA, et al. **Semin Vasc Surg** 1998 Sep; 11(3):215-23 (24 ref.)
Plasmapheresis in collagen vascular diseases. Lewis EJ. **Ther Apher** 1999 May;3(2):172-7 (58 ref.)
Chronic allograft vasculopathy: new strategies for drug development. Häyry P. **Transplant Proc** 1998 Dec; 30(8):3989-90 (22 ref.)
[Role of endovascular treatments in the management of arteriopathies of the aged subject] Fiessinger JN, et al. **Bull Acad Natl Med** 1999;183(1):97-104; discussion 104-5 (23 ref.) (Eng. Abstr.) **(Fre)**
[Modulation of angiogenesis. A new therapeutic tool for vascular diseases] Blot E, et al. **J Mal Vasc** 1999 Jun; 24(3):189-93 (26 ref.) (Eng. Abstr.) **(Fre)**
[Vascular gene therapy--the choice of procedures as a function of strategies] De Caterina R, et al. **Cardiologia** 1999 Jan;44(1):9-17 (52 ref.) **(Ita)**
[Gene therapy of vascular diseases] Zelenin AV. **Vopr Med Khim** 1999 May-Jun;45(3):200-5 (36 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Power Doppler imaging: principles and applications. Hudson-Dixon CM, et al. **Radiol Technol** 1999 Jan-Feb; 70(3):235-43 (36 ref.)
2-D and 3-D endoluminal ultrasound: vascular and nonvascular applications. Liu JB, et al. **Ultrasound Med Biol** 1999 Feb;25(2):159-73 (94 ref.)

VIROLOGY

[Microorganisms in vascular pathology and myocardial ischemia] López-Sendón J, et al. **Rev Clin Esp** 1998 Sep; 198 Suppl 1:40-3 (22 ref.) **(Spa)**

VASCULAR DISEASES, PERIPHERAL see **PERIPHERAL VASCULAR DISEASES**

VASCULAR ENDOTHELIUM see **ENDOTHELIUM, VASCULAR**

VASCULAR FISTULA

COMPLICATIONS

Coronary artery fistula and atrial septal defect: a case report and brief review of the literature. Hijazi A, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):286-7 (11 ref.)

CONGENITAL

Congenital coronary artery fistula treated surgically in the right atrium and the atrial septum. Tsukamoto S, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):359-62 (12 ref.)

ETIOLOGY

Type IV thoraco-abdominal aortic aneurysm complicated by an aorto-enteric fistula due to previous infrarenal aortic graft. Karacagil S, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):268-70 (9 ref.)
Rupture of an iliac artery pseudo-aneurysm into a ureter. Levi N, et al. **Eur J Vasc Endovasc Surg** 1999 Mar; 17(3):264-5 (14 ref.)
Successful treatment of aortoesophageal fistula resulting from aneurysm of the aortic arch. Goto H, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):425-7 (7 ref.)
[A fatal aorto-esophageal fistula due a foreign body: a foreseeable accident?] Pons J, et al. **Presse Med** 1999 Apr 17;28(15):781-3 (12 ref.) (Eng. Abstr.) **(Fre)**
[An aortoesophageal fistula as the initial manifestation of esophageal carcinoma (letter)] García de Lucas MD, et al. **Gastroenterol Hepatol** 1999 Jun-Jul;22(6):320-1 (9 ref.) **(Spa)**

PATHOLOGY

Uretero-arterial fistula: a case report and review of the literature. Camps JI, et al. **Bol Asoc Med P R** 1998 Apr-Jun;90(4-6):82-4 (11 ref.)

SURGERY

Congenital coronary artery fistula treated surgically in the right atrium and the atrial septum. Tsukamoto S, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):359-62 (12 ref.)
Successful surgical treatment of aortogastric fistula after an esophagectomy and subsequent endovascular graft placement: report of a case. Sato O, et al. **Surg Today** 1999; 29(5):431-4 (10 ref.)

VASCULAR GRAFT OCCLUSION see **GRAFT OCCLUSION, VASCULAR**

VASCULAR GRAFT RESTENOSIS see **GRAFT OCCLUSION, VASCULAR**

VASCULAR HEADACHE

DRUG THERAPY

[Migraine and other "vascular" headache] Diener HC. **Internist (Berl)** 1999 Feb;40(2):153-61 (45 ref.) **(Ger)**

VASCULAR HEMOSTATIC DISORDERS

DIAGNOSIS

The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Male C, et al. **Clin Lab Med** 1999 Mar;19(1):39-69 (150 ref.)

THERAPY

The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Male C, et al. **Clin Lab Med** 1999 Mar;19(1):39-69 (150 ref.)

VASCULAR INTIMA see **TUNICA INTIMA**

VASCULAR MEDIA see **TUNICA MEDIA**

VASCULAR NEOPLASMS

Primary malignant tumors of the venous system in the lower extremities. Reix T, et al. **Ann Vasc Surg** 1998 Nov; 12(6):589-96 (49 ref.)
Leiomyosarcoma of the thoracic aorta. Iorgulescu DG, et al. **Aust N Z J Surg** 1999 Jul;69(7):537-40 (41 ref.)
Intracavernous teratoma in a school-aged child. Becherer TA, et al. **Pediatr Neurosurg** 1999 Mar;30(3):135-9 (20 ref.)
The infant with a vascular tumor. Mueller BU, et al. **Semin Perinatol** 1999 Aug;23(4):332-40 (75 ref.)

COMPLICATIONS

Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. Kraus MD, et al. **Am J Med** 1999 Aug; 107(2):169-76 (31 ref.)

DIAGNOSIS

Case report of a patient with an intimal sarcoma of the pulmonary trunk presenting as a pulmonary embolism. Weijmer MC, et al. **Neth J Med** 1999 Aug;55(2):80-3 (7 ref.)
[An intimal sarcoma of the pulmonary artery. An immunohistochemical study] Pérez del Río MJ, et al. **Rev Esp Cardiol** 1998 Oct;51(10):850-2 (8 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Metastases that interfere with circulation. Joyce M, et al. **Semin Oncol Nurs** 1998 Aug;14(3):230-9 (43 ref.)

VASCULAR NEOPLASMS

PATHOLOGY

[An autopsy case of intravascular malignant lymphomatosis with hemophagocytic syndrome, mental confusion and liver dysfunction] Onishi Y, et al. **Rinsho Ketsueki** 1998 Aug;39(8):586–92 (18 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Metastases that interfere with circulation. Joyce M, et al. **Semin Oncol Nurs** 1998 Aug;14(3):230–9 (43 ref.)

SURGERY

[Leiomyosarcoma of the heart and great vessels] Babatasi G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jul–Sep; 47(7):451–8 (43 ref.) (Eng. Abstr.) **(Fre)**

VASCULAR PATENCY

see related
GRAFT OCCLUSION, VASCULAR

Long–term arterial patency after coronary reperfusion. Branzi A, et al. **Int J Cardiol** 1999 Apr 10;68 Suppl 1:S29–33 (34 ref.)

VASCULAR PERMEABILITY see **CAPILLARY PERMEABILITY**

VASCULAR PROSTHESIS see **BLOOD VESSEL PROSTHESIS**

VASCULAR RESISTANCE

see related
VASCULAR CAPACITANCE

Heterogeneity of coronary vasomotion. Tiefenbacher CP, et al. **Basic Res Cardiol** 1998 Dec;93(6):446–54 (74 ref.)

Blood pressure set point. Taquini AC. **Biol Res** 1998; 31(3):131–4 (17 ref.)

Vascular remodelling of resistance vessels: can we define this? Mulvany MJ. **Cardiovasc Res** 1999 Jan;41(1):9–13 (34 ref.)

Low systemic vascular resistance after cardiopulmonary bypass: are we any closer to understanding the enigma? [editorial; comment] Johnson MR. **Crit Care Med** 1999 Jun; 27(6):1048–50 (14 ref.) Comment on: Crit Care Med 1999 Jun;27(6):1121–7.

Aldosterone and artery compliance in heart failure [editorial; comment] Struthers A. **Eur Heart J** 1998 Sep;19(9):1273 (6 ref.) Comment on: Eur Heart J 1998 Sep;19(9):1371–6.

Control of microvascular resistance in physiological conditions and reperfusion. DeFily DV. **J Mol Cell Cardiol** 1998 Dec;30(12):2547–54 (56 ref.)

Role of total arterial compliance and peripheral resistance in the determination of systolic and diastolic aortic pressure. Stergiopulos N, et al. **Pathol Biol (Paris)** 1999 Jun; 47(6):641–7 (14 ref.)

DRUG EFFECTS

[Alcohol and myocardial infarct. Epidemiological and experimental studies on the effect of alcohol on vascular relaxation and coronary sclerosis (see comments)] Flesch M, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1490–6 (35 ref.) Comment in: Dtsch Med Wochenschr 1999 May 7;124(18):575. **(Ger)**

PHYSIOLOGY

Physiology of nonpulsatile circulation: acute versus chronic support. Jett GK. **ASAIO J** 1999 May–Jun;45(3):119–22 (41 ref.)

Pulse pressure, arterial compliance and cardiovascular morbidity and mortality. Mitchell GF. **Curr Opin Nephrol Hypertens** 1999 May;8(3):335–42 (89 ref.)

Arterial pressure, vascular input impedance, and resistance as determinants of pulsatile blood flow in the umbilical artery. Adamson SL. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):119–25 (24 ref.)

Effects of angiotensin–converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. Mulvany MJ. **Metabolism** 1998 Dec;47(12 Suppl 1):20–3 (38 ref.)

[Modeling of elastic deformation and vascular resistance of arterial and venous vasa vasorum] Maurice G, et al. **J Mal Vasc** 1998 Oct;23(4):282–8 (21 ref.) (Eng. Abstr.) **(Fre)**

VASCULAR SMOOTH MUSCLE see **MUSCLE, SMOOTH, VASCULAR**

VASCULAR SURGICAL PROCEDURES

Cardiovascular surgery in the elderly. Aziz S, et al. **Cardiol Clin** 1999 Feb;17(1):213–31 (121 ref.)

New trends in the surgical and endovascular reconstructions of large veins for nonmalignant chronic venous occlusive disease. Alimi YS, et al. **Curr Opin Cardiol** 1998 Sep; 13(5):375–83 (51 ref.)

The change in concept and surgical treatment on Buerger's disease--personal experience and review. Nakajima N. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S273–80; discussion S281 (5 ref.)

Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations. Nevarre DR, et al. **J Endovasc Surg** 1998 Aug;5(3):282–91 (47 ref.)

Current trends in peripheral vascular surgery. When is surgical intervention the best option? Gorton ME. **Postgrad Med** 1999 Sep;106(3):87–94 (23 ref.)

Venous bypass and valve reconstruction: long–term efficacy. Eklof BG, et al. **Vasc Med** 1998;3(2):157–64 (43 ref.)

Endovascular manipulation to restrict restenosis. Gershlick AH. **Vasc Med** 1998;3(3):177–88 (86 ref.)

Monitoring of oxygen delivery in cardiac and vascular surgery. Spahn DR. **Vox Sang** 1998;74 Suppl 2:395–7 (17 ref.)

[Preoperative management of patients with high–risk cardiovascular conditions] Broustet JP, et al. **Arch Mal Coeur Vaiss** 1998 Aug;91 Spec No 4:7–16; discussion 29–30 (39 ref.) (Eng. Abstr.) **(Fre)**

[Echo–doppler surveillance of revascularization of the legs in asymptomatic postoperative patients. Why? With what rhythm? How much time? How?] Mellière D, et al. **J Mal Vasc** 1999 Jun;24(3):233–8 (20 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of hypertensive crisis by narcosis induction in vascular surgery] Loguercio G, et al. **Minerva Anestesiol** 1981 Jul;47(7):401–3 (16 ref.) **(Ita)**

[Multiply distributed atherosclerotic arteriopathy. Indications and limits of surgical treatment] D'Addato M, et al. **Minerva Cardioangiol** 1998 Oct;46(10):423–7 (36 ref.) **(Ita)**

[Revascularization of the corpora cavernosa in vasculogenic impotence] Sica GS, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):129–34 (16 ref.) (Eng. Abstr.) **(Ita)**

[Choice of hemorrhoids treatment] Vorob'ev GI, et al. **Khirurgiia (Mosk)** 1999;(8):50–5 (43 ref.) **(Rus)**

ADVERSE EFFECTS

Non–cardiogenic pulmonary oedema in vascular surgery. Pararajasingam R, et al. **Eur J Vasc Endovasc Surg** 1999 Feb;17(2):93–105 (154 ref.)

Lower limb oedema following distal arterial bypass grafting. Soong CV, et al. **Eur J Vasc Endovasc Surg** 1998 Dec; 16(6):465–71 (58 ref.)

Oral anticoagulation in peripheral vascular surgery: how intense, for how long, or at all? Kretschmer G, et al. **J Intern Med** 1999 Apr;245(4):389–97 (44 ref.)

HISTORY

[Curriculum vitae aortae] Solberg S. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4644–7 (45 ref.) (Eng. Abstr.) **(Nor)**

INSTRUMENTATION

The new operating room environment. Mansour MA. **Surg Clin North Am** 1999 Jun;79(3):477–87 (28 ref.)

METHODS

Expanding surgical options using minimally invasive techniques for cardio–aortic and aortic procedures. Svensson LG, et al. **Arch Surg** 1998 Nov;133(11):1160–5 (25 ref.)

Adjuvant medical therapy in peripheral bypass surgery. Watson HR, et al. **Br J Surg** 1999 Aug;86(8):981–91 (58 ref.)

End–stage renal disease (ESRD) and vascular access grafting: a critical review. Szycher M. **J Biomater Appl** 1999 Apr; 13(4):297–350 (125 ref.)

Vascular disorders of the hand: surgeons' perspective. Levin LS, et al. **J Hand Ther** 1999 Apr–Jun;12(2):152–9 (14 ref.)

Comprehensive management of arteriovenous malformations. de Oliveira E, et al. **Neurol Res** 1998 Dec;20(8):673–83 (1 ref.)

Endovascular treatment of spinal vascular malformations. Niimi Y, et al. **Neurosurg Clin N Am** 1999 Jan;10(1):47–71 (76 ref.)

The surgical management of spinal dural vascular malformations. Watson JC, et al. **Neurosurg Clin N Am** 1999 Jan;10(1):73–87 (47 ref.)

Management of abdominal vascular injuries. Biffl WL, et al. **Semin Vasc Surg** 1998 Dec;11(4):243–54 (47 ref.)

Vascular trauma associated with fractures and dislocations. Winkelaar GB, et al. **Semin Vasc Surg** 1998 Dec; 11(4):261–73 (51 ref.)

Laparoscopically assisted abdominal aortic aneurysm repair. Cerveira JJ, et al. **Surg Clin North Am** 1999 Jun; 79(3):541–50 (24 ref.)

New imaging techniques in endovascular surgery. Fillinger MF. **Surg Clin North Am** 1999 Jun;79(3):451–75 (36 ref.)

Less–invasive saphenous harvest. Iafrati MM. **Surg Clin North Am** 1999 Jun;79(3):623–44 (62 ref.)

Endoscopic perforating vein surgery. Rhodes JM, et al. **Surg Clin North Am** 1999 Jun;79(3):667–81 (55 ref.)

Minimally invasive in situ bypass. Rosenthal D, et al. **Surg Clin North Am** 1999 Jun;79(3):645–52, x (07 ref.)

Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. Schindler N, et al. **Surg Clin North Am** 1999 Jun;79(3):683–94, xi (36 ref.)

Use of digital ciné–fluoroscopy and catheter–directed techniques to improve and simplify standard vascular procedures. Wain RA, et al. **Surg Clin North Am** 1999 Jun; 79(3):489–505 (38 ref.)

Endovascular treatment of vascular injuries. Weiss VJ, et al. **Surg Clin North Am** 1999 Jun;79(3):653–65 (40 ref.)

Vascular reconstruction in urology. Sorcini A, et al. **Urol Clin North Am** 1999 Feb;26(1):219–34, x–xi (31 ref.)

Minimally invasive vascular surgery: review of current modalities. Weiss VJ, et al. **World J Surg** 1999 Apr; 23(4):406–14 (73 ref.)

[Endovascular procedures in central nervous system diseases] Porras M, et al. **Duodecim** 1995;111(21):2049–57 (23 ref.) **(Fin)**

[Recent advances in vascular surgery] Shindo S, et al. **Nippon Rinsho** 1999 Jul;57(7):1583–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Methods of concealed exclusion of lower extremities perforated and varicose veins in chronic venous insufficiency] Gervaziev VB. **Khirurgiia (Mosk)** 1999; (4):52–5 (6 ref.) (Eng. Abstr.) **(Rus)**

[On the impact of surgery on mucosal vessels of the turbinates (10 years of submucosal vasotomy)] Piskunov SZ. **Vestn Otorinolaringol** 1999;(2):19–22 (29 ref.) (Eng. Abstr.) **(Rus)**

[The venous autograft] Davidović LB, et al. **Srp Arh Celok Lek** 1999 Mar–Apr;127(3–4):118–24 (44 ref.) **(Scc)**

STANDARDS

Plea for a "surgical conscience" in the interventional radiology suite. Joffre F, et al. **Cardiovasc Intervent Radiol** 1998 Nov–Dec;21(6):445–7 (15 ref.)

TRENDS

Vascular surgery. Stanley JC. **J Am Coll Surg** 1999 Feb; 188(2):202–14 (120 ref.)

VASCULITIS

Pulmonary vasculitis. Sullivan EJ, et al. **Clin Chest Med** 1998 Dec;19(4):759–76, ix (138 ref.)

Kawasaki syndrome. Mason WH, et al. **Clin Infect Dis** 1999 Feb;28(2):169–85; quiz 186–7 (172 ref.)

Cutaneous small–vessel vasculitis. Lotti T, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):667–87; quiz 688–90 (218 ref.)

Vasculitis of the central nervous system. Ferro JM. **J Neurol** 1998 Dec;245(12):766–76 (84 ref.)

Vasculitic peripheral ulcerative keratitis. Messmer EM, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):379–96 (231 ref.)

[Primary systemic vasculitis. I. General overview] Gross WL. **Internist (Berl)** 1999 Jul;40(7):779–94 (14 ref.) **(Ger)**

[Recent advance in vasculitis syndrome] Kobayashi S, et al. **Nippon Rinsho** 1999 Feb;57(2):388–92 (12 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Clinical case seminar: Anti–thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. Gunton JE, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):13–6 (33 ref.)

CLASSIFICATION

[Angiitis of the central nervous system in systemic diseases] Biousse V, et al. **Rev Med Interne** 1998 Jun;19(6):415–26 (77 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Is vasculitis a significant component of atherosclerosis? Juvonen T, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):3–10 (93 ref.)

The effects of vasculitis on the gastrointestinal tract and liver. Bailey M, et al. **Gastroenterol Clin North Am** 1998 Dec; 27(4):747–82, v–vi (173 ref.)

[Vasculitis during human acquired immunodeficiency virus infection] Gisselbrecht M. **Pathol Biol (Paris)** 1999 Mar; 47(3):245–7 (16 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of the development of tubulo–interstitial nephropathies due to collagen diseases, angiitis, or granuloma and its significance] Imai H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1467–74 (9 ref.) **(Jpn)**

[Multiple cerebral infarction associated with cerebral vasculitis in rheumatoid arthritis] Ohta K, et al. **Rinsho Shinkeigaku** 1998 May;38(5):423–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Angiitis of the central nervous system. Zuber M, et al. **J Neuroradiol** 1999 Jun;26(2):101–17 (97 ref.)

Interpretation of ANCA serology. Halfpenny CA, et al. **N Z Med J** 1999 Mar 12;112(1083):65–6 (15 ref.)

[Central nervous system angiitis excluding systemic diseases] Biousse V, et al. **Rev Med Interne** 1998;19 Suppl 1:49S–51S (5 ref.) **(Fre)**

[Neurologic complications in ANCA–associated vasculitis] Arbusow V, et al. **Dtsch Med Wochenschr** 1999 Jul 9; 124(27):835–41 (33 ref.) **(Ger)**

DRUG THERAPY

Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Grimbacher B, et al. **Br J Rheumatol** 1998 Sep; 37(9):1023–8 (13 ref.)

New concepts in treatment protocols for severe systemic vasculitis. Gross WL. **Curr Opin Rheumatol** 1999 Jan; 11(1):41–6 (63 ref.)

ETIOLOGY

Models of antineutrophil cytoplasmic antigen-associated systemic vasculitis and their clinical relevance. Weening JJ, et al. **Adv Nephrol Necker Hosp** 1998;28:63–81 (67 ref.)

A 12-year-old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paueksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)

Animal models of infection-mediated vasculitis. Dal Canto AJ, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):17–23 (23 ref.)

Cellular and molecular mechanisms of inflammation and thrombosis. Tan P, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):373–89 (181 ref.)

Suspected hepatitis B vaccination related vasculitis. Le Hello C, et al. **J Rheumatol** 1999 Jan;26(1):191–4 (28 ref.)

Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Blanco R, et al. **Medicine (Baltimore)** 1998 Nov;77(6):403–18 (101 ref.)

Pathophysiology of ANCA-associated glomerulonephritis. Muller Kobold AC, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1366–75 (105 ref.)

[A case with rheumatoid arthritis complicated with ANCA-associated vasculitis] Amano K, et al. **Ryumachi** 1998 Oct;38(5):741–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Current concepts on the etiology and pathogenesis of systemic vasculitis: the role of infection and genetic predisposition (I)] Nasonov EA, et al. **Klin Med (Mosk)** 1998;76(7):5–11 (122 ref.) **(Rus)**

[Current views about etiology and pathogenesis of systemic vasculitis: role of autoantibodies and disturbances of cellular immunity (part II)] Nasonov EL, et al. **Klin Med (Mosk)** 1998;76(8):4–9 (90 ref.) **(Rus)**

GENETICS

Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. Nowack R, et al. **Am J Kidney Dis** 1999 Aug;34(2):364–73 (99 ref.)

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Fruchart JC, et al. **Curr Opin Lipidol** 1999 Jun;10(3):245–57 (99 ref.)

Molecular approaches for identification of infectious agents in Wegener's granulomatosis and other vasculitides. Nikkari S, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):11–6 (52 ref.)

Vasculitis-susceptible genes in mice with a deficit in Fas-mediated apoptosis. Nose M, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S37–41; discussion S43 (25 ref.)

IMMUNOLOGY

What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications. Kallenberg CG, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):307–15 (58 ref.)

Evolving concepts about the role of antineutrophil cytoplasm autoantibodies in systemic vasculitides. Bajema IM, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):34–40 (70 ref.)

The role of superantigens in vasculitis. Cohen Tervaert JW, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):24–33 (92 ref.)

Vasculopathy, Behçet's syndrome, and familial Mediterranean fever. Ozen S. **Curr Opin Rheumatol** 1999 Sep;11(5):393–8 (36 ref.)

Autoantibodies to myeloperoxidase: clinical and pathophysiological significance. Kallenberg CG. **J Mol Med** 1998 Sep;76(10):682–7 (38 ref.)

METABOLISM

Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Kevil CG, et al. **Am J Med** 1999 Jun;106(6):677–87 (92 ref.)

PATHOLOGY

Injury mechanisms in vasculitis. Savage CO. **Kidney Blood Press Res** 1998;21(2–4):269–70 (11 ref.)

Infantile disseminated visceral giant cell arteritis presenting as sudden infant death. Kagata Y, et al. **Pathol Int** 1999 Mar;49(3):226–30 (19 ref.)

THERAPY

Immunoadsorption in systemic connective tissue diseases and primary vasculitis [editorial] Schneider M, et al. **Ther Apher** 1997 May;1(2):117–20 (22 ref.)

[Treatment of viral vasculitis] Lhote F, et al. **Pathol Biol (Paris)** 1999 Mar;47(3):257–64 (38 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenetic validation of systemic vasculitis treatment] Nasonov EL, et al. **Klin Med (Mosk)** 1999;77(7):15–8 (9 ref.) **(Rus)**

[Treatment of patients with systemic vasculitis (review)] Nasonov EL, et al. **Ter Arkh** 1998;70(11):53–8 (65 ref.) **(Rus)**

VIROLOGY

Vasculitis and chronic persistent viral infections [editorial] Calabrese LH. **Ann Med Interne (Paris)** 1998 Nov; 149(7):395–7 (17 ref.)

[Physiopathology of viral vasculitis] Généreau T, et al. **Pathol Biol (Paris)** 1999 Mar;47(3):226–31 (64 ref.) (Eng. Abstr.) **(Fre)**

[Vasculitis associated with antiviral vaccines and antiviral agents] Le Hello C. **Pathol Biol (Paris)** 1999 Mar; 47(3):252–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of viral vasculitis] Lhote F, et al. **Pathol Biol (Paris)** 1999 Mar;47(3):257–64 (38 ref.) (Eng. Abstr.) **(Fre)**

[Viral vasculitis not related to HBV, HCV and HIV] Lortholary O, et al. **Pathol Biol (Paris)** 1999 Mar; 47(3):248–51 (38 ref.) (Eng. Abstr.) **(Fre)**

VASCULITIS, ALLERGIC CUTANEOUS

ETIOLOGY

[Allergic vasculitis] Jansen T, et al. **Fortschr Med** 1998 Oct 20;116(29):55–7 (5 ref.) **(Ger)**

VASCULITIS, CHURG-STRAUSS see **CHURG-STRAUSS SYNDROME**

VASCULITIS, HEMORRHAGIC see **PURPURA, SCHOENLEIN-HENOCH**

VASCULITIS, HYPERSENSITIVITY

DIAGNOSIS

A palpable clue to vasculitis. Arvan ME, et al. **Postgrad Med** 1999 Mar;105(3):229–32 (11 ref.)

[Leukocytoclastic vasculitis associated with Helicobacter pylori infection (letter)] Herranz P, et al. **Rev Clin Esp** 1998 Nov;198(11):779 (8 ref.) **(Spa)**

ETIOLOGY

[Infection and vascular purpura] Lévesque H, et al. **J Mal Vasc** 1999 Jun;24(3):177–82 (30 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pathogenesis of leukocytoclastic vasculitis. Claudy A. **Eur J Dermatol** 1998 Mar;8(2):75–9 (38 ref.)

[Physiopathology of leukocytoclastic vasculitis] Claudy A. **Ann Dermatol Venereol** 1998 Nov;125(11):791–6 (30 ref.) **(Fre)**

THERAPY

Treatment of polyarteritis nodosa and microscopic polyangiitis. Guillevin L, et al. **Arthritis Rheum** 1998 Dec; 41(12):2100–5 (49 ref.)

VASCULITIS, LEUKOCYTOCLASTIC see **VASCULITIS, HYPERSENSITIVITY**

VASECTOMY

see related
STERILIZATION REVERSAL

[Commentary and considerations related to vasectomy (editorial)] Pellicé i Vilalta C. **Actas Urol Esp** 1998 Jul-Aug;22(7):547–51 (31 ref.) **(Spa)**

METHODS

Vasectomy techniques. Clenney TL, et al. **Am Fam Physician** 1999 Jul;60(1):137–46, 151–2 (26 ref.)

VASOACTIVE AGONISTS see **VASOCONSTRICTOR AGENTS**

VASOACTIVE ANTAGONISTS see **VASODILATOR AGENTS**

VASOACTIVE INTESTINAL PEPTIDE

see related
GASTROINTESTINAL AGENTS
RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE
VASODILATOR AGENTS

ANALYSIS

Vipergic innervation of the mammalian pineal gland. Cozzi B. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):257–64 (109 ref.)

Peptidergic peripheral nervous systems in the mammalian pineal gland. Matsushima S, et al. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):265–80 (77 ref.)

CHEMISTRY

Solution structure comparison of the VIP/PACAP family of peptides by NMR spectroscopy. Wray V, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:37–44 (17 ref.)

GENETICS

Cis-regulatory elements controlling basal and inducible VIP gene transcription. Hahm SH, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:10–26 (48 ref.)

METABOLISM

Autoantibody catalysis: no longer hostage to Occam's razor. Paul S. **Ann N Y Acad Sci** 1998 Dec 11;865:238–46 (27 ref.)

PHYSIOLOGY

VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Brenneman DE, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:207–12 (24 ref.)

VIP and PACAP in the CNS: regulators of glial energy metabolism and modulators of glutamatergic signaling. Magistretti PJ, et al. **Ann N Y Acad Sci** 1998 Dec 11; 865:213–25 (38 ref.)

Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Delgado M, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1–2):97–107 (81 ref.)

Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Nussdorfer GG, et al. **Peptides** 1998;19(8):1443–67 (346 ref.)

VIP and PACAP: very important in pain? Dickinson T, et al. **Trends Pharmacol Sci** 1999 Aug;20(8):324–9 (77 ref.)

SECRETION

Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Smith SL, et al. **Surgery** 1998 Dec;124(6):1050–5 (25 ref.)

VASOACTIVE INTESTINAL PEPTIDE RECEPTORS see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

VASOCONSTRICTION

see related
VASOCONSTRICTOR AGENTS

Endothelial dysfunction and hypertensive vasoconstriction. De Artinano AA, et al. **Pharmacol Res** 1999 Aug; 40(2):113–24 (143 ref.)

DRUG EFFECTS

Pharmacology of coronary artery bypass grafts. Rosenfeldt FL, et al. **Ann Thorac Surg** 1999 Mar;67(3):878–88 (46 ref.)

The role of corticosteriods in the regulation of vascular tone. Ullian ME. **Cardiovasc Res** 1999 Jan;41(1):55–64 (115 ref.)

Acute effects of angiotensin-converting enzyme inhibition on coronary vasomotion in hypertensive patients. Nitenberg A, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J45–51 (39 ref.)

PHYSIOLOGY

The discovery of endothelins. Masaki T. **Cardiovasc Res** 1998 Sep;39(3):530–3 (14 ref.)

Subcellular mechanisms of endothelin action in vascular system. Masaki T, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):133–8 (38 ref.)

Splanchnic circulatory physiology. Ralevic V. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1409–13 (35 ref.)

Signaling mechanisms underlying the vascular myogenic response. Davis MJ, et al. **Physiol Rev** 1999 Apr; 79(2):387–423 (402 ref.)

[Endothelium in the control of vascular tone: the physiological role] Bachetti T, et al. **Cardiologia** 1998 Aug; 43(8):793–804 (81 ref.) **(Ita)**

VASOCONSTRICTOR AGENTS

ADMINISTRATION & DOSAGE

Appropriate migraine therapy for children and adolescents. Farkas V. **Cephalalgia** 1999 Mar;19 Suppl 23:24–6; discussion 26–8 (26 ref.)

Adrenaline dosage and buffers in cardiac arrest. Adgey AA. **Heart** 1998 Oct;80(4):412–4 (10 ref.)

Neuropsychological effects of vasopressin in healthy humans. Born J, et al. **Prog Brain Res** 1998;119:619–43 (126 ref.)

[New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses] Dahlöf CG. **Lakartidningen** 1998 Nov 11;95(46):5175, 5178–82, 5184–6 (60 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Mechanism of erythropoietin-induced hypertension. Vaziri ND. **Am J Kidney Dis** 1999 May;33(5):821–8 (50 ref.)

METABOLISM

Endothelin and restenosis. Kirchengast M, et al. **Cardiovasc Res** 1998 Sep;39(3):550–5 (51 ref.)

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Rittenhouse HG, et al. **Crit Rev Clin Lab Sci** 1998 Aug;35(4):275–368 (457 ref.)

Release of vasoactive substances from endothelial cells by

shear stress and purinergic mechanosensory transduction. Burnstock G. **J Anat** 1999 Apr;194 (Pt 3):335–42 (103 ref.)
Arginine vasopressin, fever and temperature regulation. Pittman QJ, et al. **Prog Brain Res** 1998;119:383–92 (90 ref.)

PHARMACOLOGY

Effect of the angiotensin–(1–7) peptide on nitric oxide release. Brosnihan KB. **Am J Cardiol** 1998 Nov 19;82(10A):17S–19S (12 ref.)
Effects of vasoactive drugs on gastric intramucosal pH [see comments] Silva E, et al. **Crit Care Med** 1998 Oct; 26(10):1749–58 (98 ref.) Comment in: Crit Care Med 1998 Oct;26(10):1637–8.
Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. Part V of a series [see comments] Yagiela JA. **J Am Dent Assoc** 1999 May; 130(5):701–9 (53 ref.) Comment in: J Am Dent Assoc 1999 Sep;130(9):1272, 1274.
Vasoactive properties of synthetic blood substitutes. de Figueiredo LF. **Medicina (B Aires)** 1998;58(4):403–10 (74 ref.)
Deleterious action of vasopressin in gastroduodenal ulceration: experimental and clinical observations. László F, et al. **Scand J Gastroenterol Suppl** 1998;228:62–7 (59 ref.)

THERAPEUTIC USE

Naratriptan: an alternative for migraine. Dulli DA. **Ann Pharmacother** 1999 Jun;33(6):704–11 (39 ref.)
Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen P. **Cephalalgia** 1998 Oct;18(8):532–8 (56 ref.)
Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. **Crit Care Med** 1999 Mar;27(3):639–60 (197 ref.)
A practical guide to the management of oesophageal varices. McCormack G, et al. **Drugs** 1999 Mar;57(3):327–35 (37 ref.)

VASOCONSTRICTOR AGENTS, NASAL see **NASAL DECONGESTANTS**

VASODILATATION see **VASODILATION**

VASODILATION

see related

VASODILATOR AGENTS

Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Weber AA, et al. **Basic Res Cardiol** 1998;93 Suppl 3:54–7 (20 ref.)
Squeezing tubes: a case of remodeling and regulation: coronary reserve in hypertensive heart disease. Schwartzkopff B, et al. **Cardiovasc Res** 1998 Oct;40(1):4–8 (30 ref.)
Regulation of vasodilator synthesis during lung development. Shaul PW. **Early Hum Dev** 1999 Apr;54(3):271–94 (87 ref.)
Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. Britten MB, et al. **J Intern Med** 1999 Apr;245(4):315–27 (138 ref.)

DRUG EFFECTS

Vascular reactivity. Baron AD. **Am J Cardiol** 1999 Jul 8; 84(1A):25J–27J (7 ref.)
Overall cardiovascular profile of sildenafil citrate. Zusman RM, et al. **Am J Cardiol** 1999 Mar 4;83(5A):35C–44C (33 ref.)
Role of non-nitric oxide non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. Resende AC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1229–35 (58 ref.)
Systemic and ocular vascular roles of the antiglaucoma agents beta-adrenergic antagonists and Ca2+ entry blockers. Yu DY, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S214–22 (82 ref.)

PHYSIOLOGY

The effects of diadenosine polyphosphates on the cardiovascular system. Flores NA, et al. **Cardiovasc Res** 1999 Apr;42(1):15–26 (82 ref.)
The myogenic response: established facts and attractive hypotheses. Schubert R, et al. **Clin Sci (Colch)** 1999 Apr; 96(4):313–26 (101 ref.)
Functional role of nitric oxide in regulation of ocular blood flow. Koss MC. **Eur J Pharmacol** 1999 Jun 18;374(2):161–74 (200 ref.)
Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Balasch J, et al. **Hum Reprod** 1998 Oct;13(10O):2718–30 (85 ref.)
Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. Tsao PS, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S48–53 (62 ref.)
Adaptation of blood flow during the rest to work transition in humans. Shoemaker JK, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):1019–26 (87 ref.)
Signaling mechanisms underlying the vascular myogenic response. Davis MJ, et al. **Physiol Rev** 1999 Apr; 79(2):387–423 (402 ref.)
Involvement of the 5-HT7 receptor in craniovascular vasodilatation: potential impact in migraine. Terrón JA. **Proc West Pharmacol Soc** 1998;41:247–51 (78 ref.)
Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation. Pelligrino DA, et al. **Prog Neurobiol** 1998 Oct; 56(1):1–18 (130 ref.)
Flow-dependent vasodilation in the coronary circulation: alterations in diseased states. Mandinov L, et al. **Semin Interv Cardiol** 1998 Mar;3(1):5–12 (49 ref.)
[Endothelium in the control of vascular tone: the physiological role] Bachetti T, et al. **Cardiologia** 1998 Aug; 43(8):793–804 (81 ref.) **(Ita)**
[Endothelium-derived hyperpolarizing factor and vasodilatation] Suzuki H, et al. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):195–202 (50 ref.) (Eng. Abstr.) **(Jpn)**

VASODILATOR AGENTS

The role of adrenomedullin. Charles CJ, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):166–73 (99 ref.)
Long-acting isosorbide mononitrate [published erratum appears in Drugs 1999 Mar;57(3):438] Prakash A, et al. **Drugs** 1999 Jan;57(1):93–9; discussion 100 (24 ref.)
[Adrenomedullin. A new peptide involved in the regulation of the cardiovascular system] Letizia C, et al. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):407–11 (37 ref.) (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. Carter BL. **Am J Health Syst Pharm** 1998 Nov 15;55 Suppl 3:S17–23 (26 ref.)
Low-dose inhaled nitric oxide and oxygenation in pediatric hypoxic respiratory failure. Wrong bullet, wrong target [editorial; comment] Tibby S, et al. **Crit Care Med** 1999 May;27(5):871–2 (21 ref.) Comment on: Crit Care Med 1999 May;27(5):989–96.
Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. Carrier M, et al. **J Heart Lung Transplant** 1999 Jul;18(7):664–7 (9 ref.)
Acute respiratory distress syndrome. Inhaled nitric oxide. Hanania NA, et al. **Respir Care Clin N Am** 1998 Dec; 4(4):695–709 (93 ref.)
[Transurethral alprostadil administration with MUSE ("Medicated Urethral System for Erection"). Current overview and personal experiences] Porst H. **Urologe A** 1998 Jul;37(4):410–6 (28 ref.) (Eng. Abstr.) **(Ger)**
[Short-term versus long-term use of nitrates in acute myocardial infarction] Nakamura Y, et al. **Nippon Rinsho** 1998 Oct;56(10):2617–22 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Inhaled nitric oxide: one modality in the treatment of ARDS] Carrillo-Esper R, et al. **Gac Med Mex** 1999 Jul–Aug; 135(4):417–21 (28 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Is the administration of inhaled nitric oxide (NO) associated with electroencephalogram abnormalities? There is NO harm in looking [editorial; comment] Kochanek PM, et al. **Crit Care Med** 1998 Nov;26(11):1788–9 (12 ref.) Comment on: Crit Care Med 1998 Nov;26(11):1887–92.
The 'vasovagal effect' of nitrates: an under-recognised complication of nitrate use. Lydakis C, et al. **Int J Clin Pract** 1998 Sep;52(6):418–21 (40 ref.)

DIAGNOSTIC USE

Dipyridamole stress echocardiography. Picano E, et al. **Cardiol Clin** 1999 Aug;17(3):481–99, viii (101 ref.)

METABOLISM

Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. Burnstock G. **J Anat** 1999 Apr;194 (Pt 3):335–42 (103 ref.)

PHARMACOLOGY

Angiotensin–(1–7): a novel vasodilator of the coronary circulation. Brosnihan KB, et al. **Biol Res** 1998;31(3):227–34 (45 ref.)
Dopexamine: much more than a vasoactive agent [editorial; comment] Bennett ED. **Crit Care Med** 1998 Oct; 26(10):1621–2 (10 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1639–45.
Effects of vasoactive drugs on gastric intramucosal pH [see comments] Silva E, et al. **Crit Care Med** 1998 Oct; 26(10):1749–58 (98 ref.) Comment in: Crit Care Med 1998 Oct;26(10):1637–8.
Cilostazol. Sorkin EM, et al. **Drugs Aging** 1999 Jan; 14(1):63–71; discussion 72–3 (35 ref.)
How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions? Jost S, et al. **Int J Card Imaging** 1998 Dec;14(6):357–72 (105 ref.)
Nitric oxide and the vascular surgeon. Makhoul RG, et al. **J Vasc Surg** 1999 Sep;30(3):569–72 (5 ref.)
The effects on the central nervous system of nitroglycerin--putative mechanisms and mediators. Tassorelli C, et al. **Prog Neurobiol** 1999 Apr;57(6):607–24 (127 ref.)
Neurohumoral fluid regulation in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):361–72 (107 ref.)
Ulster says 'NO': explosion, resistance and tolerance. Nitric oxide and the actions of organic nitrates. Johnston GD. **Ulster Med J** 1998 Nov;67(2):79–90 (99 ref.)

THERAPEUTIC USE

Newer pharmacologic alternatives for erectile dysfunction. Viera AJ, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1159–66, 1169, 1172 (23 ref.)
Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? [editorial; comment] Sias TM, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):206–9 (26 ref.) Comment on: Am Heart J 1999 Aug;138(2 Pt 1):369–75.
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Girolami B, et al. **Arch Intern Med** 1999 Feb 22;159(4):337–45 (116 ref.)
Chronic aortic regurgitation. Role of medical therapy and optimal timing for surgery. Bonow RO. **Cardiol Clin** 1998 Aug;16(3):449–61 (72 ref.)
The role of third-generation beta-blocking agents in chronic heart failure [published erratum appears in Clin Cardiol 1999 Mar;22(3):following table of contents] Bristow MR, et al. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I3–13 (76 ref.)
Vasodilators in mechanical ventilation. Zimmerman JL, et al. **Crit Care Clin** 1998 Oct;14(4):611–27 (89 ref.)
An intensivist's dilemma: support of the splanchnic circulation in critical illness [editorial; comment] Marshall JC. **Crit Care Med** 1998 Oct;26(10):1637–8 (20 ref.) Comment on: Crit Care Med 1998 Oct;26(10):1749–58.
Management of postoperative chylothorax with nitric oxide: a critical review [editorial; comment] Mavroudis C. **Crit Care Med** 1999 May;27(5):877 (4 ref.) Comment on: Crit Care Med 1999 May;27(5):1022–4.
New therapeutic approaches to reversing insulin resistance. Sonnenberg GE, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):551–5 (51 ref.)
Inhaled nitric oxide therapy for pulmonary disease in pediatrics. Abman SH, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):236–42 (33 ref.)
Long-term therapy for pulmonary hypertension in children. Dent CL, et al. **Curr Opin Pediatr** 1999 Jun;11(3):218–22 (27 ref.)
Inhaled nitric oxide in the treatment of hypoxemic respiratory failure. Kass LJ, et al. **Curr Opin Pediatr** 1998 Jun; 10(3):284–90 (27 ref.)
Comparative tolerability and efficacy of treatments for impotence. Meinhardt W, et al. **Drug Saf** 1999 Feb; 20(2):133–46 (114 ref.)
Glyceryl trinitrate for anal fissure? **Drug Ther Bull** 1998 Jul; 36(7):55–6 (21 ref.)
Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. McClellan KJ, et al. **Drugs** 1999 Jul;58(1):143–57 (64 ref.)
Recognition and management of pulmonary hypertension. Wanstall JC, et al. **Drugs** 1998 Dec;56(6):989–1007 (163 ref.)
A systematic review of vinpocetine therapy in acute ischaemic stroke. Bereczki D, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):349–52 (30 ref.)
Trimetazidine: potential mechanisms of action in hypertrophic cardiomyopathy. D'hahan N. **J Cardiovasc Pharmacol** 1999 Mar;33(3):500–6 (89 ref.)
A rationale for treatment of endothelial dysfunction in hypertension. Ruschitzka F, et al. **J Hypertens Suppl** 1999 Feb;17(1):S25–35 (161 ref.)
Therapy for cardiac failure: treatments old and new. Pavia SV, et al. **Med J Aust** 1999 Sep 6;171(5):265–71 (32 ref.)
Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Passani MB, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):725–33 (96 ref.)
Use of nitroglycerin for uterine relaxation. Smith GN, et al. **Obstet Gynecol Surv** 1998 Sep;53(9):559–65 (57 ref.)
Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes. Moreno AJ, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II63–77 (100 ref.)
Raynaud's phenomenon: state of the art 1998 [editorial] Ho M, et al. **Scand J Rheumatol** 1998;27(5):319–22 (37 ref.)
How to use cerebral vasodilators and metabolic activators. Isozumi K, et al. **Tokai J Exp Clin Med** 1998 Oct; 23(4):187–92 (39 ref.)
[The treatment of chronic fissure in ano with nitrate ointment (see comments)] Stassen LP, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):13–6 (26 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Feb 13;143(7):381. **(Dut)**
[Contribution of vastarel 20 mg (trimetazidine) in the treatment of vertigo: synopsis of clinical trials] Bouccara D. **Ann Otolaryngol Chir Cervicofac** 1999 Apr;116(1):43–6 (6 ref.) **(Fre)**
[Today's amiodarone] Burri M. **Rev Med Suisse Romande** 1998 Aug;118(8):665–9 (9 ref.) **(Fre)**
[Vasotropic therapy and artificial respiration for pulmonary hypertension] Grimminger F, et al. **Internist (Berl)** 1999 Jul;40(7):747–55 (16 ref.) **(Ger)**
[The role of nitrogen oxide in migraine attack] Stępień A. **Neurol Neurochir Pol** 1999 Mar–Apr;33(2):435–44 (20 ref.) (Eng. Abstr.) **(Pol)**
[Molsidomine: importance in treatment of circulation

disorders] Kmieć M, et al. **Przegl Lek** 1998;55(10):532–6 (47 ref.) (Eng. Abstr.) **(Pol)**

[The use of Vasaprostan in patients with systemic lupus erythematosus and the antiphospholipid syndrome] Reshetniak TM, et al. **Ter Arkh** 1999;71(5):40–7 (52 ref.) **(Rus)**

[The range of clinical use of current calcium antagonists] Sidorenko BA, et al. **Ter Arkh** 1998;70(12):80–4 (24 ref.) **(Rus)**

VASOMOTOR SYSTEM

see related
BAROREFLEX
MUSCLE, SMOOTH, VASCULAR
VASOCONSTRICTION
VASOCONSTRICTOR AGENTS
VASODILATION
VASODILATOR AGENTS

DRUG EFFECTS

Role of non-nitric oxide non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. Resende AC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1229–35 (58 ref.)

How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions? Jost S, et al. **Int J Card Imaging** 1998 Dec;14(6):357–72 (105 ref.)

[Vascular effects of gestagens—biochemistry versus epidemiology] **Kuhl H. Zentralbl Gynakol** 1999; 121(2):67–78 (99 ref.) (Eng. Abstr.) **(Ger)**

[Effects on vasomotor tone and hemostatic function of radiologic contrast media used during invasive cardiological procedures] De Caterina R, et al. **G Ital Cardiol** 1999 Sep;29(9):1047–52 (40 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Vasomotor flushes in menopausal women. Bachmann GA. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):312–6 (26 ref.)

Role for NADPH/NADH oxidase in the modulation of vascular tone. Münzel T, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:386–400 (47 ref.)

Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone [editorial; comment] Campbell WB, et al. **Circ Res** 1999 Mar 5;84(4):484–8 (57 ref.) Comment on: Circ Res 1999 Mar 5;84(4):371–7.

Role of potassium channels in regulation of cerebral vascular tone. Faraci FM, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1047–63 (209 ref.)

Nervous control of blood flow in the orofacial region. Izumi H. **Pharmacol Ther** 1999 Feb;81(2):141–61 (275 ref.)

Vasomotor tone and the role of nitric oxide. Fields CE, et al. **Semin Vasc Surg** 1998 Sep;11(3):181–92 (69 ref.)

Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension. Cardillo C, et al. **Vasc Med** 1998;3(2):138–44 (79 ref.)

Oxidized low-density lipoprotein enhances intimal thickening and alters vascular reactivity. Herman A, et al. **Verh K Acad Geneeskd Belg** 1999;61(1):19–36; discussion 36–8 (63 ref.)

[Role of endothelial nitric oxide in the regulation of the vasomotor system] Michel JB. **Pathol Biol (Paris)** 1998 Mar; 46(3):181–9 (29 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Endothelial control of vascular tone in chronic heart failure. Kiowski W, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S67–73 (73 ref.)

Leukotrienes and lipoxins: lipoxygenase-derived modulators of leukocyte recruitment and vascular tone in glomerulonephritis. Clarkson MR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3043–51 (92 ref.)

VASOPRESSIN, ARGININE see **ARGIPRESSIN**

VASOPRESSIN, DEAMINO ARGININE see **DESMOPRESSIN**

VASOPRESSIN, ISOLEUCYL see **VASOTOCIN**

VASOPRESSIN, LYSINE see **LYPRESSIN**

VASOPRESSIN, NON-MAMMALIAN see **VASOTOCIN**

VASOPRESSIN RECEPTORS see **RECEPTORS, VASOPRESSIN**

VASOPRESSINS

see related
INAPPROPRIATE ADH SYNDROME
RECEPTORS, VASOPRESSIN

Regulation of the synthesis and secretion of vasopressin. Murphy D, et al. **Prog Brain Res** 1998;119:137–43 (27 ref.)

ADMINISTRATION & DOSAGE

Neuropsychological effects of vasopressin in healthy humans. Born J, et al. **Prog Brain Res** 1998;119:619–43 (126 ref.)

ANALYSIS

Vasopressin binding sites in the central nervous system: distribution and regulation. Tribollet E, et al. **Prog Brain Res** 1998;119:45–55 (76 ref.)

ANTAGONISTS & INHIBITORS

Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Mayinger B, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):157–65 (90 ref.)

Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Bossmar T. **J Perinat Med** 1998;26(6):458–65 (67 ref.)

Aquaporin-2 water channels and vasopressin antagonists in edematous disorders. Schrier RW, et al. **Mol Genet Metab** 1998 Dec;65(4):255–63 (56 ref.)

GENETICS

Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons. Gainer H. **Adv Exp Med Biol** 1998; 449:15–27 (59 ref.)

Vasopressin processing defects in the Brattleboro rat: implications for hereditary central diabetes insipidus in humans? Kim JK, et al. **Proc Assoc Am Physicians** 1998 Sep–Oct;110(5):380–6 (42 ref.)

Phenotypic and state-dependent expression of the electrical and morphological properties of oxytocin and vasopressin neurones. Armstrong WE, et al. **Prog Brain Res** 1998; 119:101–13 (91 ref.)

The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Bohus B, et al. **Prog Brain Res** 1998;119:555–73 (112 ref.)

Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoid feedback. Kovács KJ. **Prog Brain Res** 1998;119:31–43 (70 ref.)

The magnocellular neurons of the hypothalamo-neurohypophyseal system display remarkable neuropeptidergic phenotypes leading to novel insights in neuronal cell biology. van Leeuwen FW, et al. **Prog Brain Res** 1998;119:115–26 (62 ref.)

METABOLISM

Comparative neuroanatomy of vasotocin and vasopressin in amphibians and other vertebrates. Moore FL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):251–60 (114 ref.)

Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy. Schrier RW, et al. **Proc Assoc Am Physicians** 1998 Sep–Oct; 110(5):407–11 (46 ref.)

Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Ingram CD, et al. **Prog Brain Res** 1998;119:351–64 (92 ref.)

Vasopressin acting at V1-type receptors produces membrane depolarization in neonatal rat spinal lateral column neurons. Kolaj M, et al. **Prog Brain Res** 1998;119:275–84 (63 ref.)

Coping with stress in rats and mice: differential peptidergic modulation of the amygdala-lateral septum complex. Koolhaas JM, et al. **Prog Brain Res** 1998;119:437–48 (68 ref.)

Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoid feedback. Kovács KJ. **Prog Brain Res** 1998;119:31–43 (70 ref.)

Release of vasopressin within the brain contributes to neuroendocrine and behavioral regulation. Landgraf R, et al. **Prog Brain Res** 1998;119:201–20 (99 ref.)

Functions of the perikaryon and dendrites in magnocellular vasopressin-secreting neurons: new insights from ultrastructural studies. Morris JF, et al. **Prog Brain Res** 1998;119:21–30 (59 ref.)

Vasopressin binding sites in the central nervous system: distribution and regulation. Tribollet E, et al. **Prog Brain Res** 1998;119:45–55 (76 ref.)

Voles and vasopressin: a review of molecular, cellular, and behavioral studies of pair bonding and paternal behaviors. Wang Z, et al. **Prog Brain Res** 1998;119:483–99 (79 ref.)

Steroid hormone regulation of vasopressinergic neurotransmission in the central nervous system. Watters JJ, et al. **Prog Brain Res** 1998;119:247–61 (60 ref.)

[Relationship between corticotropin and arginine vasopressin in endocrine diseases] Vantyghem MC, et al. **Presse Med** 1999 Jun 5;28(20):1085–90 (60 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Role of the mesolimbic dopamine system in cardiovascular homeostasis. Stimulation of the ventral tegmental area modulates the effect of vasopressin on blood pressure in conscious rats. van den Buuse M. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):661–8 (74 ref.)

[Vasopressin: cellular and molecular aspects of its antidiuretic effect] Ivanova LN. **Vestn Ross Akad Med Nauk** 1999; (3):40–5 (74 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Electrophysiological distinctions between oxytocin and vasopressin neurons in the supraoptic nucleus. Armstrong WE, et al. **Adv Exp Med Biol** 1998;449:67–77 (47 ref.)

Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Grazzini E, et al. **Adv Exp Med Biol** 1998;449:325–34 (26 ref.)

Mechanisms of neuroendocrine cell excitability. Hatton GI, et al. **Adv Exp Med Biol** 1998;449:79–95 (86 ref.)

Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Insel TR, et al. **Adv Exp Med Biol** 1998; 449:215–24 (50 ref.)

Modulation of vasopressin-elicited water transport by trafficking of aquaporin2-containing vesicles. Ward DT, et al. **Annu Rev Physiol** 1999;61:683–97 (97 ref.)

Something fishy in the rat brain: molecular genetics of the hypothalamo-neurohypophysial system. Murphy D, et al. **Bioessays** 1998 Sep;20(9):741–9 (62 ref.)

Oxytocin, vasopressin, and autism: is there a connection? Insel TR, et al. **Biol Psychiatry** 1999 Jan 15;45(2):145–57 (85 ref.)

Endogenous vasopressin and the central control of heart rate during dynamic exercise. Michelini LC. **Braz J Med Biol Res** 1998 Sep;31(9):1185–95 (52 ref.)

Vasopressin : a potent autocrine/paracrine regulator of mammal adrenal functions. Guillon G, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):703–10 (16 ref.)

A review of water balance in ageing in health and disease. Stout NR, et al. **Gerontology** 1999;45(2):61–6 (43 ref.)

Regulation of thick ascending limb transport by vasopressin. Knepper MA, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):628–34 (75 ref.)

From vasopressin receptor to water channel: intracellular traffic, constraint and by-pass. Laycock JF, et al. **J Endocrinol** 1998 Dec;159(3):361–72 (77 ref.)

Aquaporins (water channels): role in vasopressin-activated water transport. Dibas AI, et al. **Proc Soc Exp Biol Med** 1998 Dec;219(3):183–99 (183 ref.)

Role of vasopressin and oxytocin in the control of social behavior in Syrian hamsters (Mesocricetus auratus). Albers HE, et al. **Prog Brain Res** 1998;119:395–408 (71 ref.)

Osmoregulation of vasopressin neurons: a synergy of intrinsic and synaptic processes. Bourque CW. **Prog Brain Res** 1998; 119:59–76 (120 ref.)

The suprachiasmatic nucleus-paraventricular nucleus interactions: a bridge to the neuroendocrine and autonomic nervous system. Buijs RM, et al. **Prog Brain Res** 1998; 119:365–82 (93 ref.)

Vasopressin, gonadal steroids and social recognition. Dantzer R. **Prog Brain Res** 1998;119:409–14 (23 ref.)

Anatomy and function of extrahypothalamic vasopressin systems in the brain. de Vries GJ, et al. **Prog Brain Res** 1998;119:3–20 (97 ref.)

Vasopressin in the mammalian brain: the neurobiology of a mnemonic peptide. Diaz Brinton R. **Prog Brain Res** 1998; 119:177–99 (103 ref.)

Vasopressin and sensory circumventricular organs. Jurzak M, et al. **Prog Brain Res** 1998;119:221–45 (181 ref.)

Electrophysiological studies of neurohypophysial neurons and peptides. Pittman QJ, et al. **Prog Brain Res** 1998; 119:311–20 (57 ref.)

Vasopressin in the locus coeruleus and dorsal pontine tegmentum affects posture and vestibulospinal reflexes. Pompeiano O. **Prog Brain Res** 1998;119:537–54 (65 ref.)

Neurohypophyseal peptides and social recognition in rats. Popik P, et al. **Prog Brain Res** 1998;119:415–36 (167 ref.)

Vasopressin and oxytocin action in the brain: cellular neurophysiological studies. Raggenbass M, et al. **Prog Brain Res** 1998;119:263–73 (62 ref.)

A peptidergic basis for sexual behavior in mammals. Smock T, et al. **Prog Brain Res** 1998;119:467–81 (113 ref.)

Role of brain vasopressin in regulation of blood pressure. Toba K, et al. **Prog Brain Res** 1998;119:337–49 (135 ref.)

Physiological pathways regulating the activity of magnocellular neurosecretory cells. Leng G, et al. **Prog Neurobiol** 1999 Apr;57(6):625–55 (278 ref.)

Deleterious action of vasopressin in gastroduodenal ulceration: experimental and clinical observations. László F, et al. **Scand J Gastroenterol Suppl** 1998;228:62–7 (59 ref.)

[Polyuropolydipsic syndromes] Fouqueray B, et al. **Presse Med** 1998 Oct 10;27(30):1545–53 (67 ref.) (Eng. Abstr.) **(Fre)**

[Vasopressin and water metabolism] Oiso Y. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):392–5 (5 ref.) **(Jpn)**

SECRETION

Differential central and peripheral release of vasopressin and oxytocin in response to swim stress in rats. Engelmann M, et al. **Adv Exp Med Biol** 1998;449:175–7 (15 ref.)

Intrahypothalamic vasopressin release. An inhibitor of systemic vasopressin secretion? Ludwig M, et al. **Adv Exp Med Biol** 1998;449:163–73 (50 ref.)

Dendritic release of vasopressin and oxytocin. Ludwig M. **J Neuroendocrinol** 1998 Dec;10(12):881–95 (182 ref.)

Functions of the perikaryon and dendrites in magnocellular vasopressin-secreting neurons: new insights from ultrastructural studies. Morris JF, et al. **Prog Brain Res** 1998;119:21–30 (59 ref.)

VASOPRESSOR AGENTS see **VASOCONSTRICTOR AGENTS**

VASORELAXATION see **VASODILATION**

VASOTOCIN

ANALOGS & DERIVATIVES

Oxytocin receptor antagonists. Update. Goodwin TM, et al. **Clin Perinatol** 1998 Dec;25(4):859–71, vi (49 ref.)

Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Bossmar T. **J Perinat Med** 1998;26(6):458–65 (67 ref.)

METABOLISM

Comparative neuroanatomy of vasotocin and vasopressin in amphibians and other vertebrates. Moore FL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):251–60 (114 ref.)

VATER'S AMPULLA

see related
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE
SPHINCTEROTOMY, ENDOSCOPIC

Pancreaticoduodenectomy for melanoma metastatic to the duodenum: a case report and review of the literature. Meyers MO, et al. **Am Surg** 1998 Dec;64(12):1174–6 (15 ref.)

Preventative strategies for periampullary tumours in FAP. Wallace MH, et al. **Ann Oncol** 1999;10 Suppl 4:201–3 (19 ref.)

Management of periampullary adenoma. Norton ID, et al. **Dig Dis** 1998 Sep–Oct;16(5):266–73 (52 ref.)

Multiple parapapillary choledochoduodenal fistulas with ampullary carcinoma. Imaeda K, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2097–100 (9 ref.)

Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. Hoffman JP, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):251–4 (22 ref.)

[Stenosing papillitis] Nastashenko IL. **Klin Khir** 1998; (9–10):62–4 (38 ref.) **(Rus)**

VAULT RIBONUCLEOPROTEIN PARTICLES

METABOLISM

[Vaults: forgotten organelles rediscovered] Pulaski L. **Postepy Biochem** 1998;44(2):151–7 (34 ref.) **(Pol)**

ULTRASTRUCTURE

[Vaults: forgotten organelles rediscovered] Pulaski L. **Postepy Biochem** 1998;44(2):151–7 (34 ref.) **(Pol)**

VAULT RNP PARTICLES see **VAULT RIBONUCLEOPROTEIN PARTICLES**

VCAM-1 see **VASCULAR CELL ADHESION MOLECULE-1**

VECTORS, GENETIC see **GENETIC VECTORS**

VEGETABLE OILS see **PLANT OILS**

VEGETABLES

Potential of vegetable processing to increase the delivery of carotenoids to man. van het Hof KH, et al. **Int J Vitam Nutr Res** 1998;68(6):366–70 (26 ref.)

[Fruit and vegetables in the prevention of cancer] Blomhoff R. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3462–5 (30 ref.) (Eng. Abstr.) **(Nor)**

CLASSIFICATION

Isoelectric focusing in the vegetable seed industry. van den Berg BM. **Electrophoresis** 1998 Jul;19(10):1780–7 (63 ref.)

IMMUNOLOGY

New allergens in fruits and vegetables. Pastorello EA, et al. **Allergy** 1998;53(46 Suppl):48–51 (30 ref.)

THERAPEUTIC USE

Health effects of vegetables and fruit: assessing mechanisms of action in human experimental studies. Lampe JW. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):475S–490S (118 ref.)

VIROLOGY

Tomato spotted wilt virus in ornamental plants, vegetables and weeds in the Czech Republic. Mertelík J, et al. **Acta Virol** 1998 Nov;42(5):347–51 (27 ref.)

VEGETARIANISM

The Oxford Vegetarian Study: an overview. Appleby PN, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):525S–531S (21 ref.)

Vegetarian food guide pyramid: a conceptual framework. Haddad EH, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):615S–619S (37 ref.)

Physical fitness and vegetarian diets: is there a relation? Nieman DC. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):570S–575S (81 ref.)

Nut consumption, vegetarian diets, ischemic heart disease risk, and all-cause mortality: evidence from epidemiologic studies. Sabaté J. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):500S–503S (30 ref.)

Essential fatty acid requirements of vegetarians in pregnancy, lactation, and infancy. Sanders TA. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):555S–559S (28 ref.)

Choices for achieving adequate dietary calcium with a vegetarian diet. Weaver CM, et al. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):543S–548S (43 ref.)

Convergence of philosophy and science: the third international congress on vegetarian nutrition. Willett WC. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):434S–438S (41 ref.)

Health benefits of a vegetarian diet. Key TJ, et al. **Proc Nutr Soc** 1999 May;58(2):271–5 (21 ref.)

The nutritional adequacy of plant-based diets. Sanders TA. **Proc Nutr Soc** 1999 May;58(2):265–9 (37 ref.)

ADVERSE EFFECTS

Vegetarianism and menstrual cycle disturbances: is there an association? Barr SI. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):549S–54S (61 ref.)

PSYCHOLOGY

Complex systems model of dietary choice with implications for improving diets and promoting vegetarianism. Phillips CV. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):608S–614S (27 ref.)

VEGETATIVE STATE, PERSISTENT see **PERSISTENT VEGETATIVE STATE**

VEHICLE EMISSIONS

ADVERSE EFFECTS

Is diesel exhaust a cause for increasing allergies? [editorial; comment] Salvi SS, et al. **Clin Exp Allergy** 1999 Jan; 29(1):4–8 (44 ref.) Comment on: Clin Exp Allergy 1999 Jan;29(1):52–9.

Diesel exhaust in the occupational setting. Current understanding of pulmonary health effects. Comstock ML. **Clin Lab Med** 1998 Dec;18(4):767–79 (45 ref.)

Human health effects of air pollution from mobile sources in Europe. Viegi G, et al. **Int J Tuberc Lung Dis** 1998 Nov;2(11):947–67 (132 ref.)

Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. Nel AE, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):539–54 (115 ref.)

ANALYSIS

Inhalation health risks of manganese: an EPA perspective. Davis JM. **Neurotoxicology** 1999 Apr–Jun;20(2–3):511–8 (40 ref.)

Traffic-related air pollutants: exposure of road users and populations living near busy roads. van Wijnen JH, et al. **Rev Environ Health** 1998 Jan–Jun;13(1–2):1–25 (51 ref.)

VEHICLES

ADMINISTRATION & DOSAGE

Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. Désormeaux A, et al. **J Drug Target** 1998;6(1):1–15 (105 ref.)

VEILED CELLS see **DENDRITIC CELLS**

VEIN CUTDOWN see **VENOUS CUTDOWN**

VEIN OF GALEN see **CEREBRAL VEINS**

VEINS

see related
PHLEBOGRAPHY

Primary venous aneurysms--case reports. Uematsu M, et al. **Angiology** 1999 Mar;50(3):239–44 (28 ref.)

Antithrombotic measures for indwelling intravenous haemodialysis catheters--Columbus' egg yet to be found [editorial] Barendregt JN, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1834–5 (8 ref.)

ABNORMALITIES

Orbital vascular malformations: a consensus statement on terminology and its clinical implications. Orbital Society. Harris GJ. **Am J Ophthalmol** 1999 Apr;127(4):453–5 (7 ref.)

PHYSIOLOGY

Importance of venous flow assessment for clinical decision-making. Gudmundsson S. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):173–8 (26 ref.)

Venous return in the fetal-placental cardiovascular system. Moll W. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun; 84(2):133–7 (13 ref.)

[Methods for vascular exploration in man: microcirculation and veins] Carpentier PH. **Therapie** 1999 May–Jun; 54(3):369–74 (30 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Endoscopic perforating vein surgery. Rhodes JM, et al. **Surg Clin North Am** 1999 Jun;79(3):667–81 (55 ref.)

[Update mid-term review of the pedicular extension in reverse YV flow. Review of a 7-year experience] Martin D, et al. **Ann Chir Plast Esthet** 1997 Dec;42(6):581–6 (8 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Antithrombotic therapy and venous graft disease. Schussheim AE, et al. **Curr Opin Cardiol** 1998 Nov;13(6):459–64 (43 ref.)

Techniques in conduit harvesting. Levine AJ, et al. **Hosp Med** 1999 Mar;60(3):178–82 (19 ref.)

[The venous autograft] Davidović LB, et al. **Srp Arh Celok Lek** 1999 Mar–Apr;127(3–4):118–24 (44 ref.) **(Scc)**

VELOCIMETRY see **RHEOLOGY**

VELOCIMETRY, LASER-DOPPLER see **LASER-DOPPLER FLOWMETRY**

VELOPHARYNGEAL INSUFFICIENCY

see related
SPEECH DISORDERS

GENETICS

Congenital heart defects in patients with DiGeorge/velocardiofacial syndrome and del22q11. Marino B, et al. **Genet Couns** 1999;10(1):25–33 (73 ref.)

The behavioural phenotype in velo-cardio-facial syndrome (VCFS): from infancy to adolescence. Swillen A, et al. **Genet Couns** 1999;10(1):79–88 (17 ref.)

Presenting symptoms and clinical features in 130 patients with the velo-cardio-facial syndrome. The Leuven experience. Vantrappen G, et al. **Genet Couns** 1999;10(1):3–9 (16 ref.)

The velo-cardio-facial syndrome: the otorhinolaryngeal manifestations and implications. Vantrappen G, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 2;45(2):133–41 (51 ref.)

SURGERY

The timing and management of dynamic muscular pharyngeal sphincter construction in velopharyngeal incompetence. Orticochea M. **Br J Plast Surg** 1999 Mar;52(2):85–7 (6 ref.)

VELUM PALATINUM see **PALATE, SOFT**

VENA CAVA FILTERS

Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. Greenfield LJ, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1013–9 (97 ref.)

Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. **J Vasc Surg** 1999 Sep;30(3):573–9 (97 ref.)

[The caval filter in prevention of pulmonary embolism] Fiorani P, et al. **Cardiologia** 1998 Jun;43 Suppl 1:79–82 (18 ref.) **(Ita)**

STANDARDS

Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. Greenfield LJ, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1013–9 (97 ref.)

UTILIZATION

[The use of vena cava filters in Denmark] Sajadieh A, et al. **Ugeskr Laeger** 1998 Nov 16;160(47):6824–6 (15 ref.) (Eng. Abstr.) **(Dan)**

VENA CAVA, INFERIOR

Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator. Lam KK, et al. **Am J Kidney Dis** 1998 Dec;32(6):1075–9 (27 ref.)

Proposal of a new nomenclature for Budd–Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Okuda K, et al. **Hepatology** 1998 Nov;28(5):1191–8 (105 ref.)

Inferior vena caval thrombosis after traumatic liver injury. Kimoto T, et al. **HPB Surg** 1998;11(2):111–6 (22 ref.)

The spontaneous aortocaval fistula: a complication of the abdominal aortic aneurysm. Case report and review of the literature. Abbadi AC, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):433–6 (25 ref.)

[Duodeno-caval fistula: a rare cause of upper gastrointestinal hemorrhage] Runkel N, et al. **Chirurg** 1998 Aug;69(8):883–6 (22 ref.) (Eng. Abstr.) **(Ger)**

[Successful preoperative interferon-alpha therapy of renal cell carcinoma with tumor thrombus extending into the inferior vena cava--case report] Miki T, et al.

Nippon Hinyokika Gakkai Zasshi 1998 Sep;89(9):796–9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[A hydatid cyst in the vena cava inferior and right atrium with venous flow obstruction and pulmonary dissemination] Caballero J, et al. **Rev Esp Cardiol** 1999 Apr; 52(4):281–4 (8 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Absence of the infrarenal inferior vena cava with preservation of the suprarenal segment as revealed by CT and MR venography. Bass JE, et al.
AJR Am J Roentgenol 1999 Jun;172(6):1610–2 (8 ref.)
Anomalies of the inferior vena cava and renal veins: embryologic and surgical considerations. Mathews R, et al. **Urology** 1999 May;53(5):873–80 (51 ref.)
[Thrombosis of the deep leg and pelvic veins in congenital agenesis of the vena cava inferior] Klessen C, et al.
Dtsch Med Wochenschr 1999 Apr 30;124(17):523–6 (17 ref.) (Eng. Abstr.) **(Ger)**
[Duplication of the vena cava inferior with a continuation into the vena azygos. A report of a rare case] Esposito S, et al. **Minerva Chir** 1999 Apr;54(4):261–5 (11 ref.) (Eng. Abstr.) **(Ita)**

INJURIES

Seat-belt transection of the pararenal vena cava in a 5-year-old child: survival with caval ligation. DeCou JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1074–6 (30 ref.)

PATHOLOGY

Absence of the infrarenal inferior vena cava with preservation of the suprarenal segment as revealed by CT and MR venography. Bass JE, et al.
AJR Am J Roentgenol 1999 Jun;172(6):1610–2 (8 ref.)
Adrenal neuroblastoma in an adult with tumor thrombus in the inferior vena cava. Custodio CM, et al.
J Magn Reson Imaging 1999 Apr;9(4):621–3 (11 ref.)

RADIOGRAPHY

Absence of the infrarenal inferior vena cava with preservation of the suprarenal segment as revealed by CT and MR venography. Bass JE, et al.
AJR Am J Roentgenol 1999 Jun;172(6):1610–2 (8 ref.)

SURGERY

New trends in the surgical and endovascular reconstructions of large veins for nonmalignant chronic venous occlusive disease. Alimi YS, et al. **Curr Opin Cardiol** 1998 Sep; 13(5):375–83 (51 ref.)
Seat-belt transection of the pararenal vena cava in a 5-year-old child: survival with caval ligation. DeCou JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1074–6 (30 ref.)
[Neoplastic obstruction of the vena cava inferior in general surgery] Forni E, et al. **G Chir** 1999 Jun-Jul; 20(6–7):296–306 (70 ref.) (Eng. Abstr.) **(Ita)**
[An iliac-mesenteric-atrial shunt in the Budd-Chiari syndrome with extensive thrombosis of the inferior vena cava] Bancu S, et al. **Chirurgia (Bucur)** 1998 May-Jun; 93(3):165–9 (7 ref.) (Eng. Abstr.) **(Rum)**

VENA CAVA, SUPERIOR

see related
SUPERIOR VENA CAVA SYNDROME

VENAE CAVAE

PHYSIOLOGY

Complex flow patterns in the great vessels: a review. Bogren HG, et al. **Int J Card Imaging** 1999 Apr;15(2):105–13 (48 ref.)

VENEREAL DISEASES see **SEXUALLY TRANSMITTED DISEASES**

VENEREAL DISEASES, BACTERIAL see **SEXUALLY TRANSMITTED DISEASES, BACTERIAL**

VENEREAL DISEASES, VIRAL see **SEXUALLY TRANSMITTED DISEASES, VIRAL**

VENEREAL WARTS see **CONDYLOMATA ACUMINATA**

VENEREOLOGY

see related
SEXUALLY TRANSMITTED DISEASES

VENESECTION see **PHLEBOTOMY**

VENIPUNCTURE see **PHLEBOTOMY**

VENO-OCCLUSIVE DISEASE, HEPATIC see **HEPATIC VENO-OCCLUSIVE DISEASE**

VENO-OCCLUSIVE DISEASE, PULMONARY see **PULMONARY VENO-OCCLUSIVE DISEASE**

VENOGRAPHY see **PHLEBOGRAPHY**

VENOMS

see related
ANTIVENINS

VENOSTOMY see **VENOUS CUTDOWN**

VENOUS CATHETERIZATION, CENTRAL see **CATHETERIZATION, CENTRAL VENOUS**

VENOUS CATHETERIZATION, PERIPHERAL see **CATHETERIZATION, PERIPHERAL**

VENOUS CUTDOWN

The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation [editorial] Parsonnet V, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):695–7 (17 ref.)

VENOUS INSUFFICIENCY

Neutrophil activation and mediators of inflammation in chronic venous insufficiency. Smith PD. **J Vasc Res** 1999; 36 Suppl 1:24–36 (48 ref.)

BLOOD

[Role of leukocytes in the pathogenesis of trophic venous disorders] Carpentier PH. **J Mal Vasc** 1998 Oct;23(4):274–6 (23 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Pittler MH, et al.
Arch Dermatol 1998 Nov;134(11):1356–60 (43 ref.)
Clinical efficacy of micronized purified flavonoid fraction: an overview. Struckmann JR. **J Vasc Res** 1999;36 Suppl 1:37–41 (27 ref.)
[Prescriptions and consumption of venotonic drugs in France (à propos of the report of the French National Institute for prescriptions and consumption of drugs)] Bouvenot G. **Bull Acad Natl Med** 1999;183(5):865–75; discussion 875–8 (19 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Perforating veins and venous insufficiency] Clerici T, et al. **Zentralbl Chir** 1999;124(6):525–9 (10 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical management of chronic venous insufficiency. Weiss VJ, et al. **Ann Vasc Surg** 1998 Sep;12(5):504–8 (33 ref.)
Surgical intervention in venous ulceration. Padberg FT Jr. **Cardiovasc Surg** 1999 Jan;7(1):83–90 (44 ref.)
Endoscopic perforating vein surgery. Rhodes JM, et al. **Surg Clin North Am** 1999 Jun;79(3):667–81 (55 ref.)
[Perforating veins and venous insufficiency] Clerici T, et al. **Zentralbl Chir** 1999;124(6):525–9 (10 ref.) (Eng. Abstr.) **(Ger)**
[Methods of concealed exclusion of lower extremities perforated and varicose veins in chronic venous insufficiency] Gervaziev VB. **Khirurgiia (Mosk)** 1999; (4):52–5 (6 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

[Compression therapy of chronic venous insufficiency] Lok C, et al. **Ann Dermatol Venereol** 1998 May;125(5):349–53 (31 ref.) **(Fre)**
[Leg perforating veins] Perrin M. **J Mal Vasc** 1999 Feb; 24(1):19–24 (39 ref.) (Eng. Abstr.) **(Fre)**

VENOUS LEAKAGE, PENILE see **IMPOTENCE, VASCULOGENIC**

VENOUS PRESSURE, CENTRAL see **CENTRAL VENOUS PRESSURE**

VENOUS RESERVOIRS see **CATHETERS, INDWELLING**

VENOUS THROMBOSIS

Deep venous thrombosis and pulmonary embolism: diagnosis, prophylaxis, and treatment. Alexander P, et al.
Ann Vasc Surg 1999 May;13(3):318–27 (48 ref.)
Prevention of venous thromboembolism in general surgery. Kakkar VV, et al. **Baillieres Clin Haematol** 1998 Sep; 11(3):605–19 (56 ref.)
Issues and controversies in venous thromboembolism. Carman TL, et al. **Cleve Clin J Med** 1999 Feb;66(2):113–23 (54 ref.)
Venous thromboembolic disease in the pediatric intensive care unit. Donnelly KM. **Curr Opin Pediatr** 1999 Jun; 11(3):213–7 (36 ref.)
Deep-vein thrombosis [see comments] Lensing AW, et al. **Lancet** 1999 Feb 6;353(9151):479–85 (44 ref.) Comment in: Lancet 1999 May 15;353(9165):1708.
Mesenteric venous thrombosis. Hassan HA, et al.
South Med J 1999 Jun;92(6):558–62 (61 ref.)

BLOOD

Venous thromboembolism and cancer. Kakkar AK, et al.
Baillieres Clin Haematol 1998 Sep;11(3):675–87 (77 ref.)

CHEMICALLY INDUCED

Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? Walker ID.
Blood Rev 1999 Mar;13(1):8–13 (22 ref.)
Venous thromboembolism and the pill. Learning from the past: a response from The Committee on Safety of Medicines [comment] Rawlins MD. **Hum Reprod** 1998 Jul; 13(7):1781 (4 ref.) Comment on: Hum Reprod 1998 May;13(5):1115–6.
Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. Hassan HA.
J Clin Gastroenterol 1999 Jul;29(1):90–5 (54 ref.)

COMPLICATIONS

Venous thromboembolism and cancer. Kakkar AK, et al.
Baillieres Clin Haematol 1998 Sep;11(3):675–87 (77 ref.)
Paradoxical emboli: the relationship between patent foramen ovale, deep vein thrombosis and ischaemic stroke. d'Iaudiffret A, et al. **Eur J Vasc Endovasc Surg** 1999 Jun; 17(6):468–71 (28 ref.)
Cancer and venous thromboembolism: an overview. Prandoni P, et al. **Haematologica** 1999 May;84(5):437–45 (102 ref.)
Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Rickles FR, et al.
Haemostasis 1998;28 Suppl 3:43–9 (49 ref.)
A patient who survived total colonic type ulcerative colitis complicated by toxic megacolon, disseminated intravascular coagulation, methicillin-resistant Staphylococcus aureus infection and bilateral femoral phlebothrombosis. Arai H, et al. **J Gastroenterol** 1999 Jun; 34(3):395–9 (8 ref.)
Thrombosis in pregnancy: maternal and fetal issues [see comments] Greer IA. **Lancet** 1999 Apr 10; 353(9160):1258–65 (61 ref.) Comment in: Lancet 1999 Jul 10;354(9173):162–3.
Venous thromboembolism as first manifestation of cancer. Monreal M, et al. **Semin Thromb Hemost** 1999;25(2):131–6 (31 ref.)
Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May-Jun;85(3):199–204 (41 ref.)

DIAGNOSIS

Portal vein thrombosis in paroxysmal nocturnal haemoglobinuria. Tomizuka H, et al. **Acta Haematol** 1999; 101(3):149–52 (20 ref.)
Venous thromboembolism. Hyers TM.
Am J Respir Crit Care Med 1999 Jan;159(1):1–14 (160 ref.)
The clinical diagnosis of deep venous thrombosis: integrating incidence, risk factors, and symptoms and signs [see comments] Kahn SR. **Arch Intern Med** 1998 Nov 23; 158(21):2315–23 (57 ref.) Comment in: Arch Intern Med 1999 May 24;159(10):1144.
Diagnostic management of venous thromboembolism. Kraaijenhagen RA, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):541–86 (221 ref.)
Laboratory diagnosis of venous thromboembolism. Lee AY, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):587–604 (86 ref.)
Venous thrombosis: diagnosis and treatment; new methods and strategies for management. Freedman MD, et al.
Compr Ther 1999 Jan;25(1):13–9 (36 ref.)
Diagnosis of deep venous thrombosis and pulmonary embolism in pregnancy. Macklon NS.
Curr Opin Pulm Med 1999 Jul;5(4):233–7 (40 ref.)
Upper extremity deep vein thrombosis. Prandoni P, et al.
Curr Opin Pulm Med 1999 Jul;5(4):222–6 (39 ref.)
Spiral CT and pulmonary embolism: is the emperor still unclothed? Lally JF, et al. **Del Med J** 1999 May;71(5):221–3 (5 ref.)
Diagnostic strategies in venous thromboembolism. Pini M, et al. **Haematologica** 1999 Jun;84(6):535–40 (35 ref.)
Symptomatic endpoints for venous thromboembolism treatment. Anderson DR. **Haemostasis** 1998;28 Suppl 3:120–6 (31 ref.)
Venous thromboembolic events in pediatric patients. Diagnosis and management. Streif W, et al.
Hematol Oncol Clin North Am 1998 Dec;12(6):1283–312, vii (167 ref.)
Mesenteric venous thrombosis associated with protein C deficiency. Mitani M, et al. **J Gastroenterol** 1999 Jun; 34(3):387–9 (17 ref.)
Adrenal neuroblastoma in an adult with tumor thrombus in the inferior vena cava. Custodio CM, et al.
J Magn Reson Imaging 1999 Apr;9(4):621–3 (11 ref.)
Diagnosis and management of venous thrombosis in the surgical patient. Jackson MR. **Semin Thromb Hemost** 1998; 24 Suppl 1:67–76 (44 ref.)
Rapid D-dimer assays to exclude deep venous thrombosis and pulmonary embolism: current status and new developments. Janssen MC, et al.
Semin Thromb Hemost 1998;24(4):393–400 (46 ref.)
Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May-Jun;85(3):199–204 (41 ref.)

VENOUS THROMBOSIS

[Diagnosis and treatment of deep vein thrombosis: recommendations for clinical practice. Work group "TVP guidelines"] **Rev Med Suisse Romande** 1999 Jun; 119(6):517-29 (24 ref.) **(Fre)**

[1998 update on deep vein thrombosis] Bounameaux H. **Rev Med Suisse Romande** 1998 Oct;118(10):847-51 (10 ref.) **(Fre)**

[Post-thrombotic syndrome of the legs: complementary examinations and therapeutic options] Buchheim G. **Rev Med Suisse Romande** 1998 Oct;118(10):859-65 (13 ref.) **(Fre)**

[Deep vein thrombosis--diagnosis and therapy] Partsch H. **Acta Med Austriaca** 1999;26(2):41-6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Thrombosis of the deep leg and pelvic veins in congenital agenesis of the vena cava inferior] Klessen C, et al. **Dtsch Med Wochenschr** 1999 Apr 30;124(17):523-6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Thrombosis of the portal vein] Calabrese L, et al. **Acta Biomed Ateneo Parmense** 1998;69(1-2):37-45 (19 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis of severe venous thrombosis] Ciccone M, et al. **Cardiologia** 1998 Jun;43 Suppl 1:59-63 (29 ref.) **(Ita)**

[Recurrent thrombosis of the venous supply of the upper extremity] Scarone PC, et al. **Minerva Chir** 1999 Apr; 54(4):267-72 (18 ref.) (Eng. Abstr.) **(Ita)**

[Deep venous thrombosis in pregnant women] Hervig T, et al. **Tidsskr Nor Laegeforen** 1998 Oct 30;118(26):4093-7 (29 ref.) (Eng. Abstr.) **(Nor)**

[Current and future diagnostic strategies in venous thromboembolic disease] Gabriel Botella F, et al. **An Med Interna** 1999 Aug;16(8):427-33 (58 ref.) (Eng. Abstr.) **(Spa)**

[A hydatid cyst in the vena cava inferior and right atrium with venous flow obstruction and pulmonary dissemination] Caballero J, et al. **Rev Esp Cardiol** 1999 Apr; 52(4):281-4 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis. Grossman C, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):667-72 (42 ref.)

Low-molecular-weight heparin in preventing and treating DVT. Rydberg EJ, et al. **Am Fam Physician** 1999 Mar 15;59(6):1607-12 (21 ref.)

Low-molecular-weight heparin in outpatient treatment of DVT. Yeager BF, et al. **Am Fam Physician** 1999 Feb 15; 59(4):945-52 (22 ref.)

Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator. Lam KK, et al. **Am J Kidney Dis** 1998 Dec;32(6):1075-9 (27 ref.)

Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Dunn AS, et al. **Am J Med** 1999 Jun;106(6):660-9 (99 ref.)

Oral anticoagulants for the treatment of venous thromboembolism. Ansell JE. **Baillieres Clin Haematol** 1998 Sep;11(3):639-61 (112 ref.)

Thrombolytic therapy for venous thrombosis and pulmonary embolism. Gallus AS. **Baillieres Clin Haematol** 1998 Sep; 11(3):663-73 (65 ref.)

Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. Pineo GF, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):621-37 (112 ref.)

Thrombolytic therapy for venous thromboembolism. Elliott G. **Curr Opin Hematol** 1999 Sep;6(5):304-8 (35 ref.)

Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism [editorial] Grendys EC Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):71-9 (75 ref.)

Upper extremity deep vein thrombosis. Prandoni P, et al. **Curr Opin Pulm Med** 1999 Jul;5(4):222-6 (39 ref.)

Symptomatic endpoints for venous thromboembolism treatment. Anderson DR. **Haemostasis** 1998;28 Suppl 3:120-6 (31 ref.)

Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Bossuyt PM, et al. **Haemostasis** 1998;28 Suppl 3:100-7 (14 ref.)

Treatment of venous thromboembolism in cancer patients. Levine M, et al. **Haemostasis** 1998;28 Suppl 3:66-70 (17 ref.)

Unfractionated heparin and low-molecular-weight heparin for the initial treatment of acute venous thromboembolism. Prandoni P. **Haemostasis** 1998;28 Suppl 3:85-90 (33 ref.)

Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring [editorial] Hull RD, et al. **Int Angiol** 1998 Dec; 17(4):213-24 (95 ref.)

Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme [editorial] Hull RD, et al. **Int Angiol** 1998 Sep;17(3):131-4 (31 ref.)

Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings. Schulman S. **J Intern Med** 1999 Apr;245(4):399-403 (25 ref.)

Anticoagulant treatment during pregnancy: an update. Dizon-Townson D, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:55-62 (80 ref.)

[Fibrinolytic therapy of deep vein thrombosis] Weidmann B, et al. **Med Klin** 1999 Mar 15;94(3):140-9 (81 ref.) (Eng. Abstr.) **(Ger)**

[Acute venous thrombosis: new directions in prophylaxis and treatment] Fedorov VD, et al. **Khirurgiia (Mosk)** 1998; (12):60-3 (26 ref.) **(Rus)**

[Clexane + + treatment of acute venous thrombosis] Kirienko AI, et al. **Ter Arkh** 1998;70(9):91-2 (15 ref.) **(Rus)**

EPIDEMIOLOGY

The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Lewis MA. **Am J Obstet Gynecol** 1998 Oct; 179(4):1086-97 (85 ref.)

[Interaction of estrogens and genetic risk factors for thrombosis] Aiach M. **Therapie** 1999 May-Jun;54(3):357-61 (25 ref.) (Eng. Abstr.) **(Fre)**

[Synthesis: certainties/uncertainties in the prevention of venous thrombosis in medical patients] Bergmann JF, et al. **Therapie** 1998 Nov-Dec;53(6):571-4 (8 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of the risk of venous thromboembolism in the medical patients] Mismetti P, et al. **Therapie** 1998 Nov-Dec; 53(6):565-70 (14 ref.) (Eng. Abstr.) **(Fre)**

[Thromboembolism--genetic and acquired risk factors] Pabinger-Fasching I. **Acta Med Austriaca** 1999;26(2):37-40 (6 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Advances in the etiology and treatment of venous thromboembolism. Comp PC. **Adv Intern Med** 1999; 44:59-89 (118 ref.)

Hereditary thrombophilia and venous thromboembolism. Murin S, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1369-73 (35 ref.)

Thrombophilia and activated protein C resistance. Selzman CH, et al. **Ann Vasc Surg** 1998 Nov;12(6):601-4 (12 ref.)

Thrombophilia: disorders predisposing to venous thromboembolism. Pineo GF, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):525-40 (89 ref.)

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Oger E, et al. **Drugs Aging** 1999 Jan;14(1):55-61 (38 ref.)

Portal vein thrombosis associated with antiphospholipid syndrome: a case report. Ishida H, et al. **Eur J Ultrasound** 1998 Sep;8(1):39-42 (10 ref.)

Treatment of venous thromboembolism in cancer patients. Levine M, et al. **Haemostasis** 1998;28 Suppl 3:66-70 (17 ref.)

Inferior vena caval thrombosis after traumatic liver injury. Kimoto T, et al. **HPB Surg** 1998;11(2):111-6 (22 ref.)

Mesenteric venous thrombosis associated with protein C deficiency. Mitani M, et al. **J Gastroenterol** 1999 Jun; 34(3):387-9 (17 ref.)

Venous thromboembolism in the patient with acute traumatic brain injury: screening, diagnosis, prophylaxis, and treatment issues. Hammond FM, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):36-50 (100 ref.)

Venous thrombosis: a multicausal disease [see comments] Rosendaal FR. **Lancet** 1999 Apr 3;353(9159):1167-73 (76 ref.) Comment in: Lancet 1999 Jun 19;353(9170):2158.

Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty. Maling TJ. **N Z Med J** 1999 Aug 27;112(1094):305-7 (30 ref.)

Hepatic aneurysm and portal vein thrombosis in a patient with lupus erythematosus on dialysis. Huang JW, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):753-6 (12 ref.)

Deep vein thrombosis in patients with large uterine myomata. Chong YS, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):707 (4 ref.)

Hyperhomocysteinemia and venous thrombosis. Bos GM, et al. **Semin Thromb Hemost** 1998;24(4):387-91 (29 ref.)

Deep venous thrombosis in the trauma patient. Meissner MH. **Semin Vasc Surg** 1998 Dec;11(4):274-82 (67 ref.)

Mesenteric venous thrombosis in protein S deficiency: case report and literature review. Lau LL, et al. **Ulster Med J** 1999 May;68(1):33-5 (10 ref.)

[Hyperhomocysteinemia as a risk factor for venous thrombosis] Willems HP, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13;143(11):552-6 (36 ref.) (Eng. Abstr.) **(Dut)**

[Pulmonary embolism. Risk factors of venous thromboembolic disease] Gagnadoux F, et al. **Presse Med** 1998 May 2-9;27(17):814-8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature] Crétel E, et al. **Rev Med Interne** 1999 Jul;20(7):602-6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Thromboembolism--genetic and acquired risk factors] Pabinger-Fasching I. **Acta Med Austriaca** 1999;26(2):37-40 (6 ref.) (Eng. Abstr.) **(Ger)**

[Severe venous thrombosis in pulmonary embolism: physiopathological aspects] Mercuro G, et al. **Cardiologia** 1998 Jun;43 Suppl 1:53-7 (34 ref.) **(Ita)**

GENETICS

Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? Walker ID. **Blood Rev** 1999 Mar;13(1):8-13 (22 ref.)

Novel inherited risk factors for venous thrombosis [editorial; comment] Key NS. **J Lab Clin Med** 1998 Dec;132(6):444-5 (15 ref.) Comment on: J Lab Clin Med 1998 Dec;132(6):452-5.

[Interaction of estrogens and genetic risk factors for thrombosis] Aiach M. **Therapie** 1999 May-Jun;54(3):357-61 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Severe venous thrombosis in pulmonary embolism: physiopathological aspects] Mercuro G, et al. **Cardiologia** 1998 Jun;43 Suppl 1:53-7 (34 ref.) **(Ita)**

PREVENTION & CONTROL

Low-molecular-weight heparin in preventing and treating DVT. Rydberg EJ, et al. **Am Fam Physician** 1999 Mar 15;59(6):1607-12 (21 ref.)

Graduated compression stockings in the prevention of venous thromboembolism. Agu O, et al. **Br J Surg** 1999 Aug; 86(8):992-1004 (135 ref.)

Prevention of venous thromboembolism. Rosen SF, et al. **Curr Opin Hematol** 1999 Sep;6(5):285-90 (28 ref.)

Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism [editorial] Grendys EC Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):71-9 (75 ref.)

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation? Schulman S. **Haemostasis** 1998;28 Suppl 3:17-21 (15 ref.)

Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty. Maling TJ. **N Z Med J** 1999 Aug 27;112(1094):305-7 (30 ref.)

Deep vein thrombosis and pulmonary embolism prophylaxis in joint replacement surgery. Merli GJ. **Rheum Dis Clin North Am** 1999 Aug;25(3):639-56, ix (91 ref.)

Treatment and prevention of venous thromboembolism. Hull RD, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:21-31 (128 ref.)

Diagnosis and management of venous thrombosis in the surgical patient. Jackson MR. **Semin Thromb Hemost** 1998; 24 Suppl 1:67-76 (44 ref.)

Should surgical patients be screened for thrombophilia? Wheeler HB. **Semin Thromb Hemost** 1998;24 Suppl 1:63-5 (10 ref.)

Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients. Wade WE, et al. **Thromb Res** 1999 Apr 1;94(1):65-8 (18 ref.)

[Hyperhomocysteinemia as a risk factor for venous thrombosis] Willems HP, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13;143(11):552-6 (36 ref.) (Eng. Abstr.) **(Dut)**

[Synthesis: certainties/uncertainties in the prevention of venous thrombosis in medical patients] Bergmann JF, et al. **Therapie** 1998 Nov-Dec;53(6):571-4 (8 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of the risk of venous thromboembolism in the medical patients] Mismetti P, et al. **Therapie** 1998 Nov-Dec; 53(6):565-70 (14 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of venous thrombosis: role of heparins] Wahl D, et al. **Therapie** 1998 Nov-Dec;53(6):575-8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy. Modern therapeutic approaches] Harenberg J, et al. **Internist (Berl)** 1999 Aug;40(8):885-93 (61 ref.) **(Ger)**

[Prevention of severe venous thrombosis in pulmonary embolism] Palareti G. **Cardiologia** 1998 Jun;43 Suppl 1:65-8 (16 ref.) **(Ita)**

[Acute venous thrombosis: new directions in prophylaxis and treatment] Fedorov VD, et al. **Khirurgiia (Mosk)** 1998; (12):60-3 (26 ref.) **(Rus)**

[Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism] Kirienko AI, et al. **Ter Arkh** 1998;70(11):78-80 (25 ref.) **(Rus)**

SURGERY

New trends in the surgical and endovascular reconstructions of large veins for nonmalignant chronic venous occlusive disease. Alimi YS, et al. **Curr Opin Cardiol** 1998 Sep; 13(5):375-83 (51 ref.)

[Recanalization of an extensive fresh portal vein thrombosis by transjugular intrahepatic portosystemic stent-shunt (TIPS)] Vogl T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):163-5 (10 ref.) **(Ger)**

THERAPY

Venous thromboembolism. Hyers TM. **Am J Respir Crit Care Med** 1999 Jan;159(1):1-14 (160 ref.)

Venous thrombosis: diagnosis and treatment; new methods and strategies for management. Freedman MD, et al. **Compr Ther** 1999 Jan;25(1):13-9 (36 ref.)

Venous thromboembolic events in pediatric patients. Diagnosis and management. Streif W, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1283-312, vii (167 ref.)

Patient education: a tool in the outpatient management of deep vein thrombosis. Haines ST. **Pharmacotherapy** 1998 Nov-Dec;18(6 Pt 3):158S-164S (33 ref.)

[How to provide practical treatment for ambulatory patients with deep venous thrombosis] Achkar A, et al. **J Mal Vasc** 1999 Feb;24(1):58-65 (42 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of venous thromboembolic disease in the elderly] el Kouri D, et al. **J Mal Vasc** 1999 Jun;24(3):183-8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of deep vein thrombosis: recommendations for clinical practice. Work group "TVP guidelines"] **Rev Med Suisse Romande** 1999 Jun;

119(6):517-29 (24 ref.) **(Fre)**
[1998 update on deep vein thrombosis] Bounameaux H. **Rev Med Suisse Romande** 1998 Oct;118(10):847-51 (10 ref.) **(Fre)**
[Post-thrombotic syndrome of the legs: complementary examinations and therapeutic options] Buchheim G. **Rev Med Suisse Romande** 1998 Oct;118(10):859-65 (13 ref.) **(Fre)**
[Deep vein thrombosis--diagnosis and therapy] Partsch H. **Acta Med Austriaca** 1999;26(2):41-6 (30 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of severe venous thrombosis] Andreozzi GM. **Cardiologia** 1998 Jun;43 Suppl 1:69-71 (14 ref.) **(Ita)**
[Deep vein thrombosis] Sakakibara Y. **Nippon Rinsho** 1999 Jul;57(7):1631-5 (20 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Clinical outcomes of untreated symptomatic patients with negative findings on sonography of the thigh for deep vein thrombosis: our experience and a review of the literature [see comments] Gottlieb RH, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1601-4 (30 ref.) Comment in: AJR Am J Roentgenol 1999 Jun;172(6):1473.
The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Kearon C, et al. **Ann Intern Med** 1998 Dec 15; 129(12):1044-9 (56 ref.)
Recent clinical trials in the diagnosis of deep-vein thrombosis. Birdwell B. **Curr Opin Hematol** 1999 Sep; 6(5):275-9 (18 ref.)
Deep venous thrombosis: recent advances and optimal investigation with US. Fraser JD, et al. **Radiology** 1999 Apr;211(1):9-24 (118 ref.)

VENOUS ULCER see **VARICOSE ULCER**

VENOVENOUS HEMOFILTRATION see **HEMOFILTRATION**

VENTILATION

see related
CONFINED SPACES

METHODS

Buildings operations and ETS exposure. Spengler JD. **Environ Health Perspect** 1999 May;107 Suppl 2:313-7 (18 ref.)
[Thermal comfort and fever or research on how to feel better] Corrard F. **Arch Pediatr** 1999 Jan;6(1):93-6 (6 ref.) (Eng. Abstr.) **(Fre)**

VENTILATION, HIGH-FREQUENCY see **HIGH-FREQUENCY VENTILATION**

VENTILATION, INTERMITTENT POSITIVE-PRESSURE see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

VENTILATION, MECHANICAL see **RESPIRATION, ARTIFICIAL**

VENTILATION, MIDDLE EAR see **MIDDLE EAR VENTILATION**

VENTILATION-PERFUSION RATIO

PHYSIOLOGY

[Pulmonary diagnosis with model aerosols. II: Aerosol bolus dispersion--a marker for convection gas transport. Basic principles and initial clinical results] Kohlhäufl M, et al. **Pneumologie** 1999 Jan;53(1):50-6 (42 ref.) **(Ger)**

VENTILATION, PULMONARY see **PULMONARY VENTILATION**

VENTILATION TESTS see **PULMONARY VENTILATION**

VENTILATOR WEANING

Predicting extubation failure after open-heart surgery: can we harness the strength of large clinical databases? [editorial; comment] Afifi S, et al. **Crit Care Med** 1999 Feb; 27(2):246-7 (17 ref.) Comment on: Crit Care Med 1999 Feb;27(2):340-7.
Weaning from mechanical ventilation. Hendra KP, et al. **Int Anesthesiol Clin** 1999 Summer;37(3):127-43 (38 ref.)
Weaning from mechanical ventilation. Vassilakopoulos T, et al. **J Crit Care** 1999 Mar;14(1):39-62 (119 ref.)
Therapeutic strategies in weaning failure. Appendini L, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):372-6 (36 ref.)
Weaning from artificial ventilation. Mancebo J. **Monaldi Arch Chest Dis** 1998 Jun;53(3):350-4 (42 ref.)
Predicting the outcome of attempts to discontinue mechanical ventilation. Tobin MJ. **Monaldi Arch Chest Dis** 1998 Aug; 53(4):493-7 (35 ref.)
Factors determining the weaning outcome. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):365-71 (35 ref.)
[Weaning from artificial respiration. 2.] Kuhlen R, et al. **Anaesthesist** 1998 Aug;47(8):693-703 (15 ref.) **(Ger)**

METHODS

Weaning from mechanical ventilation. Chao DC, et al. **Crit Care Clin** 1998 Oct;14(4):799-817, viii (79 ref.)
Clinical management of weaning from mechanical ventilation [see comments] Esteban A, et al. **Intensive Care Med** 1998 Oct;24(10):999-1008 (78 ref.) Comment in: Intensive Care Med 1999 Apr;25(4):423-4.
[Difficult weaning from mechanical ventilation: a graduated approach and teamwork] Van Der Werf TS, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2390-5 (38 ref.) (Eng. Abstr.) **(Dut)**

VENTILATORS, MECHANICAL

Nosocomial pneumonia in the ICU--year 2000 and beyond. Bowton DL. **Chest** 1999 Mar;115(3 Suppl):28S-33S (26 ref.)
New modes of ventilatory support. Branson RD, et al. **Int Anesthesiol Clin** 1999 Summer;37(3):103-25 (32 ref.)
Experience with new autotitrating nasal continuous positive airway pressure machines. Becker HF. **Monaldi Arch Chest Dis** 1998 Oct;53(5):582-5 (9 ref.)
Patient-ventilator interactions. Stroetz RW, et al. **Monaldi Arch Chest Dis** 1998 Jun;53(3):331-6 (22 ref.)
[Anesthesia ventilators (published erratum appears in Ann Fr Anesth Reanim 1998;17(1):90)] Otteni JC, et al. **Ann Fr Anesth Reanim** 1997;16(7):895-907 (31 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Body position and pneumonia [editorial; comment] deBoisblanc BP. **Crit Care Med** 1999 Apr;27(4):678-9 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):745-8.
Controversies on diagnosis and prevention of ventilator-associated pneumonia. Bonten MJ. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):199-204 (38 ref.)
Ventilator-induced injury: from barotrauma to biotrauma. Tremblay LN, et al. **Proc Assoc Am Physicians** 1998 Nov-Dec;110(6):482-8 (56 ref.)
[Ventilator-associated pneumonia; controversies with respect to diagnosis, pathogenesis, therapy and prevention] Bonten MJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):726-30 (24 ref.) (Eng. Abstr.) **(Dut)**

STANDARDS

The ventilator: selection of mechanical ventilators. Grace K. **Crit Care Clin** 1998 Oct;14(4):563-80 (43 ref.)

SUPPLY & DISTRIBUTION

The ventilator: selection of mechanical ventilators. Grace K. **Crit Care Clin** 1998 Oct;14(4):563-80 (43 ref.)

TRENDS

Non-invasive ventilation--mechanisms of benefit. Elliott MW. **Med Klin** 1999 Apr;94(1 Spec No):2-6 (18 ref.)

VENTILATORS, NEGATIVE-PRESSURE

Being more positive about negative ventilation? [editorial; comment] Wysocki M. **Eur Respir J** 1998 Sep;12(3):515-6 (19 ref.) Comment on: Eur Respir J 1998 Sep;12(3):519-25.
Negative pressure ventilation. Carrado A, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):488-92 (28 ref.)

VENTILATORS, PULMONARY see **VENTILATORS, MECHANICAL**

VENTILATORS, PULMONARY, NEGATIVE-PRESSURE see **VENTILATORS, NEGATIVE-PRESSURE**

VENTILATORY MUSCLES see **RESPIRATORY MUSCLES**

VENTRAL HERNIA see **HERNIA, VENTRAL**

VENTRAL ROOTS see **SPINAL NERVE ROOTS**

VENTRAL TEGMENTAL AREA

DRUG EFFECTS

Role of the mesolimbic dopamine system in cardiovascular homeostasis. Stimulation of the ventral tegmental area modulates the effect of vasopressin on blood pressure in conscious rats. van den Buuse M. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):661-8 (74 ref.)

METABOLISM

Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. Garzón M, et al. **J Comp Neurol** 1999 Jul 26;410(2):197-210 (108 ref.)

PHYSIOLOGY

Role of the mesolimbic dopamine system in cardiovascular homeostasis. Stimulation of the ventral tegmental area modulates the effect of vasopressin on blood pressure in conscious rats. van den Buuse M. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):661-8 (74 ref.)

VENTRICLE-ASSIST DEVICE see **HEART-ASSIST DEVICES**

VENTRICULAR DYSFUNCTION

DIAGNOSIS

Effects of injectate volume on thermodilution measurements of cardiac output in patients with low ventricular ejection fraction. McCloy K, et al. **Am J Crit Care** 1999 Mar; 8(2):86-92 (33 ref.)
Ventricular constraint in the fetus and newborn. Grant DA. **Can J Cardiol** 1999 Jan;15(1):95-104 (84 ref.)

PHYSIOPATHOLOGY

Role of nitric oxide in ventricular dysfunction. Arstall MA, et al. **J Card Fail** 1998 Sep;4(3):249-60 (131 ref.)
[Electrophysiology of the atrioventricular node during atrial fibrillation. I. Ventricular rhythm] Meijler FL, et al. **Ned Tijdschr Geneeskd** 1999 Jun 12;143(24):1245-52 (66 ref.) (Eng. Abstr.) **(Dut)**

THERAPY

Role of PTCA and mechanical devices in cardiogenic shock. Shawl FA. **Indian Heart J** 1998 Oct;50 Suppl 1:57-61 (50 ref.)

ULTRASONOGRAPHY

[Asynchrony of ventricular contraction and relaxation--pathophysiologically recognized phenomenon, now can be clinically assessed] Bruch C, et al. **Herz** 1998 Dec;23(8):506-15 (47 ref.) (Eng. Abstr.) **(Ger)**

VENTRICULAR DYSFUNCTION, LEFT

BLOOD

Neuroendocrine activation in left ventricular dysfunction [editorial; comment] Ferrari R, et al. **Eur Heart J** 1998 Oct;19(10):1423-4 (8 ref.) Comment on: Eur Heart J 1998 Oct;19(10):1552-63.
Natriuretic peptides in assessment of left-ventricular dysfunction. Mair J, et al. **Scand J Clin Lab Invest Suppl** 1999;230:132-42 (21 ref.)

COMPLICATIONS

Diastolic dysfunction: old dog, new tricks [editorial; comment] Douglas PS. **Am Heart J** 1999 May;137(5):777-8 (9 ref.) Comment on: Am Heart J 1999 May;137(5):910-8.
Is sinus bradycardia a factor facilitating overt heart failure? Alboni P, et al. **Eur Heart J** 1999 Feb;20(4):252-5 (34 ref.)
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Sander GE, et al. **Prog Cardiovasc Dis** 1999 Jan-Feb;41(4):265-300 (241 ref.)
Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Naughton MT. **Thorax** 1998 Oct;53 Suppl 3:S37-40 (40 ref.)
[Revised insights and therapeutic goals in the treatment of chronic heart failure] van Veldhuisen DJ. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1507-11 (31 ref.) (Eng. Abstr.) **(Dut)**

DIAGNOSIS

Rest-injected 201thallium in the evaluation of myocardial viability. Perrone-Filardi P, et al. **Cardiologia** 1999 Jun; 44(6):515-20 (31 ref.)
Natriuretic peptides in assessment of left-ventricular dysfunction. Mair J, et al. **Scand J Clin Lab Invest Suppl** 1999;230:132-42 (21 ref.)
Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function [see comments] Stainback RF. **Tex Heart Inst J** 1999; 26(1):34-41 (45 ref.) Comment in: Tex Heart Inst J 1999;26(2):158.
[Heterogeneities of ventricular repolarization and vulnerability to arrhythmia. How to detect them with noninvasive methods?] De Ambroggi L. **Cardiologia** 1999 Apr;44(4):355-60 (53 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

New treatment strategies in patients with impaired left ventricular systolic function. Part II: Treatment of moderate to severe cardiac dysfunction [clinical conference] Rozo JC, et al. **Am J Med Sci** 1999 May; 317(5):312-7 (36 ref.)
[Progress in the study on left ventricular diastolic dysfunction in traditional Chinese medicine] Li SH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Sep; 17(9):571-3 (28 ref.) **(Chi)**
[Revised insights and therapeutic goals in the treatment of chronic heart failure] van Veldhuisen DJ. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1507-11 (31 ref.) (Eng. Abstr.) **(Dut)**

VENTRICULAR DYSFUNCTION, LEFT

ETIOLOGY

Predictive value of pulmonary venous flow patterns in detecting mitral regurgitation and left ventricular abnormalities. Hynes MS, et al. **Can J Cardiol** 1999 Jun; 15(6):665–70 (24 ref.)

Reversible biventricular dysfunction secondary to ischemia in a patient with acute airway obstruction: a case report and review of the literature on reversible causes of acute ventricular dysfunction. Lee C, et al. **Can J Cardiol** 1999 Jun;15(6):705–8 (23 ref.)

Pregnancy-induced severe left ventricular systolic dysfunction in a patient with hypertrophic cardiomyopathy. Kazimuddin M, et al. **Clin Cardiol** 1998 Nov;21(11):848–50 (8 ref.)

Left ventricular outflow obstruction. Fedderly RT. **Pediatr Clin North Am** 1999 Apr;46(2):369–84 (37 ref.)

[Predictive indices of the persistence of left ventricular dilatation after valve replacement for chronic aortic insufficiency. Echocardiographic study] Khatouri A, et al. **Ann Cardiol Angeiol (Paris)** 1998 Dec;47(10):716–21 (31 ref.) (Eng. Abstr.) **(Fre)**

[Analysis and quantification of longitudinal contraction of the left ventricle in myocardial infarction. Value of Doppler myocardial tissue imaging] Jamal F, et al. **Arch Mal Coeur Vaiss** 1999 Mar;92(3):315–22 (30 ref.) (Eng. Abstr.) **(Fre)**

[Management of ventricular arrhythmia in chronic congestive heart failure] Pulignano G, et al. **Clin Ter** 1998 Jul–Aug; 149(4):297–305 (63 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[The clinical importance of myocardial vitality in chronic, postischemic left ventricular dysfunction] Agati L, et al. **Cardiologia** 1998 Jun;43 Suppl 1:95–8 (20 ref.) **(Ita)**

PHYSIOPATHOLOGY

Prognostic utility of myocardial viability assessment. Iskander S, et al. **Am J Cardiol** 1999 Mar 1;83(5):696–702, A7 (81 ref.)

Programmed cell death in the progression of heart failure. Sabbah HN, et al. **Ann Med** 1998 Aug;30 Suppl 1:33–8 (45 ref.)

The basics of ventricular function. Penny DJ. **Cardiol Young** 1999 Mar;9(2):210–23 (49 ref.)

Right-sided pulsus alternans in diastolic left ventricular dysfunction [see comments] Ilia R, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):336–9 (10 ref.) Comment in: Catheter Cardiovasc Interv 1999 Jul;47(3):340.

Predicting improved function after myocardial revascularization. Di Carli MF. **Curr Opin Cardiol** 1998 Nov;13(6):415–24 (60 ref.)

Left ventricular systolic function after acute myocardial infarction: prognostic importance, relation to congestive heart failure and as a target for intervention. Køber L. **Dan Med Bull** 1999 Jun;46(3):235–48 (53 ref.)

Myocardial hibernation and stunning: from physiological principles to clinical practice. Redwood SR, et al. **Heart** 1998 Sep;80(3):218–22 (47 ref.)

Genetically engineered mice: model systems for left ventricular failure [see comments] Kadambi VJ, et al. **J Card Fail** 1998 Dec;4(4):349–61 (59 ref.) Comment in: J Card Fail 1998 Dec;4(4):263–70.

Physical and geometrical modeling for image-based recovery of left ventricular deformation. Duncan J, et al. **Prog Biophys Mol Biol** 1998;69(2–3):333–51 (50 ref.)

Advanced systolic heart failure: emerging pathophysiology and current management. Albert NM. **Prog Cardiovasc Nurs** 1998 Summer;13(3):14–30 (77 ref.)

[The basis of chronic ischemic reversible left ventricular dysfunction (hibernating myocardium)] Mates M, et al. **Cesk Fysiol** 1999 Feb;48(1):4–8 (33 ref.) (Eng. Abstr.) **(Cze)**

RADIONUCLIDE IMAGING

BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction. Franken PR, et al. **Int J Card Imaging** 1999 Feb;15(1):27–34 (28 ref.)

Nuclear cardiology, Part IV: Viability. Mesotten L, et al. **J Nucl Med Technol** 1999 Jun;27(2):93–102; quiz 104–5 (74 ref.)

Radionuclide techniques for the assessment of myocardial viability. Skoufis E, et al. **Tex Heart Inst J** 1998;25(4):272–9 (77 ref.)

[Diagnosis of myocardial viability in chronic myocardial ischemia with nuclear medicine techniques] vom Dahl J, et al. **Z Kardiol** 1998;87 Suppl 2:92–9 (61 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Exercise training in the treatment of heart failure: what is achieved and how? Balady GJ. **Ann Med** 1998 Aug;30 Suppl 1:61–5 (34 ref.)

[Difficult weaning from mechanical ventilation: a graduated approach and teamwork] Van Der Werf TS, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2390–5 (38 ref.) (Eng. Abstr.) **(Dut)**

SURGERY

Rapid-staged strategy for concomitant critical carotid and left main coronary disease with left ventricular dysfunction: IABP use. Allie DE, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1230–5 (31 ref.)

THERAPY

Transvenous biventricular pacing for heart failure: can the obstacles be overcome? Auricchio A, et al. **Am J Cardiol** 1999 Mar 11;83(5B):136D–142D (22 ref.)

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Klein H, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):91D–97D (23 ref.)

New treatment strategies in patients with impaired left ventricular systolic function. Part I: Background and treatment of mild cardiac dysfunction [clinical conference] Rozo JC, et al. **Am J Med Sci** 1999 Apr;317(4):247–50 (25 ref.)

Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. McKelvie RS, et al. **BMJ** 1999 May 22; 318(7195):1400–2 (32 ref.)

Optimizing exercise training for subgroups of patients with chronic heart failure. Coats AJ. **Eur Heart J** 1998 Nov; 19 Suppl O:O29–34 (53 ref.)

Advanced systolic heart failure: emerging pathophysiology and current management. Albert NM. **Prog Cardiovasc Nurs** 1998 Summer;13(3):14–30 (77 ref.)

[Reversible postischemic left ventricular dysfunction: treatment by coronary angioplasty] Sganzerla P, et al. **Cardiologia** 1998 Sep;43(9):919–24 (76 ref.) **(Ita)**

ULTRASONOGRAPHY

From systole to diastole: will the detection of regional diastolic dysfunction allow recognition of coronary artery disease at an earlier stage? [editorial; comment] van de Werf F. **Eur Heart J** 1999 Apr;20(7):476–7 (7 ref.) Comment on: Eur Heart J 1999 Apr;20(7):496–505.

Is tissue Doppler echocardiography ready for clinical application? [editorial; comment] Zamorano J. **Eur Heart J** 1999 Apr;20(8):558–60 (8 ref.) Comment on: Eur Heart J 1999 Apr;20(8):593–603.

Prevalence of left ventricular diastolic filling abnormalities in adult cardiac surgical patients: an intraoperative echocardiographic study. Lappas DG, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):125–33 (47 ref.)

[Diagnosis of myocardial vitality using contrast echocardiography—ready for routine clinical use?] Firschke C. **Herz** 1998 Dec;23(8):483–90 (33 ref.) (Eng. Abstr.) **(Ger)**

VENTRICULAR DYSFUNCTION, RIGHT

DIAGNOSIS

Radiology of the right ventricle. Boxt LM. **Radiol Clin North Am** 1999 Mar;37(2):379–400 (96 ref.)

DRUG THERAPY

Safety of antiarrhythmics during pregnancy: case report and review of the literature. Fagih B, et al. **Can J Cardiol** 1999 Jan;15(1):113–7 (30 ref.)

ETIOLOGY

Reversible biventricular dysfunction secondary to ischemia in a patient with acute airway obstruction: a case report and review of the literature on reversible causes of acute ventricular dysfunction. Lee C, et al. **Can J Cardiol** 1999 Jun;15(6):705–8 (23 ref.)

PHYSIOPATHOLOGY

Pathophysiology and clinical management of right heart ischemia. Goldstein JA. **Curr Opin Cardiol** 1999 Jul; 14(4):329–39 (38 ref.)

Right ventricular involvement in acute myocardial infarction. Burgess MI, et al. **Hosp Med** 1999 Jun;60(6):430–4 (21 ref.)

VENTRICULAR DYSPLASIA, RIGHT, ARRHYTHMOGENIC see **ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA**

VENTRICULAR ECTOPIC BEATS see **VENTRICULAR PREMATURE COMPLEXES**

VENTRICULAR EJECTION FRACTION see **STROKE VOLUME**

VENTRICULAR END-DIASTOLIC VOLUME see **STROKE VOLUME**

VENTRICULAR END-SYSTOLIC VOLUME see **STROKE VOLUME**

VENTRICULAR FIBRILLATION

Ventricular arrhythmias, electrophysiologic studies, and devices. Dhala A, et al. **Cardiol Clin** 1999 Feb;17(1):189–95, x (34 ref.)

CHEMICALLY INDUCED

Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity? [editorial; comment] Roden DM, et al. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):219–23 (30 ref.) Comment on: J Cardiovasc Electrophysiol 1998 Nov;9(11):1167–72. Comment on: J Cardiovasc Electrophysiol 1999 Feb;10(2):214–8.

DIAGNOSIS

What is the Brugada syndrome? Corrado D, et al. **Cardiol Rev** 1999 Jul–Aug;7(4):191–5 (23 ref.)

DRUG THERAPY

Beta blockers: evidence versus wishful thinking. Andresen D, et al. **Am J Cardiol** 1999 Mar 11;83(5B):64D–67D (29 ref.)

Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. Gonzalez ER, et al. **Resuscitation** 1998 Oct–Nov;39(1–2):33–42 (51 ref.)

ETIOLOGY

Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Curtis MJ. **Cardiovasc Res** 1998 Jul; 39(1):194–215 (104 ref.)

[Idiopathic ventricular fibrillation] Chevalier P, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:29–36 (33 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent ventricular fibrillation in acute myocardial infarct treated successfully by coronary angioplasty: a clinical case in favor of the hypothesis of the arrhythmogenicity of the coronary thrombus?] Trabattoni D, et al. **Cardiologia** 1998 Oct;43(10):1095–9 (19 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

The Brugada syndrome: clinical, electrophysiologic and genetic aspects. Gussak I, et al. **J Am Coll Cardiol** 1999 Jan;33(1):5–15 (129 ref.)

MORTALITY

Survival from ventricular fibrillation [editorial; comment] Dembo DH. **Crit Care Med** 1999 Aug;27(8):1671–2 (13 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1542–50.

PHYSIOPATHOLOGY

Activation of beta 2-adrenergic receptors and ventricular fibrillation. Billman GE, et al. **Cardiologia** 1998 Aug; 43(8):811–8 (69 ref.)

Sudden death in dilated cardiomyopathy. Wu AH, et al. **Clin Cardiol** 1999 Apr;22(4):267–72 (71 ref.)

Ion channels and ventricular arrhythmias: cellular and ionic mechanisms underlying the Brugada syndrome. Antzelevitch C. **Curr Opin Cardiol** 1999 May;14(3):274–9 (74 ref.)

Current concepts of ventricular defibrillation. Chen PS, et al. **J Cardiovasc Electrophysiol** 1998 May;9(5):553–62 (59 ref.)

Progressive depolarization: a unified hypothesis for defibrillation and fibrillation induction by shocks. Dillon SM, et al. **J Cardiovasc Electrophysiol** 1998 May; 9(5):529–52 (136 ref.)

Electrical restitution, critical mass, and the riddle of fibrillation [editorial; comment] Gilmour RF Jr, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1087–9 (20 ref.) Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1077–86.

Can shocks timed to action potentials in low-gradient regions improve both internal and out-of-hospital defibrillation? Jones J, et al. **J Electrocardiol** 1998;31 Suppl:41–4 (12 ref.)

PREVENTION & CONTROL

Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era [editorial; comment] Tan HL, et al. **Am Heart J** 1999 May;137(5):770–3 (27 ref.) Comment on: Am Heart J 1999 May;137(5):792–8. Comment on: Am Heart J 1999 May;137(5):799–805.

Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Brugada P, et al. **Am J Cardiol** 1999 Mar 11;83(5B):98D–100D (6 ref.)

Antiarrhythmic drugs in resuscitation. Chamberlain DA. **Heart** 1998 Oct;80(4):408–11 (45 ref.)

THERAPY

The implantable cardioverter defibrillator and primary prevention of sudden death: the Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)-Patch Trial. Block M, et al. **Am J Cardiol** 1999 Mar 11;83(5B):74D–78D (18 ref.)

Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart". Böcker D, et al. **Am J Cardiol** 1999 Mar 11;83(5B):83D–87D (36 ref.)

Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study. Cappato R.

Am J Cardiol 1999 Mar 11;83(5B):68D–73D (45 ref.)
Navigation in the mega-trials waters: reflections on the Multicenter Automatic Defibrillator Implantation Trial and the Antiarrhythmics Versus Implantable Defibrillators Study. Farré J. **Am J Cardiol** 1999 Mar 11;83(5B):5D–7D (28 ref.)
New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Klein H, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):91D–97D (23 ref.)
A preview of implantable cardioverter defibrillator systems in the next millennium: an integrative cardiac rhythm management approach. Morris MM, et al.
Am J Cardiol 1999 Mar 11;83(5B):48D–54D (50 ref.)
What risk should justify implantable cardioverter defibrillator therapy? Schläpfer J, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):101D–103D (31 ref.)
What is the Brugada syndrome? Corrado D, et al.
Cardiol Rev 1999 Jul–Aug;7(4):191–5 (23 ref.)
Implantable cardioverter–defibrillator follow-up: what everyone needs to know. Wilbur SL, et al. **Cardiol Rev** 1999 Jul–Aug;7(4):176–90 (32 ref.)
Survival from ventricular fibrillation [editorial; comment] Dembo DH. **Crit Care Med** 1999 Aug;27(8):1671–2 (13 ref.)
Comment on: Crit Care Med 1999 Aug;27(8):1542–50.
Technologic advances in implantable cardioverter defibrillators. Swygman CA, et al. **Curr Opin Cardiol** 1999 Jan;14(1):9–14 (34 ref.)
Determinants of successful defibrillation. Dalzell GW.
Heart 1998 Oct;80(4):405–7 (27 ref.)
Public access defibrillation: a review. Kern KB. **Heart** 1998 Oct;80(4):402–4 (16 ref.)
The automated external cardiac defibrillator: lifesaving device for medical emergencies. Alexander RE.
J Am Dent Assoc 1999 Jun;130(6):837–45 (26 ref.)
[Successful resuscitation of a patient with ventricular fibrillation in Bland–White–Garland syndrome in adulthood. A case report] Kreutzer U, et al. **Z Kardiol** 1998 Jul;87(7):560–5 (18 ref.) (Eng. Abstr.) **(Ger)**

VENTRICULAR FUNCTION

see related
HEART FUNCTION TESTS

The functional significance of ventricular geometry for the transition from hypertrophy to cardiac failure. Does a critical degree of structural dilatation exist? [editorial] Jacob R, et al. **Basic Res Cardiol** 1998 Dec;93(6):423–9 (55 ref.)
Automatic analysis of ventricular function by nuclear imaging. Germano G. **Curr Opin Cardiol** 1998 Nov; 13(6):425–9 (41 ref.)
Programmed stimulation of the ventricles--back to the future. Buxton AE. **J Interv Card Electrophysiol** 1997 Dec; 1(4):281–5 (27 ref.)
Three-dimensional analysis of regional cardiac function: a model of rabbit ventricular anatomy. Vetter FJ, et al.
Prog Biophys Mol Biol 1998;69(2–3):157–83 (142 ref.)
Quantitative SPECT techniques. Watson DD.
Semin Nucl Med 1999 Jul;29(3):192–203 (35 ref.)

PHYSIOLOGY

The search for the hibernating myocardium--have we reached the limit? Ferrari R. **Cardiovasc Drugs Ther** 1999 Apr;13(2):137–43 (50 ref.)
Heart development and function before birth [editorial] Thornburg KL, et al. **Indian Pediatr** 1998 May;35(5):409–13 (18 ref.)
Atrial fibrillation--maintaining sinus rhythm versus ventricular rate control: the PIAF trial. Pharmacological Intervention in Atrial Fibrillation. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S121–6 (29 ref.)
Ventricular function. Greenberg SB, et al.
Radiol Clin North Am 1999 Mar;37(2):341–59, vi (93 ref.)
[Contribution of doppler echocardiography in the evaluation of ventricular filling in cardiac insufficiency and estimation of filling pressures] Coisne D, et al.
Arch Mal Coeur Vaiss 1998 Dec;91(12 Suppl):43–9 (30 ref.) (Eng. Abstr.) **(Fre)**

VENTRICULAR FUNCTION, LEFT

Hemofiltration and left ventricular function in sepsis: mechanisms and clinical implications [editorial; comment] Dhainaut JF, et al. **Crit Care Med** 1999 Mar;27(3):473–4 (13 ref.) Comment on: Crit Care Med 1999 Mar;27(3):588–96.
Two-dimensional and Doppler echocardiography for the assessment of congestive heart failure. Wilansky S.
Tex Heart Inst J 1998;25(4):260–4 (33 ref.)
Assessment of left-ventricular function. Schertel ER.
Thorac Cardiovasc Surg 1998 Sep;46 Suppl 2:248–54 (22 ref.)
[Relation of the pressure-volume loop and mechanical energy properties of the left ventricle] Popović Z, et al.
Srp Arh Celok Lek 1998 Nov–Dec;126(11–12):467–71 (11 ref.) (Eng. Abstr.) **(Scc)**
[Evaluation of left ventricular diastolic function using Doppler echocardiography] Vlahović A, et al.
Med Pregl 1999 Jan–Feb;52(1–2):13–8 (17 ref.) (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

[Thrombolytic treatment of acute myocardial infarct. 2] Soares-Costa TJ, et al. **Acta Med Port** 1998 May; 11(5):421–9 (0 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Left ventricular restoring forces: modulation by heart rate and contractility. LeWinter MM, et al.
Basic Res Cardiol 1998;93 Suppl 1:143–7 (21 ref.)
Influence of left ventricular pressures and heart rate on myocardial high-energy phosphate metabolism. Neubauer S. **Basic Res Cardiol** 1998;93 Suppl 1:102–7 (23 ref.)
Importance of the blood pressure–heart rate relationship. Folkow B, et al. **Blood Press** 1998 May;7(3):133–8 (30 ref.)
The basics of ventricular function. Penny DJ.
Cardiol Young 1999 Mar;9(2):210–23 (49 ref.)
New ultrasound contrast agents for left ventricular and myocardial opacification. Kasprzak JD, et al. **Herz** 1998 Dec;23(8):474–82 (62 ref.)
State of the art: "diastology" research 1998. Oki T.
J Med Invest 1998 Aug;45(1–4):9–25 (100 ref.)
Clinical assessment of left ventricular relaxation. Constable P, et al. **J Vet Intern Med** 1999 Jan–Feb;13(1):5–13 (40 ref.)
Myocardial tagging for the analysis left ventricular function. Nagel E, et al. **MAGMA** 1998 Sep;6(2–3):91–3 (0 ref.)
Physiological and pathological aspects of exercise left ventricular function. Foster C, et al.
Med Sci Sports Exerc 1998 Oct;30(10 Suppl):S379–86 (53 ref.)
Estimates of regional work in the canine left ventricle. Delhaas T, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):273–87 (53 ref.)
Physical and geometrical modeling for image-based recovery of left ventricular deformation. Duncan J, et al.
Prog Biophys Mol Biol 1998;69(2–3):333–51 (50 ref.)
Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function [see comments] Stainback RF. **Tex Heart Inst J** 1999; 26(1):34–41 (45 ref.) Comment in: Tex Heart Inst J 1999;26(2):158.
[The effect of thrombolytic treatment on the development of global and regional left ventricular function] Paparoni S, et al. **Cardiologia** 1998 Jun;43 Suppl 1:85–8 (25 ref.) **(Ita)**
[Hemodynamic differences between the right and left ventricles (editorial; comment)] Zarco P.
Rev Esp Cardiol 1999 Jan;52(1):43–6 (22 ref.) Comment on: Rev Esp Cardiol 1999 Jan;52(1):37–42. **(Spa)**

VENTRICULAR FUNCTION, RIGHT

The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Riedel B.
Int Anesthesiol Clin 1999 Spring;37(2):55–79 (141 ref.)
[The complex quantitative assessment of right ventricular function: the potentials of echocardiography] Bobyleva ZD, et al. **Ter Arkh** 1998;70(8):79–81 (39 ref.) **(Rus)**

PHYSIOLOGY

The basics of ventricular function. Penny DJ.
Cardiol Young 1999 Mar;9(2):210–23 (49 ref.)
Moon phases and ocean tides: the relationship between the inspiratory–expiratory phases of mechanical ventilation and right ventricular function [editorial; comment] Popovich MJ. **Crit Care Med** 1999 May;27(5):864–5 (14 ref.)
Comment on: Crit Care Med 1999 May;27(5):953–8.
[Hemodynamic differences between the right and left ventricles (editorial; comment)] Zarco P.
Rev Esp Cardiol 1999 Jan;52(1):43–6 (22 ref.) Comment on: Rev Esp Cardiol 1999 Jan;52(1):37–42. **(Spa)**

VENTRICULAR HYPERTROPHY, LEFT see
HYPERTROPHY, LEFT VENTRICULAR

VENTRICULAR HYPERTROPHY, RIGHT see
HYPERTROPHY, RIGHT VENTRICULAR

VENTRICULAR INFLOW OBSTRUCTION see
VENTRICULAR OUTFLOW OBSTRUCTION

VENTRICULAR OUTFLOW OBSTRUCTION

ETIOLOGY

Left ventricular outflow obstruction. Fedderly RT.
Pediatr Clin North Am 1999 Apr;46(2):369–84 (37 ref.)
[Ventricular outflow tract obstruction by cardiac tumors during ACTH therapy of an infant with tuberous sclerosis] Yoshimi S, et al. **No To Hattatsu** 1999 Mar;31(2):165–70 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Subpulmonary obstruction caused by an aneurysm of the membranous ventricular septum. A study of 2 cases] Santos de Soto J, et al. **Rev Esp Cardiol** 1999 May;52(5):351–4 (10 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Exercise testing in children with pulmonary valvar stenosis. Steinberger J, et al. **Pediatr Cardiol** 1999 Jan–Feb; 20(1):27–31; discussion 32 (17 ref.)

VENTRICULAR OUTFLOW OBSTRUCTION, LEFT see
VENTRICULAR OUTFLOW OBSTRUCTION

VENTRICULAR OUTFLOW OBSTRUCTION, RIGHT see
VENTRICULAR OUTFLOW OBSTRUCTION

VENTRICULAR PREMATURE COMPLEXES

DIAGNOSIS

[Ventricular extrasystoles as a form of presentation of neonatal lupus (letter)] Bringué Espuny X, et al.
An Esp Pediatr 1998 Dec;49(6):644–5 (16 ref.) **(Spa)**

PHYSIOPATHOLOGY

[Infundibulum of the right ventricle: an overlooked site of arrhytmogenic dysplasia?] Proclemer A, et al.
Cardiologia 1998 Aug;43(8):805–10 (20 ref.) **(Ita)**

SURGERY

Radiofrequency catheter ablation of right ventricular outflow tract tachycardia in a preschooler. Millane T, et al.
Pediatr Cardiol 1999 Mar–Apr;20(2):143–6 (12 ref.)

THERAPY

The modern treatment of ventricular arrhythmias: drugs or defibrillators. Gill JS. **J R Coll Physicians Lond** 1999 Mar–Apr;33(2):116–23 (11 ref.)

VENTRICULAR PRESSURE

PHYSIOLOGY

Clinical assessment of left ventricular relaxation. Constable P, et al. **J Vet Intern Med** 1999 Jan–Feb;13(1):5–13 (40 ref.)
[Contribution of doppler echocardiography in the evaluation of ventricular filling in cardiac insufficiency and estimation of filling pressures] Coisne D, et al.
Arch Mal Coeur Vaiss 1998 Dec;91(12 Suppl):43–9 (30 ref.) (Eng. Abstr.) **(Fre)**

VENTRICULAR REMODELING

Ventricular remodeling. Mechanisms and prevention. Goldstein S, et al. **Cardiol Clin** 1998 Nov;16(4):623–32, vii–viii (70 ref.)
Models and remodeling: mechanisms and clinical implications. Sonnenblick EH, et al. **Cardiologia** 1999 Jul; 44(7):609–19 (63 ref.)
Squeezing tubes: a case of remodeling and regulation: coronary reserve in hypertensive heart disease. Schwartzkopff B, et al. **Cardiovasc Res** 1998 Oct;40(1):4–8 (30 ref.)
Cardiac remodeling as a consequence and cause of progressive heart failure. Kurrelmeyer K, et al.
Clin Cardiol 1998 Dec;21(12 Suppl 1):I14–9 (40 ref.)
Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. Nakamura M. **J Card Fail** 1999 Jun; 5(2):127–38 (110 ref.)
[Left ventricular hypertrophy remodeling in hypertension] Hu Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun; 36(6):424–6 (19 ref.) **(Chi)**

DRUG EFFECTS

The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Colucci WS. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I20–4 (42 ref.)
Left ventricular remodelling during treatment with beta-blockers. Ertl G, et al. **J Cardiovasc Risk** 1999 Jun; 6(3):145–50 (37 ref.)

PHYSIOLOGY

Early predictors of left ventricular remodeling after acute myocardial infarction. Bolognese L, et al. **Am Heart J** 1999 Aug;138(2 Pt 2):79–83 (49 ref.)
Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Sun Y, et al. **Ann Med** 1998 Aug; 30 Suppl 1:3–8 (52 ref.)
Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds [editorial] Mann DL, et al. **Circulation** 1998 Oct 27;98(17):1699–702 (20 ref.)
Medical and surgical therapy for cardiac remodeling. Bozkurt B. **Curr Opin Cardiol** 1999 May;14(3):196–205 (73 ref.)
Cardiac and vascular remodelling: effect of antihypertensive agents. Mallion JM, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S35–41; discussion S49–50 (48 ref.)
Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. Yamazaki T, et al.
J Hum Hypertens 1999 Jan;13 Suppl 1:S43–7; discussion S49–50 (32 ref.)
Molecular mechanisms of myocardial remodeling. Swynghedauw B. **Physiol Rev** 1999 Jan;79(1):215–62 (527 ref.)
Intraoperative echocardiography: interpretation of changes

VENTRICULAR REMODELING

in left ventricular wall thickness. Spotnitz HM, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):273–83 (42 ref.)

[The role of angiotensin II in the development of cardiovascular remodeling] Komuro I, et al. **Nippon Rinsho** 1999 May;57(5):1090–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

VENTRICULAR SEPTAL DEFECTS see **HEART SEPTAL DEFECTS, VENTRICULAR**

VENTRICULOCISTERNOSTOMY see **VENTRICULOSTOMY**

VENTRICULOGRAPHY, EQUILIBRIUM RADIONUCLIDE see **GATED BLOOD-POOL IMAGING**

VENTRICULOGRAPHY, FIRST-PASS

see related
GATED BLOOD-POOL IMAGING

VENTRICULOGRAPHY, GATED RADIONUCLIDE see **GATED BLOOD-POOL IMAGING**

VENTRICULOGRAPHY, RADIONUCLIDE see **RADIONUCLIDE VENTRICULOGRAPHY**

VENTRICULOPERITONEAL SHUNT

Cerebral ventricular shunts. Naradzay JF, et al. **J Emerg Med** 1999 Mar–Apr;17(2):311–22 (78 ref.)

ADVERSE EFFECTS

Pneumocephalus after shunting for hydrocephalus. Villarejo F, et al. **Childs Nerv Syst** 1998 Jul;14(7):333–7 (25 ref.)

Mycobacterium fortuitum infection of ventriculoperitoneal shunt. Midani S, et al. **South Med J** 1999 Jul;92(7):705–7 (12 ref.)

[Extraneural metastasis of pineal germinoma through a ventriculoperitoneal shunt, following histological change] Uchino M, et al. **No Shinkei Geka** 1999 Mar;27(3):269–74 (23 ref.) (Eng. Abstr.) **(Jpn)**

VENTRICULOSTOMY

ADVERSE EFFECTS

[Infectious risk from ventriculostomy] Korinek AM. **Ann Fr Anesth Reanim** 1999 May;18(5):554–7 (14 ref.) (Eng. Abstr.) **(Fre)**

METHODS

The role of endoscopic third ventriculostomy in the management of shunt malfunction. Cinalli G, et al. **Neurosurgery** 1998 Dec;43(6):1323–7; discussion 1327–9 (34 ref.)

NURSING

External ventriculostomy: a practical application for the acute care nurse. Pope W. **J Neurosci Nurs** 1998 Jun; 30(3):185–90 (11 ref.)

VENULES, LYMPHATIC see **LYMPHATIC SYSTEM**

VENULES, POSTCAPILLARY see **LYMPHATIC SYSTEM**

VERAPAMIL

PHARMACOKINETICS

Effect of age on pharmacokinetics and pharmacodynamics in man. Klotz U. **Int J Clin Pharmacol Ther** 1998 Nov; 36(11):581–5 (16 ref.)

PHARMACOLOGY

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

THERAPEUTIC USE

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

VERBAL BEHAVIOR

see related
LANGUAGE DISORDERS
SPEECH DISORDERS

Rethinking eliminative connectionism. Marcus GF. **Cognit Psychol** 1998 Dec;37(3):243–82 (95 ref.)

Women's narratives: evolving symptoms of myocardial infarction. McSweeney JC. **J Women Aging** 1998; 10(2):67–83 (30 ref.)

DRUG EFFECTS

The application of a computerized measurement of the content analysis of natural language to the assessment of the effects of psychoactive drugs. Gottschalk LA. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):133–8 (67 ref.)

VERBAL LEARNING

see related
LANGUAGE DISORDERS

Patterns of acquisition in the emerging mental lexicon: the case of to and for in English. Rice S. **Brain Lang** 1999 Jun 1–15;68(1–2):268–76 (21 ref.)

The study of child language in South Africa [see comments] Penn C. **Folia Phoniatr Logop** 1998;50(5):256–70 (87 ref.) Comment in: Folia Phoniatr Logop 1998 ;50(5):239–42.

Determinants of positive and negative generation effects in free recall. Steffens MC, et al. **Q J Exp Psychol A** 1998 Nov;51(4):705–33 (62 ref.)

PHYSIOLOGY

[100 years research in reading and spelling--what do we know today?] von Suchodoletz W. **Z Kinder Jugendpsychiatr Psychother** 1999 Aug; 27(3):199–206 (70 ref.) **(Ger)**

[Procedural learning in aphasic patients] Arroyo-Anlló EM, et al. **Rev Neurol** 1998 Dec;27(160):926–32 (51 ref.) (Eng. Abstr.) **(Spa)**

VERMIFUGES see **ANTHELMINTICS**

VERNER-MORRISON SYNDROME see **VIPOMA**

VERO CELLS

Experience with the Vero cell line. Montagnon BJ, et al. **Dev Biol Stand** 1998;93:119–23 (13 ref.)

VERRUCA see **WARTS**

VERRUGA PERUANA see **BARTONELLA INFECTIONS**

VERSION, FETAL

ADVERSE EFFECTS

Fetal complication after external cephalic version at term: case report and literature review. Ghidini A, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):190–2 (22 ref.)

METHODS

[Instrumental and manual maneuvers during delivery] Schaal JP, et al. **Rev Prat** 1999 Jan 15;49(2):139–45 (8 ref.) (Eng. Abstr.) **(Fre)**

VERTEBRAE see **SPINE**

VERTEBRAL ANKYLOSING HYPEROSTOSIS see **HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL**

VERTEBRAL ARTERY

Dissecting vertebral aneurysm. Report of a case. Fiori L, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):87–91 (23 ref.)

[Cervical deficit radiculopathy in 3 cases of vertebral artery dissection] de Bray JM, et al. **Rev Neurol (Paris)** 1998 Nov; 154(11):762–6 (13 ref.) (Eng. Abstr.) **(Fre)**

[Cerebellar infarction due to vertebral artery dissection in a girl] Ushida M, et al. **No To Hattatsu** 1998 Nov; 30(6):535–41 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Spontaneous dissection of carotid and vertebral arteries. II. Vertebral arteries and their branches] Jankowicz E, et al. **Neurol Neurochir Pol** 1998 Sep–Oct;32(5):1237–45 (18 ref.) (Eng. Abstr.) **(Pol)**

ABNORMALITIES

Anomalous origin of the right vertebral artery: review of the literature and case report of right vertebral artery origin distal to the left subclavian artery. Lemke AJ, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1318–21 (10 ref.)

Anomalous origin of both vertebral arteries. Gluncic V, et al. **Clin Anat** 1999;12(4):281–4 (13 ref.)

Dissecting aortic aneurysm involving an anomalous right subclavian artery and isolated left vertebral artery: case report and review of the literature. Nonami Y, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):743–6 (10 ref.)

INJURIES

Vertebral artery trauma. Opeskin K, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):206–17 (84 ref.)

Detection of vertebral artery injury after cervical spine trauma using magnetic resonance angiography. Weller SJ, et al. **J Trauma** 1999 Apr;46(4):660–6 (40 ref.)

Bilateral vertebral artery occlusion following cervical spine trauma--case report. Ozveren F, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):28–32 (44 ref.)

Cervicothoracic vascular injuries. McIntyre WB, et al. **Semin Vasc Surg** 1998 Dec;11(4):232–42 (50 ref.)

PATHOLOGY

Fusiform vertebral artery aneurysms as a cause of dissecting aneurysms. Report of two autopsy cases and a review of the literature. Yasui T, et al. **J Neurosurg** 1999 Jul; 91(1):139–44 (25 ref.)

Spontaneous bilateral vertebral artery dissections: case report and literature review. Chang AJ, et al. **Mayo Clin Proc** 1999 Sep;74(9):893–6 (26 ref.)

Ruptured anterior spinal artery aneurysm: a case report. Kawamura S, et al. **Surg Neurol** 1999 Jun;51(6):608–12 (25 ref.)

RADIOGRAPHY

[Cerebral and basilar artery thrombosis following cervical spinal injury] Niedeggen A, et al. **Zentralbl Neurochir** 1999; 60(1):20–6 (25 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical treatment of vertebral and posterior inferior cerebellar artery aneurysms. Ogilvy CS, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):851–60 (51 ref.)

Pseudoaneurysm of the vertebral artery. Schittek A. **Tex Heart Inst J** 1999;26(1):90–5 (27 ref.)

VERTEBRAL ARTERY INSUFFICIENCY see **VERTEBROBASILAR INSUFFICIENCY**

VERTEBRATES

ANATOMY & HISTOLOGY

Tunicate tails, stolons, and the origin of the vertebrate trunk. Lacalli TC. **Biol Rev Camb Philos Soc** 1999 May; 74(2):177–98 (142 ref.)

Structural and functional evolution of the basal ganglia in vertebrates. Reiner A, et al. **Brain Res Brain Res Rev** 1998 Dec;28(3):235–85 (508 ref.)

Phylogenetic development of the cochlea and its innervation. Manley GA, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):468–74 (42 ref.)

Zebrafish in context: uses of a laboratory model in comparative studies. Metscher BD, et al. **Dev Biol** 1999 Jun 1;210(1):1–14 (63 ref.)

Neural stem cells: from fly to vertebrates. Doe CQ, et al. **J Neurobiol** 1998 Aug;36(2):111–27 (119 ref.)

[The differentiation of the endocrinocytes of the large intestine in vertebrate animals and man] Ivanova OV, et al. **Morfologiia** 1998;114(4):107–11 (58 ref.) **(Rus)**

EMBRYOLOGY

Germline development in vertebrates and invertebrates. Saffman EE, et al. **Cell Mol Life Sci** 1999 Jul; 55(8–9):1141–63 (230 ref.)

Extrinsic influences on limb muscle organisation. Blagden CS, et al. **Cell Tissue Res** 1999 Apr;296(1):141–50 (139 ref.)

Genetic and epigenetic control of muscle development in vertebrates. Brand-Saberi B, et al. **Cell Tissue Res** 1999 Apr;296(1):199–212 (181 ref.)

Muscle development during vertebrate limb outgrowth. Büscher D, et al. **Cell Tissue Res** 1999 Apr;296(1):131–9 (78 ref.)

Dorsoventral patterning of the vertebrate limb: a process governed by multiple events. Chen H, et al. **Cell Tissue Res** 1999 Apr;296(1):67–73 (49 ref.)

Molecular control of vertebrate limb development, evolution and congenital malformations. Cohn MJ, et al. **Cell Tissue Res** 1999 Apr;296(1):3–17 (170 ref.)

Regulation of hypaxial muscle development. Dietrich S. **Cell Tissue Res** 1999 Apr;296(1):175–82 (59 ref.)

The recombinant limb as a model for the study of limb patterning, and its application to muscle development. Fernandez-Teran M, et al. **Cell Tissue Res** 1999 Apr; 296(1):121–9 (58 ref.)

Myotome formation: a multistage process. Kalcheim C, et al. **Cell Tissue Res** 1999 Apr;296(1):161–73 (71 ref.)

T-box genes and the formation of vertebrate forelimb- and hindlimb specific pattern. Simon H. **Cell Tissue Res** 1999 Apr;296(1):57–66 (71 ref.)

Hox genes in digit development and evolution. Zákány J, et al. **Cell Tissue Res** 1999 Apr;296(1):19–25 (57 ref.)

Somitogenesis: segmenting a vertebrate. McGrew MJ, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):487–93 (50 ref.)

Wnt signaling and dorso–ventral axis specification in vertebrates. Sokol SY. **Curr Opin Genet Dev** 1999 Aug; 9(4):405–10 (73 ref.)

Epithelial cell movements and interactions in limb, neural crest and vasculature. Tickle C, et al. **Curr Opin Genet Dev** 1999 Aug;9(4):455–60 (28 ref.)

Molecular and cellular basis of pattern formation during vertebrate limb development. Ng JK, et al. **Curr Top Dev Biol** 1999;41:37–66 (137 ref.)

Comparison of early nerve cord development in insects and vertebrates. Arendt D, et al. **Development** 1999 Jun; 126(11):2309–25 (266 ref.)

The morphological pattern of the vertebrate brain. Nieuwenhuys R. **Eur J Morphol** 1999 Apr;37(2–3):81–4 (11 ref.)

Multipotential stem cells and progenitors in the vertebrate retina. Reh TA, et al. **J Neurobiol** 1998 Aug;36(2):206–20 (114 ref.)

Identifying the missing links: genes that connect neural induction and primary neurogenesis in vertebrate embryos. Sasai Y. **Neuron** 1998 Sep;21(3):455–8 (20 ref.)

Notch signalling and the control of cell fate choices in vertebrates. Lewis J. **Semin Cell Dev Biol** 1998 Dec; 9(6):583–9 (61 ref.)
Head in the WNT: the molecular nature of Spemann's head organizer. Niehrs C. **Trends Genet** 1999 Aug;15(8):314–9 (68 ref.)

GENETICS

Evolutionary genomics of vertebrates and its implications. D'Onofrio G, et al. **Ann N Y Acad Sci** 1999 May 18; 870:81–94 (44 ref.)
Molecular biology of odorant receptors in vertebrates. Mombaerts P. **Annu Rev Neurosci** 1999;22:487–509 (76 ref.)
How to build a vertebrate hindbrain. Lessons from genetics. Schneider-Maunoury S, et al. **C R Acad Sci III** 1998 Oct; 321(10):819–34 (137 ref.)
Selector genes and limb identity in arthropods and vertebrates. Weatherbee SD, et al. **Cell** 1999 Apr 30; 97(3):283–6 (20 ref.)
The one-to-four rule and paralogues of sex-determining genes. Ohno S. **Cell Mol Life Sci** 1999 Jun;55(6–7):824–30 (19 ref.)
"Dumb" versus "smart" kinetochore models for chromosome congression during mitosis in vertebrate somatic cells. Khodjakov A, et al. **Cell Motil Cytoskeleton** 1999; 43(3):179–85 (28 ref.)
Vertebrate hox gene regulation: clustering and/or colinearity? Duboule D. **Curr Opin Genet Dev** 1998 Oct; 8(5):514–8 (58 ref.)
T-cell receptors in ectothermic vertebrates. Charlemagne J, et al. **Immunol Rev** 1998 Dec;166:87–102 (35 ref.)
Insight into the primordial MHC from studies in ectothermic vertebrates. Flajnik MF, et al. **Immunol Rev** 1999 Feb; 167:59–67 (77 ref.)
The immunoglobulin light chain in poikilothermic vertebrates. Pilström L, et al. **Immunol Rev** 1998 Dec; 166:123–32 (86 ref.)
Evolution and diversity of the complement system of poikilothermic vertebrates. Sunyer JO, et al.
Immunol Rev 1998 Dec;166:39–57 (119 ref.)
The notion of the Cambrian pananimalia genome and a genomic difference that separated vertebrates from invertebrates. Ohno S. **Prog Mol Subcell Biol** 1998; 21:97–117 (43 ref.)
Regulation of RNA polymerase I transcription in yeast and vertebrates. Reeder RH.
Prog Nucleic Acid Res Mol Biol 1999;62:293–327 (212 ref.)
[Genetic control of the early stages of cardiac development in vertebrates] Mglinets VA. **Genetika** 1998 Aug; 34(8):1029–39 (84 ref.) (Eng. Abstr.) **(Rus)**
[Multiple role of hedgehog genes in vertebrates: data from analysis of mutations] Korzh VP. **Ontogenez** 1998 Sep–Oct; 29(5):323–34 (80 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Development of the vertebrate neuromuscular junction. Sanes JR, et al. **Annu Rev Neurosci** 1999;22:389–442 (332 ref.)
Molecular control of vertebrate limb development, evolution and congenital malformations. Cohn MJ, et al.
Cell Tissue Res 1999 Apr;296(1):3–17 (170 ref.)
Multipotential stem cells and progenitors in the vertebrate retina. Reh TA, et al. **J Neurobiol** 1998 Aug;36(2):206–20 (114 ref.)
Molecular regulators involved in vertebrate eye development. Jean D, et al. **Mech Dev** 1998 Aug; 76(1–2):3–18 (204 ref.)

IMMUNOLOGY

Churchill and the immune system of ectothermic vertebrates. Flajnik MF. **Immunol Rev** 1998 Dec;166:5–14 (47 ref.)
What brought the adaptive immune system to vertebrates?—The jaw hypothesis and the seahorse. Matsunaga T, et al. **Immunol Rev** 1998 Dec;166:177–86 (72 ref.)

METABOLISM

Aspects of GnRH neurobiology conserved across vertebrate forms [comment] Dellovade T, et al.
Gen Comp Endocrinol 1998 Dec;112(3):276–82 (33 ref.)
Comment on: Gen Comp Endocrinol 1998 Dec;112(3):322–9.
Endogenous relatives of ADP-ribosylating bacterial toxins in mice and men: potential regulators of immune cell function. Haag F, et al. **J Biol Regul Homeost Agents** 1998 Jul–Sep;12(3):53–62 (87 ref.)
[Current concepts on structure and catalytic properties of cholinesterase from vertebrates and invertebrates] Maralev SM, et al. **Zh Evol Biokhim Fiziol** 1999 Jan–Feb;35(1):3–14 (88 ref.) **(Rus)**

PHYSIOLOGY

Complex movement patterns: modifiability and constraints. Bout RG. **Acta Anat (Basel)** 1998;163(3):144–56 (79 ref.)
The cytoskeleton of the vertebrate smooth muscle cell. Small JV, et al. **Acta Physiol Scand** 1998 Dec;164(4):341–8 (63 ref.)
The specification of dorsal cell fates in the vertebrate central nervous system. Lee KJ, et al. **Annu Rev Neurosci** 1999; 22:261–94 (140 ref.)
Evolution of the vertebrate cardio-pulmonary system. Farmer CG. **Annu Rev Physiol** 1999;61:573–92 (95 ref.)
Controversial issues in vertebrate olfactory transduction. Gold GH. **Annu Rev Physiol** 1999;61:857–71 (71 ref.)
The role of timing in the brain stem auditory nuclei of vertebrates. Oertel D. **Annu Rev Physiol** 1999;61:497–519 (216 ref.)
Frugivory and seed dispersal by vertebrates in the Oriental (Indomalayan) Region. Corlett RT.
Biol Rev Camb Philos Soc 1998 Nov;73(4):413–48 (230 ref.)
Patterns of vertebrate neurogenesis and the paths of vertebrate evolution. Finlay BL, et al.
Brain Behav Evol 1998;52(4–5):232–42 (47 ref.)
Of mice and genes: evolution of vertebrate brain development. Fritzsch B. **Brain Behav Evol** 1998; 52(4–5):207–17 (71 ref.)
Structural and functional evolution of the basal ganglia in vertebrates. Reiner A, et al. **Brain Res Brain Res Rev** 1998 Dec;28(3):235–85 (508 ref.)
Melatonin's role in vertebrate circadian rhythms. Cassone VM. **Chronobiol Int** 1998 Sep;15(5):457–73 (86 ref.)
Evolution of surface activity related functions of vertebrate pulmonary surfactant. Daniels CB, et al.
Clin Exp Pharmacol Physiol 1998 Sep;25(9):716–21 (40 ref.)
Inhibition and activation of the thyroidal axis by the adrenal axis in vertebrates. Kühn ER, et al.
Comp Biochem Physiol A Mol Integr Physiol 1998 May; 120(1):169–74 (49 ref.)
Comparative neuroanatomy of vasotocin and vasopressin in amphibians and other vertebrates. Moore FL, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Jun;119(3):251–60 (114 ref.)
Functional role of plateau potentials in vertebrate motor neurons. Kiehn O, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):746–52 (39 ref.)
Intersegmental coordination in invertebrates and vertebrates. Skinner FK, et al. **Curr Opin Neurobiol** 1998 Dec; 8(6):725–32 (54 ref.)
Modulation of vertebrate and invertebrate neuromuscular junctions. Worden MK. **Curr Opin Neurobiol** 1998 Dec; 8(6):740–5 (47 ref.)
A comparison of hair bundle mechanoreceptors in sea anemones and vertebrate systems. Watson GM, et al.
Curr Top Dev Biol 1999;43:51–84 (75 ref.)
Evolution of colour vision in vertebrates. Bowmaker JK. **Eye** 1998;12 (Pt 3b):541–7 (78 ref.)
Sexual differentiation of the vertebrate brain: principles and mechanisms. Cooke B, et al. **Front Neuroendocrinol** 1998 Oct;19(4):323–62 (222 ref.)
Organic osmolyte channels in cell volume regulation in vertebrates. Perlman DF, et al. **J Exp Zool** 1999 Jun 1; 283(7):725–33 (58 ref.)
Regulation of synaptic function by neurotrophic factors in vertebrates and invertebrates: implications for development and learning. McKay SE, et al. **Learn Mem** 1999 May–Jun; 6(3):193–215 (196 ref.)
Evolution, discovery, and interpretations of arthropod mushroom bodies. Strausfeld NJ, et al. **Learn Mem** 1998 May–Jun;5(1–2):11–37 (155 ref.)
Cellular magnesium transport in the vertebrate intestine. Bijvelds MJ, et al. **Magnes Res** 1998 Dec;11(4):315–22 (80 ref.)
Homology and convergence in vertebrate and invertebrate nervous systems. Sandeman D. **Naturwissenschaften** 1999 Aug;86(8):378–87 (41 ref.)
Gaba as an afferent neurotransmitter in the vestibular sensory periphery of vertebrates. Meza G. **Neurobiology (Bp)** 1998; 6(1):109–25 (85 ref.)
Amiloride and vertebrate gustatory responses to NaCl. Halpern BP. **Neurosci Biobehav Rev** 1998;23(1):5–47 (128 ref.)
Central control of the cardiovascular and respiratory systems and their interactions in vertebrates. Taylor EW, et al.
Physiol Rev 1999 Jul;79(3):855–916 (673 ref.)
Role of calcium ions in vertebrate phototransduction. Gorczyca WA. **Pol J Pharmacol** 1999 Mar–Apr; 51(2):167–72 (47 ref.)
Molecular mechanisms of vertebrate left-right development. Ramsdell AF, et al. **Trends Genet** 1998 Nov;14(11):459–65 (49 ref.)

VERTEBROBASILAR INSUFFICIENCY

ETIOLOGY

Bilateral vertebral artery occlusion following cervical spine trauma—case report. Ozveren F, et al.
Neurol Med Chir (Tokyo) 1999 Jan;39(1):28–32 (44 ref.)
Vertebrobasilar ischaemia. Martin PJ. **QJM** 1998 Dec; 91(12):799–811 (107 ref.)

RADIOGRAPHY

Bilateral vertebral artery occlusion following cervical spine trauma—case report. Ozveren F, et al.
Neurol Med Chir (Tokyo) 1999 Jan;39(1):28–32 (44 ref.)

THERAPY

Recurrent abrupt occlusion after transluminal angioplasty for basilar artery stenosis: case report. Jimenez C, et al.
Neurosurgery 1999 Jan;44(1):210–5 (40 ref.)

VERTICAL DIMENSION

Structural dentofacial variations in maxilla expansion. Bertelè G, et al. **Minerva Stomatol** 1999 Apr;48(4):101–13 (36 ref.) **(Eng, Ita)**

VERTICAL TRANSMISSION see **DISEASE TRANSMISSION, VERTICAL**

VERTIGO

Benign paroxysmal positional vertigo. State of the art. Boniver R. **Acta Otorhinolaryngol Belg** 1998;52(4):281–9 (44 ref.)
Benign paroxysmal positioning vertigo. Brandt T.
Adv Otorhinolaryngol 1999;55:169–94 (86 ref.)

CHEMICALLY INDUCED

[A vertiginous syndrome due to sulfasalazine (letter)] Sáez J, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):207–8 (5 ref.) **(Spa)**

DIAGNOSIS

Diagnostic criteria for central versus peripheral positioning nystagmus and vertigo: a review. Büttner U, et al.
Acta Otolaryngol (Stockh) 1999 Jan;119(1):1–5 (27 ref.)
[Vertigo in adults: diagnostic strategies, role of vestibular rehabilitation. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Chauplannaz G, et al.
Ann Otolaryngol Chir Cervicofac 1998 Oct;115 Suppl 1:S5–21 (126 ref.) **(Fre)**
[Atypical Cogan syndrome: a case report and review of the literature] De Righetti F, et al.
Rev Med Suisse Romande 1998 Oct;118(10):889–93 (50 ref.) **(Fre)**
[Diagnosis and therapeutic options in benign paroxysmal positional vertigo] Suzuki AR, et al.
Acta Otorrinolaringol Esp 1999 Mar;50(2):106–17 (42 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Drug treatment for vertigo and dizziness. Darlington CL, et al. **N Z Med J** 1998 Sep 11;111(1073):332–4 (19 ref.)
[Contribution of vastarel 20 mg (trimetazidine) in the treatment of vertigo: synopsis of clinical trials] Bouccara D. **Ann Otolaryngol Chir Cervicofac** 1999 Apr;116(1):43–6 (6 ref.) **(Fre)**
[Chemical labyrinthectomy: results and applications] Mondain M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115(4):234–42 (40 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Solitary plasmacytoma of the skull base presenting with unilateral sensorineural hearing loss. Vijaya-Sekaran S, et al. **J Laryngol Otol** 1999 Feb;113(2):164–6 (13 ref.)
Vertigo [see comments] Baloh RW. **Lancet** 1998 Dec 5; 352(9143):1841–6 (27 ref.) Comment in: Lancet 1999 Feb 13;353(9152):591.
Treatment for positional vertigo [see comments] Hornibrook J. **N Z Med J** 1998 Sep 11;111(1073):331–2 (28 ref.) Comment in: N Z Med J 1998 Sep 11;111(1073):349.
Acute vertigo: peripheral versus central etiology [letter] Drozd CE. **Nurse Pract** 1999 Apr;24(4):147–8 (5 ref.)
The dizzy patient. Baloh RW. **Postgrad Med** 1999 Feb; 105(2):161–4, 167–72 (20 ref.)
[Benign paroxysmal positional vertigo (see comments)] van der Plas JP, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5; 142(49):2669–74 (25 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Jan 30;143(5):276. **(Dut)**
[Chemical labyrinthectomy: results and applications] Mondain M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Oct;115(4):234–42 (40 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

[Vertigo in adults: diagnostic strategies, role of vestibular rehabilitation. Work Group assembled by the National Agency for Health Accreditation and Evaluation (ANAES)] Chauplannaz G, et al.
Ann Otolaryngol Chir Cervicofac 1998 Oct;115 Suppl 1:S5–21 (126 ref.) **(Fre)**

THERAPY

Update on vertigo management. Antonelli PJ.
Compr Ther 1999 Jan;25(1):5–12 (25 ref.)
Vertigo [see comments] Baloh RW. **Lancet** 1998 Dec 5; 352(9143):1841–6 (27 ref.) Comment in: Lancet 1999 Feb 13;353(9152):591.
Treatment for positional vertigo [see comments] Hornibrook J. **N Z Med J** 1998 Sep 11;111(1073):331–2 (28 ref.) Comment in: N Z Med J 1998 Sep 11;111(1073):349.
The effectiveness of piracetam in vertigo. Oosterveld WJ. **Pharmacopsychiatry** 1999 Mar;32 Suppl 1:54–60 (23 ref.)
[Advances in the therapy of benign paroxysmal positional vertigo] Bai Q.
Lin Chuang Erh Pi Yen Hou Ko Tsa Chih 1997 Dec; 11(12):580–2 (24 ref.) **(Chi)**
[Benign paroxysmal vertigo or benign postural vertigo] Boniver R. **Rev Med Liege** 1998 Sep;53(9):553–63 (23 ref.) (Eng. Abstr.) **(Fre)**

VERTIGO

[Diagnosis and therapeutic options in benign paroxysmal positional vertigo] Suzuki AR, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):106–17 (42 ref.) (Eng. Abstr.) **(Spa)**

VERTIGO, AURAL see **MENIERE'S DISEASE**

VERY HIGH FREQUENCY WAVES see **RADIO WAVES**

VERY-LOW-DENSITY LIPOPROTEINS see **LIPOPROTEINS, VLDL**

VESICAL CALCULI see **BLADDER CALCULI**

VESICAL FISTULA see **BLADDER FISTULA**

VESICANTS see **IRRITANTS**

VESICATION see **BLISTER**

VESICO-URETERAL REFLUX

Pediatric urinary tract infection and reflux. Ross JH, et al. **Am Fam Physician** 1999 Mar 15;59(6):1472–8, 1485–6 (28 ref.)

Vesicoureteral reflux in infants. Sillén U. **Pediatr Nephrol** 1999 May;13(4):355–61 (52 ref.)

COMPLICATIONS

Vesico ureteric reflux and urinary tract infections in children. Woodward A. **Aust Fam Physician** 1998 Dec;27(12):1095–7 (4 ref.)

Hypertension in reflux nephropathy. Goonasekera CD, et al. **BJU Int** 1999 Apr;83 Suppl 3:1–12 (165 ref.)

Reflux nephropathy and hypertension. Goonasekera CD, et al. **J Hum Hypertens** 1998 Aug;12(8):497–504 (128 ref.)

[The nephropathies of reflux] **Prog Urol** 1998 Nov; 8(5):703–25 (114 ref.) **(Fre)**

[Ambulatory monitoring of arterial pressure in a group of children with reflux nephropathy of different degrees] Jiménez-Hereza JM, et al. **An Esp Pediatr** 1998 Nov; 49(5):461–6 (34 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Fetal reflux--neonatal reflux] **Prog Urol** 1998 Nov; 8(5):897–907 (58 ref.) **(Fre)**

[Primary vesico-renal reflux in children and adults. Clinical diagnosis] **Prog Urol** 1998 Nov;8(5):729–36 (51 ref.) **(Fre)**

[Primary vesico-renal reflux in children and adults. Diagnostic imaging and classification] **Prog Urol** 1998 Nov; 8(5):737–69 (185 ref.) **(Fre)**

[Primary vesicoureteral reflux in childhood. The current aspects and future outlook] Estornell Moragues F, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):616–24 (65 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Vesico-renal reflux and duplication of the urinary tract] **Prog Urol** 1998 Nov;8(5):869–81 (54 ref.) **(Fre)**

[Vesico-ureteral reflux in pediatrics] Fanos V, et al. **Minerva Pediatr** 1998 Jul–Aug;50(7–8):367–74 (45 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

[Familial vesico-renal reflux (genetic aspects of primary reflux)] **Prog Urol** 1998 Nov;8(5):909–17 (48 ref.) **(Fre)**

PATHOLOGY

Reflux nephropathy. Dillon MJ, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2377–83 (91 ref.)

PHYSIOPATHOLOGY

Reflux nephropathy and hypertension. Goonasekera CD, et al. **J Hum Hypertens** 1998 Aug;12(8):497–504 (128 ref.)

[Primary reflux in adults] **Prog Urol** 1998 Nov;8(5):923–37 (117 ref.) **(Fre)**

[The natural history of primary vesico-renal reflux. The probability of spontaneous remission] **Prog Urol** 1998 Nov; 8(5):783–9 (39 ref.) **(Fre)**

[The physiopathology of vesico-renal reflux] **Prog Urol** 1998 Nov;8(5):685–701 (108 ref.) **(Fre)**

PREVENTION & CONTROL

Results of the Gil Vernet procedure in preventing contralateral reflux in unilateral ureteric reflux. Liard A, et al. **BJU Int** 1999 Apr;83(6):658–61 (19 ref.)

SURGERY

Results of the Gil Vernet procedure in preventing contralateral reflux in unilateral ureteric reflux. Liard A, et al. **BJU Int** 1999 Apr;83(6):658–61 (19 ref.)

Ileal ureteral substitution in reconstructive urological surgery: is an antireflux procedure necessary? Waldner M, et al. **J Urol** 1999 Aug;162(2):323–6 (20 ref.)

[Primary vesico-renal reflux in children and adults. Conventional surgical treatment] **Prog Urol** 1998 Nov; 8(5):805–40 (240 ref.) **(Fre)**

[Endoscopic treatment of vesico-renal reflux] **Prog Urol** 1998 Nov;8(5):841–62 (116 ref.) **(Fre)**

[Primary vesico-renal reflux in children and adults. Contralateral reflux after treatment of unilateral reflux] **Prog Urol** 1998 Nov;8(5):863–7 (27 ref.) **(Fre)**

THERAPY

New advances in injectable therapies for the treatment of incontinence and vesicoureteral reflux. Kershen RT, et al. **Urol Clin North Am** 1999 Feb;26(1):81–94, viii (77 ref.)

The office management of recurrent urinary tract infection and vesicoureteral reflux in children. Shapiro E, et al. **Urol Clin North Am** 1998 Nov;25(4):725–34, x (73 ref.)

VESICOSTOMY see **CYSTOSTOMY**

VESICOVAGINAL FISTULA

Vesicovaginal fistula. Smith GL, et al. **BJU Int** 1999 Mar; 83(5):564–9; quiz 569–70 (40 ref.)

DRUG THERAPY

[Hormonal dependence of vesicouterine fistulas] Jóźwik M, et al. **Ginekol Pol** 1998 Sep;69(9):717–21 (21 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Urological problems and the treatment of gynaecological cancer. Davies Q, et al. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):401–3 (13 ref.)

Genital fistulae. A continuing tragedy. Rizvi JH. **J Obstet Gynaecol Res** 1999 Feb;25(1):1–7 (17 ref.)

The O'Conor technique: the gold standard for supratrigonal vesicovaginal fistula repair. Nesrallah LJ, et al. **J Urol** 1999 Feb;161(2):566–8 (21 ref.)

[Hormonal dependence of vesicouterine fistulas] Jóźwik M, et al. **Ginekol Pol** 1998 Sep;69(9):717–21 (21 ref.) (Eng. Abstr.) **(Pol)**

VESICULAR SKIN DISEASES see **SKIN DISEASES, VESICULOBULLOUS**

VESICULAR STOMATITIS-INDIANA VIRUS

IMMUNOLOGY

Vesicular stomatitis. Letchworth GJ, et al. **Vet J** 1999 May; 157(3):239–60 (267 ref.)

VESICULAR STOMATITIS VIRUS see **VESICULAR STOMATITIS-INDIANA VIRUS**

VESICULOBULLOUS SKIN DISEASES see **SKIN DISEASES, VESICULOBULLOUS**

VESTIBULAR APPARATUS see **VESTIBULE**

VESTIBULAR DISEASES

COMPLICATIONS

The dizzy patient. Baloh RW. **Postgrad Med** 1999 Feb; 105(2):161–4, 167–72 (20 ref.)

DIAGNOSIS

Diagnostic criteria for central versus peripheral positioning nystagmus and vertigo: a review. Büttner U, et al. **Acta Otolaryngol (Stockh)** 1999 Jan;119(1):1–5 (27 ref.)

Current status of electronystagmography testing. Bhansali SA, et al. **Otolaryngol Head Neck Surg** 1999 Mar; 120(3):419–26 (35 ref.)

[Imaging of the cochleo-vestibular system] Marsot-Dupuch K, et al. **J Radiol** 1999 Apr;80(4):351–62 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Endolymphatic sac tumours. Kempermann G, et al. **Histopathology** 1998 Jul;33(1):2–10 (74 ref.)

SURGERY

Vestibular schwannoma management in the next century: a radiosurgical perspective. Pollock BE, et al. **Neurosurgery** 1998 Sep;43(3):475–81; discussion 481–3 (48 ref.)

VESTIBULAR NERVE

Vestibular neuritis. Strupp M, et al. **Adv Otorhinolaryngol** 1999;55:111–36 (87 ref.)

VESTIBULAR NUCLEI

PHYSIOLOGY

Intrinsic physiological and pharmacological properties of central vestibular neurons. Vidal PP, et al. **Adv Otorhinolaryngol** 1999;55:26–81 (247 ref.)

Potassium currents and excitability in second-order auditory and vestibular neurons. Peusner KD, et al. **J Neurosci Res** 1998 Sep 1;53(5):511–20 (76 ref.)

PHYSIOPATHOLOGY

Molecular mechanisms of vestibular compensation in the central vestibular system--review. Kitahara T, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:19–27 (59 ref.)

VESTIBULE

BLOOD SUPPLY

[Ischemia of the anterior vestibular artery (Lindsay-Hemenway syndrome). Review and comments] Pardal Refoyo JL, et al. **Acta Otorrinolaringol Esp** 1998 Nov-Dec;49(8):599–602 (21 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Involvement of insulin-like growth factor-I in inner ear organogenesis and regeneration. León Y, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):126–32 (57 ref.)

INNERVATION

Effect of gravity on vestibular neural development. Ross MD, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):44–51 (61 ref.)

PHYSIOLOGY

Vestibular evoked myogenic potentials in humans: a review. Ferber-Viart C, et al. **Acta Otolaryngol (Stockh)** 1999 Jan; 119(1):6–15 (51 ref.)

Vestibular compensation. Curthoys IS, et al. **Adv Otorhinolaryngol** 1999;55:82–110 (124 ref.)

The contributions of vestibular signals to the representations of space in the posterior parietal cortex. Andersen RA, et al. **Ann N Y Acad Sci** 1999 May 28;871:282–92 (44 ref.)

The vestibular cortex. Its locations, functions, and disorders. Brandt T, et al. **Ann N Y Acad Sci** 1999 May 28;871:293–312 (58 ref.)

Vestibulo-oculomotor research and measurement technology for the space station era. Clarke AH. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):173–84 (72 ref.)

Interaction of vestibular, somatosensory and visual signals for postural control and motion perception under terrestrial and microgravity conditions--a conceptual model. Mergner T, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):118–35 (67 ref.)

Post-spaceflight orthostatic intolerance: possible relationship to microgravity-induced plasticity in the vestibular system. Yates BJ, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):73–82 (61 ref.)

Modelling motion sickness and subjective vertical mismatch detailed for vertical motions. Bos JE, et al. **Brain Res Bull** 1998 Nov 15;47(5):537–42 (15 ref.)

Visual-vestibular control of posture and gait: physiological mechanisms and disorders. Bronstein AM, et al. **Curr Opin Neurol** 1999 Feb;12(1):5–11 (62 ref.)

Involvement of insulin-like growth factor-I in inner ear organogenesis and regeneration. León Y, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):126–32 (57 ref.)

Gaba as an afferent neurotransmitter in the vestibular sensory periphery of vertebrates. Meza G. **Neurobiology (Bp)** 1998; 6(1):109–25 (85 ref.)

[Structure of receptor organs of the vestibule and animal behavior during weightlessness] Lychakov DV. **Zh Evol Biokhim Fiziol** 1998 May-Jun;34(3):364–85 (56 ref.) **(Rus)**

PHYSIOPATHOLOGY

Vestibular autonomic regulation (including motion sickness and the mechanism of vomiting). Balaban CD. **Curr Opin Neurol** 1999 Feb;12(1):29–33 (45 ref.)

VESTIBULO-OCULAR REFLEX see **REFLEX, VESTIBULO-OCULAR**

VESTIBULOCOCHLEAR NERVE see **ACOUSTIC NERVE**

VETERANS

Stress and immune dysfunction in Gulf War veterans. Everson MP, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:413–8 (27 ref.)

Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature. Chuang TY, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):126–32 (42 ref.)

Smoking and anxiety in combat veterans with chronic posttraumatic stress disorder: a review. Beckham JC. **J Psychoactive Drugs** 1999 Apr-Jun;31(2):103–10 (69 ref.)

[Review of the cooperative study of Veterans' affairs on the control and complications of type 2 diabetes, especially cardiovascular diseases] Nuttall FQ. **Journ Annu Diabetol Hotel Dieu** 1998;:99–112 (53 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Does the VA provide "primary" primary care? [editorial; comment] Petersen LA, et al. **J Gen Intern Med** 1999 May; 14(5):318–9 (17 ref.) Comment on: J Gen Intern Med 1999 May;14(5):274–80.

VETERANS ADMINISTRATION (U.S.) see **UNITED**

STATES DEPARTMENT OF VETERANS AFFAIRS

VETERANS AFFAIRS (U.S.) see **UNITED STATES DEPARTMENT OF VETERANS AFFAIRS**

VETERANS HOSPITALS see **HOSPITALS, VETERANS**

VETERINARIANS

see related
ANIMAL TECHNICIANS

The role of Eskimo hunters, veterinarians, and other biologists in improving the humane aspects of the subsistence harvest of bowhead whales. O'Hara TM, et al. **J Am Vet Med Assoc** 1999 Apr 15;214(8):1193–8 (35 ref.)
Chemical hazards faced by animal handlers. Meggs WJ. **Occup Med** 1999 Apr–Jun;14(2):213–24 (63 ref.)
Anesthesia hazards to animal workers. Meyer RE. **Occup Med** 1999 Apr–Jun;14(2):225–34 (35 ref.)
Euthanasia hazards. Morrow WE. **Occup Med** 1999 Apr–Jun; 14(2):235–46 (52 ref.)
Occupational allergy to animals. Seward JP. **Occup Med** 1999 Apr–Jun;14(2):285–304 (130 ref.)
Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr–Jun;14(2):247–84 (222 ref.)
[Capnocytophaga canimorsus infections: a possibly fatal complication of bite wounds] Kramer AM, et al. **Tijdschr Diergeneeskd** 1999 Feb 15;124(4):108–10 (19 ref.) (Eng. Abstr.) **(Dut)**

LEGISLATION & JURISPRUDENCE

Jurisprudence for ratite practitioners. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):525–31, vii (2 ref.)

STATISTICS & NUMERICAL DATA

Physical hazards of animal handlers. Langley R. **Occup Med** 1999 Apr–Jun;14(2):181–94 (56 ref.)

VETERINARY ASSISTANTS see **ANIMAL TECHNICIANS**

VETERINARY DRUGS

The issues of residues and human health. Paige C. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1735–6 (8 ref.)
Drugs prohibited from extralabel use in food animals. Payne MA, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):28–32 (49 ref.)
The human food safety evaluation of new animal drugs. Friedlander LG, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):1–11, vii (3 ref.)
Center for Veterinary Medicine's perspective on the beef hormone case. Leighton JK. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):167–80, x (9 ref.)
Federal surveillance of veterinary drugs and chemical residues (with recent data). Paige JC, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):45–61, viii (6 ref.)
The Food Animal Residue Avoidance Databank (FARAD). Past, present and future. Payne MA, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):75–88 (23 ref.)
The national milk safety program and drug residues in milk. Talley MR. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):63–73 (7 ref.)
Drug interactions during anesthesia. General principles. Mealey KA, et al. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):629–43, v (54 ref.)

ADVERSE EFFECTS

Monitoring adverse reactions to veterinary drugs. Pharmacovigilance. Bataller N, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):13–30, vii–viii (1 ref.)
Health implications of residues of veterinary drugs and chemicals in animal tissues. Paige JC, et al. **Vet Clin North Am Food Anim Pract** 1999 Mar;15(1):31–43, viii (34 ref.)
[Risks of using cytostatic drugs in veterinary medical practice] Pellicaan CH, et al. **Tijdschr Diergeneeskd** 1999 Apr 1;124(7):210–5 (25 ref.) (Eng. Abstr.) **(Dut)**

CHEMISTRY

The effect of processing on veterinary residues in foods. Moats WA. **Adv Exp Med Biol** 1999;459:233–41 (37 ref.)
Special series—use of pharmacokinetics in veterinary medicine. Article III: Physicochemical properties of pharmaceuticals. Martinez MN. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1274–7 (33 ref.)

CLASSIFICATION

Testing for therapeutic medications: analytical/pharmacological relationships and limitations' on the sensitivity of testing for certain agents. Tobin T, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):220–33 (29 ref.)

PHARMACOKINETICS

Special series—use of pharmacokinetics in veterinary medicine. Article III: Physicochemical properties of pharmaceuticals. Martinez MN. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1274–7 (33 ref.)
Article IV: clinical application of pharmacokinetics. Martinez MN. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1418–20 (33 ref.)
Primer on estimating withdrawal times after extralabel drug use. Riviere JE, et al. **J Am Vet Med Assoc** 1998 Oct 1; 213(7):966–8 (2 ref.)
Population pharmacokinetics in veterinary medicine: potential use for therapeutic drug monitoring and prediction of tissue residues. Martín-Jiménez T, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):167–89 (64 ref.)
Testing for therapeutic medications: analytical/pharmacological relationships and limitations' on the sensitivity of testing for certain agents. Tobin T, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):220–33 (29 ref.)

STANDARDS

International harmonization issues. Thompson SR. **Vet Clin North Am Food Anim Pract** 1999 Mar; 15(1):181–95, x (7 ref.)
Drug development for use by the aquaculture industry: the producers' perspective. MacMillan JR. **Vet Hum Toxicol** 1998;40 Suppl 2:7–9 (4 ref.)
Approval of drugs and chemicals for use by the aquaculture industry. Schnick RA. **Vet Hum Toxicol** 1998;40 Suppl 2:9–17 (17 ref.)
[Infections and bacterial resistance in the community] Goettsch WG, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1296–9 (33 ref.) (Eng. Abstr.) **(Dut)**

SUPPLY & DISTRIBUTION

[Survey of 50 years of veterinary remedy provision in the Netherlands] van den Bos T. **Tijdschr Diergeneeskd** 1998 Dec 15;123(24):743–8 (31 ref.) (Eng. Abstr.) **(Dut)**

TOXICITY

Evaluation of veterinary drug residues in food for their potential to affect human intestinal microflora. Cerniglia CE, et al. **Regul Toxicol Pharmacol** 1999 Jun;29(3):238–61 (130 ref.)
Veterinary drugs no longer need testing for carcinogenicity in rodent bioassays. Galer DM, et al. **Regul Toxicol Pharmacol** 1998 Oct;28(2):115–23 (53 ref.)

VETERINARY MEDICINE

see related
ANIMAL DISEASES
ANIMAL TECHNICIANS

Jurisprudence for ratite practitioners. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):525–31, vii (2 ref.)
Pediatric dermatology. Ackerman L. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):909–20 (8 ref.)
Pediatric health care and management. Hoskins JD. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):837–52, v (7 ref.)
Dental diseases of puppies and kittens. Lobprise HB, et al. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):871–93 (19 ref.)
Pediatric intensive care. Macintire DK. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):971–88, vii–viii (13 ref.)
An update of antidote availability in veterinary medicine. Post LO, et al. **Vet Hum Toxicol** 1999 Aug;41(4):258–61 (1 ref.)
Impact of liposomes as delivery systems in veterinary medicine. Sallovitz JM, et al. **Vet Res** 1998 Sep–Oct; 29(5):409–30 (115 ref.)
[The role of the veterinarian during natural disasters] Grandidier G. **Rev Sci Tech** 1999 Apr;18(1):239–55 (16 ref.) (Eng. Abstr.) **(Fre)**
[Antibiotic treatment in animals has repercussions in humans.] Torres C, et al. **Rev Esp Quimioter** 1998 Mar;11(1):29–35 (75 ref.) **(Spa)**

METHODS

Anesthesia of the sighthound. Court MH. **Clin Tech Small Anim Pract** 1999 Feb;14(1):38–43 (26 ref.)
Macrolide antibiotics, drug interactions and microsomal enzymes: implications for veterinary medicine. Anadón A, et al. **Res Vet Sci** 1999 Jun;66(3):197–203 (70 ref.)
[Computer-assisted analysis of sperm morphology in veterinary medicine] Boersma A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Mar;112(3):81–5 (50 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Animal health emergencies: prevention and preparedness in Asia. Hashim HD. **Rev Sci Tech** 1999 Apr;18(1):47–51 (4 ref.)
Model framework and principles of emergency management. Murray G, et al. **Rev Sci Tech** 1999 Apr;18(1):15–20 (2 ref.)

STATISTICS & NUMERICAL DATA

Nonselection and nonresponse bias in clinical research [see comments] Roush JK. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1270–3 (21 ref.) Comment in: J Am Vet Med Assoc 1999 Jan 1;214(1):27–8.

TRENDS

An overview of proteinase inhibitors. Hibbetts K, et al. **J Vet Intern Med** 1999 Jul–Aug;13(4):302–8 (91 ref.)
Newer endodontic therapeutic treatment. Anthony JM. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1237–60 (36 ref.)
Gene therapy in veterinary medicine. Argyle DJ. **Vet Rec** 1999 Apr 3;144(14):369–76 (65 ref.)
[Animal nutrition in veterinary science] van 't Klooster AT. **Tijdschr Diergeneeskd** 1999 Jan 15;124(2):36–9 (28 ref.) (Eng. Abstr.) **(Dut)**

VETERINARY NURSES see **ANIMAL TECHNICIANS**

VETERINARY SCHOOLS see **SCHOOLS, VETERINARY**

VIBRATION

ADVERSE EFFECTS

Noise-induced extra-aural pathology: a review and commentary. Alves-Pereira M. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A7–21 (98 ref.)
The vibroacoustic disease—an emerging pathology. Castelo Branco NA, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A1–6 (55 ref.)
Exposure-response relationship in the hand-arm vibration syndrome: an overview of current epidemiology research. Bovenzi M. **Int Arch Occup Environ Health** 1998 Nov; 71(8):509–19 (61 ref.)
A minireview of studies conducted in japan using finger-skin temperature during cold-stress tests for the diagnosis of hand-arm vibration syndrome. Harada N, et al. **Int Arch Occup Environ Health** 1999 Aug;72(5):330–4 (54 ref.)
[The vibration syndrome] Noël B. **J Mal Vasc** 1998 Oct; 23(4):251–6 (59 ref.) (Eng. Abstr.) **(Fre)**

VIBRIO

GENETICS

Genetic organization of the regions associated with surface polysaccharide synthesis in Vibrio cholerae O1, O139 and Vibrio anguillarum O1 and O2: a review. Stroeher UH, et al. **Gene** 1998 Nov 26;223(1–2):269–82 (61 ref.)

PATHOGENICITY

Pathogenesis of Vibrio vulnificus. Linkous DA, et al. **FEMS Microbiol Lett** 1999 May 15;174(2):207–14 (34 ref.)

PHYSIOLOGY

Protein toxins produced by pathogenic vibrios. Shinoda S. **J Nat Toxins** 1999 Jun;8(2):259–69 (78 ref.)

VIBRIO CHOLERAE

see related
CHOLERA TOXIN

[Vibrio cholerae O139 (Bengal) infection] Sagara H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):30–3 (9 ref.) **(Jpn)**
[Vibrio cholerae non 01 sepsis in a healthy patient: review of reported cases in Spain (letter)] Catalá Barceló MT, et al. **Rev Clin Esp** 1998 Dec;198(12):850–1 (13 ref.) **(Spa)**

CLASSIFICATION

Cholera in the 1990s. Reeves PR, et al. **Br Med Bull** 1998; 54(3):611–23 (40 ref.)

GENETICS

Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Faruque SM, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1301–14 (150 ref.)
Gene capture in Vibrio cholerae. Manning PA, et al. **Trends Microbiol** 1999 Mar;7(3):93–5 (17 ref.)

IMMUNOLOGY

Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. Killeen K, et al. **Curr Top Microbiol Immunol** 1999;236:237–54 (68 ref.)
Pathogenic and vaccine significance of toxin-coregulated pili of Vibrio cholerae E1 Tor. Attridge SR, et al. **J Biotechnol** 1999 Aug 20;73(2–3):109–17 (44 ref.)

ISOLATION & PURIFICATION

The survival strategy of Vibrio cholerae. Sood S, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):96–7 (17 ref.)

PATHOGENICITY

Microbial-host interactions at mucosal sites. Host response

VIBRIO CHOLERAE

to pathogenic bacteria at mucosal sites. Phalipon A, et al. **Curr Top Microbiol Immunol** 1999;236:163–89 (154 ref.)

Pathogenic and vaccine significance of toxin–coregulated pili of Vibrio cholerae E1 Tor. Attridge SR, et al. **J Biotechnol** 1999 Aug 20;73(2–3):109–17 (44 ref.)

Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Faruque SM, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1301–14 (150 ref.)

VIBRIO COMMA see **VIBRIO CHOLERAE**

VIBRIO FETUS see **CAMPYLOBACTER FETUS**

VIBRIO INFECTIONS

[Vibrio parahaemolyticus enteritis] Sakamoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):490–2 (7 ref.) **(Jpn)**

[Vibrio cholerae non 01 sepsis in a healthy patient: review of reported cases in Spain (letter)] Catalá Barceló MT, et al. **Rev Clin Esp** 1998 Dec;198(12):850–1 (13 ref.) **(Spa)**

COMPLICATIONS

Necrotizing fasciitis due to Vibrio alginolyticus following an injury inflicted by a stingray. Ho PL, et al. **Scand J Infect Dis** 1998;30(2):192–3 (13 ref.)

MICROBIOLOGY

Pathogenesis of Vibrio vulnificus. Linkous DA, et al. **FEMS Microbiol Lett** 1999 May 15;174(2):207–14 (34 ref.)

VIBRIO PARAHAEMOLYTICUS

[Vibrio parahaemolyticus enteritis] Sakamoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):490–2 (7 ref.) **(Jpn)**

VIBRIONACEAE

GENETICS

Mobile drug resistance genes among fish bacteria. Sørum H. **APMIS Suppl** 1998;84:74–6 (10 ref.)

VIBRISSAE

INNERVATION

Anatomical loops and their electrical dynamics in relation to whisking by rat. Kleinfeld D, et al. **Somatosens Mot Res** 1999;16(2):69–88 (145 ref.)

PHYSIOLOGY

Experience–dependent changes in vibrissae evoked responses in the rodent barrel cortex. Glazewski S. **Acta Neurobiol Exp (Warsz)** 1998;58(4):309–20 (70 ref.)

Experience–dependent changes in function and anatomy of adult barrel cortex. Kossut M. **Exp Brain Res** 1998 Nov; 123(1–2):110–6 (30 ref.)

Gating of the sensory activity within barrel cortex of the awake rat. Wróbel A, et al. **Exp Brain Res** 1998 Nov; 123(1–2):117–23 (39 ref.)

VIDARABINE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

VIDARABINE PHOSPHATE

ADMINISTRATION & DOSAGE

Concurrent emergence of hepatitis B e antigen–negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate. Bécheur H, et al. **Dig Dis Sci** 1998 Nov;43(11):2479–82 (30 ref.)

VIDEO DISPLAY TERMINALS see **COMPUTER TERMINALS**

VIDEO MICROSCOPY see **MICROSCOPY, VIDEO**

VIDEO RECORDING

Role of video–assisted thoracic surgery (VATS) in staging, diagnosis and treatment of lung cancer. Van Schil P. **Acta Chir Belg** 1999 May–Jun;99(3):103–8 (39 ref.)

Thoracoscopy and video–assisted thoracic surgery. Yim AP. **Curr Opin Pulm Med** 1999 Jul;5(4):256–8 (24 ref.)

Videofluoroscopic evaluation in the assessment of swallowing disorders in paediatric and adult populations. O'Donoghue S, et al. **Folia Phoniatr Logop** 1999 Jul–Oct; 51(4–5):158–71 (55 ref.)

Video–assisted thoracic surgery (VATS). Rao A, et al. **Heart Lung** 1999 Jan–Feb;28(1):15–9 (38 ref.)

Videolaparocholecystectomy: casuistry of 1000 cases. Fahel E, et al. **J Soc Laparoendosc Surg** 1998 Apr–Jun;2(2):141–5 (15 ref.)

INSTRUMENTATION

[VATS (video–assisted thoracoscopic surgery): possibilities and limits of surgical therapy of malignant lung diseases] Stoelben E, et al. **Zentralbl Chir** 1998;123(10):1129–33 (36 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Application of the advanced communications technology satellite to teleradiology and real–time compressed ultrasound video telemedicine. Stewart BK, et al. **J Digit Imaging** 1999 May;12(2):68–76 (12 ref.)

VIDEOKERATOGRAPHY see **CORNEAL TOPOGRAPHY**

VIDEOMICROGRAPHY see **MICROSCOPY, VIDEO**

VIDEOMICROSCOPY see **MICROSCOPY, VIDEO**

VIDEOTAPE RECORDING

Techniques of pneumonectomy. Video–assisted thoracic surgery pneumonectomy. Roviaro G, et al. **Chest Surg Clin N Am** 1999 May;9(2):419–36, xi–xii (17 ref.)

Synchronous communication technology tools in practice—future and current uses. Miller PA, et al. **Comput Nurs** 1998 Nov–Dec;16(6):303–6 (13 ref.)

A video data base system for studying animal behavior. Morrow–Tesch J, et al. **J Anim Sci** 1998 Oct;76(10):2605–8 (15 ref.)

Use of digital ciné–fluoroscopy and catheter–directed techniques to improve and simplify standard vascular procedures. Wain RA, et al. **Surg Clin North Am** 1999 Jun; 79(3):489–505 (38 ref.)

METHODS

Knee joint motion: description and measurement. Bull AM, et al. **Proc Inst Mech Eng [H]** 1998;212(5):357–72 (122 ref.)

VIDINE see **CHOLINE**

VIF GENE PRODUCTS see **GENE PRODUCTS, VIF**

VIF PROTEIN see **GENE PRODUCTS, VIF**

VIGILANCE, CORTICAL see **AROUSAL**

VILLAGE HEALTH WORKER see **COMMUNITY HEALTH AIDES**

VIMENTIN

ANALYSIS

Intermediate filaments in motion: observations of intermediate filaments in cells using green fluorescent protein–vimentin. Martys JL, et al. **Mol Biol Cell** 1999 May; 10(5):1289–95 (18 ref.)

GENETICS

Regulation of the expression of the human vimentin gene: application to cellular immortalization. Kryszke MH, et al. **Pathol Biol (Paris)** 1998 Jan;46(1):39–45 (30 ref.)

METABOLISM

Vimentin and lipid metabolism. Schweitzer SC, et al. **Subcell Biochem** 1998;31:437–62 (72 ref.)

VINBLASTINE

ANALOGS & DERIVATIVES

Vinorelbine–related acute cardiopulmonary toxicity. Karminsky N, et al. **Cancer Chemother Pharmacol** 1999; 43(2):180–2 (11 ref.)

[Navelbine (vinorelbine): a review of its antitumor activity and toxicity in clinical studies] Niitani H. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1495–507 (66 ref.) (Eng. Abstr.) **(Jpn)**

VINCA ALKALOIDS

CHEMISTRY

Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Shi Q, et al. **Curr Pharm Des** 1998 Jun;4(3):219–48 (211 ref.)

PHARMACOKINETICS

Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Chan JD. **Pharmacotherapy** 1998 Nov–Dec;18(6):1304–7 (13 ref.)

THERAPEUTIC USE

A systematic review of vinpocetine therapy in acute ischaemic stroke. Bereczki D, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):349–52 (30 ref.)

VINCALEUKOBLASTINE see **VINBLASTINE**

VINCENT'S INFECTION see **GINGIVITIS, NECROTIZING ULCERATIVE**

VINCRISTINE

ADMINISTRATION & DOSAGE

Intrathecal vincristine: an analysis of reasons for recurrent fatal chemotherapeutic error with recommendations for prevention. Fernandez CV, et al. **J Pediatr Hematol Oncol** 1998 Nov–Dec;20(6):587–90 (13 ref.)

ADVERSE EFFECTS

[Acute vincristine neurotoxicity in a non–Hodgkin's lymphoma patient with Charcot–Marie–Tooth disease] Uno S, et al. **Rinsho Ketsueki** 1999 May;40(5):414–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Neurologic complications of chemotherapy (vincristine etc.)] Nomura K, et al. **Ryoikibetsu Shokogun Shirizu** 1999; (27 Pt 2):576–81 (17 ref.) **(Jpn)**

THERAPEUTIC USE

Vincristine revisited. Gidding CE, et al. **Crit Rev Oncol Hematol** 1999 Feb;29(3):267–87 (366 ref.)

VINCULIN

PHYSIOLOGY

Vinculin and alpha–catenin: shared and unique functions in adherens junctions. Rüdiger M. **Bioessays** 1998 Sep; 20(9):733–40 (79 ref.)

VINEGAR see **ACETIC ACID**

VINYL CHLORIDE

ADVERSE EFFECTS

Formation of DNA etheno adducts in rodents and humans and their role in carcinogenesis. Barbin A. **Acta Biochim Pol** 1998;45(1):145–61 (93 ref.)

VINYL COMPOUNDS

Implanon. A review of clinical studies. Edwards JE, et al. **Br J Fam Plann** 1999 Jan;24(4 Suppl):3–16 (28 ref.)

TOXICITY

Vinyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:923–8 (17 ref.)

VINYL CYANIDE see **ACRYLONITRILE**

VIOLENCE

see related
BATTERED CHILD SYNDROME
BATTERED WOMEN

Critical care medicine, terrorism and disasters: are we ready? [editorial; comment] Kvetan V. **Crit Care Med** 1999 May; 27(5):873–4 (15 ref.) Comment on: Crit Care Med 1999 May;27(5):1004–8.

Violence against women: the physician's role. Schmuel E, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 80(2):239–45 (20 ref.)

The assessment and management of risk in adolescents. Sheldrick C. **J Child Psychol Psychiatry** 1999 May; 40(4):507–18 (73 ref.)

Interpersonal violence and the pregnant homeless woman. Robrecht LC, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):684–91 (32 ref.)

Current understanding of violence and aggression: assessment and treatment. Littrell KH, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Dec;36(12):18–24 (40 ref.)

Children, adolescents, and the media: issues and solutions. Strasburger VC, et al. **Pediatrics** 1999 Jan;103(1):129–39 (156 ref.)

Violence in the emergency department. Managing aggressive patients in a high–stress environment. Kuhn W. **Postgrad Med** 1999 Jan;105(1):143–8, 154 (30 ref.)

The medical impact of a bioterrorist attack. Is it all media hype or clearly a potential nightmare? Osterholm MT. **Postgrad Med** 1999 Aug;106(2):121–4, 129–30 (9 ref.)

Unusual diagnoses among violent patients. Tardiff K. **Psychiatr Clin North Am** 1998 Sep;21(3):567–76 (28 ref.)

The looming threat of bioterrorism. Henderson DA. **Science** 1999 Feb 26;283(5406):1279–82 (24 ref.)

[Sexual violence and the abuse of children and adolescents] Stambolova S, et al. **Akush Ginekol (Sofiia)** 1998; 37(1):47–50 (10 ref.) **(Bul)**

[Chemical warfare poisoning in time of peace] Ishøj T, et al. **Ugeskr Laeger** 1999 Feb 8;161(6):808–10 (9 ref.) **(Dan)**

CLASSIFICATION

Juvenile violence. Scott CL. **Psychiatr Clin North Am** 1999 Mar;22(1):71–83 (76 ref.)

ECONOMICS

Burma: the political economy of violence. Brown C.

Disasters 1999 Sep;23(3):234–56 (55 ref.)

LEGISLATION & JURISPRUDENCE

Legal and ethical duties of the clinician treating a patient who is liable to be impulsively violent. Beck JC. **Behav Sci Law** 1998 Summer;16(3):375–89 (33 ref.)

Neurobiologic correlates of violence: relevance to criminal responsibility. Berman ME, et al. **Behav Sci Law** 1998 Summer;16(3):303–18 (55 ref.)

Recent changes in Danish law on drugs and drug offences. Jepsen J, et al. **Eur Addict Res** 1998 Sep;4(3):113–27 (18 ref.)

Does psychiatric disorder affect the likelihood of violent offending? A critique of the major findings. Mitchell EW. **Med Sci Law** 1999 Jan;39(1):23–30 (45 ref.)

Violence and the epilepsy defense. Treiman DM. **Neurol Clin** 1999 May;17(2):245–55 (42 ref.)

PREVENTION & CONTROL

Social, community, and preventive interventions. Reppucci ND, et al. **Annu Rev Psychol** 1999;50:387–418 (192 ref.)

Legal and ethical duties of the clinician treating a patient who is liable to be impulsively violent. Beck JC. **Behav Sci Law** 1998 Summer;16(3):375–89 (33 ref.)

Threat assessment: defining an approach for evaluating risk of targeted violence. Borum R, et al. **Behav Sci Law** 1999; 17(3):323–37 (52 ref.)

Suicide and violence risk in law enforcement: practical guidelines for risk assessment, prevention, and intervention. Mohandie K, et al. **Behav Sci Law** 1999;17(3):357–76 (56 ref.)

Assessing threats of targeted group violence: contributions from social psychology. Pynchon MR, et al. **Behav Sci Law** 1999;17(3):339–55 (52 ref.)

Adolescents and violent crime. Cohall A, et al. **Curr Opin Pediatr** 1998 Aug;10(4):356–62 (44 ref.)

Aid and violence, with special reference to Sierra Leone. Keen D. **Disasters** 1998 Dec;22(4):318–27 (33 ref.)

Violence in the emergency department. Blanchard JC, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):717–31, viii (39 ref.)

Adolescent violence. Grausz HM, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):595–602, v (66 ref.)

Violence in the prehospital setting. Lucas R. **Emerg Med Clin North Am** 1999 Aug;17(3):679–83, vii (15 ref.)

Violence as a public health emergency. Scott JL. **Emerg Med Clin North Am** 1999 Aug;17(3):567–73, v (17 ref.)

Recent changes in Danish law on drugs and drug offences. Jepsen J, et al. **Eur Addict Res** 1998 Sep;4(3):113–27 (18 ref.)

Gender violence and reproductive health. Diniz SG, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S33–42 (44 ref.)

Multisystemic treatment of criminality and violence in adolescents. Borduin CM. **J Am Acad Child Adolesc Psychiatry** 1999 Mar;38(3):242–9 (36 ref.)

Love shouldn't hurt: strategies for health care providers to address adolescent dating violence. Cohall A, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):144–8 (38 ref.)

Potential for violence toward psychiatric nursing students: risk reduction techniques. Echternacht MR. **J Psychosoc Nurs Ment Health Serv** 1999 Mar;37(3):36–9 (9 ref.)

Children and violence. Kelley B, et al. **J Soc Pediatr Nurs** 1998 Jul–Sep;3(3):127–9 (14 ref.)

The clinician's role in assessing workplace violence. Lion JR. **Psychiatr Clin North Am** 1999 Mar;22(1):101–8, vii (68 ref.)

Constructing violence as a public health problem. Winett LB. **Public Health Rep** 1998 Nov–Dec;113(6):498–507 (25 ref.)

Behavioral sciences concepts in research on the prevention of violence. **Rev Panam Salud Publica** 1999 Apr–May; 5(4–5):316–21 (43 ref.)

Who is violent?: factors associated with aggressive behaviors in Latin America and Spain. Orpinas P. **Rev Panam Salud Publica** 1999 Apr–May;5(4–5):232–44 (51 ref.)

[Epidemiologic surveillance for the prevention and control urban violence] Concha-Eastman A, et al. **Rev Panam Salud Publica** 1999 Apr–May;5(4–5):322–31 (49 ref.) (Eng. Abstr.) **(Spa)**

[Victimization by urban violence: incidence and associated factors in cities in Latin America and Spain] Cruz JM. **Rev Panam Salud Publica** 1999 Apr–May;5(4–5):259–67 (39 ref.) (Eng. Abstr.) **(Spa)**

[Violence between couples] Moreno Martin F. **Rev Panam Salud Publica** 1999 Apr–May;5(4–5):245–58 (61 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Reinterpreting physical violence: outcome of intense stimulation-seeking behavior [letter] Mawson AR. **Acad Emerg Med** 1999 Aug;6(8):863–5 (12 ref.)

Domestic terrorism with chemical or biological agents: psychiatric aspects. DiGiovanni C Jr. **Am J Psychiatry** 1999 Oct;156(10):1500–5 (59 ref.)

Neurobiologic correlates of violence: relevance to criminal responsibility. Berman ME, et al. **Behav Sci Law** 1998 Summer;16(3):303–18 (55 ref.)

Threat assessment: defining an approach for evaluating risk of targeted violence. Borum R, et al. **Behav Sci Law** 1999; 17(3):323–37 (52 ref.)

Assessing threats of targeted group violence: contributions from social psychology. Pynchon MR, et al. **Behav Sci Law** 1999;17(3):339–55 (52 ref.)

Stress in children exposed to violence. Reenactment and rage. Pfefferbaum B, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):121–35, ix (50 ref.)

Food, nutrition, anti-social behaviour and criminality. Dickerson JW. **J R Soc Health** 1998 Aug;118(4):224–6 (11 ref.)

Psychopathy as a risk factor for violence. Hare RD. **Psychiatr Q** 1999 Fall;70(3):181–97 (65 ref.)

Criminal and violent behavior in schizophrenic patients: an overview. Modestin J. **Psychiatry Clin Neurosci** 1998 Dec; 52(6):547–54 (35 ref.)

When symptoms of psychosis drive serious violence. Taylor PJ. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S47–54 (24 ref.)

[Violence our medical trauma in specialized multidisciplinary consultation] Albrecht E, et al. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):280–4 (4 ref.) (Eng. Abstr.) **(Fre)**

[Schizophrenia and violence: epidemiological, forensic and clinical aspects] Steinert T. **Fortschr Neurol Psychiatr** 1998 Sep;66(9):391–401 (124 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Injuries and violence: risk factors and opportunities for prevention during adolescence. Cohen LR, et al. **Adolesc Med** 1999 Feb;10(1):125–35, vi (90 ref.)

The significance of alcohol for violence and accidents. Brismar B, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):299S–306S (80 ref.)

Mental illness and violence: an epidemiological appraisal of the evidence. Arboleda-Flórez J. **Can J Psychiatry** 1998 Dec;43(10):989–96 (69 ref.)

Adolescents and violent crime. Cohall A, et al. **Curr Opin Pediatr** 1998 Aug;10(4):356–62 (44 ref.)

Burma: the political economy of violence. Brown C. **Disasters** 1999 Sep;23(3):234–56 (55 ref.)

Aid and violence, with special reference to Sierra Leone. Keen D. **Disasters** 1998 Dec;22(4):318–27 (33 ref.)

Adolescent violence. Grausz HM, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):595–602, v (66 ref.)

Violence as a public health emergency. Scott JL. **Emerg Med Clin North Am** 1999 Aug;17(3):567–73, v (17 ref.)

Violence towards doctors: prevalence and effects. Zahid MA, et al. **Hosp Med** 1999 Jun;60(6):414–8 (18 ref.)

Health trends in northern Finland. Näyhä S, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):94–103 (51 ref.)

Mental disorder and violence: results of epidemiological studies in the era of de-institutionalization [editorial] Angermeyer MC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S1–6 (34 ref.)

Understanding causal paths between mental illness and violence. Arboleda-Flórez J, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S38–46 (96 ref.)

The psychiatric epidemiology of violent behaviour. Eronen M, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S13–23 (60 ref.)

Mental illness and criminal violence. Tehrani JA, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33 Suppl 1:S81–5 (19 ref.)

[Differences in incidence of (violent) traumatic events in the national registration systems, population surveys and studies from family practice; a review of literature] Mol SS, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1308–14 (29 ref.) (Eng. Abstr.) **(Dut)**

[Cholesterolemia and pathology: update] Schlienger JL, et al. **Rev Med Interne** 1998 Mar;19(3):180–4 (42 ref.) (Eng. Abstr.) **(Fre)**

[Mentally ill patients--a danger?] Angermeyer MC, et al. **Psychiatr Prax** 1998 Sep;25(5):211–20 (55 ref.) (Eng. Abstr.) **(Ger)**

VIP see **VASOACTIVE INTESTINAL PEPTIDE**

VIP RECEPTORS see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

VIPER VENOMS

Viper venom disintegrins and related molecules. McLane MA, et al. **Proc Soc Exp Biol Med** 1998 Nov;219(2):109–19 (103 ref.)

Vipera palaestinae antivenin. Moroz C. **Public Health Rev** 1998;26(3):233–6 (8 ref.)

VIPERIDAE

see related
VIPER VENOMS

Vipera palaestinae antivenin. Moroz C. **Public Health Rev** 1998;26(3):233–6 (8 ref.)

[An accelerated idioventricular rhythm and incomplete right bundle-branch block secondary to the bite of Vipera latasti (letter) (published erratum appears in Med Clin (Barc) 1999 Apr 17;112(13):494)] Meseguer Ruiz VA, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):278–9 (9 ref.) **(Spa)**

VIPERINAE see **VIPERIDAE**

VIPOMA

[Vipoma of pancreas] Egorov AV, et al. **Khirurgiia (Mosk)** 1999;(4):68–72 (91 ref.) **(Rus)**

DIAGNOSIS

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Nguyen HN, et al. **Dig Dis Sci** 1999 Jun;44(6):1148–55 (37 ref.)

SECONDARY

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Nguyen HN, et al. **Dig Dis Sci** 1999 Jun;44(6):1148–55 (37 ref.)

SURGERY

Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report. Pasieka JL, et al. **Can J Surg** 1999 Feb;42(1):55–8 (12 ref.)

VIRAL ANTIBODIES see **ANTIBODIES, VIRAL**

VIRAL ANTIGENS see **ANTIGENS, VIRAL**

VIRAL BURDEN see **VIRAL LOAD**

VIRAL COAT PROTEINS see **CAPSID**

VIRAL CONJUNCTIVITIS see **CONJUNCTIVITIS, VIRAL**

VIRAL CORE PROTEINS

BIOSYNTHESIS

Expression of the major core structural proteins VP3 and VP7 of African horse sickness virus, and production of core-like particles. Maree S, et al. **Arch Virol Suppl** 1998; 14:203–9 (22 ref.)

CHEMISTRY

Hepatitis B core particles as a universal display model: a structure-function basis for development. Pumpens P, et al. **FEBS Lett** 1999 Jan 8;442(1):1–6 (70 ref.)

Courageous science: structural studies of bluetongue virus core. Rossmann MG, et al. **Structure Fold Des** 1999 Mar 15;7(3):R43–6 (31 ref.)

VIRAL DNA see **DNA, VIRAL**

VIRAL ENCEPHALITIS see **ENCEPHALITIS, VIRAL**

VIRAL ENVELOPE PROTEINS

CHEMISTRY

Viral ion channels: molecular modeling and simulation. Sansom MS, et al. **Bioessays** 1998 Dec;20(12):992–1000 (71 ref.)

Virus maturation by budding. Garoff H, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1171–90 (313 ref.)

IMMUNOLOGY

alpha-Gal epitopes on viral glycoproteins. Rother RP, et al. **Subcell Biochem** 1999;32:143–72 (116 ref.)

[Current status and strategy of the research on hepatitis C vaccine] Nie Q, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):47–9 (15 ref.) **(Chi)**

[Prevalence of hepatitis G virus RNA and antibodies to HGV envelope protein (anti-E2) in patients with liver injury in Japan] Matsushita E, et al. **Nippon Rinsho** 1999 Jun; 57(6):1274–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Virus maturation by budding. Garoff H, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1171–90 (313 ref.)

PHYSIOLOGY

Properties and functions of feline herpesvirus type 1 glycoproteins. Maeda K, et al. **J Vet Med Sci** 1998 Aug; 60(8):881–8 (97 ref.)

Structural basis for membrane fusion by enveloped viruses. Weissenhorn W, et al. **Mol Membr Biol** 1999 Jan–Mar; 16(1):3–9 (78 ref.)

Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance. Olofsson S, et al.

VIRAL ENVELOPE PROTEINS

Scand J Infect Dis 1998;30(5):435–40 (39 ref.)

VIRAL EYE INFECTIONS see **EYE INFECTIONS, VIRAL**

VIRAL FUSION GLYCOPROTEINS see **VIRAL FUSION PROTEINS**

VIRAL FUSION PROTEINS

Gene therapy using HVJ–liposomes: the best of both worlds? Kaneda Y, et al. **Mol Med Today** 1999 Jul;5(7):298–303 (41 ref.)

CHEMISTRY

Coiled coils in both intracellular vesicle and viral membrane fusion. Skehel JJ, et al. **Cell** 1998 Dec 23;95(7):871–4 (19 ref.)

Structural intermediates in influenza haemagglutinin–mediated fusion. Chernomordik LV, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):33–42 (53 ref.)

PHYSIOLOGY

Rabies virus–induced membrane fusion. Gaudin Y, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):21–31 (88 ref.)

VIRAL GAG PROTEINS see **GENE PRODUCTS, GAG**

VIRAL GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, VIRAL**

VIRAL GENE PRODUCTS see **VIRAL PROTEINS**

VIRAL GENE PROTEINS see **VIRAL PROTEINS**

VIRAL GENES see **GENES, VIRAL**

VIRAL GENOME see **GENOME, VIRAL**

VIRAL HEPATITIS VACCINES

Perspectives for a hepatitis C virus vaccine. Abrignani S, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):181–5 (16 ref.)

Vaccination of travelers against hepatitis A and B. Löscher T, et al. **J Travel Med** 1999 Jun;6(2):107–14 (68 ref.)

[Current status and strategy of the research on hepatitis C vaccine] Nie Q, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):47–9 (15 ref.) **(Chi)**

[Vaccination against hepatitis A] Zamir D, et al. **Harefuah** 1998 Aug;135(3–4):114–8 (40 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Control of hepatitis A infection in the U.S. Le C. **West J Med** 1999 Jun;170(6):324 (10 ref.)

Universal childhood immunization against hepatitis A: whoa! Takayama JI. **West J Med** 1999 Jun;170(6):325–6 (11 ref.)

[Viral hepatitis: preventable illnesses] Baumgarten R. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):677–80 (6 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Clinical development of a new inactivated hepatitis A vaccine] Vidor E, et al. **Sante** 1998 Sep–Oct;8(5):361–8 (45 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Vaccines for prevention of viral hepatitis. Shouval D. **Haemophilia** 1998 Jul;4(4):587–94 (96 ref.)

[Anti–hepatitis vaccination in children] Azzari C, et al. **Minerva Pediatr** 1998 Jun;50(6):249–53 (18 ref.) **(Ita)**

VIRAL INSERTIONAL MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

VIRAL INTERFERENCE

see related
INTERFERONS
SUPERINFECTION

VIRAL LOAD

Combinations of four virostatics applied in rotational sequences induce an exponential VL regression curve, the first part of which is rapidly decreasing to a PCR–undetectable level, while the last part is insensitive to the model. Indications for virostatic and immunotherapeutic reinforcements? [editorial] Mathé G. **Biomed Pharmacother** 1999 Mar;53(2):57–62 (24 ref.)

Measurement of plasma HIV viral load--clinical applications. Churchill D, et al. **J Infect** 1999 May;38(3):147–50 (38 ref.)

[AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment] Notermans DW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1909–12 (48 ref.) (Eng. Abstr.) **(Dut)**

METHODS

HIV–1 viral load testing. Clarke JR, et al. **J Infect** 1999 May; 38(3):141–6 (32 ref.)

VIRAL M PROTEINS see **VIRAL MATRIX PROTEINS**

VIRAL MARKERS see **BIOLOGICAL MARKERS**

VIRAL MATRIX PROTEINS

CHEMISTRY

Molecular dynamics simulations of membranes with embedded proteins and peptides: porin, alamethicin and influenza virus M2. Sansom MS, et al. **Biochem Soc Trans** 1998 Aug;26(3):438–43 (27 ref.)

METABOLISM

Processing of the Ebola virus glycoprotein. Volchkov VE. **Curr Top Microbiol Immunol** 1999;235:35–47 (76 ref.)

PHYSIOLOGY

Rabies virus–induced membrane fusion. Gaudin Y, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):21–31 (88 ref.)

VIRAL NONSTRUCTURAL PROTEINS

Hepatitis C virus NS3/4A protease. Kwong AD, et al. **Antiviral Res** 1998 Dec;40(1–2):1–18 (98 ref.)

GENETICS

Characterization of two African horse sickness virus nonstructural proteins, NS1 and NS3. van Staden V, et al. **Arch Virol Suppl** 1998;14:251–8 (17 ref.)

METABOLISM

Hepatitis C virus NS3/4A protease. Kwong AD, et al. **Antiviral Res** 1999 Feb;41(1):67–84 (100 ref.)

PHARMACOLOGY

Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Gale MJ Jr, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):157–62 (30 ref.)

PHYSIOLOGY

Role of the nonstructural polyproteins in alphavirus RNA synthesis. Sawicki DL, et al. **Adv Exp Med Biol** 1998; 440:187–98 (58 ref.)

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

VIRAL ONCOGENE PROTEINS see **ONCOGENE PROTEINS, VIRAL**

VIRAL PACKAGING see **VIRUS ASSEMBLY**

VIRAL PHYSIOLOGY

see related
GENETICS, MICROBIAL

Role of virus–induced apoptosis in a host defense mechanism against virus infection. Koyama AH, et al. **J Med Invest** 1998 Aug;45(1–4):37–45 (44 ref.)

Marine viruses and their biogeochemical and ecological effects. Fuhrman JA. **Nature** 1999 Jun 10;399(6736):541–8 (105 ref.)

VIRAL PROTEINS

An exegesis of IAPs: salvation and surprises from BIR motifs. Miller LK. **Trends Cell Biol** 1999 Aug;9(8):323–8 (43 ref.)

[Cytoplasmic polyhedrosis virus and polyhedrin] Mori H, et al. **Uirusu** 1998 Jun;48(1):81–8 (42 ref.) **(Jpn)**

[Genome and proteins of rotavirus] Taniguchi K. **Uirusu** 1998 Dec;48(2):137–51 (63 ref.) **(Jpn)**

BIOSYNTHESIS

The arterivirus replicase. The road from RNA to protein(s), and back again. Snijder EJ. **Adv Exp Med Biol** 1998; 440:97–108 (54 ref.)

CHEMISTRY

Structural biology of HIV. Turner BG, et al. **J Mol Biol** 1999 Jan 8;285(1):1–32 (321 ref.)

DIAGNOSTIC USE

Vascular targeting with phage peptide libraries. Pasqualini R. **Q J Nucl Med** 1999 Jun;43(2):159–62 (43 ref.)

GENETICS

Regulation of gene expression by HTLV–I Tax protein. Bex F, et al. **Methods** 1998 Sep;16(1):83–94 (174 ref.)

Glycoprotein K of herpes simplex virus: a transmembrane protein encoded by the UL53 gene which regulates membrane fusion. Rajčáni J, et al. **Virus Genes** 1999; 18(1):81–90 (63 ref.)

IMMUNOLOGY

Immune modulation by proteins secreted from cells infected by vaccinia virus. Smith GL, et al. **Arch Virol Suppl** 1999; 15:111–29 (56 ref.)

Viral complement regulatory proteins. Rosengard AM, et al. **Immunopharmacology** 1999 May;42(1–3):99–106 (61 ref.)

METABOLISM

The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Feldmann H, et al. **Arch Virol Suppl** 1999;15:159–69 (53 ref.)

Immune modulation by proteins secreted from cells infected by vaccinia virus. Smith GL, et al. **Arch Virol Suppl** 1999; 15:111–29 (56 ref.)

Antitermination by bacteriophage lambda Q protein. Roberts JW, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:319–25 (35 ref.)

Co– and posttranslational modifications and functions of Marburg virus proteins. Becker S, et al. **Curr Top Microbiol Immunol** 1999;235:23–34 (53 ref.)

Relationships between proteasomes and viral gene products. Jarrousse AS, et al. **Mol Biol Rep** 1999 Apr;26(1–2):113–7 (54 ref.)

Glycoprotein K of herpes simplex virus: a transmembrane protein encoded by the UL53 gene which regulates membrane fusion. Rajčáni J, et al. **Virus Genes** 1999; 18(1):81–90 (63 ref.)

PHYSIOLOGY

The role of herpes simplex virus glycoproteins in the virus replication cycle. Rajčáni J, et al. **Acta Virol** 1998 Apr; 42(2):103–18 (195 ref.)

Interaction of viral proteins with host cell death machinery. Granville DJ, et al. **Cell Death Differ** 1998 Aug;5(8):653–9 (84 ref.)

Probing plant cell structure and function with viral movement proteins. Lazarowitz SG. **Curr Opin Plant Biol** 1999 Aug;2(4):332–8 (50 ref.)

Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Ensoli B, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):63–83 (215 ref.)

DNA strand exchange proteins: a biochemical and physical comparison. Bianco PR, et al. **Front Biosci** 1998 Jun 17; 3:D570–603 (307 ref.)

History of coat protein–mediated protection. Miller ED, et al. **Methods Mol Biol** 1998;81:25–38 (87 ref.)

Coat–protein–mediated resistance to tobacco mosaic virus: discovery mechanisms and exploitation. Beachy RN. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):659–64 (34 ref.)

Tobacco mosaic virus: a pioneer of cell–to–cell movement. Citovsky V. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):637–43 (60 ref.)

Intercellular adhesion molecule–1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins [comment] Moss P. **Transplantation** 1999 Jan 15; 67(1):2–3 (14 ref.) Comment on: Transplantation 1999 Jan 15;67(1):137–44.

VIRAL REGULATORY PROTEINS

METABOLISM

Structure and mechanism in transcriptional antitermination by the bacteriophage lambda N protein. Greenblatt J, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:327–36 (88 ref.)

VIRAL RNA see **RNA, VIRAL**

VIRAL SHEDDING see **VIRUS SHEDDING**

VIRAL STRUCTURAL PROTEINS

IMMUNOLOGY

Characterization of the main protein components of adenovirus virion and its possible use in laboratory diagnostics. Lengyel A, et al. **Acta Microbiol Immunol Hung** 1998;45(3–4):281–3 (13 ref.)

VIRAL TAIL PROTEINS

CHEMISTRY

Structure and evolution of parallel beta–helix proteins. Jenkins J, et al. **J Struct Biol** 1998;122(1–2):236–46 (44 ref.)

There's a right way and a wrong way: in vivo and in vitro folding, misfolding and subunit assembly of the P22 tailspike. Betts S, et al. **Structure Fold Des** 1999 Jun 15; 7(6):R131–9 (44 ref.)

GENETICS

A tail of protein folding. Villafañe RJ, et al. **P R Health Sci J** 1999 Jun;18(2):105–15 (82 ref.)

VIRAL TRANSFORMING PROTEINS see **ONCOGENE PROTEINS, VIRAL**

VIRAL VACCINES

Rotavirus vaccine studies in Europe. Vesikari T. **Acta Paediatr Suppl** 1999 Jan;88(426):9–13 (45 ref.)

Forty years of canine vaccination. Appel MJ. **Adv Vet Med** 1999;41:309–24 (95 ref.)
Canine viral vaccines at a turning point––a personal perspective. Carmichael LE. **Adv Vet Med** 1999;41:289–307 (48 ref.)
Diagnosis and prevention of equine infectious diseases: present status, potential, and challenges for the future. Desmettre P. **Adv Vet Med** 1999;41:359–77 (129 ref.)
Analysis of the protective immunity induced by feline immunodeficiency virus vaccination. Hosie MJ, et al. **Adv Vet Med** 1999;41:325–32 (28 ref.)
Contribution of advances in immunology to vaccine development. Morrison WI, et al. **Adv Vet Med** 1999; 41:181–95 (44 ref.)
Enteric viral infections of pigs and strategies for induction of mucosal immunity. Saif LJ. **Adv Vet Med** 1999;41:429–46 (54 ref.)
Evaluation of risks and benefits associated with vaccination against coronavirus infections in cats. Scott FW. **Adv Vet Med** 1999;41:347–58 (52 ref.)
Viral vectors for veterinary vaccines. Sheppard M. **Adv Vet Med** 1999;41:145–61 (90 ref.)
Grease, anthraxgate, and kennel cough: a revisionist history of early veterinary vaccines. Tizard I. **Adv Vet Med** 1999; 41:7–24 (37 ref.)
Swinepox virus as a vaccine vector for swine pathogens. Tripathy DN. **Adv Vet Med** 1999;41:463–80 (45 ref.)
Bovine viral vaccines, diagnostics, and eradication: past, present, and future. van Oirschot JT. **Adv Vet Med** 1999; 41:197–216 (82 ref.)
Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447–61 (60 ref.)
Lessons for AIDS vaccine development from non-AIDS vaccines. Clements-Mann ML. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S197–203 (85 ref.)
Rotavirus vaccines: development and use for the prevention of diarrhoeal disease. Vesikari T. **Ann Med** 1999 Feb; 31(1):79–85 (51 ref.)
Japanese encephalitis. Sabchareon A, et al. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S67–71 (28 ref.)
Epidemiology of African horse sickness and the role of the zebra in South Africa. Barnard BJ. **Arch Virol Suppl** 1998; 14:13–9 (23 ref.)
Foot-and-mouth disease and beyond: vaccine design, past, present and future. Brown F. **Arch Virol Suppl** 1999; 15:179–88 (43 ref.)
Future international management of African horse sickness vaccines. House JA. **Arch Virol Suppl** 1998;14:297–304 (33 ref.)
New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles. Roy P, et al. **Arch Virol Suppl** 1998;14:177–202 (41 ref.)
Dengue vaccine design: issues and challenges. Cardosa MJ. **Br Med Bull** 1998;54(2):395–405 (50 ref.)
Vaccination against enteric pathogens: from science to vaccine trials. Lindberg AA. **Curr Opin Microbiol** 1998 Feb;1(1):116–24 (35 ref.)
The rotavirus vaccine. Offit PA, et al. **Curr Opin Pediatr** 1999 Feb;11(1):9–13 (39 ref.)
Cowpea mosaic virus-based vaccines. Lomonossoff GP, et al. **Curr Top Microbiol Immunol** 1999;240:177–89 (25 ref.)
Herpes. Vaccines for HSV. Stanberry LR. **Dermatol Clin** 1998 Oct;16(4):811–6, xiv (27 ref.)
Human diploid cell strains (HDCS) viral vaccines. Fletcher MA, et al. **Dev Biol Stand** 1998;93:97–107 (28 ref.)
Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Snoeck R, et al. **Drugs** 1999 Feb;57(2):187–206 (230 ref.)
Papillomavirus vaccines. Duggan-Keen MF, et al. **Front Biosci** 1998 Dec 1;3:D1192–208 (195 ref.)
Canine papillomavirus––A centenary review. Nicholls PK, et al. **J Comp Pathol** 1999 Apr;120(3):219–33 (95 ref.)
Human papillomavirus vaccines for cervical cancer. Murakami M, et al. **J Immunother** 1999 May;22(3):212–8 (60 ref.)
BHV-1: new molecular approaches to control a common and widespread infection. Turin L, et al. **Mol Med** 1999 May;5(5):261–84 (195 ref.)
Vaccination against cytomegalovirus, the changeling demon. Plotkin SA. **Pediatr Infect Dis J** 1999 Apr;18(4):313–25; quiz 326 (141 ref.)
Viral diseases of the respiratory system. Villegas P. **Poult Sci** 1998 Aug;77(8):1143–5 (24 ref.)
Economic rate of discount and estimating cost benefit of viral immunisation programmes. West RR. **Rev Med Virol** 1999 Jan-Mar;9(1):51–5 (20 ref.)
New approaches to the development of virus vaccines for veterinary use. Yamanouchi K, et al. **Rev Sci Tech** 1998 Dec;17(3):641–53 (61 ref.)
DNA-vaccines against hepatitis B and C viral infections: a brief overview. Irshad M. **Trop Gastroenterol** 1999 Apr-Jun;20(2):64–7 (30 ref.)
Vaccination of cattle against bovine viral diarrhoea. van Oirschot JT, et al. **Vet Microbiol** 1999 Jan;64(2-3):169–83 (73 ref.)
DNA-antiviral vaccines: new developments and approaches––a review. Giese M. **Virus Genes** 1998; 17(3):219–32 (86 ref.)
[Vaccines against cytomegalovirus infect. Perspectives] Cadoz M, et al. **Arch Pediatr** 1999;6 Suppl 3:655s–658s (16 ref.) **(Fre)**
[Vaccines against respiratory syncytial virus] Freymuth F, et al. **Arch Pediatr** 1999;6 Suppl 3:650s–654s (26 ref.) **(Fre)**
[Rotavirus vaccines] Gault E, et al. **Arch Pediatr** 1999;6 Suppl 3:639s–642s (15 ref.) **(Fre)**
[Prophylactic vaccination against hepatitis B: present and future] Mommeja-Marin H, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):452–63 (80 ref.) **(Fre)**
[How technology and vaccination have changed the Pap test] Bondi A, et al. **Pathologica** 1999 Feb;91(1):36–41 (28 ref.) **(Ita)**
[Chemotherapy and vaccines used for the management of viral infections] Yamane S. **Rinsho Byori** 1998 Nov;Suppl 108:36–41 (4 ref.) **(Jpn)**
[Rotavirus vaccines as a model vaccine against enteric viral infections] Nakagomi O, et al. **Uirusu** 1998 Dec; 48(2):189–200 (68 ref.) **(Jpn)**
[Efficacy of commercially available virus vaccines and their problems] Suga S, et al. **Uirusu** 1998 Dec;48(2):175–82 (33 ref.) **(Jpn)**
[An introduction to the special section on "viral vaccines, their present and future"] Ueda S. **Uirusu** 1998 Dec; 48(2):173–4 (0 ref.) **(Jpn)**
[Progress in developing viral polynucleotide (DNA) vaccines] Gendon IuZ. **Vopr Virusol** 1999 Jul-Aug; 44(4):148–54 (64 ref.) (Eng. Abstr.) **(Rus)**
[Advances in the development of a vaccine against dengue] Guzmán MG. **Acta Cient Venez** 1998;49 Suppl 1:38–45 (84 ref.) (Eng. Abstr.) **(Spa)**
[Vaccine against rotavirus] Pérez-Trallero E, et al. **Enferm Infecc Microbiol Clin** 1998 Aug-Sep;16(7):334–8 (52 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

First rotavirus vaccine licensed: is there really a need? Glass RI, et al. **Acta Paediatr Suppl** 1999 Jan;88(426):2–8 (47 ref.)
In ovo vaccination technology. Ricks CA, et al. **Adv Vet Med** 1999;41:495–515 (51 ref.)
Papillomaviruses: prophylactic vaccine prospects. Lowy DR, et al. **Biochim Biophys Acta** 1999 Jan 29;1423(1):M1–8 (60 ref.)
Formulation, stability, and delivery of live attenuated vaccines for human use. Burke CJ, et al. **Crit Rev Ther Drug Carrier Syst** 1999;16(1):1–83 (436 ref.)
Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Kovarik J, et al. **Immunol Cell Biol** 1998 Jun;76(3):222–36 (134 ref.)
[Recommended vaccines and immunoglobulins for immunocompromised patients] Bricks LF. **Rev Saude Publica** 1998 Jun;32(3):281–94 (75 ref.) (Eng. Abstr.) **(Por)**

ADVERSE EFFECTS

[Vasculitis associated with antiviral vaccines and antiviral agents] Le Hello C. **Pathol Biol (Paris)** 1999 Mar; 47(3):252–6 (38 ref.) (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

Formulation, stability, and delivery of live attenuated vaccines for human use. Burke CJ, et al. **Crit Rev Ther Drug Carrier Syst** 1999;16(1):1–83 (436 ref.)

CHEMISTRY

Safety of biological products prepared from mammalian cell culture. Host-cell proteins. **Dev Biol Stand** 1998;93:139–40 (0 ref.)
SV40 in adenovirus vaccines and adenovirus-SV40 recombinants. Lewis AM Jr. **Dev Biol Stand** 1998;94:207–16 (17 ref.)

IMMUNOLOGY

Defective adenoviruses as novel vaccines for the Flaviviridae. Stephenson J. **Clin Diagn Virol** 1998 Jul 15; 10(2-3):187–94 (30 ref.)
Protective immunity induced by live attenuated simian immunodeficiency virus. Johnson RP, et al. **Curr Opin Immunol** 1998 Aug;10(4):436–43 (62 ref.)
Recombinant viruses as vectors for mucosal immunity. Morrow CD, et al. **Curr Top Microbiol Immunol** 1999; 236:255–73 (49 ref.)
Immunological issues in vaccine trials: T-cell responses. Kourilsky P, et al. **Dev Biol Stand** 1998;95:117–24 (33 ref.)
Assessment of human CD4+ and CD8+ T lymphocyte responses in experimental viral vaccine studies. Rothman AL, et al. **Dev Biol Stand** 1998;95:95–104 (14 ref.)
Rotavirus. Parashar UD, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):561–70 (52 ref.)
Herpesvirus vaccines. Development, controversies, and applications. Krause PR, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):61–81, vi (88 ref.)
The rotavirus vaccine. Offit PA. **J Clin Virol** 1998 Dec; 11(3):155–9 (31 ref.)
Perspective: edible vaccines––a concept coming of age. Mor TS, et al. **Trends Microbiol** 1998 Nov;6(11):449–53 (36 ref.)
Herpes simplex virus vaccines. Bernstein DI, et al. **Vaccine** 1999 Mar 26;17(13-14):1681–9 (90 ref.)
Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Bresee JS, et al. **Vaccine** 1999 May 4; 17(18):2207–22 (148 ref.)
Optimisation of the immune response to foot-and-mouth disease vaccines. Doel TR. **Vaccine** 1999 Mar 26; 17(13-14):1767–71 (10 ref.)
Vital elements for the successful control of foot-and-mouth disease by vaccination. Garland AJ. **Vaccine** 1999 Mar 26; 17(13-14):1760–6 (26 ref.)
The current status of the rotavirus vaccine. Jacobson RM. **Vaccine** 1999 Mar 26;17(13-14):1690–9 (150 ref.)
[Viral mucosal vaccines] Gendon IuZ. **Vopr Virusol** 1999 May-Jun;44(3):100–5 (40 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Lassa fever: implications of T-cell immunity for vaccine development. ter Meulen J. **J Biotechnol** 1999 Aug 20; 73(2-3):207–12 (21 ref.)

PHARMACOLOGY

Immunological issues in vaccine trials: T-cell responses. Kourilsky P, et al. **Dev Biol Stand** 1998;95:117–24 (33 ref.)
Assessment of human CD4+ and CD8+ T lymphocyte responses in experimental viral vaccine studies. Rothman AL, et al. **Dev Biol Stand** 1998;95:95–104 (14 ref.)
Overview of current preclinical testing strategies for viral vaccines. Wood DJ. **Dev Biol Stand** 1998;95:19–23 (17 ref.)
Diva vaccines that reduce virus transmission. van Oirschot JT. **J Biotechnol** 1999 Aug 20;73(2-3):195–205 (69 ref.)

STANDARDS

Quality control of bovine serum used for vaccine production. Mareschal JC. **Dev Biol Stand** 1999;99:61–8 (6 ref.)
Overview of current preclinical testing strategies for viral vaccines. Wood DJ. **Dev Biol Stand** 1998;95:19–23 (17 ref.)

SUPPLY & DISTRIBUTION

[The first rotavirus vaccine approved in the USA and Europe] Svensson L, et al. **Lakartidningen** 1999 Jun 30; 96(26–27):3158–60 (18 ref.) (Eng. Abstr.) **(Swe)**
[Promising experiments with DNA vaccine against HIV. A complete eradication of the virus is a formidable task] Wahren B. **Lakartidningen** 1999 Feb 17;96(7):722–5 (20 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Tetravalent rotavirus vaccine. Wandstrat TL, et al. **Ann Pharmacother** 1999 Jul-Aug;33(7-8):833–9 (26 ref.)
Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Zajac AJ, et al. **Curr Opin Immunol** 1998 Aug; 10(4):444–9 (53 ref.)
Vaccines. Lee A. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S75–9 (41 ref.)
Prevention strategies for respiratory syncytial virus: passive and active immunization. Englund JA. **J Pediatr** 1999 Aug; 135(2 Pt 2):38–44 (66 ref.)
Papillomavirus-like particle vaccines for cervical cancer. Schiller JT. **Mol Med Today** 1999 May;5(5):209–15 (33 ref.)
Overview of viruses, cancer, and vaccines in concept and in reality. Hilleman MR. **Recent Results Cancer Res** 1998; 154:345–62 (94 ref.)
Control of STDs––the role of prophylactic vaccines against herpes simplex virus. Stanberry LR. **Sex Transm Infect** 1998 Dec;74(6):391–4 (40 ref.)
Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Bresee JS, et al. **Vaccine** 1999 May 4; 17(18):2207–22 (148 ref.)

VIREMIA

DIAGNOSIS

Genomic screening for blood-borne viruses in transfusion settings. Lee HH, et al. **Vox Sang** 1998;74 Suppl 2:119–23 (22 ref.)

IMMUNOLOGY

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117–24; discussion 125–6 (43 ref.)

VIROLOGY

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117–24; discussion 125–6 (43 ref.)

VIRGINIAMYCIN

ANALOGS & DERIVATIVES

Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin. Rotschafer JC, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):95–9 (13 ref.)

VIRGINIAMYCIN

PHARMACOKINETICS

Streptogramins and their potential role in geriatric medicine. Lomaestro BM, et al. **Drugs Aging** 1998 Dec;13(6):443–65 (105 ref.)

PHARMACOLOGY

Recent developments in streptogramin research. Barrière JC, et al. **Curr Pharm Des** 1998 Apr;4(2):155–80 (232 ref.)

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Jones RN, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):101–12 (65 ref.)

THERAPEUTIC USE

Streptogramins and their potential role in geriatric medicine. Lomaestro BM, et al. **Drugs Aging** 1998 Dec;13(6):443–65 (105 ref.)

VIRGINIAMYCIN FACTOR M1 see **VIRGINIAMYCIN**

VIRGINIAMYCIN FACTOR S1 see **VIRGINIAMYCIN**

VIRGINITY see **SEXUAL ABSTINENCE**

VIRILISM

ETIOLOGY

Hilus cell tumour of the ovary in a virilized, premenopausal woman. Case report and review of hyperandrogenism of ovarian origin. Moore A, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):75–8 (16 ref.)

VIRION

CHEMISTRY

Analysis of X-ray diffraction from fibres of Pf1 Inovirus (filamentous bacteriophage) shows that the DNA in the virion is not highly ordered. Welsh LC, et al. **J Mol Biol** 1998 Dec 18;284(5):1265–71 (27 ref.)

GENETICS

Analysis of X-ray diffraction from fibres of Pf1 Inovirus (filamentous bacteriophage) shows that the DNA in the virion is not highly ordered. Welsh LC, et al. **J Mol Biol** 1998 Dec 18;284(5):1265–71 (27 ref.)

IMMUNOLOGY

New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles. Roy P, et al. **Arch Virol Suppl** 1998;14:177–202 (41 ref.)

ISOLATION & PURIFICATION

Virus removal by filtration. Graf EG, et al. **Dev Biol Stand** 1999;99:89–94 (21 ref.)

METABOLISM

Expression of the major core structural proteins VP3 and VP7 of African horse sickness virus, and production of core-like particles. Maree S, et al. **Arch Virol Suppl** 1998; 14:203–9 (22 ref.)

PHYSIOLOGY

The tobacco mosaic virus particle: structure and assembly. Klug A. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):531–5 (20 ref.)

ULTRASTRUCTURE

Tobacco mosaic virus particle structure and the initiation of disassembly. Stubbs G. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):551–7 (45 ref.)

VIROIDS

GENETICS

Encapsidated circular viroid-like satellite RNAs (virusoids) of plants. Symons RH, et al. **Curr Top Microbiol Immunol** 1999;239:81–105 (73 ref.)

METABOLISM

Viroids with hammerhead ribozymes: some unique structural and functional aspects with respect to other members of the group. Flores R, et al. **Biol Chem** 1999 Jul–Aug; 380(7–8):849–54 (36 ref.)

PHYSIOLOGY

Viroids and the nature of viroid diseases. Diener TO. **Arch Virol Suppl** 1999;15:203–20 (89 ref.)

VIROLOGY

HISTORY

The Journal of Virology: a personal retrospective. Wagner RR. **J Virol** 1999 May;73(5):3515–9 (4 ref.)

METHODS

Detection of human papillomaviruses in tissue specimens. Poljak M, et al. **Adv Anat Pathol** 1998 Jul;5(4):216–34 (134 ref.)

VIRTUAL SYSTEMS see **USER-COMPUTER INTERFACE**

VIRULENCE

Protein translocation: delivering virulence into the host cell. Gauthier A, et al. **Curr Biol** 1998 Oct 22;8(21):R768–70 (11 ref.)

Host–pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Casadevall A, et al. **Infect Immun** 1999 Aug;67(8):3703–13 (35 ref.)

Immunogenic and protective Candida albicans constituents. Cassone A, et al. **Res Immunol** 1998 May–Jun; 149(4–5):289–99; discussion 504 (50 ref.)

GENETICS

Virulence genes of Clostridium perfringens. Rood JI. **Annu Rev Microbiol** 1998;52:333–60 (137 ref.)

Fungal avirulence genes: structure and possible functions. Laugé R, et al. **Fungal Genet Biol** 1998 Aug;24(3):285–97 (80 ref.)

Virulence gene regulation in pathogenic Escherichia coli. Harel J, et al. **Vet Res** 1999 Mar–Jun;30(2–3):131–55 (139 ref.)

PHYSIOLOGY

Secretion of virulence factors by Escherichia coli. China B, et al. **Vet Res** 1999 Mar–Jun;30(2–3):131–202 (122 ref.)

[Pathogenic power of Salmonellae: virulence factors and study models] Millemann Y. **Vet Res** 1998 Sep–Oct; 29(5):385–407 (132 ref.) (Eng. Abstr.) **(Fre)**

VIRUS ACTIVATION

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Corash L. **Transfus Med Rev** 1999 Jan;13(1):18–30 (92 ref.)

[Reactivation of HBV following allogeneic bone marrow transplantation: new outlook (the hepatitis B virus and the bone marrow transplant) (letter)] Otero López-Cubero S, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):229–30 (5 ref.) **(Spa)**

GENETICS

An evolutionary link between sporulation and prophage induction in the structure of a repressor:anti-repressor complex. Lewis RJ, et al. **J Mol Biol** 1998 Nov 13; 283(5):907–12 (34 ref.)

IMMUNOLOGY

Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Hillyer CD, et al. **Transfus Med Rev** 1999 Jan; 13(1):1–17 (174 ref.)

VIRUS ASSEMBLY

Molecular events in the assembly of retrovirus particles. Sakalian M, et al. **Adv Exp Med Biol** 1998;440:329–39 (33 ref.)

Virus assembly: Imaging a molecular machine. Wikoff WR, et al. **Curr Biol** 1999 Apr 22;9(8):R296–300 (24 ref.)

Visualization of viral assembly in the infected cell. Risco C, et al. **Histol Histopathol** 1999 Jul;14(3):905–26 (117 ref.)

Structure and function of the encapsidation signal of hepadnaviridae. Kramvis A, et al. **J Viral Hepat** 1998 Nov; 5(6):357–67 (90 ref.)

Self-assembly of tobacco mosaic virus: the role of an intermediate aggregate in generating both specificity and speed. Butler PJ. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):537–50 (80 ref.)

The tobacco mosaic virus particle: structure and assembly. Klug A. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29;354(1383):531–5 (20 ref.)

Tobacco mosaic virus particle structure and the initiation of disassembly. Stubbs G. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):551–7 (45 ref.)

HIV-1 gag proteins: diverse functions in the virus life cycle. Freed EO. **Virology** 1998 Nov 10;251(1):1–15 (179 ref.)

GENETICS

Virus reconstitution and the proof of the existence of genomic RNA. Fraenkel-Conrat H, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Mar 29; 354(1383):583–6 (24 ref.)

PHYSIOLOGY

Precise packaging of the three genomic segments of the double-stranded-RNA bacteriophage phi6. Mindich L. **Microbiol Mol Biol Rev** 1999 Mar;63(1):149–60 (88 ref.)

VIRUS CULTIVATION

METHODS

Problems with BHK 21 cells. Brown F. **Dev Biol Stand** 1998; 93:85–8 (17 ref.)

VIRUS DISEASES

see related
ANTIVIRAL AGENTS

Seminal tract infections: impact on male fertility and treatment options. Keck C, et al. **Hum Reprod Update** 1998 Nov–Dec;4(6):891–903 (132 ref.)

Pleural space infections: microbiology and antimicrobial therapy. Everts RJ, et al. **Semin Respir Infect** 1999 Mar; 14(1):18–30 (67 ref.)

[Virus infections, their onsets, and immunology] Ikari J. **Rinsho Byori** 1998 Nov;Suppl 108:8–12 (4 ref.) **(Jpn)**

[Virus-associated hemophagocytic syndrome] Kawaguchi H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):365–7 (7 ref.) **(Jpn)**

[Acute upper airway infection] Narushima M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):407–9 (12 ref.) **(Jpn)**

BLOOD

Emergence of new viral infections: implications for the blood supply. Nathanson N. **Biologicals** 1998 Jun;26(2):77–84 (25 ref.)

COMPLICATIONS

Vasculitis and chronic persistent viral infections [editorial] Calabrese LH. **Ann Med Interne (Paris)** 1998 Nov; 149(7):395–7 (17 ref.)

Mechanisms of viral pathogenesis in rheumatic disease. Perl A. **Ann Rheum Dis** 1999 Aug;58(8):454–61 (113 ref.)

From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Kawai C. **Circulation** 1999 Mar 2;99(8):1091–100 (107 ref.)

Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Wagner M, et al. **Clin Infect Dis** 1998 Nov;27(5):1299–308 (112 ref.)

Animal models of infection-mediated vasculitis. Dal Canto AJ, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):17–23 (23 ref.)

Viruses and atherosclerosis: do they play a pathogenic role? Vercellotti GM. **J Investig Med** 1998 Oct;46(8):403–7 (71 ref.)

Postencephalitic parkinsonism—a review. Casals J, et al. **J Neural Transm** 1998;105(6–7):645–76 (144 ref.)

Overview of viruses, cancer, and vaccines in concept and in reality. Hilleman MR. **Recent Results Cancer Res** 1998; 154:345–62 (94 ref.)

Selected pediatric viral infections. Powell S, et al. **Semin Pediatr Neurol** 1995 Sep;2(3):211–9 (44 ref.)

[The infection theory in atherosclerosis] Capron L, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:21–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Viral implications in the etiopathogenesis of type 1 diabetes: current update] Radermecker R, et al. **Rev Med Liege** 1998 Oct;53(10):597–602 (27 ref.) (Eng. Abstr.) **(Fre)**

[Viral respiratory infection in bronchial asthma] Suzuki S. **Arerugi** 1999 Jan;48(1):5–8 (28 ref.) **(Jpn)**

[Potential mechanism of viral infection in immunological diseases] Saito I. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):412–6 (20 ref.) **(Jpn)**

[Virus-associated malignancies] Takada K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):421–4 (2 ref.) **(Jpn)**

[Current concepts on the etiology and pathogenesis of systemic vasculitis: the role of infection and genetic predisposition (I)] Nasonov EA, et al. **Klin Med (Mosk)** 1998;76(7):5–11 (122 ref.) **(Rus)**

DIAGNOSIS

Viruses and athletes. Madeley CR. **Br J Sports Med** 1998 Dec;32(4):281–6 (9 ref.)

Viral infections in asthma. Peebles RS Jr, et al. **Compr Ther** 1998 Oct;24(10):511–8 (51 ref.)

Diagnosis of respiratory viruses in cancer and transplant patients. Englund JA, et al. **Curr Clin Top Infect Dis** 1999; 19:30–59 (121 ref.)

Diagnostic electron microscopy is still a timely and rewarding method. Biel SS, et al. **J Clin Virol** 1999 Jun; 13(1–2):105–19 (104 ref.)

[Fever of unknown origin in a young child: diagnosis and treatment] Oostenbrink R, et al. **Ned Tijdschr Geneeskd** 1999 Jan 23;143(4):185–90 (25 ref.) (Eng. Abstr.) **(Dut)**

[Tropical viral diseases] Meyer CG, et al. **Dtsch Med Wochenschr** 1999 Sep 10;124(36):1043–51 (49 ref.) **(Ger)**

[Diagnosis of infections with difficulty in isolation and

identification of causative agents. 5) Virus infections] Nagafuchi S, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2218–22 (6 ref.) **(Jpn)**

[Laboratory diagnosis of viral infections. 4. Viral food poisoning, gastroenteritis, and diarrhea] Kawamoto H. **Rinsho Byori** 1998 Nov;Suppl 108:74–83 (11 ref.) **(Jpn)**

[Laboratory diagnosis of viral infections. 12. Urogenital diseases and sexually transmitted diseases] Kubota T. **Rinsho Byori** 1998 Nov;Suppl 108:128–31 (2 ref.) **(Jpn)**

[Laboratory diagnosis of viral infections. 10. Circulatory and muscular diseases and arthritis caused by virus infections] Matsuoka R. **Rinsho Byori** 1998 Nov;Suppl 108:116–23 (26 ref.) **(Jpn)**

[Serodiagnosis of viral infections] Nakamura Y. **Rinsho Byori** 1998 Nov;Suppl 108:29–35 (5 ref.) **(Jpn)**

[Laboratory diagnosis of viral infections. 11. Ocular diseases] Osawa M, et al. **Rinsho Byori** 1998 Nov;Suppl 108:124–7 (2 ref.) **(Jpn)**

[Laboratory diagnosis of viral infections. 1. Respiratory tract infections] Takeuchi K. **Rinsho Byori** 1998 Nov;Suppl 108:43–58 (22 ref.) **(Jpn)**

[Nucleic acid based diagnosis in clinical microbiology] Kalland KH, et al. **Tidsskr Nor Laegeforen** 1999 Feb 28; 119(6):802–9 (72 ref.) (Eng. Abstr.) **(Nor)**

[Infectious esophagitis] Arenas Miravé JI, et al. **Gastroenterol Hepatol** 1999 Jun–Jul;22(6):302–8 (65 ref.) **(Spa)**

[Increased travelling—increased risk of imported viruses. A review of the diagnostic capacity of the Swedish Institute for Infectious Disease Control] Vene S, et al. **Lakartidningen** 1999 Jun 9;96(23):2838–41 (20 ref.) (Eng. Abstr.) **(Swe)**

DRUG THERAPY

Moroxydine: the story of a mislaid antiviral. Sheppard S. **Acta Derm Venereol Suppl (Stockh)** 1994;183:1–9 (42 ref.)

Antiviral activity of lactoferrin. Valenti P, et al. **Adv Exp Med Biol** 1998;443:199–203 (31 ref.)

Antiinfectives update: focus on treatment and prevention of viral and associated infections. McNicholl IR, et al. **Ann Pharmacother** 1999 May;33(5):607–14 (67 ref.)

Approaches to antiviral chemotherapy for acute respiratory infections. Shigeta S. **Antivir Chem Chemother** 1998 Mar; 9(2):93–107 (87 ref.)

Protease inhibitors as antiviral agents. Patick AK, et al. **Clin Microbiol Rev** 1998 Oct;11(4):614–27 (169 ref.)

Advances in antiviral therapy. Zerr DM, et al. **Curr Opin Pediatr** 1999 Feb;11(1):21–7 (51 ref.)

Upper respiratory tract infections. Moore DA, et al. **Curr Opin Pulm Med** 1999 May;5(3):157–63 (63 ref.)

Antiviral drugs. Balfour HH Jr. **N Engl J Med** 1999 Apr 22;340(16):1255–68 (100 ref.)

[Chemotherapy and vaccines used for the management of viral infections] Yamane S. **Rinsho Byori** 1998 Nov;Suppl 108:36–41 (4 ref.) **(Jpn)**

EPIDEMIOLOGY

Molecular epidemiology and evolution of emerging infectious diseases. Holmes EC. **Br Med Bull** 1998;54(3):533–43 (30 ref.)

Emerging viral diseases: an Australian perspective. Mackenzie JS. **Emerg Infect Dis** 1999 Jan–Feb;5(1):1–8 (71 ref.)

["Emerging" viral zoonoses in native animals who can be the host in the Netherlands] van der Poel WH. **Tijdschr Diergeneeskd** 1999 Jan 1;124(1):3–11 (90 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Transfusion-transmitted diseases: risks, prevention and perspectives. Moor AC, et al. **Eur J Haematol** 1999 Jan; 62(1):1–18 (183 ref.)

The lung in the immunocompromised patient. Infectious complications part 2. Tamm M. **Respiration** 1999; 66(3):199–207 (77 ref.)

[Pulmonary infections other than AIDS] Perdu D, et al. **Presse Med** 1998 May 23–30;27(19):934–40 (39 ref.) **(Fre)**

[Human diseases associated with ubiquitin/proteasome proteolytic system] Anan T, et al. **Tanpakushitsu Kakusan Koso** 1999 May;44(6):776–86 (45 ref.) **(Jpn)**

GENETICS

Viral persistence: mechanisms and consequences. Oldstone MB. **Curr Opin Microbiol** 1998 Aug;1(4):436–41 (58 ref.)

IMMUNOLOGY

Mechanisms for induction of autoimmunity in humans. Möller E. **Acta Paediatr Suppl** 1998 Jun;424:16–20 (27 ref.)

Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. Biron CA, et al. **Adv Exp Med Biol** 1998;452:143–9 (32 ref.)

Natural killer cells in antiviral defense: function and regulation by innate cytokines. Biron CA, et al. **Annu Rev Immunol** 1999;17:189–220 (253 ref.)

The immune system in viral myocarditis: maintaining the balance [editorial; comment] Knowlton KU, et al. **Circ Res** 1999 Sep 17;85(6):559–61 (20 ref.) Comment on: Circ Res 1999 Sep 17;85(6):551–8.

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Zajac AJ, et al. **Curr Opin Immunol** 1998 Aug; 10(4):444–9 (53 ref.)

Initial and innate responses to viral infections—pattern setting in immunity or disease. Biron CA. **Curr Opin Microbiol** 1999 Aug;2(4):374–81 (76 ref.)

Viral-induced neurodegenerative disease. Buchmeier MJ, et al. **Curr Opin Microbiol** 1999 Aug;2(4):398–402 (38 ref.)

The new numerology of immunity mediated by virus-specific CD8(+) T cells. Doherty PC. **Curr Opin Microbiol** 1998 Aug;1(4):419–22 (37 ref.)

Cytokine responses in virus infections: effects on pathogenesis, recovery and persistence. Estcourt MJ, et al. **Curr Opin Microbiol** 1998 Aug;1(4):411–8 (55 ref.)

Cytokine-induced viral purging—role in viral pathogenesis. Guidotti LG, et al. **Curr Opin Microbiol** 1999 Aug; 2(4):388–91 (53 ref.)

Viral persistence: mechanisms and consequences. Oldstone MB. **Curr Opin Microbiol** 1998 Aug;1(4):436–41 (58 ref.)

Viruses as triggers of autoimmunity: facts and fantasies. Whitton JL, et al. **Curr Opin Microbiol** 1999 Aug;2(4):392–7 (58 ref.)

Defense mechanisms against infections. Reynolds HY. **Curr Opin Pulm Med** 1999 May;5(3):136–42 (61 ref.)

IL-12 and viral infections. Komastu T, et al. **Cytokine Growth Factor Rev** 1998 Sep–Dec;9(3–4):277–85 (75 ref.)

Sudden infant death syndrome, virus infections and cytokines. Raza MW, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):85–96 (140 ref.)

Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction [published erratum appears in Immunol Cell Biol 1999 Jun;77(3):287] Edwards KM, et al. **Immunol Cell Biol** 1999 Feb;77(1):76–89 (180 ref.)

Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo? Borrow P, et al. **Immunol Rev** 1998 Aug;164:37–51 (115 ref.)

Persisting viruses and chronic inflammation: understanding their relation to autoimmunity. Di Rosa F, et al. **Immunol Rev** 1998 Aug;164:17–27 (132 ref.)

CTL granules: evolution of vesicles essential for combating virus infections. Trapani JA, et al. **Immunol Today** 1999 Aug;20(8):351–6 (71 ref.)

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses [comment] Kalams SA, et al. **J Exp Med** 1998 Dec 21;188(12):2199–204 (51 ref.) Comment on: J Exp Med 1998 Dec 21;188(12):2205–13.

Stress and immunity: implications for viral disease and wound healing. Rozlog LA, et al. **J Periodontol** 1999 Jul; 70(7):786–92 (57 ref.)

U'/-induced immunosuppression in virus infections. Norval M, et al. **Mutat Res** 1998 Nov 9;422(1):131–8 (29 ref.)

Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Biron CA. **Semin Immunol** 1998 Oct; 10(5):383–90 (76 ref.)

T cell receptor usage in infectious disease. Callan MF, et al. **Springer Semin Immunopathol** 1999;21(1):37–54 (78 ref.)

Apoptosis: an innate immune response to virus infection. Everett H, et al. **Trends Microbiol** 1999 Apr;7(4):160–5 (57 ref.)

[Virus infections, their onsets, and immunology] Ikari J. **Rinsho Byori** 1998 Nov;Suppl 108:8–12 (4 ref.) **(Jpn)**

[Innate nonspecific antiviral immunity] Blach-Olszewska Z. **Postepy Hig Med Dosw** 1999;53(1):3–21 (67 ref.) (Eng. Abstr.) **(Pol)**

[Viral persistence: immunological and pathogenetic aspects] Maianskii AN, et al. **Klin Med (Mosk)** 1998;76(12):19–25 (44 ref.) **(Rus)**

METABOLISM

The 2-5A system in viral infection and apoptosis. Castelli J, et al. **Biomed Pharmacother** 1998;52(9):386–90 (47 ref.)

PHYSIOPATHOLOGY

Mechanisms of asthma exacerbation. Johnston SL. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:181–6; discussion 203–5 (34 ref.)

Host cell glycosylation of viral glycoproteins—a battlefield for host defence and viral resistance. Olofsson S, et al. **Scand J Infect Dis** 1998;30(5):435–40 (39 ref.)

Perspective: virus infections and the death of neurons. Griffin DE, et al. **Trends Microbiol** 1999 Apr;7(4):155–60 (44 ref.)

PREVENTION & CONTROL

DNA vaccines for viral diseases. Donnelly JJ, et al. **Braz J Med Biol Res** 1999 Feb;32(2):215–22 (25 ref.)

Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Singer NG, et al. **Curr Opin Rheumatol** 1999 May;11(3):173–8 (21 ref.)

Risks of virus transmission associated with animal sera or substitutes and methods of control. Eloit M. **Dev Biol Stand** 1999;99:9–16 (10 ref.)

Bovine serum: reducing the variables through the use of donor herds. Rolleston WB. **Dev Biol Stand** 1999;99:79–86 (14 ref.)

Key developments in the battle against infection. Venkatesan P. **Practitioner** 1997 Dec;241(1581):720–2 (9 ref.)

The use of epidemiological data in the control of foodborne viruses. Powell SC, et al. **Rev Environ Health** 1999 Jan–Mar;14(1):31–7 (37 ref.)

Immunisation strategies for viral diseases in developing countries. Ruff TA. **Rev Med Virol** 1999 Apr–Jun; 9(2):121–38 (61 ref.)

Genomic screening for blood-borne viruses in transfusion settings. Lee HH, et al. **Vox Sang** 1998;74 Suppl 2:119–23 (22 ref.)

Virus inactivation of fresh plasma. Mohr H. **Vox Sang** 1998; 74 Suppl 2:171–2 (12 ref.)

[Chemotherapy and vaccines used for the management of viral infections] Yamane S. **Rinsho Byori** 1998 Nov;Suppl 108:36–41 (4 ref.) **(Jpn)**

[Efficacy of commercially available virus vaccines and their problems] Suga S, et al. **Uirusu** 1998 Dec;48(2):175–82 (33 ref.) **(Jpn)**

[DNA vaccines] Gendaszewska E. **Postepy Biochem** 1998; 44(2):117–24 (46 ref.) **(Pol)**

RADIOGRAPHY

The utility of CT in imaging chest infections in HIV-negative patients. Richenberg J, et al. **Curr Opin Pulm Med** 1999 May;5(3):179–84 (33 ref.)

THERAPY

Vector development: a major obstacle in human gene therapy [editorial] Jane SM, et al. **Ann Med** 1998 Oct;30(5):413–5 (9 ref.)

Recent advances in the management of viral infections. Wingard JR. **Cancer Treat Res** 1998;96:183–200 (119 ref.)

Viral infections in asthma. Peebles RS Jr, et al. **Compr Ther** 1998 Oct;24(10):511–8 (51 ref.)

[Intracellular antibodies: a new therapeutic concept for virus infections and neoplasms] zu Putlitz J, et al. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):357–60 (0 ref.) **(Ger)**

TRANSMISSION

Main viral diseases with in utero transmission of pathogen during pregnancy: epidemiology, pathological features and outcome. Shlyakhov E, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):875–82 (115 ref.)

Emergence of new viral infections: implications for the blood supply. Nathanson N. **Biologicals** 1998 Jun;26(2):77–84 (25 ref.)

Transfusion virology: progress and challenges. Simmonds P. **Blood Rev** 1998 Sep;12(3):171–7 (45 ref.)

Emerging viral diseases: an Australian perspective. Mackenzie JS. **Emerg Infect Dis** 1999 Jan–Feb;5(1):1–8 (71 ref.)

Transfusional transmitted viruses in pregnancy. Eleftheriou A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:901–14 (65 ref.)

Emerging viral diseases. Nuttal PG, et al. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):306–9 (10 ref.)

Xenotransplantation. The viral issue. Groth CG. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV26 (5 ref.)

Emerging viruses in blood transfusion. Allain JP. **Vox Sang** 1998;74 Suppl 2:125–9 (24 ref.)

[Digestive infections and nurseries] Gendrel D. **Arch Pediatr** 1999;6 Suppl 3:628s–632s (17 ref.) **(Fre)**

[Respiratory and community infections] Ovetchkine P, et al. **Arch Pediatr** 1999;6 Suppl 3:633s–635s (12 ref.) **(Fre)**

[Nosocomial infections implying viruses and unconventional transmissible agents] Zandotti C, et al. **Rev Prat** 1998 Sep 15;48(14):1563–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Virologic aspects of blood and plasma product safety] Gärtner BC, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):486–8 (12 ref.) **(Ger)**

[Seafood transmitted diseases] Feldhusen F. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):319–25 (60 ref.) (Eng. Abstr.) **(Ger)**

[Emergence of "new" viral zoonoses] Greiser-Wilke I, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):332–8 (37 ref.) (Eng. Abstr.) **(Ger)**

[The Phlebotominae (Diptera, Phlebotomidae) as vectors of parasitic and viral diseases from the aspect of biomedical research] MišćevićZ, et al. **Srp Arh Celok Lek** 1999 May-Jun;127(5–6):190–5 (42 ref.) **(Scc)**

VETERINARY

Forty years of canine vaccination. Appel MJ. **Adv Vet Med** 1999;41:309–24 (95 ref.)

Canine viral vaccines at a turning point—a personal perspective. Carmichael LE. **Adv Vet Med** 1999;41:289–307 (48 ref.)

Diagnosis and prevention of equine infectious diseases: present status, potential, and challenges for the future. Desmettre P. **Adv Vet Med** 1999;41:359–77 (129 ref.)

In ovo vaccination technology. Ricks CA, et al. **Adv Vet Med** 1999;41:495–515 (51 ref.)

Viral vectors for veterinary vaccines. Sheppard M. **Adv Vet Med** 1999;41:145–61 (90 ref.)

Swinepox virus as a vaccine vector for swine pathogens. Tripathy DN. **Adv Vet Med** 1999;41:463–80 (45 ref.)

Bovine viral vaccines, diagnostics, and eradication: past,

VIRUS DISEASES

present, and future. van Oirschot JT. **Adv Vet Med** 1999; 41:197–216 (82 ref.)
Virus infections of the gastrointestinal tract of poultry. Guy JS. **Poult Sci** 1998 Aug;77(8):1166–75 (69 ref.)
Viral diseases of the respiratory system. Villegas P. **Poult Sci** 1998 Aug;77(8):1143–5 (24 ref.)
New approaches to the development of virus vaccines for veterinary use. Yamanouchi K, et al. **Rev Sci Tech** 1998 Dec;17(3):641–53 (61 ref.)
Infectious diseases and parasites of ratites. Shane SM. **Vet Clin North Am Food Anim Pract** 1998 Nov; 14(3):455–83, iv (41 ref.)
[Emergence of "new" viral zoonoses] Greiser-Wilke I, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):332–8 (37 ref.) (Eng. Abstr.) **(Ger)**
[Infectious diseases of animals and their prevention] Mikula I, et al. **Bratisl Lek Listy** 1998 Aug–Sep;99(8–9):465–73 (94 ref.) (Eng. Abstr.) **(Slo)**

VIROLOGY

Emerging viral diseases. Nuttal PG, et al. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):306–9 (10 ref.)
Mixed viral–bacterial pulmonary infections in children. Korppi M. **Pediatr Pulmonol Suppl** 1999;18:110–2 (14 ref.)

VIRUS INDUCTION see **VIRUS ACTIVATION**

VIRUS INHIBITORS

IMMUNOLOGY

Interferon-inducible Mx proteins in fish. Leong JC, et al. **Immunol Rev** 1998 Dec;166:349–63 (103 ref.)

PHYSIOLOGY

Endogenous salivary inhibitors of human immunodeficiency virus. Shugars DC, et al. **Arch Oral Biol** 1999 Jun; 44(6):445–53 (68 ref.)

VIRUS INTEGRATION

see related
INTEGRASE
PROVIRUSES

Host proteins in retroviral cDNA integration. Bushman FD. **Adv Virus Res** 1999;52:301–17 (81 ref.)
Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Fouchier RA, et al. **Adv Virus Res** 1999;52:275–99 (113 ref.)
The regional integration of retroviral sequences into the mosaic genomes of mammals. Rynditch AV, et al. **Gene** 1998 Nov 5;222(1):1–16 (160 ref.)
[Prevalence of TT virus infection and viral integration in human hepatocellular carcinoma] Yamamoto T, et al. **Nippon Rinsho** 1999 Jun;57(6):1370–4 (12 ref.) (Eng. Abstr.) **(Jpn)**
[HIV-1 integration and viral replication] Masuda T. **Uirusu** 1998 Jun;48(1):19–25 (38 ref.) **(Jpn)**

PHYSIOLOGY

Reconstitution of concerted DNA integration with purified components. Hindmarsh P, et al. **Adv Virus Res** 1999; 52:397–410 (41 ref.)

VIRUS LATENCY

see related
VIRUS ACTIVATION

Alphaherpesvirus latency: its role in disease and survival of the virus in nature. Jones C. **Adv Virus Res** 1998;51:81–133 (268 ref.)
Herpes simplex virus latency and the immune response. Daheshia M, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):430–5 (50 ref.)
Latency of varicella zoster virus; a persistently perplexing state. Kinchington PR. **Front Biosci** 1999 Feb 15;4:D200–11 (114 ref.)
Epstein-Barr virus immortalization and latency. Rowe DT. **Front Biosci** 1999 Mar 15;4:D346–71 (263 ref.)
[Viral persistence: immunological and pathogenetic aspects] Maianskii AN, et al. **Klin Med (Mosk)** 1998;76(12):19–25 (44 ref.) **(Rus)**

DRUG EFFECTS

Herpes simplex virus latency and nucleoside analogues. Efstathiou S, et al. **Antiviral Res** 1999 Apr;41(3):85–100 (60 ref.)

VIRUS PARTICLE see **VIRION**

VIRUS PEPLOMER PROTEINS see **VIRAL ENVELOPE PROTEINS**

VIRUS RECEPTORS see **RECEPTORS, VIRUS**

VIRUS REPLICATION

see related
DNA REPLICATION

Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Smith GL, et al. **Adv Exp Med Biol** 1998; 440:395–414 (87 ref.)
Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Huber SA, et al. **Adv Virus Res** 1998;51:35–80 (245 ref.)
Nuclear domain 10, the site of DNA virus transcription and replication. Maul GG. **Bioessays** 1998 Aug;20(8):660–7 (63 ref.)
Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Pelletier I, et al. **Cell Mol Life Sci** 1998 Dec; 54(12):1385–402 (107 ref.)
A tale of two strands: reverse-transcriptase polymerase chain reaction detection of hepatitis C virus replication. Sangar DV, et al. **Hepatology** 1998 Nov;28(5):1173–6 (31 ref.)
Chemokine receptor trafficking and viral replication. Pelchen-Matthews A, et al. **Immunol Rev** 1999 Apr; 168:33–49 (158 ref.)
The control of lytic replication of Epstein-Barr virus in B lymphocytes (Review). Schwarzmann F, et al. **Int J Mol Med** 1998 Jan;1(1):137–42 (44 ref.)
Alfalfa mosaic virus and ilarviruses: involvement of coat protein in multiple steps of the replication cycle. Bol JF. **J Gen Virol** 1999 May;80 (Pt 5):1089–102 (100 ref.)
Strategies used by human immunodeficiency virus that allow persistent viral replication. Desrosiers RC. **Nat Med** 1999 Jul;5(7):723–5 (43 ref.)
A review of alphavirus replication in neurons. Griffin DE. **Neurosci Biobehav Rev** 1998 Oct;22(6):721–3 (30 ref.)
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Rein A, et al. **Trends Biochem Sci** 1998 Aug;23(8):297–301 (54 ref.)
[In vitro and in vivo inhibition of HIV1 replication by retroviral transfer of interferon alpha, beta, or gamma genes: application to gene therapy of AIDS] Leissner P, et al. **Ann Biol Clin (Paris)** 1998 Mar–Apr;56(2):167–73 (31 ref.) (Eng. Abstr.) **(Fre)**
[HIV-1 integration and viral replication] Masuda T. **Uirusu** 1998 Jun;48(1):19–25 (38 ref.) **(Jpn)**

DRUG EFFECTS

Oxygen tension and virus replication. Ebbesen P, et al. **Acta Virol** 1998 Dec;42(6):417–21 (38 ref.)
Hepatitis viruses under immunosuppressive agents. Liaw YF. **J Gastroenterol Hepatol** 1998 Jan;13(1):14–20 (75 ref.)
Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Romanelli F, et al. **Pharmacotherapy** 1999 Feb; 19(2):196–204 (39 ref.)

GENETICS

How do animal DNA viruses get to the nucleus? Kasamatsu H, et al. **Annu Rev Microbiol** 1998;52:627–86 (420 ref.)
The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy. Salemi M, et al. **Gene** 1999 Jun 24;234(1):11–21 (92 ref.)
The plasmid prophage N15: a linear DNA with covalently closed ends. Rybchin VN, et al. **Mol Microbiol** 1999 Sep; 33(5):895–903 (40 ref.)
Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Nagai Y. **Rev Med Virol** 1999 Apr–Jun;9(2):83–99 (95 ref.)
[Molecular biology of dengue virus] Rojas Mazzei A. **Acta Cient Venez** 1998;49 Suppl 1:2–7 (48 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

HIV entry and tropism. When one receptor is not enough. Berger EA. **Adv Exp Med Biol** 1998;452:151–7 (39 ref.)
HIV transmission and immune protection at mucosal surfaces. Neutra MR. **Adv Exp Med Biol** 1998;452:169–75 (60 ref.)
Immune control of HIV-1 replication. Walker BD, et al. **Adv Exp Med Biol** 1998;452:159–67 (32 ref.)
Restricted replication of non-syncytium-inducing HIV in Th1 and Th2 lymphocytes. Poli G, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):95–6 (10 ref.)
Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339–46 (80 ref.)

PHYSIOLOGY

The role of herpes simplex virus glycoproteins in the virus replication cycle. Rajčáni J, et al. **Acta Virol** 1998 Apr; 42(2):103–18 (195 ref.)
Exploring brain circuitry with neurotropic viruses: new horizons in neuroanatomy. Card JP. **Anat Rec** 1998 Dec; 253(6):176–85 (44 ref.)
Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. Poli G. **Eur J Clin Invest** 1999 Aug; 29(8):723–32 (126 ref.)
Mechanism of DNA replication in eukaryotic cells: cellular host factors stimulating adenovirus DNA replication. de Jong RN, et al. **Gene** 1999 Aug 5;236(1):1–12 (114 ref.)
Cell-dependent functional roles of HIV-1 Nef for virus replication (review). Adachi A, et al. **Int J Mol Med** 1999 Apr;3(4):427–30 (30 ref.)
Cell-dependent function of HIV-1 Vif for virus replication (Review). Inubushi R, et al. **Int J Mol Med** 1999 May; 3(5):473–6 (11 ref.)
Virological aspects of human immunodeficiency virus infection. Catton MG. **P N G Med J** 1996 Sep;39(3):166–73 (7 ref.)
Intracellular determinants of picornavirus replication. Andino R, et al. **Trends Microbiol** 1999 Feb;7(2):76–82 (61 ref.)

VIRUS SHEDDING

Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. Overbaugh J, et al. **J Infect Dis** 1999 May;179 Suppl 3:S401–4 (11 ref.)

VIRUSES

see related
ANTIVIRAL AGENTS
RECEPTORS, VIRUS

The origin and evolution of viruses (a review). Sinkovics J, et al. **Acta Microbiol Immunol Hung** 1998;45(3–4):349–90 (299 ref.)
Viruses and asthma. Johnston SL. **Allergy** 1998 Oct; 53(10):922–32 (91 ref.)
[Viruses found in animals] Ishihama A. **Tanpakushitsu Kakusan Koso** 1999 Jul;44(9):1419–22 (6 ref.) **(Jpn)**

CHEMISTRY

Virus assembly. Liljas L. **Curr Opin Struct Biol** 1999 Feb; 9(1):129–34 (54 ref.)

CLASSIFICATION

[Viral morphology, structure, and classification] Furuta K. **Rinsho Byori** 1998 Nov;Suppl 108:1–7 (8 ref.) **(Jpn)**

DRUG EFFECTS

Antiviral activity of lignans. Charlton JL. **J Nat Prod** 1998 Nov;61(11):1447–51 (27 ref.)
Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates. Corash L. **Vox Sang** 1998;74 Suppl 2:173–6 (45 ref.)

GENETICS

Viral vectors for veterinary vaccines. Sheppard M. **Adv Vet Med** 1999;41:145–61 (90 ref.)
Viruses: exquisite models for cell strategies. Bernardi F, et al. **Biochimie** 1998 Dec;80(12):1035–41 (47 ref.)
The genomic tag hypothesis: modern viruses as molecular fossils of ancient strategies for genomic replication, and clues regarding the origin of protein synthesis. Weiner AM, et al. **Biol Bull** 1999 Jun;196(3):327–8; discussion 329–30 (5 ref.)
The challenge of vector development in gene therapy. Dani SU. **Braz J Med Biol Res** 1999 Feb;32(2):133–45 (33 ref.)
Mechanisms of viral activators. Berk AJ, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:243–52 (65 ref.)
In pursuit of new developments for gene therapy of human diseases. Palù G, et al. **J Biotechnol** 1999 Feb 5;68(1):1–13 (45 ref.)
Limitations of molecular biological techniques for assessing the virological safety of foods. Richards GP. **J Food Prot** 1999 Jun;62(6):691–7 (95 ref.)
Viral vectors for gene therapy. Robbins PD, et al. **Pharmacol Ther** 1998 Oct;80(1):35–47 (75 ref.)

GROWTH & DEVELOPMENT

Virus assembly. Liljas L. **Curr Opin Struct Biol** 1999 Feb; 9(1):129–34 (54 ref.)

IMMUNOLOGY

Viral effects on antigen processing. Miller DM, et al. **Curr Opin Immunol** 1999 Feb;11(1):94–9 (49 ref.)
Viral-induced neurodegenerative disease. Buchmeier MJ, et al. **Curr Opin Microbiol** 1999 Aug;2(4):398–402 (38 ref.)
Cytokine-induced viral purging—role in viral pathogenesis. Guidotti LG, et al. **Curr Opin Microbiol** 1999 Aug; 2(4):388–91 (53 ref.)
Viruses as triggers of autoimmunity: facts and fantasies. Whitton JL, et al. **Curr Opin Microbiol** 1999 Aug;2(4):392–7 (58 ref.)
A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Früh K, et al. **Immunol Rev** 1999 Apr;168:157–66 (76 ref.)
Viruses, host responses, and autoimmunity. Horwitz MS, et al. **Immunol Rev** 1999 Jun;169:241–53 (125 ref.)
Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Wang J, et al. **Immunol Rev** 1998 Jun;163:197–215 (104 ref.)
The influence of antiviral T-cell responses on the alloreactive repertoire. Burrows SR, et al. **Immunol Today** 1999 May; 20(5):203–7 (39 ref.)
Cytotoxic T lymphocytes, chemokines and antiviral immunity. Price DA, et al. **Immunol Today** 1999 May; 20(5):212–6 (60 ref.)
Subversion of cytokine networks by viruses. Wall EM, et al. **Int Rev Immunol** 1998;17(1–4):121–55 (200 ref.)
[Innate nonspecific antiviral immunity] Blach-Olszewska Z.

Postepy Hig Med Dosw 1999;53(1):3-21 (67 ref.) (Eng. Abstr.) **(Pol)**
[Viral persistence: immunological and pathogenetic aspects] Maianskii AN, et al. **Klin Med (Mosk)** 1998;76(12):19-25 (44 ref.) **(Rus)**

ISOLATION & PURIFICATION

Safety of biological products prepared from mammalian cell culture. Detecting viruses in cell banks. **Dev Biol Stand** 1998;93:129 (0 ref.)
Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents. **Dev Biol Stand** 1998;93:130-1 (0 ref.)
Safety of biological products prepared from mammalian cell culture. Testing source materials. **Dev Biol Stand** 1998; 93:131-3 (0 ref.)
Viral validation design of a manufacturing process. Larzul D. **Dev Biol Stand** 1999;99:139-50 (1 ref.)
Limitations of molecular biological techniques for assessing the virological safety of foods. Richards GP. **J Food Prot** 1999 Jun;62(6):691-7 (95 ref.)
[Virus resistance in a hospital environment: overview of the virucide activity of disinfectants used in liquid form] Soule H, et al. **Ann Biol Clin (Paris)** 1998 Nov-Dec;56(6):693-703 (49 ref.) (Eng. Abstr.) **(Fre)**
[Viral isolation and identification] Machida K. **Rinsho Byori** 1998 Nov;Suppl 108:13-20 (5 ref.) **(Jpn)**

PATHOGENICITY

Viral invasion and host defense: strategies and counter-strategies. Carrington JC, et al. **Curr Opin Plant Biol** 1998 Aug;1(4):336-41 (62 ref.)
Viruses, host responses, and autoimmunity. Horwitz MS, et al. **Immunol Rev** 1999 Jun;169:241-53 (125 ref.)
Major histocompatibility complex class I genes in primates: co-evolution with pathogens. Vogel TU, et al. **Immunol Rev** 1999 Feb;167:327-37 (81 ref.)
Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. Wadström T, et al. **J Med Microbiol** 1999 Mar;48(3):223-33 (90 ref.)
Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance. Olofsson S, et al. **Scand J Infect Dis** 1998;30(5):435-40 (39 ref.)
Experimental evolution of parasites. Ebert D. **Science** 1998 Nov 20;282(5393):1432-5 (78 ref.)
Apoptosis: an innate immune response to virus infection. Everett H, et al. **Trends Microbiol** 1999 Apr;7(4):160-5 (57 ref.)
Virus interception of cytokine-regulated pathways. Kalvakolanu DV. **Trends Microbiol** 1999 Apr;7(4):166-71 (57 ref.)
[The emergence of new pathogens. The human species in the living universe] Ciufecu C, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec; 43(4):211-4 (0 ref.) **(Rum)**
[Viral persistence: immunological and pathogenetic aspects] Maianskii AN, et al. **Klin Med (Mosk)** 1998;76(12):19-25 (44 ref.) **(Rus)**

ULTRASTRUCTURE

[Viral morphology, structure, and classification] Furuta K. **Rinsho Byori** 1998 Nov;Suppl 108:1-7 (8 ref.) **(Jpn)**

VIRUSES, SMALL ROUND-STRUCTURED see **NORWALK VIRUS**

VISCERA

Relation between visceral fat and disease risk in children and adolescents. Goran MI, et al. **Am J Clin Nutr** 1999 Jul; 70(1):149S-56S (89 ref.)
Visceral adipose tissue: a critical review of intervention strategies. Smith SR, et al. **Int J Obes Relat Metab Disord** 1999 Apr;23(4):329-35 (38 ref.)

BLOOD SUPPLY

CT angiography of the visceral vasculature. Nghiem HV, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):439-46 (43 ref.)
[Gastrointestinal hemorrhage caused by rupture of an aneurysm of visceral arteries. Presentation of 4 cases] Quandalle P, et al. **Chirurgie** 1998 Apr;123(2):139-47 (40 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Visceral chest pain in unstable angina pectoris and effects of transcutaneous electrical nerve stimulation. (TENS). A review. Börjesson M. **Herz** 1999 Apr;24(2):114-25 (130 ref.)
Toward a biobehavioral model of visceral hypersensitivity in irritable bowel syndrome [editorial] Naliboff BD, et al. **J Psychosom Res** 1998 Dec;45(6):485-92 (48 ref.)
Visceral pain. Cervero F, et al. **Lancet** 1999 Jun 19; 353(9170):2145-8 (32 ref.)
A visceral pain pathway in the dorsal column of the spinal cord. Willis WD, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7675-9 (13 ref.)

PATHOLOGY

[Abdominal lymphoma: lymph node and visceral involvemnet] Sánchez del Peral Otero G, et al. **Sangre (Barc)** 1998 Dec;43(6):483-92 (42 ref.) **(Spa)**

PHYSIOLOGY

Prefrontal cortical networks related to visceral function and mood. Price JL. **Ann N Y Acad Sci** 1999 Jun 29;877:383-96 (46 ref.)
[Visceral sensitivity and digestive functional disorders. Clinical significance and therapeutic perspectives] Coffin B, et al. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B109-17 (114 ref.) **(Fre)**

RADIOGRAPHY

CT angiography of the visceral vasculature. Nghiem HV, et al. **Semin Ultrasound CT MR** 1998 Oct;19(5):439-46 (43 ref.)

VISCERAL AFFERENTS

DRUG EFFECTS

Modulation of sensory nerve function in the airways [published erratum appears in Trends Pharmacol Sci 1999 Jan;20(1):8] Spina D, et al. **Trends Pharmacol Sci** 1998 Nov; 19(11):460-6 (121 ref.)

PHYSIOLOGY

Stress and visceral perception. Delvaux MM. **Can J Gastroenterol** 1999 Mar;13 Suppl A:32A-36A (27 ref.)
Neurogastroenterology--information processing from the viscera to the brain in humans. Enck P, et al. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):468-71 (28 ref.)

PHYSIOPATHOLOGY

Gastrointestinal sensory abnormalities in functional dyspepsia. Schmulson MJ, et al. **Baillieres Clin Gastroenterol** 1998 Sep;12(3):545-56 (64 ref.)
Dimensions of gut dysfunction in irritable bowel syndrome: altered sensory function. Azpiroz F. **Can J Gastroenterol** 1999 Mar;13 Suppl A:12A-14A (17 ref.)

VISCERAL ARCHES see **BRANCHIAL REGION**

VISCERAL MYOPATHY see **INTESTINAL PSEUDO-OBSTRUCTION**

VISCOSITY

see related
BLOOD VISCOSITY

Dynamic mechanical analysis of polymeric systems of pharmaceutical and biomedical significance. Jones DS. **Int J Pharm** 1999 Mar 15;179(2):167-78 (40 ref.)

VISION

see related
VISUAL PERCEPTION

The consciousness of sight. Zeman A. **BMJ** 1998 Dec 19-26; 317(7174):1696-7 (11 ref.)
Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Ewing FM, et al. **Endocr Rev** 1998 Aug;19(4):462-76 (108 ref.)
Preserving human vision: eliminating blindness from diabetes mellitus [editorial] Aiello LM. **J Am Optom Assoc** 1998 Nov;69(11):690-2 (20 ref.)
Observations on the optical effects of a cataract. Campbell C. **J Cataract Refract Surg** 1999 Jul;25(7):995-1003 (3 ref.)

PHYSIOLOGY

The neuronal basis of visual memory and imagery in the primate: a neurophysiological approach. Nakahara K, et al. **Adv Biophys** 1998;35:103-19 (43 ref.)
The neuroanatomy of visual consciousness. Koch C. **Adv Neurol** 1998;77:229-41; discussion 241-3 (66 ref.)
Short-latency visual stabilization mechanisms that help to compensate for translational disturbances of gaze. Miles FA. **Ann N Y Acad Sci** 1999 May 28;871:260-71 (57 ref.)
Neural selection and control of visually guided eye movements. Schall JD, et al. **Annu Rev Neurosci** 1999; 22:241-59 (86 ref.)
Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates. Kurlak LO, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F148-54 (40 ref.)
Major review: ocular sighting dominance: a review and a study of athletic proficiency and eye-hand dominance in a collegiate baseball team [see comments] Portal JM, et al. **Binocul Vis Strabismus Q** 1998 Summer-Winter;13(2 2nd Qtr):125-32 (12 ref.) Comment in: Binocul Vis Strabismus Q 1998 Fall;13(3 3rd Qtr):165-6.
Molecular development of sensory maps: representing sights and smells in the brain. O'Leary DD, et al. **Cell** 1999 Jan 22;96(2):255-69 (87 ref.)
Active vision: visual activity in everyday life. Findlay J. **Curr Biol** 1998 Sep 10;8(18):R640-2 (12 ref.)
Control of rhodopsin activity in vision. Baylor DA, et al. **Eye** 1998;12 (Pt 3b):521-5 (22 ref.)
Forever young: visual functions not affected or minimally affected by aging: a review. Enoch JM, et al. **J Gerontol A Biol Sci Med Sci** 1999 Aug;54(8):B336-51 (105 ref.)
Structure determines function of the retina, a neural center. 4. The 'duplex' nature of vision. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):463-74 (88 ref.)
Parietal neglect and visual awareness. Driver J, et al. **Nat Neurosci** 1998 May;1(1):17-22 (45 ref.)
The sensory world of the platypus. Pettigrew JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1199-210 (38 ref.)
Long range interactions in vision [editorial] Levi DM. **Spat Vis** 1999;12(2):125-7 (19 ref.)
Neuronal chemistry and functional organization in the primate visual system. Hendry SH, et al. **Trends Neurosci** 1998 Aug;21(8):344-9 (82 ref.)
[Professional vision of flying personnel in the context of occupational health] Ushakov IB, et al. **Aviakosm Ekolog Med** 1999;33(1):16-20 (10 ref.) (Eng. Abstr.) **(Rus)**
[Visual suppression during eye movements (a brief review on the problem of the mechanisms and their role in visual perception). I. A brief review and the mechanisms] Baziian BKh. **Usp Fiziol Nauk** 1999 Apr-Jun;30(2):63-73 (97 ref.) (Eng. Abstr.) **(Rus)**
[Visual suppression during eye movements (a brief review on the problem of the mechanisms and their role in visual perception). II. Their role in visual perception] Baziian BKh. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):3-13 (47 ref.) (Eng. Abstr.) **(Rus)**

VISION, BINOCULAR

PHYSIOLOGY

Binocular vision: the neural integration of depth and motion. Freeman RD. **Curr Biol** 1998 Oct 22;8(21):R761-4 (10 ref.)
Single units and conscious vision. Logothetis NK. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1801-18 (163 ref.)
Plasticity in the tectum of Xenopus laevis: binocular maps. Udin SB, et al. **Prog Neurobiol** 1999 Oct;59(2):81-106 (162 ref.)

VISION DISORDERS

Acute visual change. Morgan A, et al. **Emerg Med Clin North Am** 1998 Nov;16(4):825-43, vii (25 ref.)

COMPLICATIONS

Sleep disorders in visually impaired children. Stores G, et al. **Dev Med Child Neurol** 1999 May;41(5):348-52 (49 ref.)
The somatic component of schizophrenia: a dissociation of the goals of visual attention and bifoveal fixation? Korn H. **Med Hypotheses** 1999 Feb;52(2):163-70 (24 ref.)
Vision impairment and driving. Owsley C, et al. **Surv Ophthalmol** 1999 May-Jun;43(6):535-50 (189 ref.)

DIAGNOSIS

The eye in childhood. Mills MD. **Am Fam Physician** 1999 Sep 1;60(3):907-16, 918 (18 ref.)
Differential diagnosis of common etiologies of photopsia. Amos JF. **J Am Optom Assoc** 1999 Aug;70(8):485-504 (102 ref.)
Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Davis PC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):93-114 (80 ref.)
Vision screening of preschool children: evaluating the past, looking toward the future. Ciner EB, et al. **Optom Vis Sci** 1998 Aug;75(8):571-84 (246 ref.)
Learning disabilities, dyslexia, and vision: a subject review. Committee on Children with Disabilities, American Academy of Pediatrics (AAP) and American Academy of Ophthalmology (AAO), American Association for Pediatric Ophthalmology and Strabismus (AAPOS). **Pediatrics** 1998 Nov;102(5):1217-9 (24 ref.)
[Visual hallucinations and illusions, symptoms frequently misdiagnosed by the practitioner] Borruat FX. **Klin Monatsbl Augenheilkd** 1999 May;214(5):324-7 (16 ref.) (Eng. Abstr.) **(Fre)**
[Vision examination in young children. Experience of Grepa Nord (France)] Walbaum O. **Rev Med Suisse Romande** 1999 Feb;119(2):121-7 (13 ref.) (Eng. Abstr.) **(Fre)**
[Disorders of visual fields. Diagnostic orientation] Mondon H. **Rev Prat** 1998 Oct 1;48(15):1705-9 (00 ref.) **(Fre)**
[Ophthalmologic examination of the infant] Klaeger-Manzanell C. **Klin Monatsbl Augenheilkd** 1999 May;214(5):336-9 (13 ref.) (Eng. Abstr.) **(Ger)**
[Visual evoked potentials and static perimetry in functional visual deficits] Sobolewski P, et al. **Klin Oczna** 1998; 100(4):221-4 (25 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Visual and visual cognitive dysfunction in Parkinson's

disease: spatial and chromatic vision. Bodis-Wollner IG, et al. **Adv Neurol** 1999;80:383–8 (30 ref.)
Common causes of vision loss in elderly patients. Quillen DA. **Am Fam Physician** 1999 Jul;60(1):99–108 (28 ref.)
Developing visual systems and exposure to virtual reality and stereo displays: some concerns and speculations about the demands on accommodation and vergence. Rushton SK, et al. **Appl Ergon** 1999 Feb;30(1):69–78 (45 ref.)
Gradual painless visual loss: chronic optic neuropathies. Benes SC, et al. **Clin Geriatr Med** 1999 Feb;15(1):47–85, vi (130 ref.)
Gradual painless visual loss: retinal causes. Elner SG. **Clin Geriatr Med** 1999 Feb;15(1):25–46, v–vi (47 ref.)
Sudden painless visual loss: optic nerve and circulatory disturbances. Kosmorsky GS. **Clin Geriatr Med** 1999 Feb; 15(1):1–13, v (70 ref.)
Differential diagnosis of common etiologies of photopsia. Amos JF. **J Am Optom Assoc** 1999 Aug;70(8):485–504 (102 ref.)
Sudden loss of vision. Cormack G, et al. **Practitioner** 1998 Dec;242(1593):851–3 (7 ref.)
[Unilateral visual field defect due to optic nerve compression by sclerotic internal carotid artery: a case report] Uchino M, et al. **No Shinkei Geka** 1999 Feb;27(2):189–94 (8 ref.) (Eng. Abstr.) **(Jpn)**
[The effect of heavy metals (lead, cadmium, and manganese) on the function of the visual system] Mulak M. **Med Pr** 1998;49(6):603–7 (28 ref.) (Eng. Abstr.) **(Pol)**
[Ergo-ophthalmologic problems of electronic display devices] Francisc F, et al. **Oftalmologia** 1998;45(4):4–9 (7 ref.) (Eng. Abstr.) **(Rum)**

MICROBIOLOGY

Visual loss due to cryptococcal meningitis in AIDS patients [letter] Torres OH, et al. **AIDS** 1999 Mar 11;13(4):530–2 (16 ref.)

PHYSIOPATHOLOGY

Primary transsphenoidal microsurgery in the treatment of craniopharyngiomas. Norris JS, et al. **Br J Neurosurg** 1998 Aug;12(4):305–12 (35 ref.)
The somatic component of schizophrenia: a dissociation of the goals of visual attention and bifoveal fixation? Korn H. **Med Hypotheses** 1999 Feb;52(2):163–70 (24 ref.)

PREVENTION & CONTROL

Prevention of visual loss in older adults. Das A. **Clin Geriatr Med** 1999 Feb;15(1):131–44, vii (49 ref.)
Lowering the risk of visual impairment and blindness. Cunha-Vaz J. **Diabet Med** 1998;15 Suppl 4:S47–50 (18 ref.)

THERAPY

The eye in childhood. Mills MD. **Am Fam Physician** 1999 Sep 1;60(3):907–16, 918 (18 ref.)
Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Guy J, et al. **Arch Ophthalmol** 1999 Apr;117(4):471–7 (36 ref.)

VISION, LOW see **VISION, SUBNORMAL**

VISION, MONOCULAR

Monovision and LASIK. Hom MM. **J Am Optom Assoc** 1999 Feb;70(2):117–22 (35 ref.)

VISION SCREENING

It's time to doctor our approach to vision screening [editorial] **Ruben JB. Binocul Vis Strabismus Q** 1999 Spring;14(1):11–2 (3 ref.)
Guidelines for screening for diabetic retinopathy revisited [editorial; comment] **Klein R. Ophthalmic Epidemiol** 1999 Mar;6(1):1–4 (20 ref.) Comment on: Ophthalmic Epidemiol 1999 Mar;6(1):61–72.

METHODS

[Vision examination in young children. Experience of Grepa Nord (France)] Walbaum O. **Rev Med Suisse Romande** 1999 Feb;119(2):121–7 (13 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Vision screening of preschool children: evaluating the past, looking toward the future. Ciner EB, et al. **Optom Vis Sci** 1998 Aug;75(8):571–84 (246 ref.)

VISION, SUBNORMAL

DIAGNOSIS

What is low vision? A re-evaluation of definitions. Leat SJ, et al. **Optom Vis Sci** 1999 Apr;76(4):198–211 (89 ref.)

VISION TESTS

[Rules for granting a driver's license as of May 6, 1999] Gramberg-Danielsen B. **Klin Monatsbl Augenheilkd** 1999 Jun;214(6):aA10–1 (5 ref.) **(Ger)**
[Ophthalmologic examination of the infant] Klaeger-Manzanell C. **Klin Monatsbl Augenheilkd** 1999 May;214(5):336–9 (13 ref.) (Eng. Abstr.) **(Ger)**

METHODS

A protocol for the evaluation and treatment of atrophic age-related macular degeneration. Richer S. **J Am Optom Assoc** 1999 Jan;70(1):13–23 (77 ref.)

VISITING NURSES see **COMMUNITY HEALTH NURSING**

VISUAL ACUITY

see related
FORM PERCEPTION
REFRACTION, OCULAR
REFRACTIVE ERRORS

Metastatic adenocarcinoma of the prostate to the choroid with loss of visual acuity as a presenting symptom [see comments] Wiegel T, et al. **J Urol** 1998 Dec;160(6 Pt 1):2158–9 (4 ref.) Comment in: J Urol 1999 Sep;162(3 Pt 1):809.
Assessment of long-chain polyunsaturated fatty acid nutritional supplementation on infant neurobehavioral development and visual acuity. Jacobson SW. **Lipids** 1999 Feb;34(2):151–60 (65 ref.)
Can laser photocoagulation of eyes with high-risk drusen prevent vision loss from age-related macular degeneration? [editorial; comment] Folk JC, et al. **Ophthalmology** 1999 Jul;106(7):1241–2 (19 ref.) Comment on: Ophthalmology 1999 Jul;106(7):1367–73; discussion 1374.

PHYSIOLOGY

Retinal structure and visual acuity in a polyprotodont marsupial, the fat-tailed dunnart (Sminthopsis crassicaudata). Arrese C, et al. **Brain Behav Evol** 1999; 53(3):111–26 (154 ref.)
Computing with self-excitatory cliques: A model and an application to hyperacuity-scale computation in visual cortex. Miller DA, et al. **Neural Comput** 1999 Jan 1; 11(1):21–66 (105 ref.)

VISUAL ANALOGUE PAIN SCALE see **PAIN MEASUREMENT**

VISUAL CONTRAST SENSITIVITY see **CONTRAST SENSITIVITY**

VISUAL CORTEX

ANATOMY & HISTOLOGY

Computational neuroimaging of human visual cortex. Wandell BA. **Annu Rev Neurosci** 1999;22:145–73 (86 ref.)
The clinical and functional measurement of cortical (in)activity in the visual brain, with special reference to the two subdivisions (V4 and V4 alpha) of the human colour centre. Zeki S, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1371–82 (75 ref.)
MR imaging anatomy of the optic pathways. Tamraz JC, et al. **Radiol Clin North Am** 1999 Jan;37(1):1–36, ix (65 ref.)
[Contemporary knowledge on the subject of visual cortex structure and function] Czepita D. **Klin Oczna** 1998; 100(5):331–4 (15 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Re-evaluating the role of vascular changes in the differential diagnosis of Alzheimer's disease and vascular dementia. Gold G, et al. **Eur Neurol** 1998 Oct;40(3):121–9 (140 ref.)

PHYSIOLOGY

Recordings from the striate cortex in awake behaving animals. Hubel DH. **Adv Neurol** 1998;77:219–26; discussion 226–7 (3 ref.)
The consciousness of sight. Zeman A. **BMJ** 1998 Dec 19–26; 317(7174):1696–7 (11 ref.)
Stepping into the same river twice: homologues as recurring attractors in epigenetic landscapes. Striedter GF. **Brain Behav Evol** 1998;52(4–5):218–31 (116 ref.)
On the neural correlates of visual perception. Pollen DA. **Cereb Cortex** 1999 Jan-Feb;9(1):4–19 (216 ref.)
Temporal coding as a means of information transfer in the primate visual system. Gawne TJ. **Crit Rev Neurobiol** 1999; 13(1):83–101 (89 ref.)
Visual attention: spotlight on the primary visual cortex. Sengpiel F, et al. **Curr Biol** 1999 May 6;9(9):R318–21 (16 ref.)
Spike timing in the mammalian visual system. Bair W. **Curr Opin Neurobiol** 1999 Aug;9(4):447–53 (49 ref.)
Central neural mechanisms for detecting second-order motion. Baker CL Jr. **Curr Opin Neurobiol** 1999 Aug; 9(4):461–6 (56 ref.)
Linking visual perception with human brain activity. Heeger DJ. **Curr Opin Neurobiol** 1999 Aug;9(4):474–9 (66 ref.)
Ocular tracking: behavior and neurophysiology. Kawano K. **Curr Opin Neurobiol** 1999 Aug;9(4):467–73 (59 ref.)
Feedforward, horizontal, and feedback processing in the visual cortex. Lamme VA, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):529–35 (83 ref.)
Mechanisms of stereoscopic vision: the disparity energy model. Ohzawa I. **Curr Opin Neurobiol** 1998 Aug; 8(4):509–15 (30 ref.)
Complex microstructures of sensory cortical connections. Rockland KS. **Curr Opin Neurobiol** 1998 Aug;8(4):545–51 (55 ref.)
Complex motion perception and its deficits. Vaina LM. **Curr Opin Neurobiol** 1998 Aug;8(4):494–502 (75 ref.)
Visual-vestibular control of posture and gait: physiological mechanisms and disorders. Bronstein AM, et al. **Curr Opin Neurol** 1999 Feb;12(1):5–11 (62 ref.)
Alpha-band oscillations in visual cortex: part of the neural correlate of visual awareness? Sewards TV, et al. **Int J Psychophysiol** 1999 Apr;32(1):35–45 (63 ref.)
Cellular mechanisms of visual cortical plasticity: a game of cat and mouse. Gordon JA. **Learn Mem** 1997 Sep–Oct; 4(3):245–61 (113 ref.)
Computing with self-excitatory cliques: A model and an application to hyperacuity-scale computation in visual cortex. Miller DA, et al. **Neural Comput** 1999 Jan 1; 11(1):21–66 (105 ref.)
Reading neural representations. Groh JM. **Neuron** 1998 Oct; 21(4):661–4 (11 ref.)
Vision for perception and vision for action in the primate brain. Goodale MA. **Novartis Found Symp** 1998;218:21–34; discussion 34–9 (47 ref.)
Single units and visual cortical organization. Lennie P. **Perception** 1998;27(8):889–935 (315 ref.)
The autonomy of the visual systems and the modularity of conscious vision. Zeki S, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1911–4 (43 ref.)
The clinical and functional measurement of cortical (in)activity in the visual brain, with special reference to the two subdivisions (V4 and V4 alpha) of the human colour centre. Zeki S, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1371–82 (75 ref.)
The theory of multistage integration in the visual brain. Bartels A, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2327–32 (55 ref.)
Monocular focal retinal lesions induce short-term topographic plasticity in adult cat visual cortex. Calford MB, et al. **Proc R Soc Lond B Biol Sci** 1999 Mar 7; 266(1418):499–507 (37 ref.)
Dynamic modulation of cerebral cortex synaptic function by nitric oxide. Kara P, et al. **Prog Brain Res** 1998;118:183–98 (135 ref.)
How does the cerebral cortex work? Learning, attention, and grouping by the laminar circuits of visual cortex. Grossberg S. **Spat Vis** 1999;12(2):163–85 (105 ref.)
Long range interactions in vision [editorial] Levi DM. **Spat Vis** 1999;12(2):125–7 (19 ref.)
Functional architecture of long-range perceptual interactions. Polat U. **Spat Vis** 1999;12(2):143–62 (93 ref.)
Mechanisms for spatial integration in visual detection: a model based on lateral interactions. Usher M, et al. **Spat Vis** 1999;12(2):187–209 (37 ref.)
High spatial resolution functional magnetic resonance imaging at very-high-magnetic field. Chen W, et al. **Top Magn Reson Imaging** 1999 Feb;10(1):63–78 (111 ref.)
Imprinting, learning and development: from behaviour to brain and back. Bolhuis JJ, et al. **Trends Neurosci** 1998 Jul;21(7):306–11 (51 ref.)
Visual imprinting and the neural mechanisms of recognition memory. Horn G. **Trends Neurosci** 1998 Jul;21(7):300–5 (79 ref.)
Solutions for the binding problem. Roelfsema PR. **Z Naturforsch [C]** 1998 Jul-Aug;53(7–8):691–715 (138 ref.)
[Long-term potentiation in mammalian visual cortex] Sha Q, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct; 27(4):371–3 (9 ref.) **(Chi)**
[Contemporary knowledge on the subject of visual cortex structure and function] Czepita D. **Klin Oczna** 1998; 100(5):331–4 (15 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

From cortical plasticity to unawareness of visual field defects. Safran AB, et al. **J Neuroophthalmol** 1999 Jun;19(2):84–8 (31 ref.)

VISUAL EVOKED RESPONSE see **EVOKED POTENTIALS, VISUAL**

VISUAL FIELDS

see related
PERIMETRY

Perspectives of electrogastrography and motion sickness. Cheung B, et al. **Brain Res Bull** 1998 Nov 15;47(5):421–31 (44 ref.)
Psychophysical endpoints. Johnson CA. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S48–51 (10 ref.)
[Unilateral visual field defect due to optic nerve compression by sclerotic internal carotid artery: a case report] Uchino M, et al. **No Shinkei Geka** 1999 Feb;27(2):189–94 (8 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

[Amiodarone-induced bilateral optic atrophy—a case report] Gobbelé R, et al. **Nervenarzt** 1999 Jun;70(6):560–5 (39 ref.) (Eng. Abstr.) **(Ger)**
[Vigabatrin and alterations of the visual field] Argumosa A,

et al. **Rev Neurol** 1999 Apr 16-30;28(8):741-5 (36 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

From cortical plasticity to unawareness of visual field defects. Safran AB, et al. **J Neuroophthalmol** 1999 Jun;19(2):84-8 (31 ref.)

VISUAL MOTOR COORDINATION see **PSYCHOMOTOR PERFORMANCE**

VISUAL PATHWAYS

ANATOMY & HISTOLOGY

Functional magnetic resonance imaging in the visual system. McFadzean RM, et al. **J Neuroophthalmol** 1999 Sep; 19(3):186-200 (138 ref.)

Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Davis PC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):93-114 (80 ref.)

CYTOLOGY

Structure determines function of the retina, a neural center. 4. The 'duplex' nature of vision. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):463-74 (88 ref.)

GROWTH & DEVELOPMENT

Retinal waves and visual system development. Wong RO. **Annu Rev Neurosci** 1999;22:29-47 (121 ref.)

Nitric oxide as a signaling molecule in visual system development. Cramer KS, et al. **Prog Brain Res** 1998; 118:101-14 (109 ref.)

The role of nitric oxide in development of the patch-cluster system and retinocollicular pathways in the rodent superior colliculus. Mize RR, et al. **Prog Brain Res** 1998;118:133-52 (92 ref.)

PATHOLOGY

Neuro-ophthalmology of the pregeniculate afferent visual system: December, 1997-May, 1998 (Part I). Balcer LJ, et al. **J Neuroophthalmol** 1999 Mar;19(1):17-27 (46 ref.)

PHYSIOLOGY

Synchronous activity in the visual system. Usrey WM, et al. **Annu Rev Physiol** 1999;61:435-56 (131 ref.)

Efferent connections of the anteromedial nucleus of the thalamus of the rat. van Groen T, et al. **Brain Res Brain Res Rev** 1999 Jul;30(1):1-26 (200 ref.)

Temporal coding as a means of information transfer in the primate visual system. Gawne TJ. **Crit Rev Neurobiol** 1999; 13(1):83-101 (89 ref.)

Mechanisms of central color vision. Komatsu H. **Curr Opin Neurobiol** 1998 Aug;8(4):503-8 (58 ref.)

Object vision and visual awareness. Logothetis N. **Curr Opin Neurobiol** 1998 Aug;8(4):536-44 (67 ref.)

Parallel processing in the mammalian retina: the Proctor Lecture. Boycott B, et al. **Invest Ophthalmol Vis Sci** 1999 Jun;40(7):1313-27 (134 ref.)

Transcranial magnetic stimulation in study of the visual pathway. Amassian VE, et al. **J Clin Neurophysiol** 1998 Jul;15(4):288-304 (74 ref.)

Neuro-ophthalmology of the pregeniculate afferent visual system: Part II: June-December 1998. Balcer LJ, et al. **J Neuroophthalmol** 1999 Sep;19(3):207-16 (38 ref.)

Structure determines function of the retina, a neural center. 4. The 'duplex' nature of vision. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):463-74 (88 ref.)

Cellular mechanisms of visual cortical plasticity: a game of cat and mouse. Gordon JA. **Learn Mem** 1997 Sep-Oct; 4(3):245-61 (113 ref.)

Roger Sperry and his chemoaffinity hypothesis. Meyer RL. **Neuropsychologia** 1998 Oct;36(10):957-80 (166 ref.)

Brain waves and brain wiring: the role of endogenous and sensory-driven neural activity in development. Penn AA, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):447-58 (201 ref.)

Early integration of retinal and extra-retinal information: recent results and hypotheses. Sauvan XM. **Rev Neurosci** 1998;9(4):291-9 (35 ref.)

Functional architecture of long-range perceptual interactions. Polat U. **Spat Vis** 1999;12(2):143-62 (93 ref.)

High spatial resolution functional magnetic resonance imaging at very-high-magnetic field. Chen W, et al. **Top Magn Reson Imaging** 1999 Feb;10(1):63-78 (111 ref.)

Sight and insight--on the physiological role of nitric oxide in the visual system. Cudeiro J, et al. **Trends Neurosci** 1999 Mar;22(3):109-16 (104 ref.)

PHYSIOPATHOLOGY

Complex visual hallucinations. Clinical and neurobiological insights. Manford M, et al. **Brain** 1998 Oct;121 (Pt 10):1819-40 (192 ref.)

Backward masking in bipolar affective disorder. McClure RK. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Feb; 23(2):195-206 (13 ref.)

VISUAL PERCEPTION

Reduce risk of inducing spatial disorientation using physiologically compatible ground lighting. Schmidt RT. **Aviat Space Environ Med** 1999 Jun;70(6):598-603 (22 ref.)

Visual perception: mind and brain see eye to eye. Moore C, et al. **Curr Biol** 1999 Jan 28;9(2):R74-6 (8 ref.)

Subordinate-level object classification reexamined. Biederman I, et al. **Psychol Res** 1999;62(2-3):131-53 (79 ref.)

From objects to names: a cognitive neuroscience approach. Humphreys GW, et al. **Psychol Res** 1999;62(2-3):118-30 (56 ref.)

[Visual hallucinations in ophthalmological and neurological diseases] Kerty E. **Tidsskr Nor Laegeforen** 1998 Dec 10; 118(30):4738-41 (17 ref.) (Eng. Abstr.) **(Nor)**

CLASSIFICATION

Towards an analytic framework for the visuospatial domain: spatial reference frames, cognitive operations, and neural systems. Jagaroo V. **J Clin Exp Neuropsychol** 1999 Feb; 21(1):134-46 (89 ref.)

GENETICS

Functional diversity of the DNA photolyase/blue light receptor family. Todo T. **Mutat Res** 1999 Jun 23; 434(2):89-97 (50 ref.)

PHYSIOLOGY

The neuronal basis of visual memory and imagery in the primate: a neurophysiological approach. Nakahara K, et al. **Adv Biophys** 1998;35:103-19 (43 ref.)

The role of the otoliths in perception of the vertical and in path integration. Mittelstaedt H. **Ann N Y Acad Sci** 1999 May 28;871:334-44 (31 ref.)

High-level scene perception. Henderson JM, et al. **Annu Rev Psychol** 1999;50:243-71 (132 ref.)

Representation is representation of similarities. Edelman S. **Behav Brain Sci** 1998 Aug;21(4):449-67; discussion 467-98 (321 ref.)

Finding out about filling-in: a guide to perceptual completion for visual science and the philosophy of perception. Pessoa L, et al. **Behav Brain Sci** 1998 Dec;21(6):723-48; discussion 748-802 (314 ref.)

The effect of gravity on human recognition of disoriented objects. Leone G. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):203-14 (113 ref.)

On the neural correlates of visual perception. Pollen DA. **Cereb Cortex** 1999 Jan-Feb;9(1):4-19 (216 ref.)

From perception to action: temporal integrative functions of prefrontal and parietal neurons. Quintana J, et al. **Cereb Cortex** 1999 Apr-May;9(3):213-21 (52 ref.)

Detecting connectedness. Roelfsema PR, et al. **Cereb Cortex** 1998 Jul-Aug;8(5):385-96 (57 ref.)

Vision: modular analysis--or not? Burr D. **Curr Biol** 1999 Feb 11;9(3):R90-2 (12 ref.)

Active vision: visual activity in everyday life. Findlay J. **Curr Biol** 1998 Sep 10;8(18):R640-2 (12 ref.)

Visual perception: here's mud in your mind's eye. Snowden RJ. **Curr Biol** 1999 May 6;9(9):R336-7 (11 ref.)

The cognitive neuroscience of visual attention. Behrmann M, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):158-63 (58 ref.)

Encoding of motion in real time by the fly visual system. Egelhaaf M, et al. **Curr Opin Neurobiol** 1999 Aug; 9(4):454-60 (65 ref.)

Linking visual perception with human brain activity. Heeger DJ. **Curr Opin Neurobiol** 1999 Aug;9(4):474-9 (66 ref.)

Feedforward, horizontal, and feedback processing in the visual cortex. Lamme VA, et al. **Curr Opin Neurobiol** 1998 Aug;8(4):529-35 (83 ref.)

Visual size processing in spatial neglect. Milner AD, et al. **Exp Brain Res** 1998 Nov;123(1-2):192-200 (41 ref.)

Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1-2):90-4 (43 ref.)

Alpha-band oscillations in visual cortex: part of the neural correlate of visual awareness? Sewards TV, et al. **Int J Psychophysiol** 1999 Apr;32(1):35-45 (63 ref.)

Emotion and motivation: measuring affective perception. Lang PJ, et al. **J Clin Neurophysiol** 1998 Sep;15(5):397-408 (78 ref.)

Vision for perception and vision for action in the primate brain. Goodale MA. **Novartis Found Symp** 1998;218:21-34; discussion 34-9 (47 ref.)

How do visual instructions influence the motor system? Passingham RE, et al. **Novartis Found Symp** 1998; 218:129-41; discussion 141-6 (52 ref.)

Single units and visual cortical organization. Lennie P. **Perception** 1998;27(8):889-935 (315 ref.)

Single units and conscious vision. Logothetis NK. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1801-18 (163 ref.)

The autonomy of the visual systems and the modularity of conscious vision. Zeki S, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1911-4 (43 ref.)

More than one way to see it move? [comment] Albright TD. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7611-3 (36 ref.) Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8289-94.

The theory of multistage integration in the visual brain. Bartels A, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2327-32 (55 ref.)

Serial attention mechanisms in visual search: a critical look at the evidence. Chelazzi L. **Psychol Res** 1999; 62(2-3):195-219 (39 ref.)

Visual and mental exploration of visuo-spatial configurations: behavioral and neuroimaging approaches. Cocude M, et al. **Psychol Res** 1999;62(2-3):93-106 (57 ref.)

The psychophysics of perceptual memory. Magnussen S, et al. **Psychol Res** 1999;62(2-3):81-92 (74 ref.)

Visual-spatial working memory, attention, and scene representation: a neuro-cognitive theory. Schneider WX. **Psychol Res** 1999;62(2-3):220-36 (106 ref.)

Early integration of retinal and extra-retinal information: recent results and hypotheses. Sauvan XM. **Rev Neurosci** 1998;9(4):291-9 (35 ref.)

Speechreading: advances in understanding its cortical bases and implications for deafness and speech rehabilitation. Campbell R. **Scand Audiol Suppl** 1998;49:80-6 (31 ref.)

How does the cerebral cortex work? Learning, attention, and grouping by the laminar circuits of visual cortex. Grossberg S. **Spat Vis** 1999;12(2):163-85 (105 ref.)

Long range interactions in vision [editorial] Levi DM. **Spat Vis** 1999;12(2):125-7 (19 ref.)

Functional architecture of long-range perceptual interactions. Polat U. **Spat Vis** 1999;12(2):143-62 (93 ref.)

Evidence for multi-functional interactions in early visual motion processing. Giese MA. **Trends Neurosci** 1999 Jul; 22(7):287-90 (35 ref.)

Active sensing--closing multiple loops. König P, et al. **Z Naturforsch [C]** 1998 Jul-Aug;53(7-8):542-9 (62 ref.)

Solutions for the binding problem. Roelfsema PR. **Z Naturforsch [C]** 1998 Jul-Aug;53(7-8):691-715 (138 ref.)

[Role of the right and left cerebral hemispheres in space perception. I. Object perception and reflection in the frontal plane] Nikolaenko NN, et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):54-64 (38 ref.) **(Rus)**

[Visual suppression during eye movements (a brief review on the problem of the mechanisms and their role in visual perception). I. A brief review and the mechanisms] Baziian BKh. **Usp Fiziol Nauk** 1999 Apr-Jun;30(2):63-73 (97 ref.) (Eng. Abstr.) **(Rus)**

[Visual suppression during eye movements (a brief review on the problem of the mechanisms and their role in visual perception). II. Their role in visual perception] Baziian BKh. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):3-13 (47 ref.) (Eng. Abstr.) **(Rus)**

VISUAL PIGMENTS see **RETINAL PIGMENTS**

VISUAL PURPLE see **RHODOPSIN**

VISUAL STIMULATION see **PHOTIC STIMULATION**

VISUAL TRANSDUCTION see **PHOTOTRANSDUCTION**

VISUALLY IMPAIRED PERSONS

see related
BLINDNESS

VITAL CAPACITY, TIMED see **FORCED EXPIRATORY VOLUME**

VITAMIN A

Optimal nutrition: vitamin A and the carotenoids. Thurnham DI, et al. **Proc Nutr Soc** 1999 May;58(2):449-57 (64 ref.)

ADMINISTRATION & DOSAGE

Safety of vitamin A: recent results. Wiegand UW, et al. **Int J Vitam Nutr Res** 1998;68(6):411-6 (15 ref.)

Vitamin A and zinc supplementation of preschool children. Smith JC, et al. **J Am Coll Nutr** 1999 Jun;18(3):213-22 (54 ref.)

Requirements of fat-soluble vitamins for dairy cows: a review. Weiss WP. **J Dairy Sci** 1998 Sep;81(9):2493-501 (67 ref.)

Excess retinol intake may explain the high incidence of osteoporosis in northern Europe. Whiting SJ, et al. **Nutr Rev** 1999 Jun;57(6):192-5 (27 ref.)

[Correlation between dietary vitamin A consumption and onset of precancerous lesions in the oral cavity] Cianfriglia F, et al. **Minerva Stomatol** 1998 Jul-Aug;47(7-8):325-43 (32 ref.) (Eng. Abstr.) **(Ita)**

[The AD-drops can be replaced by D-drops] Axelsson I, et al. **Lakartidningen** 1999 May 5;96(18):2200-4 (33 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Leo MA, et al. **Am J Clin Nutr** 1999 Jun;69(6):1071-85 (208 ref.)

Dietary vitamin A and teratogenic risk: European Teratology Society discussion paper. Dolk HM, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):31-6 (52 ref.)

Safety of vitamin A: recent results. Wiegand UW, et al. **Int J Vitam Nutr Res** 1998;68(6):411-6 (15 ref.)

Excess retinol intake may explain the high incidence of osteoporosis in northern Europe. Whiting SJ, et al. **Nutr Rev** 1999 Jun;57(6):192-5 (27 ref.)

VITAMIN A

ANALOGS & DERIVATIVES

Plant sources of vitamin A and human nutrition: red palm oil does the job. Solomons NW. **Nutr Rev** 1998 Oct; 56(10):309–11 (12 ref.)

BLOOD

Vitamin A and zinc supplementation of preschool children. Smith JC, et al. **J Am Coll Nutr** 1999 Jun;18(3):213–22 (54 ref.)

Vitamin A and the acute-phase response [editorial] Filteau SM. **Nutrition** 1999 Apr;15(4):326–8 (34 ref.)

Plasma vitamins A and E in HIV-positive patients. Constans J, et al. **Subcell Biochem** 1998;30:145–55 (49 ref.)

HISTORY

Vitamin A as "anti-infective" therapy, 1920–1940. Semba RD. **J Nutr** 1999 Apr;129(4):783–91 (97 ref.)

METABOLISM

Role of vitamin A in the formation of congenital heart defects. Sinning AR. **Anat Rec** 1998 Oct;253(5):147–53 (42 ref.)

Quantification of the "SLAMENGHI" factors for carotenoid bioavailability and bioconversion. West CE, et al. **Int J Vitam Nutr Res** 1998;68(6):371–7 (45 ref.)

Chronic alcohol intake interferes with retinoid metabolism and signaling. Wang XD. **Nutr Rev** 1999 Feb;57(2):51–9 (68 ref.)

PHARMACOLOGY

Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Palace VP, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):746–61 (158 ref.)

Modulation of genotoxic and related effects by carotenoids and vitamin A in experimental models: mechanistic issues. De Flora S, et al. **Mutagenesis** 1999 Mar;14(2):153–72 (146 ref.)

Antioxidant activity of vitamin A within lipid environments. Livrea MA, et al. **Subcell Biochem** 1998;30:113–43 (112 ref.)

PHYSIOLOGY

Vertebrate development: a nervous vitamin. Maden M. **Curr Biol** 1998 Nov 19;8(23):R846–9 (11 ref.)

Role of retinoids in renal development: pathophysiological implication. Merlet-Bénichou C, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):39–43 (41 ref.)

Retinoids and adipose tissues: metabolism, cell differentiation and gene expression. Villarroya F, et al. **Int J Obes Relat Metab Disord** 1999 Jan;23(1):1–6 (47 ref.)

Photoreceptor "retinoid pumps" in health and disease. Bok D. **Neuron** 1999 Jul;23(3):412–4 (11 ref.)

Vitamin A functions in the regulation of the dopaminergic system in the brain and pituitary gland. Wolf G. **Nutr Rev** 1998 Dec;56(12):354–5 (12 ref.)

The effect of vitamin A on epithelial integrity. McCullough FS, et al. **Proc Nutr Soc** 1999 May;58(2):289–93 (37 ref.)

Vitamins and arthritis. The roles of vitamins A, C, D, and E. Sowers M, et al. **Rheum Dis Clin North Am** 1999 May; 25(2):315–32 (79 ref.)

[Molecular mechanisms of fat-soluble vitamins: vitamin receptor knockout mice] Kato S. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1321–35 (74 ref.) **(Jpn)**

[Dietary iron absorption. Role of vitamin A] García-Casal MN, et al. **Arch Latinoam Nutr** 1998 Sep;48(3):191–6 (65 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Palace VP, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):746–61 (158 ref.)

VITAMIN A ACID see **TRETINOIN**

VITAMIN A ALDEHYDE see **RETINALDEHYDE**

VITAMIN A DEFICIENCY

see related
NIGHT BLINDNESS

COMPLICATIONS

The interaction of ethanol and vitamin A as a potential mechanism for the pathogenesis of Fetal Alcohol syndrome. Zachman RD, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1544–56 (127 ref.)

The effect of vitamin A on epithelial integrity. McCullough FS, et al. **Proc Nutr Soc** 1999 May;58(2):289–93 (37 ref.)

[Ocular manifestations of vitamin A deficiency and their prevention] Maurin JF, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1997;74:21–42 (0 ref.) **(Fre)**

DIET THERAPY

Plant sources of vitamin A and human nutrition: red palm oil does the job. Solomons NW. **Nutr Rev** 1998 Oct; 56(10):309–11 (12 ref.)

EPIDEMIOLOGY

Vitamin A deficiency in Latin America and the Caribbean: an overview. Mora JO, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):178–86 (51 ref.)

PREVENTION & CONTROL

Vitamin A deficiency in Bangladesh: a review and recommendations for improvement. Ahmed F. **Public Health Nutr** 1999 Mar;2(1):1–14 (58 ref.)

VITAMIN B 1 see **THIAMINE**

VITAMIN B 2 see **RIBOFLAVIN**

VITAMIN B4 see **ADENINE**

VITAMIN B 6 see **PYRIDOXINE**

VITAMIN B 12

Folate and vitamin B12. Scott JM. **Proc Nutr Soc** 1999 May; 58(2):441–8 (22 ref.)

ADMINISTRATION & DOSAGE

Practitioners' guide to meeting the vitamin B-12 recommended dietary allowance for people aged 51 years and older. Ho C, et al. **J Am Diet Assoc** 1999 Jun; 99(6):725–7 (24 ref.)

ANALOGS & DERIVATIVES

Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing. Bauer JA. **Med Hypotheses** 1998 Jul;51(1):65–7 (20 ref.)

METABOLISM

Receptor-mediated endocytosis of cobalamin (vitamin B12). Seetharam B. **Annu Rev Nutr** 1999;19:173–95 (93 ref.)

Use of vitamin B12 conjugates to deliver protein drugs by the oral route. Russell-Jones GJ. **Crit Rev Ther Drug Carrier Syst** 1998;15(6):557–86 (73 ref.)

Cobalamin metabolism in chronic myelogenous leukemia. Gimsing P. **Dan Med Bull** 1998 Nov;45(5):459–79 (289 ref.)

Ethnic and racial factors in cobalamin metabolism and its disorders. Carmel R. **Semin Hematol** 1999 Jan;36(1):88–100 (103 ref.)

PHYSIOLOGY

B vitamins and homocysteine in cardiovascular disease and aging. Wilcken DE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:361–70 (29 ref.)

THERAPEUTIC USE

Vitamin B12 deficiency in older people: improving diagnosis and preventing disability [editorial; comment] Stabler SP. **J Am Geriatr Soc** 1998 Oct;46(10):1317–9 (21 ref.) Comment on: J Am Geriatr Soc 1998 Oct;46(10):1199–206.

Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing. Bauer JA. **Med Hypotheses** 1998 Jul;51(1):65–7 (20 ref.)

VITAMIN B 12-BINDING PROTEINS see **TRANSCOBALAMINS**

VITAMIN B 12 COENZYMES see **COBAMIDES**

VITAMIN B 12 DEFICIENCY

Ethnic and racial factors in cobalamin metabolism and its disorders. Carmel R. **Semin Hematol** 1999 Jan;36(1):88–100 (103 ref.)

CHEMICALLY INDUCED

Omeprazole and vitamin B12 deficiency. Bradford GS, et al. **Ann Pharmacother** 1999 May;33(5):641–3 (12 ref.)

COMPLICATIONS

MR1 of the spinal cord in myelopathy complicating vitamin B12 deficiency: two additional cases and a review of the literature. Bassi SS, et al. **Neuroradiology** 1999 Apr; 41(4):271–4 (17 ref.)

The danger of B12 deficiency in the elderly. Wynn M, et al. **Nutr Health** 1998;12(4):215–26 (45 ref.)

Cobalamin deficiency in patients infected with the human immunodeficiency virus. Remacha AF, et al. **Semin Hematol** 1999 Jan;36(1):75–87 (110 ref.)

[Neurological disorders of vitamin B12 deficiency] Tomczykiewicz K, et al. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1473–84 (20 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Snow CF. **Arch Intern Med** 1999 Jun 28;159(12):1289–98 (59 ref.)

Vitamin B12 deficiency in older people: improving diagnosis and preventing disability [editorial; comment] Stabler SP. **J Am Geriatr Soc** 1998 Oct;46(10):1317–9 (21 ref.) Comment on: J Am Geriatr Soc 1998 Oct;46(10):1199–206.

Modern clinical testing strategies in cobalamin and folate deficiency. Zittoun J, et al. **Semin Hematol** 1999 Jan; 36(1):35–46 (80 ref.)

[Diagnosis of vitamin B12 deficiency: only apparently child's play] Bächli E, et al. **Schweiz Med Wochenschr** 1999 Jun 12;129(23):861–72 (79 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Ambulatory management of common forms of anemia. Little DR. **Am Fam Physician** 1999 Mar 15;59(6):1598–604 (38 ref.)

EPIDEMIOLOGY

Vitamin B12 deficiency in the elderly. Baik HW, et al. **Annu Rev Nutr** 1999;19:357–77 (149 ref.)

The danger of B12 deficiency in the elderly. Wynn M, et al. **Nutr Health** 1998;12(4):215–26 (45 ref.)

ETIOLOGY

Cobalamin and folate deficiency: acquired and hereditary disorders in children. Rosenblatt DS, et al. **Semin Hematol** 1999 Jan;36(1):19–34 (78 ref.)

PREVENTION & CONTROL

Practitioners' guide to meeting the vitamin B-12 recommended dietary allowance for people aged 51 years and older. Ho C, et al. **J Am Diet Assoc** 1999 Jun; 99(6):725–7 (24 ref.)

VITAMIN B COMPLEX

BLOOD

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence [see comments] Eikelboom JW, et al. **Ann Intern Med** 1999 Sep 7;131(5):363–75 (95 ref.) Comment in: Ann Intern Med 1999 Sep 7;131(5):387–8.

VITAMIN B DEFICIENCY

COMPLICATIONS

B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Cook CC, et al. **Alcohol Alcohol** 1998 Jul-Aug;33(4):317–36 (127 ref.)

THERAPY

B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Cook CC, et al. **Alcohol Alcohol** 1998 Jul-Aug;33(4):317–36 (127 ref.)

VITAMIN B T see **CARNITINE**

VITAMIN C see **ASCORBIC ACID**

VITAMIN C DEFICIENCY see **ASCORBIC ACID DEFICIENCY**

VITAMIN D

see related
RECEPTORS, CALCITRIOL

Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis [see comments] Giovannucci E. **Cancer Causes Control** 1998 Dec;9(6):567–82 (122 ref.) Comment in: Cancer Causes Control 1998 Dec;9(6):541–3.

ADMINISTRATION & DOSAGE

Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety [see comments] Vieth R. **Am J Clin Nutr** 1999 May;69(5):842–56 (135 ref.) Comment in: Am J Clin Nutr 1999 May;69(5):825–6.

Iatrogenic vitamin D intoxication: report of a case and review of vitamin D physiology. Lee KW, et al. **Conn Med** 1999 Jul;63(7):399–403 (24 ref.)

Vitamin D and prostate cancer risk. Peehl DM. **Eur Urol** 1999;35(5–6):392–4 (22 ref.)

Requirements of fat-soluble vitamins for dairy cows: a review. Weiss WP. **J Dairy Sci** 1998 Sep;81(9):2493–501 (67 ref.)

Vitamin D and calcium: recommended intake for bone health. Dawson-Hughes B. **Osteoporos Int** 1998;8 Suppl 2:S30–4 (35 ref.)

[The AD-drops can be replaced by D-drops] Axelsson I, et al. **Lakartidningen** 1999 May 5;96(18):2200–4 (33 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Iatrogenic vitamin D intoxication: report of a case and review of vitamin D physiology. Lee KW, et al. **Conn Med** 1999 Jul;63(7):399–403 (24 ref.)

Vitamin D and prostate cancer. Blutt SE, et al. **Proc Soc Exp Biol Med** 1999 Jun;221(2):89–98 (143 ref.)

ANALOGS & DERIVATIVES

Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety [see comments] Vieth R.

Am J Clin Nutr 1999 May;69(5):842–56 (135 ref.) Comment in: Am J Clin Nutr 1999 May;69(5):825–6.
Vitamin D analogues. Brown AJ. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S25–39 (106 ref.)
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis [see comments] Giovannucci E. **Cancer Causes Control** 1998 Dec;9(6):567–82 (122 ref.) Comment in: Cancer Causes Control 1998 Dec;9(6):541–3.
Recent developments in the use of vitamin D analogues. Verstuyf A, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):397–403 (70 ref.)

METABOLISM

Vitamin D resistance. Malloy PJ, et al. **Am J Med** 1999 Mar; 106(3):355–70 (107 ref.)
Vitamin D and the parathyroid. Beckerman P, et al. **Am J Med Sci** 1999 Jun;317(6):363–9 (75 ref.)
Nongenomic signaling by vitamin D: a new face of Src. Gniadecki R. **Biochem Pharmacol** 1998 Nov 15; 56(10):1273–7 (27 ref.)
Targeted inactivation of vitamin D hydroxylases in mice. St-Arnaud R. **Bone** 1999 Jul;25(1):127–9 (21 ref.)
Genetic causes of rickets. Miller WL, et al. **Curr Opin Pediatr** 1999 Aug;11(4):333–9 (40 ref.)
Vitamin D metabolism and action. Bouillon R, et al. **Osteoporos Int** 1998;8 Suppl 2:S13–9 (32 ref.)
[Role of phosphate, vitamin D and acidosis in the secretion and synthesis of parathyroid hormone at the cellular level] Fournier A, et al. **Presse Med** 1998 Sep 12;27(26):1349–54 (59 ref.) **(Fre)**

PHARMACOLOGY

Gene regulation by extracellular calcium, vitamin D and osmolarity. Okazaki T. **Endocr J** 1999 Feb;46(1):1–9 (53 ref.)
Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. James SY, et al. **Gen Pharmacol** 1999 Jan;32(1):143–54 (174 ref.)

PHYSIOLOGY

Mechanism of vitamin D action and its regulation. Dusso AS, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S13–24 (106 ref.)
Vitamin D. Brown AJ, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):F157–75 (197 ref.)
The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Amin S, et al. **Arthritis Rheum** 1999 Aug;42(8):1740–51 (67 ref.)
Vitamin D and retinoids in parathyroid glands (review). Hellman P, et al. **Int J Mol Med** 1999 Apr;3(4):355–61 (79 ref.)
Is vitamin D redundant in an aquatic habitat? Rao DS, et al. **J Nutr Sci Vitaminol (Tokyo)** 1999 Jan;45(1):1–8 (25 ref.)
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Rostand SG, et al. **Kidney Int** 1999 Aug;56(2):383–92 (124 ref.)
Vitamin D and serotonin in winter. Partonen T. **Med Hypotheses** 1998 Sep;51(3):267–8 (4 ref.)
Molecular mechanisms of vitamin D hyporesponsiveness in renal failure [editorial] Vanholder R, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):16–9 (23 ref.)
Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Holick MF. **Osteoporos Int** 1998;8 Suppl 2:S24–9 (54 ref.)
Current understanding of the molecular actions of vitamin D. Jones G, et al. **Physiol Rev** 1998 Oct;78(4):1193–231 (368 ref.)
Vitamins and arthritis. The roles of vitamins A, C, D, and E. Sowers M, et al. **Rheum Dis Clin North Am** 1999 May; 25(2):315–32 (79 ref.)
[Molecular mechanisms of fat-soluble vitamins: vitamin receptor knockout mice] Kato S. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1321–35 (74 ref.) **(Jpn)**

STANDARDS

Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety [see comments] Vieth R. **Am J Clin Nutr** 1999 May;69(5):842–56 (135 ref.) Comment in: Am J Clin Nutr 1999 May;69(5):825–6.

THERAPEUTIC USE

Vitamin D analogues. Brown AJ. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S25–39 (106 ref.)
Vitamin D and its metabolites in the treatment of osteoporosis. Burckhardt P, et al. **Osteoporos Int** 1998;8 Suppl 2:S40–4 (53 ref.)
Vitamin D in the prevention and treatment of prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1999 May;17(2):77–84 (51 ref.)

VITAMIN D 2 see **ERGOCALCIFEROLS**

VITAMIN D 3 see **CHOLECALCIFEROL**

VITAMIN D 3 RECEPTORS see **RECEPTORS, CALCITRIOL**

VITAMIN D DEFICIENCY

see related
RICKETS
Importance of vitamin D repletion in uraemia [editorial; comment] Fournier A, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):819–23 (43 ref.) Comment on: Nephrol Dial Transplant 1997 Jan;12(1):16–8.
Vitamin D deficiency and osteopathies. Ringe JD. **Osteoporos Int** 1998;8 Suppl 2:S35–9 (26 ref.)

COMPLICATIONS

Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. McKenna MJ, et al. **Osteoporos Int** 1998;8 Suppl 2:S3–6 (38 ref.)
Effects of calcium and vitamin D insufficiency on the skeleton. Peacock M. **Osteoporos Int** 1998;8 Suppl 2:S45–51 (93 ref.)

DIAGNOSIS

[Disease caused by lack of sunlight: rickets and osteomalacia] Wauters IM, et al. **Ned Tijdschr Geneeskd** 1999 Mar 20; 143(12):593–7 (22 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Vitamin D and its metabolites in the treatment of osteoporosis. Burckhardt P, et al. **Osteoporos Int** 1998;8 Suppl 2:S40–4 (53 ref.)

EPIDEMIOLOGY

Vitamin D deficiency rickets in developing countries. Karrar ZA. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S89–92 (36 ref.)
Prevalence of subclinical vitamin D deficiency in different European countries. Scharla SH. **Osteoporos Int** 1998;8 Suppl 2:S7–12 (30 ref.)
Seasonal variations in vitamin-D status and the incidence of tuberculosis in different countries [letter] Chan TY. **Respiration** 1999;66(2):196 (6 ref.)

ETIOLOGY

[Vitamin D receptor and its abnormality in human diseases] Ozono K. **Nippon Rinsho** 1998 Jul;56(7):1892–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[1,25(OH)2-vitamin D3. The vitamin D hormone] Jakob F. **Internist (Berl)** 1999 Apr;40(4):W414–30 (23 ref.) **(Ger)**

VITAMIN D-DEPENDENT CALCIUM-BINDING PROTEIN see **CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT**

VITAMIN D RECEPTORS see **RECEPTORS, CALCITRIOL**

VITAMIN DEFICIENCY see **AVITAMINOSIS**

VITAMIN E

Optimal nutrition: vitamin E. Morrissey PA, et al. **Proc Nutr Soc** 1999 May;58(2):459–68 (89 ref.)
[Carotenoids: 2. Diseases and supplementation studies] Faure H, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):273–82 (77 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: emphasison vitamin C, vitamin E, and beta-carotene: A statement for healthcare professionals from the American Heart Association. Tribble DL. **Circulation** 1999 Feb 2;99(4):591–5 (42 ref.)
Requirements of fat-soluble vitamins for dairy cows: a review. Weiss WP. **J Dairy Sci** 1998 Sep;81(9):2493–501 (67 ref.)
[Vitamin E is beneficial for the immune system in the elderly] Landmark K. **Tidsskr Nor Laegeforen** 1998 Nov 20; 118(28):4403–4 (36 ref.) **(Nor)**

ANALOGS & DERIVATIVES

A function for the vitamin E metabolite alpha-tocopherol quinone as an essential enzyme cofactor for the mitochondrial fatty acid desaturases. Infante JP. **FEBS Lett** 1999 Mar 5;446(1):1–5 (73 ref.)

BIOSYNTHESIS

Production of high-value compounds: carotenoids and vitamin E. Hirschberg J. **Curr Opin Biotechnol** 1999 Apr; 10(2):186–91 (48 ref.)

BLOOD

Evaluating serum alpha-tocopherol (vitamin E) in terms of a lipid ratio. Winbauer AN, et al. **Ann Clin Lab Sci** 1999 Jul-Sep;29(3):185–91 (16 ref.)
Plasma vitamins A and E in HIV-positive patients. Constans J, et al. **Subcell Biochem** 1998;30:145–55 (49 ref.)

CHEMISTRY

The role of tocopherols in biomembrane lipid peroxidation. Burlakova EB, et al. **Membr Cell Biol** 1998;12(2):173–211 (204 ref.)
Products from reaction of peroxynitrite with gamma-tocopherol. Hoglen NC, et al. **Methods Enzymol** 1999;301:483–90 (23 ref.)
Antioxidant chemistry of alpha-tocopherol in biological systems. Roles of redox cycles and metabolism. Liebler DC. **Subcell Biochem** 1998;30:301–17 (63 ref.)

METABOLISM

Recycling and redox cycling of phenolic antioxidants. Kagan VE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:425–34 (27 ref.)
Molecular mechanisms of vitamin E transport. Traber MG, et al. **Annu Rev Nutr** 1999;19:343–55 (45 ref.)
Cytochrome b5 and tocopherol provide functions of lipid-radical cycles and energy conversion in membranes. Dmitriev LF. **Biochemistry (Mosc)** 1998 Oct;63(10):1233–6 (22 ref.)
Vitamin E and vascular homeostasis: implications for atherosclerosis. Keaney JF Jr, et al. **FASEB J** 1999 Jun; 13(9):965–75 (125 ref.)
Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Upston JM, et al. **FASEB J** 1999 Jun; 13(9):977–94 (151 ref.)
Vitamin C and E as antioxidants in hemodialysis patients. Hegbrant J, et al. **Int J Artif Organs** 1999 Feb;22(2):69–73 (70 ref.)
The role of tocopherols in biomembrane lipid peroxidation. Burlakova EB, et al. **Membr Cell Biol** 1998;12(2):173–211 (204 ref.)
Role of coenzyme Q and superoxide in vitamin E cycling. Kagan VE, et al. **Subcell Biochem** 1998;30:491–507 (77 ref.)
Antioxidant chemistry of alpha-tocopherol in biological systems. Roles of redox cycles and metabolism. Liebler DC. **Subcell Biochem** 1998;30:301–17 (63 ref.)
Localization of vitamin E in membranes. Quinn PJ. **Subcell Biochem** 1998;30:319–43 (72 ref.)
Vitamin E. Its role in aging. Urano S. **Subcell Biochem** 1998; 30:391–412 (89 ref.)

PHARMACOLOGY

Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitrone and vitamin E. Butterfield DA, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:448–62 (61 ref.)
Dynamics of vitamin E action against LDL oxidation. Noguchi N, et al. **Free Radic Res** 1998 Jun;28(6):561–72 (77 ref.)
Vitamin E: focus on microcirculation. Lehr HA, et al. **Microcirculation** 1998;5(2-3):117–28 (140 ref.)
The molecular action of alpha-tocopherol in lipoprotein lipid peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions. Witting PK, et al. **Subcell Biochem** 1998;30:345–90 (145 ref.)
[Modification of nitrate tolerance using antioxidants] Nickenig G, et al. **Dtsch Med Wochenschr** 1998 Dec 18; 123(51-52):1556–61 (46 ref.) **(Ger)**

PHYSIOLOGY

Vitamin E: function and metabolism. Brigelius-Flohé R, et al. **FASEB J** 1999 Jul;13(10):1145–55 (112 ref.)
Dynamics of vitamin E action against LDL oxidation. Noguchi N, et al. **Free Radic Res** 1998 Jun;28(6):561–72 (77 ref.)
The role of vitamin E in T-cell differentiation and the decrease of cellular immunity with aging. Moriguchi S, et al. **J Med Invest** 1998 Aug;45(1-4):1–8 (35 ref.)
Vitamin E and atherosclerosis. Chan AC. **J Nutr** 1998 Oct; 128(10):1593–6 (56 ref.)
Vitamin E as a universal antioxidant and stabilizer of biological membranes. Evstigneeva RP, et al. **Membr Cell Biol** 1998;12(2):151–72 (150 ref.)
Vitamins and arthritis. The roles of vitamins A, C, D, and E. Sowers M, et al. **Rheum Dis Clin North Am** 1999 May; 25(2):315–32 (79 ref.)
The ambivalence of vitamin E in atherogenesis. Stocker R. **Trends Biochem Sci** 1999 Jun;24(6):219–23 (40 ref.)

THERAPEUTIC USE

Vitamin E and heart disease: a case study. Kushi LH. **Am J Clin Nutr** 1999 Jun;69(6):1322S–1329S (38 ref.)
Antioxidant vitamins and cardiovascular disease: Dr Jekyll or Mr Hyde? [editorial] Hercberg S, et al. **Am J Public Health** 1999 Mar;89(3):289–91 (14 ref.)
Vitamin E and coronary artery disease [see comments] Spencer AP, et al. **Arch Intern Med** 1999 Jun 28; 159(12):1313–20 (44 ref.) Comment in: Arch Intern Med 1999 Jun 28;159(12):1279–80.
Is the placebo control obsolete in a world after donepezil and vitamin E? [see comments] Karlawish JH, et al. **Arch Neurol** 1998 Nov;55(11):1420–4 (35 ref.) Comment in: Arch Neurol 1998 Nov;55(11):1396–8.
alpha-Tocopherol in atherogenesis: do we know its real role? [editorial] Neuzil J, et al. **Cardiovasc Drugs Ther** 1998 Oct; 12(5):421–3 (31 ref.)

VITAMIN E

Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Upston JM, et al. **FASEB J** 1999 Jun; 13(9):977–94 (151 ref.)

Potentials and limitations of the natural antioxidants RRR-alpha-tocopherol, L-ascorbic acid and beta-carotene in cutaneous photoprotection. Fuchs J. **Free Radic Biol Med** 1998 Nov 1;25(7):848–73 (380 ref.)

Vitamin E in diabetes. Increased oxidative stress and its prevention as a strategy to prevent vascular complications? Rösen P, et al. **Int J Vitam Nutr Res** 1999 May;69(3):206–12 (62 ref.)

Vitamin E and atherosclerosis. Chan AC. **J Nutr** 1998 Oct; 128(10):1593–6 (56 ref.)

Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Rösen P, et al. **Mol Cell Biochem** 1998 Nov;188(1–2):103–11 (64 ref.)

Vitamin E: blocking the beginnings of atherosclerosis? Ivanov E. **Mol Med Today** 1999 Jan;5(1):8 (1 ref.)

Vitamin E may slow kidney failure owing to oxidative stress. Fryer MJ. **Redox Rep** 1997 Oct-Dec;3(5–6):259–61 (32 ref.)

Vitamin E, alpha- and gamma-tocopherol, and prostate cancer. Moyad MA, et al. **Semin Urol Oncol** 1999 May; 17(2):85–90 (74 ref.)

[Vitamin E in therapy of rheumatic diseases (see comments)] Sangha O, et al. **Z Rheumatol** 1998 Aug;57(4):207–14 (63 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1998 Aug;57(4):203–6. **(Ger)**

VITAMIN E DEFICIENCY

COMPLICATIONS

[Ataxia with isolated vitamin E deficiency] Saito Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):218–20 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Electrophysiologic recovery after vitamin E-deficient neuropathy. Ko HY, et al. **Arch Phys Med Rehabil** 1999 Aug;80(8):964–7 (28 ref.)

Vitamin E may slow kidney failure owing to oxidative stress. Fryer MJ. **Redox Rep** 1997 Oct-Dec;3(5–6):259–61 (32 ref.)

VITAMIN G see **RIBOFLAVIN**

VITAMIN H see **BIOTIN**

VITAMIN K

[Vitamin K: biochemistry, function, and deficiency. Review] Mijares ME, et al. **Invest Clin** 1998 Sep;39(3):213–29 (85 ref.) (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

[Heparins, antivitamins K. Principles and rules for their use. Dosage of non-fractionated heparins] Sié P. **Rev Prat** 1998 Jun 15;48(12):1361–5 (3 ref.) **(Fre)**

METABOLISM

Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Stenflo J. **Crit Rev Eukaryot Gene Expr** 1999;9(1):59–88 (231 ref.)

Vitamin K metabolism. Newman P, et al. **Subcell Biochem** 1998;30:455–88 (140 ref.)

Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Lian JB, et al. **Vitam Horm** 1999;55:443–509 (261 ref.)

PHARMACOLOGY

Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Furie B, et al. **Blood** 1999 Mar 15;93(6):1798–808 (82 ref.)

PHYSIOLOGY

Blood coagulation. Mann KG. **Alcohol Clin Exp Res** 1999 Jun;23(6):1111–3 (11 ref.)

THERAPEUTIC USE

Respiratory chain complex in deficiency with pruritus: a novel vitamin responsive clinical feature. Mowat D, et al. **J Pediatr** 1999 Mar;134(3):352–4 (13 ref.)

VITAMIN K 1 see **PHYTONADIONE**

VITAMIN K DEFICIENCY

[Bleeding due to vitamin K deficiency] Ootsuka H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):525–8 (10 ref.) **(Jpn)**

[Idiopathic vitamin K deficiency in infancy] Shirahata A. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):521–4 (9 ref.) **(Jpn)**

[Vitamin K: biochemistry, function, and deficiency. Review] Mijares ME, et al. **Invest Clin** 1998 Sep;39(3):213–29 (85 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Prevention of vitamin K deficiency bleeding in newborns. Zipursky A. **Br J Haematol** 1999 Mar;104(3):430–7 (58 ref.)

Oral versus intramuscular phytomenadione: safety and efficacy compared. von Kries R. **Drug Saf** 1999 Jul; 21(1):1–6 (33 ref.)

VITAMIN K-DEPENDENT BONE PROTEIN see **OSTEOCALCIN**

VITAMIN K-DEPENDENT PROTEIN S see **PROTEIN S**

VITAMIN K REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

VITAMIN M see **FOLIC ACID**

VITAMIN P COMPLEX see **BIOFLAVONOIDS**

VITAMIN PP see **NIACINAMIDE**

VITAMINS

Red wine, green tea and vitamins: do their antioxidants play a role in immunologic protection against cancer or even AIDS? [editorial] Mathé G. **Biomed Pharmacother** 1999 May;53(4):165–7 (19 ref.)

Can antioxidant vitamins maternally reduce oxidative damage in humans? McCall MR, et al. **Free Radic Biol Med** 1999 Apr;26(7–8):1034–53 (92 ref.)

Toward a new definition of essential nutrients: is it now time for a third 'vitamin' paradigm? Challem JJ. **Med Hypotheses** 1999 May;52(5):417–22 (48 ref.)

Vitamins and lung cancer. Virtamo J. **Proc Nutr Soc** 1999 May;58(2):329–33 (41 ref.)

Micronutrients, vitamins, and cancer risk. Schorah CJ. **Vitam Horm** 1999;57:1–23 (131 ref.)

ADMINISTRATION & DOSAGE

Breast cancer and the western diet: role of fatty acids and antioxidant vitamins. Stoll BA. **Eur J Cancer** 1998 Nov; 34(12):1852–6 (81 ref.)

Compatibility and stability of additives in parenteral nutrition admixtures. Allwood MC, et al. **Nutrition** 1998 Sep; 14(9):697–706 (78 ref.)

[Use of natural vitamin supplements in children during convalescence and in children with athletic activities] Savino F, et al. **Minerva Pediatr** 1999 Jan-Feb;51(1–2):1–9 (48 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

[Is supplementation of vitamins and minerals dangerous?] Poleszynski DV. **Tidsskr Nor Laegeforen** 1999 May 20; 119(13):1926–9 (36 ref.) **(Nor)**

METABOLISM

The impact of food processing on the nutritional quality of vitamins and minerals. Reddy MB, et al. **Adv Exp Med Biol** 1999;459:99–106 (50 ref.)

Interactions between drugs and vitamins at advanced age. Schümann K. **Int J Vitam Nutr Res** 1999 May;69(3):173–8 (54 ref.)

Antioxidant vitamins and cardiovascular disease. Gaziano JM. **Proc Assoc Am Physicians** 1999 Jan-Feb;111(1):2–9 (55 ref.)

PHARMACOKINETICS

Vitamin absorption in the elderly. Kasper H. **Int J Vitam Nutr Res** 1999 May;69(3):169–72 (31 ref.)

THERAPEUTIC USE

Antioxidant vitamins and the prevention of coronary heart disease [see comments] Adams AK, et al. **Am Fam Physician** 1999 Sep 1;60(3):895–904 (46 ref.) Comment in: Am Fam Physician 1999 Sep 1;60(3):742, 744.

Cheilognathopalatoschisis and its prophylaxis in animal experiments. Malek FA, et al. **Anat Anz** 1999 Jan; 181(1):107–10 (43 ref.)

Chemoprevention of colorectal cancer. Langman M, et al. **Gut** 1998 Oct;43(4):578–85 (118 ref.)

Vitamin V: the sildenafil craze. Kuritzky L. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):163–5 (3 ref.)

The role of antioxidative vitamins in primary and secondary prevention of coronary heart disease. Biesalski HK. **Int J Vitam Nutr Res** 1999 May;69(3):179–86 (34 ref.)

The potential preventive effects of vitamins for cataract and age-related macular degeneration. Jacques PF. **Int J Vitam Nutr Res** 1999 May;69(3):198–205 (50 ref.)

The role of vitamins in the prevention of osteoporosis--a brief status report. Weber P. **Int J Vitam Nutr Res** 1999 May;69(3):194–7 (41 ref.)

Uses of vitamins A, C, and E and related compounds in dermatology: a review. Keller KL, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):611–25 (200 ref.)

High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. Prasad KN, et al. **J Am Coll Nutr** 1999 Feb; 18(1):13–25 (71 ref.)

Complementary and alternative medicines for Alzheimer's disease. Ott BR, et al. **J Geriatr Psychiatry Neurol** 1998 Winter;11(4):163–73 (117 ref.)

Vitamin supplementation and breast cancer: is homeostasis a factor? Rose RC. **Med Hypotheses** 1998 Sep;51(3):239–42 (17 ref.)

Antioxidant vitamins and age-related eye disease. Christen WG. **Proc Assoc Am Physicians** 1999 Jan-Feb;111(1):16–21 (53 ref.)

Antioxidant vitamins and cardiovascular disease. Gaziano JM. **Proc Assoc Am Physicians** 1999 Jan-Feb;111(1):2–9 (55 ref.)

Antioxidant vitamins in the prevention of cancer. Lee IM. **Proc Assoc Am Physicians** 1999 Jan-Feb;111(1):10–5 (44 ref.)

[Vitamins and trace elements in abnormal hemostasis] Khoksi DK. **Klin Med (Mosk)** 1998;76(8):15–8 (29 ref.) **(Rus)**

VITILIGO

DIAGNOSIS

The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Merimsky O, et al. **Clin Rev Allergy Immunol** 1998 Fall;16(3):227–36 (30 ref.)

[Acquired angioneurotic edema associated with Graves' disease and vitiligo (letter)] Losa Garcia JE, et al. **An Med Interna** 1999 Feb;16(2):106–7 (7 ref.) **(Spa)**

DRUG THERAPY

5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. McNeely W, et al. **Drugs** 1998 Oct;56(4):667–90 (80 ref.)

IMMUNOLOGY

[Vitiligo in multiple autoimmune syndrome: a retrospective study of 11 cases and a review of the literature] Klisnick A, et al. **Rev Med Interne** 1998 May;19(5):348–52 (26 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

A systematic review of autologous transplantation methods in vitiligo. Njoo MD, et al. **Arch Dermatol** 1998 Dec; 134(12):1543–9 (59 ref.)

VITRECTOMY

Diagnosis and management of idiopathic macular holes. Saxena S, et al. **Indian J Ophthalmol** 1998 Dec;46(4):185–93 (57 ref.)

Surgical management of macular hole. Miller DG, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):261–74 (55 ref.)

Diagnostic vitrectomy and uveitis. Uy HS, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):223–35 (49 ref.)

The role of vitrectomy for diabetic retinopathy. Arrigg PG, et al. **J Am Optom Assoc** 1998 Nov;69(11):733–40 (19 ref.)

Management of retained intravitreal lens fragments after cataract surgery. Monshizadeh R, et al. **Surv Ophthalmol** 1999 Mar-Apr;43(5):397–404 (54 ref.)

Vitrectomy in the management of diabetic retinopathy. Smiddy WE, et al. **Surv Ophthalmol** 1999 May-Jun; 43(6):491–507 (155 ref.)

METHODS

Surgical advances in retinopathy of prematurity. Andrews AP, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):275–90 (41 ref.)

Surgical approaches for the removal of posteriorly dislocated crystalline lenses. You TT, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):249–59 (26 ref.)

[Liquid perfluorocarbons in vitreo-retinal surgery] Benchekroun O, et al. **J Fr Ophtalmol** 1998 Dec; 21(10):773–81 (54 ref.) **(Fre)**

[Intraocular gases in vitreous and retinal surgery. I: Basic principles] Faude F, et al. **Ophthalmologe** 1999 May; 96(5):W349–58 (66 ref.) **(Ger)**

VITREORETINOPATHY, PROLIFERATIVE

DRUG THERAPY

[A survey of clinically used drugs in PVR: a review] Faude F, et al. **Klin Monatsbl Augenheilkd** 1999 Jun;214(6):362–6 (56 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Liquid perfluorocarbons in vitreo-retinal surgery] Benchekroun O, et al. **J Fr Ophtalmol** 1998 Dec; 21(10):773–81 (54 ref.) **(Fre)**

PATHOLOGY

[The role of apoptosis in physiology and pathology of the retina] Obuchowska I, et al. **Klin Oczna** 1999;101(2):139–43 (43 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Matrix and the retinal pigment epithelium in proliferative retinal disease. Hiscott P, et al. **Prog Retin Eye Res** 1999 Mar;18(2):167–90 (140 ref.)

VITREOUS BODY

see related
VITRECTOMY

ABNORMALITIES

Ultrasonographic diagnosis of persistent hyperplastic tunica vasculosa lentis/persistent hyperplastic primary vitreous in two dogs. Boroffka SA, et al. **Vet Radiol Ultrasound** 1998 Sep-Oct;39(5):440-4 (13 ref.)

PATHOLOGY

Diagnostic vitrectomy and uveitis. Uy HS, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):223-35 (49 ref.)
Coats' disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Edward DP, et al. **Radiol Clin North Am** 1998 Nov;36(6):1119-31, x (64 ref.)

ULTRASONOGRAPHY

Ultrasonic evaluation of the vitreous and retina. Coleman DJ, et al. **Semin Ophthalmol** 1998 Dec;13(4):210-8 (11 ref.)

VITREOUS DETACHMENT

Managing ocular flashes and floaters. Duguid G. **Practitioner** 1998 Apr;242(1585):302-4 (1 ref.)

VITRONECTIN

CHEMISTRY

Vitronectin. Schvartz I, et al. **Int J Biochem Cell Biol** 1999 May;31(5):539-44 (15 ref.)

PHARMACOLOGY

[Adhesive proteins and endothelialization of biomaterials] Wei S, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Jun; 14(2):148-51 back cover (25 ref.) **(Chi)**

PHYSIOLOGY

Vitronectin. Schvartz I, et al. **Int J Biochem Cell Biol** 1999 May;31(5):539-44 (15 ref.)

VIVERRIDAE see **CARNIVORA**

VIVISECTION

see related
ANIMAL WELFARE

VMW65 PROTEIN see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

VNTR see **MINISATELLITE REPEATS**

VNTR LOCI see **MINISATELLITE REPEATS**

VNTR REGION see **MINISATELLITE REPEATS**

VNTR SEQUENCES see **MINISATELLITE REPEATS**

VOCABULARY

Cerebral hemispheric mechanisms linking ambiguous word meaning retrieval and creativity. Atchley RA, et al. **Brain Cogn** 1999 Aug;40(3):479-99 (79 ref.)
Patterns of acquisition in the emerging mental lexicon: the case of to and for in English. Rice S. **Brain Lang** 1999 Jun 1-15;68(1-2):268-76 (21 ref.)

VOCABULARY, CONTROLLED

The ICNP's relevance in the US. Henry SB, et al. **Int Nurs Rev** 1998 Sep-Oct;45(5):153-9 (40 ref.)
Desiderata for controlled medical vocabularies in the twenty-first century. Cimino JJ. **Methods Inf Med** 1998 Nov;37(4-5):394-403 (85 ref.)
The Copernican era of healthcare terminology: a re-centering of health information systems. Chute CG. **Proc AMIA Symp** 1998;:68-73 (35 ref.)

VOCABULARY TESTS see **LANGUAGE TESTS**

VOCAL CORD PARALYSIS

Vocal cord paralysis. Fitzpatrick PC, et al. **J La State Med Soc** 1998 Aug;150(8):340-3 (7 ref.)

CHEMICALLY INDUCED

Hydralazine-induced lupus and vocal fold paralysis. Hari CK, et al. **J Laryngol Otol** 1998 Sep;112(9):875-7 (31 ref.)

DIAGNOSIS

Left vocal cord paralysis as a primary manifestation of invasive pulmonary aspergillosis in a nonimmunocompromised host. Nakahira M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):691-3 (6 ref.)

ETIOLOGY

Bilateral recurrent nerve paralysis associated with multinodular substernal goiter: a case report. Souza JW, et al. **Am Surg** 1999 May;65(5):456-9 (10 ref.)
Recurrent laryngeal nerve injury caused by a laryngeal mask airway. Lowinger D, et al. **Anaesth Intensive Care** 1999 Apr;27(2):202-5 (26 ref.)
Early complications. Recurrent nerve palsy. Carew JF, et al. **Chest Surg Clin N Am** 1999 Aug;9(3):597-608, viii-ix (20 ref.)
Bilateral vocal cord paralysis following anterior cervical discectomy and fusion. Case report. Manski TJ, et al. **J Neurosurg** 1998 Nov;89(5):839-43 (97 ref.)

VOCAL CORDS

Analysis of the forces and position required for direct laryngoscopic exposure of the anterior vocal folds. Hochman II, et al. **Ann Otol Rhinol Laryngol** 1999 Aug; 108(8):715-24 (38 ref.)

ANATOMY & HISTOLOGY

Surgery for voice. Davies DG. **Hosp Med** 1999 Mar; 60(3):196-201 (11 ref.)

SURGERY

[Critical review of phonosurgical methods in the treatment of sulcus vocalis] Milutinović Z. **Srp Arh Celok Lek** 1998 Nov-Dec;126(11-12):495-8 (9 ref.) (Eng. Abstr.) **(Scc)**

VOCAL FOLD see **VOCAL CORDS**

VOCALIZATION, ANIMAL

PHYSIOLOGY

Birdsong and human speech: common themes and mechanisms. Doupe AJ, et al. **Annu Rev Neurosci** 1999; 22:567-631 (220 ref.)
Mating vocalizations of female frogs: control and evolutionary mechanisms. Emerson SB, et al. **Brain Behav Evol** 1999;53(4):187-97 (122 ref.)
Neuronal control of mammalian vocalization, with special reference to the squirrel monkey. Jürgens U. **Naturwissenschaften** 1998 Aug;85(8):376-88 (53 ref.)
Neuronal cell death during sexual differentiation and lateralisation of vocal communication. Holman SD. **Neurosci Biobehav Rev** 1998 Oct;22(6):725-34 (94 ref.)

VOCATIONAL REHABILITATION see **REHABILITATION, VOCATIONAL**

VOCATIONS see **OCCUPATIONS**

VOGT-KOYANAGI-HARADA SYNDROME see **UVEOMENINGOENCEPHALITIC SYNDROME**

VOICE

Earwitness testimony. Bull R, et al. **Med Sci Law** 1999 Apr; 39(2):120-7 (42 ref.)
[Surgical voice restoration following laryngectomy] Herrmann IF. **Laryngorhinootologie** 1999 Jun; 78(6):OP57-68 (0 ref.) **(Ger)**

PHYSIOLOGY

[Hormones and voice or does Orpheus have an age?] Marco-Dutoit ML. **Rev Med Suisse Romande** 1999 Apr; 119(4):335-9 (21 ref.) **(Fre)**

VOICE DISORDERS

Surgery for voice. Davies DG. **Hosp Med** 1999 Mar; 60(3):196-201 (11 ref.)
Vocal problems among teachers: a review of prevalence, causes, prevention, and treatment. Mattiske JA, et al. **J Voice** 1998 Dec;12(4):489-99 (42 ref.)
The GP's role in managing voice disorders. Rubin J, et al. **Practitioner** 1998 Jun;242(1587):448-50, 453-4 (3 ref.)

DIAGNOSIS

Acoustic studies of dysarthric speech: methods, progress, and potential. Kent RD, et al. **J Commun Disord** 1999 May-Jun; 32(3):141-80, 183-6; quiz 181-3, 187-9 (140 ref.)
The vocal athlete and endotracheal intubation: a management protocol. Loucks TM, et al. **J Voice** 1998 Sep;12(3):349-59 (35 ref.)
[Video-laryngostroboscopy in phonation] Haddad AC, et al. **J Med Liban** 1998 May-Jun;46(3):140-5 (26 ref.) **(Fre)**
[Dysphonia. Diagnostic guidance] Brasnu D. **Rev Prat** 1998 May 15;48(10):1151-4 (0 ref.) **(Fre)**

DRUG THERAPY

Increased stability of airflow following botulinum toxin injection. Finnegan EM, et al. **Laryngoscope** 1999 Aug; 109(8):1300-6 (22 ref.)

ETIOLOGY

Otolaryngologic complications of the anterior approach to the cervical spine. Winslow CP, et al. **Am J Otolaryngol** 1999 Jan-Feb;20(1):16-27 (64 ref.)
Perceptual strategies in phonological disorder: assessment, remediation and evaluation. Watson J, et al. **Int J Lang Commun Disord** 1998;33 Suppl:475-80 (18 ref.)
Goitre presenting as an oropharyngeal mass: an unusual finding in the elderly. Berenholz LP, et al. **J Laryngol Otol** 1999 Feb;113(2):170-1 (6 ref.)
[Hormones and voice or does Orpheus have an age?] Marco-Dutoit ML. **Rev Med Suisse Romande** 1999 Apr; 119(4):335-9 (21 ref.) **(Fre)**
[Some aspects of prebyphonia] Reiss M, et al. **Schweiz Rundsch Med Prax** 1999 Jun 10;88(24):1078-80 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. Carding PN, et al. **J Voice** 1999 Mar;13(1):72-104 (77 ref.)

VOICE PROSTHESIS see **LARYNX, ARTIFICIAL**

VOICE QUALITY

see related
PHONATION

PHYSIOLOGY

[Expert phoniatric assessment of voice adaptation in male to female transsexualism] Rosanowski F, et al. **HNO** 1999 Jun;47(6):556-62 (36 ref.) (Eng. Abstr.) **(Ger)**

VOICE TRAINING

A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. Carding PN, et al. **J Voice** 1999 Mar;13(1):72-104 (77 ref.)

VOLES see **MICROTINAE**

VOLITION

PHYSIOLOGY

The antisaccade: a review of basic research and clinical studies. Everling S, et al. **Neuropsychologia** 1998 Sep; 36(9):885-99 (133 ref.)
Towards a functional neuroanatomy of conscious perception and its modulation by volition: implications of human auditory neuroimaging studies. Silbersweig DA, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1883-8 (57 ref.)

VOLKMANN CONTRACTURE see **COMPARTMENT SYNDROMES**

VOLTAGE-CLAMP TECHNIQUES see **PATCH-CLAMP TECHNIQUES**

VOLUNTARY STERILIZATION see **STERILIZATION, SEXUAL**

VOLUNTARY WORKERS

Adult participation in youth sports. A developmental perspective. Libman S. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):725-44, vii (71 ref.)
HIV and the returning expatriate. Jones ME. **J Travel Med** 1999 Jun;6(2):99-106 (47 ref.)

ORGANIZATION & ADMINISTRATION

[Volunteerism and the reorientation of health services] Tomás Sancho A, et al. **Aten Primaria** 1998 Oct 31;22(7):450-6 (62 ref.) (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Religion, community service, and identity in American youth. Youniss J, et al. **J Adolesc** 1999 Apr;22(2):243-53 (23 ref.)

VOLUNTEERS see **VOLUNTARY WORKERS**

VOLVOX see **ALGAE, GREEN**

VOLVULUS see **INTESTINAL OBSTRUCTION**

VOMER see **NASAL SEPTUM**

VOMERONASAL NERVE see **VOMERONASAL ORGAN**

VOMERONASAL ORGAN

ANATOMY & HISTOLOGY

Structure and function of the vomeronasal organ. Døving KB, et al. **J Exp Biol** 1998 Nov;201 (Pt 21):2913-25 (106 ref.)

DRUG EFFECTS

Electrophysiological and biochemical responses of mouse

VOMERONASAL ORGAN

vomeronasal receptor cells to urine-derived compounds: possible mechanism of action. Moss RL, et al. **Chem Senses** 1998 Aug;23(4):483–9 (48 ref.)

METABOLISM

Expression of candidate pheromone receptor genes in vomeronasal neurons. Dulac C, et al. **Chem Senses** 1998 Aug;23(4):467–75 (44 ref.)

PHYSIOLOGY

Pheromones, the vomeronasal system, and communication. From hormonal responses to individual recognition. Johnston RE. **Ann N Y Acad Sci** 1998 Nov 30;855:333–48 (62 ref.)

Vomeronasal, olfactory, hormonal convergence in the brain. Cooperation or coincidence? Meredith M. **Ann N Y Acad Sci** 1998 Nov 30;855:349–61 (43 ref.)

The human vomeronasal system. A review. Monti-Bloch L, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:373–89 (86 ref.)

Integration of chemosensory and hormonal input in the male Syrian hamster brain. Wood RI. **Ann N Y Acad Sci** 1998 Nov 30;855:362–72 (20 ref.)

Pheromone signalling in the mouse: role of urinary proteins and vomeronasal organ. Cavaggioni A, et al. **Arch Ital Biol** 1999 May;137(2–3):193–200 (52 ref.)

Vomeronasal function. Meredith M. **Chem Senses** 1998 Aug; 23(4):463–6 (33 ref.)

Electrophysiological and biochemical responses of mouse vomeronasal receptor cells to urine-derived compounds: possible mechanism of action. Moss RL, et al. **Chem Senses** 1998 Aug;23(4):483–9 (48 ref.)

Structure and function of the vomeronasal organ. Døving KB, et al. **J Exp Biol** 1998 Nov;201 (Pt 21):2913–25 (106 ref.)

Role of the vomeronasal input in maternal behavior. Del Cerro MC. **Psychoneuroendocrinology** 1998 Nov; 23(8):905–26 (93 ref.)

Molecular aspects of pheromonal communication via the vomeronasal organ of mammals. Tirindelli R, et al. **Trends Neurosci** 1998 Nov;21(11):482–6 (58 ref.)

VOMERONASAL SYSTEM see **VOMERONASAL ORGAN**

VOMITING

see related
ANTIEMETICS
EMETICS

Proceedings of the 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. Milwaukee, Wisconsin, USA. April 17–18, 1998. **Dig Dis Sci** 1999 Aug;44(8 Suppl):1S–119S (0 ref.)

CHEMICALLY INDUCED

Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Herrstedt J. **Dan Med Bull** 1998 Sep;45(4):412–22 (168 ref.)

About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. Lehoczky O. **Neoplasma** 1999;46(2):73–9 (50 ref.)

Antiemetic therapy. Gralla RJ. **Semin Oncol** 1998 Oct; 25(5):577–83 (24 ref.)

DIAGNOSIS

[Vomiting in infants] Roquelaure B, et al. **Rev Prat** 1999 Jan 15;49(2):223–6 (3 ref.) **(Fre)**

DRUG THERAPY

Domperidone: a peripherally acting dopamine2-receptor antagonist. Barone JA. **Ann Pharmacother** 1999 Apr; 33(4):429–40 (154 ref.)

About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. Lehoczky O. **Neoplasma** 1999;46(2):73–9 (50 ref.)

Antiemetics. Wadibia EC. **South Med J** 1999 Feb;92(2):162–5; quiz 166 (8 ref.)

[The neurochemical mechanisms and pharmacological routes to eliminate vomiting in seasickness] Naletov SV, et al. **Voen Med Zh** 1998 Sep;319(9):74–6 (20 ref.) **(Rus)**

ETIOLOGY

Vestibular autonomic regulation (including motion sickness and the mechanism of vomiting). Balaban CD. **Curr Opin Neurol** 1999 Feb;12(1):29–33 (45 ref.)

Cyclic vomiting syndrome: timing, targets, and treatment--a basic science perspective. Andrews PL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):31S–38S (41 ref.)

Consensus statement--2nd International Scientific Symposium on CVS. The Faculty of The 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. Li BU, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):9S–11S (0 ref.)

Is cyclical vomiting an abdominal form of migraine in children? Symon DN. **Dig Dis Sci** 1999 Aug;44(8 Suppl):23S–25S (21 ref.)

Scientific basis of migraine: speculation on the relationship to cyclic vomiting. Welch KM. **Dig Dis Sci** 1999 Aug;44(8 Suppl):26S–30S (42 ref.)

Cyclic vomiting syndrome: light emerging from the black box [editorial;comment] Li BU. **J Pediatr** 1999 Sep; 135(3):276–7 (13 ref.) Comment on: J Pediatr 1999 Sep;135(3):363–6.

Vomiting. Murray KF, et al. **Pediatr Rev** 1998 Oct; 19(10):337–41 (11 ref.)

Radiotherapy-induced emesis. An overview. Feyer P, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:56–61 (36 ref.)

[Vomiting in infants] Roquelaure B, et al. **Rev Prat** 1999 Jan 15;49(2):223–6 (3 ref.) **(Fre)**

[Vomiting as the main symptom] Mörk H, et al. **Internist (Berl)** 1998 Oct;39(10):W1055–61; quiz 1061 (8 ref.) **(Ger)**

METABOLISM

[The neurochemical mechanisms and pharmacological routes to eliminate vomiting in seasickness] Naletov SV, et al. **Voen Med Zh** 1998 Sep;319(9):74–6 (20 ref.) **(Rus)**

NURSING

A symptom review: nausea and vomiting in HIV. Capili B, et al. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):47–56 (44 ref.)

PHYSIOPATHOLOGY

Mitochondrial disease and cyclic vomiting syndrome. Boles RG, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):103S–107S (22 ref.)

Serotonin receptor physiology: relation to emesis. Hasler WL. **Dig Dis Sci** 1999 Aug;44(8 Suppl):108S–113S (59 ref.)

Noxious stimulation of emesis. Lang IM. **Dig Dis Sci** 1999 Aug;44(8 Suppl):58S–63S (60 ref.)

Cyclic vomiting syndrome: features to be explained by a pathophysiologic model. Li BU, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):13S–18S (28 ref.)

Central mechanisms of vomiting. Miller AD. **Dig Dis Sci** 1999 Aug;44(8 Suppl):39S–43S (56 ref.)

Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptácek LJ. **Dig Dis Sci** 1999 Aug;44(8 Suppl):94S–96S (22 ref.)

Mitochondrial fatty acid oxidation disorders and cyclic vomiting syndrome. Rinaldo P. **Dig Dis Sci** 1999 Aug;44(8 Suppl):97S–102S (38 ref.)

Tachykinins and in vivo gut motility. Sarna SK. **Dig Dis Sci** 1999 Aug;44(8 Suppl):114S–118S (28 ref.)

Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Taché Y. **Dig Dis Sci** 1999 Aug;44(8 Suppl):79S–86S (94 ref.)

Enteric nervous control of motility in the upper gastrointestinal tract in defensive states. Wood JD. **Dig Dis Sci** 1999 Aug;44(8 Suppl):44S–52S (15 ref.)

PREVENTION & CONTROL

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery [see comments] **Am J Health Syst Pharm** 1999 Apr 15;56(8):729–64 (423 ref.) Comment in: Am J Health Syst Pharm 1999 Apr 15;56(8):728.

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). **Ann Oncol** 1998 Aug;9(8):811–9 (103 ref.)

Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Herrstedt J. **Dan Med Bull** 1998 Sep;45(4):412–22 (168 ref.)

Guidelines for anti-emetic therapy: acute emesis. Fauser AA, et al. **Eur J Cancer** 1999 Mar;35(3):361–70 (94 ref.)

Antiemetic therapy. Gralla RJ. **Semin Oncol** 1998 Oct; 25(5):577–83 (24 ref.)

PSYCHOLOGY

Psychological and social characteristics and precipitants of vomiting in children with cyclic vomiting syndrome. Forbes D, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):19S–22S (30 ref.)

THERAPY

Alternative therapies for nausea and vomiting of pregnancy. Zeidenstein L. **J Nurse Midwifery** 1998 Sep–Oct; 43(5):392–3 (0 ref.)

VIROLOGY

A symptom review: nausea and vomiting in HIV. Capili B, et al. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):47–56 (44 ref.)

VOMITING, ANTICIPATORY

CHEMICALLY INDUCED

[Anticipatory nausea and anticipatory vomiting, food aversion and anticipatory immunomodulation: classical conditioning in cytostatic drug treatment of pediatric chemotherapy patients] Stockhorst U, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1140–7 (37 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). **Ann Oncol** 1998 Aug;9(8):811–9 (103 ref.)

VON GIERKE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE I**

VON HIPPEL-LINDAU DISEASE see **HIPPEL-LINDAU DISEASE**

VON WILLEBRAND DISEASE

Acquired von Willebrand disease. van Genderen PJ, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):319–30 (54 ref.)

von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease. Vischer UM, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):93–109 (138 ref.)

Females with von Willebrand disease: 72 years as the silent majority. Kouides PA. **Haemophilia** 1998 Jul;4(4):665–76 (110 ref.)

[Acquired von Willebrand disease] Matsuda J. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):532–4 (8 ref.) **(Jpn)**

[Variant type von Willebrand disease with defective binding to factor VIII] Shima M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):430–3 (7 ref.) **(Jpn)**

[von Willebrand disease type 1] Sugimoto M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):476–8 (6 ref.) **(Jpn)**

[Platelet-type von Willebrand disease] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):485–7 (8 ref.) **(Jpn)**

[Type 2 von Willebrand disease] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):479–82 (13 ref.) **(Jpn)**

[Type 3 von Willebrand disease] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):483–4 (7 ref.) **(Jpn)**

CLASSIFICATION

Biochemistry and genetics of von Willebrand factor. Sadler JE. **Annu Rev Biochem** 1998;67:395–424 (154 ref.)

COMPLICATIONS

[Joint preserving operations and endoprosthetic joint substitutions in hemophiliacs. Indications and long term results] Hovy L. **Orthopade** 1999 Apr;28(4):356–65 (29 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Diagnosis of von Willebrand disease. Federici AB. **Haemophilia** 1998 Jul;4(4):654–60 (42 ref.)

Laboratory diagnosis of von Willebrand disease. Veyradier A, et al. **Int J Clin Lab Res** 1998;28(4):201–10 (33 ref.)

[Willebrand disease] Rothschild C. **Transfus Clin Biol** 1998 Oct;5(5):357–61 (7 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Federici AB, et al. **Haemophilia** 1998;4 Suppl 3:7–10 (10 ref.)

Treatment of von Willebrand disease. Mannucci PM. **Int J Clin Lab Res** 1998;28(4):211–4 (33 ref.)

GENETICS

The molecular basis of von Willebrand disease. Mohlke KL, et al. **Int J Clin Lab Res** 1999;29(1):1–7 (55 ref.)

THERAPY

Treatment of von Willebrand disease. Mannucci PM. **Haemophilia** 1998 Jul;4(4):661–4 (28 ref.)

VON WILLEBRAND FACTOR

see related
COAGULANTS

von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease. Vischer UM, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):93–109 (138 ref.)

ANALYSIS

Laboratory diagnosis of von Willebrand disease. Veyradier A, et al. **Int J Clin Lab Res** 1998;28(4):201–10 (33 ref.)

GENETICS

The molecular basis of von Willebrand disease. Mohlke KL, et al. **Int J Clin Lab Res** 1999;29(1):1–7 (55 ref.)

METABOLISM

Biochemistry and genetics of von Willebrand factor. Sadler

JE. **Annu Rev Biochem** 1998;67:395–424 (154 ref.)
Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura. Moake JL, et al. **J Clin Apheresis** 1998;13(3):126–32 (28 ref.)
[Endothelial activation markers (thrombomodulin, Willebrand's factor antigen and angiotensin-converting enzyme): clinical significance] Nasonov EL, et al. **Klin Med (Mosk)** 1998;76(11):4–10 (116 ref.) **(Rus)**

PHARMACOLOGY

Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Federici AB, et al. **Haemophilia** 1998;4 Suppl 3:7–10 (10 ref.)

PHYSIOLOGY

Von Willebrand factor in diabetic angiopathy. Kessler L, et al. **Diabetes Metab** 1998 Sep;24(4):327–36 (60 ref.)
The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia. Federici AB, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):491–9 (41 ref.)

THERAPEUTIC USE

Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Federici AB, et al. **Haemophilia** 1998;4 Suppl 3:7–10 (10 ref.)

VP-16 see **ETOPOSIDE**

VP 16-213 see **ETOPOSIDE**

VP16 PROTEIN see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

VPR GENE PRODUCTS see **GENE PRODUCTS, VPR**

VPR PROTEIN see **GENE PRODUCTS, VPR**

VS-I VIRUS see **VESICULAR STOMATITIS-INDIANA VIRUS**

VULPES see **FOXES**

VULVA

PATHOLOGY

Genital variant of folliculosebaceous cystic hamartoma. Bolognia JL, et al. **Dermatology** 1998;197(3):258–60 (17 ref.)

VULVAR DISEASES

Vulvar disorders in adolescents. Fivozinsky KB, et al. **Adolesc Med** 1999 Jun;10(2):305–19, vii (65 ref.)
[Bartholinitis, Bartholin's abscess, Bartholin's cyst] Yamamoto T. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):201–5 (15 ref.) **(Jpn)**

DIAGNOSIS

Vulvodynia and vulvar vestibulitis: challenges in diagnosis and management. Metts JF. **Am Fam Physician** 1999 Mar 15;59(6):1547–56, 1561–2 (29 ref.)
Vulvodynia--a dermatovenereologist's perspective. Mroczkowski TF. **Int J Dermatol** 1998 Aug;37(8):567–9 (14 ref.)
Vulvar disorders in adolescent patients. Quint EH, et al. **Pediatr Clin North Am** 1999 Jun;46(3):593–606, ix (31 ref.)
Vulvodynia and its differential diagnoses. Bohl TG. **Semin Cutan Med Surg** 1998 Sep;17(3):189–95 (53 ref.)
[Vulvar involvement as a rare extra-intestinal manifestation of Crohn disease] Leupold U, et al. **Med Klin** 1998 Aug 15;93(8):492–6 (26 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Vulvar disorders in adolescent patients. Quint EH, et al. **Pediatr Clin North Am** 1999 Jun;46(3):593–606, ix (31 ref.)

PATHOLOGY

Primary breast carcinoma of the vulva: a case report and literature review. Irvin WP, et al. **Gynecol Oncol** 1999 Apr; 73(1):155–9 (11 ref.)
Vulvar porokeratosis: case report and review of the literature. Robinson JB, et al. **Int J Gynecol Pathol** 1999 Apr; 18(2):169–73 (34 ref.)
Vulvar disorders in prepubertal girls. A literature review. Fivozinsky KB, et al. **J Reprod Med** 1998 Sep;43(9):763–73 (64 ref.)

PHYSIOPATHOLOGY

[Vaginal infections and sexually transmitted diseases] van den Brûle F. **Rev Med Liege** 1999 Apr;54(4):296–302 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Vulvodynia and vulvar vestibulitis: challenges in diagnosis and management. Metts JF. **Am Fam Physician** 1999 Mar 15;59(6):1547–56, 1561–2 (29 ref.)
Clinical management of vulvodynia. Davis GD, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):221–33 (20 ref.)
Management of radiation injuries of vulva and vagina. Fraunholz IB, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:90–2 (29 ref.)

VIROLOGY

Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Hudson LB, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):642–4 (4 ref.)
Genital ulcers associated with acute Epstein-Barr virus infection. Taylor S, et al. **Sex Transm Infect** 1998 Aug; 74(4):296–7 (6 ref.)

VULVAR NEOPLASMS

COMPLICATIONS

Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Fanning J, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):24–7 (13 ref.)

DIAGNOSIS

Vulvar intraepithelial neoplasia and carcinoma. Campion MJ, et al. **Semin Cutan Med Surg** 1998 Sep;17(3):205–12 (50 ref.)

EPIDEMIOLOGY

[Current epidemiology of vulvar cancer] Sasco AJ, et al. **Contracept Fertil Sex** 1998 Dec;26(12):858–64 (45 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Aspects of malignant progression of vulvar epithelial disorders [editorial] Kagie MJ. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):1–3 (13 ref.)
Primary breast carcinoma of the vulva: a case report and literature review. Irvin WP, et al. **Gynecol Oncol** 1999 Apr; 73(1):155–9 (11 ref.)
Epithelioid sarcoma of the vulva. Tjalma WA, et al. **Gynecol Oncol** 1999 Apr;73(1):160–4 (21 ref.)
Acquired vulvar lymphangioma mimicking genital warts. A case report and review of the literature. Mu XC, et al. **J Cutan Pathol** 1999 Mar;26(3):150–4 (62 ref.)
Malignant rhabdoid tumor of the vulva: case report with cytological, immunohistochemical, ultrastructural and DNA ploidy studies and a review of the literature. Igarashi T, et al. **Pathol Int** 1998 Nov;48(11):887–91 (19 ref.)
Lymphatic mapping in gynecologic malignancies. Grendys EC Jr, et al. **Surg Oncol Clin N Am** 1999 Jul;8(3):541–53, x (40 ref.)
[Breast-like carcinoma of the vulva] Erb-Gremillet S, et al. **Ann Pathol** 1999 Apr;19(2):124–7 (17 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Vulvar metastasis from breast carcinoma: a case report and review of the literature. Sindico R, et al. **Eur J Gynaecol Oncol** 1998;19(4):386–8 (28 ref.)

SURGERY

Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Fanning J, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):24–7 (13 ref.)
Current management of early vulvar cancer. Hacker NF. **Ann Acad Med Singapore** 1998 Sep;27(5):688–92 (28 ref.)
Skinning vulvectomy for the treatment of vulvar intraepithelial neoplasia 2–3: a study of 21 cases. Ayhan A, et al. **Eur J Gynaecol Oncol** 1998;19(5):508–10 (12 ref.)
Extramammary Paget's disease of the vulva: report of five cases and review of the literature. Piura B, et al. **Eur J Gynaecol Oncol** 1999;20(2):98–101 (26 ref.)
Adenoid cystic carcinoma of Bartholin's gland: what is the optimal approach? Anaf V, et al. **Eur J Surg Oncol** 1999 Aug;25(4):406–9 (19 ref.)

THERAPY

Radical resection of vulvar malignancies: a paradigm shift in surgical approaches. Hacker NF. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):61–4 (28 ref.)

VIROLOGY

The role of human papillomaviruses in anogenital cancers. Melbye M, et al. **Semin Cancer Biol** 1998 Aug;8(4):307–13 (79 ref.)

VULVITIS

[Vulvitis] Kawabata M. **Ryoikibetsu Shokogun Shirizu** 1999; (25 Pt 3):206–8 (2 ref.) **(Jpn)**

VULVOVAGINITIS

Vulvovaginitis in healthy women. Sobel JD. **Compr Ther** 1999 Jun-Jul;25(6–7):335–46 (54 ref.)

NURSING

Human seminal plasma protein allergy: a diagnosis rarely considered. Ludman BG. **J Obstet Gynecol Neonatal Nurs** 1999 Jul–Aug;28(4):359–63 (18 ref.)

VVEDENSKII INHIBITION see **NEURAL CONDUCTION**

VZ VIRUS see **HERPESVIRUS 3, HUMAN**

WAARDENBURG'S SYNDROME

[Waardenburg's syndrome] Mouriaux F, et al. **J Fr Ophtalmol** 1999 Aug–Sep;22(7):799–809 (44 ref.) **(Fre)**

COMPLICATIONS

Hirschsprung's disease: genetic and functional associations of Down's and Waardenburg syndromes. Moore SW, et al. **Semin Pediatr Surg** 1998 Aug;7(3):156–61 (71 ref.)

WAGES see **SALARIES AND FRINGE BENEFITS**

WAIST-HIP RATIO see **BODY CONSTITUTION**

WAITING LISTS

Mechanical circulatory support as a bridge to cardiac transplantation: toward the 21st century. Scherr K, et al. **Am J Crit Care** 1999 Sep;8(5):324–37; quiz 338–9 (150 ref.)
Priority care for employees: a blessing in disguise? Brouwer WB, et al. **Health Econ** 1999 Feb;8(1):65–73 (21 ref.)
Managing the clinic wait: an important quality of care challenge. Rondeau KV. **J Nurs Care Qual** 1998 Dec; 13(2):11–20 (24 ref.)
Consensus conference on standardized listing criteria for renal transplant candidates. **Transplantation** 1998 Oct 15; 66(7):962–7 (0 ref.)
[Waiting list guarantee between medicine and bureaucracy] Lian OS, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20; 118(25):3921–6 (21 ref.) (Eng. Abstr.) **(Nor)**

WAKEFULNESS

see related
INSOMNIA

Is there an optimal sleep-wake pattern in shift work? Akerstedt T. **Scand J Work Environ Health** 1998;24 Suppl 3:18–27 (98 ref.)
[Wake disorders. I. Primary wake disorders] Billiard M, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):111–29 (189 ref.) (Eng. Abstr.) **(Fre)**
[Effect of awakening and sleep deprivation in triggering idiopathic generalized epilepsy] Crespel A, et al. **Rev Neurol (Paris)** 1999 Feb;155(2):131–4 (39 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Differences in gene expression during sleep and wakefulness. Cirelli C, et al. **Ann Med** 1999 Apr;31(2):117–24 (66 ref.)
Differences in brain gene expression between sleep and waking as revealed by mRNA differential display and cDNA microarray technology. Cirelli C, et al. **J Sleep Res** 1999 Jun;8 Suppl 1:44–52 (66 ref.)

PHYSIOLOGY

Recordings from the striate cortex in awake behaving animals. Hubel DH. **Adv Neurol** 1998;77:219–26; discussion 226–7 (3 ref.)
The neural basis of consciousness across the sleep-waking cycle. Jones BE. **Adv Neurol** 1998;77:75–94 (89 ref.)
Adenosine in sleep and wakefulness. Porkka-Heiskanen T. **Ann Med** 1999 Apr;31(2):125–9 (40 ref.)
Electro-oscillographic correlation between dorsal raphe nucleus, neocortex and hippocampus during wakefulness before and after serotoninergic inactivation. Fonoff ET, et al. **Braz J Med Biol Res** 1999 Apr;32(4):469–72 (14 ref.)
Response properties of spinal interneurons in awake, behaving primates. Fetz EE. **Pain** 1999 Aug;Suppl 6:S55–60 (37 ref.)
Endogenous and exogenous factors on sleep-wake cycle regulation. Garcia-Garcia F, et al. **Prog Neurobiol** 1999 Jul;58(4):297–314 (294 ref.)
The neurophysiology of sleep and waking: intracerebral connections, functioning and ascending influences of the medulla oblongata. Gottesmann C. **Prog Neurobiol** 1999 Sep;59(1):1–54 (267 ref.)
Changes in sleep and wakefulness following 5-HT1A ligands given systemically and locally in different brain regions. Bjorvatn B, et al. **Rev Neurosci** 1998;9(4):265–73 (97 ref.)
[Molecular and neuroanatomical mechanisms of sleep-wakefulness regulation by prostaglandins D2 and E2] Onoe H. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):343–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

WALDENSTROM MACROGLOBULINEMIA

B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Pangalis GA, et al. **Semin Hematol** 1999 Apr;36(2):104–14 (139 ref.)

WALDENSTROM MACROGLOBULINEMIA

[Primary macroglobulinemia] Kimura N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):449–52 (16 ref.) **(Jpn)**

[Solitary primary macroglobulinemia] Kimura N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):457–9 (17 ref.) **(Jpn)**

[Hyperviscosity syndrome] Sato T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):609–10 (11 ref.) **(Jpn)**

COMPLICATIONS

Waldenström macroglobulinemia–induced bullous dermatosis. West NY, et al. **Arch Dermatol** 1998 Sep; 134(9):1127–31 (19 ref.)

DIAGNOSIS

[Waldenström's macroglobulinemia and primary cerebral diffuse large-cell lymphoma (letter)] Domingo JM, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):800–1 (7 ref.) **(Spa)**

DRUG THERAPY

[Interferon-alpha treatment for chemotherapy-resistant primary macroglobulinemia with stomach and lung invasion] Kitamura N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):137–44 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetics of small lymphocyte disorders. Panayiotidis P, et al. **Semin Hematol** 1999 Apr;36(2):171–7 (77 ref.)

WALKING

see related
GAIT

Wandering in dementia. Algase DL. **Annu Rev Nurs Res** 1999;17:185–217 (136 ref.)

Walking after spinal cord injury: evaluation, treatment, and functional recovery. Barbeau H, et al. **Arch Phys Med Rehabil** 1999 Feb;80(2):225–35 (153 ref.)

PHYSIOLOGY

[Assessing exertion capacity in COPD. A critical review of walking tests] Montemayor T, et al. **Arch Bronconeumol** 1999 May;35 Suppl 3:34–9 (41 ref.) **(Spa)**

WALLABIES see **KANGAROOS**

WALLERIAN DEGENERATION

PHYSIOPATHOLOGY

Nerve injury, axonal degeneration and neural regeneration: basic insights. Stoll G, et al. **Brain Pathol** 1999 Apr; 9(2):313–25 (123 ref.)

WAR

see related
COMBAT DISORDERS

Trauma-induced dissociative amnesia in World War I combat soldiers. van der Hart O, et al. **Aust N Z J Psychiatry** 1999 Feb;33(1):37–46 (62 ref.)

Science for evil: the scientist's dilemma. Atiyah M. **BMJ** 1999 Aug 14;319(7207):448–9 (1 ref.)

New challenges for humanitarian protection. Bruderlein C, et al. **BMJ** 1999 Aug 14;319(7207):430–5 (31 ref.)

Mortality associated with use of weapons in armed conflicts, wartime atrocities, and civilian mass shootings: literature review. Coupland RM, et al. **BMJ** 1999 Aug 14; 319(7207):407–10 (36 ref.)

What if Astyanax had survived? War, children, and youth. Allen JR, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):137–51 (106 ref.)

The dermatologist in military operations. Keeling JH, et al. **Dermatol Clin** 1999 Jan;17(1):209–34, x (36 ref.)

Burma: the political economy of violence. Brown C. **Disasters** 1999 Sep;23(3):234–56 (53 ref.)

Waiting for peace: perspectives from action-oriented research on the humanitarian impasse in the Caucasus. Hansen G, et al. **Disasters** 1999 Sep;23(3):257–70 (0 ref.)

Depolarising the 'broadened' and 'back-to-basics' relief models. Jackson S, et al. **Disasters** 1999 Jun;23(2):93–114 (31 ref.)

In defence of humanitarianism. Stockton N. **Disasters** 1998 Dec;22(4):352–60 (9 ref.)

Smoking and anxiety in combat veterans with chronic posttraumatic stress disorder: a review. Beckham JC. **J Psychoactive Drugs** 1999 Apr–Jun;31(2):103–10 (69 ref.)

To South Sudan with operation lifeline Sudan and UNICEF. Taylor-Robinson SD. **J R Coll Physicians Lond** 1999 May–Jun;33(3):276–9 (4 ref.)

Removal of unexploded ordnance from patients: a 50-year military experience and current recommendations. Lein B, et al. **Mil Med** 1999 Mar;164(3):163–5 (9 ref.)

Hantavirus infection—haemorrhagic fever in the Balkans—potential nephrological hazards in the Kosovo war [editorial] Bugert JJ, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1843–4 (17 ref.)

Food aid in emergencies: a case for wheat? Landman J. **Proc Nutr Soc** 1999 May;58(2):355–61 (53 ref.)

A critique of seven assumptions behind psychological trauma programmes in war-affected areas. Summerfield D. **Soc Sci Med** 1999 May;48(10):1449–62 (52 ref.)

Banning the anti-personnel mine: a treaty too far? Chaloner E. **Trop Doct** 1999 Apr;29(2):102–3 (8 ref.)

[Without shame, no moral. How physicians could commit murder] Riksen KI. **Tidsskr Nor Laegeforen** 1999 Mar 20; 119(8):1096–9 (22 ref.) (Eng. Abstr.) **(Nor)**

[Problems in the medical evaluation of the combat fitness of Armed Forces personnel] Zhiliaev EG, et al. **Voen Med Zh** 1999 Mar;320(3):56–61 (17 ref.) **(Rus)**

HISTORY

Adolf Hitler's cognitive disorder and how it affected his conduct of World War II. Lieberman A. **Adv Neurol** 1999; 80:459–66 (22 ref.)

Horsemen of the Apocalypse: lessons from the Gulf War. Boyle JS, et al. **ANS Adv Nurs Sci** 1998 Dec;21(2):30–41 (34 ref.)

WAR NEUROSES see **COMBAT DISORDERS**

WARFARIN

ADMINISTRATION & DOSAGE

Warfarin prophylaxis after total knee arthroplasty. Lieberman JR. **Am J Knee Surg** 1999 Winter;12(1):49–53 (22 ref.)

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Hirsh J, et al. **Chest** 1998 Nov;114(5 Suppl):445S–469S (250 ref.)

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation? Schulman S. **Haemostasis** 1998;28 Suppl 3:17–21 (15 ref.)

ADVERSE EFFECTS

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44–8 (36 ref.)

An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Brown MC. **Chemotherapy** 1999 Sep–Oct;45(5):392–5 (6 ref.)

A stuck pig—even on warfarin—doesn't always bleed [editorial; comment] Kitchens CS. **Chest** 1999 Jun; 115(6):1492–3 (6 ref.) Comment on: Chest 1999 Jun;115(6):1667–71.

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation? Schulman S. **Haemostasis** 1998;28 Suppl 3:17–21 (15 ref.)

CONTRAINDICATIONS

Fortnightly review: anticoagulation in heart disease. Hardman SM, et al. **BMJ** 1999 Jan 23;318(7178):238–44 (43 ref.)

THERAPEUTIC USE

Warfarin therapy: evolving strategies in anticoagulation. Horton JD, et al. **Am Fam Physician** 1999 Feb 1; 59(3):635–46 (33 ref.)

Challenges of prescribing low-dose drug therapy for older people. Rochon PA, et al. **CMAJ** 1999 Apr 6; 160(7):1029–31 (34 ref.)

The special case of venous thromboembolism in pregnancy. Greer IA. **Haemostasis** 1998;28 Suppl 3:22–34 (45 ref.)

Atrial fibrillation, thromboembolism and antithrombotic therapy. Li-Saw-Hee FL, et al. **Int J Clin Pract** 1999 Mar; 53(2):110–7 (86 ref.)

Primary antiphospholipid syndrome with recurrent transient ischemic attacks: report of a case and its successful treatment. Ihara M, et al. **Intern Med** 1998 Aug;37(8):704–7 (15 ref.)

Towards the safer use of warfarin I: an overview. Gallus AS. **J Qual Clin Pract** 1999 Mar;19(1):55–9 (22 ref.)

WARTHIN TUMOR see **ADENOLYMPHOMA**

WARTS

[Verruca vulgaris] Egawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):256–8 (15 ref.) **(Jpn)**

COMPLICATIONS

Aggressive bowel lymphoma in a patient with intestinal lymphangiectasia and widespread viral warts [letter] Gumà J, et al. **Ann Oncol** 1998 Dec;9(12):1355–6 (6 ref.)

DIAGNOSIS

[Verruca plana juvenilis] Egawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):259–61 (12 ref.) **(Jpn)**

THERAPY

Topical immunotherapy in dermatology. Buckley DA, et al. **Int J Clin Pract** 1999 Mar;53(2):130–7 (135 ref.)

[Modern wart therapy] Rüdlinger R. **Ther Umsch** 1998 Aug; 55(8):498–502 (12 ref.) (Eng. Abstr.) **(Ger)**

WARTS, GENITAL see **CONDYLOMATA ACUMINATA**

WARTS, VENEREAL see **CONDYLOMATA ACUMINATA**

WASPS

Acute renal failure following multiple wasp stings. Thiruventhiran T, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):214–7 (25 ref.)

PHYSIOLOGY

Management of ectoparasites with biological control organisms. Hogsette JA. **Int J Parasitol** 1999 Jan; 29(1):147–51; discussion 153–4 (19 ref.)

VIROLOGY

[Relationship between parasotoid wasps and polydnaviruses] Hayakawa Y. **Uirusu** 1998 Jun;48(1):67–72 (27 ref.) **(Jpn)**

WASSERMANN REACTION see **SYPHILIS SERODIAGNOSIS**

WASTE DISPOSAL, FLUID

Anaerobic treatment of sulphate-rich wastewaters. Hulshoff Pol LW, et al. **Biodegradation** 1998;9(3–4):213–24 (75 ref.)

Assessment of organic contaminant fate in waste water treatment plants. I: Selected compounds and physicochemical properties. Alcock RE, et al. **Chemosphere** 1999 Apr;38(10):2247–62 (60 ref.)

Genetic improvement of bacteria for enhanced biological removal of phosphate from wastewater. Ohtake H, et al. **Prog Mol Subcell Biol** 1999;23:299–311 (33 ref.)

WASTE DISPOSAL, MEDICAL see **MEDICAL WASTE DISPOSAL**

WASTE DISPOSAL, SOLID see **REFUSE DISPOSAL**

WASTE MANAGEMENT

Nuclear magnetic resonance in environmental engineering: principles and applications. Lens PN, et al. **Biodegradation** 1998;9(6):393–409 (107 ref.)

Management and utilization of poultry wastes. Williams CM, et al. **Rev Environ Contam Toxicol** 1999;162:105–57 (338 ref.)

METHODS

Health, safety, and environmental concerns of farm animal waste. Cole DJ, et al. **Occup Med** 1999 Apr–Jun; 14(2):423–48 (177 ref.)

Safe handling and disposal of laboratory animal waste. Hill D. **Occup Med** 1999 Apr–Jun;14(2):449–68 (41 ref.)

WASTE PRODUCTS

Mycological control and surveillance of biological waste and compost. Beffa T, et al. **Med Mycol** 1998;36 Suppl 1:137–45 (31 ref.)

WASTING DISEASE see **WASTING SYNDROME**

WASTING DISEASE, HIV see **HIV WASTING SYNDROME**

WASTING SYNDROME

see related
CACHEXIA

[Body composition and constitution: constitutional syndrome (second of two parts)] Terán Díaz E. **An Med Interna** 1999 May;16(5):256–62 (122 ref.) **(Spa)**

DIET THERAPY

Dietary treatment in secondary wasting and cachexia. Bistrian BR. **J Nutr** 1999 Jan;129(1S Suppl):290S–294S (58 ref.)

DRUG THERAPY

Anabolic steroids. Creutzberg EC, et al. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):243–53 (43 ref.)

ETIOLOGY

Working group session report: cancer. Hirschfeld S. **J Nutr** 1999 Jan;129(1S Suppl):306S–307S (15 ref.)

Pathophysiology of protein-energy wasting in chronic renal failure. Kopple JD. **J Nutr** 1999 Jan;129(1S Suppl):247S–251S (48 ref.)

Neuropeptide Y: a key molecule in anorexia and cachexia in wasting disorders? Inui A. **Mol Med Today** 1999 Feb; 5(2):79–85 (44 ref.)

GENETICS

New insights into the pathogenesis of inherited phosphate wasting disorders. Econs MJ. **Bone** 1999 Jul;25(1):131–5 (59 ref.)

PHYSIOPATHOLOGY

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Anker SD, et al. **Chest** 1999 Mar;115(3):836–47 (101 ref.)
Nutritional and metabolic endpoints. Haymond MW. **J Nutr** 1999 Jan;129(1S Suppl):273S–278S (20 ref.)
Pathophysiology of protein-energy wasting in chronic renal failure. Kopple JD. **J Nutr** 1999 Jan;129(1S Suppl):247S–251S (48 ref.)
Working group session report: wasting in geriatrics and special consideration in design of trials involving the elderly subjects. Poehlman ET. **J Nutr** 1999 Jan;129(1S Suppl):308S–310S (16 ref.)
The pathophysiology of wasting in the elderly. Roubenoff R. **J Nutr** 1999 Jan;129(1S Suppl):256S–259S (31 ref.)

THERAPY

Perspectives on exercise and wasting. Buskirk ER. **J Nutr** 1999 Jan;129(1S Suppl):295S–302S (24 ref.)
Nutritional and metabolic endpoints. Haymond MW. **J Nutr** 1999 Jan;129(1S Suppl):273S–278S (20 ref.)

WASTING SYNDROME, HIV see **HIV WASTING SYNDROME**

WATER

see related
BODY WATER
FRESH WATER
SEAWATER

Octanol–water partition: searching for predictive models. Buchwald P, et al. **Curr Med Chem** 1998 Oct;5(5):353–80 (308 ref.)
Diuretics, beta-blockers, and gin and tonic [see comments] Messerli FH, et al. **Eur Heart J** 1999 Jan;20(1):25–30 (54 ref.) Comment in: Eur Heart J 1999 Jan;20(1):5–6.
The role of water structure in conformational changes of nucleic acids in ambient and high-pressure conditions. Barciszewski J, et al. **Eur J Biochem** 1999 Mar; 260(2):293–307 (116 ref.)
The puzzle of hydrodynamic information processing: how are complex water motions analyzed by the lateral line? Mogdans J, et al. **Eur J Morphol** 1999 Apr;37(2–3):195–9 (17 ref.)
The Galilean satellites. Showman AP, et al. **Science** 1999 Oct 1;286(5437):77–84 (121 ref.)

ANALYSIS

Quantitative measurements of water concentration of the stratum corneum In vivo by high-frequency current. Tagami H. **Acta Derm Venereol Suppl (Stockh)** 1994; 185:29–33 (23 ref.)
Water analysis. Richardson SD. **Anal Chem** 1999 Jun 15; 71(12):181R–215R (631 ref.)

CHEMISTRY

The decisive role of the water structure in changes of conformation of nucleic acids. Barciszewski J, et al. **Acta Biochim Pol** 1999;46(1):133–44 (37 ref.)
Disinfection by-products and adverse pregnancy outcomes: what is the agent and how should it be measured? [editorial; comment] Swan SH, et al. **Epidemiology** 1998 Sep; 9(5):479–81 (13 ref.) Comment on: Epidemiology 1998 Sep;9(5):484–9.
Comparison of various cosolvency models for calculating solute solubility in water–cosolvent mixtures. Jouyban-Gharamaleki A, et al. **Int J Pharm** 1999 Jan 15; 177(1):93–101 (35 ref.)
Application of capillary electrophoresis to the analysis of inorganic ions in environmental samples. Fukushi K, et al. **J Chromatogr A** 1999 Feb 26;834(1–2):349–62 (67 ref.)
Crystallographic water sites from a theoretical perspective. Feig M, et al. **Structure** 1998 Nov 15;6(11):1351–4 (44 ref.)

METABOLISM

Recent advances in the understanding of water metabolism in heart failure. Schrier RW, et al. **Adv Exp Med Biol** 1998; 449:415–26 (78 ref.)
Modulation of vasopressin-elicited water transport by trafficking of aquaporin2-containing vesicles. Ward DT, et al. **Annu Rev Physiol** 1999;61:683–97 (97 ref.)
Managing hypoosmotic stress: aquaporins and mechanosensitive channels in Escherichia coli. Booth IR, et al. **Curr Opin Microbiol** 1999 Apr;2(2):166–9 (24 ref.)
Evolving ideas about osmosis and capillary fluid exchange. Hammel HT. **FASEB J** 1999 Feb;13(2):213–31 (38 ref.)
Importance of interfacial water in permeabilization of ceramide bilayers. Neitchev V, et al. **Histol Histopathol** 1998 Jul;13(3):911–20 (51 ref.)
The renin-angiotensin system and its receptors. Stroth U, et al. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S21–8; discussion S41–3 (115 ref.)
Guide for judicious use of the paracetamol absorption technique in a study of gastric emptying rate of liquids. Sanaka M, et al. **J Gastroenterol** 1998 Dec;33(6):785–91 (51 ref.)
Aquaporins. Echevarría M, et al. **J Physiol Biochem** 1998 Jun;54(2):107–18 (96 ref.)
Water transport revisited. Powell DW. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):1 (6 ref.)
Urinary excretion of aquaporin-2 in disorders of water metabolism [editorial] Ishikawa S, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1615–6 (13 ref.)
Aquaporins (water channels): role in vasopressin-activated water transport. Dibas AI, et al. **Proc Soc Exp Biol Med** 1998 Dec;219(3):183–99 (183 ref.)
[Vasopressin and water metabolism] Oiso Y. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):392–5 (5 ref.) **(Jpn)**

PARASITOLOGY

Cryptosporidium in water. Report of the consensus conference on Cryptosporidium in water, Melbourne, October 1998. Douglas R, et al. **Commun Dis Intell** 1999 Jun 10;23(6):170–2 (0 ref.)
Cryptosporidia and microsporidia—waterborne diseases in the immunocompromised host. Franzen C, et al. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):245–62 (140 ref.)
Protozoa in drinking water: is legislation the best answer? [editorial] Sinclair MI, et al. **Med J Aust** 1998 Sep 21; 169(6):296–7 (14 ref.)
[Cryptosporidium and water] Lerman de Abramovich B, et al. **Rev Argent Microbiol** 1999 Apr–Jun;31(2):97–105 (73 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

[Use of water activated by electrochemical method] Deviatov VA, et al. **Khirurgiia (Mosk)** 1998;(7):61–3 (57 ref.) **(Rus)**

PHYSIOLOGY

Water and electrolyte requirements for exercise. Latzka WA, et al. **Clin Sports Med** 1999 Jul;18(3):513–24 (74 ref.)
Water: an essential but overlooked nutrient [published erratum appears in J Am Diet Assoc 1999 Apr;99(4):411] Kleiner SM. **J Am Diet Assoc** 1999 Feb;99(2):200–6 (81 ref.)

STANDARDS

Water quality for on-line haemodiafiltration. Cappelli G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:12–6 (34 ref.)

WATER BUFFALOES see **BUFFALOES**

WATER CHANNEL PROTEINS see **AQUAPORINS**

WATER CHANNELS see **AQUAPORINS**

WATER CONSUMPTION see **DRINKING**

WATER DEPRIVATION

see related
THIRST

WATER-ELECTROLYTE BALANCE

see related
FLUID THERAPY
OSMOLAR CONCENTRATION
REHYDRATION SOLUTIONS
WATER-ELECTROLYTE IMBALANCE

Fluid management of bacterial meningitis in developing countries. Duke T. **Arch Dis Child** 1998 Aug;79(2):181–5 (30 ref.)
Osmoregulation in clinical disorders of thirst appreciation. McKenna K, et al. **Clin Endocrinol (Oxf)** 1998 Aug; 49(2):139–52 (91 ref.)
Water and electrolyte requirements for exercise. Latzka WA, et al. **Clin Sports Med** 1999 Jul;18(3):513–24 (74 ref.)
Fluid and electroylyte balance in the elderly. Beck LH. **Geriatr Nephrol Urol** 1999;9(1):11–4 (16 ref.)
Stress and water balance: the roles of ANP, AVP and isatin. Bhattacharya SK, et al. **Indian J Exp Biol** 1998 Dec; 36(12):1195–200 (85 ref.)
The role of hyperthermia in the water economy of desert birds. Tieleman BI, et al. **Physiol Biochem Zool** 1999 Jan–Feb;72(1):87–100 (67 ref.)
Fluid and electrolyte balance for adults (without a biochemical laboratory). Tovey F. **Trop Doct** 1999 Jan; 29(1):49–53 (0 ref.)
Fluid therapy and newer blood products. Broadstone RV. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):611–28 (30 ref.)
Colonic fluid and electrolyte transport in health and disease. Rolfe V. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):577–88, viii (60 ref.)
[Hyponatremia, toward a logical approach: the balance of tonicity (published erratum appears in Nephrologie 1999;20(1):51)] Mallié JP, et al. **Nephrologie** 1998; 19(8):469–80 (44 ref.) (Eng. Abstr.) **(Fre)**
[Guanylin family: new intestinal peptides regulating salt and water homeostasis] Date Y, et al. **Nippon Rinsho** 1998 Sep; 56(9):2427–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Effect of ethanol ingestion on renal regulation of water and electrolytes. Rodrigo R, et al. **Arch Med Res** 1998 Autumn; 29(3):209–18 (96 ref.)

GENETICS

Brain mechanisms of mammalian fluid homeostasis: insights from use of immediate early gene mapping. Rowland NE. **Neurosci Biobehav Rev** 1998;23(1):49–63 (124 ref.)

PHYSIOLOGY

Recent advances in the understanding of water metabolism in heart failure. Schrier RW, et al. **Adv Exp Med Biol** 1998; 449:415–26 (78 ref.)
Something fishy in the rat brain: molecular genetics of the hypothalamo-neurohypophysial system. Murphy D, et al. **Bioessays** 1998 Sep;20(9):741–9 (62 ref.)
Role of urinary and cloacal bladders in chelonian water economy: historical and comparative perspectives. Jørgensen CB. **Biol Rev Camb Philos Soc** 1998 Nov; 73(4):347–66 (134 ref.)
Cellular osmoregulation in kidney medulla. Beck FX, et al. **Contrib Nephrol** 1998;123:169–84 (115 ref.)
Osmoregulation of liver cell function: signalling, osmolytes and cell heterogeneity. Häussinger D. **Contrib Nephrol** 1998;123:185–204 (100 ref.)
Renal aquaporins: key roles in water balance and water balance disorders. Nielsen S, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):509–16 (53 ref.)
A review of water balance in ageing in health and disease. Stout NR, et al. **Gerontology** 1999;45(2):61–6 (43 ref.)
Role of nitric oxide in intestinal water and electrolyte transport. Mourad FH, et al. **Gut** 1999 Feb;44(2):143–7 (78 ref.)
Fluid–electrolyte balance during labor and exercise: concepts and misconceptions. Armstrong LE, et al. **Int J Sport Nutr** 1999 Mar;9(1):1–12 (73 ref.)
Physiology and pathophysiology of renal aquaporins. Nielsen S, et al. **J Am Soc Nephrol** 1999 Mar;10(3):647–63 (119 ref.)
From vasopressin receptor to water channel: intracellular traffic, constraint and by-pass. Laycock JF, et al. **J Endocrinol** 1998 Dec;159(3):361–72 (77 ref.)
Unique evolution of neurohypophysial hormones in cartilaginous fishes: possible implications for urea-based osmoregulation. Acher R, et al. **J Exp Zool** 1999 Oct 1; 284(5):475–84 (60 ref.)
Osmoregulation in the mammalian kidney: the role of organic osmolytes. Grunewald RW, et al. **J Exp Zool** 1999 Jun 1;283(7):708–24 (153 ref.)
Organic osmolyte channels in cell volume regulation in vertebrates. Perlman DF, et al. **J Exp Zool** 1999 Jun 1; 283(7):725–33 (58 ref.)
Vertebrate salt glands: short- and long-term regulation of function. Shuttleworth TJ, et al. **J Exp Zool** 1999 Jun 1; 283(7):689–701 (104 ref.)
Pathophysiology of renal fluid retention. Schrier RW, et al. **Kidney Int Suppl** 1998 Sep;67:S127–32 (62 ref.)
Hormones and hemodynamics in heart failure. Schrier RW, et al. **N Engl J Med** 1999 Aug 19;341(8):577–85 (60 ref.)
Osmoregulation of vasopressin neurons: a synergy of intrinsic and synaptic processes. Bourque CW. **Prog Brain Res** 1998; 119:59–76 (120 ref.)
[Kidney aging: cellular mechanisms of problems of hydration equilibrium] Teillet L, et al. **Therapie** 1999 Jan–Feb; 54(1):147–54 (43 ref.) (Eng. Abstr.) **(Fre)**
[Stoma physiology] Stern J, et al. **Chirurg** 1999 Jun; 70(6):627–34 (35 ref.) (Eng. Abstr.) **(Ger)**
[Renal renin-angiotensin system in homeostatic water-electrolyte regulation] Lis GJ. **Przegl Lek** 1999; 56(2):164–8 (30 ref.) (Eng. Abstr.) **(Pol)**

WATER-ELECTROLYTE IMBALANCE

see related
FLUID THERAPY
REHYDRATION SOLUTIONS

Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Siegel AJ, et al. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):190–200 (53 ref.)
[Acute renal failure and electrolyte problems in the elderly] Okuda S. **Nippon Ronen Igakkai Zasshi** 1998 Aug; 35(8):615–8 (6 ref.) **(Jpn)**

COMPLICATIONS

Salt and hypertension in end-stage renal disease [editorial] Kooman JP, et al. **Blood Purif** 1998;16(6):301–11 (69 ref.)
Chest wall elastance and acute respiratory failure [editorial; comment] Jardin F. **Crit Care Med** 1999 Aug;27(8):1653–4 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1454–60.
[Tubulo-interstitial nephropathies caused by electrolyte disturbances] Imai E. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1454–8 (6 ref.) **(Jpn)**

DIAGNOSIS

Bioimpedance and the estimation of net fluid balance in critical care patients: problems and possibilities [editorial; comment] Zarowitz BJ, et al. **Crit Care Med** 1999 Aug; 27(8):1655–7 (14 ref.) Comment on: Crit Care Med 1999 Aug;27(8):1472–7.
[Disturbances of effective osmolality regulation in disorders of the central nervous system and possible methods of monitoring] Balik M, et al. **Cas Lek Cesk** 1998 Aug 24;

WATER-ELECTROLYTE IMBALANCE

137(16):488–92 (0 ref.) (Eng. Abstr.) **(Cze)**
[Disorders of sodium and water balance. Diagnosis and therapy.] Rüchardt A, et al. **Internist (Berl)** 1999 Aug; 40(8):W861–71 (9 ref.) **(Ger)**
[Urinary excretion of aquaporin-2 in water metabolism disorders] Ishikawa S, et al. **Rinsho Byori** 1999 May; 47(5):402–7 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Serum uric acid level and fractional excretion of urate in fluid and electrolyte disturbances] Shichiri M, et al. **Rinsho Byori** 1999 May;47(5):417–23 (15 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Neurohormonal responses during positive pressure mechanical ventilation. Frazier SK. **Heart Lung** 1999 May–Jun;28(3):149–65; quiz 166–7 (58 ref.)
[Sodium and water balance for clinical routine practice] Luft FC. **Internist (Berl)** 1998 Aug;39(8):804–9 (9 ref.) **(Ger)**

METABOLISM

Renal aquaporins: key roles in water balance and water balance disorders. Nielsen S, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):509–16 (53 ref.)
Pathogenesis of sodium and water retention in cardiac failure. Schrier RW, et al. **Ren Fail** 1998 Nov;20(6):773–81 (41 ref.)

PHYSIOPATHOLOGY

A review of water balance in ageing in health and disease. Stout NR, et al. **Gerontology** 1999;45(2):61–6 (43 ref.)
Neurohormonal responses during positive pressure mechanical ventilation. Frazier SK. **Heart Lung** 1999 May–Jun;28(3):149–65; quiz 166–7 (58 ref.)
[Aging and water metabolism in health and illness] Miller M. Z **Gerontol Geriatr** 1999 Jul;32 Suppl 1:120–6 (44 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diabetic ketoacidosis. Brink SJ. **Acta Paediatr Suppl** 1999 Jan;88(427):14–24 (58 ref.)
Selective review of key perioperative renal–electrolyte disturbances in chronic renal failure patients. Yee J, et al. **Chest** 1999 May;115(5 Suppl):149S–157S (40 ref.)
[Disorders of sodium and water balance. Diagnosis and therapy.] Rüchardt A, et al. **Internist (Berl)** 1999 Aug; 40(8):W861–71 (9 ref.) **(Ger)**

WATER INTAKE see **DRINKING**

WATER INTOXICATION

see related
WATER-ELECTROLYTE IMBALANCE
Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Siegel AJ, et al. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):190–200 (53 ref.)

NURSING

Water intoxication awareness [letter] Searcy CE. **Nurse Pract** 1999 Feb;24(2):26, 141–2 (12 ref.)

WATER LOSS, INSENSIBLE

Quantitative measurements of water concentration of the stratum corneum In vivo by high-frequency current. Tagami H. **Acta Derm Venereol Suppl (Stockh)** 1994; 185:29–33 (23 ref.)

PHYSIOLOGY

Skin hydration: recent advances. Ozawa T, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;185:26–8 (6 ref.)
Bioengineering and the skin: from standard error to standard operating procedure. Serup J. **Acta Derm Venereol Suppl (Stockh)** 1994;185:5–8 (15 ref.)
Aging and the epidermal permeability barrier: implications for contact dermatitis. Ghadially R. **Am J Contact Dermat** 1998 Sep;9(3):162–9 (77 ref.)

WATER MICROBIOLOGY

Water analysis. Richardson SD. **Anal Chem** 1999 Jun 15; 71(12):181R–215R (631 ref.)
Bacterial dehalogenation. Fetzner S. **Appl Microbiol Biotechnol** 1998 Dec;50(6):633–57 (183 ref.)
The chemical control of biofouling in industrial water systems. Cloete TE, et al. **Biodegradation** 1998;9(1):23–37 (83 ref.)
Microsensors as a tool to determine chemical microgradients and bacterial activity in wastewater biofilms and flocs. Santegoeds CM, et al. **Biodegradation** 1998;9(3–4):159–67 (46 ref.)
Water, water everywhere but not a drop to drink? Smith AJ, et al. **Br Dent J** 1999 Jan 9;186(1):12–4 (27 ref.)
Biofilms, infectious agents, and dental unit waterlines: a review. Barbeau J, et al. **Can J Microbiol** 1998 Nov; 44(11):1019–28 (90 ref.)
Barophiles: deep-sea microorganisms adapted to an extreme environment. Horikoshi K. **Curr Opin Microbiol** 1998 Jun; 1(3):291–5 (30 ref.)
Structure and function of anthropogenically altered microbial communities in coastal waters. Paerl HW. **Curr Opin Microbiol** 1998 Jun;1(3):296–302 (68 ref.)
Cyclospora: an enigma worth unraveling. Sterling CR, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):48–53 (43 ref.)
Extremophiles and their adaptation to hot environments. Stetter KO. **FEBS Lett** 1999 Jun 4;452(1–2):22–5 (40 ref.)
Protozoa in drinking water: is legislation the best answer? [editorial] Sinclair MI, et al. **Med J Aust** 1998 Sep 21; 169(6):296–7 (14 ref.)
A natural view of microbial biodiversity within hot spring cyanobacterial mat communities. Ward DM, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1353–70 (177 ref.)
The survival strategy of Vibrio cholerae. Sood S, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):96–7 (17 ref.)
[Waterborne microbiological risk assessment: a state of the art and perspectives] Gofti L, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):61–73 (43 ref.) (Eng. Abstr.) **(Fre)**
[Calicivirus. The virus which emerges in ocean reservoirs] Reina J, et al. **Enferm Infecc Microbiol Clin** 1999 Apr; 17(4):184–7 (41 ref.) **(Spa)**
[Human parasites and amoeba: lower warm-water temperature is favourable to Legionella bacteria] Bernander S, et al. **Lakartidningen** 1998 Sep 30;95(40):4340–4 (43 ref.) (Eng. Abstr.) **(Swe)**

WATER POLLUTANTS

Pollutants in our water: effects on human health and the environment. Hicks JN. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):502–5 (20 ref.)

ANALYSIS

Environmental analysis. Clement RE, et al. **Anal Chem** 1999 Jun 15;71(12):257R–292R (756 ref.)
Water analysis. Richardson SD. **Anal Chem** 1999 Jun 15; 71(12):181R–215R (631 ref.)
Human exposures to arsenic from consumption of well water in West Bengal, India. Subramanian KS, et al. **Int J Occup Environ Health** 1998 Oct–Dec;4(4):217–30 (22 ref.)

PHARMACOLOGY

The effects of pollutants on the immune response of fish: implications for helminth parasites. Hoole D. **Parassitologia** 1997 Sep;39(3):219–25 (58 ref.)

TOXICITY

An ecological risk assessment for the use of Irgarol 1051 as an algaecide for antifoulant paints. Hall LW Jr, et al. **Crit Rev Toxicol** 1999 Jul;29(4):367–437 (103 ref.)
Manganese in the context of an integrated risk and decision process. Weiss B. **Neurotoxicology** 1999 Apr–Jun; 20(2–3):519–25 (17 ref.)

WATER POLLUTANTS, CHEMICAL

Reducing phosphorus runoff and improving poultry production with alum. Moore PA Jr, et al. **Poult Sci** 1999 May;78(5):692–8 (26 ref.)

ADVERSE EFFECTS

Environmental selenium and cancer: risk or protection? [editorial; comment] Clark LC, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):847–8; discussion 851–2 (14 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.
False presumptions and continued surprises: how much do we really know about nutritional supplements and cancer risk? [editorial; comment] Kristal AR, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):849–50; discussion 851–2 (12 ref.) Comment on: Cancer Epidemiol Biomarkers Prev 1998 Oct;7(10):853–6.
Infantile methemoglobinemia: reexamining the role of drinking water nitrates. Avery AA. **Environ Health Perspect** 1999 Jul;107(7):583–6 (37 ref.)
Disinfection by-products and adverse pregnancy outcomes: what is the agent and how should it be measured? [editorial; comment] Swan SH, et al. **Epidemiology** 1998 Sep; 9(5):479–81 (13 ref.) Comment on: Epidemiology 1998 Sep;9(5):484–9.
The impact of rice pesticides on the aquatic ecosystems of the Sacramento River and Delta (California). Byard JL. **Rev Environ Contam Toxicol** 1999;159:95–110 (32 ref.)
Aquatic biotoxins: design and implementation of seafood safety monitoring programs. Park DL, et al. **Rev Environ Contam Toxicol** 1999;161:157–200 (182 ref.)
[The effect of the mineral composition of drinking water on the health of the population (a review)] Mudryi IV. **Gig Sanit** 1999 Jan–Feb;(1):15–8 (44 ref.) **(Rus)**

ANALYSIS

Biomonitoring in the aquatic environment: use of molecular biomarkers. Goldfarb P, et al. **Biochem Soc Trans** 1998 Nov;26(4):690–4 (19 ref.)
Cyanobacterial toxins in Portugal: effects on aquatic animals and risk for human health. Vasconcelos VM. **Braz J Med Biol Res** 1999 Mar;32(3):249–54 (40 ref.)
Selenium transport and bioaccumulation in aquatic ecosystems: a proposal for water quality criteria based on hydrological units. Lemly AD. **Ecotoxicol Environ Saf** 1999 Feb;42(2):150–6 (27 ref.)
Disinfection by-products and adverse pregnancy outcomes: what is the agent and how should it be measured? [editorial; comment] Swan SH, et al. **Epidemiology** 1998 Sep; 9(5):479–81 (13 ref.) Comment on: Epidemiology 1998 Sep;9(5):484–9.
Relationship of lead in drinking water to bone lead levels twenty years later in Boston men: the Normative Aging Study. Potula V, et al. **J Occup Environ Med** 1999 May; 41(5):349–55 (32 ref.)
Organochlorine residues and elemental contaminants in U.S. freshwater fish, 1976–1986: National Contaminant Biomonitoring Program. Schmitt CJ, et al. **Rev Environ Contam Toxicol** 1999;162:43–104 (160 ref.)

METABOLISM

Anaerobic treatment of sulphate-rich wastewaters. Hulshoff Pol LW, et al. **Biodegradation** 1998;9(3–4):213–24 (75 ref.)
Degradation of polydimethylsiloxane fluids in the environment--a review. Griessbach EF, et al. **Chemosphere** 1999 Mar;38(6):1461–8 (18 ref.)
Bioremediation of petroleum hydrocarbon contaminants in marine habitats. Head IM, et al. **Curr Opin Biotechnol** 1999 Jun;10(3):234–9 (39 ref.)
Microbial dehalogenases: enzymes recruited to convert xenobiotic substrates. Copley SD. **Curr Opin Chem Biol** 1998 Oct;2(5):613–7 (39 ref.)

PHARMACOKINETICS

The fate of organic xenobiotics in aquatic ecosystems: quantitative and qualitative differences in biotransformation by invertebrates and fish. Livingstone DR. **Comp Biochem Physiol A Mol Integr Physiol** 1998 May; 120(1):43–9 (39 ref.)
Bioaccumulation of contaminants in fish. Streit B. **EXS** 1998; 86:353–87 (80 ref.)

TOXICITY

An overview of recent studies on the potential of pulp-mill effluents to alter reproductive parameters in fish. Munkittrick KR, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct–Dec; 1(4):347–71 (92 ref.)
Epizootics of cancer in fish associated with genotoxins in sediment and water. Baumann PC. **Mutat Res** 1998 Nov; 411(3):227–33 (48 ref.)
Molecular epizootiology of genotoxic events in marine fish: linking contaminant exposure, DNA damage, and tissue-level alterations. Reichert WL, et al. **Mutat Res** 1998 Nov;411(3):215–25 (40 ref.)
The internal critical level concept of nonspecific toxicity. Chaisuksant Y, et al. **Rev Environ Contam Toxicol** 1999; 162:1–41 (196 ref.)
Spatial and temporal trends of contaminants in Canadian Arctic freshwater and terrestrial ecosystems: a review. Braune B, et al. **Sci Total Environ** 1999 Jun 1; 230(1–3):145–207 (204 ref.)

WATER POLLUTION

The importance of water quality for media preparation. Wiemer KE, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:166–72 (10 ref.)
Evaluation of environmental deterioration by analysing fish parasite biodiversity and community structure. D'Amelio S, et al. **Parassitologia** 1997 Sep;39(3):237–41 (7 ref.)
Freshwater fish parasites and environmental quality: an overview and caution. Kennedy CR. **Parassitologia** 1997 Sep;39(3):249–54 (12 ref.)
[Waterborne microbiological risk assessment: a state of the art and perspectives] Gofti L, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):61–73 (43 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

The development of marine environmental monitoring using fish diseases. McVicar AH. **Parassitologia** 1997 Sep; 39(3):177–81 (15 ref.)
Legionella infection and control in occupational and environmental health [published erratum appears in Rev Environ Health 1999 Jan–Mar;14(1):following table of contents] Fujii J, et al. **Rev Environ Health** 1998 Oct–Dec; 13(4):179–203 (46 ref.)

ANALYSIS

Cyanobacterial toxins in Portugal: effects on aquatic animals and risk for human health. Vasconcelos VM. **Braz J Med Biol Res** 1999 Mar;32(3):249–54 (40 ref.)

LEGISLATION & JURISPRUDENCE

Statistics and environmental policy: case studies from long-term environmental monitoring data. Goudey R, et al. **Novartis Found Symp** 1999;220:144–53; discussion 154–7 (12 ref.)
Better late than never? Injecting statistical know-how into legislation on water quality. Warn AE. **Novartis Found Symp** 1999;220:158–66; discussion 166–9 (3 ref.)

PREVENTION & CONTROL

Solutions for a water-short world. **Popul Rep M** 1998 Sep; (14):1-31 (223 ref.)

STATISTICS & NUMERICAL DATA

Water pollution and human health in China. Wu C, et al. **Environ Health Perspect** 1999 Apr;107(4):251-6 (32 ref.)

Statistics and environmental policy: case studies from long-term environmental monitoring data. Goudey R, et al. **Novartis Found Symp** 1999;220:144-53; discussion 154-7 (12 ref.)

Better late than never? Injecting statistical know-how into legislation on water quality. Warn AE. **Novartis Found Symp** 1999;220:158-66; discussion 166-9 (3 ref.)

WATER POLLUTION, CHEMICAL

see related
EUTROPHICATION

Structure and function of anthropogenically altered microbial communities in coastal waters. Paerl HW. **Curr Opin Microbiol** 1998 Jun;1(3):296-302 (68 ref.)

ADVERSE EFFECTS

Tetrahymena pyriformis: a tool for toxicological studies. A review. Sauvant MP, et al. **Chemosphere** 1999 Mar; 38(7):1631-69 (177 ref.)

Kerosene-induced severe acute respiratory failure in near drowning: reports on four cases and review of the literature. Segev D, et al. **Crit Care Med** 1999 Aug; 27(8):1437-40 (14 ref.)

Chronic environmental arsenic poisoning. Piamphongsant T. **Int J Dermatol** 1999 Jun;38(6):401-10 (90 ref.)

WATER POLLUTION, RADIOACTIVE

ADVERSE EFFECTS

Is technetium-99 (Tc-99) radiologically significant? Barnaby F, et al. **Med Confl Surviv** 1999 Jan-Mar;15(1):57-70 (28 ref.)

ANALYSIS

Review of historical monitoring data on Techa River contamination. Vorobiova MI, et al. **Health Phys** 1999 Jun; 76(6):605-18 (35 ref.)

WATER POLLUTION, THERMAL see **WATER POLLUTION**

WATER PURIFICATION

Workshop report. Health risks of drinking water chlorination by-products: report of an expert working group. Mills CJ, et al. **Chronic Dis Can** 1998;19(3):91-102 (52 ref.)

Safe drinking water: a public health challenge. Wigle DT. **Chronic Dis Can** 1998;19(3):103-7 (36 ref.)

LEGISLATION & JURISPRUDENCE

Protozoa in drinking water: is legislation the best answer? [editorial] Sinclair MI, et al. **Med J Aust** 1998 Sep 21; 169(6):296-7 (14 ref.)

METHODS

The chemical control of biofouling in industrial water systems. Cloete TE, et al. **Biodegradation** 1998;9(1):23-37 (83 ref.)

Disinfection by-products and adverse pregnancy outcomes: what is the agent and how should it be measured? [editorial; comment] Swan SH, et al. **Epidemiology** 1998 Sep; 9(5):479-81 (13 ref.) Comment on: Epidemiology 1998 Sep;9(5):484-9.

Chelant extraction of heavy metals from contaminated soils. Peters RW. **J Hazard Mater** 1999 Apr 23;66(1-2):151-210 (91 ref.)

Application of remedy studies to the development of a soil washing pilot plant that uses mineral processing technology: a practical experience. Richardson WS 3rd, et al. **J Hazard Mater** 1999 Apr 23;66(1-2):47-65 (20 ref.)

[Use of water activated by electrochemical method] Deviatov VA, et al. **Khirurgiia (Mosk)** 1998;(7):61-3 (57 ref.) **(Rus)**

WATER SUPPLY

see related
WATER PURIFICATION

Sources of human exposure: overview of water supplies as sources of boron. Coughlin JR. **Biol Trace Elem Res** 1998 Winter;66(1-3):87-100 (17 ref.)

Managing the ecosystem to improve human health: integrated approaches to safe drinking water. Forget G, et al. **Int J Occup Environ Health** 1999 Jan-Mar;5(1):38-50 (42 ref.)

The unique riverine ecology of hepatitis E virus transmission in South-East Asia. Corwin AL, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):255-60 (30 ref.)

[Waterborne microbiological risk assessment: a state of the art and perspectives] Gofti L, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):61-73 (43 ref.) (Eng. Abstr.) **(Fre)**

[Chlorination of drinking water--possible cancer risk from a by-product] Holme JA, et al. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2528-30 (19 ref.) (Eng. Abstr.) **(Nor)**

[The effect of the mineral composition of drinking water on the health of the population (a review)] Mudryi IV. **Gig Sanit** 1999 Jan-Feb;(1):15-8 (44 ref.) **(Rus)**

ANALYSIS

Infantile methemoglobinemia: reexamining the role of drinking water nitrates. Avery AA. **Environ Health Perspect** 1999 Jul;107(7):583-6 (37 ref.)

Human exposures to arsenic from consumption of well water in West Bengal, India. Subramanian KS, et al. **Int J Occup Environ Health** 1998 Oct-Dec;4(4):217-30 (22 ref.)

LEGISLATION & JURISPRUDENCE

Water analysis. Richardson SD. **Anal Chem** 1999 Jun 15; 71(12):181R-215R (631 ref.)

Protozoa in drinking water: is legislation the best answer? [editorial] Sinclair MI, et al. **Med J Aust** 1998 Sep 21; 169(6):296-7 (14 ref.)

STANDARDS

Selenium transport and bioaccumulation in aquatic ecosystems: a proposal for water quality criteria based on hydrological units. Lemly AD. **Ecotoxicol Environ Saf** 1999 Feb;42(2):150-6 (27 ref.)

Protozoa in drinking water: is legislation the best answer? [editorial] Sinclair MI, et al. **Med J Aust** 1998 Sep 21; 169(6):296-7 (14 ref.)

Solutions for a water-short world. **Popul Rep M** 1998 Sep; (14):1-31 (223 ref.)

[Human parasites and amoeba: lower warm-water temperature is favourable to Legionella bacteria] Bernander S, et al. **Lakartidningen** 1998 Sep 30;95(40):4340-4 (43 ref.) (Eng. Abstr.) **(Swe)**

WATERHOUSE-FRIDERICHSEN SYNDROME

ETIOLOGY

Reminder--necrotizing fasciitis complicated by Waterhouse-Friderichsen syndrome. Dunstan SP. **Br J Oral Maxillofac Surg** 1999 Jun;37(3):217-8 (14 ref.)

WATERMELON STOMACH see **GASTRIC ANTRAL VASCULAR ECTASIA**

WATERY DIARRHEA SYNDROME see **VIPOMA**

WATERY DIARRHEA WITH HYPOKALEMIC ALKALOSIS see **VIPOMA**

WDHA see **VIPOMA**

WDHH see **VIPOMA**

WEANING

[Nutrition of young piglets in relation to weaning problems] Everts H, et al. **Tijdschr Diergeneeskd** 1999 Jan 15; 124(2):44-7 (15 ref.) (Eng. Abstr.) **(Dut)**

WEASELS see **CARNIVORA**

WEATHER

[Exploration of the effects of el nino on cholera epidemic] Wang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):53-4 (12 ref.) **(Chi)**

[Climatic changes and transmissible diseases] Amat-Roze JM. **Med Trop (Mars)** 1998;58(2 Suppl):42-7 (22 ref.) (Eng. Abstr.) **(Fre)**

WEAVER MICE see **MICE, NEUROLOGIC MUTANTS**

WEBER-CHRISTIAN DISEASE see **PANNICULITIS, NODULAR NONSUPPURATIVE**

WEBER-COCKAYNE SYNDROME see **EPIDERMOLYSIS BULLOSA SIMPLEX**

WEDENSKY INHIBITION see **NEURAL CONDUCTION**

WEGENER'S GRANULOMATOSIS

Rare diseases.3: Wegener's granulomatosis. Langford CA, et al. **Thorax** 1999 Jul;54(7):629-37 (68 ref.)

[Wegener's granulomatosis] Okabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):110-4 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. Pillinger M, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):124-9 (31 ref.)

COMPLICATIONS

Wegener's granulomatosis presenting as facial palsy. Magliulo G, et al. **Am J Otolaryngol** 1999 Jan-Feb;20(1):43-5 (6 ref.)

Urethral diverticulum: an unusual presentation of Wegener's granulomatosis. Goldman HB, et al. **J Urol** 1999 Mar; 161(3):917-8 (3 ref.)

Wegener's granulomatosis in pregnancy--the therapeutic dilemma. Harber MA, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1789-91 (33 ref.)

An overlap syndrome with features of atypical Cogan syndrome and Wegener's granulomatosis. Gran JT, et al. **Scand J Rheumatol** 1999;28(1):62-4 (12 ref.)

DIAGNOSIS

Pathogenesis of Wegener's granulomatosis. Gross WL, et al. **Ann Med Interne (Paris)** 1998 Sep;149(5):280-6 (44 ref.)

Urethral diverticulum: an unusual presentation of Wegener's granulomatosis. Goldman HB, et al. **J Urol** 1999 Mar; 161(3):917-8 (3 ref.)

Current aspects of the pathogenesis and therapy of Wegener's granulomatosis. Gross WL, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):299-302 (16 ref.)

[Clinical significance of "ANCA" in the diagnosis of Wegener's granulomatosis: 8 years of experience] Vacchi Suzzi M, et al. **Acta Otorhinolaryngol Ital** 1998 Aug; 18(4):239-48 (39 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Squamous cell carcinoma of the nasal septum with Wegener's granulomatosis treated with cyclophosphamide and corticosteroids. Wakisaka N, et al. **Auris Nasus Larynx** 1998 Dec;25(4):393-6 (18 ref.)

Current aspects of the pathogenesis and therapy of Wegener's granulomatosis. Gross WL, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):299-302 (16 ref.)

[Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis] Shimizu A, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Jan;90(1):53-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular approaches for identification of infectious agents in Wegener's granulomatosis and other vasculitides. Nikkari S, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):11-6 (52 ref.)

IMMUNOLOGY

[Clinical significance of "ANCA" in the diagnosis of Wegener's granulomatosis: 8 years of experience] Vacchi Suzzi M, et al. **Acta Otorhinolaryngol Ital** 1998 Aug; 18(4):239-48 (39 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes. Ferrario F, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1627-31 (37 ref.)

Wegener's granulomatosis: case report and literature review. Stein SL, et al. **Pediatr Dermatol** 1998 Sep-Oct;15(5):352-6 (11 ref.)

WEIBEL-PALADE BODIES

see related
VON WILLEBRAND FACTOR

WEIGHT-BEARING

A review of metallic, ceramic and surface-treated metals used for bearing surfaces in human joint replacements. Dearnley PA. **Proc Inst Mech Eng [H]** 1999;213(2):107-35 (87 ref.)

[How does one manage the off-loading of a chronic diabetic foot ulcer?] Ha Van G, et al. **Diabetes Metab** 1999 Sep; 25(3):264-9 (22 ref.) **(Fre)**

PHYSIOLOGY

The psychophysical approach to manual materials handling task design. Ayoub MM, et al. **Ergonomics** 1999 Jan; 42(1):17-31 (55 ref.)

[What is the value of biomechanical knowledge for surgery of the hand?] Kummer B, et al. **Handchir Mikrochir Plast Chir** 1998 Jul;30(4):212-8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanical aspects of load-bearing capacity after total endoprosthesis replacement of the hip joint. An evaluation of current knowledge and review of the literature] Wirtz DC, et al. **Z Orthop Ihre Grenzgeb** 1998 Jul-Aug; 136(4):310-6 (69 ref.) (Eng. Abstr.) **(Ger)**

WEIGHT GAIN

see related
OBESITY

Invited commentary on "early and late weight gain following smoking cessation in the Lung Health Study" [comment] Thun MJ, et al. **Am J Epidemiol** 1998 Nov 1;148(9):831-2 (21 ref.) Comment on: Am J Epidemiol 1998 Nov

WEIGHT GAIN

1;148(9):821–30.
Perimenopausal weight gain and progression of breast cancer precursors. Stoll BA. **Cancer Detect Prev** 1999;23(1):31–6 (67 ref.)
Slow weight gain and low milk supply in the breastfeeding dyad. Powers NG. **Clin Perinatol** 1999 Jun;26(2):399–430 (76 ref.)
Weight, weight gain and coronary heart disease mortality [editorial; comment] Gunnell DJ, et al. **Eur Heart J** 1999 Feb;20(4):246–8 (6 ref.) Comment on: Eur Heart J 1999 Feb;20(4):269–77.
Long-acting hormonal contraception: assessing impact on bone density, weight, and mood. Kaunitz AM. **Int J Fertil Womens Med** 1999 Mar–Apr;44(2):110–7 (27 ref.)
Metabolic predictors of weight gain. Ravussin E, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:37–41 (44 ref.)
Cutting fat absorption to halt weight gain. Lean M. **Practitioner** 1998 Dec;242(1593):860–5 (5 ref.)

DRUG EFFECTS

Prescription medications: a modifiable contributor to obesity. Cheskin LJ, et al. **South Med J** 1999 Sep;92(9):898–904 (44 ref.)

PHYSIOLOGY

Gaining weight: the scientific basis of increasing skeletal muscle mass. Houston ME. **Can J Appl Physiol** 1999 Aug; 24(4):305–16 (48 ref.)
What are the health risks? The medical consequences of obesity and its health risks. James WP. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:1–6 (17 ref.)
The influence of sex hormones on obesity across the female life span. Lovejoy JC. **J Womens Health** 1998 Dec; 7(10):1247–56 (53 ref.)

WEIGHT LIFTING

Strength training and nutritional supplement use in adolescents. Metzl JD. **Curr Opin Pediatr** 1999 Aug; 11(4):292–6 (35 ref.)
Prescription of resistance training for health and disease. Feigenbaum MS, et al. **Med Sci Sports Exerc** 1999 Jan; 31(1):38–45 (59 ref.)
The effects of progressive resistance training on bone density: a review. Layne JE, et al. **Med Sci Sports Exerc** 1999 Jan; 31(1):25–30 (34 ref.)
Acute responses to resistance training and safety. McCartney N. **Med Sci Sports Exerc** 1999 Jan;31(1):31–7 (37 ref.)
Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older? Zachwieja JJ, et al. **Phys Ther** 1999 Jan;79(1):76–82 (38 ref.)
Leucine supplementation and intensive training. Mero A. **Sports Med** 1999 Jun;27(6):347–58 (56 ref.)

PHYSIOLOGY

Nutritional requirements to increase lean mass. Grandjean A. **Clin Sports Med** 1999 Jul;18(3):623–32 (18 ref.)
EMG assessment of back muscle function during cyclical lifting. Roy SH, et al. **J Electromyogr Kinesiol** 1998 Aug; 8(4):233–45 (33 ref.)
Resistance exercises in older adults. Garber CE. **Med Health R I** 1999 Apr;82(4):135–6 (6 ref.)
Role of resistance training in heart disease. McCartney N. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S396–402 (38 ref.)
Strength training. Single versus multiple sets. Carpinelli RN, et al. **Sports Med** 1998 Aug;26(2):73–84 (59 ref.)
Dietary supplements and the promotion of muscle growth with resistance exercise. Kreider RB. **Sports Med** 1999 Feb; 27(2):97–110 (103 ref.)

WEIGHT LOSS

Evaluation and treatment of weight loss in adults with HIV disease. Williams B, et al. **Am Fam Physician** 1999 Sep 1; 60(3):843–54, 857–60 (25 ref.)
Body weight loss and maintenance with physical activity and diet. Doucet E, et al. **Coron Artery Dis** 1998;9(8):495–501 (87 ref.)
Selections from current literature: effects of dieting and exercise on resting metabolic rate and implications for weight management. Connolly J, et al. **Fam Pract** 1999 Apr;16(2):196–201 (7 ref.)
Weight loss education: the challenge of a new paradigm. Gast J, et al. **Health Educ Behav** 1998 Aug;25(4):464–73 (43 ref.)
Psychological symptoms in individuals successful at long-term maintenance of weight loss. Klem ML, et al. **Health Psychol** 1998 Jul;17(4):336–45 (55 ref.)
Why should obesity be managed? The obese individual's perspective. Evans E. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S3–5; discussion S6 (11 ref.)
The impact of pharmacotherapy on weight management in type 2 diabetes. Hauner H. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S12–7 (44 ref.)
Maintenance programmes after weight reduction--how useful are they? Mustajoki P, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23(6):553–5 (21 ref.)
Obesity and type 2 diabetes: a conflict of interests? Williams G. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S2–4 (8 ref.)
Promoting body size acceptance in weight management counseling. Parham ES. **J Am Diet Assoc** 1999 Aug; 99(8):920–5 (58 ref.)
Response to promoting size acceptance in weight management counseling. Strain GW. **J Am Diet Assoc** 1999 Aug;99(8):926–8 (17 ref.)
Fat: can't live with it, can't live without it part II. Finn SC. **J Womens Health** 1999 Jan–Feb;8(1):33–8 (17 ref.)
Thinness and weight loss: beneficial or detrimental to longevity? Gaesser GA. **Med Sci Sports Exerc** 1999 Aug; 31(8):1118–28 (157 ref.)
How effective are traditional dietary and exercise interventions for weight loss? Miller WC. **Med Sci Sports Exerc** 1999 Aug;31(8):1129–34 (68 ref.)
Individualizing the approach to treating obesity. Ammon PK. **Nurse Pract** 1999 Feb;24(2):27–31, 36–8, 41; quiz 42–3 (47 ref.)
Is the prevalence of successful weight loss and maintenance higher in the general community than the research clinic? Bartlett SJ, et al. **Obes Res** 1999 Jul;7(4):407–13 (45 ref.)
The importance of timing and accurate interpretation of the benefits of weight reduction on plasma lipids [editorial; comment] Eckel RH. **Obes Res** 1999 Mar;7(2):227–8 (19 ref.) Comment on: Obes Res 1999 Mar;7(2):170–8.
[Parotid swelling with night sweat, fever and weight loss symptoms. A rare differential diagnosis] Herrmann G. **Dtsch Med Wochenschr** 1999 Feb 26;124(8):209–12 (25 ref.) (Eng. Abstr.) **(Ger)**
[What should be done in weight loss of unknown origin?] Schwenk A. **Med Klin** 1998 Dec 15;93(12):719–25 (57 ref.) (Eng. Abstr.) **(Ger)**
[Surgery for obesity--the most successful long-term therapy?] Husemann B. **Wien Med Wochenschr** 1998; 148(17):407–12 (51 ref.) (Eng. Abstr.) **(Ger)**
[Weight loss by changing eating behavior: the target goal in therapy of obesity] Pudel V. **Wien Med Wochenschr** 1998;148(17):397–9, 400 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

The war against obesity: attacking a new front [editorial; comment] [see comments] Klein S. **Am J Clin Nutr** 1999 Jun;69(6):1061–3 (13 ref.) Comment on: Am J Clin Nutr 1999 Jun;69(6):1108–16. Comment in: Am J Clin Nutr 1999 Jun;69(6):1059–60.

PHYSIOLOGY

What are the benefits of moderate weight loss? de Leiva A. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:10–3 (18 ref.)
Obesity--what are the current treatment options? Lean ME. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:22–6 (14 ref.)
Weight loss and mortality in persons with type-2 diabetes mellitus: a review of the epidemiological evidence. Williamson DF. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:14–21 (23 ref.)
Fit, fat and fat free: the metabolic aspects of weight control. Saris WH. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S15–21 (50 ref.)
Special considerations in design of trials with elderly subjects: unexplained weight loss, body composition and energy expenditure. Poehlman ET. **J Nutr** 1999 Jan;129(1S Suppl):260S–263S (25 ref.)
[Weight loss by increasing energy consumption and thermogenesis] Ludvik B. **Acta Med Austriaca** 1998; 25(4–5):136–7 (8 ref.) (Eng. Abstr.) **(Ger)**

WEIGHT-LOSS AGENTS see **ANTI-OBESITY AGENTS**

WEIGHT REDUCTION see **WEIGHT LOSS**

WEIGHTLESSNESS

see related
HYPOGRAVITY

Problems of sensorimotor coordination in weightlessness. Bock O. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):155–60 (48 ref.)
Autonomic control of cardiovascular dynamics during weightlessness. Fortrat JO, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):66–72 (44 ref.)
Growth factor-induced signal transduction in adherent mammalian cells is sensitive to gravity. Boonstra J. **FASEB J** 1999;13 Suppl:S35–42 (77 ref.)
The effect of microgravity on morphology and gene expression of osteoblasts in vitro. Carmeliet G, et al. **FASEB J** 1999;13 Suppl:S129–34 (53 ref.)
Implications for interrelationships between nuclear architecture and control of gene expression under microgravity conditions. Stein GS, et al. **FASEB J** 1999; 13 Suppl:S157–66 (84 ref.)
Age-dependent atrophy and microgravity travel: what do they have in common? Wang E. **FASEB J** 1999;13 Suppl:S167–74 (72 ref.)
[Mechanisms of homeostasis establishment during prolonged microgravity] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1998;32(6):20–6 (35 ref.) (Eng. Abstr.) **(Rus)**
[Use of academician P.K.Anokhin's creative heritage for analysis of mechanisms responsible for homeostasis formation under microgravity] Grigor'ev AI, et al. **Vestn Ross Akad Med Nauk** 1999;(6):11–5 (21 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

A review of the effects of microgravity and of hypergravity on aging and longevity. Le Bourg E. **Exp Gerontol** 1999 Jun;34(3):319–36 (50 ref.)
[Structure of receptor organs of the vestibule and animal behavior during weightlessness] Lychakov DV. **Zh Evol Biokhim Fiziol** 1998 May–Jun;34(3):364–85 (56 ref.) **(Rus)**

WEIGHTLESSNESS SIMULATION

Postnatal development under conditions of simulated weightlessness and space flight. Walton K. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):25–34 (35 ref.)

WELDING

Optical radiation hazards of welding arcs. Tenkate TD. **Rev Environ Health** 1998 Jul–Sep;13(3):131–46 (99 ref.)
[Effects of iron-containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27–37 (123 ref.) **(Rus)**

WELLNESS PROGRAMS see **HEALTH PROMOTION**

WERDNIG-HOFFMANN DISEASE

[Spinal muscular atrophy (type I, II)] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):364–70 (26 ref.) **(Jpn)**

GENETICS

The role of the SMN gene in proximal spinal muscular atrophy. Lefebvre S, et al. **Hum Mol Genet** 1998; 7(10):1531–6 (83 ref.)
Congenital autosomal dominant distal spinal muscular atrophy. Adams C, et al. **Neuromuscul Disord** 1998 Aug; 8(6):405–8 (13 ref.)

WERLHOF'S DISEASE see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

WERMER SYNDROME see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

WERNER SYNDROME

[Premature aging: recent advances] Nakura J, et al. **No To Shinkei** 1998 Nov;50(11):977–87 (49 ref.) **(Jpn)**

GENETICS

WRN mutations in Werner syndrome [published erratum appears in Hum Mutat 1999;14(1):84–5] Moser MJ, et al. **Hum Mutat** 1999;13(4):271–9 (89 ref.)
What geriatricians should know about the Werner syndrome. Martin GM, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1136–44 (69 ref.)
DNA repair and transcription in human premature aging disorders. Bohr VA, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(1):11–3 (27 ref.)

WERNICKE AREA see **TEMPORAL LOBE**

WERNICKE'S ENCEPHALOPATHY

[Wernicke's encephalopathy] Hoshino H. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):762–6 (5 ref.) **(Jpn)**

DIAGNOSIS

Do acute lesions of Wernicke's encephalopathy show contrast enhancement? Report of three cases and review of the literature. Mascalchi M, et al. **Neuroradiology** 1999 Apr;41(4):249–54 (20 ref.)
Early diagnosis of pediatric Wernicke's encephalopathy. Vasconcelos MM, et al. **Pediatr Neurol** 1999 Apr; 20(4):289–94 (43 ref.)

THERAPY

Early diagnosis of pediatric Wernicke's encephalopathy. Vasconcelos MM, et al. **Pediatr Neurol** 1999 Apr; 20(4):289–94 (43 ref.)

WEST INDIAN MANATEE see **TRICHECHUS MANATUS**

WEST NILE FEVER

EPIDEMIOLOGY

[The epidemiological process of West Nile viral infection] Pitigoi D, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct–Dec;43(4):281–8 (24 ref.) (Eng. Abstr.) **(Rum)**

WEST SYNDROME see **SPASMS, INFANTILE**

WESTERN BLOTTING see **BLOTTING, WESTERN**

WESTERN IMMUNOBLOTTING see **BLOTTING, WESTERN**

WESTERN WORLD

Western nutrition and the insulin resistance syndrome: a link to breast cancer. Stoll BA. **Eur J Clin Nutr** 1999 Feb; 53(2):83–7 (52 ref.)

Nursing in Thailand: western concepts vs Thai tradition. Ekintumas D. **Int Nurs Rev** 1999 Mar–Apr;46(2):55–7 (19 ref.)

The doctrine of informed consent: a tale of two cultures and two legal traditions. Walter P. **Issues Law Med** 1999 Spring; 14(4):357–73 (53 ref.)

WET LUNG see **PULMONARY EDEMA**

WETTING AGENTS

Wetting solutions in ultrasound-assisted lipoplasty. Fodor PB, et al. **Clin Plast Surg** 1999 Apr;26(2):289–93; ix (27 ref.)

WHALE, FALSE KILLER see **DOLPHINS**

WHALE, KILLER see **DOLPHINS**

WHALE, MELON-HEADED see **DOLPHINS**

WHALE, PIGMY KILLER see **DOLPHINS**

WHALES

The role of Eskimo hunters, veterinarians, and other biologists in improving the humane aspects of the subsistence harvest of bowhead whales. O'Hara TM, et al. **J Am Vet Med Assoc** 1999 Apr 15;214(8):1193–8 (35 ref.)

WHALES, PILOT see **DOLPHINS**

WHEAT

Food aid in emergencies: a case for wheat? Landman J. **Proc Nutr Soc** 1999 May;58(2):355–61 (53 ref.)

CHEMISTRY

Wheat minerals--a review. Anglani C. **Plant Foods Hum Nutr** 1998;52(2):177–86 (37 ref.)

GENETICS

Transformation of wheat via particle bombardment. Vasil IK, et al. **Methods Mol Biol** 1999;111:349–58 (18 ref.)

GROWTH & DEVELOPMENT

Embryo rescue following wide crosses. Sharma HC. **Methods Mol Biol** 1999;111:293–307 (45 ref.)

IMMUNOLOGY

In vivo gluten ingestion in coeliac disease. Ciclitira PJ, et al. **Dig Dis** 1998 Nov–Dec;16(6):337–40 (20 ref.)

WHEEZING see **RESPIRATORY SOUNDS**

WHIPLASH INJURIES

Long-term functional and psychological problems in whiplash associated disorders. Söderlund A, et al. **Int J Rehabil Res** 1999 Jun;22(2):77–84 (47 ref.)

Whiplash: heading for a higher ground. Ferrari R, et al. **Spine** 1999 Jan 1;24(1):97–8 (12 ref.)

A review and methodologic critique of the literature refuting whiplash syndrome. Freeman MD, et al. **Spine** 1999 Jan 1;24(1):86–96 (49 ref.)

Whiplash injury. Biomechanical experimentation [editorial] Yoganandan N, et al. **Spine** 1999 Jan 1;24(1):83–5 (6 ref.)

COMPLICATIONS

Whiplash and temporomandibular disorders: a critical review [see comments] Ferrari R, et al. **J Am Dent Assoc** 1998 Dec;129(12):1739–45 (41 ref.) Comment in: J Am Dent Assoc 1999 Feb;130(2):162, 164; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Feb;130(2):164, 166; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Feb;130(2):166, 168; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Feb;130(2):168; discussion 168, 170. Comment in: J Am Dent Assoc 1999 Mar;130(3):316, 318. Comment in: J Am Dent Assoc 1999 Apr;130(4):468, 470.

DIAGNOSIS

[Whiplash injuries of the cervical spine. Neurologic contribution to diagnosis. Therapy and expert evaluation] Welter FL, et al. **Orthopade** 1998 Dec;27(12):834–40 (28 ref.) (Eng. Abstr.) **(Ger)**

[Controversy regarding the sequelae of minor craniocervical trauma with special reference to neurobiological aspects of cognitive disorders] Radanov BP. **Schweiz Rundsch Med Prax** 1999 Feb 25;88(9):365–73 (76 ref.) (Eng. Abstr.) **(Ger)**

[New information on so-called whiplash cervical trauma] Lucka J. **Versicherungsmedizin** 1998 Aug 1;50(4):124–30 (38 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Whiplash injuries of the temporomandibular joint in motor vehicle accidents: speculations and facts. McKay DC, et al. **J Oral Rehabil** 1998 Oct;25(10):731–46 (95 ref.)

PHYSIOPATHOLOGY

[Biomechanics of injury of the cervical spine] Grifka J, et al. **Orthopade** 1998 Dec;27(12):802–12 (102 ref.) (Eng. Abstr.) **(Ger)**

[Characteristics of the innervation of the head and neck] Neuhuber WL. **Orthopade** 1998 Dec;27(12):794–801 (56 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanics of whiplash injury] Panjabi MM, et al. **Orthopade** 1998 Dec;27(12):813–9 (34 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Whiplash and post-traumatic stress disorder. Jaspers JP. **Disabil Rehabil** 1998 Nov;20(11):397–404 (31 ref.)

WHIPPLE'S DISEASE

Whipple's disease. Ramaiah C, et al. **Gastroenterol Clin North Am** 1998 Sep;27(3):683–95, vii (40 ref.)

[Whipple's disease] Bamba T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):274–7 (15 ref.) **(Jpn)**

DIAGNOSIS

[Whipple's disease (see comments)] Zaaijer HL, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20;143(8):388–92 (18 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 May 15;143(20):1067. **(Dut)**

MICROBIOLOGY

[Tropheryma whippelii, an emerging intracellular pathogen causing Whipple disease] Drancourt M. **Presse Med** 1999 Feb 27;28(8):435–9, 433 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Intracerebral Whipple's disease diagnosed by stereotactic biopsy: a case report and review of the literature. Mendel E, et al. **Neurosurgery** 1999 Jan;44(1):203–9 (32 ref.)

Whipple's disease presenting as sarcoidosis and valvular heart disease. Wolfert AL, et al. **South Med J** 1999 Aug; 92(8):820–5 (33 ref.)

WHIRLPOOL BATHS see **HYDROTHERAPY**

WHISKERS see **VIBRISSAE**

WHISTLEBLOWING see **TRUTH DISCLOSURE**

WHITE-BEAKED DOLPHINS see **DOLPHINS**

WHITE BLOOD CELL COUNT see **LEUKOCYTE COUNT**

WHITE BLOOD CELL TRANSFUSION see **LEUKOCYTE TRANSFUSION**

WHITE BLOOD CELLS see **LEUKOCYTES**

WHITE PEPPER see **SPICES**

WHITE-SIDED DOLPHINS see **DOLPHINS**

WHITE SPOTS see **DENTAL CARIES**

WHITE WHALE see **WHALES**

WHITEFIN DOLPHIN see **DOLPHINS**

WHITEFISH see **SALMONIDAE**

WHITEFLIES see **HEMIPTERA**

WHITES

see related
CAUCASOID RACE

Cultural sensitivity in public health: defined and demystified. Resnicow K, et al. **Ethn Dis** 1999 Winter;9(1):10–21 (98 ref.)

Prostate cancer treatment outcome in blacks and whites: a summary of the literature. Alexander GA, et al. **Semin Urol Oncol** 1998 Nov;16(4):232–4 (16 ref.)

STATISTICS & NUMERICAL DATA

Primary prevention of cardiovascular disease in high-risk patients: physiologic and demographic risk factor differences between African American and white American populations. Clark LT. **Am J Med** 1999 Aug 23; 107(2A):22S–24S (34 ref.)

WHOLE-BODY IRRADIATION

see related
LYMPHATIC IRRADIATION

Total-body irradiation for bone marrow transplantation. Lawton C. **Oncology (Huntingt)** 1999 Jul;13(7):972, 975–8, 981–2 (1 ref.)

ADVERSE EFFECTS

[Total body irradiation: techniques, dosimetry, and complications] Belkacémi Y, et al. **Cancer Radiother** 1999 Mar–Apr;3(2):162–73 (86 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Total body irradiation: techniques, dosimetry, and complications] Belkacémi Y, et al. **Cancer Radiother** 1999 Mar–Apr;3(2):162–73 (86 ref.) (Eng. Abstr.) **(Fre)**

WHOLE-CELL RECORDING see **PATCH-CLAMP TECHNIQUES**

WHOOPING COUGH

see related
PERTUSSIS VACCINE

[Pertussis] Kato T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):131–3 (6 ref.) **(Jpn)**

DIAGNOSIS

Could it be whooping cough? Sturmberg JP, et al. **Aust Fam Physician** 1999 Feb;28(2):129–31 (13 ref.)

[Pertussis: a current disease. New diagnostic techniques] Marguet C, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S170–2 (12 ref.) **(Fre)**

DRUG THERAPY

State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Hoppe JE. **Infection** 1998 Jul–Aug;26(4):242–6 (48 ref.)

IMMUNOLOGY

Immunity to pertussis. Not all virulence factors are protective antigens. Robbins JB, et al. **Adv Exp Med Biol** 1998; 452:207–18 (124 ref.)

PREVENTION & CONTROL

Whooping cough vaccines: where next? Elliman D. **Child Care Health Dev** 1998 Jul;24(4):259–65 (18 ref.)

A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity. Mills KH, et al. **Dev Biol Stand** 1998;95:31–41 (26 ref.)

Acellular pertussis vaccines in adults. Keitel WA, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):83–94, vi (65 ref.)

Using acellular pertussis vaccines for childhood immunization. Potential benefits far outweigh potential risks. Conrad DA, et al. **Postgrad Med** 1999 Jun; 105(7):165–8, 171–3, 177–8 (19 ref.)

THERAPY

Could it be whooping cough? Sturmberg JP, et al. **Aust Fam Physician** 1999 Feb;28(2):129–31 (13 ref.)

Standardized management of patients and employees exposed to pertussis [see comments] Haiduven DJ, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):861–4 (09 ref.) Comment in: Infect Control Hosp Epidemiol 1998 Nov;19(11):825–8.

TRANSMISSION

Standardized management of patients and employees exposed to pertussis [see comments] Haiduven DJ, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):861–4 (09 ref.) Comment in: Infect Control Hosp Epidemiol 1998 Nov;19(11):825–8.

WIFE ABUSE see **SPOUSE ABUSE**

WILCOX TEST see **STATISTICS, NONPARAMETRIC**

WILCOXON RANK TEST see **STATISTICS, NONPARAMETRIC**

WILL see **VOLITION**

WILLIAMS-BEUREN SYNDROME see **WILLIAMS SYNDROME**

WILLIAMS SYNDROME

DIAGNOSIS

Williams-Beuren syndrome: an update and review for the primary physician. Lashkari A, et al. **Clin Pediatr (Phila)** 1999 Apr;38(4):189–208 (74 ref.)

GENETICS

Williams-Beuren syndrome: unraveling the mysteries of a

microdeletion disorder. Osborne LR. **Mol Genet Metab** 1999 May;67(1):1-10 (82 ref.)
Elastin mutation and cardiac disease. Chowdhury T, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):103-7 (28 ref.)
Bridging cognition, the brain and molecular genetics: evidence from Williams syndrome. Bellugi U, et al. **Trends Neurosci** 1999 May;22(5):197-207 (82 ref.)

WILMS' TUMOR see **NEPHROBLASTOMA**

WILMS' TUMOR GENES see **GENES, WILMS' TUMOR**

WILSON'S DISEASE see **HEPATOLENTICULAR DEGENERATION**

WINE

Red wine, green tea and vitamins: do their antioxidants play a role in immunologic protection against cancer or even AIDS? [editorial] Mathé G. **Biomed Pharmacother** 1999 May;53(4):165-7 (19 ref.)
Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. Halpern MJ, et al. **J Int Med Res** 1998 Aug-Sep;26(4):171-80 (53 ref.)
[Wine at moderate doses: health or disease?] Bujanda L, et al. **Med Clin (Barc)** 1999 Jan 16;112(1):29-35 (152 ref.) **(Spa)**

ANALYSIS

Flavonoids in food and natural antioxidants in wine. Lairon D, et al. **Curr Opin Lipidol** 1999 Feb;10(1):23-8 (41 ref.)
Stilbene compounds: from the grapevine to wine. Bavaresco L, et al. **Drugs Exp Clin Res** 1999;25(2-3):57-63 (56 ref.)
Nonalcoholic compounds of wine: the phytoestrogen resveratrol and moderate red wine consumption during menopause. Calabrese G. **Drugs Exp Clin Res** 1999; 25(2-3):111-4 (32 ref.)
Cardioprotection of red wine: role of polyphenolic antioxidants. Das DK, et al. **Drugs Exp Clin Res** 1999; 25(2-3):115-20 (25 ref.)
Advances in the study of secondary metabolites occurring in grapes and wines. Di Stefano R. **Drugs Exp Clin Res** 1999;25(2-3):53-6 (6 ref.)
Beneficial effects of white wines. Lamuela-Raventós RM, et al. **Drugs Exp Clin Res** 1999;25(2-3):121-4 (21 ref.)
Wine: risk factors for liver disease and antifibrotic compounds. Svegliati-Baroni G, et al. **Drugs Exp Clin Res** 1999;25(2-3):143-5 (13 ref.)
Volatile flavour of wine: correlation between instrumental analysis and sensory perception. Rapp A. **Nahrung** 1998 Dec;42(6):351-63 (77 ref.)
[In vitro findings of antioxidant properties of Hungarian red wines] Lugasi A, et al. **Orv Hetil** 1999 Sep 12; 140(37):2051-6 (44 ref.) (Eng. Abstr.) **(Hun)**

WING

EMBRYOLOGY

Cell determination and transdetermination in Drosophila imaginal discs. Maves L, et al. **Curr Top Dev Biol** 1999; 43:115-51 (172 ref.)
Formation of morphogen gradients in the Drosophila wing. Strigini M, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):335-44 (72 ref.)

GROWTH & DEVELOPMENT

Ultrabithorax function in butterfly wings and the evolution of insect wing patterns. Weatherbee SD, et al. **Curr Biol** 1999 Feb 11;9(3):109-15 (32 ref.)

METABOLISM

Formation of morphogen gradients in the Drosophila wing. Strigini M, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):335-44 (72 ref.)

WINKING see **BLINKING**

WIRSUNG'S DUCT see **PANCREATIC DUCTS**

WISKOTT-ALDRICH SYNDROME

The Wiskott-Aldrich syndrome. Ochs HD. **Semin Hematol** 1998 Oct;35(4):332-45 (89 ref.)
[Wiskott-Aldrich syndrome] Aoki S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):249-51 (15 ref.) **(Jpn)**

GENETICS

Learning from the slime mold: Dictyostelium and human disease. Saxe CL. **Am J Hum Genet** 1999 Jul;65(1):25-30 (26 ref.)
Understanding the molecular basis of Wiskott-Aldrich syndrome. Abo A. **Cell Mol Life Sci** 1998 Oct; 54(10):1145-53 (73 ref.)
Characterization of the Wiskott-Aldrich syndrome protein and its role in the disease. Nonoyama S, et al. **Curr Opin Immunol** 1998 Aug;10(4):407-12 (46 ref.)
Wiskott-Aldrich syndrome: a gene, a multifunctional protein and the beginnings of an explanation. Kirchhausen T. **Mol Med Today** 1998 Jul;4(7):300-4 (30 ref.)

IMMUNOLOGY

Is Wiskott--Aldrich syndrome a cell trafficking disorder? Thrasher AJ, et al. **Immunol Today** 1998 Dec;19(12):537-9 (27 ref.)
[Rare hyperimmunoglobulinemia E syndromes] Katchourine I, et al. **Rev Med Interne** 1998 Mar;19(3):185-91 (29 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Wiskott-Aldrich syndrome protein, WASP. O'Sullivan E, et al. **Int J Biochem Cell Biol** 1999 Mar-Apr;31(3-4):383-7 (19 ref.)
Waltzing with WASP [see comments] Ramesh N, et al. **Trends Cell Biol** 1999 Jan;9(1):15-9 (58 ref.) Comment in: Trends Cell Biol 1999 Jun;9(6):211-2.

PATHOLOGY

Is Wiskott--Aldrich syndrome a cell trafficking disorder? Thrasher AJ, et al. **Immunol Today** 1998 Dec;19(12):537-9 (27 ref.)

THERAPY

Recent advances in our understanding of Wiskott-Aldrich syndrome. Sullivan KE. **Curr Opin Hematol** 1999 Jan; 6(1):8-14 (50 ref.)

WITCH DOCTOR, AFRICAN see **MEDICINE, AFRICAN TRADITIONAL**

WITHDRAWAL SYMPTOMS see **SUBSTANCE WITHDRAWAL SYNDROME**

WITHDRAWING CARE see **EUTHANASIA, PASSIVE**

WITTENBORN SCALES see **PSYCHIATRIC STATUS RATING SCALES**

WIVES see **SPOUSES**

WOLFF-PARKINSON-WHITE SYNDROME

Clinical features of Wolff-Parkinson-White syndrome. Al-Khatib SM, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):403-13 (102 ref.)

DIAGNOSIS

Identifying patients with Wolff-Parkinson-White Syndrome [letter] Borsody JM. **Nurse Pract** 1998 Aug;23(8):13, 96, 98 (11 ref.)

ETIOLOGY

[Atrial fibrillation and the Wolff-Parkinson—White syndrome in a 68-year-old patient with tuberous sclerosis] López-Minguez JR, et al. **Rev Esp Cardiol** 1999 Mar; 52(3):207-10 (10 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Identifying patients with Wolff-Parkinson-White Syndrome [letter] Borsody JM. **Nurse Pract** 1998 Aug;23(8):13, 96, 98 (11 ref.)

SURGERY

[The radiofrequency ablation of a left lateral accessory pathway during pre-excitation atrial fibrillation] Siller Rodriguez J, et al. **Arch Inst Cardiol Mex** 1998 Mar-Apr; 68(2):113-8 (10 ref.) (Eng. Abstr.) **(Spa)**

WOLFFIAN BODY see **MESONEPHROS**

WOLFFIAN DUCT

Gartner's duct cyst with unilateral renal dysplasia presenting as an introital mass in a new born. Holmes M, et al. **Pediatr Surg Int** 1999;15(3-4):277-9 (12 ref.)

WOLFRAM SYNDROME

DIAGNOSIS

[Wolfram syndrome. Three case reports] Hajji Z, et al. **J Fr Ophtalmol** 1998 Dec;21(10):734-40 (20 ref.) (Eng. Abstr.) **(Fre)**

WOLFS BANE see **ARNICA**

WOLMAN DISEASE

[Wolman disease, Fabry disease and beta-galactosidase deficiency] Kitamura K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):393-6 (1 ref.) **(Jpn)**

WOLVERINES see **CARNIVORA**

WOMEN

Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement. Mosca L, et al. **Circulation** 1999 May 11;99(18):2480-4 (23 ref.)
The evaluation of women with schizophrenia. Canuso CM, et al. **Psychopharmacol Bull** 1998;34(3):271-7 (78 ref.)
Recognizing eating disorders in women. Casper RC. **Psychopharmacol Bull** 1998;34(3):267-9 (17 ref.)
Comprehensive evaluation of current and past mental health in women. Endicott J. **Psychopharmacol Bull** 1998; 34(3):283-7 (18 ref.)
Future directions for studies of women's mental health. Halbreich U. **Psychopharmacol Bull** 1998;34(3):327-31 (22 ref.)
Diagnostic evaluation of alcohol and drug abuse problems in women. Mendelson JH, et al. **Psychopharmacol Bull** 1998;34(3):279-81 (39 ref.)
Women and infertility. Rosenthal M. **Psychopharmacol Bull** 1998;34(3):307-8 (10 ref.)
Clinical evaluation in studies of perimenopausal women: position paper. Schmidt PJ, et al. **Psychopharmacol Bull** 1998;34(3):309-11 (19 ref.)
Cognitive assessment for postmenopausal women and general assessment of their mental health. Sherwin BB. **Psychopharmacol Bull** 1998;34(3):323-6 (28 ref.)
Assessing unipolar mood disorders in women. Yonkers KA. **Psychopharmacol Bull** 1998;34(3):261-6 (70 ref.)
[Women and Science-Helena Rubinstein Awards for Women in Science] Isogai E. **Nippon Saikingaku Zasshi** 1998 Aug; 53(3):531-5 (7 ref.) **(Jpn)**

EDUCATION

Improving women's access to emergency contraception: innovative information and service delivery strategies. Blanchard K. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):238-41 (23 ref.)

PSYCHOLOGY

Theoretical perspectives on female sexual behaviour in Africa: a review and conceptual model. Djamba YK. **Afr J Reprod Health** 1997 Sep;1(2):67-78 (57 ref.)
Womanism: a methodologic framework for African American women. Taylor JY. **ANS Adv Nurs Sci** 1998 Sep; 21(1):53-64 (60 ref.)
Psychoanalytic contributions to the study of gender issues. Barbieri NB. **Can J Psychiatry** 1999 Feb;44(1):72-6 (53 ref.)
Young females in the athletic arena. Baum AL. **Child Adolesc Psychiatr Clin N Am** 1998 Oct;7(4):745-55, viii (48 ref.)
Contraceptive use: the US perspective. Burnhill MS. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S17-23 (7 ref.)
Contraceptives: regional perspectives, issues, and unmet needs--the European perspective. Newton J. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S25-30 (13 ref.)
Women's narratives: evolving symptoms of myocardial infarction. McSweeney JC. **J Women Aging** 1998; 10(2):67-83 (30 ref.)
Why physician gender matters in shaping the physician-patient relationship. Roter DL, et al. **J Womens Health** 1998 Nov;7(9):1093-7 (24 ref.)
Eating disorders and the cultural forces behind the drive for thinness: are African American women really protected? Williamson L. **Soc Work Health Care** 1998;28(1):61-73 (23 ref.)
The promise of a multiple roles paradigm for women's health research [editorial] Repetti RL. **Womens Health** 1998 Winter;4(4):273-80 (32 ref.)

WOMEN, ABUSED see **BATTERED WOMEN**

WOMEN, BATTERED see **BATTERED WOMEN**

WOMEN PHYSICIANS see **PHYSICIANS, WOMEN**

WOMEN, WORKING

What's a mother to do? Welfare, work, and family [editorial; comment] Chavkin W. **Am J Public Health** 1999 Apr; 89(4):477-9 (13 ref.) Comment on: Am J Public Health 1999 Apr;89(4):502-5.
Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299-303 (12 ref.)
Health and work among women in Italy: an overview of the epidemiological literature. Pirastu R, et al. **Eur J Epidemiol** 1999 Jan;15(1):51-7 (67 ref.)
Ballet dancers--pregnancy outcomes. Barry S. **J R Soc Health** 1998 Dec;118(6):360-2 (10 ref.)
Women, welfare, and work: one view of the debate. Schroeder C, et al. **Nurs Outlook** 1998 Sep-Oct; 46(5):226-32 (34 ref.)
Women workers: the social construction of a special population. Stellman JM. **Occup Med** 1999 Jul-Sep; 14(3):559-80 (39 ref.)

STATISTICS & NUMERICAL DATA

Occupational cancer among women: research status and methodologic considerations. Blair A, et al. **Am J Ind Med** 1999 Jul;36(1):6-17 (42 ref.)
Measuring aspects of women's life and work for the study of variations in health. Dunnell K, et al.

Am J Ind Med 1999 Jul;36(1):25–33 (15 ref.)
Cancer and occupation in women: identifying associations using routinely collected national data. Carpenter L, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:299–303 (12 ref.)

WOMEN'S HEALTH

Medicinal plants used for treating female diseases in Malaysia--a review. Ling SK, et al. **Am J Chin Med** 1998; 26(2):211–22 (18 ref.)
Women in the intensive care unit [editorial] Baggs JG. **Am J Crit Care** 1999 Jul;8(4):207–9 (24 ref.)
Occupational cancer among women: research status and methodologic considerations. Blair A, et al. **Am J Ind Med** 1999 Jul;36(1):6–17 (42 ref.)
Measuring aspects of women's life and work for the study of variations in health. Dunnell K, et al. **Am J Ind Med** 1999 Jul;36(1):25–33 (15 ref.)
Women's reproductive health: some recent developments in occupational epidemiology. Lindbohm ML. **Am J Ind Med** 1999 Jul;36(1):18–24 (51 ref.)
Selective estrogen receptor modulators: Women's panacea for the next millennium? Spencer CP, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):763–70 (120 ref.)
International developments in abortion law from 1988 to 1998. Cook RJ, et al. **Am J Public Health** 1999 Apr; 89(4):579–86 (122 ref.)
Meeting primary oral health care needs of HIV-infected women [editorial; comment] Zabos GP. **Am J Public Health** 1999 Jun;89(6):818–9 (7 ref.) Comment on: Am J Public Health 1999 Jun;89(6):834–9.
Understanding women's risk of HIV infection in Thailand through critical hermeneutics. Ruangjiratain S, et al. **ANS Adv Nurs Sci** 1998 Dec;21(2):42–51 (28 ref.)
Colonizing images and diagnostic labels: oppressive mechanisms for African American women's health. Taylor JY. **ANS Adv Nurs Sci** 1999 Mar;21(3):32–45 (58 ref.)
Incontinence in women. Don't suffer it. Rane A. **Aust Fam Physician** 1999 Jun;28(6):584–6 (18 ref.)
Spondyloarthritides in females. Gran JT, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):695–715 (98 ref.)
Stress echocardiography in women. Tong AT, et al. **Cardiol Clin** 1999 Aug;17(3):573–82 (68 ref.)
Expectations about alternative therapies and women with gynecological cancer. Granai CO. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):3–10 (89 ref.)
Women, dyslipoproteinemia, and estrogens. LaRosa JC. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):627–39, x (65 ref.)
Violence against women: the physician's role. Schmuel E, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 80(2):239–45 (20 ref.)
Women battering in primary care practice. Naumann P, et al. **Fam Pract** 1999 Aug;16(4):343–52 (79 ref.)
Psychiatric disorders and gynecological oncology: a review of the literature. Thompson DS, et al. **Gen Hosp Psychiatry** 1998 Jul;20(4):241–7 (35 ref.)
A lifetime of healthy skin: implications for women. Bergfeld WF. **Int J Fertil Womens Med** 1999 Mar–Apr;44(2):83–95 (49 ref.)
Understanding sexual and reproductive violence: an overview. Barzelatto J. **Int J Gynaecol Obstet** 1998 Dec; 63 Suppl 1:S13–8 (10 ref.)
Current reversible contraceptive methods: a global perspective. Huezo CM. **Int J Gynaecol Obstet** 1998 Aug; 62 Suppl 1:S3–15 (50 ref.)
Long-term effects on women of assisted reproduction. Shelley J, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):36–51 (78 ref.)
Position of the American Dietetic Association and Dietitians of Canada: women's health and nutrition. Affenito SG, et al. **J Am Diet Assoc** 1999 Jun;99(6):738–51 (227 ref.)
Nongynecologic healthcare screening in women. Krueger PM. **J Am Osteopath Assoc** 1998 Dec;98(12 Suppl):S15–9 (24 ref.)
Women and the prevention of HIV infection: an integrative review of the literature. Mallory C, et al. **J Assoc Nurses AIDS Care** 1999 Jan–Feb;10(1):51–63 (56 ref.)
The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL. **J Health Polit Policy Law** 1999 Jun;24(3):531–65 (35 ref.)
Women's health issues and nuclear medicine, Part I: Women and heart disease. Mann A. **J Nucl Med Technol** 1999 Jun; 27(2):89–92; quiz 103, 105 (45 ref.)
Acupuncture and acupressure. Applications to women's reproductive health care. Beal MW. **J Nurse Midwifery** 1999 May–Jun;44(3):217–30 (57 ref.)
Unintended pregnancy. Consequences and solutions for a worldwide problem. Klima CS. **J Nurse Midwifery** 1998 Nov–Dec;43(6):483–91 (39 ref.)
Complementary and alternative medicine in women's health. Developing a research agenda. Murphy PA, et al. **J Nurse Midwifery** 1999 May–Jun;44(3):192–204 (107 ref.)
Addressing nicotine addiction in women. Role of the midwife. Ward S. **J Nurse Midwifery** 1999 Jan–Feb; 44(1):3–18 (103 ref.)
Menopause and beyond. The wise woman way. Weed SS. **J Nurse Midwifery** 1999 May–Jun;44(3):267–79 (76 ref.)
Differential diagnosis of fatigue in women. Cahill CA. **J Obstet Gynecol Neonatal Nurs** 1999 Jan–Feb;28(1):81–6 (22 ref.)
Assessment of women for partner abuse. Fishwick NJ. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):661–70 (15 ref.)
Promoting women's health via the World Wide Web. Hern MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):606–10 (6 ref.)
The dynamics of leaving and recovering from an abusive relationship. Landenburger KM. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):700–6 (30 ref.)
Culture and systems of oppression in abused women's lives. Phillips DS. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):678–83 (16 ref.)
Critical review: synthesis and recommendations for research, education, and policy [comment] Kivett VR. **J Women Aging** 1998;10(4):81–90 (17 ref.) Comment on: J Women Aging 1998 ;10(4):7–24. Comment on: J Women Aging 1998 ;10(4):25–39. Comment on: J Women Aging 1998 ;10(4):41–65. Comment on: J Women Aging 1998 ;10(4):67–80.
Old, female, and rural. Introduction [editorial] McCulloch BJ. **J Women Aging** 1998;10(4):1–5 (15 ref.)
Prevalence of heart disease in older women in a nursing home. Aronow WS. **J Womens Health** 1998 Nov; 7(9):1105–12 (50 ref.)
Medical aspects of pregnancy. Thacker HL. **J Womens Health** 1999 Apr;8(3):335–46 (20 ref.)
Lifestyle change in women with coronary heart disease: what do we know? Toobert DJ, et al. **J Womens Health** 1998 Aug;7(6):685–99 (77 ref.)
A critical European view of the HERS trial. Lauritzen C. **Maturitas** 1998 Nov 30;31(1):15–9 (28 ref.)
The heart and estrogen/progestin replacement study (HERS). Speroff L. **Maturitas** 1998 Nov 30;31(1):9–14 (38 ref.)
Helping women achieve long-term continuance of estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) [letter] Keenan NL, et al. **Menopause** 1999 Summer;6(2):179–80 (6 ref.)
Models of intervention in menopause: proposal of a holistic or integral model. Olazábal Ulacia JC, et al. **Menopause** 1999 Fall;6(3):264–72 (50 ref.)
Should there be a breast cancer risk chart for New Zealand women? Richardson A, et al. **N Z Med J** 1999 Apr 23; 112(1086):129–30 (34 ref.)
Management issues for women with epilepsy: a review of the literature. Zahn CA, et al. **Neurology** 1998 Oct; 51(4):949–56 (83 ref.)
The care of women with AIDS: special needs and considerations. Sowell RL, et al. **Nurs Clin North Am** 1999 Mar;34(1):179–99 (147 ref.)
Subtle clues of alcohol use in elderly women [letter] Martsolf DS, et al. **Nurse Pract** 1999 Feb;24(2):24–6 (19 ref.)
Micronized progesterone: a new option for women's health care. Wetzel W. **Nurse Pract** 1999 May;24(5):62–6, 71, 75–6 (29 ref.)
Polycystic ovary syndrome: clinical perspectives and management. Futterweit W. **Obstet Gynecol Surv** 1999 Jun; 54(6):403–13 (91 ref.)
Focus on primary care diagnosis and management of headache in women. Marcus DA. **Obstet Gynecol Surv** 1999 Jun;54(6):395–402 (53 ref.)
Women workers: the social construction of a special population. Stellman JM. **Occup Med** 1999 Jul–Sep; 14(3):559–80 (39 ref.)
Key developments in women's health. Hope S. **Practitioner** 1999 Jun;243(1599):455–6, 459–61 (11 ref.)
Risk factors for cardiovascular disease in Latina women. Juarbe TC. **Prog Cardiovasc Nurs** 1998 Spring;13(2):17–27 (93 ref.)
Women's health. Lautenbach GL, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):539–65 (111 ref.)
Gender matters: an integrated model for understanding men's and women's health. Bird CE, et al. **Soc Sci Med** 1999 Mar;48(6):745–55 (51 ref.)
'With the best of reasons': cervical cancer prevention policy and the suppression of sexual risk factor information. Braun V, et al. **Soc Sci Med** 1999 May;48(10):1463–74 (56 ref.)
Outcomes and effectiveness in reproductive health. Graham WJ. **Soc Sci Med** 1998 Dec;47(12):1925–36 (66 ref.)
Dead mothers and injured wives: the social context of maternal morbidity and mortality among the Hausa of northern Nigeria. Wall LL. **Stud Fam Plann** 1998 Dec; 29(4):341–59 (128 ref.)
The differential diagnosis and management of breast lumps in the tropics. Holcombe C, et al. **Trop Doct** 1999 Jan; 29(1):42–6 (17 ref.)
Primary hyperparathyroidism of postmenopausal women. Prospective population-based case-control analysis on prevalence, clinical findings and treatment. Minireview based on a doctoral thesis. Lundgren E. **Ups J Med Sci** 1999;104(2):87–130 (338 ref.)
Women's choice between indigenous and Western contraception in urban Mozambique. Agadjanian V. **Women Health** 1998;28(2):1–17 (25 ref.)
Travelling with "excess baggage": health problems of refugee women in Western Australia. Allotey P. **Women Health** 1998;28(1):63–81 (31 ref.)
Community perceptions of health, illness and care: identifying issues for indigenous communities. Kelaher M, et al. **Women Health** 1998;28(1):41–61 (36 ref.)
"Run, Jane, run": central tensions in the current debate about enhancing women's health through exercise. Vertinsky P. **Women Health** 1998;27(4):81–111 (160 ref.)
Migraine: a "woman's disease?" Warshaw LJ, et al. **Women Health** 1998;28(2):79–99 (52 ref.)
Engendering stress in Australia: the embodiment of social relationships. Whittaker A, et al. **Women Health** 1998; 28(1):97–115 (31 ref.)
The promise of a multiple roles paradigm for women's health research [editorial] Repetti RL. **Womens Health** 1998 Winter;4(4):273–80 (32 ref.)
What factors affect women's experiences with Medicaid managed care? Bernstein AB. **Womens Health Issues** 1998 Nov–Dec;8(6):325–38; discussion 350–8 (38 ref.)
Women's health, chronic disease, and disease management: new words and old music? Bierman AS, et al. **Womens Health Issues** 1999 Jan–Feb;9(1):2–17; discussion 30–41 (66 ref.)
Chronic disease, women's health, and "disease management": the latest trend? Gevirtz F, et al. **Womens Health Issues** 1999 Jan–Feb;9(1):18–29; discussion 30–41 (23 ref.)
Managed care and unintended pregnancy: testing the limits of prevention. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):26S–35S (24 ref.)
Confronting STDs: a challenge for managed care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):36S–46S (25 ref.)
Managed care and women's mental health: a focus on depression. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):47S–56S (41 ref.)
Quality of care for women: where are we now and where are we headed? McGlynn EA. **Womens Health Issues** 1999 Mar–Apr;9(2):65–80; discussion 93–106 (22 ref.)
New approach to assessing clinical quality of care for women: the QA Tool system. McGlynn EA, et al. **Womens Health Issues** 1999 Jul–Aug;9(4):184–92 (9 ref.)
["Uncertain" health complaints of women--a challenge for medicine and welfare state policy] Malterud K. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1790–3 (38 ref.) **(Nor)**
[Menstruation still full of myths] Bergqvist A. **Lakartidningen** 1999 Apr 14;96(15):1860–7 (28 ref.) **(Swe)**
[Medical aspects of diving--a sport for both women and men] Gustavsson LL, et al. **Lakartidningen** 1999 Feb 17; 96(7):749–53 (11 ref.) (Eng. Abstr.) **(Swe)**

WOMEN'S HEALTH SERVICES

The key to the door: Medicaid's role in improving health care for women and children. Rowland D, et al. **Annu Rev Public Health** 1999;20:403–26 (106 ref.)
Human rights and abortion laws. Cook RJ, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):81–7 (50 ref.)
Mental illness and substance abuse: implications for women's health and health care access. Reed BG, et al. **J Am Med Womens Assoc** 1999 Spring;54(2):71–8 (171 ref.)

ECONOMICS

Welfare reform and women's health: review of the literature and implications for state policy. O'Campo P, et al. **J Public Health Policy** 1998;19(4):420–46 (59 ref.)

ORGANIZATION & ADMINISTRATION

Travelling with "excess baggage": health problems of refugee women in Western Australia. Allotey P. **Women Health** 1998;28(1):63–81 (31 ref.)
Health plans and purchasers: managing women's primary care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):15S–25S (36 ref.)
Women's primary care in managed care: clinical and provider issues. Gonen JS. **Womens Health Issues** 1999 Mar–Apr; 9(2 Suppl):5S–14S (46 ref.)
Medicaid managed care: the challenge of providing care to low-income women. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):57S–67S (32 ref.)
Neither prevention nor cure: managed care for women with chronic conditions. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):68S–78S (23 ref.)

STANDARDS

Ethics, justice and women's health. Cook RJ, et al. **Int J Gynaecol Obstet** 1999 Jan;64(1):81–5 (23 ref.)
Gender violence and reproductive health. Diniz SG, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S33–42 (44 ref.)
Outcomes and effectiveness in reproductive health. Graham WJ. **Soc Sci Med** 1998 Dec;47(12):1925–36 (66 ref.)
By women, for women: the continuing appeal of women's health centres. Broom DH. **Women Health** 1998;28(1):5–22 (60 ref.)
Community perceptions of health, illness and care: identifying issues for indigenous communities. Kelaher M, et al. **Women Health** 1998;28(1):41–61 (36 ref.)
Quality in women's health: taking the measure of managed care. Gonen JS. **Womens Health Issues** 1999 Mar–Apr;9(2 Suppl):79S–88S (16 ref.)

WOMEN'S HEALTH SERVICES

TRENDS

Women, the welfare state, and their transnational dimension: the case of Mexico's community health worker programs. Ramirez-Valles J. **Int J Health Serv** 1999;29(3):597–621 (117 ref.)

Women's healthcare in the 21st century [editorial] Speroff L. **Maturitas** 1999 May 31;32(1):1–9 (21 ref.)

WOMEN'S LIBERATION see **WOMEN'S RIGHTS**

WOMEN'S RIGHTS

see related
FEMINISM

Selecting subjects for participation in clinical research: one sphere of justice. Weijer C. **J Med Ethics** 1999 Feb; 25(1):31–6 (34 ref.)

LEGISLATION & JURISPRUDENCE

International developments in abortion law from 1988 to 1998. Cook RJ, et al. **Am J Public Health** 1999 Apr; 89(4):579–86 (122 ref.)

TRENDS

International developments in abortion law from 1988 to 1998. Cook RJ, et al. **Am J Public Health** 1999 Apr; 89(4):579–86 (122 ref.)

WOOLLY MONKEY see **CEBIDAE**

WORK

see related
EFFICIENCY
EMPLOYMENT

Protecting the health and safety of working teenagers. Rubenstein H, et al. **Am Fam Physician** 1999 Aug; 60(2):575–80, 587–8 (07 ref.)

Evaluating patients for return to work. Wyman DO. **Am Fam Physician** 1999 Feb 15;59(4):844–8 (14 ref.)

[Psychosocial factors at work and cardiovascular diseases: contribution of the Effort-Reward Imbalance model] Niedhammer I, et al. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):398–410 (92 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Fluid–electrolyte balance during labor and exercise: concepts and misconceptions. Armstrong LE, et al. **Int J Sport Nutr** 1999 Mar;9(1):1–12 (73 ref.)

WORK CAPACITY EVALUATION

Work ability of young adults. Laitinen J, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):162–9 (41 ref.)

WORK OF BREATHING

PHYSIOLOGY

Inspiratory flow rate: more may not be better [editorial; comment] Jubran A. **Crit Care Med** 1999 Apr;27(4):670–1 (13 ref.) Comment on: Crit Care Med 1999 Apr;27(4):715–22.

WORK SATISFACTION see **JOB SATISFACTION**

WORK SCHEDULE TOLERANCE

Vehicle accidents related to sleep: a review. Horne J, et al. **Occup Environ Med** 1999 May;56(5):289–94 (60 ref.)

Is there an optimal sleep–wake pattern in shift work? Akerstedt T. **Scand J Work Environ Health** 1998;24 Suppl 3:18–27 (98 ref.)

Shift work, risk factors and cardiovascular disease. Bøggild H, et al. **Scand J Work Environ Health** 1999 Apr; 25(2):85–99 (112 ref.)

Innovative worktime arrangements. Knauth P. **Scand J Work Environ Health** 1998;24 Suppl 3:13–7 (15 ref.)

Shift work and reproductive health. Nurminen T. **Scand J Work Environ Health** 1998;24 Suppl 3:28–34 (27 ref.)

[Biologic rhythms: their changes in night-shift workers] Weibel L, et al. **Presse Med** 1999 Feb 6;28(5):252–8 (67 ref.) (Eng. Abstr.) **(Fre)**

[Painful somatoform disorder and work incapacity] Fauchère PA. **Rev Med Suisse Romande** 1998 Sep;118(9):801–5 (10 ref.) **(Fre)**

[Work shifts, sleep and biological rhythms] Gaspar S, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):239–45 (13 ref.) **(Por)**

PSYCHOLOGY

Individual and social determinants of shiftwork tolerance. Nachreiner F. **Scand J Work Environ Health** 1998;24 Suppl 3:35–42 (50 ref.)

WORKERS' COMPENSATION

see related
DISABILITY EVALUATION

Occupational cancer in France: epidemiology, toxicology, prevention, and compensation. Aubrun JC, et al. **Environ Health Perspect** 1999 May;107 Suppl 2:245–52 (65 ref.)

Psychosocial issues: their importance in predicting disability, response to treatment, and search for compensation. Gatchel RJ, et al. **Neurol Clin** 1999 Feb;17(1):149–66 (73 ref.)

The independent medical examination: purpose and process [editorial] Vasudevan SV, et al. **WMJ** 1999 Mar–Apr; 98(2):10–2 (5 ref.)

ECONOMICS

Denied worker's compensation claims: what physicians can and cannot do [editorial] Drury DL, et al. **WMJ** 1998 Dec; 97(11):20–2 (10 ref.)

LEGISLATION & JURISPRUDENCE

Regulatory trends in workers' compensation managed care. Eccleston SM, et al. **Occup Med** 1998 Oct–Dec; 13(4):787–98, iv (15 ref.)

ORGANIZATION & ADMINISTRATION

Evaluating the impact of managed health care in workers' compensation. Dembe AE. **Occup Med** 1998 Oct–Dec; 13(4):799–821, v (32 ref.)

The role of prevention in workers' compensation managed care arrangements. Dembe AE, et al. **Occup Med** 1998 Oct–Dec;13(4):663–77, iii (48 ref.)

Disability management and occupational health. Margoshes B. **Occup Med** 1998 Oct–Dec;13(4):693–703, iii (23 ref.)

Networks in workers' compensation medical delivery. Miller LA. **Occup Med** 1998 Oct–Dec;13(4):717–25, iv (1 ref.)

STANDARDS

Performance measurement in workers' compensation managed care organizations. Greenberg EL, et al. **Occup Med** 1998 Oct–Dec;13(4):755–72, iv (28 ref.)

Managed care workers' compensation outcome measurements: how can a clinic compete? Mueller KL. **Occup Med** 1998 Oct–Dec;13(4):773–86, iv (35 ref.)

Denied worker's compensation claims: what physicians can and cannot do [editorial] Drury DL, et al. **WMJ** 1998 Dec; 97(11):20–2 (10 ref.)

WORKING WOMEN see **WOMEN, WORKING**

WORKLOAD

Current techniques for assessing physical exposure to work-related musculoskeletal risks, with emphasis on posture-based methods. Li G, et al. **Ergonomics** 1999 May; 42(5):674–95 (147 ref.)

International standards on mental work-load--the ISO 10,075 series. Nachreiner F. **Ind Health** 1999 Apr; 37(2):125–33 (14 ref.)

Work ability of young adults. Laitinen J, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):162–9 (41 ref.)

Relationship between TISS and costs in intensive care [editorial; comment] Edbrooke D, et al. **Intensive Care Med** 1998 Oct;24(10):995–6 (13 ref.) Comment on: Intensive Care Med 1998 Oct;24(10):1009–17. Comment on: Intensive Care Med 1998 Oct;24(10):1062–9.

Innovative worktime arrangements. Knauth P. **Scand J Work Environ Health** 1998;24 Suppl 3:13–7 (15 ref.)

[Workload and stress in caring for the elderly: status of research and research agenda] Zimber A. **Z Gerontol Geriatr** 1998 Dec;31(6):417–25 (78 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Daily demands during pregnancy, gestational age, and birthweight: reviewing physical and psychological demands in employment and non-employment contexts. Woo GM. **Ann Behav Med** 1998 Fall;19(4):385–98 (73 ref.)

WORKMEN'S COMPENSATION see **WORKERS' COMPENSATION**

WORKPLACE

Worksite physical activity interventions. Dishman RK, et al. **Am J Prev Med** 1998 Nov;15(4):344–61 (95 ref.)

Exposure of U.S. workers to environmental tobacco smoke. Hammond SK. **Environ Health Perspect** 1999 May;107 Suppl 2:329–40 (48 ref.)

Workshop summary: assessing exposure to environmental tobacco smoke in the workplace. Samet JM. **Environ Health Perspect** 1999 May;107 Suppl 2:309–12 (20 ref.)

Ergonomic strategies for improving working conditions in some developing countries in Asia. Kawakami T, et al. **Ind Health** 1999 Apr;37(2):187–98 (33 ref.)

Collaborative field research and training in occupational health and ergonomics. Kogi K. **Int J Occup Environ Health** 1998 Jul–Sep;4(3):189–95 (24 ref.)

Emotions at work [editorial] Moodie R, et al. **Med J Aust** 1999 Apr 5;170(7):296–7 (18 ref.)

Psychiatric illness and the workplace: perspectives for occupational medicine in the military. Pflanz S. **Mil Med** 1999 Jun;164(6):401–6 (62 ref.)

Minority workers and communities. Frumkin H, et al. **Occup Med** 1999 Jul–Sep;14(3):495–517 (174 ref.)

[The role of biological factors in the formation of working conditions at agricultural enterprises] Tsapko VG, et al. **Med Tr Prom Ekol** 1999;(4):15–9 (34 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Navigating between a rock and a hard place: an employer's obligation to reasonably accommodate the disabled in the unionized workplace. Hankinson KD. **J Contemp Health Law Policy** 1998 Fall;15(1):245–74 (0 ref.)

ORGANIZATION & ADMINISTRATION

The impact of lean production and related new systems of work organization on worker health. Landsbergis PA, et al. **J Occup Health Psychol** 1999 Apr;4(2):108–30 (132 ref.)

[When work organization becomes the source of pathologies] Gonik V. **Rev Med Suisse Romande** 1999 Jul;119(7):549–54 (12 ref.) **(Fre)**

PSYCHOLOGY

Calling for the absent male. Edgar D. **Aust Fam Physician** 1999 Aug;28(8):797–9 (5 ref.)

The impact of lean production and related new systems of work organization on worker health. Landsbergis PA, et al. **J Occup Health Psychol** 1999 Apr;4(2):108–30 (132 ref.)

[When work organization becomes the source of pathologies] Gonik V. **Rev Med Suisse Romande** 1999 Jul;119(7):549–54 (12 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Exposure of U.S. workers to environmental tobacco smoke. Hammond SK. **Environ Health Perspect** 1999 May;107 Suppl 2:329–40 (48 ref.)

WORLD HEALTH

Selected global health care activities of the Hospital Infections Program, Centers for Disease Control and Prevention. Manangan LP, et al. **Am J Infect Control** 1999 Jun;27(3):270–4 (8 ref.)

Host genes and infectious diseases. HIV, other pathogens, and a public health perspective. McNicholl JM, et al. **Am J Prev Med** 1999 Feb;16(2):141–54 (131 ref.)

International developments in abortion law from 1988 to 1998. Cook RJ, et al. **Am J Public Health** 1999 Apr; 89(4):579–86 (122 ref.)

A world behaving badly: the global challenge for behavioral surveillance [editorial] McQueen DV. **Am J Public Health** 1999 Sep;89(9):1312–4 (26 ref.)

The Safe Motherhood Initiative: why has it stalled? Maine D, et al. **Am J Public Health** 1999 Apr;89(4):480–2 (18 ref.)

The global burden of mental disorders [see comments] Ustün TB. **Am J Public Health** 1999 Sep;89(9):1315–8 (24 ref.) Comment in: Am J Public Health 1999 Sep;89(9):1309–11.

Global migration and health: ecofeminist perspectives. McGuire S. **ANS Adv Nurs Sci** 1998 Dec;21(2):1–16 (50 ref.)

Social capital and its relevance to health and family policy. Leeder S, et al. **Aust N Z J Public Health** 1999 Aug; 23(4):424–9 (12 ref.)

The World Bank and world health: focus on South Asia–II: India and Pakistan. Abbasi K. **BMJ** 1999 Apr 24; 318(7191):1132–5 (12 ref.)

The World Bank and world health: changing sides [see comments] Abbasi K. **BMJ** 1999 Mar 27;318(7187):865–9 (9 ref.) Comment in: BMJ 1999 Mar 27;318(7187):822–3.

The World Bank and world health. Healthcare strategy. Abbasi K. **BMJ** 1999 Apr 3;318(7188):933–6 (4 ref.)

The World Bank on world health: under fire. Abbasi K. **BMJ** 1999 Apr 10;318(7189):1003–6 (15 ref.)

Advances and challenges for the expanded programme on immunization. Cutts FT. **Br Med Bull** 1998;54(2):445–61 (64 ref.)

Food safety in the 21st century. Käferstein F, et al. **Bull World Health Organ** 1999;77(4):347–51 (15 ref.)

Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Ippolito G, et al. **Clin Infect Dis** 1999 Feb; 28(2):365–83 (122 ref.)

Proliferating principles; or how to sup with the devil without getting eaten. Leader N. **Disasters** 1998 Dec;22(4):288–308 (44 ref.)

Evaluation of WHO's antimalaria programme during the past 50 years and prospects for the future. Farid MA. **East Mediterr Health J** 1998;4 Suppl:S111–24 (21 ref.)

Domestic violence against women in the international community. Haile-Mariam T, et al. **Emerg Med Clin North Am** 1999 Aug;17(3):617–30, vi (22 ref.)

Toxicology of chemical mixtures: international perspective. Feron VJ, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1281–9 (111 ref.)
Fragmented ethics and "bridge bioethics". Potter VR. **Hastings Cent Rep** 1999 Jan–Feb;29(1):38–40 (17 ref.)
Current reversible contraceptive methods: a global perspective. Huezo CM. **Int J Gynaecol Obstet** 1998 Aug; 62 Suppl 1:S3–15 (50 ref.)
A fundamental shift in the approach to international health by WHO, UNICEF, and the World Bank: instances of the practice of "intellectual fascism" and totalitarianism in some Asian countries. Banerji D. **Int J Health Serv** 1999; 29(2):227–59 (146 ref.)
Global climate change and environmental health: proceedings of the 1997 annual conference of the Society for Occupational and Environmental Health. Kovats S, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):41–52 (7 ref.)
Emergency contraception: a global overview. Westley E. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):215–8, 237 (40 ref.)
Prevalence of gallstones in sonographic surveys worldwide. Kratzer W, et al. **J Clin Ultrasound** 1999 Jan;27(1):1–7 (66 ref.)
Imperialism, research ethics and global health [editorial] [see comments] Benatar SR. **J Med Ethics** 1998 Aug;24(4):221–2 (14 ref.) Comment in: J Med Ethics 1999 Feb;25(1):62.
How much human helminthiasis is there in the world? [comment] Crompton DW. **J Parasitol** 1999 Jun; 85(3):397–403 (75 ref.) Comment on: J Parasitol 1999 Jun;85(3):392–6.
Global risk of sexually transmitted diseases. Wang CC, et al. **Med Clin North Am** 1999 Jul;83(4):975–95, vi (78 ref.)
Across the water and down the ladder: occupational health in the global economy. Frumkin H. **Occup Med** 1999 Jul–Sep;14(3):637–63 (114 ref.)
Solutions for a water-short world. **Popul Rep M** 1998 Sep; (14):1–31 (223 ref.)
Maintaining the habitable condition of the planet: balancing technological and ecosystem services. Cairns J Jr. **Qual Assur** 1998 Jan–Mar;6(1):13–22 (13 ref.)
Features of spondyloarthritis around the world. Lau CS, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):753–70 (88 ref.)
Global prevalence and incidence estimates of selected curable STDs. Gerbase AC, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S12–6 (14 ref.)
Socioeconomic inequalities in stroke mortality among middle-aged men: an international overview. European Union Working Group on Socioeconomic Inequalities in Health. Kunst AE, et al. **Stroke** 1998 Nov;29(11):2285–91 (49 ref.)
Epidemiology of the hepatitis C virus. Ebeling F. **Vox Sang** 1998;74 Suppl 2:143–6 (14 ref.)
Health centres—the future of health depends on them. Kahssay HM. **World Health Forum** 1998;19(4):341–7; discussion 348–60 (6 ref.)
World trade: bringing health into the picture. Kinnon CM. **World Health Forum** 1998;19(4):397–406 (13 ref.)
Exporting hazards to developing countries. Menkes DB. **World Health Forum** 1998;19(4):412–6 (14 ref.)
[Malaria, a worldwide scourge] Danis M, et al. **Rev Prat** 1998 Feb 1;48(3):254–7 (11 ref.) (Eng. Abstr.) **(Fre)**
[Why has menopause become a public health problem?] Rozenbaum H. **Therapie** 1998 Jan–Feb;53(1):49–59 (47 ref.) (Eng. Abstr.) **(Fre)**
[Tropical medicine and the pathology of poverty. New paradigms in international health policy] Stefanini A. **Ann Ig** 1998 Sep–Dec;10(5–6):387–93 (28 ref.) (Eng. Abstr.) **(Ita)**
[Risk of food-borne infections is both reduced and increased. Expertise is greater, but so is the risk of exposure] Lindberg A. **Lakartidningen** 1999 Jun 23;96(25):3064–6 (13 ref.) (Eng. Abstr.) **(Swe)**

WORLD HEALTH ORGANIZATION

Essential drugs for cancer therapy: a World Health Organization consultation. Sikora K, et al. **Ann Oncol** 1999 Apr;10(4):385–90 (29 ref.)
WHO consensus statement on the role of nutrition in colorectal cancer. Scheppach W, et al. **Eur J Cancer Prev** 1999 Feb;8(1):57–62 (45 ref.)
Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: state-of-the-art. World Health Organization. Helmerhorst FM, et al. **Hum Reprod** 1998 Nov;13(11):2981–3 (19 ref.)

ORGANIZATION & ADMINISTRATION

Primary health care in the eastern Mediterranean region before and after Alma-Ata. Abdullatif AA. **East Mediterr Health J** 1998;4 Suppl:S85–102 (18 ref.)
Evaluation of WHO's antimalaria programme during the past 50 years and prospects for the future. Farid MA. **East Mediterr Health J** 1998;4 Suppl:S111–24 (21 ref.)
The WHO Informal Working Group on Echinococcosis. Coordinating Board of the WHO-IWGE. Vuitton DA. **Parassitologia** 1997 Dec;39(4):349–53 (21 ref.)
WHO and health planning—the past, the present and the future. Sapirie SA. **World Health Forum** 1998;19(4):382–7 (24 ref.)

WORLD WIDE WEB see **INTERNET**

WORM DISKS see **OPTICAL STORAGE DEVICES**

WORMS, PARASITIC see **HELMINTHS**

WORMS, SEGMENTED see **ANNELIDA**

WOUND HEALING

see related
CICATRIX
GRANULATION TISSUE

Chronic inflammation: links with angiogenesis and wound healing [comment] Majno G. **Am J Pathol** 1998 Oct; 153(4):1035–9 (27 ref.) Comment on: Am J Pathol 1998 Oct;153(4):1099–112.
Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. LeGrand EK. **Am J Surg** 1998 Aug;176(2A Suppl):48S–54S (48 ref.)
Foundations of good ulcer care. Steed DL. **Am J Surg** 1998 Aug;176(2A Suppl):20S–25S (19 ref.)
Cellular and molecular mechanisms of tissue repair. Scharffetter-Kochanek K, et al. **Basic Res Cardiol** 1998;93 Suppl 3:1–3 (24 ref.)
Collagen organization in wound healing after myocardial injury. Whittaker P. **Basic Res Cardiol** 1998;93 Suppl 3:23–5 (10 ref.)
Cigarette smoking, wound healing, and face-lift. Campanile G, et al. **Clin Dermatol** 1998 Sep–Oct;16(5):575–8 (48 ref.)
What's new in human wound-healing myofibroblasts? Moulin V, et al. **Curr Top Pathol** 1999;93:123–33 (35 ref.)
Lasers in the military for cutaneous disease and wound healing. Ross EV, et al. **Dermatol Clin** 1999 Jan; 17(1):135–50, ix (67 ref.)
The effect of surgical wounding on tumour development. Hofer SO, et al. **Eur J Surg Oncol** 1999 Jun;25(3):231–43 (153 ref.)
Mast cells and their mediators in cutaneous wound healing—active participants or innocent bystanders? Artuc M, et al. **Exp Dermatol** 1999 Feb;8(1):1–16 (195 ref.)
The chronic non-healing wound: how to make it better. Grey JE, et al. **Hosp Med** 1998 Jul;59(7):557–63 (28 ref.)
Effects of cigarette smoking on gastric ulcer formation and healing: possible mechanisms of action. Ma L, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S80–6 (81 ref.)
The use of Apligraf in acute wounds. Kirsner RS. **J Dermatol** 1998 Dec;25(12):805–11 (39 ref.)
Articular cartilage: injuries and potential for healing. Buckwalter JA. **J Orthop Sports Phys Ther** 1998 Oct; 28(4):192–202 (60 ref.)
Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing. Bauer JA. **Med Hypotheses** 1998 Jul;51(1):65–7 (20 ref.)
Ultrasound of fracture and bone healing. Craig JG, et al. **Radiol Clin North Am** 1999 Jul;37(4):737–51, ix (24 ref.)
Skin grafting in difficult situations. James J. **Trop Doct** 1999 Jan;29(1):41–2 (2 ref.)
[Wound healing after glaucoma filtering surgery—a review] Knorr M, et al. **Klin Monatsbl Augenheilkd** 1999 Mar; 214(3):147–55 (79 ref.) (Eng. Abstr.) **(Ger)**
[Electrically enhanced damaged tissues healing. Part I: direct current in bone healing] Franek A, et al. **Pol Merkuriusz Lek** 1999 May;6(35):294–6 (17 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Signal transduction in wound pharmacology. Kim WJ, et al. **Arch Pharm Res** 1998 Oct;21(5):487–95 (107 ref.)
[Advance in the study of post-wound effects of arginine] Luo X, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):124–6 (26 ref.) **(Chi)**
[Use of growth factors in therapy of chronic wounds. Experimental, clinical and financial aspects] Vogt PM, et al. **Chirurg** 1998 Nov;69(11):1197–206 (30 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

[Dorsal closure in Drosophila. A genetic model for wound healing?] Agnès F, et al. **C R Acad Sci III** 1999 Jan; 322(1):5–13 (69 ref.) (Eng. Abstr.) **(Fre)**
[Significance of molecular biology research for trauma surgery exemplified by wound and bone healing] Hanselmann RG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:86–9 (0 ref.) (Eng. Abstr.) **(Ger)**
[Molecular biology contributions to wound healing and practical applications] Werner S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:678–82 (14 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Similarities and differences of the immune response to exercise and trauma: the IFN-gamma concept. Northoff H, et al. **Can J Physiol Pharmacol** 1998 May;76(5):497–504 (53 ref.)
Stress and immunity: implications for viral disease and wound healing. Rozlog LA, et al. **J Periodontol** 1999 Jul; 70(7):786–92 (57 ref.)

PHYSIOLOGY

Physiology and healing dynamics of chronic cutaneous wounds. Stadelmann WK, et al. **Am J Surg** 1998 Aug; 176(2A Suppl):26S–38S (73 ref.)
Impediments to wound healing. Stadelmann WK, et al. **Am J Surg** 1998 Aug;176(2A Suppl):39S–47S (57 ref.)
Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Pilcher BK, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:12–24 (34 ref.)
Signal transduction in wound pharmacology. Kim WJ, et al. **Arch Pharm Res** 1998 Oct;21(5):487–95 (107 ref.)
Neuropeptides: mediators of inflammation and tissue repair? Schäffer M, et al. **Arch Surg** 1998 Oct;133(10):1107–16 (170 ref.)
Scar formation and ligament healing. Hildebrand KA, et al. **Can J Surg** 1998 Dec;41(6):425–9 (16 ref.)
Signal transduction pathways activated during fibroblast contraction of collagen matrices. Grinnell F. **Curr Top Pathol** 1999;93:61–73 (106 ref.)
Fibroblast-cytokine-extracellular matrix interactions in wound repair. Siméon A, et al. **Curr Top Pathol** 1999; 93:95–101 (13 ref.)
Skin wound healing and ischaemia. Studies on possible interventions. Quirinia A. **Dan Med Bull** 1999 Apr; 46(2):85–105 (178 ref.)
Modifying perfusion, nutrition, and stress to promote wound healing in patients with acute wounds. Whitney JD, et al. **Heart Lung** 1999 Mar–Apr;28(2):123–33 (74 ref.)
Activin: a novel player in tissue repair processes. Hübner G, et al. **Histol Histopathol** 1999 Jan;14(1):295–304 (61 ref.)
The role of apoptosis in wound healing. Greenhalgh DG. **Int J Biochem Cell Biol** 1998 Sep;30(9):1019–30 (50 ref.)
Cultivation and transplantation of epidermal keratinocytes. Terskikh VV, et al. **Int Rev Cytol** 1999;188:41–72 (154 ref.)
The healing and regeneration of articular cartilage. O'Driscoll SW. **J Bone Joint Surg Am** 1998 Dec; 80(12):1795–812 (255 ref.)
Wound healing and chronic wounds. Falanga V. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1–1–5 (20 ref.)
Tissue engineering. Sefton MV, et al. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1–18–23 (41 ref.)
A novel role of activin in inflammation and repair. Munz B, et al. **J Endocrinol** 1999 May;161(2):187–93 (34 ref.)
Dupuytren's disease. The way forward? Fitzgerald AM, et al. **J Hand Surg [Br]** 1999 Aug;24(4):395–9 (56 ref.)
Cell migration into a wounded area in vitro. Lampugnani MG. **Methods Mol Biol** 1999;96:177–82 (33 ref.)
Cutaneous wound healing. Singer AJ, et al. **N Engl J Med** 1999 Sep 2;341(10):738–46 (86 ref.)
Molecular biology and biomechanics of normal and healing ligaments—a review. Frank CB, et al. **Osteoarthritis Cartilage** 1999 Jan;7(1):130–40 (65 ref.)
Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Jester JV, et al. **Prog Retin Eye Res** 1999 May;18(3):311–56 (111 ref.)
Keloids and hypertrophic scars: review and treatment strategies. Urioste SS, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):159–71 (141 ref.)
Fetal wound repair: where do we go from here? Stelnicki EJ, et al. **Semin Pediatr Surg** 1999 Aug;8(3):124–30 (48 ref.)
Cytokines and the role they play in the healing of ligaments and tendons. Evans CH. **Sports Med** 1999 Aug;28(2):71–6 (43 ref.)
Modern therapy of chronic wounds with respect to radiation. Frank J, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:69–73 (26 ref.)
The wound repair-associated keratins 6, 16, and 17. Insights into the role of intermediate filaments in specifying keratinocyte cytoarchitecture. McGowan K, et al. **Subcell Biochem** 1998;31:173–204 (120 ref.)
Wound healing—scar wars. Ferguson MW. **Ulster Med J** 1998 Jun;67 Suppl 1:37–40 (23 ref.)
Predicting healing of arterial leg ulcers by means of segmental systolic pressure measurements. Wütschert R, et al. **Vasa** 1998 Nov;27(4):224–8 (13 ref.)
Functions of hyaluronan in wound repair. Chen WY, et al. **Wound Repair Regen** 1999 Mar–Apr;7(2):79–89 (105 ref.)
The mast cell-nerve axis in wound healing: a hypothesis. Gottwald T, et al. **Wound Repair Regen** 1998 Jan–Feb; 6(1):8–20 (160 ref.)
Studies on the biological activity of the dermal regeneration template. Yannas IV. **Wound Repair Regen** 1998 Nov–Dec; 6(6):518–23 (42 ref.)
[Wound healing and extracellular matrix] Yang Y, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1997 May;13(3):212–4 (24 ref.) **(Chi)**
[Effect of dressing materials on wound healing] Linder R. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:694–7 (16 ref.) (Eng. Abstr.) **(Ger)**
[Differentiated local therapy of chronic wounds with modern wound dressings] Eich D, et al. **Vasa** 1999 Feb;28(1):3–9 (57 ref.) (Eng. Abstr.) **(Ger)**
[Wound dressings in chronic wounds] Mohr VD, et al. **Zentralbl Chir** 1999;124 Suppl 1:56–64 (61 ref.) (Eng. Abstr.) **(Ger)**
[Local application of G-CSF, GM-CSF and EGF in treatment of wounds] Grzybowski J, et al. **Postepy Hig Med Dosw** 1999;53(1):75–86 (52 ref.) (Eng. Abstr.) **(Pol)**

WOUND INFECTION

WOUND INFECTION

DIAGNOSIS

Diabetic foot infections. Saltzman CL, et al. **Instr Course Lect** 1999;48:317-20 (8 ref.)

[Principles of biochemical diagnosis of early infection process] Pisarzhevskii SA, et al. **Vestn Ross Akad Med Nauk** 1998;(8):46-51 (60 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Targeting lurking pathogens in acute traumatic and chronic wounds. Eron LJ. **J Emerg Med** 1999 Jan-Feb;17(1):189-95 (35 ref.)

Opportunities for mupirocin calcium cream in the emergency department. Williford PM. **J Emerg Med** 1999 Jan-Feb; 17(1):213-20 (74 ref.)

[Clinico-laboratory effectiveness of modern ointments with a polyethylene glycol base in the treatment of purulent wounds] Blatun LA, et al. **Antibiot Khimioter** 1999; 44(7):25-31 (12 ref.) (Eng. Abstr.) **(Rus)**

[Infections and treatment of chronic leg ulcers: the use of antibiotics is too excessive, restrictive prescription is recommended] Wiström J, et al. **Lakartidningen** 1999 Jan 6;96(1-2):42-6 (18 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

Aggressive treatment of 119 open fracture wounds. DeLong WG Jr, et al. **J Trauma** 1999 Jun;46(6):1049-54 (25 ref.)

ETIOLOGY

[Infection in burn patients: the problems of pathogenesis, prevention and treatment] Alekseev AA, et al. **Khirurgiia (Mosk)** 1999;(6):4-9 (14 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

An outbreak of extended-spectrum, beta-lactamase-producing Salmonella senftenberg in a burns ward. Revathi G, et al. **J Hosp Infect** 1998 Dec; 40(4):295-302 (36 ref.)

New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds [editorial] Goldstein EJ. **J Med Microbiol** 1998 Feb;47(2):95-7 (18 ref.)

[Capnocytophaga canimorsus infections: a possibly fatal complication of bite wounds] Kramer AM, et al. **Tijdschr Diergeneeskd** 1999 Feb 15;124(4):108-10 (19 ref.) (Eng. Abstr.) **(Dut)**

PREVENTION & CONTROL

A rational approach to the outpatient management of lacerations in pediatric patients. Kanegaye JT. **Curr Probl Pediatr** 1998 Aug;28(7):205-34 (198 ref.)

Modifying perfusion, nutrition, and stress to promote wound healing in patients with acute wounds. Whitney JD, et al. **Heart Lung** 1999 Mar-Apr;28(2):123-33 (74 ref.)

Subcutaneous fluid administration--better than the intravenous approach? Jain S, et al. **J Hosp Infect** 1999 Apr;41(4):269-72 (13 ref.)

THERAPY

Secondarily infected wounds and dermatoses: a diagnosis and treatment guide. Bikowski J. **J Emerg Med** 1999 Jan-Feb; 17(1):197-206 (46 ref.)

WOUNDS AND INJURIES

see related
FIRST AID
TRANSPORTATION OF PATIENTS

Bear-inflicted human injury and fatality. Floyd T. **Wilderness Environ Med** 1999 Summer;10(2):75-87 (32 ref.)

BLOOD

Lactate in sepsis and trauma--hindrance or help? Sladen RN. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):237-8 (14 ref.)

TNF in trauma--whither our focus? [editorial; comment] Reines HD. **Crit Care Med** 1999 Feb;27(2):239 (9 ref.) Comment on: Crit Care Med 1999 Feb;27(2):313-8.

CLASSIFICATION

Current trauma scoring systems and their applications. Van Camp LA, et al. **Eur J Emerg Med** 1998 Sep;5(3):341-53 (73 ref.)

Abbreviated injury scale unification: the case for a unified injury system for global use. Garthe E, et al. **J Trauma** 1999 Aug;47(2):309-23 (29 ref.)

ABCs of scoring systems for pediatric trauma. Furnival RA, et al. **Pediatr Emerg Care** 1999 Jun;15(3):215-23 (90 ref.)

COMPLICATIONS

Trauma-induced linear scleroderma. Yamanaka CT, et al. **Cutis** 1999 Jan;63(1):29-32 (36 ref.)

Chronically elevated proliferation as a risk factor for neoplasia. Moore MA, et al. **Eur J Cancer Prev** 1998 Oct; 7(5):353-85 (634 ref.)

Thromboprophylaxis in non-surgical patients: who, when and how? Gallus AS, et al. **Haemostasis** 1998;28 Suppl 3:71-82 (71 ref.)

Hypothermia in trauma patients. Peng RY, et al. **J Am Coll Surg** 1999 Jun;188(6):685-96 (107 ref.)

Postinjury neuropathic pain syndromes. Schwartzman RJ, et al. **Med Clin North Am** 1999 May;83(3):597-626 (112 ref.)

Second messengers, the substantia gelatinosa and injury-induced persistent pain. Petersen-Zeitz KR, et al. **Pain** 1999 Aug;Suppl 6:S5-12 (87 ref.)

Deep venous thrombosis in the trauma patient. Meissner MH. **Semin Vasc Surg** 1998 Dec;11(4):274-82 (67 ref.)

[The pathogenesis of multiple organ failure in severe mechanical trauma] Sheiko VD. **Klin Khir** 1999;(6):39-42 (43 ref.) **(Ukr)**

DIAGNOSIS

Employment of trauma and injury severity score and a severity characterization of trauma in the outcome evaluation of trauma care and their research advances. Zhu P, et al. **Chin Med J (Engl)** 1998 Feb;111(2):169-73 (22 ref.)

Diagnostic imaging in pediatric trauma. Grasso SN, et al. **Curr Opin Pediatr** 1998 Jun;10(3):299-302 (20 ref.)

Practical issues in the care of pediatric trauma patients. Knapp JF. **Curr Probl Pediatr** 1998 Nov-Dec; 28(10):309-20 (77 ref.)

Measures of injury severity in childhood: a critical overview. Beattie TF, et al. **Inj Prev** 1998 Sep;4(3):228-31 (26 ref.)

Analysis of laparoscopy in trauma. Villavicencio RT, et al. **J Am Coll Surg** 1999 Jul;189(1):11-20 (62 ref.)

Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. James JH, et al. **Lancet** 1999 Aug 7; 354(9177):505-8 (47 ref.)

Analysis of thoracoscopy in trauma. Villavicencio RT, et al. **Surg Endosc** 1999 Jan;13(1):3-9 (39 ref.)

[Trauma during pregnancy] Siebenga J, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1144-8 (59 ref.) (Eng. Abstr.) **(Dut)**

[Clinical examination of accident victims] Echtermeyer V, et al. **Unfallchirurg** 1999 Apr;102(4):305-18 (21 ref.) **(Ger)**

DRUG THERAPY

Signal transduction in wound pharmacology. Kim WJ, et al. **Arch Pharm Res** 1998 Oct;21(5):487-95 (107 ref.)

Efficacy of homeopathic arnica: a systematic review of placebo-controlled clinical trials. Ernst E, et al. **Arch Surg** 1998 Nov;133(11):1187-90 (23 ref.)

Pharmacological treatment of wounds. Flour M, et al. **Semin Cutan Med Surg** 1998 Dec;17(4):260-5 (47 ref.)

[Advance in the study of post-wound effects of arginine] Luo X, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):124-6 (26 ref.) **(Chi)**

[Role of corticosteroid therapy in non-malignant diseases] Vignes S, et al. **Rev Med Interne** 1998 Nov;19(11):799-810 (87 ref.) (Eng. Abstr.) **(Fre)**

[Local application of G-CSF, GM-CSF and EGF in treatment of wounds] Grzybowski J, et al. **Postepy Hig Med Dosw** 1999;53(1):75-86 (52 ref.) (Eng. Abstr.) **(Pol)**

[Does prehospital hypertonic infusion therapy improve the survival of trauma patients?] Haljamäe H. **Lakartidningen** 1999 Mar 3;96(9):1014-7 (21 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

Injuries and violence: risk factors and opportunities for prevention during adolescence. Cohen LR, et al. **Adolesc Med** 1999 Feb;10(1):125-35, vi (90 ref.)

Childhood injuries: extent of the problem, epidemiological trends, and costs. Roberts I, et al. **Inj Prev** 1998 Dec;4(4 Suppl):S10-6 (29 ref.)

Systematic review of trauma system effectiveness based on registry comparisons [see comments] Jurkovich GJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S46-55 (28 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S56-8.

Population-based research assessing the effectiveness of trauma systems [see comments] Mullins RJ, et al. **J Trauma** 1999 Sep;47(3 Suppl):S59-66 (32 ref.) Comment in: J Trauma 1999 Sep;47(3 Suppl):S67-8.

Physical hazards of animal handlers. Langley R. **Occup Med** 1999 Apr-Jun;14(2):181-94 (56 ref.)

Military parachuting injuries: a literature review. Bricknell MC, et al. **Occup Med (Lond)** 1999 Jan;49(1):17-26 (27 ref.)

Physical training and exercise-related injuries. Surveillance, research and injury prevention in military populations. Jones BH, et al. **Sports Med** 1999 Feb;27(2):111-25 (61 ref.)

Injuries at school: a review. Haq SM, et al. **Tex Med** 1999 Apr;95(4):62-5 (33 ref.)

[A new branch of epidemiology--injury epidemiology] Wu XK. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Jun; 18(3):167-70 (17 ref.) **(Chi)**

ETIOLOGY

Snowboarding injuries [published erratum appears in Am Fam Physician 1999 Feb 15;59(4):786] Young CC, et al. **Am Fam Physician** 1999 Jan 1;59(1):131-6, 141 (16 ref.)

The child as a projectile [see comments] Tibbs RE Jr, et al. **Anat Rec** 1998 Dec;253(6):167-75 (21 ref.) Comment in: Anat Rec 1998 Dec;253(6):155.

Alcohol-related injuries: Do we really need more proof? [editorial; comment] Hargarten SW. **Ann Emerg Med** 1999 Jun;33(6):699-701 (9 ref.) Comment on: Ann Emerg Med 1999 Jun;33(6):659-68.

Complications of hemodynamic monitoring. Coulter TD, et al. **Clin Chest Med** 1999 Jun;20(2):249-67, vii (138 ref.)

Dumpers, rips, and other hazards for the environmental surfer [editorial] Langley J. **Inj Prev** 1999 Jun;5(2):84 (4 ref.)

NHTSA: putting the brakes on the air bag crisis or just a lot of hot air? Pacelli L. **J Contemp Health Law Policy** 1999 Spring;15(2):757-77 (231 ref.)

Rear-end impacts: vehicle and occupant response. Davis CG. **J Manipulative Physiol Ther** 1998 Nov-Dec;21(9):629-39 (171 ref.)

Somnambulism and trauma: case report and short review of the literature. Milliet N, et al. **J Trauma** 1999 Aug; 47(2):420-2 (12 ref.)

Physical hazards of animal handlers. Langley R. **Occup Med** 1999 Apr-Jun;14(2):181-94 (56 ref.)

Illness and injury in animal confinement workers. Von Essen S, et al. **Occup Med** 1999 Apr-Jun;14(2):337-50 (69 ref.)

Chronic avulsive injuries of childhood. Donnelly LF, et al. **Skeletal Radiol** 1999 Mar;28(3):138-44 (8 ref.)

[Accidental falls and fall-related injuries in the elderly. Diagnosis and intervention] Becker C, et al. **Fortschr Med** 1998 Nov 20;116(32):22-6, 28-9 (28 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immunological consequences of trauma and shock. Catania RA, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):120-32 (147 ref.)

Similarities and differences of the immune response to exercise and trauma: the IFN-gamma concept. Northoff H, et al. **Can J Physiol Pharmacol** 1998 May;76(5):497-504 (53 ref.)

The cytokine response to strenuous exercise. Pedersen BK, et al. **Can J Physiol Pharmacol** 1998 May;76(5):505-11 (54 ref.)

Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589-97 (71 ref.)

Immune responses to inflammation and trauma: a physical training model. Shephard RJ, et al. **Can J Physiol Pharmacol** 1998 May;76(5):469-72 (33 ref.)

Augmented enhancement of in vitro production of inflammatory cytokines...[editorial; comment] Dunn DL. **Crit Care Med** 1999 May;27(5):859-60 (10 ref.) Comment on: Crit Care Med 1999 May;27(5):929-36.

Trauma and the immune response. Smith RM, et al. **J R Soc Med** 1998 Aug;91(8):417-20 (52 ref.)

The effects of injury on the adaptive immune response. Lederer JA, et al. **Shock** 1999 Mar;11(3):153-9 (75 ref.)

METABOLISM

Pathways of muscle protein breakdown in injury and sepsis. Hasselgren PO. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):155-60 (37 ref.)

Indirect calorimetry: can this technology impact patient outcome? McClave SA, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):61-7 (39 ref.)

Which metabolic strategies in the early phase of injury? Iapichino G, et al. **Minerva Anestesiol** 1999 Jun; 65(6):455-63 (63 ref.)

The metabolic needs of critically ill children and neonates. Shew SB, et al. **Semin Pediatr Surg** 1999 Aug;8(3):131-9 (88 ref.)

Therapeutic implications of interleukin-10 in surgical disease. Selzman CH, et al. **Shock** 1998 Nov;10(5):309-18 (156 ref.)

Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127-37 (163 ref.)

Measuring tissue oxygen tension: a review. Sheffield PJ. **Undersea Hyperb Med** 1998 Fall;25(3):179-88 (67 ref.)

MORTALITY

Alcohol-related injuries: Do we really need more proof? [editorial; comment] Hargarten SW. **Ann Emerg Med** 1999 Jun;33(6):699-701 (9 ref.) Comment on: Ann Emerg Med 1999 Jun;33(6):659-68.

Invited commentary: panel reviews of trauma mortality. Trunkey DD. **J Trauma** 1999 Sep;47(3 Suppl):S44-5 (28 ref.)

NURSING

Modifying perfusion, nutrition, and stress to promote wound healing in patients with acute wounds. Whitney JD, et al. **Heart Lung** 1999 Mar-Apr;28(2):123-33 (74 ref.)

PATHOLOGY

Genetic approaches to neurotrauma research: opportunities and potential pitfalls of murine models. Steward O, et al. **Exp Neurol** 1999 May;157(1):19-42 (130 ref.)

PHYSIOPATHOLOGY

Genetic approaches to neurotrauma research: opportunities and potential pitfalls of murine models. Steward O, et al. **Exp Neurol** 1999 May;157(1):19–42 (130 ref.)
Wound healing and chronic wounds. Falanga V. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1–1–5 (20 ref.)

PREVENTION & CONTROL

Prevention of injuries to children and adolescents. Rivara FP, et al. **Adv Pediatr** 1998;45:37–72 (168 ref.)
Protecting the health and safety of working teenagers. Rubenstein H, et al. **Am Fam Physician** 1999 Aug; 60(2):575–80, 587–8 (07 ref.)
Dumpers, rips, and other hazards for the environmental surfer [editorial] Langley J. **Inj Prev** 1999 Jun;5(2):84 (4 ref.)
Austrian Committee for Injury Prevention in Childhood. Purtscher K, et al. **Inj Prev** 1998 Sep;4(3):236–7 (3 ref.)
Reducing the burden of injury. Rivara FP. **Inj Prev** 1999 Jun;5(2):85–6 (7 ref.)
Injury prevention in the UK—the European dimension. Sibert J, et al. **Inj Prev** 1998 Dec;4(4 Suppl):S34–41 (33 ref.)
Prevention of injuries to children and young people: the way ahead for the UK. Towner E, et al. **Inj Prev** 1998 Dec; 4(4 Suppl):S17–25 (127 ref.)
House fire injury prevention update. Part I. A review of risk factors for fatal and non-fatal house fire injury. Warda L, et al. **Inj Prev** 1999 Jun;5(2):145–50 (38 ref.)
Injury control strategies: extending the quality and quantity of data relating to road traffic accidents in children. Henson R, et al. **J Accid Emerg Med** 1999 Mar;16(2):87–90 (33 ref.)
Potential for violence toward psychiatric nursing students: risk reduction techniques. Echternacht MR. **J Psychosoc Nurs Ment Health Serv** 1999 Mar;37(3):36–9 (9 ref.)
Optimum machine guarding. Brubaker SA. **Occup Health Saf** 1997 Dec;66(12):37–40 (12 ref.)
Pediatric injury control in 1999: where do we go from here? Rivara FP. **Pediatrics** 1999 Apr;103(4 Pt 2):883–8 (75 ref.)

PSYCHOLOGY

Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event. Yehuda R, et al. **Biol Psychiatry** 1998 Dec 15;44(12):1305–13 (75 ref.)
Consensus criteria for traumatic grief. A preliminary empirical test. Prigerson HG, et al. **Br J Psychiatry** 1999 Jan;174:67–73 (17 ref.)
Cognitive impact of traumatic events. Bower GH, et al. **Dev Psychopathol** 1998 Fall;10(4):625–53 (182 ref.)
The fate of traumatic memories in childhood and adulthood. Christianson SA, et al. **Dev Psychopathol** 1998 Fall; 10(4):761–80 (109 ref.)
Trauma, memory, and suggestibility in children. Eisen ML, et al. **Dev Psychopathol** 1998 Fall;10(4):717–38 (155 ref.)
Models of human memory and their implications for research on aging and psychopathology. Estes WK. **Dev Psychopathol** 1998 Fall;10(4):607–24 (82 ref.)
Children's recollections of traumatic and nontraumatic events. Fivush R. **Dev Psychopathol** 1998 Fall; 10(4):699–716 (105 ref.)
Individual differences in factors that modulate storage and retrieval of traumatic memories. Howe ML. **Dev Psychopathol** 1998 Fall;10(4):681–98 (118 ref.)
Repression: a mistaken impression? Loftus E, et al. **Dev Psychopathol** 1998 Fall;10(4):781–92 (61 ref.)
The effects of stress and trauma on brain and memory: a view from developmental cognitive neuroscience. Nelson CA, et al. **Dev Psychopathol** 1998 Fall;10(4):793–809 (87 ref.)
Stress, memory, and emotion: developmental considerations from the study of child maltreatment. Pollak S, et al. **Dev Psychopathol** 1998 Fall;10(4):811–28 (98 ref.)
Remembering, forgetting, and the effects of trauma on memory: a developmental psychopathology perspective [editorial] Toth SL, et al. **Dev Psychopathol** 1998 Fall; 10(4):589–605 (110 ref.)
The bezoaric effect: working with traumatic process. Stanton M. **Psychoanal Rev** 1998 Jun;85(3):331–48 (31 ref.)
[Post-traumatic stress disorder after traffic accidents] Meyer C, et al. **Unfallchirurg** 1998 Dec;101(12):878–93 (152 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Topical anesthesia. Keyes PD, et al. **Can Fam Physician** 1998 Oct;44:2152–6 (13 ref.)
Common problems seen by the plastic surgery emergency room service. Shook JE. **Clin Plast Surg** 1998 Oct; 25(4):619–29, ix (41 ref.)
Pitfalls in the care of the injured patient. Wall MJ Jr, et al. **Curr Probl Surg** 1998 Dec;35(12):1019–74 (78 ref.)
Trauma and critical care. Fallon WF Jr. **J Am Coll Surg** 1999 Feb;188(2):191–7 (35 ref.)
Apligraf treatment of venous ulcers and other chronic wounds. Falanga V. **J Dermatol** 1998 Dec;25(12):812–7 (18 ref.)
The use of Apligraf in acute wounds. Kirsner RS. **J Dermatol** 1998 Dec;25(12):805–11 (39 ref.)
Analysis of thoracoscopy in trauma. Villavicencio RT, et al. **Surg Endosc** 1999 Jan;13(1):3–9 (39 ref.)
[Serratus anterior muscle flap: indications and sequelae. 26 cases and review of the literature] Fassio E, et al. **Ann Chir Plast Esthet** 1999 Apr;44(2):175–82; discussion 183 (34 ref.) (Eng. Abstr.) **(Fre)**
[Use of growth factors in therapy of chronic wounds. Experimental, clinical and financial aspects] Vogt PM, et al. **Chirurg** 1998 Nov;69(11):1197–206 (30 ref.) (Eng. Abstr.) **(Ger)**
[Significance of molecular biology research for trauma surgery exemplified by wound and bone healing] Hanselmann RG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:86–9 (0 ref.) (Eng. Abstr.) **(Ger)**
[Complications in trauma surgery] Piltz S, et al. **Unfallchirurg** 1998 Nov;101(11):856–65 (18 ref.) **(Ger)**

THERAPY

Impediments to wound healing. Stadelmann WK, et al. **Am J Surg** 1998 Aug;176(2A Suppl):39S–47S (57 ref.)
"Alternative" surgery in trauma management. Britt LD, et al. **Arch Surg** 1998 Nov;133(11):1177–81 (44 ref.)
Practical issues in the care of pediatric trauma patients. Knapp JF. **Curr Probl Pediatr** 1998 Nov–Dec; 28(10):309–20 (77 ref.)
Gene therapy of wounds with growth factors. Davidson JM, et al. **Curr Top Pathol** 1999;93:111–21 (27 ref.)
The debridement of chronic wounds: a systematic review. Bradley M, et al. **Health Technol Assess (Rockv)** 1999;3(17 Pt 1):iii–iv, 1–78 (62 ref.)
Perioperative management of the elderly trauma patient. Dickson RE, et al. **Hosp Med** 1999 Jun;60(6):425–9 (21 ref.)
Improving post-impact care—a form of injury prevention. Yates D. **Inj Prev** 1998 Dec;4(4 Suppl):S42–5 (14 ref.)
A review of the quality of trauma protocols on the Internet. Branfoot T, et al. **Injury** 1999 Jan;30(1):1–7 (11 ref.)
Tissue engineering. Sefton MV, et al. **J Cutan Med Surg** 1998 Dec;3 Suppl 1:S1–18–23 (41 ref.)
Dohi Memorial Lecture. From occlusive to living membranes. Eaglstein WH. **J Dermatol** 1998 Dec; 25(12):766–74 (35 ref.)
Addressing trauma in substance abuse treatment with American Indian adolescents. Gray N. **J Subst Abuse Treat** 1998 Sep–Oct;15(5):393–9 (42 ref.)
Which metabolic strategies in the early phase of injury? Iapichino G, et al. **Minerva Anestesiol** 1999 Jun; 65(6):455–63 (63 ref.)
CPR in the trauma patient: indications and contraindications. Vincent JL. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):6–9 (32 ref.)
The effects of injury on the adaptive immune response. Lederer JA, et al. **Shock** 1999 Mar;11(3):153–9 (75 ref.)
[Phytotherapy in chronic dermatoses and wounds: what is the evidence?] Grimme H, et al. **Forsch Komplementarmed** 1999 Apr;6 Suppl 2:5–8 (36 ref.) (Eng. Abstr.) **(Ger)**
[Wound dressings in chronic wounds] Mohr VD, et al. **Zentralbl Chir** 1999;124 Suppl 1:56–64 (61 ref.) (Eng. Abstr.) **(Ger)**
[Keratinocyte transplantation and tissue engineering. New approaches in treatment of chronic wounds] Tánczos E, et al. **Zentralbl Chir** 1999;124 Suppl 1:81–6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Damage control surgery] Ikegami K. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):430–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

WOUNDS, GUNSHOT

CLASSIFICATION

[Comparison of wound morphology following gunshots by machine guns and sub-machine guns] Grellner W, et al. **Arch Kriminol** 1999 Jan–Feb;203(1–2):32–9 (3111 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Recurrent pericardial effusion due to gunshot wound of the heart in a hemodynamically stable child—a case report. Tutar HE, et al. **Angiology** 1999 Apr;50(4):337–40 (12 ref.)
Traumatic thoracobiliary fistula: report of a case successfully managed conservatively, with an overview of current diagnostic and therapeutic options. Sheik-Gafoor MH, et al. **J Trauma** 1998 Oct;45(4):819–21 (16 ref.)
Multidisciplinary approach to traumatic intracranial aneurysms secondary to shotgun and handgun wounds. Horowitz MB, et al. **Surg Neurol** 1999 Jan;51(1):31–41; discussion 41–2 (20 ref.)

EPIDEMIOLOGY

Use of national data systems for firearm-related injury surveillance. Annest JL, et al. **Am J Prev Med** 1998 Oct; 15(3 Suppl):17–30 (31 ref.)
Why firearm injury surveillance? Frattaroli S, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):2–5 (17 ref.)
Firearm injury surveillance at the local level from data to action. Kellermann AL, et al. **Am J Prev Med** 1998 Oct; 15(3 Suppl):109–12 (25 ref.)
Prospects and challenges in implementing firearm-related injury surveillance in the United States. Not a flash in the pan. Koo D, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):120–4 (36 ref.)
Firearm-related injury surveillance. An overview of progress and the challenges ahead. Mercy JA, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):6–16 (41 ref.)
[Mortality by firearms in the state of Rio de Janeiro, Brazil: a spatial analysis] Szwarcwald CL, et al. **Rev Panam Salud Publica** 1998 Sep;4(3):161–70 (41 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Use of national data systems for firearm-related injury surveillance. Annest JL, et al. **Am J Prev Med** 1998 Oct; 15(3 Suppl):17–30 (31 ref.)
Why firearm injury surveillance? Frattaroli S, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):2–5 (17 ref.)
Firearm-related injury surveillance. An overview of progress and the challenges ahead. Mercy JA, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):6–16 (41 ref.)

MORTALITY

Fatal firearm-related injury surveillance in Maryland. Wiersema B, et al. **Am J Prev Med** 1998 Oct;15(3 Suppl):46–56 (4 ref.)
Mortality associated with use of weapons in armed conflicts, wartime atrocities, and civilian mass shootings: literature review. Coupland RM, et al. **BMJ** 1999 Aug 14; 319(7207):407–10 (36 ref.)

PHYSIOPATHOLOGY

Biomechanics of penetrating trauma. Yoganandan N, et al. **Crit Rev Biomed Eng** 1997;25(6):485–501 (94 ref.)
[The dynamics of projectile wounding. Concepts in ballistic injuries (editorial)] Houdelette P. **Ann Chir Plast Esthet** 1998 Apr;43(2):109–16 (14 ref.) (Eng. Abstr.) **(Fre)**
[Ballistic data for plastic surgeons (editorial)] Rocca A, et al. **Ann Chir Plast Esthet** 1998 Apr;43(2):117–24 (10 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Pellet embolization to the right atrium following double shotgun injury. Pollak S, et al. **Forensic Sci Int** 1999 Jan 4;99(1):61–9 (32 ref.)

SURGERY

Iliac to popliteal artery bypass through the iliac wing: An alternative extracavitary route for management of complex groin injuries. Donayre CE, et al. **Ann Vasc Surg** 1999 Mar; 13(2):209–15 (23 ref.)
Z-plasty closure of the donor defect of the radial forearm free flap. Hui KC, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):19–21 (10 ref.)
Removal of unexploded ordnance from patients: a 50-year military experience and current recommendations. Lein B, et al. **Mil Med** 1999 Mar;164(3):163–5 (9 ref.)
[Surgical tactics in firearm wounds of abdomen] Revskoi AK, et al. **Khirurgiia (Mosk)** 1998;(10):15–9 (4 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

The management of penetrating trauma to the hand. Nathan R. **Hand Clin** 1999 May;15(2):193–9, vii (22 ref.)

WOUNDS, MULTIPLE see **MULTIPLE TRAUMA**

WOUNDS, NONPENETRATING

The management of blunt liver injuries. Strong RW. **Aust N Z J Surg** 1999 Aug;69(8):609–16 (42 ref.)
Blunt cerebrovascular injuries. Biffl WL, et al. **Curr Probl Surg** 1999 Jul;36(7):505–99 (163 ref.)
Tracheobronchial avulsion and associated innominate artery injury in blunt trauma: case report and literature review. Hemmila MR, et al. **J Trauma** 1999 Mar;46(3):505–12 (31 ref.)
Blunt vena azygos trauma: report of a case and review of world literature. Sharma OP, et al. **J Trauma** 1999 Jan; 46(1):192–5 (17 ref.)
[Closed thoracic injuries: physiopathology, diagnosis, management in emergencies] de Wailly G, et al. **Rev Prat** 1998 Nov 1;48(17):1953–7 (0 ref.) **(Fre)**
[The application of laparocentesis and peritoneal lavage and the analysis of hemo-peritoneal volume in the diagnosis of closed abdominal wound] Tishchenko VV. **Klin Khir** 1999;(1):11–2 (2 ref.) (Eng. Abstr.) **(Rus)**
[Diaphragmatic closed injuries in an acute phase of the injury] Makarov AV, et al. **Klin Khir** 1999;(1):43–7 (42 ref.) **(Ukr)**

CLASSIFICATION

Complete traumatic avulsion of the gallbladder. Losanoff JE, et al. **Injury** 1999 Jun;30(5):365–8 (23 ref.)

COMPLICATIONS

Traumatic rupture of the thoracic aorta. Mattox KL. **Adv Card Surg** 1998;10:271–83 (10 ref.)
Chylothorax in blunt trauma: a case report. Golden P. **Am J Crit Care** 1999 May;8(3):189–92 (8 ref.)
Traumatic hematuria in patients with polycystic kidney disease. Klein AJ, et al. **Am Surg** 1999 May;65(5):464–6 (25 ref.)

Inferior vena caval thrombosis after traumatic liver injury. Kimoto T, et al. **HPB Surg** 1998;11(2):111–6 (22 ref.)
Bilateral thrombosis of the internal carotid arteries after a closed trauma. Advantages of magnetic resonance imaging and review of the literature. Gouny P, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):417–24 (23 ref.)
Perforation of the intrathoracic esophagus from blunt trauma in a child: case report and review of the literature. Sartorelli KH, et al. **J Pediatr Surg** 1999 Mar;34(3):495–7 (17 ref.)
Diaphragmatic paralysis following minor blunt trauma. Dalshaug GB, et al. **J Trauma** 1999 Aug;47(2):413–5 (15 ref.)
Hypopharyngeal perforation after blunt neck trauma: case report and review of the literature. Jacobs I, et al. **J Trauma** 1999 May;46(5):957–8 (4 ref.)
Bilateral vertebral artery occlusion following cervical spine trauma--case report. Ozveren F, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):28–32 (44 ref.)
Delayed presentation of traumatic arterial vasospasm. Davis GM, et al. **Pediatr Emerg Care** 1999 Feb;15(1):22–4 (12 ref.)
Anxiety and closed head injury in young people. Thurber CA. **Pediatr Rehabil** 1998 Oct–Dec;2(4):149–55 (39 ref.)
Imaging of acute thoracic aortic injury due to blunt trauma: a review. Patel NH, et al. **Radiology** 1998 Nov; 209(2):335–48 (182 ref.)
Posttraumatic intestinal stenosis presenting as a perforation: report of a case. Konobu T, et al. **Surg Today** 1999; 29(6):564–7 (16 ref.)
[Dissection of the ramus interventricularis anterior in blunt chest trauma] Kettering K, et al. **Dtsch Med Wochenschr** 1999 Aug 6;124(31–32):930–4 (10 ref.) (Eng. Abstr.) **(Ger)**
[A case of gas occurrence in the venous hepato-portal area after blunt trauma of the abdomen] Torriero F, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):118–20 (6 ref.) **(Ita)**
[Posttraumatic priapism in a 6-year-old boy: a case report] Iwata K, et al. **Hinyokika Kiyo** 1998 Sep;44(9):679–82 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Scapulothoracic dissociation. Lee L, et al. **Am J Orthop** 1998 Oct;27(10):699–702 (31 ref.)
Traumatic fracture of the hyoid bone: three case presentations of cardiorespiratory compromise secondary to missed diagnosis. Kaufman HJ, et al. **Am Surg** 1999 Sep; 65(9):877–80 (10 ref.)
Evaluation of the patient with blunt abdominal trauma: an evidence based approach. Amoroso TA. **Emerg Med Clin North Am** 1999 Feb;17(1):63–75, viii (42 ref.)
Intraoral blunt carotid injury in an adult: case report and review of the literature. Mikulaschek A, et al. **J Trauma** 1999 Jul;47(1):179–82 (43 ref.)
Delayed diagnosis of splenic injury after falls from less than 10 feet. Young KD, et al. **Pediatr Emerg Care** 1998 Dec; 14(6):413–5 (19 ref.)
Complete pyelo-calyceal avulsion as a result of blunt abdominal trauma. Pagano S, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):66–8 (8 ref.)
Cervicothoracic vascular injuries. McIntyre WB, et al. **Semin Vasc Surg** 1998 Dec;11(4):232–42 (50 ref.)
[Trauma during pregnancy] Siebenga J, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1144–8 (59 ref.) (Eng. Abstr.) **(Dut)**
[Ruptures and injuries to the diaphragm] Slim K. **J Chir (Paris)** 1999 Jun;136(2):67–75 (67 ref.) (Eng. Abstr.) **(Fre)**
[Closed trauma of the abdominal aorta--current update] Bednarkiewicz M, et al. **Swiss Surg** 1998;(5):221–4 (20 ref.) (Eng. Abstr.) **(Fre)**
[Management and diagnostics in blunt abdominal trauma in pregnancy] Turczynowski W, et al. **Przegl Lek** 1998; 55(6):328–33 (12 ref.) (Eng. Abstr.) **(Pol)**
[Injuries to the urinary tract] de Matos S, et al. **Acta Med Port** 1999 Jan–Mar;12(1–3):49–56 (49 ref.) (Eng. Abstr.) **(Por)**
[Diagnostic and treatment difficulties in posttraumatic duodenal wounds] Palade V, et al. **Chirurgia (Bucur)** 1998 Nov–Dec;93(6):407–12 (11 ref.) (Eng. Abstr.) **(Rum)**

ETIOLOGY

Seat-belt transection of the pararenal vena cava in a 5-year-old child: survival with caval ligation. DeCou JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1074–6 (30 ref.)
Handlebar hernia: case report and review of pediatric cases. Kubota A, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):411–2 (15 ref.)
Traumatic abdominal wall hernia caused by persistent cough. Vasquez JC, et al. **South Med J** 1999 Sep;92(9):907–8 (11 ref.)

PATHOLOGY

[Hepatic trauma: pediatric features] Moog R, et al. **Ann Chir** 1998;52(10):1022–7 (33 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Imaging of pancreatic trauma. Patel SV, et al. **Br J Radiol** 1998 Sep;71(849):985–90 (9 ref.)
The diagnostic problem associated with blunt traumatic azygous vein injury: delayed appearance of right haemothorax after blunt chest trauma. Sugimoto K, et al. **Injury** 1998 Jun;29(5):380–2 (11 ref.)
Use of CT scan and transesophageal echocardiography in blunt thoracic trauma. Cinnella G. **Intensive Care Med** 1998 Sep;24(9):986–7 (4 ref.)
Radiographic and CT findings of blunt chest trauma: aortic injuries and looking beyond them. Kuhlman JE, et al. **Radiographics** 1998 Sep–Oct;18(5):1085–106; discussion 1107–8; quiz 1 (28 ref.)
CT in blunt chest trauma: indications and limitations. Van Hise ML, et al. **Radiographics** 1998 Sep–Oct;18(5):1071–84 (29 ref.)
Helical CT grading of traumatic aortic injuries. Impact on clinical guidelines for medical and surgical management. Gavant ML. **Radiol Clin North Am** 1999 May;37(3):553–74, vi (61 ref.)
Imaging diagnosis of nonaortic thoracic injury. Shanmuganathan K, et al. **Radiol Clin North Am** 1999 May; 37(3):533–51, vi (99 ref.)

SURGERY

Scapulothoracic dissociation. Lee L, et al. **Am J Orthop** 1998 Oct;27(10):699–702 (31 ref.)
Combined blunt cardiac and pericardial rupture: review of the literature and report of a new diagnostic algorithm. May AK, et al. **Am Surg** 1999 Jun;65(6):568–74 (12 ref.)
Traumatic aortic rupture and retroperitoneal haematoma--treatment including combined operative and endovascular approach. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):451–5 (6 ref.)
Seat-belt transection of the pararenal vena cava in a 5-year-old child: survival with caval ligation. DeCou JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1074–6 (30 ref.)
Management of abdominal vascular injuries. Biffl WL, et al. **Semin Vasc Surg** 1998 Dec;11(4):243–54 (47 ref.)
Vascular trauma associated with fractures and dislocations. Winkelaar GB, et al. **Semin Vasc Surg** 1998 Dec; 11(4):261–73 (51 ref.)
[Blunt injuries of the liver. Reliable approaches to treatment] Létoublon C, et al. **Ann Chir** 1998;52(2):166–71 (9 ref.) **(Fre)**
[Ruptures and injuries to the diaphragm] Slim K. **J Chir (Paris)** 1999 Jun;136(2):67–75 (67 ref.) (Eng. Abstr.) **(Fre)**
[Trauma to the colon in civilian surgery] Chanson C, et al. **Swiss Surg** 1998;(5):244–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Surgical management of liver rupture] Safi F, et al. **Chirurg** 1999 Mar;70(3):253–8 (33 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Endoluminal stent placement for the treatment of traumatic carotid artery pseudoaneurysm: case report and review of the literature. Shames ML, et al. **J Trauma** 1999 Apr; 46(4):724–6 (16 ref.)
Trauma in the obstetric patient. Stone IK. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):459–67, viii (21 ref.)
Cervicothoracic vascular injuries. McIntyre WB, et al. **Semin Vasc Surg** 1998 Dec;11(4):232–42 (50 ref.)
Traumatic posterior urethral injury and early primary endoscopic realignment: evaluation of long-term follow-up. Jepson BR, et al. **Urology** 1999 Jun; 53(6):1205–10 (23 ref.)

ULTRASONOGRAPHY

Use of CT scan and transesophageal echocardiography in blunt thoracic trauma. Cinnella G. **Intensive Care Med** 1998 Sep;24(9):986–7 (4 ref.)
Ultrasound in blunt abdominal trauma. Fernandez L, et al. **J Trauma** 1998 Oct;45(4):841–8 (53 ref.)
Focused abdominal sonogram for trauma: the learning curve of nonradiologist clinicians in detecting hemoperitoneum. Shackford SR, et al. **J Trauma** 1999 Apr;46(4):553–62; discussion 562–4 (40 ref.)
Ultrasound of blunt abdominal trauma. McKenney KL. **Radiol Clin North Am** 1999 Sep;37(5):879–93 (34 ref.)

WOUNDS, PENETRATING

Treatment of vascular injuries from penetrating and nonpenetrating trauma. Hess AV. **Hand Clin** 1999 May; 15(2):249–59, viii (82 ref.)
Peripheral nerve injuries secondary to missiles. Katzman BM, et al. **Hand Clin** 1999 May;15(2):233–44, viii (67 ref.)
High-pressure injection injuries to the hand. Schnall SB, et al. **Hand Clin** 1999 May;15(2):245–8, viii (23 ref.)

COMPLICATIONS

Management principles to treat nerve loss after violent trauma to the upper extremity. Thoder JJ, et al. **Hand Clin** 1999 May;15(2):289–98, ix (23 ref.)
Ear-piercing techniques as a cause of auricular chondritis. More DR, et al. **Pediatr Emerg Care** 1999 Jun;15(3):189–92 (13 ref.)

DIAGNOSIS

Radiology case of the month. Nail puncture wound to the foot. Mycobacterium chelonei osteomyelitis. Wilson S, et al. **J La State Med Soc** 1999 May;151(5):251–2 (6 ref.)
Cervicothoracic vascular injuries. McIntyre WB, et al. **Semin Vasc Surg** 1998 Dec;11(4):232–42 (50 ref.)
[Trauma during pregnancy] Siebenga J, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1144–8 (59 ref.) (Eng. Abstr.) **(Dut)**
[Diagnostic strategy in abdominal injuries] Alves A, et al. **Ann Chir** 1998;52(9):927–34 (39 ref.) (Eng. Abstr.) **(Fre)**
[Ruptures and injuries to the diaphragm] Slim K. **J Chir (Paris)** 1999 Jun;136(2):67–75 (67 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Unusual maxillofacial injury caused by a model airplane. Aldegheri A, et al. **J Oral Maxillofac Surg** 1999 Aug; 57(8):1009–12 (8 ref.)
Hypopharyngeal perforation after blunt neck trauma: case report and review of the literature. Jacobs I, et al. **J Trauma** 1999 May;46(5):957–8 (4 ref.)
Cardiac nail gun injuries: lessons learned. Vosswinkel JA, et al. **J Trauma** 1999 Sep;47(3):588–90 (21 ref.)

RADIOGRAPHY

Imaging of pancreatic trauma. Patel SV, et al. **Br J Radiol** 1998 Sep;71(849):985–90 (9 ref.)

SURGERY

A rational approach to the outpatient management of lacerations in pediatric patients. Kanegaye JT. **Curr Probl Pediatr** 1998 Aug;28(7):205–34 (198 ref.)
Lasers in the military for cutaneous disease and wound healing. Ross EV, et al. **Dermatol Clin** 1999 Jan; 17(1):135–50, ix (67 ref.)
Cardiac nail gun injuries: lessons learned. Vosswinkel JA, et al. **J Trauma** 1999 Sep;47(3):588–90 (21 ref.)
Use of topical lidocaine in pediatric laceration repair: a review of topical anesthetics. Stewart GM, et al. **Pediatr Emerg Care** 1998 Dec;14(6):419–23 (39 ref.)
Controversies in management of penetrating injuries of the pancreas. Degiannis E, et al. **S Afr J Surg** 1999 May; 37(2):38–40 (5 ref.)
Management of abdominal vascular injuries. Biffl WL, et al. **Semin Vasc Surg** 1998 Dec;11(4):243–54 (47 ref.)
Cervicothoracic vascular injuries. McIntyre WB, et al. **Semin Vasc Surg** 1998 Dec;11(4):232–42 (50 ref.)
Vascular trauma associated with fractures and dislocations. Winkelaar GB, et al. **Semin Vasc Surg** 1998 Dec; 11(4):261–73 (51 ref.)
Reconstructive surgery for trauma of the upper urinary tract. Brandes SB, et al. **Urol Clin North Am** 1999 Feb; 26(1):183–99, x (52 ref.)
[Ruptures and injuries to the diaphragm] Slim K. **J Chir (Paris)** 1999 Jun;136(2):67–75 (67 ref.) (Eng. Abstr.) **(Fre)**
[Trauma to the colon in civilian surgery] Chanson C, et al. **Swiss Surg** 1998;(5):244–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Surgical management of liver rupture] Safi F, et al. **Chirurg** 1999 Mar;70(3):253–8 (33 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Laceration management. Hollander JE, et al. **Ann Emerg Med** 1999 Sep;34(3):356–67 (118 ref.)
Paediatric lacerations and burns. Davey B. **Aust Fam Physician** 1999 Feb;28(2):117–23 (2 ref.)
The treatment of forearm fractures from penetrating trauma. Kozin SH, et al. **Hand Clin** 1999 May;15(2):221–31, viii (29 ref.)
Management principles to treat nerve loss after violent trauma to the upper extremity. Thoder JJ, et al. **Hand Clin** 1999 May;15(2):289–98, ix (23 ref.)
Impalement and anorectal injuries in childhood: a retrospective study of 12 cases. Beiler HA, et al. **J Pediatr Surg** 1998 Aug;33(8):1287–91 (11 ref.)
Trauma in the obstetric patient. Stone IK. **Obstet Gynecol Clin North Am** 1999 Sep;26(3):459–67, viii (21 ref.)
[Acute management of patients bitten by poisonous snakes (see comments)] Carels RA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 19;142(51):2773–7 (20 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1999 Mar 6;143(10):541. **(Dut)**

VETERINARY

Radiology of pharyngeal balling gun injuries. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):391–5, vii (0 ref.)

WOUNDS, STAB

COMPLICATIONS

Pneumopericardium and pneumoperitoneum after penetrating chest injury. Rashid MA, et al. **Eur J Surg** 1999 Mar;165(3):278–9 (8 ref.)

DIAGNOSIS

The management of stab wounds to the back. Kahn JH. **J Emerg Med** 1999 May-Jun;17(3):497-502 (17 ref.)
Puncture wounds. Baldwin G, et al. **Pediatr Rev** 1999 Jan; 20(1):21-3 (8 ref.)

PSYCHOLOGY

Antidepressants for the virtually eviscerated patient: options instead of oral dosing. Koelle JS, et al. **Psychosom Med** 1998 Nov-Dec;60(6):723-5 (20 ref.)

SURGERY

Traumatic aneurysms of the face and temple: a patient report and literature review, 1644 to 1998. Conner WC 3rd, et al. **Ann Plast Surg** 1998 Sep;41(3):321-6 (84 ref.)

THERAPY

Puncture wounds. Baldwin G, et al. **Pediatr Rev** 1999 Jan; 20(1):21-3 (8 ref.)

WPW SYNDROME see **WOLFF-PARKINSON-WHITE SYNDROME**

WR-2721 see **AMIFOSTINE**

WRESTLING

see related
MARTIAL ARTS

INJURIES

Wrestling. Martin WR, et al.
Phys Med Rehabil Clin N Am 1999 Feb;10(1):117-40, vii (46 ref.)

WRIST

Deep subfascial space infections. Jebson PJ. **Hand Clin** 1998 Nov;14(4):557-66, viii (15 ref.)
Mycobacterium malmoense infection. An unusual cause of wrist swelling. Syed AA, et al. **J Hand Surg [Br]** 1998 Dec;23(6):811-2 (12 ref.)

INNERVATION

Ulnar neuropathy at the wrist. Kothari MJ. **Neurol Clin** 1999 Aug;17(3):463-76, vi (37 ref.)

PATHOLOGY

Magnetic resonance imaging of the painful wrist. Seymour R, et al. **Br J Radiol** 1998 Dec;71(852):1323-30 (9 ref.)
Primary synovial osteochondromatosis of the hand and wrist. Report of a series of 21 cases and literature review. Roulot E, et al. **Rev Rhum Engl Ed** 1999 May;66(5):256-66 (116 ref.)

ULTRASONOGRAPHY

High-frequency ultrasound examination of the wrist and hand. Bianchi S, et al. **Skeletal Radiol** 1999 Mar;28(3):121-9 (59 ref.)

WRIST INJURIES

DIAGNOSIS

Injuries to the hand and wrist. Huurman WW.
Adolesc Med 1998 Oct;9(3):611-25, vii (12 ref.)

PATHOLOGY

Intra-articular fractures of the distal aspect of the radius. Trumble TE, et al. **Instr Course Lect** 1999;48:465-80 (40 ref.)

RADIOGRAPHY

[Distal radius fractures] Rikli D, et al.
Schweiz Med Wochenschr 1999 May 22;129(20):776-85 (43 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

The radioulnar joints and forearm axis: therapist's commentary. Contesti LA. **J Hand Ther** 1999 Apr-Jun; 12(2):85-91 (6 ref.)
The carpus: therapist's commentary. Feinberg NR. **J Hand Ther** 1999 Apr-Jun;12(2):108-10 (16 ref.)
Management of fractures of the distal radius: therapist's commentary. Weinstock TB. **J Hand Ther** 1999 Apr-Jun; 12(2):99-102 (9 ref.)

SURGERY

Intra-articular fractures of the distal aspect of the radius. Trumble TE, et al. **Instr Course Lect** 1999;48:465-80 (40 ref.)
Simultaneous ipsilateral avulsion of the extensor carpi radialis longus and brevis tendon insertions: case report and review of the literature. Boles SD, et al. **J Hand Surg [Am]** 1999 Jul;24(4):845-9 (8 ref.)
Pseudarthrosis of the capitate. Rico AA, et al.
J Hand Surg [Br] 1999 Jun;24(3):382-4 (11 ref.)
Management of fractures of the distal radius: surgeon's perspective. Raskin KB. **J Hand Ther** 1999 Apr-Jun; 12(2):92-8 (11 ref.)
The carpus: surgeon's perspective. Weiss AP.
J Hand Ther 1999 Apr-Jun;12(2):103-7 (24 ref.)
[Ulna impaction syndrome therapy: decompressive surgical procedures of the head of the ulna] Krimmer H, et al.
Handchir Mikrochir Plast Chir 1998 Nov;30(6):370-4 (20 ref.) (Eng. Abstr.) **(Ger)**
[Instability of the distal radio-ulnar joint] Nagy L.
Handchir Mikrochir Plast Chir 1998 Nov;30(6):361-9 (40 ref.) (Eng. Abstr.) **(Ger)**
[Is panarthrodesis the gold standard in wrist joint surgery?] Nagy L, et al. **Handchir Mikrochir Plast Chir** 1998 Sep; 30(5):291-7 (36 ref.) (Eng. Abstr.) **(Ger)**
["Around the head of the ulna": injury pattern and classification] van Schoonhoven J, et al.
Handchir Mikrochir Plast Chir 1998 Nov;30(6):351-60 (22 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

High-frequency ultrasound examination of the wrist and hand. Bianchi S, et al. **Skeletal Radiol** 1999 Mar;28(3):121-9 (59 ref.)

WRIST JOINT

Diabetic Charcot's arthropathy of the wrist. Case report and literature review. Bayne O, et al. **Clin Orthop** 1998 Dec; (357):122-6 (17 ref.)
Septic arthritis of the hand and wrist. Murray PM.
Hand Clin 1998 Nov;14(4):579-87, viii (27 ref.)
Pneumococcal arthritis in the wrist and ankle. A case report and short review of the literature. Levi N, et al.
Panminerva Med 1999 Jun;41(2):171-4 (53 ref.)

PATHOLOGY

Magnetic resonance imaging of the painful wrist. Seymour R, et al. **Br J Radiol** 1998 Dec;71(852):1323-30 (9 ref.)
Magnetic resonance imaging of the wrist. Anderson MW, et al. **Curr Probl Diagn Radiol** 1998 Nov-Dec;27(6):187-229 (136 ref.)
Trigger wrist and flexor tenosynovitis. Smith RD, et al.
J Hand Surg [Br] 1998 Dec;23(6):813-4 (8 ref.)

PHYSIOPATHOLOGY

The radioulnar joints and forearm axis: surgeons' perspective. Tang P, et al. **J Hand Ther** 1999 Apr-Jun;12(2):75-84 (40 ref.)
Role of physical load factors in carpal tunnel syndrome. Viikari-Juntura E, et al. **Scand J Work Environ Health** 1999 Jun;25(3):163-85 (87 ref.)

SURGERY

Total wrist arthroplasty. Carlson JR, et al.
J Am Acad Orthop Surg 1998 Sep-Oct;6(5):308-15 (28 ref.)
Arthroplasty of the hand and wrist: surgeon's perspective [see comments] Kozin SH. **J Hand Ther** 1999 Apr-Jun; 12(2):123-32 (63 ref.) Comment in: J Hand Ther 1999 Apr-Jun;12(2):133-4.
[Prosthesis of the upper extremity] Rozing PM.
Ned Tijdschr Geneeskd 1998 May 30;142(22):1256-61 (12 ref.) (Eng. Abstr.) **(Dut)**
[Is panarthrodesis the gold standard in wrist joint surgery?] Nagy L, et al. **Handchir Mikrochir Plast Chir** 1998 Sep; 30(5):291-7 (36 ref.) (Eng. Abstr.) **(Ger)**
[New methods of joint replacement in the hand yield better function and pain relief] Sollerman C. **Lakartidningen** 1999 Jun 16;96(24):2958-60 (17 ref.) (Eng: Abstr.) **(Swe)**

WRITING

Get your book published. Banks M. **BMJ** 1998 Dec 19-26; 317(7174):1715-8 (3 ref.)
Empirical foundations for writing in prevention and psychotherapy: mental and physical health outcomes. Esterling BA, et al. **Clin Psychol Rev** 1999 Jan;19(1):79-96 (76 ref.)
Writing poetry: a way of knowing nursing. Holmes V, et al. **J Adv Nurs** 1998 Dec;28(6):1191-4 (11 ref.)
Story telling: is it really research? Koch T. **J Adv Nurs** 1998 Dec;28(6):1182-90 (54 ref.)
Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. **Med Educ** 1999 Jan;33(1):66-78 (00 ref.)
Social work in health care: do practitioners' writings suggest an applied social science? Rehr H, et al.
Soc Work Health Care 1998;28(2):63-81 (33 ref.)
[Writer's cramp] Yamamoto H.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):132-5 (4 ref.) **(Jpn)**

WRONGFUL BIRTH see **WRONGFUL LIFE**

WRONGFUL LIFE

'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369-75 (4 ref.) Comment in: J Med Ethics 1998 Dec;24(6):363-4.

WRYNECK see **TORTICOLLIS**

WUCHERERIA BANCROFTI

[Bancrofitian filariasis, Malayan filariasis] Takeuchi T.
Ryoikibetsu Shokogun Shirizu 1999;(24 Pt 2):451-4 (6 ref.) **(Jpn)**
[Bancroftian filariasis in Brazil] Rocha EM, et al.
Rev Saude Publica 1998 Feb;32(1):98-105 (41 ref.) (Eng. Abstr.) **(Por)**

X CHROMOSOME

The timing of twinning: more insights from X inactivation [editorial; comment] Puck JM. **Am J Hum Genet** 1998 Aug; 63(2):327-8 (12 ref.) Comment on: Am J Hum Genet 1998 Aug;63(2):339-36.
XLMR genes: update 1998. Lubs H, et al.
Am J Med Genet 1999 Apr 2;83(4):237-47 (102 ref.)
Lethal multiple pterygium syndrome in four male fetuses in a family: evidence for an X-linked recessive subtype? [letter] Meyer-Cohen J, et al. **Am J Med Genet** 1999 Jan 1;82(1):97-9 (11 ref.)
Extracutaneous analogies of Blaschko lines. Rott HD.
Am J Med Genet 1999 Aug 6;85(4):338-41 (18 ref.)
De novo duplication xq22-q23 in a girl with short stature and gonadal dysgenesis. Correa-Cerro L, et al.
Ann Genet 1999;42(1):41-4 (20 ref.)
Partial Xp duplication due to a translocation t(X;15) in two male and two female patients: a familial case report and review of the literature. Melaragno MI, et al.
Ann Genet 1998;41(4):189-94 (27 ref.)
Left-handedness as a function of sex, maternal versus paternal inheritance, and report bias. Annett M. **Behav Genet** 1999 Mar;29(2):103-14 (50 ref.)
New insights into the pathogenesis of inherited phosphate wasting disorders. Econs MJ. **Bone** 1999 Jul;25(1):131-5 (59 ref.)
Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature. Joyama S, et al. **Cancer** 1999 Oct 1;86(7):1246-50 (24 ref.)
Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype. Désangles F, et al. **Cancer Genet Cytogenet** 1999 Sep;113(2):141-4 (22 ref.)
The molecular genetics of X-linked lymphoproliferative (Duncan's) disease. Sumegi J, et al. **Cancer J Sci Am** 1999 Mar-Apr;5(2):57-62 (33 ref.)
The abnormal gene in X-linked lymphoproliferative syndrome. Sullivan JL. **Curr Opin Immunol** 1999 Aug; 11(4):431-4 (16 ref.)
Pigmentary mosaicism in hypomelanosis of Ito. Further evidence for functional disomy of Xp. Fritz B, et al.
Hum Genet 1998 Oct;103(4):441-9 (51 ref.)
Monosomy X as the sole cytogenetic abnormality in acute lymphoblastic leukemia: a report of two new patients. Bueno JL, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):381-4 (14 ref.)
Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Funakoshi M, et al. **Neuromuscul Disord** 1999 Mar;9(2):108-14 (55 ref.)
The role of the gap junction protein connexin32 in the pathogenesis of X-linked Charcot-Marie-Tooth disease. Scherer SS, et al. **Novartis Found Symp** 1999;219:175-85; discussion 185-7 (32 ref.)
Case report of a 22-week fetus with 47,XXX karyotype and multiple lower mesodermal defects. Hoang MP, et al.
Pediatr Dev Pathol 1999 Jan-Feb;2(1):58-61 (17 ref.)
The Xg blood group system: a review. Tippett P, et al.
Transfus Med Rev 1998 Oct;12(4):233-57 (58 ref.)
The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Dubois-Dalcq M, et al. **Trends Neurosci** 1999 Jan;22(1):4-12 (73 ref.)
[X-chromosomal recessive spinobulbar muscular atrophy (Kennedy type). Description of a family, clinical aspects, molecular genetics, differential diagnosis and therapy] Kuhlenbäumer G, et al. **Nervenarzt** 1998 Aug;69(8):660-5 (19 ref.) (Eng. Abstr.) **(Ger)**
[X-linked recessive myotubular myopathy with a splice-site mutation in the myotubularin gene] Watanabe T, et al.
No To Hattatsu 1998 Nov;30(6):523-7 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Lubag syndrome (Xq13-linked dystonia-parkinsonism)] Ishikawa A. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):148-50 (15 ref.) **(Jpn)**
[X-linked hyper IgM syndrome] Kimura N.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):460-3 (22 ref.) **(Jpn)**
[X chromosome inactivation--a biological phenomenon of clinical significance for women] Orstavik KH.
Tidsskr Nor Laegeforen 1999 Mar 10;119(7):972-5 (21 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

X-linked mental retardation. Neri G, et al. **Adv Genet** 1999; 41:55-94 (188 ref.)
Smith-Fineman-Myers syndrome in apparently monozygotic twins. Guion-Almeida ML, et al. **Am J Med Genet** 1998 Sep 23;79(3):205-8 (4 ref.)
Random X-inactivation in a girl with duplication Xp11.21-p21.3: report of a patient and review of the

X CHROMOSOME

literature. Matsuo M, et al. **Am J Med Genet** 1999 Sep 3;86(1):44–50 (50 ref.)

An autosomal dominant or X-linked osteodysplastic disorder with severe cervical involvement. Robertson SP, et al. **Am J Med Genet** 1999 Mar 5;83(1):17–22 (19 ref.)

X-chromosome inactivation. Lyon MF. **Curr Biol** 1999 Apr 8;9(7):R235–7 (5 ref.)

The role of Xist in X-inactivation. Brockdorff N. **Curr Opin Genet Dev** 1998 Jun;8(3):328–33 (45 ref.)

Pathological consequences of sequence duplications in the human genome. Mazzarella R, et al. **Genome Res** 1998 Oct; 8(10):1007–21 (120 ref.)

Mutational analyses of AVPR2 gene in three Japanese families with X-linked nephrogenic diabetes insipidus: two recurrent mutations, R137H and deltaV278, caused by the hypermutability at CpG dinucleotides. Shoji Y, et al. **Hum Mutat** 1998;Suppl 1:S278–83 (27 ref.)

Recent advances in the diagnosis of X-linked agammaglobulinemia [editorial; comment] Nonoyama S. **Intern Med** 1999 Sep;38(9):687–8 (6 ref.) Comment on: Intern Med 1999 Sep;38(9):722–5.

Genomic imprinting of the X chromosome: a novel mechanism for the evolution of sexual dimorphism. Skuse DH. **J Lab Clin Med** 1999 Jan;133(1):23–32 (47 ref.)

X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)–MIM 302060 [editorial; comment] Barth PG, et al. **J Pediatr** 1999 Sep;135(3):273–6 (19 ref.) Comment on: J Pediatr 1999 Sep;135(3):311–5.

The genetic origins of ovarian failure. Bondy CA, et al. **J Womens Health** 1998 Dec;7(10):1225–9 (23 ref.)

X-linked recessive spondyloepiphyseal dysplasia tarda. Clinical and radiographic evolution in a 6-generation kindred and review of the literature. Whyte MP, et al. **Medicine (Baltimore)** 1999 Jan;78(1):9–25 (60 ref.)

Xist and X chromosome inactivation. Kay GF. **Mol Cell Endocrinol** 1998 May 25;140(1–2):71–6 (57 ref.)

X-linked hypophosphataemia: a homologous disorder in humans and mice. Tenenhouse HS. **Nephrol Dial Transplant** 1999 Feb;14(2):333–41 (88 ref.)

On the front of X-linked adrenoleukodystrophy. Aubourg P. **Neurochem Res** 1999 Apr;24(4):515–20 (46 ref.)

X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Smith KD, et al. **Neurochem Res** 1999 Apr; 24(4):521–35 (76 ref.)

X-linked dilated cardiomyopathy and the dystrophin gene. Ferlini A, et al. **Neuromuscul Disord** 1999 Jul;9(5):339–46 (39 ref.)

Imprinting and X-chromosome inactivation. Lyon MF. **Results Probl Cell Differ** 1999;25:73–90 (75 ref.)

Mammalian Y chromosome evolution and the male-specific functions of Y chromosome-borne genes. Delbridge ML, et al. **Rev Reprod** 1999 May;4(2):101–9 (63 ref.)

The X-linked hyperimmunoglobulin M syndrome. Fuleihan RL. **Semin Hematol** 1998 Oct;35(4):321–31 (96 ref.)

X-linked SCID and other defects of cytokine pathways. Uribe L, et al. **Semin Hematol** 1998 Oct;35(4):299–309 (70 ref.)

PATHOLOGY

Pathological consequences of sequence duplications in the human genome. Mazzarella R, et al. **Genome Res** 1998 Oct; 8(10):1007–21 (120 ref.)

X INACTIVATION see **DOSAGE COMPENSATION (GENETICS)**

X-LINKED LYMPHOPROLIFERATIVE SYNDROME see **LYMPHOPROLIFERATIVE DISORDERS**

X-RAY ABSORPTIOMETRY, DUAL-ENERGY see **DENSITOMETRY, X-RAY**

X-RAY CRYSTALLOGRAPHY see **CRYSTALLOGRAPHY, X-RAY**

X-RAY DEPARTMENTS see **RADIOLOGY DEPARTMENT, HOSPITAL**

X-RAY, DIAGNOSTIC see **RADIOGRAPHY**

X-RAY EMISSION SPECTROMETRY, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

X-RAY EMISSION SPECTROMETRY, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

X-RAY FILM

Digital film processing: a comparison of wet and dry processing methods. **Health Devices** 1998 Aug;27(8):293–8 (11 ref.)

X-RAY INFORMATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

X-RAY MICROANALYSIS, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

X-RAY MICROANALYSIS, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

X-RAY TOMOGRAPHY, COMPUTED see **TOMOGRAPHY, X-RAY COMPUTED**

X SYNDROME see **SYNDROME X**

XANTHACRIDINUM see **ACRIFLAVINE**

XANTHINE DEHYDROGENASE

METABOLISM

Alcohol-induced breast cancer: a proposed mechanism. Wright RM, et al. **Free Radic Biol Med** 1999 Feb; 26(3–4):348–54 (92 ref.)

XANTHINES

PHARMACOKINETICS

[Pharmacokinetic interactions between fluoroquinolones and methylxanthines] Iakovlev VP, et al. **Antibiot Khimioter** 1999;44(3):35–41 (78 ref.) **(Rus)**

PHARMACOLOGY

Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Schubert P, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S21–8 (45 ref.)

[New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)] Kapl D, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):317–21 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Mielke R, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S29–35 (21 ref.)

Methylxanthine use in anaphylaxis: what does the evidence tell us? Ernst ME, et al. **Ann Pharmacother** 1999 Sep; 33(9):1001–4 (28 ref.)

Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Rother M, et al. **Dement Geriatr Cogn Disord** 1998 Jul;9 Suppl 1:36–43 (26 ref.)

Therapeutic strategies based on immunological hypotheses of Alzheimer's disease. Möller HJ. **J Neural Transm Suppl** 1998;54:175–86 (28 ref.)

[New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)] Kapl D, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):317–21 (26 ref.) (Eng. Abstr.) **(Ger)**

XANTHOGRANULOMA, JUVENILE

COMPLICATIONS

Update on juvenile xanthogranuloma: unusual cutaneous and systemic variants. Chang MW. **Semin Cutan Med Surg** 1999 Sep;18(3):195–205 (104 ref.)

DIAGNOSIS

Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Hidayat AA, et al. **Radiol Clin North Am** 1998 Nov;36(6):1229–40, xii (68 ref.)

Update on juvenile xanthogranuloma: unusual cutaneous and systemic variants. Chang MW. **Semin Cutan Med Surg** 1999 Sep;18(3):195–205 (104 ref.)

XANTHOGRANULOMATOUS PYELONEPHRITIS see **PYELONEPHRITIS, XANTHOGRANULOMATOUS**

XANTHOMA see **XANTHOMATOSIS**

XANTHOMA DISSEMINATUM see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

XANTHOMA, JUVENILE see **XANTHOGRANULOMA, JUVENILE**

XANTHOMATOSIS

ETIOLOGY

Xanthomas of the Achilles tendon: report of a bilateral case and review of the literature. Carranza-Bencano A, et al. **Foot Ankle Int** 1999 May;20(5):314–6 (21 ref.)

PATHOLOGY

Verruciform xanthoma of the nose. Than T, et al. **J Laryngol Otol** 1999 Jan;113(1):79–81 (14 ref.)

XANTHOMATOSIS, FAMILIAL see **WOLMAN DISEASE**

XANTHOMATOSIS, WOLMAN'S see **WOLMAN DISEASE**

XANTHOMONAS

Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia. Munter RG, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):353–6 (18 ref.)

[Xanthomonas maltophilia pneumonia] Maruyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):389–91 (7 ref.) **(Jpn)**

XANTHOMONAS CAMPESTRIS

GENETICS

Xanthan gum biosynthesis and application: a biochemical/genetic perspective. Becker A, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):145–52 (65 ref.)

METABOLISM

Xanthan gum biosynthesis and application: a biochemical/genetic perspective. Becker A, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):145–52 (65 ref.)

XANTHOPHYLL

PHARMACOLOGY

Effect of lutein on beta-carotene absorption and cleavage. van den Berg H. **Int J Vitam Nutr Res** 1998;68(6):360–5 (23 ref.)

XANTHOTOXIN see **METHOXSALEN**

XENOANTIBODIES see **ANTIBODIES, HETEROPHILE**

XENOBIOTICS

[Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes] Ozawa S. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):69–81 (126 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

The effects of environmental hormones on reproduction. Danzo BJ. **Cell Mol Life Sci** 1998 Nov;54(11):1249–64 (186 ref.)

Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Cook JC, et al. **Crit Rev Toxicol** 1999 Mar; 29(2):169–261 (550 ref.)

ISOLATION & PURIFICATION

Effect of separation conditions on chromatographic determination of hydrophobicity of acidic xenobiotics. Kaliszan R. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9;717(1–2):125–34 (98 ref.)

METABOLISM

Metabolism of xenobiotics in the central nervous system: implications and challenges. Ravindranath V. **Biochem Pharmacol** 1998 Sep 1;56(5):547–51 (46 ref.)

Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Li AP, et al. **Chem Biol Interact** 1999 Jun 1;121(1):117–23 (15 ref.)

Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids. Knights KM. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):776–82 (75 ref.)

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Wormhoudt LW, et al. **Crit Rev Toxicol** 1999 Jan; 29(1):59–124 (545 ref.)

Microbial dehalogenases: enzymes recruited to convert xenobiotic substrates. Copley SD. **Curr Opin Chem Biol** 1998 Oct;2(5):613–7 (39 ref.)

Xenobiotic metabolism, oxidant stress and chronic pancreatitis. Focus on glutathione. Wallig MA. **Digestion** 1998;59 Suppl 4:13–24 (100 ref.)

Species differences in N-glucuronidation. Chiu SH, et al. **Drug Metab Dispos** 1998 Sep;26(9):838–47 (64 ref.)

N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Hawes EM. **Drug Metab Dispos** 1998 Sep;26(9):830–7 (75 ref.)

The role of CYP2B6 in human xenobiotic metabolism. Ekins S, et al. **Drug Metab Rev** 1999 Aug;31(3):719–54 (194 ref.)

The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates. Miller JA. **Drug Metab Rev** 1998 Nov;30(4):645–74 (111 ref.)

Sex-dependent metabolism of xenobiotics. Mugford CA, et al. **Drug Metab Rev** 1998 Aug;30(3):441–98 (185 ref.)

Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. Lewis DF, et al. **Environ Health Perspect** 1998 Oct;106(10):633–41 (96 ref.)

Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Raunio H, et al. **Exp Toxicol Pathol** 1999 Jul;51(4–5):412–7 (49 ref.)

The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption. Gonzalez

FJ. **Toxicol Lett** 1998 Dec 28;102–103:161–6 (31 ref.)
Functional consequences of polymorphism of xenobiotic metabolising enzymes. Ingelman-Sundberg M. **Toxicol Lett** 1998 Dec 28;102–103:155–60 (17 ref.)
Concise review of the cytochrome P450s and their roles in toxicology. Omiecinski CJ, et al. **Toxicol Sci** 1999 Apr; 48(2):151–6 (35 ref.)
Effect of diet and nutrition on the expression of cytochromes P450. Ioannides C. **Xenobiotica** 1999 Feb;29(2):109–54 (230 ref.)

PHARMACOKINETICS

The fate of organic xenobiotics in aquatic ecosystems: quantitative and qualitative differences in biotransformation by invertebrates and fish. Livingstone DR. **Comp Biochem Physiol A Mol Integr Physiol** 1998 May; 120(1):43–9 (39 ref.)
Microbial models of mammalian metabolism of xenobiotics: An updated review. Abourashed EA, et al. **Curr Med Chem** 1999 May;6(5):359–74 (77 ref.)
Cytochrome-P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues. Juchau MR, et al. **Drug Metab Rev** 1998 Aug;30(3):541–68 (120 ref.)
Impact of diseases on detoxication. Blouin RA, et al. **J Biochem Mol Toxicol** 1999;13(3–4):215–8 (27 ref.)
Metabolism of polychlorinated dibenzo-p-dioxins and related dioxin-like compounds. Hu K, et al. **J Toxicol Environ Health B Crit Rev** 1999 Apr–Jun; 2(2):183–210 (182 ref.)
Ethanol interactions with other cytochrome P450 substrates including drugs, xenobiotics, and carcinogens. Djordjević D, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):760–70 (103 ref.)
Mechanisms for xenobiotic transport in biological membranes. Zimniak P, et al. **Toxicol Lett** 1999 Jun 1; 106(2–3):107–18 (80 ref.)
[Human drug metabolizing enzymes. II. Conjugation enzymes] Vereczkey L, et al. **Acta Pharm Hung** 1998 Sep; 68(5):284–8 (21 ref.) (Eng. Abstr.) **(Hun)**
[Human drug metabolizing enzymes. I. Oxidative enzymes] Vereczkey L, et al. **Acta Pharm Hung** 1998 Sep; 68(5):276–83 (30 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Waxman DJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):11–23 (128 ref.)
Cytochrome P450 enzymes in chickens: characteristics and induction by xenobiotics. Gupta RP, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):73–83 (64 ref.)
Immunochemical approaches to studies of CYP1A localization and induction by xenobiotics in fish. Goksøyr A, et al. **EXS** 1998;86:165–202 (207 ref.)
Developmental effects of estrogenic chemicals are predicted by an in vitro assay incorporating modification of cell uptake by serum. Nagel SC, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):343–57 (68 ref.)
The perturbation of apoptosis and mitosis by drugs and xenobiotics. Hasmall SC, et al. **Pharmacol Ther** 1999 Apr; 82(1):63–70 (67 ref.)

TOXICITY

Evaluation of xenoestrogenic effects in fish on different organization levels. Schrag B, et al. **Adv Exp Med Biol** 1998;444:207–14 (20 ref.)
The Ah receptor: a regulator of the biochemical and toxicological actions of structurally diverse chemicals. Denison MS, et al. **Bull Environ Contam Toxicol** 1998 Nov; 61(5):557–68 (45 ref.)
Tetrahymena pyriformis: a tool for toxicological studies. A review. Sauvant MP, et al. **Chemosphere** 1999 Mar; 38(7):1631–69 (177 ref.)
Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids. Knights KM. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):776–82 (75 ref.)
Cytochrome P450 knockout mice: new toxicological models. McKinnon RA, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):783–7 (38 ref.)
Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Wormhoudt LW, et al. **Crit Rev Toxicol** 1999 Jan; 29(1):59–124 (545 ref.)
Current approaches toward chemical mixture studies at the National Institute of Environmental Health Sciences and the U.S. National Toxicology Program. Bucher JR, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1295–8 (13 ref.)
Human health and chemical mixtures: an overview. Carpenter DO, et al. **Environ Health Perspect** 1998 Dec; 106 Suppl 6:1263–70 (69 ref.)
Toxicology of chemical mixtures: international perspective. Feron VJ, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1281–9 (111 ref.)
Public health challenges posed by chemical mixtures. Hansen H, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1271–80 (71 ref.)
Role of tissue repair in toxicologic interactions among hepatotoxic organics. Soni MG, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1307–17 (79 ref.)
Cultured keratinocytes in in vitro dermatotoxicological investigation: a review. Bernstein IA, et al. **J Toxicol Environ Health B Crit Rev** 1999 Jan–Mar; 2(1):1–30 (91 ref.)
A strategy for assessing the effects of xenobiotics on fish reproduction. Kime DE. **Sci Total Environ** 1999 Jan 12; 225(1–2):3–11 (38 ref.)
Immunotoxicity of pesticides: a review. Voccia I, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):119–32 (115 ref.)
Xenoendorine disrupters--environmental impacts. Sumpter JP. **Toxicol Lett** 1998 Dec 28;102–103:337–42 (20 ref.)
Altered cytokine (receptor) mRNA expression as a tool in immunotoxicology. Vandebriel RJ, et al. **Toxicology** 1998 Sep 1;130(1):43–67 (225 ref.)

XENOGRAFT see **TRANSPLANTATION, HETEROLOGOUS**

XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

XENON

see related
XENON RADIOISOTOPES

DIAGNOSTIC USE

[Magnetic resonance tomography with inhalation of polarized noble gases: new perspectives in functional imaging diagnosis of emphysema] Kauczor HU, et al. **Pneumologie** 1998 Oct;52(10):563–7 (22 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Xenon: recent developments. Dingley J, et al. **Anaesthesia** 1999 Apr;54(4):335–46 (81 ref.)

XENON RADIOISOTOPES

DIAGNOSTIC USE

Xenon-enhanced CT: clinical applications. Massaro LM. **J Cardiovasc Nurs** 1998 Oct;13(1):45–56 (20 ref.)

XENOPUS

EMBRYOLOGY

Nuclear responses to MPF activation and inactivation in Xenopus oocytes and early embryos. Lohka MJ. **Biol Cell** 1998 Nov;90(8):591–9 (98 ref.)
An overview of Xenopus development. Jones CM, et al. **Methods Mol Biol** 1999;97:331–40 (13 ref.)
A gradient of BMP activity specifies dorsal-ventral fates in early Xenopus embryos. Dale L, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):319–26 (59 ref.)
Activin as a morphogen in Xenopus mesoderm induction. McDowell N, et al. **Semin Cell Dev Biol** 1999 Jun; 10(3):311–7 (39 ref.)

GENETICS

Molecular genetics of the complement C3 convertases in lower vertebrates. Nonaka M, et al. **Immunol Rev** 1998 Dec;166:59–65 (50 ref.)
[Transcription in Xenopus early embryos and apoptotic program preset in the fertilized egg] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):32–41 (26 ref.) **(Jpn)**

IMMUNOLOGY

T-cell and natural killer cell development in thymectomized Xenopus. Horton JD, et al. **Immunol Rev** 1998 Dec; 166:245–58 (90 ref.)
Evolution of immune surveillance and tumor immunity: studies in Xenopus. Robert J, et al. **Immunol Rev** 1998 Dec; 166:231–43 (86 ref.)

PARASITOLOGY

Correlation of parasite speciation and specificity with host evolutionary relationships. Tinsley RC, et al. **Int J Parasitol** 1998 Oct;28(10):1573–82 (34 ref.)

XENOPUS LAEVIS

EMBRYOLOGY

Cell cycle transition in early embryonic development of Xenopus laevis. Masui Y, et al. **Biol Cell** 1998 Nov; 90(8):537–48 (68 ref.)
Development of neural crest in Xenopus. Mayor R, et al. **Curr Top Dev Biol** 1999;43:85–113 (114 ref.)
Confocal microscopy on Xenopus laevis oocytes and embryos. Robb DL, et al. **Methods Mol Biol** 1999; 122:173–83 (11 ref.)
Organisation of Xenopus oocyte and egg cortices. Chang P, et al. **Microsc Res Tech** 1999 Mar 15;44(6):415–29 (120 ref.)
Thyroid hormone regulation of Xenopus laevis metamorphosis: functions of thyroid hormone receptors and roles of extracellular matrix remodeling. Shi YB, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):314–22 (63 ref.)
[The essential character of the Spemann's organizer] Hashimoto C. **Tanpakushitsu Kakusan Koso** 1998 Aug; 43(10):1336–46 (26 ref.) **(Jpn)**

GENETICS

Development of neural crest in Xenopus. Mayor R, et al. **Curr Top Dev Biol** 1999;43:85–113 (114 ref.)
RNA sorting in Xenopus oocytes and embryos [see comments] Mowry KL, et al. **FASEB J** 1999 Mar; 13(3):435–45 (98 ref.) Comment in: FASEB J 1999 Mar;13(3):419–20.

GROWTH & DEVELOPMENT

Plasticity in the tectum of Xenopus laevis: binocular maps. Udin SB, et al. **Prog Neurobiol** 1999 Oct;59(2):81–106 (162 ref.)

METABOLISM

Intermediate filament organization during oogenesis and early development in the clawed frog, Xenopus laevis. Gard DL, et al. **Subcell Biochem** 1998;31:35–70 (110 ref.)

XENOTRANSPLANTATION see **TRANSPLANTATION, HETEROLOGOUS**

XERODERMA see **ICHTHYOSIS**

XERODERMA PIGMENTOSUM

[Xeroderma pigmentosum] Nishizawa M. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):408–10 (11 ref.) **(Jpn)**

GENETICS

A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Cleaver JE, et al. **Hum Mutat** 1999; 14(1):9–22 (110 ref.)
Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. van Steeg H, et al. **Mol Med Today** 1999 Feb;5(2):86–94 (53 ref.)
Cancer predisposition in mutant mice defective in the XPC DNA repair gene. Friedberg EC, et al. **Prog Exp Tumor Res** 1999;35:37–52 (45 ref.)
Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing. van Steeg H, et al. **Toxicol Pathol** 1998 Nov–Dec;26(6):742–9 (63 ref.)

PATHOLOGY

Discordance between DNA analysis and the clinical picture in a case of xeroderma pigmentosum [letter] Tessari G, et al. **Acta Derm Venereol** 1999 Jan;79(1):94–5 (4 ref.)
Xeroderma pigmentosum in black South Africans. Jacyk WK. **Int J Dermatol** 1999 Jul;38(7):511–4 (17 ref.)

XEROSTOMIA

DRUG THERAPY

[Pilocarpine--new use for an old drug] Tishler M. **Harefuah** 1998 Aug;135(3–4):150–2 (25 ref.) **(Heb)**

ETIOLOGY

Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Taylor SE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):14–26 (154 ref.)

PREVENTION & CONTROL

Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Taylor SE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):14–26 (154 ref.)

THERAPY

Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome. van der Reijden WA, et al. **Ann Rheum Dis** 1999 Aug;58(8):465–74 (115 ref.)

XIPHOSURA see **HORSESHOE CRABS**

XYLAZINE

TOXICITY

The regulatory status of xylazine for use in food-producing animals in the United States. Chamberlain PL, et al. **J Vet Pharmacol Ther** 1998 Aug;21(4):322–9 (44 ref.)

XYLENES

Musk xylene: analysis, occurrence, kinetics, and toxicology. Käfferlein HU, et al. **Crit Rev Toxicol** 1998 Sep;

XYLENES

28(5):431-76 (258 ref.)

ADVERSE EFFECTS

ATSDR evaluation of health effects of chemicals. V. Xylenes: health effects, toxicokinetics, human exposure, and environmental fate. Fay M, et al. **Toxicol Ind Health** 1998 Sep-Oct;14(5):571-781 (760 ref.)

XYLOBIASES see **XYLOSIDASES**

XYLOSE

DIAGNOSTIC USE

D-xylose testing. Craig RM, et al. **J Clin Gastroenterol** 1999 Sep;29(2):143-50 (112 ref.)

PHARMACOKINETICS

[D-xylose test of resorption as a method to determine radiation side effects in the small intestine] Köst S, et al. **Strahlenther Onkol** 1998 Sep;174(9):462-7 (33 ref.) (Eng. Abstr.) **(Ger)**

XYLOSIDASES

METABOLISM

Molecular and biotechnological aspects of xylanases. Kulkarni N, et al. **FEMS Microbiol Rev** 1999 Jul; 23(4):411-56 (416 ref.)

Y CHROMOSOME

Sexual dimorphism in the neonatal gonad. Hughes IA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):23-30 (54 ref.)

Left-handedness as a function of sex, maternal versus paternal inheritance, and report bias. Annett M. **Behav Genet** 1999 Mar;29(2):103-14 (50 ref.)

Advances in Y chromosome mapping. Yen PH. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):275-81 (71 ref.)

Genetic abnormalities and male infertility. A comprehensive review. Thielemans BF, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):217-25 (85 ref.)

Y chromosome and male infertility. Krausz C, et al. **Front Biosci** 1999 Jan 15;4:E1-8 (62 ref.)

Genetic contribution to male infertility. Chandley AC. **Hum Reprod** 1998 Jun;13 Suppl 3:76-83; discussion 84-8 (43 ref.)

Male infertility: analysis of the markers and genes on the human Y chromosome. Kostiner DR, et al. **Hum Reprod** 1998 Nov;13(11):3032-8 (53 ref.)

Principles of sequence-tagged site selection in screening for Y deletions [comment] [see comments] Pryor JL, et al. **Hum Reprod** 1998 Jul;13(7):1768 (2 ref.) Comment on: Hum Reprod 1998 Jul;13(7):1764-8. Comment in: Hum Reprod 1999 Feb;14(2):572.

Current status of the molecular diagnosis of Y-chromosomal microdeletions in the work-up of male infertility. Initiative for international quality control [see comments] Simoni M, et al. **Hum Reprod** 1998 Jul;13(7):1764-8 (32 ref.) Comment in: Hum Reprod 1998 Jul;13(7):1768. Comment in: Hum Reprod 1999 Feb;14(2):572.

Y bind RNA for spermatogenesis? Ruggiu M, et al. **Int J Androl** 1999 Feb;22(1):19-27 (73 ref.)

Human chromosome deletions in Yq11, AZF candidate genes and male infertility: history and update. Vogt PH. **Mol Hum Reprod** 1998 Aug;4(8):739-44 (51 ref.)

[Genetic control of spermatogenesis: Y chromosome and male infertility] Krausz C, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):309-17 (50 ref.) **(Fre)**

[Y chromosome microdeletions in male infertility] Siffroi JP, et al. **Contracept Fertil Sex** 1998 Dec;26(12):825-9 (34 ref.) **(Fre)**

[Amyloid goiter as the beginning symptom of amyloidosis in a patient with sex-linked agammaglobulinemia (letter)] López J, et al. **Rev Clin Esp** 1999 Jul;199(7):481 (4 ref.) **(Spa)**

[Male infertility is often of genetic origin. Y chromosome deletions are discovered by the PCR technique] Arver S, et al. **Lakartidningen** 1998 Nov 25;95(48):5485-6 (9 ref.) **(Swe)**

GENETICS

Sex chromosome aneuploidies in sperm of 47,XYY men. Morel F, et al. **Arch Androl** 1999 Jul-Aug;43(1):27-36 (28 ref.)

The Y-chromosome and reproductive disorders. McDonough PG. **Reprod Fertil Dev** 1998;10(1):1-16 (76 ref.)

Y chromosome and male infertility. Cooke HJ. **Rev Reprod** 1999 Jan;4(1):5-10 (40 ref.)

Mammalian Y chromosome evolution and the male-specific functions of Y chromosome-borne genes. Delbridge ML, et al. **Rev Reprod** 1999 May;4(2):101-9 (63 ref.)

The role of Y-encoded genes in mammalian spermatogenesis [see comments] Burgoyne PS. **Semin Cell Dev Biol** 1998 Aug;9(4):423-32 (56 ref.) Comment in: Semin Cell Dev Biol 1998 Aug;9(4):379-91.

YAC see **CHROMOSOMES, YEAST ARTIFICIAL**

YAGEINE see **HARMINE**

YAM see **LILIACEAE**

YANG see **YIN-YANG**

YAWNING

PHYSIOLOGY

Yawning and stretching--a behavioral syndrome associated with transcranial application of electromagnetic fields in multiple sclerosis. Sandyk R. **Int J Neurosci** 1998 Jul; 95(1-2):107-13 (47 ref.)

YAWS

RADIOGRAPHY

[Osteoarticular involvement in parasitic diseases: bone treponematosis] Arteaga C, et al. **J Radiol** 1998 Nov; 79(11):1363-6 (7 ref.) (Eng. Abstr.) **(Fre)**

YEAST ARTIFICIAL CHROMOSOMES see **CHROMOSOMES, YEAST ARTIFICIAL**

YEAST, BAKER'S see **SACCHAROMYCES CEREVISIAE**

YEAST, BREWER'S see **SACCHAROMYCES CEREVISIAE**

YEAST, BUDDING see **SACCHAROMYCETALES**

YEAST, FISSION see **SCHIZOSACCHAROMYCES**

YEASTS

Yeast forward and reverse 'n'-hybrid systems. Vidal M, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):919-29 (97 ref.)

Expanding yeast knowledge online. Dolinski K, et al. **Yeast** 1998 Dec;14(16):1453-69 (33 ref.)

CHEMISTRY

Overview of N- and O-linked oligosaccharide structures found in various yeast species. Gemmill TR, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):227-37 (96 ref.)

The structure and function of yeast xylose (aldose) reductases. Lee H. **Yeast** 1998 Aug;14(11):977-84 (29 ref.)

CLASSIFICATION

Molecular taxonomy of yeasts. Deák T. **Acta Microbiol Immunol Hung** 1999;46(2-3):181-6 (17 ref.)

DRUG EFFECTS

Use of tests in yeasts and fungi in the detection and evaluation of carcinogens. Parry JM. **IARC Sci Publ** 1999;(146):471-85 (66 ref.)

ENZYMOLOGY

Regulation and function of PLDs in yeast. Rudge SA, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):167-74 (56 ref.)

Yeast cell permeabilizing beta-1,3-glucanases: A tool for the integration of downstream processes and metabolic engineering applications to yeast. Ferrer P, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):321-4 (27 ref.)

Stereoselectivities of microbial epoxide hydrolases. Orru RV, et al. **Curr Opin Chem Biol** 1999 Feb;3(1):16-21 (30 ref.)

Subunits of yeast RNA polymerases: structure and function. Ishihama A, et al. **Curr Opin Microbiol** 1998 Apr;1(2):190-6 (49 ref.)

Production of pectic enzymes in yeasts. Blanco P, et al. **FEMS Microbiol Lett** 1999 Jun 1;175(1):1-9 (36 ref.)

Structure and properties of the clathrin-coated vesicle and yeast vacuolar V-ATPases. Forgac M. **J Bioenerg Biomembr** 1999 Feb;31(1):57-65 (48 ref.)

Assembly of the yeast vacuolar proton-translocating ATPase. Graham LA, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):39-47 (32 ref.)

Biosynthesis and regulation of the yeast vacuolar H+-ATPase. Kane PM. **J Bioenerg Biomembr** 1999 Feb; 31(1):49-56 (32 ref.)

GFP-labelling of 26S proteasomes in living yeast: insight into proteasomal functions at the nuclear envelope/rough ER. Enenkel C, et al. **Mol Biol Rep** 1999 Apr;26(1-2):131-5 (35 ref.)

The structure and function of yeast xylose (aldose) reductases. Lee H. **Yeast** 1998 Aug;14(11):977-84 (29 ref.)

GENETICS

Molecular taxonomy of yeasts. Deák T. **Acta Microbiol Immunol Hung** 1999;46(2-3):181-6 (17 ref.)

Impact of yeast genetics and molecular biology on traditional and new biotechnology. Maráz A. **Acta Microbiol Immunol Hung** 1999;46(2-3):289-95 (15 ref.)

The inventory of all ion and drug ATPases encoded by the yeast genome. Goffeau A. **Acta Physiol Scand Suppl** 1998 Aug;643:297-300 (8 ref.)

Yeast cell permeabilizing beta-1,3-glucanases: A tool for the integration of downstream processes and metabolic engineering applications to yeast. Ferrer P, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):321-4 (27 ref.)

Mitotic DNA damage and replication checkpoints in yeast. Rhind N, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):749-58 (88 ref.)

AP-1 transcription factors in yeast. Toone WM, et al. **Curr Opin Genet Dev** 1999 Feb;9(1):55-61 (42 ref.)

Subunits of yeast RNA polymerases: structure and function. Ishihama A, et al. **Curr Opin Microbiol** 1998 Apr;1(2):190-6 (49 ref.)

Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis. Das S, et al. **Front Biosci** 1998 Dec 1;3:D1241-52 (61 ref.)

Recombinogenic targeting: a new approach to genomic analysis--a review. Shashikant CS, et al. **Gene** 1998 Nov 26;223(1-2):9-20 (83 ref.)

Functional interaction of yeast elongation factor 3 with yeast ribosomes. Chakraburtty K. **Int J Biochem Cell Biol** 1999 Jan;31(1):163-73 (50 ref.)

The yeast [PSI+] prion: making sense of nonsense. Liebman SW, et al. **J Biol Chem** 1999 Jan 15;274(3):1181-4 (60 ref.)

Analyzing chromatin structure and transcription factor binding in yeast. Gregory PD, et al. **Methods** 1998 Aug; 15(4):295-302 (31 ref.)

Yeast three-hybrid system to detect and analyze interactions between RNA and protein. Zhang B, et al. **Methods Enzymol** 1999;306:93-113 (19 ref.)

Prospects for drug screening using the reverse two-hybrid system. Vidal M, et al. **Trends Biotechnol** 1999 Sep; 17(9):374-81 (57 ref.)

GROWTH & DEVELOPMENT

High-cell-density cultivation of microorganisms. Riesenberg D, et al. **Appl Microbiol Biotechnol** 1999 Apr;51(4):422-30 (80 ref.)

Does microbial life always feed on negative entropy? Thermodynamic analysis of microbial growth. von Stockar U, et al. **Biochim Biophys Acta** 1999 Aug 4;1412(3):191-211 (59 ref.)

Dynamic adaptation of microbes. Sonnleitner B. **J Biotechnol** 1998 Oct 19;65(1):47-60 (15 ref.)

METABOLISM

Yeast as an expression system for the study of P-glycoprotein and other ABC transporters. Gros P, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:219-25 (64 ref.)

The dolichol pathway of N-linked glycosylation. Burda P, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):239-57 (125 ref.)

Reglucosylation of glycoproteins and quality control of glycoprotein folding in the endoplasmic reticulum of yeast cells. Parodi AJ. **Biochim Biophys Acta** 1999 Jan 6; 1426(2):287-95 (44 ref.)

Simultaneous bioconversion of cellulose and hemicellulose to ethanol. Chandrakant P, et al. **Crit Rev Biotechnol** 1998; 18(4):295-331 (190 ref.)

Peroxisome biogenesis: from yeast to man. Kunau WH. **Curr Opin Microbiol** 1998 Apr;1(2):232-7 (61 ref.)

Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Whitmarsh AJ, et al. **Trends Biochem Sci** 1998 Dec;23(12):481-5 (33 ref.)

Responding to attraction: chemotaxis and chemotropism in Dictyostelium and yeast. Arkowitz RA. **Trends Cell Biol** 1999 Jan;9(1):20-7 (52 ref.)

PHYSIOLOGY

Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? Macfarlane GT, et al. **BMJ** 1999 Apr 10;318(7189):999-1003 (48 ref.)

Characterization of the yeast mitochondria unselective channel: a counterpart to the mammalian permeability transition pore? Manon S, et al. **J Bioenerg Biomembr** 1998 Oct;30(5):419-29 (57 ref.)

YELLOW FEVER

[Yellow fever] Yoshikawa Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):150-1 (4 ref.) **(Jpn)**

DIAGNOSIS

[Laboratory diagnosis of viral infections. 8. Viral hemorrhagic fever] Morikawa S. **Rinsho Byori** 1998 Nov; Suppl 108:105-10 (9 ref.) **(Jpn)**

EPIDEMIOLOGY

[Molecular epidemiology of yellow fever] Tolou H, et al. **Med Trop (Mars)** 1998;58(2 Suppl):37-41 (13 ref.) (Eng. Abstr.) **(Fre)**

YELLOW FEVER VIRUS

GENETICS

[Molecular epidemiology of yellow fever] Tolou H, et al. **Med Trop (Mars)** 1998;58(2 Suppl):37-41 (13 ref.) (Eng. Abstr.) **(Fre)**

YELLOW JACKETS see **WASPS**

YELLOW MARROW see **BONE MARROW**

YERSINIA

Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections. Smego RA, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):1-15 (183 ref.)

ENZYMOLOGY

[Pyrazinamidase as a p6rker of Yersinia pathogenicity] Kuznetsov VG. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr;(2):107-11 (54 ref.) **(Rus)**

GENETICS

The virulence plasmid of Yersinia, an antihost genome. Cornelis GR, et al. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1315-52 (395 ref.)

PATHOGENICITY

The tranquilizing injection of Yersinia proteins: a pathogen's strategy to resist host defense. Aepfelbacher M, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):795-802 (47 ref.)

Yersiniosis. II: The pathogenesis of Yersinia infections. Koornhof HJ, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):87-112 (264 ref.)

Type III secretion machines and the pathogenesis of enteric infections caused by Yersinia and Salmonella spp. Lee VT, et al. **Immunol Rev** 1999 Apr;168:241-55 (154 ref.)

The Yersinia deadly kiss. Cornelis GR. **J Bacteriol** 1998 Nov; 180(21):5495-504 (123 ref.)

The virulence plasmid of Yersinia, an antihost genome. Cornelis GR, et al. **Microbiol Mol Biol Rev** 1998 Dec; 62(4):1315-52 (395 ref.)

[Pyrazinamidase as a p6rker of Yersinia pathogenicity] Kuznetsov VG. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr;(2):107-11 (54 ref.) **(Rus)**

PHYSIOLOGY

Yersiniosis. II: The pathogenesis of Yersinia infections. Koornhof HJ, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):87-112 (264 ref.)

YERSINIA ENTEROCOLITICA

Yersinia enterocolitica and mycotic aneurysm. Tame S, et al. **Aust N Z J Surg** 1998 Nov;68(11):813-4 (9 ref.)

[Yersinia enteritis] Sakamoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):493-5 (7 ref.) **(Jpn)**

[Yersinia enterocolitica septicemia] Uchiyama M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):252-4 (12 ref.) **(Jpn)**

YERSINIA INFECTIONS

see related
ARTHRITIS, REACTIVE

Yersiniosis. II: The pathogenesis of Yersinia infections. Koornhof HJ, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):87-112 (264 ref.)

Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections. Smego RA, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):1-15 (183 ref.)

[Yersinia enteritis] Sakamoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):493-5 (7 ref.) **(Jpn)**

[Yersinia enterocolitica septicemia] Uchiyama M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):252-4 (12 ref.) **(Jpn)**

DIAGNOSIS

Yersinia enterocolitica and mycotic aneurysm. Tame S, et al. **Aust N Z J Surg** 1998 Nov;68(11):813-4 (9 ref.)

ETIOLOGY

[Development of studies on problem of infectious arthritis at the Institute of RHeumatology, Russian Academy of Medical Sciences in 1970 to 1990] Agababova ER. **Vestn Ross Akad Med Nauk** 1998;(12):23-6 (41 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Type III secretion machines and the pathogenesis of enteric infections caused by Yersinia and Salmonella spp. Lee VT, et al. **Immunol Rev** 1999 Apr;168:241-55 (154 ref.)

YERSINIA PSEUDOTUBERCULOSIS

[Yersinia enteritis] Sakamoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):493-5 (7 ref.) **(Jpn)**

PATHOGENICITY

Interference of eukaryotic signalling pathways by the bacteria Yersinia outer protein YopJ. Spiik AK, et al. **Immunol Lett** 1999 Jun 1;68(2-3):199-203 (44 ref.)

YERSINIA PSEUDOTUBERCULOSIS INFECTIONS

[Yersinia pseudotuberculosis infection] Abe J, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):107-10 (14 ref.) **(Jpn)**

[Yersinia enteritis] Sakamoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):493-5 (7 ref.) **(Jpn)**

[Yersinia pseudotuberculosis infection] Takeda N. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):496-9 (15 ref.) **(Jpn)**

YIN DEFICIENCY

DRUG THERAPY

Advances in TCM treatment of diabetic acromelic gangrene. Li Y, et al. **J Tradit Chin Med** 1998 Mar;18(1):66-70 (16 ref.)

YIN HSU see **YIN DEFICIENCY**

YIN-YANG

[Adjustment function of life message apparatus type SMS-03] Zheng XW. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov; 16(11):701-2 (13 ref.) **(Chi)**

YINXU see **YIN DEFICIENCY**

YOGA

Yoga: intuition, preventive medicine, and treatment. Collins C. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct; 27(5):563-8 (33 ref.)

YOGHURT see **YOGURT**

YOGURT

Yogurt as oral bacteriotherapy for diarrhea: back to the future? [editorial] Ullman T, et al. **Indian Pediatr** 1998 Jun; 35(6):503-6 (13 ref.)

YOLK PROTEINS see **EGG PROTEINS**

YOLK SAC

CYTOLOGY

Role of endothelium in the control of mouse yolk sac stem cell differentiation. Auerbach R, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):333-8 (14 ref.)

PHYSIOLOGY

Rearranging gastrulation in the name of yolk: evolution of gastrulation in yolk-rich amniote eggs. Arendt D, et al. **Mech Dev** 1999 Mar;81(1-2):3-22 (133 ref.)

YOLK SAC TUMOR see **ENDODERMAL SINUS TUMOR**

YOUTH see **ADOLESCENCE**

YTTRIUM

see related
YTTRIUM RADIOISOTOPES

YTTRIUM RADIOISOTOPES

THERAPEUTIC USE

[Intracoronary brachytherapy with strontium/yttrium-90. Initial experiences in Germany] Silber S, et al. **Herz** 1998 Sep;23(6):380-93 (36 ref.) (Eng. Abstr.) **(Ger)**

YUCCA see **LILIACEAE**

Z-DNA see **DNA**

ZEA see **CORN**

ZEBRAFISH

Overview of the Zebrafish system. Detrich HW 3rd, et al. **Methods Cell Biol** 1999;59:3-10 (39 ref.)

Vectors and techniques for ectopic gene expression in zebrafish. Hyatt TM, et al. **Methods Cell Biol** 1999; 59:117-26 (17 ref.)

Collection, storage, and use of zebrafish sperm. Ransom DG, et al. **Methods Cell Biol** 1999;60:365-72 (3 ref.)

[Maintenance of laboratory strain of zebrafish, Danio rerio] Takeda H. **Tanpakushitsu Kakusan Koso** 1999 May; 44(6):803-6 (5 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Zebrafish in context: uses of a laboratory model in comparative studies. Metscher BD, et al. **Dev Biol** 1999 Jun 1;210(1):1-14 (63 ref.)

EMBRYOLOGY

The zebrafish organizer. Schier AF, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):464-71 (89 ref.)

Pattern formation in zebrafish--fruitful liaisons between embryology and genetics. Solnica-Krezel L. **Curr Top Dev Biol** 1999;41:1-35 (140 ref.)

Gastrulation in zebrafish: what mutants teach us. Kodjabachian L, et al. **Dev Biol** 1999 Sep 15;213(2):231-45 (114 ref.)

Kinesin-like microtubule motors in early development. Chen MC, et al. **Methods Cell Biol** 1999;59:227-50 (45 ref.)

Neurogenesis in zebrafish embryos. Chitnis AB, et al. **Methods Cell Biol** 1999;59:367-86 (87 ref.)

Confocal microscopic analysis of morphogenetic movements. Cooper MS, et al. **Methods Cell Biol** 1999;59:179-204 (27 ref.)

Analysis of zebrafish development using explant culture assays. Grinblat Y, et al. **Methods Cell Biol** 1999;59:127-56 (31 ref.)

Strategies to perturb zebrafish development. Hammerschmidt M, et al. **Methods Cell Biol** 1999;59:87-115 (165 ref.)

Zebrafish embryonal cell culture. Helmrich A, et al. **Methods Cell Biol** 1999;59:29-37 (27 ref.)

Analysis of protein and gene expression. Jowett T. **Methods Cell Biol** 1999;59:63-85 (8 ref.)

Cell cycles and development in the embryonic zebrafish. Kane DA. **Methods Cell Biol** 1999;59:11-26 (30 ref.)

Development of the retina. Malicki J. **Methods Cell Biol** 1999; 59:273-99 (102 ref.)

Techniques in neural development. Moens CB, et al. **Methods Cell Biol** 1999;59:253-72 (68 ref.)

Embryonic axis formation in the zebrafish. Mullins MC. **Methods Cell Biol** 1999;59:159-78 (89 ref.)

Vascular and blood gene expression. Parker LH, et al. **Methods Cell Biol** 1999;59:313-36 (75 ref.)

Cell lineage tracing in heart development. Serluca FC, et al. **Methods Cell Biol** 1999;59:359-65 (18 ref.)

Cytoskeletal dynamics of the zebrafish embryo. Topczewski J, et al. **Methods Cell Biol** 1999;59:205-26 (50 ref.)

Analyzing morphogenetic cell behaviors in vitally stained zebrafish embryos. Cooper MS, et al. **Methods Mol Biol** 1999;122:185-204 (12 ref.)

Small-scale marker-based screening for mutations in zebrafish development. Currie PD, et al. **Methods Mol Biol** 1999;97:441-60 (38 ref.)

The zebrafish. An overview of its early development. Holder N, et al. **Methods Mol Biol** 1999;97:431-9 (37 ref.)

Transgenic zebrafish. Jowett T. **Methods Mol Biol** 1999; 97:461-86 (42 ref.)

Zebrafish genetics: the enigma of arrival. Fishman MC. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10554-6 (36 ref.)

GENETICS

Saving zebrafish mutants. Ekker M. **Bioessays** 1999 Feb; 21(2):94-8 (29 ref.)

Pattern formation in zebrafish--fruitful liaisons between embryology and genetics. Solnica-Krezel L. **Curr Top Dev Biol** 1999;41:1-35 (140 ref.)

Less is more: compact genomes pay dividends. Angrist M. **Genome Res** 1998 Jul;8(7):683-5 (30 ref.)

Zebrafish: a new model for human disease [comment] Zon LI. **Genome Res** 1999 Feb;9(2):99-100 (17 ref.) Comment on: Genome Res 1999 Feb;9(2):121-9.

Zebrafish YAC, BAC, and PAC genomic libraries. Amemiya CT, et al. **Methods Cell Biol** 1999;60:235-58 (122 ref.)

Banded chromosomes and the zebrafish karyotype. Amores A, et al. **Methods Cell Biol** 1999;60:323-38 (52 ref.)

Retrovirus-mediated insertional mutagenesis in zebrafish. Amsterdam A, et al. **Methods Cell Biol** 1999;60:87-98 (28 ref.)

Early pressure screens. Beattie CE, et al. **Methods Cell Biol** 1999;60:71-86 (68 ref.)

Production of haploid and diploid androgenetic zebrafish (including methodology for delayed in vitro fertilization). Corley-Smith GE, et al. **Methods Cell Biol** 1999;59:45-60 (27 ref.)

Zebrafish/mouse somatic cell hybrids for the characterization of the zebrafish genome. Ekker M, et al. **Methods Cell Biol** 1999;60:303-21 (26 ref.)

Gene mapping in zebrafish using single-strand conformation polymorphism analysis. Foernzler D, et al. **Methods Cell Biol** 1999;60:185-93 (13 ref.)

Zebrafish expressed sequence tags and their applications. Gong Z. **Methods Cell Biol** 1999;60:213-33 (23 ref.)

Genetic applications of transposons and other repetitive elements in zebrafish. Ivics Z, et al. **Methods Cell Biol** 1999; 60:99-131 (110 ref.)

Genetic backgrounds and some standard stocks and strains used in zebrafish developmental biology and genetics. Johnson SL, et al. **Methods Cell Biol** 1999;60:357-9 (8 ref.)

Centromeric markers in the zebrafish. Kane DA, et al. **Methods Cell Biol** 1999;60:361-3 (4 ref.)

Construction and characterization of zebrafish whole genome radiation hybrids. Kwok C, et al. **Methods Cell Biol** 1999; 60:287-302 (12 ref.)

Transgenesis. Meng A, et al. **Methods Cell Biol** 1999; 60:133-48 (28 ref.)

A gynogenesis-based screen for maternal-effect genes in the

ZEBRAFISH

zebrafish, Danio rerio. Pelegri F, et al. **Methods Cell Biol** 1999;60:1-20 (56 ref.)
The zebrafish genome. Postlethwait J, et al. **Methods Cell Biol** 1999;60:149-63 (57 ref.)
Using random amplified polymorphic DNAs in zebrafish genomic analysis. Postlethwait JH, et al. **Methods Cell Biol** 1999;60:165-79 (43 ref.)
Mapping zebrafish mutations by AFLP. Ransom DG, et al. **Methods Cell Biol** 1999;60:195-211 (19 ref.)
Positional cloning of mutated zebrafish genes. Talbot WS, et al. **Methods Cell Biol** 1999;60:259-86 (47 ref.)
Developmental mutant screens in the zebrafish. van Eeden FJ, et al. **Methods Cell Biol** 1999;60:21-41 (46 ref.)
Haploid screens and gamma-ray mutagenesis. Walker C. **Methods Cell Biol** 1999;60:43-70 (34 ref.)
Zebrafish informatics and the ZFIN database. Westerfield M, et al. **Methods Cell Biol** 1999;60:339-55 (9 ref.)
Small-scale marker-based screening for mutations in zebrafish development. Currie PD, et al. **Methods Mol Biol** 1999;97:441-60 (38 ref.)
Transgenic zebrafish. Jowett T. **Methods Mol Biol** 1999; 97:461-86 (42 ref.)
Zebrafish genetics: the enigma of arrival. Fishman MC. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10554-6 (36 ref.)

GROWTH & DEVELOPMENT

Genetic backgrounds and some standard stocks and strains used in zebrafish developmental biology and genetics. Johnson SL, et al. **Methods Cell Biol** 1999;60:357-9 (8 ref.)

PHYSIOLOGY

Zebrafish as a model system for studying neuronal circuits and behavior. Fetcho JR, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:333-45 (53 ref.)
Monitoring activity in neuronal populations with single-cell resolution in a behaving vertebrate. Fetcho JR, et al. **Histochem J** 1998 Mar;30(3):153-67 (34 ref.)
Analysis of hemostasis in the zebrafish. Jagadeeswaran P, et al. **Methods Cell Biol** 1999;59:337-57 (55 ref.)
Growth control in the ontogenetic and regenerating zebrafish fin. Johnson SL, et al. **Methods Cell Biol** 1999;59:301-11 (27 ref.)

ZEBRAS see **EQUIDAE**

ZELLWEGER SYNDROME

ENZYMOLOGY

Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. de Launoit Y, et al. **J Mol Endocrinol** 1999 Jun;22(3):227-40 (110 ref.)

ZENKER'S DIVERTICULUM

ETIOLOGY

Pharyngeal pouch following anterior cervical fusion. Sood S, et al. **J Laryngol Otol** 1998 Nov;112(11):1085-6 (15 ref.)

PATHOLOGY

[New surgical and pathological aspects of Zenker's diverticulum. Diagnostic imaging and analysis of function] Ekberg O. **Chirurg** 1999 Jul;70(7):747-52 (11 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[The physiopathological basis for Zenker's diverticulum] Peters JH, et al. **Chirurg** 1999 Jul;70(7):741-6 (24 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Endoscopic treatment of Zenker's diverticulum [editorial; comment] Bremner CG, et al. **Gastrointest Endosc** 1999 Jan;49(1):126-8 (16 ref.) Comment on: Gastrointest Endosc 1999 Jan;49(1):93-7.
[New surgical and pathological aspects of Zenker's diverticulum. Diagnostic imaging and analysis of function] Ekberg O. **Chirurg** 1999 Jul;70(7):747-52 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Intraluminal therapy for Zenker's diverticulum] Mulder CJ, et al. **Chirurg** 1999 Jul;70(7):757-60 (20 ref.) (Eng. Abstr.) **(Ger)**

ZEOLITES

La roca magica: uses of natural zeolites in agriculture and industry. Mumpton FA. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3463-70 (106 ref.)

ZERO GRAVITY see **WEIGHTLESSNESS**

ZHONG YI XUE see **MEDICINE, CHINESE TRADITIONAL**

ZIDOVUDINE

ADMINISTRATION & DOSAGE

[Reducing perinatal transmission by antiretroviral therapy] Schmied B. **Wien Med Wochenschr** 1998;148(23-24):550-5 (29 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Mitochondria as cell targets of AZT (zidovudine). Barile M, et al. **Gen Pharmacol** 1998 Oct;31(4):531-8 (53 ref.)

THERAPEUTIC USE

Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee [editorial] **AIDS** 1998 Jul 30;12(11):1259-65 (19 ref.)
Failures of zidovudine postexposure prophylaxis. Jochimsen EM. **Am J Med** 1997 May 19;102(5B):52-5; discussion 56-7 (20 ref.)
Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Simpson DM. **Clin Infect Dis** 1999 Jul;29(1):19-34 (89 ref.)
Insights into the mechanisms of vertical transmission of HIV-1. BIOMED2 Working Group on the in utero transmission of HIV-1. Menu E, et al. **Early Pregnancy** 1997 Dec;3(4):245-58 (130 ref.)
AZT trials and tribulations. Crouch RA, et al. **Hastings Cent Rep** 1998 Nov-Dec;28(6):26-34 (32 ref.)
Zidovudine. Sperling R. **Infect Dis Obstet Gynecol** 1998; 6(5):197-203 (27 ref.)
HIV infection and pregnancy. de Ruiter A, et al. **Int J STD AIDS** 1998 Nov;9(11):647-54; quiz 655 (34 ref.)
Update on vertical HIV transmission. Groginsky E, et al. **J Reprod Med** 1998 Aug;43(8):637-46 (72 ref.)
[Antiretroviral therapy in pregnant women with HIV] Niemiec KT, et al. **Ginekol Pol** 1998 Nov;69(11):820-6 (34 ref.) (Eng. Abstr.) **(Pol)**
[Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment] Villegas Castrejón H, et al. **Ginecol Obstet Mex** 1999 May;67:196-206 (35 ref.) (Eng. Abstr.) **(Spa)**

ZINC

Copper-zinc superoxide dismutase and ALS. Valentine JS, et al. **Adv Exp Med Biol** 1999;448:193-203 (50 ref.)
Zinc, exercise, and thyroid hormone function. Ganapathy S, et al. **Crit Rev Food Sci Nutr** 1999 Jul;39(4):369-90 (122 ref.)
Considerations for determining 'optimal nutrition' for copper, zinc, manganese and molybdenum. Failla ML. **Proc Nutr Soc** 1999 May;58(2):497-505 (74 ref.)
[Recent progress on the study of structural zinc] Wakagi T. **Seikagaku** 1999 Jan;71(1):69-74 (17 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Vitamin A and zinc supplementation of preschool children. Smith JC, et al. **J Am Coll Nutr** 1999 Jun;18(3):213-22 (54 ref.)
Zinc deficiency in Crohn's disease [editorial; comment] Matsui T. **J Gastroenterol** 1998 Dec;33(6):924-5 (17 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):876-9.

ANALYSIS

Measurement of nitric oxide-mediated effects on zinc homeostasis and zinc finger transcription factors. Kröncke KD, et al. **Methods Enzymol** 1999;301:126-35 (23 ref.)

BLOOD

Nutritional and zinc status of head and neck cancer patients: an interpretive review. Prasad AS, et al. **J Am Coll Nutr** 1998 Oct;17(5):409-18 (38 ref.)
Vitamin A and zinc supplementation of preschool children. Smith JC, et al. **J Am Coll Nutr** 1999 Jun;18(3):213-22 (54 ref.)

CHEMISTRY

RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Borden KL. **Biochem Cell Biol** 1998; 76(2-3):351-8 (44 ref.)
A new decoration for nitric oxide synthase - a Zn(Cys)4 site. Ludwig ML, et al. **Structure** 1999 Apr 15;7(4):R73-9 (35 ref.)

DEFICIENCY

Zinc deficiency in Crohn's disease [editorial; comment] Matsui T. **J Gastroenterol** 1998 Dec;33(6):924-5 (17 ref.) Comment on: J Gastroenterol 1998 Dec;33(6):876-9.
Zinc and immunity. Prasad AS. **Mol Cell Biochem** 1998 Nov; 188(1-2):63-9 (52 ref.)
[Zinc: pathophysiological effects, deficiency status and effects of supplementation in elderly persons--an overview of the research] Abbasi A, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I/75-9 (31 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis of zinc deficiency] Roth HP, et al. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I/55-63 (47 ref.) (Eng. Abstr.) **(Ger)**
[Zinc deficiency in liver cirrhosis: a curiosity or a problem?] Marchetti P, et al. **Ann Ital Med Int** 1998 Jul-Sep; 13(3):157-62 (64 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Zinc, T-cell pathways, aging: role of metallothioneins. Mocchegiani E, et al. **Mech Ageing Dev** 1998 Dec 1; 106(1-2):183-204 (117 ref.)
Zinc and immunity. Prasad AS. **Mol Cell Biochem** 1998 Nov; 188(1-2):63-9 (52 ref.)

METABOLISM

New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Heizmann CW, et al. **Biometals** 1998 Dec;11(4):383-97 (160 ref.)
Zinc-catalyzed sulfur alkyation:insights from protein farnesyltransferase. Hightower KE, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):176-81 (57 ref.)
Zeroing in on zinc uptake in yeast and plants. Guerinot ML, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):244-9 (49 ref.)
Mounting evidence for the involvement of zinc and copper in Alzheimer's disease [comment] Moir RD, et al. **Eur J Clin Invest** 1999 Jul;29(7):569-70 (29 ref.) Comment on: Eur J Clin Invest 1999 Jul;29(7):637-42.

PHARMACOLOGY

Cysteine, glutathione (GSH) and zinc and copper ions together are effective, natural, intracellular inhibitors of (AIDS) viruses. Sprietsma JE. **Med Hypotheses** 1999 Jun; 52(6):529-38 (100 ref.)

PHYSIOLOGY

The role of copper, molybdenum, selenium, and zinc in nutrition and health. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):673-85 (54 ref.)
Regulation of caspase activation and apoptosis by cellular zinc fluxes and zinc deprivation: A review. Chai F, et al. **Immunol Cell Biol** 1999 Jun;77(3):272-8 (39 ref.)
The significance of zinc for leukocyte biology. Wellinghausen N, et al. **J Leukoc Biol** 1998 Nov;64(5):571-7 (110 ref.)
The molecular basis for the role of zinc in developmental biology. Falchuk KH. **Mol Cell Biochem** 1998 Nov; 188(1-2):41-8 (59 ref.)

THERAPEUTIC USE

Zinc lozenges for the common cold. Macknin ML. **Cleve Clin J Med** 1999 Jan;66(1):27-32 (36 ref.)
Treatment of Wilson's disease with zinc [letter] Brewer GJ. **J Lab Clin Med** 1999 Sep;134(3):322-4 (30 ref.)
Zinc treatment of Wilson's disease [editorial] Hoogenraad TU. **J Lab Clin Med** 1998 Oct;132(4):240-1 (13 ref.)

TOXICITY

Zinc. Barceloux DG. **J Toxicol Clin Toxicol** 1999; 37(2):279-92 (98 ref.)

ZINC FINGERS

Sp1 and its likes: biochemical and functional predictions for a growing family of zinc finger transcription factors. Cook T, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:94-102 (38 ref.)
WT1: what has the last decade told us? Little M, et al. **Bioessays** 1999 Mar;21(3):191-202 (87 ref.)
FYVE finger proteins as effectors of phosphatidylinositol 3-phosphate. Gaullier JM, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):87-94 (45 ref.)
A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Philipsen S, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):2991-3000 (113 ref.)
Zinc-finger proteins: the classical zinc finger emerges in contemporary plant science. Takatsuji H. **Plant Mol Biol** 1999 Apr;39(6):1073-8 (13 ref.)
Zinc fingers in Caenorhabditis elegans: finding families and probing pathways [see comments] Clarke ND, et al. **Science** 1998 Dec 11;282(5396):2018-22 (39 ref.) Comment in: Science 1998 Dec 11;282(5396):1972-4.

GENETICS

[ZAP genes: characterizing the protein structure of a new family of proliferation associated genes in the exocrine pancreas] Günther R, et al. **Med Klin** 1999 Apr 15; 94(4):233-8 (22 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Zinc finger proteins: watchdogs in muscle development. Krempler A, et al. **Mol Gen Genet** 1999 Mar;261(2):209-15 (72 ref.)

ZINC SULFATE

THERAPEUTIC USE

Does oral zinc aid the healing of chronic leg ulcers? A systematic literature review. Wilkinson EA, et al. **Arch Dermatol** 1998 Dec;134(12):1556-60 (16 ref.)

ZINSSER-COLE-ENGMAN SYNDROME see **DYSKERATOSIS CONGENITA**

ZIPHIIDAE see **WHALES**

ZIPHIUS see **WHALES**

ZIRCONIUM

CHEMISTRY

Development of plasma-sprayed bioceramic coatings with bond coats based on titania and zirconia. Kurzweg H, et al. **Biomaterials** 1998 Aug;19(16):1507-11 (20 ref.)
Zirconia as a ceramic biomaterial. Piconi C, et al. **Biomaterials** 1999 Jan;20(1):1-25 (166 ref.)

ZOLAZEPAM

Etomidate and telazol. Pablo LS, et al. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):779-92 (57 ref.)

ZOLLINGER-ELLISON SYNDROME

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

[Zollinger-Ellison syndrome] Nicolás D, et al. **Gastroenterol Hepatol** 1999 Feb;22(2):100-12 (117 ref.) **(Spa)**

PATHOLOGY

Clinical aspects of ECL-cell abnormalities. Hirschowitz BI. **Yale J Biol Med** 1998 May-Aug;71(3-4):303-10 (65 ref.)

ZONA see **HERPES ZOSTER**

ZONA PELLUCIDA

Mammalian fertilization misread? Sperm penetration of the eutherian zona pellucida is unlikely to be a lytic event. Bedford JM. **Biol Reprod** 1998 Dec;59(6):1275-87 (149 ref.)

CHEMISTRY

Protein-carbohydrate interactions during fertilization. Sinowatz F, et al. **Acta Anat (Basel)** 1998;161(1-4):196-205 (92 ref.)

METABOLISM

New aspects of sperm-zona pellucida binding. Franken DR. **Andrologia** 1998 Aug-Sep;30(4-5):263-8 (35 ref.)

PHYSIOLOGY

Investigations into the molecular basis of human sperm-egg interactions: what's next? [comment] Benoff S. **Mol Hum Reprod** 1998 Oct;4(10):925-8 (85 ref.) Comment on: Mol Hum Reprod 1998 Jun;4(6):523-4. Comment on: Mol Hum Reprod 1998 Jun;4(6):524-5.

ZONA RETICULARIS

SECRETION

[Dehydroepiandrosterone, reticular area of adrenal cortex and resistance to stress and disease] Obut TA. **Vestn Ross Akad Med Nauk** 1998;(10):18-22 (52 ref.) (Eng. Abstr.) **(Rus)**

ZONE THERAPY see **MASSAGE**

ZOOLOGY

see related
ANIMALS

ZOONOSES

see related
DISEASE RESERVOIRS

Salmonella typhimurium DT104: a virulent and drug-resistant pathogen. Poppe C, et al. **Can Vet J** 1998 Sep;39(9):559-65 (48 ref.)
Emerging viral diseases: an Australian perspective. Mackenzie JS. **Emerg Infect Dis** 1999 Jan-Feb;5(1):1-8 (71 ref.)
Companion animal issues and the physician. Hoff GL, et al. **South Med J** 1999 Jul;92(7):651-9 (78 ref.)
[Surveillance and control of some emerging zoonoses] Yu ES. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Feb; 18(1):47-9 (5 ref.) **(Chi)**
["Emerging" viral zoonoses in native animals who can be the host in the Netherlands] van der Poel WH. **Tijdschr Diergeneeskd** 1999 Jan 1;124(1):3-11 (90 ref.) (Eng. Abstr.) **(Dut)**
[Spongiform encephalopathies] Pastoret PP. **Bull Soc Sci Med Grand Duche Luxemb** 1998;135(1):25-38 (43 ref.) (Eng. Abstr.) **(Fre)**
[Dermatomycosis in human and animals] Nakamura Y, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(1):9-14 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Zoonotic parasitic diseases recently observed in Japan] Otsuru M. **Rinsho Byori** 1998 Nov;Suppl 108:160-5 (5 ref.) **(Jpn)**
[Zoonosis] Ohtomo H. **Ryoikibetsu Shokogun Shirizu** 1999; (25 Pt 3):384-8 (12 ref.) **(Jpn)**
[Infectious diseases of animals and their prevention] Mikula I, et al. **Bratisl Lek Listy** 1998 Aug-Sep;99(8-9):465-73 (94 ref.) (Eng. Abstr.) **(Slo)**

CLASSIFICATION

Epidemiology of human fascioliasis: a review and proposed new classification. Mas-Coma MS, et al. **Bull World Health Organ** 1999;77(4):340-6 (80 ref.)

EPIDEMIOLOGY

Epidemiology of human fascioliasis: a review and proposed new classification. Mas-Coma MS, et al. **Bull World Health Organ** 1999;77(4):340-6 (80 ref.)
Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr-Jun;14(2):247-84 (222 ref.)
[Parasitic zoonoses] Janitschke K. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):358-61 (20 ref.) (Eng. Abstr.) **(Ger)**
[The current epizootic situation of prospects for eradicating rabies] Selimov MA. **Vopr Virusol** 1998 Sep-Oct; 43(5):196-8 (20 ref.) **(Rus)**

ETIOLOGY

Rabies prophylaxis following the feeding of a rabid pony. Feder HM, et al. **Clin Pediatr (Phila)** 1998 Aug; 37(8):477-81 (38 ref.)
Zoonosis in xenotransplantation. Patience C, et al. **Curr Opin Immunol** 1998 Oct;10(5):539-42 (39 ref.)

MICROBIOLOGY

Zoophilic and geophilic fungi as a cause of skin disease in farmers. Spiewak R. **Ann Agric Environ Med** 1998; 5(2):97-102 (23 ref.)
Xenotransplant-associated infections. Michaels MG. **Lab Anim Sci** 1998 Jun;48(3):228-33 (67 ref.)

PARASITOLOGY

Animal waste: risk of zoonotic parasite transmission. Murrell KD, et al. **Rev Environ Health** 1998 Oct-Dec;13(4):169-78 (67 ref.)

TRANSMISSION

Vaccination of cats against emerging and reemerging zoonotic pathogens. Olsen CW. **Adv Vet Med** 1999; 41:333-46 (62 ref.)
Risks of virus transmission associated with animal sera or substitutes and methods of control. Eloit M. **Dev Biol Stand** 1999;99:9-16 (10 ref.)
Animal waste: risk of zoonotic parasite transmission. Murrell KD, et al. **Rev Environ Health** 1998 Oct-Dec;13(4):169-78 (67 ref.)
Shared vector-borne zoonoses of the Old World and New World: home grown or translocated? Childs JE, et al. **Schweiz Med Wochenschr** 1999 Aug 10; 129(31-32):1099-105 (46 ref.)
Infection in xenotransplantation: a clinical approach. Fishman JA. **Transplant Proc** 1999 Sep;31(6):2225-7 (23 ref.)
[Immunology in clinical practice. XXIII. Xenotransplantation] Schraa EO, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1455-60 (16 ref.) (Eng. Abstr.) **(Dut)**
[Cutaneous zoonoses transmitted by dogs and cats] Piérard GE, et al. **Rev Med Liege** 1998 Sep;53(9):532-6 (31 ref.) (Eng. Abstr.) **(Fre)**
[Swine and wild pigs as carriers of zoonoses] Deutz A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Aug; 112(8):305-10 (48 ref.) (Eng. Abstr.) **(Ger)**
[Animals as a source of infections for humans--diseases caused by EHEC] Baljer G, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):339-43 (29 ref.) (Eng. Abstr.) **(Ger)**
[Emergence of "new" viral zoonoses] Greiser-Wilke I, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):332-8 (37 ref.) (Eng. Abstr.) **(Ger)**
[Bovine spongiform encephalopathy in ruminants and the new variant of Creutzfeldt-Jakob disease in humans] Groschup MH. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):329-31 (22 ref.) (Eng. Abstr.) **(Ger)**
[Animals as sources of infections in humans--salmonellosis] Meyer H. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug; 106(8):344-51 (58 ref.) (Eng. Abstr.) **(Ger)**
[Wild animals as transmitters of infectious diseases] Pohlmeyer K. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug; 106(8):325-8 (7 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Zoonoses and haemorrhagic fever. Mahy BW. **Dev Biol Stand** 1998;93:31-6 (9 ref.)
[Risk of infection causes by viruses in xenotransplantation] von der Helm K, et al. **Zentralbl Chir** 1999;124(7):600-3 (19 ref.) (Eng. Abstr.) **(Ger)**

ZOOPHAGINAE see **VIRUSES**

ZOOPHTHORA see **ENTOMOPHTHORALES**

ZOSTER see **HERPES ZOSTER**

ZUCLOMIFENE see **CLOMIPHENE**

ZYGOMA

Carcinoma of the uterine cervix metastatic to behind the zygomatic arch: a case report. Challagalla JD, et al. **Am J Otolaryngol** 1999 May-Jun;20(3):195-7 (14 ref.)

SURGERY

Zygomatico-coronoid ankylosis: a case report. Vanhove F, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):258-9 (10 ref.)

ZYGOMATIC ARCH see **ZYGOMA**

ZYGOMYCOSIS

ETIOLOGY

Gastrointestinal zygomycotic infection caused by Basidiobolus ranarum: case report and review. Zavasky DM, et al. **Clin Infect Dis** 1999 Jun;28(6):1244-8 (18 ref.)

PATHOLOGY

Rhinocerebral zygomycosis following bone marrow transplantation in chronic myelogenous leukaemia. Report of a case and review of the literature. Nenoff P, et al. **Mycoses** 1998 Nov;41(9-10):365-72 (12 ref.)

ZYGOMYCOTA

PHYSIOLOGY

Flavonoids and arbuscular-mycorrhizal fungi. Vierheilig H, et al. **Adv Exp Med Biol** 1998;439:9-33 (72 ref.)
Legume nodulation and mycorrhizae formation; two extremes in host specificity meet. Albrecht C, et al. **EMBO J** 1999 Jan 15;18(2):281-8 (66 ref.)

ZYGOMYCOTINA see **ZYGOMYCOTA**

ZYGOTE

Production of transgenic rodents by the microinjection of cloned DNA into fertilized one-celled eggs. Si-Hoe SL, et al. **Methods Mol Biol** 1999;97:61-100 (25 ref.)

PHYSIOLOGY


Microinjection of DNA, RNA, and protein into the fertilized zebrafish egg for analysis of gene function. Holder N, et al. **Methods Mol Biol** 1999;97:487-90 (9 ref.)
Hypothesis: sex determination and germline formation are committed at the pronucleate stage in mammalian embryos. Edwards RG, et al. **Mol Hum Reprod** 1999 Jul;5(7):595-606 (148 ref.)
[Transcription in Xenopus early embryos and apoptotic program preset in the fertilized egg] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):32-41 (26 ref.) **(Jpn)**

ULTRASTRUCTURE

Formation and localization of cytoplasmic domains in leech and ascidian zygotes. Fernández J, et al. **Int J Dev Biol** 1998 Nov;42(8):1075-84 (86 ref.)

ZYGOTES, PLANT see **SEEDS**

ZYMOGENS see **ENZYME PRECURSORS**


1.0
1.1
1.25
1.4
1.6
2.8
3.2
3.6
4.0
2.5
2.2
2.0
1.8